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TH-OR001 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Extracellular DNA Drives Cholesterol Crystal Embolism-Related Tissue 
Injury
Chongxu Shi,1 Shrikant R. Mulay,1 Barbara M. Klinkhammer,2 Helen Liapis,3 
Peter Boor,2 Hans J. Anders.1 1Medizinische Klinik und Poliklinik IV, Klinikum 
der Universität München, Munich, Germany; 2RWTH University Aachen, 
Aachen, Germany; 3Missouri (Retired) and Arkana Laboratories, Pathology and 
Immunology School of Medicine, Washington University, Washington, WA.
Background: Cholesterol crystal (CC) embolism may be an under recognized cause 
of acute kidney injury (AKI), especially of catheter intervention- or major surgery- related 
AKI. Little is known about the pathophysiology of CC embolism-related for the lack of 
animal models.
Methods: Injecting CC into the left renal artery of C57BL/6N, Mlkl-/- and CypD-/- 
mice, transcutaneous measurement of GFR after CC injection 24h, quantify renal tubular 
and endothelial cell injury, crystal clot formation inside arteries, quantify the occlusion of 
renal arteries of varies sizes. Neutrophil depletion and DNase I interventions were used on 
mice before CC injection, all experiments same as descripted before.
Results: CC injection to mice caused a sudden drop in glomerular filtration rate 
(GFR) associated CC embolism and crystal clot formation leading to either partial CC or 
complete occlusion of numerous interlobar arcuate, and interlobular arteries documented 
by histology and 3D reconstructions of vascular contrast micro-CT scans. 24h after CC 
injection partial obstruction was associated with ischemic necrosis of respective tubular 
S3 segments, while complete obstruction caused large territorial infarction. Such infarcts 
were surrounded by massive neutrophil infiltrates apparently also derived from vessels of 
the renal capsule (rim sign). Necroptosis and mitochondrial permeability transition-related 
regulated necrosis are known to drive post-ischemic AKI but lack of Mlkl, CypD or both 
had no effect on GFR loss or infarct size probably because crystal clot obstruction remained 
unaffected. Crystal clots stained positive for platelets, neutrophils, fibrin, and DNA. While 
neutrophil depletion only partially attenuated GFR loss and infarct size recombinant DNAse 
I was fully protective as it reduced the number of complete vascular occlusion. In vitro 
studies revealed that CC induce membrane rupture and DNA release from endothelial cells, 
neutrophils, and platelets and that CC-induced activation of platelets induces neutrophil 
extracellular traps formation. CC embolism was found in 446 of 92,000 diagnostic kidney 
biopsies (0.5%).
Conclusions: CC embolism activates numerous cell types to release DNA, which is a 
central component of crystal clot formation, vascular occlusion, and kidney infarct-related 
AKI.
Funding: Other U.S. Government Support
TH-OR002 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Mitochondrial DNA Leakage Causes Inflammation via the cGAS-STING 
Axis in Cisplatin-Mediated Tubular Damage
Hiroshi Maekawa,1,2 Tzu-Ming Jao,3 Reiko Inoue,1 Hiroshi Nishi,1 
Tsuyoshi Inoue,1,2 Masaomi Nangaku,1 Reiko Inagi.2 1Div of Nephrol and 
Endocrinol, The Univ of Tokyo Grad Sch of Med, Tokyo, Japan; 2Div of CKD 
Pathophysiol, The Univ of Tokyo Grad Sch of Med, Tokyo, Japan; 3National 
Taiwan University Hospital, Taipei, Taiwan.
Background: Cisplatin is an anti-neoplastic drug that induces tubular inflammation. 
However, its detailed mechanisms are not fully understood. Stimulator of interferon genes 
(STING) and its upstream or downstream molecules (cGAS-STING axis) play an important 
role in 3self/non-self DNA-triggered signal transduction, leading to inflammation. Here, 
we investigated the potential role of STING-mediated inflammation in cisplatin-induced 
tubular inflammation.
Methods: The human proximal tubular cell line, HK-2, was treated with 10 μM of 
cisplatin and the renal cortex of C57BL/6 mice, injected with 25 mg/kg of cisplatin for 72 h, 
was analyzed. The changes in cGAS-STING activation, mitochondrial DNA (mtDNA) 
leakage, or BAX expression were evaluated using real-time PCR, western blotting, or 
immunofluorescence analysis. Cisplatin and/or STING siRNA-treated HK-2 culture 
supernatants were analyzed using cytokine arrays and migration assays. Amlexanox 
and ethidium bromide (EtBr) were used for cGAS-STING axis inhibition and mtDNA 
depletion, respectively.
Results: In cisplatin-treated HK-2 or kidney cortex, STING expression was upregulated 
and translocated from the ER to the Golgi apparatus, indicating STING activation by 
cisplatin. Subsequently, the cGAS-STING axis(TBK-1, IRF3, and P65) was activated due 
to cisplatin-mediated phosphorylation. Cisplatin also induced inflammatory cytokine(IL-6, 
IL-8, ICAM-1, CXCL10, and GMCSF) production and neutrophil chemotaxis, which were 
ameliorated by STING knockdown (P < 0.05). Amlexanox prevented cytokine production 
via cGAS-STING axis inhibition (IRF3 inactivation). Interestingly, cisplatin-mediated 
mtDNA leakage to the cytosol activated cGAS-STING axis-mediated inflammation. In fact, 
EtBr-mediated mtDNA depletion inhibited the inflammation by cisplatin in HK-2. Cisplatin-
induced BAX expression, which interacted with the mitochondrial permeability transition 
pore, suggested that mtDNA leakage was caused by the increase in BAX expression.
Conclusions: mtDNA leakage to the cytosol induces tubular inflammation by 
activating the cGAS-STING axis in cisplatin nephrotoxicity.
TH-OR003 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Knockout of DNA Methyltransferases in Proximal Tubules Preserves 
Klotho and Improves Kidney Repair after Ischemia/Reperfusion Injury
Chunyuan Guo,1 Qingqing Wei,1 Man J. Livingston,2 Zheng Dong.3 1Medical 
College of Georgia, Augusta University, Augusta, GA; 2Augusta University 
Medical College of Georgia, Augusta, GA; 3Medical College of Georgia, 
Augusta, GA.
Background: DNA methylation, catalyzed by DNA methyltransferases (DNMTs), 
is an important epigenetic mechanism that has been implicated in renal development, 
function, and disease pathogenesis. However, the role of DNA methylation in renal 
ischemia/reperfusion (I/R) injury and subsequent kidney repair remains largely unknown.
Methods: Mice were subjected to: i) 30 minutes of bilateral renal ischemia with 
48 hours of reperfusion to examine renal I/R injury, and ii) 30 minutes of unilateral renal 
ischemia with 2 weeks of reperfusion to analyze post-injury kidney repair. To determine the 
role of DNA methylation, we established kidney proximal tubule-specific DNMT1 knockout 
(PT-DNMT1-KO) or DNMT1 and DNMT3a double knockout (PT-DNMT1/3a-DKO) 
mouse models.
Results: DNMT1 and DNMT3a were markedly increased in renal tubular cells during 
renal I/R injury as well as post-injury kidney repair. Knockout of DNMT1 or knockout of 
both DNMT1 and DNMT3a in proximal tubules did not affect renal I/R injury. However, 
DNMT1 and DNMT3a double knockout (PT-DNMT1/3a-DKO) promoted post-injury 
kidney repair and attenuated renal fibroblast activation and interstitial renal fibrosis. Two 
weeks after I/R injury, PT-DNMT1/3a-DKO mice showed lower kidney injury molecule-1 
(Kim-1) and vimentin expression than wild type mice, suggesting better kidney repair in 
DKO mice. Furthermore, DKO mice showed less accumulation of fibronectin and α-SMA 
(myofibroblast marker) with lower levels of collagen deposition in kidneys, indicating 
less interstitial fibrosis. Mechanistically, post-injury kidneys showed hypermethylation of 
Klotho, the anti-aging gene with anti-fibrosis activity. Hypermethylation of Klotho was 
accompanied by a dramatic decrease of Klotho expression in kidneys. Notably, DNMT1/3a-
DKO prevented Klotho hypermethylation and preserved Klotho expression in post-injury 
kidneys.
Conclusions: These results indicate that DNMT1 and DNMT3a-dependent DNA 
methylation in proximal tubules plays an important role in kidney repair following renal 
I/R. Changes in DNA methylation in specific genes, such as Klotho, may lead to aberrant 
gene expression to promote maladaptive repair and interstitial fibrosis.
Funding: NIDDK Support, Veterans Affairs Support
TH-OR004 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Orphan Nuclear Receptor COUP-TFII Regulates Pericyte Detachment in 
AKI
Li Li, Pierre Galichon, Takaharu Ichimura, Joseph V. Bonventre. Brigham and 
Women’s Hospital/Harvard Medical School, Boston, MA.
Background: Pericytes are essential to maintain capillary integrity. Acute kidney 
injury (AKI) causes pericyte detachment from capillaries, triggering endothelial cell 
injury, capillary rarefaction, and hypoxia, contributing to interstitial fibrosis. The molecular 
mechanisms underlying pericyte detachment and subsequent transition to myofibroblasts 
are poorly understood. We hypothesized that Chicken Ovalbumin Upstream Promoter-
Transcription Factor II (COUP-TFII) is important for maintaining kidney pericyte function 
by preventing detachment/activation in the setting of kidney injury.
Methods: COUP-TFII mRNA was measured by quantitative real-time PCR (qRT-
PCR) and protein by immunostaining at different times after unilateral ischemia reperfusion 
(IRI). In vitro, knockdown of COUP-TFII was attained by transfecting a small interfering 
RNA (siRNA) into CH310T1/2 (pericyte-like cells). Angiopoietin 1 (Ang1, a angiotrophic 
protein produced by pericyte to maintain vessel stability) expression was evaluated. In 
addition, we generated CRISPR-cas9 COUP-TFII knock out and tetracycline-inducible 
COUP-TFII overexpressing CH310T1/2 cells. By modulating COUP-TFII expression, 
we studied the effect on αSMA expression (a marker of myofibroblast) and cell migration 
(using scratch motility assay) in CH310T1/2 cells.
Results: COUP-TFII mRNA and protein expression initially decreased at 4 hours after 
IRI, returned to baseline at 24 hours, and was significantly increased at day 21 post-IRI. 
In vitro, knockdown of COUP-TFII by siRNA resulted in decreased Ang1 expression in 
CH310T1/2 cells. Furthermore, knock out of COUP-TFII resulted in increased αSMA 
mRNA expression and promoted migration compared to wild type CH310T1/2 cells. In 
contrast, over-expression of COUP-TFII decreased αSMA mRNA expression and inhibited 
migration compared to control-transfected cells.
Conclusions: Down regulation of COUP-TFII in AKI is an early event regulating 
pericyte fate. It results in: 1) decreased Ang1 expression, which is important for pericyte-
endothelial crosstalk; 2) increased αSMA expression and cell migration, which is important 
for the pericyte to myofibroblast transdiferentiation. Maintaining COUP-TFII expression 
may stabilize pericytes, protect endothelial cells in the early phase of AKI, and prevent 
vascular rarefaction, secondary ischemia and subsequent fibrosis.
Funding: NIDDK Support
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TH-OR005 Oral Abstract Thursday
AKI: New Players and New Mechanisms
The Orphan Nuclear Receptor RORα Is a Potential Endogenous Protector 
in Renal Ischemia/Reperfusion Injury
Jieru Cai. Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Emerging evidence indicates that retinoid-related orphan receptor alpha 
(RORα), a member of the ROR nuclear receptor (NR) subfamily, mediates key cellular 
adaptions to hypoxia and contributes to the pathophysiology of many disease states. 
However, the effects of RORα in renal ischemia/reperfusion (I/R) injury remain unclear.
Methods: Wild-type C57BL/6 mice, ROR-deficient stagger [ROR (sg/sg)] mice and 
their wild-type (WT) littermates were used for in vivo studies. Renal I/R injury model was 
induced by bilateral renal pedicle clamping for 35 minutes. HK-2 cells and human kidney 
samples were used for in vitro studies. HK-2 cells were treated with hypoxia (1% oxygen) 
to establish the cell hypoxia/reoxygenation (H/R) model.
Results: We found that RORα was significantly down-regulated after renal I/R injury. 
RORα-deficient stagger mice displayed dramatically augmented renal dysfunction and 
morphological damage compared with wild-type (WT) mice at 24 hours post-I/R. Further 
study revealed that the detrimental effects of RORα deficiency were attributable to tubular 
epithelial cell apoptosis and, consequently, renal inflammation and oxidative stress. The 
proapoptotic effect of RORα deficiency was associated with aggravated mitochondrial 
dysfunction in renal tubular cells after I/R. However, pretreatment of WT mice with the 
RORα agonist SR1078 ameliorated I/R-induced renal dysfunction and damage and elicited 
a concomitant decrease in tubular epithelial cell apoptosis.
Conclusions: In summary, our study provides experimental evidence showing that 
RORα is a novel endogenous protector against renal I/R injury and that RORα activation is 
a promising therapeutic strategy for the prevention of acute kidney injury.
Funding: Government Support - Non-U.S.
RORα deficiency aggravates renal injury at 24 hours post-I/R.
TH-OR006 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Stress Response Gene NUPR1 Protects Renal Tubular Cells from 
Proliferation-Induced Energy Exhaustion
Pierre Galichon, Li Li, M. Todd Valerius, Joseph V. Bonventre. Brigham and 
Women’s Hospital/Harvard Medical School, Boston, MA.
Background: Energy depletion in renal tubular cells is a hallmark of acute kidney 
injury associated with cell death. NUPR1 (Nuclear protein 1, transcriptional regulator) 
promotes survival, increases ATP and inhibits proliferation in renal tubular cells. Although 
proliferation of tubular cells is necessary for kidney repair after resolution of injury, it 
could increase vulnerability in the context of ongoing injury. The effect of proliferation on 
energy in cells is unknown. We hypothesized that NUPR1 protects renal tubular cells from 
proliferation-induced energy exhaustion.
Methods: Stable renal proximal tubular cell lines were generated from HK-2 cells with 
inducible expression of NUPR1 (gain-of-function) or of CRISPR-dCas9-KRAB repression 
of NUPR1 (loss-of-function). The cells were transfected with the fluorescent biosensor 
PercevalHR to visualize the intracellular ATP/ADP ratio and with the intracellular pH 
sensor pHRed to adjust the ATP/ADP measures. The RatioPlus plugin from Fiji was used to 
measure ATP/ADP and pH from dual wavelength acquisitions of PercevalHR and pHRed, 
and the TrackMate plugin was used for monitoring single cell trajectories. The effect 
of tenovin-1 (p53 agonist for G1/S arrest), rigosertib (PLK1 inhibitor for G2/M arrest), 
pifithrin-α (p53 inhibitor for G1/S passage) and KU55933 (ATM kinase inhibitor for G2/M 
passage) on the ATP/ADP ratio was assessed.
Results: NUPR1 overexpression increased the ATP/ADP ratio in tubular cells. 
Conversely, NUPR1 inhibition decreased the ATP/ADP ratio. Modeling proliferative 
repair after injury by a scratch assay or facilitation of cell cycle passage by pifithrin-α  
or KU55933 decreased ATP/ADP ratio in migrating and proliferating cells. In contrast, 
inhibition of proliferation by either contact inhibition, tenovin-1 or rigosertib recapitulated 
NUPR1’s protective effect on ATP/ADP levels. Proliferating cells undergo cyclic variations 
of the ATP/ADP ratio, with a mitotic peak followed by a sudden drop of ATP/ADP ratio 
and a gradual recovery.
Conclusions: NUPR1 protects renal tubular cells from energy depletion caused by 
proliferation. Proliferation is associated with decreased energy, characterized by cyclic 
steep diminution of ATP/ADP ratio after mitosis. Delaying proliferation is a potential 
therapeutic goal to minimize damage during acute kidney injury and prevent maladaptive 
repair after injury.
Funding: NIDDK Support, Private Foundation Support
TH-OR007 Oral Abstract Thursday
AKI: New Players and New Mechanisms
C-Type Lectin Mincle Accelerates Renal Ischemia-Reperfusion Injury
Miyako Tanaka,1,2 Marie Saka-Tanaka,1,3 Naotake Tsuboi,3 Shoichi Maruyama,3 
Takayoshi Suganami.1,2 1Department of Molecular Medicine and Metabolism,
Research Institute of Environmental Medicine, Nagoya University, Nagoya,
Japan; 2Department of Immunometabolism, Nagoya University Graduate
School of Medicine, Nagoya, Japan; 3Department of Nephrology, Nagoya
University Graduate School of Medicine, Nagoya, Japan.
Background: Evidence has accumulated suggesting that pathogen sensors such as 
Toll-like receptors contribute to the pathogenesis of various non-infectious diseases. It 
is also known that Macrophage-inducible C-type lectin (Mincle), a pathogen sensor for 
Mycobacterium tuberculosis, can sense cell death, suggesting the role of Mincle in sterile 
inflammation. Indeed, we recently demonstrated that Mincle plays an important role in 
obesity-induced adipose tissue inflammation, thereby regulating systemic insulin resistance. 
In this study, we investigated the pathophysiologic role of Mincle in a mouse model of acute 
kidney injury.
Methods: Eight to eleven week-old male Mincle-deficient mice or wildtype mice were 
subjected to ischemia-reperfusion injury. After 30 minutes of ischemic period, the clamp 
of left kidney was released to induce reperfusion. The right side of kidney was resected at 
this time point.
Results: There was a marked upregulation of Mincle mRNA in the injured kidney from 
6 hours after the reperfusion. Histological and flow cytometric analysis revealed that most 
of the Mincle-expressing cells were proinflammatory M1 macrophages infiltrating toward 
the damaged tubules. All of the Mincle-deficient mice were alive during the experimental 
period, while about half of wildtype mice died due to renal failure. Consistently, serum 
concentrations of BUN and creatinine along with mRNA expression of proinflammatory 
cytokines were significantly ameliorated in the kidney of Mincle-deficient mice compared 
to wildtype mice. Moreover, wildtype mice were protected against ischemia-reperfusion 
injury when they received bone marrow transplantation from Mincle-deficient mice.
Conclusions: This study indicates that Mincle in macrophages plays an important 
role in the pathogenesis of acute kidney injury. Our data also suggest that Mincle senses 
damaged tubular epithelial cells to accelerate inflammation.
Funding: Government Support - Non-U.S.
TH-OR008 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Novel Liposomal Nanocarriers of Preassembled Glycocalyx Restore Renal 
Microcirculation in Sepsis
Michael S. Goligorsky, Dong Sun. New York Medical College, Valhalla, NY.
Background: Endothelial cell dysfunction is a weighty contributor to the pathogenesis 
of sepsis. Endothelial glycocalyx (EG) is a guardian of endothelial functions, but during the 
course of sepsis its integrity is compromised. We observed that mice with the polymicrobial 
sepsis exhibit a drastic reduction in the global volume of EG. The loss of EG leads to 
leukocyte infiltration, impaired microvascular circulation, increased vascular permeability, 
thrombogenesis, and circulatory collapse, eventuating in the development of multiorgan 
dysfunction. Therapeutic attempts to prevent EG loss showed success, however, clinically 
more important restorative therapies of EG have been unsuccessful.
Methods: We have recently invented liposomal nanocarriers of preassembled EG 
(LNPEG) to expeditiously restore EG and halt vascular complications of sepsis. We used 
atomic force microscopy, DAF-based NO detection, flow-induced vasodilation and in vivo 
LPS Laser-Doppler studies.
Results: In vitro testing of LNPEG using atomic force microscopy of cultured endothelial 
cells showed that they increased thickness of EG and restored mechanoactivation-induced 
NO production, both severely affected by exposure to LPS. Ex vivo perfused isolated 
arterioles with degraded EG obtained from LPS-injected mice showed subnormal flow-
induced dilation and exhibited increased vascular permeability, whereas perfusion of these 
vessels with LNPEG restored both and increased flow-induced NO production. In LPS mice, 
AKI: New Players and New Mechanisms
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
3
J Am Soc Nephrol 29: 2018 Oral Abstract/Thursday
infusion of LNPEG either systemically or into the renal artery significantly improved renal 
microcirculation (laser-Doppler imaging and flowmetry). Electron microscopy of kidneys 
localized LNPEG to be tethered to or embedded into the plasma membrane of glomerular 
and peritubular capillary endothelial cells. Immunostaining of EG showed its significant 
restoration after administration of LNPEG.
Conclusions: In conclusion, this is the first demonstration that our invented LNPEG 
are functionally capable of expeditiously restoring EG and halting vascular complications 
of sepsis. In summary, wepropose that the early loss of EG facilitates multiorgan failure in 
sepsis, and treatment with LNPEG has a potential to alleviate it.
TH-OR009 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Human Recombinant Alkaline Phosphatase (recAP) Protection from 
Kidney Ischemia-Reperfusion Injury (IRI) Is Mediated by Dephosphory-
lation of ATP to Adenosine and Activation of Adenosine A2a Receptors
Diane L. Rosin,5 James P. Hall,3 Andrea G. Bree,3 Shuqiu Zheng,1 
Iain M. Encarnacion,1 Andrea van Elsas,4 Bruce A. Molitoris,2 Mark D. Okusa.1 
1Division of Nephrology and Center for Immunity, Inflammation and Regenerative 
Medicine, University of Virginia School of Medicine, Charlottesville, VA; 
2Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN; 
3Inflammation & Immunology Research Unit, Pfizer Inc., Cambridge, MA; 
4AM-Pharma B.V., Bunnik, Netherlands; 5Department of Pharmacology, 
University of Virginia School of Medicine, Charlottesville, VA.
Background: Acute kidney injury (AKI) results in high mortality (up to 50%), and 
surviving patients are at risk for progressive chronic kidney disease (CKD). ATP released 
from dying cells acts as a potent pro-inflammatory ‘danger’ signal. Alkaline phosphatase 
(AP), a common endogenous enzyme that de-phosphorylates ATP, appears to play a 
significant anti-inflammatory role in host defense and innate immunity. Human recombinant 
AP (recAP) is currently in Phase 2 clinical trials for treatment of sepsis-associated AKI. We 
hypothesized that recAP protects kidneys from IRI by metabolizing released extracellular 
ATP to adenosine, producing anti-inflammatory effects through activation of adenosine A2a 
receptors (A2aR).
Methods: RecAP (500-2000 U/kg, iv) ± ZM-241,385 (ZM, 20, 200 mg/kg, sc)
(adenosine A2a receptor antagonist) were administered 1h before renal ischemia in mice 
and at times after ischemia in rats; kidney injury in mice was evaluated at 24h.
Results: RecAP dose-dependently decreased kidney injury in WT mice after 
26 min ischemia; the 80% decrease in plasma creatinine with 2000 U recAP/kg was 
prevented completely by co-administration with ZM (20 mg/kg). Enzymatically inactive 
(mutant) recAP was not protective, suggesting that ATP dephosphorylation is necessary 
for protection. RecAP also protected CD73-/- mice, which lack a 5’ ectonucleotidase 
that de-phosphorylates AMP to adenosine and are more sensitive to IRI than WT mice 
(22 min ischemia); this beneficial effect of recAP in CD73-/- mice (34% of control) was 
partially blocked by 200 mg/kg ZM (86% of control). In rats recAP ameliorated IRI when 
administered after initiation of acute injury, an effect reversed by ZM, thus providing 
relevance for therapeutic dosing of recAP clinically. In a CKD ischemic rat model, recAP 
given after the 3rd instance of IRI also significantly reduced renal injury (61% reduction).
Conclusions: These results strongly suggest that during renal IRI recAP promotes 
production of adenosine from liberated ATP in injured kidney tissue, thereby amplifying 
endogenous mechanisms that can reverse tissue injury, in part through A2aR-dependent 
anti-inflammatory signaling pathways.
Funding: Commercial Support - Pfizer Inc./AM-Pharma B.V.
TH-OR010 Oral Abstract Thursday
AKI: New Players and New Mechanisms
Inactivation of Mtorc1 in Proximal Tubular Epithelial Cells Reduces 
KIM-1-Mediated Kidney Fibrosis and Inflammation in Mice
Wenqing Yin,1 Craig R. Brooks,2 M. Todd Valerius,3 Joseph V. Bonventre.1 
1Brigham and Women’s Hospital, Boston, MA; 2Vanderbilt University Medical 
Center/Division of Nephrology & Hpertension, Nashville, TN; 3Brigham and 
Women’s Hospital, Boston, MA.
Background: Acute kidney injury (AKI) predisposes patients to progressive chronic 
kidney disease (CKD). Previously we reported that persistent expression, beginning 
prenatally, of kidney injury molecule-1 (KIM-1) in tubule epithelial cells of the nephron 
causes murine kidney fibrosis through a mechanism involving mTOR. Since prenatal 
activation of KIM-1 in this system also decreases nephron number, we tested the hypothesis 
that postnatal activation of KIM-1 expression specifically in proximal tubular cells (PTCs) 
would lead to fibrosis independent of any potential effect on kidney development, and 
evaluated the role of mTOR in this context.
Methods: We created proximal tubular cell specific KIM-1 overexpression 
transgenic mice by treating Slc34a1CreERT2/+;CAG-Z/Kim1-APtg/+ (KIM-1PTCtg) mice 
with tamoxifen beginning at 4 weeks of age to express KIM-1 in proximal tubules in a 
postnatal, post kidney development, context. The resulting KIM-1PTCtg mice (and non-
KIM-1 overexpression controls) were subjected to bilateral renal ischemia-reperfusion 
injury (IRI) for 26 minutes, or sham surgery, at 3 months of age and then evaluated at 
3 or 6 months later for kidney fibrosis. We also created KIM-1PTCtg/RaptorPTCko mice, where 
mTORC1 is deleted at 4 weeks of age in KIM-1 overexpressing PTCs, using the same 
tamoxifen-inducible promoter, and these animals were then evaluated for kidney fibrosis 
with or without bilateral IRI.
Results: With tamoxifen-induced postnatal KIM-1 overexpression in proximal tubular 
cells, KIM-1PTCtg mice developed fibrosis with progressive renal insufficiency at 6 months 
of age. Bilateral IRI in KIM-1PTCtg mice at 3 months of age caused maladaptive repair and 
a persistence of renal insufficiency post injury, leading to progressive kidney fibrosis and 
renal failure with an earlier onset (5 months of age) than sham controls. In contrast, KIM-
1PTCtg/RaptorPTCko mice subjected to bilateral IRI had less kidney fibrosis and a reduced 
inflammatory response, demonstrating a role for mTOR in the fibrotic response.
Conclusions: Persistent expression of KIM-1 may play an important role on the link 
between AKI and progressive CKD. mTORC1 is a potential therapeutic target in KIM-1-
mediated kidney injury and fibrosis in mice.
Funding: NIDDK Support, Other U.S. Government Support
TH-OR011 Oral Abstract Thursday
CKD: Mechanisms of Kidney Fibrosis
The Hyaluronan Synthase-1 Isoenzyme Promotes Differentiation to a 
Distinct Subset of Myofibroblasts That Limit Fibrosis Progression
Aled P. Williams,3,1 Adam C. Midgley,2,1 Charlotte V. Brown,3,1 Talea H. Roberts,3,1 
Nathanael G. Morris,3,1 Robert Steadman,3,1 Aled O. Phillips,3,1 Soma Meran.3,1 
1Cardiff University, Llanelli, United Kingdom; 2Nankai University, Tianjin, 
China; 3Wales Kidney Research Unit, Cardiff, United Kingdom.
Background: Renal interstitial fibrosis is a key determinant of CKD progression, and 
increased synthesis of the glycosaminoglycan, Hyaluronan (HA), in renal tissue correlates 
with fibrosis and renal outcomes. Factors that regulate HA synthesis therefore influence 
CKD progression. HA is synthesized by three HA Synthase enzymes (HAS1, HAS2 and 
HAS3). Our work has specifically shown that increased HAS2 expression is causally 
linked with fibrosis in vivo and is a critical mediator of pro-fibrotic cell phenotype in 
vitro. Furthermore, the anti-fibrotic growth factor BMP7 (Bone Morphogenetic Protein-7) 
prevents/reverses pro-fibrotic cell phenotype and renal fibrosis in murine models. Recent 
data shows BMP7 significantly increases HAS1 expression, indicating a possible protective 
role for this enzyme in fibrosis
Methods: Studies were performed on human proximal tubular epithelial cells our 
established library of scarring versus non-scarring primary fibroblasts. Genetic and 
histological analysis of kidneys from HAS1, HAS3 and HAS1/3 double knockout mice and 
Ischaemia Reperfusion Injury (IRI) -induced renal fibrosis were used
Results: In response to TGF-β1, cells primarily expressing the HAS2 isoenzyme 
assembled large pericellular HA coats tethered to the principal HA receptor CD44-standard. 
The cells were significantly α-smooth muscle actin (αSMA) positive and had a contractile 
phenotype. TGF-β1 stimulation in HAS1 isoenzyme expressing cells had negligible HA 
pericellular coats and enhanced cell-surface expression of the CD44 variant isoform, 
CD44v7/8. These cells had a limited contractile response, were pro-migratory, with low 
αSMA expression and laid down different matrix. Mice with IRI have elevated levels of 
both HAS1 and HAS2 in acute early injury, and HAS2 in late injury; whilst kidneys from 
HAS1/3 DKO mice were predisposed to pro-fibrotic renal injury
Conclusions: Different HAS isoenzymes have distinct and likely conflicting roles 
in response to pro-fibrotic stimuli. Whilst HAS2 promotes a pro-fibrotic contractile cell 
phenotype associated with tissue fibrosis, HAS1 appears to limit pro-fibrotic phenotypes 
and promotes a distinct subset of myofibroblasts that are pro-migratory and may be involved 
in reparative processes that limits fibrotic injury
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PINK1-MFN2-Parkin-Mediated Mitophagy Dependent Macrophage 
Reprogramming Protects against Renal Fibrosis
Divya Bhatia,1 Kuei-Pin Chung,1,2 Thangamani Muthukumar,1 
Augustine M. Choi,1 Mary E. Choi.1 1Weill Cornell Medicine, New York City, 
NY; 2National Taiwan University Hospital, Tapei, Taiwan.
Background: Mitophagy, by maintaining mitochondrial quality, plays critical role 
for normal kidney function. Kidney injury-induced mitochondrial oxidative stress triggers 
proinflammatory cytokine production by M1 macrophages and their reprogramming 
towards profibrotic/M2 phenotype. We investigated the role of mitophagy regulatory 
proteins: PTEN-induced kinase1 (PINK1), Mitofusin 2 (MFN2) and Parkin in macrophage 
reprogramming during renal fibrosis.
Methods: Renal fibrosis in wild type, PINK1 and Parkin knockout (KO) mice was 
induced by unilateral ureteral obstruction (UUO) (7-days) or adenine diet (14-days). 
Renal macrophages from mice and human kidneys were isolated by magnetic beads. Flow 
cytometry (F4/80, CD11b, Ly6c, CCR1, CX3CR1) and western blots (iNOS, arginase I, 
mannose receptor-1, fibronectin, rictor, TGFβ1, TGFβR1) were performed to determine 
macrophage phenotypes and fibrotic response. MitoTracker & MitoSox dyes were used to 
access mitochondrial membrane potential (MMP) and reactive-oxygen species (mROS). 
Mitophagy was suppressed by transfection of PINK1-siRNA/Mdivi1 or induced by FCCP 
treatment.
Results: Obstructed kidneys from PINK1/Parkin KO mice displayed higher expression 
of FN, MR-1, TGFβ1, TGFβRI & CD45+ mononuclear cells. Renal macrophages from 
obstructed kidneys of KO mice showed amplified fibrotic response. TGFβ1-treated BMDM 
from the KO mice displayed greater levels of mROS, rictor, Arg I but not iNOS expressing 
M1 macrophages. PINK1-knockdown THP-1 human macrophages showed lower 
phosphorylation at MFN2. Mitochondria from FCCP treated MFN2-KO macrophages 
showed reduced expression of Parkin and lower MMP. Inhibition of mitophagy in human 
primary renal macrophages resulted in: i) elevated expression of FN, MR-1, TGFβ1 & 
CX3CR1, ii) reduced MMP & iii) enhanced mROS production. Human fibrotic kidney 
showed higher relative mRNA expression of MRC1 (P=0.002), TGFβ1 (P=0.03) and a 
trend of decrease in Parkin (P=0.07) expression than control kidney.
Conclusions: UUO and adenine diet-induced oxidative stress and renal fibrosis were 
exaggerated in absence of mitophagy. Deficiency of PINK1 in macrophages resulted in 
decreased phosphorylation of MFN2, suppressed recruitment of Parkin to mitochondria and 
rictor-mediated reprogramming of macrophages towards M2/profibrotic phenotype.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Loss of Transcription Factor A (Mitochondrial, Tfam) in Tubule Cells 
Causes Renal Failure by Linking Metabolic Insufficiency to Enhanced 
Inflammation
Kiwung Chung, Shizheng Huang, Rojesh Shrestha, Chengxiang Qiu, 
Jihwan Park, Katalin Susztak. University of Pennsylvania, Philadelphia, PA.
Background: Renal tubule cells have one of the highest mitochondrial density to keep 
up with their high energy need. Loss and dysfunction of mitochondria has been proposed 
to play key role in kidney disease development. On the other hand, the key transcriptional 
regulator that maintains mitochondrial integrity in renal tubule cells of healthy kidneys have 
not been defined.
Methods: To investigate the role of Tfam on renal tubule epithelial cells (TECs), we 
generated and characterized tubule specific Tfam (Transcription Factor A, mitochondrial) 
knock-out mice (Ksp cre/Tfam flox/flox). To perform in vitro mechanism studies, we 
cultured primary TECs from wild-type and WT/Tfam flox/flox mice and infected them with 
Ad5CMVCre adenovirus to delete Tfam.
Results: Tfam deficient mice were viable at birth but they died by 12 weeks of 
age. Blood chemistry indicated significant renal damage and azotemia. Structurally, the 
kidneys were enlarged, the tubules were dilated. There was an increase in inflammatory 
cells and matrix accumulation. Renal epithelial cells showed abnormally enlarged 
mitochondria and structural defect. Mitochondrial oxidative phosphorylation associated 
proteins were decreased with mild lipid accumulation. Mechanistic studies, using primary 
cultured tubule epithelial cells demonstrated that aberrant mtDNA packaging upon 
Tfam deficiency results in an escape of mtDNA into the cytosol. These events induced 
the activation of cytosolic DNA sensing pathway such as Stimulator of interferon genes 
(STING)-Cyclic GMP-AMP synthase (cGAS), and downstream NF-κB activation. The 
NF-κB activation was also evident in kidneys of the knock-out mice. Blunting of the 
NF-κB activation, reduced inflammatory gene expression, proliferation of tubule cells and 
protected from cellular dedifferentiation.
Conclusions: Collectively, we show Tfam maintains mitochondrial integrity and 
cellular metabolism at baseline. Loss of Tfam results in NF-κB activation linking metabolic 
signals to inflammation.
Funding: NIDDK Support
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Novel Rho-Associated Coiled Kinase 2 Inhibitor (ANG4201) Reduces 
Renal Fibrosis and Improves Kidney Function in Subtotal Nephrectomy 
Mice Model
Quaisar Ali,1 Dibyendu Dana,1 Prakash Narayan,2 An-Hu Li,1 
Satishkumar V. Gadhiya,1 Jingsong Li,1 Dong sung Lim,1 Dawoon Jung,1 
Latha Paka,2 Michael A. Yamin,1 Itzhak D. Goldberg.1 1Angion Biomedica 
Corp., Uniondale, NY; 2Angion Biomedica Corp, Uniondale, NY.
Background: Rho associated coiled kinase 1 (ROCK1) and 2 (ROCK2) are implicated 
in variety of cellular processes including organ fibrosis. Earlier we demonstrated that kidney 
ROCK2 and not ROCK1 is upregulated in animal models of renal fibrosis. The present 
study was done to investigate if inhibiting ROCK2 reduces renal fibrosis and improves 
kidney function.
Methods: Using core hopping and structure based drug design approach, we 
synthesized highly selective (>200 fold for ROCK2 vs ROCK1), orally bioavailable 
ROCK2 inhibitor (ANG4201). We evaluated the antifibrotic effects of ANG4201 in subtotal 
nephrectomy (Nx) mice model. Adult male SV129 mice were subjected to Nx, wherein 
poles of one kidney were ablated and contralateral kidneys were removed after two weeks. 
The Nx were then randomized to vehicle or ANG4201 (20 mg/Kg, PO, BID) and treated 
for 8 weeks. A week prior to sacrifice, GFR was measured by using FITC-Inulin clearance 
method. Blood pressure was measured by direct cannulation of the carotid artery. Kidney 
tissues were analyzed for fibrotic, molecular and inflammatory markers.
Results: Compared to control, Nx mic exhibited increase in both renal ROCK2 
expression and phosphorylation of myosin phosphatase, a downstream marker of ROCK2 
activity. Treating Nx mice with ANG4201 blocked the upregulation of these proteins. The 
increase in ROCK2 activity correlated with increase in renal fibrosis characterized by 
increase in kidney hydroxyproline and α-SMA expression. Nx mice also had elevated blood 
pressure (MAP; ~165 mm Hg). Intervention with ANG4201 did not affect blood pressure 
but attenuated hydroxyproline and α-SMA expression which were confirmed with Mason’s 
trichrome and Picrosirius red staining. The reduction in fibrosis was associated with 
significant improvement in GFR by ~38%, measured by FITC-Inulin clearance method. 
Urinary EGF, marker of renal function loss was found to be elevated in Nx and subsequently 
reduced with ANG4201 treatment.
Conclusions: This study demonstrates that ROCK2 upregulation contributes to renal 
fibrosis and renal functional loss in subtotal nephrectomy mice model. ANG4201 is highly 
promising orally bioavailable therapeutic ROCK2 inhibitor with potential use in chronic 
kidney disease.
Funding: NIDDK Support
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Inhibition of Tubulointerstitial Fibrosis by Targeting the p70 Ribosomal 
Protein S6 Kinase 1
Ting Liu, Jinxian Xu, Caihong Dai, Jian-Kang Chen. Medical College of 
Georgia at Augusta University, Augusta, GA.
Background: Tubulointerstitial fibrosis strongly correlates with the decline of 
renal function in chronic kidney disease (CKD), regardless of the primary etiology. 
Tubulointerstitial fibrosis is the major characteristic of the patients with aristolochic acid 
(AA) nephropathy, which is caused by the ingestion of herbs containing AA. Studies 
using rapamycin suggested that activation of the target of rapamycin (mTOR) might be 
causally linked to renal fibrosis, but mTOR knockout caused embryonic lethality; mTOR 
has multiple downstream effectors, including the p70 S6 kinase 1 (S6K1). Here we report 
the effect of S6K1 knockout on renal fibrosis.
Methods: Induction of tubulointerstitial fibrosis was accomplished by aristolochic acid 
I (AAI, given at a dose of 3 mg/kg body weight by daily I.P. for 3 consecutive days) or 
unilateral urethra obstruction (UUO) in wild type and S6K1 knockout mice. Renal lesions, 
kidney function and mTOR-S6K1 signaling activities were evaluated.
Results: AAI caused a marked increase of kidney injury molecule 1 (KIM-1) and 
necrosis of proximal tubular epithelial cells. In addition, we observed that the S2 segment 
of renal proximal tubule is more susceptible to injury than the S1 and S3 segments 
of proximal tubule in response to AAI treatment. These lesions resulted in a significant 
decrease in renal function (indicated by elevated serum creatinine and BUN levels) within 
3 days, peaked by day 7. AAI treatment or UUO induced massive tubulointerstitial fibrosis 
within 2-4 weeks, revealed by a marked reduction of renal tubules, proliferation of a-smooth 
muscle actin-positive cells, Masson trichrome stains, and deposition of extracellular matrix 
proteins including fibronectin and fibroblast-specific protein 1 (FSP1). Interestingly, 
mechanistic studies revealed marked activation of S6K1 and ribosomal protein S6 (rpS6) 
phosphorylation in the kidney in response to either AAI or UUO. Importantly, mice with 
global (whole animal) homozygous S6K1 knockout were viable and protected from 
tubulointerstitial fibrosis.
Conclusions: The present study provides the first unequivocal evidence that activation 
of S6K1 plays an important pathogenic role during the development of tubulointerstitial 
fibrosis. Thus, specifically targeting S6K1 may represent a viable strategy for the prevention 
and treatment of renal fibrosis.
Funding: NIDDK Support
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CD47 Blockade Modulates Fibrosis in Chronic Kidney Injury
Natasha M. Rogers,1,2 Barkha Sanganeria.1 1Westmead Institute for Medical 
Research, Westmead, NSW, Australia; 2Renal Unit, Westmead Hospital, Sydney, 
NSW, Australia.
Background: Acute kidney injury triggers a complex cascade of cellular esponses that 
can culminate in maladaptive repair and fibrosis. The matrix protein thrombospondin-1 
(TSP1) is known to activate latent TGF-beta, a crucial mediator of fibrosis. We have 
previously reported that the TSP1 and its receptor CD47 are are induced following kidney 
injury. However, the role of this axis has not been characterized in chronic kidney disease.
Methods: Age and gender-matched wild-type (WT), CD47-/- and WT mice treated 
with CD47 blocking antibody (WT+αCD47Ab) were compared in two chronic kidney 
injury models: ischemia-reperfusion injury and contralateral nephrectomy (RN), and 
unilateral ureteric obstruction (UUO). All animals underwent analysis of renal function and 
biomolecular phenotyping. Human and murine WT and CD47-/- renal tubular epithelial cells 
(rTEC) were studied in vitro.
Results: WT, WT + CD47Ab, and CD47-/- RN mice showed no difference in serum 
creatinine at 4 weeks regardless of injury model, however there was clear amelioration of 
renal histological changes and fibrosis with blockade or global knockout of CD47, defined 
by light microscopy and Sirius red staining. WT RN mice showed upregulated mRNA and 
protein expression of TSP-1 and pro-fibrotic markers TGF-ß, SMAD2, α-smooth muscle 
actin (SMA), fibronectin and type I collagen. These markers were significantly abrogated 
in both CD47-/- and WT + αCD47Ab counterparts. Interestingly, both WT and CD47-/- 
UUO mice at day+7 showed equivalent increases in pro-fibrotic tendency, by histology 
and qPCR, regardless of overall TSP1 expression. Only treatment with αCD47Ab reduced 
markers of matrix protein deposition. Renal tubular epithelial cells isolated from WT mice 
showed robust upregulation of TSP1 and elaborated pro-fibrotic markers under hypoxic 
stress, which was mitigated in CD47-/- cells. Incubation of rTEC with exogenous TSP1 
demonstrated epithelia-to-mesenchyme transition with increased expression of TGF-ß and 
α-SMA. Immunohistochemistry of human kidney biopsy samples showed upregulated 
tubular TSP1 expression in stages 3-4 CKD (eGFR 15-59ml/min), and concurrently raised 
plasma TSP1 levels (8-10 fold) when compared to control samples (eGFR>60ml/min).
Conclusions: These data suggest that renal tubular epithelial cells contribute to 
fibrosis by activating TSP1-CD47 signalling, and point to CD47 as a target to limit fibrosis 
following some types of renal injury.
Funding: Government Support - Non-U.S.
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Klotho Overexpression Improves Interstitial Fibrosis, Accumulation of 
Cell Cycle Arrested Cells, and Increased Levels of Oxidative Stress in the 
Kidneys of Aging Mice
Hiroaki Ohishi, Shigehiro Doi, Ayumu Nakashima, Takao Masaki. Department 
of Nephrology Hiroshima University Hospital, Hiroshima, Japan.
Background: Klotho is reported to suppress growth factor signaling by transforming 
growth factor (TGF)-β1, insulin-like growth factor (IGF)-1, and Wnt. Notably, previous 
studies have reported that renal function decreases with age, and that interstitial fibrosis, 
accumulation of cell cycle arrested cells, and increased levels of oxidative stress are major 
features of the aging kidney. In this study, we investigated whether klotho overexpression 
improves these factors in the kidneys of aging mice together with the expression of growth 
factor signaling molecules.
Methods: Male mice that overexpress klotho under the control of the human 
elongation factor 1 promoter EFmKL46 (KLTG) or wild type 129 mice (WT) were used. 
Mice at 2 and 24 months old were defined as young mice and aging mice, respectively. 
Expression of klotho, fibrotic markers (α-smooth muscle actin, vimentin, collagen I, 
collagen III), cell cycle markers (p16, p21, p53, proliferating cell nuclear antigen), and 
oxidative stress markers (8-hydroxy-2′-deoxyguanosine, manganese superoxide dismutase, 
catalase, 3-nitroturosine) were examined using immunohistochemistry, western blotting, 
and/or quantitative PCR. We also investigated the expression of TGF-β1 (Smad2/3/4), 
IGF-1 (c-Jun N-terminal kinase, extracellular signal-regulated kinase, p38, protein kinase B, 
forkhead box protein O1), and Wnt (β-catenin, RAS-related C3 botulinus toxin substrate 1) 
signaling molecules.
Results: Klotho expression decreased in aging WT mice, whereas it was maintained in 
aging KLTG mice. Although expression of fibrotic markers did not differ between young 
KLTG and WT mice, they were significantly suppressed in aging KLTG mice compared 
with aging WT mice. Similarly, aging KLTG mice demonstrated significantly less 
expression of cell cycle arrest markers, as well as oxidative stress markers, than aging WT 
mice. Furthermore, expression of TGF-β1, IGF-1, and Wnt signaling molecules increased 
in aging WT mice; however, this upregulation was not observed in aging KLTG mice.
Conclusions: Klotho overexpression protects against kidney aging that is characterized 
by interstitial fibrosis, accumulation of cell cycle arrested cells, and increased levels of 
oxidative stress in mice, which is accompanied by suppression of signaling for multiple 
growth factors.
Funding: Commercial Support - Astellas, Novartis, Kyowa Kirin, Daiichi Sankyo, 
Shionogi, Private Foundation Support
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Twist1 in Macrophages Attenuates Kidney Fibrosis after Ureteral 
Obstruction
Jiafa Ren,1 Xiaohan Lu,1 Yi Wen,2 Jamie Privratsky,3 Steven D. Crowley.3 1Duke 
University, Durham, NC; 2Southeast University, Nanjing, China; 3Duke 
University Medical Center, Durham, NC.
Background: Macrophages play a critical role in directing kidney fibrogenesis. The 
transcription factor Twist1 limits pro-fibrotic cytokine production in macrophages, and we 
have recently found that activating type 1 angiotensin receptors in macrophages induces 
Twist1 but paradoxically attenuates renal fibrosis. To directly test the role of macrophage 
Twist1 in kidney scar formation, we subjected mice with macrophage-specific deletion 
(“MKO”) of Twist1 and controls (“WT”) to the unilateral ureteral obstruction model.
Methods: C57BL/6 mice with a floxed allele for the gene encoding Twist1 were bred 
with LysM-Cre mice to yield Twist1 MKO mice with robust but selective deletion of Twist1 
in macrophages (>80% vs. WTs; p < 0.0001). Twist1 MKO and WT littermate controls 
underwent unilateral ureteral ligation with assessment of kidney fibrosis and macrophage 
phenotype at 14 days.
Results: 2 weeks after UUO, Twist1 MKO mice developed more kidney fibrosis 
compared to WTs as quantitated by western blots for collagen I (1.5 ± 0.1 vs 1.00 ± 0.1 au; 
p = 0.01) and α-SMA (1.5 ± 0.15 vs 1.00 ± 0.12 au; p = 0.01) and hydroxyproline assay 
(10.7 ± 0.8 vs 8.2 ± 0.6 mg/10mg; p = 0.02). As certain MMPs may limit renal fibrosis by 
degrading extracellular matrix, we profiled kidney MMP expression after UUO and found 
that the obstructed Twist1 MKO kidneys compared to WTs had blunted mRNA levels for 
MMP11 (0.65 ± 0. 05 vs 1.00 ± 0.13; p = 0.03) and MMP13 (0.38 ± 0.11 vs 1.00 ± 0.20; 
p = 0.03) but preserved expressions of MMP2 and 7 (0.90 ± 0.14 vs 1.1 ± 0.15; p = 0.78 
and 0.84 ± 0.30 vs 1.0 ± 0.19; p = 0.66, respectively). Other gene expression patterns in 
the Twist1 MKO kidneys consistent with macrophage-driven fibrosis were blunted Arg-1 
levels (0.14 ± 0.06 vs 1.00 ± 0.30; p = 0.05) and upregulation of Fizz1 (2.35 ± 0.69 vs 
1.0 ± 0.19; p = 0.03). We therefore used flow cytometry to detect enhanced accumulation of 
CD11b+Ly6Chi infiltrating monocytes in the obstructed Twist1 MKO kidneys vs WTs (271 
± 41 vs 169 ± 17 cells/mg kidney; p = 0.049). Consistent with a role for Twist1 to suppress 
inflammatory cytokines in myeloid cells, LPS-stimulated peritoneal macrophages from the 
Twist1 MKO cohort had upregulated IFN-γmRNA compared to WTs (5.9 ± 0.3 vs 1.0 ± 
0.2 au; p < 0.001).
Conclusions: Twist1 suppresses myeloid cell-dependent fibrosis in the kidney, possibly 
through effects on matrix degradation.
Funding: NIDDK Support, Veterans Affairs Support
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Smad Anchor for Receptor Activation (SARA) Prevents Pericyte 
Activation and Protects Kidney from Fibrosis
Xiaoyan Liang,1 H. William Schnaper,1 Benjamin D. Humphreys,2 
Tomoko Hayashida.1 1Northwestern University, Chicago, Illinois; 2Washington 
University School of Medicine, Clayton, Missouri.
Background: Pericytes are a major source of fibrogenic cells in injured kidneys. We 
previously reported that decreasing SARA expression drives cultured proximal tubular 
epithelial cell dedifferentiation to a pro-fibrotic phenotype, and last year at ASN showed 
that pericyte-specific overexpression of SARA prevents interstitial fibrosis induced by 
aristolochic acid (AA) in mice. Here, we characterize the actions of SARA in pericytes.
Methods: Conditional human SARA-overexpressing mice were bred with PDGFRβ-
Cre mice to drive pericyte SARA expression. The offspring were further bred with Z/
EGFP or COL1A1-GFP mice to mark cells where Cre or type I collagen transcription is 
active, respectively. Mice were given AA (2.5 mg/kg, i.p., 3x week, for 3 weeks), then 
sacrificed after 3 more weeks. Harvested kidneys were enzymatically digested and sorted 
for GFP+ cells to obtain pericytes that were analyzed by flow cytometry and qPCR. A 
pericyte line (Gli1+-iPeri) was isolated from a Gli1+ tdTomato Immortomouse.
Results: As anticipated, native SARA mRNA expression was 62% decreased after AA 
treatment in GFP+ cells isolated from both phenotypically wild-type (SARAWT; PDGFRβ-
Cre+; Z/EGFP) and SARA-overexpressing (SARATg; PDGFRβ-Cre+; Z/EGFP) mice. 
Transgene-derived SARA was detected even after AA, only in SARATg mice. SARAWt 
mice showed significant expansion of the renal interstitial, GFP+ pericyte population after 
AA treatment, but this did not occur in mice with SARA-overexpression in pericytes. 
GFP+ cells isolated from wild-type mice without AA were NG2+, CD90.1-, confirming 
their pericyte origin. AA treatment induced 45% of the wild-type GFP+ cells to become 
CD90.1+, suggesting pericyte fibroblastic transition. This shift was not observed in GFP+ 
cells isolated from AA-treated, SARA-overexpressing mice. COL1A1 mRNA expression 
was incrased by 10 fold in GFP+ cells from SARAWt but not SARATg littermates. The 
Gli1+-iPeri cell line expressed very little SARA in culture and strongly expressed αSMA. 
However, transfection with SARA significantly reduced TGF-β1-induced αSMA and 
COL1A2 promoter activity, suggesting that re-introduction of SARA at least partially 
reverses the fibrotic nature of Gli1+-iPeri cells.
Conclusions: These data suggest that SARA expression in pericytes suppresses their 
activation to produce extracellular matrix.
Funding: NIDDK Support
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Anti-dsDNA Antibodies Bind to Ku70 in Proximal Renal Tubular 
Epithelial Cells and Increased Matrix Protein and Cytokine Secretion
Daniel Tak Mao Chan, Shirli S. Ho, Chi pang Tai, Caleb C. Chan, Wai-
Ming Cheng, Mel Chau, Susan Yung. The University of Hong Kong, Hong 
Kong, China.
Background: Anti-dsDNA antibodies can lead to immune-mediated kidney injury 
through complement activation or trigger downstream pro-inflammatory or fibrotic 
responses after cellular binding. Immune deposition along tubular basement membrane is 
commonly observed. We investigated the binding of anti-dsDNA antibodies to proximal 
renal tubular epithelial cells (PTEC).
Methods: Human polyclonal anti-dsDNA antibodies were isolated from the sera of 
lupus nephritis patients using affinity chromatography and samples demonstrating high 
binding affinity to PTEC were studied. Cultured PTEC were incubated with serum-free 
medium, control IgG, or anti-dsDNA antibodies for up to 48h. PTEC plasma membrane 
proteins were isolated and immuno-precipitated with anti-dsDNA antibodies to identify 
cross-reactive antigens using LC-MS/MS. The role of Ku70 in inflammatory and fibrotic 
processes was investigated by gene silencing with RNAi.
Results: The 70 kDa on PTEC cell membrane that bound anti-dsDNA antibodies was 
identified as Ku70 by LC-MS/MS. Exogenous DNA, histones, or nucleosomes did not 
affect its binding by anti-dsDNA antibodies. Anti-dsDNA antibodies binding to Ku70 was 
accompanied by increased fibronectin and laminin expression, and increased MCP-1 and 
IL-6 secretion (P<0.05, for all). Ku70 gene silencing with ninety percent efficacy resulted 
in reduced PTEC binding by anti-dsDNA antibodies as shown by immunohistochemistry. 
Ku70 knockdown significantly decreased the expression of fibronectin, laminin, and Bax, 
and and also the secretion of MCP-1 and IL-6, induced by TGF-β1, MCP-1, IL-1β, and 
IL-6 (P<0.05, for all). Kidney specimens from lupus nephritis patients and NZB/W F1 
mice showed markedly increased Ku70 expression in the proximal tubules.
Conclusions: Our data shows that Ku70 mediates the binding of anti-dsDNA 
antibodies to PTEC, which is accompanied by downstream pro-inflammatory and pro-
fibrotic cellular responses.
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FGF23 and Falls in SPRINT
Anna J. Jovanovich,1,2 Charles Ginsberg,3 Zhiying You,4 Alfred K. Cheung,5 
Michel Chonchol,2 Michael Shlipak,6 Joachim H. Ix.3 1Denver VA, Denver, CO; 
2University of Colorado, Aurora, CO; 3UCSD, San Diego, CA; 4UC Denver, 
Aurora, CO; 5University of Utah, Salt Lake City, UT; 6San Francisco VA 
Medical Center, San Francisco, CA.
Background: Fibroblast growth factor 23 (FGF23) is elevated in chronic kidney 
disease and associated with kidney disease progression and increased mortality. There are 
little data on circulating FGF23 levels and falls despite the fact that FGF23 is derived from 
bone and regulates phosphorus and 1,25-dihydroxyvitamin D. The purpose of this analysis 
was to evaluate the relationship between intact FGF23 (iFGF23) and falls in the Systolic 
Blood Pressure Interventional Trial (SPRINT).
Methods: SPRINT was a randomized multicenter trial evaluating the effects of 
standard (SBP <140 mmHg) vs. intensive (SBP <120 mmHg) blood pressure lowering 
on cardiovascular outcomes among older adults without diabetes. iFGF23 was measured 
among 2488 participants with eGFR < 60 mL/min/1.73m2. Cox proportional hazards 
models adjusted for demographics, comorbidities, randomization group, baseline number of 
antihypertensives, eGFR, and serum calcium, phosphorus, and intact parathyroid hormone 
identified the relationship between baseline iFGF23 and time to first fall.
Results: Mean age was 73 ± 9 years, 40% were female, and 66% were white. Mean 
eGFR was 49 ± 11 mL/min/1.73m2 and median iFGF23 was 66 [52-88] pg/mL. After full 
adjustment, participants with iFGF23 levels in the highest quartile (compared to the lowest) 
demonstrated >2-fold increased risk of falling (HR 2.00 [95% 1.20-2.67]), and a doubling 
of iFGF23 level was associated with an increased risk of fall (HR 2.34 [95% CI 1.28-4.28]). 
Intact FGF23 did not modify the relationship between randomization to intensive blood 
pressure lowering and fall (p for interaction 0.96).
Conclusions: Among SPRINT participants with baseline eGFR < 60 mL/min/1.73m2, 
iFGF23 was significantly associated with increased risk of falls; however, FGF23 did not 
modify the relationship between randomization to intensive blood pressure lowering and 
falls. FGF23 has been associated with frailty in a large cohort of older community-dwelling 
adults. Our novel finding that FGF23 increases risk of fall supports a link between FGF23 
and frailty. Further investigation is necessary.
Funding: NIDDK Support, Veterans Affairs Support
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Genetic Variants Associated with Circulating Fibroblast Growth Factor-23 
among Patients with CKD
Cassianne Robinson-Cohen,1 Farzana Perwad,2 Elvis A. Akwo,1 Loren Lipworth,1 
Myles Wolf,5 Bryan R. Kestenbaum,4 Adriana Hung,3 Talat Alp Ikizler.1 
1Vanderbilt University Medical Center, Nashville, TN; 2University of California 
San Francisco, San Francisco, CA; 3VA & Vanderbilt University, Nashville, TN; 
4University of Washington, Seattle, WA; 5Duke University, Durham, NC.
Background: Recent genome-wide association studies (GWAS) identified loci 
associated with differences in fibroblast growth factor 23 (FGF23) concentrations, near 
genes involved in vitamin D metabolism, ABO blood group system, and renal phosphate 
transport. These studies were conducted among individuals with preserved kidney function. 
It is possible that genetic contributions to circulating FGF23 may differ among individuals 
with mineral metabolism disturbances, such as those with chronic kidney disease (CKD), in 
whom the biologic implications and potential treatment options are most relevant.
Methods: We examined 5 SNPs previously identified in GWAS of FGF23 (index 
SNPs) and 44 putatively functional SNPs in the surrounding regions (±250kb) among 
unrelated individuals of European ancestry (n=1,666) who participated in the Chronic Renal 
Insufficiency Cohort (CRIC) Study. We additionally tested for interactions of eGFR on the 
SNP-FGF23 association.
Results: Two index SNPs were associated with FGF23, after adjustment for age, sex, 
eGFR and BMI: rs11741640 at 5q35.3/RGS14/SLC34A1 (beta for the G allele: 5.7% higher 
FGF23 95% CI: 3.6,13.9, p=0.001) and rs2769071 at 9q34.2/ABO (beta coefficient for the G 
allele: 7.3% higher FGF23, 95% CI: 2.8,11.8, p=0.001). When we expanded to surrounding 
functional variants, 9 SNPs were associated with FGF23 (false discovery rate ≤ 0.05), all 
within the 5q35.3 region. The strongest association was for rs4075958 in RGS14 (beta for 
the A allele: 7.3% lower FGF23, 95% CI: -11.3,-3.1, p=9x10-4). Statistically significant 
interaction by eGFR was noted for the association of rs17216707 at 20q13.2/CYP24A1 
(p=0.019).
Conclusions: Our findings provide evidence that a subset of genetic variants associated 
with FGF23 under normal conditions are also associated in the setting of CKD. Larger, 
more comprehensive studies are needed to fully assess the generalizability of published 
GWAS findings and to identify potential novel associations in CKD. Both replication and 
lack of replication of published GWAS findings in CKD provide important information on 
the genetic etiology and on pathways influencing mineral metabolism disorders.
Funding: NIDDK Support
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Burosumab Improves Phosphorus Metabolism and Fracture Healing in 
Adults with X-Linked Hypophosphatemia (XLH)
Anthony A. Portale,1 Karl Insogna,7 Erik Imel,2 Peter Kamenicky,8 
Yasuo Imanishi,4 Nobuaki Ito,5 Farzana Perwad,1 Lin Zhang,6 Christina Theodore-
Oklota,3 Matt Mealiffe,3 Javier San martin,3 Thomas Carpenter.7 1University of 
California San Francisco, San Francisco, CA; 2Indiana University School of 
Medicine, Indianapolis, IN; 3Ultragenyx Pharmaceutical Inc., Novato, CA; 
4Osaka City Univ Graduate School of Med, Abeno-ku, Japan; 5University of 
Tokyo Hospital, Tokyo, Japan; 6Ultragenyx Pharmaceutical Inc, Novato, CA; 
7Yale University, New Haven, CT; 8Université Paris-Sud, Le Kremlin-Bicêtre, 
France.
Background: In an ongoing, Phase 3, double-blind, multicenter study, we examined 
the efficacy and safety of burosumab, a human monoclonal antibody against FGF23, in 134 
adults with XLH.
Methods: Subjects were randomized 1:1 to receive burosumab 1 mg/kg (n=68) or 
placebo (n=66) subcutaneously every 4 weeks (wks). After 24 wks, subjects receiving 
placebo crossed-over to receive burosumab, and all subjects received burosumab during 
wks 24-48, while remaining blinded to prior treatment.
Results: From wks 0 to 24, a significantly greater percentage of burosumab subjects 
than placebo subjects (94% vs 8%; p<0.0001) attained the primary endpoint of a mean 
serum phosphorus level within the normal range at the midpoint of dosing intervals; 
from wks 24-48, phosphorus was within the normal range in both groups (crossover 
89%, burosumab-continuation 84%). At baseline, 65 active fractures/pseudofractures 
(Fx/PFx) were present in 47% (32/68) of subjects in the burosumab group and 91 Fx/
PFx in 58% (38/66) of subjects in the placebo group. At wk 24, 43% (28/65) of Fx/
PFx fully healed with burosumab and 8% (7/91) healed with placebo (odds ratio of full 
healing 16.8, p<0.0001). By wk 48, the burosumab-continuation group showed additional 
Fx/PFx healing, and the crossover group showed healing similar to that of the burosumab-
continuation group at wk 24. At wk 48, both groups showed significant decreases from 
baseline (or wk 24 for crossover) in stiffness, physical functioning, and pain scores (all 
p<0.001). At wk 48, PTH decreased from baseline by 9% in the burosumab-continuation 
group and by 7% in the crossover group. Serum creatinine and calcium levels and urine 
calcium excretion were unchanged. Most subjects had no change in nephrocalcinosis 
severity score (5-point scale), and no subject had a change >±1 point. Serious AEs were 
reported in 15 subjects; none were assessed as drug-related.
Conclusions: Inhibition of FGF23 with burosumab was associated with improvements 
in serum phosphorus levels, pain, stiffness, and physical functioning, and healing of Fx/PFx 
in adults with XLH. The improvements seen with burosumab at wk 24 were replicated in 
placebo subjects who crossed over to receive burosumab from wks 24-48.
Funding: Commercial Support - Ultragenyx Pharmaceutical Inc.
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Association of Serum Calcification Propensity with Presence and 
Progression of Coronary Artery Calcification among Patients with CKD: 
The CRIC Study
Joshua D. Bundy,1 Xuan Cai,1 Julia J. Scialla,2 Geoffrey A. Block,3 
Harold I. Feldman,4 Ian H. de Boer,5 James P. Lash,6 Jing Chen,7 Chi-yuan Hsu,8 
Mirela A. Dobre,9 Jungwha Lee,1 Panduranga S. Rao,10 Alan S. Go,11 
Raymond R. Townsend,4 Myles Wolf,2 Andreas Pasch,12 Tamara Isakova.1 
1Northwestern University Feinberg School of Medicine, Chicago, IL; 2Duke 
University, Durham, NC; 3Colorado Kidney Care, Denver, CO; 4University of 
Pennsylvania School of Medicine, Villanova, PA; 5Division of Nephrology and 
Kidney Research Institute, University of Washington, Seattle, WA; 6University of 
Illinois at Chicago, Chicago, IL; 7Tulane School of Medicine, New Orleans, LA; 
8University of California San Francisco, San Francisco, CA; 9Case Western 
Reserve University, Cleveland, OH; 10University of Michigan Health System, 
Ann Arbor, MI; 11Kaiser Permanente Northern California, Oakland, CA; 
12University Hospital Bern, Bern, Switzerland.
Background: Coronary artery calcification (CAC) is prevalent among patients with 
chronic kidney disease (CKD) and predicts the risk of cardiovascular disease and mortality. 
We hypothesized that a novel measure of serum calcification propensity is associated with 
CAC among patients with CKD stages 2-4.
Methods: Among 780 participants from the CRIC Study, CAC was measured at 
baseline and a follow-up visit using electron beam or multidetector computed tomography. 
Calcification propensity was quantified at baseline as the transformation time (T50) from 
primary to secondary calciprotein particles, with lower T50 corresponding to higher 
calcification propensity. Poisson and linear regression were used to estimate associations 
between T50 and CAC, with a priori stratification by absence or presence of CAC at 
baseline.
Results: At baseline, 460 (59%) participants had any CAC and 255 (33%) participants 
had CAC score ≥100 Agatston units. Over an average 3-year follow-up, 65 (20%) 
participants without baseline CAC developed CAC while 89 participants (19%) with 
baseline CAC increased ≥100 Agatston units per year. After multivariable adjustment, 
lower T50 was associated with more severe CAC at baseline and over follow-up among 
those with baseline CAC (Table).
Conclusions: Among patients with CKD, higher serum calcification propensity is 
associated with more severe CAC and progression of CAC. Future studies should evaluate 
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whether T50 predicts the risk of clinical cardiovascular disease and whether its determinants 
represent novel therapeutic targets.
Funding: NIDDK Support, Other NIH Support - National Heart, Lung, and Blood 
Institute Cardiovascular Epidemiology training grant T32HL069771
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Serum Bicarbonate Level and Coronary Artery Calcification – A Report 
from the Chronic Renal Insufficiency Cohort (CRIC) Study
Mirela A. Dobre,1 Neil H. Patel,1 Wei Yang,6 Jing Chen,2 L. Lee Hamm,7 
Tamara Isakova,4 Bernard G. Jaar,3 Ana C. Ricardo,5 Thomas H. Hostetter,1 
Mahboob Rahman.1 CAC 1Case Western Reserve University, Cleveland, OH; 
2Tulane School of Medicine, New Orleans, LA; 3Johns Hopkins University and 
Nephrology Center of Maryland, Baltimore, MD; 4Feinberg School of Medicine, 
Northwestern University, Chicago, IL; 5University of Illinois at Chicago, 
Chicago, IL; 6University of Pennsylvania, Philadelphia, PA; 7Tulane University 
School of Medicine, New Orleans, LA.
Background: There is a graded relationship between the severity of chronic kidney 
disease (CKD) and coronary artery calcification (CAC), though the mechanism is unclear. 
Metabolic acidosis, a common complication of CKD, contributes to decreased mineral bone 
content and may lead to worsening vascular calcification. We hypothesize that low serum 
bicarbonate level, an expression of metabolic acidosis, is a risk factor for CAC in CKD.
Methods: Serum bicarbonate and CAC were simultaneously measured in 862 
CRIC participants at baseline and after 3 years. CAC was measured using electron beam 
or multidetector computed tomography and calculated using Agatston score. Serum 
bicarbonate was analyzed both as a continuous and a categorical variable by the following 
groups: <22 mEql/L (low), 22-26 mEq/L (normal) and >26 mEq/L (high). CAC progression 
was defined as follows: CAC> 0 at follow-up, if CAC=0 at baseline; annualized change 
≥10 Agatston units at follow-up if 0<CAC≤100 at baseline; and annualized percent change 
(annualized change in CAC score divided by the baseline CAC score) ≥ 10% at follow-up, 
if CAC > 100 at baseline. Logistic regression models were built to study the association
of interest.
Results: The mean eGFR was 43±17ml/min per 1.73m2, mean serum bicarbonate was 
24.4±3.3 mEq/L, and 42.7% participants had diabetes. A total of 412 (48%) participants 
experienced CAC progression. Participants with low bicarbonate were more likely to 
have CAC >400 at baseline, and to experience CAC progression, compared to those in 
the normal group (57.3% vs 46.2%, p=0.003). The low group had 52% higher risk of CAC 
progression, compared to normal group (OR1.52; 95%CI: 1.02–2.29), in models adjusted 
for demographics, baseline co-morbidities, medications, calcium and phosphorus. Addition 
of eGFR and proteinuria to these models attenuated the association (OR 1.34; 95%CI: 0.87–
2.08). In fully adjusted models, each 1mEq/L lower serum bicarbonate was associated with 
6% higher risk of CAC progression (OR 1.06; 95%CI: 1.01-1.12).
Conclusions: In a cohort of patients with CKD, low serum bicarbonate level was 
associated with CAC progression. This association may not be independent of kidney 
function. Further studies are needed to determine a causal link between low serum 
bicarbonate and CAC.
Funding: Private Foundation Support
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A Serum Biomarker Panel of Low Bone Turnover Identifies Higher 
Fracture Risk in Community Dwelling Individuals with CKD
Jan M. Hughes-Austin,1 Ronit Katz,2 Richard Semba,3 Doug Bauer,4 
Mark J. Sarnak,5 Michael Shlipak,6 Florence Lima,7 Hartmut H. Malluche,7 
Joachim H. Ix.8 1University of California, San Diego, La Jolla, CA; 2University 
of Washington, Seattle, WA; 3Johns Hopkins University, Baltimore, MD; 4UCSF, 
San Francisco, CA; 5Tufts Medical Center, Boston, MA; 6San Francisco VA 
Medical Center, San Francisco, CA; 7University of Kentucky, Lexington, KY; 
8UCSD, San Diego, CA.
Background: Individuals with chronic kidney disease (CKD) can have low or high 
turnover bone disease, either of which could lead to low bone mineral density (BMD). We 
identified a panel of biomarkers on biopsy that marked low turnover bone disease. Then, in 
a community-dwelling cohort of persons with CKD, we determined if this panel identified 
a subset at high risk for fracture.
Methods: Among 58 patients with CKD stage 2-5 who had undergone bone biopsies, 
we used CART analysis to define a panel of serum biomarkers that could differentiate low 
turnover from non-low turnover bone disease. We then applied this panel of biomarkers 
to 676 participants in the Health ABC study who had eGFR < 60 mL/min/1.73m2and had 
BMD measurements at baseline. We used Cox proportional hazards models to evaluate the 
association of BMD with fracture risk and to determine whether biomarker defined low- vs 
non-low bone turnover modified the risk of fracture.
Results: CART analysis in 58 CKD patients defined cut-off points for differentiation 
of low bone turnover: PTH below the median, soluble a-klotho above the median, 
and FGF-23 below the median (AUC = 0.6, 0.7, and 0.7, respectively). Among the 676 
participants with CKD in Health ABC, mean age was 75±3 years, and were 51% female 
and 36% African-American. Average eGFR was 48±10 mL/min/1.73m2. For every standard 
deviation (SD=0.16 g/cm2) lower hip BMD at baseline there was higher risk for hip (HR 
2.5 (1.9, 3.2)) and spine fractures (HR 1.6 (1.3, 2.1)) during follow-up. This risk differed 
in individuals with biomarker defined low vs non-low bone turnover (pinteractionhip= 0.05; 
spine= 0.07), where individuals characterized as having low bone turnover had higher risk 
of fracture (Table)
Conclusions: In individuals with CKD, a biomarker panel of PTH, a-klotho, and 
FGF-23 can be used to identify individuals more likely to have low bone turnover. In such 
individuals, the relationship of low BMD with risk for incident hip and spine fractures is 
much higher than in others.
Funding: Other NIH Support - NHLBI (K01 HL122394)
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A MicroRNA Approach to Diagnosing Renal Osteodystrophy
Tom Nickolas,1 Neal X. Chen,2 Donald J. Mcmahon,5 Pieter Evenepoel,3 
Patrick C. D’Haese,4 Fabrice Mac-Way,6 Sharon M. Moe.2 1Columbia University 
Medical Center, New York, NY; 2Indiana University School of Medicine, 
Indianapolis, IN; 3University Hospitals Leuven, Leuven, Belgium; 4University 
Antwerp, Edegem, Belgium; 5Columbia University, New York, NY; 6CHU de 
Quebec, Hotel-Dieu de Quebec Hospital, Quebec, QC, Canada.
Background: The primary goal of treating renal osteodystrophy (ROD) is reducing 
high bone turnover with calcitriol and/or calcimimetics while avoiding the development 
of low turnover. A main obstacle in managing ROD is identifying the underlying bone 
turnover-type. Bone biopsy, the gold standard to define turnover, is impractical for routine 
clinical use. Therefore, KDIGO recommends that clinical use (starting/stopping) of these 
agents is guided by parathyroid hormone (PTH) and bone specific alkaline phosphatase 
(BSAP). However, bone biopsy studies demonstrated that PTH and BSAP are poor guides 
for ROD treatment. We hypothesized that 4 circulating microRNAs (miRs) that regulate 
osteoblast (30b, 30c, 125b) and osteoclast development (155) would provide superior 
discrimination of low and high turnover than PTH and BSAP.
Methods: In 24 patients with CKD 3-5D, we obtained tetracycline double-labeled 
iliac crest bone biopsy and measured levels of intact PTH, BSAP and circulating 
miR-30b, 30c, 125b and 155 (evaluated independently and together as a panel). Spearman 
correlations assessed relationships between miRs, dynamic parameters of bone biopsy, 
and PTH and BSAP. Discrimination of low / high turnover were determined by receiver 
operator curve analysis; areas under curve were compared by χ2.
Results: miRs moderately correlated with bone formation and adjusted apposition rate 
(ρ 0.43-0.51; p<0.05) by biopsy but were not correlated with PTH or BSAP. Discrimination 
of low vs. non-low and high vs. non-high turnover for PTH, BSAP and miRs (both
individually and as a panel) are shown in the Table.
Conclusions: These data suggest that a panel of circulating miRs provide accurate 
non-invasive identification of low and high turnover and individually identified low 
turnover. Future work will discover and validate additional miR biomarkers of turnover and 
determine their impact on clinical decision making and outcomes.
Funding: NIDDK Support
Areas under the curve for diagnosis turnover by bone biopsy
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Cholecalciferol vs Small Doses of Alfacalcidol in Hemodialysis Patients: A 
Randomized Placebo-Controlled Study
Pawel Kulicki,1 Stanislaw Niemczyk,4 Pawel Zebrowski,3 Jolanta Malyszko,2 
Joanna Matuszkiewicz-Rowinska.3 1Medical University of Warsaw, Warsaw, 
Poland; 2Warsaw Medical University, Warsaw, Poland; 3The Medical University 
of Warsaw, Warsaw, Poland; 4Military Medical Institute of Warsaw, Warsaw, 
Poland.
Background: The ability of extrarenal tissues to convert 25OHD into 1,25(OH)2D 
and its dependence on substrate levels provide the rationale for supplementing vitamin D 
in dialysis patients who usually have severe depletion of both: calctriol and vitamin D. 
The primary aim of the study was to compare effects of cholecalciferol (CHOL, 4000 IU) 
with frequently used in Europe, small doses of alfacalcidol (ALFA, 0.5 microg) or placebo 
(PLC), given thrice weekly for 12 weeks, on serum 1,25(OH)2D in hemodialysis (HD) 
patients with vitamin D deficiency. Secondary outcomes were changes in serum calcium, 
phosphate, 25(OH)D, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23) and 
sclerostin during the treatment.
Methods: This was a prospective, randomized, partly double-blind (CHOL vs 
PLC), partly open-label (ALFA vs CHOL or PLC) study. Out of 522 patients dialyzed 
in 5 centers in the Mazovian Province, 93 gave informed consent and met the inclusion 
criteria: vitamin D and calcimimetics naïve; no history of liver or intestinal disease; serum 
25(OH)D <20 ng/ml, iPTH <1000 ->110 pg/ml, calcium <10.2 and phosphate < 6.8 mg/dl. 
The subjects were stratified by serum iPTH, then randomized into 3 groups according to 
the treatment
Results: To our knowledge, this is a first study comparing head-to-head these drugs 
in HD population. There were no significant differences between the groups at baseline. 
81 patients completed the study. CHOL normalized serum 25OHD, with a mean rise from 
12.9±6.7 to 31.3±10.1 ng/ml (p<0.0001). This was accompanied by a marked increase of 
1,25(OH)2D (from 13.8±9.3 to 25.1±14.2 pmol/l (p<0.0001). A rise in serum 1,25(OH)2 
was observed also in ALFA treated patients, however much smaller (from 13.5±10.1 to 
18.5±11.0 pmol/l; p=0.02). Neither CHOL nor ALFA treatment resulted in significant 
changes in the remaining parameters.
Conclusions: In most HD patients treatment with CHOL in a dose of 12000 IU/week 
permits safe correction of vitamin D deficiency and is more effective than small doses of 
ALFA in rising serum 1,25(OH)2D. This together with a lack of influence on circulating 
iPTH question the usefulness of this treatment in HD patients.
TH-OR029 Oral Abstract Thursday
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Randomized Trial to Evaluate the Effect of Cholecalciferol Supplementa-
tion on Parathyroid Hormone in Hemodialysis Patients
Laura Sola, Susana B. Gonzalez, Juan C. Diaz, Sandra D. Fleitas, Manuela Bello, 
Maria noel Leyun, Ricardo A. Hermo. CASMU-IAMPP, Montevideo, Uruguay.
Background: Vitamin D (25VD) supplementation is associated with a decrease in 
parathyroid hormone (iPTH) in general population, not confirmed in hemodialysis (HD) 
patients (Pts). The aim of the study was to evaluate if cholecalciferol supplementation can 
normalize 25VD levels and reduce iPTH in HD Pts with vitamin D deficiency.
Methods: Randomized, controlled trial with 2 arms: cholecalciferol vs placebo. 
Inclusion Criteria: Adult Pts, on HD for ≥ 3 months, 25VD < 30 ng/ml and iPTH >300 ng/ml. 
Randomization was done using a table of random numbers, and allocation was blinded for 
Pts and investigators. Intervention: Pts received one tablet with 5000 IU 25VD or placebo 
during dialysis thrice a week for 12 weeks. Hemoglobin (Hb), Calcium (Ca), Phosphorous 
(P), erythropoietin dose (IU/kg/week), Alkaline Phosphatase (AP), 25VD and iPTH were 
measured at 0 and 12 weeks. Assuming a dropout rate of 15%, sample size of 120 Pts 
was needed for a 20% reduction on iPTH in 35% of treated Pts. Analysis was done per 
protocol for the primary outcome. Quantitative data was expressed were compared by 
t test and categorical by chi square. Significant differences were considered with p values 
<0.05. Institutional Ethics Committee authorization was obtained.
Results: 118 Pts were randomized, 60 to 25VD and 58 to PLA with no significant 
differences (Table I). 17 Pts were lost of follow-up, 101 Pts completed treatment (54 
with 25VD and 47 with PLA). Pts on 25VD normalized 25VD (increased x 20.9 ± 11.9) 
significantly more frequently than those on PLA (41 (75.9%) vs 11 (23.4%)). A 20% iPTH 
reduction was seen in 17 Pts (29.3%) on 25VD (x reduction 45 ± 194) and 9 Pts (19.1%) 
on PLA (p=0.1). A reduction on AP was seen in 25VD Pts (29.5 ± 84.8, p=0.016) and not 
on PLA (21.9 ± 81.3).
Conclusions: Significant increase in 25VD was observed in treated group, with a 
reduction on AP but with no significant effect on iPTH
Funding: Commercial Support - Celsiuss, Government Support - Non-U.S.
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Multicentre Randomized Control Trial of Phosphate Control with a 
Modified as Compared to Standard Renal Diet
Fiona N. Byrne,1,2 Joe Eustace,2 Barbara A. Gillman.3 1Department of Nutrition 
& Dietetics, Cork University Hospital, Cork, Ireland; 2Clinical Research 
Facility, University College Cork, Cork, Ireland; 3Mater Misericordiae 
University Hospital, Dublin, Ireland.
Background: The standard renal diet fails to distinguish between phytate and non 
phytate bound phosphorus, despite consensus that the latter is poorly absorbed. A modified 
renal diet based on the increased use of pulses, nuts and whole grains, the avoidance of P 
additives and of over-prescription of protein may offer improved or similar [P] levels as the 
standard renal diet but with a wider food choice.
Methods: We conducted a national, multicentre, pragmatic, parallel arm, open label, 
randomized controlled trial (1:1 allocation ratio) of 1 month of modified vs. standard 
diet in 74 prevalent anuric adults on maintenance hemodialysis with a 3 mt mean pre-
dialysis serum phosphate ([P]) >1.6mmol/L and a stable phosphate binder and vitamin D 
prescription. Subjects with a history of severe hyperkalemia, parathyroidectomy or recent 
acute illness were excluded. Subjects were re-educated on the standard diet or educated on 
the modified diet by the renal dietitian. Analysis was on a modified intention-to-treat basis 
of the difference between diets in follow-up [P] minus baseline [P] using an independent 
sample t test and a 2 sided type 1 error rate of 0.05.
Results: We recruited 74 subjects from 13 university dialysis units. Two patients did 
not have a follow-up [P], due to an insufficient sample and transplantation and thus could 
not contribute to the primary analysis. The study population was 96% Caucasian, 69% male, 
36% of subjects had diabetes. Both diets were similarly well tolerated. The modified diet 
resulted in a significantly higher phytate and fiber intake (both p<0.01). Baseline and follow-
up [P] in modified diet arm was 2.1 (0.5) and 2.0 (0.7) mmol/L, and in the Standard Diet 
arm were 2.0 (0.6) and 1.9 (0.6) mmol/l; the mean (95% CI) change in [PO4] in modified 
vs. standard arm was 0.01 (-0.24,0.21), p=0.91. The mean (sd) difference in follow-up [K] 
-baseline [K] in the modified and standard arms was 0.01 (0.7) and 0.09 (0.6) mmol/L 
respectively; the mean (95% CI) change in [K+] modified v standard was -0.07(-0.23,0.38),
p = 0.63. C terminal FGF23 (n=27) was not significantly different. Limitations of this study 
include its modest sample size and limited intervention period.
Conclusions: The modified renal diet was well tolerated and was associated with 
similar [P] control but with a wider food choice and greater fiber intake than the standard 
diet.
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Combination of Changes in eGFR and Albuminuria and the Risk of 
Major Clinical Outcomes in Type 2 Diabetes Mellitus (T2DM)
Min Jun,1 Toshiaki Ohkuma,1 Vlado Perkovic,2 John P. Chalmers,4 
Mark Woodward.3 ADVANCE Collaborative Group 1The George Institute for 
Global Health, UNSW Sydney, Newtown, NSW, Australia; 2The George Institute 
for Global Health, Newtown, NSW, Australia; 3Johns Hopkins University, 
Baltimore, MD; 4The George Institute for Global Health, Camperdown, NSW, 
Australia.
Background: Whether combining changes in eGFR and UACR more accurately 
predicts outcomes in T2DM compared with assessing either change alone is unknown. 
We assessed the association between changes in eGFR and UACR and subsequent risk 
of the composite of major macrovascular and renal events and all-cause mortality in the 
ADVANCE-ON study.
Methods: We defined eGFR and UACR change (baseline to 2 years) as ≥40% decrease, 
<40% decrease to <40% increase (minor change; reference) and ≥40% increase. Follow-up 
for outcomes commenced at the second eGFR or UACR measurement. Cox regression 
models (adjusted for demographics, ADVANCE randomized treatment, comorbidities and 
laboratory measurements [including baseline eGFR and UACR]) were used to estimate the 
hazard ratio (HR) and 95% confidence intervals (CIs) relating changes in eGFR and UACR 
to the combination endpoint.
Results: Of 8766 patients, from baseline to 2 years, 3% experienced an eGFR decrease 
≥40%, 93% experienced a minor change, and 4% experienced an increase ≥40%. For UACR 
change, the proportions were 29%, 34% and 37%, respectively. 1% experienced both an
eGFR decrease ≥40% and a UACR increase ≥40%. Over the next 7.7 years (median), 2191 
composite outcome events were recorded. Strong linear associations between eGFR and
UACR changes and the subsequent risk of the outcome were observed (p for trend <0.001 
for each marker). For eGFR change, the HRs for a decrease ≥40% was 1.59 (95% CI:
1.28-1.97) compared with those with minor change whilst that for an increase ≥40% was
0.82 (0.64-1.04). For UACR change, the HRs were 0.96 (0.85-1.07) for a decrease ≥40% 
and 1.32 (1.19-1.46) for those with ≥40% increase compared to minor change. Compared
to patients with minor changes, patients who experienced an eGFR decrease ≥40% and a
UACR increase ≥40% had 2.31 (1.67-3.18) times the risk of the outcome, with evidence of 
interaction between the 2 markers (p for interaction=0.047).
Conclusions: In patients with T2DM, clinically meaningful decreases in eGFR and 
increases in UACR over 2 years significantly predicted, independently and in combination, 
increased risk of major clinical outcomes. Our results suggest that a combined assessment 
of clinically meaningful changes in both eGFR and UACR compared with separate 
assessments of the 2 markers may further improve risk stratification in T2DM.
Funding: Commercial Support - The ADVANCE trial was funded by grants from 
the National Health and Medical Research Council of Australia and Servier, Government 
Support - Non-U.S.
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Diabetic Kidney Disease Trials: Progress Being Made
Metformin Treatment in Patients with Type 2 Diabetes and CKD
Soie Kwon,4,3 Yong Chul Kim,1 Jae Yoon Park,2 Jung Nam An,3 Dong Ki Kim,4 
Jung Pyo Lee.3 1SNUH, Seoul, Republic of Korea; 2Dongguk University Ilsan 
Hospital, Gyeonggido, Republic of Korea; 3Seoul National University Boramae 
Medical Center, Seoul, SEOUL, Republic of Korea; 4Seoul National University 
Hospital, Seoul, Republic of Korea.
Background: Metformin is widely used as the first pharmacological option in the 
patients with type 2 diabetes mellitus. However, use of this drug has not been recommend 
in individuals with impaired kidney function because of the perceived risk of lactic acidosis. 
We aimed to assess the efficacy and safety of metformin in patients with type 2 diabetic 
chronic kidney disease (CKD).
Methods: We conducted a retrospective, observational, cohort study of 10,426 patients 
with type 2 diabetic CKD who followed the nephrology clinic at two tertiary hospitals from 
2001 to 2016. We compared 3,183 patients who used metformin with 7,243 who did not use 
metformin. Primary outcomes were all-cause-mortality and end-stage renal disease (ESRD) 
progression. Secondary outcomes were event of metformin associated lactic acidosis 
and maximal lactate level in all events of lactic acidosis. Cox multivariate analysis and 
propensity score matching were conducted.
Results: The patients who used metformin had more female proportion, younger, higher 
eGFR, higher BMI and higher HbA1c level at the time of enrollment. All-cause-mortality 
for metformin-user group was significantly better than that that of non-metformin user in the 
multivariable cox analysis (P value <0.001 adjusted hazard ratio [aHR] 0.54, 95% confidence 
interval [C.I.] 0.48 - 0.62). Also, MFM group has longer duration of ESRD progression. (P 
value < 0.001, aHR 0.47, 95% CI 0.41 – 0.53). Because two group had significantly different 
baseline characteristics, we did a propensity score matching by age, gender, hypertension, 
liver disease, BMI, Hba1c and eGFR. Metformin usage consistently has superiority in all-
cause-mortality (P value <0.001, aHR 0.52, 95% CI 0.46 – 0.60) and ESRD progression (P 
value <0.001, aHR 0.50, 95% CI 0.43 – 0.58) in matched group. There was only one case 
of metformin associated lactic acidosis event in metformin user group. But there was no 
difference in maximal lactate level. (P value 0.966)
Conclusions: In Korean diabetic CKD patients, metformin can be safely considered. 
However, more researches about cumulative dose effect, dose adjustment and monitoring 
method are needed.
Edit Table - Uni-variate cox analysis about primary outcome in matched group
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CKD Outcomes in Type 2 Diabetes and Moderate-to-Severe CKD Treated 
with Dulaglutide Versus Insulin Glargine: AWARD-7
Katherine R. Tuttle,1 Mark Lakshmanan,2 Brian Rayner,3 Alan G. Zimmermann,4 
Brad Woodward,2 Fady T. Botros.2 1University of Washington School of 
Medicine, Spokane, WA; 2Eli Lilly and Company, Indianapolis, IN; 3Division of 
Nephrology and Hypertension, Groote Schuur Hospital and University of Cape 
Town, Cape Town, South Africa; 4Formerly at Eli Lilly and Company, 
Indianapolis, IN.
Background: In the Assessment of Weekly AdministRation of Dulaglutide in 
Diabetes-7 (AWARD-7) study, dulaglutide (DU) treatment was associated with slower 
decline in estimated glomerular filtration rate (eGFR) compared to insulin glargine (IG) 
in participants with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease 
(CKD). The present analysis is aimed to determine CKD outcomes by treatment group.
Methods: As treatment for T2D, participants with T2D and CKD stages 3-4 were 
randomized (1:1:1) to receive DU 0.75 mg, DU 1.5 mg, or titrated IG, all added-on to 
titrated insulin lispro, for 1 year in this open-label (DU dose-blinded), phase 3 clinical 
study. In this prespecified exploratory analyses, proportions of participants experiencing 
≥40% eGFR decline, end-stage renal disease (ESRD), or kidney disease-related death
were compared between groups as composite and individual outcomes. For the composite 
outcome, a time-to-event analysis was conducted using a Cox proportional hazards model.
Results: The age (mean ± SD) of participants was 64.5 ± 8.5 years and 264/549 (48%) 
were women. At baseline, diabetes duration (mean ± SD) was 18.1 ± 8.8 years, HbA1c was 
8.6 ± 1.0%, eGFR was 38 ± 13 mL/min/1.73 m2, and median (interquartile range) urine 
albumin-creatinine ratio was 209 (39, 965) mg/g. HbA1c declined similarly in all groups 
by a mean of approximately 1% over 1 year. The composite outcome was experienced 
by 47/576 (8.2%) participants: 10/192 (5.2%) in DU 1.5 mg, 16/190 (8.4%) in DU 0.75 
mg, and 21/194 (10.8%) in IG (p=0.046, p=0.548 versus IG, respectively). The time-to-
event for the composite outcome was significantly better for DU 1.5 mg versus IG (Cox 
model; p=0.038). Proportions with eGFR decline ≥40% occurred in: 2/192 (1.0%) in DU 
1.5 mg, 7/190 (3.7%) in DU 0.75 mg, and 6/194 (3.1%) in IG. Proportions reaching ESRD 
were: 8/187 (4.3%) in DU 1.5 mg, 14/184 (7.6%) in DU 0.75 mg, and 16/191 (8.4%) in 
IG. Between-group comparisons were not significant for individual outcomes. No kidney 
disease-related deaths were reported.
Conclusions: One-year treatment with DU 1.5 mg was associated with a lower rate 
of CKD outcomes, including the composite outcome of eGFR decline ≥40% or ESRD, 
compared to IG at similar levels of glycemic control.
Funding: Commercial Support - Eli Lilly and Company
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Reduction in Albuminuria Is Associated with Cardiorenal Protection 
Independent of Baseline Albuminuria – A Post-Hoc Analysis of the 
LEADER Trial
Frederik Persson,1 Stephen Bain,2 Ofri Mosenzon,3 Hiddo J. Lambers 
Heerspink,4 Johannes F. Mann,5 Itamar Raz,6 Thomas Idorn,7 Soren Rasmussen,7 
Bernt Johan Von Scholten,7 Peter Rossing.1 The LEADER Publication 
Committee on behalf of the LEADER Trial Investigators 1Steno Diabetes Center 
Copenhagen, Gentofte, Denmark; 2Institute of Life Science, Swansea University, 
Swansea, United Kingdom; 3Hadassah Hebrew University Hospital, Jerusalem, 
Israel; 4University Medical Center Groningen, Groningen, Netherlands; 5KfH 
Kidney Center, and Friedrich Alexander University of Erlangen, Munich, 
Germany; 6Hadassah Hebrew University Hospital, Jerusalem, Israel; 7Novo 
Nordisk A/S, Soborg, Denmark.
Background: We investigated association between changes in urinary albumin-to-
creatinine ratio (UACR) and subsequent risk of cardiovascular (CV) and renal events in the 
LEADER trial according to baseline UACR.
Methods: LEADER was a randomized, double-blind, multicenter, placebo-controlled 
CV outcomes trial of liraglutide up to 1.8 mg/day vs placebo added to standard care for 
3.5–5 years in 9340 patients with type 2 diabetes and high risk for CV disease. Using a 
Cox regression model including subjects with a UACR measurement at baseline and after 
1 year (N=8231 [88%]) adjusted for treatment, we analyzed the risk of major adverse CV 
events (MACE) and adjudicated renal events (doubling of serum creatinine and estimated 
glomerular filtration rate ≤45 ml/min/1.73 m2; the need for continuous renal-replacement 
therapy; or death from renal disease) from 1 year to end of trial in subgroups defined by 
first-year change in UACR: >30% reduction, 30-0% reduction, any increase, and according 
to absolute level of baseline UACR (normo- [<30 mg/g], micro- [30 to 300 mg/g] 
or macroalbuminuria [>300 mg/g]).
Results: For first MACE, the hazard ratios (HRs) according to baseline UACR 
groups were: HR=2.49, 95%CI (2.09;2.97) for macro- vs normoalbuminuria and HR=1.38 
(1.18;1.60) for micro- vs normoalbuminuria. Correspondingly for first renal event: 
HR=39.4 (26.3;58.9) and HR=3.57 (2.20;5.80) (Figure). Within each subgroup the risk for 
CV and renal events was lower in patients with >30% UACR reduction than in those with 
any UACR increase. There were no interactions between groups (Figure).
Conclusions: These findings highlight the benefit of UACR reduction, even in patients 
with normoalbuminuria at baseline.
Funding: Commercial Support - Novo Nordisk
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Treatment with Dipeptidyl-Peptidase Inhibitors (DPP4_Rx) Delays 
Progression of Kidney Disease and Reduces Mortality
Thomas Wiegmann,1 Olurinde Oni,1 Peter S. Wiegmann,2 Archana Goel,1 
Mukut Sharma,1 Ram Sharma,1 Maria N. Gomes,1 Virginia J. Savin,1 
Mariana Garcia-Touza.1  Cardiovascular and Renal Clinical Research at MidWest 
BioMedical Research Foundation 1Kansas City VA Medical Center, Kansas City, 
MO; 2Midwest Biomedical Research Foundation, Kansas City, MO.
Background: Effects of DPP4_Rx on cardiovascular morbidity are disputed and e 
ffects on renal function are not known.
 Methods: Data from a large cohort of veterans diagnosed with type 2 diabetes mellitus 
(T2DM) were used to identify patients on DPP4_Rx (group 1). and without DPP4_Rx 
(group 2). Groups were matched for age (yrs), sex, BMI, initial renal function, follow-
up time (FU, minimum 365 days). Propensity score matching (PSM) was used to adjust 
groups 1 and 2 with a best odds ratio about 1:2. Groups were compared to determine 
the effect of DPP4_Rx on the progression of CKD and all-cause mortality. Increase in 
serum creatinine (creat, mg/dl) over time (days) was taken as a measure of progression of 
CKD. Data were extracted using the Veterans Administration Informatics and Computing 
Infrastructure (VINCI), and analyzed using SPSS and SAS. Results were compared using 
t-tests, frequency tables, Kaplan Meier survival curves, hazard ratios (HR) and p values.
Results: Results show that subjects in group 1 (N=20,424) had baseline variables (creat 
1.061, FU 1117, age 68.2 yrs and BMI 31.9) similar to Group 2 (N=52,118, creat 1.09,
FU 1197, age 69.9, BMI 31.7). DM control improved in group 1 (HgbA1c 8.3% to 7.9%, 
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p < 0.001) but remained worse than group 2 (7.2% to 7.1%) A significant reduction in 
progression of CKD was seen in group 1. The proportion of patients exceeding creat of 1.5, 
3, and 6 mg/dl was reduced by 6.5, 40.8 and 47.4%, all p<0.01 respectively. Time to ESRD 
(creat >6.0 mg/dl) was delayed also by 143.7 days p < 0.01. Mortality from all causes was 
reduced by 78.1%, but time to death was not changed.
Conclusions: We conclude that DPP4_Rx associates with a significant reduction in 
frequency of all-cause mortality and progression toward ESRD independent of glucose 
control. The data are consistent with a reduction in the number and severity of discrete 
morbid events that would associate with progressive renal disease and all cause mortality..
Funding: Veterans Affairs Support
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Does Glucose Control Influence the Effect of Empagliflozin on Kidney 
Outcomes in Type 2 Diabetes (T2D)? Insights from the EMPA-REG 
OUTCOME® Trial
Mark E. Cooper,1 Silvio E. Inzucchi,2 Bernard Zinman,3 Stefan Hantel,5 
Maximilian von Eynatten,5 Christoph Wanner,4 Audrey Koitka-Weber.1,5 
1Monash University, Melbourne, VIC, Australia; 2Yale University School of 
Medicine, New Haven, CT; 3Mount Sinai Hospital, Toronto, ON, Canada; 
4Würzburg University Clinic, Würzburg, Germany; 5Boehringer Ingelheim 
International GmbH, Ingelheim, Germany.
Background: In the EMPA-REG OUTCOME® trial, empagliflozin (EMPA), a 
selective SGLT2 inhibitor given in addition to standard of care, significantly reduced pre-
specified kidney outcomes by 39% in T2D patients with established cardiovascular disease 
(CVD). There is evidence that intensified glycemic control in T2D prevents microvascular 
complications including progression of kidney disease. We sought to determine whether the 
renal benefits of EMPA were linked to its effect on HbA1c.
Methods: Patients were randomized (1:1:1) to EMPA 10 mg, EMPA 25 mg, or placebo 
(PBO). Background glucose-lowering therapy was to remain unchanged for the first 12 
weeks. Kidney outcomes were analyzed in the pooled EMPA group vs PBO after adjustment 
by baseline HbA1c, for HbA1c control during the trial as a time-dependent factor, and by 
reduction in HbA1c from baseline to week 12. Differences in risk between treatment groups 
were assessed using a Cox proportional hazards model.
Results: A total of 7020 patients were treated. Median observation time was 3.1 years. 
The reduction in risk of incident or worsening nephropathy with EMPA vs PBO was found 
to be consistent irrespective of either HbA1c at baseline or subsequent changes in glycemic 
control during active study treatment (Figure).
Conclusions: In patients with T2D and established CVD, the beneficial effect of EMPA 
on kidney outcomes was consistent irrespective of HbA1c prior to and during therapy. 
EMPA-KIDNEY, the outcome study of heart and kidney protection with EMPA, will 
provide additional insights into potential glycemia-independent kidney effects of EMPA in 
patients with and without diabetes.
Funding: Commercial Support - Boehringer Ingelheim & Eli Lilly and Company 
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Prediction of the Effect of Dapagliflozin on Renal and Heart Failure 
Outcomes Based on Short-Term Changes in Multiple Risk Markers
Nienke Idzerda,1 David Sjostrom,2 Bergur V. Stefansson,3 David C. Wheeler,4 
Hiddo J. Lambers Heerspink.1 1University Medical Center Groningen, 
Groningen, Netherlands; 2AstraZeneca LP, Molndal, Sweden; 3AstraZeneca, 
Molndal, Sweden; 4University College London, London, United Kingdom.
Background: Sodium glucose cotransporter 2 inhibition with dapagliflozin reduces 
blood pressure, body weight and urinary albumin:creatinine ratio (UACR) in patients with 
type 2 diabetes (T2DM). We previously developed an algorithm, the PRE score, to predict 
how short term effects of a drug on risk factors may translate into long-term changes in 
clinical outcomes. We applied the PRE score to clinical trials of dapagliflozin to model the 
effect of the drug on renal and heart failure (HF) outcomes in T2DM patients with impaired 
renal function.
Methods: The relationships between multiple risk markers and long-term outcome 
were determined by means of a multivariable Cox model in a subgroup of T2DM patients 
derived from the ALTITUDE trial. These relationships were applied to short-term changes 
in risk markers observed in a pooled database of seven dapagliflozin clinical trials to predict 
the expected drug-induced changes to renal and HF outcomes. Patient characteristics within 
the background population were matched with respect to UACR and eGFR to those from 
the dapagliflozin trial participants. The renal outcome was defined as a composite of end-
stage renal disease (ESRD) and a sustained doubling of serum creatinine. The heart failure 
outcome was defined as hospitalization due to HF.
Results: A total of 372 and 136 patients had UACR>30 mg/g and UACR>200 mg/g at 
baseline, respectively. The PRE score predicted a renal risk reduction of 39% (95% CI 17 
to 61%) and 43% (95% CI 4 to 83%) with dapagliflozin 10 mg/day for the UACR>30 mg/g 
and UACR>200 mg/g subgroups. The predicted reduction in HF events was 21% (95% CI 
8 to 35%) and 28% (95% CI 7 to 49%), respectively. Dapagliflozin decreased albuminuria 
by approximately 35% in both UACR subgroups. Simulation analyses showed that even 
with a smaller albuminuria lowering effect of dapagliflozin (10%), the estimated renal risk 
reduction was still 26.5% and 26.8% in the two UACR subgroups.
Conclusions: The PRE score predicted clinically meaningful reductions in renal and 
HF endpoints associated with dapagliflozin therapy in patients with diabetic kidney disease. 
These results support a large long-term outcome trial in this population to confirm the 
benefits of the drug on these endpoints.
Funding: Commercial Support - AstraZeneca
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Canagliflozin Induced Reduction in TNF Receptor 1 Is Associated with a 
Reduction in eGFR Decline
Hiddo J. Lambers Heerspink,1 Paul Perco,2 Skander Mulder,1 Johannes Leierer,2 
Michael K. Hansen,3 Andreas Heinzel,4 Gert J. Mayer.2 1Department of Clinical 
Pharmacy and Pharmacology, University of Groningen, Groningen, 
Netherlands; 2Department of Internal Medicine, Medical University of 
Innsbruck, Innsbruck, Austria; 3Janssen Research & Development, LLC, Spring 
House, PA; 4emergentec biodevelopment GmbH, Vienna, Austria.
Background: Circulating levels of the pro-inflammatory biomarker Tumor Necrosis 
Factor Receptor 1 (TNFR1) predict the risk of end-stage renal disease (ESRD) in patients 
with type 2 diabetes. Experimental studies suggested that sodium glucose co-transporter 
2 (SGLT2) inhibitors exert anti-inflammatory effects. Here we examined the effect of the 
SGLT2 inhibitor canagliflozin (CANA) on TNFR1 and assessed whether the change in 
TNFR1 is associated with eGFR decline.
Methods: TNFR1 levels were measured at baseline, 52 and 104 weeks in plasma 
samples of 297 patients with type 2 diabetes and urinary albumin:creatinine ratio >15 mg/g 
participating in a phase 3 clinical trial. Patients were randomly assigned to CANA 100 or 
300 mg or glimepiride (GLIM) uptitrated to 6 to 8 mg. Repeated measure models were used 
to compare effects of CANA vs. GLIM on TNFR1 over 104 weeks follow-up and to assess 
associations between change in TNFR1 with eGFR change.
Results: During 104 weeks of follow-up, TNFR1 increased in the GLIM group but 
stabilized or decreased in the CANA 100 and 300 mg groups. Compared with glimepiride, 
treatment with CANA 100 and 300 mg dose-dependently decreased TNFR1 by 5.9% 
(1.3 to 10.3; p=0.013) and 9.2% (4.7 to 13.5%; p<0.001). The change in TNFR1 at week 52 
(the earliest available time point) was significantly and independently associated with eGFR 
decline during 104 weeks follow-up (p=0.0234). In increasing tertiles of TNFR1 change, 
eGFR change during 104 weeks follow-up was -0.4 (95%CI -2.3 to 1.5), -4.7 (95%CI -6.5 
to -2.8), and -7.1 (95%CI -9.0 to -5.2) ml/min/1.73m2. Reductions in HbA1c were similar 
with GLIM and CANA during follow-up.
Conclusions: The reduction in TNFR1 with CANA and association between changes 
in TNFR1 and eGFR suggests that TNFR1 may be used to monitor effects of CANA on 
long-term kidney function.
Funding: Commercial Support - Janssen Research & Development, LLC
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Canagliflozin in Patients with Type 2 Diabetes and Macroalbuminuria: 
Data from the CANVAS Program
Vlado Perkovic,1 Brendon L. Neuen,1 Toshiaki Ohkuma,1 Bruce Neal,1 
David R. Matthews,2 Dick de Zeeuw,3 Kenneth W. Mahaffey,4 Greg Fulcher,5 
Richard Oh,6 Qiang Li,1 Meg J. Jardine.1 1The George Institute for Global 
Health, UNSW Sydney, Sydney, NSW, Australia; 2Oxford Centre for Diabetes, 
Endocrinology and Metabolism and Harris Manchester College, University of 
Oxford, Oxford, United Kingdom; 3University of Groningen, University Medical 
Center Groningen, Groningen, Netherlands; 4Stanford Center for Clinical 
Research, Department of Medicine, Stanford University School of Medicine, 
Stanford, CA; 5The Royal North Shore Hospital, University of Sydney, 
St. Leonards, NSW, Australia; 6Janssen Research & Development, LLC, 
Raritan, NJ.
Background: High levels of albuminuria are associated with increased progressive 
loss of kidney function in type 2 diabetes mellitus (T2DM). SGLT2 inhibitors reduce 
glomerular hyperfiltration, which might therefore have particular benefits for people with 
T2DM and macroalbuminuria.
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Methods: The CANagliflozin cardioVascular Assessment Study (CANVAS) Program 
randomized patients with T2DM and a history or high risk of cardiovascular (CV) disease 
to canagliflozin or placebo. This analysis assessed effects of canagliflozin on renal and CV 
outcomes in participants with macroalbuminuria at baseline (urinary albumin:creatinine 
ratio [UACR] >300 mg/g).
Results: The CANVAS Program included 760 participants (7.5%) with 
macroalbuminuria (mean age 64 y, BP 145/80 mmHg, HbA1c 8.5%, estimated glomerular 
filtration rate [eGFR] 66 mL/min/1.73 m2, median UACR 722 mg/g). As compared with 
placebo, canagliflozin significantly reduced the geometric mean UACR (change from 
baseline to end of follow-up –36%, 95% CI –43 to –28); slowed the chronic annual decline 
in eGFR: –1.76 mL/min/1.73 m2 with canagliflozin vs. –4.77 mL/min/1.73 m2 with placebo 
(difference 3.01 mL/min/1.73 m2, 95% CI 2.03-3.99); and reduced the risk of the composite 
outcome of end-stage kidney disease or renal death in combination with either 40% 
decrease in eGFR or doubling of serum creatinine (Figure). Canagliflozin also reduced the 
risk of all-cause mortality (Figure), while effects on CV outcomes were broadly consistent 
with those previously reported for the overall trial population.
Conclusions: Canagliflozin lowers albuminuria and improves outcomes in patients 
with T2DM and macroalbuminuria.
Funding: Commercial Support - Janssen Research & Development, LLC
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Effect of Canagliflozin on Cardiovascular and Renal Outcomes across 
KDIGO Risk Categories: Analysis from the CANVAS Program
Brendon L. Neuen,1 Toshiaki Ohkuma,1 Bruce Neal,2 David R. Matthews,3 
Dick de Zeeuw,4 Kenneth W. Mahaffey,5 Greg Fulcher,6 Jaime Blais,7 Qiang Li,1 
Meg J. Jardine,1,8 David C. Wheeler,9 Vlado Perkovic.1,6 1The George Institute 
for Global Health, UNSW Sydney, Sydney, NSW, Australia; 2The George 
Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia; 3Oxford 
Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester 
College, University of Oxford, Oxford, United Kingdom; 4University of 
Groningen, University Medical Center Groningen, Groningen, Netherlands; 
5Stanford Center for Clinical Research, Department of Medicine, Stanford 
University School of Medicine, Stanford, CA; 6Royal North Shore Hospital, 
Sydney, NSW, Australia; 7Janssen Scientific Affairs, LLC, Titusville, NJ; 
8Concord Repatriation General Hospital, Sydney, NSW, Australia; 9Centre for 
Nephrology, University College London, London, United Kingdom.
Background: The CANagliflozin cardioVascular Assessment Study (CANVAS) 
Program randomized patients with type 2 diabetes to canagliflozin or placebo and 
demonstrated that the drug reduced the risk of cardiovascular (CV) and renal outcomes. 
The Kidney Disease: Improving Global Outcomes (KDIGO) chronic kidney disease 
classification is a risk stratification tool based on estimated glomerular filtration rate (eGFR, 
mL/min/1.73 m2) and urinary albumin:creatinine ratio (UACR, mg/g).
Methods: Absolute effects on CV and renal outcomes were analyzed by baseline 
KDIGO risk category, defined as low risk (eGFR ≥60 and UACR <30), moderate risk 
(eGFR 45-<60 and UACR <30, or eGFR ≥60 and UACR 30-300), high risk (eGFR 
30-<45 and UACR <30, eGFR 45-<60 and UACR 30-300, or eGFR ≥60 and UACR >300), 
and very high risk (eGFR <30 with any UACR, eGFR 30-<45 and UACR ≥30, or eGFR 
45-<60 and UACR >300).
Results: Of 10,142 participants, 10,031 (98.9%) had available baseline eGFR and 
UACR data. The proportion of participants in low, moderate, high, and very high risk 
categories was 58.6%, 25.8%, 10.6%, and 5.0%, respectively. Heterogeneity in absolute 
effects across KDIGO risk categories was observed for the primary outcome (CV death, 
nonfatal myocardial infarction, or nonfatal stroke; P heterogeneity=0.023), hospitalization 
for heart failure (P=0.047), and the renal composite outcome (40% decrease in eGFR, end-
stage kidney disease, or renal death; P=0.001; Figure).
Conclusions: The absolute reduction in CV and renal outcomes with canagliflozin may 
be greater in patients at higher renal risk.
Funding: Commercial Support - Janssen Research & Development, LLC
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Effects of Hyperoxia with and without Klotho Supplementation in a 
Murine Model of Post-Natal Nephrogenesis
Mohammed Farhan Ali,1 Sunil kumar Batlahally venkatarayappa,2 
Merline Benny,2 Claudia P. Rojas,3 Naimeh Da Silva,1 Michael Freundlich,1 
Carolyn L. Abitbol,1 Marissa J. Defreitas,1 Karen C. Young.2 1Department of 
Pediatrics, Division of Pediatric Nephrology, University of Miami, Miami, FL; 
2Department of Pediatrics, Division of Neonatology, University of Miami, 
Miami, FL; 3Department of Pediatrics, Division of Pediatric Pathology, 
University of Miami, Miami, FL.
Background: Preterm infants are born during active nephrogenesis and exposure to 
high oxygen levels has been proposed to cause kidney related injury due to oxidative stress. 
Studies investigating the effects of hyperoxia on nephrogenesis are limited and have not 
evaluated whether these effects are reversible by administration of an agent with antioxidant 
properties. The aim of our study was to determine whether the administration of exogenous 
Klotho, a multi-functional protein that is known to diminish oxidative stress and apoptosis, 
attenuates hyperoxia induced glomerular and tubular injury in rats during nephrogenesis.
Methods: Newborn rat pups were raised in hyperoxia (85% oxygen for 3 weeks and 
then recovered in room air for 3 weeks) or room air (21% oxygen for 6 weeks). Klotho was 
administered intraperitoneally to half of the pups in both groups every other day for the first 
3 weeks. All pups were sacrificed at the end of 6 weeks and the kidneys were assessed for 
glomerular diameter and area using Image J software, and tubular injury using a tubular 
injury scoring system (0- no injury, 5- >75% of tubules injured).
Results: Hyperoxia exposed rats had greater glomerular diameter, area and tubular 
injury scores. The administration of Klotho attenuated tubular injury (Figure A) and 
prevented glomerulomegaly (Figure B).
Conclusions: The findings of this study demonstrate that hyperoxia exposure during 
active nephrogenesis in the neonatal rat pups results in increased glomerular size and 
tubular injury and that the exogenous administration of Klotho in these pups attenuates 
hyperoxia induced tubular injury and prevents glomerulomegaly at 6 weeks. Future studies 
aimed at exploring the therapeutic potential of Klotho in neonatal models of kidney injury 
are needed.
Funding: Private Foundation Support
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Increased Mortality in Underweight but Not Obese Critically Ill Patients – A 
Secondary Analysis of the AWARE Study
Rajit K. Basu,2 Itay Ayalon,1 Jessica G. Woo,3 Ahmad Kaddourah,3 
Stuart Goldstein,3 Jennifer M. Kaplan.4 1Dana-Dwek Children’s Hospital, Tel-
Aviv Medical Center, Tel-Aviv, Israel; 2Children’s Healthcare of Atlanta, Atlanta, 
GA; 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 
4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Background: Obesity is a significant public health problem with an increasing 
prevalence in both adults and children. The effect of obesity on critical care mortality is 
controversial and even less is known about the effect of underweight status on mortality. We 
investigated the prevalence and outcomes of obesity and underweight in a large, critically 
ill pediatric cohort.
Methods: We conducted a secondary analysis of the prospective, observational, 
multinational Assessment of Worldwide Acute kidney injury, Renal angina, and 
Epidemiology (AWARE) study data. PICU patients, 3mos to 25yrs, were eligible but only 
subjects with documented age, sex, height and weight were analyzed. Patients were divided 
into 4 groups (under, normal, overweight and obese) based on their BMI percentile-for-age 
and sex according to WHO (for patients 3mos- 2yrs) and CDC criteria (for patients ≥2yrs). 
The primary outcome was 28d mortality. We planned for an analysis of a subgroup of septic 
patients.
Results: A total of 3,719 patients were evaluated of which 542 (14%) had a primary 
diagnosis of sepsis. Twenty-nine percent of patients were underweight, 44% normal 
weight, 11% overweight and 16% obese. The 28d mortality rate was 3.5% for the 
entire cohort and 8.9% for the septic group and differed significantly by weight status 
(5.7%, 3%, 2.1% and 1.7% for under, normal, overweight and obese subjects, p<0.0001 
and 14.9%, 6.5%, 3.5%, 5.3% in the septic group respectively, p=0.003). In a fully adjusted 
model, 28d mortality risk was 1.8-fold higher in underweight (adjusted Odds Ratio [OR] 
and 95%CI: 1.2-2.8]) compared to normal weight in the entire group and 3.4 [1.4-8.4] 
in the septic group with overweight and obese not having increased risk in both cohorts. 
Interestingly underweight patients had a significantly higher frequency of fluid overload 
>10% at day 3 (44.0% vs. 32.5%, 26.1%, 19.1% for under, normal, overweight and obese 
subjects, p<0.0001) without increased frequency of KDIGO-AKI or renal replacement
therapy.
Conclusions: Underweight subjects make up a significant proportion of patients in 
the PICU. Underweight, not obesity, is independently associated with increased risk for 
mortality which may be associated to their higher frequency of fluid overload during their 
ICU stay.
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Central Blood Pressure and Measures of Vascular Health in Children with 
ADPKD
Paul Winyard,1 Matko Marlais,1,2 Haotian Gu,3 Manish Sinha.2 1Nephro-Urology 
Unit, UCL GOS Institute of Child Health, London, United Kingdom; 2Evelina 
London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, 
London, United Kingdom; 3King’s College London, London, United Kingdom.
Background: Hypertension is increasingly recognised in children with Autosomal 
dominant polycystic kidney disease (ADPKD) but underlying cardiovascular factors such 
as central blood pressure (cBP) and pulse wave velocity (PWV) may change before overt 
hypertension. We assessed peripheral BP (pBP), cBP, pulse pressure (PP) amplification 
ratio, carotid-femoral PWV (PWVcf) and indexed left ventricular mass (LVMI) in children 
with ADPKD.
Methods: This was a two-centre prospective observational study of children with 
ADPKD versus age and BMI-matched healthy controls. All children underwent manual 
pBP, cBP using radial applanation tonometry and PWVcf with a SphygmoCor device. 
LVMI was measured by 2D m-mode echocardiography. 24-hour ambulatory BP monitoring 
(ABPM) and urine albumin: creatinine ratio was assessed in children with ADPKD. 
Estimated GFR was calculated in children where blood tests were performed.
Results: 47 ADPKD and 49 healthy controls (mean ages 11.4 and 11.7 years, 55% and 
39% male respectively) were recruited from two paediatric nephrology centres. Children 
with ADPKD had significantly higher pBP (mean 112/65mmHg vs. 104/60mmHg, systolic 
p<0.001) and cBP (mean 97/67mmHg vs. 87/61mmHg, systolic p<0.001) compared to 
healthy children. There was no significant difference between clinic pBP and 24-hour 
ABPM. 9 children (19%) with ADPKD were on anti-hypertensive medication. Children 
with ADPKD had a significantly lower PP amplification ratio (1.59 vs. 1.67, p=0.04) 
compared to healthy children. There was no difference in PWVcf between affected and 
healthy children (mean 5.74m/s vs. 5.57m/s, p=0.46). Children with ADPKD had a 
significantly higher LVMI (mean 30.4 g/m2.7 vs. 26.2 g/m2.7, p=0.01), although only one 
had frank hypertrophy. There was significantly lower eGFR (mean 89.9ml/min/1.73m2 
vs. 101.4ml/min/1.73m2, p<0.01) and 42% of children with ADPKD had evidence of 
microalbuminuria with a raised albumin:creatinine ratio.
Conclusions: This study confirmed that a significant percentage of children with 
ADPKD have higher blood pressure, with novel cardiovascular findings of normal PWV 
but significantly lower PP amplification and increased LVMI. These early cardiovascular 
abnormalities should be amenable to antihypertensive therapy, reinforcing the need for 
routine screening of children and young people with ADPKD. eGFR and microalbuminaria 
warrant checking at the same visit.
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Should RAAS Inhibition Be Discontinued in Children with Advanced 
CKD? Results of the 4C Study
Valentina Gracchi,1 Sophie Van den Belt,1 Hiddo J. Lambers Heerspink,1 
Elke Wuehl,2 Dick de Zeeuw,1 Franz S. Schaefer.2 4C Study group 1University 
Medical Center Groningen, Groningen, Netherlands; 2University of Heidelberg, 
Heidelberg, Germany.
Background: RAAS inhibition (RAASi) is used for renoprotection in children with 
Chronic Kidney Disease (CKD). RAASi is sometimes discontinued in advanced stages of 
CKD. We studied the reasons and impact of RAASi discontinuation on important markers 
of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children 
with CKD (4C) study.
Methods: 69 children with CKD (67% male, mean age 13.7 years, mean eGFR 
27 ml/min/1.73m2) who discontinued RAASi during prospective follow-up were studied. 
Initial 6-month changes in blood pressure, albuminuria and potassium after discontinuation 
were assessed. The rate of eGFR decline (eGFR slope) during a median of 1.9 years before 
and 1.2 years after discontinuation were estimated using a linear mixed effects model.
Results: Reported reasons for RAASi discontinuation were increase in serum creatinine 
(33%), hyperkalemia (23%), and symptomatic hypotension (17%). After discontinuation of 
RAASi, blood pressure and albuminuria increased whereas potassium decreased. eGFR 
loss accelerated after RAASi discontinuation from -1.5 (95%CI -2.4 to -0.6) during RAASi 
treatment to -3.9 (95%CI -5.1 to -2.6) ml/min/1.73m2 per year (p=0.005). In a matched 
control group of children who continued RAASi, renal function decline was stable before 
and after timepoint of matching (eGFR slope -1.8 (95%CI -2.6 to -1.1) versus -1.2 (95%CI 
-2.0 to -0.4) ml/min/1.73m2/year; p=0.30; Figure).
Conclusions: Discontinuation of RAASi in children with CKD is associated with an
acceleration of renal function decline. These results indicate that RAASi is nephroprotective 
even in advanced CKD and that stopping this therapy, even for good clinical reasons, should 
be weighed against a potential negative impact on long term renal function.
eGFR over time in patients who discontinued RAASi (blue) and matched controles (red). 
Grey area: 95%CI per group.
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Uric Acid, Kidney Function, and Cardiovascular Risk among Children 
with CKD
Shireen Hashmat,1 Shuai Jiang,2 Derek Ng,3 Susan L. Furth,6 Bradley A. Warady,5 
Cynthia G. Pan.4 1Pediatrics, University of Chicago, Chicago, IL; 2Johns 
Hopkins University, Baltimore, MD; 3Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD; 4Children’s Corporate Center, Milwaukee, WI; 
5Children’s Mercy Kansas City, Kansas City, MO; 6The Children’s Hospital of 
Philadelphia, Philadelphia, PA.
Background: Previous studies have shown that high uric acid (UA) is associated with 
cardiovascular risk factors in adults with and without chronic kidney disease (CKD), but 
the relationships in children with CKD are not well characterized. We used longitudinal 
data from the Chronic Kidney Disease in Children (CKiD) cohort study to investigate the 
relationships between UA, kidney function and cardiovascular outcomes.
Methods: The primary exposure was time-varying UA measured at annual visits. 
The primary outcomes were blood pressure (BP; clinical and ambulatory) and markers of 
cardiometabolic health (ie, lipids). Multivariate linear mixed effects models described UA 
z-scores (scaled within the CKiD population) with BP and lipid outcomes.
Results: A total of 718 participants (mean age= 13, 60% male and 29% with a
glomerular-based CKD diagnosis) with at least 1 UA measurement were included in the 
analysis. At baseline, 47% had a high UA based on age- and gender-specific cutpoints. 
The figure (below) demonstrates that the UA increased with age, as well as decreasing 
eGFR even when adjusted for age. Whereas UA was associated with higher clinical 
and ambulatory BP, the differences were not significant. In models adjusted for age, 
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gender, race, BMI, CKD diagnosis and eGFR, participants with one SD higher UA had 
significantly lower HDL (47 vs 50 mg/dL), higher LDL (93 vs 89 mg/dL) and higher 
total triglycerides (116 vs 110 mg/dL) at baseline compared to those with the average 
UA. Higher UA was also significantly associated with slower increase in HDL with time 
(p= 0.002). UA was not associated with longitudinal changes in clinical or ambulatory BP 
measurements.
Conclusions: There is a strong relationship between eGFR and UA in children with 
CKD. Higher UA is associated with a more severe lipid profile at baseline and over time, 
but is not independently associated with hypertension.
Funding: NIDDK Support
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Kidney Biomarkers for CKD Risk Stratification after Pediatric Cardiac 
Surgery in the ASSESS-AKI Study
Jason H. Greenberg,1 Michael Zappitelli,2 Vernon M. Chinchilli,3 
Steven G. Coca,4 Mark M. Wurfel,5 Edward D. Siew,6 Alan S. Go,7 
Paul L. Kimmel,8 James S. Kaufman,9 Prasad Devarajan,10 Chirag R. Parikh.11 
ASSESS-AKI 1Yale University, New Haven, CT; 2Toronto Hospital for Sick 
Children, University of Toronto, Toronto, ON, Canada; 3Penn State College of 
Medicine, Hershey, PA; 4Icahn School of Medicine at Mount Sinai, New York, 
NY; 5University of Washington, Seattle, WA; 6Vanderbilt University School of 
Medicine, Nashville, TN; 7Kaiser Permanente Northern California, Oakland, 
CA; 8National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), 
Bethesda, MD; 9VA New York Harbor Healthcare System, New York, NY; 
10Cincinnati Children’s Hospital, Cincinnati, OH; 11Yale University and VAMC, 
New Haven, CT.
Background: We have previously demonstrated that children who require surgery for 
congenital heart disease have increased risk for long-term hypertension and chronic kidney 
disease (CKD). Biomarkers of ongoing kidney injury and fibrosis after surgery may indicate 
subclinical kidney disease and assist with prognosis for long-term hypertension and CKD.
Methods: We enrolled children from 1 month to 18 years old undergoing cardiac 
surgery in the ASSESS-AKI Study. We used Cox proportional hazards regression to 
assess the association between eight urinary biomarkers (log2 transformed) measured 
3 months after cardiac surgery: NGAL, KIM-1, IL-18, L-FABP, uromodulin, MCP-1, 
YKL-40, and albumin, with the outcomes of incident hypertension (systolic or diastolic 
BP ≥ 95% for age, height, and gender) and CKD (modified Schwartz eGFR<90 ml/
min/1.73m2) at yearly in-person visits over 4 years.
Results: 117 children undergoing cardiac surgery were enrolled. During 48 months 
of follow-up there were 44 (38%) and 71 (61%) children who developed hypertension 
and CKD, respectively. After adjustment for sex, AKI during the index hospitalization 
for surgery, and pre-surgery eGFR, only urine albumin was independently associated 
with incident CKD (HR, 1.52; 95% CI, 1.20-1.93), but was not associated with incident 
hypertension (Table). None of the other 7 urinary biomarkers of injury or fibrosis were 
associated with either outcome.
Conclusions: At 3 months after cardiac surgery, children with higher urine albumin, 
but not any other tubular injury and fibrosis biomarkers, were more likely to develop CKD.
Funding: NIDDK Support
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Adaptation of the Kidney Failure Risk Equation to Predict Risk of ESRD 
in Children
Elaine Ku,1 Elke Wuehl,6 Erica Winnicki,1 Mark Mitsnefes,2 
Charles E. McCulloch,3 Bradley A. Warady,4 Susan L. Furth,5 Franz S. Schaefer.6 
1UC San Francisco, San Francisco, CA; 2Cincinnati Children’s Hospital, 
Cincinnati, OH; 3University of California San Francisco, San Francisco, CA; 
4Children’s Mercy Kansas City, Kansas City, MO; 5The Children’s Hospital of 
Philadelphia, Philadelphia, PA; 6University of Heidelberg, Heidelberg, 
Germany.
Background: The Kidney Failure Risk Equations (KFREs) have been shown to 
predict ESRD risk in children with mild-to-moderate CKD in the US. Whether the KFRE 
accurately predicts progression to ESRD in children with more advanced CKD and children 
outside of the US is unknown. KFREs to predict ESRD risk in North American (NA) and 
non-North American (NNA) adults are currently available.
Methods: We studied 653 children from 4C study, 341 children from ESCAPE trial, 
and 633 children from CKiD study with an eGFR <60 mL/min/1.73 m2. The primary 
predictors were the 4-variable (age, sex, bedside eGFR, albumin-to-creatinine ratio) NA 
and NNA KFRE score which provides estimates of the risk of ESRD over a 2- and 5-year 
horizon. C-statistics were used to compare discrimination of the risk for ESRD by the 
KFRE, and this predicted risk of ESRD was compared to observed failure rates.
Results: Median follow-up time was 2.8 years in 4C, 4.7 years in ESCAPE, and 3.8 
years in CKiD. The NA and NNA 4-variable KFRE strongly discriminated risk of ESRD 
in children outside the US, with a C-statistic of 0.82 and 0.79 in 4C and 0.90 and 0.87 in 
ESCAPE over a 2- and 5-year horizon, respectively. The predicted risk closely matched 
the observed ESRD rates in CKD stage 3, but over-predicted ESRD risk in CKD stage 4-5 
across all cohorts (Figure 1). After we re-calibrated the equation, performance of the KFRE 
in advanced CKD improved (Figure 2).
Conclusions: The KFRE is a simple tool that strongly discriminates the risk of ESRD 
in children with CKD in the US and internationally, although its performance was less 
robust in children with advanced CKD. With re-calibration, its performance in more 
advanced CKD was substantially improved.
Funding: NIDDK Support
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Children in CKiD with Congenital, Non-Glomerular Form of Progressive 
CKD Will Experience Renal Replacement Therapy by 40 Years of Age
Derek Ng,1 Matthew Matheson,1 Bradley A. Warady,2 Susan L. Furth,3 
Alvaro Munoz.1 1Johns Hopkins Bloomberg School of Public Health, Baltimore, 
MD; 2Children’s Mercy Kansas City, Kansas City, MO; 3The Children’s Hospital 
of Philadelphia, Philadelphia, PA.
Background: The Chronic Kidney Disease in Children (CKiD) study provides a 
unique opportunity to prospectively describe a life course characterization of progressive 
non-glomerular disease prior to renal replacement therapy (RRT). Our aim was to maximize 
the heterogeneous disease duration at entry in this cohort to estimate the age by which all 
children with congenital, non-glomerular disease will require RRT.
Methods: The times to RRT in CKiD children were characterized by parametric 
survival models (generalized gamma (GG) distribution). The time scale was years from 
NG diagnosis (age) and accounted for late entries due to heterogeneous disease duration at 
enrollment. Models were fit overall, and stratified by race and gender.
Results: Among 626 children, the median duration of disease at entry was 9 years 
(range 2 to 18) and median duration at end of follow-up was 15 years (maximum= 27). 
Three diagnosis groups represented 67%: obstructive uropathy (24%), hypo/dysplasia 
(24%) and reflux nephropathy (19%). Over approximately 25 years (capitalizing on 
staggered entries), 186 initiated RRT. The GG fit was excellent and demonstrated that 50% 
received RRT by age 18.5 and estimated that 99.6% will receive RRT by age 40 (Figure). 
The times to RRT did not differ significantly by race (p=0.25) or gender (p=0.40), with 
similar 40 year estimates of RRT for nonblacks (99.9%), blacks (98.8%), males (99.9%) 
and females (97.9%).
Conclusions: Practically all CKiD participants with progressive non-glomerular 
disease will receive RRT by 40 years old, much earlier than reports from European 
registries. This is likely due to a combination of access to care, organ availability and 
disease severity. Methodologically, these data enable handling right censored observations 
as interval censored, thus enriching parametric survival methods.
Funding: NIDDK Support
Percent of children with non-glomerular CKD initiating RRT by age
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Racial and Ethnic Disparities in Pediatric Kidney Transplant Outcomes in 
the United States: Have We Made Any Progress over the Last Twenty 
Years?
Tanjala S. Purnell,1 Xun Luo,1 Karina Covarrubias,1 Deidra C. Crews,1 
Lisa A. Cooper,1 Sunjae Bae,1 O. N. Ray Bignall,2 Macey L. Henderson,1 
Allan Massie,1 L. Ebony Boulware,3 Dorry L. Segev.1 1Johns Hopkins University 
School of Medicine, Baltimore, MD; 2Cincinnati Children’s Hospital Medical 
Center, Cincinnati, OH; 3Duke University School of Medicine, Durham, NC.
Background: A recent JASN study demonstrated dramatic reductions in disparities in 
adult kidney transplant (KT) outcomes in the US. We examined twenty-year trends in pediatric 
KT outcomes to determine whether pediatric KT disparities also changed over time.
Methods: Using OPTN data, we performed Cox proportional hazards regression 
models to compare patient outcomes among 3,295 White, 2,049 Black, and 2,073 Hispanic 
children (aged 0-17 years) who received a KT in the US between January 1, 1995 and 
December 31, 2014. We adjusted regression models for differences in recipient, donor, and 
transplant center factors.
Results: From 1995 to 2014, survival after KT improved for all recipients. (Figure 1)  
However, racial/ethnic disparities in long-term survival worsened over time (p<0.05 for 
statistical interaction). In 1995, compared with long-term mortality in White KT recipients, 
the adjusted hazard ratio (aHR) for Black recipients was 0.89 (95% CI: 0.67, 1.18) 
and for Hispanic recipients was 0.51 (95% CI: 0.34, 0.76). In 2014, compared with White 
recipients, the aHR for Black recipients was 1.84 (95% CI: 1.10, 3.07) and for Hispanic 
recipients was 0.71 (95% CI: 0.37, 1.35).
Conclusions: In stark contrast to the prior findings of reduced disparities for adult KT 
recipients, we found that disparities in long-term survival among pediatric kidney transplant 
recipients worsened over the last two decades in the US. Strategies to elucidate and 
intervene on mechanisms for disparities in long-term outcomes among pediatric recipients 
are needed.
Funding: NIDDK Support, Other NIH Support - NHLBI, AHRQ, Other U.S. 
Government Support, Private Foundation Support
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Prevalence of Blood Pressure Control in Children with Kidney Transplant
Pamela D. Winterberg,1,2 Rouba Garro,1,2 Devesh S. Dahale,3 Jens W. Goebel,4 
David K. Hooper.3 Improving Renal Outcomes Collaborative 1Department of 
Pediatrics, Emory University School of Medicine, Atlanta, GA; 2Children’s 
Healthcare of Atlanta, Atlanta, GA; 3Cincinnati Children’s Hospital Medical 
Center, Cincinnati, OH; 4Children’s Hospital Colorado, Aurora, CO.
Background: Hypertension (HTN) is common in children following kidney transplant 
(KT) with reported prevalence of 60-90%. Uncontrolled blood pressure (BP) is associated 
with cardiovascular mortality and decreased graft survival. The Improving Renal Outcomes 
Collaborative (IROC) is a networked learning health system of 23 pediatric centers 
dedicated to improving health outcomes and longevity for children with kidney disease 
by sharing best practices and clinical data, and engaging in quality improvement (QI). We 
aimed to determine the baseline prevalence of systolic BP control and treatment within 
the collaborative after implementing standardized processes for BP measurement across 
centers.
Methods: Patient and KT characteristics were uploaded into the IROC registry via 
UNOS TEIDI reports. Biometric data, BP measurements, and medications are prospectively 
entered by centers for each clinic visit. BP percentiles are automatically calculated in the 
registry using the 2004 NHBPEP 4th Report to determine BP status for each visit (e.g. 
normal, pre-HTN, stage 1, stage 2). We examined the latest clinic visit for each patient >90 
days post-transplant in the registry. Patients were classified by systolic BP control (<90th 
percentile) and treatment status.
Results: Of the 935 unique patients with at least 1 visit in the registry, 56% had 
uncontrolled systolic BP (pre-HTN or greater) and/or were on BP medications. Of the 492 pts 
receiving BP meds, 132 (27%) had uncontrolled systolic BP at last visit. In addition, 31 patients 
(3% of total) had uncontrolled systolic BP at last visit but no record of BP medication. Of those 
treated, 80% had one, 16% had 2, and 8% had 3 or more active BP meds. Calcium channel 
blockers (80%) were most commonly used for treatment of BP followed by renin-angiotensin 
system blockade (33%), and beta-adrenergic blockade (23%).
Conclusions: HTN is common in pediatric KT patients in the IROC registry. Nearly 
one-quarter of those treated for HTN have not achieved systolic BP control. Future studies 
within IROC will evaluate patient- and center-level factors influencing BP control.
Patients categorized by BP control and treatment status.
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Glomerular Diseases: Spotlighting Immunology and Inflammation - I
IL-17 Signaling in CD4+ T Cells Control TH17 Responses
Tilman Schmidt,1 Sonja Kapffer,1 Christian F. Krebs,1 Hans-Joachim Paust,2 
Ulf Panzer.1 1Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 
2Hamburg University Hospital, Hamburg, Germany.
Background: The interleukin-17 family (IL-17A-F) plays a critical role in 
autoimmune and chronic inflammatory diseases, such as crescentic GN. A heterodimeric 
receptor complex consisting of IL-17RA and a ligand specific IL-17 receptor subunit 
(IL-17RB-E), which is expressed by epithelial and endothelial tissue cells, mediates 
their biological effects. In contrast, the IL-17 receptor expression pattern and function on 
hematopoietic cells, e.g. CD4+ T cell subsets, remains to be determined.
Methods: Crescentic GN (Nephrotoxic Nephritis, NTN) was induced in IL-17A, IFNγ 
and Foxp3 triple-reporter mice for in vivo cell sorting of renal CD4+ T cell subsets and 
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subsequent single cell RNAseq of CD4+ T cells using the 10X Single Cell system. The effect 
of IL-17 signaling in CD4+ T cells was analyzed by CD4 T cell polarization experiments. 
Moreover, we generated TH17 cell specific IL-17RA gene-deficient mice to study the role of 
IL-17 signaling in Th17 cells in the NTN model.
Results: mRNA expression analysis of sorted T cells revealed a predominant 
expression of IL-17RC and IL-17RE by IL-17Apositive TH17 cells, high IL-17RB expression 
by Foxp3positiveTregs, whereas IL-17RA is ubiquitously expressed by all CD4+ T-cell 
subsets, demonstrating for the first time a T cell specific expression pattern of IL-17 
receptors. In vitro T cell polarization experiments revealed that IL-17A-RC signaling 
downregulates IL-17A expression of TH17 cells. In line, competitive adoptive transfer 
experiments of wildtype and IL-17RA-/- CD4+ T cells into nephritic Rag1-/- mice revealed 
that TH17 genes were upregulated in cells lacking the IL-17RA, indicating that IL-17 
signaling on CD4+ T-cells is instrumental for the control of the TH17 response. In addition, 
scRNAseq analysis of 12,971 renal CD4+ T cells revealed that, TH17 cells lacking the 
IL-17RA form a distinct cluster which is characterized by upregulation TH17 marker genes. 
Most importantly, mice lacking IL-17 signaling specifically in TH17 cells demonstrated 
dysregulation of TH17 immune response with higher production of IL-17A and F after 
induction of NTN and an accelerated course of the disease.
Conclusions: Our findings indicate that IL-17 receptor signaling in CD4 T cells control 
TH17 immune response via a self-inhibitory loop. These findings might provide new insight 
into the development of more efficient anti-TH17 treatment strategies.
Funding: Government Support - Non-U.S.
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Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Bowman Capsule Provides Protective Podocyte Niche: Implications for 
Crescentic Glomerulonephritis
Anqun Chen,1,2 Kyung Lee,2 Vivette D. D’Agati,3 Tianjun Guan,1 John C. He,2 
Judith Agudo,2,4 Detlef O. Schlondorff.2 1ZhongShan Hospital, Xiamen 
University, XiaMen, China; 2Icahn School of Medicine at Mount Sinai, New 
York, NY; 3Columbia University College of Physicians and Surgeons, New York, 
NY; 4Department of Cancer Immunology & Virology, Dana-Farber Cancer 
Institute, Boston, MA.
Background: A role for CD8+ cytotoxic T cells (CTLs) in peri-glomerular infiltrates 
during glomerulonephritis (GN) has been proposed, but how and if CTLs can enter 
Bowman’s space remains unclear.
Methods: CD8+ T cells from a newly generated transgenic mouse, termed Jedi (for 
Just EGFP Death Inducing) T cells that are cytotoxic for any EGFP expressing cells were 
used. Jedi T cells and lentivirus expressing EGFP were injected into transgenic mice with 
podocyte-specific EGFP expression mice in normal conditions and in a nephrotoxic serum 
nephritis (NTSN) model. 4 days after induction of NTSN, Jedi or control CD8+T cells were 
injected, and the mice were sacrificed at day 12. Proteinuria and blood urea were measured. 
EGFP+ podocyte areas were analyzed. In biopsies from patients with crescentic GN co-
staining of CD8+ T cells and Bowman’s capsule were performed.
Results: In control mice, Jedi T cells could not access EGFP+ podocytes. Conversely, 
when we induced NTSN and injected Jedi T cells, EGFP+ podocyte transgenic mice showed 
enhanced proteinuria and higher blood urea levels. Morphometric analysis showed greater 
loss of EGFP+ podocytes, which was associated with severe crescentic and necrotizing 
GN. Notably, only glomeruli with disrupted Bowman’s capsule displayed massive CD8+ 
T cell infiltrates that were in direct contact with EGFP+ podocytes, causing their apoptosis. 
Comparable findings were obtained in biopsies from patients with crescentic GN, where 
infiltration of CD8+ T cells inside Bowman’s capsule also only occurred after breaches in 
the capsule allowed access of CD8+ T cells to the glomerular tuft, resulting in its destruction.
Conclusions: Under control conditions Bowman’s capsule provides an immunologically 
protected niche for podocytes from CTL. However any breach in Bowman’s capsule, as 
occurs during crescentic GN, allows access of CTLs to Bowman’s space with catastrophic 
consequences for the glomerulus, converting a potentially reversible GN into a rapidly 
progressive GN leading to end stage kidney disease. Translating these mechanistic insights 
to human crescentic nephritis should direct future therapeutic interventions at blocking 
CD8+ T cells, especially in progressive stages of rapidly progressive GN.
Funding: Other NIH Support - R01DK078897; R01DK98126, Veterans Affairs 
Support
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Myeloperoxidase Mediates Renal Damage in Crescentic Glomerulonephri-
tis That Can Be Successfully Targeted In Vivo
Marilina Antonelou,1 Erik Michaëlsson,2 Chun J. Wang,3 Lucy S. Walker,3 
Robert J. Unwin,2,1 Alan D. Salama.1 1Centre for Nephrology, University College 
London, London, United Kingdom; 2Heart Failure Bioscience and Early 
Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), IMED 
Biotech Unit, AstraZeneca, Sweden, AstraZeneca, Gothenburg, Sweden; 
3Institute of Immunity and Transplantation, University College London, London, 
United Kingdom.
Background: Myeloperoxidase (MPO) released following neutrophil and monocyte 
activation can lead to host tissue damage by generating ROS and promoting further 
leukocyte activation. Extracellular glomerular MPO deposition has been shown in ANCA 
associated vasculitis (AAV) and may promote T and B cell glomerular targeting to enhance 
crescentic glomerulonephritis (CGN). MPO-deficient mice have less CGN but enhanced T 
cell activity (Odobasic, 2007). We investigated the role of MPO in mediating glomerular 
damage and leukocyte activation using a novel MPO inhibitor, AZM198.
Methods: A) We stained renal biopsies from patients with CGN due to SLE, IgA, 
anti-GBM disease, ANCA- and ANCA+ GN, for MPO and CD15. B) We measured MPO 
activity in the supernatants of AAV patient neutrophils and healthy controls, stimulated 
by different means in the absence and presence of AZM198. C) We induced nephrotoxic 
nephritis (NTN) in C57BL/6 mice investigating the effect of AZM198 on CGN severity and 
T cell activity and D) tested the effect of AZM198 on antigen-specific T cell responses using 
adoptive transfer of DO11.10 lymphocytes into OVA immunised mice.
Results: All biopsies with CGN had extracellular glomerular MPO deposition. In 
vitro, AZM198 led to a significant reduction in MPO activity measured in the supernatants 
of PMA (n=16, median(IQR) 37.4(9-175.6) vs12.93(1.9-152.8)U/g, p<0.05), TNF(n=8, 
229.2(130.3-950.6) vs108.5(33.3-138.1)U/g, p<0.05) and pANCA(n=6,185.8(79.9-278.9) 
vs114.3(45.9-340.6)U/g, p=0.19) stimulated neutrophils. In vivo, AZM198 attenuated 
glomerular inflammation (NTN model), defined by proteinuria (A,p=0.01) and glomerular 
thrombosis (B,p=0.04,vehicle n=13, MPOi n=15), while reducing CD4 activation. In the 
adoptive cell transfer model, AZM198 led to a non-significant reduction of CD44 and KJ 
expression on CD4+ T cells in the draining lymph nodes (C, vehicle n=3, MPOi n=3).
Conclusions: Therapeutic MPO inhibition reduced neutrophil degranulation in patients 
with AAV and attenuated kidney damage in preclinical models of CGN without augmenting 
adaptive immune responses, suggesting it may be a novel adjunctive therapy in various 
forms of CGN.
TH-OR054 Oral Abstract Thursday
Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Proteinase 3 Promotes Giant Cell Formation and Granulomata In Vitro 
and In Vivo Implicating a Key Role in GPA Pathogenesis
Scott R. Henderson, Maryam Khosravi, Alan J. Greig, Paul Frankel, 
Alan D. Salama. University College London, London, United Kingdom.
Background: Granulomatosis with polyangiitis (GPA) is characterised by ANCA 
reactivity towards proteinase 3 (PR3), PR3 deposition in granulomatous lesions and 
increased neutrophil membrane PR3 expression, inhibiting apoptotic cell phagocytosis by 
macrophages. We investigated whether persistent and excessive PR3 expression in GPA 
may underlie giant cell and granuloma formation.
Methods: PBMCs were isolated from healthy controls(HC)(n=10), GPA(n=10) 
and microscopic polyangiitis(MPA)(n=10) patients and monocytes isolated. Cells were 
stimulated with either enzymatically active (aPR3) or inactive PR3(iPR3) or control auto-
antigen myeloperoxidase (MPO). Light, epifluorescence and confocal microscopy was used 
to confirm cell fusion at different time points. Mpeg:mcherry macrophage zebrafish at 24 
hours post-fertilisation were injected with aPR3 or iPR3 or albumin. Fish were imaged by 
lightsheet microscopy 6 days later.
Results: Monocyte aggregation and giant cell formation occurred following stimulation 
with both aPR3 and iPR3 with a greater number (p<0.01) and size of aggregates (p<0.001) 
in GPA patients compared to MPA patients and HC. Typical granuloma were observed using 
PBMC preparations with a greater number (p<0.001) and size (p<0.001) of aggregates seen 
in GPA patients. There was no significant difference between aPR3 or iPR3. No effect 
was seen with MPO. Supernatant profiling implicated specific roles for pro-inflammatory 
cytokines. In zebrafish (n=9/group), both aPR3 and iPR3 were associated with a significant 
increase in cell fusion and aggregate volume (p<0.001) when compared to albumin injected 
controls (figure).
Conclusions: These models support a role for PR3 in promoting monocyte and 
macrophage fusion and granuloma formation in vitro and in vivo, and provide an opportunity 
to test specific therapeutics.
Macrophage aggregation in zebrafish (volume=purple min;red max)
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TH-OR055 Oral Abstract Thursday
Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Sortilin-Related Receptor (SORL1) Mediates Glomerulopathic Light 
Chain Interactions with Mesangial Cells (MCs)
Guillermo A. Herrera, Jiamin Teng, Xinggui Shen, Chun Zeng, Elba A. Turbat-
Herrera. Louisiana State University Health Sciences Center, Shreveport, LA.
Background: It has been proven that glomerulopathic (G), but not tubulopathic (T) 
light chains (LCs) interact with mesangial cells (MCs) using a receptor membrane. Both 
light chain deposition disease (LCDD) and amyloid- producing (AL) LCs use the same 
receptor but lead to divergent downstream mesangial cell/matrix alterations. Tubulopathic 
LCs do not interact with MCs.
Methods: Three AL, two LCDD and one tubulopathic-LCs (10 ug/ml) were incubated 
with MCs for 30 minutes, cross-linked using DSTTP and subsequently, SPS-PAGE gels were 
run to identify bands. Bands above 70kD were cut and analyzed using mass spectroscopy 
(MS). Proteins obtained from various LCs cross linked to MCs were compared to identify 
receptors shared by the GLCs. TLC was used as a control. Fluorescein-labeled antibody to 
the SORL1 protein receptor and a second Texas red labeled antibody for the GLCs were 
used to evaluate for colocalization.
Results: Several transient MC receptors were shared by the 5 GLCs including: 
G-protein coupled, ligand-gated ion channel/transient receptor potential cation channel,
subfamily M, and extracellular matrix linker protein receptor/cell adhesion-molecule
extracellular matrix glycoprotein receptors. The one unique membrane receptor shared
by the 5 GLCs was SORL1 located on chromosome 11, a lysosomal sorting receptor
engaged in directing internalized proteins to the endolysosomal system and participating
in microvesicular protein movement inside MCs. SORL1 was colocalized with both AL
and LCDD light chains using double fluorescence labeling techniques. No localization was 
noted with TLC.
Conclusions: SORL1 (238 kD mw) was expressed when GLCs interact with MCs 
and not when TLCs were incubated with MCs or when MCs were incubated without LCs. 
Engagement of this receptor serves to direct GLCs, depending on their physicochemical 
characteristics, to various intracellular compartments where crucial pathogenetic events 
occur. SORL1 had not been previously identified as a MC receptor but it had been found to 
be present in the kidneys with no specific localization yet defined prior to this study. SORL1 
was colocalized with LCDD and AL-LCs at the cell surfaces and inside MCs. There was no 
colocalization with TLC.
TH-OR056 Oral Abstract Thursday
Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Disruption of Endosomal Trafficking of Membrane Bound Nephrin 
Results in an Earlier Phenotype in Nephrin Deleted Adult Mice
Rakesh Verma,1 Madhusudan M. Venkatareddy,1 Gabriel M. Cara-Fuentes,1 
Sanjeevkumar R. Patel,2 Puneet Garg.1 1University of Michigan, Ann Arbor, MI; 
2University of Michigan Hospitals, Ann Arbor, MI.
Background: In a recent publication we reported that deletion of nephrin in an adult 
mature glomerulus results in FSGS. Following cre-induction a small fraction (10-15%) of 
nephrin remains at the membrane and is sufficient to maintain the slit diaphragm for 4-6 
weeks. In vitro studies have suggested that membrane bound nephrin undergoes endocytic 
recycling. Vesicular trafficking is an important part of cellular development and growth, 
helping in maintaining a balance between synthesis, degradation and recycling of cellular 
components. Vps34, an important phosphoinositol kinase that generates PI3P, plays critical 
role in vesicular trafficking. We hypothesized that in our model recycling is responsible for 
maintenance of nephrin at the membrane following nephrin deletion.
Methods: Standard biochemical and cell biology techniques were used to analyze 
kidneys from knock out mice. Cre-loxP system was used to generate podocyte specific 
deletion of nephrin and vps34.
Results: Nephrin deleted adult animals have normal phenotype at 4-6 weeks age, 
when mice develop proteinuria. Vps34fl/fl, cre+ mice have normal phenotype at birth, develop 
massive proteinuria and accumulation of vesicles by 3 weeks of age and majority of 
them die by 9 weeks of age. Immunogold EM analysis reveals accumulation of Nephrin 
in vesicles suggesting involvement of Vps34-dependent endocytic pathway in nephrin’s 
maintenance at the slit diaphragm. In order to examine the role of endocytic recycling of 
nephrin at the membrane we generated a mouse model where both nephrin and vps34 are 
simultaneously deleted using tamoxifen in an adult mature mouse podocytes. These double 
knockout mice develop proteinuria at 1 week of age and die at 10-12 days indicating a 
earlier phenotype compared to deletion of vps34 or nephrin alone. Immunostaining revealed 
nephrin in vesicles that are EEA1 and Rab5 positive indicating nephrin localization in early 
endosomes and not in vesicles originating from the Golgi network.
Conclusions: We report an in vivo model that provides evidence for nephrin 
endocytosis and recycling at the membrane. A small fraction of nephrin is stably present at 
the membrane once production of new nephrin is stopped. Our data provides evidence of 
recycling of this nephrin from and to the membrane.
Funding: NIDDK Support
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Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Induction of a Glomerular Reparative Program in Lupus Glomerulone-
phritis by a Novel Treg-Enhancing Cytokine Therapy
Rajkumar Venkatadri, Vikram Sabapathy, Marta Stremska, Hongyang Wang, 
Sun-sang J. Sung, Saleh Mohammad, Shu man Fu, Rahul Sharma. University of 
Virginia School of Medicine, Charlottesville, VA.
Background: Lupus glomerulonephritis (GN) is an autoimmune disease marked 
with glomerular inflammation and with reduced levels of IL-2 and T-regulatory cell as 
contributing factors. Earlier we showed that a novel hybrid cytokine IL233 utilizes the 
synergy of IL-2 and IL-33 to increase Tregs and protect mice from acute kidney injury 
and onset of accelerated GN in lupus prone NZM2328 mice. Here we investigated whether 
IL233 can reverse ongoing lupus GN and restore renal structure and function.
Methods: We made use of the recombinant hybrid cytokine (IL233) bearing activities 
of IL-2 and IL-33 and tested its efficacy to induce a glomerular repair program in three 
animal model systems: spontaneous lupus GN in NZM2328, adenovirus (Ad)-IFNa-
accelerated lupus GN model and MRL/lpr mice.
Results: Treatment of NZM2328 mice after the onset of GN, induced rapid and 
persistent remission from severe proteinuria in Ad-IFNa-accelerated GN in NZM2328 
mice as well as spontaneous lupus GN in NZM2328 and MRL/lpr mice. IL233 strongly 
inhibited glomerular hypertrophy and mesangial expansion and induced skewing of 
immune complex deposits towards IgG2b as compared to predominantly IgG2a deposits 
in control mice. Markers of glomerular integrity (nephrin, podocin, podocalyxin and 
synaptopodin) were elevated in IL233 treated animals confirming its therapeutic effects. 
Furthermore, IL233 treatment in mice with established GN also induced elevated levels of 
renal progenitor markers (Sox9, Six2, Lgr4, Lgr5 and Pax8) indicating an IL233-mediated 
cellular programming involving regeneration and repair.
Conclusions: We present a novel cytokine therapy of lupus GN with implications for 
induction of a glomerular reparative program with the use of IL233 hybrid cytokine.
Funding: Other NIH Support - National Institute of Diabetes and Digestive and 
Kidney Diseases
TH-OR058 Oral Abstract Thursday
Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Non-Classical Monocytes Act as Glomerular Sentinels, Sensing Deposited 
Immune Complexes and Orchestrating the Inflammatory Response via 
LFA-1 in Experimental Crescentic Glomerulonephritis
Kevin Woollard, Tabitha Turner-Stokes, Ana Isabel Garcia Diaz, H. 
Terence Cook, Charles D. Pusey. Imperial College London, London, United 
Kingdom.
Background: Non-classical monocytes (NC Mo) crawl along the resting endothelium, 
orchestrate the inflammatory response in some vascular beds and express high levels of 
FcγRIII(CD16). They may be important in triggering inflammation to immune complex 
(IC) deposition in glomerulonephritis (GN). Nephrotoxic Nephritis (NTN) in the WKY rat 
is a widely used, clinically-relevant model of crescentic GN but the distinct roles of myeloid 
subsets and the dynamics of their glomerular recruitment are unknown.
Methods: We developed a novel rat transgenic WKY-hCD68-GFP Mo/macrophage 
reporter. Mo subsets and endothelial cells were sorted from glomeruli of rats with NTN 
to investigate effector functions. Intravital confocal microscopy, with in vivo antibody 
labelling, was performed in the hydronephrotic kidney of anaesthetised WKY-hCD68-GFP 
rats, permitting high-resolution glomerular imaging and real-time, in vivo visualisation of 
myeloid recruitment and intravascular behaviour during NTN.
Results: Classical and NC Mo subsets were phenotyped as GFPposCD43loHIS48hi and 
GFPposCD43hiHIS48int respectively and neutrophils (PMNs) as GFPnegCD43intHIS48hi. RNA 
expression confirmed NC Mo were CD16hiCX3CR1hiCD14loCCR2lo relative to classical 
Mo i.e. homologous to mice and humans. During intravital imaging, NC Mo surveyed the 
glomerular endothelium for prolonged periods in the steady state. Classical Mo and PMNs 
had only transient endothelial interactions. There were subset-specific differences in the 
behavioural response to IC deposition during NTN: Increased recruitment of NC Mo vs. 
increased retention of classical Mo and PMNs. CD16 and pro-inflammatory cytokines (IL-
1β, TNFα) were upregulated in NC compared to classical Mo and a unique chemokine 
axis was overexpressed by the endothelium and NC Mo. LFA-1 blockade inhibited the 
distinctive migratory phenotype of NC Mo, reducing their recruitment and the retention 
of PMNs.
Conclusions: LFA-1-mediated endothelial surveillance by CD16hi NC Mo may be an 
important mechanism for IC detection in GN, orchestrating the subsequent inflammatory 
response through a unique chemokine axis and cytokine-mediated retention of classical 
Mo and PMNs. Targeting NC Mo may lead to effective treatments for GN, with fewer side 
effects.
Funding: Government Support - Non-U.S.
TH-OR059 Oral Abstract Thursday
Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Classical Monocytes Promote Crescent Formation and Necrosis in 
ANCA-Associated Necrotizing Crescentic Glomerulonephritis
Anthony Rousselle,2 Ralph Kettritz,2,1 Adrian Schreiber.2,1 1Charite Berlin, 
Berlin, Germany; 2ECRC, Berlin, Germany.
Background: The binding of circulating antineutrophil cytoplasmic autoantibodies 
(ANCAs) to neutrophils and monocytes and their subsequent activation are key events 
in the development of ANCA-associated vasculitis (AAV) and necrotizing crescentic 
glomerulonephritis (NCGN). In contrast to neutrophils, the exact role of monocytes remains 
poorly described. Murine monocytes are classified into two functionally different subsets: 
Ly6Chi CCR2+ classical (inflammatory) monocytes (CM) and Ly6Clo CCR2- non-classical 
(patrolling) monocytes (NCM). Differentiation of circulating Ly6Chi monocytes into 
Ly6Clo monocytes is controlled by the transcription factor C/EBPβ. We showed recently 
that global monocyte depletion protected from ANCA-induced necrotizing crescentic 
glomerulonephritis (NCGN) in vivo. We now studied the exact contribution of the two 
distinct monocyte subsets in AAV.
Methods: To assess the role of both monocyte subsets in vivo, we used our AAV 
murine model: MPO-/- mice were immunized with murine MPO, sublethally irradiated 
and subsequently transplanted with hematopoietic cells from either WT, CCR2-/-, 
C/EBPβ+/+ or C/EBPβ-/- mice (all MPO positive). CCR2-/- mice had a reduction of circulating 
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Ly6Chi monocytes whereas C/EBPβ-/- mice lacked circulating Ly6Clo monocytes. Mice were 
sacrificed and analyzed 8 weeks following transplantation. Urine was analyzed by dipstick, 
albuminuria by ELISA, glomerular necrosis and crescents by histology, and circulating and 
renal cell influx by flow cytometry.
Results: Blood composition confirmed the expected engraftment as CM and NCM 
were indeed significantly decreased in CCR2-/- and C/EBPβ-/- chimeric mice, respectively. 
WT, C/EBPβ+/+ and C/EBPβ-/- chimeric mice developed urine abnormalities and glomerular 
necrosis and crescent formation. In contrast, CCR2-/- chimeric mice did neither develop 
erythrocyturia and albuminuria nor NCGN. Flow cytometry showed significantly reduced 
renal infiltration of CM CCR2-/-. In contrast, renal neutrophil, macrophage and dendritic cell 
infiltration remained similar in all groups.
Conclusions: Our findings provide novel experimental evidence that classical 
monocytes are important contributors of kidney damage in ANCA-mediated NCGN. 
The exact molecular mechanisms by which classical monocytes promote kidney damage 
remains to be clarified.
Funding: Government Support - Non-U.S.
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Glomerular Diseases: Spotlighting Immunology and Inflammation - I
Inflammasome Priming and Activation Glomerular Gene Expression 
Scores Associate with Poor Outcome in Nephrotic Syndrome
Jeffrey B. Hodgin, Laura H. Mariani, Jinghui Luo, Yingbao Yang, 
John R. Hartman. University of Michigan, Ann Arbor, MI.
Background: Recent studies have shown that the inflammasome, a cytoplasmic protein 
complex that processes interleukins IL-1beta and IL-18, is functional in resident cells of the 
glomerulus, such as the podocyte. Before activation of the NLRP3 inflammasome, a priming 
step occurs consisting of upregulation of NLRP3, pro-IL-1beta, and other genes. Here we 
interrogate glomerular mRNA of patients with nephrotic syndrome to test our hypothesis 
that gene expression profiles of inflammasome priming and activation (IL-1beta-regulated 
genes) correlate with eGFR and proteinuria at time of biopsy and outcome measures.
Methods: Using the Nephrotic Syndrome Study Cohort (NEPTUNE), a prospective 
longitudinal cohort study enrolling patients at time of biopsy, we correlated glomerular gene 
expression Z-scores of inflammasome priming (5 genes) and activation (100 genes) with 
clinical characteristics at enrollment (Pearson for eGFR; Spearman for UPCR). Linear GEE 
models of eGFR and urine protein to creatinine ratio (UPCR) were fit to associate baseline 
inflammasome Z-scores with disease status over time.
Results: 97 patients with NS (50 FSGS, 47 MCD) were available for analysis. At time 
of biopsy, both the priming (r=-0.33, p<0.001) and activation (r=-0.45, p<0.001) Z-scores 
negatively correlated with eGFR. Priming (r=0.23, p=0.02) and activation (r=0.28, p=0.01) 
Z-scores positively correlated with UPCR as well. Over a follow-up time of 45 months,
baseline inflammasome priming and activation Z-scores were associated with lower eGFR 
over time (-12.6 mg/dL, p=0.028 and -55.4 mg/dL, p<0.001 respectively) in unadjusted
models. After adjusting for baseline eGFR and UPCR, diagnosis, age, black race,
immunosuppression and time, only the activation Z-score association was significant (-17.4 
mg/dL, p=0.05). The inflammasome priming and activation Z-scores did not associate with 
UPCR over time in adjusted models.
Conclusions: Inflammasome priming and activation Z-scores based on glomerular 
gene expression profiles significantly correlate with eGFR and UPCR at time of biopsy and 
associate with lower eGFR, but not UPCR, over time. This approach offers the opportunity 
to discover novel molecular tests to predict outcome in nephrotic syndrome and highlight 
pathways for therapeutic intervention.
Funding: NIDDK Support
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Harnessing Molecular, Machine-Learning, and Genomic Innovations in Pathology
Label-Free Imaging of Human Kidney Biopsies Guides Downstream 
Interrogation
Michael J. Ferkowicz,1 Seth Winfree,2 Daria Barwinska,1 Ken Dunn,1 
Katherine J. Kelly,1 Timothy A. Sutton,2 Michael T. Eadon,3 Pierre C. Dagher,1 
Tarek M. El-Achkar.1 1Indiana University, Indianapolis, IN; 2Indiana University 
School of Medicine, Indianapolis, IN; 3Indiana University Division of 
Nephrology, Indianapolis, IN.
Background: Label-free (LF) imaging of human kidney biopsies is a novel and under-
utilized approach to characterize kidney pathology. Unlabeled kidney biopsies have auto-
fluorescence (AF) across the visible spectrum that encodes specific signatures of nephron 
structures and can be correlated with pathology. In addition, AF intensity can be extended 
using fluorescence lifetime imaging (FLIM) to resolve endogenous fluorophores in health 
and disease. Second harmonic generation (SHG) by collagen fibers is an LF imaging 
approach that can be simultaneously acquired, allowing for rapid measurement of fibrosis.
Methods: Scanning multiphoton excitation microscopy was used to rapidly collect AF, 
FLIM and SHG images of human kidney sections. These same sections were subsequently 
stained by immuno-fluorescence and imaged with spectral multi-channel three-dimensional 
laser scanning confocal microscopy. These volumes were then analyzed by 3D tissue 
cytometry (3DTC).
Results: AF provides LF imaging and identification of tubular sub-segments. 
Supervised machine learning approaches can automatically and accurately identify tubular 
sub-segments in AF images. Lifetime imaging of AF provides an additional signature. SHG 
provides LF imaging of collagen fibrosis. Using 3DTC, LF images can be correlatively 
integrated into the analysis of stained tubular and infiltrating cells from the same kidney 
section.
Conclusions: Thus, the label-free imaging of human kidney biopsies using AF, FLIM 
and SHG will complement our existing confocal spectral imaging approach. This combined 
multi-dimensional imaging approach will maximize the informational yield of a biopsy 
when combined with downstream interrogation methods.
Funding: NIDDK Support, Veterans Affairs Support
Label-free imaging informs analysis. A. SHG imaging delineates fibrosis (b) that spatially 
correlates with spectrally imaged F-actin+ cells (c and d) and inflammatory cells (e, in red 
and f, in red and yellow).
TH-OR062 Oral Abstract Thursday
Harnessing Molecular, Machine-Learning, and Genomic Innovations in Pathology
SPECTRUM: A Quantitative Pipeline for Optically Cleared Tissue 
Validated in Crescentic Nephritis
Victor G. Puelles,1,2 Lena Ortz,2 Stella Papadouri,2 Thiago Strieder,2 
Turgay Saritas,2 Michael Vogt,2 Christoph Kuppe,2 David J. Nikolic-Paterson,3 
Marcus J. Moeller.2 1University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 2RWTH Aachen University, Aachen, Germany; 3Monash Medical 
Centre, Clayton, VIC, Australia.
Background: Optical clearing and advanced light microscopy have revolutionised 
three-dimensional quantification in cell biology. Here, we present a Systematic Pipeline 
of Enhanced Clarification for Three-dimensional Rendering and Unbiased Morphometrics 
(SPECTRUM) as a unique tool for the comprehensive analysis of glomerular health and 
disease.
Methods: SPECTRUM is based on a combination of single cell identification (ie. 
lineage tracing), optical clearing, advanced light microscopy with single cell resolution, 
and 3D morphometrics. Podocytes and parietal epithelial cells (PECs) were genetically 
labelled with eGFP using inducible mouse systems (POD or PEC -rtTA/H2B-eGFP). 
Crescentic nephritis was used as a validation model. Several optical clearing protocols were 
optimized for kidney tissue, including aqueous, hydrogel, and solvent-based approaches. 
Image acquisition was based on whole structures (ie. glomeruli and lesions) using light 
sheet, confocal and two-photon microscopy. Subsequent tissue de-clarification with 
immunolabelling and classical histopathology allowed the combination of 3D and 2D 
analyses.
Results: While IgG deposition showed a homogeneous distribution among all analysed 
glomeruli, only 80% showed signs of podocyte loss (podocyte loss per glomerulus of about 
60%). Only glomerular lesions showed significant increases in numbers of PECs (sign of 
PEC activation) in close association with reductions in glomerular capillary volume (sign of 
capillary injury). PEC activation was confirmed via immunofluorescence in recycled tissue 
samples (ie. de-novo CD44 expression). Based on 3D analysis of intraglomerular lesion 
location, we identified a progressive pattern from localised tubular lesions to segmental 
lesions and development of atubular glomeruli.
Conclusions: SPECTRUM provides new roadmap for morphometrics in the kidney. 
In crescentic nephritis, SPECTRUM revealed that despite of uniform IgG deposition, there 
was focal lesion development and podocyte loss, and allowed us to characterise for the first 
time the 3D evolution of extracapillary lesions.
Funding: Government Support - Non-U.S.
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Harnessing Molecular, Machine-Learning, and Genomic Innovations in Pathology
Mass Spectrometry Imaging Rapidly Discriminates between Ischemic 
Injury in Renal Tissue
Patrick A. de Hoogt,1 Tim C. Van smaalen,1 Maarten G. Snoeijs,1 Geert 
willem H. Schurink,1 Carine Peutz-Kootstra,1 Berta Cillero pastor.2 1Maastricht 
University Medical Center, Maastricht, Netherlands; 2M4I, Maastricht, 
Netherlands.
Background: The increasing analytical speed of mass spectrometry imaging (MSI), 
leads to growing interest in the medical field. When transplanting donor kidneys, ischemic 
injury to donor kidneys leads to significant short and long term risk for recipients. No 
reliable cut-offs are known to decide if a donor kidney can be safely transplanted. Thus, 
there is a need for new tools to rapidly and accurately assess acute ischemic injury in renal 
transplantation to aid in graft selection. We investigated the value of MSI to assess acute 
ischemic kidney tissue in a porcine model.
Methods: A perfusion model was developed where paired kidneys received warm 
(severe) or cold (minor) ischemia (n=8 per group). First, ischemic tissue damage was 
systematically assessed by two blinded pathologists. Secondly, MALDI-MSI of kidney 
tissues was performed to study spatial distributions and compositions of lipids in the tissues.
Results: Histopathological examination revealed no significant difference between 
kidneys, while MALDI-MSI was capable of a detailed discrimination of warm and cold 
ischemia by differential expression of characteristic lipid degradation products within 
2 hours. In particular lysolipids, including lysocardiolipins, lysophosphatidylcholines and 
lysophosphatidylinositol, were dramatiaclly elevated after warm ischemia.
Conclusions: This study demonstrates the significant potential of MSI to differentiate 
and identify molecular patterns of early ischemic injury in a clinically acceptable time 
frame. The observed changes highlight the underlying biochemical processes of acute 
ischemic kidney injury and provide a molecular classification tool that can be deployed for 
graft viability assessment.
TH-OR064 Oral Abstract Thursday
Harnessing Molecular, Machine-Learning, and Genomic Innovations in Pathology
Can Nephrectomy Tissue Be Considered as Normal? A Comparison of the 
Molecular Expression between Nephrectomy and Donor Kidney Tissue 
Samer Mohandes, Huijuan Song, John P. Shapiro, Paolo Fadda, Jianying Zhang, 
Lianbo Yu, Anjali A. Satoskar, Brad H. Rovin, Samir V. Parikh. Ohio State 
University Wexner Medical Center, Columbus, OH.
Background: The molecular interrogation of kidney tissue provides important 
information on disease pathogenesis. Uninvolved areas of tumor nephrectomies have been 
used as normal reference tissue. We postulated that nephrectomy tissue may be remotely 
affected by the tumor and tested this by comparing compared renal transcript expression 
of nephrectomy tissue to biopsies of living donor (LD) kidneys at the time of implantation.
Methods: Formalin-fixed paraffin-embedded nephrectomy (n=8) and LD (n=8) tissue 
was laser dissected and RNA from the glomerular and tubulointerstitial (TI) compartments 
was extracted. The expression of 564 immune transcripts was analyzed using Nanostring 
technology. Transcript expression between nephrectomy and LD samples was compared. 
Differences are reported by fold change (FC) and p-value.
Results: Overall, 116 glomerular transcripts and 67 TI transcripts were differentially 
expressed between nephrectomy and LD. The top overexpressed nephrectomy glomerular 
transcripts were FCER1G (FC: 8.5, P: 0.02), CD45RB (FC: 7, P: 0.02), and PDCD1LG2 
(FC: 5, P: 0.014), and the top TI transcripts were TNFRSF1B (FC: 6.7, P=0.01), CD45RB 
(FC: 6, P: 0.02), and C1R (FC: 4.9, P: 0.02). The top under-expressed glomerular 
transcripts included AIRE (FC: 0.1, P: 0.0001), XCL1 (FC: 0.1, P: 0.02) and IL-20  
(FC: 0.13, P: 0.001), and ATM (FC: 0.15, P: 0.03), VTN (FC: 0.16, P: 0.03) and CD160 (FC: 
0.17, P: 0.008) in the TI. Panther Pathway analysis revealed upregulation of inflammation 
mediated by cytokine/chemokines, integrin and interleukin signaling pathways in 
nephrectomy compared to LD.
Conclusions: To our knowledge, this is the first study comparing the gene expression 
between nephrectomy and LD. Despite being ostensibly unafflicted by the tumor, the 
gene expression of nephrectomies was different than LD and reflected overexpression 
of inflammatory and immune pathways. This study highlights the potential pitfall in 
using nephrectomy samples as controls, especially when comparing to autoimmune and 
inflammatory kidney diseases.
Funding: NIDDK Support
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Primary Membranous Nephropathy: Glomerular RNA Sequencing from 
Archival Kidney Biopsies
Oystein Eikrem,1,2 Even Koch,1 Thomas Knoop,2 Bjorn Egil Vikse,1,4 
Eric Schordan,5 Hanna Debiec,3,6 Pierre M. Ronco,3,6 Sabine Leh,2,1 Hans-
Peter Marti.1,2 1University of Bergen, Bergen, Norway; 2Haukeland University 
Hospital, Bergen, Norway; 3Inserm UMR_S1155, Paris, France; 4Haugesund 
Hospital, Haugesund, Norway; 5Firalis S.A., Huningue, France; 6Hôpital 
Tenon, Paris, France.
Background: Our study aim was to expand the usability of archival kidney biopsies 
with primary membranous nephropathy (MN) by next generation sequencing of glomerular 
mRNA & lncRNA.
Methods: Formalin-fixed & paraffin-embedded (FFPE) renal biopsies from six female 
and six male adult patients (mean age 55±16 y, mean proteinuria 2.9±3.5 g/d) from the 
Norwegian Kidney Biopsy Registry (NKBR) with primary MN were divided into: i) 
PLA2R antibody positive MN (n=6), and ii) PLA2R antibody negative MN (n=6). In 
addition, we included iii) normal NBKR control samples (n=8; mean age 27±11 y). All 
subjects had eGFR>60ml/min/1.73m2. RNA inputs of 0.15-3 ng of total RNA per sample 
from microdissected glomerular cross-sections (High Pure FFPE Extraction kit, Roche) 
were used for library preparation (Truseq RNA Exome kit, Illumina) and sequenced as 75 
bp paired end on a NextSeq500 by Firalis SA, France. Reads were aligned to Homo sapiens 
hg38 reference genome using Gencode v.26 for mRNA and LNCipedia 5.0 for lncRNA.
Results: From alignment on their databases, 3473 mRNA & 1719 lncRNA were above 
a threshold of 2 fragments per kilobase of exon per million reads mapped (FPKM). Principal 
component analyses and heatmaps with differentially regulated mRNA & lncRNA clustered 
anti-PLA2R positive and anti-PLA2R negative MN together with some separation from 
normals (esp. lncRNA). Pathways of renal inflammation and of glomerular injury were 
upregulated in MN (IPA analyses). Overall, 197 mRNA and 59 lncRNA were differentially 
regulated comparing MN combined to normal controls. Within the two MN groups, 84 
mRNA and 19 lncRNA were differentially expressed. Among these 84 mRNA, subgroups 
of 12 mRNA (e.g. IGFBP2) and 22 mRNA (e.g. MIF) differed also between normal controls 
and anti-PLA2R positive or negative MN, respectively. Among the 19 lncRNA, subgroups 
of 4 and 2 lncRNA differed also between normal controls and anti-PLA2R positive or 
negative MN, respectively. Thus, these mRNA & lncRNA could represent candidates of 
diagnostic/prognostic markers and of therapeutic targets if confirmed later.
Conclusions: Sequencing of mRNA & lncRNA from microdissected glomerular 
cross-sections of FFPE kidney biopsies is feasible and potential biomarker & drug target 
candidates that discriminate anti-PLA2R positive from anti-PLA2R negative MN were 
identified.
Funding: Government Support - Non-U.S.
TH-OR066 Oral Abstract Thursday
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Predicting APOL1 Risk Category from Kidney Donor Biopsies Using 
Deep Learning
Jun Xu,1 Andrew Janowczyk,2 L. Barisoni,4 Chengfei Cai,1 Jeffrey J. Nirschl,5 
Matthew Palmer,5 Michael Feldman,5 Dhruti P. Chen,6 John F. O’Toole,3 
Ziad S. Zaky,3 Emilio D. Poggio,3 John R. Sedor,3 Anant Madabhushi.2 1Nanjing 
University of Information Science and Technology, Nanjing, China; 2Case 
Western Reserve University, Cleveland, OH; 3Cleveland Clinic, Cleveland, OH; 
4U. Miami, Miller School of Medicine, Miami Beach, FL; 5University of 
Pennsylvania, Philadelphia, PA; 6University of North Carolina, Chapel Hill, 
NC.
Background: African Americans (AA) subjects with two APOL1 gene variants (G1 
and G2) are at higher risk (HR) to develop non-diabetic kidney disease, while individuals 
with 0 or 1 APOL1 variants are at low risk (LR). Conventional visual histologic analysis 
of renal biopsies does not identify structural differences between LR and HR subjects 
with or without kidney disease. In this work we sought to evaluate whether deep-learning 
(DL) based analysis could help identify phenotypic representations that were predictive of 
APOL1 variants from whole slide images (WSI) of kidney biopsies.
Methods: WSI’s from kidney allograft implant biopsies stained with H&E from 19 
APOL1 LR and 12 APOL1 HR AA donors were annotated by a pathologist to identify 
artifact-free regions of interest (ROIs). The ROIs from the training set (8 LR and 5 HR) 
were divided into non-overlapping 256x256 patches for processing at 40X magnification. 
Each patch was assigned a HR or LR label based on the subject’s APOL1 genotype. An 
8 layer AlexNet model was trained to predict the likelihood that a previously unseen test 
input patch belongs to the APOL1 HR genotype. This patch-wise output was then overlaid 
as a heatmap on the original image such that red and blue pixels predicts HR and LR class, 
respectively. Majority voting across the individual patches were aggregated to generated the 
combined prediction of APOL1 risk status as either HR or LR. (Figure 1).
Results: The prediction accuracy of trained model was 84.67% and 91.02% for LR and 
HR cases respectively (n=18, LR=11, HR=7) on the test set.
Conclusions: In this preliminary study, the DL model was able to distinguish between 
APOL1 HR and LR genotypes in AA patients. Future work will involve larger scale multi-
site independent validation.
Funding: Other NIH Support - National Natural Scientific Foundation of China, Other 
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Figure 1: Flowchart illustrating the training and testing for predicting APOL1 risk status, 
where the bottom right image heatmap is the output from the DL classifier where redder 
pixels indicate higher likelihood of belonging to the HR class.
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Harnessing Molecular, Machine-Learning, and Genomic Innovations in Pathology
Bevacizumab Associated Glomerulopathy: An Occlusive Hyaline 
Microangiopathy
Fermin J. Person,1,7 Markus M. Rinschen,2 Silke R. Brix,3 Sonia Wulf,7 Maria de 
las Mercedes Noriega,7 Jessica Schmitz,4 Anke Schwarz,4 Philipp Ivanyi,9 
Oliver M. Steinmetz,5 Linda Reinhard,5 Elion Hoxha,5 Peter F. Zipfel,8 
Jan H. Braesen,6 Thorsten Wiech.7 1UKE, Hamburg, Germany; 2CECAD, 
Cologne, Germany; 3University Hospital Hamburg-Eppendorf, Hamburg, 
Germany; 4Hannover Medical School, Hannover, Germany; 5III. Department of 
Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 6Medizinische Hochschule Hannover, Hannover, Germany; 
7Department of Pathology, University Hospital Hamburg Eppendorf, Hamburg, 
Germany; 8Leibniz Institute for Natural Product Research and Infection Biology, 
Jena, Germany; 9Hannover medical school, Hannover, Germany.
Background: Bevacizumab is a humanized monoclonal IgG1 antibody which 
neutralizes vascular endothelial growth factor (VEGF) and is used for treating multiple 
cancer types. As a known and frequent adverse event, it can lead to renal damage including 
proteinuria and nephrotic syndrome.
Methods: In a retrospective approach we analyzed 16 renal biopsies from patients 
receiving bevacizumab treatment. We observed a distinctive pseudothrombotic pattern 
different from the previously reported thrombotic microangiopathy (TMA). Since the 
newly described pattern includes some features similar to TMA and cryoglobulinemic 
membranoproliferative glomerulonephritis (MPGN), biopsies with these diagnoses were 
included for comparison. Clinical, laboratory, light microscopic, immunohistochemical 
(including a proximity ligation assay (PLA)), proteomic and electron microscopic features 
were assessed in 16 proteinuric patients after bevacizumab therapy and compared to seven 
cases of cryoglobulinemic MPGN and six cases of typical acute TMA.
Results: Nephrotic syndrome was present in 14 of the 16 bevacizumab-treated 
patients. All 16 displayed a patchy pattern of variably PAS-positive hyaline pseudothrombi 
occluding markedly dilated glomerular capillaries in their biopsies. Mass spectrometry 
based proteome analysis revealed a special protein pattern demonstrating some features 
of TMA and some of MPGN, including a strong accumulation of IgG in the thrombi. PLA 
did not show interaction of IgG with C1q, arguing for accumulation without classical 
complement activation. Compared to thrombi in TMA cases, the hyaline pseudothrombi did 
not contain clusters of CD61-positive thrombocytes. Electron microscopy of bevacizumab 
cases did not show extensive loss of podocyte foot processes.
Conclusions: Bevacizumab therapy can lead to a unique hyaline occlusive 
glomerulopathy, likely arising from endothelial leakage followed by subendothelial 
accumulation of serum proteins. Bevacizumab associated glomerulopathy can be diagnosed 
by light microscopy and is an important differential diagnosis in cancer patients with 
nephrotic syndrome.
Funding: Government Support - Non-U.S.
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A Nuclear Magnetic Resonance-Based Method for Accurate Assessment of 
Glomerular Filtration Rate
Jochen H. Ehrich,1 Laurence Dubourg,2 Sverker Hansson,3 Tobias Steinle,4 
Jana Fruth,4 Sebastian Höckner,4 Eric Schiffer.4 1Hannover Medical School, 
Hannover, Germany; 2Néphrologie, Dialyse, Hypertension et Exploration 
Fonctionnelle Rénale, Hopital E Herriot, Lyon, France; 3Sahlgrenska University 
Hospital, Göteborg, Sweden; 4numares AG, Regensburg, Germany.
Background: Measuring glomerular filtration rate (mGFR) using renal or plasma 
clearance of an exogenous filtration marker (tracer) is the gold standard for assessing 
kidney function, but this procedure is time consuming and associated with a high burden for 
patients. Therefore, GFR is commonly estimated from serum creatinine (eGFRcreat) or serum 
cystatin C (eGFRcysC). However, there exist different estimating equations for adult and 
paediatric patients and these equations often perform only moderately outside the cohort in 
which they were developed.
Methods: We used metabolomics based on nuclear magnetic resonance (NMR) 
spectroscopy and biostatistical modeling to identify metabolites correlated with mGFR 
and to combine these metabolites to biomarker networks for accurate GFR prediction. The 
biomarker networks were established and tested in two separate cohorts from two European 
centres. These cohorts comprised serum samples from both paediatric and adult patients 
with various nephrological conditions, covering the whole GFR range from hypo- to 
hyperfiltration.
Results: By combining creatinine with the uremic toxin myo-inositol, valine as indicator 
of metabolic acidosis, and a marker of oxidative stress into a metabolic network, we were 
able to generate reliable results over the whole GFR range. Compared to eGFRcreat and 
eGFRcysC, the marker network showed a higher correlation with mGFR (Pearson correlation 
coefficient r = 0.880 vs. 0.848 and 0.636) and a 31% and 41% reduction, respectively, 
in overall root mean square error (RMSE 19.2 vs 28.0 and 32.8) in an independent 
test cohort. Especially in the “creatinine blind spot” between 60-90 ml/min/1.73m2, 
it more than halved the variation from 24.5 to 11.0 compared to eGFRcreat. The marker 
network increased the percentage of estimated GFR values within 30% of mGFR (P30) from 
72% (66%) observed for eGFRcreat (eGFRcysC) to 82%, which is within the performance 
range of plasma clearance methods, depending on the tracer used for mGFR measurement.
Conclusions: We developed a metabolomics-based serum test for accurate prediction 
of GFR in both adult and paediatric patients. It combines the precision of plasma clearance 
with the convenience of creatinine-based eGFR and obviates the need of invasive tracer 
application.
Funding: Commercial Support - numares AG
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Histologic Predictors of Renal Outcome in Myeloma Cast Nephropathy: A 
Multicenter Study
Virginie Royal,1 Samih H. Nasr,2 Laure Ecotiere,4 Stephan Troyanov,3 
Mariam P. Alexander,2 Nelson Leung,2 Frank Bridoux.5 1Pathology, Université 
de Montréal, Montreal, QC, Canada; 2Mayo Clinic, Rochester, MN; 3Hopital du 
Sacre-Coeur de Montreal, Town of Mount Royal, QC, Canada; 4CHU Poitiers 
Néphrologie, Poitiers, France; 5Hôpital Jean Bernard, CHU Poitiers, Poitiers, 
France.
Background: Cast nephropathy (CN) is the main cause of acute kidney injury (AKI) 
in multiple myeloma (MM). Renal prognosis is poor and chronic renal impairment strongly 
affects survival. Whether renal biopsy can help in the management of AKI is unclear. The 
aim of this study was to investigate the prognostic value of renal biopsy findings in CN.
Methods: We retrospectively reviewed renal biopsies from 161 CN patients in a 
multicenter cohort (9 centers). Histological features, including the extent of cast formation, 
were independently scored by 2 pathologists. We assessed reproducibility, correlations 
with clinical presentation and, in patients with 〉3 months follow-up (n=135), associations 
between biopsy findings, hematologic and renal outcomes.
Results: Interclass Correlation (ICC) for inter-reader concordance was good to excellent 
(〉0.60) for medullary interstitial inflammation, giant cell reaction around casts, highest and 
mean cortical and medullary cast numbers. It was moderate (0.40-0.59) for interstitial
fibrosis, cortical interstitial inflammation, tubular rupture, interstitial giant cell and Tamm-
Horsfall extravasation. We found 46% of kappa CN and 54% of lambda CN. The severity of 
AKI correlated with higher serum free light chain level (sFLC), ß2-microglobulin, LDH and 
bone marrow infiltration. The presence of giant cell reaction, highest and mean medullary 
and cortical number of casts and medullary interstitial inflammation also correlated with a 
lower initial eGFR. Following therapy, renal response rate was lower with higher age, ß2-
microglobulin and baseline sFLC. It was greater with a lower serum creatinine level and
greater sFLC reduction. The presence of giant cell reaction, moderate or severe interstitial 
fibrosis, highest and mean medullary and cortical number of casts and, marginally (p=0.06), 
medullary interstitial inflammation, also correlated with lower renal recovery rate.
Conclusions: Histologic scoring of CN enables reproducible assessment of 
morphologic parameters with prognostic significance and may guide the management of 
MCN. Participants: G. Touchard, H. Fatima, F. Rosenblum, P. Sanders, M. Drosou, M. 
Rabant, C. Cohen, B. Knebelmann, B. Adam, B. Sis, C. Venner, H. Rennke, S. Motwani, R. 
Manso, K. Soto, A. Barraca, F. Maletta, D. Rocatello, R. Fenoglio, AM. Asuntis, P. Bianco, 
A. Pani, A. Angioi.
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Digital Pathology and Computer-Aided Quantitative Analysis for Lupus 
Nephritis
Srikanth Ragothaman,2 Anthony Chang,1 J. Michelle Kahlenberg,2 
Stephanie Wylie,2 Jeffrey B. Hodgin.2 1UChicago Medicine, Chicago, IL; 
2University of Michigan, Ann Arbor, MI.
Background: The kidney biopsy has allowed a better understanding of the pathogenesis 
of renal injury in lupus nephritis (LN) and is routinely used for patients with active LN 
or previously untreated disease. Currently, the ISN/RPS classification system is used to 
identify subgroups with different prognoses and response to treatment. However, the ISN/
RPS classification suffers from poor reproducibility, raising doubts about its validity and 
clinical application. Thus novel approaches are required to obtain continuous, quantitative 
data to improve accuracy, reproducibility, and prognostic utility. We have assembled a 
novel computer-aided digital pathology image analysis pipeline to improve the utility of 
the kidney biopsy in LN.
Methods: To facilitate our analyses, we have created the University of Michigan Lupus 
Nephritis Digital Pathology Image Repository (DPIR). Currently it contains 200+ cases 
with access to clinical data over many years. Slides are scanned to whole-slide images 
(WSI) at 40x with Leica Biosystems AT2 scanners. We employ QuPath, a cross-platform 
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open source software for digital pathology and WSI image analysis, for quality control, 
annotation, and as a framework to run in-house algorithms on WSI. Algorithms to quantitate 
morphologic features of interest are designed using the image processing package FIJI, a 
distribution of ImageJ.
Results: Our image analysis pipeline allows supervised WSI annotation (glomeruli, 
vessels, etc.) and quantitation of glomerular size, glomerular cellularity, mesangial index, 
interstitial fibrosis and fractional interstitial area, and tubulointerstitial cellularity using 
PAS and trichrome stained slides. Complete analysis can be performed within one day. 
Preliminary data comparing glomerular cellularity to ISN/RPS classification groups reveals 
that cellularity varies widely within each classification group, indicating novel information 
beyond classification groups are captured.
Conclusions: We have generated a computer-aided, quantitative image analysis 
pipeline for morphologic features in a lupus nephritis biopsy. The pipeline has a short 
enough turnaround time suitable for clinical application and generation of an adjunct report 
wherever cases can be scanned to WSIs. Future studies will seek to improve turnaround 
time and determine which analyses best predict patient outcome and response to therapy.
Funding: NIDDK Support
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The Role of Megalin in the Regulation of Renal RAS: Investigation Using 
LC/MS-Based Multiple-Reaction Monitoring Quantification of Angioten-
sin Peptides
Sawako Goto, Yutaka Yoshida, Michihiro Hosojima, Tomomichi Iida, 
Shoji Kuwahara, Hideyuki Kabasawa, Ryohei Kaseda, Ichiei Narita, 
Akihiko Saito. Niigata University, Chuo-ku, Japan.
Background: The mechanisms underlying the regulation of the renal renin-angiotensin 
system (RAS) are largely unknown. Megalin, an endocytosis receptor in proximal tubular 
cells, reabsorbs angiotensinogen (AGT) and angiotensin (Ang) peptides filtered through 
glomeruli. We have developed liquid chromatography (LC)/mass spectrometry (MS)-
based multiple-reaction monitoring quantification of Ang peptides. This study aimed to 
investigate the role of megalin in the renal RAS by measuring Ang peptides in biological 
samples obtained from kidney-specific, tamoxifen-inducible conditional megalin knock-out 
mice (KO) and their controls (Ctl).
Methods: Stable isotope-labeled Ang peptides were added to each sample as 
internal standards. Under the steady condition and 30 min after AGT administration, Ang 
peptides were extracted by reverse phase chromatography and evaluated by LC/MS-based 
quantification.
Results: Under the steady condition, Ang-I and -II were quantified in the kidney and 
plasma without significant differences between KO and Ctl (e.g., kidney Ang-II: 573±257 
in KO and 569±172 fmol/g in Ctl). High levels of Ang-I, -II, -1-7 and -1-9 were detected in 
KO’s fresh urine (e.g., Ang-II: 3.8±4.5 pmol/mL), whereas their concentrations were below 
the limit of detection in Ctl. AGT administration increased kidney Ang peptides without 
significant increase in plasma. Kidney Ang-II and -1-9 levels in KO administered with AGT 
were significantly lower than those in Ctl (e.g., Ang -II: 1760±1043 in KO and 2489±836 
fmol/g in Ctl, p<0.05); kidney Ang-I showed a similar tendency, whereas there was no 
difference in Ang -1-7.
Conclusions: High-level excretion of Ang peptides in KO’s urine indicated that they 
were produced in the tubular lumen. AGT administration increased kidney Ang peptides 
independently of the systemic RAS. The increase of kidney Ang-I, -II, and -1-9 induced 
by AGT administration was suppressed in KO compared with Ctl, whereas there was no 
difference in Ang-1-7. Ang-I, -II and -1-9 generated in the tubular lumen may be excreted 
more in KO than Ctl or converted to Ang-1-7. Megalin blockade could be beneficial for 
modulating the renal RAS by regulating the renal handling of AGT and Ang peptides.
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Hypertension and CVD: Basic Mechanisms
Cholesterol, a Repressor of Natriuretic Genes
Robert L. Repetti,1,2 Jennifer Meth,1 Daniel Flores,3 Lisa M. Satlin,3 
Rajeev Rohatgi.1,2 1Northport VAMC, Northport, NY; 2Medicine, Stony Brook 
University School of Medicine, Stony Brook, NY; 3Icahn School of Medicine at 
Mount Sinai, New York, NY.
Background: Salt-sensitivity in Dahl rats is due, in part, to the reduction of 
hemoxygenase-1 (HO1), cyclooxygenase 2 (COX2), and nitric oxide synthase-2 (NOS2) 
in the renal medulla. Renal overexpression of HIF1-α, a regulator of HO1, COX2, and 
NOS2, enhances salt and water excretion and reduces blood pressure. Cholesterol (chol) 
incorporation into collecting duct (CD) cells, in vivo or in vitro, represses COX2 activity 
in response to tubular flow or fluid shear stress (FSS). We hypothesized that dietary chol 
ingestion represses flow responsive genes necessary to effectuate salt and water excretion.
Methods: To this end, mice were fed either a 0% or 1% chol diet for up to 12 weeks, 
injected with SQ isotonic saline at 5% of body weight, and urine collected at 2, 4, and 6 hrs. 
Kidneys were extracted to measure medullary expression of HO1, COX1, and NOS2. Mice 
were divided into three dietary time points: (1) 3-5 (2) 6-8 and (3) >9 weeks of diet.
Results: Urine volume was less in the chol group at the 6 hr urine collection for 6-8 wks 
of diet group (n=8 control and chol; p<0.05). Urinary [Na], [K] and osmolality were higher 
while Na excretion was lower at the 6 hr urine collection time point in the chol (p<0.05) vs. 
control fed mice. Renal medullary HO1 (0.76±0.09; p<0.05), and NOS2 (0.76±0.1; p<0.05) 
mRNA levels were reduced compared to controls (HO1, 1.00±0.02; NOS2, 1.00±0.03) 
while COX2 and HIF1-α were unaffected. ATP-binding cassette transporter (ABCA1), a 
tissue chol efflux transporter, was increased in the medulla (2.0±0.3 fold; p<0.05) of chol 
vs. control fed mice. To test the flow responsiveness of HO1, COX2, NOS2 and HIf1-
α, IMCD3 cells were exposed to 0.4 dynes/cm2 of FSS for up to 6 hours. HO1 mRNA 
increased by 350X fold, COX2 by 25X fold, and NOS2 by 8X fold at 6 hrs in sheared (n=4-
6; p<0.01) vs.static (n=3-6) cells. HIF1-α mRNA increased by ~50% (p<0.05) at 4 and 6 
hrs. Western blotting of FSS exposed cells demonstrated an increase in HIF1-α and HO1 
protein compared to static cells (p<0.05). Similar to mouse, chol incorporation into cells 
raised ABCA1 mRNA levels 3.7±0.2 fold vs. untreated cells.
Conclusions: Dietary chol is associated reduced urine volume and Na excretion at 6 
hrs after saline injection and suppressed flow induced HO1 and NOS2 gene expression. 
Studies will test whether chol incorporation into the tubule represses of natriuretic factors 
to reduce Na excretion..
Funding: Veterans Affairs Support
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Tubular Deficiency of Heterogeneous Nuclear Ribonucleprotein F 
Enhances Development of Hypertension and Kidney Injury via Elevated 
Renal Angiotensinogen and Attenuated SGLT2 Expression in Mice
Chao-Sheng Lo,1 Isabelle Chenier,1 Janos G. Filep,3 Julie R. Ingelfinger,2 Shao-
Ling Zhang,1 John S. Chan.1 1CRCHUM, Universite de Montreal, Montreal, QC, 
Canada; 2The New England Journal of Medicine, Boston, MA; 3Research 
Centre, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.
Background: We reported previously that overexpression of the transcription factor, 
heterogeneous nuclear ribonucleoprotein F (hnRNP F) in renal proximal tubular cells 
attenuates systolic blood pressure (SBP), kidney injury and renal angiotensinogen (Agt) 
gene expression in mice with both type 1 and type 2 diabetes (Diabetes 2012, 2017). Here, 
we investigated whether deletion of hnRNP F in renal tubules would elevate SBP and 
aggravate kidney injury through increasing renal Agt gene expression.
Methods: Tubule-specific hnRNP F knockout (KO) mice were generated by 
crossbreeding Pax8-Cre mice with floxed hnRNP F mice on a C57BL/6 background. Both 
male and female Pax8-hnRNP F KO mice and control littermates were studied. Body 
weight (BW), SBP, blood glucose (BG), urinary glucose (UG) and albumin/creatinine 
ratio (ACR) were monitored up to 24 weeks of age. Kidneys were processed for histology. 
Western blotting and real-time qPCR were used to quantify hnRNP F, Agt, sodium-glucose 
co-transporter-2 (Sglt2) protein and mRNA expression in renal proximal tubules (RPTs), 
respectively.
Results: Both male and female Pax8-hnRNP F KO mice developed hypertension and 
elevated ACR as compared with control littermates with no detectable differences in BW 
and BG. Intriquingly, both male and female Pax8-hnRNP F KO mice developed glucosuria 
at 8 weeks of age. However, glucosuria disappeared in male Pax8-hnRNP F KO at the age 
of 12 weeks, whereas glucosuria was persistent in females. HnRNP F protein and mRNA 
expression are barely detectable in RPTs of Pax8-hnRNP F KO mice. In contrast, Agt 
expression was elevated, and Sglt2 expression was attenuated in RPTs of both male and 
female Pax8-hnRNP F KO mice as compared to controls at 8 and 24 weeks.
Conclusions: Our data demonstrate that hnRNP F plays an important role in the 
development of hypertension and kidney injury through modulation of renal Agt expression. 
Pax8-hnRNP F KO mice may provide a novel experimental model to study the development 
of glycosuria in non-diabetic mice.
Funding: Government Support - Non-U.S.
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Haploinsufficiency of Transcription Factor ETS-1 Improves Renal 
Autoregulation in Dahl Salt Sensitive Rats
Wenguang Feng,1 Zhengrong Guan,1 Dongqi Xing,1 Xingsheng Li,1 Wei-
zhong Ying,1 Edward W. Inscho,1 Paul W. Sanders.1,2 1University of Alabama at 
Birmingham, Birmingham, AL; 2Birmingham Veterans Affairs Medical Center, 
Birmingham, AL.
Background: The mechanisms underlying the susceptibility to hypertension-
associated kidney injury are not well defined. Previously, we showed that the transcription 
factor ETS-1 mediates glomerular injury in Dahl Salt Sensitive (SS) rats. Hypertensive SS 
rats with a single functioning ETS-1 gene (ES, developed with zinc-finger nuclease (ZFN) 
technology), exhibit less glomerular injury. Because renal autoregulation is critical for 
protecting glomeruli from arterial hypertension, we hypothesized that ETS-1 transactivity 
is involved in afferent arteriolar autoregulatory behavior.
Methods: SS and ES rats were maintained on either a 0.3% (LS SS and LS ES) or a 4% 
NaCl diet (HS SS and HS ES) for one week.
Results: Assessment of serum creatinine and albuminuria revealed that renal 
dysfunction was present in the hypertensive HS SS rats, but was abrogated in the HS 
ES rats despite similar increases in telemetry mean blood pressures. Afferent arteriolar 
autoregulation was assessed using the in vitro blood-perfused juxtamedullary nephron 
preparation. Average baseline diameter of afferent arterioles were similar across the four 
groups of rats (P>0.05). Afferent arterioles from LS SS and LS ES rats exhibited normal 
autoregulatory behavior. Decreasing renal perfusion pressure from 100 to 65 mmHg 
increased arteriole diameter to 118 ± 2% and 119 ± 4% of baseline diameter, respectively. 
Stepwise increases in perfusion pressure to 170 mmHg decreased arteriolar diameter to 
75.4 ± 3% and 72.9 ± 4% respectively. In contrast, pressure-mediated afferent arteriolar 
responses were markedly impaired in HS SS rats. Baseline diameter averaged 15.1 ± 1.2 μm 
and remained between 107 ± 3% and 89 ± 4% (p< 0.05 vs. LS SS) of baseline over the 
65-170 mmHg pressure range tested. Importantly, renal autoregulation was significantly 
improved in HS ES rats. Baseline diameter averaged 15.6 ± 0.9 μm, and decreasing renal
perfusion pressure from 100 to 65 mmHg resulted in a diameter increase to 114 ± 2% 
while increasing perfusion pressure to 170 mmHg resulted in a pressure-dependent
vasoconstriction to 73 ± 3% (P<0.05 vs SS HS).
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Conclusions: These results show that ETS-1 influences renal arteriolar autoregulation 
in SS rats and that impaired autoregulation may contribute to hypertension-induced kidney 
injury in SS rats.
Funding: Veterans Affairs Support
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Renal Artery Stenosis Magnifies Mitochondrial Damage, Aggravating 
Post-Stenotic Kidney Injury in Pigs with Metabolic Syndrome
Arash Aghajani Nargesi, Hui Tang, Lilach O. Lerman, Alfonso Eirin. Mayo 
Clinic Rochester MN, Rochester, MN.
Background: Renal artery stenosis (RAS) often develops in the context of prevalent 
cardiovascular risk factors, and can induce hypertension, renal injury, and fibrosis. We have 
shown that metabolic syndrome (MetS) induces mitochondrial damage associated with 
glomerular hyperfiltration and tubular injury. We hypothesized that superimposition of RAS 
on MetS would exacerbate mitochondrial damage, aggravating post-stenotic kidney injury 
in swine.
Methods: Domestic pigs were studied after 16 weeks of either high-fat/high-fructose 
or standard diet with or without superimposed RAS (n=7 each). Single-kidney GFR was 
assessed in-vivo with multi-detector-CT, and renal tubular mitochondrial morphology ex 
vivo by electron microscopy. ATP production was measured by colorimetric/fluorimetric 
methods in isolated mitochondria and renal fibrosis by trichrome staining.
Results: Blood pressure was higher in MetS, Lean+RAS, and MetS+RAS compared 
to Lean (Table). Both RAS groups achieved significant stenosis. Single-kidney GFR was 
higher in MetS vs Lean, but decreased in Lean+RAS and MetS+RAS vs. their respective 
controls. MetS+RAS further decreased renal mitochondrial matrix density (Fig. B-C) and 
ATP production (Fig. D), and increased renal fibrosis (Fig. E) compared to Lean+RAS.
Conclusions: RAS superimposed on MetS aggravates mitochondrial structural damage 
and dysfunction, which may contribute to structural injury and dysfunction in the post-
stenotic kidney.
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Renal Artery Stenosis Induces Renal Cellular Senescence
Seo Rin Kim,1 Amrutesh Puranik,1,2 Kai Jiang,1 Christopher M. Ferguson,1 
LaTonya J. Hickson,1 Tamara Tchkonia,3 James L. Kirkland,3 Lilach O. Lerman.1 
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Clinic, Rochester, MN.
Background: Cellular senescence (CS) is an irreversible proliferation arrest with 
secretory phenotype evoked in response to stress, which can be identified by upregulation 
of the cyclin-dependent kinase inhibitor p16INK4a. Renal artery stenosis (RAS) induces 
stenotic kidney (STK) ischemia and injury, but whether these involve activation of CS 
remains unclear. We studied CS in the STK of transgenic INK-ATTAC mice, in which 
p16 INK4a-expressing cells can be selectively eliminated by injection of AP20187.
Methods: INK-ATTAC mice were randomized to a 4-week treatment with AP20187 
(3.3μg/g, IP, 3/week) or vehicle starting after 2 weeks of RAS or sham (n=6-8 each). 
Single kidney function (GFR) and oxygenation were studied in vivo using 16.4T magnetic 
resonance imaging at baseline and 6 weeks after surgery. CS was assessed by plasma levels 
of Activin-A, and by image cytometry analysis of p16 INK4a-positive cells in dissociated 
kidney tissue.
Results: After 6 weeks of RAS blood pressure, Activin-A, STK tissue hypoxia were all 
elevated, and plasma creatinine tended to be higher compared to sham, whereas STK RBF 
and GFR were decreased. The percentage of p16 INK4a-positive cells increased in the STK, 
many of which expressed epithelial, but not endothelial, cell markers (Fig. E). Clearance of 
p16 INK4a-positive cells restored blood pressure, Activin-A, and plasma creatinine levels, and 
prevented the fall in GFR, and rise in tissue hypoxia (Fig. A-D), whereas RBF remained 
unchanged.
Conclusions: Renal artery stenosis induces cellular senescence in the stenotic kidney, 
particularly in tubular epithelial cells, and their clearance improves renal function. These 
observations suggest a role for cellular senescence in pathogenesis of renal artery stenosis, 
supporting development of senotherapy.
Funding: NIDDK Support, Other NIH Support - HL123160, DK100081, DK104273, 
DK102325, DK109134, and AG013925, Private Foundation Support
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Evidence for Female Protection from Kidney Injury during Angiotensin II 
Hypertension
Borna S. Shirvani, Luciana C. Veiras, Donna Ralph, Hillmin Lei, 
Alicia A. McDonough. Keck School of Medicine of USC, Los Angeles, CA.
Background: To address resistance to cardiovascular and kidney disease in females 
(F) vs. males (M), we recently defined sexual dimorphisms in renal transporters’ abundance 
and distribution along the nephron. We reported lower proximal and higher distal Na+ 
transporters’ abundance and activity along nephrons of F vs. M rats and mice. This study
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aimed to examine susceptibility to renal injury during Ang II Hypertension (AngII-HTN) in 
F vs. M Sprague Dawley rats.
Methods: Rats were either implanted with osmotic minipumps that infused 400 ng/kg/min 
AngII for 2 weeks or sham operated (n=6/group). Systolic blood pressure (tail-cuff) 
increased to 190 mmHg in both sexes. Urine was collected overnight in metabolic cages 
before sacrifice after which blood and kidney were collected. Quantitative immunoblotting 
was used to assess protein levels of kidney injury molecule-1 (KIM-1), angiotensinogen 
(aogen) and plasmin in urine and/or renal cortex; serum and urine albumin were quantified 
via ELISA and BCG method, respectively, and confocal immunohistochemistry (IHC) used 
to detect endocytosed albumin.
Results: Urinary albumin, similar at baseline in M and F, was 10-fold higher in M vs. 
F during AngII-HTN (p<0.001) associated with a 10% fall in serum albumin in M (p=0.05, 
no change in F). Urinary KIM-1, aogen and plasmin were markedly increased in M during 
AngII-HTN while near undetectable in F. Higher urinary plasmin in M vs. F correlated with 
twice as much cleaved (activated) epithelial Na+ channel gamma subunit during AngII-
HTN (p<0.0001). In renal cortex homogenates at baseline, KIM-1, aogen and megalin were 
higher in M vs F; during AngII-HTN cortical megalin increased in F only while KIM-
1 and a’ogen were unchanged. AngII-HTN increased cortical albumin in both sexes and 
endocytosed albumin was evident by IHC in M PT but not F.
Conclusions: Despite similar increases in blood pressure, M vs. F rats exhibit greater 
susceptibility to renal injury during AngII-HTN, evident as greatly increased urinary 
albumin, KIM-1, aogen, plasmin associated ENaC activation, and endocytosed PT albumin.
Funding: NIDDK Support
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Sex Differences in the Renal Hemodynamic Response to Angiotensin II 
Post-CPAP Therapy in Women and Men with Obstructive Sleep Apnea
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Background: Women have slower loss of kidney function and chronic kidney 
disease (CKD) progression. The renin-angiotensin system (RAS) and the vascular effects 
of obstructive sleep apnea (OSA) differ by sex. OSA is associated with glomerular 
hypertension which can be reversed by continuous positive airway pressure (CPAP) 
therapy. We sought to determine whether sex differences exist in the effect of CPAP for 
OSA on renal hemodynamics and the renal RAS in humans.
Methods: Twenty-nine (10 female, 19 male; 49±2y) incident, otherwise healthy, OSA 
subjects (respiratory disturbance index [RDI]>15h-1) with nocturnal hypoxemia (SaO2<90% 
>12%/night) were studied in high-salt balance, a state of maximal RAS suppression, pre-
CPAP and after 4 weeks of effective CPAP therapy (>4h/night). Renal plasma flow (RPF) 
and glomerular filtration rate (GFR) were measured by para-aminohippurate and inulin 
clearance technique at baseline and in response to Angiotensin II (AngII) challenge (3ng/
kg/min x 30min, 6ng/kg/min x 30min), a marker of renal RAS activity, pre- and post-CPAP. 
The primary outcome was the effect of CPAP on the renal hemodynamic responses to AngII 
in women compared to men.
Results: CPAP corrected OSA and nocturnal hypoxemia (RDI: 44±4 vs 4±1hr-1, 
p<0.001; duration SaO2<90%: 45±6 vs 7±2%, p<0.001). In women, CPAP was associated 
with a significant increase in RPF (626±22 vs 718±43 mL/min, p=0.007) but no change 
in GFR (108±2 vs 105±3 mL/min, p=0.8), whereas in men, CPAP use was not associated 
with changes in renal hemodynamics (RPF: 710±37 vs 756±38 mL/min, p=0.11; p=0.7 
vs women; GFR: 124±8 vs 113±6 mL/min, p=0.085; p=0.5 vs women). Pre-CPAP, there 
was no difference in the RPF or GFR responses to AngII between women and men. 
Post-CPAP, there was a significantly greater renovasoconstrictive response to AngII 
in women (RPF: Δ30min: -100±27 vs -161±25 mL/min, p=0.007; Δ60min: -138±27 vs 
-206±32 mL/min, p=0.007), but not in men (RPF: Δ30min: -142±14 vs -154±19 mL/min, 
p=0.4; Δ60min: -168±23 vs -200±23 mL/min, p=0.053). Post-CPAP women had a larger
initial reduction in GFR in response to AngII compared to men (Δ30min: -5±3 vs 0±2 mL/min, 
p=0.039; vs men).
Conclusions: CPAP therapy for OSA is associated with altered renal hemodynamics 
and downregulation of renal RAS activity in women but not in men.
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Role of Klotho Genetic Polymorphisms in Salt-Sensitivity Hypertension: A 
Link between Salt and Aging?
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Background: Hypertension is a common aging-related disorder. Salt intake is one of 
the main environmental factors contributing to the development of hypertension. Recently, 
an elegant paper showed that one-half Klotho transgenic mice displayed a spontaneous 
BP increase and a salt-sensitive hypertension in response to high Na intake. Commonly, 
serum levels of alpha-Klotho decrease with age and this reduction may be stronger in 
patients with several aging-related diseases. Aim of the study: to evaluate the role of Klotho 
polymorphisms in human essential hypertension and salt sensitivity.
Methods: 32 SNPs in Klotho gene identified with a previous GWA were used in the 
genetic analysis. Selected SNPs were studied for Pressure-natriuresis relationship (PNat) 
in 677 naïve essential hypertensive patients, never treated before, (NHP) by Acute salt 
load (NaLoad: 310 mMol in 2 h iv). Salt sensitivty (SS) is defined as mean BP increase 
(DMBP120) greater than 4 mm Hg at the end of infusion.
Results: We genotyped 32 SNPs within KL gene and 20 kb flanking regions. The best 
associated SNP with Na sensitivity resulted the missense rs9536314 common SNP, MAF 
0.17 for G allele. According to salt sensitivity definition, 64% of NHPs resulted SR, while 
36 % were SS. An inverse relationship was found between plasma klotho and DMBP120. 
Moreover KL rs9536314 GG and GT genotypes are more represented among SS. Again, 
GG group shows a less steep PNat curve, that is a significant increase in MBP occurred to 
excrete the same quantity of salt compared to salt resistant subjects.
Conclusions: In summary, this study showed, for the first time, that KLOTHO 
rs9536314 polymorphism is associate to salt-sensitive hypertension by activating a right 
shift of the pressure-natriuresis relationship in NHP. Therefore, klotho supplement in 
those hypertensive patient carrying the GG o mr GT variants may be potential therapeutic 
strategies for the treatment of salt-sensitive hypertension and kidney damage in elderly 
patients.
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Malignant Hypertension Can Be Partially Attenuated and Reversed by a 
20-Hydroxyeicosatetraenoic Acid Antagonist
Vera Certikova chabova,1 Lenka Sedláková,2 Ludek Cervenka.3 11st Faculty of
medicine, Charles University, Praha 2, Czechia; 2Institute for Clinical and
Experimental Medicine, Praha 4, Czechia; 3Institute of Clinical and
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Background: 20-hydroxyeicosatetraenoic acid (20-HETE), the product of cytochrome 
P450-dependent ω-hydroxylase might potentiate prohypertensive actions of angiotensin 
II (ANG II) in Cyp1a1-Ren-2 transgenic rats, a model of ANG II-dependent malignant 
hypertension. Therefore, we evaluated the antihypertensive effectiveness of a 20- HETE 
receptor antagonist (AAA) in this model.
Methods: Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by 
activation of the renin gene using indole-3-carbinol (I3C), a natural xenobiotic. Treatment 
with AAA (N-disodium succinate-20-hydroxyeicosa-6(Z),15(Z)-diencarboxamide) was 
started either simultaneously with induction of hypertension or 10 days later, during 
established hypertension. Systolic blood pressure (SBP) was monitored by radiotelemetry, 
indices of renal and cardiac injury, and kidney ANG II levels were determined.
Results: In I3C-induced hypertensive rats, early AAA treatment reduced SBP 
elevation (to 161±3 vs. 199±3 mmHg in untreated I3C-induced rats), reduced albuminuria, 
glomerulosclerosis index and cardiac hypertrophy (p<0.05 in all cases). Untreated I3C-
induced rats showed augmented kidney ANG II (405±14 vs. 52±3 fmol/g in noninduced 
rats, p<0.05). AAA treatment lowered it to levels not significantly different from that in 
noninduced rats (72±6 fmol/g). Remarkably, in TGR with established hypertension, AAA 
also decreased SBP (from 187±4 to 158±4 mmHg, p<0.05) and exhibited organoprotective 
effects in addition to a marked suppression of kidney ANG II levels. In conclusion, 20-HETE 
antagonist attenuated the development and largely reversed the established ANG II 
dependent malignant hypertension, likely via suppression of intrarenal ANG II levels.
Conclusions: Intrarenal ANG II activation by 20-HETE is important in the 
pathophysiology of this model of ANG II -dependent hypertension. 20-HETE antagonists 
can partially reverse both developing and established hypertension and target organ damage.
Funding: Government Support - Non-U.S.
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Urinary Biomarkers of Kidney Damage and Incident CKD in SPRINT
William R. Zhang,1 Timothy Craven,2 Rakesh Malhotra,9 Alfred K. Cheung,3 
Michel Chonchol,4 Paul E. Drawz,5 Mark J. Sarnak,6 Chirag R. Parikh,7 
Michael Shlipak,8 Joachim H. Ix.9 1UCSF School of Medicine, San Francisco, 
CA; 2Wake Forest School of Medicine, Winston-Salem, NC; 3University of Utah, 
Salt Lake City, UT; 4University of Colorado, Aurora, CO; 5University of 
Minnesota, Minneapolis, MN; 6Tufts Medical Center, Boston, MA; 7Yale 
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Background: Randomization to the intensive arm (SBP<120mmHg) in the Systolic 
Blood Pressure Intervention Trial (SPRINT) was associated with a 3-fold increased 
incidence of CKD, compared with the standard arm (SBP<140mmHg). However, it is 
unknown whether incident CKD in the setting of intensive SBP lowering is accompanied 
by intrinsic kidney injury.
Methods: Among the 162 incident CKD cases (128 in the intensive arm and 34 in 
the standard arm) that occurred during SPRINT follow-up and 162 controls matched on 
age, sex, race, baseline eGFR, and randomization arm, we measured 9 validated urinary 
biomarkers of kidney damage at baseline and 1 year. Linear mixed-effects models adjusting 
for baseline SBP and urine creatinine estimated 1-year biomarker changes to compare 
incident CKD cases vs. matched controls in the intensive arm; and to contrast cases in the 
intensive vs. standard arms.
Results: At 1 year of SPRINT follow-up, incident CKD cases vs. matched controls in 
the intensive arm had mean eGFR declines of -22 vs. -4 mL/min/1.73m2. However, incident 
CKD cases in the intensive arm had either significantly greater 1-year reductions or similar 
changes of kidney damage biomarkers, compared with both matched controls and with 
cases in the standard arm (Figure).
Conclusions: Incident CKD cases in the intensive arm had substantial 1-year eGFR 
reductions yet did not have relative increases in biomarkers, compared with matched 
controls; rather, these cases had decreases in several biomarkers, compared with both 
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matched controls and cases in the standard arm. Thus, incident CKD in the setting of 
intensive SBP lowering may reflect hemodynamic accommodation rather than intrinsic 
injury.
Funding: NIDDK Support
1-year percent changes of nine urinary biomarkers among incident CKD cases and matched
controls, stratified by randomization arm, in SPRINT.
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Urinary Oxalate Excretion and the Risk of ESRD and CKD Progression
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John C. Lieske,6 Dawei Xie,12 Xiaoming Zhang,13 Harold I. Feldman,7 
Gary C. Curhan.8 1Northwestern University Feinberg School of Medicine, 
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Pennsylvania School of Medicine, Philadelphia, PA; 14University of Texas 
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Background: Kidney failure from oxalate nephropathy is a devastating complication of 
rare disorders of oxalate metabolism (e.g., primary hyperoxaluria), oxalate over-absorption 
(e.g., enteric hyperoxaluria), and ingestion of large amounts of oxalate or its precursors. 
We hypothesized that higher urinary oxalate excretion, even within the typical range of 
excretion, would be associated with progression of CKD.
Methods: We measured 24h urinary oxalate excretion in stored specimens from 3,123 
participants of the Chronic Renal Insufficiency Cohort study. Baseline eGFR was 43 ml/
min/1.73m2. CRIC study participants were followed longitudinally for incident ESRD and/
or halving of eGFR. We used Cox proportional hazards models to test whether urinary 
oxalate excretion was associated with two outcomes: (1) Incident ESRD; and (2) CKD 
progression, defined as halving of eGFR or incident ESRD. Multivariable models were 
adjusted for a number of demographic, clinical, and laboratory variables.
Results: The median 24h oxalate excretion in CRIC participants was 18.6 mg (IQR, 
12.9 - 25.7 mg). Cross sectionally, higher oxalate excretion was correlated with lower 
baseline eGFR (r=-0.1, p<0.001) and greater albuminuria (r=0.15, p<0.001). In prospective 
multivariable-adjusted analyses, those in the highest vs lowest quintile of oxalate excretion 
had a 1.41-fold (95% CI 1.09-1.83) higher risk of ESRD and a 1.28-fold (95% CI 1.02-1.61) 
higher risk of CKD progression (p<0.001).
Conclusions: Among individuals with CKD, higher baseline urinary oxalate excretion 
is associated with greater risk of ESRD and CKD progression. Oxalate excretion should be 
tested as a potentially modifiable risk factor for progression of kidney disease.
Funding: NIDDK Support
Risk of ESRD and CKD progression by quintiles of urinary oxalate excretion
Adjusted for age, sex, race/ethnicity, systolic blood pressure, diabetes, body mass index, 
medications, hemoglobin, serum albumin, and baseline eGFR
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Association of Soluble TNFR-1 Concentrations with Long-Term Decline in 
Kidney Function: The Multiethnic Study of Atherosclerosis
Pavan K. Bhatraju,1,2 Leila R. Zelnick,2 Ronit Katz,3 Bryan R. Kestenbaum.3 
1Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA; 
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Background: Tumor necrosis factor receptor-1 (TNFR-1) is a cell surface receptor 
predominantly expressed in the glomerular and peritubular capillary endothelium and 
plays a causative role in the development of endothelial cell dysfunction and inflammation. 
Soluble TNFR-1 (sTNFR-1) concentrations are associated with early glomerular structural 
lesions and kidney disease progression among persons with established diabetic kidney 
disease. No studies have assessed the potential impact of sTNFR-1 on long-term changes in 
kidney function among healthy people.
Methods: We tested associations between sTNFR-1 concentration, measured at 
study enrollment, and incident decline in eGFR (≥40% decline and annual proportional 
decline) among 2,551 participants in the Multiethnic Study of Atherosclerosis (MESA). 
Participants were recruited into the MESA from six U.S. communities and were free of 
clinical cardiovascular disease at baseline. Serum creatinine concentrations were obtained 
at enrollment and study years three, five, and ten.
Results: Mean age was 61 years, 53% were women, an equal proportion was White, 
Black, Chinese or Hispanic (≈25%). Mean baseline eGFR was 79 ± 16 mL/min/1.73m2. 
Serum sTNFR-1 was inversely associated with baseline eGFR. Over a median follow-up 
time of 9.3 years, 110 participants developed a ≥40% decline in eGFR [adjusted hazard 
ratio, 1.45 (95% CI, 1.18 to 1.78) per standard deviation increment, p=0.0004] Table1. 
The highest sTNFR-1 tertile was associated with an adjusted annualized decline in eGFR 
1.80% (95% 1.10 to 4.70) after multivariate adjustment. Associations were robust across 
subgroups defined by demographics, hypertension, diabetes, and baseline CKD status.
Conclusions: Serum sTNFR-1 concentrations are associated with long-term decline 
in eGFR among a healthy, multi-ethnic cohort. Endothelial dysfunction and inflammation 
may be modifiable targets for the preservation of kidney function in ambulatory patients.
Funding: NIDDK Support, Other NIH Support - Kidney Research Institute, University 
of Washington, Government Support - Non-U.S.
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Transethnic Genome-Wide Association Studies of Kidney Function 
Measures Identify Associations at >300 Genomic Loci
Matthias Wuttke. CKDGen Consortium Institute of Genetic Epidemiology, 
Department of Biometry, Epidemiology and Medical Bioinformatics, Faculty of 
Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Background: Chronic kidney disease (CKD) affects 10% of the adult population 
globally. Reduced estimated glomerular filtration rate (eGFR) is the primary measure used to 
define CKD. Although previous[MW1] genetic studies have revealed many loci associated 
with eGFR, most of the genetic variation is still unexplained. The CKDGen Consortium 
is an international collaborative effort aimed at identifying the genetic underpinnings of 
renal health.
Methods: In an ongoing effort, 121 studies totaling >750,000 participants from five 
different ethnicities contributed genome-wide association summary statistics relating log-
transformed creatinine-based eGFR (CKD-EPI formula) to ~9 million high-quality 1KGP- 
or HRC-imputed genetic markers, using an additive genetic model adjusted for sex and 
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age. Summary statistics were combined using fixed-effects inverse variance-weighted 
meta-analysis.
Results: Across ethnicities, 308 genomic loci (1 Mb-segments, MHC region joined) 
contained at least one significantly eGFR-associated SNP (p<5E-08). The LD score 
regression intercept was 1.04, suggesting no residual inflation of the test-statistics. Of the 
308 loci, 228 were novel (mapping outside of 500 kb of previously reported index variants), 
and 80 were consistent with previous findings. Loci were characterized by their association 
with blood urea nitrogen and CKD, by tissue-specific enrichment of expressed genes, as 
well as by their heterogeneity correlated with ancestry. Approximate conditional meta-
analysis among European-ancestry individuals identified 277 independent trait-associated 
variants, which together explained 7.6% of the phenotypic variance, almost doubling 
previous estimates. We fine-mapped 212 non-overlapping regions, of which 46 contained 
>1 independent SNPs. Credible sets with 99% probability for including a causal variant
consisted of 7-74 SNPs (IQR). There were 20 single-SNP sets; for example, rs881858 (close 
to VEGFA) maps to open chromatin and represents a CTCF binding site.
Conclusions: Ongoing analyses include gene expression, tissue enrichment and 
network analyses of gene expression, and functional follow-up studies. These results of 
the largest genetic screen of kidney function to date will enhance the understanding of the 
biologic mechanisms of this trait.
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Genetic and Epigenetic Analysis in Genes Affecting Mitochondrial 
Function Are Associated with CKD in an Older Population
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Cassio P. De campos,3 Ryan Skelly,1 Sharon Cruise,1 Frank Kee,1 
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Background: The Northern Ireland COhort for the Longitudinal study of Ageing 
(NICOLA) is a ten-year project exploring health and lifestyle information in 8,504 
people ≥ 50 years of age via a computer assisted personal interview with an associated 
bioresource. Chronic kidney disease (CKD) affects ~10% of the World’s population and 
is more prevalent in older individuals. Optimal renal function is critically dependent upon 
efficient mitochondria, therefore genetic and epigenetic features that lead to mitochondrial 
dysfunction may influence CKD.
Methods: The discovery cohort comprised 2,567 white European individuals 
with body mass index ranging from 18.5 - 40 kg/m2. Genotyping was performed using 
Illumina’s Infinium CoreExome array (n=551,839 SNPs directly typed), with data imputed 
to the Haplotype Reference Consortium. Methylation data was generated using Illumina’s 
Infinium MethylationEPIC array (866,554 features with single site resolution). PLINK 
and Partek Genomics Suite were employed to investigate association with eGFR, serum 
albumin, urea and creatinine. Replication was conducted in an independent cohort of 402 
individuals.
Results: SNPs that demonstrated the most evidence for association include an exonic 
SNP in the mitochondrial genome MT-TL2 gene (rs2853498; A12308G; a key SNP defining 
mitochondrial Haplogroup U) with increased creatinine levels (P=0.000153, OR=1.185, 
95% CI=1.0929-1.2812). SNPs in nuclear genes that influence mitochondrial function 
include rs77790196 within SLC39A1 (P= 4.4 x10-07, OR=0.0055, 95% CI=0.0007-0.0412) 
and rs12564199 within JTB (P=6.6 x10-07, OR=0.006, 95% CI=0.0008-0.0449) associated 
with decreased eGFR. Analysis of epigenetic data identified eight genes demonstrating 
differential methylation with p<10-08 and Δβ ±0.2, including ZBED3, ZNF672, and AHCTF1 
for participants with early stage CKD compared to individuals with CKD stages 3-5.
Conclusions: These analyses have identified novel associations linking CKD with 
SNPs and CpG sites. This may serve as a future basis for the development of predictive 
multi-omic biomarkers and/or increased understanding of CKD pathogenesis.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Metabolomic Alterations Associated with Proteinuria
Shengyuan Luo,1,2 Josef Coresh,1,2 Adrienne Tin,1,2 Casey Rebholz,1,2 
Andrew S. Levey,3 Lesley Inker,3 Mark J. Sarnak,3 Morgan Grams.1,2 1Johns 
Hopkins University, Baltimore, MD; 2Welch Center for Prevention, Epidemiology 
& Clinical Research, Baltimore, MD; 3Tufts Medical Center, Boston, MA.
Background: Metabolomic profiling may reveal important pathophysiological 
mechanisms underlying proteinuria in chronic kidney disease (CKD).
Methods: Among 962 participants in the African-American Study of Hypertension and 
Kidney Disease (AASK) and 670 participants in the Modification of Diet in Renal Disease 
(MDRD) Study, we evaluated the cross-sectional association between log-transformed 
urine protein-to-creatinine ratio (UPCR) and known, non-drug metabolites (N =801) 
identified in stored serum samples (pre-randomization visit in AASK and 12-month follow-
up visit in MDRD) via an untargeted approach. The metabolites with statistically significant 
associations (adjusted for age, sex, race, trial arm, measured GFR, history of heart disease, 
smoking, and BMI) after Bonferroni correction were included in a pathway analysis.
Results: In AASK and MDRD, respectively, median UPCR was 80 (IQR: 28-359) 
and 185 (IQR: 54-894) mg/g, mean age was 56 and 53, 39% were female, 100% and 7% 
were black, 0% and 5% were diabetic, and mean GFR was 48 and 28 mL/min/1.73m2. 
Linear regression identified 64 metabolites associated with proteinuria in one or both 
cohorts, 55 of which were statistically significant in meta-analysis (p<8x10-4). There were 
moderate within-pathway correlations among these metabolites (Figure). Metabolites 
with the lowest p-values (p<10-17) included 4-hydroxychlorthalonil, 1,5-anhydroglucitol 
(1,5-AG), perfluoroctanesulfonic acid (PFOS), and 3-carboxy-4-methyl-5-propyl-2-
furanpropanoate (CMPF), all of which negatively associated with UPCR. Pathway analysis 
showed over-representation of metabolites in the phosphatidylethanolamine (PE) and 
phosphatidylinositol (PI) pathways.
Conclusions: Metabolomic profiling identified metabolites (including 1,5-AG, CMPF 
and chemicals such as hydroxychlorthalonil and PFOS), as well as metabolic pathways 
(such as PE and PI metabolism), that were strongly associated with non-nephrotic range 
proteinuria in CKD.
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An Investigation into the DNA Methylation Patterns of CKD in Older 
Individuals
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Background: Changes in DNA methylation are associated with chronic diseases. The 
study assessed whether methylation status of CpG sites differs between individuals with and 
without CKD between the ages of 60 and 79.
Methods: Participants were recruited as part of the Northern Ireland COhort for the 
Longitudinal study of Ageing (NICOLA), a large-scale population-based prospective 
cohort study. Estimated GFR was calculated for each individual (n=1,097) using the CKD-
EPI formula. CKD stages, based on eGFR, were determined and all individuals with stage 2 
CKD (eGFR >60 - <90mL/min/1.73m2) were removed to increase discrimination between 
CKD case and control groups. Using the Infinium HD Methylation Assay, MethylationEPIC 
BeadChips from Illumina, the methylation status of >850,000 CpG sites, gene bodies, 
promoters and CpG islands were determined in each individual. Blood-derived DNA was 
processed consistently within our single genetics centre. Partek Genomics Suite 7.0 was 
utilised for data analysis, with standard quality control applied. In total, 155 individuals 
had CKD stages 3, 4 or 5 and were compared with 240 individuals with eGFR >90ml/
min/1.73m2 and no evidence of renal disease.
Results: In total, 306 CpG sites were identified as having significantly different levels 
of methylation in individuals with CKD compared with controls (p<1x10-07). Among the 
genes identified with altered methylation status, several, including CLU, NOS3, IQSEC1 
and NPHP4 have been linked with CKD. High concordance between duplicate samples was 
also observed for this array. Three of the significantly associated CpG sites demonstrated 
a graduated increase in the methylation fold change with worsening renal function i.e. 
comparing control individuals with persons having CKD stages 3, 4 and 5 respectively.
Conclusions: Epigenetic modifications, such as DNA methylation, may represent 
important biomarkers for the loss of kidney function in individuals with CKD. Data from 
this longitudinal cohort study provides the opportunity to monitor and assess the relationship 
between methylation status and CKD over time with a view to identifying new biomarkers 
or expanding knowledge of those previously identified CKD biomarkers.
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Novel Risk Factors for CKD
Prognostic Value of Extracellular Fluid Volume in CKD: A Prospective 
Cohort Study
Anne-Laure Faucon,1 Martin Flamant,4,8 Marie Metzger,2 Jean-Jacques Boffa,5,9 
Jean-philippe Haymann,6,9 Pascal Houillier,7,3 Eric Thervet,10,3 Benedicte Stengel,1 
Guillaume Geri,11 Emmanuelle Vidal-Petiot.4,8 1CESP, INSERM U1018, Villejuif, 
France; 2CESP U1018, INSERM, Villejuif, France; 3Paris Descartes University, 
Paris, France; 4Physiology Department, Hôpital Bichat, Paris, France; 
5Nephrology Department, Hôpital Tenon, Paris, France; 6Physiology 
Department, Hôpital Tenon, Paris, France; 7Physiology Department, Hôpital 
Européen Georges Pompidou, Paris, France; 8Paris-Diderot University, Paris, 
France; 9Pierre et Marie Curie University, Paris, France; 10Nephrology 
Department, Hôpital Européen Georges Pompidou, Paris, France; 11Intensive 
care Unit, Hôpital Ambroise Paré, Paris, France.
Background: Volume overload has been shown to be an independent risk factor for 
mortality in chronic dialysis patients. However, few studies have analyzed the prognostic 
value of extracellular fluid (ECF) volume in patients with chronic kidney disease (CKD), 
not on dialysis. The aim of this study was to analyze the association between ECF volume 
and end-stage renal disease (ESRD) and mortality in patients with non-dialysis CKD.
Methods: The NephroTest study is a prospective hospital-based tricentric cohort which 
included 2,084 patients with CKD stage 1-5 of various aetiologies, between 2000 and 2012. 
ECF volume was measured as the distribution volume of 51CrEDTA, and expressed as a 
ratio of measured over theoretical ECF (rECF) - the latter being calculated using Moore 
formula. Measured glomerular filtration rate (mGFR) was assessed from the renal clearance 
of 51Cr-EDTA. Cause-specific Cox regression models were used to estimate hazard ratios 
(HR, 95% confidence intervals) of ESRD and death before ESRD associated with rECF 
tertiles in 1,610 patients with mGFR > 15 ml/min/1.73 m2.
Results: Mean age of patients was 58.7±15.1years, and 66.8% were men. Baseline 
mean mGFR was 43.7±18.7mL/min/1.73m2, mean ECF volume and rECF were 16.1±3.8L 
and 0.96±0.14, respectively. After a median follow-up of 6.1 [IQR: 3.64;8.37] years, 
ESRD occurred in 329 (20.4%) patients and 187 (11.6%) patients died before ESRD. 
After adjustment for age, sex, site, ethnicity, cardiovascular risk factors, underlying renal 
disease, mGFR, proteinuria, 24-hour sodium excretion, diuretics and diuresis, a higher 
baseline rECF was significantly associated with ESRD (HR for second vs. first tertile = 
1.28 [0.94;1.74], HR for third vs. first tertile = 1.51 [1.08;2.10]), and with mortality (HR 
for second vs. first tertile = 0.99 [0.63;1.56], HR for third vs. first tertile = 1.81 [1.17;2.80]).
Conclusions: Our data suggest that rECF volume is an independent risk factor of 
ESRD and mortality. Monitoring and avoiding excessive fluid overload is important for the 
clinical management of patients with CKD.
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Specific Mitochondrial Genetic Variants Are Associated with Kidney 
Dysfunction and Injury in Older Adults
Vasantha Jotwani,1 Ronit Katz,2 Mark J. Sarnak,3 Samir M. Parikh,4 
Adrienne Tin,5 Dan Arking,5 Michael Shlipak,6 Gregory J. Tranah.7 1UCSF, San 
Francisco, CA; 2University of Washington, Seattle, WA; 3Tufts Medical Center, 
Boston, MA; 4Beth Israel Deaconess Medical Center, Boston, MA; 5Johns 
Hopkins University School of Medicine, Baltimore, MD; 6San Francisco VA 
Medical Center, San Francisco, CA; 7Sutter Health, San Francisco, CA.
Background: Mitochondrial dysfunction is an important contributor to acute 
and chronic kidney damage, due to the critical roles of mitochondria for oxidative 
phosphorylation. Mitochondrial genetic variation has been associated with age-related 
cardiovascular and functional impairments, but little is known regarding the impact of 
common inherited mitochondrial DNA (mtDNA) variants on kidney health.
Methods: In this study of 2,728 ambulatory older adults enrolled in the Health, Aging, 
and Body Composition Study, we evaluated associations of 10 common inherited mtDNA 
haplotypes and 137 single nucleotide polymorphisms (SNPs) with estimated glomerular 
filtration rate (eGFR), albumin/creatinine ratio (ACR), and urine concentrations of kidney 
injury molecule-1 (KIM-1) and interleukin-18 (IL-18). DNA was extracted from blood 
buffy coat specimens and mtDNA genotype was determined using the Illumuna 1M chip. 
A total of 60 SNPs with minor allele frequency >=1% were examined for associations with 
kidney outcomes. All analyses stratified participants by European and African ancestry and 
adjusted for age, sex, and mitochondrial genetic ancestry.
Results: Among persons of European ancestry (n=1,660), m.10589G>A was associated 
with lower eGFR (57 vs 71 ml/min/1.73m2; p=0.009) and m.6776T>C was associated 
with higher ACR (98 vs 29 mg/g; p<0.0001), whereas haplogroup V (1721 vs 1172 pg/
ml, p=0.0066) and m.3916G>A (2599 vs 1207 pg/ml, p<0.0001) were each associated 
with higher urine KIM-1. Among persons of African ancestry (n=1,137), m.15758A>G 
was associated with higher urine KIM-1 (3476 vs 1074 pg/ml, p<0.0001). There were no 
statistically significant associations of mtDNA variants with urine IL-18.
Conclusions: Specific inherited mtDNA variants are associated with kidney 
dysfunction and injury in older adults, suggesting that mitochondrial genetic variability may 
contribute to risk of kidney disease.
Funding: NIDDK Support
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Provider Perception of Frailty Influences Dialysis Modality Choice for 
Late Stage CKD Patients Receiving Multidisciplinary Care
Ranveer S. Brar,1,2 Reid Whitlock,1,2 Blake Lerner,2 Clara Bohm,1,2 
Paul Komenda,1,2 Claudio Rigatto,1,2 Bhanu Prasad,3 Navdeep Tangri.1,2 1Seven 
Oaks General Hospital, Chronic Disease Innovation Center, Winnipeg, MB, 
Canada; 2University of Manitoba, Winnipeg, MB, Canada; 3Nephrology, Regina 
Qu’Appelle Health Region, Regina, SK, Canada.
Background: Frailty is common in patients with Chronic Kidney Disease (CKD) 
and is associated with accelerated aging. While there have been several studies examining 
frailty in patients with earlier stages of CKD and those on dialysis, little is known about 
the prevalence and impact of frailty on decisions surrounding renal replacement therapy 
modalities in patients with advanced CKD (Stages G4-G5). We sought to determine the 
prevalence of frailty in patients with advanced CKD and the association of these measures 
with dialysis modality decisions and mortality.
Methods: We studied 587 patients with advanced CKD who were enrolled in 
multidisciplinary CKD clinics at 4 centers. We collected demographics, comorbid 
conditions, and laboratory results in addition to objective [Fried Frailty Criteria and Short 
Physical Performance Battery (SPPB)], and subjective measures (physician and nurse 
impression) of frailty. Our primary outcomes were choice of dialysis modality based on 
provider perception of frailty. Our secondary outcomes were agreement between frailty 
assessment tools and all-cause mortality.
Results: Our cohort had a mean age of 66.3 and 41% were female. Estimates of 
frailty prevalence varied as 54.8% of the cohort were considered frail according to SPPB, 
33.2% according to Fried, 35.2% according to physician impression, and 32.5% according 
to nursing impression. Agreement between objective frailty assessments was moderate 
(κ = 0.42), as was agreement between subjective frailty assessments (κ = 0.47). In
unadjusted and adjusted analyses, frailty measured objectively using Fried was associated
with mortality (HR 2.15 [95% CI: 1.27-3.62]), and frailty measured subjectively (OR 4.20 
[95% CI: 1.88-9.76) was associated with choosing in center hemodialysis.
Conclusions: Frailty is common in patients with advanced CKD, but its operational 
definition can classify different patients as frail. Patients classified as frail by Fried have a 
higher risk of death, and patients considered frail by nurses and physicians are more likely 
to choose in-center hemodialysis. Further research to understand the longitudinal trajectory 
of frailty and its impact on therapeutic choices, morbidity, mortality, and quality of life after 
the initiation of dialysis is needed.
Funding: Government Support - Non-U.S.
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Twenty-Year Trends in Mortality Due to Myocardial Infarction and 
Stroke in Dialysis Patients
Gurbey Ocak,1 Marlies Noordzij,2 Maarten B. Rookmaaker,1 
Marianne C. Verhaar,1 Ziad Massy,3,4 Friedo W. Dekker,5 Kitty J. Jager.2 
1Department of Nephrology and Hypertension, University Medical Center 
Utrecht, Utrecht, Netherlands; 2Department of Medical Informatics, ERA-EDTA 
Registry, Amsterdam, Netherlands; 3Department of Nephrology, Ambroise Pare 
University Hospital, Boulogne Billancourt/ Paris, France; 4Inserm Unit 1018, 
CESP, Team 5, (EpReC, Renal and Cardiovascular Epidemiology), UVSQ, 
Villejuif, France; 5Department of Clinical Epidemiology, Leiden University 
Medical Center, Leiden, Netherlands.
Background: In the last decades, important improvements have been made in 
the prevention and treatment of myocardial infarction and stroke resulting in reduced 
mortality rates in the general population. However, it is unknown whether mortality rates 
of myocardial infarction and stroke have also decreased with time in dialysis patients. The 
aim of this study was to assess the mortality rates due to myocardial infarction and stroke 
in a large cohort of dialysis patients as compared with the general population for three time 
periods.
Methods: We included incident dialysis patients from eleven European countries 
providing data to the ERA-EDTA Registry who started dialysis between 1994 and 2011 
and followed them for three years. The causes of death in dialysis patients were compared 
with the causes of death in the general population in the same time period. We calculated 
age- and sex-standardized mortality rate ratios (SMRs) with 95% confidence intervals 
(CIs) by dividing the mortality rates in dialysis patients by the mortality rates in the general 
population for three time periods (1994-1999, 2000-2005 and 2006-2011).
Results: Of the 201,918 dialysis patients, 79,327 patients died during follow-up of 
whom 10.3% died due to myocardial infarction and 6.6% due to stroke. In the general 
population, 19,058,469 persons died during follow-up of whom 7.4% died due to 
myocardial infarction and 6.1% due to stroke. Compared with the general population, the 
SMRs of myocardial infarction for dialysis patients were 11.4 (95% CI 10.8-12.0) between 
1994 and 1999, 12.1 (95% CI 11.5-12.8) between 2000 and 2005 and 14.0 (95% CI 13.2-
14.8) between 2006 and 2011. The SMRs of stroke were 11.0 (95% CI 10.3-11.9) between 
1994 and 1999, 11.7 (95% CI 10.8-12.6) between 2000 and 2005 and 12.4 (95% CI 11.5-
13.3) between 2006 and 2011.
Conclusions: Mortality rate ratios for myocardial infarction and stroke increased with 
time. Dialysis patients seem to benefit less of improvements made in the prevention and 
treatment of myocardial infarction and stroke than non-dialysis patients which may be 
related to the underlying pathophysiological mechanisms of the atherosclerotic disease or 
to the limited optimal cardiovascular therapeutic strategies.
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International Comparisons of Mortality Among Hemodialysis Patients in 
the DOPPS
Keith McCullough,1 Eric W. Young,4 Steven M. Brunelli,2 Daniel E. Weiner,3 
John Hartman,5 Dino B. Capone,6 Bruce M. Robinson.1 1Arbor Research 
Collaborative for Health, Ann Arbor, MI; 2DaVita Clinical Research, Needham, 
MA; 3Tufts Medical Center, Boston, MA; 4Arbor Research, Ann Arbor, MI; 
5Visonex LLC, Green Bay, WI; 6Visonex, LLC, Green Bay, WI.
Background: Case-mix-adjusted mortality rate among hemodialysis patients has been 
higher in the US than in Europe or Japan, although this gap has been shrinking. Patient 
population and clinical practices have changed over time. We are evaluating the effects of 
case mix, practice patterns, and country factors on mortality rates across countries.
Methods: In DOPPS phase 5 data (2012-15) from hemodialysis facilities in Europe, 
Japan, and North America, Cox models with cumulative covariate adjustment were 
fitted to estimate adjusted hazard ratios (HR) for death. Case-mix-based propensities for 
transplantation or change to peritoneal dialysis (PD) were generated using models based 
on data from the previous DOPPS phase, while within-country general population all-cause 
and kidney-related death rates were based on WHO data.
Results: The unadjusted death rate in the US was generally comparable to that of many 
European countries (figure). Adjustment for case mix, especially age and race, results in 
lower hazard ratios for most European countries compared to the US, while adjustment for 
skipped treatments and selected practice measures (fistula use, phosphorous levels <6 mg/dl, 
intra-dialytic weight gain <5.7% of body weight) increased the hazard ratios for these 
European countries compared to the US, although most were still somewhat below that of 
the US. Japan Canada had consistently lower adjusted mortality than the US.
Conclusions: Unadjusted mortality in the US is comparable to that of European 
countries. Case-mix adjustment yields lower hazard ratios in most countries compared 
to US, indicating outcomes are still worse in US. Adjustment for practice measures 
substantially attenuates this effect in some countries, indicating that these factors may 
provide a means for the US to improve its outcomes. Japan has lower mortality in DOPPS 
data than any other country; this is not explained by any adjustment explored thus far.
Funding: NIDDK Support, Commercial Support - The DOPPS Program is supported 
by Amgen, Kyowa Hakko Kirin, Baxter Healthcare. Additional support for specific 
projects and countries is provided by AstraZeneca, European Renal Association-European 
Dialysis & Transplant Association (ERA-EDTA), Fresenius Medical Care Asia-Pacific Ltd, 
Fresenius Medical Care Canada Ltd, German Society of Nephrology (DGfN), Janssen, 
Japanese Society for Peritoneal Dialysis (JSPD), Keryx, Kidney Care UK, MEDICE 
Arzneimittel Pütter GmbH & Co KG, Proteon, and Vifor Fresenius Medical Care Renal 
Pharma. Public funding and support is provided for specific DOPPS projects, ancillary 
studies, or affiliated research projects by National Health & Medical Research Council 
(NHMRC) in Australia, Cancer Care Ontario (CCO) through the Ontario Renal Network 
(ORN) in Canada, French National Institute of Health and Medical Research (INSERM) 
in France, Thailand Research Foundation (TRF), Chulalongkorn University Matching 
Fund, King Chulalongkorn Memorial Hospital Matching Fund, and the National Research 
Council of Thailand (NRCT) in Thailand, National Institute for Health Research (NIHR) 
via the Comprehensive Clinical Research Network (CCRN) in the United Kingdom, and 
National Institutes of Health (NIH) in the US. All support is provided without restrictions 
on publications. All grants are made to Arbor Research Collaborative for Health and not to 
Mr. McCullough directly., Private Foundation Support, Government Support - Non-U.S.
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The Comparative Cardiac Safety of Selective Serotonin Reuptake 
Inhibitors (SSRIs) in the Hemodialysis (HD) Population
Magdalene M. Assimon, Jennifer E. Flythe. University of North Carolina 
Kidney Center, Chapel Hill, NC.
Background: HD patients may be particularly susceptible to the lethal consequences 
of drug-induced QT prolongation due to their tremendous cardiovascular disease burden 
and recurrent exposure to electrolyte shifts during HD treatments. Electrophysiologic 
data indicate that citalopram and escitalopram prolong the QT interval more than other 
SSRIs. Even though 37% of HD patients receive SSRI therapy, the relative cardiac safety of 
individual SSRIs in this vulnerable population is not well-established.
Methods: Data were taken from a cohort of Medicare-enrolled HD patients in the 
United States Renal Data System registry (2007–2014). Using a new-user design, we 
conducted a retrospective cohort study to assess the comparative 1-year risk of sudden 
cardiac death between HD patients initiating SSRIs with higher (citalopram, escitalopram) 
vs. lower (fluoxetine, fluvoxamine, paroxetine, sertraline) QT prolonging potential. We 
used propensity-score weighted survival models, adjusted for numerous demographic and 
clinical covariates, to estimate adjusted hazard ratios (aHRs) and their 95% confidence 
intervals (CIs). All analyses used an on-treatment analytic approach and treated non-sudden 
cardiac death as a competing event.
Results: Of 65,654 study patients, 30,932 (47.1%) started an SSRI with higher QT 
prolonging potential and 34,722 (52.9%) started an SSRI with lower QT prolonging 
potential. Initiation of an SSRI with higher (vs. lower) QT prolonging potential was 
associated with an increased 1-year risk of sudden cardiac death, aHR [95% CI] = 1.14 
[1.05–1.25]. Observed associations were particularly elevated among females (1.21 
[1.07–1.37]); individuals ≥75 years old (1.14 [1.01–1.28]); individuals with structural heart 
disease (1.13 [1.03–1.23]); and those concurrently using other QT prolonging medications 
(1.16 [1.04–1.29]). Sensitivity analyses 1) evaluating a composite outcome of sudden 
cardiac death or new-onset ventricular arrythmia, and 2) using an intent-to-treat analytic 
approach yielded similar results (not shown).
Conclusions: Initiation of an SSRI with higher (vs. lower) QT prolonging potential 
was associated with an increased risk of sudden cardiac death. When prescribing SSRIs 
to HD patients, providers should consider the QT prolonging potential of these agents, 
especially among individuals with sudden cardiac death risk factors.
Funding: NIDDK Support
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Association of Ultrafiltration Rate and Decline in Residual Kidney 
Function among Thrice-Weekly Hemodialysis Patients
Yuji Lee,1 Yusuke Okuda,1 Yoshitsugu Obi,1 Jason A. Chou,1 Elani Streja,1 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh,1 Connie Rhee.1 1Harold Simmons 
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Background: The association between ultrafiltration rate (UFR) and decline in residual 
kidney function (RKF) has not been well examined in conventional hemodialysis (HD) 
patients with RKF.
Methods: We retrospectively reviewed a cohort of 7,753 patients who initiated thrice-
weekly HD from 2007 to 2011, had available UFR and renal urea clearance (KRU) data at 
baseline, and had KRU data at 1 year after HD initiation. Patients were categorized into 4 
UFR groups (<6, 6 to <10, 10 to <13, and ≥13 mL/h/kg). We defined rapid decline in RKF 
as a decline in KRU of more than 20% per year. We explored the association between UFR 
and rapid decline in RKF using logistic regression models with adjustments for case-mix 
variables, baseline RKF, and maximal change of blood pressure during dialysis.
Results: Mean ± SD UFR level was 7.0 ± 3.1 mL/h/kg. Median (interquartile range) 
baseline KRU was 3.5 (2.1 – 5.3) mL/min/1.72m2. Mean annual changes of KRU were 
-1.1, -1.2, -1.4, and -1.6 mL/min/1.73m2 in UFR <6, 6 to <10, 10 to <13, and ≥13 mL/h/kg 
groups, respectively (P = 0.004). In a cubic spline model, higher UFR was associated
with increased risk for rapid decline in KRU [figure 1A]. Additionally, we found a graded 
association between categorized UFR and rapid decline of RKF in the fully adjusted
multivariable regression models: odds ratios (95% confidence intervals) were 0.80 (0.72-0.88), 
1.33 (1.14-1.57), and 1.39 (1.08-1.80) in UFR <6, 10 to <13, and ≥13 mL/h/kg groups,
respectively (reference: UFR 6 to <10 mL/h/kg) [figure 1B].
Conclusions: In incident thrice-weekly HD, higher UFR was associated with rapid 
decline in RKF. Strategies to avoid high UFR may be useful for RKF preservation in 
incident HD patients.
Funding: NIDDK Support
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Opioid and Benzodiazepines Use in Patients on Hemodialysis
Rupam Ruchi, Shahab Bozorgmehri, Tezcan Ozrazgat-baslanti, Mark S. Segal, 
Sanjeev Kumar. University of Florida, Gainesville, FL.
Background: Opioid & Concomitant use of benzodiazepines is a public health 
problem. Little is known about opioids and benzodiazepine prescription in HD patients
Methods: This is retrospective study of USRDS data on ESRD patients ≥18 yrs, 
on HD, enrolled in Medicare & part D between 2006-2012, excluding those on PD & 
malignancy. We used ESRD Medicare Prescription Drug Events dataset for narcotics & 
benzodiazepines. We categorized narcotics into three safety classes per literature (safe, use 
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caution, unsafe) and analyzed their prescription pattern. We used hospitalization dataset to 
identify hospitalization with opioid overdose using ICD-9 CM codes, total LOS and ICU 
LOS
Results: Out of 2,657,352 patients, 643,859 were included, & divided into opioid 
(n=480,460, 74.6%) and non-opioid group. The biggest difference b/w 2 groups is in the use 
of benzos (30% in opioid vs 11% in non-opioid P<0.001). There is significant association 
between opioid & benzo use (OR = 3.27, P<0.001). 6,665,906 narcotic prescriptions were 
written averaging 13.8 prescriptions/patient. 52.2% patients were prescribed narcotics/year. 
Each patient got an average of 8 prescriptions/year. 30% of patients who got a prescription 
for opioid, also got a prescription for a benzo. 56.5% received prescriptions for both within 
a week of each other. Adverse events (A/E): 2225 patients with narcotic prescription 
(0.46%) had 3231 admissions with opioid overdose. 4 died. Median LOS is 4d, median ICU 
LOS is 2d. Benzo use prior to hospitalization was significantly higher in patients admitted 
for narcotic overdose as compared to others (40% vs 24%, p <0.001). Association between 
opioid class and A/E: Among the “safe” drugs, fentanyl & hydromorphone were associated 
with moderately high odds of hospitalization within 30 days (OR 3 and 2.4 respectively). 
This persisted at 60 & 90 days with fentanyl but decreased with hydromorphone at 90 days 
(1.6). Methadone was associated with a very high risk of hospitalization at 30 days (OR 
5.9), that persisted at 60 & 90 days. Among the drugs to be used with caution hydrocodone 
had the least OR among all the drugs (1.8, 1.7 and 1.6 at 30, 60 and 90d). Oxycodone was 
moderate risk and oxymorphone (Opana) was high risk.
Conclusions: opioid and benzodiazpeine prescription in HD patients is very high. Drug 
safety based on pharmacokinetic profile in dialysis does not translate to clinical safety.
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Prevalence, Indications, and Risks of Muscle Relaxant Use among 
Hemodialysis Patients
Diana Mina, Kirsten L. Johansen, Charles E. McCulloch, Michael Steinman, 
Barbara A. Grimes, Julie H. Ishida. UCSF, San Francisco, CA.
Background: Muscle relaxants are used to treat musculoskeletal pain and cramping, 
which are commonly experienced symptoms among hemodialysis patients. However, 
epidemiologic data characterizing the prevalence, indications, and risks of muscle relaxant 
use in this population are lacking.
Methods: From the USRDS, we identified 140,899 adults receiving in-center 
hemodialysis with Medicare Part D in 2011. We determined the prevalence of muscle 
relaxant use and the presence of a relevant indication, defined by ICD-9 codes, within 
60 days preceding the date of a prescription by examining Medicare claims data. Using 
Cox regression models, we investigated the association between receipt of muscle relaxants 
(e.g., cyclobenzaprine, baclofen), modeled as a time-varying exposure, and time to first 
emergency room visit or hospitalization for altered mental status (AMS), fall, and fracture 
defined by ICD-9 and CPT codes. We adjusted for demographics, comorbidities, duration of 
muscle relaxant exposure, number of medications, and concomitant medications. Exposure 
was time-lagged (i.e., ascertained from the prior day) for fall and fracture in order to account 
for possible effect/cause.
Results: Ten percent (14,312) of the cohort received muscle relaxants, and 17% 
(24,067) had an episode of AMS, fall, or fracture in 2011. The most common diagnoses 
associated with muscle relaxant use were musculoskeletal pain other than neck or back 
pain (72%), back pain (48%), and muscle spasticity (25%). Fourteen percent of patients 
with a muscle relaxant prescription lacked a relevant indication. Muscle relaxant use was 
significantly associated with AMS, fall, and fracture (Table).
Conclusions: Muscle relaxants are commonly used by hemodialysis patients. They 
were most frequently prescribed for musculoskeletal pain and spasticity, but a sizeable 
proportion of patients lacked a clear indication based on claims data. Muscle relaxants 
are associated with a high risk for AMS, fall, and fracture. Future research to define the 
appropriate use of these agents in this population is warranted.
Funding: NIDDK Support
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Temporal Trend of the Provision of Palliative Care Encounter in 
Hospitalized Patients with ESRD: A Nationwide Analysis
Yumeng Wen,1,2 Marcelo X. Hernandez Cuchillas,1,2 David Mariuma,1,2 
Changchuan Jiang,1,2 Di Pan.1,2 1Department of Medicine, Mount Sinai St. Luke’s 
and Mount Sinai West, New York, NY; 2Icahn School of Medicine at Mount Sinai, 
New York, NY.
Background: End stage renal disease (ESRD) is major cause of worldwide mortality 
and morbidity. We sought to investigate the temporal trend of the utilization of palliative 
care (PC) in hospitalized patients with ESRD in United States.
Methods: We conducted a retrospective study using the national inpatient sample 
to identify patients with ESRD admitted to hospitals from 2006 to 2014. We sought to 
determine the temporal trend and factors associated with utilizing palliative care in 
hospital. Multivariate logistic analysis was performed to calculate odds ratios, adjusting 
for demographics, hospital characteristics, comorbidities and code status. Analysis was 
performed using Stata 14.0.
Results: A cohort of 6,280,637 patients was identified from 2006 to 2014, of whom 
1.65% had a PC consult referral. The incidence of PC contact increased from 0.39% in 
2006 to 2.98% in 2014 (aOR 1.11, p<0.01). Patients who received PC contact, compared 
to who did not, were older (68.79 vs 64.28, p<0.01), had longer hospital stay (8.37 vs. 6.20 
days, p<0.01) and were more likely to die in hospital (49.40% vs. 4.04%, p<0.01). Factors 
associated with more frequent PC referral included more cormobidities, Caucasian race 
(compared to minorities), teaching hospitals, larger hospitals, hospitals region other than 
Northeastern area, household income, medicaid or private insurance, and do not resuscitate 
(DNR) status (shown in Table 1).
Conclusions: The use of palliative care consultation for patients with ESRD who are 
admitted to hospitals is approximately 1.65%. Race, socioeconomic status, hospital size, 
region and teaching status all were associated with differential rates of referral. There was a 
significant increase in palliative care use observed from 2006 to 2014.
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Centre, Montreal, QC, Canada; 6Chronic Disease Innovation Centre, Winnipeg, 
MB, Canada; 7Sunnybrook Health Science Centre, Toronto, ON, Canada; 
8University of British Columbia, North Vancouver, BC, Canada; 9Foothills 
Medical Center, Calgary, AB, Canada; 10Toronto General Hospital, University 
Health Network, Toronto, ON, Canada.
Background: In August 2010, the Initiating Dialysis Early and Late (IDEAL) trial was 
published and randomized patients with pre-dialysis CKD to planned initiation of dialysis in 
the eGFR range of 10 to 14 ml/min/1.73m2 (early start) vs. 5 to 7 ml/min/1.73m2 (late start). 
It concluded that earlier initiation was not associated with improved survival or clinical 
outcomes. The degree by which this information was disseminated and applied in practice 
is unknown. We aimed to determine the impact of the IDEAL trial on the proportion of 
patients who initiate dialysis early (eGFR > 10.5 ml/min/1.73m2).
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Methods: A segemented regression analysis was performed including all incident 
adult dialysis patients from the Canadian Organ Replacement Register (CORR) with at 
least 90 days of nephrologist care before starting dialysis with a recorded eGFR at dialysis 
initiation. The primary outcome was the change in the proportion of early dialysis starts 
(eGFR at initiation > 10.5 ml/min/1.73m2). Secondary outcomes included the change in the 
proportion of acute inpatient dialysis initiations, the proportion of patients who received 
home dialysis as initial therapy, and the proportion of hemodialysis patients who started 
dialysis with an arteriovenous (AV) fistula.
Results: Following the IDEAL trial we observed an immediate decline in the 
proportion of early dialysis starts of 4.49% (95% confidence interval 1.24 to 7.74; 
p = 0.0080), and there was a significant decrease from the pre-trial annual slope of 2.76% 
(1.68 to 3.84; p = < 0.001), resulting in an annual decrease of 1.44% (0.84 to 2.16; 
p < 0.001) in the post-trial period. Acute inpatient dialysis initiations increased immediately 
following the publication by 2.86% (0.10 – 5.62; p = 0.0440), however there was no 
sustained change. The proportion of patients who received home dialysis as initial therapy 
and the proportion who initiated hemodialysis with an AV fistula did not have immediate 
or sustained differences.
Conclusions: The IDEAL trial had a strong and sustained impact on the timing of 
dialysis initiation in Canada. These changes were accompanied by no sustained effects on 
home dialysis as initial therapy, AV fistula construction, or acute inpatient dialysis initiation
Funding: Government Support - Non-U.S.
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Impact of Rescheduling a Missed Hemodialysis Treatment on Clinical 
Outcomes
Dena E. Cohen,1,2 Kathryn S. Gray,1,2 Carey Colson,1,2 David B. Van Wyck,2 
Francesca Tentori,1,2 Steven M. Brunelli.1,2 1DaVita Clinical Research, 
Minneapolis, MN; 2DaVita Institute for Patient Safety, Denver, CO.
Background: Among patients treated with hemodialysis (HD), a missed treatment is 
associated with elevated hospitalization risk in the subsequent 30 days. It is not known 
whether attending a rescheduled treatment on the following day ameliorates this risk.
Methods: This retrospective study used electronic health records and 2014 USRDS 
claims merged via direct linkage. Eligible patients were adults receiving HD on a Monday/
Wednesday/Friday schedule who, as of index, had dialysis vintage ≥90 days, available 
Medicare A & B claims, and had not missed a treatment for any reason in the 30 days prior 
to index. For each of 12 index dates, patients were classified based on attending treatment; 
those who did not were classified as “rescheduled” or “missed” based on whether or not they 
dialyzed the following day. In separate analyses, “rescheduled” and “missed” patients were 
each matched (1:5) to patients who attended based on index day of week and propensity 
score. Hospitalization was considered over the subsequent 7 and 30 days, or until censoring, 
and compared using generalized linear models.
Results: Prior to matching, patients who missed or rescheduled treatment were 
of younger age and dialysis vintage than those who attended. All characteristics were 
balanced after matching. Compared to attending (N=20,725), a missed treatment (N=4145) 
was associated with a 100% higher rate of hospitalization in the subsequent 7 days, and 
a 39% higher rate over 30 days. Attending a rescheduled treatment on the day after a 
missed treatment (N=2308) was associated with a 49% higher rate of hospitalization in 
the subsequent 7 days, and a 31% higher rate over 30 days, versus attending (N=11,540).
Conclusions: Rescheduling treatment attenuated but did not fully mitigate the 
hospitalization risk imposed by a missed treatment.
Funding: Commercial Support - This was a research project conducted by the DaVita 
Institute for Patient Safety and supported by DaVita Kidney Care.
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Association of Baseline eGFR and AKI-D with Early Mortality after 
ESRD
Raymond K. Hsu, Anna Rubinsky, Michael Shlipak, Carmen A. Peralta, 
Benjamin J. Lee, Chi-yuan Hsu. UCSF & SF VA Medical Center, San Francisco, 
CA.
Background: Abrupt decline in kidney function and non-recovery of dialysis-requiring 
AKI (AKI-D) have both been shown to be associated with adverse outcomes in patients 
with incident ESRD. We hypothesized that distinct patterns of transition to ESRD based on 
both the mean 1-year baseline eGFR and presence of AKI-D preceding ESRD would help 
prognosticate 90-day mortality after hemodialysis (HD) initiation.
Methods: We identified a national cohort of Veterans who initiated maintenance HD 
in 2009-2013 and had outpatient creatine (Cr) measured within 1 year prior to ESRD. 
Patients were categorized based on A) mean outpatient eGFR within 1 year prior to incident 
ESRD (≥ or < 30); and B) occurrence of in-hospital AKI-D leading to ESRD. AKI-D was 
defined using KDIGO criteria of [≥0.3mg/dL rise and/or ≥50% rise in Cr from mean 1-year 
baseline], and inpatient dialysis. The association between patterns of transition and all-
cause mortality within 90 days after HD initiation were examined using multivariable Cox 
models.
Results: Patients with incident ESRD (N=22,815) were 69±11 years old, 98% male, 
27% black, and 68% diabetic. 4114 (18%) had mean 1-year outpatient eGFR≥30; 2644 
(12%) experienced AKI-D with peak inpatient Cr rise was ≥50% from baseline. Relative to 
refence group of mean outpatient eGFR<30 and no AKI-D, patients with mean outpatient 
eGFR≥30 had ~2-fold adjusted risk of 90-day mortality, regardless of presence/absence of 
AKI-D (Table1). Among patients with mean eGFR<30, those with AKI-D and ≥50% rise in 
Cr had a small increase in mortality, whereas those with AKI-D and smaller peak Cr (<50% 
but ≥0.3mg/dl rise) had lower 90-day adjusted mortality.
Conclusions: Nearly 1 in 5 incident ESRD patients had a mean outpatient eGFR≥30 
within the 1 year prior to HD initiation. This pattern of abrupt transition to ESRD was 
strongly associated with early mortality regardless of whether or not AKI-D directly 
preceded ESRD.
Funding: NIDDK Support
*refers to mean outpatient eGFR within 1 year prior to ESRD. **adjusted for demographics, 
co-morbidities, and pre-ESRD nephrology care.
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Anti-MicroRNA Screen Uncovers miR-17 Family within miR-17~92 
Cluster as the Primary Driver of Kidney Cyst Growth
Matanel Yheskel,1,2 Ronak Lakhia,1 Vishal Patel.1 1University of Texas 
Southwestern Medical Center, Dallas, TX; 2MD/PhD (MSTP) training program, 
Albert Einstein College of Medicine, Bronx, NY.
Background: We have recently shown that inhibiting miR-17~92 is a potential 
novel therapeutic approach for autosomal dominant polycystic kidney disease (ADPKD). 
However, miR-17~92 is a polycistronic cluster that encodes microRNAs (miRNAs) 
belonging to the miR-17, miR-18, miR-19 and miR-25 families. The relative pathogenic 
contribution of these miRNA families to ADPKD progression is unknown.
Methods: We performed an in vivo anti-miR screen to identify drug targets within the 
miR-17~92 miRNA cluster. Locked nucleic acid-modified anti-miRs (12 to 16 nucleotides) 
were used to selectively inhibit either the miR-17, miR-18, miR-19, or miR-25 family in 
an orthologous model of ADPKD. miRNAs belonging to one family harbor identical seed 
sequence but there are minor differences in flanking nucleotides. To simultaneously inhibit 
all members of one family, anti-miRs were designed to Watson-Crick base pair with the 
majority but not the entire length of cognate mature miRNA sequence. Mice were randomly 
assigned to receive either 20 mg/kg of anti-miR-17, anti-miR-18, anti-miR-19, or anti-
miR-25 family inhibitors, or vehicle at postnatal days (P) 10-12 and 15, and were sacrificed 
at P18 to assess cyst burden.
Results: Q-PCR analysis showed that anti-miRs specifically inhibit the cognate 
miRNA family members without affecting the expression of unrelated miRNAs. Treatment 
with anti-miRs against the miR-17 family reduced cyst proliferation, kidney-weight-to-
body-weight ratio, and cyst index. In contrast, treatment with anti-miRs against the miR-18, 
19, or 25 families did not affect cyst growth. RNA-seq analysis showed that anti-miR-17 
treatment recapitulated the gene expression pattern observed after miR-17~92 genetic 
deletion. Additional analysis revealed that anti-miR-17 treatment was associated with 
upregulation of mitochondrial metabolism, suppression of the mTOR pathway, induction of 
autophagy, and reduction of cyst-associated inflammation (M2-like macrophages).
Conclusions: Our results argue against functional cooperation between the various 
miR-17~92 cluster families in promoting cyst growth and instead point to miR-17 family 
as the primary pathogenic component and therapeutic target for ADPKD. This new 
information is vital because it guides the substantial on-going drug development efforts 
aimed at targeting the miR-17~92 cluster for the treatment of human ADPKD.
Funding: NIDDK Support
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Kidney Organoids without Cilia Establish a Human Model of Ciliopa-
thy-Associated Polycystic Kidney Disease
Nelly M. Cruz,1 Jonathan Himmelfarb,2 Benjamin S. Freedman.1 1University of 
Washington, Seattle, WA; 2Kidney Research Institute, Seattle, WA.
Background: Primary cilia are specialized, antenna-like organelles at the plasma 
membrane associated with a spectrum of human syndromes called ciliopathies. Phenotypes 
of polycystic kidney disease (PKD) are commonly associated with ciliopathies, but how 
cilia function to prevent kidney cysts remains poorly understood. A major barrier to 
understanding ciliary function is the absence of cellular models that accurately reconstitute 
the complex human phenotypes of ciliopathies.
Methods: We used the CRISPR-Cas9 genome editing system to introduce mutations in 
two genes that are required for ciliogenesis, kinesin family member 3A (KIF3A) and KIF3B, 
in human pluripotent stem cells (hPSC). Genome modified KIF3A-/- or KIF3B-/- hPSC were 
differentiated in vitro into kidney organoids containing proximal tubules, distal tubules, and 
podocytes in nephron-like segments. Structure and composition of organoids were analyzed 
by immunofluorescence. To determine the mechanistic consequences of ciliary loss, a 
biochemical assay was used to measure ciliopathy-linked protein levels in both whole cell 
lysates and extracellular vesicles.
Results: We isolated four independent cell lines with indel mutations in the KIF3A 
gene and three cell lines with indels in KIF3B. Immunoblots confirmed that no full-length 
protein is produced in these mutants. The gene-edited hPSC completely lacked cilia, while 
~50% of cells were ciliated in the isogenic controls. Importantly, the absence of cilia did not 
alter hPSC growth, pluripotency, self-renewal, or their ability to differentiate into kidney 
organoids. Upon differentiation, however, the cilia-deficient kidney organoids formed large 
cysts from tubular epithelial cells, which were absent in controls. Defects were furthermore 
observed in the expression of the disease-associated proteins polycystin-1 and polycystin-2 
in kinesin mutants.
Conclusions: Genome modified KIF3A-/- or KIF3B-/- hPSC establish a general tool 
for studying the function of human cilia in diverse cell types and organoids. Our findings 
directly link the loss of ciliary kinesins to polycystin expression defects and kidney cyst 
formation in human cells. Using this new tool, it is now possible to perform phenotypic 
screens and mechanistic studies to reveal the functions of human cilia and test interventional 
strategies for ciliopathy syndromes.
Funding: Private Foundation Support
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Polycystin Signaling: Control of Tubule Cell Shape by Actomyosin-Depen-
dent Apical Constriction
Alexis Hofherr,3 Claudia Seger,3 Eryn E. Dixon,2 Samuel L. Svendsen,1 
Owen M. Woodward,2 Jens G. Leipziger,1 Michael Kottgen.3 1Aarhus University, 
Aarhus C, Denmark; 2University of Maryland School of Medicine, Baltimore, 
MD; 3Medical Center – University of Freiburg, Freiburg im Breisgau, Germany.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common monogenic cause of end-stage renal disease affecting approximately 1 in 500 
adults. Mutations in two genes cause ADPKD. Polycystic kidney disease 1 (PKD1) accounts 
for 85 % of patients and PKD2 accounts for the remaining 15 % of patients. Elegant 
experiments in model organisms have uncovered that the respective proteins, Polycystin-1 
(PC1) and transient receptor potential ion channel Polycystin-2 (TRPP2), form a receptor-
ion channel complex which is essential for renal morphogenesis and maintenance. The 
molecular components, however, connecting the two ADPKD proteins to these processes 
have remained elusive. Or more specifically, the intracellular effectors translating PC1/
TRPP2 receptor-ion channel activity into three-dimensional tissue organization connecting 
genetics, cellular output, and tissue mechanics are unknown.
Methods: We have addressed this issue for the kidney with an unbiased high-resolution 
mass spectrometry-based screen for TRPP2-binding proteins in polarized renal epithelial 
cells followed by targeted analyses of PC1/TRPP2 function in vitro and in vivo. In vitro 
analyses of PC1/TRPP2 and candidate proteins were performed using CRISPR/Cas- and 
TALEN-based gene-specific knock-out and knock-in Madin-Darby canine kidney (MDCK) 
cell models. Wild-type and mutant zebrafish, mice, and human samples were used to 
validate results in vivo.
Results: Here we identify an apical junction associated multi protein signaling complex 
as functional PC1/TRPP2 effector and show: 1) how the PC1/TRPP2 complex controls 
cellular shape by actomyosin-dependent apical constriction; 2) that this cellular contraction 
translates on a tissue-scale into a coordinated fine-tuning of renal tubular diameter in vivo; 
and 3) that in human ADPKD kidneys, tubular shape is lost, because of impaired signal 
integration disconnecting mutant cells from their healthy surroundings.
Conclusions: ADPKD is a prime example for a disease affecting renal morphogenesis 
and maintenance. We anticipate that our detailed characterization of the various levels of 
polycystin-dependent renal tubular cell shape control may help to elucidate the complex 
cellular machinery integrating genetic, cellular, and mechanical inputs in health and renal 
disease.
Funding: NIDDK Support, Government Support - Non-U.S.
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Role of the Mechanosensitive Ion Channel Piezo1 in Autosomal Dominant 
Polycystic Kidney Disease
Fouad T. Chebib,1 Maria V. Irazabal,2 Vicente E. Torres.1 1Mayo Clinic, 
Rochester, MN; 2Mayo Clinic, Rochester, MN.
Background: Disruption of intracellular calcium (iCa2+) likely underlies the 
upregulation of cAMP signaling and the proliferative and secretory phenotype of the cystic 
epithelium in ADPKD. However, the mechanisms by which polycystins reduce iCa2+ 
remain elusive. Impaired flow-induced Ca2+ entry through ciliary polycystin complex has 
been previously proposed as a pathogenic mechanism, but newer evidence suggests the 
involvement of polycystins in modulation of other mechanosensitive ion channels such 
as Piezo1, the novel stretch-activated cation channel. We hypothesized that polycystins, 
through their physical and functional interaction with Piezo1, modulate various cellular 
responses to mechanical stimulation.
Methods: Wild type inner medullary collecting duct cells (mIMCD3) were stably 
transfected with genetically encoded biosensors, jRGeco1a and Flamindo2, to study 
spatiotemporal dynamics of Ca2+ and cAMP during live cell imaging, respectively. These 
cells were also cultured in 3D matrigel matrix. Metanephric embryonic kindeys were 
cultured and stimualted with forskolin.
Results: Piezo1 is expressed in both WT mIMCD3 cells and PKD2 null cells (~3 
fold higher than wild type). Piezo1 activation by Yoda1 increased cytoplasmic calcium 
and simultaneously lowered forskolin-induced cAMP (Figure 1A). Additionally, exerting 
physiological fluid shear stress (FSS) (ibidi pump system) led to reduction in cAMP (Figure 
1B). Yoda1 significantly reduced forskolin-induced in vitro cystogenesis by 68% in WT 
and by 48% in PKD2 null mIMCD3 cells (Figure1C). Low dose Yoda1 (750nM) prevented 
cyst formation in forskolin-induced cystogenesis of metanephric organ culture (Figure1D).
Conclusions: Piezo1 activation inhibits cystogenesis in matrigel matrices and 
metanephric organ cultures. Further studies are required to determine in vivo effect of 
Piezo1 on renal cystogenesis.
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Enhanced Protein Folding via XBP1 Activation Ameliorates ADPKD Due 
to PC1 Misfolding
Matteus Krappitz,5 Tobias Staudner,4 Parisa Westergerling,4 Till A. Hollmann,2 
David R. Rümmele,3 Charlotte E. Roosendaal,5 Bruno Eduardo Pedroso Balbo,6 
Rachel Gallagher,1 Stefan Somlo,5 Sorin V. Fedeles.1 1Yale University School of 
Medicine, New Haven, CT; 2Yale School of Medicine, New Haven, CT; 3Yale 
university, New Haven, CT; 4Friedrich-Alexander-Universität Erlangen-
Nürnberg, Erlangen, Germany; 5Yale University, New Haven, CT; 6Yale 
University, New Haven, CT.
Background: Pkd1 is one of the two genes responsible for autosomal dominant 
polycystic kidney disease (ADPKD). In ADPKD, ~30% of mutations are missense 
predicted to result in reduced PC1 function. XBP1 encodes the main chaperone modulator 
of the ER unfolded protein response. Here we investigated the role of XBP1 as a “genetic” 
chaperone therapy which may affect the levels of functional PC1 carrying patient derived 
missense mutations using the p.R2220W human REJ mutant (p.R2216W in mouse) as a 
representative candidate.
Methods: The effect of XBP1 on the expression and trafficking of the PC1-R2220W-V5 
mutant was determined in vitro. A Pkd1R2216W knock-in mouse model was generated. Using 
this backbone, Pkd1R2216W/fl;Pkhd1-Cre and Pkd1R2216W/fl;Pkhd1-Cre;XBP1-Rosa-floxstop-TG 
mice were examined by morphological, functional and biochemical analyses.
Results: Expression of XBP1 in transiently cells expressing PC1-R2220W-V5 leads 
to increased expression and GPS cleavage of the mutant protein. Ciliary trafficking of 
PC1-R2220W was markedly improved by co-expression of XBP1 as compared with PC1-
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R2220W alone. At P16, Pkd1R2216W/fl;Pkhd1-Cre mice developed cystic disease compared 
with Pkd1R2220W/+ animals as seen via a significant increase in renal parameters [KW/BW, 
0.01±0.001 vs. 0.13±0.008, ****p<0.0001; BUN, 33.35±4.44 vs. 102.2±26.4, **p=0.0042; 
n=10, 7]. Expression of the conditional XBP1 transgene in Pkd1R2216W/fl;XBP1-TG;Pkhd1-
Cre mice at P16 led to a significant decrease in the cystic burden compared to the controls 
[KW/BW, 0.07±0.006 vs. 0.13±0.008, ****p<0.0001; BUN 50.57±8.47 vs. 102.2±26.49, 
*p=0.027, n=10, 7]. Using TUNEL and Ki67 assays we found that induction of XBP1 in the 
cyst lining cells led to a significant reduction in proliferation with no impact on apoptosis 
suggesting that the improved cystic phenotype in the Pkd1R2216W/fl;XBP1-TG;Pkhd1-Cre 
animals is due to a reduction in cyst growth.
Conclusions: Our data raises the possibility that in vivo chaperone therapy for the 
treatment of ADPKD may have a beneficial role for a subset of PC1 missense mutations.
Funding: NIDDK Support, Private Foundation Support
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Cystic Epithelial Cells Modify Their Microenvironment to Promote 
Fibrosis in Polycystic Kidney Disease
Nidhi Dwivedi, Sonali Sinha, Darren P. Wallace, James P. Calvet, Reena Rao. 
University of Kansas Medical Center, Kansas City, KS.
Background: Progressive tubulo-interstitial fibrosis accompanies cyst expansion in 
polycystic kidney disease (PKD) and is a major cause for loss of renal function and end 
stage renal disease. However, the mechanisms for development of renal fibrosis in PKD 
are currently unclear. A significant number of myofibroblasts, the primary producers of 
ECM, are often found in the pericystic areas in PKD kidneys. We tested the hypothesis 
that cystic epithelial cells can activate interstitial myofibroblasts and thus modify the cystic 
microenvironment to promote fibrosis.
Methods: Renal tubular epithelial-specific vasopressin type-2 receptors (V2R) were 
stimulated or inhibited in pre-weaning and adult inducible conditional Pkd1 gene knockout 
mice with cystic kidneys. Wild type and PKD mice were treated with the V2R agonist 
dDAVP, or the antagonist OPC31260 by daily intraperitoneal injections for 3 days.
Results: Treatment with dDAVP increased myofibroblast numbers and ECM deposition 
in PKD mouse kidneys, while OPC31260 had the opposite effect. Expression of connective 
tissue growth factor (CTGF), a matricellular protein, and its transcriptional regulator YAP 
were increased in the dDAVP treated PKD mouse kidneys. CTGF and YAP were expressed 
in mouse and human ADPKD renal cystic epithelium, and CTGF secreted by cultured 
human ADPKD epithelial cells induced myofibroblast activation and migration in vitro. 
In contrast, YAP inactivation by pharmacological inhibition or renal tubule specific gene 
deletion suppressed CTGF production and cyst expansion in vitro, and the development of 
fibrosis in Pkd1 knock out mice.
Conclusions: These results suggest that epithelial specific V2R stimulation can induce 
YAP dependent CTGF production to activate interstitial myofibroblasts and renal fibrosis 
in PKD.
Funding: NIDDK Support
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A Central Role of the Enzyme Asparagine Synthetase (ASNS) in Driving 
Glutamine Anaeplerosis in the Metabolic Rewiring of ADPKD
Christine Podrini,1 Isaline Rowe,1 Roberto Pagliarini,1 Ana Sofia Henriques da 
Costa,2 Marco Chiaravalli,1 Hyunho Kim,3,4 Feng Qian,4 Christian Frezza,2 
Alessandra Boletta.1 1San Raffaele Scientific Institute, Milan, Italy; 2MRC 
Cancer Unit, University of Cambridge, Cambridge, United Kingdom; 3Center 
for Medical Innovation, Seoul National University Hospital, Seoul, Republic of 
Korea; 4University of Maryland School of Medicine, Baltimore, MD.
Background: We showed that the Warburg effect is a feature of PKD. However, 
additional pathways involved in the metabolic deregulation of ADPKD are likely present. 
Here, we explore global metabolomics and isotope tracing experiments to identify new 
targetable metabolic pathways in PKD.
Methods: 16 newborn (P4) kidneys of Ksp-Cre;Pkd1flox/− mice and their respective 
littermate controls were collected. Metabolomics was performed with LC-mass 
spectrometry (MS). Tracing studies with13C-labeled carbons from glucose or glutamine 
were performed in Pkd1-mutant cells, using LC-MS.
Results: Metabolomics screen identified 488 significantly altered metabolites. PCA 
and HCA showed a clear separation between cystic and control samples. The alterations 
included glycolysis, fatty acid oxidation and biosynthesis, and massive TCA cycle. To test 
which energy source was fuelling the accumulation of TCA cycle metabolites, alternate 
labelling with [13C6] glucose or [
13C5,
15N2] glutamine was performed in-vitro. Pkd1
-/- cells had 
an enhanced glucose uptake, mostly used to produce lactate and minimally funneled into the 
TCA cycle. To compensate, Pkd1-/- cells uptake more glutamine and use it both oxidatively 
and reductively in the TCA cycle to drive fatty acids biosynthesis. Following the fate of the 
15N2-glutamine, we found a significant increase of 
15N-labelled asparagine in Pkd1-/- cells 
suggesting that they exhibit increase asparagine synthesis from glutamine. This reaction is 
catalyzed by Asparagine synthetase (ASNS). Indeed, Asns was upregulated in Pkd1-/- cells 
and KspCre;Pkd1 kidneys. Tracing with 15N2 and 
13C5-glutamine showed that silencing of 
Asns reduced significantly the levels of labelled asparagine and glutamine-derived α-KG. 
Importantly, the down-regulation of Asns reduced growth in Pkd1-/- cells, but not in controls. 
Combination with glucose starvation was lethal in Pkd1-/- cells. Microarray analysis on 
Pkd1 mutant kidneys (Pkd1V/V) and human PKD1 samples confirmed upregulation of ASNS 
and further validated the global metabolic perturbations observed.
Conclusions: Our data show that increased glutaminolysis, interlinked with asparagine 
metabolism is an important feature of PKD and targeting ASNS might offer a novel 
therapeutic opportunity.
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CD8+ T-Cells Regulate Progression of Autosomal Dominant Polycystic 
Kidney Disease
Logan C. Tyler,1 Emily K. Kleczko,1 Kenneth H. Marsh,1 Darren P. Wallace,2 
Michel Chonchol,1 Berenice Y. Gitomer,1 Raphael A. Nemenoff,1 
Katharina Hopp.1 1University of Colorado Denver, AMC, Aurora, CO; 
2University of Kansas Medical Center, Kansas City, KS.
Background: Therapeutic strategies to treat Autosomal Dominant Polycystic Kidney 
Disease (ADPKD) have largely focused on targeting abnormal renal epithelial cell signaling. 
In cancer, a disease with many parallels to ADPKD, modulating the activity of cells within 
the microenvironment, specifically CD8+ T-cells, has shown remarkable therapeutic effects. 
However, the role of CD8+ T-cells and their potential as a novel therapeutic target in 
ADPKD has not been well studied.
Methods: Using the murine ADPKD model Pkd1 p.R3277C [RC], as well as stored 
human ADPKD/Autosomal Recessive PKD (ARPKD) kidney tissue, we explored the role 
of renal CD8+ T-cells via flow cytometry, in situ/immunofluorescence (IF) imaging, qPCR, 
and pharmacological intervention.
Results: Using flow cytometry and IF, we previously showed that CD8+ T-cells 
increase in numbers, become selectively activated, and localize to cystic regions in 
Pkd1RC/RC vs. wildtype (WT) kidneys. Further, CD8+ T-cell depletion worsened PKD 
pathology in Pkd1RC/RC mice. By in situ hybridization we now show that Pkd1RC/RC interstitial 
and cystic epithelial cells express higher levels of CD8+ T-cell recruiting chemokines 
(Cxcl9/Cxcl10) vs. WT, implying active recruitment of CD8+ T-cells to cystic lesions. 
We confirmed these findings in human ADPKD/ARPKD vs. healthy control kidneys and 
demonstrated in vitro that human PKD1-/- renal epithelial cells have higher basal CXCL9/10 
levels, as well as a greater increase in response to IFNg vs. PKD1+/+ cells. To understand 
how CD8+ T-cells may halt cyst progression, we performed TUNEL and PCNA staining in 
Pkd1RC/RC anti-IgG and anti-CD8 treated animals. Mice depleted of CD8+ T-cells had fewer 
apoptotic and more proliferating cystic epithelial cells vs. control, consistent with CD8+ 
T-cell-mediated cytotoxicity and IFNg-induced reduction in proliferation.
Conclusions: These data indicate that CD8+ T-cells are recruited specifically to cystic 
lesions via chemokine production by interstitial and cystic epithelial cells and halt ADPKD 
progression through modulating cyst expansion via apoptosis/proliferation. Hence, 
therapeutic strategies aimed at increasing CD8+ T-cell numbers/activity may represent novel 
treatment approaches to slow ADPKD progression.
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CD4 T Cells Promote Cystic Kidney Disease
Kurt Zimmerman,1 Cheng Song,2 Michal Mrug,1 Bradley K. Yoder.1 1University 
of Alabama at Birmingham, Birmingham, AL; 2Amgen & University of southern 
california, Los Angeles, CA.
Background: The majority of renal cystic diseases are caused by mutations in proteins 
localized to the primary cilia or proteins required for cilia assembly. Previous data indicate 
that renal injury markedly accelerates cyst formation and that macrophage numbers are 
increased prior to and during cyst formation. Depletion of macrophages reduces renal cysts 
in multiple models of cystic kidney disease. These data led to the hypothesis that cilia and 
cilia-related proteins regulate innate immune response and cystic disease following renal 
injury. However, the involvement of adaptive immune cells in renal injury induced cystic 
disease remains unknown.
Methods: We set out to identify and define the contribution of adaptive immune cells, 
particularly CD4 T cells, in an ischemia reperfusion injured cilia mutant model of renal 
cyst formation and in human patients with autosomal dominant polycystic kidney disease 
(ADPKD).
Results: Our data show that CD4 T cell numbers are increased prior to the formation 
of renal cysts and are located in regions adjacent to cysts in conditional cilia mutant mice 
following injury. Further subtyping of CD4 T cells shows that IL-17A producing CD4 T 
cells (Th17 cells) are increased prior to the formation of renal cysts whereas T regulatory 
cells (Tregs) are increased during periods of rapid cyst progression. These data suggest that 
Th17 cells may contribute to the initial stages of cyst formation whereas Tregs may promote 
cyst expansion. In support of this idea, genetic deletion of adaptive immune cells (RAG1-
/- mouse) or pharmacological depletion of CD4 T cells reduced renal cyst formation. These 
results are complemented by studies in ADPKD patients where we found an increased 
number of CD4 T cells in regions adjacent to developing cysts. In addition, our preliminary 
studies revealed the highest serum levels of IL-17A in young ADPKD patients (<30 yrs 
old) suggesting that, similar to the mouse model, the number of Th17 cells is also highest 
in early stages of ADPKD. In contrast, PKD patients with ESRD had increased numbers of 
Tregs, resembling our data obtained in the mouse. Finally, we point to urinary CD4 T cells 
as a predictor of renal function decline in ADPKD.
Conclusions: Our results suggest that CD4 T cells are an integral component of renal 
cystic disease and a candidate marker of the disease activity in ADPKD.
Funding: NIDDK Support, Other NIH Support - NIH 2T32AI007051-38, Veterans 
Affairs Support
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Bimodal Activation of Macrophages Promotes Proliferation Independent 
and Dependent Cyst Expansion in PKD
Vijayakumar R. Kakade,1 Marcelo F. Cassini,1 Stefan Somlo,1 Lloyd G. Cantley.2 
1Yale University, New Haven, CT; 2Yale University School of Medicine, New 
Haven, CT.
Background: Macrophages progressively accumulate adjacent to cyst lining cells in 
PKD. Macrophage chemoattractant protein-1 (Mcp1) is highly upregulated at the time of 
cyst initiation following knock-out of Pkd1, and dual deletion of Mcp1 and Pkd1 in renal 
tubules results in less renal macrophages, slower cyst growth, preserved GFR and better 
survival than deletion of Pkd1 alone. The current study addresses the mechanisms by which 
the Mcp1-induced macrophages promote cyst growth.
Methods: Expression profiling was performed by qPCR using RNA from whole 
kidney and flow sorted macrophages. Multiphoton microscopy was used to analyze tubule 
morphology from doxycycline-treated Mcp1fl/flPkd1fl/flPax8rtTA;TetOCre mice (DKO) and 
Pkd1fl/flPax8rtTA;TetOCre mice (SKO). Tubular cell responses were analyzed using Ki67, 
BrdU, comet assay and anti-8OHdG staining.
Results: Macrophages that accumulate at cyst initiation (8 weeks age, 2 weeks after 
doxy induction) express high levels of proinflammatory cytokines Tnfa, Nos2 and IL12, 
correlating with increased tubular cell injury as judged by Kim1 expression (SKO dCt 0.002 
vs DKO dCt 0.0005, p=0.002) and oxidative DNA damage (14.4% 8OHdG+ cells in SKO vs 
3.6% in DKO, p=0.009). Analysis of tubular cell proliferation rates and tubule morphology 
in SKO and DKO kidneys during at cyst initiation shows that the macrophage-dependent 
component of cyst growth corresponds to decreased tubular epithelial area (tubular cell 
flattening consistent with injury) and enlarged tubule area (tubule/epithelial area ratio 
of 3.8±1.0 in SKO vs 1.04±0.02 in control and 1.4±0.5 in DKO p<0.0001) rather than 
proliferation. At the late cystic stage (18 weeks age), macrophages express high levels of 
the alternative activation genes Arg1 and Mrc1, with a 3-fold increase in Ki67+ cells in the 
presence of macrophages (6.4±0.6 in SKO vs. 1.8±0.8 in DKO, p<0.0001), correlating with 
a late acceleration in cyst growth in the SKO kidneys.
Conclusions: The results demonstrate two distinct effects of macrophages: early 
proinflammatory induction of tubule cell injury and tubule dilation that is proliferation 
independent and late alternative activation mediated induction of proliferation-dependent 
cyst growth.
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AKI in Pediatric Sepsis Is an Independent Risk Factor for Death and New 
Substantive Disability
Michelle C. Starr,1 Ron W. Reeder,3 Jerry J. Zimmerman,2 Russell K. Banks,3 
Sangeeta R. Hingorani.1 Collaborative Pediatric Critical Care Research Network 
1Seattle Children’s Hospital, Seattle, WA; 2Seattle Children’s Hospital, University 
of Washington School of Medicine, Seattle, WA; 3University of Utah, Salt Lake 
City, UT.
Background: Acute kidney injury (AKI) is common in critically ill children. The 
incidence of septic AKI and its impact on PICU survivor functional status are unknown. 
We used data from a multicenter cohort with sepsis to evaluate functional outcomes of 
children with AKI.
Methods: Using the prospective Life after Pediatric Sepsis Evaluation (LAPSE) study 
[R01HD073362], we evaluated the association of AKI with a composite of death or new 
substantive functional disability at day 28 of hospitalization or discharge as a primary 
outcome. We defined AKI using KIDGO criteria, comparing patients with no AKI or Stage 
1 AKI to those with Stage 2 or 3 AKI (Severe AKI). New substantive disability was defined 
as a Functional Status Scale (FSS) score increase ≥3 points from baseline to 28 days. 
Wilcoxon rank-sum and likelihood ratio tests were used to compare variable associations 
between groups. We used multivariable logistic regression to assess the association of AKI 
with outcomes.
Results: 176 (50.5%) of 348 patients had severe AKI; of those, 38 (21.6%) required 
renal replacement therapy. Patients with severe AKI had higher median PRISM III scores 
(excluding creatinine) (12 vs 8; p<0.001), and were treated more often with vasoactive 
agents (97.7 vs 91.9%; p=0.011), blood products (65.3 vs 44.8%; p<0.001), and 
corticosteroids (74.4 vs 61.0%; p=0.007). Twice as many patients with severe AKI died 
or developed new substantive disability (38.1 vs 16.3%; p<0.001). Children with severe 
AKI had longer PICU stays (11.7 vs 7.1 days; p<0.001), and longer duration of mechanical 
ventilation (11.0 vs 7.0 days; p<0.001). After adjustment for age, malignancy, and PRISM 
III score, severe AKI was independently associated with mortality or new substantive 
disability (adjusted odds ratio 2.77; 95% CI 1.63–4.81, p<0.001). Despite similar baseline 
FSS scores, children who survived with severe AKI had a greater sustained change in FSS 
scores at 28 days or hospital discharge than those without AKI (adjusted effect 1.35; 95% 
CI 0.27–2.43; p=0.014).
Conclusions: In critically ill children with sepsis, severe AKI is common and is 
independently associated with increased risk of death or new substantive disability. 
Survivors of sepsis with severe AKI were more likely to have persistent decreased 
functional status at discharge than those without severe AKI.
Funding: NIDDK Support, Other NIH Support - NICHD R01HD073362
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Long-Term Outcomes after AKI Requiring Dialysis Among Neonates and 
Children in Ontario: A Population-Based Study
Rahul Chanchlani,1 Danielle M. Nash,3 Eric McArthur,7 Michael Zappitelli,6 
John paul Kuwornu,8 Amit X. Garg,3 Jason H. Greenberg,4 Stuart Goldstein,5 
Ron Wald.2 1Pediatric Nephrology, McMaster Children Hospital, Hamilton, ON, 
Canada; 2St. Michael’s Hospital, Toronto, ON, Canada; 3London Health 
Sciences Centre, London, ON, Canada; 4Yale University, New Haven, CT; 
5Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 6Toronto 
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 
7Institute for Clinical Evaluative Sciences, London, ON, Canada; 8Government 
of Saskatchewan, Regina, SK, Canada.
Background: There is limited knowledge on the long-term impact of an episode of 
acute kidney injury requiring dialysis (AKI-D) among neonates and children.
Methods: Using health administrative databases housed at the Institute for Clinical 
Evaluative Sciences, we conducted a retrospective cohort study of all hospitalized neonates 
and children who received dialysis for AKI across Ontario between 1996 and 2015 and 
survived to hospital discharge (exposed cohort). We assembled a comparator cohort (up 
to 4 neonates and children without AKI-D for every patient with AKI-D) matched on 
demographics and comorbidities. Primary outcomes were all-cause mortality and end-
stage renal disease (ESRD, defined as receipt of chronic dialysis or a kidney transplant) 
and secondary outcomes were de novo CKD and hypertension. Incidence rates (IR) were 
calculated and Cox proportional hazards models were fitted for all outcomes.
Results: There were 466 neonates and 1641 children hospitalized with AKI-D in 
Ontario between 1996 and 2015, of whom 356 neonates and 1500 children, had matched 
counterparts without AKI-D. The median follow-up time was 9.2 years (Interquartile Range 
(IQR) 4.7,12.0) for neonates and 12.4 years (IQR 5.8,16.9) for children. After adjusting for 
confounders, survivors of AKI-D during the neonatal period had a 21-fold risk of death and 
a 7-fold higher risk of hypertension, as compared to neonates with no AKI-D. Similarly, 
children surviving an episode of AKI-D had a higher risk of death, CKD and hypertension 
as compared to hospitalized children who did not experience AKI-D. (Table 1).
Conclusions: Neonates and children with AKI-D remain at higher risk of long-term 
adverse outcomes compared to those without AKI-D suggesting that they need a close 
follow-up after discharge.
Table 1:Incident rates and hazard ratios of long-term adverse outcomes among neonates 
and children with AKI-D in Ontario between 1996 and 2015
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Multiple Episodes of AKI and Their Association with Kidney Function 
and Death
Edward D. Siew,1 Kathleen D. Liu,3 Amit X. Garg,4 Mark M. Wurfel,5 
Vernon M. Chinchilli,6 James S. Kaufman,7 Paul L. Kimmel,8 Chirag R. Parikh.2 
on behalf of the ASSESS-AKI Investigators 1Vanderbilt University School of 
Medicine, Nashville, TN; 2Yale University and VAMC, New Haven, CT; 
3University of California at San Francisco School of Medicine, San Francisco, 
CA; 4London Health Sciences Centre, London, ON, Canada; 5University of 
Washington, Seattle, WA; 6Penn State College of Medicine, Hershey, PA; 7VA 
New York Harbor Healthcare System, New York, NY; 8National Institute of 
Diabetes and Digestive Kidney Diseases (NIDDK), Bethesda, MD.
Background: Recurrent AKI may mediate the risk for future CKD outcomes. Prior 
studies on recurrent AKI lacked appropriate controls. We compared the incidence of future 
AKI between hospitalized AKI and nonAKI patients and the impact of AKI on kidney 
disease progression.
Methods: ASSESS-AKI is a prospective multi-center study of matched AKI and non-
AKI patients followed longitudinally beginning 3 months after initial hospitalization. AKI 
was defined as a 0.3 mg/dl or 50% increase in baseline serum creatinine during subsequent 
hospitalizations. The determinants of future AKI were examined using multivariate Cox 
regression. Outcomes included time to event for (1) a composite renal outcome of incident 
or progressive CKD or ESRD, and (2) the competing risk of death. Predictors of outcome 
were examined using a multivariable trivariate Weibull regression model, along with a zero-
inflated Poisson regression model for the number of AKI events prior to the composite renal 
endpoint.
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Results: Among 769 matched pairs of AKI and non-AKI patients, 465(30%) 
experienced a future AKI episode over a median follow-up of 57 months. Future AKI 
was more common among patients with AKI compared to nonAKI status at index 
hospitalizations, with 8 compared to 5 AKI episodes per 100 person-years (PYs)(p < 0.0001). 
After multivariate adjustment, index AKI remained independently associated with the risk 
for future AKI [aHR 1.5 (95%CI:1.2-1.8)]. The rates of the composite renal outcome were 
2, 5, and 6 per 100 PYs among patients with 0, 1, and ≥2 episodes of AKI (p < 0.0001). 
The rates for death prior to a CKD event were 2, 4, and 9 among patients with 0, 1, and 
≥2 episodes of AKI (p < 0.0001). After multivariable adjustment, the presence of 1 and
≥2 episodes of AKI conferred an increased risk for the CKD outcome [aHR 3.3(2.2-4.9) 
and 2.8(1.8-4.2)], respectively, compared to patients without AKI. There were incremental 
increases in the risk of death prior to a CKD event with 1[aHR 1.7(1.2-2.6)] and ≥2[aHR 
2.8(1.8-4.2)] episodes of AKI compared to no AKI.
Conclusions: AKI is an independent risk factor for future hospitalized AKI and loss of 
kidney function. The association between multiple AKI events and future CKD outcomes 
may be affected by the competing risk of death.
Funding: NIDDK Support
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Post-Discharge Long-Term Cardiovascular Outcome of Dialysis 
Requiring AKI after Cardiac Surgery
Soojin Lee,1 Sehoon Park,1 Min woo Kang,1 Yaerim Kim,1 Jung Pyo Lee,2 Kwon 
Wook Joo,1 Chun Soo Lim,2 Dong Ki Kim.1 1Seoul National University Hospital, 
Seoul, Republic of Korea; 2Seoul National University Boramae Medical Center, 
Seoul, Republic of Korea.
Background: Dialysis requiring acute kidney injury (AKI-D) is one of the serious 
complications following the cardiac surgery and it is known to increase in short-term in 
hospital mortality. Nevertheless, long-term prognosis and risk of major cardiovascular 
events (MACE) has not been examined yet.
Methods: We conducted a nationwide, population-based cohort study using the data of 
Korean National Health Insurance System. Adult patients who underwent cardiac surgery 
in tertiary hospitals between 2006 and 2015 were considered. Patients previously received 
dialysis were excluded. Then, the patients were divided into those who underwent dialysis 
after cardiac surgery and those who did not.
Results: Of 52,803 patients received cardiac surgery, 1,261 underwent dialysis 
during the perioperative period of cardiac surgery. All-cause mortality [adjusted hazard 
ratio (HR) 2.93 (2.65-3.23), P<0.001], progression to end-stage renal disease (ESRD) 
[adjusted HR 15.95 (13.89-18.33), P<0.001] and risk of MACE [adjusted HR 2.26 (2.04-
2.51), P<0.001] were increased in AKI-D group (Figure 1). In the AKI-D group, all-cause 
mortality [adjusted HR 1.07 (0.83-1.38), P=0.593] and the risk of MACE [adjusted HR 1.25 
(0.94-1.67), P=0.126] were comparable between the continuous renal replacement therapy 
(CRRT) and intermittent renal replacement therapy (IRRT) group.
Conclusions: Patients required dialysis after the cardiac surgery were associated 
with high all-cause mortality and rate of dialysis dependence. Although AKI-D patients 
independently survive, they persistently had increased risk of MACE development. Despite 
higher patient severity in patients requiring CRRT, outcomes among these patients were not 
deteriorated, compared to IRRT group.
Funding: NIDDK Support, Commercial Support - Baxter (LSO-18-70260)
The x-axes represent the time (years), and the y-axes represent the incidence probability. 
The black, and red lines represent the survival curves of the control, and AKI-D groups, 
respectively.
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Outcomes after Left Ventricular Assist Device Implantation in Patients 
with AKI
Samuel A. Silver,1,2 Jin Long,4 Yuanchao Zheng,4 Glenn M. Chertow.3 1Queen’s 
University, Kingston, ON, Canada; 2Kingston Health Sciences Center, Kingston, 
ON, Canada; 3Stanford University School of Medicine, Palo Alto, CA; 4Stanford 
University, Palo Alto, CA.
Background: Left ventricular assist devices (LVAD) are increasingly used as a bridge 
to heart transplant and destination therapy for heart failure. Although acute kidney injury 
(AKI) is a common complication in these patients, there are few multicenter studies on 
how AKI affects LVAD outcomes. We sought to determine outcomes associated with AKI 
among patients receiving LVADs in a nationally representative sample of hospitalizations 
in the US.
Methods: Using the National Inpatient Sample from 2008 to 2013, we identified 
patients who received a LVAD during a hospitalization using ICD-9 code 37.66. We 
ascertained AKI and acute dialysis using validated ICD-9 codes. The primary outcome 
was in-hospital mortality. Secondary outcomes included procedural complications and 
discharge destination. We used logistic regression to adjust for demographics, hospital-level 
factors, comorbidities, and acute hospitalization details.
Results: We identified 8362 patients who received a LVAD, of whom 3760 (45%) 
developed AKI without dialysis (AKI-ND) and 426 (5%) developed AKI-requiring dialysis 
(AKI-D). In-hospital mortality increased from 4% for patients without AKI, to 12% for 
patients with AKI-ND, to 48% for patients with AKI-D. We observed similar increases 
for major bleeding (25% vs 33% vs 49%) and sepsis (9% vs 22% vs 43%). Discharge 
destination was home for 84% of patients without AKI, 72% of patients with AKI-ND, 
and 56% of patients with AKI-D. After multivariable adjustment, patients with AKI-ND 
and AKI-D had higher odds of mortality (OR 3.24, 95% CI 2.04-5.13 and 20.8, 95% CI 
9.7-44.2), major bleeding (1.38, 95% CI 1.08-1.77 and 2.43, 95% CI 1.47-4.04), sepsis 
(2.69, 95% CI 1.93-3.75 and 5.75, 95% CI 3.46-9.56), and discharge to a nursing facility 
(2.15, 95% CI 1.51-3.07 and 5.89, 95% CI 2.67-12.99). Patients with AKI-ND and AKI-D 
on mechanical ventilation had a markedly increased adjusted odds of death (14.2, 95% CI 
7.5-26.9 and 90.9, 95% CI 41.4-199.6). None of the patients with AKI-D received a heart 
transplant during the same hospitalization as LVAD implantation.
Conclusions: During a hospitalization in which a LVAD is implanted, patients 
with AKI are at increased risk of procedural complications and death. The prognosis is 
particularly poor for patients with AKI-D. This information is necessary to support shared 
decision-making for patients with advanced heart failure and AKI.
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AKI Is Associated with an Increased Risk of Dementia
Jessica B. Kendrick,1 John R. Holmen,2 Titte Srinivas,6 Zhiying You,3 
Michel Chonchol,4 Anna J. Jovanovich.5 1University of Colorado School of 
Medicine, Aurora, CO; 2Intermountain Healthcare, Murray, UT; 3UC Denver, 
Aurora, CO; 4University of Colorado, Aurora, CO; 5Denver VA / University of 
Colorado, Denver, CO; 6Intermountain Medical Center, Murray, UT.
Background: Acute kidney injury (AKI) is associated with long-term adverse 
outcomes including development of chronic kidney disease, cardiovascular disease and 
mortality. Acute neurologic complications of acute kidney injury are well described but 
the long-term consequences of AKI on neurologic outcomes are unclear. We tested the 
hypothesis that AKI, even with complete kidney function recovery, is associated with a 
higher risk of developing dementia.
Methods: We performed a retrospective propensity score-matched analysis of 2,082 
patients without prior history of dementia from an integrated health care delivery system 
in Utah, who had a hospital admission between January 1, 1999 and December 31, 2009. 
AKI was defined by ICD-9 codes and AKI Network serum creatinine values. 1041 patients 
with AKI followed by complete recovery, defined as discharge creatinine <1.10 times the 
pre-admission baseline value, were propensity score-matched with 1041 patients without 
AKI during the index admission. Dementia was defined by ICD-9 codes. Demographic, 
baseline serum creatinine, prior inpatient visits, season of admission, and all components of 
the Charlson Comorbidity index were used to generate the propensity score. Proportional 
hazards analysis was used to compare time to dementia among patients with and without 
AKI.
Results: After propensity score matching, covariates were well balanced between the 
groups. The mean (SD) age and baseline creatinine was 61 ± 16 years and 0.9 ± 0.2 mg/dL, 
respectively. During a median follow-up time of 5.8 years, 97 patients developed dementia. 
More patients with AKI developed dementia (7.0% vs. 2.3%). Patients with AKI had more 
than a 3-fold increased risk of developing dementia compared to those without AKI (Hazard 
Ratio 3.4, 95% CI 2.14 to 5.40).
Conclusions: AKI, even with complete kidney recovery, is associated with a 
significantly increased risk of hospitalized dementia. Further studies are needed to examine 
the association of AKI with cognitive dysfunction.
Funding: Other NIH Support - NHLBI
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Recognizing Sepsis: A High-Throughput Non-Invasive Assessment Using 
Machine Learning and Urinary MicroRNAs
Ferdous Kadri,1,2 Sabyasachi Bandyopadhyay,6,4 Lasith Adhikari,1,2 
Tezcan Ozrazgat-baslanti,1,2 Laura Sautina,1,3 Maria C. Lopez,5,3 
Henry V. Baker,5,3 Mark S. Segal,1,3 Parisa Rashidi,4,2 Azra Bihorac.1,2 PRISMA-P 
1Division of Nephrology, Hypertension, and Renal Transplantation, Department 
of Medicine, University of Florida, Gainesville, FL; 2Precision and Intelligent 
Systems in Medicine (PrismaP), University of Florida, Gainesville, FL; 3Sepsis 
and Critical Illness Research Center, University of Florida, Gainesville, FL; 4J. 
Crayton Pruitt Family Department of Biomedical Engineering, University of 
Florida, Gainesville, FL; 5Department of Molecular Genetics and Microbiology, 
University of Florida, Gainesville, FL; 6Department of Surgery, University of 
Florida, Gainesville, FL.
Background: Identifying early differences between Systemic Immune Response 
Syndrome, SIRS, and sepsis remains at the fulcrum of surviving sepsis: without early 
identification, shock and eventual death ensues. MicroRNAs (miRNAs) are non-coding 
RNAs that regulate gene expression. Given their selective secretion and extensive role 
in cellular communication, miRNAs have been utilized in diagnosis, prognosis, and 
therapeutics in various disciplines of medicine. As the kidneys are one of critical organs 
affected by sepsis, we surveyed the miRNA population in urine at the time of sepsis. 
Here we isolate urinary exosomes to identify miRNAs that are associated with sepsis in 
comparison to patients with vascular disease prior to surgery serving as a control group.
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Methods: We collected urine samples from 41 patients within 12 hours of sepsis 
onset and 29 control patients. Using exosomal isolation protocol (Norgen), we extracted 
miRNAs from urine supernatant. Subsequently, we utilized Affymetrix® RNA Labeling 
Kit and GeneChip Arrays to obtain expression values of 2,578 miRNAs in each patient. For 
machine learning, we randomly divided patients into 70% training set for feature selection 
of microRNAs and prospectively tested the performance in the validation set (30%) using 
area under the receiver operating curve (AUC).
Results: 94 miRNAs were dysregulated in sepsis (log2FC > 1, p-value < 0.01). 29 
miRNAs were highly associated with the septic cohort. Testing the performance of 
these miRNAs, the validation set performed well with an AUC of 0.94 (95% CI 0.84 - 
1.00). Among these, mir-455 is validated to induce hypoxia signaling, whereas mir-
3201 upregulates monocyte chemoattractant protein. The mir-548 family is extensively 
intercalated in the network of TLR signaling, a pathway at the foundation of sepsis.
Conclusions: Uniting machine learning with miRNA arrays allowed us to identify 
dysregulated miRNAs and peer deeper into the specific pathways activated at the time of 
sepsis. Actively, we are utilizing this methodology to delineate expression patterns in septic 
patients as compared to SIRS+ and control groups to further define the fulcrum between 
SIRS and sepsis.
Funding: Other NIH Support - R01 GM110240 from the National Institute of General 
Medical Sciences. P50 GM-111152 from the National Institute of General Medical Sciences
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The Circular RNA ciRs-126 Predicts Survival in Critically Ill Patients 
with AKI
Malte Kölling,1 Harald Seeger,1 Andreas D. Kistler,4 Jan T. Kielstein,2 
Hermann G. Haller,3 Rudolf P. Wuthrich,1 Johan Lorenzen.1 1University Hospital 
Zurich, Zurich, Switzerland; 2Academic Teaching Hospital Braunschweig, 
Braunschweig, Germany; 3Hannover Medical School, Hannover, Germany; 
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Background: Circular RNAs (circRNAs) have recently been described as novel 
non-coding regulators of gene expression. They might impact on microRNA expression 
by their sponging activity. The detectability in blood of these RNA transcripts has been 
demonstrated in patients with cancer and cardiovascular disease. We tested the hypothesis, 
that circulating circRNAs in blood of critically ill patients with acute kidney injury (AKI) at 
inception of renal replacement therapy may also be dysregulated and associate with patient 
survival.
Methods: We performed a global circRNA expression analysis using RNA isolated 
from blood of patients with AKI as well as controls. This global screen revealed several 
dysregulated circRNAs in patients with AKI. Most highly increased circRNA-array-based 
transcripts as well as expression of the circRNA target miR-126-5p were confirmed in 
blood of 109 patients with AKI, 30 age-matched healthy controls, 25 critically-ill non-AKI 
patients and 20 patients on maintenance hemodialysis by quantitative realtime-PCR.
Results: Circulating concentrations of 3 novel circRNAs were amplified in blood 
of patients with acute kidney injury and controls. Circular RNA sponge of miR-126 (or 
ciRs-126) was most highly altered compared to healthy controls and disease controls (fold 
change of 52.1). CiRs-126 was shown to bioinformatically sponge miR-126-5p, which was 
found to be highly suppressed in AKI patients and hypoxic endothelial cells. Cox regression 
and Kaplan-Meier curve analysis revealed ciRs-126 as an independent predictor of 28-day 
survival (p<0.01).
Conclusions: Circulating concentrations of circRNAs in patients with acute kidney 
injury are detectable. CiRs-126 may potentially sponge miR-126-5p and acts as a predictor 
of mortality in this patient cohort.
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San Diego, CA.
Background: The Furosemide Stress Test (FST) has been previously shown to predict 
which patients with Stage 1 or 2 AKI will progress to Stage 3 AKI.
Methods: We conducted a prospective multicenter validation of the FST at 5 centers 
across North America. Euvolemic or hypervolemic patients with Stage 1 & 2 AKI were 
given 1 or 1.5 mg/kg of intravenous furosemide, depending on prior exposure. Hourly urine 
output (UOP) was measured for 6 hours (hrs) to validate the previously published cutoff of 
200 ml of urine in the first 2 hrs as well as to explore other cutoffs. We assessed the ability 
of the FST to predict the development of KDIGO Stage 3 AKI (primary endpoint – 200% 
increase in serum creatinine or receipt of renal replacement therapy (RRT)) and just the 
receipt of RRT, as well as occurrence of adverse events.
Results: We prospectively enrolled 92 patients with Stage 1 or 2 AKI who received 
a mean(SE) dose of 108(3.7) mg of furosemide. Twenty-three (25%) patients developed 
subsequent Stage 3 AKI, with 10 (11%) receiving RRT. There was no difference in baseline 
serum creatinine or eGFR, dose of furosemide, cardiovascular SOFA score or APACHE 
II score between those with and without Stage 3 AKI. Patients who progressed had 
significantly lower UOP in the 6hrs before the FST (median[IQR]) (241[93-357] compared 
to 336[199-578] p=0.024). The total UOP for the first 2hrs post-FST provided an AUC(SE) 
of 0.85(0.05) for progression to stage 3 (p<0.001) and 0.73(0.10) for RRT (p<0.05) (Table) 
UOP of less than 200ccs in the first 2hrs was 89.8% specific for AKI progression. In terms 
of adverse events, hypotension developed in 9(10%) patients post FST and 5(6%) patients 
developed hypokalemia and 5(6%) patients developed hypophosphatemia.
Conclusions: In this multicenter validation, the 2 hour total UOP following FST 
predicted the progression to Stage 3 AKI and the need for RRT. UOP of less than 200 cc in 
the first 2hrs post-FST is a highly specific for progression to Stage 3 AKI, while less than 
400 cc is highly sensitive for AKI progression.
Funding: Commercial Support - Satellite Healthcare
Sensitivity Analysis for 2 hour UOP following FST to predict Stage 3 AKI
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Impact of Echocardiographic Parameters on Mortality in ICU Patients 
Undergoing CRRT
Panagiotis Kompotiatis,1 Brandon M. Wiley,2 Jacob Jentzer,2 Kianoush Kashani.2 
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Background: Echocardiographic abnormalities have been associated with adverse 
outcomes in various Intensive care unit (ICU) populations. However, the impact of 
echocardiographic abnormalities on the prediction of mortality in patients undergoing 
continuous renal replacement therapy (CRRT) has not been examined.
Methods: Historical cohort study of consecutive adults admitted to the ICUs at one 
tertiary care hospital from December 2006, through November 2015 who underwent CRRT 
and had an echocardiogram done within 7 days of CRRT initiation. The primary outcome 
was 30-day death rate. Logistic regression was used to determine predictors of 30-day 
mortality.
Results: We included 1,276 patients, 1,040 (81.5%) with acute kidney injury (AKI) 
and 236 (18.5%) with end-stage renal disease (ESRD). Median patient age was 63 (IQR 
53-73) years, and 514 (40%) were female, median Charlson score was 5 (IQR 3-7), and
median SOFA score on the day of CRRT initiation was 12 (IQR 10-14). Echocardiographic 
parameters associated with 30-day mortality on univariate analysis included: Moderate
or greater right ventricular (RV) dysfunction (OR 1.47, 95% CI: 1.08-1.60), moderate or
greater tricuspid regurgitation (OR 1.67, 95% CI: 1.26 – 2.21) and right ventricular systolic 
pressure (RVSP) (OR 1.12 per 10 mmHg increase, 95% CI: 1.02-1.23). RV dysfunction
(OR 1.54, 95% CI: 1.02-2.32) and tricuspid regurgitation (OR 1.55, 95% CI:1.02-2.32)
remained significantly associated with 30-day mortality after adjusting for age, sex, SOFA 
score, Charlson comorbidity index, need for mechanical ventilation, type of ICU, fluid 
balance and AKI vs. ESRD using logistic regression analysis.
Conclusions: RV dysfunction and tricuspid regurgitation are associated with increased 
mortality in patients undergoing CRRT, emphasizing the importance of cardiorenal 
syndrome among critically-ill patients. Further study will be needed to determine if RV 
dysfunction is a risk marker or a modifiable risk factor in this patient population.
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Impact of Obesity on Kidney Transplant Outcomes: A Paired-Kidney 
Analysis
Bhavna Chopra,1 Rita L. McGill,2 Michelle A. Josephson,2 Pratik B. Shah,2 
Kalathil K. Sureshkumar.1 1Nephrology, Allegheny General Hospital, Pittsburgh, 
PA; 2University of Chicago, Chicago, IL.
Background: The prevalence of obesity is increasing in prospective kidney transplant 
recipients (KTRs). The impact of recipient obesity on long term outcomes is not clear. We 
sought to evaluate the associations of recipient body mass index (BMI) with transplant 
outcomes using a paired-kidney model.
Methods: UNOS data were used to identify all deceased donors between 1/2006 and 
12/2016 in which each kidney was used for kidney-alone transplant. Recipient BMIs were 
classified as: 18-25, >25-30, >30-35, and >35 (reference category). Hazard ratios (HR) for 
graft failure (GF), death-censored GF (dcGF), and patient death were obtained by marginal 
survival models adjusted for pairing by donor. Odds ratios (OR) for delayed graft function 
(DGF) were obtained by conditional logistic regression models. Models were adjusted for 
recipient and transplant factors.
Results: 39,334 paired recipients were evaluated, of whom 4,949 (12.6%) had 
BMI>35. Median follow up was 43.9 (IQR=22.3-71.8) months, with graft failure in 11.9% 
and death in 11.0%. Results for adjusted models are shown in table. Compared to patients 
with BMI>35, patients with BMI 18-25 had lower hazards for both GF and dcGF, but not for 
death. Patients with BMI >25-30 had lower dcGF. No significant differences seen between 
BMI >30-35 and BMI>35 for GF, dcGF or death. The odds of DGF were significantly 
decreased in all BMI groups, compared to BMI>35.
Conclusions: Our paired kidney analysis among a large national transplantation dataset 
found similar long-term graft and patient outcomes among KTRs with BMI >35 compared to 
those with BMI 30-35, despite increased DGF. Higher rates of dcGF among all patients with 
BMI>30 may reflect hyperfiltration, inflammation, subtherapeutic immunosuppression, or 
increased post-operative complications. Non-inferior patient outcomes among patients with 
BMI>35 could reflect careful pre-transplant selection among very obese candidates or a 
survival advantage similar to that of obese dialysis patients. These data support a more 
favorable consideration of obese patients for kidney transplantation and suggest that the use 
of a BMI cut off between 35 and 40, while common, is arbitrary and unfounded.
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Obesity Is Associated with Graft Failure in Pediatric Kidney 
Transplantation
Heather L. Wasik,1 Cozumel S. Pruette,1 Rebecca Ruebner,1 Allan Massie.2 
1Johns Hopkins University, Baltimore, MD; 2Johns Hopkins School of Medicine, 
Baltimore, MD.
Background: Obesity is a potentially modifiable risk factor in kidney transplantation 
(KT), but recent studies have shown conflicting results regarding the impact of recipient 
obesity on graft failure in pediatric KT.
Methods: We studied first-time KT recipients 1995-2016 aged 2-17 years at transplant 
using SRTR data. Using recipients’ height and weight at time of KT, we classified them as 
underweight (BMI <5th percentile), normal weight (BMI 5th to <85th percentile), overweight 
(BMI 85th to <95th percentile), and obese (BMI ≥ 95th percentile) based on US CDC growth 
reference charts. Normal weight recipients were the reference group. Survival analysis 
was used to compare the cumulative incidence of all-cause graft failure (ACGF) between 
recipients in each BMI category. Multivariable Cox models were used to compare time 
to ACGF between recipients in each BMI category, adjusting for recipient, donor, and 
transplant characteristics.
Results: Of 12,247 pediatric KT recipients, 62.7% were normal weight, 6.9% were 
underweight, 14.3% were overweight, and 16.1% were obese. Obese KT recipients had the 
highest incidence of ACGF (37% at 10 years vs 34% for normal/overweight and 32% for 
underweight (Figure)). After adjustment, obesity remained associated with an increased risk 
of ACGF (aHR=1.091.201.31, p<0.001).
Conclusions: Obesity at the time of transplantation is associated with increased risk 
of ACGF in pediatric KT recipients. Obesity may be a modifiable risk factor for graft loss 
in pediatric KT.
Funding: Other NIH Support - Renal Epidemiology NRSA Training Grant T32 
DK007732
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Association of Pre-Transplant Weight Loss with Mortality after Deceased 
Donor Kidney Transplantation
Meera N. Harhay,1,2 Suzanne Boyle,1 Karthik M. Ranganna,1 Mara McAdams-
DeMarco.3 1Medicine, Division of Nephrology & Hypertension, Drexel 
University College of Medicine, Philadelphia, PA; 2Epidemiology and 
Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, 
PA; 3Johns Hopkins, Baltimore, MD.
Background: Weight loss is a recognized component of frailty, signaling vulnerability 
to health stressors. Whether deceased donor kidney transplant (DDKT) recipients who lost 
weight before DDKT are at higher risk of adverse post-transplant outcomes is unknown.
Methods: Retrospective cohort study, using national registry data, of all DDKT 
recipients in the United States between January 1, 2005 and December 31, 2014 who were 
adults (age>=18 years) at wait-listing. We used unadjusted fractional polynomial methods 
and adjusted Cox proportional hazards models to examine the association of relative change 
in body weight pre-DDKT with post-DDKT mortality.
Results: Among 96,938 DDKT recipients, there was a non-linear unadjusted 
relationship between relative pre-DDKT weight change and post-DDKT mortality, with 
a steep increase in mortality among DDKT recipients who lost 10% or more of their 
listing body weight compared to those with no pre-DDKT weight change (Figure). In a 
multivariable Cox model adjusted for recipient and allograft characteristics, waiting time, 
and dialysis vintage, compared to recipients with weights at DDKT within 5% of their 
listing weights, recipients who lost 10% or more of their listing body weight before DDKT 
were 14% more likely to die post-DDKT (adjusted hazard ratio 1.14, 95% confidence 
interval 1.08-1.21, p<0.001). Pre-DDKT weight gain was not independently associated 
with post-DDKT mortality after multivariable adjustment. There was no evidence of effect 
modification by age, dialysis vintage, or body mass index (p>0.10 for interaction terms).
Conclusions: Substantial weight loss before DDKT may indicate increased 
vulnerability after DDKT. Studies are needed to identify and modify unhealthy weight 
trajectories among DDKT candidates.
Funding: NIDDK Support
Figure demonstrates the distribution of pre-DDKT weight change (light green) among 
96,938 DDKT recipients, and the unadjusted association of pre-DDKT weight change with 
post-DDKT mortality (black line) with 95% confidence intervals (light blue).
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Metabolic Acidosis Is a Risk Factor for Ischemic Cardiovascular Events in 
Kidney Transplant Recipients
Arjang Djamali,2 Nancy A. Wilson,1 Brad C. Astor.1 1University of Wisconsin, 
Madison, WI; 2School of Medicine and Public Health, Madison, WI.
Background: Metabolic acidosis is associated with disease progression and death in 
CKD. However, there is limited information on whether metabolic acidosis is a risk factor 
for poor outcomes after kidney transplantation.
Methods: We examined the association between mean total serum bicarbonate 
levels(TCO2) at one-year and the incidence of all-cause mortality, de novoischemic, 
arrhythmic, or heart failure events in 2018 kidney transplant recipients.
Results: The prevalence of metabolic acidosis defined as TCO2 <24 mEq/L, was 
16.9% (n=341). There were 593 deaths and 363 recipients with a CVE over a median 
follow-up of 3.75 years. CVE included 221 ischemic, 63 arrhythmic, and 178 heart 
failure events. TCO2 < 22 mEq/L was associated with increased risk of CVE (adjusted 
HR 2.22; 95%CI 1.41, 3.48). This association was primarily due to ischemic CVE (aHR 
2.51; 95%CI 1.43, 4.40). For every 1 mEq/L TCO2 below 24 mEq/L, the risk of all CVE 
and ischemic events was 18% and 17% higher, respectively (aHR for all CVE 0.82; 95% 
CI 0.72, 0.94, and aHR for ischemic CVE 0.83; 95% CI 0.71, 0.98). Notably, TCO2 
< 22 mEq/L was an independent risk factor for all-cause mortality (aHR 1.85; 95% CI 1.28, 
2.68). For every 1 mEq/L TCO2 below 24 mEq/L, the risk of death was 17% higher (aHR 
0.83; 95%CI 074, 0.92).
Conclusions: In summary, metabolic acidosis is a risk factor for ischemic CVE and 
all-cause mortality in kidney transplant recipients. Clinical trials are needed to determine 
the safety and efficacy of alkali therapy for CVE after renal transplantation.
TH-OR125 Oral Abstract Thursday
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Kidney Recipient-Donor KIR-HLA Ligand Mismatch Is Associated with 
Reduced Graft Survival
Andreas Heinzel,1 Lori Dolores Kregar,1 Roman Reindl-Schwaighofer,1 
Alexander Kainz,1 Kira Jelencsics,1 Karin Hu,1 Petra Hruba,2 Ondrej Viklicky,2 
Georg Bohmig,1 Brendan Keating,3 Rainer Oberbauer.1 1Medical University of 
Vienna, Vienna, Vienna, Austria; 2Institute for Clinical and Experimental 
Medicine, Department of Nephrology, Prague, Czechia; 3University of 
Pennsylvania, Philadelphia, PA.
Background: Differences in KIRs between recipients can lead to different KIR-
HLA ligand constellations not captured by HLA matching alone. These differences may 
contribute to variation in allogeneic response to the renal allograft after transplantation.
Methods: We made use of the iGeneTrain consortium and genotyped 162 first kidney 
transplant recipients and respective HLA-DR matched deceased donors from two centers 
in Vienna and Prague. KIR types were imputed using KIR*IMP. HLA eplet mismatch was 
calculated for the HLA-A, -B, -C, -DP, -DQ, and -DR loci. The median follow-up time of the 
cohort was 5.8 years. KIR HLA ligand mismatches were defined based on the presence of 
inhibitory KIRs (2DL1, 2DL2, 2DL3 and 3DL1) and activating KIRs (2DS1 and 2DS2) in 
the recipient and absence or presence of the corresponding ligand in the donor, respectively. 
Kaplan-Meier analysis and a Cox PH model were used to assess the association of KIR-
HLA ligand mismatch with death censored graft loss.
Results: Comparison of the groups of recipients with no- and at least a single KIR-HLA 
ligand mismatch revealed an elevated risk for graft loss following renal transplantation in 
the latter group (see figure 1). This association remained significant in a multivariable Cox 
model after adjustment for full HLA eplet mismatch and donor age (HR: 3.01 CI: 1.06 – 
8.56, p-value: 0.039).
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Conclusions: Presence of a KIR-HLA ligand mismatch between recipient and donor is 
associated with graft loss after HLA-DR matched kidney transplantation.
Figure 1: Kaplan-Meier survival curves comparing HLA-DR matched kidney recipient-
donor pairs without and with a KIR-HLA ligand mismatch.
TH-OR126 Oral Abstract Thursday
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Risk Prediction Score for Allograft Loss in Kidney Transplant Recipients: 
An International Derivation and Validation Study
Alexandre Loupy, Olivier Aubert, Yassine R. Bouatou, Denis Viglietti, 
Carmen Lefaucheur. Paris Translational Research Center for Organ 
Transplantation, Paris, France.
Background: The field of kidney transplantation currently lacks robust models to 
predict long-term allograft failure, hampering patient care improvement and novel clinical 
trials. We aimed at developing and validating a score that predicts individual patients’ risks 
of long-term kidney allograft failure.
Methods: This prospective international cohort study included consecutive kidney 
transplant recipients from a derivation cohort (n=4,000) recruited between 2005 and 2014 
in four centres and a validation cohort of 3,557 kidney transplant recipients from six centres 
recruited in Europe (n=2,129) and North America (n=1,428) between 2002 and 2014. 
Thirty-three candidate prognostic factors of kidney allograft were assessed. The outcome 
was the long-term allograft failure (i.e. return on dialysis or pre-emptive re-transplantation); 
NCT03474003.
Results: Amongst the 7,557 patients included, 1,067 allograft failures occurred 
(14.12%) after a median follow-up time post-transplantation of 7.12 years (IQR: 3.51-
8.77). In the derivation cohort, eight functional, histological and immunological prognostic 
factors were independently associated with allograft failure and were then combined into 
an integrative risk prediction score (iBox). This score exhibited accurate calibration and 
discrimination (C index=0.81; 95% CI, 0.79-0.83). The performance of the iBox was also 
confirmed in two validation cohorts from Europe (C-index=0.80; 95% CI=0.78-0.84) and 
the USA (C-index=0.80; 95% CI=0.76-0.84). The iBox was accurate at different times of 
posttransplant risk evaluation and outperformed conventional prediction model based on 
functional parameter assessment only. Finally, the performance of the iBox was confirmed 
in 3 independent randomised controlled therapeutic trials covering distinct clinical scenarios 
(C-index 0.87; 95% CI=0.82-0.92).
Conclusions: We developed the iBox risk prediction score, which accurately predicts 
kidney allograft failure and demonstrates generalisability across centres worldwide. This 
risk prediction score provides an accurate but simple strategy that can be easily implemented 
to stratify patients into clinically meaningful risk groups, which may help guide patient 
monitoring in everyday practice and improve the design of future clinical trials.
TH-OR127 Oral Abstract Thursday
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Sclerostin Is an Independent Risk Factor of All-Cause Mortality in Older 
Kidney Transplant Recipients and Graft Loss in Younger Kidney 
Transplant Recipients
Shufei Zeng,1,2 Wolfgang M. Pommer,1 Mohamed M. Gaballa,2 Ahmed A. Hasan,2 
Berthold Hocher.3 Institute of Nutritional Science University of Potsdam 
1Charité University Berlin, Berlin, Germany; 2Institute of Nutritional Science 
University of Potsdam, Potsdam, Germany; 3University of Potsdam, Potsdam, 
Germany.
Background: Immediate graft loss and patient survival after kidney transplantation 
have improved over the past decade, however, long-term outcomes remain an issue and 
graft loss is in some centers the leading cause for imitating renal replacement therapy. 
Sclerostin is a hormone contributing to the bone-vascular wall cross talk and has been 
implicated in cardiovascular events and mortality in patients with chronic kidney disease 
(CKD). However, the relationship between sclerostin and mortality or graft failure in renal 
transplant recipients has not been analyzed so far.
Methods: 600 stable renal transplant recipients were followed for 3 years for all-cause 
mortality and graft failure. Blood and urine samples for analysis of sclerostin, albumin, 
creatinine, total cholesterol, HbA1c, 1,25(OH)2D, calcium, phosphorus, iPTH, fasting 
blood glucose, urinary protein and clinical data were collected at baseline. We performed 
Kaplan Meier survival analysis and Cox regressions models considering confounding 
factors such as eGFR, urinary protein excretion, cold ischemia time, donor age, recipient 
age, time on dialysis and HbA1c.
Results: Elevated baseline serum sclerostin concentrations (>75 ng/ml) is an 
independent risk factor for all-cause mortality in older(>66y) stable kidney transplant 
recipients but not in young patients: Kaplan-Meier curves (older patients: P=0.003, log-rank 
test; young patients: P=0.492, log-rank test); and Cox regression (older patients: relative 
risk, 0.155; 95% CI, 0.043 to 0.561 ; P=0.004; young patients: relative risk, 1.330; 95% 
CI, 0.170-10.403; P=0.786). Elevated baseline serum sclerostin concentrations (>75 ng/
ml) is an independent risk factor for graft failure in young(≤66y) stable kidney transplant
recipients but not in older patients: Kaplan-Meier Curves(older patients: P=0.784, log-rank 
test; young patients: P=0.023, log-rank test); and Cox regression (older patients: relative
risk, 0.227; 95% CI, 0.011 to 4.855 ; P=0.343; young patients: relative risk, 0.244; 95% CI, 
0.063-0.944; P=0.041).
Conclusions: Our study showed for the first time that elevated baseline serum 
sclerostin is an independent risk factor of all-cause mortality in older patients and for graft 
failure in young patients after kidney transplantation.
TH-OR128 Oral Abstract Thursday
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Outcomes for Kidney Transplant Recipients with Hearing, Visual, 
Physical, and Walking Disabilities
Alvin G. Thomas,1,2 Jessica M. Ruck,2 Christine E. Haugen,2 Ashton A. Shaffer,2 
Hao Ying,2 Jacqueline Garonzik wang,2 Silas Norman,3 Dorry L. Segev,2 
Mara McAdams-DeMarco.2 1UNC Chapel HIll, Chapel Hill, NC; 2Johns 
Hopkins University, Baltimore, MD; 3University of Michigan Health Systems, 
Ann Arbor, MI.
Background: Lower functional status is associated with higher mortality risk in kidney 
transplant (KT) recipients. Physical disabilities might also affect post-KT outcomes through 
similar pathways, but this population has not been well characterized.
Methods: Using a prospective 2-center cohort of 500 KT recipients 6/2013-12/2017, 
we compared normally able recipients to recipients with self-reported hearing, visual, 
physical, or walking disabilities. We used hybrid registry-augmented Cox regression to 
assess the association between disability status and post-KT outcomes (death-censored graft 
failure and mortality) by adjusting for recipient, donor, and transplant characteristics in the 
national population (SRTR N=76,112).
Results: Among the 500 KT recipients in our cohort, 24.2% reported a disability: 
9.6% had a hearing disability, 16.2% had visual disability, 8.9% had a physical disability, 
and 11.7% had a walking disability. Compared to recipients that did not report a disability, 
recipients who reported a disability were more often Black (51.2% vs. 33.8%, p<0.001), 
spent longer on dialysis (median 2.7 vs. 1.9 years), less often college educated (62.1% vs. 
74.6%, p<0.01), less often employed (31.9% vs. 49.7%, p<0.001), and more often on public 
insurance (67.8% vs. 53%, p<0.01). After adjustment, visual disability was associated with 
a 3.98-fold higher risk of graft failure and walking disability was associated with a 4.12-fold 
higher risk of mortality. Other self-reported disabilities were not associated with transplant 
outcomes (all p>0.05, Table 1).
Conclusions: In this two-center cohort, 24% of KT recipients reported a disability. 
Compared to recipients without a reported disability, recipients with a visual disability 
were at higher risk of graft failure and recipients with a walking disability were at higher 
risk of mortality. These KT recipients might benefit from additional supportive care and 
monitoring post-transplant.
Funding: NIDDK Support, Other NIH Support - T32HL007055 (Thomas), 
F30DK116658 (Shaffer), F32AG053025 (Haugen), K24DK101828 (Segev), 
K01AG043501 (McAdams-DeMarco), R01AG055781 (McAdams-DeMarco)
Risk of Death-censored Graft Failure and Mortality
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Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic 
Syndrome Treated with Eculizumab: A Meta-Analysis
Maria Lourdes Gonzalez Suarez,1 Charat Thongprayoon,2 Michael A. Mao,3 
Wisit Cheungpasitporn.1 1University of Mississippi Medical Center, Jackson, 
MS; 2Bassett Medical Center, Cooperstown, NY; 3Mayo Clinic, Rochester, MN.
Background: Kidney transplantation in patients with atypical hemolytic uremic 
syndrome (aHUS) is frequently complicated by recurrence of aHUS, often resulting in 
thrombotic microangiopathy (TMA) in the renal allograft and graft loss. We aimed to assess 
the efficacy of eculizumab in the prevention and treatment of aHUS recurrence after kidney 
transplantation.
Methods: Databases (MEDLINE, EMBASE and Cochrane Database) were searched 
through March 2018. Studies that reported outcomes of adult kidney transplant recipients 
with aHUS treated with eculizumab were included. Effect estimates from the individual 
studies were extracted and combined using random-effect, generic inverse variance method 
of DerSimonian and Laird. The protocol for this meta-analysis is registered with PROSPERO 
(International Prospective Register of Systematic Reviews; no. CRD42018089438).
Results: Fourteen studies (11 cohort studies and 3 case series) that consisted of 167 
adult kidney transplant patients with aHUS who received eculizumab for prevention and/
or treatment of post-transplant aHUS recurrence were included into the analysis. Among 
patients who received prophylactic eculizumab, the pooled estimated rates of aHUS 
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recurrence and allograft loss due to TMA were 7.9% (95%CI: 3.4%-17.5%, I2 =0%) 
and 6.6% (95%CI: 2.8%-15.1%, I2 =0%), respectively. Among patients who received 
eculizumab for treatment of post-transplant aHUS recurrence, the pooled estimated 
rates of allograft loss due to TMA was 24.1% (95%CI: 14.8%-36.7%, I2 =10%). When 
the meta-analysis was restricted only to cohort studies with data on genetic mutations 
associated with aHUS, the pooled estimated incidence of allograft loss due to TMA 
after eculizumab therapy was 22.6% (95%CI: 13.2%-36.0%, I2 =10%). We found no 
publication bias as assessed by funnel plots and Egger’s regression asymmetry test 
(P values >0.05 for all analyses).
Conclusions: The use of eculizumab for prevention of aHUS recurrence after kidney 
transplantation seems to be more effective than treatment with eculizumab after post-
transplant aHUS recurrence. Our findings suggest that kidney transplant patients with 
history of aHUS may have better allograft survival when prophylactic eculizumab is started 
at the time of kidney transplantation. Randomized control trials are important to further 
investigate this.
TH-OR130 Oral Abstract Thursday
Predictors of Clinical Outcomes After Kidney Transplantation
Outcomes of Kidney Transplantation in AL Amyloidosis Patients
Avital Angel-Korman,3 Lauren D. Stern,1 Shayna Sarosiek,3 John M. Sloan,3 
Gheorghe Doros,2 Vaishali Sanchorawala,1 Andrea Havasi.3 1Boston University 
School of Medicine, Brookline, MA; 2Boston University, Boston, MA; 3Boston 
University Medical Center, Boston, MA.
Background: Therapies for AL amyloidosis have dramatically improved leading to 
longer patient survival (OS), however more patients reach end stage renal disease. Renal 
transplantation in patients with AL amyloidosis has been controversial due to lack of long 
term outcome data and appropriate and validated eligibility criteria.
Methods: We evaluated 52 patients with renal involvement who were followed 
in the Amyloidosis Center at Boston University Medical Center and underwent renal 
transplantation at various centers in the United States over the past 30 years.
Results: Median age at renal transplantation was 59.7 years (range 30.7-73.2) 
with 64% of transplantations from live donors. During a median follow up of 7.1 years 
(range 0-21), median OS from diagnosis was 16.6 years (range1-27.2), and from renal 
transplantation was 10.5 years. One, three and five-year graft survival were 92%, 87% 
and 80%, respectively. Patients with hematologic complete response (CR) or very good 
partial response (VGPR) at renal transplantation had a better OS than patients with partial 
response (PR) or no response (NR). Similarly, median time to graft loss in patients with 
CR/VGPR was 11.7 years (range 0.5-20.3) and with NR/PR was 5.3 years (range, 0.3-15) 
(HR 2.4, P=0.02). Seventeen patients (32%) had recurrent amyloidosis in the graft with 
median time from renal transplantation to recurrence of 3.7 years (range 0.3-11.9). 
Successful treatment mostly prevented graft loss in the setting of disease recurrence in the 
graft. There was a trend towards better OS and graft survival in patients who underwent 
high dose melphalan/stem cell transplantation at any time during their disease course vs. 
patients who were treated only with chemotherapy, however the difference did not reach 
statistical significance.
Conclusions: This is the largest study of patients undergoing renal transplantation 
for systemic AL amyloidosis to date. Carefully selected patients, particularly those 
who had achieved a CR and VGPR to plasma cell directed therapy at the time of renal 
transplantation demonstrated prolonged OS as well as graft survival. These good outcomes 
were independent of the type of treatment that was used for the underlying plasma cell 
dyscrasia. Overall and graft survival of the patients with AL amyloidosis were comparable 
to outcomes achieved in non-AL amyloidosis patients.
Funding: Private Foundation Support
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Kidney Organoids Generated through Heterochronic Recombination of 
Progenitors Show Nephron Segmentation and Vascular Connection with 
Host In Vivo
Ashwani K. Gupta, Michele J. Karolak, Leif Oxburgh. Maine Medical Center 
Research Institute, Scarborough, ME.
Background: In recent years procedures have been developed to differentiate human 
induced pluripotent stem cells (hiPSC) to renal tissues. In the present study, we investigated 
the potential of heterochronic recombination of hiPSC-derived kidney progenitors to 
increase tubular density in hiPSC-derived kidney organoids. Characterization of this 
technique included organoid engraftment, nephron segmentation, graft vascularization and 
perfusion in vivo.
Methods: hiPSC-derived kidney progenitors were treated with a WNT/β-catenin 
agonist for two days to induce epithelialization and were mixed with fresh progenitors, 
aggregated and cultured at the air-liquid interface. On day 9, these organoids were engrafted 
under the kidney capsule of NSG mice. Grafts were harvested after 3 weeks and nephron 
segmentation, vascularization and perfusion were evaluated.
Results: Heterochronic recombination of kidney progenitors induced robust 
tubulogenesis in kidney organoids compared with unmixed cells. Tubules stained with 
molecular markers for proximal and distal tubules and revealed segmentation. Podocytes 
(Podxl+), stromal cells (Meis1+) and endothelial cells (CD31+) were abundant. Engrafted 
organoids showed differentiation of complex graft-derived glomeruli with vascular 
networks (CD31+ Endomucin+), podocytes (Podxl+ WT1+), mesangial cells (Pdgfrβ+), 
glomerular basement membrane (Laminin+ Col I+ Col IV+), and juxtaglomerular cells 
(Renin+). Proximal tubules (E cadherin- LTL+), thick ascending limb of the loop of Henle 
(Tamm-Horsfall protein+), distal tubule (BRN1+), connecting tubule (E cadherin+ GATA3- 
DBA+), collecting duct (Troma-1+ GATA3+ DBA+), and stromal cells (Meis1+ Pdgfrβ+) were 
also present in the grafts. Engrafted organoids showed vascularization (CD31+ Endomucin+ 
SMA+) and direct connections with host vasculature. All nephron structures and stromal 
cells in the graft were iPSC derived (HuNu+), whereas endothelial cells were derived from 
the host (HuNu-).
Conclusions: Heterochronic recombination of kidney progenitors results in vigorous 
differentiation of human iPSC-derived kidney tissue in vitro and in vivo.
Funding: NIDDK Support
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Mechanistic Analysis of Flow-Enhanced Vascularization in Kidney 
Organoids
Kimberly Homan,1 Navin R. Gupta,5 Katharina T. Kroll,1 David B. Kolesky,1 
Mark A. Skylar-Scott,1 Tomoya Miyoshi,3 Donald Mau,4 M. Todd Valerius,3 
Thomas Ferrante,4 Joseph V. Bonventre,3 Jennifer A. Lewis,2 Ryuji Morizane.3 
1Harvard University, Cambridge, MA; 2Harvard School of Engineering and 
Applied Sciences, Cambridge, MA; 3Brigham and Women’s Hospital, Boston, 
MA; 4Wyss Institute, Boston, MA; 5Brigham & Women’s Hospital/Massachusetts 
General Hospital, Brighton, MA.
Background: Multilineage cellular communication is implicated in organ development 
and cellular maturation. We have recently shown that fluidic shear stress (FSS) promotes 
the vascularization and maturation of kidney organoids derived from human pluripotent 
stem cells (hPSCs) in vitro. The addition of VEGF is deemed to facilitate vascular 
formation during kidney organoid development in vivo, however, mechanisms of organoid 
vascularization and maturation under FSS conditions in vitro have yet to be identified.
Methods: Early kidney organoids (pretubular aggregate stage) derived from hPSCs 
were subjected to FSS in printed millifluidic chips. During 10 days of perfusion at a 
FSS of 0.04 dynes/cm2, they were given organoid media without growth factors or with 
either added VEGF (1, 10, 100 ng/mL) or Avastin (250 mg/mL, which inhibits VEGF). 
The degree, distribution, and maturation of CD146+and CD31+vascular networks were 
evaluated by immunostaining, RT-qPCR, and image analysis (ImageJ Angiotool plugin). 
Tubulo-vascular proximity was quantified by distance transformation and surface area 
contact calculations using Imaris software.
Results: FSS-induced vascularized organoids exhibit upregulated VEGF expression, 
compared to static controls. Interestingly, total vascular abundance was independent of 
VEGF signaling under high FSS; however, manipulation of the VEGF pathway reduced 
vascular invasion to glomeruli and tubulo-vascular surface area contact. Reducing the 
nephron epithelial communication with vasculature led to an increase in vascular branching 
and a reduction in average vessel length.
Conclusions: In developing kidney organoids under FSS, modifying the native VEGF 
intrinsic gradient results in random templating of the same amount of vasculature with less 
tubular and glomerular integration. Our results indicate that maintenance of intrinsic growth 
factor production may be critical to develop functional bioengineered kidneys from hPSCs 
in vitro, which may supplant current renal replacement therapies in the future.
Funding: NIDDK Support, Other NIH Support - T32 fellowships, U01, UG3, and 
R37 awards
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Human Kidney Organoids Model Tubular Injury and Maladaptive Repair 
with Interstitial Fibrosis In Vitro
Navin R. Gupta,1,2 Edgar Garcia,1 Tomoya Miyoshi,1 Pierre Galichon,1 
Koichiro Susa,1 Lauren D. Walter,3 Charles B. Epstein,3 Joseph V. Bonventre,1,2 
Ryuji Morizane.1,2 1Brigham and Women’s Hospital/Harvard Medical School, 
Boston, MA; 2Harvard Stem Cell Institute, Cambridge, MA; 3The Broad Institute, 
Cambridge, MA.
Background: Kidney fibrosis is a unifying feature of diseases that cause progressive 
loss of kidney function. Upon severe or repeated tubular injury, the adaptive repair response 
transitions to being maladaptive and pro-fibrotic. Determining the mechanisms involved in 
maladaptive tubular repair is vital to developing anti-fibrotic therapies. Here we propose 
kidney organoids as a model for tubular adaptive and maladaptive repair with interstitial 
fibrosis in human tissue in vitro.
Methods: Kidney organoids were generated from hPSCs by our previously established 
protocol. Organoid maturation was determined by downregulation of developmental genes 
and upregulation of adult markers using immunostaining, qPCR, flow cytometry, and 
histone ChIP-seq for epigenetic analysis of chromatin remodeling overtime. Organoids 
with mature profiles were treated with repetitive cisplatin at 5μM. Cell proliferation, 
dedifferentiation, partial epithelial-to-mesenchymal transition (pEMT), G2/M cell cycle 
arrest, pro-inflammatory cytokine expression, myofibroblast activation and interstitial 
fibrosis were evaluated using a combination of Masson Trichrome, immunostaining, qPCR, 
and flow cytometry after each treatment.
Results: Organoids exhibited mature gene expression profiles by day 49 of 
differentiation. LTL+ tubules exhibited adaptive repair responses following the initial 
cisplatin treatment, including proliferation (Ki67+), dedifferentiation (PAX2+ and SOX9+), 
and pEMT (VIM+ and SNAIL1+). Upon repeated cisplatin injury, LTL+ cells adopt a 
pro-fibrotic phenotype characterized by maladaptive repair processes, including further 
loss of an epithelial phenotype, cell cycle arrest in the G2/M phase, and upregulated pro-
inflammatory cytokine expression, followed by tubular atrophy, the transdifferentiation of 
peritubular fibroblasts (PDGFR-β+NG2-DESM-) and pericytes (PDGFR-β+NG2+DESM+) 
into αSMA+ myofibroblasts, and the advent of interstitial fibrosis (FN and COL1A1).
Conclusions: Human kidney organoids model the transition from adaptive to 
maladaptive repair in tubular epithelial cells with repeated injury. Human kidney organoids 
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enable the study of tubular repair, along the continuum from acute injury to fibrosis, and the 
screening of anti-fibrotic therapeutics in human kidney tissue.
Funding: NIDDK Support, Other NIH Support - T32 (Project DK007527), NHGRI 
(U54HG009390), Private Foundation Support
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Exo Utero Method to Regenerate Nephrons from Nephron Progenitor 
Cells in the Living Fetus
Shuichiro Yamanaka,2 Yatsumu Saito,2 Tsuyoshi Takamura,2 Toshinari Fujimoto,2 
Susumu Tajiri,3 Kei Matsumoto,1,2 Takashi Yokoo.2 1The Jikei University School 
of Medicine, Tokyo, Japan; 2The Jikei University School of Medicine,Tokyo,Japan, 
Tokyo, Japan; 3The Jikei University School of Medicine, Tokyo, Japan., 
Minato-ku, Japan.
Background: Kidney regeneration using native kidney development has been 
previously reported. We previously reported that neonephrons could be generated by 
transplanting nephron progenitor cells (NPCs) into the nephrogenic zone in mice and 
replacing exogenous cells with host cells. In this cell replacement method, the fetal kidney 
was used as a scaffold for regeneration. We postulated that direct transplantation of NPCs 
into the scaffold in utero may obtain a more suitable developmental environment for kidney 
regeneration. We tried an exo utero method for kidney regeneration was used to examine 
whether NPCs could be transplanted into the retroperitoneum near the fetal host kidney 
without fetal sacrifice in vivo, and the development of neonephrons was examined.
Methods: Using an exo utero method to dissect only the myometrial layer of the mouse 
fetus which has only one clear amnion, cells can be injected to the fetus in utero. This 
approach allows the fetus in the amniotic membrane to be returned to the uterus after cell 
transplantation. An exo utero method was used to transplant GFP-expressing NPCs into 
the retroperitoneum on E13.5. After cell transplantation, the fetus continued to develop 
in the mother’s uterus for 6 days. Following cesarean section on E19.5, histopathological 
examination was performed to determine NPC differentiation into nephrons. To determine 
whether cell transplantation in the fetus had a negative effect on fetal growth, fetal body 
weight and crown-rump-length (CRL) were measured on E19 and compared with those of 
fetuses who did not receive NPC transplantation.
Results: Glomeruli derived from transplanted NPCs expressed the nephron 
differentiation markers podocin, nephrin, megalin and aquaporin 1. CD31-positive blood 
vessels were observed inside the glomeruli. There were no significant differences in body 
weight or CRL between the fetuses with and without NPC transplantation.
Conclusions: Transplantation of exogenous NPCs into the retroperitoneum using an 
exo utero method could differentiate into nephrons in vivo. This method, which did not 
adversely affect fetal growth, is potentially applicable to kidney regeneration using NPCs.
Funding: Government Support - Non-U.S.
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Dose Related Effects of Intra-Renal Autologous Mesenchymal Stem/
Stromal Cell Infusion on Renal Hemodynamics, Function, and Cytokine 
Signaling in Human Atherosclerotic Renovascular Disease
Abdelrhman Abumoawad,1 Ahmed Saad,1 Christopher M. Ferguson,1 
Sandra Herrmann,1 LaTonya J. Hickson,1 Sanjay Misra,2 Allan B. Dietz,3 
Lilach O. Lerman,1 Stephen C. Textor.1 1Nephrology and Hypertension, Mayo 
Clinic, Rochester, MN; 2Radiology, Mayo Clinic, Rochester, MN; 3Laboratory 
Medicine and Pathology, Mayo Clinic, Rochester, MN.
Background: Preliminary data identify increased renal blood flow after intra-renal 
infusion of mesenchymal stem/stromal cells (MSC) in post-stenotic kidneys. The effects of 
cell dose on systemic effects and anti-inflammatory activity of autologous MSC in human 
renovascular disease (RVD) are poorly understood
Methods: We measured cortical and medullary blood flows (MDCT), GFR 
(iothalamate and eGFR), renal vein cytokine levels, BP, and tissue oxygenation (BOLD 
MR) in 21 human subjects with atherosclerotic RVD under controlled study conditions, 
before and 3 mo after MSC delivery. Autologous adipose-derived MSC were administered 
at 3 dose levels (1, 2.5 and 5.0x105/MSC/kg, n=7 patients each) into one affected kidney, 
without vascular intervention. Cultured MSC were also studied in vitro..
Results: At the highest dose (5x105 cells/kg), systolic BP fell (140±11.8 to 128±8.18 
mmHg, p<.01), as did urine protein (149±89 to 103±96 mg/dL, p<.01), while single kidney 
GFR rose (18±10.6 to 21±12.5 ml/min, p<.05). Serum creatinine and renal venous VEGF-A 
fell only in the highest dose (Figure), whereas VEGF-C and Angiopontin fell at all dose 
ranges. Increases in treated-kidney tissue oxygenation by BOLD MR were correlated with 
levels of hepatocyte growth factor secretion by MSC in vitro.
Conclusions: These data reinforce the capability of autologous MSC to improve 
the renal circulation in human RVD, and reveal their potential to improve renal function, 
decrease BP, and modify angiogenic signaling from post-stenotic kidneys. The observation 
that some beneficial effects are dose-dependent and related to in-vitro properties of MSC 
may serve to optimize this strategy and predict in-vivo efficacy.
Funding: Other NIH Support - R01 DK100081
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Therapeutic Effects of Genome-Engineered Angiogenic or Anti-Inflamma-
tory Factor Secreting-Mesenchymal Stem Cells in Mice with AKI
Hye-Jeong Park,1 Min Jung Kong,1 Hyo-Ju Jang,1 Eui-Jung Park,1 Hyo-
Jung Choi,1 Hyun Jun Jung,2 Kwon Moo Park,1 Tae-Hwan Kwon.1 1Kyungpook 
National University, Taegu, Republic of Korea; 2NHLBI/NIH, Bethesda, MD.
Background: Stem cell therapy has been proposed as a potential therapeutic strategy 
for acute kidney injury (AKI). By exploiting genome editing technology, we generated 
mesenchymal stem cells (MSCs) secreting angiogenic factor (angiopoietin 1: ANG1) or 
anti-inflammatory factor (erythropoietin: EPO) for therapeutic application in AKI.
Methods: To integrate each gene cassette into the safe harbor locus, AAVS1, of the 
human umbilical cord-derived MSCs (hUC-MSCs) chromosome, AAVS1-targeting Zinc 
Finger Nuclease (ZFN) system was exploited. For the application of stem cell therapy 
in vivo, a scaffold-free cell sheet system was established using a temperature-responsive 
polymer. AKI in C57BL/6 mice was established by bilateral renal pedicles occlusion for 30 
min and monitored for additional 7 days after the clamps were removed.
Results: Junction PCR analysis demonstrated the ZFN-aided gene integration in hUC-
MSCs. Flow cytometry and osteogenic and adipogenic differentiation assay revealed that 
genome editing did not affect the stemness. Protein measurement in conditioned media by 
ELISA and immunoblotting confirmed the production and secretion of each integrated gene 
product (ANG1 and EPO proteins). The in vitro angiogenic function of hUC-MSCs secreting 
ANG1 was further revealed by the increased cell migration and expression of MMP-9 and 
Tie-2 mRNAs in co-cultured HUVEC. As a control experiment, a mono-layered sheet of 
hUC-MSCs was applied to the mice kidney surface in vivo. Immunohistochemistry with 
anti-human nuclei antibody at 1 or 2 weeks after the application demonstrated that hUC-
MSCs on the mice kidney surface were intact and specifically labeled. In mice subjected 
to bilateral renal ischemia and reperfusion, cell sheets of ANG1- or EPO-secreting hUC-
MSCs applied to the kidney surface significantly ameliorated renal functional deterioration 
with lower BUN and creatinine levels, compared with sham control mice as well as mice 
treated with sheets of GFP-expressing hUC-MSCs. Moreover, treatment of EPO-secreting 
hUC-MSCs resulted in higher Hct levels.
Conclusions: A novel cell therapy of hUC-MSCs secreting ANG1 or EPO provides the 
therapeutic effects against AKI in vivo.
Funding: Government Support - Non-U.S.
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Bioprinting and Controlled Perfusion of 3D Vascularized Proximal 
Tubules on Chip
Neil Lin,1 Sanlin Robinson,5 Kimberly Homan,2 David B. Kolesky,2 
Annie Moisan,3 Jennifer A. Lewis.4 1Harvard University, Wyss Institute, 
Brookline, MA; 2Harvard University, Cambridge, MA; 3Roche, Basel, 
Switzerland; 4Harvard School of Engineering and Applied Sciences, Cambridge, 
MA; 5Havard University, Boston, MA.
Background: Building three-dimensional human renal tissues that recapitulate native 
physiological functions is a grand challenge. To date, progress towards developing 3D 
proximal tubule (PT) on chip has resulted in significantly improved cell morphology and 
function, akin to that observed in vivo. However, absent a perfusable vasculature that is 
essential to sustained renal reabsorption, these microphysiological systems are unable to 
replicate key kidney functions, such as tubulovascular exchange.
Methods: Here, we report the bioprinting and characterization of a 3D vascularized 
proximal tubule (PT) on chip that contains two co-localized channels embedded within 
an engineered extracellular matrix (ECM). In our model, the co-localization of the 
independently addressable PT and vascular channels combined with the high permeability 
of our engineered ECM enables effective vectorial transport of solutes. Specifically, we 
quantitatively measured the vectorial transport of glucose and albumin using a closed-loop 
perfusion system.
Results: We demonstrated that glucose reabsorption from the PT lumen to the 
vascular lumen is substantially improved by their 3D lumen geometry and fluid flow. We 
also observed that the glucose reabsorption by the confluent epithelium is reduced upon 
administering Dapagliflozin (SGLT2 inhibitor). Finally, to explore a disease state, we 
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created a hyperglycemic condition by quadrupling the glucose level in the PT channel 
and studied its effect on confluent endothelium within the vascular channel. We found 
that hyperglycemia-induced endothelial dysfunction is also reduced by inhibiting glucose 
transporters in the PT channel.
Conclusions: We have created a 3D vascularized PT on chip model that exhibits renal 
reabsorptive functions in vitro, which is relevant for drug screening, mechanistic safety 
studies, and disease modeling.
Funding: NIDDK Support, Other NIH Support - (Re)Building a Kidney, an NIDDK-
funded consortium, Commercial Support - F. Hoffmann-La Roche
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Endothelialization of Decellularized Porcine Kidneys Sustains In Vivo 
Perfusion in an Acute Porcine Model
Joseph S. Uzarski,1 Senthuran Atputhanathan,1 Dominique Seetapun,1 
Matthew L. Holzner,3 Ron Shapiro,3 Vikram Wadhera,3 Sander Florman,3 
Jeff Ross,2 Dylan Adamson.3 Miromatrix Medical Inc. 1Miromatrix Medical 
Inc., Eden Prairie, MN; 2Miromatrix Medical, Eden Prairie, MN; 3Mount Sinai 
Medical Center, New York, NY.
Background: The shortage of donor kidneys forces patients suffering from kidney 
failure to undergo dialysis as the only alternative to transplantation, the preferred therapy 
with lower morbidity and mortality rates. Recellularization of kidney extracellular matrix 
(ECM) scaffolds derived through decellularization is a promising strategy to produce 
humanized renal tissues for transplantation in a shorter time frame than donor kidneys may 
become available.
Methods: Porcine kidneys were decellularized via perfusion with mild detergents. 
The derived ECM scaffolds were repopulated with human umbilical vein endothelial cells 
(HUVECs) to endow the grafts with thromboresistance. Key metabolic markers were 
monitored to non-invasively assess cell proliferation, viability, and totality of vascular 
endothelialization. Re-endothelialized kidneys were functionally assessed by in vitro 
perfusion with heparinized porcine blood or in vivo anastomosis in an acute porcine 
implant. Primary epithelial cells were introduced to assess survival in co-culture.
Results: HUVECs engrafted in decellularized kidney scaffolds within both the 
arterial and venous vasculature. Daily metabolic analysis found that glucose consumption 
rate (GCR) directly correlated with graft perfusability, and grafts implanted at peak GCR 
(Fig 1A) sustained higher volumetric blood flow. Implanted grafts anastomosed to the 
porcine vasculature showed excellent perfusion of the vascular tree, as demonstrated by 
angiography (Fig 1B). Endothelialization sustained vascular patency during acute in vivo 
perfusion for up to 1 hour (Fig 1C). Co-culture of endothelialized grafts with epithelial cells 
showed dual survival in their respective vascular and nephron niches.
Conclusions: Effective engraftment and proliferation of human endothelial cells within 
porcine kidney scaffolds indicates that the renal ECM retains critical integrin adhesion 
sites. Sustained perfusion of endothelialized grafts during blood loops and acute implants 
represents an important step toward chronic transplantation of recellularized whole kidney 
grafts in human-scale preclinical models.
Funding: Private Foundation Support
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Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
A High-Throughput Microfluidic Model of Proximal Tubule with Active 
Transport Function
Else M. Vedula, Timothy J. Haggerty, Joseph L. Charest. Draper, Cambridge, MA.
Background: Models with kidney-specific function in vitro and high-throughput 
capability will speed kidney disease drug development. Microfluidic models control flow 
to cultured cells to generate tissue with kidney-specific function. However, high throughput 
is required for experiments accommodating many drug doses, assays, and biological 
variables. Microfluidic models have yet to achieve high throughput.
Methods: We developed an in vitro kidney model in a high-throughput microfluidic 
platform, PREDICT-96. PREDICT-96 co-cultured human renal proximal tubule epithelial 
cells (hRPTEC) and human microvascular endothelial cells (hMVEC) and characterized 
them via real-time trans-epithelial electrical resistance (TEER) and a high-content screening 
(HCS) approach quantifying ZO-1 expression, localization. Primary cilia, polycystin-1 
(PC1), and transporter expression were characterized via confocal microscopy. Glucose 
reabsorption via SGLT2 and organic anion transport via OAT-1 were characterized using 
real-time imaging and spectrophotometric techniques.
Results: hRPTEC and hMVEC formed polarized tissue with barrier integrity and 
active, kidney-specific transport function. Flow increased TEER, hRPTEC thickness, 
primary cilia expression with co-localized PC1, and ZO-1 localization. Drug dosing 
modulated glucose reabsorption from the filtrate to vascular channel, indicating active 
kidney-specific function. OAT-1 expression and function were characterized to quantify 
uptake and excretion functions.
Conclusions: Microfluidic flow enhanced tissue structure/morphology, polarization, 
and function, resulting in in vitro tissue with kidney-specific function. Integrated TEER 
sensing and HCS-capable platform architecture supported real-time data collection. 
Microfluidic flow-conditioned tissue actively responded to drug dosing, indicating the 
ability of the model to quantify drug effects. The PREDICT-96 kidney model can generate 
kidney tissue, study renal toxicity, and evaluate disease progression in vitro to speed 
development of kidney therapeutics.
TH-OR140 Oral Abstract Thursday
Translational Research Innovations in Kidney Organoid and Bioengineered Model Systems
Exposure to Fluid Shear Stress Enriches Tip Cell Populations in In Vitro 
Cultured Ureteric Bud Cells
Hiroshi Kimura,1,3 Masaki Nishikawa,4,3 Naomi Yanagawa,4 Hiroko Nakamura,1 
Oak D. Jo,4 Norimoto Yanagawa.2,3 1Tokai University, Hiratsuka, Japan; 2VA 
Greater Los Angeles Healthcare System, North Hills, CA; 3Department of 
Medicine, UCLA, Los Angeles, CA; 4GLAVAHS at Sepulveda, North Hills, CA.
Background: Most kidney cells are exposed to fluid shear stress (FSS) from either 
blood flow or urine flow. Previous studies have shown that changes in FSS may affect 
the function or induce injury of kidney cells. However, it remains unclear whether FSS 
influences kidney development when urinary flow starts in the embryonic kidneys, which 
occurs around embryonic age E15.5 in mouse. In this study, we evaluated the influence of 
FSS on in vitro cultured ureteric bud (UB) cells.
Methods: We used a pumpless microfluidic device, which offers the convenience of 
conducting parallel cell culture experiments without the need of cumbersome electronic 
driven equipment. We first validated the function of the device by both mathematical model 
and experimental measurements. UB cells dissected from E15.5 mouse embryonic kidneys 
were cultured in the pumpless microfluidic device and subjected to FSS for 48 hrs. Control 
UB cells were similarly cultured in the device and maintained under a no-flow condition.
Results: We found that the exposure to FSS for up to 48 hrs led to an increase in 
mRNA expression levels of UB tip cell marker genes (Wnt11, Ret, Etv4) with a decrease 
in stalk cell marker genes (Wnt7b, Tacstd2). In further support of the enrichment of 
UB tip cell population in response to FSS, we also found that exposure to FSS led to a 
remarkable reduction in the binding of lectin Dolichos Biflorus Agglutinin (DBA), which is 
a characteristic of UB tip cells.
Conclusions: Results of our present study show that exposure to FSS led to enrichment 
in UB tip cell populations. Since UB tip cells are known to be the proliferative progenitor 
cells that contribute to the branching morphogenesis of the collecting system in the kidney, 
our finding could imply an important link between the FSS from the initiation of urine flow 
and the development of the kidney.
Funding: Government Support - Non-U.S.
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Advances in Home Dialysis Modalities
Relative Survival among Incident Patients on Home Versus In-Center 
Hemodialysis
Eric D. Weinhandl,1,2 Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Relatively little research has been aimed at outcomes among incident 
dialysis patients who undergo home hemodialysis (HHD). Percolating interest in transitional 
dialysis care may result in greater utilization of HHD during the first year of dialysis. We 
assessed relative survival among incident patients on HHD versus in-center hemodialysis 
(IHD).
Methods: We analyzed merged data from the United States Renal Data System. HHD 
patients initiated at-home treatment with the NxStage System One between January 1, 
2006, and December 31, 2012, and within 3 months after dialysis initiation. IHD patients 
underwent treatment in a dialysis facility at 45 days after dialysis initiation. We followed 
HHD patients from the day of the first at-home treatment and IHD patients from the 45th 
day after dialysis initiation; all patients were followed until death, but for a maximum of 
one year. We used Cox regression to estimate the adjusted hazard ratio (AHR) of death 
for HHD versus IHD, with adjustment for age, race, sex, primary cause of end-stage renal 
disease, Medicaid enrollment, comorbid conditions, vascular access type, body mass index, 
estimated glomerular filtration rate (GFR), and hematocrit; all adjustment factors were 
ascertained from form CMS-2728.
Results: We identified 1773 HHD patients and 555,366 IHD patients. Relative to 
IHD patients, HHD patients were younger (mean age, 55.3 versus 60.3 years), more likely 
white (81.3% versus 62.7%), more likely male (71.1% versus 57.0%), less likely enrolled 
in Medicaid (9.5% versus 28.3%), and less likely to have heart failure (15.8% versus 
31.3%). Mean estimated GFR was 10.5 and 10.4 mL/minute/1.73 m2 in HHD and IHD 
patients, respectively. Survival after one year of follow-up was 91.7% and 81.4% in HHD 
and IHD patients, respectively. After adjustment, the AHR of death for HHD versus 
IHD was 0.77 (95% confidence interval, 0.66-0.91). Within age strata, corresponding 
AHRs of death were 0.56 (0.30-1.04) for 20-44 years, 0.74 (0.58-0.94) for 45-64 years, 
and 0.89 (0.70-1.13) for ≥65 years. Within estimated GFR strata, corresponding AHRs 
of death were 0.68 (0.51-0.90) for GFR <10 mL/minute/1.73 m2 and 0.80 (0.65-1.00) for 
GFR ≥10 mL/minute/1.73 m2.
Conclusions: Among incident patients, HHD is associated with better survival than 
IHD. Associations are attenuated with older age and higher estimated GFR at dialysis 
initiation.
Funding: Commercial Support - NxStage Medical, Inc.
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Advances in Home Dialysis Modalities
Efficacy of Mupirocin Prophylaxis for Prevention of Bacteremia in Home 
Hemodialysis Patients Using Buttonhole Technique for Cannulation
Frank Liu,1,2 Upali Dutta,1 Janice Herrera,1 Joel Mallare,1 Thomas Parker.1 1The 
Rogosin Institute, New York, NY; 2Medicine/Nephrology, New York Presbyterian 
- Weill Cornell Medical Center, New York, NY.
Background: Buttonhole cannulation (BC) technique is often preferred by home
hemodialysis (HHD) patients but has been associated with a significant risk of bloodstream 
infection (BI). Despite a single center report suggesting a decrease in BI with topical
mupirocin prophylaxis (MP), use of MP is not widespread, and indeed, many centers have 
shied away from using BC altogether. Because our patients have shown a strong preference 
for BC, we have continued to use BC but began mandating the use of MP in September
2013. This study is a retrospective chart review comparing the incidence of BI in patients
using BC before and after we started MP.
Methods: To establish the number of treatments-at-risk for development of access-
related BI, HHD billing records from January 2007 through March 2018 were reviewed to 
assess the total number of HHD treatments performed, as well as the access used for those 
treatments. Corresponding monthly QA reports were reviewed to identify episodes of BI
attributable to the HD access, and confirmed by review of the underlying medical record 
independently by two clinicians.
Results: From January 2007 through March 2018, 133 patients performed 63,704
HHD treatments, encompassing 298.3 patient-years of observation. Of those, 50 patients
performed 28,047 treatments using BC in the period prior to MP and 37 patients performed 
14,702 treatments using BC in the period after MP. 21 episodes of access-related BI were
observed, with 19 episodes occurring in 14 patients in the pre-MP period, and 2 episodes
occurring in 2 patients in the post-MP period. Both patients who developed BI in the
post-MP period admitted to non-adherence with MP at the time of BI. When analyzed by 
observation period, the odds ratio (OR) for BI without MP was 5 (95% confidence interval 
(CI) = 1.16 to 21.4; p=0.03). In an as-treated analysis, the OR for BI without MP was
21.9 (95% CI=1.3 to 361.7; p=0.03).
Conclusions: Topical mupirocin prophylaxis is effective in prevention of buttonhole 
cannulation-associated bloodstream infection. Buttonhole cannulation technique can be 
safely used for HHD if patients are adherent to a prophylaxis protocol.
FR-OR003 Oral Abstract Friday
Advances in Home Dialysis Modalities
Increased Hemodialysis Frequency Is Associated with Improved Clinical 
Outcomes among Patients in Skilled Nursing Facilities
Eric D. Weinhandl,1,2 Kathy Hocking,3 Susan Markovich,3 Scott Vavrinchik,3 
Allan J. Collins.1,2 1NxStage Medical, Inc., Victoria, MN; 2University of 
Minnesota, Minneapolis, MN; 3Affiliated Dialysis Centers, Glen Ellyn, IL.
Background: In light of hemodynamic instability and frailty, dialysis patients who 
reside in a skilled nursing facility (SNF), either for short-term rehabilitation or long-term 
custodial care, may benefit from on-site, frequent hemodialysis (HD). We assessed whether 
increased HD frequency was associated with risks of death and hospital admission among 
SNF patients receiving care from a single dialysis provider in the Chicago area.
Methods: We assessed Medicare Parts A and B claims in 2011-2015 to identify HD 
patients at Affiliated Dialysis Centers (ADC). For each patient-week in 2011-2015, we 
tallied the number of HD sessions at ADC. We constructed an outcome-exposure model 
that measured associations of all-cause mortality, all-cause hospital admission (HA), and 
cause-specific (cardiovascular disease, infection, and other morbidity) HA risks during one 
calendar week with mean HD frequency during the preceding two calendar weeks, with 
frequency categorized as ≥4.5 vs. 2.5-4.4 HD sessions/week. We fit logistic generalized 
estimating equations, with adjustment for age, race, sex, primary cause of end-stage renal 
disease (ESRD), duration of ESRD, vascular access type, and calendar time.
Results: We identified 3619 unique patients and 78,047 patient-weeks. Mean age 
was 69.0 years; 59% and 34% of patients were white and black, respectively; 49% were 
female; and 53% dialyzed with a central venous catheter. Between 2011 and 2015, the 
percentage of two-week intervals with ≥4.5 HD sessions/week increased monotonically, 
from 9% in 2011 to 45% in 2015. We observed 641 deaths. The adjusted mortality 
risk ratio for ≥4.5 vs. 2.5-4.4 HD sessions/week was 0.66 (95% confidence interval, 
0.52-0.83). The adjusted all-cause HA risk ratio for ≥4.5 vs. 2.5-4.4 HD sessions/week was 
0.91 (0.81-1.02). Corresponding cause-specific HA risk ratios were 0.77 (0.62-0.97), 1.05 
(0.88-1.24), and 0.86 (0.74-1.00) for cardiovascular disease, infection, and other morbidity, 
respectively. For all HAs excluding those attributable to infection, the adjusted risk ratio for 
≥4.5 vs. 2.5-4.4 HD sessions/week was 0.83 (0.73-0.95).
Conclusions: In a large study of on-site HD in the SNF setting, increased HD frequency
was associated with significantly lower risks of death and all hospital admissions excluding 
those attributable to infection.
Funding: Commercial Support - NxStage Medical, Inc.
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A Comparison of Technique Survival in Canadian Peritoneal Dialysis and 
Home Hemodialysis Patients
Emilie Trinh,1 James A. Hanley,5 Annie-Claire Nadeau-Fredette,2 Jeffrey Perl,3 
Christopher T. Chan.4 1McGill University Health Center, Montreal, QC, Canada; 
2Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; 3St. Michael’s 
Hospital, Toronto, ON, Canada; 4Toronto General Hospital, Toronto, ON, 
Canada; 5McGill University, Montreal, QC, Canada.
Background: High discontinuation rates remain a challenge for both home 
hemodialysis (HHD) and peritoneal dialysis (PD). Our study aimed to compare the 
technique failure risks between HHD and PD in a Canadian cohort.
Methods: We studied adult patients who initiated either HHD or PD within 1 year 
of dialysis initiation between 2000-2012 in the Canadian Organ Replacement Register. 
Technique failure was defined as a transfer to any alternative dialysis modality for a period 
of ≥60 days. We compared technique survival between HHD and PD using a Fine and Gray 
competing risk model. Secondary outcomes assessed the trajectory of technique survival, 
the association of patient characteristics with technique failure, causes of technique failure 
and changes of technique failure rates over time
Results: 15,314 patients were treated with a home dialysis modality between 2000-
2012: 14,461 on PD and 853 on HHD. The adjusted risk of technique failure was overall 
lower with HHD compared to PD (HR 0.79; 95% CI 0.69-0.90). However, comparisons 
varied over time (Figure 1a). During the first year of therapy, there was no significant 
difference in technique survival between HHD and PD (HR 1.13; 95% CI 0.94-1.36). 
Thereafter, the risk of technique failure was significantly lower with HHD. In PD and HHD, 
crude rates of technique failure were the highest during the first year of therapy (Figure 
1b). Among HHD patients, rates were significantly lower subsequent to that. In contrast, 
the decrease in failure rates was not as pronounced among PD patients. Furthermore, 
the majority of home dialysis discontinuation occurred for medical reasons in PD (38%) 
while the majority of HHD patients experienced technique failure due to social reasons or 
inadequate resources (50%).
Conclusions: In this Canadian study of home dialysis patients, HHD was associated 
with superior technique survival compared to PD. However, causes and patterns of technique 
failure differed significantly among these modalities. Strategies to improve patient retention 
across all home dialysis modalities are needed.
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Effect of Intensive Home Hemodialysis on Right Ventricular Systolic 
Pressure and Clinical Outcomes
Michael Y. Girsberger, Christopher T. Chan. Toronto General Hospital, Toronto, 
ON, Canada.
Background: Increased right ventricular systolic pressure (RVSP) is a marker of 
pulmonary hypertension in patients with end-stage kidney disease (ESKD). Our primary 
aim is to examine whether nocturnal home hemodialysis (NHD) will modify RVSP in 
ESKD patients. Our secondary aim is to ascertain the clinical consequence of normalization 
of RVSP.
Methods: We conducted a retrospective single center cohort study at the Toronto 
General Hospital including all patients between 1999 and 2017 with baseline and follow-
up echocardiograms on intensive home hemodialysis followed for at least 1 year. Patients 
were categorized according to RVSP response at the end of follow-up: non-responders 
with increased RVSP and responders with normal RVSP. Multivariate and cox regression 
analysis were used to identify risk factors for increased RSVP and reaching clinical 
composite endpoint (death, cardiovascular hospitalisation, treatment failure), respectively.
Results: A total of 129 patients were included in the study with a mean follow-up of 
4.1 years. 31% (40/129) of patients had increased RVSP (=/> 35 mmHg). 9 (10.1%) out 
of the 89 responders and 18 (45%) out of the 40 non-responders reached the composite 
endpoint of death, cardiovascular hospitalization or technique failure. Responder status 
is an independent predictor for reaching the composite endpoint and is associated with a 
survival benefit.
Conclusions: Increased RSVP is associated with adverse clinical outcomes in patients 
on intensive home hemodialysis.
Funding: Private Foundation Support
Cox proportional hazards analysis of the risk of the composite end point of death, technique 
failure and CV-related hospitalization.
Composite end point-free survival in responders and non-responders.
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Silicon Nanopore Membrane-Based Implantable Hemodialysis: A 
Preclinical Proof-of-Concept Study
Jarrett Moyer,1 Jimmy Ly,1 Nathan Wright,1 Charles Blaha,1 William H. Fissell,2 
Shuvo Roy.1 1UC San Francisco, San Francisco, CA; 2Vanderbilt University, 
Nashville, TN.
Background: Silicon nanopore membranes (SNM) are highly efficient biomimetic 
and blood-compatible slit-pore membranes. The high efficiency of the membrane enables 
hemofiltration and hemodialysis by utilizing cardiovascular perfusion pressure to circulate 
blood over the filters, enabling the prospect of a fully implanted hemodialysis cartridge. This 
alternative access strategy could offer a solution for patients with complicated conventional 
access, and lowers barriers to self-care home hemodialysis.
Methods: A 115 x 57 x 18 mm SNM-based parallel-plate hemodialyzer (SNMHD) 
was prototyped from polycarbonate and stainless steel. The device was implanted 
subcutaneously in the neck of a healthy Yucatan mini-pig and anastomosed to the carotid 
artery and jugular vein via ePTFE vascular grafts. Catheters to supply dialysate were 
tunneled subcutaneously and attached to the SNMHD. The animal was allowed to recover, 
and 3-hour hemodialysis sessions were performed on the day of surgery, and post-operative 
days 1, 2, and 3. Dialysate was recirculated in a counter-current fashion at 10-15 mL/min, 
and blood flow through the SNMHD was between 1.0-1.5 L/min, assessed by pulse wave 
Doppler ultrasound. Blood samples were collected at the initiation of dialysis, and dialysate 
sampled every hour to assess solute clearance over time. The animal was treated with daily 
aspirin and clopidogrel beginning three days before the implant, continuing throughout the 
post-operative period.
Results: The animal tolerated surgical implantation and subsequent dialysis sessions 
without complication. Blood flow through the dialyzer remained brisk throughout the three-
day study. All dialysis sessions were completed as planned, via recirculation of normal 
saline through the dialysate catheters. Over the course of the study, normalized creatinine 
and urea clearances ranged from 11-42 mL/min/m2and 26-74 mL/min/m2, respectively. 
Albumin concentration in the dialysate remained below the detection limit throughout the 
study.
Conclusions: We demonstrated preclinical feasibility of an implantable, pumpless 
SNM-based hemodialyzer. Further development and refinement of the SNMHD could 
provide an alternative method for hemodialysis access and facilitate frequent in-home 
dialysis.
Funding: Other NIH Support - NIH U01 EB021214
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International Trends in Mortality Soon after Switch from Peritoneal 
Dialysis to In-Center Hemodialysis: Results from the INTEGRATED 
Study Group
Nidhi Sukul,1 Purna Mukhopadhyay,6 Anneke Kramer,10 Kitty J. Jager,5 
Mark Lambie,11 James A. Sloand,12 Wim Van Biesen,9 Simon J. Davies,13 
Christopher T. Chan,4 Jeffrey Perl,7 David W. Johnson,8 Bruce M. Robinson,2 
Ronald L. Pisoni,2 Rajiv Saran,1 Annie-Claire Nadeau-Fredette.3 1University of 
Michigan, Ann Arbor, MI; 2Arbor Research Collaborative for Health, Ann 
Arbor, MI; 3Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; 4Toronto 
General Hospital, Toronto, ON, Canada; 5Academic Medical Center, 
Amsterdam, Netherlands; 6Arbor Research Collabortaive for Health, Ann Arbor, 
MI; 7St. Michael’s Hospital, Toronto, ON, Canada; 8Princess Alexandra 
Hospital, Brisbane, QLD, Australia; 9Ghent University, Ghent, Belgium; 10ERA-
EDTA Registry, Amsterdam, Netherlands; 11Keele University, Crewe, United 
Kingdom; 12Baxter Healthcare Corporation, Northbrook, IL; 13University 
Hospital of North Midlands, Stoke-on-Trent, United Kingdom.
Background: Switching between dialysis modalities is common among patients (pts) 
with end-stage kidney disease (ESKD) and has been shown to be associated with adverse 
outcomes. This international registry study describes mortality rates after switch from 
peritoneal dialysis (PD) to in-center hemodialysis (HD).
Methods: Using four longstanding international registries (ANZ, CORR, ERA, 
USRDS), and with support from the NIDDK, this study analyzed incident PD pts, defined 
as starting PD within 180 days of ESKD incidence, who switched from PD to HD for ≥1 
day. Pts were grouped into 3 cohorts by year of ESKD incidence (2000-2004, 2005-2009, 
2010-2014). Crude mortality rates (per 100 patient-years [PY]) were calculated for the first 
180 days after switch, with patients censored on the date of death, transplant, loss-to-follow 
up, or study end-date.
Results: In each registry, (1) mortality rate was highest during the first 30 days after 
switch to HD, subsequently declining to a stable rate by 120 to 180 days (Figure); (2) 
mortality rate decreased from the earliest to the most recent cohort, though remained high 
soon after switch to HD (Figure).
Conclusions: Transition from PD to HD is associated with high mortality rates 
internationally, especially during the first 30-day period. The lower mortality rates in 
recent years may reflect more timely transition and/or improved peri-transition care. Future 
studies should evaluate optimal timing of switch, as well as modifiable predictors of post-
switch mortality, to increase the likelihood of successful transition and to improve clinical 
outcomes.
Funding: NIDDK Support
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Peritoneal Dialysis Utilization in US markets and Associated Mortality 
Rate Ratios for Peritoneal Dialysis Versus Hemodialysis
Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins,1,2 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: In the United States, peritoneal dialysis (PD) is associated with lower 
mortality risk than in-center hemodialysis (HD) during the first year of dialysis. However, 
increased utilization of PD in a local area may move higher-risk patients from HD to PD, 
thus attenuating the mortality rate ratio (MRR). We assessed the influence of PD utilization 
in US markets on MRRs for PD versus HD.
Methods: We analyzed data from the United States Renal Data System. We identified 
incident dialysis patients in 2006-2013 and retained patients in markets with ≥500 patients. 
For each area, we calculated the percentage of patients on PD within 3 months of dialysis 
initiation. Using Poisson regression, we assessed the association of that percentage with 
the mortality rate between 3 and 36 months after dialysis initiation, without censoring for 
modality change and with fixed effects for markets.
Results: The cohort included 586,718 incident dialysis patients in 236 markets. 
Overall PD utilization was 8.8%. Market-specific mortality rates in PD and HD patients are 
displayed. Market-adjusted MRRs for PD versus HD were 0.56 with local PD utilization of 
2-3% (number of markets, 12), 0.55 with utilization of 4-5% (27), 0.58 with utilization of
6-7% (47), 0.61 with utilization of 8-11% (90), 0.65 with utilization of 12-15% (42), 0.64
with utilization of 16-19% (11), and 0.77 with utilization of ≥20% (7). Compared to the
market-adjusted MRR with local PD utilization of 2-3%, only the MRR with utilization of 
≥20% was significantly different (P < 0.01).
Conclusions: Across a gradient of local PD utilization from 2% to 20%, MRRs for PD
versus HD are similar. Expanded utilization of PD in incident dialysis patients may have
limited negative effect on population survival.
Funding: Commercial Support - NxStage Medical, Inc.
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Peritoneal Fluid Cell Free DNA Is a Versatile Analyte of Peritonitis
John R. Lee,1 Vesh Srivatana,2 Philip Burnham,3 Amanda D. Renaghan,1 
Xunxi S. Guo,1 Lars Westblade,1 Emmanuel Y. Edusei,1 Jeffrey I. Silberzweig,2 
Shady Y. Albakry,1 Matthew Magruder,1 Manikkam Suthanthiran,1 Iwijn De 
Vlaminck.3 1Weill Cornell Medicine, New York, NY; 2The Rogosin Institute, New 
York, NY; 3Cornell University, Ithaca, NY.
Background: Culture negative peritonitis is common in peritoneal dialysis (PD) 
patients, especially in the setting of recent antibiotic use. We investigated whether 
sequencing cell free DNA (cfDNA) extracted from peritoneal fluid supernatants can 
identify the suspected causative agent(s) in cases of peritonitis.
Methods: We recruited 7 PD subjects: 3 subjects had peritonitis and 4 subjects did 
not have evidence of peritonitis; and we collected 16 peritoneal fluid specimens. cfDNA 
was isolated using a Qiagen Circulating Nucleic Acid Kit and a single stranded library 
preparation was constructed for each specimen. The library was sequenced using an 
Illumina Next-Seq instrument (75 base pair by 75 base pair). Pathogen identification was 
performed using the bioinformatics program, GRAMMy.
Results: We obtained approximately 10 million cfDNA reads per specimen. Three 
PD subjects had an episode of culture confirmed peritonitis (Klebsiella pneumoniae, 
Staphylococcus aureus, and Staphylococcus epidermidis). cfDNA profiling identified the 
organisms in all 3 cases and importantly on subsequent days after antibiotic administration 
which had corresponding same day cultures that were negative. One of the subjects 
subsequently developed another episode of suspected peritonitis. The subject was 
treated for peritonitis with intraperitoneal antibiotics, but the peritoneal fluid cultures 
on admission were negative. The subject continued to have abdominal pain despite 
intraperitoneal antibiotics. The subject was suspected to have cholecystitis and culltures 
from a percutaneous cholecystotomy 4 days after admission grew Enterococcus faecium 
and Parabacteroides distasonis. cfDNA profiling of peritoneal fluid detected Enterococcus 
faecium and Parabacteroides distasonis on admission.
Conclusions: Our pilot data support the use of cfDNA profiling of peritoneal fluid to 
investigate peritonitis, especially in the setting of antibiotic use, and potentially as a method 
to investigate occult infections in abdominal organs.
Funding: Private Foundation Support
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Nanoparticles of Lipids with Paclitaxel Reverse Inflammation and 
Peritoneal Fibrosis in the Peritoneal Fibrosis Model in Uremic Rats
Elerson Costalonga,1 Rafael Pepineli,2 Raul C. Maranhão,3 Irene L. Noronha.2 
1School of Medicine, University of Sao Paulo, São Paulo, Brazil; 2University of 
Sao Paulo, Sao Paulo, Brazil; 3Instituto do Coração do HCFMUSP, Sao Paulo, 
Brazil.
Background: Increased cellular proliferation and inflammation of the peritoneal 
membrane (PM) are complications of long term peritoneal dialysis leading to peritoneal fibrosis 
(PF). Paclitaxel, a potent antiproliferative drug, has therapeutic efficacy, limited by toxicity. 
Nanotechnology enabled drug release systems that can concentrate the active drug on target 
tissues. LDE, a LDL similar nanoparticle, was associated to Paclitaxel (NanoPACLI) in order to 
reduce drug toxicity. NanoPACLI binds to LDL receptors, which are overexpressed on the cell 
surface of inflamed tissues. In this study, the effects of NanoPACLI administration in a model 
of experimental PF associated to uremia were analyzed.
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Methods: Uremia was induced in male Wistar rats fed with adenine-containing diet 
during a period of 21 days. Injections of chlorhexedine gluconate (CG) were administrated 
intraperitoneally (IP) to induce PF. Rats (n=27) were divided into 3 groups: Control, 
normal rats receiving saline injections; PF/CKD, uremic rats receiving CG injections; PF/
CKD-NanoPACLI, uremic rats with PF receiving NanoPACLI injections (IP; 4mg/kg 
every 3 days). The NanoPACLI treatment was initiated 7 days after PF induction. Euthanasia 
was performed on day 21. PM thickness, ultrafiltration (UF), inflammatory cell infiltration, 
and cytokine expression were analyzed.
Results: NanoPACLI significantly decreased peritoneal thickness, prevented UF 
failure, reduced inflammatory cellular infiltration as well as cytokine concentration in the 
PM.
Conclusions: NanoPACLI administration was effective in inhibiting the progression 
of PF and preserving UF in a model of established PF in uremic rats. These findings may 
be related to the anti-inflammatory effects of paclitaxel delivered locally by NanoPACLI.
Effects of NanoPACLI on PF model in uremic rats
Results were expressed as mean±SEM. *p<0.05;**p<0.01,***p<0.001
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Reducing the Incidence of Post CABG AKI by Early Intervention Guided 
by Novel Urinary Biomarker (TIMP-2, IGFBP-7): An Institutional 
Experience
Abhinav K. Tiwary,1 Barbara A. Greco,2 Michael J. Germain,3 Daniel Engelman,4 
Krishna A. Agarwal,5 Armand Golchin,5 Cheryl Crisafi.5 1Nephrology, UMMS-
Baystate, Springfield, MA; 2Renal and Transplant Associates of New England, 
Springfield, MA; 3Renal and Transplant Assoc of New England, Hampden, MA; 
4Baystate Medical Center, Springfield, MA; 5UMMS-Baystate, Chicopee, MA.
Background: AKI post cardiac surgery occurs in up to 25% of patients: KDIGO 
AKI Stage 1 (30%), Stage 2 (10-15%), Stage 3 (2-5%), RRT (1%) and adversely affects 
prognosis, prolongs hospital stay and increases readmission rate. KDIGO guidelines 
recommend preventative measures in patients at high risk for developing AKI. In two 
multicenter studies of critically ill patients, NephroCheck (NC), urinary tissue inhibitor of 
metalloproteinases-2 (TIMP2) and insulin-like growth factor-binding protein 7 (IGFBP7), 
was validated for risk stratification for moderate-severe AKI. These markers are believed to 
reflect renal tubular epithelial cell response to stress and can identify patients at risk before 
injury occurs allowing for interventions to prevent AKI
Methods: Urinary NC was measured in CABG pts (n = 98) at our institution the 
morning after surgery. All pts with NC > 0.3 (moderate positive) received a modification 
of the KDIGO support measures. For NC > 0.6 (high positive), nephrology consultation 
was added. Patients with preoperative CKD were excluded. AKI was defined as rise in 
creatinine by 0.3 from baseline until hospital discharge. Interventions included goal-
directed therapy for optimizing volume status, hemodynamics and renal perfusion pressure, 
raising the PAD pressure to 14-16 using balanced crystalloid, instituting inotropes for 
depressed cardiac function, limiting use of diuretics, avoidance of RAAS inhibitors, 
NSAIDs, and nephrotoxins, extending duration of hemodynamic monitoring, and using a 
higher transfusion threshold
Results: The AKI incidence (STS registry stage 3 KDIGO) prior to our study was 2.36 
%. During the 6-month period using NC, the incidence of Stage 3 AKI fell to 1.25%. One 
false positive test was seen. One pt with a positive NC had a 2-hour UF post operatively; no 
other patients required RRT
Conclusions: The use of NC, a urinary biomarker for renal stress, in combination 
with rapid renal supportive interventions resulted in a 47% relative reduction in AKI in our 
institution in post CABG patients.
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Preventing AKI and Improving Outcome in Critically Ill Patients Utilising 
Risk Prediction Score (PRAIOC-RISKS) – A Pilot Study
Tarek S. Abdelaziz, Wessam M. Hussin, Mohamed S. Elyamny, Moataz Fatthy, 
Ragai Fouda, Yasser M. Abdelhamid. Kasr Alaini Hosp-Cairo university, Giza-
Cairo, Egypt.
Background: Early detection and management of AKI in medical ICU is an unmet 
goal. Our study used a risk score to identify patients at high risk of developing AKI and 
apply timely preventive measures.
Methods: The study was run at two separate medical intensive care units. A recently 
validated and published risks score, developed by Malhotra and colleagues was used. A risk 
score was applied to all patients admitted to the ICU during the study period. Eligible patients 
were adults, who had mental capacity and who did not have AKI at time of recruitment. 
Patients who had established AKI at the time of recruitment were excluded from the study. 
In the (observation) ICU, patients received the standard care. In the (intervention) ICU, high 
risk patients (risk score ≥5) had very early nephrology review. A package of standardized 
recommendations was implemented. Measures included optimizing fluid balance, mean 
arterial pressure, cessation and avoidance of potential nephrotoxic medications and optimal 
sepsis management. The primary outcome was the incidence of AKI.
Results: During 8 months, we recruited 98 patients in the intervention arm and 108 
patients in the observation arm. Baseline characteristics are shown in table 1. There was 
statistically significant difference in AKI incidence between the two groups (26% in the 
observation group versus 11% in the intervention group, p=0.002). 30 day-mortality was 
lower in the intervention group but not statistically significant (25% in the intervention arm 
versus 32% in the observation arm, p=0.35).
Conclusions: It was feasible to apply very early nephrology intervention to critically ill 
patient at high risk of developing AKI. The incidence of AKI was significantly lower in the 
intervention group. Multicentre studies are needed.
Baseline characteristics
30 days Mortality
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Community AKI Reporting Improves Longer-Term Patient Outcomes
Seema Jain,2,1 Jane E. Manning,1 Bhrigu Raj Sood.2,1 1Epsom And St. Helier 
University Hospitals, Epsom, United Kingdom; 2South West Thames Renal Unit, 
Carshalton, United Kingdom.
Background: More than half a million patients develop AKI in England per year. 
Two-thirds of these occur in the community. AKI episodes have long-term implications 
with regard to morbidity and mortality. To improve detection of AKI in the community, 
automated detection systems have been developed to generate an ‘AKI Alert’ alongside 
blood test reports. In this study, we assess the outcomes of patients 3 years after the episode 
of AKI was detected.
Methods: AKI alerts were generated using the UK national AKI algorithm. Only blood 
tests done in the community were considered. 3-year outcomes were analysed for patients 
with AKI alerts in December 2014. Worsening renal function was defined as an increase in 
CKD stage by 1 or more.
Results: 79 AKI alerts were issued over this time period. Of these, 9 were excluded 
from analysis as 3 were repeat alerts and data was missing for 6. The median age of the 
patients in which AKI was detected was 80 (Min 22, Max 94). 45 patients had pre-existing 
CKD with 43% of the total cohort having an eGFR 30-60 and 21% having an eGFR of less 
than 30. 19 of the 70 alerts were incorrect with 95% overstating the stage of AKI as defined 
by KDIGO criteria. In cases when AKI was reported correctly, 70% of patients died or had 
worse renal function 3 years after the episode of AKI. In 71% of cases where an episode 
of AKI was detected by the algorithm, the alert led to a repeat blood test within 4 weeks. 
However, in the patients that did not have a repeat blood test in this time frame, there was 
a higher proportion of falsely reported AKI (45% versus 16%). This might be expected as 
the clinician may be less likely to repeat the test if deemed not to be a true episode of AKI. 
Patients in which the alert resulted in a repeat blood test in 4 weeks had a lower incidence 
of worsening renal function (40% vs 55%) and a composite outcome of death or worsening 
renal function (69% vs 73%) at 3 years.
Conclusions: A high proportion of patients who have an incidence of ‘community’ 
AKI go on to develop worsening CKD or death within 3 years. In cases when the AKI 
alert led to further investigation, there was a lower incidence of death and progressive renal 
dysfunction compared to cases where no action was taken. This suggests that a community 
blood test-based AKI alert system leads to longer lasting improved patient outcomes.
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Impact of Intensive Glycemic Control in the Development of AKI after 
Cardiac Surgery: A Randomized Clinical Trial
Eduesley Santana-Santos,1 Maria De Fatima Vattimo,2 Cassiane D. da Fonseca,3 
Kleyton A. Bastos,4 Andreia F. Menezes.4 Grupo Interdisciplinar de Estudos em 
Cuidados Críticos - GIEsCC 1Nursing Department, Federal University of 
Sergipe, Aracaju, Brazil; 2Medical and Surgical Departament, School of 
Nursing University of Sao Paulo, Sao Paulo, Brazil; 3Nursing School, Federal 
University of Sao Paulo, Sao Paulo, Brazil; 4Federal University of Sergipe, 
Aracaju - Sergipe, Brazil.
Background: Hyperglycemia is directly linked to higher rates of morbidity and 
mortality in hospitalized patients and is recognized as an important risk factor for 
postoperative complications. We performed a randomized controlled trial to evaluate the 
impact of an intensive glycemic control strategy in the occurrence of acute kidney injury in 
patients undergoing cardiac surgery.
Methods: Were included patients who presented blood glucose greater than 200 mg/dl 
in the first 6 hours of admission to the ICU. Patients aged less than 18 yo, diagnosed 
with congenital heart disease and heart transplantation were excluded. The patients were 
allocated in one of the groups: conventional group (CG), glucose target between 140 
and 180 mg/dl and the intensive group (IG), glucose target between 90 and 110 mg/dl. 
The primary endpoint was AKI defined according with KDIGO criteria. The secondary 
outcomes were mortality, need for dialysis, renal function recovery, hypoglycemia, ICU 
discharge, length of stay in ICU.
Results: Were included 95 patients, 36 (37.9%) in the IG and 59 (62.1%) in the CG. 
In the comparison between groups, no significant difference was observed in relation to 
the surgical risk (p = 0.511) and the risk for acute kidney injury (p = 0.962), measured 
by the EuroSCORE and Cleveland Clinic Score, respectively. Using vasoactive drugs 
was higher in the IG as compared to CG (97.2% vs. 83.1%; p = 0.047). There was no 
difference in the incidence of AKI in IG, when compared with CG (61.1% vs. 49.2%; 
p = 0.294, respectively). Nevertheless, the return of kidney function to the basal values 
was smaller in the IG as compared to CG (41.7% vs. 69.5%; p = 0.010, respectively). 
There was no found any difference between the groups in relation to mortality (p = 0.066), 
need for dialysis (p = 0.364) and episodes of hypoglycemia (p = 0.151). There was a 
higher number of ICU discharges in the CG, when compared with IG (98.3% vs. 86.1%; 
p = 0.028, respectively) as well as shorter length of stay in the ICU (4.2 ± 3.0 vs. 5.7 ± 4.2; 
p = 0.046, respectively).
Conclusions: The intensive glycemic control strategy used in this study was not 
associated with decrease in the incidence of acute kidney injury in patients undergoing 
cardiac surgery also influenced negatively in secondary outcomes.
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One-Year Mortality Follow-Up in Subjects Treated with QPI-1002 at Risk 
of AKI Following Cardiac Surgery (CS)
Lukas J. Lehner,2 U. Schwertschlag,1 D. J. Odenheimer,3 David Corteville,4 
Gabor Szabo,5 Madhav Swaminathan,6 Andre Lamy,7 Matthias Thielmann,8 
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Yuval Mathews,14 D. Rothenstein,15 Elizabeth C. Squiers.13 QRK209 AKI Study 
Group 1Quark Pharmaceuticals, Inc, Fremont, CA; 2Charité Universitätsmedizin 
Berlin, Berlin, Germany; 3Quark Pharmaceuticals, Inc, Fremont, CA; 4McLaren 
Northern Michigan, Petoskey, MI; 5University of Heidelberg, Heidelberg, 
Germany; 6Duke University Medical Center, Durham, NC; 7McMaster 
University, Hamilton, ON, Canada; 8West-German Heart and Vascular Center 
Essen, University Duisburg-Essen, Essen, Germany; 9New Brunswick Heart 
Centre, Saint John, NB, Canada; 10Quark Pharmaceuticals, Inc, Fremont, CA; 
11Quark Pharmaceuticals, Inc, Fremont, CA; 12Quark Pharmaceuticals, Inc, 
Fremont, CA; 13Quark Pharmaceuticals, Inc, Fremont, CA; 14Quark 
Pharmacuticals, Inc, Nes Ziona, Israel; 15Quark Pharmaceuticals, Inc, Nes 
Ziona, Israel.
Background: QPI-1002 (QPI), a siRNA targeting p53, is being developed for 
prevention of Delayed Graft Function (DGF) (NCT#02610296) and for reduction of acute 
kidney injury (AKI) and its consequences following CS. In a large global Phase 2 double-
blind study (N=341: QPI=165, Placebo (PL)=176) (NCT#02610283), QPI reduced the 
incidence, severity and duration of AKI and reduced the proportion of subjects with major 
adverse kidney events (MAKE) at Day 90 as previously reported (ASN 2017 Abstract SA-
OR124).
Methods: For the primary study, deaths were recorded through Day 90 and causes of 
death adjudicated by medical dictionary for regulatory activities (MedDRA) coding in a 
blinded fashion by the medical monitor and safety physician. Longer term mortality was 
collected at Day 365
Results: Deaths: 22/176 subjects receiving PL and 13/165 subjects receiving QPI 
died within 365 Days after receiving study drug (p=0.1713). Causes of death were coded 
to System organ class (SOC): Cardiac Disorders system (3QPI/3 PL), General disorders, 
(1QPI/5 PL), Infectious disorders (4QPI/4PL), Neoplasm (1PL), Nervous system 
disorders (2PL), Respiratory disorders (2QPI/2PL), Metabolism (1QPI), Vascular (1QPI) 
and Not Reported/Unknown(1QPI,5PL). None of the deaths were reported as related to 
study drug. Eighteen subjects (10 PL and 8 QPI) died within 90 days and 17 subjects 
(12 PL and 5 QPI) died between D90 and D365.
Conclusions: The results indicate a survival trend through Day 365 in favor of QPI 
treatment. Additional studies are required to confirm these findings.
Funding: Commercial Support - Quark Pharmaceuticals
FR-OR016 Oral Abstract Friday
AKI: Can We Improve Outcomes?
Mortality Outcomes Related to Acute Declines in eGFR following RAAS 
Inhibition in Patients with Heart Failure
Wendy I. McCallum,1 Hocine Tighiouart,1 Elaine Ku,2 Deeb N. Salem,1 
Mark J. Sarnak.1 1Tufts Medical Center, Boston, MA; 2University of California 
San Francisco Medical Center, San Francisco, CA.
Background: Blockade of the renin-angiotensin-aldosterone system (RAAS) is 
beneficial for cardiovascular outcomes in heart failure with reduced ejection fraction 
(HFrEF). However, it is associated with acute declines in estimated glomerular filtration 
rate (eGFR). Whether the benefit of RAAS inhibition persists for all magnitudes and timing 
of acute declines remains unclear.
Methods: We performed a retrospective analysis of the Studies Of Left Ventricular 
Dysfunction (SOLVD) trial, in which patients with HFrEF were randomized to enalapril 
vs placebo. Multivariable Cox models were used to evaluate the association of % eGFR 
change from baseline to three follow-up time points (2 weeks, 6 weeks, 12 months) with 
mortality. We tested for an interaction between treatment group and % eGFR decline. In 
effort to separate eGFR decline secondary to RAAS inhibition from eGFR decline due to 
other causes, we also calculated the mortality hazard ratios for enalapril and placebo using 
the reference point of 0% eGFR decline on placebo.
Results: Using the 2-week follow-up time point, 6,031 participants were included in 
the analysis (n=3,015 in the enalapril group, n=3,016 in placebo). Compared to placebo, 
enalapril was associated with a lower hazard of mortality at all levels of eGFR decline, 
with no significant interaction between treatment assignment and eGFR decline (Figure 
A). When compared to patients randomized to placebo with 0% eGFR decline, up to 20% 
decline in the enalapril group was still associated with a lower hazard of mortality (Figure 
B). Declines of >20% in placebo had higher hazard of mortality compared to placebo with 
0% decline, but similar declines in the enalapril group were not. Results were consistent 
using the time points of 6 weeks and 12 months.
Conclusions: Enalapril decreases mortality at all levels of eGFR decline when 
compared to placebo. In patients with HFrEF, ACE inhibitors should be continued even if 
there is an acute decline in GFR up to 20%.
Funding: Other NIH Support - T32 grant: 1T32DK07777
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Thrombotic Microangiopathy Frequency in Patients with Atypical HUS: 
Discontinuing vs Remaining on Eculizumab Treatment
Gema Ariceta,6 Gianluigi Ardissino,1 Lisa Sartz,2 Fadi Fakhouri,3 
Christoph Gasteyger,4 Imad Al-Dakkak.5 1Center for HUS Prevention, Control 
and Management, Milano, Italy; 2Skåne University hospital, Lund, Sweden; 
3Centre Hospitalier Universitaire de Nantes, Nantes, France; 4Alexion Pharma 
GmbH, Zurich, Switzerland; 5Alexion, Lexington, MA; 6Hospital Universitari 
Vall d’ Hebron, Barcelona, Spain.
Background: Atypical hemolytic uremic syndrome (aHUS) is characterized by 
thrombotic microangiopathy (TMA). Eculizumab (Ecu), a C5 inhibitor, is the first approved 
treatment for patients (pts) with aHUS. Using data from the Global aHUS Registry, the 
largest database of patients with aHUS, we report TMA rate in pts receiving ongoing Ecu 
vs those who discontinued Ecu.
Methods: Pts enrolled in the non-interventional Global aHUS Registry (NCT01522183) 
up to 1 January, 2018 were included in this study of real-world data. Pts with unknown 
treatment status were excluded from this analysis. Additionally, pts with a cobalamin 
deficiency or diacyl glycerol kinase-ε mutation were excluded from the Ecu treated group. 
Data were stratified according to Ecu treatment status and descriptive statistics on TMA 
rate were calculated.
Results: Of the 1475 pts eligible for this analysis, 532 pts were never treated with 
Ecu and 943 pts were treated with Ecu. Among the latter, 682 pts remained on Ecu 
without discontinuing treatment, 218 pts discontinued Ecu without restarting and 43 pts 
discontinued and restarted Ecu. Overall, pts who remained on Ecu had a lower TMA rate 
than pts who were never treated and pts who discontinued treatment (3.6, 27.5 and 10.7 per 
100 pt-years, respectively; Table).
Conclusions: In this, the largest cohort ever analyzed in a real-world, non-randomized 
setting to address the question of treatment maintenance in aHUS, pts who continued to 
receive Ecu had a substantially lower risk of TMA than those who discontinued or never 
received Ecu.
Funding: Commercial Support - Alexion Pharmaceuticals
Clinical characteristics per eculizumab treatment status
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Dutch Initiative to Improve Therapy and Economize Healthcare in 
Atypical HUS
Kioa L. Wijnsma,1 Caroline Duineveld,2 Jack F. Wetzels,3 Nicole Van De Kar.4 
on behalf of the Dutch national aHUS working group 1Pediatric Nephrology, 
Radboudumc, Radboud Institute for Molecular Life Sciences, Amalia Children’s 
Hospital, Nijmegen, Netherlands; 2Radboudumc, Nijmegen, Netherlands; 
3Radboud University Medical Center, Nijmegen, Netherlands; 4UMC St. 
Radboud Nymegen, Nijmegen, Netherlands.
Background: With the introduction of eculizumab, a new era began for patients 
with atypical hemolytic uremic syndrome (aHUS); a rare but severe form of thrombotic 
microangiopathy (TMA). Although the results were promising, a worldwide debate started 
regarding optimal treatment strategy. Lifelong treatment with this highly expensive orphan 
drug was advised, despite any evidence. In the Netherlands, an unique and challenging 
initiative was undertaken by the national working group aHUS, comprising a delegation 
of (pediatric) nephrologists of all academic hospitals. In 2016, the new Dutch guideline for 
the diagnostics and treatment of aHUS, drafted by this working group, was implemented. 
This guideline advocates a restrictive treatment regimen and is monitored by the national, 
observational, CUREiHUS study. Here we present first preliminary results.
Methods: All known and suspected aHUS patients up till September 2017, were 
discussed in the working group and included. Patients received plasma therapy and/or 
eculizumab following the guideline and therapy was evaluated and tapered when patients 
were stable and in remission. Follow up data were only available from those registered in 
CUREiHUS study.
Results: In total, 69 patients with TMA have been discussed of which 44 new patients 
with TMA. In 27 out of the 44, aHUS was suspected and eculizumab was initiated in 25 
patients. In the remaining 17 patients, other diagnoses explanatory for the TMA were 
present, hence no eculizumab treatment was started. Of the 32 patients included in the 
CUREiHUS study, therapy was adjusted in all. Only 19% of the patients experienced 
recurrence. After rapid initiation of eculizumab, eculizumab therapy was tapered again with 
good clinical outcome. A costs reduction of 55% was accomplished.
Conclusions: The new Dutch guideline on the treatment of aHUS regarding a 
restrictive eculizumab regimen appears safe and effective. Moreover, by critically evaluating 
eculizumab therapy, aHUS treatment can be economized. Although this first annual report 
showed promising results, the majority of patients is within their first year of follow up and 
continuous careful monitoring remains warranted.
FR-OR019 Oral Abstract Friday
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Renal Immune Related Adverse Events in Patients Treated with PD-1 
Inhibitors: An Emerging Complication of Immunotherapy
Ilya Glezerman, Sheron Latcha, Edgar A. Jaimes. Memorial Sloan Kettering 
Cancer Center, New York, NY.
Background: Inhibition of programmed cell death protein 1 (PD-1) immune checkpoint 
pathway activates patient’s immune system, which is responsible for anti-tumor effect but 
may cause unwanted immune-related adverse events (IrAE) including renal effects.
Methods: Retrospective review of cases of acute kidney injury (AKI) or nephrotic 
syndrome while on treatment with PD-1 inhibitors seen at MSKCC between 2012 and 2018. 
Patients concurrently treated with another checkpoint therapy were excluded.
Results: Thirty-one patients were identified and twenty-three met inclusion criteria. 
Eight were male and the average age was 61.7 years. Fourteen patients had a biopsy while 
nine were treated empirically. The mean number of immunotherapy cycles prior to onset of 
AKI was 5.08 (1-14). In the biopsy group (Table 1), thirteen patients had AIN and one had 
membranous glomerulonephropathy (MGN). All had either full or partial recovery of renal 
function. Two patients were re-challenged with PD-1 inhibitors and tolerated 2 and 5 cycles 
respectively accompanied by low dose steroid therapy. One patient was re-challenged 
without corticosteroids and AKI recurred after 10 cycles. One patient with biopsy proven 
AIN received 5 additional cycles without further worsening of renal function. The patient 
with MGN developed a relapse after re-challenge with checkpoint inhibitor but tolerated 
additional 5 cycles with supportive care.
Conclusions: Most patients with renal IrAE developed AIN and all recovered kidney 
function. These patients can be re-challenged with PD-1 inhibitors if clinically indicated 
with concomitant steroid therapy support.
Funding: Other NIH Support - MSK Cancer Center Support Grant/Core Grant (P30 
CA008748)
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Polymyxin Hemoperfusion Shows No Benefits on Kidney Outcomes in 
Severe Sepsis Patients
Somkanya Tungsanga,1 Nuttha Lumlertgul,1 Nicha Thamrongsat,1 
Sadudee Peerapornratana,2 Kriang Tungsanga,1 Nattachai Srisawat.1 1Division of 
Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, 
Thailand; 2Chulalongkorn University, Bangkok, Thailand.
Background: Polymyxin B Hemoperfusion (PMX-HP) has been introduced as one of 
the treatments for sepsis over the past 25 years. Previous randomized control trials (RCT) 
examining the efficacy of PMX-HP reached different conclusions. We aimed to study the 
effect of PMX-HP on kidney outcomes in patients with severe sepsis.
Methods: An RCT was conducted in sepsis patients who were admitted at intensive 
care units and had blood endotoxin activity assay (EAA) level ≥ 0.6. They were randomized 
into 2 groups. The PMX-HP group received standard treatment plus 2-hour PMX-HP for 
2 consecutive days whereas the non PMX-HP group received only standard treatment for 
sepsis. The primary outcome was Major Adverse Kidney Events by 28 days (MAKE28) 
which consisted of mortality, renal replacement therapy (RRT) status, and persistent 
renal dysfunction. Secondary outcomes were the mean or median change in mHLA-DR 
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expression, CD11b expression, neutrophil chemotaxis, cardiovascular sequential organ 
failure assessment (CVS SOFA) score, vasopressor dose, and EAA level between day 3 and 
day 0. Other parameters included serum creatinine on day 7, ICU free days, and ventilator 
free days.
Results: 59 patients were randomized to PMX-HP (n=29) and non PMX-HP (n=30) 
groups. At baseline, clinical and immunologic parameters were comparable between 
groups. The MAKE28 were not significantly different between the two groups, p=1.0. The 
median change in mHLA-DR expression, parameter of monocyte function, was higher in 
PMX-HP patients than in non PMX-HP patients, p=0.027. The mean change in CD11b, 
sparameter of neutrophil activation, was significantly lower in PMX-HP than in non PMX-
HP, p=0.002. There were no significant changes in neutrophil chemotaxis, CVS SOFA 
scores, vasopressor doses, or EAA levels between groups. The serum creatinine on day 7, 
ICU-free days, and ventilator-free days were comparable between groups.
Conclusions: PMX-HP had no benefits on kidney outcomes in severe sepsis patients. 
However, it showed beneficial effects on immunomodulation processes. Whether this 
effects should improve clinical outcomes needs further larger scale clinical trial.
Funding: Commercial Support - Toray provided Polymyxin-B cartridge and endotoxin 
activity assay kits for use in this study. The company had no influenced on the study 
design or analysis or on the comment of this article. None of the other authors have any 
disclosures., Private Foundation Support
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Associations of Tubular Injury, Inflammation, and Repair Biomarkers 
with AKI in the SPRINT Trial
Michelle M. Estrella,2 Alexandra K. Lee,2 Alexander Bullen,1 Vasantha Jotwani,2 
Rakesh Malhotra,1 Chirag R. Parikh,3 Joachim H. Ix,1 Michael Shlipak.2 1UCSD, 
San Diego, CA; 2Kidney Health Research Collaborative, UCSF & VA, San 
Francisco, CA; 3Yale University and VAMC, New Haven, CT.
Background: Randomization to intensive BP treatment (SBP <120 mmHg) in SPRINT 
led to higher AKI risk compared to standard BP treatment (SBP <140 mmHg). Whether a 
greater burden of tubular disease predisposes to AKI has not been well evaluated.
Methods: Among SPRINT participants with CKD (eGFR <60 mL/min|1.73 m2), we 
measured baseline urine levels of tubular injury (NGAL, KIM1 and IL18), inflammation 
(IL18 and MCP1) and repair (YKL40) biomarkers using multiplex panels. Cox proportional 
hazards models were used to examine whether baseline biomarker levels (log2-transformed 
and in quartiles) were independently associated with AKI, defined by hospital discharge 
AKI diagnosis listed within the top three reasons for hospitalization. We examined whether 
treatment arm assignment modified these associations by inclusion of interaction terms.
Results: Among 2412 CKD participants with urine biomarkers, the mean age was 73 
and mean eGFR 45.9 mL/min/1.73m2. A total of 190 AKI events occurred over a median 
3.2 years of follow-up. YKL40, per 2-fold higher, was independently associated with higher 
risk of AKI (HR=1.09; 95% CI: 1.01-1.18). The highest versus lowest YKL40 quartile was 
significantly associated with risk of AKI in adjusted analyses (HR=1.82; 95% CI:1.17-
2.83) (Figure). Treatment arm assignment did not influence this association. In contrast to 
YKL40, biomarkers of tubular injury and inflammation were not significantly associated 
with AKI risk in adjusted analyses.
Conclusions: Higher baseline urine YKL40 levels were associated with higher risk of 
AKI among SPRINT participants with CKD. These results suggest that CKD patients with 
greater activation of tubular repair mechanisms are more vulnerable to AKI.
Funding: NIDDK Support
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Plasma Angiopoietin-2 Concentrations Mediate the Contribution of 
Genetic Variation in the Angiopoietin-2 Gene to Development of AKI 
Sub-Phenotypes
Pavan K. Bhatraju,1,2 Jonathan Himmelfarb,3 Mark M. Wurfel.1 1University of 
Washington, Seattle, WA; 2Kidney Research Institute, University of Washington, 
Seattle, WA; 3Kidney Research Institute, Seattle, WA.
Background: Plasma angiopoietins 1 (Ang-1) and 2 (Ang-2), markers of endothelial 
stability and dysfunction, have been implicated in the development of acute kidney injury 
(AKI). Using latent class analysis, we previously identified two AKI sub-phenotypes (AKI-
SP1 and AKI-SP2). Critically ill subjects classified as AKI-SP2 had worse clinical outcomes 
and higher markers of endothelial dsyfuntion (high Ang-2 and low Ang-1) compared to 
AKI-SP1 (low Ang-2 and high Ang-1). It is unknown whether Ang-1 and 2 are markers of 
disease or act as a causal mediator in the development of AKI sub-phenotypes.
Methods: A targeted genetic study was performed to identify SNPs within 50 kb of the 
Angiopoietin 1 (ANGPT1) and Angiopoietin 2 (ANGPT2) genes associated with AKI- SP2 
in 452 AKI subjects from the iSPAAR cohort. Association testing was performed on 190 
SNPs. Causal inference analysis was used to determine the role of genetic variation and 
circulating angiopioetins in the development of AKI-SP2.
Results: An intronic SNP, rs2920656, near the ANGPT2 gene (≈ 30kb downstream to 
the 3’ position) was associated with reduced risk of AKI-SP2 (Bonferroni, p=0.003) and 
decreased Ang-2 concentrations (p=0.002) adjusting for age, gender, sepsis and 5 principal 
components of ancestry. Causal inference analysis indicated that the total effect of the SNP 
(rs2920656) on AKI-SP2 was Beta = -0.16 (95% CI -0.23 to -0.09, p=1.0 x 10-4) and the 
indirect effect was Beta = -0.07 (95% CI -0.11, -0.03, p=0.001). This suggests that for each 
minor allele (T allele) of the genetic variant the risk of developing AKI-SP2 decreases by 
16%. When comparing the total effect to the indirect effect through a mediation analysis, 
42% of the SNP’s prognostic effect was mediated through Ang-2 plasma concentrations 
(Figure 1).
Conclusions: Our findings support the importance of ANGPT2 in AKI pathophysiology 
by mediating plasma Ang-2 levels.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Impact of Kinetic Glomerular Filtration Rate Estimation on Medication 
Dosing in AKI
Yuenting D. Kwong,1 Sheldon Chen,2 Kathleen D. Liu.1 1University of California 
at San Francisco School of Medicine, San Francisco, CA; 2MD Anderson, 
Houston, TX.
Background: Medication dosing during acute kidney injury (AKI) is often based on 
Cockcroft-Gault (CG) creatinine clearance (CrCl) or estimated glomerular filtration rate 
(eGFR) equations (Dowling et al, Pharmacotherapy 2010). However, these equations are 
not valid in AKI as serum creatinine (SCr) is not in steady state. A kinetic estimate of CrCl 
or eGFR (keGFR) may be a more accurate method of estimating renal function. The aim of 
this study was to determine the impact of using kinetic estimates of renal function on drug 
dosing in critically ill patients with fluctuating SCrs.
Methods: We used data from subjects in the NIH ARDS Network Fluid and Catheters 
Treatment Trial (Wiedemann et al, NEJM 2006) with more than 2 serial SCrs. SCrs post-
dialysis initiation were censored. Daily renal function was calculated using the 1)CG CrCl 
2)MDRD and 3)CKD-EPI equations. Kinetic estimates of each formula were calculated
using: [Steady State or baseline SCr X CrCl or eGFR/mean SCr at 2 time points]X(1-
[(24XΔScr)/(ΔTime (h) X MaxΔSCr/day)]. We evaluated the frequency with which the 
kinetic estimate of each formula changed medication dosing categories (≥60, 30-59, 15-29, 
and <15mL/min) compared with the use of CG CrCl, eGFRMDRD, or eGFRCKD-EPI.
Results: Among 947 subjects, 46.0%, 28.5% and 30.0% of the population required 
recategorization of the dosing category if the kinetic estimate was used instead of CG CrCl, 
eGFRMDRD, and eGFRCKD-EPI , respectively. Recategorization occurred more in those with 
AKI by AKIN criteria. If CG CrCl was adjusted using the kinetic counterpart, 62.8% of 
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those with AKI would change dosing categories, compared to 25.6% of patients without 
AKI.
Conclusions: In a critically ill population, use of kinetic estimates of renal function 
would change medication dosing in the majority of subjects with AKI on at least one 
calendar day. Further studies will be needed to test whether use of keGFR in clinical 
practice would lower the incidence of medication toxicity and avoid subtherapeutic dosing 
during renal recovery.
Funding: Other NIH Support - T32-DK007219-41
Subjects requiring recategorization using kinetic estimates within 7 days of Acute 
Respiratory Distress Syndrome
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Variable Economic Impacts of Clinical Decision Support Algorithms That 
Predict AKI among Postoperative Patients: A Nationwide Analysis
Felix K. Chang,1,4 Allan D. Kirk,2 Timothy G. Buchman,3 Eric Elster.1 
1Uniformed Services University of the Health Sciences and the Walter Reed 
National Military Medical Center, Bethesda, MD; 2Duke University School of 
Medicine, Durham, NC; 3Emory University, Atlanta, GA; 4DecisionQ, Arlington, 
VA.
Background: New clinical decision support (CDS) algorithms are being developed 
to predict the likelihood of AKI among patients who undergo operative treatment. 
Conceptually those predictions enable early prophylactic interventions that could prevent 
AKI and thereby avoid its adverse health effects and associated treatment costs. We 
sought to assess (1) how accurate such CDS algorithms and (2) how effective their paired 
prophylaxes would have to be to yield a net positive economic impact.
Methods: We searched the 2014 National Inpatient Sample using ICD-9 codes to 
identify patients ≥18 years old with one or more operative treatments. We combined our 
findings with data on the incidences and treatment costs of AKI at three RIFLE classification 
stages. We then performed a sensitivity analysis of the costs associated with the use of 
CDS algorithms designed to predict AKI-R, AKI-I, and AKI-F in concert with their paired 
prophylaxes.
Results: We found that CDS algorithms designed to predict AKI-R yielded greater 
net economic benefits than those designed to predict AKI-I or AKI-F. With an algorithm 
accuracy of 0.75 and a prophylaxis effectiveness of 0.50, an AKI-R CDS algorithm 
could create an annual nationwide benefit of $11.6 billion, whereas AKI-I and AKI-F 
CDS algorithms could create benefits of only $8.3 billion and $4.7 billion, respectively. 
(Figure.) The area under each curve represents the combinations of algorithm accuracy 
and prophylaxis effectiveness that would produce a net economic benefit for each CDS 
algorithm.
Conclusions: Our study revealed that lower incidences of AKI-I and AKI-F relative 
to AKI-R in postoperative patients would likely result in higher false positive rates among 
CDS algorithms focused on AKI-I and AKI-F. Those higher rates, when combined with 
likely higher prophylaxis costs to treat potential AKI-I and AKI-F patients, add new costs 
that, in many cases, overwhelm the costs avoided through early intervention. Barring more 
effective AKI prophylaxes, future development of AKI-related CDS algorithms should 
focus on the prediction of AKI-R.
Funding: Other U.S. Government Support
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Defining Kidney Dysfunction in the Community Setting: The ISN 0by25 
Initiative
Etienne Macedo,6 Sanjib Kumar Sharma,1 Ulla Hemmila,7 Rolando Claure-Del 
Granado,5 Bhupendra Shah,1 Henry E. Mzinganjira,8 Jorge Cerda,2 
Emmanuel A. Burdmann,3 Michael V. Rocco,4 Ravindra L. Mehta.6 ISN 0by25 
1B.P.Koirala Institute of Health Sciences, Dharan, Nepal; 2Capital District 
Renal Physicians, Albany, NY; 3University of Sao Paulo Medical School, Sao 
Paulo, Brazil; 4Wake Forest School of Medicine, Winston-Salem, NC; 5Hospital 
Obrero #2 Universidad Mayor de San Simon, Zona Sarco, Bolivia, Plurinational 
State of; 6University of California San Diego Medical Center, La Jolla, CA; 
7College of Medicine, Malawi, Kokemäki, Finland; 8MOH, Blantyre, Malawi.
Background: Community-acquired acute kidney injury (AKI) is common, but often 
unrecognized in resource-constrained settings. Limited lab assessments and unavailable 
informationon the prior state of kidney health contribute to this lack of recognition. In this 
study, we evaluated the efficacy of point of care (POC) serum creatinine (sCr) and urine 
dipstick tests to identify patients with kidney dysfunction at presentation to community 
health centres (CHC) and emergency departments (ED), as part of the International Society 
of Nephrology (ISN) 0by25 Pilot Feasibility Project.
Methods: Patients (pts) presenting at CHC or ED with signs or symptoms associated 
with high/moderate risk of developing AKI underwent sCr POC test and urine dipstick. 
At enrollment, pts were classified as chronic kidney disease (CKD) based on prior 
history, proteinuria(>1+) and/or baseline sCr within 12 mos by estimated GFR (CKD-
EPI equation)) <60 mL/min/1.73 m2; normal renal function (NRF) (no proteinuria and 
eGFR>75ml/min/1.73 m2); and Acute Kidney Disease (AKD) neither meeting criteria for 
CKD or NRF. AKI was confirmed within 7days by sCr increase or decrease of 0.3 mg/dl 
or 1.5x from the enrollment value. Pt outcomes: progression of AKI, need for RRT, 
hospitalization, mortality and renal functional recovery, were assessed at 7days and 1, 3 
and 6 mos.
Results: 3577pts were screened, 2101enrolled; 91%adults, 9%children. At enrollment, 
9% were CKD and 66% AKD. At 7 days, 30% of pts fulfilled criteria for AKI: 67 from NRF 
(13%), AKD 470 (33%) and CKD 91 (46%). Overall mortality rate was 7.4% at 7 days and 
increased to 13% at 6 months. In comparison to NRF, AKD and CKD patients had higher 
mortality at 7 days and follow up, and the development of AKI trended for higher mortality 
in both AKD and CKD groups. Of 434 patients with 3 months sCr follow up, new onset 
CKD was encountered in 40(26%) of AKD and 54(33%) of AKI patients. Of patients dying 
from CKD and AKD groups, non-provision of dialysis occurred in 31 (11%).
Conclusions: Kidney dysfunction is common in CHC and is associated with adverse 
outcomes. POC tests can identify patients with AKD and CKD at increased risk for AKI, 
progression of CKD and mortality. Early implementation of targeted interventions may help 
improve outcomes.
Funding: Private Foundation Support
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Epidemiology of Pediatric AKI in a Nationally-Representative Cohort of 
American Children
Erica C. Bjornstad,3,1 Amy K. Mottl,3 Keisha L. Gibson,3 Steve Marshall,1 
Yvonne Golightly,1 Anthony Charles,2 Emily Gower.1 1Epidemiology, UNC 
Gillings School of Public Health, Chapel Hill, NC; 2University of North 
Carolina at Chapel Hill, Chapel Hill, NC; 3University of North Carolina Kidney 
Center, Chapel Hill, NC.
Background: Acute kidney injury (AKI) significantly increases morbidity and 
mortality for hospitalized children. However, few studies have evaluated the relationship 
between race/ethnicity, socioeconomic status (SES) and pediatric AKI. We proposed to 
evaluate those relationships with the outcome of AKI in a national pediatric cohort.
Methods: The Kids’ Inpatient Database, developed by the Agency for Healthcare 
Research and Quality’s Hospital Care and Utilization Program, is a nationally representative 
database of pediatric discharges from >4100 community hospitals throughout the United 
States. We conducted a secondary analysis of the most recent data (2012) to assess for 
racial disparities and socioeconomic differences in the development of pediatric AKI (age 
1-20 years) using weighted sampling methods to obtain national estimates. We used logistic 
regression to assess the relationship between race/ethnicity and SES and the development of 
AKI, adjusting for comorbidities. SES was defined using three variables: type of insurance 
(private, Medicaid, other, no insurance), median household income of a patient’s zip code 
in quartiles, and urbanization of patient’s home address.
Results: In 2012, approximately 1.2% of all pediatric hospitalizations had an AKI 
episode, which is a national estimate of almost 30,000 children. After adjusting for chronic 
illnesses, African American children (Risk difference (RD) 0.00139, 95% CI 0.00064-
0.00214) and Asian American children (RD 0.00323, 95% CI 0.00167-0.00478) were at an 
increased risk for AKI compared to Caucasian children. Children without insurance were 
more likely to have an episode of AKI compared to those with any form of insurance (e.g., 
Medicaid versus no insurance has RD of -0.014 with 95% CI -0.016 to -0.012). Based on 
these data, we estimate that one episode of AKI could be prevented if 73 children currently 
hospitalized without insurance were provided with Medicaid. No significant differences 
were seen based on urbanization or median household income.
Conclusions: AKI occurs more frequently in African American and Asian American 
children compared to Caucasian children. However, the most protective aspect prior to 
hospitalization is having insurance, regardless of race/ethnicity and type of insurance.
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Reduction in Nephrotoxic Antimicrobial Exposure Decreases Associated 
AKI in Pediatric Hematopoietic Stem Cell Transplant Patients (HSCT)
Stefanie W. Benoit, Stuart Goldstein, Devesh S. Dahale, David B. Haslam, 
Adam Nelson, Kori Truono, Stella M. Davies. Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH.
Background: Exposure to nephrotoxic medications (NTMx) is a common risk factor 
for AKI. Quality improvement work in antimicrobial stewardship and NTMx-associated 
AKI (NAKI) reduction took place at Cincinnati Children’s Hospital from 2013 to 2018. We 
hypothesized that choosing less nephrotoxic antimicrobial medications for HSCT patients 
would be associated with lower NAKI rates and no increase in treatment failures.
Methods: We used data from a prospective NAKI monitoring system within our 
electronic health record. AKI days and severity were extracted for patients exposed to 3+ 
NTMx or 3+ days of IV aminoglycosides (AG). AKI was defined using KDIGO creatinine 
criteria. We assessed rates of NTMx exposure and NAKI in all HSCT inpatients from 
09/2013 to 03/2018. The percent of repeat positive cultures was used to capture treatment 
failures. Data were grouped and analyzed by calendar month.
Results: The HSCT division changed frontline fever treatment from piperacillin-
tazobactam (pip-tazo) to cefipime, and AG use was limited. Cidofovir use decreased with 
availability of brincidofovir and antiviral cytotoxic T-lymphocytes. There were no other 
major changes in supportive care practices. Rates of NTMx exposure, NAKI, and percent of 
repeat positive cultures all decreased, as shown in Table 1. Mean rates of all stages of NAKI 
decreased >50% after 01/2016, which coincided with the divisional change from pip-tazo 
to cefipime. Rates of NAKI have since remained stable.
Conclusions: Reduction of nephrotoxic antimicrobial exposure may decrease the 
amount and severity of NAKI in HSCT patients without an increase in treatment failures.
Change in Rate of NTMx Exposure, Associated AKI, and Repeat Positive Cultures.
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Damage to the Mesangium Mediates the Loss of Podocytes in Glomerular 
Hypertension
Wilhelm Kriz,1 Hermann-Josef Groene.2 1Neuroanatomy, Medical Faculty 
Mannheim, University Heidelberg, Mannheim, Germany; 2German Cancer 
Research Center, Heidelberg, Germany.
Background: Glomerular hypertension damages the glomerulus leading to progressive 
glomerular disease. It is widely believed that increased perfusion pressure exposes the tuft 
to increased tensile stress challenging the adhesion of podocytes to the GBM favouring 
their detachment. This hypothesis has been based on the view that podocyte foot processes, 
like pericyte processes, actively counteract the pressure-driven expansion of the GBM and 
fail in hypertension. Recent findings have compromised this view. Instead, counteraction 
of tensile stress to the filtration barrier seems to be almost exclusively performed by the 
GBM. The GBM displays a non-linear elasticity (Janmey and Tyler Miller 2011, J Cell Sci 
124:9) meaning that its distensibility progressively decreases with increasing distension and 
finally reaches a limit. Thus, the expansion of a glomerular capillary and thus the expansile 
challenge to podocytes have an upper limit (Kriz and Lemley 2017, Ped.Nephrol 32:405). 
Podocytes are protected from any unphysiological pressure rises by the GBM.
Methods: High resolutiion light microscopy and transmission electron microscopy.
Results: In hypertensive models and in biopsies from patients with nephrosclerosis 
local disruptions of mesangial cell GBM connections are a common finding. They are 
consistently associated with expansions of mesangial spaces and bulging capillaries. 
These changes have been described in many previous studies. However, the danger that 
results from such local derangements of the tuft architecture to podocytes has never been 
adequately recognized. Here we show that such changes are topographically correlated 
with centrifugal displacements of capillary loops and corresponding podocytes. Depending 
on the location of the mesangial damage this may lead to a prolapse of podocytes into 
the urinary orifice with subsequent detachment of podocytes into the urine or to contacts 
with the parietal epithelium. Such contacts may initiate the formation of a tuft adhesion at 
any site of the tuft circumference, thus the committed lesion to develop focal segmental 
sclerosis (FSGS).
Conclusions: A combined failure of mesangial cells and podocytes underlies the 
development of FSGS in hypertensive glomerular diseases. The same dependence of a 
podocyte damage on a preceding mesangial failure is also seen in glomerular diseases, in 
which mesangial-cell-GBM-connections are directly damaged.
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A New Spheroid Model of the Glomerulus
Jack P. Tuffin,1 Gavin I. Welsh,1 Timothy S. Johnson,3 Simon C. Satchell,1 
Rachel Lennon,2 Salman Hosawi,4 Moin Saleem.1 1University of Bristol, Bristol, 
United Kingdom; 2University of Manchester, Manchester, United Kingdom; 
3Sheffield kidney Institute, University of Sheffield, Sheffield, United Kingdom; 
4King Abdulaziz University, Manchester, United Kingdom.
Background: 2D models of glomerular cells are limited in their ability to recreate 
accurate morphology and protein expression. The purpose of this project was to produce a 
3D co-culture of conditionally immortalised human podocytes and glomerular endothelial 
cells (GEnCs), more translationally representative of glomerular health and disease for 
medium-throughput pharmaceutical compound screening.
Methods: Magnetic spheroid bio-printing was used to assemble podocytes and GEnCs 
into organised 3D structures. Fluorescence IHC techniques were used to stain and samples 
were imaged using confocal, lightsheet and transmission electron microscopy. Western 
blotting, mass spectrometry-based proteomics and transcriptomics techniques were applied.
Results: Podocytes and GEnCs in spheroid co-culture self-assembled into a 
glomerulus-like structure, whereby peripheral podocytes wrapped a core of endothelial 
cells. An organised layer of extracellular matrix formed between the two cell types. A 
combination of TGFβ and adriamycin caused significant podocyte effacement. TGFβ alone 
was sufficient to induce a significant increase in expression of the GBM protein collagen 
IV. Incubation with an antifibrotic compound (Nintedanib) significantly reduced both of 
these effects.
Conclusions: An in-vitro spheroid model demonstrating two key aspects of 
glomerulosclerosis (foot-process effacement and matrix dysregulation) has been developed. 
This model is more physiologically relevant than 2D cultures, whilst being reproducible 
and scalable.
Funding: Commercial Support - UCB pharma, Government Support - Non-U.S.
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Cellular Crosstalk in Glomerular Diseases
Macula Densa Cells Orchestrate Podocyte Neogenesis
Georgina Gyarmati, Urvi nikhil Shroff, Anne Riquier-brison, Ina M. Schiessl, 
Janos Peti-Peterdi. University of Southern California, Los Angeles, CA.
Background: The recruitment of new podocytes from precursor cells including parietal 
epithelial cells (PECs) and cells of the renin lineage (CoRL) in response to glomerular 
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injury has been established, however the mechanism remains elusive. Here we tested the 
hypothesis that macula densa (MD) cells localized at the glomerular entrance are master 
organizers of glomerular remodeling, and can be stimulated to recruit new podocytes in 
the adult kidney.
Methods: Intravital multiphoton imaging (MPM) in genetic mouse models was 
performed to track the fate and migration pattern of mesenchymal and endothelial 
precursor cells. RNA seq and gene profiling was used to establish and analyze the gene 
profile of MD cells under control and stimulating conditions. Immunohistochemistry for 
podocyte, mesenchymal, and endothelial precursor cell markers p57, WT-1, and CD34 were 
performed in kidney sections of control WT mice and in a new genetic model of inducible 
MD-specific Wnt gain-of-function (gof).
Results: MPM provided “smoking gun” direct visual evidence for the migration of
single CoRL from the PEC layer to the glomerular tuft (sometimes within 15 s) in the 
intact mouse kidney. The newly established, exclusively MD-specific secretome includes 
several angiogenic, patterning, growth factor, and extracellular matrix remodeling peptides 
including Pappa2, Ccn1, Cxcl14, Wnt10a, Sema3c, Bmp3, Egfl6, Fgf9, Vegfd, Pdgfc, 
Frem1, etc. In MD-Wnt(gof) mice, glomerular size and podocyte number increased from 
control 17±3 to 24±3 per unit glomerular volume within 5 weeks. MD-Wnt gof also 
developed a WT-1+ cell niche at the MD base/extraglomerular mesangium transitioning 
into the Bowman’s capsule, and a CD34+ endothelial precursor cell niche at the glomerular 
vascular pole. Treatment of Ren1d-Confetti mice with GSK3b inhibitors for only 5 days 
caused a 3-fold increase in the density of CoRL at the glomerular vascular pole and in 
PEC layer.
Conclusions: These results suggest that MD cells are central players in the 
physiological remodeling of the glomerulus via Wnt signaling and secreted paracrine 
factors, that act on the mesenchymal-to-epithelial transition of glomerular precursor cells 
to become new podocytes. MD cells also stimulate angiogenesis simultaneously. This 
new mechanism protects from glomerular injury when augmented, and may be developed 
further to specifically treat glomerular diseases.
Funding: NIDDK Support
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Glomerular Filtrate Promotes Cell Detachment in Podocyte Injury
Nobuyuki Saga,1 Naoko Ito,1 Kazuo Sakamoto,1 Taiji Matsusaka,2 
Michio Nagata.1 1University of Tsukuba, Tsukuba, Japan; 2Tokai University 
School of Medicine, Isehara, Japan.
Background: Podocyte detachment is a hallmark of segmental glomerulosclerosis. 
Although glomerular filtrate may effectively drive cell detachment, it alone is insufficient 
and needs presumptive structural changes in filtration surface. We analyzed structural 
background that synergistically drives podocyte detachment in NEP25, a mouse model of 
uniform podocyte injury.
Methods: Whole glomerular profiles (73 glomeruli, n=6) in NEP25 mice with LMB2 
(8-10 days) were photographed by TEM. Entire GBM in all glomeruli were classified into 
normal, foot process effacement (FPE) or detachment and each length per glomerulus was 
measured. This method enabled us to identify the localization and continuity of each change 
within the glomerulus. UUO was performed at day 5 in the above protocol (UUO model, 
n=3) to identify the effect of filtrate on detachment. Using multiphoton microscopy (MPM), 
decreased filtration by UUO was visualized. Glomeruli in UUO model were analyzed by 
TEM in the same way as above.
Results: Detachment occurred only in the glomeruli with >50% FPE lesions. The 
length of detachment correlated with the length of FPE. Detachment was more in deep 
cortex than in surface and tended to occur in limited to 1 to 2 local areas within each 
glomerulus. In examining 43 glomeruli with both vascular and urinary poles, detachment 
dominantly occurred at the side of urinary pole. Contralateral kidneys of UUO model had 
severe podocyte detachment, which also occurred dominantly at the urinary pole side 
(n=61). Filtration effectively decreased in the obstructed kidneys of UUO by MPM and 
these glomeruli completely lacked podocyte detachment, despite diffuse FPE by TEM 
(n=55). Podocyte pseudocysts were observed in the contralateral kidneys but rarely in the 
obstructed kidneys of UUO model.
Conclusions: 1) Podocyte detachment may be caused by synergistic effects of 
podocyte changes, such as FPE, with hydrostatic forces by filtrate. Biological changes in 
podocyte that occur in “grouping” may be an additional background. 2) From the fact that 
the frequency and the length of detachment positively correlated with the extent of FPE and 
pseudocyst, the cell reaction to strengthen cell-GBM and cell-cell attachment is also a basis 
for podocyte detachment.
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Promotion of β-Catenin/Foxo Protects against Kidney Fibrosis
David C. Harris,1,5 Padmashree Rao,1 Titi Chen,1 Hong Yu,1 Min Hu,1 Qi Cao,1 
Yiping Wang,1 Chow H. P’ng,2 Brian J. Nankivell,3 Vincent W. Lee,1,3 
Stephen I. Alexander,4 Guoping Zheng.1 1Centre for Transplantation and Renal 
Research, Westmead Institute for Medical Research at University of Sydney, 
Westmead, NSW, Australia; 2ICPMR, Westmead Hospital, Department of Tissue 
Pathology and Diagnostic Oncology, Westmead, NSW, Australia; 3Westmead 
Hospital, Westmead, NSW, Australia; 4Centre for Kidney Research, Children?s 
Hospital at Westmead., Westmead, NSW, Australia; 5Sydney Medical School - 
University of Sydney, Duffys Forest, NSW, Australia.
Background: Transforming growth factor β (TGF-β) is the key cytokine in 
the development of fibrosis. The conflicting roles of TGF-β (profibrotic versus anti-
inflammatory) create a dilemma in the treatment of kidney fibrosis. β-catenin/TCF is 
central to various TGF-β’s profibrotic signaling pathways in fibrosis. β-catenin also binds to 
Foxo in competition with TCF and leads to cell cycle arrest, promoting cell survival under 
oxidative stress. We propose that promoting β-catenin/Foxo will protect against β-catenin/
TCF-mediated profibrotic changes and kidney fibrosis.
Methods: Kidney biopsies of patients with chronic kidney disease (CKD) or a kidney 
transplant were assessed by Proximity Ligation Assay (PLA) for β-catenin/Foxo and β-
catenin/TCF interactions in relation to kidney fibrosis. Murine proximal tubular epithelial 
C1.1 cells were treated with TGF-β1 (3ng/ml) with or without ICG-001 (5μM), which 
inhibits β-catenin/TCF. CRISPR/Cas9 gene technology was used to knockout Foxo1 or 
TCF1. We also evaluated kidney fibrosis in murine unilateral ureteric obstruction (UUO). 
β-catenin/Foxo and β-catenin/TCF interactions were examined by co-immunoprecipitation 
(co-IP) and PLA. Profibrotic gene expressions were examined by western blot and 
immunofluorescence.
Results: PLA of CKD and kidney transplant patient biopsies showed that β-catenin/
Foxo correlated negatively (r=-0.7405, P<0.001) and β-catenin/TCF positively (r=0.8061, 
P<0.001) with kidney fibrosis. TGF-β1 and ICG-001 treatment in C1.1 cells protected 
against TGF-β1-induced profibrotic gene expression while the protection was absent in 
Foxo1 KO C1.1 cells. Combined treatment with TGF-β1 and ICG-001 in C1.1 cells showed 
direct evidence for the promotion of β-catenin/Foxo by PLA and co-IP. UUO mice treated 
with TGF-β1 and ICG-001 had significantly reduced kidney fibrosis, via promotion of β-
catenin/Foxo interaction as shown by PLA.
Conclusions: β-catenin/Foxo protects against TGF-β’s profibrotic activity and thereby 
prevents kidney fibrosis.
Funding: Government Support - Non-U.S.
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An APOL1-Induced FSGS Mouse Model That Mimics Human FSGS 
Nephropathy
Avi Z. Rosenberg,3 Hila Roshanravan,1 Marco Delsante,4 Maarten Hoek,2 
Myung Shin,5 Jeffrey B. Kopp.1 1NIDDK, NIH, San Jose, CA; 2Third Rock 
Ventures, Redwood City, CA; 3Johns Hopkins University, Baltimore, MD; 
4Universita’ degli Studi di Parma, Baltimore, MD; 5Merck & Co., Inc, 
Kenilworth, NJ.
Background: In the present study, the we aimed to develop a CKD model in mice 
expressing apolipoprotein L1 (APO1) in order to generate a robust, reproducible model of 
APOL1 nephropathy. As reported, a bacterial artificial chromosome (BAC) that contains 
either the human APOL1 gene (BAC-APOL1 G0) or each of the renal risk variants (BAC-
APOL1-G1 and -G2) were used to generate transgenic mice that constitutively expressed 
APOL1. At baseline, BAC-APOL1 G0, G1, and G2 mice had no renal phenotype despite 
genetic risk in the latter lines; therefore, we induced hypertension as second hit.
Methods: We used a combination of Saline drinking water, Angiotensin II infusion, 
uniNephrectomy and Deoxycorticosterone acetate pellets (SAND model)
Results: After 3 weeks, mice developed albuminuria (G0, 2205 ± 84 mg/g, G1, 3840 ± 
363 mg/g, G2 3447 ± 111 mg/g, and wild type, 2085 ± 202 mg/g) and uremia, with elevated 
blood urea nitrogen (BUN). SAND intervention in G1 and G2 mice led to reduced cortical 
thickness and podocyte number compared to G0 mice. SAND G1 and G2 mouse kidneys 
showed focal global and segmental glomerulosclerosis (FSGS), as well as glomerular lipid 
accumulation by oil red O staining. Differentially expressed genes in kidney cortex were 
identified based on log2 fold change and false discovery rate (FDR) of <0.05. In SAND 
G1 mice Aoc1, C1q, Ncam1, Scamp1, and Tbca were downregulated and Hmgcs2 was 
upregulated compared to G0 mice. We examined expression of 60 FSGS-related genes, 64 
cytokines, 63 cytokine receptors, 52 chemokines and 33 chemokine receptors in order to 
identify additional differentially-expressed genes in G1 and G2 mice, using a cutoff of log2 
fold change of <0.05. Ccrl2 was shown to be upregulated in G1 and G2 transgenic mice 
compared to WT and APOL1-G0 mice
Conclusions: In summary, we have shown that with the SAND model of hypertensive 
nephropathy, BAC-APOL1 G1 and G2 mice manifest more severe proteinuria, FSGS, and 
distinct patterns of gene expression.
Funding: NIDDK Support
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PTEN/YAP Mediated Lipid-Accumulation in Podocytes Contributes to 
Glomerulosclerosis
Huizhen Wang, Yangyang Zuo, Jianteng Xie, Jing Li, Tiantian Liang, 
Yanhui Wang, Yifan Zhang, Wenjian Wang. Division of Nephrology, Guangdong 
General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 
China.
Background: The pathogenetic mechanism of focal segmental glomerulosclerosis 
(FSGS) are largely unknown. Here, we showed that phosphatase and tensin homolog 
(PTEN) was down-regulated in foamy podocytes in patients with FSGS, however, whether 
PTEN involves in accumulation of lipid in podocytes and contributes to glomerulosclerosis 
is undefined.
Methods: PTEN knockout and podocyte-specific PTEN knock-in mice were 
established.
Results: We revealed that partially deletion of PTEN increased the lipids accumulation 
in glomeruli segmentally, and boosted albuminuria and glomerulosclerosis. Conversely, 
podocyte-specific overexpression of PTEN demonstrated a marked alleviation of lipid-
retention in podocytes, serum creatinine, UACR, and characteristics of glomerulosclerosis. 
In vitro, PTEN was found down-regulated in cultured podocytes stimulated with ox-LDL. 
Forced expression of PTEN reduced ox-LDL influx via down-regulating scavenger receptor 
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A (SR-A), decreasing intracellular cholesterol content, and thus prevented podocytes from 
lipid loading. In contrast, inhibition of PTEN exhibited aggravated podocytes damage by 
more lipid accumulation. The lipid retention in ox-LDL treated podocytes was mainly 
attributed to the lipid uptaking other than lipid effusion or synthesis. Mechanistically, we 
identified PTEN as a regulator of SR-A by dephosphorylating its nuclear transcription factor, 
yes-associated protein (YAP), at Ser127 in the cytoplasm of ox-LDL treated podocytes.
Conclusions: These findings implicate a central role of PTEN in a signaling cascade 
that regulates podocytes lipid-loading which contributes to the glomerulosclerosis, and 
provide evidence for PTEN as a target for HFD-induced FSGS therapy.
Knockout of PTEN aggravated renal lipid accumulation and glomerulosclerosis in 
FSGS mice.
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The Role of HDAC Activation in Proteinuric Kidney Disease Progression 
in Mice and Humans
Kazunori Inoue, Chirag R. Parikh, Francis P. Wilson, Shuta Ishibe. Yale 
University School of Medicine, New Haven, CT.
Background: As the incidence and prevalence of End Stage Kidney Disease due to 
proteinuric diseases continue to rise, alternative novel therapies are required.
Methods: An adult-onset proteinuric disease model was generated using doxycycline 
(DOX)-induced podocyte specific Talin1 knockout (iTln1 KO) mice. Our findings were 
validated using podocyte specific germline Dynamin1 and 2 KO (Dnm DKO) and Tln1 
KO mice treated with 2 different histone deacetylase (HDAC) inhibitors (valproic acid 
(VPA) and vorinostat (SAHA)). We generated DOX-induced podocyte specific Hdac1 and 
2 KO or early growth response 1 (Egr1) KO mice. Microarray was performed from isolated 
glomeruli in control and the iTln1 KO mice +/- VPA to unearth differentially expressed 
genes (DEGs). HDAC1 and 2 activities were measured using an activity assay kit. For 
in-vitro podocyte injury models, lipopolysaccharide (LPS) or protamine sulfate (PS) were 
used. Observational data in patients on VPA in the Veterans Aging Cohort Study (VACS) 
was analyzed for estimated glomerular filtration rate (eGFR).
Results: Using Connectivity Map database and Drug Pair Seeker, Hdac1 and 2 genes 
and HDAC inhibitors were identified as potential targets regulating or reversing the 188 
DEGs in control vs iTln1 KO mice glomeruli. Deletion of podocyte Hdac1 and 2, in iTln1 
KO mice where podocyte HDAC1 and 2 are activated, and treatment with VPA, or SAHA 
ameliorated progression of proteinuria and kidney failure in these mice. VPA also improved 
survival in Dnm DKO and Tln1 KO mice that die from kidney failure (Dnm DKO:35 
(median survival (days)), Dnm DKO+VPA:77.5, Tln1 KO:30.5, and Tln1 KO+VPA:64). 
From our RNA profiling data, we also identified Egr1 as a potential VPA regulated target. 
Loss of Egr1 in iTln1 KO mice mitigated proteinuria and kidney failure (control:0.11 
+/- 0.02 (plasma creatinine (mg/dl)), iTln1 KO:0.35 +/- 0.02, Egr1, iTln1 DKO:0.19 +/- 
0.02). Egr1 KO podocytes stabilized the actin cytoskeleton following LPS or PS in vitro. 
Longitudinal analysis of VACS revealed reduction in the mean annual eGFR loss among 
those receiving VPA (-0.48 (ml/year) in VPA user vs -1.10 in non VPA user).
Conclusions: Our results demonstrate inhibition of HDAC1 and 2 activation not 
only improved proteinuric mice models but also suggests a novel therapeutic strategy in 
progressive proteinuric human kidney diseases.
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Induced Endothelial Expression of Podocyte Specific Retinoic Acid 
Receptor Responder 1 (Rarres1) in Glomerular Nephritis (GN) Acceler-
ates Renal Injury
Katja Möller-Hackbarth, Dina Dabaghie, Emmanuelle Charrin, Jaakko Patrakka. 
Karolinska Institutet, Sweden, Huddinge, Sweden.
Background: Glomerular damage, including endothelial dysfunction and podocyte 
loss, plays an important role in the pathogenesis of diabetic nephropathy (DN). Pathogenesis 
of microvascular damage in the disease is still poorly understood. High throughput 
molecular profiling (RNA seq.) identified Rarres1 as a highly podocyte specific protein, that 
is consistently up-regulated in kidney tissue of DN patients.
Methods: To identify cellular localization of Rarres1, we analysed the expression in 
human healthy and DN kidneys using immunohistochemical methods and RNA in situ 
hybridization. In vitro, we over/underexpress Rarres1 in human podocytes to investigate 
its functional role. In vivo, we generated two novel transgenic mouse lines, enabling cell-
specific inactivation and overexpression of Rarres1. We induced crescentic GN model by 
anti-glomerular basement membrane (anti-GBM) antibodies in podocyte specific knock-out 
(KO) and endothelial cell (EC) specific knock-in (KI) mice for Rarres1.
Results: In healthy kidney, Rarres1 is specifically expressed by podocytes and not 
by other glomerular cells. In DN patients, Rarres1 expression is induced in microvascular 
endothelial cells. In vitro, Rarres1 overexpression leads to elevated expression of EMT 
related genes and activation of NF-kB signaling by interaction with Receptor Tyrosin 
Kinase Axl. In vivo, EC specific Rarres1 KI animals were more prone to anti-GBM-
induced damage as they developed higher albuminuria than control animals and showed an 
accelerated immune response as well as increased levels of fibrotic makers. In contrast to 
this, podocyte-specific KO animals showed no obvious abnormalities.
Conclusions: In summary, these results suggest that the activation of Rarres1 expression 
plays a pathogenic role in renal endothelial dysfunction during disease progression by 
promoting fibrosis and inflammation in vitro and in vivo.
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Characterization of a New Mechanism of Proteinuria
Andrew Beenken,1 Andong Qiu,4 Guangchun Jin,3 Tian Shen,3 
Abraham D. Levitman,3 Jonathan M. Barasch.2 1New York Presbyterian/
Columbia University, New York, NY; 2Columbia Presbyterian, New York, NY; 
3Columbia University, New York, NY; 4Tongji University, Shanghai, China.
Background: A central problem in biology is the mechanism by which cells regulate 
iron transport. This problem arises because the common oxidized form of iron (ferric-Fe3+) 
precipitates at physiologic pH, while the reduced form of iron (ferrous-Fe2+) is unstable in 
oxygenated atmospheres, and produces toxic radicals. To investigate iron transport in the 
kidney, we performed homology searches with yeast iron transporters and identified Spin, a 
novel transporter of ferrous iron.
Methods: Using in vivo LacZ reporters and by raising antibodies we found that Spin 
is specific to the endosomes and lysosomes of the proximal tubule. We constructed a 
conditional knockout of Spin driven by Megalin-Cre and found iron deposits and intense 
ferritin staining in the cytosol indicating defective iron localization in the KO.
Results: We saw proximal tubule dysfunction in the KO as measured by proteinuria. 
Western blot revealed leakage of NGAL and transferrin in the urine, and silver stain 
showed albuminuria. We investigated this phenotype by intraperitoneally injecting FITC-
labeled dextran and found impaired endocytosis in the KO. While megalin expression 
was unchanged between KO and wild type as seen on confocal microscopy, autophagy 
appeared to be inhibited in the KO. Electron microscopy showed increased size and number 
of vesicles in the proximal tubules, and Western blot showed increased abundance of 
LC3B-II in the homogenate of kidney cortex, suggesting that the Spin KO may hinder 
autophagosome fusion with the lysosome. The endocytic phenotype appears to be regulated 
by mislocalized iron because iron deficiency can rescue endocytosis.
Conclusions: In sum, we have found a critical iron transporter that regulates the 
endocytic functions of the proximal tubule.
Funding: NIDDK Support
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Defining Cellular Composition and Mechanisms of Kidney Formation
Human Nephron Segmentation: Opportunities to Replicate Cellular 
Programs In Vitro
Nils Lindstrom. Andrew McMahon laboratory The University of Southern 
California, Los Angeles, CA.
Background: Advances in renal bioengineering have shown how pluripotent stem 
cells can be differentiated into composite cell-structures called ‘kidney organoids’. These 
technologies can, if harnessed properly, hold potential for human kidney disease modeling, 
nephrotoxicity screens, and renal replacement therapies. However, the intense interest 
into the kidney organoids have highlighted our current insufficient understanding of 
normal human kidney development and raised the question of whether the blueprint for 
nephrogenesis established in the mouse, frog, and fish, is actually applicable to the human 
system and the organoid.
Methods: To establish a cellular and molecular understanding of human development 
we have carefully scrutinized and contrasted it with mouse kidney development using a 
broad range of technologies including bulk RNA-sequencing (conventional and MARIS-
based), single-cell RNA sequencing, in situ hybridization, immunofluorescent stains (three 
dimensional and two dimensional), and confocal live fate-mapping.
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Results: We demonstrate significant conservation between human and mouse 
patterning programs alongside distinct divergences in anatomies and expression patterns 
(JASN 2018 PMIDs: 29449453, 29449451, 29449449). Further, our examination of the 
human system resulted in the proposition of a new model for how nephrons form and 
pattern. Mesenchymal nephron progenitors are recruited into the forming nephron over 
a protracted period of time and it is the order of recruitment that dictates the spatial 
identities and eventual fates of each cell. We demonstrate this model by high-resolution 
image analyses and 3D reconstructions of human nephrogenesis and confirmed it through 
direct visualization and cell fate analysis in the mouse kidney organ cultures. Single-cell 
RNA sequencing of the human nephrogenic niche revealed the molecular events occurring 
during these early patterning processes and predicted developmental trajectories adopted 
by nephron progenitor cells in forming segment-specific domains of the human nephron.
Conclusions: The temporal-recruitment model for nephron polarity and patterning 
provides a framework for how integrated signaling pathways drive mammalian 
nephrogenesis. Collectively, these studies benchmark human nephrogenesis and predicts 
why current organoids fall short of replicating the in vivo nephron.
Funding: NIDDK Support
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Manipulation of Nephron Patterning Signals Enables Selective Induction 
of Podocytes from Human Pluripotent Stem Cells
Yasuhiro Yoshimura,1,2 Atsuhiro Taguchi,1,3 Masashi Mukoyama,2 
Ryuichi Nishinakamura.1 1Department of Kidney Development, Institute of 
Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 
Japan; 2Department of Nephrology, Graduate School of Medical Sciences, 
Kumamoto University, Kumamoto, Japan; 3Max Planck Institute for Molecular 
Genetics, Berlin, Germany.
Background: Podocytes, which play an important filtration role in the kidney, are 
derived from nephron progenitor cells (NPCs). Recently, we and others have established 
the induction methods of kidney organoids via NPCs from human induced pluripotent stem 
cells (hiPSCs). However, it remains a challenge to control the patterning process of nephron 
development and selectively induce a specific nephron segment.
Methods: We first developed a method to purify NPCs from mouse embryonic kidneys 
and cultured the NPCs ex vivo to investigate the required signals for podocyte induction. We 
then applied the findings obtained from mouse NPCs to hiPSC-derived NPCs to establish a 
method to selectively induce human podocytes.
Results: Mouse NPCs differentiation experiments identified that 1) optimal duration 
and strength of Wnt signaling was essential for mesenchymal-to-epithelial transition and 
podocyte differentiation, 2) inhibition of TGF-β signaling supported the expansion of 
proximal segment of renal vesicle, and 3) inhibition of TGF-β signaling in the later step 
enriched podocyte fraction by suppressing the differentiation of other nephron segments. 
The resultant protocol was successfully applied to the induction of Nephrin/Podocalyxin-
positive podocytes from hiPSCs with more than 90% of efficiency. Importantly, the 
expression levels of Nephrin and Podocin genes in the induced podocytes were 105 to 106 
times higher than that in the immortalized podocyte cell line and comparable to the sorted 
human adult podocytes. RNA-seq analysis further confirmed characteristic similarities 
between induced podocytes and human adult podocytes. Electron microscopy revealed foot 
process-like protrusions with Nephrin protein expression on the cell surface. Furthermore, 
exposure of induced podocytes to puromycin aminonucleoside reduced the expression of 
foot process-associated proteins, suggesting their functional responsiveness.
Conclusions: We elucidated the signals required for podocyte differentiation from 
NPCs and established a novel method to selectively induce human podocytes from hiPSCs. 
Induced podocytes exhibited gene expression profiles resembling their counterparts in vivo 
as well as morphological and functional properties of podocytes and will serve as new 
resources for disease modeling, nephrotoxicity testing, and regenerative medicine.
Funding: Government Support - Non-U.S.
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Defining Cellular Composition and Mechanisms of Kidney Formation
Nephron Progenitor Commitment Is a Stochastic Process Influenced by 
Cell Migration
Kynan T. Lawlor,1 Luke Zappia,1,2 James Lefevre,4 Joo-Seop Park,3 
Nicholas A. Hamilton,4 Alicia Oshlack,1,2 Melissa H. Little,1,2 
Alexander N. Combes.2,1 1Murdoch Childrens Research Institute, Melbourne, 
VIC, Australia; 2University of Melbourne, Parkville, VIC, Australia; 3Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH; 4Institute for Molecular 
Bioscience, The University of Queensland, Highgate Hill, QLD, Australia.
Background: Nephrons in the mouse kidney are formed from self-renewing 
mesenchymal progenitors that reside within a niche defined by the cap mesenchyme and 
ureteric epithelial tip. As the kidney develops, progenitor cells differentiate in response to 
inductive cues and exit the niche to form nephrons. We previously showed that the cap 
mesenchyme population is highly dynamic, migrating both within and between domains 
in response to niche cues. In this study we examine how migrating progenitors initiate 
nephrogenesis in a precise, spatially regulated manner.
Methods: We used lineage tracing, live timelapse imaging, single cell RNA-seq and 
computational modelling to characterise the fate of commiting mouse nephron progenitors.
Results: Using a tamoxifen inducible Wnt4-CreERT2 activated reporter we show that 
committing cells give rise to both the nephrons and a proportion of the progenitor pool. 
Timelapse imaging reveals a population of cells that are labelled at sites of nephrogenesis 
but escape commitment and re-enter the progenitor niche. Re-entry occurs continually 
during kidney development, leading to an accumulation of ‘escapers’ over time. Single cell 
RNA-seq reveals that these ‘escapers’ exist in the same range of transcriptional states as 
the unlabelled progenitor pool, suggesting that progenitors may traverse the transcriptional 
hierarchy between self-renewal and commitment in both directions. Consistent with 
this plasticity, live imaging analysis of individual cell fate suggests that some cells do 
not commit immediately but remain within the pre-tubular aggregate through branching 
iterations and contribute to subsequent nephrons.
Conclusions: We propose that nephron progenitor commitment is a stochastic process 
where the duration of exposure to spatially defined inductive cues is dependant on migration 
events. Progenitor plasticity may enable robust regulation of nephrogenesis as niches grow 
and are remodelled during organogenesis.
Funding: Government Support - Non-U.S.
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Defining Cellular Composition and Mechanisms of Kidney Formation
High Throughput Single Cell RNA Sequencing Reveals a Roadmap to 
Recreate the Kidney
Alexander N. Combes,1,2 Belinda Phipson,3 Kynan T. Lawlor,2 Luke Zappia,3,4 
Alicia Oshlack,2 Melissa H. Little.2,4 1Anatomy and Neuroscience, University of 
Melbourne, Parkville, VIC, Australia; 2Murdoch Children’s Research Institute, 
Melbourne, VIC, Australia; 3Murdoch Children’s Research Institute, Parkville, 
NSW, Australia; 4University of Melbourne, Melbourne, VIC, Australia.
Background: The developing mouse kidney represents a valuable model to understand 
the formation and maturation of renal cell types. High throughput single cell RNA 
sequencing offers new opportunities to understand the formation of complex tissues.
Methods: We performed single cell RNA-seq on over 6000 cells (median 2896 
genes per cell) from E18.5 kidneys on the Chromium 10x platform. Seurat was used for 
normalisation and clustering of cells, edgeR to test for differentially expressed genes. 
Findings were investigated using immunofluorescence and lineage tracing.
Results: We used single cell profiling to define cell type-specific profiles and 
revisit the molecular regulation of kidney development in mouse. A detailed analysis of 
cellular heterogeneity in the nephron lineage identified multiple Six2+ subpopulations 
including a nephron progenitor ‘ground state’, a putative committing state with evidence 
of FGF suppression and Notch activation, and cells expressing markers of both nephron 
progenitor and stroma. In vivo lineage analysis from E12.5 with inducible Six2CreERT2 
and PdgfraCreER lines supported a rare transition from nephron progenitor to stroma, 
but not the other way. Several markers thought to be specific to one population were 
expressed more broadly. For example Hoxb7 was expressed in collecting duct, distal tubule, 
and in some endothelial cells. Likewise, most markers considered specific to the ureteric 
epithelium were also expressed in the distal tubule or connecting segment. Comparative 
analysis between these populations yielded unique markers for each, which should be 
useful for distinguishing between these cell types in kidney organoids. An analysis of 
signaling pathway component expression was performed for each lineage, identifying 
known and previously unassociated ligands and receptors with progenitor states and stages 
of maturation in each lineage.
Conclusions: This study offers new insight into the mechanisms of progenitor 
maintenance and differentiation in the stroma, the ureteric epithelium, and the nephron 
lineages and therefore provides a roadmap of the signals that regulate differentiation in 
vivo. This information can be used to refine strategies to direct differentiation of mature 
renal cell types in vitro.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Defining Cellular Composition and Mechanisms of Kidney Formation
Comparative Analysis of Kidney Organoid and Adult Human Kidney by 
Single Cell RNA-Seq
Haojia Wu, Kohei Uchimura, Erinn L. Donnelly, Yuhei Kirita, 
Benjamin D. Humphreys. The Humphreys Lab Renal Division Washington 
University School of Medicine, Saint Louis, MO.
Background: Kidney organoids differentiated from human pluripotent stem cells hold 
tremendous promise but the similarities and differences between protocols and between 
pluripotent cell sources is unknown. In addition, how closely organoid-derived kidney cell 
types model their adult human counterparts is undefined.
Methods: We used Dropseq to generate single cell transcriptomes from two different 
directed differentiation protocols (Morizane and Takasato), using both iPSC and hES cell 
lines for each. We analyzed and compared single cell gene expression from 71,390 cells 
isolated from 38 organoids using unbiased computational approaches. We could detect 
on average 1,115 genes per cell. We further compared the differentiation state of major 
organoid kidney cell types against 4,524 single nucleus transcriptomes that we generated 
from healthy adult human kidney.
Results: Both protocols generate kidney organoids that contain a diverse range of 
kidney cells at differing ratios but also substantial numbers of non-renal cell types such 
as muscle and neuron. Some organoids have up to 30% off-target cell types. Organoid-
derived cell types are substantially immature compared with adult kidney cells. We could 
detect 16 different types of adult kidney cell types by single nucleus RNA-seq, including all 
glomerular cell types, all epithelial cell types including S1-S3 proximal tubule segments and 
type A and type B intercalated cells, as well as stroma and leukocytes. Disease-related genes 
predicted by GWAS are predominantly expressed in single cell types in adult kidney and 
organoids. We also identified lineage-specific expression of transcription factors, receptors 
and ligands during organoid differentiation and in adult human kidney.
Conclusions: We provide the first direct and comprehensive comparison of separate 
differentiation protocols using both iPSC and hES cells, revealing important differences in 
cell ratio, differentiation state and off-target cell types that will be important for investigators 
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in the organoid field to appreciate. The information provided in this comprehensive dataset 
will also guide future attempts to improve differentiation protocols, including reduction of 
off-target populations.
Funding: NIDDK Support
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Reciprocal Antagonism between Ppargc1a and Sim1a Regulates Boundary 
Formation of the Proximal Straight Segment during Vertebrate Prone-
phros Development
Joseph M. Chambers, Rebecca A. Wingert. University of Notre Dame, Notre 
Dame, IN.
Background: The genetic and molecular mechanisms that regulate boundary formation 
between adjacent segment populations are not fully understood. The pronephros of several 
vertebrates provides a simplified, tractable model to investigate fundamental mechanisms 
of segmentation, as this primitive kidney is comprised of proximal and distal segments that 
are conserved with mammalian nephrons, including humans.
Methods: Through a bioactive small molecule chemical genetic screen, we discovered 
that peroxisome proliferator-activated receptor (PPAR) signaling is essential for pronephros 
segmentation. Next, we found that the co-activator, ppargc1a, which binds activated PPARs 
to regulate transcription of target genes, is dynamically expressed in renal progenitors and 
is requisite for segmentation.
Results: ppargc1asa13186-/- mutants with a T->A substitution that results in a putative 
null allele have an reduced distal tubule segment and increased proximal tubule domain, 
which was recapitulated in subsequent knockdown studies and rescued with ppargc1a 
overexpression. Further, ppargc1a acts to promote tbx2b, a transcription factor necessary 
for proper formation of the distal segment. Interestingly, ppargc1asa13186-/- have an expanded 
sim1a domain, a transcription factor which is thought to regulate proximal segments. 
Conversely, ppargc1a expression was expanded in sim1a deficient embryos. This data 
suggests a negative regulation between the two factors. To test this interaction, we examined 
the proximal straight tubule domain in sim1a deficient, ppargc1a deficient, and doubly 
deficient embryos. While the loss of sim1a resulted in an abrogated proximal straight tubule, 
loss of ppargc1a resulted in expanded proximal straight tubule, but loss of both factors 
results in a completely restored segment boundary.
Conclusions: Taken together, this data strongly suggests that Ppargc1a and Sim1a 
act to counterbalance each other in an antagonistic fashion that is necessary for proper 
nephron segment boundary formation. These findings reveal for the first time how a layer 
of redundancy within the mechanism of segment boundary delineation is used to mitigate 
segment formation. Thus, these studies have discovered a useful paradigm to advance our 
understanding of nephron segmentation mechanisms.
Funding: NIDDK Support
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Deletion of SWI/SNF Chromatin Remodeling Component Brg1 in 
Nephron Progenitors Causes Renal Hypoplasia
Michael I. Rauchman,1,2 Ajeet P. Singh,3 Jeannine M. Basta,1,2 Lynn Robbins.1,2 
1Internal Medicine- Nephrology, Washington University in St. Louis, St. Louis, 
MO; 2VA St. Louis Healthcare System, St. Louis, MO; 3Cornell University, 
Ithaca, NY.
Background: Regulation of the self-renewal and differentiation capacity of the nephron 
progenitor (NPC) is a delicately balanced process. Decreased self-renewal or increased 
differentiation during kidney development can result in decreased nephron number at birth. 
When severe, this leads to childhood kidney failure. However, even moderate reductions in 
nephron number are associated with hypertension and chronic kidney disease in adulthood. 
The molecular mechanisms that modulate expression of genes for expansion of nephron 
progenitors are not completely understood. Mounting evidence supports a role for the SWI/
SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling complex in regulating 
mesodermal cell fate. The SWI/SNF complex is a large evolutionarily conserved protein 
complex required for embryonic development. The complex is composed of 10-12 subunits 
including alternative core ATPase subunits BRM (Brahma) and Brg1 (Brahma related gene 
1) that modulate chromatin structure on targeted loci, and regulate lineage restricted gene
expression during development. We found that Brg1 associated with Sall1, suggesting that 
SWI/SNF has a functional role in NPCs.
Methods: We genetically deleted the Brg1 gene (Smarca4) in mouse NPCs.
Results: Deficiency of Brg1 in Six2+ NPCs resulted in hypoplastic kidneys by 
embryonic day (E) 17. The number of Six2+ NPCs was reduced in mutant kidneys as 
early as E14, which correlated with a significant reduction of phospho-histone H3 positive 
dividing Six2+ NPCs. The nephron progenitor cells were almost completely lost by the 
time of birth. Similar to Sall1 mutants, global gene expression changes in E17 Brg1 mutant 
kidneys suggested defects in cell adhesion. RNA-seq analysis also showed downregulation 
of many genes required for mitochondrial respiration, suggesting reduced metabolic fitness 
of mutant NPCs. Brg1 is not expressed in adult kidney, however upon nephrotoxic injury 
with aristolochic acid Brg1 was significantly upregulated, indicating that the molecular 
pathways regulating kidney development may be activated for repair processes after injury.
Conclusions: Together, these data suggest that Brg1 regulates expression of genes that 
are required for the self-renewal and maintenance of nephron progenitor cells. Our results 
reveal novel functions of Brg1 in developing kidney.
Funding: NIDDK Support
FR-OR045 Oral Abstract Friday
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Inactivation of Foxi1 Rescues Most of the Hes1-Deficient Mouse Kidney 
Collecting Duct Defects
Malini Mukherjee,1 Jennifer DeRiso,2 Kameswaran Surendran.1 1Sanford 
Research / University of South Dakota, Sioux Falls, SD; 2Sanford Research, 
Sioux Falls, SD.
Background: The distal nephron and collecting duct segments of mammalian kidneys 
consist of intercalated cell types intermingled among Aqp2-expressing (principal) cell types. 
Notch signaling ensures that a sufficient number of cells select the Aqp2-expressing instead 
of an intercalated cell state. However, the precise mechanisms by which Notch patterns 
the collecting ducts is unknown. Here we tested whether Notch signaling simply represses 
Foxi1, an essential intercalated cell specific transcription factor, to allow for principal cell 
differentiation.
Methods: Hes1, a direct target of Notch signaling, was inactivated in developing 
kidney distal nephron and collecting duct segments by generating Cdh16-Cre;Hes1f/f mice 
and compared with Cdh16-Cre;Hes1f/f;Foxi1-/- mice to determine whether the only function 
of Notch in developing collecting ducts is to repress Foxi1. We also tested whether Hes1 
directly regulates principal cell genes in a calcium/calmodulin-dependent protein kinase-II 
(CaMKII) in ex vivo embryonic kidney cultures.
Results: Inactivation of Hes1 resulted in fewer principal cells, and reduced principal cell 
specific gene expression, and ability to concentrate urine, along with increased expression 
of Foxi1. Inactivation of Foxi1 rescues the Hes1-deficient principal cell deficiency and the 
ability to concentrate urine. However, detailed examination of Cdh16-Cre;Hes1f/f;Foxi1-/- 
mouse kidneys revealed reduced expression of certain principal cell (PC) specific genes. 
Consistent with PC specific genes being regulated independent of Foxi1, Foxi1 inactivation 
in mice does not result in increased expression of all PC specific genes. Additionally, Hes1 
and PC specific genes are down-regulated upon inhibition of Notch signaling in cultured 
principal cells without activation of Foxi1 expression. Hes1 can directly activate proximal 
promoters of Aqp2, Aqp3 and Elf5 in a CaMKII sensitive manner. The expression of PC 
specific genes and not Foxi1 expression is dependent on CaMKII activity in ex vivo mouse 
embryonic kidney cultures.
Conclusions: Notch/Hes1 has at least two roles during collecting duct development: (i) 
principal cell fate selection by repressing Foxi1 expression and (ii) activation of principal 
cell gene expression in a CaMKII dependent manner.
Funding: NIDDK Support
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Molecular Programs of the Progenitor Population Directing Branching 
Morphogenesis and Differentiation of the Collecting Duct Network
Elisabeth Rutledge. Andrew McMahon Lab University of Southern California, 
Los Angeles, CA.
Background: Branching morphogenesis underpins the formation of arborized 
epithelial networks in many organs including the lung airways and the mammalian kidney 
collecting duct. Epithelial branch tip cells respond to inductive signals from the adjacent 
mesenchyme that regulate this process and maintain an uncommitted progenitor identity. 
Progenitors exit the tip to populate stalk regions where they differentiate into the regionally 
distinct, organ appropriate, cell types of the epithelial network.
Methods: We employed population-based and single cell RNA-sequencing (scRNA 
seq) screens to identify tip progenitor cell types and their differentiated progeny in the 
developing mouse and human kidney and validated key genes by in situ hybridization and 
immunostaining. Several tip-specific genes are being explored through knockout mouse 
studies to identify their role in tip-niche regulation. To establish lineages from ureteric 
progenitors to adult collecting duct cell types, we are combining cell fate studies with 
scRNA seq, facilitated by novel genetic tools.
Results: RNA sequencing has identified a tip-enriched gene set that include all 
known tip genes and conservation of tip progenitor profiles between the developing mouse 
and human kidney. Further, conservation is observed in other branching organ systems. 
Expression studies show that ureteric tips have a complex gene expression pattern and cell 
fate analysis demonstrates that subsets of cells have lineage restrictions in the establishment 
of mature cell types. We analyzed the role of Adamts18, which encodes a secreted protease in 
mouse tip cells within the collecting duct and lung. Adamts18 null mutants display enlarged 
kidneys with double ureters while all mutants exhibit reduced growth of the airways.
Conclusions: Conserved gene regulatory programs organize the kidney tip progenitor 
niche in mouse and human, and progenitor niches in other branching organs. Lineage-
tracing and scRNA seq show mosaicism of progenitor populations and how this determines 
their potential to form the mature collecting duct cell types. Analyses of Adamts18 mutants 
give new insights into mechanisms of branching growth in several branching networks.
Funding: NIDDK Support, Other NIH Support - NIH T32 training grant 
(5T32HD060549)
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Defining Cellular Composition and Mechanisms of Kidney Formation
Adult Mouse Aqp2+ Progenitor Cells Maintain and Remodel Connecting 
Tubule/Collecting Duct
Chao Gao,1 Long Zhang,1 Lihe Chen,2 Enuo Chen,1 Wenzheng Zhang.1 WZ 
Zhang lab 1Albany Medical College, Albany, NY; 2NIH, Bethesda, MD.
Background: Embryonic Aqp2+ progenitor cells generate all known cell types in the 
connecting tubule/collecting duct (CNT/CD). Aqp2ECE/+ is a highly tamoxifen-inducible 
principal-cell-specific Cre mouse line with complete fidelity in cell specificity and no 
leakiness. Here we investigate weather Aqp2+ progenitor cells have multipotency and self-
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renewal potential during CNT/CD maintenance and lithium-induced remodeling in adult 
mice.
Methods: Adult Aqp2ECE/+ RFP/+ and Aqp2ECE/+ rainbow/+ were induced with 
tamoxifen and examined at various time points post induction. Alternatively, tamoxifen-
induced adult mice were treated with dietary LiCl for 4, 7 and 14 days, respectively. RFP 
or GFP co-expression with markers for PC (Aqp2), IC (V-ATPase B1, B2, CAII, AE1, 
and Pendrin) was investigated by immunofluorescence staining. PC to IC conversion rates 
(RFP+IC+/(RFP+IC+ + RFP+IC-) and IC derivation from PC rates (RFP+IC+/(RFP+IC+ + RFP-
IC+) were determined. Uninterrupted single-colored clones in Aqp2ECE/+ rainbow/+ were 
grouped into single-cell and multiple-cell ones to represent regular and progenitor cell-like 
PC, respectively.
Results: Aqp2ECE/+ RFP/+ possessed no PC to IC conversion (no RFP+ IC+ cells) at day 
1, intermediate state cells (RFP+ PC+ IC+) at day 3, and completely converted cells (RFP+ 
PC- IC+) at day 60 and 270 post induction. The conversion rate was 5% in the cortex and 
0.02% in the medulla at day 60, which were increased to 25% and 4%, respectively, at day 
270. IC derivation from PC rates were 47% and 6% in the cortex and medulla, respectively, 
at day 270. Lithium progressively facilitated PC-IC conversion, with the highest conversion 
rate reaching to 17.3% in cortex at day 14. Among the total cortical IC population, about
31% IC were derived from PC. Clone size ranged from 1-7 cells, with the largest ones
observed at day 270 post induction and day 14 post lithium treatment. The majority of
clones were 1-2 cells.
Conclusions: Adult Aqp2+ progenitor cells possess multipotency and self-renewal 
potential, and contribute to CNT/CD maintenance and remodeling.
Funding: NIDDK Support
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Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
Whole Genome Bisulfate Sequencing and dCas9-Mediated Epigenome 
Editing Identifies a Key Role for Tumor Necrosis Factor Alpha in 
Progressive Diabetic Kidney Disease
Jihwan Park,1 Yuting Guan,1 Matthew J. Seasock,1 Chengxiang Qiu,1 
Caroline A. Gluck,2 Matthew Palmer,1 Katalin Susztak.1 1University of 
Pennsylvania, Philadelphia, PA; 2Nemours/AI DuPont Hospital for Children, 
Wilmington, DE.
Background: Epigenetic changes have been proposed as the biological mechanism 
that encodes the long-lasting impact of metabolic changes on diabetic kidney disease 
(DKD) development. Understanding the contribution of methylation changes to DKD has 
been limited by a lack of comprehensive base resolution methylation data and specific 
methylome editing.
Methods: We have performed genome-wide based resolution methylation analysis 
of microdissected human control and DKD kidney tubule samples using whole genome 
bisulfate sequencing to identify methylation differences in human DKD kidneys. We used 
RNA sequencing to define transcriptional changes in the same samples. We validated results 
with larger array-based and animal model results. We applied dCas9-Tet1 system to define 
the causality of individual cytosine methylation changes and gene expression under specific 
sgRNAs.
Results: Methylation differences with genome-wide significance were detected 
in kidney tubule samples of patients with DKD. The changes were replicated by large 
cohort array-based methylation analysis. Differentially methylated regions (DMRs) were 
enriched on regulatory regions and associated with gene expression changes; however, 
it is likely that most changes were actually the result of cell type-specific changes rather 
than cell-specific changes. Pathway analysis indicated coordinated (methylation and gene 
expression) changes in metabolic and immune response pathways; specifically, changes 
in tumor necrosis factor alpha (TNFα) signaling. dCas9-Tet1 based lowering of cytosine 
methylation level of the TNFα DMR region resulted in an increase in TNF transcription 
indicating that methylation of this locus plays an important role in controlling gene 
expression. Increasing the TNF levels in diabetic animal models resulted in high grade 
albuminuria due to increased cytokine levels and cell death indicating TNFα is functionally 
important in DKD development.
Conclusions: Our results indicate wide spread methylation differences in DKD 
kidneys. We propose that epigenetic dysregulation of TNF locus likely contributes to 
nephropathy in patients with diabetes.
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Aberrant DNA Methylation of mTOR Pathway Promotes Inflammatory 
Activation of Immune Cells in Diabetic Kidney Disease
Guochun Chen,1,2 Zheng Dong,3,2 Lin Sun.1,2 1Department of Nephrology, The 
Second Xiangya Hospital, Changsha, China; 2Kidney Research Institute, The 
Second Xiangya Hospital, Changsha, China; 3Medical College of Georgia, 
Augusta, GA.
Background: DNA methylation has been implicated in the pathogenesis of diabetic 
kidney disease (DKD), but the underlying mechanism is unclear. We hypothesize that 
aberrant DNA methylation in peripheral immune cells may contribute to the inflammation 
and pathological progression in DKD.
Methods: Whole DNA samples were extracted from human peripheral blood 
mononuclear cells (PBMCs) and applied to genome-wide methylation analysis. PBMCs 
were isolated from human whole blood samples to determine the expressions of DNMTs 
and their relationship with the inflammatory activities. At 8 weeks of age, db/db mice were 
treated with 5-Aza or PBS twice a week for 12 weeks. Peripheral immune cells were isolated 
from donor db/db mice with or without 5-Aza treatments and intravenously infused to host 
diabetic animals. In in-vitro studies, human PBMCs and mouse splenocytes were isolated 
and applied to the intervention experiments of targeting DNMT1 or mTOR pathway.
Results: The key DNA methylation enzyme DNMT1 increased along with the 
inflammatory activity of PBMCs in DKD patients. Inhibition of DNMT1 with 5-Aza 
markedly increased CD4+CD25+ regulatory T (Treg) cells in the peripheral immune cells 
from DKD patients and in db/db diabetic animals, leading to enhanced immunosuppressive 
activity. In db/db mice, adoptive transfer of Treg cells from 5-Aza-treated animals 
beneficially modified the inflammatory phenotype of host immune system, resulting 
in significant improvement of diabetic albuminuria and chronic kidney injuries. We 
demonstrated differentially methylated genes in diabetic PBMCs, revealing prominent 
DNA hypomethylation in the upstream regulatory genes of mTOR pathway. Further mRNA 
array confirmed the induction of genes predominantly in the positive, rather than negative, 
regulators of mTOR pathway in DKD. In db/db mice, mTOR activity showed a correlation 
with the level of global DNA methylation and the inflammatory capacity of kidney immune 
cells. Finally, mTOR interventions efficiently modified the regulatory effects of 5-Aza on 
diabetic immune cells.
Conclusions: Chronic hyperglycemia induces aberrant DNA methylation of mTOR 
pathway, leading to pathogenic activation of immune cells in DKD progression. Our study 
highlights the therapeutic potentials of targeting epigenetic events in the immune system for 
treatment of chronic kidney disease and DKD in particular.
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Histone Demethylation near the Serum Amyloid A Promoter: Metabolic 
Memory Associated Inflammation
Brad Dieter,1 Katherine R. Tuttle,2 Rick L. Meek.3 1Providence Health Care, 
Spokane, WA; 2University of Washington School of Medicine, Spokane, WA; 
3Providence Sacred Heart Medical Center, Spokane, WA.
Background: Episodic hyperglycemia increases risk of diabetic complications, 
also known as “metabolic memory.” The study aim was to determine if serum amyloid 
A (SAA) mediated inflammation is due to demethylation of trimethyl histone 3 lysine 
27 (H3K27Me3) near the SAA promoter in podocytes and to correlate indicators of this 
demethylation with SAA expression in kidneys of humans and mice with diabetes.
Methods: SAA knockout (CRISPR-Cas9) and control mouse podocytes were 
exposed to advanced glycation end-products (AGE, 300 μg/mL) for 7 days, followed by 
7 days without AGE. H3K27Me3 near the SAA promoter was measured via chromatin 
immunoprecipitation (ChIP). Levels of mRNA for SAA and inflammatory mediators: 
(CXCL5, CCL5, and CCL2) were measured by qt-PCR. H3K27Me3 demethylation 
was inhibited (GSK-1, 20 uM) in podocytes exposed to AGE for 1 day. ChIP measured 
H3K27Me3 near the SAA promoter in the kidney cortex of db/db and wild type mice 
(C57BLKS). Relationships between expression of JMDJ3 mRNA (H3K27Me3 specific 
demethylase) and SAA mRNA were determined in kidneys of diabetic and non-diabetic 
humans and mice (C57- BLKS, DBA/2, eNOS-deficient C57-BLKS, Nephroseq).
Results: H3K27Me3 was reduced (95%, n=6 pooled samples) after 7-day periods of 
AGE exposure and AGE withdrawal in podocytes. Levels of mRNA increased for SAA 
(17±6-fold, p=0.025) and inflammatory mediators: CXCL5 (18±12-fold, p=0.004), CCL5 
(1.6±0.6-fold, p=0.026), and CCL2 (2.0±0.7-fold, p=0.001). SAA knockout reduced 
expression of these mediators by ≥60% (p<0.05 for all). GSK-1 reduced AGE-induced 
expression of SAA and these mediators by ≥60% (p<0.05 for all). H3K27Me3 was lower 
in the kidney cortex of db/db mice compared to wild type mice (25±6%, p=0.049, n=6). 
Expression of JMDJ3 mRNA correlated with SAA mRNA in diabetic and non-diabetic 
kidney tissue from humans (r=0.54, p<0.001) and mice (r=0.54, p<0.001).
Conclusions: Episodic exposure to AGE, a hyperglycemia-related perturbation, 
caused H3K27Me3 demethylation near the SAA promoter and increased expression of 
inflammatory mediators in podocytes. Correlative studies showed that indicators of this 
histone demethylation process and increased SAA expression carried over into kidney 
tissue of humans and mice.
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Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
Genetic Inactivation of Histone H3 K79 Methyltransferase Dot1l in Aqp2+ 
Progenitor Cells Causes CKD by Upregulating Endothelin-1 in Mice and 
Humans
Long Zhang,1 Lihe Chen,2 Chao Gao,1 Enuo Chen,1 Wenzheng Zhang.1 1Albany 
Medical College, Albany, NY; 2NIH, Bethesda, MD.
Background: Histone H3 K79 methyltransferase Dot1l represses aldosterone target 
genes including endothelin-1 (ET1). Aqp2+ progenitor cells give rise to all known cell 
types in the connecting tubule and collecting duct. Here we investigate whether genetic 
inactivation of Dot1l in Aqp2+ progenitor cells causes chronic kidney disease (CKD) by 
upregulating ET1.
Methods: Dot1lf/f Aqp2Cre (Dot1lAC) and Dot1lf/f ET1f/f Aqp2Cre (DEAC) mice were 
generated to disrupt Dot1l with or without intact ET1 in the Aqp2+ progenitor cells, 
respectively. Aqp2Cre mice were used as WT control. Mice were analyzed at the ages of 12 
and 24 months. Alternatively, two-month-old mice were subject to UUO and analyzed 14 
days later. Various molecular, cellular and pathological methods were employed to assess the 
renal function and pathology. Cells with loss of dimethyl K79 (H3m2K79-) were identified 
and isolated from archived kidney biopsies from patients with diabetic nephropathy (n=50) 
by laser capture to identify hDOT1L mutations via sequencing.
Results: At both ages, WT mice were apparently normal. Dot1lAC developed slight and 
severe symptoms mimicking human chronic kidney disease (CKD). The CKD symptoms 
include extreme polyuria, proteinuria, natriuresis, a variety of tubular abnormalities, 
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interstitial fibrosis, and mononuclear cell infiltrate. These changes were coupled with 
upregulated ET1 and fibrotic markers (FSP1, Collagen IV, Vimentin, and a-SMA). However, 
all of these phenotypic features were ameliorated by inactivation of ET1 in DEAC mice. 
Consistently, Dot1lAC vs. WT developed more prominent UUO-induced kidney fibrosis, 
which was partially rescued in DEAC mice. Some CNT/CD cells in DN were H3m2K79-. 
Analysis of the microdissected H3m2K79- cells revealed two single-base deletions and an 
E129K mutation that is predicted to abolish the methyltransferase activity.
Conclusions: Dot1l is a new potential renoprotective factor by repressing ET1 in both 
mice and humans. Inactivation of Dot1l in Aqp2+ progenitor cells is sufficient to trigger 
CKD development.
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Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
Single-Cell RNA-Seq of Dissected Glomeruli in a Mouse Model of Diabetic 
Nephropathy
Jia Fu,1 Kemal M. Akat,2 Kyung Lee,1 John C. He.1 1Icahn School of Medicine at 
Mount Sinai, New York, NY; 2The Rockefeller University, New York, NY.
Background: Diabetic nephropathy is the most common etiology for end-stage renal 
disease. In recent years, single-cell RNA-seq (scRNA-seq) has evolved into a reliable tool 
to interrogate gene expression changes on a single-cell level. Previous scRNA-seq studies 
on human and animal kidneys failed to capture glomerular cells even when sequencing 
thousands of cells. Here, we use scRNA-seq on microdissected glomeruli to study changes 
in a mouse model of diabetic nephropathy (DN).
Methods: Diabetes was induced at 8 weeks of age in IRG/Nphs2.Cre/eNOS–/–mice 
(C57BL/6 background) with 50 mg/g streptozotocin (STZ) over 5 consecutive days. Single-
cell suspensions of microdissected whole glomeruli from STZ-treated (DN) and control 
(Ctrl) mice were used for scRNA-seq on the Fluidigm C1 platform using 800-cell IFCs 
(v2) according to the manufacturer’s instructions. Resulting libraries were sequenced on 
an Illumina NextSeq500.
Results: We captured 186 and 217 single-cells from control mice, and 188 and 238 
single-cells from diabetic mice. After QC filtering 99 and 199 control cells, and 107 and 
188 cells from DN were used for downstream analysis. K-means clustering identified 4 cell 
populations representing endothelial cells (marker genes Kdr, Pecam1, Emcn), podocytes 
(Nphs1/2, Podxl), mesangial cells (Pdgfrb, Myl9, Gata3), and leukocytes (Cd44, Cd52, 
Cd53, Cd74, Cd300a). The relative cell type contribution was (Ctrl %/DN %) 47%/62% for 
endothelial cells, 16%/7% for podocytes, 34%/15.5% for mesangial cells, and 3%/15.5% 
for leukocytes. Differential analysis of gene expression comparing DN and Ctrl showed 
genes known to be altered in diabetic glomeruli as well as several interesting candidate 
genes which have thus far not been demonstrated to be affected in DN.
Conclusions: Single-cell RNA-seq of glomeruli overcomes limitations of previous 
studies which largely missed glomerular cells altogether. This approach allowed us to 
confidently identify 3 major cell types of the glomerulus, and the inflammatory response 
associated in this DN model. The low percentage of podocytes and mesangial from diabetic 
glomeruli as compared those from control suggests either loss or dedifferentiated of these 
cells in the diseased condition.
Funding: NIDDK Support
FR-OR053 Oral Abstract Friday
Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
Modelling Immune Mediated Renal Injury through the Use of Induced 
Pluripotent Stem Cell Derived Organoids
Thomas K. Dodd,1 Jessica L. Davis,1 Ciarán Kennedy,1 Shane Clerkin,2 
Monica De gaetano,1 Catherine Godson,3 Orina Belton,1 John Crean.1 Diabetes 
Complications Research Centre, UCD School of Biomolecular and Biomedical 
Science, University College Dublin 1University College Dublin, Dublin, 
Ireland; 2UCD, Dublin, Ireland; 3The Conway Institute of Biomolecular and 
Biomedical, Belfield, Dublin, Ireland.
Background: The role of inflammatory cells in chronic kidney disease has been well 
documented, with macrophage infiltration and accumulation implicated in the initiation and 
progression of renal injury. However, current models of disease fail to accurately reflect 
the initial cycles of damage and resolution. At the core of this issue remains a fundamental 
gap in our knowledge of how discrete inflammatory signalling networks converge and 
interact with renal tissue to cause fibrosis. We have found that plasticity of resident cells and 
infiltrating cells is reflected by significantly increased levels of the stemness regulator, miR-
302 in exosomes of patients with CKD while additionally the TGFβ signalling network was 
identified as a mediator of macrophage reprogramming.
Methods: IPSCs were differentiated into kidney organoids over a 24 day period. 
Primitive streak formation was induced by treating cells with CHIR99021 8μM for 3 days. 
Medium was then changed to APEL medium supplemented with 200ng/ml FGF9 and 
Heparin 1μg/ml. On day 12, growth factors were removed and organoids were matured 
until day 24. Organoids were then cultured in conditioned media from peripheral blood 
mononuclear cells (PBMCs) polarised towards a pro-inflammatory phenotype using 
lipopolysaccharide 200ng/ml and Interferon γ 20ng/ml and towards a pro-resolving 
phenotype using interleukin 4 20ng/ml and interleukin 13 20ng/ml. Organoids were 
subsequently fixed, stained and imaged using confocal microscopy for known markers of 
renal damage. Similarly, organoids were also treated with the nephrotoxic agent Aristolochic 
Acid (AA) and co cultured with PBMCs.
Results: Culturing of organoids in conditioned media for a 48 hour period lead to 
significant increases in the expression of αSmooth Muscle Actin, Fibronectin and KIM-1. 
Co culture of organoids exposed to AA for up to 24 hours with PBMCs resulted in significant 
damage to the organoid, accompanied by migration and infiltration of differentiated cells 
into these damaged organoids.
Conclusions: We propose that this novel model of macrophage induced renal damage 
can be used to investigate the role of inflammatory pathways which result in fibrosis and 
that by manipulating the plasticity of resident and infiltrating cells we may inhibit or reverse 
the progression of fibrosis in vivo.
FR-OR054 Oral Abstract Friday
Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
The NGAL-Macrophage Therapy Improves Diabetic Kidney Disease in 
db/db Mice by Induction of PI3K/Akt Pathway
Roser Guiteras,1 Anna Sola,1 Anna Manonelles,2 Georgina Hotter,3 
Josep M. Cruzado.2 Nephrology and Renal Experimental Transplantation, 
Institut d’Investigació biomèdica de Bellvitge (IDIBELL), Hospitalet de 
Llobregat, Barcelona, Spain 1Nephrology and Experimental Transplantation, 
IDIBELL, Barcelona, Spain; 2Hospital Universitari de Bellvitge, Barcelona, 
Spain; 3IIBB-CSIC, Barcelona, Spain.
Background: Alternatively activated macrophages (M2) have regenerative properties 
and shown promise as cell therapy in chronic kidney disease. However, M2 plasticity is 
one of the major hurdles to overcome. Genetically modified macrophages stabilized by 
neutrophil gelatinase-associated lipocalin (NGAL) are able to preserve in stable manner 
their M2 phenotype. Nowadays, little is known about M2 macrophage effects in diabetic 
kidney disease (DKD). The aim of the study was to investigate the therapeutic effect of 
both bone marrow-derived M2 (BM-ØM2) and Ø-NGAL macrophages in the db/db mice
Methods: Seventeen wk-old mice with established DKD were divided into five 
treatment groups with their controls: D+BM-ØM2; D+Ø-BM; D+Ø-NGAL; D+Ø-
RAW; D+SHAM and non-diabetic (ND) (db/- and C57bl/6J) animals. We infused 1x106 
macrophages twice, at baseline and 2 weeks thereafter. Blood, urine samples and kidney 
tissue were collected. To further ascertain the mechanism by which NGAL macrophage 
cell therapy is involved in epithelial kidney repair, we co-cultured renal epithelial cells and 
macrophages in vitro. We assessed epithelial proliferation, repair and epithelial phenotype 
integrity.
Results: BM-ØM2 did not show any therapeutic effect whereas Ø-NGAL significantly 
reduced albuminuria and renal fibrosis in db/db mice. The Ø-NGAL therapy increased 
the anti-inflammatory IL-10 and reduced some pro-inflammatory cytokines, reduced the 
proportion of M1 glomerular macrophages and podocyte loss and was associated with a 
significant decrease of renal TGF-β1. Furthermore, we demonstrated in vitro that NGAL 
overexpression in macrophages enhanced epithelial markers and healthy epithelial 
phenotype through the induction of PI3K/Akt pathway. In addition, NGAL activated 
proliferation markers such as Ki67 and PCNA through the inhibition of PPAR-γ.
Conclusions: Overall, our study provides evidence that NGAL macrophage cell 
therapy has therapeutic effects on DKD. NGAL acts as a mediator and is a crucial player 
reducing inflammation, fibrosis and promoting epithelial proliferation.
Funding: Private Foundation Support
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Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
Macrophage-Derived Migrasomes Transfer of IL-11 Is a Novel Mecha-
nism of Renal Interstitial Fibrosis in Diabetic Nephropathy
Xiaodong Zhu, Yu Zhao, Yuteng Jiang, Yuqiu Liu, Xiaoliang Zhang. Institute of 
Nephrology, Zhong Da Hospital, Southeast University, School of Medicine, 
Nanjing, China.
Background: Migrasome is a newly discovered, migration-dependent vesicle 
which differ dramatically from common extracellular vesicles(EVs) and primarily aid in 
intercellular communications. Macrophages infiltration and fibroblasts activation have been 
closely associated with renal interstitial fibrosis in diabetic nephropathy(DN). Whether 
macrophage produce migrasomes and contribute to the pathological processes are unknown.
Methods: Macrophage migrasomes were examined in streptozotocin murine model 
and Raw264.7 cells by transmission/scanning electron microscopy. Migrasomes isolated 
from M1/M2 phenotype macrophage, high glucose treated macrophage (M1-mig, M2-mig, 
HG-mig)interaction with renal fibroblast were assessed and migrasome gene profiling to 
identify the intercellular signaling.
Results: Ultrastructural analysis revealed that macrophage produce the previously 
unrecognized vesicles (Fig1.arrowhead) that typically grow on the tips or intersections 
of retraction fibers(Fig1.triangle). The vesicles were confirmed as the newly discovered 
migrasome by morphology and biomarker data that distinguish them from common 
EVs. We noticed that activated macrophage and HG enhanced migrasome production. 
Released migrasomes can directly initiate fibroblasts transdifferentiation which fibrosis 
markers (αSMA, COL1) markedly increased in HG/M1-mig group (by 10-15fold, 
respectively), while migrasome inhibitor CK636 or Dynasore alleviate fibrosis in DN 
model. We performed migrasomes gene-profiling to determine what intercellular fibrosis 
messages might be delivering. Amongst the top ranking genes, notably, we found a specific 
enrichment of IL-11 mRNA in HG-mig and M1-mig. The knockout IL-11 migrasomes or 
blocking fibroblasts IL-11RA sharply decreased the fibrosis levels.
Conclusions: Our findings suggest a fundamental, but formerly unrecognized 
pattern via which macrophage exert their effects through migrasomes and more depth 
of their functional roles shall be unearthed. IL-11 in HG/M1-mig driving fibroblasts 
transdifferentiation may be a novel mechanism of fibrosis in DN.
Funding: Government Support - Non-U.S.
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Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
TYRO3 Is a Novel Podocyte Protective Factor in Glomerular Disease
Fang Zhong,1 Wenjun Ju,2 Matthias Kretzler,3 Kyung Lee,4 John C. He.5 1Icahn 
Medical School at Mount Sinai, New York, NY; 2University of Michigan, Ann 
Arbor, MI; 3U.Michigan, Ann Arbor, MI; 4Icahn School of Medicine at Mount 
Sinai, New York, NY; 5Mount Sinai School of Medicine, New York, NY.
Background: Our previous work demonstrated a protective role of protein S against 
podocyte loss in early diabetic kidney disease (DKD) [Zong F JASN 2018]. Protein S is 
known to have anti-inflammatory and anti-apoptotic effects through the activation of Tyro3, 
Axl, and Mer (TAM) receptors. We find that the biological effects of protein S in DKD are 
largely mediated by Tyro3 in podocytes. The aim of this study was to determine the role of 
Tyro3 in podocyte injury in glomerular disease.
Methods: Tyro3 mRNA levels were checked in different datasets of human kidneys 
with DKD. Tyro3 knockout mice and control WT mice were made diabetes or injected 
with adriamycin to induce nephropathy. Inducible podocyte-speciifc Tyro3 overexpression 
mice were generated and crossed with OVE26 diabetic mice or Tg26 mice or induced 
nephropathy with adriamycin. Albuminuria, kidney histology, and podocyte number were 
assessed in these mice. Western blot and PCR analysis were used to assess mechanisms of 
Tryo3 regulation and biological effects in cultured human podocytes.
Results: TYRO3 mRNA expression is highly enriched in human glomeruli, and 
immunostaining showed that TYRO3 co-localized with podocyte marker. Glomerular 
TYRO3 mRNA expression was suppressed in the progressive DKD. It was also suppressed 
in focal segmental glomerulosclerosis (FSGS). We showed that genetic ablation of Tyro3 
in murine models of DKD and Adriamycin-induced nephropathy (ADRN) worsened 
albuminuria and glomerular injury, suggesting a protective effect of TYRO3 in early DKD 
and FSGS. Conversely, we showed that induction of TYRO3 overexpression specifically in 
podocytes significantly attenuated albuminuria and kidney injury in mice with DKD, ADRN 
and HIV-associated nephropathy. Mechanistically, we found that TYRO3 expression was 
suppressed by activation of TNF-α/NF-κB pathway, which may contribute to decreased 
TYRO3 expression in progressive DKD and FSGS, and TYRO3 confers anti-apoptotic 
effects through the activation of AKT pathway in podocytes.
Conclusions: In conclusion, we demonstrate that TYRO3 has a critical role to maintain 
normal podocyte function and could be a potential new drug target to treat glomerular 
disease.
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Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I
Development of a Peptide Inhibitor of a Novel Target to Retard Diabetic 
Nephropathy
Zhonglin Chai,1 Mark E. Cooper.2 1Monash University Central Clinical School, 
Melbourne, VIC, Australia; 2Monash University, Melbourne, VIC, Australia.
Background: Diabetic nephropathy (DN) is the major cause of end-stage renal disease 
worldwide, and remains suboptimally treated medically. A large body of compelling data 
from our group have demonstrated a critical role of CDA1 in DN and validated CDA1/
CDA1BP1 interaction as a promising target to retard diabetic nephropathy. We have 
developed a prototype inhibitor, CHA-061, to target this novel axis.
Methods: This study focuses on the assessment of CHA-061 for its efficacy to 
attenuate parameters relevant to renal fibrosis in two models of diabetes. The first model is 
an insulin deficient model using streptozotocin (STZ)-induced diabetes in ApoE KO mice, 
a model relevant to type 1 diabetes. The second is a type 2 diabetes model using db/db mice 
which initially become obese and subsequently diabetic as a result of the leptin receptor 
mutation. Both non-diabetic control and diabetic mice with established DN after diabetes 
was developed for 10 weeks were randomly allocated to receive either vehicle or CHA-061 
treatment (10 mg/kg IP injections twice a week) for 10 weeks.
Results: The analysis of kidney tissues showed that, in the vehicle treated ApoE 
KO mice, diabetes was associated with >2-fold increase in gene expression of sclerotic 
molecules such as collagens I and III as well as proinflammatory genes such as TNFα 
and MCP1. Immunohistochemical staining of collagen III was increased >10-fold and 
the glomerulosclerosis index (GSI) as assessed by PAS staining was increased >2-fold 
in diabetic ApoE KO mice. These parameters were significantly attenuated in CHA-061 
treated diabetic ApoE KO mice. Similarly, CDA1 expression levels were increased ~2-fold 
in diabetic db/db mice accompanied by >2-fold increase in gene expression of sclerotic 
molecules such as CTGF, fibronectin, collagens I, III and IV when compared to the non-
diabetic dbh mice. CHA-061 treatment reduced these parameters in the diabetic db/db mice 
to levels similar to those in the non-diabetic controls. These results were consistent with our 
previous target validation data using CDA1 KO and CDA1BP1 KO mouse strains.
Conclusions: Taken together, the current study has demonstrated the efficacy 
and feasibility to pharmacologically target the novel CDA1/CDA1BP1 axis to retard 
nephropathy in both type 1 and type 2 diabetes by targeting not only fibrotic but also 
proinflammatory pathways.
Funding: Government Support - Non-U.S.
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Fluids and Electrolytes: New Insights on Balance
Chloride-Insensitive WNK4 Mice Reveal Differential NCC Regulations by 
Dietary Potassium
Jen-Chi Chen,1 Yi-Fen Lo,1 Chou-Long Huang,2 Shih-Hua P. Lin,1 Chih-
Jen Cheng.1 1Tri-Service General Hospital, Taipei City, Taiwan; 2University of 
Iowa Carver College of Medicine, Iowa City, IA.
Background: With-no-lysine (WNK) kinases critically regulate sodium chloride 
cotransporter (NCC) in the distal nephron. Earlier works reveal that intracellular chloride ion 
([Cl-]i) binds to a hydrophobic pocket of WNKs and inhibits autophosphorylation and activity 
of WNKs in non-transporting in vitro condition. Substitution of two leucine residues (L319, 
L321) surrounding the hydrophobic pocket with phenylalanine makes WNK4 less sensitive to 
[Cl-]i. The Cl--sensing character of WNK4 hasn’t been validated in vivo.
Methods: We generated the Cl--insensitive L319F/L321F WNK4 mice using CRISPR/
Cas9.
Results: The Cl--insensitive L319F/L321F WNK4 mice displayed hypertension, 
hyperkalemia, and metabolic acidosis along with hyperactive NCC and impaired urinary 
potassium excretion, mimicking pseudohypoaldosteronism type II. To test the Cl--sensing 
character of WNK4 in response to dietary potassium, we fed L319F/L321F WNK4 mice 
diets with various potassium contents. Potassium deprivation failed to further enhance NCC 
in L319F/L321F WNK4 mice. Chronic potassium-rich diet still dephosphorylated NCC in 
L319F/L321F WNK4 mice. These results suggest that Cl--insensitive WNK4 is an NCC 
stimulator, and the physiological [Cl-]i in the distal nephron suppresses WNK4 activity. 
Potassium deprivation enhances NCC through ameliorating Cl--mediated inhibition on 
WNK4. In chronic potassium adaptation, other mechanism(s) overrides the constitutively 
active WNK4 to suppress NCC.
Conclusions: In sum, this study provides compelling evidence supporting that WNK4 
is a bona fide NCC stimulator and Cl- sensor in the distal convoluted tubule. The Cl--sensing 
mechanism of WNK4 play an important role in potassium deprivation.
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Fluids and Electrolytes: New Insights on Balance
Regulated Dephosphorylation of NCC Shapes the Renal Potassium Switch 
Pathway
P. R. Grimm,1 Eric J. Delpire,2 Paul A. Welling.1 1University of Maryland School 
of Medicine, Baltimore, MD; 2Vanderbilt University Medical Center, Nashville, 
TN.
Background: The Renal Potassium Switch Pathway stimulates the thiazide-sensitive 
sodium chloride cotransporter (NCC) to limit urinary potassium loss at the expense of 
retaining sodium and elevating blood pressure. It has been established that low extracellular 
potassium ([K+]o) activates the WNK4-SPAK kinase cascade to drive NCC phosphorylation, 
but it remains mysterious how NCC is dephosphorylated in response to a rise in [K+]o. It has 
been assumed that high [K+]o turns off WNK4-SPAK mediated NCC phosphoactivation, 
allowing phosphatase activity to dephosphorylate WNK4, but this remains unclear.
Methods: Kinase-activating mutations were introduced in SPAK, the terminal kinase 
in the WNK signaling pathway, and renal expression of the constitutively active (CA) 
SPAK mutant was specifically targeted in mice to the early DCT. NCC abundance (tNCC) 
and phosphorylation (pNCC) were evaluated in vivo and in isolated tubules, together with 
telemetric blood pressure (BP) measurements in response to changes in dietary potassium 
and [K+]o. CA-SPAK were compared to Control mice.
Results: CA-SPAK mice display NCC hyperphosphorylation and thiazide-treatable 
hypertension. BP remained elevated in CA-SPAK mice, compared to control, over a wide 
range of [K+]o, as predicted. However, BP dropped in CA-mice when [K
+]o exceeded 
5mM, and this was coincident with a reduction in pNCC/tNCC, revealing a [K+]-regulated 
dephosphorylation mechanism. Acute elevation in [K+]o decreases pNCC in isolated DCT 
from WT but not CA-SPAK mice. However, chronic potassium loading for 2 or 5 days 
reduces pNCC abundance with an IC50 of ~4.1mM in WT. pNCC is also reduce in CA-
SPAK mice under the same conditions but with a rightward shift in pNCC vs. [K+]o curve 
(IC50 ~ 5.5mM), suggesting chronic activation of a protein phosphatase (PP). Subsequent 
RNA profiling studies revealed a network of PP-subunits are regulated to decrease pNCC 
in response to increased [K+]o.
Conclusions: Because CA-SPAK drives NCC phosphorylation independent and 
downstream of WNK, these observations provide strong support for a potassium-activated 
phosphatase that directly dephosphorylates NCC. Thus [K+]o–regulated phosphorylation as 
well as dephosphorylation of NCC shape the Renal Potassium Switch Pathway. Regulated 
NCC dephosphorylation provides new mechanism to explain why high dietary K+ 
consumption alleviates salt-sensitive hypertension.
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Fluids and Electrolytes: New Insights on Balance
Differential Functions of Chloride Channels Clc-k1 and Clc-k2 in Mouse 
Kidneys
Yi-Fen Lo, Jen-Chi Chen, Shih-Hua P. Lin, Chih-Jen Cheng. Tri-Service 
General Hospital, Taipei City, Taiwan.
Background: Two voltage-gated ClC chloride (Cl-) channels, ClC-Ka and ClC-Kb, 
conduct urinary Cl- reabsorption in renal tubules. Genetic alterations on ClC-Ka/ClC-Kb 
result in human diseases with abnormal blood pressure. Previous studies have shown that 
rodent ortholog Clc-k1 and Clc-k2 expressed in the renal medulla and cortex, respectively. 
The physiological roles of these two Cl- channels have not been compared.
Methods: We created Clc-k1 knockout and Clc-k2 knockout mice sharing the same 
genetic background using the Ksp-Cre system.
Results: Clc-k1 deficiency resulted in polyuria with a blunted response to vasopressin 
and relatively normal extracellular fluid. In contrast, Clc-k2 deficiency led to uncompensated 
renal salt wasting, hypovolemia, and impaired renal function. The sodium transporters in 
distal nephron were unanimously upregulated in Clc-k1 knockout mice but downregulated 
in Clc-k2 knockout mice. Various vasopressors, including catecholamine, endothelin, and 
serotonin, were stimulated in Clc-k2 knockout mice but not in Clc-k1 knockout mice. 
Patchy interstitial inflammation & fibrosis, hyperplasia of juxtaglomerular apparatus, and 
renal scarring were observed in Clc-k2 knockout mice. High salt diet rescued the renal 
function and ameliorated the interstitial inflammation and fibrosis in Clc-k2 knockout mice. 
In embryonic kidneys, Clc-k2 transcript first expressed in the nephron progenitors on E13.5 
and gradually extended into the inner medulla along with NKCC2. Clc-k1 was not detected 
in the embryonic kidneys and found in inner medulla on P1 after birth.
Conclusions: Clc-k1 and Clc-k2 express and function differentially in the embryonic 
and adult kidney. The critical roles of Clc-k2 in distal salt reabsorption and embryonic 
kidney explain the uncompensated salt wasting in Clc-k2 knockout mice.
Funding: Government Support - Non-U.S.
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A Single Gastric K+ Load Induces Acute Diuresis in Mice
Samuel L. Svendsen,1 Simon Kornvig,1 Casper K. Larsen,2 Iben S. Jensen,1 
Jens G. Leipziger,1 Mads V. Sorensen.1 1Aarhus University, Aarhus, Denmark; 
2LEO Pharma, Copenhagen SV, Denmark.
Background: K+ balance relies on regulated renal K+ excretion to match variable 
dietary K+ intake. Upon a K+ rich meal, rapid and effective urinary K+ excretion is obligatory. 
The renal adaptation to an acute K+ load involves an increase of the driving force for K+ 
secretion by shifting the distal tubular Na+ reabsorption from being electroneutral (NCC) to 
electrogenic (ENaC). In addition, K+ secretion in the CD is stimulated by increased luminal 
flow. Here we asked, if a high K+ intake acutely increases urinary flow.
Methods: Mice were K+ challenged through gavage, diets or a combination of these. 
After K+ loading urinary volume, [K+]u and [Na
+]u, plasma osmolality, [K
+]p and [Na
+]p 
were measured.
Results: 1) Mice switched from a 1% to a 2% K+ diet increased their diuresis markedly 
within 12h. 2) Mice switched from a 1% to a 0.01% K+ diet had a biphasic diuretic response. 
During the first 12h their diuresis decreased, whereas it increased from 12 to 36h. 3) A 
single K+ load, by gastric gavage, corresponding to 25-50% of daily K+ intake induced 
diuresis within 30 min. This occurred despite augmented plasma osmolality. [K+]u remained 
unchanged and therefore the increased urinary K+ excretion depended on the volume effect 
4) K+ gavage did not changes urinary creatinine excretion suggesting a constant GFR. 5)
Subsequently, a possible direct and acute effect of a plasma [K+] ([K+]bl) increase was tested 
in isolated perfused mTALs and CDs. An acute [K+]bl increase (from 3.6 to 6.5 mM) did
not affect TAL NaCl absorption (measured 5 and 25 minutes post K+ jump). In contrast, the 
same manoeuver reduced the CDs sensitivity to stimulated AVP-mediated water absorption 
(measured 10 minutes post K+ jump).
Conclusions: Dietary K+ load induces a rapidly on setting diuresis. This increase 
in urinary volume appears crucial for a powerful K+ elimination since it appears prior to 
alteration in [K+]u. Based on preliminary data we suggest that the physiological mechanism 
of K+-induced diuresis involves AVP desensitization of the CD.
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SPAK Is Rapidly Dephosphorylated in the Distal Convoluted Tubule 
during Acute Potassium Loading
Anindit Mukherjee,1 Chao-Ling Yang,3 David H. Ellison.2 1Oregon Health 
Science University, Portland, OR; 2Oregon Health & Science University, 
Portland, OR; 3Oregon Health and Science University, Portland, OR.
Background: The thiazide-sensitive sodium chloride cotransporter (NCC) of the distal 
convoluted tubule (DCT) is phosphorylated and activated by WNK acting through SPAK. 
High extracellular potassium leads to rapid NCC dephosphorylation and inactivation. 
However, the molecular mechanism remains unknown. Here, we examined the roles of 
SPAK in this process: specifically, testing the hypothesis that SPAK is dephosphorylated by 
high extracellular K in cultured cells and in vivo.
Methods: 1) SPAK-transfected HEK293 cells were treated with 0mM to 10Mm (high) 
KCl, for one hour. Cell extracts were analyzed by western blot. 2) Kidney slices were 
incubated for 30 minutes in 0 Mm K to increase NCC phosphorylation and then treated 
with 3mM or 10mM K for 30 minutes. Slices were snap frozen. 3) C57/BL6 mice were 
gavaged with either vehicle or 3% KCl for 15 mins. Blood collected was used for electrolyte 
measurement by iSTAT. One kidney was processed for western blot and the other kidney 
was either perfused for IF or cortex-rich kidney poles were isolated and snap frozen.
Results: In HEK293 cells, raising medium [K+] for one hour led to a reduction in 
transfected and endogenous SPAK phosphorylation at S383. This in vitro finding was 
replicated ex vivo in kidney slices by western blot analysis. We saw parallel decrease in 
NCC and SPAK phosphorylation levels in kidney slices incubated in high K (10mM) vs 
normal K (3mM) buffer. We used a model similar to Loffing and colleagues to test whether 
SPAK dephosphorylation by high K+ occurs in a physiologically relevant setting. C57/
BL6 mice gavaged with 3% KCl for 15 minutes showed an increase in plasma [K+] and 
a corresponding decrease in SPAK phosphorylation in the cortex, but not in whole kidney. 
Immunofluorescence studies also showed decreased SPAK-S383 primarily in parvalbumin-
positive ‘early’ DCT1 upon K loading. Cytosolic total-SPAK puncta observed in control 
kidneys rapidly disappeared after K loading, suggesting a rapid alteration in SPAK 
localization as well as phosphorylation by extracellular K.
Conclusions: Although prior work suggested that SPAK is not involved in rapid NCC 
dephosphorylation, the current data indicate that SPAK is rapidly dephosphorylated in vivo 
primarily along the DCT during short term K treatment. Further work will be necessary to 
establish that this effect is essential for rapid NCC dephosphorylation.
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Phosphorylation of β1Pix by AMPK and Its Role in ENaC Inhibition in 
Kidney Epithelial Cells
Pei-Yin Ho,1 Hui Li,1 Lei Cheng,2 Robert A. Fenton,2 Kenneth R. Hallows.1 
1USC/UKRO Kidney Research Center; Medicine, USC Keck School of Medicine, 
Los Angeles, CA; 2Biomedicine, Aarhus university, Aarhus, Denmark.
Background: AMP-activated kinase (AMPK) inhibits the epithelial Na+ channel 
(ENaC) by increasing the binding of the ubiquitin ligase Nedd4-2 to ENaC. We recently 
showed that AMPK inhibits ENaC by direct phosphorylation of Nedd4-2 at a site critical for 
Nedd4-2 stability. We also demonstrated that the Pak-interacting exchange factor β1Pix is 
required for ENaC inhibition by AMPK and for Nedd4-2 stability in mouse kidney cortical 
collecting duct (CCD) cells. AMPK activators increase the binding of β1Pix to 14-3-3. Thus, 
AMPK may enhance Nedd4-2-dependent ENaC degradation by promoting the formation 
of a β1Pix/Nedd4-2/14-3-3 complex. Here, we further investigate the mechanisms of how 
AMPK promotes a β1Pix-14-3-3 interaction and whether 14-3-3 binding is important for 
ENaC inhibition by AMPK.
Methods: Protein mass spectrometry (MS), in vitro translation and phosphorylation 
assays were used to detect AMPK phosphorylation sites in β1Pix. Various constructs 
were transiently expressed in polarized mpkCCDc14 cells. An epithelial volt-ohmmeter 
was used to measure amiloride-sensitive equivalent short-circuit currents in mpkCCDc14 
cells ± combined treatment with the AMPK activators AICAR and A-769662 for 24 h. 
Coimmunoprecipitation assays were used to examine modulation of β1Pix/14-3-3/Nedd4-2 
interactions by AMPK.
Results: AMPK directly phosphorylates β1Pix in vitro, and six potential AMPK 
phosphorylation sites were detected by MS. Among these sites, the Ser-71 phosphorylation 
site on β1Pix was found to be functionally significant. Compared to wild-type β1Pix, 
overexpression of the β1Pix-S71A mutant significantly reduced ENaC inhibition and the 
binding of both β1Pix and Nedd4-2 to 14-3-3 caused by AMPK activation in mpkCCDc14 
cells. Moreover, overexpression of a β1Pix-Δ602-611 mutant unable to bind 14-3-3 
decreased the interaction between Nedd4-2 and 14-3-3. Finally, in preliminary studies, 
overexpression of the R18 peptide, which inhibits 14-3-3-target interactions, reduced the 
binding of both β1Pix and Nedd4-2 to 14-3-3 and attenuated ENaC inhibition by AMPK 
in CCD cells.
Conclusions: Our results suggest that phosphorylation of β1Pix at Ser-71 by AMPK 
is involved in the formation of a β1Pix/Nedd4-2/14-3-3 complex, which promotes ENaC 
degradation caused by AMPK activation.
Funding: NIDDK Support, Private Foundation Support
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Fluids and Electrolytes: New Insights on Balance
A Pivotal Role of WNK1/OSR1 Pathway in Regulation of Renal Proximal 
Sodium Transport
Motonobu Nakamura,1 Shoko Horita,1 Nobuhiko Satoh,1 George Seki,2 
Tomohito Mizuno,1 Hiroyuki Tsukada,1 Yusuke Sato,4 Haruki Kume,4 
Masaomi Nangaku,1 Masashi Suzuki.3 1Division of Nephrology and 
Endocrinology, The University of Tokyo, Tokyo, Japan; 2Yaizu City Hospital, 
Yaizu, Japan; 3Tokyo Gakugei University, Koganei, Tokyo, Japan; 4Department 
of Urology, The University of Tokyo Hospital, Tokyo, Japan.
Background: In renal proximal tubules (PTs) we and others have shown that insulin 
stimulates both apical Na+/H+ exchanger (NHE)3 and basolateral Na+/HCO3
- co-transporter 
(NBCe1) via PI3K/Akt signaling. Pioglitazone (Pio) also stimulates both NHE3 and NBCe1 
via non-genomic PPARg/ERK signaling (Cell Metab 2011). In human PTs, angiotensin 
(Ang)II stimulates both transporters via NO/ERK signaling (JASN 2014). However, the 
mechanism underlying this coordinate regulation in apical and basolateral PT sodium 
transport is poorly understood. In this study, we investigated the role of WNK1/OSR1 
pathway in regulation of PT sodium transport.
Methods: By using a pH-sensitive dye BCECF we measured the basolateral NBCe1 
activity and apical NHE3 activity in freshly-isolated rat PTs as well as human PTs, the latter 
obtained during surgery for renal cell carcinoma. We also measured the NBCe1 activity in 
rat PTs incubated overnight with siRNA against WNK1, WNK3, OSR1 or SPAK. Protein 
phosphorylation was analyzed by Western blotting in rat and human kidney cortex tissue.
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Results: In freshly-isolated rat and human PTs, insulin and Pio markedly stimulated 
both NHE3 and NBCe1 activities, and an OSR1/SPAK inhibitor, Closantel (10mM) 
completely suppressed these stimulatory effects. Closantel also completely suppressed the 
AngII-stimulated NBCe1 and NHE3 activities in human PTs. Immunostaining analysis 
confirmed the expression of OSR1 protein in rat and human PTs. In rat and human kidney 
cortex, Closantel suppressed the insulin-induced OSR1/SPAK phosphorylation without 
affecting the Akt phosphorylation. Similarly, Closantel suppressed the OSR1/SPAK 
phosphorylation by Pio and AngII without affecting the ERK phosphorylation. In overnight 
incubated rat PTs, siRNA against WNK1 but not WNK3 abolished the stimulatory effects 
of Pio and insulin on NBCe1. Moreover, siRNA against OSR1 but not SPAK abolished the 
stimulatory effects of Pio and insulin.
Conclusions: These results indicate, for the first time to our knowledge, that diverse 
stimuli depending on the distinct signaling cascades converge into WNK1/OSR1 pathway, 
which may work as a master regulator of PT sodium transport and hence represent a novel 
therapeutic target in hypertension and/or volume expansion.
Funding: Government Support - Non-U.S.
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G-protein Pathway Suppressor 2 Abolished the WNK4-Mediated 
Inhibition of the Large Conductance Ca2+ Activated Potassium (BK) 
Channels
Yunman Wang,2 Ruidian Li,1 Shan Chen,1 Jia Xiao,3 Saier Shen,1 Xiuyan Feng,6 
Hui Cai.4,5 1Medicine/Renal, Emory University, Atlanta, GA; 2Medicine/Renal,
Emory University, Atlanta, GA; 3Medicine/Renal, Emory University, Atlanta,
GA; 4Medicine/Renal, Emory University, Atlanta, GA; 5Nephrology, Atlanta VA 
Medical Center, Decatur, GA; 6Pathology, LSU Shreveport, Shreveport, LA.
Background: G-protein pathway suppressor 2 (GPS2) is a multifunctional protein and 
transcriptional regulation factor. We have recently reported that GPS2 enhances BK channel 
activity and its protein expression by reducing ERK1/2 signaling-mediated degradation of 
the channel. Previous studies reported that WNK4 inhibits BK channel activity and protein 
expression through stimulating ERK 1/2 signaling pathway. Our yeast-two hybrid screening 
data showed that WNK4 interacts with GPS2. Thus, we hypothesized that GPS2 increases 
BK protein expression through interfering with the WNK4-mediated effect on BK.
Methods: Cell culture, transfection, western blot analysis, co-immunoprecipitation, 
and cell surface biotinylation were used in the experiments.
Results: To determine whether GPS2 modulates the WNK4-mediated inhibitory 
effect on BK, we first wanted to confirm whether GPS2 interacts with WNK4. In 
HEK293 cells cotransfected with HA-WNK4 and either myc-vector or myc-GPS2, co-
immunoprecipitation (co-IP) experiments showed that myc-GPS2 co-immunoprecipitates 
WNK4, whereas myc-vector does not. To further confirm their interaction, we performed 
the reciprocal co-IP experiments in HEK293 cells cotransfected with HA-GPS2 and 
either myc-vector or myc-WNK4. We found that myc-WNK4 co-immunoprecipitates 
HA-GPS2 while myc-vector does not. To further assess the effects of GPS2 on WNK4-
mediated inhibitory effects on BK, we performed the western blot analysis in HEK293 
cells cotransfected with BK and WNK4 in the presence or absence of GPS2. We found that 
WNK4 significantly inhibits BK protein expression as expected. However, in the presence 
of GPS2, BK protein expression is restored to the control level. We further did cell surface 
biotinylation experiments in Cos-7 cells co-transfected with BK and WNK4 in combination 
with increasing doses of GPS2. We showed that WNK4 significantly inhibits total and 
surface BK protein expressions and GPS2 reversed the WNK4-mediated inhibition of BK 
in a dose-dependent manner. We further showed that GPS2 reversed the WNK4-mediated 
inhibition of BK protein expression by partially reducing the BK degradation through a 
lysosomal pathway.
Conclusions: These data suggested that GPS2 abolishes the WNK4-mediated 
inhibition of BK by partially reducing BK degradation through a lysosomal pathway.
Funding: Veterans Affairs Support
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Response of Intercalated Cell (IC) BKα Knock-Out Mice to a High K 
(HK) Diet
Rolando Carrisoza-Gaytan,1 Evan C. Ray,2 Allison L. Marciszyn,3 Peng Wu,4 
Leah Liu,7 Arohan R. Subramanya,5 WenHui Wang,4 Daniel Flores,1 
Donald E. Kohan,6 Thomas R. Kleyman,3 Lisa M. Satlin.1 1Icahn School of 
Medicine at Mount Sinai, New York, NY; 2UPMC, Pittsburgh, PA; 3University of 
Pittsburgh, Pittsburgh, PA; 4New York Medical College, Valhalla, NY; 
5University of Pittsburgh School of Medicine, Pittsburgh, PA; 6University of 
Utah Health Sciences Center, Salt Lake City, UT; 7McGill University, Montreal, 
QC, Canada.
Background: Flow-induced K secretion (FIKS) in the cortical collecting duct (CCD) 
is mediated by BK channels, which also contribute to the renal adaptation to a high K diet 
(HKD). BK channels are expressed in both ICs and principal cells (PCs) in CCDs. We 
generated a mouse with a targeted deletion of BKα, the pore forming subunit of the BK 
channel, in ICs (IC-BKα-KO) by crossing floxed BKα mice with B1 V-ATPase Cre mice. 
Perforated cell recordings of ICs in CCDs in these KO mice revealed reduced charybdotoxin 
(CTX)-sensitive K currents vs. those in floxed controls, suggesting that the KO would have 
a limited capacity for FIKS and renal adaptation to a HKD. In fact, KO mice exhibited a 
higher blood [K] vs. controls (5.5±0.8 vs. 5.0±0.7 mM; p<0.05), yet rates of urinary K 
excretion in response to volume expansion were similar in both groups.
Methods: See results.
Results: To confirm the contribution of IC BK channels to FIKS and K adaptation, 
we measured net transepithelial transport (Jx, in pmol/min.mm) of Na and K, in control 
(n=4) and KO (n=6) microperfused CCDs from mice fed a HKD x 10 d. Similar rates 
of flow-stimulated JNa were observed in control and KO CCDs (43.3±6.5 and 26.9±8.3, 
respectively, p=NS), but FIKS, present in control CCDs (-5.0±0.6), was absent in KO 
tubules (-1.1±0.6; p<0.05). Although CTX-sensitive K currents in PCs were upregulated 
in KO mice (454±40 pA; n=6) vs. those in controls (304±28 pA; n=5; p=0.02), the failure 
to detect FIKS in KO CCDs underscored the critical role of ICs vs. PCs in BK channel-
mediated K secretion. ROMK immunolabeling of kidney cryosections revealed a 16% 
increase in apical membrane relative to whole cell expression in calbindin-positive DCTs 
of KO mice vs. controls.
Conclusions: We conclude that in the absence of IC BKα, mice have a limited capacity 
for adaptation to a HKD, as evidenced by the higher blood [K], and lack of FIKS, confirming 
a critical role of IC BK channels in K homeostasis. We speculate that upregulation of 
alternate K secretory channels, including ROMK, in other segments of the nephron occurs 
to enable K secretion in the absence of BK channel activity in ICs.
Funding: NIDDK Support
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Calcineurin Homologous Protein 1 Regulates the Renal 
Na-K-2Cl-Cotransporter
Kerim Mutig,1 Alexander Paliege,2 Sebastian Bachmann.1 1Charité 
Universitätsmedizin Berlin, Berlin, Germany; 2Universitätsklinikum Dresden, 
Dresden, Germany.
Background: The Na-K-2Cl-cotransporter (NKCC2) of the thick ascending limb (TAL) is 
essential for renal salt handling. Its activity depends on phosphorylation and dephosphorylation 
steps. Our previous work suggested that calcineurin is involved in dephosphorylation and 
deactivation of NKCC2. Calcineurin activity can be modulated by members of the calcineurin 
homologous protein family (CHP). Among these, CHP1 has been implicated in the regulation 
of several membrane proteins including ion transporters. We hypothesized that CHP1 
participates in calcineurin-dependent regulation of NKCC2 activity.
Methods: Immunofluorescence, immunoblotting, co-immunoprecipitation and GST 
pull down assays were applied in rodent kidneys and cultured cells to characterize physical 
and functional interactions between NKCC2, CHP1 and calcineurin.
Results: Double labeling of CHP1 and NKCC2 revealed their close co-localization in 
rat TAL. Both products co-immunoprecipitated, suggesting their interaction. GST pull down 
assays with recombinant N-terminal NKCC2 mutants, mimicking its (de)phosphorylation 
at functionally relevant residues (T96, T101, T114, and S126), suggested that CHP1 and 
calcineurin may compete for the binding with phosphorylated NKCC2. Overexpression of 
CHP1 in cultured macula densa cells significantly increased NKCC2 phosphorylation at 
baseline and upon low-chloride stimulation. Acute stimulation of NKCC2 by administration 
of desmopressin in rats promoted the interaction of NKCC2 with CHP1, while attenuating 
its binding with calcineurin.
Conclusions: Our data suggests that CHP1 protects NKCC2 from calcineurin-
dependent dephosphorylation and deactivation.
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APOL1 Antisense Oligonucleotide Treatment Ameliorates IFNγ-Induced 
Proteinuria in Genomic APOL1 Transgenic Mice
Mariam Aghajan,1 Sheri Booten,1 Magnus Althage,2 Anette E. Ericsson,2 
Ingela Maxvall,2 Angela Menschik lundin,2 Christine Ahlström,2 Joseph Ochaba,1 
Danielle Gattis,1 Andy Watt,1 Jeffery A. Engelhardt,1 Brett P. Monia,1 Maria 
chiara Magnone,2 Shuling Guo.1 1Ionis Pharmaceuticals, Carlsbad, CA; 
2AstraZeneca, Gothenburg, Sweden.
Background: APOL1 risk variants (G1/G2) strongly associate with CKD in African 
Americans. Not all individuals homozygous for the risk variants, however, develop renal 
disease suggesting that a second hit is required. In this study, we sought to develop a 
physiologically-relevant mouse model of APOL1-associated renal disease.
Methods: We generated genomic APOL1 G0 or G1 transgenic mice via random 
transgenesis of a human APOL1-containing fosmid, resulting in APOL1 expression in 
similar tissues as that identified in humans and at similar relative levels of expression. Mice 
were challenged with recombinant IFNγ and APOL1 induction was measured by qRT-PCR. 
Proteinuria was measured by albumin ELISA and normalized using urine creatinine levels 
measured by a clinical chemistry analyzer.
Results: Naïve APOL1 G1 Tg mice failed to show a differential renal phenotype 
compared to APOL1 G0 mice. A single dose of IFNγ, however, caused robust proteinuria 
only in G1 mice, despite inducing kidney APOL1 expression in both G0 and G1 mice. 
We identified an antisense oligonucleotide (IONIS-APOL1Rx) against APOL1 that is potent 
with an excellent safety profile. Administration of IONIS-APOL1Rx to G1 Tg mice prior 
to IFNγ challenge prevented APOL1 induction and IFNγ-induced proteinuria in a dose-
dependent manner. Treatment with a hepatocyte-targeting version of IONIS-APOL1Rx, 
however, provided incomplete protection against IFNγ-induced proteinuria, suggesting that 
local expression of APOL1 in kidney is critical for pathogenesis. In search of a kidney-
specific target engagement biomarker, we detected APOL1 mRNA in urinary shed cells 
from mice and humans and correlated its reduction to kidney APOL1 mRNA reduction in 
APOL1 Tg mice.
Conclusions: We developed a novel APOL1 transgenic mouse model that recapitulates 
the physiological attributes of APOL1 and exhibits a kidney phenotype in G1 mice upon 
IFNγ challenge. APOL1 ASO treatment in this model prevents IFNγ-induced proteinuria 
in G1 mice, demonstrating that the kidney disease cell type is sensitive to APOL1 ASO 
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treatment and that IONIS-APOL1Rx may be an effective therapeutic for APOL1-associated 
nephropathies.
Funding: Commercial Support - Ionis Pharmaceuticals, AstraZeneca
FR-OR069 Oral Abstract Friday
Genetics and Kidney Diseases: Beyond PKD
Kidney Compartment Specific eQTL Studies Highlight Causal Genes and 
Pathways for Renal Disease Development
Chengxiang Qiu,1 Shizheng Huang,1 Jihwan Park,1 Yoson Park,1 Yi-An Ko,1 
Matthew J. Seasock,1 Joshua S. Bryer,1 Wenchao Song,1 Matthew Palmer,1 
Jonathan Hill,2 Paolo Guarnieri,2 Julie Hawkins,2 Carine Boustany,2 
Steven S. Pullen,2 Katalin Susztak.1 1University of Pennsylvania, Philadelphia, 
PA; 2Boehringer Ingelheim, Ridgefield, CT.
Background: Chronic kidney disease (CKD) is a common disease condition affecting 
more than 1 in 10 people in the general population. Genome wide association studies 
(GWAS) have identified more than 100 regions where nucleotide variants are significantly 
and reproducibly associated with kidney function. Expression quantitative trait locus 
(eQTL) analysis aim to identify gene expression changes in cell and tissue samples driven 
by the underlying genetic variation. By combining GWAS and eQTL studies we can identify 
gene expression change driven by disease associated genetic variation. Genes for which 
expression are influenced by GWAS signals are likely candidates for disease development.
Methods: We conducted eQTL analyses separately on glomerular and tubular portions 
of healthy human kidney samples obtained from 151 subjects of European descent. We 
complemented our compartment-based eQTL studies with kidney-specific epigenome maps 
and single-cell RNA-sequencing results. Focusing on the DAB2-C9 CKD GWAS locus, we 
induced kidney injury by folic acid administration and unilateral ureter obstruction to test 
the effect of DAB2 and C9. To understand the mechanism of Dab2-induced kidney damage, 
we cultured primary renal tubule cells from Dab2flox/+ mice and infected them with Cre-
eGFP or control adenovirus.
Results: We identified eQTLs and generated a searchable public eQTL database from 
human whole kidney, tubules and glomeruli samples. Kidney-specific eQTLs showed 
significant enrichment for genetic variants associated with renal traits. We identified 
eQTLs at 27 genes that colocalize with CKD GWAS signals. Putative causal genes were 
enriched for proximal tubule expression and endolysosomal function. DAB2 appeared to be 
a central gene among the putative causal genes. In vivo studies, using mice with reduced 
tubule epithelial-specific gene expression demonstrated that Dab2 protects mice from CKD 
development. In vitro results indicate that Dab2 in tubule cells plays an important role in 
TGFβ-induced profibrotic gene expression.
Conclusions: This in-depth follow-up analysis of CKD GWAS, defines a novel 
framework for CKD development, and identifies DAB2 and endolysosomal pathway as key 
mechanism for kidney disease pathogenesis.
Funding: NIDDK Support, Commercial Support - Boehringer Ingelheim, the Eli Lilly 
Co., Private Foundation Support
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Allele-Specific Expression Studies Identify Tubule Epithelial DACH1 as a 
Kidney Disease Gene
Shizheng Huang,1 Chengxiang Qiu,1 Jihwan Park,1 Yoson Park,3 
Rojesh Shrestha,1 Hongliu Yang,2 Richard G. Pestell,4 Katalin Susztak.1 
1University of Pennsylvania, Philadelphia, PA; 2West China Hospital of Sichuan 
University, Chengdu, China; 3Perelman School of Medicine University of 
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Background: Genome wide association analysis (GWAS) have identified significant 
associations between over 100 genetic loci and kidney disease development. However, 
finding causal genes, cell types and biological mechanisms underlying such associations 
remains a challenge. High throughput RNA-seq data allows transcriptome-wide scan of 
millions of variants and their impact on gene expression variation (eQTLs) in specific cells 
and tissues. Furthermore, incorporating allele-specific expression (ASE) analysis enables 
us to improve statistical power for such screening methods while controlling for biases and 
potential confounding factors.
Methods: We generated genotype and gene expression data of kidney tissue samples 
obtained from 121 healthy individuals of European descent. Additionally, we generated 
mice with tubule-specific dose reduction of Dach1 (Kspcre/Dach1flox/+). Kidney injury 
was studied in aging mice or following folic acid administration. We cultured primary 
renal tubule epithelial cells (TECs) from Dach1flox/+ mice for Cre adenovirus infection. 
Furthermore, we performed single cell RNA-sequencing on control and Kspcre/Dach1flox/
flox mouse kidneys.
Results: We identified 41 ASE loci (compared to 27 eQTL loci) with genome-wide 
significant associations to kidney function. Interestingly, kidney compartment-based ASE 
analysis identified a significant tubule-specific association between the CKD risk variant 
rs716877 genotype and DACH1 level, but not in glomeruli. The GWAS risk allele was 
associated with decreased DACH1 levels. By single cell RNA-sequencing analysis, we 
found that Dach1 is expressed in the loop of Henle, distal convoluted tubules and collecting 
ducts. Mice with reduced tubule-specific Dach1 level demonstrated worsened renal damage 
at baseline and following nephrotoxic injury. Reducing Dach1 expression in primary TECs 
directly increased profibrotic gene expression. Single cell RNA-sequencing analysis of 
Kspcre/Dach1flox/flox mice indicated a significantly increased expression level of proliferating 
tubule cells.
Conclusions: Combining ASE and GWAS integration analysis, we identified 41 
putative causal associations between genetic variation and kidney development. In 
particular, we show that reducing tubule epithelial Dach1 level induces kidney fibrosis 
development via TEC proliferation.
Funding: NIDDK Support
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GWAS of Urinary Metabolite Concentrations among CKD Patients 
Identify 90 Loci
Anna Kottgen,1 Peggy Sekula,1 Robert P. Mohney,2 Florian Kronenberg,3 Kai-
Uwe Eckardt,4 Pascal Schlosser.5 1Medical Center - University of Freiburg, 
Freiburg, Germany; 2Metabolon, Inc., Durham, NC; 3Innsbruck Medical 
University, Innsbruck, Austria; 4University Medicine-Charite, Berlin, Germany; 
5Medical Center and Faculty of Medicine, University Freiburg, Germany, 
Freiburg, Germany.
Background: The kidneys play a central role in metabolite handling. Genetic studies of 
metabolite concentrations can identify proteins performing these functions. Reduced GFR 
may represent a challenge model for metabolite handling, facilitating the identification of 
such loci.
Methods: We carried out GWAS of the urinary concentrations of 1,172 metabolites 
among 1,221 European ancestry GCKD study participants with eGFR of 30-45 ml/min/1.73m2 
and UACR <30 mg/g, with further replication among 406 individuals. Dilution-corrected 
urinary metabolite concentrations were related to HRC-imputed genome-wide genotypes of 
minor allele frequency >1%, using an additive genetic model and multivariable adjustment. 
Statistical significance was defined as p<4.3e-11 (5e-8/1172) in a meta-analysis of discovery 
and replication, with concordant effect sizes.
Results: After correction for multiple testing, there were 246 genome-wide significant 
associations for 211 metabolites, distributed across 90 independent loci. These included 
previously identified loci in screens of urine (n=15) and blood (n=55) metabolite 
concentrations in the general population, and 20 novel loci. Associations between 
lead SNPs and urinary metabolite concentrations were strong, with p-values as low as 
<1e-550. Compared to associations of the same genetic variants and urinary metabolites in 
a healthy population, effects were significantly stronger among CKD patients on average 
(p<2e-16). The number of metabolites associated with a locus’ lead variant ranged up to 
30 for missense rs13538 in NAT8, consistent with the function of N-acetyl-transferase 
in detoxification reactions. Relating genome-wide genotypes to modeled relationships 
between metabolites (pairwise ratios, clusters) resulted in additional insights such as the 
identification of candidate substrates for renal transport proteins, a functional readout 
of renal enzymes, detoxification reactions of drugs commonly prescribed among CKD 
patients, and facilitated the de-orphanization of SNP-associated metabolites of previously 
unknown identity.
Conclusions: Our study increases the number of loci associated with urinary 
metabolite concentrations from 26 to 90, highlights the value of studying genetics of renal 
metabolism among CKD patients, and provides many novel insights into human renal 
(patho)physiology.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Rho Guanine Nucleotide Exchange Factor β-PIX Is Required for the 
Maintenance of Podocyte Architecture and Glomerular Function in Adult 
Mice
Jun Matsuda, Mirela Maier, Lamine Aoudjit, Tomoko Takano. Division of 
Nephrology, McGill University Health Centre, Montreal, QC, Canada.
Background: Activation of Rac1 (a small GTPase) in podocytes has been implicated in 
the development of proteinuria and focal segmental glomerulosclerosis (FSGS). Previously, 
we identified Arhgef7 (β-PIX) as a predominant GEF (guanine nucleotide exchange factor) 
that interacts with Rac1 in human podocytes (HP) using a proximity-based ligation assay, 
BioID. Furthermore, we confirmed that β-PIX is expressed in podocytes both in vitro and in 
vivo. However, its functional role remains unknown.
Methods: Cultured mouse podocytes (MP) with β-PIX knockdown (KD) and their 
controls were established using shRNA. Cell size was quantified in fixed cells stained with 
phalloidin. Cell migration and adhesive property were studied by wound healing assay and 
attachment assay, respectively. Cell proliferation was studied by MTT assay. Podocyte 
specific β-PIX deficient (KO) mice were generated by crossing β-PIX floxed mice with 
NPHS2-Cre mice. Urine albumin to creatinine ratio (ACR) and renal histology were studied 
up to 13 weeks of age. Data are provided as the mean ± SE.
Results: Compared to control MP, β-PIX KD MP were significantly smaller. Cell 
motility and adhesive property were modestly decrease in β-PIX KD MP. Proliferation rate 
was not different. Podocyte specific β-PIX KO mice presented no obvious renal phenotype 
up to 2-3 weeks of age, but developed progressive proteinuria starting at around 7-8 weeks 
of age (8 wk: KO: 117±44 x102 vs Control: 49±15 μg/mg, n=7-11, p<0.01; 13 wk: 255±128 
x102 vs 238±90 μg/mg, n=4-7, p<0.05). In addition, by PAS staining, 13-week-old KO 
mice showed global/segmental glomerulosclerosis, parietal cells proliferation, and tubular 
casts in the kidney.
Conclusions: Our findings demonstrate the previously unrecognized importance of 
β-PIX in maintaining podocyte function. To the best of our knowledge, this is the first 
evidence that a Rho GTPase GEF plays a critical role in podocytes.
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Tight Regulation of Crkl Isoforms Account for the Etiology and Pleiotro-
pic Effect of the 22q11.2 Microdeletion Syndrome (DiGeorge) on Kidney 
and Urinary Tract Development
Jeremiah Martino, Qingxue Liu, Tze Yin Lim, Nicholas J. Steers, 
Vivette D. D’Agati, Simone Sanna-Cherchi. Columbia University Medical 
Center, New York, NY.
Background: We recently showed that haploinsufficiency and point mutations in 
CRKL drive kidney and urinary tract malformations in the DiGeorge, or 22q11.2, syndrome 
and in sporadic CAKUT, respectively. We examined the developmental necessity of two 
Crkl transcript isoforms using conditional mutant mouse models.
Methods: Bulk RNAseq data from E15.5 mouse kidneys were analyzed for expression 
of Crkl T1 and T2 expression. Phenotypic analyses were carried out on conditional mouse 
mutants generated by breeding Crkl(Ex1)f/f or Crkl(Ex2)f/f with either Six2-, Hoxb7- or Pax2-
Cre mice to delete either both splice variants by removing the first of three exons (Ex1), or 
by removing T1 only via Ex2 excision.
Results: Analysis of RNAseq data show T1 and T2 expression at a mean TPM of 39.5 
and 9.3, respectively, (n=4) in E15.5 mouse kidneys. This is comparable to TPM data for 
housekeeping (Gapdh=55.5) and kidney & urinary tract genes (Pax2=10.4, Hoxb7=54.9, 
Six2=24.1). The two isoforms exist also in human embryonic kidneys. At P0, phenotypic 
analysis of Six2-Cre;Crkl(Ex1)f/f and Six2-Cre;Crkl(Ex2)f/f mice shows severe renal 
hypoplasia. When both Crkl transcripts were removed in ureteric-bud derived structures 
via Hoxb7-Cre, both unilateral and bilateral ureteropelvic dilation and early hydronephrosis 
developed by P0. However, in Hoxb7-Cre;Crkl(Ex2)f/f mice, where only T1 is absent, there 
was a decreased frequency and severity of obstructive phenotypes. Lastly, when bred with 
Pax2-Cre mice, both crosses show mild renal hypoplasia at P0 and E18.5.
Conclusions: These data suggest a tight regulation of both Crkl isoforms during mouse 
embryonic development with possible tissue-specific synergistic and modulatory effects. 
On the one hand, the presence of both Crkl isoforms in the metanephric mesenchyme is 
necessary for normal kidney development, but when inactivated in both compartments, 
hypoplasia was less severe. When T1 was removed from UB-derived structures, the 
presence of only T2 was sufficient to prevent abnormal development and obstructive 
uropathy, which were only observed with absence of both Crkl isoforms. These findings 
provide further insight into the pleiotropic effect of human CRKL mutations on kidney and 
urinary tract development.
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The LMX1βR246Q Mutation Causes FSGS through Dysregulation of 
Chloride Intracellular Channel Expression and Focal Adhesion Dynamics
Gentzon Hall,1 Maria E. Kovalik,2 Olivia G. Gregory,1 Brandon M. Lane,1 
Maxwell S. Lagas,3 Guanghong Wu,1 Megan Chryst-Stangl,4 Liming Wang,1 
Robert F. Spurney,1 Rasheed A. Gbadegesin.1 1Duke University Medical Center, 
Durham, NC; 2Duke University, Durham, NC; 3University of Arizona, Phoenix, 
AZ; 4Duke Molecular Physiology Institute, Durham, NC.
Background: We previously reported a heterozygous missense mutation of LMX1β as 
a cause of nail-platella-like renal disease in two families with hereditary FSGS. Currently, 
there are no targeted therapies for LMX1βR246Q-induced glomerulopathy. We hypothesized 
that LMX1βR246Q disrupts the expression of disease-relevant molecular targets that may be 
amenable to pharmacotherapy. To test this hypothesis, we performed an unbiased, RNA-seq 
analysis in our established LMX1β
WT
 and LMX1βR246Q-overexpressing podocyte lines to 
uncover potential therapeutic targets.
Methods: We conducted RNA-seq, qPCR, immunoblot, immunofluorescence, and 
scratch wound healing assays in LMX1β
WT
 and LMX1βR246Q-overexpressing podocytes to 
evaluate the effects of the LMX1βR246Q mutation on podocyte dysmotility.
Results: We detected significantly reduced Chloride Intracellular Channel 5 (CLIC5) 
expression in LMX1βR246Q podocytes relative to LMX1βWT controls by RNA-seq and 
qPCR. CLIC5 protein expression was similarly reduced as was the expression of CLIC3 
and CLIC4. Given the established roles of CLIC proteins in the regulation of foot process 
architecture (i.e. CLIC5) and β1-integrin recycling (i.e. CLIC3 and CLIC4), we evaluated 
motility in LMX1βR246Q podocytes. LMX1βR246Q podocytes displayed decreased wound 
closure, β1-integrin expression, FAK phosphorylation and paxillin activation. Focal 
adhesion density was increased in LMX1βR246Q podocytes relative to controls as evidenced 
by an increase in VASP staining by immunofluorescence. Gene expression of PKG II, an 
upstream activator of VASP, was also significantly downregulated by RNA-seq and qPCR 
in LMX1βR246Q podocytes. To determine the effect of NO/sGC/PKG pathway agonists 
on podocyte motility, we treated LMX1βR246Q-overexpressing podocytes with vardenafil 
(PDE5 inhibitor), cinaciguat (sGC activator) or riociguat (sGC stimulator). These NO/sGC/
PKG agonists ameliorated podocyte dysmotility.
Conclusions: The LMX1βR246Q mutation may cause FSGS, in part, through the 
dysregulation of CLIC-mediated foot process architecture and β1- integrin recycling 
and through impaired of PKG-mediated VASP activation in focal adhesions. NO/sGC/
PKG pathway agonists may be effective in ameliorating LMX1βR246Q-induced podocyte 
dysmotility.
Funding: NIDDK Support, Private Foundation Support
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Enzymatic Degradation of Cystine Decreases Nephrolithiasis in a Mouse 
Model of Cystinuria
Giulia Agnello,1 Jason F. Wiggins,1 Susan E. Alters,1 Everett Stone,2 
James E. Wooldridge,1 Scott W. Rowlinson.1 1Aeglea BioTherapeutics, Inc., 
Austin, TX; 2University of Texas at Austin, Austin, TX.
Background: Cystinuria is a genetic disease characterized by frequent recurrent stone 
formation in the kidneys requiring multiple procedural interventions with an increased risk 
of chronic kidney disease. Stone formation is the result of increased urinary excretion of 
insoluble cystine due to mutations in the SLC3A1 and/or SLC7A9 genes. Current disease 
management with hyperhydration, alkalization and cystine binding thiol drugs (CBTD) 
is challenging and problematic. Effectiveness is limited with continued stone formation 
and frequent adverse effects to CBTD requiring treatment withdrawal in some patients 
(Biyani and Cartledge, EAU-EBU update series 4, 2006). We investigated the potential of 
an alternative approach to disease management utilizing novel cystine degrading enzyme 
derived from human cystathionine gamma lyase (CGL).
Methods: In vivo efficacy of ACN00107 was tested in a murine model of cystinuria 
(SLC3A1-/-) that develops stones between 4 and 7 weeks of age (PMID: 28165480). 
ACN00107 (100 mg/kg, i.p., every other day) was administered to 5-week-old 
SLC3A1 -/- mice for up to 6 weeks. At specific timepoints prior to, during, and after 
ACN00107 treatment, bladder and kidneys were weighed and imaged by micro computed 
tomography (μCT) analysis.
Results: μCT analysis demonstrated a reduction in both volume and number of 
total kidney stones after 6 weeks of treatment which was associated with reduced kidney 
weights. A trend towards reduced bladder weight and total bladder stone volume compared 
to control was also observed.
Conclusions: This study demonstrates for the first time that enzymatic degradation of 
cystine reduces the propensity for kidney and bladder stone formation in a mouse model of 
cystinuria. Given the high morbidity, frequent requirement for procedural intervention, and 
the safety and tolerability profile of current medical approaches, enzymatic degradation of 
cystine warrants further investigation as a new potential approach for disease management.
Funding: Commercial Support - Aeglea BioTherapeutics, Inc.
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TFCP2L1 Mutations Cause a Novel Distal Tubulopathy in Humans
Verena Klambt,1 Max Werth,2 Michael Kaminski,3 Soeren S. Lienkamp,3 
Kai M. Schmidt-Ott,4 Yvette Roske,5 Jianhui Wang,6 Udo Heinemann,6 
Jonathan M. Barasch,8 Friedhelm Hildebrandt.7 1Boston Children’s Hospital, 
Boston, MA; 2Columbia University, New York, NY; 3University Hospital 
Freiburg, Freiburg, Germany; 4Charite - Universitaetsmedizin Berlin, Max-
Delbrueck Center for Molecular Medicine, Berlin, Germany; 5Max-Delbrück-
Center for Molecular Medicine, Berlin, Germany; 6Max Delbrück Center for 
Molecular Medicine, Berlin, Germany; 7Boston Children’s Hospital, Boston, 
MA; 8Columbia Presbyterian, New York, NY.
Background: An underlying monogenic cause of early-onset chronic kidney disease 
(CKD) can be detected in 20% of individuals. To date, >250 monogenic causative genes 
have been identified for the most common etiologies of CKD evident before age 25 years 
suggesting mechanisms of renal pathogenesis.
Methods: We performed whole exome sequencing to identify novel monogenic causes 
of CKD in ~1,000 families with renal tubulopathy/ echogenic kidneys.
Results: We discovered 2 different recessive, homozygous mutations in TFCP2L1 
(Transcription Factor CP2 Like 1) in 2 consanguineous families with CKD. Family 
B2003 with CKD at the age of 2 years, episodes of severe hypochloremic, hypokalemic 
alkalosis, cataracts, seizures, developmental delay, and hypotonia encoded a homozygous 
Ser290Phefs*5 mutation. A second child encoded a homozygous Gln168Arg mutation 
in A5048 with onset of CKD by 2 years of age, loss of urinary potassium and chloride, 
hypotonia and deafness. The variants are disease causing by SIFT, MutTaster and 
PolyPhen2 prediction programs and are absent from gnomAD database. Gln168Arg is 
located in the DNA-binding domain positioned at the start of the L10 loop pointing into 
the DNA minor groove. Tfcp2l1 is a transcription factor expressed in the thick limb of 
Henle, distal convoluted tubule, connecting segments and especially in the intercalating 
cells (ICs) in collecting ducts. Tfcp2l1 alone is sufficient to induce tubulogenesis in rat 
progenitors and is required for normal maturation of the distal nephron and collecting ducts 
in mice (Yamaguchi, Development, 2006; Werth, Elife, 2017). Tfcp2l1 knockout mice 
display loss of expression of direct binding targets of Tfcp2l1 including ion transporters in 
different segments of the distal nephron and regulatory proteins determining cell identity. A 
knockout caused renal hypoplasia, polyuria, renal potassium and chloride loss (Yamaguchi, 
Development 133:4737, 2006) and disruption of collecting duct patterning characterized 
by the deletion of ICs (Werth, eLIFE, 2017). Consistently, in Xenopus larvae skin tfcp2l1 
localizes to foxi1+ ICs.
Conclusions: We here identified TFCP2L1 mutations as a potential novel cause of 
distal tubulopathy in humans. Modeling these mutations in mice and segment specific 
deletions will reveal the full functions of Tfcp2l1.
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CHRNA3 Mutations Cause Neurogenic Bladder and Dysautonomia
Franziska Kause,1 Nina Mann,2 Shirlee Shril,3 Dervla M. Connaughton,2 
Caroline M. Kolvenbach,4 Rufeng Dai,2 Makiko Nakayama,2 Elisa De Franco,7 
Sian Ellard,8 Velibor Tasic,5 Jonathan M. Beckel,6 Friedhelm Hildebrandt.2 
Boston Children’s Hospital, Division of Nephrology 1Boston Children’s 
Hospital, Boston, MA; 2Boston Children’s Hospital, Boston, MA; 3Boston 
Childrens Hospital, Boston, MA; 4Harvard Medical School, Boston, MA; 
5University Children’s Hospital, Skopje, Macedonia (the former Yugoslav 
Republic of); 6University of Pittsburgh, Pittsburgh, PA; 7Royal Devon and 
Exeter NHS Foundation Trust, Exeter, United Kingdom; 8University of Exeter 
Medical School, Exeter, United Kingdom.
Background: Congenital anomalies of the kidneys and urinary tract (CAKUT) are the 
most prominent cause (>45%) of chronic kidney disease (CKD) in the first 3 decades of 
life. Although about 40 monogenic causes have been implicated in human CAKUT so far, 
many causes remain unknown.
Methods: To identify novel monogenic causes of CAKUT we applied whole exome 
sequencing (WES) to 144 families with CAKUT.
Results: By WES, we discovered a homozygous frameshift mutation 
(p.Thr337Asnfs*81) in the gene CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit) 
in a patient of consanguineous descent with CKD stage 3 secondary to neurogenic bladder, 
vesicoureteral reflux (VUR) and bilateral hydronephrosis. Screening WES data of 703 
further patients with CAKUT revealed three different homozygous recessive CHRNA3 
mutations in 3 families with neurogenic bladder (p.Ser340*; c.267+2T>G obligatory splice 
site mutation; p.Arg110His). CHRNA3 codes for an ion channel subunit in the urothelium 
and interacts with other ion channels in the neuronal network governing bladder reflexes 
and smooth muscle contraction. A Chrna3 knockout mouse has impaired bladder reflexes, 
a distended urinary bladder, dribbling urination, urinary tract infections, urinary stones and 
mydriasis (Xu PNAS 96:5746, 1999). Given the mydriasis in mice we inquired for constant 
mydriasis in the patients. This was confirmed for the index patient with p.Thr337Asnfs*81 
and two affected siblings with the p.Ser340* mutation.
Conclusions: We identified CHRNA3 recessive mutations as the first cause of 
neurogenic bladder in humans. The mutations caused additionally extrarenal dysautonomic 
phenotypes such as constant mydriasis. Our findings may disclose a pathophysiological 
sequence, in which neurogenic bladder secondarily causes CAKUT.
FR-OR078 Oral Abstract Friday
Glomerular Diseases: Clinical, Outcomes, and Trials
Confidence in Women’s Health: An International Survey of Nephrologists
Monica L. Reynolds,1 Elizabeth M. Hendren,4 Jarcy Zee,3 Laura H. Mariani,2 
Michelle A. Hladunewich.4 1Nephrology, University of North Carolina, Chapel 
Hill, NC; 2University of Michigan, Ann Arbor, MI; 3Arbor Research Collaborative 
for Health, Ann Arbor, MI; 4University of Toronto, Toronto, ON, Canada.
Background: A broad range of women’s health issues are intimately related to kidney 
disease, yet little is known about providers’ confidence in these issues. The women’s health 
working group of CureGN sought to assess adult Nephrologists’ exposure to women’s 
health, their confidence in counseling and management, and ways to improve future care.
Methods: A 25-question survey was disseminated via the CureGN email network, 
the Canadian Society of Nephrology and ASN Kidney News. Demographics, practice 
characteristics, and response prevalence were summarized with descriptive statistics. 
Responses across country of practice (United States vs Canada) were compared using 
Pearson’s chi squared test.
Results: Of the 154 respondents, 58% were from the US, 53% were women, and 
the median age was between 41-45. The majority (77%) identified their practice setting 
as academic. 55% of the respondents had fellowship training in women’s health, which 
was similar across country of training (p=0.325). Nephrologists from both countries lacked 
confidence across a spectrum of issues (Figure 1). Most provided contraception (64%) and 
pre-conception (68%) counseling to less than one woman per month though counseling 
occurred significantly more frequently in the US. In their career, 91% have cared for less 
than five pregnant women on dialysis. Only 12% had access to interdisciplinary clinics. 
Finally, 89% felt that interdisciplinary guidelines and/or continuing education seminars 
would improve knowledge.
Conclusions: As women with chronic kidney disease experience adverse maternal 
outcomes and remain at risk for disease progression postpartum, we must do better to 
bolster provider knowledge and comfort level. Further research is warranted to identify 
barriers to counseling about women’s health issues, identify best mechanisms to enhance 
physician confidence, and facilitate formation of interdisciplinary clinics. Interdisciplinary 
guidelines and case based materials may be a starting point.
Funding: NIDDK Support
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The Effect of Plasma Exchange and the Effect of Reduced-Dose Oral 
Glucocorticoids during Remission Induction in Severe ANCA-Associated 
Vasculitis
Michael Walsh,1 Peter A. Merkel,3 David R. Jayne.2 PEXIVAS Investigators 
1McMaster University, Hamilton, ON, Canada; 2University of Cambridge, 
Cambridge, United Kingdom; 3University of Pennsylvania, Philadelphia, PA.
Background: Whether plasma exchange reduces the risk of end-stage renal disease or 
death in anti-neutrophil cytoplasm antibodies (ANCA) -associated vasculitis is uncertain. 
Also uncertain is whether lower doses of oral glucocorticoids reduce the risk of infection 
without increasing the risk of end-stage renal disease or death.
Methods: We performed a 2-by-2 factorial randomized controlled trial to separately 
evaluate plasma exchange and two different regimens of oral glucocorticoids in patients 
with severe ANCA-associated vasculitis. Participants were randomly assigned to 7 
treatments of plasma exchange or no plasma exchange. Participants were also randomly 
assigned to either a reduced-dose regimen that <60% of the cumulative oral glucocorticoid 
dose or a standard regimen by 6 months or the standard regimen. All patients received 
immunosuppression. Patients were followed for up to 7 years for the primary composite 
outcome of death from any cause or end-stage renal disease.
Results: Amongst 702 participants, the primary outcome occurred in 28% of patients 
allocated to plasma exchange compared to 31% in the no plasma exchange group (hazard 
ratio 0.86, 95% confidence interval [CI] 0.65 to 1.13; p=0.27). The primary outcome 
occurred in 28% of patients in the reduced glucocorticoid group and 26% in the standard 
glucocorticoid group (absolute risk difference 2.3%, 90% CI -3.4% to 8.0%; met non-
inferiority hypothesis). Serious infections in the first year occurred less often in the reduced 
glucocorticoid group compared to the standard group (incidence rate ratio 0.70, 95% CI 
0.52 to 0.94; p=0.02).
Conclusions: Plasma exchange did not reduce the risk of end-stage renal disease or 
death. Compared to a standard dose, reduced glucocorticoids did not substantially increase 
the risk of death or end-stage renal disease and resulted in fewer serious infections.
Funding: Other U.S. Government Support
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Membranous Nephropathy: Response to Rituximab Is Dependent on 
Anti-PLA2R1 Epitope Spreading and Gender
Vesna Brglez,1 Piero L. Ruggenenti,2,3 Barbara Ruggiero,3 Luca Perico,3 
Alessia Gennarini,2 Christine Payre,1 Guillaume Dolla,1 Barbara Seitz-Polski,1,4 
Ariela Benigni,3 Gerard J. Lambeau,1 Giuseppe Remuzzi.2,3 1Université Côte 
d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 
Valbonne, France; 2Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, 
Bergamo, Italy; 3IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 
Ranica (Bergamo), Italy; 4Pasteur University Hospital, Nice, France.
Background: Membranous nephropathy (MN) is a rare autoimmune kidney disease, 
yet one of the leading causes of nephrotic syndrome (NS) in adults. Clinical evolution 
is complex and treatment controversial. There is a need for better biomarkers to identify 
patients at risk of severe disease and orient therapy. Phospholipase A2 receptor 1 (PLA2R1) 
was identified as the major autoantigen in 70% of patients with MN. Proteinuria and 
PLA2R1 antibody titer predict outcome in PLA2R1-related MN.
Methods: We evaluated the additional predictive role of PLA2R1 epitope spreading 
from the immunodominant CysR domain to CTLD1 and CTLD7 domains in 117 
consecutive, rituximab- treated patients with PLA2R1-related MN and nephrotic syndrome. 
Primary outcome was complete (proteinuria <0.3 g/24h) or partial remission (proteinuria 
<3.0 g/24h and >50% reduction vs basal). Non-spreaders had antibodies restricted to the 
CysR domain while spreaders had additional antibodies to CTLD1 and/or CTLD7 domains.
Results: Higher basal anti-PLA2R1 titer associated with higher probability of 
spreading. All patients with titer >400 RU/ml were spreaders. Fifteen of the 79 spreaders 
(19%) were females vs 16 of the 38 non-spreaders (42%; p=0.008), and 15 of 31 females 
(48%) were spreaders vs 64 of 86 males (74%; p<0.01). During a median (IQR) follow-
up of 32.2 (16.4-50.5) months, 77 patients (66%) achieved the combined endpoint of 
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complete or partial remission. Female gender (p=0.004), shorter duration of proteinuria 
(p=0.004), lower proteinuria (p=0.004), lower antibody titer (p=0.036), and no epitope 
spreading (p=0.009) predicted remission. Compared to spreader males, the HR (95% CI) 
for the endpoint was 5.15 (2.73-9.70; p<0.0001) in non-spreader females, 2.09 (1.16-3.77, 
p=0.014) in spreader females, and 1.85 (0.95-2.59, p=0.069) in non-spreader males.
Conclusions: In MN, anti-PLA2R1 titer and epitope spreading monitoring help 
to predict response to rituximab. Better response of females could be explained, at least 
partially, by protection against PLA2R1 epitope spreading. VB and PR contributed equally 
as first authors, GL and GR contributed equally as last authors.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-OR081 Oral Abstract Friday
Glomerular Diseases: Clinical, Outcomes, and Trials
Non-Invasive Diagnosis of Primary Membranous Nephropathy using 
Phospholipase A2 Receptor Antibodies
Shane A. Bobart,1 An S. De Vriese,2 Ladan Zand,1 Sanjeev Sethi,1 
Callen D. Giesen,1 John C. Lieske,1 Fernando C. Fervenza.1 1Mayo Clinic, 
Rochester, MN; 2AZ Sint-Jan, Bruges, Belgium.
Background: Kidney biopsy is the current gold standard to diagnose membranous 
nephropathy (MN). Approximately 70-80% of patients with primary MN have circulating 
anti-PLA2R antibodies. We hypothesized that PLA2R antibody testing without the need 
for a biopsy is a valid strategy to make a non-invasive diagnosis of MN in the setting of 
preserved renal function and negative work up for secondary causes such as autoimmunity, 
malignancy, medications and paraproteinemias.
Methods: The medical records of all Mayo Clinic patients with positive serum PLA2R 
antibody tests between July 2015 and December 2017 were reviewed.
Results: A total of 1065 PLA2R tests were ordered on 675 unique patients. Of these, 
113 had a positive PLA2R antibody test, of which 105 had native renal biopsies performed. 
The primary diagnosis in all biopsies was MN. Eighty-four patients had a negative work up 
for secondary causes of MN. Fifty of the 84 patients had preserved renal function (eGFR 
>60 ml/min/1.73m2). In none of these 50 patients, kidney biopsies provided significant 
information that altered diagnosis or management. Among the 34 patients with eGFR <60 
ml/min/1.73m2, additional findings that altered the treatment plan included acute interstitial 
nephritis (n=1), superimposed diabetic nephropathy (n=1) and cellular crescents (n=1).
Potential secondary causes were identified in 21 cases (positive ANA test = 4, malignancy = 
9, NSAID = 3, monoclonal protein = 5). A detailed review of the clinical data revealed that 
these were co-existing findings and not true secondary MN.
Conclusions: In patients with preserved renal function and no evidence of secondary 
causes, a positive PLA2R test confirms the diagnosis of MN. A kidney biopsy does not add 
significant data in this context.
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PLA2R1 as the Major Autoantigen in Membranous Nephropathy: From 
New Epitope Identification to Personalized Medicine
Joana Justino,1 Vesna Brglez,1 Guillaume Dolla,1 Christelle Zaghrini,1 
Christine Payre,1 Barbara Seitz-Polski,2 Hanna Debiec,3 Pierre M. Ronco,3 
Gerard J. Lambeau.1 1Institute of Molecular and Cellular Pharmacology, CNRS 
and University Cote d’Azur, Valbonne, France; 2Pasteur University Hospital, 
Nice, France; 3Hospital Tenon, Sorbonne University, Paris, France.
Background: Membranous nephropathy (MN) is a rare autoimmune kidney disease 
yet the most common cause of nephrotic syndrome. Clinical evolution is complex and 
treatment controversial. There is a need for better biomarkers to identify patients at risk of 
severe disease and orient therapy. In 2009, PLA2R1 was identified as the major autoantigen, 
with circulating autoantibodies in 70% of patients. The severity of MN and clinical outcome 
is associated with anti-PLA2R1 titer and the presence of multiple antibodies. PLA2R1 
epitopes have been identified in the CysR (CR), C1 and C7 domains and may be linked 
by a mechanism of epitope spreading. However, their exact number and location including 
controversial findings concerning their presence in the CR and C1 domains require further 
studies. The aim of this work was to clarify the number of PLA2R1 domains containing 
epitopes.
Methods: To clarify the conundrum between CR and C1 N-terminal domains, we 
expressed in HEK293 cells a series of CR-FnII-C1 triple domains with insertion of protease 
cleavage sites between each domain. Reactivities were tested with different patients’ sera 
before and after protease cleavage. To further investigate the number of epitope domains 
in the distal region of PLA2R1, we expressed a series of individual PLA2R1 domains and 
tested their reactivity for a cohort of >150 MN patients by ELISA.
Results: The triple domain CR-FnII-C1 was recognized by all patients’ sera when 
tested before cleavage. After cleavage releasing isolated domains, some sera had reactivities 
limited to CR or C1 while others reacted with both CR and C1, demonstrating the presence 
of independent epitopes targeted by different antibodies. The ELISA screening of a cohort 
of 150 patients towards individual PLA2R1 domains led us to identify C5 and C8 as two 
new epitope-containing domains.
Conclusions: Our results show that patient’s autoantibodies can target up to 5 PLA2R1 
domains: CR, C1, C5, C7 and C8 with different prevalence’s. The clinical association 
between reactivity towards these 5 PLA2R1 domains and disease activity is currently 
being analyzed and may help to design new diagnosis and prognosis tools towards better 
personalized medicine. JJ and VB contributed equally as first authors.
Funding: Government Support - Non-U.S.
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CD-19 Targeted Rituximab Is Safe and Effective in Adult Steroid 
Dependent/Resistant but Calcineurin Inhibitor Dependent Podocytopathy
Krishan Lal L. Gupta, Ritambhra N. Duseja, Raja Ramachandran. Postgraduate 
Institute of Medical Education & Research, Chandigarh, India.
Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis 
(FSGS) are common podocytopathies causing nephrotic syndrome (NS) in children and 
adults. A significant proportion of patients are either steroid dependent (SD) or resistant 
(SR), requiring alternate therapies. Long-term calcineurin inhibitors (CNI) use is 
associated with dyslipidemia, impaired glucose tolerance and, nephrotoxicity. Rituximab 
is a potential candidate in this group of patients, with a more favourable safety profile, 
so the present study was undertaken to evaluate the efficacy and safety of rituximab in 
SD/SR MCD/FSGS dependent on CNIs to maintain remission.
Methods: This was a prospective observational study conducted from July 2014 to 
February 2018. SD-NS or SR-NS (biopsy proven MCD/FSGS), who were CNI dependent 
were enrolled. All patients received rituximab at a dose of 375 mg/m2 at entry in the study. 
CD-19 levels were monitored monthly and patients having CD-19 levels >5/μL and/or >1% 
received additional low-dose (100 mg) of rituximab. Patients were followed up monthly for 
a period of 12 months, and the clinical and biochemical parameters prior to and following
rituximab administration were compared. Outcome: Cumulative percentage of patients
who experienced remission (Complete remission (CR), partial remission (PR)) at 6 and
12 months.
Results: A total of 24 patients was enrolled and followed for 12 months. Mean age at 
enrolment was 22.77±7.45 years. At the end of 6 and 12 months, 87.50% and 79.16% of the 
patients achieved remission, respectively. CR and PR at 6 and 12 months were observed in 
14 (58.33%) and 7 (29.17%), and 13 (54.16%) and 6 (25%), patients, respectively. Relapse 
occurred in 7 (29.16%) patients during the follow-up, requiring steroids (4, 57.14%) or 
CNIs (3, 42.85%). The mean dose of rituximab was 791 mg. Rituximab was well-tolerated, 
with infusion reactions, respiratory tract infection and oral candidiasis in 5 (20.83%), 5 
(20.83%) and 1 (4.17%) patient, respectively.
Conclusions: CD-19 targeted rituximab is a safe and effective agent in the management 
of adults with CNI dependent MCD/FSGS. At 12 months, over three-fourth of the patients 
with CNI dependent podocytopathy maintain clinical remission.
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Nephrotic Syndrome Is Significantly Associated with Increased Risk of 
Ischemic Stroke
Ming-Ju Wu, Tung-Min Yu. Taichung Veterans General Hospital, Taichung, 
Taiwan.
Background: Evidence on the risk of ischemic stroke in patients with nephrotic 
syndrome is scarce.
Methods: We conducted a retrospective nationwide cohort study by analyzing the 
registry data of the National Health Insurance Research Database in Taiwan. Adult patients 
who were aged ranged 18 to 110 years and had received a diagnosis of nephrotic syndrome 
were included in the nephrotic syndrome cohort. For each patient with nephrotic syndrome, 
the corresponding controls were selected 1:4 on the basis of matched age, sex, Charlson 
comorbidity index, and index date to evaluate the risk of stroke, especially the ischemic 
stroke.
Results: The first three-year incidence rates of ischemic stroke were 25% and 15.9% in 
3496 patients with nephrotic syndrome and 13984 comparison control cohorts, respectively. 
Overall, 9% patients with nephrotic syndrome developed ischemic stroke in 9.1±2.9 years 
follow-up period. A higher risk of stroke was observed in patients with nephrotic syndrome 
than in controls, adjusted hazard ratio (aHR) 1.37; 95% confidence interval (CI) 1.21-1.54, 
p<0.001. Regarding the risk of different stroke subtypes, including ischemic stroke and 
hemorrhagic stroke, the aHR for ischemic stroke was 1.38 (95% CI 1.21-1.57, p<0.001) and 
that for hemorrhagic stroke was 1.26 (95% CI 0.84-1.88, p=0.266) in patients with nephrotic 
syndrome compared with controls, after adjustment for age, sex, and comorbidities.
Conclusions: This study provides first significant evidence that patients with nephrotic 
syndrome had an increased risk of ischemic stroke.
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Treatment Response in Proliferative Glomerulonephritis with Monoclonal 
Immunoglobulin Deposits
Gauri Bhutani,1 Wai L. Lau,3 Maria E. Drosou,2 Samih H. Nasr,2 Brad C. Astor,1 
Gerald B. Appel,3 Nelson Leung.2 1University of Wisconsin, Madison, WI; 
2Mayo Clinic, Rochester, MN; 3Columbia University College of Physicians and 
Surgeons, Scarsdale, NY.
Background: Proliferative Glomerulonephritis with Monoclonal Immunoglobulin 
Deposits (PGNMID) usually results from an occult hematologic clone, making treatment 
challenging.
Methods: The Mayo Clinic pathology and Columbia U. Glomerular Ctr database 
were used to identify patients with PGNMID. Response to each treatment (Rx) regimen for 
native renal disease was evaluated. “Renal response” was defined as decrease in proteinuria 
(UPRT) by >50% without worsening of serum creatinine (Scr); “complete remission” as 
return to within 10% of normal Scr with <1 g/d UPRT; “renal progression” as reaching 
ESRD, death or need for another Rx. Chi-square, Fisher’s exact and Log-rank test were 
utilized for statistical analysis.
Results: Rx outcomes in 83 PGNMID patients were evaluated. Most had no known 
hematologic clone (87%). Median Scr at presentation was 1.6 mg/dL (1.2-2.3) with UPRT 
4.12 g/d (2.71-8.07). Over a median follow up period of 2.8 yrs, 30% (25/83) reached 
ESRD, 5% (4/83) died and a median of 2 (1-3) and total 139 Rx were received. “Renal 
response” differed significantly between the Rx regimens (p=0.012). This was primarily due 
to worse outcomes with conservative Rx and a superior response with cyclophosphamide 
(Table). “Renal progression” occurred with 60% Rx regimens over a median time of 216 
days (104-545). Time to progression was lesser with conservative vs immunosuppressive 
Rx (p=0.012) but not different among the 5 immunosuppresive regimens (p=0.369). Anti-
plasma cell Rx was less often used as 1st Rx as compared to other regimens (p=0.011).
Conclusions: PGNMID results in poor renal outcomes especially when 
immunosuppression is not used. Cyclophosphamide was most likely to lead to renal 
remission in our cohort but surprisingly, anti-plasma cell Rx, which is most appropriate 
targeted therapy in expert opinion, was not found to have improved outcomes. This may 
be due to use of this Rx later in disease course. Further prospective studies are needed to 
identify the best Rx in PGNMID.
FR-OR086 Oral Abstract Friday
Glomerular Diseases: Clinical, Outcomes, and Trials
Hypertension or Complement-Associated Thrombotic Microangiopathy 
Diagnostic Implications and Response to Eculizumab
Fernando Caravaca-Fontan,3 Teresa Cavero escribano,1 Santiago Rodriguez de 
Cordoba,2 Manuel Praga.1 Spanish Group for the Study of Glomerular Diseases 
(GLOSEN) 1Hospital 12 de Octubre, Madrid, Spain; 2Consejo Superior de 
Investigaciones Cientificas, Madrid, Spain; 3Hospital Universitario Ramón y 
Cajal, Madrid, Spain, Madrid, Spain.
Background: Malignant hypertension is listed among the causes of secondary 
thrombotic microangiopathy (TMA), but the presence of pathogenic mutations in 
complement genes have been recently reported in patients with hypertension-induced. No 
studies have investigated the frequency and severity of hypertension (HTN) in primary, 
complement-mediated atypical hemolytic uremic syndrome (aHUS).
Methods: Seventy-five patients with primary aHUS were collected in 21 hospitals in 
Spain and Portugal. Primary outcome was hematologic and renal response. Patients were 
classified according to the severity of HTN in normal blood pressure (8 patients, 10%), 
stage 1 HTN (13, 17%) and stage 2 HTN (54, 72%). Among the latter, malignant HTN 
(defined by the presence of hypertensive retinopathy grades III/IV) was found in 24 (55%) 
out of 43 patients in whom retinal examination was performed.
Results: Median age was 34 years and 27 patients (36%) had history of HTN. Fifty-five 
(75%) patients required acute hemodialysis at presentation. Plasmapheresis was performed 
in 64 patients and 35 received eculizumab. Abnormalities in complement genes were found 
in 36 /64 patients (56%) in whom genetic study was performed (68% among patients 
with malignant HTN). Response was significantly lower after plasmapheresis (25%) than 
after eculizumab (82%), as well as the rate of dialysis discontinuation (38% and 79%, 
respectively). Response to eculizumab was similar in normotensive (100%), stage 1 HTN 
(71%), stage 2 HTN (84%) and malignant HTN patients (90%) and was independent of the 
presence of genetic abnormalities. Renal survival was significantly higher in patients treated 
with eculizumab (87% at 1, 3 and 5 years) compared to patients who did not receive this 
treatment (55%, 46% and 38% at 1, 3 and 5 years, respectively).
Conclusions: Severe hypertension is very common in aHUS, frequently fulfilling the 
criteria of malignant HTN. The efficacy of eculizumab was observed also in patients with 
HTN, having or not abnormalities in complement genes.
FR-OR087 Oral Abstract Friday
Glomerular Diseases: Clinical, Outcomes, and Trials
Long-Term Effects of Sparsentan, a Dual Angiotensin and Endothelin 
Receptor Antagonist in Primary Focal Segmental Glomerulosclerosis 
(FSGS): Interim 84-Week Analysis of the DUET Trial
Jonathan J. Hogan,5 Vimal K. Derebail,6 Edward Murphy,4 Partha C. Raguram,7 
Pablo E. Pergola,1 Neil S. Sanghani,2 Howard Trachtman,3 Radko Komers.4 
1Renal Associates, PA, San Antonio, TX; 2Vanderbilt University, Nashville, TN; 
3NYU School of Medicine, New York, NY; 4Retrophin, Inc., Portland, OR; 
5University of Pennsylvania, Philadelphia, PA; 6UNC School of Medicine, 
Chapel Hill, NC; 7Catholic Health Initiatives Franciscan, Tacoma, WA.
Background: DUET is a phase 2, randomized, active-control study of patients 
(pts) 8–75 years with primary FSGS, estimated glomerular filtration rate (eGFR) >30 
mL/min/1.73 m2, and urine protein-to-creatinine ratio (UP/C) ≥1 g/g. Pts (N=109) were 
randomized to sparsentan (SPAR; 200, 400, or 800 mg/d) or irbesartan (IRB; 300 mg/d) 
for 8-week double-blind (DB) treatment in addition to current standard of care (including 
immunosuppressive treatments), followed by SPAR only (SPAR:SPAR, IRB:SPAR) in the 
open-label extension (OLE). This interim analysis was performed at Week 84.
Methods: In the OLE, UP/C, blood pressure (BP), eGFR, and FSGS partial remission 
endpoint (FPRE; UP/C ≤1.5 g/g and >40% UP/C reduction) were assessed every 12 weeks 
and compared with baseline (Week 0 for SPAR:SPAR; Week 8 for IRB:SPAR).
Results: UP/C, BP, and eGFR data are in the Table. SPAR:SPAR and transition to 
SPAR, at Week 8 in IRB:SPAR, led to statistically significant reductions in UP/C and BP, 
sustained to Week 84. FPRE was achieved by 27/45 (60%) SPAR:SPAR and 13/26 (50%) 
IRB:SPAR pts at Week 84. In both groups, eGFR decreased initially and stabilized with 
increasing follow-up duration, possibly reflecting early hemodynamic effects of the drug. 
During SPAR treatment, adverse events were reported in 63 (94%) SPAR:SPAR and 32 
(91%) IRB:SPAR pts; headache, peripheral edema, and hypotension occurred in >20% of 
pts in SPAR:SPAR or IRB:SPAR.
Conclusions: Sparsentan achieved sustained protein-lowering and BP-lowering effects 
in primary FSGS over 84 weeks, suggesting long-term nephroprotective potential of the 
drug.
Funding: Commercial Support - Retrophin, Inc., San Diego, CA
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An Autologous Cellularized In Vivo Engineered Vascular Graft Capable 
of Remodeling to a Non-Thrombogenic Blood Vessel upon Arteriovenous 
Grafting in Adult Goats
Wouter Geelhoed,1 Koen E. van der Bogt,2 Carolien Rothuizen,4 Jaap Hamming,3 
Maarten S. van Agen,8 Hetty C. de Boer,3 Boris Hinz,7 Ankur Kislaya,5 
Anton J. Van Zonneveld,3 Ton J. Rabelink,1 Lorenzo Moroni,6 Joris I. Rotmans.1 
1LUMC, Leiden, Netherlands; 2Haaglanden Medisch Centrum/LUMC, Den 
Haag, Netherlands; 3Leiden University Medical Center, Leiden, Netherlands; 
4Leiden University Medical Center/Stafsecretariat Nephrology, Leiden, 
Netherlands; 5Delft University of Technology, Delft, Netherlands; 6Maastricht 
University, Maastricht, Netherlands; 7University of Toronto, Toronto, ON, 
Canada; 8Leiden University Medical Centre, The Hague, Netherlands.
Background: The durability of prosthetic vascular grafts used for hemodialysis access 
is poor due to venous stenosis, limiting vascular access. We present a method to create 
tissue engineered blood vessels (TEBVs) capable of developing in vivo towards a functional 
vascular graft.
Methods: Polymeric rods are implanted subcutaneously in goats for 1 month, resulting 
in the formation of fibrocellular tissue capsules (TC’s) with sufficient mechanical strength 
to restrain arterial pressure. The TC’s then are grafted as arteriovenous conduit between 
the carotid artery and jugular vein. After 1 or 2 months in the vasculature the grafts were 
harvested.
Results: Ex vivo perfusion showed grafts were less thrombogenic than initial TCs, 
and also when compared to ePTFE grafts. At 1 month the TEBVs were composed of 
vascular smooth muscle cell-like cells, with confirmed contractility. At 2 months, complete 
endothelialisation and elastin formation was also observed, while in vivo graft patency was 
comparable to ePTFE.
Conclusions: Here, we demonstrate the in vivo remodelling capacity of TC into TEBV, 
and their potential as replacements for prosthetic vascular grafts.
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Lysyl Oxidase Determines Postoperative Vascular Stiffness and Neointi-
mal Formation after Arteriovenous Fistula Creation
Diana R. Hernandez,1 Laisel Martinez,1 Marwan Tabbara,1 Juan C. Duque 
Ballesteros,1 Loay H. Salman,2 Roberto I. Vazquez-Padron.1 1University of 
Miami, Miller School of Medicine, Miami, FL; 2Albany Medical College, 
Albany, NY.
Background: The transformation of a vein to a fistula is one of the most intriguing 
processes in vascular biology. The desired scenario is that the fistula matures becoming a 
larger vessel with increased luminal area and a thicker wall. Unfortunately, arteriovenous 
fistulas (AVFs) frequently fail (~40%) because venous stenosis compromises blood flow. 
Lysyl oxidase (LOX) is the main enzyme that catalyzes the oxidative deamination of 
lysine/hydroxylysine residues (ε-amino groups) in proteins to facilitate spontaneous intra/
intermolecular covalent crosslinks formation. The most recognized substrate of LOX is 
collagen. In fact, collagen tensile strength relies upon LOX mediated crosslinking. LOX is 
critical for vascular and connective tissue formation; however, deregulated LOX increases 
collagen stiffness and prevents its degradation, thereby contributing to fibrosis.
Methods: Herein, our goal was to demonstrate that upregulated LOX in the venous 
limb of the AVF mediates improper remodeling, which causes stenosis and failure.
Results: We first demonstrated that immature and mature collagen crosslinks (using 
UPLC-ESI-MS/MS) were more abundant in failed human AVFs than in fistulas that 
matured successfully (N=10/group, p< 0.05). Increased crosslinking correlated with 
vascular accumulation of LOX as determined by immunohistochemistry. Interestingly, 
LOX appeared in the interstitial space and in the nuclei of smooth muscle cells (SMCs) 
and neointimal cells, in agreement with prior reports detecting LOX within the nuclei of 
cultured fibroblasts. The nuclear location of LOX in SMCs was further demonstrated using 
cell fractioning techniques. The LOX inhibitor β-aminoproprionitrile (BAPN) decreased 
SMC growth in culture, which suggests a potential role of this enzyme in the postoperative 
expansion of the intima. Finally, we demonstrated that systemic and local inhibition of LOX 
with BAPN increases blood flow and elasticity, and prevents medial fibrosis and intimal 
hyperplasia in a rat model of AVF.
Conclusions: In conclusion, these data indicate, for the first time, the importance of 
LOX-mediated crosslinking in AVF failure and the potential role of this enzyme not only in 
vascular stiffness but also in the control of SMC fate and growth.
Funding: NIDDK Support
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Inhibition of MicroRNA-92a Enhances Arteriovenous Fistula 
Development
Yan-Ting Shiu,1 CS Jason Tey,1 Yuxia He,1 Ha D. Le,1 Isabelle D. Falzon,1 
Zhen Chen,2 Yun Fang,3 Lisa Lesniewski,1 Alfred K. Cheung.1 1University of 
Utah, Salt Lake City, UT; 2City of Hope, Duarte, CA; 3University of Chicago, 
Chicago, IL.
Background: The Hemodialysis Fistula Maturation Consortium Study showed that 
endothelial health was associated with the development of arteriovenous fistulas (AVFs). 
MicroRNA (MiR)-92a is a major contributor to vascular endothelial dysfunction. We 
recently reported that patients with chronic kidney disease (CKD) had increased serum 
miR-92a levels when compared to non-CKD control subjects, and that serum miR-92a was 
likely derived from the endothelium. Thus, we investigated the relationship between miR-
92a and AVF development in animal models.
Methods: In young male Wistar rats with normal kidney function or with adenine 
diet-induced CKD, we created femoral AVFs and then assessed AVF lumen diameter 
by ultrasound and AVF tissue miR-92a levels by RT-PCR at 4 weeks after creation. In a 
mouse carotid-jugular AVF model, miR-92a inhibition was achieved using genetic and 
pharmacological approaches: (1) whole-body knockout (miR-92a−/−) with C57BL/6 mice 
used as wild-type (WT) controls; or (2) nanoparticles (NPs) that encapsulate miR-92a 
inhibitors and target inflamed endothelium (un-encapsulated miR-92a inhibitors and saline 
were used as no-NP and no-treatment controls, respectively). C57BL/6 mice received the 
inhibitor treatment (8 mg/kg body weight) intravenously at 1 day after AVF creation and 
were sacrificed 1 week later. Mouse AVF cross-sectional lumen area was quantified by 
histology.
Results: When compared to AVFs in non-CKD rats, AVFs in CKD rats had increased 
miR-92a expression (3-fold, p<0.05) and smaller AVF lumen diameter (1.0 ± 0.51 in CKD 
vs. 1.55 ± 0.65 mm in non-CKD, p<0.05). In the knockout study, the percent open lumen 
area of AVF veins was larger in miR-92a−/− mice (72% of total area) than in WT mice (12%). 
In the inhibitor study, both NP-encapsulated (41%) and un-encapsulated (23%) miR-92a 
inhibitors resulted in larger open lumen area than saline control (5%), and the effect of 
encapsulated inhibitors was more pronounced.
Conclusions: In our rat model, CKD increased the AVF tissue miR-92a levels and 
decreased the AVF lumen area. Further, inhibition of miR-92a improved AVF development. 
Nanomedicine may offer a novel and effective therapeutic approach to enhance AVF 
maturation in CKD patients.
Funding: NIDDK Support
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Does Sex Matter? The Transcriptomics of Sex Differences in Arteriove-
nous Fistula Failure
Roberto I. Vazquez-Padron,1 Laisel Martinez,1 Diana R. Hernandez,1 
Marwan Tabbara,1 Juan C. Duque Ballesteros,1 Loay H. Salman.2 1University of 
Miami, Miller School of Medicine, Miami, FL; 2Albany Medical College, 
Albany, NY.
Background: Over 260,000 women depend on a vascular access to receive 
hemodialysis to prolong their lives. Since women have a higher risk of arteriovenous fistula 
(AVF) maturation failure compared to men, they are more likely to initiate dialysis with 
grafts and central venous catheters, further increasing their risk for hospitalization and 
complications. The reasons for sex disparities in AVF maturation have not been well studied 
despite the unmet clinical need.
Methods: Herein, we explored the nature of sex-related differences in AVF 
remodelling using high-throughput RNA sequencing of human pre-access veins and AVFs, 
and functional assessment of experimental fistulas.
Results: We first confirmed that women are at higher risk of maturation failure in a 
cohort of 161 patients. Failure was associated with female sex independently of preoperative 
luminal diameter (>4 mm), age and diabetes. Failure among women was associated with 
postoperative medial fibrosis. Interestingly, experimental AVFs in female rodents had 
lower blood flow and were stiffer than those in their male counterparts as determined by 
high precision pressure myography. The persistence of sex disparities in animal models 
that lack the confounding factors of human cohorts highlight the importance of sex-
related biological effects in fistula maturation. Transcriptomic profiling of sex-biased AVF 
remodeling revealed strong pre-existing (veins) and postoperative (fistulas) sex-related 
differences in gene expression, and uncovered novel molecular targets of maturation failure 
associated with sex effects. In women’s veins, 748 genes were significantly associated with 
nonmaturation, while 537 distinct genes were differentially expressed between men’s veins 
that matured or failed. The transcriptomic disparity persisted after fistula creation. Only 33 
out of the 763 differentially expressed genes in AVFs that matured vs. failed were common 
between sexes.
Conclusions: These results demonstrate that mechanisms leading to maturation or 
failure are sex dependent, and highlight the necessity of sex-oriented therapies in preventing 
hemodialysis access failure.
Funding: NIDDK Support
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Temporal Activation of Notch Improves Arteriovenous Fistulas 
Maturation
Jizhong Cheng,1 Qunying Guo,1 Fengzhang Huang,1 Xiaoguang Xiao,1 
Ming Liang,1 Ying Qing,1 William E. Mitch,1 Luan D. Truong.2 1Baylor College 
of Medicine, Houston, TX; 2The Methodist Hospital, Houston, TX.
Background: maturation of arteriovenous fistula (AVFs) requires arterialization of the 
venous arm in order to sustain increased blood flow and repeated punctures. Proliferation 
and migration of vascular smooth muscle cells (VSMCs) are required for thickening the 
venous wall of AVFs. But excessive VSMC accumulation forms a neointima, ultimately, 
leading to AVF failure. Notch signaling determine the artery fate. Earlier, we demonstrated 
that Notch signaling in AVFs stimulates vascular remodeling, but complete inhibition of 
Notch signaling pathway block AVF arterialization. Does temporally controlled Notch 
activation balance AVF arterialization and neointima formation?
Methods: AVFs created in wild type (WT) and conditionally inducible, VSMC-specific 
Notch KO mice (RBP-JkVSMC-KO). Temporal Notch activation was controlled by addition 
of tamoxifen to KO Notch transcription factor, RBP-Jk, in VSMCs. The VSMCs were 
labeled and tracked; VSMC dedifferentiation, activation, and neointima formation were 
determined.
Results: in AVF anastomoses, VSMC contractile markers were decreased; proliferation 
and migration markers were markedly increased. These results document VSMC activation 
and dedifferentiation. In neointimas, activated Notch was present in VSMC nuclei and 
it induced VSMC contractile markers thereby promoting neointima formation. Pre-
operative KO of RBP-Jk in VSMCs blocked expression of contractile markers causing 
non-arterialization of AVFs. However, when RBP-Jk was KO in VSMCs in day 10 or 
day 20 after AVF surgery, the VSMCs in the neointima expressed VSMC markers even 
Improving Vascular Access Outcomes
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
63
J Am Soc Nephrol 29: 2018 Oral Abstract/Friday
without RBP-Jk expression. Consequently, arterialization of the AVF was induced and the 
neointima area was smaller in AVFs created in RBP-JkVSMC-KO mice VS. WT mice. Thus, 
Notch signaling is required to initiate the expression of VSMC markers. But, the signaling 
pathway is not required for maintaining VSMC fate. As occurred in AVF, KO or inhibition 
of Notch signaling suppressed PDGF-BB-induced differentiation of progenitors into 
VSMCs. Notch overexpression promotes PDGFRβ expression plus differentiation VSMCs 
from their progenitors.
Conclusions: Temporal activation of Notch improves AVF arterialization and 
maturation.
Funding: NIDDK Support
FR-OR093 Oral Abstract Friday
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Targeting Zero Infection in Hemodialysis Patients: An Experience of an 
Intra-Hospital Hemodialysis Unit with None Catheter-Related Blood-
stream Infection in 633 Days
Claudio Luders, Renata D. Lobo, Carlucci G. Ventura, Felicio Roque, 
Fabio E. Di nizo. Hemodialysis, Hospital Sirio-Libanes, Sao Paulo, Brazil.
Background: Patients undergoing hemodialysis (HD) through tunnelled central venous 
catheter are exposed to several risks, including infection and trombosis. Catheter-related 
bloodstream infection (CR-BSI) is the second major cause of death in this population. To 
reduce the incidence of CR-BSI we conducted an intervention study aimed in lowering 
these rates.
Methods: An quasi-experimental, pre-post intervention study was conducted in 
an intra-hospital hemodialysis unit with 15 HD machines and attending 70 patients. In 
2011, we implemented an evidence-based intervention package aiming at elimination of 
all preventable CR-BSI, including the following measures: 1. Alcohol based gel delivery 
system fixed in every HD machine for hand hygiene 2. Catheter external cleaning with 
alcoholic chlorhexidine before manipulation for at least 1 minute 3. A scrub-the-hub 
protocol with strictly aseptic technic for catheter manipulation in any intervention 4. Use of 
chlorhexidine-impregnated dressing 5.Training all nurse staff admitted, annual re-training 
and evaluation of performance with infection rate feedback 6. The use of citrate 30% as 
lock solution.
Results: During the follow-up period (January 2011 to January 2018) a mean of 34 
patients (range 30-38) used tunnelled catheter as vascular access each year. The median age 
was 72 years (range 20-90 years), and 35% of patients were diabetic. After implementation 
of the intervention package, we observed a continuous reduction in the CR-BSI rate: from 
1.1/1000 catheter-days in 2010, the year before the intervention measures; to 0.6/1000, 
0.6/1000, 0.1/1000, 0.1/1000, 0.2/1000, 0.2/1000 and 0.0/1000 catheter-days from 2011 to 
2017, respectively. Between April 2016 and January 2018, we reached the longest period 
without CR-BSI events: 633 days, interrupted by a Serratia marcenses CR-BSI with tunnel 
infection in a recipient of pancreas transplant.
Conclusions: Implementation of several evidence-based practices and continuous 
education can reduce CR-BSI in HD patients to a very low and sustained level. Targeting 
zero infection proposing eliminate all preventable infection should be routine practice of 
all dialysis units.
FR-OR094 Oral Abstract Friday
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Arteriovenous Fistula Maturation Outcomes Following Local Perianasto-
motic Delivery of Sirolimus
Sriram Iyer,12 Maria V. DeVita,1 Nelson P. Kopyt,2 Nirav Gandhi,3 
Naveen K. Atray,4 Thomas D. Wooldridge,5 Joseph J. Lee,6 Kendra S. Hendon,7 
William D. Paulson,8 Osman S. Khawar,9 Robert I. Lynn,10 Prabir 
Roy-Chaudhury.11 On behalf of ACCESS Study Investigators. 1Lenox Hill 
Hospital- Northwell Health System, New York, NY; 2Lehigh Valley Hospital, 
Bethlehem, PA; 3Southern California Kidney Consultants, Anaheim, CA; 
4Capitol Nephrology, Sacramento, CA; 5Nephrology & Hypertension Associates, 
LTD, Tupelo, MS; 6Nephrology Associates Medical Group, Riverside, CA; 
7Knoxville Kidney Center, Knoxville, TN; 8Augusta University, Augusta, GA; 
9Balboa Nephrology Medical Group, Escondido, CA; 10Albert Einstein College 
of Medicine, Bronx, NY; 11University of Arizona, Tucson, AZ; 12Vascular 
Therapies, Cresskill, NJ.
Background: Arteriovenous Fistula (AVF) creation and maturation have many 
obstacles limiting successful cannulation in a timely manner. Time to first cannulation and 
rates of AVF suitability for dialysis remain unacceptable; 80% of ESRD patients initiate 
dialysis with a catheter; many require use for ≥90 days. The use of locally delivered 
perianastomotic sirolimus may help maturation of AVF in a predictable timeframe by 
attenuating the development of neointimal hyperplasia. We now report the combined 
findings of our single arm Phase 2 trial and open label portion of our ongoing US Phase 3 
multicenter, randomized controlled clinical trial (NCT02513303).
Methods: All patients underwent creation of an AVF for hemodialysis. The phase 2 
trial included 30 patients. The open label phase 3 trial, to date, includes 22 patients. For all 
patients, after creation of a successful end-to-side vascular anastomosis, sirolimus–eluting 
collagen membranes (Drug product; Vascular Therapies, Cresskill, NJ) were implanted 
around the anastomosis and outflow vein. Time to First dialysis (TTFD) defined as use with 
2 needles and 300 mL/min flow (2N/300) for 3 consecutive sessions, proportion of AVF in 
use with 2N on or before day 90, Fistula Suitability at 6 months (FSD6) defined as fistula 
use (2N/300) for two-thirds of the dialysis sessions during a 30 day period commencing on 
day 150, and thrombosis/abandonment rates are reported.
Results: Fifty two patients, 51 with ESRD on dialysis and 1 with CKD, were enrolled 
(Male 67%, mean, age 56±17 y, diabetic 42%; radiocephalic AVF 65%). There were no 
product related serious adverse events. By 6 months, 9 AVF were abandoned: 7 thrombosed 
(6 within 2 wks), 1 for central vein occlusion and 1 for pseudoaneurysm. Abandoned AVF 
are included in the calculations shown in Table. Median days (Q1, Q3) to first dialysis was 
49 (39, 67).
Conclusions: 1. In comparison to historical controls local delivery of sirolimus resulted 
in improved AVF outcomes 2. 73% of sirolimus treated AVF were mature by 3 months 
(HFM: 25%) 3. Suitability for Dialysis at 6 months was 82% (DAC: 40%)
Funding: Commercial Support - Vascular Therapies
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GlomCon Trivia: A Live Web-Based Interactive Fellows Curriculum
Pravir V. Baxi,1 Nikhil Agrawal,3 Xavier F. Parada,2 Roger A. Rodby,1 
Stewart H. Lecker,3 Ali Poyan-Mehr.3 1Rush University Medical Center, 
Chicago, IL; 2Massachusetts General Hospital, Boston, MA; 3Beth Israel 
Deaconess Medical Center, Boston, MA.
Background: Sufficient exposure during nephrology training to the variety of 
glomerulonephritides (GN) is difficult due to their rare and heterogeneous presentations. 
GN diagnosis/management and renal pathology interpretation are topics recently identified 
as areas needing further instruction (JASN 2017; 28:1983–1990). Glomerular Disease Case 
Conference (GlomCon) Trivia, recipient of the 2017 ASN Innovation in Kidney Education 
Award, was created to enhance the GN education of trainees, and connect training programs 
to foster a culture of collaborative learning.
Methods: Using GlomCon’s live web-based video platform, the “Trivia” series was 
created for nephrology training programs to provide topic-based didactic webinars. These 
sessions include an interactive Q&A audio/video chat forum centered around board-style 
Q’s answered by participants in real time. Participants access the webinars via institutional 
video conference setup, personal computers, or smartphones. A selected number of multiple-
choice Q’s (MCQ) from the Webinar were shared with the general public through social 
media (Twitter). An anonymous survey was obtained to assess participant’s perception and 
experience.
Results: From 9/17-5/18, 11 sessions have been held by different training programs. 
100% of the survey responders agreed that the sessions enhanced awareness of GN, 
and 94% either “completely agreed” or “agreed” that the sessions contributed to their 
overall knowledge base. In terms of educational quality, 84% rated it as “outstanding” or 
“above average”. In addition, 73% of participants “completely agreed” that the session 
supplemented their individual program’s curriculum. On Twitter, an average of 78 people 
responded to each publicly presented MCQ.
Conclusions: GlomCon Trivia Interactive Fellows’ Curriculum is a global initiative 
with the potential to 1) Enhance education in GN for trainees, 2) Allow participants to 
interact and collaborate beyond geographical boundaries, 3) Facilitate discussion of 
diagnosis and management approaches which can be region or center specific. This program 
adds to the expanding list of training tools with free open access, which will hopefully 
improve the education of our trainees and increase interest in the field of nephrology for 
potential applicants.
FR-OR096 Oral Abstract Friday
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Demystifying Glomerular Disease: A Worksheet Teaching Tool
Ahmed A. Awan,2 Sehrish Ali,3 Prejith P. Rajendran,1 Rajeev Raghavan.1 1Baylor 
College of Medicine, Houston, TX; 2Baylor college of medicine, Houston, TX; 
3BCM Nephrology, Sugar Land, TX.
Background: Learners of all levels express apprehension about glomerular diseases. 
This may herald from an incomplete understanding of the pathophysiology, and a focus on 
memorization. For example, understanding that IgA Nephropathy begins with an abnormal 
IgA protein helps the learner conceptualize symptoms and principles of treatment. This 
curriculum uses active learning and is broadly applicable to students, residents, and fellows. 
The goals of this worksheet include: 1) Reduce anxiety when approaching glomerular 
disease, 2) Complete a worksheet that can be used as a study guide, 3) Use illustration to 
understand the pathophysiology and histologic representation of glomerular diseases.
Methods: The learner is given a 4-page worksheet with 20 glomerular diseases, 
arranged by order of the most frequently encountered. Each disease is represented by 1 row. 
The facilitator is provided a detailed written guide, and the teaching session does not require 
power point. The learners collectively discuss each disease, but must begin by illustrating 
pathophysiologic immune marker and/or key histologic appearance of the disease. Next, 
the clinical presentation, treatment, and prognosis are discussed. The worksheet includes 
select prompts and mnemonics to aid in material retention and can be completed within a 
90 minute session.
Results: We piloted a total of 3 sessions with 42 independent learners - medical 
students (19), internal medicine residents (13), and Nephrology fellows (10). Over 90% of 
respondents ‘did not feel comfortable treating glomerular disease’ prior to the workshop. 
Over 90% (n=40) of participants agreed or strongly agreed that the worksheet was easy to 
complete. 85% of respondents plan to use use the completed workseet as a study guide. One 
representative comment was ‘Excellent review on a topic I struggle with!’
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Conclusions: Educators need a teaching tool to help trainees demystify glomerular 
diseases. The glomerular worksheet can be completed on-the-fly, emphasizes 
pathophysiology / histology, and can be used as a study guide.
FR-OR097 Oral Abstract Friday
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Easing the Difficult Job of Giving Bad News: Using a Decision Aid to 
Match Patient Values to a Dialysis Modality
Meg Wise,1 Dorian R. Schatell,2 Betty Chewning,1 Micah R. Chan,1 
Akhtar Ashfaq.3 1University of Wisconsin-Madison, Madison, WI; 2Medical 
Education Institute, Madison, WI; 3Clinical R&D, Medical Affairs, Opko 
Pharmaceuticals, Westbury, NY.
Background: Nephrologists say telling patients they need dialysis is the worst part 
of the job—and patients do not want this “bad news”. Yet, little is known about how 
nephrologists describe the options or tailor information to patients’ values—or whether 
decision support can make this challenging topic less traumatic and more effective.
Methods: Design: A 2-phase prospective, intervention study of audiorecorded 
conversations between nephrologists and stage 4-5 non-dialysis CKD patients at 2 WI 
clinics. Phase 1: 6 nephrologists and 32 patients; no decision support offered. Phase 2: 
6 nephrologists and 30 patients; patients used an online, values-based decision aid—My 
Life, My Dialysis Choice (My Life) before the visit and shared the 1-page summary of their 
values/dialysis preferences with the nephrologist. Data: Phase 1 vs. Phase 2: conversations 
for tailoring information to (1) Values, (2) Patients’ surveys for dialysis preference, and (3) 
Nephrologists’ surveys.
Results: Results Sample: Nephrologists had a mean age of 40 and 7.5 mean years of 
practice. Patients’ mean eGFR was 20; mean age was 70; 90% were non-Hispanic white; 
73% did not finish college. Phase 1: The dialysis conversation segment was the most difficult. 
0% of nephrologists elicited patients’ values. Nephrologists tailored dialysis information for 
only the 4 (13%) activated patients who inserted their values; 4 (13%) patients preferred home 
dialysis. Nephrologists said they wanted a tool to aid the dialysis discussion. Phase 2: The 
summary served as a dialysis conversation icebreaker. Nephrologists proactively addressed 
patients’ values 97% of the time and tailored their modality information accordingly (P<0.001 
vs. Phase 1). Nephrologists said it “alleviated the need to give bad news.” 15 (50%) patients 
preferred home dialysis (P <0.01 vs. Phase 1).
Conclusions: Patient use of My Life (~20 minutes) eased a difficult conversation 
for both nephrologists and patients, and increased patient preference for home dialysis 
modalities in this small study.
Funding: Commercial Support - Amgen supported Phase 1
Conversation Analysis Results
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Harnessing Technology to Enhance Medical Student Learning
Sana Waheed,1 Beth A. Altschafl.2 1University Of Wisconsin School Of Medicine 
and Public Health, Madison, WI; 2University of Wisconsin-Madison, Madison, 
WI.
Background: Various studies have shown that active learning is more effective than 
passive learning for long-term retention of concepts for students. Moreover, in this day 
and age, young learners seem to be familiar, adept, and excited about engaging with online 
learning material. Therefore, we have designed online leaning materials which allow 
medical studnents to interact with them in an active manner that leads to improved long-
term retention of renal pathophysiological principles.
Methods: Our medical school curriculum at the University of Wisconsin transformed 
in the fall of 2016 and as a part of this process we created numerous online enduring 
learning activities (ELA) in addition to the traditional in class lectures and medium group 
discussions for first year medical students. Some ELAs teach basic science concepts in an 
innovative way involving technologies like the lightboard. Other ELAs utilize Articulate 
Storyline, which allows the students to interact with online simulated cases to apply basic 
science concepts such as sodium, water, and acid- base balance to clinical care. Students 
receive immediate feedback during these activities through the use of embedded self-
assessment activities. Suggested by their name, ELAs are designed to be enduring; they are 
stored in a in a repository and are easily searchable with the intention that students revisit 
their content during their clinical years.
Results: To determine if active learning promoted better long-term retention of renal 
pathophysiological concepts, we compared the students’ scores for content taught in-class 
during traditional lectures to concepts that were taught through ELAs for the renal exam. 
Our data shows that students performed better on questions from ELA content (Table 1).
Conclusions: Our preliminary data indicates that active learning methodologies such 
as delivering content through online ELAs is an effective way to teach difficult renal 
pathophysiology concepts. Feedback indicates that students find these online activities more 
engaging, and the ELAs offer better student interaction with the material and this likely 
translates to improved long-term retention of the material in our students.
Table 1: Student scores for content taught through ELAs compared to traditional didactic 
format
FR-OR099 Oral Abstract Friday
Shaping the Future of Nephrology Education
The Acute Dialysis Orders Objective Structured Clinical Examination 
(OSCE): Results of Administration to 117 Nephrology Fellows Nationwide
Lisa K. Prince,1 Ruth C. Campbell,4 Jessica B. Kendrick,3 Laura J. Maursetter,2 
Christina M. Yuan.1 Nephrology Education Research & Development 
Consortium 1Walter Reed National Military Medical Center, Silver Spring, MD; 
2University of Wisconsin School of Medicine & Public Health, Madison, WI; 
3University of Colorado School of Medicine, Aurora, CO; 4Medical University 
of South Carolina, Charleston, SC.
Background: Few quantitative, validated, Nephrology-specific simulations assess 
ACGME fellow competency performance. We developed, validated and administered a 
formative OSCE during 2016 and 2017 to 117 Nephrology fellows nationwide to assess 
medical knowledge, patient care, and systems-based practice in acute dialysis.
Methods: Fellows use institutional protocols and order sets to write dialysis orders and 
answer evidence based questions on 3 acute dialysis scenarios (49 test items; 58 possible 
points). 10 board-certified clinical nephrologists validated the test, determining a pass 
threshold of 46 points.
Results: The 2016 administration included 25 fellows (4 programs), and the 2017 
administration included 92 fellows (15 programs). 51 first year fellows and 66 second/third 
year fellows completed the OSCE. All tests were scored by the 2 Principal Investigators. 
Median time to take the test was 65 minutes. 75% of fellows passed Scenario 1 (Acute 
CRRT), with 92% correctly prescribing a greater than 20 ml/kg/hr effluent dose, and 63% 
able to calculate CRRT clearance as effluent volume. 43% passed Scenario 2 (Urgent 
outpatient initiation) with 75% using a correct 3-4 meq/L K+ dialysate, but only 12% able to 
identify the 2 absolute, urgent indications for chronic dialysis initiation. Fellows performed 
poorly on Scenario 3 (Management prior to and dialysis prescription for acute hyperkalemia 
in ESRD). 6% passed, with only 20% correctly checking for rebound hyperkalemia with 
2 separate lab draws. However, 83% were correct in not giving IV sodium bicarbonate as 
acute medical management for hyperkalemia. 32% of fellows passed the overall OSCE. No 
significant difference was found between first and second year fellow performance (overall 
score 42.7 ± 5 vs. 44.4 ± 4; p= 0.049; 24% vs. 39% pass rate; p= 0.082) with no correlation 
between second year fellow ITE and OSCE scores. The fellow satisfaction survey had a 
56% response rate. 78% strongly agreed/agreed that the OSCE was useful in assessing 
proficiency in ordering acute renal replacement therapy.
Conclusions: The Acute Dialysis OSCE can provide quantitative data for fellow 
ACGME sub-competency assessments, and identify opportunities for dialysis curriculum 
development.
Funding: Other U.S. Government Support
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Nephrology Business Leadership University: Filling a Gap in Fellowship 
Education
Cynthia Miracle,1 Emmanuel Rodriguez Vargas,1 Samir Nangia,2 
Parin M. Makadia,2 Scott Mullaney.1 1University of California San Diego, San 
Diego, CA; 2Dallas Renal Group, P.A., Allen, TX.
Background: Historically, fellowship training programs have not focused on the 
knowledge and skills fellows need to successfully transition from training to practice. 
Concurrently there is dissatisfaction with nephrology as a career choice and interest 
in nephrology has declined. As a specialty we have focused on attracting trainees into 
nephrology but not on ensuring fellows have the skills to navigate their career post 
fellowship. To address this need we developed a weeklong conference, Nephrology 
Business Leadership University (NBLU), in partnership with practicing nephrologists and 
industry experts. Our goal was to provide fellows with education in the business aspects of 
nephrology not taught in traditional nephrology training programs.
Methods: During NBLU fellows attended workshops on topics ranging from the job 
search to growing a practice to retirement planning. Fellows also participated in sessions on 
leadership roles in nephrology. Pre- and post-course surveys, interactive feedback sessions, 
and exit interviews were used to assess the program. A Pre/Post Knowledge Level Survey 
(5-point Likert Scale) assessed improvements in knowledge level in 24 different content 
domains. Scores were compared using a paired two sample means t-test. Follow up surveys 
will be sent at the end of the academic year to assess implementation of this knowledge into 
the attendees job search.
Results: 31 fellows attended NBLU, representing 22 programs in 15 different states. 
The pre-survey confirmed that the areas covered in NBLU were absent in traditional 
training; only 2 out of 30 respondents stated “yes” to having previous instruction in any 
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business aspects of medicine. The Knowledge Survey demonstrated statistically significant 
increases in knowledge in all 24 areas. Median knowledge level in the 24 areas was 1.72 
prior to and 4.11 post course (p<0.05) .100% of surveyed fellows would recommend NBLU.
Conclusions: Education on the business aspects of nephrology is lacking in traditional 
fellowship training. NBLU is an innovative and effective program for educating fellows 
on areas they will need when they transition into practice. Fellows were satisfied with their 
experience and would recommend the program to others. Results of follow up will further 
assess if learned skills were useful during their job search and in the early days of practice.
Funding: Commercial Support - US Renal Care, Clinical Revenue Support
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Shaping the Future of Nephrology Education
The Need for Nephropathology Teaching Worldwide: The ISN-Clinical 
Nephropathology Course Survey
Vanesa Bijol,2 Kenar D. Jhaveri.1 1Nephrology, Zucker School of Medicine at 
Hofstra Northwell, Great Neck, NY; 2Pathology, Zucker School of Medicine at 
Hofstra/Northwell, Great Neck, NY.
Background: The epidemiology and pathology of kidney disease is still unknown in 
large parts of the world that are burdened with high rates of CKD, in part due to inability 
to adequately process and interpret kidney biopsies. Clinical Nephropathology Certificate 
(CNC) Program is a joined educational initiative of the International Society of Nephrology 
(ISN) and American Nephrologists of Indian Origin (ANIO) primarily focusing on needs 
of nephrologists and pathologists in parts of the world with suboptimal nephropathology 
training and service. The CNC program(started 2013) includes over 40 recorded online 
lectures and 12 live webinars run by a pathologist and a nephrologist (one each month) 
made available over a one-year period.
Methods: We surveyed previous and current participants of the ISN CNC program 
to better understand the worldwide nephropathology practices. This voluntary survey was 
emailed to participants with 12 questions regarding the nephropathology service in their 
institutions and respective countries.
Results: The survey response was received from 293 out of 494 current or former 
participants (response rate 59%) from 63 countries. The data were evaluated using ISN 
regions and world bank economy classification. Results are summarized in Table below.
Conclusions: The survey responses suggest a large gap between the nephropathology 
practices in well-developed countries and the rest of the world. Even when existent in 
L/LM/UMIC, EM services are available for select cases and not routinely. The lack of 
trained nephropathologists and inability to adequately process samples is a common 
problem for the most of Africa, Asia, and Latin America, leading to underutilization of 
kidney biopsy procedures for diagnostic purposes. The lack of financial resources in these 
countries is still a significant limiting factor in establishing functional nephropathology 
laboratories. Programs like ours help bridge the education gap that exists in these countries.
Survey results stratified by world bank classification with regards to nephropathology 
services available in respondents’ countries and institutions where they practice
FR-OR102 Oral Abstract Friday
Signaling in CKD Progression
Impaired Renal Iron Handling Leads to Iron Overload through an ET-1 
Dependent Pathway
Malgorzata Kasztan,1 Kelly A. Hyndman,2 David M. Pollock.2 1Medicine, 
University of Alabama at Birmingham, Birmingham, AL; 2University of Alabama 
at Birmingham, Birmingham, AL.
Background: Elevated plasma endothelin-1 (ET-1) reported in sickle cell disease 
correlates with microalbuminuria, an independent risk factor for renal disease progression. 
In humanized sickle cell mice (HbSS), long-term ETA receptor antagonism significantly 
attenuated renal tubular iron deposition in proximal tubules (PT). Evidence suggests a 
pathophysiological links between ET-1, renal iron deposition and early sickle nephropathy, 
therefore we hypothesize that ET-1 regulates renal iron trafficking in iron overload-
associated sickle nephropathy.
Methods: To determine the involvement of ET-1 in renal iron handling mouse primary 
PT cells (from wild type, HbSS and control (HbAA) mice) were exposed to ET-1 and iron 
trafficking mediators were assessed by PCR.
Results: Expression of the iron import transporter transferrin receptor 1, TfR-1, and 
the iron storage protein, H-ferritin, were increased in a concentration-dependent manner 
by ET-1 in mouse primary PT cells. Also, ET-1 treatment resulted in a decrease in iron 
exporter ferroportin-1, FPN-1 (65% reduction), which was associated with a doubling in 
expression of hepcidin, HAMP, a key regulator of FPN-1 and iron removal from the cell. 
Exposure of PT cells to plasma from HbSS mice, increased cellular iron uptake compared 
to plasma from control HbAA mice (98±17 vs. 4±1 pg/μl, p<0.05). The ETA antagonist, 
BQ123, completely prevented ET-1-mediated alterations in all iron mediators, suggesting 
involvement of ETA receptors in iron trafficking mechanisms. Moreover, plasma ET-1 was 
positively correlated with renal iron deposition in HbSS mice (R2=0.72, p<0.0001). PT cells 
isolated from HbSS mice showed significant elevation in expression of TfR-1, DMT-1, 
H-ferritin, and HAMP along with significantly lower FPN-1 expression compared to control 
mice. 10-week treatment (from weaning) with an ETA receptor antagonist (ambrisentan
10mg/kg/day) prevented the induction of DMT-1, preserved FPN-1 and reduced HAMP
expression in PT cells from HbSS mice.
Conclusions: These results uncover a novel role for ET-1 in PT iron trafficking and 
provide a rationale for the use of selective ETA receptor blockade as a therapeutic approach 
in iron overload-associated sickle nephropathy.
Funding: NIDDK Support, Other NIH Support - Excellence in Hemoglobinopathies 
Research Award “The Role of Endothelin-1 in Sickle Cell Disease (U01 HL117684)” to 
D.M. Pollock, Other U.S. Government Support, Private Foundation Support
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Inability to Regulate Fatty Acid Oxidation or Glycolysis Increases Renal 
Fibrosis
Mardiana Lee,1,2 Peter F. Mount,1,2 Marina Katerelos,1,3 Kurt Gleich,1,3 
David A. Power.1,2 1Austin Health, Melbourne, VIC, Australia; 2Medicine, The 
University of Melbourne, Melbourne, VIC, Australia; 3Institute of Breathing and 
Sleep, Melbourne, VIC, Australia.
Background: Changes in energy metabolism are emerging as a key contributor to renal 
fibrosis. Expression of genes regulating fatty acid metabolism is reduced in fibrotic kidneys 
and aerobic glycolysis increases in some renal disease models. We aimed to determine the 
role of phosphorylation events that control fatty acid oxidation (FAO) and glycolysis in 
renal fibrosis.
Methods: The folic acid nephropathy (FAN) and unilateral ureteric obstruction (UUO) 
models were induced in mice with knock-in mutations of phosphosites in acetyl CoA 
carboxylase 1 and 2 (ACC1/2KI mice), the major regulator of FAO, and 6-phosphofructo-
2kinase/fructose-2,6-biphosphatase (PFKFB2KI mice), the major regulator of glycolysis. 
Metformin, which activates AMPK to increase phosphorylation of ACC and PFKFB2, was 
administered to mice with FAN.
Results: ACC Ser79 phosphorylation was reduced in folate-treated tubular epithelial 
cells (p<0.01) and WT mice with FAN (p<0.05). Mutation of these sites in ACC1/2 KI mice 
with FAN or UUO caused lipid accumulation (Oil Red O p<0.01), increased triglyceride 
(p<0.01), increased collagen (PicroSirius red p<0.001; Masson’s Trichrome p<0.01; qRT-
PCR p<0.01) and increased α-SMA (Western blot p<0.05; qRT-PCR p<0.01). Metformin 
administration was associated with reduced fibrosis (PicroSirius red p<0.01) and lipid 
accumulation (Oil Red O p<0.05) in WT mice, but not in ACC1/2KI mice. To determine 
the role of control of glycolysis, UUO was induced in PFKFB2KI mice. WT mice with 
UUO had reduced PFKFB2 Ser483 phosphorylation (p<0.01). PFKFB2KI UUO mice 
had increased collagen (Picrosirius red p<0.001), increased fibronectin (Western blot 
p<0.05; qRT-PCR p<0.05), increased α-SMA (Western blot, p<0.05) (Fig.1) and glycogen 
accumulation (PAS, p<0.05).
Conclusions: These data suggest that reduced phosphorylation of ACC and PFKFB2 
are deleterious following renal injury. Drugs that reverse this, such as metformin, may be 
useful in preventing and treating renal fibrosis.
Funding: Other NIH Support - National Health and Medical Research Council of 
Australia
Western blot analysis showing increased expression of α-SMA in PFKKI UUO mice. 
*P<0.05, ***P<0.001
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Signaling in CKD Progression
Amphiregulin Drives Kidney Fibrosis in Mice and Its Elevated Serum 
Levels Correlate with CKD Outcomes in Humans
Eirini Kefalogianni,1 Manikanda raja Keerthi raja,1 Vaia Pliaka,4 
Julian Schumacher,1 Leonidas G. Alexopoulos,3 Sushrut S. Waikar,2 
Andreas Herrlich.1 1Washington University in St. Louis, St. Louis, MO; 2Harvard 
Medical School, Boston, MA; 3National Technical Univ of Athens, Glyfada, 
Greece; 4Protavio, Athens, Greece.
Background: We have shown that ADAM17-released EGFR ligands in proximal tubule 
cells (PTCs) drive kidney fibrosis in IRI and UUO kidney injury models (Kefaloyianni et 
al, JCI Insight 2016). Which specific EGFR ligands are involved remains unknown. We 
showed that amphiregulin (AREG) is the most upregulated EGFR ligand after kidney injury 
in mice and the most potent EGFR ligand in inducing pro-inflammatory and pro-fibrotic 
genes in human PTCs (HPTCs) in vitro. Soluble AREG (sAREG) is significantly elevated 
in the urine of AKI and CKD patients and AREG protein is elevated in CKD biopsies, as 
compared to healthy controls. It is not known whether AREG has a key role in mediating 
injury-induced kidney fibrosis in mice and humans.
Methods: We used tamoxifen inducible AREGfl/fl-Slc34a1GCE+/--tdTomato+ (AREG-
PTC KO) mice and ADAM17fl/fl-Slc34a1GCE+/--tdTomato+ (ADAM17-PTC KO) mice and 
their respective wt littermates, as well as HPTCs transfected with control or YAP1 siRNA. 
We also developed and extensively validated a sensitive bead-based ELISA for sAREG in 
human serum samples.
Results: We found that sAREG can uniquely sustain EGFR activation in HPTC in vitro 
via YAP1-dependent upregulation of its own transcript, followed by ADAM17-dependent 
release of sAREG (positive feedback). In vivo, AREG-PTC-KO reduced IRI-induced 
sustained EGFR phosphorylation, as well as upregulation of pro-inflammatory cytokines 
and pro-fibrotic markers. We show that in ADAM17-PTC-KO mice, which cannot release 
any injury-induced EGFR ligand in PTC, injection of sAREG alone is sufficient to induce 
production of pro-inflammatory and pro-fibrotic factors to the levels of ADAM17 wt mice. 
Finally, we show that sAREG serum levels correlate positively with serum creatinine and 
CKD stage and negatively with eGFR in a nephrectomy cohort (n=69) of patients with 
various diagnosis and levels of fibrosis.
Conclusions: These results suggest that AREG is a major driver of kidney fibrosis 
in mice and humans, acting via a YAP1-dependent positive feedback loop that sustains 
EGFR activation and induces pro-inflammatory and pro-fibrotic cytokines, and represents a 
potential functional marker of fibrosis and CKD progression.
Funding: NIDDK Support
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The Effects and Potential Role of Circulating Macrophage in Renal 
Fibrosis
Gang Xu,2 Yuxi Wang,3 Rui Zeng.1 1Tongji Hospital, Huazhong Univ of Science 
and Technology, Wuhan, China; 2Tongji hospital affiliated to Tongji medical 
college, Huazhong University of Science and Technology, Wuhan, China; 
3Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong 
University of Science and Technology Wuhan, Hubei, China, Wuhan, China.
Background: Macrophages plays an important role in the process of renal fibrosis. 
Recent studies have suggested that circulative macrophages are the major source of 
myofibroblasts, which is contradicted with traditional view, that only a few myofibroblasts 
were derived from bone marrow-derived cells. In this study, we looked for changes in CKD 
lesions and macrophages at different stages to find better classification of macrophage
Methods: Firstly, we adopted a bone marrow transplantation (BMT) model using 
GFP mouse bone marrow cells. Secondly, a parabiosis + I/R model or UUO model was 
constructed using GFP mice. To further understand the link between macrophage with 
myofibroblast, CSF1r-GFP mice were adopted in parabiosis + I/R model. Otherwise, we 
used the chlorophosphate liposome (CL) to knockout macrophages. CCR2-/- mice were 
adopted to construct parabiosis + I/R models to observe the effect of circulating macrophage 
in renal fibrosis. To directly explore the mechanism of macrophage on renal injury, we 
sorted Ly6c+ inflammatory macrophages from I/R kidneys and injected under kidney 
capsule of immunodeficient mice. At the same time, fibrosis-related markers were detected 
after co-culture the sorted Ly6c+ cells with fibroblasts.
Results: BMT+I/R model found that 22.55% of renal myofibroblasts were derived 
from bone marrow-derived cells, and 14.6% of myofibroblasts were derived from 
peripheral macrophages. The parabiosis + I/R or UUO model by using CSF1r-GFP mice 
proved that 5-9% of myofibroblasts in the kidney expressed GFP. With the treatment of 
CL, operated mice had early renal injury and delayed atrophy, and renal tubular injury was 
alleviated. Then we used CCR2-/- mice and observed that mice knocked out of peripheral 
macrophages reduced renal fibrosis; CCR2-/- mice were constructed parabiosis model with 
WT mice, in which peripheral macrophages can be replenished, and their kidney damage 
and fibrosis are aggravated. The sorted Ly6c+ inflammatory macrophages direcltly lead to 
increased fibroblast activation and fibrosis.
Conclusions: The results indicated that peripheral derived macrophages are not the 
main source of myofibroblasts. The sorted Ly6c+ macrophages have the effect on promoting 
renal fibrosis. Knockout peripheral inflammatory macrophages reduce renal fibrosis. Ly6c+ 
inflammatory macrophages can directly lead to normal kidney damage and fibrosis and can 
promote fibroblast activation.
Funding: Government Support - Non-U.S.
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DOT1L Inhibition Attenuates Renal Fibrosis through Suppressing 
Multiple Profibrotic Signaling Pathways and Preserving Expression of 
Smad7 and Klotho
Lirong Liu,2 Xiaoxu Zhou,3 Chongxiang Xiong,2 Shougang Zhuang.1 1Rhode 
Island Hospital, Alpert Medical School of Brown University, Providence, RI; 
2Rhode Island Hospital, Providence, RI; 3Rhode Island Hospital, Brown 
University, Providence, RI.
Background: Disruptor of telomeric silencing-1 like (DOT1L) protein specifically 
catalyzes the methylation of histone H3 on lysine-79 and is implicated in leukemia and 
some solid tumors, but its role in tissue fibrosis remains unknown.
Methods: In this study, we examined the role of DOT1L in renal fibroblast activation, 
epithelial-mesenchymal transition and renal fibrosis development in vitro and in vivo.
Results: We demonstrated that injury to the kidney increased DOT1L expression and 
H3K79 dimethylation (H3K79me2) in renal tubules and myofibroblasts in a murine model 
of unilateral ureteral obstruction. Administration of EZP5676, a highly selective inhibitor of 
DOT1L, attenuated renal fibrosis as evidenced by decreased activation of renal interstitial 
fibroblasts and reduced deposition of extracellular components. Treatment with EZP5676 
or DOT1L siRNA also inhibited transforming growth factor β1 and serum -induced 
activation of renal interstitial fibroblasts and epithelial-mesenchymal transition (EMT) in 
vitro. Moreover, blocking DOT1L abrogated injury-induced epithelial G2/M arrest; reduced 
expression of Snail and Twist, two transcription factors that drive EMT; downregulated 
Notch1, a transmembrane receptor protein associated with renal fibrosis; and inactivated 
several profibrotic signaling molecules, including Smad3, epidermal growth factor receptor, 
platelet growth factor receptor, STAT3, AKT as well as NF-κB in the injured kidney. 
Conversely, DOT1L inhibition increased expression of phosphatase and tensin homolog, 
a protein associated with dephosphorylation of tyrosine kinase receptors, and prevented 
decline in levels of klotho and Smad7, two renoprotective factors.
Conclusions: Our data indicate that targeting DOT1L inhibits activation of renal 
fibroblasts, EMT and renal fibrosis by suppressing activation of multiple profibrotic 
signaling pathways and retaining expression of renoprotective factors. DOT1L could be a 
novel therapeutic target for treatment of fibrotic renal diseases.
Funding: NIDDK Support
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Signaling in CKD Progression
Osteocrin, a Bone-Derived Humoral Factor, Exerts a Renoprotective Role 
in Ischemia-Reperfusion Injury in Mice
Yoshihiko Nishiguchi,1 Takashige Kuwabara,1 Shuro Umemoto,1 
Daisuke Fujimoto,1 Tomoko Kanki,1 Yusuke Hata,1 Hideki Yokoi,2 
Yuichiro Izumi,1 Yutaka Kakizoe,1 Masashi Mukoyama.1 1Kumamoto University 
Graduate School of Medical Sciences, Kumamoto, Japan; 2Kyoto University 
Graduate School of Medicine, Kyoto City, Japan.
Background: Natriuretic peptides (NPs; atrial, brain and C-type NPs: ANP, BNP and 
CNP) constitute the hormonal basis of the heart-kidney network, in which the remote organs 
influence each other under physiological and pathophysiological conditions. We recently 
reported that osteocrin (Ostn), originally identified as a secretory peptide in the bone 
and muscle, exerted bone elongation and cardioprotective effects through antagonizing 
NP clearance receptor NPR3. Of note, SNPs of the Ostn and NPPA/NPPB gene loci are 
reportedly related to a renal function decline risk by genome-wide association studies. 
However, the role of Ostn in the kidney has not been clarified yet.
Methods: To investigate the role of Ostn, we generated systemic Ostn knockout (KO) 
mice, and mated with liver-specific SAP promoter-driven Ostn-transgenic mice (KO-Tg). 
Wild-type (WT), KO and KO-Tg mice were subjected to ischemia-reperfusion injury (IRI) 
by unilateral renal artery clamping. Samples were collected at 3 weeks after IRI. Ostn 
expression in the kidney was evaluated by X-gal immunostaining using Ostn-LacZ knockin 
mice.
Results: In atrophic and fibrotic kidneys after IRI of WT, Ostn mRNA was increased in 
parallel with NPR3 and CNP upregulation, but not in the contralateral or pre-IRI kidneys. 
Furthermore, CNP expression was markedly suppressed in the contralateral kidney after 
IRI. These changes were either enhanced or suppressed in KO or KO-Tg, respectively, 
suggesting that Ostn affects the regulation of CNP and NPR3 expression in the kidney. In 
KO kidneys, mRNA expression of neutrophil gelatinase-associated lipocalin (NGAL) and 
IL-1b was further enhanced. In KO-Tg, fibrosis and atrophy were significantly ameliorated 
compared to WT and KO, together with the decreased expression of pro-fibrotic (aSMA, 
TGF-b), pro-inflammatory (IL-1b, TNFa) and tubular injury maker (NGAL, KIM-1) genes. 
X-gal immunostaining revealed that endogenous Ostn expression was induced by IRI in the 
tubular epithelial cells of corticomedullary junction in the kidney.
Conclusions: Exacerbation of IRI-induced kidney injury in Ostn-deficient mice was 
attenuated by ectopic overexpression of Ostn. Our data suggest a renoprotective role of 
Ostn, and could provide a potential therapeutic strategy against acute kidney injury.
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Signaling in CKD Progression
Temporal and Tissue-Specific Activation of AHR Signaling in Discrete 
Renal Diseases
Joshua A. Walker,1,2 Daniel M. Roth,1 Mostafa Belghasem,4 Joseph Y. Tashjian,4 
Sean Richards,1 Stephen A. Whelan,5 Nkiruka Arinze,1 Norman Lee,5 
Vijaya B. Kolachalama,2 Jean M. Francis,1 Vipul C. Chitalia.3 1Renal Section, 
Department of Medicine, Boston University, Boston, MA; 2Whitaker 
Cardiovascular Institute, Boston University, Boston, MA; 3Boston University 
School of Medicine, Boston, MA; 4Department of Pathology and Laboratory 
Medicine, Boston University, Boston, MA; 5Department of Chemistry, Chemical 
Instrumentation Center, Boston University, Boston, MA.
Background: Aryl hydrocarbon receptor (AHR) signaling is emerging as an important 
mediator of uremic toxicity regulating several manifestations of uremic solutes. While 
previous studies showed AHR activation in whole organs in response to uremia, no studies 
have examined cell- type specific AHR activation in vivo in uremic and non-uremic 
conditions in discrete models of kidney diseases.
Methods: Transgenic mice containing two dioxin-response elements upstream 
of a beta-galactosidase (β-gal) reporter gene were subjected torenalanischemia/
areperfusioninjury(I/R), andanaAdenine-induced CKD, oranda recently developed 
Indoxylsolute specific animal modelss. TCDD, a canonicalAHRligand served 
as a positive control. β-gal protein expressionswaserecompared using a recently 
validatedquantitativecolor-based image segmentation quantitative image analytical 
techniqueanalysis. Double label immunofluorescence was used to analyze cell specific 
expression of β-gal. mRNA was analyzed with qRT-PCR. Plasma was analyzed for levels 
of blood-urea nitrogen (BUN), creatinine.
Results: In all the models, β-gal expression in kidneys predominated in both the 
proximal and distal renal tubules, but distinctly sparedwas absent fromthe glomeruli. In 
I/R model, β-gal expression significantly increased within 24 hours of injury (p<0.05) and 
decreased at both 48 and 96hrs post-surgery, while renal function continued to remains 
significantly altered at all these time points (p<0.01). Along with renal tubules, CKD and 
solute specific AHR models showed significant increase β-gal expression in endothelial, 
smooth muscle cells of the aorta and liver (p<0.05). A trend towards increased AHR 
activation in cardiomyocytes and neuron cells bodies was observed. Xxx Uremic solutes
Conclusions: The current study represents the first use of this reporter animal in 
disease-specific models. The model demonstrated a broad sensitivity in uremic kidney 
diseases and also in uremia-independent mechanisms such as hypoxia. While supportive 
of our previous observations in uremic thrombosis, AHR activation in some of the organs 
provide a hypothesis-generating insight. The model demonstrated a broad sensitivity in 
uremic kidney diseases and also in uremia-independent mechanisms such as hypoxia.
Funding: Other NIH Support - NHLBI 1R01Hl123235 (VCC), T32 HL70024 (JAW)
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CKD Impairs Muscle Protein Synthesis via a Demethylase Mechanism 
That Regulates Ribosomal Biogenesis
Liping Zhang,1 William E. Mitch.2 1Nephrology, Baylor College of Medicine, 
Houston, TX; 2Baylor College of Medicine, Houston, TX.
Background: the report that patients with chronic kidney disease (CKD) require diets 
with 1.5 g protein/kg/d is based on the premise that a high protein diet will overcome a 
block in muscle protein synthesis. Such a diet, however, would cause metabolic acidosis, 
hyperphosphatemia, etc. To prevent these outcomes we are investigating mechanisms that 
can improve muscle protein synthesis even with dietary protein is restricted. We have 
identified a CKD-stimulated, chromatin-modifying, nucleolar protein, NO66 and show that 
it suppresses both ribosomal DNA transcription and muscle protein synthesis
Methods: we studied mice with CKD (subtotal nephrectomy) with BUN >80 mg/dL, 
similar to values in ESRD patients.
Results: NO66 demethylates histone proteins, H3K4ME3 and H3K36ME3, regulating 
growth. In muscles of both mice and patients with CKD, we found high levels of NO66 
mRNA and protein. These increases were found to be stimulated by inflammation and 
mediated by changes in NF-κB: NO66 expression was suppressed by a NF-κB inhibitor. In 
support of this conclusion, we identified 3 NF-κB binding sites in the NO66 promoter. Does 
NO66 cause loss of muscle mass in mice with CKD? To address this possibility, we created 
global KO of NO66 in mice (NO66-/-) or satellite cell-specific NO66 KO (NO66-Pax7-cre) 
or muscle-specific NO66 KO (NO66-MCK-cre) mice. In response to CKD, NO66 KO mice 
developed an increase in muscle mass (28±8%) and protein synthesis (71±15%) vs. results 
in control mice. From a RNA-seq analysis of soleus muscles of NO66-/- and NO66flox/flox 
mice, we found that NO66 absence in muscle stimulates ribosomal biogenesis. Consistent 
with the RNA-seq results, both rRNA and the ribosomal translational capacity were 
increased in muscles lacking NO66 vs. results from control, NO66flox/flox mice. In addition, 
NO66 overexpression was found to suppress pre-rRNA expression in C2C12 muscle cells. 
Finally, a CHIP assay revealed that NO66 represses the transcription of ribosomal DNA via 
a demethylase mechanism
Conclusions: we have uncovered a new mechanism that regulates protein synthesis 
and ultimately, muscle mass
Funding: NIDDK Support
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The Kidney Makes Gas in Defense against Urinary Bacteria
Katherine Xu, Tian Shen, Abraham D. Levitman, Max Werth, 
Jonathan M. Barasch. Columbia University, New York, NY.
Background: The kidney expresses a variety of powerful defense mechanisms to limit 
urinary infection including iron scavenging, a process called “nutritional immunity”. We 
previously demonstrated that the intercalated cells generate the archetype of the urinary iron 
defense, a lipocalin called NGAL which binds Enterochelin (Strong, FHCC), a bacterial 
siderophore. However, because urinary bacteria can evade the bacteriostatic effects 
of NGAL by modifying Enterochelin and by producing additional siderophores, other 
mechanisms of “nutritional immunity” are anticipated.
Methods: We utilized a cell type specific method of RNA isolation (adapted from 
Gay, Oregon). A promiscuous form of phosphoribosyltransferase (UPRT) was cloned into 
the Rosa26 locus using a floxed-stop design which we activated in a cell specific fashion 
with HoxB7Cre or Atp6v1b1Cre. Thiouracil was introduced 12hr and 24hrs after infection. 
Hmox1 was detected with a luciferase based reporter (Contag et al, Stanford). CO was 
detected with a novel metal-based probe synthesized at Columbia (adapted from Liu, 
China).
Results: A survey of classical iron transporters revealed segment specific expression of 
megalin (proximal tubule), TfR1 (TALH), and DMT1 (TALH-DCT). Nonetheless, despite 
ferritin accumulation, we failed to identify the mechanism of iron import in intercalated 
cells. Isolation of RNA directly from intercalated and principal cells revealed synthetic 
(NPAS-BMAL-ALAS), transport (Hrg1, Flvcr1) and metabolic enzymes (Hmox) of heme 
metabolism. Functional reporters demonstrated Hmox expression and the production of 
CO gas from cortical>medullary sources in vivo and from AtpCre-mTmG FACS isolated 
intercalated cells in vitro. Urinary bacteria (UPEC) with heme transport mutations were 
not competitive in the colonization of the kidney but conversely were markedly stimulated 
by heme, suggesting bacterial-host competition for heme capture and metabolism. In 
fact, infection upregulated both heme synthetic and metabolic genes, suggesting that CO 
production is induced by infection. Exposure to CO terminated the growth of UPEC.
Conclusions: We have identified an unusual iron trafficking system in the collecting 
ducts that mirrors the nutritional requirements of UPEC to achieve pyelonephritis. Many of 
these components are specific to the intercalated cells, consistent with the notion that these 
cells defend the urinary tract.
Funding: NIDDK Support
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Whole-Kidney Three-Dimensional Imaging Reveals the Progression of 
Renal Sympathetic Denervation after Ischemia-Reperfusion Injury
Sho Hasegawa,1 Tetsuhiro Tanaka,1 Etsuo A. Susaki,2 Hirotaka Komaba,3 
Takehiko Wada,3 Hisako Saito,1 Mai Sugahara,1 Lisa Uchida,1 Marie Ito,1 
Masafumi Fukagawa,3 Hiroki R. Ueda,2 Masaomi Nangaku.1 1Division of 
Nephrology and Endocrinology, The University of Tokyo Graduate School of 
Medicine, Tokyo, Japan; 2Department of Systems Pharmacology, The University 
of Tokyo Graduate School of Medicine, Tokyo, Japan; 3Division of Nephrology, 
Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, 
Japan.
Background: The sympathetic nervous system is critical in maintaining the homeostasis 
of renal functions. Its three-dimensional (3D) structures in the kidney, however, have not 
been elucidated because of the limitation of conventional imaging methods. CUBIC (Clear, 
Unobstructed Brain/Body Imaging Cocktails and Computational analysis) is a newly 
developed tissue clearing technique, which enables 3D imaging of whole-organ with single-
cell resolution. Here, we apply CUBIC to the kidney research, visualizing the 3D structure 
of renal sympathetic nerves, showing the process of denervation after ischemia-reperfusion 
injury (IRI).
Methods: Eight-week-old male C57BL/6 mice were subjected to sham operation or 
bilateral IRI for 45 minutes, and sacrificed 28 days after surgery. The kidneys were optically 
cleared using CUBIC protocol. After making kidneys transparent, the sympathetic nerves 
were labeled with 3D immunofluorescent staining. Whole-kidney imaging was acquired by 
a light-sheet fluorescent microscopy.
Results: The spatial distribution of sympathetic nerves was clearly visualized. 
Compared with the sham group (figure 1A), the nerve density in the cortical lesion was 
significantly decreased in the IRI group (figure 1B).
Conclusions: The new 3D imaging technique has demonstrated the sustained renal 
sympathetic denervation after IRI. Dysfunction of sympathetic nerves might be related to 
the progression of chronic kidney disease.
Funding: Government Support - Non-U.S.
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Figure 1. The representative 3D imaging of sympathetic nerves in the kidney. (A) Sham-
operated group, (B) Bilateral IRI group.
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The Epidemiology of CKD from 1990 to 2016 in the United States of 
America: An Analysis of the Global Burden of Disease Study
Benjamin C. Bowe,1,3 Yan Xie,1 Tingting Li,1,2 Yan Yan,1,2 Hong Xian,1,3 
Ziyad Al-Aly.1,2 Clinical Epidemiology Center 1Clincal Epidemiology Center, 
VA Saint Louis Health Care System, Saint Louis, MO; 2Washington University in 
St. Louis, Saint Louis, MO; 3Saint Louis University College for Public Health & 
Social Justice, St. Louis, MO.
Background: Over the last 3 decades, the United States experienced significant 
changes in demographic, social, and epidemiologic trends; these changes likely have 
contributed to changes in chronic kidney disease (CKD) epidemiology.
Methods: We used the Global Burden of Disease (GBD) study data and methodologies 
to describe the change in burden of CKD from 1990 to 2016 involving disability adjusted-
life years (DALYs) and death.
Results: Between 1990 and 2016, CKD DALYs increased by 104.7% from 945,627 
(UI: 837,774-1,053,428) to 1,935,953 (1,747,356-2,124,794). Death due to CKD increased 
by 149.5% from 33,080 (UI: 3 2,382-33,721) to 82,539 (UI: 80,297-84,652). All states 
exhibited increase in CKD burden, but there was remarkable heterogeneity in rate of 
change. In 2016, the burden varied greatly by state, where Mississippi (the state with the 
highest burden) had twice the age-standardized CKD DALY rate compared to Vermont 
(the state with the lowest burden), 697(UI:619-778) and 321 (UI:280-363), respectively. In 
the US, 37.8%, 35.6%, and 26.7% of the increase in DALYs was attributable to increased 
risk factor exposure, population growth, and aging, respectively. Decomposition analyses 
showed substantial increase in metabolic, and to a lesser extent dietary, risk factors which 
manifested in increase in CKD due to diabetes, and to a lesser extent hypertension. CKD 
due to diabetes was the primary contributor for increased probability of death due to CKD 
among those aged 20-54; among those aged 55-89, the increase in probability of death 
was driven by CKD due to diabetes and decreased probability of death from causes other 
than CKD. Improvement in socio-demographic (SDI) development was coupled with an 
increase in age-standardized DALY rates. Rate of change in burden of CKD outpaced rate 
of change of other non-communicable diseases, and rate of change of CKD in all SDI levels.
Conclusions: The US toll of CKD is significant, rising, and substantially variable 
among states; it is driven by increased risk factor exposure and demographic expansion 
leading to increased probability of death from CKD among working adults; the rate of 
change in CKD burden outpaced other diseases in the US and CKD in other areas of the 
world.
Funding: Veterans Affairs Support
FR-OR113 Oral Abstract Friday
Towards Better Medication Usage in Patients with CKD
Cumulative All-Cause Hospitalization Trajectories and Risks of ESRD 
and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study
Anand Srivastava,1 Xuan Cai,1 Jungwha Lee,1 Rupal Mehta,1 David I. Chu,2 
Sarah J. Schrauben,3 Milda R. Saunders,4 Clarissa J. Diamantidis,5 
Katherine T. Mills,6 Jonathan J. Taliercio,7 Tariq Shafi,8 Chi-yuan Hsu,9 
Sushrut S. Waikar,10 James P. Lash,11 Tamara Isakova.1 CRIC Study Investigators 
1Northwestern University Feinberg School of Medicine, Chicago, IL; 2Ann & 
Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; 3Division of Renal, 
Electrolytes, and Hypertension, University of Pennsylvania, Philadelphia, PA; 
4University of Chicago, Chicago, IL; 5Duke University School of Medicine, 
Durham, NC; 6Tulane University School of Public Health and Tropical Medicine, 
New Orleans, LA; 7Glickman Urological and Kidney Institute, Cleveland, OH; 
8Johns Hopkins University School of Medicine, Baltimore, MD; 9University of 
California San Francisco, San Francisco, CA; 10Harvard Medical School, Boston, 
MA; 11University of Illinois at Chicago, Chicago, IL.
Background: Prior studies have not evaluated whether trajectories of all-cause 
hospitalization identify high-risk sub-phenotypes of patients with chronic kidney disease 
(CKD).
Methods: We evaluated data on 3012 participants of the CRIC Study who were alive 
and did not reach end stage renal disease (ESRD) during the first 4 years of follow up. 
To identify clinically distinct trajectories of cumulative all-cause hospitalization during 
4 years, we performed trajectory analyses using latent class model. Trajectory analyses 
allow agnostic detection of subpopulations with distinct longitudinal patterns. Next, we 
fit multivariable-adjusted Cox proportional hazards models to assess the associations of 
trajectories of all-cause hospitalization with ESRD and with ESRD-censored death in 
participants who survived beyond their 5th annual visit.
Results: Trajectory analyses identified 3 discrete groups based on cumulative all-cause 
hospitalizations within the first 4 years of follow-up: none (n=1090), intermediate-utilizer 
(n=1785), or high-utilizer (n=137). Participants in the high-utilizer group were more likely 
to be black, have greater prevalence of diabetes mellitus and cardiovascular disease, have 
higher body mass index and albuminuria, and lower estimated glomerular filtration rate 
(eGFR). During a median follow-up time of 5.6 years, there were 544 ESRD events and 437 
ESRD-censored deaths. High and intermediate utilizer trajectory groups were associated 
with a higher risk of ESRD and ESRD-censored death (Figure).
Conclusions: Trajectories of cumulative all-cause hospitalization identify subgroups of 
patients with CKD who have increased risks of ESRD and death independent of known risk 
factors including eGFR and albuminuria. Population health interventions should focus on 
patients with CKD with increasing cumulative all-cause hospitalizations.
Funding: NIDDK Support
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Efficacy and Safety of Evolocumab in CKD: Data from the FOURIER 
Trial
David M. Charytan,1 Marc S. Sabatine,3 Terje R. Pedersen,2 Kyungah Im,3 
Armando Lira Pineda,6 Scott M. Wasserman,6 Peter Sever,4 Anthony C. Keech,5 
Robert P. Giugliano.3 1Brigham and Women’s Hospital/Harvard Medical School, 
Brookline, MA; 2Oslo University Hospital, Ullevål, Oslo, Norway; 3TIMI Study 
Group, Brigham and Women’s Hospital, Boston, MA; 4Imperial College London, 
London, United Kingdom; 5NHMRC Clinical Trials Centre, University of 
Sydney, Sydney, NSW, Australia; 6Amgen, Thousand Oaks, CA.
Background: The efficacy and safety of PCSK9 inhibition in patients (pts) with CKD 
is undefined. We analyzed outcomes by kidney function in FOURIER.
Methods: FOURIER randomized 27564 pts with stable atherosclerosis and LDL-
cholesterol (C) ≥70 or non-HDL-C ≥100 mg/dL to the PCSK9 inhibitor evolocumab or 
placebo. The primary endpoint (CV death, MI, stroke, hospitalization for unstable angina, 
or coronary revascularization), key secondary endpoint (CV death, MI or stroke), and safety 
outcomes were analyzed by CKD stage estimated from baseline CKD-EPI eGFR.
Results: 8077 pts had eGFR ≥90 mL/min/1.73m2, 15,034 stage 2 (eGFR 60-89), and 
4443 ≥stage 3 CKD (eGFR <60). Age and comorbidity prevalence increased with worse 
CKD. LDL-C reduction with evolocumab vs placebo at 48 weeks was similar across CKD 
groups at 58.2%, 59.4% and 58.7%, respectively. In the placebo arm, the primary and key 
secondary endpoint rates were higher with worsening CKD, especially those with ≥stage 
3 vs. preserved kidney function (primary-16.1% vs. 12.2%, P<0.01; secondary-12.8% 
Towards Better Medication Usage in Patients with CKD
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
69
J Am Soc Nephrol 29: 2018 Oral Abstract/Friday
vs. 7.1%, P<0.001, Figure). Relative risk reduction (RRR) with evolocumab was similar 
regardless of CKD stage (Pint=0.77 and 0.75, respectively). However, the absolute RRs for 
the key secondary endpoint tended to be larger among those with ≥stage 3 CKD (2.5%, 95% 
CI: 0.4%-4.7%) compared with individuals with preserved kidney function (1.7%, 95% 
CI 0.5%-2.8%). Adverse events, including eGFR decline ≥30%, were similar regardless 
of CKD stage.
Conclusions: LDL-C lowering and the relative efficacy and safety of evolocumab 
was preserved across CKD groups in patients with clinically evident atherosclerosis and 
hyperlipidemia on statin therapy. Absolute reduction in CV death, MI or stroke with 
evolocumab tended to be greater with more advanced CKD.
Funding: Commercial Support - Amgen
Kaplan-Meier event rates at 3-years according to treatment group. (A) Primary endpoint. 
(B) Key secondary endpoint. ARR-absolute risk reduction. HR-hazard ratio. CI-confidence 
interval.
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RAAS Inhibitors and Risk of ESRD and Mortality in Advanced CKD
Nayan Arora, Ronit Katz, Nisha Bansal. UW, Seattle, WA.
Background: Inhibition of the renin-angiotensin-aldosterone system (RAASi) is 
standard of care in early to moderate CKD. However their use in advanced CKD is 
controversial due to lack of data on safety and efficacy. We described the use of RAASi 
among a large advanced CKD cohort and tested the association of differing patterns of 
RAASi use with clinical outcomes.
Methods: We identified participants of the Chronic Renal Insufficiency Cohort (CRIC) 
study with eGFR <30 mL/min/1.73m2. A physician reviewed all available longitudinal 
study visit data and classified participants into groups based on RAASi use (defined as 
use of ACEi or ARBs): (1) no RAASi use; (2) continuous RAASi use; and (3) treated 
dynamically with periods off and on RAASi during advanced CKD. Cox models were used 
to test the association of patterns of RAASi use with risk of ESRD and mortality, adjusting 
for potential confounders.
Results: Of the 761 participants with advanced CKD (mean eGFR 25 ml/min/1.73 m2), 
167 (22%) did not take a RAASi throughout the study period, 319 (42%) took a RAASi 
continuously and 275 (36%) had a dynamic approach to RAASi use. Dynamic treatment 
with RAASi was associated with the lowest cumulative rates of ESRD and mortality 
(Figure). In multivariable models, a dynamic treatment strategy was associated with a 46% 
lower risk of ESRD (HR 0.54, 95% CI: 0.41,0.71) and a 23% lower risk of death (HR 0.77, 
95% CI: 0.46, 0.97) compared with no RAASi use. The association of continuous ACEi/
ARB use with clinical outcomes did not significantly differ from no RAASi use.
Conclusions: In a large, multi-center cohort of participants with advanced CKD, 
there was heterogeneity in patterns of use of RAASi. A dynamic, personalized approach to 
RAASi use in advanced CKD may be linked with lower risk of ESRD and mortality
KM curves for ESRD and death by patterns of RAASi use in advanced CKD
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Real World Dosing Practices of Renin-Angiotensin-Aldosterone System 
Inhibitors Is Associated with Risk of Adverse Clinical Events in CKD 
Patients
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Ameet Bakhai,6 Susan Grandy,4 Eirini Palaka,2 Philip McEwan.1 1Health 
Economics and Outcomes Research Ltd, Cardiff, United Kingdom; 2AstraZeneca, 
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Background: This study estimated real-world relationships between renin-angiotensin-
aldosterone system inhibitors (RAASi) dosing in chronic kidney disease (CKD) patients 
and the incidence of all-cause mortality and major adverse cardiovascular events (MACE).
Methods: Data from the UK Clinical Practice Research Datalink and linked 
Hospital Episode Statistics between Jan 2006 and Dec 2015 were used to identify 
adult non-dialysis patients with incident CKD stage 3+ (based on codes or eGFR 
≤60 mL/min/1.73m2). Kaplan-Meier survival curves were stratified by <50% and ≥50% of
guideline-recommended RAASi dose. Adjusted odds ratios (ORs) relating RAASi dosing
to mortality and MACE were estimated using Generalized Estimating Equations.
Results: 100,572 patients were included in the study (mean follow-up 6 years). 
Mortality rates for patients prescribed <50% and ≥50% of recommended RAASi dose were 
58 and 11 events per 1,000 patient-years, respectively; the corresponding rates of MACE 
were 141 and 82 events respectively. Risk of mortality over time was greater for patients 
prescribed <50% RAASi dose compared to those prescribed ≥50% (Figure 1). Adjusted 
ORs for mortality and MACE were 3.77 and 1.57 (both p<0.0001), respectively, comparing 
patients prescribed <50% and ≥50% RAASi dose.
Conclusions: CKD patients prescribed <50% RAASi dose were at significantly higher 
risk of mortality and MACE compared to those prescribed ≥50%. Although adjustment for 
factors such as clinician risk appreciation was not possible, the results highlight the need for 
treatment strategies that allow the prescription of recommended RAASi doses to optimize 
patient benefit.
Funding: Commercial Support - AstraZeneca
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Figure 1. Mortality rates stratified by RAASi dose
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Benefits and Risks of Oral Anticoagulant Therapy in CKD: A Systematic 
Review and Meta-Analysis of Randomized Controlled Trials
Jeffrey Ha,1,2 Brendon L. Neuen,1 Lap P. Cheng,1,2 Min Jun,1 Meg J. Jardine,1 
Martin P. Gallagher,1 Amit X. Garg,3 Manish M. Sood,4 Vlado Perkovic,1 
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Background: The effects of anticoagulation in chronic kidney disease (CKD) are 
uncertain. The aim of this systematic review was to study the benefits and risks of oral 
anticoagulant therapy in CKD.
Methods: Electronic databases were searched for randomized controlled trials with ≥3 
months follow-up in CKD patients (Stage 3-5D) that evaluated oral anticoagulant therapy. 
Treatment effects were summarized using random-effects meta-analysis.
Results: Nine trials (1341 participants) compared a vitamin K antagonist (VKA) 
to placebo, no study medication, aspirin, or low molecular weight heparin (LMWH). 
Twenty-three trials (27849 participants) compared a non-vitamin K oral anticoagulant 
(NOAC) to VKA, placebo, aspirin, or LMWH. Only 7 VKA trials (663 participants) 
included patients with advanced CKD, including dialysis patients. There were no clear 
differences in the risk of all-cause death (7 trials, RR 0.92, 95%CI 0.71, 1.18), and major 
bleeding (6 trials, RR 1.08, 95%CI 0.61, 1.92) between the VKA and combined control 
groups. Data on venous thromboembolism (VTE) and stroke or systemic embolism in 
atrial fibrillation (SSE-AF) with VKA were scant. Compared to VKA, NOAC reduced 
the risk of SSE-AF (5 trials, RR 0.82, 95%CI 0.70, 0.96), major bleeding (8 trials, RR 
0.71, 95%CI 0.51, 0.97), hemorrhagic stroke (3 trials, RR 0.42, 95%CI 0.20, 0.65), 
and intracranial hemorrhage (3 trials, RR 0.43, 95%CI 0.26, 0.60); and had similar risk 
of VTE/VTE-related death (4 trials, RR 0.86, 95%CI 0.47, 1.58), and all-cause death 
(4 trials, RR 0.91, 95%CI 0.78, 1.06). There were no clear differences in the risk of all-cause 
death (6 trials, RR 0.95, 95%CI 0.82, 1.11), VTE/VTE-related death (7 trials, RR 0.56, 95%CI 
0.29, 1.09), and major bleeding (14 trials, RR 1.04, 95%CI 0.74, 1.44) between the NOAC 
and combined control groups. Compared to placebo, the effect of NOAC on major adverse 
cardiovascular events was uncertain (3 trials, RR 0.85, 95%CI 0.73, 1.01).
Conclusions: NOAC have a benefit-risk profile superior to VKA in early stages of 
CKD, with significant reductions in SSE-AF and major bleeding. However, there is 
insufficient evidence to conclude whether patients with advanced CKD derive benefit from 
VKA or NOAC.
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Trends in Use of Prescription Opioids by Those with CKD in the  
United States, 1999 to 2014
Daniel P. Murphy, Robert N. Foley. University of Minnesota, Minneapolis, MN.
Background: High rates of opioid prescribing in the United States have contributed to 
a national opioid epidemic. Those with chronic kidney disease (CKD) likely have not been 
immune, and may, in fact, have an increased probability of opioid prescription due to a high 
prevalence of pain and frequent contact with healthcare systems. We sought to elucidate 
trends in prescription opioid use in the CKD population over time, by levels of kidney 
function, and among CKD-relevant subgroups.
Methods: We examined trends in prescription opioid use from years 1999-2014 among 
adult National Health and Nutrition Examination Survey participants with creatinine-based 
estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or albumin-creatinine 
ratio (ACR) ≥ 30 mg/g. Differences in opioid use by racial/ethnic and other demographic 
characteristics and CKD-relevant comorbidities were described.
Results: 7.5% of the CKD population used a prescription opioid compared to 5.4% 
among those without CKD (P < 0.001). Both reduced eGFR and albuminuria were 
associated with opioid use: 8.4% among those with eGFR < 60 ml/min/1.73m2 compared 
to 5.6% (P < 0.001) among those without reduced eGFR, and 7.4% among those with ACR 
≥ 30 mg/g compared to 5.6% (P < 0.001) among those without albuminuria. No temporal 
trend in unadjusted prevalence of opioid use in the CKD population was seen. In an age,
sex, and race/ethnicity adjusted model, the most recent era 2011-2014 vs. 1999-2002 was
associated with increased opioid use in the CKD population (adjusted odds ratio 1.43, 95% 
CI 1.05-1.95). Other multivariate associations (P < 0.05) were age 40-64 years, female
sex, diabetes mellitus, hypertension, BMI ≥ 30 kg/m2, history of cancer, and arthritis. After 
statistical adjustment, no difference was seen among racial/ethnic minorities in the CKD
population.
Conclusions: Prescription opioid use is more prevalent among the CKD population 
than in the general U.S. population with 28% of opioid use among those with CKD 
attributable to the association with CKD. Multiple comorbidities, which to varying degrees 
increase risk for pain and/or exposure to healthcare systems, were associated with increased 
prevalence of prescription opioid use.
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Epidemic among Elderly CKD Patients in the United States
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Background: CKD patients are vulnerable to opioid abuse due to high burden and 
suboptimal management of pain. We assessed geographic variation and the impact of 
environmental factors on long-term opioid use in elderly CKD patients.
Methods: We used a linked dataset from Medicare 5% sample claims data (2006-09), 
the American Community Survey Data (2005-09) and the Health Resources and Services 
Administration (HRSA) Primary Care Service Area (PCSA) data (2007). Medicare Part D 
enrollees age ≥65 years were included. County-level long-term opioid use was measured 
as % patients prescribed opioids for more than 90 days during a 1-year period after CKD 
diagnosis. County-level environmental factors included % of general physicians, elderly, 
population residing in Medically Underserved Areas (MUAs) and area deprivation index. 
A mixture model separating counties into different risk categories with subgroup analysis, 
was applied to investigate the relationship between environmental factors and county-level 
long-term opioid use.
Results: : The mixture model (Fig) clustered counties (n=1,794) into 4 risk subgroups. 
The average proportion of long-term opioid use of subgroups, which corresponded to mild, 
moderate, severe and very severe long-term opioid use were 3.0%, 5.3%, 13.0% and 31.2%. 
Counties in the Northeast and Midwest were more likely in mild and moderate risk groups, 
while the West andSouth counties were more likely in the severe and very severe group. 
Counties with aging adults and higher deprivation index were associated with greater long-
term opioid use. Counties in MUAs were most likely in the very severe group.
Conclusions: Several environmental factors are associated with long-term prescription 
opioid use among elderly patients with CKD. This association varied across counties, 
highlighting the importance of allocating resources for this epidemic at county level.
Funding: NIDDK Support
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Towards Better Medication Usage in Patients with CKD
Efficacy and Safety of Oral Ferric Maltol (FM) in Treating Iron-Defi-
ciency Anemia (IDA) in Patients with CKD: Randomized Controlled Trial
Nelson P. Kopyt. AEGIS-CKD Study Group Lehigh Valley Hospital, 
Allentown, PA.
Background: IDA is common in CKD and is a leading cause of morbidity and 
mortality. Oral ferrous products for IDA may be poorly tolerated due to gastrointestinal 
(GI) adverse events (AEs). Intravenous iron can be inconvenient and has the risk of allergic 
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reactions or iron overload. Patients with CKD and IDA would benefit from effective, well 
tolerated oral iron replacement therapy. FM is an oral iron replacement therapy for IDA 
formulated to improve GI absorption. A phase 3 multicenter double-blind, randomized 
controlled trial (NCT02968368) evaluated the efficacy and safety of FM in patients with 
stage 3/4 CKD.
Methods: Patients aged ≥18 years with CKD (estimated GFR ≥15 to <60 mL/
min/1.73 m2) and IDA (hemoglobin [Hb] ≥8.0 to <11.0 g/dL, and either ferritin <250 μg/L 
with transferrin saturation [TSAT] <25% or ferritin <500 μg/L with TSAT <15%) were 
randomized 2:1 to oral FM 30 mg or placebo twice daily for 16 weeks. The primary endpoint 
was change in Hb from baseline to Week 16 using analysis of covariance of the intent-to-
treat population. Also reported are data on all iron parameters measured in the trial; changes 
from baseline in ferritin, TSAT, and serum iron were assessed at Weeks 4, 8, and 16.
Results: Of 167 patients randomized (FM 111, placebo 56), 77% completed double-
blind treatment (FM 81%, placebo 70%). All iron parameters were significantly improved 
with FM vs placebo over 16 weeks (Table). GI disorders were the most common drug-
related AEs (FM 18%, placebo 7%). Serious AEs occurred in 21% in each group; none was 
considered to be study-drug related. Two patients died (one in each group), both considered 
unrelated to study drug.
Conclusions: FM resulted in statistically significant and clinically meaningful 
increases in Hb concentration and all iron parameters from baseline to week 16 vs placebo, 
supporting the efficacy of oral FM in treating IDA in patients with stage 3 or 4 CKD. FM 
was generally well tolerated, with only minor differences in the safety profile and overall 
GI AEs vs placebo.
Funding: Commercial Support - Shield Therapeutics Ltd
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Benefits and Harms of Dual Antiplatelet Therapy in CKD: A Systematic 
Review and Meta-Analysis of Randomized Controlled Trials
Lap P. Cheng,1,2 Jeffrey Ha,1,2 Matthew H. Tong,2 Brendon L. Neuen,1 Min Jun,1 
Meg J. Jardine,1 Martin P. Gallagher,1 Manish M. Sood,3 Amit X. Garg,4 
Vlado Perkovic,1 Sunil V. Badve.1,2 1The George Institute for Global Health, 
Sydney, NSW, Australia; 2St George & Sutherland Clinical School, UNSW 
Medicine, Sydney, NSW, Australia; 3Ottawa Hospital Research Institute, Ottawa, 
ON, Canada; 4London Health Sciences Centre, London, ON, Canada.
Background: Dual antiplatelet therapy (DAPT) is the standard of care in coronary 
artery disease. Despite the high burden of cardiovascular disease in chronic kidney disease 
(CKD), the role of DAPT in improving outcomes in CKD has not been systematically 
studied. The aim of this systematic review was to study the benefits and harms of DAPT 
in CKD.
Methods: Electronic databases were searched for randomized controlled trials (RCT) 
that included CKD patients (stage 3-5D or proteinuria) and evaluated the effect of DAPT 
on cardiovascular outcomes with ≥3 months follow up. Treatment effects were summarized 
using random-effects analysis.
Results: Eleven trials (13628 participants) compared DAPT to a single antiplatelet 
agent (6 trials), placebo (3 trials), or no study medication (2 trials). DAPT interventions 
were aspirin/dipyridamole (5 trials) and aspirin/P2Y12 inhibitor (6 trials). Compared to 
the control group, DAPT reduced the risk of major adverse cardiovascular events (4 trials, 
risk ratio [RR] 0.87, 95%CI 0.78, 0.97), myocardial infarction (5 trials, RR 0.76, 95%CI 
0.61, 0.92), and stroke (6 trials, RR 0.81, 95%CI 0.68, 0.94). There were no differences 
in risk of cardiovascular death (7 trials, RR 0.95, 95%CI 0.76, 1.14), all-cause death 
(10 trials, RR 0.92, 95%CI 0.82, 1.03), and major bleeding (8 trials, RR 1.36, 95%CI 0.98, 
1.73) between DAPT and control group. Three other trials (6239 participants) compared 
DAPT using aspirin/P2Y12 inhibitor to DAPT. Compared to aspirin/clopidogrel, aspirin 
plus ticagrelor or prasugrel reduced the risk of all-cause death (2 trials, RR 0.74, 95%CI 0.6, 
0.88); and with no differences for major adverse cardiovascular events (2 trials, RR 0.88, 
95%CI 0.61, 1.14), and major bleeding (3 trials, RR 0.93, 95%CI 0.37, 1.48). Overall, 4 
trials included dialysis patients (1860 participants); 5 trials excluded dialysis patients (13725 
participants); 2 trials did not include advanced CKD (stages 4-5) (372 participants); and 3 
trials did not report the lower threshold of renal function for exclusion (3910 participants).
Conclusions: DAPT improved cardiovascular outcomes in early stages of CKD. 
However, there is insufficient evidence to conclude whether patients with advanced CKD 
derive benefit from DAPT.
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Skeletal Muscle Inflammation and Fibrosis Contribute to Weakness in 
Patients with CKD
Matthew K. Abramowitz,1 William Paredes,1 Kehao Zhang,2 Camille Brightwell,3 
Julia N. Newsom,3 Hyokjoon Kwon,4 Matthew Custodio,1 Rupinder 
singh Buttar,8 Hina Farooq,5 Bushra Zaidi,7 Rima N. Pai,6 Jeffrey E. Pessin,1 
Meredith Hawkins,1 Christopher Fry.3 1Albert Einstein College of Medicine, 
New York, NY; 2Einstein Medical School, Bronx, NY; 3University of Texas 
Medical Branch, Galveston, TX; 4Rutgers Robert Wood Johnson Medical 
School, New Brunswick, NJ; 5Louis A. Weiss Memorial Hospital, Chicago, IL; 
6Beth Israel Deaconess Medical Center, Boston, MA; 7BronxCare Health 
System, Bronx, NY; 8Jacobi medical center, Belmont, NY.
Background: Muscle dysfunction is an important cause of morbidity among patients 
with chronic kidney disease (CKD). Although muscle fibrosis is present in a CKD rodent 
model, its existence in humans and its impact on physical function are currently unknown. 
In animal models of muscle injury, TNF-α secreted by macrophages prevents muscle 
fibrosis by limiting the expansion of fibro/adipogenic progenitor cells (FAPs).
Methods: We examined isometric leg extension strength and measures of skeletal 
muscle fibrosis and inflammation in vastus lateralis muscle from CKD patients (n=10, 
stage 4 and 5 CKD) and healthy, sedentary controls of similar age (n=10). Histochemistry 
and immunohistochemistry were used to assess muscle collagen and macrophage and FAP 
cell populations, and RT-qPCR was used to assess muscle-specific inflammatory marker 
expression.
Results: Muscle collagen content was significantly greater in CKD compared with control 
(18.8 ± 6.7% vs. 11.7 ± 2.0% collagen area, p=0.008), as was staining for collagen I, pro-
collagen I, and a novel collagen-hybridizing peptide that binds remodeling collagen. Muscle 
collagen was inversely associated with leg extension strength in CKD (r= -0.74, p=0.01) but 
not control (r=0.40, p=0.28). FAP abundance was increased in CKD, was highly correlated 
with muscle collagen (r=0.84, p<0.001), and was inversely associated with TNF-α expression 
(r= -0.65, p=0.003). TNF-α, CD68, CCL2, and CCL5 mRNA were significantly lower in CKD 
than control, despite higher serum TNF-α and IL-6. Immunohistochemistry confirmed fewer 
CD68+ and CD11b+ macrophages in CKD muscle.
Conclusions: Skeletal muscle collagen content is increased in humans with CKD and is 
functionally significant. Muscle fibrosis correlated with increased FAP abundance resulting 
from insufficient macrophage-mediated TNF-α secretion. These data provide a foundation 
for future research elucidating the mechanisms responsible for this newly identified human 
muscle pathology.
Funding: NIDDK Support
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Intramuscle Fat Infiltration in Non-Dialysis CKD: Clinical Determinants 
and Association with Mortality
Carla M. Avesani,1,2 Juliana Giglio,1 Abdul Rashid T. Qureshi,3 
Maria A. Kamimura,4 André V. Bichels,7 Peter Stenvinkel,5 Bengt Lindholm,3 
Juan J. Carrero,3 Antonio C. Cordeiro.6 1Rio de Janeiro State University, Rio de 
Janeiro, Brazil; 2Clinical Science, Intervention and Technology, Division of 
Baxter Novum, Karolinska Institutet, Huddinge, Sweden; 3Karolinska Institutet, 
Huddinge, Sweden; 4Federal University of São Paulo, São Paulo, Brazil; 
5Karolinska University Hospital Huddinge, Stockholm, Sweden; 6Dante 
Pazzanese Institute of Cardiology, Sao Caetano do Sul, Brazil; 7Unifesp, São 
Paulo, Brazil.
Background: Intramuscle fat infiltration (IFI) is an important feature of aging currently 
understood as a cause of muscle weakness in elderly. Compared to healthy controls, IFI 
has been reported elevated in chronic kidney disease (CKD) patients. Its determinants and 
consequences, however, are unknown.
Methods: Cross-sectional study with mortality follow-up of 195 nephrology-referred 
patients with non-dialysis CKD stages 3-5. Mean age was 60±11 years, 61% were men 
and glomerular filtration rate (creatinine clearance) was 25±12 ml/min/1.73 m2. We used 
computed tomography (CT) scan (Slice-O-Matic software version 5.0) of the third lumbar 
vertebra to quantify the degree of IFI (reported as % of fat within muscle area). Muscles 
evaluated by CT were psoas, transversus abdominis, rectus abdominis, external and internal 
obliques, erector spinae and quadratus lumborum. Coronary artery calcification score 
(CAC) was evaluated by CT, muscle strength by dynamometry (handgrip strength, HGS) 
and shown as standard values to normative tables.
Results: IFI was higher in women than in men (9.7±6 vs 6.3±4%, P<0.05), and was 
positively correlated (Spearman test) with age (rho =0.37), Charlson comorbidity score 
(rho=0.19), CAC (r=0.16) and CT-derived visceral (rho=0.37) and subcutaneous fat 
(rho =0.57). IFI was negatively associated with HGS (rho=-0.25) and CT-derived skeletal 
muscle mass (rho=-0.37). In multiple linear regression analysis, male sex (ß=-0.66; P<0.01), 
older age (ß=0.40 per 1-SD increase; P<0.01), higher muscle mass (ß=0.48 per cm/m2  
increase; P<0.01) but lower muscle strength (ß=-0.15 per % decrease in HGS) were 
independent predictors of IFI% (r2=0.33). During 40±13 months of follow-up, 57 patients 
died. Increased IFI was associated with the risk of death (adjusted hazard ratio 1.60 per 
1-SD increase, 95% CI: 1.21 to 2.11) independently of sex, age, diabetes, CKD stage, CAC, 
subjective global assessment and standard HGS.
Conclusions: IFI is associated with lower muscle strength in non-dialysis CKD 
patients and predicts the risk of death, regardless of muscle stores. These data are consistent 
with the notion that intramuscle fat infiltration worsens muscle quality.
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Pro-Inflammatory Diets Increase Risk of ESRD in US Adults with CKD
Tanushree Banerjee,5 Deidra C. Crews,1 Nilka Rios Burrows,2 Meda E. Pavkov,2 
Rajiv Saran,3 Hal Morgenstern,3 Neil R. Powe.4 1Johns Hopkins University 
School of Medicine, Baltimore, MD; 2Centers for Disease Control and 
Prevention, Atlanta, GA; 3University of Michigan, Ann Arbor, MI; 4Priscilla 
Chan and Mark Zuckerberg San Francisco Gen Hosp & UCSF, San Francisco, 
CA; 5University of California, San Francisco, CA.
Background: CKD progression can be accompanied by chronic low-grade 
inflammation marked by elevated concentrations of inflammatory markers. We 
hypothesized that proinflammatory diets increase risk of kidney disease progression and 
systemic inflammation is a mediator of progression of kidney disease.
Methods: We analyzed a cohort study of 1084 adults with CKD (eGFR 15-59 ml/
min/1.73m2) aged≥ 20 years in the 1988-1994 National Health and Nutrition Examination 
Survey linked with the US Renal Data System, allowing for assessment of ESRD as an 
outcome over a follow-up period of 14 years. The Adapted Dietary Inflammatory Index 
(ADII, based on 26 components) was calculated at baseline from a 24-hr dietary recall. We 
used regression analysis to examine the association between ADII and an inflammatory 
score (IS) computed from C-reactive protein, serum albumin, white blood cell count, and 
mean platelet volume, adjusting for demographics, body mass index, physical activity, 
HbA1C, systolic blood pressure, total cholesterol. The Fine Gray competing risk model 
was used for exploring the association between (i) IS and ESRD, and (ii) risk of incident 
ESRD and per standard deviation (SD) increase in ADII. The models were adjusted for the 
above mentioned covariates and estimated glomerular filtration rate and urinary albumin–
to-creatinine ratio (ACR). IS was considered as a mediator of CKD progression using Valeri 
and Vanderweele’s method.
Results: 120 participants with CKD (11.1%) developed ESRD. A 1 SD increase in 
ADII was associated with a higher IS (β [95% CI]: 1.05[0.89-1.22]). IS was also associated 
with ESRD (relative hazard [RH]: 1.12 [95% CI: 1.02-1.25]). ADII was associated with 
increased risk of incident ESRD (RH per SD increase: 1.40 [1.04-1.78]). Mediation 
analyses showed that 25% of the total effect of the ADII on ESRD was explained or 
mediated by IS. Interaction tests showed a higher risk of ESRD per SD increase in 
ADII in adults with ACR≥30mg/g (RH 1.55 [1.12-1.96] than those with ACR<30 mg/g 
(RH 0.96 [0.55-1.38]; pinteraction<0.001).
Conclusions: A proinflammatory diet is independently associated with risk of ESRD 
which is mediated by the inflammatory markers. These findings have implications for 
prevention of ESRD using dietary approaches.
Funding: Other U.S. Government Support
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Multicenter Randomized Controlled Study of the Efficacy of Low-Protein 
Rice for Dietary Protein Restriction in Patients with CKD
Michihiro Hosojima,1 Hideyuki Kabasawa,1 Ryohei Kaseda,1 Tomomi Ishikawa,1 
Yoshitsugu Obi,2 Toshiko Murayama,1 Shoji Kuwahara,1 Yoshiki Suzuki,1 
Ichiei Narita,1 Akihiko Saito.1 1Niigata University, Niigata, Japan; 2University 
of California, Irvine, CA.
Background: The benefits of dietary protein restriction in chronic kidney disease 
(CKD) remain unclear, largely due to poor adherence to low-protein diet in most clinical 
studies. Rice, a major staple food globally, is a primary source of dietary plant proteins, 
especially in Asia. We examined the efficacy of low-protein rice (LPR) for dietary protein 
restriction in CKD patients.
Methods: This open multicenter randomized controlled study aimed to compare the 
efficacy of dietary protein restriction [0.7 g/kg ideal body weight (IBW)/day] between CKD 
patients without LPR (no LPR group) and those with LPR (LPR group) to be eaten in at 
least 2 meals per day for 24 weeks (UMIN000015630). We enrolled 104 patients (age, 62.7 
± 10.8 years) with CKD (stages G3aA2 and G4) from Niigata University Medical & Dental 
Hospital and 7 affiliated hospitals from August 2014 to December 2017. Patients in both 
groups were given regular instruction by dietitians to meet the nutritional goal. Maroni’s
formula was used to estimate protein intake.
Results: Analysis of covariance was performed adjusted by protein intake at the start of 
the study. After 24 weeks, estimated protein intake decreased from 0.99±0.23 to 0.80±0.20 
g/kg IBW/day in the LPR group and from 0.99±0.23 to 0.91±0.21 g/kg IBW/day in the 
no LPR group, respectively. The change was significantly higher in the LPR group than 
in the no LPR group by 0.11 (95% CI, 0.03 to 0.19) g/kg IBW/day (P = 0.001). Energy 
intake did not differ significantly between the groups; salt intake decreased significantly at 
24 weeks in the LPR group. Creatinine clearance did not differ significantly between the 
groups, but urinary protein excretion decreased significantly at 24 weeks in the LPR group. 
Also, nutritional indices including diagnostic markers of protein-energy wasting and quality 
of life showed no significant difference between the groups.
Conclusions: LPR has potential as a feasible tool for dietary protein restriction in CKD 
patients. Long-term studies are needed to investigate LRP diet and suppression of CKD 
progression.
Funding: Commercial Support - Kameda Seika Co.,Ltd., Sato Foods Industries 
Co.,Ltd., Biotech Japan Co.,Ltd., Forica Foods Co.,Ltd.
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Dietary Fiber Intake, Myocardial Injury, and Major Adverse Cardiovas-
cular Events among ESRD Patients: A Prospective Cohort Study
Angela Yee Moon Wang,1,2 Mei Wang,2 John E. Sanderson,2 Iris Chan,3 
Christopher W. Lam,4 Jean Woo.5 1Medicine, University of Hong Kong, Queen 
Mary Hospital, Hong Kong, China; 2Chinese University of Hong Kong, Prince 
of Wales Hospital (Previous), Hong Kong, Hong Kong; 3Chemical Pathology, 
Prince of Wales Hospital, Hong Kong, Hong Kong; 4Macau University Science 
Technology, Macau, China; 5The Chinese University of Hong Kong, Hong Kong 
SAR, China.
Background: Dialysis patients are frequently advised to restrict fruits, vegetables, 
wholegrain or nuts intake due to their high potassium or phosphate content. The importance 
of fiber intake in relation to cardiovascular health in dialysis patients is not known.
Methods: Two hundred and nineteen prevalent dialysis patients was prospectively 
recruited from a university teaching hospital and regional dialysis center and followed for 
4 years. Dietary fiber intake was estimated using a 7-day validated food frequency dietary 
questionnaire and examined in relation to a composite of major adverse cardiovascular 
events (MACE).
Results: Higher fiber intake was associated with less inflammation, lower serum 
cardiac troponin T, N-terminal pro-brain natriuretic peptide and less cardiac hypertrophy. 
During 4 years’ follow-up, 127 patients were complicated with one or more MACE. 
Higher fiber intake (hazard ratio [HR], 0.87, 95% confidence intervals [CI], 0.80 – 0.94) 
and higher fiber intake density (HR, 0.85, 95% CI, 0.74 – 0.97) were associated with a 
lower risk of MACE on univariate analysis. In the multivariable Cox regression analysis, 
higher fiber intake predicted a lower risk of MACE (adjusted HR, 0.89, 95% CI, 0.81 – 
0.97, P=0.008) independent of other clinical, demographic, biochemical, hemodynamic, 
adequacy parameters, dietary protein and energy intake, as well as inflammatory and 
cardiac markers. Similarly, fiber intake density retained significance in predicting MACE 
both as a continuous variable [adjusted HR, 0.87, 95% CI, 0.77 – 0.99] and when stratified 
into tertiles, adjusting for the same confounders. Those in the lower tertile of fiber intake 
density showed an increased hazard for MACE [adjusted HR, 1.78, 95% CI, 1.13 – 2.80] 
compared to those in the upper tertile.
Conclusions: Higher dietary fiber intake and fiber nutrient density were associated 
with less inflammation, less myocardial hypertrophy and injury and predicted a lower 
risk of MACE in dialysis patients. These data form an important basis for a randomized 
controlled trial to examine the effects of fiber supplementation on cardiovascular outcomes 
in dialysis patients.
Funding: Government Support - Non-U.S.
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Resistant Starch Supplementation Reduces Indoxyl Sulfate Levels in 
Hemodialysis Patients: A Randomized, Double-Blind, Crossover, 
Placebo-Controlled Study
Denise Mafra,1 Marta Esgalhado,1 Renata D. Macedo,2 Julie ann Kemp,1 
Bruna Paiva,1 Lia S. Nakao,3 Diana B. Cunha,4 Natalia A. Borges.5 1Federal 
University Fluminense, Rio de Janeiro, Brazil; 2Federal Fluminense University, 
Rio de Janeiro, Brazil; 3UFPR, Curitiba, Brazil; 4State University of Rio de 
Janeiro, Rio de Janeiro, Brazil; 5Universidade Federal Fluminense, Rio de 
Janeiro, Brazil.
Background: Protein-bound uremic toxins produced from intestinal bacterial protein 
fermentation, including indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), tend to accumulate 
in chronic kidney disease (CKD) patients. These patients have a gut microbiota imbalance 
that leads to loss of gut barrier integrity, facilitating the passage of IS and p-CS into the 
bloodstream. Both solutes are linked with the progression of renal disease, as well as, 
cardiovascular disease (CVD). Strategies like prebiotic supplementation may be effective 
to restore the balance of the gut microbiota. This study tested whether prebiotic resistant 
starch (RS) supplementation would reduce IS and p-CS plasma levels in hemodialysis 
patients (HD).
Methods: Thirty eight stable HD patients were randomized in RS (n=19) or Placebo 
(n=19) groups to receive alternately 9 cookies/day (dialysis days) and 1 sachet/day (non-
dialysis days) containing 16 g of RS (Hi-Maize 260, Ingredion®) or manioc flour for 4 
weeks and then after the washout period (4 weeks) were crossed over to the alternative for 
an additional 4 weeks. Fasting pre-dialysis plasma IS and p-CS were analyzed by reversed-
phase high-performance liquid chromatography. Food intake was also recorded. Intention-
to-treat analysis were performed in order to verify the variation of IS and p-CS plasma 
levels according to allocation groups, by means of mixed linear models is SAS.
Results: Twenty six patients concluded the study, 12 in RS-Placebo group (42% male, 
54.8±7.9 years, 53.0±40.5 months of HD, 26.7±5.1 Kg/m2) and 14 in Placebo-RS group 
(71% male, 54.2±11.9 years, 44.1±23.0 months of HD, 26.2±4.8 Kg/m2). After 4 weeks, IS 
plasma levels were significantly reduced in the RS group [-6.2 (-9.7/-3.3)mg/L] compared 
to placebo [2.2 (-5.9/4.5)mg/L] (p=0.006). No significant alterations was observed in 
plasma p-CS levels or food intake (besides fiber intake has increased with RS).
Conclusions: Prebiotic RS supplementation seems to be an effective nutritional 
strategy to reduce plasma IS levels in CKD patients on HD. These findings support the 
hypothesis that prebiotics may be a new non-pharmacological intervention to modulate gut 
microbiota.
Funding: Government Support - Non-U.S.
Translational Advances in Nutrition and Metabolism
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
73
J Am Soc Nephrol 29: 2018 Oral Abstract/Friday
FR-OR128 Oral Abstract Friday
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Probiotic Dietary Supplementation in Hemodialysis Patients: A Dou-
ble-blind, Randomized, Placebo-Controlled Trial
Sixiu Liu, Hongli Jiang. First Affiliated Hospital of Medicine School, Xi’an 
Jiaotong University, Xi’an, China.
Background: Recent studies have highlighted that gut microbiota is a key origin of 
uremic retention solutes in patients with chronic kidney disease, and is involved in triggering 
systemic microinflammation. The objective of this study was to evaluate the effects of 
probiotics on the gut microbiota profile and inflammatory markers in hemodialysis (HD) 
patients.
Methods: This was a randomized, double-blind, placebo-controlled study. Fifty HD 
patients were assigned to receive 1 of 2 treatments: probiotic (Pro0,n = 25; Enterococcus 
faecalis, Lactobacillus acidophilus, Bifidobacterium longum, 4 capsules each, twice 
daily, totally containing 30 billion colony-forming units per day) or placebo (PL0,n = 25) 
daily for 6 months. Blood samples and feces samples were collected at baseline and after 
intervention. The gut microbiota profile, inflammatory markers (IL-6, TNF-α and hs-CRP) 
and endotoxin were assessed.(Trial registration number NCT02929225.)
Results: Twenty-three patients remained in the probiotic group(Pro2) and 22 in the 
placebo group(PL2). Compared with the placebo group, probiotics did not induce major 
changes in the faecal microbiome. The alpha and beta diversity of gut microbiota in probiotic 
group were not significantly different from placebo group(Fig.1(A)and(B)). However, 
according to the Linear discriminant analysis coupled with effect size measurements 
(LEfSe) further identified four bacterial families that significantly changed. Particularly, 
Family Enterococcaceae was increased, while Ruminococcaceae was reduced in probiotic 
group. In addition, the plasma levels of inflammatory markers and endotoxin were not 
affected by probiotics.
Conclusions: In HD patients, probiotics did not significantly induce major alterations 
in the fecal microbiome but several specific bacteria relative abundance were restored.
Funding: Government Support - Non-U.S.
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Dysbiosis in Renal Failure Causes Insulin Resistance and Leaky Gut
Kiyotaka Uchiyama, Shu Wakino, Tomoaki Ito, Takaya Tajima, Ayumi Matsui, 
Hiroshi Itoh. Keio University, School of Medicine, Tokyo, Japan.
Background: Chronic Kidney disease (CKD) leads to clinically relevant insulin 
resistance (IR), which is a novel cardiovascular risk factor in patients with CKD. However, 
the pathophysiology of IR in CKD remains unclear. Recently, gut microbiota alterations 
have been reported to be associated with the etiology and progression of CKD. Using germ-
free mice, we sought to determine whether dysbiosis in renal failure (RF) contributes to 
CKD-associated IR.
Methods: RF was induced in 7-week-old male ICR mice by feeding a diet containing 
0.2% adenine for 6 weeks; these were compared with a control group that was fed a 
normal diet. Fecal microbiota transplantation (FMT) was performed by oral gavage on the 
8-week-old, germ-free, male, ICR mice using cecal microbiota obtained from either the
control group (control-FMT) or RF group (RF-FMT). The vehicle group was gavaged with 
only sterile phosphate-buffered saline. Two weeks after inoculation, glucose and insulin
tolerance and intestinal microbiota and barrier function were evaluated in each group.
Results: In the mice from the RF group, whose body and adipose tissue weight were 
markedly lower, IR was evident where insulin stimulation failed to activate insulin signaling 
in skeletal muscles and adipose tissues. The expression of tight junctions in the colon was 
also reduced. In the RF-FMT group, glucose and insulin tolerance were impaired compared 
with those in the control-FMT and vehicle groups; insulin-induced signal transduction was 
attenuated, especially in skeletal muscles. Additionally, adipose tissue weight, adipocyte 
size and tight junction protein expression in the colon were lower in the RF-FMT group 
compared with those in the control-FMT group. These results mimicked those of the RF and 
the control groups. The differences in gut microbiota between the RF and control groups 
were mostly consistent between the RF-FMT and the control-FMT groups, including a 
decrease in Bacteroides and Prevotella species and an increase in Clostridium species in 
the RF and RF-FMT groups.
Conclusions: The gut microbiota from mice with RF induced IR along with impaired 
adipose tissue maturation, and disruption of the intestinal barrier associated with RF. Our 
data demonstrated for the first time, that uremic dysbiosis directly affects CKD-related 
metabolic abnormality.
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CKD Attenuates the Plasma Metabolome Response to Insulin
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Bryan R. Kestenbaum,6 Daniel Raftery,6 Ian H. de Boer.7 1University of 
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Background: Chronic kidney disease (CKD) leads to decreased sensitivity to the 
metabolic effects of insulin contributing to protein energy wasting and muscle atrophy. 
Targeted metabolomics profiling during hyperinsulinemic euglycemic insulin clamp testing 
may help identify potential aberrant metabolic pathways contributing to insulin resistance 
among patients with CKD.
Methods: Using a targeted metabolomics profiling, we examined the plasma 
metabolome in 95 adults without diabetes in the fasted state (58 with moderate-severe CKD, 
37 with normal glomerular filtration rate (GFR)) of whom 60 had plasma collected during a 
hyperinsulinemic-euglycemic clamp (40 with CKD). We assessed heterogeneity in fasting 
metabolites and the response to insulin to identify potential cellular metabolic pathways 
linking CKD with insulin resistance. Differences and changes in metabolite concentrations 
by CKD status and with insulin clamp testing were adjusted for potential confounders of 
age, sex, race/ethnicity (white versus non-white) and body weight. Pathway analysis was 
performed using Metaboanalyst
Results: Mean GFR among participants with CKD was 37.3 mL/min per 
1.73m2compared to 89.3 ml/min per 1.73m2among controls. In the fasting state, differences 
between CKD and control subjects included significant abnormalities in tryptophan 
metabolism, ubiquinone biosynthesis, and the TCA cycle (Figure). Insulin infusion 
markedly decreased plasma metabolite levels, predominantly amino acids and their 
metabolites. CKD was associated with attenuated insulin-induced changes in nicotinamide, 
arachidonic acid, and glutamine/glutamate metabolic pathways (Figure).
Conclusions: Targeted plasma metabolomics profiling suggests broad disruption 
in amino acid metabolism and mitochondrial function as putative manifestations or 
mechanisms of the impaired anabolic effects of insulin in CKD.
Funding: NIDDK Support
Comparison of fasting (left panel) and insulin clamp (right panel) metabolic pathway 
differences between CKD and controls.
FR-OR131 Oral Abstract Friday
Translational Advances in Nutrition and Metabolism
Endurance Exercise-Derived Exosomal miRNA Exerkines Attenuate 
Progressive CKD
Bjoern Tampe, Michael Zeisberg. University Medical Center Goettingen, 
Goettingen, Germany.
Background: Progressive CKD is still an unmet biomedical challenge because no 
effective therapies are available as of yet for clinical use. While various studies across 
multiple organs which demonstrated that endurance exercise (EE) protects from progressive 
organ failure by endocrine-like signalling via specific nucleic acids (so-called exerkines), 
little consideration has been paid as to whether any exerkines are released in a manner 
other than direct discharge into the circulation. It is becoming increasingly apparent that one 
of the main mechanisms by which scelettal muscle cells and distant organs communicate 
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is by the release of cell-derived extracellular exosomes. Based on these pre-requisits, we 
here aimed to gain insights into the molecular mechanisms underlying successful reno-
protection and to explore whether such pathways could be therapeutically targeted.
Methods: EE was performed in C57BL/6mice for 4 weeks before challenging with 
unilateral ureteral obstruction (UUO) for 7 days without EE. Exosomal miRNA signatures 
were analyzed by unbiased array-based approaches and confirmed by qRT-PCR in 
sclettal muscles, plasma exosomes and corresponding kidneys. By using miRNA mimics 
administered systemically, miRNA candidates for succesful protection during EE were 
confirmed for therapeutical implications.
Results: We identified a unique miRNA signature in muscle-derived exosomes and 
kidneys specifically during endurance exercise, associated with attenuation of progressive 
CKD. Systemic administration of miRNA mimics was equally effective to attenuate 
progressive CKD, supporting that endurance exercise-derived exosomal miRNAs are 
involved in reno-protection. On a mechanistic level, we provide evidence that exosomal 
miRNAs directly target and degrade PAI-1, associated with activation of the tPA/uPAR/
plasmin pathway. Increased tPA/uPAR/plasmin stimulates ECM remodelling and 
degradation by activation of latent MMPs, in particular MMP-2 and MMP-9.
Conclusions: In summary, we here provide evidence that EE attenuates progressive 
CKD by enrichment of exosomal miRNA exerkines modulating ECM remodelling and 
degradation in chronically injured kidneys. Because miRNA mimics equally protect from 
progressive CKD, these findings further support therapeutical implications of exosomal 
exerkines as nature’s exercise pill.
FR-OR132 Oral Abstract Friday
Translational and Transplant Pathology
Genome-Wide Non-HLA Incompatibility between Donor and Recipient 
Contributes to Kidney Allograft Attrition
Rainer Oberbauer,1 Roman Reindl-Schwaighofer,1 Andreas Heinzel,1 
Petra Hruba,2 Ondrej Viklicky,2 Kira Jelencsics,1 Karin Hu,1 Alexander Kainz,1 
Michael Kammer,1 Georg Heinze,1 Georg Bohmig,1 Frans Claas,3 
Farsad A. Eskandary,1 Brendan Keating.4 1Medical University of Vienna, Vienna, 
Austria; 2Institute for Clinical and Experimental Medicine, Department of 
Nephrology, Prague, Czechia; 3University Leiden, Leiden, Netherlands; 
4University of Pennsylvania, Philadelphia, PA.
Background: The introduction of HLA matching of donors and recipients was a 
breakthrough in kidney transplantation but epidemiological data suggest also a fundamental 
role of non-HLA alloimmunity.
Methods: 477 deceased donor and first kidney transplant recipient pairs from a 
prospective multi-center transplant cohort study were successfully genotyped and genome-
wide genetic mismatches in nsSNPs were calculated to identify incompatibilities in 
transmembrane and secreted proteins. Association of nsSNP mismatch and graft loss was 
estimated in a Cox model adjusting for HLA mismatch and clinical covariates. Customized 
peptide arrays were generated to screen for antibodies against genotype-derived mismatched 
epitopes.
Results: The median nsSNP mismatch in immune-accessible transmembrane and 
secreted proteins between donors and recipients was 1,892 with an interquartile range (IQR) 
of 86. The degree of nsSNP mismatch was independently associated with graft loss in a 
multivariable model adjusted for HLA eplet mismatch (HLA-A, B, C, DP, DQ, DR). Each 
increase by a unit of one IQR exhibited a HR of 1.68 (95% CI 1.17-2.41, p=0.005). Five-
year death censored graft survival was 98% in the quartile with the lowest mismatch but 
only 82% in the highest quartile (p=0.003, logrank test).(Figure). Customized peptide arrays 
verified a donor-specific alloimmune response to genetically predicted mismatched epitopes 
for selected transmembrane proteins.
Conclusions: Genetic mismatch of non-HLA haplotypes coding for transmembrane 
or secreted proteins is associated with an increased risk of functional graft. DSAs can be 
identified against genotype derived non-HLA epitopes.
FR-OR133 Oral Abstract Friday
Translational and Transplant Pathology
Single Cell Transcriptome Analysis of Human Kidney Allograft
Hemant Suryawanshi,2 Hua Yang,3 Milagros T. Lagman,4 Michelle L. Lubetzky,5 
Thomas Tuschl,7 Manikkam Suthanthiran,6 Thangamani Muthukumar.1 1Weill 
Cornell Medicine, New York, NY; 2The Rockefeller University, New York, NY; 
3Weill-Cornell, New York, NY; 4Weill Medical College of Cornell University, 
New York, NY; 5Division of Nephrology and Hypertension, New York, NY; 6Weill 
Cornell Medical College, New York, NY; 7Howard Hughes Medical Institute, 
New York, NY.
Background: Unbiased transcriptome-based clustering analysis of cells within the 
kidney allograft may help identify cell type-specific injury and has the potential to redefine 
the current pathology-based classification of allograft rejection/injury.
Methods: Kidney allograft tissue obtained at the time of core needle biopsy (n=2, TK1 
and TK2, Figure 1) was digested to generate single cell suspension. Droplet-based 10X 
Chromium platform (10X Genomics) was used to capture single cells in emulsion, followed 
by cDNA synthesis, sequencing, and analysis.
Results: We obtained 2,657 (TK1) and 2,207 (TK2) high-quality scRNA-seq profiles 
and identified 13 and 11 major cell clusters, respectively (Figure 2). In both biopsies, T cells 
(27% TK1 and 24% TK2) were abundant despite the differences in histopathology findings. 
Cell types restricted to TK1 were NK, MZB and SMC, whereas cell types restricted to TK2 
were NKT, MC and IC. Only TK2 had fibrosis but we found FB cells in both the samples.
Conclusions: Our single cell expression atlas of human kidney allograft has deciphered 
the complex cellular environment of kidney allograft and provides a powerful step towards 
better understanding of the cellular basis of kidney allograft dysfunction.
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FR-OR134 Oral Abstract Friday
Translational and Transplant Pathology
Accelerated Podocyte Detachment Early after Kidney Transplantation 
and Relationship to Long-Term Allograft Loss-of-Function
Abhijit S. Naik,1 Farsad Afshinnia,1 Jawad Aqeel,1 Diane M. Cibrik,2 
Milagros D. Samaniego-Picota,3 Larysa T. Wickman,1 Su Q. Wang,1 
Mahboob A. Chowdhury,1 Roger C. Wiggins.1 1University of Michigan, Ann 
Arbor, MI; 2University of Kansas, Kansas city, KS; 3Henry Ford Hospital, 
Detriot, MI.
Background: Kidney allograft half-life has not improved despite excellent short-
term survival. Recent long-term surveillance biopsy studies identify accumulating 
glomerulosclerosis associated with late allograft loss. While podocyte depletion is well-
known to drive proteinuria and glomerulosclerosis in animal models and human glomerular 
diseases, its role in renal allograft loss-of-function is not generally recognized.
Methods: To address these questions, we collected urine from 125 kidney transplant 
recipients in the first post-transplant year for urine pellet mRNA and protein analysis, with 
a median follow up of 4.5-years.
Results: Using multivariable linear models adjusted for proteinuria, transplant, 
recipient and donor factors, we observed that the average rate of podocyte detachment 
in the first post-transplant year was significantly associated with eGFR decline. The 
relationship between podocyte detachment rate and eGFR decline persisted even among 
recipients who were non-proteinuric (<0.3g/g creatinine) and who had no recurrent or 
de novo glomerular disease identified on 1yr protocol biopsy.
Conclusions: These findings support the concept that in kidney allografts accelerated 
podocyte loss precedes proteinuria, is associated with inferior long-term allograft 
outcomes as measured by eGFR decline. Modulating factors driving early podocyte 
detachment after kidney transplantation may help improve long-term outcomes.
Funding: NIDDK Support, Other NIH Support - O'Brien and Michigan Nutrition and 
Obesity Research Center
Predictors of eGFR slope over median 4.5 years of follow-up: Multivariable analysis.
Adjusted for recipient & donor factors (age,race,sex, race,BSA), transplant factors (HLA 
mismatch, cold ischemia time), first year events (de novo DSA and rejection), average of 
other urine mRNA markers (UTGFbeta1CR,UAqp2CR) and IFTA.
Abbreviations: UpodCR, urine podocin mRNA to urine creatinine ratio; UAqp2CR, urine 
aquaporin2 mRNA to urine ratio; UTGFbeta1CR, urine transforming growth factor beta 
mRNA to creatinine, UProtCR; urine protein to creatinine ratio.
FR-OR135 Oral Abstract Friday
Translational and Transplant Pathology
The Banff Working Group Classification of Polyomavirus Nephropathy: A 
Validation Study in the Modern Era
Volker Nickeleit,1 Darshana Dadhania,2 Adil H. Gasim,1 Vicki G. Davis,1 
Surya V. Seshan,2 Harsharan K. Singh.1 1The University of North Carolina at 
Chapel Hill, Chapel Hill, NC; 2Weill Cornell Medical College, New York, NY.
Background: The Banff multicenter working group on polyomavirus nephropathy 
(PVN) recently proposed a morphologic, clinically significant PVN classification scheme 
with three disease classes based on the histologic degree of intra-renal PV replication and 
the Banff-ci score. Transplant recipients with definitive PVN managed between 1996-2010 
were analyzed (JASN 29: 680, 2018). Aim: To evaluate the validity of the proposed PVN 
classification in the modern transplant era.
Methods: 652 consecutive adult renal allograft recipients transplanted at UNC after 
1/1/2009 were enrolled. In patients with definitive PVN, the first diagnostic biopsy (index 
biopsy) was scored and PVN classes defined. Clinical and histologic data were statistically 
analyzed following the Banff working group approach (JASN 29: 680, 2018). Biopsies 
with TCMR (type II/III), ABMR or other severe renal diseases were excluded from some 
analyses.
Results: PVN affected 57/652 patients (incidence 8.7%; 39 (68%) males; median age 
54 years). 2/57 patients were excluded due to recurrent disease at time of index biopsy. 
PVN class I: 29/55 (53%), class II: 25/55 (45%), class III: 1/55 (2%; small case number 
in class III precluded further statistical analysis). Class I was diagnosed earlier (median 18 
weeks post grafting) than class II (24 weeks). Baseline S-Cr levels before index biopsy were 
similar between class I and II: class I 1.4 mg/dl, class II 1.3 mg/dl, p=0.823. At index biopsy, 
class I compared to II had only a minor rise of S-Cr: median % change from baseline, 10% 
class I, 37% class II, p=0.004. Over 12-month follow-up, class I showed minimal increase 
in S-Cr levels compared to baseline (+0.2 mg/dl; median change) in contrast to class II (+0.6 
mg/dl; p=0.003). In the study cohort, graft failure was rare: overall 3/55 (5%); class I: 2/29 
(7%), class II: 1/25 (4%), class III: 0/1 (0%).
Conclusions: The histologic classification of PVN as proposed by the Banff working 
group also carries clinical significance in the modern era. PVN class I characterizes cases 
with stable graft function. Overall graft failure rates for this single site are lower (5%) 
than reported by the Banff working group (30%). The PVN disease classification provides 
additional clinical information, therefore it should be incorporated into diagnostic and 
scientific communications.
FR-OR136 Oral Abstract Friday
Translational and Transplant Pathology
Archetype Analysis Identifies Distinct Profiles in Renal Transplant 
Recipients with Transplant Glomerulopathy Associated with Allograft 
Survival
Yassine R. Bouatou,2,1 Olivier Aubert,2 Sarah Higgins,3 Denis Viglietti,2 
Carmen Lefaucheur,2 Alexandre Loupy.2 1Pathology, AMC, Amsterdam, 
Netherlands; 2Paris Translational Research Center for Organ Transplantation, 
Paris, France; 3Université de Sherbrooke, Sherbrooke, QC, Canada.
Background: Transplant glomerulopathy (TG) is a common glomerular lesion 
observed after kidney transplantation and a well-known contributing factor for allograft 
loss. However, overlapping pathways, associated etiologies and clinical courses have not 
been addressed at a population level.
Methods: All consecutive kidney transplant recipients from 3 referral centers from 
France and 1 in Canada with a diagnosis of TG (Banff cg score≥1) in biopsies performed 
between January 2004 and January 2014 were included and assessed by light microscopy, 
immunohistochemistry, immunofluorescence and electron microscopy. All patients 
underwent circulating anti-HLA donor-specific antibodies testing at the time of TG 
diagnosis.
Results: Among the 8,207 post-transplant allograft biopsies performed during the 
inclusion period in the 4 centers, 552 presented with TG (incidence of 6.7%). The median 
time to TG diagnosis post-transplant was 33.18 months (IQR: 12.12 – 78.72 months). Kidney 
allograft survival rates after TG diagnosis were 69.4%, 57.1%, 43.3% and 25.5% at 3, 5, 7 
and 10 years, respectively. Unsupervised learning method integrating clinical, functional, 
immunological and histological parameters revealed 5 TG archetypes characterized by 
distinct features, and associated etiologies. The 5 TG archetypes unraveled distinct allograft 
survival profiles with incremental 5-year allograft loss rates between archetypes (Fig 1).
Conclusions: A probabilistic data-driven archetypical approach applied in a large well 
defined multicentric cohort, refines the diagnostic and prognostic features associated with 
TG, reducting heterogeneity, which might help improving disease characterization and 
individual patient risk stratification, opening avenues for an archetype-based strategy for 
TG treatment.
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Figure 1: Kidney allograft survival after TG diagnosis overall (A) and archetype-based 
(B). The overall difference between the five archetypes was significant (p-value<0.0001).
FR-OR137 Oral Abstract Friday
Translational and Transplant Pathology
A Phase-I Clinical Trial of Donor-Derived MIC Cell Infusion for the 
Induction of Donor-Specific Hyporesponsiveness after Living Donor 
Kidney Transplantation (TOL-1 Study)
Christian Morath,2,1 Anita Schmitt,2 Christian Kleist,2 Volker Daniel,2 
Gerhard Opelz,2 Caner Süsal,2 Florian Kälble,2,1 Claudius Speer,2,1 Luiza Pego 
silva,2,1 Claudia Sommerer,2,1 Lei Wang,2 Angela Hückelhoven-Krauss,2 
Uta Merle,2 Arianeb Mehrabi,2 Carsten Mueller-Tidow,2 Martin G. Zeier,2,1 
Michael Schmitt,2 Matthias Schaier,2,1 Peter Terness.2 1Nierenzentrum 
Heidelberg, Heidelberg, Germany; 2Heidelberg University Hospital, Heidelberg, 
Germany.
Background: MIC cells are donor-derived monocytes that gain immunosuppressive 
properties after incubation with the proliferation inhibitor mitomycin C.
Methods: PBMCs were harvested from living donors by leukapheresis and MIC 
cells were manufactured under GMP conditions. Transplant recipients received either 
1.5x10E6 MIC cells/kg body weight on day -2 (N=3,group A), 1.5x10E8 MIC cells/kg 
body weight on day -2 (N=3,group B) or day -7 (N=4,group C) before living donor kidney 
transplantation. Patients received immunosuppressive therapy with CyA,EC-MPS and CS. 
Primary outcome measure was the frequency of adverse events (AE) on day 30.
Results: A total of 72 AEs (3 severe AEs) occurred in treated patients that were unrelated 
to MIC cell infusion. No positive cross match results, de novo donor specific antibodies, or 
rejection episodes but 2 infectious complications were recorded. Median serum creatinine 
on day 30 was 1.4 mg/dL with no significant proteinuria. In vitro, MIC cells were capable 
of inducing tolerogenic dendritic cells with low expression of costimulatory molecules 
CD80, CD86 and a 30% increase of immunosuppressive molecule CD103. Beyond day 30 
after surgery, serum creatinine remained stable (median 1.48 mg/dL on day 180) with no 
significant proteinuria (median 10 g/mol creatinine on day 180) and no rejection episodes. 
The patients from group C who received low-dose CyA and low-dose EC-MPS during the 
observation phase had no or only minimal reactivity against irradiated donor lymphocytes 
in mixed lymphocyte culture while reactivity against 3rd party lymphocytes was preserved. 
CD19+ B cells increased to a median of 300/μL until day 30 but decreased to a median of 
35/μL on day 180.CD19+CD24highCD38high transitional Bregs increased from a median 
of 2% on day 30 to a median of 20% of the total CD19+ B cell pool on day 180. There was 
an increase in the plasma IL-10/TNFalpha ratio from a median of 0.05 before cell therapy 
to a median of 0.11 on day 180.
Conclusions: MIC cell therapy represents a promising option for individualized 
immunosuppression after living donor kidney transplantation.
FR-OR138 Oral Abstract Friday
Translational and Transplant Pathology
The Effect of Pulse Steroids/IVIG/Rituximab on Circulating Lymphocytes 
and Cytokines in Kidney Transplant Recipients with Chronic Active 
ABMR)
Nancy A. Wilson,1 Natalie M. Bath,1 Sarah E. Panzer,2 Arjang Djamali,3 
Shannon Reese.1 1University of Wisconsin, Madison, WI; 2University of 
Wisconsin Madison, Madison, WI; 3School of Medicine and Public Health, 
Madison, WI.
Background: There is no information on the effect of combination therapy with 
pulse steroids/IVIG/Rituximab on circulating T-cell and B-cell phenotypes and cytokines 
in kidney transplant recipients (KTR) with chronic active antibody mediated rejection 
(cABMR).
Methods: We examined this questions in 8 KTR with cABMR who underwent follow 
up evaluation with a repeat protocol biopsy within 3 months of the initial diagnosis. PBMC 
subsets were identified using flow cytometry. Plasma was analyzed using Luminex 45-
plex assay for cytokines. Paired Wilcoxon rank sum test was utilized to assess the effect of 
therapy on pre and post samples. Pre-treatment samples were also compared to a group of 
11 healthy volunteers matched for age, gender, and race.
Results: Median age at the diagnosis of cABMR was 48 years. The diagnosis was 
made at a median of 9.8 years post-transplant. Median Scr and urine PC at biopsy were 2.43 
mg/dL and 1.24 g/g. Treatment with pulse steroids/IVIG/Rituximab was associated with 
a statistically significant decline in ptc and mvi Banff scores (p<0.05) at the three-month 
protocol biopsy. Similarly, B cells, Naïve B cells, plamablasts, and transitional B cells were 
significantly reduced (p<0.05 for all). However, treatment was associated with a significant 
increase in CD3 T cells and IL17 levels (p=0.02 for both). There was no significant 
difference in other Banff scores, kidney function, and Treg or Breg populations. Compared 
to controls, KTR had significantly lower naïve B cells, plasmablasts, and transitional B 
cells, while cirtculating fractaline, IL1-alpha, IL7, IL13, IL15, PDL1, and VEGF levels 
were significantly increased (p<0.04 for all).
Conclusions: In conclusion, KTR with ABMR have significantly different circulating 
B cell and cytokine profiles than healthy volunteers. Short term therapy with Pulse steroids/
IVIG/Rituximab effectively inhibits disease activity in cABMR. However, treatment is 
associated with an upregulation of T cell response suggesting a negative feedback role for 
B cells in cABMR.
FR-OR139 Oral Abstract Friday
Translational and Transplant Pathology
G2/M Cycle Arrest in Human Transplanted Kidneys Correlates to 
Fibrosis, Functional Decline, and Graft Loss
Tobias Pieters,3 Thomas Vanhove,4 Tri Q. Nguyen,1 Marianne C. Verhaar,3 
Dirk R. Kuypers,4 Roel Goldschmeding,3 Maarten B. Rookmaaker.2 1UMC 
Utrecht, Utrecht, Netherlands; 2UMCU, Utrecht, Netherlands; 3University 
Medical Center Utrecht, Utrecht, Netherlands; 4University Hospitals Leuven, 
Leuven, Belgium.
Background: Kidney transplantation (KTx) is the only curative treatment of end-stage 
renal failure. However, some KTx recipients suffer from long-term graft loss associated 
with interstitial fibrosis and tubular atrophy (IF/TA), especially after delayed graft function 
(DGF) due to acute tubular injury (ATI). Maladaptive repair, characterized by G2/M arrested 
tubular cells, has emerged as a key mediator of IF/TA after ATI in animal experiments, 
although little is known about its role in human kidney fibrosis. In this retrospective study, 
we studied the relation between G2/M cell cycle arrest in tubular cells in biopsies and 
histological and functional outcome of kidney allografts.
Methods: We included 64 patients, of which 32 presented with DGF and 32 with early 
graft function (EGF). Surveillance biopsies taken at 3 months after KTx were evaluated for 
G2/M cell cycle arrest by staining for the G2/M marker pHH3 and the proliferation marker 
Ki67. ATI was quantified morphologically in the indication biopsies taken approximately 
7 days after KTx in the DGF group. Renal outcome was evaluated by fibrosis 2 years after 
KTx (Remuzzi score), kidney function decline in 2 years (CKD-epi), and 10-year death-
censored graft survival.
Results: At 3 months after KTx, DGF kidneys had more G2/M arrested cells (median 
1.17 cells/mm2 [0.0-3.8] vs median 0.6 cells/mm2 [0.0-1.8]; p<0.05) and the number of 
arrested cells/mm2 correlated to acute histological damage in the 7 day biopsy (ρ=-0.78 
p<0.0005), to histological severity of fibrosis in biopsies taken 2 years after transplantation 
(ρ =0.52, p<0.01), and to functional decline over these 2 years (ρ = -0.44, p<0.01). Finally, 
the amount of G2/M arrested cells was associated with a higher risk of 10- year death-
censored graft survival (univariate cox regression, HR=3.98, p<0.01).
Conclusions: Our data suggest that in the regenerative response following ATI 
damaged cells in kidney allografts can get arrested in G2/M and subsequently contribute to 
progressive IF/TA, functional decline and eventually graft loss.
Funding: Commercial Support - Astellas Pharma inc.
FR-OR140 Oral Abstract Friday
Translational and Transplant Pathology
Clinical Utilization of Donor-Derived Cell-Free DNA (AlloSure) for 
Monitoring Kidney Transplants: The Colorado Experience
Alexander C. Wiseman,2 James E. Cooper,3 Scott Davis,1 Monica Grafals,1 
Erik Stites.1 1University of Colorado, Denver, CO; 2University of Colorado at 
Denver and Health Sciences Center, Denver, CO; 3University of Colorado at 
Denver, Denver, CO.
Background: Cell-free DNA is released by cellular apoptosis or damage. Donor-
derived cell-free DNA (dd-cfDNA) released from kidney allografts can be differentiated 
from recipient cfDNA and correlates with graft injury due to rejection. Dd-cf-DNA may be 
an effective biomarker for monitoring immunologic risk and damage in kidney transplants. 
We recently implemented dd-cfDNA surveillance in all eligible kidney transplant recipients 
within three years of transplant at our center. Here we present our early experience.
Methods: All eligible kidney transplant recipients within three years of transplant at our 
center were enrolled in the surveillance protocol. Blood samples for dd-cfDNA are collected 
at 1, 2, 3, 4, and 6months post-transplant and then quarterly for the first 3years. A dd-cfDNA 
proportion of >1.0% was considered positive based on published data. Management of 
positive results were left to clinical discretion. Patients also undergo surveillance biopsy at 
3 months post-transplant per our institutional protocol.
Results: In the first four months of the protocol, 394 samples have been collected from 
256 patients. The dd-cfDNA was negative (<1.0%) in 95.2% (n=375) of samples analyzed. 
Nineteen samples from 18 patients were positive (>1.0%) with 13 patients undergoing 
subsequent biopsy. Six biopsies (46.2%) were confirmed diagnosis of rejection (2 with 
clinical rejection, 4 with subclinical rejection). Seven biopsies were not diagnostic of 
rejection (3 with no pathologic abnormality, 1 with ATN, 1 with glomerular disease, 1 with 
moderate glomerulitis, 1 with borderline cellular rejection). Twelve patients have had dd-
cfDNA monitoring (a total of 22 samples, all <1.0%) and 3-month surveillance biopsies. 
Biopsies demonstrated no pathologic abnormality in 11 of 12 surveillance biopsies (91.7%). 
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One biopsy had moderate peritubular capillaritis, moderate glomerulitis, and negative 
staining for C4d. The patient has stable graft function and no DSA.
Conclusions: To our knowledge, this is the largest published series to date using dd-
cfDNA to monitor immunologic risk in kidney transplant recipients. A positive dd-cfDNA 
(>1.0%) had a PPV of 46.2% for biopsy-proven acute rejection, and importantly, 4 out of 
6 of these cases were subclinical. A negative dd-cfDNA (<1.0%) had a NPV of 91.7% on 
3-month surveillance biopsies.
Funding: Commercial Support - CareDx
FR-OR141 Oral Abstract Friday
Translational and Transplant Pathology
Gene Expression Profiles of Post-Transplant Glomerular Disease
Enver Akalin,1 Maria Ajaimy,1 Sai Vineela Bontha,2 Mariel Barbachan e Silva,3 
Pilib Ó Broin,3 Valeria Mas.2 1Montefiore Medical Center, Bronx, NY; 2University 
of Virginia, Charlottesville, VA; 3National University of Ireland, Galway, 
Galway, Ireland.
Background: Intragraft gene expression profiles of glomerular disease after kidney 
transplantation has not been well described other than transplant glomerulopathy (TG) 
which develops due to chronic rejection. We aimed to evaluate intragraft gene expression 
profiles of post-transplant glomerular disease including membranous glomerulopathy 
(MG), secondary or primary focal segmental glomerulosclerosis (FSGS), comparing to 
normal and TG biopsies.
Methods: The gene expression profiles of the 83 kidney biopsy specimens were studied 
by Affymetrix HuGene 1.0 ST expression arrays. TG (n=33), MG (n=10), secondary/
late FSGS (n=16), and primary FSGS (n=6) were compared to normal transplant kidney 
biopsies (n=16).
Results: Gene Ontology analysis showed that all 4 glomerular disease groups had 
increased expression of gene transcripts related to activation, regulation, and differentiation 
of T cells, B cells, leukocytes, cytokines, chemokines, chemotaxis, and immune response 
compared to normal biopsies. Ingenuity Pathways Analysis demonstrated majorly 
overlapping differentially expressed genes between different comparisons indicating 
majorly common pathways and gene expression (Figure). Comparing canonical pathways 
the MG was least aggressive in terms of gene expression differences, followed by the 
secondary/late FSGS when compared to normal allografts. Primary FSGS and TG had the 
most differentially expressed genes, with most of them involved in inflammatory pathways 
and immune response. ILK signaling pathway and IL9 signaling pathway were uniquely 
activated in primary FSGS. All 4 groups demonstrated increased interferon gamma and 
rejection, cytotoxic T cell and macrophage associated pathogenesis based transcript 
expression.
Conclusions: Post-transplant glomerular disease including MG and FSGS had 
intragraft gene transcripts associated with increased immune activity similar to rejection 
and share overlapping gene transcripts with TG.
SA-OR001 Oral Abstract Saturday
Access, Organ Utilization, and Infectious Disease
Frailty and Age Disparities in Access to Kidney Transplantation
Christine E. Haugen,1 Mary G. Bowring,1 Courtenay M. Holscher,3 Hao Ying,4 
Daniel C. Brennan,2 Niraj Desai,5 Jacqueline Garonzik wang,2 Dorry L. Segev,3 
Mara McAdams-DeMarco.2 1Johns Hopkins Hospital, Baltimore, MD; 2Johns 
Hopkins, Baltimore, MD; 3Johns Hopkins University, Baltimore, MD; 4Johns 
Hopkins School of Medicine, Baltimore, MD; 5Physician, Baltimore, MD.
Background: Older age is a known barrier to kidney transplantation (KT). One 
mechanism to explain age disparities is frailty, a decreased physiologic response to stressors 
associated with poor outcomes after KT.
Methods: We studied 3,548 KT candidates (2009-2017) in a multi-center cohort study 
of frailty. We estimated time to listing, waitlist mortality, and transplant rate using Cox 
proportional hazards, competing risks, and Poisson regression.
Results: The association between KT listing and candidate age varied by frailty 
status (interaction p=0.03): Older (age≥65) frail candidates were 27% less likely to 
be listed compared to older nonfrail candidates (aHR:0.73,95%CI:0.59-0.92,p<0.01), 
whereas younger (age:18-64) frail candidates were 23% less likely to be listed for KT 
(aHR:0.77,95%CI:0.68-0.88,p<0.001) (Figure 1A). Both older (aSHR:1.97,95%CI:1.54-
2.53,p<0.001) and frail (aSHR:1.38,95%CI:1.05-1.83, p=0.02) KT candidates had higher 
waitlist mortality; but there was no synergistic effect (interaction p=0.12) (Figure 1B). The 
association between candidate age and transplant rate differed by frailty status (interaction 
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p=0.02): younger frail KT candidates were transplanted less frequently than younger 
nonfrail candidates (aIRR:0.68,95%CI:0.55-0.83,p<0.001). However, older frail KT 
candidates had similar transplant rates to older nonfrail candidates (aIRR:1.12,95%CI0.78-
1.61,p=0.5) (Figure 1C).
Conclusions: The synergistic effect of older age and frailty is associated with a lower 
chance of listing, but not seen in older frail candidates with regards to waitlist mortality. 
Frailty assessment at KT evaluation can help guide patient counseling for candidates all of 
all ages, and prehabilitation strategies to improve pre-KT outcomes.
Funding: NIDDK Support, Other NIH Support - National Institute on Aging, 
F32AG053025, R01AG055781
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Identification of Factors That Explain Racial Disparities during the 
Evaluation Process for Kidney Transplantation
Karly A. Murphy, Hao Ying, Dorry L. Segev, Mara McAdams-DeMarco. Johns 
Hopkins University, Baltimore, MD.
Background: Racial disparities between blacks and white patients are observed 
in evaluation completion rates, a step required for kidney transplantation (KT) listing. 
However, the role of patient-level demographics and medical comorbidities as explanatory 
factors for these disparities is unclear. We compared the risk of listing in black versus white 
adults referred to clinic for KT evaluation and identified whether the association of socio-
economic factors and medical co-morbidities account for racial disparities in listing for KT.
Methods: As part of a prospective multi-center cohort study of aging and ESRD, 
3,540 black and white candidates were enrolled at evaluation for KT (1/2009-12/2017). 
Self-reported demographic data, education, income, employment, and frailty status was 
collected at time of first evaluation. Medical comorbidities were ascertained from self-
report and chart review. Time to listing in the first year was our primary outcome. We 
used multivariate Cox proportional hazard models to estimate incidence for listing and 
the association of patient-level factors between black and white participants. Mediation 
analysis was performed using percent reduction in beta coefficient for race in expanded 
model versus a base model, adjusted for age and sex.
Results: Among 3,540 participants, the mean age was 54.7 years (sd=13.5) with 41.2% 
female and 49.2% self-reported black race. Overall, 1,930 patients were listed for KT in the 
first year. Likelihood of listing was lower for blacks compared with whites (HR=0.77, 95% 
CI:0.70-0.84) after adjusting for age and gender. Racial differences in listing rates were 
partially explained by socio-economic factors (% reduction in beta coefficient, 38.5%) and 
partially explained by medical co-morbidity (% reduction in beta coefficient, 35.6%). After 
accounting for age, gender, patient-level socioeconomic factors, and medical comorbidity, 
disparity by race persisted (adjusted HR 0.89, 95% CI 0.81-0.98, % reduction in beta 
47.6%).
Conclusions: Racial disparities during the listing stage of KT are partly explained by 
differences in patient-level socio-economic factors and medical comorbidity. Higher socio-
economic status may indicate greater personal resources to navigate the transplant process 
and could direct future intervention.
Funding: Other NIH Support - NIA, 2T32-HL00718041A
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Exploring the Viability of Kidneys Discarded in the US: A Comparison of 
Kidney Utilization Patterns and Outcomes in the US and France
Olivier Aubert,1 Peter P. Reese,2 Yassine R. Bouatou,3 Denis Viglietti,4 
Carmen Lefaucheur,3 Alexandre Loupy.5 1Paris Translational Research Center 
for Organ Transplantation, Paris, France; 2University of Pennsylvania, 
Philadelphia, PA; 3Paris Transplant Group, Paris, France; 4Saint-Louis 
Hospital, Paris, France; 5INSERM, Paris, France.
Background: Approximately 2,000 donated kidneys are discarded in the US each year. 
Some transplant leaders have questioned the viability of these lost organs, while others 
suggest instead that allocation inefficiencies or risk-aversion due to center report cards are 
responsible for the high discard rates. However, few studies have examined whether kidneys 
discarded in the US might be transplanted with acceptable outcomes in other countries.
Methods: Using UNOS registry and the Paris Transplant Group prospective cohort 
data from 2004 – 2014, we compared kidney quality and outcomes between the US and 
France.
Results: During this period, 125,936 kidneys in the US and 4,287 kidneys in the 
Paris Transplant Group cohort were procured for transplant. As shown in the upper 
panel, a much higher proportion of transplanted French kidneys were higher-risk organs 
(as measured by the kidney donor profile index, KDPI) compared to the US (median 
65 [39-90] vs 42 [19-67] in the US, p<0.0001). During the decade, the KDPI of US kidneys 
only increased modestly (from a mean KDPI of 42 to 44), while in France, a steadily rising 
KDPI (from a mean KDPI of 54 to 67) reflected a trend of more aggressive organ use. We 
used the Kaplan-Meier method to estimate death-censored graft survival for higher-KDPI 
kidneys transplanted in France. Three and five-year survival for KDPI 80 – 90 kidneys 
was 88 and 83%, for KDPI 91-99 kidneys was 83 and 79% and for KDPI 100 was 81 and 
78%. Finally, we fit a logistic regression model to predict kidney discard in the US (AUC 
0.80) and estimated the probability that kidneys transplanted in France would have been 
discarded if instead allocated in the US. Many transplanted French kidneys would have had 
a high probability of discard in the US system. Using 951 transplanted kidneys in France 
randomly selected according to their probability of being discarded in the US, we calculated 
that the use of those kidneys in the US would have translated to a 3,000 allograft life-years 
saved.
Conclusions: In summary, these results provide fresh evidence that some kidneys 
discarded in the US are a lost opportunity that could have benefitted some wait-listed 
patients.
SA-OR004 Oral Abstract Saturday
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Clinical Utility and Interpretation of CKD Stages in Living Kidney 
Donors
Allan Massie,1 Alvin G. Thomas,2 Jon J. Snyder,3 Dorry L. Segev.4 1Johns 
Hopkins School of Medicine, Baltimore, MD; 2UNC Chapel HIll, Chapel Hill, 
NC; 3Minneapolis Medical Research Foundation, Minneapolis, MN; 4Johns 
Hopkins University, Baltimore, MD.
Background: Current definitions of chronic kidney disease (CKD) staging define any 
individual with estimated glomerular filtration rate (eGFR)<60 as having stage 3 or higher 
CKD. Nearly half of living kidney donors (LKDs) have post-donation eGFR below this 
threshold, but the clinical interpretation of eGFR<60 in donors is unknown, and the “CKD” 
label may not be appropriate. Evidence of risk associated with decreased post-donation 
eGFR is needed to inform international guidelines and best practices for donor followup 
and care management.
Methods: Using national registry data, we studied end-stage renal disease (ESRD) 
risk in 67,571 LKDs 1999-2015 with at least one reported postdonation serum creatinine 
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(SCr). eGFR was calculated via the CKD-EPI equation. Measurements with eGFR<15 
were excluded from analysis. We modeled the association between eGFR category 
(≥60, 45-59, 30-44, 15-30, corresponding to no CKD, CKD stage 3, stage 4A, and stage 
4B) using Cox regression with eGFR category as a time-varying exposure and adjusting 
for donor age, sex, race (black vs nonblack), BMI, and 1st-degree biological relationship 
to recipient.
Results: 117,051 CKD measurements were reported at median (IQR) 11 (4-14) 
months post-donation (90th percentile 25m post-donation). Of these, 33.9% were in the 
range 45-59, 5.7% were in the range 30-45, and 0.8% were in the range 15-29. Lower 
eGFR categories were associated with greater ESRD risk: 5-fold higher risk for eGFR 
30-45 (aHR = 5.3 (2.1-13.3)) and 54-fold higher risk for eGFR 15-29 (aHR=53.7 
(4.8-421.3); both p<0.001). Donors with eGFR 45-60 had elevated risk but the association 
was not statistically significant (aHR=1.9 (0.9-3.8), p=0.08).
Conclusions: There is insufficient evidence to support the category eGFR 45-60 
as clinically meaningful “CKD stage 3” among LKDs. Nevertheless, eGFR category is 
associated with ESRD risk among donors with eGFR<45, and our results support current 
guidelines recommending longitudinal followup of renal function in living kidney donors.
Funding: NIDDK Support
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Variation in Access to Transplant Referral and Evaluation Start among 
Dialysis Facilities
Laura J. McPherson,1 Derek Dubay,3 Matthew J. Ellis,4 Heather Jones,9 
Carlos F. Zayas,2 Laura L. Mulloy,5 Brenda B. Thrasher,8 Joseph A. Gulotta,6 
Shannon Wright,7 Reem Hamoda,1 Stephen O. Pastan,1 Rachel E. Patzer.1 on 
behalf of the Southeastern Kidney Transplant Coalition 1Emory University 
School of Medicine, Atlanta, GA; 2Augusta University (MCG) School of 
Medicine, Augusta, GA; 3Medical University of South Carolina, Charleston, SC; 
4Duke University Medical Center, Durham, NC; 5Medical College of Georgia, 
Augusta, GA; 6IPRO, Lake Success, NY; 7IPRO ESRD Network of the South 
Atlantic, Morrisville, NC; 8Carolinas Medical Center, Charlotte, NC; 9Vidant 
Medical Center, Greenville, NC.
Background: Variation exists in transplant access across US dialysis facilities. 
However, little is known about the proportion of end-stage renal disease (ESRD) patients 
who initiate or complete transplant steps prior to waitlisting. We describe dialysis facility-
level variation in referral and evaluation start among dialysis facilities in ESRD Network 6 
using our regional pre-transplant data registry.
Methods: In collaboration with the community-based Southeastern Kidney Transplant 
Coalition, patient-level data from all 9 transplant centers in ESRD Network 6 (GA, NC, 
and SC) on kidney transplant referral (date referral form was received by transplant center) 
and evaluation start (date patient started evaluation) were collected from January 1, 2012 
to December 31, 2016. Referral and evaluation start data were linked with ESRD Network 
data, including prevalent patients by dialysis facility and year, to calculate the proportion of 
patients referred and starting evaluation.
Results: Among 47,804 prevalent dialysis patients from all ESRD Network 6 dialysis 
facilities in 2016 (n=705) with a median of 60 patients/facility, approximately 16.1% 
(n=7717) were referred for evaluation and 9.2% (n=4406) started an evaluation. The median 
proportion of patients referred in 2016 was 14.5% (IQR: 8.9-21.2%), with 48 facilities not 
referring any patients (Figure 1). The median proportion of patients starting an evaluation 
in 2016 was 7.7% (IQR: 4.2-12.2%); 67 facilities had no patients start evaluation in 2016.
Conclusions: In the Southeastern United States, a small proportion of dialysis patients 
are referred for kidney transplant evaluation, and fewer start the evaluation at a transplant 
center. There is considerable variation in the proportion of patients referred and starting 
evaluation across dialysis facilities in ESRD Network 6. Interventions targeting these early 
steps in the kidney transplant process could improve equitability in transplant.
Funding: NIDDK Support
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Favorable Cardiac Remodeling Following Ligation of Arteriovenous 
Fistula in Stable Renal Transplant Recipients: A Randomized Controlled 
Study
Nitesh N. Rao,1,2 Stephen P. McDonald,3 Randall J. Faull,3 Patrick T. Coates.4 
CNARTS 1University Of Adelaide, Adelaide, SA, Australia; 2Nephrology, Lyell 
McEwin Hospital, Adelaide, SA, Australia; 3Royal Adelaide Hospital, Adelaide, 
SA, Australia; 4University of Adelaide, Adelaide, SA, Australia.
Background: Cardiovascular morbidity and mortality remains high in recipients 
of kidney transplantation. Persistence of a functional arteriovenous fistula (AVF) post-
transplant may contribute to maladaptive cardiovascular remodeling. In this study we aimed 
to determine whether ligation of AVF would improve myocardial mass in stable kidney 
transplant recipients, assessed at baseline and 6 months after closure using cardiac magnetic 
resonance imaging (CMR).
Methods: We recruited 63 adult kidney transplant recipients with stable kidney 
function and functioning AVF. Participants were randomly assigned to AVF ligation versus 
no intervention, after a baseline CMR scan followed by a repeat scan six months following 
AVF ligation. Primary outcome was assessment of left ventricular(LV) mass at 6 months. 
Secondary outcomes were changes in left and right ventricular volumes, pulmonary flows, 
left and right atrial areas.
Results: Of the 93 participants assessed for eligibility, 63 eligible participants 
underwent randomisation: 32 to the intervention and 31 to non-intervention. 54 out of 63 
participants completed the study. At the end of 6 months, a decrease of 21.6 gm (95% 
CI -32.1to -11.0, p<0.001) was observed between the mean LV mass in the AV fistula 
closure group compared to no significant change in the non-intervention control group. 
The difference in LV mass index (gm/m2) was a drop by 11.7 gm (95 % CI -17.2 - -6.1, 
p<0.001) in the intervention group from the baseline versus no change in the control group. 
Decrease in LV end diastolic volume, LV end systolic volume, right ventricular and bi-atrial 
volumes were also observed in the AVF closure group. No significant complications were 
noted after AVF ligation.
Conclusions: Elective ligation of AVF in adults with stable kidney transplantation 
and functioning AVF is associated with marked reduction in both absolute and 
indexed measurements of myocardial mass. (Funded by the Royal Adelaide Hospital 
Research Foundation grant; Australian and New Zealand clinical trials registry, number 
ACTRN12613001302741)
Funding: Private Foundation Support
SA-OR007 Oral Abstract Saturday
Access, Organ Utilization, and Infectious Disease
Gut Microbiota Dysbiosis Is a Novel Risk Factor for Urinary Tract 
Infections in Kidney Transplant Recipients
John R. Lee,1 Matthew Magruder,1 Adam N. Sholi,1 Emmanuel Y. Edusei,1 
Lisa T. Zhang,1 Shady Y. Albakry,1 Michelle L. Lubetzky,1 Darshana Dadhania,1 
Ying Taur,2 Lilan Ling,2 Philip Burnham,3 Iwijn De Vlaminck,3 Eric Pamer,2 
Manikkam Suthanthiran.1 1Weill Cornell Medicine, New York, NY; 2Memorial 
Sloan Kettering Cancer Center, New York, NY; 3Cornell University, Ithaca, NY.
Background: The gut is the presumed source of urinary tract infection (UTI) but direct 
evidence for this supposition is lacking.
Methods: We recruited 169 kidney transplant recipients for serial collection of fecal 
specimens and profiled 516 fecal specimens using 16S rRNA gene deep sequencing of 
the V4-V5 hypervariable region. Among the cohort, 36 subjects developed Escherichia 
bacteriuria within the first 6 months of transplantation (Escherichia Group) and 133 
subjects did not (No Escherichia Group); 36 subjects developed Enterococcus bacteriuria 
(Enterococcus Group) and 133 subjects did not (No Enterococcus Group).
Results: The relative gut abundance of Escherichia was significantly higher in the fecal 
specimens in the Escherichia Group than in those in the No Escherichia Group (P<0.001, 
Wilcoxon rank sum test) (Fig 1A) and the relative gut abundance of Enterococcus was 
significantly higher in the fecal specimens in the Enterococcus Group than in those in the 
No Enterococcus Group (P<0.001) (Fig 1B). Using a Cox Regression with gut abundance 
as a time-dependent covariate, a relative gut abundance of 1% Escherichia was a risk factor 
for future development of Escherichia bacteriuria (HR= 3.2, P<0.001), and a relative gut 
abundance of 1% Enterococcus was a risk factor for future development of Enterococcus 
bacteriuria (HR = 2.6, P= 0.006). Strain analysis of the Escherichia coli in paired urine-fecal 
specimens using shotgun metagenomic sequencing revealed that the E. coli strain in the 
urine specimens was most similar to the E. coli strain in the fecal specimens from the same 
subject, supporting the gut as the source of the urine strain (Fig 1C).
Conclusions: Our findings support the hypothesis that gut microbial composition is a 
contributor to UTI in kidney transplant recipients. Modulating the gut microbiota may be a 
novel and effective strategy for preventing this frequent complication.
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Association of Recipient APOL1 Kidney Risk Alleles and Hepatitis C 
Status with Kidney Transplant Outcomes
Karim H. Anis,1 Simin Goral,4 Jeffrey B. Kopp,2 Cheryl A. Winkler,3 Rui Feng,4 
Sylvia E. Rosas.1 1Joslin Diabetes Center, Boston, MA; 2NIDDK, NIH, Bethesda, 
MD; 3NCI, NIH, Frederick National Laboratory, Frederick, MD; 4University of 
Pennsylvania, Philadelphia, PA.
Background: African-Americans (AA) are more likely to have worse kidney 
transplant outcomes compared to non-AA transplant recipients. The mechanism is unknown 
but the APOL1 risk alleles (RA) have been postulated as likely contributors. Given the high 
prevalence of APOL1 RA in AA a two-hit theory has been embraced. We examined the 
outcomes of kidney transplant recipients (KTR) stratified by APOL1 RA and hepatitis C 
virus (HCV) antibody status.
Methods: We conducted a multicenter observational prospective study of incident 
KTR. Incident KTR were genotyped for APOL1 RA. Baseline characteristics and graft 
survival rates were compared by number of APOL1 RA and/or by HCV antibody presence.
Results: Among 221 participants, approximately 43% had 2 APOL1 RA. The prevalence 
of HCV antibody in the cohort was 17%. KTR with 2 APOL1 RA were younger compared 
to those with none or one APOL1 RA [51.8 vs 42.2 years old, P<0.0001]. Two APOL1 RA 
was associated with early (prior to 1500 days) [1.98 (95% CI 1.01-3.85); P=0.045], but not 
late graft failure (up to 2000 days) [HR 1.39 (95% CI 0.79-2.45); P=0.25] adjusted for acute 
rejection and age at transplant. However, recipients with both two APOL1 RA and HCV 
antibodies demonstrated lower graft survival compared to recipients with only one or none of 
those risk factors. [HR 2.74(95%CI 1.06-7.10); P=0.04].
Conclusions: Our study demonstrates the effect of APOL1 risk status in KTR on graft 
survival. Furthermore, it illustrates that the effect of recipient APOL1 RA on graft outcome 
may be altered by viral infections such as HCV and is likely time dependent.
Funding: NIDDK Support
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Characteristics and Outcomes of Deceased Donor Kidney Transplants 
Performed in the US Based on Donor HCV NAT and Recipient HCV Ab 
Status
Venkatesh Kumar Ariyamuthu,1 Cagla Keceli,2 Bekir Tanriover,1 
Burhaneddin Sandikci,3 Yuan Zhong,4 Nashila AbdulRahim,1 Ricardo M. La 
Hoz.5 1UT Southwestern, Richardson, TX; 2The University of Chicago Booth 
School of Business, Chicago, IL; 3University of Chicago, CHICAGO, IL; 
4University of Chicago, Booth School of Business, Chicago, IL; 5UT 
Southwestern Medical Center, Dallas, TX.
Background: HCV nucleic acid testing (NAT) testing for deceased donors has become 
routine since April 2014. Comparative outcomes of deceased donor renal transplants 
(DDRT) based on HCV NAT and antibody (Ab) testing in different donor-recipient pairs 
are not well known.
Methods: We queried the UNOS dataset for DDRT performed between April 2015 
and September 2017. Pediatric age, multiorgan transplants, and cases with unknown HCV 
NAT / Ab status were excluded. The final study cohort (N=27,930) were stratified into 4 
groups: 1) Donor (D) Ab-/NAT- Recipient (R) Ab- (reference group, n=27,070); 2) D Ab+/
NAT- R Ab- (n=133); 3) D Ab+ / NAT+ R Ab- (n=65); 4) D Ab+/NAT+ R Ab+ (n=662). A 
propensity score was calculated based on donor KDPI, recipient age, race, and underlying 
kidney diagnosis. An exact propensity score matching was performed 1:4 ratio between 
the reference group and other 3 stratified groups. Primary outcomes were overall allograft 
survival (failure defined as death or graft failure), acute rejection at 1 year and DGF.
Results: The results are shown in Table 1.
Conclusions: HCV NAT + kidneys do have similar outcomes compared to NAT 
negative donors. Utilization of HCV NAT + kidneys should be encouraged.
Characteristics and outcomes of DDRT based on HCV NAT and Ab testing
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BK Virus Nephropathy: Characterization of an Interferon Signature and 
Identification of Risk Factors for Graft Failure
Darshana Dadhania,4 Weeraporn Srisung,1 Essa Abuhelaiqa,1 
Catherine Snopkowski,6 Carol Y. Li,4 John R. Lee,2 Thangamani Muthukumar,3 
Ruchuang Ding,5 Surya V. Seshan,3 Manikkam Suthanthiran.4 1NYP-Weill 
Cornell Medical Center, New York, NY; 2Weill Cornell Medicine-, New York, 
NY; 3Weill Cornell Medical Center, New York, NY; 4Weill Cornell Medical 
College, New York, NY; 5weill Cornell Medical College, Beechhurst, NY; 6Weill 
Medical College of Cornell University, New York, NY.
Background: BK virus nephropathy(BKVN) is an important cause of allograft failure. 
Identification of its immune pathways may help design better therapeutics.
Methods: We measured urinary cell mRNAs in 53 BKVN patients and 43 patients with 
normal protocol biopsies. Among the 53 BKVN cases, 18 grafts failed within 3 years post 
diagnosis and none in the normal group. Levels of mRNA were measured using kinetic, 
quantitative polymerase-chain assays. We compared mRNA levels of 53 BKVN vs. 43 
normal patients, and within BKVN group, the 18 BKVN with graft loss vs. 35 BKVN 
without graft loss.
Results: Among the transcripts quantified in a total of 96 renal graft recipients, urinary 
cell levels of 18S rRNA, IP-10 and MIG were significantly higher in the BKVN group 
vs. normal group (all P<0.0001)(Table 1). Of the 53 BKVN cases, 18 lost their grafts and 
they were more likely to have received a deceased-donor renal transplant(DDRT) (P=0.03) 
and a higher creatinine(SCr) at time of BKVN diagnosis (2.88+/-1.18 mg/dl vs. 1.96+/-
0.69 mg/dl;P=0.005). Urinary cell levels of PAI-1 mRNA predicted graft failure(Figure 
1). Multivariate analysis demonstrated that PAI-1 mRNA level (OR: 2.6;P= 0.005), biopsy 
SCr (OR: 9.1;P<0.001) and DDRT (OR: 8.3;P=0.01) were independent predictors of graft 
failure.
Conclusions: BKVN is associated with an inflammatory milieu characterized by an 
interferon signature. Urinary cell levels of the acute phase reactant PAI-1 offer a noninvasive 
means to predict graft failure after BKVN diagnosis.
Table 1.
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Alpha 2 Adrenergic Receptor Blockade Prevents AKI to CKD Transition
Hee-Seong Jang, Babu J. Padanilam. University of Nebraska Medical Center, 
Omaha, NE.
Background: Increased sympathetic nerve activity and norepinephrine (NE) levels 
are of importance in the onset and the early development of end stage renal disease. We 
reported that renal denervation (DNx) can prevent renal fibrosis and inflammation in renal 
fibrogenesis models. However, the underlying mechanism by which renal denervation 
prevents the long-term sequelae of acute kidney injury (AKI) remains to be elucidated.
Methods: Based on our data, we hypothesized that NE mediates its effect through 
activation of alpha 2 adrenergic receptors (α2ARs). In this study, we investigated whether 
genetic or pharmacological inhibition of α2ARs prevents ischemia/reperfusion injury (IRI)-
induced CKD progression.
Results: IRI resulted in severe kidney fibrosis in medullary region over 2 weeks 
with tubular cast and atrophy and massive macrophage infiltration. Renal DNx and 
pharmacological inhibition of α2AR did not affect renal functional and histological 
damage in the acute phase of the IRI. However, renal tubular damage, inflammation, and 
fibrosis progression was suppressed 2 weeks post-IRI by renal DNx and pharmacological 
inhibition of α2AR with downregulation of downstream targets of NE-α2AR axis, 
including angiotensinogen, fibrogenic factors and inflammatory cytokines. Similar with 
results in pharmacological inhibition of α2A-AR subtype, blockage of α2C-AR subtype 
by pharmacological or genetic manipulation prevented the long-term sequelae of IRI, 
including renal tubular atrophy, inflammation and fibrosis progression.
Conclusions: Collectively, inhibition of α2AR subtypes prevents IRI-induced AKI 
to CKD transition through inhibition of persistent renal tubular injury and inflammation, 
and fibrosis progression, suggesting that targeting α2ARs may be a potential therapeutic 
strategy to prevent long-term sequelae of ischemic AKI.
Funding: Private Foundation Support
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Regeneration of Proximal Tubules after Severe Injury Depends on Clonal 
Proliferation of eR1-Active Subpopulation of Proximal Tubular Cells
Yuichiro Kitai, Motoko Yanagita. Department of Nephrology, Kyoto University 
Graduate School of Medicine, Kyoto, Japan.
Background: Proximal tubular cells (PTC) are considered to repair injured proximal 
tubules by their own proliferation. However, whether this process depends on stochastic 
proliferation of surviving PTCs or expansion of a specific population of PTCs is still 
debated, and whether severity of injury affects the repair process is uncertain. In mammals, 
RUNX transcription factors are essential in diverse biological processes. Along with the 
elucidation of the roles of Runx1 in hematopoietic homeostasis and blood malignancies, a 
Runx1 enhancer named Runx1+24mCNE (eR1) has been identified recently, and shown to 
be active in adult long-term hematopoietic stem cells and gastric stem cells, but the role of 
eR1 in the kidney is unknown.
Methods: We first compared the proliferation of PTCs after 30- (moderate injury) and 
60-min ischemia reperfusion injury (IRI) (severe injury) by bromodeoxyuridine (BrdU)
labeling. We next explored the role of eR1 in kidney injury, utilizing eR1-ECFP and eR1-
CreERT2 mice.
Results: As indicated by BrdU incorporation, PTCs of the superficial cortex were more 
proliferative in 60-min IRI than in 30-min IRI, whereas proliferation rate was comparative 
in the deep cortex. While ECFP+ PTCs were almost absent in healthy kidneys of eR1-ECFP 
mice, ECFP+ cells increased to about 20% of total PTCs in the superficial cortex after 60-min 
IRI, but not after 30-min IRI. Then, we subjected eR1-ECFP:eR1-CreERT2:R26-tdTomato 
mice to 60-min IRI, and showed that ECFP+ and tdTomato+ PTCs mostly overlapped in 
acute phase even without tamoxifen. This result indicated that eR1-CreERT2 mice show leaky 
CreERT2 activity when eR1 was highly activated, and could be used to trace the fate of PTCs 
with strong eR1 activity. In acute phase of 60-min IRI, tdTomato+ PTCs showed a higher 
rate of BrdU incorporation than other PTCs, and clustered with several tdTomato+ PTCs. 
Clonal analysis using eR1-CreERT2: R26-Confetti multicolor reporter mice revealed that 
clusters of PTCs were mostly labeled with a single color, indicating the clonal expansion of 
labeled cells. Notably, tdTomato+ PTCs in acute phase were mostly positive for Kim-1 and 
vimentin, and negative for PTC markers such as aquaporin 1.
Conclusions: In severe injury, transiently dedifferentiated eR1-active PTCs clonally 
expand and repair superficial proximal tubules.
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Tubular HIF-1α Activates Macrophages via Exosomal MicroRNA-23a to 
Promote Tubulointerstitial Inflammation
Zuolin Li,1 Linli Lv,1 Jialing Ji,2 Ye Feng,1 Bi-Cheng Liu.1 1Institute of 
Nephrology, Zhong Da Hospital, Southeast University School of Medicine, 
Nanjing, China; 2Nanjing Medical University, Nanjing, China.
Background: Hypoxia is a key instigator of tubulointerstitial inflammation (TI) which 
has been assumed related with hypoxia inducible factor-1 (HIF-1), a master regulator 
response to hypoxia. While the exact mechanism of HIF-1 on this pathophysiological 
process is still largely unclear.
Methods: Hypoxia-related TI was induced in I/R injury and UUO models. Exosomes 
from hypoxic kidney and hypoxic TECs were isolated. The role of HIF-1 on miR-23a 
expression was studied using CHIP-PCR. Besides, exosomal miR-23a was inhibited 
or overexpressed to explore its functional role in macrophage. In vivo, TECs exosomes 
overexpressed or silenced miR-23a was transferred to mice via kidney parenchyma 
injection. Furthermore, treatment of miR-23a inhibitor in I/R model was also performed.
Results: TI was highly associated with the time-course expression of tubular HIF-1α 
in I/R injury and UUO mice. Meanwhile, the kidney exosomal miR-23a was markedly 
increased. In vitro, hypoxic TECs presented with higher HIF-1α and upregulation of NF-
κB as well as exosomal miR-23a. HIF-1α could transcriptionally regulate miR-23a in 
exosomes. Exosome from hypoxic TECs could develop more severe macrophage activation 
compared to exosome from normal TECs. Furthermore, we demonstrated that exosomal 
miR-23a directly suppressed its target A20, leading to macrophage activation. Inhibition of 
miR-23a reversed macrophage activation. In vivo, TI was significantly increased when mice 
transferred with miR-23a enriched exosomes, which was not shown by miR-23a silenced 
exosomes. Furthermore, treatment of miR-23a inhibitor in I/R model could ameliorate TI 
significantly.
Conclusions: Our study firstly demonstrates that tubular HIF-1 regulated macrophage 
function via exosomal miR-23a to promote hypoxia-related TI. The finding provides a 
novel strategy to target HIF1α-miR-23a axis in preventing hypoxia induced kidney injury.
Funding: Government Support - Non-U.S.
SA-OR014 Oral Abstract Saturday
AKI: Inflammation and Regeneration
Arginase 1 Knockout Macrophages Fail to Promote Epithelial Prolifera-
tion and Impair Kidney Repair after AKI
Arnaud Marlier,1 Serena M. Tharakan,1 Søren Nielsen,2 Lloyd G. Cantley.1 1Yale 
University School of Medicine, New Haven, CT; 2Aalborg University, Aalborg, 
Denmark.
Background: Renal ischemic injury induces epithelial cell death which leads to an 
innate immune response that includes initial proinflammatory macrophage activation that 
promotes additional epithelial injury followed by alternative activation that is required for 
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kidney repair. Alternative activation is marked by the expression of several genes including 
arginase 1 (Arg1), mannose receptor (Mrc1) and macrophage scavenger receptor (Msr1), 
but the actual function of the protein products of these genes in the injured kidney is not 
known. This work addresses the role of Arg1 expression by reparative macrophages in 
kidney repair.
Methods: AKI model: Unilateral renal ischemia reperfusion with contralateral 
nephrectomy in Arg1f/f;LysMCre/+ (Arg1ko: knock-out of Arg1 in macrophages) and 
Arg1+/+;LysMCre/+ (Arg1con: control) mice. RNA was isolated either from whole kidney 
or from flow sorted macrophages (CD45+F4/80+). Gene expression profiling by qPCR. 
Immunohistology performed on paraffin embedded kidney sections.
Results: Arg1ko (n=8) and Arg1Ctrl (n=9) mice were therefore subjected to 27 minutes 
of unilateral IR with contralateral nephrectomy. The initial rise in creatinine on day 1 was 
equivalent in the 2 groups (1.55±0.05 and 1.61±0.05 mg/dl, p=ns). 85% of the control 
mice survived to day 7 after IR, whereas only 37% Arg1ko mice survived until day 7, with 
mortality observed on day 3. Renal macrophage expression of Arg1 on day 7 after IR is 
0.755±0.484 in control mice but only 0.020±0.012 in Arg1ko mice (dCt relative to Hprt1, 
p=0.04). Quantification of F4/80+ cells in the kidney on day 3 revealed no difference in 
macrophage numbers between control and Arg1ko mice (298±83 vs. 315±17 F4/80+ cells/
mm2, p=ns), whereas tubular cell proliferation as determined by Ki67 positivity was 
significantly reduced in Arg1ko kidneys (343±86 vs. 110±33 Ki67+ cells/mm2, p=0.03). 
Finally, morphometric analysis of day 7 kidney sections showed a pronounced loss 
of healthy tubular mass in Arg1ko kidneys compared to control kidneys (normal tubule/ 
section: 34.2%±2.7 vs. 44.7%±0.5, p=0.004).
Conclusions: These results indicate that the upregulation of macrophage Arg1 
expression facilitates tubular regeneration by promoting epithelial cell proliferation and 
limiting nephron loss at the site of injury.
Funding: Other NIH Support - NIH RO1-DK093771
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Tamm-Horsfall Protein (Uromodulin) Inhibits Systemic Oxidative Stress 
by Inactivating the TRPM2 Channel
Kaice A. LaFavers,2 Shehnaz Khan,3 Seth Winfree,2 Takashi Hato,1 
Pierre C. Dagher,1 Tarek M. El-Achkar,1 Radmila Micanovic.2 1Indiana 
University, Indianapolis, IN; 2Indiana University School of Medicine, 
Indianapolis, IN, IN; 3Indina university of school of medicine Nephrology, 
Indianapolis, IN.
Background: Tamm-Horsfall protein (THP) is produced exclusively in the thick 
ascending limb (TAL) of the loop of Henley. In TAL cells, THP is secreted apically in 
the urine but also released basolaterally in the interstitium and circulation. We previously 
showed that THP downregulates inflammatory signaling in S3 proximal tubules. Here, we 
investigate potential targets of THP on these cells and the role of systemically released THP.
Methods: We used THP+/+ and THP -/- mice. Various assays and technologies as 
described in results
Results: We performed laser microdissection on S3 and TAL tubules for transcriptomic 
studies. Bioinformatic analysis determined that, in the setting of THP deficiency, JNK stress 
kinase signaling is activated in S3 segments but not in TAL. JNK activation uniquely in 
S3 segments was confirmed by 3D tissue cytometry. Additional proteomic studies on S3 
segments and human proximal tubular cell suggested that THP inhibits oxidative stress 
and Rac-1 activity, both known to be upstream of JNK. This was confirmed in vivo using 
intravital imaging and other measures of oxidative stress. Furthermore, we observed that 
THP deficiency increased oxidative injury not only in the kidney, but also systemically and 
in distant organs, such as the lungs. Since TRPM2, a nonvoltage activated nonselective 
cationic channel, is implicated in regulating oxidative stress, we investigated if THP 
modulates its activity. Indeed, TRPM2 is expressed in the kidney, lungs and other organs. 
In HEK-293 recombinant cells with inducible TRPM2, we show that THP specifically 
inhibits TRPM2 dependent calcium influx in a dose dependent manner. Furthermore, 
pharmacological inhibition of TRPM2 in THP-/- mice reduced systemic oxidative damage.
Conclusions: We show that THP inhibits oxidative stress not only in the kidney but 
also systemically in other organs. This effect is likely mediated through the circulating 
form of THP. Our data suggest that this effect, in part, is due to inhibition of the TRPM2 
channel, which in some tissue types, conditions and experimental models, is known to cause 
downstream oxidant injury. These findings underscore the importance of THP in mediating 
a systemic cross-talk between the kidney and other organs and identify, for the first time, a 
molecular target for circulating THP.
Funding: NIDDK Support, Veterans Affairs Support
SA-OR016 Oral Abstract Saturday
AKI: Inflammation and Regeneration
Inhibition of Orai1-Mediated Ca2+ Signaling Ameliorates AKI-to-CKD 
Transition Following Ischemia and High Salt Diet
Purvi Mehrotra,1 Michael Sturek,3 David P. Basile.2 1Indiana School of Medicine, 
Indianapolis, IN; 2Indiana University School of Medicine, Indianapolis, IN; 
3Indiana University School of Medicine, Indianapolis, IN.
Background: Store-operated Ca2+entry (SOCE) through Orai1 channels raise 
intracellular Ca2+concentrations in T cells, which induce proliferation and cytokine 
production in immune cells. The Orai-1 gene has been linked to SCID, and loss-of-function 
mutation of Orai-1 in murine T cells shown to be protective in models of autoimmune 
disease, due to impaired production of the cytokine IL-17. T-helper 17 (Th17) cells increase 
following renal injury and exposure to high-salt diet and IL-17 blockade reduces AKI-to-
CKD progression. We have recently identified Orai-1 expression in AKI primed renal T 
cells and hypothesize that Orai1-mediated Ca2+signaling may influence Th17 differentiation 
and modulate CKD progression.
Methods: Rats were allowed to recover from renal ischemia for 1 week and CD4+ 
lymphocytes were analyzed for Ca2+and IL-17 responses in vitro. In other studies, rats were 
subjected to bilateral I/R and allowed to recover 24 hours with or without SOCE antagonist 
YM-58483 (1mg/kg). To study CKD progression, rats following unilateral ischemia were 
allowed to recover for 5 weeks 0.4% NaCl diet. CKD was hastened by Unx and elevated 
dietary NaCl (4%) for 4 weeks. In this study, rats were fed YM-58483 or vehicle daily 
during the high salt treatment.
Results: AKI primed CD4+ lymphocytes manifested an induction of IL-17 production 
in vitro to angiotensin II and 170 mMol/L Na+while ~30% of cells manifested an increase 
in cytosolic Ca2+; these responses were blocked by 10mM YM-58483. Rats treated with 
YM-58483 were protected from bilateral ischemia as indicated by lower serum creatinine 
(vehicle 3.3±0.4; YM-58483 2.2±0.5 mg/dl; p£0.05) and significantly reduced by ~40% 
Th17 infiltration. When post ischemic rats were exposed to 4% dietary salt, there was an 
increase in inflammatory cells and fibrosis. YM 58483 initiated during high salt feeding 
significantly attenuated renal CD4+, CD8+, B cells and dendritic/macrophage cells by 
~50%. Th17 cells (CD4+/IL17+) were also reduced significantly (vehicle 19425±23086, 
YM-58483 6494±1146 cells/g; p£0.05). In addition, YM-58343 treatment also attenuated 
the development of interstitial fibrosis by ~86% relative to vehicle (p< 0.05).
Conclusions: Taken together, these data suggest that Orai1 activity is enhanced by 
renal ischemia and that Orai1-mediated Ca2+signaling increases Th17 activity and AKI-
CKD progression.
Funding: NIDDK Support
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Hepcidin Mitigates Sepsis-Induced AKI through Its Antibacterial and 
Anti-Inflammatory Effects
Yogesh M. Scindia,1 Ewa U. Mandziak,2 Joseph T. Leeds,2 Valentina Loi,3 
Sundararaman Swaminathan.2 1Univerisity of Virginia, Charlottesville, VA; 
2University of Virginia, Charlottesville, VA; 3AO Brotzu Cagliari, Cagliari, Italy.
Background: Sepsis-induced acute kidney injury (AKI) is a common cause of in-
hospital morbidity and mortality. Sepsis induces hepcidin-dependent iron sequestration 
to limit iron availability to pathogens. Hepcidin can limit inflammation. Therefore, we 
investigated if hepcidin pretreatment would mitigate endotoxin- and peritonitis-induced 
systemic pathology and AKI.
Methods: C57BL/6 mice were treated with saline or 50 μg hepcidin, 24 hours before 
LPS injection (Escherichia coli O111:B4, 6.5 mg/kg) or subjected to Cecal ligation and 
puncture (CLP) to induce peritonitis. Some mice underwent splenectomy (SPLX) and 
were challenged with LPS, with and without Hepcidin. Mice undergoing CLP received 
another dose of hepcidin, 2 hours prior to CLP. Renal injury and inflammatory markers were 
assessed. After CLP, mice were euthanized at different time points. Mouse macrophages 
(J774A) were treated with SiRNA to H-ferritin or scramble, treated with 1μg/mL Hepcidin 
for 4 hours, and cultured with 1 ng/mL LPS for 6 hours.
Results: LPS-induced AKI (plasma creatinine, renal NGAL and KIM-1 gene 
expression) were significantly reduced by hepcidin pretreatment. Hepcidin also reduced 
LPS-induced renal Cox-2, loss in PGC1a and enzymatic activity of cytochrome c 
oxidase. Hepcidin induced higher splenic H-ferritin, reduced splenocytes apoptosis, and 
inflammation. SPLX reduced LPS-induced AKI, and hepcidin did not provide additional 
protection in these settings. In CLP model, Hepcidin significantly reduced bacteremia, AKI, 
and mortality (colony forming units in the blood, renal NGAL and KIM-1 gene expression) 
and increased survival (up to 6 days in hepcidin-treated mice compared to approximately 24 
hrs in PBS-treated mice). Compared to scramble siRNA, H-ferritin-deficient macrophages 
treated with Hepcidin secreted more LPS-induced IL-6.
Conclusions: Our results demonstrate a protective role of hepcidin in endotoxin- 
and peritonitis-induced pathologies and AKI, exerted through H-ferritin-dependent anti-
inflammatory effects, and antibacterial property. Splenectomy protects against LPS-induced 
AKI.
Funding: NIDDK Support
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TLR9 Mediated IL-17A Responses Are Associated with the Pathogenesis 
of Polymicrobial Septic AKI
Yoshitaka Naito,2 Takayuki Tsuji,1 Tomoyuki Fujikura,2 Naro Ohashi,2 
Akihiko Kato,3 Hideo Yasuda.2 1NIDDK/NIH, Bethesda, MD; 2Hamamatsu 
University School of Medicine, Hamamatsu, Japan; 3Hamamatsu University 
Hospital, Hamamatsu, Japan.
Background: Toll-like receptor 9 (TLR9) contributes to the development of 
polymicrobial septic AKI. Recently, interleukin (IL) -17A has been shown to play a 
pathogenic role in septic AKI. According to the previous study, TLR 9 mediated IL-
17A responses were associated with the pathogenesis of many conditions, including 
murine hypersensitivity pneumonitis, mycobacteria-elicited pulmonary granuloma, and 
neurotoxicity induced by microglia. However, its role in septic AKI remains unclear. We 
hypothesized that TLR9-mediated IL-17A responses are associated with the pathogenesis 
of polymicrobial septic AKI.
Methods: Tlr9-knockout (Tlr9KO) mice and IL-17A knockout mice (IL-17AKO) 
and both wild type (WT) littermates were subjected to cecal ligation and puncture (CLP) 
operation to induce polymicrobial sepsis. We performed functional and pathological 
assessment of the kidney and splenic apoptosis evaluated by immunohistochemistry of 
caspase 3 at 18 hours after CLP. Survival were assessed for the following 7 days after CLP. 
We assessed IL-17A consentrations in plasma and ascites from Tlr9KO and WT mice at 3, 
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6, 18 hours after CLP by enzyme-linked immunosorbent assay (ELISA) also. Furthermore, 
we examined IL-17A production of immune cells in spleen by flow cytometry.
Results: Although WT mice developed kidney injury at 18 hours after CLP, Tlr9KO 
and IL-17AKO mice exhibited decreased serum creatinine levels, expression of Kidney 
Injury Molecule-1 in proximal tubular cells, and improved tubular damage score in 
cortex. Splenic apoptosis were decreased at 18 hours after CLP in both Tlr9KO and 
IL-17AKO mice compared with WT mice. Mortalities were less in both Tlr9KO and IL-
17AKO mice compared with WT mice after CLP. Furthermore, IL-17 A levels of both 
plasma and ascites were significantly higher in WT mice than Tlr9KO mice at 18 hours 
after CLP, and IL-17A levels in ascites tended to increase in earlier phase than in plasma. 
IL-17A production of splenic γδ T cells was less in Tlr9KO mice compared to WT mice at 
3 hours after CLP.
Conclusions: We showed that Tlr9KO and IL-17AKO could protect against 
polymicrobial septic AKI, and Tlr9KO mice decreased IL-17A secretion in plasma, ascites, 
and splenic γδ T cells. These findings suggest that TLR9 mediate IL-17A production, and 
this pathway is associated with the pathogenesis of septic AKI.
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Renal Ischemia Resistant Rat Strains and Ischemic Preconditioned (IPC) 
Kidneys Share Upregulated Mitochondria Proteins
Alexander L. Kolb,1 Jason A. Collett,1 Frank Witzmann,1 Uma Aryal,3 
David P. Basile,1 Robert L. Bacallao.1,2 1Indiana University School of Medicine, 
Indianapolis, IN; 2Medicine, Richard Roudebush VAMC, Indianapolis, IN; 
3Bindley Bioscience Center, Purdue University, West Lafayette, IN.
Background: Brown-Norway (BN) rats are resistant to renal ischemia reperfusion 
injury as compared to Sprague-Dawley (SD) or Dahl Salt Sensitive (DS) rats. This 
resistance is linked to 3 chromosomes in BN rats. Also IPC kidney mitochondria have 
significant changes in their proteome. The study goal was to identify mitochondria proteins 
that are over-expressed in both IPC and genetically resistant tissues. Quantitative proteomic 
analysis of mitochondria was performed in IPC kidneys and compared to sham conditioned 
kidneys. A second set of comparisons was performed on kidney cortex mitochondria 
isolated from BN rats and DS rats.
Methods: Mitochondria were isolated from renal cortex of BN rats, DS rats, IPC and 
IPC sham treated kidneys of SD rats. 4 animals were used for each group with 3 replicant 
samples. Mitochondria proteomes were identifed using label free quantitative proteomic 
analysis using LC-MS/MS. LS-MS/MS data were collected in Thermo Q Exactive Orbitrap 
High Field (HF) MS coupled to Dionex UltiMate 3000 RP HPLC system. Raw data were 
analyzed using MaxQuant and Andromeda search engines. Highest stringency conditions 
were used in protein identification in all searches. Proteins were identified by searching 
against the rat protein sequences database from Uniprot. Relative protein quantitation was 
performed using the MaxQuant LQF algorithm.
Results: Greater than 1300 proteins were identified in the sham versus IPC 
mitochondria, 571 proteins are significantly overexpressed in the IPC group (p values 
<0.05). In the proteomic comparison between BN and DS rats, 1184 proteins were 
identified with high confidence. Of the 1184 proteins 770 proteins were expressed 
1.8-fold or greater in BN versus SS rats (p values <0.05). Comparing the two groups 
revealed 78 common proteins. Ingenuity pathway analysis revealed enhanced pathways 
that include response to drug, negative regulation of apoptosis, protein transport, metabolic 
processes and redox homeostasis.
Conclusions: 78 endogenous mitochondria proteins are significantly overexpressed in 
mitochondria from kidney cells in an ischemic preconditioned state or isolated from a rat 
strain with genetic resistance to ischemia. These proteins represent important targets for 
pharmacologic exploration to develop preventative agents for acute kidney injury.
Funding: Veterans Affairs Support
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Transcriptional Trajectories of Human Kidney Disease Progression
Pietro E. Cippa, Andrew P. McMahon. McMahon Lab University of Southern 
California, Los Angeles, CA.
Background: The molecular understanding of the transcriptional program determining 
the progression from acute to chronic kidney injury in humans is limited.
Methods: We performed RNAseq-based transcriptional profiling on protocol biopsies 
obtained from 42 kidney transplant recipients at 4 time points (before and after reperfusion, 
3 and 12 months after transplantation) and we applied machine learning techniques to 
identify and group patient responses over time. Our previously described mouse model of 
ischemia/reperfusion injury was used for data validation.
Results: In the first hours after reperfusion all patients underwent a similar response 
characterized by a biphasic transcriptional program under the control of immediate early 
response genes. In the following months we identified two main transcriptional trajectories 
corresponding to recovery and to a sustained injury response leading to fibrosis and renal 
function deterioration. The molecular map generated by this computational approach 
delineated the transcriptional program determining the transition from acute to chronic 
kidney injury: genes associated with mitochondrial dysfunction, kidney injury/repair 
and innate immunity were followed by genes related to fibrosis and adaptive immunity. 
Moreover, the computational model highlighted early markers of kidney disease progression 
(e.g. EP300). The characterization of a similar process in mice showed evidence for 
substantial similarities in the response to kidney injury across species and expanded the 
relevance of the findings beyond kidney transplantation.
Conclusions: The integration of multiple transcriptomes from serial biopsies 
in advanced computational algorithms overcame the analytical hurdles related to 
interindividual variability and identified shared transcriptional elements of kidney disease 
progression. For the first time, this new concept allowed an unsupervised analysis of the 
molecular mechanisms of kidney disease in a clinical setting.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Decreased KAT5 Expression Impairs DNA Repair and Induces DNA 
Methylation in Diabetic Nephropathy Podocytes
Akihito Hishikawa, Kaori Hayashi, Norifumi Yoshimoto, Hiroshi Itoh. Division 
of Nephrology, Endocrinology and Metabolism, Department of Internal 
Medicine, Keio University School of Medicine, Tokyo, Japan.
Background: Podocytes are terminally differentiated cells with a very low capacity of 
regeneration. Therefore, the mechanism of DNA damage repair in podocytes is expected 
to be highly significant. We have recently reported that podocyte specific deletion of 
DNA double strand break (DSB) repair factor KAT5 causes glomerulosclerosis in mice 
(KAT5 KO mice) (ASN Kidney week 2017). Here we investigated the role of KAT5 in the 
pathogenesis of diabetic nephropathy (DN).
Methods: We generated tamoxifen-inducible podocyte-specific KAT5 knockout mice 
(iKO) to investigate the physiological role of KAT5 excluding its role in the maturation of 
podocytes. Expression of KAT5 was examined in streptozotocin (STZ)-induced DN mice 
model and the effect of KAT5 gene transfer was evaluated. We performed in vitro studies 
using cultured human podocytes to examine the mechanism of KAT5-associated epigenetic 
changes.
Results: KAT5 iKO mice showed massive albuminuria (WT 40±9 mg/gCr, iKO 
2455±153 mg/gCr, p<0.01) and FSGS lesion with foot process effacement of podocytes 
after 12 weeks induction of KAT5 knockdown, similar to the KAT5 KO mice. Nephrin 
expression was significantly decreased, as shown by both isolated podocytes and 
glomerular immunofluorescence staining. Interestingly, thickening of glomerular basement 
membrane was observed in some glomeruli of KAT5 iKO mice just like in DN, which was 
observed especially in the glomeruli near the corticomedullary junction. Podocyte KAT5 
expression was decreased in DN mice, accompanied by increased DNA DSBs and DNA 
methylation and restoration of decreased KAT5 by gene transfer attenuated albuminuria 
and glomerulosclerosis. In cultured human podocytes, knockdown of KAT5 increased 
DNA DSBs and decreased nephrin expression with increased DNA methylation of the 
nephrin promoter region. High-glucose treatment (30mM) induced KAT5 reduction and 
overexpression of KAT5 increased nephrin expression with decreased DNA DSBs and 
decreased DNA methylation at the same nephrin promoter region, indicating that KAT5-
mediated DNA repair may be related to the DNA methylation status.
Conclusions: KAT5-mediated DNA repair is essential for podocyte maintenance 
and has relation to the changes in DNA methylation status in DN. KAT5 may be a good 
therapeutic target for DN.
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Selective Deletion of EGFR in Podocytes Protects against Nephropathy in 
Type II Diabetes
Yan Li,2,1 Kensuke Sasaki,2 Yinqiu Wang,2 Aolei Niu,2 Suwan Wang,2 
Xiaofeng Fan,2 Jianchun Chen,2 Ming-Zhi Zhang,2 Raymond C. Harris.2 
1Shanghai Ninth People’s Hospital, Shanghai JiaoTong University, Shanghai, 
China; 2Vanderbilt University Medical Center, Nashville, TN.
Background: Previous studies by us and others have indicated that renal epidermal 
growth factor receptor (EGFR) signaling is activated in DN and EGFR inhibition protects 
against DN. In the present study, we examined whether selective EGFR deletion in 
podocytes affected development of DN in type II diabetes.
Methods: db/db mice with selective podocyte EGFR deletion (podocin-Cre; EGFRf/f; 
db/db: EGFRpodKO;db/db) and an accelerated type II diabetic model (eNOS-/-; db/db mice) 
with selective podocyte EGFR deletion (podocin-Cre; EGFRf/f; eNOS-/-; db/db: EGFRpodKO; 
eNOS-/-; db/db) were generated and used. Genotypes were confirmed before sacrifice. A 
mouse podocyte cell line was used for in vitro studies.
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Results: Selective podocyte EGFR deletion was confirmed by reduced EGFR co-IF 
with WT1. Podocyte EGFR deletion had no effect on body weight and fasting blood sugar 
in either db/db or eNOS-/-; db/db mice. However, podocyte EGFR deletion led to marked 
reduction in albuminuria in both db/db and eNOS-/-; db/db mice [albumin vs. creatinine ratio 
(μg/mg): 175 ± 11 vs. 495 ± 16 in 40 week old db/db , P < 0.01; 2185 ± 175 vs. 3434 ± 418
in 20 week old eNOS-/-; db/db mice, P < 0.05]. Glomerulosclerosis index was lower in 
EGFRpodKO; eNOS-/-; db/db mice than in eNOS-/-; db/db mice at 20 weeks. In eNOS-/-; db/db
mice, podocyte EGFR deletion produced less podocyte loss, as indicated by increased
mRNA levels of podocin and higher podocyte number per glomerulus section (10.7 ± 0.5 
vs. 7.0 ± 0.2, P < 0.001), in association with decreases in proinflammatory cytokine/
chemokine levels, including iNOS, IRF5, IL-23, IL-1α, IL-1β, CCL-3, TNF-α and IL-6 as 
well as pro-fibrotic and fibrotic components, TGF-β1 and collagen I and IV. Both in vivo
and in cultured podocytes exposed to high glucose, inhibition of podocyte EGFR signaling 
suppressed the mTOR/p70 S6K signaling pathway, leading to stimulation of a podocyte
protective autophagic pathway, as indicated by increased beclin 1 and decreased rubicon, an 
inhibitor of beclin 1, and decreases in the autophagic substrate, p62.
Conclusions: These studies indicate that activation of a podocyte EGFR signaling 
pathway contributes to progression of diabetic nephropathy, at least in part due to activation 
of an EGFR/mTOR/p70 S6K pathway, leading to inhibition of podocyte autophagy and 
subsequent cell injury.
Funding: NIDDK Support
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Exosome-Mediated miR-26a Treatment Attenuates Muscle Atrophy and 
Kidney Fibrosis in Diabetic Mice
Aiqing Zhang,1,2 Janet D. Klein,1 Xiaonan H. Wang.1 1Renal Medicine, Emory 
University, Atlanta, GA; 2Dept of Pediatric Nephrology, 2nd affiliated hospital 
of Nanjing Medicial University, Nanjing, China.
Background: The treatment of muscle wasting is well known to be accompanied by 
benefits in other organs. However, how the muscle communicates with these organs is less 
understood. Exosomes, natural carriers of many signal molecules including microRNA 
(miR), mediate organ to organ communication. We hypothesized that intramuscular 
injection of miR-26a would counteract both muscle wasting and renal fibrosis through 
exosome-mediated muscle-kidney crosstalk in diabetic mice.
Methods: We used an engineered exosome vector which contains an exosomal 
membrane protein gene - lysosomal-associated membrane protein 2b (Lamp2b) fused 
with kidney specific surface peptide [(KKEEE)3K] for kidney targeting delivery. 
Exosome encapsulated miR-26a (Exo/miR26) were generated in cultured skeletal muscle 
satellite cells, collected from conditioned media, and injected into the tibialis anterior 
muscle of diabetic mice. Diabetes mellitus was induced by low dose STZ injection 
(5-days). A NanoSight instrument was used to quantify exosomes. MiR deep sequencing 
and qPCR were used to identify microRNA expression. The In-Vivo Xtreme camera system 
was used to detect exosomes in vivo.
Results: miR-26a was decreased in skeletal muscle and kidney of diabetic mice. 
Diabetic serum enhanced secretion of miR-26a exosomes from cultured skeletal satellite 
cells and HEK293 kidney cells. The delivery of exogenous Exo/miR26a into muscle 
increased the levels of miR-26a in skeletal muscle and kidney, as well as increasing muscle 
cross-sectional area and decreasing diabetes-induced upregulation of atrogin-1 and MuRF1. 
Interestingly, renal fibrosis lesions were partially depressed, and α-SMA, connective tissue 
growth factor (CTGF), fibronectin and collagen1α were decreased in diabetic kidney with 
intramuscular injection of Exo/miR-26a. Blood urea nitrogen was decreased in diabetic 
mice treated with Exo/miR26a. Using fluorescent dye labeled Exo/miR26a, we found that 
the fluorescence intensity in kidney was linearly correlated with skeletal muscle.
Conclusions: overexpression of miR-26a in muscle prevents diabetes-induced muscle 
loss and attenuates renal fibrosis via exosome-mediated muscle-kidney crosstalk. These 
results could provide new approaches for developing therapeutic strategies for kidney 
diseases with muscle wasting.
Funding: Other NIH Support - Xiaonan Wang: NIH R01 AR060268, Private 
Foundation Support
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miR-379 Knockout Mice and CLASH Technique Reveal Fis1 as a Novel 
miR-379 Target Related to Diabetic Nephropathy
Mitsuo Kato,1 Rama Natarajan.2 1City of Hope, Duarte, CA; 2Beckman Research 
Institute of City of Hope, Duarte, CA.
Background: We recently showed that microRNAs (miRNAs) in the miR-379 
megacluster and the host noncoding RNA (lncMGC) are co-regulated by endoplasmic 
reticulum stress, are upregulated in kidneys of diabetic mice and promote features of early 
diabetic nephropathy (DN). Here we hypothesized that miR-379-mutant mice created by 
CRISPR-Cas9 editing (miR-379-knockout, KO) are valuable tools to examine the in vivo 
functions of the miR-379 cluster and miR-379 in DN. Furthermore, new miR-379 targets 
identified using miR-379KO mouse mesangial cells (MMC) and the CLASH technique 
(crosslinking, ligation, and sequencing of hybrids) can uncover new therapeutic targets for 
DN.
Methods: Cas9 nickase and two guide RNAs (gRNAs) were injected into mouse eggs 
to create miR-379KO mice. To identify new miR-379 targets, UV-crosslinked RNA-protein 
complexes from wild type (WT) and miR-379KO mouse mesangial cells (MMC) were 
sonicated, immunoprecipitated (IP) with Ago2 antibody and ligated. Hybrid RNAs were 
subjected to RNA sequencing (CLASH).
Results: Several founders identified by PCR were crossed with WT mice, and 
homozygous miR-379KO mice (harboring 36bp deletion in the miR-379 locus) were 
obtained. Multiple miR-379 hybrid sequences were identified by CLASH and RNA-seq. 
Fis-1 (mitochondrial fission) was confirmed as a bonafide miR-379 target by Ago2 IP 
qPCR and Fis1 3’UTR reporter assays. siRNA-mediated Fis1 knockdown reduced key 
mitochondrial signals in MC, suggesting Fis1 is a new player in mitochondrial dysfunction 
in DN. Notably, miR-379-KO mice were protected from early features of DN, and Fis1 
expression was decreased in kidneys of diabetic WT but not diabetic miR-379KO mice.
Conclusions: Combination of miR-379-mutant mice created by CRISPR-Cas9 editing 
and CLASH technique identified Fis1 as a new miR-379 target with key mitochondrial 
functions in the diabetic kidney. Fis1 could be a novel therapeutic target for DN.
Funding: NIDDK Support
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Mice with Drp1-S600 Knockin Mutation Exhibit Reduced Mitochondrial 
Fission and Attenuation of Diabetic Nephropathy
Daniel L. Galvan,1 Jianyin Long,3 Nathanael Green,4 Jamie Lin,3 
Benny B. Chang,4 Farhad R. Danesh.2 1University of Texas MD Anderson 
Cancer Center, Houston, TX; 2UT MD Anderson, Houston, TX; 3The University 
of Texas MD Anderson Cancer Center, Houston, TX; 4Baylor College of 
Medicine, Houston, TX.
Background: Mitochondrial fission has been linked to the pathogenesis of diabetic 
nephropathy (DN), but how this process affects progression of DN in vivo remains elusive. 
We have previously reported the role Dynamin-related protein1 (Drp1), a key component 
of mitochondrial fission, and its phosphorylation at serine 600 on mitochondrial dynamics 
in podocytes in vitro. We now report the in vivo consequences of S600 phosphorylation in 
progression of DN in a mouse model of Type 2 diabetes.
Methods: We generated a S600 phospho-dead Drp1 knockin mouse on the C57BL/6 
background via point mutation of serine 600 to alanine. Following C57Bl6/J ES cell 
electroporation, selection, and screening of colonies by southern blot and PCR analysis, we 
identified several positive clones and generated chimeric S600A mice. We next generated 
heterozygous S600+/A and homozygous S600A/A mice. We crossed the Drp1-S600 mice with 
Leprdb/+ mice, a well-established model of Type 2 diabetes, to generate homozygous diabetic 
Drp1-S600A/A mice (Leprdb/db; Drp1-S600A/A).
Results: Diabetic Drp1-S600 mutant mice were followed over the course of 16 weeks. 
Diabetic mice did not exhibit any differences in their body weight or blood glucose levels. 
In contrast, as compared to diabetic wild-type, both hetero- and homozygous diabetic 
Drp1-S600A mice exhibited significantly reduced albuminuria. Histological analysis 
by Periodic-Schiff’s Acid (PAS) stain and quantification of glomerular area positive for 
PAS stain, revealed attenuated mesangial matrix expansion in glomeruli of db/db;Drp1-
S600A/+;A/A compared to controls. Transmission electron micrographs (TEM) also revealed 
reduced podocyte foot process effacement and reduced glomerular basement membrane 
thickening in diabetic Drp1-S600A/+;A/A compared to diabetic controls. TEM of podocytes 
also revealed elongated mitochondria and increased aspect ratio in mitochondria from 
db/db;Drp1-S600A mice compared to wild-type diabetic mice. Our results are consistent 
with preservation of mitochondrial morphology and structure in S600 mutant mice.
Conclusions: These findings demonstrate that a single phosphorylation site in Drp1 
regulate mitochondrial fission and progression of DN and elucidate a potential role for 
targeting Drp1-S600 phosphorylation in DN.
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Inhibition of Complement C5a/C5a Receptor 1 Decreases Renal Injury in 
Diabetic Kidney Disease via Metabolic Reprogramming
Melinda T. Coughlan,1 Sih Min Tan,1 Mark Ziemann,1 Trent M. Woodruff,2 
Mark E. Cooper.1 Department of Diabetes 1Monash University, Melbourne, VIC, 
Australia; 2The University of Queensland, St. Lucia, QLD, Australia.
Background: The complement system plays a central role in the activation of innate 
immunity, inflammation and tissue remodelling. The complement activation fragment C5a 
is a potent pro-inflammatory effector molecule. We have shown complement activation in 
patients with diabetes including renal deposition of the canonical C5a receptor C5aR1 and 
C5a/C5aR1 activation in experimental diabetes. This study aimed to determine whether 
genetic deletion or pharmacological inhibition of C5aR1 could confer renoprotection in 
diabetes.
Methods: Streptozotocin (STZ)-induced diabetic C57BL/6 mice were treated with the 
highly selective C5aR1 antagonist, PMX-53 (2mg/kg/day) in drinking water for 24 weeks 
(n=10). C5aR1 deficient mice (C5ar1-/-) and their wild type littermates were rendered 
diabetic with STZ and followed for 24 weeks (n=10). Kidney injury was assessed by urinary 
albumin excretion and glomerulosclerosis (GSI). Immunohistochemistry for Collagen IV, 
FoxP3+ regulatory T cells and F4/80+ cells was performed. Transcriptomics of renal cortex 
was performed by RNA-sequencing using the Illumina platform and pathway analyses 
using Gene Set Enrichment Analysis.
Results: Diabetic C5ar1-/- mice showed protection against renal injury with decreased 
albumin excretion. Treatment of diabetic mice with PMX-53 led to a reduction in proteinuria, 
inhibition of glomerular injury and fibrosis and resolution of inflammation via a decrease in 
F4/80+ macrophages and activation of FoxP3+ regulatory T cells. Transcriptomic analyses 
showed that the diabetes gene signature was reversed by PMX-53. Pathways that were 
reduced by PMX-53 in diabetic mice were related to mitochondrial function and lipid 
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metabolism. The top differential gene downregulated in the diabetic kidney was acyl-CoA 
dehydrogenase 10 (Acad-10), which participates in the beta-oxidation of fatty acids in 
mitochondria. Blockade of C5aR signalling in diabetic mice restored Acad-10 expression.
Conclusions: Our findings demonstrate that genetic or pharmacological disruption 
of C5aR1 is renoprotective in diabetes via restoration of pathways involved in fatty acid 
oxidation and by suppressing the pathogenic inflammatory response. This study indicates 
that targeting the C5a/C5aR1 pathway may provide a substantial therapeutic benefit for this 
devastating complication of diabetes.
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Klotho Ameliorates Diabetic Nephropathy via AMPK-PGC1α Mediated 
Renal Mitochondrial Protection
Jinho Lee, Tsogbadrakh B. Bodokhsuren, Sohyun Yun, Hyunjin Ryu, 
Eunjeong Kang, Minjung Kang, Curie Ahn, Kook-Hwan Oh. Seoul National 
University Hospital, Seoul, Republic of Korea.
Background: Diabetic nephropathy(DN) is associated with renal mitochondrial injury, 
and decreased renal klotho. Klotho is known as ageing suppressor, and mitochondrial 
dysfunction is the hallmark of ageing. Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1α) is a master regulator of mitochondrial biogenesis, and 
adenosine monophosphate-activated protein kinase(AMPK) is known as a guardian of 
mitochondria. Here, we report that recombinant klotho protein (rKL) is protective against 
DN in db/db mice by PGC1α-AMPK mediated mitochondrial recovery in the kidney.
Methods: We injected rKL into db/db and db/m mice for 8 weeks, and collected the 
serum and the kidney. Also, we treated rKL to various renal tubular cells in vitro, with or 
without 30mM high glucose (HG) exposed.
Results: rKL-treated db/db mice showed recovered renal proximal tubular 
mitochondria, as well as significantly reduced renal ROS and serum glucose, compared 
to vehicle-treated db/db mice. Also, rKL increased renal p-AMPK, PGC1α, and down-
regulated mTOR/TGF-β in db/db mice. Moreover, we confirmed that rKL treatment 
ameliorated HG-mediated cellular damage, with an increase of PGC1α-AMPK induced 
mitochondrial recovery in cultured renal tubular cells.
Conclusions: Our data suggest a mitochondrial protective role of klotho against 
diabetic kidney disease by inducing AMPK-PGC1α expression.
Funding: Government Support - Non-U.S.
a) renal mitochondiral recovery by rKL in db/db mice, and b) rKL increased renal p-AMPK
and PGC1α expression in db/db mice.
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Effects of Sodium Glucose Cotransporter 2 Deletion on Bone and Mineral 
Metabolism
Claire Gerber,1 Valentin David,3 Susan E. Quaggin,1 Aline Martin,1 
Tamara Isakova.2 1Northwestern University, Chicago, IL; 2Feinberg School of 
Medicine, Northwestern University, Chicago, IL; 3Northwestern University - 
Feinberg School of Medicine, Chicago, IL.
Background: Type 2 diabetes mellitus (T2DM) and chronic kidney disease are 
associated with an increased risk of developing bone and mineral metabolism abnormalities. 
A new class of glucose-lowering agents, sodium-glucose cotransporter 2 (SGLT2) 
inhibitors, promotes urinary glucose excretion and improves renal and cardiovascular 
outcomes in patients with T2DM. However, SGLT2 inhibitors are associated with increased 
risk of bone fractures. Because loss of SGLT2 function may decreases urinary phosphate, 
we hypothesize that inhibition of SGLT2 induces mineral metabolism alterations that could 
contribute to increased bone fragility.
Methods: Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of SGLT2 
function in proximal tubules. To understand the effects of loss of SGLT2 function on mineral 
metabolism, urine and serum was collected from fasted wild type (WT) and SP mice. Levels of 
fractional excretion of calcium and phosphate; serum phosphate, calcium, PTH, 1,25(OH)2D, 
and FGF23 were evaluated at 15 and 25 weeks. To determine the longitudinal impact of loss of 
SGLT2 function on bone metabolism, bone architecture, remodeling, and mineralization was 
assessed in SP mice and WT mice at 15 and 25 weeks of age.
Results: At 25 weeks, SP mice showed significantly decreased body weight compared 
to WT mice (21.6±3.8 vs 25.1±2.9 g, p<0.05). Consistently, femoral length was significantly 
shorter in SP mice compared to WT mice (14.1±0.4 vs 14.5±0.2 mm, p<0.05). Overall renal 
function was not impaired in SP mice compared to WT mice (blood urea nitrogen: 18±4 
vs 21±5 mg/dL, NS). Fasted SP mice did not show modification of fractional excretion 
of calcium. Serum calcium, PTH, and 1,25(OH)2D levels were similar between WT and 
SP mice at 15 and 25 weeks. Fractional excretion of phosphate was significantly higher at 
25 weeks in SP mice compared to WT (5.5±2.0 vs 2.5±1.9 %, p<0.05), despite unchanged 
levels of FGF23. SP mice had reduced cortical bone mineral density, compared to WT mice 
at 25 weeks (1240±16 vs 1264±14 mg/cm3, p<0.05).
Conclusions: These results suggest that loss of SGLT2 function in the absence of 
T2DM may contribute to bone fragility. Future studies are required to determine how loss 
of SGLT2 function impacts bone fragility in T2DM.
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Unravelling Reno-Protective Effects of SGLT2 Inhibition in Human 
Proximal Tubular Cells
Markus Pirklbauer, Ramona Schupart, Lisa Fuchs, Petra Staudinger, 
Ulrike Corazza, Sebastian Sallaberger, Johannes Leierer, Gert J. Mayer, 
Herbert Schramek. Medical University Innsbruck, Innsbruck, Austria.
Background: Large clinical trials recently demonstrated that SGLT2 inhibitors 
(SGLT2i) slow the progression of kidney function decline in type 2 diabetes independently 
of their glucose lowering effects. However, the underlying molecular mechanisms of these 
beneficial renal effects are unknown. As the proximal tubule (PT) is supposed to play a role 
as initiator and contributor in early pathogenesis of diabetic kidney disease, we conducted a 
systematic molecular approach to study the effects of SGLT2i on gene expression in human 
PT cells. Utilizing two SGLT2i, namely empagliflocin and canagliflocin, we investigated 
their effects on differential gene expression in the presence and absence of TGF-ß1, a well 
established pro-fibrotic ligand.
Methods: human proximal tubular cell culture (HK-2 and RPTEC/TERT1), microarray 
hybridization, pathway enrichment analysis, real-time PCR, ELISA
Results: Microarray hybridization analysis identified 94 genes that were both 
upregulated by TGF-ß1 and downregulated by two SGLT2i in HK-2 and RPTEC/TERT1 cells 
(n=2). Functional annotation of these genes revealed 152 involved pathways in 7 annotation 
clusters (EASE score < 0,05). Within the top-ranked clusters (enrichment score > 3), 
annotations for extracellular matrix organisation (p=6,4x10-7) and extracellular space 
(p=2,8x10-6) showed the highest significance. Differential gene expression of 3 annotated 
genes of interest within this pathway, namely thrombospondin 1 (THBS1), tenascin C 
(TNC) and platelet derived growth factor subunit B (PDGFB), was verified on mRNA 
level in HK-2 and RPTEC/TERT1 cells: While TGF-ß1 significantly induced mRNA 
expression of THBS1 (5-fold), TNC (8-fold) and PDGFB (4,2-fold), SGLT2i significantly 
downregulated basal mRNA expression of THBS1 (0,2-fold), TNC (0,5-fold) and PDGFB 
(0,5-fold). Administration of SGLT2i in the presence of TGF-ß1 resulted in a significant 
inhibition of TGF-ß1-induced THBS1 and TNC mRNA expression by approximately 
50 % (n=4; p<0,05). TGF-ß1-induced PDGFB protein expression was almost completely 
blocked in the presence of SGLT2i (n=6; p<0,001).
Conclusions: We conclude that SGLT2i block basal and TGF-ß1-induced expression 
of key mediators of renal fibrosis and kidney disease progression, namely of THBS1, TNC 
and PDGFB in two independent human PT cell lines.
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Dysregulated Translation and Differential p53 Isoform Expression in the 
Kidney during Diabetes
Bernhard Maier, Takashi Hato, Timothy A. Sutton, Pierre C. Dagher. Indiana 
University School of Medicine, Indianapolis, IN.
Background: Over 30 million people in the US have diabetes and it remains the leading 
cause of ESRD. Critically missing from investigation into the pathogenesis of diabetic 
nephropathy (DN) is the detailed examination of translation, the fundamental process 
linking gene expression to the synthesis of functional proteins. In this study we use a mouse 
model of diabetes to examine differential and sequential changes in global translation as 
well as expression of p53, an important regulator of transcription and translation during cell 
stress, in the kidney.
Methods: Transcriptional (RNA-seq) and translational (polysome, Ribo-seq) profiling 
are used to study changes in the translatome during progression of diabetes in the kidney 
of db/db (B6.BKS(D)-Lepr db/J) mice. p53 isoform expression is examined by biochemical, 
proteomic, and translational profiling in db/db mice and nondiabetic background 
(WT) mice.
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Results: Transcriptional profiling reveals that pathways regulating translation are 
the most differentially altered in the kidney of db/db mice as the diabetic state progresses 
from 8 weeks to 12 weeks old. Significant changes are observed broadly across ribosomal 
proteins and regulators of both ribosomal biogenesis and translation. Direct analysis of 
translation by polysome profiling demonstrates translational activity is increased by 50% 
in 12 week-old compared to 8 week-old db/db mice. In addition, Ribo-seq confirms the 
increase in translational activity in the kidney from db/db mice as compared to WT mice. 
Further analysis of Ribo-seq data reveals four general variations of ribosomal kinetics in 
the kidney of db/db mice as compared to WT mice. Given the relationship between cell 
stress and altered translation, we examined p53 isoform expression in the kidney of db/
db mice. Immunoblotting reveals the presence of a ~44kDa band consistent with ΔNp53, a 
translationally-regulated (IRES-mediated) p53 isoform modulating aging and metabolism, 
in the kidney of db/db mice that is absent in WT mice. Proteomic analysis and ribosome 
footprint profiling (Ribo-seq), an indispensable method to examine IRES-mediated 
generation of proteins, further substantiate the differential generation of ΔNp53 in the 
kidney of db/db mice.
Conclusions: Dysregulated translation in the diabetic state is associated with ΔNp53 
expression that can in turn alter translation and contribute to DN.
Funding: NIDDK Support
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The Renal Na-Cl and Na-K-2Cl Cotransporters Are Increased in Urinary 
Exosomes of Patients with Severe Preeclampsia
Elba O. Medina,1 L. M. Perez-Navarro,1 Jesús C. Briones,1 Ivonne Hurtado,2 
Fabiola Gallardo,2 Rafael Valdez-Ortiz,1 Lorena L. Rojas,2 Gerardo Gamba.2,3 
1Hospital General de México Dr. Eduardo Liceaga, México, Mexico; 2INCMNSZ, 
Mexico, Mexico; 3IIB, UNAM, Mexico City, Mexico.
Background: Arterial hypertension (AH) in preeclampsia (PE) is in part due to 
increased sodium reabsorption in the kidney. One of the major pathways for salt reabsorption 
is the Na-Cl cotransporter (NCC), whose expression and activity is modulated by female 
hormones (AJP Renal, 2015). Here we assessed the presence of NCC and NKCC2 in 
urinary exosomes of women with PE as compared with women with healthy pregnant (HP).
Methods: We included ten women diagnosed with severe PE (ACOG 2013; SBP 
≥160mmHg or DBP ≥ 110mmHg, protein/creatinine ratio > than 0.3mg/dl), which were
matched with a HP patients by age and gestation weeks. The urine sample was taken at the 
time of detection of arterial hypertension with criteria of severity. Urinary exosomes were 
used for Western Blot analysis for total and phosphorylated NCC, NKCC2 and the kinase 
SPAK. Serum and urinary electrolytes were measured.
Results: Mean age (years), gestation (weeks) and mean blood pressure (mmHg) were 
28 ± 4.6, 36 ± 3.7 and 123 ± 11 for PE group and 25 ± 6.7, 37 ± 3.9 and 83 ± 8.5 in HP, 
respectively. A remarkable increase in the expression of NCC was found in PE group vs HP, 
3.0 ± 0.77 vs 1.0 ± 0.7321 (p<0.01, Fig 1). There was no difference in the expression of 
NKCC2, but a significant increase in the phosphorylated form was observed in PE group 
(2.56 ± 1.11 vs 1.00 ± 0.15, p=0.015, Fig. 1). Additionally, increase in the expression and 
activation of SPAK/OSR1 were observed in the PE group. Serum K+ was similar between 
PE and HP groups (p=NS).
Conclusions: Our data revealed increased expression/activation of NCC and NKCC2 
in PE, suggesting the participation of these cotransporters in the development of AH. The 
increased phosphorylation of SPAK/OSR1 suggests that these kinases are responsible for 
NCC and NKCC2 activation.
Funding: Government Support - Non-U.S.
Figure 1. Total and phosphorylated NCC and NKCC2 in five PE and HP patients
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Intense Renal Sodium Retention in Healthy Individuals Subjected to a 
Potassium Deprived Diet
Andrew Kowalski,1 Daniel Batlle.2 Northwestern University Feinberg School of 
Medicine 1Northwestern University, Lombard, IL; 2Northwestern University 
Feinberg Medical School, Chicago, IL.
Background: Diets poor in potassium (K) have been associated with hypertension, 
cardiovascular disease and all-cause mortality. Our study aims to quantify sodium (Na) 
balance in the setting of total dietary potassium deprivation of brief duration while keeping 
dietary sodium constant.
Methods: 10 male healthy volunteers were studied in the clinical research unit while 
on a strict calorie and electrolyte balanced liquid diet for a 10 day control period followed 
by a 5 day study period with total dietary K deprivation. The Na intake was kept constant 
throughout the entire study period (1.8 mEq/KBW) and the intake of K was reduced from 
1.5 mEq/KBW to 0 mEq/KBW. Body weights, systolic and diastolic blood pressure (SBP, 
DBP), serum and 24 hour urine electrolytes were collected daily.
Results: At the end of the control period, urinary K was 81 ± 8.6 mEq/24hrs and fell 
to 16 ± 1.68 mEq/24Hr (p=0.0006) by day 5 of the K deprived diet. After 5 days on a K 
deprived diet the cumulative K deficit was -132 ±10 mEq with a fall in plasma K from 4.54 
±0.15 to 3.68 ±0.05 mEq/dL (p=0.0016) by the end of the study period. Urinary Na excretion 
fell on day one on the K deprived diet, and by day 5 renal Na retention resulted in a positive 
Na balance of 507 ± 3.8 mEq/L. Bodyweight did not significantly increase during the initial 
5 days of the study diet (from 91.6 ± 5.2kg to 91.8 ± 5.3kg; p=0.71). SBP at the end of 5 day 
increased slightly, but not significantly from 111.2 ± 2 .58 mmHg to 115.49 ± 2.94 mmHg; 
p=0.083, and DBP decreased but not significantly from 72.6 ± 1.6 mmHg 
to 71.3 ± 2.4mmHg; p=0.50. There was a marked fall in hematocrit by day 5 with a fall
from 45.6 ± 0.53% to 42 ± 0.44% (p=0.01). From the change in hematocrit and body weight 
plasma volume was estimated to have increased by 192mL (from 3483 ± 379 mL to 3675 ± 
409 mL; p=0.005) over the 5 day period.
Conclusions: This study shows that total dietary K deprivation is a potent stimulus for 
the kidney to rapidly retain Na over a very short period of time. Even more striking was the 
observed magnitude of the positive Na balance of 507 mEq/L with only a small increase 
in plasma volume along with no significant increase in body weight or blood pressure. 
This observation supports recent evidence of a large Na reservoir with the ability to store 
significant amounts of Na, thus limiting its impact on body weight and blood pressure.
Funding: NIDDK Support
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Sodium Concentration in Tissues of Dialysis Patients
Elena Qirjazi,1,2 Alireza Akbari,3,2 Timothy J. Scholl,2,3 Christopher W. McIntyre.4,2 
1Nephrology, Western University, London, ON, Canada; 2Medical Biophysics, 
Western University, London, ON, Canada; 3Robarts Research Institute, Western 
University, London, ON, Canada; 4London Health Sciences Centre, London, 
ON, Canada.
Background: Dialysis patients are unable to fully remove sodium (23Na). Thus, 23Na is 
buffered in the skin, muscle and skeleton (osmotically inactive, but not biologically inert). 
We measured 23Na content in these reservoirs using novel 23Na MRI, in dialysis patients 
and healthy controls.
Methods: We undertook a pilot cross-sectional study of 26 subjects (10 controls and 
16 dialysis - 9 peritoneal dialysis and 7 hemodialysis - patients). Subjects participated in 
a study session, which included collection of baseline information, bloodwork and a 23Na 
MRI study using a multinuclear-capable 3.0T MRI (Discovery MR750, General Electric 
Healthcare). An axial proton T1-weighted fast-low-angle-shot sequence was acquired to 
delineate the anatomy; followed by a 23Na MR image obtained with a custom-made lower-
leg 23Na coil and 23Na-optimized pulse sequence (DA-3DPR). Maps of absolute tissue 23Na 
concentration were generated using calibration vials of known 23Na concentration included 
in the field-of-view. Four regions of interest were drawn, highlighting different tissues: 
1) pre-tibial skin, 2) posterior leg skin (included because 23Na distribution in skin was
inhomogeneous), 3) soleus muscle, and 4) tibia.
Results: 23Na concentrations in the different tissues for both groups are shown in Fig. 1. 
Dialysis patients had statistically significant higher 23Na levels in all four regions (p<0.05). 
Dialysis modality and gender did not have a significant effect.
Conclusions: Dialysis patients have significantly higher 23Na level in their skin, muscle 
and bone compared to healthy controls.
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Fig. 1: A: 23Na concentration map of the lower leg and calibration vials for a dialysis patient. 
B: 23Na concentration in different tissues in dialysis patients and controls. Error bars = 
standard deviation. * = statistically significant differences (p<0.05)
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Incidence and Outcomes of Hyperkalemia in Solid Organ Transplant 
Recipients
Masaaki Yamada, Karthikeyan Meganathan, Taranpreet Kaur, Silvi Shah, 
Amit Govil, Charuhas V. Thakar. University of Cincinnati, Cincinnati, OH.
Background: Hyperkalemia is a serious complication resulting in a critical adverse 
event. Solid organ transplant (SOT) recipients can experience hyperkalemia contributed by 
both pathophysiological and medication related mechanisms. We examined incidence and 
outcomes of hyperkalemia in SOT recipients receiving acute care.
Methods: In a multi-center national sample (Cerner Health Facts database, 1/1/2000 
to 6/30/2016), we examined patients with first hospitalization after transplant surgery or 
during the study period, whichever occurred earlier. Based on the peak potassium (K) 
level in mEq/L during the index admission, we classified K as normal ≤5.0, mild 5.1-5.5, 
moderate 5.6-6.0, and severe >6.0; hyperkalemia was defined as moderate or severe K 
groups. By logistic regression, we analyzed the effect of hyperkalemia and its severity on 
in-hospital mortality/hospice discharge and 30-day readmissions after adjustment for major 
confounders.
Results: Of the 14,684 SOT recipients, 65% kidney; 8% heart; 17% liver; and 10% 
other transplants. The cohort was 60% male with median age of 56 years (Q1, Q3, 45, 
64) and median creatinine of 1.6 mg/dL (Q1, Q3, 1.2, 2.7). Overall, 16% experienced
hyperkalemia (K levels: 69% normal; 15% mild; 8% moderate; 8% severe); frequency
of hyperkalemia across organ type ranged between 13% and 17%. Overall in-hospital
mortality was 2.6%; hyperkalemia group 6.1% vs. others 2.0% (p<0.001); mortality by
K class was 1.6%, 3.7%, 5.4% and 6.8%, respectively (p<0.001). Hyperkalemia increased
the risk of death [adjusted odds ratio (aOR), 3.1; 95% confidence interval (CI), 2.5-4.0]; 
compared to normal level, the severity of K class was associated with a graded increase
in risk of death: mild K, aOR 2.2; 95% CI, 1.7-3.0; moderate K, aOR 3.4; 95% CI, 2.4-
4.7; severe K, aOR 4.6; 95% CI, 3.3-6.2. There was a synergistic interaction between
hyperkalemia and type of SOT, which was statistically significant (p=0.025). Hyperkalemia 
also increased risk of 30-day readmissions, 27% vs. others 18% (p<0.001); aOR 1.5; 95%
CI, 1.4-1.7.
Conclusions: Hyperkalemia occurs in 1-in-6 SOT recipients during acute care; it is 
associated with a 3-fold increase in the risk of hospital mortality and 1.4-fold increase in the 
risk of readmission. Hyperkalemia prevention or treatment during acute care may improve 
patient survival in transplant recipients.
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Urine Citrate Excretion Reliably and Non-Invasively Identifies Acid 
Retention in CKD 2 Patients without Metabolic Acidosis
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Donald E. Wesson.5,2 1Internal Medicine, Baylor Scott and White Health, 
Temple, TX; 2Internal Medicine, Texas A&M HSC College of Medicine, Temple, 
TX; 3Reaserch Institute, Baylor Scott & White, Temple, TX; 4Medicine, Tufts 
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Background: Dietary acid (H+) reduction slows eGFR decline in CKD stage 2 
(eGFR=60-89 ml/min/1.73 m2, CKD 2) patients without metabolic acidosis (conventionally 
defined as plasma total CO2 <22 mM) (Mahajan et al, Kid Int, 2010) but who have H
+ 
retention identified using cumbersome and invasive methods. Earlier studies from this 
laboratory supported the potential utility of urine citrate excretion to non-invasively identify 
H+ retention in such patients but its reliability to do so was not assessed.
Methods: We measured H+ retention and 8-hour urine citrate excretion (UcitrateV) in 
macroalbuminuric, non-diabetic CKD 2 (n=40) and CKD stage 1 (eGFR >90 ml/min/1.73 m2, 
CKD 1, n=26) patients with hypertension-associated nephropathy but without metabolic 
acidosis (mean plasma total CO2 25.9±0.8 and 26.4±0.6 mM, respectively). H
+ retention 
was measured by comparing observed to the expected increase in plasma [HCO3] in 
response to retained HCO3 (dose minus UHCO3V) 6 hours after oral NaHCO3 bolus 
(0.5 mmol/kg bw), assuming 50% body weight HCO3 apparent space of distribution.
Results: H+ retention was higher in CKD 2 than CKD 1 (28.1±9.4 vs. 5.2±12.0 mmol, 
respectively, p<0.01) but UcitrateV was lower in CKD 2 than CKD 1 (187±40 vs. 335±125 mg, 
respectively, p<0.01). Overall Pearson correlation for UcitrateV with H
+ retention was -0.76 
(p<0.001) and a mixed effects regression model showed lower UcitrateV to be strongly 
predictive of higher H+ retention (p<0.001). Using the 90th percentile of H+ retention in 
CKD 1 (19.5 mmol) as normal, UcitrateV of 230 mg in CKD 2 patients had sensitivity 93.7%, 
specificity 62.5%, positive predictive value 90.9%, negative predictive value 71.4%, and an 
accuracy of 87.5% to predict H+ retention.
Conclusions: Lower UcitrateV reliably identifies CKD 2 patients with higher H+ retention 
in the absence of metabolic acidosis by acid-base parameters. Because <2% of CKD 2 
patients have metabolic acidosis (Shah et al, AJKD, 2009), follow-up studies should further 
refine this simple, non-invasive method to identify CKD 2 patients who are candidates for 
dietary H+ reduction which might reduce their risk for nephropathy progression.
SA-OR036 Oral Abstract Saturday
Fluids and Electrolytes: Clinical, Translational, and Acid-Base
A Multicenter, Randomized Pilot Study of Oral Sodium Bicarbonate 
Supplementation in Non- to Mildly-Acidotic CKD: The BASE Pilot Study
Kalani L. Raphael,1 Tamara Isakova,2 Joachim H. Ix,3 Dominic S. Raj,4 
Myles Wolf,5 Linda F. Fried,6 Jennifer J. Gassman,7 Brett Larive,7 Kevin C. Abbott,8 
Susan R. Mendley,8 Geoffrey A. Block,9 Ping Li,4 John P. Middleton,5 
Stuart M. Sprague,10 Donald E. Wesson,11 Alfred K. Cheung.12 The CKD Pilot 
Studies Consortium 1VA Salt Lake City Health Care System, Salt Lake City, UT; 
2Feinberg School of Medicine, Northwestern University, Chicago, IL; 3UCSD, 
San Diego, CA; 4GWU Medical Faculty Associates, Washington, DC; 5Duke 
University, Durham, NC; 6VA Pittsburgh Healthcare System, Pittsburgh, PA; 
7Cleveland Clinic, Cleveland, OH; 8The National Institutes of Health, NIDDK, 
Bethesda, MD; 9Colorado Kidney Care, Denver, CO; 10NorthShore University 
HealthSystem University of Chicago Pritzker School of Medicine, Chicago, IL; 
11Baylor Scott and White Health and Wellness Center, Dallas, TX; 12University of 
Utah, Salt Lake City, UT.
Background: Chronic oral NaHCO3 may preserve GFR in CKD, even in those with 
normal serum (S) HCO3
-. However, definitive proof of efficacy and the optimal dose 
have not been demonstrated. We performed a randomized, double-blinded, placebo-
controlled multicenter pilot study to determine the safety, tolerability, compliance, 
and pharmacodynamics of two doses of oral NaHCO3 and the feasibility to conduct a 
multicenter Phase-3 trial.
Methods: Individuals (n=194) with mean age 68 yrs, eGFR 37 ml/min/1.73m2, ACR 
530 mg/g, and S-HCO3
- 24 meq/L (range 20-28 meq/L) were randomized to higher-dose 
(HD) (0.8 meq/kg-LBW/d; n=90) or lower-dose (LD) (0.5 meq/kg-LBW/d; n=52) NaHCO3 
or placebo (Plac; n=52) for 28 weeks. The dose was adjusted depending on clinical and 
laboratory side-effects. The prescribed dose at study completion was the primary outcome. 
Feasibility for a Phase 3 trial was defined a priori as ≥67% of participants completing the 
study on full dose and ≥80% on ≥25% of the dose. Pharmacodynamics were assessed by 
S-HCO3
-, 24-hour urine NH4
+ (U-NH4
+) and pH (U-pH).
Results: 87% in HD, 98% in LD, and 88% in Plac completed the study on full dose,
while 91% in HD, 98% in LD, and 94% in Plac completed the study on ≥25% of the dose. 
Compliance by pill count was ≥88%, with >80% of participants having ≥80% compliance 
in all arms during follow-up. BP, weight, and S-K+ were similar between Plac, LD and HD 
during follow-up. Table 1 shows dose-response effects of NaHCO3 on S-HCO3
-, U-pH and 
U-NH4
+.
Conclusions: In persons with non- to mildly-acidotic stage 3/4 CKD, safety, tolerability 
and compliance of HD and LD NaHCO3 were each comparable to Plac. NaHCO3 had a 
mild effect on S-HCO3
- and substantial dose-dependent effects on U-NH4
+ and U-pH, but 
no significant effect on BP, weight, or S-K+. A Phase-3 multicenter trial using NaHCO3 0.8 
meq/kg-LBW/d is feasible.
Funding: NIDDK Support
Fluids and Electrolytes: Clinical, Translational, and Acid-Base
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
88
J Am Soc Nephrol 29: 2018 Oral Abstract/Saturday
Dose response effects of NaHCO3 on acid-base indices
SA-OR037 Oral Abstract Saturday
Fluids and Electrolytes: Clinical, Translational, and Acid-Base
The Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Random-
ized, Placebo-Controlled, Multi-Center Clinical Trial
Michal L. Melamed,1 Edward J. Horwitz,2 Mirela A. Dobre,2 
Matthew K. Abramowitz,1 Yungtai Lo,1 Thomas H. Hostetter.2 1Albert Einstein 
College of Medicine, Bronx, NY; 2Case Western Reserve University, 
Cleveland, OH.
Background: The chronic metabolic acidosis associated with kidney disease may 
contribute to muscle dysfunction, bone disease and progression of kidney disease.
Methods: We enrolled 149 patients with CKD stages 3 and 4 and randomized them 
to either placebo or sodium bicarbonate (NaBicarb) (0.4 mEq/kg ideal body weight/
day) between 7/2011 and 4/2016 at 3 clinical sites across the US. Participants were seen 
at baseline, 2, 6, 12 and 24 months. The dual primary outcomes were muscle function 
assessed by sit-to-stand-to-sit test and bone mineral density. At each visit, blood pressure 
(BP), weight, a 5-repetition sit-to-stand-to-sit test, and laboratory studies were conducted. 
Bone mineral density scans were performed at baseline, 12 and 24 months.
Results: Of the 149 participants, 74 were on NaBicarb, 75 were on placebo. Mean age 
was 61.0 years (standard deviation(SD) 12.6), 54% were women, 58% were non-Hispanic 
black, 13% were Hispanic and 27% were non-Hispanic white, 62% had diabetes mellitus 
and 93% had hypertension at baseline. Baseline serum bicarbonate level was 23.5 (SD 1.7) 
mEq/L, baseline eGFR was 36.3 (SD 11.2) ml/min/1.73m2 and baseline systolic BP was 137 
(SD 17) mmHg. There were no differences in baseline characteristics by treatment group. 
104 participants completed the 24 months study. At 2, 6, 12 and 24 months, the mean serum 
bicarbonate levels in the NaBicarb arm were 26.4 mEq/L (SD 2.2), 25.5 mEq/L (SD 2.3), 
25.6 mEq/L (SD 2.6) and 24.4 mEq/L (SD 2.8). These were significantly higher than in the 
placebo group (p<0.001). NaBicarb caused a significant decrease in serum potassium levels 
by approximately 0.1 mEq/L (p= 0.047). There were 14 patients in the NaBicarb group who 
had a potassium level >5.0 mEq/L over the course of the study compared to 30 patients 
in the placebo group (p=0.005). There were no significant differences in sit-to-stand-to-sit 
time, bone mineral density, BP or weight between the randomized groups.
Conclusions: NaBicarb therapy in patients with CKD stages 3 and 4 significantly 
increases serum bicarbonate and decreases serum potassium levels. There were no 
differences in muscle function or bone mineral density between the randomized groups. 
Larger trials are required to evaluate effects on kidney function.
Funding: NIDDK Support
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Therapeutic Efficacy and Safety of Human Adipose-Derived Stem Cells 
for Anti-GBM Nephritis
Yuko Shimamura, Naotake Tsuboi, Yutaka Kamimura, Shoichi Maruyama. 
Nagoya University Graduate School of Medicine, Nagoya, Japan.
Background: Mesenchymal stem cells (MSCs), which exert immunomodulatory 
function, would be one of the promising therapeutic agents for inflammatory disorders. We 
have been intensively studied adipose derived stem cells (ASCs) cultured under low serum 
conditions (LASCs) and recently demonstrated that systemic administration of syngeneic 
LASCs ameliorated anti-GBM nephritis in rats more effectively than ACSs grown under 
high serum conditions (HASCs). In the current study, we investigated therapeutic potency 
of human LASCs for rat anti-GBM nephritis.
Methods: Anti-GBM nephritis was induced by intravenous injection of TF78, 
a monoclonal anti-glomerular basement membrane antibody, to female WKY/NCrj 
rats. 2×106 human LASCs, HASCs or bone marrow derived MSCs (BMMSCs) were 
administrated to them on day 0, 2, 4 and sacrificed on day 7. Therapeutic efficacy was 
evaluated by proteinuria during observation period and serum creatinine (sCr), BUN, 
histological renal damage on day 7. Distribution of administrated MSCs was observed by In 
Vivo Imaging System. The clotting time after addition of MSCs into plasma was measured. 
The expression of tissue factor on the MSC surface was analyzed by flow cytometry.
Results: ASC-treatment demonstrated significant amelioration in TF78-induced renal 
dysfunction. Histologically, crescent formation and accumulations of CD68+ or CD163+ 
macrophages in inflamed glomeruli were significantly decreased in ASC-treated groups 
compared with the BMMSC-treated group. Although the therapeutic efficacy of HASC 
slightly surpassed that of LASC, therapy-related animal death caused by pulmonary 
accumulations of administrated-ASCs occurred in 4 out of 12 HASC-treated rats, while 
none in LASC-treated animals. Procoagulant function, which has emerged as a critical 
aspect in clinical application of ASCs, was remarkably diminished in LASCs compared with 
HASCs as evidenced with similar clotting time and tissue factor expression to BMMSCs.
Conclusions: Human ASCs have therapeutic potential for anti-GBM nephritis as well 
as syngeneic ASCs compared with BMMSCs. Although HASCs shows slightly superior 
efficacy, it has a serious safety drawback compared with LASCs. From a comprehensive 
perspective, LASCs would be advantageous in therapeutic potential for clinical use.
SA-OR039 Oral Abstract Saturday
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Neutralizing the Th1 Effector Cytokines, TNFα and IFNγ, in Experimen-
tal Autoimmune Myeloperoxidase ANCA Associated Glomerulonephritis 
(MPO-ANCA GN)
Kei Nagai,1,2 A. Richard Kitching,2 Stephen R. Holdsworth,2 Poh-Yi Gan.2 
1University of Tsukuba, Tsukuba-city, Japan; 2Monash University, Monash 
Medical Centre, Melbourne, VIC, Australia.
Background: Anti-cytokine monoclonal antibody (mAb) therapies have been effective 
in many autoimmune diseases but have not been successfully trialled in MPO-ANCA 
associated vasculitis. This study assessed the efficacy of blocking key CD4+ Th1 subset 
signature effector cytokines, TNFα and IFNγ in MPO-ANCA GN. Assessing therapeutic 
efficacy of these anti-cytokine mAbs is now complicated by our recent discovery that Th 
subset dominance during the development of MPO autoimmunity is biphasic with initial 
transient Th17 dominance followed by persistent Th1 responses.
Methods: Anti-MPO autoimmunity was induced in C57BL/6 mice by MPO 
immunization and GN triggered using anti-GBM Ig during early and late development of 
anti-MPO autoimmunity, and GN assessed 4 days later (days 20 and 32, respectively). mAb 
treatment began 4hrs post GN triggering.
Results: Administration of anti-TNFα mAb early in anti-MPO development (day 20) 
had no effect on kidney injury compared with vehicle treated controls: albuminuria [5.7±1.7 
vs 5.5±1.7 mg/24hr, P=0.9]; glomerular segmental necrosis [GSN: 50±4 vs 43±3%, P=0.1]. 
Similarly, anti-IFNγ mAb was ineffective in attenuating GN at this timepoint [GSN: 48±6 
vs 45±3%, P=0.53]. Failure of these treatments is concordant with our observation that early 
developing anti-MPO autoimmunity is Th17 dominant. In contrast, anti-TNFα therapy 
during established anti-MPO GN (day 32) markedly attenuated kidney injury [GSN: 27±2 
vs 50±4%, P=0.01]. TNFα blockade acts locally in the kidney as systemic MPO specific 
IFNγ and IL-17 recall responses from lymph nodes draining MPO immunization sites 
were similar to vehicle treated controls. Neutralizing IFNγ at this late timepoint induced 
a phenotypic switch from Th1 responses to a protective Th2 with increased in serum 
MPO-ANCA [1.19±0.25 vs 0.48±0.13 OD450nm, P=0.02], increased IL-4 production from 
MPO challenged LN cells and increased the proportion of activated M2 macrophages 
[F4/80+CD206+: 29.3±3.2 vs 16.0±0.9%, P=0.01]. However, 4 days of anti-IFNγ treatment 
was insufficient to improve GN.
Conclusions: In conclusion, Th1 anti-MPO effector responses direct established anti-
MPO nephritogenic autoimmunity and glomerular injury (day 32). Therapeutic TNFα 
neutralizing mAb initiated after triggering GN effectively attenuates kidney injury.
Funding: Government Support - Non-U.S.
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BB-Cl-Amidine Limits Neutrophil Extracellular Trap Formation and 
Inflammation in Murine Experimental Myeloperoxidase Anti-Neutrophil 
Cytoplasmic Antibody Associated Glomerulonephritis
Kim M. O’Sullivan,1 Poh-Yi Gan,1 A. Richard Kitching,2 Stephen R. Holdsworth.2 
Centre for Inflammatory Diseases 1Monash University, Monash Medical Centre, 
Melbourne, VIC, Australia; 2Monash University, Monash Health, Clayton, VIC, 
Australia.
Background: Accumulating evidence suggests that dysregulation of neutrophil 
extracellular traps (NETs) could be associated with the pathogenesis of anti-neutrophil 
cytoplasmic antibody (ANCA) vasculitis. Peptidyl arginine deiminases (PADs) are 
enzymes that generate citrullinated proteins, which are pro-inflammatory in both innate 
and adaptive immune responses. Citrullination of histone 3 (H3Cit) by PAD2 and PAD4 
facilitates generation of both macrophage extracellular traps (METs) and NETs. BB-Cl-
amidine is a second generation pan (PAD) inhibitor which reduces citrullination of H3Cit 
and subsequent NET formation. This study investigates the contribution of NETs in the 
pathogenesis of experimental anti-myeloperoxidase ANCA associated glomerulonephritis 
(MPO-ANCA GN) and the therapeutic possibility of BB-Cl amidine disrupting NET 
formation in vivo, and attenuating anti-MPO GN.
Methods: Experimental anti-MPO GN was induced in C57BL/6 mice by 
myeloperoxidase (MPO) immunisation and GN triggered using a subnephritogenic 
dose of anti-glomerular basement membrane globulin. BB-Cl-amidine treatment 
(1mg/kg/daily, n=6 or vehicle, n=7) was administered to disrupt NET formation after the 
establishment of MPO autoimmunity until termination of the experiment.
Results: NET accumulation identified by co-localisation of extracellular DNA, H3Cit, 
PAD4, and MPO, was prominent in glomeruli of untreated (vehicle) mice compared to 
BB-Cl-amidine treated mice (2.1 ± 0.4 vs 0.4 ± 0.1, P=0.004). Histological assessment 
of kidneys demonstrated prominent glomerular segmental necrosis in the untreated group 
versus a reduction in mice receiving BB-Cl-amidine (88 ± 3% vs 41 ± 3%, P=0.004). BB-
Cl-amidine significantly attenuated glomerular leukocyte infiltration; CD4 T cells (1.2 ± 0.3 
vs 0.3 ± 0.1, P=0.03), macrophages (1 ± 0.1 vs 0.4 ± 0.06, P=0.008) and neutrophils 
(3 ± 0.5 vs 1.6 ±0.3, P=0.03), compared to untreated mice. BB-Cl-amidine treated mice 
had increased numbers of CD4+FoxP3+ T regulatory cells in lymph nodes compared to the 
untreated mice (7.1 ± 0.9% vs 3.7 ± 0.3% P= 0.001).
Conclusions: PAD inhibtion with BB-Cl-amidine successfully attenuates in vivo 
formation of NET formation in experimental anti-MPO GN, reduces kidney injury, 
glomerular pathology, and supresses inflammation.
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Tolerogenic Dendritic Cells Attenuate Autoimmune Vasculitis by Inducing 
Interleukin 10-Expressing Regulatory T Cells
Stephen R. Holdsworth, A. Richard Kitching, Dragana Odobasic. Department of 
Medicine, Monash University, Clayton, VIC, Australia.
Background: Tolerogenic dendritic cells (DCs) are an attractive immunoregulatory 
tool for the treatment of inflammatory diseases, but their therapeutic efficacy has not been 
tested in autoimmune renal vasculitis. These studies sought to determine whether tolerogenic 
DCs can suppress experimental anti-myeloperoxidase (MPO)-associated vasculitis.
Methods: Tolerogenic DCs (BAY-DCs) were generated by culturing bone-marrow 
cells with an NFkB inhibitor BAY-11-7082. MPO-pulsed BAY-DCs or vehicle were 
administered to mice with established anti-MPO or anti-methylated bovine serum albumin 
(mBSA) immunity, after which immune responses and vasculitis were assessed. BAY-DCs 
were also transferred to DREG mice (expressing diphtheria toxin [DT] receptor under the 
Foxp3 promotor) in which foxp3+ regulatory T cells (Tregs) were depleted using DT. BAY-
DC-induced Tregs or vehicle were administered, with or without a neutralizing anti-IL-10 
receptor antibody, to mice with established anti-MPO immunity, and immune responses 
and vasculitis assessed.
Results: MPO-pulsed BAY-DCs attenuated established anti-MPO T cell autoimmunity 
(proliferation, IL-17A/IFNg production) and, after glomerulonephritis was triggered by anti-
basement membrane globulin, vasculitis (glomerular injury and leukocyte accumulation), 
in association with an induction of IL-10-producing Tregs in lymph nodes. MPO-pulsed 
BAY-DCs did not affect immune responses against mBSA. They also failed to inhibit anti-
MPO responses in Treg-depleted DREG mice, showing that Tregs are required for BAY-
DC-mediated effects on MPO-specific immunity. Furthermore, Treg transfer/IL-10 receptor 
blocking experiments showed that BAY-DC-induced Tregs suppressed established anti-
MPO immunity and glomerulonephritis via IL-10.
Conclusions: Tolerogenic BAY-DCs attenuate established anti-MPO autoimmunity 
and consequently vasculitis in an antigen-specific manner by inducing IL-10-expressing 
Tregs. This suggests that tolerogenic DCs may represent a novel therapeutic option for the 
treatment of autoimmune renal vasculitis.
Funding: Government Support - Non-U.S.
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Targeting CD103+ Dendritic Cells Using Flt3 Inhibitors for Treatment of 
Kidney Disease: Relevance to Human Kidney Disease
David C. Harris,4,1 Titi Chen,1,2 Qi Cao,5 Padmashree Rao,8,2 Natasha M. Rogers,10,2 
Guoping Zheng,6 Vincent W. Lee,3,2 Hong Yu,7 Yiping Wang.9 1The Westmead 
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5Centre for Transplant and Renal Research, Westmead Millennium Institute, 
University of Sydney, Westmead, NSW, Australia; 6The University of Sydney, 
Westmead, NSW, Australia; 7Westmead Institute for Medical Research Australia, 
Hornsby, NSW, Australia; 8Westmead Millenium Institute for Medical Research, 
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Westmead Millennium Institute, The University of Sydney, Westmead, NSW, 
Australia; 10Westmead Institute for Medical Research, Westmead, NSW, 
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Background: Whereas CD103+ dendritic cells (DCs) were previously considered to 
be a minor DC subset in kidney disease. we and others have proven that they have a major 
role. Flt3 is a receptor specifically expressed on tissue CD103+ DCs. Flt 3 inhibitors are 
currently used for cancer treatment. In this study, our aims are 1. To examine CD141+ DCs 
(human homologue of mice CD103+ DCs) in human kidney diseases. 2. To explore the role 
of CD103+ DCs and therapeutic potential of targeting CD103+ DCs by repurposing Flt3 
inhibitors in experimental kidney diseases.
Methods: For a human study, we included 294 patients who underwent kidney 
biopsies from 01/07/2016 to 01/04/2017. For animal experiments, we are using Adriamycin 
Nephropathy (AN), anti-GBM disease and ischemia reperfusion injury (IRI).
Results: In humans, the number and proportion of CD141+ DCs were significantly 
increased in proliferative glomerulonephritis and acute tubular necrosis (ATN). CD141+ 
DCs were found mainly in tubulointerstitium, except in lupus nephritis where they were 
also present in glomeruli. CD141+ DC numbers correlated with increasing severity of 
ATN (P<0.001) as well as increasing severity of fibrosis in IgA nephropathy (P=0.025), 
but not in diabetic nephropathy. In murine AN, anti-GBM disease and IRI, the number 
and proportion of kidney CD103+ DCs were significantly increased. In AN, CD103+ DCs 
played a pathogenic role through activation of CD8+ T cells. Treatment with a Flt3 inhibitor 
specifically depleted CD103+ DCs and significantly reduced renal injury. The effect of Flt3 
inhibition is currently being studied in anti-GBM disease and IRI.
Conclusions: Kidney CD103+ DC numbers correlate with severity of human kidney 
disease. In experimental kidney disease, CD103+ DCs play a pathogenic role through 
activation of CD8+ T cells. Targeting CD103+DCs with Flt3 inhibitors effectively reduces 
renal injury, suggesting a novel therapeutic strategy with accelerated translational potential 
through drug repurposing.
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Epigenetic Changes in Dendritic Cells in Patients with Systemic Lupus 
Erythematosus (SLE) with Renal Involvement
Alicja Debska-Slizien,1 Michal Komorniczak,1 Anna Wardowska,2 
Barbara Bullo-Piontecka,1 Piotr Trzonkowski.2 1Clinic and Department of 
Nephrology, Transplantology and Internal Diseases, Medical University of 
Gdansk, Gdansk, Poland; 2Department of Clinical Immunology and 
Transplantology, Medical University of Gdansk, Gdansk, Poland.
Background: SLE is a systemic autoimmune disease that affects the kidneys in about 
50% of patients. The pathogenesis of lupus is still unclear and requires further research. 
There is a mounting evidence that changes in the dendritic cell (DC) function is associated 
with SLE development.
Methods: 51 patients with lupus nephritis were enrolled to the project. The study group 
(SG) consisted of 9 men and 42 women, the average age was 44.05 (range: 21-69) years. 
The control group (CG) consisted of 22 people with no history of autoimmune diseases 
(5 male and 17 female) with average age 35 (range: 22-60) years. Each participant of the 
study was cytometrically examined for DCs subpopulations (mDC - myeloid DC, pDC - 
plasmacytoid DC), including DC activity assessed. The global DNA methylation, histone 
H3 methylation was estimated. Cytokine profile analysis of both groups was performed 
with Luminex platform.
Results: In the SG as compare to CG, the percentage of DCs (HLA-DR+ Lin2-
) was significantly lower (p=0.0259) and it was accompanied by a significant decrease 
in the CD123+ pDCs subpopulation (p=0.006). There were no statistical differences 
between the SG and CG in the mDCs (CD11c+) subpopulations (p=0.133). However, in 
the mDCs subpopulation a significant increase in the expression of activation markers 
was found in SG (for CD80+ p=0.002). The study of epigenetic changes in DCs did not 
show significant differences in the global DNA methylation between groups. However, a 
statistically significant decrease in methylation histone H3K27me3 in mDCs was found in 
CG (p=0.0005), which suggests increasing transcriptional activity of DCs in this group. 
The strongest increase in activity was present in INF-inducible genes such as IRF8 (pDC 
p=0.0002; mDC p=0.037). In both subpopulations of DCs, the second strongly activated 
gene in patients with SLE was the TNF gene (pDC p=0.0049; mDC p=0.0198). Changes 
in gene activity translate directly into the cytokine profile. The level of proinflammatory 
cytokines was statistically higher in SG: TNFα (p=0.0007), IL8 (p=0.0029).
Conclusions: DCs are vital factors in the pathogenesis of SLE. Epigenetic and 
transcriptomic studies of DCs and analysis of serum proteins have demonstrated their 
significant role in the genetic modification of the autoimmune process.
Funding: Government Support - Non-U.S.
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Transcriptomic and Proteomic Profiling Identifies Patients with Elevated 
Inflammatory and Immune Signaling in Nephrotic Syndrome
Sean Eddy,1 Habib Hamidi,1 Laura H. Mariani,1 John R. Hartman,1 
Heather N. Reich,2 Richard A. Lafayette,3 Matthias Kretzler.1 NEPTUNE 
Consortium 1University of Michigan, Ann Arbor, MI; 2Toronto General Hospital, 
Toronto, ON, Canada; 3Stanford University, Stanford, CA.
Background: Despite the high cost associated with renal disease, the reliability and 
availability of information to guide patient care using a precision medicine approach prior 
to reaching end-stage is relatively sparse. To address this, patient specific profiles were 
generated for major signaling pathways to understand the diversity of patient level signaling 
in a nephrotic syndrome cohort.
Methods: Transcriptomic profiles were generated from isolated glomeruli (glom) and 
tubulointerstitium (TI) samples from subjects with nephrotic syndrome in the NEPTUNE 
cohort. Patient-specific transcriptional profiles were generated from a curated set of genes 
for activated TNF, JAK-STAT, and major immune cell types. Patient-specific profiles 
were correlated with urine biomarker profiles generated from a panel of 54 markers to 
identify relevant surrogate markers. NMF clustering was used to identify disease-relevant 
molecular subtypes. Patient-specific profiles and clustering approaches were utilized in a 
blinded retrospective analysis to evaluate the use of high dimensional data to predict patient 
outcomes and help guide treatment decisions.
Results: Across the cohort, TNF and JAK-STAT pathway activation profiles in the 
tubulointerstitium were both positively correlated with IFTA (p<0.001). In select cases, 
profiles were identified with high pathway activation with little to no IFTA. MCP-1 and 
TIMP1 were identified as biomarkers for TNF activation with a C-statistic of 0.86. Urine 
IP-10 was correlated with intrarenal JAK-STAT activation (p<0.001), and together with 
immune cell signatures were predictive of intrarenal inflammation and immune activation. 
NMF clustering of glom and TI profiles from subjects each revealed four patient clusters that 
were associated with outcome; the poorest prognosis cluster was enriched for inflammatory 
and innate immunity pathways. In individual cases, profiling results were qualitatively 
consistent with pathology descriptors.
Conclusions: Patient-specific transcriptional and urine biomarker profiles were 
identified that can indicate degree of intrarenal signaling and damage, and by combing data 
from other domains, can be used to identify patients that may be best suited for targeted 
therapy approaches and/or pharmacodynamic patient monitoring in clinical settings.
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Molecular Profiling of Serial Kidney Biopsies to Identify Markers That 
Predict Long Term Outcomes in Lupus Nephritis
Samir V. Parikh,2 Ana Malvar,1 Huijuan Song,2 John P. Shapiro,2 
Valeria G. Alberton,1 Bruno J. Lococo,1 Isabelle Ayoub,2 Anjali A. Satoskar,2 
Paolo Fadda,2 Jianying Zhang,2 Lianbo Yu,2 Brad H. Rovin.2 1Hospital 
Fernandez, Buenos Aires, Argentina; 2Ohio State University Wexner Medical 
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Background: Proliferative lupus nephritis (LN) is treated with induction therapy 
followed by prolonged maintenance therapy for several years. The intra-renal molecular 
changes that occur during this treatment period is unknown. Here we present results of 
molecular profiling of the LN glomeruli using protocol kidney biopsies to identify markers 
of long term response.
Methods: A protocol kidney biopsy was done at flare (Bx1), after induction therapy 
(Bx2) and after 3 years of maintenance therapy (Bx3) in 9 LN patients. Controls were living 
donor transplant biopsies (n=6). Glomeruli were laser dissected and RNA was extracted 
and analyzed by nanostring. Transcript expression from LN glomeruli was compared to 
controls, and complete responders (CR, n=5) were compared to non-responders (NR, n=4). 
Response was determined by proteinuria level and renal function at Bx3. All patients were 
treated with standard induction and maintenance therapy for LN.
Results: There were 110 differentially expressed glomerular transcripts between 
NR and CR. Pathway analysis revealed upregulation of several T cell pathways in NR 
compared to CR including Th1, Th2, NFAT, ICOS-ICOSL, CD28 and PKC signaling in T 
lymphocytes. Additionally, toll-like receptor, trem1, complement, and interferon signaling 
were upregulated in NR. The expression of 8 glomerular transcripts significantly increased 
in NR and decreased in CR from Bx1 to Bx3. This included HLA-DQA1 (FC:3.9 P: 0.03), 
LAIR1 (FC:4.2, P:0.004), GBP1 (FC:2.7, P:0.001), CCR1 (FC: 3.4 P:0.04), JAK1 (FC:2.0, 
P:0.02), C1R (FC:2.5, P:0.01), CTSC (FC:2.6, P:0.04), and C1QA (FC:4.2, P:0.01).
Conclusions: Transcript expression from serial kidney biopsies in LN after prolonged 
maintenance therapy predicts T cell activation and persistent inflammation in NR compared 
to CR glomeruli. These pathways could be specifically targeted to improve response in 
NR. Several glomerular transcripts were identified to predict response in this cohort. These 
transcripts should be studied further to determine their utility as predictive markers of long-
term outcomes in LN.
Funding: NIDDK Support, Other NIH Support - CCTS SPARC Grant
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Glomerular Diseases: Spotlighting Immunology and Inflammation - II
The Influence of Microbiome Composition on the Development and 
Progression of IgA Nephropathy
Farid M. Nakhoul,1,2 Farber Evgeny,1 Omri Koren,4 Younes Bathish,7 
Anaam Hnut,3 Ido Zellner,6 Sophia Tehawkho,8 Inbal Dahan.5 1Nephrology 
%Hypertension, Baruch Padeh Poriya Medical Ctr., Lower Galilee, Israel; 
2Azieli Faculty of Medicine, Bar-Ilan, Israel; 3Nephrology %Hypertension, 
Baruch Padeh Poriya Med Ctr, Lower Galilee, Israel; 4F, Azrieli Faculty of 
Medicine, Tzfat, Israel; 5Diabetes %Metabolism Lab, Lower Galilee, Israel; 
6Azrieli Faculty of Medicine, Tzfat, Israel; 7Nephrology Division, Ezfat, Israel; 
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Background: IgA Nephropathy (IgAN) is an auto-immune dis., characterized by 
abnormal deposition of IgA1 antibody with aberrant O-glycosylation in the glomerular 
mesangium, resulting in local inflammation. Aberrantly glycosylated IgA1 may be 
synthesized in response to a mucosal infection and may include deregulated innate immune 
responses. IgAN usually characterized with variability in its manifestation between different 
patients. The human microbiome is involved in normal host physiology & several metabolic 
diseases. It was shown that IgAN patients had an altered fecal microbiota, but the exact 
relationship between microbiome composition and IgAN is still understood.
Methods: Stool sample from 26 IgAN patients and 26 healthy control individuals 
subjected to microbiome array and to taxonomic analysis, to characterize their microbiome 
compositions. Creatinine, albumin and urine proteinuria levels are used for evaluate the 
renal function of each IgAN patient. The clinical and laboratory evaluations will be crossed 
with the taxonomic data using statistical analysis.
Results: Preliminary result with 11 IgAN patients and 11 healthy controls, there are 
significant differences in the microbiome composition between the two groups. IgAN 
patients have a significant increase in the Bacteroides phylum accompanied with a significant 
decrease in the amount of both the Actinobacteria and Verrucomicrobia phyla, compared 
with the healthy individuals (Fig.1). At the genus level, there is a significant increase in the 
Prevotella bacteria in the IgAN subjects compared with the healthy individuals.
Conclusions: 1. A strong association between specific bacteria population and IgAN 
2. To isolate specific population of bacteria that leads to IgAN or even aggravate its 
manifestation. 3. Develop disease-specific therapies based on microbiome modulations 
and manipulations by modifying the gut microbiota through diet, antibiotic Tx, probiotic
interventions, fecal transplants.
SA-OR047 Oral Abstract Saturday
Glomerular Diseases: Spotlighting Immunology and Inflammation - II
Molecular Phenotype of Lupus Nephritis Histological Lesions
Salem Almaani,1 Stephenie Prokopec,4 Carmen Avila-Casado,6 Joan Wither,3 
James W. Scholey,5 Heather N. Reich.2 1The Ohio State University, Columbus, 
OH; 2Toronto General Hospital, Toronto, ON, Canada; 3University Health 
Network, Toronto, ON, Canada; 4Ontario Institute for Cancer Research, 
Toronto, ON, Canada; 5University of Toronto, Toronto, ON, Canada; 6University 
Health Network, University of Toronto, Toronto, ON, Canada.
Background: The current classification of lupus nephritis (LN) solely relies on 
histological features and does not incorporate any information about molecular changes 
that characterize pathologic features. Inclusion of molecular phenotype in histologic scoring 
may provide insights into disease pathogenesis, prognosis, and aid in surveillance. As a 
first step towards achieving a more comprehensive molecular-histopathological description 
of kidney tissue in LN, we evaluated the transcriptional changes associated with various 
histologic phenotypes in LN.
Methods: 54 kidney biopsies from 53 sequential patients were dissected and separated 
into glomerular and interstitial compartments. RNA was extracted and amplified. cDNA 
was hybridized to affymetrix Genechips, processed and data normalized. Descriptive 
statistics were used for patient demographics. Differential mRNA expression was evaluated 
according to the presence or absence of the histologic lesion of interest using Wilcoxon 
Rank Sum test, then using Spearman’s Rank Correlation, mRNA expression levels were 
correlated with lesion severity (on a semiquantitative scale). Pathway analysis of significant 
transcripts was later performed. A subset of transcripts were validated in an indepndent 
population.
Results: Histological lesions in LN demonstrated different patterns of expression. The 
most notable glomerular transcripts reflecting disease activity were osteopontin (OPN) and 
fibronectin (FN1), which correlated with cellular proliferation, and galectin 3 (LGALS3) 
which correlated with cellular crescents. On the other hand, interstitial podocin, TLR4, 
and ITGA1 expression were associated with interstitial fibrosis, and glomerular expression 
of NEAT1 and CYTIP were associated with glomerular sclerosis. Interestingly, cluster 
analysis demonstrated clear separation based on tissue type (glomerular vs interstitial), and 
not by ISN/RPS class or NIH activity and chronicity indices. OPN, FN1, and LGALS3 
correlated with proteinuria in the validation cohort.
Conclusions: Histological lesions of LN demonstrate different patterns of expression 
that do not reflect distinct immunological/inflammatory processes. Some of the identified 
gene transcripts (OPN, FN1, LGALS3) deserve further evaluation as biomarkers of LN 
activity, as they correlated with histological activity and proteinuria in two independent 
cohorts.
SA-OR048 Oral Abstract Saturday
Hypertension and CVD: Epidemiology and Outcomes
Genomic Characterization of Monogenic Hypertension in a Multiethnic 
Cohort
Kipp W. Johnson, Steven G. Coca, Ron Do, Girish N. Nadkarni. Icahn School of 
Medicine at Mount Sinai, New York, NY.
Background: Hypertension is a major risk factor for adverse outcomes, but secondary 
hypertension may not be not appropriately diagnosed. We sought to ascertain prevalence of 
monogenic hypertension mutations, and their associations with blood pressure and clinical 
outcomes.
Methods: In 10,782 individuals of predominantly African (n=4,502) or Hispanic/
Latino (n=4,621) ancestry, we examined Clinvar mutations pathogenic for secondary 
hypertension with systolic, diastolic, and mean arterial blood pressures; hypertension-
associated composite clinical outcome; acute systolic blood pressure elevation rates, and 
appropriate diagnosis.
Results: 536 individuals (4.9%) possessed pathogenic mutations. Individuals with 
pathogenic mutations had 11% increased risk for adverse outcomes (95% CI 1.01-1.20) 
and had elevated mean arterial (2±0.36 mmHg; p<0.01), systolic (3.22±0.55 mmHg, 
p<0.001), and diastolic (1.19±0.34) blood pressures. Individuals with a pheochromocytoma 
and paraganglioma-associated mutation had 2.5-fold higher rates (95% CI 1.8-3.4) for acute 
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SBP elevations above 200 mmHg. Only 4.5% of individuals with pathogenic mutation 
had appropriate diagnoses of secondary hypertension and 5.4% received appropriate 
biochemical evaluations. The majority were diagnosed with essential hypertension (65.9%). 
(Figure 1)
Conclusions: Pathogenic mutations were more frequent in Hispanic Americans. 
Individuals with pathogenic monogenic mutations for secondary hypertension have higher 
blood pressures, increased rates of acute blood pressure elevation, and elevated risk for 
adverse clinical outcomes. The majority of individuals with pathogenic mutations were not 
appropriately evaluated or diagnosed. These results suggest a need for diversity in the study 
of rare genetic diseases, and that a genotypic approach for diagnosis of hypertension may 
be beneficial.
Funding: NIDDK Support
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Hypertension and CVD: Epidemiology and Outcomes
The New 2017 ACC/AHA Guideline for High Blood Pressure in Adults: 
How It Impacts Mexican Population and Healthcare System? An Analysis 
of the SALMEX Cohort
Armando Jezael Martinez-Rueda,1 Antonio Olivas-Martínez,1 Jorge I. Fonseca-
Correa,2 Olynka Vega,2 Ricardo Correa-Rotter.2 1Department of Internal 
Medicine, National Medical Science and Nutrition Institute Salvador Zubirán, 
Mexico City, Mexico; 2Department of Nephrology and Mineral Metabolism, 
National Medical Science and Nutrition Institute Salvador Zubirán, Mexico 
City, Mexico.
Background: The new 2017 ACC/AHA High Blood Pressure Guidelines for Adults 
lower the threshold to define hypertension (HT). The impact of these new definitions on 
populations and health systems is poorly understood.
Methods: SALMEX was a cross-sectional study to evaluate Na+ and K+ intake as well 
as chronic non-communicable diseases prevalence in adults. Participants were recruited 
from 2010 to 2012. We included data from all subjects aged 20-64 yrs (n=990). HT 
prevalence and pharmacological treatment (TX) requirement were determined according to 
both: JNC 7 and 2017 ACC/AHA. Data was extrapolated to sex- and age-adjusted Mexico 
City’s (CDMX) population and annual costs of medical follow-up was calculated. The 
need for pharmacologic TX was assessed with the Atherosclerotic Cardiovascular Disease 
(ASCVD) score, and compared to Framingham scores (lipids and BMI).
Results: HT prevalence in the SALMEX cohort increased from 16.2% to 37.4% 
(18% to 39.3% adjusted to CDMX population). The proportion of subjects requiring 
pharmacological and non-pharmacological TX increased from 17.7% to 19.0% and from 
17.7% to 37.4%, respectively (19.4% to 21.8% for pharmacological and 19.4% to 39.3% 
for non-pharmacological TX, adjusted to CDMX population). Medical follow-up annual 
costs for hypertensive subjects in CDMX would increase an estimated $59,278,928 USD. 
The indication to initiate pharmacological TX was similar when assessed by Framingham 
risk score with serum lipids values or with BMI, as compared to the ASCVD score, with 
correlation kappa indexes of 0.981 and 0.972 respectively.
Conclusions: The adoption of the new HT guidelines in Mexican population not 
only has implications on its prevalence but also on medical follow-up costs. Further 
pharmacoeconomic analysis is required to evaluate the potential impact of this new HT 
definition. Framingham BMI score represents the most cost-effective alternative to assess 
cardiovascular risk at diagnosis.
Funding: Commercial Support - Danone Institute, Mexico
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Hypertension and CVD: Epidemiology and Outcomes
The DASH Diet and Blood Pressure among Black Americans with and 
without CKD: The Jackson Heart Study
Crystal C. Tyson,1 Clemontina A. Davenport,1 Pao-Hwa Lin,1 Julia J. Scialla,1 
Rasheeda K. Hall,1 Clarissa J. Diamantidis,1 Joseph Lunyera,1 
Nrupen A. Bhavsar,1 Casey Rebholz,2 Jane F. Pendergast,1 L. Ebony Boulware,1 
Laura P. Svetkey.1 1Duke University Medical Center, Durham, NC; 2Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD.
Background: Hypertension control rates are low among Black Americans, particularly 
among Blacks with CKD. CKD raises blood pressure (BP) through complex mechanisms. 
Therefore, therapies may have a different effect on BP for those with and without CKD. 
The DASH diet lowers BP in adults without CKD but its effect in CKD is not clear. Our 
preliminary data showed that markers of kidney dysfunction are associated with better BP 
response to the DASH diet. We tested the hypothesis that greater DASH diet accordance has 
a stronger association with lower BP among Blacks with CKD compared to those without 
CKD.
Methods: This cohort study of Jackson Heart Study participants involved 3135 Black 
adults enrolled between 2000 and 2004 (Exam 1) with data on office BP and habitual 
diet from food frequency questionnaires. We examined the cross-sectional relation of a 
modified-DASH diet score (excluding sodium intake; range 0-8) to SBP and DBP using 
linear models adjusting for demographic, behavioral, and clinical factors. We tested for 
interaction between the DASH score and CKD status (defined as eGFR <60 ml/min/1.73 m2 
and/or urine albumin-to-creatinine ratio ≥30 mg/g).
Results: Mean age was 55 years, 60% had hypertension, and 19% had CKD. Overall, 
the median DASH score was 1.0 (interquartile range [IQR]: 0.5-2.0), which was similar 
among participants with and without CKD (1.0 [IQR: 0.5-2] and 1.0 [IQR: 0.5-1.5], 
respectively). Among those without CKD, the DASH score was not associated with SBP 
(-0.4 [95% confidence interval: -1.0, 0.1] mmHg) or DBP (-0.1 [-0.4, 0.2] mmHg). Among 
those with CKD, a higher DASH score by one point was associated with lower SBP (-1.6 
[-2.6, -0.5] mmHg) and DBP (-0.9 [-1.5, -0.3] mmHg; Figure).
Conclusions: CKD status modified the relation of the DASH score to SBP and 
DBP. Despite poor diet quality overall, greater DASH diet accordance was more strongly 
associated with lower BP among Blacks with CKD compared to those without CKD.
Funding: Other NIH Support - NHLBI, NIMHD
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Hypertension and CVD: Epidemiology and Outcomes
Long-Term Kidney Effects of Intensive (INT) SBP Lowering in Persons 
with Type 2 Diabetes Mellitus (T2DM): ACCORD BP and ACCORDION
Srinivasan Beddhu,1 Robert E. Boucher,1 Guo Wei,1 Alfred K. Cheung,1 
Glenn M. Chertow,2 Walter T. Ambrosius,3 William C. Cushman,4 
Paul K. Whelton,5 Tom Greene.1 1University of Utah, Salt Lake City, UT; 
2Stanford University School of Medicine, Palo Alto, CA; 3Wake Forest School of 
Medicine, Winston-Salem, NC; 4Memphis VA Medical Center, Memphis, TN; 
5Tulane University School of Public Health and Tropical Medicine, New 
Orleans, LA.
Background: We recently reported that INT SBP lowering increased the risk of incident 
CKD in T2DM. It is unclear whether this risk persists long-term after discontinuation of 
INT SBP control.
Methods: ACCORD BP tested the effects of SBP goal < 120 vs. < 140 mm Hg on 
CV outcomes in T2DM. ACCORDION was a long-term, post-trial, off-intervention, cohort 
follow-up of ACCORD participants. We examined the long-term trajectories of SBP and 
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eGFR using mixed models. In separate Cox regression models, we related the intervention 
to incident CKD (defined as a >30% decrease in eGFR to a value <60 ml/min/1.73 m2) in 
participants without CKD at baseline (N = 4305) and to a composite of 50% decline in 
eGFR or incident stage IV CKD (<30 ml/min/1.73 m2) in all participants (N = 4733).
Results: SBP and eGFR trajectories are depicted in Fig 1. Mean differences in SBP and 
eGFR between the treatment arms are also summarized in Fig 1. INT SBP lowering resulted 
in increased risk of incident CKD in ACCORD BP which attenuated after the intervention 
was discontinued during ACCORDION (Fig 2), interaction p = 0.02; the pattern was similar 
for 50% decline/ stage IV CKD but the interaction p value (0.24) was not significant.
Conclusions: In persons with T2DM, INT SBP lowering resulted in a decline in eGFR 
and higher risk of kidney events which appeared to attenuate after discontinuation of the 
intervention.
Funding: NIDDK Support
SBP and eGFR trajectories
Hazard ratios for kidney events with INT SBP lowering in ACCORD BP and ACCORDION 
follow-up
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Hypertension and CVD: Epidemiology and Outcomes
The Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury 
in a Subgroup of Participants in the ACCORD Trial
Girish N. Nadkarni,1 Kinsuk Chauhan,1 Joachim H. Ix,2 Michael Shlipak,3 
Chirag R. Parikh,4 Steven G. Coca.1 1Icahn School of Medicine at Mount Sinai, 
New York, NY; 2UCSD, San Diego, CA; 3San Francisco VA Medical Center, San 
Francisco, CA; 4Yale University and VAMC, New Haven, CT.
Background: Randomization to the intensive (SBP<120 mm Hg) arm in the ACCORD-
BP trial resulted in more rapid decline in estimated glomerular filtration rate (eGFR) than in 
the standard arm (SBP <140 mm Hg). Whether this change reflects hemodynamic effects or 
accelerated intrinsic kidney damage is unknown.
Methods: Longitudinal sub-group analysis of 529 participants in the ACCORD-
Blood Pressure clinical trial. We measured urine biomarkers of tubule injury (kidney 
injury molecule-1 [KIM-1], interleukin-18 [IL-18]), repair (YKL-40) and inflammation 
(monocyte chemoattractant protein [MCP-1]) at baseline and year 2. We compared changes 
between arms using ANCOVA.
Results: Of the 529 participants, 260 were randomized to intensive and 269 to standard 
blood pressure arm. Mean age was 62 ± 6.5 and eGFR 90 ml/min/1.73m2. Baseline clinical 
characteristics, eGFR, urinary albumin-to-creatinine ratio (ACR), and all 4 biomarkers were 
similar between arms. Compared to the standard arm, eGFR was 9.2 ml/min/1.73m2 lower 
in the intensive arm at year 2. Despite the reduction in eGFR, ACR was 30% lower in the 
intensive arm and 4 urinary biomarkers were unchanged or lower at year 2 in the intensive 
arm (Figure). Moreover, participants in the intensive arm with the largest declines in eGFR 
had greater reductions in urine IL-18 and YKL-40. In a subgroup analysis stratified by 
incident CKD development (sustained 30% decline and eGFR < 60 ml/min/1.73 m2, n=77), 
ACR and 4 biomarkers were flat to decreased in the intensive arm, whereas the urinary 
biomarkers were unchanged or increased in those that developed CKD in standard arm.
Conclusions: Among a subgrop from the ACCORD trial, randomization to intensive 
BP control reduced eGFR but did not increase injury markers. These findings support the 
hypothesis that eGFR decline in intensive BP arm of ACCORD predominantly reflect 
hemodynamic alterations.
Funding: NIDDK Support
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Modification of Effect of Intensive Blood Pressure Lowering on Cardio-
vascular (CV) Outcomes by Baseline eGFR in the Secondary Prevention 
of Small Subcortical Strokes (SPS3) Trial
Adhish Agarwal, Man Li, Jianing Ma, Alfred K. Cheung. University of Utah, 
Salt Lake City, UT.
Background: The SPRINT trial reported CV benefits of intensive (INT) systolic blood 
pressure (SBP) target of <120 mm Hg vs. <140 mm Hg in patients with and without CKD. 
However, SPRINT excluded patients with a history of stroke. The SPS3 trial examined 
the CV effects of INT SBP control in patients with previous stroke and found a non-
significant reduction in all (recurrent) stroke (hazard ratio [HR] 0.81, 95% CI 0.64-1.03) 
and the CV composite outcome of myocardial infarction (MI) or vascular death (HR 0.84, 
95% CI 0.68-1.04). We conducted a post hoc analysis of the SPS3 trial to examine whether 
baseline eGFR modified the effects of INT SBP control on CV events in patients with a 
history of stroke.
Methods: 3,020 patients with recent MRI-defined symptomatic lacunar infarctions 
were randomized to a SBP target of <130 mm Hg vs. 130-149 mm Hg. Among 3,017 
patients with valid baseline eGFR measurements, we evaluated the effects of INT SBP 
control on the risk of recurrent stroke and CV composite outcome (stroke, acute MI or 
death) during the 3.7 years of mean follow-up in two strata defined by baseline eGFR 
(<60 or ≥60 ml/min/1.73m2) using Cox proportional models. We also tested the interaction 
between treatment group and baseline eGFR.
Results: Non-significant rate reduction by INT SBP control was seen for all 
(recurrent) stroke and the composite outcome in both eGFR strata. In the eGFR 
<60 ml/min/1.73m2 subgroup (N=303, mean eGFR 51.22 ml/min/1.73m2), the HR was 0.84 
(95% CI, 0.46-1.56) for all stroke, and 0.92 (95% CI, 0.58-1.44) for the CV composite 
outcome. In the eGFR ≥60 ml/min/1.73m2 subgroup (N=2714, mean eGFR 90.08 ml/
min/1.73m2), the HR was 0.83 (95%, 0.64-1.07) for all stroke, and 0.90 (95%, 0.74-1.09) 
for the CV composite outcome. Baseline eGFR did not significantly modify the effect 
of INT SBP control on either all stroke (Pinteraction=0.74) or the CV composite outcome 
(Pinteraction=0.45).
Conclusions: Baseline eGFR did not modify the effects of INT SBP lowering on CV 
events among patients with previous stroke. Studies with adequate statistical power in 
patients with a wide range of kidney functions are needed to provide conclusive evidence 
of SBP targets in CKD.
SA-OR054 Oral Abstract Saturday
Hypertension and CVD: Epidemiology and Outcomes
Influence of Intensive Glycemia Intervention on the Effects of Intensive 
Systolic Blood Pressure (SBP) Lowering in Type 2 Diabetes Mellitus: 
Reconciling Results from ACCORD BP and SPRINT
Srinivasan Beddhu,1 Tom Greene,1 Alfred K. Cheung,1 Glenn M. Chertow,2 
Holly J. Kramer,3 Paul L. Kimmel,4 Robert E. Boucher,1 Lawrence J. Fine,5 
Guo Wei,1 Chong Zhang,1 Mahboob Rahman,6 Suzanne Oparil,7 
Walter T. Ambrosius,8 Adam Bress,1 Jeffrey A. Cutler,5 Paul K. Whelton,9 
William C. Cushman.10 1University of Utah School of Medicine, Salt Lake City, 
UT; 2Stanford University School of Medicine, Palo Alto, CA; 3Loyola University 
Medical Center, Maywood, IL; 4National Institute of Diabetes and Digestive 
Kidney Diseases (NIDDK), Bethesda, MD; 5NHLBI, Washington, DC; 6Case 
Western Reserve University, Cleveland, OH; 7University of Alabama at 
Birmingham, Birmingham, AL; 8Wake Forest School of Medicine, Winston-
Salem, NC; 9Tulane University School of Public Health and Tropical Medicine, 
New Orleans, LA; 10Memphis VA Medical Center, Memphis, TN.
Background: Intensive systolic blood pressure (SBP) lowering significantly reduced 
cardiovascular disease (CVD) events in the Systolic Blood Pressure Intervention Trial 
(SPRINT) but not in the Action to Control Cardiovascular Risk in Diabetes Blood Pressure 
trial (ACCORD BP).
Methods: SPRINT (N =9361) tested the effects of intensive (<120 mm Hg) versus 
standard (<140 mm Hg) SBP goals on CVD events and all-cause mortality. Using 2x2 
factorial design, ACCORD BP (N = 4733) tested the same SBP intervention in addition to 
an intensive versus standard glycemia intervention. We compared the effects of intensive 
SBP lowering on the composite CVD endpoint and all-cause mortality in SPRINT with its 
effects within each of the glycemia arms in ACCORD BP.
Results: As shown in the figure, intensive SBP lowering decreased the hazard of the 
composite CVD endpoint similarly in SPRINT and the ACCORD BP standard glycemia 
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arm (interaction p=0.87). However, the effect of intensive SBP lowering on the composite 
CVD endpoint in the ACCORD BP intensive glycemia arm was significantly different from 
SPRINT. Patterns were similar for all-cause mortality.
Conclusions: The effects of intensive SBP control on CVD events and all-cause 
mortality were similar in persons without diabetes and in persons with diabetes on standard 
glycemic control. An interaction between intensive SBP lowering and intensive glycemic 
control may have masked beneficial effects of intensive SBP lowering in ACCORD BP.
Funding: NIDDK Support, Other NIH Support - NHLBI, NIA, NINDS
Hazard ratios for CVD events and ACM for intensive vs. standard SBP goals in SPRINT 
and ACCORD BP glycemia arms
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Safety and Efficacy of High Dose Spironolactone in Loop Diuretic 
Resistant Acute Decompensated Heart Failure
Shweta Bansal,1 Anand Prasad,2 Sonja D. Brune,2 Chakradhar Velagapudi.1 
1University of Texas Health Science Center at San Antonio, San Antonio, TX; 
2UT Health San Antonio, San Antonio, TX.
Background: Secondary hyperaldosteronism plays a key role in pathogenesis of 
volume overload and resistance to loop diuretics. However, Athena-HF trial failed to show 
response to high dose spironolactone in ADHF subjects. We aim to evaluate the safety and 
efficacy of high dose spironolactone with patiromer exclusively in loop diuretic resistant 
ADHF subjects.
Methods: ADHF subjects admitted with one symptom and one sign of hypervolemia 
were given spironolactone 100mg daily if they lost <1lb/day despite IV furosemide>160mg/
day (at least one dose of 80mg/day) or equivalent dose of other loop diuretics or remained 
significantly dyspneic despite 48hrs after admission. The dose was up titrated to 200mg 
based on response with no change in dose of loop diuretic. Subjects received oral patiromer 
if serum potassium was >4.3mEq/L. They were followed until achievement of euvolemia 
or hospital discharge.
Results: Twenty of 48 enrolled subjects with ADHF were loop diuretic resistant. One 
subject was withdrawn due to mechanical ventilation. The mean±SD age was 61±15yr, 
60% male, and 50% Hispanics. Nine did not respond to furosemide >160 mg/day and ten 
remained symptomatic after 48hrs. Median[IQR] dose of furosemide was 160[120,230] 
mg/day a day before intervention. Mean ejection fraction was 27.9±19% and 14 subjects 
had pulmonary hypertension with mean PASP 47.3±11.5 mmHg. All 19 subjects except one 
responded to addition of spironolactone. Mean±SD weight change was -3.0±3.4lb on day1 
and -6.5±4.5lb by day2 (p<0.001, ANOVA) on spironolactone. Mean urine output increased 
from 1712±686 ml a day prior to spironolactone to 2732±1374ml on day1 and 3439±1565 
ml (p=0.002, ANOVA) on day2 on spironolactone. Eight subjects required 200mg dose. 
One subject sustained worsening renal function in setting of hypotension due to worsening 
of underlying cardiac dysfunction. None of the subjects had serum potassium >5.5mEq/d. 
Three subjects were given patiromer for protocol indication and it was well-tolerated.
Conclusions: Addition of high dose spironolactone to ADHF patients resistant to loop 
diuretic provided significant decongestion without causing hyperkalemia or worsening renal 
function. A larger randomized trial is warranted in loop diuretic resisant ADHF patients.
Funding: Commercial Support - Relypsa, Inc
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Elevated Tissue Na+ Deposition in Hemodialysis Patients with Cardiovas-
cular Disease Detected by 23Na-Magnetic Resonance Imaging
Anna-Carolina Friedrich,1 Christoph Kopp,1 Peter Linz,2 Armin M. Nagel,2 
Jens Titze,3,1 Anke Dahlmann.1 1Dept. of Nephrology and Hypertension, 
Erlangen, Germany; 2University Hospital Erlangen, Friedrich-Alexander-
Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; 3Duke - National 
University of Singapore, Singapore, Singapore.
Background: Disturbances in Na+ homeostasis with accumulation of Na+ in tissues are 
present in salt sensitive hypertension and correlate with left ventricular hypertrophy. Tissue 
Na+ distribution could be recently visualized in vivo by 23Na-magnetic resonance imaging 
(23Na-MRI). We used 23Na-MRI to quantify Na+ in skin and muscle of hemodialysis (HD) 
patients either with or without concomitant cardiovascular disease (CVD). We hypothesized 
that tissue Na+ might accumulate to a higher extent in HD patients co-diagnosed with CVD.
Methods: We used 23Na-MRI at 3.0 Tesla to quantify Na+ content in skeletal muscle 
and skin of the left lower leg. We determined tissue Na+ content using a Na+ volume coil 
in 19 HD patients with a positive history of a CV event (MI, CABG, arrhythmia, stroke or 
PAD IV) and in 41 age-matched control HD patients. Additionally, total body water content, 
including extra- and intracellular water space, were determined using Body Composition 
Monitoring technique (BCM).
Results: Compared to control HD patients 23Na-MRI detected an increased Na+ 
content in muscle tissue (20.97 ± 3.60 vs. 24.59 ± 7.10 mmol/L, p<0.05) and skin tissue 
(21.95 ± 7.26 vs. 29.80 ± 10.91 mmol/L, p<0.05) of HD+CVD patients. Simultaneously 
measured excess extracellular water content detected by BCM was significantly higher in 
the HD+CVD group (1.17 ± 1.48 vs. 2.31 ± 1.61 liter, p<0.05). .
Conclusions: 23Na-MRI detected increased Na+ in muscle and skin tissue as well 
as higher excess extracellular water content in HD+CVD patients. Our findings provide 
evidence that the history of a cardiovascular event is associated with disturbances in tissue 
Na+ and water content in HD patients.
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Balancing eGFR Loss and Albuminuria Suppression during Intensive BP 
Control
Elaine Ku,1 Charles E. McCulloch,1 Mark J. Sarnak,3 Jennifer J. Gassman,2 Chi-
yuan Hsu.1 1University of California San Francisco, San Francisco, CA; 
2Cleveland Clinic, Cleveland, OH; 3Tufts Medical Center, Boston, MA.
Background: Intensive BP lowering often lowers GFR. This GFR decline is thought 
to be hemodynamic, benign, and potentially necessary for albuminuria (ACR) suppression. 
We hypothesized that the Kidney Failure Risk Equation (KFRE) which predicts 5-yr risk 
of ESRD (using age, sex, eGFR, ACR) could help guide the risk-benefit tradeoff between 
eGFR loss vs. ACR suppression during intensive BP lowering.
Methods: We determined the tradeoff between GFR loss and ACR suppression that 
could be theoretically tolerated during intensive BP lowering to maintain the same predicted 
5-year ESRD risk (based on the mathematical relationship of eGFR and ACR in the KFRE). 
We then determined the % of participants in African American Study of Kidney Disease 
and Modification of Diet in Renal Disease (MDRD) trials (two trials of intensive BP 
lowering) who achieved adequate ACR suppression during intervention. We confirmed that 
the KFRE predicted risk of ESRD (henceforth KFRE score) at baseline and at 6 mos (after 
intensification of BP control) both provided good risk discrimination for ESRD.
Results: To maintain the same KFRE score, substantial ACR suppression was needed 
to counter even small declines in eGFR (Table). For example, a 3 mL/min/1.73 m2 decline in 
eGFR would require 50% ACR suppression to maintain the same KFRE score. Only 21% of 
1523 trial participants had sufficient suppression of ACR that maintained or improved their 
KFRE score given the large magnitude of eGFR changes that occurred during BP lowering. 
The KFRE score discriminated risk of ESRD before and after intensive BP lowering well, 
with C-statistic of 0.85 (strict BP) and 0.87 (usual BP) at baseline, and c=0.88 for both 
treatment arms at 6 mos. Every 10% worsening of KFRE score predicted higher observed 
risk of ESRD (HR 1.93 [95% CI 1.66-2.25]) in the strict BP arm.
Conclusions: De-intensification of BP control should be considered when aggressive 
BP lowering leads to declines in eGFR without sufficiently large corresponding ACR 
suppression to maintain (or improve) the same predicted ESRD risk by the KFRE.
Funding: NIDDK Support
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Clinical Significance of Crescent Formation in IgA Nephropathy – A 
Multicenter Validation Study
Sehoon Park,1 Chung Hee Baek,2 Su-Kil Park,2 Hee Gyung Kang,3 
Hyesun Hyun,4 Eujin Park,5 Seung Hyeok Han,6 Dong-Ryeol Ryu,7 Dong 
Ki Kim,1 Kook-Hwan Oh,1 Kwon Wook Joo,1 Yon Su Kim,8 Ho Jun Chin,9 
Hajeong Lee.8 Korean Glomerular Disease Study Group 1Seoul National 
University Hospital, Jongno-gu, Seoul, Republic of Korea; 2Asan Medical 
Center, Songpa-gu, Seoul, Republic of Korea; 3Seoul National University 
Children’s Hospital, Seoul, Republic of Korea; 4St. Vincent’s Hospital, The 
Catholic University College of Medicine, Suwon, Republic of Korea; 5Hallym 
University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea; 6Yonsei 
University College of Medicine, Seoul, Republic of Korea; 7Ewha Womans 
University, Seoul, Republic of Korea; 8Seoul National University College of 
Medicine, Seoul, Republic of Korea; 9Seoul National University Bundang 
Hospital, Seong nam, Republic of Korea.
Background: Additional validation study was warranted to confirm the clinical 
significance of C score, which was recently added to the Oxford classification for 
immunoglobulin A (IgAN).
Methods: We performed a multicenter retrospective cohort study in four hospitals 
in Korea. Patients who had biopsied glomeruli less than eight or inadequate follow-up 
information were excluded. Clinicopathologic parameters, including the degree of cellular 
or fibrocellular crescents, were collected and included in multivariable model for Cox 
regression analysis. The main outcome was a composite renal outcome, defined as a merge 
of progression to end-stage renal disease (ESRD) and halving of estimated glomerular 
filtration rate (eGFR) from baseline.
Results: Among included 3,380 biopsy-confirmed IgAN patients, there were 664 
(19.6%) patients with C1 and 60 (1.8%) patients with C2 scores in the study population. 
Although C0 and C1 patients shared similar baseline characteristics, C2 patients frequently 
had more clinicopathologic risk factors for poor prognosis of IgAN. Both C1 [adjusted 
HR 1.33 (1.11-1.58), P=0.002] and C2 [adjusted HR 2.24 (1.46-3.43), P<0.001] scores 
were associated with increased risk of the composite outcome. C2 was a strong predictive 
parameter associated with both progression of ESRD and halving of eGFR, whereas C1 was 
mainly associated with the increased risk of halving of eGFR. Notably, the proportion of 
crescent showed a linear association with the risk of adverse renal outcome.
Conclusions: The C score in the Oxford classification is a valid predictive parameter 
for IgAN prognosis. Additional clinical attention is necessary for IgAN patients with 
identified cellular or fibrocellular crescents
SA-OR059 Oral Abstract Saturday
IgA Nephropathy and Lupus Nephritis
Percentage of Glomerular Crescents Predicts Renal Outcomes in Children 
with IgA Vasculitis – A Midwest Pediatric Nephrology Consortium Study
Scott E. Wenderfer,1 Michelle N. Rheault,2 David T. Selewski,3 Cheryl L. Tran,4 
Cynthia G. Pan,5 Meredith Seamon,6 Raoul D. Nelson,6 Katherine Twombley,7 
Ali Mirza Onder,8 Joseph T. Flynn,9 Joseph G. Maliakkal,10 William E. Smoyer,11 
Guillermo Hidalgo.12 1Pediatrics, Baylor College of Medicine, Houston, TX; 
2University of Minnesota, Minneapolis, MN; 3University of Michigan, Ann 
Arbor, MI; 4Mayo Clinic, Rochester, MN; 5Medical College of Wisconsin, 
Milwaukee, WI; 6The University of Utah, Salt Lake City, UT; 7Medical University 
of South Carolina, Charleston, SC; 8University of Tennessee, Memphis, TN; 
9Seattle Children’s Hospital, Seattle, WA; 10Saint Louis University School of 
Medicine, St. Louis, MO; 11Nationwide Children’s Hospital, Columbus, OH; 
12Eastern Carolina University, Greenville, NC.
Background: While crescents on kidney biopsy predict poor outcome for children with 
IgA vasculitis, evidence-based thresholds for %crescents most predictive of renal risk are 
not established. The International Study of Kidney Disease in Children (ISKDC) used 50% 
and 75% thresholds to grade severity of crescentic glomerulonephritis. MEST-C scoring 
for IgA nephropathy has also been proposed for IgA vasculitis: 1 point for any glomerular 
crescent and 2 when crescents involve >25% of glomeruli.
Methods: To test the validity of 25, 50, and 75% thresholds for crescents in IgA 
vasculitis, we identified 62 patients (13 centers) in the IRB-approved Midwest Pediatric 
Nephrology Consortium Glomerulonephritis with Crescents Registry (18% of total). 
Enrollment included patients <21 yo with >1 crescentic glomerulus on biopsy from 2004-
16. Primary outcome was end stage kidney disease (ESKD) at 1 year. Secondary outcomes 
included estimated glomerular filtration rate (eGFR) at 1 year and change in eGFR over 
time. Crescents were defined by local renal pathologist.
Results: The cohort was 47% female, 53% white, 3% black, 18% Hispanic, and 3% 
Asian. Median age at biopsy was 8 years (range 6-11) with 2.6 years median follow-up 
(IQR 1.7-4.8). A median of 36 glomeruli were sampled per biopsy (IQR 27-57). The 
median %crescents was 10.8 (IQR 7-18%, max 83%). Cellular crescents were seen in 95% 
of biopsies; fibrous crescents in 27%; both in 23%. Only 2% of children had crescents in 
>50% of glomeruli, and only one in >75% of glomeruli. One child with 13% cellular and
3% fibrous crescents advanced to ESKD at 26 months post-biopsy. Median change in eGFR 
was +2.8 mL/min/1.73m2/year (IQR -20 to +24) at 1 year and -1.5 (IQR -7 to +6) at latest 
follow-up. Change in eGFR was 2-fold greater for children with >25% crescents (-3.6) vs. 
those with <25% (-1.6).
Conclusions: Children with higher %crescents present with lower GFRs but most 
have significant recovery of eGFR at 1 year. Utility of the ISKDC thresholds for grading 
crescents in IgAV is limited, due to low prevalence of biopsies with crescents >50%. Long 
term, the 25% threshold for cellular crescents appears to predict worsening GFR decline.
SA-OR060 Oral Abstract Saturday
IgA Nephropathy and Lupus Nephritis
Relationship between Complement Activation and the Oxford Classifica-
tion Score and Their Combined Effects on Renal Outcome in Early Stage 
IgA nephropathy
Seon yeong Lee, Seohyun Park, Yooju Nam, Joohwan Kim, Ki Heon Nam, Tae-
Hyun Yoo, Seung Hyeok Han. Yonsei University College of Medicine, 
Seodaemun-gu, Seoul, Republic of Korea.
Background: Complement activation has been highlighted in the pathogenesis 
of IgA nephropathy. However, it is unknown how the complement is connected to the 
downstream phenotype of IgA nephropathy. In this study, we investigated the association 
of the mesangial C3 deposition with the Oxford classification and their joint effects on the 
prognosis of IgA nephropathy.
Methods: We included 408 patients with biopsy-proven early stage IgA nephropathy 
[T0 and estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73m2] between 2009 and 
2016 at Yonsei University Health System. C3 deposit was defined as the immunofluorescence 
intensity of C3 ≥2+ within the mesangium. The study subjects were classified according to 
the combination of C3 deposits and each lesion of the Oxford classification. The primary 
endpoint was the development of a ≥ 30% decline in eGFR during follow-up.
Results: Among the Oxford lesions, M1 (mesangial proliferation), S1 (segmental 
sclerosis), and crescent were significantly correlated with C3 deposit, whereas E1 
(endocapillary proliferation) was not. During a median follow-up of 32.5 (18.0 – 61.8) 
months, primary endpoint occurred in 32 patients (7.9%). In individual multivariable-
adjusted analyses, the presence of M1, S1, and C3 deposit was significantly associated with 
increased risk of primary outcome. In combined analyses with C3 deposit and each of the 
Oxford lesions, HRs were significantly higher in the presence of C3/M1 and C3/S1, and C3/
crescent than in the presence of each single lesion alone.
Conclusions: C3 deposition was significantly associated with the Oxford M-, S-, and 
crescent scores. In addition, risk of adverse renal outcome was consistently highest when 
C3 deposition was added to each score. These findings suggest that complement activation 
can strengthen the significance of the Oxford score and the presence of both components 
portends a poorer prognosis in IgA nephropathy.
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IgA Nephropathy and Lupus Nephritis
Relationship between IgA1 Lectin-Binding Specificities, Mesangial C4d 
Deposits, and Clinical Phenotypes in IgA Nephropathy
Luisa Martin-conde,1 Elias A. Jatem,5 Clara Carnicer,6 Maria Molina,1 
Cristina Martínez,4 Laura Colàs-Campàs,3 Alicia G. Carrasco,7 Alfonso Segarra.2 
1University Hospital Arnau de Vilanova, Lleida, Spain; 2Servicio Nefrologia 
Hospital Vall D’Hebron, Barcelona, Spain; 3IRB Lleida - University of Lleida, 
Lleida, Spain; 4Vall d’Hebron Institute of Research, Barcelona, Spain; 5Hospital 
Universitari Arnau de Vilanova, Lleida, Spain; 6Hospital Universitari Vall 
d’Hebron, Barcelona, Spain; 7Vascular and Renal Translational Research 
Group. IRB Lleida, Lleida, Spain.
Background: The reason why mesangial C4d deposits are detected in only certain 
biopsies of IgA nephropathy, remains unclear. In this study, we analyse the association 
between different patterns of IgA1 glycosilation, mesangial C4 deposition and clinical 
phenotypes, in IgA nephropathy
Methods: This cross-sectional study included 145 patients with idiopathic IgA 
nephropathy. We measured the serum levels of three different IgA1 lectin-binding 
specificities, using enzyme-linked-immunosorbent assays, and we analysed the relationship 
between these specificities, C4d mesangial deposits and clinical profiles at diagnosis.
Results: C4d-positive vs. Cd4-negative patients had higher proteinuria (median: 3.1 g/g 
[0.9-4.2] vs. 1.8 g/g [1-2.2]; p=0.000), hematuria (223 cel/μL [32-278] vs 99 cel/μL 
[25-186], p=0.000), and higher levels of IgA1 with ability to bind Helix Aspersa (HAA 
IgA1) (150.6 ± 52 U vs 96.2 ± 64.1 U, p= 0,000), Triticum vulgaris (TVIgA1) (85.1 ± 31.7 U 
vs 42.2 ± 26.9U, p= 0.000) and Canavalia ensiformis (ConAIgA1) (32.5 ± 18U vs 
16.7 ± 9.38U, p=0.000) but similar levels of total galactose-deficient IgA1 (338 ± 64 U 
vs 324 ± 43U p: 0.15). The levels of HAAIgA1, TVIgA1 and ConAIgA1 were all associated 
with the mesangial deposition of C4d, extracapillary proliferation and the presence of acute 
kidney injury. HAAIgA1, TVIgA1 and ConAIgA1 had a similar ability to discriminate 
between C4d positive ad C4d-negative biopsies (AUC: 0.72 ± 0.04, 0.83 ± 0.03 
and 0.81 ± 0.04, respectively, p=0.000 in all cases). In logistic models, TVIgA1 and 
ConAIgA1 were the only independent predictors of mesangial C4d deposits
Conclusions: In IgA nephropathy, the severity of the disease is associated with the 
level of desialylation of galactose-deficient IgA1 whereas C4d deposits are associated 
with elevated levels of IgA1 glycoforms involving aberrantly glycosilated N-linked glycan 
residues.
SA-OR062 Oral Abstract Saturday
IgA Nephropathy and Lupus Nephritis
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropa-
thy at High Risk of Progression
Ladan Zand,1 Pietro A. Canetta,4 Richard A. Lafayette,2 Nabeel Aslam,3 
Sanjeev Sethi,1 Nelson Leung,1 Fernando C. Fervenza.1 1Mayo Clinic, Rochester, 
MN; 2Stanford University, Stanford, CA; 3Mayo Clinic Florida, Jacksonville, 
FL; 4Columbia Universtiry, New York, NY.
Background: Patients with IgAN and elevated proteinuria despite renin-angiotensin 
inhibition (RASI) are at risk of progressive CKD, and therapeutic options are limited. 
ACTH has been shown to lower proteinuria in certain proteinuric kidney diseases. We 
hypothesized that it may be effective in lowering proteinuria and preserving renal function 
in patients with IgAN at high risk of progression.
Methods: We conducted a prospective open-label pilot study in patients with IgAN 
using ACTH (H.P. Acthar® Gel) at a dose of 80 units SC twice weekly for a total of 6 
months (m) and followed patients for a total of 12m. Patients had to have urinary protein 
(UP) > 1 g/24 hr despite adequate RASI & eGFR >30 ml/min at enrollment. Secondary 
IgAN & those with hepatitis were excluded. Glucocorticoids could not have been used for 
the prior 3m. Primary endpoint was defined as achieving CR (24 hr UP <300 mg & ≤10% 
reduction in eGFR) or PR (≥50% reduction in UP and ≤25% reduction in eGFR).
Results: Twenty patients were enrolled. One was removed from the study at 3m as 
he was hepatitis B positive. Another patient withdrew at 6m due to progression of IgAN 
but was included in the analysis at 12m. At baseline, the mean age was 34.5 ± 10.5 yrs 
with 11 males & 8 females, 14 Caucasian & 5 Asians. At 12m there was a statistically 
significant decline in 24hr UP from 2.8 to 1.9 g (P=0.006) and significant increase in serum 
albumin (3.79 to 3.93, P=0.02). There was no significant change in eGFR (65.5 to 61.1 ml/
min, P=0.1). There were 8 PRs (42%). There were total of 4 infections (1 pneumonia, 1 
otitis media, and 2 sinus infections) that required antibiotics. Most common adverse events 
included acne, hot flashes, and anxiety.
Conclusions: Patient with IgAN with >1 g/24 hr UP and eGFR >30ml/min had a 
significant reduction in 24hr UP with stable eGFR at 12m follow up after being treated with 
6 months of ACTH.
Funding: Commercial Support - Mallinckrodt
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SA-OR063 Oral Abstract Saturday
IgA Nephropathy and Lupus Nephritis
Using Long Term Outcome Data to Redefine Proteinuria and eGFR End 
Points for Lupus Nephritis Trials
Hannah R. Wilson,2 Tabitha Turner-Stokes,2 Iara Dasilva Santos,1,2 
Megan Griffith,2 Jeremy B. Levy,2 Tom Cairns,2 H. Terence Cook,2 
Liz Lightstone.2 1Fundacio Puigvert, Barcelona, Spain; 2Imperial College 
London, Hammersmith Hospital, London, United Kingdom.
Background: Lupus Nephritis (LN) is a common & severe manifestation of systemic 
lupus erythematosus (SLE) that can lead to renal failure (ESRF). Reviews of Euro-Lupus 
Nephritis & MAINTAIN cohorts suggest a less stringent cut off proteinuria at 1yr (<0.8g/d 
& <0.7g/d respectively) better predicted good renal outcome at 7yrs than usual complete 
remission (CR) criteria (<0.5g/d). This cut-off has yet to be validated using urinary protein 
creatinine ratio (uPCR) or in a larger real world cohort.
Methods: Data were reviewed for LN biopsies 1/1/1996 to 1/1/2016. Definition 
CR:uPCR (mg/mmol) <50 & estimated glomerular filtration rate (eGFR mls/min/1.73m2) 
≥60, or if b/l <60, no fall >20%; Partial remission (PR):uPCR <300 with ≥50% improvement 
& eGFR as CR; Non-remission (NR):no PR by 1yr. Factors predicting good outcome, 
defined as 1-46yr survival with eGFR >60, assessed by multiple logistic regression (LR) 
with correction & receiver operating characteristic (ROC) curves.
Results: 476 patients had 819 biopsies. Median age diagnosis:SLE 29yrs; LN 32yrs. 
Female:82%. Ethnicity:32% S Asian, 27% Black, 26% White& 3% SE Asian. At latest f/
up since diagnosis LN (median 9yrs(0-46): majority, 293(62%) had good outcome; ESRF: 
68(14%), median 5yrs(0-43); died: 31(7%), 7yrs(0-19). LR identified 1yr eGFR and 
uPCR as predictors of good outcome: eGFR odds ratio (OR) 2.186 (95% CI 1.529-3.126) 
p<0.001 for each rise 10; uPCR OR 0.547 (0.356-0.841) p=0.006 for increase between 
ranges (0-50,50-100,100-300,300-500,500-1000,>1000). ROC curves identified 1yr uPCR 
<68 (AUC0.70,p<0.0001,sens 67%,spec 65%) & eGFR >80.5 (AUC 0.83,p<0.0001,sens 
77%,spec 76%) predictive of good outcome. Standard CR&NR definitions fail to predict 
good outcome; in contrast, achieving uPCR & eGFR identified by ROC curves strongly 
predicted good outcome OR 5.68 (95% CI 2.367-13.635, p<0.001); OR good outcome if 
not achieved 0.42 (95% CI 0.188-0.926, p=0.032).
Conclusions: Our “real world” multi-ethnic cohort, the largest to date, support 
Eurolupus and MAINTAIN data: less stringent proteinuria thresholds (<68mg/mmol) and 
excellent renal function (>80.5ml/min/m2) at 1yr better predict long term outcome than 
current trial endpoints. As the key outcome that matters to patients, we argue it is time to 
change definitions of success of treatments in LN trials.
SA-OR064 Oral Abstract Saturday
IgA Nephropathy and Lupus Nephritis
Infectious Complications in Lupus Nephritis Treatment: A Systematic 
Review and Meta-Analysis
Kah Mean Thong,1,2 Daniel Tak Mao Chan.1 1Queen Mary Hospital, Pokfulam, 
HKSAR, China; 2Hospital Raja Permaisuri Bainun, Ipoh, Malaysia.
Background: Infection is an important concern in lupus nephritis treatment, but few 
studies have primarily focused on this complication. We investigated the incidence rate of 
infections, their associated risk factors, and outcomes reported in the literature.
Methods: Randomized controlled trials (RCTs) on lupus nephritis Class III/IV/V 
published between January 1980 and December 2016 and identified from Pubmed/
Medline were included in the meta-analysis. Infection risk associated with different 
immunosuppressive medications was presented as risk ratio (RR) with 95% confidence 
interval (CI) using the Mantel-Haenszel method.
Results: Thirty-two RCTs involving 3834 patients were included. Estimated incidence 
rates of overall and serious infections were both higher during the induction phase than 
maintenance phase. The rate of serious infections ranged from 8.2-50 per 100 patient-years 
during the induction phase, and 3.5 per 100 patient-years during maintenance phase. The 
rates of serious infections were 4.1-25% in Asia and 4.4-8.5% in non-Asian countries; 
with infection-related mortality rates of 0-6.7% in Asian, compared to 0-2.1% in non-
Asian locations. Mycophenolate mofetil as induction treatment was associated with lower 
overall infection risks than cyclophosphamide in non-Asian countries (RR, 0.60; 95% CI, 
0.48–0.75; p<0.001). Recent data (since 2011), predominantly from Asia, suggested that 
tacrolimus used as induction immunosuppression was associated with lower rates of overall 
infections compared with mycophenolate mofetil (RR, 0.50; 95% CI, 0.33–0.76; p=0.001).
Conclusions: Infection remains a serious complication in patients with lupus 
nephritis, especially in Asia, but the reported rates varied markedly. Mycophenolate 
mofetil was associated with lower infection rates in non-Asian patients, compared with 
cyclophosphamide; and further experience is required to confirm the infection risk 
associated with tacrolimus.
Funding: Private Foundation Support
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Lupus Nephritis Flare after Withdrawal of Immunosuppression Is 
Predicted by Kidney Biopsy Findings during Maintenance Therapy: A 
Prospective Observational Cohort Study
Marcelo A. De Rosa,2 Jorge E. Toblli,5 Graciela E. De Rosa,6 Federico Fuentes,3 
Haikady N. Nagaraja,4 Ryan R. Nash,4 Brad H. Rovin.1 1Ohio State University 
Wexner Medical Center, Columbus, OH; 2University of Buenos Aires, Buenos 
Aires, Argentina; 3Hospital de Clínicas, Buenos Aires, Argentina; 4The Ohio 
State University, Columbus, OH; 5Laboratory of Experimental Medicine 
Hospital Aleman, Buenos Aires, Argentina; 6Hospital de Clinicas, Buenos Aires, 
Argentina.
Background: The optimal duration of maintenance immunosuppressive therapy in 
lupus nephritis (LN) is unclear. Withdrawal of immunosuppression is generally based on 
a patient achieving a sustained clinical remission (CR). However, a significant proportion 
of patients in CR continue to have persistent histologic activity on kidney biopsy. We 
postulated that patients with ongoing histologic activity are at risk of LN flare when 
maintenance therapy is tapered, and designed a prospective observational study to test this 
hypothesis.
Methods: Patients with Class III/IV±V LN on maintenance therapy who had received 
at least 3 years of immunosuppression and were in complete CR for at least the last year of 
treatment were recruited to undergo a kidney biopsy. Maintenance therapy was withdrawan 
after the kidney biopsy and patients were followed prospectively for 2 years. The primary 
endpoint of the trial was LN flare.
Results: Out of 44 recruited patients, 36 completed the study. Patients withdrew due 
to pregnancy, non-renal lupus flare, or by choice. Biopsy showed that 20 patients (55.6%) 
had achieved complete histologic remission with an NIH activity index (AI) of 0, nine 
patients (25%) had an AI of 1 or 2, and 7 patients had an AI between 3 and 5. LN flared in 
11 patients (30.5%), all but one flare (91%) occurred in patients with persistent histologic 
activity, and everyone with an AI>2 flared. In multivariable analysis AI and duration of SLE 
were independent predictors of LN flare, and these variables could discriminate between 
future flare and no-flare with 100% sensitivity, 88% specificity, an 8.3% misclassification 
rate, and an area under the ROC curve of 0.98. Among the individual components of the AI, 
endocapillary proliferation and subendothelial deposits were both significantly associated 
with the odds of future flare, but endocapillary proliferation was a more robust marker.
Conclusions: Persistent histologic activity in kidney biopsies of LN patients in 
complete CR on maintenance immunosuppression, especially persistent endocapillary 
proliferation, is a risk factor for future LN relapse. A kidney biopsy during maintenance 
immunosuppression may help inform the decision of whether to withdraw or continue 
maintenance therapy in LN.
Funding: Government Support - Non-U.S.
SA-OR066 Oral Abstract Saturday
IgA Nephropathy and Lupus Nephritis
A Phase III Study of Abatacept on Standard of Care in Patients with 
Active Class III or IV Lupus Nephritis
Gerald B. Appel,3 Mary A. Dooley,11 David Wofsy,7 Tsutomu Takeuchi,10 
Ana Malvar,2 Andrea Doria,9 Juanita Romero-Díaz,4 Daniel Tak Mao Chan,5 
Ayanbola O. Elegbe,8 Richard Furie,6 David R. Jayne,1 Michael Maldonado.8 
1University of Cambridge, Cambridge, United Kingdom; 2Hospital Fernández, 
Buenos Aires, Argentina; 3Columbia University Medical Center, New York, NY; 
4Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico; 
5University of Hong Kong, Hong Kong, Hong Kong; 6Northwell Health, Great 
Neck, NY; 7University of California San Francisco, San Francisco, CA; 8Bristol-
Myers Squibb, Princeton, NJ; 9University of Padova, Padova, Italy; 10Keio 
University, Minato, Tokyo, Japan; 11University of North Carolina at Chapel Hill, 
Chapel Hill, NC.
Background: Novel treatments (tx) for active class III or IV lupus nephritis (LN) are 
needed. This study compared IV abatacept (ABA) vs placebo (pbo) on background therapy 
for tx of active proliferative LN.
Methods: This was a 24-month (M), randomized, Phase III, double-blind study with 
long-term extension. Patients (pts) were randomized to pbo or IV ABA every 4 wks on 
background of MMF + corticosteroids (CS). Primary endpoint: complete response (CR; 
UPCR ≤0.5, preserved eGFR, no cellular casts, CS ≤10 mg/day) at Year (Yr) 1. We report 
all blinded data up to Yr 3 of tx.
Results: 405 pts were randomized (ABA n=202; pbo n=203). At baseline: mean 
age=33 yrs, UPCR=3.78, eGFR=95 mL/min. ABA 77%, pbo 79% completed Yr 1; fewer 
discontinued during Yr 2 (ABA 14%, pbo 22%). There were no differences between tx arms 
in CR rates at Yr 1 (ABA 35.1%, pbo 33.5%, p=0.73; primary endpoint). Sustained CR 
(two successive visits) were more frequent and occurred earlier in ABA pts. CR rates were 
higher and non-response rates lower in ABA arm in Yr 2 and 3. Benefits were driven by 
improvement in proteinuria, seen as early as 3 M and sustained up to 3 yrs (Figure). There 
was no between-group difference in eGFR over 3 yrs. Safety in Yr 1 was consistent with the 
known profile of ABA (serious AE [SAE] rate ABA 24%, pbo 19%). SAE rates after Yr 1 
were lower (ABA 6%, pbo 13%). More sustained improvements in SLE-related biomarkers 
(C3, C4, anti-dsDNA) were seen in ABA-treated pts over 3 yrs.
Conclusions: The study failed to meet its primary endpoint. Up to 3 yrs of tx, abatacept-
treated pts had more rapid improvement in proteinuria, which led to earlier, sustained CR 
with a favorable safety profile. Writing assistance provided by Caudex.
Funding: Commercial Support - Bristol-Myers Squibb
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IgA Nephropathy and Lupus Nephritis
Correlation of Albuminuria and Hypoalbuminemia with Area Under the 
Curve Levels of Mycophenolic Acid in Lupus Nephritis
Negiin Pourafshar,1 Xuerong Wen,3 Rajesh Mohandas,2 Mark S. Segal.2 
1University of Virginia, Charlottesville, VA; 2University of Florida, Gainesville, 
FL; 3University of Rhode Island, Kingston, RI.
Background: Mycophenolate mofetil (MMF) is the mainstay of therapy for lupus 
nephritis (LN). Studies have shown targeting an area under the curve (AUC) leads to better 
outcomes in these patients. Therefore, it is critical to identify factors modifying AUC of 
MMF. Mycophenolic acid (MPA) the active metabolite of MMF binds avidly to albumin. 
Since patients with lupus often have profound albuminuria and hypoalbuminemia, we 
hypothesized that it might influence MPA-AUC.
Methods: 51 subjects with biopsy confirmed LN on 1500 mg of MMF twice daily, 
were included in this study. MPA levels were obtained at 0, 1, 2 and 4 hours. The MPA-
AUC values calculated using the linear trapezoidal rule. Spearman correlations were used 
for correlations between urine albumin creatinine ratio (UACR), serum albumin and MPA-
AUC.
Results: Subjects mean age was 33±13 years. The mean serum albumin was 3.3± 0.9 g/dL. 
90 % of patients had albuminuria with a median of median of 874 mcg/mg [IQR: 365, 2150]. 
In univariate analysis there was a statistically significant correlation between AUC and 
UACR (Rho=-0.34, P=0.02) and serum albumin (Rho=0.48, P=0.004) (Figure-1A and 1B). 
In multivariate analyses serum albumin remained an independent predictor of AUC when 
controlled for age and proteinuria [R2=0.21 p=0.03], but not for renal function[p=0.06]. 
Hypoalbuminuria was a predictor of AUC only for an eGFR > 60 ml/min/1.73 mt2.
Conclusions: Our results reveal that hypoalbuminemia is associated with lower 
therapeutic levels of MMF, particularly in those with normal renal function. Patients with 
hypoalbuminemia are more likely to have severe disease warranting higher doses of MMF. 
We will discuss the implications of these findings with regard to the monitoring of MMF-
AUC to ensure adequate therapeutic doses in such patients.
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SA-OR068 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
A Randomized Controlled Trial of Albumin Versus Saline for the 
Prevention of Intradialytic Hypotension in Hypoalbuminemic Patients
Etienne Macedo, Bethany E. Karl, Lea D. Jacinto, Euyhyun Lee, 
Ravindra L. Mehta. University of California San Diego Medical Center, La 
Jolla, CA.
Background: Intradialytic hypotension (IDH) is a frequent complication in 
hypoalbuminemic patients with AKI or ESRD limiting adequate fluid removal and 
increasing the risk for vascular access thrombosis, early hemodialysis (HD) termination, 
and mortality. Albumin infusion before and during therapy has been used for preventing and 
treating hypotension with varying results. We evaluated the efficacy of albumin infusion in 
preventing intradialytic hypotension during HD.
Methods: A randomized, crossover trial was performed in 65 patients with albumin<3g/
dl with AKI or ESRD who required HD during hospitalization. Patients were randomized to 
receive 100mL of either 0.9% sodium chloride or 25% albumin intravenously prior to their 
first dialysis session and alternated between the two solutions for up to 6 sessions. Patients’ 
vital signs and ultrafiltration removal rate were recorded every 15 to 30 minutes during 
HD. All symptoms associated with hypotension as well as interventions during the dialysis 
were recorded. IDH was assessed by different definitions reported in the literature (Table).
Results: 65 patients completed 249 sessions; mean age was 58(+/-12), 46(70%) were 
male with a mean weight of 76 (+/-18) kg. Presence of IDH was lower during albumin 
sessions based on all definitions. The risk of hypotension was significantly decreased 
based on the KDOQI, decrease in systolic blood pressure (SBP)<30 and 20mmHg and a 
nadir<90mmHg definitions.
Conclusions: In hypoalbuminemic patients who need IHD, administration of albumin 
before dialysis results in fewer episodes of intradialytic hypotension. Albumin infusion may 
be of benefit to improve safety of IHD in high-risk patients
Intradialytic hypotension definition and frequency in NS and Albumin groups
P values based on Generalized Estimating Equations to analyze the effect of albumin on 
hypotension outcome.
SA-OR069 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Thirst, Xerostomia, and Inter-Dialytic Weight Gain in the Sodium 
Lowering in Dialysate (SoLID) Trail
Brenda M. Luey,3 Joanna L. Dunlop,1 Mark R. Marshall.1,2 for the SoLID trial 
investigators 1Renal Medicine, Middlemore Hospital, Auckland, New Zealand; 
2School of Medicine, University of Auckland, Auckland, New Zealand; 
3Middlemore Clinical Trials, Auckland, New Zealand.
Background: A number of observational studies and clinical trials have shown that 
lower dialysate [Na+] is associated with reduced fluid intake in hemodialysis (HD) patients. 
We report the effect of lower dialysate [Na+] on thirst, xerostomia, and inter-dialytic weight 
gain (IDWG) in the Sodium Lowering in Dialysate (SoLID) trial (ACTRN12611000975998, 
www.solid.org.nz).
Methods: The SoLID trial randomised 99 participants on home or self-care HD from 
11 sites in New Zealand to the control group (dialysate [Na+] of 140mM) or intervention 
group (135mM) for 12 months. Thirst and xerostomia were scored by validated inventories 
- the Dialysis Thirst Inventory or DTI (Bots 2004), and the Xerostomia Inventory or XI
(Thomson 2011). IDWG was measured as the weight gain between dialysis sessions 
averaged over a two-week period. Outcomes were ascertained at baseline, 6 and 12 months,
and analysed using generalized linear models on an intention-to-treat basis.
Results: Results are tabulated in Table 1. IDWG was lower in the intervention group 
compared to the control group at all time-points There was little or no difference in thirst 
and xerostomia between the control and intervention groups at either 6 or 12 months.
Conclusions: In the SoLID trial, lower dialysate [Na+] clearly reduced fluid intake, 
consistent with previous clinical trials. The intervention did not change DTI and XI, 
however, despite previous observational studies showing positive correlation between DTI 
and XI with IDWG (Bots 2004). Further research is underway to determine the relationship 
between IDWG and the individual items within the DTI and XI instruments. It may be that 
the DTI and XI are invalid in prospective settings due to recall bias or other reasons, and 
that other methods are more suitable for determining the longitudinal effects of different 
interventions on thirst and xerostomia.
Funding: Commercial Support - Fresenius Medical Care (Australia), Private 
Foundation Support, Government Support - Non-U.S.
Mean difference (p-value) in outcomes between control and intervention group at 6 and 
12 months
SA-OR070 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Subgroup Analysis of Impact of Extended Hours Dialysis on Quality of 
Life in the Active Dialysis Trial
Brendan Smyth,1,2 Oliver van den Broek-Best,3 Kirsten Howard,2 Kris Rogers,1 
Nicholas A. Gray,4,5 Janak R. de Zoysa,6,7 Christopher T. Chan,8 Alan Cass,9 
Martin P. Gallagher,1,10 Vlado Perkovic,1 Meg J. Jardine.1,10 1The George Institute 
for Global Health, UNSW, Sydney, NSW, Australia; 2Sydney School of Public 
Health, University of Sydney, Sydney, NSW, Australia; 3Sydney Medical School, 
University of Sydney, Sydney, NSW, Australia; 4Sunshine Coast University 
Hospital, Birtinya, QLD, Australia; 5Sunshine Coast Clinical School, University 
of Queensland, Birtinya, QLD, Australia; 6Waitemata District Health Board, 
Auckland, New Zealand; 7Department of Medicine, University of Auckland, 
Auckland, New Zealand; 8Toronto General Hospital, Toronto, ON, Canada; 
9Menzies School of Health Research, Darwin, NT, Australia; 10Renal Unit, 
Concord Repatriation General Hospital, Sydney, NSW, Australia.
Background: The ACTIVE Dialysis trial of extended hours (≥24 hours per week) 
versus standard hours (≤18 hours per week) haemodialysis demonstrated a significant 
improvement in QOL as measured by Short Form-36 (SF-36) Physical Component 
Summary (PCS) and Mental Component Summary (MCS). We aimed to determine if the 
effect of extended hours dialysis on quality of life (QOL) in the ACTIVE Dialysis trial 
differed according to pre-specified subgroups.
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Methods: The ACTIVE Dialysis trial was an open-label randomised, blinded endpoint 
assessment trial. Two hundred participants were enrolled from four countries and randomised 
to 12 months of standard or extended hours dialysis. The SF-36 was administered by a 
blinded interviewer at 3-month intervals. Mean difference between extended and standard 
arms was assessed by mixed linear regression. The overall effect sizes (Cohen’s d: where 
0.2-0.5 is a small effect, 0.5-0.8 a moderate effect and >0.8 a large effect) were calculated 
as the ratio of mean difference to standard deviation. Subgroup variables were added to the 
regression model with an interaction with treatment group to test for effect modification.
Results: Extended hours dialysis was associated with significant improvement in 
PCS (2.30 [95% CI 0.55-4.06]; p=0.010) and MCS (2.54 [95% CI 0.48-4.60]; p=0.016). 
The effect size on both measures was small (PCS 0.24 [95%CI 0.06-0.42; p=0.010], MCS 
0.24 [95%CI 0.04-0.43; p=0.016]). The effect of extended hours dialysis did not vary 
significantly by baseline score, region (China vs Australia, Canada, New Zealand), dialysis 
location (home vs in-centre/satellite) or dialysis vintage (≤6 months vs >6 months).
Conclusions: Extended hours dialysis leads to a small improvement in physical and 
mental QOL. These effects did not differ significantly between key demographic and 
clinical subgroups.
Funding: Commercial Support - Baxter International, Government Support - Non-U.S.
SA-OR071 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Bioelectrical Impedance Analysis (BIA) Versus Clinical Criteria for 
Setting Ultrafiltration (UF) in Chronic Hemodialysis (HD) Patients
Jeffrey P. Mora,1 Romina A. Danguilan,2 Concesa Casasola.1 1National Kidney 
and Transplant Institute, Quezon City, Philippines; 2National Kidney and 
Transplant Institute, Quezon City, Philippines.
Background: This study compared the laboratory, echocardiographic and clinical 
outcomes of patients where dry weight (DW) was determined using BIA or clinical 
evaluation, thus guiding UF.
Methods: A prospective randomized study involving chronic stable HD patients, 
21 in BIA and 21 in Clinical-group, managed based on a structured protocol to set UF. 
The effect on volume status and CV indices after 3 months was evaluated. BIA was done 
fortnightly for BIA-grp while hypo- or hypervolemia was observed every HD session for 
the other group. CBC, electrolytes were done monthly, inferior vena cava (IVC) size and 
collapsibility index (CI), Left ventricular (LV) size, cardiac index and ejection fraction were 
done at baseline and month 3. Intradialytic events were noted.
Results: DW decreased by 1.12 kg in BIA-grp (p=0.012). Lab results were similar in 
both groups. IVC and LV size decreased by 0.1 cm in BIA-grp but remained unchanged in 
Clinical-grp, although not significant (p=0.2183, p=1.000). IVC CI significantly increased 
to 49.5% in BIA-grp but dropped to 40.8% in Clinical-grp (p=0.0186) suggesting a decrease 
in right atrial (RA) pressure and attainment of euvolemia in the former group. There was a 
non-significant increase (4%) in the EF in BIA compared to Clinical (2%) group (p=0.527). 
Significant change in diastolic BP (7 mmHg drop) and MAP (8 mmHg drop) were seen 
in the BIA-grp (p=0.034, p=0.043). Intradialytic episodes of muscle cramps, chest pain/
palpitations, and dizziness occurred only in BIA-grp (p=0.000).
Conclusions: BIA-guided determination of UF resulted in a significantly reduced 
dry weight, DBP, MAP, and RA pressure in a chronic HD population while other cardiac 
indices had a tendency to improve. All these may result in improved cardiac function and 
CV outcomes.
Funding: Commercial Support - Fresenius Medical Care
SA-OR072 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Online Haemodiafiltration Improves Inflammatory State in Dialysis 
Patients: A Longitudinal Study
Anil Bhalla, Ganesh Dhanuka, Ashwani Gupta, Aakash Shingada, Lovy Gaur, 
Anurag Gupta, Vinant Bhargava, Anant Joshi, Devinder S. Rana. Nephrology, 
Sir Ganga Ram Hospital, New Delhi, India.
Background: We conducted this study to evaluate and compare the effect of online 
haemodiafiltration(OL-HDF) and conventional haemodialysis(C-HD) on the level of 
inflammatory markers (hs-CRP,IL1, IL6 and TNF- α) in Chronic Kidney Disease V (D).
Methods: In this prospective observational study we measured levels of hs-CRP, IL-1, 
IL-6 and TNF-alpha at baseline, 3months and 6 months. 60 patients (5 excluded, underwent 
transplant) with CKD V on C-HD for minimum 3 months were included. Study population 
was divided in two groups; 27 patients were continued on C-HD; 28 patients shifted on OL-
HDF. Follow-up period was 6 months after randomization.
Results: Mean age was 50.22yrs. Mean Kt/v and dry weight were similar in both groups 
at baseline. Kt/v (P=0.78) & dry weight (P=0.591) remained stable in both groups after 6 
months. Mean hs-CRP levels were similar in both groups at baseline (2.66±1.86 mg/dl 
vs 2.60±1.96 mg/dl; p=0.916) and at 6 months, there was significant reduction of hsCRP 
in the HDF group by 33%(p-0.007). Mean IL-1 levels were similar at baseline in both 
groups (177.30±41.86pg/ml vs 166.57±30.29pg/ml; p=0.280) and at 6 months, IL- 1 
levels in HDF group decreased significantly (p<0.001) by 13 %. Mean IL-6 levels were 
similar at baseline in both groups (14.18±9.46pg/ml vs 12.74±7.63pg/ml; p=0.536) and at 
6 months IL-6 levels in HDF group decreased significantly (p=0.001) by 33%. Mean TNF-
α levels were similar at baseline in both groups (15.47±7.60pg/ml vs 14.87±7.48pg/ml; 
p=0.771) and at 6 months, TNF-α levels in HDF group decreased significantly (p=0.017) 
by 22 %. Mean Haemoglobin was similar in both groups at baseline (8.90±1.50gm/dl vs
9.16±1.33 gm/dl; p=0.498). At 6 months, haemoglobin was stable in HD group(p=0.426), 
while in HDF group it increased significantly (p=0.001) to 10.05±1.53gm/dl. This was
associated with a significant decrease on rhEPO requirement in HDF group by 14% 
(p – 0.043). Mean S. phosphorous was similar in both groups at baseline (6.12±1.72mg/dl 
vs 6.07±2.05mg/dl; p=0.923). At the end of 6 month reduction in phosphorous in HDF
group was significantly higher (p<0.001).
Conclusions: This study showed that CKD related inflammation improved significantly 
with online-HDF, with significantly decreased level of hs-CRP : 33%, IL-1 : 13%, IL-6 : 
33%, THF- α : 22% after 6 months.
SA-OR073 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Using IVC Collapsibility and Lung Ultrasound to Determine Ultrafiltra-
tion Goal in Hemodialysis Patients
Siddhartha Kattamanchi,1 Manasi Bapat,3 Girish N. Nadkarni,2 Joji E. Tokita,4 
Steven G. Coca.1 1Icahn School of Medicine at Mount Sinai, New York, NY; 
2Ichan School of Medicine, New York, NY; 3Icahn School of Medicine, Mount 
Sinai Hospital, NY, New York, NY; 4Mount Sinai School of Medicine, New York, 
NY.
Background: Intra-dialytic hypotension (IDH) and pulmonary congestion are 
two problems at the opposite ends of the spectrum of the problems related to volume 
status management in ESRD patients. Current clinical assessment tools to predetermine 
ultrafiltration (UF) goal in hospitalized patients are inadequate. We sought to determine 
the utility of employment of hand-held ultrasound at the bedside to adjust goal UF in 
hospitalized HD patients.
Methods: Hospitalized patients receiving HD for AKI or ESRD in the MSH inpatient 
dialysis unit were eligible for participation in this pilot study at Mount Sinai Hospital. HD 
encounters were randomized to the ultrasound-assisted UF goal (intervention group) vs. 
standard of care to determine UF goal (control arm). In the intervention group, the UF 
rate ordered by the treating nephrologists was additionally adjusted based upon IVC 
collapsibility and lung ultrasound patterns assessed immediately prior to the start of HD, as 
shown in the Table. The primary outcomes were A. Intradialytic hypotension (IDH) and B. 
Moderate to severe congestion on the end of HD.
Results: There were 26 HD encounters in the intervention arm and 26 in the control 
arm. Based on the US findings, the UF goal was changed in 12 out of 26 (46%) HD patients 
in the intervention group; Among those 12, 6 patients were classified as hypervolemic and 
had their UF goal increased, and 6 patients were classified as hypovolemic and had their UF 
goal decreased. IDH was observed in 1 patient in the intervention arm vs. 4 patients in the 
control arm. Post-dialysis pulmonary congestion was seen in 2 patients in the intervention 
arm vs. 4 patients in control group.
Conclusions: This pilot study suggests that adjusting UF goal based on US findings 
may improve precision of the optimal UF for that HD session and has the potential to 
decrease incidence of IDH and post-dialysis pulmonary congestion.
Intervention Arm Protocol for UF Adjustment
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SA-OR074 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
The Relationship between Non-Transferrin Bound Iron (NTBI) and Iron 
Utilization for Erythropoiesis in Maintenance Hemodialysis Patients
Takahiro Kuragano, Takeshi Nakanishi. Hyogo College of Mediicne, 
Nishinomiya, Japan.
Background: The relationship between non-transferrin bound iron (NTBI) derived 
oxidation stress and arteriosclerosis in maintenance hemodialysis (MHD) patients has been 
reported. In this study, we investigated the determinant of serum NTBI and the relationship 
between NTBI and iron utilization for erythropoiesis in MHD patients who did not receive 
the iron preparations.
Methods: Study design: multicenter cross-sectional study. We evaluated the blood 
levels of hemoglobin (Hb), β2-microglobulin (βMG), total cholesterol, triglyceride, iron, 
hepcidin, ferritin, total iron binding capacity (TIBC), NTBI, Interleukin(IL)-6, tumor 
necrosis factor (TNF)-α, and high sensitive (hs) CRP in 126 MHD patients who did not 
receive the iron preparations for the past three months. To evaluate the relationship between 
serum NITB and iron utilization for erythropoiesis, patients were divided into 4 groups 
according to Hb and ferritin levels (Hb<10 g/dL and ferritin<50 ng/mL, Hb<10 g/dL 
and ferritin≥50 ng/mL, Hb≥10 g/dL nad ferritin<50 ng/mL, and Hb>10 g/dL and 
ferritin≥50 ng/mL).
Results: There was no significant difference in the NTBI levels in patients with or 
without diabetes and hepatitis C. Moreover, there was no significant correlation among 
NTBI, age, hemodialysis duration, and inflammation index (IL-6, TNF-α, hsCRP). In 
multivariate analysis, only serum ferritin was selected as a significant (β=0.69, p<0.0001) 
predictor of serum NTBI levels. Even after adjusting according to the dose of ESA, the 
serum NTBI of patients with Hb<10 g/dL and ferritin≥50 ng/mL (0.72± 0.5(μM Fe)) 
had significantly higher levels than other groups ((Hb<10 g/dL and ferritin<50 ng/mL: 
0.57±0.35 (μM Fe), Hb≥10 g/dL and ferritin<50 ng/mL: 0.58±0.28 (μM Fe), and 
Hb>10 g/dL and ferritin≥50 ng/mL:0.62±0.41 (μM Fe).
Conclusions: In this study, we revealed that serum NTBI levels in MHD patients were 
related to the iron storage and iron utilization for erythropoiesis. Although, repleted iron 
storage patients with anemia who suspected dysutilization of iron for erythropoiesis already 
showed significantly higher serum NTBI levels; iron administration to these patients might 
cause further higher NTBI levels related with arteriosclerosis of MHD patients.
SA-OR075 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Phase 3, Multicenter, Open-Label Study of Intermittent Oral Roxadustat 
in Peritoneal Dialysis CKD Patients with Anemia
Tadao Akizawa,1 Tetsuro Otsuka,2 Michael Reusch,3 Mai Ueno.2 1Showa 
University School of Medicine, Tokyo, Japan; 2Astellas Pharma Inc., Tokyo, 
Japan; 3Astellas Pharma Europe B.V., Leiden, Netherlands.
Background: Roxadustat is an oral HIF-PHI in late-stage development for treatment 
of anemia in CKD. This Phase 3 study evaluated the efficacy and safety of roxadustat in 
Japanese CKD patients on peritoneal dialysis (PD).
Methods: This 24-week, randomized, open-label study enrolled adult, Japanese, anemic 
CKD patients on PD into two groups based on prior ESA treatment. Patients not treated with 
ESA (ESA Untreated) were randomized to roxadustat 50mg or 70mg; patients treated with 
prior ESA (ESA Treated) were switched to roxadustat 70mg or 100mg depending on prior 
ESA dose. Dose was adjusted throughout the study to maintain a target hemoglobin (Hb) 
level of 10.0-12.0 g/dL. Efficacy endpoints were maintenance rate of target Hb level at 
Weeks 18-24, cumulative response rate at the end of treatment (two Hb thresholds, 10.0 
g/dL and 10.5 g/dL; and Hb increase, ≥1.0 g/dL), average Hb levels at Weeks 18-24 and 
its change from baseline, and rate of rise in Hb levels from Week 0 to Week 4. Safety was 
assessed by occurrence of adverse events (AEs).
Results: 56 patients were enrolled (ESA Untreated, n=13; ESA Treated, n=43). 
Maintenance rates were 92.3% (95% CI: 64.0, 99.8; ESA Untreated) and 74.4% (95% 
CI: 58.8, 86.5; ESA Treated). Maintenance rates of patients with at least one Hb value at 
Weeks 18-24 were 92.3% (95% CI: 64.0, 99.8; ESA Untreated) and 86.5% (95% CI: 71.2, 
95.5; ESA Treated). In the ESA Untreated Group, cumulative response rate for both Hb 
thresholds was 100%. Mean of average Hb levels at Weeks 18-24 were 11.05 g/dL (95% CI: 
10.67, 11.42; ESA Untreated) and 10.93 g/dL (95% CI: 10.73, 11.13; ESA Treated); mean 
change in average Hb at Weeks 18–24 from baseline was 1.69 g/dL (95% CI: 1.06, 2.33; 
ESA Untreated) and 0.14 g/dL (95% CI: −0.12, 0.39; ESA Treated). In the ESA Untreated 
Group, mean (SD) rate of rise in Hb levels from Week 0 to Week 4 was 0.193 (0.203) and 
0.556 (0.408) g/dL/week with roxadustat 50mg and 70mg, respectively. The most common 
AEs were nasopharyngitis, back pain, catheter site infection, diarrhea, vomiting, abdominal 
pain, conjunctivitis, constipation, nausea, and pruritus.
Conclusions: Roxadustat was well tolerated and effective in achieving and maintaining 
Hb levels within the target range in Japanese CKD patients on PD previously treated or 
untreated with ESA.
Funding: Commercial Support - Astellas Pharma Inc
SA-OR076 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Effect of Intradialytic Exercise on Physical Performance and Echocardio-
graphic Findings in Maintenance Hemodialysis Patients
Ji-Hyung Cho, Jun Chul Kim. Department of Internal Medicine, CHA Gumi 
Medical Center, CHA University School of Medicine, Gumi, Republic of Korea.
Background: Poor physical performance (PP) is frequently observed and related to a 
high risk of mortality, cardiovascular events, and hospitalizations in dialysis patients. We 
aimed to investigate the effect of intradialytic exercise (IDE) on PP and echocardiographic 
findings in maintenance hemodialysis (MHD) patients.
Methods: This study randomly assigned ambulatory MHD patients aged≥20 years 
on dialysis≥6 months, to 4 groups: aerobic exercise (AE), resistance exercise (RE), 
combination exercise (CE), and control. A stationary bike was used for AE at moderate 
intensity and a TheraBand®/theraball for RE at vigorous intensity. A 12-week IDE 
program (3 times/week) was completed in the AE (n=11), RE (n=10), and CE (n=12) 
groups. The control group (n=13) received only warm-up stretching. At baseline and 
12-week follow-up, a sit-to-stand for 30 seconds test (STS30), a 6-minute walk test 
(6-MWT), and echocardiography were performed in all patients.
Results: We observed significant increases in STS30 (times/30 s) and 6-MWT (meters) 
in the AE (18.7±5.4 vs 16.5±4.8 and 459±122 vs 434±111, respectively), RE (24.6±4.9 
vs 21.0±5.0 and 530±106 vs 510±102, respectively), and CE (24.8±10.7 vs 21.6±9.6 and 
514±165 vs 492±167, respectively) groups at 12 weeks compared with baseline, while no 
improvement was observed in the control group. When comparing between-group changes 
in STS30 and 6-MWT, there were significant increases in the AE (2.3±2.2 vs -0.5±2.2 and 
25±29 vs -26±41, respectively), RE (3.6±2.7 vs -0.5±2.2 and 20±21 vs -26±41, respectively), 
and CE (3.3±3.1 vs -0.5±2.2 and 22±12 vs -26±41, respectively) groups compared with the 
control group. In the echocardiographic analysis, the 12-week IDE group interventions (AE, 
RE, and CE) showed no significant change on left ventricular (LV) ejection fraction (%) 
(2.5±5.2, -0.7±5.3, and -0.3±5.4 vs 0.3±3.9, respectively), LV mass index (g/m2) (-1.5±16.7, 
0.8±16.3, and -0.5±32.0 vs -11.7±30.1, respectively), and myocardial performance index 
(0.09±0.19, -0.02±0.18, and 0.12±0.21 vs 0.08±0.18, respectively) compared with the 
control group.
Conclusions: Although IDE does not affect the echocardiographic parameters 
measured, it appears to be clinically beneficial in improving PP. It may suggest that IDE 
can also contribute to improve PP even before any significant benefits in cardiac function is 
achieved in MHD patients.
SA-OR077 Oral Abstract Saturday
Improving Dialysis Delivery and Patient Outcomes
Effects of Age and Hemodialysis on Frailty Prevalence, Gait, and Balance 
in Diabetic Patients: A Randomized Controlled Trial
Abdullah Hamad,1 He Zhou,2 Fadwa S. Al-Ali,1 Rania A. Ibrahim,1 Talal Talal,3 
Bijan Najafi.2 1Hamad Medical Corporation, Doha, Qatar; 2Baylor College of 
Medicine, Houston, TX; 3hamad medical corp, Doha, Qatar.
Background: Motor skills deteriorates with aging. Some conditions may magnify 
this deterioration. This study examined whether diabetes and hemodialysis (HD) would 
negatively impact gait, balance, and physical frailty beyond aging.
Methods: Seventy-three elderly adults with diabetes (age=71.4±5.4 years, 
BMI=30.8±5.9, 49% were on HD) and seventy-eight mid-age adults with diabetes 
(age=56.7±5.7 years, BMI=31.1±7.2, 50% were on HD) were recruited. Gait and balance 
performances were objectively measured using validated wearable sensors at HD clinic. 
Frailty status was determined by Fried Frailty Criteria.
Results: Aging deteriorated motor-functions (gait and balance) in people with diabetes 
irrespective of dialysis (9%-46% deterioration, Cohen’s deffect size=0.22-0.42), with 
largest effect size observed for double support in gait performance (p=0.011). In addition, 
deteriorations in gait and balance caused by aging were more pronounced among diabetics 
with HD (19%-65% deterioration, d=0.41-0.75, p<0.05), when compared to diabetics 
without HD (1%-14% deterioration, d=0.01-0.20, p>0.05). The largest effect size for gait 
deterioration among diabetics with HD was observed in double support test (d=0.75,p = 
0.002, Fig. 1), and the largest effect size for balance deterioration was observed in ankle 
stability test (d=0.48, p = 0.042, Fig. 1). Diabetics with HD, irrespective of age, had 3 times 
higher prevalence of frailty than diabetics without HD (42% vs. 14%, p=0.017).
Conclusions: Our study showed that HD deteriorates gait and balance and magnifies 
prevalence of frailty by factor of 3 beyond aging in people with diabetes. Immobility caused 
by prolonged HD (4-hour, 3 times per week) and post-dialysis exhaustion may contribute 
to poorer motor function in older diabetics leading to frailty. This study demonstrated 
practicality of wearable sensors to assess motor performance in dialysis clinics with 
opportunity to capture early deterioration.
Funding: Government Support - Non-U.S.
Fig. 1:Gait and balance comparison between mid-age and elderly diabetic patients with 
and without HD.
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New Considerations for Renoprotection Clinical Trials
Higher eGFR at Ten Years in CKD Stage 2 Patients Treated with Chronic 
Oral NaHCO3 Despite No Metabolic Acidosis Is Associated with 
Prevented Worsening of Underlying Acid Retention
Nimrit Goraya,1,2 Jan Simoni,5 Lauren N. Sager,3 Donald E. Wesson.4,2 1Internal 
Medicine, Baylor Scott and White Health, Temple, TX; 2Texas A&M HSC 
College of Medicine, Temple, TX; 3Biostatistics, Baylor Scott & White, Temple, 
TX; 4Baylor Scott and White Health and Wellness Center, Dallas, TX; 5Surgery, 
Texas Tech University Health Sciences Center, Lubbock, TX.
Background: Chronic oral NaHCO3 but not eqimolar NaCl preserves eGFR compared 
to placebo in CKD stage 2 (eGFR=60-89 ml/min/1.73 m2, CKD 2) patients (Mahajan et al, 
KI, 2010) without metabolic acidosis (conventionally defined as plasma total CO2 <22 mM). 
Because amelioration of underlying H+ retention with dietary alkali in experimental CKD 
models without metabolic acidosis helped preserved GFR (Wesson et al, Kid Int 2010), 
we explored if eGFR preservation in CKD 2 patients without metabolic acidosis receiving 
NaHCO3 was associated with amelioration of underlying acid (H
+) retention.
Methods: We randomized 120 CKD 2 non-diabetic, macroalbuminuric subjects 
with hypertension-associated nephropathy without metabolic acidosis (plasma total CO2 
> 24 mM) to receive 0.5 meq/kg bw/day NaHCO3 (HCO3, n=40), 0.5 meq/kg bw/day
NaCl (NaCl, n=40), or to usual care (UC, n=40) and assessed them yearly for 10 years.
We measured Cystatin C-based estimated GFR (eGFR) and H+ retention by comparing
observed to expected increase in plasma total CO2 in response to retained HCO3 (dose
minus UHCO3V) 2 hours after oral NaHCO3 bolus (0.5 mmol/kg bw), assuming 50% body
weight HCO3 apparent space of distribution.
Results: Baseline eGFR was not different among groups, was lower than their 
respective baseline for each group at 10 years, but the 10-year value was higher (p<0.01) in 
HCO3 (60.3±4.8 ml/min/1.73 m
2) than NaCl and UC (52.2±5.8 and 51.4±4.6 ml/min/1.73 
m2, respectively). Baseline H+ retention was not different among groups and the 10-year vs. 
baseline value was not different for HCO3 (15.7±12.6 vs. 18.1±14.87 mmol, p=0.90). By 
contrast, 10-year H+ retention was higher than baseline in NaCl (27.5±15.2 vs. 19.2±16.7 
mmol, respectively, p<0.01) and UC (22.1±11.2 vs. 17.4±9.9 mmol, p<0.01)
Conclusions: Better eGFR preservation in NaHCO3-treated CKD 2 patients without 
metabolic acidosis was associated with no worsening of underlying H+ retention whereas 
H+ retention worsened in NaCl and UC with less eGFR preservation. The data support that 
worsening H+ retention, without metabolic acidosis, contributed to nephropathy progression 
in CKD. The data suggest that more aggressive NaHCO3 dosing might reduce H
+ retention, 
rather than preserve its level, possibly yielding even greater eGFR protection.
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New Considerations for Renoprotection Clinical Trials
Serial FGF23 Concentrations and Risk of ESRD: The Chronic Renal 
Insufficiency Cohort (CRIC) Study
Rupal Mehta,1 Xuan Cai,1 Jungwha Lee,1 Dawei Xie,2 Xue Wang,3 Julia J. Scialla,4 
Amanda H. Anderson,3 Jonathan J. Taliercio,5 Mirela A. Dobre,6 Jing Chen,7 
Michael J. Fischer,8 Susan P. Steigerwalt,9 Mary B. Leonard,10 Chi-yuan Hsu,11 
Ian H. de Boer,12 James P. Lash,13 Harold I. Feldman,3 Myles Wolf,4 
Tamara Isakova.1 CRIC Study Investigators 1Northwestern Univesrsity, Feinberg 
School of Medicine, Chicago, IL; 2University of Pennsylvania School of Medicine 
Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; 3University 
of Pennsylvania, Philadelphia, PA; 4Duke University, Durham, NC; 5Glickman 
Urological and Kidney Institute, Cleveland, OH; 6Case Western Reserve 
University, Cleveland, OH; 7Tulane School of Medicine, New Orleans, LA; 
8University of Illinois Hospital and Health Sciences Center, Chicago, IL; 
9University of Michigan, Ann Arbor, MI; 10Stanford School of Medicine, Stanford, 
CA; 11University of California San Francisco, San Francisco, CA; 12Division of 
Nephrology and Kidney Research Institute, University of Washington, Seattle, 
WA; 13University of Illinois at Chicago, Chicago, IL.
Background: Studies using a single FGF23 value suggest that elevated plasma FGF23 
is associated with increased risk of ESRD in patients with CKD. However, the data are 
inconsistent and do not include serial assessments of FGF23.
Methods: To test the association between serial plasma FGF23 and ESRD risk, we 
performed a case-cohort study within the CRIC Study. We included 1597 individuals with 
serial FGF23 measurements: 1135 randomly selected individuals, of whom 266 reached 
ESRD, and 462 individuals outside the random subcohort who also reached ESRD. 
FGF23 values were available at 2–5 annual time points in all individuals (mean 4.0 ± 1.2). 
We used weighted Cox proportional hazards models adjusted for baseline and time-varying 
covariates. To account for the possibility that eGFR could be a time-dependent confounder, 
we used marginal structural models. We performed group-based trajectory modeling and 
adjusted the analyses for baseline and final eGFR and eGFR trajectory.
Results: In all models using baseline and time-varying FGF23, elevated plasma 
FGF23 was independently associated with increased risk of ESRD (Figure). In group-based 
trajectory analyses, compared to individuals with plasma FGF23 in the stable trajectory 
group, individuals in the slowly and rapidly rising trajectory groups were at ~3-fold and 
~22-fold greater risk of ESRD (Table).
Conclusions: In multiple modeling approaches using serial FGF23 measurements, 
elevated plasma FGF23 was independently associated with risk of ESRD. Mechanistic 
studies are needed to test whether exposure to elevated and rising FGF23 levels contributes 
to accelerated CKD progression.
Funding: NIDDK Support
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New Considerations for Renoprotection Clinical Trials
Febuxostat for Patients with CKD Stage G3 with Asymptomatic 
Hyperuricemia: A Randomized Trial
Yugo Shibagaki,1 Iwao Ohno,2 Naohiko Imai,1 Shunya Uchida,3 
Shoichi Maruyama,4 Sadayoshi Ito,5 Hirofumi Makino,6 Yasuo Ohashi,7 
Tatsuo Hosoya,2 Kenjiro Kimura.8 FEATHER Study Investigators 1St. Marianna 
University, Kawasaki, Japan; 2The Jikei University School of Medicine, Tokyo, 
Japan; 3Teikyo University School of Medicine, Tokyo, Japan; 4Nagoya University 
Graduate School of Medicine, Nagoya, Japan; 5Tohoku Graduate School of 
Medicine, Sendai Miyagi, Japan; 6Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 7University 
of Tokyo, Tokyo, Japan; 8Tokyo Takanawa Hospital, Tokyo, Japan.
Background: Epidemiological and clinical studies have suggested that urate-lowering 
therapy may slow the progression of chronic kidney disease (CKD). However, clinical 
evidence is still scarce.
Methods: We conducted a randomized, double-blind, placebo-controlled trial in 
patients with CKD stage G3 [estimated glomerular filtration rate (eGFR) < 60 and  30 ml/
min/1.73m2] with asymptomatic hyperuricemia (n = 467) at 55 sites in Japan. Participants 
were randomly assigned, in a 1:1 ratio, to receive febuxostat (loading daily dose: 10 mg on 
days 1 to 28; maintenance daily dose: 40 mg at weeks 8 to 108) or placebo. The primary 
endpoint was the slope (mL/min/1.73 m2 per year) of the eGFR. The mean eGFR slope, 
time-course changes in eGFR, and serum uric acid from baseline through week 108 were 
measured.
Results: Among 443 patients who underwent randomization, 220 received 
febuxostat and 222 received placebo. No significant difference was found in the mean 
eGFR slope between febuxostat (0.23 ± 5.26) and placebo (-0.47 ± 4.48) (difference, 
0.70 mL/min/1.73 m2 per year; 95% confidence interval, -0.21 to 1.62) (Figure). A subgroup 
analysis revealed a significant between-group difference in the kidney function decline-
suppressing effect in patients who were negative for proteinuria (difference, 1.79; 95% 
confidence interval, 0.55 to 3.03) and whose serum creatinine concentration was lower than 
the median (difference, 1.76; 95% confidence interval, 0.44 to 3.07). The incidence of gouty 
arthritis was significantly lower (P = 0.007) in the febuxostat group [0.91% (2/219)] than 
in the placebo group [5.86% (13/222)]. Adverse events specific to febuxostat did not occur.
Conclusions: Febuxostat failed to show a statistically significant renoprotective effect 
as compared with placebo in Japanese patients with CKD stage G3 with asymptomatic 
hyperuricemia.
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New Considerations for Renoprotection Clinical Trials
Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by 
Baseline Clinical Characteristics or Changes in Most Other Risk Markers
Hiddo J. Lambers Heerspink,1 David Sjostrom,2 Silvio E. Inzucchi,3 
Melissa Hallow,4 Valerie Cain,5 Peter Rossing,6 Bergur V. Stefansson,2 
Peter Sartipy.2 1Clinical Pharmacy and Pharmacology, University of Groningen, 
Groningen, Netherlands; 2AstraZeneca, Gothenburg, Sweden; 3Section of 
Endocrinology, Yale University School of Medicine, New Haven, CT; 
4Department of Epidemiology and Biostatistics, University of Georgia School of 
Public Health, Athens, GA; 5Bogier Clinical and IT Solutions, Inc., Raleigh, NC; 
6Steno Diabetes Center, Copenhagen, Gentofte, Denmark.
Background: The sodium glucose co-transporter 2 inhibitor dapagliflozin (DAPA) 
has been shown to decrease the urine albumin:creatinine ratio (UACR). This effect varies 
markedly among individual patients. This study assessed the baseline characteristics and 
concurrent changes in other cardiovascular risk markers that could be associated with 
UACR response to DAPA.
Methods: A pooled analysis of 11 phase 3, randomized, controlled clinical trials was 
performed. UACR change from baseline post 24 weeks treatment with DAPA (10 mg/day) in 
531 patients with type 2 diabetes and UACR ≥30 mg/g was determined. UACR response 
was defined as >30% reduction from baseline at 24-weeks and UACR non-response was 
defined as ≤30% reduction at 24-weeks.
Results: A total of 288 (54%) patients were classified as responders and 243 (46%) as 
non-responders. At 24 weeks, the UACR adjusted mean change from baseline appeared to 
be bimodal: −71.2% (95% CI: −73.7 to −68.3) in responders and 25.9% (95% CI: 17.1 to 
35.4) in non-responders (Table). Baseline UACR, HbA1c, estimated glomerular filtration 
rate (eGFR), systolic blood pressure (SBP), body weight, cardiovascular disease history, 
and concomitant anti-diabetic medication use were similar between responders and non-
responders. Changes in HbA1c, body weight, and haematocrit were also similar between 
the two groups. Responders showed a numerically larger reduction in SBP and eGFR 
compared to non-responders (Table). The incidence of hypoglycaemia and other adverse 
events was similar between the two groups.
Conclusions: UACR reduction to DAPA is an individual characteristic that cannot be 
predicted by baseline clinical features. It is associated with a modestly larger concurrent 
reduction in SBP and eGFR. Whether UACR responders compared to non-responders show 
improved long-term renal and cardiovascular outcomes remains to be determined.
Funding: Commercial Support - AstraZeneca, Gaithersburg, MD, USA.
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New Considerations for Renoprotection Clinical Trials
Change in Albuminuria and GFR as End Points for Clinical Trials in 
Early Stages of CKD: A Scientific Workshop Collaboration by the NKF, 
EMA, and FDA
Andrew S. Levey. Planning and Operations Committees and Analytic Group 
Tufts Medical Center, Boston, MA.
Background: The workshop was held on March 15-16, 2018. We used observational 
studies, clinical trials and simulations to address the research aims (Table). At the ASN 
meeting, we will present updated and more detailed results.
Methods: For observational studies, we included 20 studies comprising 585,723 
participants with 7047 clinical endpoints (ESKD) for ACR change (or equivalent PCR 
change) and 14 studies, 3,373,368 participants, 14348 endpoints for eGFR slope. For 
clinical trials, we included 43 trials comprising 30,078 participants with 3939 clinical 
endpoints (ESKD, eGFR <15 and Scr doubling) for ACR change and 47 trials, 59,074 
participants, 6883 endpoints for eGFR slope. For simulations, we performed 1000 
independent simulations for >1200 scenarios for parameters related to eGFR trajectories 
and study design to compare power and type 1 error for eGFR slope with the clinical 
endpoint (ESKD or Scr doubling).
Results: For observational studies, after adjustment for measurement error, 
relationships between change in ACR or eGFR slope and the clinical endpoint were strong 
and consistent. For clinical trials, relationships of treatment effects on change in ACR and 
eGFR slopes with the clinical endpoint were moderately strong and strong, respectively. 
The magnitude of relationships was similar across cohorts and trials for both ACR change 
and eGFR slope (30% ACR reduction or eGFR slope improvement by 0.5-1.0 ml/min/1.73 
m2 per year were associated with a HR of approximately 0.7 for the clinical endpoint). For 
simulations, eGFR slope can substantially reduce the required sample size and duration 
of followup compared to the clinical endpoint in some circumstances, particularly when 
baseline eGFR is high.
Conclusions: These analyses suggest that both change in albuminuria and GFR slope 
can fulfill criteria for surrogacy for use as endpoints in clinical trials for CKD progression 
under some conditions (characteristics of the clinical population, intervention and trial 
design), with stronger support for GFR slope than for albuminuria change. Implementation 
requires understanding conditions under which one or the other surrogate is likely to 
perform well and restricting its use to those settings.
Funding: Private Foundation Support
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New Considerations for Renoprotection Clinical Trials
Change in Albuminuria and Subsequent Risk of ESRD: A Consortium 
Meta-Analysis
Josef Coresh.1,2 CKD Prognosis Consortium and CKD Epidemiology 
Collaboration 1CKD Prognosis Consortium, Baltimore, MD; 2CKD 
Epidemiology Collaboration, Boston, MA.
Background: A recent NKF-FDA-EMA Workshop evaluated candidate surrogate 
endpoints for clinical trials to slow kidney disease progression, particularly among 
participants with relatively preserved baseline glomerular filtration rate (GFR). Here we 
analyze the strength and consistency of the association between changes in albuminuria and 
end-stage kidney disease (ESKD) risk across a wide range of cohort studies.
Methods: We included 20 studies with 585,732 individuals and 7,047 ESKD events. 
Using linear regression of log albuminuria, we quantified the percent change in albuminuria 
during a baseline period of 1, 2, and 3 years. Associations with subsequent ESKD were 
quantified using Cox regression in each cohort, followed by random-effects meta-analysis. 
Further adjustment for regression dilution was used to take into account the high variability 
of albuminuria to relate risk to true reductions in albuminuria.
Results: Change in urine albumin-to-creatinine ratio (ACR) was strongly related to 
ESKD risk (Figure). The adjusted hazard ratio of ESKD following a 30% decrease in ACR 
during a 2-year baseline period was 0.83 (95% CI 0.74-0.94); after further adjustment for 
regression dilution it was 0.77 (95% CI 0.65-0.92). Adjusted hazard ratios were relatively 
consistent across subgroups and study types but were somewhat stronger at higher ACR 
(p-interaction<0.05). Among persons with ACR >300 mg/g, a true reduction in ACR of 
30% over 2-years was estimated to confer >1% absolute reduction in 10-year ESKD risk 
even at preserved GFR (Figure). Results were similar and slightly stronger for PCR.
Conclusions: Change in albuminuria was consistently associated with later risk of 
ESKD across a wide range of settings lending support to its use as a surrogate endpoint for 
CKD progression trials. Adjustment for high ACR variability was needed to demonstrate 
the similar magnitude of observational associations to clinical trials.
Funding: NIDDK Support, Private Foundation Support
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New Considerations for Renoprotection Clinical Trials
Early Albuminuria Change as Surrogate End Point for Kidney Disease 
Progression – Individual Patient Meta-Analysis of Randomized Controlled 
Trials: A Report from an NKF-FDA-EMA Workshop
Hiddo J. Lambers Heerspink. Chronic Kidney Disease-Epidemiology 
Collaboration University Medical Center Groningen, Groningen, Netherlands.
Background: A recent NKF-FDA-EMA Workshop evaluated candidate surrogate 
endpoints for clinical trials to slow kidney disease progression. Change in albuminuria 
(UACR) may have advantages as it occurs earlier than kidney failure or GFR decline.
Methods: Using a pooled dataset including 30078 patients from 43 RCTs with UACR 
data at baseline and 6 months post-randomization, we estimated treatment effects on UACR 
and the composite clinical end point of ESRD, eGFR < 15 or doubling of serum creatinine 
using separate intent-to-treat analyses in each RCT. We then performed Bayesian mixed 
models to relate the treatment effects on UACR to treatment effects on the clinical endpoint 
and to compute the predicted hazard ratio for the clinical endpoint given a specified 
magnitude of treatment effect on UACR.
Results: Treatment reduced 6-month UACR by a geometric mean ratio (GMR) 
22% (95%CI18-26). The figure shows a statistically significant association of treatment 
effects on change in UACR compared to that of the clinical endpoint. The association was 
strengthened when analyses were restricted to those with baseline UACR > 30mg/g [R2 
47% (95%CI 2-96) vs 72% (5-99)]. For a 30% true change in UACR, the HR for the clinical 
endpoint was predicted to be 0.68 (95%CI 0.47-0.95) vs 0.93 (0.63-1.35) with no treatment 
effect on UACR. Results were consistent by subgroups of baseline eGFR, and disease.
Conclusions: In conjunction with results from epidemiological studies presented at the 
workshop, the moderately strong association between treatment effects on early changes in 
albuminuria and treatment effects on the clinical endpoint for UACR > 30mg/g supports 
the use of sufficiently large reductions (~> 30%) in albuminuria as a surrogate end point for 
kidney failure in clinical trials of kidney disease progression.
Funding: Private Foundation Support
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Performance of eGFR-Based Surrogate End Points by Statistical 
Simulation: A Report from an NKF-FDA-EMA Workshop
Tom Greene,1 Jian Ying.2 CKD-Epidemiology Collaboration 1University of 
Utah, Salt Lake City, UT; 2Univrsity of Utah, Salt Lake City, UT.
Background: Analyses at the individual and trial level support the validity of 30% 
or 40% eGFR declines and eGFR slope as surrogate endpoints for randomized clinical 
trials (RCTs) of CKD. We apply statistical simulation to determine conditions in which 
eGFR-based surrogate endpoints a) increase statistical power, allowing shorter follow-up or 
reduced sample size compared to the clinical endpoint of doubling of SCR or kidney failure 
(CEP), and b) preserve low risk of false positive conclusions if the treatment does not affect 
the CEP (Type 1 error).
Methods: Using a dataset of 59,074 patients from 47 RCTs, we determined input 
parameters for simulations of eGFR trajectories and the relationships of these trajectories 
with kidney failure and death. 1,000 independent simulations were performed for > 1,200 
scenarios for eGFR trajectories and specific study designs. We compared the total sample 
size (N) required for 90% power and evaluated Type 1 error for mean eGFR slope from 
baseline (total slope) and from 3 months follow-up (chronic) and for composite time-to-
events endpoints based on 30%, 40% declines or kidney failure vs. the CEP.
Results: The table displays the required N for each endpoint for 9 scenarios defined 
by the acute effect of the treatment on eGFR and the type of long-term treatment effect 
(uniform across fast and slow progressors), proportional (greater for fast progressors), or 
intermediate. Other simulations show that in the absence of a positive acute effect, Type 1 
error favoring the treatment is preserved for each method except chronic slope. Type 1 error 
for chronic slope may be inflated if a negative acute effect attenuates as eGFR declines.
Conclusions: eGFR-based surrogate endpoints can substantially reduce the required 
N vs. the clinical endpoint, particularly when baseline eGFR is high and there is no acute 
effect. The optimum eGFR-based endpoint depends on the rate of eGFR decline, type of 
treatment effect and study design.
Funding: Private Foundation Support
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GFR Slope as a Surrogate End Point for Kidney Disease Progression –  
Individual Patient Meta-Analysis of RCTs: A Report from an NKF-FDA-
EMA Workshop
Lesley Inker. Chronic Kidney Disease-Epidemiology Collaboration Tufts 
Medical Center, Boston, MA.
Background: A recent NKF-FDA-EMA Workshop evaluated candidate surrogate 
endpoints for clinical trials to slow kidney disease progression. GFR slope may provide 
an advantage over time to event endpoints by increasing power but has limitations, in 
particular when early acute changes differ from longer term changes.
Methods: Using a pooled dataset of 59074 participants from 47 studies, we computed 
GFR slope from randomization to 1, 2, and 3 years (total slope[TS]) as well as after excluding 
the initial 3 months after randomization (chronic slope[CS]). We performed Bayesian mixed 
models to relate the treatment effects on GFR slope to those on the clinical endpoint (CE), 
defined as ESKD, eGFR<15 or doubling of creatinine and to compute predicted hazard 
ratio (HR) for the clinical endpoint given a specified magnitude of treatment effect on slope.
Results: The figure shows associations of treatment effects on 3-year TS and CS 
compared to that of CE. For TS, associations weaken but persist at 2 years [R2 0.82 (0.46, 
0.97)], and deteriorate at 1 year [R2 0.47 (0.09, 0.78)], likely related to presence of acute 
effects. For CS, sensitivity analyses using truncated data seem to show similar associations 
with follow-up time of 18-24 months. Results were consistent across eGFR, ACR and 
disease subgroups. For a 0.75 ml mean difference in 3-year TS and CS, predicted HR on the 
CE was 0.69 (0.59, 0.81) and 0.72 (0.60, 0.87), respectively.
Conclusions: Treatment effects on 3-year TS and CS have strong associations with 
those on the CE. TS over lesser time periods needs to consider presence of acute effect. 
These results, combined with analyses of epidemiological associations and simulation 
studies presented at the Workshop, support the use of GFR slope as a surrogate endpoint in 
clinical trials of kidney disease progression.
Funding: Private Foundation Support
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Association between GFR Slope and Subsequent ESKD and the Impact of 
Adjustment for Measurement Error: Meta-Analysis of Observational 
Studies
Morgan Grams. CKD Prognosis Consortium CKD Prognosis Consortium 
(CKD-PC), Baltimore, MD.
Background: A recent NKF-FDA-EMA Workshop evaluated candidate surrogate 
endpoints for clinical trials to slow kidney disease progression, particularly among 
participants with relatively preserved baseline glomerular filtration rate (GFR). Here, we 
investigate difference in GFR slope as a candidate surrogate endpoint using observational 
studies assembled by the CKD-PC.
Methods: We evaluated the strength of association between GFR slope and the clinical 
endpoint of end-stage kidney disease (ESKD), including the impact of error in slope 
measurement and the length of the observation period in which slope is observed, using 
random-effects meta-analysis of 14 cohorts including 3,373,368 participants followed for 
a mean of 4.4 years.
Results: In covariate-adjusted analyses, a reduction in eGFR decline of 0.75 
ml/min/1.73 m2/year was protective for ESKD in participants with baseline GFR 
≥60 ml/min/1.73 m2 (adjusted hazard ratio using 1-year slope, 0.93, 95% CI: 0.92-0.94).
Associations were stronger among participants with GFR <60 ml/min/1.73 m2 (0.88, 95%
CI: 0.86-0.91), when slopes were observed over longer observation periods (2-year slope,
0.80, 95% CI: 0.78-0.82; 3-year slope, 0.71, 95% CI: 0.69-0.74), and when adjusted for
measurement error (1-year slope 0.80, 95% CI 0.77-0.83; 2-year slope, 0.71, 95% CI: 0.69-
0.74; 3-year slope, 0.64, 95% CI: 0.60-0.67). Compared to a control group with baseline
GFR of 60 ml/min/1.73 m2 and an expected 2-year GFR decline of 3 ml/min/1.73 m2/year,
an intervention that slows GFR decline by 0.75 ml/min/1.73 m2/year would be expected to
result in an absolute 10-year risk reduction of ESKD of 1.3% (0.9% to 3.6% risk reduction 
for a baseline eGFR of 75 to 45 ml/min/1.73 m2, respectively).
Conclusions: Slope of GFR is associated with subsequent ESKD, with stronger 
associations after adjustment for measurement error as well as when observed over longer 
periods. These results, combined with analyses of clinical trials and simulation studies, may 
support the use of GFR slope as a surrogate endpoint in clinical trials.
Funding: NIDDK Support, Private Foundation Support
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Transplantation: Back to the Basics
CyTOF Analysis Identifies Antibody-Secreting and Memory B Cells >1 
Year Prior to Antibody-Mediated Rejection (AMR) Development in 
Pediatric Kidney Transplant Recipients
Clara Fischman,1 Miguel Fribourg,1 Fabrizio Ginevri,2 Patrizia Comoli,2 
Michela Cioni,2 Arcangelo Nocera,2 Chiara Cantarelli,1,3 Laura Perin,4 
Paolo Cravedi.1 1Icahn School of Medicine at Mount Sinai, New York, NY; 
2IRCCS G Gaslini, Genoa, Italy; 3Az. Osp. Univ. Parma, Gattatico (Reggio 
Emilia), Italy; 4Childrens Hospital Los Angeles, Los Angeles, CA.
Background: Development of anti-HLA donor specific antibodies (DSA) is associated 
with antibody mediated rejection (AMR) and reduced graft survival. Changes in circulating 
T and B cells before AMR development have not been investigated systematically.
Methods: We used time-of-flight mass cytometry (CyTOF) to comprehensively 
characterize T and B cells in prospectively collected PBMC from 10 pediatric kidney 
transplant recipients who developed DSA and 11 matched controls who did not develop 
DSA. PBMC were obtained at 2 months post-transplant, 3 months prior to DSA 
development, and at DSA detection (PBMC from controls were collected at the same time-
points).
Results: DSA+ and DSA- patients had similar baseline characteristics and comparable 
T cell frequencies across the different time-points. Patients who developed DSA had 
significantly more B cells with an antibody-secreting phenotype (CD27+CD38+) compared 
to DSA- controls 3 months prior to DSA detection (p=0.01; Figure 1A,B). Within DSA+ 
patients, only those that developed AMR (n=5; 18±3.6 months post-DSA detection) 
had increased B cells with a memory phenotype (CD27+CD95+IgD-) at the time of DSA 
detection (p=0.009; Figure 1A,C). There was no difference in DSA titers between patients 
who developed AMR and those who did not (13,687±4,159 vs. 11,375±1,894 MFI, 
respectively; p=0.63).
Conclusions: Our extensive phenotypic analysis by CyTOF showed that, while 
circulating T cells do not differ between patients with or without DSA, antibody-secreting 
and memory B cells are detectable prior to the development of DSA and AMR, offering a 
potential target for this serious condition.
Funding: NIDDK Support, Private Foundation Support
SA-OR089 Oral Abstract Saturday
Transplantation: Back to the Basics
Concerns over the Safety and Maturity of Nephron-Like Structures after 
Renal Subscapular Transplantation of Kidney Organoids Derived from 
Human iPS Cells
Yong Kyun Kim,2,1 Benjamin S. Freedman.1 1Division of Nephrology, Kidney 
Research Institute, and Institute for Stem Cell and Regenerative Medicine, 
Department of Medicine, University of Washington, Seattle, WA; 2Cell Death 
Disease Research Center and Department of Internal Medicine, College of 
Medicine, Catholic University of Korea, Seoul, Republic of Korea.
Background: For chronic kidney disease, regeneration of lost nephrons in human 
kidney organoids derived from induced pluripotent stem (iPS) cells is proposed to be an 
attractive potential therapeutic option, but it remains unclear whether kidney organoids 
transplanted into kidneys in vivo would be safe or functional.
Methods: Kidney organoids were differentiated from the CMC11 iPS cell line using 
the protocols decribed previously. The harvested kidney organoids were transplanted into 
subcapsular space of kidneys of immunodeficient male NOD/SCID mice.
Results: Kidney organoid grafts survived for months after transplantation and were 
vascularized from host mouse endothelial cells. Transplantation of kidney organoids 
into mouse kidneys revealed nephron-like structures with more mature characteristics, 
compared with kidney organoids in vitro, but they remained immature. Ultrastructural 
analysis revealed the filtration barrier-like structures, capillary lumens and tubules with 
brush border in the transplanted kidney organoids, which were more mature than those 
of the kidney organoids in vitro but not organized as adult mammalian kidneys. Stroma of 
transplanted kidney organoid grafts were filled with vimentin-positive mesenchymal cells, 
and cells in nephron-like structures were similarly not fully differentiated. Chondrogenesis 
and cystogenesis were observed in the transplanted kidney organoid grafts in the long term, 
characteristics reminiscent of teratoma tumors.
Conclusions: Our data suggest that kidney organoids derived from iPS cells may be 
transplantable but strategies for overcoming the immaturity and maldifferentiation are 
needed before they can be used in humans as a therapeutic option for nephron loss.
SA-OR090 Oral Abstract Saturday
Transplantation: Back to the Basics
MicroRNA Expression in Human Kidney Allografts Is Associated with 
Future Development of Fibrosis
Hua Yang,1 Lucile Amrouche,2 Kemal M. Akat,3 Carol Y. Li,4 Claire Tinel,5 
Dany Anglicheau,6 Thangamani Muthukumar.1 1Weill-Cornell, New York, NY; 
2Necker hospital, Paris, France; 3The Rockefeller University, New York, NY; 
4Weill Cornell Medical College, New York, NY; 5CHU Dijon, Dijon, France; 
6Necker Hospital, Paris, France.
Background: Biomarkers that foretell tubulointerstitial fibrosis (IFTA) of the kidney 
allograft may help redefine management of kidney transplant recipients.
Methods: We studied 16 kidney allograft surveillance biopsies from 16 recipients at 
3 months post–transplantation. All biopsies had Banff ci score (interstitial fibrosis) and ct 
score (tubular atrophy) of zero. Based on the presence of IFTA in the 12-month surveillance 
biopsy, 10 recipients were classified as ‘Progression to IFTA’ (Group A, ci score ≥2 and 
ct score ≥2) and 6 as ‘No Progression to IFTA’, (Group B, ci/ct scores=0). We did RNA 
sequencing of the 16 biopsies and compared the differential abundance of miRNA between 
Group A and Group B. We did qRT-PCR assay of the top differentially abundant miRNAs.
Results: Sixteen miRNAs were differentially abundant between the groups; 11 
increased and 5 decreased in Group A comapred to Group B (Figure 1). All 16 miRNAs, 
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as reported in prior studies, were associated with organ fibrosis. By qRT-PCR assay, the 
miRNAs discriminated the groups with high degree of accuracy (Figure 2).
Conclusions: miRNA expression in kidney allograft in 3-month surveillance biopsies 
is associated with IFTA in 12-month surveillance biopsies.
SA-OR091 Oral Abstract Saturday
Transplantation: Back to the Basics
Change of Gut Microbiome after Kidney Transplantation and Its Impact 
on Acute Rejection
Ji Eun Kim,3 Hyunjeong Cho,1 Ji In Park,2 Dong Ki Kim,3 Seung Hee Yang,4 
Jung Pyo Lee,5 Yon Su Kim,6 Hajeong Lee.6 1Internal Medicine, Chungbuk 
National University Hospital, Cheongju-si, Chungcheongbuk-do, Republic of 
Korea; 2Kangwon National University Hospital, Chuncheon-si, Republic of 
Korea; 3Seoul National University Hospital, Seoul, Republic of Korea; 4Kidney 
Research Institute, Seoul National University, Seoul, Republic of Korea; 5Seoul 
National University Boramae Medical Center, Seoul, Republic of Korea; 6Seoul 
National University College of Medicine, Seoul, Republic of Korea.
Background: Gut microbiota regulates immune responses and its dysbiosis is 
associated with various kinds of diseases, although very few studies have been conducted 
in kidney transplantation recipients. The purpose of this study is to analyze the changes of 
gut microbiome after renal transplantation and to evaluate the association between bacterial 
composition and post-transplantation outcomes.
Methods: We prospectively enrolled renal transplant recipients at 2 tertiary centers. 
We gathered their fresh feces before and three-month after receiving transplantation. The 
Illumina MiSeq system was used for sequencing of the 16S rRNA V4-V5 variable region 
from the extracted stool DNA. We explored gut microbiome profile change before and after 
transplantation and its impact on transplantation outcomes such as acute rejection (AR) and 
infection occurrences.
Results: From 76 recipients, we analyzed 76 feces before transplantation and 39 
feces after transplantation. Microbial diversity decreased significantly in three months 
after transplantation than pre-transplantation period (p<0.001). At the phylum level, 
Proteobacteria significantly increased in post-transplantation state (p=0.046). At the 
genus level, relative proportions of Oscillibacter (p=0.001), Subdoligranulum (p=0.018), 
and Alistipes (p=0.005) significantly decreased, whereas the genera Clostridium_g24 
significantly increased (p=0.016) in post-transplantation period. When we compared gut 
microbiome profiles between patients with and without transplantation outcomes, both 
observed operational taxonomic unit (p=0.029) and microbial diversity (p=0.014) were 
significantly lower in AR group. AR group tended to have lower phylum Bacteroidetes, 
higher phylum Proteobacteria, and lower abundance of the genera Faecalibacterium than 
non-AR group, although insignificant. Recipients with infection episodes had lesser the 
genera Oscillibacter (p=0.019) than those without. In addition, they had higher abundance 
of the genera Bacteroides (p=0.037) than those without.
Conclusions: In this study, we demonstrate significant sequential changes as well 
as a decreased diversity of gut microbiota after kidney transplantation. Interestingly, 
transplantation outcomes including AR and infection episodes were associated with 
changes of gut microbiota in recipients.
SA-OR092 Oral Abstract Saturday
Transplantation: Back to the Basics
Histone Deacetylase-8 Inhibition Is Protective in Renal Ischemia-Reperfu-
sion Injury
Seth Concors,1 David D. Aufhauser,2 Zhonglin Wang,2 Douglas R. Murken,2 
Guanghui Ge,4 Tricia Bhatti,5 Wayne W. Hancock,3 Matthew H. Levine.2 
1University of Pennsylvania Health System, Philadelphia, PA; 2University of 
Pennsylvania, Philadelphia, PA; 3Children’s Hospital of Philadelphia and 
University of Pennsylvania, Philadelphia, PA; 4University of Pennsylvania, 
Philadelphia, PA; 5The Children’s Hospital of Philadelphia, Philadelphia, PA.
Background: Ischemia/reperfusion injury (IRI) is a major source of morbidity in 
renal transplantation and other surgical scenarios, and has no specific therapy. In renal 
transplantation, IRI contributes to poor outcomes and early graft loss. Histone deacetylases 
(HDACs) regulate diverse cellular processes. We have previously shown that class I HDAC 
1 and 2 have reciprocal effects on renal ischemia-reperfusion injury (IRI) with HDAC1 
deletion increasing vulnerability and HDAC2 protection providing profound protection. 
HDAC8, another Class I HDAC, is structurally distinct from other members and is 
specifically targetable, making it a molecule of interest in IRI.
Methods: Whole-body tamoxifen-inducible HDAC -8 deficient (HDAC8 KO), and 
tamoxifen-treated WT female mice, as well as B6 female mice treated with specific HDAC8 
inhibitor (OJ-1) or DMSO control were used. Mice were subjected to warm renal IRI 
through unilateral clamping of the renal pedicle and contralateral nephrectomy under strict 
temperature control. Creatinine and BUN were examined at 24-, 48-, 72-, and 96-h post IRI.
Results: HDAC8 KO (Figure 1A& 1B) and inhibitor-treated (Figure 1C & 1D) mice 
developed significantly less renal injury after renal IRI than controls, with significantly 
decreased post-operative BUN and Cr (p<0.0001 for all).
Conclusions: HDAC8 knockout and pharmacologic inhibition appears to be proactive 
in a standard model of renal warm IRI. The benefit of short term HDAC8 pharmacologic 
inhibition represents an important finding, demonstrating highly novel translational 
potential. Further clinical correlation and mechanistic understanding is needed for this 
candidate molecule.
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Transplantation: Back to the Basics
Urinary Microvesicular Biomarkers for Delayed Graft Function and 
Overall Outcome after Living Donor Kidney Transplantation
Fabian Braun,1 Markus M. Rinschen,5 Denise Buchner,6 Andreas Beyer,4 
Dirk L. Stippel,4 Christine E. Kurschat,2 Bernhard Schermer,2 Thomas Benzing,4 
Roman-Ulrich Mueller.3 1University Medical Center Hamburg-Eppendorf, 
Hamburg, Germany; 2University Hospital Cologne, Cologne, Germany; 3Dept. 
2 of Internal Medicine, University of Cologne, Koeln, Germany; 4University of 
Cologne, Köln, Germany; 5CECAD, Cologne, Germany; 6Department of 
General, Visceral and Cancer Surgery, Division of Transplantation Surgery, 
Transplant Center Cologne, University Hospital of Cologne, Cologne, Germany.
Background: With a cargo of specific proteins and nucleic acids, urinary microvesicles 
represent a source for cellular material, that can be isolated easily and non-invasively. 
Despite this, their application in routine diagnostics are still a subject of investigation. 
Kidney biopsies remain the gold standard procedure in the diagnosis of transplant failure. 
We hypothesize that the addition of non-invasive biomarkers could benefit this method 
minimize the risk of a sampling error.
Methods: Via a protocol of differential centrifugation, we isolated urinary 
microvesicles from living kidney transplant recipients and their donors over the course 
of 40 kidney transplantations. Urine samples were collected on day -1 (donor sample), 0, 
1 and 3 months after transplantation (recipient samples). Microvesicular protein content 
was measured using quantitative mass spectrometry. We detected proteins, that linearly 
change their abundance corresponding to clinical parameters, e.g. GFR measured at 6 and 
12 Months after transplantation in a set of 20 transplantations, by linear regression models. 
These results were validated in a cohort of 20 additional transplantations.
Results: We identified >1500 proteins present in at least 50% of the first sample 
set. In hierarchical clustering analysis, the proteomic profiles depicted a clear clustering 
by time point of urine collection. Microvesicular proteins of glomerular (e.g. nephrin, 
podocin) or tubular origin (e.g. V-ATPase and Slc transporters) were regulated over the 
course of transplantation. Overall, specific proteomic time course patterns were apparent 
over the course of transplantation. Depending on low statistical error and high stability 
in a leave-one-out cross-validation of the linear models correlating to GFR values after 
transplantation, we created a list of 64 candidate proteins. This candidate list was validated 
in a targeted proteomics analysis in the samples of the follow-up cohort.
Conclusions: With this study, we present the first analysis of the changes in the human 
urinary microvesicular proteome over the course of kidney transplantation. We believe, 
the validated biomarkers of all 40 Transplantations to hold the potential to further aid the 
diagnosis of graft survival and possibly transplant rejection.
Funding: Government Support - Non-U.S.
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Simvastatin Modulates the Immunoregulatory Phenotype of Vascular 
Endothelial Cells
Timna Agur,1,2 Chandra C. Ghosh,1,2 Johannes Wedel,1,2 David M. Briscoe.1,2 
1Transplant Research Program and the Division of Nephrology, Boston 
Children’s Hospital, Boston, MA; 2Harvard Medical School, Boston, MA.
Background: Evidence suggests that HMG-CoA reductase inhibitors (statins) reduce 
the incidence of acute and chronic allograft rejection and have immunomodulatory effects. 
However, their mechanism of function to regulate alloimmunity is poorly understood. We 
hypothesize that statins modulate the immunogenicity of donor graft endothelial cells (EC) 
and the costimulation of recipient CD4+ Teffector cells thereby promoting a pro-tolerogenic 
intragraft microenvironment.
Methods: Pooled populations of CD4+T cells and memory CD45RO+ subsets 
were isolated from PBMC, and were co-cultured with untreated human umbilical vein 
EC (HUVEC) or EC pre-treated with simvastatin (Simva, 0.1-10μM for 24 hrs) in the 
presence of mitogen (PHA 0.1-0.3μg/ml). The ability of EC to transcostimulate CD4+T 
cell proliferation was measured after 72 hours using either [3H] thymidine incorporation or 
CFSE dilution by FACS. Released cytokines were analyzed by Luminex and by ELISPOT, 
and the direct effect of Simva on the phenotype of EC was evaluated by RNAseq and 
validated by qPCR. Controls were Simva-treated fibroblasts.
Results: We found a significant reduction (P<0.001, n=6) in the proliferation 
of CD4+T cells following coculture with Simva-pretreated EC vs. untreated cells. 
Furthermore, inhibition of memory CD4+T cell proliferation was dose dependent using up 
to five concentrations of simva (0.1-10μM, n=3). Multianalyte luminex assays of coculture 
supernatants revealed a reduction in several pro-inflammatory cytokines, and ELISPOT 
assays confirmed a notable effect on the reduction of IL-2, IFNg and IL-6 production 
following coculture with Simva-pretreated EC vs. untreated cells. In contrast, fibroblasts 
pretreated with Simva failed to inhibit PHA-induced proliferation of CD4+T cells as 
a control, indicating that there are cell intrinsic effects of Simva on the EC phenotype. 
To determine mechanism, we evaluated RNAseq and performed mRNA gene arrays on 
Simva-treated EC vs untreated and found increased expression of immunoregulatory genes 
including LGALS family molecules and reduced expression of IL-6, IL-8 and OX40L.
Conclusions: Simvastatin modulates the immunogenicity of EC and their function 
in the activation of memory CD4+T cells. These studies support the use of simvastatin as 
an adjunct immunomodulatory therapy to augment tolerance and promote long-term graft 
survival.
Funding: Other NIH Support - 1R03AI138083-01, Private Foundation Support
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Transplantation: Back to the Basics
Single Cell RNA-Seq of Sequential Kidney Biopsies in Antibody Mediated 
Rejection Reveals a Highly Diverse Inflammatory Response
Andrew F. Malone, Sai Mukund Ramakrishnan, Haojia Wu, Erinn L. Donnelly, 
Benjamin D. Humphreys. Washington University School of Medicine, Saint 
Louis, MO.
Background: Antibody mediated rejection (AMR) remains a major cause of allograft 
failure yet current treatments are suboptimal reflecting our poor understanding of this 
disease process. To better understand the impact of current AMR treatments we performed 
single cell RNA-seq on human kidney biopsies both at AMR diagnosis and at 1 month post 
treatment.
Methods: Single cell suspensions were prepared by enzymatic digestion. The 10X 
Genomics platform was used for library preparation. Libraries were sequenced to a depth 
of ~50k reads/cell. Gene-cell matrices were obtained using CellRanger and the downstream 
analyses were done using R and Seurat.
Results: 11,592 cells (1,841 genes/cell) and 5,581 cells (1,253 genes/cell) from the 
pre- and post-treatment biopsy, respectively, were included in the final analysis of each 
biopsy. AMR treatment included rituximab, bortezomib, IVIG, high dose steroids and 
tocilizumab. Allograft function did not return to baseline and post treatment histology 
showed no improvement in Banff scores. We detected all major epithelial cell types. A 
combined analysis of all immune cells from both biopsies revealed 16 separate immune 
cell clusters (Fig A). These included distinct monocyte(x8), dendritic cell(x3), CD8 T cell, 
NK cell, B cell and plasma cell clusters. Treatment resulted in a modest reduction in B cell 
and plasma cell proportions of 0.56 to 0.44 and 0.6 to 0.4, respectively (Fig B; red, pre-
treatment cells; blue, post-treatment cells). By contrast, the number of these cells expressing 
TNFRSF17 (BMCA, B cell maturation antigen) increased from 1.2% to 24.9%, before and 
after treatment. Furthermore, the number of TNFSF13B (BAFF, B cell activating factor) 
expressing cells remained high after treatment (42% to 32%).
Conclusions: Aggressive anti-B cell and anti-plasma cell therapy failed to substantially 
reduce intra-graft antibody secreting cell numbers. Elevated intra-graft antibody secreting 
cell number may be maintained by BAFF-BCMA signaling. scRNA-seq provides a 
quantitative description of the cellular landscape in rejection.
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Transplantation: Back to the Basics
IgG Glycosylation Causes Podocyte Injury in Transplant Glomerulopathy 
via Calcium Calmodulin Kinase IV
Rhea Bhargava,1 Kayaho Maeda,3 Martha Pavlakis,2 George C. Tsokos.1 1Beth 
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 2Beth 
Israel Deaconess Medical Center, Boston, MA; 3Beth Isreal Deaconess Medical 
Center, Harvard Medical School, Brookline, MA.
Background: Transplant glomerulopathy(TG) is a major cause of late allograft 
loss. Increase in urine podocin/creatinine ratio in TG signifies acceleration of podocyte 
detachment from glomerular basement membrane. We evaluated the mechanism by which 
antibodies lead to podocyte injury in transplant glomerulopathy. We focused on calcium 
calmodulin kinase IV(CAMKIV), a serine threonine kinase which we have shown to be 
upregulated in immune podocytopathies.
Methods: Expression of CaMKIV in transplant biopsy kidney specimens was 
evaluated by immunofluorescence. Immortalized human podocytes were examined for 
actin cytoskeleton changes after exposure to IgG from patients with TG versus controls. 
We subjected IgG from TG patients to deglycosylation and silenced the podocyte expressed 
neonatal Fc receptor (FcRn) by CRISPR technology and siRNA.
Results: CaMKIV was increased in podocytes of transplant kidney biopsies from 
patients with TG but not in samples without TG. Culture of podocytes in the presence of 
IgG from TG patients or patients who eventually developed TG, led to increased CAMKIV 
expression in a dose dependent manner along with reduction in expression of nephrin and 
alpha actinin 4, podocyte migration and significant actin cytoskeleton changes. This was 
not seen with IgG from normal transplant subjects. Silencing of FcRn reduced the entry 
of IgG into podocytes. IgG from patients with TG subjected to N-deglycosylation failed 
to increase the expression of CaMKIV. CAMKIV deficiency or pharmacologic inhibition 
preserved nephrin and alpha actinin 4 expression and prevented the disruption of actin 
cytoskeleton in podocytes. CAMKIV inhibited GSK3beta by phosphorylating it at serine 
9 which led to stabilization of transcription factor SNAIL and subsequent repression of 
nephrin transcription.
Conclusions: We conclude that targeting CaMKIV may represent a novel biomarker 
for the early detection of transplant glomerulopathy and a pathway for development of 
novel therapeutics in this disease. Furthermore, glycosylated IgG from patients with TG 
enters podocytes through the FcRn causing an increase in CaMK4 and transcriptional 
repression of nephrin. The ability of IgG in the sera of patients with TG vs controls to 
disrupt structure and function of podocytes can serve as a bioassay for impending TG. 
Targeting the glycosylation of IgG may prevent allograft failure.
Funding: NIDDK Support
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Late B Lymphocyte Action in Dysfunctional Tissue Repair Following 
Kidney Injury and Transplantation
Pietro E. Cippa, Andrew P. McMahon. McMahon Lab University of Southern 
California, Los Angeles, CA.
Background: Immune-mediated injury contributes to unsatisfactory long-term 
outcomes after kidney transplantation, but the mechanisms initiating late immunoreactivity 
are poorly understood.
Methods: In this translational study, we combined transcriptional profiling of serial 
protocol biopsies after kidney transplantation in humans (RNAseq analysis from 163 
protocol biopsies) with the extensive characterization of immunological processes up to 18 
months after ischemia/reperfusion injury (IRI) in mice (RNAseq, immunofluorescence, B 
cell receptor analysis and autoantibody detection).
Results: In human kidney allografts, a transcriptional B cell signature correlated 
with fibrosis and reduced graft function. The presence of a B cell signature at 1 year was 
associated with an injury/repair response earlier after transplantation, not primarily related 
to episodes of allograft rejection. In the mouse model, we identified a sustained immune 
response in the absence of foreign antigens in conjunction with the transition to chronic 
kidney disease. The late intrarenal response after IRI was characterized by the appearance 
of ectopic lymphoid structures hosting the proliferation and maturation of B lymphocytes 
into antibody secreting cells. The B cell receptor analysis was consistent with a process 
of clonal expansion and affinity maturation of B lymphocytes in the damaged kidney. In 
the absence of foreign antigens this process resulted in the production of systemically 
detectable broadly-reacting antibodies.
Conclusions: These findings highlight stage specific immunological responses to 
kidney injury shared between the mouse and human kidney and suggest a new disease 
model for chronic forms of injury and rejection after transplantation with dysfunctional 
kidney repair as the primum movens of late B cell mediated immunity.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Vascular Calcification, FGF-23, and Phosphate
Glycerol-3-Phosphate Is a Novel FGF23 Regulator Derived from the 
Injured Kidney
Petra Simic,1 Wondong Kim,1 Bryan R. Kestenbaum,2 Ian H. de Boer,3 
David E. Leaf,4 Sushrut S. Waikar,4 Robert Gerszten,7 Ravi I. Thadhani,8 
Clary B. Clish,6 Harald Jüppner,1 Marc N. Wein,5 Eugene P. Rhee.1 
1Massachusetts General Hospital, Brookline, MA; 2University of Washington, 
Seattle, WA; 3Division of Nephrology and Kidney Research Institute, University 
of Washington, Seattle, WA; 4Harvard Medical School, Boston, MA; 5MGH 
Endocrine Unit, Boston, MA; 6Broad Institute of MIT and Harvard, Cambridge, 
MA; 7Beth Israel Deaconess Medical Center, Boston, MA; 8Cedars-Sinai, Los 
Angeles, CA.
Background: Disorders of FGF23 are associated with significant morbidity and 
mortality, but an understanding of what regulates FGF23 in bone is lacking. Because the 
kidney is the major end-organ of FGF23 action, we hypothesized that it releases a factor that 
regulates bone FGF23 synthesis.
Methods: Using aptamer based proteomics and liquid chromatography-mass 
spectrometry (LC-MS) based metabolomics, we profiled >1600 molecules in renal venous 
plasma obtained from human subjects. After identifying the molecule that has the strongest 
correlation with FGF23, we used in vitro techniques and genetically modified mice to 
investigate its effects on bone FGF23 production. Further, we examined the association 
between the molecule and FGF23 levels in an ischemia-reperfusion (IRI) model of acute 
kidney injury (AKI) in mice, and in 26 individuals who did (cases) or did not (controls) 
develop AKI after cardiac surgery.
Results: Renal vein glycerol-3-phosphate (G-3-P) had the strongest correlation with 
circulating intact FGF23 (iFGF23) levels (r2 = 0.76, P = 5.2x10-6) in humans. Injection of 
G-3-P, as well as its downstream product lysophosphatidic acid (LPA) in mice increased
plasma iFGF23 and c-terminal FGF23 (cFGF23) levels at 24 hours. G-3-P increased LPA 
levels in bone marrow and in osteoblast cell culture, and this effect on LPA as well as G-3-
P’s stimulatory effect on FGF23 production, were blocked with the glycerol-3-phosphate
acyltransferase (GPAT) inhibitor FSG67 in vivo and Gpat2 knock-down in vitro. The
stimulatory effect of G-3-P and LPA on FGF23 production were similarly abrogated in
Lpar1 deficient cells and mice. In mice subjected to IRI, kidney tissue G-3-P levels rose
rapidly; the increase in iFGF23 levels following IRI was significantly attenuated with GPAT 
inhibition or Lpar1 deletion. In humans undergoing cardiac surgery, plasma G-3-P levels
increased significantly and correlated with the plasma iFGF23 levels (r2 = 0.31) in AKI
cases but not controls.
Conclusions: Our findings establish G-3-P as a molecule released from the injured 
kidney, that is converted to LPA via GPAT-2 in bone where it triggers FGF23 production 
through LPAR1. This is a novel mechanism in mineral metabolism and outlines potential 
targets to modulate FGF23 production during kidney injury.
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Vascular Calcification, FGF-23, and Phosphate
DMP1 Prevents Bone Alterations, FGF23 Elevations, and Cardiac 
Hypertrophy in Mice with CKD
Corey Dussold,1 Claire Gerber,1 Samantha Neuburg,1 Xueyan Wang,1 
Connor Francis,1 Lixin Qi,1 Ying Liu,3 Chaoyuan Li,3 Jian Feng,3 Myles Wolf,2 
Valentin David,1 Aline Martin.1 1Northwestern University Feinberg School of 
Medicine, Chicago, IL; 2Duke University, Durham, NC; 3Texas A&M-Baylor 
College of Dentistry, Dallas, TX.
Background: Disordered bone and mineral metabolism is a common complication 
of CKD. Excessive secretion of the osteocyte-derived hormone fibroblast growth factor 
23 (FGF23) during CKD progression is independently associated with increased risk of 
cardiovascular disease and mortality, perhaps by contributing to development of left 
ventricular hypertrophy (LVH). Dentin matrix protein 1 (DMP1), an extracellular matrix 
protein produced by osteocytes, is an established inhibitor of FGF23 production and 
a promoter of bone mineralization. We hypothesized that overexpression of DMP1 in 
CKD would improve bone health and prevent FGF23 elevations and consequent adverse 
cardiovascular outcomes in CKD.
Methods: We studied the Col4a3KO mouse, an established model of progressive CKD, 
which typically shows a shortened lifespan (21.4±0.6 weeks). We overexpressed DMP1 
(DMP1Tg-3.6Kb ColIa1 promoter) in the bone of WT (DMP1Tg) and Col4a3KO (Col4a3KO/DMP1Tg) 
mice and we assessed renal function, serum FGF23 and phosphate (Pi) levels, bone and 
cardiac phenotype in 20 week-old mice, and overall survival.
Results: Col4a3KO mice showed impaired renal function (blood urea nitrogen: 94±18 
vs 25±2 mg/dL), reduced bone mineral density (BMD: 1154±14 vs 1194±5 mg/cm3), 
altered osteocyte morphology and connectivity, an 8-fold increase in serum FGF23 levels, 
hyperphosphatemia (serum Pi: 9.2±0.6 vs 6.2±0.2 mg/dL), and LVH (LV Mass: 124±7 vs 
101±4 mg) (p<0.05 vs WT for each). Overexpression of DMP1 in Col4a3KO/DMP1Tg did 
not improve renal function but corrected the reduction in BMD by 40% and fully prevented 
osteocyte alterations. Col4a3KO/DMP1Tg also showed lower FGF23 levels (631±124 
vs 1161±196 pg/mL) resulting in higher serum phosphate levels (11.4±1.0 mg/dL) 
(p<0.05 vs Col4a3KO for each). As opposed to Col4a3KO, Col4a3KO/DMP1Tg mice did not 
have LVH (LV Mass: 93±5 mg; NS vs WT) and showed improved survival (24.2±0.9 
weeks; p<0.05 vs Col4a3KO).
Conclusions: DMP1 prevented CKD-associated osteocyte alterations, FGF23 
elevations and LVH, and improved survival, despite persistently impaired renal function 
and worsened hyperphosphatemia. This supports the contribution of FGF23 excess to 
cardiac injury in CKD and suggests that DMP1 represents a novel therapeutic approach to 
improve bone and cardiac outcomes in CKD.
Funding: NIDDK Support
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Vascular Calcification, FGF-23, and Phosphate
The Osteocyte Is Not the Only Source of FGF23 in Folic Acid-Induced AKI
Marta Christov,1 Zhiqiang Cheng,5 Seham M. Rabadi,1 Jenna Hwong,7 
Hanson Ho,4,2 Amanda L. Herberger,6 Harald Jüppner,3 Wenhan Chang.2 1New 
York Medical College, Valhalla, NY; 2Endocrine Unit, SF-VAMC, University of 
California San Francisco, San Francisco, CA; 3Massachusetts General 
Hospital, Boston, MA; 4Adaptive Biotechnology, South San francisco, CA; 
5UCSF, San Francisco, CA; 6University of California, San Francisco/ San 
Francisco Veterans Affairs Medical Center, San Francsicso, CA; 7SFVAMC, San 
Francisco, CA.
Background: Fibroblast growth factor 23 (FGF23) is thought to be produced 
predominantly by osteocytes in bone and to exert a phosphate-regulating action in the 
kidneys. Its levels increase with development of chronic kidney disease and acute kidney 
injury (AKI) and are linked to morbidity and mortality. Recently, other tissues were reported 
to be additional sources of FGF23 in kidney injury or iron deficiency. However, it is unclear 
to what extent the extra-skeletal sources contribute to the baseline and the massively 
elevated serum FGF23 levels in AKI.
Methods: FGF23fl/fl mice carrying loxP sequences flanking exon 1 of Fgf23 gene were 
bred with Zp3-Cre and DMP1-Cre lines to produce global (FGF23-null) and osteocyte-
specific FGF23 (OcyFGF23-KO) KO mice, respectively. AKI was induced after a single folic 
acid (FA) injection in adult male and female OcyFGF23-KO and control mice and circulating 
intact and c-terminal FGF23, PTH, and mineral levels as well as Fgf23 mRNA expression 
in various tissues were determined 24 hours after induction of AKI.
Results: The FGF23-null mice recapitulated serum and skeletal phenotypes of the 
previously reported germ-line FGF23 KO mice, validating our gene KO strategy. Basal 
serum FGF23 and PTH levels in the OcyFGF23-KO mice were 39-50% and 48-67% lower 
(depending on sexes) compared to control mice, respectively. While serum cFGF23 levels 
were increased by AKI more robustly in control (6904±1272 pg/ml) vs OcyFGF23-KO mice 
(3178±836.1 pg/ml) (p<0.05), the fold-change over baseline value was similar between the 
2 groups (35 in control vs 41 fold in KO mice, p=0.69). Accordingly, AKI induced higher 
PTH levels in control (2583±339.5 pg/ml) vs OcyFGF23-KO mice (1349±363.9 pg/ml, 
p<0.05), despite no difference in phosphate, calcium, and BUN levels between the two 
mouse groups after 24 hrs of AKI. As expected, FA did not increase FGF23 mRNA levels in 
the bone of OcyFGF23-KO mice, but raised FGF23 mRNA levels in their kidney and spleen 
by 5-10 fold.
Conclusions: We conclude that although the osteocytes contribute greatly to baseline 
FGF23 levels and to the increase of FGF23 in AKI, extra-skeletal tissues, particularly 
spleen and kidney, are also significant sources of FGF23 at physiological and injury states.
Funding: NIDDK Support, Private Foundation Support
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Vascular Calcification, FGF-23, and Phosphate
Dietary Phosphate Restriction Attenuates Renal Cystic Disease in pcy/pcy 
Mice
Cassandra R. Johnson, Ogorchukwu F. Omede, Emily A. Daniel, 
Darren P. Wallace, Jason R. Stubbs. University of Kansas Medical Center, 
Kansas City, KS.
Background: Abnormalities in phosphate metabolism strongly predict future 
development and progression of chronic kidney disease (CKD); however, the mechanism 
remains undefined. Previously, we showed that dietary phosphate restriction reduced 
tubular injury in mice with glomerulonephritis. Here, we determined if dietary phosphate 
restriction slows renal cyst growth and fibrosis in pcy/pcy mice, a slowly progressive model 
of polycystic kidney disease (PKD).
Methods: At 7 weeks of age, pcy/pcy mice were randomized to receive either a control 
phosphate (0.54%) or low phosphate (0.02%) diet (n=10/group) until 20 weeks of age. All 
other major dietary constituents, including protein source and content were comparable 
between diets. Mice were sacrificed for measurement of kidney weight to body weight 
(KW/BW), cystic index (% cystic area), and renal expression of early markers of fibrosis.
Results: Pcy/pcy mice that received the low phosphate diet had a 25% lower KW/
BW (low phosphate 2.9±0.3% vs. control 4.3±0.6%; P<0.001) and 30% lower cystic index 
(low phosphate 21.7±6.6% vs. control 31.5±4.4%; P<0.01). When examining the renal 
gene expression of markers of fibrosis, pcy/pcy mice fed the low phosphate diet had a 50% 
reduction in the expression of collagen 1a1 (P<0.05) and a 40% reduction in the expression 
a-smooth muscle actin (P<0.01).
Conclusions: Dietary phosphate restriction attenuates PKD progression and renal gene 
expression for early markers of fibrosis in pcy/pcy mice.
Funding: NIDDK Support
Effect of dietary phosphate on cyst burden in pcy/pcy mice. (A) Cross-sections of 
kidneys from 20 week-old pcy/pcy mice receiving either a control diet or low phosphate 
diet. (B) Kidney cystic index scoring from pcy/pcy mice receiving either control or low 
phosphate diet. **P<0.01
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Vascular Calcification, FGF-23, and Phosphate
Dietary Magnesium Prevents Vascular Calcification and Bone Mineraliza-
tion in Klotho Knock-Out Mice
Anique D. Ter Braake,1 Wynand Alkema,3 Joost Hoenderop,4 Jeroen H. De 
Baaij.2 1Physiology, Radboud University Medical Center, Nijmegen, 
Netherlands; 2Physiology, Radboud University Medical Center, Nijmegen, 
Netherlands; 3Center for Molecular and Biomolecular Informatics, Radboud 
University Medical Center, Nijmegen, Netherlands; 4Physiology, Radboud 
University Medical Center, Nijmegen, Netherlands.
Background: Klotho is a key modulator of the phosphate (Pi) and calcium (Ca2+) balance 
and is diminished in chronic kidney disease (CKD). Klotho knock-out (-/-) mice are therefore 
an important model for CKD, mimicking all essential features including hyperphosphatemia 
and development of calcification. In CKD, serum magnesium (Mg2+) inversely correlates 
with incidence and severity of vascular calcification. The mechanisms by which Mg2+prevents 
vascular calcification are poorly understood. Therefore, this study aims to determine the effects 
of Mg2+on development of aortic calcification using Klotho-/-mice.
Methods: Klotho-/-and Klotho+/+mice were fed a normal (0.05% w/w) or high (0.48% 
w/w) Mg2+diet from birth. Aortic calcification was detected by Von Kossa staining and 
RNA-sequencing was performed. Serum electrolyte and hormone concentrations were 
determined. MicroCT was used to study bone integrity.
Results: Von Kossa staining revealed that aortic calcification developed extensively 
in Klotho-/-mice on a normal Mg2+diet and was absent in Klotho+/+mice. Strikingly, high 
Mg2+diet prevented calcification in Klotho-/-mice. Moreover, Mg2+rescued increased 
expression of RUNX2 and osteopontin as well as upregulation of matrix gla protein, 
demonstrating the preventive effect of Mg2+on pro-osteogenic signaling. Potential novel 
mechanisms by which Mg2+prevented calcification were studied by RNA sequencing, 
revealing that pathways mediating inflammation and extracellular matrix remodeling 
enriched in Klotho-/-mice were reversed by Mg2+. Though Mg2+prevented calcification, 
klotho-/-mice on high Mg2+diet had reduced weight and smaller stature. Interestingly, 
high Mg2+impaired bone formation in Klotho-/-mice as femoral mineral-bone density 
decreased by 20% compared to mice on normal Mg2+ diet. High Mg2+did not change known 
mineralization modulators parathyroid hormone, 1.25-dihydroxyvitamin D and Ca2+in 
serum. Interestingly, Mg2+prevented calcification despite increasing fibroblast growth 
factor-23 and Pi concentration in Klotho-/-mice.
Conclusions: This study shows that Mg2+prevented vascular calcification in Klotho-
/-mice. Importantly, Mg2+prevented mineralization in the aortic media as well as bone, 
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potentially involving anti-inflammatory signaling and disruption of extracellular matrix 
remodeling.
Funding: Government Support - Non-U.S.
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Cinacalcet Ameliorates Cardiac Valve Calcification in CKD via Suppress-
ing Endothelial-to-Osteoblast Transition
Li-ting Wang, Kai-yun Song, Li-Hua Ni, Xiao-chen Wang, Meng Zuo, 
Yu-xia Zhang, Bi-Cheng Liu, Ri-ning Tang. Institute of Nephrology, ZhongDa 
Hospital, school of medicine, Southeast University, Nanjing, China.
Background: Clinical studies found cinacalcet (CINA) markedly ameliorated cardiac 
valve calcification in chronic kidney disease (CKD) patients, but it underlying mechanisms 
are still unknown. Previous studies demonstrated endothelial cell participate in ectopic 
calcification in part by mediating endothelial-to-mesenchymal transition (EndMT) that 
could be transitioned into mesenchymal stem cells and further differentiated into osteoblast. 
Thus we investigated whether cinacalcet ameliorated cardiac valve calcification in two 
CKD models via suppression of endothelial-to-osteoblast transition.
Methods: SD rats were randomly divided into three group: control group (CTL, n=10), 
CKD group(n=30), and CINA treatment group(n=30). CKD group were established by 
5/6 nephrectomy (n=15) or 0.75% adenine (n=15) for 4 weeks, both followed with 2.0% 
phosphorus diet for next 8 weeks. Meanwhile, rats of CINA treatment group were orally 
administered CINA (10 mg/kg one day). The expression of EndMT and osteoblast markers 
in valve was examined with the use of western blot, real time PCR, immunofluorescence 
staining and immunohistochemistry. Pathological examinations of the valves included 
histological characterization and Von Kossa staining. And we finished echocardiography 
for three groups. Besides, the important makers of Notch signal pathway were also detected 
in our study with the use of western blot and real time PCR.
Results: In CKD rats, CINA treatment significantly decreased the serum PTH 
concentration, calcium but did not affect the elevated levels of serum creatinine, blood urea 
nitrogen and phosphorus. Besides, CINA significantly attenuated aortic valve calcification, 
and inhibited the expression of osteogenic markers (osteopontin and osterix). Moreover, 
CINA treatment largely abolished the up-regulation of mesenchymal markers (FSP1 and 
α-SMA), stem cell markers (CD44 and CD10) and down-regulation of the endothelial 
marker (CD31, E-cadherin), which accompanied calcification in CKD aortic valve samples. 
Besides, Notch signal pathway was activated with Notch1, NICD, HES and HEY increased, 
while CINA could ameliorates this process.
Conclusions: These findings suggest CINA could attenuate valve calcification by 
abrogating Notch mediated endothelial-to-osteoblast transition in rats with CKD.
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Vascular Calcification, FGF-23, and Phosphate
Pharmacokinetic and Pharmacodynamic Evaluation of a New Vascular 
Calcification Inhibitor (INS-3001) in Rats
Marc P. Maillard,1 David Mordasini,1 Dany Spaggiari,3 Olivier Phan,1 
Mattias E. Ivarsson,2 Roberto Maj,2 Laurent A. Décosterd,3 Michel Burnier.1 
1Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland; 
2Inositec Inc., Zurich, Switzerland; 3Service of clinical pharmacology, Lausanne 
University Hospital, Lausanne, Switzerland.
Background: Morbidity and mortality of patients with CKD increase with the 
progression of vascular calcifications. In the context of the development of drugs capable of 
reducing pathological crystallization, myo-inositol hexaphosphate (IP6) has been shown to 
be a promising candidate but needs to be administered via intravenous infusion. This study 
demonstrates the in vivo inhibitory effect of an IP6 analog (INS-3001), and characterizes its 
pharmacokinetic profile in uremic and non-uremic rats.
Methods: Efficacy of INS-3001 versus IP6 to prevent severe vascular calcification 
was studied in non-uremic rats (vitamin D3 model, n = 5 – 11/group), while the PK of 
INS-3001 was determined after after single i.v. or s.c dosing of 10mg/kg in uremic rats 
(adenine diet model) and non-uremic controls (n = 6/group). Vascular calcifications were 
visualized by von Kossa staining and calcium tissue content measured by ICP-MS. INS-
3001 concentrations in EDTA plasma were measured using a HILIC-MS/MS bioanalytical 
method.
Results: INS-3001 significantly blunted carotid calcification reducing the amount of 
calcium in tissues by a factor of two compared to controls (p=0.017) while a numerical 
decrease was observed at the level of abdominal aorta (p>0.05). Treatment with IP6 could 
not be completed due to the appearance of necrotic lesions at the injection site. INS-3001 
displayed high s.c. bioavailability. In the s.c. group, uremic rats displayed higher AUC, 
mean residence time and Tmax than non-uremic controls (1327.1 vs 802.3 μg/mL*min; 124 
vs 66 min; 23 vs 50 min, respectively) whereas Cmax remained unchanged (8348 vs 8325 
ng/mL). Similar trends were observed following i.v. administration.
Conclusions: IINS-3001 is a potent inhibitor of vascular calcification after Vitamin 
D overdose in rats, in addition INS-3001 has a beneficial effect on the renal function of 
animals in this model. The uremic state appeared to significantly influence the rat plasma 
PKs of INS-3001 after s.c. and i.v. administration. The data suggests that uremia extends 
plasma exposure of INS-3001 without increasing peak plasma levels and that therapeutic 
levels can be attained following s.c. administration in the context of uremia.
Funding: Government Support - Non-U.S.
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Inhibition of Tissue-Nonspecific Alkaline Phosphatase Protects against 
Medial Arterial Calcification in the CKD-MBD Mouse Model
Takashi Tani,1,2 Meguji Fujiwara,2 Hideo Orimo,2 Akira Shimizu,3 
Shuichi Tsuruoka,1 Anthony B. Pinkerton,4 Jose luis Millan.4 1Department of 
Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, 
Japan; 2Department of Metabolism and Nutrition, Graduate School of Medicine, 
Nippon Medical School, Tokyo, Japan; 3Department of Analytic Human 
Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, 
Japan; 4Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Background: Medial arterial calcification (MAC), the main manifestation of chronic 
kidney disease - mineral and bone disorder (CKD-MBD), is a serious complication of 
patients with CKD. The overexpression of tissue-nonspecific alkaline phosphatase (TNAP) 
on vascular smooth muscle cells is reported to accelerate MAC formation. The aim of this 
study was to assess the inhibitory effect of SBI-425, novel and potent pharmacological 
TNAP inhibitor, on MAC formation in a CKD-MBD mouse model.
Methods: Eight-week-old C57/BL6J male mice in CKD groups (Vehicle, SBI-10 and 
SBI-30) (n=10 each) mice were fed a 0.2% adenine and 0.8% phosphorus (Pi) diet for 6 
weeks to induce CKD, followed by a high phosphorus (0.2% adenine and 1.8% Pi) diet for 
6 weeks. Mice in the SBI-10 and SBI-30 groups were administrated 10mg/kg and 30mg/kg 
of SBI-425 by gavage once per day, respectively, from 14 to 20 weeks of age. Control group 
mice (n=6) were fed a standard chow (0.8% Pi) from 8 to 20 weeks of age. At sacrifice, 
animals were scanned by computed tomography (CT) and aorta, kidney and blood samples 
were harvested.
Results: In contrast to major MAC formation in the vehicle group, administration of 
SBI-425 drastically halted MAC formation confirmed by aortic calcification volume (CT 
imaging), percentage calcified area in histology (positive Von Kossa staining) and aortic 
tissue calcium content (OCPC assay). Aortic tissue mRNA expression of osteoblastic trans-
differentiation-related genes including TNAP were upregulated in the Vehicle group, while 
they were suppressed to Control levels in the SBI-10 and SBI-30 groups. Plasma and aortic 
tissue TNAP activities were increased in the Vehicle group, and they were suppressed by 
SBI-425 administration. Blood levels of urea nitrogen and creatinine, phosphorus, intact 
PTH and FGF-23 were higher in the CKD groups than in the Control group and were 
comparable between CKD groups. Plasma pyrophosphate (PPi) levels were shown to be 
higher in SBI-10 and SBI-30 group than the others.
Conclusions: These results showed that TNAP inhibition protects the vascular media 
from MAC formation in a mouse model of CKD-MBD. As PPi is a potent protective agent 
for calcification, elevated PPi concentrations in the SBI-425 treated groups, resulting from 
TNAP activity suppression, reduced MAC.
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The Direct Inhibitory Effect of Ferric Citrate on Phosphate-Induced 
Calcification and Osteoblastic Trans-Differentiation via Suppression of 
HIF1a Expression in Human Vascular Smooth Muscle Cells
Masanori Tokumoto,1 Shunsuke Yamada,2 Toshiaki Nakano,2 Kazuhiko Tsuruya,3 
Takanari Kitazono,2 Hiroaki Ooboshi.1 1Department of Internal Medicine, 
Fukuoka Dental College, Fukuoka, Japan; 2Department of Medicine and 
Clinical Science, Graduate School of Medical Sciences, Kyushu University, 
Fukuoka, Japan; 3Department of Nephrology, Nara Medical School, Kashihara, 
Japan.
Background: Vascular calcification is a life-threatening pathophysiological 
abnormality in chronic kidney disease (CKD). Phosphate (P) is known as its main inducer, 
and it was recently reported that P enhances HIF1a expression, leading to osteoblastic 
trans-differentiation and calcification of cultured vascular smooth muscle cells (VSMCs). 
Because iron degrades HIF1a via activation of proryl hydroxylase (PHD), we examined 
direct effects of ferric citrate (FC), an iron-containing P binder, on P-induced calcification, 
osteoblastic trans-differentiation, and HIF1a expression in VSMCs.
Methods: Human VSMCs were cultured in DMEM plus 10%FCS and 2.0mM P with 
0, 1, 5, 10, 50, 100, or 500mM FC for one or two weeks. The precipitated calcium (Ca) 
contents and expression of calcification inducers or inhibitors were evaluated.
Results: At 1 week, moderate to high concentrations (>=5mM) of FC equally decreased 
P-induced calcification by about 80% (p<0.01), while, at 2 weeks, FC inhibited calcification 
in a concentration-dependent manner and high concentrations (>=50mM) of FC reduced
calcification by almost 90% (p<0.01). Moderate to high concentrations (>=5mM) of FC 
not only suppressed expression of osteoblastic trans-differentiation inducers (BMP2,
RUNX2, SOX9, MSX2, PiT1, and MMP2), but also increased expression of calcification 
inhibitors, OPG and MGP (p<0.01). Moreover, moderate to high concentrations of FC
inhibited expression of HIF1a and VEGF, a downstream gene of HIF1 (p<0.01). Expression 
of HIF1a and VEGF positively correlated with precipitated Ca content and expression of
BMP2, RUNX2, SOX9, MSX2, PiT1, and MMP2, respectively (p<0.01), and negatively
correlated with OPG and MGP expression (p<0.01).
Conclusions: FC, an iron-containing P binder, can directly inhibit P-induced 
calcification and osteoblastic trans-differentiation via suppression of HIF1a expression in 
cultured human VSMCs.
Funding: Government Support - Non-U.S.
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Sucroferric Oxyhydroxide (PA21) Improves Mineral Homeostasis, 
Reduces Vascular Calcification, and Exerts a Beneficial Effect on Renal 
Function in a Rat Model with CKD
Anja Verhulst,1 Ellen Neven,1 Sebastian Walpen,3 Britt Opdebeeck,2 
Felix W. Funk,4 Patrick C. D’Haese.2 1University of Antwerp, Wilryk, Belgium; 
2University Antwerp, Edegem, Belgium; 3Vifor Fresenius Medical Care Renal 
Pharma, Glattbrugg, Switzerland; 4Vifor Pharma Management Ltd., Glattbrugg, 
Switzerland.
Background: PA21 (or sucroferric oxyhydroxide) is an efficacious, well-tolerated 
iron-based phosphate binder and a promising alternative to existing compounds. We 
aimed to evaluate the effect of PA21 on renal function, mineral homeostasis and vascular 
calcification in a CKD rat model.
Methods: To induce stable CKD, 64 male Wistar rats were administered a 0.25% 
adenine diet during for 8 weeks. CKD rats were assigned to 4 treatment groups: (i) vehicle 
(n=16), (ii) 2.5 g/kg/day PA21 (n=16), (iii) 5.0 g/kg/day PA21 (n=16) and (iv) 3.0 g/kg/
day CaCO3 (n=16). Evolution in renal function and mineral metabolism was followed 
by measurement of serum creatinine, phosphorus, calcium, 1,25 (OH)2 vitamin D, PTH 
and FGF-23. Serum ionized calcium, iron, hematocrit, hemoglobin, pH and bicarbonate 
were also measured. Calcification was assessed by determining the calcium content in the 
arteries.
Results: Vehicle treated CKD rats developed severe renal impairment, with creatinine 
values around 3.5-4 mg/dL, and anemia as indicated by decreased serum hematocrit and 
hemoglobin levels. CKD went along with hyperphosphatemia, hypocalcemia, low 1,25 
(OH)2 vitamin D and high PTH and FGF-23 levels. Both PA21 and CaCO3 treatment 
showed efficient phosphate binding capacity and prevented the pronounced increase in 
serum PTH. CKD rats treated with 2.5 or 5 g/kg PA21 showed significant lower serum 
creatinine and phosphorus levels and higher ionized calcium levels after 8 weeks of daily 
treatment as compared to vehicle treated CKD rats. The better preserved renal function 
with PA21 treatment went along with less severe anemia. Both PA21 doses prevented the 
dramatic increase in FGF-23, whereas CaCO3 did not. Daily treatment with PA21 did not 
increase circulating iron levels. Finally, PA21 treatment significantly reduced the calcium 
content in the aorta as well as the carotid and femoral arteries, whereas CaCO3 did not affect 
calcification in the arteries.
Conclusions: In contrast to CaCO3, treatment with PA21 had, aside from its phosphate 
lowering capacity, a beneficial impact on the development towards severe CKD and 
prevented the pronounced rise in serum FGF-23. Arterial calcification was significantly 
reduced by PA21 treatment.
Funding: Commercial Support - Vifor (International) Ltd.
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Interventions in Patient Pathways Reduce the Incidence and Complica-
tions of AKI
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Background: We investigated the management and outcomes of patients developing 
AKI-3 in the South Tyneside area of the North East of England (population:153,700, census 
2011). We proactively introduced interventions to aide early recognition and management 
of AKI. These interventions included intensive education for clinical staff in the community 
and hospitals, the launch of a nephrology outreach service in the South Tyneside Hospital 
and an online AKI health pathway tool. The study aims to scrutinize any changes in 
outcomes since interventions were delivered.
Methods: Methods: Data was gathered by interrogating the regional pathology 
database for all patients who developed AKI 3 during the periods of 1st October 16 – 31st 
December 2016 and subsequently from 1st October 2017 – 31st December 2017. Paediatric 
patients, palliative care patients and those on renal replacement therapy were excluded.
Results: We demonstrate an overall reduction of 17% in the development of AKI3 
during the study period (68 vs 82 cases) additionally; we demonstrate a 29% reduction in 
the development of AKI-3 in hospital. The discharge to baseline creatinine ratio improved 
from 1.5:1 to 1.3:1. The admission to baseline creatinine ratio improved from 3.8:1 to 4.4:1. 
The overall mortality rates remain at 30.88% and the overall hospital stay did not change 
(16.1 days vs 16.2 days).
Conclusions: In conclusion, we demonstrate a significant improvement in the incidence 
of AKI-3. There is early recognition of AKI and significant improvement in the renal 
function on discharge. We recognise that there was no improvement in overall mortality 
and the total number of in-patient days did not improve. Our data suggests that simple 
interventions at multiple levels in a patient’s pathway can lead to significant improvement 
in outcomes.
Comparison of Admission: Baseline and Discharge: Baseline Creatinine Ratios
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Real-Time, Model-Driven Diagnostic and Therapeutic Evaluation of 
Patients at Risk of AKI: A Pilot and Feasibility Study
Francis P. Wilson,1 Ugochukwu C. Ugwuowo,2 Melissa Martin,1 Aditya Biswas,2 
Yu Yamamoto.2 1Yale School of Medicine, New Haven, CT; 2Yale University, 
New Haven, CT.
Background: Acute kidney injury is typically defined by a rise in serum creatinine, 
but this is a late marker of the syndrome. Real-time, updated modeling of AKI risk using 
electronic health record (EHR) parameters may allow for targeting of diagnostic and 
therapeutic interventions earlier in the course of AKI.
Methods: We deployed a time-updated AKI prognostic model into the EHR of a large, 
tertiary care hospital. The model alerted study team members when any hospitalized adult 
had a greater than 30% risk of developing AKI within the next 48 hours: the “pre-AKI 
Alert”. Study personnel took urine and blood samples, examined the medical record, and 
followed patients for the development of creatinine-defined AKI. Our primary goal was to 
determine the feasibility of providing tailored pre-AKI recommendations in this clinical 
setting.
Results: Of 98 patients who met eligibility criteria, 68 were unable or refused to 
consent to study participation. Of the 30 who were enrolled, 5 developed AKI within 24 
hours, 1 additional patient within 48 hours, and 1 later during the subsequent hospital 
admission. Lower-than-expected AKI rates were seen due to difficulty obtaining consent 
from the highest-risk patients. At the time of pre-AKI alert, 3 patients were receiving a 
potentially nephrotoxic agent, 24 had at least one electrolyte abnormality that could be 
addressed, and 3 had mean arterial pressure < 65mmHg (Table). Oxygen saturation was 
significantly lower in those who went on to develop AKI compared to those who did not 
with median (IQR) SPO2 94 (92 - 94) compated to 97 (95-98), p=0.03.
Conclusions: A real-time updated model successfully identified a group of patients 
at high risk for AKI, many of whom had nephrotoxin, electrolyte, blood pressure, or 
oxygenation abnormalities that could be proactively addressed. Model-based pre-AKI 
interventions are feasible and their efficacy should be explored in a larger study.
Funding: NIDDK Support
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Epidemiology of Emergency Department AKI
David A. Foxwell,2,1 Sara Pradhan,2 Soha Zouwail,3 Timothy H. Rainer,2 
Aled O. Phillips.2 1Wales Kidney Research Unit (WKRU), Cardiff, United 
Kingdom; 2Cardiff University School of Medicine, Cardiff, United Kingdom; 
3University Hospital of Wales, Cardiff, United Kingdom.
Background: The epidemiology of Acute Kidney Injury (AKI) diagnosed in the 
Emergency Department (ED) is poorly described. This study describes the incidence, 
demographics and outcomes of patients diagnosed with AKI in the ED (ED-AKI).
Methods: Between April and August 2016 20,421 adult patients attended the ED of 
a University Teaching Hospital (UK) and had a serum creatinine measurement. Using 
an electronic AKI reporting system, 548 incident ED-AKI patients were identified and 
compared to a randomly selected cohort of non-AKI ED patients (n=571). Admission, short 
term and 12-month follow-up data was collated and compared.
AKI: Epidemiology, Risk Factors, Prevention
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Results: 572 patients had a confirmed eAlert AKI (548 incident cases), giving an 
incidence of ED-AKI of 2.8%. ED-AKI was associated with a 24.4% inpatient mortality of 
which 22.3% of deaths occurred in the first 24-hours and 58% within 7 days. Progression of 
admission AKI stage to a higher AKI stage was associated with a 38.8% mortality compared 
to a 21.4% mortality in those who did not progress (p<0.001). In multivariate analysis ED-
AKI was an independent risk factor for mortality (HR, 6.293; 95% CI, 1.887 to 20.790, 
p=0.003). For those discharged from hospital 20.4% of ED-AKI patients were re-admitted 
within 30-days (non-AKI 7.6%, p<0.001). At 90-days following hospital discharge 10.0% 
of the discharged ED-AKI group died (non-AKI discharged 90-day mortality 1.4%, 
p<0.001). 12-months post discharge 17.8% of ED-AKI group developed CKD progression 
or de-novo CKD compared to 6.0% in the non-AKI cohort.
Conclusions: AKI diagnosed in the ED is a strong independent predictor of death. 
ED-AKI mortality is predominantly in the first days following presentation, but for those 
surviving to discharge there is significant long-term morbidity and mortality
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Derivation of a Prediction Model for Emergency Department AKI
David A. Foxwell,2,1 Sara Pradhan,2 Soha Zouwail,3 Timothy H. Rainer,2 
Aled O. Phillips.2 1Wales Kidney Research Unit (WKRU), Cardiff, United 
Kingdom; 2Cardiff University School of Medicine, Cardiff, United Kingdom; 
3University Hospital of Wales, Cardiff, United Kingdom.
Background: Acute Kidney Injury (AKI) is an independent risk factor for death. 
Over 50% of community acquired AKI cases are identified in the Emergency Department 
(ED), which is the main route for acute hospital admissions. Accurate risk stratification 
is essential to facilitate prompt medical investigation and treatment. This study aimed to 
derive a hospital front-door model for predicting AKI in the ED (ED-AKI).
Methods: Between April and August 2016 20,421 adult patients attended the ED 
of a University Teaching Hospital in Wales and had a serum creatinine measurement. A 
retrospective analysis was conducted on 1119 cases (548 incident ED-AKI patients and 571 
randomly selected non-AKI ED patients). Univariate and stepwise backwards removal of 
insignificant variables in a multivariate analyses were used to derive a pragmatic model for 
predicting and risk-stratifying AKI. The primary outcome was ED-AKI.
Results: An 18-point model using four variables was derived for assessing patients 
on ED arrival, where 0 is low chance of ED-AKI and 18 a high chance. The adjusted odds 
ratios for AKI were: age 1.03; male gender 1.45; known Chronic Kidney Disease 2.08; 
and number of comorbidities (from 0 to 10) 1.31. At a score of >2, the sensitivity was 
99.8% (95%CI 99.0-11.0), and specificity was 5.1% (95%CI 3.4-7.2). At a score of >5.5, the 
sensitivity was 85.8% (95%CI 82.6-88.6), and specificity was 52.7% (95%CI 48.5-56.9). 
At a score of >11, the sensitivity was 15.0% (95%CI 12.1-18.2), and specificity was 96.5% 
(95%CI 94.6-97.8). The probability of AKI increased with score groups (chi-squared 
<0.0001). The AUROC was 0.745 (95%CI 0.720-0.772; p<0.0001; R2 18%). There were 
positive correlations between the score and peak creatinine (r=0.415; p<0.0001) but not 
with AKI stage.
Conclusions: A simple, pragmatic 18-point score for predicting probability of ED-AKI 
on ED arrival has been derived. This now requires refinement and prospective validation.
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Comparison of Community and In-Hospital Acquired AKI in the Clinical 
Emergency Department at a University Tertiary Hospital
Lia J. Marçal,2 Flávia B. Azevedo,2 Veronica Torres,2 Graziela R. de Souza,2 
Leila Antonangelo,2 Dirce M. Zanetta,1 Luis Yu,2 Emmanuel A. Burdmann.2 
1University of São Paulo, S Paulo, Brazil; 2University of Sao Paulo Medical 
School, Sao Paulo, Brazil.
Background: Prospective studies comparing frequency and outcomes of community 
and in-hospital (IH) acquired acute kidney injury (AKI) in patients (pts) admitted to the 
Emergency Department (ED) are scarce, especially in developing countries.
Methods: This study aimed to compare the frequency, characteristics and outcomes of 
community AKI (CAKI) vs. IH acquired AKI diagnosed by RIFLE or/and KDIGO (serum 
creatinine criteria - SCr) in pts admitted to the ED through a referred emergency room (ER) 
of a tertiary university hospital. All pts ≥ 18 years old hospitalized in the ED were included. 
Exclusion criteria: decline to sign the informed consent, IH < 48 h, chronic kidney disease 
stage 5, pts on palliative care and renal transplant. Pts were assessed until the hospitalization 
day 7 or discharge. SCr(mg/dl) was assessed at admission and daily or every 48h. Pts were 
divided in the following groups: non-AKI, community-acquired AKI (CAKI), AKI by 
RIFLE (ARIFLE), AKI by KDIGO (AKDIGO) and ARIFLE negative AKDIGO positive 
(K+R-). The assessed outcomes were length of IH stay (LoS, d), and IH mortality. Data are 
presented as median (minimum-maximum values) or percent (%). Statistical significance 
is set at p<0.05.
Results: A total of 788 pts were included, mean age 63 y (18-98y), 55.1% were male, 
LoS was 8d (2-132) and IH mortality was 16.7%. A total of 231 pts (29.3%) developed IH 
AKDIGO – mostly KDIGO I (69.7%) and 167 pts (13.6%) presented CAKI, resulting in 
398 AKI pts (50.5%) Causes of hospitalization were pulmonary (36.2%), cardiovascular 
(11.3%), gastric (16.3%) and others (36,2%). Major outcomes among AKI groups and Non-
AKI group (IMAGE1):
Conclusions: The frequency of AKI at reference ER admission and IH acquired in 
the first 7d of hospitalization was strikingly high in the clinical ED. CAKI showed high 
frequency and mortality. KDIGO criteria diagnosed more pts than RIFLE criteria IH pts. IH 
mortality of AKI pts was significantly higher than non-AKI pts at the ED.
Funding: Government Support - Non-U.S.
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Transition of Hospital-Associated AKI to Acute Kidney Disease and CKD
Kevin Ho, David Riviello, Jason Brown, Sara Saunders, Ion D. Bucaloiu, 
Gurmukteshwar Singh, Jamie A. Green, H. Lester Kirchner. Geisinger, Danville, 
PA.
Background: Acute kidney injury (AKI) is closely tied bidirectionally to the 
pathogenesis and public health burdens of chronic kidney disease (CKD) together with 
increased risks for hospital readmission, endstage kidney disease, and death. Bridging 
transient AKI and CKD, acute kidney disease (AKD) may represent a potentially modifiable 
stage in the natural history of kidney disease.
Methods: We performed a retrospective analysis of hospitalization data from the 
electronic health records for Geisinger, a large healthcare delivery system in Central 
Pennsylvania and New Jersey, 2013-2017 inclusive of baseline SCr and eGFR values 
12-18 months preceding hospital admission. We examined AKI events (KDOQI 
criteria, duration 7 days or less), length of stay, AKD (persistent AKI based on SCr
during Days 8 to 89 post-AKI start date), incident CKD (patients with baseline eGFR 
<60ml/min/1.73m2), and CKD progression (eGFR ≥5 ml/min below baseline eGFR).
Results: Of 282,418 patient admissions, we identified 53,741 hospital admissions 
characterized by AKI events (19.0%). Length of stay (LOS) was increased following an 
AKI event (5.8 days) and exceeded 7 days in 24.7% of AKI patients versus a LOS of 3.7 
days in non-AKI patients. Among admissions with AKI events, AKI transitioned to acute 
kidney disease in 38.2% of occurrences. Moreover in 35,190 patients admitted with a 
baseline eGFR ≥60 ml/min, 18.8% of patients developed incident CKD following either 
AKI or AKD within 1 year of the AKI start date. Combining AKI and AKD occurrences in 
9,245 patients with baseline CKD prior to hospital admission, 29.0% of patients exhibited 
post-AKI/AKD progression of their CKD within 1 year of the AKI event.
Conclusions: Hospital-associated acute kidney injury is observed to occur in 
conjunction with increased hospital length of stay, a relatively high transition rate to acute 
kidney disease, and both incident and progression of chronic kidney disease within 1 year 
of an event. Close clinical follow-up of AKI survivors is needed to promote renal recovery 
and/or delay progression of kidney disease.
Funding: Private Foundation Support
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Predictive Factors of Renal Recovery Following AKI
Josee Bouchard,1 Maria Ostermann,2 Ashita J. Tolwani,3 Rogerio Passos,4 
Andrew J. Lewington,5 Iain Mccullagh,6 Kent Doi,7 Xinling Liang,8 
Elizabeth R. Maccariello,15 Rolando Claure-Del Granado,9 
Christopher J. Thompson,10 Enrico Fiaccadori,11 Nigel M. Chee,18 
Ajay H. Raithatha,19 Anjali Acharya,17 Jorge Cerda,12 Rajasekara C. Madarasu,16 
Etienne Macedo,13 Ravindra L. Mehta.14 1Hopital du Sacre-Coeur de Montreal, 
Montreal, QC, Canada; 2Guy’s & St Thomas’ Hospital, London, United 
Kingdom; 3University of Alabama at Birmingham, Birmingham, AL; 4Hospital 
Sao Rafael, Salvadir, Brazil; 5Leeds Teaching Hospitals, Leeds, United 
Kingdom; 6Newcastle Hospitals NHS Trust, Newcastle upon tyne, United 
Kingdom; 7University of Tokyo, Tokyo, Japan; 8Guangdong general hospital, 
Guangzhou, China; 9Unaer Srl, Zona Sarco, Bolivia, Plurinational State of; 
10Royal Stoke University Hospital, Stoke on Trent, United Kingdom; 11Universita 
Degli Studi-Dip. Clinica Medica Nefrologia, Parma, Italy; 12Capital District 
Renal Physicians, Albany, NY; 13University of California San Diego, San Diego, 
CA; 14University of California San Diego Medical Center, La Jolla, CA; 
15Hospital Quinta D’Or, Rio de Janeiro, Brazil; 16STAR Kidney Center, STAR 
Hospitals, Hyderabad, India; 17Jacobi Medical Center, Albert Einstein College 
of Medicine, Bronx, NY; 18Royal Bournemouth Hospital, Bournemouth, United 
Kingdom; 19Sheffield Teaching Hospitals NHS Foundation Trust, UK, Sheffield, 
United Kingdom.
Background: AKI is frequent and predictors of renal recovery are incompletely 
understood. We aimed to determine the association between clinical characteristics and risk 
factors for AKI with renal recovery.
Methods: This prospective observational study was conducted among intensive care 
unit patients from 25 centers in 9 countries. AKI was defined as an increase in creatinine of 
at least 0.3 mg/dl within 48 hours, and renal recovery, as a creatinine at hospital discharge 
within less than 0.5 mg/dl of reference creatinine.
Results: Between 2008 and 2018, 14,460 patients were screened, of whom 4,241 
(29%) developed AKI. A total of 2,009 (47%) of AKI patients had sufficient data. Median 
age was 64 years (IQR 50-74), 63% were male, 67% were Caucasian, 19% Asian and 
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7% were Black. Thirty-two percent came from emerging countries and 44% had CKD. 
Thirty-six percent underwent surgery, 47% had sepsis, and 47% received vasopressors. 
APACHE III scores at ICU admission was 61 (IQR 43-83). Within the first 7 days of AKI, 
43% had hypotension, 14% received iodinated contrast, 26% required anesthesia and 72% 
received nephrotoxins (including any antibiotics). In-hospital mortality was 20%, and 
19% received dialysis during hospital stay. Seven percent of 1613 survivors were dialysis-
dependent at discharge, while 72% recovered their renal function. A lower probability of 
renal recovery was associated with older age, residence in an emerging country, presence 
of diabetes and liver disease, medical reason for ICU admission and provision of dialysis, 
while administration of vasopressors was associated with a better probability of renal 
recovery. Additional risk factors for AKI were not associated with a lower probability of 
renal recovery.
Conclusions: In our study, older age, residence in an emerging country, diagnosis 
of diabetes and liver disease, medical reason for ICU admission, as well as severe AKI 
were independently associated with a lower renal function at hospital discharge. However, 
ongoing risk factors for AKI within days of diagnosis did not modify renal prognosis at 
discharge.
Funding: NIDDK Support
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Post-Discharge Major Adverse Cardiovascular Events of Intensive Care 
Unit Survivors Who Received Acute Renal Replacement Therapy: A 
Nationwide Population Based Study
Sehoon Park,1 Soojin Lee,2 Min woo Kang,1 Yaerim Kim,1 Jung Nam An,3 Kwon 
Wook Joo,1 Chun Soo Lim,3 Yon Su Kim,4 Dong Ki Kim.1 1Seoul National 
University Hospital, Jongno-gu, Seoul, Republic of Korea; 2Seoul national 
university hospital, Seoul, Republic of Korea; 3Seoul National University 
Boramae Medical Center, Seoul, Seoul, Republic of Korea; 4Seoul National 
University College of Medicine, Seoul, Republic of Korea.
Background: The long-term risk of a major adverse cardiovascular events (MACE) 
in intensive care unit (ICU) survivors who underwent acute renal replacement therapy 
(ARRT) requires further investigation.
Methods: We performed a nationwide population-based study using the claims 
database of Korea, including ICU survivors in over 40 government-designated tertiary 
hospitals from 2005 to 2016. The study group consisted of ICU survivors who underwent 
ARRT, and the control group consisted of those without ARRT. Patients were excluded 
if they 1) were under age 20, 2) expired within 30 days after discharge, 3) received ICU 
care for less than 24 hours, 4) had a previous ICU admission, 5) had a history of MACE 
or MACE-related cardio/cerebrovascular diseases. The outcomes of the patients who 
received CRRT were compared with those of patients who received only intermittent renal 
replacement therapy (IRRT). The main outcome was MACE, including acute myocardial 
infarction, revascularization, and acute ischemic stroke. Patient mortality and progression 
to end-stage renal disease were also evaluated.
Results: We included 12,380 ARRT patients and 382,018 patients in the control group. 
Among the study group, 6,891 patients were included in the CRRT group, and 5,034 in 
the IRRT group. The risks of MACE [adjusted hazard ratio (HR) 1.463 (1.323-1.619), 
P<0.001], all-cause mortality [adjusted HR 1.323 (1.256-1.393), P<0.001], and end-stage 
renal disease [adjusted HR 18.110 (15.779-20.786), P<0.001] were higher in the ARRT 
patients than the control group. When we compared the CRRT patients to the IRRT patients, 
the risk of a MACE was comparable [adjusted HR 1.049 (0.888-1.239), P=0.575].
Conclusions: Clinicians should note the increased risk of a long-term MACE in ARRT 
survivors and consider appropriate risk factor management. Receiving CRRT did not 
increase the risk of MACE when compared to receiving IRRT only.
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Simple Postoperative-AKI Risk (SPARK) Classification in Major 
Non-Cardiovascular Surgery
Sehoon Park,1 Hyunjeong Cho,2 Seokwoo Park,1 Soojin Lee,3 Sejoong Kim,4 
Dong Ki Kim,1 Kwon Wook Joo,1 Yon Su Kim,5 Hajeong Lee.5 1Seoul National 
University Hospital, Jongno-gu, Seoul, Republic of Korea; 2Chungbuk National 
University Hospital, Cheongju-si, ChungcheongBuk-Do, Republic of Korea; 
3Seoul national university hospital, Seoul, Republic of Korea; 4Seoul National 
University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea; 
5Seoul National University College of Medicine, Seoul, Republic of Korea.
Background: We aimed to develop a patient-oriented outcome-based postoperative 
acute kidney injury (PO-AKI) risk index and classification for planning PO-AKI monitoring 
before performing major non-cardiac surgery.
Methods: We performed an observational cohort study in two tertiary referral hospitals, 
each consisting a discovery and validation cohort. Patients who underwent a major non-
cardiac operation (≥ 1 hour) were included. We fitted a proportional logistic regression 
model for an ordinal outcome consisting of the following three categories: no PO-AKI, 
low-stage AKI, and critical AKI. Critical AKI was defined as KDIGO AKI stage ≥ 2, post-
AKI death, or renal failure within 90 days after surgery. PO-AKI events not fulfilling the 
definition of critical AKI were defined as low-stage AKI.
Results: A total of 50,792 and 39,537 patients were included in the discovery and 
validation cohorts, respectively. After building a robust model with variables that could be 
collected or estimated when surgery was scheduled, further simplification was performed. 
The final Simple PO-AKI RisK (SPARK) index included scores of the following ten 
variables: age, sex, eGFR, surgery duration, emergency operation, diabetes mellitus, renin-
angiotensin-aldosterone system blockades, hypoalbuminemia, anemia, and hyponatremia. 
The calibration and discrimination results were acceptable. The AUC for low-stage AKI 
and critical AKI was 0.701 and 0.779 in the validation cohort. When we designated cutoff 
values to define four classifications, the incidences of the outcomes showed class-dependent 
increments.
Conclusions: The SPARK index and classification prior to surgery reflects not only 
the risk of PO-AKI but also the severity and patient-oriented outcomes associated with 
PO-AKI.
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Geographic Correlation Between Dialysis-Requiring AKI and Recovery 
from ESRD
Zijin Chen,1,2 Benjamin J. Lee,2 Charles E. McCulloch,2 Rajiv Saran,3 
Michael Heung,3 Meda E. Pavkov,4 Nilka Rios Burrows,4 Chi-yuan Hsu.2 CDC 
CKD Surveillance Team 1Ruijin Hospital affiliated to Shanghai Jiaotong 
University School of Medicine, Shanghai, China; 2University of California San 
Francisco, San Francisco, CA; 3University of Michigan, Ann Arbor, MI; 
4Centers for Disease Control and Prevention, Atlanta, GA.
Background: We recently reported that about 5% of incident end stage renal disease 
(ESRD) patients in the U.S. recover enough kidney function to discontinue maintenance 
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dialysis (Lee AJKD 2017). Large geographic variations in rates of renal recovery among 
ESRD patients have also been reported (Mohan PLoS One 2013). We hypothesized that 
this may be related to variation in rates of dialysis-requiring acute kidney injury (AKI-D).
Methods: Incidence rates of AKI-D hospitalization in 2011 for AZ, AR, CA, FL, IA, 
KY, MA, MD, MI, NJ, NM, NY, NV, OR, RI, SC, VT and WA were calculated from the 
State Inpatient Database using validated diagnostic and procedure codes. Rates of renal 
recovery among ESRD patients in 2011 were calculated using U.S. Renal Data System data. 
U.S. Census data were used to define underlying population sizes. Correlation (unadjusted) 
was determined using Pearson’s r.
Results: We found a positive correlation between rate of renal recovery and incidence 
of AKI-D, both overall (Figure) and in subgroups (Table).
Conclusions: Rates of renal recovery among incident ESRD patients varied 
considerably across states and correlated with geographic variation in AKI-D incidence. 
These findings support the hypothesis that renal recovery among ESRD patients mostly 
represents recovery from AKI-D. When reporting counts of “end-stage” renal disease, 
subtracting those who recovered renal function (which ranges in magnitude from 3% to 8% 
in the sampled states) might be a consideration.
Funding: NIDDK Support, Other U.S. Government Support, Private Foundation 
Support, Government Support - Non-U.S.
State-level correlation between AKI-D incidence and rate of renal recovery among ESRD 
patients stratified by age and sex
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Population-Based Trends in Pediatric AKI (2008-2016): The Kaiser 
Permanente Experience
Rishi V. Parikh,1 Thida C. Tan,1 Elaine Ku,2 Tracy Y. Jonelis,1 Alan S. Go.1 
1Kaiser Permanente Northern California, Oakland, CA; 2University of 
California San Francisco, San Francisco, CA.
Background: Acute kidney injury (AKI) may lead to long-term consequences in 
children but its epidemiology has not been well-described outside of ICU settings. We 
evaluated recent temporal trends in rates of AKI in a large, diverse pediatric population 
receiving care within an integrated healthcare delivery system.
Methods: We identified calendar year-based cohorts from 2008-2016 of Kaiser 
Permanente Northern California members <18 years old. We excluded those <1 year old or 
who received prior renal replacement therapy before entry into a yearly cohort. Hospitalized 
AKI was identified and its severity assessed using KDIGO criteria. Baseline SCr was 
defined as the most recent outpatient, non-emergency department value 7-365 days before 
admission, and eGFR was calculated using the bedside Schwartz equation. We examined 
age- and sex-adjusted incidence of AKI per 100 person-years and per 100 hospitalizations 
per year, directly standardized to the 2008 population. Trends were evaluated using Poisson 
regression.
Results: Among 1,500,546 pediatric members, mean age was 9.8 years and 48.9% were 
female. The age-and sex-adjusted incidence of hospitalized AKI did not change significantly 
across the study period. There were 69,645 hospitalizations during the study period, with 
the hospitalization rate in the population declining from 1.45 per 100 PY in 2008 to 1.12 per 
100 PY in 2016 (p<0.001). Among hospitalizations, the age-and sex-adjusted incidence of 
Stage 1 AKI increased from 2008 to 2016, with borderline significance.
Conclusions: Population-level pediatric AKI incidence did not significantly change 
between 2008-2016, but Stage 1 AKI incidence slightly increased over time among the 
subset of hospitalized children.
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Theophylline Use to Mitigate AKI in Infants Undergoing Total Body 
Cooling for Perinatal Asphyxia
Kyle Merrill, Jennifer G. Jetton, Jonathan M. Klein, Jason Misurac. University 
of Iowa, Iowa City, IA.
Background: Perinatal asphyxia is a common cause of acute kidney injury (AKI) 
and hypoxic ischemic encephalopathy (HIE). Theophylline is protective against AKI in 
infants with HIE who are not treated with total body cooling. However, there is a paucity of 
information on the effect of theophylline to protect against AKI in infants with HIE treated 
with total body cooling.
Methods: Single-center retrospective cohort analysis of infants diagnosed with HIE 
treated with total body cooling from 1/2007 to 12/2017. Inclusion criteria were: moderate 
or severe HIE, gestational age > 36 weeks, measurement of at least two serum creatinine 
(SCr) values at least 12h apart, and absence of prenatally diagnosed renal disease. Included 
infants were stratified based on receipt of theophylline and theophylline dose strategy: 
either a single dose of 5-8 mg/kg on day of life (DOL) 0 (standardized) or multiple doses 
(non-standardized). AKI was defined according to a Kidney Disease: Improving Global 
Outcomes (KDIGO) definition modified for neonates: SCr ≥50% above the lowest previous 
baseline; increase in SCr of ≥0.3 mg/dL within 48h; or urine output (UOP) ≤1 ml/kg/h for 
24h.
Results: There were 116 infants who met the inclusion criteria. Among included 
infants, SCr was missing on 374/812 days (46%) from DOL 0-6, limiting the detection of 
AKI by SCr. AKI incidence was 63/116 (54%). There was no significant difference in AKI 
incidence between groups (χ2=0.18, p=0.91). AKI severity was higher in the no theophylline 
group but the difference was not significant (χ2=3.9, p=0.42). UOP was different between 
groups on DOL 1 (p=0.008) but not on DOL 2-6.
Conclusions: In this cohort of infants with HIE treated with total body cooling, 
theophylline administration was not associated with a significant difference in the incidence 
or severity of AKI.
*Median (IQR) **Gentamicin, vancomycin, piperacillin/tazobactam, acyclovir, and
captopril
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Hyponatremia and AKI in Critically Ill Children
Cassandra L. Formeck,3,1 Emily L. Joyce,3,1 Priyanka Priyanka,1 
Shashank Badavanahalli Rajashekar,1 Juan Carlos Ayus,2 John A. Kellum,1 
Michael L. Moritz.3 1The University of Pittsburgh, Pittsburgh, PA; 2Renal 
Consultants of Houston, Houston, TX; 3Children’s Hospital of Pittsburgh of 
UPMC, Pittsburgh, PA.
Background: Hyponatremia is associated with increased morbidity and mortality in 
hospitalized patients for unknown reasons. Hyponatremia is also associated with osmotic 
cellular stress. Renal tubular epithelial are exposed to numerous stressors in critically 
ill patients. We hypothesized that hyponatremia would be associated with a greater rate 
of acute kidney injury (AKI) in critically ill children. Our objective was to evaluate the 
association between hyponatremia and AKI, controlling for sepsis, a primary coexposure.
Methods: Using a pediatric ICU database of 12,806 admissions, we included patients 
with a measured sodium value within 6 hours of ICU admission, and excluded patients 
with AKI or significant chronic renal dysfunction. We analyzed the association between 
hyponatremia (serum Na < 135 mEq/L), sepsis and known nephrotoxic drug exposure 
within 48 hours of ICU admission, on the development of stage 2 or 3 AKI within 7 days. 
For the primary analysis, we stratified by the presence or absence of sepsis at ICU admission, 
and compared rates of AKI in patients with and without expsoure to hyponatremia or 3 or 
more nephrotoxic medications.
Results: A total of 5,300 patients (male 58%; mean age 7.5 years) were included in 
the analysis. 16.1% of patients had hyponatremia, 7.0% nephrotoxic medication exposure 
and 30.1% developed sepsis. The incidence of stage 2 or 3 AKI was 8.8% in hyponatremic 
patients with sepsis compared to 14.7% in hyponatremic patients without sepsis. Patients 
with hyponatremia and nephrotoxic medication exposure were at increased risk for AKI in 
the absence of sepsis (p <0.001, p 0.008). Patients with hyponatremia, with and without 
sepsis, were more likely to develop AKI compared to patients with normonatremia (RR 
1.11, RR 1.82). In children without sepsis, patients with hyponatremia were at higher risk 
of developing AKI than patients with exposure to 3 or more nephrotoxic medications (RR 
1.82, RR 1.57).
Conclusions: Hyponatremia is a significant risk factor for AKI in critically in children 
in the absence of sepsis.
Funding: NIDDK Support
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Hyperuricemia Is Associated with AKI and All-Cause Mortality in 
Hospitalized Patients
Min woo Kang,1 Minjung Kang,2 Soie Kwon,3 Ho Jun Chin,4 Dong Ki Kim,1 
Kwon Wook Joo,1 Yon Su Kim,5 Sejoong Kim,4 Seung Seok Han.5 1Seoul 
National University Hospital, Seoul, Republic of Korea; 2Seoul National 
University Hospital, Seoul, Republic of Korea; 3Seoul national university, Seoul, 
Republic of Korea; 4Seoul National University Bundang Hospital, Seong nam, 
Republic of Korea; 5Seoul National University College of Medicine, Seoul, 
Republic of Korea.
Background: Hyperuricemia as a risk factor of high morbidity and mortality has been 
documented in several disease status. Nevertheless, the relationship between uric acid (UA) 
and the risks of acute kidney injury (AKI) and mortality remains unresolved in hospitalized 
patients.
Methods: All patients (aged ≥ 17 years old) admitted to Seoul National University 
Bundang Hospital from January 2013 to December 2013 were retrospectively reviewed. 
UA at the time of admission was categorized based on the quartiles. Odds ratio (OR) for 
AKI and hazard ratio (HR) for all-cause mortality were calculated after adjustment of 
multiple variables. All the analyses were stratified by gender.
Results: The 4th quartile UA group (male, UA ≥ 6.8 mg/dL; female, UA ≥ 5.4 mg/dL) 
showed a higher risk of AKI than the 1st quartile group (male, UA < 4.4 mg/dL; female, 
UA < 3.5 mg/dL) as following ORs: 2.3 (1.76-2.90) in males (P < 0.001); and 2.5 (1.86-
3.32) in females (P < 0.001). There were more patients who did not recover from AKI 
in the 4th quartiles than in the 1st quartiles, as following ORs: 1.5 (1.11-1.95) in males 
(P < 0.001); and 2.5 (1.63-3.98) in females (P < 0.001). The 4th quartile group had a higher 
risk of all-cause mortality than the 1st quartile group, as following HRs: 1.5 (1.30-1.71) 
in males (P < 0.001); and 1.3 (1.08-1.52) in females (P = 0.004). The in-hospital mortality 
risk was also higher in the 4th quartile than in the 1st quartile, which was only significant in 
males: OR, 2.4 (1.56-3.77) (P < 0.001).
Conclusions: Hyperuricemia increases the risks of AKI and all-cause mortality in 
hospitalized patients.
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Improvement of the Renal Angina Index Clinical Application Through 
Multiple Baseline Creatinine estimation Methods
Jean-Philippe Roy,1,2 Stuart Goldstein.3 1Division of Nephrology and 
Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 
2Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical 
Center, Cincinnati, OH; 3Cincinnati Children’s Hospital Medical Center, 
Cincinnati, OH.
Background: The Renal Angina Index (RAI) is a validated screening tool used at 
12h of pediatric intensive care unit (PICU) admission that predicts severe AKI on PICU 
day 3. A baseline serum creatinine (SCr) value is essential for AKI diagnosis as well 
as RAI, yet, is often not available. In this situation, our RAI algorithm uses a validated 
height-dependent imputation method (Baseline SCr (mg/dL) = 0.413 x height (cm) / 
120ml/min/1.73m2), yet patient height often is not available in the medical record within 
12 hours of PICU admission. To improve the reliability of the RAI algorithm, we compared 
the height-dependent method with an age-based, height-independent baseline SCr 
calculation.
Methods: In April 2017, we implemented an electronic algorithm to automatically 
generate an RAI score for every patient (pt) admitted to our PICU. We reviewed 157 pt 
records from May 2017, selecting those who had an appropriate calculation of their RAI at 
12h. We compared the RAI using an age-based SCr imputation method of Pottel to the RAI 
using a SCr imputed by the height-dependent method. Our primary outcome was a change 
in fulfillment of the RAI positivity threshold (RAI≥8). A secondary outcome compared 
height-based imputed and age-based baseline SCr to assess for a discrepancy of >25% 
between the two methods.
Results: We found 15/157 false positive RAI results on screening due to a lack of 
previously measured SCr and height, 42 without SCr measurement within 12h of their 
admission, leaving 100 that had sufficient data for RAI calculation. Only 2/100 pt had the 
RAI reclassified when using the Pottel imputed baseline SCr (one in each direction). 20% 
of pt had a discrepancy of 25% or more between the two methods. A Cochrane-Mantel-
Haenszel Chi-square test confirmed that being small for age (<3rd percentile of height) or 
being older (≥14 years old) were both independently associated with an overestimation of 
the baseline SCr when using the age-based method.
Conclusions: The age-based method to estimate baseline SCr offers a viable height-
independent alternative for RAI calculation. While being less precise than a height-based 
approach, this lack of precision rarely leads to reclassification of pt RAI status.
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U-Shape Association of Serum Albumin Level and AKI Risk in Hospital-
ized Patients
Wisit Cheungpasitporn,1 Charat Thongprayoon,2 Michael A. Mao,3 
Ankit Sakhuja,4 Kianoush Kashani.3,4 1Nephrology, University of Mississippi
Medical Center, Jackson, MS; 2Bassett Medical Center, Cooperstown, NY; 
3Nephrology and Hypertension, Mayo Clinic, Rochester, MN; 4Pulmonary and
Critical Care Medicine, Mayo Clinic, Rochester, MN.
Background: While an association between hypoalbuminemia and increased risk 
of acute kidney injury (AKI) is well-established, the risk of AKI development and its 
severity among patients with elevated serum albumin is unclear. The aim of this study was 
to evaluate the risk of AKI in hospitalized patients stratified by various admission serum 
albumin levels.
Methods: This single-center retrospective study was conducted at a tertiary referral 
hospital. All adult hospitalized patients who had admission albumin levels available 
between January 2009 and December 2013 were enrolled. Admission albumin was 
categorized based on its distribution into six groups (≤2.4, 2.5-2.9, 3.0-3.4, 3.5-3.9, 4.0-4.4, 
and ≥4.5 mg/dL). The primary outcome was the incidence of hospital-acquired AKI 
(HAKI). Logistic regression analysis was performed to obtain the odds ratio of AKI for 
various admission albumin strata using the albumin 3.5 to 3.9 mg/dL (lowest incidence of 
AKI) as the reference group.
Results: Of the total 9,552 studied patients, HAKI occurred in 1,556 (16.3%) 
patients. The incidence of HAKI among patients with admission albumin ≤2.4, 2.5-2.9, 
3.0-3.4, 3.5-3.9, 4.0-4.4, and ≥4.5 mg/dL was 18.3%, 14.3%, 15.5%, 14.2%, 16.7%, and 
26.0%, respectively. After adjusting for potential confounders, admission serum albumin 
levels ≤2.4 and ≥4.5 mg/dL were associated with an increased risk of HAKI with odds 
ratios of 1.52 (95% CI 1.18-1.94) and 2.16 (95% CI 1.74-2.69), respectively. While 
stage 1 HAKI was significantly more frequent among patients with admission albumin 
≥4.5 mg/dL (23.0% vs. 11.6%, P<0.001), incidence of stage 3 HAKI was higher in those
with albumin ≤2.4 mg/dL (2.8% vs 0.3%, P<0.001).
Conclusions: Admission serum albumin levels ≤2.4 and ≥4.5 mg/dL were associated with 
an increased risk for HAKI. Patients with admission albumin ≥4.5 mg/dL had HAKI with a 
lower intensity when compared with those who had admission albumin levels ≤2.4 mg/dL.
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Admission Calcium-Phosphate Product Levels and Risk of AKI in 
Hospitalized Patients
Michael A. Mao,1 Wisit Cheungpasitporn,2 Charat Thongprayoon,3 
Stephen B. Erickson.1 1Nephrology and Hypertension, Mayo Clinic, Rochester, 
MN; 2Nephrology, University of Mississippi Medical Center, Jackson, MS; 
3Bassett Medical Center, Cooperstown, NY.
Background: An increased serum calcium-phosphate product (CaP) can result in acute 
kidney injury (AKI) due to tubular and interstitial calcium phosphate deposits. In addition, 
CaP of >55 mg2/dL2 is associated with systemic calcification. However, the risk of AKI 
development among hospitalized patients with different calcium-phosphate product levels 
on admission remains unclear.
Methods: All adult hospitalized patients who had both admission serum calcium and 
phosphate levels available between years 2009 and 2013 were enrolled. Admission CaP 
was categorized based on its distribution into six groups (<22, 22-<27, 27-<32, 32-<37, 
37-<42 and ≥42 mg2/dL2). The odds ratio (OR) of in-hospital mortality by admission CaP, 
using the CaP category of <22 mg2/dL2 as the reference group, was obtained by logistic 
regression analysis.
Results: After excluding patients with end stage renal disease (ESRD), without 
serum creatinine measurement, and those with AKI at presentation, a total of 9,864 
patients were studied. In-hospital AKI occurred in 1,478 (15.0%) patients. The incidence 
of AKI among patients with admission CaP <22, 22-<27, 27-<32, 32-<37, 37-<42 and 
≥42 mg2/dL2 was 11.1%, 12.4%, 14.9%, 15.2%, 17.5%, and 19.9%, respectively. After
adjusting for potential confounders, CaP >37 mg2/dL2 was associated with an increased
risk of developing AKI, with ORs of 1.53 (95% CI 1.19-1.96) and 1.63 (95% CI 1.25-
2.14) in patients with admission CaP 37-<42 and ≥42, respectively. Among a subgroup of 
patients with available serum albumin, after adjusting for potential confounders, corrected
CaP >27 mg2/dL2 was associated with an increased risk of developing AKI with ORs of 
1.50 (95% CI 1.06-2.15), 1.49 (95% CI 1.06-2.13), 1.85 (95% CI 1.30-2.67) and 1.69
(95% CI 1.16-2.49) when CaP were within 27-<32, 32-<37, 37-<42 and ≥42 mg2/dL2, 
respectively.
Conclusions: Elevated admission CaP was associated with an increased risk for in-
hospital AKI.
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Lower Serum Bicarbonate Is Associated with an Increased Risk of AKI
Neil R. Shah,2 Zhiying You,3 Anna J. Jovanovich,4 Michel Chonchol,2 
Jessica B. Kendrick.1 1University of Colorado School of Medicine, Aurora, CO; 
2University of Colorado, Denver, CO; 3UC Denver, Aurora, CO; 4Denver VA / 
University of Colorado, Denver, CO.
Background: Lower serum bicarbonate levels are associated with an increased risk of 
kidney disease progression. Whether lower serum bicarbonate levels are associated with an 
increased risk of developing acute kidney injury (AKI) is unclear. We tested the hypothesis 
that lower serum bicarbonate levels are associated with a higher risk of developing AKI.
Methods: We included 8,393 patients from the Systolic Blood Pressure Intervention 
Trial (SPRINT). Serum bicarbonate levels were measured at baseline in the SPRINT study. 
AKI was a predetermined adjudicated adverse event that was determined by hospital 
admission and discharge records with AKI as a recorded diagnosis. Serum bicarbonate was 
examined in clinically significant cutoffs ≤ 24, 25-28 and >28 mEq/L, with 25-28 mEq/L as 
the reference group. Cox proportional hazard models were used to examine the association 
between serum bicarbonate and development of AKI.
Results: The mean (SD) age, estimated glomerular filtration rate (eGFR), and serum 
bicarbonate level at baseline were 68 (9) years, 77 (23) ml/min/1.73m2 and 26.3 (2.6) mEq/L, 
respectively. Participants with serum bicarbonate levels ≤ 24 mEq/L were more likely to 
be male and to have lower baseline eGFR. After a median follow-up time of 3.3 years, 
293 participants developed AKI. More patients in the lower bicarbonate group developed 
AKI (6.1% vs 2.8% in the 25-28 mEq/L and 2.1% in the >28 mEq/L). A bicarbonate level 
≤ 24 mEq/L was associated with a significantly increased risk of AKI compared to those with a 
bicarbonate level of 25-28 mEq/L after full adjustment (HR 1.42, 95% CI 1.1 to 1.8).
Conclusions: Lower serum bicarbonate levels are an independent risk factor for the 
development of AKI.
Funding: Other NIH Support - NHLBI
Hazard Ratio (95%CI) of AKI
*Model 1: adjusted for age, gender, race, treatment assignment, smoking status, history 
of cardiovascular disease, heart failure, baseline body mass index, blood pressure and
eGFR.
**Model 2: adjusted for model 1 plus class of antihypertensive medication.
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Risk Factors for Community-Acquired Kidney Disease
Etienne Macedo,6 Ulla Hemmila,7 Sanjib Kumar Sharma,2 Rolando Claure-Del 
Granado,1 Henry E. Mzinganjira,8 Bijay Bartaula,2 Michael V. Rocco,3 
Emmanuel A. Burdmann,4 Jorge Cerda,5 Ravindra L. Mehta.6 ISN 0by25 
1Hospital Obrero#2-Universidad Mayor de San Simon, Zona Sarco, Bolivia, 
Plurinational State of; 2B P Koirala Institute of Health Sciences, Dharan, 
Nepal; 3Wake Forest School of Medicine, Winston-Salem, NC; 4University of 
Sao Paulo Medical School, Sao Paulo, Brazil; 5Capital District Renal 
Physicians, Albany, NY; 6University of California San Diego Medical Center, La 
Jolla, CA; 7College of Medicine, Malawi, Kokemäki, Finland; 8MOH, Blantyre, 
Malawi.
Background: Risk factors for the development of AKI in the community, either 
presenting to Community Health Center (CHC) or emergency departments (ED), have not 
been well studied in Low and Lower-Middle Income Countries (LLMIC). A key limitation 
is the heterogeneity of diseases and a lack of a standardized approach to evaluating renal 
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dysfunction. We evaluated the risk factors associated with acute kidney disease (AKD) 
within the International Society of Nephrology 0by25 Pilot Feasibility Project, designed to 
improve detection and management of community acquired-AKI in LLMIC.
Methods: Patients (pts) presenting to CHC or ED were screened for signs or symptoms 
a priori associated with risk of developing AKI. Pts with high/moderate risk underwent a 
serum creatinine (sCr) POC test and a urine dipstick. Pts were classified as chronic kidney 
disease (CKD) based on prior history, proteinuria (>1+) and/or baseline sCr within 12 
mos by estimated GFR (CKD-EPI equation)) <60 mL/min/1.73 m2; normal renal function 
(NRF) (negative proteinuria and eGFR>75ml/min/1.73 m2); Acute Kidney Disease (AKD) 
neither meeting criteria for CKD or NRF. AKI was confirmed within 7 days by sCr increase 
or decrease of 0.3mg/dl, or 1.5x from the reference value.
Results: 3,577 pts were screened; 319 CKD and 379 children <12 years old were 
excluded from this analysis. Of 2,879 remaining pts, 1248 (43%) were classified as AKD 
at enrollment; 496 had NRF; and 1,135 with low risk for AKI, were assumed to have a 
normal renal function. Over the first 7 days, 438(3.5%) from AKD and 58(35%) from NRF 
group met criteria for AKI. In comparison to NRF, pts with AKD had a higher frequency of 
diabetes (13% AKD vs. 9%NRF), hypertension (22%AKD vs.16%NRF) and chronic liver 
disease (5%AKD vs. 2%NRF). Dehydration associated with vomiting and low oral intake 
was the most common risk factor for AKD, followed by diarrhea, hypotension and appetite 
loss. Pts with AKD were more often hospitalized and had high mortality rates; 9% at 7 days 
and 15% at 6months.
Conclusions: Comorbidities and a set of signs and symptoms can identify adult 
patients at risk for AKD and can be used to select patients that may benefit from POC testing 
in CHC. Crucially, identification of kidney dysfunction can help discriminate patients who 
may benefit from higher levels of care.
Funding: Private Foundation Support
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National AKI Risk Estimates After a Variety of Inpatient Surgeries
Mohammed J. Saeed,1 Tarek Alhamad.2 1Capital Health, Trenton, NJ; 
2Washington University in St. Louis, St. Louis, MO.
Background: Postoperative acute kidney injury (AKI) is not well studied in non-
cardiac procedures. Our aim was to quantify the risk of AKI and dialysis-requiring AKI 
(AKI-D) after various inpatient surgeries.
Methods: We used the National Inpatient Sample (NIS), which is a nationally 
representative sample of hospitalizations in the United States and includes records from 
all payers (including the uninsured). We identified 37 types of surgeries from 1/1/2013 to 
9/30/2015 in adults (age ≥18 years) on first 2 days of hospitalization, excluding patients 
with end stage renal disease. Procedures, AKI and AKI-D were defined using ICD-9-CM 
diagnosis and procedure codes. Certain same-day surgery combinations were identified as 
well. Weighted frequencies and proportions of AKI and AKI-D were calculated for each 
surgery with 95% confidence intervals (CI).
Results: Our study sample of 2,504,894 surgical hospitalizations represented 
12,524,470 hospitalizations when weighted. AKI and AKI-D risk was plotted in figure 1 
sorted by AKI risk. Surgeries with the highest AKI-D percentages were heart transplant 
(2.6%, 95% CI 1.0-4.2), liver transplant (3.7%, 95% CI 2.4-4.9) and abdominal aortic 
aneurysm repair (4.2%, 95% CI 3.4-5.0). Small bowel surgery had the highest AKI risk 
among bowel surgeries (8.7%, 95% CI 8.3-9.0) and had even higher risk when combined 
with colon surgery (18.3%, 95% CI 17.4-19.3) or with exploratory laparotomy (14.2%, 95% 
CI 13.5-14.8). Exploratory laparotomy combined with an abdominal procedure (except 
gastric and cesarean procedures) had significantly higher AKI risk (range of percentage 
difference 0.4-5.5).
Conclusions: Using nationally representative data, we estimated the risk of AKI and 
AKI-D in a large population of surgical hospitalizations including certain same-day surgery 
combinations.
Figure 1. AKI Risk After Inpatient Surgeries
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Predictors for AKI in Old Age
Natalie Ebert,3 Doerte Huscher,4 Jens Gaedeke,2 Markus van der Giet,2 
Martin K. Kuhlmann,1 Nina Mielke,3 Elke Schaeffner.3 Berlin Initiative Study 
(BIS) 1Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Dept. of 
Nephrology, Charité, Berlin, Germany; 3Institute of Public Health, Charité 
Universitaetsmedizin Berlin, Berlin, Germany; 4Institute for Biostatistics and 
Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Background: Acute kidney injury (AKI) is a feared condition especially in old age. 
Data on incidence rates however as well as predictors are scarce. The Berlin Initiative Study 
(BIS) evaluates the incidence of AKI and potential predictors in older adults.
Methods: The BIS is a prospective population-based cohort initiated in 2009 whose 
participants are members of a German insurance company with the largest fraction of older 
adults. Patients are documented biannually by a standardized questionnaire. All intermediate 
hospitalizations with referral and acute ICD-10 (N17.xx) diagnoses were provided by the 
insurance company. N17.xx events during hospitalizations were identified. From the group 
without incident AKI 16 patients with prevalent events were excluded. Multivariate Cox-
PH regression analysis was used to detect predictors for the first incident AKI.
Results: As of May 04, 2018, 2053 participants (47.4% male, mean age 80.3 at 
inclusion) were observed for 7.4±0.4 years. Of those, 189 (9.2%) experienced at least one 
AKI during the observation. In total, 292 events were observed (incidence ratio / 100.000 
person-yrs: 1900). At baseline, patients with incident AKI were about 2.4 years older, more 
frequently male (57 vs. 47%), had a worse waist-hip-ratio (WHR, median 1.0 vs. 0.9), 
eGFR(BIS2) (median 49 vs. 60 mL/min per 1.73m
2) and albumin-creatinine ratio (median 17 
vs. 10 mg/g) and suffered more often from comorbidities at baseline (hypertension 91 vs. 
77%, diabetes 40 vs. 25%, myocardial infaction 22.0 vs 13%, stroke 15 vs. 8%, anemia 32 
vs. 16%). Of the 189 patients with AKI, 26 (13.8%) were admitted to the hospital with an 
N17.xx ICD-10 code, all other patients with other primary referral diagnoses; the median 
number of hospitalization during the observation period was 7 (median duration of stay 11 
days). Of the patients without AKI, 41% had hospitalizations with a median number of 4 
(median duration of 7.6 days). In the multivariate model, eGFR(BIS2) (OR=0.873 [0.83;0.92] 
per 5 units), waist-hip-ratio (OR=1.47 [1.24;1.74] per 0.1 units), hypertension (OR=2.00 
[1.18;3.38]), diabetes (OR=1.61 [1.19;2.18]), and anemia (OR=1.52 [1.09;2.12]) were 
predictive for AKI in older adults.
Conclusions: With 1900 per 100.000 person-yrs AKI is frequent in a representative 
sample ≥70 yrs. Potential predictors apart from eGFR(BIS2) were WHR, hypertension, 
diabetes and anemia.
Funding: Veterans Affairs Support
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AKI Mortality and Weekend Nephrologist Consultation
Ana carolina N. Tome,3 Rodrigo J. Ramalho,1 Emerson Q. Lima.2 Hospital de 
Base / FAMERP - São José do Rio Preto - Brazil 1Hospital de Base/FAMERP, Sao 
Jose Rio Preto, Brazil; 2FAMERP, São José do Rio Preto, Brazil; 3Faculdade de 
Medicina de São José do Rio Preto, São José do Rio Preto, Brazil.
Background: Admission to the hospital on weekends (WKD) is associated with 
increased mortality for acute illnesses than weekdays (WDAY). Previous analysis showed 
that this phenomenom also occurs in patients with acute kidney injury (AKI). However, 
there is still no data about this association and nephrologist consultation. Aim: analyse the 
impact of the day of the week of nephrologist consultation on the mortality in patients with 
AKI.
Methods: Database of patients over 18 years with AKI between 1srt January 2012 
and 28st February 2018. Patients were analyzed according to the day of the week of first 
nephrologist consultation.
Results: During the period 6177 patients diagnosed with AKI were attended. The 
mean age was 64.1±15.7 years. They were classified in KDIGO I (46.3%), KDIGO II 
(26.5%) e KDIGO III (27.2%) at the nephrologist’s called. The mean SOFA was 7.3 ± 4.7, 
34.1% dialyzed and global mortality was 37.1%. WDAY called group has 4761 (77.1%) 
and WKD, 1416 (22.9%) patients. SOFA (7.8±4.7 vs 7.1±4.6, p<0.001) and mortality 
(41.5% vs 35.8%, p <0,001) were higher on WKD group. The following mortality risk 
factors were identified: age (OR 1.02; IC 1.02-1.03; p<0.001), obstructive AKI (OR 
0.39; IC 0.26-0.58; p<0.001), sepsis (OR 1.26; IC 1.10-1.45; p=0.001), liver disease 
(OR 1.40; IC 1.11-1.77; p=0.004), cancer (OR 1.17; IC 1.19-2.62; p=0.005), dialysis (OR 
1.54; IC 1.31-1.80; p<0.001), SOFA at the moment of the call (OR 1.18; IC 1.16-1.20; 
p<0.001) and at the first dialysis (OR 1.07; IC 1.05-1.08, p<0.001). In the model with only 
patients hospitalized in intensive care unit (ICU) (3283 patients; 53.14%), nephrologist 
consultation at WKD (OR 1.22; IC 1.02-1.46; p=0.028), age (OR 1.01; IC 1.01-1.02; 
p<0.001), obstructive AKI (OR 0.51; IC 0.27-0.96; p=0.037), cancer (OR 2.30; IC 
1.34-3.94; p=0.002), dialysis (OR 1.57; IC 1.31-1.88; p<0.001), SOFA at the moment of 
the call (OR 1.11; IC 1.09-1.13; p<0.001) and at the first dialysis (OR 1.08; IC 1.07-1.10; 
p<0.001) were identified as risk factors of mortality.
Conclusions: First nephrologist consultation at WKD was associated a higher 
mortality, particularly those hospitalized in ICU. This association can be due to the highest 
severity of this population.
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Incidence and Risk Factors of AKI After Coronary Artery Bypass 
Grafting
Ahmad Salha,1 Jose O. Valencia,1 Bayiha daho Klaud francheska,1 
Racquel M. Lowe-Jones,1 Joe Wang,2 Robin Kanagasabay,1 Debasish Banerjee.1 
1St George’s University Hospital NHS Foundation Trust, London, United 
Kingdom; 2Epsom & St Helier Hospital NHS Trust, London, United Kingdom.
Background: Acute kidney injury (AKI) Post-coronary artery bypass graft (CABG) is 
common, but the exact incidence remains controversial, and contributing risk factors varies 
in different studies. We aimed to investigate the true incidence and risk factors of AKI 
post Cardiopulmonary bypass (CPB) CABG; in a large inner-city, multi-ethnic, population.
Methods: We examined 2413 patients undergoing first time CPB CABG in a large 
tertiary care, UK hospital. Creatinine measurements (on isotope dilution mass spectroscopy 
or spectrometry) were derived from hospital records, pre-surgery and post-surgery days 
1,2,3 and 4. AKI was defined as a rise of serum creatinine 26.4 μmol/L or 50% or 1.5-fold 
from baseline creatinine.. All data for the study was recorded prospectively, as a part of 
institutional audit process. All statistics were done using SPSS 17 and p value<0.05 was 
considered significant.
Results: Baseline characteristics of the patients are shown in table 1. The incidence 
of AKI was 23%. Majority of new AKI cases occurred on the second day post-operatively 
with 19% occurring on day 2 compared to 6%, 9% and 3% occurring on days 1, 3 and 4 
respectively. Patients who developed AKI were older, with higher proportion of blacks, 
diabetics, hypertensives, higher CCS score (Canadian Cardiovascular Society grading of 
angina) and higher NYHA class compared to non-AKI patients (table 2). Incidence of AKI 
was associated with increased in-hospital mortality (4.4% vs 0.5%; p=0.000) and length of 
stay (8[IQR5] vs 6[IQR3] days; p=0.000). On multiple regression analysis, the independent 
predictors of AKI were age, CCS score 3-4, hypertension, emergency nature of surgery, 
insulin dependent diabetes and raised pre-operative creatinine (table 3).
Conclusions: In a multi-ethnic, inner-city population the incidence of AKI was 23% in 
first time CPB CABG patients and the independent risk factors were age, CCS score 3-4, 
hypertension, emergency surgery, diabetes and CKD.
Tables on baseline characteristics; comparisons & predictors of AKI
TH-PO024 Poster Thursday
AKI: Epidemiology, Risk Factors, Prevention
Patient-Centered AKI: Baseline Characteristics of the Change AKI Study
Clarissa J. Diamantidis,1 L. Ebony Boulware,1 Aviel N. Alkon,3 Joseph Lunyera,1 
Jennie Riley,2 Cassandra Bowman,3 Jennifer St. Clair Russell.1 1Duke University 
School of Medicine, Durham, NC; 2Duke Un, Durham, NC; 3Duke University, 
Durham, NC.
Background: Hospital-related AKI carries a threat of poor outcomes that persist 
after discharge, yet few interventions support patient-centered AKI awareness and self-
management beyond the hospital. We describe the study protocol and baseline characteristics 
of the ongoing Change AKI Study, a pilot study testing the feasibility and acceptance of an 
mHealth-based educational intervention for AKI survivors.
Methods: Hospitalized AKI survivors at Duke University Hospital seen by the 
inpatient nephrology service were recruited in 2017-2018. Eligible participants complete 
baseline surveys including questions regarding their outpatient safety behaviors (e.g. 
regular use of pain medication such as NSAIDs), perceived AKI knowledge (e.g. “Which of 
the following statements best describe how much you know about what causes AKI?”), and 
perceived risk of AKI outcomes (e.g. “How likely do you think it is that you will develop 
AKI in the future?”). Participants are then randomized to receive an mHealth educational 
program promoting AKI awareness/self-management, or usual care. Surveys are repeated 
by phone 1-month after discharge to evaluate changes in behaviors, perceived knowledge, 
and perceived risk.
Results: To date, 56 participants have completed baseline (28 intervention, 28 
control). Half (50%) are female, 57% are aged 45-64 years old, and 42% are Black. 
Most have completed high school (98%), with a high proportion reporting a history of 
hypertension (61%) and diabetes (50%). Over half reported regular pain medication prior to 
hospitalization. Despite receiving a nephrology consult, only 28 (50%) report being aware 
of their AKI diagnosis – 23% report being told by their primary hospital team. Perceived 
AKI-related knowledge was variable: what kidneys do (95%), what is AKI (36%) causes of 
AKI (59%), what to do after AKI (48%). Most (70%) were concerned about recurrent AKI, 
52% felt it was likely. While 63% reported confidence in knowing what questions to ask 
their outpatient provider about AKI, only 50% felt confident they had information to lower 
their future AKI risk.
Conclusions: AKI awareness, perceived knowledge, and self-management are 
suboptimal among hospitalized survivors receiving inpatient nephrology care. Interventions 
designed to improve these patient-centered outcomes may prevent recurrence.
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Risk Factors for AKI in High-Risk Populations: Systematic Review and 
Meta-Analyses
Waleed Zafar,1 Andres Garcia-Arce,1 Yirui Hu,1 Sara J. Kwiecien,1 
Gurmukteshwar Singh,2 Sara Saunders,1 Ion D. Bucaloiu,3 H. Lester Kirchner,4 
Kevin Ho.3 1Geisinger, Dnville, PA; 2Geisinger Medical Center- Nephrology, 
Danville, PA; 3Geisinger Medical Center, Danville, PA; 4Geisinger Clinic, 
Danville, PA.
Background: Predictive models help identify patients at increased risk for Acute 
kidney injury (AKI) for preventive care. It is unclear how various risk factors perform in 
different clinical settings. We systematically reviewed predictive models for AKI in four 
high risk settings and performed meta-analyses of common AKI risk factors
Methods: We searched MedLine, EMBASE, CINAHL and Cochrane Library, and 
performed hand searches of the retrieved reference lists, from 2010 through 2017 for 
English language studies of prediction models for hospital-acquired AKI (KDIGO, AKIN 
or RIFLE criteria) in adult hospital populations, patients undergoing cardiac surgery, 
patients in intensive care unit (ICU) and those undergoing contrast procedures. PRISMA-P 
2015 statement was used for data extraction and study appraisal. For the meta-analyses of 
risk factors, studies with insufficient or non-standardized data and unadjusted risk factors 
were excluded. Random effects meta-analyses were used to assess pooled adjusted odds 
ratio (OR) for diabetes (DM), congestive heart failure (CHF) and chronic kidney disease 
(CKD) for developing AKI
Results: 74 studies testing AKI prediction models in the four clinical settings were 
included. Of these, 10 were in the general hospital setting, 8 were in the ICU, 27 in 
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percutaneous coronary interventions, and 29 in cardiac surgery. There was considerable 
heterogeneity among studies in the choice and definition of predictors. Meta-analyses 
included 14 studies reporting diabetes (135955 patients), 16 studies reporting CKD (137846 
patients) and 22 studies reporting CHF (180224 patients). Stratified analyses based on high-
risk clinical settings were consistent with the overall results (Table 1)
Conclusions: In the combined as well as sub-populations, DM, CKD, and CHF are 
associated with increased risk for AKI. Analyses of differential risk levels in sub-populations 
was limited by heterogeneity. Using uniform definitions for AKI and its risk factors in the 
development of predictive models for AKI is essential for their clinical application
Funding: Private Foundation Support
Meta-analyses results
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Frequency and Consequences of AKI in Patients with CKD in Public 
Nephrology Practices in Queensland, Australia
Wendy E. Hoy,1,2 Jianzhen Zhang,1,2 Zaimin Wang,1,2 Anne Cameron 
(Salisbury),3,1 Helen G. Healy,4,2 Sree Krishna Venuthurupalli,5,2 
Andrew J. Mallett.4,2 NHMRC CKD.CRE and CKD.QLD Collaborative 
1Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; 
2NHMRC CKD.CRE and CKD.QLD Collaborative, The University of 
Queensland, Brisbane, QLD, Australia; 3CKD.QLD and the NHMRC CKD.
CRE, Brisbane, NSW, Australia; 4Kidney Health Service, MNHHS, Queensland 
Health, Brisbane, QLD, Australia; 5Renal Service, DDHHS, Queensland 
Health, Toowoomba, QLD, Australia.
Background: It is recognised that acute kidney injury (AKI) contributes to, and 
complicates, CKD and can exacerbate its progression. We describe acute kidney injury 
(AKI) documented in hospital episodes in patients enrolled in the CKD.QLD registry, based 
in the public nephrology sector in Queensland.
Methods: Queensland Health supplied data on CKD.QLD patients on admissions to all 
Queensland hospitals, public and private, as well as associated costs, and deaths, from May 
2011 to June 2016. We describe the frequency of AKI and associated conditions, recognised 
by ICD codes.
Results: Among 6,365 CKD.QLD patients, 2,198 (34.5%) had a total of 4,711 hospital 
encounters with an AKI diagnosis. 550 patients had three or more AKI-related admissions. 
64.9% of AKI admissions were through the emergency department. People with AKI were 
somewhat older (68.2 vs 64.6 yr) and more often male (57.1% vs 52%), than those without 
AKI, p<0.001 for both. Leading diagnoses associated with AKI were congestive heart 
failure, urinary tract infection, myocardial infarction, dehydration, pneumonia and COPD, 
gastroenteritis/colitis, and sepsis, and diabetic nephropathy was the leading underlying renal 
condition. Of those with AKI, 553 (25.2%) subsequently died in the 5 year interval and 238 
(10.8%) started renal replacement therapy (RRT), compared with 282 (12.8%) who died 
and 295 (13.4%) who started RRT among those who did not have AKI, p<0.001 for each. 
Adjusted for all other significant factors, the hazard ratio (95%CI) of AKI patients relative 
to those without AKI for death without RRT was 3.32 (CI 2.8-3.9), p<0.001, and for RRT 
was 1.21 (CI 1-1.5), p=0.06.
Conclusions: AKI that comes to clinical attention is very common among these CKD 
patients. It usually presents through unplanned, emergency admissions. It is associated with 
strikingly increased rates of death but only marginally increased rates of RRT. Preventable 
causes of AKI should be better understood and addressed.
Funding: Commercial Support - AMGEN Australia, Government Support - Non-U.S.
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Characteristics of Patients Readmitted to Hospital One Year Following an 
Episode of AKI
Andrew J. Lewington,1 Steven Goorachan,3 Fazeel Ahmad,4 Adrian G. Miller.2 
1Leeds Teaching Hospitals, Leeds, United Kingdom; 2Leeds teaching Hospitals 
NHS Trust, Leeds, United Kingdom; 3St. James Hospital, Leeds, United 
Kingdom; 4Leeds teaching Hospitals, Leeds, United Kingdom.
Background: Acute kidney injury (AKI) is a risk factor for further episodes of AKI. 
We have analysed the characteristics of a cohort of patients who had an AKI identified by 
an AKI e-alert and who were readmitted within a 1 year
Methods: Data was gathered on patients admitted to a teaching hospital who had 
an AKI e-alert (2015 - 2017) and who were subsequently readmitted within 1 year. The 
electronic health care records (EHR) of these patients were reviewed
Results: 2010 patients were identified of which 1513 patients had an initial length of 
stay〈 30 days. Initial review of 302 patient EHR from this subgroup (n=1513) excluded 52 
patients who did not have a clinical episode of AKI. The remaining cohort (n=251) had a 
mean age of 73 yrs (25-99 yrs) with 135 (54%) males and 116 (46%) females. The mean 
length of stay was 16 days and the cause of AKI was poorly documented in the EHR. 
The reason for admission was multifactorial (30%) sepsis (26%), cardiac failure (15%), 
hypovolaemia (8%), malignancy (8%) obstruction (5%), trauma (5%) and abdominal 
surgery (3%). The 1 yr mortality was 37% and this increased with age; 20.9% (〈 60 yrs), 
33.3% (〈 60-79 yrs) and 42.2% (〉80yrs). At 3 months recovery of kidney function to the 
original eGFR occurred in 20.3% of patients. 10.7% of patients experienced a reduction in 
kidney function to〈 50% of their baseline eGFR. Recovery of eGFR to baseline at 3 months 
did not result in improvement in 1 year mortality rate 32.8% versus 29.2% in those patients 
whose kidney function did not return to baseline eGFR. The mean time to readmission 
was 68.4 days (range 1-336 days). The cause for readmission was the same in only 20% of 
patients. Only 23.9% of those readmitted had a further episode of AKI either at the time of 
readmission or throughout the subsequent length of hospital stay.
Conclusions: Acute kidney injury has been identified as a risk factor for recurrent 
episodes of AKI. In our ongoing analysis of a large cohort of patients only 23.9% of those 
readmitted had an episode of AKI at the time of readmission or throughout the subsequent 
length of hospital stay. The reason for readmission was the same for only 20% of the 
patients. Nearly 80% of patients fail to fully recover kidney function by 3 months. Further 
analysis of the characteristics of this cohort are ongoing and will be presented.
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Temporal Trends in the Inpatient Mortality of Patients with AKI After 
Coronary Revascularization in a Nationwide Study
Siddartha Bhandary,1 Jaeil Ahn,3 Wen Shen.2 1Providence Hospital, Washington, 
DC; 2Nephrology, Georgetown University, Washington, DC; 3Georgetown 
University, Washington, DC.
Background: The major modalities of coronary revascularization - coronary artery 
bypass grafting (CABG) and percutaneous coronary intervention (PCI) both carry high risk 
of acute kidney injury (AKI). Our previous studies have shown that both CABG and PCI 
were associated with increasing temporal trends in AKI incidence over the years; and in-
hospital mortality after CABG was more than 40% higher than that of PCI. In this study, 
we compared the temporal trends of total in-hospital mortality, and in-hospital mortality 
associated with AKI after CABG vs PCI.
Methods: We generated a propensity-matched cohort of 274,464 hospitalizations that 
had first time CABG or PCI for multi-vessel coronary disease in 2004 to 2012 from the 
National Inpatient Sample. Patients received concomitant valvular repair or both CABG 
and PCI on same admission, history of organ transplant, CKD stage V or ESRD on dialysis 
were excluded. Both groups were propensity score matched. The odds ratios were estimated 
by the random intercept logistic regression model.
Results: The temporal trends of in-hospital mortality in CABG-AKI group had been 
decreasing from 16.52 % in 2004 to 6.51% in 2012 whereas in the PCI- AKI group, the 
in-hospital mortality has been stable, 14.17% in 2004 to 13.11% in 2012. Compared to PCI-
AKI group, the likelihood of in-hospital death for CABG- AKI group in 2004 was 20 % 
higher (OR 1.20, 95% CI 0.89-1.61, P=0.35). But after 2004, the odds reversed.. From 2005 
to 2012, the odds of in-hospital death in the patients with post-CABG AKI became 23%-
54% lower than the PCI-AKI group (OR 0.77, 95% CI 0.60-0.99, P=0.05; OR 0.46, 95%CI 
0.36-0.59, P<0.0001). Interestingly, when we compared the overall in-hospital mortality 
between both groups irrespective of the kidney function, CABG was associated with higher 
in-hospital mortality from 2004-2010 than PCI group with down-trending ORs. In 2011 and 
2012, PCI was associated with higher in-hospital mortality.
Conclusions: CABG patients with post procedural AKI have shown a decreasing 
temporal trends in in-hospital mortality over the years whereas the in-hospital mortality 
remains high in the PCI patients with AKI.
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Incidence and Outcomes of Dialysis-Requiring AKI in Taiwan—A 
Nationwide Study 2003-2014
Jinn-Yang Chen. Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Dialysis-requiring acute kidney injury (AKI-D) is associated with high 
morbidity and mortality. Despite increasing incidence of AKI-D, information pertaining to 
trends and prognosis remains limited due to underreporting of discharge code of AKI code 
and differences in definition. We identify first in-hospital dialysis using procedure code to 
evaluate the time trend and outcome of AKI-D over a twelve-year period in Taiwan.
Methods: In a retrospective nationwide study based on National Health Insurance 
Database 2000-2015, all adults requiring the first hospitalized dialysis treatment between 
2003 and 2014 were identified. Patients with previous renal transplantation or chronic 
dialysis were excluded. Through cross-linking of several administrative datasets, 
information pertaining to comorbidity, concurrent surgical interventions and sepsis, and 
clinical outcome were ascertained.
Results: A total of 203,071 first hospitalized dialysis was retrieved. Among them, 
22,746 patients (11.2%) had advanced chronic kidney disease (CKD); 121,054 patients 
(59.6%) had history of CKD; 59,271 patients (29.2%) received dialysis during admission 
without documented CKD. Among patients without pre-existing CKD, 46.7% had sepsis; 
6.6% were related to cardiac surgery; 91.2% had been admitted to ICU and 42.5% received 
CRRT. Patients without pre-existing CKD showed the highest in-hospital mortality (71.1%). 
However, only 47% of patients without pre-existing CKD could be identified with ICD-9 
code of acute kidney injury (584). Time trend analysis showed that there were decreased 
trends of in-hospital mortality and increased trends of long-term dialysis from 2003 to 2014. 
For those who was discharged without receiving regular dialysis, 25% and 12% of patients 
died within 1 and 2 years after discharge.
Conclusions: In a nationwide retrospective study of 1st hospitalized dialysis treatment 
using procedure code, we found AKI-D was underreported and associated with high 
mortality. For the AKI-D survivors, high mortality was also noted.
AKI: Epidemiology, Risk Factors, Prevention
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Kinetic Estimated Glomerular Filtration Rate (KeGFR) in Liver 
Transplantation: An Early Predictor of Significant AKI
Antonio Olivas-Martínez,1 Armando Jezael Martinez-Rueda,1 Gerardo Zavala-
Garcia,1 Silvana Bazua-Valenti,2,3 Ignacio García juárez,3 Ricardo Correa-
Rotter.4 1Department of Internal Medicine, National Medical Science and 
Nutrition Institute Salvador Zubirán, Mexico City, Mexico; 2Instituto de 
Investigaciones Biomedicas, UNAM, Mexico City, Mexico; 3National Medical 
Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico; 
4Department of Nephrology and Mineral Metabolism, National Medical Science 
and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.
Background: Acute kidney injury (AKI) is a common clinical problem in patients 
undergoing liver transplantation (LT) and up to 20% of these patients progress to CKD. 
Kinetic estimated glomerular filtration rate (KeGFR) is a recommended formula in non-
steady states. Aim: to evaluate the diagnostic yield of KeGFR for early prediction of AKI 
in patients following LT.
Methods: We retrospectively studied all patients who underwent LT from 
06/ 2017 to 04/2018. Clinical data and all SCr measurements during the first 5 days after 
transplantation were recorded. SCr before surgery was considered as baseline. Significant 
AKI was defined as an increase of at least 2 times in SCr baseline or requirement of renal 
replacement therapy (RRT). Early decline of eGFR was defined as a decreased of more than 
50% from baseline eGFR in the first postoperative 24 hours. Early decline of eGFR was 
evaluated by the KeGFR, Cockfort-Gault, CKD-EPI, and MDRD-4 formulas and compared 
with the development of significant AKI in the first 5 postoperative days.
Results: Forty nine patients were included, mean age of 47.3 ± 11.68 y, 55.1% were 
female. Median baseline SCr was 0.7 mg/dL (range 0.43 - 3.03). Three patients had 
significant AKI prior transplantation. Twenty-four (49.0%) patients developed significant 
AKI in the first 5 days postoperative, of which 33.3% required RRT and 12.5% died. 
Diagnostic performance of studied formulas is shown in Table 1.
Conclusions: KeGFR was the only formula that predicted significant AKI within the 
first 24 hours, with a high sensitivity (87%) and a strong negative likelihood ratio (0.17) 
and improved area under the curve (0.846). The KeGFR formula is an affordable diagnostic 
tool, which improves our capability of significantly detecting AKI in patients following 
liver transplantation.
TH-PO031 Poster Thursday
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Using Kinetic Glomerular Filtration Rate to Predict AKI
Rolando Claure-Del Granado,1 Cristian G. Sanchez,1 Josee Bouchard,3 
Ravindra L. Mehta.2 1Hospital Obrero #2 - C.N.S.; Universidad Mayor de San 
Simon, School of Medicine, Cochabamba, Bolivia, Plurinational State of; 
2University of California San Diego Medical Center, La Jolla, CA; 3Hopital du 
Sacre-Coeur de Montreal, Montreal, QC, Canada.
Background: Monitoring renal function changes during critical illness is difficult as 
current MDRD and CKD-EPI GFR estimating equations usually under or overestimate renal 
function during an episode of acute kidney injury (AKI). The kinetic glomerular filtration 
rate (KeGFR) equation (J Am Soc Nephrol 2013; 24: 877–888) has been developed to better 
evaluate rapid changes in renal function. We hypothesized that changes in KeGFR would 
predict the development of AKI in critically ill patients.
Methods: We prospectively evaluated 208 patients admitted to our general ICU. 
Serum creatinine (sCr) was measured daily for 7 days. KeGFR was calculated from the 
change in consecutive values of sCr (ICU baseline sCr and 24 h ICU sCr). In patientswith 
no baseline sCr available we back calculated sCr using MDRD equation (for an 
eGFR = 75 ml/m/1.73m2). Patients diagnosed with AKI in the first 24 hours after ICU 
admission according to the KDIGO definition were excluded. AKI was defined as an increase 
of sCr value 1.5 times the baseline value or 0.3 mg/dl above the baseline within 48 hours to 7 
days after ICU admission. The predictive performance of KeGFR was assessed by the receiver 
operator characteristic analysis to determine the area under the curve (AUC).
Results: From 208 patients enrolled in the study 98 patients developed AKI (47 %). 
Age, baseline serum creatinine, and eGFR (CKD-EPI) were not different between patients 
with and without AKI. At 24 h post ICU admission AKI patients had lower KeGFR 
(47.7 ml/m vs. 81.1 ml/m; p < 0.0001); at this time point KeGFR predicted AKI with an 
AUC of 0.778 (95% CI 0.689 - 0.867; p < 0.001). A KeGFR reduction from a baseline 
eGFR (ICU admission) ≥ 22.6% had a sensitivity of 95.3% and a specificity of 87.5% for 
predicting subsequent AKI development within 48 h and 7 days of ICU admission with an 
AUC of 0.969 (95% CI 0.932 – 1.000; p < 0.001). This reduction in KeGFR percentage 
from a baseline eGFR had an odds ratio of 4.5 (95% CI 1.675 – 12.090; p = 0.002) for 
subsequent development of AKI after 48 h of ICU admission.
Conclusions: The use of KeGFR accounts for non-steady state conditions and could 
improve clinical risk prediction models for AKI development in the ICU. sCr measurements, 
which can be obtained at modest cost, remain useful to guide early management of AKI if 
performed frequently.
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Early Biomarkers in the Detection and Risk Stratification of Sepsis 
Patients
Vishal G. Patel,1 R. w. m. anusha Madushani,2 Tezcan Ozrazgat-baslanti,2 
Lasith Adhikari,2 Quran Wu,2 Nicholas Lysak,2 Sabyasachi Bandyopadhyay,2 
Azra Bihorac.2 1University of Florida College of Medicine, Lake Worth, FL; 
2University of Florida, Gainesville, FL.
Background: Treatment of sepsis requires early hemodynamic support and antibiotic 
initiation, making timely diagnosis and risk stratification critical to improving survival. The 
reliance on clinical judgment, rather than diagnostic guidelines, to diagnosis and risk stratify 
sepsis patients results in a wide range of clinical outcomes.
Methods: In a prospective cohort study of 157 sepsis patients in a surgical ICU, we 
used 42 biomarkers that includes laboratory and vital measurements as well as age and 
Charlson comorbidity index using the earliest measurement within 48 hours of sepsis onset. 
We used hierarchical clustering to group patients with similar clinical characteristics. We 
compared clinical characteristics and outcomes between two main clusters identified using 
Fisher’s exact test for categorical variables and student’s t-test or Wilcoxon rank sum test 
for continuous variables as appropriate. Composite biomarker mosaic images were created 
using clustering variables.
Results: We identified two main clusters with 18 and 139 subjects in Clusters I and 
II, respectively. Cluster I consisted of more septic shock patients (78% vs 17%) who had 
early multiorgan failure and acute physiologic derangements in the first 24 hours of sepsis 
onset (median APACHE II score of 30 vs 16 and total SOFA score of 13 vs 5, respectively, 
p<.0001). Chronic diseases that differentiated the two clusters were cardiovascular and 
renal diseases (p<.0001). Renal biomarkers were significantly elevated two to three folds 
with higher prevalence of AKI (93% vs 45%) in cluster I compared to cluster II (p<0.01). 
Cluster I had significantly higher hospital mortality of (33% vs 2.2%, p<.0001) and one year 
mortality (50% vs 18%, p=0.005).
Conclusions: Using early biomarkers, we were able to identify two major clusters 
that had clinically different profiles which were reflected in composite biomarker mosaic 
images. We would be able identify patients at risk for adverse outcomes using our clustering 
and imaging methodology in order to improve hospital and long-term outcomes.
Funding: Other NIH Support - National Institute of General Medical Sciences
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Identification of AKI Subtypes in Patients with Sepsis Using Unsupervised 
Clustering
Lili Chan, Kumardeep Chaudhary, Aine Duffy, Priti Poojary, Aparna Saha, 
Kinsuk Chauhan, Ron Do, Tielman T. Van Vleck, Steven G. Coca, 
Girish N. Nadkarni. Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Acute kidney injury is highly prevalent in critically ill patients. 
Physicians recognize that subphenotypes of sepsis associated AKI exist. Our goal was to 
identify subphenotypes of AKI in patients admitted to the intensive care unit with sepsis.
Methods: This was a retrospective analysis using the Medical Information Mart 
for Intensive Care (MIMIC)-III database. We identified AKI using the Kidney Disease 
Improving Global Outcomes criteria and sepsis utilizing the Clinical Classification 
Software. We used unsupervised machine learning to identify clusters using laboratory 
results and vital signs prior to AKI diagnosis.
Results: 1,865 patients were identified with sepsis associated AKI. After data processing 
and feature selection, 59 features, of which 28 were measures of variability, remained for 
inclusion into our unsupervised machine learning model. We utilized k-means clustering 
with k ranging from 2 – 10; k=2 had the highest silhouette score (0.62). Cluster 1 had 1,358 
patients while Cluster 2 had 507 patients. There were no significant differences between 
clusters on age or gender. Small but significant differences were found on comorbidities, 
several laboratory results, and vital sign parameters. In-hospital mortality was significantly 
higher in cluster 2 patients (25%) vs. cluster 1 (20%, p=0.008). Features with the largest 
differences between clusters included basophil variability, eosinophil variability, ALT 
variability, and Creatine Kinase values.
Conclusions: To our knowledge this is the first study to identify two distinct 
subphenotypes of sepsis associated AKI utilizing electronic medical record data. Variability 
among laboratory values was important for clustering. Future studies in other cohorts and 
additional features are needed to validate and expand on the results of our study.
Funding: NIDDK Support, Government Support - Non-U.S.
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AKI Predicts 30 Day Mortality in Community Acquired Infection
Dimitrios J. Poulikakos,1 James Tollitt,2 James Ritchie,3 Philip A. Kalra,5 
Smeeta Sinha.4 1Salford Hospital, Manchester, United Kingdom; 2Salford Royal 
NHS Trust, Salford, United Kingdom; 3Salford Royal Hospital, Chorlton, United 
Kingdom; 4Salford Royal NHS Foundation Trust, Salford, United Kingdom; 
5Salford Royal Hospital NHS Trust, Salford, United Kingdom.
Background: The National Institute for Health and Care Excellence has recently 
introduced new guidance for sepsis that risk stratifies patients to high, moderate and low risk 
based on clinical observations from the National Early Warning Score (NEWS). Laboratory 
assessment for Acute Kidney Injury (AKI) is mandated in patients with moderate risk, and 
if present warrants intravenous antibiotics within one hour. Our aim was to evaluate the 
association between AKI in suspected community acquired (CA) infection (I) and 30 day 
mortality.
Methods: Data of hospital admissions with CA-I (defined as prescription of antibiotics 
within 24 hours from A&E arrival) were extracted from the Electronic Patient Records 
from 07/2013 to 02/2018. Dialysis patients were excluded. CA-AKI was defined as AKI 
alerting within 24 hours. NEWS score was analysed in groups 0 (low risk), 1-4 (moderate 
risk) and >4 (high risk). A binary logistic model was used to assess associations with 30 
day mortality. The model was tested separately in each group of NEWS. AKI 2 and 3 were 
analysed together as AKI2&3.
Results: There were 3764 patients aged 61 ±22 years, 2047 (54.4%) females, 292 
(7.8%) CA- AKI {AKI 1, 201 (5.3%), AKI 2 60 (1.6%) and AKI 3 31 (0.8%)}. Lactate 
was tested in 1382 (36.7%) patients and was above 2 in 398 (10.6%) cases. NEWS was 
0 in 1140 (30.3%), 1-4 in 2150 (57.1%) and >4 in 474 (12.6%) cases. 316 patients (8.4%) 
died within 30 days. In logistic regression analysis for the whole cohort age (OR 1.07 
CI 1.06-1.08, p=<0.001), male (OR 1.48, CI 1.15-1.91, p= 0.002), lactate (OR 1.67, CI 
1.19-2.34, p= 0.003), NEWS 1-4 (OR 2.23, CI 1.54-3.29, p=0<.001), NEWS>4 (OR 4.58, 
CI 2.99-7.01, p=0<.001), AKI 1 (OR 2.14 CI 1.44-3.20, p=<0.001) and AKI2&3 (OR 
4.12 CI 2.46-6.90, p=<0.001) were associated with 30 day mortality. AKI2&3 retained 
a significant association in NEWS=0 group (20(1.8%) cases of AKI2&3 OR 5.41 CI 
1.62-18.13, p =0.006),(Table 1)
Conclusions: CA-AKI is associated with an increased risk for mortality in CA-I even 
in patients with normal clinical observations. Convergence of sepsis and AKI guidance 
should be prospectively assessed.
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Association of AKI on Outcomes in Patients with ARDS - Secondary 
Analysis of LUNG-SAFE Patient Cohort
Bairbre A. McNicholas,1 Emanuele Rezoagli,1 Elsa Guiard,3 Giacomo Bellani,4 
Matthew D. Griffin,1 Tài Pham,2 John G. Laffey.1 1National University of 
Ireland, Galway, Galway, Ireland; 2University of Toronto, Toronto, ON, Canada; 
3Toronto General Hospital UHN, Toronto, ON, Canada; 4University of Milan-
Bicocca, Monza, Italy.
Background: The impact of Acute Kidney Injury (AKI) in Adult Respiratory Distress 
Syndrome (ARDS) is poorly understood. We addressed this in a secondary analysis of the 
large observational study to understand the global impact of severe acute respiratory failure 
(LUNG SAFE) patient cohort. LUNG SAFE was an international, multicentre, prospective 
cohort study of patients with severe respiratory failure conducted during 4 consecutive 
weeks in winter 2014, in 459 intensive-care units (ICU) in 50 countries across six continents.
Methods: Patients undergoing invasive mechanical ventilation (IMV) with a diagnosis 
of ARDS at D1 or D2 post onset of acute hypoxic respiratory failure (AHRF) with no 
history of chronic kidney disease (eGFR<60ml/min/1.73m2) and not transferred from 
another ICU were included in the analysis. Patients were categorised based on worst serum 
creatinine (Scr) or urine output between D1-D7 post diagnosis of ARDS into (1) no AKI 
Serum creatinine <1.5mg/dl or urine output >0.5mL/kg/h (2) Moderate AKI: Scr 1.5-4mg/
dl or min urine output<0.5mL/kg/h or (3) severe AKI: Scr >4mg/dl or Renal Replacement 
Therapy (RRT) during D1-D7 following onset of ARDS.
Results: 2016 patients were included in the analysis; 1193 (59%) with no AKI, 619 
(31%) moderate AKI and 204 (10%) with severe AKI. RRT was required in 1.2% of patient 
with no AKI, 24.6% of moderate AKI and 100% of severe AKI over the 28 day follow-up 
period. Sequential organ failure assessment score was higher with worsening category of 
AKI (8.8±3.8, no AKI, 11.5±3.7 moderate AKI, 12.2±3.8 severe AKI, p<0.001). Lower pH, 
PaO2-FiO2 ratio and higher positive end-expiratory pressure were noted with advancing 
AKI category. Ventilatory free days was lower and ICU mortality and hospital mortality was 
higher with advancing AKI category (table 1).
Conclusions: The development of AKI, even in those who do not require RRT is 
associated with a substantial increase in mortality in patients with ARDS, with over half of 
these patients dying in hospital.
Funding: Government Support - Non-U.S.
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Assessment of Fluid and Nutritional Status Using Bioimpedance Methods 
in AKI Patients Treated with Continuous Renal Replacement Therapy
Huijuan Mao. First Affiliated Hospital of Nanjing Medical University, Nanjing, 
China.
Background: Bioelectrical impedance analysis is an essential method for maintenance 
hemodialysis patients to assess nutritional and fluid status, however, there is still a lack 
of research on the value of bioelectrical impedance analysis in evaluating the prognosis 
of acute kidney injury (AKI) patients treated with continuous renal replacement therapy 
(CRRT).
Methods: Patients with severe AKI treated with CRRT in the first affiliated hospital 
of Nanjing medical university from 2014 to 2017 were prospectively enrolled. They 
were divided into death group and survival group according to 28-day survival. Logistic 
regression was used to analyze 28-day survival and Lean Tissue Index (LTI), Fat Tissue 
Index (FTI), the ratio of extracellular water(ECW) and body cell mass (BCM) (ECW/
BCM), and overhydration (OH) were recorded.
Results: A total of 145 patients were included. The average age was 62.6±15.6 ys, 
average APACHE II score 21.7±6.5, SOFA score 9.4±3.6, and body mass index of 
24.1±4.3 kg/m2. The pre-CRRT body composition analysis parameters were as followed:OH 
3.9 ± 3.1L, LTI 12.4 ± 3.4kg/m2, FTI 10.3 ± 4.5kg/m2, ECW 18.0 ± 4.2L, BCM 18.6 ± 
7.3L. The 28-day mortality rate was 44.8%.The pre-CRRT OH values and ECW/BCM 
values in survival group and death group were 3.4±3.2L, 4.6±3.0L and 1.0±0.4,1.1±0.4 
(P<0.05), respectively. The changes of OH values and ECW/BCM values between CRRT 
1st day and CRRT 7th day were 1.4±2.2L, 3.0±3.0L and 0.08±0.22,0.25±0.27 (P<0.05), 
respectively in two groups. Univariate and multivariate logistic regression analysis showed 
that pre-CRRT high OH values and high ECW/BCM values were associated with 28-day 
death, while LTI values and FTI values were not significant correlated with 28-day death; 
After CRRT initiation, the changes of OH values and ECW/BCM values between CRRT 
7th-1st day were significantly associated with 28-day mortality.
Conclusions: The pre-CRRT fluid status(indicators of OH and ECW/BCM)were 
associated with 28-day mortality in patients with AKI, while the nutritional indicators 
LTI and FTI were not significantly related to short-term mortality. The correction of fluid 
overload by CRRT within 7 days may reduce the 28-day risk of death.
Funding: Government Support - Non-U.S.
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Body Composition for Predicting Exertional Rhabdomyolysis-Induced 
AKI During Intensive Physical Training Program for Military Recruits
Chaken Maniyan, Bancha Satirapoj, Naowanit Nata, Amnart Chaiprasert, 
Ouppatham Supasyndh. Phramongkutklao hospital, Bangkok, Thailand.
Background: Exertional rhabdomyolysis-induced acute kidney injury (AKI) is a 
life-threatening condition. The risk factors for developing this condition are partially 
documented and changing in the body composition of these population is still poorly 
understood.
Methods: A prospective cohort study in the military recruits between May to July 
2017 were conducted. Demographic and laboratory data including body mass index (BMI), 
serum creatinine, electrolyte, creatine phosphokinase (CPK), and body composition using 
dual frequency body impedance analysis (BIA) were measured before training and every 2 
weeks until program had been completed.
Results: Total of 301 participants with mean age of 22 ± 2.5 years old were included. 
The incidence of exertional rhabdomyolysis-induced AKI was 19.2 %. At baseline, 
subjects who developed exertional rhabdomyolysis-induced AKI had lower frequency 
of exercise before recruitment (1.02 ± 0.13 times/week vs 3.49 ± 0.93 times/week, 
p <0.001), lower total body water (TBW) (45.08 ± 2.95 % vs 54.31 ± 5.21%, p < 0.001) 
and lower plasma potassium (3.6 ± 0.3 mEq/L vs 4.0± 0.4 mEq/L, p < 0.001). Along the 
course of training, AKI group had a significant loss of muscle mass (-5.65 ± 2.55% vs -4.06 
±1.75%, p < 0.001) and fat mass (-3 ± 1.41% vs -2.17 ± 0.98% p < 0.001) in the first 2 week. 
Moreover, there was a statistically significant increased in percentage of TBW at week 2 
(2.57 ± 4.95% VS 0.24 ± 2.41 P<0.001) in AKI group compared with non-AKI group.
Multivariate analysis revealed that low baseline of total body water (OR 5.51 (5.15-10.75), 
p < 0.01) and increased TBW at week 2 (OR 2.46 (1.49-2.97, p < 0.01) were the strong 
independent predictors for exertional rhabdomyolysis-induced AKI.
Conclusions: The study demonstrates that lack of adequate exercise before recruitment, 
low baseline potassium, low baseline TBW and increased TBW in early training period 
are the additional risk factors for exertional rhabdomyolysis-induced AKI. To our best 
knowledge this is the first study which explore the body composition change for prediction 
of exertional rhabdomyolysis induced. Early detection of these parameters should be 
implemented for AKI prevention program.
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Trajectories of AKI in Chronic Critical Illness After Sepsis
Tezcan Ozrazgat-baslanti,1 Tyler J. Loftus,2 Quran Wu,1 Zhongkai Wang,1 
Nicholas Lysak,1 Laura Sautina,1 Scott Brakenridge,1 Babette A. Brumback,1 
Philip A. Efron,1 Lyle L. Moldawer,1 Frederick A. Moore,1 Mark S. Segal,1 
Azra Bihorac.1 Sepsis and Critical Illness Research Center Investigators 
1University of Florida, Gainesville, FL; 2University of Florida Health, 
Gainesville, FL.
Background: Acute kidney injury (AKI) is one of the most common complications 
among hospitalized patients. Besides the severity of an initial episode of AKI, the timing 
and duration of renal recovery are required to characterize the natural history of this 
complex condition and its effect on kidney health. We have determined the epidemiology 
of persistent AKI and renal recovery, the development of chronic critical illness (CCI), 
hospital outcomes, and long-term survival in sepsis patients. We hypothesize that patients 
with persistent AKI, especially those without renal recovery, have worse hospital and long-
term outcomes after sepsis.
Methods: In the prospective observational study of 245 sepsis patients, AKI types 
were adjudicated using KDIGO criteria and ADQI recommendations. In contrast to rapidly 
reversed AKI, persistent AKI is characterized by the persistence of KDIGO creatinine 
beyond 48 hours of the onset. Patients whose renal function did not completely recover 
at discharge were considered to have no recovery. Development of CCI and six-month 
survival were compared using Fisher’s exact and log-rank test, respectively.
Results: Two percent (6/245) had preexisting end-stage renal disease (ESRD) and 15% 
(36/245) had pre-existing chronic kidney disease (CKD). Among non-ESRD subjects, while 
about 46% (109/239) developed AKI within 48 hours of sepsis onset, overall 59% (140/239) 
developed AKI; 28% (39/140) having rapidly reversed AKI and 72% (101/140) having 
persistent AKI. Among 101 patients who had persistent AKI, 41% (58/140) did not recover 
at discharge and they had had longer ICU stay, more days on mechanical ventilation, greater 
prevalence of CCI (55%), and higher hospital mortality (27%). Patients with no recovery 
had lower 6-month cumulative survival (43%) compared to patients with recovery (88%) 
and no AKI (94%) (p<0.0001). Among CCI patients, survival was significantly worse for 
patients with no complete recovery compared to patients who recovered (p=0.0003) or did 
not develop AKI among patients with CCI (p=0.0001). Among non-CCI patients survival 
was similar across groups.
Conclusions: Among critically ill septic patients, persistent AKI and absence of renal 
recovery are significant risk factors for adverse outcomes and long-term mortality.
Funding: Other NIH Support - National Institute of General Medical Sciences
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Improved Mortality of Critically Ill Patients with AKI: Population-Based 
Cohort Study in Korea Between 2008 and 2015
Subin Hwang,1 Ho seok Koo,1 Jung eun Lee,2 Wooseong Huh,2 Yoon-Goo Kim,2 
Dae Joong Kim,2 Ha Young Oh,2 Hye Ryoun Jang.2 1Department of Internal 
Medicine, Inje University Seoul Paik Hospital, Inje University School of 
Medicine, Seoul, Republic of Korea; 2Division of Nephrology, Department of 
Internal Medicine, Samsung Medical Center Sungkyunkwan University School 
of Medicine, Seoul, Republic of Korea.
Background: Although there is still no specific treatment facilitating renal tubule 
regeneration in acute kidney injury (AKI), the rapid increase aging population with more 
comorbidities and advance in critical care management were expected to change the 
epidemiology of AKI. However, few recent studies dissecting the current epidemiology 
characteristics of critically ill patients with AKI. We investigated the recent epidemiologic 
changes of AKI in critically ill patients.
Methods: All adult admissions to intensive care units (ICU) in Korea from 2008 to 
2015 were screened using the national health insurance review and assessment database, 
and a total of 1,744,235 patients were included. The clinical characteristics and change in 
incidence and mortality rate of AKI were analyzed.
Results: The incidence of AKI increased from 7.4% in 2008 to 8.3% in 2015 (p for 
trend <.001). The age-standardized AKI rates in were 7018.6 per 100,000 person-years. 
The in-hospital mortality was significantly decreased from 39.1% in 2008 to 37.2% in 
2015 (p for trend <.001) with 2427.6 deaths per 100,000 person-years. Patients with AKI 
showed higher in-hospital mortality, prolonged ICU length of stay, and higher total cost. 
Multivariable analysis showed increased risk of in-hospital mortality (OR 6.25), mechanical 
ventilation (OR=4.63), ECMO (OR=18.22), and vasopressor requirement (OR=4.02) in 
AKI patients.
Conclusions: Recent advances in medical management for AKI have attenuated in-
hospital mortality of critically ill patients with AKI despite increase of the elderly population 
as well as the incidence of AKI.
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Association of Serum Potassium Level at the Initiation of Renal Replace-
ment Therapy with All-Cause Mortality Among Burn Intensive Care Unit 
Patients with AKI
Jui-Ting Hsiung,1 Kamyar Kalantar-Zadeh,1 Elani Streja,1 Hamid Moradi,1 
Victor C. Joe,2 Julie A. Rizzo,3 Ian J. Stewart,4 Kevin Chung.5 1Harold Simmons 
Center for Kidney Disease Research and Epidemiology, Division of Nephrology 
and Hypertension, University of California, Irvine, Orange, CA; 2Burn Center, 
University of California, Irvine, Orange, CA; 3Burn Center, US Army Institute of 
Surgical Research, Fort Sam Houston, TX; 4David Grant Medical Center, Travis 
Air Force Base, CA; 5Department of Medicine, Brooke Army Medical Center, 
Fort Sam Houston, TX.
Background: Burn injury is associated with serious complications including acute 
kidney injury (AKI) requiring renal replacement therapy (RRT). There is little data on the 
association between baseline serum potassium (K) and outcomes in burn patients initiated 
on RRT. Therefore, we evaluated the association of K at the RRT initiation with survival in 
a cohort of burn patients.
Methods: We examined 170 burn patients enrolled in a multicenter observational 
study in eight burn centers across the United States. We used Cox regression models with 
adjustments for covariates including severity of illness, laboratory values, urine output, total 
burn surface area, and vasopressor requirement to evaluate the association of K level at RRT 
initiation with in-hospital all-cause mortality. We further explored the association between 
K slope, from the initiation to 48 hours after beginning of RRT, and mortality, using the 
same multilevel Cox models. Patients without either baseline or 48 hours K measurements 
were excluded from the slope analysis.
Results: The cohort was comprised of 169 AKI patients who required RRT and had a 
baseline K. 20% of patients were female with a mean±SD age of 51±17 years. Hypokalemia 
was associated with a higher risk of subsequent mortality. 150 patients were included in 
the slope analysis. There was a linear association between increasing K slope and higher 
mortality based on the result of restricted cubic splines.
Conclusions: While baseline hypokalemia at the time of RRT initiation was associated 
with higher risk of mortality, increasing K at 48 hours was also associated with worse 
outcomes in patients with burn-associated AKI. This finding may be due to inadequate 
dialysis, ongoing tissue destruction, or both. Future investigations are needed to examine 
the mechanisms which can explain these observations.
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Comparison Between Creatinine vs Urinary Output Criteria in RIFLE 
and KDIGO Definitions for AKI Post Major Elective Non-Vascular 
Abdominal Surgeries
Graziela R. de Souza,1 Lia J. Marçal,4 Luis Yu,3 Leila Antonangelo,4 
Dirce M. Zanetta,4 Emmanuel A. Burdmann.5 1São Paulo University, São Paulo, 
Brazil; 3University of Sao Paulo School of Medicine, Sao Paulo, Brazil; 
4University of São Paulo, S Paulo, Brazil; 5University of Sao Paulo Medical 
School, Sao Paulo, Brazil.
Background: Most of the studies using RIFLE and KDIGO AKI definitions are solely 
based on serum creatinine (SCr) changes. However, the urinary output (UO) criteria may 
be more sensitive especially for surgical patients. Therefore, the aim of this study was to 
compare the efficacy of SCr and UO criteria for RIFLE and KDIGO AKI diagnosis and 
outcome of patients (pts) submitted to major elective non vascular abdominal surgeries 
(MENVAS) admitted to the ICU.
Methods: Two hundred and twenty five pts were prospectively evaluated, peri-
operatively, from the ICU admission until 7 days of hospitalization. Serum creatinine (mg/
dl) was measured before surgery and once a day until day 7 or ICU discharge. Hourly UO 
(ml/kg/h) was measured daily. AKI was diagnosed using either SCr or UO according to
RIFLE and KDIGO definitions. Data are presented as mean ± SD or frequencies. Statistical 
significance was set at p<0.05.
Results: A total of 225 pts were analysed, 126 (56%) developed AKI. Most frequent 
types of surgery were: hepatectomy, sleeve gastroplasty, gastrectomy, hepatectomy + 
cholecystectomy, gastroduodenopancreatectomy and, adrenalectomy. AKI pts were older 
57.6 ± 1.2 vs. 50.8 ± 1.6 Non -AKI (p = 0.0007). Duration (min) of surgery in AKI pts was 
365.6 ± 18.3 vs. 341.5 ± 16.8 Non-AKI (NS). The AKI diagnoses according to RIFLE were: 
118 by UO and 38 by SCr criteria. According to KDIGO definition: 118 by UO and 39 by 
SCr criteria. In addition, 31 pts fullfilled both criteria simultaneously. Using the SCr criteria 
alone for AKI diagnosis, a total of 87 patients in RIFLE group and KDIGO group would be 
overlooked while only one additional patient was diagnosed by KDIGO. AKI pts (KDIGO 
definition) diagnosed by UO or SCr criteria changes, presented, compared to Non-AKI pts: 
hospital LoS 21.4 ± 1.9 vs. 25.6 ± 3.8 (p <0.0004), ICU LoS 3.6 ± 0.3 vs 5.8 ± 0.97 (p < 
0.0001). Mortality in the AKI group was 10.2% vs. 2.0 % in Non-AKI (p=0.0149).
Conclusions: Utilization of SCr criteria instead of UO for RIFLE and KDIGO 
definitions in surgical patients would overlook a very high number of AKI patients (69%). 
Urinary output criteria seems to be pivotal for early AKI recognition in these patients. 
Furthermore, AKI post MENVAS is frequent and carries worse outcome and mortality.
Funding: Government Support - Non-U.S.
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FGF23 and AKI in SPRINT
Anna J. Jovanovich,1,2 Charles Ginsberg,3 Zhiying You,4 Alfred K. Cheung,5 
Michel Chonchol,2 Michael Shlipak,6 Joachim H. Ix.3 1Denver VA, Denver, CO; 
2University of Colorado, Aurora, CO; 3UCSD, San Diego, CA; 4UC Denver, 
Aurora, CO; 5University of Utah, Salt Lake City, UT; 6San Francisco VA 
Medical Center, San Francisco, CA.
Background: Fibroblast growth factor 23 (FGF23) is elevated in chronic kidney 
disease and associated with kidney disease progression and increased mortality but data 
on FGF23 in humans with acute kidney injury (AKI) are limited. We hypothesize that high 
circulating intact FGF23 (iFGF23) concentrations will identify individuals at high risk of 
AKI and may modify the relationship between randomization to intensive blood pressure 
lowering and AKI in the Systolic Blood Pressure Interventional Trial (SPRINT).
Methods: The SPRINT study was a randomized multicenter trial evaluating the effects 
of standard (SBP <140 mmHg) vs. intensive (SBP <120 mmHg) blood pressure lowering 
on cardiovascular outcomes in older adults without diabetes. iFGF23 was measured 
in 2488 subjects with GFR < 60 mL/min/1.73m2. Cox proportional hazards models 
adjusted for demographics, comorbidities, randomization group, and baseline number of 
antihypertensives, eGFR, and serum calcium and phosphorus identified the relationship 
between baseline iFGF23 and time to first AKI event.
Results: Mean age was 73 ± 9 years, 40% were female, and 66% were white. At 
baseline, mean eGFR was 49 ± 11 mL/min/1.73m2 and median FGF23 was 66 [52-88] pg/
mL. After full adjustment, there was no significant association between baseline iFGF23 
and time to first AKI event; HR for Q4 (vs. Q1) was 0.93 (95% CI 0.60-1.44) and HR for 
iFGF23 modeled as a continuous variable was 0.96 (95% CI 0.75-1.23). FGF23 did not 
modify the relationship between randomization to intensive blood pressure lowering and 
AKI (p for interaction 0.12).
Conclusions: Among SPRINT participants with baseline eGFR < 60 mL/min/1.73m2, 
there was no significant association between baseline iFGF23 and AKI events. iFGF23 did 
not modify the relationship between randomization to intensive blood pressure lowering 
and AKI.
Funding: NIDDK Support, Veterans Affairs Support
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Exosomal Mitochondrial DNA Is a Prognostic Factor in Septic AKI 
Patients
Naoko Tsuji, Takayuki Tsuji, Akihiko Kato, Hideo Yasuda. 1st Depertment of 
Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Background: We reported the amount of circulating mitochondrial DNA (mtDNA) 
was increasing in septic rodent models and contributed development of AKI via toll-
like receptor 9. The levels of mtDNA in septic patients have varied according to reports, 
which might occur because of the difference of the blood plasma fraction due to different 
centrifugal processing. We assayed mtDNA according to blood plasma fractions and 
evaluated whether mtDNA in circulating exosome was a prognostic factor in septic shock 
and septic AKI patients.
Methods: Septic patients who needed polymyxin B immobilized hemoperfusion 
(PMX) in intensive care unit of Hamamatsu University School of Medicine from November 
2013 to March 2017 were enrolled. Patient’s plasma was collected from just before the 
PMX initiation followed by centrifugation at 17,000g for 15 minutes to remove dead cell 
and cell debris. Exosome was obtained by ultracentrifugation at 200,000g for 1 hour. We 
extracted exosomal DNA and quantified exosomal mtDNA (Ex-mtDNA) by using real-time 
PCR. We prospectively observed their outcomes.
Results: The level of Ex-mtDNA in septic shock patients with hospital death 
(n=6) was significantly higher than those survivors (n=16) and health volunteers (n=4) 
(log2.80±1.19 vs log0.91±0.81 vs log-0.56±1.09, p<0.05). The ROC curve analysis 
revealed that Ex-mtDNA is the best prediction for in-hospital death compared with total 
mtDNA and blood lactic acid and SOFA score and urine volume [AUC: 0.90 (0.74-1.08) 
vs 0.86 (0.69-1.03), 0.80 (0.58-1.03), 0.84 (0.64-1.06)] and has high sensitivity and 
specificity and also odds ratio [0.83 (0.36-1.00), 0.93 (0.66-1.00), 65.0 (2.27-125), 
p<0.05, cut-off value: log1.91] The level of Ex-mtDNA in AKI patients was also higher 
than those in non-AKI patients (log1.84±1.20 vs log0.63±1.10, p<0.05) but was not 
better prediction than blood lactic acid and SOFA score [AUC: 0.76 (0.53-1.00) vs 0.82 
(0.63-1.01), 0.85 (0.67-1.02)].
Conclusions: Ex-mtDNA has a potential as a good predictor of survival and AKI in 
septic shock patients.
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Exosomal MicroRNAs in Urine Are Associated with Children’s Blood 
Pressure and Renal Biomarkers: An Exploratory Cross-Sectional Study
Alison P. Sanders,1 Daniel Flores,1 Vasily Aushev,1 Gleicy M. Hair,1 Ivan Pantic,2 
Andrea A. Baccarelli,4 Lisa M. Satlin,1 Martha M. Tellez-Rojo,3 
Robert O. Wright,1 Paul Curtin.1 1Icahn School of Medicine at Mount Sinai, New 
York, NY; 2National Institute of Perinatology, Mexico City, Mexico; 3National 
Institute of Public Health, Cuernavaca, Mexico; 4Columbia University, New 
York, NY.
Background: Urinary extracellular microRNAs are potential biomarkers of renal 
health and disease that may originate from epithelial cells in the renal or urogenital tract. 
Traditional analytical methods examine individual miRNA biomarkers; here we employ a 
mixtures approach to identify combinations of miRNAs associated with renal health.
Methods: We assessed the association between a mixture of exosomal miRNAs and 
systolic blood pressure (SBP), as well as 8 protein biomarkers measured in spot urine 
samples collected from 103 healthy children aged 4-5 years. We performed differential 
centrifugation and visualized exosomes using electron microscopy. miRNA were 
extracted and analyzed for 754 miRNAs using OpenArray qPCR. Expression data were 
normalized using the global mean. A miRNA was considered ‘detectable’ if it produced 
reliable qPCR signal in ≥70% of participant samples. We applied weighted quantile 
sum (WQS) regression to create a composite renal biomarker index of 252 ‘detectable’ 
miRNAs, and tested for association between the miRNA mixture with either SBP or the 
8 protein biomarkers, adjusting for age, BMI, sex, and parental report of indoor smoking. 
We analyzed the levels of 8 proteins (albumin, cystatin C, clusterin, osteopontin (OPN), 
α-1-microglobulin (A1M), kidney injury molecule-1 (KIM-1), TFF (trefoil factor 3), 
β2-microglobulin (β2M)). We considered substantive contributors to the mixture index as 
those with ≥ 2% weight.
Results: Increased SBP was associated with the miRNA index (β: 0.08, 95%CI: 0.1, 
1.5; p=0.02), driven by miR-590 and miR-885 (out of 13 total miRNA with weights ≥2%). 
Seven proteins (albumin, A1M, KIM1, TFF3, B2M and clusterin were positively associated 
with the miRNA mixture. Levels of cystatin C were not associated with the miRNA index. 
Notably, the associations of A1M, clusterin, and KIM-1 with the miRNA mixture were 
consistently driven by miR-574; the associations of TFF and OPN were consistently driven 
by miR-146b. The mRNA targets of miR-146b and miR-574 are enriched for nephrotoxic 
functions including renal inflammation, nephritis, tubule damage, and necrosis.
Conclusions: These findings highlight combinations of exosomal miRNAs as potential 
sensitive and non-invasive early life biomarkers of renal health.
Funding: Other NIH Support - NIEHS
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Urine Biomarkers and AKI Associations with CKD and Hypertension 3 
Months Post-Cisplatin in Children
Kelly McMahon,1 Tom D. Blydt-Hansen,2 Maury N. Pinsk,3 Cherry Mammen,2 
Louis Huynh,4 Mariya Yordanova,1 Frédérik Crépeau-Hubert,1 
Shahrad R. Rassekh,2 Kirk R. Schultz,2 Prasad Devarajan,5 Michael Zappitelli.6 
1McGill University, Montreal, QC, Canada; 2British Columbia’s Children’s 
Hospital, Vancouver, BC, Canada; 3University of Manitoba, Winnipeg, MB, 
Canada; 4School of Medicine, Queen’s University, Kingston, ON, Canada; 
5Cincinnati Children’s Hospital, Cincinnati, OH; 6Toronto Hospital for Sick 
Children, University of Toronto, Toronto, ON, Canada.
Background: Cisplatin (CisP) causes acute kidney injury (AKI) and may lead to 
chronic kidney disease (CKD) and hypertension (HTN) in children. Aims: 1) Describe 
3-month post-CisP CKD/HTN; 2) Determine if a) AKI during CisP treatment and b) urine 
neutrophil gelatinase-associated lipocalin (uNGAL) and kidney injury molecule-1 (uKIM-
1) near end of CisP therapy are associated with 3-month CKD/HTN.
Methods: 12-site prospective pediatric study. Exposures: a) Serum creatinine (SCr)-
AKI during CisP therapy (KDIGO definition); b) Electrolyte AKI(eAKI): low serum Mg++, 
K+ or PO4
- during therapy; c)uNGAL/KIM-1 at discharge from a late CisP cycle. Outcomes: 
a) CKD: urine albumin/creatinine ratio≥3mg/mmol(≥7.5mg/mmol if <2 years old), urine
protein/creatinine ratio≥15mg/mmol or SCr-estimated glomerular filtration rate<90mL/
min/1.73m2; b) HTN: blood pressure≥95thpercentile (adults:≥140/90mmHg) or treated
for HTN. Univariate tests and multiple logistic regression were performed to evaluate
exposure-outcome relations and adjusted associations.
Results: Of 154/158 with 3-month data: 77(50%) boys; median[IQR] age: 
6[3-12] years. 96/142(68%) had CKD; 14/141(10%) had HTN; 100/154(65%) had 
CKD or HTN. SCr-AKI, ≥Stage 2 SCr-AKI and eAKI+SCr-AKI were associated with 
3-month HTN(Table). AKI was not associated with CKD(Table). Adjusting for age and
gender, only ≥Stage 2 SCr-AKI was associated with 3-month HTN (adjOR 4.4(95% CI 
1.1-18.4)). Biomarkers were not associated with CKD or HTN(Table).
Conclusions: CKD and HTN are common 3 months after CisP. AKI is associated with 
3-month HTN. Ongoing 3-year follow-up will determine if associations change and/or
persist. Measures to reduce HTN after cancer therapy are needed.
Funding: Government Support - Non-U.S.
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Markers of Kidney Tubule Cell Function and Risk of AKI
Alexander Bullen,1 Cheryl A. Anderson,9 Alfred K. Cheung,2 
Michelle M. Estrella,3 Pranav S. Garimella,9 Vasantha Jotwani,3 James P. Lash,4 
Javier A. Neyra,5 Henry A. Punzi,6 Ronit Katz,7 Michael Shlipak,8 Joachim H. Ix.1 
1UCSD, San Diego, CA; 2University of Utah, Salt Lake City, UT; 3University of 
California, San Francisco and San Francisco VA Medical Center, San Francisco, 
CA; 4University of Illinois at Chicago, Chicago, IL; 5University of Kentucky 
Medical Center, Lexington, KY; 6Punzi Medical Center, Carrollton, TX; 
7University of Washington, Seattle, WA; 8San Francisco VA Medical Center, San 
Francisco, CA; 9University of California San Diego, La Jolla, CA.
Background: Novel biomarkers can quantify kidney tubular functions including 
proximal tubule reabsorption (alpha 1 microglobulin [a1m], and beta 2 microglobulin 
[b2m]) and tubule protein synthesis (uromodulin [umod]). Associations of tubule function 
measures with acute kidney injury (AKI) risk are uncertain. We evaluated associations 
of markers of kidney tubular function with AKI risk in participants with chronic kidney 
disease (CKD) in the SPRINT Trial.
Methods: Among 2351 participants with CKD (eGFR<60 ml/min), urine a1m, b2m 
and umod were measured by multiplex immunoassay (MesoScale Diagnostics) at the 
randomization visit. Cox proportional hazard models evaluated log-transformed biomarker 
levels as risk factors for AKI during 3.8 years mean follow-up. Sequential models adjusted 
for demographics, randomization arm, and urine creatinine (Model 1); baseline eGFR, 
uACR, and AKI risk factors (Model 2); and the other tubule function biomarkers (Model 3).
Results: Lower urine umod and higher a1m levels were each associated with higher 
AKI risk (Table). The association with uromodulin was independent of baseline eGFR and 
uACR (Model 2). Adjustment for all 3 tubule function markers strengthened associations of 
a1m which was independently associated with AKI in the final model. Results were similar 
in analyses stratified by randomization arm.
Conclusions: Assessment of tubule function by measurement of urine umod and a1m 
provides information of AKI risk independent of eGFR and albuminuria in persons with 
hypertension and CKD but without diabetes. Future studies should evaluate if dynamic 
changes in these markers can predict AKI risk in those exposed to intensive blood pressure 
lowering.
Funding: NIDDK Support
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Combination of ITRAQ-Based Quantitative Proteomics and Parallel 
Reaction Monitoring Identifies Biomarkers for the Early Diagnosis of AKI 
Following Percutaneous Coronary Intervention
Lulu Huang,1 Fangfang Zhou,1 Qun Luo,2 Gen Shen,1 Honghua Ye,1 Yumei Li.1 
1Ningbo NO.2 Hospital, Ningbo, China; 2Ningbo No.2 Hospital, Ningbo, China.
Background: In this study, we used Isobaric Tags for Relative and Absolute 
Quantitation(ITRAQ) to identify novel diagnostic biomarkers and to explore the underlying 
mechanisms of acute kidney injury (AKI) following percutaneous coronary intervention 
(PCI).
Methods: 114 patients (>60yrs) admitted for elective PCI were included in the study. 
We identified 14 elderly patients with PCI-AKI, 14 patients of whom did not develop AKI 
were selected as controls, matched by age, gender. Urine samples were collected before 
PCI, and 24 hours post-PCI. Blood collected for serum creatinine (Scr) concentrations 
and biochemical analysis. Isobaric Tags for Relative and Absolute Quantitation (ITRAQ) 
technology followed by Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) 
was used to discover differentially expressed proteins (DEPs) in a training set of PCI-AKI 
(n=6) and controls (n=6). DEPs were then investigated in an independent cohort of PCI-
AKI (n=8) and controls (n=8) using parallel reaction monitoring (PRM). We also identified 
DEPs potentially involved in PCI-AKI pathogenesis by analyzing biological processes, 
cellular components, molecular functions, Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways and protein-protein interactions (PPI).
Results: Comparing to patients before PCI, a total of 167 DEPs (106 upregulated 
proteins and 61 downregulated proteins) were identified in the urine of PCI-AKI patients 
(24h post-PCI). Among the upregulated proteins, 12 proteins were overlapped in both 
comparisons of AKI-24h/AKI-Pre and AKI-24h/CON-24h. Using the PRM approach, we 
successfully confirmed the differential accumulation of Haptoglobin (HPT), apolipoproteins 
A-I (APOA1) and Peroxiredoxin-2 (PRDX2) at 24h post-PCI comparing to pre-PCI and 
controls in the validation set. And they were earlier than Scr for diagnosis PCI-AKI. GO 
and KEGG pathway analysis described that these proteins were mainly involved in the 
peroxisome pathway(PRDX2), and the PPARγ signaling pathway (APOA1).
Conclusions: Our research showed HPT, APOA1 and PRDX2 were potential urine 
biomarkers and may play key roles in the pathogenesis of PCI-AKI. And these biomarkers 
might be prospective to made into “AKI panel” similar to myocardial enzyme for the 
diagnosis of PCI-AKI in the future.
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Identification of Urine Potential Biomarkers of AKI Patients with 
Cirrhosis by iTRAQ-Based Quantitative Proteomics
Lulu Huang,1 Fangfang Zhou,1 Qun Luo,2 Zemin Wang,1 Yumei Li,1 
Wenhong Zhou.1 1Ningbo NO.2 Hospital, Ningbo, China; 2Ningbo No.2 
Hospital, Ningbo, China.
Background: To identify novel diagnostic biomarkers and to explore the underlying 
mechanisms of acute kidney injury (AKI) patients with cirrhosis.
Methods: We performed a prospective nested case-control study. We collected urine 
samples of cirrhotic patients with risk factors of AKI (bacterial infections, bleeding from 
oesophageal varices, large volume paracentesis (>3L/d), increased dosage of diuretics, and 
receiving contrast medium) at the time of risk factors occurred and 1d after the risk factors. 
Blood was collected for serum creatinine (Scr) concentrations and biochemical analysis. 
iTRAQ technique followed by Liquid Chromatography tandem Mass Spectrometry (LC-
MS/MS) was used to screen differentially expressed proteins (DEPs). And DEPs were also 
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analyzed by Gene Ontology (GO),Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways and protein-protein interactions (PPI) analysis.
Results: 90 cirrhotic patients with risk factors of AKI were included in the study. 
Among these patients, 11 patients were diagnosed as AKI (KDIGO AKI criteria, 2012), and 
9 patients were selected as controls (matched by age and gender). Using iTRAQ approach,a 
total of 289 DEPs (64 upregulated proteins and 225 downregulated proteins) were 
identified in the urine of AKI group (1d after risk factors occurred) comparing to controls. 
20 biological process, 20 cellular components, 20 molecular functions and 20 significant 
KEGG pathways were identified. Among them, renin-angiotensin system pathways, and 
apoptosis pathways may play a role in the pathogenesis of AKI with cirrhosis. Combined 
with the PPI results, alpha-1-antitrypsin precursor(SERPINA1), S100 calcium binding 
A9(S100A9)and mucin-5AC(MUC5AC)were significantly up-regulated at 1d after risk 
factors occurred in AKI group. And they were earlier than Scr which significantly rose in 
both comparisons of AKI-48h/AKI-Pre and AKI-48h/CON-48h till at 48h for diagnosis of 
AKI with cirrhosis.
Conclusions: iTRAQ technology was useful in the selection of DEPs from proteomes, 
and might provide a theoretical basis for the study of biomarkers and mechanisms in AKI 
with cirrhosis. The identified panel of SERPINA1, S100A9 and MUC5AC proteins might 
serve as potential biomarkers and thereby aid in the detection of AKI with cirrhosis.
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Predictive Value of Current Biomarkers for Early Reversal of AKI
Sadudee Peerapornratana,2,1 Priyanka Priyanka,3 John A. Kellum.2 Center for 
Critical Care Nephrology, The CRISMA Laboratory, Department of Critical 
Care Medicine, University of Pittsburgh 1Chulalongkorn University, Bangkok, 
Thailand; 2University of Pittsburgh, Pittsburgh, PA; 3The University of 
Pittsburgh, Pittsburgh, PA.
Background: Acute kidney injury (AKI) is associated with various recovery patterns. 
Early reversal of AKI is common in critically ill patients and associated with good outcomes. 
The predictive role of current biomarkers for reversal of AKI is still unknown.
Methods: Using data from an ancillary study to a large randomized trial, including 
1,341 patients with septic shock we focused on patients with stage 2 or 3 AKI at presentation 
or manifesting within the first day of hospital admission. Early reversal of AKI was defined 
as no longer meet any criteria for AKI (for at least 24 hours) on any day within the 7 
days after first documented AKI. Any subsequent AKI episode after initial reversal was 
considered a relapse. Final recovery status was then assessed at hospital discharge. Several 
urinary biomarkers were measured at 24 hours after enrollment and used for prediction of 
early reversal.
Results: Among the 604 patients with KDIGO stage 2 or 3 AKI, 345 (57.1%) patients 
had early reversal of renal function. Of these, 50 (14.5%) patients had a relapse of AKI 
during their hospital stay after early reversal. A total of 327 (54.1%) patients finally had 
recovery at hospital discharge. About 40% of patients never reversed AKI. None of the 
urinary biomarkers TIMP-2●IGFBP7, NGAL, Kim-1, L-FABP, or type IV collagen were 
predictive of early reversal of AKI (C-statistics: 0.37, 0.45, 0.49, 0.48, 0.45, respectively). 
Patients who had early sustained reversal of renal function experienced the best survival at 
day 90, while those who had relapse of AKI and those who never recovered had the worst 
outcomes.
Conclusions: Currently available AKI biomarkers are not useful for prediction of early 
reversal of renal function after AKI. Novel predictive biomarkers for renal recovery are 
needed.
Survival by recovery patterns.
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Circulating Cardiac Stress, Vascular Dysfunction, and Inflammatory 
Biomarkers Predict AKI in French Type 2 Diabetes Patients: The 
SURDIAGENE Cohort
Benedicte Sautenet,1 Pierre Jean Saulnier,3 Gand Elise,3 Ronan Roussel,6 
Stephanie Ragot,5 Gilberto Velho,6 Samy Hadjadj.3 1CHRU Tours, Tours, 
France; 3CHU Poitiers, Poitiers, France; 5University of Poitiers, Poitiers, 
France; 6INSERM, Paris, France.
Background: Acute kidney injury (AKI) is related to chronic kidney disease and death 
in patients from the general population, with or without type 2 diabetes. Nevertheless AKI 
biomarkers are rarely validated in diabetes population. We aimed to explore the individual 
and combined prognostic value of 8 circulating candidate markers for AKI.
Methods: We prospectively followed-up 1345 (565 women/780 men) type 2 diabetes 
participants of a French single-centre hospital-based cohort (SURDIAGENE) with baseline 
GFR≥30 ml/min/1.73m2 and no renal replacement to onset of AKI, death, or December 31, 
2015. Intrahospital AKI was diagnosed and staged using the KDIGO criteria. We assessed 
3 markers of cardiac and endothelial dysfunction (mid-regional-pro-adrenomedullin 
[MRproADM], angiopoietinlike-2 [ANGPTL2], N-terminal prohormone brain natriuretic 
peptide [NTproBNP]), 1 of oxidative stress (fluorescent advanced glycation endproducts 
[AGE], carbonyls), 1 for cardio-renal pathways (copeptin [CTproAVP]), and 1 of 
inflammation (soluble TNF receptor 1 [TNFR1]). Cox models were used to estimate the risk 
of AKI for each biomarker at baseline after adjustement for usual risk factors: sex, diabetes 
duration, HbA1c, systolic blood pressure, GFR, ACR, use of antihypertensive, and history 
of cardiovascular disease. Hazard ratios were reported per 1 SD increment of the logarithm 
of the biomarker concentration.
Results: At baseline, mean±SD age was 64±11 years, diabetes duration 14±10 years, 
HbA1c 7.8±1.6%, and eGFR 77±21 ml/min/1.73m2, and median (IQR) ACR 3 (1-10) mg/
mmol. During a median follow-up of 4.7 years, 449 (33%) patients developed an AKI. In 
univariate analysis, each biomarker was significantly associated with AKI, and 6 remained 
associated after multivariable adjustment (Table). The addition of a multimarker score 
summing standardized and weighted values of these 6 markers to the model including 
usual risk factors significantly improved C-statistics (0.724 to 0.759, P<0.0001), and 5-year 
risk-predictive performance (relative integrated discrimination improvement index=0.435, 
P<0.0001).
Conclusions: A panel of 6 biomarkers representing cardiac, vascular and inflammatory 
pathways improved the prediction of AKI over usual risk factors in patients with type 2 
diabetes.
TH-PO051 Poster Thursday
AKI: Biomarkers, Drugs, Onco-Nephrology
Heat Shock Protein 72 (Hsp72) Is a Useful Biomarker for AKI in Liver 
Transplant
Armando Jezael Martinez-Rueda,1 Silvana Bazua-Valenti,1,2 Antonio Olivas-
Martínez,1 Jose V. Jimenez,1 Diego L. Carrillo Perez,1 Leoneli I. Grajeda-
Medina,1 Juan A. Ortega-Trejo,1,2 Andrea Sanchez-Navarro,1,2 Rosalba Pérez-
villalva,1,2 Ignacio García juárez,1 Luis E. Morales-Buenrostro,1 
Norma Bobadilla,1,2 Gerardo Gamba.1,2 1Instituto Nacional de Ciencias Médicas 
y Nutrición Salvador Zubirán, Mexico City, Mexico; 2Instituto de Investigaciones 
Biomedicas, UNAM, Mexico City, Mexico.
Background: Acute Kidney Injury (AKI) after liver transplantation (LT) is a frequent 
complication and an important risk factor for mortality. We have shown that Hsp72 is 
an early AKI biomarker in animal models of ischemic acute renal injury and in a variety 
of critically ill patients in the ICU (EMBO MM 2011 and Plos One 2014). Since the LT 
program in our institute performs one transplant per week, we designed the present study to 
determine the incidence and risk factors of AKI during the postoperative period of LT, and 
to assess whether Hsp72 can be a useful tool to predict AKI.
Methods: We conducted a single-center prospective and observational study for LT 
patients (N=26). AKI was defined as a two-fold increase in baseline serum creatinine (SCr). 
Urine samples were collected before LT and at 0, 6, 12, 24 and 48 hours after. Urinary 
samples were resolved in SDS-PAGE gels and analyzed by western blot with a monoclonal 
anti-Hsp72 antibody. Hsp72 values were adjusted to urinary creatinine concentration.
Results: The mean age of our cohort was 49±10.58 years with 57.7% females. Hepatitis 
C infection was the main etiology for cirrhosis (42.3%). 14 patients (53.8%) developed AKI 
in the 5 days post-LT, and four of them required dialysis. Multivariate analysis showed that 
AKI was associated with encephalopathy prior to LT (OR 10.99, p=0.029). Based on SCr, 
AKI was diagnosed with a median of 24 h post-LT. Conversely, Hsp72 levels significantly 
increased at 6 h post-LT in patients that developed AKI vs. the non-AKI (p=0.042). The 
AUC-ROC analysis revealed that at 6 h Hsp72 predicts AKI with an AUC of 0.732.
Conclusions: Our observations indicate that urinary Hsp72 increases in patients that 
develop AKI in the post-LT several hours before they reach AKI criteria based on SCr, 
suggesting that Hsp72 could be a useful biomarker for the development of AKI.
Funding: Government Support - Non-U.S.
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Utilizing Neutrophil Lymphocyte Ratio to Detect Early AKI
Asif Khan, Elie El-Charabaty, Suzanne E. El Sayegh. Staten Island University 
Hospital, Brooklyn, NY.
Background: The ability to detect early Acute Kidney Injury (AKI) prior to elevation 
of Cr has always been a challenge to physician. Traditionally, serum Cr level is used 
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to diagnose AKI. However, it has been shown to be poor predictor of AKI occurrence. 
Multiple inflammatory markers for AKI have been studied, but they are expensive 
and their clinical values remain limited. NLR has been found to be strongly associated 
with inflammatory states in last decade, thus can potentially be used as marker for AKI. 
Our primary objective is to investigate the role of NLR in prediction of early AKI prior 
elevation of Cr. We compared NLR’s predictive power of AKI in both inflammatory and 
non-inflammatory conditions.
Methods: Retrospective study included 413 patients with age ≥ 18 who were 
admitted with the diagnosis of pneumonia without AKI (PWOA) and those admitted with 
pneumonia who developed AKI (PWA) as well as the patients admitted with diagnosis of 
heart failure without AKI (HFWOA) and those admitted with heart failure who developed 
AKI (HFWA). NLR and renal function were compared from 3 days before Day 0, and 
3 days after Day 0. Day 0 represents as the day of diagnosis of AKI in PWA and HFWA 
groups; Day 0 is also represented by day of diagnosis of pneumonia or heart failure in 
PWOA and HFWOA groups. Subjects with ESRD, contrast induced AKI, drug induced 
AKI, hematologic proliferative diseases, on immunosuppressive agents or chronic steroid 
were excluded from the study.
Results: Patients in PWOA group has significantly hight NLR value (p value <0.0001) 
and longer lenght of stay (pvalue: <0.01) when compared to HFWOA, owing to higher 
sensitivity of NLR. Significant rise in NLR was also observed 72 hours earlier than serum 
Cr in PWA group (p value <0.0001). Thus, NLR not only strongly associated with AKI 
rather than infectious process, but also able to predict AKI significantly earlier than serum 
Cr level.
Conclusions: Our result suggests that NLR that was found to be associated with 
inflammatory conditions, can potentially be utilized as a marker to detect early AKI.
PWA vs HFWA
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Remote Ischemic Preconditioning in the Prevention of Contrast Induced 
Nephropathy in Patients Undergoing Peripheral Angiography: A Pilot 
Randomized Controlled Trial
Debajyoti M. Roy,1 Tjun Y. Tang,2 Tarchoon Aw.3 1Changi General Hospital, 
Singapore, Singapore; 2Singapore General Hospital, Singapore, Singapore; 
3Changi Hospital, Singapore, Singapore.
Background: Contrast induced nephropathy (CIN) is a leading cause of hospital 
acquired acute Kidney injury (AKI). Remote ischemic preconditioning (RIPC) has been 
found to be protective against AKI in patients undergoing coronary surgery This project 
aims to evaluate the potential of RIPC prior to vascular angiography in preventing CIN.
Methods: This study is a single centre, experimental, randomised controlled trial of 
the effect of RIPC with the induction of brief episodes of upper limb ischemia followed 
by reperfusion using blood pressure cuffs to determine protection against CIN in advanced 
periphereal arterial disease undergoing elective angiography. The inclusion criteria for this 
study are: patients above age of 21 yrs undergoing elective periphereal arterial angiography/
angioplasty who have an eGFR≥ 45ml/min and have given written informed consent. 
There are two arms of this trial: Control and preconditioned arm (RIPC). Patients will be 
randomised 1:1. Group 1(Control arm) : IV hydration with 0.9% normal saline (1ml/kg/
hour) prior to angiographic procedure Group 2 (RIPC) : patients will receive IV hydration 
prior to procedure, similar to control group. Additionally patients will receive RIPC, where 
a blood pressure cuff will be placed around one arm of the patientand inflated to a pressure 
of 250mm Hg for 5 minutes, deflated and allow arm to re-perfuse for 5 min. This is repeated 
for atotal of 3 ischemia-reperfusion cycles. Patients in both arms had serial measurements 
of serum creatinine as wellas serum cystatin and urinary NGAL at 2 hours, 24 hours, 48 and 
72 hours post procedure
Results: There was no signicant differences between Control and RIPC groups with 
regards baseline characteristics. There was no reduction in development CIN in the RIPC 
group compared to Control.
Conclusions: RIPC did not offer any protection against development of CIN in our 
group of patients with eGFR >45ml/min over and above the standard therapy ie. intravenous 
hydration. The protective effect of RIPC in patients with more advanced chronic kidney 
disease needs further study
Table 1.RIPC versus Control
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The Effect of Remote Ischemic Preconditioning for Preventing Con-
trast-Induced AKI in CKD Patients Undergoing Elective Coronary 
Angiography
Tatiporn Tusnapituk,1,2 Thanit Chirananthavat.3 1Police general hospital, 
Bangkok, Thailand; 2Internal medicine, Phrae hospital, Phrae, Thailand; 
3Police General Hospital, Nonthaburi, Thailand.
Background: Despite the increasing use of pre- and post-hydration protocols and low-
osmolar contrast media, the incidence of Contrast-Induced Acute Kidney Injury (CI-AKI) 
is still significant. The underlying mechanism has been attributed in part to ischemic kidney 
injury. Remote ischemic preconditioning (RIPC) is a non-invasive, safe, and low-cost 
method to reduce ischemic reperfusion injury. We aim to investigate whether RIPC, as an 
adjunct to standard preventive measures, reduces CI-AKI in chronic kidney disease (CKD) 
patients who are in high risk of CI-AKI.
Methods: This randomized double-blind control trial compared standard care with or 
without ischemic preconditioning (4 cycles of intermittent arm ischemia) in patients with 
impaired renal function (estimated glomerular filtration rate, eGFR < 60 mL /min/1.73 m2 
by CKD-EPI equation) undergoing elective coronary angiography in the Police General 
Hospital between May 2017 and February 2018. The primary outcome was the incidence of 
CI-AKI, defined as an increase in serum creatinine > 0.3 mg/dL or 1.5 times above baseline 
at 48 hours after contrast medium exposure.
Results: A total of 50 patients, 55 episodes were enrolled, out of which 28 were in 
the RIPC group, and 27 were in the control group. The medians of contrast media volume, 
serum creatinine, and eGFR at baseline did not differ between the groups. The primary 
outcome, CI-AKI, occurred in a total of 7 episodes, consisting of 2 (7%) in the RIPC group 
and 5 (18%) in the control group, with no significant difference between the two groups 
(p=0.21).
Conclusions: RIPC cannot reduce the incidence of CI-AKI after contrast administration 
in CKD patients who are at risk of CI-AKI.
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AKI Is Common in Patients Receiving Immune Checkpoint-Inhibitors 
(CPIs)
Harish Shanthanu Seethapathy,2 Donald F. Chute,2 Yaa Oppong,2 
Frank B. Cortazar,2 David E. Leaf,1 Kerry Reynolds,2 Meghan E. Sise.2 1Brigham 
and Women’s Hospital, Boston, MA; 2Massachusetts General Hospital, Boston, 
MA.
Background: Immune CPI use for first-line or salvage cancer immunotherapy is 
rapidly increasing. Because acute interstitial nephritis may complicate CPI therapy, the 
American Society of Clinical Oncology suggests holding CPIs and evaluating any patient 
(pt) whose serum creatinine (SCr) rises at least 1.5-fold above baseline (BL) i.e., ≥ grade 
1 AKI. Empiric steroid therapy is recommended for pts with a Grade ≥ 2 AKI without an 
alternate cause. We sought to determine the frequency, severity, and predictors of AKI in a 
real-world population receiving CPIs.
Methods: We included all pts on CPIs from 2011-2017 at our institution. We determined 
CPI start date by oncology infusion records. BL SCr was established by averaging all SCr 
values during the 6 months prior to CPI start date. We compared all SCr values within 
6 months after starting CPIs to the BL SCr to determine the fold-change from BL. We 
used logistic regression to determine if age, sex, race, hypertension, diabetes, cirrhosis or 
baseline CKD (GFR < 60) predicted AKI.
Results: 1843 pts started CPI therapy. 1039 (56%) had sufficient data to determine 
a BL SCr and had ≥1 SCr checked within 6 months of starting CPIs. Average age was 63 
(SD, 13) yrs, 60% were male and 91% were Caucasian. The mean BL SCr was 0.9 (SD, 
0.4) mg/dl, and 175 (17%) had CKD at BL. Pts had a median of 7 (IQR, 2-14) SCr values 
measured during the BL period, and 12 (IQR, 8-18) SCr values measured in the 6 months 
after CPI. 140 pts (13.5%) had an AKI event within 6 months of starting CPI therapy; 79 
(56%) were grade 1 (>1.5-2-fold rise in SCr), 46 (33%) were grade 2 (>2-3-fold rise in SCr) 
and 15 (11%) were grade 3 (>3-fold rise in SCr or needed dialysis). Of the 140 pts with 
AKI, 42 (30%) had multiple AKI events within the first 6 months of starting CPIs. The first 
AKI event occurred on average 67 (SD, 52) days after starting CPIs. 69 pts (6.6% of the 
total cohort) had a sustained AKI event lasting > 48 hours. No baseline pt characteristics, 
including BL SCr, predicted AKI in a multivariable models.
Conclusions: AKI events are common in pts receiving CPIs. BL CKD does not appear 
to be a risk factor for AKI after CPIs. Nephrologists are likely to be increasingly called upon 
to evaluate the cause of AKI and assist oncologists in determining the best course of therapy 
in pts receiving CPIs.
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Incidence of AKI Among Critically Ill Patients with Brief Empiric Use of 
Anti-Pseudomonal Beta-Lactams with Vancomycin
Diana J. Schreier,1 Kianoush Kashani,2 Ankit Sakhuja,2 Kristin C. Mara,4 
Mohammad samie Tootooni,5 Heather A. Personett,1 Sarah Leung,1 
Andrew D. Rule,2 James Steckelberg,3 Aaron J. Tande,3 Erin F. Barreto.1 
1Department of Pharmacy, Mayo Clinic, Rochester, MN; 2Division of Pulmonary 
and Critical Care Medicine, Mayo Clinic, Rochester, MN; 3Division of Infectious 
Diseases, Mayo Clinic, Rochester, MN; 4Division of Biomedical Statistics and 
Informatics, Mayo Clinic, Rochester, MN; 5Department of Health Sciences 
Research, Mayo Clinic, Rochester, MN.
Background: Nephrotoxins contribute to 20-40% of acute kidney injury (AKI) 
cases in the intensive care unit (ICU). The combination of piperacillin/tazobactam and 
vancomycin (PTZ/VAN) has been identified as nephrotoxic, but existing studies focus on 
extended durations of therapy rather than the brief empiric courses often used in the ICU. 
The objective of this study was to compare the risk of AKI with a short course of PTZ/VAN 
to other anti-pseudomonal beta-lactam/vancomycin combinations
Methods: Retrospective cohort of 3299 ICU patients that received at least 24 hours, 
but no more than 72 hours of an antipseudomonal beta-lactam and vancomycin [(PTZ/VAN, 
cefepime (CEF/VAN), or meropenem (MER/VAN)]. The risk of developing stage 2 or 3 AKI 
was compared between antibiotic groups with multivariable logistic regression adjusted for 
relevant confounders. We also compared the risk of persistent kidney dysfunction, dialysis 
dependence, or death at 60-days between groups.
Results: The overall incidence of stage 2 or 3 AKI was 9%. Brief exposure to PTZ/
VAN did not confer a greater risk of stage 2 or 3 AKI after adjustment for demographics, 
baseline serum creatinine, AKI risk prediction score, severity of illness, or sepsis [PTZ/
VAN vs. CEF/VAN: adjusted OR, 95% CI 1.11 (0.85, 1.45); PTZ/VAN vs. MER/VAN 1.04 
(0.71, 1.42)]. No significant differences were noted between groups at 60-day follow up in 
the outcomes of persistent kidney dysfunction (P = 0.081), new dialysis dependence (P = 
0.15), or death (P = 0.091).
Conclusions: Short courses of PTZ/VAN were not associated with a greater risk of 
short- or long-term adverse renal outcomes compared to other empiric broad-spectrum 
combinations.
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AKI After Intravenous Vancomycin Compared to Other Common 
Intravenous Antibiotics
Martina M. Gaggl,2,1 Til Stürmer,5 Abhijit V. Kshirsagar,3 J. Bradley Layton.4 
1Medical Universitiy of Vienna, Vienna, Austria; 2Department of Epidemiology, 
Gillings School of Global Public Health, Chapel Hill, NC; 3University of North 
Carolina at Chapel Hill, Chapel Hill, NC; 4RTI Health Solutions, Research 
Triangle Park, NC; 5UNC Gillings School of Global Publich Health, Chapel 
Hill, NC.
Background: Vancomycin is a mainstay treatment for Gram-positive infection, but 
it may be associated with nephrotoxicity and acute kidney injury (AKI). AKI contributes 
to short-term morbidity, mortality, and increased risk of chronic kidney disease (CKD). 
The study aimed to evaluate the 2-week risk of AKI after ≥3 days of intravenous (IV) 
vancomycin treatment compared to patients treated with a comparator using U.S. 
commercial claims data.
Methods: From Truven MaketScan claims data (United States), we identified patients 
with a first hospitalization with IV vancomycin or comparator treatments with similar clinical 
indications (table 1) for ≥3 days with a treatment onset ≤ five days after hospital admission 
(2000-2015). Patients with claims for prior AKI, CKD, or use of immunosuppressive 
medications were excluded. We estimated incidence rates (IR) and hazard ratios (HR) with 
cox-regression adjusted for age, sex, main diagnosis, surgical procedure, and 1-year history 
of comorbidities and co-medication.
Results: We identified 32,997 hospitalized patients with vancomycin or comparator 
mono-therapy. The mean age was 50 (±15) years and 60% were female. Covariates were 
evenly distributed across treatment cohorts. Vancomycin was used in 5,449 (17%) patients 
and in 83% a comparator. Overall, there were 129 cases of AKI, and the IR of AKI was 
9.32 (95% CI: 7.84-11.07) per 100 person-years. The crude HR comparing vancomycin 
vs. comparators was 1.04 (95% CI: 0.85-1.90). After adjustment the HR for vancomycin 
vs. all comparators was 0.74 (95% CI 0.45-1.21). Similarly, separate adjusted models for 
individual comparators did not result in elevated HR for vancomycin.
Conclusions: Our study using US claims data did not demonstrate an association 
between treatment with vancomycin alone and an increased risk of AKI compared to other 
commonly used intravenous antibiotics in hospitalized patients.
Table 1.
*per 100 person-years
TH-PO058 Poster Thursday
AKI: Biomarkers, Drugs, Onco-Nephrology
Levetiracetam and the Risk of AKI: A Population-Based Cohort Study
Kevin Yau,1,2 Eric McArthur,2 Racquel Jandoc,2 Flory T. Muanda,1,2 
Chirag R. Parikh,3 Ron Wald,4 Amit X. Garg.1,2 1Western University, London, 
ON, Canada; 2Institute for Clinical Evaluative Sciences, London, ON, Canada; 
3Yale University and VAMC, New Haven, CT; 4St. Michael’s Hospital, Toronto, 
ON, Canada.
Background: Regulatory agencies warn about the risk of acute kidney injury (AKI) 
with levetiracetam use based on information contained in case reports. We conducted this 
population-based cohort study to determine whether new levetiracetam use versus non-use 
is associated with AKI.
Methods: We performed a population-based retrospective cohort study in Ontario, 
Canada. Adults who received a new outpatient prescription for levetiracetam from an 
outpatient pharmacy between January 1, 2004 and March 1, 2017 were matched to two 
non-users on stage of chronic kidney disease, recorded seizure in the prior 90 days, and logit 
of a propensity score for levetiracetam use. The primary outcome was a hospital encounter 
(emergency department visit or hospitalization) with AKI within 30 days of cohort entry. 
Secondary outcomes were AKI within 180 days and change in the serum concentration 
of creatinine. We assessed the primary outcome using health care diagnosis codes. We 
evaluated the change in the concentration of serum creatinine in a subpopulation with 
laboratory measurements.
Results: We matched 3,980 levetiracetam users to 7,960 non-users (mean age 
55 years, 51% women). Levetiracetam use was not significantly associated with a higher 
risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events 
in non-users [odds ratio, 1.24; 95% CI, 0.62-2.47]). Similarly, there was no significant 
association with AKI within 180 days (odds ratio, 0.70; 95% CI, 0.43-1.13). The change 
in the concentration of serum creatinine did not significantly differ between levetiracetam 
users and non-users.
Conclusions: In this population-based study it is reassuring that levetiracetam use was 
not associated with a higher risk of AKI.
Funding: Private Foundation Support, Government Support - Non-U.S.
Outcomes Assessed Using Database Codes
To comply with privacy regulations to minimize the chance of identifying a study patient, 
numbers of patients were suppressed in the case of 1 to 5 patients (reported as ≤5).
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Longer-Interval Regimen of Colistin Reduces Nephrotoxicity in 
Kidney-on-a-Chip
Kipyo Kim, Ji Young Ryu, Hyung Eun Son, Ho Jun Chin, Sejoong Kim. Seoul 
National University Bundang Hospital, Gyeonggi-do, Republic of Korea.
Background: Potential nephrotoxicity of colistin is of growing concerns due to relative 
high incidence and recent extensive use; however, which dosing regimen is less nephrotoxic 
remained uncertain. Previous animal and clinical studies have showed conflicting results 
for less toxic dosing regimen. We investigated whether bolus-mimicking regimens or 
continuous infusion regimen of colistin may be less nephrotoxic using microfluidic organ-
on-a-chip device applying the Pharmakokinetic profile of colistin.
Methods: We introduced colistin to the kidney epithelial cells on kidney-on-a-chips 
under physiological shear stress condition(1 dyn/cm2) and separated chip devices into two 
groups: bolus-mimicking regimen group and continuous infusion regimen group. Two drug 
treatment regimens were given the same total colistin dose over a 48 h period. Bolus-like 
regimen mimicked pharmacokinetic profiles for human bolus injection with starting colistin 
concentration of 1138 μg/ml and reducing by half every 9 h known as half-life of colistin 
in critically ill patients. Continuous Infusion regimen groups were exposed at colistin 
concentration of 400 μg/ml for 48 h.
Results: The bolus-mimicking regimen injured 1.64% out of total observed cells, 
whereas the continuous infusion regimen damaged 3.44% after 48-hour colistin exposed 
period. (P < 0.05). Bolus-mimicking regimen sustained lower transmembrane permeability 
of FITC-albumin and tight junction protein expression ZO-1 and occludin compared to the 
prolonged exposed regimen.
Conclusions: We found that a bolus-mimicking regimen dramatically alleviates kidney 
injury compared to the continuous infused regimen. Longer interval regimens may help to 
reduce nephrotoxicity in long-term colistin-using patients. In addition, kidney-on-a-chip 
experiments could be useful for selecting optimal dosing regimen of nephrotoxic drugs.
Funding: Government Support - Non-U.S.
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Figure 1. (A) Two different administration regimen of colistin: Bolus-mimicking regimen 
and continuous infusion regimen (B) The schematic design of kidney-on-a-chip used in 
this study
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The Characteristic of Drug Spectrum That Induced AKI and Clinicopath-
ological Features of Drug-Induced AKI
Yu Cui,1 Xiabing Lang,2 Lan Lan.2 1Zhejiang university, Hangzhou, China; 
2Zhejiang University, Hangzhou, China.
Background: To analyze the changes and characteristics of drug spectrum, and to 
analyze the kidney pathological characteristics of drug-induced acute kidney injury.
Methods: Retrospective analysis the characteristics of the patients of our center in 
2012 January to October 2016, who were diagnosed of drug-induced AKI. According to the 
data of medical history and clinical manifestations, record the related drugs, analysis of the 
changes of drug composition and the renal pathological characteristics.
Results: There are 228 patients diagnosed drug-induced AKI, and 51 patients 
underwent renal biopsy. In 228 patients, 70 patients were caused by antibacterial and 
antiviral drugs, 63 patients were caused by non-steroidal anti-inflammatory drugs, 17 
patients were caused by Chinese herbal medicine, and other drugs including the ACEI / 
ARB drugs, proton pump inhibitors, weight-loss drugs, lipid-lowering drugs, anti-hepatitis 
B virus medicine, antidepressants, albumin, platinum chemotherapy drugs, colchicine, 
calcineurin inhibitors. 14 patients cannot named which drugs. There were 31 patients 
had 2 or 3 types of drugs used before kidney injury. The antibiotics and antiviral drugs 
were the most frequently drugs associated with AKI, including cephalosporins, acyclovir, 
azithromycin, clindamycin, levofloxacin. In the 51 underwent renal biopsy patients, 
12 patients showed allergic interstitial nephritis, 19 cases of patients showed interstitial 
nephritis, 8 patients showed renal tubular epithelial cell injury, and 2 cases showed 
Minimal Change Nephropathy, 2 cases showed IgA nephropathy, 2 cases of mild mesangial 
hyperplasia with glomerulosclerosis.
Conclusions: The first three types of drugs induce AKI were antibiotics and antiviral 
drugs, non- steroidal anti-inflammatory drugs and Chinese herbal medicine. In the group 
of antibacterial drugs and antiviral drugs, the most common drugs were cephalosporins, 
acyclovir, clindamycin, azithromycin and levofloxacin, but not aminoglycosides. Allergic 
interstitial nephritis, interstitial nephritis and tubular epithelial cell injury is the main 
pathological manifestations of drug - induced AKI, but some patients had no obvious 
changes of the pathological performance.
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NSAID Use and NSAID-Associated AKI Before and After Implementation 
of Pennsylvania’s Prescription Drug Monitoring Program
Evan C. Ray,1 Andrew Bilderback,3 Amanda Schwenk,2 Dilhari Dealmeida,2 
John A. Kellum.2 1Internal Medicine - Renal Electrolyte, University of 
Pittsburgh, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA; 3UPMC, 
Pittsburgh, PA.
Background: Few studies describe the influence of prescription drug monitoring 
programs (PDMPs) on NSAID use or NSAID-associated adverse effects. We asked whether 
implementation of Pennsylvania’s PDMP, designed to reduce narcotic use, was associated 
with changes in inpatient NSAID administration or NSAID-related Acute Kidney Injury 
(AKI) in western Pennsylvania (UPMC) hospitals.
Methods: We examined retrospective data from 16 UPMC hospitals in three PA PDMP 
phases: pre-PDMP (Jan 1-Aug 25, 2016), voluntary PDMP participation (Aug 26-Dec 31, 
2016), and mandatory PDMP participation (Jan 1-Dec 31, 2017). Patients with ICD-10 
codes indicating ESRD or kidney transplant were excluded. Outcomes included percent of 
admissions with any NSAID use and with prolonged NSAID use (≥ 4 days) and frequency 
of NSAID-associated AKI. AKI was defined by presence of both a creatinine-based 
electronic flag and an ICD-10 code for atraumatic, non-obstructive AKI. Outcomes were 
compared during each phase using chi-square tests, and interrupted time-series analyses 
were used to examine the impact of each phase over time.
Results: Inpatient visits in the pre-, voluntary, and mandatory PDMP phases totaled 
95,550; 52,344; and 151,251, respectively. Across the three phases, hospitalizations with 
any NSAID use increased (77.1% pre- vs 78.3% voluntary vs 79.5% mandatory PDMP, 
p<0.001). Additionally, hospitalizations with prolonged NSAID use increased across the 
three phases (32.1% pre- vs 32.6% voluntary vs 33.9% mandatory PDMP, p=0.001). In 
interrupted time series analysis, receipt of any NSAIDs increased 1.4% with implementation 
of the voluntary phase (p <0.001), and AKI incidence increased 0.7% with implementation 
of the mandatory phase (p=0.06). Across all phases, patients with CKD were particularly 
susceptible to NSAID-associated AKI with prolonged NSAID use, as 42.0% of CKD 
patients receiving NSAIDs for ≥ 4 days experienced AKI, compared to 29.9% of CKD 
patients receiving < 4 days of NSAIDs (p = 0.001).
Conclusions: We find that implementation of the PA PDMP was associated with 
a significant increase in NSAID use and duration in inpatient UPMC facilities and a 
marginally significant and temporally correlated increase in AKI. Further analyses will 
examine whether AKI increased more dramatically in specific high-risk patient subsets.
Funding: NIDDK Support
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Bortezomib-Induced Tumor Lysis Syndrome in Patients with Untreated 
Symptomatic Multiple Myeloma: A Retrospective Study
Masahiro Kondo,1 Yuji Hotta,2 Karen Yamauchi,2 Akimasa Sanagawa,1,2 
Hirokazu Komatsu,3 Shinsuke Iida,3 Kazunori Kimura.1,2 1Pharmacy, Nagoya 
City University Hospital, Nagoya, Japan; 2Hospital Pharmacy, Graduate 
School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan; 
3Hematology and Oncology, Nagoya City University Graduate School of 
Medical Sciences, Nagoya, Japan.
Background: Tumor lysis syndrome (TLS) causes acute kidney injury (AKI) and is 
a complication of cancer chemotherapy. TLS risk is classified by malignant disease type. 
Although multiple myeloma (MM) is a low-risk disease, treatment by novel therapies, 
including bortezomib (Bor), may increase TLS risk. Thus, we evaluated the association 
between Bor-based therapy and TLS in MM patients.
Methods: We retrospectively reviewed patients who received first-line therapy for 
untreated symptomatic MM between May 2007 and December 2017. Patients treated by 
Bor-based therapy comprised the Bor group; all remaining patients (i.e., those treated by 
conventional anti-cancer agents) comprised the Non-Bor group. Incidences of laboratory and 
clinical TLS (LTLS and CTLS) during first-line therapy were compared between groups.
Results: There were 129 and 75 patients in Bor and Non-Bor groups, respectively. 
Baseline laboratory data were similar between groups. More patients received prophylactic 
administration for hyperuricemia in Bor group than in Non-Bor group. However, LTLS 
incidence was significantly higher in Bor group than in Non-Bor group (12.4% vs. 4.0%, 
P<0.05); CTLS was observed in eight patients (6.2%) in Bor group and one (1.3%) in 
Non-Bor group [Table]; these patients were diagnosed with CTLS due to elevated serum 
creatinine. Three CTLS patients with AKI were in Bor group. No CTLS patients died or 
referred for dialysis during treatment period.
Conclusions: Bor-based therapy may increase risk of AKI in LTLS and CTLS, even 
with prophylactic interventions. TLS risk must be further evaluated in low-risk diseases 
such as MM, as an increasing number of novel therapies can achieve tumor shrinkage.
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Risk of AKI and Hyperkalemia Among Older Patients Prescribed 
Non-Steroidal Anti-Inflammatory Drugs
Danielle M. Nash,2,1 Amit X. Garg.3,1 1Institute for Clinical Evaluative Sciences, 
London, ON, Canada; 2Department of Health Research Methods, Evidence and 
Impact, McMaster University, Hamilton, ON, Canada; 3Medicine, Western 
University, London, ON, Canada.
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat pain 
and inflammation. Clinical guidelines caution against NSAID use in older patients due to 
high risk of acute kidney injury, but better evidence is needed to inform clinical care for 
those most at risk. The objective of this study was to determine the risk of acute kidney 
injury and hyperkalemia associated with long-term prescription NSAID use among older 
patients, and risk factors associated with these outcomes.
Methods: We conducted a population-based retrospective cohort study using linked 
healthcare data from Ontario, Canada. We identified patients >66 years with a new NSAID 
prescription with a day supply >14 days between 2007 and 2015. We propensity-score 
matched NSAID users to non-users and performed conditional logistic regression on 30-
day risk of acute kidney injury, hyperkalemia, all-cause mortality, and hospital encounter 
with ventricular arrhythmia. We also developed a logistic regression model of predictors for 
acute kidney injury or hyperkalemia among NSAID users.
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Results: We identified 61,219 eligible NSAID users and 156,589 eligible non-users. 
We matched 46,107 NSAID users to 46,107 non-users (mean age 74 years, 58% female). 
NSAID users were significantly more likely to develop acute kidney injury and hyperkalemia 
compared to non-users (see Table). Our prediction model included six baseline factors 
that were significantly associated with acute kidney injury or hyperkalemia (C-statistic 
adjusted for Harrell’s optimism: 0.72, 95% CI: 0.70-0.74): older age, male gender, lower 
baseline estimated glomerular filtration rate, higher baseline serum potassium, angiotensin 
converting enzyme inhibitor or angiotensin receptor blocker prescription, and diuretic 
prescription. This model will be available as an online calculator through the QxMD 
Calculate application.
Conclusions: Older patients prescribed NSAIDs for more than 14 days are at greater 
risk for acute kidney injury and hyperkalemia compared to non-users. We have developed 
an online calculator to help inform clinical decision making for NSAID prescribing in this 
population.
Funding: Government Support - Non-U.S.
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Routine Laboratory Monitoring Following Initiation of an ACEi or ARB 
and the Association with Adverse Outcomes
Danielle M. Nash,2,1 Rishi V. Parikh,5 Amit X. Garg,3,1 Alan S. Go.5,4 1Institute 
for Clinical Evaluative Sciences, London, ON, Canada; 2Health Research 
Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; 
3Medicine, Western University, London, ON, Canada; 4Epidemiology and 
Biostatistics, University of California, San Francisco, CA; 5Kaiser Permanente 
Northern California, Oakland, CA.
Background: Clinical guidelines recommend serum creatinine and potassium 
monitoring shortly after initiating an Angiotensin Converting Enzyme Inhibitor (ACEi) 
or Angiotensin Receptor Blocker (ARB). However, it is unclear if monitoring prevents 
adverse outcomes. The objective of this study was to identify the association between 
obtaining laboratory monitoring shortly after initiating an ACEi or ARB prescription and 
adverse outcomes across two large North American regions.
Methods: We conducted two population-based retrospective cohort studies using 
healthcare data from Kaiser Permanente Northern California and the Institute for Clinical 
Evaluative Sciences, Ontario, Canada. We included patients initiating an ACEi or ARB 
prescription between 2007 and 2015. We compared patients with both outpatient serum 
creatinine and potassium tests in the 30 days following the prescription date to a group 
without such tests, where we randomly assigned a test date. Patients with and without follow-
up tests were matched using high dimensional propensity scores to have similar indicators 
of baseline health. We assessed outcomes of all-cause mortality and hospitalization with 
acute kidney injury or hyperkalemia within 30 days of the test date using Cox proportional 
hazards regression.
Results: In the Kaiser cohort, 55,487 (34%) eligible patients received follow-up 
outpatient serum creatinine and potassium tests (mean 12 days after ACEi / ARB initiation). 
The final cohort included 54,274 patients with follow-up tests matched to 54,274 without 
tests (mean age 63 years). There was no significant difference in 30-day all-cause mortality 
between patients with follow-up tests compared to patients without tests (see Table). 
Patients with follow-up tests were more likely to be hospitalized with acute kidney injury, 
but not hyperkalemia, compared to patients without tests. The findings were similar in the 
Ontario cohort (mean age 75 years).
Conclusions: Routinely measuring serum creatinine and potassium after initiation 
of an ACEi or ARB does not appear to prevent adverse outcomes compared to no such 
measurements.
Funding: Government Support - Non-U.S.
*Adjusted models did not converge
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Incidence, Pathology Findings, and Outcomes of Patients with Kidney 
Biopsy Proven Acute Interstitial Nephritis
Neelofar R. Khan,1 Vanesa Bijol,2 Rimda Wanchoo,1 Kenar D. Jhaveri,1 
Nupur N. Uppal.1 1Zucker School of Medicine at Hofstra Northwell, 
Great Neck, NY; 2Pathology, Zucker School of Medicine at Hofstra/Northwell, 
Great Neck, NY.
Background: Acute interstitial Nephritis (AIN) is a common cause of AKI. However, 
there have been no recent studies that have reviewed the incidence, and/ or etiology of AIN.
Methods: Using our Health System’s kidney biopsy database, we reviewed charts of 
total 322 patients who underwent kidney biopsies in last 1 year. Patients with pathological 
diagnosis of AIN were analyzed for related clinical presentations and concurrent 
pathological findings. Patients with pure AIN were then compared to patients with AIN and 
associated kidney pathology findings using students t-tests and chi-square.
Results: AIN was present in 13% (42/322) patients. 38% had pure tubulo-interstitial 
diseases (Pure AIN) and 62% also had findings of other kidney diseases. 44% had 
simultaneous glomerular pathologies including primary and secondary FSGS (3 cases with 
collapsing glomerulopathy, 2 with secondary FSGS and 1 with primary FSGS), diabetic 
nephropathy, membranous nephropathy, immune complex GNs and lupus nephritis. To our 
surprise, concurrent oxalate deposition was seen in 12% patients. Mean age of patients with 
AIN was 54.2 years and 61% were females. Overall mean peak Scr was 3.9mg/dl and last 
known mean Scr post treatment was 2.5mg/dl. Mean proteinuria was 2.8 grams for both 
groups. There was no statistical difference in both groups in terms of age, proteinuria at 
baseline, and change Scr. Pure AIN group presented with a higher mean Scr (4.8) compared 
to AIN with concurrent glomerular disease group(3.2)(p= 0.09). Urine eosinophils were 
present only in 2 of 11 patients who were tested, and up trending peripheral eosinophilia 
was seen in only 9 patients. 10/42 patients received treatment with corticosteroids only. 11 
patients required hemodialysis(HD). Pure AIN group was more likely to require HD (64% 
vs. 36%). Beta lactam antibiotics (13.9%), NSAIDs (11.6%) and proton pump inhibitors 
(6.9%) were most common agents causing AIN.
Conclusions: AIN remains a prevalent cause of AKI. AIN with concurrent kidney 
pathology is more common than pure AIN. Patients with Pure AIN presented with higher 
Scr and were more likely to require treatment with HD. Although few patients with AIN 
were noted to have up-trending peripheral eosinophil counts, neither eosinophiluria nor 
peripheral eosinophilia were associated with predicting the kidney biopsy findings.
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Prevention of Cisplatin-Induced AKI by Magnesium Supplementation: A 
Systematic Review and Meta-Analysis
Aghiles Hamroun,1 Remi Lenain,1 Jean joel R. Bigna,2 Mehdi Maanaoui,1 
Linh Bui,1 Paul Chamley,1 Francois Glowacki.1 1Nephrology, Lille University 
Hospital Center, Lille, France; 2University of Paris Saclay, Paris, France.
Background: Cisplatin-induced AKI (CIA) is a serious adverse event that affects 
30-40% of exposed patients. To date, no prevention method has demonstrated its
indisputable effectiveness. Nevertheless, magnesium appears to play a nephroprotective
role, partly through its action on the Organic Cation Transporter 2 (OCT2), a renal proximal 
tubular receptor. The aim of this work is therefore to study the potential nephroprotective
effect of magnesium supplementation on CIA.
Methods: After a systematic review on Pubmed, Embase and Web of Science, from 
January 1978 to January 2018, without language restriction, we performed a meta-analysis 
with a random effect model. Primary outcome was the occurrence of a CIA, according AKI-
KDIGO classification and grading (2012). Heterogeneity between studies was quantified 
(I2) and the analysis completed by a meta-regression to adjust the results for potential 
confounders. This study is registered in the PROSPERO International Prospective Register 
of systematic reviews, registration number CRD42018090612.
Results: Within the 1125 eligible records, 15 studies fulfilling the selection criteria 
were included in this work (4 prospective and 11 retrospective cohort studies), for a 
total of 1841 patients. The meta-analysis showed a significant nephroprotective effect of 
magnesium supplementation on grade 2 (OR=0.22, 95% CI 0.14-0.33, I2=0.0%), grade 3 
(OR=0.25, 95% CI 0,08-0.76, I2=0.0%) and all combined grades of CIA (OR=0.24, 95% 
CI 0.19-0.32, I2=0.0%). This effect remained after adjustment for all potential confounding 
factors (sex, age, cumulative dose of Cisplatin, baseline renal function, performance status 
index, type of cancer, stage of disease and type of comolecule).
Conclusions: Today, relatively unknown, magnesium supplementation could become, 
in the future, an effective method of low-cost prevention for CIA. In any case, these 
promising results encourage the implementation of a large-scale randomized trial.
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High Incidence of Early AKI in Cord Blood Transplantation (CBT) 
Recipients
Victoria Gutgarts,1,2 Junting Zheng,4 Sean Devlin,4 Alexandra Jacob,3 
Molly A. Maloy,3 Valkal Bhatt,3 Ioannis Politikos,3 Ilya Glezerman,2 
Thangamani Muthukumar,1 Edgar A. Jaimes,2 Insara Jaffer Sathick,2 
Juliet N. Barker.5 1Nephrology, Weill Cornell, New York, NY; 2Nephrology, 
Memorial Sloan Kettering Cancer Center, New York, NY; 3Adult Bone Marrow 
Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, 
NY; 4Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 
New York, NY; 5Hematology/Oncology, Memorial Sloan Kettering Cancer 
Center, New York, NY.
Background: CBT can be curative in patients with high-risk hematologic malignancies 
but may be associated with a risk of acute kidney injury (AKI).
Methods: We analyzed AKI incidence and risk factors in adult CBT recipients 
(18-65 years) transplanted for hematologic malignancies with cyclophosphamide/ 
fludarabine/ thiotepa / TBI 400, cyclosporine (CSA)/ mycophenolate mofetil and double 
unit CB grafts from 2006-2016. Maximum grade AKI (KDIGO criteria 1, 2 or 3) was 
calculated using day 0 - +100 creatinines. If patients had multiple episodes, the highest AKI 
grade was analyzed.
Results: 154 patients (median age 51 years) were transplanted. No patient had chronic 
kidney disease. Median age-adjusted hematopoietic cell transplantation comorbidity index 
(aaHCT-CI) was 3 (range 0-9). 58 (38%) patients also received haploidentical CD34+ cells. 
96% engrafted, 74% had grade II-IV acute graft-vs-host disease (aGVHD), and 138 (90%) 
were alive/ disease-free at day 100. 125 patients had AKI (41 grade 1, 62 grade 2, 22 grade 
3) for a grade 1-3 cumulative incidence of 82% (median onset 30 days, range 0-96) and
54 % for grade 2/3. High-toxic CSA levels (3 day average greater than 350) were seen
immediately prior to AKI in 11/41 (27%) patients with grade 1 vs 33/84 (39%) of grade
2-3 patients. There were 29 patients who did not have an AKI event. Significant variables
associated with AKI are shown in Table 1.
Conclusions: CBT recipients are at significant risk for AKI. Early recognition and 
prompt intervention are critical to lessen severe injury. Strategies to mitigate AKI are 
required as well as analysis of the effect of AKI on long-term renal function.
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AKI in Hospitalized Patients with Solid Organ Cancer Who Undergo 
Cancer Treatment
Marianne Camargo,1 Yuanchao Zheng,2 Margaret R. Stedman,2 
Glenn M. Chertow.3 1Nephrology, Icahn School of Medicine at Mount Sinai, 
New York, NY; 2Stanford University, Palo Alto, CA; 3Stanford University School 
of Medicine, Palo Alto, CA.
Background: Acute Kidney Injury (AKI) is common in patients with cancer and 
associated with interruptions in therapy, increased testing and procedures, and higher 
healthcare costs. However, the epidemiology of AKI complicating solid organ cancer is 
not well-understood. We aimed to explore correlates and consequences of AKI in patients 
hospitalized for treatment of solid organ cancer in the United States.
Methods: Using the National Inpatient Sample (NIS) database from 2012 we included 
patients over the age of 20 with a primary diagnosis of solid organ cancer with a concomitant 
diagnosis code for cancer treatment category (surgery, chemotherapy or radiation). We 
excluded patients with a diagnosis code for end-stage renal disease (ESRD), or if they had 
a procedure code for dialysis without associated AKI. In our analysis we created separate 
models for the interaction between cancer type and treatment category and the outcomes: 
AKI, hospitalization length of stay (LOS) and cost. Multivariate models were adjusted for 
age, sex, comorbidities, region, primary payer, bedsize and teaching status of the hospital.
Results: The weighted sample had 321,345 hospital admissions for solid organ cancer 
treatment. Approximately half were for women and >60% were for persons over the age of 
60. More than half had hypertension, more than one in five had diabetes. Overall, 5.5% of 
patients who underwent surgical treatment had AKI, compared to 11% and 9% of patients 
who received chemotherapy and radiation therapy (XRT) respectively. After adjustment
for covariates, patients with the highest risk of AKI were those admitted for kidney and
liver cancer XRT who had a 32% (CI 13%-50%), and 23% (CI 7%-40%) probability of
AKI respectively, followed by admissions for XRT of colon cancer 19% (CI 11%-27%),
and chemotherapy for prostate cancer 18% (CI 2%-34%). After adjusting for cancer type,
treatment type, and covariates, hospitalizations with AKI had on average, double LOS (CI 
1.92-2.11) and 1.78 times higher hospitalization costs (CI 1.70-1.86).
Conclusions: The probability of AKI in hospitalized patients with solid organ cancer 
is significantly different among different cancer types and treatment modalities. Presence 
of AKI is associated with increases in hospitalization costs and LOS. Further analysis will 
evaluate risk factors and inform clinical decision making.
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AKI Drives Papillary Renal Cell Carcinoma Formation from Tubular 
Progenitor Cells
Anna J. Peired,1 Giulia Antonelli,1 Maria Lucia Angelotti,1 Alessandro Sisti,1 
Marco Allinovi,1,2 Paola Romagnani.1,2 1Department of Biomedical, Experimental 
and Clinical Sciences “Mario Serio”, University of Florence, Florence, Italy; 
2Nephrology Unit, Meyer Children’s University Hospital, Florence, Italy.
Background: Renal cell carcinoma (RCC) accounts for 2% of all cancers, with about 
190,000 new cases per year worldwide. As the Notch pathway has a critical role in kidney 
injury and repair, and Notch hyperexpression was reported in patients with RCC, we 
hypothesized that a persistent activation of the Notch pathway may drive tubular epithelial 
cell (TEC) hyperplasia, leading to cancer formation. Other risk factors for RCC include 
obesity, diabetes, hypertension and genetic factors, but the majority of cancers occur in 
apparent absence of clear risk factors. As tissue injury is an important cofactor for many 
types of cancers, we proposed to verify whether acute kidney injury (AKI) plays a role in 
RCC development.
Methods: We developed mouse models in which the intracellular domain of Notch 1 
(NICD1) is expressed constitutively by all Pax8+ TECs (Pax8/NICD1) or only by Pax2+ 
renal progenitors (Pax2/NICD1) upon induction in adult mice. Both models were further 
bred with Confetti mice, allowing clonal analysis of the lesions. Following induction, the 
mice were either left to age for 9 months or underwent unilateral ischemia-reperfusion 
injury (IRI), an experimental model of AKI, and were sacrificed at 28 days.
Results: At 9 months, Pax8/NICD1 mice presented a significant decline of renal 
excretory function as well as numerous, multicentric and progressive pretumoral and 
tumoral lesions. Histological analysis indicate the presence of papillary RCCs (pRCCs). In 
Pax8/NICD1/Confetti mice, we observed that most of the pRCCs were mono- or biclonal, 
suggesting that they could originate from a local stem cell/progenitor population. Pax2/
NICD1 mice presented exclusively papillary tumors. Lineage tracing in Pax2/NICD1/
Confetti mice identified single Pax2+ tubular progenitors as the source of pRCCs. Mice 
subjected to IRI presented mono- and biclonal papillary tumors in only 28 days, indicating 
that AKI strongly accelerated the development of pRCCs.
Conclusions: These mouse models represent useful new tools to study the mechanisms 
of tumor development in the kidney and indicate Pax2+ renal progenitors as the cell of 
origin of pRCC. Additionally, this study provides the first experimental demonstration of 
the link between AKI and the development of papillary tumors, with important clinical 
implications for RCC patients.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Epidemiology and Outcomes of AKI in Hospitalized Cancer Patients in China
Yichun Cheng,1 Sheng Nie,2 Diankun Liu,2 Yanqin Li,2 Long Wang,2 
Mengqi Xiong,2 Shuwang Ge,1 Gang Xu.3 1Department of Nephrology, Tongji 
Hospital, Tongji Medical College, Huazhong University of Science and 
Technology, Wuhan, China; 2National Clinical Research Center for Kidney 
Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, 
Southern Medical University, Guangzhou, China; 3Tongji hospital affiliated to 
Tongji medical college, Huazhong University of Science and Technology, 
Wuhan, China.
Background: Acute kidney injury (AKI) is a common complication in cancer patients, 
but the data are lacking in Asian countries. We aimed to assed the epidemiology, correlated 
risk factors and outcomes of AKI in cancer patients from China.
Methods: We conducted a nationwide cohort study of cancer patients who were 
admitted to 25 general and children hospitals across China from January 1, 2013 to 
December 31, 2015. We obtained patient-level data from the electronic hospitalization 
information system and laboratory databases of all inpatients who had at least two serum 
creatinine tests within any 7-day window during their first 30 days of hospitalization. 
AKI was defined and staged according to Kidney Disease Improving Global Outcomes 
criteria. Incidence rate and risk factor profiles for AKI were examined. Outcomes of interest 
included in-hospital mortality, length of stay and daily costs.
Results: A total of 136,834 adult cancer patients were assessed in our study. The overall 
incidence of AKI was 7.6%, of which 1.6% were community acquired and 5.9% hospital 
acquired. The top three cancer types with high incidence of AKI were bladder cancer, 
leukemia, and lymphoma. Risk factors for community-acquired and hospital-acquired AKI 
were similar, including age, increased baseline serum creatinine, shock and urinary tract 
obstruction. In-hospital occurred in 12.0 % with AKI versus 0.9% cancer patients without 
AKI. After adjustment for confounders, the severe AKI was associated with higher risk of 
in-hospital death, prolonged length of stay and higher daily costs.
Conclusions: Clinicians should increase their awareness of AKI in hospitalized 
cancer patients.
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AKI in Stem Cell Transplant Patients: Role of Hemoglobinuria
Panagiotis Kompotiatis, Sandhya Manohar, Nelson Leung. Mayo Clinic, 
Rochester, MN.
Background: The available evidence regarding the risk factors of hemoglobinuria 
shortly after hematopoietic stem cell transplant (HSCT) and its association with outcomes 
including acute kidney injury (AKI), mortality, and engraftment is very limited.
Methods: The objectives of this study were: 1. Identify risk factors of hemoglobinuria 
within 24 hours of HSCT 2. Assess whether hemoglobinuria is a risk factor for early post-
HSCT AKI 3. Assess outcomes (mortality, engraftment, and infection) with AKI as the 
predictor in the group of patients with post-HSCT hemoglobinuria. Methods: Retrospective 
cohort study of adults that underwent hematopoietic stem cell transplantation from January 
6, 1999, to November 6, 2017. Patients that underwent bone marrow transplantation (BMT) 
or peripheral blood stem cell transplantation (PBSCT) were included in the study (n= 5992). 
Of these, we identified 50 patients that developed gross hemoglobinuria within 24 hours 
after HSCT (In 7 out of 50 patients gross hemoglobinuria was confirmed with urinalysis).
Results: Univariable analysis showed that post-HSCT hemoglobinuria was associated 
with graft type (BMT vs. PBSCT, OR 12.99 CI 7.3-23.16), underlying disease (lymphoma 
OR 13.82, CI 4.2-45.43, acute leukemia OR 7.79, CI 1.94-31.22, reference group: 
multiple myeloma) and fludarabine-based conditioning regimen (OR 2.4, CI 1.09-5.47). 
In multivariable analysis these associations persisted for all predictors except for acute 
leukemia. Of the 11 patients that underwent allogeneic HSCT and had hemoglobinuria, 
only one had a transplant with ABO mismatch (bidirectional). ABO incompatibility hence, 
was not included in the analysis. Additionally, post-HSCT hemoglobinuria was also 
associated with early (48-72h) posttransplant AKI (OR 6.3, CI 3.4 -11.7) in univariable 
analysis. Finally, AKI in patients with hemoglobinuria was associated with delayed platelet 
engraftment (P= 0.049) but not white blood cells (WBC) engraftment (P=0.11), infection 
(P=0.77) or 100-day mortality (P=0.52).
Conclusions: Our study demonstrated a significant association between post-HSCT 
hemoglobinuria and graft type (BMT), fludarabine-based conditioning regimen and 
underlying disease (lymphoma). Hemoglobinuria was also associated with early post-Tx 
AKI. Future studies should focus on preventing post-HSCT hemoglobinuria induced AKI 
in these high-risk patients.
TH-PO072 Poster Thursday
AKI: Biomarkers, Drugs, Onco-Nephrology
Temporal Trends and Impact on Mortality of AKI in Cancer Patients
Young Lee Jung,1 Minsu Park,2 Eunjeong Kang,3 Dong Ki Kim,3 Kwon 
Wook Joo,3 Kook-Hwan Oh,3 Yon Su Kim,4 Hajeong Lee.4 1Seoul National 
unioversity Hospital, Bucheon, Republic of Korea; 2Yonsei University College of 
Medicine, Seoul, Republic of Korea; 3Seoul National University Hospital, Seoul, 
Republic of Korea; 4Seoul National University College of Medicine, Seoul, 
Republic of Korea.
Background: Recently, overall death rate in cancer patients has been improved in 
virtue of advanced preventive and treatment modalities. Acute kidney injury (AKI) is one 
of serious complication associated with worse outcomes, although its temporal trend and 
impact on outcome remain unclear in cancer patients.
Methods: This study retrospectively assembled newly diagnosed cancer patients at 
Seoul National University Hospital between January 2005 and December 2013. Among a 
total of 98,284 incident cases of cancer, we excluded patients with multiple primary cancer, 
age under 18 years-old, advanced renal dysfunction with eGFR less than 15 ml/min/1.73m2. 
We evaluated annual trends of AKI occurrence within the first year after diagnosis of cancer.
Results: We finally included 68,302 patients after exclusion, and 14,152 (23.4%) 
patients in them developed AKI within the first year after cancer diagnosis. Overall 
incidence of AKI was highest in lung cancer (289.5 /1000 person-year), followed by 
genitourinary tract cancer (260.8/1000 person-year) and hematologic malignancies (217.1 
/1000 person-year). As times go by, cancer patients has been older, more hypertensive and 
more diabetic, and exposed more radiocontrast. With this trend, annual AKI development 
has increased from 21.0% to 27.8% (P for trend <0.001). On the contrary, 5-year mortality 
has decreased from 42.9% to 26.5% (P for trend <0.001). Multivariate analysis showed 
adjusted odd ratio of AKI on mortality has been increasing continuously.
Conclusions: Although overall death rate has decreased, AKI incidence and the impact 
of AKI on mortality have been increasing over time in cancer patients. Our study suggested 
that appropriate preventive strategy and adequate management for AKI in patients with 
malignancy, which is an important role of nephrologists.
Figure 1. Temporal trends of AKI incidence and Impact on Mortality from 2005 to 2013.
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Partial Nephrectomy Is Associated with Increased Risk of AKI Compared 
to Radical Nephrectomy for Renal Cell Cancer
Pradeep Arora,1 James W. Lohr,1 Csaba Gajdos,2 Oussama Darwish,2 
Hasan H. Dosluoglu,2 Leili Pourafkari,3 Nader D. Nader.3 1Nephrology, VAMC, 
Buffalo, NY; 2Surgery, VAMC, Buffalo, NY; 3Anesthesiology, VAMC, Buffalo, NY.
Background: Acute kidney injury (AKI) is a common complication after major 
surgery including partial (PN) or radical nephrectomy (RN).
Methods: We evaluated if nephron-sparing surgery is associated with lower incidence 
of acute kidney injury (AKI). We used data from the national surgical quality improvement 
program (NSQIP) from Jan 2005 to Dec 2013. The primary endpoint was the occurrence 
of AKI as defined as over 200% increase in serum creatinine within 72 hours after surgery 
which is coded by the NSQIP. The main secondary endpoint was the occurrence of 
progressive kidney failure (PKF) as defined as a need for renal replacement therapy during 
the course of hospital stay or within 30 days of surgery. In order to identify the confounding 
variables for the occurrence of AKI and PKF, initially univariate analyses were performed 
and those factors and covariates which had a trend of significance (P<0.10) were included 
in multivariable binary logistic regression model. Propensity weighted analyses were then 
performed between the PN and RN groups for the occurrence of AKI and PKF, using 
confounding factors and covariates which were significant contributors of AKI and PKF.
Results: There were more male patients in both groups and the RN patients were 
older. PN patients had lower preoperative weight. Patients who underwent RN had higher 
prevalence of hypertension, CAD, CHF, dyspnea on exertion, dependent functional status, 
CKD as defined by eGFR <60 ml/min/1.73m2, disseminated neoplastic disease, significant 
weight loss of history of bleeding episodes. PN patients had higher serum hematocrit, but 
lower serum creatinine values. AKI was observed in a total of 143 patients. Multivariable 
analysis showed increasing age, female gender, eGFR <60 ml/min/1.73m2 and increased 
operative times were significantly associated with increased risk of AKI. Post-operative 
progressive renal failure, occurred in 149 patients. In multivariable analysis only age, sex, 
GFR weight loss serum albumin and operative time were significant. Propensity analysis 
showed increased risk of AKI with PN compared to RN (OR: 1.683 (95% CI;1.073-3.181). 
PN also had a trend in increasing the risk of postoperative progressive kidney failure (OR: 
1.683(95% CI:0.980-2.229)
Conclusions: PN was associated with increased risk of AKI.
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Burden and In-Hospital Mortality of Dialysis-Requiring AKI (AKI-D) 
Among Hospitalized Adults with Granulomatosis with Polyangiitis (GPA)
Boonphiphop Boonpheng,1 Billy Brooks,1 Pratyaksha Sankhyan,1 
William S. Moore.2,1 1East Tennessee State University, Johnson City, TN; 
2Mountain Home VA Medical Center, Mountain Home, TN.
Background: To describe the incidence of acute kidney injury (AKI) requiring 
renal replacement therapy (dialysis-requiring AKI, AKI-D) and the impact on in-hospital 
mortality among hospitalized adults with granulomatosis with polyangiitis (GPA).
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Methods: We reviewed the Healthcare Cost and Utilization Project’s Nationwide 
Inpatient Sample (NIS) Database, a large nationally representative sample of inpatient 
hospital admissions, to identify all adult hospitalizations with AKI-D and primary or 
secondary diagnosis of granulomatosis with polyangiitis (GPA) from 2004–2014. We 
investigated the trend of AKI-D in each disease for each year and performed multivariate 
logistic regression to evaluate the impact of AKI-D and co-morbidities on in-hospital 
mortality.
Results: Among 339,856 hospitalizations with AKI-D, the proportion of GPA as an 
associated diagnosis remained stable at 0.31-0.47% per year. From 2004-2014, AKI-D 
complicated 0.32% of hospitalizations with GPA as a primary or secondary diagnosis. The 
age-adjusted odds of in-hospital mortality associated with AKI-D in patients with GPA 
decreased over the study period, from 0.92 (95% CI 0.88–0.96) in 2008 to 0.79 (95% CI 
0.75–0.82) in 2014. Compared to other causes of AKI-D, GPA was significantly associated 
with lower in-hospital mortality with adjusted OR 0.64 (95% CI 0.55 - 0.76).
Conclusions: These data suggest that the incidence of dialysis-requiring AKI among 
hospitalized adults with GPA remained stable; however, the in-hospital mortality seemed to 
decrease and significantly lower than other causes of severe acute kidney injury.
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AKI in Pediatric Cancer Patients: Incidence and Outcome
Peong Gang Park,1 Eunjeong Kang,2 Minsu Park,2 Hajeong Lee,2 Yo Han Ahn,3 
IL-Soo Ha,1 Hae Il Cheong,1 Hyung-Jin Yoon,2 Hee Gyung Kang.1 1Seoul National 
University Children’s Hospital, Seoul, Republic of Korea; 2Seoul National 
University College of Medicine, Seoul, Republic of Korea; 3Seoul National 
University Bundang Hospital, Seongnam, Kyunggi-do, Republic of Korea.
Background: Pediatric patients with cancer are known to experience acute kidney 
injury (AKI) but its incidence and clinical impact has not been well established. The 
purpose of this study is to analyze the incidence of AKI within 1 year of diagnosis of cancer 
in children, and to assess its impact on the development of impaired renal function and the 
development of proteinuria.
Methods: Retrospective review of medical records was done on patients who were 
diagnosed and treated for cancer at Seoul National University Hospital between 2004 and 
2013. Patients who were 18 years old or younger at diagnosis of cancer and who had their 
Cr levels measured at least two times within one year of diagnosis were eligible. AKI was 
defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria: 
stage 1 as 0.3 mg/dL rise of Cr within two days or 1.5 times rise within seven days, stage 2 
as two times rise, stage 3 as three times rise or Cr above 4 mg/dL. Impaired renal functionof 
eGFR of cancer survivors less than 90ml/min/1.73m2, and development of proteinuria were 
also assessed.
Results: Among 2,170 candidate patients assessed, 1,868 patients were eligible. 
Patients were diagnosed with cancer at a median age of 7.9 years old. Their median initial 
eGFR at diagnosis was 90.0ml/min/1.732. A total of 983 patients (52.6%) developed AKI 
and the cumulative incidence of AKI within two weeks, three months, and one year of 
diagnosis were 28.9%, 39.6%, 53.6%, respectively. The 1-year cumulative incidence of 
AKI was the highest in patients with acute myeloid leukemia (88.4%) and lowest in patients 
treated for retinoblastoma (14.1%). Within the 1 year of cancer diagnosis, AKI occurred 
once in 520 (27.8%), 2-3 times in 349 (18.7%), more than 4 times in 114 (6.1%) patients. 
18.7%, 22.1%, and 11.8% of the patients had stage 1, stage 2, and stage 3 AKI respectively. 
22.6% of the survivors had impaired renal function. Male sex, lower eGFR at diagnosis, 
frequent AKI occurrence and nephrectomy was independent risk factor. Also, 8.2% of 
the survivors developed proteinuria and female gender, older age were the associated 
independent risk factors.
Conclusions: Current study showed that AKI occurred in a relatively large percentage 
of pediatric patients with cancer and that it may adversely affect their long-term renal 
function.
Funding: Government Support - Non-U.S.
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Platelet Count and Serum Creatinine in the Differential Diagnosis of 
TMA: An Analysis from the CESAR Study
Ulf Schoenermarck,1 Bernd Schroppel,5 Daniel Schmidbauer,4 Michael Jeglitsch,3 
Wolfgang Ries.2 1University Hospital Munich-Grosshadern, Muenchen, 
Germany; 2Diako Flensburg, Flensburg, Germany; 3Alexion, Munich, Germany; 
4CRI - The Clinical Research Institute GmbH, Munich, Germany; 5University of 
Ulm, Ulm, Germany.
Background: Thrombotic thrombocytopenic purpura (TTP), Shiga toxin-producing 
E. coli hemolytic uremic syndrome (STEC-HUS), and atypical HUS (aHUS) require
a fast differential diagnosis in order to initiate urgent therapy. TTP may be excluded by
an ADAMTS13 activity assay result of >5–10%, however, this test is not immediately
available at many centers. Data from the CESAR study1 were used to assess whether routine
laboratory parameters can be used to predict/rule out TTP.
Methods: CESAR was a cross-sectional, multicenter, epidemiologic study of the 
relative incidence of aHUS, TTP and STEC-HUS in Germany. We developed an algorithm 
to predict severe ADAMTS13 deficiency in adult patients at clinical presentation. 
All available variables were analyzed for correlation with final diagnosis. Thresholds 
were identified maximizing the sum of sensitivity and specificity (Youden Index: 
J=sensitivity+specificity-1) and then rounding to the nearest easy-to-recall value.
Results: A total of 219 adult patients with a mean (SD) age of 56.2 (18.9) years were 
enrolled, of whom 31 (14%) were diagnosed with TTP. Platelet (Plt) and serum creatinine 
(SCr) levels significantly correlated with TTP diagnosis (p<0.01). Multivariate analysis 
(Table 1) revealed that if Plt and SCr levels are above threshold values (Plt: 30 x 109/L and 
SCr: 1.8 mg/dL), TTP is almost certainly ruled out (negative predictive value 98.1 and 92.3 
for one or both values, respectively, above threshold).
Conclusions: This analysis shows that Plt and SCr are strong predictors to rule out 
a diagnosis of TTP. This finding confirms previous studies2 and may help to accelerate 
differential diagnosis of TMA. 1Schoenermarck U, et al. 2017; presented at ASN Kidney 
Week [SA-PO421] 2Coppo P, et al. PLoS One 2010;5(4):e10208.
Funding: Commercial Support - Alexion Pharma GmbH
Table. Multivariate analysis to predict TTP diagnosis
Values expressed as %. NPV, negative predictive value; Plt, platelets; PPV, positive 
predictive value; SCr, serum creatinine.
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Outcomes of Renal Function After Urinary Diversion for AKI among 
Patients with Obstructive Uropathy Secondary to Malignancy Admitted in 
a Tertiary Hospital
Renee glorien E. Comonsad.1,2 1Philippine Society of Nephrology, Cagayan de 
Oro City, Philippines; 2Medicine, Philippine General Hospital, Manila, 
Philippines.
Background: Acute kidney injury secondary to malignant obstructive uropathy is 
associated with poor prognosis. Urinary diversion with percutaneous nephrostomy or DJ 
ureteral stenting have been used to manage this potentially life-threatening condition. The 
study aimed to compare the renal function outcomes of patients with malignant obstructive 
uropathy and to determine the predictors of poor renal function after urinary diversion.
Methods: A retrospective cohort study was conducted to collect data on 112 patients 
admitted in a tertiary training hospital in Metro Manila from January 2015 to January 2018. 
EpiInfo 6 was used to compute for the sample size. Both descriptive and inferential statistics 
were used to describe the baseline patient characteristics and to compare the pre- and post-
urinary diversion renal function outcomes.
Results: The mean age of patients was 51.52 ± 11 years with majority being females, 
96/112 (85.71%). The mean number of days from admission to urinary diversion was 
10.31 ± 13.08 days while the mean hospital days from admission to discharge was 
24.45 ± 16.38 days. In paired t-test, there was a significant improvement in the post-urinary 
diversion renal function parameters including BUN, creatinine, GFR, sodium, potassium, 
and calcium (all p-value < 0.05) but not albumin (p-value 0.0785). Recovery of renal 
function (i.e. creatinine reduction of more than 25% from baseline) was achieved by 79/103 
(76.7%) of patients. On multiple linear regression, for every one year increase in age, 
there was a corresponding 0.81 ml/min/1.73 m2 reduction in GFR (95% CI -1.35 - -0.27, 
p-value 0.004) while for every one day delay in urinary diversion from admission, there
was a corresponding 1.09 ml/min/1.73 m2 reduction in GFR (95% CI -1.86 - -0.31, p-value
0.007). On multiple logistic regression, the significant predictors of poor GFR (<60 ml/
min/1.73 m2) post-urinary diversion were age (OR 1.11, 95% CI 1.03-1.19, p-value 0.006)
and number of days delay from admission to urinary diversion (OR 1.24, 95% CI 1.02-1.51, 
p-value 0.034).
Conclusions: Prompt urinary diversion significantly improved renal function outcomes. 
Urinary diversion should not be delayed especially in the older patient population.
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Immunophenotypic Analysis of Humanized Mouse Kidney in Comparison 
with Human Kidney
Sanjeev Noel,1 Johanna T. Kurzhagen,1 Sul A Lee,1 Mohanraj Sadasivam,1 
Abdel Hamad,1 Phillip M. Pierorazio,2 Hamid Rabb.1 1Johns Hopkins University, 
Baltimore, MD; 2Brady Urological Institute, Johns Hopkins University, 
Baltimore, MD.
Background: Most positive intervention studies in mice fail in human trials, in part 
due to fundamental differences between mice and humans. Humanizing mouse tissue aims 
to bring the mouse experimental model closer to human responses. Given the strong data 
supporting immune cells in acute kidney injury pathogenesis and repair, it is important to 
test relevance to humans. However, there is little information on immune phenotype of 
humanized mouse kidney in comparison to normal human kidney. We evaluated immune 
cell composition in the kidneys of two humanized mice strains and compared it to that of 
normal human kidney tissue.
Methods: For humanization, 4 week old NOG and NOGEXL female mice were 
irradiate (100 cGy) and 1x105 human cord blood derived CD34+ hematopoietic stem cells 
transferred intravenously. Kidneys were harvested from well perfused humanized NOG 
(huNOG) and huNOGEXL mice, 20 weeks post engraftment. Normal human kidney 
samples were collected from visibly unaffected portion of nephrectomies from renal cell 
carcinoma. Kidney mononuclear cells isolated from mouse and human kidneys were 
analyzed for human CD45, TCR, CD4, CD8, CD20, CD16, CD14, CD11c and CD206 
using flow cytometry. n=3/group each humanized mouse strain and human kidney.
Results: The frequency (mean%±SEM) of human CD45+ cells was higher (p=0.04) in 
huNOG (12.5±2.9) mouse kidney compared to normal human kidney (6.4±1.3). Similarly, 
the frequency of CD11c+ cells was higher (p=0.02) in huNOG (28.0±4.1) kidney compared 
to normal human kidney (17.8±1.4). The frequency of CD16+ cells was significantly 
reduced in both huNOG (7.6±5.5, p=0.03) and huNOGEXL (4.9±1.0, p=0.01) kidney 
compared to human kidney (31.5±6.3). CD8 T cell frequency was significantly lower 
(p=0.03) in huNOGEXL (17.2±2.6) compared to human kidney (34.8±4.4). There was no 
statistically significant difference in the frequency of TCR+, CD4+, CD20+, CD14+ and 
CD206+ cells between humanized mice kidney and human kidney.
Conclusions: These data demonstrate that huNOG and huNOGEXL kidneys have 
significant numbers of human immune cells. Furthermore, there are key similarities and 
differences between different background strains compared to human kidney. Humanizing 
mice to study kidney disease is a useful approach however it is important to know key 
strengths and limitations of this approach.
Funding: NIDDK Support
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Role of Toll Like Receptors in the Pathogenesis of Myeloma Kidney
Rohit Upadhyay,1 Wei-zhong Ying,2 Paul W. Sanders,2 Edgar A. Jaimes,3 
Vecihi Batuman.1 1Tulane University, New Orleans, LA; 2University of Alabama 
at Birmingham, Birmingham, AL; 3Memorial Sloan-Kettering Cancer Center, 
New York, NY.
Background: Free light chains (FLCs) lead to kidney injury (KI) in myeloma patients. 
We previously demonstrated that inflammatory pathways triggered by endocytosis of FLCs 
in proximal tubule cells (PTCs) lead to KI. The role of innate immunity mediated by toll-
like receptors (TLR) in FLC-associated KI has not been previously investigated. Here we 
present our initial observations on the role of TLRs in FLC-induced KI in PTCs in-vitro.
Methods: Human kidney PTCs cultures were exposed to κ and λ FLCs. Cell 
supernatant and pellets were used for ELISA and gene expression studies. Cell proliferation 
was checked through MTS assay. Data were analyzed using one-way ANOVA with post hoc 
Tukey test and P values <0.05 were considered significant.
Results: Both κ and λ FLCs induced TNFα secretion and suppressed proliferation 
of PTCs in a dose- and time-dependent manner. Several innate-immunity (TLRs 2, 3, 4, 
6, 9, HMGB1, MYD88, TICAM1), inflammatory (IL6, IL18, IL1B, IL2, TNFα, TGFβ), 
apoptotic (BCL2, TP53), and KI markers (HAVCR1, ABCB1, LCN2) were assayed. 
Increased lipocalin 2 (LCN2) and decreased TP53 appeared as the most prominent KI 
biomarkers for both FLC subtypes. FLCs increased the expression of TLRs 2, 3, 4, 6 and 
9, with marked increases in TLR4 gene and in HMGB1 protein levels. Our data show that 
HMGB1 significantly increases the expression of TLR4 gene in PTCs with or without 
FLCs exposure. Knock-down of HMGB1 through R, S- Sulforaphane inhibits FLC-induced 
TLR4 expression suggesting HMGB1 as a likely candidate damage-associated molecular 
pattern (DAMP) activating TLR4 in FLC exposed PTCs.
Conclusions: PTCs exposed to FLCs release HMGB1, which induces TLR4 expression 
and downstream inflammation leading to KI. TLRs may be novel diagnostic biomarkers and 
therapeutic targets for KI in myeloma.
Funding: Veterans Affairs Support, Private Foundation Support
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Kidney Proximal Tubular TLR9 Exacerbates Ischemic AKI
Sang Jun Han,1 Mihwa Kim,2 H. Thomas Lee.3 1Columbia University Medical 
Center, New York, NY; 2Columbia University, New York, NY; 3Department of 
Anesthesiology, New York, NY.
Background: Ischemic acute kidney injury (AKI) is a major clinical problem. 
Although Toll-like receptor 9 (TLR9) mediates cell death and inflammation in the liver, the 
role for kidney TLR9 in ischemic AKI is unknown. Here, we tested the hypothesis that renal 
proximal tubular TLR9 activation exacerbates ischemic AKI by promoting renal tubular 
apoptosis and inflammation.
Methods: Wild type mice (WT, TLR9fl/fl) or renal proximal tubular TLR9 null 
mice (TLR9fl/fl PEPCK Cre) were subjected to sham surgery or 30min kidney ischemia/
reperfusion (IR) injury. A separate cohort of mice was pretreated with a selective TLR9 
agonist (1mg/kg ODN-1668) or control ODN and subjected to 20min renal IR injury. 
Cultured mouse proximal tubule cells or immortalized human proximal tubule (HK-2) cells 
were treated with a selective TLR9 agonist (1-5 μM ODN-BW006) to determine whether 
TLR9 activation induces renal proximal tubular pro-inflammatory cytokines and NFκB 
activation in vitro.
Results: Renal proximal tubular TLR9 null mice were protected against renal IR 
injury with decreased plasma creatinine (1.8±0.2mg/dL), NGAL mRNA (362.6±61.6 fold 
increase over sham), neutrophil infiltration and TUNEL positive cells compared to WT mice 
(Cr=2.6±0.1mg/dL, NGAL=667.6±122.3 fold increase over sham, N=8 for all groups). 
In addition, renal proximal tubular TLR9 deletion reduced pro-inflammatory cytokine 
synthesis, caspase 3 and 8 activation when compared to WT mice after renal IR injury. 
Consistent with this, a selective TLR9 agonist exacerbated renal IR injury in WT mice 
(Cr=1.4±0.1mg/dL, 0.93±0.04mg/dL of vehicle) but not in renal proximal tubular TLR9 
null mice (Cr=0.7±0.02mg/dL, 0.73±0.02mg/dL of vehicle, N=5 for all groups). In HK-2 
cells, a TLR9 selective ligand induced NFκB activation, pro-inflammatory cytokine mRNA 
synthesis as well as caspase 3 and 8 activation. In primary cultures of mouse proximal 
tubule cells from TLR9fl/fl PEPCK Cre mice, TLR9 selective ligand induced significantly 
less pro-inflammatory cytokine mRNA synthesis compared to cells from WT mice.
Conclusions: Taken together, our studies suggest that renal proximal tubular TLR9 
activation exacerbates ischemic AKI by promoting renal tubular inflammation and 
apoptosis after IR via NFκB, caspase 3, and 8 activation. Our studies provide novel insight 
to the pathophysiology of kidney proximal tubule TLR9 in ischemic AKI, suggesting a 
potential therapy for ischemic AKI.
TH-PO081 Poster Thursday
AKI: Inflammation, New Technologies, Omics
Role of Interleukin-4 Receptor-JAK3-STAT6 Signaling in the AKI-to-
CKD transition
Jonatan Barrera-Chimal,1,2 Gabriel R. Estrela,2 Soumaya El moghrabi,2 
Peter Kolkhof,3 Frederic Jaisser.2 1UNAM, Instituto de Investigaciones 
Biomedicas - Instituto Nacional de Cardiologia, Ignacio Chavez, Mexico City, 
Mexico; 2INSERM U1138 - Centre de Recherche des Cordeliers, Paris, France; 
3BAYER AG, Wuppertal, Germany.
Background: Mineralocorticoid receptor (MR) antagonism is highly efficient to 
prevent both acute injury and the progression to chronic kidney disease (CKD) after an 
ischemic episode by enhancing a macrophage M2 polarization in the early post-ischemic 
phase and might be therefore an efficient repair mechanism. Interleukin-4 (IL-4) receptor 
activation in myeloid cells appears to be part of the protective mechanism. The exact 
contribution of IL-4 receptor downstream signaling potentially through JAK3-STAT6 in 
renal protection mediated by finerenone remains unclear. We tested the involvement of IL-4 
receptor signaling induced by MR inhibition in the development of kidney fibrosis after an 
ischemic acute kidney injury (AKI) episode.
Methods: Thirty male C57/B6 mice were divided in: sham, renal ischemia for 22.5 
min (IR), IR plus treatment with the non-steroidal MR antagonist finerenone (10 mg/kg) 
at -48, -24 and -1 h before IR and two groups of mice subjected to IR and receiving 
finerenone plus a STAT6 or JAK3 inhibitor. The mice were followed-up during 4 weeks 
to test for AKI to CKD transition. In another set of mice, the macrophages were sorted 
from kidneys after 24 h of reperfusion and flow cytometry characterization was performed.
Results: The progression of AKI to CKD after 4 weeks of renal ischemia in the 
untreated mice was characterized by a 40% increase in plasma creatinine, a 6-fold increase 
in proteinuria, severe tubule-interstitial fibrosis and increased mRNA levels of NGAL, Kim-
1, alpha-SMA, fibronectin, TGF-beta and collagen-I. The mice that received finerenone 
were protected against all these alterations. MR inhibition promoted increased IL-4 receptor 
expression and phosphorylation in the whole kidney and in isolated macrophages. The 
protective effect conferred by MR antagonism was partially reversed by STAT6 inhibition 
as evidenced by a 5-fold increase in proteinuria and by the JAK3 inhibitor which partially 
reversed the tubule-interstitial fibrosis protection, and completely prevented the reduction 
in Kim-1 and fibrosis related gene expression.
Conclusions: Finerenone modulates the IL-4 receptor-JAK3-STAT6 signaling 
pathway, leading to macrophage phenotype switching and protection against AKI to CKD 
transition.
Funding: Government Support - Non-U.S.
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Mineralocorticoid Receptor Antagonism Prevents the Acute and Chronic 
Effects of Ischemic AKI in the Large White Pig
Jonatan Barrera-Chimal,2,1 Sebastien Giraud,4 Sihem Kaaki,4 Frederic Jaisser,1 
Thierry Hauet.3 1INSERM U1138, Paris Cedex 13, France; 2UNAM, Instituto de 
Investigaciones Biomedicas - Instituto Nacional de Cardiologia, Ignacio 
Chavez, Mexico City, Mexico; 3Inserm / Université de Poitiers / CHU de 
Poitiers, Poitiers, France; 4INSERM U1082- CHU de Poitiers, service de 
biochimie, Poitiers, France.
Background: In rodent models of kidney ischemia/reperfusion (IR), mineralocorticoid 
receptor (MR) antagonism has shown beneficial effects against acute kidney injury (AKI) 
and its progression to chronic kidney disease (CKD); whether these findings might be 
translated to the human pathology remains to be clarified. The Large White pig is a useful 
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preclinical animal model to test the effectiveness of therapeutic strategies aimed to protect 
against AKI due to the kidney similarities between the human and the pig. In this study we 
evaluated the effect of MR antagonism against the acute and chronic effects of ischemic 
AKI in the Large White pig.
Methods: Eighteen Large White male pigs were divided in three groups: sham, pigs 
that received vehicle and underwent bilateral renal ischemia for 60 min and a group of pigs 
subjected to renal ischemia and receiving Soludactone (potassium canreonate). Soludactone 
(7mg/kg, i.v.) or vehicle doses were given at 48 h, 24 h and 30 min before the induction of 
the ischemia and 24 h and 48 h after reperfusion. Urine collection and blood sampling was 
carried out at days 1, 3, 5, 7, 11, 14 and 90. Kidney biopsies were taken at days 14 and 90.
Results: Renal IR induced kidney dysfunction in the untreated pigs at day 1 (plasma 
creatinine: 443±7 mmol/L). In contrast, the pigs that received canrenoate showed an 
impressive prevention of plasma creatinine elevation (145±3 mmol/L). Tubular injury was 
evidenced by a significant increase in urinary NGAL, KIM-1, L-FABP and NAG excretion 
and by histological abnormalities at day 14 (tubular injury and increased inflammatory 
infiltrate). Canreonate treatment decreased by 50% the excretion of these markers and 
prevented the histological damage. At day 90, the untreated pigs presented kidney fibrosis 
which was absent in the canreonate-treated pigs. Plasma creatinine was higher in untreated 
pigs at day 90 (120±2 mmol/L) as compared to the treated pigs (92±4 mmol/L)
Conclusions: MR antagonism is effective against the acute and chronic kidney 
dysfunction and structural injury in a preclinical model of AKI in the Large White pig. 
These findings support clinical trials testing the potential benefits of MRAs in AKI.
Funding: Government Support - Non-U.S.
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Knockout of Interleukin-36 Receptor Prevents Fibrosis in Mice Models of 
AKI-to-CKD Progression
Ogasawara Masami, Yoshio Terada, Hirofumi Nishikawa, Yoshinori Taniguchi. 
Kochi University, Nankoku, Japan.
Background: IL-36, a newly named member of the IL-1 cytokine family, includes 3 
isoforms, IL-36α, IL-36β, and IL-36γ, all of which bind to a heterodimer containing IL-36 
receptor (IL-36R). Little is known about the role of the IL-36 axis in fibrosis during AKI 
to CKD progression. We examined IL-36 function using mice AKI to CKD models and 
clinical samples.
Methods: We evaluated IL-36 function in two models of AKI to CKD progression by 
using IL-36R knockout (KO) and wild-type (WT) mice. First model, left renal ischemia was 
performed for 35min and right kidney was removed 21days later, and left kidney analyses at 
28 days (IRI). Second model, we used aristolochic acid toxic nephropathy (AAN) in mice 
at 28 days. We evaluate the renal function and histological analysis of KO and WT mice 
in both models. Fibrotic changes were evaluated by RT-PCR, Western blot analysis, and 
immunohistologial analysis of collagen type IV, CTGF, and Masson trichrome staining. In 
clinical study, we performed immunohistological examination of IL-36α in AKI to CKD 
patients and minimal change renal biopsy sample.
Results: IL-36R was found to be expressed in the kidney mainly in proximal tubules 
in WT mice. IL-36R KO mice had significantly lower Cr and BUN at 28 days compared 
to WT mice in both models. Immunohistological examination showed mild tubular injury 
and fibrotic change in IL-36R KO mice compared to WT mice in both models. IL-36α/β/γ 
levels were increased after IRI and AAN, and IL-36α was expressed in lymphocytes and 
renal tubular cells. Immunohistologial analysis of collagen type IV and CTGF, and Masson 
trichrome staining revealed that massive fibrotic changes were observed in WT mice 
compared to KO mice in both models. Protein expression of collagen type IV and CTGF 
were also increased in WT mice compared to KO mice. Notably, IL-36α staining in renal-
biopsy samples of AKI to CKD patients was enhanced.
Conclusions: Our results demonstrate that IL-36α is up-regulated in renal tissues in 
both mouse and human AKI to CKD transition, and that IL-36α stimulates collagen type IV 
and CTGF in AKI to CKD transition models. Thus, IL-36α/IL-36R blockage could serve as 
a potential therapeutic target in AKI to CKD transition.
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Deficiency of IKKα in Macrophages Mitigate the Fibrosis Progression of 
Kidney After Renal Ischemia-Reperfusion Injury
Feng Zhang,1 Xin Wan.2 1Nanjing Medical University, Nanjing, China; 2Nanjing 
First Hospital, Nanjing, China.
Background: Acute kidney injury (AKI) could lead to chronic kidney disease (CKD) 
and the macrophages play key roles in this process. The aim of this study was to the 
discovery the role of IκB kinase α (IKKα) in macrophages in the process of AKI-to-CKD 
transition.
Methods: We crossed lyz2-Cre mice with IKKa floxed mice to generate mice with 
IKKα ablation in macrophage (Mac IKKa-/-). Mice renal ischemia/reperfusion injury (IRI) 
model was induced by clamping the renal artery for 45 min. Treated mice were evaluated 
for blood biochemistry, tissue histopathology and epithelial mesenchymal transition 
(EMT) markers. Macrophages isolated from peritoneal cavity for co-culturing with tubular 
epithelial cells (TEC)and flow cytometry analysis.
Results: We found that mice with Mac IKKa-/- significantly alleviated the fibrosis 
and ameliorated the kidney function loss after IRI compare with wide type (WT) mice. 
The expression of EMT markers and the infiltration of M2 macrophages were decreased in 
kidneys of Mac IKKa-/- mice after IRI. The in vitro experiment showed that the IRI TECs 
co-cultured with IKKa-/- macrophages (KO MΦ) downregulated the EMT accompany with 
downregulating Wnt/β-catenin signal.
Conclusions: These data support the hypothesis that IKKα was involved in mediating 
the macrophage polarization and elevating the fibrotic promoting inflammatory factor in 
macrophages. So knockdown the IKKα in macrophage may be a potential method that can 
be used to alleviate the AKI-to-CKD transition after IRI.
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Divergent Sphingosine 1-Phosphate (S1P) Signaling Pathways Control 
Pericyte Function in AKI to CKD Transition
Kinga P. Rudnicka,1 Shinji Tanaka,1 Shuqiu Zheng,1 Amandeep Bajwa,1 
Junlan Yao,1 Diane L. Rosin,2 Mark D. Okusa.1 1Division of Nephrology, CIIR, 
University of Virginia, Charlottesville, VA; 2Departament of Pharmacology, 
University of Virginia, Charlottesville, VA.
Background: Acute kidney injury (AKI) can lead to chronic kidney disease (CKD). 
S1P, a sphingolipid that regulates AKI and fibrosis, is produced by two different kinases, 
sphingosine kinase (SphK) 1 and 2, and after its export can bind to S1P1-S1P5 receptors. 
S1P1, a key player during AKI and CKD, is expressed in both endothelial cells (EC) 
and pericytes (PC; Foxd1Cre+) and plays an important role in angiogenesis and EC-
PC communication. We showed previously that EC S1P1 is protective after ischemia 
reperfusion injury (IRI) and that the global Sphk2 KO has less fibrosis after AKI, however 
the role of S1P signaling in pericytes is unknown.
Methods: Folic acid (FA; 250 mg/kg) or vehicle (0.3 M NaHCO3, Veh) was given ip 
to 12-14 wk old male Foxd1Cre+Sphk2fl/fl (Sphk2KO), Foxd1Cre– Sphk2fl/fl (WT control), 
Foxd1Cre+S1P1fl/fl (S1P1KO), and Foxd1Cre–S1P1fl/fl (WT) mice. For IRI kidneys were 
clamped for 26 min ischemia followed by 24h reperfusion (8-10 wk old mice). AKI 
(24-72h) was assessed by plasma creatinine (PCr), blood urea nitrogen (BUN), qPCR (Kim-
1 and Ngal) and histology (H&E staining). 14 days after injection of FA or Veh to Sphk2 
mice, PCr and BUN were measured, and kidneys were analyzed for fibrosis by picrosirius 
red staining and by qPCR for expression of fibrotic markers.
Results: After bilateral IRI, in S1P1KO mice PCr was lower than in WT (0.91 vs. 0.55). 
After FA, in S1P1KO mice PCr was lower (0.78 vs. 0.23 mg/dl, p<0.05), as was ATN score 
(78.6 vs. 53.6%, p<0.05), Kim1 (0.63 vs. 0.33 p<0.01) and Ngal (0.85 vs. 0.50, p<0.05). 
There was no difference between Sphk2KO and its WT control in PCr, BUN, Kim-1, Ngal 
or histology (days 1-3). However, by day 14, FA-treated Sphk2KO mice had less fibrosis (by 
histology), smaller increases in BUN (39.6 vs. 55.5 mg/dL, p<0.05), and smaller increases 
in expression of fibrosis-related genes (Col1a1, Col3a1, Acta2, fibronectin, and vimentin) 
than WT control mice.
Conclusions: These divergent results suggest that: 1) sphingolipid signaling through 
SphK2 and S1P1 in perivascular cells is critical in controlling the phenotype in AKI and 
CKD and 2) controlling intracellular S1P through sphingosine kinases and extracellular 
S1P1 may serve as specific therapeutic targets in both AKI and AKI-CKD transition.
Funding: NIDDK Support
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Neutrophil Depletion Alters Macrophage (Mo) Phenotype and Modulates 
Inflammation in Unilateral Ureteral Obstructed (UUO) Kidney
Siddhartha S. Ghosh,1 Austin J. Gonzalez,2 Richard Krieg,3 Todd W. Gehr.2 
1VCU Medical Ctr, Richmond, VA; 2Virginia Commonwealth University, 
Fredericksburg, VA; 3VCU, Richmond, VA.
Background: UUO is a model to study inflammation and fibrosis in the kidney. 
Neutrophils (Neu) are the first line of defense in response to injury. Mo closely coordinate 
with Neu to regulate inflammation. This study investigated if neutrophil depletion can alter 
macrophage infiltration and inflammation in UUO fibrosis.
Methods: UUO surgery was done by the method adapted from the Vanderbilt O’Brien 
Center. Neutrophil depletion was done by injecting clone 1A8 to a cohort of five mice 
labeled (ND), 3 days pre and 2 days post UUO. An equal number of mice underwent UUO 
but did not receive any treatment (UT). Contralateral kidneys were used as control (C). 
Mice were sacrificed 3 days and 10 days after UUO. Neu, Mo, and macrophage phenotype 
M1 and M2 were determined by flow cytometry. Inflammation markers MCP1, IL1β, and 
fibrosis marker α-smooth muscle actin (SMA) were assessed by immunoblot.
Results: There was no significant influx of Mo and trace levels of inflammatory 
markers in C, hence comparison was made between ND and UT. 3 days after UUO, Neu 
levels in the blood and kidney of UT were 28% and 60% respectively. In contrast, Neu 
levels in ND blood and kidney was <1% and <12% respectively, suggesting significant 
neutrophil depletion. 3 Day UUO: Mo influx in the kidney of ND was significantly lower 
than UT. The M1 phenotype in UT was 1.5 fold higher (p<0.05) and M2 phenotype was 
2 fold lower than ND (p<0.05). Kidney MCP-1 and IL-1β of UT was 3 fold (p<0.01) 
and 2.5 fold (p<0.01) higher than ND, respectively. Kidney SMA was not significantly 
altered between the groups. 10-day UUO: The M1 phenotype in UT was still 1.5 fold 
higher (p<0.05) than ND but the difference in M2 phenotype between UT and ND was 
not significant. MCP-1 and IL-1β were 2 and 1.5 (p<0.05) fold higher in UT, suggesting 
sustained inflammation in UT. SMA levels in the ND kidney were 1.8 fold higher than UT 
but was not statistically significant.
Conclusions: Chronic inflammation frequently leads to fibrosis, however, the 
mechanisms are not clearly understood. In the ND cohort the decrease in M1 phenotype 
(thought to be proinflammatory) and increase in M2 (reparative type) following neutrophil 
depletion can explain the reduced inflammation but not fibrosis. This suggests controlling 
inflammation at an early stage may not positively modulate fibrosis.
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Selenoprotein-T Exerts a Protective Role in Cisplatin-Induced AKI by 
Suppression of ER Stress
Hua Su, Chun Zhang. Union Hospital, Tongji Medical College, Huazhong 
University of Science and Technology, Wuhan, China.
Background: Selenium (Se) is an essential trace element with important roles in 
human health. Acute kidney injury (AKI) as well as chronic kidney disease are often 
associated with low serum and tissue levels of Se. Se is incorporated with a wide range 
of Se-dependent enzymes, also known as selenoproteins, at its active site. Selenoprotein-T 
(Sel-T), a member of the selenoprotein family, is a novel thioredoxin-like enzyme. However, 
it’s role, especially in ER stress, during renal disease remains unexplored. In this study, we 
aim to explore the role of Sel-T in the pathogenesis of cisplatin-induced AKI.
Methods: Twenty C57 mice were randomly divided into four groups (n=8-10): sham, 
AKI-1d, AKI-2d and AKI-4d. Western blot or immunohistochemistry was used to detect 
the expression of Sel-T, NGAL, cleaved-caspase-3, caspase-12, Bax, Bcl-2 and GRP78. In 
vitro, NRK-52E cells were exposed to cisplatin (20uM) for 6h, 12h and 24h respectively. 
Lentivirus transfection or non-specific Sel-T agonists, PACAP and db-cAMP, were utilized 
to regulate Sel-T before cisplatin stimuli. Flow cytometry and commercial kit were adopted 
individually for apoptosis and ROS detection.
Results: Comparing to sham groups, the expression of Sel-T was significantly down-
regulated in the AKI-4d group. Meanwhile, the levels of NGAL, cleaved-caspase-3 and 
Bax were increased with the reduction of Bcl-2. Consistently, in vitro Sel-T was lessened, 
especially after 24h of cisplatin exposure. And Sel-T deficiency aggravated cisplatin induced 
ER-stress as well as cell apoptosis and ROS generation in NRK-52E cells. Pretreatment of 
non-specific Sel-T agonists ameliorated the ER stress in cisplatin group.
Conclusions: Sel-T deficiency is occurred in cisplatin-induced AKI in which ER 
stress-associated apoptosis and oxidative stress are the underlying mechanisms. Hopefully, 
Sel-T agonists may be effective remedies for cisplatin-induced AKI.
Funding: Government Support - Non-U.S.
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TGF-β Promotes Fibrosis After Severe AKI by Enhancing Renal 
Macrophage Infiltration
Sungjin Chung,2,1 Jessica M. Overstreet,2 Yan Li,2 Yinqiu Wang,2 Aolei Niu,2 
Leslie S. Gewin,2 Ming-Zhi Zhang,2 Raymond C. Harris.2 1The Catholic 
University of Korea College of Medicine, Seoul, Republic of Korea; 2Vanderbilt 
University Medical Center, Nashville, TN.
Background: TGF-β, a central mediator of renal fibrosis, signals through a 
heterotetrameric receptor complex composed of two type I and two type II transmembrane 
subunits. Although macrophages are implicated as mediators of renal fibrosis and produce 
TGF-β1, macrophage TGF-β1 deletion did not prevent fibrosis after severe renal I/R injury. 
The current studies investigated the role of macrophage TGF-β signaling in post AKI 
fibrosis.
Methods: Male C57BL/6 wild type (WT, Tgfbr2f/f) or LysM-Cre;Tgfbr2f/f (TGFßRII-/-) 
mice underwent uninephrectomy plus 29 min renal I/R and were sacrificed after 4 weeks. 
Both in vitro and in vivo chemotaxis assays were performed.
Results: At 4 weeks after injury, there was increased renal expression of TGF-ß1 and 
tubulointerstitial fibrosis in WT mice. TGFßRII-/- mice had markedly decreased renal 
fibrosis and decreased renal macrophages. TGF-ß is a potent chemoattractant. The in vitro 
chemotactic response to a known chemotaxin, f-Met-Leu-Phe, was not different between 
isolated bone marrow monocytes (BMMs) from WT and TGFßRII-/- mice. Although 
TGF-ß was also a potent chemoattractant to WT BMMs, TGFßRII-/- BMMs did not 
respond. The SMAD inhibitor, SIS3, markedly inhibited the chemotactic response to TGF-ß 
in WT BMMs, but had minimal effect in TGFßRII-/- BMMs. To confirm these findings in 
an in vivo setting, we utilized a chemotaxis assay using matrigel plugs. Matrigel suffused 
with either f-Met-Leu-Phe or TGF-ß1 was injected subcutaneously into the subscapular 
regions of WT or TGFßRII-/- mice. After 6 days, f-Met-Leu-Phe induced equal numbers 
of macrophage infiltration into the matrigel plugs of WT and TGFßRII-/- mice. TGF-ß 
also induced matrigel macrophage infiltration in WT mice but not in TGFßRII-/- mice. To 
determine macrophage infiltration into post AKI kidneys, we determined the number of 
PKH26 labeled BMMs infiltrating into WT kidneys for 3 days 12 days after AKI. There 
were significantly more PKH26 labeled WT BMMs than TGFßRII-/- BMMs.
Conclusions: Macrophage TGFßRII deletion protects against the development 
of tubulointerstitial fibrosis following severe ischemic renal injury. Chemoattraction 
of macrophage to the injured kidney through a TGF-β/TGFßRII axis is a heretofore 
undescribed mechanism by which TGF-ß can mediate renal fibrosis during progressive 
renal injury.
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Inhibition of H3K4 Trimethylation Attenuates Renal Senescence in Mice 
with Ischemic Reperfusion Injury
Hironori Shimoda, Shigehiro Doi, Ayumu Nakashima, Takao Masaki. Hiroshima 
University Hospital, Hiroshima, Japan.
Background: Renal senescence is induced by not only aging, but also various stimuli, 
and plays important roles in the development of renal inflammation and fibrosis. Recently, 
accumulation of p16INK4a-positive cells in the kidney has been considered a molecular 
feature of renal senescence, which is regulated by Mixed-lineage leukemia 1 (MLL1)/WD-
40 repeat protein 5 (WDR5)-mediated histone 3 lysine 4 trimethylation (H3K4me3). In this 
study, we investigated whether MLL1/WDR5 complex inhibitor MM-102 attenuates renal 
senescence together with renal inflammation and fibrosis in ischemic reperfusion injury 
(IRI) mice and cultured renal fibroblasts.
Methods: Male C57BL/6 mice were subjected to IRI (renal pedicle was clamped 
for 30 minutes), and administered MM-102 every 24 hours for 7 days postoperatively. 
Expression of MLL1, WDR5, H3K4me3, and p16INK4a was examined by western blotting 
and immunohistochemistry. Senescence-associated β-galactosidase (SA-β-gal) staining 
was performed as a senescence marker. Renal fibrosis was examined by the expression of 
transforming growth factor (TGF)-β1, α-smooth muscle actin (αSMA), and collagens. The 
effect of MM-102 on inflammation was investigated by the expression of nuclear factor-κB 
(NF-κB), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNFα), and 
CD11b. For the in vitro study, TGF-β1-stimulated normal renal fibroblasts with and without 
MM-102 preincubation were examined for expression of MLL1, WDR5, H3K4me3, and 
p16INK4a. Chromatin immunoprecipitation assays were performed to clarify the status of
p16INK4a gene promoter as an H3K4me3-enrichment region.
Results: MM-102 suppressed expression of p16INK4a and β-gal in IRI mice, 
accompanied by decreased expression of MLL1 and WDR5 as well as H3K4me3. MM-102 
also attenuated renal fibrosis and inflammation in the kidneys of IRI mice. In the in vitro 
study, TGF-β1 induced expression of MLL1, WDR5, H3K4me3 and p16INK4a. Finally, the 
p16INK4a promoter was revealed to be an H3K4me3 site in renal fibroblasts.
Conclusions: The MLL1/WDR5 inhibitor MM-102 ameliorates IRI-induced renal 
senescence together with renal fibrosis and inflammation through a reduction in H3K4me3.
Funding: Government Support - Non-U.S.
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Long-Term Sequelae of AKI: A Year-Long Male and Female Murine 
Model
Danielle Soranno,1 Sarah Faubel.2 1Pediatrics, Medicine and Bioengineering, 
University of Colorado, Aurora, CO; 2University of Colorado Denver, Denver, CO.
Background: There is growing appreciation that acute kidney injury (AKI) leads to 
systemic sequelae as well as chronic kidney disease (CKD), however most murine models 
of disease evaluate AKI and CKD as distinct entities, thus limiting their translational value. 
Herein, we performed a 1 year study of male and female BLK6 mice to determine the long-
term renal and systemic sequelae of AKI.
Methods: Male and female adult BLK6 mice underwent bilateral ischemia 
reperfusion injury or sham procedure. Female mice underwent longer clamp times (34 min 
compared to 24 min) to overcome the protective effects of estrogen. Renal and systemic 
outcomes were tracked longitudinally in the males (1, 3, 7, 14 days, 1, 3, 6, 9, and 12 
months) and at 12 months in the females.
Results: Measurements of glomerular filtration rate (tGFR), systemic inflammation, 
and diastolic dysfunction remained abnormal for the duration of the study.
Conclusions: Despite early normalization of serum and urine biomarkers of renal 
function, long-term renal and systemic sequelae were evident in both the male and female 
cohorts following AKI.
Funding: Private Foundation Support
Representative data from the male cohort of AKI vs sham. (A) serum creatinine normalizes 
within several days following bilateral ischemia-reperfusion injury. (B) Measured 
transcutaneous glomerular filtration rate (tGFR) remains persistently low in the AKI 
group compared to sham. (C) Echocardiography demonstrates diastolic dysfunction with 
inversion of A’ E’ following AKI. (D) 1 year after AKI, mice weigh less than mice that 
underwent sham procedure.
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AKI to CKD Transition After Acute Cardiorenal Syndrome in the Mouse
Katsuyuki Matsushita,1 Turgay Saritas,1 James A. McCormick,1 
Michael Hutchens.2,1 1Oregon Health & Science University, Portland, OR; 
2Portland VA Medical Center, Portland, OR.
Background: Acute cardiorenal syndrome (CRS type 1, CRS1) is an common cause 
of acute kidney injury (AKI) with high mortality and significant potential to transition to 
chronic kidney disease (CKD). Mechanistic data from translational models is lacking. We 
report AKI-to-CKD transition following CRS1 in a mouse model, accompanied by long-
term renal inflammation.
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Methods: CRS1 was modeled in male C57BL/6 mice (n=16) using potassium-
induced 8 minute cardiac arrest followed by cardiopulmonary resuscitation (CA/CPR) and 
compared with sham (n=8). α-smooth muscle antibody, KIM-1, cleaved caspase-3, Ki-67, 
macrophage F4/80, and CD3 were quantified from immunohistology 1, 7, 14, and 60 days 
later. Glomerular filtration rate (GFR) was measured by FITC-sinistrin transcutaneous 
clearance and serum urea nitrogen by autoanalyzer.
Results: Sham survival was 100%. 24h survival after CA/CPR was 100% and 60 day 
survival was 88%. CA/CPR induced severe AKI with near-zero GFR at 24h, and early 
macrophage infiltration demonstrated by robust F4/80 signal. 7 days after CA/CPR, KIM-1, 
F4/80, and CD3 revealed severe tubular injury, predominantly of proximal tubules, and 
inflammation with extensive cell proliferation, although GFR was recovering. At 14 
days, GFR had normalized, but at 60 days GFR was again significantly below baseline, 
accompanied by elevated serum urea nitrogen, continued macrophage and t-cell infiltrate, 
apoptotic cell death, and widespread tubulointerstitial fibrosis.
Conclusions: Acute cardiorenal syndrome induces extensive tubular injury and 
inflammation in the renal cortex and outer medulla which progresses to renal fibrosis and 
chronic kidney disease despite initial functional recovery. We present a clinically relevant 
mouse model of AKI-CKD transition which we expect to provide insight into the the 
mechanisms underlying renal sequelae of cardiac arrest.
Funding: NIDDK Support, Veterans Affairs Support
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Binding of Cell Surface Carboxypeptidase M Contributes to Tubulo-Pro-
tective Effects of Fibrinopeptide Bß15-42
Inga Soerensen-Zender, Song Rong, Sascha David, Hermann G. Haller, 
Roland Schmitt. Hannover Medical School, Hannover, Germany.
Background: Acute and chronic kidney disease is often associated with activation 
of the coagulation cascade and with parallel activation of the fibrinolytic system. During 
fibrinolysis the peptide Bβ15-42 is cleaved off the end of the fibrin Bβ chain. Previous 
studies have demonstrated a protective effect of Bβ15-42 in sepsis, myocardial infarction 
and renal ischemia/reperfusion. The responsible molecular mechanism was attributed to 
binding of Bβ15-42 to endothelial VE-cadherin. Our preliminary work had shown that 
Bβ15-42 also has a direct protective effect on renal tubular cells. It was the goal of the 
present study to clarify this VE-cadherin independent mechanism.
Methods: Repetitive doses of Bβ15-42 (3 mg / kg i.v.) or control peptide were tested 
in vivo in unilateral ureteral obstruction (UUO) and in aristolochic acid nephropathy 
(AAN). Kidneys were examined at different time points by histomorphology and damage 
marker expression. In vitro, renal tubular cells were stressed by AA or staurosporine before 
treatment with Bβ15-42 or control peptide. Target proteins were knocked-down by siRNA 
and cell damage was quantified by LDH release and qPCR. Bβ15-42 binding partners were 
identified by ligand-receptor capture (LRC) technology LRC-TriCEPS. Carboxypeptidase 
M activity was measured by Dansyl-Ala-Arg-OH trifluoroacetate assay.
Results: In vivo, Bβ15-42 improved the tubular damage pattern after induction of AAN 
and after UUO. To identify potential new Bβ15-42 interaction partners on tubular cells, 
we used LRC-TriCEPS and found the membrane protein carboxypeptidase M (CBPM) as 
a highly specific binding partner. Despite its strong tubular expression the physiological 
role of renal CBPM which modifies a variety of candidate signal peptides by C-terminal 
cleavage is unknown. CBPM enzymatic activity was significantly inhibited by Bβ15-42, 
both in vitro and in vivo. Knockdown of CBPM by siRNA resulted in a marked reduction 
in the protective effect of Bβ15-42.
Conclusions: The fibrinopeptide Bβ15-42 has a direct protective effect on tubular 
epithelial cells, which is largely determined by binding to CBPM and inhibition of CBPM 
enzymatic activity. Our results show a novel mode of action for Bβ15-42 and suggest that 
CBPM may represent a new target that can be used therapeutically for nephroprotection.
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Loss of Proximal Tubular Krüppel-Like Factor 6 Is Protective Against 
Renal Injury
Sian Piret,1 Yiqing Guo,1 Monica P. Revelo Penafiel,3 Sandeep K. Mallipattu.2 
1Stony Brook University, Oyster Bay, NY; 2Stony Brook Medicine, Stony Brook, 
NY; 3University of Utah, Murray, UT.
Background: Transcriptional regulators of DNA-damage pathways leading to kidney 
fibrosis are relatively unknown. Krüppel-like factor 6 (KLF6), a zinc finger transcription 
factor, has diverse roles in various tissues. KLF6 is highly expressed in the proximal 
tubule (PT) and upregulated in renal ischemia-reperfusion injury and sepsis models, but its 
specific role in PT DNA damage and tubulointerstitial fibrosis is unknown. Our aim was to 
investigate the role of PT KLF6 in the setting of DNA damage, using the PT-specific DNA 
damaging toxin aristolochic acid I (AAI).
Methods: PT-specific Klf6 knockdown (Klf6PTKO) mice were generated by breeding 
Klf6fl/fl and Pepck-Cre mice. Klf6fl/fl littermates were used as controls. Mice were given 
3mg/kg AAI or vehicle DMSO i.p. every 3 days for 3 weeks (active phase), followed by 3 
weeks without injections (remodeling phase), and euthanized. Renal damage was assessed 
by: serum creatinine and urea nitrogen (SUN); histology (H&E, PAS and trichrome 
staining with blinded scoring for inflammation and fibrosis); IF for deposition of collagen 
1A1 (COL1A1); and qRT-PCR for vimentin and E-cadherin expression. RNA-Seq was 
undertaken in active and remodeling phase samples. Data were analyzed using ANOVA 
with corrections for multiple comparisons.
Results: AAI caused renal damage and significantly increased serum creatinine and 
SUN in all mice. These were significantly lower in Klf6PTKO mice versus Klf6fl/fl mice in 
the acute phase, with lower vimentin expression, and preserved PT area and E-cadherin 
expression. In the remodeling phase, Klf6PTKO kidneys had maintained weight, preserved 
PT area and less inflammation, fibrosis, COL1A1 deposition and vimentin expression, 
compared to Klf6fl/fl kidneys. RNA-Seq combined with ENCODE ChIP-Seq data showed 
that many integrin signaling components that contribute to fibrosis were upregulated by 
AAI in Klf6fl/fl mice, which was reversed in Klf6PTKO mice with AAI, and contain KLF6 
binding sites. Likely protective genes were upregulated by AAI and upregulated further in 
Klf6PTKO mice, e.g. Gas6, which has a predicted KLF6 binding site.
Conclusions: PT-specific loss of KLF6 protects against renal injury and fibrosis in 
the setting of DNA damage. This may have relevance for DNA damaging nephrotoxic 
chemotherapeutic drugs e.g. cisplatin.
Funding: NIDDK Support
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Using Transdermal Measurement of GFR to Evaluate Long-Term 
Outcomes in Mouse Models of AKI
Lauren N. Scarfe, Charlene Finney, Anna Menshikh, Rachel Delgado, Mark P. de 
Caestecker. Vanderbilt University Medical Center, Nashville, TN.
Background: There are no specific treatments for patients with acute kidney injury 
(AKI). In part this relates to the preclinical studies that have been used to assess therapeutic 
efficacy: these are often short-term studies, commonly using cisplatin or ischemia 
reperfusion (IR) injury. However, to identify target populations with meaningful long-term 
outcomes, therapeutic efficacy should be tested in a range of models over longer periods, 
including the long-term effects of therapy on the development of progressive chronic 
kidney disease (CKD) after episodes of AKI.
Methods: We established a range of mouse models of AKI that reflect the diverse 
injuries seen in human AKI and allow long-term functional analyses of CKD progression: 1) 
unilateral IR with a delayed contralateral nephrectomy (Nx), modeling profound renal 
hypoperfusion; 2) repeat-dosing cisplatin, modeling the injury in patients receiving 
cisplatin chemotherapy; 3) reversible UUO with delayed contralateral Nx, modeling the 
relief of urinary obstruction; and 4) rhabdomyolysis, modeling crush injury, sepsis and 
cardiopulmonary bypass-associated AKI. We are currently developing new models in 
female and diabetic mice, to recapitulate more complex clinical scenarios. To evaluate 
the effects of these injuries on CKD progression, we used transdermal monitors to assess 
glomerular filtration rate (GFR) in conscious mice by detecting the clearance of exogenous 
FITC-sinistrin through the skin 26-46 days after the initial injury.
Results: Here, we present for the first time, data on the long-term effects of AKI on 
GFR in multiple mouse models of AKI. GFR was significantly reduced in several models, 
but not in the rhabdomyolysis model (Table).
Conclusions: We have assessed the use of transdermal GFR measurement in a range 
of mouse models of AKI. This method of assessing renal function is more clinically 
relevant than standard methods and will be useful for preclinical efficacy testing of novel 
therapeutics on long-term renal outcomes in mouse models of AKI.
Funding: NIDDK Support, Other U.S. Government Support
Transdermal GFR measurement in a range of mouse models of AKI
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Myo-Inositol Oxygenase Promotes Ferroptosis in Cisplatin-Induced AKI
Fei Deng,2 Isha Sharma,3 Lin Sun,4 Yashpal S. Kanwar.1 1Northwestern 
University Medical School, Chicago, IL; 2Northwestern University, Chicago, 
IL; 3Northwestern University, Chicago, IL; 4Second Xiangya Hospital Central 
South University, Changsha, China.
Background: Over-expression of myo-inositol oxygenase (MIOX), a kidney tubular 
specific enzyme, exacerbates renal redox injury in cisplatin-induced AKI. Recently, a 
newly coined term, i.e., ferroptosis, has been reported, which is closely associated with 
lipid peroxidation and it plays a significant role in the pathogenesis of AKI. Whether or 
not MIOX exacerbates tubular damage by accelerating ferroptosis in cisplatin-induced AKI 
needs to be investigated.
Methods: CD1 mice were subjected to intraperitoneal cisplatin injection with or 
without Fer-1, a potent ferroptosis inhibitor. Samples were collected for various studies 
three days later.
Results: Fer-1 substantially decreased the blood creatinine and urine protein excretion, 
and ameliorated renal pathological changes in cisplatin-treated mice. Wild-type (WT) 
mice, MIOX-overexpressing transgenic (MIOX-TG) mice and MIOX-Null (MIOX-KO) 
mice were injected with cisplatin. In comparison to cisplatin-treated WT mice, MIOX-TG 
mice had a relatively greater increase in blood creatinine and urine protein excretion, and 
severe renal pathological changes. These perturbations were minimal in cisplatin-treated 
MIOX-KO mice. Various ferroptosis metabolic sensors, including lipid peroxidation, 
GPX4 activity, NADPH, GSH, ferritinophage, mitochondrial deformation and lysosomal 
permeability, had undergone severe perturbations in MIOX-TG compared to WT mice, 
and these were not observed in MIOX-KO mice. In vitro studies revealed that cisplatin-
induced HK-2 cell death was considerably reduced by Fer-1, DFO (iron cleator), and 
VAD (apoptosis inhibitor), but not by Nec-1 (necroptosis inhibitor). Also, cisplatin-treated 
HK-2 cells had severe perturbations in ferroptosis metabolic sensors, which were further 
accentuated by transfection of MIOX-pcDNA, while ameliorated by MIOX-siRNA.
Conclusions: In conclusion, these findings indicate that ferroptosis, conceivably 
integral to the pathogenesis of cisplatin-induced AKI, is modulated by the expression of 
MIOX.
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Cisplatin-Induced AKI Is Attenuated in Hepatic Sulfotransferase (Sult) 
1a1-Deficient Mice by Suppressing Production of Indoxyl Sulfate (IS) and 
Oxidative Stress
Rika Fujino,1 Keisuke Matsushita,2 Nao Gunda,2 Hirofumi Jono,1,2 
Hideyuki Saito.1,2 1Pharmacy, Kumamoto University Hospital, Kumamoto, 
Japan; 2Kumamoto University Graduate School of Pharmaceutical Sciences, 
Kumamoto, Japan.
Background: The toxicological process leading to cisplatin-induced AKI is caused 
by several mechanisms, including inflammatory responses, oxidative stress and apoptosis 
in renal tubules. We have reported that IS, a sulfate-conjugated uremic solute, accumulates 
extensively in serum and kidney of animal models of cisplatin AKI. IS is derived from 
the liver through metabolic process by hepatic CYP2A6/2E1 and Sult1a1, however, 
pathophysiological role of Sult1a1 in cisplatin AKI has not been elucidated. We generated 
the Sult1a1 gene-deficient mice (Sult1a1-/-), and evaluated the toxico-pharmacological role 
of IS in cisplatin AKI.
Methods: C57BL/6 mice (WT) and Sult1a1-/- were treated with cisplatin (20 mg/kg) 
by intraperitoneal injection. In additional experiments, Sult1a1-/- were treated with IS after 
cisplatin administration. Gene expression of Sult1a1 and other Sult species were determined 
by qRT-PCR. IS and indoxyl-β-D-glucuronide (IG) levels were determined by LC-MS/MS. 
Accumulation of IS and 4-hydroxy-2-nonenal (4-HNE), an oxidative stress marker, in renal 
tissue were examined immunohistochemically. BUN, serum creatinine, Kim-1 and Ngal 
were determined. Cisplatin concentration in serum and kidney was measured as the 194Pt 
levels using ICP-MS.
Results: Sult1a1 mRNA expression was not detected in the liver of Sult1a1-/-, and 
was significantly elevated (5.9-fold) in WT liver with cisplatin AKI, whereas mRNA 
expression of other Sult gene family members were not significantly differed between WT 
and Sult1a1-/- after cisplatin treatment. In cisplatin-treated Sult1a1-/-, kidney injury markers, 
renal IS level and 4-HNE accumulation were markedly reduced compared with those in WT 
kidney. IG concentrations in serum and kidney were elevated in cisplatin-treated Sult1a1-/-, 
suggesting that glucuronidation serves as an alternative detoxification pathway for indoxyl. 
Administration of IS to cisplatin-treated Sult1a1-/- reproduced severe AKI as observed in 
WT. Renal accumulation of 194Pt showed no significant difference between Sult1a1-/- and 
WT.
Conclusions: IS could be one of exacerbation factors in cisplatin AKI by accelerating 
oxidative stress. Hepatic Sult1a1 was the enzyme responsible for deriving IS, suggesting a 
potent preventive target for cisplatin nephropathy.
Funding: Government Support - Non-U.S.
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MUTYH, a DNA Repair Enzyme, Protects Against Cisplatin-Induced AKI
Aihua Zhang, Yunwen Yang, Yue Zhang, Guixia Ding, Songming Huang, 
Zhanjun Jia. Children’s Hospital of Nanjing Medical University, Nanjing, 
China.
Background: MutY homolog (MUTYH) is a DNA Repair Enzyme and plays a key role 
in base excision repair (BER) for mitochondria (type I MUTYH works for mitochondrial 
DNA repair) and nuclear genome (type II MUTYH works for nuclear DNA repair). The 
current study aimed to evaluate the role of MUTYH in cisplatin-induced acute kidney 
injury.
Methods: In Vivo, Male MUTYH-/- mice and littermate WT controls were treated 
with cisplatin (20 mg/kg, ip). In vitro, mouse proximal tubular cells (mPTCs) with stable 
overexpression of MUTYH I or II were treated with cisplatin (5 mg/mL).
Results: In WT mice, cisplatin strikingly reduced MUTYH protein expression by 
40%. MUTYH deficiency aggravated cisplatin-induced renal dysfunction (Scr: MUTYH 
-/- 112.5±18.8 vs. WT 33.60±9.14 mM, p<0.01; BUN: MUTYH -/- 67.65±4.0 vs. WT 
37.83±4.99 mM p<0.01). Meanwhile, the renal tubular injury markers of KIM-1 and 
NGAL in MUTYH -/- mice were also further enhance by 191% and 94.11%, respectively, 
as compared with the WT mice after cisplatin treatment. The levels of cleaved caspase-3 
and the number of TUNEL-positive cells in the kidneys of cisplatin-treated MUTYH-/- 
mice were higher than those in the kidneys of WT mice, showing the aggravated apoptotic 
response. Moreover, MUTYH deficiency resulted in the accumulation of 8-OHdG 
(indicating more severe DNA damage) and the aggravation of mitochondrial dysfunction. 
In vitro, Overexpression of type II MUTYH strikingly ameliorated cell apoptosis and 
oxidative stress induced by cisplatin, while MUTYH I overexpression showed a marginal 
role against cisplatin-induced cell injury.
Conclusions: MUTYH II but not MUTYH I played a significant role in protecting 
against cisplatin-induced acute kidney injury. Targeting type II MUTYH could be a 
promising strategy for the treatment of AKI.
TH-PO098 Poster Thursday
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Treatment of Cisplatin-Induced AKI with Renal Selective Nanotherapy
Edgar A. Jaimes,1 Ryan M. Williams,2 Elizabeth Mercer,3 Daniel A. Heller.2 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Memorial Sloan 
Kettering Cancer Center, New York, NY; 3Indiana University School of Medicine, 
Evansville, IN.
Background: Acute kidney injury (AKI) occurs in up to 30% of patients treated with 
cisplatin and up to 25% of patients in intensive care. AKI is linked to increased morbidity 
and mortality. Unfortunately there are no effective interventions for the treatment or 
prevention of AKI in humans. In prior work, we developed mesoscale nanoparticles 
(MNPs) that selectively localize to the kidneys primarily to the proximal tubular epithelium. 
We hypothesize that these MNPs can be used a delivery platform of small molecules for 
the treatment of AKI.
Methods: We synthesized nanoparticles from poly(lactic-co-glycolic acid) and 
polyethylene glycol (PLGA-PEG) which were encapsulated with the reactive oxygen 
species scavenger edaravone. The particles are approximately 400 nm in diameter with a 
negative surface charge. AKI was induced wit cisplatin induction (25 mg/kg IP) followed by 
intravenous injection of therapeutic MNPs (50mg/kg) loaded with edaravone(3.9 mcg/100 
mg MNP) or the free drug alone 24 hours after induction of AKI. Mice were sacrificed 
after 72 hours.
Results: Compared to cisplatin alone, mice treated with drug-encapsulating MNPs had 
a significant reduction in serum creatinine. We stained for the renal injury marker NGAL, 
DNA-damage induced protein p53, TUNEL for apoptosis, and nitrotyrosine for oxidative 
stress. In each, we found significantly increased injury and staining in mice with cisplatin 
alone or cisplatin plus dose-matched free drug, with reduced or baseline levels in mice 
receiving therapeutic MNPs.
Conclusions: These studies demonstrate the therapeutic efficacy of our MNP as a 
delivery system of drugs to the proximal tubules for the treatment of cisplatin induced AKI. 
This approach may result in the development of novel therapeutic strategies for patients 
affected by AKI of different etiologies.
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a) Electron micrograph of MNPs. b) MNP localization to the kidneys c) Serum creatinine in 
mice treated with therapeutic nanoparticles or edaravone
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C-Terminal Binding Protein 2 (CtBP2), a NADH-Dependent Transcription 
Regulator Contributes to Renal Cell Dysfunction and AKI
Ji Young Kim, Yuntao Bai, Laura A. Jayne, Navjotsingh P. Pabla. The Ohio State
University, Columbus, OH.
Background: Worldwide, acute kidney injury (AKI) occurs in more than 13 million 
patients annually. AKI is associated with high short-term morbidity, a long-term risk of 
chronic kidney disease (CKD) as well as adverse cardiovascular events. Mechanistically, 
renal tubular cell dysfunction and cell death is the hallmark and the underlying cause of 
AKI. However, the transcriptional regulators that control shifts in epithelial cell gene 
expression that triggers renal tubular cell death and dysfunction remain underexplored. 
Here we have examined the role of NADH-dependent transcription regulator C-terminal 
binding protein 2 (CtBP2) in the pathogenesis of AKI.
Methods: We have used three AKI-associated mouse models, namely cisplatin 
nephrotoxicity (30 mg/kg, i.p.), rhabdomyolysis (50% glycerol, 7.5 ml/kg, i.m.) and 
ischemia reperfusion injury (30 bilateral ischemia) and determined the mRNA and protein 
expression of CtBP2 during kidney injury. Furthermore, we have examined the effect of 
CtBP2 inhibition on AKI by using a pharmacological inhibitor (MTOB) and CtBP2-specific 
siRNA knockdown (hydrodynamic intravenous injection). Finally, to uncover the associated 
mechanisms, we carried out chromatin-immuno-precipitation (ChIP) experiments and gene 
expression analysis to identify CtBP2 target genes in renal epithelial cells.
Results: Renal protein expression analysis showed that CtBP2 levels are very low 
in normal murine kidneys. However during the early phase of cisplatin, ischemia or 
rhabdomyolysis induced AKI, there is a striking increase in CtBP2 protein expression 
in renal epithelial cells. Functional in vivo studies showed that pharmacological or 
genetic inhibition of CtBP2 function significantly mitigates renal impairment (BUN, 
Serum Creatinine and renal damage score, Control vs. CtBP2 inhibition group, p>0.05) 
in all the three mouse models of AKI. Through ChIP and RNA expression analysis, we 
have identified a CtBP2 target gene expression signature that likely contributes to renal 
dysfunction associated with AKI.
Conclusions: Here we have identified CtBP2 as an essential regulator of renal 
dysfunction and AKI. Future development of CtBP2 targeting small molecules could 
provide a therapeutic strategy for the prevention or treatment of AKI.
Funding: Private Foundation Support
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PGC1α in Complex Models of AKI
Mei T. Tran, Samir M. Parikh. Beth Israel Deaconess Medical Center, 
Boston, MA.
Background: Acute kidney injury (AKI) in patients is often complex, arising in the 
context of background chronic kidney disease (CKD) or even recent AKI from a different 
etiology. In experimental models of simple AKI, we have identified a critical role for the 
mitochondrial biogenesis regulator PPAR-γ coactivator-1α (PGC1α) in resistance to and 
recovery from AKI. Renal PGC1α expression is markedly reduced in both septic and post-
ischemic mice. And PGC1α knockout (KO) mice suffer worse renal function and overall 
survival after transient renal ischemia, whereas PGC1α induction in the renal tubule 
improves AKI recovery and survival. The potential role for PGC1α in a more translatable 
“multi-hit” experimental model of AKI, however, remains unexplored.
Methods: 1st AKI insult: PGC1α KO and WT mice underwent 15 minutes of bilateral 
renal ischemia. Serum creatinine measurements were collected at 24 hours, 1 month, and 
6 months after ischemia reperfusion injury (IRI). 2nd AKI insult: Six months following 
the initial renal IRI, mice were administered cisplatin (intraperitoneal, 10 mg/kg), then 
monitored for 72 hours post-injection.
Results: PGC1α KO mice exhibited increased serum creatinine relative to WT 
littermates at 24 hours after IRI. At 1 month and 6 months post-IRI, creatinine in both 
genotypes had recovered to normal levels. However, 6-month survival in KO mice was 83% 
compared to 100% survival in WT mice. Within 48 hours of the second AKI insult, survival 
was 33% in KO versus 75% in WT.
Conclusions: PGC1α may impact both kidney function and overall survival after 
AKI. Despite KO survivors of the initial AKI insult recovering to indistinguishable and 
normal serum creatinine as compared to control littermates, PGC1α KO mice suffered 
worse outcomes after the second insult. The results suggest that PGC1α, and by extension 
mitochondrial homeostasis, may have important effects on the renal response to cumulative 
insults. Given the increasingly appreciated connections between AKI and CKD, models 
of repeated AKI may illuminate mechanisms of transition from acute insult to chronic 
impairment.
Funding: NIDDK Support
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Dysregulated Tubular Autophagy Promotes Maladaptive Kidney Repair 
and Interstitial Fibrosis During AKI-CKD Transition
Man J. Livingston, Zheng Dong. Augusta University Medical College of 
Georgia, Augusta, GA.
Background: Tubular cell injury is a key pathological feature of AKI. Renal tubules 
have the capacity to regenerate after injury, but kidney repair following severe AKI is often 
incomplete, leading to interstitial fibrosis and CKD. The mechanisms underlying AKI-CKD 
transition are poorly understood. Autophagy is induced in tubular cells during AKI and 
protects against injury. Recent work further reveals a profibrotic role of tubular autophagy 
in UUO. However, the role of autophagy in kidney repair and fibrosis after AKI remains 
unknown.
Methods: We established an inducible, conditional knockout mouse model where 
Atg7 can be ablated specifically from renal tubules at a desired time. Using this model we 
examined the role of tubular autophagy in the development of chronic renal pathologies 
after ischemic AKI.
Results: Mice underwent 30-min unilateral renal ischemia followed by reperfusion 
for up to 4 wks. Autophagy was persistently activated in proximal tubules of post-
ischemic kidneys, as indicated by LC3-II accumulation and increased formation of both 
autophagosomes and autolysosomes. We generated a doxycycline-inducible, renal tubule-
specific Atg7 knockout mouse model (iAtg7 KO) where Atg7 was specifically deleted from 
renal tubules only during the recovery phase after AKI without affecting initial injury. The 
inducible Atg7 KO blocked autophagy in renal tubules and also suppressed post-ischemic 
fibrosis. Proliferation and activation of fibroblasts was inhibited in iAtg7 KO mice, so was 
the accumulation of ECM components. Wild-type (WT) mice had 10.1% interstitial fibrosis 
2-wk after AKI and 17.5% at 4-wk, which were reduced to 6.7% at 2-wk and 9.9% at
4-wk respectively in iAtg7 KO mice. AKI in WT mice led to decreased staining of brush 
border marker LTL and increased expression of vimentin in renal tubules indicating tubular 
degeneration, which were reversed in iAtg7 KO mice. Renal tubules in WT mice displayed 
remarkable senescent changes after ischemic AKI, which were significantly attenuated by 
autophagy deficiency. Under these conditions, G2/M cell cycle arrest was also induced in
renal tubules of WT but suppressed in iAtg7 KO kidneys.
Conclusions: These results suggest that autophagy in renal tubules may contribute to 
maladaptive kidney repair during AKI-CKD transition by promoting interstitial fibrosis via 
tubular atrophy, senescence, and cell cycle arrest.
Funding: NIDDK Support, Veterans Affairs Support
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Metabolic Reprogramming in Sepsis-Associated AKI
Ying Li,2 Prabhleen Singh.1 1UC San Diego & VA San Diego Healthcare System, 
San Diego, CA; 2University of California, San Diego, Santee, CA.
Background: AKI significantly contributes to the morbidity and mortality. Therapeutic 
strategies are limited due to incomplete understanding of its pathogenesis. Changes in 
tubular metabolism in response to cellular stress during sepsis may play an important role. 
A sepsis-associated AKI (s-AKI) model induced by cecal ligation and puncture (CLP) 
was used to investigate the early and late changes in mitochondrial function and tubular 
metabolism in s-AKI.
Methods: C57bl/6 mice underwent CLP or sham surgery. Mitochondrial biogenesis, 
content and dynamics were examined at 4 hours (4 h’) and 24 hours (24 h’) post CLP. 
Mitochondrial respiration is freshly isolated proximal tubules was examined with XF96 
Seahorse analyzer. Expression of glycolytic enzymes and other assays of tublar metabolism 
were performed. Lastly, the role of AMP-activated protein kinase (AMPK), the principal 
cellualr metabolic sensor, was also investigated.
Results: Mitochondrial DNA copy number, PGC1α and Tfam expression were 
increased at 4 h’ but significantly decreased at 24h’ post-CLP. Mitochondrial fusion proteins 
were unchanged at 4’ but decreased significantly at 24h’ in CLP kidneys. Basal respiration 
in proximal tubules was significantly diminished in CLP at 4h’. At 24h’, a significantly 
increased maximum respiration rate was observed, suggesting a shift to glycolytic 
metabolism. The expression of phosphofructokinase (PFK), a rate-limiting glycolytic 
enzyme, was significantly elevated, while carnitine palmitoyltransferase I (CPT1), a rate-
limiting enzyme of lipid oxidation, was dramatically reduced at 24h’. Treatment with 
AICAR, an AMPK activator, prevented CLP-induced alteration of mitochondrial function 
(dynamics and biogenesis) and improved GFR.
Conclusions: Our novel findings demonstrate early changes in mitochondrial function 
and metabolic preprogramming in s-AKI. Mitochondrial dysfunction with a shift to 
glycolytic metabolism with dimished fatty oxidation under cellular stress is seen. Activation 
of AMPK improves mitochondrial function by improving mitochondrial biogenesis and 
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fusion. Additional effects on tubular metabolic reprogramming with AMPK activation is 
being investigated.
Funding: NIDDK Support, Veterans Affairs Support
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Hsp70 Induction by GGA Treatment Attenuates the Proapoptotic 
Unfolded Protein Response and Inhibits Gentamicin-Induced Renal Cell 
Death
Chinaemere Igwebuike,1 Leah Huiting,1 Hui Feng,1 Zhiyong Wang,2 
Andrea Havasi,2 John H. Schwartz,2 Michael Sherman,3 Steven C. Borkan.2 
1Boston Univerisity School of Medicine, Boston, MA; 2Boston Medical Center, 
Boston, MA; 3Ariel University, Jerusalem, Israel.
Background: Exposure to nephrotoxic antibiotics damages the proximal tubule 
epithelial cells and causes substantial morbidity and mortality. Gentamicin is a common 
nephrotoxic antibiotic that promotes proximal tubule damage and acute kidney injury 
(AKI). However, the lack of a unifying mechanism for gentamicin-induced renal cell injury 
limits AKI therapy. We hypothesize that computational analysis of an unbiased, broad-
based shRNA cell signal screen will identify a “best fit” mechanism(s) of renal cell injury as 
well as targeted drugs to ameliorate gentamicin-induced AKI.
Methods: Dual shRNA screens of 25,000 individually barcoded signal pathway 
genes were performed in gentamicin-exposed human proximal tubule cells. Differentially 
expressed shRNAs were analyzed by Ingenuity Pathways Analysis (IPA) software. 
Predictions based on computational data were then tested using Unfolded Protein Response 
(UPR) markers: ATF6, CHOP, BiP and XBP1. Additionally, protein ubiquitination, protein 
misfolding (thioflavin T staining), oxidative stress (4HNE), mitochondrial integrity 
(MitoTracker), endoplasmic reticulum (ER)-mitochondrial association (ER Tracker), and 
cell death (cleaved PARP and propidium iodide staining) were measured.
Results: Interference RNA screening detected 226 differentially expressed shRNAs. 
Pathway analysis of these shRNAs identified the UPR as the “best fit” mechanism of cell 
injury and suggested Hsp70 as a potential cytoprotectant. Gentamicin exposure increased 
protein ubiquitination, protein misfolding, oxidative stress, activated all 3 UPR arms, 
caused mitochondrial fragmentation followed by mitochondria-ER dissociation, and finally, 
induced cell death. Chemical induction of Hsp70, a protein that regulates several UPR steps, 
markedly reduced protein ubiquitination, misfolding, oxidative stress, suppressed both 
mitochondrial fragmentation and dissociation from ER, and dramatically improved renal 
cell survival.
Conclusions: This study suggests that the proapoptotic UPR contributes to gentamicin-
induced renal cell injury. Hsp70 induction by chemical treatment ameliorates the 
proapoptotic UPR events and significantly improves renal cell survival during gentamicin 
exposure.
Funding: NIDDK Support
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Sex-Specific Regulation of Sirtuin-3 Mediates Differences in Isch-
emia-Reperfusion Kidney Injury
Jenny S. Pan,2,1 Chengtai Yu,1 Qingtian Li,1 David Sheikh-Hamad.1,2 1Baylor 
College of Medicine, Houston, TX; 2Nephrology, Michael E. DeBakey VAMC, 
Houston, TX.
Background: Sex influences susceptibility to kidney ischemia-reperfusion injury 
(IRI), and sex hormones play a crucial role. We previously showed that a pathway from 
stanniocalcin-1 (STC1) mediated AMPK activation to induction of mitochondrial sirtuin-3 
(mtSIRT3) suppresses ROS and confers resistance to kidney IRI. Current observations 
reveal increased baseline kidney expression of STC1 and SIRT3, and AMPK activation 
in female vs male mice. We hypothesized that SIRT3 mediates sex differences in response 
to IRI.
Methods: Male and female wild-type (WT) or SIRT3 transgenic (Tg) mice were 
subjected to bilateral kidney IR (clamping of renal pedicles for 30 min). Male or female WT 
mice were treated with testosterone for 2 weeks (s.c. implantation of 21-day release, 200mg 
pellet). HEK cells were treated with 17β-estradiol, testosterone or vehicle.
Results: pAMPK and mtSIRT3 expression are higher in kidneys of WT female mice 
vs. males; pAMPK and SIRT3 decline with age but sex differences persist. At age 6 months, 
male WT kidneys display tubular vacuolization, which is absent in male SIRT3Tg mice. 
Male SIRT3Tg mice demonstrate resistance to IR [preserved creatinine clearance (CrCl) 
and morphology; less ROS] and better survival vs WT males; outcomes similar to WT 
females. In WT females, kidney mtSIRT3 expression correlates positively with plasma 
estradiol and negatively with testosterone levels. In WT males, kidney mtSIRT3 only 
correlates negatively with plasma testosterone. Testosterone administration to 6 months-
old WT males causes kidney injury (decreased CrCl; increased tubular vacuolization), and 
decreases kidney mtSIRT3 expression with no effect on whole cell SIRT3. Testosterone 
administration to WT females increases whole cell- and mtSIRT3 (maybe due to associated 
rise in plasma estradiol) and causes no measurable kidney injury. In HEK cells, estradiol 
dose-dependently increases SIRT3 mRNA, whole cell- and mtSIRT3 protein, and ERβ and 
ERRα mRNA. Testosterone dose-dependently decreases mtSIRT3 protein expression with 
no effect on whole cell SIRT3 protein or SIRT3 mRNA.
Conclusions: The data suggest: 1) SIRT3 ameliorates kidney IRI; 2) decreased SIRT3 
expression underlies increased susceptibility to ischemic injury in male mice; 3) sex steroids 
regulate mtSIRT3 expression, estrogen via transcriptional regulation and testosterone via 
reduced mitochondrial targeting.
Funding: Veterans Affairs Support, Private Foundation Support
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Pubertal Surge of Sex Hormones Induces Kidney Maturation but Confers 
Ischemic Vulnerability to Postnatal Kidney
Yuichiro Kitai, Yuki Sato, Motoko Yanagita. Department of Nephrology, Kyoto 
University Graduate School of Medicine, Kyoto, Japan.
Background: While neonatal kidney is still immature and maturation continues after 
birth, comprehensive studies on postnatal kidney maturation are limited, and how kidney 
maturation affects disease susceptibility has not been evaluated.
Methods: We set out to characterize female kidney maturation from infancy to 
adulthood by morphological analysis and comprehensive gene expression analysis. We also 
aimed to assess the impact of pubertal sex hormones on postnatal kidney maturation and 
disease susceptibility.
Results: Comprehensive analysis revealed the increase of transcripts encoding 
transporters and metabolic enzymes during puberty, associated with the elongation of brush 
borders of proximal tubules in the deep cortex. Upregulated transporters included solute 
carriers that transport sodium, organic anion, phosphate, glucose and amino acids, and 
the most enriched motif near the transcription start sites of these genes was the binding 
motif of hepatocyte nuclear factor 4a, a transcription factor essential for proximal tubule 
differentiation, presumably indicating the differentiation of proximal tubule during puberty. 
Notably, the maturation of adult mice was attenuated by the ovariectomy before puberty, 
whereas the administration of estrogen, but not progesterone reversed these changes. 
Unexpectedly, adult mice ovariectomized before puberty unexpectedly showed tolerance 
to renal ischemia, whereas adult mice ovariectomized after puberty were vulnerable to 
renal ischemia. Latter result was consistent with recent studies on the protective effects of 
estrogen against injury. Importantly, insulin-like growth factor 1 receptor (IGF-1R) protein 
in the kidney decreased during puberty, whereas kidneys of adult mice ovariectomized 
before puberty showed high expression of IGF-1R like infant kidney, indicating that 
pubertal sex hormone surge decreases IGF-1R expression. In vivo knockdown of IGF-
1R in proximal tubules substantially reduced renal IGF-1R expression, and significantly 
attenuated ischemic tolerance of adult mice ovariectomized before puberty, implying that 
IGF-1R signaling in proximal tubule contributes to the tolerance of these mice.
Conclusions: Pubertal sex hormones accelerate kidney maturation but paradoxically 
confer ischemic vulnerability to postnatal kidney, possibly by inhibiting IGF-1R signaling 
in proximal tubules.
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Remote Ischemic Preconditioning Confers Renoprotection Against Septic 
AKI via Exosomal miR-21
Tianyi Pan.1,2 AKI 1zhongshan hospital affiliated to Fudan University, Shanghai, 
China; 2Institute of Biomedical Sciences, Shanghai, China.
Background: Renal ischemic preconditioning is beneficial for multiple organs in 
response to ischemic injury. Whether limb remote ischemia preconditioning (limb rIPC) 
functions as a protective effector against sepsis-associated AKI is unclear, and the underlying 
mechanism has not been fully elucidated. Our study aimed to explore the protective role of 
limb rIPC in mice with AKI induced bycecal ligation and puncture (CLP).
Methods: In vivo, we preconditioned CLP-challenged mice with remote ischemia and 
reperfusion in the bilateral femoral arteries, which were subjected to 4 cycles of clamping 
for 5 minutes and unclamping for 5 minutes. Organ function and indicators of inflammation 
and apoptosis were examined, and the potential mechanism was determined. In vitro, 
we extracted myocyte-derived exosomes under hypoxia and re-oxygen preprocessing, 
and these exosomes were pre-added to lipopolysaccharide (LPS)-treated mouse tubular 
epithelial cells (mTECs).
Results: In vivo, limb rIPC protected polymicrobial septic mice from multiple organ 
dysfunction and morphological damage, via anti-inflammatory and anti-apoptotic effects. 
However, limb rIPC could not attenuate CLP-induced renal injury in miR-21 knockout 
mice. rIPC enhanced local miR-21 expression in ischemic limbs in a hif-1α dependent 
way, and miR-21 expression in serum exosomes and remote organs, such as the kidney and 
lung, was up-regulated. This beneficial effector was potentially transmitted in circulation by 
exosomal transfer. Meanwhile, an elevation in miR-21 was detected in exosomes derived 
from myocytes with hypoxia and re-oxygen pretreatment. The exosomal preconditioning 
resulted in renal protection and a reduction in inflammatory cytokines and in mTEC 
apoptosis in response to septic injury. We further found that high miR-21 expression 
inhibited miR-21 target genes, exerting anti-inflammation and anti-apoptosis effects.
Conclusions: Enhanced exosomal miR-21 that is induced by limb remote ischemia 
preconditioning contributes to renoprotection against sepsis. Our data suggest a novel and 
promising therapeutic strategy for septic AKI.
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Myeloid Heavy Chain Ferritin Mitigates Ischemic AKI
Laurence M. Black, Amie Traylor, Kayla R. Mccullough, Jeremie M. Lever, 
Yanlin Jiang, Gunars Osis, Abolfazl Zarjou, Subhashini Bolisetty. University of 
Alabama at Birmingham, Birmingham, AL.
Background: Acute kidney injury (AKI) stimulates crosstalk between damaged renal 
tubular epithelium and infiltrating inflammatory cells by chemokine and cytokine release. 
Perpetual inflammation drives worsened kidney function, structural damage and fibrosis, 
highlighting the importance of understanding immune cell trafficking in AKI. Heavy 
chain ferritin (FtH), a protein with ferroxidase activity responsible for iron metabolism, 
is implicated in macrophage polarization. Here, we investigate the role of myeloid FtH in 
immune cell trafficking and resolution of AKI.
Methods: We subjected mice deficient in myeloid FtH (FtHLysM-/-) and floxed controls 
(FtHfl/fl) to bilateral renal ischemia-reperfusion injury (IR, 20 minutes). We measured renal 
function, structural damage, chemokine and cytokine expression, and inflammatory cell 
infiltration.
Results: FtHfl/fl and FtHLysM-/- mice experience similar functional (serum creatinine; 
SCr levels (FtHfl/fl 1.6 ± 0.11 mg/dL; FtHLysM-/- 1.3 ± 0.12 mg/dL) and structural damage 
at day 1. At day 2, only FtHLysM-/- mice continue to worsen (2.4 ± 0.38 mg/dL), which 
subsequently results in significant mortality. FtHLysM-/- mice also exhibit elevated levels 
of growth differentiation factor-15, a marker of renal injury, at day 2 while FtHfl/fl levels 
are significantly decreased. Interestingly, day 2 after IR, while chemokine and cytokine 
expression in FtHfl/fl mice is reduced, levels of intrarenal inflammatory markers, such as 
CXCL2 and IL-6, and serum IL-5 remain elevated in FtHLysM-/- mice. Following IR, the 
absolute number of intrarenal F4/80int/low CD11b+ Ly6Clow/neg CD11c+ mononuclear 
phagocytes in FtHfl/fl mice increases, while this cell population does not change from sham 
levels in FtHLysM-/- mice. After IR, FtHfl/fl mice have a robust induction of neutrophil elastase, 
an enzyme important for digestion of cellular debris, while it is significantly blunted in 
FtHLysM-/- mice.
Conclusions: Our findings demonstrate that, while deletion of myeloid FtH does not 
influence the ischemic insult to the kidney, it regulates the resolution of AKI potentially 
via activation of pro-resolving macrophages. This study underscores the significance of 
harnessing macrophages in immunotherapy for AKI resolution and prevention of chronic 
kidney disease.
Funding: NIDDK Support
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The Role of Hemopexin as a Protectant Against AKI
Anthony J. Croatt,1 John D. Belcher,2 Joseph P. Grande,1 Raymond F. Regan,3 
Gregory M. Vercellotti,2 Karl A. Nath.1 1Mayo Clinic, Rochester, MN; 2University 
of Minnesota, Minneaplis, MN; 3Thomas Jefferson University, Philadelphia, PA.
Background: In ischemic and nephrotoxic acute kidney injury (AKI), renal heme 
content and plasma heme levels are increased. Heme is prooxidant, proinflammatory, and 
nephrotoxic. Levels of heme are restrained by degradation by heme oxygenase (HO) and by 
the binding of heme to hemopexin (HPX). HPX is also anti-inflammatory. We questioned 
whether induction of HPX occurs in AKI and its functional significance.
Methods: Renal HPX mRNA and protein expression was assessed by RT-PCR and 
western analysis respectively. Renal function was evaluated by serum creatinine and blood 
urea nitrogen (BUN). Multiple AKI models were employed, including glycerol-induced, 
heme protein-mediated AKI, and AKI induced by either acute ischemia, endotoxin, or 
hemoglobin.
Results: HPX mRNA and protein were vigorously induced in the kidney exposed 
to hemoglobin, along with the receptor for the HPX-heme complex CD91. We thus 
examined the effect of glycerol-induced, heme protein-mediated AKI in HPX+/+ and 
HPX-/- mice. Renal function was comparable in these mice prior to the administration 
of hypertonic glycerol and on days 1 and 2 after the induction of AKI. However, HPX-/- 
mice as compared to HPX+/+ mice exhibited significantly higher BUN at day 3 (166 ± 24 
vs 104 ± 17 mg/dl) and day 4 (142 ± 23 vs 82 ± 11 mg/dl) following the induction of AKI; 
similarly, serum creatinine values were also higher on day 3 (1.4 ± 0.2 vs 0.8 ± 0.1 mg/dl) 
and day 4 (1.2 ± 0.2 vs 0.7 ± 0.1 mg/dl) in HPX-/- mice compared with HPX+/+ mice. In 
ischemia-induced AKI, HPX mRNA and protein are also vigorously induced in the kidney, 
along with CD91. However, no differences were observed in renal function in HPX+/+ and 
HPX-/- mice at days 1 and 2 following ischemia. No differences in renal function were 
observed in HPX+/+ and HPX-/- mice at days 1 and 2 following endotoxin-induced AKI, and 
at days 1 and 7 following hemoglobin-induced AKI.
Conclusions: HPX is significantly induced in both nephrotoxic and ischemic models 
of AKI. A beneficial, functional effect of such induction is observed in glycerol-induced, 
heme protein-mediated AKI, but only in the recovery phase of such AKI. We suggest that 
when HO-1, the potent, broad-based protectant in AKI, is intact, HPX provides a secondary 
backup system for guarding against heme toxicity.
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Trib1 Is Involved in Renal Recovery and Regeneration in a Mouse Model 
of Ischemia/Reperfusion Injury
Xiangcheng Xie,1 Ming Wang,2 Xiu Yang,3 Wei Wei.4 1Hangzhou First People’s 
Hospital, Nanjing Medical University, Hangzhou, China; 2Hangzhou First 
People’s Hospital, Hangzhou, China; 3Hangzhou First People’s Hospital, 
Hangzhou, China; 4Hangzhou First People?s Hospital, Hangzhou, China.
Background: Acute kidney injury (AKI) is one of the most common serious 
complications in hospitalized patients. Despite tremendous effort has been made, AKI is still 
strongly associated with poor outcomes. Maladaptive repair after AKI exhibit a persistently 
increased risk of progression to chronic kidney disease (CKD). Macrophages are implicated 
in the initial injury after ischemic/reperfusion (I/R) and also participate in tubular repair 
after I/R. Macrophages are classified into two subsets, M1 (inflammatory) and M2 (anti-
inflammatory). M1 macrophages play a pathogenic role in boosting inflammatory and 
kidney injury, whereas M2 macrophages exhibit an anti-inflammatory and wound healing. 
Evidence demonstrates that macrophage polarization plays a critical role in the process 
of kidney recovery and chronic fibrosis, hence, enhancement of M1 to M2 phenotype 
transition might promote renal recovery after I/R. Trib1 is critical for the differentiation of 
macrophages, therefore, we aimed to investigate the role of trib1 in the process of kidney 
recovery following I/R and the link between trib1 and macrophage phenotype.
Methods: We used lentiviral vector mediated RNA interfering (RNAi) to knock down 
expression of trib1 in mice to investigate the role of trib1 in the process of renal repair.
Results: Our results showed that mice with down regulation of trib1 showed markedly 
reduced renal function, severe renal pathological damage, and exacerbated inflammation. 
Inhibition the expression of trib1 resulted in an impaired ability to form M2 macrophages in 
the kidney, whereas coincided with increased M1 macrophages. Expression of TNF-α, IL-
6, and IL-12 increased markedly in the trib1 suppressed mice accompanied with a decreased 
expression of IL-4 and IL-10. Inhibition of Trib1 led to reduced PCNA and Ki67-positive 
proliferating tubular cells.
Conclusions: Our results showed that trib1 is involved in kidney recovery and 
regeneration through the regulation of macrophage polarization. This might be a viable 
therapeutic option to enhance renal repair after I/R injury.
Funding: Government Support - Non-U.S.
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Arginase 2 as a Mediator of Ischemia-Reperfusion Injury in the Kidney 
Through Regulation of Nitrosative Stress
Masatoshi Hara,1 Kumiko Torisu,1 Yasuhiro Kawai,1 Kazuhiko Tsuruya,2 
Toshiaki Nakano,1 Takanari Kitazono.1 1Department of Medicine and Clinical 
Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 
City, Japan; 2Nara Medical University, Kashihara, Japan.
Background: Arginase 2 (Arg2) is expressed exclusively in the kidney and catabolizes 
the hydrolysis of L-arginine, which is common substrate for nitric oxide synthase, to 
produce L- ornithine and urea. There were several reports that administration of arginase 
blockade protected hepatic and myocardial ischemia-reperfusion injury. However, the role 
of Arg2 for renal ischemia-reperfusion injury is still poorly unknown.
Methods: Human renal tubular epithelial cells, (HK-2 cells) were cultured under 
6-hour hypoxic condition (1% O2) and subsequent 24-hour reoxygenation (21% O2) (H/R).
To knockdown Arg2, cells were transfected with Arg2 siRNA. Eight to ten week-old wild 
type (WT) and Arg2 knockout (Arg2KO) male mice were subjected to clamping of bilateral 
renal pedicles for 28 minutes and euthanized 24 hours after reperfusion (I/R).
Results: The level of Arg2 mRNA and ARG2 protein was increased at 24 h after I/R 
in mouse kidney. Immunohistochemistry revealed that ARG2 was localized specifically 
in renal proximal tubules and increased after I/R. In HK-2 cells, the immunofluorescent 
signals of ARG2 were significantly elevated after H/R. ARG2 distributed in a punctate 
pattern throughout the cytoplasm and partly colocalized with mitochondrial marker. 
Arg2 knockdown in HK-2 cells resulted in attenuated 3-nitorotyrosine (3-NT) formation 
after H/R, though the extent of apoptosis was not changed. Arg2KO mice were markedly 
resistant to ischemic kidney injury as measured by serum urea nitrogen (WT 150 ± 23 
vs Arg2KO 106 ± 34 mg/dL, p <0.05) and creatinine (WT 1.06 ± 0.65 vs Arg2KO 
0.43 ± 0.45 mg/dL, p <0.05). The level of 3-NT in ARG2KO kidney was decreased as 
compared to WT at 24-h reperfusion.
Conclusions: Arg 2 was strongly induced after renal I/R injury particularly in tubular 
epithelial cells. Suppressing Arg2 by knockdown or knockout method resulted in reduced 
3-NT in renal tubular cells. Deficiency of ARG2 significantly alleviated I/R injury in mouse 
kidney. Our results suggest that ARG2 is a cause of nitrosative stress and inhibition of
ARG2 may be beneficial for treatment of renal I/R injury.
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Lowering of Pathological Asymmetric Dimethyl Arginine by a Novel 
Dimethylarginine Dimethylaminohydrolase Improves Kidney Function 
After Ischemia-Reperfusion Injury
Young Lee,2,1 Purvi Mehrotra,1 David P. Basile,1 Jaipal Singh.1,2 1Indiana 
University School of Medicine, Indianapolis, IN; 2Indiana Center for Biomedical 
Innovation, Indianapolis, IN.
Background: Asymmetric dimethyl arginine (ADMA) is an endogenously produced 
inhibitor of nitric oxide synthase (NOS) which contributes to endothelial dysfunction, 
endothelial to mesenchymal transition, reduced organ perfusion, and fibrosis. High 
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levels of ADMA are produced in patients with kidney disease and in response to renal 
ischemia which may contribute to the pathogenesis of kidney disease. In this study, we 
have investigated ADMA lowering and therapeutic efficacy of novel dimethylarginine 
dimethylaminohydrolase (DDAH) in the setting of acute kidney injury produced by 
ischemia-reperfusion (I/R).
Methods: DDAH gene was cloned and expressed in E. coli to generate recombinant 
DDAH (rDDAH). In vivo circulating DDAH activity was determined at various times after 
i.v. administration to rats using a colorimetric assay. I/R injury in rats was produced by renal 
artery ligation for 40 min followed by reperfusion in male Sprague-Dawley rats. The effect 
of I/R injury on renal DDAH was measured by changes in DDAH mRNA and enzymatic
activity. rDDAH was post-translationally modified by PEGylation (M-DDAH) to achieve 
prolonged in vivo activity. The effect of M-DDAH on I/R injury in rats was determined by 
changes in creatinine and histology.
Results: DDAH mRNA expression and activity rapidly declined following renal 
I/R injury in rats, and were ~20% of the values in sham-operated controls within 6 hours 
(P<0.05). Reduction in DDAH was accompanied by increased ADMA in the kidney 
from 0.14±0.05 uM/mg protein at baseline to 0.42±0.09 uM/mg protein at 6h (P<0.05). 
Native rDDAH was rapidly cleared within 15 min after i.v. administration to rats, whereas 
PEGylated DDAH (M-DDAH) exhibited 15-fold greater in vivo half-life than the native 
rDDAH. M-DDAH treatment attenuated the degree of renal injury in the I/R model as 
indicated by reduced serum creatinine (2.23±0.38 mg/dL I/R vs 1.15±0.17 mg/dL 
M-DDAH, P<0.05) and the degree of renal tubular damage.
Conclusions: Our studies are first to synthesize a novel pharmacologically viable 
DDAH molecule which lowered ADMA in rats. M-DDAH significantly improved renal 
function in a model of I/R in rats, suggesting that M-DDAH may offer a new therapeutic 
approach for improving endothelial function in the setting of AKI.
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GDF15 Marked Stressed Tubular Epithelium and Alleviated Ischemic 
AKI
Jing Liu,2 Sanjeev Kumar,2,1 Michael Gao,2 Jinjin Guo,2 Pietro E. Cippa,2 
Andrew P. McMahon.2 1Cedars Sinai Medical Center, Los Angeles, CA; 2Keck 
School of Medicine of the University of Southern California, Los Angeles, CA.
Background: Renal ischemia reperfusion injury (IRI) frequently triggers tubular 
damage leading to acute kidney injury (AKI) in varied clinical settings including kidney 
transplantation. We identified Gdf15 (Growth/differentiation factor 15) as one of the genes 
rapidly activated in the mouse nephron following ischemic AKI; a similar induction is 
observed after transplant of the human kidney. First identified as an autocrine regulatory 
molecule associated with macrophage activation, Gdf15 was induced by proinflammatory 
cytokines and activated by various stressors including inflammation, oxidative stress and 
DNA damage. The role for endogenous GDF15 in ischemic kidneys is unclear.
Methods: To study Gdf15 expression and function in the mouse kidney, we generated 
a mouse line (Gdf15nuGFP-CE)producing a truncated GDF15 missing C-term 210 a.a. and 
fused with P2A-nuclearGFP-F2A-CREERT2. We examined GFP and tamoxifen dependent 
TDT expression in Gdf15nuGFP-CE/ +, R26TDT/+ mice and compared the acute and chronic renal 
response to IRI in Gdf15 heterozygous and Gdf15 null mice by qRT-PCR, histology and 
immunofluorescence. To validate the clinical relevance of our findings, we performed a 
GDF15-related single nucleotide polymorphism association study in a cohort of kidney 
transplant recipients.
Results: In steady state, GDF15 was produced mainly by the Apq1- thin descending 
limb of the Henle’s loop (tDLH), by the S3 segment of the proximal tubule and by principal 
cells in the collecting duct. After moderate bilateral renal IRI, Gdf15 was predominantly 
activated in proximal tubules, Aqp1+ tDLH, principal cells in the collecting ducts and 
connecting tubules. Moreover, GDF15 deficiency exacerbated acute tubular injury, 
enhanced inflammatory response and facilitated adaptive immunity following ischemia. 
Consistently with the immune-regulatory effect observed in the mouse model, we found 
that single nucleotide polymorphisms previously linked to lower circulating GDF15 
concentration, were associated with an increased incidence of biopsy proven acute rejection 
in the first year after kidney transplantation.
Conclusions: GDF15 is a functionally relevant, conserved element with reno-
protective and immune-regulatory properties in the immediate response to ischemic AKI.
Funding: Other U.S. Government Support
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Proximal Tubule β2 Adrenergic Receptor Is Responsible for Formoter-
ol-Induced Recovery of Mitochondrial and Renal Function After AKI
Robert B. Cameron,1,4 Whitney S. Gibbs,1 Tess Dupre,4 Siennah R. Miller,4 
Judit Megyesi,3 Rick G. Schnellmann.2 1Medical University of South Carolina, 
Charleston, SC; 2University of Arizona, Tucson, AZ; 3University of Arkansas for 
Medical Science, Little Rock, AR; 4University of Arizona College of Pharmacy, 
Tucson, AZ.
Background: Numerous cell types play a role in the pathogenesis of AKI, including 
immune, endothelial, and renal proximal tubule cells. Our laboratory demonstrated that 
the β2 adrenergic receptor (β2AR) agonist formoterol stimulates mitochondrial biogenesis 
(MB) and accelerates the recovery of renal and mitochondrial function in mice following 
ischemia-reperfusion injury (IRI). However, the cell type(s) responsible for this recovery 
remains unknown.
Methods: ADRB2Flox/Flox (WT) mice were mated with γGT-Cre mice to generate 
γGT-Cre:ADRB2Flox/Flox (KO) mice with proximal tubule deletion of the β2AR. These 
mice were subjected to renal IRI and were treated once daily with formoterol or vehicle 
beginning at 24 h and euthanized at 144 h.
Results: Compared to WT, KO mice had 80% lower renal cortical ADRB2 mRNA 
and DNA. At 24 h following IRI, WT and KO mice had a similar loss of renal function as 
measured by serum creatinine. At 144 h following IRI, both WT and KO mice treated with 
vehicle exhibited persistent renal dysfunction as measured by elevated serum creatinine 
(SCr), KIM-1 protein, and tubular necrosis. Following treatment with formoterol, WT 
mice, but not KO mice, exhibited accelerated recovery of renal function. Treatment with 
formoterol increased mitochondrial protein expression and mtDNA copy number in WT 
but not KO mice. Sham-operated KO mice also had fewer mitochondria than WT mice as 
assessed by transmission electron microscopy. Formoterol restored mitochondrial number 
and density in WT but not KO mice.
Conclusions: Following AKI, formoterol activates the β2AR and stimulates MB in 
proximal tubule cells to accelerate the recovery of renal function. The β2AR also regulates 
mitochondrial homeostasis in healthy proximal tubule cells. These data underscore the 
importance of the proximal tubule cell as a therapeutic target for AKI. Thus, targeting 
compounds that induce MB in renal proximal tubule cells may provide more effective 
treatments for AKI.
Funding: NIDDK Support, Other NIH Support - R01 GM084147, T32 GM008716, 
Veterans Affairs Support, Other U.S. Government Support
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Inhibition of Semaphorin-3a Suppresses Lipopolysaccharide-Induced AKI
Xiaofang Tian,1 Hua Gan,2 Yizhou Zeng,3 Hongfei Zhao,4 Rong Tang,5 
Yunfeng Xia.6 1Nephrology, The First Affiliated hospital of Chongqing Medical 
University, Chongqing, China; 2Nephrology, The First Affiliated hospital of 
Chongqing Medical University, Chongqing, China; 3Urology, The First 
Affiliated hospital of Chongqing Medical University, Chongqing, China; 
4Nephrology, The First Affiliated hospital of Chongqing Medical University, 
Chongqing, China; 5Cardiology, The First Affiliated hospital of Chongqing 
Medical University, Chongqing, China; 6Nephrology, The First Affiliated 
hospital of Chongqing Medical University, Chongqing, China.
Background: Acute kidney injury (AKI) is a common and catastrophic complication 
in sepsis-associated patients. Endotoxin is a common cause of sepsis-associated AKI. 
Lipopolysaccharide (LPS) is the major component of endotoxin derived from gram-
negative bacteria and has been found to be involved in the pathogenesis of AKI. 
Semaphorin-3a (Sema3A), a soluble axon guidance cue, appears to play an important role 
in the development of AKI. However, the role of Sema3A in sepsis related AKI remains 
unknown.
Methods: Lipopolysaccharide (LPS) was used to simulate sepsis-associated AKI 
in male C57BL/6 mice and NRK-52E cells (rat tubular epithelial cells). The role of 
Sema3A in LPS-induced AKI was investigated in vivo and in vitro. Firstly, mice were 
intraperitoneally injected by LPS with different times to examine Sema3A expression. 
Next, (-)-Epigallocatechin-3-gallate (EGCG) was administrated to inhibit Sema3A. Then, 
Renal function, kidney injury, inflammation, and apoptosis were measured to investigate the 
effect of Sema3A in LPS-induced AKI. Furthermore, to explore the mechanism of Sema3A 
regulates inflammation and apoptosis in vitro, NSC23766 (a specific Rac1 inhibitor) and 
SP600125 (a specific JNK inhibitor) were used. Then, the mRNA expression of IL-6 and 
TNF-α, cell apoptosis, the expression of Rac1/NF-κBp65 and JNK signaling molecules 
were examined.
Results: The expression of Sema3A was upregulated in renal tubular epithelial cells 
(TECs) in LPS induced AKI model. Similar change was found in NRK-52E cells incubated 
with LPS (5μg/ml). Notably, inhibition of Sema3A by EGCG significantly reduced renal 
inflammation and the apoptosis of TECs in LPS induced AKI mice. EGCG intervention 
also ameliorated LPS-induced inflammation and apoptosis in NRK-52E cells in vitro. Our 
results also indicated that Rac1/NF-κBp65 and JNK signaling were involved in Sema3A-
mediated inflammation and apoptosis of TECs, respectively.
Conclusions: Our results suggested that the upregulation of Sema3A probably 
play a pathogenic role in LPS-induced AKI, which promote renal inflammation and 
TECs apoptosis. Rac1/NF-κBp65 and JNK signaling pathways might be involved in the 
inflammation and cell apoptosis respectively.
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PAC-Mediated AKI Protection Is Critically Dependent on Cell-Derived 
Microvesicles
Daniel Patschan. University Hospital Göttingen, Goettingen, Germany.
Background: Acute Kidney Injury (AKI) significantly worsens the prognosis of 
hospitalized patients. In recent years, cell-based strategies have been established as reliable 
option for improving AKI outcomes in experimental AKI. Own studies focused on so-
called Proangiogenic Cells (PACs). Mechanisms that contribute to PAC-mediated AKI 
protection include production / secretion of extracellular vesicles (EV). In addition, the 
cells act by paracrinic processes (secretome). The current study evaluated whether AKI may 
be preventable by the administration of either PAC-derived EV and / or the secretome alone.
Methods: AKI was induced in male C57/Bl6N mice (8-12 weeks) by bilateral 
renal ischemia (IRI - 40 minutes). Syngeneic murine PACs were stimulated with either 
melatonine, Angiopoietin-1 or -2, or with Bone Morphogenetic Protein-5 (BMP-5) for one 
hour respectively. PAC-derived EV and the vesicle-depleted supernatant were subsequently 
collected and i.v. injected post-ischemia. Mice were analyzed 48 hours later.
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Results: IRI induced significant kidney excretory dysfunction as reflected by higher 
serum cystatin C levels. The only measure that improved AKI was the injection of EV, 
collected from native PACs. The following conditions worsened post-ischemic renal 
function even further: EV+Ang-1, EV+BMP-5, EV+melatonin, and EV+secretome+Ang-1.
Conclusions: Together, our data show that PAC-mediated AKI protection critically 
depends on the availability of cell-derived EV. The secretome, either collected from native 
or preconditioned cells does not prevent mice from ischemia-induced dysfunction. Certain 
PAC preconditioning protocols may even worsen the renal prognosis of EV(/secretome)-
treated animals.
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Early Inflammatory Response to Pyelonephritis Induced by Uro-Patho-
genic E. coli Requires P2Y2 Receptor Activation
Mette G. Christensen, Jacob R. Therkildsen, Rikke Norregaard, 
Helle A. Praetorius. Aarhus University, Aarhus, Denmark.
Background: Urinary tract infections are exceedingly common and severe infections 
including pyelonephritis are often caused by E. coli that produces the pore-forming 
virulence-factor alpha-hemolysin (HlyA). We have previously demonstrated that HlyA 
releases cellular ATP directly through its membrane pore and that the associated erythrocyte 
lysis is completely prevented by blocking ATP-signalling. Renal epithelia are not lysed by 
the toxin. Instead the released ATP causes P2Y2-receptor dependent intracellular [Ca
2+] 
oscillations followed by epithelial IL-6 release. Thus, we speculated that P2Y2 receptor 
deficient mice may be more susceptible to pyelonephritis as a result of inadequate epithelial-
induced immune activation.
Methods: Acute pyelonephritis was induced by injecting 100 million HlyA-producing, 
uropathogenic E. coli into the urinary bladder of balb/c mice. After 24 hours, pyelonephritis 
was confirmed by culture of the right kidney, the urine and plasma were collected and the 
left kidney was isolated for histology after perfusion fixation.
Results: The mice showed relatively modest change in overall behaviour in response 
to the renal infection compared to vehicle controls and the survival or degree of infection 
was similar in P2Y2
-/- and P2Y2
+/+ mice after 24 h. The P2Y2
+/+ mice with confirmed 
pyelonephritis, showed marked elevation of plasma IL-6 (42.0±7.3 pg/ml) compared to 
control (12.2±4.5 pg/ml, p=0.001). Preliminary data show reduced plasma IL-6 in P2Y2
-
/- mice with confirmed pyelonephritis (24.7±10.3 pg/ml). Similarly, we found significant 
elevation in keratinocyte chemoattractant (KC, a murine homologue of IL-8) in plasma of 
P2Y2
+/+ mice subjected to HlyA-producing E. coli (91.3±27.4 pg/ml) compared to control 
(23.9±7.1 pg/ml, p=0.003). In contrast, plasma KC were markedly lower in P2Y2
-/- mice 
with pyelonephritis (33.6±14.7 pg/ml). These changes are likely to reflect early interaction 
between bacteria and renal epithelium, since the degree of neutrophil infiltration had not 
increased in pyelonephritic kidneys at this early time point.
Conclusions: These results indicate that ATP signalling via the P2Y2 receptor plays a 
pivotal role in the early response to pyelonephritis with HlyA-producing E. coli. Data on 
ATP release to the urine, survival and immune reaction after 3 days are pending.
Funding: Government Support - Non-U.S.
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The Effect of Adenosine Kinase on Acute Renal Injury
Chang Ying Xing, Wei Cao, Yanggang Yuan, Bo Zhang, Huijuan Mao. First 
Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Numerous studies have demonstrated that several mechanisms, including 
necrosis, apoptosis, inflammatory reaction and oxidative stress are closely linked to acute 
kidney injury. Adenosine, emerging as a key regulatory molecule, is mostly protective in 
the pathophysiology of inflammatory diseases. Previous study showed that some of the 
adenosine receptors led to renal-protection against ischemia-reperfusion injury. However, 
these adenosine receptors agonists lack a useful therapeutic index due to cardiovascular 
side effects. We hypothesized that inhibition of adenosine kinase exacerbates extracellular 
adenosine levels to reduce cisplatin and ischemia reperfusion-induced renal injury.
Methods: 1.(1)C57BL/6 mice(24g, 6-8week, male) were randomly divided into 4 
groups: Control, ABT-702, Cisplatin, and ABT-702+ Cisplatin, (2)C57BL/6 mice were 
randomly divided into 4 groups: sham operation group (Sham), ABT-702, ischemia-
reperfusion (IR), ABT-702 +IR group (ABT-702+IR), kidney pathological changes, and 
protective effects were observed. 2.(1) HK-2 cells were pretreated with 1uM ABT-702 then 
incubated with cisplatin at 20uM concentration for 24 h. (2) HK-2 cells were treated with 
the ADK small interfered RNA, then incubated with Cocl2 at 250uM concentration for 12 
h to induce chemical hypoxia, followed by reperfusion for 24 h. The apoptosis-associated 
protein (cleaved caspase-3, Bcl-2, Bax), ROS, and four types of adenosine receptors were 
detected. Four receptors antagonists were added before ABT-702 to detect the changes in 
cell viability.
Results: In this study, inhibition of adenosine kinase could markedly attenuate 
cisplatin-induced and renal ischemia reperfusion-induced acute kidney injury, tubular cell 
apoptosis, oxidative stress and inflammation in the kidneys. Consistent to in vivo results, 
the inhibition of ADK suppressed cisplatin and Cocl2-induced apoptosis, ROS production 
and inflammation in HK2 cell. Additionally, the protective effect of ADK inhibition 
was abolished byA1 or A2Badenosine receptors inhibition and enhanced by A2Aor A3 
adenosine receptors inhibitor.
Conclusions: Inhibition of ADK increases adenosine and attenuates acute renal 
injury by anti-inflammatory, antioxidant stress and anti-apoptosis mechanism and partly 
dependents on A1 and A2b receptors to protect HK2 cells injury.
Funding: Government Support - Non-U.S.
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Acute and Chronic Renal Ischemia-Reperfusion Injury and Angiotensin 
II-Induced Hypertension Are Attenuated in Mice with Proximal 
Tubule-Selective Deletion of Angiotensin AT1a Receptors
Xiao C. Li,1 Jian F. Zhang,2 Xiao W. Zheng,2 Jia L. Zhuo.1 1The University of
Mississippi Medical Center, Jackson, MS; 2Guangxi Medical University,
Nanning, China.
Background: The present study tested the hypothesis that genetic deletion of 
angiotensin II (ANG II) AT1a receptors selectively in the proximal tubule of the kidney 
attenuates renal ischemia-reperfusion injury and ANG II-induced hypertension in mice.
Methods: Proximal tubule-specific AT1a receptor-knockout mice (PT-AT1a-KO) were 
generated using the standard Cre/LoxP recombination approach. Adult male C57BL/6J 
(WT), global AT1a-KO, and PT-AT1a-KO mice were subjected to sham surgery or 45 min 
bilateral renal ischemia, followed by reperfusion for 24 h or 7 days. ANG II-dependent 
hypertension was induced by infusing ANG II at 1.5 mg/kg/day, i.p., for 2 weeks. Systolic 
blood pressure (SBP), renal function, glomerular, tubuointerstital, and perivascular fibrotic 
responses were determined and compared
Results: Basal systolic blood pressure was 22 ± 5 mmHg lower in global AT1a-KO or 
11 ± 3 mmHg lower in PT-AT1a-KO mice (p<0.05 vs. WT). WT mice developed significant 
glomerular, cortical tubulointerstitial and perivascular injury 24 h or 7 days after renal 
ischemia-reperfusion was induced (p<0.01). Ischemia and reperfusion renal injury was not 
prevented in global AT1a-KO mice (n.s. vs. WT), but it was significantly attenuated in PT-
AT1a-KO mice 24 h or 7 days after renal ischemia-reperfusion was induced (p<0.05 vs. WT 
or AT1a-KO). WT developed severe ANG II-induced hypertension, as expected, but it was 
significantly attenuated in PT-AT1a-KO mice (p<0.01 vs. WT).
Conclusions: We concluded that AT1a receptors in the proximal tubule of the kidney 
play a key role in the pathogenesis of renal ischemia-reperfusion injury and ANG II-
dependent hypertension.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Necroptosis and Ferroptosis Inhibitors Have Significant Benefit in Acute 
Ischemic Kidney Injury In-Vivo and In-Vitro
Kevin M. Gallagher,1 Allison M. Beal,3 Yuen bun Tam,1 James A. Ross,1 
Lorna Marson,2 John Bertin,3 Stephen J. Wigmore,1 Jeremy Hughes,2 
Ewen M. Harrison.1 1University of Edinburgh, Edinburgh, United Kingdom; 
2The Queens Medical Research Institute, Edinburgh, United Kingdom; 
3GlaxoSmithKline, Collegeville, PA.
Background: We aimed to determine if necroptosis or ferroptosis inhibitors are 
beneficial in murine ischemia reperfusion injury, and if necroptosis or ferroptosis occur in 
human tubular cells.
Methods: Mice were subjected to 18m of bilateral renal ischemia with 24 or 
48h reperfusion. Highly specific RIPK1 inhibitor, GSK547a, or ferroptosis inhibitor 
Liproxstatin-1 were given from 4h after injury. Outputs included creatinine, acute tubular 
necrosis (ATN) score, phosphorylated MLKL (pMLKL, end effector of necroptosis) 
stain, TUNEL stain and qPCR. Human renal tubular cells (HK-2) underwent 3 models of 
ischemia in-vitro +/- necroptosis/ferroptosis inhibitors.
Results: With drug given 4h after injury, both RIPK1 inhibitor and liproxstatin-1 
significantly reduced serum creatinine (mmol/L)(Vehicle:239.8 (+/- 51.8), RIPK1 
inhibitor:103.9 (+/- 48.2) p<0.001, Liproxstatin-1:43.1 (+/-14.4) p<0.001) and ATN 
score (Vehicle: 3/4 (3-4), RIPK1 inhibitor: 2/4 (1-2) p=0.008, Liproxstatin 1: 2/4 (1-2) 
p<0.001)(9/group) 48h after injury. 24h after injury there was extensive pMLKL in vehicle 
treated injured kidneys. pMLKL, ATN score and TUNEL stain were significantly reduced by 
RIPK1 inhibition(N=6). There was median 5-fold increase in renal RIPK3 expression 48h 
after injury compared to sham animals, this was significantly reduced by RIPK1 inhibition 
(p=0.004) but not by liproxstatin-1 (p=0.67) (N=9). A20 (necroptosis inhibitor) expression 
was significantly higher vs vehicle in RIPK1 inhibitor (p=0.02) and liproxstatin-1 (p=0.01) 
treated kidneys. Despite less ATN, Liproxstatin-1, but not RIPK1 inhibitor treated kidneys 
demonstrated higher expression of MCP-1 (p=0.002) and TNF-α (p<0.001) compared to 
vehicle. In in-vitro ischemic HK2 cell injury, there was evidence of both necroptosis (MLKL 
phosphorylation) and ferroptosis (iron dependent lipid peroxidation) with associated benefit 
for cell survival from necroptosis and ferroptosis inhibitors (N=3-6), although to different 
extents depending on the type and severity of injury.
Conclusions: Both necroptosis and ferroptosis contribute to ischemic kidney injury. 
There may be differential effects of related inhibitors on inflammatory genes. Further study 
is required to determine if this impacts long term renal function after an ischemic injury.
Funding: Other NIH Support - Medical Research Council UK, Commercial Support - 
GlaxoSmithKline
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Novel Imaging Technique Visualizing Spatiotemporal ATP Dynamics 
During AKI Predicts Renal Prognosis and Provides Proof-of-Concept for 
Hypothermia
Shigenori Yamamoto,1 Motoko Yanagita,2 Shinya Yamamoto,3 
Masamichi Yamamoto.3,4 1Department of Nephrology, Kyoto University 
Graduate School of Medicine, Kyoto, Japan; 2Department of Nephrology, Kyoto 
University Graduate School of Medicine, Kyoto, Japan; 3Department of 
Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan; 
4Japan Science and Technology Agency, PRESTO, Tokyo, Japan.
Background: The kidney constantly utilizes adenosine 5’ triphosphate (ATP), and 
mitochondrial dysfunction, which leads to ATP depletion, plays an important role in the 
pathogenesis of kidney diseases. In spite of importance of ATP dynamics, however, lack 
of technology to visualize in vivo ATP dynamics has hindered further analysis. Here we 
enabled the visualization of spatiotemporal renal ATP dynamics and analyzed whether the 
ATP dynamics during AKI could predict the renal prognosis.
Methods: To enable intravital ATP imaging, we generated a novel mouse line, which 
expressed the FRET-based ATP biosensor systemically. We monitored renal ATP dynamics 
in both warm and cold ischemic reperfusion (IR) models with two-photon microscope. 
Furthermore, we performed the quantification of fibrosis two weeks after IR, and assessed 
the correlation between the ATP recovery in acute phase and fibrosis in chronic phase.
Results: The ATP level of proximal tubules (PTs) rapidly decreased to the basal 
level in only 2 minutes after ischemia induction, whereas that of distal tubules (DTs) was 
maintained even after 30 minutes. The ATP dynamics in PTs after reperfusion was variable 
depending on the duration of ischemic time. The longer ischemic time led to slower and 
more insufficient ATP recovery in PTs. The ATP recovery after 15, 30, and 60 minute-warm 
IR took 2, 5, and 30 minutes to reach a peak plateau, and the % ATP recovery were 90%, 
83%, and 69%, respectively, while the ATP recovery after 30 and 60 minute-cold IR took 2 
and 4 minutes, and the % ATP recovery were 90% and 87%, indicating rapid and complete 
ATP recovery in cold ischemia. Interestingly, the fibrosis in chronic phase was inversely 
well correlated with the ATP recovery of PTs in acute phase in both warm and cold IR.
Conclusions: We, for the first time, succeeded in visualizing the spatiotemporal ATP 
dynamics in the kidney and revealed the tolerance of DTs to ischemia from the point of 
ATP dynamics. After reperfusion, the ATP recovery in PTs was variable depending on the 
severity of injury, and the ATP dynamics in acute phase might determine the outcome in 
chronic phase. In addition, cold ischemia results in much more rapid and complete ATP 
recovery than warm ischemia, which provides proof of concept for renal hypothermia.
TH-PO121 Poster Thursday
AKI: Inflammation, New Technologies, Omics
No-Reflow in Experimental AKI
Jesus H. Dominguez,3,1 Danhui Xie,1,2 James M. Dominguez,1,2 
Katherine J. Kelly.1,2 1Indiana University, Indianapolis, IN; 2Medicine/
Nephrology, Roudebush Veterans’ Affairs Medical Center, Indianapolis, IN; 
3VAMC, Indianapolis, IN.
Background: In acute kidney injury (AKI), multiple redundant pathways contribute 
to renal failure. Renal microvascular congestion has been observed in clinical AKI. We 
sought to test the hypothesis that inadequate reperfusion, activation of coagulation and 
microthrombi are significant factors that result in renal failure following ischemia. We 
have previously (Dominguez et al, J Am Soc Neph 28:3533) demonstrated improvement in 
multiple abnormal pathways of injury with exosome therapy.
Methods: The role of activated coagulation, microthrombi formation and fibrinolysis 
were examined in a model of ischemic AKI using multiphoton, intravital imaging 
performed 48 hours postischemia. Four groups of rats were studied: sham surgery, bilateral 
renal ischemia/reperfusion (IR)/vehicle, IR/exosomes, IR/urokinase. Exosomes derived 
from renal tubular epithelia, urokinase or vehicle (0.9% NaCl) was administered 24 hours 
postischemia when renal failure was established.
Results: Diffuse renal microvascular thrombi resulted in a heterogeneous decrease in 
intrarenal blood flow within postischemic kidneys. Administration of exosomes after renal 
failure occurred, resulted in improved renal blood flow and decreased inflammation, fibrin 
formation and immunoreactive tissue factor. Urokinase, given after renal failure, improved 
intrarenal blood flow and decreased renal fibrin and tissue factor, but had less effect on 
inflammation. Renal function improved rapidly in both the exosome and urokinase groups.
Conclusions: Our data indicate that the no-reflow phenomenon follows global 
renal ischemia and contributes to heterogeneous, ongoing ischemia leading to a cycle 
of inflammation, tissue injury and postischemic renal failure. In this model, fibrinolysis 
improves renal function postischemia.
Funding: Veterans Affairs Support, Private Foundation Support
RENAL PARAMETERS 48 hours postischemia/24 hours post therapy (exosomes or 
urokinase)
*p<0.05 v ischemia/vehicle; #p<0.05 v ischemia/exosomes; PMN, polymorphonuclear
neutrophil
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Selective Decontamination of Digestive Tract Attenuates Kidney Ischemia/
Reperfusion Injury and Distant Organ Damage via Immune Modulatory 
Effect
Jihyun Yang, Sang-Kyung Jo, Sewon Oh, Junyong Lee, Myung-Gyu Kim. 
Korea University Anam Hospital, Seoul, Republic of Korea.
Background: Emerging evidence suggests the critical role of gut as an amplifier of 
systemic inflammation in diverse pathological conditions. Selective decontamination of 
digestive tract (SDD) is known to inhibit colonization by aerobic gram-negative bacilli 
while preserving anaerobic microflora and is currently being used to prevent infection and 
also to reduce mortality in critically ill patients. We aimed this study to examine the effect 
of SDD on the severity of kidney injury as well as on distant organ damage and also the 
underlying mechanisms.
Methods: We used male C57L/B6 mouse bilateral ischemia/reperfusion injury(IRI) 
after SDD, which was the mixture of three antibiotics (neomycin 25mg/kg, ampicillin 
60mg/kg, and metronidazole 25mg/kg) given by orogastric gavage once daily for 12 days. 
The renal function, colon immunity, local and systemic inflammation level was assessed. 
We measured liver function test to check distant organ injury.
Results: Kidney IRI but not bilateral nephrectomy provoked increased intestinal 
permeability. The “leaky gut” following IRI was accompanied by increased colon apoptosis, 
decreased claudin-1 expression. Ly6G+ neutrophil infiltration and M1proinflammatory 
macrophages increased in colon after kidney IRI. SDD before IRI but not bilateral 
nephrectomy resulted in significant attenuation of kidney injury and inflammation as well 
as distant organ injury. The protective effect of SDD was associated with better preservation 
of intestinal permeability, reduced colon apoptosis and restored claudin-1 expression. SDD 
also led to the expansion of M2 anti-inflammatory macrophages and Tregs in colon. Spleen 
Tregs and Foxp3 expression were also increased in SDD mice. Mesenteric lymph node cells 
from SDD mice showed reduced proliferative response upon TCR stimulation, suggesting 
the state of immune tolerance compared to control mice.
Conclusions: Our results showed the critical role of intestine as an amplifier of kidney 
injury, inflammation and distant organ damage after IRI. We also showed the protective 
effect of SDD might be partially mediated by immune modulatory effect through expansion 
of M2 macrophages and Tregs. Strategies aimed at restoring intestinal integrity, microbiome 
and intestinal mucosal tolerance could be novel therapeutics in acute kidney injury.
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Spatially-Preserved, Multiplexed Expression Analysis of the Normal and 
Injured Human Kidney
Nikhil Singh, Judith Kliegel, Gilbert W. Moeckel, Brian Shuch, Lloyd G. Cantley. 
Yale University, New Haven, CT.
Background: Tissue obtained by renal biopsy is a useful substrate for understanding the 
biology of human acute tubular injury (ATI) with preservation of spatial context - including 
interactions between resident renal cells and those of the immune system. However, the 
small amount of tissue obtained in biopsies places a practical limitation on the number of 
markers that can be analyzed by conventional immunostaining, thereby limiting discovery.
Methods: Imaging mass cytometry (IMC) is a mass spectrometry-based technology 
that allows for simultaneous analysis of up to 40 protein and mRNA markers on a single 
section of formalin-fixed paraffin-embedded tissue, with no spectral overlap or background 
fluorescence. Using a prototype imaging mass cytometer and human kidney obtained by 
nephrectomy, we have sought to validate a panel of metal-conjugated monoclonal antibodies 
for use in mapping the human kidney with IMC, while also developing technology to 
simultaneously interrogate mRNA targets.
Results: We have developed and validated a panel of over 20 metal-conjugated 
monoclonal antibodies detectable by IMC in the kidney. We have successfully generated 
two-dimensional reconstructions to 1 micron resolution of reference and injured kidneys 
simultaneously stained with over 15 metal-tagged antibodies, better defining the spatial 
relationships between cell types.
Conclusions: With our current panel of antibodies, we will be able to interrogate true 
normal biopsies from living kidney donors and banked biopsies from patients with ATI. 
This will allow us to construct semi-quantitative two-dimensional atlases of the resident 
cell types, immune cells, and markers of cellular injury, stress, activation, regeneration and 
death in the normal and acutely injured human kidney.
Funding: NIDDK Support, Private Foundation Support
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An Unbiased Functional Genomic Screen Identifies Fibroblast Growth 
Factor 9 as a Novel Regulator of AKI
Yuntao Bai,1 Ji Young Kim,1 Laura A. Jayne,2 Navjotsingh P. Pabla.1 1The Ohio 
State University, Columbus, OH; 2The Ohio State University, Columbus, OH.
Background: Renal epithelial cell death and dysfunction are the hallmark and 
underlying cause of acute kidney injury (AKI), a common disorder characterized by sudden 
loss of renal function, high mortality and lack of therapeutic options. Identification of 
therapeutic strategies to prevent AKI is an essential but unmet medical need. Here we have 
used an unbiased functional genomic screen to identify therapeutic and druggable targets 
for AKI.
Methods: In this study, we carried out an unbiased siRNA-based high throughput 
screen (HTS) using a mouse renal tubular cell line. In this screen, 5169 druggable genomic 
genes (number of 384-well plates: 68; quadruplicate) were silenced in BUMPT cells and 
their effect on cisplatin-mediated cell death was examined by Cell Titer Glo assay. The 
siRNAs that significantly protected cells from cisplatin-induced cell death were selected 
for confirmatory secondary screens. Subsequently, by using a pharmacological inhibitor 
and renal tubule specific knock-out mice (GGT-Cre and FGF9 flox mice), one of the 
top hits from these screens was validated as a potential therapeutic target in three mouse 
models of AKI, namely cisplatin-, ischemia-, and rhabdomyolysis-induced AKI. In these 
mouse models, renal impairment was determined by accumulation of nitrogenous waste 
(blood urea nitrogen and serum creatinine), biomarkers of kidney injury (KIM1 and NGAL 
expression) and histological analysis (H&E staining and renal damage score).
Results: Our primary and confirmatory screens identified FGF9 as one of the regulators 
of renal cell death and injury. Infigratinib, a pan inhibitor of FGF9 receptors, mitigated 
kidney injury (KIM1, NGAL and renal damage score) and significantly improved renal 
function (blood urine nitrogen and creatinine) in three mouse AKI models (Vehicle vs. 
Infigratinib group, p ≤ 0.01). Furthermore, renal tubule specific FGF9 knock-out mice 
exhibited significant protection from AKI as compared to their control littermates.
Conclusions: Using a novel HTS mediated functional genomic screen, we have 
identified FGF9 associated signaling network as a crucial modulator of renal dysfunction 
and AKI. Proof-of-principle experiments also suggest that pharmacological or genitic 
inhibition of FGF9 signaling can mitigate AKI.
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Translating Ribosome Affinity Purification (TRAP) Molecular Profiling of 
Kidney Cell Types: A Data Resource
Jie Huang,1 John Vekich,1 Konstantin Bobkov,2 Corine Holub,1 Debashree Das,1 
Pranali Taskar,3 Mats I. Ekstrand,1 Eun ji Yoo,1 Naishan Chen,1 Huey-Jing Huang,1 
Sara J. Mcsweeney,5 David C. Bedford,4 Joseph P. Doyle.1 1Takeda California, 
Inc., San Diego, CA; 2SGI, San Diego, CA; 3NGM Biopharmaceuticals, Santa 
Clara, CA; 4Mission Therapeutics Ltd, Cambridge, United Kingdom; 5Clinical 
Network Services, Bishop?s Stortford, United Kingdom.
Background: The Translating Ribosome Affinity Purification (TRAP) methodology 
was developed in the labs of Nathaniel Heintz and Paul Greengard at Rockefeller University 
in order to overcome the inherent cellular complexity of tissues and to obtain cell-type 
specific translational profiles of critically relevant cell types in these tissues (Doyle et 
al., Heimann et al., Cell, 2008). Using bacTRAP transgenic mouse lines licensed from 
Rockefeller University or generated at Takeda, California, we here apply the TRAP 
methodology to profile relevant kidney cell types, both in a basal state as well as in models 
of acute kidney injury.
Methods: We employed the TRAP methodology in order to obtain translational 
profiling data from multiple kidney cell types. Transgenic mice expressing the EGFP-
ribosomal L10a fusion protein under kidney cell type specific promoters were generated 
using standard techniques and characterized for EGFP-L10a expression in the cell types of 
interest. For collection of TRAP samples, whole kidneys were isolated from several mice, 
homogenized, and processed following standard TRAP protocols. Total tissue mRNA and 
cell-type enriched TRAP mRNA samples were amplified, libraries prepared, and sequenced 
following routine protocols.
Results: We have collected kidney TRAP data covering two general areas: 1. 
Baseline data, collected from unperturbed transgenic bacTRAP mice, targeting specific 
cell types (podocytes, proximal tubule epithelial cells (PTECs) and subsets of PTECs, 
and perivascular mesenchymal cells) 2. Data from disease model studies (sepsis, bilateral 
ischemia-reperfusion).
Conclusions: Here we demonstrate that bacTRAP is a powerful tool for translational 
profiling of kidney cell types. In order to make best use of our kidney TRAP datasets, we 
are making this data available to the greater scientific community. This data is an invaluable 
resource for identification of potential drug targets and biomarkers for kidney disease, as 
well as for elucidating the mechanism of action for kidney disorders and drug response. In 
addition to the RNAseq data, we have access to many TRAP mouse lines on the C57Bl6/J 
strain which are also available. Details of data and transgenic mouse lines will be available 
at this poster session.
Funding: Commercial Support - Takeda California, Inc
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Optogenetic Stimulation of Either Efferent or Afferent Vagus Neurons 
Protects Kidneys from Ischemia-Reperfusion Injury
Shinji Tanaka,1 Chikara Abe,2,3 Diane L. Rosin,2 Patrice G. Guyenet,2 
Mark D. Okusa.1 1Medicine, University of Virginia, Charlottesville, VA; 
2Pharmacology, University of Virginia, Charlottesville, VA; 3Physiology, Gifu 
University Graduate School of Medicine, Gifu, Japan.
Background: We recently reported that electrical vagus nerve stimulation (VNS) 
in the neck protects mouse kidneys from ischemia-reperfusion injury (IRI) by activating 
the cholinergic anti-inflammatory pathway (CAP). Stimulation of vagal efferent neurons 
is believed to be essential to the activation of CAP. However, we found that electrical 
stimulation of the cephalic end of a divided vagus nerve was equally effective against IRI. It 
is therefore still unclear whether afferent or efferent VNS is most important in ameliorating 
renal IRI.
Methods: Channelrhodopsin-2 (ChR2) is a light-sensitive, non-selective cation channel 
that is opened only during blue light application. We crossed loxP-STOP-loxP ChR2 mice 
with choline acetyltransferase (Chat)-cre and vesicular glutamate transporter 2 (Vglut2)-cre 
mice to generate Chat-ChR2 and Vglut2-ChR2 mice expressing ChR2 in vagal efferent 
and afferent neurons, respectively. Illumination of the cervical vagus nerve with blue laser 
selectively stimulated vagal efferent and afferent neurons (“efferent VNS” and “afferent 
VNS”) in Chat-ChR2 and Vglut2-ChR2 mice, respectively. Optogenetic stimulation with 
blue laser (wavelength: 473 nm) of left cervical vagus nerve was performed with 50 Hz (10 
sec) to observe physiological changes and with 5 Hz (10 min) in renal IRI experiments to 
minimize physiological changes. IRI surgery was performed 24 h after optogenetic VNS; 
mice were euthanized 24 h later.
Results: Blue laser (50 Hz) applied to the cervical vagus nerve, decreased heart rate 
markedly (300→180 bpm) with no change in respiratory rate in Chat-ChR2 mice and 
completely paused breathing by activation of Hering-Breuer inflation reflex in Vglut2-ChR2 
mice, proving selective efferent VNS and afferent VNS. Both efferent VNS (plasma Cr: 
1.53±0.20 vs. 0.48±0.05 mg/dL) and afferent VNS (plasma Cr: 1.09±0.22 vs. 0.44±0.06 
mg/dL) with 5 Hz protected kidneys from IRI, improved kidney histology and decreased 
renal Kim-1 expression. Splenectomy abolished the protective effect in both groups.
Conclusions: Afferent VNS as well as efferent VNS protects the kidneys from IRI. In 
both cases protection requires the spleen. These results support the hypothesis that CAP 
underlies the beneficial effect of efferent VNS on IRI and propose that a sympathetic reflex 
mediates the protective effect of afferent VNS.
Funding: NIDDK Support
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Enhancer and Super-Enhancer Dynamics in Kidney Repair
Julia Wilflingseder,1,2 Michaela Willi,2 Takaharu Ichimura,1 Chaochen Wang,2 
Hannes Olauson,3 M. Todd Valerius,1 Reinhold Erben,4 Lothar Hennighausen,2 
Joseph V. Bonventre.1 1Brigham & Women’s Hospital/Harvard Medical School, 
Boston, MA; 2NIDDK, National Institute of Health, Bethesda, MD; 3Clinical 
Sciences, Karolinska Institute, Stockholm, Sweden; 4Physiology, University of 
Veterinary Medicine, Vienna, Austria.
Background: The endogenous repair process of the mammalian kidney allows rapid 
recovery after acute kidney injury (AKI) through robust proliferation of tubular epithelial 
cells. There is currently limited understanding of which transcriptional regulators activate 
these repair programs. Here we investigate the existence of enhancer dynamics in the 
regenerating mouse kidney.
Methods: RNA-seq and ChIP-seq (H3K27ac, H3K4m3, BRD4, MED1, POL2) were 
performed on samples from repairing kidney cortex 4 hours and 2 days after ischemia/
reperfusion injury (IRI) to identify activated genes, transcription factors, enhancer and 
Transplantation: Cardiovascular and Metabolic Diseases
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
143
J Am Soc Nephrol 29: 2018 Poster/Thursday
super-enhancer dynamics. Further, we investigated the role of super-enhancer activation 
after IRI through pharmacological BET inhibition via the small chemical compound JQ1 in 
vitro and in AKI models in vivo.
Results: AKI leads to genome-wide alterations in enhancer repertoire in vivo. We 
identified 16,781 enhancer sites (H3K27ac / BRD4 positive, H3K4me3 negative) active in 
Sham and IRI samples; 6,512 lost and 9,774 gained after IRI. The lost and gained enhancer 
sites could be annotated to 62% and 63% of down- and up-regulated transcripts after AKI, 
respectively. The top 5 transcription factor binding motifs enriched in lost enhancer sites 
are Hnf4a, Esrrb, PPARE, RXR and Esrra. In contrast Fra1, Fosl2, Atf3, Jun-AP1 and 
BATF binding motifs are enriched in gained enhancer sites after injury. Both transcription 
factor groups show corresponding mRNA changes after injury. Super-enhancer analysis 
reveals 164 lost and 216 gained super-enhancer sites after IRI. 385 super-enhancers 
maintain activity before and after injury. Pharmacological inhibition of super-enhancer 
activity by BRD4 inhibition (JQ1 50 mg/kg/day) before IRI led to suppression of 40% of 
injury-induced transcripts associated with cell cycle regulation, and significantly increased 
mortality between days 2 and 3 after AKI.
Conclusions: These results are the first demonstration of enhancer and super-enhancer 
function in the repairing kidney. In addition, our data call attention to potential caveats for 
use of small molecule inhibitors of BET proteins that are already being tested in clinical 
trials. Our comprehensive analysis of enhancer changes after kidney injury in vivo has the 
potential to identify new targets for therapeutic intervention.
Funding: NIDDK Support, Other NIH Support - Marie Curie, Austrian Science Fund
TH-PO128 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Application of New Hypertension Guidelines to Renal Transplant 
Recipients: Impact on Cardiovascular Outcome and Graft Survival
Nikolaos Pagonas,1 Felix S. Seibert,1 Frederic Bauer,1 Benjamin Rohn,1 
Richard Viebahn,2 Nina Babel,1 Timm H. Westhoff.1 1Medical Department I, 
Ruhr-University Bochum, Germany, Herne, Germany; 2Dept. of Surgery, Ruhr-
University Bochum, Bochum, Germany.
Background: Based on data of the SPRINT trial, American national guidelines recently 
reduced the blood pressure goal from 140/90 mm Hg to 130/80 mm Hg for subjects with 
increased cardiovascular risk, e. g. those with chronic kidney disease. To date it remains 
elusive whether renal transplant recipients benefit from these goals as well.
Methods: We performed a retrospective analysis of 877 patients who underwent kidney 
transplantation between 1997 and 2011 in three transplant centers in Germany (Berlin and 
Bochum) with a follow-up of 12 - 120 months. Blood pressure was obtained at regular 
follow-up examinations in the transplant outpatient clinic. Patient and graft survival was 
defined as composite endpoint. Subjects were stratified according to mean systolic blood 
pressure values < 130 mmHg, 130-139 mmHg, or ≥ 140 mmHg.
Results: Mean SBP of the overall follow-up period was significantly associated with 
patient and graft survival. Cumulative survival was significantly higher for those patients 
with a systolic blood pressure (SBP) < 130 mmHg than those with 130-140 mmHg. 
Survival was lowest in renal transplant recipients with a mean SBP ≥ 140 mmHg. 
Analogously, mean SBP of the first 12 months posttransplant < 130 mmHg was associated 
with better cumulative patient and graft survival than higher blood pressure values in 
Kaplan Maier analyses.
Conclusions: Renal transplant recipients who achieve a mean systolic blood pressure 
< 130 mmHg have a significantly lower mortality and a better allograft outcome than with 
the conservative blood pressure goal < 140 mmHg. The new blood pressure targets should 
be considered suitable for renal transplant recipients as well.
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Progression of Cardiovascular Calcification in Renal Transplant 
Recipients
Maria Yaseen, Amr E. Mohamed, Bilal Ashqar, Waleed Hassan, Radwa Awad, 
Conor Lowry, Roberto Gedaly, Daniel Davenport, Florence Lima, 
Hartmut H. Malluche. University of Kentucky, Lexington, KY.
Background: Cardiovascular disease is the leading cause of death in renal transplant 
patients. We conducted a study to determine the progression of cardiovascular calcification 
in renal transplant recipients.
Methods: 192-slice computed tomography was used to longitudinally examine 
abdominal and thoracic aortic calcification (AAC, TAC) and CAC in 34 renal transplant 
recipients at time of transplantation, at 6 months (n=28), and at 12 months (n=24). Univariate 
analyses were used to assess risk factors for CAC progression. Transplant patients were 
matched to 50 dialysis patients. Linear regression was used to adjust for baseline CAC in 
evaluating groups’ calcification progression.
Results: Boxplots for AAC, TAC and CAC scores are shown in fig. 1. Pre-transplant 
square root of CAC volume (SqrtCACVol) correlated with serum calcium (r=.44, p=.012), 
magnesium (r=.43, p=.018), male gender (r=.56, p=.001), CAD (r=.49, p=.004) and age 
(r=.65, p < .001), but not with presence of diabetes, phosphorous, or dialysis vintage. 
None of these variables were associated with 1-year changes in SqrtCACVol. In the 
matched groups, transplant patients gained less SqrtCACVol compared to dialysis patient 
(Transplant: 1.3, 95% CI -0.4 - 3.1; Dialysis: 3.9, 95% CI 1.9 – 5.9, fig. 2), though this 
difference was not significant (p = 0.07).
Conclusions: Renal transplantation does not stop or reverse vascular calcification; 
however the rate of progression was less compared to dialysis patients.
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Vascular Calcification Slows but Does Not Regress After Renal 
Transplantation
Harish R. Alappan,2 Payaswini Vasanth,1 Shumila Manzoor,3 W. Charles O’Neill.1 
1Emory University, Atlanta, GA; 2Emory University - Undergraduate, Atlanta, 
GA; 3Renal Division,Department Of Medicine, Emory University, Atlanta, GA.
Background: While prevention of uremic vascular calcification has been extensively 
studied, it is not clear whether this lesion is reversible. To address this, we measured the 
change in breast arterial calcification (BAC), a marker of generalized medial arterial 
calcification, after successful kidney transplantation (Tx) in women without other risk 
factors for medial arterial calcification.
Methods: Women with kidney transplantation between 2009 and 2016 who had BAC 
and at least 2 digital mammograms performed at this institution after Tx were included. 
Women with diabetes, warfarin use, or serum creatinine > 1.4 were excluded. Breast arterial 
calcification (BAC) was measured on serial mammograms and linear regression was 
performed on each patient. Comparison was made to randomly selected cohorts of women 
with ESRD or eGFR ≥ 60 ml/min/1.73 m2.
Results: Characteristics of the final cohort of 16 patients (with ranges) were: mean age 
at Tx, 56 (39-67); mean pre-Tx ESRD duration, 7.0 years (0.3-14); mean serum creatinine at 
most recent mammogram, 1.05 mg/dl (0.60-1.40); median baseline BAC, 41 mm/breast (2-
776); mean number of mammograms, 3.6 (2-6). The slopes of BAC vs. time showed a mean 
increase of 5.3 ± 2.6 mm/breast/y or 9.8 ± 5.2 %/y, which was significantly ≥0 (p<0.05). 
This was significantly less than the rate of 18.1 ± 5.6 mm/breast/y in 23 ESRD women 
(p=0.017) and similar to the rate of 4.3 ± 0.7 mm/breast/y in 43 women with eGFR ≥ 60 ml/
min/1.73 m2. The rate decreased in all 3 patients in whom it could also be measured pre-Tx. 
The post-Tx slope was negative in 7 patients but within the error of the measurement. In 
the 10 patients with >2 mammograms, none showed consistent decreases in BAC with each 
mammogram. There was no difference in age, pre-Tx ESRD duration, baseline BAC, or 
serum creatinine between patients with positive and negative slopes.
Transplantation: Cardiovascular and Metabolic Diseases
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
144
J Am Soc Nephrol 29: 2018 Poster/Thursday
Conclusions: We conclude that medial arterial calcification significantly slows but 
does not regress after renal transplantation. This irreversibility emphasizes the importance 
of strategies to prevent vascular calcification during CKD and ESRD.
Funding: Clinical Revenue Support
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Factors Associated with Coronary Artery Calcification Score in Renal 
Transplant Recipients
Jennifer S. Lees,1,2 Elaine Rutherford,1,2 Giles Roditi,2 Alan G. Jardine,1,2 
Patrick B. Mark.1,2 1Institute of Cardiovascular and Medical Sciences, University 
of Glasgow, Glasgow, United Kingdom; 2NHS Greater Glasgow and Clyde, 
Glasgow, United Kingdom.
Background: Coronary artery calcification (CAC) is associated with cardiovascular 
morbidity. The presence and severity of CAC amongst renal transplant patients may vary 
because of heterogeneity within the population. We sought to determine factors associated 
with CAC using baseline data from a clinical trial.
Methods: Prevalent renal transplant patients recruited to a clinical trial of vitamin 
K supplementation (ViKTORIES: ISRCTN22012044) were included. Biochemical tests 
were performed and demographic data recorded at the baseline visit. Coronary artery 
calcification (CAC) was determined by non-contrast CT coronary calcium (Agatston) score; 
score >160 was considered high. Binary logistic regression analysis was used to determine 
factors associated with high CAC score. Analyses were conducted using stats and oddsratio 
for R statistical software.
Results: There were 68 trial participants included: 70.6% were male; 97.1% were 
Caucasian. Patients with high CAC score (58.8%; median score 1269, IQR 502-3245) 
were older (60.8 vs 54.7 years; p=0.01) with similar systolic blood pressure (152 vs 144 
mmHg; p=0.08) and proteinuria (urine protein creatinine ratio 98 vs 72 mg/mmol; p=0.56), 
but had longer time since renal transplant (11.2 vs 7.4 years; p=0.05) and time since first 
renal replacement therapy (17.0 vs 9.8 years; p=0.002). There was no difference in graft 
function (GFR 50.6 vs 54.2 ml/min; p=0.54) and both groups had controlled calcium, 
phosphate and parathyroid hormone. Vitamin D insufficiency (vitamin D <30 ng/nl) 
was common in both groups (71.4 vs 65.0%; p=0.58). On binary logistic regression analysis, 
factors associated with high CAC score were older age (OR 1.18 per 10-year increase; 95% 
CI 1.05-1.33), longer duration of non-transplant RRT (OR 1.02 per year; 95% CI 1.01-1.04) 
and current or previous smoking history (OR 1.35; 95% CI 1.09-1.67).
Conclusions: In a diverse group of renal transplant recipients, high CAC score was 
associated with older age, dialysis vintage and smoking status, but not with traditional 
markers of CKD mineral and bone disorder or vitamin D insufficiency. These offer few 
modifiable risk factors for intervention, though smoking cessation may be worthwhile. 
Activity of calcification inhibitors may be important in this patient group and warrant 
further study.
Funding: Private Foundation Support
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High Molecular Weight Adiponectin Inhibits Vascular Calcification in 
Renal Allograft Recipients
Kanae Nomura, Hiroki Adachi, Keiichiro Okada, Keiji Fujimoto, 
Hitoshi Yokoyama. Kanazawa medical university, Kahoku, Japan.
Background: Adiponectin (ADPN) prevents the development/recurrence of 
cardiovascular events via its anti-atherogenic effects. However, few long-term studies have 
examined the changes in serum ADPN levels and arterial calcification seen in renal allograft 
recipients.
Methods: The effects of the serum ADPN level on arterial calcification were examined 
in 51 Japanese renal allograft recipients. Abdominal aorta calcification was evaluated on 
computed tomography using the aortic calcification area index (ACAI). The change in the 
ACAI and serum high-molecular-weight (HMW) - ADPN fractions were studied over an 
8-year period. The arterial expression of ADPN, ADPN receptors (AdipoR)1 and 2, and
T-cadherin (cadherin-13) were also examined by immunohistochemistry.
Results: 1) The change in the ACAI were grouped into quartiles and compared with
the alterations in the serum levels of each ADPN fraction over an 8-year period. The change 
in the ACAI was much lower in the patients with highly elevated HMW-ADPN levels. 
2) Multiple regression analysis demonstrated that an advanced age at transplant and a
history of cardiovascular complications were associated with an increased change in the
ACAI, while higher HMW-ADPN concentrations were associated with improvements in 
the ACAI. Serum HDL-C level was also identified as a positive factor to increase serum 
HMW-ADPN level. 3) In immunohistochemical examinations, ADPN was detected on 
CD31-positive arterial endothelial cells from renal allograft biopsy samples. ADPN co-
localized with T-cadherin and AdipoR1, but only partially co-localized with AdipoR2.
Conclusions: Both HMW-ADPN and HDL-C might inhibit the progression of vascular 
calcification by promoting ADPN binding to vascular endothelial cells via T-cadherin and 
AdipoR in Japanese renal allograft recipients.
TH-PO133 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovas-
cular Disease in Long-Term Kidney Transplant Recipients
Andrew Bostom. For The FAVORIT Study Investigators Memorial Hospital of 
Rhode Island, Chepachet, RI.
Background: “T50,” shortened transformation time from primary to secondary 
calciprotein particles, may reflect deranged mineral metabolism predisposing to vascular 
calcification, and cardiovascular disease [CVD]. The glycoprotein fetuin-A is a major T50 
determinant.
Methods: The FAVORIT cohort, is a completed, large, multiethnic controlled clinical 
trial cohort of chronic, stable kidney transplant recipients (KTRs). We conducted a 
longitudinal case-cohort analysis using a randomly selected subcohort of patients, and all 
individual cases who developed CVD. Serum T50 and fetuin-A were determined in this 
total of n=685 FAVORIT trial participants at randomization.
Results: 311 incident or recurrent CVD events occurred during a median surveillance 
of 2.18-years. Shorter T50 (minutes), or reduced fetuin-A concentrations (g/L) were 
associated with CVD after adjustment for treatment assignment, systolic blood pressure, 
age, sex, race, pre-existing CVD and diabetes, smoking, body mass index, total cholesterol/
HDL cholesterol, kidney allograft vintage and type, calcineurin inhibitor, or lipid lowering 
drug use, estimated glomerular filtration rate, and urinary albumin/creatinine: tertile 
1 (lowest) to tertile 3 (highest) comparisons, T50, [HR= 1.86; 95% CI= (1.20, 2.89)]; 
fetuin-A, [HR=2.25, 95% CI= (1.38, 3.69)]. Elevated high sensitivity c-reactive protein 
[hsCRP] was an effect modifier of both these associations.
Conclusions: Shortened T50, as well as reduced fetuin-A levels, ostensible promoters 
of vascular calcification, remained associated with greater risk for CVD outcomes, after 
adjustment for major CVD risk factors, measures of kidney function and damage, and KTR 
clinical characteristics and demographics, in a large, multiethnic cohort of long-term KTRs. 
Increased hs-CRP was an effect modifier of these CVD risk associations.
TH-PO134 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Impact of Hypertension and White Coat Hypertension on Renal Function 
and Blood Pressure Post Kidney Donation
Aruni Ratnayake, Pauline A. Swift, Peter A. Andrews, Mysore K. Phanish. 
Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom.
Background: The effects of nephrectomy on blood pressure (BP) and renal function 
in kidney donors with hypertension (HTN) and white coat HTN are unclear. This study is a 
pilot of a planned larger project aimed at investigating this in UK kidney donor population.
Methods: Living donors with HTN and white-coat HTN (BP >140/90 but normal 
ABPM) between January 2010 to December 2014 were identified. Matched normotensive 
donors were chosen as controls.
Results: N=30, 10 in each category. Table 1 shows demographics pre-donation. There 
was no significant difference in percentage reduction of eGFR post-donation across all 
donor groups (Figure 1). No donor had proteinuria pre-donation. Post-donation, donors 
with normal BP and white coat HTN did not develop proteinuria. However 20% donors 
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in HTN group developed proteinuria. All normotensive donors had normal BP readings 
post-donation. No donors in the white coat HTN group took anti-hypertensive medication 
pre-donation; post-donation, 40% required medication. All donors in HTN group took anti-
hypertensive medications pre-donation; of these, 70% had raised BP post-donation needing 
uptitration of medications.
Conclusions: There was no significant difference in change in renal function across 
all 3 groups. Our observations of higher incidence of proteinuria and uptitration of BP 
medications in donors with HTN, and significant proportion of donors with white coat HTN 
requiring antihypertensive medications post-donation merits further investigation. Our 
future work will investigate the impact of pre-donation HTN and white coat HTN on renal 
function and cardiovascular health in a large cohort of kidney donors.
TH-PO135 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Association Between Malnutrition – Inflammation Score and Bone 
Fractures in Prevalent Kidney Transplant Recipients
Miklos Z. Molnar,1,4 Abduzhappar Gaipov,1 Orsolya Cseprekál,2 Praveen 
Kumar Potukuchi,1 Kairat Kabulbayev,5 Manish Talwar,6 James D. Eason,7 
Istvan Mucsi,3 Csaba P. Kovesdy.1 1University of Tennessee Health Science 
Center, Memphis, TN; 2Semmelweis University, Budapest, Hungary; 3University 
of Toronto, Toronto, ON, Canada; 4Transplant Nephrology- Methodist Le 
Bonheur, Memphis, TN; 5Kazakh national medical university, Almaty, 
Kazakhstan; 6UTHSC, Germantown, TN; 7University of TN/Methodist 
Transplant Institute, Memphis, TN.
Background: Kidney transplant recipients (KTR) have a 4-fold higher risk of fracture 
compared to the general population. Chronic inflammation and protein energy wasting 
(PEW) syndrome are common in KTR and associated with poor outcomes. The presence of 
inflammation and PEW syndrome can directly affect bone resorption and bone formation, 
leading to bone loss and fractures. We assessed the association between Malnutrition-
Inflammation Score (MIS) a marker of PEW and bone fractures in KTR.
Methods: This prospective cohort study included 839 prevalent KTR. MIS is a 
semiquantitative instrument for the evaluation of Malnutrition–Inflammation Complex 
Syndrome, was calculated at the study entry. Self-reported history of fractures was recorded 
during the 2-year follow-up period. The association between MIS and bone fractures was 
examined in logistic regression analyses with adjustment for age, gender, eGFR, smoking 
habits, history of pre-transplant bone fractures and acute rejection.
Results: Mean age was 51±13 years and 56% of patients were males. Fifty-five (7%) 
patients experienced bone fractures during the follow-up period. In logistic regressions, 
MIS score showed linear association with increased risk of fracture (Figure 1). Each 1-point 
higher MIS was associated with 23% higher risk of bone fractures (odds ratio (OR) and 
95%CI: 1.23, 1.12–1.34), which remained significant after multivariable adjustments (OR: 
1.17, 95%CI: 1.06–1.29).
Conclusions: The MIS is independently associated with new bone fractures in 
prevalent KTR.
Figure 1. An association of MIS with bone fractures using cubic splines
TH-PO136 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Association Between Serum Pre-Albumin Level and Outcomes in 
Prevalent Kidney Transplant Recipients
Miklos Z. Molnar,1,3 Abduzhappar Gaipov,1 Christopher D. Jackson,1 
Manish Talwar,1,3 Vasanthi Balaraman,1,3 Arijit Chakravarty,1,3 
Orsolya Cseprekál,2 Zoltan Mathe,2 Adam Remport,2 Csaba P. Kovesdy,1 
James D. Eason,1,5 Istvan Mucsi.4 1University of Tennessee Health Science 
Center, Memphis, TN; 2Semmelweis University, Budapest, Hungary; 3Transplant 
Nephrology- Methodist Le Bonheur, Memphis, TN; 4University of Toronto, 
Toronto, ON, Canada; 5University of TN/Methodist Transplant Institute, 
Memphis, TN.
Background: Prealbumin, a transport protein mostly synthesized in the liver, is a 
marker of nutrition. While decreased prealbumin levels are associated with increased 
mortality in end stage kidney disease patients, its association with mortality in kidney 
transplant recipients remains unknown. We evaluated the association between prealbumin 
levels and outcomes in kidney transplant recipients.
Methods: This prospective cohort study included 991 kidney transplant recipients 
enrolled from December 31, 2006 to December 31, 2007 and followed over a 6-year period. 
Sociodemographic, past medical history, clinical and laboratory data were collected at the 
study entry. Associations between prealbumin levels and death with functioning graft, all-
cause mortality and graft loss were examined using survival models.
Results: Serum prealbumin levels showed significant negative correlation with eGFR 
(R=-0.28, p<0.001), and hsCRP (R=-0.24, p<0.001) (Figure 1). Each 5 mg/dL lower serum 
prealbumin level was associated with 20% higher risk of death with functioning graft 
(Hazard Ratio (HR) [95% Confidence Interval (CI)]: 1.20 [1.08–1.35], p=0.001), which 
persisted after multivariable adjustments (HR [95%CI]: 1.13 [1.00–1.28], p=0.039) (Figure 
2). Qualitatively similar trend was observed in all-cause mortality; however, there was no 
association between prealbumin levels and graft loss (Figure 2).
Conclusions: Lower serum prealbumin level is associated with increased risk of death 
with functioning graft and all-cause mortality in prevalent kidney transplant recipients.
Figure 1: Association between serum prealbumin level with eGFR (panel A) and serum 
C-reactive protein (panel B).
Figure 2: An adjusted association of serum prealbumin levels with death with functioning 
graft (panel A), all-cause mortality (panel B) and death censored graft loss (panel C) using 
cubic splines
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TH-PO137 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Myocardial Perfusion Reserve Is Preserved in Patients with Kidney 
Transplant
Johanna M. Päivärinta,2,1 Kaj P. Metsarinne,2 Juhani Knuuti,4,3 Eliisa Löyttyniemi,3 
Niina S. Koivuviita.2 1Department of Medicine, University of Turku, Turku, 
Finland; 2Turku University Central Hospital, Turku, Finland; 3University of 
Turku, Turku, Finland; 4PET center, Turku, Finland.
Background: Chronic kidney disease (CKD) has been associated with decreased 
myocardial perfusion reserve (MPR), the ratio of stress and rest perfusion. MPR reflects 
the capacity of vascular bed to increase perfusion and reflects the endothelial function and 
microvascular responsiveness. The effect of kidney transplantation on MPR is unknown. In 
this study our aim was to assess MPR of kidney transplant patients.
Methods: 10 healthy subjects and 19 kidney transplant patients without manifest 
atherosclerotic disease and with mild to moderate kidney impairment were included in 
the study. The average age of kidney transplant patients was 37 +/-23 months. Myocardial 
perfusion (MP) was measured by means of [15O]H2O PET (positron emission tomography) 
at rest and during adenosine infusion.
Results: MP was statistically significantly higher at rest in the kidney transplant patients 
than in the healthy controls (p=0.0015). After correction by cardiac work load (basal MPcorr, 
corrected basal myocardial blood flow, [(MP/own RPP)xRPP average of the healthy]) the 
difference between the groups disappeared. Coronary vascular resistance (CVR) at rest and 
CVR and MP at stress were comparable between the groups. Although MPR was reduced, 
MPRcorr (=stress flow/basal MPcorr) did not differ between the kidney transplant patients and 
the healthy controls.
Conclusions: MP and CVR during stress are preserved in the kidney transplant patients 
with mild to moderate CKD. The reduced MPR is explained by increased resting MP which 
is likely linked with increased cardiac workload due to sympathetic overactivation in the 
transplant patients.
Funding: Private Foundation Support
Values are mean (SD), 
*P<0.05 controls versus kidney transplant patients
TH-PO138 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Arterial Stiffness and Immunosuppressive Regimen in Renal Transplants 
Recipients
Zbigniew Heleniak,1 Jakub Ruszkowski,1 Fabian Halleck,2 Sarah M. Illersperger,2 
Susanne Brakemeier,2 Alicja Debska-Slizien,1 Klemens Budde.3 1Nephrology, 
Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, 
Poland; 2Charité Universitätsmedizin Berlin, Berlin, Germany; 3Charite 
Universitatsmedizin Berlin, Berlin, Germany.
Background: Reduction of cardiovascular influences on the long-term survival rates of 
renal transplant recipients (RTRs) The aim of the study was to assess the relation between 
immunosuppression and pulse wave velocity in RTRs.
Methods: 103 RTRs, who were visiting outpatient clinic in February 2018 were 
enrolled into the study. eGFR was calculated with the CKD-EPI formula. Arterial stiffness 
was assessed by means of brachial-ankle and carotid-femoral pulse wave velocity (baPWV, 
cfPWV) measured by ABI-system 100. Patient characteristics and results were described 
by median and interquartile range (IQR) for continuous variables and by frequencies for 
categorical variables.
Results: Median age of 103 studied RTRs was 53 (37-61) years, 64 (62.1%) patients 
were male. Details are presented in figure 1. The immunosuppressive regimen was as follow: 
calcineurin inhibitors (CNI) (68.9/17.5% on TAC/CsA, respectively), antiproliferative agents 
(48.5/47.6% on MPS/MMF, respectively), steroids (39.8/7.8/3.9% on methylprednisolone/
prednisolone/prednisone, respectively), belatacept (6.8%). There was linear correlation 
between CsA level and cfPWV (p <0,05). CsA concentration/dose (C/D) ratio correlated 
with baPWV (p<0,05). Neither tacrolimus daily dose nor concentration correlated with 
baPWV and cfPWV, respectively. C/D ratio of TAC correlated with cfPWV p<0,05). There 
were observed linear correlations between age of the patients, duration of renal replacement 
therapy and baPWV, cfPWV (p<0,05). eGFR correlated negatively with cfPWV (p<0,05)
Conclusions: CsA and TAC were administered in the majority of the study population. 
CNI increased the arterial stiffness. Both CsA and TAC C/D ratio had the influence on PWV. 
Age, RRT duration time and eGFR correlated with arterial stiffness markers
TH-PO139 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Progression of Endothelial Dysfunction, Atherosclerosis, and Arterial 
Stiffness in Kidney Transplant Patients
Joey Junarta,1 Nina Hojs,2 Racquel M. Lowe-Jones,1 Juan carlos Kaski,1 
Debasish Banerjee.1 1St. George’s, University of London, London, United 
Kingdom; 2University Clinical Centre Maribor, Maribor, Slovenia.
Background: Cardiovascular events are the commonest cause of mortality and 
morbidity in kidney transplant recipients, yet little is known about the changes in vascular 
structure and function with time. This pilot study investigated changes vascular structure 
and function over time, in stable kidney transplant patients (KTxPs) compared to controls.
Methods: Brachial artery flow-mediated dilation (FMD), nitroglycerine-mediated 
dilation (NMD), carotid-femoral pulse wave velocity (cf-PWV), ankle-brachial pressure 
index (ABPI), and common carotid artery intima-media thickness (CCA-IMT) were 
assessed in 18 KTxPs and 17 controls at baseline and 3-6 months after. All subjects were 
recruited after written consent and all measurements were done in our vascular laboratory 
under standard conditions.
Results: There were more dyslipidaemics in KTxPs compared to controls (10 vs. 3; 
P=0.02). There was no difference in age (51.28 ± 13.29 vs. 45.82 ± 10.85; P=0.19), body 
mass index (25.56 ± 5.18 vs. 24.59 ± 2.59; P=0.49), or diabetes status (3 vs. 0; P=0.08). 
No difference existed in vascular markers between KTxPs and controls at baseline: FMD 
(4.34 ± 3.45 vs. 4.63 ± 3.02 %; P=0.79), NMD (15.15 ± 6.08 vs. 16.00 ± 5.47 %; P=0.67), 
cf-PWV (7.83 ± 1.76 vs. 6.96 ± 1.26 m/s; P=0.10), ABPI (1.27 ± 0.15 vs. 1.18 ± 0.08; 
P=0.47), CCA-IMT (5.73 ± 0.95 vs. 5.54 ± 1.08 mm; P=0.05). Vascular measurements 
did not change in controls upon follow-up (see table 1). In KTxPs, FMD decreased (-1.52 
± 2.74 %; P=0.03), cf-PWV increased (0.62 ± 1.06 m/s; P=0.03), and CCA-IMT increased 
(0.35 ± 0.53 mm; P=0.02).
Conclusions: Markers of vascular structure and function worsened in stable kidney 
transplant patients follow-up. We propose that after initial improvement in cardiovascular 
health immediate post-transplant; the newly acquired cardio-vascular risk factors, 
immunosuppression and persistent mild CKD may cause further deterioration explaining 
the elevated risk for CV events.
Table showing the changes in vascular abnormalities over time in kidney transplant patients 
and controls
TH-PO140 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Incidence of Cardiovascular Diseases in Pediatric Solid Organ Transplant 
Recipients
Sandeep Brar,1,2 Stephanie Dixon,5,8 John M. Paterson,5,7 Joseph Kim,1,2 
Diane Hebert,1,3 Jade S. Dirk,5 Emma J. Hahn,6 Rulan S. Parekh,3,1 
Rahul Chanchlani.4 1Department of Medicine, University of Toronto, Toronto, 
ON, Canada; 2Division of Nephrology and the Kidney Transplant Program, 
University Health Network, Toronto, ON, Canada; 3The Hospital For Sick 
Children, Toronto, ON, Canada; 4McMaster Children’s Hospital, Hamilton, ON, 
Canada; 5Institute for Clinical Evaluative Sciences, London, ON, Canada; 
6Institute of Clinical Evaluative Sciences, London, ON, Canada; 7Institute of 
Health Policy, Management, and Evaluation, Toronto, ON, Canada; 
8Department of Epidemiology and Biostatistics, Western University, Toronto, 
ON, Canada.
Background: Cardiovascular disease (CVD) is a long-term complication in pediatric 
solid organ transplant (SOT) recipients; however, the incidence is not well described.
Methods: We conducted a cohort study comparing CVD rates in children with SOT 
(heart, liver, lung, kidney, small bowel) at the Hospital for Sick Children in Toronto, 
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Canada (n = 979) with a random sample of healthy, non-transplanted children in Ontario 
(n = 1,000,000) between 1993 and 2014 using provincial health administrative data. 
Outcomes included non-fatal CVD events, CVD-specific death, and a composite of 
non-fatal and fatal CVD events. Non-fatal CVD events were defined as atherosclerotic 
(acute myocardial infarction, stroke, peripheral vascular disease, carotid endarterectomy, 
percutaneous coronary intervention, coronary artery bypass grafting) and non-
atherosclerotic (congestive heart failure, arrhythmia, cardiac defibrillation, insertion of 
pacemaker, out of hospital cardiac arrest).
Results: Among SOT recipients, 41% had a kidney transplant, 32% had a liver 
transplant and 22% had a cardiac transplant. The remaining 5% had lung, small bowel 
or multi-organ transplants. Mean age at index was 7.7 and 8.1 years in the transplant and 
non-transplant group, respectively. During an overall median follow-up time of 11.0 years 
(interquartile range: 5.7-17.5 years), CVD events were at least 50 times more likely to occur 
in SOT recipients versus healthy, non-transplanted children (table).
Conclusions: The increased incidence of CVD in children post transplantation 
highlights the need for surveillance and prevention during transition into early adulthood.
Events and incidence rate ratios for cardiovascular outcomes in pediatric solid organ 
transplant recipients
TH-PO141 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Obesity as a Predictor of Renal Allograft Function
Nathan A. Luke,3 Ekamol Tantisattamo.1,2 1Division of Nephrology and 
Hypertension, Department of Medicine, University of California Irvine School 
of Medicine, Orange, CA; 2Multi-Organ Transplant Center, Division of 
Nephrology, Department of Internal Medicine, William Beaumont Hospital, 
Oakland University William Beaumont School of Medicine, Royal Oak, MI; 
3Oakland University William Beaumont School of Medicine, Rochester, MI.
Background: While being underweight in ESRD is associated with increased morbidity 
and mortality, obesity in these patients leads to unfavorable post-transplant outcomes. 
The aim of this study is to explore associations between pre-transplant obesity and early 
readmission (ERA), as well as renal allograft function at 12 months post-transplantation.
Methods: Demographic data of 84 patients receiving a kidney transplantation from 
January to December 2014 were retrieved. The patients were categorized into non-obese 
and obese groups based on BMI. ERA, defined as any admission within 30 days after the 
discharge date from transplant admission, and eGFR was associated with pre-transplant 
obesity status.
Results: Of all 83 patients, 53 were non-obese and the remaining 30 patients were 
obese with mean BMIs of 24.65±3.08 and 34.12±2.98, respectively (95% CI -10.85, 
-8.09, p <0.001). Pre-transplant diabetes were lower in the non-obese group than in
the obese group (30% vs 60%, p 0.015); otherwise, all other baseline characteristics
between non-obese and obese groups were similar. There were 19, 4, and 2 patients who
had 1, 2, and 3 ERA, respectively. One patient died at the early post-transplant period.
The remaining 57 patients were never readmitted. Obese patients had 33% higher odds
of being readmitted when compared to non-obese patients (OR 1.33, 95% CI 0.50,
3.51, p 0.562). Among 50 non-obese and 28 obese patients with functioning allografts
at 12 months post-transplantation, mean eGFR at 12 months was 59.4±19.55 and 
50.9±15.81 ml/min/1.73 m2, respectively. Obese patients had a decrease in eGFR of 8.56
ml/min/1.73 m2 at 12 months post-transplantation compared to non-obese patients (95%
CI -17.17 to 0.04, p 0.051). After adjusted for all variables including age, race, type of
kidney transplantation, induction immunosuppressive medications, pre-transplant diabetes, 
hypertension, hyperlipidemia, and smoking, obese patients had a significant decrease in 
eGFR at 12 months post-transplantation by 10.10 ml/min/1.73 m2when compared to non-
obese patients (95% CI -20.18 to -0.02, p-value 0.0495).
Conclusions: Although ESRD patients who are underweight are at risk of poor 
outcomes during the pre-transplant period, pre-transplant obesity increases the risk of 
poorer renal allograft function. Patients who will undergo a kidney transplantation should 
control and maintain their weight in a normal range.
TH-PO142 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Overweight and Size Mismatch Are Risk Factors of De Novo Focal 
Segmental Glomerulosclerosis After Kidney Transplantation from Parent 
to Child
Tomo Suzuki,3 Masahiko Yazawa,3 Daisuke Ichikawa,3 Naohiko Imai,3 
Hideo Sasaki,1 Yuhji Marui,1 Junki Koike,2 Yugo Shibagaki.3 1Department of 
Urology, St. Marianna university school of medicine, Kawasaki, Japan; 2St.
Marianna University, Kawasaki, Japan; 3St Marianna University Hospital, 
Kawasaki, Japan.
Background: Proteinuria among transplant recipients is an important factor for 
allograft and patient survival. In addition, the mean age of donor is increasing in Japan. 
The aging donor is a risk factor of de novo focal segmental glomerulosclerosis (FSGS) due 
to podocytopenia and loss of nephron number. The aim of this study is to evaluate the risk 
factor in de novo FSGS after kidney transplantation (KTx) from parent to child.
Methods: This is an observational case control study. The subjects were 45 patients 
who underwent KTx from parent to child between 2009 Apr to 2016 Aug in our Hospital 
and whose allograft survived to have allograft biopsy not showing FSGS at both 0 and 12 
months. Cases of recurrent FSGS (N=1), IgA nephropathy (N=1), and nephrosclerosis of 
0h biopsy (N=1) and those without protocol biopsy at 12 months (N=3) were excluded, 
leaving total of 39 patients. We examined clinical and histological features, with all values 
are expressed as mean ± standard error (SE).
Results: Five out of 39 recipients showed FSGS in biopsy which was done after 
> 12 months (FSGS group). Comparing FSGS group vs non-FSGS group, male accounted 
for 100% vs 61.8 %, the ages were 41.2 ± 3.3 vs 35.0 ± 1.3 (p=0.088), body weight (BW)
were 74.9 ± 6.1 vs 59.5 ± 2.4 kg (P=0.024), body mass index (BMI) were 26.2 ± 2.0 vs
21.9 ± 0.8 kg/m2(P = 0.049), the donor age was 68.8 ± 3.2 vs 62.4 ± 1.2 (p=0.069), and
the donor eGFR was 72.3 ± 6.2 vs 77.6 ± 2.4 ml/min/1.73m2, respectively. So, there were
significant differences for BW and BMI of recipients. Before KTx, the difference between 
the recipient and donor’s BW was significantly higher in FSGS group [18.3 ± 7.3 vs 
1.4 ± 2.8 kg (p=0.038)]. At protocol biopsy of 12 months after KTx, BW and BMI in FSGS 
group were also significantly higher than non-FSGS group [BW; 78.0 ± 6.1 vs 60.6 ± 2.3 kg 
(P=0.012), BMI; 27.3 ± 1.9 vs 22.3 ± 0.8 kg (P=0.027)]. The duration to FSGS diagnosis 
after KTx was 1066 ± 277 day. The Columbia classification of FSGS group was all NOS 
variant (no perihilar). The range of foot process effacement was not diffuse, indicating these 
FSGS were secondary.
Conclusions: Overweight of the recipient and size mismatch are risk factors of de novo 
FSGS after 12 months post-KTx from parent to child.
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Obesity Is a Risk Factor for ESRD in Prior Living Kidney Donors
Amarpali Brar,1 Angelika C. Gruessner,1 Rahul M. Jindal,3 Robert Nee,2 
Dimitre Stefanov,1 Moro O. Salifu.1 1SUNY Downstate Medical Center, 
Brooklyn, NY; 2Walter Reed National Military Medical Center, Vienna, VA; 
3Uniformed Services University of Health Sciences, Silver Spring, MD.
Background: Living donors undergo extensive evaluation prior to donation. Despite 
that some living kidney donors (LKDs) progress to end stage renal disease (ESRD). 
We evaluated the trends and characteristics of LKDs who were waitlisted for kidney 
transplantation.
Methods: We used the United Network for Organ Sharing data to identify 524 LKDs 
who were listed for kidney transplantation from 1993-2017. For qualitative variables, 
frequencies were computed and the tests of association were performed using the chi-square 
test.
Results: In this cohort, 59.8% (n=313) were men and 40.2% (n= 211) women. Cause 
of ESRD was diabetes in 17.5%, hypertension in 32% and other in 44%. Forty six % 
were White, 38.5% Black, 10% Hispanic, 2.2% Asian, 1.9 % Native -American and 1.1% 
were multiracial. Mean age at listing was 55 yrs ±11.4. Figure 1 shows the increasing 
number of prior LKDs who waitlisted from 1993- 2017. The number of Black LKDs who 
waitlisted were disproportionately higher (38.5%) as compared to the proportion of Black 
LKDs in this time period varying from 8% to 12%. Hypertension as a cause of ESRD 
was observed to be much higher in Blacks (41.1%) and Hispanics (32%) as compared 
to Whites (26%), p= 0.02. Mean BMI at time of waitlisting was 29.5 ± 5.2 kg/m2. 
Among LKDs who were listed for transplantation, majority were overweight (36%) or obese 
(43.%). Forty-one percent of (n=100) white, 46% (n=93) black, 46 % Hispanic (n=24) and 
25.3% (n=7) multiracial prior LKDs were obese (>30kg/m2) at time of wait listing, p=0.18.
Conclusions: Transplantation centers now approve more medically complex obese 
LKDs without supporting data. Informed consent with obese individuals are critical in those 
considering LKD. Life style changes and modifications should be addressed in those with 
normal BMI at time of donation to avoid future obesity. Long-term studies are needed to 
understand risks associated with hypertension and obesity focused on minority LKDs
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Association of Visceral Obesity After Kidney Transplantation with Graft 
Survival in Living Kidney Transplant Recipients: A Retrospective Cohort 
Study
Reibin Tai,1 Yasushi Ohashi,2 Masaki Muramatsu,1 Takeshi Kawamura,2 
Nobuyuki Shiraga,3 Seiichiro Shishido,1 Ken Sakai.1 1Nephrology, School of Medicine, 
Faculty of Medicine, Toho University, Tokyo, Japan; 2Nephrology, Sakura Medical 
Center, School of Medicine, Toho University, Chiba, Japan; 3Radiology, School of 
Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
Background: Excessive weight gain is common after kidney transplantation. However, 
the relationship between visceral obesity and kidney allograft outcome remains unclear. We 
measured the visceral fat area by computed tomography and examined the relation with the 
kidney allograft survival.
Methods: We identified 254 recipients who underwent living kidney transplantation 
from 2004 to 2014. Of those, 196 recipients evaluated metabolic risk factors and visceral fat 
area at the level of the umbilicus on abdominal computed tomography before transplantation 
and 12 months after transplantation and were followed until February 2018. Visceral 
obesity was defined as visceral fat area of ≥100cm2. Metabolic syndrome was defined 
by the NCEP ATP III criteria modified for the Japanese population. Treatment-resistant 
hypertension was defined as an office blood pressure of ≥130/80 mmHg, despite receiving 
≥3 antihypertensives including diuretics, or ≥4 drugs usage. The adverse graft outcomes
were defined as a decline of 50% or more of estimate glomerular filtration rate with baseline 
one month after transplantation or initiation of renal replacement therapy.
Results: Recipients with visceral obesity were seen in 69 (35.2%) at 12 months post-
transplantation. Compared to recipients with no visceral obesity, they were more likely 
to be male, older, have a higher weight gain from 1 month to 12 months after kidney 
transplantation (7.0 ± 7.5 vs. 4.6 ± 8.8%, P <0.05), prevalence of metabolic syndrome (23.2 
vs. 3.9%, P <0.01), and treatment-resistant hypertention (17.4 vs. 7.1%, P <0.05), and have 
a lower glomerular filtration (44 ± 12 vs. 48 ± 15 ml/min/1.73m2, P <0.05). During median 
9.5-year follow-up, they also had higher adverse graft outcome (3.2 vs 1.3 per 100 patient-
years, P <0.05). In multivariate analysis, visceral obesity independently remained as a risk 
factor for kidney allograft outcome (hazard ratio, 2.27 ; 95% confidence interval, 1.11−4.72, 
P=0.033).
Conclusions: Visceral obesity at 1 year post-transplantation becomes a risk factor for 
metabolic syndrome and graft survival, which emphasizes the importance of management 
of obesity after transplantation.
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Effect of Obesity on Transplant Outcome One Year Post Kidney 
Transplant
Muna Alnimri,1 Golnaz G. Friedman.2 1University of California Davis, 
Sacramento, CA; 2University of California, Davis Health, Sacramento, CA.
Background: Kidney transplant is the preferred option of treatment for patients with 
Chronic kidney disease, studies have shown poor outcome for obese patients BMI≥30kg/m2 
and more perioperative complications, the aim of this study is to compare outcomes of 
obese patients BMI ≥30kg/m2 to patients with BMI<30kg/m2.
Methods: A retrospective single center cohort study of adult kidney transplant recipients 
between 1/2014 - 1/2016 compairing 308 patient BMI<30 to110 patients BMI≥30, one year 
patient and graft survival, incidence of delayed graft function, average hospital stay, wound 
and cardiac complications, new onset diabetes after transplant (NODAT), proteinuria and 
rejection.
Results: Table1 shows obese patient with BMI≥30kg/m2 were older, diabetics, on 
peritoneal dialysis, had higher incidence of delayed graft function worse patient suvival in 
one year, other complcations were not significantly different among both groups
Conclusions: Kidney transplant recipients with BMI ≥30kg/m2 have higher incidence 
of mortality, delayed graft function than patients with BMI <30kg/m2. Dietery counseling 
and referral for bariatric surgery is recommended for weight loss to improve post transplant 
outcome.
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Advanced Glycation End Products and Risk of Late Graft Failure and 
Cardiovascular Mortality in Renal Transplant Recipients: A Prospective 
Cohort Study
Camilo G. Sotomayor,1 Antonio Gomes Neto,1 Marco van Londen,1 
Reinold O. Gans,1 Stefan P. Berger,1 Ramon Rodrigo,2 Stephan J. Bakker.1 
1University Medical Center Groningen, Groningen, Netherlands; 2Faculty of 
Medicine, University of Chile, Institute of Biomedical Sciences, Molecular and 
Clinical Pharmacology Program, Santiago, Chile.
Background: Advanced glycation endproducts (AGE) have been implicated in the 
pathogenesis of chronic transplant dysfunction and cardiovascular (CV) disease of renal 
transplant recipients (RTR), but no prospective studies have been performed to date. We 
investigated the association of plasma AGE levels with graft failure (GF) and CV mortality 
in a cohort of RTR with long-term follow-up.
Methods: Tandem mass spectrometry was performed to simultaneously measure the 
AGE Nε-(Carboxymethyl)lysine (CML) and Nε-(Carboxyethyl)lysine (CEL) levels in 
hydrolysates of plasma proteins. Multivariate-adjusted Cox-proportional hazards regression 
analysis was used to assess prospective associations with clinical outcomes.
Results: We included 555 RTR (mean (SD) age 51±12 years old, 56% males). During 
median follow-up for 6.9 [IQR, 6.2-7.2] years, 67 (12%) RTR developed GF, and 122 (22%) 
died (52% were due to CV causes). In analyses adjusted for potential confounders, including 
age, sex, estimated Glomerular Filtration Rate (eGFR) and proteinuria, CML levels were 
not independently associated with GF, but they were with CV mortality (Table 1). In similar 
analyses, CEL levels were independently associated with GF and CV mortality (Table 1). 
The association of CML levels with GF was modified by renal function (Pint<0.001), with a 
significant and independent association in RTR with eGFR≤45 mL/min/1.73m2 (HR, 1.75; 
95% CI, 1.06-2.89; P=0.03).
Conclusions: High plasma levels of the AGE CML and CEL were independently 
associated with increased risk of GF and premature CV mortality. These results strengthen 
the quest for studying AGE-targeted interventions as potential therapeutic strategy to 
improve long-term outcomes in RTR.
Funding: Government Support - Non-U.S.
Table 1. Multivariate-adjusted associations of plasma CML and CEL levels with GF and 
CV mortality in RTR.
Hazard ratios are adjusted for age, sex, eGFR, proteinuria, primary renal disease, pre-
transplant dialysis vintage, time between transplantation and inclusion, BMI, total 
cholesterol, systolic blood pressure, personal history of diabetes mellitus and CV disease, 
and familiar history of CV disease.
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Fruit and Vegetable Consumption and Cardiovascular Mortality in Renal 
Transplant Recipients: A Prospective Cohort Study
Camilo G. Sotomayor,1 Antonio Gomes Neto,1 Michele F. Eisenga,1 
Josephine Anderson,1 Ilja M. Nolte,2 Martin H. De Borst,1 Maryse Osté,1 
Ramon Rodrigo,3 Reinold O. Gans,4 Stefan P. Berger,1 Stephan J. Bakker.1 
1Division of Nephrology, Internal Medicine, University Medical Center 
Groningen, Groningen, Netherlands; 2Department of Epidemiology, University 
Medical Center Groningen, Groningen, Netherlands; 3Molecular and Clinical 
Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, 
University of Chile, Santiago, Chile; 4Internal Medicine, University Medical 
Center Groningen, Groningen, Netherlands.
Background: We investigated the associations of fruit and vegetable (F&V) 
consumption after kidney transplantation with risk of CV mortality in an extensively 
phenotyped cohort of renal transplant recipients (RTR) with long-term follow-up.
Methods: F&V consumption were assessed by means of an item-specific food-
frequency questionnaire. Multivariable-adjusted Cox-proportional hazards regression 
analysis was performed to assess the risk of CV mortality.
Results: We included 400 RTR (age 52±12 (SD) years old, 54% males). At a median 
follow-up of 7.2 [interquartile range, 6.7-7.6] years, 93 (23%) patients died, of which 49 
(53%) were due to CV disease. Overall, fruit consumption was not associated with CV 
mortality, whereas vegetable consumption was inversely associated with risk of CV mortality 
(Table 1). This association remained independent of adjustment for several potential 
confounders. The association of fruit consumption with CV mortality was significantly 
modified by renal function (Pint=0.01) and proteinuria (Pint=0.01), with significant inverse 
associations in patients with estimated Glomerular Filtration Rate (eGFR)>45 mL/
min/1.73m2 (HR, 0.56; 95% CI, 0.35-0.92; P=0.02) or absence of proteinuria (HR, 0.62; 
95% CI, 0.41-0.92; P=0.02).
Conclusions: In RTR, a relatively high vegetable consumption is independently 
and strongly associated with lower risk of premature CV mortality. A relatively high 
fruit consumption is also associated with lower risk of premature CV mortality, although 
particularly in RTR with eGFR>45 mL/min/1.73m2 or absence of proteinuria. Further 
studies are warranted to investigate whether increasing F&V consumption may open 
opportunities for interventional pathways to decrease the burden of CV mortality in RTR.
Funding: Government Support - Non-U.S.
Table 1. Association of fruit and vegetable consumption with CV and all-cause mortality 
of RTR
Hazard ratios are adjusted for age, sex, income, educational level, physical activity, eGFR, 
proteinuria, time since transplantation, primary renal disease, total cholesterol, blood 
pressure, BMI, diabetes and smoking status.
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The Incidence and Related Factors of Post-Transplantation Diabetes 
Mellitus within 1-Year After Kidney Transplantation: Korean Cohort 
Study for Outcome in Patients with Kidney Transplantation (KNOW-KT)
Seungyeup Han,1,2 Seong Sik Kang,1,2 Hayeon Park,1 Jin hyuk Paek,1,2 Sang 
Mok Yeo,1 Woo Yeong Park,1,2 Kyubok Jin,1,2 Sung Bae Park.1,2 KNOW-KT 
Study Group 1Keimyung University School of Medicine, Daegu, Republic of 
Korea; 2Keimyung University Kidney Institute, Daegu, Republic of Korea.
Background: Posttransplantation diabetes mellitus (PTDM) is associated with poor 
graft survival and greater mortality. The incidence of PTDM after kidney transplantation 
(KT) reported to date is varied from 10-74% and varies by country and race. There are few 
nationwide cohort study reports on the incidence of PTDM and associated risk factors in 
Korea. The purpose of this study was to evaluate incidence and related factors of PTDM 
early after KT in Korea.
Methods: A total of 1,080 recipients were enrolled in KoreaN cohort study for Outcome 
in patients With Kidney Transplantation (KNOW-KT) between July 2012 and August 2016. 
This study included 723 recipients, excluding 273 patients with pretransplant DM and 84 
patients lost of follow-up within 1-year after KT. We evaluated associated factors of PTDM 
within 1-year after KT.
Results: Among the 723 recipients, 85 (11.8%) was diagnosed and treated with PTDM. 
In the univariate logistic regression analysis, pretransplantation variables that showed 
significant associations with PTDM were older recipient age, end-stage renal disease due to 
polycystic kidney disease, smoking history, high body mass index, waist–hip ratio (WHR), 
HbA1C levels, numbers of HLA total and HLA-DR mismatches and lower transferrin 
saturation. Posttransplant variables that were significantly associated with PTDM were high 
WHR, triglyceride/high density lipoprotein ratio, and serum triglyceride levels, low serum 
albumin levels, acute rejection, statin use, and vitamin D replacement. In the multivariate 
logistic regression analysis, predictors of PTDM were older recipient age, high WHR and 
HbA1C before KT, and statin use after KT.
Conclusions: In Korean cohort study, the incidence of PTDM was 11.8%. Risk factors 
for PTDM within 1-year after KT were older recipient age, higher WHR and HbA1C before 
KT. To prevent PTDM, it is important to control the overweight and abdominal obesity 
through life style modification prior to KT.
TH-PO149 Poster Thursday
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Withdrawal of Antihypertensive Medication One Year After Kidney 
Transplantation: Korean Cohort Study for Outcome in Patients with 
Kidney Transplantation (KNOW-KT)
Seungyeup Han,1,2 Seong Sik Kang,1,2 Hayeon Park,1 Jin hyuk Paek,1,2 Sang 
Mok Yeo,1 Woo Yeong Park,1,2 Kyubok Jin,1,2 Sung Bae Park.1,2 KNOW-KT 
Study Group 1Keimyung University School of Medicine, Daegu, Republic of 
Korea; 2Keimyung University Kidney Institute, Daegu, Republic of Korea.
Background: Cardiovascular disease (CVD) is a major cause of graft and patient loss 
in kidney transplant (KT) recipients. Inadequate control of hypertension in KT recipient 
is associated with an increased risk of CVD. Therefore blood pressure control after KT is 
important and it is also important to evaluate the related factors. The purpose of this study 
was to evaluate the incidence and related factors of withdrawing antihypertensive (AH) 
medication early after KT.
Methods: A total of 1,080 patients were enrolled in KoreaN cohort study for Outcome 
in patients With Kidney Transplantation (KNOW-KT) between July 2012 and August 
2016. The study included 857 recipients who had been treated for hypertension prior to KT 
and followed-up for 1-year after KT. We evaluated associated factors of withdrawing AH 
medication within 1-year after KT.
Results: Among 857 the recipients, 278 (32.4%) withdrawn AH medication within 
1-year after KT. The medication withdrawn (MW) group was younger than the medication 
continued (MC) group and the proportion of female, nondiabetic patients, and non-smokers 
were higher. In the pre-transplant evaluation, the MW group had lower systolic blood 
pressure (SBP), body mass index (BMI), triglyceride/high density lipoprotein (TG/HDL)
ratio, and serum TG levels and showed thinner left ventricular posterior wall thickness
(LVPWT) and smaller left atrial diameter in echocardiography. One year after KT, the MW 
group had lower BMI, TG/HDL ratio, and serum TG levels and had a lower incidence of
delayed graft function (DGF), acute rejection (AR), and coronary artery disease (CAD). In 
multivariate logistic regression analysis, predictors of withdrawing AH medication after KT 
were female, lower SBP before KT and thin LVPWT in pre-transplant echocardiography.
Conclusions: In a Korean cohort study, 32.4% of recipients who were treated with 
hypertension before KT stopped AH medication 1-year after KT. For better control of BP 
and prevention of additional administration of AH medication after KT, it is important 
not only to prevent DGF, AR, and CAD after KT, but also to control SBP and prevent 
cardiovascular remodeling before KT.
TH-PO150 Poster Thursday
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New Onset Diabetic Foot Ulcer After Renal Transplantation Increases 
Risk of Transplant Failure
Angelica Sharma,3 Siew Cohen,1 Luigi Gnudi,3,1 Prashanth R. Vas,2 
Janaka J. Karalliedde.3,1 1Guy’s and St Thomas’ NHS Trust, London, United 
Kingdom; 2King’s College Hospital, London, United Kingdom; 3King’s College 
London, UK, London, United Kingdom.
Background: Patients with diabetic kidney disease are at high risk of diabetic 
foot ulcers (DFU). Whether this risk is modified after renal transplant is unclear. There 
is a paucity of information on the burden and risk factors for DFU development after 
transplantation and impact of DFU on renal transplant viabilty.
Methods: We evaluated the incidence and predictors of new onset DFU post renal 
transplant in a single centre retrospective study. Patients who underwent renal transplant for 
diabetic kidney disease between 2004-2016 were evaluated. In total 144 (66% male, 26% 
Type 1, 74% Type 2) diabetic patients were evaluated. Median (range) follow up was 6 (3 
to 13) years. Median (range) age was 62 (28 to 80) years and duration of diabetes 23 (7-60) 
years. Electronic patient medical notes were reviewed.
Results: Over the follow up period 22 (15%) patients developed a new DFU. Patients 
with a DFU were of similar age, body mass index, diabetes duration and had similar pre-
transplant haemoglobin, as compared to those without a DFU. Patents who developed a 
DFU were more likely to have Type 1 than Type 2 diabetes (29% vs. 10%), history of 
peripheral vascular disease (PVD) [32 % vs. 8%], had higher pre-transplant HbA1c, mean ± 
standard deviation (7.5 ±1.2% vs. 6.8±1.4%) and serum creatinine (809±243μmol/l 
vs. 660±202μmol/l) p<0.05 for all. Of the cohort 8 patients had a history of DFU pre-
transplant and all 8 developed a new onset DFU post-transplant. Median (range) duration 
of healing was 5 (1-26) weeks. Nearly 50% of all DFU occurred within the first 1000 days 
post-transplant. Of the 22 cases, 6 needed a minor amputation; no major amputations were 
documented. Mortality was 27.3% in patients with DFU compared to 20.3% without DFU 
p=0.25. Patients with DFU had more than twofold increased risk of transplant failure as 
compared to those without DFU (50% vs 23.3% p=0.02).
Conclusions: Nearly 1 in 7 patients post renal transplant develop a new onset DFU. 
Type 1 diabetes, higher pre-transplant HbA1c, serum creatinine and history of PVD and 
prior DFU are associated with increased risk of new onset DFU post-transplant. DFU 
increases risk of transplant failure nearly twofold. Our results indicate a high burden of 
DFU post-transplant and emphasises the requirement for regular foot surveillance by renal 
and diabetes clinical teams in this high-risk population.
Funding: Government Support - Non-U.S.
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Glucose Metabolism After Renal Transplantation: Oral Glucose Tolerance 
Test-Derived Insulin Release and Insulin Sensitivity Under Tacrolimus 
versus Belatacept-Based Immunosuppression
Manfred Hecking,4 Martin Müller,1 Michael Haidinger,1 Elisabeth Schwaiger,2 
Giovanni Pacini,6 Andrea Tura,5 Johannes Werzowa,1 Marcus D. Saemann.3 
1Medical University of Vienna, Vienna, Austria; 2Medical University Vienna, 
Vienna, Austria; 3Wilhelminen Hospital, Vienna, Austria; 4Medical University of 
Vienna, Nephrology & Dialysis, Vienna, Austria; 5CNR Institu of Neuroscience, 
Padova, Italy; 6Institute of Neuroscience, National Research Council, Padova, 
Italy.
Background: In our previous oral glucose tolerance test (OGTT)-based study 
(PMID23656979), calcineurin inhibitor-treated kidney transplant recipients (KTRs) showed 
lower insulin release but higher insulin sensitivity than non-KTRs. We aimed at refining 
our analysis, using only Tacrolimus-treated KTRs (Tac-KTRs) vs Belatacept-treated KTRs 
(Bela-KTRs) as controls.
Methods: We revisited our database and analysed indices of insulin release and insulin 
sensitivity from OGTTs of 67 Tac- vs 26 Bela-KTRs.
Results: Our center’s outpatient records showed 38 Tac-KTRs vs 0 Bela-KTRs 
among 113 KTRs with treated posttransplant diabetes mellitus. The randomly assigned 
OGTTs among KTRs with unknown glycemic status differed between Tac- vs Bela-
KTRs: 11 vs 0 diabetics (2-h glucose [2-h G] ≥200 mg/dL), 24 vs 2 prediabetics 
(2-h G 140-199) and 32 vs 24 with normal glucose tolerance (NGT) (2-h G <140) [p<0.01]. 
Tac- vs Bela-KTRs with NGT had similar age, body mass index, 0-h and 2-h G, but higher 
HbA1c and insulin sensitivity and lower insulin release (Table and Figure).
Conclusions: In line with our previous study, impaired insulin release was the main 
pathophysiological feature for diabetes development in Tac-KTRs, while Bela-KTRs had 
no impaired glucose metabolism. It is tempting to speculate that impaired insulin secretion, 
due to beta-cell damage, in Tac-KTRs is compensated by increased insulin sensitivity, but 
this mechanism seems more complex and deserves further study.
TH-PO152 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Empagliflozin in Posttransplantation Diabetes Mellitus: Effect on Glucose 
Metabolism and Fluid Volume
Manfred Hecking,1 Elisabeth Schwaiger,1 Lorenzo Signorini,2 Robin Ristl,3 
Andrea Tura,4 Giovanni Pacini,4 Chantal M. Kopecky,1 Marlies Antlanger,1 
Johannes Werzowa,5 Marcus D. Saemann.6 1Medical University of Vienna, 
Nephrology & Dialysis, Vienna, Austria; 2Azienda ospedaliera universitaria 
integrata - ospedale civile di Verona, Sommacampagna, Italy; 3Center for 
Medical Statistics, Informatics and Intelligent Systems, Medical University 
Vienna, Vienna, Austria; 4Institute of Neuroscience, Padova, Italy; 51st Medical 
Department, Hanusch Hospital, Vienna, Austria; 6Wilhelminen Hospital, 
Vienna, Austria.
Background: Empagliflozin decreases cardiovascular morbidity and mortality in type 
2 diabetics, but safety and efficacy in patients with posttransplant diabetes mellitus (PTDM) 
is unknown.
Methods: We conducted a prospective non-inferiority trial, converting stable kidney 
transplant recipients with PTDM from insulin (<40 IU/day) to 10 mg empagliflozin, aiming 
at eliminating exogenous insulin. Oral glucose tolerance tests, fluid volume status and 
adverse events were compared from baseline to 4 weeks after empagliflozin conversion 
(clinicaltrials.gov:NCT03113110).
Results: 14 patients (the required sample size, using change in intra-individual 2-hour 
glucose as primary endpoint) completed the study visits. The primary endpoint was negative 
(p=0.06) but glucose control was clinically inferior after insulin withdrawal (27.2±10.5 
IU/day; Figure & Table). Insulin sensitivity and bioimpedance spectroscopy-derived 
extracellular fluid volume decreased with empagliflozin therapy. No patient developed 
ketoacidosis, 3 had bacterial urinary tract infections (UTIs).
Conclusions: Despite risk of UTIs and moderatly inferior glucose control under 
empagliflozin monotherapy following exogenous insulin therapy, empagliflozin is a 
valuable antidiabetic for PTDM patients which should be studied as add-on therapy. Plasma 
volume contraction might contribute to the cardiovascular risk reduction observed in type 
2 diabetics.
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Cardiovascular Events After Kidney Transplantation: Seven-Year 
Follow-Up of the Vienna Treat-to-Target Trial of Basal Insulin in 
Post-Transplant Hyperglycemia (TIP)
Manfred Hecking,2 David Topitz,1 Marcus D. Saemann.3 1Medical University of 
Vienna, Vienna, Austria; 2Medical University of Vienna, Nephrology & Dialysis, 
Vienna, Austria; 3Wilhelminen Hospital, Vienna, Austria.
Background: In our previous proof-of-concept clinical trial, basal insulin therapy 
early after kidney transplantation significantly reduced the odds of posttransplant diabetes 
mellitus (PTDM) throughout 1 year of follow-up (PMID22343119). We investigated 
whether the occurrence of cardiovascular events (CVEs) differed by insulin therapy, 
respectively by oral glucose tolerance test (OGTT)-derived glycemic status.
Methods: We obtained ethics approval for following up on the Vienna TIP-study 
patients, in order to compare CVEs in those who had received insulin versus standard of 
care control treatment; and in patients with normal glucose tolerance (NGT, 2-hour glucose 
[2-h G] <140 mg/dL), versus in prediabetics (2-h G 140-199) plus diabetics (2-h G ≥200), 
per OGTT-result at 3, 6 and 12 months posttransplantation.
Results: Seven of the original 50 TIP-study patients were lost to follow-up. Occurrence 
of CVEs differed by diabetic status, but not by treatment status (Figure). None of the patients 
with NGT experienced any CVE, but NGT patients were significantly younger (Table).
Conclusions: The present results lead to the hypothesis that PTDM might be a read-out 
for older, potentially sicker patients, and that CVE occurrence might not be modifiable by 
antidiabetic treatment.
TH-PO154 Poster Thursday
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High Incidence of Recurrent Diabetic Nephropathy in Kidney Transplant 
Alone (KTA) Recipients
Aleksandra Kukla,1 Martha Catalina Morales Alvarez,3 Andrew J. Bentall,1 
Mariam P. Alexander,1 Naim S. Issa,2 Walter Park,4 Matthew R. D’Costa,1 
Mark D. Stegall.1 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN; 
3Mount Sinai Beth Israel, Rochester, MN; 4The Mayo Clinic, Rochester, MN.
Background: Improving long-term kidney allograft survival is a major challenge. 
Recurrent diabetic nephropathy (RDN) in kidney transplant recipients is not well studied. 
We aimed to determine the incidence, timing and severity of recurrent diabetic nephropathy 
(RDN) in recipients with pre-transplant type 1 (T1DM) and type 2 diabetes (T2DM).
Methods: We studied 118 diabetic transplant recipients (recs) -T1DM (simultaneous 
kidney pancreas [SPK] and KTA), and T2DM (all KTA) transplanted between 2002 and 
2009. Recs with SPK had functioning pancreas allograft at 5y post transplant. All recs 
underwent surveillance protocol kidney biopsy at 4 months, 1y, 2 y and 5 y post transplant. 
RDN was diagnosed based on light microscopy according to Banff 2015 criteria (MM 
score) and/or as described by pathologist if MM score was not assigned. Advanced RDN 
was diagnosed if MM score was >1. Patients with immune complex diseases were excluded.
Results: We identified 52 T1DM (46% SPK and 54% KTA) and 66 T2DM (all 
KTA) recs. T1DM were younger (47y ± 1.3 vs. 62.1y±1.2 for T2DM; p<0.001). BMI 
was comparable (31.2 T1DM vs. 33.2 T2DM). The earliest RDN was seen at 1 year post 
transplant. At 5 years, the incidence of RDN was only 4.3% in T1DM SPK, compared to 
34% in T1DM with KTA and 46% in T2DM with KTA (p<0.05). BMI was higher in those 
with RDN (34.5 vs 29.9; p<0.05) regardless od diabetes type. 13 (11%) recs developed 
advanced RDN (mm>1) at 5 years. Those recs were more likely to be T2DM (74% vs. 
26% for T2DM and T1DM, respectively, p<0.05). Mean HbA1C in this group at 5 y 
was 8.12%±1.8. Creatinine has not changed over the 5 years post transplant (mean delta 
creatinine 0.03 ± 0.38). Mean albuminuria at 5 y was 52 mg/24h ± 345. 7 (53 %) of recs 
with advanced RDN did not have significant albuminuria at 5 years (30 mg/24 h or less).
Conclusions: Histologic changes of RDN can be seen as early as 1 year post kidney 
transplant and have high incidence at 5 years. HIgh BMI is a risk factor. Pancreas 
transplantation is associated with histological protection. Advanced RDN is significantly 
more common in T2DM recipients and may be clinically silent. Future studies should focus 
on identifying risk factors for RDN, its impact on graft survival and development of better 
noninvasive biomarkers of histologic injury.
TH-PO155 Poster Thursday
Transplantation: Cardiovascular and Metabolic Diseases
Liraglutide May Be Safe After Kidney Transplantation
Nizar M. Attallah,1 Lina Yassine.2 1Cleveland Clinic Abu Dhabi, Abu Dhabi, 
United Arab Emirates; 2Imperial College of London Diabetes Center Abu 
Dhabi, Abu Dhabi, United Arab Emirates.
Background: Kidney transplant has offered better outcomes for patients with end stage 
renal disease (ESRD). Diabetes is a common comorbidity in patients with renal transplants 
which requires treatment. Diabetes is the most common cause of ESRD. Patients could 
develop post-transplant DM (PTDM), or have pre-existing diabetes mellitus. Management 
of DM after transplant (whether the patient had it from before or after the transplant) is 
challenging. Different medications could be used to manage PTDM. Those medications 
have good safety and efficacy record in the general population and patients with mild 
degrees of kidney disease.
Methods: We conducted a retrospective single center analysis of safety and efficacy of 
Liraglitude after kidney transplant. The study was approved by institutional review board. 
We collected data (demographics, laboratory tests and any symptoms or hospitalizations) 
for 32 consecutive patients for 18 months.
Results: All 32 patients received subcutaneous Liraglitude at an average of 1.2 mg/day 
throughout the study period. Patients’ average age was 64. 18 were females and all from 
Middle Eastern decent and had kidney transplant on average 32 months when they were 
included in the study. 13 patients had DM before the transplant and the rest had PTDM. 
15 patients were on metformin and 10 were on insulin while the rest were not on any other 
medications. Average baseline creatinine was 1.2 mg/dL (106.3 mmol/L) and glycated 
hemoglobin (HbA1c) of 8.4 g/dL while creatinine was 1.1 mg/dL (97.5 mmol/L) and 
HbA1c was 7.2 g/dL at the end. HbA1c dropped 1.2 on average within 6 weeks of initiating 
Liraglitude and was maintained for the rest of the study. Urine protein did not change 
significantly throughout the study. One patient developed acute myocardial infarction 
during the study and another patient was hospitalized with acute pancreatitis. A third 
patient developed an opportunistic infection. Ten patients developed nausea and vomiting 
following the initiation of Liraglitude but that resolved 4 weeks later with lowering the dose. 
No allergic reactions or hypoglycemia episodes were reported. The average weight dropped 
2.4 kg during the study and body mass index changed from 28.6 to 27.8. Only one patient 
stopped the medication due to acute pancreatitis.
Conclusions: In this retrospective analysis, Liraglitude seems to be safe and efficacious 
after kidney transplant. It can be considered to manage DM after transplant.
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Linagliptin May Be Safe After Kidney Transplant
Nizar M. Attallah,1 Lina Yassine.2 1Cleveland Clinic Abu Dhabi, Abu Dhabi, 
United Arab Emirates; 2Imperial College of London Diabetes Center Abu 
Dhabi, Abu Dhabi, United Arab Emirates.
Background: The incidence and prevalence of end-stage renal disease (ESRD) 
is increasing. The most common cause of ESRD is diabetes mellitus (DM). Kidney 
transplantation offers better quality of life and survival for patients with ESRD. Patients 
could develop post-transplant DM (PTDM). Management of DM after transplantation 
(whether the patient had it from before or after the transplant) is a challenge. Different 
medications could be used to manage PTDM. Those medications have good safety and 
efficacy record in general population and patients with mild degrees of kidney disease.
Methods: We conducted a retrospective single center analysis of safety and efficacy 
of Linagliptin post kidney transplantation. The study was approved by institutional 
review board. We collected data (demographics, laboratory tests and any symptoms or 
hospitalizations) for 28 consecutive patients for 16 months.
Results: All 28 patients were initiated on Linagliptin throughout the study period. 
Patients’ average age was 62. Fifteen were females and all from Middle Eastern decent 
and had kidney transplant on average of 25 months when they were included in the study. 
Twelve patients had DM before the transplant and the rest had PTDM. 13 patients were on 
metformin and 8 were on insulin while the rest were not on any other medications at the 
start of the study. Baseline average creatinine was 1.5 mg/dL (132.9 mmol/L) and glycated 
hemoglobin (HbA1c) of 8.2 g/dL at the start of the study while creatinine was 1.6 mg/
dL (141.8 mmol/L) and HbA1c was 7.4 g/dL at the end. HbA1c dropped 0.8 on average 
within 5 weeks of starting Linagliptin and was maintained at the same level for the rest of 
the study. Urine protein did not change significantly throughout the study. Two patients 
developed acute myocardial infarction during the study and a third patient was hospitalized 
with an opportunistic infection. Two patients had urinary tract infections. 3 patients had 
nausea and vomiting after starting Linagliptin but that resolved 2 weeks later. No allergic 
reactions, hypoglycemia or acute pancreatitis episodes were reported. The average weight 
and body mass index did not change throughout the study. None of the patients stopped the 
medication.
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Conclusions: In this retrospective analysis, Linagliptin seems to be safe and efficacious 
after kidney transplantation. It can be considered in the management of diabetes post kidney 
transplantation.
TH-PO157 Poster Thursday
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Serum Bicarbonate Levels Are Associated with Graft Survival and 
Mortality in Swiss Kidney Transplant Recipients
Anna Wiegand,1 Sandar F. Lim,2 Rudolf P. Wuthrich,1 Leonhard Held,2 
Nilufar Mohebbi.1 1Division of Nephrology, University Hospital Zürich, Zürich, 
Switzerland; 2Epidemiology, Biostatistics and Prevention Institute, University of 
Zurich, Zurich, Switzerland.
Background: Metabolic acidosis (MA) is a frequent complication of chronic kidney 
disease (CKD) and an independent risk factor for kidney disease progression. MA is also 
highly prevalent after kidney transplantation (12%-58%). A recent study has shown that 
MA after kidney transplantation was associated with increased risk of graft loss and death 
indicating an impact of MA on long-term graft function. However, the cohort had a fairly 
low prevalence of MA. Also a cut-off value for bicarbonate of 22 mEq/L, as commonly 
used for the definition of MA, may be questionable since kidney outcome and mortality 
have been shown to correlate best with TCO2 values of 24-28 mEq/L. Thus, we wanted to 
investigate if serum bicarbonate is associated with graft outcome and mortality in Swiss 
kidney transplant recipients (KTRs).
Methods: We performed a single-center retrospective study including adult (≥ 18 
years) patients that have been subjected to de novo kidney transplantation between 1999 and 
2015. Cox proportional hazard model was used to analyze a possible association between 
time-dependent serum bicarbonate measurements and graft loss (defined as re-entry to 
dialysis or second kidney transplantation) or death
Results: 430 KTRs were included in the analysis with a mean age of 50.9±13.4 
years. Mean observation time was 4.7±2.8 years. 284 (66%) were male and 318 (74%) 
had received a deceased donor kidney transplant. Mean bicarbonate and eGFR levels one 
year post-transplant were 22.7±3.1 mmol/L and 61±26 ml/min, respectively. Prevalence of 
MA (defined as bicarbonate <22 mmol/L) was 51.2% after transplantation and decreased 
to 30.8% one year post-transplant. 14 (3%) patients died and 31 (7%) suffered from graft 
failure. Higher bicarbonate levels were associated with significantly lower hazards for graft 
failure (HR=0.88; 95% CI, 0.79-0.98; p=0.022) and mortality (HR=0.79; 95% CI, 0.66-
0.93; p=0.006) after adjusting for potential confounders such as age, type of donor and 
time-varying eGFR.
Conclusions: Our analysis showed that higher serum bicarbonate levels are associated 
with long-term graft and patient survival in Swiss KTRs. Thus, serum bicarbonate may 
serve as a predictor for graft and patient outcome after kidney transplantation as has been 
previously shown for patients with CKD.
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Prevalence of Gout in the Surviving US Solid Organ Transplant 
Population
Mark D. Brigham,1 Thilan Tudor,1 Gavin Miyasato,1 Jeffrey Kent,2 
Brian Lamoreaux,2 Richard J. Johnson.3 1Trinity Partners, Waltham, MA; 2Horizon 
Pharma, Lake Forest, IL; 3University of Colorado Denver, Aurora, CO.
Background: Although incidence and survival are frequent topics within the solid 
organ transplant (SOT) literature, there are no recent publications on the total size of the 
surviving SOT population. Existing studies of gout in SOT have focused on the incident 
SOT population. This analysis was performed to characterize the prevalent SOT population 
and the prevalence of gout within it.
Methods: 2017 U.S. population sizes of kidney, heart, liver, and lung recipients were 
estimated by combining Organ Procurement and Transplantation Network (OPTN) primary 
transplant cohort sizes (1988-2017) with previously published survival rates for each annual 
cohort’s time since transplant (0-29 yrs), adjusted for recent improvements in 1-5 yr survival. 
Gout among prevalent SOT patients was assessed via 2 administrative claims databases: 
Medicare Fee-For-Service Limited Data Set (5% sample) and a commercial claims sample 
(IQVIATM Real-World Data Adjudicated Claims – US). Definitions used were – SOT: a 
claim with an SOT procedure code OR any claim with a history of SOT status code; Gout: 
≥1 claim with any gout diagnosis code. Total gout prevalence was calculated by weighting 
Medicare and commercially insured patient estimates by OPTN payer distribution.
Results: 637,231 U.S. patients received a primary kidney (393,953), liver (142,186), 
heart (66,637), or lung (34,455) transplant between 1988 and 2017. An estimated 355,000 
(55.8%) recipients were alive in 2017, comprising nearly two-thirds (233,000) kidney, as 
well as 78,700 liver, 29,300 heart, and 14,700 lung recipients. Gout was identified in 11% 
of prevalent SOT patients in 2016. Higher rates of gout were seen in kidney (13%) and 
heart (13%) recipients compared to liver (6.4%) and lung (5.3%) recipients (p<0.0001 in 
both datasets).
Conclusions: Hundreds of thousands of U.S. patients are living with an organ transplant 
today and these numbers are likely to increase. Within the SOT clinical picture, gout is a 
frequent co-morbidity of which physicians should be aware. This study suggests a markedly 
higher rate of gout for the most common SOT types (11%) compared to established rates 
reported for the general population (e.g. 3.9%). Kidney recipients, with the largest surviving 
population and high rates of gout, bear much of this disease burden.
Funding: Commercial Support - Horizon Pharma
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Gout Severity in Kidney Transplant Recipients
Lauren Radeck,1 Clive M. Mendonca,1 Isabel Lang,1 Jeffrey Kent,2 
Brian Lamoreaux,2 Richard J. Johnson.3 1Trinity Partners, Waltham, MA; 2Horizon 
Pharma, Lake Forest, IL; 3University of Colorado Denver, Aurora, CO.
Background: Gout is a frequent co-morbidity of solid organ transplant (SOT), 
especially among kidney recipients. Less well understood are any differences in gout 
severity and treatment success between gout patients with and without SOT. This 
retrospective analysis of medical patient chart data was performed to compare disease 
severity and treatment history in recent gout case examples with vs. without a history of 
kidney transplant.
Methods: An online survey was completed using a panel of board certified U.S. 
nephrologists. Respondents were asked to pull de-identified patient charts for their 3 
most recent gout patients. Measures evaluated included: SUA level, numbers of swollen/
tender joints (at visit), visible tophi (at visit), gout flare events (prior 12 months), gout drug 
treatment history, and presence of “severe, uncontrolled gout” defined as: SUA ≥7.0 mg/dL, 
1 or more visible tophi AND 2 or more gout flares, and history of xanthine oxidase inhibitor 
treatment. Case examples were weighted by number of visits in last 12 months and 
respondents’ overall gout treatment volume.
Results: 23 out of 299 (7.7%) Rx-treated patients had a history of kidney transplant 
(N=104 nephrologist respondents). Compared to non-SOT patients, SOT patients were 
more likely to meet severe uncontrolled gout criteria (25% vs. 7%, p<0.05). Univariate 
analysis found that SOT patients, compared to non-SOT patients had: higher prevalence 
of visible tophi (32% vs. 13%, p<0.01), lower allopurinol treatment rates (28% vs. 50%, 
p<0.05), and higher rates of failure or contraindication to febuxostat (22% vs. 4%, p<0.01).
Conclusions: This study provides preliminary evidence that gout is more severe 
and poses more challenges for pharmacologic management in kidney transplant patients 
compared to other nephrology gout patients. Although gout has been linked to a higher 
all-cause mortality rate among kidney recipients in the literature, to our knowledge 
there are no published comparisons of gout severity among such patients vs. the general 
nephrology patient population. Further investigation of symptom severity and unmet need 
in appropriate, effective treatment options in transplant recipients with gout is warranted.
Funding: Commercial Support - Horizon Pharma
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Immunosuppressant Use and Gout in the Prevalent Solid Organ 
Transplant Population
Andrew Milgroom,1 Mara Onita Lenco,1 Kevin Francis,1 Jeffrey Kent,2 
Brian Lamoreaux,2 Richard J. Johnson.3 1Trinity Partners, Waltham, MA; 2Horizon 
Pharma, Lake Forest, IL; 3University of Colorado Denver, Aurora, CO.
Background: Gout is a frequent co-morbidity of solid organ transplant (SOT). 
Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as other 
immunosuppressant (IS) regimens were associated with lower gout rates (e.g. 1980s studies 
of azathioprine monotherapy). In most guidelines & institutions, tacrolimus (TAC) has 
replaced CsA in SOT IS regimens. However, two questions are largely unknown: (1) to 
what degree is CsA still used among prevalent SOT patients? (2) can CsA fully explain high 
rates of gout still seen among SOT patients? This retrospective patient claims data analysis 
was performed to evaluate IS use and gout in the prevalent SOT population.
Methods: IS regimens and gout prevalence among prevalent SOT patients were 
assessed via commercial claims data (IQVIATM Real-World Data Adjudicated Claims – 
US). Definitions used were – SOT: claim with an SOT procedure code OR any claim with 
a history of SOT status code; IS: ≥1 claim for a given IS drug in the calendar year; Gout: 
≥1 claim with any gout diagnosis code. IS use at time of transplant for 2016 recipients was
obtained from the Organ Procurement and Transplantation Network (OPTN).
Results: The proportion of prevalent SOT patients on CsA declined from 2012 to 2016: 
heart 22% to 18%, kidney 21% to 17%, lung 16% to 11%, liver 15% to 12% (all p<0.01). 
TAC use increased: heart 66% to 73%, kidney 67% to 74%, lung 75% to 80%, liver 77% 
to 82% (all p<0.01). CsA use was higher in prevalent vs. incident SOT populations (e.g. 
17% vs. 1.7% kidney 2016, p<0.0001). 2016 gout prevalence was 16% vs. 8% among CsA 
vs. non-CsA patients. Among all SOT patients with gout, 69% and 26% were on TAC and 
CsA, respectively.
Conclusions: Despite declining CsA use, gout remains a problem in SOT patients. For 
one, this study finds that many prevalent SOT patients still receive CsA. Additionally, gout 
prevalence in the non-CsA population was much higher (8%) than established rates reported 
in the general population (e.g. 3.9%). This suggests CsA is not the sole driver of gout in 
SOT. In fact, this analysis finds that post SOT, more than twice as many gout sufferers 
are on TAC than on CsA. Physicians should be aware that with any transplant IS regimen 
including calcineurin inhibitors, gout is likely to remain a frequent co-morbidity of SOT.
Funding: Commercial Support - Horizon Pharma
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Role of Coronary Interventions in High Cardiovascular Risk Patients on 
Kidney Transplant Waitlist
Bayiha daho Klaud francheska, Maria Fernandez, Ahmad Salha, 
Racquel M. Lowe-Jones, Debasish Banerjee. St George’s University Hospitals 
NHS Foundation Trust, London, United Kingdom.
Background: High cardiovascular risk patients on the kidney transplant list 
often undergo cardiac interventions to improve their outcome and survival following 
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transplantation. However the benefits of these interventions are currently unknown and 
were explored in this study.
Methods: The study, approved by hospital Clinical Effectiveness and Audits Committee, 
included 164 episodes in 126 patients discussed in discussed in a multidisciplinary cardio-
renal MDT, between 1-10-2014 to 30-09-2017 and followed until 23-05-2018.
Results: 126 patients were discussed in the multidisciplinary meeting, some more 
one than once. Clinical characteristics of the 164 patient episodes were; age 61±8years, 
BMI 28±5kg/m2, cholesterol 4.0±1.1mmol/L, 61% diabetes, 96% hypertension, 63% 
haemodialysis and 27% pre-dialysis. After discussion 96 cardiac procedures were suggested 
and performed, including stress echocardiogram (68%), echocardiogram (9%), coronary 
angiogram (13%), percutaneous coronary intervention (4%), and coronary artery bypass 
graft (4%). The non-invasive tests resulted in further 19 angiograms, 10 PCI and 1 CABG. 
Thirty-five percent of patients had no cardiac intervention performed; 44% had a single 
intervention and 21% had multiple interventions. 28 patients had an event (death, ACS or 
stroke) during follow-up, who were more likely to be diabetic, the clinical characteristics 
are in table 1. 37% (n= 13) of patients who had invasive cardiac intervention developed an 
event, while 16% (n=7) of patients who did not receive any cardiac tests or intervention 
developed an event (p=0.246). Of the 91 patients who did not have invasive procedures, 
only 15 (16%) had an event as opposed to 13 (37%) in the remaining cohort who had 
invasive procedures done (Figure 1).
Conclusions: Out of 126, events occurred in 28 patients, mainly cardiovascular. 
Cardiac interventions including angiograms, CI or CABG were unable to lower the CV 
event rate in high-risk patients on transplant waitlist..
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Non-Skeletal Effects of High Doses Versus Minimum Recommended 
Intake of Vitamin D3 in Renal Transplant Recipients in a Prospective, 
Multicenter, Double-Blind, Randomized Study
Marie Courbebaisse,1,2 Sandra Colas,3 Rebecca Sberro-Soussan,4,2 Valerie Moal,11 
Yannick Le Meur,7 Nassim Kamar,5 Laetitia Albano,10 Antoine Thierry,15 
Jacques Dantal,9 Julien Allard,6 Karine Moreau,8 Corinne Alberti,13,14 
Eric Thervet.12,2 1European Georges Pompidou Hospital, APHP, Paris, France; 
2Paris Descartes University, Paris, France; 3URC/CIC Necker-Cochin, Paris, 
France; 4Necker Hospital, APHP, PARIS, France; 5Toulouse University 
Hospital, Toulouse, France; 6University Hospital Limoges, LImoges, France; 
7University Hospital, Brest, Brest, France; 8Pellegrin Hospital, Bordeaux, 
France; 9Institut de Transplantation Urologie Néphrologie, Nantes, France; 
10Hôpital Pasteur CHU de Nice, Nice, France; 11Assistance Publique Hopitaux 
de Marseille, Marseille, France; 12European Georges Pompidou Hospital, 
APHP, Paris, France; 13Robert Debré Hospital, Paris, France; 14Paris-Diderot 
University, Paris, France; 15CHU La Miletrie, Poitiers, France.
Background: High doses of vitamin D3 (cholecalciferol, CL) have been advocated 
to reduce the risk of diabetes mellitus (DM), major cardiovascular events (MACE), and 
cancer, which are frequent complications in renal transplant recipients (RTR).
Methods: The VITALE study is a prospective, multicenter (30 French transplantation 
departments), double-blind, controlled trial (NCT01431430). Adult RTR with serum 
25(OH)-vitamin D levels (25OHD) <30 ng/mL, were randomized between 12 and 48 
months after transplantation to receive either high doses (HD, 100,000 IU) or low doses 
(LD, 12,000 IU corresponding to the minimum recommended intake, MRI) of CL every 
2 weeks for 2 months then monthly for 22 months. The primary objective was to evaluate 
the effect of HD vs LD on a composite endpoint: DM, MACE, de novo cancer, and patient 
death. The sample size calculation was based on the assumption of an incidence of a first 
event of the composite endpoint of 22% in the LD group versus 13% in the HD group. The 
inclusion of a total of 480 RTR was required to test this hypothesis with a power of 80%.
Results: Between January 2012 and December 2013, 536 RTR (mean (SD) age 50.8 
(13.7) years, 335 males) were included. Baseline clinical and biological characteristics did 
not differ between HD (n=269) and LD (n=267) groups. In the HD and the LD group, 25OHD 
was 20.2 (8.1) vs 19.2 (7.0) ng/mL at D0 and 43.1 (12.8) vs 25.1 (7.4) ng/mL after 24 months 
(<0.0001). The intention to treat analysis showed that the number of events of the composite 
endpoint did not differ between HD and LD groups (15% vs 16%, respectively). There was 
also no difference for infections (51% vs 47%), acute rejection episodes (3% vs 2%) and 
graft loss (0.37% in both groups). The number of patients with incident hypercalcemia or 
hyperphosphatemia did not differ between groups (17% vs 13%, p=0.24, and 5% vs 4%, 
p=0.41, in HD and LD group respectively). Of note, evolution of valvular calcifications was 
not significantly different between groups (p= 0.59).
Conclusions: In conclusion, HD of CL are well-tolerated but do not reduce the 
incidence of non-skeletal complications in RTR when compared to the MRI.
Funding: Commercial Support - Crinex Laboratory (France), Government Support - 
Non-U.S.
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A Prospective Observational Study Comparing Bone Loss in Renal 
Transplant and Dialysis Patients
Waleed Hassan, Maria Yaseen, Hasan Ashqar, Amr E. Mohamed, Conor Lowry, 
Roberto Gedaly, Daniel Davenport, Florence Lima, Hartmut H. Malluche. 
University of Kentucky, Lexington, KY.
Background: Bone loss has been reported with chronic dialysis and after renal 
transplantation. This study compared the differences in longitudinal changes in BMD 
between dialysis and transplant patients using quantitative computed tomography (QCT).
Methods: Total hip BMD was assessed using QCT in 29 renal transplant recipients 
at the time of transplantation, at 6 months (n=25), and at 12 months (n=19). In addition 50 
dialysis patients of similar gender, age, race, dialysis vintage, diabetes, non-smoking status, 
coronary artery disease, and exercise were studied. BMD at baseline and after 12 months 
was compared between the two groups.
Results: In transplant patients, total hip BMD by QCT decreased from a mean of 
0.88 g/mm3 at time of transplantation to 0.83 g/mm3 at 6 months after transplant, then 
stabilized at 0.83 g/mm3 at 12 months for an average loss of 0.05 ± SE 0.02 g/mm3 (fig. 1). 
While the average dialysis patient lost 0.02 ± SE 0.01 g/mm3 of BMD at the hip over 12 
months (p= 0.07, Figure 2). The average bone loss was higher for transplant patients with 
normal baseline BMD compared to patients with low BMD (Normal: -0.05 g/mm3; Low: 
-0.02, p=0.314).
Conclusions: Significant bone loss occurs in renal transplant recipients during the first 
6 months then stabilized at 12 months. This bone loss is more than what is observed in
matched dialysis patients. Normal BMD is still of concern because bone loss may be higher 
compared to patients with low BMD.
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Association of Post-Transplant Calcium and Phosphate Levels with Graft 
Outcomes
Julio L. Chevarria,1 Donal J. Sexton,2 Chaudhry Adeel Ebad,1 Claire Kennedy,1 
Susan L. Murray,1 Peter J. Conlon.3 1Beaumont Hospital, Dublin, Ireland; 2The 
Irish Longitudinal Study on Ageing (TILDA), Trinity College Dublin., Dublin, 
Ireland; 3Beaumont Hospital, Dublin 9, Co Dublin, Ireland.
Background: Alterations in Ca and P are observed with varying impact on post-
transplant outcomes and its implications in graft function are unclear. Our study assesses 
the relation between serum P and Ca during the first year and graft outcomes
Methods: Longitudinal single centre cohort study, we analyse 1524 first transplants, 
since 1991 to 2016. Our data was prospectively collected in the national kidney transplant 
registry. The primary outcome was graft failure and association with P and Ca on first 
year. We include patients >18 years and immunosuppression MMF + CNI + steroids. We 
categorized the P and Ca as low, normal or high. The analysis include Kaplan Meier and 
cox regression
Results: The age was 47.9 y (SD13.9), donor age 43.2 (SD13.3), 64.4% male, 59% 
HD, 29.5% PD, and 10.1% pre emptied, HLA mean 3.35 (SD1.5), time to fail 8.2 y (SD5.0), 
297 grafts failed (18.4%), 85.1% has P<0.7 mmol/L the first year 0.52 (SD0.15), reached at 
26.9 (SD46) days, 35.9% Ca >2.6 mmol/L, reached at 74.7 (85.9) days. The KM analysis 
show increase graft failure with low P or Ca pre transplant (p:0.03), better outcomes with 
low P at 1, 6 and 12 m (p:0.014, 0.04, 0.004), and high Ca at 1 month, but not so at 6 and 12 
m (p:0.03, 0.7 and 0.6). Cox regression show HR 0.60; 95% CI 0.29 to 1.26 with low P and 
HR 0.71; 95% CI 0.52 to 0.98 with high Ca for graft failure
Conclusions: The derangements in Ca and P are frequent post transplant and develop 
the first months. The post transplant hypercalcemia is associated with better graft outcomes 
however the hypophosphatemia not. Futures trials will investigate if the treatment of these 
conditions would be a risk factor in these patients
Cox regresion model for High Calcium at 1st month
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Effects of Denosumab on Bone Metabolism and Bone Mineral Density in 
Kidney Transplant Patients: A Meta-Analysis
Prakrati C. Acharya,1 Charat Thongprayoon,2 Aldo E. Torres Ortiz,1 Maria 
Lourdes Gonzalez Suarez,1 Wisit Cheungpasitporn.1 1University of Mississippi 
Medical Center, Ridgeland, MS; 2Bassett Medical Center, Cooperstown, NY.
Background: The uses of immunosuppressive agents, are associated with increased 
risks of bone loss in kidney transplant (KTx) patients. Denosumab, a potent anti-resorptive 
agent, has been shown to increase bone mineral density (BMD) in patients with CKD. 
However, its effects on bone metabolism and BMD in KTx patients remain unclear.
Methods: A literature search was conducted using MEDLINE, EMBASE and 
Cochrane Database from inception through April 2018 to identify studies evaluating 
the effects of denosumab on changes in bone metabolism and BMD from baseline to 
post-treatment course in KTx patients. Study results were pooled and analyzed using a 
random effects model. The protocol for this meta-analysis is registered with PROSPERO 
(CRD42018095055).
Results: 5 studies (a clinical trial and 4 cohort studies) with a total of 162 KTx patients 
were identified. Majority of patients had baseline eGFR ≥ 30 mL/min/1.73 m2. After the 
treatment (≥6 to 12 months), there were significant increases in BMD with standardized 
mean differences (SMDs) of 3.26 (95%CI 0.88-5.64) and 1.83 (95%CI 0.43 to 3.22) for 
lumbar spine and femoral neck, respectively. There were also significant increases in T 
scores with SMDs of 0.92 (95%CI 0.58 to 1.25) and 1.14 (95%CI 0.17 to 2.10) for lumbar 
spine and femoral neck, respectively. There were no significant changes in serum Ca or PTH 
from baseline to post-treatment course (≥ 6 months) with mean differences (MDs) of 0.52 
(95%CI, -0.13 to 1.16) mmol/L and -13.24 (95% CI, -43.85 to 17.37) ng/L, respectively. 
Data from a clinical trial demonstrated that asymptomatic hypocalcemia occurred more 
common in denosumab group (12 episodes in 39 patients) than in control (1 episode in 42 
patients). From cohort studies, the pooled incidence of hypocalcemia following denosumab 
treatment was 1.7% (95%CI 0.4% to 6.6%). All reported hypocalcemic episodes were mild 
and asymptomatic, but majority of patients required Ca and Vit D supplements.
Conclusions: Among KTX patients with good allograft function, denosumab 
effectively increases BMD and T scores in the lumbar spine and femur neck. From 
baseline to post-treatment, there are no differences in serum Ca and PTH. However, mild 
hypocalcemia can occur following denosumab treatment, requiring monitoring and titration 
of Ca and Vit D supplements.
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Safety and Efficacy of Patiromer in Kidney and Liver Transplant 
Recipients
Rickinder Grewal, Akram Audi, Jeremy G. Taylor, Jennifer I. Melaragno, 
David M. Dewolfe. University of Rochester Medical Center, Rochester, NY.
Background: Patiromer has been FDA approved for the management of chronic 
hyperkalemia, however, there is a paucity of data regarding its safety and efficacy in 
transplant recipients.
Methods: We retrospectively reviewed the use of patiromer in 16 transplant recipients 
at our center from 2016 to 2018 including 9 Kidney, 6 Liver, and 1 Kidney after Liver 
recipients. Patiromer was given mid-day, separated from immune suppression medications 
by 3 hours. It was started a median of 24 (8-548) days (d) post-transplant and used for a 
median of 44 (1-160) d. Maximum dose used was 8.4 g/d in 7, 16.8 g/d in 6, and 25.2 g/d in 
3 patients. In 5 (31.3%) patients, patiromer was added to other therapies for hyperkalemia: 
fludrocortisone in 3, diuretics in 3, and discontinuation of sulfamethoxazole/trimethoprim 
in 2 for an alternative agent.
Results: Mean serum K decreased (Fig. 1A) though serum Cr did not change (Fig. 1B). 
Patiromer did not appear to interfere with tacrolimus absorption as 13 (81.3%) patients were 
within goal tacrolimus trough range 1 week after starting patiromer and no change in mean 
tacrolimus troughs was seen (Fig. 1C). Serum magnesium decreased from initiation to 1 
week later but post-initiation levels were not different from pre-initiation levels (Fig. 1D). 
10 (62.5%) patients required magnesium repletion. There were no adverse events attributed 
to patiromer and no observed episodes of rejection. 1 patient stopped patiromer due to 
intolerance, but later resumed the medication without issue. 3 patients were readmitted 
with hyperkalemia: 1 in the setting of AKI, 1 after self-discontinuing patiromer, and 1 after 
provider-instructed dose reduction.
Conclusions: In this observational cohort, patiromer appears to be both safe and 
effective for treating hyperkalemia in kidney and liver transplant recipients.
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Potential Beneficial Association of Renin-Angiotensin-Aldosterone-System 
Blockade and Graft Prognosis in Allograft IgA Nephropathy
Sehoon Park,1 Chung Hee Baek,2 Hyunjeong Cho,3 Mi-yeon Yu,4 Yong 
Chul Kim,5 Jung Pyo Lee,6 Yon Su Kim,7 Su-Kil Park,2 Curie Ahn,1 Hajeong Lee.7 
1Seoul National University Hospital, Jongno-gu, Seoul, Republic of Korea; 
2Asan Medical Center, Songpa-gu, seoul, Republic of Korea; 3Chungbuk 
National University Hospital, Cheongju-si, Chungcheongbuk-do, Republic of 
Korea; 4Seoul National University, Jong-no gu, Republic of Korea; 5SNUH, 
Seoul, Republic of Korea; 6Seoul National University Boramae Medical Center, 
Seoul, Republic of Korea; 7Seoul National University College of Medicine, 
Seoul, Republic of Korea.
Background: Clinical evidence supporting suggestions of using renin-angiotensin-
aldosterone-system blockades (RAASB) for proteinuric recurrent glomerulonephritis after 
renal transplant was scarce. For allograft IgA nephropathy (IgAN), benefits of RAASB for 
graft prognosis remained controversial although the medication is consisting the mainstay 
for treatment of native IgAN.
Methods: We performed a bi-center retrospective cohort study on kidney transplant 
recipients diagnosed for IgAN in allograft biopsy. The included patients were stratified 
according to their prescribed maintenance hypertensive medication types within 6 months 
from their diagnosis. Patients those had follow-up duration less than 6 months were not 
considered in the analysis. The main outcome was 5-year death-censored-graft-failure 
(DCGF). Additional adjustment for other variables including presence of acute rejection or 
time-averaged eGFR after 3 months from diagnosis of allograft IgAN was performed, as 
clinicians may prescribe RAASB to those who were at stable allograft function.
Results: Among 558 patients with allograft IgAN, there were 38 patients who only 
received RAASB, and 33 patients who received single agent of CCB or BB. The other 121 
patients were prescribed for other medications, mostly combination therapies. The RAASB 
group had relatively higher eGFR at the time of diagnosis for allograft IgAN but had higher 
degree of albuminuria and worse pathologic findings. The group of patients who received 
single antihypertensive agent other than RAASB (calcium channel blockers (CCB) or beta 
blockers (BB)) had significantly increased risk of DCGF (adjusted HR 2.68, 95% CI 1.08-
6.67, P=0.03) than those who received single RAASB agent, and this was also similar in 
patients who received multiple antihypertensive medications (adjusted HR 2.20, 95% CI 
1.02-4.74, P=0.04). In addition, this possible beneficial association of RAASB usage and 
graft prognosis was more prominent in patients who had albuminuria at the time of allograft 
IgAN diagnosis.
Conclusions: Usage of RAASB during the time of allograft IgAN diagnosis was 
associated with better prognosis compared with using other antihypertensive drugs. Our 
study is one of evidences encouraging the usage of RAASB in allograft IgAN patients.
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Background: In chronic kidney disease, intensive systolic blood pressure (SBP) control 
reduces mortality, but increases rate of estimated glomerular filtration (eGFR) decline and 
acute kidney injury risk. The optimal blood pressure target in KTRs is uncertain. Prior 
observational studies from FAVORIT demonstrate lower mortality at lower SBP levels, but 
the relationship of SBP with kidney allograft function is largely unknown. We investigated 
the relationship of baseline SBP with risk of kidney allograft failure and eGFR slope during 
long-term follow-up among stable KTRs.
Methods: The FAVORIT trial, a multicenter, double-blind, randomized trial examining 
the effect of B-vitamin therapy on CVD and mortality, recruited KTRs who were at least 6 
months post-transplant. SBP was measured at baseline, and subsequent eGFR values and 
kidney failure events were assessed. Cox proportional hazards and multivariable linear 
regression models were used to determine association of SBP with time to ≥50% eGFR 
decline or dialysis dependence, and annualized eGFR decline, respectively. Restricted cubic 
spline plots were developed to evaluate the functional form of the relationships. Models 
were adjusted for demographics, transplant characteristics, baseline eGFR, urine ACR and 
comorbidities.
Results: Among 3,598 KTRs, mean age was 52±9 years, mean baseline SBP was 
136±20 mmHg and mean eGFR was 49±18 ml/min/1.73m2. There were 369 ≥50% eGFR 
decline or dialysis dependence events during mean follow-up of 4.0±1.5 years. The 
relationships of SBP with both ≥50% eGFR decline or dialysis (SBP: Pnonlinearity = 0.2) and 
annualized eGFR slope (SBP: Pnonlinearity = 0.8) were linear without evidence of J or U shaped 
relationships (figure).
Conclusions: In a large sample of stable KTRs, we found no evidence of threshold at 
which lower baseline SBP was related to higher risk of eGFR decline. While reassuring in 
light of prior findings of mortality benefit at lower SBP, future trials are required to establish 
optimal BP targets in KTRs.
Funding: NIDDK Support
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Background: Dyslipidemia is common in renal transplant recipients(RTRs). Recent 
studies have shown that TG/HDL-C ratio may be a better predictor of cardiovascular(CV) 
events and CV mortality than other lipid parameters. We analyzed the TG/HDL of the first 
year of transplantation to identify the risk factors for major cardiovascular events(MACE). 
MACE was defined as heart failure, coronary artery disease with percutaneous coronary 
artery intervention(PCI), and cerebrovascular disease confirmed as an imaging study.
Methods: We retrospectively included 1301 RTRs who had lipid profile after 1 year of 
transplantation between 2000-2018. We identified TG/HDL from the lipid profile at 1 year 
and classified it into 3 groups as follows: low; less than 1, moderate; 1 to 2.5, high; 2.5 or 
more. After then, we explored an association between TG/HDL group and MACE.
Results: The mean age of included patients was 40.9 years and male sex was 61.7%. 
The prevalence of diabetes was 29.1%. Statin was prescribed in 30.3% of RTRs within 1 
year after transplantation. RTRs with higher TG/HDL tended to be more men, more obese 
and diabetic. Proportion receiving statin was lowest in moderate TG/HDL group. During 
follow-up, 80 patients experienced MACE. Time to MACE occurrence was 92.7 month. As 
expected high TG/HDL group showed elevated MACE risk even after adjustment with age, 
sex, BMI, DM, prior history of CVD, and statin use (adjusted HR 1.98 [1.20-3.29] p=0.008), 
compared with moderate TG/HDL group. Interestingly, also low TG/HDL group revealed 
higher risk of MACE, compared to moderate TG/HDL group (adjusted HR 2.14[1.03-4.47] 
p=0.041). These associations were represented similarly in statin users, whereas only low 
TG/HDL group, not high TG/HDL group, showed elevated MACE risk in non-statin users.
Transplantation: Cardiovascular and Metabolic Diseases
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
156
J Am Soc Nephrol 29: 2018 Poster/Thursday
Conclusions: High TG/HDL of 2.5 or more may be a risk factor for cardiovascular 
events in RTRs, especially in patients requiring statin therapy. Additionally, our study 
suggested low TG/HDL may paradoxically increase cardiovascular risk, especially in low 
risk patients.
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Background: Pre-transplant dialysis duration is associated with increased mortality 
in renal transplant recipients (RTRs) due to intradialytic volume overload and subsequent 
progression of left ventricular hypertrophy. As a result, the cardiovascular system could 
deteriorate into a worse state in potential RTRs. N-terminal pro brain natriuretic peptide 
(NT-proBNP), a protein released by stretch of ventricular cells caused by volume overload, 
is a prognostic predictor of mortality in end-stage renal disease patients. The aim is to assess 
if dialysis duration (DD) is independently associated with mortality in RTRs and if NT-
proBNP explains the association between DD with mortality in RTRs.
Methods: 648 patients, transplanted (1995-2005) in the University Medical Center 
Groningen, were prospectively analyzed after exclusion of 225 patients without sera NT-
proBNP and 39 patients with graft failure within 1 year after transplantation. Multivariable 
Cox regression models were used to study the association of DD and NT-proBNP with 
all-cause mortality. Mediation analysis was performed to evaluate whether the associations 
between DD and mortality were mediated by NT-proBNP.
Results: In multivariable Cox regression DD was associated with increased risk for 
post-transplant mortality, independent of potential confounders including age, gender, 
creatinine, diastolic blood pressure, diabetic nephropathy, donor type, delayed graft 
function, pre-emptive transplantation and CMV seropositivity (Hazard ratio [HR]: 1.39; 
95% confidence interval [CI]: 1.11-1.75; P=0.004). This association weakened after 
adjustment for NT-proBNP (HR: 1.25; 95% CI: 0.99-1.58; P=0.06). NT-proBNP was 
independently associated with all-cause mortality in RTRs (HR: 1.46; 95% CI: 1.23-1.74; 
P=<0.001). In mediation analysis NT-proBNP was found to explain 47.3% of the effect of 
DD on all-cause mortality in RTRs.
Conclusions: DD is a predictor of mortality in RTRs and variation in NT-proBNP at the 
time of transplantation to a large extent captures and mediates the effect of DD on mortality 
risk in RTRs. Future studies are needed to evaluate the potential value of NT-proBNP as 
check of cardiac patency of patients on the transplantation waiting list.
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Background: This meta-analysis was conducted with aims to summarize all available 
evidence on prevalence of pre-existing atrial fibrillation (AF) and/or incidence of AF 
following kidney transplantation and the outcomes of KT recipients with AF.
Methods: A literature search was conducted utilizing MEDLINE, EMBASE and 
Cochrane Database from inception through March 2018. We included studies that reported 
1) prevalence of pre-existing AF or incidence of AF following kidney transplantation or
2) outcomes of KT recipients with AF. Effect estimates from the individual study were
extracted and combined utilizing random-effect, generic inverse variance method of
DerSimonian and Laird. The protocol for this meta-analysis is registered with PROSPERO 
(International Prospective Register of Systematic Reviews; no. CRD42018086192).
Results: 8 cohort studies with 137,709 kidney transplant recipients were enrolled. 
Overall, the pooled estimated prevalence of pre-existing AF in patients undergoing 
kidney transplantation was 7.0% (95%CI: 5.6%-8.8%) and pooled estimated incidence of 
AF following kidney transplantation was 4.9% (95%CI: 1.7%-13.0%). Meta-regression 
analyses were performed and showed no significant correlations between year of study 
and either prevalence of pre-existing AF (p =0.93) or post-operative AF after kidney 
transplantation (p =0.16). The pooled OR of mortality among KT recipients with AF was 
1.86 (3 studies; 95%CI: 1.03-3.35). In addition, AF is also associated with death-censored 
allograft loss (2 studies; OR: 1.55, 95%CI: 1.02-2.35) and stroke (3 studies; OR: 2.54, 
95%CI: 1.11-5.78) among KT recipients.
Conclusions: The overall estimated incidence of AF following kidney transplantation 
is 4.9%. Despite advances in medicine, incidence of AF following KT doesn’t seem to 
decrease over time. In addition, there is a significant association of AF with increased 
mortality, allograft loss, and stroke after kidney transplantation.
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Background: The aim of this study was to determine i) the prognostic value of 
autoantibodies against apoA-1 (anti-apoA-1 IgG) for incidence of cardiovascular disease 
(CVD) specific mortality, all-cause mortality and graft failure in renal transplant recipients 
(RTR), patients known to have a high CVD burden only partly explained by traditional CVD 
risk factors, and ii) to delineate the relationship of anti-apoA-1 IgG with HDL functionality.
Methods: 462 prospectively included RTR were followed for 7.0 years. Baseline anti-
apoA-1 IgG were determined and associations with incidence of CVD mortality (n=48), 
all-cause mortality (n=92) and graft failure (n=39) were tested.
Results: HDL functionality assessed in vitro by measuring anti-oxidative and 
cholesterol efflux capacity was not associated with anti-apoA-1 IgG levels. Kaplan–Meier 
analyses demonstrated significant associations of anti-apoA-1 IgG with CVD mortality (log 
rank test among tertiles: P=0.048). Adjusted Cox regression analysis showed that for each 
standard deviation increase of log transformed anti-apoA-1 IgG values, there was a 4-fold 
increase (hazard ratio [HR]: 4.00; 95% confidence interval [95%CI]:1.32-12.11; p=0.01) in 
risk for CVD mortality and a more than 2-fold increase for all-cause mortality (HR:2.69, 
95%CI:1.25-5.83; P=0.01), independent of CVD risk factors, renal and HDL function. The 
association with all-cause mortality disappeared after excluding cases of CVD specific 
mortality. The sensitivity, specificity, positive predictive value, and negative predictive 
value of anti-apoA-1 positivity for CVD mortality were 18.0%, 89.3%, 17.0%, and 90.0%, 
respectively.
Conclusions: In conclusion, this prospective study demonstrates that in RTR, anti-
apoA-1 IgG are independent predictors of CVD mortality. In RTR, anti-apoA-1 IgG are not 
associated with HDL functionality.
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Introduction: Renal artery stenosis is a common complication after transplantation. 
In our institution, we have experienced a high rate of false-positive Doppler ultrasound 
and “confirmatory” non-contrast time-of-flight MRA studies that needlessly go to invasive 
catheterization. We present one of many of our cases which show the utility of high-quality 
3D MRA using a non-flow dependent non-contrast technique, NATIVE TrueFISP.
Case Description: A 13-year-old male with a history of idiopathic dilated 
cardiomyopathy and end-stage renal disease underwent a combined cardiac transplant 
and deceased donor kidney transplant. Two months after the transplant, the patient was 
admitted for respiratory distress, pulmonary edema, and worsening cardiac function. On 
admission, the patient was mildly hypertensive. Further investigation showed an increase 
in serum creatinine to 1.6 mg/dl. A Doppler study showed elevated peak systolic velocity 
of the transplant renal artery anastomosis, up to 434 cm/sec. To confirm the sonographic 
suspicion of renal artery stenosis, a non-contrast 3D MRA was requested which showed 
tight juxta-anastomic stenosis (see Figure 1A). A diagnostic angiogram confirmed the pre-
invasive imaging findings with nearly 1:1 correlation with the MRA 3D volume-rendered 
images (see Figure 1B). Angioplasty of this lesion was achieved by serial balloon dilation. 
Follow-up ultrasounds up to six-months post angioplasty show interval normalization of the 
renal artery velocities and blood pressure.
Discussion: The correct diagnosis of post-transplant renal artery stenosis is critical to 
avoid unnecessary, risky, costly, and time-consuming procedures. Under the supervision of 
a qualified radiologist, we have found our initial experience with NATIVE TrueFISP MRA 
technique to be reliable in evaluating transplant renal artery stenosis without the need for 
intravenous contrast.
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Figure 1 (A) 3D volume-rendered MRA shows tight juxta-anastomotic narrowing. (B) 
Conventional angiogram shows nearly 1:1 correlation of the stenosis as compared with 
the MRA.
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Background: Metabolic acidosis as defined as serum bicarbonate of <22 mmol/L is 
commonly seen in patients with advanced chronic kidney disease, and is observed among 
Kidney transplant recipients (KTRs) due to maladaptive changes during early post-
transplant causing subacute kidney injury despite preserved estimated glomerular filtration 
rate. Post-transplant metabolic acidosis is potentially an early marker of chronic allograft 
nephropathy, and eventual graft loss. However, graft survival is not well studied due to 
lack of periodic determination of serum bicarbonate post-transplant. This study aims to 
determine clinical outcome of graft loss among patients with post-transplant metabolic 
acidosis.
Methods: This is a single-centered retrospective cohort study, which included 132 
eligible subjects from January 1995-December 2012 at the St. Luke’s Medical Center, 
Quezon City. Laboratory measurements were determined at 12 months post-transplant, 
which included serum bicarbonate, creatinine, and proteinuria. Clinical outcomes were 
determined as graft loss, either by death or death censored graft failure, based on follow-up 
records.
Results: A total of 132 recipients were analyzed for baseline characteristics 
according to serum bicarbonate at 12 months post-transplant. The low serum bicarbonate 
(<22 mmol/L) group included 26 patients, with an incidence rate of 19.7%. Risk factors 
for metabolic acidosis include: eGFR of 15- 30 ml/min, deceased donor status, presence of 
one DR mismatch, acute rejection, presence of proteinuria, and use of alkalinizing agents. 
Graft loss, death, and death censored graft failure were not significantly associated with 
post-transplant metabolic acidosis, with the following risk ratios for graft loss (HR=2.293, 
95% CI 0.849-6.191, p=NS), mortality (HR=1.885, 95% CI 0.311 -11.436, p=NS), and 
death censored graft failure, (HR=2.502, 95% CI 0.759-8.246, p=NS). The mean allograft 
survival with metabolic acidosis is 124.8 months, compared with 134.1 months in the group 
without metabolic acidosis.
Conclusions: Post-transplant metabolic acidosis has fairly high incidence rate of 
19.7%. Graft loss, death, and death censored graft failure were not significantly associated 
with post-transplant metabolic acidosis. Periodic monitoring of serum bicarbonate is 
recommended to yield a well-represented large prospective cohort study in the future.
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Background: Renal transplantation (RTx) only partially corrects certain metabolic 
alterations, especially in mineral metabolism (MM). We aim to examine the effect of RTx 
during the 1st year of RTx on P levels, exploring the factors related and influencing P levels 
after 1 month (T1) and 12 months (T2) of RTx. The impact on long term graft outcome of 
1st year average P levels (P-avr) will also be explored.
Methods: In 132 RTx pts (age: 48[37;58] yrs – 87 males), up to the 476 transplanted 
in our unit between 2006 and 2015, clinical parameters, blood and urinary samples were 
collected at T1 and T2. In addition, in all the patients intact FGF23 (iFGF23) was tested at 
T1 and T2. Median follow up (FU) was 5[3-9] yrs.
Results: 84% percent of patients received a kidney from a deceased donor; 68% and 
23% of patients were treated with haemodialysis and peritoneal dialysis before RTx. Dialysis 
vintage was 49[27-64] mths. Cold ischemia time was 13[11-16]h. MM parameters at T1 
were: Ca 9.7[9.3-10.2]mg/dL, iPTH 68[42-114]pg/mL, ALP 94[72-127]U/L, 25OHVitD 
12[8-17]ng/mL. Between T1 and T2, an increase of P levels was noted (T1:2.3[1.9-2.8]
mg/dL – T2 3.1[2.7-3.6] mg/dL, p<0.001). iFGF23 was reduced (T1: 80[6-1360] pg/mL– 
T2 62[14-489] pg/mL, p=0.01). P-avr was 2.7[2.3-3.1]mg/dL. Thirty-five percent and 11% 
of patients were treated with active and native vitamin D during the first year of RTx. In 
multivariate analysis, T1-iFGF-23, T2-ALP and T2-Ca resulted the most influencing 
parameters of T1-P, T2-P and P-av (p=0.009, p=0.03 and p=0.002 resp.). No relationship 
between T2-P and T2-iFGF23 as like as between P-av and renal function was found. No 
influence of immunosuppressive therapy was found. During FU, 8 patients restarted dialysis 
(D+). D+ were different to those patients with functioning graft only for higher T2-PTH 
(p=0.01) and P-av (p<0.0001). In Cox and ROC curve analysis, P-av was the best predicting 
and discriminatory factor for graft loss (Cox: p<0.0001; ROC: AUC 0.71±0.10– p=0.04).
Conclusions: Our data confirm that RTx has an impact to MM from the beginning, and 
that P levels are influenced by different factors at T1 and T2. However, independently to 
renal function, P-av might influence long-term graft outcome.
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Background: Hyperphosphatemia is a well-established and independent risk factor for 
fracture, cardiovascular disease, and mortality in dialyzed and non-dialyzed patients with 
chronic kidney disease. Recent studies showed that high serum phosphate is associated 
with rapid decline in kidney function. Kidney transplantation dramatically decreases 
serum phosphate levels; however, the association of hypophosphatemia with graft survival 
remains unclear.
Methods: This was a single-center, retrospective study comprising 90 patients who 
underwent a kidney transplant at our institution between 2008 and 2016. Patients were 
divided into two groups, with and without hypophosphatemia. The hypophosphatemia was 
defined as those with less than or equal to the lowest quartile of serum phosphate levels at 
3 months post-transplant. The endpoints were defined as 30% decrease in the eGFR. The 
cumulative kidney survival rates were calculated for each group using the Kaplan–Meier 
method, and the adjusted hazard ratio (HR) was calculated using the Cox regression model.
Results: No significant differences were observed in age, diabetes, living donor, 
pre-emptive kidney transplantation, ABO incompatibility, donor-specific antigen, or 
biochemical parameters of mineral bone disorders at transplantation between the two 
groups. The proportion of male recipients was higher in the hypophosphatemia group 
than in the control group (88% vs. 65%). The hypophosphatemia group received a higher 
proportion of cinacalcet prescriptions during the dialysis period than the control group (33% 
vs. 14%). The median follow-up duration was 47.5 months, and the 90 transplantations 
resulted in 6 cases of graft loss, 2 of mortality, and 37 of 30% decline in eGFR. The Kaplan–
Meier analysis revealed that patients in the hypophosphatemia group had a significantly 
lower risk of 30% decline in eGFR than those in the control group. After adjusting for 
confounding factors, hypophosphatemia was associated with a significantly lower risk of 
30% decline in eGFR [HR, 0.37; 95% confidence interval (CI), 0.14–0.88] compared with 
the control group.
Conclusions: The results of the present study suggested that hypophosphatemia at 3 
months post transplant is a favorable sign for the successful outcome of transplantation.
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Background: It is essential to determine the optimum nutrition (protein intake) in 
renal transplant recipients on steroids with renal dysfunction to maintain a neutral nitrogen 
balance. It was our aim to study the effect of variable protein intake [i.e.higher (1.2g/kg/d) 
and lower (0.8g/kg/d) protein intake] on nitrogen balance, body composition, glomerular 
filtration rate and proteinuria in renal transplant recipients with low eGFR (15–44 ml/
min/1.73m2).
Methods: This prospective, open-labelled, randomized, cross-over, interventional 
study enrolled 35 patients who were ≥ 4 months post-transplant and who had an eGFR 
between 15 - 44 ml/min/1.73m2. Thirty-two patients completed the study. The subjects 
were randomised to either Group 1 [Diet: proteins (1.2 g/kg/day) and 35 kcal/kg/day] or 
Group 2 [Diet: proteins (0.8 g/kg/day with 50% first class proteins) and 35 kcal/kg/day] 
for one month. The subjects crossed over to the other diet for the second month. The body 
composition analysis, sr. creatinine, blood urea nitrogen, sr. protein, sr. albumin, 24 hours 
proteinuria, GFR measurement (24 hours creatinine clearance), three day diet recall and 
nitrogen balance estimation were performed at baseline and at the end of the first and second 
months. Statistical analysis was performed using SPSS version 21.
Results: The three day diet recall showed that the daily protein and energy 
consumption was 1.2 g/kg and 36.47 kcal/kg with the higher protein diet and 0.94 g/kg 
protein with 31.94 kcal/kg with the lower protein diet. The nitrogen balance was positive 
with both the diets, +3.61 g/d with the higher protein diet (p=0.0002) and +1.66 g/d with the 
lower protein diet. The waist hip ratio showed a significant decrease on the higher protein 
diet (p=0.011) and increase on the lower protein diet (p=0.011). There was significant gain 
in muscle mass (0.70 kg gain; p=0.0317) with the higher protein diet. Significant increase 
was noted in blood urea nitrogen (p=0.0048) and GFR (p=0.0114) with the higher protein 
diet. 24 hours urinary protein excretion increased significantly after consuming the higher 
protein diet (320mg/d, p=0.010).
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Conclusions: Renal transplant recipients remained in positive nitrogen balance with 
both diets. Muscle mass and proteinuria increased significantly with the higher protein diet.
Funding: Private Foundation Support
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Background: The effectiveness of exercise in kidney transplant recipients is not well 
established. We therefore performed a systematic review of the effects of exercise training 
in kidney transplantation recipients.
Methods: We searched two electronic databases for articles up to April 2017. Inclusion 
criteria were as follows: randomized controlled trial and kidney transplant recipients 
aged 18 years or older. The main outcomes were allograft function (estimated glomerular 
filtration rate, eGFR), exercise tolerance (VO2 peak), and quality of life (QOL).
Results: After screening of 1,303 references in PubMed and Ichushi, six randomized 
control trials were analyzed. For kidney transplant recipients, supervised exercise training 
was shown to significantly improve VO2 peak (mean difference, 2.42; 95% confidence 
interval (95%CI) 0.22–4.63) and QOL (mean difference, 7.23; 95%CI 0.94–13.52). 
However, exercise training did not improve allograft kidney function (mean difference, 
6.22; 95%CI -13.00–25.44). No reporting bias was observed in any of the outcomes.
Conclusions: Exercise training for kidney transplant recipients significantly improved 
exercise tolerability and QOL, but a significant improvement was not obtained with respect 
to allograft kidney function.
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Fibroblast Growth Factor 23 and Arterial Stiffness in SPRINT
Anna J. Jovanovich,1,2 Zhiying You,3 Charles Ginsberg,4 Joachim H. Ix,4 
Mark A. Supiano,5 Michael Shlipak,6 Alfred K. Cheung,7 Michel Chonchol,2 
Kristen L. Nowak.8 1Denver VA, Denver, CO; 2University of Colorado, Aurora, 
CO; 3UC Denver, Aurora, CO; 4UCSD, San Diego, CA; 5University of Utah 
Geriatrics Division, Salt Lake City, UT; 6San Francisco VA Medical Center, San 
Francisco, CA; 7University of Utah, Salt Lake City, UT; 8University of Colorado 
Denver: Anschutz Medical Campus, Aurora, CO.
Background: Fibroblast growth factor 23 (FGF23) and arterial stiffness are both 
associated with cardiovascular disease and mortality in chronic kidney disease (CKD). 
The relationship between FGF23 and arterial stiffness needs further investigation. We 
hypothesized that higher serum FGF23 levels would be associated with greater arterial 
stiffness in participants with CKD in the Systolic Blood Pressure Intervention Trial 
(SPRINT).
Methods: The SPRINT study was a randomized multicenter trial evaluating the effects 
of standard (SBP <140 mmHg) vs. intensive (SBP <120 mmHg) blood pressure lowering on 
cardiovascular outcomes among older adults without diabetes. Intact FGF23 (iFGF23) was 
measured at baseline among 2384 participants with an estimated glomerular filtration rate 
(eGFR) < 60 mL/min/1.73m2. Multivariable linear regression determined the association 
between baseline iFGF23 and pulse pressure (PP; a surrogate measure of arterial stiffness) 
(N = 2384) and aortic pulse wave velocity (aPWV) (N = 202), the latter of which was 
measured in an ancillary study. Models were adjusted for demographics, comorbidities, 
randomization group, baseline number of antihypertensives, eGFR, albuminuria, and serum 
calcium and phosphorus.
Results: In the PP analysis, mean age was 73 ± 9 years, mean eGFR was 49 ± 11 mL/
min/1.73m2, and median iFGF23 level was 71 [53-95] ng/mL. There was no significant 
association between baseline iFGF23 and PP (β: -0.08, 95% CI: -1.06 to 0.89). Notably, 
baseline serum phosphorus was significantly associated with PP (β: 1.33, 95% CI: 0.23 to 2.43) 
in the fully adjusted model. In the ancillary study, mean age was 73 ± 10 years, mean 
eGFR was 47 ± 12 mL/min/1.73m2, and median iFGF23 level was 71 [53-95] ng/mL. 
In the unadjusted model, higher iFGF23 was significantly associated with lower aPWV 
(β: -0.009, 95% CI: -0.02 to -0.003). However, in the fully adjusted model, this association 
was no longer significant (β: -0.003, 95% CI: -0.01 to 0.004).
Conclusions: Among SPRINT participants with baseline eGFR < 60 mL/min/1.73m2, 
iFGF23 was not associated with arterial stiffness as measured by PP and aPWV. However, 
higher serum phosphorus was associated with increased PP. The analysis of aPWV was 
limited due to a smaller sample size.
Funding: NIDDK Support, Veterans Affairs Support
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Fibroblast Growth Factor 23 (FGF23) and Cystic Liver Disease in Patients 
with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Anna J. Jovanovich,2 Zhiying You,4 Berenice Y. Gitomer,5 Myles Wolf,6 
Isidro B. Salusky,7 Michel Chonchol,1 Kristen L. Nowak.3 1University of 
Colorado, Aurora, CO; 2Denver VA / University of Colorado, Denver, CO; 
3University of Colorado Denver: Anschutz Medical Campus, Aurora, CO; 4UC 
Denver, Aurora, CO; 5Div. Renal Diseases and Hypertension, Aurora, CO; 
6Duke University, Durham, NC; 7Mattel Children’s Hospital, Los Angeles, CA.
Background: Previous studies have demonstrated that the cystic liver from ADPKD 
patients markedly expresses FGF23 mRNA and protein. Epidemiological studies have 
reported an elevation in circulating FGF23 levels in adult ADPKD patients compared to 
non-ADPKD patients with similar kidney function. We hypothesize that elevated serum 
iFGF23 levels are associated with greater increases in cystic liver volume in early ADPKD.
Methods: 440 participants with early ADPKD and normal kidney function (mean 
eGFR 92± 18mL/min/1.73m2) who participated in HALT Study A were included in this 
analysis. The cross-sectional and longitudinal (5-year) association of iFGF23 with liver 
volume, measured as baseline total liver volume and change in total liver volume by 
magnetic resonance imaging, respectively, were evaluated using linear regression models. 
iFGF23 levels were measured using stored serum samples obtained at baseline
Results: Participants had a mean (SD) age of 37 ± 8 years. Mean (SD) serum phosphate 
level and the median (IQR) iFGF23 level were 3.4 ± 0.5 mg/dL and 43 (33–56) pg/mL, 
respectively. The median (IQR) baseline liver volume was 1790 (1572-2088)ml. After 
adjustment for age, sex, body mass index, randomization group, systolic blood pressure, 
estimated glomerular filtration rate, urinary albumin excretion, serum calcium, phosphate, 
parathyroid hormone level and PKD genotype, higher circulating iFGF23 levels were not 
associated with liver volume at baseline (ß=35.39, [95% CI -86.75 to 157.53; p=0.60] 
per doubling in iFGF23). Similarly, higher circulating iFGF23 was not associated with 
greater percentage increase in liver volume (ß=-1.94, [95% CI -17.04 to 13.15; p=0.80])
per doubling in iFGF23.
Conclusions: Our results indicate that circulating iFGF23 is not independently 
associated with liver volume in ADPKD patients. FGF23 does not appear to represent a 
valid therapeutic target or a pertinent biomarker for liver cysts progression in patents with 
early ADPKD.
Funding: NIDDK Support
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The Effect of Intensive Blood Pressure Lowering on Markers of Mineral 
Metabolism in Persons with CKD in SPRINT
Charles Ginsberg,1 Ronit Katz,2 Michel Chonchol,3 Alexander Bullen,1 
William R. Zhang,4 Michael Shlipak,5 Joachim H. Ix.1 1UCSD, San Diego, CA; 
2University of Washington, Seattle, WA; 3University of Colorado, Aurora, CO; 
4UCSF School of Medicine, San Francisco, CA; 5San Francisco VA Medical 
Center, San Francisco, CA.
Background: Serum fibroblast growth factor 23 (FGF23) and parathyroid hormone 
(PTH) concentrations are high in chronic kidney disease (CKD) and have been associated 
with increased cardiovascular disease (CVD) risk. The SPRINT trial demonstrated that 
intensive blood pressure (BP) lowering reduced risk of CVD despite more rapid eGFR 
decline. The effects of intensive blood pressure lowering on serum FGF23 and PTH are 
currently unknown.
Methods: Among individuals with CKD (eGFR < 60ml/min/1.73m2), we randomly 
selected 1000 participants and measured serum intact FGF23 (iFGF23; Kainos ELISA), 
intact PTH (iPTH), calcium, phosphate, and urine phosphate/creatinine at baseline and year 
1. Thirteen were missing serum samples, resulting in 987 for analysis. We used linear mixed 
models to assess the effect of intensive BP lowering on iFGF23 and iPTH, in addition to
changes in serum calcium, phosphate and fractional excretion of phosphate (FePhos).
Results: Mean age was 72±9 years, 42% were female, and mean eGFR was 
46±10 ml/min/1.73m2. Demographics, baseline BP, kidney function, iFGF23, and iPTH 
were well-balanced across arms. Randomization to the intensive arm resulted in an increase 
in iFGF23 over 1 year compared with the standard BP arm (p=0.01) but no change in PTH 
[-1.6% (95% CI -6.1, 2.9]. After adjustment for 1 year changes in eGFR and albuminuria, 
persons in the intensive arm experienced an 11.2% (95% CI 6.2, 17.5) increase in serum 
iFGF23 compared with the standard arm. Randomization to the intensive arm did not 
impact calcium and phosphate or FePhos
Conclusions: In SPRINT participants with CKD, compared with the standard arm, 
randomization to the intensive BP arm led to an increase in iFGF23 that was independent of 
changes in eGFR. Future studies should determine whether increasing iFGF23 in persons 
receiving intensive BP therapy impacts CVD risk.
Funding: NIDDK Support, Other NIH Support - NIH Loan Repayment Program, 
NHLBI, NINDS, National Institute on Aging, Private Foundation Support
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Change in FGF23 and PTH1-84 and Subsequent Cardiovascular and 
Renal Events in Patients with Advanced CKD
Mark Canney,1 Ognjenka Djurdjev,2 Mila Tang,1 Claudia Zierold,3 
Frank A. Blocki,3 Fabrizio Bonelli,3 Adeera Levin.1 1St. Paul’s Hospital and 
University of British Columbia, Vancouver, BC, Canada; 2BC Renal Agency, 
Vancouver, BC, Canada; 3DiaSorin, Stillwater, MN.
Background: Elevated levels of parathyroid hormone (PTH1-84) and fibroblast 
growth factor 23 (FGF23), measured at a single time, are associated with increased risk 
of cardiovascular (CV) and renal events in patients with CKD. Few studies have examined 
the longitudinal association between bone mineral biomarkers (BMB) and outcomes. We 
sought to describe changes in PTH1-84 and FGF23 over time and their association with 
subsequent CV and renal events.
Methods: Using data from a prospective cohort of 1078 patients with advanced CKD 
in Canada under the care of nephrologists (2008-2013), we measured serial PTH1-84 and 
FGF23 (3 time-points) in a central laboratory using sensitive DiaSorin assays. Adjudicated 
CV (coronary artery disease, congestive heart failure, stroke, sudden cardiac death) and 
renal outcomes (initiation of renal replacement therapy (RRT)) were recorded over 3 years 
of follow-up after the last BMB measurement. We used group-based trajectory models to 
characterize patterns of change in BMB, and Cox regression models to relate these changes 
to CV and renal outcomes.
Results: Mean age was 69.9, 62% were male, 45% were diabetic and 45% had pre-
existing CV disease. Mean eGFR was 27mL/min/1.73m2; 28%, 34% and 38% had eGFR 
<20, 20-29 & >30mL/min/1.73m2 respectively. We identified 3 distinct patterns of BMB 
change over time: low & stable (reference group), mid-level & stable, high & slowly 
rising. The proportions of patients in each category for PTH1-84 were 26%, 55% and 20% 
respectively. A small subgroup of patients (6%) had a high & rising pattern for FGF23. 
During median follow-up of 29 months, 11% experienced a CV event and 13% initiated 
RRT. Compared with the reference group, patients with mid-level & stable and high & 
rising patterns of each BMB had higher risk of CV events and RRT (Table). In multivariable 
models, only the high & rising patterns of PTH1-84 and FGF-23 demonstrated increased 
risk of CV events.
Conclusions: The majority of patients with advanced CKD had stable BMB values 
over time. A subgroup of patients had a high & rising pattern of change in PTH1-84 and 
FGF23 which conferred increased risk of CV events.
Funding: Commercial Support - DiaSorin
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Adjustment for ProBNP Substantially Attenuates Prognostic Implications 
of Plasma FGF23 Levels in CKD
Insa E. Emrich,1 Vincent Brandenburg,2 Alexander Sellier,1 Sarah Seiler-
Mussler,4 Gunnar H. Heine.3 1Saarland University Medical Center, Homburg 
(Saar), Germany; 2Nephrology, Rhein-Maas Klinikum, Würselen, Germany; 
3Saarland University Faculty of Medicine, Homburg, Germany; 
4Gemeinschaftspraxis Dr. Schürfeld, Dr. Möller, Dr. Henrich, Saarlouis, 
Germany.
Background: Various epidemiological studies linked high plasma levels of the 
phosphatonin FGF23 with cardiovascular events in non-dialysis CKD. It remains enigmatic 
whether high FGF23 exerts adverse cardiovascular effects, or whether it reflects detrimental 
effects of residual confounders. Earlier epidemiological studies adjusted for chronic kidney 
disease – mineral bone disease (CKD-MBD) regulators of FGF23 rather than for recently 
discovered non-CKD-MBD regulators, among which iron deficiency and heart failure are 
of particular importance. Moreover, they used c-terminal FGF23 assays (cFGF23) rather 
than more specific intact FGF23 assays (iFGF23).
Methods: The CARE FOR HOMe study analyzed plasma ferritin, hepcidin, iFGF23, 
cFGF23 and proBNP along with conventional risk factors, among 575 CKD G2-G4 
patients. The participants were followed 5.1 ± 2.1 years for the occurrence of atherosclerotic 
events and hospitalization for acute decompensated heart failure, respectively.
Results: cFGF23 correlated strongly with high iFGF23, fairly with high proBNP and 
weakly with low ferritin; correlation coefficients of iFGF23 with proBNP and ferritin were 
numerically lower. In Kaplan-Meier analyses, both endpoints were predicted by cFGF23 
and iFGF23. In Cox regression models, cFGF23 remained an outcome predictor after 
adjustment for conventional risk factors and iron deficiency. This prediction was largely 
eliminated when further adjusting for proBNP. iFGF23 was less consistently associated 
with adverse outcome in partly adjusted models, and failed to predict outcome in fully 
adjusted models.
Conclusions: In summary, iron deficiency and heart failure affect plasma FGF23. As 
adjustment for proBNP virtually eliminates the prognostic implications of plasma FGF23, 
we speculate that high FGF23, rather than exerting detrimental cardiovascular effects, 
merely mirrors prevalent heart disease.
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Effect of Renal Transplantation on Carotid Intimal Medial Thickness 
(CIMT), Left Ventricular Mass Index (LVMI), and CKD-MBD Markers: 
A Longitudinal Study
Sandeep Mahajan. All India Institute of Medical Sciences, New Delhi, India.
Background: Various nontraditional risk factors (NTRFs) including serum markers of 
CKD-MBD (serum calcium, phosphorus, intact PTH, vitamin D & FGF-23) & increased 
LVMI have been implicated for high cardiovascular (CV) mortality in CKD. Renal 
transplant (RT) by correcting uremic milieu improves most NTRFs. However compared to 
general population, CV mortality remains high post RT. This could be due to new risk factors 
or legacy effect of previous CKD period. CIMT is marker of structural atherosclerosis & 
has been shown to decrease after correction of risk factors in some clinical settings. This 
prospective, longitudinal study in CKD 5D patients looks at any change in CIMT & LVMI 
post RT & their correlation with changes in CKD-MBD markers.
Methods: 83 consecutive, eligible & consenting patients aged 18-65 years undergoing 
first live RT were enrolled. All investigations, CIMT & LVMI assessments were done at 
baseline (≤1 week prior to RT) & at 6 & 12 months post RT. Patients with pre-transplant 
diabetes, established coronary/valvular heart disease & those having persistent eGFR 
<40 ml/min post RT were excluded
Results: 74 patients completed study, 91.8% were male, mean age was 35.5±10.6 
years & median dialysis vintage was 14 months. All were on MMF, steroids & calcineurin 
inhibitors. At baseline CIMT did not correlate with any of CKD-MBD parameters while 
LVMI correlated positively with FGF-23 (correlation coeffficent 0.57, p-value <0.001). 
There was a significant reduction in CIMT & LVMI at 6 & 12 months post RT & 
improvement some CKD-MBD markers (table). There was however no correlation between 
changes in CIMT & LVMI & changes in CKD-MBD markers
Conclusions: In low risk CKD-5D population we document a significant decline in 
CIMT & LVMI post RT. Though there was significant improvement in CKD-MBD markers 
post RT they did not correlate with change in CIMT & LVMI
TH-PO185 Poster Thursday
Bone and Mineral Metabolism: Clinical - I
FGF23 as a Risk Factor for Cardiovascular Events and Mortality in 
Patients in the EVOLVE Trial
Mark D. Danese,2 Glenn M. Chertow,3 Kerry Cooper,7 Marc Halperin,4 
William W. Stark,1 David C. Wheeler,5 Geoffrey A. Block.6 1Amgen INC, Newbury 
Park, CA; 2Outcomes Insights, Inc., Westlake Village, CA, CA; 3Stanford University 
School of Medicine, Palo Alto, CA; 4Outcomes Insights, Inc, Westlake Village, CA; 
5University College London, London, United Kingdom; 6Colorado Kidney Care, 
Denver, CO; 7Amgen Inc., Thousand Oaks, CA.
Background: Risk factors for all-cause mortality and cardiovascular events in dialysis 
patients with CKD-MBD have not been fully elucidated. Historically, analyses using 
mineral metabolism biomarkers to predict clinical outcomes have used neither FGF23 nor 
clinically-adjudicated events.
Methods: We evaluated FGF23 and other risk factors using data from EVOLVE, a 
randomized, double-blind placebo-controlled, event-driven trial (N=3883 with CKD-
MBD) in which subjects were followed for up to 64 months. EVOLVE compared 
cinacalcet to placebo with a composite endpoint of death, myocardial infarction, 
hospitalization for unstable angina, heart failure (HF), or peripheral vascular event. 
Inclusion criteria included PTH ≥300 pg/mL, calcium ≥8.4 mg/dL, and phosphorus 
≥5.3 mg/dL. Our study quantified FGF23-associated risk following dose titration (week 
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20). We used Cox proportional hazards models to estimate the relative risk of the composite 
endpoint and its components, adjusting for age, albumin, race, sex, smoking status, Hb, P, 
Ca, PTH, and alkaline phosphatase as well as history of diabetes, coronary artery disease, 
HF, and stroke. Laboratory values and age were modeled using penalized splines to allow 
for a flexible relationship between the measure and risk (e.g., S or U-shaped).
Results: We included 2,411 patients who were event-free at week 20, and had an 
FGF23 measure. There were 1100 events (526 deaths and 574 non-fatal events). In adjusted 
models, higher log FGF23 was associated with a higher risk of the composite endpoint and 
its components. See Figure.
Conclusions: FGF23 appears to be an important, independent risk factor for mortality 
and CV events in addition to those traditionally associated with CKD-MBD.
Funding: Commercial Support - This study was funded by Amgen, Inc.
Association of Log(FGF23) with the Composite Endpoint and its Components
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Interactions Between FGF23 and Genotype in Autosomal Dominant 
Polycystic Kidney Disease (ADPKD)
Laura K. Grau,1 Berenice Y. Gitomer,1 Michel Chonchol,1 Myles Wolf,2 
Peter C. Harris,3 Godela M. Brosnahan,1 Vicente E. Torres,3 Theodore I. Steinman,6 
Alan S. Yu,4 Arlene B. Chapman,5 Kristen L. Nowak.1 1University of Colorado 
Denver: Anschutz Medical Campus, Aurora, CO; 2Duke University, Durham, 
NC; 3Mayo Clinic, Rochester, MN; 4University of Kansas Medical Center, 
Kansas City, KS; 5University of Chicago, Chicago, IL; 6Beth Israel Deaconess 
Medical Center, Boston, MA.
Background: Among individuals with ADPKD, higher serum intact fibroblast 
growth factor 23 (iFGF23) was associated with disease progression in participants 
in the HALT-PKD study. PKD mutation is also an important determinant of ADPKD 
progression. We hypothesized that serum levels of iFGF23 and vitamin D metabolites 
(1,25-dihydroxyvitamin D [1,25(OH)2D] and 25-hydroxyvitamin D [25[OH]D]) differed 
in adults with ADPKD according to ADPKD mutation and that the interaction between 
genotype and mineral metabolites would predict clinical endpoints.
Methods: 921 individuals with ADPKD who participated in the HALT-PKD study A 
or B and had measurement of mineral metabolites (1,25(OH)2D, 25(OH)D, and iFGF23) 
were categorized by PKD mutation (PKD1 truncating, PKD1 non-truncating, PKD2, or 
no mutation detected [NMD]). The longitudinal (5-yr) association of the interactions of 
genotype * iFGF23 and genotype * 1,25(OH)2D with clinical endpoints of (a) 50% decline 
in eGFR; b) end-stage renal disease (ESRD); c) composite of 50% decline in eGFR, ESRD, 
or death) were evaluated using cox proportional hazards regression.
Results: Median (IQR) 1,25(OH)2D differed (PKD1 truncating: 31.0 (24.4, 39.1); PKD1 
non-truncating: 32.0 (24.8, 40.1), PKD2: 33.9 (24.8,41.0); NMD: 38.2 (27.8, 46.4) pg/ml; 
p=0.01) and iFGF23 tended to differ (PKD1 truncating: 55.9 (40.5, 76.2); PKD1 non-
truncating: 49.9 (37.7, 72.2); PKD2: 48.6 (33.9, 69.8); NMD: 49.8 (39.7, 65.8) pg/ml; 
p=0.07) according to PKD genotype. There was a significant interaction between FGF23 
and genotype (p<0.01) for the composite endpoint in the fully adjusted models (Figure), but 
no significant interaction between 1,25(OH)2D and genotype for clinical endpoints.
Conclusions: ADPKD genotype interacts significantly with FGF23 to influence 
clinical endpoints, with the worst outcomes in individuals with a PKD1 truncating or non-
truncating mutation and the highest tertile of iFGF23.
Funding: NIDDK Support
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Association of Serum Bicarbonate Levels with Serum Fibroblast Growth 
Factor-23 Levels
Jessica B. Kendrick,1 Zhiying You,2 Berenice Y. Gitomer,3 Michel Chonchol,4 
Judith Blaine.5 1University of Colorado School of Medicine, Aurora, CO; 2UC 
Denver, Aurora, CO; 3Div. Renal Diseases and Hypertension, Aurora, CO; 
4University of Colorado, Aurora, CO; 5University of Colorado Denver, 
Aurora, CO.
Background: The regulation of fibroblast growth factor-23 (FGF23) is not understood. 
In vitro studies have found that metabolic acidosis increases FGF23. However, small 
pilot studies have found that treatment of low bicarbonate levels with sodium bicarbonate 
increases FGF23 levels. We tested the hypothesis that lower serum bicarbonate levels are 
associated with higher levels of FGF23.
Methods: We included 822 patients from the HALT-PKD Study A (n=540; mean eGFR 
= 91±17 ml/min per 1.73 m2) and B (n=462; mean eGFR = 48±12 ml/min per 1.73 m2) 
with serum bicarbonate and FGF23 levels measured at baseline. Bicarbonate was examined 
as a continuous variable and in categories (≤ 24, 25-28 and >28 mEq/L, with 25-28 mEq/L 
as the reference group). We used linear regression models to examine the cross-sectional 
association between baseline serum bicarbonate and FGF23 levels.
Results: The mean (SD) age and estimated glomerular filtration rate (eGFR) was 
43 ± 10 years and 70 ± 26 ml/min/1.73m2. The mean (SD) serum bicarbonate level was 
26.7 ± 2.4 mEq/L and the median (IQR) serum FGF23 level was 53 (39-74) pg/mL. 
Participants with bicarbonate levels ≤ 24 mEq/L had lower baseline eGFR and higher 
systolic blood pressure. In unadjusted analysis, every 1 mEq/L increase in serum 
bicarbonate was associated with a decrease of 1.25 pg/mL in FGF23 levels (β -1.25, 95% 
CI -2.48 to -0.01). However, after adjustment for demographics, randomization group, 
baseline eGFR, smoking, cardiac history, body mass index, blood pressure, serum calcium 
and phosphorus, the association was no longer significant (p=0.20). A serum bicarbonate 
 ≤ 24 mEq/L trended towards an increased risk of higher FGF23 in unadjusted analysis but 
it did not reach statistical significance (p=0.05).
Conclusions: Serum bicarbonate levels are not associated with FGF23 levels in patients 
with polycystic kidney disease. Further studies are needed to examine the relationship 
between metabolic acidosis and FGF23 in other causes of kidney disease.
Funding: Other NIH Support - NHLBI
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Genome-Wide Association Study Reveals That Distinct Genetic Factors 
Regulate Intact and C-Terminal FGF23 Levels in Humans
William T. Barrington,1 Mark R. Hanudel,1 Renata C. Pereira,4 
Sarada Charugundla,1 Markku H. Laakso,5 Aldons J. Lusis,2 Isidro B. Salusky.2,3 
1UCLA, Los Angeles, CA; 2UCLA, Los Angeles, CA; 3Mattel Children’s Hospital, 
Los Angeles, CA; 4University of California, Los Angeles, CA; 5University of 
Eastern Finland, Kuopio, Finland.
Background: Elevated fibroblast growth factor 23 (FGF23) levels have been associated 
with chronic kidney disease (CKD) progression, cardiovascular disease (CVD) and 
increased mortality. FGF23 also directly induces cardiac myocyte hypertrophy. Recently, 
non-mineral factors such as iron, anemia, inflammation and erythropoietin (EPO) have been 
identified in FGF23 production. Such factors are also associated with CKD progression, 
CVD and mortality. Thus, several lines of evidence suggest that FGF23 could play an 
important link. However, no studies have examined genetic factors underlying FGF23 
levels in humans. We conducted the first-ever genome-wide association study (GWAS) 
study of FGF23.
Methods: We measured both the active, intact form (iFGF23), and the total amount 
of FGF23 as measured by c-terminal form (cFGF23) via ELISA in a population of 1,400 
Finnish men aged 58+7 (SD) yrs. and eGFR 85+15 ml/min/1.73 m2. We performed GWAS 
mapping using a linear mixed model removing, SNPs with less than 5% minor allele 
frequency.
Results: We identified suggestive loci for cFGF23 on chromosomes 3 (p = 4.3 x 10-7) 
and 21 (p = 8.9 x 10-8), and suggestive for iFGF23 levels on chromosomes 7 (p = 3.6x10-6), 
12 (p = 3.6x10-6) and chromosome 18 (p = 4.5x10-6). The locus influencing iFGF23 levels 
on chromosome 7 is near the erythropoietin (EPO) gene, which stimulates hematopoiesis 
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and is deregulated in CKD patients. It is known that serum EPO and recombinant EPO 
administration are associated with FGF23 levels. Genetic manipulation of FGF23 has 
been shown to regulate erythropoiesis through EPO, indicating that regulation of EPO 
and FGF23 is complex. Our results show that genetic variants near EPO regulate iFGF23, 
raising the possibility that iFGF23 is genetically controlled by EPO. In contrast, the cFGF23 
levels were not associated with the locus near EPO possibly due interindividual variation 
in FGF23 cleavage.
Conclusions: Our results improve the understanding of the complex regulation between 
FGF23 and EPO. Our results provide evidence that complex and distinct genetic factors are 
involved in the regulation iFGF23 and cFGF23 that may help identify populations with 
different FGF23 levels at similar GFR, and indicate that natural genetic variation near EPO 
is involved in the regulation of FGF23.
Funding: Other NIH Support - NIH T32
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Effects of Induced Whole-Body Hypoxia on FGF23 in Obese Men
Bhupesh Panwar,1 Courtney M. Peterson,2 Eric Ravussin,3 Orlando M. Gutierrez.1 
1The University of Alabama at Birmingham, Birmingham, AL; 2University of 
Alabama at Birmingham, Birmingham, AL; 3Pennington Biomedical Research 
Center, Louisiana State University, Baton Rouge, LA.
Background: Higher fibroblast growth factor 23 (FGF23) is associated with higher 
risk of heart disease and mortality in patients with chronic kidney disease (CKD). Recent 
evidence shows that Hypoxia Inducible Factor 1α (HIF-1α) is a direct transcriptional 
activator of FGF23. No study has directly tested the effect of induced hypoxia on FGF23 
levels.
Methods: In a single-arm study design, 8 healthy obese men (BMI: 32.7 ± 3.7 kg/m2; 
age: 28 ± 3 years) were exposed to 10 consecutive nights of moderate hypoxia (15 ± 0.5% O2, 
simulating oxygen tension at 2400 m elevation) using hypoxic tents. Blood specimens and 
skeletal muscle and adipose biopsies were taken at baseline and after 10 days of hypoxic 
exposure. The primary outcomes were change in plasma intact FGF23 (iFGF23), c-terminal 
FGF23 (cFGF23) and FGF23 ratio (cFGF23:iFGF23). Paired t-test analysis was used to 
examine changes in log transformed values for iFGF23, cFGF23 and the FGF23 ratio. We 
also examined associations of muscle and adipose HIF-1α expression with FGF23.
Results: There were no statistically significant changes in either cFGF23 or iFGF23 
after induced hypoxia. There was a statistically significant increase in the FGF23 ratio 
(1.05±0.11 to 1.08±0.11) post exposure to hypoxia (p=0.02)(Table). HIF-1α expression 
in muscle was significantly associated with iFGF23 (r=0.86,p<0.05) but not cFGF23 
(r=0.11,P=0.45).
Conclusions: Exposure to hypoxia significantly increased the FGF23 ratio in obese 
men. In addition, muscle expression of HIF-1α was associated with iFGF23 plasma levels, 
suggesting that hypoxia influences FGF23 transcription and cleavage in humans.
Geometric mean Change (95%CI) in plasma FGF23 and arithmetic mean change (±SD) in 
FGF23 ratio with exposure to hypoxia.
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FGF23, Erythropoietin, and Erythroferrone Levels in Autosomal 
Dominant Polycystic Kidney Disease Patients
Mark R. Hanudel,1 Isidro B. Salusky,1 Renata C. Pereira,1 Wei Wang,2 
Zhiying You,2 Berenice Y. Gitomer,2 Kristen L. Nowak,2 Michel Chonchol.2 
1UCLA, Los Angeles, CA; 2University of Colorado Anschutz Medical Campus, 
Aurora, CO.
Background: Circulating FGF23 levels are higher in patients with autosomal dominant 
polycystic kidney disease (ADPKD) compared to patients with similar kidney function 
and other causes of CKD. Although bone is the major source of FGF23, erythropoietic 
bone marrow cells may also express FGF23 in response to erythropoietin (EPO), levels of 
which increase in ADPKD. We tested whether serum EPO levels in ADPKD patients are 
associated with circulating and bone FGF23. We also assessed serum levels of the EPO-
responsive hormone erythroferrone (ERFE).
Methods: 20 adult subjects with ADPKD and normal kidney function (mean ± SD 
eGFR 97 ± 29 ml/min/1.73m2) and 9 healthy controls participated in the study. We 
measured circulating C-terminal (total) FGF23 (cFGF23), intact FGF23 (iFGF23), EPO, 
ERFE, phosphate, calcium, PTH, 25D, 1,25D, iron, ferritin, hepcidin, and hemoglobin. 
Quantitative bone FGF23 levels were determined by immunohistochemical staining from 
bone biopsies.
Results: Circulating total FGF23 was higher in ADPKD subjects than in controls 
(geometric mean (95% CI) 109 (78, 153) vs. 73 (56, 95) RU/ml, p=0.050). Intact FGF23 
tended to be higher (67 (57, 80) vs. 51 (39, 67) pg/ml, p=0.073). Quantitative bone FGF23 
levels did not differ between the groups. Serum EPO levels were higher in ADPKD subjects 
(11.1 ± 6.7 vs. 6.1 ± 3.8 mIU/ml, p=0.019). Consistent with increased EPO, serum ERFE 
levels were also increased (17.6 ± 7.4 vs. 7.6 ± 6.2 ng/ml, p=0.001). The ADPKD subjects 
had higher phosphate (4.0 ± 0.5 vs. 3.6 ± 0.4 mg/dl, p=0.036) and lower 1,25D (44 (39, 49) 
vs. 61 (45, 82) pg/ml, p=0.039). Serum calcium, PTH, 25D, iron, ferritin, hepcidin, and 
hemoglobin did not differ between the groups. In the ADPKD subjects, EPO correlated with 
Log cFGF23 (r=0.55, p=0.021), and tended to correlate with Log iFGF23 (r=0.42, p=0.069), 
but not bone FGF23. After adjusting for phosphate, EPO remained associated with Log 
cFGF23 (β=0.58, p=0.011) and Log iFGF23 (β=0.44, p=0.053).
Conclusions: ADPKD patients with normal kidney function have increased EPO 
levels, which are associated with increased ERFE, and may contribute to increased 
circulating FGF23. EPO-induced marrow FGF23 expression has been demonstrated in 
rodents, and may explain the observation that EPO is associated with circulating FGF23 
but not bone FGF23.
TH-PO191 Poster Thursday
Bone and Mineral Metabolism: Clinical - I
Associations of Food Environment with Bone Mineral Disorders in the 
Chronic Renal Insufficiency Cohort (CRIC) Study
Jessica M. Madrigal,1 Esteban A. Cedillo-Couvert,2 Ana C. Ricardo,1 
Lawrence J. Appel,5 Cheryl A. Anderson,6 Rajat Deo,3 L. Lee Hamm,7 
Daohang Sha,3 Jesse Y. Hsu,3 Shannon Zenk,1 Milda R. Saunders,4 
Victoria Persky,1 James P. Lash.1 CRIC Investigators 1University of Illinois at 
Chicago, Chicago, IL; 2South Texas Renal Care Group, San Antonio, IL; 
3University of Pennsylvania, Philadelphia, PA; 4University of Chicago, Chicago, 
IL; 5Johns Hopkins Medical Institutions, Baltimore, MD; 6University of 
California San Diego, La Jolla, CA; 7Tulane University School of Medicine, 
New Orleans, LA.
Background: Access to fast food outlets may influence eating behaviors and contribute 
to disordered mineral metabolism through increased consumption of phosphates. The 
influence of food outlet density on mineral disorders has not been studied in chronic kidney 
disease (CKD).
Methods: Baseline cross-sectional analysis of the association between food outlet 
density (within 1 km of census block group) and phosphate ≥5.3 mg/dL, fibroblast 
growth factor 23 (FGF23) ≥100 RU/mL, and parathyroid hormone (PTH) ≥100 pg/mL 
using multivariable logistic regression. Data on food outlets included a count of fast food 
restaurants (unhealthy), convenience stores (unhealthy), and grocery stores (healthy). A 
food outlet index was categorized as no food outlets; only unhealthy outlets; few healthy 
food outlets (a ratio of healthy to unhealthy ≤0.2); or mostly healthy (a ratio of >0.2).
Results: The study included 2,484 participants with CKD (mean age 58 years, 46% 
female, 42% white, 39% black, and mean eGFR 44 ml/min/1.73 m2). A total of 455 (18%) 
participants had no food outlets within 1 km, 973 (39%) had only unhealthy food, 716 (29%) 
had few healthy food outlets, and 340 (14%) had mostly healthy outlets. Hyperphosphatemia 
was rare (n=50, 2%); 73% and 41% of participants had excess FGF23 and PTH, respectively. 
The table summarizes analyses. Compared to persons living in an area with only unhealthy 
food, increased availability of healthy food outlets was significantly associated with 
increased odds of hyperphosphatemia [OR=2.3 (1.1, 4.9)].
Conclusions: Our results highlight the possibility that changes to the food environment 
at the neighborhood level may impact important health indicators in CKD. Increased food 
availability may influence behaviors, and access to healthy food may not prevent unhealthy 
choices.
Funding: NIDDK Support, Other U.S. Government Support
Multivariable Logistic Regression for Association* Between Food Outlet Density and 
Markers of Mineral Disorders
*Adjusted for center, age, sex, race/ethnicity, income, eGFR, diabetes, activated vitamin D 
and phosphorus binder use.
TH-PO192 Poster Thursday
Bone and Mineral Metabolism: Clinical - I
Effect of Ferric Citrate Hydrate on FGF23 and Serum α-Klotho in 
Hemodialysis Patients with Hyperphosphatemia and Controlled Serum 
Phosphate Levels: ASTRIO Study, Supplementary Analysis
Keitaro Yokoyama,1 Masafumi Fukagawa,2 Masaaki Nakayama,3 Ito Kyoko,4 
Koji Hanaki,5 Hideki Hirakata.6 1Division of Nephrology and Hypertension, 
Department of Internal Medicine, The Jikei University School of Medicine, 
Tokyo, Japan; 2Tokai University School of Medicine, Isehara, Japan; 3St Luke’s 
International Hospital, Tokyo, Japan; 4Torii Pharmaceutical Co., Ltd, Tokyo, 
Japan; 5Japan Tobacco Inc., Tokyo, Japan; 6Fukuoka Renal Clinic, Fukuoka 
City, Japan.
Background: Elevated serum Fibroblast Growth Factor (FGF) 23 level is an 
independent risk factor for the progression to ESRD, and high FGF23 levels are reportedly 
associated with cardiovascular events. There is growing interest in α-klotho, a co-receptor 
for FGF23, as a biomarker of kidney function, because low α-klotho levels have been 
associated with adverse kidney disease outcome. However, the effect of phosphate binders 
(PBs) on α-klotho has not been extensively evaluated.
Methods: ASTRIO was a prospective, randomized, multicenter, 24-week study. 
93 HD patients who had been taking non-iron based PBs were randomized to Ferric Citrate 
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Hydrate (FC) group (n=45) or Control group (n=48). In Control, patients maintained 
treatment with their existing PBs. Serum P and Hb were controlled within 3.5 to 6.0 mg/dL 
and 10.0 to 12.0 g/dL, respectively. The primary endpoint was change in ESA dose; we also 
evaluated serum FGF23 and α-klotho.
Results: Serum P was maintained in both groups. C-terminal FGF23 (cFGF23) 
significantly decreased in FC compared to Control (p=0.04). There were no statistical 
differences in the changes in intact FGF23 (iFGF23) and α-klotho between groups. Serum 
ferritin and TSAT were significantly increased in FC compared to Control.
Conclusions: In this study, while there was no difference in the change of serum P 
between the groups, cFGF23 significantly decreased in FC compared to Control, but did not 
change iFGF23 and α-klotho.
*Logarithmic transformation, **End of treatment
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Soluble Klotho Is Associated with Cardiovascular Disease Events in 
Patients with Hemodialysis: Prospective Cohort Study
Akio Nakashima, Ichiro Ohkido, Keitaro Yokoyama, Takashi Yokoo. Division 
of Nephrology and Hypertension, Department of Internal Medicine, Jikei 
University School of Medicine, Tokyo, Japan.
Background: Patients with hemodialysis are higher mortality and their main cause of 
death is CVD events. Mineral bone disorder recently has been regarded as the important 
risk factors of CVD events. Klotho, which is known as an antiaging gene, serves as the 
cofactor for fibro blast growth factor 23 (FGF23) and regulate phosphorus and vitamin D 
metabolism. We aimed to evaluate whether serum soluble klotho levels are associated with 
CVD events in hemodialysis patients.
Methods: This prospective cohort study analyzed 1029 hemodialysis patients. We 
divided the study population into four groups based on serum Klotho levels. In this study, 
we defined the primary outcome was cardiovascular events, defined as a composite of 
death due to cardiac disease, sudden death, ischemic heart disease, heart failure requiring 
hospitalization and cerebral vascular events including cerebral hemorrhage and cerebral 
infarction. Association between Klotho levels and CVD events were analyzed using Cox 
proportional hazard model.
Results: The median soluble Klotho level was 305.9 (233.4-400.6) pg/ml. Their mean 
age (±standard deviation) was 63.1 (±11.9) years and median dialysis vintage was 109 (38-
153) months. During follow up, 394 CVD events occurred. CVD events were more frequent 
in the lowest than highest soluble Klotho quartile [hazard ratio, 1.50; 95% confidence 
interval, 1.04-2.18; P-value, 0.032]. These associations were confirmed in patients with
higher age (>65 years), higher phosphate levels (> 6.0mg/dl), or cinacalcet.
Conclusions: In this study, we found that soluble klotho is associated with CVD events 
in hemodialysis patients.
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Association of Serum Mineral Parameters with Mortality in Hemodialysis 
Patients: Data Analysis from Korean ESRD Registry
Yunmi Kim,1 Kyung Don Yoo,1 Hyo Jin Kim,2 Junga Koh,5 Yeonsil Yu,3 Yeong 
Hoon Kim,6 Kook-Hwan Oh.4 1Dongguk University Gyeongju Hospital, 
Gyeongsangbuk-do, Republic of Korea; 2Dongguk University College of 
Medicine, Gyeongju-si, GyeongSangBuk-do, Republic of Korea; 3JHospital, 
Seongnam-si, Republic of Korea; 4Seoul National University Hospital, Seoul, 
Republic of Korea; 5Gangneung Dongin Hospital, Gangneung-si, Gangwon-do, 
Republic of Korea; 6Inje University Medical School, Busan, Republic of Korea.
Background: We investigated the association between mineral metabolism parameters 
and mortality in Korean hemodialysis patients to identify optimal targets in Korean 
population.
Methods: Among hemodialysis patients registered in the End-stage renal disease 
Registry of the Korean Society of Nephrology between March 2012 and June 2017, 
those with serum calcium, phosphorus, and intact parathyroid hormone (iPTH) measured 
at enrollment were included. Analysis for the association of serum levels of calcium, 
phosphorus, and iPTH with all-cause mortality was conducted.
Results: Among the total 21,433 enrolled patients, 3,135 (14.6%) patients died during 
24.8 ± 14.5 months follow-up period. After multivariable adjustment, patients in the 1st 
quintile of corrected calcium was associated with lower mortality (HR, 0.84; 95% CI, 
0.71-0.99; P=0.003), while those in the 5th quintile of corrected calcium was associated 
with higher mortality (HR, 1.39; 95% CI, 1.20-1.61; P<0.001) compared with those in 
the 3rd quintile. For phosphorus, only the lowest quintile was significantly associated with 
increased mortality (HR, 1.24; 95% CI, 1.08-1.43; P=0.003). The lowest (HR, 1.18; 95% 
CI, 1.02-1.36; P=0.026) and the highest quintile of iPTH (HR, 1.24; 95% CI, 1.05-1.46; 
P=0.013) were associated with increased mortality. Regarding target counts achieved 
according to the KDOQI guideline, patients who achieved none of the mineral parameter 
targets had higher mortality than those who achieved all of the 3 targets (HR, 1.37; 95% 
CI, 1.12-1.67; P=0.003).
Conclusions: In Korean hemodialysis patients, high serum calcium, low phosphorus, 
as well as high and low iPTH levels were associated with increased all-cause mortality.
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Changes in Serum Phosphorus (sP) Among Patients with Hyperphospha-
temia (sP >5.5 mg/dL) Switched to Sucroferric Oxyhydroxide for Two 
Years
Stuart M. Sprague,1 Vidhya Parameswaran,2 Linda Ficociello,2 Claudy Mullon,2 
Robert J. Kossmann.2 1NorthShore University HealthSystem University of 
Chicago Pritzker School of Medicine, Chicago, IL; 2Fresenius Medical Care 
Renal Therapies Group, Waltham, MA.
Background: Hemodialysis (HD) patients are advised to keep sP levels ≤ 5.5 mg/dl 
through diet modification and use of phosphate binders (PB). Sucroferric oxyhydroxide 
(SO) has been prescribed to hemodialysis patients for the control of sP as part of routine 
clinical care. This database analysis retrospectively analyzed sP and PB pill burden in 
patients who had a mean sP level > 5.5 mg/dl at baseline and were prescribed SO for up 
to two years.
Methods: The analysis included adult HD patients with sP > 5.5 mg/dl at baseline 
(3-month, -Q1) who were switched to SO as part of routine care for up to two years 
(Q1-Q8). Patients were stratified into 3 groups based on baseline sP: Group 1: sP 5.6-7 mg/
dl, Group 2: sP 7.1-8.5 mg/dl, and Group 3: sP >8.5 mg/dl. Mixed effects linear regression 
was used for significance testing.
Results: There were 2067, 1381, and 479 patients in Groups 1, 2, and 3, respectively. 
84% had recorded PB prescriptions at baseline with the majority prescribed sevelamer. 
Table 1 shows the percent of patients who achieved sP ≤5.5 mg/dl and mean sP levels 
by group. In Groups 1 and 2, 42% and 22% of patients had sP ≤5.5 mg/dl after 2 years 
of follow-up. In the group with the highest baseline sP level, Group 3, sP ≤ 5.5 mg/d was 
achieved in 8.3% of patients, and the mean sP for this group decreased from 9.36 mg/dl to 
7.62 at Q8, a 19% reduction in sP (-1.74 mg/dl). On average, the PB pill burden was reduced 
in groups 1, 2, and 3 from 8.7, 9.7, and 9.9 PB pills/day at baseline to 4.9, 5.3 and 5.4 SO 
pills/day at Q8, respectively.
Conclusions: Patients with elevated sP levels at baseline switched to sucroferric 
oxyhydroxide for up to two years as part of routine care, experienced significant 
reductions in sP along with a >40% reduction in PB pills/day and increase in patients with 
sP ≤5.5 mg/dl.
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
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Serum Phosphorus (sP) Lowering Effect of Sucroferric Oxyhydroxide 
(SO) in Phosphate-Binder (PB) Naïve Hemodialysis Patients (pts) over 12 
Months
Kamyar Kalantar-Zadeh,1 Linda Ficociello,2 Vidhya Parameswaran,2 
Claudy Mullon,2 Robert J. Kossmann,2 Stuart M. Sprague.3 1University of 
California Irvine, School of Medicine, Orange, CA; 2Fresenius Medical Care 
Renal Therapies Group, Waltham, MA; 3NorthShore University HealthSystem 
University of Chicago Pritzker School of Medicine, Chicago, IL.
Background: Achieving recommended levels of sP ≤5.5 mg/dL by restricting dietary 
phosphate alone can be a major challenge and may compromise nutritional status leading to 
poor outcomes in hemodialysis (HD) pts. Whereas most HD pts are prescribed PB therapy to 
control sP, the efficacy and bill burden vary substantially across agents. We hypothesize that 
SO can effectively control sP with a low PB pill burden in pts naïve to PB.
Methods: Data, rendered de-identified, were extracted for all adult, HD pts with their first 
SO prescription between 3/1/2014-3/1/2015 and SO prescription for 12 months. 172 adult HD 
pts with SO prescribed as a first-line PB were identified. A subset of 44 pts prescribed SO as late 
as one year after dialysis start were also analyzed. Baseline (BL) was defined as the 3 months 
before SO (-Q1) and SO follow-up was divided into quarters (Q1-Q4).
Results: Pts were 54 (±14) years old with a dialysis vintage of 49 (±52) months. 
Comparing BL vs SO follow-up (Q1-Q4) among all 172 pts, there were consistent 
improvements in pts achieving target sP ≤5.5 mg/dL (increased from 23.7% at BL to 
32.6%-38.8% during SO treatment, p<0.0001) [Figure]. Pts were prescribed between 
4.0–4.1 SO pills/day. For the subset of 44 pts prescribed SO during the first year of dialysis, 
31.8% of pts had sP ≤5.5 mg/dl at BL and during SO follow-up, 40.9%-52.4% of pts had a 
sP ≤5.5 mg/dl, a 29%-65% increase from baseline. Mean PB pills/day for this subset ranged 
from 3.7 to 3.9 pills/day during Q1-Q4.
Conclusions: SO was effective in achieving sP ≤5.5 mg/dL as a first line PB with a low 
pill burden (4.0–4.1 pills/day) in HD pts. This was confirmed in a subset of pts who began 
HD as late as one year of starting SO.
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
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Serum Phosphorus and Phosphate Binder (PB) Pills/Day Among 
Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide (SO) for a 
Year Compared to Patients Who Discontinue SO and Are Prescribed 
Other PB
Daniel W. Coyne,1 Linda Ficociello,2 Vidhya Parameswaran,2 Claudy Mullon,2 
Robert J. Kossmann.2 1Washington University School of Medicine, St. Louis, 
MO; 2Fresenius Medical Care Renal Therapies Group, Waltham, MA.
Background: The high pill burden of most PBs has been associated with hemodialysis 
(HD) patients’ lack of adherence to prescribed therapy. SO is an iron-based PB indicated 
for the control of serum phosphorus (sP) in patients with chronic kidney disease on dialysis 
with a starting dose of 3 pills/day. This retrospective database analysis compared sP levels 
and PB pills/day for patients who continued use of SO and patients who discontinued SO.
Methods: Analysis included adult, HD patients prescribed PB for 12 months as part 
of routine care with sP measurements recorded during the quarter (Q) before and 4 Q 
after switch to SO. Continued use of SO was defined as SO monotherapy for 12 months 
(cSO-Pt). Discontinuing SO (dSO-Pt) was defined as discontinuation of SO within 90 
days of initiation followed by a switch to other PB(s). Pre-SO baseline was 6 months 
(-Q2 and -Q1) and follow-up was 12 months (Q1 to Q4). Statistical analysis was conducted 
using chi-square test.
Results: 653 cSO-Pt and 2294 dSO-Pt were analyzed. 74% of dSO-Pt had a switch 
to sevelamer after discontinuing SO. Up to 38.4% of cSO-Pt achieved sP ≤5.5 mg/dL 
compared to up to 34.4% for dSO-Pt [Figure]. During a 12-month follow-up, crude mean 
sP was 6.19 mg/dL for cSO-Pt and 6.37 mg/dL for dSO-Pt (p<0.0001). After controlling 
for age, gender, baseline sP, and baseline serum albumin, the follow-up mean sP was 
6.22 mg/dL for cSO-Pt and 6.39 mg/dL for dSO-Pt, p<0.0001. The mean PB pill/day was 
4.8 for cSO-Pt and 9.2 for dSO-Pt.
Conclusions: During a 12-month follow-up, SO patients had a lower mean sP, were 
more likely to achieve in-sP ≤5.5 mg/dl, and were prescribed 50% fewer pills/day than 
patients who discontinued SO and were prescribed other PB(s).
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
TH-PO198 Poster Thursday
Bone and Mineral Metabolism: Clinical - I
Hepcidin, Iron Indices, and Bone Mineral Metabolism in Non-Dialysis 
CKD
Sung Woo Lee,1 Su Ah Sung.2 1Eulji General Hospital, Seoul, Republic of 
Korea; 2Eulji Medical Center, Seoul, Republic of Korea.
Background: There have been some small studies which have reported that 
intravenous iron replacement was associated with levels of bone mineral metabolism 
markers. Disordered bone mineral metabolisms are also well-known risk factors of 
erythropoietin (EPO) resistance. Hepcidin is a key peptide for the EPO resistance and iron 
metbolism. Although the intimate association between hepcidin, iron indices, and bone 
mineral metabolism was expected, particularly in non-dialysis chronic kidney disease 
(CKD) patients, it has been studied sparsely. Therefore, we performed this study.
Methods: We reviewed data of 2,238 patients from a large-scale multicenter 
prospective Korean study (2,011–2,016), and excluded 214 patients with missing data on 
markers and related-medications of iron and bone mineral metabolism, hemoglobin, blood 
pressure and causes of CKD. Multivariate linear regression analysis was used to identify the 
association between iron and bone mineral metabolism.
Results: The proportion of CKD stage 1-5 were 16.2%, 18.7%, 37.1%, 21.6%, and 
6.4%, respectively. Per each 10% increase in transferrin saturation (TSAT), there was a 
0.013 mmol/l decrease in phosphorus [95% confidence interval (CI) -0.021–-0.004; 
P = 0.003] and a 0.022 nmol/l increase in logarithmic 25-hydroxyvitamin D (Ln-
25OHD) levels (95% CI 0.005–0.040; P = 0.019). A 1 pmol/l increase in Ln-ferritin was 
associated with a 0.080 ng/l decrease in Ln-intact parathyroid hormone (Ln-iPTH) (95% 
CI -0.122–-0.039; P <0.001). Meanwhile, beta (95% CI) per 1 unit increase in phosphorus, 
Ln-25OHD, and Ln-iPTH for the square root of the serum hepcidin were 0.594 (0.257–
0.932; P= 0.001), -0.270 (-0.431–-0.108; P = 0.001), and 0.115 (0.004–0.226; P = 0.042), 
respectively. In subgroup analysis, the relationship between phosphorus, 25OHD, and 
hepcidin was strongest in the positive-inflammation group.
Conclusions: Increased TSAT was associated with decreased and increased phosphorus 
and 25OHD levels, respectively, while increased ferritin was associated with decreased 
iPTH levels. Increased phosphorus and iPTH and decreased 25OHD were independently 
associated with increased hepcidin levels.
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Effects of Patiromer on Markers of Mineral Metabolism in Patients with 
Hyperkalemia and Hyperphosphatemia
David A. Bushinsky,1 David M. Spiegel,2 Jinwei Yuan,2 Suzette Warren,2 
Jeanene Fogli,2 Pablo E. Pergola.3 1University of Rochester Medical Center, 
Rochester, NY; 2Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, 
CA; 3Renal Associates, PA, San Antonio, TX.
Background: Patiromer (PAT) is a once-daily K binder for hyperkalemia (HK) 
treatment; Ca is the counterexchange ion. In TOURMALINE (NCT02694744) patients 
(pts) with serum K >5.0 mEq/L were randomized to PAT 8.4 g QD without/with food for 
4 wks, with doses adjusted to achieve/maintain serum K 3.8-5.0 mEq/L (target range). The 
primary endpoint (% of pts in target range at wk 3/4) was met in 83% dosed without food 
and 87% with food, with overlapping 95% CIs. We report the effects of PAT on markers 
of mineral metabolism in the pts with baseline (BL) hyperphosphatemia (HyperP, serum 
phosphate >4.8 mg/dL).
Methods: BL and wk 4 serum and 24-hr urine phosphate and Ca, and other markers, 
are reported for all HyperP pts combined (without/with food). Time-corrected 24-hr 
urine phosphate/Ca values were normalized to each pt’s mean of the time-corrected urine 
creatinine (Cr) level.
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Results: 16 pts had HyperP; 11 dosed without and 5 with food. All had CKD (median 
[Q1, Q3] eGFR 18.0 [11.5, 20.5] mL/min/1.73m2) and hypertension; 14/16 had diabetes. 
Two pts were on stable doses of sevelamer during the study. The primary endpoint was 
met in 14/16 pts (10/11 without and 4/5 with food in target range). There were significant 
reductions in serum and 24-hr urine phosphate (Table). Mean serum Mg decreased 
significantly. Mean serum Ca and 24-hr urine Ca were not different from BL at wk 4. Serum 
PTH levels decreased at wk 4 (P=0.19). Overall, 15/16 had ≥1 post-BL serum phosphate 
assessment; 9/15 had serum phosphate in the normal range by wk 4.
Conclusions: The decrease in serum and urine phosphate in the small number of 
HyperP pts in this study supports that intestinal phosphate is bound to some of the released 
Ca when PAT is used to lower serum K. These findings suggest that PAT may aid in the 
management of HyperP in pts with CKD requiring both K and phosphate binders.
Funding: Commercial Support - Funded by Relypsa, Inc., a Vifor Pharma Group 
Company
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Effects of Lanthanum Carbonate on Mineral Metabolism in Normophos-
phatemic Patients with CKD: Secondary Analysis of the COMBINE Trial
Tamara Isakova,1 Brett Larive,8 Jennifer J. Gassman,8 Kalani L. Raphael,4 
Alfred K. Cheung,5 Dominic S. Raj,6 Linda F. Fried,7 John P. Middleton,3 
Kevin C. Abbott,11 Susan R. Mendley,12 Geoffrey A. Block,10 Joachim H. Ix,2 
Myles Wolf,3 Stuart M. Sprague.9 CKD Optimal Management with Binders and 
NicotinamidE (COMBINE) Investigators 1Feinberg School of Medicine, 
Northwestern University, Chicago, IL; 2UCSD, San Diego, CA; 3Duke 
University, Durham, NC; 4VA Salt Lake City Health Care System, Salt Lake City, 
UT; 5University of Utah, Salt Lake City, UT; 6GWU Medical Faculty Associates, 
Washington, DC; 7VA Pittsburgh Healthcare System, Pittsburgh, PA; 8Cleveland 
Clinic, Cleveland, OH; 9NorthShore University HealthSystem University of 
Chicago Pritzker School of Medicine, Chicago, IL; 10Colorado Kidney Care, 
Denver, CO; 11The National Institutes of Health, NIDDK, Bethesda, MD; 
12NIDDK/NIH, Bethesda, MD.
Background: Disordered mineral metabolism is a nearly universal complication of 
reduced kidney function that develops early in the course of CKD and is associated with 
adverse clinical outcomes. Strategies aimed at reducing dietary phosphate absorption may 
prevent abnormalities in markers of mineral metabolism, but data from large and long-term 
interventional studies are lacking.
Methods: The COMBINE trial was a randomized, double-blinded, 12-month, 4-group 
parallel trial of nicotinamide and lanthanum carbonate vs. placebo in 205 CKD stage 3–4 
patients that tested the effects of active therapies on serum phosphate and FGF23 levels 
and on safety and tolerability. The primary results demonstrated that compared to placebo 
(n=51), lanthanum carbonate (n=50), nicotinamide (n=51) or dual treatment (n=53) did not 
significantly lower serum phosphate or FGF23. To determine the efficacy of each individual 
therapy, we performed secondary analyses to test the main effects of lanthanum carbonate 
(treated, n=103 vs. untreated, n=102) and nicotinamide (treated, n=104 vs. untreated, 
n=101).
Results: At baseline, mean eGFR was 33±7 ml/min/1.73m2, serum phosphate was 
3.7±0.5 mg/dL, FGF23 was 103.6 [IQR 76.8, 145.1] pg/ml, and PTH was 96 ± 64 pg/ml. 
Baseline characteristics were well-balanced across comparison groups. In intention to treat 
analyses, the overall 12-month effect of lanthanum carbonate treatment on serum phosphate 
was -0.051 mg/dL (95% CI= -0.191 to 0.089, P=0.48); FGF23 was -14.0% (95% CI= -24.2 
to -3.7, P=0.0077); PTH was -6.7% pg/mL (95% CI= -20.1 to 6.9, P=0.33); FEPI was -3.56 
(95% CI= -5.76 to -1.36, P=0.0016); and 24 hr urine phosphate/creatinine was -0.042 mg/dL 
(95% CI= -0.081 to -0.003, P=0.033). No significant effects were observed with 
nicotinamide treatment.
Conclusions: In a secondary analysis of the COMBINE trial, we demonstrated that 
lanthanum carbonate treatment decreased urinary phosphate excretion and reduced FGF23 
levels. Our findings provide support for targeting dietary phosphate absorption to modify 
FGF23 levels in patients with CKD stages 3-4.
Funding: NIDDK Support, Commercial Support - Shire
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Effectiveness of Sucroferric Oxyhydroxide in Phosphate Binder-Naïve and 
-Experienced Patients: A Real-World Retrospective Database Analysis
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Background: Retrospective analysis of a clinical database (EuCliD5) assessed the 
real-world effectiveness of an iron-based phosphate binder (PB), sucroferric oxyhydroxide 
(SFOH), to control serum phosphorus (sP) levels in hemodialysis (HD) patients (pts) in 
European countries.
Methods: De-identified data were extracted from electronic records for adult HD pts 
in 4 countries (France, Italy, Spain, Portugal) who were newly prescribed SFOH as part of 
routine care between Jan 2016 and Oct 2017. Baseline (BL) was defined as the 3-month 
period prior to SFOH prescription. Mean PB pill burden and sP levels were analyzed for 
Months 1–3 (Q1) and Months 4–6 (Q2) of SFOH treatment using mean values from the 
BL period as the reference. Effectiveness of SFOH for control of sP levels was evaluated 
for pts who had not received PB therapy during BL (PB-naïve) and those who had 
(PB-experienced).
Results: 1347 pts were included (mean age: 61.6 years; 63.5% male), of whom 605 pts 
were PB-experienced and 742 were PB-naïve. Characteristics of pts in these subgroups 
were generally comparable; median dialysis vintage was longer in PB-experienced vs. 
-naïve pts (50 vs. 34 months). The % of pts with sP control (≤5.5 mg/dL) during BL was
lower in the PB-experienced (31.6%) vs. the PB-naïve (44.9%) subgroup (Figure). In both
subgroups, the % pts achieving sP ≤5.5 mg/dL increased significantly from BL through Q1 
and Q2. For PB-experienced pts, these sP improvements were achieved with a reduction in 
PB pill burden.
Conclusions: In routine practice, SFOH therapy improved sP control in both PB-naïve 
and PB-experienced HD pts, with a relatively low daily pill burden.
Funding: Commercial Support - Vifor Fresenius Medical Care Renal Pharma
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Association Between Serum Phosphorus level and Decline of Glomerular 
Filtration Rate in Heathy Individuals
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Background: High serum phosphorus levels are strongly and independently associated 
with a more rapid decline of renal function in patients with advanced chronic kidney disease 
(CKD). We hypothesized that phosphorus was also associated with decline of Glomerular 
Filtration Rate (GFR) in heathy individuals.
Methods: We identified 1,340 healthy individuals with measured serum creatinine 
from the Rugao aging cohort over the period of Nov 2014 (baseline) to Nov 2017 (2nd 
follow-up). The association of phosphorus at the 2nd follow-up (Nov 2017), which was not 
measured at the baseline, with decrease of GFR between baseline and 2nd follow-up was 
examined using logistic models with adjustment for baseline demographics characteristics 
and laboratory variables.
Results: The mean age (mean±SD) of the cohort was 75±4 years old and included 
55% females, 7% diabetics, and 44% hypertension. Mean GFR estimated by CKD-EPI 
equation at baseline and the 2nd follow-up was 88.0 (±10) and 85.9 (±12) ml/min/1.73m2, 
respectively, with an average of 2 ml/min/1.73m2 decrease across the 3 years. Mean serum 
phosphorus level was 1.17(±0.16) mmol/l. Serum phosphorus was not associated with GFR 
at the baseline (P=0.1) or at the 2nd follow up (P=0.5). However, each 1-mmol/l increase 
in phosphorus concentrations was associated with approximately 3-fold increased risk for 
rapid GFR decline (defined as at least 4.5ml/min/1.73m2 decrease during the 3 years) after 
adjusted for age, gender, smoking, hypertension, cardiovascular disease, BMI, Low-density 
lipoprotein, triglyceride, albumin, and baseline GFR (OR 3.1, 95%CI 1.3-7.2, P = 0.01).
Conclusions: Higher phosphorus levels are associated with GFR decline in heathy 
individuals. Further studies are needed to validate this finding.
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Background: According to USRDS, over two-thirds of patients treated with 
hemodialysis had serum phosphate (PO4) greater than the KDIGO guidelines of 4.5 mg/dl 
(USRDS 2017, KDIGO 2009). In practice, most clinicians try to achieve PO4 levels between 
3.0 and 5.5 mg/dl (Handbook on dialysis 2015). Proactively identifying patients who may 
transition from the normal clinical range to greater than 5.5 mg/dl may help clinicians target 
their interventions and avoid elevated PO4 levels.
Methods: We built a machine learning model with over 1000 variables to predict which 
HD patients will realize a PO4 lab value greater than 5.5mg/dl during the following month. 
We restrict our model to patients using a pharmacy specializing in renal medications with 
all PO4 draws less than 5.5 mg/dl in the last 180 days. Some of the variables included in this 
model are history of lab values, treatment vital signs, treatment no shows, comprehensive 
assessments from dieticians and social workers, and PO4 binder medication possession 
ratios. To train the XGBoost machine learning model, we utilized data from patients who 
were treated in Fresenius Medical Care North America clinics between January 2016 and 
October 2017. The results shown below are from un-seen test data with 16639 patients in 
2017.
Results: For the patients enrolled in the specialty pharmacy who have all PO4 values 
less than 5.5 mg/dl in the previous 180 days, the prevalence of having next month’s lab draw 
greater than 5.5 mg/dl is approximately 10%. Results from the test data include area under 
the receiver operating curve (AUROC) of 0.75, sensitivity of 72% and specificity of 66%. 
The confusion matrix for test data is shown in Table 1.
Conclusions: We created a predictive model to help identify patients who may 
unexpectedly have elevated PO4 lab values in the next month. Identifying these patients 
may help to target interventions that mitigate negative consequences associated with high 
PO4 levels.
Funding: Commercial Support - Fresenius Medical Care North America
Confusion matrix for test data (n = 16639)
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Safety, Efficacy, and Cost-Effectiveness of Mg/Al Type Hydrotalcite Drug 
versus Conventional Phosphate Binders in Hemodialysis CKD Patients 
with Hyperphosphatemia
Yingying Chen, Lan Chen, Tianjun Guan, Yisheng Ling. Department of 
Nephrology, Zhongshan Hospital, Xiamen University, Xiamen, China.
Background: Hyperphosphatemia is a risk factor for the increased of mortality rates 
in chronic kidney disease (CKD) patients and associated to several clinical diseases. In this 
study, we assess safety, efficacy and clinical cost between Mg/Al hydrtoalcite (Talcid) and 
conventional non-calcium, non-aluminum phosphate binders (Lanthanum carbonate, LC) 
for hemodialysis (HD) chronic kidney disease (CKD) patients with hyperphosphatemia.
Methods: In this open-label, randomized, parallel-group study, 64 maintenance 
hemodialysis patients were matched to our selected procedure. Serum phosphate levels 
were over 1.78 mmol/L (5.5 mg/dl) and they were randomized to treat Talcid 1000 mg three 
times/day or LC 500 mg two or three times/day for 6 months. Serum calcium, phosphate, 
parathyroid hormone (iPTH) and alkaline phosphatase (ALP) levels were examined serially 
for 6 months.
Results: In hemodialysis patients with hyperphophatemia, both Talcid and LC 
significantly moderated serum phosphate levels, from 2.323±0.392 to 1.702±0.360 
mmol/L(P<0.01) and from 2.379±0.393 to 1.890±0.403 mmol/l (P<0.01), respectively. 
Serum calcium and intact parathyroid hormone (iPTH) level in the both groups did not 
significantly change when comparing to baseline parameters during the study. No severely 
adverse events were reported on both groups. Total cost of 6-month treatment with Talcid 
was 839.79±96.97 RMB while 6-month treatment with LC was 10292.96±4018.10 RMB 
(P<0.01).
Conclusions: The efficacy and safety of hydrotalcite are similar to LC but it presents 
higher reaching-target rate and lower economic burden in hemodialysis CKD patients 
with hyperphosphatemia. It can be severed as another option for dialysis patients with 
hyperphosphatemia patients.
Comparisons of the daily average cost and total cost between Talcid group and LC group 
during 6 months treatment.
Data are presented as mean+SD
** P < 0.001, Talcid group verse LC group
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Acute Mineral Metabolism Disorders Following Kidney Donation Are Not 
Different Compared to Those Observed in Other Surgical Procedures
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Background: Emerging studies have suggested that living kidney donors (LKD) have 
acute mineral metabolism (MM) abnormalities after unilateral nephrectomy related to loss 
of eGFR, in particular significant disturbances in P and Ca. Nevertheless, these changes have 
not been compared to controls undergoing other major surgical procedures. Our aim was to 
analyze acute MM abnormalities (serum Ca y P levels) in 3 groups: following laparoscopic 
(LN) vs. open nephrectomy (ON) and elective laparoscopic cholecystectomy (LC).
Methods: Single-center retrospective cohort study (n=293). Biochemical parameters 
were evaluated before and after surgery on days 1-6 and 30, in 100 consecutive LKD 
undergoing LN, compared with 91 subjects undergoing ON for kidney cancer or urolithiasis, 
and 102 subjects with gallstone disease undergoing elective LC. We excluded cases with 
CKD G4.
Results: LN group was younger compared to ON and LC groups (41±19, 58±14, and 
58±19 years; p<0.001), and eGFR was higher in LN compared to ON and LC (101±17, 
79±23, and 85±28 mL/min/1.73m2; p<0.001). As expected, only LN and ON reduced 
eGFR by day 2: -11.4 (-27 to 6) and -14 (-51 to 3) mL/min/1.73m2 respectively. Serum 
P levels did not change significantly from baseline to day 1, but decreased by day 2 in all 
groups (LN=-1.2 [-1.6 to -0.2], ON=-1.0 [-1.7 to -0.1] and LC=-0.6 [-1.0 to 0.0] mg/dL) 
before normalizing by day 30 (Figure). Serum P decline was not modified by concurrent 
changes in eGFR in any group. Moderate hypophosphatemia (reduction to 1-2 mg/dL) 
was similarly present in all groups (LN 14%, ON 7%, and LC 12%; p=0.16). No 
hypophosphatemia <1 mg/dL occurred during follow-up. Transient non-corrected 
hypocalcemia and hypoalbuminemia appeared by day 3 in all groups.
Conclusions: Acute MM disturbances (serum P and Ca) occur after surgical procedures 
independent of changes in eGFR, and are not related to kidney donation or nephrectomy 
indicated for other causes. Postoperative slight hypophosphatemia is frequent and appears 
to be a multifactorial.
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Hyperphosphatemia and Acid-Base Equilibrium Disorders Are Newly 
Recognized Risk Factors for Mönckeberg’s Sclerosis of Vascular Access 
Artery
Takashi Tani,1,2 Tomohiro Kaneko,1 Mariko Ikeda,1 Hideo Orimo,2 
Akira Shimizu,3 Shuichi Tsuruoka.1 1Department of Nephrology, Graduate 
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Background: Medial arterial calcification (MAC), also known as Mönckeberg’s 
sclerosis, in vascular access (VA) artery is reported to be observed with high frequency in 
end-stage renal disease (ESRD) patients with advanced age and/or diabetic nephropathy. 
MAC in VA artery is also associated with increased risk of VA failure and cardio-vascular 
disease (CVD) events. The purpose of this study was to clarify risk factors for MAC 
formation in VA arteries of patients with ESRD.
Methods: Forty-one patients with ESRD, who underwent VA operation at the initiation 
of hemodialysis therapy, were enrolled in this study. In addition to clinical information 
(primary disease, age, gender, blood biochemical and computed tomography (CT) imaging 
findings etc.), the presence of calcification was examined pathologically by Von Kossa 
staining of arterial specimens (radical artery).
Results: MAC was observed in 21 patients (51.2%), and their serum phosphorus (Pi) 
(6.2 vs 4.9), Ca x Pi product (53.3 vs 42.4), blood urea nitrogen (79.7 vs 60.7), urinary 
osmolality (U-OSM) (333 vs 246) levels were significantly higher, while HCO3
- (20.1 vs 
23.0), base excess (-5.45 vs -2.33) and urinary pH (5.80 vs 6.47) levels were significantly 
lower than the averages of 20 patients without MAC formation (48.8%). Other biochemical 
parameters (e.g. i-PTH, FGF-23, α-klotho and pyrophosphate) and patients’ age, gender 
and treatment history did not differ between MAC positive and MAC negative patients. The 
ROC analysis revealed that the area under curve for serum phosphorus and U-OSM were the 
highest, 0.771 and 0.874, respectively. By Fisher’s test, a serum phosphorus level of 4.8 mg/
dl or more significantly increased the probability of MAC (66.7% vs 17.65%, p<0.0037), 
and its odds ratio was 9.33 times. The U-OSM of 312 mOsm or more significantly increased 
the incidence of MAC (76.9% vs 9.1%, p<0.0013) with an odds ratio of 33.3.
Conclusions: It was shown that higher serum phosphorus level and severer renal 
dysfunction and acid-base equilibrium disorders at the start of hemodialysis were risk 
factors for MAC in VA artery. Particularly, patients with hyperphosphatemia over 
4.8 mg/dl were highly likely to display MAC in VA artery, so that attention should be paid 
to potential VA failure and CVD events.
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Background: Intestinal phosphorus (P) absorption is an important component of P 
homeostasis. In CKD, limiting P absorption is the goal of many pharmacologic therapies. 
24-hr urine P has been used as a surrogate for P absorption, but recent balance studies
demonstrate that this measure is highly variable and not related to net P absorption (Stremke, 
CJASN 2018). Further, 24-hr urine P is not useful in oliguric/anuric patients. Changes in
serum P are equally problematic due to diurnal variation, fluxes with dialysis, and erratic 
dietary intake. We tested a 33P absorption method as a sensitive and direct assessment of P 
absorption in humans that can be used for clinical research in hemodialysis (HD) patients.
Methods: HD patients with stage 5D CKD were enrolled. Following 10 days of 
controlled study diet (~800 mg/d P), patients underwent HD and then were admitted as 
inpatients to a clinical research center for 2 days for P absorption testing. 33P radiotracer 
was administered PO with a meal containing a load of ~300 mg P, and blood sampled 
over 24-hr. The next day, a second dose of 33P was administered by IV and blood sampled 
for another 24-hr, followed by a second HD treatment. Serum 33P activity was measured 
by liquid scintillation, adjusted for decay and expressed as % of dose. The 33P data were 
analyzed by compartmental modeling using WinSAAM software. Intestinal absorption was 
calculated as the fraction moving into blood vs. moving down the intestinal tract into stool. 
Descriptive results from 14 unique subjects are presented.
Results: Serum P increased during the 48-hr of study that was during an interdialytic 
interval. To estimate how much additional P (i.e., over absorption) was entering the system, 
a second model was used. Average fractional P absorption was 58±17%. The absorption test 
was well-tolerated by patients in the study. Complications were limited to difficulties with 
venous access in some patients.
Conclusions: Fractional P absorption can be estimated directly by a test using 
oral and IV 33P administration; the test is feasible and well-tolerated in HD patients. 
This novel methodology can be used for clinical studies aimed at assessing physiology, 
pathophysiology, or interventions related to P absorption in HD patients.
Funding: NIDDK Support, Other NIH Support - Partial support from Grant # 
UL1TR001108 (A. Shekhar, PI) from NIH, National Center for Advancing Translational 
Sciences, Clinical and Translational Sciences Award, Commercial Support - Chugai 
Pharmaceutical, Co, Ltd.
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Phosphate Binders for Preventing and Treating CKD-Mineral and Bone 
Disorder (CKD-MBD)
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Background: Phosphate binders are used to reduce positive phosphate balance for 
people with CKD to prevent tissue calcification, cardiovascular events and mortality, and 
bone complications. In this Cochrane review we aimed to update the available evidence for 
phosphate binders to manage CKD-MBD.
Methods: We searched the Cochrane Kidney and Transplant Specialised Register 
through 30 November 2017 for all randomized trials (RCTs) of adults with any stage 
of CKD comparing a phosphate binder with another phosphate binder, placebo or usual 
care. Key outcomes were cardiovascular events, all-cause and cause-specific mortality, 
symptomatic bone disease, adverse events, and surrogate measures of vascular calcification. 
We used random-effects meta-analysis, the Cochrane risk of bias tool, and the GRADE 
process to adjudicate evidence certainty.
Results: 104 RCTs (13,744 adults) were eligible. Placebo-controlled RCTs were 
generally in CKD G3-5 not requiring dialysis, while active comparator RCTs involved CKD 
5D on dialysis. In CKD 3a to 5, compared with placebo or usual care, sevelamer, lanthanum, 
iron, and calcium-based phosphate binders had uncertain effects with respect to all-cause 
and cardiovascular mortality, myocardial infarction, stroke, fracture, or coronary artery 
calcification. In patients on dialysis, sevelamer may decrease all-cause mortality (RR 0.53, 
CI 0.30-0.91; low certainty evidence) and induce less hypercalcemia (RR 0.30, CI 0.20-0.43) 
compared with calcium-based binders, while the evidence indicates that sevelamer had 
uncertain effects with respect to cardiovascular mortality, myocardial infarction, stroke, 
or fracture, coronary artery calcification, or fracture. Compared with calcium, lanthanum 
had uncertain effects with respect to all-cause or cardiovascular mortality, myocardial 
infarction, stroke, fracture, or coronary artery calcification.
Conclusions: For patients with CKD G3a to 5 not requiring dialysis, there is no 
evidence that phosphate binders improve clinical vascular and bone outcomes. For dialysis 
patients, sevelamer lowers all-cause mortality compared to calcium-based binders and incurs 
less treatment-related hypercalcemia. Data for patient-centered outcomes of lanthanum and 
iron-based binder treatment and placebo-controlled trials in the dialysis setting are limited.
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Background: Lower corrected calcium (cCa) levels were reported to be associated 
with better prognosis among incident dialysis patients. On the other hand, hypocalcemia 
(HypoCa) often leads to arrhythmia and heart failure. Prognostic importance of true calcium 
(Ca) status defined by ionized calcium (iCa) remains to be revealed.
Methods: We performed a retrospective cohort study of incident hemodialysis (HD) 
patients. We collected the latest data just before the initiation of HD. We divided patients 
into 3 categories: Apparent HypoCa (low iCa: <1.15 mmol/L and low cCa: <8.4 mg/dL), 
Hidden HypoCa (low iCa and normal cCa), and Normocalcemia (NormoCa: normal iCa 
and normal cCa). The primary outcome was the composite outcome of all-cause death and 
cardiovascular diseases (CVD) after the initiation of HD. Using log-rank tests, Kaplan-
Meier curves, and cox proportional hazards models, we examined whether Ca status 
predicts the primary outcome.
Results: Among the enrolled 321 patients, 75% of the patients showed true HypoCa 
defined as iCa <1.15 mmol/L, 57% of whom showed Hidden HypoCa. Over a median follow-
up period of 31.5 months, 31% of the patients reached the primary endpoint. The risk for 
the primary outcome was not significantly different between HypoCa and normocalcemia 
defined by cCa. In contrast, patients with true HypoCa had higher risk than patients with 
normal iCa levels (Figure). In univariate analysis, Hidden HypoCa was significantly 
associated with increased risk for death or CVD compared with NormoCa (hazard ratio 
[HR], 2.35; 95% confidence interval [CI], 1.27-4.32), whereas Apparent HypoCa was not. 
Even after adjustment for age, sex, eGFR, diabetes, QTc prolongation, serum albumin, 
phosphate, and ALP levels, Hidden HypoCa was associated with significantly higher risk 
(HR, 2.28; 95% CI, 1.08-4.80).
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Conclusions: Hidden HypoCa at the initiation of dialysis was a significant risk factor 
of the combined outcome of all-cause mortality and CVD morbidity, independently of QTc 
prolongation, phosphate, and ALP, suggesting the importance of measuring iCa.
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Background: Mineral and bone disorder (MBD) is highly prevalent in patients with 
chronic kidney disease (CKD). Serum phosphorus (Phos), calcium (Ca) and calcium 
phosphorus product have been shown to be independently associated with mortality risk in 
hemodialysis patients. We sought to examine whether evaluating the combination of Phos 
and Ca can better predict mortality rates among dialysis patients.
Methods: Our analytical cohort consists of 109,205 incident hemodialysis patients 
receiving treatment from a large dialysis organization between 2007 and 2011. Associations 
between combined serum Phos and Ca values for the first dialysis quarter (dialysis start + 91 
days) and mortality were estimated using Cox proportional hazard models with adjustment 
for demographics and markers of malnutrition and inflammation.
Results: Mean patient age was 63 ±15 years, while 44% were female, 32% were 
African American, and 58% were diabetic. The mean amount of Phos in the total cohort 
was 4.9 ± 1.1 mg/dL and the mean amount for Ca was 9.1 ± 0.6 mg/dL. Compared to the 
reference group (Phos ≥10.2 mg/dL and Ca ≥7 mg/dL), all-cause mortality tended to be 
lowest in patients with Phos 3.5-<5.5 mg/dL and Ca 8.4-<9.5 mg/dL (Hazard Ratio 0.60, 
95% CI 0.44, 0.82). Besides, patients in the highest Phos group (≥ 7mg/dL) had the highest 
mortality risk across all strata of serum Ca. (Figure 1)
Conclusions: In hemodialysis patients, keeping serum Phos and Ca within or close 
to the physiological range might result in better survival. Further studies are needed to 
examine this association.
Funding: NIDDK Support
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Background: Animal studies demonstrate that magnesium (Mg) supplementation 
inhibits arterial calcification in CKD. In humans, both CKD and diabetes mellitus (DM) are 
independent risk factors for arterial calcification; however, it is unknown if Mg influences 
calcification in CKD patients and whether DM alters this potential relationship. We tested 
the hypotheses that higher serum Mg concentration was associated with lower coronary 
artery calcification (CAC) and thoracic aortic calcification (TAC) scores in incident 
hemodialysis (HD) patients and that these associations, if any, were modified by DM.
Methods: We performed cross-sectional analyses of 367 incident HD patients in 
the Predictors of Arrhythmic and Cardiovascular Risk in ESRD (PACE) cohort. Serum 
Mg was measured on a non-HD day. CAC and TAC were quantified with computed 
tomography, which was done at a median time of 3.6 months after initiation of HD. We 
used logistic regression to study the association of Mg with CAC (>0 vs. 0) and TAC 
(>0 vs. 0) scores among all participants and linear regression for log-transformed CAC 
among those with CAC >0. Models were tested for interaction with DM status and adjusted 
for age, sex, race, smoking, body mass index, serum calcium, phosphate, parathyroid 
hormone, albumin, hemoglobin, low-density lipoprotein and Kt/V.
Results: Mean age was 55 years; 40% were female; 72% were black and 58% had 
DM. Mean serum Mg was 1.8±0.2 mEq/L; 63% had CAC >0 and 50% had TAC >0. DM 
did not modify the association between Mg and CAC. Among all participants, Mg was not 
associated with CAC. However, among those with CAC >0, per 0.1 mEq/L higher Mg, 
CAC score was 15% lower [% change: -15% (95% CI: -25%, -3%), p=0.02]. DM modified 
the association between Mg and TAC (p for interaction=0.003). Per 0.1 mEq/L higher serum 
Mg, the odds of having TAC >0 was 34% lower [OR: 0.66 (95% CI: 0.47, 0.92), p=0.02] 
among non-diabetics, but was 55% greater [OR: 1.55 (95% CI 1.08, 2.23), p=0.02] among 
diabetics.
Conclusions: Consistent with animal studies, higher serum Mg was associated with 
a lower CAC score among incident HD patients with CAC >0 and with a lower odds of 
having TAC >0 among non-diabetics. Why Mg was associated with a higher odds of having 
TAC >0 among diabetics remains to be elucidated.
Funding: NIDDK Support, Private Foundation Support
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Serum Magnesium Value at 1 Year After Initiation of Hemodialysis Is a 
Significant Predictive Factor of All-Cause Mortality
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Background: Recent studies reported that higher levels of serum magnesium (Mg) 
were associated with better prognosis in patients undergoing hemodialysis. However, 
it remains unclear which measurement point of the serum Mg value is crucial for vital 
prognosis after initiation of hemodialysis. In this study, we evaluated the association of 
serum Mg for 3 years after initiation of hemodialysis with subsequent all-cause mortality.
Methods: We conducted a single-center retrospective cohort study in 205 patients who 
initiated hemodialysis between March 2004 and May 2014 and could be followed-up for 
at least three years or more. We analyzed the influence of annual serum Mg value on all-
cause mortality for 3 years using Cox’s hazard proportional model. The hazard ratio (HR) 
of all-cause mortality was adjusted for demographic data, 3-year-averaged laboratory data 
and medications.
Results: The median follow-up period was 6.1years and fifty patients reached the 
outcome. Since the median of 3-year-averaged Mg level was 2.6mg/dl, we evaluated the 
significance of Mg≥2.6mg/dL versus Mg<2.6mg/dL using Cox’s proportional hazard 
model. Although, at the time of initiation of hemodialysis, HR of Mg≥2.6mg/dL was 
1.15[0.52-2.26], HRs of Mg≥2.6mg/dL at 1 year, 2 years and 3 years after initiation of 
hemodialysis, were 0.33[0.15-0.74], 0.41[0.15-0.74] and 0.30[0.16-0.53] and found to be 
significant factors in univariate analysis. Even adjusted for age, presence of diabetes, 3-year-
averaged serum albumin and phosphorus and use of non-calcium containing phosphate 
binder, which were also significant factors in univariate analysis, HRs of Mg≥2.6mg/dL 
at 1 year, 2 years and 3 years were 0.48[0.26-0.87], 0.45[0.25-0.82] and 0.50[0.26-0.96], 
respectively, showing that Mg≥2.6mg/dL was a significantly better prognostic factor at 1 
year or longer after hemodialysis initiation.
Conclusions: In this study, we found that higher levels of serum Mg at 1 year or later 
after initiation of hemodialysis were associated with subsequent better prognosis.
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Hypomagnesemia and Body Composition in Maintenance Hemodialysis 
Patients
Sonoo Mizuiri,1 Yoshiko Nishizawa,1 Kazuomi Yamashita,1 Kyoka Ono,1 
Kohji Usui,2 Michiko Arita,3 Takayuki Naito,4 Shigehiro Doi,5 Takao Masaki,5 
Kenichiro Shigemoto.1 1Division of Nephrology, Ichiyokai Harada Hospital, 
Hiroshima, Japan; 2Ichiyokai Ichiyokai Clinic, Hiroshima, Japan; 3Ichiyokai 
East Clinic, Hiroshima, Japan; 4Ichiyokai Yokokawa Clinic, Hiroshima, Japan; 
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Background: The aim of this study was to investigate the relationships between 
serum magnesium (Mg) levels and body composition, clinical parameters, or survival in 
maintenance hemodialysis (MHD) patients.
Methods: The subjects were 215 MHD patients on dialysate Mg of 1.0 mEq/L. Pre-
dialysis laboratory data collection and post-dialysis body composition analysis with the 
Body Composition Monitor® (Fresenius Medical Care) were performed at the baseline. 
The patients were divided into serum Mg tertiles [T1-3]. Kaplan-Meier survival, and 
logistic regression analyses for T1 were examined.
Results: Among all patients, the mean age was 72±12 years, 39.1% were diabetics, 
and the median dialysis vintage was 44 (8-96) months. The serum Mg values of T1 (n=67), 
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T2 (n=76) and T3 (n=72) were <2.3, 2.3-2.5 and >2.5 mg/dl, respectively. The differences 
in body cell mass index (BCMI) among T1, T2, and T3 were significant (5.7±1.9, 6.4±2.1, 
6.6±2.2 kg/m2, p<0.05), as were those in overhydration/extracellular water ratio (OH/
ECW) (15.1±16.5, 7.1±11.1, 9.1±14.2%, p<0.01), but no significant differences were 
seen for the body mass index (20.2±5.3, 22.1±6.4, 20.3±4.9 kg/m2), lean tissue index 
(11.2±2.6, 12.0±3.3, 12.1±3.0 kg/m2), or fat tissue index (8.0±3.7, 9.1±4.4, 8.7±4.6 kg/m2). 
T1 exhibited a significantly greater age (75±11, 73±12, 69±13 years), a shorter dialysis 
vintage, and lower normalized protein nitrogen appearance (nPNA), serum albumin 
(3.2±0.5, 3.3±0.4, 3.4±0.5 g/dl) and uric acid values (6.5±1.7, 6.9±1.4, 7.2±1.4 mg/dl) 
but higher C-reactive protein levels (1.4±2.4, 1.1±2.7, 0.9±1.9 mg/dl) compared with T2 
and T3 (p<0.05). During the 3 years, 47 (21.9%) patients died. Three-year survival rates 
were 57.7% and 67.9% in T1 and T2+T3, respectively (p<0.05). Multivariate analyses 
included all significant variables in the univariate analyses showed that T1 was significantly 
associated with the BCMI [Odds ratio (OR) 0.83, 95% confidence interval (CI) 0.70-0.97] 
or OH/ECW [OR (95%CI): 1.03 (1.01-1.06)], respectively, independent of age, dialysis 
vintage, nPNA, serum albumin and uric acid levels (p<0.05).
Conclusions: Hypomagnesemia is associated with lower 3-year survival rate, and 
worse body composition parameters such as BCMI and OH/ECW, which reflect muscle 
depletion and overhydration, respectively, in MHD patients.
Funding: Private Foundation Support
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Background: It is unclear whether hypomagnesemia causes increased mortality as 
agent provocateur or bystander in maintenance hemodialysis (MHD) patients. This study 
aimed to investigate the associations between hypomagnesemia and mortality, and to study 
the factors related to hypomagnesemia in MHD patients.
Methods: The subjects were 353 Japanese MHD patients. Laboratory parameters 
including the serum magnesium (Mg), coronary artery calcium score (CACS) and 
medication use were studied at baseline. The subjects were stratified into baseline Mg 
level quartiles (Q). Kaplan-Meier survival, Cox proportional hazards models for the factors 
associated with mortality and logistic regression analyses for Q1 were examined.
Results: Among all patients), the median age was 68 (60-78), 39.7% were diabetics, 
and the median dialysis vintage was 75 (32-151) months. The Mg values of Q1 (n=86), Q2 
(n=97), Q3 (n=99), and Q4 (n=71) were <2.2, 2.2-2.4, 2.5-2.7, and >2.7 mg/dl, respectively. 
The patients in Q1 exhibited significantly lower serum albumin, phosphate, uric acid, 
fibroblast growth factor 23, Kt/Vurea and normalized protein nitrogen appearance (nPNA) 
levels (P<0.01), but significantly higher serum high sensitivity C-reactive protein (hsCRP) 
levels (P<0.05) than the patients in Q2-4. During the 3 years, 91 patients died. The 3-year 
cumulative survival rate was 54.4%, 70.3%, 84.3%, and 85.2% in Q1, Q2, Q3, and Q4, 
respectively (P<0.05), and 3-year cardiovascular (CV) mortality was also significantly 
higher in Q1/Q2 than in Q3/Q4 (P<0.05). The Q1 was significantly associated with 3-year 
all-cause mortality [Hazard ratio (HR) 2.09, 95% confidence interval (CI) 0.96-4.49, 
P<0.01] and 3-year CV mortality [HR (95%CI): 3.03 (1.02-8.84), P<0.05], independent 
of Log (CACS+1), age, dialysis vintage, serum hsCRP and uric acid but the significance 
was lost in the model which included serum albumin, nPNA and medication use. The 
most significant determinant of Q1 was serum albumin levels (g/dl) [Odds ratio (95% CI): 
0.10 (0.02-0.37), p<0.01], and Q1 was not found to be related to CACS or medication use 
including sevelamer or proton pump inhibitor.
Conclusions: Hypomagnesemia per se may not cause increased 3-year all-cause and 
CV mortality as agent provocateur but associated with malnutrition in MHD patients.
Funding: Private Foundation Support
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Background: Hypovitaminosis D is recognized as a worldwide epidemic. It is 
associated with elevation in parathormone (PTH), increasing the risk of fractures. Studies 
on general population have reported that the relationship between PTH and 25vitamin D 
(PTH/vitD) is influenced by aging. However, in chronic kidney disease (CKD) patients, 
the effect of on PTH/vitD remains unknown. This study aims to analyze the impact of age 
(≥ 65 years old) on PTH/vitD in non-dialytic CKD patients.
Methods: This is a cross-sectional study that analysed data from digital medical 
records of stage 3 CKD patients of outpatient Nephrology service of Hospital das 
Clínicas, Universidade de São Paulo. PTH/vitD was analyzed for the following categories: 
renal function, sex, furosemide and hydrochlorothiazide intake, serum calcium, oral 
cholecalciferol supplementation, phosphate binder and omeprazole.
Results: 1178 patients (506 women and 672 men) with glomerular filtration rate (GFR) 
= 44.03 ± 8.74 mL/min/1.73m2 were analyzed. Elderly and women accounted for 57 and 
48.7% of total patients, respectively. PTH/vitD was higher in women [2.81(1.79-4.18) 
vs. 2.5 (1.6-3.97), p<0.0001], elderly [2.83(1.91-4.38) vs. 2.33 (1.54-3.61); p<0.0001], 
CKD stage 3b [2.9 (1.95-4.55) vs. 2.34 (1.49-3.52), p<0.0001], furosemide [3.48 
(2.22-5.58) vs. 2.5 (1.59-3.69), p<0.0001] and cholecalciferol users [2.9 (1.82-4.44) vs. 
2.46 (1.57-3.55), p<0.0001]; and lower in hydrochlorothiazide users [2.54 (1.6-3.66) 
vs. 2.7 (1.7-4.3), p = 0.018]. We did not find any association with phosphate binders or 
omeprazole. There was a correlation between PTH/vitD and serum calcium (r= -0.140; 
p <0.0001). The multivariate analysis revealed that PTH/vitD was dependent on eGFR, sex, 
furosemide intake, serum calcium and age.
Conclusions: Our data shows that, elderly patients with CKD present higher PTH 
levels when compared with young adults with similar eGFR, calcium and vitamin D levels. 
Prospective studies are required to determine whether cholecalciferol reposition has an 
impact on vitamin D and PTH levels in this population.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Background: Clinical management of chronic kidney disease - mineral and bone 
disorder is largely based on parathyroid hormone (PTH) concentrations, measured at regular 
intervals. The existence of PTH fragments, detected by first and second generation (“intact”) 
PTH (i-PTH) assays, led to the development of third generation (“biointact”) whole PTH 
(w-PTH) assays detecting only full length PTH. Despite efforts to use only w-PTH assays, 
i-PTH assays, which are usually less costly, are still being used and marketed, such that
it may be indispensable to convert PTH values from one assay to another. We aimed at 
assessing the technical performance of a novel i-PTH assay, in comparison to 2 widely used 
w-PTH assays and to another i-PTH assay.
Methods: PTH levels of 134 patients on chronic hemodialysis were measured at 2
timepoints within 3 months, using: the novel new i-PTH assay by Siemens Healthcare (SH) 
and Roche Diagnostic (RD), respectively; the w-PTH assay by RD and DiaSorin (DS), 
respectively. All concentrations were measured in pg/ml by automated analyzers: Advia 
Centaur CP (SH), Cobas e 602 (RD) and Liaison XL (DS). Statistical methods included 
Passing-Bablok regression analyses and Bland Altmann plots.
Results: The i-PTH SH was slightly higher calibrated than i-PTH RD. Compared 
with w-PTH assays, the i-PTH SH assay yielded 2.5-fold higher results, while i-PTH RD 
was about 2-fold higher. Among the w-PTH(1-84) assays a rather good concordance was 
observed, with a mean bias of 12 ± 45.6 pg/mL (±2 SD) by Bland Altmann plots. In contrast, 
there was a substantial bias of -88.7 ± 183.4 pg/mL between the two iPTH assays (RD 
minus SH).
Conclusions: The table provided above enables method conversions, which are of 
interest, if a laboratory switches the assay or if a patient changes the treatment center.
Funding: Commercial Support - Simens Healthcare
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Peritoneal Dialysis Mineral Metabolism Disorders: Results from the 
BRAZPDII
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Background: Few studies evaluate mineral and bone disorders (MBD) in patients 
treated with peritoneal dialysis (PD), and the main guideline guiding their treatment were 
based on studies performed in patients treated with hemodialysis. BRAZPDII is a cohort 
of patients from 114 dialysis centers in Brazil, which contains data from 9.905 patients 
on peritoneal dialysis. We analyzed biochemical markers related to MBD (calcium (Ca), 
phosphorus (P) and parathormone (PTH)), categorized patients in accordance with the 
targets proposed guideline Kidney Disease: Improving Global Outcomes (KDIGO), and 
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compared the survival index between the groups which maintained the biochemical markers 
within or without the normal ranges
Methods: We recruited 844 patients from BRAZPDII, who had MBD biomarker data, 
and followed them up for 24 months. Cox proporcional was used to eliminate potencial 
variable confounders, and Kaplan-Meier estimator was used to compare the survival rate 
between the groups.
Results: Patients with Ca and P within the normal range using KDIGO definitions 
(8.4-10.2mg/dL and 3.5-5.5mg/dL, respectively) were associated with lower mortality 
(p<0.05; HR 1.63 and 1.79, respectively). PTH levels were not associated with mortality, 
regardless of the ranges proposed by KDIGO guideline (150-600).
Conclusions: Keeping calcium and phosphate within the range as suggested by 
KDIGO was associated with lower mortality in PD patients. PTH levels were not associated 
with mortality risks.
Funding: Commercial Support - Baxter
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Background: Chronic kidney disease-mineral and bone disorder has been recognized 
as a risk factor for dialysis patients survival. Clinical guidelines identify secondary 
hyperparathyroidism (SHPT) as the main target for therapeutic measures leaving aside the 
low level of parathyroid hormone (PTH). We used data from Czech Registry of dialysis 
patients (RDP) to analyze occurence of hypoparathyroidism in incident hemodialysis 
patients and its association with clinical outcomes.
Methods: In RDP we found 4878 patients who started dialysis from 2012 to 2015. Data 
of 576 patients treated by hemodialysis (HD) and 2615 patients treated by hemodiafiltration 
(HDF) were examined using multivariable regression, log-rank test and Cox survival 
models. Patients treated by peritoneal dialysis and patients with incomplete data were 
excluded. Laboratory values are recorded in RDP every 3 months in all patients, for analysis 
we used their respective mean values over entire follow-up.
Results: Mean follow-up of 3191 patients was 1394 days, 3-years survival 71% in all 
patients, 74% in HDF and 55% in HD subgroups. Mean age of patients was 65.3 years, 
proportion of diabetics 45%. Mean PTH < 150 pg/ml was found in 31.8% of patients, PTH 
150-600 pg/ml in 64.4% and PTH > 600 pg/ml in 3.8% patients. We merged patients with 
PTH > 150 pg/ml into single group and compared all variables between subgroups with
discriminating value of PTH 150 pg/ml (low PTH vs high PTH). Low PTH was associated 
with lower BMI, lower albumin and phosphate level, higher age and Kt/V. 3-years survival 
was significantly better in high PTH group, 65% vs 74%, this association was preserved 
after adjustment for mean serum calcium, phosphate, Kt/V, dialysis method (HD vs HDF), 
age, BMI and diagnosis of diabetes. The difference in survival between low and high PTH 
group dissapeared after adjustment for serum albumin. The same proportion of patients
treated with phosphate binders was found in both groups. Proportion of patients treated
with PTH-lowering drugs (cinacalcet, paricalcitol, calcitriol) was significantly lower in low
PTH group.
Conclusions: In our study one third of incident dialysis patients have low PTH which 
was associated with decreased survival. Low PTH behaves as a marker of malnutrion not 
related to diabetes and treatment of SHPT. Whether therapeutic measures increasing PTH 
translate into better patient outcome warrants prospective studies.
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Background: It is known that patients who have done dialysis due to end stage renal 
disease have progressive vascular calcification, and that the more severe it is, the more 
frequent the occurrence and resulting death of cardiovascular disease. But so far very little 
is known about the causes of progressive vascular calcification. We aimed to investigate the 
risk factors for progressive abdominal aortic calcification in patients doing hemodialysis.
Methods: We conducted cross-sectional study of 281 subjects at six centers who 
agreed to this study and underwent lateral lumbar radiography. Kauppila score was used to 
measure abdominal aortic calcification, and progressive vascular calcification was defined 
as a median vascular calcification score of 7 or more. Radiographs of the lateral lumbar 
spine were analyzed by two staff members and the identities of the Kauppila scores between 
the two were 91%.
Results: The mean age of the 281 hemodialysis patients was 62.7 years, and 250 
patients (89%) had calcification. The distribution of the abdominal aortic calcification score 
was 49.5% in 0-6, 28.5% in 7-12, 17.1% in 13-18, and 5% in 19-24. The risk factors for 
progressive vascular calcification were Kt / V (OR 8.2, 95% CI 2.39-28.1), cardiovascular 
disease (OR 2.54, 95% CI 1.27-5.06), DM (OR 2.38, 95% CI 1.21-4.68), age (OR 1.05, 
95% CI 1.03-1.08), serum Ca (OR 1.63 1.13-2.34), total CO2 (OR 1.15, 95% CI 1.04-1.27), 
serum Na (OR 0.86 95% CI 0.79-0.93) and serum chloride (OR 0.88, 95% CI 0.82-0.94).
Conclusions: Several factors were associated with progressive vascular calcification. 
Further longitudinal studies are needed to determine the association of these factors with 
progressive vascular calcification.
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Trabecular Bone Score May Manifest as CKD-Mineral and Bone Disorder 
(CKD-MBD) Phenotype Reciprocal to Major Cardiovascular Outcome
Hyojin Yun, Inwhee Park, Gyu Tae Shin, Heungsoo Kim, Jong Cheol Jeong. 
Ajou University School of Medicine, Suwon, Republic of Korea.
Background: In general population, trabecular bone score (TBS) represents bone 
microarchitecture and predicts fracture risk independent of bone mineral density (BMD). A 
few studies reported that TBS is significantly reduced in dialysis patients. Chronic kidney 
disease-mineral and bone disorder (CKD-MBD) are accompanied by increased fracture risk 
and cardiovascular morbidity and mortality. We investigated whether TBS is associated 
with comorbidity related to CKD-MBD or frailty in hemodialysis patients.
Methods: In this cross-sectional study, TBS was obtained using the TBS iNsight 
software program (Med-Imaps) with BMD dual energy x-ray absorptiometry (DXA) 
images (L1–L4) from prevalent hemodialysis patients. For frailty evaluation, Tilburg frailty 
indicator was used. Hand grip test and bio-impedance (InBody) were measured. Patient 
generated subjective global assessment (PG-SGA) was measured as nutritional assessment. 
History of major adverse cardiovascular event (MACE) was collected. Demographic, 
clinical, laboratory and biomarker data were also collected.
Results: Total 57 patients were enrolled. Mean age of population was 56.8 ± 15.9 
years old. Female was 50.9%. Diabetes mellitus (DM) was 40.4% and MACE was 
prevalent in 36.8 %. Mean TBS value was 1.44 ± 0.10. TBS was significantly reduced 
in MACE group (1.48 ± 0.10 vs. 1.38 ± 0.08, p<0.01). Multivariable regression analysis 
was conducted adjusting age, sex, dialysis vintage, DM, MACE, phase angle and intact 
parathyroid hormone. Age (ß=-0.003; p<0.01) and MACE (ß =-0.053; p=0.02) were 
significant predictors of TBS. α-klotho neither showed any significant difference in MACE 
outcome (MACE vs. no MACE, 474.0 ± 370.0 pg/mL vs. 582.8 ± 740.1 pg/mL, p=0.54), 
nor association with TBS (r=-0.001, p=0.41). During the period of follow up after TBS 
measure (about 20 months), 4 deaths, 7 new onset fractures, and 6 new onset MACEs were 
recorded. Lower TBS was associated with mortality (p<0.05) or new onset fracture (p<0.01, 
by log-rank test).
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Conclusions: TBS was associated with age and MACE in hemodialysis patients. 
TBS may manifest as phenotype of frailty, also may manifest as CKD-MBD phenotype 
reciprocal to MACE.
TH-PO221 Poster Thursday
Bone and Mineral Metabolism: Clinical - I
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Background: Vascular calcification is a critical complication of chronic kidney disease 
(CKD), and its mechanism is multifactorial. It has been reported that kidney transplantation 
(KT) may slow down the progression of vascular calcification along with the improvement 
of kidney function. However, there is a paucity of data about the comparison of the 
progression of vascular calcification between KT and hemodialysis (HD) patients. The aim 
of the present study is to compare the progression of abdominal aortic calcification between 
KT recipients and incident HD patients.
Methods: Ninety-one patients who underwent KT from January 2008 to January 
2016 and 56 patients who initiated hemodialysis from December 2012 to June 2014 in 
our institutes were included in this study. We assessed the abdominal aortic calcification 
index (ACI) using a non-contrast computed tomography. The timing of assessment of the 
baseline and follow-up ACI was as follows; KT group: at the time of KT and at 1∼2 years 
after KT, incident HD group: at the time of HD initiaion and at 1 year after HD initiation, 
respectively. The progression of ACI (ΔACI (%/year)) was calculated and compared 
between KT recipients and incident HD patients.
Results: The KT group included 17 pre-emptive KT (PKT) recipients (Living donor; 
n= 17, Deceased donor; n= 0) and 74 non-PKT recipients (Living donor; n= 69, Deceased 
donor; n= 5). The dialysis vintage was 51.2±55.6 months in the KT group. The KT group 
had significantly lower ΔACI compared to the incident HD group. Even after excluding the 
patients with pre ACI=0 (KT; n=34, incident HD; n=4), its relationship remained significant 
among the two groups. The baseline characteristics showed that the incident HD group had 
significantly higher prevalence of diabetes mellitus (DM) and higher age and body mass 
index (BMI) compared to the KT group. After adjustment for these traditional risk factors 
for vascular calcification using a propensity score matching, baseline ACI was comparable 
among the two groups, but the KT group had significantly lower ΔACI compared to the 
incident HD group.
Conclusions: Our findings suggest that KT slows the progression of ACI compared 
to HD initiation.
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Progression of Medial Arterial Calcification in CKD and ESRD
W. Charles O’Neill, Shumila Manzoor. Renal Division,Department Of Medicine, 
Emory University, ATLANTA, GA.
Background: Medial arterial calcification, as distinguished from atherosclerotic 
calcification, is common in chronic kidney disease (CKD) and portends poor clinical 
outcomes, but its progression relative to the severity of CKD and the role of other risk 
factors is unknown. Calcification of breast arteries detected by mammography, a marker of 
generalized medial calcification, was used to measure progression in women with CKD and 
end-stage renal disease (ESRD).
Methods: Women with and without CKD were identified from a computerized 
search of medical records. Subjects with current warfarin use, which is associated with 
medial arterial calcification, were excluded. Estimated glomerular filtration rate (eGFR) 
was determined by the four-variable MDRD formula and ESRD was defined as chronic 
outpatient hemodialysis. The lengths of calcified segments of breast arteries on digital 
mammograms were summed and expressed as millimeters per breast. Results are presented 
as medians and interquartile ranges with analysis by the Mann-Whitney U or Kruskall-
Wallis test.
Results: Progression of calcification was measured in 60 control subjects (estimated 
glomerular filtration rate (eGFR) ≥ 90 ml/min/1.73 m2) and 137 subjects with CKD 
(eGFR <90 ml/min/1.73 m2) divided into tertiles by eGFR (Table). Progression in control 
subjects was linear over time and independent of age. An increased rate of progression was 
observed only in the lowest CKD tertile (eGFR <40 ml/min/1.73 m2), p=0.006. Progression 
accelerated markedly in ESRD (n=36), with a median of 20 mm/breast/y (7.4-51), p=0.006 
vs CKD 3rd tertile. Diabetes significantly augmented progression in CKD (2-fold, p=0.029) 
and ESRD (4.4-fold, p=0.004) but not in the absence of CKD:4.0 (1.1-8.5) vs. 3.9 (0.7-7.8) 
mm/breast/y.
Conclusions: CKD is a risk factor for medial arterial calcification but only when 
advanced (eGFR < 40 ml/min/m2). This is consistent with hyperphosphatemia rather 
than earlier derangements in mineral metabolism as a contributing factor. Progression 
is markedly accelerated in ESRD patients, suggesting the possibility of dialysis-specific 
effects. Diabetes is a significant risk factor in the presence of CKD or ESRD.
Funding: Clinical Revenue Support
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The Prognostic Value of Serum Galectin 3 to Abdominal Aortic Calcifica-
tion Progression in Maintenance Hemodialysis Patients
Zhiyu Wang,1 Zijin Chen,2 Haijin Yu,3 Xiaonong Chen.3 1Dapartment of 
Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 
Shanghai, China; 2Ruijin Hospital affilliated to Shanghai Jiaotong University, 
Shanghai, China; 3Division of Nephrology, Ruijin Hospital, Shanghai Jiao Tong 
University, Shanghai, China.
Background: Heterotopic vascular calcification is one of the complications of 
maintenance hemodialysis (MHD) patients contributed to adverse prognosis. Basic research 
results indicated the relation of Galectin-3 (Gal-3) with cardiovascular calcification. 
However whether serum Gal-3 is associated with uremic vascular calcification has not been 
investigated yet.
Methods: A prospective cohort study was performed. Eligible patients undergoing 
hemodialysis during July 2014 enrolled from Blood Purification Center of Ruijin Hospital 
were followed up for 3 years. Twice AAC assessment have been performed at the baseline 
and after 3-year follow-up respectively. Baseline laboratory measurement results, clinical 
data and blood samples were collected. Serum Gal-3 was detected by quantified ELISA kits. 
SPSS 23.0 and Medcalc 11.4.2.0 were used to analyze data.
Results: 152 patients were recruited. Mean Gal-3 concentration was 29.24±10.15ng/ml. 
All patients has finished first lateral lumbar X-ray examination and 104 patients finished 
repetitive examination 3 years later. Serum Gal-3 was positively associated with blood 
phosphonium, baseline abdominal aortic calcification score (AACS), andΔAACS of MHD 
patients. Logistic regression analysis indicated that serum Gal-3 was an independent risk 
factor to both severe AAC and AAC progression in 3 years. ROC analysis revealed a 
significant prognostic value of serum Gal-3 to severe AAC and AAC progression in 3 years. 
High serum Gal-3 was one of the characteristics of patients with rapid AAC progression.
Conclusions: Serum Gal-3 is a novel biomarker of vascular calcification in uremic 
patients. Our research first demonstrated that serum Gal-3 was a promising biomarker 
predicting severe AAC and AAC progression in 3years of MHD patients. Serum Gal-3 
maybe a potential intervention target for vascular calcification of MHD patients.
Funding: Government Support - Non-U.S.
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Ankle-Brachial Index Predicts Vascular Calcification in Hemodialysis 
Patients with Severe Hyperparathyroidism
Maurilo Leite,1 Alinie D. Pichone,1 Carlos P. Gomes.2 1Federal University of Rio 
de Janeiro, Niteroi, RJ, Brazil; 2UFRJ, Rio de Janeiro, Brazil.
Background: Vascular calcification, which is a common complication of secondary 
hyperparathyroidism (sHPT), is related with high mortality in chronic kidney disease 
(CKD) patients. Besides the increase of intact parathyroid hormone (iPTH), high levels 
of phosphorus induce phenotypic changes in vascular smooth muscle cells (VSMC) that 
differentiate on osteoblast-like cells causing calcification at the media of arterial wall. This 
study aims to correlate ankle-brachial index (ABI) with biochemical abnormalities and 
presence of vascular calcification on X-Ray exams.
Methods: We analyzed thirty hemodialysis (HD) patients over eighteen years of 
age and with iPTH higher than 1000pg/ml. All patients underwent an assessment of their 
clinical history, laboratory data and radiographic evaluation. ABI was measured by portable 
Doppler Medpej®DF 7001.
Results: The age was 44.8±8.7yo, 70% women, HD vintage 136.8±61.6 months, 
serum phosphorus 6.1±1.0mg/dl and iPTH 2883.7±1165.2pg/ml. 66% of patients had 
Adragão Score>3, 76% had arteriovenous fistula (AVF) calcification and 52% had lumbar 
aortic calcification. Adragão Score correlated with AVF calcification (r=0.5;p<0.01) and 
lumbar aorta (r=0.70;p<0.01). The ABI was 1.79±0.96 and correlated with Adragão score 
(r=0.54;p<0.01), AVF calcification (r=0.47;p<0,05) and phosphorus level (r=0.84;p<0.05). 
In sHPT evaluation, we routinely use a simple vascular calcification score on plain 
radiographic films of pelvis and hands (Adragão score). We verified significant correlation 
between this score compared to AVF and lumbar aortic calcifications. Moreover, ABI, a 
simple clinical tool performed at bedside, was strongly correlated with serum phosphorus, 
Adragão score and AVF calcification. All this findings corroborate with the role of 
phosphorus in osteoblastic differentiation of VSMC and vessel stiffness caused by media 
calcification.
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Conclusions: We observed high prevalence of vascular calcification in hemodialysis 
patients with severe hyperparathyroidism using conventional image methods and the ABI 
was a practice tool for this diagnosis in this population.
Funding: Government Support - Non-U.S.
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Enarodustat (JTZ-951), an Oral HIF-PH Inhibitor, Elevates and 
Maintains Hemoglobin Levels over 30 Weeks in Japanese Anemic Patients 
with CKD Not on Dialysis
Tadao Akizawa,1 Yuya Miyazawa,2 Atsushi Matsui,2 Ryosuke Koretomo,2 
Masanobu Arai.2 1Showa University School of Medicine, Tokyo, Japan; 2Japan 
Tobacco Inc., Tokyo, Japan.
Background: The dose response in Hb and safety of enarodustat administered for 6 
weeks in anemic patients with CKD not on dialysis (ND-CKD) was assessed in a placebo-
controlled, randomized, double-blind manner (period I). In addition, the maintenance 
dosage and safety of long-term treatment with enarodustat was assessed in an open-label 
manner for 24 weeks (period II).
Methods: ESA naïve subjects (G1) and subjects receiving a stable dose of ESAs 
(G2), who have protocol specified Hb criteria, were respectively randomized in 1:1:1:1 
ratio to receive either enarodustat doses of 2, 4, 6 mg or placebo once daily. Subjects, who 
completed the period I and were eligible for the period II, received long-term treatment with 
enarodustat that was adjusted in the range of 2 to 8 mg to maintain Hb in a target range of 
10.0-12.0. Use of IV iron was prohibited by the end of period I.
Results: The weekly Hb elevation rate in G1 was significantly increased with dose. In 
G2, the changes in Hb from baseline at endpoint were also increased with dose. In period 
II, the proportion of subjects who maintained Hb level within the target range at end of 
treatment in G1 and G2 were 71.4% and 83.1%, respectively. While Hb levels over the 
course of Period II stayed in a target range, more than 70% subjects experienced ≤ 1 dose 
adjustment during the period II. Median hepcidin and ferritin levels were decreased across 
all the enarodustat arms during period I in contrast with increase in TIBC levels. These 
parameters remained stable during period II. Enarodustat was generally well tolerated.
Conclusions: Enarodustat corrected and maintained Hb levels in anemic patients with 
ND-CKD with minimum dose adjustment requirement. Furthermore, better iron availability 
and utilization by enarodustat are suggested to be contributed to erythropoietic responses, 
which is expected to provide alternative and more physiologic treatment option to ESA 
for anemic patients with CKD. The efficacy and safety compared with ESA and long-term 
studies are being examined in phase 3 studies.
Funding: Commercial Support - Japan Tobacco Inc.
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Anemia and Iron Metabolism: Clinical
Enarodustat (JTZ-951), an Oral HIF-PH Inhibitor, Maintains Hemoglo-
bin Levels Switching from ESAs over 30 Weeks in Japanese Anemic 
Patients with CKD Receiving Maintenance Hemodialysis
Tadao Akizawa,1 Yuya Miyazawa,2 Kazuo Maeda,2 Ryosuke Koretomo,2 
Masanobu Arai.2 1Showa University School of Medicine, Tokyo, Japan; 2Japan 
Tobacco Inc., Tokyo, Japan.
Background: The dose response in Hb and safety of enarodustat administered for 6 
weeks was assessed in anemic patients with CKD receiving maintenance hemodialysis 
(HD-CKD) in a placebo-controlled, randomized, double-blind manner (period I). In 
addition, the maintenance dosage and safety of long-term treatment with enarodustat was 
assessed in an open-label manner for 24 weeks (period II).
Methods: Subjects, who have been receiving a stable dose of ESAs and have protocol 
specified Hb criteria, were randomized in 1:1:1:1 ratio to receive either enarodustat doses 
of 2, 4, 6 mg or placebo once daily and switched from ESAs. Subjects, who completed the 
period I and were eligible for the period II, received long-term treatment with enarodustat 
that was adjusted in the range of 2 to 8 mg to maintain Hb in a target range of 10.0-12.0. Use 
of IV iron was prohibited by the end of period I.
Results: In period I, the changes in Hb from baseline at endpoint were increased with 
dose. In period II, the proportion of subjects who maintained Hb level within the target 
range on Ext Week 24 and end of treatment were 70.9% and 65.1%, respectively. Beside 
Hb levels were within a target range, approximately 80% subjects experienced ≤ 2 dose 
adjustments during period II. Mean prescribed dose was 4.30 mg/day. Median hepcidin and 
ferritin levels were decreased across all the enarodustat arms during period I in contrast with 
increase in TIBC levels. These parameters remained stable during period II. Enarodustat 
was generally well tolerated.
Conclusions: Enarodustat maintained Hb levels in anemic patients with HD-CKD 
switching from ESAs with minimum dose adjustment requirement. Furthermore, iron 
availability and utilization by enarodustat are suggested to be contributed to erythropoietic 
responses, which is expected to provide alternative and more physiologic treatment option 
to ESA for anemic patients with CKD. The efficacy and safety compared with ESA and 
long-term studies are being examined in phase 3 studies.
Funding: Commercial Support - Japan Tobacco Inc.
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Efficacy and Safety of Daprodustat on Anemia Management in Japanese 
Hemodialysis Patients Not Using Erythropoiesis-Stimulating Agents
Taku Fujii,1 Yoshiharu Tsubakihara,2 Tadao Akizawa,3 Masaomi Nangaku,4 
Tomohiro Onoue,6 Taeko Yonekawa,1 Yukihiro Endo,5 Alexander R. Cobitz.1 
1GlaxoSmithKline, Tokyo, Japan; 2Graduate School of Health Care Science, 
Jikei Institute, Yodogawa-ku, Osaka, Japan; 3Showa University School of 
Medicine, Tokyo, Japan; 4the University of Tokyo School of Medicine, Tokyo, 
Japan; 5GlaxoSmithKline, Tokyo, Japan; 6GlaxoSmithKline, Tokyo, Japan.
Background: This Phase 3, open-label, non-comparative, multi-center study (funded 
by GlaxoSmithKline) examined the efficacy and safety of daprodustat (Hypoxia Inducible 
Factor-Prolyl Hydroxylase Inhibitor) over the 24 weeks in 28 Japanese hemodialysis (HD) 
subjects not using erythropoiesis stimulating agents (ESA).
Methods: Subjects on newly started dialysis or maintenance dialysis with hemoglobin 
(Hgb) of 8.0-<10.0 g/dL not using ESA were enrolled to receive daily oral daprodustat. After 
the first 4 weeks of the fixed starting dose of 4 mg, doses were adjusted monthly to achieve 
a Hgb target of 10.0–12.0 g/dL over the 24 weeks, utilizing doses ranging from 1-24 mg. 
The primary endpoint was to evaluate Hgb at Week 4. All subjects received the full 
ophthalmologic examinations (best corrected visual acuity, intraocular pressure, an anterior 
segment exam, and a fundoscopic exam) at baseline, Week 12 and the end of study.
Results: The mean baseline Hgb value was 9.10 g/dL. After the first 4 weeks, the mean 
change in Hgb from baseline was 0.79 g/dL (95%CI: 0.53, 1.05). No subjects experienced 
a rapid Hgb increase, defined as > 2 g/dL over the first 4 weeks. The mean Hgb value 
increased and reached the target range (10-12 g/dL) at Week 8 (10.76 g/dL), and was 
maintained within the target range at Week 24 (11.12 g/dL). At Week 24, 23 subjects (82%) 
had a Hgb value within the target range, and 18 (64%) subjects reached the lower target 
Hgb value without a dose adjustment. Ninety-two percentage of on-therapy AEs were 
reported as either mild or moderate in severity. There were no AEs leading to withdrawal/
discontinuation of study treatment and no pre-defined ocular AEs of special interest were 
reported from the full ophthalmologic exam.
Conclusions: Daprodustat 4mg safely and effectively increased Hgb over the initial 
first 4 weeks of treatment. Daprodustat had an ability to achieve and maintain Hgb within 
target range and was generally well tolerated over the 24-week of treatment.
Funding: Commercial Support - GlaxoSmithKline
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Randomized, Placebo-Controlled Phase 2 Trials of Vadadustat, an Oral 
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), to 
Treat Anemia of CKD
Masaomi Nangaku,1 Zeeshan Khawaja,2 Wenli Luo,2 Svetlana Garafola,2 
Emil deGoma,2 Yasuhiro Komatsu.3 1University of Tokyo Graduate School of 
Medicine, Tokyo, Japan; 2Akebia Therapeutics, Inc., Cambridge, MA; 3Gunma 
University, Graduate School of Medicine, Maebashi, Gunma, Japan.
Background: The HIF-PHI vadadustat (VDT) was investigated in two phase 2, 
randomized, double-blind, placebo-controlled trials in Japanese subjects with anemia due 
to non-dialysis-dependent (NDD) or dialysis-dependent (DD) CKD.
Methods: Trials consisted of a 6-wk fixed-dose, placebo-controlled, primary efficacy 
period and a 10-wk dose adjustment period. In each trial, subjects were randomized to 
VDT 150 mg, 300 mg, 600 mg, or placebo. After 6 wks, subjects randomized to placebo 
were switched to VDT, and all subjects had their dose adjusted according to Hb response. 
For the primary efficacy analysis in each study, an ANCOVA model was used in the MITT 
population to compare mean change in Hb from baseline to Wk 6 between the VDT and 
placebo groups. Last observation carried forward (LOCF) was used for missing Hb data.
Results: Fifty-one and 60 subjects were randomized in the NDD and DD studies, 
respectively. Mean changes in Hb from baseline to Wk 6 were statistically significant in all 
VDT treatment arms compared with placebo (Table). Treatment with VDT 300 mg or 600 
mg was associated with statistically significant increases in total iron binding capacity and 
decreases in ferritin and hepcidin from baseline to Wk 6 compared with placebo (P<0.01). 
Incidence of AEs during the 6-wk period in the VDT groups (150 mg, 300 mg, 600 mg) 
and placebo was 33%, 58%, 54%, and 36% (NDD study) and 53%, 73%, 40%, and 40% 
(DD study). During the 16-wk treatment period and 2-wk follow-up, the most common 
AEs reported were hypertension and viral upper respiratory infection (NDD study) and 
nasopharyngitis, diarrhea, and headache (DD study). 13 SAEs in 11 subjects (NDD study) 
and 10 SAEs in 7 subjects (DD study) were reported. No deaths were reported.
Conclusions: These data support continued development of VDT for patients with 
renal anemia.
Funding: Commercial Support - Akebia Therapeutics, Inc.
Table. Changes in Hemoglobin (g/dL) Between Baseline and Week 6: Vadadustat vs Placebo
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Effects of Dosing Frequency on the Efficiency of EPO Administration in 
Hemodialysis Patients
Sabrina Rogg,1 Doris H. Fuertinger,1,2 Stefan Volkwein,3 Peter Kotanko.2,4 
1Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany; 2Renal 
Research Institute, New York, NY; 3University of Konstanz, Konstanz, Germany; 
4Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Achieving target hemoglobin (Hgb) levels in hemodialysis (HD) patients 
treated with short-acting erythropoietin (EPO) is challenging. It is highly desirable to keep 
drug doses low to mitigate adverse events and to reduce costs. Based on a mathematical 
model of erythropoiesis we developed a model predictive control (MPC) algorithm for 
patient-level EPO dose optimization.
Methods: Using an individualized model of erythropoiesis (Fuertinger et al, PLoS 
ONE 2018) an MPC algorithm is designed for computation of EPO doses at predefined 
dosing frequencies. The MPC aims to stabilize Hgb levels at 10.5 g/dl. Hgb variability and 
total amount of administered EPO are compared in an in-silico study in 60 chronic HD 
patients over a period of 150 days for a thrice weekly versus a daily EPO administration 
regimen.
Results: Daily and thrice weekly administration maintain Hgb levels equally within the 
target Hgb range of 10-12 g/dl except one patient reaching the target range only via daily 
administration. Compared to thrice weekly EPO administration, the daily administration 
scheme reduces Hgb variability by 8.9% and lowers the cumulative EPO dose by 18.1%. 
Figure 1 shows the results obtained in a single patient.
Conclusions: Our analysis shows a clear potential for reducing the risk of adverse 
events and saving costs by increasing the EPO dosing frequency and thereby reducing the 
required amount of EPO to correct the patient’s anemia. Clinical studies are warranted to 
validate these findings.
TH-PO230 Poster Thursday
Anemia and Iron Metabolism: Clinical
Recombinant Erythropoietin Reduces Endothelium-Mediated Vasodila-
tion in Patients with CKD – A Prospective Controlled Study
Zoe D. Sun,1 Viknesh Selvarajah,1,2 Annette Hubsch,1 Nicholas R. Pritchard,2 
Joseph Cheriyan,1,3 Ian Wilkinson,1,3 Thomas F. Hiemstra.1,3 11Division of 
Experimental Medicine and Immunotherapeutics, Department of Medicine, 
University of Cambridge, Cambridge, United Kingdom; 2Department of 
Nephrology, Cambridge University Hopitals NHS Foundation Trust, Cambridge, 
United Kingdom; 3Cambridge Clinical Trials Unit, Cambridge University 
Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Background: Recombinant erythropoietin (rhEPO) is used for the treatment of 
CKD-associated anaemia, despite the hypertension and cardiovascular risks. Postulated 
mechanisms include endothelial dysfunction. Given the emergence of non-rhEPO 
treatments, elucidating the vascular effects of rhEPO in CKD-associated anaemia is 
important for comparative studies with non-rhEPO treatments.
Methods: We conducted a single centre open-label prospective non-randomised 
matched-control study in pre-dialysis rhEPO-naïve patients with CKD (n=12) and 
matched-healthy controls (n=12) to assess the effect of rhEPO on endothelial function 
(NCT02987465). Forearm blood flow responses to intra-arterial acetylcholine (ACh 
endothelium-dependent vasodilator), noradrenaline (NA) and BQ123 (ETA receptor 
antagonist) were assessed using venous occlusion plethysmography in CKD patients before 
and 6-weeks after rhEPO and in controls at baseline. Blood pressure, blood parameters and 
aortic stiffness (carotid-femoral pulse-wave velocity PWV) were measured. The primary 
outcome was change in log-transformed forearm blood flow compared using mixed-effects 
ANOVA.
Results: Baseline characteristics were similar between CKD patients and controls 
(age±SD 65±16 vs 64±16 years, male 83% vs male 83%). Although median eGFR 
(16, IQR 13-25 vs 83, IQR 78-90 ml/min, p<0.001) and haemoglobin (Hb 97±11 g/L vs 
140±9 g/L, p<0.001) were lower, mean arterial pressure (110±21 vs 92±9 mmHg, p=0.02) 
and PWV (11.5±4.8 vs 8.3±2.2 m/s, p=0.04) were higher in patients with CKD. Response 
to ACh did not differ significantly between CKD patients and controls at baseline. In the 
CKD group, rhEPO increased haemoglobin (Hb) to 110 ± 17g/L (p<0.001) after 6 weeks, 
and reduced endothelium-dependent vasodilation by 23% (95% CI, 5% to 40%, p=0.009). 
The response to BQ123 did not differ after rhEPO treatment (-5%, 95% CI, -13% to 2%, 
p=0.15), but there was a greater vasoconstrictor response to NA (10%, 95% CI, 2% to 17%, 
p=0.01). Blood pressure and arterial stiffness did not change significantly after rhEPO.
Conclusions: Endothelium-dependent vasodilation is impaired after rhEPO treatment 
in patients with CKD, and NA-induced vasoconstriction is enhanced, suggesting possible 
mechanisms for rhEPO-associated hypertension and adverse cardiovascular outcomes.
Funding: Commercial Support - Clinical Training Fellowship with Experimental 
Medicine Initiative co-funded by GlaxoSmithKline (GSK)
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Erythropoietin Stimulating Agents (ESA) Hyporesponsiveness and 
Outcomes: Patient Characteristics and Major Adverse Cardiovascular 
Events (MACE)
Helen T. Smith,1 Borut Cizman,1 Rebecca M. Lisle,1 Yong Chen,1 Zhou Zhou,2 
Mark Meiselbach,2 Julie Reiff,2 Jipan Xie,2 Eric Wu,2 Daniel W. Coyne.3 1GSK, 
London, United Kingdom; 2Analysis Group, Boston, MA; 3Washington 
University School of Medicine, St. Louis, MO.
Background: Studies of ESA hyporesponsivness prior to 2011 showed increased 
morbidity and mortality potentially associated with high doses of ESA. US ESRD payment 
change (bundling), introduced in 2011, contributed to lower ESA use and lower targeted 
hemoglobin and may have altered the relationship of ESA hyporesponse to clinical 
outcomes.
Methods: Using the CROWNWEB clinical database from 2012-14, we characterised 
ESA hyporesponder patients (HR) on dialysis and, using inpatient diagnosis codes, 
evaluated rates of MACE in this population compared to ESA normoresponders (NR). 
MACE outcomes were modelled using negative binomial regressions. HR were identified 
using ESA resistance index (ERI) or dose; for epoetin alfa an ERI of ≥2.0 U/kg/wk/g/L or 
dose of ≥450 U/kg/wk was used.
Results: 119,742 patients met inclusion criteria; 43% (51,544) were classified as HR. 
At baseline, most were on hemodialysis (HD) (95.7% HR and 97.0% NR) and receiving 
epoetin alfa (97.0% HR and 95.6% NR); the mean dose (U/kg/wk) in the 2 months 
prior to index date was 336.0 in HR and 69.5 in NR. HR had a longer dialysis duration 
(5.7 vs. 4.9 years) and more comorbidities, with a Charlson Comorbidity Index of 3.8 vs. 
3.2. Heart failure and coronary artery disease were more common in HR vs. NR, 47.8% vs. 
36.3% and 41.1% vs. 35.0%, respectively. However, rates of T2DM were similar (51.5% 
in HR vs. 53.9% in NR). Over one year of follow up, 23% of patients died (24.1% HR vs. 
22.6% NR). MACE and thromboembolic event-related hospitalizations were significantly 
higher for HR vs. NR (0.14 vs. 0.09 hospitalizations per patient-month). Non-adjusted and 
adjusted models for MACE incidence rate ratio comparing HR vs. NR are presented in the 
table below.
Conclusions: Our analysis showed ESA HR and NR have similar one year mortality 
rates despite epoetin alfa doses 4.8 times higher in HR. However, ESA hyporesponsivness 
was associated with increased risk of MACE and thromboembolic event related 
hospitalizations.
Funding: Commercial Support - GlaxoSmithKline
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Effects of Erythropoietin-Stimulating Agents on Blood Pressure in 
Patients with Non-Dialysis CKD and Renal Anemia
Kohji Ohki, Hiromichi Wakui, Sho Kinguchi, Takahiro Yamaji, Kazushi Uneda, 
Kotaro Haruhara, Ryu Kobayashi, Kengo Azushima, Yoshiyuki Toya, 
Kouichi Tamura. Yokohama City University, Yokohama, Japan.
Background: Erythropoietin-stimulating agents (ESAs) are widely used for treating 
renal anemia in patients with non-dialysis chronic kidney disease (CKD). Elevation of 
blood pressure (BP) is an adverse event of ESA treatment. Rigorous BP control has an 
important role in managing and treating non-dialysis CKD. Therefore, investigating the 
effects of ESA treatment on BP is important. This randomized, open-label, parallel-group, 
controlled study investigated that the effects of two main long-acting ESAs (continuous 
erythropoietin receptor activator [CERA] and darbepoetin alfa [DA]) on office BP and the 
ambulatory BP profile in 36 patients with non-dialysis CKD and renal anemia. We also 
examined the relationships of ESAs with progression of CKD and CVD events.
Methods: Participants were randomly assigned to receive CERA or DA treatment. 
The doses of ESAs were adjusted to maintain hemoglobin levels within the target range of 
10–12 g/dL. In both groups, the antihypertensive therapy was aimed at achieving the target 
office BP. The primary outcomes were office BP and the ambulatory BP profile at 24 weeks 
after randomization.
Results: Hemoglobin levels of the two groups were within the target range at 24 weeks 
after randomization. There were no significant differences in office BP and the ambulatory 
BP profile, including short-term BP variability, between the CERA and DA groups. Although 
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some patients required an increase in antihypertensive agents in the CERA and DA groups, 
the rate of these patients was comparable between the two groups. ESA treatment did not 
increase BP in both groups. There were no significant differences in vascular function, renal 
function, and the urinary protein/creatinine ratio between the CERA and DA groups.
Conclusions: Our results suggest that CERA and DA have similar effects on BP in 
patients with non-dialysis CKD and renal anemia. ESAs can improve anemia without 
worsening the BP profile with adequate use of antihypertensive agents.
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Real-World Experience with C.E.R.A. in Pediatric Dialysis Patients Fits 
Modeling-Based Predictions: Results from the IPDN Registries
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Background: The International Pediatric Dialysis Network (IPDN, www.pedpd.
org) maintains two global registries with children on chronic peritoneal dialysis (IPPN) 
and hemodialysis (IPHN). We compared registry data to PK/PD modeling and simulation 
results to validate the modeling approach for Continuous Erythropoiesis Receptor Activator 
(C.E.R.A.) in children and to examine the use of C.E.R.A. in pediatric patients (pts).
Methods: Among a total of 3225 (IPPN) and 673 (IPHN) pts registered by April 2018 
with at least one update, 126 (IPPN) and 32 (IPHN) pts received C.E.R.A. sc (IPPN) or iv 
(IPHN) and were included in a retrospective assessment of pts characteristics, efficacy (Hb, 
ferritin) and safety (hospitalization in past 6 months). A model-based evaluation of clinical 
trial data was conducted in parallel. Subsequent prospective simulations in pediatric pts 
were performed, i.e. without adjusting for baseline characteristics of IPDN pts.
Results: The mean age (SD) of pts at last visit was 12.0 (6.4; IPPN) yrs and 14.2 
(5.3; IPHN) yrs. With median [Q1;Q3] monthly doses (μg/kg body weight) of 3.0 [2.2;4.9] 
for IPPN and 1.7 [1.1;3.0] for IPHN, mean (SD) Hb levels (g/dL) were 10.8 (1.7; IPPN) 
and 10.5 (1.8; IPHN). Mean (SD) ferritin levels (μg/L) were 264 (289; IPPN) and 499 
(3339; IPHN). In pts with longitudinal follow-up, Hb and ferritin levels were stable during 
C.E.R.A. treatment. The most common causes of 132 (IPPN) and 41 (IPHN) reported
hospitalizations were hypertension and peritonitis (n=19, both) in IPPN and hypertension
(n=7) and pyelonephritis (n=5) in IPHN. Results of prospective simulations were in
excellent accordance with observed IPDN data: simulated mean [95% CI] Hb levels 
(g/dL) were 10.9 [10.5;11.3] for sc and 11.0 [10.6;11.3] for iv. Simulated median [95% 
CI] doses (μg/kg every 4 weeks) after Hb stabilization were 2.7 [2.0;3.9] for sc and 2.3 
[1.6;3.2] for iv.
Conclusions: The real-world outcomes regarding steady state C.E.R.A. doses and Hb 
responses confirm simulations based on models developed with adult and pediatric clinical 
trial data. With C.E.R.A. the Hb and ferritin levels were within clinical target ranges in 
peritoneal and hemodialysis settings. No new safety signals were observed.
Funding: Commercial Support - Baxter, Fresenius Medical Care
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Simultaneous Dosing of Iron and ESA Using Model Predictive Control 
(MPC)
Michael E. Brier, Adam E. Gaweda. University of Louisville, Louisville, KY.
Background: Advances have been made to assist the dosing of erythropoietic 
stimulating agents (ESA) beyond the use of a “paper protocol”. These methods have been 
dependent on either assuming that iron stores are replete or that a separate iron dosing 
protocol is followed. Since ESA response is influenced by the iron status and changes as 
patients become iron replete, it would be beneficial to perform these dosing procedures 
in parallel. We tested the hypothesis that we could develop a MPC algorithm for the 
simultaneous dosing of both ESA and iron.
Methods: ESA dose prediction was performed using our previously published work 
(J Am Soc Nephrol 25:159-66 2014). Dose determination is based on an estimate of the red 
blood cell life span, sensitivity to the ESA and dose of ESA. Further, a close-loop design 
was used to “feed back” the error between observed and desired Hb. A second MPC model 
was developed for Iron dosing that determines the dose of iron based on baseline ferritin, 
iron and Tsat sensitivity to iron administration based on our previously published model 
(Clin J Am Soc Nephrol 5:576-81, 2010). The current model was developed in Matlab/
Simulink. We simulated several iron deficient states with ferritin between 80 and 120 with 
ESA sensitivity values from 0.1 to 2.0. Simulations were performed to determine the impact 
of iron supplementation on ESA dose.
Results: The results of the simulations are shown in the following table where the 
effect of simultaneous iron dosing on total ESA dose is shown. Total iron administered was 
independent of ESA dosing in this simulation and resulted in 10,000, 8,000 and 4,000 mg 
over 2 years for ferritins of 80, 100, and 120, respectively.
Conclusions: We simulated the effect of concurrent ESA and iron dosing in ESRD 
using advanced computational approach. The algorithm optimizes both, ESA and iron dose. 
Further work needs to be performed on the dynamics of the response during all phases of 
iron repletion and in the face of elevated ferritin levels due to inflammation.
Funding: NIDDK Support
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Effects of Targeting 11 to 13 g/dL of Hb on Renal Outcome in Non-Dia-
betic Patients with Advanced CKD: A Randomized Control Study, 
PREDICT
Enyu Imai,1,2 Terumasa Hayashi,9 Shoichi Maruyama,8 Ichiei Narita,10 
Hideki Hirakata,5 Kenichiro Tanabe,6 Satoshi Morita,11 Masaomi Nangaku,3 
Yoshiharu Tsubakihara,4 Tadao Akizawa.7 1Nakayamadera Imai Clinic, 
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University of Tokyo School of Medicine, Tokyo, Japan; 4Graduate School of 
Health Care Science, Jikei Institute, Yodogawa-ku, Osaka, Japan; 5Fukuoka 
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Background: Anemia, a common complication of chronic kidney disease (CKD) 
is associated with high mortality. Target hemoglobin (Hb) levels using erythropoiesis 
stimulating agent for CKD remain controversial between 10 and 12g/dL, especially in non-
diabetic patients with CKD.
Methods: The open-label randomized controlled trial, PREDICT, aims to study the 
impact of targeting Hb levels of 11–13 g/dL using darbepoetin alfa with reference to a 
low Hb target of 9–11 g/dL. The primary outcome is a renal composite endpoint (starting 
chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, and 50% decrease 
in eGFR).
Results: The study enrolled 479 non-diabetic Japanese patients with eGFR 8–20 mL/
min/1.73m2. Of the 479 patients evaluated, 239 were assigned to maintain high Hb and 
240 were assigned to maintain low Hb. Mean Hb level reached at 11.0g/dL at 16 week 
in high Hb group and maintained at 11.1g/dl during the study, while it was maintained at 
10.0 g/dL in low Hb group. Mean doses of darbepoetin alfa in high and low Hb groups 
were 317 and 185μg/12 weeks, respectively. The renal composite endpoint occurred 
105 (43.9%) in high Hb group and 116 (48.3%) in low Hb group (p=0.315 for log-rank 
test, Cox HR 0.78, p=0.075). Mean GFR reduction rate from baseline was significantly 
lower in high Hb group than in low Hb group at 24 week (-3.1 vs -11.0 %, p=0.001), 48 
week (-11.0 vs -17.6 %, p=0.016), and 72 week (-9.34 vs -18.3%, p=0.024). Cardiovascular 
events occurred in 19 patients (7.9%) assigned to high Hb group and in 16 patients (6.7%) 
to low Hb group (HR 1.07, p=0.841). All cause death occurred 14 patients (5.9%) in high 
Hb group and 11 patients (4.6%) in low Hb group (HR 1.28, p=0.561).
Conclusions: Maintaining Hb at 11-13g/dL compared with Hb 9-11 g/dL by use 
of darbepoetin alfa did not improve renal outcome in patients with advanced CKD 
without diabetes, while it did not exacerbate cardiovascular outcome or all cause death. 
(ClinicalTrials.gov No. NCT01581073).
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Background: Anemia is a common complication in chronic kidney disease (CKD) 
patients and is a risk factor for increasing the incidence of cardiovascular disease (CVD). 
Epoetin used to treat these anemia has also been shown to increase CVD incidence in CKD 
patients. However, the risk of CVD of Epoetin use in dialysis patients has not yet been 
determined.
Methods: Data were collected from a prospective observational study in Clinical 
Research Center for ESRD (CRC-ESRD) registry. A total of 857 patients were enrolled in 
this study, all of whom received Epoetin and were enrolled in the registry at initiation of 
dialysis. The relationship between the incidence and mortality of CVD and Epoetin dose 
was analyzed. The patients were divided into groups by median hemoglobin (Hb) value and 
dialysis modality, and were analyzed.
Results: A mean dose of Epoetin was 4454.2±5114.0 IU/week. Median Hb level was 
10.7g/dL and mean Hb level was 10.9±1.1 g/dL. There was no difference in Hb levels 
between hemodialysis (HD) patients and peritoneal dialysis (PD) patients. However, 
Epoetin dose was 4850.1±5370.5 IU/week in HD patients, which was significantly higher 
than 2753.2±3335.7 IU/week in PD patients (p<0.001). In the low Hb group, the mean Hb 
was 10.1±0.6 g/dL and the epoetin dose was 6206.2±5651.5 U/week. In the high Hg group, 
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the mean Hb was 11.7±0.8 g/dL and the epoetin dose was 2732.1±3811.8 IU/week. Hb level 
and epoetin dose were significantly different between the two groups. The dose of Epoetin 
has a correlation with CVD event in HD patients (p<0.001), but not in PD patients (p>0.05). 
The incidence of CVD was 77 cases in the low Hb group which is significantly high than 49 
cases in the high Hb group (p=0.003). The Epoetin dose and CVD incidence were related 
in low Hb and high Hb group, respectively (each p<0.05). The CVD mortality was also 
associated with Epoetin dose in HD patients (p=0.009).
Conclusions: Epoetin dose is associated with CVD incidence and mortality in patients 
who initially initiate hemodialysis.
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Renal Outcome by Different Target Hemoglobin Levels Using Epoetin 
Beta Pegol in Predialysis CKD Patients with ESA Hyporesponsiveness: A 
Multicenter Open-Label Randomized Controlled Study 
(RADIANCE-CKD)
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Shinichi Nishi,4 Kunihiro Yamagata,5 Masaomi Nangaku,6 Takashi Wada,7 
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of Tokyo School of Medicine, Tokyo, Japan; 7Kanazawa University, Ishikawa, 
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Background: Although ESA hyporesponsiveness has emerged with respect to a poor 
renal and overall survival in CKD patients, appropriate ESA treatments to patients with ESA 
hyporesponsiveness remain uncertain.
Methods: We randomly assigned 362 predialysis CKD patients with ESA 
hyporesponsiveness to the intensive treatment group (target hemoglobin [Hb] level  11g/
dl) and conservative treatment group (target Hb level; baseline Hb levels ± 1g/dl) using
epoetin beta pegol (CERA). The primary renal composite endpoint was a transition to renal 
replacement therapy, a reduction of eGFR to less than 6ml/min/1.73m2 or a reduction of
eGFR more than 30%. The observation period was 21 months from the assignment.
Results: Mean age was 74.7 years and 58.6% were male. Mean baseline eGFR in the 
intensive and conservative groups were 15.3 and 15.9ml/min/1.73m2, respectively. Mean 
baseline hemoglobin level was similar of 9.9g/dl in both groups despite an appropriate and 
similar median dose of ESA (86 and 100 μg/month for CERA, P 0.913; 120 and 80 μg/
month for darbepoetin alfa, P 0.136, respectively). Mean Hb levels during observation 
period in each group were 10.44 and 10.05 g/dl (P < 0.0001) and median doses of CERA 
were 120.0 and 96.3 μg/month, respectively (P < 0.0001). Kaplan-Meier analysis showed 
no significant difference in the primary end point between the two groups (99 and 109 
events; log-rank test, P 0.837). Cox proportional hazards analysis also showed no significant 
difference between the two groups (Hazard ratio, 0.972; 95% confidence interval, 0.74 
to 1.28; P = 0.84. The incidence of cardiovascular events (CVEs) was not different in 
both groups [20 (10.9%) and 24 (13.4%) patients, respectively (P 0.522)]. Heart failure 
accounted for approximately 65% of CVEs in both groups.
Conclusions: Although there was no significant difference in renal outcome, our 
results suggest that targeting Hb level of 11g/dl or higher using CERA may be safe in terms 
of CVEs in predialysis Japanese CKD patients with ESA hyporesponsiveness. This study is 
funded by Chugai Pharmaceutical Co., Ltd.
Funding: Commercial Support - Chugai Pharmaceutical Co., Ltd.
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The Pursuit of a More Physiologic Iron and ESA Treatment: Results from 
a Triferic and Individualized ESA Protocol QA Project
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Background: We implemented a new standard of care (SOC) anemia protocol 
using a web-based tool that individualizes Aranesp treatments and uses Triferic for iron 
supplementation. The objective was to observe changes in anemia parameters.
Methods: A QA project was conducted in a single hemodialysis (HD) clinic in 6/16-
4/18: the standard bi-weekly Aranesp protocol and Venofer (phase A), Triferic replacing 
Venofer (phase B, 2 months “washout”+6 months), a new web-based weekly Aranesp dose 
titration tool and Triferic (phase C, 2 months “washout”+6 months). Target Hgb range 
was 9-11 g/dL with means 10 and 10.2 in phases A-B and C, respectively, and Tsat>30%. 
Monthly stats included patients who received at least one Aranesp dose during the recent 
3-months period. We compared clinic-level monthly means for anemia related variables
corresponding to standard SOC (6 months prior to phase B) and phases B and C using
ANOVA with repeated measures and Cuzick’s nonparametric test for trend.
Results: A total of 105 patients were treated at the clinic during the 3 project phases. 
Monthly totals varied due to transfers, transplantation, and death (11, 10.5%). Demographics 
mean (SD) age 61.6 (15.4) years, 52 female (50%), 35 Latino (33%), 25 (24%) white, 20 
(19%) black, 6 (6%) Asian, and 19 (18%) unknown. Anemia results for each phase are 
shown in Figure 1. Hgb means increased with the higher target mean; mean ferritin levels 
were significantly lower in phase C vs phase A or phase B (p<0.001); Tsat levels modestly 
decreased compared to phase A but remained on target; and mean Aranesp and mean total 
iron (Venofer and/or Triferic) were lower but statistically similar across protocols.
Conclusions: A more frequent dosing schedule, which integrates Triferic for iron 
management with a web-based tool for individualized Aranesp treatments, performed better 
than a standard anemia protocol in HD patients. Patients were more likely to have Hgb in 
the target range or higher, lower but not significantly different dosages of Aranesp and total 
iron, reduced Ferritin levels and maintain Tsat levels on target.
Funding: Commercial Support - Rockwell Medical Inc.
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Intravenous Ferric Carboxymaltose Is Efficacious and Safe in Management  
of Iron Deficiency Anemia Among Hemodialysis Patients
Mahmoud H. Imam, Mohammed Shawki. Internal Medicine Department, 
Faculty of medicine,Benha University, Benha, Egypt.
Background: Anemia has a high prevalence among hemodialysis patients. Therapy 
mainly includes erythropoietin (EPO) and iron supplementation. Ferric carboxymaltose is 
a recent intravenous iron that proved to be efficacious among nondialysis CKD patients 
with no data regarding its use among dialysis patients. The aim of this study is to assess the 
efficacy and safety of Ferric carboxymaltose among hemodialysis patients.
Methods: In this prospective randomized study, 104 patients on maintenance 
hemodialysis were recruited. Inclusion criteria included: anemia (hemoglobin less than 
10 gm/dL) and inadequate iron status (ferritin level < 200 mg/dL and TSAT < 20%). 
Exclusion criteria included: patient received other forms of iron within the last 4 weeks or a 
patient has recent blood loss event. Patients were randomized to receive either intravenous 
Ferric carboxymaltose (once weekly)or Iron Sucrose (three times weekly). Hemoglobin 
hematocrit, ferritin, and TSAT were recorded at baseline and after 4 and 8 weeks. The dose 
of EPO was kept the same as before the study for patients already on EPO and on a fixed 
initial EPO dose for naive patients. Adverse effects including pain at injection site, allergy, 
fever were documented. ANOVA test was performed to compare the means of hemoglobin 
and iron studies. Chi x2 test was performed to compare the frequency of adverse effects 
between the two groups. Linear regression analysis was done to assess the likelihood of 
response to IV Ferric carboxymaltose.
Results: The mean age of patients was 56.4 ± 12.2 years. Female patients were 46%. 
In the Ferric carboxymaltose group, the mean ferritin increased from 148 ± 34 to 634 ± 154 
ng/mL (95% CI: -527.07 to -444.92, p. value < 0.001). in Iron Sucrose group, mean ferritin 
increased from 134 ± 42 to 596 ± 112 ng/mL (95% CI: -491.8 to -432.12; p-value < 0.001). 
There was no significant difference in the increase in both ferritin and TSAT between the 
two groups. In addition, There was no difference in the frequency of adverse effects among 
the two groups.
Conclusions: Intravenous Ferric carboxymaltose is efficacious in restoring iron 
repletion with tolerable adverse effects.
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Real World Experience: A Conversion of Haemodialysis Patients from 
Iron Sucrose to Iron Isomaltoside
Jorge Jesus Silva,1 James Burton.1,2 1John Walls’ Renal Unit, University 
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Background: Anaemia is common in haemodialysis (HD) patients, and associated with 
significant morbidity and mortality. Intravenous (IV) iron combined with erythropoietin 
(EPO) is the mainstay treatment of anaemia in these patients. Iron isomaltoside 100, 5% 
(Diafer) is the newest IV iron available to HD patients in the UK. Objective: To assess the 
efficacy and safety of converting patients from iron sucrose (IS) to iron isomaltoside (IIM).
Methods: The clinical notes of 880 HD patients were retrospectively reviewed for 
the period between September 2015 - April 2017. 633 were prescribed IIM of which 97 
patients made a direct switch from IS to IIM. Haemoglobin (Hb), ferritin (FER), transferrin 
saturation (TSAT), and EPO dose were collected 1 month before conversion (T-1), month 
of first IIM dose (T0), 6 (T6) and 12 (T12) months post conversion. ANOVA or Friedman 
tests were used for statistical analyses with post-hoc adjustment for multiple comparisons 
using T0 as control.
Results: Differences in clinical variables are shown in the table. There was a 
statistically significant effect on Hb over time although after converting (T0), there was 
no significant change at 6 or 12 months. There were significant improvements in ferritin 
and TSAT over time, which remained at 6 months for both (P<0.01) and at 12 months for 
TSAT (P<0.05). There was an overall decrease in weekly iron dose that was significant at 
12 months (P=0.02) and no change in EPO dose. In total there were 28,125 prescriptions of 
IIM and 8,145 of IS with no difference in reported adverse events during the audit period (6 
each, none required adrenaline).
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Conclusions: Hb, TSAT and FER were maintained at satisfactory levels for at least 12 
months post-conversion, indicating that the drugs have similar efficacy with no difference 
in reported adverse events.
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When It Comes to Intravenous Iron, More or Less, Outcomes Are Same
Srikanth Thiruvarudsothy,1,2 Theesitha Srikanth,3 Jennine Michaud,2 
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Background: Intravenous (IV) iron supplementation is required in the management 
of anemia in most chronic hemodialysis patients. Although iron supplementation will 
replete iron stores and provide available iron to maximize effectiveness of erythropoietin 
stimulating agents (ESAs), it is a potent oxidant and known for having several potentially 
toxic side effects including worsening of infections and iron overload. Thus, lower doses of 
iron would be preferable, provided anemia is adequately managed and ESA requirements 
are not increased as a result.
Methods: In a single hemodialysis unit of 48 male veterans, we prospectively treated 
patients with standard dosing of IV sodium ferric gluconate (loading dose: 1000mg when 
transferrin saturation (Tsat) <20% and/or ferritin <100 μg/L or maintenance dose: 500mg 
when Tsat 20-50% and ferritin 100-800 μg/L), to maintain a hemoglobin (hb) level of 
10-11 g/dL. Iron loading dose was 125mg IV with each dialysis treatment X 8 doses and
maintenance dose was 125mg IV weekly X 4 weeks. The subsequent six months, iron
dosing was reduced by half, and all other treatments were continued per protocol. Hb
and iron parameters were assessed throughout the treatment periods, along with dosing
requirements of erythropoietin and iron.
Results: There were no differences seen in the hb and iron profile during the standard 
vs reduced dosing periods, hb (mean 10.46 g/dL SD 1.57 vs mean 10.41 g/dL SD 1.39, 
p=0.72), Tsat (mean 22.83% SD 11.99 vs mean 24.76% SD 12.69, p=0.086) and ferritin 
(mean 565 μg/L SD 410 vs mean 606 μg/L SD 419, p=0.11). During the 6 month standard 
dosing period, 19.1% of the patients received IV iron and 23.8% during the reduced dosing 
period. The average amount of iron administered was 126.6mg/month in the standard 
dosing group and 51.2mg/month in the reduced dosing group. Erythropoietin dosage was 
similar during the two periods: 16,517 units/week (SD 8413) vs 14,064 units/week (SD 
8612) respectively, p=0.055, however, more patients required erythropoietin treatment 
(32.8% vs 52.4%).
Conclusions: In our study population, iron stores were equally maintained during the 
standard dosing compared to a 50% reduction in IV iron administration, but more patients 
required ESA therapy. Implementation of a lower dosing IV iron regimen may mitigate 
potential adverse effects of iron supplementation without effecting iron stores.
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Risk of Infection Post Intravenous Iron Therapy in Patients with Anemia 
of CKD
Summer Dyer,1 Chai L. Low,1 Hugh V. Nguyen.2 1VA San Diego Healthcare 
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Background: The use of intravenous (IV) iron therapy has escalated in the treatment 
of anemia of chronic kidney disease (CKD) in order to optimize hemoglobin outcomes with 
the use of erythropoiesis-stimulating agents. The risk of infection associated with IV iron 
administration in patients with non-dialysis-dependent CKD has not been well defined. The 
purpose of this study was to investigate the risk of infection in patients with non-dialysis-
dependent CKD who have received IV iron versus those patients who have not received IV 
iron within 3 months post index date.
Methods: This was a retrospective cohort, single center study of patients receiving 
care at the VA San Diego Healthcare System. Patients were included if they were enrolled 
in an outpatient CKD clinic from January 1, 2014 to June 1, 2017. Patients were excluded 
if they had end stage renal disease, active infection, or had an active prescription for 
immunosuppression therapy. The treatment arm included patients who had received at least 
one dose of IV iron for treatment of anemia of CKD. The control arm included patients 
enrolled in CKD clinic who did not receive IV iron during the study period. Control patients 
were matched to the treatment arm patients in a 3:1 ratio based on the season of their index 
date. Infection was defined as prescription of IV or PO antibiotic within 3 months post index 
date. Chi square test was performed to determine statistical significance for our primary 
outcome.
Results: 33 out of the 411 (8.0%) control patients and 22 out of the 136 (16.2%) IV iron 
patients developed at least one infection over the course of 3 months after the index date 
(p=0.006). CKD patients who received IV iron where twice as likely to develop an infection 
versus CKD patients who did not receive IV iron (OR=2.21, 95% CI 1.2-3.9).
Conclusions: This study provides support that the use of IV iron is associated with 
increased infection risk in the non-dialysis-dependent CKD population. This study however 
is limited in the ability to account for all baseline confounding variables between our study 
populations as it is retrospective in nature. A prospective study will be imperative to further 
investigate this increased risk of infections associated with IV iron therapy. Thoughtful 
consideration of the risks and benefits are warranted in prescribing IV iron for the treatment 
of iron deficiency anemia in CKD.
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Effect of Intravenous Ferumoxytol on Serial Platelet Counts in CKD 
Patients with Iron Deficiency Anemia
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Background: Iron deficiency often leads to reactive thrombocytosis; theoretically, its 
correction should lead to a lowering of the platelet count (PLT). Only a few studies have 
investigated this aspect, with some showing a reduction in PLT, whereas others did not. We 
investigated the effect of iron repletion with intravenous (IV) ferumoxytol (Fm) on serial 
PLT counts in CKD patients with iron deficiency anemia (IDA).
Methods: We conducted a retrospective chart review, including all patients with CKD 
and IDA who were treated with IV ferumoxytol at our medical center during a 24-month 
period. Patient demographics were recorded, as were baseline laboratory values for 
creatinine, eGFR, hemoglobin (Hgb), hematocrit (HCT), iron, transferrin saturation, ferritin 
and PLT. The serial counts for Hgb, HCT and PLT continued to be recorded at 1, 2, 3, 4, 6, 
8, 12 and 16 weeks after the Fm dose. If data was unavailable at the exact time point, the 
nearest date was used if within a week.
Results: A total of 264 doses of IV ferumoxytol (each 510 mg) were given in 119 
patients with age 57±13 years, Creatinine 3.1±1.5 mg/dL, eGFR 26±12 mL/min, Hgb 
10.2±1.3 g/dL, T-sat 16.5±6 % and PLT 242±85. All CKD stages were represented in 
the study sample. Hgb and Fe stores improved post-dose. The change in post-dose PLT 
over time is depicted in the table below. In fact, PLT were reduced compared to baseline 
throughout the 16-week period of follow-up, reaching statistical significance at weeks 3, 
6, 8, 12 and 16.
Conclusions: Correction of iron deficiency significantly lowered PLT in CKD patients 
with IDA who received IV ferumoxytol. This finding stands in contrast to some previous 
evidence that PLT counts were not significantly reduced with IV iron dextran used as total 
dose infusion. Our findings may help guide choice of IV iron therapy, given the possibility 
that increased PLT in the short-term post-dose period may contribute to the thrombotic 
events noted in clinical trials of erythropoiesis stimulating agents in CKD patients.
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Once Daily versus Twice Daily Oral Iron for Iron Repletion in CKD: A 
Randomized, Controlled, Open Label Trial
Vivek Kumar,1 Vivek D. Sood,2 Samir Malhotra,2 Krishan Lal L. Gupta,3 
Kajal Kamboj.4 1Postgraduate Institute of Medical Education and Research, 
Chandigarh, India; 2PGIMER, New Delhi, India; 3Postgraduate Institute of 
Medical Education & Research, Chandigarh, India; 4Nephrology, PGIMER 
Chandigarh, Chandigarh, India.
Background: In healthy individuals, the amount of iron absorbed with once 
daily (OD) dosing has been shown to be as good as with twice daily (BD) dosing 
despite double cumulative dose with BD dosing. Increase in serum hepcidin impairs 
absorption from subsequent dose when multiple doses are given. Oral iron 
supplementation, given as divided daily doses, is commonly prescribed in pre-dialysis 
CKD as iron deficiency and anemia are common. Therefore, in view of recent findings 
of impaired iron absorption with multiple daily dosing in normal individuals, we 
decided to compare iron repletion by OD versus BD oral iron dosing in subjects with 
stage G3-4 CKD and iron deficiency. The primary objective was difference in change in 
% transferrin saturation (%TS) between groups over 12 weeks. The main secondary 
objectives were differences in change in serum ferritin and blood hemoglobin over 12 
weeks.
Methods: In this open label, randomized, controlled trial (CTRI/2017/02/007799 at 
ctri.nic.in), stable adult subjects with CKD stage G3-4 and iron deficiency (%TS <30 %  
and serum ferritin <500 ng/ml) were randomized (1:1) to receive tablets of ferrous ascorbate 
(equivalent to 100 mg elemental iron) in either OD (one tablet daily, total 100 mg) or 
BD (one tablet twice daily, total 200 mg) dosage. Hemoglobin <9 g/dL, iron use in last 3 
months, previous gastrointestinal disease, bleeding or use of anti-acid drugs were 
exclusion criteria. Repeated measure ANOVA was used to assess change in % TSAT and 
serum ferritin over 2, 6 and 12 weeks in either dosage group and test the interaction of 
dosage form with change in % TSAT and serum ferritin in study population.
Results: Out of 328 screened subjects, 80 were enrolled. At baseline, the groups 
were similar except for higher hemoglobin and eGFR in the OD group. In both groups, 
there were significant effects (increase) of the dosage group on % TS and serum ferritin. 
However, there were no interaction between the dosage group and change in %TS [Wilks’ 
Lambda=0.951, F (3, 222) = 1.359, p=0.258] or change in serum ferritin [Wilks’ 
Lambda=0.916, F (2.533, 187.450) = 2.666, p=0.059] or change in hemoglobin. 
Interestingly, there was significant interaction of dosage group with change in MCHC 
with significant rise in OD group (p < 0.001).
Conclusions: Iron incorporation in hemoglobin might be better with OD dosing.
Funding: Government Support - Non-U.S.
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Anemia and Iron Metabolism: Clinical
Effect of Oral Ferric Maltol on Iron Parameters in Patients with CKD and 
Varying Degrees of Inflammation; A Randomized, Controlled Trial
Nelson P. Kopyt. AEGIS-CKD Study Group Lehigh Valley Hospital, Allentown, 
PA.
Background: The incidence of anemia increases with the severity or stage of CKD. 
Further, some patients with CKD have chronic inflammation, which can reduce the 
absorption and utilization of iron, including that from oral ferrous iron products. Alternative 
intravenous iron administration can be inconvenient and has the risk of allergic reactions 
or iron overload. Patients with CKD and iron-deficiency anemia (IDA) would benefit from 
an oral iron replacement therapy that is effective irrespective of the degree of underlying 
inflammation.
Methods: In this phase 3, multicenter, randomized, controlled trial (NCT02968368), 
patients aged ≥18 years with CKD (estimated glomerular filtration rate ≥15 to 
<60 mL/min/1.73 m2) and IDA were randomized 2:1 to ferric maltol or placebo orally 30 
mg twice daily for 16 weeks. IDA was defined as hemoglobin ≥8.0 g/dL to <11.0 g/dL, and 
either ferritin <250 μg/L with transferrin saturation (TSAT) <25% or ferritin <500 μg/L 
with TSAT <15%. Changes in iron storage indices were assessed at weeks 4, 8, and 16 for 
different levels of high-sensitivity C-reactive protein (hsCRP).
Results: 111 patients were randomized to ferric maltol and 56 to placebo. In the 
intent-to-treat population (last observation carried forward), the mean change in ferritin 
from baseline to week 16 for ferric maltol vs placebo was 25.32 vs –3.67 μg/L for those 
with hsCRP <1 mg/L, 32.54 vs –3.88 μg/L for those with hsCRP ≥1 to ≤3 mg/L, and 
23.78 vs –12.87 μg/L for those with hsCRP >3 mg/dL. Corresponding changes in TSAT 
concentrations from baseline to week 16 were 3.95% vs –1.89% in ferric maltol recipients 
vs placebo recipients with hsCRP <1 mg/L, 3.31% vs –0.12% in those with hsCRP ≥1 to ≤3 
mg/L, and 3.86% vs –0.97% in those with hsCRP >3 mg/dL.
Conclusions: Ferric maltol improved iron parameters – ferritin and TSAT – from 
baseline to week 16 vs placebo in patients with IDA and CKD irrespective of the degree of 
chronic inflammation.
Funding: Commercial Support - Shield Therapeutics Ltd
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Anemia and Iron Metabolism: Clinical
Effect of Oral Iron on Serum Hepcidin and Erythroferrone in CKD 
Patients
Bhupesh Panwar,2 Rebecca L. Womack,3 Orlando M. Gutierrez.1 1UAB School 
of Medicine, Birmingham, AL; 2The University of Alabama at Birmingham, 
Birmingham, AL; 3University of Alabama at Birmingham, Birmingham, AL.
Background: Hepcidin regulates iron metabolism by blocking iron egress from iron-
handling cells. Erythroferrone (ERFE) is a hormone that is stimulated by erythropoietin 
and directly inhibits hepcidin production. Despite the key role of both hormones in iron 
metabolism, little is known about the change in hepcidin and ERFE in response to oral iron 
in CKD patients.
Methods: A total of 24 patients with stage 3b-4 CKD and iron deficiency were 
randomized to take either ferric citrate (FC;n=12, 2 gms tid with meals) or ferrous sulfate 
(FS;n=12, 325 mg tid) for 12 weeks. Follow-up visits were done 2, 6 and 12 weeks after 
baseline, at which time serum samples were collected to measure hepcidin and ERFE. 
Linear mixed models were used to examine changes in hepcidin and ERFE overtime and 
whether this differed by treatment arm.
Results: There were no significant differences in baseline characteristics by treatment 
arm [Figure1]. Serum TSAT and ferritin increased by 10% and 37%, respectively, in the 
FC arm and 0.1% and 6%, respectively, in the FS arm after 12 weeks. The change in serum 
hepcidin differed by randomization arm (P=0.03). Hepcidin concentrations significantly 
increased in participants taking FC but not those taking FS [Figure2]. There was no 
significant change in serum ERFE over time in either group.
Conclusions: Treatment with FC, but not FS, increased serum hepcidin in CKD 
patients. Neither drug significantly changed ERFE.
Funding: Commercial Support - Keryx Biopharmaceuticals
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Oral Iron Administration (OIA) Transiently Increased Serum  
Malondialdehyde Modified Low-Density Lipoprotein (MDA-LDL) and 
Non-Transferrin Bound Iron (NTBI) in Hemodialysis (HD) Patients
Noriko Saito,1 Kazuhide Saito,2 Tetsuo Morioka,1 Hisaki Shimada,1 
Katsuya Ikuta,4 Yutaka Kohgo,3 Shigeru Miyazaki.1 1Nephrology, Shinraku-en 
Hospital, Niigata, Japan; 2Urology, Niigata University, Niigata, Japan; 
3International University of Health and Welfare, Nasushiobara, Japan; 
4Asahikawa Medical University, Asahikawa, Japan.
Background: Intravenous iron administration may increase NTBI which appears 
in iron overload and cause organ damage through free radical production. OIA is not 
considered to increase NTBI because of slow iron adsorption rate. Aim of this study is to 
assess the kinetics of transferrin saturation(TSAT), NTBI and MDA-LDL in HD patients 
after OIA.
Methods: 16 HD patients without any iron load within 4 weeks, whose Hb<12g/dl, 
ferritin<100ng/ml and CRP<1.0mg/dl and 8 healthy volunteers were enrolled. Both 
groups received oral ferrous sulfate 105mg. We evaluated the following markers before 
and at 1,2,3,4 and 48 hours(hrs) after OIA : MDA-LDL, NTBI, Hepcidin-25(HPC), serum 
iron(Fe), TSAT, ferritin and standard hematological parameters. Vitamin C(VC) and 
selenium(Se) were measured before and 48hrs. Other 9 HD patients without OIA were 
also enrolled as HD control. MDA-LDL was measured by ELISA. NTBI was measured by 
recently described reliable method(Clin Chim Acta437:129-135, 2014).
Results: 1. Fe before OIA was 30(24-49)μg/dl and significantly increased at 1hr and 
reached the peak level of 272(104-320)μg/dl at 4hrs (medians(interquartile range)). 2. 
MDA-LDL before OIA was 97(68-124)U/L and significantly increased to 116(73-166)U/L 
at 1hr and reached the peak level of 121(81-165)U/L at 3hrs and decreased to 117(79-134)
U/L at 48hrs, not significantly different from the level before OIA. 3. TSAT before OIA 
was 12(7-17)% and significantly increased at 2hrs, reached the peak level of 70(34-80)% 
at 4hrs. 4. NTBI before OIA was 0.02(0-0.10)μM and significantly increased to 0.15(0.03-
0.56) μM at 4hrs. 5. HPC before OIA was very low (0.55(0.14-1.78)ng/ml) and unchanged 
during 48hrs. 6. In healthy and HD controls Fe, MDA-LDL, TSAT, NTBI and HPC were 
not significantly changed during 48hrs. 7. VC before OIA in HD patients was 3.0(1.8-6.2)
mg/ml and significantly lower than that in healthy volunteers (7.7(6.5-10.7) mg/ml). 8. Se 
before OIA in HD patients was 14.5(12.5-16.1) mg/dl and significantly lower than that in 
healthy volunteers (18.4(17.6-20.3) mg/dl).
Conclusions: Fe and MDA-LDL at 1hr, TSAT at 2hrs, and NTBI at 4hrs significantly 
increased after OIA in HD patients. The lower anti-oxidant level in HD patients may 
influence the early increase of MDA-LDL.
Funding: Private Foundation Support
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Economic Burden of Anemia-Related Transfusions in Medicare Dialysis 
Patients
David T. Gilbertson,1 Suying Li,1 Tara Matsuda,2 Yi Peng,1 Vasily Belozeroff,2 
Nisha Bhatt,2 James B. Wetmore.3 1Chronic Disease Research Group, 
Minneapolis, MN; 2Amgen, Thousand Oaks, CA; 3Hennepin County Medical 
Center, Minneapolis, MN.
Background: Red blood cell transfusions are unwanted outcomes of poor anemia 
management, and remain important enough that Medicare has instituted a quality measure 
to ensure adequate care of dialysis patients. Previous studies investigated the burden of 
transfusions in Medicare dialysis patients, but did not investigate anemia-related transfusions 
(in the absence of another acute medical indication), or costs of inpatient transfusions due 
to anemia. We estimated Medicare spending for both inpatient and outpatient transfusions 
administered solely to manage anemia.
Methods: We used the USRDS dataset to analyze patients receiving dialysis in 2014. 
We included Medicare Parts A/B patients on dialysis at the beginning of 2014 and those 
initiating dialysis during 2014. Transfusions were identified using an algorithm requiring 
Anemia and Iron Metabolism: Clinical
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
177
J Am Soc Nephrol 29: 2018 Poster/Thursday
ICD-9 procedure and/or revenue center codes. We identified hospitalizations with 0- or 
1-day stays with anemia as the principal diagnosis and no evidence of another reason for
the hospitalization based on other diagnosis, procedure, and DRG codes. We identified 
outpatient, emergency department (ED), and observation (Obs) stays that appeared to be
solely for transfusions. We calculated associated total Medicare paid costs by identifying 
costs directly associated with the transfusion and related costs for screening or monitoring 
in the pre- (day -3 to day -1) and post- (day 1 to day 3) period, and post-transfusion-related 
complications.
Results: We identified 9669 transfusions associated with anemia in the absence of other 
acute illness: 974 inpatient, 1264 ED/Obs, 7431 other outpatient. Total Medicare payments 
for these transfusions were $13.78 million: $7.37 million inpatient, $1.47 million ED/Obs, 
$4.95 million other outpatient. Inpatient transfusions accounted for 10% of total anemia-
related transfusions, but for over 50% of total transfusion costs.
Conclusions: Costs related to anemia-induced transfusions are substantial. Savings can 
be potentially achieved by more closely following anemia treatment guidelines, and using 
outpatient settings in lieu of more expensive care settings.
Funding: Commercial Support - Amgen
TH-PO249 Poster Thursday
Anemia and Iron Metabolism: Clinical
Anemia Treatment Patterns in CKD: Results from Three International 
Surveys Among Physicians
James Jackson,1 Heleen van Haalen,2 Hanna Salehi,1 Gary R. Milligan,1 
Rebecca Moon.1 1Adelphi Real World, Macclesfield, United Kingdom; 
2AstraZeneca, Gothenburg, Sweden.
Background: Patients with chronic kidney disease (CKD) are at risk of developing 
anemia. We describe the use of anemia medications, internationally and in the US, by year, 
by Hb level and across CKD stages.
Methods: Data were drawn from the 2012, 2015 & 2018 Adelphi CKD Disease Specific 
Programmes. The real-world, point in time surveys included data from physicians (mostly 
nephrologists) and a random sample of their CKD patients across France, Germany, Italy, 
Spain, United Kingdom (EU5; included in 2012 and 2015), US (all years) and China (2015 
only). Disease and treatment information, including oral iron, IV iron and erythropoiesis-
stimulating agents (ESAs), was provided by the physicians and was analyzed descriptively. 
Blood transfusions were not considered.
Results: Data were available from 5488 non-dialysis (NDD) and 3490 dialysis (DD) 
patients (1350 and 1255 from the US, respectively). The overall prevalence across regions 
of Hb<10 g/dL was 8%, 7%, 15%, 20%, and 19% in patients CKD stage 3a, 3b, 4, 5 and 
dialysis, respectively, which increased slightly over time. Across regions, these patients 
were more likely to be treated for anemia in higher CKD stages. Although treatment rates 
varied by practice type, the overall proportion of US patients prescribed anemia medication 
increased to 42% of NDD patients (and varied by Hb levels; figure) and 80% of DD patients 
in 2018. The proportional use of ESAs in US NDD patients decreased from 75% to 49%, 
yet was stable in DD patients. In 2015, proportional ESA use in NDD patients was higher 
in EU5 countries than in the US.
Conclusions: CKD-anemia is most often treated in DD patients. Medication rates in 
NDD patients increased over time, yet anemia prevalence also increased, suggesting that 
anemia management can be optimized.
Funding: Commercial Support - AstraZeneca
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Anemia and Iron Metabolism: Clinical
Associations of Hemoglobin Levels and Quality of Life in Patients with 
CKD: Pooled Results from Three International Surveys
James Jackson,1 Heleen van Haalen,4 Hanna Salehi,1 Gary R. Milligan,2 
Rebecca Moon.3 1Adelphi Real World, Macclesfield, United Kingdom; 2Adelphi 
Real World, Macclesfield, United Kingdom; 3Adelphi Real World, Macclesfield, 
United Kingdom; 4AstraZeneca, Gothenburg, Sweden.
Background: Anemia is a common comorbidity in patients with chronic kidney 
disease (CKD), which can affect patients’ quality of life (QoL). The current study aims to 
determine the burden of anemia in CKD, by analyzing patients’ QoL by CKD stage and 
hemoglobin (Hb) levels.
Methods: Data were drawn from the 2012, 2015 & 2018 Adelphi CKD Disease 
Specific Programmes. The real-world, point in time surveys included data from physicians 
and a random sample of their CKD patients across France, Germany, Italy, Spain, United 
Kingdom (EU5), USA and China. Data were pooled to create a large cross-sectional dataset. 
Patient demographics, disease characteristics and concomitant conditions were provided 
by the physicians. Patients completed the Kidney Disease Quality of Life Instrument 
(KDQOL), including the short form 12 (SF-12), and the EuroQol Visual Analog Scale (EQ 
VAS). Multivariable analyses were performed on SF-12 and EQ VAS scores, adjusting for 
age, sex, CKD stage, common comorbidities and CV risk.
Results: KDQOL and EQ VAS results were available for 2781 and 2789 NDD 
patients and 1749-1726 DD patients, respectively. As CKD stage increased, patients’ QoL 
deteriorated across all KDQOL domains. In the total population, lower Hb levels were 
associated with lower KDQOL and EQ VAS scores (Table). This association was also 
apparent within CKD stages. Adjusted analyses showed statistically significant positive 
associations between Hb level and the SF-12 physical and mental summary scales as well as 
EQ VAS scores (all p<0.001), which were numerically strongest in patients not on dialysis.
Conclusions: This study revealed a consistent relation between lower Hb level and 
deteriorated QoL, which was significant when adjusted for potential confounding factors. 
Anemia should be recognized as a contributing factor to lower QoL in patients with CKD.
Funding: Commercial Support - AstraZeneca
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Incidence, Prevalence, and Correlates of Anemia and Iron Deficiency in 
US Veterans with Non-Dialysis Dependent CKD (NDD-CKD)
Carl P. Walther, Peter Richardson, Maulin Shah, Sreedhar A. Mandayam, 
Wolfgang C. Winkelmayer, Sankar D. Navaneethan. Baylor College of 
Medicine, Houston, TX.
Background: Anemia in CKD is often multifactorial, including from low 
erythropoietin production, absolute (true) iron deficiency, and functional iron deficiency 
related to a chronic inflammatory state. However, there is limited evidence regarding the 
incidence, prevalence, and correlates of anemia and iron deficiency in NDD-CKD, which 
is the objective of this study.
Methods: We identified persons with NDD-CKD receiving care through the 
Veterans Affairs healthcare system from 2005-2015. Eligible patients had ≥2 eGFRs 
<60ml/min/1.73m2 separate by >90 days and a Hgb measured within 180 days of the 
2nd measured eGFR. We calculated incidence and prevalence of anemia (Hgb<12g/dl), 
characterized concurrent iron parameters (iron deficiency: absolute, transferrin saturation 
[TSAT] ≤20% and ferritin <100ng/ml; functional, TSAT ≤20% and ferritin ≥100ng/ml), and 
identified correlates of iron deficiency status using logistic regression.
Results: We included 944,175 persons with NDD-CKD and measured Hgb. At incident 
eGFR <60, 78.4% were non-anemic, 16.9% had mild (Hgb 10-<12g/dl), 4% moderate (Hgb 
8-<10g/dl), and 0.6% severe anemia (Hgb <8g/dl). Incidence of anemia among 686,649 
at-risk patients was 110.3 (95%CI; 109.9-110.7) per 1000 patient years. Iron parameter 
measurement varied with presence and severity of anemia: the proportion with both 
transferrin saturation and ferritin varied from 37.1% in the severely anemic, to 5.2% among 
those without anemia (Table). In the multivariable analysis, the only significant predictor of 
absolute iron deficiency anemia was prior GI bleed, and there were no significant predictors 
of functional iron deficiency.
Conclusions: One in five patients had anemia at CKD diagnosis; among those without 
it, 11 of 100 developed it for each year of follow-up. Prevalence of both absolute and 
functional iron deficiency increased with severity of anemia at incident CKD. Outcomes 
associated with absolute and functional iron deficiency anemia merit further studies.
Funding: Commercial Support - Keryx
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The Impact of Newly Developed Inflammation, Characterized by Rise in 
C-Reactive Protein, on Anemia Management Practices in Hemodialysis 
Patients: A Before-After Design in the DOPPS
Angelo Karaboyas,1 Hal Morgenstern,2 Raymond C. Vanholder,6 
Nancy L. Fleischer,2 Douglas E. Schaubel,2 Elke Schaeffner,4 Tadao Akizawa,3 
Nafeesa N. Dhalwani,5 Marvin Sinsakul,7 Ronald L. Pisoni,1 Bruce M. Robinson.1 
1Arbor Research Collaborative for Health, Ann Arbor, MI; 2University of
Michigan, Ann Arbor, MI; 3Showa University School of Medicine, Tokyo, Japan; 
4Charite, Berlin, Germany; 5Evidera, London, United Kingdom; 6University 
Hospital Gent, Gent, Belgium; 7AstraZeneca, Gaithersburg, MD.
Background: Inflammation, as assessed by a rising C-reactive protein (CRP), may 
lower hemoglobin (Hgb) level and lead to increased ESA dose to support the unmet need.
Methods: Using data from Dialysis Outcomes and Practice Patterns Study (DOPPS) 
phases 4-6 (2009-2018) in 10 countries where CRP is routinely measured, we identified 
hemodialysis patients who had a new inflammation event, defined here as CRP >10 mg/L 
following a 3-month period with all available CRP measurements ≤5 mg/L. In a “before-
after” design treating patients as their own controls, we used adjusted linear mixed models 
to estimate within-patient effects of inflammation on changes in Hgb and log-transformed 
ESA dose, comparing mean values from the 3 months “before” vs. “after” observing high 
CRP. Sensitivity analyses used different CRP thresholds as a proxy for a new inflammation 
event (e.g., ≤3 to >10 mg/L, ≤5 to >20 mg/L).
Results: Among 12389 patients, 40158 CRP values (21% of all measurements) were 
>10 mg/L, and 3752 measurements (from 2976 patients) met the eligibility criteria (Fig).
In the “before” vs. “after” periods, mean Hgb was 11.2 vs. 10.9 g/dL and mean ESA dose 
was 6347 vs. 6994 units/week. In 56% of the cases, patients experienced either a Hgb drop 
of >0.5 g/dL (40% of cases) or a >20% increase in ESA dose (33% of cases). In adjusted
models, the average within-patient change was 0.26 g/dL (95% CI: 0.22, 0.30) lower Hgb 
and an 8.6% (95% CI: 6.4, 10.8) increase in ESA dose. Results were robust to sensitivity
analyses varying the CRP thresholds.
Conclusions: After patients experienced an inflammation event, Hgb levels declined 
and ESA doses rose, suggestive of increased ESA resistance. Routine measurement of CRP 
is not practiced in the US but could help identify inflamed patients. These patients may 
benefit from proactive adjustment of medications or, in the future, anemia therapies that 
may be less subject to effects of inflammation.
Funding: NIDDK Support, Commercial Support - This analysis was supported 
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Baxter Healthcare. Additional support for specific projects and countries is provided by 
AstraZeneca, European Renal Association-European Dialysis & Transplant Association 
(ERA-EDTA), Fresenius Medical Care Asia-Pacific Ltd, Fresenius Medical Care Canada 
Ltd, German Society of Nephrology (DGfN), Janssen, Japanese Society for Peritoneal 
Dialysis (JSPD), Keryx, Kidney Care UK, MEDICE Arzneimittel Pütter GmbH & Co KG, 
Proteon, and Vifor Fresenius Medical Care Renal Pharma. Public funding and support is 
provided for specific DOPPS projects, ancillary studies, or affiliated research projects by 
National Health & Medical Research Council (NHMRC) in Australia, Cancer Care Ontario 
(CCO) through the Ontario Renal Network (ORN) in Canada, French National Institute 
of Health and Medical Research (INSERM) in France, Thailand Research Foundation 
(TRF), Chulalongkorn University Matching Fund, King Chulalongkorn Memorial Hospital 
Matching Fund, and the National Research Council of Thailand (NRCT) in Thailand, 
National Institute for Health Research (NIHR) via the Comprehensive Clinical Research 
Network (CCRN) in the United Kingdom, and National Institutes of Health (NIH) in the 
US. All support is provided without restrictions on publications. All grants are made to 
Arbor Research Collaborative for Health and not to Mr. Karaboyas directly., Private 
Foundation Support, Government Support - Non-U.S.
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Factors Associated with Anemia in Nondialysis CKD
Lucas A. Zanetti,2 Alexandre K. Samorano,2 Thais Tiemi Kato,2 Maria 
Eugenia F. Canziani,1 Miguel Angelo Goes.1 1Federal University of Sao Paulo, 
Sao Paulo, Brazil; 2Faculdade das Américas, São Caetano do Sul, Brazil.
Background: Anemia is common among chronic kidney disease (CKD) patients with 
increased hospitalizations and mortality and is associated with inflammatory cytokines 
and iron status. Objective: To assess factors associated with anemia in nondialysis CKD 
patients.
Methods: We analyzed 100 nondialysis CKD outpatients no erythropoiesis-stimulating 
agent. Anemia was defined as hemoglobin (Hb) concentration <13.0 g/dL for men and <12.0 
g/dL for women. Thus, 63 patients were in anemia group and 37 in non-anemia group. 
We performed analyzes of demographic data, CKD-EPI, Hb concentration, albumin, iron 
status, serum sFas, iPTH, inflammatory cytokines and erythropoietin (Epo) levels. We used 
correlations to all variables. We performed comparisons between two groups and multiple 
linear regression was used to determine the factors associated with Hb concentration when 
p<0.1.
Results: The primary causes of CKD were diabetes and hypertension followed by 
chronic glomerulonephritis. We observed in all patient together positive correlation between 
Hb and transferrin saturation (r=0.20, p=0.04), Hb and CKD-EPI (r=0.42, p<0.001), Hb 
and albumin (r=0.39, p=0.003). There was negative correlation between Hb and sFas 
(r=-0.50, p<0.001). We observed lower CKD-EPI (48±23, 27±10 mL/min; p=0.001), 
Hb (14.1±1.4, 10.9±1.6 g/dL; p<0.001) and serum Epo (14.2±9.5, 9.4±4.7 pg/mL; 
p=0.08) in anemia group. We found higher levels of sFas (3575±1109, 2533±1025 pg/mL; 
p<0.001), IFNg (7.1±5.9, 5.7±3.2 pg/mL; p=0.09) and iPTH (271±47.3, 110±47.8 pg/mL; 
p=0.003) in anemia group. Albumin (b = 3.518, 95%CI 1.059-3.873; p<0.001) and sFas (b = 
-0.252, 95%CI -0.852-0.17; p=0.001) were independently associated with Hb concentration.
Conclusions: This study shows that levels of albumin and sFas were associated with 
anemia in nondialysis CKD outpatients.
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Serum Soluble-Fas Is a Predictor of Need for Erythropoiesis-Stimulating 
Agents in Nondialysis CKD
Marcella A. Barros,3 Thais D. Takahashi,4 Bruna Hernandez,2 Lucas A. Zanetti,2 
Maria Eugenia F. Canziani,1 Miguel Angelo Goes.1 1Federal University of Sao 
Paulo, Sao Paulo, Brazil; 2Faculdade das Américas, São Caetano do Sul, 
Brazil; 3UNIFESP, Sao Paulo, Brazil; 4INICIAÇÃO CIENTÍFICA UNIFESP, 
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Background: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat 
anemia in chronic kidney disease (CKD). Soluble-Fas (sFas) and inflammatory cytokines 
are associated with renal anemia. Objective: To assess predictor factors of need for ESAs 
in nondialysis CKD patients.
Methods: We retrospectively analyzed and identified 80 nondialysis CKD outpatients 
with Hb>10g/dl. Thus, CKD outpatients that needed ESA up to 48 months after enrolment 
in nephrology office were identified. Initiated ESA when Hb values <9.0-10.0 g/dL with 
iron store replete. Demographic data, ESA use, CKD-EPI, Hb concentration, albumin, 
iron status, serum sFas, iPTH, inflammatory cytokines and erythropoietin (Epo) levels 
were recorded. 24 patients needed ESA and 56 patients no needed ESA in this period. 
We performed comparisons between two groups (ESA and non-ESA). Binary logistic 
regression was used to determine the impact of factors on ESA need.
Results: The primary causes of CKD were diabetes and hypertension. ACEi were used 
more in ESA group (46%, 20%; p=0.04). At baseline we observed lower CKD-EPI (42±22, 
29±12 mL/min; p=0.01), serum Epo (10.8±1.8, 8.8±2.4 pg/mL; p=0.07) and Hb (13.5±1.7 
g/dl, 12±1.8; p=0.09) in ESA group. We found higher levels of serum sFas levels (3537± 
578, 2751±1258 pg/mL; p=0.005) in ESA group. We did not observed difference in levels 
of iPTH, albumin, iron status and inflammatory cytokines. Serum sFas (b = 1.002, 95%CI 
1.001-1.004; p=0.01) was independently associated with Hb concentration.
Conclusions: In this study serum sFas was a predictor of need for ESA in nondialysis 
CKD outpatients within 48 months.
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Estimated Glomerular Filtration Rate (eGFR) and Hemoglobin (Hb) 
Levels Associated with Anemia Therapy in CKD Patients in a US 
Commercial Insured/Medicare Advantage Population
Haechung Chung,2 Julia Catini,1 Shaum Kabadi,1 Vincent Willey.2 1AstraZeneca, 
Gaithersburg, MD; 2HealthCore Inc., Wimlington, DE.
Background: Little is known about the eGFR and Hb levels that trigger initiation of 
anemia treatment in non-dialysis-dependent CKD patients in the real-world setting. The 
study objective was to explore Hb and eGFR levels prior to anemia treatment in non-
dialysis CKD patients and assess the trigger for anemia treatment based on these test results.
Methods: CKD patients treated for anemia were identified in the HealthCore 
Integrated Research Database from 1/1/07 to 6/30/15 by the presence of ≥ 1 medical claim 
each with a CKD and anemia diagnosis. Patients were required to have ≥ 12 months of 
health plan eligibility prior to their first CKD claim, during which they could not have 
any claims for CKD or anemia. These patients were 1:1 propensity score matched to CKD 
patients not treated for anemia. An anemia “at-risk” period was defined as the period 
between the first CKD diagnosis and anemia treatment date or “pseudo” treatment date 
assigned to the untreated group. Patients in both groups had an eGFR during the at risk-
period and an Hb outpatient result within 90 days prior to treatment/pseudo treatment date. 
Hb and eGFR levels associated with anemia treatment were evaluated; trigger values were 
assessed using logistic regression with Youden’s J index.
Results: We identified a total of 1724 matched pairs (anemia treated/untreated), with a 
mean age of 65 years. Anemia treatments included darbepoetin (9.6%), epoetin (24.8%), 
prescription iron (31.6%) and blood transfusion (60.9%). The mean Hb during the at-
risk period was 10.0 and 12.5 g/dL for the anemia treated/untreated cohorts. The mean 
eGFR during the at-risk period was 41.0 and 52.5 mL/min for the anemia treated/untreated 
cohorts, with 1/3 of patients in the treated group at stage 4/5 CKD and another 1/3 at stage 
3b. The trigger point for anemia treatment was 10.3 g/dL for Hb and 33.3 mL/min/1.73 m2  
for eGFR, with Hb being a stronger predictor of anemia treatment than eGFR. Type of 
anemia treatment received depended on Hb level.
Conclusions: Two thirds of patients in the anemia-treated group were stage 3b CKD 
or worse when treatment was initiated, with Hb being the main impetus for therapy. Future 
research on the interplay among renal function, Hb levels, and anemia treatment initiation 
is warranted.
Funding: Commercial Support - AstraZeneca LP
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Anemia and Iron Metabolism: Clinical
Role of Soluble Transferrin Receptors, Serum Ferritin, and Inflammatory 
Markers in Assessment of Functional Iron Deficiency in Anemia of CKD
Om P. Kalra,1 Neha Garg,2 Anil K. Yadav,2 Usha Rusia,2 Meera Sikka,2 
Mrinalini Kotru.2 1Pt. B.D. Sharma University of Health Sciences, Rohtak, 
Haryana, India; 2University College of Medical Sciences and GTB Hospital, 
Delhi, India.
Background: Anemia in chronic kidney disease (CKD) is multifactorial and functional 
iron deficiency (FID) is very common. The presence of coexisting inflammation may alter 
transferrin saturation (TSAT) and serum ferritin (SF) values, thus affecting their utility 
in assessment of iron stores. Interleukin-6 (IL-6) is the prime mediator of FID through 
hepcidin induction and has a direct role in the pathogenesis of anemia in CKD. The present 
study was conducted to explore the role of soluble transferrin receptors (sTfR), SF, IL-6 
and high-sensitive C- reactive protein (hsCRP) in anemia of CKD. ESR was measured by 
Westergren method.
Methods: A total of 77 patients of CKD {Stage 3 (n=31), 4 (n=17) and 5 (n=29)} of 
either sex, aged >18 years with hemoglobin (Hb) <11 g/dL were studied. Patients with 
active bleed, chronic infection, systemic disorders, history of recent blood transfusion and 
those receiving iron supplements were excluded. Hb, serum iron (SI), total iron binding 
capacity (TIBC) were measured in all the cases and TSAT was calculated. SF, sTfR, hsCRP 
and IL-6 were measured by ELISA technique.
Results: Taking sTfR/log ferritin (cut-off >1) as gold standard, CKD patients were 
divided into two groups:- Group-A: Iron deficient erythropoiesis (IDE) (n=31) and Group-B: 
Non-iron deficient erythropoiesis (NIDE) (n=46). No statistically significant difference was 
found in the values of Hb, MCV, MCH, MCHC, SI, TIBC, TSAT and SF between the two 
groups. All patients had raised IL-6 while hsCRP was raised in 60/77 (79.93%) patients. 
A positive correlation was found between hsCRP and SF (r=0.311, p=0.006) and between 
ESR and SF (r=0.451, p=0.000); however, no correlation was found with sTfR, indicating 
that sTfR levels are not affected by inflammation. The criteria i.e. TSAT <20% and SF>100 
μg/L showed a sensitivity of only 6.45% in detection of FID. On the other hand, SF levels 
from 12 to 70 μg/L were able to identify 14/19 (73.7%) cases of FID. Further, sTfR showed 
significantly higher values in the IDE group (p=0.000).
Conclusions: hsCRP, ESR and IL-6 levels were raised in majority of the patients 
of CKD with anemia and were not useful in the diagnosis of FID; however, raised sTfR 
levels and SF values between 12 to 70 μg/L were found to be useful for assessment of IDE 
(p=0.000).
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Efficient Management of Renal Anemia Is Achieved by Low Ferritin 
Levels and Moderate Transferrin Saturation Analyzed by Combination of 
the Hemoglobin Content of Reticulocytes and Iron Markers
Chie Ogawa,1,2 Ken Tsuchiya,3,2 Fumiyoshi Kanda,1 Kunimi Maeda.1,2 1Maeda 
Institute of Renal Research, Kawasaki, Japan; 2Biomarker Society, INC, 
Kawasaki, Japan; 3Tokyo Women’s Medical University, Shinjuku-ku, Japan.
Background: Excessive iron induces negative iron metabolism by production of 
hepcidin25 (Hep25), but the optimal iron levels for hematopoiesis on hemodialysis (HD) 
patients is unclear. The hemoglobin content of reticulocytes (CHr) is sensitive indicator of 
used iron for hematopoiesis. The previous studies indicated CHr level increased by iron 
therapy in iron deficiency patients, whereas showed no change in iron sufficiency patients. 
So we investigated the relation among CHr level, iron status, reticulocytes counts and 
Hep25.
Methods: 181 outpatients on maintenance HD treated with recombinant human 
erythropoietin were enrolled and examined CHr, serum ferritin(s-ft), transferrin saturation 
(TSAT), reticulocytes (Ret) counts and Hep 25. The sample was comprised of 115 men 
with a mean (SD) age of 59.9 (13.8) years, and mean HD duration of 8.6 (6.8) years. 
CHr and Hep 25 was measured using ADVIA 120 hematology system and LC-MS/MS 
assay. As management of anemia, the target Hb level was 10–11 g/dL according to the 
Japanese guidelines. We performed sensitivity analysis using the generalized linear 
regression model including the interaction term to determine the optimal cut-off values, 
which correlation coefficients show greatest changes, of s-ft, TSAT and Hep25 for CHr. 
The correlation between CHr and Ret count was evaluated in four groups classified by 
iron status.
Results: The optimal cut-off values of s-ft and TSAT for CHr were showed 50 ng/mL 
(≤50 ng/mL, r=0.47 vs >50 ng/mL, r=0.22; F-statistic, 17.64) and 24% (≤24%, r=0.58 
vs >24%, r=0.08; F-statistic, 34.45), respectively. Moreover, two values were suggested 
for the optimal cut-off of CHr and Hep25. The under and upper values were 20 ng/mL 
(≤20 ng/mL, r=0.52 vs >20 ng/mL, r=-0.01; F-statistic, 21.12) and 70 ng/mL (≤70 ng/mL, 
r=0.36 vs >70 ng/mL, r=-0.45; F-statistic, 24.52), respectively. As the Ret count increased, 
CHr most greatly decrease in the “s-ft ≤50 ng/mL and TSAT ≤ 24%” group, however 
showed almost no change in the “s-ft >50 ng/mL and TSAT > 24%” group.
Conclusions: This study showed that the iron status of s-ft >50 ng/mL or/and TSAT > 
24% had almost no influence on CHr, indicator of used iron for hematopoiesis. However, 
high level of Hep25 may impair the efficiency of iron use for hematopoiesis.
Funding: NIDDK Support
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Red Blood Cell Volume Is Not Always Decreased in Anemic CKD Patients
Sophie M. De Seigneux,1 Belen Ponte,3 Pierre-Yves F. Martin,4 Carsten Lundby.2 
1Nephrology, University Hospital of geneva, Geneva, Switzerland; 2Copenhagen 
University Hospital, Copenhagen, Denmark; 3University Hospital of Geneva, 
Geneva, Switzerland; 4Hospital Universitaire de Geneve, Geneva City, 
Switzerland.
Background: Anemia is defined according to blood hemoglobin concentration ([Hb]), 
which can be considered a marker of total red blood cell volume (RBCV). However, 
alterations of plasma volume (PV) may also modify [Hb] without concomitant changes 
in RBCV. Since anemia and fluid retention are frequent complications of chronic kidney 
disease (CKD), we hypothesized that anemia during CKD may in part be related to 
expanded PV without a simultaneous decrease in RBCV.
Methods: To test this hypothesis, we quantified in 50 consecutive stable stage 3-5 CKD 
outpatients not on dialysis and 7 controls in the same age cathergory: hemoglobin mass, 
RBCV, PV and total blood volume (BV) using an automated carbon monoxide device. Epo 
was measured by Elisa. Predicted values for PV, RBCV, and BV were calculated according 
to nadler’s formula for each patient.
Results: CKD patients were divided into anemic and non-anemic patients based on 
their hemoglobin [Hb] values. While we demonstrated that RBCV was within the predicted 
range in anemic patients (+8%, p=0.35) but higher than predicted in non-anemic (+14.5%, 
p=0.02) patients, both BV and PV were higher than predicted values for non-anemic 
(+15.5% and +19%, p<0.01) and anemic patients (+ 10.5 and +22%, p<0.01), respectively. 
Anemic patients had a higher PV than controls (p<0.01) whereas their RBCV was not 
different, whereas non anemic CKD patients had higher RBCV than controls (p<0.01). 
Thus the cause for anemia in the large majority of the investigated patient population was 
related mainly to hemodilution and not to a limited erythropoiesis, as also confirmed by the 
erythropoietin values. [Hb] based anemia over-diagnosed anemia in 20 of the 26 anemic 
patients.
Conclusions: In conclusion, anemia in CKD as diagnosed by low [Hb] is not 
necessarily only associated to low RBCV but may also reflect increased plasma volume. 
This finding could have implications for the treatment of CKD patients and may explain 
the increased mortality associted to normalization of [Hb] values by rhEpo treatment in the 
predialysis CKD population.
Funding: Government Support - Non-U.S.
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Estimation of Pre-Dialysis Hemoglobin Concentration Using Intradialytic 
Crit-Line Monitor Readings
Ohnmar Thwin,1 Priscila Preciado,1 Xia Tao,1 Samir D. Patel,3 Mirell Tapia,1 
Lemuel Rivera,1 Stephan Thijssen,1 Peter Kotanko.1 1Renal Research Institute, 
New York, NY; 3Renal Research Institute, Weehawken, NJ.
Background: Anemia is a major complication in hemodialysis (HD) patients. The 
Crit-Line monitor (CLM) is widely use to determine oxygen saturation, hematocrit and 
hemoglobin (Hgb) levels. It would be desirable to use CLM to estimate pre-HD Hgb values 
to reduce blood draws. However, due to hemodilution by the priming fluid, the initial Hgb 
values at the HD start are consistently lower than pre-HD values. A high initial ultrafiltration 
rate (UFR) allows rapid removal of the priming fluid while limiting the impact associated 
with saline extravasation and vascular refill. Our goal was to implements a high initial UFR 
to evaluate the agreement between the two measurements.
Methods: Prospective, observational study in chronic HD patients. Subjects were 
studied 3 times. Two pre-HD blood samples were drawn, measured in triplicate by Spectra 
East Laboratories (Rockleigh, NJ, USA), and the average used for comparison to CLM. 
Initial UFR was set to 3 L/hr for 8 minutes and then returned to prescribed rate. Hgb was 
recorded continuously with CLM. Difference of CLM to lab Hgb value was calculated as 
CLM reading at each time point minus averaged lab value
Results: We included 27 subjects (56.4±15 years, 70% males, 63% African-Americans) 
and a total of 61 treatments. With rapid ultrafiltration, the difference between CLM and 
lab values decreased and reached minimal at approximately 6 minutes (Fig.1), and about 
75% of subjects had CLM Hgb values that were within ±0.5 g/dL of the corresponding lab 
reference Hgb
Conclusions: With a high initial UFR, 75% of CLM Hgb values were within ±0.5 g/dL 
difference of the averaged lab measurement at minute 6. Of note, the lab values are afflicted 
with some degree of measurement variability contributing to the data spread. Next steps 
should include development of mixed effects models for prediction of an individualized 
time point at which to read CLM Hgb, to further increase the agreement between the two 
methods.
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Fig.1. Delta of lab and CLM Hgb values at each time point for the first 20 minutes of HD
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Reduced Hemoglobin Level Increases Risk of Incident Heart Failure and 
Atherosclerotic Events in CKD: The CRIC Study
Santosh Saraf,1 Jesse Y. Hsu,2 Ana C. Ricardo,1 Mayank Kansal,1 Jing Chen,3 
Michael J. Fischer,4 Jiang He,5 Rupal Mehta,6 Thida C. Tan,7 Alan S. Go,7 
James P. Lash.1 On behalf of the CRIC investigators 1University of Illinois at 
Chicago, Chicago, IL; 2University of Pennsylvania, Philadelphia, PA; 3Tulane 
School of Medicine, New Orleans, LA; 4University of Illinois Hospital and 
Health Sciences Center, Chicago, IL; 5Tulane School of Public Health and 
Tropical Medicine, New Orleans, LA; 6Northwestern Univesrsity, Feinberg 
School of Medicine, Chicago, IL; 7Kaiser Permanente Northern California, 
Oakland, CA.
Background: Anemia may exacerbate cardiac ischemia or contribute to abnormal left 
ventricular remodeling but data regarding the impact of anemia on cardiovascular outcomes 
in chronic kidney disease (CKD) have been inconsistent.
Methods: We used Cox proportional hazards to examine the association of hemoglobin 
(Hgb) level (per 1 gm decrease) with incident heart failure, atherosclerotic events 
(myocardial infarction, stroke, or peripheral artery disease), and all-cause death among 
participants with CKD in the Chronic Renal Insufficiency Cohort Study.
Results: Among 3,919 participants with CKD (mean age 58 yrs, 45% women, 42% 
white, 42% black, 13% Hispanic, mean eGFR 45 ml/min/1.73 m2, median proteinuria 0.19 
g/24h, and mean entry Hgb 12.6±1.8), 1,859 (47.4%) participants had anemia (defined 
using WHO criteria of Hgb <12 g/dL in women and <13 g/dL in men) at study entry. 
Compared to individuals without anemia, those with anemia were older, more likely to 
be black or Hispanic, have prior clinical cardiovascular disease, and had a lower mean 
eGFR at baseline. Over a median follow-up of 8.8 years, we observed 757 heart failure 
events, 692 atherosclerotic events, and 1148 deaths. In multivariable analyses, lower Hgb 
was associated with significantly higher rates of heart failure and atherosclerotic events that 
may be partially explained by subclinical cardiac ischemia.
Conclusions: In a large, diverse CKD cohort, lower Hgb was independently associated 
with an increased risk for heart failure and atherosclerotic events.
Funding: Other NIH Support - NHLBI K23HL125984
(a) Adjusted for center, age, sex, race/ethnicity, education, income
(b) Model 1 + cardiovascular disease, systolic BP, HgbA1c, smoking, LDL, eGFR, urine
protein, ACE-inhibitor/ARB, aspirin/anti-platelet, statin, erythrocyte stimulating agent
(c) Model 2 plus LVH by ECG
(d) Model 2 plus troponin I.
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Association of Anemia with Clinical Outcomes in Patients with Severe 
CKD: A Danish Population-Based Study
Reimar W. Thomsen,1 Uffe Heide-Jørgensen,1 Gunnar Toft,1 Marvin Sinsakul,2 
Heleen van Haalen,2 Lars Pedersen,1 Henrik T. Sorensen.1 1Aarhus University 
Hospital, Aarhus, Denmark; 2AstraZeneca, Gothenburg, Sweden.
Background: Real-world evidence is limited on clinical outcomes associated with 
anemia in patients with chronic kidney disease (CKD). We investigated the association of 
anemia with incident dialysis, adverse cardiovascular (CV) outcomes and death in patients 
with severe CKD.
Methods: We linked laboratory and healthcare databases to identify individuals with 
stage 4 or 5 CKD (eGFR <30) in Northern Denmark on 1 Jan 2012. We classified patients by 
anemia grade using lowest hemoglobin (Hb) value in 2011 (grade 1: Hb 10 to <12/<13 g/dL; 
grade 2+: Hb <10 g/dL). Patients were stratified by dialysis status on 1 Jan 2012 and 
followed for incident dialysis, first CV event (myocardial infarction, stroke, and heart 
failure hospitalization) and all-cause death. We computed incidence rates and derived risk 
curves and adjusted hazard ratios (HRs) through cumulative incidence function and Cox 
proportional hazards regression.
Results: Of 4,120 patients with severe CKD (median age 77 years), 45% had no 
anemia, 41% had grade 1 anemia, and 14% had grade 2+ anemia. Incidence rates for 
dialysis, CV events and death increased with increasing anemia severity (Table). After 
controlling for baseline differences in age, gender, CV history, other comorbidities, eGFR 
level and CKD duration, HRs for incident dialysis were increased for patients with grade 
1 and particularly with grade 2+ anemia. Moreover, HRs for CV events and death were 
elevated among both non-dialysis and dialysis patients. A similar risk pattern for CV events 
and death was observed when non-dialysis patients were censored at dialysis initiation.
Conclusions: In routine clinical care patients with severe CKD, the presence and 
severity of anemia was associated with increased risks of incident dialysis, CV events and 
death.
Funding: Commercial Support - AstraZeneca
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Delta-He It Is a Novel Biomarker of Mortality in Prevalent Hemodialysis 
Patients: A Multivariate Regression Predictive Model Development 
Manuel B. Sánchez. Nephrology, Hospital Juan Ramon Jimenez, Huelva, Spain.
Background: Delta-He is a marker of iron availability, which has been suggested as 
a marker of the inflammation. It is calculated as the difference between the hemoglobin 
content of reticulocytes (Ret-He) reflects the incorporation of iron into the erythroid 
progenitor cells over the previous 2–4 days, and the hemoglobin content of erythrocytes 
(RBC-He). Under normal conditions, Delta-He has a positive value. As iron homeostasis 
and inflammation are related through the action of Hepcidin, an acute inflammatory 
response suppresses the availability of iron to erythropoietic progenitor cells and rapidly 
induces a decrease in Ret-He, leading to a negative value of Delta-He.
Methods: 78 patients prevalent in Hemodialysis were followed during 1 year. We 
have analyzed time to the event (mortality from any cause). Has been acknowledged 
Mortality as Dependente Variable and Delta-He Dicotomized as independent variable. 
Time in Hemodialysis, KtV, the treatment with erythropoiesis-stimulating agents (ESA) 
and Fe iv therapy was taken into account, PCR, RET-He and Delta-He. We have realise 
the determinations through the Sysmex XE 500. A survival study was carried out trougt 
using Multivariate Regression Cox Model . The predictive model is developed with the 
regression coefficients. Internal validity was realise by Bootstrap. The model is presented 
as a nomogram.
Results: 22/78 patients (28.2%) presented exitus. 19/78 patients (24.4%) had Delta-He 
Negative and require a higher weekly dose of ESA. The delta He has a protective effect 
against mortality, that is, the greater the value of Delta-He, the less mortality, for each unit 
that increases Delta He above 0 the mortality decreases by 27%. Discrimination: Index C: 
0.74, Calibration: I. Brier: 0.171, R2 Nagelkerke: 0.22.
Conclusions: Delta-He Negative is a predictive factor of all-cause mortality at one year 
in patients on hemodialysis, associated with inflammation and hypo-responsiveness to ESA.
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The Association of the Difference in Hemoglobin Levels Before and After 
Hemodialysis with the Risk of 1-Year Mortality in Patients Undergoing 
Hemodialysis: Results from the Japanese Renal Data Registry
Hiroki Nishiwaki,1 Takeshi Hasegawa,1 Takayuki Hamano,2 Ikuto Masakane.3 
The Japanese Society for Dialysis Therapy, Committee of Renal Data Registry 
1Showa University Fujigaoka Hospital, Yokohama, Japan; 2Osaka University 
Graduate School of Medicine, Suita, Japan; 3Honcho-Yabuki Clinic, Yamagata, 
Japan.
Background: Few clinical studies have directly examined the associations of 
hemoglobin (Hb) levels after hemodialysis (HD) and of the difference in Hb levels before 
and after HD (ΔHb) with patient outcomes. The present study aimed to determine ΔHb and 
post-HD Hb levels with nationwide data and to examine their associations with all-cause 
mortality in patients undergoing HD.
Methods: Study Design: Retrospective cohort study Setting and Participants: This 
study is based on data from 2008 and 2009 recorded in the Japanese Renal Data Registry. 
Exposures: The ΔHb and the absolute post-HD Hb value. Outcomes: 1-year mortality 
Analytical Approach: The ΔHb and post-HD Hb level as categorical variables using Cox 
regression for 1-year mortality, adjusting for potential confounders.
Results: Eligible patients were 38,636 patients. The median ΔHb was 1.0 g/dl (first 
quartile, 0.4 g/dl; third quartile, 1.5 g/dl), and the median post-HD Hb level was 11.3 g/dl 
1.0 g/dl (first quartile, 10.3 g/dl; third quartile, 12.4 g/dl). The median pre-HD Hb level was 
10.4 g/dl (first quartile, 9.6 g/dl; third quartile, 11.1 g/dl). The risk of mortality was lower 
with a ΔHb of 0 to 1.0 g/dl (adjusted hazard ratio [aHR], 0.82; 95% confidence interval 
[CI], 0.74–0.92) or > 1.0 g/dl (aHR, 0.62; 95% CI, 0.55–0.70) than with a ΔHb < 0 g/dl. The 
risk for mortality was also lower with a post-HD Hb of 10 to 11 g/dl (aHR, 0.79; 95% CI, 
0.71–0.89), 11 to 12 g/dl (aHR, 0.72; 95% CI, 0.64–0.80), or > 12 g/dl (aHR, 0.71; 95% CI, 
0.64–0.80) than with a post-HD Hb < 10 g/dl.
Conclusions: Both a low ΔHb and a low post-HD Hb level were associated with a 
higher risk of 1-year mortality.
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Differential Effect of Hemoglobin Level on Patient Mortality According to 
Patient Age in ESRD Patients
Eun jeong Ko,4 Bumsoon Choi,1 Cheol Whee Park,2 Chul Woo Yang,3 Byung 
ha Chung.3 1Division of Nephrology, Department of Internal Medicine, Seoul, 
Republic of Korea; 2The Catholic University of Korea, Seoul, Republic of Korea; 
3Seoul St. Mary’s Hospital, Seoul, Republic of Korea; 4Seoul St.Mary’s Hospital, 
Seoul, Republic of Korea.
Background: In chronic dialysis patients, achieving an adequate hemoglobin (Hb) 
concentration is very important because lower than 10 g/dL or higher than 12g/dl can be 
associated with increased patient mortality. However, it has not been confirmed that it can 
be applied irrespective of patient age. Therefore, the aim of this study is to investigate the 
impact of Hb level on the clinical outcomes of dialysis patients according to patient age 
using the Clinical Research Center registry for end-stage renal disease (CRC-ESRD) data.
Methods: A total of 3,409 patients form CRC-ESRD were included. They were divided 
into three group by age, age < 40 (n=488), 40<age≤60 (n=1,650), and age >60 (n=1,271). 
We compared the overall mortality, cardiovascular mortality, all-cause and cardiovascular 
hospitalization according to mean Hb level.
Results: In age <40 group, Hb ≥12 g/dl group showed higher all-cause mortality 
(adjusted HR 3.894, 95% CI 1.037-14.624; p=0.044) compared to 10≤Hb <12 g/dl group, 
whereas HR of cardiovascular hospitalization was higher in Hb < 10g/dl group (adjusted 
HR 2.268; 95% CI 1.044-4.926, p=0.039). Meanwhile, in age≥60 group, all-cause and 
cardiovascular mortality was higher in Hb <10 g/dl (adjusted HR 2.098, 95% CI 1.567-
2.808, p<0.001 and adjusted HR 2.796, 95% CI 1.669-4.686, p<0.001) compared to 
10≤ Hb < 12g/dl group, however the difference between 10≤ Hb < 12g/dl group and 
Hb ≥ 12g/dl was not significant. In 40<age≤ 60 group, Hb <10g/dl showed higher all-cause 
mortality (adjusted HR 1.719, 95% CI 1.158-2.252, p=0.007), all-cause hospitalization 
(adjusted HR 1.572, 95% CI 1.213-2.036, p=0.001) and cardiovascular hospitalization 
(adjusted HR 1.455, 95% CI 1.037-2.043, p=0.030) compared to 10≤Hb <12 g/dl group, 
whereas there was no significant difference between 10≤Hb <12 and Hb ≥ 12 g/dl group
Conclusions: Thus, in elderly patient on dialysis, the effect of low or higher hemoglobin 
level than 10 - 12 g/dL in elderly patients was different from that in young patient.
Funding: Government Support - Non-U.S.
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Measuring Quality of Life in Patients with CKD Anemia – SF36 and 
KDQOL
Roberto Pecoits-Filho,1,2 Bruce S. Spinowitz,3 Pablo E. Pergola,4 
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Gigi Shafai,6 Myrlene Sanon,7 Holly Krasa.7 1Pontificia Universidade Catolica 
do Parana, Curitiba, Brazil; 2George Institute for Global Health, Newtown, 
NSW, Australia; 3New York Hospital Medical Center of Queens, New Rochelle, 
NY; 4Renal Associates, PA, San Antonio, TX; 5Analysis Group, Inc., Montreal, 
QC, Canada; 6Akebia Therapeutics, Inc., Cambridge, MA; 7Otsuka 
Pharmaceutical Development & Commercialization, Inc., Rockville, MD.
Background: Anemia of chronic kidney disease (CKD) has deleterious impacts on 
patients’ quality of life (QoL). The Standardized Outcomes in Nephrology (SONG) initiative 
identified QoL components as essential trial outcomes to be reported in hemodialysis and 
peritoneal dialysis-dependent (DD) patients. Resolving anemia of CKD may lead to more 
important QoL benefits in non-DD (NDD) patients than in DD patients (Eriksson 2016). 
QoL is frequently assessed using the 36-item general Short Form (SF-36) and the CKD-
targeted Kidney Disease QoL (KDQoL), the latter being preferred in US dialysis clinics 
(Peipert 2017). It is unclear to which extent QoL tools are used to study anemia of CKD, and 
specifically in NDD patients. Therefore, we aimed to describe the evidence on treatments for 
anemia of CKD in which SF-36 and/or KDQoL were used, in both DD and NDD patients.
Methods: Studies included in a broader systematic literature review of treatments 
for anemia of CKD were reviewed. The Cochrane Library, MEDLINE, EMBASE, NHS 
EED, and NHS HTA were searched for English publications. Studies published between 
1/1/2000-3/17/2017 meeting the following criteria were included: adult patients; focus 
is anemia of CKD; patients receiving iron, red blood cell transfusions, erythropoiesis-
stimulating agents (ESA); results on QoL. Studies that used SF-36 or KDQoL were retained 
and qualitatively synthesized.
Results: 1,625 publications were identified and 17 met the eligibility criteria. All 
studies focused on ESA, with or without iron replacement. SF-36 was used more frequently 
than KDQoL (11/17, 64.7%) across studies. Notably, KDQoL was used more frequently 
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(vs. SF-36) in studies on DD patients (4 vs. 2) than in studies on NDD patients (1 vs. 8; 
2 studies with mixed DD/NDD patients). Both tools showed QoL improvements (SF-36: 
8/11, KDQoL: 4/6). QoL domains improved (e.g., vitality, physical/social functioning) and 
magnitude of results varied widely.
Conclusions: KDQoL was less frequently used in the NDD population than in DD 
patients (as expected, given CMS guidelines). Findings highlight how QoL treatment 
benefits are variable, and that there is a lack of standardized use of adapted QoL tools in 
studies of NDD patients.
Funding: Commercial Support - Akebia Therapeutics, Inc.
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Associations of Anemia with Quality of Life in CKD Stage 3-5 Patients: 
Results from CKDopps in the US and Brazil
Nidhi Sukul,1 Daniel G. Muenz,2 Elodie Speyer,3 Antonio A. Lopes,4 
Koichi Asahi,5 Junichi Hoshino,6 Nafeesa N. Dhalwani,7 Heleen van Haalen,8 
Roberto Pecoits-Filho,9 Brian Bieber,2 Bruce M. Robinson,2 Ronald L. Pisoni.2 
1University of Michigan, Ann Arbor, MI; 2Arbor Research Collaborative for 
Health, Ann Arbor, MI; 3CESP Inserm U1018, VILLEJUIF Cedex, France; 
4Faculdade de Medicina da Universidade Federal da Bahia, Salvador, Brazil; 
5Department of Chronic Kidney Disease Initiatives, Fukushima Medical 
University School of Medicine, Fukushima, Japan; 6Toranomon Hospital, 
Tokyo, Japan; 7Evidera, London, United Kingdom; 8AstraZeneca, Gothenburg, 
Sweden; 9Pontificia Universidade Catolica do Parana, Curitiba, Brazil.
Background: The risk of anemia increases with chronic kidney disease (CKD) 
progression. Some studies suggest that anemia is associated with poorer quality of life 
(QOL) among non-dialysis CKD patients. Using the Chronic Kidney Disease Outcomes 
and Practice Patterns Study (CKDopps), we report the associations of anemia with QOL 
outcomes among CKD patients in the US and Brazil.
Methods: We analyzed CKDopps data on patient characteristics, laboratory 
measurements and the Kidney Disease QOL-36 (KDQOL-36) survey collected 
prospectively for stage 3-5 CKD patients (N=1212) at 22 US and 15 Brazilian nephrologist-
run clinics from 2014-2018. Hemoglobin (Hgb) levels, reported closest in time to 
KDQOL-36 completion (median gap: 13 days, IQR: 1-57 days), were modelled separately 
as continuous and categorical exposures in GEE linear regression models for each QOL 
outcome, adjusting for country, age, sex, race, smoking history, eGFR, serum albumin, and 
13 comorbidities, and accounting for clustering by clinic.
Results: More severe anemia was most strongly associated with poorer scores for 
QOL domains of general health, physical role, emotional role, burden, effects of kidney 
disease, as well as the physical and mental component summary scores. Weak to moderate 
associations were observed with the domains of energy, physical function, and pain.
Conclusions: These findings show moderate associations between anemia and poorer 
outcomes on several QOL domains in CKD stage 3-5 patients from the US and Brazil, 
even after accounting for numerous comorbidities. Longitudinal studies would be valuable 
to understand how patient QOL and well-being are impacted by anemia and its treatment 
over time.
Funding: NIDDK Support, Commercial Support - This analysis was supported 
by AstraZeneca. The DOPPS Program is supported by Amgen, Kyowa Hakko Kirin, 
Baxter Healthcare. Additional support for specific projects and countries is provided by 
AstraZeneca, European Renal Association-European Dialysis & Transplant Association 
(ERA-EDTA), Fresenius Medical Care Asia-Pacific Ltd, Fresenius Medical Care Canada 
Ltd, German Society of Nephrology (DGfN), Janssen, Japanese Society for Peritoneal 
Dialysis (JSPD), Keryx, Kidney Care UK, MEDICE Arzneimittel Pütter GmbH & Co KG, 
Proteon, and Vifor Fresenius Medical Care Renal Pharma. Public funding and support is 
provided for specific DOPPS projects, ancillary studies, or affiliated research projects by 
National Health & Medical Research Council (NHMRC) in Australia, Cancer Care Ontario 
(CCO) through the Ontario Renal Network (ORN) in Canada, French National Institute 
of Health and Medical Research (INSERM) in France, Thailand Research Foundation 
(TRF), Chulalongkorn University Matching Fund, King Chulalongkorn Memorial Hospital 
Matching Fund, and the National Research Council of Thailand (NRCT) in Thailand, 
National Institute for Health Research (NIHR) via the Comprehensive Clinical Research 
Network (CCRN) in the United Kingdom, and National Institutes of Health (NIH) in the 
US. All support is provided without restrictions on publications. All grants are made to 
Arbor Research Collaborative for Health and not to Dr. Muenz directly., Private Foundation 
Support, Government Support - Non-U.S.
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Relationship Between Anemia Profile and Nutritional Status as Assessed 
by Subjective Global Assessment in Incident Dialysis Patients
Seung Yun Chae, Byung ha Chung, Bumsoon Choi, Cheol Whee Park, Chul 
Woo Yang, Yong-Soo Kim, Tae Hyun Ban. Seoul St. Mary’s hospital, Seoul, 
SEOUL, Republic of Korea.
Background: Anemia is a major complication in patients with end-stage renal disease 
(ESRD). Subjective global assessment (SGA) is a useful tool assessing nutritional status. 
We investigated an association with changes of anemia, iron and erythropoietin (ESA) 
prescription rate, and prescribed ESA dosage after assessing nutritional status using SGA 
over time in incident ESRD patients.
Methods: The cohort was prospectively collected in 36 centers of the Clinical Research 
Center for ESRD in Republic of Korea. The incident ESRD patients started hemodialysis or 
peritoneal dialysis between November 2008 and Feburary 2014. We excluded patients who 
were younger than 18 years old, or had an underlying liver disease and malignancy. Finally, 
we included 898 incident ESRD patients in this study. Nutritional status was calssified to 
well nourished (WN, SGA A) or malnourished (MN, SGA B or C). The patients based on 
the change of nutritional status was divided into four groups as following: group 1, WN to 
WN; group 2, WN to MN; group 3, MN to WN; and group 4, MN to MN. Data between 
baseline and 12 months after dialysis initiation was analyzed.
Results: Serum hemoglobin and hematocrit levels, iron and ESA prescription rate, 
and ESA dosage were improved in all the patients at 1 year after dialysis commencement 
(P<0.05 for all). In subgroup analysis based on dialysis modality, serum hemoglobin and 
hematocrit levels of the hemodialysis patients were ameliorated in all the groups (P<0.001 
for all). In addition, iron and ESA prescription rate, and ESA dosage were more definitely 
reduced in group 1 and 3 than the other groups (P<0.001 for both). However, these trends in 
the patients with peritoneal dialysis diminished or dissipated in all the groups.
Conclusions: Maintaining proper nutritional status based on SGA improved anemia in 
the incident dialysis patients, with reducing iron and ESA usage in especially hemodialysis 
patients.
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Different Effects of Iron Indices on Mortality in Patients with Autosomal 
Dominant Polycystic Kidney Disease After Long-Term Hemodialysis: A 
Nationwide Population-Based Study
Shu-Ching Yeh.1,2 1Taipei Medical University Hospital, Taipei, Taiwan; 2Taipei 
Medical University, Taipei, Taiwan.
Background: Iron supplementation and erythropoietin stimulating agents (ESAs) 
are essential for maintaining hemoglobin levels in hemodialysis (HD) patients. However, 
patients with autosomal-dominant polycystic kidney disease (PKD) have higher endogenous 
erythropoietin levels, so their recommended iron indices for HD patients may be different.
Methods: This cohort study from the Taiwan Renal Registry Data System (TWRDS) 
enrolled 84,219 HD patients with valid baseline iron profiles. We stratified mortality risk 
by presence of PKD recorded as underlying disease. The primary outcome was 3-year 
all-cause mortality. Predictors included time-averaged and baseline serum ferritin levels 
and transferrin saturation (TSAT, %). Cox regression multivariate analysis adjusting age, 
comorbidities, important relevant laboratories was used to pursue estimated all-cause 
hazard ratio (HR) of mortality.
Results: We enrolled 1346 HD patients with PKD and 82,873 HD patients without 
PKD. Mean ages were 56.2±13.2 and 61.7±13.5 years and follow-up durations were 
2.62±0.89 and 2.28±1.04 years, respectively. Mortality risks for ferritin >800 ng/mL 
(HR=1.32; 95% confidence interval (CI)=1.21-1.43) or TSAT >50% (HR=1.34; 95% 
CI=1.18-1.52) were significantly higher among patients without PKD than those with 
normal iron indices. However, a U-shape curve between mortality and Ferritin/TSAT levels 
was not observed in patients with PKD. In sensitivity test, PKD patients underwent regular 
ESAs therapy showed no difference with non-ESAs user.
Conclusions: Iron indices affect mortality differently among patients with and 
without PKD. Iron supplementation, recommended serum ferritin levels, or TSAT should 
be monitored in HD patients especially without PKD. Clinicians should consider to treat 
anemia in HD patients individually, especially in PKD.
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C-Reactive Protein Levels Might Affect the Association of Ferritin and 
Survival in Hemodialysis Patients
Shunji Suzuki,1 Norio Hanafusa,2 Hiroshi Kawaguchi,3 Ken Tsuchiya,2 
Kosaku Nitta.2 1Tokyo Woman Medical University, Shinjuku-ku, Japan; 2Tokyo 
Women’s Medical University, Shinjuku-ku, Japan; 3Tokiwa-kai Medical
Corporation, Iwaki, Japan.
Background: Ferritin is associated with survival in hemodialysis (HD) patients; higher 
ferritin levels are associated with worse survival. Inflammatory status is also associated 
with worse survival in the same population. Serum ferritin itself increases in the presence 
of inflammation. Therefore, we hypothesized that inflammation affects the association 
between ferritin and survival. We investigated the interaction of C-reactive protein (CRP) 
and ferritin for dialysis patient survival.
Methods: All patients who were receiving hemodialysis HD treatment thrice a week 
at Jyoban Hospital, Fukushima, Japan were included in the study. The study period was set 
as July 2012 through August 2014. Baseline laboratory data including CRP, ferritin, and 
other clinical indices were collected in July 2012. CRP and ferritin were dichotomized in 
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the subsequent analysis. The study outcome was set as all-cause mortality. Analyses were 
conducted using Cox’s proportional hazard models. Interaction between CRP and ferritin 
was also included in the study. Analyses stratified by CRP levels were also conducted.
Results: This study examined 397 patients, 258 of whom were male; 44.6% 
were diabetic. Their average age was 70.6 years, with an average of 3.6 years using on 
HDhemodialysis. During the observation period, 73 patients died. Examination of the entire 
population demonstrated that high CRP (>0.2 mg/dl), but not high ferritin (>200 ng/ml), is 
associated with worse survival: HR 3.31 (95%CI 1.35–14.5) and HR 0.64 (95%CI 0.15–
1.54), respectively. Interaction of CRP and ferritin was also significant. Stratified analysis 
demonstrated that high ferritin was associated with better survival (HR 0.17, 95%CI 0.01–
0.81) only in the low-CRP stratum, but not (HR 2.24, 95%CI 0.94–4.77) in the high-CRP 
stratum.
Conclusions: Results demonstrated that inflammation status might affect the 
association between ferritin and survival in hemodialysis HD patients. Iron dosing might be 
individualized in light of inflammation results.
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Iron Rather than Erythropoietin Mediates the Role of Fibroblast Growth 
Factor 23 in Renal Anemia in Humans
Bernhard O. Bielesz, Fabian P. Hammerle, Thomas J. Reiter, Marija Bojic, 
Andreas Gleiss, Rodrig Marculescu. Medical University of Vienna, Vienna, 
Austria.
Background: Renal anemia is an almost universal complication of chronic kidney 
disease (CKD). In animal experiments, Fibroblast growth factor 23 (FGF23), a well-
known key-player in mineral metabolism, has been causally implicated by suppressing 
erythropoietin (EPO). We assessed whether FGF23 might contribute to anemia by inducing 
relative EPO deficiency.
Methods: Hemoglobin, EPO, iron, and mineral metabolism parameters, including both 
intact (Diasorin) and c-terminal (Immutopics) FGF23 were measured in 225 non-dialysis 
CKD (stage 1-5, median eGFR 30 ml/min/1.75m2) patients not on erythrocyte stimulating 
agent or intravenous iron therapy. To approximate relative EPO deficiency, EPO values 
from 5483 patients collected at the General Hospital of Vienna with CRP<1 mg/dl and 
GFR>60 (median eGFR 87) were chosen as reference population for modelling of gender-
specific EPO-standard deviation scores (EPO-SDS) stratified to corresponding hemoglobin 
levels. Analysis was performed by multiple linear regression.
Results: Both intact and c-terminal FGF23 were associated with hemoglobin in 
univariate analysis but only cFGF23 remained significant after adjustment. Inclusion of 
EPO-SDS did not alter the association of cFGF23 with hemoglobin. In contrast, iron indices 
largely displace this interaction.
Conclusions: In patients with predominantly moderate to severe renal function 
impairment, relative EPO deficiency fails to explain the association of cFGF23 with 
anemia, which rather seems to be mediated by iron metabolism.
Table 2
Dependent variable:Hemoglobin;Base model:eGFR, gender, albumin, DM II;Iron 
model:Base PLUS serum iron, hepcidin, transferrin saturation, ferritin, transferrin; EPO 
model: Base PLUS EPO-SDS; Inflammation model: Base PLUS CRP, interleukin 6
Table 1
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Iron Overload in Patients on Hemodialysis: Hepatic, Myocardial, and 
Bone Tissue Deposit
Lucas A. Nunes,1 Cesar A. Truyts,3 Luciene dos Reis,5 Rosse C. Osorio,7 
Hilton M. Leao-Filho,1 Rosa M. Moyses,4 Rosilene M. Elias,2 Carlos E. Rochitte,6 
Vanda Jorgetti,2 Melani Custodio.1 1Universidade de São Paulo, Belem, Brazil; 
2Universidade de Sao Paulo, Sao Paulo, Brazil; 3university of sao paulo, 
Jacarei, Brazil; 4Universidade Nove de Julho, São Paulo, Brazil; 5University of 
Sao Paulo - Medical School - Nephrology Division, Sao Paulo, Brazil; 6Heart 
Institute (InCor) University of São Paulo Medical School, São Paulo, Brazil; 
7INCOR, Salvador, Brazil.
Background: Anemia is commonly observed among ESRD patients on hemodialysis 
patients, most of the time requesting intravenous correction of iron deficiency (Fe). 
However, excessive Fe supplementation leads to increased risk of Fe overload with 
consequent deposition in organs and tissues such as liver, heart and bone tissue. The 
objective of the current study was to evaluate this issue in a cross-sectional cohort of ESRD 
on hemodialysis.
Methods: We included 28 adult patients (16 men), on hemodialysis for at least 3 
months, and with serum ferritin levels ≥1,000 mg/l. Serum ferritin, transferrin saturation 
index (STI), Fe, C reactive protein (CRP), Calcium (Ca), phosphorus (P), parathyroid 
hormone (PTH) and alkaline phosphatase (AP) levels were recorded. T2* image acquisition 
of Magnetic Resonance Imaging (MRI) 1,5 Tesla, were used for the assessment of Fe of 
liver, and heart. R2* were used only of liver. Bone biopsy was also performed
Results: Mean age was was 54±13 years (57% men). Laboratorial values are depicted 
at the Table 1. T2* [Reference value(RV) > 16 ms] and R2* (RV < 60 s-1 ms) MRI of liver 
showed 6.95 ms [IQR 3.57] and 143.85 s-1 ms [IQR 84.52], respectively. MRI T2* of the 
heart did not show presence of Fe. Bone biopsy revealed that 100% of patients had Fe 
deposition.
Conclusions: These data detail the Fe distribution throughout the bone and liver but 
not myocardial in selected high-risk patients on hemodialysis (serum ferritin levels ≥1,000 
ng/ml). The impact of Fe deposition on these tissues whether the use of chelation therapy 
would change this scenario should be evaluated in subsequent studies.
Table 1. Main baseline characteristics of patients
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Socio-Demographic Characteristics, Out of Pocket Expenditure and 
Quality of Life of Hemodialysis Patients in India
Abhinav Bassi,2 Oommen John,2,4 Kamal D. Shah,1 Sradha S. Kotwal,3,4 
Rohina Joshi,3 Sanjay K. Singh,2 Sumathi Kolli,1 Prasanna K. Thota,1 
Beverley M. Essue,5 Stephen Jan,3,4 Martin P. Gallagher,3,4 John Knight,3,4 
Vivekanand Jha.2,4 1NephroPlus Dialysis Centres, Hyderabad, India; 2George 
Institute for Global Health, New Delhi, India; 3The George Institute for Global 
Health, Sydney, NSW, Australia; 4University of New South Wales, Sydney, NSW, 
Australia; 5University of Sydney, Sydney, NSW, Australia.
Background: The Dialysis Outcomes in India (DOI) Study is following a cohort 
of incident dialysis patients to evaluate the impact of socio-demographic and economic 
factors on clinical outcomes among end stage kidney disease (ESKD) patients initiated 
on hemodialysis in India. Here we present the baseline socio-demographic and clinical 
characteristics and Quality of Life (QoL) in the enrolled subjects.
Methods: A total of 1000 subjects were recruited between Nov 2016 & Mar 2018 in 
18 facilities across 10 states in India. Routine medical records were utilized for collection 
of demographic and clinical information. Structured interviews were conducted to collect 
socio-economic parameters, including out-of-pocket expenses (OoP), with QoL measured 
using Euroqol-5D-3L®.
Results: Mean age (±standard deviation) of enrolled subjects was 54±16 years, and 
there were 341 females. Nearly two-thirds of the participants had school education or less 
(female 73% and males 62%). Over 80% of the female subjects worked within the home 
and 44% of the males were either retired or not working. A history of hypertension was 
reported in 64% of subjects (duration 7±6 years) and diabetes in 50% (duration 8±7 years). 
Mean monthly family income was reported as US$ 602±408. Only one-third of the subjects 
had health insurance. The mean monthly OoP expenditure was US$ 491±299 for uninsured 
subjects and US$ 191±103 for insured subjects. Nearly 9% of the subjects had to change 
their occupation due to kidney disease and treatment schedules. Mean distance travelled to 
the dialysis unit was 25±15 kms (female 15±9 and males 21±14 km, respectively). Over 
16% of the patients reported severe anxiety/depression and 14% reported severe problems 
related to activities of daily living. Mean QoL Score on the VAS Scale (0-100), was reported 
at 58 ± 18 (male) and 64 ± 14 (female).
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Conclusions: Our study found high dialysis-related OoP expenditure, particularly in 
those who were uninsured. Low levels of health insurance coverage represents a major 
challenge for policy makers in mitigating the economic burden of dialysis treatment. 
High number of participants leaving the workforce highlights the challenges related to 
maintaining employment for patients undergoing dialysis.
Funding: Commercial Support - Baxter Healthcare Ltd, United Kingdom
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Marginal Cost of Frailty Among Dialysis Patients
John Sy,1 Elani Streja,3 Kirsten L. Johansen.2 1Long Beach VA Medical Center, 
Long Beach, CA; 2University of California, San Franicsco, San Francisco, CA; 
3Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Orange, CA.
Background: Patients on dialysis incur disproportionately high costs compared to 
other Medicare beneficiaries, and frail individuals may cost more. We examined the extent 
to which frailty contributes to higher costs among dialysis patients.
Methods: The ACTIVE/ADIPOSE study enrolled adult hemodialysis patients from 
June 2009 to August 2011. Individuals utilizing Medicare as the primary payer with active 
claims were selected for inclusion. Frailty was assessed at baseline and annually for 2 years 
using Fried’s frailty phenotype. Baseline demographic data and costs were derived from 
linkage with the USRDS and Medicare claims (Part A, B, and D) standard analysis files. 
We used generalized estimating equations incorporating time-updated frailty to estimate 
the marginal cost of being frail at the beginning of each year of follow-up, adjusting for 
age, gender, body mass index (BMI), and comorbid conditions (diabetes, coronary artery 
disease, and congestive heart failure). All costs were adjusted for inflation to 2017 US 
dollars and reported per patient per year (pppy).
Results: Among 771 individuals enrolled in the ACTIVE/ADIPOSE study, 345 met 
inclusion criteria with an average age of 56.1 years and BMI of 29 kg/m2. 28% of patients 
were considered frail at baseline, whereas 54% were frail at any time point. Over mean 2.3 
years of follow up, frail individuals incurred 23% (95% CI 10-37%) higher costs compared 
with non-frail individuals ($101,000 pppy, 95% CI $89,000-$116,000, vs $83,000 pppy, 
95% CI $75,000 – $91,000). The difference in costs between frail and non-frail patients 
appears to be driven primarily by higher hospitalization expenditures (26% higher, 95% CI 
11%-43%). Neither physician/supplier costs (12% higher, 95% CI 2% lower to 29% higher) 
nor were expenditures for pharmacy benefits (2% higher, 95% CI 8% lower to 13% higher) 
statistically different between frail and non-frail individuals.
Conclusions: Frail dialysis patients incur a significantly higher cost relative their non-
frail counterparts, primarily driven by higher hospitalization costs. Efforts to address frailty 
and its association with hospitalizations may lead to a significant reduction in health care 
expenditure among dialysis patients.
Funding: NIDDK Support
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The Health and Economic Consequences of Missed Dialysis at the Robley 
Rex Veterans Affairs Medical Center
Liza Cholin,1 Jordan Burlen,1 Farrah Harden,1 Nevin Murthy,1 Michael E. Brier,1 
Eleanor D. Lederer.2 1University of Louisville, Louisville, KY; 2University of 
Louisville; Robley Rex VA Medical Center, Louisville, KY.
Background: Non-adherence to hemodialysis (HD) is associated with increased 
morbidity and mortality risk, as well as increased health care costs. These patients frequently 
present to the emergency department (ED) needing urgent HD for volume overload, 
hyperkalemia, or uremic symptoms. At present, the Robley Rex VAMC does not offer 
outpatient HD, necessitating full hospital admission for patients who present with urgent 
need for HD. We hypothesized that offering outpatient HD to patients who missed their 
scheduled appointments would reduce costs attributed to missed HD hospital admissions, 
even taking into account increased dialysis nurse overtime utilization.
Methods: We conducted a retrospective analysis of established HD patients evaluated in 
the ED of the Robley Rex VAMC, between October 2015 and May 2017, for complications 
secondary to missed dialysis. Individuals that were admitted for any reason other than 
urgent HD were excluded. The costs for ED evaluation, hospitalization, and dialysis labor 
costs were obtained. We calculated costs of the full inpatient admission including dialysis 
and compared those results with the projected cost providing a single outpatient dialysis 
treatment for each presentation.
Results: There were 92 individual admissions resulting in 209 inpatient dialysis 
treatments, indicating that patients were often kept for additional HD treatments. The 
total cost for these admissions was $729,360.93, which roughly equates to $7,927.84 
spent per admission. The cost for an outpatient dialysis session (including ED cost) ranges 
between $1,032.12 and $1,177 accounting for standard labor versus time-and-a-half labor, 
respectively. Thus, the total expected range for an equivalent 209 HD sessions, if they were 
to be done as an outpatient, would be between $215,713.08 and $245,993. This results in 
total savings ranging from $483,367.93 to $513,647.85.
Conclusions: Forming outpatient dialysis capabilities in an acute dialysis unit would 
help reduce health-care spending in patients being admitted to VA hospitals for missed HD. 
Further research is still needed in identifying possible reversible barriers in non-adherent 
patients.
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Fast Track Dialysis: A Novel Triage and Communication Pathway  
to Reduce Resource Utilization for ESRD Patients Presenting with  
Missed HD
Tahsin Masud,1 Ethan Molitch-Hou,3 Kyle P. James,2 Christopher M. O’Donnell.3 
1Renal, Emory University, Atlanta, GA; 2Hospital medicine, Emory University 
Hospital Midtown, Atlanta, GA; 3Hospital Medicine, Emory University Hospital 
Midtown, Atlanta, GA.
Background: Many end stage renal disease (ESRD) patients present to emergency 
department (ED) with complaints related to missed hemodialysis (HD) or have no 
established dialysis clinic. Provision of inpatient HD necessitates short stay admission, use 
of extra resources, coordination between multiple specialties, resulting in substantial cost.
Methods: A multidisciplinary team sought to improve the flow of ESRD patients 
through the ED by creating a unique triage pathway, Fast Track Dialysis (FTD). FTD care 
was facilitated with standardized communication between ED, Nephrology, Hospitalist 
and Nursing. The FTD pathway emphasized use of venous blood gasses for potassium 
levels, limited telemetry, chest X-ray, and peripheral IV lines. Patients eligible for FTD 
were identified by ED providers. Exclusions were BP > 200/100, heart rate > 120/ minute, 
hypoxia requiring oxygen > 4 L/min, potassium > 6.5 mEq/L and clinical concern that 
would require admission beyond one session of HD, and dialysis access issues requiring 
immediate intervention. A six-month historical control group (Pre-FTD) was compared 
with a six-month FTD cohort with hospital stay < 48 hours. The historical group was 
filtered by admitting diagnosis (ICD-10 codes) related to dialysis conditions, stay < 48 
hours, and above exclusion criteria. Outcome measures were time parameters from triage to 
ED discharge, HD start, and hospital discharge. The estimates of cost were obtained from 
hospital generated billing.
Results: FTD led to significant reduction in all time parameters studied (Table). The 
billing cost was lower but reached significance level after excluding 3 outliers who require 
additional diagnostic testing for head injury, paracentesis and chest pain.
Conclusions: The implementation of a novel patient care pathway intended to identify, 
triage, and facilitate the care of low risk ESRD patients that required urgent HD led to a 
reduction in resource utilization.
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Cost Savings Associated with Post-Hospital Medication Therapy 
Management Program Dialysis Patients
Harold J. Manley,1,2 Gideon N. Aweh,1 Daniel E. Weiner,3,1 Eduardo K. Lacson.1,3 
1Dialysis Clinic, Inc., Nashville, TN; 2Reach MTM, Albany, NY; 3Tufts Medical 
Center, Boston, MA.
Background: Dialysis Clinic, Inc. implemented a medication therapy management 
(MTM) program for End-Stage Renal Disease Seamless Care Organization patients 
following hospital discharge. Prior results suggested a 56% reduction in readmission rate 
with MTM compared to no MTM. We determined the potential impact of the MTM process 
on costs associated with readmision.
Methods: We used a propensity score (PS) to match MTM 1:1 to non-MTM discharges 
based on clinical characteristics and on the day post-discharge MTM was initiated. Actual 
readmission costs were obtained from claims data; the percent difference between MTM 
and non-MTM groups were calculated and used to estimate cost impact if MTM process 
applied to non-MTM discharges. Readmission rates after MTM completed, or similar time 
at risk in matched non-MTM patients, was determined. Cost estimates incorporated MTM 
implementation time (median, interquartile range) and assumed 25%, 50% or 75% of 
reported MTM program impact on readmission rate.
Results: In the original cohort, there were 162 discharges with 17 readmissions costing 
$253,652 in the MTM group and 586 discharges with 170 readmissions costing $2,161,163 
in the non-MTM group. Median time to complete MTM was 11 days. There were 135 PS 
matched pairs used, with 26 (19.26%) readmissions in MTM patients and 50 (37.04%) 
in non-MTM patients (p=0.0002). Readmission costs were $202,659 vs. $580,549, 
respectively (p<0.001). MTM was associated with 12%, 26%, or 49% cost savings if 
implemented ≥14 days, ≥11 days or ≥7 days post discharge, respectively. Extrapolating 
results to the entire non-MTM group, savings ranges from $117,586 to $600,642 (see 
Table). Cost savings with MTM performed within 11 days of discharge assuming 50% 
impact approximates $286,020.
Conclusions: MTM process is associated with fewer readmissions and lower inpatient 
costs. The statements contained in this document are solely those of the authors and do not 
necessarily reflect the views or policies of CMS. The authors assume responsibility for the 
accuracy and completeness of the information contained in this document.
Savings estimates if MTM process implemented in 586 no-MTM discharges
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In-Center Hemodialysis Consumer Assessment of Healthcare Providers 
and Systems (ICH CAHPS) Survey Response and Long-Term Clinical 
Outcomes
Taimur Dad,1 Hocine Tighiouart,1 Megan Grobert,2 Eduardo K. Lacson,1 
Klemens B. Meyer,1 Daniel E. Weiner,1 Michelle M. Richardson.3 1Tufts Medical 
Center, Boston, MA; 2Dialysis Clinic Inc, Nashville, TN; 3New England Medical 
Center, Boston, MA.
Background: The In-Center Hemodialysis Consumer Assessment of Healthcare 
Providers and Systems (ICH CAHPS) survey, introduced into the ESRD Quality Incentive 
Program, is the only patient-reported outcome measure currently used for value-based 
reimbursement in dialysis. It is administered twice yearly to assess hemodialysis patient 
experience. Current response rates are approximately 30%. The relationship between 
response status and long-term clinical outcomes is unknown.
Methods: All Dialysis Clinic Inc. (DCI) hemodialysis patients age 18 and older 
treated at their facility for at least 3 months as of August 2012 were eligible for the survey. 
Covariates included patient demographic, clinical, and treatment related characteristics. 
Outcomes included mortality, kidney transplantation, and all cause-hospitalization.
Results: Among 10,395 eligible patients who survived the 3-month survey 
administration, 3,794 (36%) responded to the survey. Over median follow-up of 30 
months, 4,178 patients died, 5,336 patients were hospitalized at least once, and 717 patients 
received a transplant. In multivariable models, survey response was associated with lower 
mortality (HR 0.80; 95% CI: 0.74-0.85) and hospitalization (HR 0.84; CI: 0.79-0.89) and 
higher likelihood for kidney transplant (HR 1.15; 95% CI: 0.98-1.35). Sensitivity analyses 
evaluating the receipt of transplant with competing risk for death, or a composite outcome 
of death or hospitalization, yielded similar results.
Conclusions: Response to the ICH CAHPS survey is associated with a lower risk 
for mortality and hospitalization and higher likelihood for kidney transplantation. These 
findings raise concern about survey result generalizability and use for quality improvement 
since experiences of high-risk patients are less likely to be captured.
Funding: Other NIH Support - NIH T32 grant-PI Andrew Levey
TH-PO278 Poster Thursday
Dialysis: Cost, Socioeconomics, Quality of Life
Do the Better Medical Results Mean a Higher Costs for the Dialysis 
Clinic?
Wojciech Marcinkowski,4 Jacek P. Zawierucha,1 Jolanta Malyszko,2 
Jacek S. Malyszko.3 1Fresenius Medical Care Polska S.A., Poznan, Poland; 
2Warsaw Medical University, Warsaw, Poland; 3Nephrology Department, 
Bialystok, Poland; 4Fresenius, Krakow, Poland.
Background: The quality of care for hemodialyzed patients is determined by 
commonly accepted biochemical parameters controlled periodically. In everyday practice 
evaluation includes, among other things, the dose of dialysis provided, the control of anemia, 
the control of calcium-phosphate balance, and the patients’ nutrition status. Obtaining good 
results is related to, among other things, the time of dialysis sessions, water consumption, 
electricity, prescribed pharmacotherapy. The aim of the study was to retrospectively assess 
the correlation between the obtained medical results and the costs directly related to the 
dialysis treatment of patients with chronic renal failure.
Methods: The analysis included 5,500 patients treated in 68 centers in the years 2014-
2016. Medical evaluation was based on the percentage of patients achieving the individual 
target in particular categories: weekly dialysis time > 240 minutes, single-pool kt/v > 1.4, 
dialysis with arteriovenous fistula, relative overhydration < 13% (female) or <15% (male), 
Hb concentration in the range of 10-12 g/dl or > 12 g/dl without the use of erythropoiesis 
stimulating agents (ESA), albumin > 35 g/l, phosphate concentration < 5.5 mmol/l, patient’s 
protection against new HBV infection and the percentage of patients active on the waiting 
list for kidney transplantation > 7%. For reaching the clinic target in a single category the 
center was awarded 1 point. The clinic medical result was the sum of points. The assessment 
was made on a monthly basis. Monthly treatment costs were also assessed. Costs of dialyzers 
and dialysis lines, electricity, water, concentrates, ESA, iron, anticoagulation, dialysis fluid 
concentrates, hygiene and dressing agents were included. The medical results were then 
correlated with the costs incurred in individual months in subsequent years.
Results: The correlation coefficient r between medical results and costs in 2014, 2015 
and 2016 was -0.35 (p <0.005), -0.42 (p <0.001) and -0.51 (p <0.001), respectively.
Conclusions: A statistically significant negative correlation between medical results 
and costs directly related to the treatment of hemodialyzed patients in three consecutive 
years suggests that better medical results are obtained in centers that better control medical 
expenses. Better medical care does not necessarily means higher costs for dialysis centers.
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Dialysis Facility Acquisitions and Patient Health Outcomes
Kevin F. Erickson,1 Bo Zhao,1 Wolfgang C. Winkelmayer,1 Glenn M. Chertow,2 
Vivian Ho.3 1Baylor College of Medicine, Bellaire, TX; 2Stanford University School 
of Medicine, Palo Alto, CA; 3Baker Institute for Public Policy, Houston, TX.
Background: Mergers and acquisitions among healthcare providers are increasingly 
common. Although dialysis markets have undergone several decades of mergers and 
acquisitions, their effects on patient health outcomes are unknown.
Methods: We identified patients initiating in-center hemodialysis between 2001 and 
2013 from a national ESRD registry and used difference-in-differences (DID) models to 
estimate the associations among dialysis facility acquisitions, mortality and hospitalization. 
We used multivariable Cox models and negative binomial models (with predicted marginal 
effects) to examine mortality and hospital days, respectively. All analyses adjusted for 
observed differences in patient and geographic characteristics. In addition to examining 
all facility ownership types, we conducted stratified analyses of facilities that were 
independently-owned and chain-owned prior to acquisition.
Results: When examining all facility ownership types, dialysis facility acquisitions 
were independently associated with 0.63 additional hospital days per patient-year (95% CI 
0.00 to 1.27; p=0.07). When examining independently-owned facilities, acquisitions led to 
2.01 additional adjusted hospitalization days per patient-year (95% CI 0.53 to 3.48) and a 
nominally significant 13% relative increase in adjusted mortality (95% CI 4% to 22%).
Conclusions: Acquisition of independently-owned dialysis facilities by large dialysis 
organizations led to higher adjusted mortality and an increase in adjusted hospital days per 
patient-year.
Funding: NIDDK Support
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The Impact of Debility on Inpatient Mortality and Hospital Costs of 
ESRD Patients in the United States: A Nationwide Study
Mark A. Nader,1,2 Oussama Hassan,3 Rodrigo Aguilar Campos,4 Rehan Shafique,1 
Carmen E. Cervantes,5 Ricardo Correa,6 Prabin Sharma,7 Hieu Q. Vo,9 
Omar Hamze,11 Judit Gordon,8 Ping Li.10 1Nephrology and Hypertension, Kidney 
Care consultants, Memphis, TN; 2Nephrology and Hypertension, Georgetown 
University, Washington, DC; 3Royal London Hospital, Austin, TX; 4Georgetown 
University Hospital, Washington, DC; 5Aventura Hospital and Medical Center, 
Aventura, FL; 6University of Arizona, Phoenix, AZ; 7Yale University Bridgeport 
Hospital, Bridgeport, CT; 8Medstar Georgeotown University Hospital, 
Washington, DC; 9University of Tennessee, Memphis, TN; 10Nephrology and 
Hypertension, George Washington University, Washington, DC; 11Kidney Care 
Consultants, Memphis, TN.
Background: Patients on dialysis often suffer from muscle wasting and reduced 
exercise tolerance compared with the general population. The impact for this debility on 
the in-patient dialysis population remains unclear. The purpose of the current study was 
to determine the inpatient mortality and cost effects of debility between dialysis patients.
Methods: Data was extracted from the 2005 to 2012 Nationwide Inpatient Sample 
(NIS). Using propensity score matching, end stage renal disease (ESRD) patients with 
debility were matched with ESRD patients without debility at a 1:1 ratio. We compared 
inpatient mortality, length of stay and total hospital charges between both groups. Analyses 
were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Results: Among 1,070,450 hospitalized ESRD patients during 2005 to 2012; 
only 16,810 (1.57%) were identified with debility. These patients were associated with 
significantly higher rate of gastrointestinal bleed (2.01 vs 1.77%; p=0.02), obesity (11.92 
vs 8.37%), acute CHF (39.12 vs 33.94%; p=0.0001), Atrial fibrillation (23.11 vs 15.06%; 
p=0.0001) and CAD (41.74 vs 33.99; p=0.0001). Surprisingly, ESRD patients with debility 
had a significantly lower in-hospital mortality compared with ESRD patients without 
debility before (4.52 vs 5.09%; p=0.001) and after matching (4.53 vs 6.17%, p = 0.0001). 
Mean length of stay for those with debility was 11.12 days compared with 7.53 days (p < 
0.0001). Similarly, mean hospital charges were greater for those who had debility compared 
with control ($69,596 vs $57,752; p < 0.001).
Conclusions: Debility in dialysis patients appears to have a lower in hospital mortality 
compared to more conditioned ESRD patients. It does however increase the costs and length 
of stay. Interventions to lower debility may help reduce hospital expenditures.
TH-PO281 Poster Thursday
Dialysis: Cost, Socioeconomics, Quality of Life
Can Dialysis Facility Compare (DFC) Star Ratings Inform Patient Choice 
of Dialysis Facility? Geographic Co-Location of Facilities by Star Rating 
Category
Stephen Salerno, Garrett W. Gremel, Richard A. Hirth, Yi Li, Claudia Dahlerus, 
Lan Tong, J. M. Messana. University of Michigan, Kidney Epidemiology and 
Cost Center, Ann Arbor, MI.
Background: Beginning in 2015, Medicare’s DFC site implemented a Star Rating 
system summarizing the selected clinical quality measures reported on DFC. The Star 
Ratings are intended to provide an easily interpretable summary of dialysis facility’s quality 
performance and to assist consumer decision-making. We hypothesize that patients’ choice 
of dialysis facility might be influenced by the reported Star Ratings, particularly for those 
whose choice is not limited by distance to a dialysis facility.
Methods: Based on facilities’ zip codes and their reported Star Ratings on DFC, we 
geocoded all 6000+ dialysis facilities in the contiguous U.S.. Facilities with lower star rating 
performance were defined as those with 1 or 2 Stars; higher star rating performance was defined 
by 3 to 5 Stars. Distances between two facilities were calculated based on the spherical distance 
between the centroids of their zip codes using the geosphere package in R.
Results: Fig. 1 shows the locations of dialysis facilities and Star category. A clear 
geographic pattern for distribution of lower performing facilities is not apparent. Fig. 2 
demonstrates that 84% of facilities with lower star rating are within 10 miles of facilities 
with higher performance.
Conclusions: These results demonstrate that most patients receiving dialysis care in 
lower star rating facilities have the option to transfer care to higher star rating facilities 
based on their geographic proximity. Whether the availability of a higher star rating facility 
in close proximity contributes to the patient’s choice of a new or transfer facility remains 
unanswered by these analyses. Subsequent analyses will stratify lower and higher star rating 
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facilities to evaluate if patients’ choice of dialysis provider is associated with higher rated 
facilities in close proximity.
Funding: Other U.S. Government Support
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Medicare Payments for Ambulance Transport Between Skilled Nursing 
and Dialysis Facilities
Debabrata Ray,1 Kristine Kubisiak,1 Allan J. Collins,1,2 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Most dialysis patients receiving care in a skilled nursing facility (SNF) 
undergo hemodialysis in off-site dialysis facilities and thus require transportation before 
and after each session. In specific circumstances, Medicare Part B provides coverage for 
ambulance transport between such facilities. However, Medicare payments to ambulance 
service providers have been scrutinized by the federal government. By year, we aimed 
to quantify trends in Medicare expenditures on ambulance transport between SNFs and 
dialysis facilities.
Methods: We analyzed data from the United States Renal Data System. We searched 
Medicare Part B claims in payment years 2011-2015 for ambulance transport and retained 
such claims with an origin/destination code pair that indicated transport between SNF and 
dialysis facility. We tallied the number of patients with ≥1 ambulance transport between 
SNF and dialysis facility, the cumulative number of patient-days with ambulance transport, 
and cumulative Medicare payments for ambulance transport.
Results: Ambulance transport utilization was similar in 2011 and 2012 and subsequently 
increased to an apex in 2014: 24,327 patients with ≥1 transport between SNF and dialysis 
facility and 783,786 patient-days with transport (32.2 days per patient). In 2015, utilization 
fell to 21,601 patients with ≥1 transport between SNF and dialysis facility and 643,808 
patient-days with transport (29.8 days per patient). Cumulative Medicare payments for 
ambulance transport increased from $305.7 million in 2011 to $312.4 million in 2013; 
thereafter, payments fell to $285.4 million in 2014 and $235.3 million in 2015. In 2015, 
the Medicare payment rate for ambulance transport was $365 per patient-day, down from 
$411 per patient-day in 2012. As a share of all Medicare Parts A and B payments among 
beneficiaries with end-stage renal disease, cumulative Medicare payments for ambulance 
transport between SNFs and dialysis facilities fell from nearly 1.1% in 2011-2013 to 0.8% 
in 2015.
Conclusions: Medicare expenditures for ambulance transport between SNFs and 
dialysis facilities are falling, initially due to lower per-diem payments and later due to lower 
utilization. Nevertheless, even in 2015, the per-diem Medicare payment for ambulance 
transport remained more than 50% higher than the base-level Medicare payment ($239) for 
an outpatient hemodialysis session.
Funding: Commercial Support - NxStage Medical, Inc.
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The 13-Year Experience of Performing In-Center Short Daily  
Hemodialysis - Who Pays for It?
Mateus Pascoal, Andre Fernandes, Adolfo Simon, Kelia Xavier, Vilber Bello, 
Juliane Lauar, Istenio Pascoal. Centro Brasiliense de Nefrologia & Dialise, 
BRASILIA, Brazil.
Background: Conventional hemodialysis (CHD: 4h3x/wk) has been associated 
with poor quality of life and high morbidity, hospitalization and mortality rates. An ideal 
hemodialysis prescription requires ultrapure dialysate, single-use biocompatible membranes, 
on-line blood monitoring and more frequent and/or longer treatments. Hospitalization 
represents a significant financial burden, accounting for 40% of total dialysis expenditures. 
We have successfully run an in-center short daily hemodialysis program (SDHD: 2h6-7x/
wk) complying with all requirements for an ideal prescription in the last 13 years. This study 
aims to demonstrate how we have configured dialysis delivery, improved outcomes and 
managed resources to achieve an optimal sustainable dialysis practice.
Methods: Operational (productive efficiency, patient compliance and payers 
coverage), clinical (hospitalization, kidney transplantation and survival rates) and 
economic (supply dialysis cost, cost-savings and net savings) landscapes were assessed in 
176 consecutive unselected private-insured patients (108M/68F; mean age 57.6±19.0 yrs, 
range 8-97) receiving in-center SDHD treatments (6-7x/wk; lasting 117.2±8.8min, range 
105-150; ultrapure dialysate and single-use high-flux dialyzer) from Jun/05 to May/18. 
Reimbursement has been largely based on patient outcomes and hospitalization rates.
Results: Our in-center SDHD program operates five 2-hour shifts a day (67% higher 
productivity without increasing fixed costs), the average missed treatment rate was 1.47% 
and an incremental negotiated approach reached universal insurance coverage for daily 
regimen. Average hospital stay (2.97 days per patient-year), kidney transplantation rate 
(7.5%) and mortality rate (7.3%) were better than reported for CHD hospital stay (12 days 
per patient-year), kidney transplantation rate (4.6%) and mortality rate (19.9%). Daily 
hemodialysis consumables costs doubled, adding 25% for patient overall cost. Conversely, 
hospital total length of stay was 75% lower, reducing overall costs by 30% and offseting 
the additional supply cost.
Conclusions: Our dialysis care redesign has markedly improved patient outcomes 
and dramatically reduced hospital stays and expenses. With clinical and economic 
variables combined, it has been possible to sustain a distinctive yet affordable maintenance 
hemodialysis program.
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Estimated Revenue Gains Associated with Relative Blood Volume 
Monitoring (RBV-M) in Hemodialysis (HD) Clinics: An Economic Model 
Using Real-World Data and a Case Size of 12 Medicare Incident Patients
Melissa M. Rosen,1 Yisha Li,1 Linda Ficociello,1 Paul Balter,2 Claudy Mullon,1 
Robert J. Kossmann,1 Gary G. Singer.3 1Fresenius Medical Care Renal Therapies 
Group (RTG), Waltham, MA; 2Nephrology Associates of Northern Illinois and 
Indiana (NANI), Oak Brook, IL; 3Midwest Nephrology Associates, Saint Peters, MO.
Background: There are over 100,000 new HD patients (pts) per year (USRDS). 
For these pts, the first 90 days following HD initiation are associated with elevated 
hospitalization and mortality rates, along with high healthcare costs. We conducted an 
economic analysis for incident HD pts using data from a fluid management (FM) quality 
improvement project (QIP) using RBV-M.
Methods: RBV-M was performed using Crit-Line® Monitors in 9 Renal Research 
Institute (RRI) Clinics. The QIP was associated with an average of 5.3 fewer hospital 
days and an estimated reduction of 2.5 missed treatments (txs) per year in incident HD pts 
(n=1068). Revenue gains from fewer missed txs were calculated using a cost minimization 
model from a facility level perspective. We assumed that HD clinics continuously served 
12 Medicare incident pts with 2 monitors and disposable supplies associated with RBV-M. 
It was also assumed that pts received HD 3 times per week and HD txs were reimbursed at 
$350 per patient (i.e. standard Medicare reimbursement amount plus the onset of dialysis 
adjustment).
Results: Implementing a FM initiative with RBV-M has the potential to generate 
additional revenue from reducing 2.5 missed txs per year. This translated into gains of 
$2,048, annually per clinic (with 12 Medicare incident pts) in the implementation year, after 
accounting for the cost of the monitors and disposable supplies. Once the machines are paid 
for, either in the second year or if the clinic already owns monitors, annual gains are $6,048, 
including the cost of disposable supplies. These results do not include potential savings 
associated with averted hospitalizations or other benefits of the QIP.
Conclusions: RBV-M QI initiatives have the potential to reduce missed txs in incident 
pts and increase revenue in HD clinics. Assuming a reimbursement of $350 per dialysis 
treatment and 12 incident pts per clinic, potential revenue gains associated with RBV-M 
were found to be $2,048 in the start year and $6,048 in the year following implementation 
(or for clinics who already own monitors). Future cost-effectiveness studies of FM 
initiatives should consider the additional value gained from including prevalent HD pts 
who are also likely to benefit from RBV-M.
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
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Analytical Methods for Assessing Clinic-Level Outcomes
V. Shane Pankratz,2 Huan Jiang,1 S. Paine,1 Ambreen Gul,1 Dana Miskulin,3 
Philip Zager.1 1Dialysis Clinic, Inc., Albuquerque, NM; 2UNM Health Sciences
Center, Albuquerque, NM; 3Tufts Medical Center, Boston, MA.
Background: Patient outcomes from dialysis units are important indicators of the 
quality of care provided by each unit. Clinical outcomes for dialysis providers are typically 
assessed on a per-clinic level. However, the number of patients in each clinic varies greatly, 
and this can impact the validity of ratings. Different analytical approaches might enhance 
the estimated ratings.
Methods: Using 2009-2017 data from Dialysis Clinic, Inc. (DCI) clinics, as well as 
simulated data, we assessed the impact of different estimation approaches (fixed vs. random 
clinic effects) on ratings based on clinic-level mortality.
Results: Simulations demonstrate that random effects estimates are shrunk towards the 
overall mean, and have lower standard errors than fixed effects estimates, and that random 
effects estimates more reliably provide estimates that agree with truth, particularly for 
smaller clinics. Estimates of mortality from DCI clinics illustrate the degree of shrinkage 
that is induced through the application of random effects methods (Figure 1).
Conclusions: Random effects approaches are more likely to provide correct rankings of 
clinics than fixed effects estimates, and might reliably be used to obtain stabilized estimates 
of mortality rates. However, obtaining estimates in this way may require larger numbers 
of patients per unit than are often treated within individual clinics. Enhancing information 
content, either by aggregating across years or by incorporating other data types into an 
aggregated rating measure, would enable more accurate estimation of clinic performance.
Funding: Clinical Revenue Support
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Figure 1. Distribution of unit-specific mortality rates in 2014
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The Centers for Medicare & Medicaid Services ESRD Quality Incentive 
Program (QIP): Measurement, Monitoring, and Evaluation
Jeffrey Pearson,1 Dominick Esposito,2 Adebola O. Adeleye,3 Delia Houseal,3 
Marc Turenne,1 Alissa Kapke,1 Meg G. Tucker,2 Whitney B. Schott,2 Josh Chen,2 
Amanda Szymanski,1 Eric W. Young,1 Alan B. Leichtman.1 1Arbor Research 
Collaborative for Health, Ann Arbor, MI; 2Insight Policy Research, Arlington, 
VA; 3Centers for Medicare and Medicaid Services, Woodlawn, MD.
Background: Mandated in 2008, QIP is Medicare’s premier value-based purchasing 
program. Congress designed QIP to link dialysis facility quality with payment. Initially QIP 
used measures of anemia and hemodialysis adequacy; it now includes a broad set of clinical, 
safety, and reporting measures. With the recent Meaningful Measures Initiative, CMS is 
interested in a measure set that reflects the highest priorities for quality measurement and 
improvement. We describe ongoing monitoring of QIP measures and evaluation of QIP 
influence on quality, overall and among subgroups of patients and facilities.
Methods: We used Medicare claims, CROWNWeb, and other CMS data to monitor 
monthly trends in QIP measures during 2010-17.
Results: Performance has improved over time under the QIP for most quality indicators, 
and has remained relatively stable for the remainder (figure). Smaller recent changes for 
some indicators may reflect diminishing opportunities for improvement where performance 
levels are already relatively high (e.g. hemodialysis adequacy, hypercalcemia). Performance 
was lower for some patient subgroups (e.g. black race, young adults) for some indicators (e.g. 
fistula use, readmissions, emergency department visits). Many indicators varied by facility 
characteristics, including ownership, hospital-based vs freestanding, and size. For example, 
facilities not affiliated with large chains often had consistently lower performance (e.g. 
peritoneal dialysis adequacy, hospitalizations) or took longer to achieve similar performance 
levels (e.g. hemodialysis adequacy, fistula use).
Conclusions: In the era of the QIP, overall performance has improved on many 
indicators of quality of care. Variation in performance on some indicators based on patient 
and facility characteristics suggests continued opportunities for improvement.
Funding: Other U.S. Government Support
National Trends in QIP Measures, 2010-17
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A Case Study of the Barriers to the Practice of Person-Centered Care 
within the Context of Hemodialysis Services
Rachel A. Lewis, Marcello Tonelli. University of Calgary, Calgary, AB, Canada.
Background: People dependent upon hemodialysis have a high illness and treatment 
burden. This can be accentuated by care delivery systems that are disease specific, episodic, 
process focused and fragmented. Person-centered care (PCC) has been shown to provide 
a number of benefits including: improved health outcomes; increased patient satisfaction; 
and a reduction in healthcare utilization. Although conceptually PCC is widely supported, 
its translation into practice is proving to be a challenge. This research explores stakeholder 
perspectives of how care is provided within hemodialysis services. It particularly focuses 
on factors that inhibit PCC.
Methods: A case study approach was used that included semi-structured interviews 
and observation of clinical encounters, including physician rounding. Data was coded 
inductively and categorized into emergent themes using Nvivo®. Interpretive description 
was used to analyse the data. A total of 48 people were interviewed: 20 patients, 5 family 
members, 9 nurses, 6 physicians, 5 managers and 3 social workers. 30 hours of observation 
were undertaken.
Results: Care was largely limited to the technical aspects of dialysis treatment and 
whilst there was evidence of PCC, this was episodic and specific to individual clinicians 
and/or patients. Patients did not perceive their care as individualized, were not involved 
in decisions regarding it and felt the staff did not have time to listen to their concerns. 
Nurses described an oppressive and stressful environment with a culture of bullying. The 
routinization of nursing care and micromanagement, reduced their autonomy and scope of 
practice. Physician scheduling required reviewing a large number of patients within a short 
time span; care was often limited to addressing immediate issues and physicians had some 
concerns regarding continuity. Many of the healthcare professionals alluded to the lack of 
multi-professional working.
Conclusions: A complex mix of individual, environmental and organizational barriers 
mitigate against the adoption and practice of PCC within hemodialysis services. In 
particular, how professionals’ practised was often constrained by care processes aimed at 
meeting demand. This was accentuated by the absence of integrated work practices.
Funding: Other NIH Support - Canadian Institutes for Health Research
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Patient-Nephrologist Prognostic Awareness and Discordance in ESRD on 
Renal Replacement Therapy
Sassine Ghanem,1 Nicholas Fuca,1 Samer Saouma,1 Sami U. Hossri,1 
Frank Forte.2 SIUH Medicine/Nephrology 1Staten Island University Hospital, 
Staten Island, NY; 2Staten island university hospital Nothwell Health, Staten 
island, NY.
Background: The one-year mortality rate of patients with ESRD on renal replacement 
therapy is 20-25%, comparable to many cancers. Several studies have documented that 
patients with cancer commonly overestimate their likelihood of survival relative to their 
physicians however it is unclear if this translates into other terminal illnesses.
Methods: Patients with ESRD on RRT age 18 years and older with no cognitive defect 
were interviewed to evaluate their prognostic estimates at one and five years. Their past 
medical history and demographic data were abstracted from medical charts. Each patient’s 
nephrologist was then interviewed regarding the prognostic estimate of the patient. Both 
patient and nephrologist estimates were then compared and a difference of greater than 20% 
divided the patients into two groups, prognostic concordance or discordance.
Results: 77% of the patients were found to be in prognostic discordance with their 
nephrologists. This group was older, had more comorbidities, a lower albumin level and 
a worse prognostic score. The majority of these patients were in disagreement with their 
nephrologists regarding whether a discussion about prognosis had occurred. The goals of 
care for 55% of patients was oriented towards an end of life focused on relieving pain and 
discomfort even if that meant a shorter duration of life.
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Conclusions: Communication of prognosis and discussions related to life expectancy 
and planning for end of life care are lacking in routine care of ESRD patients. ESRD 
patients therefore tend to overestimate their prognosis, while half of the patients interviewed 
preferred an end of life care oriented towards symptom control, not longevity, this may lead 
to overutilization of invasive procedures and higher healthcare costs as well as a delay in 
palliative or hospice measures.
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The Primary Cares Survey of In-Unit Dialysis Patient Primary Care 
Choices
Alan Perlman,1,2 David L. Epstein,1,2 Thomas Parker,1 Daniel Levine,1 
Jonathan T. Lin,1,2 Xunxi S. Guo,2 Omar Farrukh,2 Victoria Gutgarts,2 
Molly R. Phillips,1 Weeraporn Srisung,2 Perola Lamba,2 Samuel Baskharoun,3 
Frank Liu.1,2 1Rogosin Institute, New York, NY; 2NYP-Weill Cornell, New York, 
NY; 3Frank H. Netter MD School of Medicine, New Haven, CT.
Background: The complexity of primary care(PC) management of patients undergoing 
chronic dialysis often leads to confusion by the patient, nephrologist and traditional PC 
practitioners regarding the responsibility for the management of their care. In addition to 
renal failure, dialysis patients have a significant number of co-morbid medical conditions 
and require numerous medications. Common beliefs regarding PC by patients and their 
practitioners are not well characterized. Centers for Medicare and Medicaid Services(CMS) 
has advanced the notion of the patient centered model of care. With the implementation of 
the ESRD Seamless Care Organizations(ESCO), CMS has placed the dialysis facility and 
providers as the principal coordinators of patient care, thus implying that PC provisions are 
incorporated. Ultimately, patients preferences are integral to care delivery and may prove 
intrinsic to the success or failure of the ESCO model. The objective of the survey is to 
characterize attitudes amongst dialysis patients regarding PC provisions.
Methods: The PRIMARY CARES (Primary Care Attitudes and Renal Replacement 
Selection) survey was performed in 7 HD units in the NYC area representing a diverse 
population of ethnicities, languages (5) and socioeconomic categories with the objective of 
assessing factors influencing the utilization of PC services.
Results: 832 patients were approached and 511 completed the survey. Of these, 
396 (77%) completed the question regarding having someone whom they consider to be 
their PC provider(PCP) with 44% reporting their PCP was their internist(IM) or family 
practitioner(FP) vs 45% reporting their nephrologist as their PCP. Regarding which 
practitioner they would seek for first management of an acute issue, 48% stated their 
IM/FP vs 38% their nephrologist. Regarding patient preference for PCP, 41% reported their 
IM/FP vs 44% for nephrologist.
Conclusions: Our results indicate that a significant percentage of dialysis patients 
identify, utilize and prefer non-nephrology practitioners rather than their nephrologists 
for acute medical care and PC needs. In the ESCO model, patient preference for, and 
utilization of, services outside the purview of the dialysis center is likely to have important 
consequences on the overall success of the program.
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Obstetric Outcomes in Poor CKD Pregnant Women in Mexico
Margarita Ibarra-Hernández,1,2 Maria de la luz Alcantar Vallin,1,2 
Patricia M. Jimenez,1 Francisco V. Villagrana,1 Jose D. Diaz-Avila,1 
Giorgina B. Piccoli,3 Guillermo Garcia-Garcia.1,2 1Hospital Civil de Guadalajara 
FAA, Guadalajara, Mexico; 2CUCS University of Guadalajara, Guadalajara, 
Mexico; 3University of Torino, Torino, Italy.
Background: CKD affects up to 6% of women of childbearing age. Despite that 
adverse obstetric outcomes are common in CKD pregnant women, the number of successful 
preganancies has increased over time, especially in high-income countries. We report 
outcomes in CKD pregnant women, followed at our integrated Obstetric and Renal Clinic.
Methods: Prospective study in CKD pregnant women followed between June 
2013-December 2017. CKD was defined as per KDIGO guidelines. Dialysis was initiated 
when BUN was ≥ 45 mg/dL or when RRT was clinically indicated. Outcomes were 
compared between patients who required RRT vs conservative treatment.
Results: Table 1
Conclusions: Poor CKD pregnant women have a high rate of adverse obstetric 
outcomes. However, an integrated nephrological and obstetric prenatal care throughout all 
stages of CKD, could lead to successful pregancies, even in resource-constrained settings 
like ours.
Table 1
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Sex- and Age-Associated Differences in the Prevalence of Comorbidities in 
Dialysis Patients
Sophia Rosen, Dugan Maddux, John W. Larkin, Len A. Usvyat, 
Franklin W. Maddux, Marta Reviriego-Mendoza. Fresenius Medical Care 
North America, Waltham, MA.
Background: In dialysis patients, the presence of non-renal comorbidities is associated 
with decreased quality of life and poorer outcomes. The prevalence of comorbidities in 
dialysis may vary by sex and age. We aimed to investigate the prevalence of the common 
comorbidities in dialysis patients within different age groups for both women and men.
Methods: We analyzed data from all hemodialysis (HD) patients at a large dialysis 
provider in 2016. Patients were grouped in 14 five-year age categories from 25 years old 
(y/o) to 95 y/o. For each age-group, we plotted the percent (%) of patients with an active 
comorbidity of anemia, diabetes (DM), cardiovascular disease (CVD), hyperparathyroidism 
(HPT), gastrointestinal (GI) bleeding, hypertension (HTN), and infection.
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Results: Overall, we studied data from 230,091 patients; 43% were female. When 
compared to men in the same age group, we observed that: i) Anemia appears to affect a 
higher % of women 50 y/o and over 65 y/o, ii) Women suffer more infections at younger 
ages (25 y/o) and >75 y/o, iii) HTN is more prevalent in younger women (30-35 y/o) and 
in women >65 y/o when compared to men, iv) women show higher or similar prevalence 
of HPT at all ages, v) DM is more prevalent in women of most ages and, vi) CVD appear 
similar in men and women with a slight increase in men at age 75-85 y/o. No differences in 
GI bleeding were noted (Figure 1).
Conclusions: In this analysis we noted that the prevalence of comorbidities in dialysis 
patients varies by sex and age with a higher percent of women affected by anemia, HTN and 
DM. Further analyses are needed to elucidate if these differences affect dialysis outcomes.
Funding: Commercial Support - Fresenius Medical Care North America
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Gender-Specific Differences Associated with Sociocultural Attributes in 
Dialysis Patients: A National Cohort Analysis
Sophia Rosen,1 Maria E. Ferris,2 Nwamaka D. Eneanya,3 Carly R. Van Zandt,1 
Priscila Preciado,4 John W. Larkin,1 Len A. Usvyat,1 Franklin W. Maddux,1 
Dugan Maddux,1 Marta Reviriego-Mendoza.1 1Fresenius Medical Care North 
America, Waltham, MA; 2University of North Carolina at Chapel Hill, Chapel 
Hill, NC; 3Massachusetts General Hospital, Boston, MA; 4Renal Research 
Institute, New York, NY.
Background: Women and men have physiological differences that distinctly affect 
their health, treatment regimens, and clinical outcomes. Sociocultural factors may also play 
a significant role on these differences. We investigated whether certain sociocultural and 
certain clinical factors varied between men and women on dialysis.
Methods: All adult patients from a large dialysis provider who had a comprehensive 
social worker assessment and/or patient health questionnaire-2 (PHQ2) completed in 2016 
were included. The association between sex, age (as of Jan 1, 2016) and sociocultural and 
clinical attributes noted in Table 1 was investigated. Chi-square and t-tests were used as 
appropriate.
Results: We included data from 209,378 patients. In both age groups, housing barriers 
and PHQ2 scores were greater in women, and physical component scores were higher 
for men. Food security was lower in younger women, but there was no difference by sex 
in older patients. In both age groups, married and unmarried men tended to rely on their 
spouse/partner while women tended to rely on a family member other than spouse/partner 
(Table 1).
Conclusions: Our analysis shows that among dialysis patients, several sociocultural 
and clinical factors differ between men and women. Further investigation is warranted to 
elucidate whether these factors influence sex disparities in health outcomes.
Funding: Commercial Support - Fresenius Medical Care North America
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Are Hemoglobin Levels Affected by Sex, Age, and Race in Dialysis 
Patients?
Marta Reviriego-Mendoza, Sophia Rosen, Dugan Maddux, John W. Larkin, 
Len A. Usvyat, Franklin W. Maddux. Fresenius Medical Care North America, 
Waltham, MA.
Background: In the general population, women have lower reference ranges for 
hemoglobin (Hgb) levels compared to men, yet no differences are considered for anemia 
targets in people with chronic kidney disease (CKD). We aimed to explore if differences 
exist in Hgb levels between men and women initiating dialysis within different age groups 
and races.
Methods: Data from all incident patients in the United States Renal Data System 
(USRDS) from 2011-2015 was utilized via the RenDER system. Patients’ were separated 
by sex, race (Asian (ASN), Black (BLK) and White (WHT), and age groups (0-19 years 
old (y/o), 20-39, 40-55, 56-79 and 80+). Average Hgb levels were obtained from the 
2728 Medical Evidence form and compared among categories. The sex gap in Hgb levels 
((FemaleHgb-MaleHgb)/MaleHgb) is evaluated for each category.
Results: Data from a total of 481,823 patients was analyzed; 203,804 (42%) were 
women. Although anemia targets do not differ between men and women with CKD, women 
tend to have lower levels of Hgb when starting dialysis, and this difference is greater for 
younger women. Young BLK women show a -4% and a -5.3% difference at ages 0-19 and 
20-39, respectively, when compared to men. For young WHT women, Hgb levels differ 
from men by a -5.3% for the 0-19 y/o group, and a -3.3% for the 20-39 y/o group. However, 
young ASN women tend to have a smaller gap/difference in Hgb levels when compared to 
men (between -1 to 1% for 0-19 y/o and 20-39 y/o). The sex gap/difference in Hgb levels 
becomes less apparent in older age groups of women for the races analyzed (Figure 1).
Conclusions: Findings suggest that there may be differences in Hgb levels between the 
sexes that vary with age and race, which are most noticeable in WHT and BLK patients. 
More analyses are necessary to investigate if these sex, age and race dependent differences 
in Hgb levels affect health outcomes.
Funding: Commercial Support - Fresenius Medical Care North America
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Evaluation of Diabetes-Related Knowledge Among African American 
Dialysis Patients
Mary O. Muoneke,1 Jason Cobb,2 James L. Bailey,2 Janice P. Lea.1 Emory 
University Hospital 1Emory University, Atlanta, GA; 2Emory University School 
of Medicine, Atlanta, GA.
Background: Diabetic nephropathy is the leading cause of End Stage Renal Disease 
(ESRD) in the United States, accounting for nearly half of all cases. Although training 
patients with diabetes on self-management may help improve their health outcomes, the vast 
majority of U.S. dialysis clinics do not provide diabetes self-management education. As part 
of a diabetes education program introduction assessment, we examined baseline diabetes-
related knowledge and care practices among patients with diabetes at the Emory dialysis 
clinic. Our overall aim is to introduce diabetes education in the clinic and subsequently 
assess the impact on clinical outcomes among dialysis patients with diabetes.
Methods: A questionnaire assessing diabetes knowledge and practices was administered 
on all ESRD patients with diabetes attending the clinic. Data on endocrinology care, most 
recent HbA1c results and history of amputations were also obtained. Introduction of regular 
foot checks during dialysis treatment with appropriate referrals to podiatry has now been 
introduced as a routine clinical practice in the clinic. Review of a diabetes curriculum and 
recruitment of a specialist diabetes educator is ongoing.
Results: Of the 155 patients, 87 (56%) have a diagnosis of diabetes. 85 (98%) 
were African Americans, 50 (58%) are males. The mean age was 63 years. The average 
HbA1C was 6.5%. Only 20 (25%) of the patients were aware of their most recent HbA1C 
results. About 12 (16%) had a history of limb amputations. A history of vascular studies 
was documented in 38 (48%) of the patients. Approximately 65 (82%) and 60 (76%) of 
the patients practiced self-foot and glucose checks respectively. About half of all patients 
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reported receiving endocrinology care. A total of 17 (20%) patients had abnormal foot 
examination and were referred for podiatry evaluation
Conclusions: A small proportion of the African American Diabetic ESRD patients were 
aware of factors that could impact their outcome. Introducing diabetes self-management 
education at dialysis clinics may help improve patient knowledge and potential clinical 
outcomes.
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The Impact of Race and Ethnicity upon Health-Related Quality of Life 
and Mortality in Dialysis Patients
Sara S. Kalantar,1 Amy S. You,2 Alejandra Novoa,3 Kimberly M. Juarez,1 
Tracy Nakata,4 Connie Rhee.1 1University of California Irvine, Huntington 
Beach, CA; 2University of California, Irvine, Orange, CA; 3UC Irvine Health, 
Orange, CA; 4UC Irvine, Orange, CA.
Background: While health-related quality of life (HRQOL) has been increasingly 
recognized as a strong predictor of mortality among hemodialysis (HD) patients, differences 
in these associations across diverse racial/ethnic groups have not been thoroughly 
investigated.
Methods: We examined the relationship between HRQOL and mortality among a 
prospective cohort of racially/ethnically diverse HD patients recruited across 18 dialysis 
units over 2011-16. Using Short Form 36 (SF36) surveys administered every 6 months, 
HRQOL was ascertained by 36 questions summarized as 2 physical and mental health 
dimension and 8 subscale scores. Associations of time-varying SF36 scores with all-cause 
mortality were estimated using multivariable Cox models in the overall cohort and within 
racial/ethnic subgroups.
Results: Among 753 HD patients who met eligibility criteria, the lowest quartiles (Q) 
of physical and mental health dimension scores were associated with higher mortality in 
the overall cohort (ref: highest Q): HRs (95% CIs): 2.18 (1.43-3.32) and 1.56 (1.06-2.28), 
respectively. In analyses stratified by race/ethnicity, among Blacks and Hispanics the lowest 
Q of physical health dimension scores was significantly associated with higher mortality, 
whereas in Non-Hispanic Whites and Asian/Pacific Islanders point estimates of the lowest 
Q suggested higher death risk but did not reach statistical significance. The lowest Q of 
physical functioning, energy/fatigue, and pain subscale scores were associated with higher 
mortality in the overall cohort, and were particularly pronounced in Blacks and Hispanics.
Conclusions: Lower self-reported HRQOL scores, particularly related to impaired 
physical health dimension and subscales, were associated with higher mortality in HD 
patients, including those of minority background. Further studies are needed to determine 
whether interventions that augment physical function improve the survival of these diverse 
populations.
Funding: NIDDK Support
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Quality of Life Reported by Patients with Expanded Hemodialysis by the 
TheraNova Dialyzer in RTS Colombia
Mauricio Sanabria,1 Alfonso Bunch,1 Ricardo Sanchez,2 Jasmin Vesga,1 
Angela S. Rivera,3 Lars-Goran Nilsson,4 Adriana M. Suarez,1 Juan Alarcon,1 
Mauricio Guerrero,1 Jorge A. Diaz,1 David Varon,1 Rafael A. Gomez,1 
Freddy Ardila,1 Roberto D’Achiardi,1 Eduardo Zuniga.1 1RTS, Bogota, 
Colombia; 2Universidad Nacional de Colombia, Bogotá, Colombia; 3Baxter, 
Bogota, Colombia; 4Baxter International Inc., Lund, Sweden.
Background: Patients on hemodialysis have a lower quality of life compared to the 
general healthy population. Some factors such as restrictions on diet and physical activity, 
presence of symptoms and time consumed in treatment greatly affect the level of quality 
of life perceived by patients. The purpose this study was to evaluate changes in quality of 
life and prevalence of restless legs in the first six months after initiating a change in dialysis 
therapy from high-flux HD to expanded hemodialysis(HDx) with Theranova dialyzer.
Methods: Cross-sectional study in prevalent hemodialysis patients older than 18 years, 
enrolled between September 1st and November 30th, 2017, when converted to HDx, in 12 
renal clinics of the Renal Therapy Services (RTS) Colombia network. KDQOL ™ 36 and the 
diagnostic criteria of restless legs were administered 2 times, at baseline and 6 months later. 
For the analysis, descriptive statistics, ANOVA and Mc Nemar test were used.
Results: 666 patients were evaluated, 61.4% (n =409) were men, the mean age was 
59.8 years (SD = 15.3), 60.3%(402) were more than 3 years old in dialysis. We found 
significant improvements in a large part of the dimensions of quality of life in the time. 
Details are presented in table 1 In addition, we observed significant reduction of the 
diagnosis of restless legs. See table 2.
Conclusions: The expanded hemodialysis positively impacts on quality of life and 
diagnosis of restless legs The results reported by the patients are a valuable intervention that 
can guide health interventions in search of better clinical results.
Funding: Commercial Support - Baxter Healthcare Corporation
Table 1. KDQOL ™ Quality of Life 36
*Anova ** McNemar Test
TH-PO297 Poster Thursday
Dialysis: Cost, Socioeconomics, Quality of Life
Impact of Extended Hours Dialysis on Quality of Life Measured by 
EQ-5D and SF-6D Utility Instruments
Brendan Smyth,1,5 Kirsten Howard,1 Janak R. de Zoysa,2,6 Nicholas A. Gray,3,7 
Alan Cass,4 Martin P. Gallagher,5,8 Vlado Perkovic,5 Meg J. Jardine.5,8 1Sydney 
School of Public Health, University of Sydney, Sydney, NSW, Australia; 
2Waitemata District Health Board, AUCKLAND, New Zealand; 3Sunshine Coast 
University Hospital, Birtinya, QLD, Australia; 4Menzies School of Health 
Research, Darwin, NT, Australia; 5The George Institute for Global Health, 
UNSW, Newtown, NSW, Australia; 6Department of Medicine, University of 
Auckland, Auckland, New Zealand; 7Sunshine Coast Clinical School, University 
of Queensland, Birtinya, QLD, Australia; 8Renal Unit, Concord Repatriation 
General Hospital, Sydney, NSW, Australia.
Background: Health economic evaluations often rely on measurements of health 
utility. Validated health utility assessment tools are available but whether they perform 
similarly is rarely assessed. We aimed to estimate the effect of extended hours dialysis on 
utility-based quality of life (QOL) using two multi-attribute utility instruments.
Methods: The ACTIVE Dialysis trial randomised 200 participants to extended hours 
(≥24 hours/week) or standard hours (≤18 hours/week) haemodialysis for 12 months. Utility-
based QOL was assessed every three months by the EuroQOL-5 Dimensions (EQ-5D) and 
Short Form-6 Dimensions (SF-6D). The mean difference in utility weights between groups 
was obtained by mixed linear regression. Quality adjusted life years (QALYs), a measure 
that combines survival and quality of life, were calculated.
Results: Extended dialysis hours did not improve utility-based QOL measured by 
the EQ-5D (0.036 [95%CI -0.022, 0.093]; p=0.223) but did significantly improve it when 
measured by the SF-6D (0.027 [95%CI 0.003, 0.052]; p=0.026). There was no significant 
difference in mean QALYs gained per patient from extended over standard dialysis as 
measured by the SF-6D (0.015 [95%CI -0.070, 0.041]) or the EQ-5D (0.029 [95%CI 
-0.108, 0.049]) - equivalent to a mean per patient gain of 5.5 (95%CI -25.6, 15.0) and 10.6 
(95%CI -39.4, 17.9) days of perfect health, respectively.
Conclusions: The EQ-5D and SF-6D resulted in distinct interpretations of utility-
based QOL differences in extended hours dialysis, although the significant improvement in 
utility-based QOL found with the SF-6D did not translate into a significant gain in QALYs. 
These results emphasise the need for a better understanding of the impact of different 
scoring algorithms and instrument properties on the performance of multi-attribute utility 
instruments to measure QOL in dialysis patients.
Funding: Commercial Support - Baxter International, Government Support - Non-U.S.
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The Symptom Profile of Hemodialysis Patients in Ontario
Alysha Glazer,2 Marnie Mackinnon,2 Esti Heale,2 Carey Moolji,2 Jane Ip,3 
Yingbo Na,3 Yanqing Xu,4 Peter G. Blake,5 Michael Walsh.1 1McMaster 
University, Hamilton, ON, Canada; 2Ontario Renal Network, Toronto, ON, 
Canada; 3Cancer Care Ontario, Toronto, ON, Canada; 4Bristol-Myers Squibb, 
Lawrenceville, NJ; 5London Health Sciences Centre, London, ON, Canada.
Background: People requiring dialysis reportedly experience a high symptom burden. 
However, there are few large studies assessing symptoms of this patient population over 
time. The Ontario Renal Network (ORN) is pilot testing a standardized provincial approach 
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to symptom screening, assessment, and management using the Edmonton Symptom 
Assessment System Revised: Renal (ESAS-r:Renal).
Methods: Eight Regional Renal Programs in Ontario were selected to participate in a 
one year pilot project. Participating programs routinely assess patients undergoing in-facility 
hemodialysis with ESAS-r:Renal every 4 to 6 weeks. The ESAS-r:Renal questionnaire asks 
patients to self-report the severity of 12 symptoms between 0 (no symptom) and 10 (worst 
possible symptom).
Results: Between April 1 and December 31, 2017, there were 5,839 screening 
attempts by 1,267 patients with 90% of the questionnaires fully completed and 5% partially 
completed. Forty-two percent of patients were female, 48% had diabetes (Type 1 or 2), and 
32% were on dialysis for 5 or more years. Patients frequently reported changes in symptom 
scores over time. Tiredness was the most common symptom reported (76% of all surveys) 
and nausea the least reported (26% of all surveys). Scores of 7 or greater were recorded 
frequently (pain [14%], tiredness [22%], drowsiness [12%], nausea [3%], poor appetite 
[7%], shortness of breath [6%], depression [7%], anxiety [6%], poor wellbeing [11%], 
itching [12%], problems sleeping [17%], and restless legs [13%]).
Conclusions: Patients receiving in-facility dialysis frequently have symptoms. The 
degree to which the symptoms reported through ESAS-r:Renal can be modified and 
improved requires further research.
Funding: Government Support - Non-U.S.
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What Patients and Caregivers Want in a Personalized Mobile Dialysis 
Unit
Larry Kessler,1 Ji-Eun Kim,1 Zach Mccauley,1 Glenda V. Roberts,2 
Linda N. Boyle.1 1University of Washington, Seattle, WA; 2Kidney Research 
Institute at the University of Washington, Seattle, WA.
Background: The Center for Dialysis Innovation (CDI) at the University of Washington 
(UW) is designing an Ambulatory Kidney to Improve Vitality (AKTIV), a personalized 
and ambulatory device that will function as an artificial kidney for ESRD patients. Project 
objectives include developing, testing, and conducting clinical trials demonstrating 
feasibility of AKTIV to improve the current thrice-weekly hemodialysis treatment. Modern 
theory of device/product construction calls for user input during conception and design. As 
we develop the technical aspects of AKTIV, user input is crucial to ensure that engineers and 
clinicians have target parameters for their final output. Our first set of interviews gathered 
data from patients and their caregivers and focused on ways to increase the usability of a 
mobile and self-contained dialysis device.
Methods: At the National Kidney Foundation meeting in Portland in March 2018, we 
interviewed 26 patients and caregivers with a pre-interview survey and semi-structured 
interview about their design and feature preferences for a novel, personalized mobile 
dialysis unit. The 26 participants were between the ages of 24 and 82 years (M = 60.2, SD 
= 13.9), of which 14 were female, and 19 were patients. Content analysis was performed 
on the interviews.
Results: Participants chose the belt type for most preferred and the distributed type 
(parts of the device are separated from each other on the body) for least preferred compared 
to backpack, vest, and shoulder bag types (F (4, 124) = 2.80, p < 0.05). Participants reported 
that the most important features of a wearable dialysis unit were its accuracy and safety, 
compared to ease of use, comfort, compact, and simplicity to operate (F (5, 143) = 13.14, 
p < 0.001). Such preferences varied based on age, gender, and familiarity with wearable 
devices. Based on this input, we will design up to three different prototypes that were ranked 
the most preferred.
Conclusions: The interest and motivation of patients and caregivers to be involved 
in the creation of a personalized and mobile dialysis unit that works essentially as an 
artificial kidney is extremely high. From qualitative analysis and discussions, the dominant 
impression we have is patients want the device to be as unobtrusive as possible. We 
summarize by quoting a patient, “I don’t want to be identified as a dialysis patient when 
I walk into a room.”
Funding: Private Foundation Support
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Patient Satisfaction Score in Relation to Hemodialysis Guidelines and 
Practices: A European Multicenter Analysis
Maciej B. Drozdz,1 Joao M. Frazao,2 Szymon Brzosko,3,4 Fatima F. Silva,5 
Werner Kleophas,6 Abdulkareem Alsuwaida,7,8 Mahesh Krishnan,9 
Stefan H. Jacobson.10 1DaVita Poland, Krakow, Poland; 2Nephrology and 
Infectiology Research and Development Group, INEB, and School of Medicine, 
Porto University, Portugal, Porto, Portugal; 3DaVita Poland, Bialystok, Poland; 
4Department of Nephrology, Medical University of Bialystok, Bialystok, Poland; 
5Davita Portugal, Alfragide, Portugal; 6DaVita Germany, Dusseldorf, Germany; 
7King Saud University, Riyadh, Saudi Arabia; 8DaVita Saudi Arabia, Riyadh, 
Saudi Arabia; 9DaVita, Inc, Denver, CO; 10Danderyd Hospital, Stockholm, 
Sweden.
Background: Understanding patient values and exploring their preferences is critical 
to caring for the dialysis population. Little is known about the factors that influence patient 
satisfaction compared with other measured clinical indices of care. We investigated these 
factors in an international European multicenter descriptive analysis.
Methods: We enrolled 845 HD patients from 13 DaVita centers in Poland (8 centers, 
n=453) and Portugal (5 centers, n=392). An anonymous patient survey was conducted (14 
questions; 5-grade scale: “agree completely” to “disagree”) focusing on patient satisfaction 
with their care at the local facility. Practices, demographic, and laboratory data were 
analyzed for the same month that the survey was performed and correlated to the survey 
results at the facility level.
Results: The survey response rate was 81% (range 72-100%). Mean (SD) age was 
68 (14) years; 53% were male. Mean Charlson comorbidity index was 7.1 (3.0); 76.3% 
used AVF, 16.5% used CVC. Mean (SD) Kt/V was 1.8 (0.4), albumin was 39.5 (4.3) g/L, 
phosphorus was 4.7 (1.3) mg/dL and PTH was 512 (481) pg/mL Mean (SD) patient 
satisfaction score (0-10) was high 9.1 (1.6) and the net promoter score was 71. High scores 
(> 90% agree) were observed for all but one of the 14 questions (“I’m happy with my 
transportation provider”; 85% agree). Spearman correlation analyses at the facility level 
showed that patients involved in decision making had higher Kt/V (p=0.02). Patients who 
agreed that their “chairs and linen were comfortable” had lower phosphorus (p=0.02) and 
higher Kt/V (p<0.001). Patients “happy with their transportation provider” had higher Kt/V 
(p=0.002) and lower phosphorus (p<0.05) and patients who agreed that their “treatment 
started on time” had higher Kt/V (p=0.05). The overall satisfaction score was higher with 
low Kt/V (p=0.004) and high phosphorus (p<0.05).
Conclusions: Patient satisfaction surveys provide a critical perspective on the quality of 
patient-centered healthcare delivery. Information derived from direct evaluation of patient 
experience of care can be used to identify areas for improvement and support changes in 
care provision with the aim of improving the overall quality of care for patients.
Funding: Commercial Support - DaVita, Inc
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Assessing a Modified Edmonton Symptom Assessment System as a Patient 
Report Outcome Measure for Patients on Dialysis in Canada
Juliana Wu,1 Michael Terner,1 Michael Manno,1 Helen Chiu,2 Ognjenka Djurdjev,2 
Adeera Levin.3 1Canadian Institute for Health Information, Toronto, ON, 
Canada; 2BC Renal Agency, Vancouver, BC, Canada; 3St. Paul’s Hospital and 
University of British Columbia, Vancouver, BC, Canada.
Background: Patients with end-stage renal disease (ESRD) often experience heavy 
symptom burden that is under-recognized in the absence of routine and systematic 
assessment and management, resulting in poor quality of life. In Canada, British Columbia 
has implemented a modified Edmonton Symptom Assessment System (mESAS) to monitor 
symptom burden in patients with ESRD. Completion of the mESAS was voluntary. 
Implementation started in 2010 and was staggered across facilities. We investigated 
whether the mESAS functions as a patient-reported outcome measure (PROM) for patients 
on dialysis, specifically whether the mESAS is feasible to use in routine assessment and is 
responsive to changes in patient symptoms over time.
Methods: The dataset comprised 3,573 patients from 7 dialysis facilities in British 
Columbia, 62% of whom had completed at least 1 assessment. Of these, 77% completed 
more than one assessment that can be used for longitudinal analysis. The dataset included 
assessments performed between March 2010 and April 2016. We used descriptive statistics 
to examine mESAS practice and changes in symptom scores over time.
Results: Of the patients with more than 1 mESAS assessment, the majority (69%) of 
adjacent assessments were completed within a 3 ± 1.5 month timeframe, and an additional 
16% were completed within a 6 ± 1.5 month timeframe. For symptoms that were scored 
within the severe category (between 7 and 10 on the scale), the majority improved to below 
the severe category in a subsequent assessment. Across years, the proportion of symptom 
scores in the severe category demonstrated a change to lower scores using the mESAS. The 
results for improved symptoms scores across centres and years varied between 68 and 93%.
Conclusions: There was sufficient data available for analysis of mESAS scores and 
changes in scores over time. Serial collection of this data allows a real time opportunity to 
assess symptom burden at a specific point in time as well as the responsiveness of mESAS 
over time. There is also important value in collecting PROMs in renal patients to further 
explore how PROMs can be used to evaluate symptom management strategies and thereby 
optimize patient quality of life.
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A Multicenter Survey in Toronto of Opinions on Driving Safety in 
Hemodialysis Patients
Bourne L. Auguste,1 Lauren A. Glick,1 Christopher T. Chan,3 
Karthik K. Tennankore,2 Darren A. Yuen.1 1University of Toronto, Toronto, ON, 
Canada; 2Dalhousie University/NS Health Authority, Halifax, NS, Canada; 
3Toronto General Hospital, Toronto, ON, Canada.
Background: Hemodialysis patients are at an increased risk of adverse health events 
from operating a motor vehicle and may have their license withdrawn due to safety 
concerns. However, little is known about the perspectives of nephrology health care 
practitioners towards driving safety for hemodialysis patients and their awareness of best 
practice. The purpose of this study was to survey health care practitioners to identify their 
opinions towards driving practice and safety for hemodialysis patients.
Methods: We developed a 16-item questionnaire about driving safety using a Delphi 
model with input from 4 nephrologists, 2 nurse practitioners, 2 social workers and 1 
nephrology fellow. The questionnaire was distributed amongst the 3 academic hemodialysis 
centers affiliated with the University of Toronto in Toronto, Canada. All voluntary 
participants were healthcare professionals caring for dialysis patients. Questionnaires were 
emailed to participants and their responses were completed on a secure website link.
Results: The survey was distributed to 154 persons with a response rate of 39%. 
52% (31) of responders were hemodialysis nurses, 15% (9) were nephrologists and 
other responders included fellows and other allied healthcare professionals. 60% (36) of 
responders had greater than 10-years of experience. 88.3% of responders knew of at least 
one patient who drove regularly. 80% of responders never reported a patient to the provincial 
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driving authority despite safety concerns. Responses were unchanged despite participants 
being presented with 3 clinical hypothetical scenarios of unstable patients that drove to 
hemodialysis sessions. This suggests that participiants did not recognize the safety concerns 
in hypothetical situations where reporting should have occurred. Participants likely did not 
report patients due to the lack of clear guidelines along with no current mandated reporting 
requirements. This was further supported by 97% of all responders agreeing that more 
robust driving guidelines are warranted.
Conclusions: Our preliminary results underscore the lack of clarity, consistency and 
knowledge with regards to driving safety in hemodialysis patients. Larger national scale 
surveys will further support the prevalent opinion in Toronto that more comprehensive 
driving guidelines for hemodialysis patients are warranted.
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Employment 6 Months Prior to and at Dialysis Start: Validation Evidence 
for CMS-2728 Data
Nancy G. Kutner,1 Rebecca H. Zhang.2 1Emory University School of Medicine, 
Atlanta, GA; 2Emory University, Atlanta, GA.
Background: The CMS-2728 is a unique source of patient employment status 
6 months prior and at dialysis start. A USRDS analysis of patients 18-54 initiating in-center 
hemodialysis (HD) or home dialysis 1996-2013 showed a persistent pattern of job loss in 
the 6-month pre-dialysis interval (CJASN 2018). The CMS-2728 employment field has not 
been independently validated, however. We compared incident patients’ interview responses 
obtained approximately 2 months after dialysis start with corresponding employment 
information from their CMS-2728 report.
Methods: Patients who began in-center HD or home dialysis July 1996-August 
1997, English- or Spanish-speaking and without documented cognitive impairment, were 
recruited for a study of health behaviors/quality of life from 26 dialysis clinics serving 
the Atlanta GA 23-county area. Participants represented eligible patients in age, race and 
functional status but the cohort included fewer women. Structured in-person interviews 
were conducted at a non-dialysis facility location convenient for the patient 67.3 ± 19.5 
days after dialysis start. 95/226 study participants were ages 20-54 (median 43) with women 
47%; blacks 58%; non-Hispanic whites 35%; and Hispanic, Asian, other 7%. CMS-2728 
employment status options include: unemployed, employed full time (FT), employed 
part time (PT), homemaker, retired (age/preference), retired (disability), medical leave of 
absence, and student. The patient interview asked: Are you working now (hours/week)? job 
being held? retired or stopped working; when? keeping house? student (FT, PT)? Using 
FT, PT, or student to define employment (CJASN 2018), we identified the unadjusted 
proportion of patients employed 6 months prior and at dialysis start, reported by the CMS-
2728 and by patients.
Results: Compared with their CMS-2728 data, 8% more patients reported being 
employed 6 months prior, while 6% fewer patients reported current employment. Potential 
job maintenance opportunities were suggested by patients who reported having switched 
from FT to PT work, said their prior job was “being held,” cited a medical leave of absence, 
or reported being “let go” from their job (in all, 14% of the cohort).
Conclusions: Our study suggests that CMS-2728 employment fields have good 
validity. Effective interventions are needed to help patients remain in the workforce as they 
transition to dialysis.
Funding: NIDDK Support
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Reducing Polypharmacy in Dialysis Patients
Travis R. Jameson,1 Julia Schneider,2 Holly J. Kramer.2 1Nephrology, Loyola 
University Medical Center, MAYWOOD, IL; 2Loyola University Medical Center, 
Maywood, IL.
Background: Polypharmacy is a freqent problem for patients receiving maintenance 
dialysis and may increase risk of adverse events and drug interactions. Previous studies have 
identified 4 drug classes (proton pump inhibitors [PPI], alpha 1 blockers [A1B], diuretics, 
and statins) in which use may not be necessary in patients receiving maintenance dialysis. 
This study examined overall medication use and use of 4 non-essential drug classes. 
Methods: This study was comprised of 168 patients receiving maintenance dialysis at a 
single dialysis unit. The mean age was 60.4 (SD 15.8) and median dialysis vintage was 2.4 
years with a range of 0.2 to 13.9 years. Overall 49.1% were male. Diabetes mellitus (49.1%) 
and hypertention (18.0%) were the two main causes of end stage renal disease. The average 
number of prescribed medications was 11 (SD 5) and ranged from 2-26 medications but was 
higher among women (11[SD 4]) than among men (10[SD 5]).
Results: Of the 4 non-essential drugs, 51.5% were taking at least one of these drugs, 
36.9% were taking at least 2, and 11.5% were taking at least three non-essential medications. 
Statin use was most common at 56.3% overall and among patients age 70+ years, 75% were 
using statins. PPI and diuretic use wee noted in 32.5% and 31.7% respectively. A1B use was 
noted in 8.5% of men with a dialysis vintage of 2.4 years. If the 4 non-essential drugs were 
eliminated, the average number of medications would decrease to 9 (SD 4) overall, to 9 (SD 
5) among men and to 10 (SD 4) for women.
Conclusions: In conclusion, use of non-essential medications is common among
patients receiving maintenance dialysis. Elimination of non-essential medications would 
lead to a reduction of about 1 medication on average. Targeted de-prescribing may help 
reduce polypharmacy in this patient population.
TH-PO305 Poster Thursday
Dialysis: Cost, Socioeconomics, Quality of Life
Long-Term Follow-Up of Respiratory Function in Maintenance Hemodi-
alysis Patients Following an In - Center Exercise Program for 24 Months
Andreas Bozikas,1 Maroula Papacharalambous,5 Pinelopi Pisanidou,1 
Styliani Vakiani,1 Antigoni Martika,1 Iliana Kiriakoutzik,1 Eleni Kitoukidi,1 
Ioannis Akrivopoulos,3 Soultana Falakidou,2 Stergios Papastergiou,4 
Sofia Spaia.2 1Nephrology, General Hospital of Thessaloniki “Agios Pavlos”, 
Thessaloniki, Greece; 2Hemodialysis Unit, General Hospital of Thessaloniki 
“Agios Pavlos”, Thessaloniki, Greece; 3Physicotherapy, General Hospital of 
Thessaloniki “Agios Pavlos”, Thessaloniki, Greece; 4Orthopedic, General 
Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece; 5Pneumonologist, 
General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece.
Background: In spite the well documented benefit of physical exercise on hemodialysis 
patients (HD) only few reports concern the long-term effect on respiratory function. We 
designed this study to investigate the effects of continuous moderate-intensity programme 
applied during hemodialysis sessions by a physiotherapist, on parameters in spirometry.
Methods: We enrolled 60 maintenance HD patients in this study. 44 stable HD patients 
participated in a 20 – 30 minute exercise program of moderate intensity targeting muscle 
strengthening and elasticity, articular flexibility in every session for 24 months. 16 HD 
patients who did not participated served as controls. Spirometry: Forced Vital Capacity 
(FVC), FVC %, Forced Expiratory Volume in One second (FEV1), FEV1 % and Forced 
Expiratory Flow over middle half of the FVC – that is, average flow from 25 % of the FVC 
to 75 % of the FVC during forced expiration (FEF 25 – 75 %) was performed at 0, 12 and 
24 months along with biochemical tests: Hct, CRP, Chol, TG, LDL, HDL, TP, Alb, HbA1C 
and dialysis adequacy (Urr, Kt/V).
Results: Overwhelming acceptance of the program resulted in continuous and constant 
participation. 7 patients (12 %) were found with undiagnosed COPD in the beginning of the 
study. Respiratory indices were comparable either the test was performed before or after the 
HD session. FEV1/FVC index was improved at 12 months and remained improved at 24 
months only in the exercising group (76.6 ± 10 v s79.6 ± 8 vs 81.5 ± 7, p<0.05).
Conclusions: Adaptation of a thrice weekly exercise program under physiotherapist 
guidance resulted in the enthusiastic participation of patients and it is one of the longest 
that have been reported. Patients following the long term exercise improved FEV1/FVC 
over the follow-up period. Evaluation of respiratory function should be performed in all 
patients starting dialysis since it reveals latent morbidity. In spite the reports of deterioration 
of pulmonary function in the long term of maintenance HD the latter remained stable in the 
control group.
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Aerobic versus Anaerobic Exercise and Oral Nutritional  
Supplementation Related to Nutritional Status and Physical  
Function of Adult Haemodialysis Patients: AVANTE Study
Geovana Martin-Alemañy,1 L. M. Perez-Navarro,1 Angeles Espinosa-Cuevas,2 
Rafael Valdez-Ortiz.3 1Hospital General de México, Dr. Eduardo Liceaga, 
Mexico, City, Mexico; 2National Medical Science and Nutrition Institute, 
Mexico, Mexico; 3Hospital General de Mexico, Mexico City, Mexico.
Background: Protein energy wasting affects the nutritional status (NS) and physical 
function (PF) of dialysis patients. Oral nutritional supplementation (ONS) and resistance 
exercise (RE) or aerobic exercise (AE), have been shown to be effective for NS and PF. 
Nevertheless, the combination of RE and AE with ONS has not been completely elucidated. 
The aim of this study was to assess the effect of a 12-week intradialytic RE or AE program 
combined with ONS versus ONS without exercise on PF and NS indicators.
Methods: Patients were divided in to three groups: 1) ONS, 2) ONS + RE and 3) ONS 
+ AE. Anthropometrics [body mass index (BMI), body weight (BW), midarm circunference 
(MAC), arm muscle circumference (AMC) and arm muscle area (AMA)], PF tests [sit to 
stand, time up and go and six minute walk tests (6 MWT)] and quality of life (QOL) by 
KDQOL-SF36 were recorded.
Results: All groups had statistical significant increases in BW, BMI, MAC, AMC 
and AMA (p<0.05). All patients significantly improved the three different PF tests and 
muscle strength; however, groups with AE and RE increased 43 and 42 metres respectively 
the distance walked in six minutes; while the ONS group increased 11 metres (p<0.05). 
Regarding QOL, the group with ONS + RE shown to have more areas of improvement at 
the end of the study (sleep, general health and social function, p<0.05), followed by the 
group with ONS + AE (emotional role, p<0.05).
Conclusions: The effect of RE or AE combined with ONS versus ONS without 
exercise improves the PF and NS; however, PF measured with the 6 MWT and QOL 
was better at the end of the study in both groups with exercise. No statistical significant 
differences were observed between groups at the end of the study. All interventions have a 
positive effects on NS and PF.
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Dialysis Therapy and Gait Speed: A Repeated Measures Analysis of US 
Patients on Chronic Dialysis
Christopher A. Carlos,1 Barbara A. Grimes,3 Kirsten L. Johansen.2 1University of 
California, San Francisco, San Francisco, CA; 2University of California, San 
Franicsco, San Francisco, CA; 3UCSF, San Francisco, CA.
Background: Slow gait speed, a patient-centered yet understudied clinical outcome, 
is a common and independent predictor of future disability, hospitalizations and death 
among patients with chronic kidney disease. Prior studies have shown that improper fluid 
management is a likely contributor to physical impairment, but lack of data on the relative 
importance of the many fluid-related components of dialysis therapy (e.g. baseline fluid 
overload, blood pressure, and ultrafiltration rate) has limited consensus and evidence-based 
guideline development. Analyses are needed to understand which managed aspects of 
dialysis therapy are most associated with functional status declines.
Methods: We measured gait speed at baseline, 12 months, and 24 months, among 652 
patients on hemodialysis recruited in the ACTIVE/ADIPOSE cohort study. We used linear 
mixed effects modeling to examine associations between demographic, comorbid, social, 
and laboratory data with gait speed trajectory. We then added degree of bioimpedance-
measured predialysis volume overload (defined as a fluid state >= 15% relative to 
extracellular water volume in men and >=13% in women), dialysis treatment time, 
ultrafiltration rate, and predialysis systolic blood pressure to ascertain whether treatment-
related factors were associated with gait speed or its change over time.
Results: Mean gait speed at baseline was 0.94 m/s and declined an average of 0.08 m/s 
per year. In adjusted analysis, nonwhite race (-0.14 m/s, 95% CI -0.19 to -0.08), female sex 
(-0.10 m/s, 95% CI -0.13 to -0.06), and BMI > 35 kg/m2 (-0.09 m/s, 95% CI -0.15 to -0.03) 
were associated with slower gait speeds. Predialysis volume overload was associated with 
slower gait speed (-0.06 m/s, 95% CI -0.11 to -0.01), but was not a statistically meaningful 
predictor of future gait speed trajectory. Dialysis treatment time, ultrafiltration rate, and 
predialysis systolic blood pressure were not independently associated with gait speed.
Conclusions: Certain factors place patients on dialysis at increased risk of slowed gait 
speed, including a state of predialysis volume overload. Interventions that focus on limiting 
states of volume overload, compared to other managed aspects of the dialysis treatment, 
may be more meaningful in limiting gait speed impairment.
Funding: NIDDK Support
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Intradialytic Activities and Health-Related Quality of Life
Fatima M. Warsame,1 Hao Ying,2 Christine E. Haugen,3 Alvin G. Thomas,4 
Deidra C. Crews,5 Tariq Shafi,5 Bernard G. Jaar,6 Dorry L. Segev,1 
Mara McAdams-DeMarco.7 1Johns Hopkins University, Baltimore, MD; 2Johns 
Hopkins School of Medicine, Baltimore, MD; 3Surgery, Johns Hopkins Hospital, 
Baltimore, MD; 4UNC Chapel HIll, Chapel Hill, NC; 5Johns Hopkins University 
School of Medicine, Baltimore, MD; 6Johns Hopkins University and Nephrology 
Center of Maryland, Baltimore, MD; 7Johns Hopkins, Baltimore, MD.
Background: Given the time burden and physiologic effects of hemodialysis, 
patients who spend dialysis time physically or intellectually engaged may have better 
health-related quality of life (HRQOL). We sought to characterize the association between 
intradialytic activities and HRQOL and explore patients’ interest in performing intradialytic 
interventions.
Methods: In a prospective cohort study of 431 prevalent hemodialysis patients, an 
activity score was assigned on a scale of 0-5 points for each active intradialytic task (read, 
electronic games, puzzles, chat, other-physical/cognitive). We quantified the association 
between KDQOL components and activity using adjusted linear regression.
Results: The two most common intradialytic activities reported by patients were 
passive [watching TV (87.9%) and sleeping (72.4%)]. Patients who were female 
(aOR=1.85, 95%CI:1.28, 2.66; p=0.001), nonfrail (aOR=1.70, 95%CI:1.06-2.70; p=0.03), 
and nonsmokers (aOR=2.61, 95%CI:1.39, 4.90; p=0.003) had a higher intradialytic activity. 
Additionally, higher intradialytic activity was associated with better mental HRQOL (+0.83 
points, 95%CI: +0.04, +1.62; p=0.04) and kidney disease-specific HRQOL (+1.70 points, 
95%CI: +0.47, +2.93; p=0.007), but not physical HRQOL. Each one-point increase in the 
activity index was associated with a 1.29-fold and 1.25-fold increased odds of interest in 
intradialytic cognitive training and physical exercise.
Conclusions: Hemodialysis patients with more active intradialytic activities report 
better mental and kidney disease-specific HRQOL and increased interest in participating 
in intradialytic interventions. Dialysis providers may consider offering patients with low 
levels of activity additional support and opportunities to engage in beneficial intradialytic 
activities.
Funding: NIDDK Support, Other NIH Support - National Institute on Aging, Private 
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The Association Between Handgrip Strength (HGS) and Predialysis 
Sodium (sNa) in Patients with CKD Stage 5D
Periklis P. Kyriazis,1 Anastasia Markaki,2 Eleftheria-Kleio Dermitzaki,3 
Dimitra Lygerou,3 Aspasia Spyridaki,2 Emmanouil Psylinakis,2 
Panagiotis T. Kanellos,2 Argyro Gioume,2 Konstantina Kyriakidi,2 
Nikolaos Kalemikiarakis.2 1Internal Medicine, Baystate Medical Center/
University of Massachussetts, Springfield, MA; 2Nutrition & Dietetics, 
Technological Educational Institute of Crete, Siteia, Greece; 3Nephrology, 
University Hospital of Heraklion, Heraklion, Greece.
Background: HGS is a useful tool for continuous and systematic assessment of muscle 
function related to nutritional status. Reduced HGS has been associated with adverse 
clinical outcomes in patients with stage 5D CKD. In the same patients, low sNa has been 
associated with malnutrition and mortality. Here, we investigated the role of sNa on muscle 
mass and function in stage 5D CKD patients.
Methods: We evaluated 73 CKD stage 5D (45 on hemodialysis and 28 on peritoneal 
dialysis) patients (43 men and 30 women) with HGS, bioimpedance analysis (BIA), 
anthropometric measurements and malnutrition inflammation score (MIS). According to 
the diagnostic criteria for sarcopenia established by EWGSOP, patients were diagnosed 
with reduced HGS, if HGS was below 30 Kg and 20 Kg in men and women, respectively. 
Predialysis sNa values were defined as the mean of all predialysis measurements available 
during the preceding 6 months.
Results: Patients with reduced (n=28) as compared to the those with normal HGS 
(n=45) were older in age (p=0.006), had lower skeletal muscle index (SMI) (p=0.004), 
mid-arm muscle circumference (MAMC) (p=0.043), sNa (137±2.3 vs. 139.5 ± 2.2 mmol/L; 
p=0.004), serum albumin (sAlb) (p=0.029) and higher MIS (5.13±2.62 vs. 3.82±2.34; 
p=0.034). In multivariate logistic analysis, after controlling for age, SMI, MAMC, sAlb 
and MIS, each increase in sNa by 1 mmol/l was associated with 28 % (OR= 0.72, 95% CI: 
0.55-0.94; p <0.05) lower odds of having reduced HGS. sNa was positively associated with 
HGS (r=0.384; p<0.001) and SMI (r=0.295; p<0.05). In a forward stepwise multivariate 
(sex, SMI, MAMC, sALB, MIS) model (R2= 0.499; p<0.001), sNa, along with SMI and 
sex, emerged as a strong independent predictor of HGS (B=0.791; p<0.05) explaining about 
3 % of its variance.
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Conclusions: Our results show that a) sNa is strongly associated with both muscle 
mass and muscle function, b) sNa impacts on muscle strength independently of muscle 
mass, nutritional status and inflammatory state and c) irrespective of the mechanism(s) 
underlying the HGS-sNa association, optimizing predialysis sNa may improve HGS and 
thus clinical outcomes in 5D CKD patients.
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Utility of Regular Management of Physical Activity and Physical Function 
in Hemodialysis Patients
Shohei Yamamoto,1 Ryota Matsuzawa,2 Yoshifumi Abe,1 Manae Harada,1,3 
Takaaki Watanabe,1,3 Yuta Suzuki,1 Kentaro Kamiya,1 Atsushi Yoshida,3 
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Japan; 3Sagami Circulatory Organ Clinic, Sagamihara, Japan.
Background: Several clinical practice guidelines recommend regular assessment of 
physical activity and physical function as part of routine care in hemodialysis patients. 
However, there is no clear evidence to support these recommendations. We investigated 
whether the proportion of attendance at a regular program for management of physical 
activity and physical function can predict all-cause mortality and cardiovascular events in 
hemodialysis patients.
Methods: This retrospective cohort study consisted of 266 hemodialysis patients 
participating in the management program at least once. Participants were tracked for 3 
years after their first attendance at the management program to determine their attendance 
proportion. The main study outcomes included all-cause mortality and a composite of fatal 
and nonfatal cardiovascular events.
Results: Median patient age was 64.5 (interquartile range, 56.8–72.0) years, 45% were 
women, and the median time on hemodialysis was 35.5 (interquartile range, 12.0–114.3) 
months at baseline. Sixty-five patients died over a median follow-up of 79 months (Figure 
1A). The incidence of cardiovascular events was 60 over a median follow-up of 68 months 
(Figure 1B). Even after adjusting for any of the prognostic models, participants who 
attended %75% of sessions (n=140) had higher risks of mortality (hazard ratio (HR), 1.79 ; 
95% confidence interval (CI) : 1.00–3.36 ; P = 0.049) and cardiovascular events (HR, 1.84 ; 
95% CI : 1.07–3.48 ; P=0.03) than those attending >75% of sessions (n=126).
Conclusions: Hemodialysis patients in whom physical activity and physical function 
could be assessed more regularly had better prognosis than those with only intermittent 
assessment.
Figure 1. Kaplan–Meier analysis of survival (A) and cardiovascular events (B) in 266 
patients undergoing hemodialysis. The High attendance group (attended >75% of all 
available sessions in the management program) had significantly better survival and lower 
incidence of cardiovascular disease than the Low attendance group (≤75% attendance).
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A Retrospective Study on the Decline of Muscle Mass in Maintenance 
Hemodialysis Patients in China
Yiqi Song,1 Qian Zhang,1 Li Ni,2 Jing Chen.3 1Division of Nephrology, National 
Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan 
University, Shanghai, China; 2huashan hospital,Fudan University, Shanghai, 
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Background: Sarcopenia is characterized by age-related decline of skeletal muscle 
plus low muscle strength and/or physical performance. Studys have demonstrated that 
sarcopenia was associated with adverse health outcomes, such as disability, hospital 
admission, poorer quality of life and mortality. A high prevalence of sarcopenia is 
also observed in maintenance hemodialysis (MHD) patients, which need for further 
investigation. Hence, this study aimed to analyze the risk factors that affect the speed of 
muscle mass decline in MHD patients.
Methods: The retrospective study was performed in hemodialysis center of Huashan 
hospital, Fudan university in Shanghai, China. MHD patients suffered muscle mass loss in 
the past three years were eligible to participate in this study. Patients were divided into low 
speed group and high speed group according to the speed of muscle mass decline. Univariate 
linear regression analysis was conducted to assess the associations between muscle mass 
decline speed and the variables. These variables included age, gender, dialysis vintage, body 
mass index, normalized protein catabolic rate, serum levels of albumin, hsCRP, 25(OH)D, 
CO2-CP. Variables with P≤0.20 were included in the multivariate logistic analysis.
Results: A total of 47 MHD patients were included in this study, of which 23 were 
male and 24 were female. Mean patient age was 59.30±12.49 years. The mean dialysis 
duration was 7.24±4.88 years. The low speed group showed shorter dialysis vintage, higher 
level of serum 25(OH)D and lower Log NT-proBNP, compared with the high speed gruop. 
There were no significant differences in albumin, prealbumin, cholesterol, nPCR, CO2-CP, 
hsCRP, BMI, deltoid skin fold thickness, grip strength and daily steps. Multivariate linear 
regression analysis showed that dialysis vintage (β=0.309, P=0.017), 25 (OH) D(β=-0.370, 
P=0.004), Log NT-proBNP (β=0.339,P=0.011) were risk factors associated with muscle 
mass decline speed in MHD patients.
Conclusions: Risk factors associated with the muscle mass decline speed in 
maintenance hemodialysis patients include dialysis vintage, 25 (OH)D, and log NT-
proBNP. Higher levels of 25 (OH) D contributes to the maintenance of muscle mass.
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Background: End-stage renal disease (ESRD) patients on maintenance hemodialysis 
(HD) endure debilitating fatigue. Kidney function is essential for the synthesis, balance, 
and interorgan exchange of several amino acids (AA) notably aromatic amino acids (AAA) 
such as phenylalanine, tyrosine, and tryptophan and branched-chain amino acids (BCAA): 
leucine, isoleucine and valine. Dysregulation of these AA has been implicated in the genesis 
of fatigue as they may affect neurotransmitters. The relationship of AA with fatigue in HD 
patients is not known.
Methods: In a cross-sectional study, we examined the relationship between AA and 
fatigue in a well-characterized cohort of HD patients with T2 diabetes (N=119). The 
mean±SD age was 54.77±12.76 yr and 48% were female. Mean serum albumin was 
3.46±0.38 g/dl, Hgb 11.04±1.43 mg/dl, and HgbA1c 6.93±1.86%. Fatigue on HD day was 
assessed by the 9-item Brief Fatigue Inventory (BFI) which measures fatigue severity and 
fatigue impact on daily functioning. BFI has internal consistency coefficient 0.96 and scores 
range from 0 to 90, lower score = less fatigue. BFI item #3 (Please rate your fatigue that 
best describes your WORST level of fatigue) was chosen to represent fatigue severity for 
conceptual simplicity. Free AA in pre- and post-HD plasma were quantified using HPLC-
mass spectrometry.
Results: BCAA and AAA levels decreased significantly post HD (p<0.0001 and 0.0009, 
respectively). Post-HD AA, except for tyrosine, correlated with BFI item #3 and global 
fatigue scores (mean of all BFI 9 items). On Pearson correlation, post-HD BCAA and AAA 
levels correlated negatively with worst fatigue (r=−0.24, p=0.015 and r=−0.26, p=0.009, 
respectively) and global fatigue (r=−0.26, p=0.008 and r=−0.26, p=0.01, respectively). 
These correlations remained significant after adjustments for HD duration, dialysis shift, 
and intradialytic changes in body weight and blood pressure. Fatigue intensity, categorized 
into mild (1-3), moderate (4-6), and severe (≥7) based on BFI item #3 score, inversely 
related to post-HD AA levels: BCAA (p for trend 0.028) and AAA (p for trend 0.008).
Conclusions: HD procedure depletes BCAA and AAA. Post-HD levels of both BCAA 
and AAA correlate with fatigue on HD day in ESRD patients. Depleted AA may contribute 
to impaired neurotransmitters synthesis.
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Preliminary Analysis of the Effect of Blood Flow Rate Reduction on 
Post-Dialysis Fatigue
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Background: Post-dialysis fatigue is a common complaint among patients undergoing 
maintenance hemodialysis (HD). It is not known whether hemodialysis blood flow rate (Qb) 
affects post-dialysis fatigue. We aimed to determine if a reduction in Qb affected the time 
to recover from HD treatments in patients with significant baseline post-dialysis fatigue.
Methods: We conducted a randomized, controlled trial of patients undergoing 
maintenance HD ≥3x/week who reported post-dialysis fatigue ≥6 hours at baseline. 
Preliminary data included 94 subjects randomized to Qb reduction of up to 100 mL/min 
(minimum Qb 300 mL/min; intervention group, 47 subjects) or to usual care (control 
group, 47 subjects). Patients with borderline dialysis adequacy were excluded. Subjects 
were surveyed weekly for 4 weeks regarding their dialysis recovery time (DRT) using the 
validated question “How long did it take you to recover from dialysis?” Primary outcome 
was change in DRT.
Results: Mean age was 65.1±12.7 years, 62.8% were men, median vintage was 3.73 
years (IQR 2.0–6.7), and 68.1% of subjects had diabetes. Baseline characteristics in post-
randomization groups were fairly balanced. Prescribed Qb was reduced from 398±39.8 mL/min 
to 314±23.1 mL/min in the intervention arm. Prescribed Qb was 389±41.6 mL/min in 
controls. During the intervention period, median DRTs decreased in both groups (Figure 1). 
Repeated measures analysis performed on the difference from each time point to baseline 
did not show a significant difference between intervention and control arms [F(1,67) = 0.74, 
p = 0.39].
Conclusions: In maintenance hemodialysis patients with a baseline post-dialysis 
recovery time of 6 or more hours, we did not observe an effect of Qb reduction of up to 100 
mL/min on post-dialysis recovery time.
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Association of Psychosocial Factors with Adherence to Treatment Among 
Prevalent Dialysis Patients
Joshua B. Ang,1 Janice P. Lea,4 Olufunmilola Adisa,3 Abyalew Sahlie,1 
Catherine I. Obadina,2 Laura Plantinga.1 1Emory University, Atlanta, GA; 
2Emory University School of Medicine, Marietta, GA; 3Emory School of 
Medicine, Buford, GA; 4Emory University, Atlanta, GA.
Background: Dialysis patients are expected to adhere to dialysis treatments, 
medications, and dietary and fluid restrictions; these may be complicated by patient 
psychosocial issues. The aim of this study was to examine the relationship between social 
worker-assessed psychosocial factors and patients’ perceived ease of adherence to treatment 
among prevalent dialysis patients.
Methods: Data were extracted from the initial comprehensive assessment performed 
by social workers for patients starting dialysis treatment at three outpatient Emory Dialysis 
centers. Exposures were social worker-assessed psychosocial factors, primarily depression/
anxiety. Outcome was patient-perceived ease of adherence across five categories: ability to 
come to dialysis, complete dialysis, take medications, follow dietary restrictions, and follow 
fluid restrictions. Responses were dichotomized as “easy” vs. “not easy.” Statistical analysis 
was performed using ANOVA, t test, and Pearson’s chi-square.
Results: Of 1334 patients, 205 (15.4%) were reported to have depression/anxiety. 
Compared to those without depression/anxiety, patients with depression/anxiety were 
significantly less likely to find adherence across all categories to be easy vs. not easy (Table; 
P<0.001 for all). Daily vs. less frequent social support was associated with greater perceived 
ease of adherence to coming to (75.5% vs. 65.2%, P=0.001) and completing (75.6% vs. 
64.3%, P<0.001) dialysis. Memory impairment vs. none was associated with lower ease 
of adherence in the same categories (66.2% vs. 74.4%, P=0.03; 64.7% vs. 74.7%, P=0.01). 
History of substance abuse, marital status, living alone, employment, community-dwelling 
status, and ambulatory assistance were not associated with ease of adherence.
Conclusions: Our results suggest that patients who have depression/anxiety, infrequent 
social support, or memory impairment are more likely to perceive adherence to various 
aspects of dialysis treatment as difficult. Further investigation of perceived and actual 
adherence by these psychosocial factors, which could inform targeted interventions to 
improve adherence, is warranted.
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The Psychological Burden Associated with Functional Dependency in 
Hemodialysis Patients
Gabriel B. Gutierrez Peredo, Marcelo Lopes, Gildete B. Lopes, Antonio A. Lopes. 
UNIVERSIDADE FEDERAL DA BAHIA, Salvador, Brazil.
Background: Functional dependency is highly prevalent in maintenance hemodialysis 
(MHD) patients. We investigated associations between functional dependency and the 
psychological burden reported by MHD patients
Methods: Cross section of 235 MHD patients treated in Salvador, Brazil. Responses 
to Katz’s and Lawton-Brody’s functional status questionnaires were used to create 3 
groups: highly dependent (n=44), mild dependent (n=109) and independent (n=82). Using 
KDQOL-SF patients were asked how true was the 4 questions of the kidney disease burden 
(KDB) scale: 1) disease interferes too much with life, 2) too much time dealing with the 
disease, 3) feel frustrated with the disease, 4) feel like a burden on my family. Responses 
varied from definitely true to false; definitive/mostly true defined higher burden. The KDB 
score (range from 0 to 100) was determined based on patient’s responses; higher scores 
indicate lower burden. Regression models adjusted for age and comorbidities were used to 
estimate associations of functional status with KDB scores.
Results: Mean age was 51.2±12.4 yr and significantly higher in highly dependent 
patients (P<0.001). The Table shows score differences and the Figure shows the trend in % 
of responses for each KDB question, by functional status.
Conclusions: The results indicate that functional dependency represents a strong 
psychological burden for MHD patients.
Funding: Government Support - Non-U.S.
MEANS AND ADJUSTED DIFFERENCES OF THE KIDNEY DISEASE BURDEN 
SCORE
KDB = kidney disease burden
Percentages of True or Definitely True Responses for each Item of the Kidney Disease 
Burden Scale, by Functional Status
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Deep Cerebral Microbleeds Associate with Cognitive Impairment in 
Dialysis Patients: A Cross-sectional Observational Study
Qian Yujun,1 Ke Zheng,2 Xuemei Li.2 1Peking Union Medical College Hospital, 
Chinese Academy of Medical Sciences, Beijing, China, Beijing, China; 2Peking 
Union Medical College Hospital, Beijing, China.
Background: Cerebral microbleeds (CMBs) are common in dialysis patients, and 
different location of CMBs resulted from different pathologies. The relationship between 
CMBs and cognitive impairment (CI) in dialysis patients was controversial. This study 
aimed to explore whether the distribution of CMBs affects cognitive function in dialysis 
patients.
Methods: In this cross-sectional study, we enrolled a total of 189 dialysis patients. 
Patients were divided into 4 groups: without-MBs group, strictly lobar group, strictly deep 
group, and mixed group. A wide range of cognitive tests were administered to evaluate 
cognitive function.
Results: In our study, the prevalence of CMBs was 32.8%, 35.2% in HD patients and 
29.7% in PD patients. 17 subjects (9.0%) classified as lobar group, 14 subjects (7.4%) 
as mixed group, and 31 subjects (16.4%) as deep group. Mean arterial pressure (MAP) 
was significantly associated with the lobar group and deep group. Dialysis vintage was 
associated with deep group only. Self-reported stroke history and current antiplatelet 
medication had relevance to the lobar group. There was a significant association between 
deep CMBs and impaired cognitive function, involving overall cognitive function, memory, 
language ability and executive function.
Conclusions: Deep CMBs are closely associated with global and specific cognitive 
impairment in dialysis patients.
Funding: Government Support - Non-U.S.
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Memory Deficit in Hemodialysis Patients: Clinical Characteristics and 
Cerebral Imaging Findings
Wenjin Liu,1 Lulu Wang,1 Junwei Yang.2 1Nanjing Medical University, Nanjing, 
China; 2Center for Kidney Disease, Second Affiliated Hospital of Nanjing 
Medical University, Nanjing, China.
Background: The current study aimed to investigate the characteristics of memory 
deficit in dialysis patients, as well as using magnetic resonance imaging (MRI) to explore 
associated cerebral structural and functional changes.
Methods: Sixty patients on maintenance hemodialysis and 60 healthy controls were 
included. Patients and controls were frequency-matched by age, sex and education. All 
subjects underwent evaluation of global cognition (The Montreal Cognitive Assessment, 
MoCA) and episodic memory (Auditory Verbal Learning Test, AVLT). Brain structure and 
function were evaluated using MRI with 3DT1 and BOLD (blood-oxygen-level dependent) 
sequences. Voxel-based morphometry (VBM) was used to calculate grey matter volume 
while ReHo (regional homogeneity) was calculated to assess brain activity.
Results: Compared with controls, patients had significantly lower scores of MoCA and 
AVLT (learning memory, short delayed recall, long delayed recall). The memory curve plot 
based on AVLT results demonstrate that patients had a similar memory curve from learning 
memory to short delayed memory, whereas their memory declined significantly from short 
delayed recall to long delayed recall while the controls’ memory remained stable during 
this period. Multiple stepwise regression analysis revealed that end-stage renal disease is 
associated with memory deficit independently. VBM revealed that dialysis patients have 
significantly reduced grey matter volume in the following area: right cerebellum anterior 
lobe, bilateral cerebellum posterior lobe, right hippocampus, amygdala, parahippocampus 
gyrus, left medial frontal gyrus, left fusiform gyrus, bilateral caudate and subcallosal gyrus 
and left insula. fMRI showed that ReHo declined in dialysis in the left middle and inferior 
frontal gyrus, as well as in the right supra marginal gyrus. Correlation analysis demonstrated 
that ReHo of left middle/inferior frontal gyrus correlated with learning memory test score 
(r=0.34,p=0.02).
Conclusions: Our study reveals memory deficit with a special pattern in dialysis 
patients, as well as that dialysis patients are with diffuse cerebral atrophy and reduced brain 
functional activity in certain areas. Cerebral functional changes are associated with memory 
alterations in the patients.
Funding: Government Support - Non-U.S.
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Orthostatic Blood Pressure Decline as a Possible Explanation for Memory 
Deficit in Dialysis Patients
Wenjin Liu,1 Lulu Wang,1 Junwei Yang.2 1Nanjing Medical University, Nanjing, 
China; 2Center for Kidney Disease, Second Affiliated Hospital of Nanjing 
Medical University, Nanjing, China.
Background: Memory deficit is usually ignored by nephrologists but can be 
detrimental to patients’ quality of life as well as prognosis. A better understanding of the 
mechanisms underlying this condition could improve the care of CKD patients. Here we 
sought to test the hypothesis that orthostatic blood pressure decline contributes to memory 
deficit in patients with end-stage renal disease.
Methods: Sixty patients on maintenance hemodialysis and 60 healthy controls (without 
CKD, cardiovascular diseases or neurologic diseases) were included. Patients and controls 
were frequency-matched by age, sex and education. The Montreal Cognitive Assessment 
(MoCA) was used to assess global cognition while the Auditory Verbal Learning Test 
(AVLT) was used for episodic memory evaluation. Seated and standing blood pressure were 
measured. Frequency domain heart rate variability (HRV) were recorded and analyzed.
Results: Compared with controls, patients had significantly lower scores of MoCA 
and AVLT (learning memory, short delayed recall, long delayed recall). They also exhibited 
rapid blood pressure decline upon standing, with a delayed compensatory rebound 
following. Correlation analyses showed that orthostatic blood pressure decline was not 
associated with cognition or memory in the controls, whereas it was correlated significantly 
to both short recall and delayed recall scores in the patients. Multiple stepwise regression 
analysis revealed that orthostatic blood pressure decline is an independent predictor for 
memory deficit (both short recall and delayed recall). The association between orthostatic 
blood pressure decline and short recall remained significant after adjusting for HRV.
Conclusions: Our study reveals significant memory deficit and overt orthostatic 
blood pressure decline upon standing in patients receiving maintenance hemodialysis. 
Orthostatic blood pressure decline is associated independently with memory test scores in 
a reverse fashion in hemodialysis patients and this association remained significant even 
after adjusting for heart rate variability, suggesting that orthostatic blood pressure decline 
possibly induce memory deficit directly, rather than merely a reflection of general cerebral 
injury.
Funding: Government Support - Non-U.S.
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Improved Thinking Through Dialysis: A Pilot Study Using the 
BrainCheck Assessment Platform
Horacio E. Adrogue,2,1 Alexander H. Adrogue,3 Yael Katz,3 Karina Soto-Ruiz,3 
Benjamin Flores,3 David M. Eagleman.3 1Dialyspa Medical Center, Houston, 
TX; 2Nephrology, Houston Methodist Hospital, Houston, TX; 3BrainCheck, Inc., 
Houston, TX.
Background: It is estimated that 27-67% of the ESRD population is plagued by 
cognitive dysfunction. This impairment not only decreases QOL and dialysis compliance, 
but also increases depression and mortality. Drew et al demonstrated that each 1 SD higher 
executive function score was associated with a 35% lower hazard of mortality. We tested 
hemodialysis patients with a novel, mobile and digital neurocognitive test, BrainCheck, in 
an effort to evaluate cognitive improvement after dialysis treatment.
Methods: We prospectively consented and enrolled patients at Dialyspa dialysis center 
in Houston, TX and administered BrainCheck before and after dialysis. Their performance 
pre and post-dialysis was shared with the patients in real-time. We also compared the 
neurocognitive performance of our patients against age-matched controls without ESRD.
Results: We enrolled a total of 29 patients, 17 (58.6%) female. Their ages ranged from 
25 to 88, average was 59 years. 11 (37.9%) were African American, 9 (31%) Hispanics, 7 
(24.1%) White, and 2 (6.9%) Asians. The educational level breakdown was 12 (41.4%) had 
some college education, 8 (27.6%) completed high school, 5 (17.2%) had a college degree 
and 4 (13.8%) a graduate degree. Our findings show that patients who are compliant with 
dialysis have cognitive function similar to the non-dialysis population. We also found that 
sharing cognitive performance results with patients could be used as a motivator to increase 
compliance.
Conclusions: Standard dialysis practice appears to help patients regain cognitive 
function to levels similar to their non-ESRD counterparts. While more data is needed, this 
study shows that a brief cognitive test could be used to promote compliance with dialysis 
treatment. This could translate into QOL gains and decreased mortality in this patient 
population.
Funding: Private Foundation Support
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Depressive Symptoms as a Function of Race, Gender, and Perceived Social 
Support in End-Stage Kidney Disease
Marcus G. Wild,2 Devika Nair,2 Ebele Umeukeje,1 Kerri L. Cavanaugh,1 
Ken Wallston.1 Behavioral Medicine in Chronic Conditions Research Group 
1Vanderbilt University Medical Center, Nashville, TN; 2Vanderbilt University, 
Nashville, TN.
Background: Depression negatively impacts physical health and quality of life, and 
the prevalence of depressive symptoms in individuals receiving maintenance hemodialysis 
(HD) is 2-3 times higher than in the general population. Further, women and members of 
minority groups are at an increased risk for depression. Perceived social support (PSS) is 
found to have protective effects against depression. Yet, the effects of social support, gender, 
and race on depressive symptoms in HD patients is not well described.
Methods: 117 patients (55% female, 72% self-reported African American (AA)) 
receiving in-center HD completed questionnaires assessing depressive symptoms and 
PSS. A 2x2x2 ANOVA was conducted to assess the main effects of PSS, gender, and race 
on depressive symptoms. Two-way interactions of race x PSS, gender x PSS, and race x 
gender, as well as the three-way interaction of race, gender, and PSS were also evaluated. 
Age and self-rated overall health were included as covariates.
Results: Analyses revealed significant main effects of age (p<.01), overall health 
(p<.01), and PSS (p<.01) on depressive symptoms. There was a significant interaction 
between PSS and race (p<.05), such that AAs had lower levels of depressive symptoms 
at low levels of PSS and higher levels of depressive symptoms at higher levels of PSS, as 
compared to whites. Further, there was a significant 3-way interaction among PSS, race, 
and gender (See Figure 1).
Conclusions: Gender and race are important modifiers of the effects of PSS on 
depressive symptoms. Patient characteristics such as race and gender should be taken into 
account when creating tailored, social support-based interventions to treat depression in 
HD patients.
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Figure 1. Effect on depressive symptoms of the interaction of PSS, gender, and race.
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Acceptance of Erectile Dysfunction Treatment by Patients on Hemodialy-
sis and Their Renal Providers
Amoghavarsha Puli,1 Hossam Abdalla,1 Steven D. Weisbord.1,2 1University of 
Pittsburgh Medical Center, PIttsburgh, PA; 2VA Pittsburgh Healthcare System, 
PIttsburgh, PA.
Background: Erectile Dysfunction (ED) is highly prevalent in men receiving chronic 
hemodialysis (HD). Past studies demonstrate that treatment of ED with phosphodiesterase-5 
inhibitors is safe and effective in this population. However, it is unknown whether these 
medications and other therapies are routinely used. We sought to investigate the acceptance 
of treatment for ED among men on chronic HD and their renal providers.
Methods: As part of a clinical trial of symptom management in patients on chronic 
hemodialysis, we assessed erectile dysfunction monthly using the Sexual Health Inventory 
of Men (SHIM) tool. For men with erectile dysfunction (SHIM score < 22), trained 
research nurses provided treatment recommendations and if patients and providers 
accepted them, helped facilitate their implementation. We assessed patients’ acceptance of 
recommendations, reasons for refusal, and providers implementation of therapy. All data 
was analyzed at the level of monthly assessments.
Results: Of the 101 patients followed for up to 12 months, 46 of 47 (98%) men 
met criteria for erectile dysfunction. These 46 patients reported ED on 426 monthly 
assessments. In 49 of the 426 (11.5%) assessments, patients accepted the recommendation 
for treatment. On 59 assessments (14%) patients were already on treatment or had received 
a prescription. On 11 monthly assessments (2.5%) patients reported having financial 
obstacles precluding treatment. On 260 (61%) monthly assessments, patients refused the 
treatment recommendations. The primary reason patients refused the recommendations was 
no desire to discuss treatment options (53%) and not interested in being sexually active or 
not having a partner (38%). In 14 of the 27 assessments (51%) where patients accepted the 
recommendation, renal providers were unwilling to provide treatment.
Conclusions: Despite the high prevalence of ED in the hemodialysis population, a 
large majority of patients are not interested in pursuing treatment. For patients interested 
in treatment, renal providers are commonly unwilling to modify or initiate therapy. Future 
efforts should focus on identifying patients interested in treatment and improving the 
provision of therapy for these individuals.
Funding: Veterans Affairs Support
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Management of Uremic Pruritus in Hemodialysis: Effectiveness of a 
Quality Improvement Treatment Algorithm
Karthik K. Tennankore,1 Erin P. Westby,1 Kailee L. Mccarron,2 Marsha Wood,2 
Tabassum ata Quraishi,2 Jo-Anne S. Wilson,1 Jaclyn Y. Tran,2 Amanda J. Vinson,1 
Samuel A. Silver.3 1Dalhousie University/NS Health Authority, Halifax, NS, 
Canada; 2Nova Scotia Health Authority, Halifax, NS, Canada; 3Queen’s 
University, Kingston, ON, Canada.
Background: Uremic pruritus (UP) is highly prevalent among dialysis patients and 
associated with significant morbidity. However, management of UP is inconsistent across 
centres and many patients remain inadequately treated. The purpose of this study was to 
analyze the effectiveness of a UP treatment algorithm for chronic dialysis patients.
Methods: We analyzed a cross-section of in-center hemodialysis patients at a tertiary 
care center and assessed pruritus character (localized or generalized) and severity (0; no itch 
to 10; worst imagineable itch) using a numerical rating scale (NRS). Those with generalized 
pruritus rated as moderate to severe (NRS ≥4) were entered into a treatment algorithm 
consisting of hydrous emollients (all patients) and step-wise use of a topical agent (menthol 
0.5%/camphor 0.5% cream), gabapentin (dose increased from 100-300 mg 3X/week) and 
UV-light. UP severity was recaptured at entry into the algorithm, and assessed at one month 
after the topical agent and two week intervals after each dose increase of gabapentin.
Results: Overall, 64/196 patients (33%) rated their pruritus as ≥4, and 56/64 entered 
the algorithm. A total of 39/56 patients (70%) had a persistent pruritus score of ≥4 on 
reassessment and were prescribed the topical agent; 16/39 patients had a complete response 
at one month post initiation, 2/39 could not afford the topical, 2/39 developed side effects 
necessitating discontinuation and 3/39 did not fill the prescription due to other delays. A 
total of 11 non-responders/non-users of the topical agent received gabapentin; 3/11 patients 
had a complete and sustained pruritus score of <3 at last follow-up while 3/11 patients failed 
to respond and were referred for UV light treatment. The remainder had not completed 
titration of gabapentin or experienced spontaneous remission. Overall, the mean pruritus 
score fell from 6.5 ± 2.1 to 2.9 ± 1.9 (P<0.001) for those who initiated treatment with the 
topical agent and had an assessment of their pruritus severity (N=31/39) at four months.
Conclusions: Implementation of a treatment algorithm for UP management effectively 
reduced UP severity in a cross-section of in-center hemodialysis patients. Future external 
validation of the algorithm is needed prior to widespread implementation.
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Comparison of Retinal Neurodegenerative Changes in Patients with CKD 
Undergoing Hemodialysis versus Healthy Controls Assessed by Spectral- 
Domain Optical Coherence Tomography
Susanne Jung,1 Agnes Bosch,4 Christian Ott,2 Dennis Kannenkeril,4 
Thomas Dienemann,4 Joanna M. Harazny,3 Roland E. Schmieder.4 1Departments 
of Cardiology, Nephrology and Hypertension, Friedrich-Alexander-University 
Erlangen-Nuremberg, Erlangen, Germany; 2Friedrich-Alexander University 
Erlangen-Nürnberg, Erlangen, Germany; 3University Erlangen-Nueremberg, 
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Background: Spectral-domain optical coherence tomography (SD-OCT) represents a 
reliable tool for retinal layer volume measurement. The aim of this study is to evaluate 
retinal changes indicating neurodegenerative processes in patients with chronic kidney 
disease (CKD) undergoing hemodialysis (HD) compared to healthy controls.
Methods: In a prospective observational single center study, we included a total of 70 
subjects–32 CKD patients undergoing HD and 38 healthy controls. Circular scans of the 
optic disc area to determine retinal nerve fiber layer (RNFL) thickness were obtained by 
SD-OCT and macular retinal layer volumes of both eyes including total retinal volume but 
also each layer were evaluated.
Results: The group of CKD patients (11 females, 21 males, aged 60.3±15 years) was 
compared to healthy controls (28 females, 10 males, aged 57.9±10 years). The age- and 
gender-adjusted temporal superior RNFL sector of the right eye was significantly thinner in 
HD patients as were several retinal layer volumes such as total retinal volume, ganglion cell 
layer (GCL), ganglion cell layer + inner plexiform layer (GCL-IPL) and inner retinal layer 
volume (IRL, comprising RNFL, GCL and IPL) of the right eye and IPL volume of both 
eyes. To eliminate additive effects of HD and diabetes, we performed a subgroup analysis 
excluding patients with diabetes mellitus (n=25). The temporal superior RNFL sector was 
still significantly thinner than in the control group (p=0.021) as were GCL (p=0.014) and 
GCL-IPL volume of the right eye (p=0.024).
Conclusions: In patients undergoing HD, we observed a decrease in temporal RNFL 
thickness and retinal layer volumes indicating neurodegenerative retinal alterations in 
patients with CKD. Thereby, SD-OCT represents a valuable high-resolution imaging 
technique to explore retinal neurodegenerative changes.
RNFL thickness and retinal volumes
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The Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on 
Improvement of Mental Health and Clinical Parameters in Hemodialysis 
Patients – Pilot Study
Jin Ho Hwang, Seongyup Yeo. Department of Internal Medicine, Chung-Ang 
University Hospital, Seoul, Republic of Korea.
Background: The prevalence of major depressive disorder in patients with ESRD 
is higher than in diabetes or congestive heart failure. However, it is difficult to prescribe 
antidepressant treatment because of concern about potential adverse effects in CKD 
patients. Here, we studied the therapeutic effect of rTMS as a nonpharmacologic treatment 
in depressed hemodialysis patients.
Methods: The patients with more than 5 points in Patient health Questionnair-9 were 
randomized to rTMS group and sham group. The rTMS group was stimulated on the left 
dorsolateral prefrontal cortex for 20 minutes, three times a week. We collected and analyzed 
the clinical indices before and after TMS treatment, and also collected data of quantitative 
electroencephalogram (qEEG), and the results of various psychiatric questionnaires (Beck’s 
depression index-II [BDI-II], Beck’s anxiety index [BAI] and SCL-90R-Somatization 
subscales [SCL-90R-SOM]).
Results: In this study, a total of 13 patients were randomized, 7 patients assigned to 
the sham group and 6 were assigned to the rTMS group. When laboratory findings were 
compared 1 month after TMS, hemoglobin A1c was significantly improved in rTMS group 
(8.3% to 7.1%, P=0.046 by pared t-test, P=0.032 by mixed ANOVA). Although there was 
no statistical significance, serum potassium and intact PTH also showed an improving 
tendency. The frontal alpha asymmetry (FAA) F4-F3 (P=0.009), and F8-F7 (P=0.027) 
values in qEEG was significantly improved in the rTMS group than the others. The BDI-
II score was improved both with sham (24.0 to 18.4, P=0.009) and rTMS group (21.2 to 
13.8, P=0.005), the BAI (rTMS: 11.2±6.1 vs. sham: 16.9±13.0; F 6.7, P=0.025) and SCL-
90R-SOM scores (rTMS: 20.2±5.4 vs. sham: 22.4±5.6; F 4.9, P=0.048) showed prominent 
improvement after rTMS.
Conclusions: In hemodialysis patients, rTMS may improve depression, anxiety, and 
somatization symptoms, which may lead to improvements in clinical measures.
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Interventions to Improve Sleep Quality in People with CKD: A Cochrane 
Systematic Review
Patrizia Natale,1,2 Suetonia Palmer,3 Marinella Ruospo,1 Valeria M. Saglimbene,1,4 
Jorgen B. Hegbrant,5 Giovanni F. Strippoli.1,2 1Diaverum, Bari, Italy; 2Emergency 
and Organ Transplantation, University of Bari, Bari, Italy; 3University of Otago, 
Christchurch, New Zealand; 4School of Public Health, University of Sydney, 
Sydney, Italy; 5Diaverum Renal Services Group, Lund, Sweden.
Background: Sleep quality is lower for people with chronic kidney disease (CKD). 
The prevalence of sleep disorder ranges from 45% to 80% in adults with end-stage kidney 
disease (ESKD) and half of patients with earlier stages of CKD. People with CKD have 
identified the importance of research focused on better treatments to reduce symptoms of 
CKD. This Cochrane review evaluates the benefits and harms of interventions to improve 
sleep quality for adults and children with CKD.
Methods: We searched the Cochrane Kidney Transplant Specialised Register for 
randomized trials reporting treatment on sleep quality for people with CKD through April 
2018. Two authors independently screened citations for eligibility, extracted data, and 
assessed risk of bias using the Cochrane tool. Evidence certainty was adjudicated using 
GRADE. Sleep quality was measured by validated sleep scores.
Results: Sixty-seven studies (3427 participants) met review eligibility criteria. 
Sixty-one studies (3201 participants) involved dialysis patients, three studies involved 
104 transplant recipients, and one study involved 45 patients with CKD. Median trial 
duration was 5 weeks. Mean trial age was 54.3 years. Interventions included acupressure, 
aromatherapy, benzodiazepine therapy, cognitive-behavioral therapy, dopaminergic 
agonists, education, exercise, light therapy, massage, melatonin, music therapy, peritoneal 
dialysis technique, reflexology, relaxation, and telephone support. Methodological reporting 
was incomplete for most studies. Relaxation had uncertain effects on sleep quality (mean 
difference [MD] -1.62, 95% confidence interval [CI] -5.03, 1.79; very low certainty 
evidence). Exercise may provide improvements in sleep quality (standardized MD -1.10, 
-2.26, 0.05; very low certainty). Acupressure compared to no treatment may improve sleep 
quality (MD -1.27, -2.13, -0.40; very low certainty) and sleep latency (MD -0.59, -0.92,
-0.27; moderate certainty), although effects were smaller than clinically important changes
in sleep scores. Effects of other interventions on sleep quality were very uncertain. Evidence 
in children was absent.
Conclusions: Exercise and acupressure may provide small clinical improvements 
in sleep quality for people with CKD, although limitations in existing trials reduce the 
certainty of these findings.
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Association of Self-Reported Sleep Quality with Frailty in Patients on 
Hemodialysis
Kendra E. Wulczyn,1 Barbara A. Grimes,2 Kirsten L. Johansen.3 1University of 
California San Francisco, San Francisco, CA; 2UCSF, San Francisco, CA; 
3University of California, San Franicsco, San Francisco, CA.
Background: Poor sleep quality is associated with frailty in the elderly, yet the 
relationship has not been examined in patients on hemodialysis, among whom the 
prevalence of both poor sleep quality and frailty is higher. We examine the association of 
sleep quality with frailty in patients on hemodialysis over a two-year period.
Methods: We used ordinal generalized estimating equation analysis to examine the 
association between self-reported sleep quality and frailty and change in frailty over time in a 
cohort of 762 hemodialysis patients. Frailty was measured using the Fried frailty phenotype 
and modeled according to the number of components met. Participants rated sleep quality 
on a Likert scale in 3 domains: sleep initiation, sleep maintenance, and returning to sleep. A 
score of 16 or greater on the Center for Epidemiologic Studies-Depression scale indicated 
depressive symptoms. Measures were conducted at baseline, 12, and 24 mos.
Results: Self-reported difficulty with sleep initiation, sleep maintenance, and trouble 
returning to sleep were associated with significantly higher odds of being frail in multivariate 
analysis (table). Impaired sleep maintenance and trouble returning to sleep were also 
associated with worsening frailty over time. Addition of the inflammatory marker IL-6 did 
not weaken the association between sleep quality and frailty. The addition of depression to 
the multivariate model markedly attenuated the association between sleep quality and frailty 
in all three sleep domains.
Conclusions: Poor sleep quality was associated with higher odds of frailty in patients 
on hemodialysis, and impaired sleep maintenance and trouble returning to sleep were 
associated with worsening frailty over time. Our analyses suggest that inflammation does 
not solely account for these findings and that depression may play a large role in the causal 
pathway between sleep and frailty.
Funding: NIDDK Support
Odds ratio of higher frailty score and change in frailty over time
*p<0.05
‡Adjusted for age, race, ethnicity, sex, BMI, serum albumin, smoking, diabetes, 
atherosclerotic heart disease, heart failure
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Dialysis After Displacement
Madhavi E. Ryali,1 Sejal K. Kalawadia,2 Wadah Atassi,2 Cybele Ghossein.3 
1Nephrology Associates of Northern Illinois, Elmhurst, IL; 2Nephrology 
Associates of Northern Illinois and Indiana (NANI), Blue Island, IL; 
3Northwestern University- Feinberg School of Medicine, Chicago, IL.
Background: The Syrian war and the influx of approximately 1.5 million refugees 
into neighboring Lebanon has led to a humanitarian crisis. Refugees have a multitude of 
chronic medical and psychosocial problems and few resources. End stage renal disease 
(ESRD) refugees patients have the additional stressor of trying to obtain life-saving therapy 
under extreme hardship. Here we report on the current experience of ESRD Syrian refugee 
patients in Lebanon.
Methods: As part of a medical mission through the Syrian American Medical Society 
(SAMS), four US nephrologists along with ground staff evaluated the dialysis services 
provided to refugees in Lebanon. The Lebanese government covers dialytic services for 
their citizens but Syrian refugees depend on Non Government Organizations (NGO) or 
personal finances to cover their treatments. Two NGOs currently fund the majority of HD 
treatments for Syrian refugees in Lebanon – Norwegian Aid Committee (NORWAC) and 
SAMS. Hemodialysis (HD) is the only available dialysis option. Each dialysis session costs 
approximately $100 per 4 hour treatment session but does not include transportation and oral 
medications. Patients travel up to 6 hours by bus round-trip to receive HD. Transplantation 
is not an option due to costs.
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Results: There are currently 218 Syrian refugees in Lebanon who require HD, and this 
number grows by 1-2 monthly. 114 are covered by NORWAC, 37 are covered by SAMS, 
and 67 patients are on a waiting for list for a sponsored dialysis chair. Waiting list patients 
wait for NGO coverage, self-pay for an HD session intermittently if they are able to afford 
it, or die waiting.
Conclusions: The primary obstacle for providing Syrian refugees in need with HD in 
Lebanon is cost. This vulnerable population mortality risk is high given the limited financial 
resources available to them and the chronicity of their condition.
Funding: Private Foundation Support
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Vibration Perception Threshold as a Measure of Peripheral Neuropathy in 
Dialysis Patients: A Pilot Project
Paras Dedhia,1 Rachana H. Jasani,1 Viswanath Billa,2 J. Kothari,1 Shrirang Bichu,3 
Rajesh B. Kumar.1 1Apex Kidney Care, Mumbai, India; 2Bombay Hospital, 
Mumbai, India; 3Bombay Hospital Near Liberty Theater New Marine Lines, 
Mumbai, India.
Background: Dialysis patients are at increased risk of fall due to neuropathy and 
myopathy. Also, significant percentages of dialysis patients are diabetic; making them 
vulnerable to neuropathy, foot ulcers and fall.
Methods: Vibration perception threshold (VPT) was measured by handheld digital 
biothesiometer in prevalent dialysis patients. The biothesiometer probe, which vibrates at 
amplitude proportional to the square of the applied voltage, was applied perpendicular to 
the test site. VPT value was defined as the voltage level at which subject first felt vibration 
sense. Measurements were taken at 6 points of plantar aspects of both feet at great toe, 1st 
metatarsal, 3rd metatarsal, 5th metatarsal, instep and heel. Average of these 6 points was 
further graded as normal (<15 volts), mild (16-20 volts), moderate (21-25 volts) and severe 
(>26 volts). All patients were on thrice a week hemodialysis.
Results: Of the 304 subjects, 59.5% were males. Average age was 51.1± 14.1 years 
and average dialysis vintage was 4.6 ± 3.8 years. 65 % subjects had hypertension, 31.9% 
had diabetes, 13% subjects had ischemic heart disease. VPT was found to be normal in 
41.1%, mild impairment of VPT in 21.3%, moderate in 11.1% and severe impairment in 
24.6% of subjects.
Conclusions: Moderate to severe vibration perception threshold impairment was found 
in 1-in-3 dialysis patients. This calls for quality improvement program to assess prevalence 
of neuroapthy and to decrease the burden of morbidities and falls.
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Association Between Psychosocial Factors and Receipt of Nocturnal 
In-Center Hemodialysis Among Prevalent Dialysis Patients
Zhaoli Tang,1 Adam S. Wilk,1 Courtney E. Hoge,1 Laura Plantinga,2,1 
Janice P. Lea.3,2 1Rollins School of Public Health, Emory University, Atlanta, 
GA; 2Emory University School of Medicine, Atlanta, GA; 3Emory Dialysis 
Centers, Atlanta, GA.
Background: Compared to traditional in-center hemodialysis (HD), nocturnal dialysis 
(ND) is characterized by longer sessions and nighttime administration, which may lead to 
better outcomes for some patients. Given the importance of patient choice in the decision 
to initiate ND, we explored associations between patients’ psychosocial factors and their 
receipt of ND.
Methods: Among HD patients at a medium-sized dialysis organization, we identified 
ND patients as those for whom ≥80% of dialysis sessions were ND sessions—starting at 
6:30 pm or later and lasting ≥5 hours—over the 3 months (≥20 sessions total) after their 
first ND session. We extracted dialysis session data from electronic medical records and 
psychosocial data from social worker assessments typically performed at dialysis start. 
We performed descriptive analyses of ND and non-ND patients among all HD patients. 
We also analyzed the subsample of patients whose available psychosocial assessment data 
were more timely: i.e., patients whose psychosocial assessment was conducted between 
1 year before and 1 month after their first ND session (for ND patients) or within the first 
year of dialysis at the dialysis organization (for non-ND patients). We tested associations of 
psychosocial factors with ND receipt in logistic regression models.
Results: We identified 64 ND patients in the total sample (5.5% of 1,169 HD patients). 
ND versus non-ND patients had greater full or part-time employment (26.8% vs. 8.5%, 
p<0.01), were less likely to require ambulatory assistance (14.1% vs. 41.2%, p<0.01), and 
were more likely to live alone (33.3% vs. 19.3%, p<0.01). Factors not associated with ND 
status included being married (26.7% vs. 30.9%, p=0.49) and having daily access to support 
at home (70.0% vs. 71.6%, p=0.79). For the subsample of 25 ND patients with timely 
psychosocial data (3.2% of 792 subsample HD patients), the relationships between ND and 
psychosocial characteristics were similar. Regression results were also qualitatively similar 
for both samples.
Conclusions: Patient psychosocial characteristics strongly predict receipt of ND care. 
It may be important to account for differences in psychosocial factors, which are typically 
unmeasured, when comparing outcomes for ND and non-ND patients.
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Altered Fingerprint Patterns: Revelation of an Unexplored Phenomenon 
in Patients Receiving Maintenance Hemodialysis
Hari K. Mogili,2 Indirakshi J. Jamalpuri,2 Abhilash Koratala.1 1University of 
Florida, Gainesville, FL; 2Sri venkateswara institute of medical sciences, 
TIRUPATI, India.
Background: Epidermal ridge patterns on fingers, commonly known as fingerprints, 
are not only unique to each individual, but are also thought to remain unchanged over 
time. As such, they are one of the most commonly used means for identification. In our 
maintenance hemodialysis [HD] program, an unexpectedly high number of patients 
reported experiencing difficulty using fingerprints as a biometric for identification. This 
observation prompted a study to explore whether there are alterations in the papillary ridges 
in HD population and if so, evaluate its magnitude.
Methods: In this cross-sectional study, a total of 300 subjects including 150 patients 
receiving HD and an equal number of healthy controls [HC] were enrolled from October 
2016 to March 2017. The fingerprints were obtained from all 10 fingers and were analyzed 
for clarity and pattern. They were classified as intact, partially lost, and completely lost. 
Based on their occupation, the subjects were categorized into 3 groups: ‘Blue-collar’ [BC], 
‘White-collar’ [WC], and ‘unemployed’ [UE]. The patterns of fingerprints (i.e. loops, 
whorls, and arches) were identified and compared for each group.
Results: The mean age of the HD population and the HC were 46.8 and 47.2 years 
respectively (72% men in each group). The BC, WC, and UE proportions in the HD group 
were 70, 30, and 23% respectively, while they were 38, 62, and 20 in the HC. Fingerprint 
clarity was normal in 76.6 and 98.7% of the HD population and HC respectively (p<0.009). 
Partially lost fingerprints were detected in 13.3% of the HD group and 1.3% of the HC 
(p<0.001). While the prints were completely lost in 10% of the HD group, none of the HC 
was found with found to have lost patterns. Loss of fingerprints was more common in those 
with BC than WC.
Conclusions: While patients receiving maintenance HD can host a multitude of 
specific and non-specific skin conditions, to our knowledge, this is the first study on altered 
fingerprints in this patient population. It shows that compared to HC, a significant number of 
HD patients lose their fingerprint patterns partially or completely over time. Future studies 
are needed to confirm these findings, identify the pathophysiology and contributing factors, 
and explore its potential correlation with common comorbidities in this setting.
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Physician Attribution of Long-Term Catheter Use: A New Way of Looking 
at Clinical Performance Measures
Jonathan H. Segal, Abhijit S. Naik, Tammie A. Nahra, Mia Wang, Jingya Gao, 
Kathryn Sleeman, J. M. Messana. University of Michigan Kidney Epidemiology 
and Cost Center, Ann Arbor, MI.
Background: Quality metrics in national ESRD programs are traditionally calculated 
at the dialysis facility level. With the Medicare Quality Payment Program, there is interest 
in physician-level metrics that could complement existing facility-level measures without 
increasing provider reporting burden. Our objective was to develop methodology to attribute 
patient outcomes to either individual physicians or group practices and then compare long-
term catheter (LTC) use at the facility and provider-level.
Methods: We used NPI numbers to determine the single provider who received the 
Monthly Capitated Payment (MCP) from 2016 Medicare physician supplier claims, and 
identified hemodialysis (HD) patient months from Medicare dialysis facility claims. A 
group practice arrangement was inferred if multiple practitioners shared a common Tax 
Identification Number (TIN) and provided MCP services to a specific patient in the year. 
The percent of total HD patient-months with a LTC from CROWNWeb was then assigned 
to a practitioner or group practice.
Results: 9307 providers were identified by NPI caring for 338,718 eligible patients. 
Using NPI alone, 61% of patients were associated with only one MCP practitioner, while 
using the TIN matching algorithm an additional 33% of patients stayed within a single 
group practice during 2016 (See Figure). The mean LTC rate of 14.4% at the provider level 
for 2 of 3 consecutive months was similar to the LTC facility rate of 13.4%. The LTC rate 
of 9.7% at the provider level for 3 of 3 consecutive months was less sensitive but more 
specific.
Conclusions: MCP claims can identify the responsible practitioner for a patient’s care 
during a given month. The TIN matching algorithm may allow development of a low-
burden patient attribution paradigm for ESRD practitioner quality metrics. This approach 
yields similar results as the facility-level measure of LTC use and could help align dialysis 
facility and MCP practitioner quality initiatives.
Funding: Other U.S. Government Support
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Dialysate Potassium (K) Concentration and Total Dialysate Volume per 
Week During More Frequent Hemodialysis (MFHD) Determine Serum K 
After Transfer from In-Center Hemodialysis (ICHD): Model Predictions
J. Ken Leypoldt,1 Eric D. Weinhandl,2 Michael A. Kraus,3 Allan J. Collins.2 
1Unaffiliated, San Clemente, CA; 2NxStage Medical, Inc., Victoria, MN; 
3NxStage Medical, Inc, FISHERS, IN.
Background: Low dialysate K concentrations during ICHD induce rapid intradialytic 
K removal and low postdialysis serum K concentrations; low dialysate K concentrations 
are also associated with a higher risk of sudden cardiac arrest. Using a mathematical model, 
we evaluated the effect of the MFHD prescription on predialysis serum K concentration 
(Kpre), postdialysis serum K concentration (Kpost) and intradialytic decrease in serum K 
concentration (ΔKintra) after transfer from ICHD.
Methods: The mathematical model was modified from one previously published (Agar 
et al, Hemodial Int 2015) by accounting for colonic K clearance. MFHD prescriptions 
included treatment frequencies of 3.5, 4, 5 and 6 treatments per week, dialysate volumes 
of 20-60 L/treatment and treatment durations of 120-240 min. Predialysis serum K 
concentration during ICHD was assumed between 4.0 and 5.5 mEq/L with a dialysate K 
concentration of 2 mEq/L.
Results: Model-predicted Kpre, Kpost, and ΔKintra during MFHD were primarily 
dependent on total dialysate volume per week (TDV) and dialysate K concentration. A 
schematic weekly profile of serum K during ICHD and MFHD is illustrated in the figure. 
The range of TDV on MFHD with dialysate K concentrations of 1 and 2 mEq/L required to 
decrease Kpre, Kpost and ΔKintra below that during ICHD are tabulated.
Conclusions: We conclude that transfer from ICHD to MFHD with low TDV can result 
in a lower Kpre without reducing Kpost or ΔKintra for dialysate K and MFHD prescriptions 
typically seen in clinical practice. As with any hemodialysis therapy, additional vigilance 
is required for patients persistently presenting with hypokalemia or those prescribed high 
TDV.
Funding: Commercial Support - NxStage Medical
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Effect of Dialysate Potassium (K) Bath During Daily Hemodialysis (DHD) 
on Serum K Concentration After Transfer from In-Center Hemodialysis 
(ICHD)
J. Ken Leypoldt,1 Michael A. Kraus,4 Bertrand L. Jaber,2 Eric D. Weinhandl,3 
Allan J. Collins.3 1Unaffiliated, San Clemente, CA; 2St. Elizabeth’s Medical 
Center, Boston, MA; 3NxStage Medical, Inc., Victoria, MN; 4NxStage Medical,
Inc, FISHERS, IN.
Background: The choice of the dialysate K bath influences serum K concentration 
during thrice-weekly ICHD; however, the prescription of the dialysate K bath during DHD 
has not been extensively studied. We examined the effect of the dialysate K bath during 
DHD on serum K concentration after transfer from ICHD.
Methods: This post hoc analysis evaluated patients who transferred from ICHD to 
DHD during the FREEDOM Study (N=345). DHD was performed at low dialysate flow 
rates; treatment frequency per week and dialysate volume per session were 5.9±0.2 and 
22.2±4.0 L, respectively. The change in serum K concentration after transfer from ICHD 
to DHD (ΔK) was calculated based on the average serum K concentration from the last 3 
months of ICHD and the first 3 months of DHD.
Results: ICHD serum K concentration was 5.3±0.7, 4.8±0.6 and 4.4±0.5 mEq/L 
with ICHD dialysate K bath of 1, 2 and 3 mEq/L, respectively. Mean±SD (N) serum ΔK 
for combinations of ICHD and DHD dialysate K baths are tabulated. By multiple linear 
regression, ΔK was inversely associated with both higher ICHD dialysate K bath (P<0.001) 
and ICHD serum K concentration (P<0.001) when DHD dialysate K bath was 1 mEq/L; no 
such associations were noted when DHD dialysate K bath was 2 mEq/L.
Conclusions: Transfer from ICHD to DHD at low dialysate flow rates with a dialysate 
K bath of 1 mEq/L resulted in decreased serum K concentrations, but no changes in 
serum K concentration occurred with a dialysate K bath of 2 mEq/L. Control of serum K 
concentration during DHD at low dialysate flow rates is effective; however, the choice of 
the dialysate K bath can be informed when transfer is from ICHD to DHD.
Funding: Commercial Support - NxStage Medical
*(P<0.001) & **(P=0.0013) denote different from zero.
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Misclassification of Acid-Base Status Using Serum Bicarbonate in 
Hemodialysis
Tyler Woodell,1 Dena E. Rifkin,2 David H. Ellison,1 Jessica W. Weiss.1 1Oregon 
Health & Science University, Portland, OR; 2University of California, San 
Diego, La Jolla, CA.
Background: Acid-base status is a potentially modifiable determinant of mortality 
among ESRD patients. Little is known about how acid-base status changes during 
hemodialysis, when potential imbalance is directly attributable to treatment. How serum 
bicarbonate performs in ESRD patients at estimating acid-base status compared to the gold 
standard – pH – is unknown.
Methods: In a cohort of veterans with ESRD, we prospectively assessed acid-base 
status monthly at the beginning and end of routine hemodialysis for three months by 
measuring bicarbonate (as total CO2) and pH. Bias of measured bicarbonate was evaluated 
with Bland-Altman plots and concordance correlation coefficients comparing measured 
bicarbonate to that calculated from the Henderson-Hasselbalch equation using pH and 
pCO2. Categorizing measured bicarbonate and pH, we determined the proportion of pre-
dialysis paired samples for which measured bicarbonate misclassified acid-base status (i.e. 
measured bicarbonate < 24 mmol/L when pH > 7.40, or vice versa).
Results: Among 25 participants, mean pH was 7.41 (± 0.04) pre-dialysis and 
7.48 (± 0.05) post-dialysis; 75% of post-dialysis pH measurements were ≥ 7.45. Compared 
to calculated bicarbonate, measured bicarbonate produced lower estimates of acid-base 
status both pre-dialysis (mean difference ranged from -1.52 [95% CIs -1.91 to -1.13] to 
-1.35 [95% CIs -1.69 to -1.00] mmol/L) and post-dialysis (mean difference ranged from 
-2.70 [95% CIs -3.41 to -1.99] to -0.80 [95% CIs -1.29 to -0.31] mmol/L). There was 
considerable month-to-month variability in concordance both pre-dialysis (ranging from
0.61 [95% CIs 0.42 to 0.79] to 0.85 [95% CIs 0.76-0.95]) and post-dialysis (0.44 [95% 
CIs 0.25-0.64] to 0.87 [95% CIs 0.77-0.97]). Compared to pH, 21 of 71 (30%) pre-dialysis 
bicarbonate samples misclassified acid-base status.
Conclusions: The majority of patients became alkalemic during hemodialysis despite 
arriving with normal acid base status – a finding currently under recognized in clinical 
practice. Measured bicarbonate suggested a more acidemic state than was measured by 
pH. Serum bicarbonate measurements misclassified acid base status in 30% of cases. If 
confirmed, this observation could impact how physicians prescribe dialysate bicarbonate.
Funding: Other NIH Support - NIH/NCTSA through Oregon Clinical and Translational 
Research Insitute award TL1TR002371
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Hepatic Response to Cooler Hemodialysis
Elena Qirjazi,1,2 Raanan Marants,2 Megan A. Mio,3 Brad Urquhart,3 Ting Lee,2,4 
Christopher W. McIntyre.1,2 1Nephrology, Western University, London, ON, 
Canada; 2Medical Biophysics, Western University, London, ON, Canada; 
3Physiology and Pharmacology, Western University, London, ON, Canada; 
4Lawson Health Research Institute, London, ON, Canada.
Background: Hemodialysis (HD) exerts significant hemodynamic effects on 
vulnerable vascular beds. The liver has preserved blood flow during dialysis due to its dual 
blood supply. Even so, its excretory function is lower, despite an increase in toxin-rich 
portal vein flow. Extracorporeal cooling has a protective effect on multiple organs during 
dialysis, but its effect on the liver is unknown. We used CT perfusion imaging to examine 
the effect of cooling on hepatic blood flow and detoxifying function during HD.
Methods: In this pilot randomized cross-over study, 16 HD patients underwent two 
HD study sessions – one at standard dialysis temperature (36.5 degrees Celsius), and one 
at cooler dialysis (35 degrees Celsius; order of the sessions was randomly allocated). 
Participants had dynamic contrast-enhanced CT studies of their liver using a 256-slice GE 
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scanner pre (baseline), 3 hours into (peak hemodynamic stress), and post HD. Perfusion 
maps of total liver, hepatic arterial and portal venous blood flow were generated and 
analyzed by CT Perfusion (GE Healthcare). Furthermore, subjects had non- invasive pulse 
dye densitometry (Nihon Kohden) measurements of indocyanine green (ICG) clearance as 
a marker of liver excretory function and serial blood sampling to assess endotoxin levels.
Results: The cohort had an average age of 63years old (range 47-84 years), 37.5% 
were female and the average dialysis vintage was 66.5 months (range 9-305 months). An 
increase in portal vein blood flow at peak HD stress compared to baseline was seen in 62.5% 
(10/16) of subjects with standard HD (118.6±10.0%). Cooler HD prevented this perfusion 
change in the portal vein (95.7±12.6%, p=0.03). Total liver blood flow and hepatic arterial 
flow were not statistically different amongst standard vs. cooler HD treatments. Standard 
HD also resulted in a significant decrease in ICG clearance at peak stress relative to baseline 
(85.5±10.4%, p=0.02), which was absent in the cooler HD sessions (92.6±12.1%, p=0.25). 
Cooler HD also had a trend of increased clearance of uremic toxins: indoxyl sulfate, 
hippuric acid and phenyl sulfate.
Conclusions: In a subgroup of patients, standard HD causes significant increases in 
toxin-rich portal vein blood flow at peak hemodynamic stress, which can be mitigated by 
extracorporeal cooling. Cooler HD also preserves the liver detoxifying function, which 
usually decreases with standard treatment.
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The Effect of Dialysate Sodium Concentration on Intradialytic  
Hemodynamic Outcomes
Marko Skrtic, Christian G. Rabbat, Amber O. Molnar, K. S. Brimble, 
Michael Walsh. McMaster University, Hamilton, ON, Canada.
Background: The effects of modest changes in dialysate sodium concentrations on 
inter-dialytic weight gain (IDWG), blood pressure and intra-dialytic hypotension (IDH) are 
uncertain. We studied the association between a change in sodium dialysate from 142 to 140 
mmol/L and IDWG, blood pressure and IDH in in-centre hemodialysis patients.
Methods: The dialysate sodium concentration was changed from 142 mmol/L to 140 
mmol/L in four dialysis units in Hamilton, Canada as part of a policy change. We assessed 
changes in IDWG, pre- and post- treatment systolic blood pressures, intra-dialytic change in 
systolic blood pressure, ultrafiltration volume, and frequency of intra-dialytic hypotension 
(intra-dialytic SBP < 90 mmHg) 8 weeks before and in two 8 week blocks after switching 
dialysate sodium from 142 to 140 mmol/L. All analyses were done using mixed-effects 
models in which patients were considered random intercepts and dialysate sodium was 
considered a fixed effect. All models were adjusted for age and sex.
Results: Analyses included a total of 559 patients. Compared to the 8 weeks before 
changing the dialysate sodium, 8 to 16 weeks after the change to 140 mmol/L the mean 
ultrafiltration volume decreased by 0.11 L (95% confidence interval [CI] 0.07 to 0.12, 
p<0.001), the mean IDWG decreased by 0.10 kg (95% CI 0.02 to 0.18, p=0.01) and the 
mean pre-dialysis systolic blood pressure fell by 2.8 mmHg (95% CI 2.3 to 2.3, p<0.001). 
The odds of intra-dialytic hypotension were not significantly different (odds ratio 1.07, 95% 
CI 0.97 to 1.18, p=0.17).
Conclusions: Decreasing dialysate sodium from 142 to 140 mmol/L was associated 
with a reduced pre-dialysis SBP and IDWG without increasing the risk of IDH. Large 
randomized trials to understand the effects of modest changes in dialysate sodium on 
patient-important outcomes are needed to inform this fundamental component of dialysis 
care.
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Effects of Ultrafiltration Rate on Decline in Residual Kidney Function 
Among Patients Receiving Less-Frequent Hemodialysis
Yuji Lee,1 Yusuke Okuda,1 Yoshitsugu Obi,1 Connie Rhee,1 Elani Streja,1 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh.1 1Harold Simmons Center for 
Kidney Disease Research and Epidemiology, Division of Nephrology and 
Hypertension, University of California, Irvine, Orange, CA; 2University of 
Tennessee Health Science Center, Memphis, TN.
Background: High ultrafiltration rate (UFR) may lead to poor preservation of residual 
kindey function (RKF) by causing hemodynamic instability. However, there are no data 
about the association between UFR and decline in RKF in patients receiving less-frequent 
hemodialysis (HD).
Methods: This study included the patients who started less-frequent HD from 2007 
to 2011 and had available UFR and renal urea clearance (KRU) data at baseline and KRU 
data at 1 year after less-frequent HD initiation. Less-frequent HD was defined as dialysis 
with a consistent treatment schedule of <3 times per week for 6 or more continuous 
weeks. Patients were grouped into 4 UFR categories (<6, 6 to <10, 10 to <13, and 
≥13 mL/h/kg). We defined rapid decline in RKF as a decline in KRU of more than 20% per 
year. We explored the association between UFR and rapid decline in RKF using logistic 
regression models with adjustments for case-mix variables, baseline RKF, and maximal
change of blood pressure during dialysis.
Results: Among eligible patients, mean (SD) UFR level was 7.0 (4.7) mL/h/kg. 
Median (interquartile range) baseline KRU was 5.6 (3.6 – 7.7) mL/min/1.72m2. In 
adjusted cubic spline models, we found a nonlinear association between higher UFR 
and the risk for rapid decline in KRU. In an adjusted logistic regression analysis, UFR 
≥13 mL/h/kg had a 2.1-fold higher risk of rapid decline in RKF compared to UFR of 6 to 
<10 mL/h/kg (odds ratio (OR) and 95% confidence intervals (CI): 2.09 (1.14 – 3.82)). In 
subgroup analyses based on vintage, the association between UFR and decline of KRU
was attenuated in patients who started less-frequent HD more than 6 months after dialysis
initiation [Figure 1].
Conclusions: High UFR increased the risk for rapid decline in RKF among patients 
receiving less-frequent HD.
Funding: NIDDK Support
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Association of Treatment Time and One Year Change in Residual Renal 
Urea Clearance in Hemodialysis Patients
Steven Nguyen,1 Yuji Lee,1 Christina Park,1 Jui-Ting Hsiung,1 Connie Rhee,1 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh,1 Elani Streja.1 1Harold Simmons 
Center for Kidney Disease Research and Epidemiology, Division of Nephrology 
and Hypertension, University of California, Irvine, Orange, CA; 2University of 
Tennessee Health Science Center, Memphis, TN.
Background: Longer hemodialysis (HD) treatment time has been associated with 
lower mortality risk. However, there are scant data regarding the effects of increased 
treatment time with regards to residual renal function (KrU).
Methods: We retrospectively examined associations of baseline (first 91 days of 
dialysis) HD treatment time and 1-year renal residual urea clearance change in 6,659 
patients receiving thrice weekly HD at a large dialysis organization between 2007-2011 
and who survived the first year of dialysis and had available KrU data in the first and 
fifth patient-quarters. Patients were grouped into 4 exposure categories based on average 
treatment duration during the baseline quarter. Significant KrU loss was defined as a 
drop ≥20% ([KrU quarter 5 - baseline KrU quarter] / baseline KrU). Logistic regression 
models were used with covariate adjustment for case-mix, markers of malnutrition and 
inflammation, and ultrafiltration volume.
Results: The mean age of patients in the cohort was 62±14 years and 35% were 
female. Treatment duration of <3 hours was associated with higher risk for KrU loss. 
Longer treatment durations were linearly associated with lower risk of significant KrU loss. 
These trends persisted across all models of adjustment. In the shortest duration category 
(<3 hours), the fully adjusted odds ratio (OR) was 1.40 (95% CI, 1.16, 1.69). In the longest 
duration category (>4 hours), the OR was 0.81 (95% CI, 0.68, 0.98). [Figure]
Conclusions: Among HD patients, shorter treatment duration was found to be 
associated with higher odds of loss of KrU whereas longer treatment duration was found 
to be associated with lower odds of KrU loss. Further studies are needed to understand the 
relationship between treatment time and KrU loss.
Funding: NIDDK Support
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Incremental and Twice Weekly Hemodialysis in Australia and New 
Zealand
Martin Wolley,2,1 Carmel M. Hawley,5 Mark R. Marshall,4 Matthew A. Roberts.3 
1Department of Nephrology, Royal Brisbane and Women’s Hospital, Brisbane, 
QLD, Australia; 2Faculty of Medicine, University of Queensland, Brisbane, 
QLD, Australia; 3Eastern Health, Blackburn, VIC, Australia; 4Middlemore 
Hospital, Auckland, New Zealand; 5Princess Alexandra Hospital, Brisbane, 
QLD, Australia.
Background: Most patients with end stage kidney failure starting hemodialysis do so 
at a standard frequency of three times a week, with occasional patients starting at a twice 
weekly frequency (“incremental dialysis”). Incremental dialysis may preserve residual 
kidney function, and has been associated with reduced mortality in dialysis patients. In this 
study we aimed to report the prevalence of incremental dialysis in an Australian and New 
Zealand incident dialysis cohort, and outcomes associated with this approach.
Methods: A cohort of incident adult patients starting hemodialysis between 2004 and 
2015 was created. We constructed multivariate Cox proportional hazards models with a 
primary exposure of dialysis frequency at the first survey date. The primary outcome was 
all-cause mortality with secondary outcomes of cardiovascular and non-cardiovascular 
mortality.
Results: The cohort comprised 27513 subjects with complete dialysis frequency 
data, with 970528 patient months of follow up. Of these, 850 started on twice weekly 
hemodialysis and 783 had complete data for analysis. Compared to patients starting 
on conventional dialysis, those started on incremental dialysis were older (67 vs 62 
years, p<0.001), had a lower BMI (26.1 vs 27.7 kg/m2, p<0.001), were more likely to 
be female (45% vs 38%, p<0.001) had a higher eGFR at dialysis start (7.59 vs 6.66ml/
min P<0.001) and were less likely to have diabetes (39.2% vs 50.2%, p<0.001). In a 
multivariate cox model, incremental start dialysis was not associated with reduced hazards 
for all-cause mortality (HR 1.03, 95% CI 0.92 – 1.16) but in death cause-specific models 
was associated with an increased risk for non-cardiovascular mortality (HR 1.25, 95% 
1.11 – 1.42) but not cardiovascular mortality (HR 0.87, 95% CI 0.71 – 1.07).
Conclusions: In this cohort, incremental dialysis was used infrequently and there was 
evidence of patient level differences which imply specific selection criteria are used in 
practice. Outcomes overall were similar, but cause specific mortality risks demonstrated 
increased non-cardiovascular mortality risks in the incremental cohort, likely reflecting the 
differences in patient characteristics. A prospective trial to test the safety and efficacy of 
incremental dialysis should be considered.
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Short Frequent Haemodialysis at Home and Loss of Residual Renal 
Function
Hannah K. Beckwith,1,2 Raja mohammed Kaja kamal,1 Roger N. Greenwood,1 
Ken Farrington,1,3 Enric Vilar.1,3 1Renal Department, Lister Hospital, Stevenage, 
United Kingdom; 2Imperial College London, London, United Kingdom; 
3University of Hertfordshire, Hertfordshire, United Kingdom.
Background: The importance of preserving residual renal function (RRF) in dialysis 
patients has long been recognised with benefits in survival, nutrition and biochemical 
parameters. Frequent nocturnal haemodialysis (FNH) may accelerate loss of RRF but 
effects of short frequent haemodialysis (SFHD) are less clear. We studied rate of loss of 
RRF in our cohort of home SFHD patients, comparing to matched thrice-weekly in-centre 
haemodialysis (ICHD) patients.
Methods: We identified 2 cohorts of patients at our centre both of whom had 
intermittent measures of residual renal urea clearance (KrU). The SFHD cohort comprised 
patients initiating SFHD at home between 2009-2017. A separate control historical cohort 
of ICHD patients was used of those commencing dialysis 1989-2009. Vintage from time 
of HD initiation was calculated for the SFHD cohort. Each patient was matched against 
3 patients in the ICHD control cohort for KrU (±0.5ml/min) at the equivalent vintage 
(±6 months). Only KrU data after SFHD initiation was used in the SFHD cohort, and from 
the equivalent vintage time in matched controls. We compared trajectories of KrU decline 
in both cohorts, correcting for potential confounding variables.
Results: 1073 patients were in the control cohort and 84 patients in the SFHD 
cohort. 24 patients on SFHD had ≥2 KrU measures following initiation but only 22 
patients could be matched with 66 control patients according to the above criteria. 
KrU at SFHD initiation was 2.3ml/min(IQR 1.3-5.4) in the SFHD group and 1.7(IQR 
1.0-4.9) in the control group,p=0.25. Patients in the SFHD group were younger than control 
patients at the equivalent vintage time (50±SD17 v 64±SD14 years,p<0.001). There was no 
significant difference in frequency of diabetes, cardiac disease, peripheral vascular disease 
or gender between SFHD and control ICHD patients. Slope of decline in kidney function 
was -0.8ml/min/yr(IQR -1.8 to 0.1) in the SFHD group and -0.5(IQR -1.2 to -0.1) in the 
ICHD control group(p=0.60). Using multiple linear regression to determine predictors of 
slope of decline in KrU, neither group (SFHD or ICHD) nor age or gender were independent 
predictors of KrU slope.
Conclusions: We did not find evidence that SFHD at home was associated with an 
increased rate of decline in RRF. Patients with RRF on home HD might benefit from SFHD 
rather than FNH, but this needs further exploration.
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Residual Renal Function Loss in Hemodialysis Patients: Is Kidney 
Stunning the Culprit and Can Dialysate Cooling Help?
Raanan Marants,1 Elena Qirjazi,1 Claire Grant,3 Ting Lee,1 
Christopher W. McIntyre.2 The Lilibeth Caberto Kidney Clinical Research Unit 
1University of Western Ontario, London, ON, Canada; 2London Health Sciences 
Centre, London, ON, Canada; 3University of Nottingham, Nottingham, 
United Kingdom.
Background: Residual renal function (RRF) declines in patients with ESRD after 
hemodialysis (HD) initiation, necessitating more aggressive fluid removal in subsequent 
sessions. It has been postulated that recurrent HD-induced renal ischemic insults lead to 
RRF decline, while dialysate cooling (DC), a feasible intervention which does not burden 
patient treatment, has been shown to ameliorate HD-induced circulatory stress in the heart 
and brain. The purpose of this work was to assess the effects of HD on renal hemodynamics 
using CT perfusion imaging and to explore DC as a protective intervention against renal 
intradialytic circulatory stress and RRF decline.
Methods: 26 patients provided written informed consent. All patients received standard 
(36.5°C) HD and a subgroup of 15 patients were randomized to receive either standard or 
cooled (35°C) HD first in a 2-visit crossover study design. For each visit, CT perfusion 
imaging was performed at three timepoints (before, 3 hrs into, and after HD) on a 256-slice 
CT scanner (GE Healthcare) without interrupting HD treatment. Parametric renal perfusion 
maps were generated and used to measure kidney blood flow.
Results: Renal perfusion loss (‘kidney stunning’) was observed in 63% (33/52) of 
kidneys during standard HD but declined to 50% of kidneys during cooled HD. The drop 
in renal perfusion at 3 hrs into HD was statistically significant (p<0.05) for the standard 
HD case but not for the cooled HD case. Figure 1 summarizes the per kidney perfusion 
measurements.
Conclusions: HD causes an acute drop in renal perfusion, and it may be these recurring 
ischemic insults over many sessions which result in irreversible renal tissue damage and 
RRF reduction. However, DC ameliorates these perfusion changes and may help slow RRF 
decline in HD patients.
Figure 1: Percent of baseline renal perfusion before, 3 hours into, and after HD. Results are 
given as average ± standard error of the mean for 26 patients (52 kidneys).
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Allo-Hemodialysis: Intermittent Donation of Kidney Function as a Novel 
Treatment for Patients with Kidney Failure in Limited Resource Settings
Peter Kotanko,1,2 Vaibhav Maheshwari,1 Stephan Thijssen.1 1Renal Research 
Institute, New York, NY; 2Icahn School of Medicine at Mount Sinai, New York, NY.
Background: A global report suggests that 2.2 to 7.1 million people might have died 
in 2010 prematurely because renal replacement therapy could not be accessed (Liyanage 
et al, Lancet, 2015); the authors noted the largest treatment gaps in low-income countries. 
Current hemodialysis (HD) is expensive and technically challenging. HD requires a 
substantial amount of water (300 to 1000 L of tap water per HD, depending on dialysate 
flow rate, treatment time, and reverse osmosis system rejection rate), a dialyzer, blood lines, 
and a sophisticated dialysis machine with pumps, heating, and ultrafiltration control systems 
to safely deliver HD, mostly in-centers. In our research, we systematically questioned long-
held paradigms and conceptualized a novel treatment option that may have the potential to 
increase access to HD and reduce the loss of human life owing to kidney failure.
Methods: We conceptually reduced HD to its essential components, the dialyzer, blood 
lines, a pump, and ultrafiltration control. While - as in traditional HD - on the dialyzer’s 
blood side the patient’s blood flows, the dialysate side is connected to the circulation of a 
healthy subject (“buddy”) and perfused with his/her blood (hence called alloHD). Because 
the “most physiologic dialysate i.e. physiosate” is provided by the buddy, the complexity 
of HD is substantially reduced. We employed extensive mathematical modeling to explore 
the feasibility of the alloHD.
Results: Our model simulations show that fluid and urea transferred into the buddy are 
cleared effectively by the buddy’s kidneys, while bicarbonate diffuse into the patient. We 
show that a child can sufficiently be treated by an adult buddy with 3-4 weekly treatments. 
We show that blood flow rates are a key factor, thus alloHD may require catheters or 
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permanent vascular access in buddy. We also address a host of ethical, societal, biological, 
and technical questions in our ongoing research.
Conclusions: While dialyzing one human against another may seem unthinkable at 
first, we challenge the kidney community to rethink pre-conceived notions and reflect on the 
proposed concept. Prototyping of an alloHD device is underway that may be used for bench 
testing and, ultimately, in vivo studies in animals and humans. We believe that alloHD holds 
promise to ease the human burden of kidney disease.
Funding: Commercial Support - Fresenius Medical Care
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Renal Survival in Patients with Multiple Myeloma Requiring Renal 
Replacement Therapy – A Single Centre Experience
Aruni Ratnayake, Mukunthan Srikantharajah, Simon C. Stern, 
David Makanjuola. Epsom and St Helier University Hospitals NHS Trust, 
London, United Kingdom.
Background: Renal impairment is a recognised complication of multiple myeloma 
(MM). The incidence of renal impairment at diagnosis of MM ranges between 20-50%; 
of these, approximately 10% present with acute kidney injury (AKI) requiring renal 
replacement therapy (RRT). Advances in MM treatments have improved overall patient 
survival and can result in complete or partial recovery of renal function. We reviewed 
outcomes of patients with MM requiring RRT over a 14 year period.
Methods: Patients diagnosed with MM requiring RRT between January 2003 and 
December 2017 were identified. Patient data was obtained from electronic records.
Results: 38 patients met the inclusion criteria. Median age was 62 years (range 
45-86); 53% were male, 76% were Caucasian. Median follow up time was 37 months
(range 6–168 months). 55% required RRT at presentation with a new diagnosis of MM.
Of the rest, 21% started RRT within a year of diagnosis and 24% started RRT >12 months 
after diagnosis. Additional factors contributing to initiating RRT included infection (21%), 
hypercalcaemia (13%) and fluid overload (10%). Median creatinine at start of RRT 
was 550μmol/l (range 235-1372μmol/l). 37% of all patients had a renal biopsy, which
identified cast nephropathy (43%), amyloidosis (43%), light chain deposition disease 
(7%), and other diagnoses (7%). 44% of patients requiring RRT at presentation recovered
sufficient renal function to stop RRT, with a median time to dialysis independence 
of 1 month (range 1 week - 21 months) and median eGFR 42 mls/minute (range 
12-78mls/minute). Only 6% of the cohort who required dialysis later (not at presentation)
recovered adequate renal function to stop dialysis. Overall 1 year survival was 93% (N=36), 
and 5 year survival was 48% (N=21). 47% of all patients had died by the end of 2017; of
these, 94% were dialysis-dependent at time of death, with a median time on dialysis of 1
year (range <1 week to 8 years).
Conclusions: In our cohort, more patients (55%) presented with AKI requiring RRT at 
the time of diagnosis of myeloma than in published literature (10% in Evison et al, British 
Journal of Haematology 2016); 44% of these patients became dialysis-independent. Our 
data demonstrates a positive correlation between recovery of renal function and reduced 
mortality, further reinforcing the importance of prompt treatment of myeloma.
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Effect of Hemofiltration on Anemia, Adequacy, and Bone Mineral Disease 
in Hemodialysis Patients
Mostafa A. Abdelkhalek,1,2 Tarek M. Demerdash,1,3 Mohammed M. Assem,1,3 
Muhammad Awais,1 Mahmoud M. Shaheen,1,3 Ayman Sabri,1 Hany A. Salama,1 
Ibrahim A. Jubran,1 Saad S. Alobaili,1 Wisam H. Al-Badr,1 
Abdulkareem Alsuwaida,1 Abdullah Kashgary.1,4 1DaVita-Saudi Arabia, Riyadh, 
Saudi Arabia; 2Mansoura University, Mansoura, Egypt; 3Cairo University, 
Cairo, Egypt; 4King Abdulaziz University, Jeddah, Saudi Arabia.
Background: Hemofiltration (HF) is not associated with lower mortality risk compared 
to standard hemodialysis (HD). However, there are many critical clinical outcomes in 
dialysis patients in addition to mortality; the impact of HF on these other outcomes is not 
clear.
Methods: This retrospective study included all patients referred to DaVita clinics 
in the Kingdom of Saudi Arabia. High-flux HD was the initial modality in all patients. 
Those who did not achieve adequacy targets or who had poorly controlled phosphorus were 
switched to post-dilution HF using 18-23L exchange per treatment. Patients dialyzing with 
a central venous catheter, patients who dialyzed less than 90 days at DaVita, and those with 
interrupted HF were excluded.
Results: Of the 1115 patients, 215 (19%) were on HF and 900 on high-flux HD; 
median follow-up was 6 months for all patients. The HF group showed a significant 
reduction in serum phosphate (p<0.001), a significant increase in serum calcium (p<0.012) 
and a significant improvement in Kt/V (p<0.0001). The HF group had significantly higher 
hemoglobin level than the HD group (p=0.024), with a significant reduction in weekly 
erythropoietin (ESA) dose after starting HF (p<0.001).
Conclusions: HF improved anemia, ESA dose, dialysis adequacy, and phosphate 
control in this retrospective analysis of a cohort selected for failure to meet Kt/V and 
phosphorus targets. Thus, HF can enable achievement of adequate dialysis care in some 
patients. Randomized-controlled clinical trials are necessary to confirm these findings.
Funding: Commercial Support - DaVita
Comparison of anemia, mineral bone disorder, and adequacy parameters before and after 
initiation of HF
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A Bi-National Cross-Sectional Survey of Clinician Attitudes Towards 
Haemodiafiltration in Australia and New Zealand
Emily J. See,2 James Hedley,3 John W. Agar,4 Carmel M. Hawley,1 
David W. Johnson,1 Vincent W. Lee,5 Kathy Mac,5 Kevan Polkinghorne,2 
Kannaiyan S. Rabindranath,6 Kamal Sud,7 Angela C. Webster.3 1Princess 
Alexandra Hospital, Greenslopes, QLD, Australia; 2Monash Health, Melbourne, 
VIC, Australia; 3University of Sydney, Camperdown, NSW, Australia; 4University 
Hospital Geelong, Geelong, VIC, Australia; 5Westmead Hospital, Westmead, 
NSW, Australia; 6Waikato Hospital, Hamilton, New Zealand; 7Nepean Hospital, 
Castle Hill, NSW, Australia.
Background: High convection volume hemodiafiltration may improve survival 
compared to high-flux hemodialysis, however there is significant variation in its use. 
Clinician attitudes towards hemodiafiltration are poorly understood but may explain 
differences in practice patterns.
Methods: A 17-question online survey was administered from February 2017 to January 
2018. Clinicians involved in the care of hemodialysis patients were invited to participate via 
the Australian and New Zealand Society of Nephrology. The survey addressed domains of 
clinician knowledge; hemodiafiltration prescription; perceived benefits, harms, and barriers 
to use; and indications and contraindications.
Results: Eighty-two responses were received from clinicians affiliated with 49 of 81 
hemodialysis units (60% unit response rate). Hemodiafiltration was prescribed by 87% 
of respondents, but generally to less than 25% of patients. The percentage of respondents 
prescribing hemodiafiltration to most of their patients was greater for those in privately 
funded (60%) than publicly funded units (28%). Only 26% of respondents considered 
the level of evidence supporting the superiority of hemodiafiltration over high-flux 
hemodialysis to be high. Its key benefits were perceived to be superior middle molecule 
clearance, hemodynamic stability, phosphate clearance, and amyloid prevention. Common 
indications included frequent intradialytic symptoms, intradialytic hypotension, and uremic 
polyneuropathy. Few respondents (14%) agreed hemodiafiltration conveyed harm to 
patients, however 25% considered frequent circuit clotting to be a relative contraindication. 
Although most respondents (63%) believed hemodiafiltration was more expensive than 
high-flux hemodialysis, this was not a barrier to its use. Three-quarters of respondents 
prescribed post-dilution hemodiafiltration, but only 55% targeted a convection volume 
greater than 20L.
Conclusions: Most clinicians in Australia and New Zealand prescribe hemodiafiltration, 
but generally to a small proportion of patients, and high convection volumes are not 
routinely targeted. Although no specific barriers to its use were identified, the majority of 
clinicians did not consider the level of evidence supporting its use to be high.
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Effect of Centre and Patient Related Factors on Uptake of Haemodiafil-
tration in Australia and New Zealand: A Cohort Study Using ANZDATA
Kathy Mac,1 James Hedley,3 Vincent W. Lee,2 John W. Agar,4 Carmel M. Hawley,5 
David W. Johnson,5 Emily J. See,5 Kevan Polkinghorne,7 
Kannaiyan S. Rabindranath,6 Kamal Sud,8 Angela C. Webster.3 1Centre for 
Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia; 
2Westmead Hospital, Westmead, NSW, Australia; 3University of Sydney, 
Camperdown, NSW, Australia; 4University Hospital Geelong, Geelong, VIC, 
Australia; 5Princess Alexandra Hospital, Brisbane, QLD, Australia; 6Waikato 
Hospital, Hamilton, New Zealand; 7Monash Medical Centre and Monash 
University, Melbourne, VIC, Australia; 8Nepean Hospital, Castle Hill, NSW, 
Australia.
Background: We described the use of haemodiafiltration (HDF) in Australia and New 
Zealand over time, and any patient or centre-related associations with use of HDF.
Methods: We included all incident patients commencing haemodialysis in Australia 
and New Zealand between 2000-2014. The primary outcome was commencement of HDF 
over time, which was evaluated using multivariable logistic regression stratified by country.
Results: Of 27,433 patients starting haemodialysis, 3,339 (14.4%) of 23,194 patients 
in Australia and 810 (19.1%) of 4,239 in New Zealand received HDF. Uptake increased 
over time in both countries but was more rapid in New Zealand. In Australia, HDF use 
was more likely in males (OR 1.13, 95%CI 1.03-1.24, p=0.009) with BMI>30 kg/m2(OR 
1.46, 95%CI 1.33-1.61), and less likely in older patients (reference <40 years; 40-54 years 
OR 0.85, 95% confidence interval [CI] 0.72-0.99; 55-69 years OR 0.79, 95% CI 0.67-
0.91; >70 years OR 0.48, 95% CI 0.41-0.56) and those with chronic lung disease (OR 
0.84, 95%CI 0.76-0.94, p<0.001), cerebrovascular disease (OR 0.76, 95%CI 0.67-0.85, 
p<0.001) or peripheral vascular disease (OR 0.77, 95%CI 0.70-0.85, p<0.001). Larger 
centres (defined by number of new patients/year) were more likely to prescribe 
HDF: 36-147/year OR 26.75 (95%CI 18.54-38.59); 17-35/year OR 7.51 (95%CI 
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5.35-10.55); 7-16/year OR 3.00 (95%CI 2.19-4.13; <6/year reference. HDF was used more 
in private dialysis clinics (public OR 0.13, 95%CI 0.05-0.32). In New Zealand, where there 
is no private dialysis, HDF use was more likely in Maori and Pacific Islanders (OR 1.32, 
95%CI 1.05 – 1.66) compared to Caucasians and less likely in males (OR 0.76, 95%CI 
0.62 – 0.94, p=0.01). In both countries, centres with higher HD:PD patient ratios were 
significantly more likely to prescribe HDF. Centre differences explained 36% of variability 
in HDF uptake in Australia and 48% in New Zealand.
Conclusions: HDF uptake has increased over time, and was associated with similar 
centre characteristics, but different patient characteristics in each country.
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The Effect of Frequent Hemodialysis on Phosphate and Fibroblast 
Growth Factor 23: Results from the Frequent Hemodialysis Network 
Trials
Christopher T. Chan,1 George A. Kaysen,5 Gerald J. Beck,4 Michael V. Rocco,2 
Alan S. Kliger.3 FHN Trials Group 1Toronto General Hospital, Toronto, ON, 
Canada; 2Wake Forest School of Medicine, Winston-Salem, NC; 3Yale New 
Haven Health System, New Haven, CT; 4Cleveland Clinic Foundation, 
Cleveland, OH; 5Medicine, UC Davis, Sacramento, CA.
Background: Hyperphosphatemia is associated with elevations in fibroblast growth 
factor 23 (FGF23) and blood pressure in patients with end-stage kidney disease (ESKD). 
We aimed to ascertain whether reduction in phosphate by frequent hemodialysis is 
associated with specific changes in biomarker profile amongst patients enrolled in the 
Frequent Hemodialysis Network (FHN) trials.
Methods: This was a post hoc observational cohort study. We hypothesized that reduction 
in phosphate is associated with changes in FGF23. We further hypothesized that changes in 
FGF23 may correlate with variations in blood pressure and markers of collagen turnover.
Results: Among 332 randomized patients, 243 had biomarker data available. 
Of these, 124 were assigned 3 times a week hemodialysis (94 [Daily Trial] and 30 
[Nocturnal Trial]) and 119 patients were assigned to 6 times a week hemodialysis (87 
[Daily Trial] and 32 [Nocturnal Trial]). Frequent hemodialysis lowered phosphate, blood 
pressures, logFGF23 and tissue inhibitors of metalloproteinase (TIMP) - 2 levels. The fall 
in phosphate correlated to the changes in FGF23 (r = 0.48, p <0.001 [Daily Trial] and 
r = 0.55, p < 0.001 [Nocturnal Trial]) and trended with changes in systolic blood pressure (r 
= 0.18, p = 0.057 [Daily Trial] and (r = 0.31, p = 0.04) [Nocturnal Trial].
Conclusions: Reduction of serum phosphate by frequent hemodialysis may modulate 
FGF23 levels and systolic blood pressure. Frequent hemodialysis may affect pathological 
mediators of chronic kidney disease – mineral bone-metabolism disorder.
Funding: NIDDK Support
Effect (95% CI) of hemodialysis frequency on phosphate, blood pressure and selected 
biomarkers
* denotes p < 0.05 (within group); # p =0.052 (within group); **expressed as percent
difference based on log transformed analysis
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Comparison of the Removal of Uremic Toxins with Medium Cut-Off and 
High-Flux Dialyzers: A Randomized Clinical Trial
Mohamed Belmouaz, Marc Bauwens, Iseline Bouteau, Antoine Thierry, 
Laure Ecotiere, Frank Bridoux. Nephrology, CHU POITIERS, Poitiers, France.
Background: Accumulation of middle weight toxins (500 Da-60 kDa) in hemodialysis 
(HD) patients results in increased morbidity and mortality. Conventional high-flux (HF) 
dialyzers allow efficient removal of beta2 microglobulin (11.8 kDa), but their effect on 
higher molecular weight molecules is not well established. Whether new generation of 
medium cut-off (MCO) dialyzer improve removal of middle to high molecular weight 
uremic toxins remains to be demonstrated.
Methods: Theranova, a randomized, open-label, cross-over study (NCT03211676) 
was designed to compare MCO-HD to HF-HD on the epuration of middle weight uremic 
toxins. Forty six patients treated with HF dialyzer Elisio 21H™ for more than 6 months 
were randomized to either continue on this membrane (n=22) or to receive the Theranova 
500™ dialyzer (n=24). After 3 months, patients crossed over to the other dialyzer during 
3 other months. Primary outcome was myoglobin (17 kDa) reduction ratio (RR) at 3 
months. Secondary outcomes were RR, pre and post dialysis levels of beta2 microglobulin, 
prolactin, hepcidin, leptin, retinol binding protein, alpha 1 glycoprotein, fibroblast growth 
factor-23, hyaluronic acid, homocystein and cytokines (IL6, IL1-beta, TNF-alpha) at 3 and 
6 months. Nutritional and inflammatory parameters, level of albumin and oxidative stress 
mediators (8-iso-Prostaglandin, oxidized LDL, superoxide dismutase), anemia parameters 
and erythropoietin resistance index were also determined.
Results: Forty patients completed the study. Mean age was 76 ± 9 years (male gender 
74%). MCO-HD provides higher median RR of myoglobin [59% vs 36%, p<0.0001] 
whereas beta2 microglobulin RR was similar [77% vs 69%, p=0.7], as compared to HF-
HD. Mean pre-dialysis beta2 microglobulin levels [26.9 mg/l vs 28.4 mg/l, p =0.001] and 
post dialysis myoglobin levels [76 μg/l vs 126 μg/l, p<0.0001] were significantly lower with 
MCO-HD. Pre and post dialysis albumin levels were significantly lower with MCO-HD 
[36.9 g/l vs 38.2 g/l, p=0.004] and [40 g/l vs 42.3 g/l, p=0.004].
Conclusions: These preliminary data indicate that MCO-HD provides significant 
removal of myoglobin and decrease in beta2 microglobulin pre dialysis level, with higher 
albumin loss than HF-HD. Complete results will be presented during the meeting.
Funding: Commercial Support - BAXTER
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Six Months Evaluation of the Expanded Hemodialysis (Hdx) on Removal 
Efficiency, Anemia, and Quality of Life
Giuseppe Gernone. ASL BA - “S. Maria degli Angeli” Hospital - Putignano 
(Bari) - Italy, Putignano, Italy.
Background: The High-Flux (HF) dialysers in standard-hemodialysis (HD) allow 
the removal of a wider spectrum of uremic toxin. However the HD can remove mostly 
low molecular weight solutes while the HDF can remove solutes around 15kDa, so-called 
Middle Molecules (MM), improving morbidity and mortality by exchange volumes >15L 
per session. The new medium cut-off (MCO) filter Theranova® is designed to expand 
the removal of toxins up to 45kDa in HD compared to HF membranes (HemoDialysis 
eXpanded, HDx) even with conventional blood flows and without exchange fluid infusion. 
The aim of this study is to evaluate the performance of HDx and its impact on anemia and 
quality of life (QoL) in hemodialysis patients (pts).
Methods: 13 stable HD pts were enrolled (M/F 10/3, age 70.8±9) with Qb ≤300 ml/
min in a six months’ observational case-control study. Each patient was evaluated first 
with HF filter (T0) and then in HDx for six months. Pre-dialysis (T0-T6) were evaluated: 
urea, phosphate (P), beta2-microglobulin (B2m), myoglobin (Myo), free light-chains 
K and λ (FLC-K and FLC-λ), C-Reactive Protein (CRP), hemoglobin (Hb) and albumin. 
Furthermore Kt/V, dose of EPO, ERI and SF-36 questionnaire were evaluated at the 
beginning and end of observation. We treat hemodialysis pts according to the KDIGO 
Guideline for Anemia in CKD. The values have been reported as mean±SD.
Results: HDx (Qb= 275 ± 41 ml/min, TT 215 ± 21 m) shows a significant increase 
in KT/V (T0 1,31 ± 0,23; T6 1,55 ± 0,17; p= 0.001) with relevant RR of: Urea 69%; P 
56%; B2m 63%; Myo 55%; FLC-k 61%; FLC-λ 59%. There is a significant reduction at 
6 months for FLC-λ (Tab.1). HDx reduced ERI (T0 9.8 ± 10.5; T6 4.4 ± 5.5; p <0.05) 
and EPO dose (T0 7692 ± 8518; T6 3615 ± 4464, p <0.05), keeping the Hb unchanged. 
QoL is significantly improved (ISF: T0 27.3 ± 10.1; T6 40.2 ± 8.4 p= 0.0001) (ISM: 
T0 43.8 ± 14.2; T6 51.1 ± 9.8 p= 0.001).
Conclusions: HDx effectively removes uremic toxins up to 45kDa, even with Qb 
<300 ml/min, without reducing serum albumin and with promising results on inflammation. 
Reduction of ERI and improvement of QoL are encouraging and suggest the use of HDx 
even in pts who cannot benefit from convective techniques because of vascular access or 
intolerance to high volumes of exchange.
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Middle Molecules Elimination in Expanded Hemodialysis: Only 
Convective Transport?
Nicolás Macías,1 Almudena Vega,1 Soraya Abad,1 Ana M. Garcia Prieto,1 
Esther Torres aguilera,1 Alba Santos,4 Ines Aragoncillo,3 Jose Luno.2 1Hospital 
Gregorio Marañón., Madrid, Spain; 2Hospital General Universitario Gregorio 
Marañón, Madrid, Spain; 3Hospital Gregorio Marañón, Madrid, Spain; 
4Gregorio Mara?on Hospital, Madrid, Spain.
Background: Hemodialysis using high flux membranes leads to convective transport 
by internal filtration(IF) [Direct Filtration(DF)/Backfiltration(BF)] and allows middle 
molecules(MM) elimination. The development of High Retention Onset dialyzers has 
achieved greater elimination of MM and their depurative capacity could be similar to high 
convective volumes of online hemodiafiltration. The aim of the study was to assess solute 
transport mechanisms in expanded hemodialysis(HDx) with Theranova 500(Baxter).
Methods: We analyzed fourteen HDx sessions with similar dialysis conditions: 
blood flow 400 ml/min, dialysate flow 700 ml/min, dialysate temperature 35.5C and 240 
minutes length. Pressures at the inlet and the output of both dialyzer compartments(Pbi, Pbo, 
Pdi, Pdo) were collected hourly with DBB-EXA monitor(Nikkiso) to estimate convective 
volume(CV) using different semi-empirical methods previously used to model IF. Blood 
viscosity data and uremic toxins with various molecular weight were measured pre-dialysis, 
at 1 hour(pre-filter and post-filter) and post-dialysis to calculate molecules reduction over 
time and dialyzer in vivo clearances.
Results: Ultrafiltration was 1.47±0.9 L and Kt/V 1.74±0.3. Hydrodynamic data 
(average Pbi:259±39, Pbo:155±27, Pdi:271±30, Pdo:145±29 mmHg, monitor TMP 1.8±4 
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mmHg, oncotic pressure 20,8±3,4 mmHg, blood viscosity 1,51±0,10 cP) allowed 
to estimate DF and BF rates and volumes. Models showed a DF flow range from 
18.2±4.5 to 29.8±3.1 ml/min and BF flow range from 16.8±1.8 to 26.6±2.3 ml/min. 
The highest calculated CV was 7160.2±738.9 ml/session. Global, convective and diffusive 
clearances and molecules RR are summarized in Table. CV was correlated with urea(r:-
0.785,p=0.001), creatinine(r:-0.675,p=0.008) and myoglobin(r:0.587,p=0.027) clearances.
Conclusions: Results suggest that diffusive transport is a main mechanism of middle 
molecules elimination in HDx with Theranova 500. HDx offers a potential advantage 
achieving efficient depuration of middle molecules without the need for high convective 
transport volumes.
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Higher In Vivo β2 Microglobulin Clearance in Expanded Hemodialysis: 
Preliminary Results of a Cross-Over Trial
Isis S. Cordeiro, Benedito J. Pereira, Marcelo D. Silveira, Lilian Cordeiro, 
Hugo Abensur, Rosilene M. Elias, Bruno C. Silva. Renal Division, University of 
São Paulo, São Paulo, Brazil.
Background: In conventional hemodialysis (HD), β2 microglobulin (β2M), a medium-
range molecule (MRM), tend to accumulate in tissues. Online hemodiafiltration (olHDF) 
increases MRM clearance at expense of more complex dialysis machines. The development 
of medium cut-off with high albumin retention onset membranes allowed a new therapy, 
known as expanded hemodialysis (HDx). However, so far, in vivo extraction of MRM in 
this modality is unknown.
Methods: Prospective trial, in which 8 patients switched from HD to olHDF or HDx 
for 1 month, and then crossed to the other modality for another month, after a washout 
period of 2 weeks. Pre- and post-dialysis urea, albumin, phosphorus, and β2M were 
measured in blood and in a sample of homogeneously collected spent dialysate, throughout 
dialysis procedure. High-flux Diacap™ dialyzers (BBraun, Germany) were used both in 
HD and in olHDF, while Theranova 400™ dialyzers (Gambro, Germany) in HDx. Ongoing 
trial is registered at NCT03274518.
Results: Mean age was 48 ± 13 years (75% men), and dialysis duration was 
225 ± 12 minutes. Total convection volume in olHDF was 20.3 ± 1.1L. β2M clearance was 
higher in HDx in comparison to high-flux HD and olHDF (62.2 ± 10.2 vs. 36.5 ± 2.6, p = 
0.012 and 45.5 ± 18.3 ml/min, p = 0.026 respectively). β2M extraction during dialysis was 
higher in HDx in comparison to olHDF (196.4 ± 31.3 vs. 122.1 ± 43.8 mg, p=0.023). Pre-
dialysis serum β2M was not different among the three modalities.
Conclusions: Preliminary results of this trial indicate that in vivo clearance and total 
mass extraction of β2M is higher in HDx in comparison to olHDF.
Laboratorial data from patients, according to dialysis modality
* HD vs HDx; † olHDF vs HDx
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Medium-Range Molecule Extraction and Intradialytic Hemodynamics: 
Comparison of Two Convective Dialysis Methods
Isis S. Cordeiro, Marina Romagnoli, Rodrigo S. Adao, Telma Dos santos, 
Mariana H. de Mendonça, Edilene M. Santos, Bruno C. Silva. Renal Division, 
University of São Paulo, São Paulo, Brazil.
Background: Online hemodiafiltration (olHDF) improves intradialytic hemodynamic 
(IH) stability in comparison to hemodialysis (HD), possibly by lowering dialysate 
temperature (DT) and increasing medium-range molecule extraction. Using medium cut-
off dialyzers in HD machines (HDx) might exert similar effects on IH.
Methods: Prospective trial, in which 8 patients switched from olHDF to HDx. DT 
was set to 36 °C. Pre-dialysis Beta2 microglobulin (β2M) was measured both in blood and 
spent dialysate. IH was assessed by Finometer™ during the first and the last 15 minutes 
of each dialysis session. High-flux Diacap™ dialyzers (BBraun) were used in olHDF, and 
Theranova 400™ (Gambro) in HDx.
Results: Total convection volume in olHDF was 20.3±1.1L. Post minus pre dialysis 
variation of systolic blood pressure (ΔSBP), diastolic blood pressure (ΔDBP), stroke 
volume (ΔSV), cardiac output (ΔCO) and peripheral arterial resistance (ΔPAR) were similar 
between olHDF and HDx. Positive ΔPAR, indicating increased post-dialysis vascular tonus, 
was observed both in olHDF and HDx (table), yet correlation between ΔPAR and β2M 
extraction was observed in HDx (r=0.785, p=0.021), but not in olHDF (r=-0.096, p=0.85).
Conclusions: At a same DT, olHDF and HDx led to similar IH stability. β2M extraction 
was associated with increased intradialytic PAR only in HDx.
Study data, according to dialysis modality
Correlation: β2M extraction vs ΔPAR
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Trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin 
and Light Chains in Hemodialysis Patients (REMOVAL-HD): A Safety 
and Efficacy Study
Rathika Krishnasamy,1 Colin A. Hutchison.1,2 on behalf of the REMOVAL-HD 
investigators 1Australasian Kidney Trials Network, The University of 
Queensland, Brisbane, QLD, Australia; 2Department of Medicine, Hawke’s Bay 
District Health Board, Hawke’s Bay Hospital, Hawkes Bay, New Zealand.
Background: A medium cut-off (MCO) dialyzer is a novel form of hemodialysis (HD) 
therapy designed to increase clearances of larger middle molecules and uremic toxins but 
may result in short-term loss of albumin. The safety and efficacy profile following sustained 
use of this dialyzer has not been established.
Methods: REMOVAL-HD is an investigator led, single-arm, multi-center device 
study that examined the safety, efficacy and patient-centered outcomes of MCO dialyzer 
use in chronic HD patients over 6 months. The primary outcome was change in serum 
albumin between baseline and 6 months. Secondary outcomes included 4-weekly trends 
in serum albumin, six-minute walk test (6MWT), malnutrition inflammation score (MIS) 
and symptom burden using restless leg syndrome rating scale and Edmonton Symptom 
Assessment System Revised (ESAS-R) measured at baseline, 3 and 6 months.
Results: Of 92 enrolled participants, 87 completed the required protocol and were 
included for analysis. Participants had a mean age of 67± 15 years, 63% were men and 
51% were diabetic. The average serum albumin decreased by 1.06 g/L (95% confidence 
interval [CI] 0.43,1.69], or 2.92%, from baseline. The trend in serum albumin during the 
intervention period is shown in Figure 1. A sustained, unexplained reduction in serum 
albumin (>25%) was not observed in any participant. Functional and nutritional assessment 
using 6MWT (Δ5.7m 95% CI -29.9, 41.3) and MIS (Δ-0.4 95%CI -0.9, 0.1) were stable 
throughout the treatment period. Similarly, there was no significant change in patient-
reported symptom burden.
Conclusions: Regular HD using the MCO dialyzer in a chronic HD population resulted 
in a small but acceptable reduction in serum albumin. Future randomised controlled trials 
should now assess the impact of the MCO dialyzer on clinical and long-term patient-
centered outcomes.
Funding: Commercial Support - Baxter : Investigator Initiated Research (IIR) Grant
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Trend in serum albumin under MCO dialyzer use
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Increasing the Removal of Protein-Bound Uremic Toxins by 
Hemolipodialysis
Yuanyuan Shi, Yifeng Wang, Qiuyu Zhu, Feng Ding. Shanghai Ninth People?s 
Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Background: Protein-bound uremic toxins (PBUTs) accumulate at high plasma 
levels and cause various deleterious effects in ESRD patients because their removal by 
conventional hemodialysis (HD) is severely limited by their low free-fraction levels in 
plasma. Here, we assessed the extent to which solute removal can be increased by adding 
liposomes to the dialysate.
Methods: A reservoir that contained PBUTs and artificial plasma was used for 
determinating the adsorption capacity of liposomes for p-cresyl sulfate (PCS), indoxyl 
sulfate (IS) and hippuric acid (HA). The effect of adding liposomes to the dialysate was 
then quantified and compared with the effect of adding bovine serum albumin (BSA) to 
the dialysate and dialysate without addition of any sorbent in a rapid equilibrium dialysis 
(RED) setup and an in vitro closed HD model respectively. Finally, male Sprague-Dawley 
rats were subjected to 5/6 nephrectomy and fed for 20 weeks to establish the end stage renal 
failure. They received HD for 240 min at a blood and dialysate flow rate of 1.0 and 5.0 mL/
min, respectively. Removal of solutes was determined by reduction ratios (RRs) and total 
solute removal (TSR) in dialysate.
Results: The uptake of liposomes by direct incubation in vitro showed an obvious 
dose-response relationship for PCS and IS but not for HA. The percent removal of both 
PCS and IS but not of HA was gradually increased with the increased concentration of 
liposomes in the RED setup. In vitro closed HD circulation showed that adding liposomes 
to the dialysate markedly increased the clearance of PBUTs without greatly altering that 
of urea and creatinine. The difference was more noticeable for strongly albumin bound 
compounds. In vivo experiments in uremic rats demonstrated that adding liposomes to the 
dialysate resulted in higher reduction ratios (RRs) and more total solute removal (TSR) for 
several PBUTs compared to the conventional dialysate, which was approximately similar 
to the addition of BSA to the dialysate. There were no significant differences in RRs and 
TSR of blood urea nitrogen and creatinine with addition of liposomes or BSA to dialysate 
compared to conventional dialysis.
Conclusions: As an adjunct to conventional hemodialysis, adding liposomes to the 
conventional dialysate may significantly improve the removal of protein-bound uremic 
solutes without greatly altering the removal of small, water-soluble solutes.
Funding: Government Support - Non-U.S.
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Bias Between In Vitro and In Vivo Mass-Transfer Coefficient of Urea 
(KoA) Is Larger in Pediatric Than in Adult Patients on Chronic 
Hemodialysis
Verena Gotta,1 Olivera Marsenic Couloures,2 Marc Pfister.3 1University of Basel 
Children’s Hospital, Basel, Switzerland; 2Yale University, New Haven, CT; 
3University of Basel Children’s Hospital, Basel, Switzerland, Hilterfingen, 
Switzerland.
Background: Hemodialysis (HD) prescription with respect to blood flow (QB) 
dialysate flow (QD) and filter KoA significantly differs between pediatric and adult patients. 
This may explain why urea dialytic clearance (KD) has been observed to be significantly 
underpredicted from QB, QD and KoA in pediatric HD patients using a mechanistic equation. 
The objective of this analysis was to evaluate factors that could explain this bias, assuming 
that it results from a bias between reported in vitro determined KoA and actual in vivo KoA.
Methods: An urea kinetic model previously developed in adult patients was scaled 
to 923 paediatric and young adult patients aged 1-29 years based on a priori physiologic 
knowledge (inter-compartmental clearance and volumes of distribution; “base model”). 
Utilizing data from 2676 HD sessions of those patients with pre- and post-HD urea 
concentration measurements, a mixed effect modelling approach was applied to evaluate 
the relationship between individual estimates of KoA correction factors (fKoA) required 
for unbiased prediction of KD (as indicated by unbiased post-HD urea predictions), and 
prescription related parameters (QB, QD, QD/QB ratio, filter reuse, low/high-flux, ultra-
filtration rate, duration of treatment).
Results: QD/QB ratio was the parameter most strongly associated with individual 
estimates of fKoA (≈ -10%, 10%, 100% and 200% increased in vivo KoA estimated at 
QD/QB ratios of 1.5, 2, 5, and 10, respectively; p<0.001), explaining 18% of inter-individual 
variability (decrease from 42.8 to 35.1%). Inclusion of QD/QB ratio as a covariate removed 
bias observed with QB and QD. A proposed correction equation for QB (true QB lower than 
nominal QB at rates >200 mL/min) also corrected bias observed at QB > 300 mL/min, but 
did not reduce inter-individual variability. Inclusion of session duration, low-flux filters, 
and ultra-filtration rate did further improve the model fit, however with small reductions in 
inter-individual variability.
Conclusions: While in vivo KoA has been reported to be lower in adult patients than 
established in vitro, the opposite was observed for pediatric patients in the present study. 
The observed bias could best be explained by high QD/QB ratios used in pediatric patients 
indicating that dialyzers require specific characterization under pediatric conditions.
Funding: Private Foundation Support
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Intracellular ATP and Inorganic Phosphate Depletion During  
Maintenance Hemodialysis
Guillaume Chazot,1 Sandrine Lemoine,1 Gabriel Kocevar,2 Emilie Kalbacher,1 
Gabrielle L. Normand,1 Dominique Sappey-Marinier,3 Olivier Rouviere,4 
Laurent Juillard.3,1 1Nephrology and Renal Functional Explorations, Hôpital 
Edouard Herriot, Hospices Civils de Lyon, Lyon, France; 2CREATIS (UMR 
5220 CNRS & U 1044 INSERM), Université Claude Bernard Lyon 1, France, 
Villeurbanne, France; 3University of Lyon, Lyon, France; 4Hospices Civils de 
Lyon, Department of Urinary and Vascular Imaging, Hôpital E. Herriot, Lyon, 
France; Université de Lyon, Lyon, France; Université Ly, Lyon, France.
Background: The origin of depurated phosphate during hemodialysis (HD) remains 
unknown. Using phosphorus magnetic resonance spectroscopy (31P-MRS), we previously 
showed in an acute kidney failure model in pig, an increase of intracellular inorganic 
phosphate (Pi) concentration during hemodialysis associated with a decrease in ATP. This 
result strongly supports the hypothesis that depurated phosphate could come from the 
intracellular space. The aim of this study was to measure intracellular Pi in patients during 
maintenance HD using 31P-MRS.
Methods: Eleven maintenance HD patients were included in the CIPHEMO 
(Intracellular ATP and Pi Concentrations measurements in HEMOdialysis patients) study, 
a single-center prospective trial. They underwent a 31P-MRS exam using a 3-Tesla system 
and a surface coil placed over the calf muscle region for measuring Pi and ATP contents 
during a standard hemodialysis session (4 hours). 31P-MR spectra were acquired before, 
during (every 152 seconds) and after the HD session. Phosphatemia, depurated phosphate 
and calcemia were monitored during HD and parathyroid hormone levels were measured at 
the beginning and at the end of the session. Calcium balance was also measured.
Results: Intracellular Pi and βATP kinetics can be described in 2 phases. During the 
first hour of HD, phosphatemia decreased rapidly (-41%, p<0.001) whereas intracellular 
Pi didn’t change (p=0.9) and intracellular βATP decreased (-17%, p=0.038). After 1 hour 
of HD, phosphatemia decreased slowly, intracellular Pi decreased (p=0.001) and βATP 
remained constant until the end of the session (p=0.46). Depurated phosphate is nearly 
constant during the session. Calcemia increased (p<0.01) and parathyroid hormone 
decreased (p<0.05) during HD. Calcium balance is positive (mean of 17.1 mmol).
Conclusions: This study showed a significant decrease in both intracellular ATP and Pi 
during hemodialysis. These findings, reported for the first time in HD patients, support the 
hypothesis that a large part of depurated phosphate could come from the intracellular space 
in patients on maintenance hemodialysis.
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Removal of Large-Middle Molecules on Expanded Hemodialysis (HDx): A 
Multicentric Observational Study of 6 Months Follow-Up
Vincenzo Cantaluppi,1 Gabriele Donati,2 Antonio Lacquaniti,3 Francesco Cosa,4 
Giuseppe Gernone,5 Marita Marengo,6 Ugo Teatini.7,8 1University of Piemonte 
Orientale (UPO), Novara, Italy; 2Azienda Ospedaliero-Universitaria di 
Bologna, Bologna, Italy; 3Papardo Hospital, Messina, Italy; 4Ospedale Civile 
Di Legnano, Taranto, Italy; 5ASL BA - “S. Maria degli Angeli” Hospital - 
Putignano (Bari) - Italy, Putignano, Italy; 6S.C. Nefrologia e Dialisi, ASLCNI, 
Savigliano, Italy; 7ASST Rhodense, Milano, Italy; 8ASST Rhodense, 
Milano, Italy.
Background: HemoDialysis expanded (HDx) may potentially represent an innovative 
way to remove uremic toxins of Large-Medium Molecular weight (LMMs, ≤45 Kda) 
thanks to the membrane medium cut-off (MCO, Theranova®, Baxter). LMMs are involved 
in the pathogenic mechanisms of organ dysfunction associated with uremia including 
inflammation, malnutrition and atherosclerosis. The aim of this study was to evaluate the 
efficacy of LMMs removal in HDx during an observational multicentric study of 6 months 
follow-up.
Methods: 41 HD stable patients (age 67,6±13,4) were dialyzed in HDx with 
Theranova® 400 (1.7 m2). Each patient was evaluated at baseline with standard HD (T0), 3 
months (T3) and 6 months (T6) after HDx. In the first session of the week (for each period), 
we evaluated the following pre-dialysis parameters: Urea, Creatinine (Creat), Phosphate 
(P), Beta2-microglobulin (B2m), Myoglobin (Myo), Free Light Chains (FLC-k, FLC-λ), 
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Hemoglobin (Hb), Albumin and C Reactive Protein (CRP). Data are reported as mean ± 
standard deviation (SD).
Results: HDx therapy was well tolerated without evidence of major adverse side effects. 
The main results of the study are summarized in Figure 1. After 3 months of HDx (T3), we 
observed a significant decrease of pre-dialysis levels of urea (p=0,008), B2m (p=0,003), 
FLC-k (p=0,026), FLC-λ (p=0,001). No significant differences of the other uremic toxins 
between the periods (T3 vs. T6) were observed. Albumin levels remained stable during all 
the study period. A significant decrease of CRP was observed at T3 and T6, suggesting a 
positive effect of HDx on inflammatory parameters correlated with a worse outcome.
Conclusions: HDx therapy provided high removal of different LMMs, leading to a 
significant reduction of molecules involved in uremia-associated organ dysfunction in the 
first 3 months of treatment (T0-T3). Long-term studies with a larger sample size are needed 
to evaluate the clinical impact of HDx. However, our preliminary data suggest that HDx 
may improve LMMs removal and inflammatory parameters.
Figure 1: Pre-dialysis levels of different uremic toxins at study start (T0) and after 3 (T3) 
and 6 (T6) months of HDx.
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Comparison Between Online Clearance Monitoring (OCM) and 
Calculated kt/V in Adult Population on Hemodialysis
Sidra Saleem, Haris Naveed, Asad Mahmood, Zain Rasool, Abeera Mansur. 
DHMC, Lahore, Pakistan.
Background: Morbidity and mortality in hemodialysis patients is closely correlated to 
the delivered dialysis dose. The delivered dose is measured in maintenance hemodialysis 
patients either by blood samples to calculate Kt/V single pool or by measuring the ionic 
dialysance in real time using OCM. The aim of this study was to compare the quality 
of dialysis delivered by calculated kt/V obtained with the formula of lowrie(L) and 
Daugridas(D) with the results measured by Online Clearance Monitoring(OCM).
Methods: Using Fresenius 4008S machines equipped with OCM, we prospectively 
studied 42 hemodialysis patients from February 1, 2018 to April 30, 2018. All patients 
were on hemodialysis for more than three months. Pre and post dialysis urea samples were 
collected for estimation of Single pool Kt/V and compared with OCM. Patient information 
was collected and all data analysed using SPSS for windows software package.
Results: The average age of the patients was 56.07 ±13.89 years and the mean duration 
of dialysis was 28.34 ±34.95 months. Mean blood flow rate was 307.67 ±45.87 mL/min. 
The mean Kt/V was 1.499 ±0.222 (p=0.000) and the mean OCM was 1.465 ±0.190 
(p=0.000). We found a positive correlation between the two parameters i.e a Pearson’s 
Correlation: 0.83 (p=0.000) and an R square value of 0.645. We found that OCM is a good 
indicator of Kt/V. However, it underestimated Kt/V by 2.07%±8.53%.
Conclusions: Online Kt/V calculated by ionic dialysance is a useful method to estimate 
dialysis dose without the need of blood samples, however it slightly underestimates Kt/V. 
In clinical practice Kt/V is done on a monthly basis. Any change in the dialysis prescription 
would entail repeat labs. OCM can be performed at each dialysis session at no extra cost and 
in real time. Thus, it can prove to be a helpful tool in the assessment of dialysis adequacy.
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Comparison of Removal Efficiency and Biocompatibility Between 
Pre- and Post-Dilution On-line Hemodiafiltration
Kenji Sakurai,1 Takeshi Saito,1 Hiromi Hosoya,1 Yoshitaka Kurihara,1 
Daisuke Ishii,2 Kazunari Yoshida,3 Kenichi Kokubo,4 Toru Hyodo.5 1Hashimoto 
Clinic, Sagamihara, Japan; 2Kitasato University Hospital, Sagamihara 
Kanagawa, Japan; 3Department of Urology Kitasato University School of 
Medicine, Sagamihara, Japan; 4Kitasato University School of Allied Health 
Sciences, Sagamihara, Japan; 5Eijin Clinic and Cambodian Association of 
Nephrology, Hiratsuka, Japan.
Background: In Japan in late-2016, 329,609 patients received dialysis, 24.2% of whom 
received hemodiafiltration (HDF). In 79% of HDF, the on-line mode is used, which is mostly 
performed with the pre-dilution mode (pre-HDF). However, in Europe, all HDF sessions use 
the post-dilution mode (post-HDF). We previously assessed differences in biocompatibility 
between pre- and post-HDF based on inflammatory markers and lymphocyte stimulation tests, 
and reported that pre-HDF is less physically stressful. Here, we used a more biocompatible 
hemodiafilter to study whether biocompatibility would differ between pre- and post-HDF, 
and assessed the solute removal efficiency of both modes.
Methods: Eight stable dialysis patients were included in this study. HDF was 
performed with Fineflux 210S eco (asymmetric triacetate membrane, NIPRO) at a blood 
flow rate of 250 mL/min and a total dialysate flow rate of 500 mL/min for 4 h/session. The 
substitution fluid volumes were 60 and 12 L/session for pre- and post-HDF, respectively. To 
test removal efficiency, urea, creatinine, b2-microglobulin (MG) (MW:11.8kDa) and a1-MG 
(MW:33kDa) levels were measured to determine the reduction rates. Albumin (Alb) leakage 
was also measured. To test biocompatibility, hs CRP, interleukin (IL)-6, tumor necrosis 
factor (TNF)-a, pentraxin (PTX)-3, intercellular adhesion molecule (ICAM)-1, and cluster 
of differentiation 62 platelet (CD62P; a platelet cell surface marker) levels were measured.
Results: Post-HDF was more efficient at removing small-molecular-weight solutes 
than pre-HDF. The reduction rate of b2-MG was 81.2±2.6% for both modes. The reduction 
rates of a1-MG were 33.1±5.8% for pre-HDF and 37.4±3.9% for post-HDF, showing a 
significant difference (p<0.05). Alb leakages (g/session) were 2.8 for pre-HDF and 3.4 for 
post-HDF (p<0.05). No differences between the two modes were observed in the rates of 
changes in CRP, IL-6, TNF-a, ICAM-1, and PTX-3 levels. Increases in the expression rates 
of CD62P were 164.7±24.1% for pre-HDF and 210.7±44.2% for post-HDF (p<0.05).
Conclusions: The percent change in the CD62P expression rate was smaller for pre-
HDF than for post-HDF; platelets may have been less activated during pre-HDF than during 
post-HDF under this study’s conditions. Post-HDF was more efficient at removing solutes.
Funding: Private Foundation Support
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Using Binding Competitors of Albumin to Promote the Removal of 
Protein-Bound Uremic Toxins in Hemodialysis: Proof of Concept and 
Screening of Candidates
Nans Florens,1,2 Dan Yi,2 Laurent Soulère,3 Laurent Juillard,1,2 
Christophe O. Soulage.2 1Hospices Civils de Lyon, Lyon, France; 2CarMeN, 
INSERM u1060, INSA LYON, VILLEURBANNE, France; 3INSA LYON, 
Villeurbanne, France.
Background: Protein-bound uremic toxins (PBUT) remain a concerning burden as 
their removal in hemodialysis is limited by their strong interaction with albumin. Despite 
interesting animal data, the limitation of their intestinal production is disappointing. By 
enhancing their circulating free-fraction during hemodialysis, the use of binding competitors 
could be undertaken. The aim of this work was to evaluate the displacing capabilities of 
some selected solutes and to identify potential candidates for an in vivo development.
Methods: Displacement capacity of a fluorescent probe (dansylsarcosine) specific to 
Sudlow’s site II on albumin was tested in spectrofluorimetry. Displacement capacity was 
then expressed as a concentration displacer/albumin ratio. Short chain fatty acids were 
provided by Sigma-Aldrich. The selection of potential candidate solutes was realized by 
an in-silico screening (virtual screening and docking) of 12,055 compounds from Asinex 
chemotech library. The effect on the free-fraction of indoxyl-sulfate (IS) was tested after an 
addition of a 1mM solution of octanoic C8 in a solution of bovine serum albumin previously 
incubated with a solution of IS.
Results: Among the short chain fatty acids tested, C8 and C10 were the more prone 
to displace dansylsarcosine from site II of albumin (75% for C8 ; displacer/albumin ratio 
of 5). In silico sreening identify 10 potential candidates among which N-phelyl-glycine 
and N-phenyl-N-benzenesulfonyl glycine (PBSG) were the best candidates. Indeed, the 
displacement obtained was roughly 60% for a displacer/albumin ratio between 50 and 250. 
The addition of a 1mM solution of C8 to a solution of bovine serum albumin permitted an 
increase of 22% of the free-fraction of IS (p<0.05).
Conclusions: C8 permitted a significant increase in the free fraction of IS in vitro. 
Nevertheless, significant concentrations of short chain fatty acids can lead to a significant 
hemolysis. Hence, we identified two interesting solutes that could be interesting to promote 
the removal of PBT: N-phenyl-glycine and PBSG. Those hydrophilic solutes need to prove 
their safety under physiological conditions and their effects on other compounds bound onto 
site II of albumin need further investigations.
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A Novel Post-Dilution CVVHDF-RCA with Personalized Initial Calcium 
Dosing and Fixed Citrate to Blood Flow Ratio
Lenar T. Yessayan, Michael Heung, Ryann Sohaney, Vidhit Puri, Benjamin Wagner, 
Balazs Szamosfalvi. University of Michigan, Ann Arbor, MI.
Background: Regional citrate anticoagulation (RCA) use is limited by concerns of 
electrolyte complications. We describe a novel approach for post-dilution CVVHDF that 
minimizes nurse workload, achieves desired circuit anticoagulant activity, and avoids life-
threatening hypocalcemia even in patients with fulminant liver failure.
Methods: Post-dilution CVVHDF was performed using Prismaflex machines at one of 
three blood flow rates 60, 100, or 150ml/min based on patient’s body weight. Acid citrate 
dextrose-A solution (113 mmol/L) was infused into the arterial limb of the extracorporeal 
circuit at one of three rates 150, 250, 300 ml/h depending on blood flow rate. Equal 
dialysate/replacement flow rates are determined from a table according to body weight (for 
25-30 ml/kg/h total effluent) in those with expected normal citrate metabolism and modified 
according to weight and circuit plasma flow in those with absent citrate metabolism. 
Dialysate/replacement fluid electrolyte concentrations were as follows: Na 136-151, K 
2-4, Ca 0, and HCO3 25-45 mEq/L, phosphate 0 to 1.36 mmol/L. Initial calcium chloride 
solution (136 mmol/L) infusion rate was determined according to a dosing table based on
effluent rate and daily serum albumin and titrated thereafter according to systemic ionized 
calcium (iCa) every 6 hours. Circuit iCa was obtained every 12 hours. RCA effectiveness
was measured in terms of circuit iCa and filter life. Electrolyte trends for 30 consecutive 
patients are reported.
Results: The protocol achieves adequate circuit anticoagulation (circuit iCa <0.4 mM 
in >95% of measured samples). The risk of clinically significant hypocalcemia is less than 
1%. The risk of hypernatremia or metabolic alkalosis is abrogated. Clinically significant 
hypophosphatemia is avoided by spiking commercial solutions with sodium or potassium 
phosphate.
Conclusions: The approach achieves desired circuit anticoagulant activity, avoids life-
threatening hypocalcemia and poses no risks related to RCA.
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Pre-Filter CVVH Results in Longer Filter Life Than CVVHD
Benjamin Griffin,1 Nigel Arruda,1 Isaac Teitelbaum,2 Sophia L. Ambruso,1 
Joao P. Teixeira,1 Katja M. Gist,3 Anna J. Jovanovich,4 Sarah Faubel.5 1University 
of Colorado, Aurora, CO; 2University of Colorado Health Science Center, 
Aurora, CO; 3University of Colorado, Children’s Hospital Colorado, Aurora, 
CO; 4Denver VA / University of Colorado, Denver, CO; 5University of Colorado 
Denver, Denver, CO.
Background: Continuous renal replacement therapy (CRRT) is used to treat severe 
acute kidney injury (AKI) in hemodynamically unstable patients. The two main CRRT 
modalities are continuous venovenous hemofiltration (CVVH, convective clearance) and 
continuous venovenous hemodialysis (CVVHD, diffusive clearance). Filtration fraction, an 
estimate of hemoconcentration through a filter, is thought to be a major determinant of filter 
clotting risk in CRRT. In theory, CVVHD produces less hemoconcentration, and therefore 
less potential for filter clotting, than either pre-filter or post-filter CVVH. However, data to 
support this claim remain limited. The purpose of this study was to examine filter life in 
patients treated with either pre-filter CVVH or CVVHD.
Methods: We conducted a retrospective analysis of adult patients initiated on CRRT 
at the University of Colorado Hospital (UCH) between 2014 and 2016. Filter life was 
recorded for all filters, which were changed if clinically warranted or after a maximum of 72 
hours. Cox regression was used to evaluate time to filter loss in CVVH versus CVVHD, and 
the model was adjusted for blood flow rate, anticoagulation type, replacement or dialysis 
fluid flow rate, ultrafiltration rate, and patient weight.
Results: A total of 415 filters from 160 patients were included in the analysis, of which 
275 were used in a CVVH circuit and 140 in a CVVHD circuit. The average filter life 
in those undergoing pre-filter CVVH was 42 hours (SD 25.2) compared to 35 hours (SD 
24.3) in CVVHD (p = 0.01). Cox regression showed a hazard ratio of 1.3 (CI 1.03 – 1.65, 
p=0.028) for filter loss with CVVHD.
Conclusions: Contrary to out hypothesis, pre-filter CVVH had a longer average filter 
life than CVVHD, and this pattern remained significant in a Cox regression model. CVVHD 
results in less hemoconcentration than CVVH, but is not associated with increased filter life. 
Pre-filter CRRT may be associated with longer filter life through dilution of clotting factors, 
but further investigation into the mechanism of filter clotting in these CRRT modalities is 
needed.
Funding: Other NIH Support - T32 DK 007135
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Multipoint Dilution Hemofiltration (MPD-HF): A New Technology for 
Maximum Convective Clearance
Vienna L. Mott, Violet G. Finley, Daniel Rossetti, Jose Santos, Christopher Dibiasio, 
Dorit S. Berlin, Joseph L. Charest. Draper, Cambridge, MA.
Background: Convection-based renal replacement therapies (RRT) have the potential 
to improve patient outcomes when compared to diffusion-based RRT such as hemodialysis 
(HD), but have limited clearance rates. We propose and characterize Multipoint Dilution 
HF (MPD-HF), a purely convective blood purification technology which removes the 
fundamental filtration limit associated with convective RRT. In MPD-HF, filtration 
of liquid and solutes occurs along the length of the hollow fibers that convey the blood 
and substitution fluid is pushed into the fibers at multiple points along their length. Since 
multiple filtration and dilution steps are contained within one pass of the blood through 
the hollow fiber, the fraction of fluid that can be filtered may be increased to allow a high 
clearance rate.
Methods: We designed, simulated, fabricated, and tested MPD-HF cartridges 
comprising commercial Fresenius F200NR hollow fibers passed through 3 filtration and 2 
infusion chambers, quantifying clearance of molecules across a range of molecular weights.
Results: Figure 1 shows steady state clearance versus molecular weight for the in vitro 
MPD-HF experiment, a COMSOL model prediction of the MPD-HF, an FX CorDiax 800 
HDF dialyzer and an F160 dialyzer. In vitro tests yielded an average steady state filtrate 
fraction of 68%, exceeding commercial HDF cartridge filtrate fractions by a factor of 
approximately 3 and matching the COMSOL model.
Conclusions: MPD-HF offers substantial increases in the filtrate fraction relative to 
both HD and HDF. Extrapolating the MPD-HF to 5 or more filtration and dilution chambers 
allows for a theoretical 100% fluid fraction removal in a single pass, yielding clearance rates 
higher than HD and HDF.
Figure 1. MPD-HF Model and In Vitro Performance
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Measured Dialysate Sodium Deviates Frequently and Sometimes 
Substantially from Ordered Dialysate Sodium in Acute Care Hemodialysis
Vishwa C. Sheth, Heejung Bang, Burl R. Don, Vincent Paracuelles, 
Maureen Craig, Andrew I. Chin. University of California, Davis University of 
California Davis, Sacramento, CA.
Background: It is unknown if measured dialysate sodium (meas DNa) differs from 
the ordered DNa (ord DNa) in the acute care setting where hemodialysis (HD) dialysate is 
created at the point of care via individual acid and bicarbonate concentrates
Methods: We examined HD treatments in an acute care setting where meas DNa was 
obtained at HD start. An absolute difference between meas DNa and ord DNa >2 mEq/L 
was considered out of range. Factors in a simple/univariate logistic regression model with 
random intercept for each dialysis machine included: machine factors (ID#, model, hours 
of use) and dialysate factors (ord DNa, additives in acid or bicarb jug, dialysate flow rate)
Results: There were 1230 HD treatments on 21 unique Fresenius machines in a 3-mo 
period. After exclusions (machine ID# unknown, machine <20 HD’s), 1196 treatments were 
analyzed. The difference between meas DNa and ord DNa was close to normally distributed 
but skewed towards meas DNa <ord DNa; meas DNa was out of range in 46.8% (n=560) 
of the cases (Fig 1). In the logistic regression analysis, there was a significant effect of 
machine ID# clustering, with an ICC of 0.20-0.25, on out of range DNa. Other factors 
(machine model, hours of use, dialysate flow, ord DNa, additives in acid or bicarb jug) were 
not associated with DNa out of range, when machine clustering was taken into account. In 
227 treatments where the meas DNa was out of range (91.5% were <ord DNa), the nurse 
made a manual DNa adjustment based on the difference between meas DNa and ord DNa. A 
subsequent meas DNa level was checked during HD. After this adjustment, the meas DNa 
was within range of the originally ord DNa in 176 (77.5%) of the treatments.
Conclusions: Measured DNa was >2 mEq/L off from ordered DNa in about half of the 
treatments, with a bias towards a lower level. There appears to be a difference between 
dialysis machines, with some having a higher % of treatments with out of range DNa, despite 
consistent and rigorous machine maintenance and testing
Funding: Clinical Revenue Support
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Efficacy and Safety of Oxabact® OC5 in Dialysis Patients with Primary 
Hyperoxaluria Type 1 (PH1): A Phase II, Prospective, Open-Label Study
Bernd Hoppe,1 Bastian Dehmel,2 Ulrike Herberg.3 1University Hospital Bonn, 
Bonn, Germany; 2OxThera AB, Thousand Oaks, CA; 3University of Bonn, Bonn, 
Germany.
Background: In PH1, endogenous overproduction of oxalate in the liver and, 
therefore, extremely elevated urinary oxalate excretion lead to early end-stage renal 
disease with patients requiring dialysis and/or liver (±kidney transplantation). Removal of 
oxalate via dialysis is insufficient and cannot match the endogenous production. Oxabact®, 
a formulation of an oxalate-metabolizing bacterium (Oxalobacter formigenes), induces 
active secretion of oxalate in the intestinal lumen and generates reductions in plasma and 
urinary oxalate (Pox and Uox, respectively) in patients with PH1 at various stages of renal 
impairment. This Phase II, prospective, open-label study investigated efficacy and safety 
of an improved Oxabact® formulation, OC5, in patients with PH1 treated with a stable 
dialysis regimen.
Methods: After a 4-week baseline period, patients received OC5 (one oral capsule 
containing ≥109 CFU lyophilized O.formigenes, twice a day) for 6 weeks and were 
monitored for an additional 4 weeks (initial treatment), before they started an extended 
treatment at the same dose until transplantation or a maximum of 36 months. Total and 
free Pox were evaluated monthly. Traditional and Speckle-Tracking Echocardiography 
were performed at baseline and then every 6 months. Fecal analyses for O. formigenes and 
standard safety assessments were conducted. This is the interim analysis of the study’s first 
12 months.
Results: To date, 12 subjects have been enrolled and six subjects with a mean (SD) age 
of 30.5 (14.0) years have received OC5 for up to 12 months. Total Pox (mean at baseline 
153.48 μmol/L, maximum mean decrease: 43.52 μmol/L at Week 44) and total:free Pox 
ratio (mean at baseline 1.468, 1.223 at Week 52; p <0.05) decreased. Cardiac parameters 
clearly indicated that systemic oxalosis did not worsen under treatment. O.formigenes 
genotype 1 was detectable in all patients. Six subjects reported 52 adverse events; most were 
mild or moderate (88.5%) and not related (90.4%) to treatment. Two subjects experienced 
serious adverse events, unrelated to treatment.
Conclusions: A 52-week treatment regimen with OC5 in patients with PH1 undergoing 
dialysis was safe, reduced Pox, and provided evidence that systemic oxalate deposition was 
attenuated, which would be of a substantial clinical significance for future transplantation 
outcome.
Funding: Commercial Support - OxThera AB
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Low Rates of Outpatient Intensified Hemodialysis in Pregnant Women 
with ESRD
Andrea L. Oliverio,1 Jennifer L. Bragg-Gresham,1,2 Rajiv Saran,1,2 
Michael Heung.1,2 1University of Michigan, Ann Arbor, MI; 2U-M Kidney 
Epidemiology and Cost Center, Ann Arbor, MI.
Background: Pregnancy is a rare event for women on hemodialysis (HD). 
Observational data suggests that increasing HD hours per week to >20-36hrs and targeting 
pre-HD BUN<50 during pregnancy improves likelihood of successful delivery. We aimed 
to characterize pre-delivery HD regimens of pregnant women with ESRD in the US and to 
identify patient characteristics associated with receipt of intensified HD.
Methods: Deliveries were identified using inpatient claims data from USRDS for all 
women age 18-44 undergoing HD with Medicare as primary payer in 2012-2015 (n=390). 
41 weeks of preceding outpatient HD treatment data in CROWNWeb was examined, 
including: number of sessions per week, prescribed and delivered HD time, Kt/V, 
ultrafiltration rate, and pre-HD BUN. We stratified women into “intensified HD” group 
(5+ sessions per week; INT-HD) vs. “standard HD” (<5 sessions; STD-HD). Comparison 
of demographic and treatment variables were made for women receiving INT-HD vs. STD-
HD using student’s t-test.
Results: There was no difference in age, ethnicity, or dialysis vintage of women who 
received INT-HD vs. STD-HD (Table), nor were there individual patient characteristics 
which predicted receipt of INT-HD. 39.2% of women in the STD-HD group did not achieve 
the recommended pre-HD BUN<50 compared to 17.2% of women in the INT-HD group 
(p<0.0001). Only 12.8% of women were dialyzed at least 5 times per week as outpatients, 
and less than 5% received ≥20 hrs (1200 minutes) per week. The average total treatment 
time per week for all delivering women was 745.5 min.
Conclusions: Experts advocate for at least 20 hours (if no residual renal function >36 
hours) of HD per week in order to improve pregnancy outcomes. We observed that very few 
women with ESRD on HD in the US are receiving >20 hrs of HD per week in the outpatient 
setting and a significant proportion do not achieve the recommended pre-HD BUN.
Funding: NIDDK Support, Other NIH Support - T32 DK007378-38
Demographics and Treatment Characteristics in Delivering Women by Group
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Pregnancy Delivery Rates Amongst Women of Child-Bearing Age with 
ESRD: 2002-2015
Andrea L. Oliverio,1 Jennifer L. Bragg-Gresham,1,2 Rajiv Saran,1,2 
Michael Heung.1,2 1University of Michigan, Ann Arbor, MI; 2U-M Kidney 
Epidemiology and Cost Center, Ann Arbor, MI.
Background: Fertility is depressed in women with advanced CKD and ESRD 
and improves after transplant. Women with ESRD are at higher risk for pregnancy 
complications and loss. We sought to identify trends in delivery incidence amongst women 
with ESRD receiving renal replacement therapy (RRT) in the United States Renal Data 
System (USRDS).
Methods: We identified deliveries from inpatient claims of all prevalent female ESRD 
patients aged 18-44 yrs (n=650,282) between 2002-2015. Treatment modality at time of 
delivery was taken from treatment history files. Modality assignment for non-pregnant 
women was defined as last modality reported in each year. Rates were expressed as number 
of delivering women for every woman of child-bearing age receiving that RRT modality 
within each year. Logistic regression examined associations between patient characteristics 
and delivery.
Results: 1833 deliveries were observed over the study period. Delivery rates increased 
overall from 0.23% to 0.34% from 2002-2015 (Figure). Rates were highest for transplant 
patients, while PD patients had significantly lower rates. Older age was associated with 
lower odds of delivery (OR=0.91 for each additional year, 95% CI: 0.91-0.92). Black and 
Hispanic women (compared to White) were more likely to deliver (OR=1.46, 95% CI: 1.29-
1.65 and OR=1.44, 95% CI:1.26-1.65, respectively), as were women whose primary cause 
of ESRD (compared to diabetes) was glomerulonephritis (OR=1.78, 95% CI=1.49-2.13) 
and hypertension (OR=1.65, 95% CI: 1.35-2.02). For each additional year after ESRD 
diagnosis, the odds of delivery were lower by 3% (OR=0.98, 95% CI: 0.97-0.99).
Conclusions: The absolute number of deliveries for women of childbearing age with 
ESRD remains low, but is increasing. The rate of delivery in women receiving HD nearly 
doubled between 2002 and 2015. Further work is needed to identify factors contributing to 
this increase. Younger women with shorter ESRD vintage are more likely to deliver and it 
may be prudent to focus family planning counseling to this subset of patients.
Funding: NIDDK Support, Other NIH Support - T32 DK007378-38
Percentage of delivering women per year amongst prevalent female ESRD patients aged 
18-44
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Switching Dialysis Modalities for a Better Outcome: Analysis from the 
United States Renal Data System (USRDS)
Farah Abifaraj,1 Yasir Lal,2 Wayne G. Fischer,2 John Badalamenti,2 
Hania Kassem.2 1Internal Medicine, University of Texas Medical Branch at 
Galveston, Galveston, TX; 2University of Texas Medical Branch, Galveston, TX.
Background: Since 2011, the prospective payment system dialysis bundle has created 
more incentive for providers to place patients (pts) on Peritoneal Dialysis (PD) leading 
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to more pts switching from Hemodialysis (HD) to PD. Previous studies showed that, 
compared to pts who started with HD, those who started with PD were more likely to be 
white, younger, non-diabetic, and with less prevalence of obesity and other comorbidities. 
They were also described to have either better or similar survival. However, patient factors 
and outcome in those who switch from HD to PD have not been well described. In this 
study, we compared demographics and survival between pts on HD and those switched 
from HD to PD.
Methods: Using the USRDS, we analyzed demographics and mortality for 594,872 
pts from May 2012 till December 2015. Kidney transplant recipients were excluded. 
Pts were divided into: HD only, PD only, and HD-to-PD switch groups. Comparison of 
continuous demographic variables, such as age, BMI, and albumin, was based on t-tests 
(pooled variances). Comparison of demographic categorical variables, such as sex, race, 
region, and presence of diabetes, was based on Contingency Analysis. Survival Analyses 
were performed using Kaplan-Meier curves. A Cox Proportional Hazards model was used 
to estimate the effects of predictor variables on pts survival as well as on PD modality 
survival after the switch.
Results: Comparing the HD only (n= 574,606) and switch groups (n= 20,266), we 
found that switch pts were more likely to be younger at time of 1st ESRD service (5.0 
years, p<0.01), males, white, non-diabetics, and to have a higher serum albumin (0.05 g/dl, 
p<0.01). Average BMI was surprisingly higher in the switch group (0.4 kg/m2, p<0.01). 
The switch group had better survival than both the HD only and PD only groups. Among 
pts who switched, non-diabetics and those with a higher serum albumin had better overall 
survival as well as PD modality survival. BMI and sex had no significant effect on either.
Conclusions: Demographics in pts who transitioned from HD to PD were similar to 
those previously reported in pts initiated on PD. Additionally, the HD to PD group had 
improved survival. These findings provide insight into the demographics influencing the 
decision to switch pts to PD and the positive impact on survival among those pts.
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Factors Affecting Initial Dialysis Modality in Pediatric ESRD
Celina Brunson,1 Justine Shults,3 Sandra Amaral.2 1The Children’s Hospital of 
Philadelphia, Philadelphia, PA; 2The Children’s Hospital of Philadelphia, 
Philadelphia, PA; 3Perelman School of Medicine University of Pennsylvania, 
Philadellphia, PA.
Background: Children from minority and immigrant backgrounds are more likely to 
be placed on hemodialysis (HD) vs. peritoneal dialysis (PD) at onset of end stage renal 
disease (ESRD). We hypothesize that social determinants of health (SDOH), beyond the 
effect of race/ethnicity, influence initial dialysis modality.
Methods: We performed a retrospective cohort study of children 1-18 years who 
started dialysis between 2000-2012 using the US Renal Data System database. Using 
national census and American community survey data based on the patient’s residence zip 
code, we derived a community level health risk score comprised of 17 items representing 
the five elements of SDOH defined by Healthy People 2020. (Table 1) Used a multivariable 
logistic regression model to identify associations between dialysis modality (HD vs. PD) 
and the health risk score, adjusting for age at incident ESRD, race, sex and ESRD cause.
Results: Among 5,607 patients, 3,472 (61.9%) had HD as their initial modality vs. 
2,135 (31.8%) who were started on PD. Patients in the lower quintile for risk score (more 
favorable community based on the included variables) were more likely to be placed on PD 
(OR 1.456, p-value 0.000, 95%CI 1.21-1.75) vs those in the highest quintile of risk score 
(OR 1.267, p-value 0.014, 95% CI 1.049-1.53) when adjusting for age at incident ESRD, 
race, sex and ESRD cause. In this multivariable model, race was not associated with initial 
dialysis modality.
Conclusions: Children with highest risk scores were less likely to be placed on PD vs 
patients in neighborhoods with lower risk. Race was not associated in our model with initial 
dialysis modality unlike earlier studies looking at similar associations. Our findings suggest 
that it may be informative to examine SDOH along with race when examining inequities in 
health care access. Next steps will include differential weighting of variables within the risk 
score to determine whether there are modifiable factors that impact initial dialysis modality 
for children.
Funding: NIDDK Support
Variables of Health risk score
TH-PO370 Poster Thursday
Dialysis: Peritoneal Dialysis - I
Developing Consensus-Based Outcome Domains for Trials in Peritoneal 
Dialysis: An International Delphi Survey
Karine E. Manera,1,2 Allison Tong,1,2 Jonathan C. Craig,1,2 David W. Johnson.3,4 
on behalf of the SONG-PD Steering Group 1Sydney School of Public Health, 
The University of Sydney, Sydney, NSW, Australia; 2Centre for Kidney Research, 
The Children’s Hospital at Westmead, Westmead, NSW, Australia; 3Princess 
Alexandra Hospital, Brisbane, QLD, Australia; 4University of Queensland, 
Brisbane, QLD, Australia.
Background: Major inconsistencies in the reporting of outcomes, the omission of 
patient-reported outcomes, and frequent reporting of surrogate outcomes in trials impedes 
evidence-informed decision making by patients and their clinicians.
Methods: In an international online 3-round Delphi survey, patients/caregivers and 
health professionals rated the importance of outcomes using a 9-point Likert scale and 
provided comments. In rounds 2 and 3, participants re-rated the outcomes after reviewing 
the scores and comments of other respondents. For each outcome we calculated the mean, 
median, and proportion rating 7-9 (critically important).
Results: In total, 873 participants (207 [24%] patients/caregivers and 666 [76%] health 
professionals) from 68 countries completed round 1, and 530 (61%) completed round 3. 
The top outcomes based on a threshold (mean >8; median ≥8; proportion >85% in both 
groups) were PD-infection, membrane functioning, PD failure, cardiovascular disease, 
mortality, catheter complications, and ability to do usual activities. Compared with health 
professionals, patients/caregivers gave higher priority to 6 outcomes: blood pressure (mean 
difference of 0.4), fatigue (0.3), membrane functioning (0.3), impact on family/friends 
(0.1), peritoneal thickening [EPS] (0.1), and usual activities (0.1).
Conclusions: Clinical outcomes were highly prioritised by both stakeholder 
groups. Patients/caregivers gave higher priority to lifestyle-related outcomes than health 
professionals. This process will inform a core outcome set to improve the consistency and 
relevance of outcomes reported in trials in peritoneal dialysis.
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Regional Variation in Peritoneal Dialysis (PD) Time on Therapy (ToT): 
Results from the Peritoneal Dialysis Outcomes and Practice Patterns 
Study (PDOPPS)
Jeffrey Perl,1 Junhui Zhao,2 Bruce M. Robinson,2 Simon J. Davies,3 
Hideki Kawanishi,4 David W. Johnson,5 James A. Sloand,6 Mauricio Sanabria,7 
Talerngsak Kanjanabuch,8 Yong-Lim Kim,9 Jenny I. Shen,10 Ronald L. Pisoni.2 
1St. Michael’s Hospital, Toronto, ON, Canada; 2Arbor Research Collaborative 
for Health, Ann Arbor, MI; 3Keele University, Stoke-on-Trent, United Kingdom; 
4Tsuchiya General Hospital, Hiroshima, Japan; 5Princess Alexandra Hospital, 
Brisbane, QLD, Australia; 6JAS Renaissance, Chicago, IL; 7RTS Baxter, Bogota, 
Colombia; 8Chulalongkorn University, Bangkok, Thailand; 9School of Medicine, 
Kyungpook National University Hospital, Daegu, Republic of Korea; 
10LaBiomed at Harbor-UCLA, Torrance, CA.
Background: Transition to hemodialysis (HD) carries significant morbidity and 
reduced quality of life for PD patients. PDOPPS seeks to identify practices aimed at 
meaningfully prolonging technique survival on PD. Here we describe PD discontinuation 
and death rate in PDOPPS.
Methods: PDOPPS is a prospective cohort study of randomly selected patients across 
national samples of PD facilities from Australia/New Zealand (A/NZ), Canada, Japan, 
Thailand, the UK, and the US. The study population included 20532 patients who were 
followed until death (on PD) or permanent switch to HD, based on initial designation as a 
permanent transfer or a temporary transfer with no return at 12 weeks. ToT (from PD start 
to death or permanent transfer to HD) and hazard ratios (HR) were estimated using Cox 
models based on PD vintage at study entry (age, sex, and diabetes adjusted).
Results: 16% of patients transferred to HD and 13% of patients died. Median (IQR) 
ToT was 3.0 (1.3-5.7) years, ranging from 2.3 (1.1-4.4) in the UK to 4.5 (2.3-9.0) in Japan. 
Relative to the US, HR (95% CI) for transfer to HD were similar in Japan, Canada, and A/
NZ, lower in Thailand (0.5, 0.3-0.7), and higher in the UK (1.5, 1.0-2.0). Compared to the 
US, HR for death was lower in Japan (0.4, 0.3-0.5), higher in Thailand (1.9, 1.4-2.5), and 
similar in A/NZ, Canada, and the UK. Variation in death, and transfer to HD (was seen 
across facilities [figure].
Conclusions: In PDOPPS, rates of permanent transfer to HD, and death vary 
significantly by country and facility. Future work will identify reasons for variation in PD 
outcomes, and identify practices to reduce the risk of PD attrition.
Funding: Commercial Support - The DOPPS Program is supported by Amgen, Kyowa 
Hakko Kirin, Baxter Healthcare. Additional support for specific projects and countries is 
provided by AstraZeneca, European Renal Association-European Dialysis & Transplant 
Association (ERA-EDTA), Fresenius Medical Care Asia-Pacific Ltd, Fresenius Medical 
Care Canada Ltd, German Society of Nephrology (DGfN), Janssen, Japanese Society for 
Peritoneal Dialysis (JSPD), Keryx, Kidney Care UK, MEDICE Arzneimittel Pütter GmbH 
& Co KG, Proteon, and Vifor Fresenius Medical Care Renal Pharma. Public funding and 
support is provided for specific DOPPS projects, ancillary studies, or affiliated research 
projects by National Health & Medical Research Council (NHMRC) in Australia, Cancer 
Care Ontario (CCO) through the Ontario Renal Network (ORN) in Canada, French 
National Institute of Health and Medical Research (INSERM) in France, Thailand Research 
Foundation (TRF), Chulalongkorn University Matching Fund, King Chulalongkorn 
Memorial Hospital Matching Fund, and the National Research Council of Thailand (NRCT) 
in Thailand, National Institute for Health Research (NIHR) via the Comprehensive Clinical 
Research Network (CCRN) in the United Kingdom, and National Institutes of Health (NIH) 
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in the US. All support is provided without restrictions on publications. All grants are made 
to Arbor Research Collaborative for Health and not to Dr. Perl directly.
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Differing Attitudes Towards Peritoneal Dialysis (PD) Among PD and 
Hemodialysis (HD) Medical Directors
Jenny I. Shen,1 Martin J. Schreiber,2 Junhui Zhao,3 Bruce M. Robinson,3 
Ronald L. Pisoni,3 Rajnish Mehrotra,4 Matthew J. Oliver,5 Tadashi Tomo,6 
Kriang Tungsanga,7 Isaac Teitelbaum,8 Arshia Ghaffari,9 Mark Lambie,10 
Jeffrey Perl.11 1LaBiomed at Harbor-UCLA, Torrance, CA; 2DaVita HealthCare 
Partners Inc., Cleveland, OH; 3Arbor Research Collaborative for Health, Ann 
Arbor, MI; 4University of Washington, Seattle, WA; 5Sunnybrook Health Sciences 
Centre, Toronto, ON, Canada; 6Oita University Hospital, Yufu, Japan; 
7Chulalongkorn University, Bangkok, Thailand; 8University of Colorado School 
of Medicine, Aurora, CO; 9University of Southern California, Los Angeles, CA; 
10Keele University, Crewe, United Kingdom; 11St. Michael’s Hospital, Toronto, 
ON, Canada.
Background: Negative perceptions towards PD may be limiting its use. We compared 
differences in attitudes towards PD among medical directors in PD vs. HD units.
Methods: PDOPPS and DOPPS are international prospective cohort studies based on 
national samples of PD and HD patients. From 2014-18 we asked medical directors of 
dialysis units in Canada, Japan, US, and UK: 1) to rate the level of training and support 
for PD in their units, 2) whether certain patient factors would influence recommendations 
to use PD, and 3) to cite potential reasons PD was not more widely used in their program.
Results: 178 (74%) HD and 134 (67%) PD directors responded. PD directors agreed 
more than HD directors that their nephrologists and nursing staff were well trained in and 
were enthusiastic about PD (72-96% vs. 59-72%, by country). HD directors were less likely 
to recommend PD among certain patients (Figure). Among PD medical directors (78%), a 
leading reason for the lack of PD utilization was due to the myth that “in-center HD would 
result in the highest quality of care compared to PD” compared to 29% of HD medical 
directors. Among HD medical directors, leading reasons included patient fears about PD 
(68%), and comfort with facility HD (75%) as major barriers to PD growth.
Conclusions: Compared to HD medical directors, PD medical directors feel their units 
have higher levels of trained, enthusiastic staff towards PD, are more likely to recommend 
PD, and have different opinions regarding drivers of low PD use. Given the majority of 
patients receive HD, educating HD physicians and staff about PD may lead to consideration 
of more patients for PD, and greater PD utilization.
Funding: Other U.S. Government Support
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Changes over Time in Outcomes of Incident Peritoneal Dialysis Patients in 
Southern China
Yuan Peng,1,2 Chunyan Yi,1,2 Meiju Wu,1,2 Xueqing Yu,1,2 Xiao Yang.1,2 1The First 
Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 2Department of 
Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 
China.
Background: The present study was to investigate the changes in outcomes of incident 
patients who stated peritoneal dialysis (PD) between 2006-2010 and 2011-2015 in Southern 
China.
Methods: In this single center retrospective cohort study, incident PD patients from 
January 1, 2005, to December 31, 2015 at the PD center of The First Affiliated Hospital, 
Sun Yat-sen University, Guangzhou, China were enrolled. Collected baseline data include 
demographic characteristics and clinical outcomes. Patients initiated PD during 2006-
2010 and 2011-2015 were followed-up until December 31, 2011 and December 31, 2016, 
respectively. The outcomes were compared between the two incident cohorts.
Results: A total of 2021 incident PD patients were enrolled, with mean age 47.2±15.2 
years, 40.6% were female. Compared with the 2006–2010 cohort (n=1073), patients 
initiating PD during 2011-2015(n=948) were younger (46.2±14.8 vs 48.1±15.5 years, 
p=0.006), had similar baseline eGFR(5.81±2.41 vs. 5.81±2.89 ml/min/1.73m2, p=0.109) 
and comparable percentage of diabetes mellitus (24.9% vs 25.7%,p=0.682). The overall 
peritonitis rate between 2011 and 2015 was lower than 2006-2010 (0.157 vs. 0.160 per 
patient year, p=0.001). By the end of 1, 3 and 5 years, patients survival rates were 94%, 
82% and 63% in 2006-2010 and 97%, 87% and 73% in 2010-2015, respectively (p<0.001); 
and technique survival rates were 98%, 92% and 85% in 2006-2010 and 98%, 90% and 
80% in 2010-2015, respectively (p=0.204). After multivariable-adjusted, patients starting 
PD in 2011-2015 was associated with lower risk of all-cause mortality (HR 0.76, 95%CI 
0.60-0.97, p=0.029).
Conclusions: Peritonitis episodes and patient survival on PD continues to improve, 
while technical survival remains unchanged. Patients initiating PD between 2010 and 2015 
was associated with better patient survival.
Funding: Government Support - Non-U.S.
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The Effect of Combined Therapy with Peritoneal Dialysis and  
Hemodialysis: A Prospective Multicenter Study in Japan
Yukio Maruyama,1 Keitaro Yokoyama,1 Yoshihide Tanaka,2 Ken Sakai,2 
Yoshihiko Kanno,3 Tsutomu Sanaka,4 Tsutomu Sakurada,5 Munekazu Ryuzaki,6 
Masaaki Nakayama,7 Chieko Higuchi,8 Teruhiko Maeba,9 Tatsuo Hosoya.1 
EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study 
Group 1Division of Nephrology and Hypertension, The Jikei University School 
of Medicine, Tokyo, Japan; 2Toho University School of Medicine, Tokyo, Japan; 
3Tokyo Medical University, Tokyo, Japan; 4Edogwa Hospital, Medical Center, 
Tokyo, Japan; 5St. Marianna University School of Medicine, Kawasaki, Japan; 
6Tokyo Saiseikai Central Hospital, Tokyo, Japan; 7St Luke’s International 
Hospital, Tokyo, Japan; 8Division of Internal Medicine, Tokyo Women’s Medical 
University Medical Center East, Tokyo, Japan; 9Asao Kidney Clinic, 
Kawasaki, Japan.
Background: Combined therapy with peritoneal dialysis (PD) and hemodialysis (HD) 
was widely performed to correct underdialysis and/or overhydration in Japan. However, 
its clinical result was only reported in retrospective observational studies. We conducted a 
prospective study to investigate its clinical efficacy in Japan.
Methods: In this prospective multicenter study, we recruited 42 patients started PD 
from January 1, 2011 to December 31, 2016 (61±9 years, 35 males, and 14 diabetes), 
and collected clinical information at the start of combined therapy and six months after 
initiation, prospectively. The changes in parameters between the start of combined therapy 
and six months later were evaluated using a paired t-test or the Wilcoxon signed-rank test.
Results: Two cases transferred to HD within six months. In the remaining cases, 
body weight, urine volume, and serum creatinine levels decreased, whereas hemoglobin 
and serum albumin levels increased. Additionally, dialysate-to-plasma ratio of creatinine 
(D/P Cr), obtained from a peritoneal equilibration test (PET) decreased significantly from 
0.71 ± 0.10 to 0.66 ± 0.10 (P = 0.01) (Figure 1).
Conclusions: In this prospective observational study, both underdialysis and 
overhydration appear to have been improved by switching from PD alone to combined 
therapy. Additionally combined therapy could limit further deterioration of the peritoneal 
membrane. Long-term patient and technical survival will be clarified by the results of 
ongoing our larger prospective study.
TH-PO375 Poster Thursday
Dialysis: Peritoneal Dialysis - I
Peritoneal Dialysis Utilization in US Markets and Associated Hospitalization  
Rate Ratios for Peritoneal Dialysis versus Hemodialysis
Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins,1,2 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, 
MN.
Background: In the United States, peritoneal dialysis (PD) is associated with lower 
hospitalization risk than in-center hemodialysis (HD) during the first and second years of 
dialysis. However, increased utilization of PD in a local area may move higher-risk patients 
from HD to PD, thus attenuating the hospital admission (HA) rate ratio (RR). We assessed 
the influence of PD utilization in US markets on HA RRs for PD versus HD.
Methods: We analyzed data from the United States Renal Data System. We identified 
incident dialysis patients in 2006-2013 and retained patients in markets with ≥500 patients. 
For each area, we calculated the percentage of patients on PD within 3 months of dialysis 
initiation. Using Poisson regression, we assessed the association of that percentage with 
the admission rate between 3 and 36 months after dialysis initiation, without censoring for 
modality change and with fixed effects for markets; only the subset of Medicare patients 
were included in the model.
Results: The cohort included 323,045 incident dialysis patients in 236 markets. Overall 
PD utilization was 8.8%. Market-specific HA rates in PD and HD patients are displayed. 
Market-adjusted HA RRs for PD versus HD were 0.81 with local PD utilization of 2-3% 
(number of markets, 12), 0.86 with utilization of 4-5% (27), 0.86 with utilization of 6-7% 
(47), 0.82 with utilization of 8-11% (90), 0.90 with utilization of 12-15% (42), and 0.95 with 
utilization of ≥16% (18). Compared to the market-adjusted HA RR with local PD utilization 
of 2-3%, RRs with utilization of ≥12% were significantly different (P < 0.05).
Conclusions: Across a gradient of local PD utilization from 2% to 12%, HA RRs for 
PD versus HD are similar. Local PD utilization ≥12% is associated with attenuated RRs.
Funding: Commercial Support - NxStage Medical, Inc.
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Incremental Peritoneal Dialysis Is Beneficial in Preserving Residual Renal 
Function, Compared to Full-Dose Peritoneal Dialysis
Yeonhee Lee, Seokwoo Park, Seung Seok Han, Hajeong Lee, Dong Ki Kim, 
Kwon Wook Joo, Curie Ahn, Kook-Hwan Oh. Seoul National University 
College of Medicine, Seoul, Republic of Korea.
Background: Maintaining residual renal function (RRF) is a crucial issue in peritoneal 
dialysis (PD). Incremental dialysis is the practice of initiating PD exchanges less than four 
times a day in consideration of RRF, and increasing dialysis dose step-wisely as the RRF 
decreases. Effects of incremental PD on the RRF and technique survival have not been 
widely studied yet. The aim of this study was to compare the outcomes of incremental PD 
and full-dose PD in terms of RRF preservation and other outcomes.
Methods: Data were extracted from a retrospective PD cohort (16 years of age or 
older) who started PD between 2007 and 2015 in the PD Unit of Seoul National University 
Hospital. Full-dose PD was defined as a maximal 4 dwell-times per day for continuous 
ambulatory peritoneal dialysis (CAPD) and as nightly dialysis sessions for automated 
peritoneal dialysis (APD). Incremental PD was defined as all other PD except full-dose 
PD. Outcomes were compared with the use of propensity scores and inverse-probability-
weighting (IPW) adjustment to reduce treatment selection bias between incremental and 
full-dose PD groups. Multivariate time-dependent Cox analyses were performed.
Results: Among 443 included patients, 277 underwent incremental PD and 
132 underwent conventional full-dose PD. After IPW adjustment, Incremental PD 
group exhibited a lower risk of developing anuria (hazard ratio [HR] 0.99; 95% CI, 
0.983-0.998). Patient survival, technical survival and peritonitis free survival was similar 
(Log rank test, P>0.05).
Conclusions: In this observational study, incremental PD was beneficial for preserving 
residual renal function compared to conventional full-dose PD and showed similar patient 
survival.
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Early Mortality Hazard of Peritoneal Dialysis Is Also Present in Dialysis 
Modality Converted Patients
Jong Cheol Jeong,1 Sejoong Kim,2 Dong-Chan Jin,3 Ki Young Na.2 1Ajou 
University Hospital, Suwon, Republic of Korea; 2Seoul National University 
Bundang Hospital, Seongnam, GyeongGi-Do, Republic of Korea; 3The catholic 
university of Korea, Suwon, Republic of Korea.
Background: Peritoneal dialysis showed increased mortality in previous registry 
reports from east Asian countries. However, hazard pattern according to time have never 
been investigated. Also, there have been few reports about the outcome of dialysis modality 
converted patients. We examined 22,210 incident dialysis patients from Korean Society of 
Nephrology registry.
Methods: We evaluated whether hazard ratio of peritoneal dialysis has time-dependent 
nature. Survival analysis was performed using a non-proportional hazard fractional 
polynomial model. Treatment effect of peritoneal dialysis was tested by using inverse 
probability weighted regression adjustment
Results: During a median follow up of 7.9 years (from 0 to 13.9 years), 13,218/22,210 
(59.5%) patients died. Peritoneal dialysis showed significantly elevated hazard ratio till 8 
years after dialysis initiation, which has its peak value reaching 1.4 at 3 years. Multivariable 
analysis adjusted for age at dialysis initiation, sex, and cause of end stage renal disease 
was conducted. The average treatment effect of peritoneal dialysis showed -0.946 (95% 
C.I. -1.356 - -0.536, p<0.001) of beta, which is interpreted as -0.946 years less survival
in average peritoneal dialysis group. Within those patients who died before 8 years, death 
related to diabetes was more prevalent in peritoneal dialysis group (35.5% vs 27.8%,
p<0.001) For the dialysis modality converted patients, 1,561 patients were analyzed.
Peritoneal dialysis converted from hemodialysis showed worse survival with an early
bimodal peak of increased hazard ratio.
Conclusions: Peritoneal dialysis showed increased early mortality hazard. Early 
death within 8 years of peritoneal dialysis might be associated with metabolic risk. This 
phenomenon was also present for the dialysis modality converted patients.
Figure A. Early mortality hazard is elevated in peritoneal dialysis. B. Bimodal peak of 
early mortality hazard of peritoneal dialysis. HR, hazard ratio; PD, peritoneal dialysis; HD, 
hemodialysis
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Dialysis Modality and Bleeding Risk
Gurbey Ocak,1 Alferso C. Abrahams,1 Maarten B. Rookmaaker,1 
Marianne C. Verhaar,1 Friedo W. Dekker,2 Merel Van diepen.2 1Department of 
Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, 
Netherlands; 2Department of Clinical Epidemiology, Leiden University Medical 
Center, Leiden, Netherlands.
Background: Bleeding as a manifestation and complication of renal failure was already 
recognized in the 18th century. However, there is limited information whether bleeding risks 
are different for peritoneal dialysis patients and hemodialysis patients. From a clinical point 
of view, there could be a preferred dialysis modality for patients with bleeding problems. 
Therefore, the aim of this study was to investigate the association between dialysis modality 
and bleeding risk.
Methods: In total, 1745 incident dialysis patients from the NECOSAD study were 
prospectively followed for major bleeding events within three years of dialysis. Hazard 
ratios (HRs) with 95% confidence intervals (CIs) were calculated for hemodialysis as 
compared with peritoneal dialysis using Cox proportional hazard analyses. Hazard ratios 
were adjusted for age, sex, primary kidney disease, antiplatelet drug use, vitamin K 
antagonist use, EPO use, prior history of bleeding, cardiovascular disease, systolic blood 
pressure, residual GFR and albumin levels.
Results: Of the 1745 dialysis patients, 1211 started with hemodialysis and 534 started 
with peritoneal dialysis. A total of 183 patients had a bleeding event during a median follow-
up of 2.2 years (interquartile range 1.0-3.0). The bleeding rate was 60.8 per 1000 person-
years for hemodialysis patients and 34.6 per 1000 person-years for peritoneal dialysis 
patients. The crude hazard ratio of bleeding was 1.7 (95% CI 1.2-2.5) for hemodialysis 
patients as compared with peritoneal dialysis. Hemodialysis patients as compared with 
peritoneal dialysis patients had a 1.5-fold (95% CI 1.0-2.2) increased bleeding risk after 
adjustment for age, sex, primary kidney disease, prior history of bleeding and cardiovascular 
disease. After additional adjustment for antiplatelet drug use, vitamin K antagonist use, EPO 
use, systolic blood pressure, residual GFR and albumin levels, the HR did not change 1.5 
(95% CI 1.0-2.4).
Conclusions: In this large prospective cohort of incidence dialysis patients with 
detailed information, hemodialysis as compared with peritoneal dialysis was associated 
with an increased bleeding risk. An explanation could be the use of heparin for hemodialysis 
sessions to prevent clotting of dialysis lines and dialyzers. Future studies should examine 
whether starting or switching to peritoneal dialysis could be beneficial for patients with 
bleeding problems.
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Anemia and Mortality in a Mexican PD Cohort
Javier Soto-Vargas, Judith J. Velasco, Renato Parra Michel, Jorge fernando Topete 
reyes, Leonardo Pazarin-Villaseñor, Mario A. García Cárdenas, 
Julio A. Gutierrez-Prieto. Universidad de Guadalajara, Centro Universitario de 
Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional 
No 46 del IMSS, GUADALAJARA, Mexico.
Background: The impact of anemia and its management on mortality is controversial 
in PD patients, despite of being considered and important part of the adequacy therapeutic 
plan, and the recommendations are based on evidence derived from HD patients. Thus, our 
aim was to study the association of anemia in all-cause mortality in a PD cohort.
Methods: During January 2012 to December 2017 we included 802 prevalent 
PD patients to investigate the impact of anemia (Hgb <10 g/dL) in all-cause mortality. 
We collected relevant information as demographic characteristics, anthropometric, 
biochemical, type (i.e. automatized PD or continuous ambulatory PD), dose of dialysis, 
peritoneal transport rate, as well as residual kidney function and comorbidities, and used 
them as covariates for a multivariate analysis.
Results: The median follow-up was 23 months (IQR 23-36.4). During the study period, 
there were 109 (13.6%) deaths. The median age was 47.9 years (IQR 28.3-64.4), 270 
(33.7%) were female, and the main etiology of CKD was unknown in 383 (48.7%) patients, 
and T2D in 336 (42.7%), twenty (4.5%) had a previous kidney transplant, and 71 (14.5%) 
were initially on HD and then transferred to PD. The prevalence of anemia was 25.2% (202 
patients), with a median Hgb level of 11 g/dL (IQR 9.7-12.0). In a binary logistic regression 
model adjusted for the variables afore mentioned, anemia was associated with all-cause 
mortality (OR 2.9 CI 95% 1.62-5.25 p<0.001), and this association was confirmed in a 
multivariate Cox regression (HR 2.5 CI 95% 1.6-4.2 p<0.001).
Conclusions: The presence of anemia is associated with a twofold increased risk for 
all-cause mortality in PD patients.
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Mean Corpuscular Volume and Mortality in Peritoneal Dialysis
Sara S. Kalantar,1 Carola-Ellen Kleine,1 Christina Park,1 Jui-Ting Hsiung,1 
Csaba P. Kovesdy,2 Elani Streja.1 1Harold Simmons Center for Kidney Disease 
Research and Epidemiology, Division of Nephrology and Hypertension, 
University of California, Irvine, Orange, CA; 2University of Tennessee Health 
Science Center, Memphis, TN.
Background: Normocytic and normochromic anemia is a common sequela in chronic 
kidney disease, however some patients with end-stage renal disease present with macrocytic 
anemia. In hemodialysis patients abnormal mean corpuscular volume (MCV) was 
associated with mortality, while so far this association has not been explored in peritoneal 
dialysis (PD) patients.
Methods: We retrospectively examined a cohort of 14,251 incident PD patients from 
a large dialysis organization from 2007 to 2011 with MCV measurement within the first 91 
days of PD treatment. PD patients were grouped into five a priori selected MCV categories. 
Using Cox models, we explored the association between baseline serum MCV and all-cause 
death with adjustments for case-mix variables and laboratory markers of malnutrition and 
inflammation (MICS).
Results: Mean age was 56±16 years and 43% of study participants were women. Higher 
MCV levels trended towards higher mortality across all levels of adjustment, although the 
association was attenuated after adjustment of case-mix and MICS variables. The highest 
MCV category (≥96 fL) was significantly associated with a higher risk of all-cause mortality 
when compared to the reference group (90-<93 fL) in the fully adjusted model (HR 1.29, 
95%Cl 1.11-1.49). Lower MCV categories trended towards lower mortality. [figure1]
Conclusions: In incident PD patients, macrocytosis/higher MCV was associated with 
higher all-cause mortality risk. The underlying mechanisms of the observed MCV-mortality 
association remains unclear and should be explored in further studies.
Funding: NIDDK Support
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Renin-Angiotensin System Blockade and Mortality in Peritoneal Dialysis 
Patients
Godhy E. Hernandez Gonzalez, Javier Soto-Vargas, Denisse Arellano-Mendez, 
Omar I. Delgado-Ayon, Carlos Daniel Jiménez Mejía, Leonardo Pazarin-
Villaseñor, Renato Parra Michel, Julio A. Gutierrez-Prieto. Universidad de 
Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en 
Nefrologia, Hospital General Regional No 46 del IMSS, Guadalajara, Mexico.
Background: Renin-Angiotensin System (RAS) blockade in Peritoneal dialysis (PD) 
patients has not been widely examined, however, its use in hemodialysis (HD) patients has 
been associated with risk reduction in all-cause and cardiovascular mortality. Moreover, 
mortality in PD patients still represents a challenge for the clinician. Our objective was to 
determine if RAS blockade improve survival or reduce all-cause mortality in PD patients.
Methods: A total of 248 adult PD patients were prospectively enrolled from January 
to October 2017. The preliminary findings of 85 patients are presented here. Sixty-four 
(75%) with RAS blockade and 21 (25%) without it were analysed. The mean follow-up 
was 13.5±3.4 months. We performed a survival and multivariate analysis adjusted for age, 
gender and diabetes mellitus, between groups to estimate the all-cause mortality risk.
Results: The median age was 42 years (IQR 27-62) and 64 (74.4%) were male. There 
were no significant differences in baseline characteristics between groups (e.g. residual renal 
function, etiology of CKD, comorbidities, type of peritoneal transport and dyslipidemia 
profile). Four deaths were recorded during follow-up, one (1.6%) in the RAS blockade 
group and 3 (14.3%) in the control group (p=0.02). Patients with RAS blockade had higher 
serum potassium (p =0.01) as well as reduced risk for all-cause mortality compared with 
the group without RAS blockade (OR 0.05, CI 95% 0.03-0.85, p=0.04) in the multivariate 
analysis.
Conclusions: In this prospective cohort of PD patients, the use of RAS blockers was 
associated with all-cause mortality risk reduction and higher serum potassium.
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Baseline Echocardiographic Parameters Predict Mortality in Peritoneal 
Dialysis Patients
Rodolfo Mario Orihuela,1,2 Lucino Bahena,6 Rocio B. Cruz,7 Ricardo Correa-
Rotter,3 Luis E. Morales-Buenrostro,5 Abraham Cohen-Bucay.4 Departamento 
de Nefrología Hospital Central Militar 1Nefrología, Hospital Central Militar, 
Ciudad de México, Mexico; 2Nefrología y Metabolismo mineral, Instituto 
Nacional de Ciencias Medicas y Nutrición, Ciudad de México, Mexico; 
3Institutor Nacional de la Nutricion, Mexico City, Mexico; 4Boston University 
Medical Center, Boston, MA; 5Instituto Nacional de Ciencias Medicas y 
Nutricion Salvador Zubiran, Mexico City, Mexico; 6Hospital central militar, 
México, DF, Mexico; 7Hospital Central Militar, Mexico City, Mexico.
Background: Patients with end-stage renal disease (ESRD) have high mortality rates 
and the leading cause of death is CV disease. Multiple baseline factors including age, 
comorbidities and frailty, have been associated with higher mortality risk. Here we evaluate 
the prognostic value of baseline echocardiographic structural and functional cardiac 
abnormalities in incident peritoneal dialysis (PD) patients.
Methods: Prospective cohort study of patients with CKD5 that started PD between 
2014 and 2016 at Hospital Central Militar in Mexico City, Mexico. A bi-dimensional 
transthoracic echocardiogram was performed within 7-14 days before starting PD. The 
primary objective was to correlate structural and functional echocardiographic parameters 
with the primary outcome of death by any cause.
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Results: We included 138 patients, 44.9% were male, median age 52.3 +/- 15.3, the 
cause of ESRD was DM in 71%. During a median follow up of 26.8 months 73 patients 
(52%) died, with a median survival of 30.8 months. In univariate analysis we identified 
age (p=0.001), DM (p=0.001), residual urine volume (RUV) (p,0.001), serum albumin 
(p<0.001) and B-type natriuretic peptide (BNP) (p=0.001) as risk factors for mortality. 
By Kaplan-Meier method we identified the following echocardiographic parameters to be 
correlated with higher mortality: left atrium volume >20 (p=0.007), mitral insufficiency 
(p=0.001), LV ejection fraction (EF) <53% (p=0.017), LV hypokinesis (p=0.001) and 
diastolic dysfunction with a restrictive pattern (p<0.001). Multivariate analysis identified 
age >50y (OR=2.05, p=0.046), gender (OR=0.53, p=0.010), RUV (OR=0.99, p=0.002), 
LV EF (OR=0.97, p=0.042), and diastolic dysfunction with a restrictive pattern (OR=3.08, 
p=0.003) as independent risk factors for mortality.
Conclusions: Baseline echochardiogram (lower LV EF and diastolic dysfunction) at 
dialysis initiation is a strong predictor of mortality in PD patients, in particular in those with 
DM. We hereby confirm high mortality rate in patients that start PD, and the previously 
reported correlation of age, gender, and RUV with mortality.
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A Fast Decline of Residual Renal Function in the First Year Is a Predictor 
for Early Withdrawal from Peritoneal Dialysis in Non-Diabetic Patients
Fei Han. First Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou, China.
Background: Little is known about the relationship of residual renal function (RRF) 
decline in early period with survival in peritoneal dialysis (PD).
Methods: Total of 567 patients who began PD between January 1, 2005, and June 30, 
2013 was investigated. The rate of decline of RRF was determined by the “slope of the 
trend equation” of serial RRFs. A composite end-point of all-cause mortality and transfer to 
hemodialysis was used, survival status was censored on June 30, 2016.
Results: The median of “the slope of RRF decline equation” was 0.308 (0.001-
2.111) mL/min/1.73 m2/month. In the median follow-up period of 43 months (12 to 120 
months), 65 patients died, 90 patients transferred to HD, and 171 patients underwent 
kidney transplantation. Male, high baseline RRF, high baseline peritoneal Kt/V urea, low 
serum albumin and low uric acid were independently associated with the rate of RRF in 
the first year of PD. RRF decline in the first year remained a predictor of composite end-
point (HR, 2.74, P =0.001). When the patients were divided into high RRF decline group 
(>0.308 mL/min/1.73m2/month) and low RRF decline group (≤0.308 mL/min/1.73m2/
month) at the first three years of PD period, end-point events incidence was higher in 
high RRF decline group (23.2%) than in low RRF decline group (11.0%) (log-rank test 
P < 0.001). There were 189 patients in low RRF decline group and 171 patients in high RRF 
decline group maintaining PD for more than 3 years, in a median follow-up of 54 months 
(range 37 to 120 months), no significant difference of survival was observed (30.9% in high 
group vs 46.4% in low group, log-rank test P=0.883). In high RRF decline group, there were 
92 patients reaching composited end-point and 112 patients maintaining PD; multivariate 
Cox regression model showed high peritoneal Kt/V urea after 1 year of PD period and high 
albumin level were the protective factor for composite end-point (HR, 0.29, P = 0.001; HR, 
0.94, P=0.022, respectively), while fast RRF decline remained the risk factor for composite 
end-point (HR, 3.28, P=0.004).
Conclusions: A faster RRF decline in the first year was a predictor for all-cause 
mortality and transfer to hemodialysis in non-diabetic PD patients, mainly in the first three 
year. For patients with faster RRF decline, increase the PD dose was effective to improve 
survival.
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The Effect of Traditional Chinese Medicine (TCM) Practice on Mortality 
Risk in a Large Cohort of Patients on Continuous Ambulatory Peritoneal 
Dialysis (CAPD) from China
Pei Ming,5 Mark R. Marshall,1 Haiming Li,2 Tao Feng,4 Qiang Yao,3 
Hongtao Yang.5 1Middlemore Hospital, Auckland, New Zealand; 2Baxter China, 
Shanghai, China; 3Baxter, Shanghai, China; 4Baxter (China) Investment Co., 
Ltd, Guangzhou, China; 5First teaching hospital of Tianjin university of TCM, 
Tianjin, China, Tianjin, China.
Background: We report mortality risk in a cohort of patients on CAPD from China, 
comparing outcomes between hospitals classified as TCM hospitals versus conventional 
ones.
Methods: Data were sourced from the Baxter Healthcare (China) support program 
database, comprising an inception cohort commencing PD between Jan-2005 and 
September-2015, followed until death, dropout, loss to follow-up, or November-2015, 
whichever occurred first. The primary outcome was death. The primary exposure was 
official classification of the treating hospital as TCM versus conventional, although we 
separated TCM further according to whether the hospital was affiliated with the China TCM 
PD Federation (TCM-PDF) or not. We made comparison using Cox proportional hazards 
models with shared frailty by center, censoring for kidney transplantation and change to 
HD, adjusting for age, gender, employment, insurance, primary renal disease, size of PD 
program.
Results: We modelled 100,558 subjects from 1,134 centres over 241,051patient-years. 
CAPD patients at TCM hospitals were younger, more likely female, with hypertension as 
kidney disease, urban, unemployed, from larger programs, and treated with < 4 exchanges 
per day. The modelling results are presented in Table 1.
Conclusions: TCM is associated with better outcomes for PD patients in China. 
TCM interventions include traditional diet therapy optimizing digestive tract symptoms 
and therefore nutrition, traditional medications to increase urinary volume and ameliorate 
the micro-inflammatory state, the use of enemas to reduce accumulation of uremic toxins 
and maintain bowel habit, and traditional Wu Style Tai Chi Chuan athletics. However, the 
indentified benefit with TCM appears to be restricted to hospital with an affiliation with 
the TCM-PDF, and we believe this is due to greater standardization of management, and a 
greater focus on continuing medical education and scholarly activities in affiliated centers.
Funding: Commercial Support - Baxter Healthcare (China)
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Impact of CMS-Kidney Disease Education Policy on Home Dialysis Rates
Ashutosh M. Shukla,1 Shahab Bozorgmehri,2 Rajesh Mohandas,2 
Tezcan Ozrazgat-baslanti.2 1Department of Nephrology, Hypertension, and 
Transplantation, University of Florida, Gainesville, FL; 2University of Florida, 
Gainesville, FL.
Background: Multiple US and international studies have shown that Kidney disease 
education (KDE) improves informed selection of home dialysis (HoD) in CKD patients. In 
2010, Center for Medicare and Medicaid Services (CMS) approved reimbursement for the 
KDE services for patients with advanced stage 4 & 5 pre-dialysis CKD. No data is available 
on the efficacy of this policy change on the patient use of HoD.
Methods: we evaluated the effect of the use of CMS KDE billing code during the pre-
dialysis period on the rates of post-ESRD HoD use, and factors associated with HoD use.
Results: Out of 369,938 Medicare enrollees between 2010 and 2014, who were 18 
years and older and started dialysis first time after 2010, we identified 3,681 patients (1% of 
included cohort) in whom KDE services were billed for a total of 6,166 times. KDE services 
were provided with a median of 218 (25th, 75th:74-462) days prior to the initiation of dialysis 
therapies. Of the 3,681 KDE recipients, 15% (n=538) used HoD as the initial dialysis 
modality and 25% (n=903) used HoD at any time after KDE. Twelve percent (n=365) 
of those initiating dialysis with in-center hemodialysis switched to HoD at a median of 
216 (25th, 75th:74-581) days after dialysis initiation. Multivariate logistic regression model 
showed that younger age, white race, non-diabetes renal disease, employment, absence of 
congestive heart failure, and atherosclerotic disease, higher MDRD eGFR, albumin>3g/dl, 
not having a need for assistance with daily activities, prior renal care, and group rather than 
individual KDE were independently associated with higher odds of HoD therapy. Gender, 
overall diabetes, cystic kidney disease, BMI, or number of KDE services did not have any 
impact on the use of HoD therapies.
Conclusions: Despite being recognized by CMS, KDE services are vastly underutilized 
for the patients with incident ESRD. Use of KDE services is associated with marginal 
improvements in the HoD rates among incident ESRD patients. A significant proportion of 
those receiving KDE and using HoD therapy need to initiate with in-center hemodialysis. 
Better pre-ESRD care coordination may be needed among those who choose HoD but 
require in-center initiation of dialysis.
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Increased Peritoneal Dialysis as Initial Treatment Modality: A Canadian 
Costing Analysis
Thomas W. Ferguson,1 Reid Whitlock,2 Navdeep Tangri,1 Claudio Rigatto,3 
Michelle S. DiNella,4 Paul Komenda.2 1Seven Oaks General Hospital, Winnipeg, 
MB, Canada; 2University of Manitoba, Winnipeg, MB, Canada; 3Chronic 
Disease Innovation Centre, Winnipeg, MB, Canada; 4Seven Oaks General 
Hospital Research Centre, Winnipeg, MB, Canada.
Background: Kidney failure is increasing in prevalence in Canada. Patients with 
kidney failure are often treated with dialysis: either hemodialysis (HD) or peritoneal dialysis 
(PD). There are economic considerations relevant to these therapies, with HD provided in 
hospital costing over $60,000 and home dialysis (HD or PD) costing between $35,000 and 
$45,000 per patient annually. Increasing home PD as a modality choice may afford the 
health care system substantial cost savings.
Methods: We aimed to evaluate the cost-utility of scenarios in which the number of 
patients offered PD as initial treatment modality is increased to 30% and 40% of incident 
dialysis starts (baseline Canadian incidence: 20.8%). We accomplished this by performing 
an incremental cost-utility analysis from the perspective of the Canadian public health payer 
including all costs related to treating kidney failure with dialysis in the Canadian adult 
incident dialysis population using data from the Canadian Organ Replacement Register 
(CORR) between 2004 and 2013. Threshold analysis was performed on the relative risk 
of infections and hospitalizations from increased PD prescription. Second order Monte 
Carlo simulations were performed to evaluate parameter uncertainty. Our outcomes were 
expressed as cost per quality adjusted life years.
Results: Increasing initial uptake of PD to 30% resulted in an average cost savings 
of $3,132, and increasing uptake to 40% resulted in an average cost savings of $6,529 
($33,970 per new additional PD patient initial therapy over a lifetime horizon). The models 
were robust to changes in the risk of infection and hospitalization, requiring over 10-fold 
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increased risk of infection, 7.6-fold increased risk of cardiovascular-related hospitalization, 
or 2.5-fold increased risk of all-cause hospitalization to reach cost neutrality. Retrospectively 
applying these findings to the Canadian incident dialysis population for the 10 years 
between 2004 and 2013 would have resulted in cost savings of $123.1 million and $256.7 
million in the 30% and 40% scenarios respectively.
Conclusions: Policy recommendations to increase the initial prescription of home 
peritoneal dialysis should be considered and are highly cost-effective.
Funding: Commercial Support - Baxter Canada Inc.
TH-PO387 Poster Thursday
Dialysis: Peritoneal Dialysis - I
Health-Related Quality of Life: Seeking Novel Targets for Effective 
Interventions
Juliya Hemmett,3,2 Kiersten Colbran,1 Dilraj S. Sanghera,1 Saad Chahine,2 
Christopher W. McIntyre.3,2 1Schulich School of Medicine & Dentristy, Sarnia, 
ON, Canada; 2Western University, London, ON, Canada; 3London Health 
Sciences Centre, London, ON, Canada.
Background: Understanding patients’ perceived quality of life (QOL) is important in 
order to provide quality care for chronic kidney disease (CKD) patients. QOL is shaped 
by several factors including patients’ beliefs, symptoms, and behaviours, and yet the 
interaction between these is not well studied. We studied the interaction between these 
factors using well-established instruments, to help identify priority targets to meaningfully 
improve patient care.
Methods: The sample of study were patients with CKD and end-stage renal disease 
(ESRD). This was a single-phase, cross-sectional survey-based study of adult patients 
from two centers in London, ON. Patients were recruited in three cohorts: in-center 
hemodialysis (cHD), CKD (eGFR <30 ml/min), and home dialysis (peritoneal (PD) and 
home hemodialysis (HHD)). Each set of surveys included the KDQOL-36SF, Illness 
Intrusiveness Scale (IIS), Dialysis Recovery Time (DRT), Grit Scale, Physical and 
Emotional Symptom (PES) Questionnaire, BMQ, and PHQ-9. Demographic information 
was also collected. Surveys were individually scored results from the three cohorts were 
compared and analyzed using correlation and regression techniques.
Results: Seventy two patients (24 cHD, 24 home dialysis (19 PD, 5 HHD), and 24 
CKD) completed the survey package. The cohorts were well balanced with respect to age 
and comorbidities. There was no difference between the cohorts with respect to any of the 
surveys except for DRT (cHD=384.63 mins, SD 411.13 versus home dialysis= 142.75 mins, 
SD 404.46). Physical QOL (pQOL) and mental QOL (mQOL) were not significantly related 
(R2=0.045). IIS was significantly associated with decreased pQOL (R2=0.27, p<0.001). The 
linear combination of depression, PES, and grit were significantly associated with mQOL 
(R2=0.54, p<0.001). While depression (b=-0.31) and PES (b=-0.31) were negatively 
associated with mQOL, grit (b=0.34) was found to be partially protective.
Conclusions: Using a rigorous series of validated questionnaires, we did not find a 
significant difference between CKD and ESRD patients on home and in-center dialysis 
modalities with regards to pQOL or mQOL. We have identified several targets for potential 
patient education and engagement strategies. Further studies are required to identify how to 
best integrate this knowledge into practice.
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Development of a Novel Connection Device for Patients on Peritoneal 
Dialysis (PD)
Sandra B. Neumann. Peripal AG, Zurich, Switzerland.
Background: The dialysis population has changed significantly with an increasing 
age, multi morbidity and frailty. At the same time, home care is a major trend in health 
care systems for clinical and financial reasons.. Overall PD usage is decreasing due to 
difficulties preparing elderly patients for PD without additional support. A first need finding 
suggested that there exists the need to develop a novel auto-connect device for PD patients, 
to overcome current hurdles to PD use. The aim was to understand how such a device could 
support home care patients and what functionalities would be required to better standardize 
the therapy.
Methods: The user interface of functional prototypes were tested with more than 30 PD 
patients, nurses and doctors. Based on the feedback of the test persons, we optimized and 
iterated the functional prototypes six times over a period of 18 months.
Results: During the tests we identified the following needs for an auto-connect device: 
(1) a connecting mechanism to accommodate both continuous ambulatory PD (CAPD), as 
well as automated PD therapy, (2) a therapy guidance that leads the patient through drain, 
flush, fill, preventing user errors, (3) an antiseptic environment that may better protect the 
patients from infections, (4) a user interface that was suited for the respective users. After
six generations, it was felt that these were merged in a final product design.
Conclusions: The new prototypic device could allow more patients to be treated at 
home, better protect these patients from infections, further standardize the PD therapy, and 
support assisted home care models.
Funding: Commercial Support - Peripal AG (start-up), Government Support - 
Non-U.S.
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Racial and Ethnic Disparities in Treatment Modalities for ESRD Vary by 
Patient Age
Adam S. Wilk,1 Wairimu Magua,2 Janet Cummings,1 Laura Plantinga,2,1 
Harold A. Franch,3,2 Rachel E. Patzer,4,2 Janice P. Lea.3,2 1Rollins School of 
Public Health, Emory University, Atlanta, GA; 2Emory University School of 
Medicine, Atlanta, GA; 3Emory Dialysis Centers, Atlanta, GA; 4Emory 
Transplant Center, Atlanta, GA.
Background: Black patients present with end-stage renal disease (ESRD) at younger 
ages than whites, while younger patients are more likely to undergo transplantation (Tx) and 
to use peritoneal dialysis (PD) or home hemodialysis (HHD) versus in-center hemodialysis 
(HD). It is unknown whether disparities in treatment modality use across racial/ethnic 
groups are consistent among all ages.
Methods: We used 2011-2015 USRDS data to identify treatment modalities—Tx, HD, 
PD, HHD, or Other—at day 90 of therapy (persisting for ≥60 days) for all incident US 
ESRD patients. We compared use of each modality between racial/ethnic groups (Hispanic, 
non-Hispanic [NH] Black, NH White, Other) pairwise using t tests, both overall and 
stratified by age: 22-44, 45-64, 65-74, and 75-99. We computed relative risks (RRs) across 
groups and tested whether age modified these RRs in multinomial logit models, controlling 
for patient factors. Missing data, discontinued dialysis/recovered function, and lost follow 
up (e.g., died before day 90) were excluded.
Results: During 2011-2015, 81.5% of 552,896 patients used HD at day 90, 10.0% 
used PD, 0.7% used HHD, 2.8% underwent Tx, and 4.9% were classified as Other. NH 
Blacks and Hispanics were less likely to use PD and Tx and more likely to use HD versus 
NH Whites (all p<0.01). Tx disparities were greatest among age 22-44 for NH Blacks 
(RR 0.144) and among age 45-64 for Hispanics (RR 0.318), and were smallest among age 
75+ (RRs 0.269 and 0.444, respectively) (all p<0.01; see Table). PD disparities were 
greatest among age 75+ (RRs 0.476 and 0.625, respectively) and smallest among age 
22-44 (RRs 0.691 and 0.825, respectively) (all p<0.01). HHD disparities varied across
groups by age. Results were similar in adjusted multinomial logit models.
Conclusions: There are large racial/ethnic disparities in HD, PD, and Tx use by 
incident ESRD patients. Tx disparities are worse for younger patients, and PD disparities 
are worse for older patients.
Funding: Other NIH Support - NIMHD R01-MD010290
Results do not add to 100%: “other” modalities (e.g., center self-hemodialysis, unknown 
dialysis) excluded.
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Impacts of Medicare Bundled Payment on Utilization of Peritoneal 
Dialysis and Changes in Treatment Modality
Virginia Wang,1,2 Cynthia Coffman,1,2 Linda L. Sanders,1 Richard A. Hirth,3 
Shoou-Yih D. Lee,3 Caroline E. Sloan,1,2 Matthew L. Maciejewski.1,2 1Duke 
Univ, Durham, NC; 2Durham VA HCS, Durham, NC; 3U of Michigan, Ann 
Arbor, MI.
Background: In 2011, Medicare implemented a new policy that bundled reimbursement 
for dialysis treatment and ancillary services, removing incentives that made HD a more 
profitable therapy than PD under the prior payment model. This study examined whether 
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2011 Medicare ESRD bundled payment (BP) was associated with increased rates of PD 
utilization and modality switches.
Methods: We used USRDS and Medicare data to identify all US patients with ESRD 
initiating dialysis (n=619,130) and outpatient dialysis facilities (n=6,433) before (2006-
2010) and after (2011-2013) BP. We used logistic models to examine the BP effect on two 
outcomes of interest observed 90 days after dialysis initiation up to 2 years: any patient 
utilization of PD and change in treatment modality (HD-PD and PD-HD), adjusting for 
patient, dialysis provider, and regional characteristics.
Results: Observed PD utilization increased from 12.5% in 2006, to 15.0% in 2010 (the 
year prior to policy change), and to 18.7% in 2013. In adjusted models, BP was associated 
with increases in PD use in the pre- vs. post-BP era (OR=1.6; 95% CI 1.5,1.6; p<0.0001) and 
an estimated BP effect of 5 percentage points in PD use between pre and post policy periods 
(14% pre vs 19% post, for fixed values of covariates). Observed rates of modality switches 
increased from 6.1% in 2006, to 7.5% in 2010 and 9.0% in 2013. Of those initiating HD in 
the first 90 days, 4.7% switched to PD up to 2 years later in the pre-policy period and 6.3% 
in the post-policy period. Of those initiating PD in the first 90 days, 24.6% switched to HD 
in the pre-policy period and 24.1% in post-policy. In adjusted models, BP was associated 
with higher rates of modality switches for both PD-HD (OR=1.1 95% CI 1.0,1.1; p=0.009) 
and HD-PD (OR=1.4 95% CI 1.4,1.5; p<0.0001). There was an estimated 0.4 percentage 
point BP effect on PD-HD switches (18.0% pre vs 18.4% post) and 1.7 percentage points 
for HD-PD switches (4.4% pre vs 6.1% post).
Conclusions: ESRD bundled payment was associated with increased PD use without 
a substantial increase in modality failure, achieving a secondary goal of payment reform. 
More work is needed to determine whether increased use and HD-PD modality switches 
from payment reform also led to changes in patient characteristics associated with modality 
use.
Funding: NIDDK Support
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Identification of Factors That Are Associated with Risk of Modality 
Failure Among Patients Treated with Peritoneal Dialysis
Steven M. Brunelli,1,2 Dena E. Cohen,1,2 Kathryn S. Gray,1,2 Michelle Cassin,3 
Bram Van hout,3 Julie A. Rodriguez,3 David B. Van Wyck,2 Martin J. Schreiber.3 
1DaVita Clinical Research, Minneapolis, MN; 2DaVita Institute for Patient 
Safety, Denver, CO; 3DaVita Kidney Care, Denver, CO.
Background: Treatment with peritoneal dialysis (PD) is associated with better quality 
of life and clinical outcomes compared to in-center hemodialysis (ICHD). However, a 
substantial number of patients who initiate PD later fail the modality and switch to ICHD. 
Identification of factors that are associated with greater risk of modality failure may 
facilitate targeted interventions to retain patients on PD.
Methods: This retrospective, observational study considered adult patients who, during 
2014-2016, were either prevalent on PD or initiated the modality during that time. Data were 
derived from deidentified electronic health records. The index event was considered as the 
first of at least 3 consecutive PD treatments (exclusive of training treatments). Follow-up 
time began on the first day of the calendar month after index and continued until modality 
failure, or until censoring for study end (31 July 2017) or loss to follow-up. Exposures were 
time-updated on a monthly basis. In this time to event analysis, Cox regression models 
(with robust variance estimators) were each tested on a bivariable basis against outcome, 
followed by joint modeling where multiple potential factors were entered into the model 
simultaneously. Models were adjusted for age, sex, race, history of congestive heart failure 
or amputation, and Charlson comorbidity index. Interactions were tested using likelihood 
ratio testing.
Results: This analysis considered a total of 303,126 patient-months. Factors 
associated with increased risk of PD modality failure included use of continuous 
ambulatory PD, total daily exchange volume >12L, indication that the patient needed 
support for treatment, weight >100kg, change in weight of >2kg, low serum albumin or 
change in albumin >0.4mg/dL, Kt/V<1.7, hospital admission, and clinical indications 
of peritonitis. Factors associated with a lower risk of modality failure were receipt of ≥4 
retraining sessions, residing >20 miles from the treatment center, albumin>4.0 mg/dL, and 
treatment in a facility with >150 patients or a facility in which ICHD was not available.
Conclusions: Modifiable factors may contribute to the risk of modality failure among 
patients treated with PD. Programs targeting these factors may improve time on therapy for 
patients using this modality.
Funding: Commercial Support - This was a research project conducted by the DaVita 
Institute for Patient Safety and supported by DaVita Kidney Care
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Trends in the Rate of Conversion from Peritoneal Dialysis to Hemodialysis
Eric D. Weinhandl,1,2 Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, 
MN.
Background: Conversion from peritoneal dialysis (PD) to hemodialysis (HD) is 
frequently necessitated by medical complications, including peritonitis and ultrafiltration 
failure. Conversion can be disruptive to the patient, as it usually involves a transition from 
dialysis in the home to dialysis in a facility and may require placement of a permanent 
vascular access. In addition, high rates of conversion impose stress on dialysis providers, 
as high rates necessitate additional training in order to maintain program size. We assessed 
rates of conversion from PD to HD among US incident patients in 2006-2015.
Methods: We analyzed data from the United States Renal Data System. For each 
calendar year from 2006 to 2015, we identified all patients that initiated PD within 3 months 
after dialysis initiation. We retained patients with age between 20 and 99 years and non-
missing data regarding race, sex, and primary cause of end-stage renal disease (ESRD). We 
followed patients from first date of PD until the earliest of conversion to HD (defined as 
treatment with HD for ≥2 months), death, kidney transplant, or recovery of renal function, 
but for a maximum of one year. We calculated crude rates of conversion from PD to HD 
in each per-annum cohort and used Fine-Gray regression to estimate the relative hazard of 
conversion from PD to HD as a function of PD initiation year, with adjustment for age, race, 
sex, and primary cause of ESRD.
Results: The number of incident patients on PD reached a nadir of 7924 in the 2008 
cohort and monotonically increased thereafter, with 14,273 incident patients on PD in the 
2015 cohort. Mean age increased slightly during the study era and reached 59.0 years in the 
2015 cohort. The rate of conversion from PD to HD was 20.8 events per 100 patient-years 
in the 2006 cohort and reached a low of 17.6 events per 100 patient-years in 3 subsequent 
cohorts: 2010, 2013, and 2015. By Fine-Gray regression, with the 2010-2011 cohorts as 
referent, the adjusted hazard ratios of conversion from PD to HD were 1.10 (P < 0.001) in 
both the 2006-2007 and 2008-2009 cohorts and 0.99 (P > 0.5) in both the 2012-2013 and 
2014-2015 cohorts.
Conclusions: Although the number of incident patients on PD grew every year from 
2008 to 2015, the rate of conversion from PD to HD during the first year after initiation of 
PD was essentially unchanged between 2010 and 2015.
Funding: Commercial Support - NxStage Medical, Inc., Clinical Revenue Support
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Prescription Patterns in Dialysis Patients – Differences Between  
Hemodialysis and Peritoneal Dialysis and Opportunities for 
Deprescription
Judith G. Marin,1 Laura M. Beresford,2 Gabriela Espino-Hernandez,3 
Monica C. Beaulieu.2 1Providence Health, North Vancouver, BC, Canada; 
2University of British Columbia, North Vancouver, BC, Canada; 3Cancer Care 
Ontario, Toronto, ON, Canada.
Background: Dialysis patients are at high risk for polypharmacy with many 
comorbidities and complications from their disease and treatment. The prescribing patterns 
and burden of polypharmacy in dialysis patients, and specifically the difference between 
hemodialysis and peritoneal dialysis prescribing, are not well characterized. The objectives 
of this study were to review prescribing patterns for dialysis patients, to analyse any 
differences in prescribing patterns between hemodialysis (HD) and peritoneal dialysis (PD), 
and to identify potential opportunities for deprescription.
Methods: We completed a retrospective analysis of demographic and medication data 
for patients who were on chronic dialysis from June 3rd 2015 to October 1st 2015. Both 
prescription and non-prescription medications were collected. Medications were classified 
by indication - (1) renal complications, (2) cardiovascular (CV), (3) diabetes (DM), or 
(4) symptom management. Medications were also classified as “Potentially Inappropriate 
Medications” (PIMs) or not. Ethics approval was granted from the University of British
Columbia Research and Ethics Board.
Results: 3017 patients met inclusion/exclusion criteria (2,243 HD, 774 PD). The 
mean (SD) age was 66.2 (14.8) years. The HD group had more patients over 80 years old 
(22.1% vs 12.5%) and more patients with DM and CV disease. The mean number (SD) of 
prescribed medications was 17.71 (5.72) with more medications in the HD group versus the 
PD group. The mean number of medications increased with dialysis vintage in both groups. 
HD patients were on more medications for renal complication and symptom management 
than PD patients. Patients on HD were prescribed more PIMs than patients on PD (5.37 
(2.83) vs 4.02 (2.37)).
Conclusions: This is the first study to review and characterize both the prescription and 
non-prescription medication use in HD and PD patients. Patients in both groups experienced 
polypharmacy and prescription of PIMs. Patients on HD received more overall medications 
and more PIMs compared to PD patients. There are opportunities for future systematic and 
patient informed deprescription initiatives in both patient groups.
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A Peritonitis Surveillance System Developed by a Large Dialysis 
Organization to Improve the Accuracy and Consistency of Peritonitis Rate 
Reporting in the United States
Martin J. Schreiber, Levi Njord, Meredith L. Zywno, Bram Van hout, 
Julie A. Rodriguez, Michelle Cassin, James R. Tetley. DaVita, Inc, Denver, CO.
Background: Peritonitis (PTN) remains a major reason for hospitalization of peritoneal 
dialysis (PD) patients and may result in transfer to in-center hemodialysis. In August 2015, 
a standardized approach to PTN surveillance was introduced by a large dialysis organization 
(LDO) to improve the consistency and accuracy of PTN event identification across affiliated 
programs in the US. The goal of this analysis was to examine the impact of this new 
surveillance system on the reporting of PTN events since 2015.
Methods: Under the surveillance system, patients with PTN are identified following 
6 hierarchical business rules that include the 4 standard diagnostic rules for PTN (based on 
positive culture, positive cell count, abdominal pain) as well as hospitalization for infection 
and receipt of intraperitoneal (IP) antibiotics (>8 days, >2 vancomycin doses within 8 
days, or >5 doses of non-vancomycin within 8 days). An exemption process exists for PTN 
events based on the IP antibiotic dosing rule alone. Episodes occurring within 28 days of 
identification of a prior episode with the same causal organism were considered relapse 
episodes and were not included in calculations of PTN rates.
Results: During the period August 2015 to December 2017, 10,814 cases of PTN were 
identified under the surveillance system. Of these, 6280 (58.1%) were identified by standard 
diagnostic rules, an additional 2793 (25.8%) were identified based on hospitalization, and 
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a further 1741 (16.1%) were identified based on receipt of IP antibiotics. Exemption filings 
have remained relatively constant over time. The average time to first PTN event was 19.4 
months, with 8.6% of events occurring in the first 90 days on PD. Among PD patients 
overall, 88% experienced no episodes of PTN, 10% developed 1 episode/year, and 2% were 
observed to have 2 or more PTN events/year.
Conclusions: A consistent approach to identifying PTN events combining standard 
criteria with infection-related hospitalizations and IP antibiotic dosing is necessary to 
compare rates between practices in the US and across LDOs and different countries.
Funding: Commercial Support - DaVita, Inc
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Analysis of After-Hours Oral Antibiotic Protocol for the Treatment of 
Suspected Peritonitis in Peritoneal Dialysis Patients
Martin J. Schreiber,1 David A. Pegues,2 Bram Van hout,1 Julie A. Rodriguez,1 
Michelle Cassin,1 Aaron Huwe,1 Levi Njord,1 George R. Aronoff.1 1DaVita, Inc, 
Denver, CO; 2Hospital of the University of Pennsylvania, Philadelphia, PA.
Background: Delays in initiating antibacterial therapy for the treatment of peritonitis 
may lead to increased risk of peritoneal dialysis (PD) failure. Because intraperitoneal 
(IP) antibiotic treatment is not available after business hours at most dialysis centers, it is 
important to have a protocol in place for oral “bridge” therapy until a patient can receive 
IP treatment. The current analysis was conducted, following FDA fluoroquinolone alert 
notifications, to evaluate the probability of activity of selected oral antibiotic agents against 
observed PD infections.
Methods: Causative organisms and oral antibiotic susceptibility were analyzed for all 
peritonitis cases identified during 2016 among PD patients treated by an LDO. Based on 
these findings, we determined the probability of activity of selected oral antibiotic agents 
(cefazolin, cefdinir, ciprofloxacin, trimethoprim/sulfamethoxazole [TMP/SMX]) against 
infections overall, gram-positive infections, and gram-negative infections.
Results: A total of 4534 cases of peritonitis were analyzed. Causative organisms were: 
coagulase-negative Staphylococcus (41.4%), gram-negative rods (21.2%), Staphylococcus 
aureus (8.1%), Streptococcus (9.9%), Enterococcus (5.5%), fungal (3.9%), other (12.5%). 
Assuming this distribution of pathogens for PD infections overall, TMP/SMX was predicted 
to be the most active agent (57.2% of episodes susceptible), followed by cefdinir (50.6%), 
ciprofloxacin (42%), and cefazolin (39.4%). Among gram-positive infections alone, 74.3% 
would be expected to be susceptible to TMP/SMX, and 62.7% to cefdinir. Among gram-
negative infections, ciprofloxacin was predicted to be the most active agent (84.3% of 
episodes susceptible).
Conclusions: Early initiation of treatment for peritonitis is critical to avoid PD failure. 
Designing a strategy for early therapy administered at home, until a patient can receive IP 
treatment, can potentially improve outcomes. Based on the current analyses, TMP/SMX 
and cefdinir are predicted to be the most active oral agents for the treatment of suspected 
gram-positive infections. Ciprofloxacin should be used only in the case of suspected high-
risk, gram-negative infections.
Funding: Commercial Support - DaVita, Inc.
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Serum Galactomannan and (1→3)-β-D-Glucan Testing for Rapid 
Detection of Fungal Peritonitis
Talerngsak Kanjanabuch,1 Tamonwan Chamroensakchai,2 Thunvarat Saejew.2 
1Medicine, Pathumwan, Thailand; 2chulalongkorn hospital, Bangkok, Thailand.
Background: Fungal peritonitis is one of the most serious complications of peritoneal 
dialysis. Early detection of the causative organism is a key determining outcome; however, 
routine culture is time consuming and KOH staining has very low sensitivity. Hence serum 
(1→3)-β-D-glucan (BG) or galactomannan (GM), both fungal cell wall components, may 
be candidate biomarkers of fungal peritonitis.
Methods: A comparative multi-centered cross-sectional analysis of paired serum and 
peritoneal dialysis fluid (PDF) BG (Fungitell, Cape Cod, MA, USA) and GM (Platelia 
Aspergillus Ag kits, Bio-rad, France) from all PD patients with and without fungal 
peritonitis (23 cases, 8 cases with bacteria and 23 cases control identified by culture), over 
a 1 year period, was performed.
Results: PDF and serum of the fungal peritonitis group showed very high GM 
(2.42±2.15, 1.85±1.22) and BG (410.0±158.3, 355.9±246.9) compared to bacterial 
peritonitis (0.28±0.12, 0.34±0.14), (7.81±0, 7.81 ±0) and healthy control (0.42±0.16, 
0.39±0.10), (7.81 ± 0, 7.81±0), respectively. A GM cut-off value at at 0.5 and BG at 80 pg/
ml. showed positive predictive value (PPV) of GM test was 95.45% and negative predictive 
value (NPV) was 93.75%. The sensitivity and specificity of GM testing in PDF and serum 
were 91.3% and 96.8% respectively.
Conclusions: BG and GM in peritoneal dialysis fluid and serum with provisional cut-
off values were applicable as surrogate biomarkers for the diagnosis of fungal peritonitis 
in PD patients.
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Smartphone-Based Point-of-Care Diagnostics for Early Detection of 
Peritonitis
Nadja Grobe,1 Xia Tao,1 Mia G. Garbaccio,1 Maricar Villarama,2 
Christopher Hanrahan,2 Stephan Thijssen,1 Peter Kotanko.1 1Renal Research 
Institute, New York, NY; 2RRI/Avantus, New York, NY.
Background: Peritonitis is a serious complication in peritoneal dialysis (PD) and 
associated with significant morbidity and mortality. Diagnostic criteria include turbid 
effluent with >100 leukocytes/μl, abdominal pain, and a positive culture. Since accurate 
diagnosis and a short time-to-treatment are essential for therapy success, we developed 
a smartphone-based system to measure turbidity in PD fluid. Its use was evaluated in the 
settings of continuous ambulatory PD (CAPD) and continuous cycling PD (CCPD).
Methods: Total cells of one normal PD effluent were isolated, concentrated, and 
characterized by count, differential, Wright-Giemsa staining, and flow cytometry. PD 
effluent was spiked with known amounts of cells isolated from the PD effluent ranging 
from 5 to 90 leukocytes/μl. Solutions were analyzed in a cuvette (CAPD setup) or pumped 
through a drain line at 100 ml/min (CCPD setup). Turbidity was measured using the light 
sensor of a commercially available smartphone. An app (developed in-house) recorded 
illuminance in real time.
Results: PD effluent contained a total of 159 cells/μl of which 94.4% were red blood 
cells, 2.5 % leukocytes and 3.1% platelets. The differential showed 7.7% neutrophils, 71% 
lymphocytes, 18.7% monocytes, 0.8% eosinophils and 1.8% basophils. The PD effluent cell 
population was confirmed by Wright-Giemsa stain. Flow cytometry showed 20% peritoneal 
debris. Using the light sensor of the smartphone, a decrease in illuminance was detected 
with increasing cell concentration. At 90 leukocytes/μl, illuminance was decreased by 15% 
and 13% in CAPD and CCPD, respectively. The figure exemplifies the tight relationship 
between cell concentration in the PD effluent and illuminance in the CCPD setting.
Conclusions: A sensitive method to detect an increase of leukocytes in PD effluent was 
developed. This smartphone-based approach may aid in earlier detection of peritonitis in PD 
patients since even minor cloudiness can be measured.
Funding: Commercial Support - Fresenius Medical Care North America
Relationship between cell concentration in the PD effluent and illuminance.
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Relative Dialysate White Blood Cell Change Can Predict Treatment 
Failure in Peritoneal Dialysis-Related Peritonitis: Development and 
Validation Studies
Pichaya Tantiyavarong,1,2 Natapol Khumsiri,1 Krittapong Somboon,3 
Piyatida Chuengsaman.4 1Division of Nephrology, Department of Medicine, 
Thammsat University Hospital, Pathum thani, Thailand; 2Division of Clinical 
Epidemiology, Faculty of Medicine, Thammsat University, Pathumthani, 
Thailand; 3Department of Medicine, Kalasin Hospital, Kalasin, Thailand; 
4Banphaeo-Pattanakarn Peritoneal Dialysis Center, Banphaeo Hospital, 
Bangkok, Thailand.
Background: Absolute dialysate white blood cell count (aWBC) can predict treatment 
failure; however, no study explores predictive ability of relative dialysate white blood cell 
count (rWBC).
Methods: In this study, there were 3 cohorts. The first (Development set) and second 
cohorts (Temporal validation set) were conducted in Banphaeo Hospital in different periods. 
The third cohort (Geographic validation set) was conducted in Kalasin Hospital. Treatment 
failure was defined as either peritonitis-associated death or transferring to hemodialysis 
according to physician’s judgment. Area under receiving-operating characteristics curve 
(AUC) of rWBC and aWBC on day 0, 3 and 5 after initial antibiotic treatment were 
compared. Finally, we defined a cut point of remaining rWBC on day 3 and 5 of ≥33% and 
≥15% as a non-response criteria, and compared predictive probability to aWBC criteria 
(aWBC on day 3 and 5 of ≥1,090 and ≥100 cell/mm3).
Results: There were 316 (cohort 1), 202 (cohort 2) and 110 (cohort 3) episodes of 
PD-related peritonitis included for analysis. The majority of initial antibiotic regimens in all 
cohorts were intraperitoneal Cefazolin and Ceftazidime. Overall treatment failure rate was 
19%, 24% and 32%, respectively. Discriminative ability showed similar AUC of rWBC 
and aWBC on day 3 and day 5 (Figure 1). Baseline WBC had poor AUC. Using a defined 
cut-off criteria, rWBC ≥15% on day 5 had a better predictive ability comparing to aWBC 
≥100 cell/mm3 in the development set (52% vs 44%) and in two validation sets (61% vs 
55% and 57% vs 51%).
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Conclusions: rWBC ≥15% on day 5 showed a good predictive probability. We suggest 
to use this pattern as an alternative criteria to predict treatment failure in PD-related 
peritonitis.
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Association Between Serum Diamine Oxidase, D-Lactic Acid, and 
Peritoneal Dialysis Related Peritonitis
Jieshuang Jia.1,2 1Shanghai general hospital, Shanghai, China; 2school of 
medicine, Shanghai Jiaotong University, Shanghai, China.
Background: Abdominal infection is one of serious complications of peritoneal 
dialysis patients. Studies have shown dysfunctional intestinal barrier seriously affects the 
efficacy of peritoneal dialysis, and increases serum diamine oxidase(DAO) and D-lactic 
acid(DLA) levels.
Methods: To investigate the changes of DAO and DLA in patients with peritoneal 
dialysis-associated abdominal infection, and to find predictable indicators of abdominal 
infection. We collected 45 peritoneal dialysis patients from January 2017 to January 2018. 
They include 30 patients without abdominal infection and 15 patients with abdominal 
infection. We observe the serum levels of DAO, DLA, albumin(ALB), hemoglobin(Hb), 
interleukin-6(IL-6), and tumor necrosis Factorα(TNFα).
Results: 1. In the patients with abdominal infection, the levels of DAO 18.7±4.9(U/L), 
DLA 40.1±10.2(mg/L), IL-6 12.8±3.5(pg/ml), TNFα18.9±6.7 (pg/ml)(P<0.05) after 
abdominal infection were significantly higher than those before abdominal infection. 
2. In the patients without infection, the levels of DAO 2±0.5 (U/L), DLA 10±2 (mg/L),
IL-6 2.8±2.1 (pg/ml) and TNFα4.2±3.4 (pg/ml) (P<0.05) were obviously lower than
those of pre-infection indicators in patients with abdominal infection.3. In patients with
abodminal infection, pre-infection serum ALB 25.1±5.6 (g/L), Hb 90±10.7 (g/L) (P<0.05) 
decreased compared with the data in non-infection group. 4. According to the medical
histories we found that in the 15 cases of abdominal infection, 10 cases had a history of
diarrhea. Among them, 3 cases of patients had taken drugs regulating intestinal flora;In 
contrast to patients without drugs, the interval of abdominal infection were prolonged from 
1.5 ± 2 months to 10±5.3 months (P>0.05), the levels of DAO, DLA, IL-6 and TNFα were 
decreased(P<0.05), and ALB and Hb levels were decreased(P>0.05).
Conclusions: Serum DAO, DLA levels may be predictors of peritoneal dialysis 
abdominal infection;Intestinal barrier disorders induces elevated DAO and DLA which 
induce the increase of inflammatory cytokines IL-6 and TNFα, affect the nutritional 
status of patients, decrease ALB and Hb level and promote the abdominal infection; drugs 
regulating intestinal bacteria prolong the period of infection but the data are not statistically 
significant. Large sample studies are needed. The mechanism how intestinal barrier 
dysfunction induced abdominal infection needs further study.
Funding: Private Foundation Support
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A New Initiative to Measure the Provincial Rate of Peritoneal Dialysis 
Related Peritonitis in Ontario
Philip McFarlane,1 Angie Yeung,2 Janet L. Graham,5 Jane Ip,2 Arsh Jain,3 
Monisha Patel,4 Gihad E. Nesrallah.6 1St. Michael’s Hospital, Toronto, ON, 
Canada; 2Cancer Care Ontario, Toronto, ON, Canada; 3London Health Sciences 
Center, London, ON, Canada; 4Ontario Renal Network, Toronto, ON, Canada; 
5The Ottawa Hospital, Ottawa, ON, Canada; 6The University of Western 
Ontario, Toronto, ON, Canada.
Background: Peritonitis is an important complication of peritoneal dialysis (PD), as it 
is the most common cause of PD technique failure. In April 2016, the Ontario Renal Network 
(ORN, which funds dialysis in Ontario) launched a provincial quality improvement (QI) 
initiative with the aim to shift from local monitoring of peritonitis rates to a province-wide 
standardized tracking system. The initiative was launched with the objectives of defining 
a provincial average rate of peritonitis, and an individualized rate for each of the Regional 
Renal Programs (RRP), comparing provincial rates against the ISPD benchmark of 0.67 
cases per annualized patient and sharing provincial data and developing program-level QI 
plans to help minimize peritonitis risk.
Methods: All 26 RRPs in Ontario collected and reported data from May 2016 – 
December 2017 using a tracking tool incorporating indicator methodology developed by 
an expert panel. Reported peritonitis events formed the numerator for the rate calculation, 
while the denominator was derived from the Ontario Renal Reporting System database 
(ORRS) to calculate person-time on PD. The peritonitis rate is expressed as number of 
infections per year at risk, combining patient-time from all PD patients at each RRP.
Results: Over a period of 20 months (May 2016 to December 2017), 888 unique 
peritonitis cases were reported over a total of 1,426,243 patient days (3908 annualized 
patients). Program-level peritonitis rates ranged from 0.10 – 0.44 and the provincial average 
was 0.23 episodes/365 PD catheter-days. Quarterly reports were shared with the programs 
for data validation, comparison and monitoring purposes. The initiative enabled consistent 
measurement and reporting of peritonitis that allowed programs to benchmark themselves 
against their peers, and design local quality improvement plans.
Conclusions: The risk of peritonitis is deemed to be relatively low in Ontario, and 
consistently below ISPD targets. This initiative has produced a sustainable system of data 
collection for monitoring the risk of peritonitis, and is part of a larger strategy to ensure that 
all patients receiving dialysis therapy experience as few complications as possible for safe 
and individualized dialysis access.
Funding: Government Support - Non-U.S.
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Significant Decrease in PD Peritonitis Rate Using FMC Multiple Tubing 
Segment Set with Stay Safe Pin Technology Compared to Baxter MiniCap 
Extended Life PD Transfer Set
Harish R. Alappan,1 Jennifer Thompson,2 Raj Alappan.3 1Emory University - 
Undergraduate, Atlanta, GA; 2Davita, Columbus, GA; 3Renal Associates, LLC, 
Columbus, GA.
Background: Peritoneal Dialysis Peritonitis (PDP) is a common and serious 
complication of Peritoneal Dialysis (PD) resulting in structural & functional alteration in 
membrane function and membrane failure. Reporting PDP rates varies by country. As of 
2016, ISPD recommends a rate < 0.5 episodes/year at risk. Any measures to reduce PDP rate 
is of utmost importance. We analyzed our PDP data retrospectively, comparing Baxter to 
FMC transfer sets for PDP. Our center has one of the lowest PDP rates compared to ISPD’s 
2016 PDP recommendation.
Methods: PD data from Davita Home Dialysis Center, Columbus GA was 
retrospectively analyzed from Aug. 2013 to Dec. 2017. During this period a total of 111 PD 
patient data was available for analysis. Baxter transfer sets were used initially from Aug. 
2013, and then transitioned to FMC transfer set from 2016 onwards. During this period (53 
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months) there were 39 PDP episodes; of these 32 were single episode. PDP rate per year 
and per month was calculated for overall study group and between Baxter and FMC Sets.
Results: Total of 111 patients, mean age is 57.82 ± 1.89 yrs, 68(61%) male, 66 
(59.5%) used Baxter & 45(40.5%) used FMC transfer set. Mean BMI was 32.15, nPR 
0.727, Albumin 3.41 g/dL, HB 10.25 g/dL, PTH 465.93, with a mean K+ of 4.35 mmol/dL. 
21 PDP episodes (53.8%) were due to Staph species. For a total of 159.67 PD years, overall 
PDP rate in the cohort was 0.244/year, and 1 PDP in every 4.304 years or 1 in every 51.65 
months. First PDP occurred at a mean of 465.2 days from the start of PD. Baxter patient had 
higher KTV at 2.101 ± 0.11, versus FMC 1.746 ± 0.11 (p=0.035).
Conclusions: Data from our center indicates our PDP rate is significantly lower 
in comparison to ISPD data, suggesting both Baxter and FMC transfer sets are equally 
effective in achieving such a low PDP rate. Baxter’s higher KTV rate correlates to higher 
PDP rate. Between the two, the FMC transfer set was more effective in reducing PDP, with 
the lowest rate and more delayed occurrence of PDP. We recommend a large prospective 
study to validate our data.
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Apartment vs Single Family Home and Its Effect on Peritonitis Among 
Peritoneal Dialysis Patients, A Single Center Study in an Urban 
Population
Omar Farrukh,1 Vesh Srivatana.2 1NYP-Weill Cornell, New York, NY; 2The 
Rogosin Institute, New York, NY.
Background: Peritonitis is a significant complication among patients undergoing 
Peritoneal Dialysis (PD). It can lead to significant morbidity, loss of ultrafiltration, permanent 
membrane damage, and treatment failure. Social aspects including geographical location 
and educational status have been implicated in the risk of developing peritonitis however 
no studies have assessed the impact of living space on peritonitis risk. We hypothesize that 
nephrologists may not offer PD to patients with small living quarters due to a perceived 
increased risk of peritonitis. This issue is exacerbated in urban populations where most 
patients live in apartments and not single family homes. Our aim was to determine if home 
size has any impact on PD peritonitis.
Methods: A retrospective review of prevalent patients undergoing Peritoneal Dialysis 
between 1998 and 2005 in a single center in an urban population. Inclusion Criteria were 
all adult patients with complete follow up and housing information for the duration of PD 
treatment. Data collected for each individual patient included Race, Gender, Age at time of 
initiation of PD, Presence of Diabetes, BMI, Type of living quarters (House vs Apartment), 
occurence of Peritonitis and time to first peritonitis or PD discontinuation.
Results: A total of 85 patients met the inclusion criteria and had 35 individual episodes 
of PD peritonitis. A Univariate Logistic Regression between type of living quarters and 
Peritonitis had an Odds Ratio 0.53, 95% Confidence Interval, 0.22 to 1.27, p=0.158. We 
then performed a multivariate logistic regression to control for known independent risk 
factors for peritonitis including, age, gender, race, diabetes, BMI and residual renal function 
and found an Odds Ratio 0.48, 95% confidence interval, 0.18 to 1.28. p=0.144. A Cox 
Regression analysis was then performed to assess the time to peritonitis in relation to living 
in an apartment with a Hazard Ratio 0.65, 95% confidence interval 0.33 to 1.24, p= 0.186.
Conclusions: To our knowledge this is the first study to examine the effect of living 
quarters on PD peritonitis in an urban population. Our data suggests that there is no increased 
risk of peritonitis based on living quarters and should not be a contraindication for PD.
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Development of Risk Prediction Model for Infection-Related Mortality in 
Peritoneal Dialysis Patients
Hiroaki Tsujikawa,1 Shigeru Tanaka,2 Hidetoshi Kanai,3 Kazuhiko Tsuruya,4,6 
Toshiaki Nakano,1 Takanari Kitazono.5 1Department of Medicine and Clinical 
Science, Kyushu University, Fukuoka, Japan; 2Fukuoka Dental College, 
Fukuoka, Japan; 3Kokura Memorial Hospital, Kita Kyushu, Japan; 4Nara 
Medical University, Kashihara, Japan; 5Department of Medicine and Clinical 
Science, Fukuoka, Japan; 6Department of Integrated Therapy for Chronic 
Kidney Disease, Kyushu University, Fukuoka, Japan.
Background: The risk assessment for infection-related mortality remains limited in 
patients on peritoneal dialysis (PD). The aim of this study was to develop a risk model to 
predict the 2-year infection-related mortality risks in PD patients.
Methods: A total of 606 patients who started and continued PD over 90 days from 
Fukuoka PD Registry Study in Japan were enrolled into the study. Participants were 
enrolled from January 1, 2006 to December 31, 2016 and followed up until December 31, 
2017. To create a prediction rule, the score for each variable was weighted by the regression 
coefficients calculated using a Cox proportional hazards adjusted by the risk factors for 
infection-related mortality, including demographic, comorbidities and laboratory data.
Results: During a follow-up period (median, 2.2 years), a total of 138 patients died; 
58 of these patients died of infectious disease. The final model for infection-related 
mortality consisted of six factors, including age, sex, serum albumin, serum creatinine, total 
cholesterol and renal Kt/V. The incidence of infection-related mortality increased linearly 
with an increase in the total risk score (P for trend <0.001). Furthermore, the prediction 
model showed adequate discrimination [c-statistic=0.73 (0.67–0.79)] and calibration 
(Hosmer-Lemeshow test, P=0.66).
Conclusions: In this study, we developed a new prediction model using clinical 
measures for infection-related mortality in PD patients.
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Peritonitis Before Peritoneal Dialysis Training: A Single Center 
Experience
Saw Yu Mon,1,2 Usman Mahmood,3 Carmel M. Hawley,1,2 David W. Johnson,1,2 
Magid Fahim,1,2 Yeoung Jee Cho.1,2 1Department of Nephrology, Princess 
Alexandra Hospital, Brisbane, QLD, Australia; 2School of Medicine, University 
of Queensland, Brisbane, QLD, Australia; 3Toowoomba Hospital, Toowoomba, 
QLD, Australia.
Background: Peritoneal dialysis (PD)-related peritonitis is an important risk factor 
for death and technique failure in PD patients. The predictors and outcomes of peritonitis 
prior to commencing PD (pre-training peritonitis [PTP]) are poorly understood. The aim 
of this study was to examine risk factors and long-term patient outcomes in those who 
experience PTP.
Methods: This single-center, matched case-control study included patients 
commencing PD from 1January 2005 to 31December 2015. PTP patients were matched 1:3 
with those who developed peritonitis after PD training, based on tertiles of age and diabetic 
status. We examined risk factors for PTP, immediate and long-term outcomes, including 
technique and patient survival.
Results: Thirty-eight patients with PTP were identified and matched to 114 control 
patients. Compared to controls, PTP patients were significantly more likely to have history 
of hypertension (100% vs 89%, p=0.04), late nephrologist referral (21% vs 9%,p=0.04), 
open surgical PD catheter insertion (82% vs 44%,p<0.001), and pre-training exit site 
infection (34% vs 2%,p<0.001). PTP patients experienced comparable rates of peritonitis 
cure (58% vs 65%, p=0.50), temporary haemodialysis transfer (13% vs 11%,p=0.77), 
technique survival (HR 1.47, 95% CI 0.94-2.29,p=0.09) and patient survival (HR 1.35, 
95% CI 0.52-3.49,p=0.54). There was a significant two-way interaction between history of 
ischaemic heart disease (IHD) and PTP status (p=0.02), such that technique failure risk was 
increased in PTP patients with IHD (HR 2.82, 95% CI 1.37-5.84,p=0.005) but not those 
without IHD (HR 0.88, 95% CI 0.41-1.92,p=0.75).
Conclusions: The risk of PTP was increased by factors relating to patient, catheter 
insertion approach and clinical events. Patient outcomes were comparable between PTP 
and post-training peritonitis, except for a greater risk of technique failure in patients with 
PTP and IHD.
Technique survival for PTP group compared with non-PTP group
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Feasibility of Resuming Peritoneal Dialysis After Catheter Removal Due 
to Severe Peritonitis
María C. Chediak, Haridian Sosa Barrios, Victor Burguera, Melissa Cintra 
Cabrera, Milagros Fernandez lucas, Maite Rivera. Nephrology, Hospital Ramón 
y Cajal, Madrid, Spain.
Background: The resumption of peritoneal dialysis (PD) after a peritonitis requiring 
peritoneal catheter (PC) removal is unlikely and remains poorly studied. We analyzed the 
characteristics and outcomes of patients resuming PD after peritonitis.
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Methods: We reviewed all episodes of peritonitis between 1996 and 2017 and identified 
the cases in which the catheter was removed. We compared the data of patients who restarted 
PD after PC removal (Group 1) with those who did not (Group 2) and identified the causes.
Results: Of 483 peritonitis episodes, PC was removed in 48 patients (16.9%). 
Of these, 18 (37.5%) resumed PD and 30 (62.5%) did not. The median duration of PD 
before catheter removal was 24.5 months (range 14.2-40) and the number of previous 
peritonitis episodes was 2 (range 1-3). The indications for catheter removal were: 
refractory and relapsing peritonitis; fungal, mycobacterial and polymicrobial peritonitis. 
The organisms identified were: S. aureus 20.8% (n=10), Candida sp 18.8% (n=9), P. 
aeruginosa 14.6% (n=7), other Gram-negative bacilli 20.8% (n=10), mixed growth 8.3% 
(n=4), Mycobacterium sp 6.3% (n=3), other Gram-positive 4.2% (n=2) and no growth 
6.3% (n=3). Group 1 (n=18): 89.9% (n=16) were male, median age was 53 years (range 
44 – 64) and Charlson Index was 4 (range 2 – 6). PD was resumed successfully in all 
with a median duration of PD afterwards of 14.1 months (range 4-69). Group 2 (n=30): 
60% (n=18) were male, median age was 64 years (range 48 – 76) and Charlson Index 
was 6 (range 4 – 8). Causes of no reinsertion were: death due to peritonitis 16.7% (n = 5), 
transplantation 6.7% (n = 2) and transfer to hemodialysis (HD) 76.6% (n = 23). 
HD- switch was due to non- medical reasons in 47.8% (n = 11), including fear of 
peritonitis 10.4% (n=5), family decision 36.3% (n = 4) and social dependence in 18.2% 
(n = 2). Group 1 was younger (p = 0.041), had a higher proportion of men (p = 0.049) and 
a lower Charlson index (p = 0.045). No other statistically significant difference was found 
between both groups.
Conclusions: Resuming PD after PC removal is feasible. A high proportion of patients 
do not restart PD for non-medical reasons, mostly fear of peritonitis and family decision.
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Linoleic Acid Co-Treatment Inhibits Bacterial Biofilm Formation in 
Continuous Ambulatory Peritoneal Dialysis (CAPD) Catheter
Gang Jee Ko,1 Shin-Young Ahn,1 Eunjung Cho,1 Young-Joo Kwon,1 Eunji Cha,2 
Han shin Kim,2 Hee deung Park.2 1Department of Internal Medicine, Korea 
University College of Medicine, Guro Hospital, Seoul, Republic of Korea; 
2School of Civil, Environmental and Architectural Engineering, Korea 
University, Seoul, Republic of Korea.
Background: Peritonitis is a serious complication in patients receiving PD responsible 
for significant morbidity and technical failure. Biofilm formation of catheter is considered 
as an underlying mechanism for relapsing, recurrent and intractable peritonitis. However, 
little has been known to prevent it. Here we aimed to investigate the protective effect of 
linoleic acid (LA) on catheter biofilm formation, which is one of the elements of ginger 
extract demonstrated an inhibitory effect on biofilm of industrial and environmental settings 
such as water pipes system.
Methods: Biofilm was formed by overnight culture of S.aureus and P. aeruginosa (PA 
14) with and without treatment of LA, and quantified by measurement of OD at 595nm after 
staining of crystal violet. The amount of extracellular polymeric substance (EPS) attached 
to biofilm was also examined. Additive therapeutic effect of LA on biofilm formation was 
examined by co-treatment of antibiotics (cefazolin(CF) for S.aureus and tobramycin(TM)
for P.aeruginosa) with LA. Intracellular cyclic digulanylate (c-di-GMP) and related gene
activity under LA treatment were also examined. Cellular and functional toxicity of LA was 
assessed using human mesothelial cells and mice.
Results: LA treatment reduced biofilm formation (0, 10 and 100nM: 1.41±0.17, 
0.95±0.11, 0.64±0.07, p<0.001, respectively), and EPS production was also markedly 
decreased. After LA treatment, reduction of c-di-GMP, secondary messenger of 
microorganism, and related gene activities were observed. Bacterial biofilm inhibitory 
effect was synergistically increased by co-treatment of LA (25nM) with antibiotics (CF vs. 
CF+LA: 0.60±0.03 vs. 0.13±0.19, TM vs. TM+LA 0.18±0.05 vs. 0.06±0.04). Cytotoxicity 
measured by LDH and MTS assay was not increased, and liver and renal functional and 
histologic abnormalities were not observed in mice after LA treatment.
Conclusions: Co-treatment of LA with antibiotics was effective to inhibit bacterial 
biofilm formation in catheter. It should be studied further as a therapeutic strategy to reduce 
recurrent peritonitis.
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Predictive Values of Different Blood Pressure Measurements for Left 
Ventricular Diastolic Dysfunction in Peritoneal Dialysis Patients
Yun Jung Oh,1 Su mi Lee,2 Jiwon Ryu,1 Chungsik Lee.1 1Internal Medicine, 
Cheju Halla General Hospital, Jeju, Republic of Korea; 2Internal Medicine, 
Dong-A University Hospital, BUSAN, Republic of Korea.
Background: Cardiovascular diseases (CVDs) are main causes of death in end stage 
renal disease (ESRD) patients and one of the CVDs, left ventricular diastolic dysfunction is 
suggested to be associated with increased mortality in these patients. Hypertension is known 
to be implicated in the pathogenesis of diastolic dysfunction and an important modifiable 
risk factor for diastolic heart failure. In this study, we compared different methods of blood 
pressure (BP) measurement and evaluated comparative values of BP measurement for 
predicting diastolic heart dysfunction in patients on peritoneal dialysis (PD).
Methods: A total of 52 prevalent PD patients were enrolled. We measured ambulatory 
BP, office BP, home BP, and central BP. The ambulatory BP was recorded for 24 hours, 
office BP was measured at least in two visits, and home BP was measured for one week. The 
central BP was estimated using radial artery tonometry. Patients underwent transthoracic 
echocardiography and the presence of diastolic dysfunction was determined according to 
2016 American Society of Echocardiography and European Association of Cardiovascular 
imaging (ASE/EACVI) guideline.
Results: Left ventricular diastolic dysfunction was best predicted by ambulatory 
systolic BP (area under the curve (AUC), 0.845; 95% CI, 0.726-0.964). The office 
systolic BP (AUC, 0.661; 95% CI, 0.457-0.866), home systolic BP (AUC, 0.661; 95% CI, 
0.481-0.842), and central systolic BP (AUC, 0.623; 95% CI, 0.441-0.805) were inferior 
to ambulatory systolic BP monitoring in predicting diastolic dysfunction. In multivariate 
analysis adjusted for age, sex, PD vintage, diabetes and coronary artery disease, only 
ambulatory systolic BP had significantly increased OR for diastolic dysfunction (OR, 1.094; 
95% CI 1.004-1.192). The other adjusted ORs of office, home, and central systolic BP for 
diastolic dysfunction were not statistically significant.
Conclusions: Ambulatory systolic BP was the strongest predictor of left ventricular 
diastolic dysfunction in comparison with the other BP measurements including office, 
home, and central systolic BP, in ESRD patients on PD.
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A Machine Learning Model to Predict Patient Risk of Peritonitis Episodes
Tommy C. Blanchard, Joanna Willetts, Michael R. O’Connell, Sheetal Chaudhuri, 
Len A. Usvyat, Brian C. Ellison, Judith Moran, Melissa Herman, 
Susan M. Dunphy, Franklin W. Maddux. Fresenius Medical Care North 
America, Waltham, MA.
Background: Peritonitis infections are one of the primary complications in the use 
of peritoneal dialysis. Predicting what patients are at a higher risk of peritonitis is of great 
interest so that cases of peritonitis can be caught early, or patients can be given additional 
training to prevent peritonitis infections altogether.
Methods: We analyzed data of 36,329 peritoneal dialysis patients who were treated 
by a large dialysis provider from 2016-2017. We had 10,522 cases of peritonitis over this 
period. We trained a machine learning model (XGBoost boosted tree model) to predict 
which patients will be diagnosed with a peritonitis infection in the next month based on 
patients’ history of peritonitis, symptoms noted by nurses during assessments, routine 
clinical laboratory values, and demographic data.
Results: Our machine learning model achieved an area under the ROC curve of 0.736. 
The features that were found to be most important for prediction were: whether the patient 
has had a previous peritoneal infection, how long the patient has been on peritoneal dialysis 
days since previous infection, changes in potassium levels, and albumin levels (Table 1).
Conclusions: We built a machine learning model that was able to predict which 
patients will have a peritonitis infection in the next month. This model can be used to 
allocate resources to try to catch infections early or prevent them. Future work can expand 
the features the model has access to in order to improve the model performance.
Funding: Commercial Support - Fresenius Medical Care
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Short Patient and Technique Survival Following First Peritonitis in 
Peritoneal Dialysis Patients: Does Timing of First Peritonitis Matter?
Wael A. Al-Bader,1,2 Hossam A. Nassef.3 1Medicine, Kuwait University, Kuwait, 
Kuwait; 2Nephrology, Al-Sabah Hospital, Kuwait, Kuwait; 3Ministry of Health, 
Kuwait, Kuwait.
Background: To investigate whether patient and technique survival in peritoneal 
dialysis (PD) are related to timing of first peritonitis.
Methods: In this retrospective study, 144 patients on peritoneal dialysis who were 18 
years of age and older and had at least one episode of peritonitis between 2004 and 2016 
were included. They were divided into early peritonitis (EP) group (n = 97) which included 
patients who had their first peritonitis within 12 months from start of PD therapy, and late 
peritonitis (LP) group (n = 47) which included patients who had their first peritonitis after 
12 months from start of PD therapy. Technique and patient survival of both groups were 
compared in terms of time following first incident peritonitis using Cox proportional hazard 
model.
Results: EP group had shorter time on PD therapy compared to LP group (median 16.7 
± 13.1 vs 39.8 ± 20.1 months respectively, p < 0.001). However, EP and LP groups had
similar patient survival in relation to time following first incident peritonitis (16 % vs 19 % 
at 24 months, HR: 0.96, CI 95%: 0.84 – 1.23, p = 0.9) and similar technique survival (16% 
for both groups at 24 months, HR: 1, CI 95%: .96 – 1.04, p = 0.7). There was no difference 
in causal microorganisms between both groups (p = 0.45).
Conclusions: Incident first peritonitis is associated with short patient and technique 
survival independently of time taken to develop the event.
Funding: Government Support - Non-U.S.
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Exit-Site Infection Associated with Baseline Body Mass Index in Patients 
Initiating Peritoneal Dialysis
Hironori Nakamura, Anayama Mariko, Yasushi Makino, Masaki Nagasawa. 
Department of nephrology, Sinonoi General Hospital, Nagano, Japan.
Background: The International Society for Peritoneal Dialysis (PD) guidelines 
recommend the monitoring of PD-related infections as well as the incidence of peritonitis. 
However, the incidence rate of PD-related infections or the associated clinical factors have 
not been well investigated.
Methods: Forty-seven patients who initiated PD between 2012 and 2017 were 
retrospectively reviewed. The clinical data were compared between the patients developing 
exit-site infection (ESI) and those who did not during the initial 60 days after initiating 
PD. Kaplan–Meier analysis and Cox proportional hazards model were used to identify the 
factors associated with ESIs using the time to initial ESI from data in the cohort. An ESI was 
defined as the presence of purulent drainage with positive culture results, and was counted 
as one occurrence when the infection lasted for <4 weeks.
Results: The number of annual ESI events and their annual incidence rates between 
2012 and 2017 were 1, 6, 18, 32, 20, and 36 and 0.83, 0.86, 1.36, 1.09, and 1.59 (per 
patient-years), respectively. The body mass index (BMI) in patients who developed ESIs 
before the initial 60 days (25.9 ± 4.4 kg/m2) was significantly higher than that of patients 
who did not develop ESIs (21.7 ± 2.8 kg/m2); the occurrence of diabetes mellitus (DM) 
was also significantly higher (9/16 vs. 7/31) and the D/P Cr was significantly lower 
(0.57 ± 0.08 vs. 0.66 ± 0.10) in patients with ESIs than in those without ESIs. There were 
no significant differences in variables, such as age, sex, stepwise PD initiation, presence 
of caregiver, and serum albumin, between the two groups. Kaplan–Meier revealed that the 
high BMI group divided by the median value and the occurrence of DM indicated a higher 
rate of ESI (Log-Rank: p = 0.006 and 0.026, respectively) compared with the group with 
low BMI and that without DM. The Cox proportional hazards model revealed that ESI 
events during the 2 years were significantly affected by the patients’ BMI [hazard ratio 
(HR), 1.236; 95% confidence interval (95% CI), 1.07–1.41; p = 0.002] but not by the 
presence of DM (HR, 0.952; 95% CI, 0.29–3.03; p = 0.934).
Conclusions: Our findings suggest that ESIs are associated with baseline BMI of 
patients initiating PD in our study population. Body weight control at the time of PD 
initiation can potentially diminish the risk of ESI.
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Estimating Residual Kidney Function in Dialysis Patients Without Urine 
Collection
Dominik Steubl,1,12 Li Fan,3 Lesley Inker,1 Hocine Tighiouart,1 Friedo W. Dekker,6 
Amy B. Karger,7 John H. Eckfeldt,8 Hao Zhang,9 Jing Hu,2 Yunhua Liao,10 
Tariq Shafi,4 Wei Chen,11 Xueqing Yu,5 Andrew S. Levey.1 1Tufts Medical Center, 
Boston, MA; 2The third Xiangya hospital of Central South Univercity, Changsha, 
China; 3Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen 
University; Key Laboratory of Nephrology, Ministry of Health; Guangdong 
Provincial Key Laboratory of Nephrology, Guangzhou, China; 4Johns Hopkins 
University School of Medicine, Baltimore, MD; 5Department of Nephrology, The 
First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 6Leiden 
University Medical Center, Leiden, Netherlands; 7University of Minnesota, 
Minneapolis, MN; 8University of Minnesota Medical School, Minneapolis, MN; 
9The Third Xiangya Hospital of Central South University, Changsha, China; 
10The First Affiliated Hospital of Guangxi Medical University, Nanning, China; 
11The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 
12Nephrology, Klinikum rechts der Isar, Technische Universitaet Muenchen, 
Munich, Germany.
Background: Measurement of RKF is recommended for adjustment of the dialysis 
prescription, but timed urine collections are difficult and prone to errors. Few equations 
to estimate RKF in dialysis patients using serum concentrations of low molecular weight 
proteins (LMWP) have been externally validated (Shafi T et al, Kidney Int 2016).
Methods: We developed RKF estimating equations using linear regression analysis 
in 823 peritoneal dialysis patients in the Guangzhou PD Study. The reference tests were 
measured clearance of urea nitrogen (UN) (mClUN, ml/min) and average clearance of 
UN and creatinine (mClUN-cr, ml/min/1.73 m
2). The index tests were estimated clearance 
(eCl) using UN and creatinine (eClUN-cr), beta-trace-protein (eClBTP), beta-2-microglobulin 
(eClB2M), cystatin C (eClcys) and combinations. Equations were then externally validated in 
826 hemo- and peritoneal dialysis patients in the NECOSAD study and also compared to 
published validated equations.
Results: In external validation, bias was within ±1.0 (Table). Precision and accuracy 
were significantly better for eClBTP, eClB2M and eClBTP-B2M than eClUN-cr. The area-under-the-
curve for predicting mClUN >2.0 ml/min for eClB2M and eClBTP-B2M was 0.853 and 0.848, 
respectively (Figure). Results were similar to other validated equations.
Conclusions: These results confirm the validity and extend the generalizability of 
estimation of RKF from serum concentrations of LMWPs without urine collection.
Funding: Commercial Support - Siemens, Dialysis Clinic Inc., Private Foundation 
Support
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Lipid Level and Its Impact on Cardiovascular Mortality in Peritoneal 
Dialysis Patients
Yong kyu Lee, Elani Streja, Hamid Moradi, Kamyar Kalantar-Zadeh. Harold 
Simmons Center for Kidney Disease Research and Epidemiology, Division of 
Nephrology and Hypertension, University of California, Irvine, Orange, CA.
Background: Peritoneal dialysis (PD) patients show different characteristics in terms 
of lipid profile and qualitative function compared to hemodialysis (HD) patients, however 
there are limited large-scale studies regarding the influence of lipid level on cardiovascular 
mortality in PD patients. The guideline for lipid control, which is focused on cardiovascular 
mortality in HD patients, needs validation with respect to its application in PD patients.
Methods: 7,543 PD patients were selected from a national cohort of patients treated by 
a large dialysis organization during 2007-2011. We sought to verify the relationship between 
lipid levels—including total cholesterol, LDL cholesterol, and triglyceride levels—and 
cardiovascular mortality. Lipid levels were divided into 6 strata and 3 different hierarchical 
adjustment models were applied to observe the change in relationship after adjustment.
Results: Total cholesterol, LDL cholesterol, and triglyceride showed a consistent 
trend, whereby patients in the lowest stratum were observed to have highest cardiovascular 
mortality: hazard ratios were 2.183 (1.634-2.916), 1.513 (1.166-1.963), and 1.788 (1.348-
2.373), respectively in case-mix adjusted models. Cardiovascular mortality risk showed a 
reversed J-shaped association with inflection at a total cholesterol level of 200-230mg/dL, 
LDL cholesterol level of 100-120mg/dL, and triglyceride level of 200-250mg/dL.
Conclusions: In contrast to conventional belief, PD patients with low total cholesterol, 
LDL cholesterol, and triglyceride levels showed higher cardiovascular mortality.
Funding: NIDDK Support
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HDL Cholesterol Level and Its Impact on Cardiovascular Mortality in 
Peritoneal Dialysis Patients
Yong kyu Lee, Elani Streja, Kamyar Kalantar-Zadeh, Hamid Moradi. Harold 
Simmons Center for Kidney Disease Research and Epidemiology, Division of 
Nephrology and Hypertension, University of California, Irvine, Orange, CA.
Background: HDL cholesterol is traditionally believed to be beneficial in preventing 
cardiovascular mortality by reverse cholesterol transport and restricting LDL cholesterol 
oxidation. However, in ESRD patients, the effect of HDL cholesterol was shown to deviate 
due to its qualitative and quantitative alteration.
Methods: 7,839 peritoneal dialysis (PD) patients were selected from a national cohort 
of patients treated at a large dialysis organization during 2007~2011. We sought to verify 
the relationship between HDL cholesterol and total cholesterol/HDL cholesterol ratio and 
all-cause mortality. Each exposure parameter was divided into 6 strata and 3 different 
hierarchical adjustment models were applied to observe the change in relationship after 
adjustment.
Results: Although patients with low HDL cholesterol showed higher all-cause mortality 
risk in the unadjusted model, the risk was attenuated after adjustment, with a hazard ratio 
of 1.235 (0.970-1.573) in the case-mix adjusted model. However, patients with low total 
cholesterol/HDL ratio showed higher all-cause mortality risk which was robust even after 
adjustment for case-mix and markers of malnutrition/inflammation (MICS), with a hazard 
ratio of 1.433 (1.183-1.736) in the case-mix adjusted model. Both showed a reversed 
J-shaped association with the inflection point at 50-60mg/dL for HDL cholesterol and 4-5 for 
total cholesterol:HDL cholesterol ratio. The highest HDL cholesterol level group showed a 
mortality risk of 1.090 (0.836-1.421) and the highest total cholesterol:HDL cholesterol ratio 
group showed a mortality risk of 1.178 (0.940-1.477).
Conclusions: PD patients with low HDL cholesterol and total cholesterol:HDL 
cholesterol ratio showed higher all-cause mortality. However, higher HDL cholesterol and 
total cholesterol:HDL cholesterol ratios showed neither the beneficial effect observed in the 
general population nor the deleterious effect observed in HD patients.
Funding: NIDDK Support
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Serum Osteopontin Level Is Positively Associated with Central Arterial 
Stiffness in Patients with Peritoneal Dialysis
Wei-Chen Lin, Bang-Gee Hsu. Buddhist Tzu Chi General Hospital, Hualien, 
Taiwan.
Background: Osteopontin (OPN) is generally regarded as a proinflammatory and 
proatherogenic molecule and is associated with atherosclerosis. The aim of this study was 
to evaluate the relationship between serum OPN on central arterial stiffness by measuring 
of carotid-femoral pulse wave velocity (cfPWV) values in patients with peritoneal dialysis 
(PD).
Methods: Fasting blood samples were obtained from 70 PD participates in the study. 
Carotid-femoral pulse wave velocity was measured by a validated tonometry system. 
cfPWV values of > 10 m/s were used to define the high central arterial stiffness group, 
while values ≤ 10 m/s were regarded as the control group, according to the ESH-ESC 
2013 guidelines. Serum OPN levels were measured using a commercial enzyme-linked 
immunosorbent assay kit.
Results: Twenty-two patients (31.4%) had high central arterial stiffness and were of 
older age (P = 0.001) and had longer PD vintage (P = 0.024), higher C-reactive protein 
(P = 0.005) and OPN levels (p < 0.001) compared to subjects with control group. Multivariate 
logistic regression analysis of the factors significantly associated with central arterial 
stiffness revealed that OPN (odds ratio: 1.044, 95% confidence interval: 1.020–1.069, P < 
0.001) and PD vintage (odds ratio: 1.027, 95% confidence interval: 1.007–1.047, P = 0.009) 
were the independent predictors of central arterial stiffness in PD patients. Multivariate 
forward stepwise linear regression analysis also showed that OPN level (β = 0.477, adjusted 
R2 change = 0.269, P = 0.001) was positively associated with cfPWV values in PD patients.
Conclusions: In this study, serum OPN level was positively associated with cfPWV 
values in PD patients and was the independent predictors of central arterial stiffness in 
PD patients.
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Serum Osteoprotegerin Level Is Positively Associated with Peripheral 
Artery Disease in Patients with Peritoneal Dialysis
Wei-Chen Lin,2 Bang-Gee Hsu.1 1Division of Nephrology, Buddhist Tzu Chi 
General Hospital, Hualien, Taiwan; 2Buddhist Tzu Chi General Hospital, 
Hualien, Taiwan.
Background: Osteoprotegerin (OPG) levels may be a potential biomarker of 
complications and severity of cardiovascular disease. Peripheral arterial disease (PAD) is 
associated with an increased risk of death in peritoneal dialysis (PD) patients. Our aim was 
to evaluate the relationship between serum OPG levels and PAD by ankle-brachial index 
(ABI) among PD patients.
Methods: Fasting blood samples were obtained from 70 PD patients. The ABI values 
were measured using an ABI-form device (VaSera VS-1000). Serum OPG levels were 
measured using a commercial enzyme-linked immunosorbent assay kit. Left or right ABI 
values that were < 0.9 were included in the low ABI group.
Results: Among 70 PD patients, 13 patients (18.6%) were in the low ABI group. 
Compared with patients in the normal ABI group, patients in the low ABI group had 
higher prevalence of diabetes (p = 0.044), higher serum C reactive protein (CRP) 
(P < 0.001), and higher serum OPG level (P < 0.001), while lower serum creatinine level (P 
= 0.013) and peritoneal Kt/V (P = 0.048). According to the multivariate logistic regression 
analysis, OPG (Odds ratio [OR]: 1.027, 95% confidence interval [CI]: 1.010-1.045, P = 
0.002) and CRP (each increase of 0.1 mg/dL, OR: 1.102, 95% CI: 1.006-1.207, P = 0.037) 
were the independent predictors of PAD in PD patients. The area under the receiver 
operating characteristic (ROC) curve (AUC) indicates the diagnostic power of OPG at 
predicting PAD of PD patients was 0.823 (95% CI: 0.714-0.904, P < 0.001).
Conclusions: In this study, serum OPG level was proved to be involved in the 
pathogenetic process of PAD in PD patients.
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Relationship Between Hypomagnesemia and Abdominal Calcification 
Index in Peritoneal Dialysis Patients: A Cross-Sectional Study
Kenji Harada,1 Hidetoshi Kanai,2 Shigeru Tanaka.3 1Kokura memorial hospital, 
Kitakyusyu city, Japan; 2Kokura Memorial Hospital, Kita Kyushu, Japan; 
3Fukuoka Dental College, Fukuoka, Japan.
Background: Several previous reports have reported that hypomagnesemia was 
associated with high mortality in hemodialysis (HD) patients. However, the influence 
of hypomagnesemia on the prognosis of peritoneal dialysis (PD) remains unclear. We 
investigated relationship between abdominal calcification index (ACI) and cardiovascular 
risk factors in PD patients.
Methods: A total of 184 PD patients were included in the current study. ACI was 
calculated calculated as average calcification area of consecutive 20 slices of abdominal 
aorta measured by abdominal plain CT (computerized tomography). We evaluated 
relationships between ACI and cardiovascular risk factors, including serum phospahte, 
serum calcium, whole parathyroid hormone, serum agnesium, lipid status, Hemoglobin A1c 
(HbA1c), blood pressure (BP), peritoneal function, echocardiographic findings.
Results: The overall, mean age was 64.9 years old, male/female was 132/52, average 
PD vintage was 12 months. Median value of magnesium was 1.92±0.3 mg/dl. We deviated 
participants into two groups; low magnesium (Mg<1.9) group and high magnesium (Mg≥2) 
group. Low magnesium group had a lower HbA1c and higher ACI. There was no difference 
in age, sex, ejection fraction, BP, peritoneal function, past history of cardiovascular 
disease between two groups. In the multiple regression analysis, hypomagnesemia was an 
independent predictor for high ACI (β=-2.73, P<0.007).
Conclusions: Hypomagnesemia at initiation of PD was strongly correlated with high 
ACI and its relationship did not change even after adjusting by plausible cardiovascular risk 
factors, hypomagnesemia was an independent predictor for high ACI. These results suggest 
that hypomagnesemia might be involved in calcification progression in PD patients.
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Concentric Left Ventricular Hypertrophy at Peritoneal Dialysis Initiation 
May Predict Death and Cardiovascular Disease in Patients Using 
Neutral-pH Solution
Yoshifumi Hamasaki,1 Teruhiko Yoshida,2,3 Akihiko Matsumoto,1 Rei Isshiki,1 
Eisei Noiri,2 Masaomi Nangaku.2 1The University of Tokyo Hospital, Tokyo, 
Japan; 2The University of Tokyo, Tokyo, Japan; 3National Institute of Diabetes 
and Digestive and Kidney Diseases, NIH, Bethesda, MD.
Background: Left ventricular hypertrophy (LVH) is known as one of the risk factors 
of mortality and cardiovascular disease (CVD) in the patients undergoing peritoneal dialysis 
(PD). Concentric LVH (cLVH) is the most frequent left ventricular geometry model in 
dialysis patients. The relationship between cLVH at PD initiation and prognosis is not well 
known. We investigated whether cLVH at PD initiation is associated with mortality and 
incidence of CVD in PD patients.
Methods: The data from patients who started PD at The University of Tokyo Hospital 
were collected retrospectively. Clinical parameters measured at PD initiation were 
obtained. The definition of cLVH was as follows; left ventricular mass index is 115 g/m2  
and relative wall thickness is 0.42. All patients were divided into two groups with 
and without cLVH. Morality, incidence of CVD, technique survival rate were compared 
between two groups. We also investigated the relationship between clinical parameters and 
cLVH at PD initiation.
Results: A total of 126 patients was included and mean follow-up period was 
44 months. The mean age was 58.5±11.8 y.o., male was 76%, and automated PD was 
selected in more than 90% patients. All patients were treated using neutral-pH PD solution. 
Twenty-six patients (21%) had cLVH at PD initiation. Kaplan-Meier analysis revealed 
that cLVH group had significant higher mortality, higher incidence of CVD, and lower 
technique survival rate compared with non-cLVH group (Log rank: p < 0.01, = 0.02, and < 
0.01, respectively). The result of Cox proportional hazards model demonstrated that age and 
cLVH were independent predictors of mortality (hazard ratio, 1.08 and 3.67; 95%CI, 1.04 
to 1.14 and 1.18 to 11.46; p < 0.01 and = 0.02; respectively). Age, hemoglobin, and geriatric 
nutrition risk index (GNRI) were independently correlated with cLVH (odds ratio [95% 
confidence interval]: 1.07 [1.02-1.11], 0.53 [0.30-0.93], and 0.92 [0.86-0.99], respectively).
Conclusions: Concentric LVH at PD initiation may be a possible predictor of mortality 
and CVD in patients using neutral-pH PD solution.
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Peritoneal Ultrafiltration on Refractory Heart Failure
Tomas Alexis Becerra-Gamba,1 Gabriela Leal,3 Bernardo Moguel.2 Instituto 
Nacional de Cardiología “Ignacio Chávez” 1Nephrology, Instituto Nacional de 
Cardiología, Mexico City, Mexico; 2Instituto Nacional de Cardiologia, Mexico 
City, Mexico; 3Instituto Nacional de Cardiología, México, Mexico.
Background: Fluid Overload (FO) in Heart Failure (HF) is a major risk factor for 
morbidity and mortality.
Methods: The primary outcome of this study was to evaluate the safety and efficacy 
of Icodextrin for peritoneal ultrafiltration in Refractory HF (RHF) patients with FO and 
to assess the change in New York Heart Association (NHYA) Class, body composition 
measurement by electrical bio-impedance, length of hospital stay (LHS) and hospital costs 
(HC) in a 1 year follow up.
Results: we included a total of 6 patients with RHF and FO, table 1 shows baseline 
and post-intervention characteristics of participants. During the follow up we registered 
1 episode of peritonitis and 1 mechanical dysfunction of peritoneal catheter. The median 
of LHS in one year previous treatment was 35 (RIC 23-50) vs 3 (RIC 2-25) days in 1 year 
follow-up (p 0.07). Also, a 1 year HC pre-intervention was $6,804.82 (RIC $4,308.62 - 
11,579.14) vs $676.56 (RIC $420.69 –4,093.65) US dollars (p 0.06). At 6 months follow up 
we registered 2 deaths (34%).
Conclusions: we observed a better FO control and an improvement of symptoms 
(NYHA class), also a decrease of LHS and HC. The limitation of this study is the sample 
size but with a tendency towards statistical significance.
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Pilot Study to Determine Whether Cooled Peritoneal Dialysis Confers 
Cardioprotective Effect
Shemer Ratner,1 Aaron So,2 Tanya Tamasi,1 Christopher W. McIntyre.1 1London 
Health Sciences Centre, London, ON, Canada; 2Lawson Health Research 
Institute, London, ON, Canada.
Background: Despite lack of dialysis induced ischema (characteristic of hemodialysis), 
patients receiving peritoneal dialysis (PD) also suffer excess cardiac morbidity and 
mortality- driven by high rates of heart failure and sudden cardiac death. Currently there 
are no effective primary prevention therapies. Moderate hypothermia is well established 
in animal models to provide protection against demand ischemia. Furthermore, perfusion 
heterogeneity disrupts the passage of myocardial depolarization increasing the risk of 
ventricular re-entrant circuits. The aim of this study was to explore PD as a method of 
delivering a cooling intervention and test whether or not it could reduce segmental or global 
stress induced cardiac ischemia.
Methods: We studied 6 patients at 2 study visits. Myocardial perfusion was measured 
using high resolution 256 slice CT scanning at rest and with adenosine stress. The first visit 
was done on patients’ usual PD regimen, second visit utilised peritoneal dialyzate cooled 
to 32-33 0 C, to reduce body temperature by 0.5 0 C. Myocardial Perfusion was assessed 
using the American Heart Association segmentation model with ANOVA test, and perfusion 
pattern heterogeneity was measured by standard deviation of segmental perfusion.
Results: Cooled dialysate was tolerated well by all patients. No symptoms of cold 
or drain pain were reported. Cooling significantly decreased rest and trended towards 
decreased stress global and segmental cardiac perfusion (mean values being 75.53 to 
165.83 mL/min/100g). Pharmacological stress was associated with an increase in perfusion 
heterogeneity (mean increase in SD from 10.87 to 21.09). However, cooling the dialysate 
significantly reduced this effect by 25%.
Conclusions: Moderate hypothermia can be safely delivered using PD. It provides 
significant reduction in a potential key risk factor for cardiac sudden death and warrants 
further investigation to reduce cardiovascular attrition in PD patients.
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Lower Risk of Hospitalizations in Cardiorenal Patients Using  
Once-Nightly Icodextrin Peritoneal Exchanges
Ravleen K. Saini,1 Jaibir Bhullar,1 Shaheen Jadidi,2 Anis A. Rauf,4 
Rayaan A. Rauf.3 1Avalon University School of Medicine, Youngstown, OH; 
2Midwestern University, Downers Grove, IL; 3Advocate Good Samaritan 
Hospital, Downers Grove, IL; 4Nephrology Associates of Northern Illinois and 
Indiana, Oakrook, IL.
Background: The purpose of this study is to investigate the benefits of using a nightly 
icodextrin peritoneal dialysis (PD) solution in the cardiorenal (diuretic-resistant congestive 
heart failure) patient. Icodextrin is a glucose polymer that has been used as a replacement 
for the glucose traditionally used in the PD long dwells, as the oncotic pressure gradient 
can be maintained at adequate ultrafiltration (UF) values for 8-12 hours during sleep. 
Icodextrin-based solutions (ICO) are well tolerated, lack the metabolic side effects of 
glucose, and enhance the clearance of small and middle-sized molecules as a consequence 
of increased convective flow. Patients using one exchange nightly lead a more “normal” 
life when compared to patients using continuous cycling peritoneal dialysis (CCPD) with 
glucose solutions, as CCPD requires a nightly cycler apparatus which restricts the patient 
ability to ambulate at night.
Methods: This study provides data from a sample size of 11 individuals (9 males and 
2 females) currently on once-nightly icodextrin peritoneal exchanges. Hospital admissions 
over an equal date range before and after starting extraneal dialysis treatment were 
compared.
Results: In our study, we observed that patients using once-nightly icodextrin exchange 
had fewer hospitalizations (p=0.0149), and reported an overall better quality of life after 
initiation of icodextrin peritoneal dialysis with decreased hospital admissions for CHF and 
progressive chronic kidney disease.
Conclusions: By augmenting UF in the cardiorenal patient with recurrent episodes of 
decompensated heart failure through once-nightly icodextrin exchanges, patients receive 
adequate clearance with preserved residual renal function as well as fewer hospitalizations. 
In addition, patients report more restful sleep and a better quality of life as a result of 
not being attached to a machine at night. They also enjoy being able to travel with their 
solutions delivered to their destination without having to carry a cycler.
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Association Between Use of Alpha-Blockers in Older Adults and 
Hypotension and Hypotension-Related Clinical Events
Swapnil Hiremath,2 Marcel Ruzicka,2 William Petrcich,3 Gregory L. Hundemer,4 
Kevin D. Burns,5 Cedric A. Edwards,5 Amit X. Garg,6 Manish M. Sood.1 1Ottawa 
Hospital Research Institute, Ottawa, ON, Canada; 2University of Ottawa, 
Ottawa, ON, Canada; 3Institute for Clinical Evaluative Sciences, Ottawa, ON, 
Canada; 4Massachusetts General Hospital, Arlington, MA; 5The Ottawa 
Hospital - Riverside Campus, Ottawa, ON, Canada; 6London Health Sciences 
Centre, London, ON, Canada.
Background: Alpha- blockers (AB) are effective and commonly prescribed 
medications as part of a multi-drug regiment in the management of hypertension. Little is 
known regarding the risk of hypotension and hypotension-related clinical outcomes in older 
adults with ongoing AB use. We set out to assess the risk of hypotension and related adverse 
events with AB use compared to other anti-hypertensives in the older adults.
Methods: A population-based, retrospective cohort study of 933,033 older adults 
(≥ 66 years) prescribed an anti-hypertensive medication between 1995 and 2015 in Ontario, 
Canada. A high dimensional propensity score was used to match the dispensing of AB 
compared to other anti-hypertensives. AB exposure was modeled as a time-varying and 
cumulative covariate using extended, conditional Cox proportional hazards to examine 
the association with outcomes. Study outcomes were hospital admissions or emergency 
room visits for hypotension, related events (syncope, fractures, falls), major adverse 
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cardiovascular events (MACE) and all-cause mortality. We examined subgroups of age, 
total number of anti-hypertensives and concurrent beta-blocker use.
Results: Among 69,092 matched patients prescribed AB (mean age 75.1 SD 6.5 years) 
with a median follow up 3.7 (IQR 1.4 to 9.5) years, the incident rate of hypotension and 
related events were significantly higher compared to other anti-hypertensives (hypotension 
1.15 vs. 0.39, syncope 1.47 vs. 0.46, falls 4.37 vs. 1.37, fractures 2.23 vs. 0.69 per 100 
person-years of follow-up). In time-varying exposure models with additional adjustment 
for the total number of anti-hypertensives, the higher risk persisted (hypotension HR 1.34 
95%CI 1.26-1.43, syncope HR 1.49 95%CI 1.41-1.57, falls HR 1.27 95%CI 1.23-1.32, HR 
fractures 1.41 95%CI 1.34-1.48). Secondary outcomes of MACE and all-cause mortality 
were higher or similar among AB users (MACE IR 7.03 vs. 2.31, mortality 6.54 vs 6.37 per 
100 person-years follow-up).
Conclusions: Treatment of hypertension in older adults with AB is associated with a 
higher risk of hypotension, hypotension-related events and MACE. Our findings suggest 
that AB should be used with caution, even as add on therapy for hypertension in older 
adults.
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Beta Blocker (BB) Use Patterns at ESRD Transition and Mortality 
Outcomes Among Congestive Heart Failure (CHF) Patients Starting 
Hemodialysis (HD)
John J. Sim,1 Hui Zhou,2 Jiaxiao Shi,2 Sally F. Shaw,2 Ming-Sum Lee,1 
Csaba P. Kovesdy,3 Kamyar Kalantar-Zadeh,4 Steven J. Jacobsen.2 1Nephrology 
and Hypertension, Kaiser Permanente Los Angeles Medical Center, Pasadena, 
CA; 2Kaiser Permanente Southern California, Pasadena, CA; 3University of 
Tennessee Health Science Center, Memphis, TN; 4University of California 
Irvine, School of Medicine, Orange, CA.
Background: While BB have demonstrated benefit in CHF, there is uncertainty among 
HD pts. Comparative BB outcomes (beta selective, dialyzability, lipophilic) in the ESRD 
transition period are lacking; while studies on newly initiated BB after ESRD are conflicting 
and overall sparse. Among CHF patients on BB at ESRD transition, we evaluated BB use 
patterns and 1-year mortality.
Methods: A retrospective cohort study (1/1/2007-6/30/2016) within Kaiser 
Permanente Southern California (an integrated health system) of CKD patients with CHF 
who transitioned to HD while on BB. BB use and type [dialyzable (D) vs non dialyzable 
(ND)] were evaluated. Multivariable regressions were used to estimate 1-year mortality HR 
based on post ESRD transition BB use and type.
Results: A total of 2756 pts w CHF on BB transitioned to HD (age 68 yrs, 57% males, 
31% whites, 23% blacks, and 34% Hispanics). Within 120 days post transition, 25% of pts 
discontinued BB, 38% were on D BB, and 24% were on ND BB. Post ESRD transition, 
6.5% switched their BB dialyzable types (similar both directions). Mean blood pressure w/
in 120days post transition was 130/65mmHg but lowest among ND BB pts. Mortality rates 
were 126.5 (per 1000 person-yrs), 205.7, and 223.2 for D BB, ND BB, and pts off BB, 
respectively. 1-yr mortality HR’s were 1.37 (1.07-1.74) and 1.66 (1.32-2.09) for ND BB and 
off BB compared to D BB pts. Carvedilol (ND) pts had a mortality HR of 1.32 (1.00-1.73) 
vs metoprolol (D).
Conclusions: Among CHF pts on BB who transitioned to HD, 25% discontinued 
BB while 6.5% switched BB dialyzability types. The highest short-term mortality were 
observed in pts off BB followed by ND BB compared to D BB. Given the vulnerable state 
of ESRD transition and the high-risk CHF ESRD population, BB use may be an area of 
focus to help improve ESRD transition outcomes.
Funding: NIDDK Support
All-cause mortality
* Adjusted for age, sex, race, Afib, mean SBP<110 w/in 120days post ESRD, CCI, & cause 
of ESRD 
^HD-dialyzable BB: atenolol, metoprolol, nadolol, sotalol; HD-nondialyzable BB: 
bisoprolol, carvedilol, labetalol, propranolol.
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Use of Calcium Channel Blockers Before Dialysis until Dialysis Initiation 
Is Associated with All-Cause Mortality During Maintenance Dialysis
Daijo Inaguma, Yukio Yuzawa, Midori Hasegawa, Kazuo Takahashi. 
Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Background: Angiotensin-converting enzyme inhibitors and angiotensin receptor 
blockers are reno-protective renin-angiotensin system blockade agents (RASBs) that are 
recommended for patients with chronic kidney disease (CKD), especially for diabetic 
nephropathy. However, a meta-analysis of CKD patients including those on dialysis 
demonstrated no significant difference in mortality between those on RASBs or calcium 
channel blockers (CCBs). Therefore, we examined whether the use of CCBs was associated 
with all-cause mortality and cardiovascular (CV) events in patients with incident dialysis.
Methods: The subjects were patients in 17 centers participating in the Aichi Cohort 
Study of Prognosis in Patients Newly Initiated into Dialysis between October 2011 and 
September 2013. We enrolled 1,520 subjects in the study. Baseline was defined as the 
time at which dialysis was initiated. Survival prognosis and incidence of CV events as 
of September 30, 2016, were determined from medical records. We classified patients 
into two groups according to the use of CCBs at the time of dialysis initiation: those who 
received CCBs (CCB group; n = 1,199) and those did not receive CCBs (non-CCB group; 
n = 321). Study outcomes included mortality and the incidence of CV events in the two 
groups. Factors contributing to all-cause mortality were examined using multivariate Cox 
proportional hazards regression analysis. In addition, we compared all-cause mortality 
stratified by use of RASBs.
Results: A log-rank test showed significant differences in all-cause mortality and the 
incidence of CV events between the two groups (p = 0.001 and p = 0.003, respectively). 
Multivariate stepwise Cox proportional hazards analysis revealed that all-cause mortality 
and the incidence of CV events were significantly lower in the CCB group than in the 
non-CCB group (hazard ratio [HR] = 0.62, 95% confidence interval [CI]: 0.46 – 0.85, 
p = 0.003 and HR = 0.74, 95% CI = 0.56 – 0.98, p = 0.037) (Table). All-cause mortality rates 
were significantly lower in the CCB group than in the non-CCB group among patients who 
did not receive RASBs (HR = 0.70, 95% CI: 0.52 – 0.95, p = 0.021).
Conclusions: The use of CCBs in patients before dialysis initiation was associated with 
reduction in all-cause mortality and CV events during maintenance dialysis.
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Effect of Aspirin on Cardiovascular Disease Outcomes in ALLHAT 
Participants with and Without CKD
Michael Bond,1 Niraj Desai,2,1 Brigid Wilson,2,3 Mahboob Rahman.1,2 1Case 
Western Reserve University/University Hospitals Cleveland Medical Center, 
Cleveland, OH; 2Louis Stokes Cleveland Department of Veterans Affairs 
Medical Center, Cleveland, OH; 3Case Western Reserve University School of 
Medicine, Cleveland, OH.
Background: Those with chronic kidney disease (CKD) are at increased risk of 
cardiovascular disease (CVD), as well as increased CVD-related and all-cause mortality. In 
the general population, aspirin is effective in the secondary prevention of CVD, for those at 
high risk of occlusive vascular events. For patients with CKD, however, it remains unclear 
whether aspirin is useful in either the primary or secondary prevention of CVD.
Methods: We performed a secondary analysis of the randomized controlled trial, 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 
to assess the effect of baseline aspirin use on the initial primary endpoint, nonfatal 
myocardial infarction (MI), or fatal coronary heart disease (CHD) and secondary end points, 
all-cause mortality and stroke. Differences in baseline characteristics between subjects with 
and without aspirin use were examined and then used to generate a propensity-matched 
analysis population. Using conditional logistic regression models, we estimated the effect of 
aspirin on the outcomes. We created additional models testing for differences in the effect of 
aspirin across 3 levels of kidney function (eGFR ≥ 90, 60-89, and <60).
Results: The ALLHAT trial (n=33,537) contained 11,250 participants with complete 
data who reported using aspirin at baseline. There were significant differences in the 
race, sex, and cardiovascular disease history of aspirin versus non-aspirin users. The 
propensity-matched dataset included 6,894 non-aspirin users matched with replacement 
to aspirin users and achieved an analysis population (n=22,500) with balance across 
possible confounders. The risk of the primary study endpoint (OR = 0.98, 95% 
CI = 0.90-1.06) and stroke (OR = 0.92, 95% CI = 0.82-1.03), was not significantly different 
between aspirin users/non-users. Aspirin users were at significantly lower risk of all-
cause mortality compared to non-users (OR = 0.75, 95% CI = 0.70-0.80). There were no 
significant interactions between aspirin and baseline eGFR kidney function for these three 
endpoints.
Conclusions: Aspirin use is not associated with decreased odds of non-fatal MI, fatal 
CHD or stroke but is associated with decreased odds of all-cause mortality for participants 
in the ALLHAT trial. These results are consistent across baseline eGFR.
Funding: Veterans Affairs Support
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Association of Hyperuricemia and Serum Uric Acid Lowering Medication 
with Mortality in Hemodialysis Patients
Benjamin Rohn,2 Felix S. Seibert,5 Nina Babel,4 Frederic Bauer,3 
Timm H. Westhoff.1 1Ruhr-University Bochum, Germany, Herne, Germany; 
2Marien Hospital Herne, Herne, Germany; 3Ruhr-University Bochum, Herne, 
Germany; 4Ruhr University Bochum, Herne, Germany; 5University Hospital 
Marien Hospital Herne, Herne, Germany.
Background: In the general population hyperuricemia is associated with increased 
cardiovascular risk and mortality. It is unknown whether this association exists in 
hemodialysis patients as well and whether this population benefits from serum uric acid 
(SUA) lowering medication.
Methods: We performed a retrospective analysis of 601 patients on chronic 
hemodialysis therapy in five dialysis outpatient centers for a maximum follow-up of 100 
months (mean follow-up 41 months). Death was defined as primary endpoint. Hyper- and 
normouricemic subjects differed in age. Therefore a Cox regression analysis adjusted for 
age was performed in addition to Kaplan Meier survival analyses.
Results: Kaplan Meier survival curves showed a higher cumulative survival rate for 
those subjects with a higher than median SUA concentration both based on mean annual 
SUA concentrations and baseline SUA concentrations (three months after the initiation 
of dialysis, p<0.05 each). Groups showed no significant difference in survival anymore 
after adjustment for age in Cox regression analyses (p>0.05 each). SUA lowering therapy 
(allopurinol or febuxostat) revealed no effect on cumulative survival, neither in Kaplan 
Meier nor in Cox regression analysis (p>0.05 each). Body mass index had no impact on 
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survival rates. There were 22 symptomatic gout attacks during the follow-up corresponding 
to an incidence of 1/93.3 patient years. Among those with prior symptomatic hyperuricemia 
(10.1% of overall population) 47.5% continued on medication, 52.5% discontinued. Only 6 
subjects with prior symptomatic hyperuricemia developed additional gout attacks after the 
initiation of hemodialysis (1/342.2 patient years), all of them despite medication.
Conclusions: The present analysis shows that – in contrast to the general population 
– hyperuricemia is not associated with increased mortality in patients undergoing
hemodialysis. A “reversed epidemiology phenomenon” of better survival with higher
SUA concentrations disappears after adjustment for age. SUA lowering therapy is neither
associated with a survival benefit nor a significant reduction of gout free patient years. 
These data indicate that SUA lowering medication might be dispensable after the initiation 
of dialysis.
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Association Between Warfarin Use and Clinical Outcomes in Late-Stage 
CKD Patients with Atrial Fibrillation
Manyoo Agarwal,2 Praveen Kumar Potukuchi,1 Adnan Naseer,5 
Miklos Z. Molnar,1 Lekha K. George,1 Santhosh K. Koshy,3,1 Fridtjof Thomas,1 
Kamyar Kalantar-Zadeh,4 Csaba P. Kovesdy.5,1 1University of Tennessee Health 
Science Center, Memphis, TN; 2University of Tennessee Health Science Center, 
Memphis, TN; 3Regional One Health - University of TN Health Sciences Ctr, 
Memphis, TN; 4University of California Irvine, School of Medicine, Orange, 
CA; 5Memphis VA Medical Center, Memphis, TN.
Background: The effect of warfarin on clinical outcomes in late-stage chronic kidney 
disease (CKD) patients with atrial fibrillation (AF) is unclear.
Methods: We examined a national cohort of 23,201 US veterans with incident end 
stage renal disease (ESRD) who developed incident AF prior to initiating renal replacement 
therapy. We examined the association of warfarin therapy following the diagnosis of AF 
with cerebrovascular accidents (CVA) (ischemic stroke or transient ischemic attack), 
hemorrhagic strokes, post-dialysis fatal bleeding and all-cause mortality in multivariable 
adjusted time dependent Cox models adjusting for demographic characteristics and 
comorbidities.
Results: Patients were 77±9 year old, 95% male, 13% African-American, 99% 
hypertensive, 79% diabetic, and 88%, 88% and 64% had histories of ischemic heart disease, 
congestive heart failure and CVA, respectively. 5,632 (24.3%) patients received treatment 
with warfarin during the study period. As shown in the Table, the risk of all outcomes 
except all-cause mortality were higher in those exposed to warfarin when compared to 
those not exposed to warfarin. These differences in outcomes remained significant even 
after multivariable adjustment, except fatal bleeding events, which showed no significant 
associaiton (Table).
Conclusions: Warfarin use in advanced CKD is associated with higher risk of ischemic 
and hemorrhagic CVA, but lower risk of mortality after ESRD transition. Randomized 
controlled trials are needed to determine the risks and benefit of warfarin therapy in patients 
with incident AF and advanced CKD.
Funding: NIDDK Support, Veterans Affairs Support
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Hyperkalemia and Renin-Angiotensin Aldosterone System Inhibitor 
(RAASi) Therapy in CKD: A General Practice-Based, Observational 
Study
Min Jun, Meg J. Jardine, Vlado Perkovic, Quentin Pilard, Laurent Billot, 
Anthony Rodgers, Kris Rogers, Martin P. Gallagher. The George Institute for 
Global Health, UNSW, Newtown, NSW, Australia.
Background: Data on hyperkalemia frequency among chronic kidney disease (CKD) 
patients receiving RAASis and its impact on subsequent RAASi treatment are limited. We 
sought to assess the incidence of clinically significant hyperkalemia in CKD patients who 
were prescribed a RAASi and the proportion of patients with RAASi medication change 
after experiencing incident hyperkalemia.
Methods: We conducted a retrospective, population-based cohort study (1 January 
2013-30 June 2017) using Australian national general practice data from the NPS 
MedicineWise’s MedicineInsight program. The study included adults aged ≥18 years 
who received ≥1 RAASi prescription during the study period and had CKD (estimated 
glomerular filtration rate [eGFR] <60 ml/min/1.73m2). Study outcomes included 
incident clinically significant hyperkalemia (serum potassium >6 mmol/L or a record of 
hyperkalemia diagnosis) and among patients who experienced incident hyperkalemia, the 
proportion who had RAASi medication changes (cessation or dose reduction during the 
210-day period after the incident hyperkalemia event).
Results: Among 20,184 CKD patients with a median follow-up of 3.9 years, 1,992
(9.9%) patients experienced an episode of hyperkalemia. The overall incidence rate was 
3.1 (95% CI: 2.9-3.2) per 100 person-years. Rates progressively increased with worsening 
eGFR (e.g. 3.5-fold increase in patients with eGFR <15 vs. 45-59 ml/min/1.73m2). Among 
patients who experienced incident hyperkalemia, 47% had changes made to their RAASi 
treatment regimen following the first occurrence of hyperkalemia (discontinuation: 37% 
and dose reduction: 10%). In the full multivariable model, higher levels of serum potassium 
at the time of the hyperkalemia event was significantly associated with a greater likelihood 
of medication change (per 0.1 mmol/L increase: odds ratio [OR] 1.05, 95% CI: 1.02-1.08).
Conclusions: In this analysis of adult RAASi users with CKD, hyperkalemia and 
subsequent RAASi treatment changes were common. Further assessment of strategies for 
hyperkalemia management and optimal RAASi use among people with CKD are warranted.
Funding: Other U.S. Government Support, Commercial Support - This study was 
funded by AstraZeneca Pty Ltd and commissioned by VentureWise (a wholly owned 
commercial subsidiary of NPS MedicineWise). AstraZeneca had no role in study design 
and conduct; in the collection, analysis and interpretation of the data; or in the preparation 
or approval of the abstract.
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The Feasibility of Interventions to Increase Potassium Intake for 
Hypertension: A Systematic Review of the Evidence
Maryam Zaree,2 Marcel Ruzicka,2 Swapnil Hiremath.1 1University of Ottawa, 
Ottawa, ON, Canada; 2University of Ottawa Faculty of Medicine, Windsor, ON, 
Canada.
Background: Increased potassium (K) intake has been reported to decrease blood 
pressure (BP) in animal studies as well as clinical trials. On this basis, major organizations 
including the American Heart Association recommend increasing K intake, preferably 
by diet, as a non pharmacological mean of reducing BP. However, it is not clear if the 
interventions for efficaciously increasing K intake are reproducible or feasible for translation 
into public health. Hence, we conducted a systematic review of the evidence to review this 
from randomized controlled trials (RCTs).
Methods: We conducted a literature search using an information specialist of 
MEDLINE, EMBASE and Cochrane CENTRAL till November 2017. Two reviewers 
selected RCTs that were in adults, with an intervention aimed at increasing K intake, with 
blood pressure as an outcome. From RCTs which reported both a significant change in BP 
and K using 24 hour urine K, we evaluated the interventions for ease of reproducibility and 
feasibility based on prespecified criteria.
Results: The initial search retrieved 1199 non-duplicate citations. After applying 
eligibility criteria, 90 studies were selected for inclusion. In 31 studies, the change in BP 
or K was not significant. Of the remaining 59 studies which reported a significant change 
in K and BP, 47 reported a change in K based on 24 hour urinary K measurement. 32/47 
studies used a K supplement, with details provided on dose and administration to make it 
both reproducible and feasible. 15/47 studies used a dietary intervention, of which in 4, the 
intervention was not described in sufficient detail to be reproducible. The remaining 11 
studies were feeding trials, with intervention consisting of provision of prepared meals, or 
of food items on a daily basis to make them unfeasible for routine clinical practice.
Conclusions: Dietary potassium interventions from trials in which there was a 
significant change in K based on 24 hour urine, and a significant change in BP, and which 
describe methods insufficient detail to be reproduced, are not feasible for routine clinical 
practice.
Funding: Clinical Revenue Support
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Variation in Use of Antihypertensive Medications After Kidney Transplant 
and Associated Outcomes: A National Study
Hala Yamout,1,2 Rosemary Ouseph,8 Mark Schnitzler,13 Vikas R. Dharnidharka,3 
Abhijit S. Naik,4 Ngan Lam,5 Farrukh M. Koraishy,6,1 Huiling Xiao,7 
Zidong Zhang,6 Henry B. Randall,12 Dorry L. Segev,9 Bertram L. Kasiske,10 
Gregory P. Hess,11 Krista L. Lentine.6 1Nephrology, VA St. Louis HealthCare 
System, Saint Louis, MO; 2Nephrology, St. Louis University, Saint Louis, MO; 
3Washington University School of Medicine, St Louis, MO; 4University of 
Michigan, Ann Arbor, MI; 5University of Alberta, Edmonton, AB, Canada; 
6Saint Louis University, Saint Louis, MO; 7St. Louis University, St. Louis, MO; 
8St Louis University, St Louis, MO; 9Johns Hopkins University, Baltimore, MD; 
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Background: Hypertension is a common comorbidity in kidney transplant (KTx) 
recipients. Impact of antihypertensive medication (AHM) regimen on patient and graft 
outcomes is not clear.
Methods: A novel database linking SRTR registry data for 54,153 KTx recipients 
with AHM fill records from a large pharmaceutical claims warehouse (2008-2015) was 
used. Mutually exclusive regimens were defined hierarchically as based in: Angiotensin 
converting enzyme inhibitor/angiotensin receptor blockers (ACEi/ARB), dihydropyridine 
calcium channel blockers (DHP-CCB), beta blockers (BB) and vasodilators/others. 
Associations (adjusted hazard ratio, 95% LCL aHR 95% UCL) of AHM regimen 7-12 months post-
transplant with patient and graft survival over 5 years were quantified by multivariate Cox 
regression with adjustment for recipient, donor and transplant factors, and clustering for 
center.
Results: The most common AHM post-transplant was DHP-CCB, followed by BB, 
ACEi/ARB, and diuretics. Regimen patterns varied by transplant centers (Fig 1). In bi-
level hierarchical modeling, compared to DHP-CCB-based treatment, ACEi/ARB use was 
more common in those with diabetes, obesity, and mTORi-based immunosuppression. 
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Unadjusted survival varied with AHM treatment (Fig 2). Compared to DHP-CCB reference, 
adjusted mortality was higher in those on NDHP-CCB (aHR 1.111.241.37) and ‘other’ agents 
(aHR 1.111.241.37), but lower in those on ACEi/ARB (aHR 1.441.691.99).
Conclusions: While associations may in part reflect unobserved selection factors, 
controlled studies are needed to determine optimal AHM regimens after KTx, reduce 
unjustified practice variation, and inform evidence-based best practices.
Funding: NIDDK Support
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Effect of Vitamin D Repletion on Cardiorenal Biomarkers and Vascular 
Function in a High-Risk African American Cohort
Satyesh K. Sinha,2,1 Jae eun Lee,3 Ling Sun,1 Keith C. Norris,1 
Susanne B. Nicholas.1 1Medicine, David Geffen School of Medicine at UCLA, 
Los Angeles, CA; 2Charles R Drew University of Medicine and Science, Los 
Angeles, CA; 3Jackson State Univerity, Madison, MS.
Background: African Americans (AAs) suffer disproportionately from cardiovascular 
disease and chronic kidney disease (CKD), and eighty percent of AAs are vitamin D 
deficient. The effects of vitamin D on vascular and renal health in patients with CKD have 
been contradictory in part due to different study designs. We previously showed that vitamin 
D repletion significantly decreased markers of inflammation and oxidative stress in a high-
risk cohort of AAs with controlled hypertension and preserved renal function. In this study, 
we examined the effect of vitamin D on c-terminal fibroblast growth factor-23 (cFGF23), 
plasminogen activator inhibitor-1 (PAI-1), and vascular and renal function in a subset of 
the cohort.
Methods: We performed a randomized, placebo-controlled study of high-risk AAs 
(N=65) with vitamin D deficiency treated with 100,000 IU vitamin D3 or placebo every 4 
weeks for 12 weeks. We measured eGFR (MDRD) albumin-to-creatinine ratio (ACR), and 
quantified plasma cardiorenal biomarkers (cFGF23 and PAI-1 by ELISA) and determinants 
of vascular function (pulse wave velocity, augmentation index, ambulatory systolic and 
diastolic blood pressure). We performed multiple regression analysis controlling for the 
placebo-treated group to understand the relationship between FGF23 and PAI-1 with 
cardiovascular and renal risk factors.
Results: Vitamin D3 levels increased (p<0.0001) and iPTH levels decreased (p=0.0060) 
with vitamin D3 repletion. There was no change in systolic/diastolic blood pressure and 
no correlation between vitamin D3 repletion and levels of cFGF23 or PAI-1. However, 
logPAI-1 was associated with improved augmentation index (p=0.045) and a trend for 
improved ACR (p=0.074), and reduced PAI-1 levels were associated with improved eGFR 
(p<0.0300). There was a trend for reduced FGF23 with improved augmentation index 
(p=0.078); and for logcFGF23 with improved pulse wave velocity (p<0.069).
Conclusions: Vitamin D3 repletion may modulate vascular and renal function in AAs 
with controlled hypertension and vitamin D3 deficiency. Further study may provide a better 
understanding of the genetic predisposition of vitamin D repletion on vascular and renal 
function in high-risk AAs with vitamin D deficiency.
Funding: Other NIH Support - NIMHD
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Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors (P2Y) in 
Chronic Dialysis
Nishank Jain,1,2 Deepa Raghavan,2 Milind A. Phadnis,3 Huizhong Cui,3 
Suzanne L. Hunt,3 Jonathan D. Mahnken,4 Theresa I. Shireman,5 Rafia Rasu.6 
1Little Rock VA Hospital, Little Rock, AR; 2University of Arkansas for Medical 
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KS; 4The University of Kansas Medical Center, Kansas City, MO; 5Brown 
University School of Public Health, Providence, RI; 6University of Kansas, 
Kansas City, KS.
Background: Due to systematic exclusion of patients on chronic dialysis in P2Y 
clinical trials, risk factors associated with their choice remain unknown.
Methods: Using U.S. Renal Data System data, we identified dialysis patients who 
received new P2Y prescriptions, and analyzed trends in P2Y use and clinical risk factors 
associated with their choice using regression models.
Results: From 2011 to 2014, 36,590 ESRD patients received P2Y (95% clopidogrel, 
3% prasugrel and 2% ticagrelor) with a proportional decrease in clopidogrel use, no 
change in prasugrel use and a proportional increase in ticagrelor use (p-for trend <0.0001, 
0.61 and <0.0001). Median age was 64.0 years, 18% were ≥75 years, 54% men, 36% 
African American, 19% Hispanic and 93% on hemodialysis. History of atherosclerotic 
heart disease (ASHD) and thrombotic cardiovascular (CV) events were associated with 
choice of ticagrelor over clopidogrel [adjusted OR 5.43 (3.23, 9.15) and 2.13 (1.73, 2.62)] 
and prasugrel over clopidogrel [10.24 (6.66, 15.74) and 1.88 (1.63, 2.16)]. Severity of 
comorbidities and presence of diabetes mellitus were not associated with P2Y choice. Of 
the clinical events occuring 90-days prior to the index date of P2Y, percutaneous coronary 
intervention was the strongest independent factor favoring ticagrelor over others, adjusted 
OR 10.21 (8.09, 12.89) and 1.75 (1.32, 2.30).
Conclusions: Ticagrelor has gained popularity while prasugrel use remained unchanged 
in dialysis patients. In the absence of outcomes data in dialysis patients, clinicians favored 
use of ticagrelor over other P2Ys when patients had history of ASHD or CV events or were 
undergoing coronary revascularization. These findings suggest presence of channeling bias 
in prescribing P2Y to this patient population.
Funding: Private Foundation Support
Figure showing semiannual trend in dialysis patients receiving new prescriptions for P2Y 
from July 2011 to December 2014
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48-Hour Ambulatory BP (ABPM) Monitoring and the Estimated Risk of 
Death in the Hemodialysis Population: A Multicenter, International Study
Francesca Mallamaci. on behalf of the TACTIC study working group* G.O.M. 
Bianchi Melacrino Morelli Reggio Calabria, Reggio Calabria, Italy.
Background: ABPM extended to 44h or 48h has been proposed by 
consensus documents by the ASN and the ESH and the ERA-EDTA (EURECAm) as the 
ideal metric for estimating the BP-related health burden in ESRD but information on the 
relationship between this metric and the risk of death is still restricted to a limited 
number of single center studies.
Methods: We investigated the relationship between 48h ABPM and the probability 
of death as estimated by the ARO risk score in a cohort of 278 hemodialysis patients in 
7 centers in 3 European countries. The ARO risk score is a well-validated instrument based 
on 14 risk factors for death specific to the hemodialysis population (KI 87, 996–1008, 
2015).
      Results: Average 48h diastolic BP robustly correlated in an inverse fashion with the 
estimated risk of death at 1 year (r=-0.350, P<0.001) and at 2 years (r=-0.331, P<0.001) and 
these associations were confirmed in separate analyses of day-time and night-time average 
values (P<0.001). Furthermore, 48h pulse pressure was a direct predictor of the estimated 
death risk at 1 year (r=0.330, P<0.001) and at 2 years (r=0.293, P<0.001) and again this 
metric predicted the estimated risk of death in separate analyses of day and night time 
recordings. 
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Conclusions: In a multicenter study in 3 countries 48h diastolic and Pulse Pressure 
correlated strongly with the estimated risk of death and this was true for both average day-
time and night-time values. Extended ABPM recordings reflect the health burden of BP in 
the hemodialysis population. *Torino C, Sarafidis PA, Ekart R, Loutradis C, Karpetas A, 
Raptis V, Bikos A, Papagianni A, Balafa O, Siamopoulos K, Pisani G, Morosetti M, Del 
Giudice A, Aucella F, Di Lullo L, Battaglia G, Tripepi R, Tripepi G, London G, Zoccali C.
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Ambulatory Blood Pressure Monitoring: Assessing Capacity and Practice 
Patterns of the Improving Renal Outcomes Collaborative (IROC) Charles 
D. Varnell,1 Devesh S. Dahale,2 David K. Hooper.1 1Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH; 2Cincinnati Childrens 
Hospital Medical Center, Cincinnati, OH.
Background: Ambulatory Blood Pressure Monitoring (ABPM) is recommended 
for assessment of hypertension in patients with a kidney transplant (KTx) and/or chronic 
kidney disease (CKD). IROC is a multicenter learning health system comprised of patients 
and families, clinicians, and researchers from 23 pediatric nephrology centers, working 
together to improve health of patients with kidney disease.
Methods: 23 IROC centers were surveyed from July to December 2017 and asked to 
report the number of transplant and CKD patients under their care, their center’s protocol 
for ABPM, ABPM unit availability vs need, ABPM return mechanism, challenges and 
barriers to performing ABPM.
Results: All centers responded to the survey and cumulatively care for approximately 
4256 CKD and 2497 KTx patients. There were an average (std dev) of 109 (+/- 51) KTx and 
224 (+/- 114) CKD patients at each center. 17 (74%) centers report intending to use the 
IROC protocol: yearly if last ABPM was abnormal OR every 3 years if last ABPM was 
normal for patients ≥ 7 years old and 1 year post-transplant. One center reported once a year 
screening regardless of last ABPM result. Five centers reported using other protocols. With 
regard to ABPM device needs, 16 (70%) of centers report a shortage of units, 1 center 
reports just enough units, and 6 (26%) of centers report excess units. The majority of centers 
(20/23, 87%) report ABPM devices are returned by the patient or through courier/postal 
service. The main barriers to performing ABPM per protocol are insurance approval, 
workflow, and shortage of ABPMs.
Conclusions: Three-quarters of IROC centers plan to use the recommended IROC 
ABPM protocol, however many centers report a shortage of ABPM units for the number of 
patients cared for. In order to decrease the negative impact of barriers to performing ABPM 
according to recommendations and standards, structured quality improvement is underway 
to optimize workflow and utilization of existing ABPM units.
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Magnitude of the Difference Between Clinic and ABPM BPs Predicts 
Mortality Risk
Elaine Ku,1 Raymond K. Hsu,1 Delphine S. Tuot,1 Se ri Bae,1 
Michael S. Lipkowitz,2 Barbara A. Grimes,1 Matthew R. Weir.3 1University of 
California, San Francisco, San Francisco, CA; 2Georgetown University Medical 
Center, Washington, DC; 3University of Maryland School of Medicine, 
Baltimore, MD.
Background: Ambulatory blood pressure (ABP) monitoring is recommended for the 
detection of masked and white coat hypertension in patients with CKD. Our objective was 
to determine whether the magnitude of the difference between ambulatory and clinic BP’s 
has prognostic implications.
Methods: We examined data from 610 participants of the African American Study 
of Kidney Disease and Hypertension (AASK) Cohort Study, who had completed the 
AASK Trial and had both clinic BP and ABP performed at Cohort entry. We performed 
multivariable Cox proportional hazards models to determine the association between 
absolute systolic BP (SBP) difference between clinic and awake ABPs with death.
Results: Mean age was 61 years, 38% were female, and mean eGFR was 39. During 
median follow-up of 10 years, 33% died; 30% developed ESRD. The association between 
the clinic-awake SBP difference and risk of death is shown in Figure1 and Table1. Higher 
clinic-versus-awake SBP (white coat phenomenon) was associated with higher mortality 
risk compared to 0-5mm Hg clinic-awake SBP difference. A ≤ -5 mmHg lower clinic-
versus-awake SBP (masked phenomenon) was also associated with higher mortality. 
Additonal adjustment for clinic SBP or ambulatory SBP did not change these findings.
Conclusions: Our data revealed a U-shaped, independent association between the 
magnitude of the difference between clinic and ambulatory SBP and mortality in black 
patients with CKD. Further studies are needed to examine whether interventions to lower 
clinic-ABP differences will improve patient outcomes.
Funding: NIDDK Support
Difference between clinic and mean awake ABP and long-term risk of death
*Adjusted for age, sex, heart disease, proteinuria, and eGFR at entry
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Office Blood Pressure Measurement (OBPM) in Children: The SPA 
Project
Gianluigi Ardissino,1 Silvia Ghiglia,5 Sebastiano A. Lava,3,1 Selena Longhi,1 
Laura Martelli,1 Michela Perrone,1 Patrizia Salice,4 Sandra Piantanida.2 The SPA 
Project 1Center for HUS Prevention, Control and Management, Milano, Italy; 
2Polo Materno Infantile- Ospedale F. del Ponte - Varese, COMERIO, Italy; 
3University Children’s Hospital, Inselspital, Bern, Switzerland; 4Fondazione 
Policlinico IRCCS Ca’ Granda Milano, MILANO, Italy; 5Cardiology Unit. 
Ospedale Policlinico, MILANO, Italy.
Background: If blood pressure (BP) measurement still remains challenging in adults, 
it is even more in children. Current guidelines suggest to measure office BP with three 
readings and average them when the first BP is elevated otherwise to perform only one BP 
reading (AAP 2017) or to measure BP 3 times every 3 min using the average of the last 
two (ESH 2016).
Methods: Since 2010, we regularly perform unattended multiple OBPM (mOBPM) 
with a validated (OMRON M3) device: after 5 min rest, at least 10 automated readings are 
taken every 3 min on the non-dominant arm. Readings <5th or >95th centile and mOBPM 
with coefficient of variation (CV)>15% are discarded.
Results: 286 healthy, non-obese children (141 females; median BMI 15.4 Kg/m2 
IQR 14.5-16.4), median age 5.7 (IQR 5.3-6.1) years, were analyzed. The median CVs of 
included mOBPMs were 7% (IQR 5-9) for systolic and 4% (IQR 3-6) for diastolic BP. The 
readings #1-10 were compared with the mean of all 10 measurements (Wilcoxon matched-
paired-signed-rank-test, significance assigned at p<0.01). The first 3 measurements were 
significantly different from the mean, while the readings #4-10 were not. Based on the 
mean, only 11 subjects had a systolic or diastolic BP >90th centile (n=5 >95th c.le) while 
single measurement significantly over-estimated high BP (Fig.1).
Conclusions: Although most guidelines advice ≥2 BP readings, these findings 
suggest that mOBPM should include ideally 10, but at least 4 repeated measurements. 
Acknowledgements:F.Argirò,P.Bardelli,A.Bianchi,T.Bollani,M.Bonvissuto,G.Bosetti,R.
Cambria,G.Capobianco,G.Casani,G.Catanese,C.Cauda,P.Cinquepalmi,S.Coletta,E.
Dardi,A.Daverio,M.DiPietro,L.Filippucci,A.Fornaro,S.Francario,V.Gandini,S.Genoni,L.
Loguercio,A.Manolo,P.Marchetto,R.Marinello,L.Martignoni,A.Mezzopane,A.Monolo,M.
Morelli,M.Musetti,S.Paparone,G.Pastorelli,M.Picca,C.Poletti,M.Scarazatti,L.Simionato,A.
Spalla,F.Tel,V.Valdambrini,M.Vinciguerra.
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Multiple Spot Urine Sampling Is More Precise, Accurate, and Simpler 
Compared to 24-Hours Collection for Estimating Sodium Excretion
Gianluigi Ardissino,1 Selena Longhi,1,2 Laura Martelli,1,3 Antenore Giussani,8,1 
Giovanni R. Pieri,6,1 Patrizia Salice,10 Roberto Romano,9 Marta Brambilla,5 
Michela Perrone,1 Francesca Tel,1,4 Florjan Mehmeti,7,1 Silvia Ghiglia.11 1Center 
for HUS Prevention, Control and Management, Milano, Italy; 2Università degli 
Studi Milano Bicocca, Milano, Italy; 3Ospedale Papa Giovanni XXIII, Bergamo, 
Bergamo, Italy; 4Ospedale dei Bambini V.Buzzi, MILANO, Italy; 5Università 
degli Studi di Milano, Italy, MILANO, Italy; 6IRCCS San Matteo Pavia, 
Lacchiarella, Italy; 7Pediatric Nephrology and dialisys unit, Milano, Italy; 
8Fondazione IRCCS Cà granda policlinico Milano, Milano, Italy; 9Università 
degli Studi di Milano, Campobasso, Italy; 10Fondazione Policlinico IRCCS Ca’ 
Granda Milano, MILANO, Italy; 11Cardiology Unit. Ospedale Policlinico, 
MILANO, Italy.
Background: The estimate of Sodium (Na) intake is of important for monitoring 
hypertensive patients on Na restriction. 24 hours urinary collection (24-hrsUC) is inaccurate 
because of errors in time and/or volume measuring. In addition, the urinary collection is 
unpractical and often done during weekends thus is not representative of the usual Na 
intake. Since spot urine sampling (SUS) is not affected by any of the above mentioned 
sources of error, we hypothesized that the mean urinary Sodium-to-urinary Creatinine ratio 
(uNa-to-uCrR) of multiple SUS, collected in different days, is more precise and accurate for 
estimating the average Na excretion compared to 24-hrsUC.
Methods: A total of 301 urine samples (1 for each voiding) and the related 52 
24-hrsUC performed in different days in 10 heathy subjects (age range 3-65, 6 females, up 
to 11 voidings per day) were collected. For the purpose of comparison, uNa excretion in
mEq/Kg/day from each sample was derived multiplying by 2 each uNa-to-uCrR (the mean 
conversion constant obtained from all ratios as determined from 24-hrsUCs). We calculated 
Lin’s correlation coefficient, mean bias, and 95% limits of agreement (LOA), of uNa for: 1) 
The single 24-hrsUC, using the individual overall 24-hrsUC average as reference; 2) 1000 
random samples of means of 4 spot urine samples (1 per subject in 4 different days) using 
the individual overall 24-hrsUC average as reference. Statistical analysis was performed
using Stata 15.
Results: 1) The single 24-hrs-UC urine collections showed a Lin’s coefficient of 0.78, 
with 95% limits of agreement (LOA) of +1.39 mq/Kg/die (difference between upper and 
lower LOA: 2.78). 2) In the 1000 random samples the average Lin’s coefficient was 0.82. 
Difference between upper and lower LOA was smaller than 2.78 in 58.2% of samples.
Conclusions: Sodium excretion can be estimated, on average, more precisely, 
accurately and practically, as the mean of 4 uNa-to-uCrR in different days, then with a single 
24-hrsUC. In details the mean of 4 spot samples (expressed as mean ((uNa-to-uCr) x 2) will 
provide a more reliable estimate (in mEq/kg/day) in as many as 58% of determinations.
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Evaluating Blood Pressure Control in a VA Renal Clinic: A Performance 
Improvement (PI) Initiative
Maryyam Ali,1 Yoav Segal,2,1 Ashish Malhotra,2 Scott Reule.2,1 1U of MN Renal 
Division, Minneapolis, MN; 2Minneapolis VAMC, Minneapolis, MN.
Background: The suboptimal control of hypertension in adult Americans highlights a 
major need for performance improvement activities at the practice level to achieve better 
blood pressure (BP) control and meet national benchmarks. We evaluated factors associated 
with poor BP control among hypertensives referred to our Veterans Administration Renal 
Clinic with the goal of defining potential correctable characteristics of the persistently 
hypertensive patient. This abstract presents the data of our baseline assessment - the 
essential first step in a PI initiative.
Methods: Study cohort: Veterans followed at the Renal Clinic in September 2017, 
including new consults and follow-up appointments. Site: VA Health Care System, 
Minneapolis, Minnesota Study Type: Retrospective, as a part of PI initiative Methodology: 
Manual review of medical records beginning September 2017. Patient follow-up: 3 months 
Data recorded: Demography, co-morbidities and medications control of BP defined by 
JNC 8 guidelines as a core clinical metric, unless a different goal was documented by 
the provider. Statistics: Chi-square analysis for unadjusted comparisons of patients by BP 
control and logistic regression for odds ratio (OR) calculations.
Results: A total of 105 veterans were included in the final study cohort. Compared to 
those not achieving goal BP (n = 55), those achieving BP goal (n = 50) had an average BP 
of 129/75 mmHg (vs. 151/82 mmHg) with a mean age of 68.2 years (vs. 69.8 years). The 
average medication number was 3.1 (vs. 2.4). Those not achieving BP goal during follow-
up period were less likely to receive any intervention (43.6% vs. 68%; OR 0.36) and more 
likely to remain uncontrolled on subsequent clinic follow up (81.8% vs. 40%; OR 6.67). No 
significant differences by comorbidity or individual provider were observed.
Conclusions: Veterans not achieving BP goals in Renal Clinic were less likely to 
receive any intervention, a finding that did not vary by comorbidity. This data signifies a 
preliminary step to design future quality improvement interventions to identify high-risk 
groups and direct efforts to improve our population-level cardiovascular outcomes.
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What New Guideline Brought to Turkish Hypertension Profile?
Serpil muge Deger,1 Ulver Derici,3 Sukru Sindel,3 Sule Sengul,2 
Mehmet T. Akpolat,5 Yunus Erdem,6 Mustafa Arici,7 Oktay Karatan,2 
Cetin Turgan,4 Enver Hasanoglu,3 Sehsuvar Erturk,2 Sali Caglar.4 1Nephrology, 
Yuksek ihtisas University Faculty of Medicine, ANKARA, Turkey; 2Ankara 
University School of Medicine, Ankara, Turkey; 3Gazi University Faculty of 
Medicine, ANKARA, Turkey; 4Hacettepe University Faculty of Medicine, 
ANKARA, Turkey; 5Liv Hospital ULUS-ISTANBUL, ISTANBUL, Turkey; 
6Hacettepe University Faculty of Medicine, ANKARA, Turkey; 7Hacettepe 
University Medical Faculty, Sihhiye-Ankara, Turkey.
Background: 2017 ACC/AHA guideline lowered the numbers for the diagnosis of HT 
to 130/80 mmHg for adult population with the aim for the early diagnosis of life threatening 
complications of HT such as heart attack and/ or stroke. Turkey is a developing Euroasian 
country with the population of 82 million and has dominance of relatively younger age. 
Although, young population is predominating, cardiovascular disease is still major public 
health concern in Turkey. In 2003, the first large sample sized (n=4910) epidemiological 
study (PatenT study) showed the prevalence of HT as 31.8% in Turkey. After nine years, 
PatenT 2 trial showed prevalence of hypertension as 30.3 %.This study aimed to determine 
to assess current epidemiology of hypertension including, prevalence, awareness and 
control rates among Turkish adults, using criteria from the 2017 ACC/AHA guideline and 
the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC7).
Methods: We analyzed data from PatenT 2 study (n= 5437). Blood pressure 
measurements were performed three times and awareness and treatment were assessed by 
self-reporting and control was defined as SBP/DBP less than 140/90 mmHg.
Results: According to the 2017 ACC/AHA and JNC7 guidelines, the crude prevalence 
of hypertension among Turkish adults was 48.4% and 30.3%, respectively and the 
awareness rate of the hypertension diagnosis was 34.2 % and 54.7 %, respectively. The 
control rate in hypertensives was 28.7 % according to the JNC 7, 17.9 % according to the 
2017 ACC/AHA guideline.
Conclusions: Compared with the JNC7 guideline, the 2017 ACC/ AHA guideline 
results in a considerable increase in the prevalence of hypertension and substantial decrease 
in control rates and awareness of hypertension in Turkish adults.
Funding: Private Foundation Support
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New Guidelines Shift Prevalence of Elevated Blood Pressure (BP) Among 
US Adults Both with and Without CKD
Joanne E. Rodrigue,2 Tanushree Banerjee,6 Kirsten L. Johansen,1 
Jennifer L. Bragg-Gresham,4 Sharon Saydah,5 Nilka Rios Burrows,5 
Rajiv Saran,4 Neil R. Powe.3 1University of California, San Franicsco, San 
Francisco, CA; 2University of California San Francisco, San Francisco, CA; 
3Priscilla Chan and Mark Zuckerberg San Francisco Gen Hosp & UCSF, San 
Francisco, CA; 4University of Michigan, Ann Arbor, MI; 5Centers for Disease 
Control and Prevention, Atlanta, GA; 6San Francisco General Hospital, San 
Francisco, CA.
Background: In 2017, the American College of Cardiology/American Heart 
Association (ACC/AHA) published guidelines that redefine criteria for hypertension 
(HTN) using a lower threshold of BP. We sought to determine the number of individuals 
reclassified as having HTN by prior treatment with antihypertensive medication (Rx) and 
presence or absence of CKD.
Methods: We used National Health and Nutrition Examination Survey data (1999-
2014) to estimate the total number of non-pregnant adults aged ≥20 years who would have 
been reclassified from having pre-HTN (systolic BP [SBP] 120-139 mmHg) per the 2003 
Seventh Report of the Joint National Committee (JNC7) BP guidelines to having elevated 
BP (SBP 120-129 mmHg) or stage 1 HTN (SBP 130-139 mmHg) per 2017 ACC/AHA 
definitions. BP measures were averaged from three readings taken during medical 
examination, and medication use was obtained from the household interview. We further 
examined the number of people with and without CKD having HTN status reclassified. 
CKD was defined as having an estimated glomerular filtration rate (eGFR) between 
15-59 ml/min/1.73m2 or eGFR ≥60 mL/min/1.73m2 with urine albumin to creatinine ratio
≥30 mg/g.
Results: About two-thirds of people initially defined as having pre-HTN in the JNC7
were reclassified to stage 1 HTN according to the ACC/AHA guidelines. The proportion 
was similar among individuals with and without CKD; among those receiving and not
receiving pharmacologic treatment for HTN; and over time. This represents approximately 
one-quarter to one-third of all adults with CKD (28 M; 16 M on Rx) or without CKD (173 
M; 36 M on Rx).
Conclusions: According to the latest guidelines, during the period 1999-2014, a
large proportion of people would have been reclassified from pre-HTN to stage 1 HTN. 
In addition, these results suggest that the new guidelines may stimulate intensification of 
therapy for individuals already being treated for HTN, whether or not they have CKD.
Funding: Other U.S. Government Support
Pre-HTN Reclassified by New BP Guideline n (% of 201M U.S. adults)
M=million
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Applying the New Intensive Blood Pressure Categories to Non-Dialysis 
CKD Population from PATRIOTIC Survey
Ying Zheng, Weiguang Zhang, Guangyan Cai, Xiangmei Chen. Chinese PLA 
General Hospital, Beijing, China.
Background: The 2017 high blood pressure clinical practice guideline reported by the 
American College of Cardiology/American Heart Association put forward new categories 
of blood pressure (BP). This study aimed to assess the applicability of the new guideline in 
non-dialysis chronic kidney disease (CKD) population.
Methods: This is a nationwide, multicenter, cross-sectional study with a large sample. 
A total of 8927 non-dialysis CKD patients in 61 tertiary hospitals in all 31 provinces, 
municipalities, and autonomous regions of China (except Hong Kong, Macao, and Taiwan) 
were analyzed. The categories of BP were defined as normal BP (<120/80 mmHg), 
elevated BP (systolic BP 120–130 mmHg and diastolic BP <80 mmHg), and stages 
1 (systolic BP 130–139 mmHg or diastolic BP 80–89 mmHg) and stage 2 (systolic BP 
≥140 mmHg or diastolic BP ≥90 mmHg) hypertension. The prevalence and control of
hypertension were estimated using a new definition, and the association between the main 
target organs’ injury and new categories of BP was analyzed.
Results: The prevalence, awareness, and treatment of hypertension in non-dialysis 
CKD patients were 79.8%, 72.4%, and 68.3%, respectively. Approximately 11.9% had 
BP <130/80 mmHg, and 6.6% had BP <120/80 mmHg. Subgroups via categories of BP 
had significant difference in age, sex, body mass index (BMI) categories, primary causes, 
and CKD stages (P <0.001). After multivariable adjustment, only stage 2 hypertension was 
associated with decreased renal function (odds ratio [OR] 2.4, 95% confidence interval 
[CI] 1.9–3.0, P<0.001), cardiovascular disease (OR 2.0, 95% CI 1.3–3.1, P=0.001), and
cerebrovascular disease (OR 2.7, 95% CI 1.2–5.8, P=0.015).
Conclusions: Using the new definition of hypertension, the higher prevalence and 
lower control of hypertension were shown in non-dialysis CKD participants. More studies 
are necessary to confirm the applicability of new categories of BP in CKD population 
because only stage 2 hypertension showed statistical association with the main target 
organs’ injury.
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Screening and Management of Albuminuria in a Large Integrated Health 
System
Waleed Zafar,1 Jamie A. Green,2 Ion D. Bucaloiu,2 Alex R. Chang.2 1Geisinger, 
Dnville, PA; 2Geisinger Medical Center, Danville, PA.
Background: Kidney Disease Improving Global Outcomes (KDIGO) guidelines 
recommend albuminuria screening in patients with hypertension or diabetes for appropriate 
risk stratification. Little is known about factors associated with adherence to KDIGO-
recommended treatment goals for patients with albuminuria.
Methods: We used data from 212,068 adults ≥ 18 years of age with 
eGFR ≥ 15 ml/min/1.73m2, who were seen by a primary care provider between 2015-
2016 in a large, integrated health system. Patients were categorized as having severely 
increased albuminuria per KDIGO guidelines (ACR 300+ mg/g, PCR 500+ mg/g, or 
urine dipstick 1+), using quantitative tests if available. We then examined associations 
between sociodemographic and clinical factors with attainment of KDIGO-recommended 
goals [renin-angiotensin-aldosterone system (RAAS) inhibition, blood pressure (BP) goal 
<130/80, and statin treatment] in patients with severely increased albuminuria.
Results: Mean age was 55.2 years, 55.7% were female, 19% were current smokers, and 
13.0% had baseline eGFR < 60 ml/min/1.73m2. Among 87193 patients with hypertension, 
70.5% were screened using any method, 41.3% were screened with ACR or PCR, and 
9.9% had severely increased albuminuria. Among 33655 patients with diabetes, 91.3% 
were screened using any method, 82.9% were screened with ACR or PCR, and 10.4% had 
severely increased albuminuria. Of the 22153 patients with 1+ or greater protein on dipstick, 
only 40.2% also completed an ACR or PCR. Adherence to KDIGO-recommended goals 
was low in severely albuminuric patients (30.8% taking RAAS inhibitors, 33.8% taking 
statins, 48.2% with clinic BP <130/80); only 7.8% achieved all 3 goals. Factors associated 
with attainment of all 3 KDIGO-recommended goals in severely albuminuric patients 
included older age, cardiovascular risk factors, cardiovascular disease, and quantitative 
protein testing (Table). CKD was not associated with attainment of these goals.
Conclusions: Adherence to KDIGO guidelines for albuminuria remains suboptimal. 
Future research is needed to improve screening and management of albuminuria.
Funding: NIDDK Support
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CKD Screening Rate and Blood Pressure (BP) Control in Veterans with 
Hypertension
Shweta Bansal,1,3 Luci Leykum,2 Jacqueline Pugh.4 1University of Texas Health 
Science Center at San Antonio, San Antonio, TX; 2General Internal Medicine, 
UTHSCSA, SAN ANTONIO, TX; 3Renal Section, STVHCS, San Antonio, TX; 
4STVHCS, SAN ANTONIO, TX.
Background: Hypertension (HTN) control is a key strategy to prevent CKD 
progression. Earlier recognition of CKD (by eGFR and albuminuria) and volume 
optimization using diuretics are important to achieve adequate BP control. Prevalence of 
CKD is a third higher in Veterans; however, CKD screening rate in hypertensive Veterans, 
HTN control and utilization of diuretics in Veterans with CKD is unclear.
Methods: We analyzed Veterans Integrated Service Network corporate Data Warehouse 
for Veterans seen at least twice in primary clinics with ICD-9 codes for HTN and diabetes. 
The Final cohort of 241,235 subjects was examined for serum creatinine/eGFR reported at 
least twice 90 days apart, urine protein and ICD-9 for CKD. BP readings from last two clinic 
visits were averaged to evaluate the HTN control.
Results: Ten percent of final cohort did not have any CKD screening procedures. 
Figure 1 shows the percentage of hypertensive subjects with (N=92,129) or without 
diabetes (N=128,099) with available serum creatinine or urine protein measurements or 
both. CKD (eGFR<60 ml/min and/or ACR>30mg/g) was present in 27.2% subjects but 
only 6% had CKD ICD-9 code in the chart. Table 1 demonstrates the HTN control and 
baseline characteristics in these 27.2% subjects.
Conclusions: While hypertensive Veterans get eGFR checked, identification of 
albuminuria is suboptimal and despite screening procedures the recognition of CKD is 
low. Only one third CKD Veterans had BP <130/80 mmHg and 29% were on diuretics. 
These results warrant exploration of factors responsible for these low rates and design 
interventions to address those factors to improve HTN control.
Funding: Veterans Affairs Support
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Prediction Model for Cardiovascular Death Including Proteinuria and 
Estimated Glomerular Filtration Rate in a General Population
Masatoshi Nishimoto,1 Miho Tagawa,1 Kazuhiko Tsuruya,1 Masaru Matsui,1 
Masahiro Eriguchi,1 Ken-ichi Samejima,1 Kunitoshi Iseki,2 Chiho Iseki,2 
Koichi Asahi,2 Kunihiro Yamagata,2 Tsuneo Konta,2 Shouichi Fujimoto,2 
Ichiei Narita,2 Masato Kasahara,2 Yugo Shibagaki,2 Toshiki Moriyama,2 
Masahide Kondo,2 Tsuyoshi Watanabe.2 1Nara Medical University, Kashihara, 
Japan; 2Steering Committee of Research on Design of the Comprehensive 
Health Care System for Chronic Kidney Disease (CKD) Based on the Individual 
Risk Assessment by Specific Health Check, Fukushima, Japan.
Background: There are several prediction models for coronary or cardiovascular (CV) 
events, some of which include estimated glomerular filtration rate (eGFR). However, there 
has been no prediction model for CV death that includes proteinuria and eGFR.
Methods: This was a longitudinal cohort study. Inclusion criteria was subjects aged 
40–74 years in a Japanese nationwide Specific Health Checkup database in 2008. Exclusion 
criteria were subjects with missing data. The exposures of interest were demographics, 
comorbidities, blood pressure, laboratory data, and lifestyle factors. Outcome variable was 
CV death. Subjects were randomly assigned to derivation and validation cohorts by 2:1 
ratio. Points for prediction model were determined based on regression coefficients derived 
from the Cox proportional hazards model in the derivation cohort. The model was validated 
by Kaplan-Meier curves and calibration plot in the validation cohort.
Results: Among 295,297 subjects, data for 120,823 were available for analysis (80,549 
and 40,274 in the derivation and validation cohorts, respectively). During a mean follow-up 
of 3.6 years, there were 204 and 106 CV deaths in the derivation and validation cohorts, 
respectively. Proteinuria and eGFR were significantly associated with CV death and were 
included in the model. Other variables included in our prediction model were shown in the 
figure. Kaplan-Meier curves of 3 risk groups defined by points in the prediction model were 
matched between the derivation and the validation cohorts, and calibration plot was well 
calibrated (y = 1.00x, R2 = 0.90).
Conclusions: Our prediction model for CV death including proteinuria and eGFR was 
well calibrated. External validation in another cohort is required before clinical use.
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Prevalence of Cardiovascular Risk Factors and Association with CKD in 
sub-Saharan Africa
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7College of Medicine, University of Nigeria, Enugu, Nigeria; 8Duke University 
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Background: Cardiovascular disease (CVD) risk factors are also risk factors for 
initiation and progression of CKD. The epidemiology of CVD risk factors and their 
associations with CKD have not been defined in a well-characterized cohort of patients 
with CKD in sub-Saharan Africa which may differ from high income countries.
Methods: We studied 919 patients with CKD from diabetes, hypertension, sickle cell 
disease, HIV, and unknown causes compared with 3504 healthy participants with no CKD 
from the H3Africa Kidney Disease Research Network. We determined the prevalence of 
self-reported hypertension, diabetes, smoking, and dyslipidaemia in sub-Saharan African 
population, and their relationship with CKD risk. Multivariate logistic regression method 
was used to determine association between the risk factors and CKD.
Results: The mean age was 45.7±15.5years and 59.4%% were females. Patients with 
CKD were older (48.9±15.8years) than the control participants (45.6±14.9years), p=0.001; 
they have lower BMI (25.3±5.4kg/m2 versus 26.4±6.1kg/m2, p=0.001), lower hemoglobin, 
(11.3±2.1g/dL versus 13.3±1.7g/dL, p=0.001) and higher Albumin-Creatinine Ratio 
(65.1±37.6mg/g versus 6.2±4.1mg/g, p=0.001). Compared with the control participants, 
patients with CKD have higher prevalence of hypertension (68.87% versus 31.44%, 
p=0.001); diabetes (28.61% versus 18.46%, p=0.001), dyslipidaemia (11.42% versus 
5.96%, p=0.001); and smoking (7.39% versus 3.11%, p=0.001). Table 1 shows the odds of 
each CVD risk factor and having CKD.
Conclusions: Traditional CVD risk factors are prevalent and consistently associated 
with CKD especially hypertension in middle aged adults in sub-Saharan Africa. Prevention 
and optimal treatment of these risk factors may reduce CKD progression in sub-Saharan 
Africa.
Funding: Other NIH Support - National Human Genome Research Institute (1U54-
HG006939-01)
Table 1: Association of self-reported cardiovascular risk factors with CKD in Sub-Saharan 
Africa
*Each CVD risk factor was adjusted for others
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Arterial Stiffness and Kidney Function Decline in SPRINT
Kristen L. Nowak,1 Anna J. Jovanovich,1,2 Zhiying You,1 Michel Chonchol,1 
Mark A. Supiano.3 1University of Colorado Denver: Anschutz Medical Campus, 
Aurora, CO; 2Denver VA, Denver, CO; 3University of Utah and VA Salt Lake 
City, Salt Lake City, UT.
Background: Arterial stiffness increases with advancing age and chronic kidney 
disease. Arterial stiffness may contribute to a decline in kidney function; however, evidence 
is inconsistent. We hypothesized that greater baseline arterial stiffness was independently 
associated with rapid decline in kidney function over the longitudinal follow-up period in 
the Systolic Blood Pressure Intervention Trial (SPRINT).
Methods: 538 adults who participated in an ancillary study of SPRINT which measured 
arterial stiffness (aortic pulse-wave velocity [aPWV]) were included in this analysis. 
Multivariable logistic regression was used to examine the association between baseline 
aPWV and rapid decline in kidney function (estimated glomerular filtration [eGFR] decline 
>3 ml/min/1.73m2/yr) over the follow-up period (median of 3.7 yrs).
Results: Mean age was 72±3 years with a mean baseline aPWV of 10.6±2.6 m/sec
and eGFR of 67±21 ml/min/1.73 m2. 109 participants had rapid decline in renal function
over the follow-up period. After adjustment demographics, randomization group, co-
morbid conditions, smoking, body-mass index, estimated glomerular filtration rate, urinary 
albumin to creatinine ratio, antihypertensive medications, systolic blood pressure, and heart 
rate, baseline aPWV was not associated with increased odds of rapid decline in kidney 
function (OR: 1.03, 95% CI: 0.93-1.13 per unit increase in aPWV). In the fully adjusted 
model, baseline aPWV above the median also did not associate with rapid decline in kidney 
function (OR: 0.92, 95% CI: 0.56-1.51).
Conclusions: Among adults at high risk for cardiovascular events, greater arterial
stiffness is not associated with rapid decline in kidney function.
Funding: NIDDK Support, Other NIH Support - NHLBI, NIA
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Plasma Sodium Is Associated with Arterial Stiffness in SPRINT
Kristen L. Nowak,1 Anna J. Jovanovich,1,2 Zhiying You,1 Mark A. Supiano,3 
Michel Chonchol.1 1University of Colorado Denver: Anschutz Medical Campus, 
Aurora, CO; 2Denver VA, Denver, CO; 3University of Utah and VA Salt Lake 
City, Salt Lake City, UT.
Background: High dietary sodium may induce small yet physiologically relevant 
increases in plasma sodium concentrations, which associates with increased systolic blood 
pressure. Cellular data suggests this is mediated by increased endothelial cell stiffnes, as 
measured by atomic force microscopy. We hypothesized that higher plasma sodium levels 
were associated with greater arterial stiffness in participants in the Systolic Blood Pressure 
Intervention Trial (SPRINT).
Methods: 8,004 adults who participated in SPRINT were included in the analysis of the 
association of plasma sodium level with pulse pressure (PP), a surrogate measure of arterial 
stiffness. 542 adults who participated in an ancillary study of SPRINT which measured 
aortic pulse-wave velocity (aPWV) were included in the analysis of the association 
of plasma sodium with aPWV. Multivariable linear regression was used to examine the 
association between baseline plasma sodium levels and a) PP and b) aPWV.
Results: Mean age was 68±9 years with a mean serum sodium level of 
140±3 mmol/L. In the PP analysis, after adjustment for demographics, randomization 
group, co-morbid conditions, smoking, body-mass index, estimated glomerular filtration 
rate, urinary albumin to creatinine ratio, antihypertensive medications, and heart rate, higher 
plasma sodium was associated with increased baseline PP (tertile 3 [≥141 mmol] vs. tertile 2 
[139-141 mmol]; β: 1.11, 95% CI: 0.49-1.73). In the ancillary study, higher plasma sodium 
was associated with increased baseline aPWV in the unadjusted analysis (tertile 3 vs. tertile 
2; β: 0.53, 95% CI: 0.02-1.03). However, in the fully adjusted model, this association was 
no longer significant (β: 0.39, 95% CI: -0.10-0.88).
Conclusions: Among adults at high risk for cardiovascular events, higher plasma 
sodium was independently associated with baseline arterial stiffness as measured by PP, 
but not by aPWV. The latter analysis may have been limited in power due to a smaller 
samples size.
Funding: NIDDK Support, Other NIH Support - NHLBI, NIA
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Impact of Cardiovascular Events on Mortality and Decline of Renal 
Function in Patients with CKD
Andrew J. Mallett,1,2 Andrew S. Jeyaruban,1,2 Anne Cameron (Salisbury),2 
Jianzhen Zhang,2 Helen G. Healy,1,2 Wendy E. Hoy.2 on behalf of the CKD.QLD 
consortium 1Kidney Health Service, Royal Brisbane and Women’s Hospital, 
Brisbane, QLD, Australia; 2CKD.QLD and the NHMRC CKD.CRE, The 
University of Queensland, Brisbane, QLD, Australia.
Background: CVEs are common and significant complications amongst patients 
with CKD. The association of CKD and CVE is well publicised. However, the impact of 
CVE on subsequent kidney survival is not well described. We aimed to study the impact 
of new cardiovascular events (CVE) on mortality and deterioration of kidney function in a 
prevalent chronic kidney disease (CKD) patient cohort.
Methods: A retrospective cohort study of 1,123 patients of a tertiary teaching hospital, 
registered in the CKD.QLD registry between January 2011 and August 2017 and with a 
minimum of 2 years follow up time. CVE data (ischaemic heart disease (IHD), stroke and 
peripheral vascular disease (PVD)), renal function (eGFR CKD-EPI) and mortality events 
were extracted from integrated medical records. Subjects who progressed to end stage 
kidney disease were imputed an eGFR 8mL/min/1.73m2 at the date of kidney replacement 
therapy (KRT). Delta eGFR (mL/min/1.73 m2/year, (CKD-EPI)was calculated as the 
difference between latest eGFR compared to at time of incident CVE.
Results: 222 patients had at least one incident CVE which included IHD (n=144), 
stroke (n=51) or PVD (n=40). CVE events had a significant (p<0.05) impact on 
mortality, even after adjusting for age, gender and/or history of prior IHD, stroke and/or 
PVD. Kaplan-Meier analysis showed survival was reduced by 700 days (2867 (SE=67) 
vs 2167 (SE=61)) in the CVE cohort (p<0.01). There was no significant change in 
the absolute mean delta eGFR in subjects with and without CVE, adjusted for age 
(2.6mL/min/1.73 m2/year (SE=0.4) vs 1.7mL/min/1.73 m2/year (SE=0.2); p=0.2). Nor was 
there a significant different in progression to KRT, adjusting for age, gender and previous 
IHD, stroke and PVD (CVE 11.5% vs no CVE 10.4%; p=0.6).
Conclusions: New cardiovascular events are a flag for premature mortality in the CKD 
cohort as they are for the general population. However, patients with the shortest survival 
could have been excluded due to the exclusion criteria of the study. Moreover, incident 
CVE do not seem to have a significant association with accelerated progression of renal 
dysfunction or transition to KRT in CKD patients.
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Association of Blood Pressure with Urinary Sodium, Potassium, and 
Sodium/Potassium Ratio in CKD - The French CKD-REIN Cohort Study
Natalia Alencar de Pinho,1 Jean Kabore,3 Tilman B. Drueke,1 Maurice Laville,4 
Bruce M. Robinson,5 Ziad Massy,2 Benedicte Stengel.1 1Inserm /CESP, Villejuif, 
France; 2Ambroise Pare University Hospital and Inserm U1018 Eq5, Boulogne 
Billancourt/ Paris cedex, France; 3Institute for Research in Health Science, 
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Background: The urinary sodium-to-potassium ratio (uNa/K) has been repeatedly 
shown to be more closely linked to blood pressure (BP) than urinary sodium or potassium 
excretion alone, both in general population and in patients with arterial hypertension. 
Whether this is also true for patients with CKD is unknown.
Methods: We assessed associations of BP with spot urine sodium/creatinine (uNa/Cr), 
potassium/creatinine (uK/Cr), and uNa/K in 1658 patients with CKD stages 3 or 4 under 
nephrology care. We used the mean of 2 office BP readings for analyses. Urinary Na, K, 
and creatinine concentrations were measured in second-void urine samples and expressed 
in mmol/L. Associations of BP with uNa/Cr, uK/Cr, and uNa/K modeled by 4-knot splines 
were assessed using generalized linear models adjusted for age, gender, eGFR, albuminuria, 
diabetes, heart failure, dyslipidemia, body mass index, and number of antihypertensive 
drugs.
Results: Median (IQR) age was 68 (59-76) years; most patients were men (65.3%), 
had CKD stage 3 (54.9%), and albuminuria (71.7%). Mean systolic (SBP) and diastolic 
(DBP) BP were 141 and 78 mm Hg, respectively. More than 90% of the patients had a 
history of arterial hypertension, and only 34% among them had controlled BP <140/90 
mmHg. Median (IQR) uNa/Cr, uK/Cr, and uNa/K were 11.6 (7.9-16.3), 5.3 (4.1-7.0), 
and 2.2 (1.5-3.1), respectively. Spot uNa/Cr and uNa/K were positively associated with 
SBP (p 0.004 for both urinary indices) and with pulse pressure (p 0.002 and 0.019, 
respectively). The mean difference (β) in SBP between the highest and the lowest 
quartile (Q4-Q1) was 4.48 (95%CI 1.81-7.16) mmHg for uNa/Cr and 4.47 (95%CI 1.91-
7.03) mmHg for uNa/K. Spot uK/Cr was not associated with any of the BP indices. The 
higher the quartile of uNa/K, but not of uNa/Cr, the higher the likelihood of uncontrolled 
(p 0.066) or apparently treatment resistant hypertension (p 0.033).
Conclusions: The positive association of urinary sodium, but not potassium, excretion 
with SBP and pulse pressure suggests a predominant role of sodium intake in determining 
BP level in many patients with CKD stages 3-4. In contrast with the general population, spot 
uNa/K does not appear to be more informative than uNa/Cr in such patients.
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Renal Impairment Modifies the Association Between Sodium Intake and 
Risk of Stroke – An Analysis of INTERSTROKE
Conor S. Judge,1 Andrew Smyth,2 Martin O’donnell.2 Conor Stephen Judge 
1Health Research Board Clinical Research Facility, Galway, Ireland; 2NUI 
Galway, Galway, Ireland.
Background: Stroke is the second most common cause of death and the third most 
common cause of disability worldwide (1). Excess sodium intake, and renal impairment, 
are associated with an increased risk of stroke. We performed an analysis of the 
INTERSTROKE case-control study to investigate the relationship between estimated 
urinary sodium excretion (used as a surrogate for intake) and stroke.
Methods: INTERSTROKE was a standardized international case-control study that 
recruited 26,919 participants in 32 countries (2). We included participants with urine 
samples collected and measurement of spot urine sodium, potassium, and creatinine. 
24-hour urinary sodium excretion was estimated using the Kawasaki, Intersalt,
and Tanaka equations (7–9). Multivariable unconditional logistic regression was
performed to compare the risk of stroke across four quartiles (<3.2 g/day, 3.2–4.4 g/day, 
4.4–5.8 g/day, >5.8 g/day) of estimated 24-hour urinary sodium excretion using 3.2–4.4g/day 
as the reference quartile, as this was the category with lowest risk.
Results: Of the 26,945 participants, 13,483 were cases and 13,462 were controls. 
23,258 participants had urine collected and processed. Mean eGFR (CKD-EPI) was 79.83 
(23.49) ml/min/1.73m2. Mean 24-hour estimated sodium excretion was 3.56 (1.95) g/day 
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for cases and 3.43 (1.56) g/day for controls (p<0.001). After adjustment for age, sex, 
hypertension, diabetes, ethnicity, and region, <3.2 g/day (OR 1.38 [1.28-1.48]) and 
>5.8 g/day (OR 1.67 [1.55-1.79]) of sodium excretion were both associated with increased 
odds of stroke (ischaemic stroke and intracerebral hemorrhage). 4.4 – 5.8 g/day was not
significant (OR 1.05 [0.97-1.13]). The pattern of association across quartiles was consistent 
with 24-hour sodium excretion estimated with Intersalt and Tanaka equations. The
magnitude of association increases across each CKD stage (Table 1).
Conclusions: Our data report that renal function amplifies the association of sodium 
intake with stroke, and suggest that moderate stroke intake is associated with lowest stroke 
risk in all stages of renal impairment.
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Age, Tissue Sodium, and Blood Pressure Associations in Healthy, 
Hypertensive, and Hemodialysis Subjects
Luis M. Perez,1 Hsin-Yu Fang,2 Brett Burrows,3 Gwendolyn Derk,2 
Ryan J. Larsen,3 Ken Wilund.2 Renal and Cardiovascular Research Laboratory 
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Background: Sodium magnetic resonance imaging (23Na MRI) can non-invasively 
quantify sodium (Na) concentrations in tissues such as the skin and muscle. However, 
previous tissue Na studies in healthy subjects and hemodialysis patients reported only one 
lower leg concentration. We used 23Na MRI to quantify tissue Na in the anterior (AT) and 
posterior (PT) muscle regions of the leg in healthy, hypertensive (HTN), and HD subjects. 
We also examined group differences in tissue Na concentrations and the association of 
tissue Na to age and blood pressure (BP).
Methods: We recruited 22 subjects (45±18 years, 26.0±3.7 kg/m2, 50% male, 64% 
white, 50% HTN, 27% HD) from the University of Illinois and a dialysis clinic in central 
Illinois. 23Na MRI was performed on a Siemens TIM Trio/Prisma II 3T system (birdcage 
head coil). We conducted 23Na MRI region of interest (ROI) analysis in a double-randomized 
and blinded manner for tissue Na concentrations. We also collected height, weight, and 
standardized BP.
Results: Across groups, Na concentration was significantly different (p<0.05) and 
lower in AT compared to PT (AT 18.6±5.1 mM, PT 26.0±4.9 mM; p< 0.05). PT Na was 
correlated both with age (R=0.64, p<0.01) and SBP (R=0.57, p<0.01). AT Na was also 
correlated with age (R=0.68, p<0.01), SBP (R=0.70, p<0.01), and with PT Na (R=0.62, 
p<0.01). Regression analysis demonstrated a significant relation between both age and SBP 
with both AT Na and PT Na (Table 1).
Conclusions: Na concentration in the calf differs depending on the site of quantification, 
with AT having a lower concentration than PT. This was a consistent finding across subject 
groups, despite differing Na concentrations by group. AT and PT are correlated with each 
other as well as age and SBP. Lower leg Na concentrations could differ due to muscle fiber 
type differences or because the AT region is smaller muscle group, thus more difficult to 
quantify than the PT region.
Age and BP Regression by Tissue Sodium
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Estimating the Association Between Urinary Cadmium and Hypertension: 
Bias Introduced by Missing Data on Renal Function
Martina M. Gaggl,1,2 Tiansheng Wang,2 Nora Franceschini.2 1Medical Universitiy 
of Vienna, Vienna, Austria; 2Department of Epidemiology, Gillings School of 
Global Public Health, UNC, Chapel Hill, NC.
Background: Cadmium exposure is associated with hypertension and ultimately all-
cause mortality. Reduced renal function leads to decreased urinary cadmium excretion, 
and is aside from smoking an important confounder of the causal relationship of urinary 
cadmium and hypertension. The current project aimed to demonstrate an easily applicable 
method to overcome missing data to establish an unbiased association between urinary 
cadmium and hypertension in a large U.S. cohort of postmenopausal women sampled 
between 1993-1998.
Methods: Data were derived from the Women’s health Initiative. Filtered urinary 
cadmium was measured by Inductively Coupled Mass Spectrometry and normalized 
to urine creatinine (μg/g). Hypertension was defined as a systolic blood pressure (SBP) 
>140 mmHg or a diastolic BP (DBP) > 90 mmHg or use of antihypertensive medication.
Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. 
We estimated the odds of having hypertension in relation to log-transformed urinary 
cadmium adjusted for age, ethnicity/race, education, U.S. region, smoking, body mass 
index, and anemia (hemoglobin<12g/dL). Because of 76% missing data on eGFR, 
we performed analysis (1) unadjusted for eGFR, (2) adjusted for eGFR but restricted 
to a complete sample, and (3) adjusted for eGFR with imputed eGFR values. We 
performed multiple imputation (SAS 9.4. Proc MI) using a Monte-Carlo-Chain method 
(100 iterations) and estimated variance with Rubin’s formula.
Results: In 1460 women aged 63(±7) years, the mean urinary cadmium was 
0.61(±46)μg/g and 44% had hypertension. Eight percent were current, 37% were past, and 
54% were never smokers. The unadjusted odds ratio (OR) for prevalent hypertension was 
0.84 (95% CI 0.73 – 0.96). The OR for model 1 was 0.92 (95% CI 0.78-1.07), whereas in 
model 2 restricted to complete sample on eGFR OR was 0.63 (95% CI 0.42-0.94). After 
imputation for eGFR (model 3), the OR was 0.91 (95% CI 0.77-1.07), which is similar 
to estimates obtained in model 1. Assumptions of missing out of randomness and normal 
distribution were met for the imputation.
Conclusions: Our example demonstrates that using a study sample without missing 
data may provide biased estimates of association, and imputation of important confounders 
and covariates can be used if missing is random.
Funding: Other NIH Support - NIEHS
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Relationship Between Ankle Brachial Blood Index (ABI) and Cardiac 
Ankle Vascular Index (CAVI) and Prognosis in Maintenance Hemodialysis 
Patients
Kaoru Yasuda,1 Shoichi Maruyama,2 Kunio Morozumi.3 1Masuko Memorial 
Hospital, Department of Nephrology, Nagoya, Japan; 2Nagoya University 
Graduate School of Medicine, Nagoya, Japan; 3Masuko Memorial Hospital, 
Nagoya, Japan.
Background: Ankle brachial blood index (ABI) and cardiac ankle vascular index 
(CAVI) are both indicators of systemic atherosclerosis. We investigate the relationship 
between ABI and CAVI in maintenance hemodialysis patients and their prognosis.
Methods: We measured ABI and CAVI for 297 patients undergoing maintenance 
hemodialysis treatment at Masuko memorial hospital. The cut-off value of CAVI was 
calculated by ROC analysis.
Results: During the observation period (median 28 months), 47 cases (15.8%) died. In 
2-year survival rate, the ABI abnormal group (<0.9, n = 92) was significantly lower than in 
the normal group (> 0.9, n = 205) (67.7% vs. 92.6%, p <0.0001, adjusted hazard ratio 2.18). 
There was no difference in the survival rate between the CAVI abnormal group (> 9.0, n = 
91) and the normal group (<9.0, n = 114) in the ABI normal group (91.1% vs. 93.6%, p = 
0.74). However, when a new cut-off value (7.9) by ROC analysis was used, 2-year survival 
rate in the CAVI abnormality group (n = 137) was significantly lower than that in the normal 
group (n = 68) (88.7% vs. 98.5%, p = 0.021).
Conclusions: CAVI as a prognostic indicator should have a lower Cut-off value in 
maintenance hemodialysis patients with increased arteriosclerosis than the Cut-off value 
used by general population. In addition, it was suggested that even with normal ABI 
patients, it is possible to stratify prognostic risk by measuring CAVI.
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Clinical Features of Dialysis Patients at Risk of Lower Limb Amputation
Karen G. Butler, Michael R. O’Connell, Sheetal Chaudhuri, Hao Han, 
Marta Reviriego-Mendoza, Dugan Maddux, John W. Larkin, Len A. Usvyat, 
Terry L. Ketchersid, Franklin W. Maddux. Fresenius Medical Care North 
America, Waltham, MA.
Background: Dialysis patients are at elevated risk for peripheral artery disease (PAD), 
lower extremity ulcers, and lower limb amputations (LLA) (Garimella et al, 2017). As part 
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of a quality improvement project for the current foot check process, a large dialysis provider 
piloted a Limb Preservation Project (LPP) capturing clinical features of patients’ limbs at 
risk for amputation to streamline processes for specialist referral. We analyzed what features 
were more common in patients with LLA.
Methods: LPP was deployed at 9 dialysis clinics during Sept 2017 to Jan 2018. Dialysis 
clinics received a monthly list of patients considered high risk for foot ulcer who then 
received screening for dermatologic, mechanical and vascular changes in lower extremities.
Results: Among 571 patients considered high risk, there were 458 remarkable 
features documented. In those without a prior amputation (n=496), there were 356 features 
documented, and for those with a prior amputation (n=75), 102 were features documented. 
Patients with a prior amputation most frequently had bandaged wound on their non-
amputated limb (23.53%), an open wound/ulcer on their amputated limb (18.63%), and 
abnormal nails (11.76%). Patients without a prior amputation most frequently had abnormal 
nails (36.25%), skin cracks/fissures (16.01%), and a bandaged wound (10.11%).
Conclusions: Results suggest that regardless of amputation status, the presence of 
abnormal nails and bandaged wounds may be a common clinical feature in dialysis patients 
at risk of lower extremity vascular disease.
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Interarm Difference in Blood Pressure: Prevalence, Risk Factors, and 
Relevance for Diagnosis of Disease of the Aorta Among Patients Referred 
to Specialized Regional Hypertension Center
Januvi Jegatheswaran, Swapnil Hiremath, Cedric A. Edwards, Marcel Ruzicka. 
University of Ottawa, Ottawa, ON, Canada.
Background: Initial evaluation of hypertension (HTN) should include assessment of 
blood pressure (BP) in both arms. The prevalence of high interarm BP difference ranges 
from 3% in the general adult population to about 10% in the patients with HTN. However, 
we lack proper estimates of its prevalence, and existing practice of follow up for these 
patients in a referred population.
Methods: We performed a retrospective chart review of all prevalent patients followed 
at the Hypertension Center at the Ottawa Hospital. BP data from the first visit were used for 
assessment for interarm BP difference. We considered interarm difference in either systolic 
or diastolic BP in excess of 10 mmHg for casual BP by mercury sphygmomanometry to be 
clinically significant.
Results: 493 patients of 580 patients were included in this study based on available 
data. The prevalence of clinically significant interarm difference in systolic or diastolic BP 
was 16.2% and was similar among men and women. These patients were more likely to be 
smokers (current or previous; 53.5% vs 36.8%) with peripheral arterial disease (PAD, 15% 
vs 8%). None of these patients had undergone further investigations of ascending aorta/
aortic arch.
Conclusions: A significant proportion of referred patients have a high interarm 
difference in systolic or diastolic BP. No clinical investigations were ordered to evaluate 
for ascending aorta/aortic arch disease reflecting the physicians’ lack of understanding of its 
clinical relevance. The association with smoking and PAD suggests underlying aortic/large 
vessel disease as a potential mechanism in some patients.
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Association of Vascular Calcification with Brain Atrophy in Patients with 
CKD: Cross-Sectional and Longitudinal Analyses
Kazuhiko Tsuruya,1,2 Hisako Yoshida,3,2 Toshiaki Nakano,4 Takanari Kitazono.4 
1Department of Nephrology, Nara Medical University, Kashihara, Japan; 
2Department of Integrated Therapy for Chronic Kidney Disease, Graduate 
School of Medical Sciences, Kyushu University, Fukuoka, Japan; 3Osaka City 
University Graduate School of Medicine, Osaka, Japan; 4Department of 
Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu 
University, Fukuoka, Japan.
Background: It has been reported that brain atrophy (BA) progresses rapidly in 
chronic kidney disease (CKD) patients, especially in patients on hemodialysis (HD). We 
previously demonstrated that BA progressed more rapidly in patients on peritoneal dialysis 
(PD) compared with patients with non-dialysis dependent CKD (ND) (Tsuruya K, et al. 
AJKD, 2015). Vascular calcification (VC) has been considered to be an independent risk 
factor for cardiovascular disease including cerebrovascular disease; however, it remains 
unclear whether VC affects BA. Thus, we examined the association between VC and BA by 
cross-sectional and longitudinal analyses among CKD patients.
Methods: In the present study, 157 CKD (90 ND, 42 PD, and 25 HD) patients aged 
62 (mean) ± 10 (SD) years (men 91, diabetes 46) were recruited and underwent MRI 
scanning at baseline and after two years. T1-weighted MRI images were analyzed with 
statistical parametric mapping software. Total gray matter (GM), total white matter (WM), 
and cerebrospinal fluid (CSF) were segmented and each volume was quantified using MRI 
voxel-based morphometry. GM ratio (GMR), calculated by normalization of GM volume to 
intracranial volume determined by summation of GM, WM, and CSF volume, and annual 
reduction rate of GMR (ARR-GMR) were used to evaluate BA. At baseline, all participants 
underwent multidetector computed tomography to assess coronary artery calcification score 
(CACS) and the values were transformed into the square root values (SR-CACS) to reduce 
the skewed distribution. We examined the associations of SR-CACS with GMR and ARR-
GMR using multiple regression analysis.
Results: The mean GMR significantly decreased from 40.0% at baseline to 39.2% after 
2 years, and the mean ARR-GMR was 0.38 percentage-point. SR-CACS was significantly 
negatively associated with GMR and positively associated with ARR-GMR. The 
association with GMR remained significant even after adjustment for age, sex, diabetes, 
systolic blood pressure, hemoglobin, dialysis status (ND, PD, or HD), current smoking, and 
regular drinking (Model-1), and the association with ARR-GMR also remained significant 
even after adjustment for Model-1 and baseline GMR (Model-2).
Conclusions: CACS was significantly associated with rapid progression of BA in CKD 
patients. This study suggests that VC might affect BA.
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Prevalence of Abdominal Aortic Calcifications in CKD Patients in the 
Arabian Gulf Region
Ali AlSahow,1 Fadwa S. Al-Ali,4 Basset El Essawy,2 Anas M. Al Yousef,3 
Mohamed N. Husain.5 1Nephrology, Jahra Hospital, Jahra, Kuwait; 
2Nephrology, Ibrahim Bin Hamad Obaidallah Hospital, Ras AlKhaimah, United 
Arab Emirates; 3Nephrology, Farwaniya Hospital, Sabah AlNaser, Kuwait; 
4Nephrology, Hamad Hospital, Doha, Qatar; 5Nephrology, Salmanyia Hospital, 
Manama, Bahrain.
Background: Abdominal aortic calcification (AAC) is an important risk factor for 
cardiovascular disease (CVD). CVD is the commones complication of chronic kidney 
disease (CKD). In the Arabian Gulf, few studies were conducted on CKD patients. Aim 
was to determine AAC prevalence in dialysis and non-dialysis CKD patients and determine 
relevant predictive factors.
Methods: We performed a multi-center, multi-national chart review of 546 adult CKD 
patients who have had a plain abdominal x-ray within 6 months prior to study entry. We 
collected data about patients’ demographics, CKD stage, medical history and comorbidities, 
lipid profile, current medications and reviewed X-rays for AAC presence.
Results: A total of 544 CKD patients were eligible for analysis including 325 (59.7%) 
dialysis patients and 219 (40.3%) non-dialysis patients. 290 (53.3%) patients were 
males and 369 (67.8%) were diabetics. Mean age was 57.98 years (SD ± 15.39). Table 
1 describes the distribution of patients according to CKD stage and AAC prevalence in 
each stage. Overall, AAC was reported in 203 (37.3%, 95% CI=33.2%: 41.4%) patients. 
AAC prevalence among dialysis patients (126 patients, 38.8%) did not differ significantly 
from that among non-dialysis patients (77 patients, 35.2%) (p=0.393). Higher risk of AAC 
development was associated with age, as mean age for AAC group was 66 for non AAC 
group was 53 (p< 0.001); diabetes, as 45.3% of diabetics developed AAC, compared to 
20.6% of non-diabetics developing AAC (p< 0.001), with diabetic patients 2.1 times more 
likely to have AAC than non-diabetic patients; and longer dialysis vintage, which was 
1.92 years in AAC group compared to 1.18 years in non AAC group (p= 0.003). Gender, 
hypertension and CVD had no associations with AAC.
Conclusions: Our study shows that AAC is present in more than one third of CKD 
patients in the Arabian Gulf. Risk is higher with older age, diabetes, and longer dialysis 
vintage.
Funding: Commercial Support - Sanofi
AAC Prevalence
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Thyroid Status and Coronary Artery Calcification in a Prospective 
Hemodialysis Cohort
Connie Rhee,1 Alejandra Novoa,2 Amy S. You,1 Tracy Nakata,1 Kamyar Kalantar-
Zadeh.3 1University of California, Irvine, Orange, CA; 2UC Irvine Health, 
Orange, CA; 3University of California Irvine, School of Medicine, Orange, CA.
Background: In the general population, hypothyroidism is a known risk factor 
for coronary heart disease (CHD) and death. Experimental data suggest that low levels 
of circulating thyroid hormone (e.g., triiodothyronine [T3]) are causally associated 
with vascular calcification via downregulation of matrix Gla and klotho (i.e., vascular 
calcification inhibitors), and human studies suggest that low T3 levels are associated with 
higher risk of coronary artery calcification (CAC). However, little is known about the 
association of thyroid status, defined by serum thyrotropin (TSH) as the most sensitive 
and specific biochemical metric of thyroid function, with risk of CAC in the hemodialysis 
population.
Methods: In a secondary analysis of 104 patients from the Anti-Inflammatory and Anti-
Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) trial, we examined 
the association of serum TSH levels with total Agatston CAC score. Cross-sectional 
associations of thyroid status with CAC score (total Agatston score >100, threshold for 
which moderate non-obstructive coronary artery disease highly likely) were estimated using 
logistic regression models adjusted for age, sex, and race.
Results: We observed that increasingly higher increments of serum TSH (defined as 
change in 1 standard deviation = 1.9mIU/L) were associated with a 3-fold higher risk of 
higher CAC score: OR (95%CI) 3.05 (1.26-7.37). When categorized as tertiles, the highest 
TSH tertile was also associated with a higher risk of higher CAC burden (ref: lowest tertile): 
OR (95%CI) 5.53 (1.44-26.3). Similarly TSH levels >3mIU/L were associated with a higher 
risk of higher CAC score (ref: ≤3mIU/L): OR (95%CI) 10.82 (1.78-65.8).
Conclusions: These data indicate that higher serum TSH levels are associated with 
higher risk of CAC in hemodialysis patients. Further studies are needed to determine of 
thyroid hormone supplementation ameliorates CHD burden in this population.
Funding: NIDDK Support
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Repeat Intravascular Ultrasound Guided Renal Artery Angioplasty in a 
Patient with Fibromuscular Dysplasia
Avantika Chenna. Nephrology, Southwest georgia nephrology----, Albany, GA.
Introduction: Fibromuscular dysplasia (FMD) is one of the etiologies of renal artery 
stenosis (RAS) and secondary hypertension. Balloon angioplasty has emerged is emerging 
as a mainsstay of treatment in patients with FMD usually show substantial clinical response 
to renal angioplasty without stenting.
Case Description: We report a case of 32 -year-old male case of secondary 
hypertension from RAS due to with repeat intravascular ultrasound guided renal 
artery angioplasty. Her blood pressure (BP) was 165/95 with heart rate of 89 bts/min 
on presentation with chronic headaches. Her physcial exam was within normal limits. 
Labs revealed sodium of 138, potassium of 4.6, chloride of 97 and bicarbonate of 
23 mmol/l respectively. BUN was 13 and creatinine was 0.87 mg/dl respectively. Secondary 
hypertension workup was negative except borderline elevated renin level. Doppler 
renal ultrasound showed increased velocity in the proximal portion of left renal artery 
concerning for left RAS. Patient’s medications were adjusted including maximum dose 
of lisinopril without improvement in home blood pressure readings. Renal angiography 
was performed which revealed classic beaded appearance of bilateral renal artery showing 
FMD. Therefore, percutaneous transluminal angioplasty of bilateral renal arteries was 
performed. BP improved temporarily for a month after the procedure but slowly started to 
go up with average BP being 150’s systolic and 100’s diastolic. Doppler renal ultrasound 
showed increased velocities in bilateral renal arteries. Therefore percutaneous transluminal 
angioplasty of bilateral renal arteries was performed again. BP improved after the second 
balloon angioplasty and was now sustained. 3 months after follow up her BP improved to 
systolic 110-120 and diastolic of 70-80 mm hg without requiring any antihypertensives.
Discussion: This is the only case reported in medical literature to the best of our 
knowledge where repeat balloon angioplasty was attempted with successful and sustained 
BP control. Through this case we propose that repeat intravascular ultrasound guided renal 
artery angioplasty can be considered in patients with bilateral RAS due to FMD in whom 
the first attempt fails to control BP without stent placement. Further studies are needed to 
study the long term benefits of this procedure on BP control and kidney function.
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Impact of Ageing and Cardiovascular Risk Factors on Retinal Neurode-
generation Assessed by Spectral-Domain Optical Coherence Tomography
Susanne Jung,1 Agnes Bosch,3 Nikolas L. Kohler,1 Christian Ott,1 
Dennis Kannenkeril,3 Thomas Dienemann,3 Joanna M. Harazny,2 
Roland E. Schmieder.3 1Friedrich-Alexander-University Erlangen-Nuremberg, 
Erlangen, Germany; 2University Erlangen-Nueremberg, Erlangen, Germany; 
3University Hospital Erlangen, Erlangen, Germany.
Background: Spectral-domain optical coherence tomography (SD-OCT) has become 
a reliable imaging technique for the evaluation of retinal layer volumes. The aim of this 
study is to characterize age-related neuroretinal alterations and thereby identify risk factors 
for the process of retinal ageing.
Methods: This was a prospective observational single center study including 62 
healthy subjects–25 young (aged<40 years) and 37 elderly healthy individuals (aged≥40 
years). Macular retinal layer volumes of both eyes were evaluated by SD-OCT, comprising 
total retinal volume and each layer separately.
Results: In the group of young subjects (12 females/13 males, aged 25.1±3.5years) 
fasting plasma glucose (FPG) and HbA1c were significantly lower than in elderly subjects 
(28 females/9 males, aged 58.2±10years). There were no significant differences in systolic 
(SBP) and diastolic blood pressure (DBP). Gender-adjusted retinal layer volumes of both 
eyes including total retinal, RNFL, ganglion cell layer (GCL), inner plexiform layer (IPL), 
GCL-IPL, inner retinal layer (IRL, comprising RNFL, GCL-IPL) and outer nuclear layer 
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(ONL) volume were lower in the group of elderly subjects compared to young individuals. 
Additionally, partial correlation analysis revealed a significant negative correlation between 
retinal layer volumes and age (r range: -0.633 to -0.272, p range: <0.001-0.032), SBP (r 
range: -0.319 to -0.266, p range: 0.014-0.036), DBP (r range: -0.386 to -0.275, p range: 
0.004-0.035), FPG (r range: -0.448 to -0.297, p range: 0.001-0.036) and HbA1c (r range: 
-0.433 to -0.286, p range: 0.002-0.044).
Conclusions: In this study, we detected significant differences in retinal layer volumes
indicating age-related retinal neurodegenerative processes and identified risk factors for 
retinal ageing such as hypertension and a dysregulated glucose metabolism.
Retinal layer volumes
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Serum Magnesium Levels and Subsequent Risk of Peripheral Artery 
Disease
Steven Menez,1 Ning Ding,2 Morgan Grams,2 Pamela L. Lutsey,6 
Elizabeth Selvin,2 Josef Coresh,3 Bernard G. Jaar,4 Kunihiro Matsushita.5 
1Medicine, Div. of Nephrology, Johns Hopkins Medicine, Baltimore, MD; 2Johns 
Hopkins University, Baltimore, MD; 3Welch Center for Prevention, Epidemiology 
& Clinical Research, Baltimore, MD; 4Johns Hopkins University and 
Nephrology Center of Maryland, Baltimore, MD; 5Johns Hopkins Bloomberg 
School of Public Health, Baltimore, MD; 6University of Minnesota, Minneapolis, 
MN.
Background: Hypomagnesemia has been associated with increased risk of several 
cardiovascular phenotypes presumably through its interaction with calcium and phosphate, 
but its relation to peripheral artery disease (PAD) is not well established. Magnesium (Mg) 
homeostasis is tightly regulated by the kidney, and thus the relationship between Mg and 
PAD may be weaker in CKD.
Methods: Using data from the Atherosclerosis Risk in Communities (ARIC) Study, we 
investigated the association of serum Mg with incident PAD in 14,293 participants free of 
prevalent PAD at baseline (mean age 54.6 years [SD 5.7], 26.2% black, 1.2% with GFR<60 
mL/min/1.73m2, 9.5% with DM). We used multivariable Cox models to quantify the 
association of Mg (< vs. ≥ the median value of 1.6 mEq/L) with incident PAD accounting 
for potential confounders. We further evaluated these associations, stratified by GFR above 
and below 60 mL/min/1.73m2.
Results: Over a median follow-up time of 25.9 years, a total of 620 cases of incident 
PAD were observed. In fully adjusted models, the association between higher Mg and PAD 
was significant (HR=0.80, 95% CI: 0.67 – 0.95) (Table). Modeled continuously, the risk 
of PAD decreased significantly with every 0.1 mEq/L increase in Mg (HR 0.49, 95% CI: 
0.30 – 0.82). In stratified analysis, this association persisted for participants with GFR above 
60 mL/min/1.73m2 but not for those with GFR<60. The interaction between Mg and GFR 
for PAD risk was significant (p=0.01). Among other electrolytes, higher calcium trended 
towards lower risk of PAD (HR=0.86, 95% CI: 0.72 – 1.01).
Conclusions: Higher serum Mg is independently associated with a lower hazard of 
incident PAD, though this association was not seen in individuals with reduced GFR. Our 
results suggest potential contribution of low serum Mg levels in the development of PAD 
independent of other calcium-phosphate metabolism.
Funding: Other NIH Support - The project described was supported by Grant Number 
T32 HL007024 from the National Heart, Lung, and Blood Institute, National Institutes of 
Health
Multivariable Cox Proportional Hazards Models for Incident PAD
Adjusted for age, sex, race, education, smoking status, drinking status, HTN, DM, prevalent 
coronary heart disease, total cholesterol, HDL cholesterol, serum electrolytes (potassium, 
calcium, phosphate), and eGFR.
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Dialysis Modality and Risk of Atrial Fibrillation: A Systematic Review and 
Meta-Analysis
Boonphiphop Boonpheng,1 Charat Thongprayoon,2 Emmanuel Addo-Yobo,1 
Wisit Cheungpasitporn.3 1East Tennessee State University, Johnson City, TN; 
2Bassett Medical Center, Cooperstown, NY; 3University of Mississippi Medical 
Center, Jackson, MS.
Background: Several studies have demonstrated that end- stage renal disease (ESRD) 
patients on dialysis are at higher risk for atrial fibrillation, which can be associated with 
stroke and increased mortality. However, the risk of atrial fibrillation in patients on different 
renal replacement modality remains unclear. We performed this meta-analysis to assess the 
risks of atrial fibrillation in ESRD patients on hemodialysis (HD) compared to peritoneal 
dialysis (PD).
Methods: A systematic review was conducted in MEDLINE, EMBASE, Cochrane 
databases from inception through April 2018 to identify studies that evaluated the risk 
of atrial fibrillation of patients on different dialysis modalities. Effect estimates from 
the individual study were extracted and combined using random-effect, generic inverse 
variance method of DerSimonian and Laird.
Results: 5 observational studies with a total of 22,779 dialysis patients (19,623 on HD 
and 3,156 on PD) were enrolled. Compared with PD, HD was associated with significantly 
increased risk of atrial fibrillation with pooled rate ratio of 1.46 (95% CI, 1.09-1.95). Meta-
regression showed significant negative correlations between risk of AF among HD patients 
and year of study (slopes = -0.049, P = 0.04).
Conclusions: HD status is associated with 46% higher risk of atrial fibrillation 
compared to PD. However, compared to those on PD, there are potential reductions in the 
risk of atrial fibrillation among ESRD patients on HD overtime.
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Sex Disparities in Cardiovascular Events in Incident Dialysis Patients
Silvi Shah,1 Annette Christianson,2 Karthikeyan Meganathan,1 
Anthony C. Leonard,1 Charuhas V. Thakar.1 1University of Cincinnati, 
Cincinnati, OH; 2Cincinnati VA, Cincinnati, OH.
Background: Cardiovascular events remains the leading cause of mortality in patients 
with end stage renal disease (ESRD) and the risk of cardiovascular events is 10 to 20 
times higher in ESRD as compared to general population. Sex disparities in the major 
cardiovascular events in dialysis patients have not been studied.
Methods: We evaluated 96,729 patients who initiated dialysis between 1/1/2007 and 
12/31/2008 from the United States Renal Data System with linked claims for Medicare 
Part A and Part B or Medicare Primary Other as the primary payer for the entire one year 
post dialysis initiation. Using ICD-9 codes, we identified hospitalizations for major adverse 
cardiovascular events (MACE), defined by unstable angina, acute myocardial infarction 
(MI), congestive heart failure (CHF), and stroke. Using case mix adjusted logistic regression 
models, we examined the impact of sex on MACE as the primary outcome.
Results: The mean age was 70±12 years. In the study cohort, 45.2% were women 
and 61.4% were white patients. All cause one-year mortality was 43.3%. Overall, women 
had higher frequency of MACE as compared to men (41.8% vs. 38.3%, p value<0.0001). 
Additionally, women had higher incidence of acute hospitalizations with CHF (36.7% vs. 
33.1%, p value<0.0001), and stroke (5.8% vs. 4.5%, p value < 0.001) as compared to men. 
The frequency of unstable angina (7.3% vs. 7.5%, p value = 0.20) and acute MI (2.6% vs. 
2.5%, p value = 0.26) was comparable between women and men. In the adjusted analyses, 
women had higher odds of MACE as compared to men (OR, 1.16; 95% CI, 1.13-1.19). 
As compared to men, women also had higher adjusted odds of CHF (OR, 1.17; 95% CI, 
1.14-1.21) and stroke (OR, 1.28; 95% CI, 1.20-1.35). Odds of acute MI (OR, 1.08; 95% CI, 
1.00-1.18) and angina (OR, 0.99; 95% CI, 0.94-1.04) did not differ significantly between 
men and women.
Conclusions: Women are 16% more likely to have acute hospitalizations with MACE 
as compared to men in the first year after incident ESRD. Additionally, women experience 
17% higher rates of hospitalization with CHF and 28% higher rates of hospitalization with 
stroke. Further studies are needed to better delineate the factors associated with this sex 
disparity in the risk of MACE, and its treatment approaches.
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The Cut-Off Value of NT-Pro BNP to Diagnose Cardiac Insufficiency with 
Both Decreased and Preserved Ejection Fraction Value in Patients with 
Stage 3 to 5D CKD
Zi Li. Department of Medicine-Nephrology, West China Hospital of Sichuan 
University, Chengdu, China.
Background: BNP and NT-Pro-BNP are widely used in clinical work for the diagnosis 
of heart failure even in patients with chronic kidney disease(CKD). Previous research 
focused on the heart failure with decreased ejection fraction (EF). However, heart failure/
insufficiency with preserved EF occurs in a large amout CKD patients especially in the early 
period. This research is to explore the diagnosis cut-off value of NT-Pro BNP for cardiac 
insufficiency in CKD patients with stage 3 to 5D, and to analyze its probable influential 
factors.
Methods: CKD patients with 3 to 5D stages who were hospitalized in the department 
of nephrology, which belongs to an affiliated hospital of our university, from April 2016 to 
April 2017 were enrolled. All the patients measured plasma NT-Pro BNP and completed 
echocardiography within 1 month. Criteria for heart insufficiency included both the patients’ 
symptoms, the 2013 ACCF/AHA heart failure guideline and recommendations and the 
American Society of Echocardiography as well. Informations of age, sex, weight, height, 
BMI, blood pressure, NT-ProBNP, GFR, serum electrolytes, index of echocardiography 
were collected. According to GFR, the patients are divided into three groups: CKD3, 
CKD4, CKD5 (non-dialysis, hemodialysis, and peritoneal dialysis). SPSS software is used 
for data analysis.
Results: (1) A total of 396 patients met our inclusion crtieria. NT-Pro BNP was 
negatively correlated with GFR, EF, sodium, potassium or chloride and positively 
correlated with E/A, LV, LA, RV, RA, IVS, LVPW, EDD, ESD, EDV, ESV and CKD stages 
(p<0.05). (2) Linear correlation analysis showed ESV, EF, ESD, EDV, E/A, NT-Pro BNP, 
LV, LA, E/e’ correlated with heart failure; multi-factor logistic regression analysis showed 
that the factors affecting heart failure included E/A, ESV and NT-pro BNP. The diagnostic 
cut-point value of NT-pro BNP for heart insufficiency increased with the increase of CKD 
stage (CKD stage 3: 3654.0pg/ml; CKD stage 4: 7584.5pg/ml; CKD stage 5 non-dialysis: 
9465.5pg/ml; peritoneal dialysis: 18667.5pg/ml; hemodialysis: 29362.0pg/ml).
Conclusions: NT-Pro BNP cut-off values for cardiac insufficiency should be established 
according to different CKD stages and considering both decreased and preserved EF value 
in order to improve early diagnosis and treatment of heart insufficiency.
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N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T for 
Detection of Left Ventricular Hypertrophy in Non-Dialysis CKD Patients
Han Zhang, Jing Chen. Zhongshan Hospital, Fudan University, Shanghai,
China.
Background: The mortality of cardiovascular disease (CVD) in the patients with 
chronic kidney disease (CKD) is significantly higher than in the general population. Plasma 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT)
have been shown to be powerful predictors of cardiovascular mortality. In subjects with
albuminuria or impaired renal function, the use of these cardiac biomarkers has been
debated. In this cross-section study, we tried to investigate whether these two biomarkers
could predict left ventricular hypertrophy (LVH) in subjects with CKD patients and the
prediction power of both.
Methods: A total of 1320 pre-dialysis CKD patients were recruited in this study. NT-
pro-BNP and cTnT were all measured on the Roche cobas E602 (Roche Diagnostics). Left 
ventricular mass index (LVMI) were determined by an echocardiographic examination.
Results: Participants in high NT-proBNP group, as well as participants in high 
cTnT group, had a worse cardiovascular risk profile and had more LVH. Participants 
with high cardiac biomarkers had also more often a lower eGFR and higher proteinuria. 
Multivariable-adjusted association of NT-proBNP level and LVH was OR 1.233(95%CI 
1.131 to 1.345) for per 1000pg/ml increase. Multivariable-adjusted association of cTnT 
level and LVH was OR 1.005(95%CI 1.001 to 1.010)for per 100ng/L increase. Then we 
identified optimal threshold value for NT-ProBNP and cTnT. The 90th percentile of NT-
proBNP had moderately high positive likehood ratios for detecting LVH, 50th percentile 
of NT-proBNP had moderately low negtive likehood ratios for detecting LVH. The 90th 
percentile and 50th percentile of cTnT had optimal positive likehood ratios and negtive 
likehood ratios separately for detecting LVH.
Conclusions: NT-proBNP and cTnT both are independent factors associated with the 
echocardiographic parameters of LVH in CKD patients. The diagnostic performance of NT-
proBNP is significantly superior than cTnT.
Association of NT-proBNP and cTnT with LVH
Data are presented as OR (95% CI).*P<0.05, **P<0.001.
Left ventricular hypertrophy was defined as LVM/height2.7 >47 g/m2.7 for women and 
>50 g/m2.7 for men.
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ADAM17 as a Predictor of CV Events in CKD Patients
Vanesa Palau,1 Marta Riera,1 David Benito,1 Jose M. Valdivielso,3 Angels Betriu,3 
Elvira Fernandez,3 Julio Pascual,1,2 Maria Jose Soler.1,2 1Hospital del Mar 
Medical Research Institute (IMIM), Barcelona, Spain; 2Parc de Salut Mar. 
Fundació IMIM, Barcelona, Spain; 3IRB LLEIDA, LLEIDA, Spain.
Background: Previous studies have demonstrated a positive correlation between 
ADAM17 and TNFα in cardiovascular (CV) disease. Increased expression of TNFα and 
ADAM17 has important implications in advanced cardiac dysfunction. We studied the 
relationship between baseline circulating ADAM17 activity, cardiovascular events and 
mortality in CKD patients from the NEFRONA study after 48 months of follow-up.
Methods: 2,570 patients without history of previous CV disease from the observational 
and multicenter NEFRONA study were divided into three groups: non-dialysis CKD stage 
3-5 patients (CKD3-5, n=1,463), hemodialysis or peritoneal dialysis patients (CKD5D,
n=538) and control patients (CONT, n=569). Baseline circulating ADAM17 activity was
analyzed using a fluorimetric assay in plasma samples. Survival was analyzed by Kaplan-
Meier curves for the following events: CV event, CV mortality, non-CV mortality and
all mortality causes according to ADAM17 activity, diabetes, age, smoking and dialysis
requirement. Cox regression analyses were used to identify risk factors for these events.
Results: Circulating ADAM17 activity was higher in patients with CV events and 
in patients with CV mortality, non-CV mortality and all-cause mortality (p<0.05). In the 
unadjusted Cox model, circulating ADAM17 activity was a risk factor for CV events, CV 
mortality and all-cause mortality in CKD patients. However, circulating ADAM17 was not 
a risk factor for non-CV mortality. In the multivariate Cox regression model, circulating 
ADAM17 activity, older age, male sex, diabetes and dialysis were identified as independent 
risk factors for CV events.
Conclusions: Higher levels of circulating ADAM17 activity correlated with a worst 
survival rate in patients with CV events, CV death and all mortality causes. Circulating 
ADAM17 activity could be an independent predictor for CV events in CKD patients 
without previous history of CV disease.
Funding: Government Support - Non-U.S.
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α-Adducin Polymorphism’s Influence on Ischemic Strokes
Paola Casanova, Lino Merlino, Chiara Lanzani, Laura Zagato, Simona Delli 
carpini, Elisabetta Messaggio, Paolo Manunta, Marco Simonini. San Raffaele 
Scientific Institute, Milan, Italy.
Background: rs4961 Gly460Trp variant of the alpha Adducin gene (ADD1) has been 
associated with renal sodium retention and salt sensitive hypertension. Previous studies 
indicated ADD1 Gly460Trp as associated to higher risk of cardiovascular diseases. The aim 
of this study is to assess whether there is a correlation between this ADD1 variant and the 
development of ischemic strokes
Methods: 212 patients with ischemic stroke (IS) were recruited from San Raffaele 
Hospital in Milan and divided into four categories according to Oxford Classification. These 
patients were compared to a cohort of elder general population (EGP, 128 patients) and a 
cohort of hypertensive patients (HYP, 2404 patients), both with no history of strokes.
Results: In IS group mean age at strokes’ diagnosis was 72.34±11.9, 61% men, 
39% women. The incidence of CV risk factors was: hypertension 66%, diabetes 22%, 
hypercholesterolemia 40% and hypertriglyceridemia 13%, previous stroke 14%, CKD 
16%. Two comparable populations were selected with similar age (71.28±6.9 years for 
EGP) and with the same incidence of risk factors (for HYP population). Notably, the 
presence of subjects homozygous for ADD1 mutated allele (rs4961 TrpTrp) is more than 
double in patients bearing ischemic stroke than in the two others (6.1% IS vs. 2.3% EP, 
p=0.049; 6.1% IS vs. 2.2 HYP, p = 0.009; fig.1). There was no statistically difference among 
the various types of stroke.
Conclusions: These data suggest a correlation between mutated alpha-Adducin and 
the increased incidence of all types of ischemic stroke. No correlation was found with 
the other hypertension-related genes analysed (as ADD2, ADD3). rs4961 alpha-Adducin 
polymorphism should be considered as an independent risk factor for ischemic strokes, 
even if these events donot appear directly linked to hypertension. Finally, alpha-Adducin 
polymorphism itself might be a candidate gene in the pathogenesis of stroke.
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APOL1 Genotypes and Vascular and Endothelial Function in the 
Multi-Ethnic Study of Atherosclerosis (MESA)
Teresa K. Chen,1 Ronit Katz,2 Michelle M. Estrella,3 Wendy S. Post,9 
Holly J. Kramer,4 Jerome I. Rotter,8 Bamidele O. Tayo,6 Josyf Mychaleckyj,7 
Christina Wassel,10 Carmen A. Peralta.5 1Johns Hopkins University School of 
Medicine, Baltimore, MD; 2University of Washington, Seattle, WA; 3University 
of California, San Francisco and San Francisco VA Medical Center, San 
Francisco, CA; 4Loyola University Medical Center, Maywood, IL; 5University of 
California San Francisco/SFVAMC, San Francisco, CA; 6Loyola University 
Chicago Stritch School of Medicine, Maywood, IL; 7University of Virginia, 
Charlottesville, VA; 8LABioMed at Harbor-UCLA Medical Center, Torrance, 
CA; 9Johns Hopkins University, Baltimore, MD; 10Premier, Inc, Charlotte, NC.
Background: The APOL1 high-risk genotypes, present in 13% of U.S. blacks, are 
associated with an increased risk for hypertension-attributed kidney disease. Biopsy studies 
show differences in kidney vasculature by APOL1 status, but less is known about the 
variants’ associations with systemic vascular and endothelial function.
Methods: Using a recessive genetic model, we examined the cross-sectional 
associations of APOL1 risk genotypes (high=2 risk alleles; low=0-1 risk allele) with 
subclinical measures of vascular and endothelial function in MESA. Outcomes included 
measures of vascular (small and large arterial elasticity [SAE, LAE] by HDI PulseWave 
CR-2000 and ascending aortic distensibility [AAD] by magnetic resonance imaging) 
and endothelial (by brachial artery Doppler flow-mediated dilation [FMD]) function. We 
constructed linear regression models, adjusting for age, sex, and genetic global ancestry.
Results: We included African-American MESA participants with available APOL1 
genotyping and measurements of SAE (n=1586), LAE (n=1586), AAD (n=985), and 
FMD (n= 777) at Exam 1 (2000-2002). Mean age was 62 years, 54% were female, 
59% had hypertension, mean systolic blood pressure was 131 ± 22 mmHg, and mean 
eGFRCysC was 90 ± 20 ml/min/1.73 m
2. Mean (SD) SAE, LAE, AAD, and FMD were 
4.2 (2.5) ml/mmHg*100, 13.5 (5.8) ml/mmHg*100, 1.7 (1.3) 1/mmHg*1000, and 
0.2 (0.1) mm, respectively. In linear regression models, the APOL1 high-risk genotypes 
were not associated with SAE, LAE, AAD, or FMD, though there was a trend of lower 
AAD among APOL1 high- vs. low-risk individuals (Table).
Conclusions: Among African Americans in MESA, the APOL1 high-risk genotypes 
were not associated with subclinical measures of vascular or endothelial function. Further 
studies are needed to clarify the potential role of APOL1 in vascular changes.
Funding: NIDDK Support
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Plasma Sphingolipid and Mortality Risk in Incident Hemodialysis Patients
Jessica Fitzpatrick,1 Stephen M. Sozio,2 Bernard G. Jaar,3 Michelle M. Estrella,4 
Jose M. Monroy-Trujillo,7 Rulan S. Parekh,5 Mark Mitsnefes.6 1The Hospital for 
Sick Children, Toronto, ON, Canada; 2Johns Hopkins University School of 
Medicine, Baltimore, MD; 3Johns Hopkins University and Nephrology Center of 
Maryland, Baltimore, MD; 4University of California, San Francisco and San 
Francisco VA Medical Center, San Francisco, CA; 5The Hospital For Sick 
Children, Toronto, ON, Canada; 6Cincinnati Children’s Hospital, Cincinnati, 
OH; 7Johns Hopkins University, Baltimore, MD.
Background: ESRD patients receiving hemodialysis (HD) are at high risk of mortality, 
particularly cardiovascular (CVD) mortality. Plasma sphingolipids have been identified 
as predictors of CVD mortality in the general population. Despite the high prevalence 
of dyslipidemia in HD, no studies have examined the associations of sphingolipids with 
mortality risk in this population.
Methods: This study included 368 incident HD patients enrolled in the Predictors 
of Arrhythmic and Cardiovascular Risk in ESRD (PACE) study. Plasma sphingolipid 
(ceramides, glucosylceramides and lactosylceramides) levels were measured at baseline 
by liquid chromatography-tandem mass spectrometry. Proportional hazards regression 
was used to examine the association of sphingolipids with CVD mortality and all-cause 
mortality.
Results: At baseline, mean age was 55 years, 39% were female, 72% were African 
American, 58% had diabetes, and the mean comorbidity index was 5.2. Over a median 2.5 
years (IQR: 1.4-3.5 years) of follow-up, there were 78 deaths from all causes, of which 
33 were from CVD. The highest tertile of glucosylceramide C16GC (0.81-5.88 μM) 
was associated with increased risk of all-cause (HR: 1.81; 95%CI: 1.02-3.22) and CVD 
mortality (HR: 2.63, 95%CI: 1.08-6.55) as compared to the lowest tertile (0.03-0.40 μM) 
after adjusting for demographics and comorbidity.[Figure] There was no evidence of 
association between other sphingolipids and risk of all-cause or CVD mortality.
Conclusions: Glucosylceramide C16GC was associated with CVD and all-cause 
mortality among adults incident to HD. These results suggest that glycosphingolipid 
imbalance may contribute to increased mortality risk in ESRD. Further studies are needed 
to confirm these new and important findings.
Funding: NIDDK Support
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Plasma Sphingolipids and Cardiovascular Disease Risk in Incident 
Hemodialysis Patients
Jessica Fitzpatrick,1 Stephen M. Sozio,2 Bernard G. Jaar,3 Michelle M. Estrella,5 
Jose M. Monroy-Trujillo,4 Rulan S. Parekh,6 Mark Mitsnefes.7 1The Hospital for 
Sick Children, Toronto, ON, Canada; 2Johns Hopkins University School of 
Medicine, Baltimore, MD; 3Johns Hopkins University and Nephrology Center of 
Maryland, Baltimore, MD; 4Johns Hopkins University, Baltimore, MD; 
5University of California, San Francisco and San Francisco VA Medical Center, 
San Francisco, CA; 6The Hospital For Sick Children, Toronto, ON, Canada; 
7Cincinnati Children’s Hospital, Cincinnati, OH.
Background: Risk of cardiovascular (CVD) morbidity is high in adults with ESRD 
undergoing hemodialysis (HD). Many CVD risk factors are prevalent in ESRD, including 
dyslipidemia. Recent studies identified plasma sphingolipids as independent predictors of 
CVD in the general population; however, no studies have examined this association in HD 
patients.
Methods: This study included 368 incident HD patients enrolled in the Predictors 
of Arrhythmic and Cardiovascular Risk in ESRD (PACE) study. At baseline, plasma 
sphingolipid (ceramides, glucosylceramides and lactosylceramides) levels were measured 
by liquid chromatography-tandem mass spectrometry. We examined the cross-sectional 
association of sphingolipids with intermediate CVD outcomes (uncontrolled hypertension 
[SBP ≥140 mm Hg or DBP ≥90 mm Hg], left ventricular hypertrophy [left ventricular 
mass index >51 g/m2.7], and low ejection fraction [ejection fraction <55%]) using multiple 
logistic regression.
Results: At baseline, mean age was 55 years, 39% were female, 72% were African 
American, 58% had diabetes, 36% had coronary artery disease, and 41% had congestive 
heart failure. Higher glucosylceramide C16GC was consistently associated with higher 
odds of uncontrolled hypertension, left ventricular hypertrophy, and low ejection fraction 
independent of demographic, CVD, and dialysis factors.[Table] No other sphingolipid was 
consistently associated with these intermediate CVD outcomes.
Conclusions: Glucosylceramide C16GC was consistently associated with intermediate 
CVD outcomes. These results suggest that abnormal glycosphingolipid metabolism may 
contribute to increased CVD risk in ESRD. Additional studies in other dialysis cohorts are 
needed to confirm our results.
Funding: NIDDK Support
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FGF-23, Hypertension, and Dyslipidemia in Glomerular Disease
Christine B. Sethna,1 Mary B. Leonard,5 Kevin E. Meyers,6 Tammy M. Brady,3 
Andrew N. Hoofnagle,4 Myles Wolf,7 Michelle Denburg.2 1Cohen Children’s 
Medical Center of NY, New Hyde Park, NY; 2The Children’s Hospital of 
Philadelphia, Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia, PA; 3Johns Hopkins University, Baltimore, MD; 4University of 
Washington, Seattle, WA; 5Stanford School of Medicine, Stanford, CA; 6The 
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PA; 7Duke University, Durham, NC.
Background: Fibroblast growth factor-23 (FGF-23) has direct effects on vasculature 
and myocardium and is a risk factor for cardiovascular disease (CVD); however, the impact 
on CVD in glomerular disease (GD) has not been addressed.
Methods: Plasma intact FGF-23, casual blood pressure (BP) and serum lipids 
were measured cross-sectionally in Nephrotic Syndrome Study Network (NEPTUNE) 
participants. Multiple regression analyzed the association of FGF-23 with BP and lipids 
adjusted for age, sex, black race, glomerular diagnosis, estimated glomerular filtration 
rate (eGFR), urine protein:creatinine (UPC), obesity and phosphorus (+ height in BP 
models). FGF-23 was divided into tertiles (<100,≥170 pg/ml). Hypertension (HTN) was 
defined as BP ≥130/80 mmHg for adults and per established definitions in children (Flynn 
2017). BP index (BPi) was calculated as BP÷130/80 for adults and 95th %tile for children. 
Dyslipidemia (DLP) was defined as abnormal triglycerides, HDL or non-HDL for age 
(AHA 2013, Daniels 2011).
Results: 204 adults (46±16 yr, 60% M, 23% black) and 93 children (9.6±5 yr, 59% 
M, 42% black) with median eGFR of 78.4 (IQR 50,104.9) ml/min/1.73m2 and UPC 1.83 
(IQR 0.57,3.8) were evaluated. Diagnoses included membranous 17%, minimal change 
24%, FSGS 33% and IgA 14%. Median FGF-23 was 73 (IQR 50,110) pg/ml, PTH 38 (IQR 
26,59) pg/ml and phosphorus 3.9 (IQR 3.4,4.4) mg/dl. HTN was present in 68% and DLP 
in 75%; mean SBPi was 0.83±0.15 and DBPi 0.94±0.18. The highest tertile of FGF-23 was 
associated with HTN, SBP, DBP, SBPi and DBPi, vs. the lowest tertile in adjusted models 
(Table 1). FGF-23 was not associated with DLP.
Conclusions: In NEPTUNE, FGF-23 was directly associated with HTN and BP. 
Further study of FGF-23 as a therapeutic target for reducing CVD in GD is warranted.
Funding: Other NIH Support - NCAS, Private Foundation Support
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Clinical Characteristics Enhancing the Predictive Ability of C-Reactive 
Protein on Incident Hypertension
Dong-Young Lee,1 Kyoung hyoub Moon.2 1Veterans Health Service medical 
center, Seoul, Republic of Korea; 2Vetrans Health Service Medical Center, Seoul, 
Republic of Korea.
Background: Previous studies have demonstrated that the elevated CRP predicts 
the development of cardiovascular disease. However, it is still argued whether elevated 
CRP was independently associated with the elevation of blood pressure. This study was to 
investigate the predictability of CRP level on incident hypertension according to the clinical 
characteristics in normotensive general Korean population.
Methods: We examined 7,481 normotensive subjects from Korean Genome and 
Epidemiology Study (KoGES). They were stratified into 4 groups by quintiles of their 
baseline CRP levels, and followed-up for 10 years to monitor the incident hypertension. 
Cox proportional hazards model was used to calculate the hazard ratios (HRs) and 95% 
confidential interval (CI) for hypertension according to quintiles of CRP level. Additionally, 
subgroup analysis was performed by gender, obesity/non-obesity, dysglycemia/normal 
glycemia and middle (40-54 years) /old age (55-69 years).
Results: In all participants, compared to group of quintile 1, adjusted HRs for 
hypertension significantly increased in group of quintile 4 (1.22 [95% CI 1.04-1.43]). 
In subgroup analyses, women, obese and middle-aged subgroup showed the statistically 
significant HRs for hypertension at quintile 4 (women subgroup: 1.37 [95% CI 1.09-1.72]; 
obese subgroup: 1.33 [95% CI 1.07-1.66]; middle-aged subgroup: 1.31 [95% CI 1.07-
1.59]), and dysglycemic subgroup had the statistically significant HRs for T2DM at both 
quintile 3 (1.33 [95% CI 1.04-1.71]) and quintile 4 (1.34 [95% CI 1.04-1.73]).
Conclusions: Our results suggest that the predictability of CRP on hypertension is 
enhanced in clinical conditions including women, obesity, dysglycemia and middle age.
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Hypertension and Dyslipidemia in Childhood Nephrotic Syndrome
Elizabeth Thomas,1 Kevin E. Meyers,2 Tammy M. Brady,3 Debbie S. Gipson,5 
Frederick J. Kaskel,4 Tarak Srivastava,7 Keisha L. Gibson,8 Cheryl L. Tran,11 
Kimberly J. Reidy,6 Rebecca Levy,9 Christine B. Sethna.10 NEPTUNE Pediatric 
Working Group 1Cohen Children Medical Center, Glen Oaks, NY; 2The Children 
Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA; 
3Johns Hopkins University, Baltimore, MD; 4Children’s Hospital at Montefiore, 
Bronx, NY; 5University of Michigan Mott Children’s Hospital, Ann Arbor, MI; 
6Children’s Hospital at Montefiore/ Albert Einstein College of Medicine, 
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Background: Children with nephrotic syndrome (NS) often have hypertension (HTN) 
and dyslipidemia (DLP). However, these CVD risk factors have not been well described 
over time and in relation to renal outcomes in NS.
Methods: Longitudinal analysis of children with new onset NS in the Nephrotic 
Syndrome Study Network (NEPTUNE) was conducted. HTN and DLP were defined as 
per established definitions (Flynn 2017, Daniels 2011). BP was indexed (BPi) to the 95%. 
Generalized Estimating Equation models compared HTN and DLP among those reaching 
complete remission (CR) (urine protein:creatinine [UPC] <0.3) vs. no CR. Regression 
models examined the association of baseline BP and lipids with outcomes of CR, 40% 
eGFR drop, eGFR <90 ml/min/1.73m2 at last follow up and eGFR slope adjusted for age, 
sex, race, follow up, medications, eGFR and obesity.
Results: 81 children (4.3±2.3 yr, 63% M, 24% black) with mean baseline eGFR 
112±48 ml/min/1.73m2 and UPC 4.5±9.2 were evaluated. At baseline, 58% had HTN and 
81% had DLP (Table). Among CR, DLP decreased over time (Q10.8, p=0.01) but HTN 
did not change (Q10.8, p=0.39). For no CR, HTN and DLP did not change over time. In 
adjusted models, no CR had greater odds of HTN (OR 3.4 CI1.16-10.8) and greater LDL 
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(β 35 CI 2.9,68) over time. For outcomes, baseline elevated total cholesterol (HR 1.01 CI
1.00-1.01), greater LDL (HR 1.01 CI1.0-1.02) and triglycerides (HR 1.01 CI 1.001-1.01)
were associated with increased risk of 40% eGFR drop. Baseline BP and lipids were not
associated with other outcomes.
Conclusions: In NEPTUNE, HTN and DLP were prevalent in children with new onset 
NS and were worse over time in those with no CR. In addition, baseline lipids were found 
to independently predict poorer renal outcomes.
Funding: Other NIH Support - NCAS
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Pericytes Detachment and Peritubular Capillaries Injury in Malignant 
Hypertensive Nephrosclerosis Patients
Peng Xia,1 Jiaxin Lang,1 Min Lin,2 Yubing Wen,1 Xiaoxiao Shi,1 Lubin Xu,1 
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Background: Peritubular capillary (PTC) injury contributes to the progression of 
various kidney disease. However, its impact on renal prognosis has not been well reported 
in malignant hypertensive nephrosclerosis (MHN) patients. The disintegration of interstitial 
pericytes may cause PTC loss and expansion of interstitium. This study investigated the role 
of PTC loss and pericytes distribution in MHN patients.
Methods: One hundred patients with essential MHN confirmed by renal biopsy from 
Jan. 2003 to Jun. 2016 in Peking Union Medical College Hospital were recruited. Clinical 
data and pathologic findings carefully reviewed. IHC and immunofluorescence staining of 
CD34 and PDGFRβ were used to evaluate PTC loss and pericytes distribution. The primary 
end point was defined as renal replacement therapy, kidney transplant as well as death. Cox 
regression was used to identify factors related to prognosis.
Results: The patients were mostly young males (male 88%; age 34.9±8.5ys) with 
significantly elevated blood pressure (225.2±26.4/152.0±25.0 mmHg), decreased eGFR 
(22.1±15.2 mL/min/1.73 m2) and proteinuria (median 1.4 g/d). Remarkable tubular atrophy 
(62.8±19.1%) and interstitial fibrosis (65.0±17.8%) were observed. PTC loss evaluated 
by CD34 staining was more significant in MHN patients (n=70), compared with benign 
hypertensive nephrosclerosis (n=17, P=0.025) and glomerular minimal lesion patients 
(n=17, P=0.001). PTC area correlated well with eGFR (r=0.496, P<0.001) and proteinuria 
(r=-0.351, P=0.006). Tubulointerstitial PDGFRβ expression (n=36) was higher than BHN 
(n=15, P=0.035) and GML patients (n=10, P=0.01). Immunofluorescence double staining 
of CD34 and PDGFRβ showed detachment of pericytes from PTC in tubulointerstitium. 
After 60.5±38.7 months’ follow up of 92 eligible subjects, the cumulative renal survival 
rate at 1, 3, 5, and 10 years was 94.6%, 84.1%, and 69.2%, and 31.2%, respectively. 
Multivariate COX regression indicated PTC injury, inadequate blood pressure control and 
proteinuria>1g/d are associated with poor renal prognosis.
Conclusions: PTC injury predicted the long-term renal outcome in patients with MHN. 
Detachment of pericytes from endothelial cells might play a role of the PTC injury.
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Hypertensive Epidemiology and Potential Blood Pressure Goals in IgA 
Nephropathy
Ying Zheng, Yong Wang, Shuwei Duan, Guangyan Cai, Xiangmei Chen. 
Chinese PLA General Hospital, Beijing, China.
Background: IgA nephropathy is the most prevalent form of primary 
glomerulonephritis worldwide. Hypertension is one of the most important risk factors in the 
progression of kidney disease. Our aim was to identify the epidemiology of hypertension 
in IgA nephropathy.
Methods: This was a nationwide, multi-center, cross-sectional study. We analyzed 
1055 patients with IgA nephropathy from 61 tertiary hospitals in China (except Hong Kong, 
Macao, and Taiwan). Hypertension was defined as blood pressure (BP) ≥ 140/90 mmHg. 
Three BP goals were used to assess BP control: < 140/90 mmHg, < 130/80 mmHg, and 
< 125/75 mmHg. The outcomes included factors associated with hypertension, decreased 
renal function, and potential BP range goals for IgA nephropathy, which were analyzed 
based on 24-hour proteinuria levels of <1 g/d or ≥ 1 g/d.
Results: We found that 63.3% of our participants with IgA nephropathy had 
hypertension. Blood pressures were controlled under 140/90 mmHg in 49.1% of participants, 
34.3% of patients with proteinuria <1 g/d reached the goal of BP <130/80 mmHg, 
and only 12.9% of patients with proteinuria >1 g/d achieved BP <125/75 mmHg. With 
proteinuria <1 g/d, the odds ratios (95% confidence interval) [ORs (95% CI)] of decreased 
renal function with BPs < 140/90 mmHg, < 130/80 mmHg, and < 125/75 mmHg 
were 0.9 (0.5 - 1.6), 1.0 (0.5 - 1.8), and 1.0 (0.5 - 2.0), respectively (P > 0.05). With 
proteinuria ≥1 g/d, the ORs of target BPs < 140/90 mmHg, < 130/80 mmHg, and < 125/75 
mmHg were 0.4 (0.2 - 0.6), 0.2 (0.1 - 0.4), and 0.3 (0.1 - 0.5), respectively (P < 0.05).
Conclusions: Hypertension was prevalent in IgA nephropathy and hypertensive control 
was suboptimal. It might be rational to keep BP < 140/90 mmHg in patients with proteinuria 
<1 g/d, and < 130/80 mmHg in patients with proteinuria ≥1 g/d, respectively. Randomized 
clinical trials in IgA nephropathy are needed to evaluate BP range goals.
TH-PO475 Poster Thursday
Hypertension and CVD: Epidemiology, Risk Factors, Prevention
Anxious Adolescents and Diastolic Hypertension
Sara G. Kibrom,2 Tanya E. Pereira,1 Dmitry V. Samsonov.1 1Pediatric 
Nephrology, New York Medical College, Valhalla, NY; 2NYMC - Westchester 
medical center, Valhalla, NY.
Background: Anxiety is prevalent in 15-20% of children, often negatively affecting 
health and quality of life. Pediatric hypertension (HTN) is on the rise, affecting 5% of all 
children. While anxiety correlates with elevated blood pressure (BP) in adults, this has not 
been studied in children. The primary objective of this study was to examine the relationship 
between anxiety and HTN in adolescents.
Methods: We screened Adolescents aged 12-18 years in a pediatric nephrology 
clinic for anxiety. Adolescents and their parents were asked to complete the generalized 
anxiety subset of the Screen for Child Anxiety Related Disorders (SCARED) questionnaire 
in regards to the adolescent. A score of ≥ 9 out of 18 was labeled as a positive screen 
for anxiety. BP was measured at the same visit. Hypertension was defined as systolic or 
diastolic BP > 95th percentile for age, height, and gender.
Results: Ninety-nine adolescents and their parents completed the questionnaire. 
The median age was 15 years with 54% of the responders being male. Sixty-two percent 
had either elevated blood pressures in the office or had diagnosis of hypertension. Nine 
percent had history of anxiety and 37% screened positive on the SCARED questionnaire. 
Adolescent’s anxiety score correlated with parental rating of adolescent’s anxiety 
(r = 0.4, p <0.01). Parents who perceive their children as anxious had a greater proportion 
of diastolic HTN compared to non-anxious children 53% vs 29% (p < 0.05) but not systolic 
hypertension 21% vs 26%, (p = 0.6). Anxious children had higher diastolic HTN (p < 0.05).
Conclusions: Parental perception of child’s underlying anxiety level may predict 
higher diastolic BP measurement at office visit. Future studies should include larger cohort 
size, and use of ambulatory BP monitoring, and assessment of anxiety score in different 
subsets of HTN (primary vs secondary). Screening for anxiety may play an important role 
in the evaluation of patients with hypertension.
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High Prevalence of Significant Structural Heart Disease by Echocardiog-
raphy in Patients Undergoing Evaluation for Kidney Transplantation
Idil Aktan, Laura Holsten, Sula Mazimba, Andrew D. Mihalek, Thu H. Le, 
Brendan T. Bowman, Alden M. Doyle, Jamie L. Kennedy. University of Virginia, 
Charlottesville, VA.
Background: Although the deleterious effect of structural heart disease in patients with 
advanced kidney disease is well known, the specific contribution of valvular abnormalities 
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has been less well characterized. Detailed echocardiographic criteria have been proposed 
by the Acute Dialysis Quality Initiative XI Workgroup to identify dialysis patients with 
underlying structural heart disease. We sought to determine the prevalence of structural 
heart disease, including valvular disease, in a single center cohort of dialysis patients 
referred for kidney transplant evaluation.
Methods: We performed a retrospective analysis of single center echocardiographic 
data obtained from patients undergoing kidney transplant evaluation from 2006 to 2018. 
Studies that took place at least six months after initiating dialysis were included. Analyses 
were performed with SAS using Chi square, ANOVA, or Fisher’s exact test.
Results: Patients undergoing initial kidney transplant evaluation at the University of 
Virginia were evaluated by echocardiography, n = 461. They were 58.6% men, and median 
age was 58 years, interquartile range (IQR) 48 - 66. Median duration of dialysis was 29 
months, IQR 17 - 50. Comorbidities included hypertension (89.6%), diabetes (55.8%), 
and coronary disease (21.7%). The table below shows the frequency of cardiac disease by 
transplant status at the time of data collection. There were no cases of significant mitral or 
tricuspid stenosis, and no significant pulmonic valve pathology.
Conclusions: Prevalence of structural heart disease in patients referred for kidney 
transplant evaluation is high. Patients who ultimately underwent kidney transplant had 
significantly lower prevalence of structural heart disease, including mitral regurgitation, 
aortic stenosis, and tricuspid regurgitation, compared to non-transplanted patients.
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Association Between Post-Dialysis Blood Pressure and Extracellular 
Volume Status in Hemodialysis Patients
Hoon Young Choi,1 Seok-hyung Kim,1 Hyunwook Kim,2 Jung eun Lee,4 Hyung 
Jong Kim,3 Hyeong cheon Park.1 1Gangnam Severance Hospital, Yonsei 
University College of Medicine, Seoul, Republic of Korea; 2Yonsei University 
College of Medicine Gangnam Severance Hospital, Seoul, GYEONGGI-DO, 
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Background: Volume status and hypertension are closely associated with 
cardiovascular outcome in receiving hemodialysis (HD) patients. New noninvasive bedside 
tools, such as bioimpedance analysis (BIA) has been reported to assess objective fluid 
status. Aim of the study was to ascertain the association between hydration status measured 
by BIA and postdialysis blood pressure in HD patients.
Methods: We conducted a cross-sectional multi-center study. All patients underwent a 
postdialysis BIA to assess hydration status which was calculated by the ratio of extracellular 
water (ECW) to total body water(TBW). Patients were divided into three groups, those in 
whom the blood pressure decreased during dialysis by≥20mm Hg (PDHYPO), those in 
whom the SBP increased by≥10mmHg (PDHYPER), and in whom the SBP did not meet 
the definitions of intradialytic hypotension or hypertension, termed as PDSTABLE group. 
DeltaSBP was calculated by SBP difference between before and after HD. Laboratory data 
including dialysate sodium as well as serum sodium level was collected and subjective 
global assessment (SGA) was used for assessing nutritional status.
Results: A total of 254 prevalent HD patients were included in this study. Fifty-four 
patients (21.3 %) had PDHYPO and seventy-four patients (39.2%) had PDHYPER. Age, 
SBP after dialysis (SBPpost), and deltaSBP were significantly higher, while hemoglobin, 
serum albumin and sodium and SGA were lower in the PDHYPER group than in PDHYPO 
and PDSTABLE group. The PDHYPER group showed higher ECW/TBW than in 
PDHYPO and PDSTABLE group. (0.414 ± 0.011 vs. 0.402 ± 0.012, 0.406 ± 0.02, p<0.001). 
In spearman correlation coefficient, deltaSBP (r=+0.231, p<0.001) and phase angle 
(r=-0.804, p<0.001) showed a significant correlation with ECW/TBW. In multiple logistic 
regression analysis, older age, lower SGA, lower albumin, and higher ECW/TBW were the 
independent risk factors affecting PDHYPER.
Conclusions: Our data support that increased ECW/TBW is significantly associated 
with postdialysis blood pressure in HD patients.
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Normal Body Mass Index with Non-Alcoholic Fatty Liver Disease Is 
Associated with Coronary Calcification in Patients with CKD
Hoon Young Choi,1 Seok-hyung Kim,1 Tae hoon Kim,1 Hyunwook Kim,2 
Hyeong cheon Park.1 1Gangnam Severance Hospital, Yonsei University College 
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Gangnam Severance Hospital, Seoul, GYEONGGI-DO, Republic of Korea.
Background: Increased coronary artery calcification (CAC) for assessing the burden 
of coronary atherosclerosis has been reported in patients with chronic kidney disease 
(CKD). Although non-alcoholic fatty liver disease (NAFLD) is associated with obesity and 
metabolic syndrome, it may also present in lean individuals. This study aimed to investigate 
whether normal body mass index (BMI) with NAFLD is associated with coronary artery 
calcification (CAC) in the patients with CKD.
Methods: Data from a total of 1,479 patients with CKD with normal BMI were 
provided from 2005 through 2017. CAC score was measured with computed tomography. 
BMI was considered to be normal if it was less than 25 kg/m2. To assess the central obesity, 
waist-to-hip ratio (WHR) was also obtained. NAFLD was diagnosed in patients with 
evidence of liver steatosis at ultrasonography.
Results: Six hundred ninety-nine (47.2%) patients had CAC in CKD with NAFLD. 
The CAC was significantly higher in the CKD patients with NAFLD than the CKD patients 
without NAFLD (66.2±238.9 vs. 39.8±158.2, p<0.001). After adjusting for age, gender, 
hypertension, diabetes, dyslipidemia, WHR, estimated glomerular filtration rate, fasting 
plasma glucose, total cholesterol, NAFLD was significantly associated with increased risk 
of CAC in CKD patients with normal BMI (OR=1.754, P<0.001).
Conclusions: Our study showed that NAFLD was significantly associated with CAC 
in the non-obese patients with CKD with normal BMI
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Obesity in Glomerular Disease
Paras P. Shah,1 Kevin E. Meyers,2 Tammy M. Brady,3 Keisha L. Gibson,4 
Tarak Srivastava,5 Christine B. Sethna.6 NEPTUNE Cardiovascular Working 
Group 1Cohen Children’s Medical Center, Fremont, CA; 2The Children Hospital 
of Philadelphia and University of Pennsylvania, Philadelphia, PA; 3Johns 
Hopkins University, Baltimore, MD; 4University of North Carolina Kidney 
Center, Chapel Hill, NC; 5Childrens’s Mercy Hospital, Kansas City, MO; 6Cohen 
Children’s Medical Center of NY, New Hyde Park, NY.
Background: Obesity is a risk factor for cardiovascular disease (CVD) and contributes 
to the development and progression of kidney disease. The impact of obesity on glomerular 
disease has not been well-described.
Methods: Longitudinal data were from 488 participants in the Nephrotic Syndrome 
Study Network (NEPTUNE). Obesity was defined as body mass index (BMI) ≥30 kg/m2 for 
adults and ≥95% for children. Blood pressure (BP), lipids, complete remission ever (urine 
protein:creatinine [UPC] <0.3) and composite endpoint (ESRD or 40% decrease in eGFR) 
were compared in obese vs. non-obese. Generalized estimating equations examined obesity 
with outcomes, adjusted for age, sex, black race, glomerular diagnosis, follow-up, edema, 
UPC, eGFR, steroids, calcineurin inhibitors (CNI), renin angiotensin blockade (RAAS), 
SBP and obesityxedema.
Results: 322 adults (46.5±16 yr, 62% M, 21% black) and 166 children (9.6±5 yr, 57% 
M, 42% black) with baseline median eGFR 83 (IQR 53,105) ml/min/1.73m2 and UPC 
2(IQR 0.7,4.3) were evaluated. 43% of adults and 38% of children were obese (35% and 
34% in non-edematous, respectively). The proportion with obesity did not change during 
mean 35±20 months of follow-up (Q=11.9, p=0.29). See Table 1. In adjusted models, 
obesity was associated with hypertension (HTN) (OR1.61 CI 1.14-2.28), greater SBP 
(β5.73 CI 0.15-11.3) and lower HDL (β-8.1 CI-12.17– -4.03) in adults. For children, obese 
had greater DBP index (0.03 CI 0.001– 0.07), greater triglycerides (β29.3 CI 1.91–56.7) and 
lower HDL (β-6.87 CI -12.07- -1.68), as well as increased odds of HTN (OR2.14 CI 1.26–
3.65), dyslipidemia (OR1.61 CI 1.04–2.5) and high HDL (OR2.24 CI 1.31–3.81) compared 
with non-obese. Obesity was not associated with renal outcomes.
Conclusions: In NEPTUNE, obesity is common and associated with CVD risk when 
compared to non-obese participants.
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Renal Transplantation Improves Cardiovascular Autonomic Efficiency 
and Decreases Stroke Volume Variability in Chronic Hemodialysis 
Patients
Dan Sapoznikov,1 Michal Dranitzki Elhalel,2 Dvora Rubinger.1 1Hadassah 
University Medical Center, Jerusalem, Israel; 2Hadassah - Hebrew University 
Medical Center, Jerusalem, Israel.
Background: Renal transplantation (TX) was shown to enhance autonomic function 
and its cardiovascular efficiency (CvE), but its effect on stroke volume (SV) variability 
(sdSV), a measure of myocardial responsiveness consistency and poor prognostic 
significance was not defined.
Methods: Beat-to-beat systolic blood pressure (SBP) and interbeat intervals (IBI) 
monitoring was performed in 72 non-diabetic chronic hemodialysis (HD) patients (pts.), in 
41 pts. after TX and in 27 healthy controls (C). The power spectral densities of IBI and SBP 
in the low frequency (LF) range were calculated from Finometer recordings of SBP and IBI 
spontaneous variations. SV and total peripheral resistance (TPR) were assessed using the 
ModelFlow method. The standard deviations (sd) of the above indices were considered to 
represent their variabilities. Differences in variability indices between SBP periods, 10% 
above (high) or below (low) the mean SBP were considered representative of CvE.
Results: : Table 1 (see below) lists hemodynamic data and SBP and IBI variability 
indices during low-high SBP periods. These periods were associated with increased SV and 
TPR in all groups and decreased sdSV in HD. SBP and IBI variability changes between 
low-high periods were blunted in HD and restored in TX. Overall sdSV was significantly 
increased in HD (p=0.025 and 0.001 vs C and TX). Overall LFIBI was lower in HD 
(p=0.001 vs C). LF SBP decreased after TX (p=0.001 vs HD).
Conclusions: In HD, increased LF SBP, decreased LF IBI and the attenuated 
variation between low-high SBP episodes are consistent with sympatheric overactivity 
and suppressed overall autonomic function. Renal TX improves CvE and decreases 
sdSV,suggesting enhanced myocardial responsiveness.These effects may contribute to the 
improved survival after TX.
Table 1. (median and interquartile ranges).
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HIFs in the Renal Medulla Regulate Natriuresis and Blood Pressure 
Through COX2
Nan Guan. Division of Nephrology,Huashan Hospital,Fudan University, 
Shanghai, Shanghai, China.
Background: Hypoxia inducible factors (HIFs) are essential for the maintenance of 
cellular oxygen homeostasis. In response to hypoxia, stabilized HIFs initiate the expression 
of genes that alleviate hypoxic stress. HIFs are now important therapeutic targets for CKD 
anemia. In the phase 2 clinical trial of FG4592(a kind of HIFs stabilizers) in our center, 
we found that this drug not only corrected anemia but also downregulated blood pressure. 
Cyclooxygenase 2 (COX2) in the renal medulla was reported to promote natriuresis and 
decrease blood pressure. HIFs could induce COX2 in some tumors. In the present study we 
investigated the mechanism underlying the blood pressure lowering effect of HIFs.
Methods: We used mice metabolic cages to measure daily sodium balance. The mice 
were fed with the same amount of gel food. To capture transient changes in the urine Na+ 
excretion prior to attainment of a new steady state, daily 8-hour urine were collected after 
the administration of the drugs. The urinary volume and urinary sodium concentration were 
measured.
Results: In the clinical trial of FG4592 in our center, patients’ mean blood pressure 
decreased about 5mmHg compared with basal condition(91.5±1.5mmHg vs. 96.5±1mmHg, 
P < 0.05,n=10) after 8-week treatment. The administration of FG4592 significantly 
increased the daily urinary volume and urinary sodium excretion of the mice on high salt 
diet (8%NaCl). The cumulative sodium excretion of consecutive 4 days was higher in the 
FG4592 group than the control group(3.77±0.36mmol vs. 2.82±0.25mmol, P < 0.05,n=8). 
The expression of COX2 in the medulla was increased in the FG4592 group. When we 
used COX2 inhibitor celecoxib together with FG4592, the natriuresis effect of the latter 
one was abolished.
Conclusions: HIFs in the renal medulla lower blood pressure through upregulating 
COX2 and promoting natriuresis.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
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Cilia Disruption May Regulate the Renal Inner Medulla NOS Pathway
Randee S. Sedaka, Bradley K. Yoder, Edward W. Inscho, Chunhua Jin, 
David M. Pollock, Jennifer S. Pollock. University of Alabama at Birmingham, 
Birmingham, AL.
Background: Primary cilia act as flow-mediated mechanosensors, signaling via 
intraflagellar transport (IFT). We previously reported that NO synthase 1 (NOS1) is the 
major isoform contributing to flow-induced nitric oxide (NO) production in the inner-
medullary collecting duct (IMCD) and contributes to natriuretic responses. In this study, 
we hypothesized that functional ciliary IFT contributes to IMCD NOS1 abundance and 
activation.
Methods: Mouse IMCD cells were studied under static or flow (10 dynes/cm2) conditions 
for 1-hr to assess NO production (HPLC) and ciliary marker expression (western blot). Inner 
medullary (IM) NOS isoform abundance and urinary NO excretion were measured in 2 
models of cilia disruption, PCK rats and conditional IFT88 knockout mice.
Results: Exposure to flow significantly increased IMCD NO production (static: 
168±18, flow: 312±26 pmol/mg pr/hr; n=6/group, p<0.05) and ciliary marker expression, 
IFT88 (static: 1.0±0.3, flow: 1.7±0.1 RDU/b-actin; n=6/group, p=0.02) and acetylated-
α-tubulin (static: 1.0±0.2, flow: 1.9±0.2 RDU/b-actin; n=6/group, p=0.01) compared 
to static controls. IM NOS1α abundance was not elevated in PCK rats (SD: 1.00±0.1, 
PCK: 1.22±0.1 RDU/b-actin; n=4/group, p>0.05), but NOS1β abundance was increased 
compared Sprague Dawley (SD) control rats (SD: 1.0±0.2, PCK: 3.9±0.2 RDU/b-actin; 
n=4/group, p<0.01). NOS3 abundance was similar between SD and PCK rats (1.0±0.1 
and 0.9±0.1 RDU/b-actin, respectively; n=4/group, p>0.05). However, pNOS3 Thr495 
expression, a NOS3 inhibitory phosphorylation site, was significantly higher in PCK rats 
(SD: 1.0±0.3, PCK 3.1±0.5 RDU/total NOS3; n=4/group, p<0.01). Similarly, NOS1β 
expression in IFT88KO mice trended to be higher compared to controls (Cre-: 1.0±0.4, 
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Cre+ 3.0±0.6 RDU/b-actin; n=3/group, p=0.06). No significant changes in NOS3 abundance 
were observed (Cre-: 1.0±0.1, Cre+ 1.2±0.2 RDU/b-actin; n=3/group, p>0.05). Urinary 
NO excretion was similar in SD and PCK rats (SD: 6.1±2.2, PCK 10.0±0.4 umol/day; 
ß∆n=4-5/group, p>0.05) as well as Cre- and Cre+ IFT88KO mice (Cre-: 211±61, Cre+ 
220±13 nmol/day; n=3/group, p>0.05) on normal salt diet. These data suggest that ciliary 
disruption influences NOS isoform abundance in the renal IM.
Conclusions: In conclusion, functional cilia may contribute to acute flow-induced NO 
production and NOS isoform abundance.
Funding: NIDDK Support, Private Foundation Support
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Regulation of ABCG2 Transporter and Uric Acid Metabolism in a Model 
of Hyperuricemia
Chikayuki Morimoto,1 Yoshifuru Tamura,2 Emiko Kuribayashi-Okuma,2 
Takayo Murase,4 Takashi Nakamura,5 Yoshikazu Nemoto,1 Shinichiro Asakawa,1 
Yoshihide Fujigaki,3 Shunya Uchida,1 Shigeru Shibata.1 1Teikyo University 
School of Medicine, Tokyo, Japan; 2Teikyo University School of Medicine, Tokyo, 
Japan; 3Teikyo University School of Medicine, Department of Internal Medicine, 
Tokyo, Japan; 4Sanwa Kagaku Kenkyusyo Co., Ltd., Inabe-shi, Japan; 5Sanwa 
Kagaku Kenkyusho, Inabe, Japan.
Background: Hyperuricemia is one of the most frequent complications in chronic 
kidney disease (CKD). Previously, we showed that the gene expression of the urate 
transporter ATP-binding cassette subfamily G member 2 (ABCG2) is upregulated in the 
ileum in the rat remnant kidney model (Yano et al. Clin Exp Nephrol 2014), indicating that 
the intestine may participate in uric acid metabolism in CKD. However, the role of each part 
of the intestinal tract in uric acid metabolism in normal and hyperuricemic states have not 
been clarified. In this study, uric acid concentrations and ABCG2 expression in the different 
part of intestine were evaluated in normal and hyperuricemia model rats.
Methods: Using Sprague-Dawley rats, we evaluated ABCG2 expression in each part 
of the intestinal tract by immunofluorescent study. Uric acid concentrations in the serum 
and in the tissue homogenates were measured by LC/MS. We also evaluated the ABCG2 
levels in the intestine of hyperuricemia rats. Hyperuricemia was induced by feeding a diet 
containing 5% oxonic acid, the uricase inhibitor.
Results: In the intestinal tract of normal rats, the concentration of tissue uric acid 
(in μg/g tissue) was 5-10 times higher in duodenum and jejunum than in ileum and 
transverse colon (duodenum 102 ± 16; jejunum 112 ± 16; ileum 17 ± 8.2; transverse colon 
7 ± 4). Co-staining of ABCG2 and villin revealed that ABCG2 was highly present in the 
villus and crypt of the duodenum. Administration of oxonic acid increased serum uric acid 
levels by 2.1 fold (P < 0.05). Comparison of the ABCG2 staining between control and 
hyperuricemic rats indicated that ABCG2 was upregulated in the ileum by hyperuricemia.
Conclusions: ABCG2 is highly expressed in the duodenum and jejunum at basal 
condition. However, Hyperuricemia upregulates ABCG2 in the ileum. These data are 
consistent with our previous studies showing the upregulation of ABCG2 in the ileum in 
the rat remnant kidney model, and suggest a compensatory role of ileum in hyperuricemic 
states.
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Insulin: Genetic and Physiological Influences on Human Uric Acid 
Homeostasis
David B. Mount,1,2 Tony Merriman,3 Asim Mandal.1 1Renal Division, Brigham 
and Women’s Hospital, Boston, MA; 2Renal Division, VA Boston Healthcare 
System, Boston, MA; 3University of Otago, Dunedin, New Zealand.
Background: Insulin plays a key role in hyperuricemia. In particular, hyperinsulinemia 
in metabolic syndrome is inversely correlated with urinary uric acid (UA) excretion and 
insulin infusion in humans reduces urinary fractional excretion of UA.
Methods: An existing GWAS cohort was analyzed, testing for association between 
genetic variants in the insulin and insulin receptor genes with serum UA (SUA). HEK 
293T cells, human PTC5 proximal tubule cells, and Xenopus oocytes were probed with 
antibodies to UA transporters, the insulin receptor, downstream kinases, and the relevant 
phospho-kinases. 14C-UA transport was assayed in these cell lines and in oocytes expressing 
individual transporters.
Results: Variants in the human insulin and insulin receptor genes demonstrated 
significance for association with variation in SUA, at p<10-4 and p<10-7, respectively. 
HEK293T and PTC5 proximal tubular cells express several endogenous UA transporter 
proteins, including GLUT9, OAT10, and URAT1. Insulin activates PI3 kinase/Akt and 
MEK/ERK signaling pathways through the insulin receptor in HEK 293T and PTC5 
cells, as detected with phospho-kinase antibodies, with activation of endogenous 14C-UA 
transport. The stimulatory effect of insulin on UA uptake is abrogated by uricosurics and 
by inhibition of protein tyrosine kinase (genistein), PI3 kinase (LY295002), and MEK/ERK 
(PD98059). UA transport mediated by GLUT9a, GLUT9b, OAT10, OAT3, OAT1, NPT1 
and ABCG2, expressed separately in Xenopus oocytes, is also activated by insulin, with 
equivalent activation of signaling pathways and differential effects of signaling inhibitors on 
insulin-stimulated UA transport. Insulin has no effect on URAT1, OAT4, and the SMCT1/2 
nicotinate transporters, when expressed in oocytes. GLUT9a is the basolateral exit pathway 
in reabsorption of filtered UA by the proximal tubule; given much greater absolute UA 
transport rates mediated by GLUT9 isoforms, much of the anti-uricosuric effect of in vivo 
insulin infusion is likely due to activation of GLUT9a.
Conclusions: Variation in the human insulin and insulin receptor genes affects SUA. 
Insulin and associated signaling pathways also activate multiple UA transporters, indicating 
a pivotal physiological role for insulin in UA homeostasis. We postulate that basolateral 
GLUT9a in the proximal tubule is the dominant post-translational target of insulin in the 
regulation of renal UA transport.
Funding: Other NIH Support - NIAMS
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Claudin-10a Confers Chloride Permeability to the Tight Junctions of the 
Proximal Tubule
Nina Himmerkus,1 Susanne Milatz,1 Tilman Breiderhoff,2 Merle Brinkhus,1 
Catarina Quintanova,1 Dominik Müller,2 Markus Bleich,1 Dorothee Günzel.3 
1Institute of Physiology, Christian-Albrechts-University Kiel, Kiel, Germany; 
2Department of Pediatric Nephrology, Charité - Universitätsmedizin Berlin, 
Berlin, Germany; 3Institute of Clinical Physiology, Charité - Universitätsmedizin 
Berlin, Berlin, Germany.
Background: In the renal proximal tubule (PT) part of the bulk reabsorption of water 
and electrolytes takes place via the paracellular pathway. This paracellular pathway is 
regulated by the tight junction (TJ) complex which consists of a belt like structure around 
the apical pole of the epithelial cells. In contrast to most other epithelia where this belt is 
composed of multiple strands forming a meshwork, the PT shows only between one and 
five strands reflecting its high paracellular permeability. The selectivity of the TJ is mainly 
determined by the claudin composition of the TJ.
Methods: Micro-dissected PTs of claudin-10a specific knock-out animals (KO) and of 
wild-type controls (WT) were investigated in a double-barreled perfusion system. Diffusion 
potentials (DPs) were generated by either replacing the basolateral solution by an isosmotic 
30 mM NaCl solution or by replacing Cl- with HCO3
-. DP were used to calculate relative 
permeability (P) ratios for Na+, Cl- and HCO3
-. Immunofluorescence against claudin-10, 
claudin-2 and claudin-3 was performed on single isolated tubules.
Results: In WT, the early convoluted part of the proximal tubule (early PCT) 
showed anion selectivity (PCl/PNa = 1.52 ± 0.07), the last straight part (PST) showed 
cation selectivity (PNa/PCl = 1.26 ± 0.06) and the convoluted segments in between showed 
intermediate selectivity. PT TJ showed higher permeability for Cl- than for HCO3
- with the 
highest PCl/PHCO3 (1.86 ± 0.25) in late PCT. In PCT, claudin-10a expression was dominant 
in the TJ, in PST claudin-2 expression predominated. In addition, in this last segment of the 
PT, the tightening claudin-3 was expressed and co-localized to the TJ. In KO early PCT, 
claudin-2 moved to the TJ. Consequently, the early PCT lost anion selectivity completely 
and displayed high cation selectivity (PNa/PCl = 2.86 ± 0.45). In KO late PCT, PCl was lower 
than PHCO3 (PCl/PHCO3 = 0.88 ± 0.15). In KO PST differences were less pronounced but 
qualitatively similar (PNa/PCl = 2.00 ± 0.14; PCl/PHCO3 = 1.05 ± 0.06).
Conclusions: In summary, PT TJ selectivity changes along its axis from anion to cation 
selectivity. The anion selectivity is further characterized by preference of Cl- over HCO3
- 
and is claudin-10a dependent.
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Functional Proteomics of Isolated Perfused Cortical Collecting Ducts
Nina Himmerkus,1 Markus Bleich,1 Thomas Benzing,2 Markus M. Rinschen.2,3 
1Institute of Physiology, Christian-Albrechts-University Kiel, Kiel, Germany; 
2Department II of Internal Medicine, University Hospital Cologne, Köln, 
Germany; 3Center of Metabolomics and Mass Spectrometry, The Scripps 
Research Institute, San Diego, CA.
Background: In renal physiology and pathophysiology large-scale omic data sets are 
generally generated from bulk samples, e.g. the complete kidney or cortex vs. medulla. 
It is therefore difficult to predict implications for functional changes taking place in 
the individual, highly specialized and very distinct nephron segments. In the context of 
hypertension it is of high clinical relevance to understand regulation of salt transport in 
the collecting duct and the phenomenon of salt-sensitivity. The aim of this study was to 
establish a method to correlate measured electrophysiological properties of individual, 
isolated perfused cortical collecting ducts (CCD) with respective proteomic data.
Methods: For the electrophysiological properties, freshly isolated CCDs of 6-8 week 
old C57Bl6 mice were investigated in a double-barreled perfusion system. Transepithelial 
voltage (Vte) was recorded and transepithelial resistance as well as amiloride sensitive 
equivalent short-circuit current (ΔI’sc) were calculated. After these measurements every 
single tubule was recovered, processed and ultrasensitive mass spectrometry was performed.
Results: In manually collected CCD segments we were able to identify more than 
4000 distinct proteins. In the perfusion experiments, protein expression patterns typical 
for intercalated cells or, principal cells, respectively, showed negative correlation in the 
proteome. Vte varied between -8.5 and -32.5 mV and correlated with the regulator protein 
NEDD4. ΔI’sc as a measure of electrogenic sodium reabsorption was reflected by the 
expression level of the b-subunit of the epithelial sodium channel.
Conclusions: We could show that functional proteomics on a single nephron segment is 
possible and allows function-proteome correlations. This unique data acquisition approach 
will allow conclusions on physiological or pathophysiological outcomes based on omics 
data at the level of functional units rather than total organ samples.
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mTORC1 Regulates Renal Proximal Tubular Megalin Function
Madlen Kunke, Luis Zanon rodriguez, Gerburg Schwaerzer, Franziska Theilig. 
Christian-Albrechts University zu Kiel, Kiel, Germany.
Background: Renal proximal tubular cells constantly recycle nutrients to ensure 
minimal loss of essential substrates into the urine. Thus, endocytosis is a hallmark of the 
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proximal tubule. Protein uptake is mediated by the scavenger receptors megalin and cubilin, 
followed by internalization of the ligand-receptor complex via the clathrin-mediated 
pathway. The mTORC1 complex is a principle regulator of proximal tubular function, 
including endocytosis. However, the effect of mTORC1 on megalin function remains 
unknown.
Methods: Tubular deletion of mTORC1 was created by crossbreeding Raptorfl/fl  
with Pax8rt-TA and TetOCre mice. Phosphoproteomics were performed to analyze the 
phosphorylation of megalin in the renal cortex. Endocytosis was detected in proximal 
tubules using Alexa555-labelled lactoglobulin. In vitro, we induced mTORC1 activity 
through transient transfection with Rheb, used megalin minireceptor 2 (MMR2) to 
introduce mutations in the respective phosphosite S4577A, S4577D, S4577E, and followed 
endocytosis through Alexa555-labelled albumin.
Results: mTORC1-deficient mice showed normal megalin expression and distribution 
within proximal tubules compared to wildtype mice. Interestingly, receptor-mediated 
endocytosis of Alexa555-labelled lactoglobulin was blocked in mTORC1-deficient 
mice. Phosphoproteomics of mTORC1 deficient mice revealed a strongly reduced 
phosphorylation at S4577 of the C-terminus of megalin, which was confirmed by transient 
transfection of MDCKII cells with Rheb stimulating mTORC1 activity. Transfection of 
wildtype or mutated MMR2 in MDCKII cells caused no difference in megalin expression 
and its cellular distribution. However, endocytosis was increased in the presence of S4577D 
mutant compared to megalin wildtype
Conclusions: mTORC1 complex is an important regulator of proximal tubular function 
and phosphorylates megalin to influence megalin function.
Funding: Private Foundation Support
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Proximal Tubule-Specific Regulation of NPT2a by NHERF1
Kenneth Gagnon,1 Michelle T. Barati,1 Kathleen Kitterman,1 Eleanor D. Lederer.2 
1University of Louisville, Louisville, KY; 2University of Louisville; Robley Rex 
VA Medical Center, Louisville, KY.
Background: NHERF1 (Na-H Exchanger Regulator Factor 1), a PDZ protein that 
expresses an Ezrin binding domain (EBD), regulates proximal tubule BBM expression 
of NPT2a (Na-phosphate cotransporter), a critical determinant of phosphate homeostasis, 
through interactions with NPT2a and Ezrin (an actin cytoskeleton linking protein). Knockout 
of NHERF1 or Ezrin results in aberrant trafficking and diminished BBM expression of 
NPT2a. Additionally, knockout of NHERF1 decreases association of NPT2a with Ezrin. 
We hypothesize that NHERF1 regulates NPT2a trafficking through PDZ interactions and 
NPT2a anchoring through EBD interactions.
Methods: To test our hypothesis, we generated cDNA constructs encoding: NPT2a 
full-length (FL); NPT2a PDZ1-deficient (TRL-); NPT2a/NHERF1 chimera wherein the 
EBD of NHERF1 replaces the TRL motif of NPT2a (Chimera); NHERF1 full-length (FL); 
and NHERF1 EBD deficient (EBD-). We transfected HEK293 cells, which express Ezrin 
but not NPT2a or NHERF1, with wild-type and mutant NPT2a and NHERF1 constructs 
and assessed their expression and function with 32P-phosphate uptake, immunofluorescence 
microscopy, and differential centrifugation/western blot experiments.
Results: HEK293 cells expressing NPT2a FL, NPT2a TRL-, or NPT2 Chimera 
constructs all exhibited 2.5-fold greater phosphate uptake versus sham- or vector-only 
transfections. Co-transfection with NHERF1 FL or NHERF1 EBD- constructs did not 
enhance phosphate uptake. Contrary to the diminished NPT2a membrane expression 
observed in proximal tubule cells lacking NHERF1 or transfected with NPT2a TRL-
, immunofluorescence of HEK293 cells transfected with wild type and mutant NPT2a 
constructs demonstrated plasma membrane localization in the absence or presence 
of NHERF1. Wild type and mutant NHERF1 constructs exhibited global expression 
throughout the cell, even at the lowest transfection level (75 ng/ul). Differential 
centrifugation/Western blotting of transfected cells revealed wild type and mutant NPT2a 
expression in only the organelle and plasma membrane compartments, while wild type and 
mutant NHERF1 construct expression was observed in organelle, plasma membrane, and 
cytosol compartments.
Conclusions: These studies suggest that 1) NHERF1 regulation of NPT2a is proximal 
tubule specific; and 2) unidentified accessory protein(s) are essential for the BBM 
trafficking, localization, and function of NPT2a in proximal tubule.
Funding: Veterans Affairs Support
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Dissecting the Na/K-ATPase Signaling Complex in Renal Proximal 
Tubule: A Cross-Linking Approach
Jiang Liu,1 Fang Bai,1 Rebecca Pratt,1 Zi-jian Xie,2 Joseph I. Shapiro.1 1Marshall 
University School of Medicine, Huntington, WV; 2Marshall University, 
Huntington, WV.
Background: The Na/K-ATPase α1 subunit and c-Src have been shown to form a 
signaling complex. Activation this signaling cascade regulates sodium handling in proximal 
tubule, systemic oxidative stress, and uremic cardiomyopathy. The present study is to 
investigate the formation of the Na/K-ATPase signaling complex, especially the binding of 
the α1 subunit and c-Src under native condition in live cells.
Methods: Crosslinking studies were performed in live LLC-PK1 cells with 
sulfhydryle-sulfhydryle crosslinkers BMH (non-cleavable) and DTME (cleavable). SDS-
PAGE and WES system were used to determine the crosslinking efficiency and molecular 
weight shifts under denatured condition. Blue Native gel electrophoresis (BN-PAGE) was 
used to identify the molecular weight of the complex under native condition. A BN-PAGE/
SDS-PAGE 2D system was used to separate and identify the components of the Na/K-
ATPase complex by silver staining and Western blot.
Results: (1) Both BMH and DTMH effectively crosslink the α1 subunit and c-Src, 
demonstrated by Western blot analysis in both SDS-PAGE and WES system. (2) In BN-
PAGE system, like in control, both BMH and DTME-treated samples showed protein bands 
closer to marker of 720 kDa (between 480 and 720 kDa markers). Western blot analysis 
showed co-existence of the α1 subunit, β1 subunit, c-Src, and caveolin-1. (3) In WES 
system, like seen in control, there is a clear crosslinking between the α1 subunit and c-Src, 
by comparing the data amongst BMH and DTME crosslinking treatments, combined with or 
without DTT/SDS cleavage. (4) In the BN-PAGE/SDS-PAGE 2D system, preliminary data 
showed that the complex contains the α1 subunit, c-Src, and caveolin-1. (5) Interestingly, 
pretreatment with pNaKtide (a peptide derived from the α1 subunit), an antagonist of the 
Na/K-ATPase signaling, increases ouabain-sensitive 86Rb+ uptake in LLC-PK1 cells. 
Moreover, pNaKtide also co-exists with the Na/K-ATPase complex.
Conclusions: Our data indicated that the Na/K-ATPase signaling complex contains the 
Na/K-ATPase α1 subunit, c-Src, and caveolin-1. Further studies with mass spectrometry 
need to be performed to confirm the findings, and might be able to find more component(s) 
of the complex.
Funding: Other NIH Support - Jiang Liu, Government Support - Non-U.S.
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Osmotic Diuresis by SGLT2 Inhibition Is Associated with Increased Renal 
Solute-Free Water Reabsorption and AQP2 Expression in Diabetic Rats
Takahiro Masuda,1 Shigeaki Muto,1 Keiko Fukuda,3 Minami Watanabe,3 
Yuko Watanabe,1 Ken Ohara,1 Hermann Koepsell,4 Akito Maeshima,1 
Volker Vallon,2 Daisuke Nagata.1 1Jichi Medical University, Shimotsuke, Japan; 
2University of California San Diego, San Diego, CA; 3Jichi Medical Universtiy, 
Shimotsuke, Japan; 4University of Würzburg, Germany, Würzburg, Germany.
Background: Most of the filtered glucose is reabsorbed in the early proximal tubule 
by the sodium-glucose cotransporter SGLT2. The glycosuric effect of the SGLT2 inhibitor 
ipragliflozin is associated with a sustained diuretic and natriuretic tone that activates 
compensatory increases in fluid and food intake to stabilize body fluid volume (Am J 
Physiol Renal Physiol 2018, May 23. doi: 10.1152/ajprenal.00143.2018). However, the 
compensatory mechanisms that are activated on the level of renal tubules remain unclear.
Methods: Non-obese type 2 diabetic Goto-Kakizaki (GK) rats were treated with 
vehicle (Veh) or 0.01% (in diet) ipragliflozin (Ipra) (n= 4-5) with free access to food and 
water. After 8 weeks, GK rats were placed in metabolic cages for 24h urine collection. 
Blood was collected by cardiac puncture and whole kidneys for western blot were harvested 
under terminal isoflurane anesthesia.
Results: Body weight (365±10 vs. 353±5 g) and serum glucose (303±46 vs. 312±25 mg/dL) 
were similar between Veh and Ipra. Ipragliflozin increased food and fluid intake (food: 
19.5±1.5 vs. 27.8±0.9 g/24h*, fluid: 37.0±7.0 vs. 87.0±5.9 mL/24h*, *P<0.05 vs Veh), urine 
volume (25.7±3.9 vs. 64.2±4.9 mL/24h*), urinary glucose excretion (1.0±0.6 vs. 5.9±0.4 
g/24h*), urinary Na+ excretion (2.2±0.2 vs. 3.2±0.3 mEq/24h*), renal osmolar clearance 
(128±17 vs. 265±13 mL/24h*) and solute-free water reabsorption (102±14 vs. 201±9 
mL/24h*). The renal membrane protein expression of SGLT2 and AQP2 was increased, 
whereas NKCC2 expression was decreased in the Ipra vs Veh group. The expression of 
SGLT1, NHE3, phosphorylated NHE3 (S605 and S552), AQP1 and ENaC (aENaC, bENaC 
and gENaC) was similar between the groups.
Conclusions: The SGLT2 inhibitor ipragliflozin induced a sustained glycosuria, 
diuresis, and natriuresis, and increased solute-free water reabsorption in the kidneys 
of diabetic rats. The latter was associated with an increase in renal AQP2 expression. 
These results suggest that the osmotic diuresis induced by SGLT2 inhibition stimulates 
compensatory fluid reabsorption in the collecting duct.
Funding: Government Support - Non-U.S.
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Acidosis Stimulates SDF/CXCR4 Expression and Antimicrobial Responses 
via HIF-1α in Mouse Collecting Duct (M-1) Cells
Hu Peng,3 George J. Schwartz,1 Jeffrey M. Purkerson.2 1University of Rochester, 
Rochester, NY; 2University of Rochester Medical Center, Rochester, NY; 
3Univeristy of Rochester medical center, Rochester, NY.
Background: Intercalated cells (ICs) mediate H+ and HCO3 secretion in the kidney 
collecting duct (CD), We reported that IC adaptation to metabolic acidosis is mediated by 
SDF1 signaling via CXCR4 (JCI 125:4365, 2015), and that metabolic acidosis stimulates 
expression of the antimicrobial peptide (AMP) cathelicidin in rabbit urine (AJP 313: F1061, 
2017).
Methods: We used M-1 cell line (ATCC CRL-2038), from mouse l (CD), as an ex vivo 
model. M-1 cells were cultured in normal (25mM NaHCO3) and acidic (10mM NaHCO3, 
10uM EIPA) medium±HIF-1α stabilizer (IOX2,100uM), HIF-1α inhibitor PX-478 (60uM), 
LPS (200ng/ml), and Arginine (5mM) for 24hr. Total RNA was isolated and antimicrobial 
peptides, cathelicidin (Camp) and beta-defensin 2 (BD2)) and SDF1/CXCR4 mRNA 
abundance determined by real-time qRT-PCR and the ΔΔCt method. Uropathogenic E. coli 
(UPEC) were incubated (5 MOI) with M-1 cells for 90min; unbound bacteria removed 
by washing, intracellular infection of M-1 cells was determined by gentamicin (100ug/ml) 
treatment, prior to lysis. Dilutions of cell lysates were plated on agar to determine UPEC 
burden.
Results: Acidosis induced Camp (2.1 fold±0.20, n=3, p< 0.001), BD 2 (2.83 fold±0.26, 
n=3, p< 0.01), SDF1 (2.44 fold±0.28, n=3, p<0.01), and CXCR4 mRNA (3.1 fold±0.29, 
n=3, p<0.01); Prior exposure to acid media decreased by 35% the UPEC burden (mean CFU/
ml: Normal=1.12±0.07x106; Acidosis= 7.37±0.03x105, p<0.01). IOX2 increased Camp 
(2.81 fold±0.31, n=6, p< 0.05) and BD2 mRNA abundance (3.80 fold±0.36, n=6, p< 0.01), 
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and PX-478 reduced M-1 cell resistance to infection conferred by acid-medium by 12% 
(mean CFU/ml: Acidosis=4.5±0.45x104; Acidosis+PX-478=5.3±0.6x104, p<0.05). M-1 
cells treated by combination of IOX2, LPS, and Arginine were substantially more resistant 
to infection (mean CFU/ml: Untreated=6.7±0.55x104; IOX2, LPS,Arg=2.8±0.35x104, 
p< 0.01), a 58.2% decrease in UPEC burden. LPS induced SDF1 and CXCR4 mRNA in 
normal (SDF1: 2.67±0.33, n=3, p< 0.01; CXCR4: 2.94±0.38, n=3, p<0.01) or acidic (SDF1: 
4.68±0.61, n=3, p< 0.01; CXCR4: 6.47±0.29, n=3, p<0.01) medium.
Conclusions: Acidosis, via activation of HIF-1α, stimulates expression and function of 
innate immune defense peptides as well as SD1 and CXCR4 in kidney collecting duct cells.
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Metabolic Acidosis Increases Susceptibility of Mice to Uropathogenic E. 
coli (UPEC)-Induced Pyelonephritis (PN)
Jeffrey M. Purkerson,2 Hu Peng,3 George J. Schwartz.1 1Pediatrics, University of 
Rochester Med Ctr, Rochester, NY; 2University of Rochester Med Ctr, Rochester, 
NY; 3University of Rochester Med Ctr, Rochester, NY.
Background: Carbonic anhydrase 2-deficient mice show metabolic acidosis with 
deficient urine acidification, and are more susceptible to UPEC-induced PN (Hains, AJP 
307:F869, 2014). Whether the susceptibility to PN is due to H+ transport abnormalities or 
acidosis is unclear. In this study we examined the impact of acidosis on susceptibility of 
refluxing C3H-HEouJ mice to PN.
Methods: Metabolic acidosis was induced in C3H-HEouJ mice via NH4Cl (2% w/w) 
supplementation of food±I.P. administration of acetazolamide (ACZ 100 mg/kg). Acid-
base state was assessed by blood gas using an iSTAT® G3+ and pH of urine collected 
under water-saturated mineral oil in metabolic cages housing 2-4 mice. Collecting duct 
(CD) fragments were enriched from collagenase-digested mouse kidney by DBA-lectin
magnetic sorting. Relative abundance of SDF1 and antimicrobial peptide (AMP) mRNAs
(cathelicidin [Camp]; beta defensin-2 [BD2]) in CDs was determined by qRT-PCR via 
ΔΔCt. Female C3H-HEouJ mice were infected with UPEC strain CFT073 @ 107 cfu/50 μl 
via transurethral inoculation. Bacterial burden (cfu/g) in bladder and kidney was determined
by culture of tissue homogenates. Statistical significance utilized T-test or Mann-Whitney 
Test.
Results: NH4Cl-fed mice were acidotic (s[HCO3] 18.2±0.65*, Ur pH 5.8±0.02*; 
N=8) compared to normal (NL) (s[HCO3] 22.2±0.68; Ur pH 6.8±0.01, *p<0.05, N=24); 
co-administration of ACZ resulted in severe acidosis and reduced urine acidification 
(s[HCO3] 12.8±0.7**; Ur pH 6.9±0.05, p<0.001 versus NL, N=5-9). UPEC infection alone 
did not induce SDF1 mRNA; however acidosis+UPEC infection induced SDF1 expression 
3.5±0.4 fold over NL (p<0.01). Severe acidosis (NH4Cl+ACZ) increased Camp (2.1±0.11) 
and BD2 (2.3±0.36) mRNA, whereas expression of SDF-1 mRNA was induced 10.5±1.0 
compared to NL (p<0.01). Acidotic mice were more susceptible to PN than NL (kidney 
mean cfu/g: NL 4.1x103; Acidosis 2.6x108, p<0.001; N=7-8). UPEC burden was also higher 
in bladders from acidotic mice compared to normal (mean cfu/g: NL 6.8x105; Acidosis 
8.6x108, p<0.001).
Conclusions: Metabolic acidosis increases the susceptibility of C3H-HEouJ mice to 
PN. Increases in AMP expression with acidosis do not compensate for an apparent loss of 
barrier function, manifested as increased production of SDF1, a key mediator of the kidney 
response to metabolic stress (e.g. hypoxia, acidosis).
TH-PO493 Poster Thursday
Fluid and Electrolytes: Basic - I
Monophosphoryl Lipid A (MPLA) Prevents LPS-Induced Inhibition of 
HCO3- Absorption in Medullary Thick Ascending Limb Through 
Negative Regulation of Interleukin-1 Receptor-Associated Kinase-1 
(IRAK-1)
Bruns A. Watts,1 Esther Tamayo,1 Edward R. Sherwood,2 David W. Good.1 
1University of Texas Medical Branch, Galveston, TX; 2Vanderbilt University 
Medical Center, Nashville, TN.
Background: LPS inhibits HCO3- absorption in the MTAL through activation of a 
basolateral TLR4-MyD88-ERK pathway that is upregulated by sepsis. Recently we showed 
that pretreatment with the nontoxic immunomodulator MPLA prevents inhibition of 
HCO3
- absorption by LPS through activation of a TLR4-TRIF-PI3K pathway that prevents 
LPS-induced ERK activation. Here, we examined molecular mechanisms that underlie 
the protective inhibitory interaction between the MPLA-PI3K and LPS-ERK signaling 
pathways.
Methods: 
Results: We first examined IRAK-1, a critical mediator of LPS signaling downstream 
of TLR4 that is downregulated in LPS tolerant cells. Treatment of mouse MTALs with 
LPS for 15 min in vitro increased IRAK-1 phosphorylation 1.5-fold. The effect of LPS to 
activate ERK in the MTAL was prevented by a selective IRAK-1 inhibitor, establishing 
IRAK-1 as the upstream mediator of ERK activation in the LPS pathway. Pretreatment 
of MTALs with MPLA for 2 h in vitro prevented LPS-induced IRAK-1 activation. This 
effect of MPLA was eliminated by a PI3K inhibitor. Toll-interacting protein (Tollip) is 
an intracellular protein that is induced in LPS tolerant cells and negatively regulates LPS 
signaling by suppressing IRAK-1 activity. To assess whether Tollip may be involved in 
MPLA’s actions in the MTAL, mice were pretreated with MPLA or vehicle 48 h prior to 
sham or cecal ligation and puncture (CLP) sepsis surgery. MPLA pretreatment increased 
Tollip expression in microdissected MTALs and inner stripe of outer medulla from sham 
and CLP mice. In addition, treatment with MPLA for 2-3 h in vitro increased Tollip 
expression in inner stripe of control mice.
Conclusions: We conclude that MPLA activates a PI3K-dependent pathway that 
inhibits LPS stimulation of IRAK-1 in the MTAL, thereby preventing LPS-induced ERK 
activation that inhibits HCO3
- absorption. These protective effects of MPLA likely are 
mediated through the induction of Tollip, an immunomodulatory protein that negatively 
regulates IRAK-1. These results provide new evidence that renal tubule epithelial cells are 
capable of undergoing immune reprogramming that affords resistance to LPS and identify 
IRAK-1 as a key molecular target through which MPLA prevents LPS impairment of HCO3
- 
absorption in the MTAL.
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Secretin-Stimulated Urinary HCO3- Excretion: A Function of CFTR and 
Pendrin
Peder Berg,1 Inês Cabrita,3 Rainer Schreiber,2 Karl Kunzelmann,2 
Jens G. Leipziger.1 1Aarhus University, Aarhus, Denmark; 2University of 
Regensburg, Regensburg, Germany; 3Physiology, University of Regensburg, 
Germany, Regensburg, Germany.
Background: The gastro-intestinal hormone secretin (SCT), the first hormone ever 
discovered (Bayliss and Starling, ca. 1905), is able to acutely increase the amount of HCO3
-
 in the urine, but the underlying mechanism remains enigmatic. The actions of secretin 
are well understood in gastro-intestinal physiology; among many functions it acts as an 
important activator of pancreatic HCO3
- secretion. Intriguingly, the SCT receptor is also 
expressed in the collecting duct (CD) of the kidney.
Methods: Real time monitoring of urine flow and urinary pH was allowed by bladder 
catheterization and insertion of micro pH-electrodes in the outflow of the catheter in i.v. 
anaesthetized mice.
Results: Here, we show that SCT elicits acute urinary alkalisation, increases urinary 
[HCO3
-] and urinary HCO3
- excretion rate in anaesthetized mice. This effect is present in 
multiple mouse strains corroborating data from older studies in healthy humans. Importantly, 
we identified that the SCT effect is completely absent in mice lacking the apical Cl-/HCO3
- 
exchanger pendrin, which, in the kidney, is exclusively expressed in the apical membrane of 
β-IC of the CNT/CD. Moreover, we found that the SCT effect on urinary pH is dramatically 
diminished in mice with either global knock-out of CFTR or renal tubule-specific knock-
out of CFTR. The effect on urinary [HCO3
-] and urinary HCO3
- excretion is completely 
abolished in both CF animal models, corroborating early data from children suffering from 
cystic fibrosis. Noteworthy, CFTR expression has been shown to be several folds higher in 
β-IC cells compared to α-IC and principal cells.
Conclusions: In conclusion, this study has defined the molecular mechanism of SCT-
induced urinary HCO3
- excretion as a function of the specific activation of the β-IC of the 
CD. Thus, in close similarity to the established mechanism of SCT-induced HCO3
- excretion
in the exocrine pancreas, an analogous mechanism was identified in the kidney.
Funding: Government Support - Non-U.S.
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MAGE-D2 Promotes Expression and Stability of Pendrin Protein
Elie Seaayfan,1 Aparna Renigunta,1 Stefanie Weber,1 Kamel Laghmani,2 
Martin Kömhoff.1 1University Children’s Hospital Marburg, Marburg, 
Germany; 2INSERM-CNRS, Paris, France.
Background: We recently showed that mutations in MAGE-D2 cause polyhydramnios 
with preterm delivery of the affected baby and a severe but transient form of antenatal 
Bartter’s syndrome (tBS). Although reduced total and apical expression of the sodium–
chloride transporters NKCC2 and NCC was shown in vivo and in vitro, which explains 
massive salt losing (Laghmani et al, N Engl J Med. 2016), additional transporters may 
also be impaired. One potential candidate is Pendrin, because its loss increases salt losing 
and because it is expressed in the distal tubule as MAGE-D2. Consequently, the aim of the 
present study was to investigate the potential role of MAGE-D2 in Pendrin biogenesis.
Methods: Pendrin protein expression was monitored in transiently transfected 
HEK293 cells by immunoblotting, which allows the detection of both the immature (core-
glycosylated) and mature Pendrin protein. Stability of Pendrin protein was assessed by 
cycloheximide chase assay. We studied the effects of wild type MAGE-D2 and mutant 
R446CMAGE-D2 on Pendrin expression. In addition, the role of endogenously expressed 
MAGE-D2 role was investigated by small interfering RNA. To assess the specificity of our 
findings, we also analyzed the effects of MAGE-D2 overexpression on NHE3 biogenesis.
Results: MAGE-D2 co-expression robustly increased expression of immature and total 
cellular Pendrin protein in a dose dependent manner. Cycloheximide chase assays (CHX) 
showed that in cells over expressing MAGE-D2, stability of immature Pendrin is increased. 
In contrast to MAGE-D2 wild type, R446CMAGE-D2, a missense mutation identified 
in a tBS patient, co-expression significantly decreases Pendrin stability. Analogous to 
R446CMAGE-D2, knockdown of endogenous MAGE-D2 by small interfering RNA also 
decreases Pendrin stability. In contrast to Pendrin, our preliminary data did not reveal an 
effect of MAGED2 on the expression of total NHE3.
Conclusions: Our findings show that MAGED2 specifically promotes the expression 
of Pendrin. Importantly, our data indicate that MAGED2 affects multiple salt transporters in 
the distal tubule, thus explaining the severe phenotype.
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Transcriptome Profiling in Pendrin Deficient Mice Provides New Insight 
into the Role of Pendrin in Kidney Physiology
Jie Xu,1 Sharon L. Barone,1,2 Kamyar A. Zahedi,1,2 Manoocher Soleimani.1,2 
1Internal Medicine, University of Cincinnati, Cincinnati, OH; 2Veterans Affairs 
Medical Center, Cincinnati, OH.
Background: Slc26a4 (Pendrin) is a Cl-/HCO3- exchanger that is primarily expressed 
on the apical membrane of B-intercalated cells in the kidney connecting tubules/cortical 
collecting ducts and plays a critical role in salt absorption and bicarbonate secretion.
Methods: To gain better insight into the role of pendrin in kidney function, RNA-Seq 
analysis was performed on kidney cortices of wild type and pendrin KO mice and results 
verified by Northern hybridization and/or immunofluorescence labeling.
Results: The most dramatic changes in the expression of solute transporters belonged to 
the families of organic anion and cation transporters and their collaborating partners, which 
are primarily expressed in the proximal tubule. The expression of the basolateral organic 
anion transporters, OAT1 and OAT3 (Slc22a6 and a8), along with their interacting partner 
NaDC-3 (Slc13a3), was significantly increased and paralleled a robust enhancement in the 
expression of the apical voltage driven urate efflux transporter Npt4 (Slc17a3). Likewise, 
the expression of the basolateral organic cation transporter, Oct2 (Slc22a2) increased and 
was matched by the enhanced expression of MATE1 (SLC47A1) and NHE-8 (Slc9a8) on 
the apical membrane. The activation of NHE-8 is likely to provide the necessary luminal 
proton for MATE1, an organic cation/H+ exchanger on the apical membrane of the proximal 
tubule. In addition, the Na+-Sulfate cotransporter (Slc13a1) which is expressed on the apical 
membrane of proximal tubules and mediates sulfate absorption showed significant up-
regulation.
Conclusions: In conclusion, deletion of Slc26a4 is associated with enhanced 
expression of organic anion and cation transporters on the basolateral and apical membranes 
of the proximal tubule. We propose that the coordinated regulation of organic anion and 
cation transporters in the kidney proximal tubule of pendrin KO mice supports an important 
role for pendrin in the excretion of endogenous and exogenous organic cations (such as 
creatinine, guanidine, metformin, cisplatinum, etc), endogenous and exogenous organic 
anions (uric acid, prostaglandins, uremic toxins, penicillin, methotrexate, linezolid, etc), 
and inorganic anions such as sulfate.
Funding: Veterans Affairs Support, Private Foundation Support
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NBCe1A Regulates Citrate Excretion During Hypokalemia Through 
NaDC1 Expression-Dependent and Independent Mechanisms
Kierstin L. Webster,1 Hyun-Wook Lee,1 Autumn N. Harris,1 Michael F. Romero,2 
Jill W. Verlander,1 I. D. Weiner.1,3 1University of Florida, Gainesville, FL; 2Mayo 
Clinic College of Medicine, Rochester, MN; 3Nephrology Section, NF/SGVHS, 
Gainesville, FL.
Background: Urinary citrate is an alkali equivalent and chelates calcium, thus is 
critical to acid-base homeostasis and prevention of calcium nephrolithiasis. Hypokalemia 
causes hypocitraturia; proximal tubule NaDC1 mediates citrate reabsorption and is thought 
to be the major regulator of citrate excretion. However, whether NaDC1 protein expression 
changes in hypokalemia and the signaling pathways involved are unknown.
Methods: Mice were fed either a K-control diet for 2 days or K-control diet for 2 
days then K-free diet for 4 days. Urinary citrate was measured using 1H-NMR. We 
determined NaDC1 expression in the proximal convoluted tubule (PCT), proximal straight 
tubule in the medullary ray (PST-MR) and outer medulla (PST-OM) using quantitative 
immunohistochemistry. To determine the role of NBCe1-A in the signaling pathway 
regulating NaDC1 expression, we compared mice with NBCe1-A deletion (KO) with wild-
type (WT) littermates.
Results: While on K-control diet, urinary citrate excretion did not differ between WT 
and NBCe1-A KO mice. However, KO mice had significantly less NaDC1 immunolabel 
than WT mice in the PCT and PST-MR. A K-free diet for 4 days decreased citrate excretion 
significantly in both genotypes, but the decrease was significantly blunted in KO mice 
compared to WT mice (WT, 95±3% decrease; KO, 83±6% decrease; P<0.05). In WT mice, 
K-free diet increased PCT and PST-MR NaDC1 immunolabel significantly compared to 
K-control. In contrast, in NBCe1-A KO mice NaDC1 expression did not differ significantly 
between K-control and K-free mice in any proximal tubule segment, PCT, PST-MR or PST-
OM.
Conclusions: (1) K-free diet decreases citrate excretion by increasing NaDC1 
expression in the PCT and PST-MR through a mechanism that involves signaling through 
the basolateral membrane protein NBCe1-A; (2) In NBCe1-A KO mice fed K-control diet, 
either alternative citrate transporters or NaDC1 regulation through a mechanism other than 
steady-state protein expression enables similar rates of citrate reabsorption despite less 
total NaDC1 expression than WT; and, (3) In the absence of NBCe1-A a K-free diet acts 
through NBCe1-A-independent signaling pathways to increase citrate reabsorption through 
a mechanism that does not involve altered NaDC1 protein expression.
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Proximal Tubule NBCe1-A-Dependent Regulation of Ammonia and 
Potassium Metabolism During Hypokalemia
Hyun-Wook Lee,1 Autumn N. Harris,1 Chao Chen,1 Richard A. Coleman,2 
Paul A. Welling,3 Michael F. Romero,4 Jill W. Verlander,1 I. D. Weiner.1,5 
1University of Florida, Gainesville, FL; 2Physiology Dept, U. of MD School of 
Medicine, Baltimore, MD; 3University of Maryland School of Medicine, 
Baltimore, MD; 4Mayo Clinic College of Medicine, Rochester, MN; 5Nephrology 
Section, NF/SGVHS, Gainesville, FL.
Background: Dietary potassium restriction is associated with increased ammonia 
excretion, but neither the specific proteins that signal this response nor the functional role of 
increased ammonia excretion are known. This study’s purpose was to determine NBCe1-A’s 
role in the effect of dietary potassium restriction on ammonia metabolism and potassium 
homeostasis.
Methods: Mice were fed either a K-control diet for 2 days or K-control diet for 2 days 
followed by K-free diet for 4 days. To determine NBCe1-A’s role we compared mice with 
NBCe1-A deletion (KO) with wild-type (WT) littermates. All studies included both male 
and female mice and inclusion of sex in statistical analyses did not change any conclusions.
Results: Urinary ammonia excretion increased during each day of K restriction in WT 
mice. In KO mice the increase in ammonia excretion was significantly less on each day than 
in WT mice. Compared to WT, NBCe1-A KO had significantly lower cortical expression 
of key ammoniagenic proteins, phosphoenolpyruvate carboxykinase and phosphate-
dependent glutaminase, and greater expression of the ammonia-recycling protein, 
glutamine synthetase. NBCe1-A deletion also altered renal K handling during K-free diet. 
After 4 days of K-free diet, hypokalemia was significantly more severe in KO mice than in 
WT (KO, 2.5±0.2; WT, 3.5±0.2 mM, P<0.001). Despite more severe hypokalemia, urinary 
K was significantly greater in KO than WT during dietary potassium restriction. Total NCC 
and phospho-NCC expression, which decrease renal K excretion, were significantly lower 
in hypokalemic KO than WT mice. Hypokalemia normally decreases ROMK expression; 
however, despite more severe hypokalemia in KO mice, ROMK expression did not differ 
significantly between WT and KO. This suggests abnormal ROMK regulation in NBCe1-A 
KO mice contributed to the more severe hypokalemia.
Conclusions: 1) NBCe1-A is essential to the signaling pathway that increases ammonia 
excretion in response to dietary potassium restriction; 2) Hypokalemia induced by a K-free 
diet appears to regulate distal K transport through a proximal tubule-dependent mechanism 
involving NBCe1-A, signaling through DCT NCC phosphorylation, and regulating ROMK 
expression.
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Renal H+/K+ ATPases Mediate Benzamil-Inhibited Urinary H+ Excretion
Niklas Ayasse,1 I. Jeanette Lynch,2 Charles S. Wingo,2 Jens G. Leipziger.1 
1Aarhus University, Aarhus, Denmark; 2University of Florida, Gainesville, FL.
Background: Acute inhibition of ENaC causes a marked urinary alkalization. It 
was previously assumed that the so-called “voltage hypothesis” explains this urinary 
pH effect. The “voltage hypothesis” states that the lumen-negative ENaC-dependent 
transepithelial voltage provides the driving force for H+ secretion via the vacuolar H+ 
ATPase in neighbouring α-intercalated cells of the CD. In two preceding studies, we have 
contested the “voltage hypothesis”. This, therefore, calls for an alternative explanation of 
the mechanism of ENaC blocker-mediated urinary alkalisation. Here we present data that 
strongly supports the involvement of renal H+/K+ ATPases, which are also located in the 
apical membrane of the α-IC.
Methods: In vivo studies in anesthetized mice were conducted to continuously measure 
urine output, urine electrolytes and urine pH.
Results: Application of benzamil acutely alkalized the urine (delta pH: 0.33±0.07). 
In parallel, the ambient luminal [K+] dropped markedly. In animals fed a low K+ diet, the 
benzamil-induced urinary alkalisation was greatly enhanced (delta pH: 0.74±0.12) and 
a significantly lower urine [K+] nadir was reached. In double knock out mice lack both 
isoforms of the H+/K+ ATPases the benzamil effect was completely absent.
Conclusions: These data support the following explanation. ENaC inhibitors elicit 
their effect indirectly via their marked K+ sparing property. They induced a strong drop 
of the ambient luminal [K+] concentration with impedes H+/K+ ATPases function and thus 
tubular H+ secretion. Thus, we postulate that the lack of substrate (K+) causes the luminal 
alkalisation by benzamil.
Funding: Government Support - Non-U.S.
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Muc1 Deficiency Causes Urinary Acidification Defects in Mice
Mohammad M. Al-bataineh,1 Evan C. Ray,2 Carol L. Kinlough,4 
Rebecca P. Hughey,3 Thomas R. Kleyman.1 1University of Pittsburgh, Pittsburgh, 
PA; 2UPMC, Pittsburgh, PA; 3Dept Medicine-Renal Electrolyte Division, 
Pittsburgh, PA; 4Department of Medicine University of Pittsburgh, Pittsburgh, 
PA.
Background: Mucin 1 (human MUC1, mouse Muc1) is expressed on the apical 
surface of most epithelial cells, including the thick ascending limb (TAL) and distal nephron 
segments. Proximal tubular expression of Muc1 is induced in ischemia-reperfusion injury, 
where it stabilizes HIF-1a and b-catenin and plays a protective role. A frame-shift mutation 
in MUC1 causes autosomal dominant tubulointerstitial kidney disease. However, there is 
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limited information regarding its functional role in normal kidney. Muc1 knockout mice 
have no clear phenotype in the absence of stressors (e.g. bacterial infection). The TRPV5 
Ca2+ channel was reported to be stabilized on the cell surface by galectin-dependent cross-
linking to MUC1, providing a novel mechanism for regulation of this ion channel. We 
observed robust Muc1 apical and sub-apical staining in type A and type B intercalated cells 
(ICs). In Type A ICs, Muc1 co-localizes with the vacuolar H+ ATPase (V-ATPase), a protein 
complex that mediates apical ATP-driven H+ secretion. V-ATPase subcellular localization 
regulates H+ secretion, while defects in V-ATPase function can cause renal tubular acidosis. 
As Muc1 and the V-ATPase are highly expressed in ICs, we tested the hypothesis that Muc1 
regulates V-ATPase expression and function.
Methods: Muc1 KO (Muc1-/-), Muc1 heterozygous (Muc1+/-) and control mice 
were given 2.5% sucrose with or without 0.28 M NH4Cl in drinking water for 7 days. 
Plasma electrolytes, urine pH and NH4
+ were measured. Kidneys were processed for 
immunoblotting and confocal immunofluorescence (IF) microscopy.
Results: IF staining of fixed mouse kidney slices revealed that Muc1 co-localizes with 
luminal V-ATPase in ICs. Moreover, V-ATPase moved from the cytosol to the apical surface 
when WT mice were subjected to an acid load. In contrast, V-ATPase remained cytosolic in 
Muc1-/- mice. In response to acid-loading, both Muc1-/- and Muc1+/- mice exhibited impaired 
urinary acidification while only Muc1 KO mice exhibited greater metabolic acidosis. The 
IC-specific a4-subunit of V-ATPase co-immunoprecipitated with Muc1 in extracts of mouse 
kidney, suggesting that they are components of a protein complex.
Conclusions: These results suggest that Muc1 interacts with the V-ATPase and 
influences its cell surface localization in type A ICs, and is necessary for a normal renal 
response to an acid load.
Funding: NIDDK Support
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AKAPs-PKA Disruptors Robustly Increase AQP2 Activity Independently 
of Vasopressin
Fumiaki Ando,1 Naofumi Yui,1 Naohiro Nomura,1 Tatemitsu Rai,2 Sei Sasaki,1 
Shinichi Uchida.1 1Tokyo Medical and Dental University, Tokyo, Japan; 2Tokyo 
Medical & Dental Univ, Tokyo, Japan.
Background: Congenital nephrogenic diabetes insipidus (NDI) is characterized 
by the inability of the kidney to concentrate urine. Congenital NDI is mainly caused by 
loss-of-function mutations in the vasopressin type 2 receptor (V2R), leading to impaired 
aquaporin-2 (AQP2) water channel activity. So far, treatment options of congenital NDI 
either by rescuing mutant V2R with chemical chaperones or by elevating cyclic adenosine 
monophosphate (cAMP) levels have failed to yield effective therapies. In this study, we 
focused on direct activators of PKA as novel therapeutic targets of congenital NDI. The 
intracellular distribution and activity of PKA are largely controlled by A-kinase anchoring 
proteins (AKAPs). We examined the effects of AKAPs-PKA disruptors, which dissociate 
the binding of AKAPs and PKA.
Methods: The effects of AKAPs-PKA disruptors, FMP-API-1 and its derivatives, 
were examined by mouse cortical collecting duct (mpkCCD) cell lines, isolated tubule 
microperfusion experiments, and V2R-inhibited NDI mouse model.
Results: FMP-API-1 increased PKA/AQP2 activity in mpkCCD cells. In 
microperfusion experiments, FMP-API-1 increased osmotic water permeability to the same 
extent as vasopressin. We then synthesized derivatives of FMP-API-1 to obtain greater 
pharmacological potency. In vivo, FMP-API-1/27 phosphorylated AQP2 at S256 and S269 
more strongly than vasopressin and increased urine osmolality in V2R-inhibited NDI 
mouse model.
Conclusions: FMP-API-1 is a promising lead compound for the treatment of congenital 
NDI caused by V2R mutations.
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Empagliflozin Contributes to Polyuria via Transcriptional and Post- 
translational Control of Aquaporin-2 in Diabetic Rat Kidneys
Sungjin Chung, Seok Joon Shin, Cheol Whee Park, Yong-Soo Kim, Chul 
Woo Yang, Eun Sil Koh. The Catholic University of Korea College of Medicine, 
Seoul, Republic of Korea.
Background: It has been suggested that one of the most possible mechanisms for 
the positive cardiovascular and renal outcomes observed with empagliflozin, a selective 
sodium-glucose contransporter type 2 (SGLT2) inhibitor, would be related to effects on 
osmotic diuresis and natriuresis. However, the natriuretic effect of SGLT2 inhibitors has 
been reported to be transient, and long-term data related to diuretic change are sparse.
Methods: This study investigated the effect of a 12-week treatment with empagliflozin 
(3 mg/kg) on renal sodium transporters and water channels in diabetic OLETF rats by 
comparing it with other antihyperglycemic agents that included lixisenatide (10 μg/kg), 
a glucagon-like peptide receptor-1 agonist, and voglibose (0.6 mg/kg), an α-glucosidase 
inhibitor.
Results: At 12 weeks of treatment, the serum sodium level and fractional excretion of 
sodium were not significantly different between empagliflozin-treated and control diabetic 
rats. Empagliflozin-treated diabetic rats produced slightly decreased, but still high, urine 
volume and glycosuria, and showed significantly higher electrolyte-free water clearance 
than diabetic rats treated with other agents. In empagliflozin-treated rats, renal protein 
expressions of Na+-K+-2Cl- cotransporter and epithelial Na+ channel were decreased, 
and Na+-Cl- cotransporter expression was unaltered compared with control diabetic rats. 
Empagliflozin increased the expression of aquaporin (AQP)7 but did not affect AQP1 
and AQP3 protein expressions in diabetic kidneys. Despite the increased expression in 
vasopressin V2 receptor, protein and mRNA levels of AQP2 in kidneys of empagliflozin-
treated diabetic rats were significantly decreased compared to control diabetic rats. In 
addition, empagliflozin increased the phosphorylation of AQP2 at S261 through the 
activation of p38- mitogen-activated protein kinase, protein phosphatase 2B and glycogen 
synthase kinase 3α, and cyclin-dependent kinases 1 and 5.
Conclusions: The collective results indicate that the long-term use of empagliflozin 
may promote diuresis associated with downregulation of AQP2 as well as its sustained 
natriuretic ability.
Funding: Government Support - Non-U.S.
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Epithelial Depolarization Induces AQP2 Up-regulation via Non-Canonical 
Ser-269 Phospho-Regulation Independently of Any Hormonal and 
Chemical Stimulation
Naofumi Yui, Fumiaki Ando, Sei Sasaki, Shinichi Uchida. Tokyo Medical and 
Dental University, Sagamihara-shi, Kanagawa-ken, Japan.
Background: Aquaporin-2 (AQP2) has multiple vasopressin-sensitive phosphorylation 
sites in its C-terminal region. We previously examined how pS256-positive AQP2 is 
catalyzed by vasopressin or forskolin stimulation using a phospho-specific AQP2 immuno-
isolation technique, and identified a combined phospho-regulation: pS256-pS261-AQP2 
changed to pS256-pS261-pS269-AQP2, and then transformed to pS256-pS269-AQP2 in 
both MDCK cells and mouse kidney. This cascade translocates pS256-positive AQP2 to 
the apical plasma membrane. We defined this phospho-regulation as canonical in this study. 
We next applied phospho-specific AQP2 immuno-isolation to quantify phospho-AQP2 in 
the total-AQP2 population. In the process of assay establishment, we hypothesized that cell 
polarization status affects AQP2 phosphorylation.
Methods: In this study, we divided MDCK cells stably expressing rat-AQP2 into two 
groups: cells were grown to confluence for 3 days and 1) their medium was just replaced 
with fresh normal DMEM without trypsinization (polarized group), or 2) they were 
trypsinized and re-plated with the same DMEM (depolarized group). Cells were lysed 24 
h later without any hormonal or chemical stimulation and subjected to western blotting.
Results: Wild-type AQP2 significantly increased in the depolarized group. Ser-256 and 
Ser-261 phosphorylation was not changed, whereas Ser-269 phosphorylation significantly 
increased in the depolarized group. In S269A-AQP2 cells, depolarization-induced AQP2 
upregulation did not occur. Interestingly, S256A-AQP2 was significantly upregulated in the 
depolarized group with a significant increase of Ser-269 phosphorylation.
Conclusions: These results demonstrate the existence of polarity-induced and 
hormone-independent AQP2 regulation, indicating a novel rationale for AQP2 function, 
i.e. in wound healing, tubular regeneration, cyst formation. In addition, we identified 
non-canonical AQP2 Ser-269 phospho-regulation, which is independent of prior Ser-256
phosphorylation and is not accompanied by subsequent Ser-261 dephosphorylation. These 
findings provide a basis for subsequent studies to investigate multi-functional roles of AQP2 
beyond the categorical flame of apical water channel in polarized epithelial cells.
Funding: Government Support - Non-U.S.
TH-PO504 Poster Thursday
Fluid and Electrolytes: Basic - I
AQP11 Plays a Role in Water Homeostasis in Concert with AQP4 in the 
Brain
Kenichi Ishibashi,1 Sei Sasaki,2 Yasuko Tanaka.1 1Meiji Pharmceutical 
university, Kiyose, Japan; 2Tokyo Medical and Dental University, Bunkyo-ku, 
Japan.
Background: Water transport in the brain is tightly controlled by blood-brain-barrier 
(BBB) composed of endothelial cells (AQP1, 11) and glial foot processes (AQP4) where 
AQP4 regulates brain edema. Here we examined AQPs mRNA expression in acute 
hyponatremic or hypernatremic mice models of wild type and AQP11-null mice as AQP11-
null mice suffer from renal failure which precludes chronic models.
Methods: By intraperitoneal injection, hypo- and hyper-natremic models were 
produced with water+desmopressin or 2M NaCl solution four or six hours before sacrifice, 
respectively. The expression of AQP1, 4 and 11 mRNA were quantified by RT-real-time 
PCR of whole brain RNA. Brain water content was calculated with 4-day-dried weight in 
80 C oven and extravascular leakage by biotin permeability assay.
Results: In the control state, AQP11-null brain showed half AQP4 expression without 
AQP1 change as compared with wild mice (Na 153.3 vs. 150.7 mEq/L), whereas brain 
water content was similar (78.98 vs 78.61%). Acute hyponatremia (123.6 vs. 126.0 mEq/L) 
enhanced AQP4 expression in AQP11-null to the level of the wild mice with no change of 
AQP1, whereas it did not change AQP1, 4, nor 11 in wild mice. Brain water content was 
similar (79.93 vs. 79.8%) with expanded perivascular space, Virchow–Robin space. On the 
other hand, acute hypernatremia (199.5 vs. 208.0 mEq/L) increased AQP4 to the level of wild 
mice in AQP11-null with half AQP1 expression, whereas it decreased AQP1 and AQP11 by 
half without change in AQP4 in wild mice. Brain water content was significantly lower in 
AQP11-null than wild mice (75.34 vs. 76.65%) which was also documented histologically by 
cellular shrinkage in the brain cortex. Biotin permeability assay revealed no leakage in hypo- 
and hyper-natremic states. The results suggested that AQP4 expression was downregulated to 
match the decreased water transport at the endothelium in AQP11-null but may be enhanced 
to compensate for AQP11-null with osmotic changes although acute hypernatremia produced 
more water loss in AQP11-null brain.
Conclusions: We conclude that AQP11 may play a role in water homeostasis in concert 
with AQP4 at BBB with compensating enhanced AQP4 expression in AQP11-null with 
osmotic challenge. The results set a stage for examining the role of AQP11 in disease states 
such as brain edema. We are currently studying middle cerebral artery hemi-infarction 
model in AQP11 null mice.
Funding: Government Support - Non-U.S.
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Lithium and Gsk3α Inhibition Reduces Aquaporin-2 Expression in 
Primary Cultured Inner Medullary Collecting Duct Cells Due to 
Independent Mechanisms
Bayram Edemir,1 Marc Kaiser.2 1Martin Luther University Halle-Wittenberg, 
Halle (Saale), Germany; 2Praxis am Markt, Froendenberg, Werl, Germany.
Background: Lithium is a widely used drug for the treatment of bipolar disorders. 
However, it has severe side effects and up to 40 % of the treated patients develop a diabetes 
insipidus. Lithium affects also the activity of the glycogen synthase kinase 3 (Gsk3) 
and mice deficient for Gsk3β isoform in the renal collecting duct showed severe urine 
concentration abilities. The respective cellular and molecular mechanisms are still not fully 
understood.
Methods: We used primary cultured inner medullary collecting duct cells to analyze the 
underlying mechanisms. The cells were treated for different time points and with different 
concentrations of lithium, the pharmacological inhibitor of the Gsk3α/β (SB216763) or the 
Gsk3β specific Inhibitor TWS119. The cells were additionally incubated with inhibitors 
of the lysosomal (using bafilomycin) or proteasomal pathways (using MG132) alone or 
together with the above mentioned drugs. The expression of Aqp2 was analyzed on the 
mRNA level by qPCR and on the protein level by Western blot and immunofluorescence 
analysis.
Results: The qPCR experiments showed that only lithium induced a down regulation of 
Aqp2 mRNA expression while Gsk3 inhibition by SB216763 had no effect and surprisingly 
TWS119 led to increased expression. While inhibition of the proteasome with MG132 did 
not prevent the lithium or SB216763 mediated down regulation of Aqp2, the inhibition of 
the lysosomal activity with bafilomycin or chloroquine prevented lithium and SB216763 
mediated down regulation of Aqp2 on the protein level. On the mRNA level lithium still 
induced down regulation of Aqp2. The treatment with bafilomycin and chloroquine induced 
accumulation of Aqp2 in lysosomal structures, which was prevented when the cells were 
treated with dbcAMP which led to phosphorylation and membrane localization of Aqp2. 
While down regulation of Aqp2 was also evident when lithium was applied together with 
dbcAMP, dbcAMP prevented the SB216763 induced down regulation of Aqp2. Interestingly 
the use of TWS119 induced the expression of Aqp2 on protein and mRNA level.
Conclusions: We showed that lithium and the Gsk3α/β inhibition by SB216763 induces 
down regulation of Aqp2 on different levels. The exclusive Gsk3β inhibitor TWS119 had 
the opposite effect indicating that Gsk3α inhibition is involved in Aqp2 down regulation.
Funding: Government Support - Non-U.S.
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Inhibition of Polo-Like Kinase 1 (PLK1), a Cell Cycle Regulator, Prevents 
the Dysregulation of AQP2, AQP3, and NKCC2 in Obstructive 
Nephropathy
Yue Zhang,1 Yang Du,2 Yun Qian,2 Yan Guo,2 Mingzhu Jiang,2 Shuang Chen,2 
Guixia Ding,3 Songming Huang,2 Aihua Zhang,2 Zhanjun Jia.2 1University of 
Utah/Nanjing Medical University, Nanjing, China; 2Nanjing Medical University, 
Nanjing, China; 3Nanjng Medical University, Nanjing, China.
Background: Obstructive kidney disease is accompanied by the dysregulation of water 
channels and sodium transporters, which could account for the water/sodium disorders after 
obstruction release. PLK1 is known as a key modulator of cell cycle progression. Recently, 
cell cycle-associated mechanism was shown to contribute to the renal tubular injury. Here 
we proposed that the inhibition of PLK1 may preserve the water channels and sodium 
transporters of renal tubules in obstructive nephropathy.
Methods: Male C57BL/6 mice were subjected to unilateral ureteral obstruction 
(UUO) surgery or sham operation. On day 4 and day 6 after UUO surgery, mice received 
i.p injection of specific PLK1 inhibitor BI6727(15mg/kg). On day 7 after UUO surgery, 
animals were sacrificed and kidney samples were collected for analysis.
Results: qRT-PCR analysis detected that the marked reduction of AQP2, AQP3, and 
NKCC2 (40-60%) in obstructed kidneys were largely normalized by BI6727 treatment at 
mRNA levels. By immunohistochemistry and Western blotting, we further confirmed that 
post therapy (day 4 and day 6 after kidney obstruction) by BI6727 entirely restored the 
reduction of AQP2 and NKCC2 proteins to the normal levels. Due to the known role of 
PGE2 cascade in regulating water channels and sodium transporters in obstructed kidney, 
we measured COX-1, COX-2 and mPGES-1 and observed 3-8 folds increments of these 
components of PGE2-generating cascade. However, BI6727 therapy did not affect the 
upregulation of COXs and mPGES-1, suggesting that inihbition of PLK1 prevserved 
AQP2, AQP3, and NKCC2 possibly through a prostaglandin-independent mechanism.
Conclusions: Inhibition of PLK1 restored the downregulation of AQP2, AQP3, and 
NKCC2 in obstructed kidneys, suggesting a novel role of tubular cell cycle progression 
in dysregulating water channels and sodium transporters independently of prostaglandin-
associated mechanism in obstructive nephropathy.
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Phosphorylation of Ser261 and Dephosphorylation of Ser269 Is Important 
for Urinary Excretion of AQP2
Sei Sasaki,1,2 Masaki Sakai,2 Hiroki Mizumura,2 Tomoki Matsumoto,2 
Yumi Noda,1 Naofumi Yui,1 Kenichi Ishibashi.2 1Tokyo Medical and Dental 
University, Bunkyo-ku, Japan; 2Meiji Pharmaceutical University, Tokyo, Japan.
Background: AQP2 a key membrane protein which determines water permeability 
of collecting ducts. AQP2 is regulated by phosphorylation at S256, S261 and S269. As 
a short-term regulation of vasopressin, intracellular amount S261 phosphorylated-AQP2 
(261-P) decreases whereas 269-P increases with relatively stable 256-P. The decrease in 
261-P can be explained by dephosphorylation, degradation, or even extrusion out of the cell.
In this sence, it is intriguing whether phoshorylation is involved in the urinary excretion of 
exosomal AQP2 and if so, which phosphorylation site is critical.
Methods: Human urine samples were obtained from a central diabetes insipidus patient 
(CDI, 45 years old, female). DDAVP 0.25ug was administered to the nasal mucosa after 
24 h withdrawal. Urine samples were collected pre and after the administration until 3 h. 
Urine exosomes were obtained by the differential centrifugation, and analyzed by Western 
blot using a usual and 256-P, 261-P and 269-P-specific antibodies. Endogenously AQP2-
expressing cells (mpkCCD) and stably rat AQP2-transfected MDCK cells (AQP2-MDCK) 
were cultured on the permeable support and the culture medium in the apical side were 
analyzed
Results: 1) In a CDI patient, DDAVP administration evoked a steady increase in 
urine osmolality until 3 h. Western blots of urine exosomal AQP2 excretion corrected for 
creatinine showed that total AQP2 rapidly increased until 1 h (8.5 times compared to the 
pre), then gradually increased until 3 h. 256-P progressively increased until 3 h. On the other 
hand, 261-P reached its peak increase at 0.5 h (2.4 times), and then, surprisingly decreased 
to the pre level at 2 h. 269-P was hardly visible throughout the study periods. 2) Western 
blots of apical culture medium of mpkCCD and AQP2-MDCK after vasopressin/forskolin 
stimulation, total, 256-P and 261-P were observed, but 269-P was minimally visible, 
although all these phosphorylated forms were observed in the cell lysates. 3) The LC-MS/
MS phosphoproteomic analysis of human urine confirmed the presence of phosphorylation 
at S256 and S261, but not at S269.
Conclusions: These results indicate the importance of phoshorylation at S261 and 
dephoshphorylation at S269 in exosomal excretion of AQP2, highlighting the significant 
role of the endocytosis-exosome pathway in AQP2 metabolism in collecting ducts.
Funding: Government Support - Non-U.S.
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Level of ENaC Activity Drives Hypertension from Chronic Activation of 
Vasopressin V2 Receptors
Alan C. Pao,1,2 Hong Xiang,1 Elena V. Mironova,3 Susan B. Gurley,4 
Mohammed Z. Ferdaus,4 James A. McCormick,4 James D. Stockand.3 1Stanford 
University, Palo Alto, CA; 2Veterans Affairs Palo Alto Health Care System, Palo 
Alto, CA; 3University of Texas Health Science Center at San Antonio, San 
Antonio, TX; 4Oregon Health & Science University, Portland, OR.
Background: Vasopressin can contribute to sodium homeostasis and blood pressure 
regulation by stimulating the epithelial sodium channel (ENaC) through activation of 
vasopressin V2 receptors (V2R) in principal cells of the distal nephron. However, a direct 
link between chronic activation of V2R, high ENaC activity, and high blood pressure 
remains to be established in vivo.
Methods: We asked whether an isolated increase in V2R-mediated ENaC activity can 
lead to high blood pressure. We tested the blood pressure effects of chronic activation of 
V2R in mice with varying levels of ENaC activity. We infused dDAVP (100 ng/hr), a specific 
V2R agonist, for two weeks into Liddle (beta-ENaC-R566X), Pseudohypoaldosteronism 
Type 1 (PHA) mice, or wild type (WT) littermates and used radiotelemetry to compare 
blood pressure responses. We fed all mice normal sodium chow because they have similar 
blood pressures at this level of dietary sodium.
Results: We found that infusion of dDAVP into WT mice increased baseline blood 
pressure (systolic (SBP) by 4.3±0.47 mmHg and mean arterial pressure (MAP) by 
3.7±0.45 mmHg, P<0.05); infusion of dDAVP into Liddle mice increased baseline blood 
pressure to a greater extent (SBP increase by 7.3±1.16 mmHg and MAP increase by 
7.0 mmHg±1.57, P<0.05). Infusion of dDAVP into PHA1 mice induced no rise in baseline 
blood pressure. Blood pressure was highest in dDAVP-infused Liddle mice compared to 
dDAVP-infused WT or PHA mice (SBP 146±5.75 mmHg (Liddle) vs 135 or 137 mmHg; 
MAP 127±4.16 mmHg (Liddle) vs 119 or 120 mmHg). We also found that administration 
of benzamil, a specific ENaC inhibitor, only restored blood pressures of dDAVP-infused 
Liddle mice (SBP decrease by 4.86±1.31 mmHg and MAP decrease by 4.9±1.21 mmHg, 
P<0.05).
Conclusions: Our findings demonstrate that a specific increase in V2R-mediated 
ENaC activity in Liddle mice is sufficient to raise blood pressure. Since infusion of dDAVP 
can raise blood pressure in Liddle mice, our findings also suggest that the Liddle (beta-
ENaC-R566X) mutation and V2R can stimulate ENaC through distinct pathways. Finally, 
since V2R-mediated increase in blood pressure in WT mice is not sensitive to benzamil 
inhibition, chronic activation of V2R is also sufficient to raise blood pressure through 
ENaC-independent pathways.
Funding: NIDDK Support
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Loss-of-Function Mutation in the Epithelial Na+ Channel Alpha Subunit 
Reduces Salt/Aldosterone-Induced Hypertension in Mice
Shaohu Sheng,1 Evan C. Ray,2 Stephanie Mutchler,1 Jingxin Chen,1 
Allison L. Marciszyn,1 Xueqi Wang,1 Thomas R. Kleyman.1 1Medicine, 
University of Pittsburgh, Pittsburgh, PA; 2UPMC, Pittsburgh, PA.
Background: Epithelial Na+ channels (ENaC) have an important role in regulating 
blood pressure and extracellular [K+]. We previously identified a point mutation in mouse 
ENaC alpha subunit (H283R) that significantly enhanced Na+ self-inhibition, reflecting a 
reduced open probability specifically due to extracellular Na+. Its homologous human variant 
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(H255R) has similar effects. In this study, we investigated whether the loss-of-function 
mutation H283R would protect mice from salt and aldosterone-induced hypertension.
Methods: H283R was introduced into the exon 2 of gene Scnn1a (encoding alpha 
ENaC) in C57/BL6J mice using CRISPR/Cas9-mediated gene editing method. Six 
homozygous H283R mice and six littermates were implanted with radio telemeters to record 
blood pressure, heart rate and activity level. Following seven days recording under normal 
salt (0.5% NaCl) diet, mice were fed with a high salt (4% NaCl) diet and implanted with 
minipumps for aldosterone infusion. Data recording continued for four additional weeks.
Results: There were no significant differences in pulse, systolic, diastolic and mean 
arterial pressures, heart rates, activity and blood electrolytes under normal Na+ diet 
conditions, except for a modest difference in blood [Na+]. Blood pressures displayed normal 
diurnal variation. Blood pressures gradually increased in all mice after switching to high 
salt diet plus aldosterone infusion. However, H283R mice displayed significantly lower 
systolic, diastolic and mean arterial pressures than wild type mice on multiple days (p < 
0.05). Both day and night blood pressures showed significant differences between the two 
groups. Heart rate and activity were similar in the two groups. Plasma aldosterone levels 
measured at the end of the experiment were not significantly different. We did not observe 
significant differences in Na+ and K+ concentrations in blood and urine samples in these 
mice.
Conclusions: The Na+ self-inhibition enhancing mutation H283R in ENaC alpha 
subunit protects mice from high salt and aldosterone-induced hypertension. Our 
observations suggest that certain loss-of-function human ENaC variants like H255R may 
protect individuals from the development of salt-sensitive hypertension.
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Interleukin 6 plus High Salt Increases Functional Epithelial Sodium 
Channel Activity
Brandi M. Wynne,1 Vadym Buncha,2 Alena Cherezova,2 Cameron G. McCarthy,3 
Gillian G. Hecht,4 Camilla F. Wenceslau,5 Robert S. Hoover,4 Mykola Mamenko.3 
1Emory University School of Medicine, Atlanta, GA; 2Medical College of 
Georgia, Augusta University, Augusta, GA; 3Augusta University, Augusta, GA; 
4Emory University, Atlanta, GA; 5The University of Toledo, Toledo, OH.
Background: Hypertension (HTN) is characterized by increased sodium (Na+) 
reabsorption, and increased cytokines such as interleukin 6 (IL6). Our data suggests that 
IL6 infusion increases blood pressure (BP) and distal nephron Na+ transporter expression/
activity, with an early reduction in urinary Na+ excretion (UNa). However, whether this 
reduction in UNa is mediated by epithelial sodium channel (ENaC) activity is unknown. We 
hypothesize that IL6 increases ENaC activity.
Methods: Mice were treated with IL-6 (16ng/hr, 0.1%BSA) or vehicle via osmotic 
minipump, and fed high salt (HS, 4%) diet for 1 or 3 days (1D, 3D). ENaC open probability 
(Po), functional expression (fN) and functional activity (fNPo) were assessed in split open 
tubules (cortical collecting duct, CCD) from IL6-treated (IL6+HS) and vehicle (HS) mice. 
Data are expressed as mean±SEM, where SEM is patch number in at least 3 mice per group.
Results: We observed a trending increase in ENaC fN in CCD from IL6+HS after only 
1D, reaching significance by 3D (0.94±0.14, n=44 vs.0.63±0.08, n=63, p<0.05), compared 
to HS only. Although open probability (Po) was not increased, fNPo was almost doubled 
in IL6+HS treated mice after 1D (0.24±0.08, n=51 vs. 0.12±0.04, n=62), and significantly 
increased after 3D (0.28±0.07, n=44 vs. 0.13±0.04, n=63, p<0.05).
Conclusions: Here, we show that increased IL6 causes trending increases in ENaC fN 
and fNPo, after only 1D. These data correlate with our data showing UNa is reduced in the 
first 24 hours. Continued IL6+HS treatment significantly increased both fN and fNPo by 
day 3, also correlating with increases in ENaCα/γ expression and BP (by D3). We later see 
increased UNa, indicating pressure natriuresis. These data suggest that, remarkably, IL6 may 
activate distal nephron Na+reabsorption, even with increased dietary salt. These data reveal 
a novel role for IL6-mediated changes in UNa excretion, leading to salt-sensitive HTN.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
Figure 1. Representative continuous current traces from cell-attached patches in CCD.
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Role for Collecting-Duct ET-1 in the Response to High-Salt Diet plus 
Mineralocorticoid Treatment
Michelle L. Gumz,1 Lauren G. Douma,1 I. Jeanette Lynch,1 Kit-yan Cheng,1 
Meaghan R. Holzworth,1 Dominique H. Barral,1 Sarah H. Masten,1 
Charles S. Wingo.1,2 1University of Florida, Gainesville, FL; 2Research, NF/SG 
VHS, Gainesville, FL.
Background: Mice lacking the circadian clock protein Per1 exhibit a reduced night:day 
ratio in urinary Na excretion during the acute response to a high salt (HS, 4% NaCl) diet plus 
mineralocorticoid (DOCP) treatment. New results indicate that 24 hr urinary Endothelin-1 
(ET-1) peptide is increased in male kidney-specific Per1 KO mice compared to control mice 
under these conditions. ET-1 is a known circadian clock target gene. These data led us to 
hypothesize that ET-1 action is important for maintaining the normal night:day ratio in renal 
Na excretion in response to HS/DOCP.
Methods: We generated renal collecting duct-specific ET-1 KO mice using Aqp2-
Cre. Male CD ET-1 KO (n=5) mice and age-matched littermate controls (WT)(n=6) were 
acclimated to metabolic cages. Urine collections (24 hr) were made over 3 days of control 
diet and 3 days of HS. Mice were then treated with 75 μg/g BW DOCP. Urine collections 
(12 hr) were made for 3 days of HS/DOCP. Cumulative Na balance was calculated. 
Genotype effects were assessed during the HS and HS/DOCP interval using linear 
regression. Genotype and treatment effects were assessed by 2-way repeated measured 
ANOVA. Night:day urine Na excretion ratios were compared by t-test.
Results: Contrary to our hypothesis, CD-specific KO of ET-1 did not alter the night:day 
ratio in urine Na excretion in response to HS/DOCP (KO 5.6±1.4, WT 3.8±0.7, p=>0.05). 
The rate of increase in cumulative Na balance was significantly greater in CD ET-1 KO 
mice vs. WT.
Conclusions: Under the conditions tested, CD ET-1 does not appear to be necessary 
to maintain night:day differences in urinary Na handling. However, consistent with the 
known natriuretic role for ET-1 in the CD, CD ET-1 mice do retain significantly more Na in 
response to HS/DOCP compared to WT. These data demonstrate that CD ET-1 is necessary 
for the natriuretic response to a high salt diet plus mineralocorticoid.
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Detection of Na+ Stores in the Myocardium and Skeletal Muscle of DOCA 
Treated Mice Using 23Na-MRI
Anke Dahlmann,1 Peter Linz,2 Stojan Perisic,4 Jonas Tschesche,5 Armin M. Nagel,7 
Jens Titze,3 Tobias Bäuerle,6 Christoph Kopp.1 1Dept. of Nephrology and 
Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, 
Germany; 2Institute of Radiology, Friedrich-Alexander-University Erlangen-
Nürnberg, Erlangen, Germany; 3Duke - National University of Singapore, 
Singapore, Singapore; 4Max Planck Institute for medical research, Stuttgart, 
Germany; 5Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, 
Germany; 6Institute of Radiology, Friedrich-Alexander-University Erlangen-
Nürnberg, Erlangen, Germany; 7Institute of Radiology, Friedrich-Alexander-
University Erlangen-Nürnberg, Erlangen, Germany.
Background: Disturbances in Na+ homeostasis with accumulation of Na+ in tissue are 
present in salt sensitive hypertension. Tissue Na+ distribution could be recently visualized in 
vivo by 23Na-MRI. If Na+ accumulation occurs also in organs of the cardiovascular system 
is unknown. We hypothesized that the myocardium is able to absorb significant amounts of 
Na+ that could be detected by 23Na-MRI.
Methods: DOCA-pellets were implanted in 10 male FVB mice while a sham 
procedure was performed on 10 FVB mice. Subsequently, both groups received 1% NaCl 
water for 2 weeks. 23Na-MRI at 7Tesla was used to quantify Na+ in heart and skeletal 
muscle. Furthermore, electrolytes were determined chemically in both tissues. In a fraction 
of mice intracellular Na+ of the myocardium was measured by electron beam microscopy. 
Echocardiography was performed and blood pressure determined.
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Results: Compared to control mice DOCA treated mice showed a significantly 
higher Na+ content in skeletal muscle (27.0 ± 5.7 vs. 46.6 ± 8.9 mmol/l, p<0.001) and 
in heart muscle (61.6 ± 9.1 vs. 73.7 ± 11.7, p<0.05, figure 1). The fraction of bound Na+ 
was increased in DOCA skeletal muscle (6.4 ± 0.8 vs. 13.0 ± 4.3 a.u., p<0.05) suggesting 
intracellular Na+ accumulation. Electron beam microscopy of heart muscle also detected 
a higher intracellular Na+ amount in DOCA animals compared to controls (0.12 ± 0.03 
(n=4) vs. 0.29 ± 0.01 a.u. (n=3), p<0.001). Chemical electrolyte analysis confirmed Na+ 
accumulation in both tissues. A reduced ejection fraction (74 ± 4 vs. 46 ± 15%, p<0.05) and 
hypertension was found in DOCA animals.
Conclusions: Na+ accumulation occurs intracellularly in skeletal muscle and in heart 
muscle in vivo upon DOCA salt treatment indicating Na+ uptake rather than extracellular 
accumulation. Increased Na+ content of the myocardium might directly contribute to cardiac 
dysfunction.
Funding: Government Support - Non-U.S.
Figure 1, representative MR images.
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Response of WNK-1 Intercalated Cell (IC) Knock-out Mice to a High  
K+ Diet
Evan C. Ray,1 Rolando Carrisoza-Gaytan,2 Allison L. Marciszyn,3 
Lubika J. Nkashama,3 Jingxin Chen,3 Aaliyah Winfrey,3 Daniel Flores,2 
Peng Wu,4 WenHui Wang,4 Chou-Long Huang,5 Donald E. Kohan,6 
Arohan R. Subramanya,7 Lisa M. Satlin,2 Thomas R. Kleyman.3 1Internal 
Medicine - Renal Electrolyte, University of Pittsburgh, Pittsburgh, PA; 2Icahn 
School of Medicine at Mount Sinai, New York, NY; 3University of Pittsburgh, 
Pittsburgh, PA; 4New York Medical College, Valhalla, NY; 5University of Iowa 
Carver College of Medicine, Iowa City, IA; 6University of Utah Health Sciences 
Center, Salt Lake City, UT; 7University of Pittsburgh School of Medicine, 
Pittsburgh, PA.
Background: In the cortical collecting duct (CCD), IC BK channels mediate flow-
induced K+ secretion (FIKS) and contribute to the renal adaptation to dietary K+ intake. 
IC BK channel apical expression and activity are enhanced by a high K+ diet. In HEK 
cells, L-WNK1 also stimulates BK channel expression and activity. The observation that 
L-WNK1 expression is enhanced in the CCD of rabbits on a high K+ (HK) diet suggests 
that L-WNK1 contributes to modulation of the BK channel by dietary K+. We asked 
whether IC L-WNK1 expression is necessary for enhanced BK activity and renal adaptation 
to a HK diet.
Methods: We generated mice with IC-specific deletion of L-WNK1 (IC-WNK1-KO) 
by crossing floxed L-WNK1 mice with V-ATPase Cre mice. KO and floxed control mice 
were placed on a HK diet for 10 days to maximally stimulate BK channel expression.
Results: Perforated whole-cell recordings of ICs in CCDs from IC-WNK1-KO mice 
revealed significant reduction in charybdotoxin (CbTX)-sensitive K+ currents vs. controls 
(440 +/- 64 pA vs. 703 +/- 92 pA, respectively; N = 4 and 4; p =0.003). IC-WNK1-KO 
mice also exhibited higher blood [K+] vs. controls (5.6 +/- 1.0 vs. 5.0 +/- 0.9 mEq/L; 
N = 21 and 19; p = 0.048). Despite the increased blood [K+] in the IC-WNK1-KO mice, 
urinary K+ excretion in response to an intra-peritoneal bolus of 10% vol/wt 0.9% saline was 
similar in KOs and controls (4.5 +/- 9.0 vs. 4.6 +/- 7.0 mcmol/hr/g; N = 9 and 7).
Conclusions: The observations that IC-WNK1-KO mice have higher blood [K+] and 
reduced CbTX-sensitive currents in CCD ICs indicate that these mice have a defect in 
urinary K+ secretion, highlighting the importance of L-WNK1 in ICs for adaptation to a HK 
diet. The retained capacity for K secretion in response to a saline load suggests upregulation 
of other K+ secretory processes.
Funding: NIDDK Support
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Novel KLHL3-Binding Motif of WNK4 and Its Potential Role in Familiar 
Hyperkalemic Hypertension
Lingyun Wang, Ji-Bin Peng. Divison of Nephrology, Department of Medicine, 
Nephrology Research and Training Center, University of Alabama at 
Birmingham, Birmingham, AL.
Background: Gene mutations in with-no-lysine [K] kinase 4 (WNK4), and in kelch 
like 3 (KLHL3), have been found in patients with familiar hyperkalemic hypertension 
(FHHt, also known as pseudohypoaldosteronism type 2, PHAII). The level of WNK4 
protein is controlled by KLHL3, which is the substrate adaptor in the cullin-RING ubiquitin 
E3 ligase complex for the degradation of WNK4. Mutations in either the acidic motif of 
WNK4 or the Kelch domain of KLHL3 impair their binding and raise the protein level of 
WNK4. The increased WNK4 protein abundance and total kinase activity stimulates the 
activity of sodium-chloride cotransporters (NCC) via SPAK/OSR1, and ultimately results 
in FHHt. Currently the acidic motif in WNK4 is recognized as the only binding motif for 
KLHL3. Our aim of this study is to determine whether additional KLHL3 binding site exists 
in WNK4, if so, whether it is relevant to FHHt.
Methods: WNK4 deletion constructs and KLHL3 FHHt mutants were made by PCR-
based mutagenesis approaches. The constructs were expressed in Xenopus laevis oocytes. 
Western blotting and GST pull-down approaches were used to evaluate the interaction and 
degradation of WNK4 constructs.
Results: In addition to the region containing acidic motif, the WNK4 C-terminal region 
(amino-acids 1046-1243) was capable of pulling down KLHL3, indicating that there is a 
new KLHL3-binding motif in this region. Using deletion constructs, the new binding motif 
was narrowed down to a 30 amino-acid stretch (amino-acids 1051-1080). WNK4 lacking 
either the acidic motif or the novel motif was rapidly degraded in the presence of KLHL3; 
however, WNK4 protein was stable when both motifs were deleted. Similar to the acidic 
motif, the new motif is also rich in Asp/Glu residues. Since the Kelch domain of KLHL3 has 
a positive surface electrostatic potential, similar to the acidic motif, the negatively charged 
residues in the new motif are likely important for the electrostatic interactions. Indeed, 
FHHt mutations in the Kelch domain of KLHL3 impaired the degradation of WNK4 
lacking the acidic motif, and this effect was more pronounced for the FHHt mutations at the 
surface of the Kelch domain.
Conclusions: A new KLHL3-binding motif was identified in the C-terminal region of 
WNK4. The new motif is likely involved in the pathogenesis of FHHt.
Funding: NIDDK Support
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WNK1 and WNK4 Form Heteromultimer to Regulate NCC In Vivo
Jian Xie,1 Yih-sheng Yang,2 Chou-Long Huang.1 1University of Iowa Carver College 
of Medicine, Iowa City, IA; 2UT Southwestern Medical Center, Dallas, TX.
Background: Sodium reabsorption via the sodium-chloride cotransporter (NCC) in 
distal convoluted tubule (DCT) plays an important role in total body sodium homeostasis. 
In vitro, with-no-lysine (WNK) kinases WNK1 and WNK4 both activate NCC through 
intermediate STE20/SPS1-related proline- and alanine-rich kinase (SPAK) and related 
oxidative stress-responsive 1 (OSR1). It has been reported that WNK1 and 4 interact in 
vitro. Yet, it is believed that in vivo WNK4 is the main regulator of NCC, in part based 
on findings that Wnk4-null mice have a nearly complete loss of NCC activity. In addition, 
WNK4 is essential for stimulation of NCC by low dietary potassium intake through 
lowering the intracellular chloride concentration. The role of WNK1 in the regulation of 
NCC in vivo remains poorly understood.
Methods: Global Wnk1-null mice are embryonic lethal, due to loss of WNK1-OSR1/
SPAK signaling in the vascular endothelium. To study the role of WNK1 in kidney, we 
generated a mouse model that expresses constitutive-active SPAK in a variety of tissues 
including vascular endothelium, but with virtually no expression in the kidney. This 
approach creates a viable mouse model with functionally kidney Wnk1-null.
Results: Kidney Wnk1-null mice exhibit renal sodium wasting and little NCC activity 
compared to wildtype mice as assayed by thiazide-sensitive urinary Na excretion and 
phospho-NCC western blotting. Reciprocal co-immunoprecipitation experiments reveal 
that WNK1 and WNK4 form complexes in the kidney. Wnk4-null mice have minimal NCC 
activity and NCC activity is not stimulated by low dietary potassium intake. Unlike that in 
Wnk4-null mice, low dietary potassium intake stimulates NCC activity in kidney Wnk1-
null mice.
Conclusions: Our results provide evidence supporting the notion that WNK1 and 
WNK4 form heteromultimers in vivo to regulate NCC. WNK4 is more sensitive than 
WNK1 to inhibition by intracellular chloride.
Funding: NIDDK Support
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WNK1-SPAK-NCC Signaling Cascade Is Involved in Salt Sensitive 
Hypertension Induced by Aristolochic Acid Nephropathy
Taisuke Furusho, Eisei Sohara, Shintaro Mandai, Hiroaki Kikuchi, 
Fumiaki Ando, Moko Zeniya, Takayasu Mori, Naohiro Nomura, Tatemitsu Rai, 
Shinichi Uchida. Department of Nephrology, Graduate School of Medical and 
Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Background: Increased salt sensitivity is one of the major reasons for resistant 
hypertension in chronic kidney disease (CKD). Recent evidence suggests that not only 
reduced glomerular filtration but also aberrant sodium handling in renal tubules contribute 
to salt sensitivity. We previously demonstrated with-no-lysine kinase (WNK) - oxidative 
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stress-responsive gene 1 (OSR1)/Ste20-related proline-alanine-rich kinase (SPAK) - NaCl 
cotransporter (NCC) signaling cascade is essential for sodium handling in the distal nephron 
and its inappropriate activation leads to salt sensitive hypertension. However, WNK 
signaling in CKD has not been evaluated. In the present study, we investigated the role of 
WNK signaling in the development of salt sensitive hypertension induced by aristolochic 
acid nephropathy (AAN).
Methods: C57BL6/J or SPAK-/-mice were administered aristolochic acid I (AA-I) 
intraperitoneally twice a week for 6 weeks followed by 6 week disease development time. 
After the treatment, sodium transporter protein expression was assessed and the effect of 
high salt diet (HSD) on blood pressure was examined.
Results: AAN mice showed salt sensitive hypertension (systolic blood pressure 
after HSD, mean±SE: 112.5±2.6 mmHg in AAN and 102±1.0 mmHg in control, p<0.05, 
unpaired t test). In the AAN model, protein levels of WNK1, phosphorylated SPAK and 
phosphorylated NCC were significantly increased. Immunofluorescent study revealed 
increased expression of WNK1 and phosphorylated SPAK at distal convoluted tubules. 
Even after mice were fed a HSD, expression level of WNK signal remained increased. 
Increased phosphorylation of NCC was not observed in AA-I treated SPAK-/-mice, 
indicating NCC was activated through WNK1-SPAK phosphorylation cascade. As tumor 
necrosis factor α (TNFα) mRNA expression level was elevated in AAN mice kidney, we 
next evaluated the effect of TNFα on WNK signaling. We found that increased expression 
of WNK1, phosphorylated SPAK and phosphorylated NCC were attenuated in AAN mice 
treated with TNFα inhibitor etanercept.
Conclusions: NCC is activated through WNK1-SPAK signaling cascade in AAN 
mice and could contribute to salt sensitive hypertension. TNFα is involved in WNK signal 
activation induced by AAN.
Funding: Government Support - Non-U.S.
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Vacuolated Podocytopathy: A Novel Injury with the Use of BRAF 
Inhibitors
Sarthak Virmani,1 Anushree C. Shirali.2 1Yale School of Medicine, New Haven, 
CT; 2Yale University, New Haven, CT.
Introduction: With expanded use of BRAF inhibitors, nephrotoxicities including acute 
interstitial nephritis (AIN) and nephrotic syndrome (NS) have been described in recent 
literature. We present a novel case of vacuolated podocytopathy with sub-nephrotic range 
proteinuria associated with BRAF inhibition.
Case Description: A 64-year-old woman with non-small-cell lung cancer on dual 
BRAF/MEK inhibition with Vemurafenib and Trametinib, was referred for AKI evaluation. 
Her serum creatinine (SCr) was 2.1 mg/dL, increased from 1.0 mg/dL 2 months prior. Urine 
protein/creatinine ratio was between 0.4 – 0.7. Urinalysis was otherwise non-contributory. 
BRAF inhibition was held due to presumed AIN, but renal function only improved to 1.4 mg/
dL. Treatment was restarted due to lack of therapy options with increase in SCr to 2.0 mg/
dL. A renal biopsy was performed for definitive diagnosis. Pathology surprisingly showed a 
minimal interstitial infiltrate but extensive podocyte injury with cytoplasmic vacuolization 
and nearly global foot process effacement (FPE) was seen on electron microscopy. Given 
stable renal function, treatment was continued. Her SCr remained around 2.0-2.2 mg/dL and 
proteinuria remained < 1g until her death from septic shock few months later.
Discussion: BRAF inhibitors are linked with AIN and NS with diffuse FPE. We 
describe a novel finding of podocyte vacuolization and FPE with sub-nephrotic proteinuria. 
We recommend renal biopsy for patients on BRAF inhibitors with AKI of undetermined 
etiology to allow precise identification of the renal lesion. Our patient continued on BRAF 
inhibitors with stable CKD and proteinuria, suggesting that drug withdrawal is not necessary 
for all patients, particularly those with limited treatment options.
EM with podocyte vacuolization (arrow) and FPE
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LECT2 Amyloidosis in a Pediatric Renal Allograft
Eliah Shamir, Marsha May Lee, Vighnesh Walavalkar. UC San Francisco 
Medical Center, San Francisco, CA.
Introduction: LECT2 amyloidosis is a common form of systemic amyloidosis. We 
present, to our knowledge, the first case of ALECT2 in a pediatric renal allograft.
Case Description: A 19 y/o Hispanic male with ESRD from posterior urethral valves, 
s/p living unrelated kidney transplant (2002, age 4), presented with a sCr of 2.4mg/dl 
(baseline 1.9mg/dl) and 3.6g/day proteinuria. He received daclizumab induction and was 
maintained on tacrolimus/MMF/sirolimus/prednisone. Past history was notable for episodes 
of ACR and C4d+AMR treated with thymoglobulin, IVIg, OKT3 and rituximab; de-novo 
C1q nephropathy; and ultimately transplant-glomerulopathy. Current biopsy showed 
Type1B ACR and chronic active AMR (C4d+). During low power ultrastructural analysis, 
unusual electron-lucent material was noticed in interstitial areas. Closer examination 
revealed disorganized fibrils measuring 8-12nm in diameter. Subsequent Congo Red 
staining confirmed scant interstitial amyloid deposits. Routine amyloid typing stains were 
negative, therefore mass spectrometry was performed, confirming ALECT2. Treatment 
with thymoglobulin, IVIg and rituximab stabilized the sCr at 1.9mg/dl. Follow-up biopsy 
showed resolution of the ACR. No further treatment changes were made. At last follow-up 
renal function was stable.
Discussion: ALECT2 is more common in elder Hispanic patients. ALECT2 can occur 
as a de-novo or recurrent process in renal transplants. Here we hypothesize that chronic 
inflammation from repeated episodes of rejection coupled with ethnic predilection resulted 
in ALECT2. Unexplained proteinuria in Hispanic patients and unusual patterns of amyloid 
distribution are clues to the diagnosis of ALECT. Detailed ultrastructural analysis could 
help to discover small amounts of amyloid not discernable by light microsopy. Mass 
spectrometry helps in cases that cannot be classified by stains. Awareness of ALECT2 in 
young patients is important due to prognostic implications and recurrence in subsequent 
allografts. There is no treatment for ALECT2.
Congo Red
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Leukocyte Chemotactic Factor 2 Amyloidosis with Concurrent Post-Infec-
tious Glomerulonephritis and Diabetic Nephropathy
Jessica Cruz Whitley, Vishwa C. Sheth, Kuang-Yu Jen, Jose A. Morfin, 
Niti Madan. University of California, Davis, Sacramento, CA.
Introduction: Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a form 
of amyloidosis that manifests with progressive renal failure. Biopsies typically exhibit 
congophilic deposits that are most prominent in the interstitium. ALECT2 is the third most 
common form of amyloidosis with strong ethnic bias, affecting mainly Hispanics with 
chronic renal insufficiency. Significant proteinuria is rarely associated with ALECT2 unless 
a second concurrent glomerulopathy is present. We report a case of ALECT2 with nephrotic 
syndrome due to concurrent post-infectious glomerulonephritis and diabetic nephropathy.
Case Description: A 50-year-old Hispanic female with no significant medical history 
admitted for anasarca, was found to have bilateral pleural effusions and newly diagnosed 
type 2 diabetes mellitus. Laboratory values were significant for HgbA1c of 13.2%, normal 
renal function, albumin of 2.5 g/dL and 4.5 grams of proteinuria. Serological workup 
showed positive ANA with decreased C3 and C4. HIV, hepatitis, SPEP and serum free 
light chains were negative. Although diabetic nephropathy (DN) can cause nephrotic range 
proteinuria, it rarely presents with nephrotic syndrome. Thus, renal biopsy was performed 
which showed multiple glomerular abnormalities including glomerulonephritis (GN) with 
dominant C3 staining along with predominat mesangial deposits and nodular diabetic 
glomerulosclerosis. Congo red was performed which showed scattered positive staining 
in the interstitium, consistent with amyloid. Mass spectroscopy further characterized the 
amyloid type as ALECT2. The patient was discharged with insulin therapy and started on an 
ACE-inhibitor. The differential diagnosis for her C3-dominant GN included post-infectious 
GN and C3 GN. At 6 weeks clinic follow up, her C3 level normalized favoring the diagnosis 
of post-infectious GN.
Discussion: ALECT2 is one of the more recently recognized amyloid proteins to affect 
the kidney and fairly prevalent however it is still under recognized. Concurrent glomerular 
disease is not uncommon in patients with ALECT2, with DN being most frequent. 
Coexistence of three disease processes (post-infectious GN, DN and ALECT2) makes our 
case exceptional. This case also illustrates the significance of renal biopsy in patients with 
atypical presentations of common renal diseases.
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Fibrillary GN vs Amyloidosis on Renal Biopsy: Dilemma on How to Treat
Pulkit Gandhi,1 Jie Tang.2 1Brown University, Providence, RI; 2University 
Medicine; Brown University, West Roxbury, MA.
Introduction: Glomerular disease may be associated with fibrillary deposits on 
glomerular basement membrane or mesangium. Frequently there is a clear distinction 
between Amyloidosis and non-amyloid fibrillary deposits based on the fibril size on electron 
microscopy and reaction to Congo red stain. But occasionally we see overlapping patterns. 
Here we present a unique case of glomerular deposition disease with an overlapping pattern, 
where the kidney biopsy showed Congo red positivity, but the fibril sizes were larger than 
as expected in amyloidosis. Patient presented with acute kidney injury (AKI) and clinical 
evidence of glomerulonephritis (GN).
Case Description: A 58 y/o male with medical history of hepatitis C status post 
treatment with Harvoni in 2015 with negative viral PCR (9/2016), well controlled type 
2 DM (HbA1C 5.2), well controlled HTN, Chronic kidney disease stage III A presented 
as an outpatient consult for worsening serum creatinine. The serum creatinine rose from a 
baseline of 1.1 mg/dl to 3.2mg/dl in a period of 3 months. 24hr urine showed significant 
proteinuria measured at 2682 mg. His urine sediment showed microscopic hematuria, but 
no dysmorphic features. Serologic studies showed elevated kappa/lambda ratio at 2.52 but 
normal serum and urine protein electrophoresis, normal C3 and C4 complement levels, 
and negative anti neutrophil cytoplasmic antibody. Patient underwent renal biopsy, which 
showed glomerulopathy - mesangioproliferative pattern, with mesangial and subendothelial 
fibrillary deposits. The fibrils measured 14.8 nm in diameter, and these deposits were congo 
red positive, and were reactive for IgG (predominant IgG4) and C3. The stain for protein A 
was negative. In addition, there were advanced chronic changes noted in the parenchyma, 
including global and segmental glomerulosclerosis (52% of glomeruli) and significant 
tubulointerstital fibrosis (60% of the cortex). Considering atypical findings on renal 
biopsy and underlying significant tubulointerstitial fibrosis, we decided to treat him with 
mycophenolate and prednisone instead of more aggressive chemotherapy for amyloidosis. 
He responded well as his serum creatinine trended down from 3.2 mg/dl to 1.5 mg /dl in 
6 months.
Discussion: We believe this is the first case of glomerular deposition disease with 
overlapping features of amyloidosis and fibrillary GN, who responded well to a rather 
conservative regimen of MMF with steroid.
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Unwanted Deposits: A Rare Cause of AA Amyloidosis
Romin Bonakdar, Srikar Kumar, Mona Shaban, Volker Nickeleit. The University 
of North Carolina at Chapel Hill, Chapel Hill, NC.
Introduction: Amyloidosis is a disorder resulting from pathologic deposition of protein 
subunits in multiple organ systems, often including the kidneys. It is divided into two major 
subgroups: AL amyloidosis due to overproliferation of light chains from a monoclonal 
plasma cell population, and AA amyloidosis resulting from chronic inflammatory states 
including a variety of autoimmune diseases, infections, and malignancies. Identification of 
the associated disorder can direct therapy to minimize further organ damage. We describe a 
case of AA amyloidosis secondary to Castleman’s disease (CD).
Case Description: A 37 year old woman with a history of anemia was referred to clinic 
for nephrotic-range proteinuria. Laboratory evaluation showed a urine protein:creatinine 
of 10.3, a serum creatinine of 0.83 mg/dL and albumin of 2 g/dL. A kidney biopsy 
showed glomerular amyloid deposits. Serum protein electrophoresis and serum free 
immunoglobulins did not show evidence of a monoclonal gammopathy. Evaluation 
for secondary causes of AA amyloidosis was notable for a 5 cm pararenal mass and 
abnormal lymph nodes on PET scan. A biopsy of the mass revealed lymph node tissue 
with amyloid deposits and morphologic features consistent with CD. HHV-8 and HIV 
testing were negative. She was started on siltuximab, a monoclonal interleukin-6 (IL-6) 
antibody, with reduction in her urine protein:creatinine to 2.1, improvement in albumin to 3 
g/dL and an increase in her hemoglobin from 6.2 g/dL to 15.6 g/dL.
Discussion: Amyloidosis carries tremendous morbidity to affected individuals with 
limited, non-curative therapy available. Identification of the patient’s CD as the underlying 
trigger of her AA amyloidosis allowed for directed treatment that resulted in dramatic 
improvement in her proteinuria and resolution of her anemia. Excess IL-6 is hypothesized 
to play a role in CD, particularly HIV and HHV-8 negative cases. This case provides 
additional support for the role of IL-6 inhibitors in the treatment of idiopathic CD.
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Amyloid Nephropathy in the Setting of Rosai-Dorfman Disease
Maria Joana A. Thomas,1 Kuang-Yu Jen,2 Burl R. Don,3 Brian Y. Young.4 
1University of California Davis Medical Center, Sacramento, CA; 2University of 
California, Davis, Sacramento, CA; 3University of California Medical Center, 
Sacramento, CA; 4UC Davis Medical Center, Sacramento, CA.
Introduction: Rosai-Dorfman disease is a non-neoplastic histiocytic disorder 
characterized by massive lymphadenopathy secondary to infiltration and dilation of 
the lymph node sinuses by large histiocytes. Massive cervical lymphadenopathy is the 
hallmark, but extranodal involvement has been described in 43% of cases. It can affect most 
organs, with about 4% of cases affecting the kidneys.
Case Description: A 64-year-old Hispanic man with diabetes mellitus and hypertension 
was diagnosed with Rosai-Dorfman disease 9 years ago. He was treated initially with 
surgical debulking, rituximab, cyclophosphamide, vincristine and prednisone. Rituximab 
was used intermittently since, with the last dose given 4 years ago. On current presentation, 
he has dysphagia and progressive cervical, hilar, mediastinal and retroperitoneal 
lymphadenopathy. Creatinine was elevated at 2 mg/dL from a baseline of 1.17 mg/dL. 
Imaging and urological studies showed no evidence of obstruction. Diagnostic work-up 
revealed dysmorphic RBCs, proteinuria of 14 g/day, hypocomplementemia, and positive 
ANA and anti-RNP70. Hepatitis panel, HIV, PR3, and MPO were negative. There was an 
abnormal monoclonal protein in the gamma region but kappa/lambda ratio was normal. He 
was empirically treated with rituximab (375mg/m2 weekly for 4 doses) and dexamethasone 
40 mg daily for disease recurrence. However, the kidney function continued to deteriorate, 
so a kidney biopsy was performed. Widespread amyloid was noted predominantly in the 
interstitium, with only focal glomerular and vascular involvement. Immunofluorescence 
showed weak IgG without light chain restriction and corresponded to scattered subepithelial 
immune deposits.
Discussion: There have been few reports of amyloidosis with Rosai-Dorfman Disease, 
one with generalized AA amyloidosis. We postulate that cytokine production by histiocytic 
cells, subsequently induced synthesis of precursor proteins facilitating amyloidogenesis 
in this patient. Amyloid can be found anywhere in the kidney, but glomerular deposition 
typically predominates in most forms. This report highlights a rare association of this 
histiocytic disorder and renal amyloidosis, predominantly with interstitial deposition.
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Apolipoprotein A-IV Amyloidosis: An Unusual Cause of Renal Amyloido-
sis and CKD
Sadaf N. Sheikh,1 Tingting Li,2 Ryan A. Kunjal.3 WashU, Nephrology 
1Washington university St Louis MO, Valley Park, MO; 2Washington University 
in St. Louis, Saint Louis, MO; 3Washington University, St Louis, MO.
Introduction: Apolipoprotein A-IV associated amyloidosis (AApoAIV amyloidosis) 
is a rare cause of amyloidosis with only few reported cases in the literature. Renal 
AApoAIV amyloidosis histologically exhibits medullary involvement with sparing of the 
cortex. The diagnosis of renal AApoAIV amyloidosis requires a high degree of suspicion 
and examination of the renal medulla on renal biopsy. The definitive diagnosis is best 
established by mass spectrometry. Here we present two patients with renal AApoAIV 
amyloidosis.
Case Description: Case 1 Fifty-three-year-old white male with past medical history of 
well-controlled type 1 diabetes mellitus and hypertension presented with a 10-year history 
of slowly declining renal function (Serum creatinine 1.1 mg/dl 10 years ago and 1.7 mg/
dl in 2018). Urinalysis was unremarkable and 24-hour urine collection showed 240 mg of 
protein. He was found to have a positive serum immunofixation with IgA kappa monoclonal 
protein and was diagnosed with IgA kappa smoldering myeloma by bone marrow biopsy. 
Subsequent renal biopsy showed multifocal, medullary deposition of amyloid of amyloid 
material. No similar deposits were seen within the renal cortex. Mass spectrometry 
surprisingly identified apolipoprotein A-IV amyloid deposition and no peptides were 
identified for any other types of amyloid. The smoldering myeloma was thought to be 
unrelated to the amyloid. Case2 Sixty-Eight-year-old white female has had stage 3 CKD 
since 2009, when her serum creatinine was 1.4. Creatinine increased to 1.6 in 2016 and she 
underwent renal biopsy which showed a focal area of amyloid deposits in the medulla. Mass 
spectrometry identified the amyloid as Apolipoprotein A-IV. The patient’s renal function 
has remained stable over the last 2 years. Neither patient had extra-renal manifestations of 
amyloidosis or family history of amyloidosis.
Discussion: Apolipoprotein A-IV amyloidosis is a rare type of amyloidosis that seems 
to have a predilection for the kidney and is limited to the renal medulla. The limitations 
of the amyloid to the medulla correlates with the clinical findings of slow decline of renal 
function, unremarkable urinalysis, and no significant proteinuria. The pathogenesis of 
apolipoprotein A-IV amyloid formation is unknown. There are no known treatment options 
at this time and management is conservative.
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Podocytic Infolding Glomerulopathy in a Patient with Systemic Lupus 
Erythematous
Alice Chedid, Mohamad A. Hanouneh, Blaithin A. McMahon. Johns Hopkins 
University School of Medicine, Division of Nehrology, Baltimore, MD.
Introduction: Podocytic infolding glomerulopathy (PIG) has been proposed as a new 
disease entity. This is first case of PIG reported in a woman patient of African American 
ancestry. Five case reports of PIG complicated by focal segmental glomerulosclerosis 
(FSGS).
Case Description: A 35-year-old African American woman with a history of systemic 
lupus erythematous and autoimmune enteritic ganglionitis presents with new acute 
kidney injury with serum creatinine 1.6 mg/dL (baseline 0.8 mg/dL) and nephrotic range 
proteinuria. Urinalysis was positive for 3 red blood cells, 5 white blood cells per high power 
field and no red blood cell casts. Urine protein/creatinine ratio was 19 g/g. C3 and C4 
levels were 90 and 30 mg/dL, respectively. Anti-DNA screen, anti-PLA2 receptor antibody, 
HIV and hepatitis panel was negative. Renal sonogram showed normal sized kidneys with 
minimally increased echogenicity and unchanged mild bilateral hydronephrosis. Kidney 
biopsy demonstrated significant FSGS with collapsing features. Under periodic acid 
methenamine silver (PAMS) staining, the glomeruli had a diffuse moth-eaten appearance 
along glomerular capillary loops (Figure A). On ultrastructural examination there were 
numerous electron dense intramembranous membrane bound structures and microspheres 
entrapped in the glomerular basement membrane (GBM) of capillary loops (Figure B and 
Inset) consistent with PIG. Despite treatment with various immunosuppressive therapies the 
patient still progressed to end stage renal disease.
Discussion: In PIG, microspheres or microtubular structures, or both, are associated 
with the infolding of cytoplasmic processes of podocytes into the GBM as a consequence 
of capillary wall remodeling. The mechanism of PIG is unknown and has been reported in 
predominantly in Asian and in the setting of connective tissue diseases.
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Collagen Glomerulopathy – A Rare Entity
Kothai divya Guruswamy sangameswaran, Krishna M. Baradhi. OU Tulsa OU 
-Tulsa School of Community Medicine, Tulsa, OK.
Introduction: Collagen glomerulopathy (CG) is a rare, non-immunoglobulin
deposition disease of unknown etiology, first reported by Arakawa et al in 1979. CG is 
characterized by agglomeration of atypical type III collagen fibrils in mesangial matrix and 
subendothelial space. CG is a rare entity, with most of the cases reported from Japan. We 
describe one such rare case of CG seen in a pediatric patient and emphasize its clinical
significance.
Case Description: A 7-year-old Hispanic girl presented with intermittent hematuria
and foamy urine since few weeks. She had no family history of renal disease. Patient
was normotensive with mild pedal edema and specifically no nail or patellar dysplasia. 
Labs revealed serum creatinine of 0.44 mg/dl, albumin of 3.3 g/dl, hyperlipidemia and
normal complement levels. Urinalysis confirmed hematuria with 2.6 gm of proteinuria on 
quantification. Renal ultrasound was unremarkable. A diagnostic renal biopsy conducted 
revealed widespread foot process effacement and nodular mesangial deposits suggestive of 
collagen III glomerulopathy. She was managed conservatively with angiotensin converting 
enzyme inhibitors with partial remission of proteinuria.
Discussion: Type III collagen is a structural protein that is normally absent in the
glomerulus. Abnormal accumulation of type III collagen in the mesangium and sub-
endothelial space leads to proteinuria. Electron microscopy showing mesangial deposits of 
large (43-65 nm) whorled fibrils is essential for definitive diagnosis. This is distinguished 
from nail-patella syndrome by the absence of collagen III accumulation in lamina densa
of basement membranes. CG typically presents with hypertension, edema, proteinuria
and progressive kidney disease. Familial occurrence with autosomal recessive inheritance
has been described. The etiopathogenesis remains elusive, but is associated with factor
H deficiency and Hemolytic uremic syndrome. Supportive therapy with control of 
hypertension and edema is recommended. Role of corticosteroids is unclear. Among patients 
who received a transplant, none have shown disease recurrence. Our case represents only
the second case of CG published from the US. Clinicians should be cognizant of this rare
entity and differentiate it from other fibrillary disorders as treatment is supportive rather 
than the toxic immunosuppressive therapy.
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A Case of Sporadic Glomerulopathy with Fibronectin Deposits with a 
Mutation in FN1
Hideo Misawa,1 Tetsuro Takeda,1 Yoshihiko Ueda.2 1Dokkyo Medical University 
Saitama Medical Center, Koshigaya, Japan; 2Saitama Medical Center,
Koshigaya, Japan.
Introduction: Glomerulopathy with fibronectin deposits (GFND) is a rare renal disease 
with massive mesangial, and subendothelial fibronectin deposits. It presents proteinuria, 
often in the nephrotic range in the third to fourth decade, and slow progression to end-stage 
renal disease. Here we describe a case with GFND from a genetic mutation.
Case Description: A 52-year-old lady presented with edema and 2-year-history 
of hypertension. Since 6 years ago, mild proteinuria and microscopic hematuria have 
been detected by regular health check-up. Family history was negative for any kidney 
diseases. She was diagnosed as having nephrotic syndrome (massive proteinuria, 
7.7 g/gCr, hypoalbuminemia, 2.6 g/dl, normal level of creatinine of 0.42 mg/dl). A renal 
biopsy showed lobular appearance and membranoproliferative glomerulonephritis-like 
lesions on light microscopy. Electron microscopy revealed homogeneous granular fine 
fibers. In a case with micro-fibrillar deposits in glomeruli, it is necessary to rule out an 
amyloidosis and a glomerulopathy derived from immunoglobulins. In this case, Direct Fast 
Scarlet staining and immunofluorescence were all negative. Following the above results, we 
suspected her of GFND. Next, we carried out mass spectrometry to identify the origin of 
deposits in laser micro-dissected glomeruli. Majority of detected proteins was fibronectin. 
Furthermore, immunohistochemistry of the fibronectin showed intense staining in the 
mesangium and subendothelium. Thus, she was diagnosed as having GFND. We performed 
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genetic analysis to identify mutations of fibronectin 1 gene (FN1) and found heterozygous 
deletional mutation (p.Pro1472del).
Discussion: Clinically, it has been difficult to identify the origin of glomerular 
deposition especially in a case with micro-fibrillar deposits. However, laser micro-
dissection and mass spectrometry could accurately identify the major protein of deposits, 
leading to a diagnosis with GFND. GFND is a rare inherited autosomal dominant disease 
and 60% of the cases have mutations in the FN1. Recently, 11 pathogenic variations (10 
exonic and one intonic) in the FN1 have been reported. In exonic variants, only one is 
in the integrin-binding domain, the others are in the heparin-binding domain. In this case 
we detected deletional mutation in the integrin-binding domain (p.Pro1472del) which was 
consistent with those reported by others.
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A Unique Case of Lipoprotein Glomerulopathy
Kishore Patcha, Josephine Abraham, Mossab Aljuaid, Sarah Gilligan, 
Divya Raghavan, Laith Al-Rabadi. University of Utah Hospital, Salt Lake, UT.
Introduction: Lipoprotein Glomerulopathy has recently been recognized as a unique 
type of glomerular injury characterized by lipid accumulation in the glomerular capillaries. 
It has been mainly reported in Asian patients, and linked with rare APOE gene mutations 
resulting in a structurally abnormal Apolipoprotein E (ApoE).
Case Description: A 47-year-old Filipino male presented to the renal clinic with 
nephrotic-range proteinuria. Past Medical history was significant for hypertension treated 
with irbesartan and carvedilol. Physical exam was unremarkable. Labs showed serum 
creatinine of 1.47mg/dl (unclear baseline). Urine microscopy revealed several red blood 
cells. Urine protein to creatinine ratio was 5.1 g/g with a urine albumin to creatinine 
ratio of 3.7 g/g. Renal Ultrasound was unremarkable. Further workup, including ANA, 
ANCA, HIV, Anti-GBM antibody, serum and urine protein electrophoresis, was negative. 
Hemoglobin A1C was 5.1. Total cholesterol was 221mg/dL with triglycerides of 180 mg/dL, 
HDL cholesterol of 55mg/dL, VLDL cholesterol of 36mg/dL and LDL cholesterol of 
142mg/dL. Patient underwent kidney biopsy for definitive diagnosis. Light microscopy 
showed 32 glomeruli, many with dilated capillary lumina filled with very pale, mesh-like 
lipoprotein “thrombi”. Five glomeruli were globally sclerosed. Oil red O stain highlighted 
glomerular capillary lumina thrombi. There was evidence of focal areas of interstitial 
fibrosis and mononuclear inflammatory infiltration. Immunofluorescence did not reveal 
any immune-complex deposits. Electron microscopy showed remodeling of the glomerular 
basement membranes and capillary loops were distended and occluded by lipid-like 
material containing vacuoles of different sizes and with lamellation. His genetic testing 
showed both APOE alleles to be E3.
Discussion: Approximately 95% of individuals with type III hyperlipoproteinemia 
have the E2/E2 genotype. The remainder have rare mutations in one copy of the APOE 
gene some of which are not detectable by the APOE genotype test. Lipoprotein thrombi 
in the glomerulus should prompt consideration for Lipoprotein glomerulopathy. Based on 
clinical information and renal biopsy results, this patient has lipoprotein glomerulopathy in 
the absence of APOE E2/E2 genotype.
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A Case of Successful Treatment of Collapsing FSGS Secondary to 
Parvovirus B19
Fatima Sheikh,1 Vanesa Bijol,2 Daniel W. Ross.2 1Northwell, New Hyde Park, 
NY; 2Northwell Health Hofstra University, Lake Success, NY.
Introduction: Parvovirus B19 is a rare cause of collapsing glomerulopathy. The 
clinical course of collapsing glomerulopathy is characterized by proteinuria and progressive 
renal failure. This case discusses the first immunocompetent patient with biopsy proven 
collapsing glomerulopathy secondary to Parvovirus B19 successfully treated with 
Intravenous Immunoglobulin (IVIG).
Case Description: A 38 year old African American man presented to our ED with 
three days of fatigue, poor appetite, fever, chills, night sweats, and joint pain with swelling. 
At time of our evaluation his vital signs were within normal limits and physical exam 
was unremarkable. Laboratory data upon admission was notable for elevated creatinine 
(1.6mg/dL) and proteinuria (7.2 g/g). The patient’s IgG, IgM and PCR for Parvovirus were 
positive. Kidney biopsy revealed collapsing glomerulopathy with acute tubular injury 
and minimal interstitial fibrosis. The patient’s PCR titer was elevated to 542,000 IU/ml 
on hospital day 5. Intravenous immunoglobulin (IVIg) was started on day 6 at a dose 
of 400 mg/kg/day for a total dose of 150 grams over five days. On day 8, his repeat 
parvovirus PCR began to trend down. The patient’s creatinine peaked at 2.29 mg/dL 
on hospital day 6 however then it began to trend down with treatment as well. The patient 
was discharged in stable condition on hospital day 11. Three weeks after discharge 
all his symptoms had abated and his serum creatinine improved to 1.38 mg/dL with 
proteinuria of 1.1g/g. Patient’s parvovirus PCR titer notably decreased to 3,400 IU/ml 
with this treatment.
Discussion: Collapsing glomerulopathy is prevalaent in patients with human 
immunodeficiency virus (HIV) and more recently, there have been several cases showing 
an association with Parvovirus B19. Optimal treatment for Parvovirus associated collapsing 
glomerulopathy is unknown. We were able to diagnose Parvovirus B19 early by elevated 
viral PCR and initiated treatment for our patient quickly preventing further progressive renal 
damage. In addition to strict blood pressure control, the patient was treated with IVIG at a 
dose of 400mg/kg for five days. The patient was not placed on any corticosteriod therapy. 
The patient’s Parvovirus viral PCR, serum creatinine and proteinuria trended downward. 
This is the first patient with successful corticosteriod-free treatment of parvovirus induced 
FSGS with intravenous immunoglobulin.
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A Unique Treatment Strategy in Collapsing Glomerulopathy in a Native 
Kidney
Fatima Sheikh,1 Sherry Shariatmadar,2 Vanesa Bijol,3 Kenar D. Jhaveri.1 
1Nephrology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY; 
2Blood Bank, Zucker School of Medicine at Hofstra Northwell, Manhasset, NY; 
3Pathology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY.
Introduction: Collapsing glomerulopathy (CGP) is a fast progressive glomerular 
disease. We present a unique case of CGP in a native kidney that responded to multi-drug 
therapy, which included therapeutic plasma exchange (TPE) leading to complete remission.
Case Description: A 62 year old Indian male presented in June 2017 with AKI (2.65 
mg/dl), and nephrotic syndrome (5.6g/24hours). His initial presentation prompted a kidney 
biopsy which revealed CGP with minimal fibrosis. The patient was started on steroid 
therapy and ARB therapy. The patient however continued to progress and tacrolimus was 
added to the regimen. His proteinuria worsened to 32.5g. The patient was subsequently re-
biopsied. The biopsy revealed CGP with minimal IFTA. All of his secondary work-up for 
autoimmune, viral and cancer causes was negative. A combination therapy approach was 
used and the patient was then initiated on TPE, MMF and continued to tacrolimus (Figure). 
Steroids were tapered off. Interestingly, with only a few sessions of TPE, his proteinuria 
improved to <3gm. When TPE was halted, proteinuria returned. This prompted re-initiation 
of TPE. The patient subsequently had a progressive decrease in proteinuria down to <2gm 
over 2-3 months. He was maintained on MMF and tacrolimus. In an attempt to come off 
TPE, he was given a dose of rituximab 1gm and then started on supplemental powder of 
galactose 0.2 g/kg orally two times per day. After 2 months of therapy he is off TPE and his 
creatinine stable at 1.2mg/dl with 0.3g proteinuria.
Discussion: This case report suggests that administration of a multimodality approach 
as used in kidney transplant patients with recurrent CGP might be useful in native kidney 
idiopathic CGP. This novel case report findings support the performance of randomized 
clinical trials to assess the efficacy of the use of multi-modal approach to idiopathic CGP.
Proteinuria trend with reference to various treatments used
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Adrenocorticotropic Hormone (ACTH) in the Treatment of Refractory 
Childhood Nephrotic Syndrome (NS)
Amirtha Chinnadurai, Julie Goodwin. Yale University School of Medicine, New 
Haven, CT.
Introduction: Treatment resistance or failure to respond to conventional therapies in 
NS is associated with poor prognosis. ACTH is recognized as therapy for podocytopathies, 
though these data are based on small observational studies in adults. There are no published 
data on the use of ACTH therapy in the pediatric population. We report a case of steroid-
resistant NS in a 10 year-old boy who failed multiple secondary therapies but showed a 
partial response to ACTH injection (ACTHAR) therapy.
Case Description: A 10-year-old Hispanic boy who was diagnosed with NS at 
the age of 2. He was initially steroid sensitive but frequently relapsing. Cyclosporine A 
(CsA) was initiated as a steroid-sparing agent and he achieved a 5-year period of stability. 
However, he eventually began to relapse while on CsA. Tacrolimus and mycophenolate 
mofetil (MMF) were also ineffective. During this time he became steroid resistant. Triple 
therapy with steroids, tacrolimus and MMF was unable to induce even a partial remission. 
A renal biopsy showed early focal segmental glomerulosclerosis (FSGS). Whole exome 
sequencing showed only a heterozygous variant in PLCE1. He became dependent on twice 
weekly albumin infusions due to anasarca and persistent hypoalbuminemia (less than 1.2g/
dl). Urine protein/creatinine (UPC) ratios were persistently in the nephrotic range. Over 18 
months he persisted in uncontrolled relapse, complicated with 5 episodes of acute kidney 
injury. His creatinine plateaued at 0.7-0.8 mg/dl, whereas in remission it had been 0.3-
0.4 mg/dL. We initiated ACTHAR as a last resort given concerns for progressive renal 
impairment. Initial therapeutic response was minimal with dose of 40 units biweekly. 
After increment to 80 units biweekly, he demonstrated significant improvement. His serum 
creatinine improved to his baseline of 0.30 mg/dl and UPCs decreased by more than 50%. 
Serum albumin improved spontaneously to 1.9-2.0g/dl, resulting in discontinuation of 
scheduled albumin infusions.
Trainee Case Reports - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
256
J Am Soc Nephrol 29: 2018 Poster/Thursday
Discussion: This case highlights that ACTHAR may be a viable therapeutic alternative 
for children who are resistant to other therapies for NS. Additionally, the role of his PLCE1 
mutation is unclear but we suspect a compound heterozygous state for another unidentified 
pathogenic mutation and/or epigenetic modifications may be playing a role in his refractory 
NS.
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Treatment of Nephrotic-Range Proteinuria with Tacrolimus in  
Mitochondrial Trifunctional Protein Deficiency
Hostensia M. Beng, Asha Moudgil, Sun-Young Ahn. Nephrology, Children’s 
National Health System and The George Washington University, Washington, DC.
Introduction: Mitochondrial trifunctional protein (MTP) deficiency is a rare autosomal 
recessive disorder of long-chain fatty acid oxidation that leads to lactic acidosis, recurrent 
rhabdomyolysis, cardiomyopathy, and hepatic dysfunction.
Case Description: A 7-month old girl, with known MTP deficiency, presented with 
poor oral intake and lethargy. Laboratory analysis revealed a low corrected serum calcium 
level of 6.6 mg/dl, elevated CK level of 14,080 U/L, and nephrotic range proteinuria with a 
urine protein to creatinine ratio (uPCR) of 7.6 mg/mg. Serum albumin was low at 2.8 g/dl and 
urine beta-2-microglobulin was mildly elevated at 556 mcg/g creatinine (nl <300 mcg/g). 
The patient was treated for primary hypoparathyroidism and rhabdomyolysis, known 
complications of MTP deficiency. Despite resolution of her rhabdomyolysis, she continued 
to have nephrotic range proteinuria and underwent a renal biopsy that demonstrated 
minimal change disease and foot process fusion. She was started on tacrolimus and her 
uPCR gradually normalized 8 months after treatment. She has continued to have normal 
renal function and uPCR values at the time of this report (2 years of age). The patient has an 
older sister with the same heterozygous deletion in the HADHB gene (c.1059delT), which 
is predicted to cause truncation and loss of long-chain-3-hydroxyacyl CoA dehydrogenase 
function, leading to MTP deficiency. This sister was diagnosed with nephrotic syndrome 
and focal segmental glomerulosclerosis at 18 months of age, and developed end stage renal 
disease at 20 months of age.
Discussion: Renal involvement has been reported in only 1 patient with MTP deficiency 
to date, the sister of our patient. The pathogenesis of proteinuria in the 2 siblings remains 
elusive. Given that other mitochondrial disorders, such as coenzyme Q10 deficiency, 
have been associated with nephrotic syndrome, the proteinuria may be related to their 
mitochondrial dysfunction. Calcineurin inhibitors have been reported to reduce proteinuria 
by stabilizing the podocyte actin cytoskeleton. Tacrolimus was an effective treatment for our 
patient, who has maintained normal renal function, unlike her sister. Further investigation 
will be needed to determine the role of calcineurin inhibitors in the treatment of nephrotic 
syndrome associated with mitochondrial disorders.
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Hepatitis B and C Dual Infection and Collapsing Glomerulopathy: Report 
of a Rare Association
Flor Espinoza, Marjan Afrouzian, Tunde O. Omitogun, Hania Kassem. 
University of Texas Medical Branch, Galveston, TX.
Introduction: Collapsing Glomerulopathy (CG) is marked by severe hypertension and 
proteinuria, poor response to corticosteroids, and a rapid progression to end-stage renal 
disease. Many viral illnesses, including HIV, have been implicated in the pathogenesis 
of this disease. However, the association between CG and Hepatitis C virus (HCV) or 
Hepatitis B virus (HBV) remains less clear.
Case Description: A 55 y/o man with a history of HTN, Hepatitis B and C, and liver 
cirrhosis presented with altered mental status. He was hemodynamically stable, however, 
had significant laboratory derangements including a Cr of 19 mg/dl (recent baseline was 
0.9), K of 7.3, CO2 11, and pH of 7.14. His lactic acid, coagulation panel and bilirubin levels 
were within normal limits. Urine microscopy showed muddy brown casts and no hematuria. 
He was also found to have nephrotic range proteinuria. HIV and Parvovirus B19 IgM 
antibodies were negative. Dialysis had to be initiated for uremia, hyperkalemia and acidemia. 
By light microscopy, the renal biopsy showed segmental glomerulosclerosis in 10/17 viable 
glomeruli with 3 glomeruli showing a collapsing pattern and podocyte hyperplasia. Severe 
interstitial fibrosis and tubular atrophy (IFTA) was noted. Immunofluorescence and electron 
microscopy showed tubulo-reticular inclusions (TRIs) within the endothelial cytoplasm. 
Patient’s mental status, electrolytes and acidemia improved with dialysis. However, he 
remained dialysis dependent and given the severity of his kidney disease on presentation 
and the degree of IFTA, renal injury was deemed unlikely to recover.
Discussion: The uncommon association of CG and HCV infection in HIV-negative 
patients has been reported, mainly in patients treated with interferon. There has been 
only one reported case of CG associated with HBV infection. As our patient was HIV-
negative and was not treated with interferon, the occurrence of CG was attributed to his dual 
infection with HBV and HCV, especially since TRIs were found on electron microscopy. It 
is possible that a synergistic action during this dual infection led to the development of CG, 
a glomerular lesion that rarely occurs with either viral infection alone. This case highlights 
the need for further research to elucidate the pathogenetic role HBV and HCV may play in 
the development of CG.
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An Infantile Nephrotic Syndrome Case Caused by COQ6 Gene Defects 
Revealed by Pair Analysis and Custom Array CGH
Keita Nakanishi,2 Kandai Nozu,2 Takayuki Okamoto,6 Asako Hayashi,6 
Toshiyuki Takahashi,6 Nana Sakakibara,2 China Nagano,2 Junya Fujimura,2 
Tomoko Horinouchi,2 Shogo Minamikawa,1 Tomohiko Yamamura,2 
Hiroshi Kaito,5 Yuko Shima,3 Koichi Nakanishi,4 Kazumoto Iijima.2 1Kobe 
University Graduate School of Medicine, Kobe, Japan; 2Department of 
Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan, Kobe, 
Japan; 3Wakayama Medical University, Wakayama City, Japan; 4Child Health 
and Welfare (Pediatrics), Graduate School of Medicine, University of the 
Ryukyus, Nishihara-cho, Japan; 5Nephrology, Hyogo Prefectural Kobe 
Children’s Hospital, Kobe, Japan; 6Hokkaido University Graduate School of 
Medicine, Sapporo, Japan.
Introduction: Comprehensive genetic analysis using next-generation sequencer 
(NGS) of causative genes for steroid resistant nephrotic syndrome (SRNS) have been 
established all over the world currently. It enables us to treat some kinds of monogenic 
SRNS patients with specific therapies and improve the renal prognosis; Coenzyme Q10 
(CoQ10) supplementation for patients with CoQ10 deficiency related gene variants, such 
as COQ6, PDSS2, COQ2, and ADCK4. In this study, we conducted NGS analysis for the 
infantile SRNS patient, and to detect a copy number variation (CNV), we performed NGS 
data-based pair analysis and custom array CGH.
Case Description: Patient was a 1-year-old boy. He was diagnosed with SRNS 
and performed a renal biopsy. Electron microscopic examination revealed abnormal 
mitochondria (dysmorphic mitochondria, lacking cristae or abnormal proliferation) in 
podocytes. We conducted targeted panel sequencing analysis using NGS and detected only 
one COQ6 monoallelic reported variant on maternal allele (c.782C>T, p.Pro261Leu). Next, 
we conducted CNV analysis with pair analysis using the NGS analysis data and custom 
array CGH. Both analysis successfully detected the same copy number changes in exons 
1–2 of the COQ6 gene on paternal allele. He was thus started supplementation of CoQ10, 
and remission was achieved.
Discussion: Comprehensive gene screening system with NGS were effective method 
to detect causative gene variants in SRNS. In addition, conducting pair analysis and custom 
array CGH were remarkably useful to detect CNVs. Specific therapy of CoQ10 for the 
patient carrying COQ6 mutations was very effective when it was started in the early stages, 
so try not to miss the opportunity for the cases with CoQ10 glomerulopathies starting 
supplementation.
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Identification of Novel Mutations and Phenotype in the Steroid Resistant 
Nephrotic Syndrome Gene NUP93
Ibrahim Sandokji,1 Jonathan Marquez,2 Weizhen Ji,2 Monica Konstantino,2 
Saquib Lakhani,2 Mustafa Khokha,2 Jillian K. Warejko.1 1Department of 
Pediatrics, Section of Nephrology, Yale University School of Medicine, New 
Haven, CT; 2Department of Pediatrics, Pediatric Genomics Discovery Program, 
Yale University School of Medicine, New Haven, CT.
Introduction: In 11-30% of steroid-resistant nephrotic syndrome (SRNS), a known 
gene mutation can be detected. NUP93 is a widely expressed gene that encodes a highly 
conserved nuclear pore protein that has been shown to cause non-syndromic autosomal 
recessive focal segmental glomerulosclerosis (FSGS). Here we describe a case of novel 
NUP93 mutations in a child with a syndromic SRNS phenotype.
Case Description: We identified compound heterozygous mutations of NUP93 gene 
using whole exome sequencing (WES) in a patient presented with syndromic SRNS 
and progressed to ESRD in her first decade of life. An African American and Hispanic 
5-year-old girl presented with nephrotic syndrome, including nephrotic-range proteinuria
(UPC of >29 mg/mg), edema, and hypoalbuminemia. She was clinically fluid overloaded, 
hypertensive, and quickly became anuric and required renal replacement therapy. She had 
signs of chronic kidney disease including hyperparathyroidism, anemia, and short stature.
A urinalysis 1 year prior showed 3+ proteinuria that was not quantified. In addition to her 
kidney involvement, she had developmental delay with autistic features; including delays
in expressive language, fine motor, social communication and repetitive hand movements. 
Additionally, she had two episodes of heart failure requiring inotropic support after having 
adequate dialysis for more than a month. Her echo showed systolic and diastolic dysfunction 
(ejection fraction as low as 35%) and dilated cardiomyopathy features of unclear etiology
that did improve with aggressive nutritional support and blood pressure management.
Discussion: We detected compound heterozygous mutations in NUP93 a maternal 
missense mutation (ch16:56855426 A>G) c.206A>G, p.Y69C and a paternal nonsense 
mutation (ch16:56868107 C>G) c.1236C>G, p.Y412X. The mutations were highly 
conserved through phylogeny and had high pathogenicity prediction scores. We describe 
in this case novel mutations in the SRNS gene NUP93 resulting in a syndromic phenotype 
with neurologic and cardiac features. It remains unclear the degree to which NUP93 
contributed to her cardiomyopathy, as this gene has also been described as localizing to cilia 
as well as the nucleoporin. WES is the ideal test for patients with SRNS as a conclusive 
molecular diagnosis does influence therapeutic choices.
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Trainee Case Reports - I
A Patient with PLA2R Membranous Nephropathy and “Non-Depletion” 
After Rituximab
Wael A. Hanna,1 Margaret Duffy,2 Mohammad N. Saqib.2 1Lehigh Valley 
Hospital, Breinigsville, PA; 2Valley Kidney specialists, Allentown, PA.
Introduction: Rituximab failure in patients with membranous nephropathy with 
nephrotic syndrome has been described in the literature. We present a case of PLA2R 
membranous nephropathy who progressed immunologically and did not show evidence of 
B cell depletion despite use of rituximab.
Case Description: A 62 year-old man with history of hyperlipidemia and hypertension 
presented with sudden onset lower extremity edema. Labs revealed sCr 1.1 mg/dL, albumin 
2.9 g/dL, total cholesterol 235 mg/dL, triglycerides 116 mg/dL, and LDL 132 mg/dL. He 
had 12.5 grams of protein/24 hour urine collection. ANA, C3, C4, hepatitis panel, serum 
and urine electrophoresis were all negative/ unremarkable. A renal biopsy was performed 
which revealed membranous nephropathy that stained positive for PLA2R. Proteinuria and 
renal function deteriorated despite maximal ARB therapy for >3 months. He was given 
rituximab infusion 1 g IV every 2 weeks x 2 doses in November 2017. PLA2R antibody 
titers, CD19 count, sAlb, and sCr were obtained after 2, 4, and 5 months from rituximab 
therapy as shown in Table 1. Unfortunately given the extent of immunologic progression, 
we considered treatment failure in this patient and decided against additional rituximab 
infusions.
Discussion: We present a case with a rare and relatively severe phenotype of PLA2R 
membranous nephropathy who did not show evidence of B cell depletion and had persistent 
PLA2R titer progression despite treatment with rituximab. In patients PLA2R membranous 
nephropathy with nephrotic phenotypes, the use of immunologic biomarkers to ascertain 
early response is critical in deciding whether to continue or to consider alternative 
treatments. Novel therapeutic targets such as newer generation anti-CD 20 agents (ie 
ofatumumab) and plasma cell targets may be helpful in patients with relapsing or rituximab 
resistant disease. Furthermore, additional biomarkers (eg long-lived plasma cell markers, 
CD38 and CD138) may be useful while assessing response.
Table 1
TH-PO536 Poster Thursday
Trainee Case Reports - I
A Case of Anti-PLA2R Antibody Positive Membranous Nephropathy 
Diagnosed in Pregnancy with Antibody Transfer to Infant
Kelly H. Beers, Niralee Patel, Amanda Dijanic, Shuchita Sharma. Nephrology, 
Icahn School of Medicine at Mt. Sinai, New York, NY.
Introduction: Phospholipase A2 receptor (PLA2R) antibody is a pathogenic agent 
found in 70-80% of patients with primary membranous nephropathy (MN). Whether 
anti-PLA2R Ab is transmitted from maternal to fetal circulation remains unknown. We 
report a case of nephrotic syndrome during pregnancy with elevated anti-PLA2R Ab 
level in maternal serum, and subsequent detection of high levels of antibody in the infant, 
suggesting that anti-PLA2R Ab likely crosses the placenta.
Case Description: A 33 year old woman was transferred to our medical center at 
28 weeks of gestation for ongoing management of pregnancy complicated by nephrotic 
syndrome. The patient had been diagnosed with the nephrotic syndrome at approximately 
16 weeks of gestation based on edema, hypoalbuminemia (0.9g/dL), and 6g of protein on 
24 hour urine collection. She had no known history of kidney disease. On arrival to our 
institution, serum creatinine (Cr) was at her baseline of 0.6 mg/dL with albumin 0.4g/dL. 
Anti-PLA2R Ab levels were found to be elevated at 479.6 RU/mL. A presumptive 
diagnosis of primary MN was made and renal biopsy was deferred due to her advanced 
gestation. Pt remained in the hospital for the duration of her pregnancy and underwent 
successful diuresis documented by 80 pound weight loss and significant improvement in 
her edema. She had successful delivery of a male baby at 34 weeks 3 days of gestation. 
24 hour urine collection from the patient immediately following delivery showed 12g 
proteinuria. Cr remained stable throughout the admission. Anti-PLA2R Ab was measured 
in both mother and baby immediately post-delivery with values of 405.1 and 43.1 RU/mL, 
respectively.
Discussion: This case suggests that anti-PLA2R Ab crosses the placenta to reach fetal 
circulation. Whether this results in renal disease in the baby is unclear, though there are case 
reports of fetal morbidity associated with maternal neutral endopeptidase deficiency leading 
to congenital membranous nephropathy. Children of mothers with primary MN during 
pregnancy should be monitored pre- and post-natally for signs of renal disease mediated 
by Anti-PLA2R Ab.
TH-PO537 Poster Thursday
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PLA2R-AB Positive Malignancy-Associated Membranous Nephropathy: 
A Case Report
Amr Habbach,1 Avi Z. Rosenberg,2 Marco Delsante,3 Blaithin A. McMahon.1 
1Johns Hopkins Hospital, Baltimore, MD; 2Johns Hopkins University, Baltimore, 
MD; 3Universita’ degli Studi di Parma, Baltimore, MD.
Introduction: Membranous nephropathy (MN) is the most common cause of nephrotic 
syndrome in adults and the most frequent paraneoplastic glomerular disease associated 
with solid tumors. MN is either idiopathic (iMN) or secondary to malignancy (M-MN), 
infections, autoimmune diseases or drugs. Features such as the presence of the M-type 
Phospholipase A2 Receptor (PLA2R) antibodies and IgG subclass have been suggested to 
help distinguish idiopathic from secondary MN. However, 15-17% of cases of M-MN are 
anti PLA2R antibody positive, raising question about the specificity of these antibodies for 
the diagnosis of iMN. This is of importance as the treatment of this disease centers upon 
whether the disease is determined to be primary or secondary.
Case Description: We present here a case of a 78-year-old African female with 
pancreatic adenocarcinoma who was referred for lower extremity swelling and evaluation 
for proteinuria. A 24hr urine collection demonstrated 8.3 g of proteinuria and serum albumin 
of 1.3 g/dl. Her glomerular filtration rate was estimated to be 96 ml/min per 1.73/m2. 
Monoclonal gammopathy was not detected. Serum anti-PLA2R Antibodies were severely 
elevated, greater than 1500 RU/ml. A kidney biopsy revealed a prominent glomerular 
basement membrane and subepithelial deposits on electron microscopy. Anti-PLA2R AB 
was strongly positive on immunofluorescence. Features of paraneoplastic glomerulopathy 
were also present (near full-house pattern on IF, Kappa chain co-dominance, equivalent 
IgG4, IgG1 and IgG3 isotypes). The patient was empirically started on high dose 
corticosteroids given the preliminary result of proliferative glomerular disease and a near 
full-house pattern. She received capecitabine and radiotherapy with significant reduction in 
tumor size. Repeat Anti-PLA2R AB titers was 4 RU/ml
Discussion: This case highlights the complexity in trying to identify iMN from M-MN 
and the challenges facing the nephrologist in the treatment of this disease. The normalization 
of Anti-PLA2R AB in the setting of treating her malignancy suggests direct involvement 
of Anti-PLA2R AB in the mechanism of M-MN. Future studies are needed to evaluate the 
importance of anti PLA2R Antibodies in M-MN
TH-PO538 Poster Thursday
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THSD7A Associated Membranous Glomerulonephritis Due to Antibody 
Produced by Lymph Node around Metastasis of the Thymoma
Wei Han,1 Tomo Suzuki,1 Shiika Watanabe,1 Mayumi Nakata,1 Daisuke Ichikawa,1 
Atsuko Ikemori,2 Junki Koike,3 Yugo Shibagaki.1 1Nephrology, St.Marianna 
university school of medicine, Kawasaki, Japan; 2St. Marianna University 
School, Kawasaki, Kanagawa, Japan; 3St.Marianna University, Kawasaki, 
Japan.
Introduction: Membranous glomerulonephritis (MGN) are known to be associated 
with malignant tumor and tumor resection can lead to remission of MGN. MGN 
with thrombospondin type-1 domain-containing 7A (THSD7A), which is one of the 
transmembrane protein antigen to podocyte, have been recently reported to be also 
associated to malignancy. We present a first case of THSD7A-associated MGN with 
thymoma that was later diagnosed with lymphatic metastasis.
Case Description: A 61-year-old woman with past medical history of asthma was 
referred to our clinic for bilateral edema in lower extremities and proteinuria. Her labs 
showed nephrotic syndrome and kidney biopsy was done. Although there was no 
proliferative nor spike lesions in glomeruli on light microscopy, IgG and THSD7A 
were stained strongly positive along glomerular capillary on immunofluorescence and 
subepithelial deposits on electron microscopy. Thus, she was diagnosed as THSD7A-
associated MGN and subsequently found to have thymoma. She underwent extended 
thymectomy and postoperative radiation since thymoma type B3 was confirmed 
pathologically. However, proteinuria persisted in spite of steroid administration for 
asthma. Three years later, positron emission tomography (PET) revealed a tumor of right 
subclavian space, in which biopsy specimen showed histology similar to that of thymoma, 
thus diagnosis of metastatic recurrence was made. She underwent another course of 
radiation, followed by a PET confirming the complete disappearance of the metastasis, and 
proteinuria decreasedto less than 1 g/gCr in a year. Additional investigation revealed that, 
although anti-THSD7A antibody was negative in thymoma itself and in metastatic lesion, it 
stained strongly positive in the cells of the lymphatic node around the metastatic lesion just 
as staining in the glomeruli.
Discussion: We report a first case as far as we know showing the THSD7A-associated 
MGN with metastatic thymoma. It is intriguing that thymectomy itself could not result in 
remission of her proteinuria presumably due to continued exposure to THSD7A antibody 
produced by the lymph node around the metastasis. We need to keep in mind of searching 
for metastasis or remnant tumor in cases which proteinuria does not respond well to tumor 
resection in THSD7A associated MGN complicated in malignancy.
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Secondary Membranous Nephropathy Was Induced by Gastrointestinal 
Stromal Tumor in Patient with Idiopathic Membranous Nephropathy
Maiko Nakayama,1 Hitoshi Suzuki,1 Yu Sasaki,1 Shigeki Tomita,2 
Yusuke Suzuki.1 1Nephrology, Juntendo University Faculty of Medicine, Tokyo, 
Japan; 2Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.
Introduction: The membranous nephropathy (MN) is a major cause of nephrotic 
syndrome. The major causes of secondary MN are malignancy, autoimmune disease, 
infection, and drug toxicity. However, gastrointenstinal stromal tumor (GIST) rarely induces 
secondary MN. We report here a biopsied case with onset of secondary MN accompanied 
by GIST on idiopathic MN successfully treated by the resection of GIST.
Case Description: A 77-year-old man was diagnosed as the idiopathic MN at 60-year-
old, and treated by oral corticosteroid, resulted in incomplete remission. From age of 
71, serum levels of CA19-9 had increased at 1278 U/mL, however, any malignancy was 
not detected. He was hospitalized because of exacerbation of urinary protein (5.1g/gCr) 
at 77-year-old. Although steroid pulse therapy was initiated, level of urinary protein was 
not improved. To rule out complication with other glomerular injuries, we performed 
renal biopsy. Light microscopic finding indicated MN, but not other glomerulonephritis. 
Immunofluorescence analysis of IgG subclass showed IgG1 and IgG2 dominant, despite 
IgG4 deposits were dominant in previous renal biopsy specimens. Furthermore, serum anti-
PLA2R antibody was negative. We thus diagnosed as the secondary membranous changes 
on idiopathic MN. We further surveyed complication of malignant disease and could find 
GIST by PET-CT. After 1 month from resection of GIST, serum CA19-9 decreased within 
normal range, and the level of proteinuria also improved to 1.4 g/gCr.
Discussion: This is the novel case with onset of secondary MN on idiopathic MN. 
Moreover, GIST typically does not show increased levels of serum CA19-9 and rarely 
induced secondary MN.
TH-PO540 Poster Thursday
Trainee Case Reports - I
Diffuse Lymphadenopathy as Red Herring for Secondary Membranous 
Nephropathy
Priyanka Wani,1 Jessica Cruz Whitley,2 Kuang-Yu Jen,3 Shubha Ananthakrishnan,2 
Brian Y. Young.4 1University of California Davis Medical Center, Sacramento, 
CA; 2UC Davis, Sacramento, CA; 3University of California, Davis, Sacramento, 
CA; 4UC Davis Medical Center, Sacramento, CA.
Introduction: Membranous nephropathy (MN) is associated with a high risk of 
thromboembolism. We describe a patient who presented with multiple thromboemboli 
with delayed diagnosis of secondary MN due to diffuse lymphadenopathy suspicious for 
malignancy.
Case Description: A 26-year-old African American female presented with dyspnea, 
pleuritic chest pain, and edema. CTA revealed multiple segmental PEs and a left renal 
vein thrombosis. Imaging also found diffuse mediastinal and axillary lymphadenopathy 
with a prominent hilar mass compressing the right lower lobe pulmonary artery, all 
of which were FDG avid on PET. Radiology findings was suspicious for lymphoma, 
however an axillary node biopsy was negative for cancer. Infectious workup was negative. 
Laboratories were significant for creatinine of 0.6mg/dl, albumin <1 gm/dl, and 7.3 grams 
proteinuria. Serologies were positive for ANA, anti-Smith, anti-dsDNA, and anti-U1RNP. 
Kidney biopsy showed widespread IgG-dominant subepithelial deposits consistent with 
MN. A secondary cause of MN was suggested by mesangial widening with deposits, 
tubuloreticular inclusions, and lack of PLA2R staining. Based on serologies, arthritis, and 
renal involvement, the patient was diagnosed with systemic lupus erythematosus (SLE). 
She was started on high dose prednisone, mycophenolate and anticoagulation. Resolution of 
proteinuria and edema was seen after six months. Followup physical exam and chest X-ray 
showed no lymphadenopathy.
Discussion: Diffuse lymphadenopathy, though less common nowadays, may be 
a prominent presenting feature of SLE and was highlighted in our case. Initial delays in 
kidney biopsy occurred due to malignancy evaluation and this atypical SLE presentation. 
Our case was ultimately diagnosed to be SLE with hypercoagulability due to nephrotic 
syndrome from MN.
TH-PO541 Poster Thursday
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Biallelic CUBN Variants as a Cause of Isolated Proteinuria - Challenging 
the Investigative Paradigm
Kushani C. Jayasinghe,1,2 Catherine Quinlan,4 Ella J. Wilkins,5 Susan M. White,5 
Cas Simons,3 Andrew J. Mallett.6 1Monash Health, Clayton, NSW, Australia; 
2Kidney Development, Disease and Regeneration, Murdoch Children’s Research 
Institute, Melbourne, VIC, Australia; 3Murdoch Childrens Research Institute, 
Parkville, NSW, Australia; 4The Royal Children’s Hospital, Melbourne, VIC, 
Australia; 5Victorian Clinical Genetics Services, Parkville, NSW, Australia; 
6Royal Brisbane and Women’s Hospital, Stafford, QLD, Australia.
Introduction: Proteinuria is a common kidney presentation. Historically, diagnostic 
workup of patients with isolated proteinuria involved thorough urinalysis, imaging and 
blood sampling before potentially proceeding to renal biopsy. However recent advances 
have resulted in reduced cost and increased availability of genomic sequencing for 
establishing clinical diagnoses.
Case Description: An 8year old boy was referred with an incidental finding of 
persistent proteinuria during investigation for nonspecific abdominal pain. He had no 
haematuria and had normal serum albumin. All other investigations including blood 
analysis for haematological, biochemical and immunological parameters, renal ultrasound, 
ophthalmology and audiology assessment were unremarkable. Further assessment 
revealed consanguineous family history and a brother also with isolated proteinuria. 
Renal biopsy demonstrated normal light microscopy and global uniform thinning of the 
glomerular basement membrane on electron microscopy. Chromosomal microarray 
revealed long continuous stretches of homozygosity (LCSH) representing ~4.5% of the 
genome. Shared regions of LCSH between the brothers were identified using the Genomic 
Oligoarray and single nucleotide polymorphism (SNP) Evaluation tool. Examination 
of these regions implicated CUBN, on chromosome 10p12.31. Research whole genome 
sequencing of both affected individuals was performed with informed consent (HREC/15/
QRCH/126). This revealed a homozygous stop-gain variant in CUBN (NM_001081.3, 
c.4689_4690delTAinsAT, p.(CysIle1263*), ACMG Class 5).
Discussion: CUBN mutations have been implicated as a hereditary cause of 
megaloblastic anaemia and variable proteinuria. This is the second reported family with 
isolated proteinuria due to biallelic CUBN variants in the absence of megaloblastic anaemia, 
demonstrating the utility of genomics to identify single gene causes of nephropathy, and in 
doing so, to expand the associated phenotypic spectrum. Therefore, genomic sequencing, 
undertaken earlier in the diagnostic workup, has the potential to reduce the need for 
invasive investigations and to reduce the time to definitive diagnosis for patients and 
families.
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Thymic Disease-Associated Nephropathy: A Report of 21 Cases from a 
Single Institution
Takamasa Miyauchi, Narihito Tatsumoto, Michifumi Yamashita. 
Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Nephropathy in patients with thymic diseases such as thymoma 
and myasthenia gravis (MG) is rare. Previously, 69 cases have been reported from 
multiple institutions, and of these, common diseases are minimal change disease 
(MCD; 56.5%), membranous nephropathy (MN; 20.3%), and focal segmental 
glomerulosclerosis (FSGS; 17.4%). Here we characterize the spectrum of new 21 renal 
disease cases associated with thymic disease from a single hospital.
Case Description: Total 36,562 renal biopsy cases from 2005 through mid 
2018 were reviewed at Cedars-Sinai Medical Center. 21 cases (0.057%) of patients have 
history of thymoma and/or MG. Pathological diagnoses are following: MCD (9 cases; 
42.9%), Immune complex-mediated glomerulonephritis (IC-GN; 4 cases; 19.0%), FSGS 
(2 cases; 9.5%), IgA nephropathy (IgAN; 2 cases; 9.5%), acute tubular injury/necrosis 
(ATI/ATN) with myoglobin casts (2 cases; 9.5%), and acute interstitial nephritis (AIN; 2 
cases; 9.5%).
Discussion: Consistent to the previous reports, MCD is the most common renal lesion 
in patients with thymic diseases. However, we did not observed MN, the second 
most common disease in the reports. We, instead, observed 4 cases of IC-GN that did not 
fit to MN: 2 showed mild IC-GN superimposing on MCD; 1 showed lupus nephritis-
like GN (ISN/RPS CLASS II) without proliferative features; and 1 showed lupus 
nephritis-like GN (CLASS II) with segmental membranous change. We also 
experienced kidney diseases that haven’t been reported before as an association with 
thymic disease: IgAN, ATI/ATN with myoglobin casts, and AIN. 2 cases of IgAN were 
low-grade without hypercellularity (endocapillary hypercellularity or crescents). 2 cases 
of ATI/ATN with myoglobin casts showed multiple myoglobin-positive tubular casts. Of 
AIN cases, one showed mild tubulitis with mild immune complex deposits both in 
mesangium and along tubular basement membranes. Another case showed 
granulomatous AIN. In conclusion, this is the largest and unique case series of 
nephropathy in patients with thymic disease from a single institution.
Summary
TH-PO543 Poster Thursday
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Spontaneous Tumor Lysis Syndrome in Renal Solid Tumor: Case Report
Bruno N. Cesar,1 Nilo E. Nunes,4 Erica L. Reghine,2 Cicero rodrigo M. Alves,3 
Renato D. Foresto,2 Maria A. Hazin,3 Marcelino S. Durao.2 1Universidade 
Federal de Sao Paulo, Sao Paulo, Brazil; 2Universidade Federal de Sao Paulo, 
São Paulo, Brazil; 3Universidade Federal de Sao Paulo, São Paulo, Brazil; 
4Universidade Federal de Sao Paulo, São Paulo, Brazil.
Introduction: Tumor Lysis Syndrome (TLS) results from a large release of intracellular 
material from malignant cells death, especially after chemotherapy. Spontaneous TLS 
(STLS) is commonly associated with aggressive hematological malignancies and rarely 
observed in solid tumors.
Case Description: A 67-year- old male presented to the hospital with progressive 
dyspnea, weakness and oliguria in the last two days. His medical records were hypertension, 
diabetes, coronary heart disease and a recently diagnosed renal mass. Blood tests showed 
creatinine: 8.8 mg/dL, urea: 272mg/dL; potassium: 6.4 mEq/L; serum uric acid: 15.9 mg/
dL; phosphate: 7.6 mg/dL; ionic calcium: 1.07mmol/L. Two months before, creatinine 
level was 1.0 mg/dL. Abdominal and renal doppler ultrasound were performed and 
showed normal sized kidneys with a hypoechoic image on the left side, without signs 
of thrombosis. Abdominal CT scan showed a Bosniak-III left expansive kidney lesion. 
According to the clinical and laboratory findings, STLS diagnosis was performed. Due to 
a lack of response to conservative measures, hemodialysis was initiated and after three 
sessions kidney function improved and dialysis was discontinued. The patient underwent 
left nephrectomy. Histological analysis showed a clear cell renal cell carcinoma Fuhrman 
3, stage T3a, with recent evidences of hemorrhage and tumor necrosis. The disease was 
restricted to kidney tissue. The patient was discharged from the hospital on the 5th post-
operative day. At this time, blood tests showed creatinine was 1.6mg/dL, potassium 
5 mEq/L, phosphate: 5.8 mg/dL, ionic calcium: 1.2 mmol/L and uric acid: 4 mg/dL.
Discussion: STLS is a serious event that affects patients with cancer. There are few 
reports of its association with solid tumors, especially in the case of renal cell carcinomas. 
In this report, the diagnosis of STLS was performed using the Cairo-Bishop criteria and was 
classified as grade 4. In most reported cases, larger masses with metastases prevailed and 
the patient died immediately after diagnosis. Physicians should be aware of the diagnosis 
since it requires prompt actions to improve outcomes.
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A Case of Intravascular Large B-Cell Lymphoma Diagnosed by Renal 
Biopsy
Rina Oba, Kentaro Koike, Naoko Nakaosa, Masahiro Okabe, Kei Matsumoto, 
Tetsuya Kawamura, Nobuo Tsuboi, Takashi Yokoo. The Jikei University School 
of Medicine, Division of Nephrology and Hypertension, Department of Internal 
Medicine. The Jikei University School of Medicine, Minato-ku, Japan.
Introduction: Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of 
large-cell lymphoma characterized by the proliferation of lymphoma cells within small 
vessels. In general, patients with IVLBCL exhibit aggressive clinical courses and most cases 
are diagnosed at autopsy. Although recent advancements in chemotherapy have markedly 
improved patient prognosis, an early diagnosis by biopsy remains critical. Therefore, 
random skin biopsy or bone marrow biopsy is performed in most cases. To date, some 
case reports have mentioned IVLBCL diagnosis by liver, lung, and brain biopsies. Here, 
we report a rare case of IVLBCL diagnosed by renal biopsy in a patient with the clinical 
phenotype of persistent proteinuria together with an elevated serum titer of proteinase-3-
anti-neutrophil cytoplasmic antibody (PR3-ANCA).
Case Description: The patient was a 66-year-old woman with a history of bilateral leg 
edema, erythema, and pruritis. Laboratory data revealed high serum PR3-ANCA titer (92.6 
U/ml), and chest computed tomography revealed lung nodules. Four months after the first 
presentation, the patient developed rapidly progressing dyspnea and persistent proteinuria 
(1.22 g/day) without hematuria. Renal biopsy revealed intraglomerular infiltration of 
enlarged atypical lymphocytes. Immunofluorescent staining showed that these cells were 
characterized as CD3-, CD5-, CD20+, CD79a+, CD10-, bcl-6+, and MUM1+. On the basis 
of these findings, the patient was eventually diagnosed with IVLBCL. After several cycles 
of chemotherapy, her proteinuria decreased (0.04 g/day) and PR3-ANCA titer declined 
(11.3 U/ml).
Discussion: We report a rare case of IVLBCL accompanied with persistent proteinuria 
and an elevated serum PR3-ANCA titer. In this case, identification of large lymphoma cells 
within the small vessels of the kidney was a key factor for early diagnosis and successful 
treatment.
TH-PO545 Poster Thursday
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Primary Bilateral Renal T-Cell Lymphoma Presenting as Rapidly 
Progressive Glomerulonephritis
Maria Carolina R. Coêlho, Camila B. Oliveira, Denise M. Costa, Gisele Vajgel, 
Luis H. Sette, Marcelo Souto maior, Maria Alina G. Cavalcante, Lucila 
Maria Valente. Hospital das Clínicas HC - UFPE, Recife, Brazil.
Introduction: Primary renal lymphoma (PRL) is a extremely rare disease defined 
as a non-Hodgkin’s lymphoma (NHL) involving the kidney in the absence of primarily 
extrarenal lymphatic disease. Acute kidney injury (AKI) as the initial presentation of 
lymphoma is even more uncommom.
Case Description: A 43 y/o man presented with edema, weight loss, asthenia and 
exertional dyspnea for 1 month. Urinalysis and renal function were normal (SCr 1.0mg/dL). 
After 2 weeks, SCr was 3.6mg/dl and he was hospitalized. He presented microscopic hematuria 
and mild proteinuria (486mg/24h) with progressive oliguric AKI (SCr 4.2) requiring dialysis. 
US showed discrete bilateral enlarged kidneys. He received methylprednisolone IV and oral 
prednisone 1mg/kg/day for the clinical diagnosis of rapidly progressive glomerulonephritis. 
Kidney biopsy showed diffuse lymphoid intersticial infiltration and immunohistochemistry 
was compatible with T-Cell lymphoma (CD 3 + / Bcl 2 + / CD 20 - / CD 10 - / CD 5 + / 
CD 23 - / Ki 67 90%). CT of the thorax, abdomen and pelvis confirmed enlarged kidneys 
and excluded infiltration in other organs. Before a specific treatment, the patient had a poor 
outcome, dying with septic shock days after.
Discussion: Despite its rarity, PRL should be kept in mind in the differential diagnosis 
of AKI with bilateral enlarged kidneys. Clinical manifestations are often nonspecific, with 
flank pain, hematuria, and weight loss predominating. Lymphomatous infiltration causing 
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AKI is a uncommon presenting finding and prognosis is poor. Although B-cell NHL are 
more commom, T-cell NHL have been described as a cause of PRL.
Intersticial lymphocytic infiltration (HE stain; magnification X 400)
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Renal Mucormycosis Presenting as Rapidly Progressive Renal Failure
Aileen Wang, Carrie L. Phillips, Asif A. Sharfuddin, Robert L. Bacallao. Indiana 
University School of Medicine, Indianapolis, IN.
Introduction: Mucormycosis is an invasive fungal infection with high mortality 
(~95% if disseminated). Caused by filamentous fungi in the Zygomycetes class, this 
infection has become increasingly frequent among immunosuppressed patients. The most 
common form of invasive mucormycosis is rhino-cerebral, with renal involvement being 
the rarest. Identification of mucormycosis as the cause of renal failure can be missed 
due to difficulty of successfully culturing mucorales. We describe a patient with chronic 
lymphocytic leukemia (CLL) and rapidly progressive renal failure (RPRF) with suspected 
Richter transformation who was diagnosed with angioinvasive mucormycosis based on 
renal biopsy specimen.
Case Description: 70-year-old Caucasian man with relapsed CLL presented with 
fevers up to 102°F daily and night sweats. Creatinine (Cr) increased from baseline 
1.1 mg/dL to 3.65 on admission. He had been maintained on rituximab/revlimid for 
the past half-year. He was recently hospitalized for dyspnea and cough, for which he 
received voriconazole for suspicion of pulmonary aspergillus. PET scan revealed a new 
metabolically active retroperitoneal mass, while kidneys were unremarkable. Urine 
sediment showed RBCs, WBCs, and no casts. ANCA was negative. Despite IV fluids and 
suspension of nephrotoxic drugs, he progressed within one week to anuric renal failure 
necessitating hemodialysis. CT-guided renal biopsy was performed. Light microscopy 
showed necrotizing granulomas with multinucleated giant cells and pleomorphic, 
PAS-positive fungal forms that were interstitial and intra-arterial. Fungi were broad, non-
septate, and thick-walled with irregularly spaced branching hyphae typical of mucor. He 
was immediately treated with liposomal amphotericin-B and IVIG, then isavuconazole 
for maintenance therapy. He defervesced after initiation of amphotericin-B but remains 
dialysis-dependent.
Discussion: This is a unique presentation of mucormycosis in a patient with underlying 
hematological malignancy and RPRF. This biopsy specimen drastically changed 
management. Manifestation of renal mucormycosis includes hematuria, pyuria and acute 
renal failure that can mimic RPRF. As mucorales are notoriously difficult to culture and 
radiologic imaging is nonspecific, histological diagnosis is required. This case speaks to 
the importance of early biopsy in renal failure of unclear etiology in immunocompromised 
patients.
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Mastocytosis of the Kidney: A Rare Manifestation of Systemic 
Mastocytosis
Regan M. Seipp, Mira T. Keddis, Margaret Ryan. Mayo Clinic, Phoenix, AZ.
Introduction: Systemic mastocytosis (SM), a rare, progressive myeloproliferative 
neoplasm, is characterized by clonal mast cell infiltration into tissues. Renal involvement of 
SM is unusual, with only three case reports currently described in the literature, and carries 
a grim prognosis.
Case Description: A 71 year old male with a history of hypertension, presented with a 
one year history of fatigue, 60 lb. weight loss, and increasing abdominal distention. Physical 
exam was notable for a frail, cachectic male with hepatosplenomegaly and peripheral 
edema. Laboratory analysis revealed acute kidney injury, decreased hepatic synthetic 
function, and pancytopenia. Urinalysis displayed grade 1 proteinuria and granular casts. 
Abdominal ultrasound showed increased echogenicity of the kidneys, ascites, and hepatic 
cirrhosis. The patient had no known risk factors for liver disease and underwent liver biopsy 
demonstrating diffuse mast cell infiltration with pericentral hepatocyte necrosis. Serum 
tryptase levels were elevated: 203 ng/ml (normal <11.5). Ensuing bone marrow biopsy 
showed 100% cellularity with 30-40% mast cells, confirming the diagnosis of SM. The 
kidney injury, initially managed as hepatorenal syndrome with albumin, midodrine, and 
octreotide, rapidly progressed requiring hemodialysis. Kidney biopsy revealed tubular 
injury and mast cell interstitial nephritis (Image 1). Midostaurin, a multikinase inhibitor, 
was initiated as disease directed therapy. The patient was eventually discharged but 
remained dialysis dependent.
Discussion: SM is associated with mutations in the receptor tyrosine kinase KIT 
(CD117). SM subtypes and median survival range from indolent (16 years) to mastocytoma 
(2 months). Renal involvement may occur even with indolent SM and has been reported as 
MPGN, interstitial nephritis, and light chain deposition disease. In each case, the kidney 
injury was progressive, requiring hemodialysis, and survival was worse than expected 
despite KIT directed therapy.
Image 2: Kidney biopsy CD117 stain highlighting increased interstitial mast cells
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Something Amiss with Cannabis: AKI Associated with Cannabidiol 
Ingestion
Timothy E. Yen,1 Armando Aponte,1 Lakshmi Chekuri,3 Irina Lytvak,3 
Xin J. Zhou,4 Hashim K. Mohmand.2 1Methodist Dallas Medical Center, Dallas, 
TX; 2Dallas Nephrology Associates, Dallas, TX; 3Methodist Richardson Medical 
Center, Plano, TX; 4Renal Path Diagnostics, Lewisville, TX.
Introduction: Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid that is 
a popular dietary supplement with proposed medicinal properties. Although synthetic 
cannabinoids (SCs) such as K2/Spice have been implicated in kidney injury in over 20 case 
reports, CBD’s renal effects are not as well documented.
Case Description: A 58 year old female with diabetes, hypertension and two weeks 
of abdominal pain and diarrhea presented with one day of emesis, anuria and CT imaging 
concerning for mild colitis. Medications were omeprazole, losartan, carvedilol, metformin 
and Insulin. She had started ingesting commercial, hemp-derived CBD Oil three months 
earlier but denied drug use, including Spice, K2 or marijuana. She had tachycardia and 
mild abdominal tenderness on physical examination. Initial lab tests showed renal failure, 
with a serum Cr 7.1 mg/dL (baseline 1.0), BUN 49 mg/dL, and potassium 7.1 mmol/L. 
The patient received emergent hemodialysis for refractory hyperkalemia. Urine output 
improved and gastrointestinal symptoms resolved in 24 hours. Urinalysis was negative for 
casts but urine protein/Cr and microalbumin/Cr ratios were 15 g/g and 4.4 g/g, respectively. 
Autoimmune and viral workups were unremarkable, as were SPEP, UPEP and free light 
chain assay. Renal biopsy showed extensive isometric cytoplasmic vacuolization of tubular 
cells. Under electron microscopy, these vacuoles were seen to be membrane-bound and 
corresponded to dilated endoplasmic reticulum. This disease pattern suggested toxic 
tubular injury and occurred on a background of diabetic glomerulosclerosis with mild 
TA/IF. Urine studies demonstrated evidence of a proximal tubulopathy with elevated 24h 
fractional excretion of phosphorous (68.4%) and Uric Acid (7.8%). The patient’s renal 
function improved over the next week and she was discharged with a Cr of 3.1 mg/dL. 
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Five weeks after discharge, her serum Cr and proteinuria had improved to 1.4mg/dL and 
215 mg/g, respectively.
Discussion: The mechanism for SC-associated kidney injury is unknown but tubular 
vacuolization has been documented in several cases. Although CBD differs from SCs in that 
it has little activity on the Cannabinoid 1 and 2 receptors, it has >65 molecular targets and 
could share a common mechanism for renal injury. This is the first reported case of renal 
injury associated with CBD use.
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ESRD Secondary to Anti-Glomerular Basement Membrane Disease in a 
Child with Common Variable Immunodeficiency
Sai Sudha Mannemuddhu, Kiran K. Upadhyay. Pediatric Nephrology, UF 
Shands, Gainesville, FL.
Introduction: Anti- glomerular basement membrane (GBM) disease is an uncommon 
autoimmune disorder that is characterized by rapidly progressive glomerulonephritis (GN) 
caused by autoantibodies against the α3-chain of type IV collagen in the GBM. Commom 
variable immunodeficiency (CVID) is a primary immunodeficiency manifested by 
hypogammaglobulinemia, inability to make functional antibody, and recurrent infections. 
We report an interesting association of anti-GBM disease with CVID.
Case Description: A 15-year-old Caucasian female with prior normal renal function 
presented with 2 weeks of nephrotic proteinuria, oliguria, AKI, and was found to have serum 
anti-GBM antibody. She had been diagnosed with CVID and West Nile meningoencephalitis 
at 3 and 12 yrs of age respectively. Her renal biopsy showed crescentic GN with at least 50% 
global glomerulosclerosis and immunofluorescence showed linear staining for IgG along 
the glomerular capillary wall. There was no clinical or radiological evidence of pulmonary 
hemorrhage. She was treated with pulse IV steroids, Cyclophosphamide, Rituximab and 
several sessions of plasmapheresis. Her serum anti-GBM antibody level decreased from 
194 U/mL at presentation to 0 U/mL post therapy. However, she progressed to ESRD 
within weeks and required dialysis. Her clinical course was complicated by hypertensive 
encephalopathy, CMV meningoencephalitis, CMV viremia, status epilepticus, and she 
passed away a few months later from lower respiratory infection related complications.
Discussion: Anti-GBM disease is a rare autoimmune condition, which has not been 
reported in association with a primary immunodeficiency syndrome. ESRD secondary to 
anti-GBM disease in a patient with CVID is an interesting association and supports role of 
immune dysregulation in systemic autoimmune disease.
Kidney Biopsy images- Anti GBM disease
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Renal Injuries Induced by Castleman’s Disease
Takeo Koshida, Hitoshi Suzuki, Yuko Makita, Tomohito Gohda, Yusuke Suzuki. 
Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Introduction: Castleman’s disease is a benign lymphoproliferative disorder in which 
interleukin-6 (IL-6) is thought to play a pathogenetic role. Although renal involvement in 
Castleman’s disease were reported, etiology of renal injuries is currently unknown, due to 
lack of data from renal biopsy. Here, we report two renal biopsied Castleman’s disease in 
which successfully treated with the tocilizumab, a humanized anti-IL-6 receptor antibody.
Case Description: < Case 1 > A 30-year-old man presented swelling of systemic 
lymph node. Pathological analysis of cervical lymph node biopsy showed plasmacyte 
infiltration, and ruled out malignant lymphoma and IgG4-related disease. Laboratory data 
indicated anemic state, hypoalbuminemia, polyclonal hypergammaglobulinemia, high 
levels of CRP (9.1 mg/dl), IL-6 (20.6 pg/ml) and VEGF (513 pg/mL). Taken together, he 
was diagnosed as multicentric Castleman’s disease. The eGFR was 110.8 ml/min/1.73m2, 
however, 0.6 g/day proteinuria and microscopic hematuria were detected. Then kidney 
biopsy was performed. The pathological findings of kidney biopsy specimen showed mild 
proliferation of mesangial cell. No immune deposits were detected by immunofluorescence 
analysis. < Case 2 > A 49-year-old man was detected anemia and swelling of systemic 
lymph node. Cervical lymph node was biopsied, and laboratory investigation showed 
anemic state, hypoalbuminemia, polyclonal hypergammaglobulinemia and high level 
of CRP (8.7 mg/dl), IL-6 (43.0 pg/ml) and VEGF (1250 pg/ml). Taken together, he was 
diagnosed as multicentric Castleman’s disease. The eGFR was 56.8 ml/min/1.73m2, and 
0.6g/day proteinuria and microscopic hematuria were detected at the time of renal biopsy. 
The pathological findings showed mild mesangial cell proliferation and global sclerosis in 
10% of total glomerulus. Immunofluorescence analysis did not show any immune deposits.
Discussion: We present cases of kidney injury induced by Castleman’s disease. In 
both cases, significant infiltration of plasmacyte and IL-6 positive cells were not detected 
in kidney biopsy specimens. Importantly, tocilizumab, but not corticosteroid successfully 
improved urinary abnormality. Although the mechanism and clinical course of renal 
involvement in Castleman’s disease is unclear, these cases suggested that kidney injury in 
patients of Castleman’s disease is induced by systemic overproduced IL-6 which proliferate 
mesangial cells.
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Prominent Swelling of Glomerular Endocapillary Cells in Two Cases of 
TAFRO Syndrome
Keiki Shimada,1,2 Takaya Sasaki,1,2 Kentaro Koike,1 Yu Honda,1,2 
Masahiro Ishikawa,1,2 Nobuo Tsuboi,1 Takashi Yokoo.1 1The Jikei University 
School of Medicine, Minato-ku, Japan; 2Kawaguchi Municipal Medical Center, 
Kawaguchi, Japan.
Introduction: TAFRO syndrome, which is characterized by thrombocytopenia (T), 
anasarca (A), fevers (F), reticulin myelofibrosis/renal disorder (R), and organomegaly (O), 
is sometimes a fatal systemic inflammatory disease. The histopathological findings remain 
unclear because it is often difficult to perform renal biopsy due to severe thrombocytopenia. 
We herein report the histopathological findings of two cases of TAFRO syndrome in which 
renal biopsies were performed.
Case Description: Case 1: A 51-year-old male was admitted due to fever, fatigue, 
high CRP value, thrombocytopenia, and resistance to antibiotic drug treatment of two 
weeks’ duration. He showed anasarca and multiple lymph node enlargement. He was 
diagnosed with TAFRO syndrome. Even though intensive care, including administration of 
corticosteroids, tocilizumab, and hemodialysis were continued, he died on the 24th day of 
hospitalization due to multiple organ dysfunction. Renal biopsy revealed marked swelling 
of glomerular endocapillary cells. Case 2: A 34-year-old man was referred due to fatigue, 
pretibial pitting edema, urinary protein, and urinary occult blood of one-month duration. He 
was admitted to the hospital for renal dysfunction and heightened inflammatory response. 
Hepatosplenomegaly, ascites, and thrombocytopenia was observed. He was diagnosed with 
TAFRO syndrome due to elevated VEGF and IL-6 levels. Prednisolone was administered 
and the heightened inflammatory response and proteinuria were ameliorated. Renal biopsy 
revealed endocapillary hypercellularity, endothelial cell enlargement, mesangiolysis, and 
duplication of basement membrane. These findings were compatible with thrombotic 
microangiopathy.
Discussion: The findings suggest that endothelial dysfunction is consistent with the 
characteristics of TAFRO syndrome, which was observed in this case as a membranous 
proliferative glomerulonephritis (MPGN)-like glomerular lesion. Renal impairment in 
TAFRO syndrome may be caused by secondary MPGN due to endothelial cell disorder.
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A Case of Multicentric Castleman Disease – TAFRO Variant, Presenting 
with Renal TMA
Fredrik Jenssen, Milos N. Budisavljevic, Andrew B. Elliott, Waleed Asfar. 
Medical University of South Carolina, Charleston, SC.
Introduction: Castleman’s disease is a rare systemic lymphoproliferative disorder in 
which immune cells become activated to produce excess cytokines, particularly IL-6. A 
subset of cases are related to HIV or HHV-8. There is a wide heterogeneity of symptoms 
in the disease, ranging from asymptomatic to multisystem organ dysfunction. TAFRO 
syndrome is a unique clinicopathologic variant of multicentric Castleman’s disease 
first described in 2010 in Japan by Takai et al. It includes thrombocytopenia, anasarca, 
microcytic anemia, fever, reticulin fibrosis, renal dysfunction, and organomegaly. To our 
knowledge, this syndrome has yet to be reported in the U.S.
Case Description: 20 y.o. male with previous normal kidney function, presented with 
AKI, lymphadenopathy, anasarca, and diarrhea after 2 month history of myalgia, malaise, 
back pain, diarrhea, vomiting, low grade fevers, and night sweats. He endorsed large 
amounts of NSAIDs use for myalgias. He presented with serum creatinine of 2.4 mg/dL 
which continued to rise despite conservative therapy with isotonic volume expansion and 
peaked at 4.7 mg/dL. The urinalysis was bland and urine protein-to-creatinine ratio was 
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0.1 g/g. Extensive workup including serologies for hepatitis and autoimmune disease were 
negative. Noncontrast CT was obtained which revealed prominent axillary, retroperitoneal, 
mesenteric, and inguinal lymphadenopathy. A renal biopsy revealed thrombotic 
microangiopathy (TMA) with mostly arterial changes, and evidence of mesangiolysis. 
Further workup for hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura 
was negative. An excisional left axillary lymph node biopsy revealed classic findings of 
Castleman’s disease. PCR for CMV, EBV, HIV, HHV-6, and HHV-8 were all negative. 
He was started on oral steroids, as well as IL-6 inhibitor (siltuximab) and developed 
hyperkalemia which was refractory to medical management, and required correction 
via conventional hemodialysis. He was continued on prednisone and received situximab 
infusion every 3 weeks with full recovery of renal function.
Discussion: Specific targeting of pathogenic mechanism of Castlaman’s associated 
TMA with siltuximab in our case resulted in complete recovery of dialysis dependent 
renal TMA. To our knowledge, this is the first case of extremely favorable outcome of 
Castlaman’s disease associated TMA treated with IL-6 inhibitor.
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Double Trouble or a Separate Entity: AKI Secondary to ANCA Vasculitis 
with IgG4 Nephropathy
Omar Mamlouk,1 Hanan A. Khairalla,1 William F. Glass,2 Aisha Khattak.1 
1Nephrology, The University of Texas Health Science Center at Houston, 
Houston, TX; 2Pathology, The University of Texas Health Science Center at 
Houston, Houston, TX.
Introduction: Antineutrophil Cytoplasmic Antibody-Associated (ANCA) vasculitis is 
reported to be associated with tissue infiltration by IgG4 cells and IgG4-related disease 
(IgG4-RD) is associated with elevated ANCA titers. IgG4-RD diagnosis is considered 
with caution in a patient with ANCA vasculitis as JSN criteria, one of widely used criteria 
for diagnosis, suggests that IgG4-RD is an unlikely diagnosis in patient with vasculitis. 
However, there is growing evidence of possible overlap between IgG4-RD and ANCA 
vasculitis, especially granulomatosis with polyangiitis, GPA. Few case reports showed 
histological evidence of both disease in the same organ. We present a case of GPA disease 
with concurrent histological evidence suggestive of IGg4 disease involving the kidney. 
These patients when treated with rituximab had good disease outcome
Case Description: A 61 year old woman with multiple co-morbidities including 
hypertension, chronic obstructive lung disease and chronic kidney disease was admitted for 
evaluation of shortness of breath and dysuria. she developed acute kidney injury during the 
first week of hospitalization along with purpuric rash on legs. no ocular, thyroid, salivary or 
oral manifestation by history or examination. urine analysis showed no dysmorphic RBCs. 
UPC was of 1.5. Serology for ANA, Anti-dsDNA, hepatitis panel and HIV was negative. 
PR3-ANCA was + and C3&4 were low. Renal biopsy was performed with finding of acute 
focal segmental necrotizing pauci-immune glomerulonephritis, active tubulointerstitial 
nephritis with interstitial and tubular basement membrane immune complex deposits, area 
of storiform fibrosis, and area of abundant IgG4 (20 cells/HPF). Serum IgG4 subclass level 
was elevated. These findings are suggestive of IgG4-RD. A CT of abdomen/pelvis did not 
reveal any other organ involvement. she was started on prednisone and rituximab with 
improvement of renal function back to baseline
Discussion: Clinical & histological evidence suggestive of IgG4-RD and ANCA 
vasculitis can co-exist in the same organ, including the kidney. Our findings support 
the growing evidence of possible association between IgG4-RD and GPA vasculitis. 
Understanding this association might help us have better understanding of underlying 
pathophysiology of both diseases. Rituximab was observed to be effective for treatment of 
IgG4-RD overlapping with ANCA vasculitis
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IgG4 Nephritis, When Rising Creatinine Is Not a Progression of CKD
Larissa Kruger gomes. University of Connecticut Internal Medicine residency, 
Farmington, CT.
Introduction: Immunoglobulin G4 (IgG4) is a rare disease with a diagnosis dependent 
on high clinical suspicion, specially when a single organ is affected. We present a case of 
IgG4 tubulointerstitial nephritis (TIN) and discuss when to suspect this disorder.
Case Description: A 64-year-old male with history of type 1 diabetes and chronic 
kidney disease with a creatinine (Cr) baseline of 1.2mg/dL, was referred to clinc after having 
an increase of Cr to 3.3mg/dL over 4 months. There were no recent changes in medications 
or sickness. Blood pressure and diabetes were under control with an HBA1C of 7.3% and 
microalbuminuria of 33mcg. Urinalysis (UA) showed 2-4 red blood cells and a protein/
cr ratio of 800mg/g. Due to the unlikelihood of rapid progression of diabetic nephropathy, 
investigation for acute kidney injury with serology and renal ultrasound were pursued. 
Results were significant for low C3 and C4 and a rising Cr of 3.5mg/dL. Consequently, a 
kidney biopsy was done, revealling diffuse TIN with a dense plasma cell infiltrate with a 
high proportion of IgG4 cells and tubular basement membrane immunocomplex deposits. 
IgG4 levels were 683.5 mg/dL. With the diagnosis of IgG4 TIN, patient was started on 
prednisone 40 mg daily. After 1 month, the patient’s Cr was 2.3mg/dL and after 4 months, 
1.9mg/dL with IgG4 levels of 118 mg/dL. Patient is currently off prednisone and is being 
monitored for recurrence.
Discussion: IgG4-related kidney disease has higher prevalence among older men 
and it is usually related to extra renal disease, with sole renal impairment in 2-12% of 
cases. The pattern of intrinsic disease is most commonly TIN but can also be membranous. 
Patients can present with worsening of baseline CKD, making it important to add IgG4 
disease in your differential. Igg4 disease should be suspected in patients with rising Cr and 
signs of tubular injury, but no white blood cells on UA neither obvious pharmacological or 
infectious etiology. Low complement levels and normal ESR/CRP are suggestive of IgG4 
disease, however, to fit the diagnosis, biopsy findings of TIN with >10 igG4positive plasma 
cells/hpf in addition to one of the clinical criteria of elevated igG4 and igG levels, specific 
imaging findings or extra renal disease must be present. Steroids are first line treatment and 
remission is achieved in 82% of cases. Rituximab is indicated in refractory cases. Patients 
with higher GFRs tend to respond well to treatment.
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Rare Case of IgG4-Related Kidney Pseudotumor
Shengjie Cui,1 Carrie L. Phillips,1 Chandru Sundaram,2 Omer A. Saeed.1 
1Indiana University School of Medicine, Indianapolis, IN; 2Indiana University 
School of Medicine, Indianapolis, IN.
Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a chronic 
fibroinflammatory condition that can involve one or multiple organs in the body. It is 
characterized by tissue lymphoplasmacytic infiltration with IgG4+ plasma cells, storiform 
fibrosis, and possibly elevated serum IgG4 levels. Renal involvement by IgG4-RD is rare 
and can be confused with kidney neoplasms as it has the tendency to form pseudotumor.
Case Description: A 40-year-old woman complained of abdominal pain for three 
months. Abdominal CT and MRI scan revealed an enhancing lesion in the lower pole 
cortex of the left kidney measuring 2.7 x 2.4 x 2.2 cm. The lesion showed central necrosis 
with thick enhancing wall and it was minimally exophytic without violation of Gerota’s 
fascia. There were also stable borderline and enlarged retroperitoneal lymph nodes. Kidney 
function tests including eGFR, BUN, and serum creatinine were normal. The patient’s 
preliminary diagnosis was renal cell carcinoma and partial nephrectomy was performed. 
Gross examination showed a 2 X 2 X 1.3 cm white, firm poorly circumscribed irregular 
lesion with no evidence of necrosis or hemorrhage. Microscopic examination showed 
large areas of storiform fibrosis with intense lymphoplasmacytic infiltrate and vascular 
involvement. Immunohistochemical stains showed increased IgG4+ plasma cells (>25 
cells/HPF). The IgG4+: IgG+ plasma cell ratio was 50%.
Discussion: IgG4-RKD is the term used to describe multiple kidney lesions including 
tubulointerstitial nephritis, renal pyelitis, or renal insufficiency as a result of retroperitoneal 
fibrosis. CT scan of patients with IgG4 tubulointerstitial nephritis usually reveals multiple 
low density parenchymal lesions. The presence of a solitary lesion with exophytic 
appearance is rare. In these circumstances, it is usually very difficult to rule out a neoplastic 
process based on imaging alone. Steroids are the first-line treatment in most patients. A high 
clinical suspicion, serum IgG4, and a representative biopsy are usually sufficient to make 
the diagnosis in most cases. Awareness about the unusual instances where imaging studies 
are worrisome for malignancy can help avoid unnecessary surgery.
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A Case of IgG4 Related Disease (IgG4-RD) Presented with Membranous 
Nephropathy (MGN) Several Years Before Other IgG4 Manifestations
Hisham Elsherbiny,1 Mary E. Fidler,3 Lynn D. Cornell,3 Nelson Leung.2 1Mayo clinic, 
Rochester, MN; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN.
Introduction: IgG4-RD is a systemic immune mediated condition that is characterized 
by mass-forming inflammatory lesions and lymphoplasmacytic infiltration with increased 
IgG4 positive plasma cells in affected tissue. Tubulointerstitial nephritis is the most common 
form of renal involvement in IgG4-RD. MGN can be secondary to IgG4-RD (“IgG4-related 
MGN”), usually identifiable as such due to concurrent or previous other organ involvement 
by IgG4-RD.
Case Description: A 67 year old man initially presented with nephrotic syndrome with 
7.8 g/day proteinuria. He underwent a renal biopsy which revealed by immunofluorescence 
global granular glomerular basement membrane staining with IgG, C3, and kappa and 
lambda light chains typical of MGN. The patient failed treatment with mycophenolate 
mofetil and subsequently was switched to oral cyclophosphamide which induced a 
remission. 3 Years later, at age 70, he developed chronic sinusitis that was resistant 
to medical treatment. At age 73, he developed bilateral large parotid glands. On further 
evaluation, serum IgG4 subclass was markedly elevated at 2180 mg/dL. A parotid fine 
needle aspiration was done which revealed a polytypic plasma cell infiltrate with increased 
numbers of IgG4-positive plasma cells consistent with IgG4-RD. He also underwent 
prostatic biopsy for enlarged prostate which revealed increased number of IgG4-positive 
plasma cells, consistent with involvement by IgG4-RD. The kidney disease remained in 
remission at the time of IgG4-RD diagnosis. Serum anti-PLA2R antibodies checked at the 
time of IgG4-RD diagnosis were negative.
Discussion: In this case a patient was diagnosed with IgG4-RD 7 years after 
initial diagnosis of MGN. PLA2R serum testing was not available at the time of initial 
presentation with proteinuria. The patient’s MGN could have represented primary (PLA2R-
associated) MGN that was treated and was in remission; alternatively, the MGN may have 
represented an early manifestation of IgG4-RD, which would provide a unifying diagnosis 
of the immune-mediated conditions. Teaching point: Clinicians should maintain high a 
suspicion for development of IgG4-RD years after initial diagnosis of MGN in the right 
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clinical setting. Serum PLA2R testing may be contributory, as reported IgG4-related MGN 
cases are negative for PLA2R.
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Tubulointerstitial Nephritis as the Initial Presentation of IgG4-Related 
Disease
Babajide Togonu-Bickersteth,1 Nelson P. Kopyt.2 1Lehigh Valley Health 
Network, Easton, PA; 2Lehigh Valley Hospital, Bethlehem, PA.
Introduction: IgG4 related disease (IgG4-RD) is a systemic, autoimune fibrosing 
condition that was recently recognized, initially as autoimmune pancreatitis, less than 
15 years ago. Since then, it has been shown to involve other organs, manifesting as 
cholangitis, retroperitoneal fibrosis, aortitis, pneumonitis and nephritis. While membraonus 
glomerulonephritis has been described, tubulointerstitial nephritis (TIN) is the most 
common for m of IgG-4 related kidney disease (IgG4-RKD). It is marked by IgG4 positive 
lymphoplasmocytic infiltrate.
Case Description: A 40 y/o caucasian male with a history of Asthma and Graves 
disease presented for evaluation of elevated creatinine, which was 1 mg/dl at baseline and 
on evaluation was 1.99 mg/dL. His creatinine increased over the next 6 months to a peak 
of 3.5. Urinalysis showed mild proteinuria and a bland sediment. He was referred for renal 
biopsy which showed significant plasma cell infiltrate with more than 50 IgG4 positive cells 
per HPF, as well as lymphocytic tubulitis. Intrestingly, eosinophils were seen on the biopsy. 
The clinical significance of this is as yet unclear. He was shown to have leveated total IgG 
as well as elevated IgG4. He subsequently developed respiratory symtoms and CT imging 
of his chest showed a nodule, with surrounding ground glass changes. Steroid therapy was 
initiated and he has had resolutionof the chest findings and improvement in creatinine.
Discussion: This case adds to our body of knowledge and supports proposed diagnostic 
criteria which combines histology, imaging and serology. It also supports the notion that 
renal involvement may precede systemic findings. Diagnosis of this condition warrants 
awareness and vigilance as specific immune staining is required and may need to be 
requested to make the diagnosis.
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Lysozyme-Induced Nephropathy as a Cause of Interstitial Nephritis in 
Sarcoidosis
Shohei Yoda,1 Satoru Sanada,1 Mitsuhiro Sato,2 Toshinobu Sato,1 
Yoshio Taguma.1 1Japan Community Health Care Organization Sendai Hospital, 
Sendai, Japan; 2Sendai Shakaihoken Hospital, Sendai, Japan.
Introduction: Sarcoidosis manifests interstitial nephritis of an unknown etiology. 
We report a case series of interstitial nephritis in patients with sarcoidosis, that could be 
associated with lysozyme-induced tubular injury.
Case Description: Kidney biopsy specimens of four cases of sarcoidosis, four cases of 
other interstitial nephritis such as drug-induced, IgG4-related and Sjogren syndrome, and 
one case of chronic myelomonocytic leukemia induced interstitial nephritis were analyzed 
retrospectively by immunohistochemistry and electron microscopy. All four patients with 
sarcoidosis showed interstitial nephritis in the kidney. Specimens were stained with anti-
lysozyme antibody and showed positive staining in proximal tubular cells, whereas negative 
immunostainings in the other three cases of interstitial nephritis. Strong lysozyme staining 
was also present in interstitial nephritis caused by chronic myelomonocytic leukemia, 
the mechanism of which is known as a lysozyme-induced tubular injury. The serum 
lysozyme level increased slightly in sarcoidosis and was markedly elevated in chronic 
myelomonocytic leukemia. Electron microscopy revealed increased number and size of 
lysosomes in proximal tubules of sarcoidosis and chronic myelomonocytic leukemia, those 
of which were associated with serum lysozyme levels.
Discussion: Underlying mechanisms of interstitial nephritis in sarcoidosis could be 
associated with proximal tubular absorption of lysozyme. We suggest that tubular injury 
of both sarcoidosis and chronic myelomonocytic leukemia could be categorized into 
lysosome-induced nephropathy. Chronic myelomonocytic leukemia induces acute kidney 
injury with overloaded lysozyme to the proximal tubules. On the other hand, chronic tubular 
injury of sarcoidosis may be associated with above average lysozyme stress on the tubules.
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ANCA Vasculitis Presenting with Chronic Active Interstitial Nephritis 
Without Glomerular Involvement
Callie Plafkin, Tripti Singh. Department of Medicine, University of Wisconsin 
School of Medicine and Public Health, Madison, WI.
Introduction: ANCA-associated vasculitis (AAV) with renal involvement typically 
causes pauci-immune glomerulonephritis. We present a rare case of chronic active interstitial 
nephritis as the sole renal lesion, without glomerulonephritis, in a patient with MPO AAV.
Case Description: A 45-year-old female with a history of Crohn’s disease, GERD 
with Barrett’s esophagus, endometriosis, and polyarthralgias was evaluated in nephrology 
clinic in 2018. Acute interstitial nephritis was initially diagnosed in 2011 on renal biopsy. 
There was no evidence of glomerulonephritis. p-ANCA was positive with MPO titer of 
>100 units/mL. She lacked systemic symptoms of AAV. Serum creatinine peaked at 2.1 mg/dL 
and improved to 0.9 mg/dL with prednisone and azathioprine. Repeat biopsy in 2013
for worsening renal function again showed acute interstitial nephritis and no vasculitic 
glomerular involvement. Prednisone and cyclosporine were started, with improvement 
in serum creatinine from 1.9 to 1.2-1.4 mg/dL. Crohn’s disease was diagnosed in 2014 
and adalimumab was started in 2016. Acute interstitial nephritis was attributed to Crohn’s 
and cyclosporine was stopped in 2016. Her gastrointestinal symptoms improved with 
adalimumab, but renal function and abnormal urine sediment did not. Attempt was made 
to switch omeprazole to an H2-blocker but this was not tolerated. Repeat renal biopsy 
in 2/2018 showed chronic active interstitial nephritis with severe interstitial fibrosis and 
tubular atrophy and no active glomerular disease. MPO titers remained high at 132 units in 
3/2018. She was started on mycophenolic acid and prednisone without significant response, 
followed by rituximab induction therapy for AAV-associated active interstitial nephritis. 
Serum creatinine continued to worsen to 5.5-5.7 mg/dL and preparations are being made to 
start peritoneal dialysis.
Discussion: AAV may present with isolated interstitial nephritis without glomerular 
involvement. The rarity of this presentation may contribute to delay in diagnosis and 
appropriate management. Alternate explanations for interstitial nephritis, such as Crohn’s 
disease or PPI use, should be considered with caution in the setting of high-titer ANCA 
positivity.
TH-PO560 Poster Thursday
Trainee Case Reports - I
Anaplasmosis Induced Acute Interstitial Nephritis (AIN) Following Tick 
Bite: A Rare Association
Neelofar R. Khan,1 Alia Hasan,2 Vanesa Bijol,3 Kenar D. Jhaveri,4 
Nupur N. Uppal.1 1Hofstra Northwell School of Medicine, Great Neck, NY; 
2Northwell Health, Briarwood, NY; 3Northwell Health Hofstra University, Lake 
Success, NY; 4Northwell Health Sys, Great Neck, NY.
Introduction: AIN usually results from immune mediated tubulointerstitial injury 
initiated by medications and infections. We present a rare case of kidney biopsy proven AIN 
associated with Anaplasmosis following a tick bite.
Case Description: 82 year old Caucasian woman with HTN, HLD presented with 
fever, tremors, myalgia and fatigue following a camping trip in Catskills where had 
significant outdoor exposure to the woods. She was found to have AKI, thrombocytopenia 
and transaminitis. She had serum creatinine(Scr) of 6.62 on admission which peaked at 
6.78 during hospitalization. Four months prior, her Scr was 0.9.She denied use of herbal 
supplements or antibiotics, however had used NSAIDs in the week before hospitalization. 
Urinalysis showed microscopic hematuria with 10-25 RBCs. Kidney ultrasound was 
negative for obstructive uropathy. Serological work up for glomerulonephritis was negative. 
Peripheral smear showed intracellular inclusions suggestive of morulae concerning for 
Anaplasmosis, and she was initiated on treatment with Doxycycline. Kidney biopsy was 
performed that revealed moderate AIN, along with 13% glomerulosclerosis, 10% interstitial 
fibrosis and tubular atrophy, and severe arterial and arteriolar sclerosis. AKI, transaminitis 
and thrombocytopenia started improving with initiation of Doxycycline. She did not require 
corticosteroid therapy. Although a tick was not noticed specifically, and work up including 
Anaplasma antibody, Ehrlicia PCR and Lyme’s titres were negative, she was continued on 
treatment for Anaplasmosis due to high clinical suspicion of the disease. She completed 10 
day course of Doxycycline. AKI resolved and Scr decreased to 1.16mg/dl 5 weeks after 
initial presentation.
Discussion: AIN mediated by various systemic bacterial, viral and parasitic infections 
is well known. However, association of AIN following anaplasmosis from a tick bite has 
not been well documented in the literature. To our knowledge, we report the first case of 
AIN in association with Anaplasmosis. Nephrologists, Infectious disease specialists and 
Internists should to be aware of this rare cause of AIN. Corticosteroids have no role in 
infection associated AIN as they are contraindicated in setting of active infection. AKI 
usually is reversible as infection is treated. Our patient regained baseline kidney function 
with antimicrobial therapy.
TH-PO561 Poster Thursday
Trainee Case Reports - I
AKI Associated with Suspected Yersinia Infection in Spring 2017
Yekyung Kim,1 Myung hyun Cho,1 Hyesun Hyun,4 Eujin Park,2 IL-Soo Ha,3 Hae 
Il Cheong,3 Hee Gyung Kang.3 1Seoul National university Children’s hospital, 
Seoul, Republic of Korea; 2Hallym University Kangnam Sacred Heart Hospital, 
Seoul, Republic of Korea; 3Seoul National University Children’s Hospital, 
Seoul, Republic of Korea; 4St. Vincent’s Hospital, The Catholic University 
College of Medicine, Soowon, Republic of Korea.
Introduction: Yersinia pseudotuberculosis, a zoonotic pathogen is known to cause 
fever, acute gastroenteritis, mesenteric lymphadenitis, or acute kidney injury (AKI). 
There have been frequent Yersinia infection outbreaks associated with contaminated food 
and unsterile water ingestion in the past. While it was considered practically eradicated 
with improvement of public health including control of mountain water cleanness, we 
experienced several cases with suspected Yersinia infection in 2017.
Case Description: There were 9 cases suspected of Yersinia infection (Male:Female 
6:3, mean age 7.57 years (range 3.01 - 12.18)). Six cases occurred in May and 8 resided in 
metropolitan Seoul area. Three cases had history of drinking mountain water. All the cases 
first presented with fever for median 13 days (range 6 - 20), and gastrointestinal symptoms 
and oliguria followed. Imaging studies revealed mesenteric lymphadenitis, terminal ileum 
wall thickening, and increased parenchymal echogenicity of kidney. Creatinine levels 
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increased to 3.03 - 9.22 mg/dL. Their urinalysis revealed sterile pyuria, proteinuria, and 
glycosuria, suggesting interstitial nephritis. Oliguria continued for 4-17 days and one 
patient required hemodialysis, however, all of them completely recovered from AKI. Rash 
developed later in four cases, and desquamation was noted in three. Mean disease duration 
from the onset of fever to discharge was 11.9 days (range 6 - 24). In the diagnostic work-up, 
Yersinia pseudotubuerculosis was isolated in stool culture in one patient. Anti-Yersinia IgA 
and IgG were found positivein six patients within three months after the onset of disease, 
suggesting recent Yersinia infection.
Discussion: Yersinia pseudotubuerculosis infection is a well-known cause of interstitial 
nephritis presenting with AKI. When a patient present fever, acute gastroenteritis, fever 
and AKI, clinician should suspect Yersinia infection. Furthermore, diagnosis of such a case 
warrants surveillance to identify the infection source and prevent an outbreak.
TH-PO562 Poster Thursday
Trainee Case Reports - I
A Unique Case of Tubulointerstitial Nephritis with Late-Onset Uveitis and 
Thrombotic Microangiopathy Induced AKI, Withdrawal from Hemodial-
ysis, and Relapse
Youlu Zhao,1,2 Jun-Wen Huang,1,2 Zhikai Yang,6 Tao Su,5 Liu Yang,4 Su X. Wang,3 
Li Yang.1,2 1Renal Division, Department of Medicine, Peking University First 
Hospital, Beijing, China; 2Peking University Institute of Nephrology, Beijing, 
China; 3Laboratory of Electron Microscopy, Peking University First Hospital, 
Bejing, China; 4Department of Ophthalmology, Peking University First 
Hospital, Beijing, China; 5Renal Division, Department of Medicine, Peking 
University First Hospital, Beijing, China; 6Peking University First Hospital, 
Beijing, China.
Introduction: Tubulointerstitial nephritis and uveitis syndrome (TINU) was first 
described in 1975 and there have been three hundred reported cases throughout the world 
since.
Case Description: A 37-year-old man presented with malignant hypertension 
(MHT) due to obstructive sleep apnea-hypopnea syndrome, acute kidney failure, and 
tubular dysfunction. Only hypertensive retinopathy was found. Renal biopsy showed 
TMA induced renal injury (possibly due to MHT)) with acute interstitial nephritis (AIN, 
Fig. 1-3). He had been taking pseudo-genseng lately. He was treated with hemodialysis, 
ACEI for MHT, oral prednisone for AIN (30mg/d for 6 weeks and then tapered to 
5mg/d). His renal function improved 5 months post biopsy. Hemodialysis was withdrawn 
and steroid was stopped. Kidney injury recurred 3 months thereafter. Bilateral uveitis 
(Fig. 5-7) was found and TINU was confirmed. Prednisone of 15mg/d was reinitiated and 
renal and tubular recovery were observed within 6 weeks. He is under follow-up. Anti-
mCRP antibody assay and Hazardous genotype were sent for tests.
Discussion: It is a unique case with severe AKI due to MHT induced TMA together 
with TINU. It is important to note that at the time of renal biopsy, with the history of pseudo-
genseng use, and ocular tests, he was misdiagnosed as drug-induced AIN and therefore 
prescribed a relatively short course of prednisone. His recurrent kidney injury with 
concomitant uveitis after prednisone withdrawal strongly suggested the needs for long-term 
follow up and elongated prednisone therapy for TINU. Another issue is that routinely ocular 
examination is critical, as here uveitis can be completely asymptomatic. In this case both 
TMA and AIN contributed to AKI, which requires further investigation.
TH-PO563 Poster Thursday
Trainee Case Reports - I
Karyomegalic Interstitial Nephritis: A Genetic Form of Renal Disease
Ignacio A. Portales castillo,1 Qiu J. Tong,1 David Gerling,2,1 Shubha Shastry.1 
1Rochester General Hospital, Rochester, NY; 2Rochester Regional Health, 
Rochester, NY.
Introduction: Karyomegalic interstitial nephritis is a rare systemic disease mainly 
manifested as progressive renal disease
Case Description: A 34 years-old man from Burkina Faso presented to the nephrology 
clinic for evaluation of CKD. He moved to the USA 1 year before presentation. On the 
initial visit to our clinic he had no acute complaints. He was seen by a nephrologist 6 years 
ago at his home town and was told that he had an elevated serum creatinine of 1.62 mg/dL. 
His medical history included untreated hepatitis B, frequent upper tract respiratory infections 
and unilateral gynecomastia. Family and social history were non-contributory. His current 
laboratory exams revealed a normal cell count, creatinine of 1.6 mg/dL, BUN of 13 mg/dL, 
a protein/creatinine ratio of 0.45 mg/g and a ALT and AST of 53 and 42 U/L respectively 
with normal bilirubin and mild elevation of alkaline phosphatase, hepatitis b viral load 
was 15428 IU/mL. Urinalysis showed trace glucose, protein and blood with normal 
appearing RBC and few granular casts on the sediment. Further work up including ANA, 
ANCA, SPEP, RF, hemoglobin A1C, hepatitis C, complement levels and immunoglobulin 
levels, were all unremarkable. A renal biopsy was performed which showed a primary 
tubulointerstitial disease with enlarged tubular epithelial nuclei, suggestive of karyomegalic 
interstitial nephritis (KIN).
Discussion: KIN was first reported in 1974 on a 22 years-old woman who died from 
hepatic carcinoma and a fungal respiratory infection, autopsy showed extreme dysplasia in 
the renal tubular cells. There have been around 40 more case reports, most include young 
patients with CKD progressing to ESRD in early adulthood, recurrent respiratory infections 
and abnormal LFTs. Our patient had this classic features in addition to hepatitis B and 
gynecomastia, which are of unclear relevance. It was initially hypothesized that KIN was 
triggered by a virus or toxin causing transient LFT elevations, but recently mutations in 
FAN1, a gene coding for a nuclease involved in DNA repair, have been identified. There 
is no specific treatment, our patient is currently being evaluated for breast biopsy and 
treatment of hepatitis B, ACE inhibitor was started for renal protection. This case adds to 
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the short list of case reports and brings to clinicians an interesting differential diagnosis of 
chronic tubulointerstitial disease.
TH-PO564 Poster Thursday
Trainee Case Reports - I
HIV Infection Associated with Plasma Cell-Rich Acute Interstitial 
Nephritis: A Case Report
Hatem Elabd,1,2 Tarek Rashid,1 Mennallah Elkholi,4 Michael B. Stokes.3 1Albert 
Einstein College of Medicine/Jacobi, New York, NY; 2University of Cairo, Cairo, 
Egypt; 3Columbia University Medical Center, New York, NY; 4University of 
Alexandria, Alexandria, Egypt.
Introduction: Acute interstitial nephritis (AIN) in HIV infected patients is usually 
attributable to drugs, opportunistic infections, and immune syndromes (e.g. immune 
reconstitution syndrome and diffuse infiltrative lymphocytosis syndrome). Whether HIV 
itself causes AIN is uncertain.
Case Description: A 59-year-old African female with a past history of hypertension 
was admitted with generalized weakness. Medications included lisinopril and nifedepine, 
and she denied NSAID, herbal, or illicit drugs. Physical exam disclosed no evidence of 
sicca syndrome. Laboratory evaluation was remarkable for serum creatinine of 12.9 mg/dl 
and blood urea nitrogen 149 mg/dl (baseline 3 months prior was 1.1mg/dl and 23 mg/dl 
respectively), hemoglobin 8.2g/dl, platelets 67 cells/mm3, 2+ schistocytes in peripheral 
smear, and LDH of 365 U/L. Urine microscopy showed innumerable WBCs/hpf, but no 
RBCs or casts. Spot urine protein–to-creatinine ratio was 1.7g/g. Given the suspicion 
for microangiopathic hemolytic anemia, she received empirical plasma exchange for 8 
sessions, with no improvement of hematological parameters. Subsequent HIV-1 antibody 
test was positive, with viral load of >715,000 copies/ml, and CD4+ count of 20 cells/mm3. 
ADAMTS-13 activity was normal. Renal biopsy showed normal appearing glomeruli 
and tubulointerstitial nephritis with numerous CD138+ plasma cells. No granulomas 
or features of thrombotic microangiopathy were seen. Immunofluorescence exam was 
negative, and no electron dense deposits or endothelial cell tubuloreticular inclusions were 
seen. Extensive infectious disease work up was negative. Bone marrow biopsy revealed 
hypercellular marrow, polyclonal plasmacytosis with CD138+ plasma cells (20%), and no 
evidence for malignancy or infections. Antiretroviral therapy (ART) regimen was started, 
with subsequent improvement in hematological parameters. Serum creatinine improved to 
2.5mg/dl and proteinuria resolved.
Discussion: To our knowledge, there are only 2 previous case reports where AIN was 
thought to be a direct complication of HIV infection, both of which also showed a plasma 
cell-rich tubulointerstitial infiltrate. The exclusion of common causes of AIN and response 
to ART therapy in our case suggest that HIV infection itself may occasionally present with 
acute kidney injury and AIN.
TH-PO565 Poster Thursday
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Taming Nephrogenic Ascites by Living Kidney Transplant in a Developing 
Country
Raja M. Rashid,1,2 Zahid Nabi,3 Zahid Ul Zahideen.4 1CPSP, Islamabad, 
Pakistan; 2Department of Nephrology, KRL hospital, Islamabad, Pakistan; 
3Nephrology, KRL hospital, Islamabad, Pakistan; 4Department of Nephrology 
KRL islamabad, Islamabad, Pakistan.
Introduction: Nephrogenic ascites is a diagnosis of exclusion and describes the 
refractory ascites in patients with renal failure before or after the initiation of dialysis. It’s 
a rare and devastating condition with an inconsistently reported incidence that is as low as 
0.7%. Renal transplant is considered the most effective management and has been described 
predominantly in deceased donor transplants from the high income countries. In low and 
middle income countries, nephrogenic ascites is still a visible problem but successful 
management with living kidney donation is not well reported.
Case Description: 45 years old male known case of ESRD was on twice weekly 
maintenance hemodialysis schedule since June 2010 via left brachiocephalic arterio-venous 
fistula, His Hypertension for the same time period was being managed by Losartan and 
Carvedilol. He presented with gradual abdominal swelling for last 6 months in the year 
2016. There was no history of current or preceding fever, abdominal pain, altered bowel 
habits, jaundice, weight loss, body aches or missed dialysis sessions. He was being dialyzed 
twice weekly with blood flow of 300 ml/min and dialysate flow rate of 500-600 ml/min. 
His average Inter-dialytic weight gain had been around 2.5 kg. Examination and work 
up demonstrated a serum albumin of 3.7mg/dl, low SAAG and exudative lymphocytic 
ascites and a normal peritoneal biopsy in a well-nourished man. After exhaustive work up; 
cardiac, hepato-billiary, infective and other causes of ascites were appropriately excluded. 
Intensification of hemodialysis and ultrafiltration with intermittent paracentesis did not 
improve his ascites. He underwent renal transplantation by donation from his spouse with 
paracentesis prior to transplantation. Instant graft function and uneventful post-transplant 
period resulted in gradual resolution and disappearance of ascites over 2 months.
Discussion: Not all patients completely fit the usual profile for nephrogenic ascites. 
Our patient developed nephrogenic ascites despite adequate nutritional status, normal serum 
albumin, ACE inhibitors and strict compliance with the dialysis schedule. Meticulous work 
up is required to exclude the direct causative pathologies. Lliving kidney transplant is an 
effective management strategy and can be carried out with only a fractional increase in work 
up related cost even in low and middle income countries.
TH-PO566 Poster Thursday
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A Unique Case of Oliguric Renal Failure in the Immediate Post-Trans-
plant Period
Irene Chernova,1 William S. Asch.2 1Yale New Haven Hospital, New Haven, CT; 
2Yale School of Medicine, New Haven, CT.
Introduction: Vascular complications are a well-recognized cause of renal allograft 
failure in the immediate post-op period. Renal allograft torsion is a rare cause of vascular 
compromise leading to graft injury that is associated with significant morbidity. We present 
a case illustrating the unique challenges of recognizing and treating this condition.
Case Description: 69yo F with history of end-stage renal disease secondary to 
polycystic kidneys on hemodialysis presented for deceased donor kidney transplantation. 
She had excellent urine output (UOP) and a transplant ultrasound with normal flow dynamics 
in the immediate post-op period; however, on post-op day #1 there was a significant decline 
in UOP which did not improve with intravenous fluid administration. Ultrasound of the graft 
demonstrated “abnormal waveforms throughout the transplanted kidney with tardus parvus 
waveforms and reversed diastolic flow” concerning for either renal artery stenosis or main 
renal vein thrombosis. She was taken emergently to the operating room for exploration. It 
was revealed that the graft had rotated 180 degrees about the axis of the artery and vein with 
the lower pole pointing toward the right flank. It appeared that the inferior aspect of her 
native right polycystic kidney may have abutted the upper pole of the allograft causing it 
to rotate medially. Upon reversal of the rotation there was immediate restoration of normal 
color, turgor and palpable pulse to the renal parenchyma and Doppler ultrasound confirmed 
excellent venous and arterial flows; a nephropexy was performed prior to closure. The 
patient had excellent post-op UOP and creatinine began downtrending in the next week and 
had stabilized at 0.8mg/dL by 1 month post-transplant.
Discussion: Fewer than 20 cases of allograft torsion have been reported in the literature 
as a cause of graft failure; over 50% of these grafts were lost. Most cases (15/16 in one 
review) occurred in simultaneous pancreas kidney (SPK) transplant recipients (13/16) or 
pediatric recipients (2/16). We present a rare case of a non-SPK allograft recipient who 
experienced allograft torsion and the first reported implicating native polycystic kidneys 
as a risk factor. While a rare complication, allograft torsion is associated with a high rate 
of graft loss and non-specific ultrasound findings; a high index of suspicion and surgical 
exploration are needed to salvage the organ.
TH-PO567 Poster Thursday
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An Atypical Cause of Autoimmune Hemolytic Anemia in a Post Kidney 
Transplant Patient
Aileen Wang, Asif A. Sharfuddin. Indiana University School of Medicine, 
Indianapolis, IN.
Introduction: Autoimmune hemolytic anemia (AIHA) is a rare but devastating 
consequence of solid organ transplantation. Commonly AIHA can be attributed to 
immunosuppression with calcineurin inhibitors or viral infection. Here we describe a 
unique cause of AIHA due to Coombs negative IgA associated AIHA that was refractory to 
both steroid therapy and adjustments in immunosuppression.
Case Description: 23-year-old Hispanic female with history of deceased donor kidney 
transplant in October 2016 (on tacrolimus, sirolimus, prednisone) presented with fatigue, 
sclera icterus, and jaundice. Recently she was given clindamycin for dental procedure. On 
lab Hgb low to 4 gm/dL (baseline 12). Work up revealed elevated LDH, low haptoglobin, 
elevated retic count, and indirect hyperbilirubinemia consistent with hemolytic anemia. 
Parvovirus B19 was negative. G6PD level was elevated. Peripheral blood smear revealed 
marked spherocytosis, anisocytosis, and schistocytes. High sensitivity Coombs test was 
negative. No splenomegaly on abdomen ultrasound. After transfusion Hgb improved to 
8.6, and she was discharged on Prednisone 60mg daily. However she was readmitted a 
week later with Hgb low to 4.8. Cr uptrended to 1.48 mg/dL (baseline 1.2). Tacrolimus was 
discontinued. PNH flow cytometry and SPEP were unremarkable. Bone marrow biopsy 
revealed increased erythropoiesis, supportive of peripheral red blood cell destruction. After 
transfusion Hgb improved to 8. Pt was continued on 60mg Prednisone along with initiation 
of azathioprine. But one week later, Hgb again low to 4.9. Sirolimus was then stopped. 
Negative coombs hemolytic panel and a drug induced antibody panel were sent. Negative 
coombs hemolytic panel detected an IgA autoantibody against red blood cells. Rituximab 
was initiated (375mg/m2 weekly). One month later, Hgb stabilized in range 13-14 with 
return of Cr to baseline. Sirolimus was restarted.
Discussion: This case illustrates an extremely rare autoimmune hemolytic process that 
is Coombs negative, non-drug induced, and steroid refractory in a kidney transplant patient. 
Splenectomy is usually considered as the first line therapeutic option for steroid refractory 
IgA associated AIHA, but in a post transplant patient there is the significant increase in 
infection risk that must be considered. Rituximab therapy though second line was the better 
choice in this patient who has achieved complete response to therapy.
TH-PO568 Poster Thursday
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AKI from Orthostatic Renal Graft Compression Following Weight Gain
Sebastian O. Hultin,1 Charles Fisher,2 Linda Thebridge,2 Carol A. Pollock.3 
1Royal North Shore Hospital, Sydney, NSW, Australia; 2Royal North Shore 
Hospital, St Leonards, NSW, Australia; 3The University of Sydney, St. Leonards, 
NSW, Australia.
Introduction: We present the first reported case of orthostatic renal graft compression 
from central adiposity resulting in acute kidney injury.
Case Description: A 61 year old man with a cadaveric transplant presented with 
hypertension and acute kidney injury with a creatinine rise from 80 to 210 μmol/L. His 
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past medical history included controlled diabetes, hypertension, ischaemic heart disease, 
and obesity requiring gastric sleeve with subsequent weight gain from 90 to 110kg. 
Renal biopsy was consistent with acute tubular necrosis without significant interstitial 
inflammation or signs of rejection. Serial renovascular duplex studies of the transplant 
graft were abnormal. Initial scanning showed severely reduced diastolic flow normalising 
towards the upper pole (RI0.78). The renal vein flow had normal phasicity and renal artery 
velocity was 336cm/s. Repeat scanning showed absence of diastolic flow and reduced 
perfusion despite a patent renal transplant artery and vein. Raising the fatty apron cephalad 
normalised renal blood flow with resistive indices between 0.76-0.79 throughout the kidney. 
Subsequent laparascopy ruled out adhesional obstruction and CO2 angiogram confirmed 
normal transplant vessels, anastomotic sites and intra-renal branches. Following initial 
empiric pre-biopsy pulsed steroids for presumed rejection, he was treated with bedrest and 
his creatinine was130μmol/L on discharge. Whilst advising weight loss, he was treated with 
an abdominal support belt.
Discussion: Our case highlights the potential growing problems of increasing obesity 
and inadequate assessment tools to assess abdominal weight gain in transplant patients. 
Transplant physicians and surgeons need to be aware of renal graft compression from an 
enlarged bulky omentum and fatty apron. Diagnosis requires positional prone doppler 
sonography. Aside from weight loss, optimal treatment is not known.
TH-PO569 Poster Thursday
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Transplant Renal Artery Thrombosis: Uncommon Complication of Acute 
Rejection
Jia Yi,1 Abhijit V. Kshirsagar,1 Randal K. Detwiler,1 Harsharan K. Singh,2 
Charles Burke.3 1University of North Carolina at Chapel Hill, Chapel Hill, NC; 
2University of North Carolina School of Medicine, Chapel Hill, NC; 3University 
of North Carolina, Chapel Hill, NC.
Introduction: Acute transplant renal artery thrombosis is rare, primarily seen in the 
immediate post-transplant setting related to surgical complication. We present a case of 
acute transplant renal artery thrombosis in a patient receiving treatment for acute cellular 
and antibody mediated rejection.
Case Description: 21 year old female with a stable renal transplant for 3 years 
(baseline creatinine 0.8 mg/dl) was admitted for acute kidney injury (creatinine 7.41) after 
not taking her immunosuppression due to gastroenteritis. She began empiric pulse dose 
methylprednisolone on presentation. Allograft biopsy on hospital day 3 showed acute 
cellular and antibody mediated rejection. She was started on thymoglobulin and plasma 
pheresis with initial improved renal function (creatinine 3.39). On hospital day 7, she began 
to have a progressive decline in urine output and kidney function. Doppler ultrasound 
revealed minimal perfusion to the transplant [Fig 1a]. Repeat kidney biopsy had near 
total renal infarction [Fig 2]. Confirmatory CT angiogram [Fig 1b] revealed no flow in the 
transplant renal artery. She re-initiated hemodialysis.
Discussion: Acute transplant renal artery thrombosis should be considered if anuria 
develops while being treated for allograft rejection. Prompt diagnosis and intervention is 
essential to prevent graft loss, unfortunately the most common outcome.
TH-PO570 Poster Thursday
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Delayed Graft Failure Secondary to Renal Vein Thrombosis in a Patient 
with a Permanent IVC Filter
Kristyn L. Lewis, Payal P. Patel, Laura Gil, Gregory Frey, Hani Wadei, 
Pramod K. Guru. Mayo Clinic, Jacksonville, FL.
Introduction: Transplanted renal vein thrombosis (RVT) is a rare cause of delayed 
graft failure in renal transplant patients. The estimated prevalence of graft vein thrombosis 
is 0.1% to 4.2%, mostly occurring in the early transplant period. The associated morbidity is 
devastating, given the high risk of permanent graft failure. Patient and donor related factors, 
along with multiple perioperative events, and immunosuppressive agents are incriminated 
for venous thrombosis in the early transplant period. We describe herein, an unusual case of 
RVT leading to severe graft failure after ten years of transplantation.
Case Description: A 53-year-old male with a deceased donor renal transplant 10 
years prior, for suspected glomerulonephritis, was admitted to the hospital with progressive 
bilateral lower extremity swelling, decreased urine output and weakness. One week prior, 
he was treated for suspected urinary tract infection at an outside facility. His graft function 
had been stable with a baseline creatinine 1.3-1.5 mg/dl on tacrolimus and mycophenolate. 
On evaluation, with help of ultrasonography and computed tomography, he was noted to 
have bilateral venous thromboses of iliac and popliteal veins with an extension into the 
transplanted renal vein. He was also noted to have a filter in his inferior vena cava, inserted 
in 2002. The patient was managed by catheter directed thrombolysis with help of tissue 
plasminogen activator (tPA), as well as systemic heparin therapy. His hospital course was 
complicated by acute severe graft dysfunction needing initiation of renal replacement 
therapy, and development of an anticoagulation related rectus sheath hematoma. His RVT 
showed partial resolution along with recovery of graft function in the ensuing two weeks. 
He was discharged on oral anticoagulation and off dialysis. Recent infection, obesity, a 
retained IVC filter, and possible undiagnosed hypercoagulable states were considered to 
have played roles in the thrombosis in this case.
Discussion: This case describes an atypically late presentation of transplanted renal 
vein thrombosis years after renal transplant. This case exemplifies both the risks associated 
with RVT, and the need for astute clinical vigilance for the early detection and timely 
initiation of appropriate therapy to salvage the precious graft in transplanted patients.
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Unusual Bilateral Renal Parenchymal Urine Leak After Pediatric En Bloc 
Kidney Transplantation
Rahul Nayak, Amit Sharma. Virginia Commonwealth University, School of 
Medicine, Richmond, VA.
Introduction: Use of en bloc kidney transplantation (EBKT) has not been universally 
accepted due to risk of technical difficulties and concerns related to inadequate nephron 
mass. We report an unusual case of renal parenchymal urine leak after EBKT that ultimately 
led to removal of both renal moieties.
Case Description: We transplanted pediatric en bloc deceased donor kidneys to a 49 
year male with ESRD. Caudal ends of donor inferior vena cava and aorta were anastomosed 
to recipient’s external iliac vein & artery. On POD 6, there was increased output of clear 
fluid in wound drain. CT-cystogram performed at this time showed mild caliectases of 
both transplant kidneys but no anastomotic bladder leak. Surgical re-exploration on POD 
8 revealed necrotic area on infero-lateral pole of lateral kidney leaking urine. Parenchymal 
leakage was repaired, but drain output remained high. On POD 31, patient was readmitted 
for abdominal pain. Renal scan revealed tracer accumulation originating from lower pole of 
lateral kidney confirming persistence of urine leak. Exploration confirmed recurrent lateral 
kidney urine leak at site of previous repair but other kidney showed a necrotic area at lower 
pole. Both kidneys were removed. Patient was relisted for transplantation.
Discussion: Early onset of urine leak from a necrotic area points towards vascular 
injury. Interestingly, pediatric recipient of liver from same donor as en bloc kidneys 
developed portal vein thrombosis. Another possible mechanism of urine leak could be 
thermal injury if Argon beam coagulation is used for superficial hemostasis on the thin 
cortex of pediatric kidneys after reperfusion. It could be speculated that prolonged surgical 
drainage along with bladder decompression could have salvaged en bloc kidneys. However, 
this patient continued to have abdominal pain despite presence of surgical drain. The second 
kidney were removed due to concern for impending infection at vascular anastomosis.
Strategies to prevent complications after EBKT
TH-PO572 Poster Thursday
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Choriocarcinoma Related to Kidney Transplantation
Guilherme P. Santa Catharina,1 Laura Onuchic,1 Ivens S. L Leite,1 
Gabriel C. Barsotti,1 Maria cristina R. Castro,1 Leonardo A. Testagrossa,2 
Flavio De paula.1 1University of Sao Paulo, Sao Paulo, Brazil; 2Hospital Sirio 
Libanes, São Paulo, Brazil.
Introduction: Malignancy related to solid-organ transplantation (Tx) due to 
immunosuppression is widely discussed and appears as one of the most common causes 
of graft failure and death. Cancer in the donated organ is rare, however, and its prognosis 
uncertain.
Case Description: A 58 year-old (y/o) male, on hemodialysis for the past 5 years 
due to hypertensive nephrosclerosis, was admitted for kidney Tx. His serologies and 
Panel Reactive Antibodies were negative. The donor was a 41 y/o female whose cause 
of death was subarachnoid hemorrhage. Her creatinine was 0.6mg/dL and 2 previous 
spontaneous abortions were the only reported significant medical history. Tx proceeded 
with a 31-hour cold ischemia time, a 0.86 KDRI and 36% KDPI. We followed institutional 
protocols for surgery and immunossupression, with no apparent complications. The 
patient presented delayed graft function, assessed by kidney ultrasound, CT scan and 
biopsy. The diagnosis of acute BANFF IIB rejection was established and treatment with 
Thymoglobulin® initiated, however no graft function improvement was observed. He 
developed infectious complications thereafter, followed by transplantectomy due to 
the possibility of pyelonephritis. Anatomopathological analysis of the graft revealed 
metastatic choriocarcinoma to the kidney. Similar findings were reported in other recipients 
of organs from the same donor. The heart recipient presented normal graft function 
and no signs of metastasis despite abnormal levels of serum beta-HCG (45mUI/mL). 
The contralateral kidney recipient evolved with normal graft function in spite of ascending 
serum beta-HCG (48.450mUI/mL). Shortly after, she presented pulmonary metastasis and 
death after refusing transplantectomy and an unsuccessful attempt of chemotherapy. The 
liver transplant in another recipient was initially successful, however ascending beta-HCG 
and hepatic nodules were identified. This patient is currently under chemotherapy. Our 
patient has presented full recovery following transplantectomy, with no signs of metastasis 
on PET-CT scan and normal serum levels of beta-HCG (1mUI/mL).
Discussion: To our knowledge, this is the second report of kidney graft with 
choriocarcinoma metastasis, however the first to compare outcomes between kidney graft 
preservation and transplantectomy, and its metastatic implications to different grafts.
TH-PO573 Poster Thursday
Trainee Case Reports - II
PML-IRIS in a Patient with Kidney Transplant
Huiwen Chen,1 Ghady Haidar.2 1University of Pittsburgh Medical Center, 
Pittsburgh, PA; 2UPMC, Pittsburgh, PA.
Introduction: Progressive multifocal leukoencephalopathy (PML) is a degenerative 
disease involving the central nervous system. It is caused by the John Cunningham virus 
(JCV) which commonly affects immunocompromised patients. We present the first case of 
PML complicated by immune reconstitution inflammatory syndrome (IRIS) described in a 
kidney transplanted patient.
Case Description: A 60 year old female with a history of kidney transplant in 
2009 and native kidney failure due to IgA nephropathy who presented to the clinic with 
partial expressive aphasia and loss of executive function. Patient was on tacrolimus (FK) 
and mycophenolate (MMF) as maintenance therapy. Physical exam does not show any 
facial droops or motor weakness. MRI brain finding was concerning for PML. Lumbar 
puncture had positive PCR for JC virus in spinal fluid. Serum JCV viral load was positive. 
Remaining serology and metabolic panel were normal. MMF and subsequently FK were 
both removed from the regimen. Patient then developed aphasia and right sided weakness. 
MRI showed new mass effect. Brain biopsy was consistent with PML-IRIS. Patient was 
started on dexamethasone with a slow prednisone taper. She exhibited a good neurological 
improvement two weeks into the treatment.
Discussion: PML is a severe opportunistic infection commonly affecting patients 
with immunosuppressed state. Manifestations of PML include motor deficit, dysarthria, 
dysphasia but most commonly weakness. MRI shows hyperintense lesion on T2 at the 
subcortical white matter. IRIS occurs due to exaggerated T cell response in patient who 
was previously immunocompromised. Symptom can occur one week to few months after 
treatment of primary disease. PML-IRIS is well documented clinical entity in human 
immunodeficiency virus infection, however, there is scant data and little awareness about 
the presentation in transplant patients. In patient with kidney transplant, post-transplant 
lymphoproliferative disease is also highly on the differentials as it is common complication 
for all solid organ recipients. The re-activation of immune system in our patient was likely 
due to discontinuation of immunosuppressant in fear of progression of PML. Diagnosis 
would be challenging without biopsy. Take home points: This is the first case of PML-IRIS 
described in patients with kidney transplant. Patient had dramatic neurological recovery 
after prednisone taper, but patient is at high risk for chronic allograft rejection.
TH-PO574 Poster Thursday
Trainee Case Reports - II
Breaking the Rules on PTLD
Brittaini D. Bunce,2,3 Jeet Gandhi,2 David N. Dado,2,3 Yanli Ding,1 
Suverta Bhayana.4 1Pathology, University of Texas Health Science Center, San 
Antonio, TX; 2Nephrology, University of Texas Health Science Center, San 
Antonio, TX; 3Nephrology, San Antonio Military Medical Center, Fort Sam 
Houston, TX; 4Transplant, University of Texas Health Science Center, San 
Antonio, TX.
Introduction: Early post-transplant lymphoproliferative disorder (PTLD) is mostly, 
but not invariably, associated with Epstein-Barr virus (EBV) infection. Most EBV-negative 
PTLDs occur more than a year post-transplant (median 50 months versus 10 for EBV-
positive) with the majority being monomorphic (67% versus 42% of EBV-positive). They 
are also more aggressive and more likely to require anti-neoplastic therapy along with 
reduced immunosuppression. Moreover, most PTLDs are B or T-cell clonal neoplasms and 
rarely plasma cell-rich entities.
Case Description: We present a unique case of a 53-year-old male with end-stage renal 
disease due to hypertensive nephrosclerosis who underwent deceased donor renal transplant 
with nadir serum creatinine (SCr) 1.6mg/dl. Perioperative course was uneventful. We 
used alemtuzumab induction with tacrolimus, mycophenolate mofetil, and corticosteroid 
maintenance therapy. Both donor and recipient were EBV seropositive. After the first month, 
patient underwent renal biopsy for suboptimal renal function, which showed nonspecific 
changes. At month two, he developed BK viremia, so immunosuppression was reduced. 
SCr then increased to 2.2mg/dl, prompting another biopsy, which showed a clonal plasma 
cell neoplasm (A, B) with lambda light chain predominance (kappa/lambda 1:10) and a 
negative EBV-encoded RNA in situ hybridization (EBER). Bone marrow biopsy showed no 
sign of plasma cell disorder. Patient was diagnosed with renal-limited polymorphic PTLD 
and treated with further immunosuppression reduction only. Biopsy six weeks later showed 
normal kappa/lambda and near complete resolution of PTLD (C, D).
Discussion: This is a very unusual case in that our patient was EBER-negative with a 
plasma cell-rich PTLD, yet presented early post-transplant with a polymorphic PTLD and 
an excellent response to reduced immunosuppression alone.
Trainee Case Reports - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
268
J Am Soc Nephrol 29: 2018 Poster/Thursday
Diffuse interstitial inflammation (A) with many plasma cells (B). Focal interstitial 
inflammation (C) with few plasma cells (D).
TH-PO575 Poster Thursday
Trainee Case Reports - II
Recurrent Monoclonal Ig Associated C3GN Post Transplant
Narsimha R. Keetha,1 Song C. Ong,3 Vineeta Kumar.2 1Nephrology, university of 
alabama at birmingham, Birmingham, AL; 2University of Alabama at 
Birmingham, Birmingham, AL; 3University of Alabama of Birmingham, 
Birmingham, AL.
Introduction: C3 glomerulopathy (C3GN) is one type of renal injury characterized by 
the predominant staining for C3 with absent or minimal staining for other immunoglobulin 
(Ig). Although the optimal treatment is unknown, success has been reported with B cell 
targeted chemotherapy. We describe a case of monoclonal Ig-associated C3GN recurring 
soon after transplant.
Case Description: A young woman with ESRD attributed to hypertension on 
hemodialysis for 7 years underwent a deceased donor kidney transplant in 2017. Creatinine 
(Cr) was 1.1 mg/dL with proteinuria of 0.35g/g at 1 week post-transplant. Within several 
weeks of transplant, she developed clinical nephrotic syndrome with Cr 2.5 mg/dL 
and proteinuria 4.3g/g. Renal allograft biopsy demonstrated a membranoproliferative 
glomerulonephritis (MPGN) on light microscopy. Immunofluorescence (IF) showed 2+ 
staining for C3. There was weak staining for IgM and C1q. Electron microscopy showed 
rare subendothelial electron dense deposits. Serum and urine were positive for a monoclonal 
IgG kappa with M spike of 0.64 g/dL. Records retrieved included a kidney biopsy in 2009 
which showed MPGN. IF showed IgG2+, C3 2+, C1q 2+, and kappa 1+. A monoclonal IgG 
kappa was detected, but a bone marrow biopsy was negative for a plasma cell dyscrasia. 
On reaching ESRD in 2010, she transferred care and records were not forwarded for 
transplant evaluation. Our patient underwent a second bone marrow biopsy that confirmed 
the presence of monoclonal plasma cells (0.2% of total). Workup for multiple myeloma 
was negative. She was commenced on cyclophosphamide, bortezomib, and dexamethasone. 
With treatment, proteinuria has improved to 2.2 g/g and renal function stabilized with a last 
follow-up Cr of 1.8.
Discussion: Our patient had a monoclonal gammopathy of renal significance 
(MGRS) which remained indolent for many years but caused recurrent disease rapidly 
after transplant. Successful treatment of monoclonal Ig associated C3GN in native kidney 
disease with chemotherapy has been described, but reports of treatment for recurrent 
disease post-transplant have been scant. In addition to chemotherapy, use of eculizumab 
has been reported to be successful. Following chemotherapy, our patient will be evaluated 
for an autologous stem cell transplant. Our case adds to the limited literature and awareness 
surrounding the diagnosis and treatment of this rare disease.
TH-PO576 Poster Thursday
Trainee Case Reports - II
New Pathogenic Mutations of Complement Factor H Causing Early 
Recurrence of C3 Glomerulonephritis After Kidney Transplantation
Juan P. Huidobro,1 Rodrigo Sepúlveda,1 Gonzalo P. Mendez,2 Rodrigo Tagle,1 
Elena Bresin,3 Aquiles Jara.1 1Nephrology, Pontificia Universidad Católica de 
Chile, Santiago, Chile; 2Pathology, Pontificia Universidad Catolica de Chile., 
Santiago, Chile; 3Mario Negri Institute for Pharmacological Research, Ranica, 
BG, Italy.
Introduction: C3 glomerulonephritis (C3GN) is a rare group of kidney disorders 
caused by over-activation of the alternative complement pathway. C3GN usually recurs 
between 3 to 6 months post-transplant. Here we report two likely pathogenic heterozygous 
variants in complement factor H (CFH), not previously described, involved in early 
recurrence of C3GN.
Case Description: A 24 year old female with history of left nephrectomy (vesicoureteral 
reflux) and ESRD with a kidney biopsy showing C3GN (MPGN with C3 deposition and 
microangiopathy (TMA)) received a deceased donor kidney transplant (KDPI 54%). She 
was on hemodialysis for 3 years with 2 vascular access thrombotic events. Her cPRA was 
0% and received steroids-basiliximab for induction. She developed early post-transplant 
renal vein thrombosis (day 1) with no urinary flow. A thrombectomy was performed and 
heparin was started. Thymoglobulin was initiated. The patient evolved with delayed graft 
function, with scintigraphy (MAG3) compatible with acute tubular necrosis (ATN), and 
was discharged on dialysis with tacrolimus, mycophenolate and prednisone. Three weeks 
later her creatinine clearance was 11 ml/min/1.73m2. A kidney graft biopsy was performed 
showing signs of ATN but also arteriolar acute TMA and extensive C3 deposition, with 
negative C4d. Anti-HLA antibodies were negative. The patient developed recurrent 
allograft infections and loss of kidney function. Therefore, a transplant nephrectomy was 
performed 3 months after transplantation. A genetic study was performed by NGS for CFH, 
CFI, CFB, C3, MCP, THBD, DGKE, and MLPA for CFH-CFHR1 hybrid gene and CFHR1-
CFHR3 deletion. Levels of CFH were slightly low 111.8 mg/L (NV 156-572). We found 
two variants in the N-terminal end of CFH: a new one in SCR1 domain (p.G60R) and a rare 
one in SCR4 domain (p.P260S) not previously reported.
Discussion: Several modeling software predicted that both mutations are probably 
pathogenic. In both cases the substitution induces the change of a hydrophobic amino-
acid for an hydrophilic one, potentially affecting structure and function of CFH. We report 
these two new CFH mutations as a potential cause for both fluid phase and cell-surface 
complement activation, accounting for the original disease and the early recurrence after 
transplant.
TH-PO577 Poster Thursday
Trainee Case Reports - II
Short Eculizumab Administration in the Treatment of De Novo Throm-
botic Microangiopathy (TMA) in Kidney Transplant: Case Series
Andrea Angeletti, Alessandra Spazzoli, Olga Baraldi, Vania Cuna, 
Valeria Corradetti, Giorgia Comai, Gaetano La Manna. University of Bologna, 
Bologna, Italy.
Introduction: De novo TMA adversely affects kidney transplant recipient and allograft 
survival. It remains unknown why only a relatively small percentage of the renal transplant 
recipients develop TMA. Complement activation is the common denominator in this 
condition. Eculizumab, a humanized monoclonal antibody targeted against complement 
C5, has been showed to be effective in the treatment of de novo TMA. How long the 
treatment have to be maintained is debated. We report the description of a prospective 
cohort of 10 patients primary treated with eculizumab (1 or 2 infusion) for de novo TMA 
after transplantation.
Case Description: All the recipients were transplanted with compatible ABO. The 
cohort were homogenous for age, sex, cold ischemic storage, inductive and mantainance 
imunosuppresive therapies. Diagnosis of de novo TMA was established by the founding of 
the triad: microangiopathic hemolytic anemia, thrombocytopenia and worsening of kidney 
function, excluding other potential secondary causes, as suggested in the literature. We 
performed kidney biopsies in 3 cases (Figure 1). All the subjects developed de novo TMA 
in the first week after transplantation. Eculizumab (600 mg) was administered once or twice 
based on lab findings at 1 week after infusion. TMA remission and impoved of kindey 
function were obtained in 9 patients (Figure 2).
Discussion: Eculizumab can be used to safely treat de novo TMA and also with 
efficacy, even if ceased in the short term.
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Trainee Case Reports - II
Allograft Membranous Nephropathy of Donor Origin – Response to the 
Immunological Environment of the Recipient
Yan Zhong,1 Philip M. Carpenter,2 Annika Khine,1 Neeraj Sharma,2 
Yasir A. Qazi,2 Thin Thin Maw,2 Miroslaw Smogorzewski.2 1LAC USC Medical 
Center, Los Angeles, CA; 2University of Southern California, Los Angeles, CA.
Introduction: Primary membranous nephropathy (MN) is the common cause of 
nephrotic syndromes in adults. The exact mechanism of kidney injury remained elusive 
until discovery of the podocyte antigen PLA2R and its IgG antibodies. We report a unique 
case of MN in the transplanted kidney.
Case Description: 59-year-old Caucasian female with history of HTN, DM and ESRD 
on hemodialysis for 6 years underwent the deceased donor renal transplant (DDRT) (HLA 
A24:68/B35:57/DR18:11 to A2:2/B35:39/DR4:14) with DGF. She required hemodialysis 
four times post DDRT. The kidney frozen section obtained before transplantation show 
135 glomeruli, 4% glomerulosclerosis, mild fibrosis and acute tubular necrosis. Eighteen 
days post DDRT, urine protein/creatinine ratio 34.2gm/gm was noted and SCr was 
1.73 mg/dL on standard therapy (tacrolimus, mycophenolate mofetil, prednisone). 
Allograft biopsy done 40 days post-transplant show thickened glomerular basement 
membranes with strong positivity for IgG, C3 and PLA2R1. Electron microscopy show 
subepithelial deposits along the basement membranes with spikes in between them. The 
original allograft biopsy performed at the time of transplant was stained with Jones silver 
and positive for PLA2R1, confirming that MN was of donor origin. The recipient’s serum 
PLA2R antibody was negative for 4 times over 8 months. Her serum albumin plummeted 
from 4.6g/dL to 2.4g/dL within 2 months after DDRT, but gradually improved to 4g/dL 
in 6 months. Proteinuria decreased to 1gm/24 hour and SCr remained 1.5-2.0mg/dL. 
Immunosuppression stays the same. We plan to repeat the allograft biopsy one year after 
DDRT to follow the expected histological recovery of the donor derived MN.
Discussion: This unique case of donor derived MN and subsequent clinical disease 
resolution after transplantation further supports the notion that PLA2R antibody is critical 
for the pathogenesis of MN. It is possible that immune mediated GN may eventually clear 
from the transplanted kidney with no adverse effect on allograft function after kidney is 
removed from the donor auto-antigenicity environment. Thus, the future allograft biopsy 
should show disappearance of PLA2R immune complex in the transplanted kidney.
TH-PO579 Poster Thursday
Trainee Case Reports - II
Secondary Focal Segmental Glomerulosclerosis in Pregnancy: A Risk for 
Renal Transplant Patients
Virginia Dines,2 Matthew R. D’Costa,1 Andrea G. Kattah.1 1Nephrology and 
Hypertension, Mayo Clinic, Rochester, MN; 2Internal Medicine, Mayo Clinic, 
Rochester, MN.
Introduction: Pre/eclampsia is usually the cause of worsening hypertension and 
proteinuria in pregnancy; however, these findings in a renal transplant patient lead to a 
wider differential. We present a case of focal segmental glomerulosclerosis (FSGS) in a 
pregnant patient 16 years post renal transplant.
Case Description: A 39 year old female with end stage renal disease secondary to lupus 
nephritis status/post living related kidney transplant, obesity, and hypertension presented 
with marked proteinuria and worsening hypertension at 14 weeks gestation. Her post-
transplant course had been uncomplicated by proteinuria. At presentation, she developed 
worsening hypertension and 24h total protein was 3.2 g. With strict blood pressure control, 
urine albumin-to-creatinine ratio (ACR) decreased to 641 mg/g (figure). At 20 weeks, ACR 
increased to 4399 in the setting of worsening hypertension. She was admitted to the hospital, 
and urinalysis showed no hematuria and C3/C4, dsDNA and other serologic workup was 
negative. Kidney biopsy revealed cellular FSGS with glomerulomegaly and 70% foot 
process effacement, concerning for hyperfiltration injury vs de novo primary FSGS. 
Proteinuria initially improved with strict blood pressure control; however she developed 
worsening hypertension, proteinuria, and edema at 36 weeks gestation due to pre-eclampsia 
and underwent cesarean section. She continued to have nephrotic range proteinuria, and 
renal biopsy at 11 weeks post-partum demonstrated features of secondary FSGS.
Discussion: The differential for proteinuria and hypertension in pregnant renal transplant 
patients includes pre/eclampsia, rejection, transplant glomerulopathy, and recurrent or de 
novo glomerular disease. Pregnancy creates a physiologic state of hyperfiltration due to 
increased fluid retention and blood flow. While allografts generally adapt to these changes, 
patients with obesity and uncontrolled hypertension are at risk for hyperfiltration-induced 
renal injury and FSGS, which in this case, was unmasked by pregnancy.
TH-PO580 Poster Thursday
Trainee Case Reports - II
A Novel Approach to Successfully Prevent Membranoproliferative 
Glomerulonephritis Recurrence in a High-Risk Transplant Patient
Suresh Murthy,1 Lachlan Mcmichael,1 Georgina Irish,1 Sean Haw Chang,2,1 
Stephen P. McDonald,1,3 Patrick T. Coates.1,3 1Royal Adelaide Hospital, 
Seacombe Gardens, NSW, Australia; 2SA Pathology, South Australia, Woodville 
South, SA, Australia; 3University of Adelaide, Adelaide, SA, Australia.
Introduction: Membranoproliferative glomerulonephritis (MPGN) is a particularly 
challenging primary pathology in kidney transplant patients due to its high rates of 
recurrence and graft loss. Aggressive or crescentic disease at presentation, low complement 
levels pre-transplantation, monoclonal gammopathy, live-related transplantation and certain 
HLA-associated risk factors are predictive of recurrence risk in the allograft. Various 
strategies have been used to manage such recurrence, but data is limited on pre-emptive 
management.
Case Description: We report the case of a 63-year-old woman with immune-complex-
mediated idiopathic MPGN who had several risk factors for allograft recurrence, receiving 
a second renal transplant following early recurrence in her first transplant. Rising creatinine 
and new proteinuria led to biopsy confirmed recurrent disease in her first transplant at Day 
76, with return to long term haemodialysis at day 86 despite maximal medical therapy to 
salvage the graft. 10 years later, she received a second, well matched transplant. Induction 
immunosuppression included anti-thymocyte globulin at day 0,1,2; plasma exchange at day 
3 and rituximab at day 5 and 18. Protocol biopsy at day 79 demonstrated minimal tubulitis 
and no recurrent primary disease. Another biopsy performed at day 197 due to elevated 
creatinine following clostridium difficile infection, again demonstrated no recurrent 
disease. She remains on prednisolone, mycophenolate mofetil and tacrolimus with stable 
graft function at 7 months.
Discussion: The optimal management of patients with idiopathic MPGN at the time 
of transplantation is unknown. We demonstrate a new approach with rituximab and plasma 
exchange for pre-emptive management of a patient with idiopathic MPGN and multiple risk 
factors for early recurrence. This strategy has been successful in maintaining recurrence-
free graft function at 7 months post transplantation
TH-PO581 Poster Thursday
Trainee Case Reports - II
Renal Replacement Lipomatosis in Transplanted Kidney
Wael A. Hanna,1 Ravindra Bollu.2 1Lehigh Valley Hospital, Breinigsville, PA; 
2Valley Kidney Specialists, Allentown, PA.
Introduction: Renal sinus lipomatosis (RSL) is a rare disorder where fatty tissue 
proliferate within the renal sinus and hilum. Renal replacement lipomatosis (RRL) is a 
severe form of RSL.
Case Description: A 63-year-old female with a history of end stage renal disease due 
to chronic glomerulonephritis underwent deceased donor renal transplant in February,1997. 
She has been diagnosed with chronic allograft dysfunction since 2002 with baseline 
S Cr 1.7-2 mg/dL. Immunosuppression has been maintained with Cyclosporine A, 
Mycophenolate mofetil and Prednisone. She experienced recurrent urinary tract infections 
since her kidney transplantation. She presented to emergency department with abdominal 
pain. On examination, a large right lower quadrant mass could be palpated. S Cr was at her 
baseline. CT scan of the abdomen and pelvis revealed a 24 cm large fatty mass centered in 
the hilum of the right lower quadrant renal transplant with splayed transplant parenchyma 
and collecting system. CT scan reading suggested the possibility of well differentiated 
liposarcoma. CT guided biopsy of the mass was performed. Pathology demonstrated mature 
adipose tissue with chronic inflammation.
Discussion: Renal replacement lipomatosis (RRL) is a rare condition, characterized 
by excessive fatty proliferation of the renal sinus with atrophy of the renal tissue. Aging, 
obesity and calculus disease are possible risk factors for RRL. Recurrent urinary tract 
infections has been described in most cases of RRL. The period between renal transplant 
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and RRL diagnosis has been variable in the literature, ranging from 6 months to 8 years. 
Our case was diagnosed after 21 years from her renal transplant. RRL is a very rare disease 
in kidney transplant. It should be differentiated from other fat containing tumors like 
liposarcoma and angiomyolipoma.
TH-PO582 Poster Thursday
Trainee Case Reports - II
A Case of a Kidney Transplant Recipient with Severe Throat Pain
Amin Khalifeh-Soltani,1,3 Peter J. Kennel,1,3 Jeffrey I. Silberzweig,2 John R. Lee.2 
1Weill Cornell Medicine, New York, NY; 2The Rogosin Institute, New York, NY; 
3NewYork-Presbyterian Weill Cornell Medical Center, New York, NY.
Introduction: Deceased donor renal transplants have a 5-year graft survival rate 
around 90% at our center. However, combination immunosupressive therapy increases 
susceptibilty to infections. Here we report the case of a patient with a history of multiple 
bacterial, viral and fungal infections who presented with throat pain.
Case Description: This 50-year-old woman had chronic kidney disease secondary 
to lupus nephritis; she received a renal transplant from a deceased donor after a failed 
transplant from a live donor. She was managed with thymoglobulin-based induction and 
maintained on mycophenolate mofetil, prednisone, and belatacept, which was switched to 
tacrolimus four weeks after transplantation. Her course was complicated by ganciclovir-
resistant CMV disease of the GI tract, recurrent ESBL E coli bacteremia, RSV bronchiolitis 
requiring prolonged intubation, Pneumocystic jiroveci pneumonia and probable pulmonary 
aspergillosis, requiring tracheostomy for ventilator weaning. Four months after being 
weaned from the ventilator, she presented with severe right neck pain, throat pain, and 
dysphagia. MRI revealed a rim enhancing collection in the left laryngeal tissue abutting the 
left lateral thyroid cartilage. Following percutaneous drainage, cultures grew no bacteria; 
she was treated with meropenem and vancomycin. Her throat pain and dysphagia worsened 
and she was started on voriconazole empirically. Left neck exploration revealed a severely 
remodeled, necrotic and fibrous sternothyroid muscle. Extensive debridement of the deep 
strap layer was performed and a subperichondrial abscess drained. Pathology revealed 
necrotic cartilage with septate fungal hyphae, compatible with a diagnosis of Aspergillus 
laryngeal abscess. Due to progression of the fungal infection on empiric voriconazole, 
the patient was switched to posaconazole. Her pain and dysphagia improved and she was 
discharged on day 23 with posaconazole. After 3 months of treatment, her throat pain 
resolved.
Discussion: We report a rare case of an Aspergillus abscess of the larynx causing neck 
and throat pain and dysphagia. Differential diagnosis for throat pain in immunosuppressed 
kidney transplant recipients needs to include bacterial, viral, and fungal pathogens.
TH-PO583 Poster Thursday
Trainee Case Reports - II
A Case of Biopsy Proven Histoplasmosis in a Renal Allograft
Anum Malik, Ziad S. Zaky, Ali Mehdi. Cleveland Clinic, Beachwood, OH.
Introduction: Fungal infections in immunocompromised hosts are well described. 
However, histoplasma capsulatum is not known to directly infect the allograft in kidney 
transplant (KT) patients. We report a case of disseminated histoplasmosis infecting the renal 
allograft.
Case Description: A 52 year old male with ESRD from IgA nephropathy, status post 
deceased donor KT in 2007, presented in 2017 with constitutional symptoms, dry cough and 
AKI for 3 weeks. His transplant course was complicated by an early Banff 1A rejection and 
was maintained on tacrolimus (FK), mycophenolate (MMF) & prednisone. Of note, he had 
recently been renovating a house in southern Ohio. CT chest & abdomen showed bilateral 
lung opacities, mediastinal/hilar lymphadenopathy & perinephric fat stranding around the 
allograft. Due to the unexplained AKI, a renal biopsy was done, showing focal granulomatous 
interstitial inflammation with silver positive organisms and glomerulitis with macrophages 
containing histoplasma. A transbronchial lung biopsy confirmed granulomatous pneumonia 
with histoplasma, meeting criteria for disseminated histoplasmosis. Histoplasma urinary 
antigen also resulted positive later. He was discharged on itraconazole and MMF was held. 
He was re-admitted a week later with diffuse morbiliform rash concerning for cutaneous 
histoplasmosis, but skin biopsy was consistent with drug reaction. Due to amphotericin B 
intolerance, he was switched to oral fluconazole, with a goal of 12 months treatment. At 3, 
6 & 9 months follow up, he continued to do well with his creatinine stabilizing at baseline. 
His MMF was resumed after 6 months of antifungal treatment.
Discussion: We present a unique case of a biopsy proven disseminated histoplasmosis 
involving renal allograft in a KT patient who has done well with treatment. Our case 
underscores the importance of a broad differential and thorough history when evaluating 
immunocompromised patients.
GMS stain showing both yeast and hyphae in the interstitium, consistent with histoplasmosis.
TH-PO584 Poster Thursday
Trainee Case Reports - II
Isolated Intrarenal Mucormycosis Due to Rhizopus Species in a Pediatric 
Renal Transplant Recipient
Kiri W. Bagley, Keia Sanderson, William A. Primack. University of North 
Carolina at Chapel Hill, Chapel Hill, NC.
Introduction: Mucormycosis (MM) is an unusual but well-known complication of 
solid organ transplant, which disseminates aggressively with a high mortality rate. Our 
patient may be the first reported child with isolated renal allograft MM.
Case Description: 3-y.o. female, with ESRD due to hypoplastic/dysplastic kidneys, 
received a cadaveric renal transplant after basiliximab induction, with subsequent pred, tac, 
and MMF. 4 weeks post Tx she developed fatigue, tachypnea, and increase in SCr to 1.7 from 
baseline of 0.4. UA revealed moderate LE, + nitrites, many WBCs and RBCs, and moderate 
bacteria. Renal US showed mildly distended ureter and renal pelvis with collecting system 
debris. She received broad-spectrum antibiotics. Renal biopsy showed tac toxicity. She 
stabilized and was discharged on reduced tac. Antibiotics discontinued as urine culture was 
negative. 5 weeks post-discharge, she redeveloped fever, pyuria, and rising SCr. US showed 
thickened ureter and renal pelvis. Parenteral antibiotics were resumed. Urine culture was 
negative. Repeat UA showed less but persistent pyuria. Antibiotics broadened on hospital 
day (HD) 2 due to unremitting fever. Steroid pulse on HD 3 for possible rejection. Fever 
abated on HD 4, and steroids tapered after no rejection on biopsy (HD 6). Tachycardia, new 
fever (HD 7) and tachypnea (HD 8) developed with progressive abdominal distention. US 
showed fluid collections within allograft. Rhizopus sp. was identified from intrarenal fluid 
aspirate, and amphotericin and posaconazole were begun. Transplant nephrectomy occurred 
the next day. CNS, chest, abdomen, and pelvis imaging were negative for disseminated 
MM. After nephrectomy, catheterized UA was benign. 10 days post-op, she developed new 
fever. Laparotomy showed no disease spread. Other organ recipients from same donor did 
not develop MM. She received a 3-month posaconazole course with clinical improvement. 
She was discharged after 2-month hospitalization. She has been off antifungal therapy for
>1 month, and is doing well on outpatient hemodialysis.
Discussion: MM is a rare, usually disseminated complication of renal transplant with
mortality reported as >50% when graft involvement occurs. MM isolated to the renal
allograft is unusual. Clinicians should consider the possibility of intrarenal allograft MM
with bacteriologic culture negative patients with pyuria.
TH-PO585 Poster Thursday
Trainee Case Reports - II
A Case Report of Pulmonary Alveolar Proteinosis in a Renal Transplant 
Recipient
Candice Khor,1 Subramanian K. Kumar.2 1Gosford Hospital, Sydney, NSW,
Australia; 2Gosford Nephrology, TERRIGAL, NSW, Australia.
Introduction: Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease 
characterised by accumulation of surfactant. Clearance of surfactant by alveolar 
macrophages is regulated by granulocyte macrophage colony stimulating factor (GM-
CSF). Autoimmune PAP due to GM-CSF antibodies is the most common cause of PAP 
Trainee Case Reports - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
271
J Am Soc Nephrol 29: 2018 Poster/Thursday
in adults. Secondary causes include dust exposure, haematological malignancy and 
immunosuppressive medications.
Case Description: A 52 year old man developed progressive shortness of breath, 
hypoxia and productive cough one year post living unrelated renal transplant for polycystic 
kidney disease. This is in the context of BK virus nephropathy at three months post-
transplant requiring a change in immunosuppressants from tacrolimus and mycophenolate 
to cyclosporine and leflunomide. A high resolution computed tomography (HRCT) of 
the chest demonstrated bilateral peri-hilar ground glass opacities. Pneumocystis jiroveci 
pneumonia (PJP) treatment was commenced with no clinical improvement. Bronchoscopy 
with bronchoalveolar lavage was inconclusive. The patient underwent a transbronchial 
biopsy which was positive for periodic acid-Schiff (PAS) proteinaceous material confirming 
the diagnosis of pulmonary alveolar proteinosis. There was no evidence of haematological 
malignancy clinically and on bone marrow biopsy. Immunosuppression was changed to 
tacrolimus and mycophenolate with no improvement in respiratory symptoms. Serum GM-
CSF antibodies subsequently returned positive with titres rising from 0.50 to 0.66 suggestive 
of autoimmune PAP. Rituximab, intravenous immunoglobulin and plasma exchange were 
considered however patient responded clinically and radiologically after a total lung lavage.
Discussion: Pulmonary alveolar proteinosis is a rare but important differential 
diagnosis to consider in patients with subacute onset of dyspnoea and hypoxia with the 
typical radiological changes of ground glass opacity and interlobular and intralobular septal 
thickening. Importantly PJP can mimic PAP and must be excluded in an immunosuppressed 
patient. Primary PAP due to GM-CSF antibodies accounts for the vast majority of adult 
PAP with whole lung lavage as the gold standard of treatment. Secondary PAP due to 
haematological malignancy, dust exposure and immunosuppressants must be considered 
and excluded.
TH-PO586 Poster Thursday
Trainee Case Reports - II
Belatacept Recovers Renal Allograft Function Despite Extensive Fibrosis
Arpita Basu,1 Hatem Amer,2 Mariam P. Alexander.1 Mayo-Transplant Neph 
1Mayo Clinic, Rochester, Rochester, MN; 2Mayo Clinic, Rochester, MN.
Introduction: Prolonging kidney allograft lifespan is a complex problem despite 
advances in the field. Histological findings of fibrosis indicate irreversible injury, that 
increases with severity, ultimately resulting in graft loss. Good renal function despite severe 
fibrosis is a goal of therapy. We present 2 patients whose renal function improved with 
Belatacept in presence of substantial chronic damage.
Case Description: Patient 1: 46 year old male recipient of a deceased donor kidney. 
Received thymoglobulin induction and maintained on Tacrolimus, Mycophenolate Mofetil 
and Prednisone. Biopsy 1 week post transplant for poor renal function, showed significant 
fibrosis(Table1). Belatacept was substituted for Tacrolimus.He was liberated from dialysis 4 
months later. Renal function continued to slowly improve over the years. Patient 2: 35 year 
old lady received a living donor kidney. Immunosuppression similar to that of Patient 1. 
Three years post transplant, she was noted to have worsening renal function. Biopsy showed 
extensive chronic changes(Table1). Conversion to Belatacept led to gradual improvement 
in renal function.
Discussion: Belatcept’s renal sparing abilities improve renal function and can extend 
allograft survival despite severe chronic injury. The improvement is gradual occurring 
over several months to years, indicating a mechanism beyond the initial mitigation of the 
vasoconstrictive effects of Tacrolimus.
Table 1
Crcl: Creatinine Clearance in ml/min
Fig 1
TH-PO587 Poster Thursday
Trainee Case Reports - II
TCR NGS Based Evidence for Differential Diagnosis and Personalized 
Therapy in BKV Nephropathy
Ulrik Stervbo,1 Mikalai Nienen,1 Richard Viebahn,2 Timm H. Westhoff,1 
Nina Babel.1 1University Hospital Marien Hospital Herne, Herne, Germany; 
2Ruhr University Bochum, Bochum, Germany.
Introduction: BKV nephropathy (BKVAN) is a disease in 10% of renal transplant 
recipients which might lead loss of the graft in up to 80% of the cases. Current the diagnosis 
is based on assessment of BKV viral load in serum with assessment of inclusion bodies 
by kidney biopsy for definitive diagnosis. In case of identified BKVAN, the principle 
treatment is to decrease or alter the immunosuppressive regimen. However, the pathological 
features of BKVAN overlap with those of acute cellular rejection, where decrease of 
immunosuppression is detrimental.
Case Description: We were presented with a German male, transplanted with a 
kidney from a close living relative. The patient had a high BKV load (432500 copies/ml), 
but histological findings demonstrated borderline rejection according to BANFF, and 
SV40 negative findings. Faced with the vexing question of increasing or decreasing 
immunosuppression we obtained blood and a biopsy from the patient. By way of magnetic 
bead enrichment of activated T-cells we isolated T-cells reactive to BKV and donor cells 
in a direct and indirect fashion. Together with the fresh renal tissue, the activated T-cells 
were prepared for next-generation sequencing (NGS) of the T-cell receptor (TCR). We 
isolated T-cells in all three activation modi, which indicates an expansion of virus as well 
as donor specific T-cells in the patient, and underpins the complexity of diagnosis. When 
we compared the TCR repertoires of activated peripheral T-cells to those in the biopsy, we 
observed a distinct and strong presence of BKV specific T-cells in the transplant. This clearly 
excluded acute cellular rejection and allowed confident decrease of the immunosuppressive 
regimen. The graft function improved and the patient shows no signs of BKV infection nor 
graft rejection.
Discussion: TCR NGS profiling is a novel, but labor insensitive technique. The 
turnaround time is about 5 days and donor derived cells are required for optimal results. 
Identification of the specificity of tissue infiltrating T-cells by TCR NGS is nonetheless a 
valuable technique for differential diagnosis and personalized therapy.
TH-PO588 Poster Thursday
Trainee Case Reports - II
The Conundrum of a Peculiar Skin Lesion on the Face of a Renal 
Transplant Recipient
Muhammad O. Saleem, Sandeep Padala, Natalie Smith, Rajan Kapoor. 
Nephron@AU Medical College of Georgia, Augusta University, Augusta, GA.
Introduction: Parasitic infections may be challenging to diagnose especially in 
transplant population. We present a rare case of cutaneous larva migrans (CLM) at an 
unusual site in a renal transplant recipient.
Case Description: 64 year African American female with a medical history of 
Autosomal Dominant Polycystic Kidney Disease, who received a cadaveric transplant 
3 months ago presented for routine follow up. She had no complaints except that of a 
disfiguring skin lesion on her forehead associated with itching. She denied fever, cough, 
other skin involvement, recent travel or exposure to sand beaches or contaminated soil. 
She does not have any pets. Physical exam revealed an expanding serpiginous papule on 
her forehead which was extremely pruritic. Home medications were not suggestive of any 
correlation. All routine labs were normal. She tried some over the counter topical and oral 
anti-allergic meds with no benefit. Although, a very unusual location but with telling clinical 
presentation a diagnosis of CLM was made and she was treated with oral Ivermectin. 
Patient reported complete resolution of her rash 5 days post treatment.
Discussion: Transplant population is prone to myriad of infections including parasitic 
infestations, incidence of which may be as high as 2.4%. The most common parasitic 
infection once reported was Strongyloids. Intestinal parasitic infestations are more common 
in Solid Organ Transplant recepients especially in developing countries. A parasitic 
infection should always be in the list of differential diagnosis, if clinically suggestive so as 
to avoid the diagnostic delay and further potential complications. CLM is rarely reported in 
transplant patients and the lesion on forehead is exceptionally rare. We present successful 
outpatient management of a rare clinical presentation of CLM.
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                    Face lesion
TH-PO589 Poster Thursday
Trainee Case Reports - II
Diffuse Alveolar Hemorrhage with Respiratory Failure: A Case of 
Strongyloides Hyperinfection Post Renal Transplantation
Imtiyaz H. Hakeem, Cristina E. Pinal, Faiza N. Khan. Baylor Scott & White 
Health/Texas A&M COM-HSC, Temple, TX.
Introduction: Strongyloides Stercoralis is an intestinal nematode which infects 
millions of people. It is endemic in South Asia, Latin America, Sub Saharan Africa and 
South Eastern United States. The infection usually is asymptomatic but can be serious in the 
immunocompromised Host.
Case Description: We present 60 y.o.African American Male an Army Veteran 2 
months post Deceased Donor Renal Transplant on Immunosuppression. He presented with 
10 days of severe fatigue, weight loss, cough, and multiple loose stools every day. He was 
born in Central Texas and lived most of his life in this area. He had no travel to Asia or the 
Middle East. Visited Mexico and Florida a few times in the remote past. Initial imaging 
was consistent with pulmonary infiltrates. Progressive Anemia with pulmonary infiltrates 
prompted Bronchoscopy with BAL which revealed Diffuse Alveolar Hemorrhage. Started 
on high dose pulse steroids, plasmapheresis. Intubated for Respiratory failure.. ANCA, 
APS, Anti-GBM, ANA profile was negative and kidney biopsy showed no evidence of 
vasculitis. Repeat BAL was positive for the larval forms of Strongyloides. Diffuse purpuric 
rash on abdomen, punch Biopsy revealed Strongyloides larvae. Stool O&P returned positive 
for the Strongyloides, but ELISA was negative.. He was started on subcutaneous Ivermectin 
and albendazole but showed no improvement. Irreversible septic shock ensued resulting in 
death. His pre transplant serum returned negative for Strongyloides antibody. Donor serum 
returned positive for Strongyloides. liver and lung tissues showed larval forms on autopsy.
Discussion: The global burden caused by Strongyloides stercoralis is not completely known. 
Humans become infected when filariform larva penetrates the skin or mucosa. Hyperinfection 
happens in immunocompromised hosts when reduced immunosurveillance leads to unrestricted 
proliferation of the worms. In hyperinfection, enteric bacteria can be carried by larvae which 
results in fatal septicemia. The American Society for Transplantation guidelines recommend 
screening for Strongyloides in recipients from endemic areas with no mention of donor screening 
Increased suspicion, surveillance, and screening of the donors and recipients from the endemic 
areas is needed to avoid any fatal effects of the superinfection in transplant recipients.
TH-PO590 Poster Thursday
Trainee Case Reports - II
APRT Deficiency Related Crystalline Nephropathy Causing Acute Renal 
Allograft Dysfunction: A Case Report
Sudip M. Patil, Sagar Gupta, Dinesh Khullar. Max Super Speciality Hospital, 
New Delhi, India.
     Introduction: APRT(Adenine Phosphoribosyl Transferase) deficiency is an AR 
metabolic disorder that leads to accumulation of insoluble purine dihydroxyadenine (DHA) 
in the kidney. It results in crystalluria & urinary stones leading to renal colic, hematuria, 
UTI & renal failure. Age at presentation can range from 5 months to late adulthood. Upto 
50% of patients may be asymptomatic. Prevalence is largely unknown. Lack of awareness, 
inadequate evaluation of stones & confusion of DHA crystals with uric acid or calcium 
oxalate contribute to diagnosis being missed. We report here a case of acute renal allograft 
dysfunction secondary to APRT deficiency related crystalline nephropathy, a relatively 
rare entity. 
Case Description: A 51 year-old male was evaluated for acute allograft dysfunction. 
His past history was significant for ESRD secondary to nephrolithiasis. No stone 
biochemical analysis or genetic studies were performed. He underwent living unrelated 
kidney transplantation (donor wife) 3 months back. Post-operative period was uneventful 
with nadir S.Crt of 1.2mg/dl. Basiliximab for induction and tacrolimus, MMF& 
prednisolone were used for maintenance immunosuppression. On routine labs he was 
found to have S.Crt of 2.3mg/dL. USG allograft was unremarkable. Renal allograft biopsy 
was performed and showed 0/5 glomeruli being sclerosed. Tubulopathic changes in form 
of tubular epithelial simplification and intraluminal polarizable crystals were noted. No 
evidence of rejection was found. A histopathological diagnosis of acute tubular injury 
with tubular crystallization was made.24hUr oxalate level was 55.6mg/d(N<45) & Pl. 
Oxalate was 3.34μmol/L(N< 3.0). Genetic analysis revealed a previously unreported 
homozygous nonsense mutation in exon 3 of APRT gene. Hence a clinical diagnosis of 
APRT deficiency related renal disease was made. He was started on Allopurinol 
100mgBID with low purine diet & increased fluid intake. S.Crt gradually improved to 1.2 
and has remained stable for last 1 year.
Discussion: Initial presentation of APRT deficiency can be insidious onset of renal 
dysfunction due to crystalline tubulopathy or interstitial nephritis without urolithiasis. High 
index of suspicion, correct identification of DHA crystals, renal biopsy & genetic testing 
are needed to clinch the diagnosis. Treatment with allopurinol, low purine diet and 
increased fluid intake is simple & effective.
TH-PO591 Poster Thursday
Trainee Case Reports - II
Clinical Tolerance - A Rare but Highly Deserved State of the Post-Trans-
plant Patient
Monzurul Chowdhury,1 Kenneth A. Bodziak.2 1UMASS Memorial, 
Worcester, MA; 2UMass Memorial Medical Center, Worcester, MA.
Introduction: Graft tolerance is a clinical situation defined as stable graft function 
without clinical features of chronic rejection, and in the absence of any immunosuppressive 
drugs, usually for longer than 1 year’s duration. This is observed more frequently in 
liver transplant patients but spontaneous graft tolerance has also been rarely reported in 
kidney allograft recipients. Many of these patients with presumed tolerance, in fact, are 
detected when they report to the treating physician with near normal graft function, but in 
the absence of immunosuppression. We present a case of immune tolerance following 
kidney transplant in an individual with normal graft function who had gone 10+ years without 
any immunosuppression.
Case Description: 62-year-old male with the history of DM II, hypertension, 
renal stone, past deceased donor kidney transplant (2002) presented with chief 
complaint of abdominal pain, fever, and diarrhea for one week. His CT of the 
abdomen and pelvis showed a perforated appendix and was treated with antibiotics and 
the abscess was drained. He recovered from his current illness and his discharge 
creatinine was 1.07 mg/dL with eGFR 75 ml/min. He received an HLA-matched 
deceased donor kidney transplant on 2002. His postoperative course was uncomplicated 
and creatinine improved from 5 mg/dL to  2 mg/dL at discharge. He was discharged 
on tacrolimus, mycophenolate, and prednisone. He gradually lost follow-up and 
stopped taking all of his medications, including his immunosuppressants, for more 
than 10 years on his own accord. He preserved his renal function for all these years 
without any immunosuppressive medications. His chimerism study from buccal mucosal 
cells was negative but could not exclude microchimerism. He was subsequently 
discharged and maintained off immunosuppressive medications.
Discussion: The evolution of tolerance to donor alloantigen in vivo is a dynamic 
process involving many mechanisms that contribute at different stages. The clinical 
characteristics of tolerance patients are limited due to its rare occurrence. Our patient 
gradually discontinued his immunosuppressive over the course of months by himself. The 
possible mechanisms for his immune tolerance could be central (intrathymic) deletion, 
peripheral deletion, anergy, ignorance and/or microchimerism, either alone or in 
combinations. He still maintains a good graft function without any immunosuppressant.
TH-PO592 Poster Thursday
Trainee Case Reports - II
Graft-versus-Host Disease After Kidney Transplant
Omar H. Sanchez vazquez, Renato Parra Michel, Marlene D. Cisneros-Carbajal, 
Antonio M. Murga, Francisco Fuentes Ramirez, Ana M. Molgado 
castillo. Universidad de Guadalajara, Centro Universitario de Ciencias de 
la Salud, Hospital General Regional No.46, Instituto Mexicano del 
Seguro Social, Guadalajara, Mexico.
Introduction: Graft-versus-host disease is an uncommon complication after 
solid organ transplantation. Few cases of graft-versus-host disease after kidney 
transplantation have been reported.
Case Description: A 32-year-old man was admitted to our hospital in August 
2017 due to cellulitis of the right leg. He received ceftriaxone and clindamycin. His past 
medical history included end-stage renal failure at the age of 19 years old. It was 
necessary to start peritoneal dialysis until he received a renal transplant in 2007 from a 
related donor (his father, 41-years-old at the time), he had matching HLA (A, B and 
DR) antigens. The recipient received induction therapy with rabbit-antithymocyte 
globulin and a triple immunosuppressive regimen. In February 2018 he developed 
bullous lesions burning pain on the back of the left leg. Skin lesions then coalesced and 
became hemorrhagic, spreading to the rest of the leg and thigh. They eventually turned into 
crusts in a month. A Dermatology evaluation was requested, and a skin biopsy was 
performed. Biopsy reported: epidermal 
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acanthosis and mild spongiosis of the basal layer; upper dermis showed blood vessels 
with lymphocytic infiltrate (without vasculitis). There was proliferation, thickening and 
homogenization of collagen tissue fibers and deep perifollicular fibrosis with a suggestive 
diagnosis of sclerodermiform dermatosis chronic variant of graft-versus-host disease.
Discussion: The main risk factors include donor HLA homozygosity, peri-organ 
lymphoid tissue transfer and the relationship between recipient immunogenicity and 
the immunosuppressive drug regimen. Diagnosis is made by specific tests which detect 
macrochimerism, single-tandem repeat and DNA analysis which quantifies relative 
amounts of different DNA.
TH-PO593 Poster Thursday
Trainee Case Reports - II
Blood in a Urine Collection...Is It an Infection or Rejection? Adenovirus Is 
Our Selection!
Nashila AbdulRahim, Natalie E. Ellington, Allen Hendricks, Bekir Tanriover, 
Venkatesh Kumar Ariyamuthu. UTSouthwestern, Dallas, TX.
Introduction: Adenovirus-induced granulomatous interstitial nephritis (AGIN) is rare 
and has a high risk of graft loss in renal transplant patients. Diagnosis can be made with 
quantitative urine and blood PCRs and biopsy. We present a case of hemorrhagic cystitis, 
AGIN, admixed with rejection.
Case Description: 53 year old male with a history of ESRD secondary to ADPKD 
had a DDRT in 2010 with no notable post-transplant complications. His baseline SCr 
was 1.6 mg/dl, and he was maintained on tacrolimus, MPA, and prednisone, with goal 
tacrolimus troughs between 5-8 ng/ml. He had presented to an urgent care with dysuria, 
hematuria, and AKI (Scr to 1.9 mg/dl) and treated with ciprofloxacin for 10 days. He came 
to our facility one week later with diarrhea, fevers, and AKI (SCr of 2.9 mg/dl) that did not 
improve with IV fluids and antibiotics. In light of hematuria, urine and serum adenovirus 
PCR were sent which resulted as greater than 2,000,000 and 72,698 copies respectively. 
Transplant kidney biopsy showed ACR Banff IB, suspicious for chronic, active ABMR with 
severe glomerulitis, moderate pertitubular capillaritis, and mild transplant glomerulopathy. 
Light microscopy showed severe tubulointerstitial inflammation with lymphohistiocytic 
proliferation, numerous monocytes and lymphocytes with areas of interstitial hemorrhage,  
epithelial cell necrosis, rupture of basement membranes, and rare tubular epithelial cells 
with enlarged nuclei with a smudgy, glassy appearance. Occasional vague necrotizing 
granulomas were identified. Electron microscopy showed 30-40% foot process 
effacement with segmental duplication of capillary walls. SCr peaked at 3.2 mg/dl; he 
received IVIG for AGIN. Dose of prednisone was increased to 10 mg, and tacrolimus 
level ran between 5-8 ng/ml with MPA at 360 mg bid. He was unable to tolerate further 
IVIG secondary to headaches. Serum adenovirus PCR one week after IVIG dosing had 
detectable viral loads but less than 500 copies. Discussion with Transplant ID colleagues 
led to the decision to hold cidofovir secondary to potential nephrotoxicity. His renal 
function remains stable at SCr of 1.8 mg/dl.
Discussion: We identified and properly treated a rare cause of AKI due to AGIN 
admixed with ACR. Prompt diagnosis and treatment led to resolution of viremia as well 
as improvement in renal function with graft salvage.
TH-PO594 Poster Thursday
Trainee Case Reports - II
A Case of Hereditary Diffuse Gastric Cancer in a Renal Transplant 
Patient
Divya Raghavan,1 Josephine Abraham,1 Eric A. Swanson,1 Monica P. 
Revelo Penafiel,1 Faris A. Ahmed,1 Isaac E. Hall,1 Fuad S. Shihab.2 Fellow 
1University of Utah, Salt Lake City, UT; 2University of Utah Health Science 
Center, Salt Lake City, UT.
Introduction: Hereditary diffuse gastric cancer is a highly invasive malignancy 
which is usually advanced at the time of presentation and associated with a poor 
prognosis. We report a case diagnosed less than one year after kidney transplantation.
Case Description: A 33-year-old woman with end stage renal disease due to 
renal agenesis post kidney transplant 8 months ago was admitted with a 5-month history 
of post-prandial abdominal pain and a 20-pound weight loss. An abdominal CT scan and 
ultrasound prior to admission were unrevealing. An endoscopy 2 months ago showed 
gastritis, at which time she started pantoprazole and sucralfate, with no improvement. She 
was also on tacrolimus, mycophenolate sodium and prednisone. Her family history was 
significant for stomach cancer in her father who died at age 33 as a result. She had normal 
vital signs and exam except for a low blood pressure of 99/64. An upper endoscopy showed 
a localized area of gastritis in the posterior body of stomach which was biopsied. CT scan of 
the abdomen and pelvis showed mild ascites and a small bowel obstruction. Posterior wall 
biopsy result came back showing diffuse type adenocarcinoma with signet ring cells. 
Diagnostic paracentesis showed malignant cells. Genetic testing identified a mutation in 
CDH1. Patient’s functional status was too poor for chemotherapy and she passed away 2 
months from diagnosis.
Discussion: Hereditary diffuse gastric cancer is associated with mutations in a tumor 
suppressor gene (CDH1) which encodes E-cadherin. Affected individuals develop 
gastric cancer at a young age. Diffuse gastric cancer in first or second degree relatives 
under the age of 40 is an indication for genetic testing. Prophylactic gastrectomy is 
recommended between the age of 20 and 30 in mutation carriers because of the extremely 
high risk of cancer.
Pathology result showing signet cell adenocarcinoma
TH-PO595 Poster Thursday
Trainee Case Reports - II
Successful Treatment and Five Years Disease-Free Survival in a Donor 
Transmitted Metastatic Melanoma with Ipilimumab Therapy
Priyamvada Singh,1 Bhavnish Bucktowarsing,1 Todd E. Pesavento,2 
Thomas Olencki.2 1The Ohio State University Wexner Medical Center, 
Columbus, OH; 2Ohio State University, Columbus, OH.
Introduction: Approximately 7% of deceased donors have unknown cancer at the time 
of organ procurement. More than 50% of these have no apparent contraindication to organ 
donation. The commonest transmitted malignancy is renal cell cancer (19%), followed 
by melanoma (17%). Donor transmission of melanoma is often fatal as it is commonly 
metastatic at the time of diagnosis. Cases with remission following transplant nephrectomy 
and withdrawal of immunosuppression are few. To our knowledge this is only the second 
case of donor-derived melanoma that was successfully treated with Ipilimumab. Our patient 
has the longest disease-free survival (five years) reported in the literature till date.
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Case Description: 66-year-old female, status post deceased donor Kidney transplant 
in December 2012 for diabetic nephropathy received a 5/6 HLA-mismatched kidney, 
underwent induction with basiliximab and glucocorticoid followed by maintenance with 
tacrolimus and mycophenolate. In March 2013, she developed acute deterioration of 
allograft function. MRI abdomen/pelvis was suspicious for neoplastic involvement of the 
allograft with metastases to spleen and bone marrow. Biopsy of the posterior iliac spine and 
sacrum was positive for metastatic melanoma. Explantation of the allograft on 3/15/2013 
showed metastatic involvement. Immunosuppressants were discontinued, and she was 
initiated on dialysis. Her melanoma was BRAF V600E mutation favorable. Staging studies 
confirmed widespread metastases involving the bone, liver, spleen, and lungs (TxNxM1c 
stage IV, allograft-associated). On 4/2013, she was started on vemurafenib (960 mg bid) 
but was discontinued in August 2013 due to several cutaneous lesions. She was then treated 
with four cycles of Ipilimumab (3 mg/kg, every three weeks, 8/13/13-10/15/13) without 
significant side-effects. Quality of life improved. No further progression of cancer was 
evident on serial imaging and she has been in remission for five years.
Discussion: Despite careful donor selection, cancer transmission to the recipient 
is inevitable. Early diagnosis, cessation of immunosuppression to allow rejection of 
the allograft and transplanted cancer cells, transplant nephrectomy, and treatment with 
chemotherapy/immunotherapy can improve survival. The role of HLA mismatch in 
prognosis is unclear and a topic for future research.
TH-PO596 Poster Thursday
Trainee Case Reports - II
A Rapid Onset of De-Novo Allograft Nephrolithiasis
Amita Maibam, Ana L. Castellanos. University of Kentucky, Lexington, KY.
Introduction: De-novo renal allograft nephrolithiasis is a rare condition with incidence 
of approximately 1 %. Persistent hyperparathyroidism (HPT) after kidney transplant occurs 
in 15-50% cases but rarely causes renal calculi. Mean duration to diagnosis is 28±22 
months. Here we report a case of allograft nephrolithiasis soon after transplantation with 
underlying tertiary HPT on cinacalcet.
Case Description: A 47-year-old Caucasian male with history of biopsy proven 
IgA nephropathy, hypertension, ESRD on peritoneal dialysis for 4 years underwent a 
deceased donor kidney transplant. He received thymoglobulin induction and was started 
on mycophenolate, tacrolimus, and prednisone for maintenance immunosuppression. 
After 2 weeks of surgery, cinacalcet was started for hypercalcemia (11 mg/dl). At 6 weeks 
post transplantation, ureteral J stent was found to be severely encrusted. The stent was 
removed with subsequent passage of several small stones. Analysis showed 100% brushite 
stones. A CT stone protocol revealed transplanted kidney with multiple calculi within the 
collecting system with evidence of obstruction. It was treated with stenting, lithotripsy, and 
percutaneous nephrostomy placement. Intact parathyroid hormone (iPTH) was 455 pg/
ml with serum ionized calcium 6.1 mg/dl and phosphorus of 2.2 mg/dl. Renal function 
remained stable with serum creatinine of 1.3 mg/dl to 1.4 mg/dl. Patient underwent 
near-total parathyroidectomy after a nuclear scan showed enlarged parathyroid glands. 
Histopathology reported hyperplastic glands. One year post parathyroidectomy, there has 
been no new stone formation with normalization of calcium and iPTH.
Discussion: The most striking aspect of our case was asymptomatic de-novo 
nephrolithiasis, which presented within 6 weeks after transplantation. It emphasizes the 
need to remain vigilant of this possible complication during the early post-transplant 
period in patients with persistent hypercalcemia and HPT. Close monitoring of calcium, 
phosphorus, and iPTH levels along with necessary imaging can lead to timely diagnosis 
of this potentially allograft threatening complication. Parathyroidectomy can be performed 
with excellent outcomes.
TH-PO597 Poster Thursday
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A Gigantic Renal Cyst Mimicking Ascites
Amita Maibam, Taha Ayach. University of Kentucky, Lexington, KY.
Introduction: The incidence of renal cyst increases with age above 50 years. Majority 
of the cyst are < 2cm and the reports of size >15cm are extremely rare. Here we present 
a peculiar case of a 75-year-old male with an exceptionally massive renal cyst, but 
unremarkable symptoms.
Case Description: A 74-year-old Caucasian male with history of type 2 diabetes 
mellitus and hypertension who was admitted to the hospital for evaluation of chest pain 
of cardiac origin. Incidentally on exam, he was found to have a protuberant abdomen with 
fluid wave concerning for ascites. He has no known history of liver disease and he reported 
gradual increase in abdominal girth for last 15 years. He was further evaluated with CT 
abdomen and pelvis which demonstrated numerous fairly simple appearing cysts noted 
to arise from both kidneys. The largest arises from the lower pole of the left kidney and 
measures 40 x 27 x 30 cm. He denies any family history of polycystic kidney disease. 
Patient underwent continuous percutaneous catheter placement in largest cyst with 20L 
of serous fluid removed over 2 days with negative microbiology, and with significant 
improvement in abdominal distention thereafter.
Discussion: Renal cyst should be considered as one of the differentials in patients with 
progressive distension of abdomen. To the best of our knowledge, this case represents the 
largest reported renal cyst. Our findings highlight the fact that benign renal cyst can grow 
over several years while remaining relatively asymptomatic, can mimic ascites and can pose 
diagnostic and therapeutic dilemma.
Computed tomography of abdomen showing bilateral renal cysts with the largest measuring 
40 x 27 x 30 cm on the left kidney.
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CMV Nephritis with Glomerular Involvement
Mohammad Y. Alsawah. Nephrology, St John Hospital & Medical Center, 
Detorit, MI.
Introduction: Cytomegalovirus (CMV) infection is common in kidney transplant 
recipients, but infection related pathologic changes of the renal allograft are uncommon. 
Histologically, it presents with viral inclusions in tubular epithelial cells and interstitial 
inflammation. We describe a case of CMV nephritis with inclusions in glomerular 
endothelial cells without associated interstitial infiltrate or epithelial cell inclusions.
Case Description: A 17 year old African American male with history of ESRD from 
focal segmental glomerulosclerosis received a preemptive living kidney allograft from his 
mother. Both donor and recipient were CMV seropositive. Post-operatively, creatinine level 
plateaued at 2 mg/dL without significant proteinuria on serial monitoring. An allograft 
biopsy was performed for elevated creatinine level 5 weeks post-transplant showed no 
evidence of rejection or recurrence of the primary disease. Staining for both SV40 and 
CMV was negative. Three months postoperatively, the patient developed abdominal pain 
and weight loss. Abdominal CT scan showed no abnormalities. Gastric endoscopy showed 
mild gastritis. A peripheral blood quantitative CMV viral load by PCR was >3 million 
copies / ml. The patient’s creatinine level increased to 2.5 mg/dL. A repeat allograft biopsy 
showed enlarged endothelial cells with cytoplasmic inclusion that stained positive for 
CMV. There was no evidence of capillary thrombosis, interstitial inflammation or tubular 
epithelial cell inclusions. Peripheral blood CMV viral load was elevated over 3 million IU/
ml despite receiving maintenance valganciclovir post-transplant prophylaxis. CMV viral
resistance pattern revealed a UL97 mutation. Viremia ultimately responded to increasing
valganciclovir dose over a 5 months period of follow-up.
Discussion: CMV induced cell inclusions in kidney allograft recipients with CMV 
disease is uncommon and usually involves epithelial tubular cells. Bhadauria et al described 
CMV infection in 74 of 521 live donor kidney recipients (1). Only 4 cases developed 
histologically confirmed CMV allograft disease. In another review of 2900 kidney 
allograft indication biopsies only 4 cases of glomerular endothelial cells were described(2). 
Ganciclovir resistance occur in 2-4% of CMV infections (3), but there are no reports of 
association of this resistance with any specific pathologic findings on kidney biopsy.
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Trainee Case Reports - II
Everything Comes Down to Poo
Kapil Mahajan,1,2 Shana M. Machado.2 1UT Health Houston, Stafford, TX; 
2UT-Houston Nephrology, Houston, TX.
Introduction: Use of immunosuppressive agents can predispose transplant recipients 
to a variety of side effects like malignancies, infections, anemia. Anemia in post transplant 
period can be from several causes including delayed graft function, blood loss, infections. 
Here we present a case of anemia from Hemphophagocytic lymphocytosis (HLH) caused 
by Cytomegalovirus (CMV) colitis in a patient with negative CMV viremia
Case Description: A 54 yom was admitted for symptomatic anemia without active 
source of bleeding. He had a history of deceased donor renal transplant, CMV Donor 
negative/Recipient positive and EBV Donor positive/Recipient positive, complicated 
by delayed graft function. He had a history of chronic anemia, unresponsive to Epogen 
therapy. Bone marrow biopsy was done which demonstrated hemophagocytosis and 
atypical erythroblasts possibly related to viral infection. Immunostains for Parvovirus, EBV, 
CMV were negative. Due to RBC hypo-proliferation as well as development of diarrhea, 
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he was empirically started on IV ganciclovir for possible CMV colitis. He underwent 
colonoscopy with colon biopsy demonstrating distortion, increased chronic inflammatory 
cells, crypt atrophy, focal crypt abscess. Immunoperoxidase staining was positive for CMV. 
The etiology of patient’s hemophagocytosis was from non-disseminated CMV. He was 
discharged home on oral valgancyclovir as well as outpatient clinic follow up
Discussion: Post transplant anemia can be due to medication side effects, frequent 
phlebotomy tests, slow graft function, viral infection. HLH is a syndrome of excessive 
inflammation and tissue destruction due to exaggerated immune response. Primary HLH 
is caused by a genetic mutation and secondary HLH occurs in autoinflammatory and 
autoimmune disease, lymphoma, viremia, iatrogenic immunosuppression. It is diagnosed 
if there is a mutation in a known causative gene or if at least 5 of 8 diagnostic criteria 
are met: fever, splenomegaly, cytopenia involving > 2 cell lines, hypertriglyceridemia or 
hypofibrinogenemia, biopsy proven hemophagocytosis, low or absent natural killer cell 
activity, elevated serum ferritin, elevated CD25 levels. The pathogenesis of HLH is not well 
understood. Impairment of Natural killer-cell (NK-cell) function caused by viral infections 
can lead to persistent activation of macrophages and production of cytokines. When HLH is 
triggered by a viral infection, treatment of the underlying viremia is recommended
TH-PO600 Poster Thursday
Trainee Case Reports - II
Spontaneous, Non-Traumatic Renal Hemorrhage: An Under-Recognized 
Entity
Gajapathiraju Chamarthi, Abhilash Koratala. University of Flroida, 
Gainesville, FL.
Introduction: We present a case of spontaneous, non-traumatic renal hemorrhage in a 
patient with end-stage renal disease (ESRD), also known as Wunderlich syndrome.
Case Description: A 61-year-old man with ESRD, on hemodialysis for two years, left 
renal cell carcinoma status post nephrectomy 20 years ago, hypertension and 40 pack-years 
smoking history presented to our institution for sudden-onset right flank pain radiating to 
the right leg. His blood pressure at presentation was 130/90 mmHg, pulse 98 bpm and 
physical examination was significant for tenderness over the right flank without signs of 
peritonitis. Laboratory testing was significant for a drop in hemoglobin to 7.9 g/dL from a 
baseline value of ~11 g/dL. Platelet count and international normalized ratio were within 
normal limits. A computed tomography (CT) scan of the abdomen demonstrated acute 
hemorrhage throughout the right kidney extending into the anterior and posterior pararenal 
spaces. In addition, there was extravasation of contrast at the upper pole, indicating active 
bleeding [Figure 1]. There was no obvious underlying renal mass or evidence for acquired 
cystic kidney disease. He underwent renal artery angiogram and embolization using 
lipiodol-ethanol mixture and gelfoam. His blood count subsequently stabilized and was 
discharged in stable condition.
Discussion: Wunderlich syndrome, first described in 1856 is a rare condition 
characterized by acute spontaneous, non-traumatic renal hemorrhage into the subcapsular 
and perirenal spaces. Patients may present with the classic ‘Lenk’s triad’ of symptoms 
consisting of acute flank or abdominal pain, a palpable flank mass, and hypovolemia but the 
presentation is variable and non-specific in most cases. CT scan is the imaging modality of 
choice and treatment often includes renal artery embolization or nephrectomy, depending 
on the severity. It is important to note that ESRD patients are predisposed to bleeding 
diathesis in the setting of uremic platelet dysfunction, anemia, increases in nitric monoxide, 
irregularities in von Willebrand factor and impaired platelet-vessel wall interaction.
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Young African American Male with Mild Bilateral Hydronephrosis and 
Kidney Failure
Thuan V. Nguyen,1 Caprice Cadacio,1 Phuong-Thu T. Pham,2 Phuong-
Chi T. Pham.1 1Olive View-UCLA Medical Center, Los Angeles, CA; 2UCLA 
Medical Center, Los Angeles, CA.
Introduction: Retroperitoneal fibrosis (RPF) is a rare condition that requires high 
clinical suspicion for prompt diagnosis as routine imaging studies may be nondiagnostic.
Case Description: A 27-year old African American man presents with a 4-week 
history of constant aching pain of abdomen and back without associated consitutional 
symptoms. Past history: unprovoked deep venous thrombosis of right leg and a recent 
episode of scotal swelling/ejaculation difficulty Medication: apixaban Exam: ill-appearing, 
blood pressure 130/75 mmHg Unremarkable cardiopulmonary exam, minimally tender 
abdomen, bilateral costovertebral angle tenderness, trace bilateral lower leg edema Labs: 
Na 133, K 5.0, total CO2 25 meq/l, blood urea nitrogen 57 mg/dl, creatinine 12.55 mg/dl 
Urinalysis bland Renal ultrasound: mild hydronephrosis Abdominal/pelvis CT without 
contrast: mild bilateral hydroureteronephrosis with inflammatory changes, no obvious 
mass/lymphadenopathy. At the insistence of the renal team to rule out RPF, a CT urogram 
was performed which revealed an infiltrative mass encasing aorta, inferior vena cava, and 
commmon iliac vessels. Evaluation for infectious, malignant, and vasculitic etiologies was 
negative. Laparoscopic biopsy revealed dense fibroadipose tissue, lymphocytic aggregates, 
focal scattered IgG4-positive plasma cells, and fibrin deposition. IgG4-related disease 
criteria not met. Patient underwent bilateral nephrostomy placement with resolution of 
kidney failure with plan to initiate corticosteroids for presumed idiopathic RPF.
Discussion: RPF is a relatively rare condition that involves chronic inflammatory 
and fibrotic changes in the retroperitoneum that can lead to encasement and compression 
of retroperitoneal structures. Implicated etiologic factors including drugs, malignancy, 
infections, radiation, and trauma may be present in 30% of cases and idiopathic in all others. 
Prompt diagnosis relies on recognition of a classic clinical presentation (Figure) as initial 
imaging studies (non-contrast CT or ultrasound) may be falsely negative for significant 
obstruction.
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Rhabdomyosarcoma: A Frightening Differential for Bladder Outlet 
Obstruction (BOO) in Children
Elizabeth Wei,2 Mohammed Khurram Faizan,1,2 Robin A. Kremsdorf.1,2 
1Pediatric Nephrology, Hasbro Children’s Hospital, Providence, RI; 2Pediatrics, 
Warren Alpert Medical School, Providence, RI.
Introduction: Posterior urethral valves (PUV) are the most common cause of bladder 
outlet obstruction (BOO) in children. While many children are diagnosed prenatally on 
ultrasound, a few children may occasionally present outside of the neonatal period. In 
toddlers, bladder outlet obstruction can present with history of dribbling or weak urinary 
stream, and more often, following a febrile urinary tract infection. While PUV remains the 
most common cause of BOO in male children beyond the neonatal period, other etiologies 
for BOO must be considered, including urethral strictures, ureteroceles, bladder diverticula, 
and masses. We describe a case of rhabdomyosarcoma presenting with bladder outlet 
obstruction.
Case Description: 13month old previously healthy full term Caucasian male presented 
with two weeks of constipation, decreased appetite, decreased urine output, and concern 
for dehydration. On exam, he had hypertension, a distended, tender abdomen, and normal 
external genitalia. Labs were notable for CO2 of 10mEq/dL, BUN 83mg/dL, creatinine 
1.4mg/dL, and WBC 17.6 x109/L. Abdominal Xray was unremarkable. Ultrasound revealed 
a distended bladder and bilateral hydronephrosis consistent with BOO. Pt experienced 
significant clinical improvement following urethral catheter placement; his creatinine 
improved to 0.2mg/dL. On voiding cystourethrogram (VCUG) for evaluation of posterior 
urethral valves, he was found to have a 2.9 x 2.8cm lobulated prostatic mass with invasion 
into the bladder. Biopsy revealed embryonal rhabdomyosarcoma. At this time, he continues 
on chemotherapy and radiation therapy.
Discussion: Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma 
and accounts for 7-8% of all solid malignant tumors in children. It has a bimodal age 
distribution, affecting children less than two years old and adolescents. 15-20% arise from 
genitourinary sites. Bladder and prostate rhabdomyosarcoma can present with symptoms 
of bladder outlet obstruction, as in this patient. Prognosis and morbidity is dependent on 
staging, histology, age, and the extent of bladder sparing interventions. Rhabdomyosarcoma 
remains a rare, but important cause of bladder outlet obstruction in infants and toddlers. 
In children presenting with new onset obstructive uropathy, a broad differential including 
malignancy must be considered as prompt diagnosis allows for definitive therapy.
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Rare Type of Pyelonephritis
Mohammad Madani,1 Joseph Schmidt.2 1Aurora St. Luke’s Medical Center, 
Milwaukee, WI; 2Aurora Medical Group, Wauwatosa, WI.
Introduction: Xanthogranulomatous pyelonephritis (XGP) is a rare chronic 
destructive granulomatous inflammatory process of renal parenchyma accounting for 0.6% 
of histologic cases of chronic pyelonephritis. Exact etiology is unknown however this 
process is associated with long term obstruction and infection. The aim of this case report 
is to enhance awareness of this rare condition in an effort to prevent delayed treatment and 
adverse outcomes.
Case Description: A 69 year old woman presented with left hip and flank pain of 3 
weeks duration. Vital signs were as follows: temp 98.5, 104 HR, 16 RR, BP 133/64. Physical 
exam revealed left costovertebral angle tenderness. Labs were notable for leukocytosis 
WBC 16.5, hemoglobin 8.4, hematocrit 26.9, MCV 83.5, creatinine 1.7, BUN 18 mg/
dL. Urinalysis revealed >100 WBCs, positive nitrite, moderate leukocyte esterase. She 
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underwent CT scan of the abdomen pelvis which revealed severe cystic replacement of left 
renal parenchyma, perinephric inflammatory changes, left ureteral calculus distal to the left 
UPJ, and left psoas muscle fluid collection (figure). IV antibiotics and pain medication were 
given. A nephrostomy tube and drain was placed with cultures showing E coli. She remained 
afebrile and had satisfactory drain outputs. She underwent left radical open nephrectomy and 
adequate postoperative recovery. Specimens showed no distinct corticomedullary junctions, 
granulomatous inflammation and cholesterol clefts.
Discussion: Clinical presentation of XGP may be vague. Its diffuse or advanced stage 
typically requires nephrectomy. Antibiotics may be used for treatment of focal or bilateral 
XGP. In summary, this case highlights many features characteristic for a rare type of chronic 
pyelonephritis with associated psoas abscess complication. Maintaining a high index of 
suspicion for this condition leading to an accurate and earlier diagnosis may influence 
prognosis.
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Encrusted Pyelitis in a Patient with Solitary Functional Kidney
Meghana Chalasani, Bruce Horowitz, Josephine Abraham. University of Utah, 
Salt Lake City, UT.
Introduction: Encrusted pyelitis is a rare infectious disease affecting the urothelium 
and is usually caused by Corynebacterium urealyticum, a non-hemolytic gram-positive 
bacillus.
Case Description: A 79-year old woman with a history of urothelial carcinoma 
and atrophic left kidney was found on a surveillance abdominal CT scan to have linear 
calcifications within the collecting system of the right kidney with bilateral urothelial 
thickening concerning for encrusted pyelitis. Patient was diagnosed with urothelial 
carcinoma after a CT scan done for evaluation of painless hematuria showed severe left 
hydronephrosis with a focal enhancing mass at the left uretero-vesicular junction. She 
did not have evidence of metastases and underwent radical cystectomy with ileal conduit. 
Scan two months later showed resolution of left hydronephrosis, atrophic left kidney, and 
normal right kidney. CT scan three months later showed diffuse atrophy of the left kidney 
with minimal enhancement of the left renal artery, consistent with chronic ischemia and 
right-sided alkaline encrusted pyelitis. Patient reported urinary discoloration but no fever or 
dysuria. Serum creatinine remained unchanged. Urine culture was obtained and patient was 
started on ciprofloxacin. Urine culture was negative. Patient stopped taking the antibiotic 
due to shoulder pain. Urinalysis one month later showed a pH of 7.5, 5-10 red blood cells 
and 5-10 white blood cells per high power field, and a large leukocyte esterase. Culture was 
again negative. CT scan 2 months later showed progression of calcifications. A 24-hour 
urine stone risk profile is being considered.
Discussion: Encrusted pyelitis is a consequence of lithiasis due to urea-splitting 
organisms, particularly Corynebacterium urealyticum. Urea is hydrolyzed via urease to 
ammonium thereby alkalinizing the urine and promoting the formation of magnesium 
ammonium phosphate stones. Risk factors include endourological procedures, renal 
transplant, immunosuppression, and prolonged broad-spectrum antibiotics. Complications 
are ureteral stenosis, renal abscesses, and obstructive uropathy with resultant end-stage 
renal disease. Diagnosis is suggested by urine culture isolation of a culprit organism 
and unenhanced imaging which classically shows calcified encrustations in the wall 
of the urinary tract. Treatment involves antibiotic therapy for at least fourteen days and 
acidification of the urine.
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Changes in Gene Expression of Hypothalamic Neuropeptides Controlling 
Feeding Regulation in Bilaterally Nephrectomized Rats
Hiromichi Ueno,1 Tetsu Miyamoto,2 Kenya Sanada,4 Yoko Fujimoto,1 
Kenichiro Bando,3 Yoichi Ueta,1 Yutaka Otsuji,1 Masahito Tamura.5 1University 
of Occupational and Environmental Health, Kitakyushu, Japan; 2Second 
Department of Internal Medicine, Kitakyushu, Fukuoka, Japan; 3University of 
occupational and environmental health, Kitakyushu, Japan; 4University of 
Occupational and Environmental Health, Japan, Kitakyushu-shi, Japan; 
5University of Occupational & Environmental Health, Kitakyushu, Japan.
Background: Anorexia is one of the most widespread eating disorders that appears 
to contribute to malnutrition in patients with advanced renal dysfunction. While several 
mechanisms underlying uremic anorexia have been proposed, the hypothalamic 
neuropeptides that regulate feeding in the hypothalamus of uremic patients are poorly 
understood. These neuropeptides act both on the hypothalamus and other appetite-
regulating centers throughout the brain.
Methods: We evaluated the gene expression of hypothalamic feeding-regulating 
neuropeptides after bilateral nephrectomy, a model of acute renal dysfunction. Adult male 
rats received bilateral nephrectomy or a sham operation. The rats were decapitated at 6, 
12, and 24 h after treatment. The brains were removed immediately, frozen on dry ice. 
The brains were then cut into 12-μm-thick sections using a cryostat and the locations of 
the hypothalamic areas, including the paraventricular nucleus (PVN), arcuate nucleus, 
and lateral hypothalamic area, were determined according to the coordinates of a mouse 
brain atlas. The gene expression of corticotrophin-releasing hormone (CRH) in the PVN; 
propiomelanocortin (POMC), cocaine- and amphetamine-regulated transcript, neuropeptide 
Y, agouti-related peptide in the ARC; and melanin-concentrating hormone and orexin in the 
LHA, were quantified by in situ hybridization histochemistry. After treatment, cumulative 
food intake, water intake, and body weight were measured.
Results: The mRNA levels of POMC and CRH, which suppress feeding behavior, were 
significantly increased after bilateral nephrectomy compared with sham-operated rats. The 
food intake of nephrectomized rats decreased compared with sham-operated rats, but there 
was no difference in body weight and water intake between both groups.
Conclusions: The results suggest that POMC and CRH in the hypothalamus may be 
involved in the development of anorexia in bilateral nephrectomized rats. This report may 
provide new insights into the physiological mechanism underlying anorexia in patients with 
renal dysfunction.
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CD147/Basigin Is Involved in the Pathogenesis of Hepato-Renal Disease 
Under the Status of Satiation and Starvation
Akihiro Ryuge,1 Tomoki Kosugi,1 Yuka Sato,2,1 Shoichi Maruyama.1 1Nagoya 
University Graduate School of Medicine, Nagoya, Japan; 2University of 
Colorado, Aurora, CO.
Background: Gluconeogenesis from lactic acids and ketogenesis from fatty acids are 
critical for maintaining energy homeostasis and physiological activity during starvation in 
mammals. Besides ATP production necessary for substance transport by themselves, the 
kidneys are constantly complementing energy production of the liver which is a critical 
regulator in this setting. Therefore, excessive accumulation of glycogen and fat in metabolic 
syndrome causes chronic kidney disease and non-alcoholic fatty liver disease (NAFLD). 
CD147/Basigin (Bsg), a glycosylated transmembrane protein, is involved in glycolysis-
lactate metabolism on carcinogenesis. We therefore investigated on physiologic functions 
of Bsg in energy metabolism under the status of satiation and starvation.
Methods: Two independent mice models were performed using wild-type (Bsg+/+) 
or Bsg-deficient (Bsg-/-) mice treated with high fat diet (HFD) or starvation (free drinking 
water), respectively.
Results: Levels of blood glucose (BS) and liver ATP in standard diet-fed Bsg-/-
 mice were lower than those of Bsg+/+ mice. Alternatively, activation of β-oxidation and 
autophagy were observed in the kidneys and liver of Bsg-/- mice. AMPK activation was also 
found in Bsg-/- liver. BS suppression in tolerance tests for pyruvate or alanine was exhibited, 
indicating that Bsg-/- mice showed a reduction of gluconeogenesis. In accordance with 
these findings, HFD-fed Bsg-/- mice ameliorated tubulointerstitial injury showing vacuolar 
formation, disease activity of NAFLD, and insulin resistance. Of note, starved Bsg-/- mice 
became NAFLD as well. This phenomenon might be caused by autophagic activation 
leading to the accumulation of triglyceride. Regardless of lower ATP values in Bsg-/- mice, 
surprisingly, life survival of Bsg-/- mice was similar with that of Bsg+/+ mice. The kidneys 
may compensate for energy shortage of Bsg-/- mice by activation of ketogenesis. Indeed, 
HMGCS2 that catalyzes the first reaction of ketogenesis was induced in Bsg-/- kidneys, but 
not liver.
Conclusions: CD147/Basigin is involved in the pathogenesis of hepato-renal disease 
through the regulation of autophagy, gluconeogenesis and ketogenesis under the status of 
satiation and starvation.
TH-PO607 Poster Thursday
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Defining the Renoprotective Mechanism of Deiodinase 3 in Podocytes
Nicholas J. Tardi, Ranadheer Dande, Jochen Reiser. Rush University Medical 
Center, Chicago, IL.
Background: Deiodinase 3 (D3) is a membrane-bound enzyme that reduces local thyroid 
hormone signaling in most cell types. By preventing the bioavailability of tri-iodothyronine 
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(T3), the metabolically active thyroid hormone, D3 efficiently regulates thyroid signaling 
in tissues to modulate vital processes such as metabolism. While deiodinases have been 
studied in several endocrine tissues, the role of D3 in controlling T3 in renal tissue has 
not been addressed, despite emerging studies demonstrating overlapping complications of 
kidney disease and thyroid hormone dysfunction. As numerous glomerulopathies can stem 
from energetic dysfunction of podocytes, which have mechanisms that respond to both 
glomeruli derived and circulating changes in hormone levels, we aimed to determine the 
significance of D3 dysfunction in podocyte derived kidney disease.
Methods: D3 expression was measured via qRT-PCR, Western blot and confocal 
analysis. Regulatory capacity of D3 was analyzed via a T3 cleavage assay. The role of D3 
in podocyte derived kidney disease was evaluated in vitro by inducing injury to cultured 
podocytes and in vivo using podocyte specific D3 KO mice challenged with LPS. Renal 
dysfunction was assessed by urine Albumin:Creatinine ratio and by quantifying effacement 
(processes/ GBM length). Cytoskeletal, metabolic and protein trafficking markers were 
measured in lentiviral-driven D3 knockdown podocytes to determine the renoprotective 
mechanism of D3. Glomerular D3 expression was measured in renal biopsies from kidney 
disease patients by immunofluorescence intensity.
Results: D3 is highly expressed in podocytes and downregulated in injury models, 
resulting in compartmentalization of D3 in the golgi and nuclear region where metabolically 
active T3 resides. Podocyte specific D3 KO mice responded poorly to LPS-induced kidney 
injury, resulting in heavy proteinuria and foot process effacement compared to control. 
Biomarkers of metabolic stress and impaired protein trafficking were upregulated in D3 
deficient podocytes. D3 expression in glomeruli of kidney disease patients suffering from 
minimal change disease, diabetic nephropathy, or focal segmental glomerulosclerosis 
showed unique profiles amongst diseases.
Conclusions: D3 plays a renoprotective role against thyroid hormone associated 
kidney disease in podocytes. We propose D3 reduces energy expenditure to prevent 
podocyte exhaustion and death.
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Caloric Restriction Improves Established Proteinuria in Adriamycin-In-
duced Nephropathy
Jürgen Sijbesma, Aren V. Waarde, Stephan J. Bakker. 1Dept. of Nuclear 
Medicine and Molecular Imaging University Medical Center Groningen, Roden, 
Netherlands.
Background: Reduction of proteinuria is an important strategy to prevent loss of 
kidney function. Preclinical studies suggest that caloric restriction (CR), induced at young 
age, protects against age-related proteinuria. None of these studies investigated the effect of 
CR in established renal disease. We hypothesized that CR in established proteinuria reduces 
urinary protein excretion (UPE).
Methods: Male Wistar rats (n= 56; age 12± 2 wk) were intravenously injected with 
2.1mg/kg Adriamycin. At 6 wks after injection, baseline UPE was measured. At 7 wks after 
injection rats were randomly assigned to 4 groups: An ad libitum (AL) and a CR group 
(60% of AL food intake) fed with a 12% protein diet (12%AL, 12%CR) and an AL and a 
CR group fed with a 20% protein diet (20%AL, 20%CR). All groups were treated for 12 
wks. UPE was measured at wk 9 and 12 and mean arterial blood pressure (BP) at the end 
of the study.
Results: Baseline UPE was similar in all groups (p>0.20) with a median value of 495 
and an interquartile range of 127mg/24h. After 12 wks of diet, all animals exposed to CR 
had a 20.3% lower UPE (p=0.003) compared to AL fed animals. At wk 9 this effect was 
only seen in the 12%CR group. BP in animals exposed to CR was -21.2% lower (p<0.0001) 
compared to AL fed animals.
Conclusions: Caloric restriction lowers UPE and BP in rats with established proteinuria. 
Protein restriction was effective if applied in combination with CR. These results may guide 
future intervention studies in patients with proteinuric and obesity-related nephropathy.
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Renal Adverse Effects of Long Term Whey Supplementation with 
Resistance Training in Rats
Atilla Kunt,1 Omer faruk Ozer,4 Ganime Coban,3 Ali Toprak,5 
Rumeyza Kazancioglu.2 1School of Medicine, Bezmialem Vakif University, 
Istanbul, Turkey; 2Nephrology, Bezmialem Vakif University, Istanbul, Turkey; 
3Pathology, Bezmialem Vakif University, Istanbul, Turkey; 4Biochemistry, 
Bezmialem Vakif University, Istanbul, Turkey; 5Biostatistics, Bezialem Vakif 
University, Istanbul, Turkey.
Background: The usage of whey protein is already widespread; as resistance trainers 
and in-patients use whey protein alike. There is reliable evidence against other supplements, 
it is lacking for whey protein. The aim of the study was to identify the adverse effects of 
whey protein usage on kidneys.
Methods: 48 young male albino wistar rats are divided into 6 (n=8); Normal (20%) 
Protein(NP)-Sedentary(NPS), NP-Resistance training(NPRT), High(45%)Protein(HP) 
Sedentary(HPS), HP-Resistance Training(HPRT), Abuse(70% Protein)(A)-Sedentary(AS), 
and Abuse-Resistance Training(ART) groups. The rats were fed ad libitum. Training was 
maintained by resistance protocol in a motorised treadmill. On days 1 and 90 12 hour urine 
and blood samples were collected. Urea, microalbuminuria and pH were detected in the 
urine. Blood analysis included: Albumin, Blood Urea, Creatinine, CRP and NGAL. Rats 
were killed and histopathologically analyzed. Tissue samples were fixed with 10% formalin 
and stained with H&E, Kongo Red stains. Statistics were done by Kruskal Wallis test.
Results: Results are shown in Table 1. Histopathological examination shows 
congestion and tubular damage on HP-RT, A-RT, and HP-S groups. There was no sclerosis 
or glomerular damage present in any of the groups.
Conclusions: Whey protein intake created a dose-response in causing significant 
microalbuminuria and tubular destruction in our study. This supports the suggestion that 
long-term intakes of protein at the upper limits from whole protein sources may compromise 
renal health.
Funding: Clinical Revenue Support
Table 1
A-RT rat with tubular desquamation.
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The Effects of Whey Protein Intake on Bone Mineral Metabolism in Rats
Atilla Kunt,1 Omer faruk Ozer,3 Ali Toprak,2 Rumeyza Kazancioglu.4 1Faculty of 
Medicine, Bezmialem Vakif University, Istanbul, Turkey; 2Biostatistics, Bezialem 
Vakif University, Istanbul, Turkey; 3Biochemistry, Bezmialem Vakif University, 
Istanbul, Turkey; 4Nephrology, Bezialem Vakif University, Istanbul, Turkey.
Background: High protein intake affects the blood and urine phosphate levels. 
Phosphate is shown to be correlated with FGF-23. The aim of the study is to investigate 
the the effects of Whey Protein intake on the whole cascade of bone mineral metabolism.
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Methods: 48 young male albino wistar rats are divided into 6 (n=8); Normal (20%) 
Protein(NP)-Sedentary(NPS), NP-Resistance training(NPRT), High(45%)Protein(HP) 
Sedentary(HPS), HP-Resistance Training(HPRT), Abuse(70% Protein)(A)-Sedentary(AS), 
and Abuse-Resistance Training(ART) groups. The rats were fed ad libitum. Training 
was maintained by resistance protocol in a motorised treadmill. On days 1,30, 60 and 90 
a 12 hour urine sample and a blood samples were collected from each animal. Calcium, 
phospate were detected in the urine. The blood analysis included: LDH, Albumin, calcium, 
phosphate. FGF-23 and vit-D was analysed by ELISA.
Results: Results are shown in Table1.
Conclusions: Whey Protein intake negatively affected the the bone mineral metabolism 
and created a dose-response while training has an alleviating positive effect. Serum, urine 
phosphate and FGF-23 were shown to be significantly correlated and supports such studies.
Funding: Clinical Revenue Support
Table1
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Monounsaturated Fatty Acids Protect Proximal Tubules from Lipotoxicity
Albert Perez-Marti, Geraldine Mollet, Corinne Antignac, Matias Simons. 
Institut Imagine, Paris, France.
Background: A disrupted glomerular filtration barrier, such as in nephrotic syndrome, 
causes loss of serum albumin into the urine. As albumin is an important carrier of fatty 
acids (FAs), the increased exposure of the tubular nephron to FAs may contribute to disease 
progression. This is particularly the case for FAs such as palmitic acid (PA) as their saturated 
acyl chains are known to damage the endoplasmic reticulum (ER) and mitochondria. To 
cope with excess lipids, FAs can be esterified with glycerol and deposited as triglycerides in 
cytoplasmic lipid droplets (LD). Here, we addressed the question in how far lipid unsaturation 
promotes lipid storage and thereby prevents lipotoxicity in proximal tubular cells.
Methods: In vitro experiments with PA and oleic acid (OA) were performed on 
iREC (induced renal tubular epithelial cells) and HK-2 cells. The inducible conditional 
knockout mouse of Nphs2 was used as an in vivo model of nephrotic syndrome. Mice were 
maintained on MUFA (monounsaturated fatty acids) or SFA (saturated fatty acids) diets two 
weeks before Cre induction until death.
Results: To mimic the overexposure of proximal tubules to albumin that takes place 
during nephrotic syndrome, iRECs were treated with different doses of albumin-FAs. While 
the treatment with PA-BSA resulted in the upregulation of ER stress markers and decreased 
cell survival, the additional treatment with OA-BSA completely rescued the phenotypes. To 
assess the capacity of OA to sequester saturated FAs into LDs, we analyzed lipid droplet 
formation. In contrast to PA, OA increased LD formation, which occurred in a DGAT1/2 
dependent manner. Moreover, lipid trafficking studies with the fluorescent analog of a 
saturated fatty acid BODIPY-C12 showed that co-treatment with OA shifted BODIPY-C12 
from the ER into LDs. Finally, our preliminary in vivo data suggest that Nphs2 KO mice live 
longer with MUFA diet compared to SFA diet.
Conclusions: Collectively, our work shows that OA protects renal tubular cells from 
lipotoxicity by channeling PA into LDs. Our findings suggest that promotion of unsaturation 
and, thereby, lipid storage can improve the homeostasis of PTs during nephrotic syndrome 
and, thus, ameliorate the progression of the disease.
Funding: Private Foundation Support
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GCN5-Like Protein 1 Controls Lipotoxicity in Proximal Tubule Cells by 
Regulating Fatty Acid Oxidation via Mitochondrial Enzyme Acetylation
Wei Xin,1 Tingting Lv,3 Yanyan Hu,2 Hongjun Sun,3 Qiang Wan.3 1Shandong 
Provincial Hospital affiliated to Shandong University, Jinan, China; 2Tai’an 
City Central Hospital, Tai’an, China; 3Shandong Provincial Qianfoshan 
Hospital affiliated to Shandong University, Jinan, China.
Background: Lipotoxicity termed as the accumulation of satuarated nonesterified fatty 
acid (NEFA) and their metabolites playS a vital role during the progression of chronic kidney 
disease (CKD). NEFA catabolism is mainly through the b-oxidation in mitochondria. Due 
to a high energy demand and relatively little glycolytic capacity, fatty acid oxidation (FAO) 
is particularly important for the proximal tubule cells. However, the upstream mechanisms 
remain unclear. Lysine acetylation is a reversible post-translational modification, and is 
particularly important in the regulation of mitochondrial metabolic enzymes. However, the 
effects of acetylation status on the NEFA b-oxidation and lipotoxicity in the proximal tubule 
cells remains unclear. In this study, we aimed to investigate how FAO rate in the tubule cells 
is controlled by mitochondrial acetylation status and how these changes affect lipotoxicity.
Methods: Human proximal tubular epithelial cells (HK-2) were stimulated with 
palmitic acid (PA) and C57BL/6 mice were received a high-fat diet (HFD) for 18 weeks. 
The expression of acetylated-lysine and GCN5-like Protein 1 (GCN5L1) were detected 
by both immunohistochemistry and western blot. The immunoprecipitation assay was 
used to evaluate the acetylation levels of long-chain acyl-CoA dehydrogenases (LCAD) 
and 3-hydroxyacyl-CoA dehydrogenase (β-HAD). Fatty acid β-oxidation rate, triglyceride 
content, ac-CoA, and the activity of LCAD and β-HAD were assessed by appropriate kits.
Results: The expression of total lysine acetylation was increased in palmictic acid (PA) 
cultured HK-2 cells and high-fat feeding mice kidneys. PA induced LCAD and β-HAD 
hyperacetylation and reduced enzymatic activity along with decreased fatty acid oxidation 
rate and ac-CoA contents. Interestingly, GCN5L1 was upregulated in vivo and vitro high fat 
conditions. Finally, the silence of GCN5L1 in HK-2 cells led to the deacetylation of LCAD 
and β-HAD and accelerated FAO rate, which eventually attenuated lipid deposition.
Conclusions: The acetylation of mitochondrial proteins supressed FAO in renal 
proximal tubule cells. GCN5L1 suppression attenuates lipotoxicity by upregulating FAO 
via reversible mitochondrial enzyme LCAD and β-HAD acetylation. The manipulation of 
acetylation status might act as a promising therapeutic intervention for lipotoxicity in CKD.
Funding: Government Support - Non-U.S.
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Effect of Exogenous Supplementation with Alpha Lipoic Acid on Nuclear 
Reduced Glutathione Levels in Rat Kidney Cortex and Medulla
Marianna J. Zamlauski-Tucker, Bingwei Ye. Ball State University, Muncie, IN.
Background: Dietary supplementation with the antioxidant alpha lipoic acid has been 
found to increase reduced glutathione (GSH) levels in mitochondria from kidney and heart 
tissue in old rats. GSH is the major antioxidant inside cells and provides protection against 
damage by free radicals produced as a consequence of oxidative metabolism. The purpose 
of this study was to investigate the effect of dietary supplementation with alpha lipoic acid 
on GSH levels in the nucleus of rat kidney cells.
Methods: Old female Experimental Lewis rats (22 months of age; n = 4) received 
alpha lipoic acid (100 mg/Kg of body wt) via i.p. injection for one week. Age-matched 
Control rats (n = 4) did not receive any supplementation. The kidneys were harvested from 
anesthetized rats and the cortex and medulla were separated and homogenized. The nuclear 
fractions were isolated using differential centrifugation. The GSH and total glutathione (Tot 
GLUT; GSH plus oxidized GSH) were measured using a spectrophotometric assay. GSSG 
(oxidized GSH) levels were estimated from the difference between Tot GLUT and GSH 
levels and then divided by 2. Comparisons were done using a Student’ s T Test.
Results: There were significant increases in GSH and Tot GLUT levels in both the 
kidney cortex and medulla with dietary supplementation.
Conclusions: These findings suggest that dietary supplementation with alpha lipoic 
acid may also be beneficial to cell nuclei in rat kidney by increasing the GSH levels and 
thus, providing protection against free radical damage.
Effect of Alpha Lipoic Acid on Nuclear GSH Levels in the Rat Kidney
All data shown as X +/- SEM; * Significantly different from Control at p < 0.05
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Inhibiting Na/K-ATPase Oxidant Amplification Loop Regulates Aging in 
C57B16 Old Mice
Rebecca L. Klug,1 Rebecca Pratt,3 Jiang Liu,1 Zi-jian Xie,2 Komal Sodhi,1 
Joseph I. Shapiro.3 1Marshall University, Joan C. Edwards School of Medicine, 
Huntington, WV; 2Marshall University, Huntington, WV; 3Marshall University 
School of Medicine, Huntington, WV.
Background: Aging is driven by accumulation of oxidative damage; Na/K-ATPase 
signaling amplifies oxidants and is linked to several oxidation-related diseases. The 
progressive decline of physiological integrity, manifests as: loss of cell division, oxidative 
stress, DNA damage and overexpression of senescence genes. Oxidant stress causes cellular 
and DNA damage contributing to impaired physiological function, disease development, 
and life span reduction. As we identified, the Na/K-ATPase amplifies oxidant signaling and 
we speculate that a peptide inhibiting this pathway, pNaKtide, may be effective to regulate 
cellular senescence, thus delaying and/or reversing aging by attenuating oxidative stress.
Methods: Using human fibroblasts we evaluated levels of senescence markers, cell 
injury, apoptosis, and Na/K-ATPase signaling activation, with and without pNaKtide. 
C57Bl6 male mice, young (4 months) and old (17 months) were fed normal chow 
diet or Western Diet (WD). They were randomly divided into 6 groups: (1) Young 
Control, (2) Young+pNaKtide (3) Old+Control, (4) Old+pNaKtide (5) Old+WD, (6) 
Old+WD+pNaKtide. After 8 weeks of control or WD diet, groups 2, 4 and 6 were injected 
with pNaKtide, (intraperitoneal dose of 25-mg/kg, every 7 days for 8 weeks). Tissues 
from liver, kidney, and heart were evaluated markers of aging and Na/K-ATPase signaling 
activation.
Results: Fibroblasts exposed to oxidative stress underwent oxidation-induced 
senescence and had increased levels of senescence markers, cell injury, apoptosis, and 
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Na/K-ATPase signaling activation. Treatment with pNaKtide significantly reversed those 
levels. Levels of aging markers and oxidant stress in old mice were higher than those 
of young mice. Among cardiac and adipose tissues, senescence, apoptosis and oxidant 
stress were exacerbated in old mice and even more so when fed WD. pNaKtide treatment 
significantly reversed levels of aging markers in old mice regardless of diet.
Conclusions: These data show that Na/K-ATPase signaling is intimately involved in 
the aging process and may serve as a target for anti-aging interventions. pNaKtide inhibited 
amplification of the oxidant signalling via blocking the Na/K-ATPase pump thus alleviating 
genetic and phenotypic attributes of aging. pNaKtide holds potential as a novel drug for 
treating cellular damage that contributes to manifestations of aging and WD.
Funding: Other NIH Support - National Institutes of Health Grants HL109015 (to 
J.I.S. and Z.X.), HL071556 and HL105649 (to J.I.S.), HL55601, DK106666-01 (J.L.), and 
HL34300 (to N.G.A.), Private Foundation Support
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Effects of Gemfibrozil on Fatty Acid Induced Insulin Resistance in 
Adipocytes
Madhura Bose,2 Sharma S. Prabhakar.1 1Texas Tech University Health Sciences 
Center, Lubbock, TX; 2Texas Tech University, Lubbock, TX.
Background: Hyperlipidemia, specifically hypertriglyceridemia has been incriminated 
in contributing to insulin resistance in diabetes. However it is unclear if correcting 
hypertriglyceriemia improves insulin sensitivity and prevent diabetes in the context of 
metabolic syndrome. We hypothesized that reduction of lipid uptake by adipocytes using 
gemfibrozil would improve insulin signaling and facilitate glucose transport.
Methods: Mouse 3T3-L1 preadipocytes were differentiated into adipocytes by 
commercial differentiation cocktail and were stimulated with fatty acids 1 mM of palmitate 
(C16:0), oleate (C18:1), and linoleate (C18:2) for 24 hrs on 8th day of differentiation. 
The fatty acid treated adipocytes were labeled as obese while the fatty acid untreated 
cells were labelled as lean. The obese cells were further treated with Gemfibrozil 
(10 μM, 25 μM, 50 μM and 100 μM) for 72 hrs. Triglyceride assay and Oil red O staining 
were performed to determine lipid droplet accumulation. Cell lysates were used to study 
expression of insulin signaling proteins by western blot analysis. For determining the 
expression of GLUT4, membrane fraction was separated from the cytosolic fraction.
Results: Upon incubation with fatty acid mixture, the lipid content in adipocytes 
significantly increased (obese cells) compared to untreated cells (lean cells). Gemfibrozil 
treatment decreased triglyceride content in the obese cells in a dose dependent manner 
with a significant change even at the lowest concentration of 25 μM. This data was further 
supported by reduction in lipid droplet accumulation in the obese cells as observed by Oil 
Red O staining. Western blot data revealed that gemfibrozil at 25 μM decreased IRS-1 
phosphorylation at Ser 307 which is significantly increased in obesity and insulin resistance. 
Gemfibrozil also increased Akt phosphorylation which was decreased in the obese cells. 
GLUT 4 expression in whole cell lysate remain unchanged but increased in the membrane 
fraction of treated obese cells. Moreover investigation of upstream signaling showed that 
gemfibrozil reduced phosphorylation of IKK-β but not JNK.
Conclusions: We conclude that Gemfibrozil reversed insulin resistance in obese 
adipocytes by modulating phosphorylation of IRS-1, Akt and IKK-β and thereby facilitated 
insulin signaling.These observations may have implications for prevention and treatment of 
diabtetes in metabolic syndrome.
Funding: Private Foundation Support
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ATP-Citrate Lyase Is an Epigenetic Regulator to Promote Renal Injury in 
Metabolic Syndrome
Yinyin Chen,1,2 Dilip K Deb,1 Yanchun Li.1 1Dept. of Medicine, University of 
Chicago, Chicago, IL; 2Dept. of Nephrology, Hunan Provincial People’s 
Hospital, Changsha, China.
Background: Metabolic syndrome, characterized by obesity and type 2 diabetes, 
is a leading cause of chronic kidney disease. Obesity-related renal injury, characterized 
by ectopic lipid accumulation in the kidney, has increased dramatically in recent years. 
Hyperglycemia and hyperlipidemia, key features of metabolic syndrome, drive excess 
nutrient flows into kidney cells; as a result, enhanced cell metabolism increases intracellular 
acetyl-CoA concentration, which provides the substrate for de novo lipid synthesis as well 
as for histone acetylation. Here we tested the hypothesis that ATP-citrate lyase (Acly), an 
enzyme that converts citrate to acetyl-CoA, functions as an epigenetic regulator of renal 
injury by promoting ectopic lipid synthesis and histone acetylation.
Methods: Acly, lipogenic and fibrogenic genes in the kidney of ob/ob BTBR mice and 
mesangial cells were quantified by qRT-PCR and Western blotting. Kidney sections were 
analyzed by H&E, PAS and oil red O staining. Histone acetylation in gene promoters was 
assessed by ChIP assays.
Results: Ob/ob BTBR mice developed glomerulomegaly, glomerulosclerosis and 
ectopic lipid accumulation in the kidney compared with ob/+ controls, accompanied by 
increases in total lipids, triglyceride and cholesterol contents in the renal cortex. Acly, 
lipogenic (ACC, FAS, HMGCR) and fibrogenic (TGF-β1, FN) genes were markedly up-
regulated in the kidney of ob/ob BTBR mice, so was histone acetylation at the H3K9/14 and 
H3K27 sites. Inhibition of Acly activity by SB-204990 not only blocked histone acetylation 
but also suppressed the expression of the lipogenic and fibrogenic genes in the ob/ob 
BTBR kidneys. ChIP assays confirmed that these gene promoters were hyperacetylated 
at the H3K9/14 and H3K27 sites. Exposing mesangial cells to a combination of high 
glucose, sodium palmitate and TNF-α synergistically stimulated Acly expression and 
enzymatic activity, increased H3K4/19 and H3K27 acetylation, up-regulated the lipogenic 
and fibrogenic genes and promoted histone acetylation in these gene promoters. Blockage 
of Acly by SB-204990 or siRNA attenuated these regulatory processes, whereas Acly 
overexpression enhanced these regulations.
Conclusions: These observations strongly suggest that Acly is a critical epigenetic 
regulator to promote renal injury via epigenetic mechanisms in obesity
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Investigating the Sex-Specific Progression of CKD: Sex Hormones and Sex 
of the Cell in Human Kidney Metabolism
Sergi Clotet-Freixas,1 Julie Anh Dung Van,1 Aman Mehrotra,1 Minna Woo,1 
Amy A. Caudy,2 Ana Konvalinka.1 1University Health Network, Toronto, ON, 
Canada; 2University of Toronto, Toronto, ON, Canada.
Background: Male sex predisposes to chronic kidney disease (CKD). We hypothesized 
that the effector androgen dihydrotestosterone (DHT) would induce key molecular alterations 
in human renal proximal tubular epithelial cells (PTECs). We quantified the proteome of 
DHT- vs. estradiol(EST)-treated PTECs, and uncovered androgen-induced perturbations in 
renal metabolism that may be directly responsible for the faster CKD progression in men. 
Our goal is to characterize sex- and sex hormone-specific alterations in the PTEC metabolic 
function, and relate them to hypertrophy, oxidative stress, and inflammation.
Methods: PTECs from 2 male vs. 2 female donors were stimulated with Control, DHT 
(100nM), or EST (100nM) for 16h or 24h. We employed a Seahorse analyzer to monitor 
glycolysis (as extracellular acidification rate, ECAR) and oxygen consumption rate (OCR). 
Changes in ECAR and OCR were related to the extracellular glucose levels, intracellular 
ATP, oxidative stress (O2
−), apoptosis (phosphatidilserine, PS) and cell diameter (n=4-6/
group). Secreted levels of 15 chemokines/cytokines were quantified through a Multiplex 
Bead-Based Assay.
Results: Male PTECs showed significantly increased ECAR and OCR, ATP-linked 
respiration, maximal glycolitic and respiratory capacity, O2
− and PS levels than female 
PTECs. In male PTECs, ECAR was increased after DHT stimulation, whereas OCR was 
increased by DHT and EST at baseline and in response to mitochondrial stress. In male 
PTECs, glucose concentration in the media was reduced by DHT treatment and glucose 
reduction was prevented by androgen receptor inhibitors. In turn, ATP, O2
−,PS levels, cell 
diameter and secretion of cytokines IL-6 and MCP1 were increased by DHT. DHT also 
augmented ATP levels in female PTECs. Interestingly, both DHT and EST increased ECAR 
and OCR in the PTECs from only one of the female donors.
Conclusions: DHT-induced proteome alterations are linked to a more glycolytic and 
oxidative phenotype in the human renal cell, and to higher glucose consumption, oxidative 
stress, apoptosis, IL-6/MCP1 secretion, and hypetrophy. Moreover, the metabolic function 
of PTECs and their susceptibility to sex hormones vary depending on the sex of the donor. 
Thus, not only hormonal but also (epi)genetic factors may contribute to a sex dimorphism 
in human renal metabolism.
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Renal Cortical Mitochondrial Dynamics and Elimination During the 
Normoalbuminuric Stage of Diabetes Mellitus
Naohito Ishii,1 Pamela K. Carmines,2 Akemi Imoto,1 Yoshifumi Kurosaki,1 
Hideki Ikenaga,3 Hajime Ojima,1 Masanori Yokoba,1 Tsuneo Takenaka,4 
Masato Katagiri.1 1Kitasato University, Sagamihara, Japan; 2University of 
Nebraska College of Medicine, Omaha, NE; 3Seiikai, Otawara, Japan; 
4International University of Health and Welfare, Sanno Hospital, Tokyo, Japan.
Background: Oxidative stress during the normoalbuminuric stage of type 1 diabetes 
mellitus (DM) damages renal cortical mitochondria (Clin Sci 124:543-52, 2013). Because 
accumulation of damaged mitochondria can contribute to renal dysfunction, we aimed to 
determine if oxidative stress in DM triggers renal cortical mitochondrial fission, fusion and 
elimination through mitochondria-selective autophagy (mitophagy).
Methods: Rats receiving i.p. injection of streptozotocin (STZ, 65 mg/kg) or vehicle 
(Sham) were either left untreated or treated with telmisartan (TLM, an angiotensin 
receptor blocker; 10 mg/kg/d). Two weeks later, blood glucose concentration (BG), 
blood pressure (BP), glomerular filtration rate (GFR), and urinary excretion of albumin 
and N-acetyl-β-D-glucosaminidase (NAG) were measured. Renal cortical 3-nitrotyrosine 
(3-NT; an oxidative stress marker) was detected by HPLC. Fission-, fusion-, and mitophagy-
related proteins were quantified in renal cortical homogenates by Western blot and localized 
by immunohistochemistry.
Results: STZ rats displayed hyperglycemia that was unaffected by TLM. BP, albumin 
excretion, and NAG excretion were similar in all groups. Compared with Sham rats, GFR 
and renal cortical 3-NT levels were increased in STZ rats, and both changes were prevented 
by TLM. Renal cortex from STZ rats displayed TLM-sensitive increases in the mitophagy-
related proteins LC3-II and PINK1 (all P<0.05). Renal cortical Drp1 levels were 3-fold 
higher in STZ than in Sham rats, with STZ+TLM rats exhibiting intermediate levels of 
this fission marker. In contrast, levels of the fusion marker Mfn2, and mitophagy-related 
proteins BNIP3 (dimer) and p62 levels did not differ among groups. Immunohistochemical 
staining confirmed that the mitophagy-related proteins in STZ were located at renal tubular 
sites.
Conclusions: These data suggest that fission, but not fusion, of renal cortical damaged 
mitochondria is enhanced by in DM. TLM-sensitive accumulation of PINK 1 and LC3-II 
the tubular epithelium during DM suggests that oxidative stress activates the PINK1-parkin 
pathway, in which PINK1 binding to LC3-II (an established marker for autophagosome 
formation) results in mitochondrial elimination via autophagy.
Funding: Government Support - Non-U.S.
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Preliminary Analyses on Dietary Inflammatory Index Among Participants 
in the Palm Tocotrienols in Chronic Hemodialysis (PATCH, USA) Study
Dina A. Tallman, Eno Latifi, Deepinder Kaur, Pramod Khosla. Wayne State 
University, Detroit, MI.
Background: Inflammation is a predictor of mortality in hemodialysis (HD) patients. 
The dietary inflammatory index (DII) assesses the potential effect of diet on systemic 
inflammation. The aim of this preliminary analysis was to evaluate the use of DII and 
examine the associations between DII, diet composition and key anthropometry.
Methods: Dietary 24 hr recalls were collected at baseline from HD patients participating 
in the PATCH clinical trial (NCT02358967), an ongoing one year double-blind intervention 
(300 mg tocotrienols or placebo, daily) which includes quarterly anthropometric measures. 
Data was analyzed using Food Processor ESHA Research. After accounting for under 
reporters, the DII score was calculated from 85 patients (Age 62 ± 12 yrs., 67% men, 95% 
African American). Handgrip strength (HGS) was measured using a Jamar dynamometer 
for 48 of the subjects. A z-score transformation was applied to mean baseline HGS scores 
using normative grip strength data and these standard scores were compared with clinical 
and demographic characteristics collected from medical records.
Results: DII showed a significant positive correlation with percent calories 
from saturated fatty acids (r = 0.38) and significant negative correlations with dietary 
monounsaturated (r = -0.38) and polyunsaturated fatty acids (r = -0.37), vitamin E 
tocopherol (r = -0.69), the vitamin E to linoleic acid ratio (r = -0.23), and the phosphorus 
to protein ratio (r=-0.43). When subjects were divided into tertiles based on DII score, 
significant decreasing trends were observed for HGS and significant increasing trends 
for serum phosphorus. Weaker grip strengths were significantly and positively correlated 
with serum ferritin levels between 800 and 1200 ng/ml for a sub-set of the population 
(n = 18; r = -0.54).
Conclusions: Inflammation may be implicated in CKD induced muscle loss. 
The restrictive nature of the renal diet, though controlling serum phosphorus, was 
proinflammatory for this study group. Thus, DII may be a useful tool for exploring the 
role of specific dietary fatty acids and antioxidants to the contribution of inflammation 
in the African American HD population. (Supported by the Malaysian Palm Oil Board, 
Government of Malaysia)
Funding: Government Support - Non-U.S.
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Impact of the Gene Encoding Canonical Transient Receptor Potential 1 
Channel (TRPC1) on Glucose Intolerance and Liver Steatosis Is 
Condition-Specific: Role of Hyperphagia, Obesity, and High Fat Diet 
(HFD)
Bonnie Eby,4 Lindsay J. Barron,1 Alexander Lau,4 Richard M. Atkins,3 
Chris Skaggs,1 Usman A. Khan,3,2 Leonidas Tsiokas,5 Kai Lau.1,2 1University of 
Oklahoma Health Science Center, Oklahoma City, OK; 2Medicine, VA Hospital 
& Medical Center, Oklahoma City, OK; 3University of Oklahoma College of 
Medicine, Oklahoma City, OK; 4University of Oklahoma Heath Sciences Center, 
Oklahoma City, OK; 5University of Oklahoma Health Sciences Center, 
Oklahoma City, OK.
Background: We recently noted spontaneous development of metabolic syndrome 
(MetS) in TRPC1 null mice vs wild type (wt). We now studied the impact of gene dosage, 
role of adipokines, & responses to a HFD (45%) vs. normal (N) (10-13%) FD x 4 m.
Methods: We did metabolic studies in ♂ littermates of all 3 genotypes, using standard 
chemical techniques & ELISA for insulin, leptin, & adiponectin
Results: On normal chow, from 4th-5th to 30th week, null mice ate & weighed more 
than +/- & wt. After 30 weeks, intake & weight gains in null became similar to +/- & 
wt. At 2 m, null mice had hyperglycemia & hypercholesterolemia. Their livers were 36% 
heavier & triglyceride content (TGC) 47% higher. Liver echogenicity was elevated by 
50-150 % at 7, 11, & 22 m, corroborated by 140% higher liver TGC. At 12 m, only null 
mice had hyperlipidemia (30% higher blood total cholesterol, 60% higher LDL, & 200% 
higher TG). In +/- & wt, blood lipids, liver density at 12 & 19 m, & liver TGC at 19 m 
were all normal. Fasting glucose was elevated only in null (up 20% at 1 m, 23% at 3.5 m
& 13% at 15.5 m). Thus on a normal diet, 1 TRPC1 gene allele could prevent hyperphagia, 
obesity, MetS & hepatic steatosis. As expected, HFD vs. NFD stimulated leptin & insulin, 
comparably in all 3 genotypes, without affecting adiponectin or weight gains. Contrary to
a normal diet, HFD increased liver density in +/- & wt, but unexpectedly & inexplicably, 
not in null. On NFD, HOMA-IR was similar among all 3 genotypes, but HFD induced the 
highest HOMA-IR in wt (3.1 vs 1.3 in +/-) & the largest liver TGC hike in wt (3.3 x vs 2 x 
in +/- vs 1.6 x in null). During glucose tolerance test, the area under the curve for plasma
glucose vs time was again paradoxically the highest in wt vs null.
Conclusions: We conclude: 1. Normally, TRPC1 helps maintain glucose & lipid 
homeostasis, presumably by preventing hyperphagia & obesity seen in diploid deficiency, 
which renders hypothalamic neurons relatively resistant to anorexigenic effects of lepin. 2. 
When stressed by a HFD, the wt TRPC1 gene dose-dependently predisposes the mice to 
glucose intolerance & steatosis. 3. Mechanisms for these diverse effects are unknown but 
unrelated to changes in insulin, leptin or adiponectin.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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Daily Oscillation of the Plasma Inorganic Phosphate Concentration: 
Impact of Nampt Deficient Mice
Sawako Tatsumi,1 Ichiro Kaneko,3 Hiroko Segawa,2 Ken-ichi Miyamoto.4 1The 
University of Shiga Prefecture, Hikone, Japan; 2University of Tokushima 
Graduate School, Tokushima, Japan; 3Tokushima University Graduate School 
of Biomedical Sciences, Tokushima, Japan; 4Tokushima University, Tokushima 
City, Japan.
Background: Circulating inorganic phosphate (Pi) exhibits a remarkable daily 
oscillation based on food intake. In humans and rodents, the daily oscillation in response to 
food intake may be coordinated to control the intestinal absorption, renal excretion, cellular 
shifts, and extracellular concentration of Pi. Hyperphosphatemia is linked to vascular 
calcification with chronic kidney disease (CKD) and is an independent risk factor for 
cardiovascular mortality in hemodialysis patients. Despite the circadian variations, it is the 
fasting morning serum Pi concentration that is linked to cardiovascular events and mortality 
in most epidemiologic studies. However, mechanisms regulating the resulting oscillation 
are unknown. Here we investigated the roles of the sodium Pi cotransporter SLC34 (Npt2) 
family and nicotinamide phosphoribosyltransferase (Nampt) in the daily oscillation of 
plasma Pi levels.
Methods: We used Npt2−/− mice, liver-specific Nampt−/− and Nampt+/− mice to reveal 
the mechanisms of daily oscillation of the plasma Pi concentration.
Results: The daily oscillation of the plasma Pi concentration is roughly linked to 
urinary Pi excretion. The expression of renal Npt2a and Npt2c, and intestinal Npt2b proteins 
also exhibit a dynamic daily oscillation. Analyses of Npt2a−/− and Npt2c −/− revealed the 
importance of renal Pi reabsorption and cellular Pi shifts in the daily oscillation. In Npt2a+/+ 
and Npt2a−/−, fasting significantly increases plasma Pi concentration and disappeared 
completely daily oscillation compared with the feeding group. The administration of 
nicotinamide (vitamin B3) and a specific Nampt inhibitor (FK866) in the active and rest 
phases revealed that the Nampt/NAD system is involved in renal Pi excretion. Additionally, 
for cellular shifts, liver-specific Nampt deletion disturbed the daily oscillation of plasma 
Pi during the rest but not the active phase. In systemic Nampt+/− mice, NAD levels were 
significantly reduced in the liver, kidney, and intestine, and the daily oscillation of the 
plasma Pi concentration was attenuated.
Conclusions: The findings of the present study suggest that the Nampt/NAD+ system, 
together with the kidney and soft tissues, plays an important role in generating the daily 
oscillation of plasma Pi levels. It may enhance our understanding of the changes in plasma 
Pi levels in CKD patients.
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Microbiota Dysbiosis Contributes to Liver Injury in Apolipoprotein 
Knockout Mice Through the Disruption of Cholesterol Homeostasis
Peipei Chen,1 Kun ling Ma,1 Yang Zhang,1 Gui hua Wang,1 Zebo Hu,1 Jian Lu,2 
Chenchen Lu.3 1Institute of Nephrology,Zhongda Hospital,Southeast University, 
Nan Jing City, China; 2Institute of Nephrology, Zhongda Hospital, Nanjing, 
China; 3Institute of Nephrology, Zhong Da Hospital, Nan Jing City, China.
Background: Our previous studies demonstrated that cholesterol accumulation in 
liver contributes to the progression of nonalcoholic fatty liver disease (NAFLD). The 
exact mechanisms of this process have not been completely explained. This study aimed 
to investigate the effects of gut microbiota on cholesterol homeostasis of liver in NAFLD.
Methods: Broad-spectrum antibiotics were used to eliminate gut microbiota in high-fat 
diet (HFD) induced apolipoprotein E knockout mice. Feces were collected and proportions 
of microbiota were analyzed by 16S rRNA gene sequencing. Serum lipids were examined 
by automatic analyzer. Cholesterol accumulation in liver was detected by Oil red O staining, 
Filipin staining, and intracellular free cholesterol quantitative assay. The expressions of 
molecules involved in cholesterol homeostasis were measured by immunohistochemical 
staining and Western blotting.
Results: As demonstrated by 16S rRNA gene sequencing,the abundance of 
Desulfovibrio was significantly increased in HFD mice while the abundance of 
Bacteroidetes, Ruminococcaceae, and Lactobacillus decreased when compared with 
the control. Antibiotics treatment effectively depleted gut microbiota in HFD mice. 
Interestingly, depletion of gut microbiota significantly decreased total cholesterol(TC) 
and low density lipoprotein(LDL) in the plasma and lipid accumulation in livers of HFD 
fed mice. Immunohistochemical staining and Western blotting further demonstrated 
that the expressions of LDL receptor (LDLR) and 3-hydroxy-3-methyl-glutaryl-CoA 
reductase(HMGR) were downregulated in antibiotics delpleted HFD fed mice.
Conclusions: Our findings demonstrated that gut microbiota dysbiosis may be 
responsible for the liver injury in NAFLD by disrupting cholesterol homeostasis. This study 
provides more evidence for that modification of gut microbita dysbiosis is suggested to be a 
potential target for NAFLD therapy.
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Nutrition and Metabolism: Basic
Arginine Bioavailability Correlates with Cardiac Remodeling in Mice with 
CKD
Loretta Reyes,1,2 Mike Kelleman,1 Frank Harris,1 Lou ann S. Brown,1,2 
Claudia R. Morris,1,2 Pamela D. Winterberg.1,2 1Pediatrics, Emory University 
School of Medicine, Atlanta, GA; 2Children’s Healthcare of Atlanta, Atlanta, GA.
Background: Nitric oxide (NO) is critical for vascular homeostasis. Arginine (Arg), the 
sole nitrogen donor for NO synthesis, is the common substrate for NO synthase & arginase 
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enzymes (Fig 1). Global arginine bioavailability ratio (GABR) has been proposed to reflect 
substrate availability for NO synthesis by accounting for Arg concentration relative to its 
catabolic products ornithine (Orn) & citrulline (Cit). Low GABR has been associated with 
increased mortality in adults with heart failure & coronary artery disease. This study aimed 
to determine the relationship between GABR & measures of cardiac structure & function 
in mice with CKD.
Methods: CKD was established in male 129X1/SvJ mice via 2-stage partial 
nephrectomy. Plasma was collected at 8 & 16 wks post surgery & Arg, Orn & Cit were 
measured by LC/MS/MS. GABR was calculated as [Arg]/([Orn]+[Cit]). Echos were 
performed at 8 & 16 wks. Relative wall thickness (RWT) was calculated using M-mode 
parasternal long-axis measurements (IVS;d+LVPW;d)/LVID;d & myocardial performance 
index (MPI) as (IVCT+IVRT/ET) on trans-mitral Doppler. In a separate experiment, CKD 
mice received diet supplemented with Arg or alanine (nitrogen control) for 12 wks to 
determine effect on myocardial function.
Results: GABR was significantly reduced in mice with CKD compared to controls at 
both 8 wks [median (IQR) 0.56 (0.52-0.61) vs 0.74 (0.72-0.78); p=0.01] & 16 wks [0.41 
(0.36-0.49) vs 0.64 (0.55-0.68); p=0.03]. There was a significant association between 
GABR & LVH (RWT; r=-0.39, p=0.02) & diastolic dysfunction (E/A ratio; r=0.37, p=0.04). 
At 12 wks, CKD mice on Arg supplementation compared to mice on control diet showed 
improved LVH (RWT 0.47±0.08 vs 0.58±0.06; p=0.01) & MPI (0.81±0.12 vs 1.05±0.11; 
p<0.01).
Conclusions: GABR is decreased in mice with CKD & correlates with worsening 
structural (RWT) & functional (E/A ratio) cardiac changes. Interestingly, Arg 
supplementation improved LVH & MPI at 12 wks. Additional studies are underway to 
determine underlying etiology of reduced GABR in CKD.
Funding: NIDDK Support
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Eliminating SIRPα Prevents Elevations in Blood Pressure, Suppresses 
Aldosterone and Cardiac Fibrosis in CKD
Jiao Wu,3 Zhaoyong Hu,3 William E. Mitch,3 Sandhya S. Thomas.2,1 1Michael E. 
Debakey Veterans Affairs Medical Center, Houston, TX; 2Baylor College of 
Medicine, Houston, TX; 3Baylor College of Medicine, Houston, TX.
Background: A major consequence of chronic kidney disease (CKD) is uremic 
cardiomyopathy characterized by cardiac dysfunction and fibrosis. Potential mechanism for 
the development of CKD-induced cardiomyopathy is increased aldosterone and impairment 
of intracellular insulin signaling (i.e., dephosphorylation of IRS1 and the insulin receptor) 
mediated by SIRPα. We reported that SIRPα is activated by inflammation and found that 
SIRPα is increased in cardiac muscles of mice with CKD. Here we examine the influences 
of SIRPα on systolic blood pressure (BP), aldosterone and cardiac fibrosis.
Methods: We used a global KO of SIRPα (SIRPα Mt) mice and compared them with 
wild type (WT) mice ± CKD (subtotal nephrectomy). At 8 weeks following CKD, we 
examined mice for cardiac fibrosis by picrosirius red staining plus systolic BP. To determine 
if over-expression of SIRPα, affects fibrosis directly we transfected myotubes with a 
plasmid expressing SIRPα vs. GFP. Finally, we immunoblotted myotubes to evaluate levels 
of SIRPα, αSMA, pSMAD3, and GAPDH.
Results: Systolic BP levels in WT mice with CKD was higher compared to values in 
WT control mice. These results mirror increases in aldosterone (2.3-fold higher) vs. WT 
control mice. Interestingly, SIRPα Mt control mice had lower systolic blood pressures; 
aldosterone levels were also significantly lower vs. WT control. Additionally, WT mice 
with CKD displayed 5.2-fold higher levels of aldosterone vs. SIRPα Mt with CKD. Next, 
we stained for fibrosis markers in WT CKD and SIRPα Mt mice with CKD. Picrosirius 
red staining revealed a significant reduction in cardiac fibrosis found in SIRPα Mt with 
CKD compared to values in WT mice with CKD. Myoblasts that had been transfected to 
overexpress SIRPα vs. GFP plasmids. We determined that fibrosis markers (i.e. αSMA) 
were significantly increased in myotubes overexpressing SIRPα. Finally, intracellular 
signaling of TGFß, pSmad3 was significantly stimulated.
Conclusions: Since cardiac fibroblasts express high affinity corticoid receptors for 
aldosterone, our results suggest that SIRPα contributes to the accumulation of collagen 
within the myocardial interstitium, leading to cardiac fibrosis and failure in CKD. Thus, 
suppression of SIRPα undoubtedly plays a critical role in blocking aldosterone secretion 
and elevations in systolic blood pressure to prevent cardiac fibrosis in CKD.
Funding: Veterans Affairs Support
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Voluntary Physical Activity Improves Physical Function and Disease 
Outcomes in a Rat Model of CKD
Keith Avin,1,2 Neal X. Chen,2 Shruthi Srinivasan,2 Kalisha O’Neill,2 
Matthew R. Allen,2 Sharon M. Moe.2 1Indiana University-Indianapolis, 
Indianapolis, IN; 2Indiana University School of Medicine, Indianapolis, IN.
Background: Chronic kidney disease (CKD) progression is associated with reduced 
muscle size, strength and overall mobility. Previous studies using exercise as an intervention 
for CKD have been inconclusive. We hypothesized that physical activity would attenuate 
musculoskeletal dysfunction and CKD-related outcomes.
Methods: Four groups of rats were used: 1) CKD, 2) CKD + voluntary wheel running, 
3) Normal littermates (NL) and 4) NL with voluntary wheel running (N=12/gr). Wheels 
were freely accessible in animal cages. Data collection began at 25 weeks (~CKD stage
2-3) and ended at 35 weeks of age (~stage 5 CKD). Muscle strength (i.e. maximal voluntary
grip), maximal aerobic capacity (VO2 max), were tested at 25 and 35 weeks; serum
biochemistries were assessed at 35 weeks. Data was analyzed via one-way ANOVA with
post-hoc comparisons.
Results: CKD rats performed the same average wheel distance/day and speed as 
NL animals indicating exercise tolerability. Wheel running had negligible effects in NL 
animals. In contrast, wheel running significantly improved multiple outcomes in CKD rats: 
1) significantly reduced phosphorous, PTH and FGF23 (Table 1); 2) reduced kidney weight 
and left ventricular mass index (-12%, p<0.05; -8.5%, p<0.01, respectively); 3) reduced
serum oxidative stress marker 8-OHdG by (-45%, p<0.05); 4) improved grip strength by
16% compared to 10% reduction in CKD alone (p<0.05); and 5) Increased time to fatigue 
(min) during VO2 testing (12.6 min, 8.5 min, p<0.001) but did not change maximal oxygen 
capacity.
Conclusions: In a progressive rat model of CKD, voluntary wheel running had 
significant improvement of the biochemistry, tissue weights, oxidative stress and physical 
function. The results suggest that physical activity may have beneficial effects in CKD.
Funding: NIDDK Support
Table 1. Biochemistry of CKD and CKD Wheel at 35 weeks of age
*p<0.05, CKD vs. CKD Wheel n=10-14 rats each group
*p<0.05, CKD vs. CKD Wheel n=10-14 rats each group
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Chondroitin Sulfate Supplement Alleviates Nephrocalcinosis in Hyperox-
aluric Rats
Thasinas Dissayabutra,1 Nuttiya Kalpongnukul,2 Kanokporn Chindaphan,1 
Wattanachai Ungjaroenwathana,3 Maroot Kaewwongse,4 Kroonpong 
Iampenkhae,5 Piyaratana Tosukhowong.1 1Chulalongkorn University, 
Pathumwan, Bangkok, Thailand; 2Biochemistry, Faculty Of Medicine, 
Chulalongkorn University, Pathumwan, Thailand; 3Surgery, Sunpasitthiprasong 
Hospital, Meung, Thailand; 4University of Phayao, Phayao, Thailand; 5King 
Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Nephrocalcinosis and nephrolithiasis are common features of primary 
hyperoxaluria that contributes to end stage renal disease. We observed low urinary 
chondroitin sulfate (CS) and high hyaluronic acid (HA) excretion in hyperoxaluric 
nephrolithiasis patients and considered these were risks of nephrocalcinosis. This study 
aimed to investigate the effect of CS and HA supplement in hyperoxaluric rats.
Methods: Hyperoxaluric Wistar rats induced by ethylene glycol and vitamin 
D intraperitoneal injection was supplemented with CS (40 mg/kg/day) and/or HA 
(10 mg/kg/day). Urinary CS and HA excretion were measured. Histopathology of kidney 
tissue was reported.
Results: All hyperoxaluric rats developed moderate to severe nephrocalcinosis in 
15 days. CS supplement entirely inhibited calcium deposition in renal tissue in all rats 
(p < 0.05). HA supplement had no effect on nephrocalcinosis formation, however, 
combination of CS and HA supplement can lessen the degree of nephrocalcinosis, but not 
as effective as giving CS alone.
Conclusions: CS supplement in hyperoxaluric patients could be beneficial in 
prevention of nephrocalcinosis. Besides, HA supplement might have detrimental effect in 
interrupt the CS activity.
Severity score of nephrocalcinosis in hyperoxaluric rats
Nephrocalcinosis grading score: 0, no deposit; 1, 1-2 deposits/section; 2, 3-5 deposit/
section; 3, 5-10 deposits/section; 4, >10 deposits/section. Tubular obstruction score: 0, 
no obstruction; 1, tubular obstruction present. Tubulo-interstitial fibrosis: 0, no fibrosis; 1, 
fibrosis present. *p < 0.05 compared with Hyperoxaluria group.
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An Oral Absorbent, Surface-Deacetylated Chitin Nano-Fiber Ameliorates 
Renal Injury and Oxidative Stress in 5/6 Nephrectomized Rats
Makoto Anraku,1 Daisuke Kadowaki,1 Daisuke Iohara,1 Toru Maruyama.2 
1Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan; 
2School of Pharmacy, Kumamoto University, Kumamoto, Japan.
Background: We recently prepared surface-deacetylated chitin nanofibers (SDACNFs) 
by the mechanical treatment of the exoskeletons of crabs, followed by partial deacetylation 
of the amide groups on the surface of the resulting chitin nanofibers. SDACNFs have 
attracted considerable interest in medical fields, because of their various bioactivities. 
For example, SDACNFs were reported to suppress increases in body weight and serum 
leptin levels in a model of obesity that was induced by feeding a high fat diet. These results 
indicate that SDACNFs are work as potent functional foods that could be used in the 
treatment of various diseases.
Methods: The rats were divided into four groups as follows: (a) untreated 
nephrectomized group (N=5). The rats received only standard rat chow. (b), (c), and (d) 
deacetylated chitin powder (DAC), SDACNFs and AST-120 treated nephrectomized group, 
respectively. These rats received standard rat chow and the above samples at a daily dosage 
of 40 mg/kg of body wt for a period of 4 weeks, respectively (n=5). After 0 and 4 weeks 
of treatment, plasma samples obtained from each of the rats were immediately frozen and 
stored at -80 °C until used for analysis.
Results: An oral administration of low doses of SDACNFs (40 mg/kg/day) over a 
4 week period resulted in a significant decrease in serum indoxyl sulfate (IS), creatinine 
and urea nitrogen levels, compared with a similar treatment with DAC or AST-120. The 
SDACNFs treatment also resulted in an increase in antioxidant potential, compared 
with that for DAC or AST-120. Immunohistochemical analyses also demonstrated that 
SDACNFs treated CRF rats showed a decrease in the amount of accumulated 8-OHdG 
compared with the CRF group.
Conclusions: The findings reported here indicate that a lower dose of SDACNFs than 
that of DAC has the potential to reduce the levels of uremic toxins (such as IS) that induce 
the production of free radicals in the intestinal tract, thereby inhibiting the subsequent 
occurrence of oxidative stress in the systemic circulation in CRF model rats. Thus, the 
removal of such substances from the systemic circulation could lead, not only to a reduction 
in oxidative stress, but also to the prevention of cardiovascular disease in CRF (Anraku et 
al., Carbohydrate Polymers, 2017).
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Development, Stem Cells, Regenerative Medicine - I
Xenogeneic Kidney Generation with Human Nephron Progenitor Cells in 
Zebrafish
Wenqing Yin,1,3 Navin R. Gupta,2,3 Tomoya Miyoshi,1 M. Todd Valerius,1,3 
Joseph V. Bonventre,1,3 Ryuji Morizane.1,3 1Brigham and Women’s Hospital, 
Boston, MA; 2Brigham & Women’s Hospital/Massachusetts General Hospital, 
Brighton, MA; 3Harvard Medical School, Boston, MA.
Background: Generating human stem cell-based tissue in animals may provide 
replacement human organs, establish novel disease models, and aid in drug development 
through toxicity screening and therapeutic testing. Human nephron progenitor cells 
(hNPCs) derived from human pluripotent stem cells (hPSCs) are attractive sources for 
human kidney generation in animals; however, techniques to replace host kidney tissue 
with hNPCs are yet to be developed. Here we employ transparent zebrafish (Casper) to 
enable real-time monitoring of xenotransplanted, fluorescent hNPCs and visualize human 
nephron formation.
Methods: hNPCs were differentiated from hPSCs by our previously established 
protocol. Cas9 mRNA and gRNAs targeting Lhx1a or Wt1b, essential transcriptional 
factors for kidney development in zebrafish, were injected into single cell stage embryos. 
Cell Tracker- or GFP-labeled hNPCs were transplanted to blastoderm stage embryos and 
nephrogenesis visualized overtime. Nephrons were evaluated by qPCR with human-specific 
primers and immunostaining for human solute transporters and segment-specific proteins.
Results: Zebrafish with targeted disruption of either Lhx1a or Wt1b died by 24 days 
post treatment (dpt), while transplantation of hNPCs rescued 14.5% of similarly treated 
zebrafish (p<0.00001). All zebrafish that underwent gRNA treatment exhibited renal 
insufficiency with evidence of edema at 3 dpt, however, hNPC transplantation resolved 
renal insufficiency by 20 dpt. Transplanted hNPCs migrated to the pronephric area, 
expressed human SIX2 in early nephrogenesis (9 dpt), and formed glomerular and tubular 
structures that connected to DBA+ zebrafish collecting ducts at a later stage (26 dpt). 
Notably, hNPCs contributed to Podocalyxin+ cells in membrane-enclosed structures that 
contained human CD31+ capillary loops, indicating human glomerular development in 
zebrafish. qPCR using human-specific primers validated human nephron formation in 
zebrafish.
Conclusions: We developed novel methods for generating human kidney tissue in 
animals. After eliminating NPCs in early zebrafish embryos using CRISPR/Cas9 genome 
editing, xenotransplantation of hNPCs generated human nephron structures in zebrafish. 
Our results serve as a proof-of-concept that isogenic patient-specific kidney tissue may be 
generated in animals for translational applications.
Funding: Private Foundation Support
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Development, Stem Cells, Regenerative Medicine - I
Developmental Trajectories Inform the Derivation of Podocytes in-a-Dish
Trinh k (tracy) Tran,1 Andrew P. McMahon.2 The McMahon Laboratory 
1University of Southern California, Los Angeles, CA; 2Keck School of Medicine 
of the University of Southern California, Los Angeles, CA.
Background: In the renal corpuscle, podocytes, mesangial cells and vascular 
endothelial cells form a highly organized filtration device that enables plasma fluid to 
pass from the circulatory system into the epithelail network of the nephron. The derivation 
of podocyte-like cells from differentiating pluripotent stem cells has been reported by a 
number of groups through a variety of approaches. Before moving to disease modeling 
and drug discovery, an evaluation of the properties of in vitro derived cells to their in vivo 
counterparts is important.
Methods: In this study, we used in vivo studies, single-cell RNA sequencing and 
bioinformatics to explore the developmental trajectory of the human podocyte. Employing 
a fluorescently labeled hESC line to visualize and isolate in vitro derived podocyte-like 
cells, we performed a comparative analysis of these cells with their human embryonic 
counterparts.
Results: Through high-resolution microscopy, chromatin structure profiling, single-
cell and bulk transcriptional profiling, we identified transcriptional landmarks during in 
vivo and in vitro podocyte development.
Conclusions: We found that hESC-derived podocytes shared molecular signatures 
with normal human podocytes, including the ability to form intricate interactions with their 
neighbors and attract blood vessels. A substantial podocyte profile is generated without 
accompanying interactions with mesangial or endothelial cell types. Our analyses also 
identified distinct transcriptional signatures between in vitro and in vivo-derived cells that 
point to opportunities to improve podocyte production in culture.
Funding: NIDDK Support
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Development, Stem Cells, Regenerative Medicine - I
Brain Derived Neurotrophic Factor (BDNF) Inhibition Dramatically 
Reduces Off-Target Cells in Kidney Organoid
Kohei Uchimura,1 Haojia Wu,2 Erinn L. Donnelly,3 Benjamin D. Humphreys.3 
1Washington University in St. Louis, Saint Louis, MO; 2Renal Division 
Washington University School of Medicine, Saint Louis, MO; 3Washington 
University School of Medicine, Saint Louis, MO.
Background: Kidney organoids differentiated from pluripotent stem cells hold great 
promise for disease modeling and ultimately as a source of replacement tissue, however 
we have shown that all protocols also generate substantial off-target cell types, primarily 
neurons. To eliminate off-target cells without altering kidney cell maturation, we performed 
single cell RNA-seq and analyzed ligand - receptor pairs expressed exclusively within the 
neuronal lineages. We identified 19 receptors with 24 cognate ligands, and determined that 
the neuron survival factor BDNF and its receptor NTRK2 was expressed exclusively in 
the neuronal lineage. We tested whethyer inhibition of BDNF-NTRK2 signaling during 
organoid differentiation would reduce neuronal populations without altering kidney 
differentiation.
Methods: A range of doses of the NTRK2 inhibitor K252a was screened as well as 
different time schedules during organoid differentiation from human induced pluripotent 
stem cells. We assessed marker expression by qPCR and immunofluorescence, as well as 
scRNA-seq on control and K252a-treated organoids. We sequenced 3,314 cells to a final 
read depth of 50K mapped reads/cell with 3,056 transcripts and 1,524 unique genes detected 
per cell.
Results: Out of 16 different dosing and timing protocols tested, we found that 250 nM, 
of K252a added at day 12 did not alter nephron formation according to marker expression 
by qPCR and immunofluorescence. By contrast, neuronal markers were reduced by almost 
ten-fold. scRNA-Seq of control vs. K252a-treated organoids showed that all major kidney 
cell types remained present with K252a treatment, but the neuronal lineage was reduced 
by over 90%, from 29.8% of total organoid cells before treatment to 2.1% after treatment.
Conclusions: We employed a rational approach based on organoid scRNA-seq to 
identify BDNF signaling as a potential neuronal survival pathway contributing to the growth 
of off-target cells in during kidney organoid differentiation. Inhibition of this pathway 
reduced off-target cells by more than an order of magnitude without affecting kidney 
differentiation, illustrating the power of scRNA-seq to improve organoid differentiation 
protocols.
Funding: NIDDK Support
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Development, Stem Cells, Regenerative Medicine - I
Generation and Validation of a Novel Primary Renal Interstitial Cell Line
Sarah Mccarthy,1,2 Leif Oxburgh.1,2 1Maine Medical Center Research Institute, 
Scarborough, ME; 2Graduate School of Biomedical Sciences and Engineering, 
Orono, ME.
Background: The renal interstitium is indispensable for proper nephrogenesis during 
mammalian kidney development. Interstitial cells also play a central role in the adult kidney 
fibrotic response. Despite the clinical significance, limited reagents are available to examine 
the signaling mechanisms that govern interstitial cell biology. To this end, we have generated 
an immortalized primary renal interstitial cell (PRIC) line. Canonical WNT signaling drives 
cellular proliferation in a number of developmental and disease contexts. Furthermore, in 
vivo deletion of Wnt7b from the collecting duct or β-catenin from interstitial cell precursors 
leads to medullary hypoplasia, suggesting a role for paracrine WNT signaling on interstitial 
cell maintenance. Biochemical analysis with our validated PRIC line confirmed that WNT 
drives renal interstitial cell proliferation.
Methods: A novel isolation method was utilized to purify PRICs from postnatal mice. 
Cells were then transduced with a mCherry-tagged SV40T temperature sensitive lentivirus 
construct to produce a heterogeneous population termed “bulk” SV40T PRICs. Clonal 
lines were isolated and expanded from single cells and screened for expression of postnatal 
interstitial zone markers. The transfection efficiency of isolated clones was evaluated with 
a GFP-expressing construct. The affects of treatment with the WNT agonist CHIR and the 
TCF/LEF1 inhibitor Fh535 on proliferation was measured by EdU labeling and ClickIt 
chemistry.
Results: As expected, “bulk” SV40T PRICs showed expression of SV40T at 33°C which 
was lost when cultured at 37°C. Clone 3-1 was selected for further characterization based on 
its transcriptional profile and expression of the common interstitial markers Pdgfrβ, α-SMA, 
Meis1, fibronectin and vimentin. The transfection efficiency of clone 3-1 was determined 
to be approximately 40%. Treatment of clone 3-1 with CHIR produced a time-dependent 
increase in the feedback pathway reporters Axin2 and Lef1. In addition, clone 3-1 exhibited 
a dose-dependent increase in proliferation in response to CHIR. Finally, co-treatment with 
Fh535 abrogated the mitotic response observed with CHIR alone.
Conclusions: These experiments confirm that clone 3-1 is a viable in vitro model to 
study interstitial cell biology and that canonical WNT signaling through TCF/LEF1 drives 
renal interstitial cell proliferation.
Funding: NIDDK Support
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Development, Stem Cells, Regenerative Medicine - I
Directed Differentiation of Functional Kidney Cells from Human Induced 
Pluripotent Stem Cells
Samira Musah.1,2 1Harvard University, Boston, MA; 2Wyss Instutute for 
Biologically Inspired Engineering at Harvard University, Boston, MA.
Background: Many diseases and drugs affect kidney function by damaging the 
glomeruli, which serve as the functional units of the kidney and the center for blood 
filtration. An in vitro model of human glomerulus could facilitate therapeutic discovery and 
illuminate kidney disease mechanisms. Efforts to develop such models are hindered by the 
lack of functional human podocytes, the specialized epithelial cells that regulate selective 
permeability in the glomerulus. Human pluripotent stem (hPS) cells have a remarkable 
capacity to self-renew indefinitely and differentiate into almost any cell type under 
appropriate conditions. Thus, hPS cells could potentially serve as an unlimited source of 
podocytes; however, a method for directing their differentiation into glomerular podocytes 
remains elusive.
Methods: We hypothesized that a systematic investigation of multiple factors 
within the cellular microenvironment -- including cell-cell interactions, soluble signaling 
molecules, and mechanical properties of the extracellular matrix (ECM) -- could yield an 
effective method for podocyte differentiation.
Results: By following this principle, we developed a highly efficient method for 
differentiation of hPS cells into podocytes. The hPS-derived podocytes express markers 
consistent with mature phenotype and exhibit primary and secondary foot processes. By 
using Organ Chip microfluidic devices, we developed an in vitro model of the human 
glomerular capillary wall that supports podocyte differentiation and recapitulate the normal 
tissue-tissue interface and selective permeability of the glomerulus.
Conclusions: Our results demonstrate the feasibility of generating mature podocytes 
in a robust manner, providing an opportunity to engineer a functional human kidney model. 
These results could facilitate investigations to illuminate developmentally regulated events 
in kidney pathophysiology, and provide a low cost alternative to animal models for the 
development of therapeutics for human kidney disease. As podocytes are unable to undergo 
regenerative proliferation in vivo, these results also provide opportunities for cell therapy 
and regenerative medicine.
Funding: NIDDK Support, Other U.S. Government Support, Private Foundation 
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A Simple Bioreactor-Based Method to Generate Kidney Organoids from 
Pluripotent Stem Cells
Alan J. Davidson. Davidson laboratory Molecular medicine & pathology, The 
University of Auckland, Auckland, New Zealand.
Background: Kidney organoids generated from human pluripotent stem cells have 
the potential to revolutionize how kidney development and injury are studied. Current 
protocols are technically complex and suffer from poor reproducibility and high reagent 
costs restricting scalability.
Methods: To overcome these issues, we have established a simple, inexpensive and 
robust method to grow kidney organoids in bulk from human induced pluripotent stem cells.
Results: Our organoids develop tubular structures by day (d) 8 and show optimal tissue 
morphology at d14. A comparison with fetal human kidney suggests that d14 organoid 
renal structures most closely resemble ‘capillary loop’ stage nephrons. We show that 
deletion of HNF1B, a transcription factor linked to congenital kidney defects, interferes 
with tubulogenesis, validating our experimental system for studying renal developmental 
biology.
Conclusions: Taken together, our protocol provides a fast, efficient and cost-effective 
method for generating large quantities of human fetal kidney tissue, enabling the study of 
normal and aberrant human renal development.
Funding: NIDDK Support, Other U.S. Government Support
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Development, Stem Cells, Regenerative Medicine - I
Generation of Induced-Pluripotent Stem Cells and Kidney Organoids 
from Pediatric Urine Specimens
Jaap Mulder,1 Sazia Sharmin,2 Theresa Chow,3 Deivid Rodrigues’,1 
Robert D’Cruz,4 Ian M. Rogers,5 James Ellis,1 Norman D. Rosenblum.1 1The 
Hospital for Sick Children, Toronto, ON, Canada; 2University Of Queensland, 
Brisbane, NSW, Australia; 3University of Toronto, Toronto, ON, Canada; 
4Sickkids Research Institiute, Toronto, ON, Canada; 5Samuel Lunenfeld 
Research Institute, Toronto, ON, Canada.
Background: Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) are 
the leading cause of renal failure in children worldwide. Mouse models are widely used 
to explore underlying mechanisms in CAKUT, but important differences exist between 
human and murine renal development. Induced-pluripotent stem cells (iPSCs) and kidney 
organoids generated from actual CAKUT-patients, and closely related, healthy controls, can 
serve as complementary tools to study processes as nephrogenesis. Objective: Generate 
patient-specific iPSCs and kidney organoids in an efficient, non-invasive manner.
Methods: Previously published protocols (Zhou et al., Nat Protoc, 2012; Takasato et al., 
Nat Protoc, 2016) were adapted. Urine cells (UCs) were grown from remnant urine samples 
routinely obtained in a nephrology outpatient clinic (incl. bag-collected urine). UCs were 
reprogrammed to urinary iPSCs (UiPSCs) using non-integrating episomal reprogramming 
vectors (Oct4/Sox2/Lin28/L-Myc/Klf4). UiPSC pluripotency was confirmed by qRT-
PCR, immunostaining and embryoid body assays, and euploidy by karyotyping. Kidney 
organoids were generated from UiPSCs and control blood-derived iPSCs (BiPSCs).
Results: Remnant urine specimens were obtained from 17 patients (1mo-17yr old). 
UC cultures were established in 71% (12/17) of single urine collections (urine bag: 4/7, 
57%, p=0.59 vs. mid-stream specimens) with median urine volume 26ml (range 10-75ml). 
Sufficient UC numbers for reprogramming were obtained within 16-25 days. Bacterial 
contamination was not observed. Episome-free UiPSC clones were obtained within 2-3 
passages after reprogramming three UC cultures. Differentiated UiPSCs showed mRNA 
expression patterns (HOXD11/GATA3) matching those of differentiated BiPSCs and 
published data of differentiated fibroblast iPSCs. Organoids generated from UiPSCs 
closely resembled BiPSC-kidney organoid morphology and mRNA/protein expression of 
glomerular, tubular and stromal markers.
Conclusions: A rapid and non-invasive protocol was established to generate iPSCs/
kidney organoids from pediatric urine samples. These results provide a readily applicable 
new platform for CAKUT-research with a low threshold for participation of patients 
(including infants) and indispensable, patient-specific controls.
Funding: Government Support - Non-U.S.
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Development, Stem Cells, Regenerative Medicine - I
Development and Characterization of Kidney Micro-Organoids from 
PSCs to Facilitate Kidney Cell Scale-Up
Santhosh V Kumar,1,2 Pei Xuan Er,1 Kynan T. Lawlor,1 Alexander N. Combes,1,3 
Melissa H. Little.1,2 Kidney development, disease and regeneration 1Murdoch 
Children’s Research Institute, Parkville, NSW, Australia; 2Department of 
Paediatrics, University of Melbourne, Melbourne, VIC, Australia; 3Department 
of Anatomy and Neuroscience, University of Melbourne, Melbourne, VIC, 
Australia.
Background: The directed differentiation of human pluripotent stem cells (hPSCs) has 
enabled the generation of kidney organoids with potential applications in disease modelling, 
drug screening and regenerative medicine. The approach is expensive and faces limitations 
to long-term culture. As a result, novel cost-effective techniques are needed to enable scale-
up of kidney cells types in vitro and facilitate higher throughput screening approaches.
Methods: To generate kidney micro-organoids, hPSCs were differentiated to 
intermediate mesoderm using 7uM CHIR for 4 days and FGF9 until 7 days in 2D monolayer 
culture. On day 7 cells were dissociated using EDTA and allowed to form cell aggregates 
via low-speed swirling using an E6 media containing a cocktail of growth factors. Within 
24hr, cell aggregates were transformed into cell aggregates which, after a further 12 to 18 
days in suspension culture, formed complex kidney micro-organoids within a single culture 
flask.
Results: Mature kidney micro-organoids revealed the presence of intact nephron 
segments, including podocytes (NPHS1+), proximal (LTL+) and distal (ECAD+) nephron 
epithelium and collecting duct (ECAD+GATA3+) segments with distinct lumens. Each 
micro-organoid contains only 6-10 nephrons. As a result, imaging through an entire 
organoid is feasible. 10x Chromium single-cell RNA sequencing analysis identified the 
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presence of 11 distinct kidney cell types, both confirming the presence of anticipated renal 
cell types and revealing a reduced level of surrounding stroma compared to our previously 
described protocol (Takasato et al, 2015). With this novel method, a starting population of 
4.5 million cells (D7+0) was expanded to 150-200 million kidney cells (40 fold) within 
20 days, providing a platform for the economical production of kidney cells for various 
biological applications. Treatment of organoids with Adriamycin induced podocyte cell 
death and decreased podocyte specific gene expression.
Conclusions: This is a cost-effective method for the generation of large numbers of 
hPSC-derived kidney cells. As a result, this technique will improve the feasibility of drug 
toxicity screening and regenerative cell therapy.
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Fluorescent Reporters in Kidney Organoids Generated with Cheap 
Mini-Bioreactors for High-Throughput Modeling of Kidney Fibrosis
Zhao Sun, Kohei Uchimura, Haojia Wu, Erinn L. Donnelly, 
Benjamin D. Humphreys. Renal Division Washington University School of 
Medicine, Saint Louis, MO.
Background: Kidney organoids from human pluripotent stem cells (hPSCs) provide 
a unique opportunity to study human kidney development and kidney diseases. Current 
protocols are low throughput, generate immature and off-target cell types, and are costly. 
We tested the ability of spinning bioreactors to overcome these limitations.
Methods: We 3D-printed spinning mini-bioreactors that fit onto 12-well plates, 
as described (Qian et.al. Cell, 2016). We adapted the Takasato organoid differentiation 
protocol to the spinning mini-bioreactors by initially differentiating hPSC in a mono-layer 
for 7 days, followed by low-attachment plate culturing to generate spheroids for another 
5 days, and then transferring the spheroids to a mini-bioreactor for maturation for 7- 42 
days. We optimized the throughput and characterized resulting kidney organoids by qPCR, 
immunofluorescence and single cell RNA-seq (scRNA-seq). Finally, we generated and 
validated three novel fluorescent reporter hPSC lines relevant to the study of fibrosis in 
kidney organoids (Fibronectin1-GFP, Col1a1-GFP and Gli1-turboGFP).
Results: One 12-well plate could generate 200-600 kidney organoids, representing 
a more than 100 – fold increase compared to the original Takasato protocol. scRNA-seq 
analysis revealed that when compared to the standard organoid protocol using a transwell 
plate, the kidney organoids generated with the mini-bioreactor exhibit more mature 
nephron structures (including ureteric bud), and more closely resemble the adult human 
kidney by Pearson correlation. We validated that Fibronectin1-GFP, CollA1-GFP and Gli1-
turboGFP all express in the correct stromal cell type in mini-bioreactor-derived organoids. 
Furthermore, kidney organoids generated by the mini-bioreactor method mount a fibrotic 
response when treated with 20 μM cisplatin for 2 days by using RPMI medium for organoid 
differentiation.
Conclusions: We used a 3D-printed spinning mini-bioreactor to increase kidney 
organoid throughput by at least 100-fold. The protocol is cheaper and results in better 
differentiation of nephron structures when compared to the standard protocol using a 
transwell plate. We have generated and validated novel fluorescent reporter hPSC lines 
relevant to studying fibrosis. This work will accelerate adoption of kidney organoid 
protocols for the research community.
Funding: NIDDK Support
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Mesenchymal Stem Cells Derived from Induced Pluripotent Stem Cells 
and Bone Marrow Are Equally Effective in Ameliorating Lipotoxicity- 
Induced Kidney Injury
Bin Li, Joseph C K Leung, Loretta Y.Y. Chan, Wai Han Yiu, Kar Neng Lai, 
Sydney C. Tang. Department of Medicine, The University of Hong Kong, Hong 
Kong, China.
Background: Human induced pluripotent stem cell-derived mesenchymal stem cells 
(iPS-MSCs) are promising as an alternative to bone marrow-derived mesenchymal stem 
cells (BM-MSCs) for cell-based therapy. Lipotoxicity is an important pathogenetic factor 
leading to chronic kidney injury. This study aims to compare the therapeutic effects of iPS-
MSCs and BM-MSCs in ameliorating lipotoxicity-induced kidney lesions.
Methods: Mice (C57BL/6J) fed normal diet (ND; 10 kcal%) or high-fat diet (HFD; 60 
kcal%) for 12 weeks were randomly divided into vehicle control, iPS-MSC and BM-MSC 
subgroups (n=8 in each group), followed by infusion of saline or MSCs via tail vein and 
fed for further 8 weeks before sacrifice. Body weight, blood glucose and urine albumin 
were monitored throughout the experiment. Renal histological changes were assessed by 
Periodic acid-Schiff staining. Renal endoplasmic reticulum (ER) stress, inflammation and 
apoptosis were evaluated by real-time quantitative PCR, Western blot and TUNEL assay.
Results: Compared to ND group, mice fed HFD had significantly increased (1) body 
weight, blood glucose and urine albumin; (2) tubular injury score (tubular vacuolation and 
tubular glycogenated nuclei), glomerular size and mesangial expansion; (3) expression of 
markers for ER stress (BiP, p-eIF2α, ATF4, p-IRE1α, CHOP) and related phosphorylated 
signaling molecules (p-NF-κB, p-ERK, p-JNK); (4) expression of pro-inflammation 
mediators (IL-6, Cxcl1, Cxcl2) and (5) apoptosis (Bax/Bcl2 ratio and number of renal 
TUNEL-positive apoptotic cells). All these events were significantly attenuated by infusion 
with iPS-MSCs or BM-MSCs to the HFD-fed mice. Notably, iPS-MSCs and BM-MSCs 
infusion to HFD-fed mice have equivalent efficacy in ameliorating all the above-mentioned 
readouts in HFD-induced kidney injury.
Conclusions: Our study suggests comparable capability of iPS-MSCs and BM-MSCs 
in ameliorating lipotoxicity-induced kidney injury, supporting iPS-MSCs as a valuable 
alterative source to BM-MSCs for therapeutic application. (Funding: Health and Medical 
Research Fund Advance Medical Research Ref. #03143726 and Mrs. Rita T. Liu SBS of L 
& T Charitable Foundation Ltd)
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Adipose-Derived Regenerative Cells: Therapeutic Potential
Rashida Lathan,1 Ryan Ghita,2 Patrick B. Mark,1 Marc J. Clancy,2 Rhian Touyz.3 
Marc Clancy and Patrick Mark Team 1University of Glasgow, Glasgow, United 
Kingdom; 2NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; 
3Glasgow University, Glasgow, United Kingdom.
Background: Studies in our hybrid rat model of transplantation/ischemic reperfusion 
injury (IRI) have demonstrated improvement in kidney function post injection of adipose-
derived regenerative cells (ADRCs) into the renal artery. This technique has translational 
value in human transplant surgery as ADRCs provide a robust supply of cells from 
accessible tissue, do not require culturing, and can be generated/delivered at point of care 
during the time of transplant. The mechanism on how these cells establish regenerative 
conditions during IRI remains elusive.
Methods: Flow cytometric analysis was performed on rat ADRCs extracted from 
inguinal tissue (n=14). Cells were surveyed for markers that identify viability, immune 
cells, immune cell subsets, epithelial cells, pericytes, and mesenchymal stem cells. Rat 
ADRC RNA expression for angiogenic, anti-oxidant, and anti-/inflammatory markers were 
measured by real-time PCR. Whole body imaging and histology was performed to track 
DiR labelled ADRCs. Protein isolated from the kidney at 1 hour 24, and 48 hours post 
injection were surveyed with a proteome profile array and through western blotting.
Results: ADRCs appear to be a pleomorphic cell suspension with multiple potential 
active subsets including T-cells, macrophages and mesenchymal stem cells. RNA 
expression from whole rat ADRCs indicate production of growth and repair factors, and 
notably- angiogenin and matrix metallopeptidase-2; and chemokine, CXCL1. ADRCs 
accumulate in clustered regions of the corpuscle 1 and 24-hours post injection of ADRCs. 
Gene expression studies performed on the kidneys at 1, 24, and 48 hours post injection 
identified an upregulation of angiogenic factors VEGFa and angiogenin; anti-oxidant HO-1; 
and inflammatory factors IFN-gamma and IL-6 when compared to sham-injected control. 
Protein profiling indicated an upregulation of TIMP-1 and of ligands important in leukocyte 
trafficking.
Conclusions: Data in the context of our model, suggest they serve as a vehicle for 
discrete administration of angiogenic and anti-oxidant factors. Counterintuitively, data also 
suggests that concomitant to secreting repair factors, at early timepoints, factors are secreted 
which attract inflammatory-related immune cells. Collectively, changes in RNA and protein 
levels of leukocyte trafficking-related factors suggest a major role for leukocytes in early 
IRI repair.
Funding: Government Support - Non-U.S.
TH-PO639 Poster Thursday
Development, Stem Cells, Regenerative Medicine - I
Kidney Organoids for Improved Prediction of Human Nephrotoxicity
Akitoshi Tamura,1 Koichiro Susa,1,3 Pierre Galichon,1 Navin R. Gupta,1,2 
Tomoya Miyoshi,1 Venkata Sabbisetti,1 Joseph V. Bonventre,1,2 Ryuji Morizane.1,2 
1Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, 
MA; 2Harvard Stem Cell Institute, Cambridge, MA; 3Department of Nephrology, 
Tokyo Medical and Dental University, Tokyo, Japan.
Background: Nephrotoxicity accounts for only 2% of drug development failures 
in pre-clinical studies which rises to 19% of drug attrition during phase 3 clinical trials, 
highlighting the need for improved pre-clinical predictive tools. The poor predictability 
stems either from inter-species differences or from an inability to distinguish drug-specific 
versus generalized toxicity due to poor expression of drug transporters (TPs), such as 
Organic Cation Transporters (OCTs) and Organic Anion Transporters (OATs) in primary 
cells, and limited availability of co-culturing models recapitulating cell-cell interactions 
in vitro. Here we demonstrate the utility of human pluripotent stem cell-derived kidney 
organoids for pre-clinical nephrotoxic assessment.
Methods: Kidney organoids were generated following a 6-step directed differentiation 
protocol. Using qPCR and immunostaining, drug TP expression was characterized overtime 
from differentiation day 8 - 50. The following known nephrotoxicants were tested: cisplatin 
(an OCT-mediated tubular toxicant), aristolochic acid and tenofovir (OAT-mediated tubular 
toxicants), and puromycin aminonucleoside (a Plasma Monoamine Transporters [PMAT]-
mediated podocyte toxicant). Injury responses were assessed by immunostaining, qPCR and 
biomarker assays. Cimetidine and probenecid, inhibitors of OCTs and OATs respectively, 
were employed to assess drug TP-mediated nephrotoxicity in tubules.
Results: Drug TPs, OAT1, OAT3, OCT2 and PMAT, were expressed in kidney 
organoids with maturity. Cisplatin 5 μM induced KIM-1 and γH2AX expression in LTL+ 
tubules which was partially reversed by cimetidine, indicating TP-mediated injury. Cisplatin 
at 50 μM resulted in widespread injury to all nephron compartments with increased levels 
of MCP-1 and TNFR1 in culture media, representing generalized toxicity responses. 
Aristolochic acid and tenofovir also caused LTL+ tubular injury at a low concentration, and 
probenecid suppressed injury responses. Puromycin aminonucleoside induced loss of foot 
processes and podocyte apoptosis without evidence of tubular injury.
Conclusions: Kidney organoids replicated drug TP-mediated nephrotoxicity in a 
segment-specific manner, serving as a novel pre-clinical tool to assess nephrotoxicity with 
the ability to distinguish between drug-specific and generalized toxicity responses.
       Funding: NIDDK Support, Private Foundation Support, Government Support - Non-
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Stem Cell-Derived Podocytes from Blacks with FSGS and High Risk 
ApoL1 Expressed More ApoL1 Protein and Reduced Viability in 
Response to Interferon γ
Opeyemi A. Olabisi,1 Savannah Moore,2 Rama Kataria.3 
1Massachusetts General Hospital/Harvard Medical School, Boston, MA; 
2Massachusetts General Hospital, Brookline, MA; 3Harvard Medical SChool, 
Boston, MA.
Background: Podocyte injury/loss is the cellular hallmark of ApoL1-
nephropathies. Blacks with high risk (HR) ApoL1 alleles (G1G1, G2G2, or G1G2) have 
7-10-fold increased risk of Focal segmental glomerulosclerosis (FSGS). HR ApoL1 is 
sensitive but not specific for FSGS. Estimated 20% of carriers of HR ApoL1 develop 
ApoL1-nephropathy. There is need for functional assay to identify truly at-risk blacks. 
Lack of disease-relevant podocyte model has stalled research progress. Our goal is to 
utilize stem-cell derived podocytes as tools for determining an individual’s risk of 
ApoL1-nephropathy.
Methods: We recruited blacks with biopsy-proven FSGS (cases) and healthy controls 
with normal GFR and no proteinuria. ApoL1 was genotyped by sanger sequencing. Induced 
pluripotent stem cells (iPSCs) generated from PBMCs were differentiated into markers-
confirmed podocytes based on published protocol. Podocytes were treated/not with 
interferon γ (IFNγ). Cell viability, comparative transcriptome, and protein expression were 
determined by cellular ATP content, RNA-seq and immunoblotting, respectively.
Results: 81.8% (9 of 11) cases have HR ApoL1 allele versus 16.7% (1 of 6) of controls. 
IFNγ induced higher ApoL1 protein expression in podocytes derived from cases despite 
similar intergroup ApoL1 mRNA levels. IFNγ reduced the viability of podocytes derived 
from cases with HR ApoL1 but not of controls, including control with HR ApoL1 genotype. 
Transcriptome analysis shows that IFNγ differentially upregulated genes involved in 
endocytic recycling, PI3K-mediated signaling, and actin filament-based movement in 
podocytes derived from cases.
Conclusions: iPSC- podocytes of blacks with ApoL1-nephropathies have a distinct 
cellular/molecular response to IFNγ which could be harnessed for Identification of blacks 
most at risk to develop ApoL1-nephropathy in future.
Funding: Private Foundation Support
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Modelling APOL1 Nephropathy Using Kidney Organoids
Justin Chun,1,2 Martin R. Pollak,3 Cristian Riella.1 1Beth Israel Deaconess 
Medical Center, Newton Center, MA; 2Harvard Medical School, Boston, MA; 
3Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Background: Apolipoprotein L1 (APOL1) is a gene expressed only in humans and 
some primates. Its genetic variants (G1 and G2) are strongly associated with kidney 
diseases including non-diabetic kidney disease, FSGS, and HIVAN. The mechanism 
leading to APOL1 nephropathy remains unclear partly due to inadequate animal models 
that can recapitulate the events leading to human disease.
Methods: We generated non-isogenic and isogenic iPSC lines for wild type APOL1 
(G0) and risk variants (G1, G2) using dermal fibroblasts reprogrammed with Sendai 
virus. Kidney organoids were generated using the protocol established by Takasato et 
al. (Nat Protoc. 2016, 11:1681-92). RNA-sequencing was performed on differentiated 
kidney organoids day 28 with and without interferon (IFN)-gamma. After QC and adaptor 
trimming, reads were mapped to the reference genome with STAR aligner and then analyzed 
in EdgeR. Network analysis was performed with Metacore.
Results: As expected, iPSCs from different sources had variable characteristics in terms 
of rate of cell division, ability to differentiate and to form kidney organoids but we were 
able to select representative, comparable iPSC lines for the generation of kidney organoids. 
Our APOL1 kidney organoid model demonstrated expected localization of APOL1 to 
podocytes and proximal tubules and appropriately upregulate interferon stimulated genes 
when treated with IFN-gamma. APOL1 was equally expressed across the genotype groups. 
Gene enrichment analysis was notable for transcription changes in HIF1 targets in the risk 
variants compared with the wild type group.
Conclusions: Our human iPSC derived model for APOL1 nephropathy will be used 
to further characterize the APOL1 genetic variants. We now have a robust model that will 
serve as a platform for understanding the mechanisms that lead to disease, drug testing and 
potential cell therapies.
Funding: Other NIH Support - NIMHD, Commercial Support - Vertex Pharmaceuticals, 
Government Support - Non-U.S.
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Identification of Nephron Progenitor Cell (NPC) Markers Derived from 
Human Embryonic Stem Cells (hESCs) by Single-Cell RNA Sequencing 
Mien Nguyen, John F. Ouyang, Owen J. Rackham, Karl Tryggvason. Duke-NUS 
Medical School, Singapore, Singapore.
Background: The steady rise of chronic kidney diseases has caused a major burden 
for the healthcare systems worldwide. Yet, most of their molecular pathomechanisms are 
understudied due to the lack of functional model systems. In vitro modeling of kidney 
diseases and nephrotoxicity drug testing mainly employ immortalized kidney cell lines 
that do not truly represent their in vivo counterparts, or rely on limited sources of mouse 
and human primary kidney cells that de-differentiate in culture. hESC-derived NPCs, 
in contrast, may provide unlimited cell source for the generation of functional kidney 
disease models. Most current protocols differentiate pluripotent cells to various kidney 
cell types that aggregate into kidney organoids. These systems utilize undefined matrices 
and xenogenic products with high variability, making it difficult to study molecular disease 
mechanisms. The objective of this study was to generate a pure population of NPCs from 
hESCs in a chemically defined system through the identification of NPC markers.
Methods: hESCs were differentiated on human recombinant laminin toward 
mesoderm, metanephric mesenchyme and NPC lineage in the presence of relevant Wnt 
signaling molecule.
Results: By day 30, we observed 82% WT1+ in total cell population via FACS 
analysis. Quantitative RT-PCR showed significant increases in mRNA expression of kidney 
lineage markers, in particular those of podocytes (OSR1, WT1, SYNPO, and NPHS1), 
and significant decreases in early metanephric mesenchymal markers from day 6 to day 
30 (CD133 and CD24). We performed single-cell RNA sequencing on hESC-derived cells 
at different time points to establish signature surface markers that could allow us to purify 
and enrich for NPC population. From the analysis of the single-cell transcriptome, we have 
identified a set of genes whose gene expression profiles are highly correlated with those of 
podocyte lineage genes. Among those, we have selected potential surface markers for NPC 
enrichment, such as CD83, PLP2, and TM7SF2.
Conclusions: Our highly reproducible protocol allows efficient production of hESC-
derived NPCs in monolayer in a chemically defined, xeno-free culture. These cells promise 
to provide an unlimited source to construct kidney disease models for analyzing drug 
clearance and toxicity, and for studying molecular disease mechanisms.
Funding: Government Support - Non-U.S.
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Identification of ROBO2 and Integrin B4 as Potential Surface Markers for 
the Isolation of Live Nephrogenic Cells from Human Fetal Kidneys
Astgik Petrosyan,1 Julia Marcheque,1 Matthew E. Thornton,2 Brendan Grubbs,2 
Laura Perin,1 Stefano Da Sacco.1 1Children’s Hospital Los Angeles, Los Angeles, 
CA; 2University of Southern California, Los Angeles, CA.
Background: In the developing kidney, the formation of new nephrons relies on a 
small population of self-renewing nephrogenic progenitors (NP) characterized by co-
expression of SIX2 and CITED1. Despite their essential role in renal formation and 
maturation, identification of surface markers that can facilitate their isolation has not yet 
been successful. We report here the isolation of a live cell population with NP traits from 
human fetal kidneys (hFK) using a novel combination of surface markers.
Methods: We have previously reported the isolation of NP cells from hFK cells 
using RNA probes. Based on our RNA-seq performed on these cells we have identified 
ROBO2 and Integrin B4 as potential surface markers for direct isolation of NP of human 
origin. ROBO2+IntegrinB4+ cells were isolated using FACS and RNAseq analysis was 
immediately performed to characterize their gene expression and evaluate their genetic 
profile. Data were compared with the SIX2+CITED1+ cells isolated by RNA-probe. 
Dissociation/reaggregation assays were performed to confirm their nephrogenic traits. 
Potential for long term expansion was also explored.
Results: Expression of ROBO2 and IntegrinB4 was histologically confirmed within 
the cap mesenchyme during development in 17-week hFK. FACS of ROBO2+IntegrinB4+ 
cells from hFK confirmed enriched expression of SIX2 and CITED1 in more than 90% of 
the cells. RNASeq analysis confirmed expression of genes including SIX2, CITED1, SIX1, 
PHF19, OSR1 and EYA1 suggesting a nephrogenic signature. Expression of human NP 
markers was validated by flow cytometry. NP showed the ability to integrate in developing 
renal structures expressing nephrogenic markers when co-cultured with dissociated/re-
aggregated hFK. Optimal culture conditions for long-term expansion without loss of NP 
traits were also successfully established.
Conclusions: Our preliminary results suggest that ROBO2 and IntegrinB4 are 
potential candidates as surface markers for the direct isolation of cells with nephrogenic 
characteristics, including the expression of SIX2 and CITED1, from hFK without the use 
of any genetic manipulation. This system represents a novel method of isolating a pool 
of NP that can be applied towards studies of renal cell specification, thus increasing our 
knowledge of human renal development
Funding: Private Foundation Support
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BMSCs Labeled with Sialyl Lewis X Had Higher Homing Rate to the 
Kidney of AKI Rats
Lin Yang,1 Qi Wang,2 Lihua Luo,3 Fuli Luo,4 Yun Li.5 1Nephrology, Jiangxi 
Provincial People’s Hospital, Nanchang, China; 2Nanchang University, Graduate 
School, Nanchang, China; 3Ganzhou People’s Hospital, Ganzhou, China; 4Jiangxi 
University of Traditional Chinese Medicine?University Hospital, Nanchang, 
China; 5Jiangxi Provincial Peoples’ Hospital, Nanchang, China.
Background: Bone marrow mesenchymal stem cells (BMSCs) were applied to treat 
various diseases. After transplantation, BMSCs could migrate to the injured organ which is 
called homing. To enhance homing, a new technology has been developed, in which biotin-
streptavidin is used to attach sialyl LewisX, the ligand of adhesion molecule to BMSCs 
surface.
Methods: BMSCs from male SD rats were isolated, amplified, and labeled with 
sialyl LewisX by biotin-streptavidin system. The acute kidney injury(AKI) rat model was 
induced by cisplatin in female SD rats. Forty-eight AKI rats were divided into three groups: 
PBS, labeled BMSCs, and unlabeled BMSCs. After application of cisplatin, rats were 
transplanted with BMSCs or PBS.
Results: BMSCs significantly improved the renal function of AKI rats. Serum 
creatinine and blood urea nitrogen in BMSCs groups were statistically significantly lower 
than those of PBS group on 4-7 days after cisplatin injection (Fig. 1,2). Unfortunately 
the differences of renal function between the labeled and unlabeled groups were not 
statistically significant. There were more cells exuded in renal glomeruli and interstitium in 
the labeled group than in the unlabeled or PBS group, suggesting that the BMSCs labeling 
may increase BMSCs’ homing to the kidney of AKI rats (Fig. 3-5). BMSCs reduced renal 
tubular and interstitial lesions to some extent, such as renal tubular dilatation, epithelial cell 
detachment, basement membrane exposure, intra-luminal cellular cast, interstitial edema 
and cell infiltration. The regeneration of renal tubular epithelium in transplanted groups 
were slightly higher (Fig. 6-8).
Conclusions: BMSCs labeled with sialyl LewisX had higher homing rate to the kidney 
of AKI rats. BMSCs transplantation significantly improved the renal function of AKI rats, 
and to some extent, reduced renal tubular and interstitial lesions.
Funding: Government Support - Non-U.S.
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Hypoxia-Preconditioned Mesenchymal Stem Cells Attenuate Renal 
Fibrosis by Upregulating Renal M2 Macrophage Polarization
Wei-Cheng Tseng,1,3 Nien-Jung Chen,4 Shih-Chieh Hung,5,6 Der-Cherng Tarng.2,3 
1Division of Nephrology, Department of Medicine, Taipei Veterans General 
Hospital; Institute of Clinical Medicine, National Yang-Ming University, Taipei, 
Taiwan; 2Division of Nephrology, Department of Medicine, Taipei Veterans 
General Hospital; Institute of Clinical Medicine, Department and Institute of 
Physiology, National Yang-Ming University, Taipei, Taiwan; 3Center for 
Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Chiao-Tung 
University, Hsinchu, Taiwan; 4Institute of Microbiology and Immunology, 
National Yang-Ming University, Taipei, Taiwan; 5Integrative Stem Cell Center, 
Department of Orthopedics, and Graduate Institute of New Drug Development, 
Biomedical Sciences, China Medical University, Taichung, Taiwan; 6Institute of 
Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Background: Tubulointerstitial fibrosis is the final common pathway of all kidney 
diseases and also represents the major determinant of renal function decline. Infiltrating 
renal macrophages critically govern the homeostasis of renal fibrogenesis and the extent of 
renal interstitial fibrosis. M1 macrophages release pro-inflammatory cytokines and result in 
tissue destruction; conversely, M2 macrophages secrete anti-inflammatory cytokines and 
promote tissue repair. Mesenchymal stem cells (MSCs) are promising cell-based therapy 
and previously we have shown hypoxia-preconditioned MSCs (HMSCs) exhibited better 
anti-inflammatory and anti-apoptotic effects. Nonetheless, whether HMSCs attenuate renal 
interstitial fibrosis through modulating the phenotype of infiltrating macrophages remains 
unclear.
Methods: Male C57BL/6J mice undergoing unilateral ureteral obstruction (UUO) 
were administered either phosphate-buffered saline, normoxic MSCs or HMSCs. Histology, 
fibrosis content, inflammation markers and macrophage phenotypes were analyzed in 
the obstructed kidney tissue. In vitro, we also determined the phenotypic change and 
inflammatory gene expression in M1 macrophages after coculture either with normoxic 
MSCs or HMSCs.
Results: The extent of fibrosis in UUO-injured kidney was significantly decreased 
by HMSCs treatment as compared with normoxic MSCs or phosphate-buffered saline. 
Interestingly, HMSCs significantly decreased the number of inducible nitric oxide synthase 
(iNOS)-positive M1 macrophages and contributed to early expression of arginase (Arg)-
1-positive M2 macrophages in obstructed kidney than normoxic MSCs, suggesting that
HMSCs facilitated an M1-to-M2 phenotypic transition in obstructed kidneys. Flow
cytometry, immunoblotting and real-time polymerase chain reaction analysis also
demonstrated that HMSCs downregulated STAT-1, iNOS expression and upregulating
mannose receptor and Arg-1 expression. Furthermore, HMSCs treatment resulted in more
anti-inflammatory M2c macrophages and less pro-fibrotic M2a macrophages infiltration in 
obstructive kidneys.
Conclusions: HMSCs treatment reduced renal fibrosis and facilitated an early M1-
to-M2 phenotypic change of renal macrophages in mice UUO, predominantly upregulating 
M2c macrophages. HMSCs can be a promising therapeutic approach for the inflammatory 
fibrotic kidney diseases.
Funding: Government Support - Non-U.S.
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Adult Renal Stem/Progenitor Cells Exert Immunomodulatory Activity on 
T Regulatory Cells and Double Negative T Cells
Fabio Sallustio, Claudia Curci, Nada Chaoul, Angela Picerno, Rossana Franzin, 
Alessandra Stasi, Chiara Divella, Paola Pontrelli, Anna Gallone, 
Giovanni B. Pertosa, Giuseppe Castellano, Loreto Gesualdo. University of Bari, 
Bari, Italy.
Background: Several studies show the active role of Adult Renal Stem/Progenitor 
Cells (ARPCs) in kidney repair processes during acute or chronic injury. However, little 
is known about their immunomodulatory properties and their capacity to regulate specific 
T cell subpopulations. The aim of our study was to investigate the immunomodulatory 
properties of ARPCs on human T cells.
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Methods: Human Peripheral Blood Mononuclear Cells (PBMCs) of healthy subjects 
were activated through incubation with Concanavalin A for 24h. ARPCs were activated by 
triggering TLR2 for 24h with Lipoteichoic acid (LTA) and co-cultured with T cells. Cell 
proliferation was measured by MTT cell viability assay. Phenotypic characterization of T 
cells was performed by flow cytometry. The relative expression levels of 36 cytokines of T 
cells and ARPCs, alone and in co-culture, were determined by Human Cytokine Proteome 
Array.
Results: TLR2-activated-ARPCs were able to decrease T cell proliferation after 24h of 
co-culture (p=0.017). In order to investigate changes in subset of T cell populations, we co-
cultured PBMCs with activated ARPCs for short (5 days) and long period (15 days) of time. 
ARPCs did not affect CD3+CD8+ nor CD3+CD4+ T cells. Instead, we observed a significant 
decrease of Tregs (p<0.001) and CD3+CD4-CD8- DN T cell (p<0.0001) subpopulations 
after 5 and 15 days. Not significant effects were shown when T cells were co-cultured with 
renal proximal epithelial cells. Finally, by proteome array we identified cytokines secreted 
by ARPCs responsible for the immunomodulatory effect. SERPIN-E1, MIF, IL-8 and IL-6 
were significantly up-regulated in the supernatant of T cells cocultured for 24h with TLR2-
activated ARPCs, while were not present in supernatant of T cells alone.
Conclusions: Our data showed that ARPCs can regulate immune response by inducing 
T cell modulation through the TLR2 engagement. Interestingly, ARPCs lead to down-
regulation of Tregs and DN T cells, which are involved in the balance between immune 
tolerance and autoimmunity. Moreover, we identified four cytokines with a key role in this 
system. These findings can help to clarify the role of ARPCs in immunomodulation and 
could be translated to potential clinical treatment.
Funding: Government Support - Non-U.S.
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Using the T30H Mouse to Investigate the Role of Myocardin in  
Obstructive Uropathy
Natalie J. Milmoe,1 Daniel J. Stuckey,2 Ahad A. Rahim,3 Robert J. Harvey,4 
Paul Winyard.1 1UCL GOS Institute of Child Health, London, United Kingdom; 
2UCL, London, United Kingdom; 3University College London, London, United 
Kingdom; 4University of the Sunshine Coast, Sippy Downs, NSW, Australia.
Background: Obstructive uropathies account for 20% of paediatric end stage renal 
failure. Irreparable damage often occurs to the kidneys before surgical correction of 
obstruction is possible. There are few in vivo models of this process. T30H mice were 
generated many years ago and have a balanced, heritable chromosomal translocation 
between chromosomes 2 and 11. The exact translocation point was previously unknown. 
They die soon after birth with large non-emptying bladders, hydronephrosis and reduced 
nephron numbers, despite there being no physical obstruction. Nevertheless, they are still a 
useful model for many features of obstructive uropathy.
Methods: We have utilised next generation sequencing, histology, RT-PCR and cell 
culture to examine gene expression and the bladder phenotype.
Results: We have investigated the T30H genome and discovered the exact translocation 
point, it does not span recognised genes, but is upstream of myocardin, a master regulator 
of smooth muscle. In the bladder, markers such as α SMA and Calponin are absent or 
expression is severely reduced. Urothelial markers such as Uroplakin 3a are unchanged. 
The translocation has no effect on all other systems involving smooth muscle, organs such 
as the heart and gut appear normal. The splice variants of myocardin present in wild type 
and T30H mice at birth are similar, suggesting expression levels of these splice variants are 
more important than whether or not they are expressed. Quantitative PCR will be required 
to confirm this hypothesis. We have isolated smooth muscle cells from wild type bladders 
at E14, then transfected them with lentivirus containing myocardin shRNA. This gene 
knockdown causes both reduced growth and expression of smooth muscle specific genes, 
including αSMA, consistent with the bladder phenotype in vivo. We are investigating the 
bladder phenotype in utero; the defect is identifiable using ultrasound from E16. In future 
we will uncover the developmental point when the defect is instigated, and whether the 
defect arises as a failure of muscle development, or whether the muscle grows and then is 
not maintained.
Conclusions: Understanding bladder smooth muscle regulation will better our 
knowledge of urinary tract development, and enable us to develop improved therapies for 
treating smooth muscle complications arising from urinary tract malformations.
Funding: Private Foundation Support
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Development, Stem Cells, Regenerative Medicine - I
Impact of Obesity on Mesenchymal Stem Cell Senescence
Sabena Conley,1 Seo Rin Kim,4 Hui Tang,2 Xiang yang Zhu,1 James L. Kirkland,1 
LaTonya J. Hickson,1 Lilach O. Lerman.3 1Mayo Clinic, Rochester, MN; 2Mayo 
Clinic, Rochester, MN; 3Mayo Clinic College of Medicine, Rochester, MN; 
4Mayo Clinic, Rochester, MN.
Background: Obesity induces inflammation and contributes to the pathogenesis of 
kidney disease. Endogenous mesenchymal stem/stromal cells (MSC) mediate tissue repair, 
and show promise as exogenous therapy of kidney injury. However, chronic inflammation 
may impair the regenerative potential of MSC. We hypothesized that in human adipose 
tissue-derived MSC, obesity induces senescence, a growth-arrest program that transitions 
cells to a pro-inflammatory state.
Methods: MSC proliferation and migration were studied in MSC harvested from 
subcutaneous abdominal fat from obese (n=6, BMI ≥35 kg/m2) and age-matched lean 
controls (n=6, BMI <30 kg/m2) during bariatric or kidney donation surgeries. Cellular 
senescence was evaluated by senescence-associated β-galactosidase (SA-β-gal) activity 
(staining), and by expression of cell cycle arrest (p21) and senescent-associated secretory 
phenotype (SASP) (MCP-1, IL-1α, and PAI-1) markers (quantitative PCR).
Results: Among all subjects, mean age was 59±8 years, eGFR 64.8±15.3 mL/min/1.73m2, 
and 66% were females. Obese-MSC exhibited similar proliferation capacity as Control-
MSC, but their migratory potential was lower, suggesting MSC dysfunction (Fig A). 
Senescence burden as per SA-β-gal staining, p21 and SASP markers expression was 
elevated in Obese-MSC (Figs B-C).
Conclusions: Human obesity induces senescence in adipose tissue-derived MSC. 
This impairment in endogenous cellular repair systems may permit development of 
kidney lesions that are inadequately repaired in subjects with obesity, and limit delivery of 
autologous MSC to the subjects kidneys’.
Funding: NIDDK Support
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The Metabolic Syndrome Alters the Transcriptome and Proteome of 
Swine Mesenchymal Stem Cells
Aditya S. Pawar, Alfonso Eirin, Xiang yang Zhu, Lilach O. Lerman. Mayo 
Clinic, Rochester, MN.
Background: Mesenchymal stem cells (MSCs) possess endogenous reparative 
properties & have been proposed as an exogenous therapeutic intervention in patients 
with chronic kidney disease (CKD). The metabolic syndrome (MetS) often coexists with 
and aggravates CKD, but whether MetS interferes with the reparative capacity of MSC 
remains unknown. We hypothesized that integrated comparison of the mRNA, microRNA, 
and protein content of MSCs isolated from Lean and MetS pigs would reveal pathways 
impacted in MSC by MetS.
Methods: Domestic pigs were fed a Lean or MetS diet (n=4 each) for 16 weeks. MSC 
were harvested from subcutaneous abdominal fat, and expression profiles of microRNAs, 
mRNAs, and proteins obtained by high throughput sequencing and LC-MS/MS proteomic 
analysis. TargetScan and ComiR were used to predict target genes of microRNAs (that often 
inhibit gene and protein expression) altered in MetS-MSCs. Functional annotation analysis 
was performed using DAVID 6.7 database.
Results: Differential expression analysis revealed 12 microRNAs upregulated 
in MetS-MSCs (fold change >1.4, p<0.05), which may target 7,728 genes, whereas 
33 mRNAs and 78 proteins were downregulated (fold change <0.7, p<0.05). Integrated 
analysis showed that microRNAs upregulated in MetS-MSCs may target 33% of mRNAs 
and 45% of proteins downregulated in MetS-MSCs (Fig. 1A), and functional analysis 
showed that targeted proteins are mainly involved in apoptosis (e.g. CASP9, LAPTM5, 
LRG1) (Fig. 1B), angiogenesis (e.g. FGF1, AKT2) (Fig. 1C), and insulin signaling (e.g. 
AKT2, PP2CB) (Fig 1D).
Conclusions: MetS alters the transcriptome and proteome of swine adipose tissue-
derived MSCs, via post-transcriptional regulation of genes and proteins involved in 
apoptosis, angiogenesis, and insulin signaling. MetS-induced changes in the MSC 
transcriptome and proteome may limit their use as an autologous cell-based regenerative 
therapy in CKD
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Development, Stem Cells, Regenerative Medicine - I
Metabolic Syndrome and Renal Artery Stenosis Induce Mitochondrial 
Damage in Swine Scattered Tubular Cells
Arash Aghajani Nargesi, Xiang yang Zhu, Ishran M. Saadiq, Amir Lerman, 
Lilach O. Lerman, Alfonso Eirin. Mayo Clinic Rochester MN, Rochester, MN.
Background: Scattered tubular cells (STC) are considered to contribute to repair 
neighboring injured renal tubular epithelial cells. Mitochondria mediate STC biology and 
function, by producing energy and modulating redox status. We hypothesized that kidney 
injury due to coexisting metabolic syndrome (MetS) and renal artery stenosis (RAS) in 
swine impairs STC mitochondrial structure and function, which can be attenuated with 
mitoprotection.
Methods: CD24+/CD133+ STC (Fig. A) were isolated from pig kidneys after 16wks 
of MetS or Lean diet with or without RAS (n=7 each). Mitochondrial structure (electron 
microscopy), membrane potential (TMRE staining), and oxidative stress (Mito-SOX 
staining) were assessed in STC untreated or incubated with the mitoprotective drug 
elamipretide (ELAM, 1nM for 6hrs).
Results: Mitochondrial area increased and matrix density decreased in Lean+RAS- and 
MetS+RAS-STC compared to Lean- and MetS-STC, but both were restored in ELAM-
treated pigs (Fig. B-C). Mitochondrial membrane potential diminished and mitochondrial 
production of reactive oxygen species increased in MetS-, Lean+RAS-, and MetS+RAS-
STC, but reversed after treatment with ELAM (Fig. D-E).
Conclusions: Coexisting MetS and RAS induce structural and functional alterations in 
swine STC mitochondria, which might limit their regenerative potential. These observations 
suggest a potential role for mitoprotection in preserving the renal reparative capacity of 
STC.
Funding: NIDDK Support, Commercial Support - Stealth Biotherapeutics Inc
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Development, Stem Cells, Regenerative Medicine - I
Mechanisms Involved in the Disturbances in Renal Development in Pups 
from Vitamin D Deficient Dams
Lucas F. Almeida,1 Heloisa D. Francescato,1 Cleonice Silva,2 Jose A. Rodrigues,3 
Terezila M. Coimbra.1 1University of Sao Paulo, Ribeirao Preto, Brazil; 
2Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil; 3FMRP-
USP, Ribeirão Preto, Brazil.
Background: Vitamin D3 (Vit.D3) has been related with cellular proliferation, 
differentiation and apoptose and with the regulation of renin gene, which are important 
events in renal development. Pups from dams submitted to a Vit.D3 deficient diet during 
nephrogenesis (gestation and lactation), present changes in renal development that can 
persist in adult life. This study investigates the influence of Vit.D3 deficiency on changes in 
renal development, the mechanisms involved and its consequences in adult life.
Methods: Offspring (Hannover rats) from mothers fed with normal (control group, 
CG) or vitamin D restricted (VitD-) diets were used in this study. Body weight (BW) was 
evaluated at birth, during lactation and at 3 months and 6 months of age. Systolic blood 
pressure (SBP) was measured monthly using a tail-cuff plethysmography. Blood and urine 
samples were collected to quantify Vit.D3, creatinine, Na+, K+, Ca+2, angiotensin II (ANGII) 
and albuminuria levels. The kidneys were removed for histological, morphometric and 
immunohistochemical studies 3 and 6 months after birth.
Results: Vit.D deficient pups presented decreased BW at the end of lactation and 
increase in adult life compared to CG (p< 0.05). These animals showed higher SBP and 
plasma ANGII levels in the adult life compared to CG (p< 0.05). These pups also presented 
a significant decrease in urine osmolality, sodium and potassium fractional excretion 
and increase in water intake and urinary volume (p< 0.05). Decreased expressions of 
JG12 (a marker of endothelial cells) in renal cortex and glomerulus, and of synaptopodin 
(a marker of filtration barrier) in glomerulus were observed in VitD- compared to CG 
(p< 0.05). These animals also presented decreased glomerular area and increased fractional 
mesangial area compared to CG (p< 0.05). However, there was no difference in serum 
calcium levels, glomerular filtration rate, and albuminuria between the groups.
Conclusions: The current findings showed that the renal development is impaired in 
pups from dams VitD restricted with consequences in their adult life. These alterations can 
be at least in part provoked by the disturbances in the renal angiogenesis induced by the 
renin angiotensin system upregulation in pups with Vit.D deficiency
Funding: Government Support - Non-U.S.
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Development, Stem Cells, Regenerative Medicine - I
Autologous Mesenchymal Stromal Cell Paracrine Function in Diabetics 
with and Without Kidney Disease
LaTonya J. Hickson,1 Alfonso Eirin,1 Sabena Conley,1 Ahmed Saad,2 
Ramila A. Mehta,1 Hui Tang,1 Ishran M. Saadiq,1 John R. Woollard,1 
Sandra Herrmann,1 Stephen C. Textor,1 Lilach O. Lerman.1 1Division of 
Nephrology and Hypertension, Mayo Clinic, Rochester, MN; 2Mayo Clinic/ 
Loyola University Medical Center, Naperville, IL.
Background: Cell-based therapy applying autologous mesenchymal stromal cells 
(MSCs) is a promising treatment option for diabetic kidney disease (DKD). MSC provide 
immunomodulatory, antioxidant, anti-fibrotic, and pro-angiogenic effects in the diseased 
kidney, but the diabetic and/or uremic milieu may diminish their regenerative capacity 
in humans. To test the relative contributions of these milieus, we studied MSC paracrine 
function in patients with diabetes with and without reduced kidney function.
Methods: MSCs were harvested from subcutaneous abdominal fat tissue of DKD 
subjects (n=44) and Controls (n=6 kidney donors). Levels of secreted cytokines [VEGF, 
hepatocyte growth factor (HGF; angiogenesis), indoleamine 2,3-dioxygenase (IDO; 
immunomodulation)] were measured in conditioned media from 3rd passage MSC. MSC 
functional capacity was measured by migration and proliferation assays.
Results: DKD subjects were older (67±7 vs 47±22 years), had higher BMI (35±6 vs 
30±4 kg/m2), and lower eGFR (46±20 vs 92±24 mL/min/1.73m2; all p<0.05), while sex 
(females 41% vs 67%) and race (whites 84% vs 100%; all p>0.2) were similar to controls. 
eGFR was <60 in 36 (82%) DKD subjects. DKD-MSC migration and proliferation 
were reduced compared to Control-MSC (Figure) and their IDO secretion was lower. 
Yet, VEGF secretion was similar and HGF was increased in DKD-MSC. Most study 
differences between DKD-MSC and Control-MSC were independent of kidney function.
Conclusions: Diabetes blunts the migration and proliferation capacity of human MSC 
in vitro, with little further contribution by a fall in kidney function. Nonetheless, angiogenic 
cytokines important for kidney regeneration are relatively intact, supporting MSC suitability 
for autologous cell-based therapy in DKD patients.
Funding: NIDDK Support, Private Foundation Support
MSC Function and Paracrine Activity in Diabetes Subjects (eGFR≥60; eGFR<60 mL/
min/1.73m2) and Controls
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Low Circulating CD34+ Cell Count Is a Significant Predictor of  
Cardiovascular Death Among Chronic Hemodialysis Patients
Ahmad B. Kaihan,1 Yoshinari Yasuda,2 Takahiro Imaizumi,3 Masaki Okazaki,3 
Naotake Tsuboi,3 Shoichi Maruyama.3 1Department of Nephrology/CKD, 
Nagoya University Graduate School of Medicine, Nagoya city, Japan; 2Nagoya 
University Graduate School of Medicine, Nagoya, Aichi-ken, Japan, Nagoya, 
Japan; 3Nagoya University Graduate School of Medicine, Nagoya, Japan.
Background: Circulating CD34-positive (CD34+) cells play an essential role in neo-
angiogenesis and in maintaining vascular endothelial function. A reduced CD34+ cell count 
was reported that associated with cardiovascular events and all-cause mortality. In this 
study, we aimed to validate association of low CD34+ cell count with cardiovascular death 
and all-cause mortality among chronic hemodialysis patients with longer follow up period.
Methods: In this prospective cohort study, 216 CKD patients on chronic hemodialysis 
enrolled from Mar 2005 to May 2005 and followed by the end of 2017 at Nagoya Kyoritsu 
Hospital. A cutoff number (0.41 cells/μl) for circulating CD34+ cells was determined by 
dividing all patients into two equal group of low CD34+ CPCs group (n=108) vs high 
CD34+ CPCs group (n=108) to predict cardiovascular death in the future, and the number 
of circulating CD34+ cells determined by flow cytometry at the time of enrollment. The 
primary outcome was cardiovascular death and all-cause mortality.
Results: During an average 59 months of follow-up, of 139 (64.7%) deaths, 38 
(17.7%) cardiovascular deaths occurred. Cumulative cardiovascular death-free survival 
was significantly less in the low numbers of circulating CD34+ cells group. By multivariate 
analyses, age, DM, current smoking, history of CVD, and GNRI were significantly 
associated with all-cause mortalities, whereas, low numbers of circulating CD34+ cells 
(HR;1.98, p=0.037), GNRI (HR;0.95,p=0.042), and history of CVD (HR;2.92; p=0.031) 
were significant predictors for cardiovascular deaths.
Conclusions: This study revealed that a low number of circulating CD34+ cells is 
significantly associated with risk of cardiovascular deaths, but not with all-cause mortalities 
in patients on chronic hemodialysis.
Funding: Commercial Support - MSD, Dainippon-Sumitomo, Kowa,Chugai,Nippon-
Boehringer, Kirin, Mochida,Nippon Boehringer Ingelheim
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Differentiation Efficiency of Human Induced Pluripotent Stem Cell (iPSC) 
to Endothelial Cells in Patients with ESRD
Do-hyun Na. Transplant research center, St. Mary’s Hospital, College of 
Medicine St. Mary’s Hospital, College of Medicine, Seoul, Republic of Korea.
Background: Human induced pluripotent stem cell-derived endothelial cells (hiPSC-
ECs) could be promising for treatment of renal disease. However, it is unclear whether hiPSC 
could be differentiated to endothelial cell (EC) in ESRD patients. Therefore, we first sought 
to generate hiPSC from peripheral blood mononuclear cell (PBMC) of ESRD patient, then 
compared the efficiency of hiPSC lines differentiating into ECs with healthy control.
Methods: The hiPSC-ECs were generated from differentiation of hiPSCs using 
vascular endothelial growth factor (VEGF) and bone morphogenetic protein-4 (BMP-4). 
At first, the expression of iPSC markers (NANOG, SSEA-4, and TRA-1-81) were assessed 
with confocal laser scanning microscopy, then hiPSC-ECs were purified based on positive 
expression of CD31. Subsequently, expression of endothelial markers (CD31, CD 34, and 
CD 133) were assessed with flow cytometric analysis. After 6 days in cell culture, stain with 
pluripotency markers (NANOG, SSEA-4, and TRA-1-81) on confocal image revealed iPSC 
were successfully generated in both healthy control and ESRD patient.
Results: Upon magnetic purification based on CD31+ expression, the hiPSC-EC 
population was observed to display typical endothelial surface markers in both groups 
(CD31, CD34, CD133, vWF, and Flt). However, hiPSC-ECs from ESRD patient showed 
much lower colonies of co-expression of CD31/CD34, CD31/CD133, and CD34/CD133 in 
FACS, compared to normal control. This was consistent with that the percentage of CD31 
expression cell or co-expression of CD31/CD34 cells to total cells were much lower in 
ESRD group compared to that of healthy control.
Conclusions: In conclusion, the efficiency of hiPSC differentiating into ECs in ESRD 
patient were diminished compared to healthy control.
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Prevalence Estimates of Polycystic Kidney and Liver Disease by 
Population Whole Genome Sequencing
Matthew B. Lanktree,1 Amirreza Haghighi,1 Elsa Guiard,1 Ioan-Andrei Iliuta,1 
Xuewen Song,1 Peter C. Harris,2 Andrew Paterson,3,4 York P. Pei.1 1Department of 
Medicine, Division of Nephrology, University Health Network, Toronto General 
Hospital, Toronto, ON, Canada; 2Mayo Clinic, Rochester, MN; 3Genetics & 
Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada; 
4Epidemiology & Biostatistics, University of Toronto, Toronto, ON, Canada.
Background: Estimating the prevalence of Autosomal Dominant Polycystic Kidney 
Disease (ADPKD) is challenging due to age-dependent penetrance and incomplete 
clinical ascertainment. ADPKD has an estimated lifetime risk of ~1 in 1000, while 
recent epidemiologic studies report a point prevalence of 3-5/10,000. Severe Autosomal 
Dominant Polycystic Liver Disease (ADPLD) is rare (<1 in 100,000), but milder forms 
may be clinically unrecognized. Quantity of functional polycystin-1 is a common genetic 
link between ADPKD and ADPLD. Using two large population sequencing databases, we 
estimated the lifetime prevalence of cystic kidney and liver diseases using stringent criteria 
for defining pathogenic variants.
Methods: Rare variants identified in genes involved in ADPKD (PKD1, PKD2), 
ADPLD (SEC63, PRKCSH, GANAB, ALG8, SEC61B, LRP5) and potential cystic disease 
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modifiers (PKHD1, DZIP1L, UMOD, REN, MUC1, TSC1, TSC2, HNF1B, VHL, COL4A1, 
COL4A3, COL4A4, COL4A5) were obtained from whole genome and exome sequencing 
from gnomAD (ngenomes=15,496, nexomes=123,136) and BRAVO (ngenomes=62,784). Variants 
were evaluated for quality and annotation, compared with the Mayo PKD mutation 
database, and evaluated by bioinformatic prediction.
Results: High confidence pathogenic mutations in whole genome sequencing provides 
a lower bound lifetime ADPKD prevalence of 9.3/10,000 (95% confidence interval, 7.2 to 
11.5). Estimates from whole genome and exome data were not statistically different. No 
significant differences in prevalence were observed between ethnicities. Protein truncating 
mutations in ADPLD genes and potential cyst modifier genes were found in 20.2/10,000 
(95% confidence interval, 18.2 to 22.1) and 124.8/10,000 (95% CI, 119.4 to 129.1), 
respectively.
Conclusions: Population whole genome and exome sequencing supports a lower 
bound lifetime prevalence of ADPKD of about 1 in 1000. Truncation mutations in genes 
causative of ADPLD are surprisingly common, found in about 1 in 500. Individually rare 
variants in other cystic genes are cumulatively common and have the potential to modify 
the phenotype of ADPKD.
Funding: Private Foundation Support, Government Support - Non-U.S.
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ADPKD: Genetic and Model Studies
Diverse Disease-Causing Genes in Clinical Diagnosed Autosomal 
Dominant Polycystic Kidney Disease in Taiwan
Daw-yang Hwang,1 Chih-Chuan Yu,2 Jer-Ming Chang,1 Yi-Wen Chiu.1 
1Kaohsiung Medical University, Kaohsiung, Taiwan; 2Kaohsiung Medical 
University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
Background: To study the disease-causing mutations of autosomal dominant 
polycystic kidney disease (ADPKD) in Taiwan; we examined a total of 10 genes related to 
kidney and liver cysts. We collected a total of 153 ADPKD families and 40 cystic kidney 
disease individuals. The diagnosis of ADPKD were established by clinical and image 
studies from nephrology investigators. The study was approved by the institutional review 
board of the Kaohsiung Medical University Hospital.
Methods: We examined our cohort by study the disease-causing genes of ADPKD 
(PKD1, PKD2, GANAB, and DNAJB11), ARPKD (PKHD1), and ADPLD (PRKCSH, 
ALG8, LRP5, SEC61B, and SEC63). Long-range PCR primers were designed for PKD1 
exon1 to 33 and PKD2 genes to avoid the amplification of PKD1 pseudogenes. Primer pool 
1 contained a total of 60 primer pairs for PKD1 exon 1 to 33 and the primer pool 2 contained 
287 primer pairs for PKD1 exon 34-46 and other genes. Multiplex microfluidic PCR system 
(Fluidigm Access Array) was used, followed by barcoding PCR with next-generation 
sequencing on Illumina MiSeq or MiniSeq. Fastq files were loaded into CLCbio Genomic 
Workbench for bioinformatic analysis. Five microsatellites markers (D4S1534, D4S1542, 
D4S1563, D4S1544, D4S414) were used to analyze families with PKD2 R803* mutation.
Results: We identified mutations in 74.5% (114/153) of the ADPKD families in 
Taiwan. PKD1 and PKD2 represented 65.8% and 34% of diagnosed families, respectively. 
More than half of PKD2 mutations (22/39) were PKD2 R803* mutation. Marker D4S1563 
differentiated those PKD2 R803* families into two groups. Heterozygous mutations of 
GANAB, ALG8, LRP5, SEC63, and PKHD1 were identified in our ADPKD cohort. Three 
missense PKD1 mutations were found in the non-ADPKD individuals.
Conclusions: Our study showed clinical diagnosed ADPKD is a genetic heterogeneous 
disease with different genes and variable clinical spectrum. De novo and compound 
heterozygous PKD1 mutations were found in individuals presented with severe disease. 
Microsatellite analysis indicated two different but closely related founders leading to 
the high prevalence of PKD2 R803* mutation in Taiwan. Furthermore, disease-causing 
ADPLD genes can be found in ADPKD families and PKD1 mutations can be found in 
individuals diagnosed as simple kidney cysts.
Funding: Government Support - Non-U.S.
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Development of Strategies for Genetic Diagnosis of Hereditary  
Glomerulopathies, Tubulopathies, and Cystic Kidney Diseases  
by the Sequencing Sets of Genes
M. Lara Besada-Cerecedo,2 Noa Carrera cachaza,3 Maria Garcia-Murias,3 
Ana Barcia de la Iglesia,2 Jorge Amigo,4 Beatriz Sobrino,4 Angel Carracedo,4 
Candido Diaz-Rodriguez,5 Miguel A. Garcia-Gonzalez.1 1Health Research
Institute of Santiago de Compostela (IDIS)., Santiago de Compostela, Spain; 
2IDIS, Santiago de Compostela, Spain; 3Fundación Instituto de Investigación
Sanitaria de Santiago (FIDIS), Santiago de Compostela, Spain; 4University of
Santiago de Compostela, Santiago de Compostela, Spain; 5University Clinical
Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain.
Background: Accurate clinical diagnosis in hereditary renal pathologies, especially 
glomerular and tubular disease, has proven to be difficult, as different pathologies may 
appear as clinical phenocopies. Genetic studies have the advantage of ensuring an accurate 
diagnosis and anticipate the disease. The implementation of NGS technology into routine 
genetic diagnostic practices allows the screening of large sets of genes in a single test.
Methods: Our group, based on the clinical classification, generated different panels for 
the sequence of renal disease genes in single tests: (1) panel for cystic kidney disease (up to 
72 genes) (2) panel for glomerular disease (26 genes) and (3) panel for tubular disease (36 
genes). Also, our group solved one of the limitations of conventional pre-designed NGS kits 
for target enrichment in regions with high homology pseudogenes (such as the PKD1 gene) 
by developing particular primers to amplify specifically the replicated region of PKD1 gene 
(exons 1-34).
Results: By analyzing a cohort of 291 families with PKD clinical diagnosis, we 
identified the causal mutation in 88% (n=255) of the families. In 94% (n=240) of these 
cases the clinical and genetic diagnosis were concordant. Of the 71 patients with a clinical 
diagnosis of glomerular disease and 31 with tubular disease subjected to genetic analysis, 
we identified the causal mutation in 62% (n=44) and 52% (n=16) of the cases, respectively. 
The concordance between genetic and clinical diagnosis was 66% (n=29) for the glomerular 
cohort and 69% (n=11) for tubular cohort. Most cases of misdiagnosis were associated with 
syndromic diseases with very similar phenotypes, such as Gitelman and Bartter syndromes.
Conclusions: The strategy of grouping genes by phenotype for genetic testing probed 
to be efficient in finding the causal mutation. Our results make clear the need of a genetic 
test to avoid misdiagnosis of certain renal pathologies.
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Whole Exome Sequencing Identifies Several Patients with Undiagnosed 
Autosomal Dominant Polycystic Kidney Disease in an Unselected Cohort
Yoosif Abdalla,2 Jonathan Z. Luo,2 Jamie A. Green,2 Prince Mohan,1,2 
Tooraj Mirshahi,2 Alex R. Chang.2 1Geisinger Medical Center, Danville, PA; 
2Geisinger, Danville, PA.
Background: The utility of whole exome sequencing (WES) to identify genetic causes 
of end-stage renal disease (ESRD) such as autosomal dominant polycystic kidney disease 
(ADPKD) is uncertain.
Methods: We used WES data from the Geisinger-Regeneron DiscovEHR cohort, 
an ongoing health system-based genetics study, to identify patients with putative loss of 
function (pLOF) PKD1 and PKD2 mutations. Clinical evidence of ADPKD was ascertained 
using electronic health record data [diagnosis codes, estimated glomerular filtration rate 
(eGFR), family history], and confirmed by chart review. We considered ADPKD to be 
undiagnosed if there was no mention of the diagnosis in clinic notes.
Results: Out of 91,365 adults with WES data, we identified 87 (66 PKD1, 21 PKD2) 
patients with pLOF mutations. A total of 44 (29 PKD1, 15 PKD2) patients had previously 
been diagnosed with ADPKD, including 24 (21 PKD1, 3 PKD2) patients with ESRD 
((Figure). Of the remaining 43 patients without existing ADPKD clinical diagnoses, 24 
had imaging data available, and 5 had radiologic findings suggesting ADPKD (3 with 
multiple renal and liver cysts, 2 with multiple bilateral renal cysts). One of the 5 patients 
with undiagnosed ADPKD had PKD2 pLOF mutation, ESRD at the age of 70 attributed to 
hypertension and diabetes and a brother with ESRD attributed to diabetes. The remaining 
4 patients with radiologic findings suggesting ADPKD but no clinical diagnosis had eGFR 
ranging from 48 to 129 ml/min/1.73m2). There were 19 patients with renal imaging (18 
PKD1, 1 PKD2) who had no renal cysts.
Conclusions: Population-based WES may provide an opportunity to identify 
previously undiagnosed ADPKD patients who could benefit from targeted treatment and 
family counseling. Additional targeted sequencing will be needed to confirm WES results 
for PKD1 mutations.
Funding: NIDDK Support
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ADPKD: Genetic and Model Studies
A Genotype-First Approach Identifies Atypical PKD in DNAJB11 
Mutation Carriers
Jonathan Z. Luo,1 Bryn S. Mooore,1 Whitney E. Besse,2 Stefan Somlo,2 
Alex R. Chang,1 Tooraj Mirshahi,1 Dustin N. Hartzel.3 1Geisinger, Danville, PA; 
2Yale University, New Haven, CT; 3Geisinger Health System, Danville, PA.
Background: Approximately 7-8% of autosomal dominant polycystic kidney disease 
(ADPKD) cases remain genetically unresolved. Mutations in DNAJB11, an ER co-
chaperone molecule with a significant role in polycystin-1 maturation and trafficking, were 
recently identified in ADPKD patients with non-enlarged, cystic kidneys in the absence of 
PKD1/2 mutations. Little is known about the association between putative loss of function 
(pLOF) DNAJB11 mutations with ADPKD in an unselected population.
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Methods: We used whole exome sequencing (WES) from 91,365 patients in the 
Geisinger-Regeneron DiscovEHR cohort to identify patients with pLOF DNAJB11 
mutations (early-termination, frameshifts and start-loss mutations). Electronic health 
record data (diagnostic billing codes, eGFR, imaging) were examined to determine clinical 
phenotype. Evidence for the presence of renal and liver cysts was determined using natural 
language processing and manual review of imaging reports.
Results: We found 7 DNAJB11 pLOF variants in 10 patients (median eGFR 
60 mL/min/1.73m2) in our cohort, of whom 9 had renal imaging. Of the 2 younger patients 
(age 26 and 28) with renal imaging, 1 had a unilateral renal cyst, and 1 had bilateral 
hydronephrosis and right nephrolithiasis. Of the 7 older patients (age 49-72) with renal 
imaging, 3 had multiple, bilateral renal cysts, and 1 had multiple, unilateral renal cysts. One 
patient was diagnosed with ESRD at age 59. Two of the 7 patients were sisters carrying the 
same early termination mutation: a 61yo presenting with bilateral renal cysts, and a 55yo 
with multiple left renal cysts. Three patients carried rare PKD1 missense variants (MAF 
0.01%-0.15%), all of which are classified as Likely Neutral in the Mayo PKDB. Three 
patients presented with nephrolithiasis. Only one patient was hypertensive.
Conclusions: Using WES in an unselected population, our findings provide further 
evidence that loss of function mutations in DNAJB11 could lead to normal-sized cystic 
kidneys and ESRD. Furthermore, we show the utility of a large-scale exome sequencing 
study combined with detailed EHR data in identifying rare genetic causes of kidney disease.
Funding: NIDDK Support
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PKD1 Duplicated Regions Limit Clinical Utility of Whole Exome 
Sequencing for Genetic Diagnosis of ADPKD
Hamad Ali,1,2 Peter C. Harris.3 PKD-KWI gorup 1Kuwait University, Jabriya, 
Kuwait; 2Functional Genomic unit, Dasman Diabetes Institute, Dasman, 
Kuwait; 3Mayo Clinic, Rochester, MN.
Background: Genetic diagnosis of ADPKD is complicated by the existence of 
PKD1 pseudogenes located proximal to the original gene. The ability of NGS platforms 
in identification of ADPKD mutations, especially in the duplicated regions of PKD1, is 
important for potential utilization of such technologies in diagnostic applications.
Methods: We evaluate the efficiency of WES, WGS & Targeted enrichment in 
sequencing PKD1 and PKD2 for the detection of ADPKD mutations in patients who were 
clinically evaluated by ultrasonography and RFT.
Results: WES had a 50% sensitivity in detection of PKD1 mutations as the reading 
depth and sequencing quality were low over the duplicated regions of PKD1.
Conclusions: Our investigation highlights a major limitation of WES platform in 
ADPKD genetic diagnosis.
WES and Target enrichment coverage map of PKD1. WES of exons 1 to 32 of PKD1 
showed low coverage while PKD2 coverage showed proper depth of all exons. Target 
Enrichment showed proper coverage for coding regions of PKD1 and PKD2. SureSelect 
v6 improved the coverage of PKD1 but in comparison to WES but exons 1 to 14 remained 
poorly covered. WGS showed proper covering of the entire PKD1.
WES, Target enrichment coverage map and WGS of PKD2. PKD2 was covered properly 
using all methods.
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The Genetic Complexity of ADPKD Is Illustrated in the HALT PKD 
Clinical Trial Cohort
Sarah R. Senum,1 Emilie Cornec-Le Gall,2 Godela M. Brosnahan,7 
Arlene B. Chapman,3 Vicente E. Torres,1 Ronald D. Perrone,4 Alan S. Yu,5 
Theodore I. Steinman,6 William E. Braun,9 Kaleab Abebe,8 Kyongtae T. Bae,8 
Peter C. Harris.1 HALT PKD Consortium 1Mayo Clinic, Rochester, MN; 2Centre 
Hospitalier Universitaire de Brest, BREST, France; 3University of Chicago, 
Chicago, IL; 4Tufts Medical Center, Boston, MA; 5University of Kansas Medical 
Center, Kansas City, KS; 6Beth Israel Deaconess Medical Center, Boston, MA; 
7University of Colorado Denver, Aurora, CO; 8University of Pittsburgh, 
Pittsburgh, PA; 9Cleveland Clinic, Cleveland, OH.
Background: The HALT PKD clinical trials consisted of hypertensive ADPKD 
patients, 15-49y with an eGFR >60 ml/min/1.73m2 (Study A; n=558) or 18-64y with 
an eGFR 25-60 ml/min/1.73m2 (Study B; n=486), but without total kidney volume 
requirements for recruitment. Hence, this population represents the cross-section of 
ADPKD seen by nephrologists and so provides an opportunity to characterize the genetics 
of a “typical” renal clinic population.
Methods: DNA samples were available from 970 patients from Study A and B that 
were screened by Sanger sequencing and MLPA for the PKD1 and PKD2 genes. Genetically 
unresolved cases were screened on a next generation sequencing (NGS) panel containing 
65 known or candidate PKD genes. In some cases, further family analysis was performed 
to test segregation.
Results: Likely pathogenic mutations were detected in 95.1% of cases, 506 (52.2%) 
and 266 (27.4%), PKD1 truncating or PKD1 non-truncating, respectively, with 166 
(15.2%) PKD2. The NGS revealed 23 mutations missed by the Sanger screen (21 PKD1, 
2 PKD2), some due to allele drop out, with two others still being evaluated. A GANAB 
and a DNAJB11 family were identified, plus one with PKD2 and COL4A1 mutations. Five 
patients were PKD1 mosaics, detected due to family analysis (2x), MLPA (1x), or NGS 
(2x), with the mutant allele at ~20-40% of the wildtype level. One patient was digenic for 
a PKD1 (2 codon, inframe deletion) and a PKD2 (nonsense) mutation, with ESRD=43y. 
Two PKD1 mutations were likely gene conversions with the PKD1 pseudogenes, and in 
three other cases the pathogenic allele consisted of three weak PKD1 variants in cis shown 
in vitro to have additive effects. Two PKD2 patients co-inheriting hypomorphic PKD1 
variants had move severe disease than expected.
Conclusions: While the majority of HALT PKD patients have ADPKD due to a 
monoallelic mutation to one of the two common genes, a total of five causative genes have 
now been identified. Mosaicism or complex inheritance were also characterized in >1% 
patients, likely an underestimate of the true complexity due to difficulty of detection and 
interpretation, in this “typical” ADPKD population.
Funding: NIDDK Support, Other NIH Support - Mayo Translational PKD Center
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ADPKD: Genetic and Model Studies
Performance of Targeted Cystogene Next Generation Sequencing in an 
ADPKD Population with CKD
Sarah R. Senum,1 Saurabh Baheti,1 Emilie Cornec-Le Gall,2 Vicente E. Torres,1 
Peter C. Harris.1 1Mayo Clinic, Rochester, MN; 2Centre Hospitalier Universitaire 
de Brest, BREST, France.
Background: Next generation sequencing (NGS) panels containing all genes in a 
disease category can provide high throughput, comprehensive coverage with a single 
screen, be cost effective, have high diagnostic efficiency, and provide information about 
possible disease modifiers. Mutation data in ADPKD is increasingly being recognized for its 
diagnostic and prognostic value. However, screening ADPKD populations is complicated 
by genic and extreme allelic heterogeneity, segmental duplication of PKD1 with six 
pseudogenes sharing >97% sequence similarity with PKD1, and several GC rich regions.
Methods: The screened ADPKD patients had impaired renal function but without 
ESRD. Samples were screened using an NGS panel containing 136 known or candidate 
renal cystic or ciliopathy genes. Read alignment and variant calling were performed 
using the Genome Analysis Toolkit, and LOG2 ratio data was generated to assess for 
large deletions or duplications. Variant mining was performed with Golden Helix SNP 
& Variation Suite. Predicted pathogenic base pair variants were confirmed by Sanger 
sequencing with Multiplex Ligation-dependent Probe Amplification (MLPA) employed to 
confirm large rearrangements.
Results: A >40x read depth was obtained for 96.80 ± 0.14% (95% CI) of the 683kb 
target region, although lower coverage of particularly GC rich regions of PKD1 was found. 
Of 384 cases with complete analysis, 187 (48.7%) were PKD1 truncating, 98 (25.5%) 
PKD1 non-truncating, and 63 (16.4%) PKD2. The pathogenic variants included 11 large 
deletions (8 in PKD1 and 3 in PKD2) and 2 large duplications (PKD1) detected by CNV 
analysis. The 36 (9.4%) unresolved cases, including some with PKD1 and PKD2 variants of 
uncertain significance, are being rescreened by the conventional LR-PCR/Sanger approach 
to determine if specific mutations were missed. Genic and allelic complexity is also being 
assessed in these cases.
Conclusions: Targeted NGS identifies PKD1 and PKD2 pathogenic variants nearly as 
effectively as cumbersome LR-PCR/Sanger approaches. Detailed analysis of negative cases 
will detect screening deficiencies and highlight possible improvements to the panel design.
Funding: NIDDK Support, Other NIH Support - Mayo Translational PKD Center
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PKD1 Truncating Mutations with Mild Kidney Disease Is 
Underrecognized
Elsa Guiard,2 Matthew B. Lanktree,2 Ioan-Andrei Iliuta,2 Beili Shi,2 
Marina Pourafkari,2 Xuewen Song,1 Korosh Khalili,2 York P. Pei.2 1University of 
Toronto, Toronto, ON, Canada; 2University Health Network and University of 
Toronto, Toronto, ON, Canada.
Background: Renal disease is highly variable in autosomal dominant polycystic 
kidney disease (ADPKD). Multiple studies have shown that PKD1 protein truncating (PT) 
mutations are associated with the most severe disease with larger TKV and earlier onset of 
renal failure among all mutation classes. In the Extended Toronto Genetic Epidemiology 
Study of Polycystic Kidney Disease (eTGESP), we sought to determine whether PKD1 PT 
mutations were uniformly associated with severe kidney disease.
Methods: The study cohort comprised 1279 patients from 555 families recruited in 
Toronto between 2006 and 2017. All recruited families were comprehensively screened for 
PKD1 and PKD2 mutations; Mayo Clinic Imaging Classification (MCIC) was performed 
in 430 patients with TKV by MRI. Kidney function and MCIC were used to assess disease 
severity.
Results: We studied 430 patients with TKV and mutation results for their renal 
disease severity. Among 146 patients with PKD1 PT mutations and TKV, 31 (21%) from 
28 families were found to have mild renal disease (MCIC 1A or 1B; most with normal 
eGFR) which is comparaible to patients with PKD2 mutations (Table 1). Three families 
displayed concordance with mild renal disease among affected family members; 13 families 
displayed discordance with both mild and severe disease among affected family members. 
Their PKD1 PT mutations were distributed across all exons and included 16 frameshift, 10 
nonsense, and 2 canonical splice site mutations. No patients had atypical kidney imaging 
patterns.
Conclusions: We found mild kidney disease comparable to that associated with 
PKD2 mutations in 21% of patients with PKD1 PT mutations. The presence of a positive 
familiy history of ADPKD in many of these patients makes somatic mosaicism an unlikely 
explanation. Rather, our data suggest a favorable modifier effect due to as yet unidentified 
genetic and/or environmental factors. Future research to identify factors underpinning this 
modifier effect can provide insight into disease mechanism and improve patient care.
* p<0.05
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Molecular Genetic Analysis in Patients with Severe Polycystic Kidney 
Disease
Lena Obeidova,1 Jitka Stekrova,1 Jana Reiterová,2 Vladimir Tesar.2 1Institute of 
Biology and Medical Genetics, First Faculty of Medicine, Charles University and 
General University Hospital in Prague, Prague, Czechia; 2Department of 
Nephrology, Charles University and General Teaching Hospital, Prague, Czechia.
Background: Autosomal recessive polycystic kidney disease (ARPKD) is a severe 
form of chronic kidney disease, frequently diagnosed prenatally. ARPKD is primaly caused 
by mutations in the PKHD1 gene, nevertheless, phenotype of polycystic kidneys with early 
onset is present as a part of several syndromes caused by mutations in number of other 
genes, such as HNF1β, PKD1, PKD2, NPHP etc. Thus, the molecular genetic analysis 
can be very useful in differential diagnosis of polycystic kidneys in young patients. The 
results of complex molecular genetic analysis of 42 patients with very early onset PKD 
are presented.
Methods: The molecular analysis was carried out using next-generation sequencing 
(NGS) method with capture-based library preparation. The panel of about 80 genes 
associated with the formation of polycystic kidneys was analyzed. Sequencing data 
were analyzed with an in-house bioinformatic pipeline designed for detection of single 
nucleotide variants, small indels and CNV (copy-number variation). Due to the existence 
of pseudogenes, the PKD1 gene was simultaneously analyzed by NGS with amplicon-
based library using long-range PCR. The group of patients comprised 39 young patients 
with polycystic kidneys (16.6±13.4) and three prenatally diagnosed fetuses. All patients 
had phenotype compatible with ARPKD, early onset ADPKD or polycystic kidneys in 
combination with additional abnormities in various organs.
Results: The panel of 80 genes was analyzed in all 42 patients. Thirteen patients 
harbored mutations in genes PKHD1 or PKD1. In one child combination of one PKHD1 and 
one TMEM237 mutation was found (p.I2957T and p.A18X, respectively). Such a finding 
could explain phenotype of polycystic kidneys arising in a young age of this patient. But 
mutations in other genes were also found in 13 patients: TMEM67, NPHP4, OFD1, BBS1, 
BBS12, PEX6. These genes with detected mutations are associated with nephronophthisis 
and developmental abnormalities of kidneys. These heterogeneous findings mirror variable 
and unclear phenotype of young patients with polycystic kidneys.
Conclusions: Because of an etiologic heterogeneity of polycystic kidney disease 
phenotype, especially in patients with polycystic kidneys arising prenatally or in a very 
early age, the complex mutational analysis of several genes is needed for reliable diagnosis. 
Supported by the grant projects GAUK 1015 and PROGRES- Q25/LF1
Funding: Government Support - Non-U.S.
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Rare Deleterious Collagen IV Gene Variants Are Overrepresented in “No 
Mutation Detected” ADPKD Patients
Ashima Gulati,1 Jungmin Choi,2 Stefan Somlo.1 1Yale University, New Haven, 
CT; 2Genetics, Yale University, New Haven, CT.
Background: Genetic investigation of autosomal dominant polycystic kidney disease 
(ADPKD) cohorts yields the underlying PKD1 (77%) or PKD2 mutation (15% cases); 8% 
cases have no mutation detected (NMD) in these genes. This NMD group may include 
ADPKD phenocopies. Type IV collagen, an integral component of the basement membrane 
exists mainly as α1α1α2 and α3α4α5 heterotrimers in the kidney. Mutations in genes 
encoding these α-chain isoforms are linked to Alport syndrome (COL4A3, COL4A4, 
COL4A5), Thin GBM disease (COL4A3, COL4A4) and HANAC (hereditary angiopathy, 
nephropathy, aneurysms, muscle cramps) (COL4A1). Bilateral kidney cysts are reported 
with heterozygous COL4A1 mutations as part of HANAC syndrome and also sporadically 
in few patients with thin GBM disease.
Methods: A clinically and radiologically defined ADPKD cohort (N=178) constituting 
patients with PKD1 or PKD2 mutation (N=161) and those with NMD (N=17) in PKD1, 
PKD2 or other genes known to associate with polycystic kidneys (GANAB, DNAJB11 
or Polycystic Liver Disease genes) was investigated using whole exome sequencing 
for rare (minor allele frequency <5x10-5) variants meeting deleteriousness criteria using 
bioinformatics scores.
Results: Analysis of NMD patients (N=17) identified pathogenic heterozygous type 
IV collagen variants in four patients. These included HANAC causing COL4A1 variants 
in 3 patients, of which 2 had missense variants each and one patient was compound 
heterozygous for a COL4A1 truncating variant and a COL4A3 missense variant. One patient 
had a splice site COL4A4 variant that we confirmed to cause complete skipping of exon 
28 by a minigene splice assay. Collagen IV variants of similar deleteriousness assessed 
in 161 patients with a PKD1 or PKD2 mutation revealed a significantly lower burden as 
compared to NMD patients (COL4A1; p-value 0.009); (COL4A3 and COL4A4; p-value 
0.029). Clinical and imaging review of NMD patients with collagen IV variants showed 
fewer or atypical appearing cysts.
Conclusions: Rare deleterious mutations in COL4A1, COL4A3, COL4A4 are 
overrepresented in the ‘no mutation detected’ ADPKD cohort. Characterization of predicted 
deleteriousness of type IV collagen variants using bioinformatics scoring and splice assay 
is useful. The causation link, if any, between the type IV collagen genes and cystic kidneys 
is however elusive.
Funding: NIDDK Support
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ADPKD: Genetic and Model Studies
Correlation of Gene Mutation and Prognosis in Japanese ADPKD Patients
Keisuke Kawashima,1 Saori Nishio,1 Kanako Watanabe,1 Toyokazu Seki,2 
Hiroki Shimada,3 Naoki Nakagawa,4 Daigo Nakazawa,1 Yasunobu Ishikawa,1 
Tatsuya Atsumi.1 1Hokkaido University, Sapporo, Japan; 2Otsuka Pharmaceutical 
Co.,Ltd, Tokushima, Japan; 3Kitami Red-crossß Hospital, Kitami, Japan; 
4Asahikawa Medical University, Asahikawa, Japan.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most 
prevalent hereditary renal disorder. PKD1 mutation is one of the risk factors of worse renal 
prognosis. Recently, the prognostic classification(Mayo classification), based on height-
adjusted total kidney volume and age, has been proposed to predict renal outcomes. It is 
still unclear, however, whether PKD 1 mutation is definitive risk factor in Japanese patients 
due to the lack of relevant studies. The aim of this study is to examine whether known risk 
factors of ESRD are valid to predict renal prognosis in Japanese ADPKD patients.
Methods: Study design: retrospective cohort study. Primary outcome : Event-free 
survival rate; more than 30% decline in eGFR and initiation of renal replacement therapy 
were defined as event. We enrolled patients who visited our hospitals during 2006-2016. 
Gene analysis to detect PKD1 or PKD2 mutation was performed in all participants. Patients 
were classified into 1A~1E according to height-adjusted TKV (HtTKV) and age according 
to the Mayo classification. Cox proportional hazard model was used to estimate hazard 
ratios for renal event.
Results: We identified 255 patients with ADPKD. Among them, 191 patients (74.9%) 
had PKD1 mutation, 50 patients (19.6%) had PKD2 mutation, and in 14 patients (5.5%), we 
could not detect the mutations. In PKD1 group, larger proportion of patients were classified 
into 1C~1E of Mayo classification [1A: 6 (3.1%), 1B: 44 (23.0%), 1C: 76 (39.8%), 1D: 38 
(19.9%), 1E: 27 (14.1%) vs 1A: 5(10%), 1B: 17(34.0%), 1C: 18 (36.0%), 1D: 9 (18.0%), 
1E: 1 (2.0%)], which indicated worse prognosis in PKD1 group compared with PKD2 
group at the baseline. The hazard ratio for renal event among PKD1 group, compared 
with PKD2 group was 2.45 (95% CI: 1.14-6.40; P=0.0196). The event free survival rates 
in patients with PKD1 truncating mutation and those with non-truncating mutation were 
34.6% and 29.8%, respectively, but their difference was not statistically significant (Hazard 
ratio 1.1, 95% CI: 0.65-1.84; P=0.70).
Conclusions: This is the one of the largest cohort studies of ADPKD patients with gene 
analysis in JAPAN. In Japanese ADPKD, patients with PKD1 mutation had significantly 
worse renal prognosis than those with PKD2 mutation, as reported in American and 
European population.
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Quality Control of Polycystin 2 Missense Mutants in the Endoplasmic 
Reticulum
Christopher J. Guerriero, Jeffrey L. Brodsky. University of Pittsburgh, 
Pittsburgh, PA.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a common 
inherited disorder and is a leading cause of end-stage renal disease. ADPKD arises from 
mutations in the PKD1 and PKD2 genes, encoding the primary ciliary proteins polycystin 
1 (PC1) and polycystin 2 (PC2), respectively. Myriad mutations have been documented 
throughout the PKD loci, ultimately resulting in aberrant signaling, cell proliferation, and 
fluid secretion. In addition to the primary cilium, PC2 also localizes to the endoplasmic 
reticulum (ER). Given PC2’s large size, topological complexity, and localization, we 
hypothesize that PC2 missense mutants may misfold and be turned over by the endoplasmic 
reticulum-associated degradation (ERAD) pathway. ERAD triages newly synthesized 
aberrant proteins and directs misfolded or misassembled confomers for degradation via 
the ubiquitin proteasome system. Due to an incomplete understanding of the factors that 
influence early events during PC2 maturation, we investigated PC2 biogenesis in the 
genetically-tractable model system, S. cerevisiae.
Methods: We have established a yeast expression system for 3XHA-PC2 to study 
the early biosynthetic decisions that mediate the folding, maturation, and degradation of 
PC2 missense mutants. Disease-causing PC2 variants were generated by site-directed 
mutagenesis, expressed in S. cerevisiae, and their metabolism was examined using 
cycloheximide chase analysis. Results from the yeast model were further confirmed via 
transient transfection of GFP-PC2 into HEK293 cells.
Results: Our preliminary data indicate that select PC2 missense mutants are more 
rapidly degraded in both yeast and HEK293 cells relative to wild type PC2. Moreover, 
unstable PC2 mutants are more highly poly-ubiquitinated than wild type PC2. In addition, 
following treatment with the proteasome inhibitor MG132, the level of polyubiquitinated 
protein increases to a greater extent for PC2 missense variants, suggesting selective turnover 
by the proteasome.
Conclusions: The findings support our hypothesis that PC2 missense mutants are 
ERAD substrates. Given recent interest in the development of protein folding modulators 
for other ERAD-related diseases, our data provide a promising hint that the maturation of 
some PC2 missense mutants may be amenable to pharmacological correction. Funded by 
NIDDK101584 to CJG and NIDDK079307 to JLB.
Funding: NIDDK Support
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HDAC6 Controls Polycystin-2 Expression in Pkd1-Null Cells
Qin N. Yao,1 Patricia Outeda,1 Feng Qian,1 Liudmila Cebotaru,2 Terry J. Watnick,1 
Valeriu Cebotaru.1 1University of Maryland School of Medicine, Baltimore, MD; 
2Johns Hopkins University, Baltimore, MD.
Background: ADPKD is a hereditary disorder that affects 1:1000 to 1:500 people and 
is characterized by fluid-filled cysts that arise from renal tubules. ADPKD results from 
mutations in either the PKD1 or PKD2 gene, which encode the gene products polycystin 
1 (PC1) and polycystin 2 (PC2), respectively. Although PC1 and PC2 have been studied 
intensively, information on how they function is still emerging. It has been previously shown 
that PC2 is degraded via proteasome in MDCK cells. We have shown that overexpression 
of PC1 accelerates PC2 degradation via the autophagy in MDCK cells. It is unknown how 
PC2 is degraded in Pkd1-null cells. Here we proposed to determine degradation pattern of 
PC2 and whether HDAC6 alters PC2 expression in Pkd1-null cells.
Methods: To determine PC2 degradation pattern we have treated Pkd1-null and control 
cells with cycloheximide to block translation and then inhibited autophagy with bafilomycin 
and proteasome with MG132, and examined PC2 expression. Next, we inhibited HDAC6 
activity with TSA and examined PC2 expression.
Results: Inhibition of proteasome with MG132 prevented degradation of PC2 in 
control cells, suggesting that PC2 is degraded via proteasome when PC1 is expressed. 
Inhibition of autophagy with bafilomycin prevented degradation of PC2 in Pkd1-null cells, 
suggesting that PC2 is degraded via autophagy when PC1 is absent. In immunoprecipitation 
assay PC2 had higher affinity for p97/VCP, a proteasome substrate, in control cells than in 
Pkd1-null cells, indicating that PC2 is degraded via proteasome when PC1 is expressed, but 
not in Pkd1-null cells. Inhibition of HDAC6 activity with TSA decreased PC2 expression in 
both Pkd1-null and control cells suggesting that HDAC6 regulates PC2 expression.
Conclusions: PC2 is mainly degraded via autophagy in Pkd1-null cells and via 
proteasome in control cells. HDAC6 regulates PC2 expression in both Pkd1-null and control 
cells. Further studies will have to determine whether HDAC6 controls PC2 trafficking in 
Pkd1-null cells.
Funding: NIDDK Support
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Human-Specific Abnormal Alternative Splicing of the Wild-Type PKD1 
Gene Induces Premature Termination of Polycystin–1
Christopher J. Ward,1 Wendy A. Lea.2 1KUMC, Kansas City, KS; 2KUMC/
Kidney Institute, Kansas, KS.
Background: Human PKD1 is unusual in that it contains two long polypyrimidine 
tracts in introns 21 and 22 (2.5kb and 602bp, respectively, 97% C+T), whereas the mouse 
and other species lack these C+T rich regions. Western blot analysis of polycystin-1 (PC1), 
using a monoclonal antibody to the extreme N—terminus indicates that humans, but not 
mice, have a smaller EndoH sensitive product, termed Trunc_PC1. Here we show that 
Trunc_PC1 is the product of differential splicing across introns 21 and 22 and that 28.8-
61.5% of human transcripts undergo splicing events that lead to premature translational 
termination. Thus, the presence of these polypyrimidine tracts leads to decreased levels of 
full length functional PC1 reducing the level of PC1 signaling from normal alleles and in 
the context of a mutant allele may force signaling below a critical ‘cystogenic’ threshold.
Methods: We used RT-PCR from exons 20-24 to quantify the number of splice forms 
terminating early using NanoPore sequencing. We also compared the number of copies PC1 
mRNA per mg total RNA at the 5’ and 3’ end of the human transcript and compared this 
with the copy number from normal mouse kidneys. We also created a stable cell line that 
produces a C-terminally FLAG tagged PC1 cDNA that terminates after exon-20, the region 
where Trunc_PC1 is predicted to end.
Results: Assaying seven adult kidneys showed that 62.2±12.6% of PC1 transcripts 
read through and had the accepted sequence while the remainder mis-spliced and truncated. 
We measured the PC1 mRNA copy number in nine adult human kidneys. For the 5’ 
probe (exon 15) and 3’ (exon 34) probes, there were 7.38±3.47x105 and 1.03±0.354x106 
copies/μg, respectively --- about 22--31 copies per cell. Mice had a similar number of total 
transcripts 9.59 ±2.30x105 copies/mg. The synthetic cDNA had an identical mass to Trunc_
PC1 showing that they are the same species.
Conclusions: About 40% of human PKD1 transcripts terminate early producing Trunc_
PC1 implying that humans are dosage hypomorphs when compared to mice. Furthermore, 
the presence of an ER resident truncated form of the PC1 protein may interfere with the 
assembly of the polycystin complex.
Funding: NIDDK Support
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Species-Specific Differences in Pkhd1 Transcriptional Regulation: The 
Role of Cystin, the Cys1 Gene Product
Naoe Harafuji,1 Santiago Cuevas,1 Chaozhe Yang,1 Maryanne Odinakachukwu,1 
Amar J. Majmundar,2 Friedhelm Hildebrandt,2 Lisa M. Guay-Woodford.1 
1Children’s National Health System, Washington, DC; 2Boston Children’s 
Hospital, Boston, MA.
Background: ARPKD (MIM 263200) typically results from mutations in PKHD1, 
which encodes a set of secreted and membrane-bound isoforms, referred to as FPC 
(Onuchic, 2002). Our previous studies showed: 1) mouse Pkhd1 is transcriptionally 
complex (Boddu, 2014); 2) cystin, the protein disrupted in the Cys1cpk mouse, interacts 
with Srsf5, a pre-mRNA splicing factor (Watts, 2016); 3) Pkhd1 exon 51 contains a 
functional Srsf5 binding site. In the current study, we compared Pkhd1/PKHD1 and cystin 
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in mouse, rat and human; assessed whether cystin is a transcriptional regulator of Pkhd1; 
and examined consanguineous families with genetically unresolved hepato-renal fibrocystic 
disease (HRFD) for CYS1 mutations.
Methods: We performed RT-PCR and comparative informatic analyses for mouse, 
rat and human Pkhd1/PKHD1 and cystin, respectively. For minigene splicing assays, we 
transfected a mouse Pkhd1 exon 6, 7, 51 construct into TERT-immortalized Cys1wt (wt) and 
Cys1cpk (cpk) stable cell lines, and wt and cpk primary collecting duct cells. Whole exome 
sequencing was performed in 258 consanguineous HRFD families.
Results: Comparative RT-PCR showed that mouse Pkhd1 encodes multiple isoforms; 
rat Pkhd1 and human PKHD1 have minimal transcriptional complexity. There is limited 
inter-species PKHD1/Pkhd1 homology (72%, human-mouse; 71%, human-rat; 86%, 
mouse-rat). In contrast, cystin is identical in mouse and rat, but rodent-human identities 
are limited (58%, human-mouse; 59%, human-rat). Quantitative minigene assays revealed 
differential splicing of the Pkhd1 construct in wt and cpk cell lines. Preliminary Iso-Seq 
analyses of wt and cpk kidneys support differential Pkhd1 splicing. Finally, we identified a 
5 yo HRFD boy with a homozygous CYS1 variant, c.318+5G>A, that is predicted to disrupt 
the exon 1 donor site.
Conclusions: Our data demonstrate that: 1) the transcriptional regulation of mouse 
Pkhd1 is distinct from its rat and human orthologues; 2) cystin is highly conserved among 
rodents, but there is limited rodent-human homology; 3) cystin is a transcriptional regulator 
of mouse Pkhd1; and 4) CYS1 mutations are a rare cause of human HRFD. Our data suggest 
that in Cys1cpk/cpk mice, loss of cystin function may contribute to renal cystogenesis due in 
part to alterations in Pkhd1 transcriptional regulation.
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Identifying Genetic Modifiers in Severe Polycystic Liver Disease (PLD) by 
Whole Exome Sequencing
Amirreza Haghighi,1 Xuewen Song,1 Emilie Cornec-Le Gall,2 
Nathalie Demoulin,3 Wybrich R. Cnossen,4 Joost Hoenderop,4 Olivier Devuyst,5 
Vicente E. Torres,6 Peter C. Harris,6 York P. Pei.1 1Division of Nephrology, 
University Health Network and University of Toronto, Toronto, ON, Canada; 
2Centre Hospitalier Universitaire de Brest, BREST, France; 3Cliniques U 
St-Luc, Brussels, Belgium; 4Radboud University Nijmegen Medical Center, 
Nijmegen, Netherlands; 5University of Zurich, Zurich, Switzerland; 6Division of 
Nephrology, Mayo Clinic, Rochester, MN.
Background: Severe PLD (sPLD) is a rare and poorly understood phenotype seen in 
both ADPKD and ADPLD. Mutations of SEC61, SEC63, PRKCSH, GANAB, and ALG8 
have been shown to cause PLD by impairing the maturation and transit of polycystin-1 
(PC1) through the endoplasmic reticulum protein-processing (ER-PP) pathway. We 
hypothesize that rare mutations including ER-PP pathway genes that segregate in multiple 
families may modify PLD in patients with ADPKD and ADPLD.
Methods: We performed whole exome sequencing (WES) using Illumina 
HiSeq2000/2500 with SSV4/5 capture kit in 203 patients from Canada, U.S., Belgium, 
and the Netherlands, including 23 affected discordant sib-pairs and 16 affected concordant 
sib-pairs for sPLD from 39 families (matched by gender and age) and 125 sporadic 
cases. All patients with sPLD had a cystic liver of >4x normal volume. We performed 
a focused analysis on 168 genes involved in ER-PP pathway. Standard algorithms for 
sequence alignment, base calling, and QC filtering were applied to identify rare (MAF 
≤1%) deleterious variants of high and moderate impact as predicted by PolyPhen-2, SIFT, 
PROVEN, Mutation Tester, Mutation Assessor, Mammalian and Vertebrate nucleotide-
level conservation, and Combined Annotation Dependent Depletion.
Results: Overall, we achieved a mean target coverage of 99X with 90% of the targeted 
exomes having >30X read depth. We identified 123 ER genes with rare deleterious variants 
and among them, we found 9 ER genes (i.e. UGGT1, UGGT2, SEC31B, SEC24D, SEC23B, 
ALG8, ALG6, PRKN and ATF6B) with rare high and/or moderate impact variant(s) present 
in more than 6 subjects and each segregated with PLD disease severity in 1 to 4 families 
and 4-10 sporadic sPLD cases.
Conclusions: Our results suggest extensive genetic heterogeneity with no one single 
gene accounting for a large proportion of severe PLD cases. Future in-vitro and/or in-vivo 
functional studies will be needed to define the potential pathogenicity of the most promising 
candidate genes. Identification of genetic modifiers of severe PLD has the potential to 
improve risk prediction and treatment of this unusual complication.
Funding: Private Foundation Support
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Disruption of the EF-Hand Domain of Polycystin-2 Ameliorates Cystic 
Disease Caused by Polycystin-1 Deficiency
Matteus Krappitz,2 Till A. Hollmann,2 David R. Rümmele,3 Tobias Staudner,3 
Ke Dong,2 Sorin V. Fedeles,4 Rachel Gallagher,4 Yiqiang Cai,4 Chao Zhang,2 
Stefan Somlo.1,2 1Yale University, New Haven, CT; 2Yale School of Medicine, 
New Haven, CT; 3Friedrich-Alexander-Universität Erlangen-Nürnberg, 
Detmold, Germany; 4Yale University School of Medicine, New Haven, CT.
Background: Polycystin-2 (PC2/TRPP2), the product of one of the genes mutated 
in ADPKD, is expressed in the endoplasmic reticulum (ER) and ciliary membranes. The 
COOH-terminal tail of PC2 contains a potential Ca2+ binding EF-hand motif. A mouse 
model termed Pkd2TEAA, in which critical residues at the EF-hand were substituted with 
alanine (T769A, E772A) to inactivate the Ca2+-binding properties of PC2-EF, was generated 
via CRISPR/Cas9 methodology [ASN2017, TH-PO597]. The Pkd2TEAA mutant does not 
result in loss of PC2 function as evidenced by the lack of cysts in Pkd2TEAA/TEAA animals. In 
this study we assessed the impact of the Pkd2TEAA allele on Pkd1 derived cysts.
Methods: The Pkd1R2220W human REJ mutant (Pkd1RW) is a representative candidate 
of a PC1 hypomorphic missense mutation as it leads to a clear yet partial defect in PC1 
biogenesis and cleavage. Mutant alleles were further modified by insertion of a V5 epitope 
tag in-frame at the C-terminus to detect the mutant proteins (Pkd1RW-V5 and Pkd2TEAA-V5). 
The Pkd2TEAA mouse was crossed onto a Pkd1RW/flox background under the control of 
Pkhd1-Cre (collecting duct-specific). The kidneys were examined by histological and 
morphological parameters.
Results: Compared to Pkd1RW/flox; Pkhd1-Cre mice, the kidneys at P24 from Pkd1RW/flox; 
Pkd2TEAA/+; Pkhd1-Cre mice displayed a decreased KW/BW ratio (0.16 ± 0.02 vs 0.067 ± 0.04, 
***p<0.001) and BUN (mg/dL: 93.6 ± 24.97 vs. 38.6 ± 19.54, **p<0.0013). We observed 
a marked increase in apoptosis specifically in cyst-lining epithelia expressing Pkd2TEAA. No 
significant difference in the protein levels of PC1 or PC2 proteins could be detected between 
the different genotypes.
Conclusions: Inactivation of the Ca2+-binding properties of PC2 EF-hand on a partially 
PC1 deficient background results in improved cystic phenotype possibly via specific 
apoptosis of PC1 mutant cyst-lining epithelial cells. Modulators of PC2 EF-hand function 
may alter PC2 function in vivo to slow cyst progression in the setting of some PC1 missense 
mutations.
Funding: NIDDK Support, Private Foundation Support, Government Support - 
Non-U.S.
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Loss of the Master Regulator of Mitochondrial Fusion Opa1 in Renal 
Tubules Is Not Sufficient to Drive Polycystic Kidney Disease
Laura Cassina,1 Marco Chiaravalli,2 Martina Maserati,1 Alessandra Boletta.1 
Molecular basis of Polycystic Kidney Disease Unit 1San Raffaele Scientific 
Institute, Milan, Italy; 2San Raffaele Scientific Istitute, Milano, Italy.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic 
disorder. The most commonly mutated gene, PKD1, encodes for polycystin-1 (PC1). We 
showed enhanced glycolysis and reduced mitochondrial-derived ATP in Pkd1 mutant cells 
and kidneys (Rowe et al. 2013). A direct role of PC1 on mitochondrial regulation has been 
recently shown, either at the mitochondria-associated membranes, MAMs (Padovano et 
al. 2017), or by direct translocation of the PC1 C-terminal tail (CTT) in the mitochondrial 
matrix (Lin et al. 2018). We wondered whether mitochondrial dysfunction is a driver, or 
else a modifier, in PKD.
Methods: Transmission electron microscopy (TEM) on kidney sections, Seahorse 
XFe96 Analyzer for mitochondrial oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR), mitochondrial network morphology by mt-DsRFP live imaging, 
genetic ablation of Opa1 using Ksp-Cre line.
Results: We detected alterations in mitochondrial network morphology, in OCR, and 
in ECAR in Pkd1-/- cells. We found decreased number of mitochondria, many with aberrant 
cristae, mitochondrial fragmentation, and decreased mitochondrial respiration in the cystic 
epithelia of Pkd1fl/−:Ksp-Cre kidneys at P4. At the molecular level we identified decreased 
mitochondrial pro-fusion protein Opa1, and increased fission regulator Drp1 in the cystic 
kidneys. To determine the contribution of reduced Opa1 and the consequent mitochondrial 
alterations in renal epithelia, we generated Opa1fl/fl:Ksp-Cre mice. Animals are born at the 
expected mendelian ratio and die within the first three months of life. At sacrifice gross 
kidney enlargement was observed, and this is mostly due to expansion of DBA positive 
tubules. Decreased mitochondrial respiration was observed, but cells maintained a cuboidal 
shape. Despite the increase in the kidney volume over time, we detected only mild tubule 
dilation at P60, and no overt cyst formation.
Conclusions: Our data indicate that deletion of PC1 in the kidney epithelium results 
in alteration in mitochondrial structure and fitness. Surprisingly, decreasing mitochondrial 
proficiency by means of Opa1 ablation is not sufficient per se to drive cystogenesis. We are 
currently verifying if crossing Opa1fl/+ with Pkd1fl/−:Ksp-Cre accelerates disease progression 
and/or other molecular players are involved in PKD.
Funding: Private Foundation Support
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Rescue of Suppressed Autophagy in Polycystic Kidney Disease
Carolyn N. Brown,2 Sara Holditch,2 Natalie J. Serkova,1 Charles L. Edelstein.2 
1University of Colorado Denver, Aurora, CO; 2UC Denver Anschutz Medical 
Campus, Aurora, CO.
Background: Autophagy maintains proteostasis by sequestering damaged organelles 
and proteins into autophagosomes for delivery to the lysosome where cargo is degraded and 
recycled. Several treatments that have been shown to ameliorate PKD in mice are potent 
activators of autophagy. The aims of the study were to determine the effects of several 
autophagy inducers on autophagy, apoptosis, and proliferation markers in PKD kidneys and 
to determine whether kidney-specific autophagy knockout results in a cystic phenotype.
Methods: Mice were treated with 2-deoxyglucose (2DG), trehalose (TRE), or 
metformin (MET) followed by bafilomycin (BAF) to measure autophagic flux. p62 
(autophagy-specific tag for degradation & marker of autophagy inhibition), LC3-II 
(marker of autophagosomes), Atg12-5 (marker of autophagosome elongation), cleaved 
caspase 3 (marker of apoptosis), and AMBRA1 (Activating molecule in Beclin1-regulated 
autophagy) that links autophagy to cell proliferation by promoting dephosphorylation 
and degradation of cMyc (transcription factor that activates pro-proliferative genes) were 
measured by immunoblot. Kidney-specific Atg7-/-mice received MRIs at 180D of age to 
precisely measure cyst volume and number.
Results: PKD kidneys had significantly reduced autophagic flux compared to WT, 
which was rescued by 2DG. Further, PKD kidneys had less Atg12-5 complex vs WT, an 
effect blocked by TRE. PKD kidneys had more cleaved caspase 3, a marker of apoptosis, 
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compared to WT, which was decreased by MET, 2DG, and TRE. cMyc phosphorylation 
was greater in PKD compared to WT, an effect blocked by 2DG. Trehalose increased 
AMBRA expression in PKD kidneys (Table 1, *p<0.05). On MRI scan, mean number of 
cysts (0.5mm) in 180 day old Atg7-/- mice was 5±2 vs. 1±0.5 in WT (p<0.05). One Atg7-
/- kidney was massively cystic.
Conclusions: In summary, 2DG restored autophagic flux in PKD kidneys. Autophagy 
inducers increased expression of autophagy-related proteins and decreased apoptosis and 
proliferation markers. Kidney-specific knockout of autophagy in 180 day old mice resulted 
in a cystic phenotype.
Funding: Other U.S. Government Support
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Head-to-Head Study of Sirolimus and an mTOR Kinase Inhibitor 
(TORK) in a Hypomorphic Model of Polycystic Kidney Disease
Carolyn N. Brown, Sara Holditch, Daniel Atwood, Charles L. Edelstein. UC 
Denver Anschutz Medical Campus, Aurora, CO.
Background: Sirolimus indirectly inhibits mTORC1 and reduces but does not 
completely inhibit cyst growth in rodent models of autosomal dominant polycystic kidney 
disease (ADPKD). Sirolimus was not effective in human PKD and was associated with 
side effects. The novel ATP competitive mTOR kinase inhibitors (TORKs) e.g. Torin2 
directly inhibit mTOR kinase that results in inhibition of both mTORC1 and 2. TORKs, 
which increase liver enzymes, have a different side effect profile to sirolimus, which 
causes mucositis. We report a head-to-head comparison of Torin2 versus sirolimus in a 
hypomorphic mouse model of PKD.
Methods: C57Bl/6 Pkd1 p.R3277C (PKD) mice were treated with 0.5mg/kg sirolimus 
(SIR) or 10mg/kg Torin2 (TORK) daily from 50 to 120 days of age. Serum BUN was 
analyzed using an enzymatic assay. Cyst area was quantified from H&E stained kidneys. 
Kidneys were immunoblotted for mTORC1 substrates, pS6 and p4E-BP1 (S65), mTORC2 
substrate, pAkt (S473), LC3-II (autophagosome marker), and p62 (autophagy-specific 
ubiquitin-binding protein). Autophagic flux was defined as the difference between LC3-II 
before and after administration of the lysosomal inhibitor bafilomycin.
Results: Kidney weight and serum BUN were significantly decreased in TORK- and 
SIR-treated mice compared to vehicle (VEH). CVD showed a tendency to decrease with 
both TORK and SIR. pAKT was decreased in both TORK and SIR treatments. pS6 was 
significantly decreased in SIR-treated mice only. TORK significantly increased autophagic 
flux (FLUX). No side effects were noted on gross examination in either treatment group.
Conclusions: For the first time, we have shown in a head-to-head study that the 
TORK, Torin2, is as effective as sirolimus in decreasing kidney size and serum BUN in a 
hypomorphic ADPKD mouse model. Both drugs inhibited pAKT. SIR had a better effect on 
pS6 than TORK. Interestingly, TORK resulted in a significant increase in autophagic flux. 
As Torin2 has a short half-life (~1 hr), further studies are warranted to determine whether 
more frequent dosing of Torin2 will be more effective than sirolimus.
Funding: Other U.S. Government Support
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The Role of LKB1-AMPK Signaling on Renal mTOR and Cyst Progres-
sion in ADPKD
Yan Zhang, Yuqiao Dai, Gail Reif, Emily A. Daniel, Aditi Khanna, 
Brenda S. Magenheimer, Darren P. Wallace. Jared Grantham Kidney Institute, 
University of Kansas Medical Center, Kansas City, KS.
Background: In ADPKD, the mTOR pathway is thought to contribute to cyst epithelial 
cell proliferation and cyst growth. Downstream components of the mTOR pathway, i.e. 
ribosomal protein S6, are aberrantly phosphorylated in cyst-lining cells. Fluid accumulation 
within the cyst cavity is driven by Cl- secretion via apical CFTR Cl- channels. AMP Kinase 
(AMPK) is an important negative regulator of both mTOR and CFTR. Liver Kinase B1 
(LKB1), a well-known tumor suppressor, directly phosphorylates and activates AMPK. 
Previously, we showed that BIT-11, a novel small molecule LKB1 activator, increased 
P-AMPK and decreased P-S6 in human ADPKD cells. BIT-11 decreased ADPKD cell
proliferation, Cl- secretion and in vitro cyst growth and blocked cyst-like tubule dilations
in Pkd1-/- mouse kidneys in metanephric organ culture. Our hypothesis is that the LKB1-
AMPK pathway regulates mTOR-mediated cell proliferation and CFTR-dependent fluid 
secretion by cystic cells and modulates ADPKD progression.
Methods: An inducible LKB1 knockout cell line was generated from Lkb1flox/
flox:ROSA26-CreERT2 mouse kidneys. To determine if the loss of LKB1 is sufficient to induce 
cystic disease, we crossed Lkb1flox/flox and Pkhd1-Cre mice to knock out LKB1 selectively in 
collecting ducts (CDs). To test the effect of direct LKB1 activation, BIT-11 was delivered by 
daily gavage from 5 to 20 weeks to Pkd1RC/RC:Pkd2+/- mice, an ADPKD model that develops 
a renal cystic disease by 5 weeks of age and a progressive decline in renal function.
Results: Lkb1flox/flox:ROSA26-CreERT2 renal cells were treated with tamoxifen to delete 
LKB1 expression. The loss of LKB1 significantly decreased P-AMPK, but had no effect 
on mTOR signaling. CD-specific knockout of LKB1 in otherwise normal mice resulted 
in hydronephrosis; however, renal cyst formation was not observed. On the other hand, 
treatment with BIT-11 caused a significant decrease in kidney weight (percent body weight), 
blood urea nitrogen and interstitial fibrosis in Pkd1RC/RC:Pkd2+/- mice.
Conclusions: The LKB1-AMPK pathway does not appear to regulate basal mTOR 
activity in the adult kidney; however, direct activation of this pathway using a novel LKB1 
activator decreased mTOR-mediated cell proliferation and the decline in renal function in 
ADPKD mice, suggesting that this may be a potential therapeutic approach for the treatment 
of ADPKD.
Funding: NIDDK Support, Private Foundation Support
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Renal Stones in Mice Compound-Heterozygous for Hypomorphic Pkd1V 
and Pkd1RC Alleles
Stephen C. Parnell,1,3 Heather A. Riddle,1,3 Feng Qian,2 Jason R. Stubbs,1,3 
Peter S. Rowe.1,3 1University of Kansas Medical Center, Kansas City, KS; 
2University of Maryland School of Medicine, Baltimore, MD; 3Jared Grantham 
Kidney Institute, Kansas City, KS.
Background: Disease severity in orthologous mouse models of ADPKD is determined 
in part by the nature of the Pkd1 mutation. While null mutations cause in utero cyst 
formation and embryonic lethality, hypomorphic mutations Pkd1V/V and Pkd1RC/RC are 
sufficient for embryonic survival. Pkd1V/V mice express a mutant form of polycystin-1 that 
fails to undergo autocatalytic cleavage at its G-protein coupled receptor proteolysis site 
and develop renal cystic disease postnatally and die between 2-6 weeks of age. Pkd1RC/RC 
mice express a temperature-sensitive folding mutant with reduced levels of mature protein 
and can live over a year with mild, slowly progressive cystic disease. The phenotypic 
consequences of these two distinct hypomorphic Pkd1 mutations together are not known.
Methods: Pkd1V/+ and Pkd1RC/+ mice on a C57 background were crossed to produce 
compound-heterozygous Pkd1V/RC mice. Mice were maintained on breeder diet from birth, 
and sacrificed at 3 or 26 weeks of age and kidneys analyzed. Presence of renal stones in 26 
week old adult mice was determined by micro computed tomography (μCT) analysis of 
kidneys following euthanasia.
Results: Three week old Pkd1V/RC mice had elevated kidney weight to body weight 
ratios (15.3 ±0.87) and their kidneys were obviously cystic by visual inspection. To 
determine the long-term consequences of disease we maintained a cohort of mice to 26 
weeks of age. The majority of the mice thrived throughout the duration of the study and 
had significantly lower kidney weight to body weight ratios compared to 3 week old mice. 
Visual inspection of kidneys from adult mice revealed the presence of numerous large, 
white masses immediately underneath the renal surface. Analysis of these kidneys by 
μCT determined that the masses were mineralized deposits of ~0.5mm diameter present
throughout the renal cortex but absent from the medulla.
Conclusions: Pkd1V/RC mice are severely cystic by 3 weeks of age. However, these 
cystic kidneys retain sufficient function to maintain survival up to 26 weeks of age and 
presumably beyond. Kidneys from adult mice had mineralized deposits throughout the renal 
cortex. To our knowledge this is the first known instance of renal stones in a mouse model 
of ADPKD.
Funding: NIDDK Support
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The Role of Interferon Regulatory Factor-5 in Acceleration of Cystogene-
sis in Polycystic Kidney Disease
Kurt Zimmerman,1 Jifeng Huang,2 Lan He,2 Molly Easter,2 Bradley K. Yoder,1 P. 
Darwin Bell,2 Takamitsu Saigusa.2 1Cell Development and Integrative Biology, 
University of Alabama at Birmingham, Birmingham, AL; 2Medicine/Nephrology, 
University of Alabama at Birmingham, Birmingham, AL.
Background: In mouse models of polycystic kidney disease (PKD), unilateral 
nephrectomy (UNx: 1K) accelerates kidney cyst growth compared to non-nephrectomized 
(2K) mice. Analysis of RNA sequencing data revealed that 1K compared to 2K Pkd1 
deficient mice have enrichment of genes associated with inflammation, phagocytosis, 
and macrophages. Previous studies showed that macrophages promote cystogenesis in 
mouse models of PKD; however, transcription factors that control cytokine production 
by macrophages in cystic disease have not been identified. Herein, we study the role of 
interferon regulatory factor-5 (IRF5), a transcription factor involved in macrophage 
activation and cytokine release, during cyst progression in 2K vs 1K Pkd1 deficient mice.
Methods: Adult Pkd1flox/flox mice with or without CAGG-cre were administered 
tamoxifen for global knockout of the Pkd1 gene. Three weeks after cre induction, mice 
underwent sham surgery or UNx to accelerate cyst formation. Kidneys were harvested at 
3 (early stage) or 6 (late stage) weeks after UNx and kidney immune cells were analyzed 
by flow cytometry. Some mice were treated with weekly injection of IRF5 antisense 
oligonucleotide (40mg/kg/wk: Ionis Pharma) or scrambled ASO for a total of 3 or 6 weeks 
after UNx and kidney was harvested for kidney immune cells/cytokine and histology.
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Results: Pkd1 deficient mice had increased kidney IRF5 mRNA levels compared to 
control mice. 1K Pkd1 mice increased inflammatory cytokine production, cyst growth 
and infiltrating (CD11bhi, F4/80lo) and resident macrophage (CD11blo, F4/80 hi) numbers 
compared to 2K Pkd1 deficient mice. Preliminary results indicate that treatment with IRF5 
ASO (total 3 and 6 weeks) in 1K Pkd1 mice had no effect on kidney macrophage numbers, 
but significantly decreased kidney T cell accumulation, inflammatory cytokine production 
and cyst growth. Further comparison of male and female mice shows that 1K female mice 
had higher kidney IRF5 levels compared to male mice and a better response to IRF5 ASO 
treatment.
Conclusions: UNx in Pkd1 mice increases the number of kidney macrophages, 
inflammatory cytokine and cyst growth. IRF5 ASO treatment suppressed kidney IRF5 
levels/reduced inflammation and attenuated the acceleration of cytogenesis in Pkd1 mice.
Funding: NIDDK Support
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AMP-Activated Protein Kinase (AMPK) Drug Re-Purposing for 
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Xuewen Song,1 Wouter N. Leonhard,3 Gregory R. Steinberg,4 Dorien J. Peters,3 
York P. Pei.2 1Division of Nephrology, University of Toronto, Toronto, ON, 
Canada; 2University Health Network and University of Toronto, Toronto, ON, 
Canada; 3Leiden University Medical Center, Leiden, Netherlands; 4McMaster 
University, Hamilton, ON, Canada.
Background: ADPKD is an important cause of end stage renal disease (ESRD). 
Multiple studies have highlighted AMPK as a potential therapeutic target for ADPKD. 
Notably, metformin (MET) attenuated cystic kidney disease in an aggressive PKD model. 
MET and canagliflozin (CAN) are indirect AMPK inducers, while salsalate (SAL) is a 
direct AMPK activator; all have excellent safety profiles for clinical use.
Methods: We tested the efficacy of MET, CAN, SAL, MET+CAN or MET+SAL in a 
tamoxifen-inducible Pkd1(iKsp-Pkd1del) conditional knock-out mouse model. Tamoxifen 
was used on days p18 and p19 to induce adult onset PKD (n=20 male mice/group). AMPK 
drug treatments were then started from p40 using dosages expected to yield serum levels 
similar to those observed in the clinical settings. Blood Urea (BU) levels were monitored 
weekly and mice with ESRD (BU >20 mmol/L) were sacrificed. The experiment continued 
until 50% of the untreated mutant mice reached ESRD.
Results: Compared to the untreated mutant mice, SAL alone (p<0.01) or SAL+MET 
(p<0.05) improved kidney survival and reduced kidney weights (Figure). MET, CAN, or 
MET+CAN did not have any effect. At the end of the study, 91% and 85% of the SAL and 
SAL+MET groups were free of ESRD versus 38%-58% in the other groups. SAL+MET did 
not differ from SAL suggesting a lack of synergism. Molecular analyses (systems biology and 
protein analyses) are currently in process to understand the mechanisms of action.
Conclusions: SAL is a promising re-purposed drug which may be readily translated to 
the clinical setting for treatment of ADPKD. MET at the dosage used in the usual clinical 
setting had no therapeutic effect in our model. *Equal contribution of first two authors and 
last two authors.
Funding: Private Foundation Support
Improved survival free of ESRD in the Salsalate and Salsalate+Metformin groups compared 
to the untreated mutant mice and other treatment groups.
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Inhibition of Wnt/β-Catenin Signaling Slowed Cystogenesis in Postnatal 
Mouse Model of ADPKD
Yun Joon Jung,1,2 Jordan A. Kreidberg.1,2 1Boston Children’s Hospital, Boston, 
MA; 2Harvard Medical School, Boston, MA.
Background: The Wnt signaling pathway has an important role for nephron 
development and elevated expression of β-catenin, master regulator of the Wnt signaling 
pathway, is shown to correlate with cystogenesis in autosomal dominant polycystic 
kidney disease (ADPKD). Here we provide further evidence that inhibition of Wnt/β-
catenin pathway slowed cystogenesis in a postnatal model of ADPKD using Ksp-CreERT2; 
Pkd1flox/flox mice.
Methods: To understand the pathological contribution of Wnt signaling in ADPKD, 
we measured expression of Wnt gene and β-catenin expression in vivo using two murine 
models of ADPKD where postnatal cystogenesis could be observed. We also tested the 
effect on cyst formation of small molecule inhibitors of β-catenin interaction with either 
CBP or p300.
Results: We observed increased expression of Wnt genes in and higher levels of 
β-catenin in cystic kidneys of both Hoxb7-Cre-IRES-eGFP;Pkd1flox/flox mice and Ksp-
CreERT2;Pkd1flox/flox mice. Although the overall pattern differed between these models, 
Wnt7a was consistently over-expressed in both models of ADPKD. To test whether 
canonical Wnt signaling was required for cystogensis, we inactivated one copy of the 
Ctnnb1 gene, encoding β-catenin, in Ksp-CreERT2;Pkd1flox/flox mice. Reduced progression of 
cyst enlargement was observed in Ksp-CreERT2;Pkd1flox/flox;Ctnnb1flox/+ mice. Furthermore, 
treatment of Ksp-CreERT2;Pkd1flox/flox mice with a small molecule, ICG-001, that blocks 
the interaction of β-catenin with CBP slowed the progression of cyst formation and mice 
showed reduced kidney:weight to body weight ratio. In contrast, a small molecule, IQ-1, 
which blocked the interaction of β-catenin with p300 had no effect in cyst progression.
Conclusions: Our study demonstrates that the canonical Wnt signaling pathway has 
an important role in cystogenesis and inhibition of the β-catenin-CBP complex by ICG-001 
may serve as a new therapeutic target to decrease cyst formation.
Funding: NIDDK Support
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COX2 Inhibition Slows Disease Progression and Improves the Altered 
Renal Lipid Mediator Profile in the Pkd2WS25/- Mouse Model of ADPKD
Md Monirujjaman,1,2 Harold M. Aukema.1,2 1Food and Human Nutritional 
Sciences, University of Manitoba, Winnipeg, MB, Canada; 2Canadian Centre 
for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research 
Centre, Winnipeg, MB, Canada.
Background: Oxylipins are bioactive lipid mediators formed by oxygenation 
of polyunsaturated fatty acids via cyclooxygenase (COX), lipoxygenase (LOX) and 
cytochrome P450 (CYP) monooxygenases. We have shown that the earliest and most 
consistent alteration in the oxylipin profile in diverse models of cystic kidney diseases is 
increased levels of COX derived prostanoids. Several of these, such as PGD2 and PGE2 have 
been shown to mediate renal cyst formation by increasing intracellular cAMP production, a 
known abnormality in various forms of cystic kidney diseases. Further, inhibition of COX 
oxylipin formation reduces disease progression in a model of nephronophthisis, as well as 
in some non-cystic renal diseases. The present study was carried out to determine whether a 
selective COX2 inhibitor would reduce disease progression and ameliorate the altered renal 
oxylipin profile in the Pkd2 orthologous mouse model of autosomal dominant polycystic 
kidney disease 2 (ADPKD2).
Methods: Weanling male Pkd2WS25/- mice were provided a standard laboratory rodent 
diet (AIN-93G) with or without 50 mg celecoxib per kg body weight per day, for 13 weeks. 
Renal cysts were analyzed histomorphometrically and serum BUN and creatinine levels 
were determined. Targeted lipidomic analysis of renal oxylipins was performed by HPLC-
tandem mass spectrometry.
Results: Diseased animals had significant cyst involvement and reduced renal 
function as indicated by elevated BUN. Consistent with our previous studies, 8 of 11 
COX derived prostanoids were higher in diseased kidneys. In addition, 24 of 33 LOX 
oxylipins and 7 of 16 CYP oxylipins were lower in diseased kidneys. Drug treatment 
reduced cyst area by 50%, cyst volume by 70%, and serum creatinine and BUN by 
10-20%. With respect to lipid mediators, drug treatment reduced 5 of the 8 elevated COX
derived prostanoids and increased 5 of the 24 LOX and 5 of the 7 CYP oxylipins that were 
reduced by disease.
Conclusions: Selective COX2 inhibition significantly ameliorates disease progression 
and improves renal function in Pkd2 mice. Further studies on dose, potential risks, and 
long-term effects of COX2 inhibition are needed to determine whether this is a viable 
therapeutic option to treat ADPKD. Supported by the Natural Sciences and Engineering 
Research Council of Canada
Funding: Veterans Affairs Support, Government Support - Non-U.S.
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A Strategy for Reducing Cysts in Autosomal Dominant Polycystic Kidney 
Disease with a CFTR Corrector
Liudmila Cebotaru,1 Murali K. Yanda.2 1Johns Hopkins University, Baltimore, 
MD; 2Johns Hopkins School of Medicine, Baltimore, MD.
Background: ADPKD is associated with progressive enlargement of cysts. Mutations 
in pkd1 and pkd2 induce growth-related pathways, including heat shock proteins raising 
the prospect that pharmacological interventions that target these pathways might alleviate 
or prevent ADPKD. The purpose of our study was to demonstrate a role for VX-809, a 
corrector of cystic fibrosis transmembrane conductance regulator (CFTR), in reducing cyst 
growth.
Methods: We used the Pkd1fl/fl; Pax8rtTA; TetO-cre mouse model which, when treated 
with doxycycline, allows for the ablation of PC1. These mice, where injected IP with 
doxycycline (4 μg of doxycycline/g body weight) on postnatal days (PND)11, PND12, and 
PND13, to induce multiple large cysts and large polycystic kidneys at approximately 3 
weeks of age. Kidneys were harvested, sectioned and analyzed.
Results: Mice injected daily with VX-809 (30 mg/kg) from PND10 to PND20 showed 
significantly less cyst growth (see Fig 1). VX-809 improved renal function, as evidenced 
by a lower blood urea nitrogen (BUN) and creatinine. In proximal tubule-derived, Pkd1-
knockout cells and in cystic kidneys, VX-809 reduced both basal and forskolin-activated 
cAMP levels, inhibited cyst growth and reduced levels of the heat shock proteins Hsp27, 
70, and 90 which are upregulated in cystic kidneys. In the cystic mice, VX-809 decreased 
an ER stress marker, the GADD153 protein, cell proliferation, and apoptosis. Importantly 
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in proximal tubule-derived, cultured Pkd1-knockout cells, VX-809 increased the activity of 
the sodium proton exchanger, NHE3 which is down regulated in these cells.
Conclusions: VX-809 reduces the ability of cysts to grow by reducing the levels of 
HSPs and restore the NHE3 activity in proximal tubule cells. VX-809 could potentially be 
a new way to treat patients with ADPKD.
Fig. 1: Cystic mice kidneys before and after treatment with VX-809. See text for details.
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Ketogenic Dietary Interventions Ameliorate Disease Progression in a Rat 
Model of Polycystic Kidney Disease
Jacob A. Torres,1 Samantha L. Kruger,2 Tselmeg Amarlkhagva,1 
Caroline M. Broderick,1 Alyssa Sahu,2 Thomas Weimbs.2 1University of 
California Santa Barbara, Goleta, CA; 2University of California Santa Barbara, 
Santa Barbara, CA.
Background: PKD cells have recently been shown to have an altered metabolism 
favoring aerobic glycolysis similar to the Warburg effect in cancer. Possible glucose 
dependency may provide an opportunity for the treatment of PKD by dietary interventions. 
We and others recently showed that a mild reduction in food intake strongly inhibits disease 
progression in PKD mouse models. Here we tested the hypothesis that these beneficial 
effects are due to ketosis caused by intermittent starvation rather than caloric restriction 
per se.
Methods: The Han:SPRD rat model of PKD was utilized to test the effects of time 
restricted feeding and a ketogenic diet, respectively, and on the progression of PKD. For 
time-restricted feeding, animals were given access to normal chow ad libitum for 8 hours 
per day. A ketogenic diet consisting of ~80% dietary fat administered ad libitum without 
time-restriction.
Results: Animals treated with either a ketogenic diet or a time-restricted feeding regime 
consumed comparable calories to ad libitum controls and showed a significant decrease in 
markers of disease progression including a decrease in fibrosis, 2-kidney to bodyweight, 
cystic index, markers of proliferation, and mTOR activity.
Conclusions: Dietary interventions that lead to ketogenesis significantly attenuate 
disease progression in the Han:SPRD rat model of PKD. Mechanistically, this may be due 
to the lack of glucose availability in ketosis. Alternatively, or in addition, the ketone body 
beta-hydroxybutyrate (BHB) is known to regulate several signaling pathways involved in 
PKD, including mTOR, and may directly influence cell growth and proliferation of cystic 
cells. These data taken together suggest that safe and feasible dietary interventions may be 
effective PKD patients.
Funding: Private Foundation Support
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Glucose Metabolic Profiles in Renal Tissue of an Orthologous PCK Rat 
Model of Human PKD Using Metabolic and Proteomic Analyses
Shizuko Nagao,1 Masanori Kugita,1 Kanako Kumamoto,1 Aya Yoshimura,1 
Tamio Yamaguchi,4 Kazuki Nakajima,3 Kazuo Takahashi,2 Yukio Yuzawa.2 
1Education and Research Facility of Animal Models for Human Diseases, Fujita 
Health University, Toyoake, Aichi, Japan; 2Department of Nephrology, Fujita 
Health University School of Medicine, Toyoake, Japan; 3Center for Research 
Promotion and Support, Fujita Health University, Toyoake, Japan; 4 Department 
of Clinical Nutrition, Suzuka University of Medical Science, Suzuka, Mie, 
Japan.
Background: Polycystic kidney disease (PKD) is an inherited disorder characterized 
by excessive cellular proliferation and fluid secretion of the tubular epithelial cells due to 
genetic mutation. To detect altered renal metabolic and enzymatic activities, we performed 
metabolic and proteomic analyses in the PCK rat, an orthologous model of human 
autosomal recessive PKD.
Methods: In renal tissue of 20-week-old PCK and age-matched normal rats, metabolic 
products were analyzed by using capillary electrophoresis time-of-flight mass spectrometry 
and MasterHands metabolome analysis software; proteomic products were analyzed using 
Orbitrap mass spectrometry and Proteome Discoverer™ software.
Results: Metabolic analysis revealed a 1.8-fold increase in cAMP content in PCK 
cystic kidneys compared with normal kidneys, the same trend seen from our previous 
study using radioimmunoassay. Upstream glycolysis metabolites were decreased as 
follows: glucose 1-phosphate (0.5-fold), glucose 6-phosphate (0.5-fold) and fructose 
6-phosphate (F6P, 0.6-fold); and downstream, 3-phosphoglyceric acid (3-PG, 4.2-fold)
was increased in PCK samples. 2-Phosphoglyceric acid and phosphoenolpyruvate were
detected in only PCK kidneys, not in normal kidneys. On proteomic analysis, increased
fructose-bisphosphate aldolase A, an enzyme that converts F6P to 3-PG, was seen in PCK 
rats (3.6-fold). Tricarboxylic acid (TCA) cycle metabolites were increased as follows: 
citric acid (23-fold), cis-aconitic acid (8.5-fold), isocitric acid (32-fold), succinic acid 
(1.6-fold), fumaric acid (1.7-fold), and malic acid (2.1-fold) in PCK kidneys; 2-oxoglutarate 
was detected in only PCK kidneys. Citrate synthase, which converts acetyl CoA (2.0-fold) 
to citric acid, was increased (7.5-fold) in PCK kidneys. In the non-oxidative phase of the 
pentose phosphate pathway, increased ribose 5-phosphate (R5P) was detected in only PCK 
kidneys. Increased transaldolase (3.0-fold), which converts sedoheptulose 7-phosphate 
(S7P, 0.6-fold) to F6P, was found in PCK kidneys. Also, transketolase (2.4-fold), which 
converts S7P to R5P, was increased in PCK cystic kidneys.
Conclusions: These findings suggest that increased activity of pentose phosphate 
pathway as well as glycolysis and TCA cycle may play important roles in promoting PKD 
progression.
Funding: Government Support - Non-U.S.
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Discovery and Preclinical Characterization of RGLS4326 for the 
Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Edmund Lee,1 Tania M. Valencia,1 Annelie E. Schairer,1 Kara Kersjes,1 Jian Li,1 
Andrea N. Flaten,2 Vishal Patel.2 1Regulus Therapeutics, San Diego, CA; 
2University of Texas Southwestern Medical Center, Dallas, TX.
Background: Autosomal dominant polycystic kidney disease (ADPKD), caused by 
mutations in the PKD1 or PKD2 genes, is among the most common human monogenetic 
disorders and a leading genetic cause of end-stage renal disease (ESRD). MicroRNAs 
(miRs) are non-coding RNAs that play central roles in cell differentiation, proliferation and 
survival by binding to complementary target mRNAs, resulting in repression of translation 
and eventual degradation of the targeted mRNAs. We have previously demonstrated that 
miR-17 promotes ADPKD progression, and inhibiting miR-17 is a promising strategy for 
the treatment of ADPKD.
Methods: RGLS4326 was discovered through screening a chemically-diverse library 
of >100 oligonucleotides for their ability to inhibit miR-17 in a miR-17 luciferase sensor 
assay. RGLS4326 was extensively profiled in multiple safety assays, including biochemical, 
ex-vivo tissues slices and in vivo studies. Preclinical efficacy of RGLS4326 was studied in 
both Pkd2-KO and Pcy mouse models of PKD.
Results: In preclinical studies, RGLS4326 potently inhibited miR-17 activity, 
displaced miR-17 from the translationally active high molecular weight polysomes, and 
de-repressed multiple miR-17 target genes in different mouse kidney cell lines. RGLS4326 
shows favorable pharmacokinetic profiles in both normal and PKD mouse models, where 
preferential distribution to kidney compare to other tissues was evident. Most importantly, 
we have demonstrated that RGLS4326 confers efficacy in two mouse models of PKD 
following subcutaneous administrations.
Conclusions: Our preclinical data support the clinical development of RGLS4326 for 
the treatment of ADPDK. RGLS4326 is currently being studied in Phase I clinical studies.
Funding: Commercial Support - Regulus Therapeutics
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Efficacy of RGLS4326 in Human Primary ADPKD 3D-Cyst Cultured 
Cells
Annelie E. Schairer,1 Tania M. Valencia,1 Steven Lockton,1 Sole Gatto,1 
Michael Kim,1 Darren P. Wallace,2 Edmund Lee.1 1Regulus Therapeutics, San 
Diego, CA; 2University of Kansas Medical Center, Kansas City, KS.
Background: Autosomal dominant polycystic kidney disease (ADPKD), caused by 
mutations in the PKD1 or PKD2 gene, is among the most common monogenetic disorders 
and a leading genetic cause of end-stage renal disease. Kidney-specific overexpression 
of miR-17~92 produce kidney cysts in mice, whereas genetic knockdown of miR-17~92 
attenuates disease progression in multiple mouse models of PKD. RGLS4326 is designed to 
specifically bind to miR-17 family of microRNAs, antagonize miR-17 activity and reduce 
disease progression in mouse models of PKD. In this study, we investigate the effect of 
RGLS4326 treatment on 3D growth of human primary ADPKD cyst cells derived from 
ADPKD donor nephrectomy samples.
Methods: Primary human ADPKD cyst cells (HuADPKD) were transfected with 
RGLS4326 or control oligo at 20nM, 100nM or 300nM for 24h. RNA samples were 
harvested for confirmation of miR-17 inhibition by measuring de-repression of a selected 
set of direct miR-17 target genes (PD-Sig) and RNA sequencing. Cells following 24h 
transfection were then seeded and further cultured in 3D cyst formation assay for 8 
additional days.
Results: Functional inhibition of miR-17 in HuADPKD following RGLS4326 treatment 
was confirmed by PD-Sig. At the end of 8 additional days of 3D culturing, RGLS4326 
consistently reduced growth of HuADPKD derived from multiple donors, decreasing 
cyst count and proliferation. Kolmogorov-Smironov test statistics on RNA sequencing 
data comparing log2FC cumulative distribution indicated significant upregulation (i.e. 
de-repression) of predicted miR-17 target genes after RGL4326 treatment. De-repression 
of selected direct miR-17 target genes were confirmed by qPCR and their implication on 
RGLS4326’s mechanism of action in conferring efficacy were investigated.
Conclusions: RGLS4326 inhibits 3D cyst formation and growth of HuADPKD cells 
in vitro compared to oligo control. Our preclinical data supports the clinical development of 
RGLS4326 which is currently in Phase 1 for the treatment of ADPKD.
Funding: Commercial Support - Regulus Therapeutics
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RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and 
Metabolic Pathways in PKD Mouse Models
Tania M. Valencia,1 Sole Gatto,1 Annelie E. Schairer,1 Steven Lockton,1 
Michael Kim,1 Kara Kersjes,1 Jian Li,1 Andrea N. Flaten,2 Vishal Patel.2 1Regulus 
Therapeutics Inc, San Diego, CA; 2University of Texas Southwestern Medical 
Center, Dallas, TX.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is caused 
by mutations in PKD1 and PKD2 genes, where expansion of fluid-filled cysts and renal 
fibrosis often leads to end-stage renal disease. MicroRNAs are short non-coding RNAs that 
modulate several biological processes. We have previously shown that aberrant expression 
of miR-17 family of microRNAs is involved in human ADPKD pathogenesis. RGLS4326 
is a chemically-modified oligonucleotide designed to sterically inhibit miR-17 functions 
and has been shown to reduce cyst growth in vitro and in vivo. The goal of this study was 
to determine the signaling pathways modulated by RGLS4326 treatment in PKD mouse 
models
Methods: RGLS4326 is efficacious in the Pkd2-KO and Pcy mouse models of PKD. 
We performed RNA sequencing and metabolite profiling using kidney samples from both 
mouse models following RGLS4326 treatment. Ingenuity Pathway Analysis was used to 
provide novel insights into signaling pathways modulated by RGLS4326 treatment.
Results: Through RNA sequencing, we identified >10000 differentially expressed 
genes in the PKD kidney samples compared to their age- and strain-matched normal 
controls. Comparative pathway analysis identified several dysregulated signaling pathways 
in the two PKD mouse models, including the Pparα, WNT/ β-catenin and cell cycle 
signaling, that were in turn modulated following RGLS4326 treatment. Next, we performed 
global metabolite profiling comparing Pkd2-KO and normal kidneys, and identified 
several biochemical alterations in the Pkd2-KO model, including substantial changes in 
lipid metabolism. In particular, decrease in β-fatty acid oxidation pathway was observed in 
the Pkd2-KO kidneys, which corroborates with previously observed Pparα-dysregulation 
in PKD mouse models. Importantly, modulation in lipid metabolites were also observed 
following RGLS4326 treatment.
Conclusions: Our results indicate that RGLS4326 confers efficacy and modulate 
aberrant PKD signaling and metabolic pathways. RGLS4326 is currently in Phase I clinical 
studies for the treatment of ADPKD.
Funding: Commercial Support - Regulus Therapeutics
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Effects of Pharmacologic Galectin-3 Inhibition on the Cardiac Phenotype 
and Survival of Pkd1-Deficient Mice
Andressa G. Amaral, Jessica A. Freitas, Marcelo D. Melo, Vera M. Salemi, 
Luiz F. Onuchic. University of São Paulo, São Paulo, Brazil.
Background: Myocardial abnormalities are a significant phenotype in ADPKD. We 
have previously shown that Pkd1-deficient mice develop cardiac dysfunction, a phenotype 
significantly rescued by galectin-3 (Gal-3) knockout.
Methods: In this scenario, we investigated the effects of 2 Gal-3 inhibitors on 
the cardiac phenotype of a Pkd1+/- noncystic mouse (HT) and on survival of a severely 
cystic mouse homozygous for a Pkd1-knockin allele that prevents polycystin-1 cleavage 
(VV). GR-MD-02 (GR, 60mg/kg), a Gal-3 extracellular inhibitor, or FTS (10mg/kg), an 
intracellular inhibitor of Gal-3/Ras interaction, was administered intraperitoneally 3x/week, 
starting at P1. Echocardiographic and protein expression analyses were performed in HT 
and wild-type (WT) mice at 5-6 weeks while survival was assessed in VVs.
Results: Left ventricular (LV) ejection fraction and shortening fraction were decreased 
in HTs compared to WTs [43.1% (35.8-54.2) vs 59.2% (52.8-66.0), p<0.01; and 23.3% 
(22.9-25.1) vs 31.2% (25.2-39.4), p<0.01; respectively], parameters partially rescued by 
FTS [52.3% (48.8-57.1) and 27.0% (22.5-29.3) vs untreated WT, NS], but not by GR. 
Interventricular septum diameter, on the other hand, was increased by GR in HTs [0.75 
(0.71-0.81) vs 0.63mm (0.55-0.68), p<0.01), with only a trend for FTS (p=0.09). GR was 
also followed by trends of increase in LV mass/BW (p=0.12) and LV posterior wall diameter 
(p=0.08) in HTs. GR increased P-ERK2 expression in HT and WT hearts [1.70 (1.19-2.46) 
vs 1.29 AU (0.82-1.32), p<0.05; and 1.65 (1.03-3.49) vs 1.01 AU (0.94-1.07), p<0.05; 
respectively], while FTS increased P-ERK2 only in WTs [1.98 AU (1.52-2.51), p<0.01]. 
GR and FTS did not modify expression of P-GSK3β and P-PKCα and δ in HT and WT 
hearts, and did not improve survival in VVs.
Conclusions: Our findings revealed that intracellular inhibition of Gal-3 partially 
rescued systolic function parameters in HTs while its extracellular inhibition induced 
cardiac hypertrophy without rescuing the systolic phenotype. Differences between effects 
of pharmacologic inhibition and genetic Gal-3 KO are likely based on their distinct timings 
of Gal-3 activity suppression, levels of suppression and action site profiles. Our data suggest 
that pharmacologic Gal-3 inhibition may lead to beneficial effects on the ADPKD cardiac 
phenotype under specific circumstances.
Funding: Government Support - Non-U.S.
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PS-341 Attenuates the Progression of Autosomal Dominate Polycystic 
Kidney Disease
Meihan Chen. Changzheng Hospital Second Military Medical University, 
Rochester, MN.
Background: The proteasome, which is a key component of the ubiquitin-proteasome 
pathway, has emerged as an important cancer therapeutic target. PS-341 (also called 
Bortezomib or Velcade) is the first proteasome inhibitor approved for multiple myeloma and 
has been tested in many clinical trials against other types of cancers. One of the mechanisms 
by which PS-341 exerts its anticancer effect is inactivation of nuclear factor-kB (NF-kB) 
through prevention of IkBa degradation.
Methods: Pkd1 conditional knock out mice were injected intraperitonealy with ps-
341 0.3mg/kg twice a week from postnatal 15th day. Then cacrificed at postnatal 32th day. 
Serum was collected to test the BUN and creatinine levels. We use IHC to measure protein 
levels of NF-kB pathways and PCNA, TUNEL and Flow cytometry to detect apoptosis, 
MTT to test proliferation.
Results: In this study, we showed that PS-341 can effectively inhibited cyst growth 
in Pkd1 conditional knock out mice. PS-341 attenuates the progression of PKD through 
alleviating the BUN and serum creatinine levels in Pkd1 conditional knock out mice as 
well as improving the survival rate. However we didn’t found a decreased level of NF-kB 
which reveals that PS-341 may not retard disease progression through NF-kB pathway. 
However we found that PS-341 inhibits renal epithelial cells proliferation and promotes 
renal epithelial cells apoptosis in vivo and in vitro.
Conclusions: Collectively, these findings suggest that PS-341 inhibits renal epithelial 
cells proliferation and promotes apoptosis which provides a new strategy for treating and 
preventing the progression of ADPKD in the future.
Funding: Government Support - Non-U.S.
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Novel Screen to Identify Kinase Drug Targets for Autosomal Dominant 
Polycystic Kidney Disease
Irfana H. Soomro,1 Aram Hong,4 Zhai Li,3 Edward Y. Skolnik.2 1Medicine- 
Nephrology, NYU Langone Medical Center, NY, NY; 2New York University of 
Medicine, New York, NY; 3NYUMC, New York, NY; 4NYU, New York, NY.
Background: Activation of kinases and the downstream signaling pathways they 
activate is central to the pathogenesis of cyst growth in ADPKD. However, while the human 
kinome consists of more than 500 kinases, only a fraction of these kinases have been tested 
to determine if they play a role in ADPKD pathogenesis. As a result, there are likely many 
kinases that are more active in ADPKD kidneys that play prominent roles in disease that are 
yet-to-be discovered and may be good therapeutic targets. We have now adapted a novel 
approach to broadly screen PKD kidneys in an unbiased manner for kinases that are more 
active in PKD kidneys compared with wild type kidneys.
Methods: Active kinases were affinity captured by passing wild type and PKD kidney 
lysates through columns containing multiplexed kinase inhibitor beads. Bound kinases 
were then identified by LC separation followed by tandem mass spectrometry. Increase 
in kinase expression and/or activity was validated by Western Blot and the specific kidney 
cells expressing the kinase was determined by Immunohistochemistry. The relevance of a 
kinase to cyst growth in vivo was assessed by treating PKD mutant mice with specific kinase 
inhibitors and/or genetically by generating kinase knockouts using CRISPR/Cas9.
Results: We identified a number of both known and unknown kinases specifically 
upregulated or downregulated in mouse PKD kidneys. Focal adhesion Kinase (FAK) is 
one of the promising kinase identified in the screen. We found that FAK and phospho-
FAK expression was upregulated in cyst lining epithelium in PKD kidneys. Consistent with 
FAK playing an important role in cyst growth, treatment of Pkhd1-Cre;Pkd1fl/fl mice with 
the FAK inhibitor VS-4718 slowed cyst growth, preserved renal function, and prolonged 
survival. VS-4718 treatment led to the inhibition of multiple signaling pathways that could 
account for the therapeutic benefit including paxillin, p130cas, AKT and Stat3.
Conclusions: This is the first time PKD kidneys have been probed proteomically in an 
unbiased manner to identify the full range of kinases that are more active in PKD kidneys 
with the goal of identifying new therapeutic targets. So far we have identified FAK as a 
potential drug target that can slow cyst growth and preserve renal function and are currently 
in the process of working up several other promising kinases
Funding: Private Foundation Support
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A Novel Zebrafish Drug-Screening Model for Cystic Kidney Disease
Maryam Khosravi,1 Katia Nazmutdinova,2 Tiago Martins,2 Philip Beales,2 
Rachel H. Giles,3 Stephen Wilson.1 1Cell and Developmental Biology, University 
College London, London, United Kingdom; 2Institute of Child Health, Great 
Ormond Street Hospital, University College London, London, United Kingdom; 
3University Medical Center Utrecht, Utrecht, Netherlands.
Background: Cystic kidney disease affects millions of people worldwide, and is most 
commonly associated with dysfunction of cilia. Ciliopathies are a highly heterogeneous 
disease group, continually expanding with the discovery of new genes and availability 
of genetic diagnostics. However, treatment options for ciliopathy lag far behind. We are 
using zebrafish to understand the genetic basis of ciliopathies and we have identified a new 
zebrafish model of ciliopathy that manifests cysts in the pronephric kidney of the zebrafish 
embryo and have developed this model for drug discovery.
Methods: In a forward genetic approach, mutagenesis of the zebrafish genome was 
carried out using an alkylating agent to cause random mutations, followed by screening 
over several generations to select for phenotypes of interest; which included body curvature 
and organ laterality defects. Further phenotypic characterisation of one mutant line revealed 
pronephric cysts. RNA sequencing was conducted to find a missense mutation in the highly 
conserved WD-40 domain of the Intraflagellar Transport protein - Ift144. This ciliopathy 
model was then used to screen selected drugs with known effect on kidney cysts. Zebrafish 
were dechorionated at 24 hours post fertilisation and exposed to treatment (drug in DMSO 
solvent, in E3 media) at 28°C until 4 days post fertilisation, and assessed under brightfield 
microscopy.
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Results: The cyst area of ift144 -/- embryos was measured repeatedly across three 
independent experiments to ensure both experimental and biological repeats. We observed 
significant reduction of cyst size compared to control, by Student’s t-test for all treatment 
groups (see figure).
Conclusions: We present a novel zebrafish model for ciliopathy with a mutation in the 
ciliary gene ift144, which consistently presents with kidney cysts that can be rescued with 
drugs that are known to ameliorate cyst size. This model has significant advantages for use 
as a high throughput drug-screening system.
Results
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Hearing Impairment, a Novel Functional Readout, in Pkd2 Mutant 
Zebrafish
Caroline R. Sussman, Elisabeth Pearson, Leah Andrews, Kaitlyn M. Johnson, 
Alaa Koleilat, Stephen C. Ekker, Lisa A. Schimmenti, Peter C. Harris, 
Vicente E. Torres. Mayo Clinic, Rochester, MN.
Background: Zebrafish have been a valuable model for studies of PKD, with 
conservation of phenotypes and signaling pathways. Phenotypic readouts have consisted 
mainly of pronephric cysts and body curvature. The only method for assessing kidney 
function in embryos is dye clearance, which is affected by many factors and, therefore, is 
not a reliable indicator. Hair cells of the ear and zebrafish lateral line share many features 
in common with renal epithelial cells and are responsible for hearing. We have identified 
hearing assays as a novel approach for assessing pkd2 function.
Methods: We assayed hearing using a standard acoustic startle response (ASR) in 
6-7 day old zebrafish. 100 or 400 Hz stimuli were delivered using MATLAB, and responses 
were recorded using a video camera. Startle responses consisted of a sudden change in
swimming velocity or direction in response to the tone and were scored as 1 or 0 for
presence or absence, respectively.
Results: The ASR assay was validated using neomycin to ablate lateral line hair cells 
by established methods. After one hour in neomycin no hair cells were visible using yo-
pro-1 or daspei vital dyes and the frequency of response to a 400 Hz tone was reduced 
50% compared to untreated sibling controls (0.5±0.2 vs 0.24±0.2, p<0.04, n=24 fish/group 
from 3 clutches). The response of hi4166 pkd2-/- zebrafish to a 400 Hz tone was reduced 
35% compared to wild-type sibling controls (0.50±0.2 vs. 0.17±0.2, p<0.03, n=56 fish/
group from 7 clutches). This population of fish also responded 30% less frequently to a 
100 Hz tone (0.83±0.1 vs 0.24±0.1, p<0.0001). Our ASR assay was additionally validated 
using a novel transposon mutant line, spinner. This line develops ventral body curvature, 
pronephric cysts, and fails to develop hair cell kinocilia analogous to the central cilium, 
as determined by acetylated alpha tubulin labeling. Spinner mutants show profound 
hearing loss at both 400 and 100 Hz (0.88±0 vs 0.04±0 and 0.93±0.1 vs 0.12±0.1, p<0.001, 
n=16-24 fish/group from 2-3 clutches).
Conclusions: These data show that the established hi4166 pkd2 mutant zebrafish line 
have hearing loss, suggesting hearing can be used as an alternative to dye clearing assays 
for pkd2 function in zebrafish. They further suggest the relevance of hair cells as a model 
for studies of PKD.
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Feline Autosomal Dominant Polycystic Kidney Disease Model to Elucidate 
Genetic Modifiers of Cyst Progression
Leslie A. Lyons,1 Yoshihiko Yu,1,2 Kate Shumway,1 Jodi S. Matheson,1 
Timothy L. Kline.3 1College of Veterinary Medicine, University of Missouri, 
Columbia, MO; 2Nippon Veterinary and Life Science University, Musashinoshi, 
Tokyo, Japan; 3Mayo Clinic, Rochester, MN.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common inherited renal disease in domestic cats. The feline PKD1 mutation (c.10063C>A) 
causes a stop codon in exon 29 (C3284X) and is the only known variant causing ADPKD 
in cats, specifically Persians and related-breeds. Many ADPKD cats remain subclinical 
though some show rapid disease progression, develop chronic kidney disease (CKD) and 
succumb to disease within seven years of life. Thus, cats are a useful model to investigate 
genetic modifiers that influence disease progression and severity. Also, because of the 
consistent genetic background of the breed and the solitary causal mutation, drug trials can 
be more accurately interpreted as to success and failure, without complications of genetic 
heterogeneity of either the patient or the causal gene mutation.
Methods: Two normal and eleven Persian-derived cats heterozygous for the PKD1 
c.10063C>A variant were evaluated by ultrasound (US), computed tomography (CT) and
magnetic resonance imaging (MRI). Glomerular filtration rate (GFR), complete blood 
count, serum chemistries, symmetric dimethylarginine (SDMA), and urine analyses were
determined.
Results: Ten clinically normal cats had multiple bilateral cysts and classified as 
feline chronic kidney disease (CKD) stage 1. Most cysts were located in the cortex 
or at the corticomedullary junction, with far fewer in the medulla. The oldest cat, 
8.1 yrs, had slightly elevated SDMA at 15 and creatinine at 16 and a slightly lowered urine 
specific gravity of 1.028, and tentatively classified as CKD stage 2. Three cats had GFRs 
below 2.5. CT-based fractional cyst volume (FCV in mls) ranged from 0.63 – 28.22% 
and increased with age (r = 0.94). One cat had fast progression when considering cystic 
development and age with 1.08 FCV/mo at 19 mo. The stage 2 cat had the highest FCV of 
28.22% but its FCV/mo was 0.29 ml/mo.
Conclusions: CT and MRI modalities are sufficient in cats to determine TKV and FCV. 
TKV is not a prognostic indicator of disease in cats. FCV is highly correlated with age. 
Fast progressing cats can be identified and used for the analysis of genetic variants that 
modify disease progression. Whole genome sequencing of slow and fast progressing cats is 
underway to elucidate the modifying variants.
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Early Imaging Biomarkers of ADPKD: Longitudinal Study of Quantita-
tive MRI and Texture Analysis in a Murine Model
Timothy L. Kline, Megan M. Constans, Marie E. Edwards, Andrew J. Metzger, 
Kai Jiang, Lilach O. Lerman, Vicente E. Torres, Peter C. Harris, Slobodan Macura, 
Bradley J. Erickson. Mayo Clinic, Rochester, MN.
Background: Currently, only a fraction of the wealth of information that could be 
disclosed by radiological imaging is used to assess disease status and follow progression 
of ADPKD. Advanced MR imaging techniques can be used to measure renal structural and 
functional properties. We hypothesized that advanced MRI acquisitions and image analysis 
methods detect renal tissue alterations preceding changes in TKV in the Pkd1RC/RC mouse 
model in different backgrounds.
Methods: Pkd1RC/RC model mice (C57BL/6 and C57Bl6 x 129s6Svev/Tac ‘F1’ 
background, n=7 each), as well as wild-type (C57BL/6 and ‘F1’ background, n=5 each) 
were imaged at 3, 6, and 12-weeks of age. Mice imaging was performed under anesthesia 
with a 16.4T NMR spectrometer. TKV and texture were measured on T2-weighted images, 
and T1 relaxation maps were calculated and measured within the kidneys. Regions-of-
interest were drawn to cover cortical and medullary regions.
Results: Figure 1 shows TKV progression for the four phenotypic groups, as well as 
the 3-week means of TKV, T1 relaxation, and entropy texture feature (a measure of tissue 
heterogeneity). The fast progressing group (‘F1’) exhibited a significant increase in TKV 
compared to wild-type, whereas the C57BL/6 model did not. In contrast, T1 relaxation and 
texture properties were found to clearly differentiate the model mice from corresponding 
wild-type.
Conclusions: Quantitative MR parameters and texture features can serve as early 
biomarkers of PKD. These parameters could be useful for pre-screening in trials as they 
inform on early disease. Moreover, they may afford more parameters to evaluate treatment 
benefits, which may be detectable over shorter study durations.
Funding: NIDDK Support
Top panel – volume progression of the four groups in this study. Bottom panel – boxplot 
comparisons of TKV (left), T1 relaxation (middle), and Entropy texture feature (right) at 
three-week time point.
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ADPKD: Genetic and Model Studies
Deletion of miR-214 Skews Macrophage Polarization to Promote Cyst 
Growth in Autosomal Dominant Polycystic Kidney Disease
Ronak Lakhia,1 Matanel Yheskel,1 Andrea N. Flaten,1 Karam S. Aboudehen,2 
Vishal Patel.1 1University of Texas Southwestern Medical Center, Dallas, TX; 
2University of Minnesota, Minneapolis, MN.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is 
characterized by fluid-filled cysts that arise from kidney tubules and compress functioning 
nephrons leading to kidney failure. MicroRNAs (miRs) are small non-coding RNAs that 
can regulate gene expression. Our understanding of the role microRNAs in ADPKD is 
limited. The goal of this study was to understand the role of miR-214 in ADPKD.
Methods: Q-PCR and in situ hybridization were performed to analyze the expression 
of miR-214 and its host lncRNA transcript, Dnm3os (Dynamin 3 opposite strand), in 
mouse and human ADPKD. Next, we genetically deleted miR-214 expression in Pkhd1/
Cre; Pkd2F/F (Pkd2-KO) mice and Pkd1RC/RC mice, two genetic models of ADPKD. Kidney 
mRNA sequencing and pathway analysis was performed to elucidate the differential gene 
expression pattern between Pkd2-KO and Pkd2-miR-214-/- double KO mice. In vitro, 
mIMCD3 and RAW264.7 cells were treated with miR-214 mimics.
Results: Q-PCR showed that miR-214 and Dnm3os expression was upregulated 
in mouse and human ADPKD kidneys. In situ hybridization revealed that miR-214 and 
Dnm3os are expressed in both the cyst epithelium and interstitium. miR-214-/- mice 
displayed no phenotypic abnormalities. Deletion of miR-214 in Pkd2-KO mice increased 
kidney weight/body weight ratio, raised serum BUN and shortened survival. Pathway 
analysis of differentially expressed genes revealed that miR-214 deletion results in a shift in 
the type of inflammation present in Pkd2-KO kidneys. Accordingly, further molecular and 
histological analysis revealed an increase in M2-like macrophages in Pkd2-miR-214-KO 
kidneys. Conversely, miR-214 mimics reduced expression of M2 markers and cytokines 
in RAW264.7 and mIMCD3 cells. Deleting miR-214 in a second long-lived, slowly-
progressing mouse model, the Pkd1RC/RC mouse, also led to increased total kidney volumes 
as measured by serial MRI and an increase in M2-like macrophages.
Conclusions: miR-214 expression is increased in mouse and human ADPKD kidneys. 
Deletion of miR-214 aggravates cyst growth and shortens survival. miR-214 may suppress 
cyst growth by inhibiting M2-like polarization of macrophages. Our studies suggest that 
augmenting miR-214 may be a potential novel therapeutic approach for ADPKD.
Funding: NIDDK Support
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miR-210-3p Inhibition Decreases Fibrosis and Improves Renal Function 
in Murine ADPKD
Ameya P. Patil,1 William E. Sweeney,1 Cynthia G. Pan,2,1 Ellis D. Avner.1 
1Medical College of Wisconsin, Wauwatosa, WI; 2Children’s Corporate Center, 
Milwaukee, WI.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is 
characterized by progressive cystic enlargement. In mcwPkd1(nl/nl) hypomorphic mice, 
peri-cystic areas are hypoxic early in the disease course. These hypoxic areas are markedly 
positive for hypoxia inducible factor-1α (HIF-1α). These areas develop fibrosis with 
disease progression. miR-210-3p is HIF-1α inducible and increases in response to hypoxia. 
We hypothesize that peri-cystic hypoxia initiates a repair response via HIF-1α and miR-
210-3p which contributes to interstitial fibrosis.
Methods: Cystic kidneys at weekly intervals starting at postnatal (PN) day 21, were
sectioned and stained with trichrome and PCNA. RNA extracted from laser capture micro-
dissection (LCM) trichrome (TC) positive peri-cystic regions at PN28, & 42 was examined 
for expression of miRNA 210-3p. PN21 peri-cystic regions negative for trichrome stain was 
used as a control. Anti-miR-210-3p was injected IP starting at PN21 Q 4 days till PN42. 
Untreated cystic kidneys were used as control. RNA was extracted from both cystic treated 
and untreated kidneys at PN42. Serum obtained at harvest was used to assess renal function.
Results: 1. In LCM captured peri-cystic regions, miRNA-210-3p is upregulated 
6-fold at PN28 and 5-fold at PN42 compared with PN21. 2. Anti-miR-210-3p treated
cystic kidneys at PN42 compared with age-matched untreated cystic kidneys has: (a) 35% 
reduction in serum creatinine; (b) 75% decrease in trichrome positive/fibrotic areas; (c) 
proliferation (PCNA) is restricted to tubular epithelia vs both tubular epithelia and peri-
cystic regions in untreated controls; (d) up-regulation of anti-fibrotic mRNA’s Hgf (19.22-
fold), IFNg (7.95-fold), Il10 (523.68-fold), II13ra2 (31.99-fold) and down-regulation of
pro-fibrotic mRNA’s Ctgf (-10.79) and II5 (-4.31) and ECM component Col1a2 (-94.86).
Conclusions: Conclusions- 1. We demonstrate that expression of miR-210-3p 
increases in hypoxic peri-cystic regions with disease progression at PN28 and PN42. 2. 
In vivo inhibition of miR-210-3p: improves kidney function; decreases interstitial fibrosis; 
reduces proliferation in peri-cystic regions; increases expression of anti-fibrotic mRNAs 
(Hgf, IFNg, II10, Il13ra2) and decreases profibrotic (Ctgf, II5) and ECM matrix component 
(Col1a2).
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Long Noncoding RNA Hoxb3os Is Dysregulated in Autosomal Dominant 
Polycystic Kidney Disease and Regulates mTOR Signaling In Vivo
Karam S. Aboudehen,1 Shayan A. Farahani,1 Mohammed S. Kanchwala,2 Siu 
Chiu Chan,1 Svetlana Avdulov,1 Alan Mickelson,1 Dayeon Lee,1 Micah D. Gearhart,1 
Vishal Patel,2 Chao Xing,2 Peter Igarashi.1 1University of Minnesota, Minneapolis, 
MN; 2University of Texas Southwestern Medical Center, Dallas, TX.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is primarily 
caused by mutations in PKD1 and PKD2. Mutations of PKD1 and PKD2 produce 
abnormalities in multiple intracellular signaling pathways, including activation of the 
mTOR pathway. Long noncoding RNAs (lncRNAs) are single-stranded RNA molecules 
over 200 nucleotides in length and lacking a long open-reading-frame. lncRNAs play 
important roles as epigenetic regulators of development and disease, but their involvement 
in PKD has not been previously described.
Methods: We have recently identified a kidney-specific lncRNA, called Hoxb3os, 
which is downregulated in kidney-specific Pkd1 and Pkd2 mutant mice and in cystic 
kidneys from ADPKD patients.
Results: Deletion of Hoxb3os in mIMCD3 mouse kidney epithelial cells resulted in 
activation of the mTOR pathway and increased oxidative phosphorylation (Aboudehen 
K, et al. J Biol Chem, 2018, in press). Consistent with activation of mTORC1 signaling, 
Hoxb3os-deficient cells displayed increased cell proliferation and defective autophagy. To 
identify the role of Hoxb3os in vivo, we used CRISPR-based gene editing to delete the 
genomic DNA encoding Hoxb3os in mouse zygotes. PCR analysis of genomic DNA and 
qRT-PCR analysis of kidney RNA demonstrated successful ablation of Hoxb3os in multiple 
independent founders. Mice lacking Hoxb3os were viable and had grossly normal kidney 
morphology up to age post-natal day P28. Immunoblot analysis of mutant kidney lysates 
showed increased phosphorylation of mTOR and downstream targets of mTORC1 but not 
mTORC2. Hoxb3os mutant kidneys also showed increased cell proliferation and defective 
autophagy. Co-immunoprecipitation experiments revealed that Hoxb3os was found in a 
complex with phosphorylated mTOR but not dephosphorylated mTOR in mouse kidney 
lysates.
Conclusions: Collectively, these findings identify Hoxb3os as a kidney-specific 
lncRNA that binds to mTORC1 and directly inhibits its downstream activity. Suppression of 
Hoxb3osmay contribute to the activation of the mTOR pathway in ADPKD, and restoration 
of Hoxb3osmay have therapeutic benefit.
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Actin and Intermediate Filament Protein LAD1 (Ladinin1) Is Dysregu-
lated in ADPKD Mouse Model
Mahiro Kurashige,1 Tsung-Jui Wu,1,2 Chengchao Lin,1 Fang Zhou,1 
Luis F. Menezes,1 Gregory G. Germino.1 1NIDDK, National Institute of Health, 
Bethesda, MD; 2Hualien Armed Forces General Hospital, National Defense 
Medical Center, Taipei, Taiwan.
Background: There have been reports that Polycystin1 (PC1) co-localizes with actin/
intermediate filament and could have functional roles in its organization, but much remains 
poorly understood. We have previously reported the transcriptomics of an orthologous 
ADPKD mouse model using 80 kidneys from Pkd1cko;Tg(Cre/Esr1) 102-210 days-old 
mice, in which Pkd1 knockout was induced at P40. We found Lad1 (Ladinin-1), a poorly 
characterized intermediate-filament protein, was one of the top differentially expressed 
genes. Here we focus on characterizing Lad1 expression and function as a candidate 
regulator of cytoskeleton dynamics in ADPKD.
Methods: 16 kidneys (8 WT, 8 KO) were used for qPCR and 12 (6 WT, 6 KO) for 
immunoblotting. Lad1 mRNA and protein expression levels were evaluated by qPCR and 
immunoblot in a pair of DBA and LTL cell lines derived from Pkd1CKO/CKO mouse, with 
corresponding mutant derived after Cre-expression. Mouse and humand Lad1 were cloned 
with various epitope tags to ease detection. A human keratinocyte cell line with high levels 
of endogenous LAD1, HaCat, and an MDCK cell line expressing recombinant, HA-tagged 
human PC1 were used for characterizing LAD1 and actin dynamics.
Results: Lad1 mRNA and protein levels were 58.8% (exon1-2; 50.0% exon4-5) and 
67% lower, respectively, in Pkd1mutant kidneys (p<0.01 for each analysis). In the cell 
lines, Lad1 mRNA and protein levels were 46.0% (n=3, p=0.16) and 67.7% (n=3, p<0.01) 
lower in mutants compared to the paired WT cells. In characterizing Lad1 protein, we found 
that both endogenous and recombinant Lad1 migrates at ~72Kda, not at the size of 59kDa 
predicted by both its MW and companies that sell Lad1 antibodies. Using the HaCat cell 
line to better characterize LAD1 function, we found that LAD1 levels increased with cell 
confluency. Confocal studies determined that LAD1 generally co-localizes with actin in 
stress fibers and in a cortical “rim” pattern at the cell edge, which is decreased at cell-cell 
junctions. This pattern was also seen in the MDCK and DBA renal epithelial cell lines.
Conclusions: LAD1 is a poorly understood cytoskeletal protein whose expression 
increases with cell density but whose level is down-regulated in cystic kidney. Further study 
will be required to determine whether the downregulation observed in cystic kidney reflects 
altered cell-cell sensing.
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Gene Expression Profile of Pkd1 Null Endothelial Cells During  
Embryonic Development
Patricia Outeda,1 Hanwen Bai,3 Joseph A. Mancini,3 Luis F. Menezes,2 
Terry J. Watnick.1 1University of Maryland School of Medicine, Baltimore, MD; 
2National Institutes of Health, Bethesda, MD; 3Vertex Pharmaceuticals, Inc., 
Boston, MA.
Background: Polycystins (PCs) play a critical role in vascular development. Pkd1/2 
null embryos die in mid gestation with polyhydramnios, subcutaneous edema and focal 
hemorrhage. A subset of these phenotypes are recapitulated by deleting Pkd1 or Pkd2 in 
endothelial cells. At the cellular level, we have shown that Pkd deficient endothelial cells 
exhibit aberrant branching morphogenesis and altered directional migration. The specific 
signaling pathways regulated by polycystins in endothelial cells, however, are unknown. 
To understand the functional consequences of polycystin deficiency in endothelial cells we 
performed RNA sequencing (RNA-seq) in Pkd1-/- endothelial cells at two embryonic time 
points.
Methods: We harvested Pkd1-/- and littermate control embryos at E13.5 and E14.5 
(N=36 total) and isolated endothelial cells using anti-CD31+ (specific marker for endothelial 
cells) coated magnetic beads. RNA was extracted and sequenced independently using 50bp 
single-end reads. Data was processed using Cutadapt and gene expression quantified using 
Salmon and R. Differential gene expression analysis was performed using DESeq2 package 
and enriched pathways were identified using clusterProfiler package.
Results: We identified more than 200 genes that were differentially expressed (Log2 
(FC)≤ ± 0.25 and a corrected p-value of <0.05) at each time point. At E13.5 functional 
clustering revealed an enrichment of genes expressing extracellular matrix components 
and genes involved in the innate immune response among top ranked. At E14.5, we found 
upregulation of genes related to cell migration, cell proliferation and angiogenesis probably 
as a mechanism to compensate the aberrantly developed embryonic vasculature. We found 
that the ATPase, H+ transporting, lysosomal V0 subunit C (Atp6v0c, Gene ID11984) 
was the most highly downregulated gene at both developmental stages analyzed, (Log2 
FC= -1.61 and -1.50 respectively, and q= 0.00E+00 for both). Silencing of this gene was 
shown to effectively suppress migration and invasion of prostate cancer cells (PC-3M-
1E8), which is relevant in the context of the migration defects we observe in Pkd mutant 
endothelial cells.
Conclusions: Our study revealed extensive transcriptional changes in Pkd1 mutant 
endothelial cells supporting the importance of polycystin signaling in endothelial cells and 
in vascular morphogenesis.
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Exome-Wide Association Study Identifies Candidate Susceptibility Genes 
for Congenital Obstructive Uropathy
Dina Ahram,1 Tze Yin Lim,1 Rik Westland,2 Priya Krithivasan,1 Adele Mitrotti,1 
Monica Bodria,3 Francesco Scolari,4 Loreto Gesualdo,5 Marijan Saraga,6 
Velibor Tasic,7 Krzysztof Kiryluk,1 Gian Marco Ghiggeri,3 Ali G. Gharavi,1 
Simone Sanna-Cherchi.1 1Columbia University, New York, NY; 2VU University 
Medical Center, Amsterdam, Netherlands; 3Istituto G. Gaslini, Genoa, Italy; 
4University of Brescia, Montichiari (Brescia), Italy; 5University of Bari, 
Altamura, Italy; 6University Hospital in Split, Split, Croatia; 7University 
Children’s Hospital, Skopje, Macedonia (the former Yugoslav Republic of).
Background: Congenital Obstructive Uropathy (COU) is a cause of kidney failure in 
children. Monogenic forms of disease account for a small portion of cases. Rare variant 
association tests are promising approaches to identify novel disease genes.
Methods: We conducted exome sequencing in 292 COU cases and 8541 controls. 
Following diagnostic variant annotation in genes implicated in congenital anomalies 
of the kidney and urinary tract (CAKUT) using ACMG criteria, we searched for novel 
susceptibility COU genes using case-control exome-wide collapsing analyses for rare 
functional variants. We tested gene-level dominant and recessive models via fisher-
exact statistics. Qualifying variants were selected using computational scores based on 
conservation and location in intolerant exons or conserved domains. We analyzed gene-set 
enrichment using 299 OMIM genes implicated in CAKUT in comparison to a control set 
of 857 olfactory genes. Finally, we cross-annotated suggestive signals with results from a 
GWAS for common variants consisting 398 cases and 8197 controls.
Results: ACMG-based variant prioritization revealed pathogenic mutations in 
11(3.7%) COU cases. Gene-level collapsing showed 20 genes with p<5x10-4 for dominant 
model (MAF<0.0005) and 2 genes for the recessive model (MAF<0.01), although 
no exome-wide significant signals (<2.5x10-6) were attained. Two candidate genes 
were particularly interesting: 1.MAZ (dominant missense model; p=3.58x10-5), a gene 
demonstrated to regulate urogenital development in a mouse model, and 2.FLNA (recessive 
model; p=4.25x10-5), a gene implicated in Otopalatodigital Spectrum Disorders, where 
hydronephrosis and megaureter were reported. Cross-annotation with GWAS signals 
revealed evidence for association of common variants to MAZ (p=7.06x10-3– 6.96x10-4). 
Gene set analysis for genes involved in kidney function showed enrichment for rare 
functional variant (χ2 = 9.12; p=2.5x10-3) compared to olfactory control genes (χ2=0.15; 
p=0.70) in cases versus controls.
Conclusions: This study addresses the contribution of rare and common variants under 
various genetic models to solve the etiology of COU. Preliminary results implicate both rare 
and common variants in MAZ as novel risk factors for COU.
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Genetic Diseases of the Kidneys: Non-Cystic - I
Analysis of De-Novo Coding Mutations Identifies New Candidate Genes 
for Kidney Malformations
Hila Milo Rasouly,1 Maddalena Marasa,1 Byum hee Kil,1 Tze Yin Lim,1 
Thomas L. Ruan,2 Jeremiah Martino,2 Nicholas J. Steers,1 Anna Materna-Kiryluk,7 
Giuseppe Masnata,6 Velibor Tasic,3 Marijan Saraga,4 Gian Marco Ghiggeri,5 
Rosemary V. Sampogna,1 Simone Sanna-Cherchi,1 Ali G. Gharavi.1 1Columbia 
University, New York, NY; 2Columbia University Medical Center, New York, NY; 
3University Children’s Hospital, Skopje, Macedonia (the former Yugoslav Republic 
of); 4University Hospital in Split, Split, Croatia; 5U.O.C. Nefrologia, Dialisi e 
Trapianto, IRCCS Istituto G. Gaslini, GENOVA, Italy; 6Azienda Ospedale G. 
Brotzu, Cagliari, Italy; 7Department of Medical Genetics, Poznan University of 
Medical Sciences, Poznan, Poland.
Background: Renal hypodysplasia (RHD) is one of the most common cause of 
pediatric kidney failure. Although multiple causative genes have been identified, they only 
account for 10-15% of cases. A search for de-novo “mutations” (DNMs), has led to the 
identification of numerous novel genes for congenital heart defects and neurodevelopmental 
disorders. We hypothesized that de-novo analysis can similarly identify new RHD-causing 
genes.
Methods: Whole-exome sequencing was performed on 88 RHD trios. The sequences 
were annotated using an in-house software, ATAV, and DNMs were identified. Potential 
enrichment for DNMs was analyzed with the denovolyzer package in R. Exploratory gene-
set enrichment analysis was performed with the Molecular Signatures Database (MSigDB).
Results: We identified a significant 1.5-fold enrichment for DNMs in cases compared 
to expectations (p= 1.7x10-4). The enrichment mostly originated from probands with renal 
agenesis or renal hypoplasia, and not from those with multicystic dysplastic kidneys. 
Globally, the DNM signal was mainly driven by genes that are highly expressed during 
murine kidney development. De-novo loss-of function mutations were detected only in two 
genes known to be associated with kidney disorders (PAX2 and TSC2) but none of the 
missense DNMs occurred in known RHD genes. In pathway analysis, we observed a 11.8-
fold enrichment for missenses in genes targeted by NF1 (p= 7.9x10-5), a 4-fold enrichment 
for DNMs in the CHEK2 network (p= 2.8x10-4) and a 6.4-fold enrichment for DNMs in 
genes potentially regulated by PAX4 (p= 1.3x10-4). We did not find independent DNMs in 
the same gene, confirming heterogeneity of disease.
Conclusions: Despite limited sample size, we detected an excess of de-novo mutations 
in RHD, identifying an important mechanism of disease. Gene-set analysis may help to 
pinpoint which genes are driving this enrichment. Analysis of larger cohorts is likely to 
identify genes with recurrent de-novo variants, enabling identification of causal genes.
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Mutations in PIK3C2A Cause Syndromic Short Stature Associated with 
Eye, Skeletal, and Renal Involvement
Markus Schueler,1 Anlu Chen,2 Dov Tiosano,11 Hagit N. Baris,3 Marrit Hitzert,8 
Adi Mory,5 Karl Knaup,10 Ronald Roepman,4 Rolph Pfundt,9 Mariam Aslanyan,12 
David A. Buchner,6 Michael S. Wiesener.7 1Department of Nephrology and 
Hypertension, University of Erlangen-Nuernberg, Erlangen, Germany; 2Case 
Western Reserve Univ, Cleveland, OH; 3Rambam Health Care Campus, Haifa, 
Israel; 4Radboud University Medical Center, Nijmegen, Netherlands; 5Rambam 
health care campus, Haifa, Israel; 6Case Western Reserve University, Cleveland, 
OH; 7University Hospital Erlangen, Erlangen, Germany; 8University Medical 
Center Groningen, Groningen, Netherlands; 9RadboudUMC, Nijmegen, 
Netherlands; 10University of Erlangen-Nuremberg, Erlangen, Germany; 
11Divison of Pediatric Endocrinology, Mayer Children’s Hospital, Haifa, Israel; 
12Department of Human Genetics, Radboud Institut for Molecular Life Science, 
Nijmegen, Netherlands.
Background: PIK3C2A is a member of the phosphoinositide 3-kinase (PI3K) family 
that catalyzes the phosphorylation of phosphatidylinositol (PI). Class II PI3Ks has been 
attributed a wide-range of biological functions including, angiogenesis, cellular signaling, 
endosomal trafficking, exocytosis as well as ciliary formation and function. However, its 
function is still poorly understood. Identifying the genetic basis of Mendelian diseases 
provide insight into gene function, susceptibility to disease and can improve clinical care.
Methods: We performed whole exome sequencing in three independent consanguineous 
families to identify the underlying single-gene disease-causing mutation. We then obtained 
dermal fibroblasts from skin biopsies of the affected individual and healthy controls for 
molecular studies.
Results: We identified three homozygous protein-truncating mutations in the gene 
PIK3C2A in five children from independent consanguineous families. The affected 
individuals show a considerable overlapping phenotype including cataract, skeletal 
abnormalities, hearing loss and renal involvement among other features. Molecular data 
of patient-derived fibroblasts were consistent with loss of PIK3C2A function as evidenced 
by the lack of PIK3C2A protein. In addition we demonstrate that the PIK3C2A deficiency 
caused impaired cilia formation, decreased levels of PI in primary cilia, and altered the 
phosphorylation status of Akt, GSK3beta as well as the expression level of AXIN2.
Conclusions: We demonstrate that loss-of-function mutations in PIK3C2A resulting in 
a novel syndrome consisting of short stature, cataracts, hearing loss, skeletal abnormalities 
and renal involvement. This discovery, together with studies of other disorders of PI 
metabolism, will enable future studies to discover the pathophysiological mechanism basis 
of this syndrome to better understand the role of PIK3C2A.
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Genetic Diseases of the Kidneys: Non-Cystic - I
ZMYM2 Mutations Cause Congenital Anomalies of the Kidneys and 
Urinary Tract (CAKUT) with Syndromic Features
Dervla M. Connaughton,1 Nina Mann,1 Makiko Nakayama,1 Rufeng Dai,1 
Caroline M. Kolvenbach,2 Franziska Kause,1 Dina Ahram,4 Hila Milo Rasouly,3 
Simone Sanna-Cherchi,3 Shirlee Shril,1 Friedhelm Hildebrandt.1 1Boston 
Children’s Hospital, Boston, MA; 2Harvard Medical School, Boston, MA; 
3Columbia University, New York, NY; 4Columbia University Medical Center, 
New York, NY.
Background: Congenital anomalies of the kidneys and urinary tract (CAKUT) 
constitute the most common cause (45%) of chronic kidney disease in the first three decades 
of life. CAKUT can present as an isolated renal condition or as part of a clinical syndrome. 
First insights into the pathogenesis of CAKUT came from identification of ~40 single-gene 
causes of isolated CAKUT and ~179 single-gene causes of syndromic CAKUT.
Methods: We performed whole exome sequencing (WES) to identify novel monogenic 
causes in a worldwide cohort of 600 individuals with CAKUT.
Results: We identified 13 different dominant heterozygous mutations in ZMYM2 
(MYM-type zinc fingers type 2) in 15 unrelated families; p.Val61del, p.Glu126Ala, p.G257fs 
p.Ile387Val, p.Gln398*, p.Cys536Leufs*13, p.Arg540ins*, p.Lys649Arg, p.Tyr763His,
p.Gly775Glu, p.Asp997del, p.Pro1002Ser, p.Glu1031Lys. ZMYM2, a transcriptional
regulator, contains 10 tandem zinc fingers called myeloproliferative and mental retardation 
(MYM)-type zinc fingers. ZMYM2 is expressed in the urothelial cells and renal tubules in
human cells and in the bladder and genital tubercle of the developing mouse. The encoded 
protein acts as a transcriptional co-repressor as part of the BHC histone deacetylase
complex and through interaction with SUMO-2. Affected individuals exhibited a broad
spectrum of CAKUT phenotypes. In addition, there were genito-urinary tract pathologies
including imperforate hymen and cryptorchidism. Interestingly, patients carrying missense 
alleles had an isolated CAKUT phenotype, whereas patients carrying truncating alleles
exhibited syndromic features such as facial dysmorphsim, developmental delay, hypotonia, 
and autism spectrum disorder.
Conclusions: We here discovered ZMYM2 mutations as a novel cause of autosomal 
dominant CAKUT. Furthermore, we found evidence of an allelic genotype-phenotype 
correlation, in which null mutations in ZMYM2 (e.g., protein truncating) cause syndromic 
CAKUT phenotypes, whereas hypomorphic mutations (e.g., missense) cause isolated 
CAKUT phenotypes.
Funding: Other NIH Support - DK076683
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COL4A1 Mutations as a Potential Novel Cause of Autosomal-Dominant 
CAKUT in Humans
Thomas Kitzler, Caroline M. Kolvenbach, Ronen Schneider, Dervla 
M. Connaughton, Amar J. Majmundar, Nina Mann, Makiko Nakayama,
Shirlee Shril, Friedhelm Hildebrandt. Boston Children’s Hospital, Boston, MA.
Background: Congenital anomalies of the kidney and urinary tract (CAKUT) are 
the most common cause of chronic kidney disease <30 years of age. While the genetic 
locus containing COL4A1 (13q33-34) has been implicated in vesicoureteral reflux (VUR), 
the role of COL4A1 in isolated kidney disease is unclear (Vats JASN 17:1158, 2006). 
We hypothesized that mutations in COL4A1 can cause abnormal kidney development in 
humans.
Methods: We performed whole exome sequencing in a cohort of 638 families (258 
families with nephronophthisis (NPHP) and 380 families with CAKUT). Genetic variants 
were analyzed assessing evolutionary conservation, in-silico prediction programs, and 
minor allele frequency in public databases (gnomAD, EVS, 1000 Genomes), as previously 
described (Braun Nat Genet 49:1529, 2017).
Results: We identified eight different heterozygous mutations in COL4A1 in eight 
unrelated families with CAKUT, while no COL4A1 mutations were present in the NPHP 
negative control cohort. All eight individuals had heterozygous only missense variants 
in COL4A1 (D928H, G1392S, G1450S L1235R, M838V, P603S, P816L, P1224L) with 
an isolated CAKUT phenotype. Affected individuals exhibited a spectrum of CAKUT 
phenotypes ranging from renal agenesis, small echogenic dysplastic kidneys, multicystic 
dysplastic kidney, left ectopic dysplastic kidney, hydronephrosis, to VUR. VUR was the 
predominant phenotype (5/8 families). Three patients had extra-renal features (facial 
dysmorphism, low set ears, hypotelorism, hearing loss, and uterus unicornis). COL4A1 
demonstrates extreme loss-of-function intolerance (pLI = 1), supporting autosomal 
dominant inheritance.
Conclusions: We identified heterozygous COL4A1 mutations as a potential novel 
autosomal dominant cause of CAKUT. The observation that some patients exhibit an extra-
renal phenotype, while others have isolated CAKUT, suggests the possibility of allelism.
Funding: NIDDK Support, Government Support - Non-U.S.
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Exome Sequencing in Human Bladder Exstrophy and Knockdown Studies 
in Zebrafish Implicate SLC20A1 as Candidate Gene and Major Regulator 
of Urinary Tract Development
Johanna Magdalena M. Schmidt,2,1 Öznur Yilmaz,1 Rong Zhang,2 Anna S. Japp,3 
Heiko M. Reutter,2,4 Benjamin Odermatt.1 1Institute of Anatomy, Faculty of 
Medicine, University of Bonn, Bonn, Germany; 2Institute of Human Genetics, 
Faculty of Medicine, University of Bonn, Bonn, Germany; 3Institute of 
Neuropathology, Faculty of Medicine, University of Bonn, Bonn, Germany; 
4Department of Neonatology and Pediatric Intensive Care, Faculty of Medicine, 
University of Bonn, Bonn, Germany.
Background: Bladder exstrophy-epispadias complex (BEEC) represents the severe 
end of human congenital anomalies of the kidney and urinary tract (CAKUT). Exome 
and Sanger sequencing in BEEC patients identified two novel de novo variants (p.G237R; 
p.V298A) and one novel maternally transmitted variant (p.K441Q) from an affected mother 
in SLC20A1. All three variants were predicted to be disease causing. SLC20A1 encodes for
a Na+/PO4 cotransporter known to play a role in proliferation and TNF-induced apoptosis.
We investigated the developmental function of slc20a1a in developing zebrafish larvae 
(zfl) performing Morpholino (MO) knockdown (KD) experiments. The urinary tract in zfl 
consists of two pronephric ducts, similar in segmentation to human nephrons, that fuse at
the cloaca. Slc20a1a is frequently used as pronephric in situ hybridization (ISH) marker.
Methods: Slc20a1a KD was done by injecting ATG-binding MOs in 1-2 cell staged 
eggs, blocking the gene’s translation. Specificity was shown by Western Blot and rescue 
experiments by co-injection of human mRNA transcripts of SLC20A1. For phenotype 
characterization different assays were used such as sulforhodamine 101 excretion, ISH, 
immunohistochemistry (IHC) on paraffin sections and the transgenic zf reporter line 
Tg(wt1b:GFP).
Results: MO KD of slc20a1a in zfl results in a severe lethal phenotype affecting 
multiple organ systems. Focusing on urinary tract, we see formation of pronephric cysts and 
disorganization of the cloaca. Excretion assay uncovers severe opening defects of the cloaca 
for the intestine, similar to our index patient with cloacal exstrophy and an imperforate anus. 
Yolk endocytosis defects resemble abdominal wall fusion deficiencies. IHC shows defects 
in proliferation and apoptosis.
Conclusions: Our data suggests slc20a1a as major player in urinary tract development 
of zf. Mild MO phenotypes present with urinary tract abnormalities. Severe MO phenotypes 
present with a high lethality among zfl - underlining the overall importance of slc20a1a 
during embryonic development. In conclusion, exome sequencing in human bladder 
exstrophy and developmental biology studies in zfl implicate SLC20A1 as disease gene for 
human BEEC and therefore CAKUT and as major regulator of urinary tract development.
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A Genome-Wide Association Study Provides Insight into the Etiology of 
Congenital Obstructive Uropathy
Tze Yin Lim,1 Dina Ahram,1 Rik Westland,2 Miguel Verbitsky,1 Priya Krithivasan,1 
Adele Mitrotti,1 Francesco Scolari,3 Marijan Saraga,4 Gian Marco Ghiggeri,5 
Velibor Tasic,6 Loreto Gesualdo,7 Ali G. Gharavi,1 Krzysztof Kiryluk,1 
Simone Sanna-Cherchi.1 1Columbia University, New York, NY; 2VU University 
Medical Center, Amsterdam, Netherlands; 3University of Brescia, Montichiari 
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Background: Congenital Obstructive Uropathy (COU) is a frequent anomaly of the 
urinary tract. Human genetic and clinical data suggest that both rare and common genetic 
variants might be involved in the pathogenesis of COU.
Methods: We conducted SNP genotyping in 398 COU cases and 8197 controls on 
different Illumina platforms. Genome-wide association study (GWAS) was performed on 
two Caucasian cohorts of 280 cases (cohort 1) and 118 cases (cohort 2), divided based 
on platform. After standard QC we retained 444614 and 632574 markers in cohort 1 and 
cohort 2, respectively. We imputed these marker sets separately using the HRC1.1 panel. 
The results were meta-analyzed with METAL. Suggestive signals were cross-annotated 
with results from our exome-wide collapsing analysis for rare variants in 292 COU cases 
and 8541 controls.
Results: Meta-analysis of the two cohorts (398 cases, 8197 controls and 7503796 
markers) revealed 3 suggestive associations. The 1st was on chr4q26 (rs4833590; 
p=3.01x10-7) in SEC24D. A disruption of this gene causes embryonic lethality in mice, 
and mutations in humans are implicated in the Cole-Carpenter Syndrome-2 with no known 
urinary tract involvement. Other genes within 250Kb of this variant are CEP170P1, 
LOC729218, METTL14 and SYNPO2. The 2nd was on chr12q21 (rs10777060; p=9.98x10-6), 
105.8kb upstream of BBS10, implicated in Bardet-Biedl syndrome, a ciliopathy with 
renal and urinary tract involvement. Neighboring genes are OSBPL8 and NAP1L1. A 3rd 
suggestive signal was on chr4q32 (rs6536312;p=9.70x10-6), 231.1kb upstream of ETFDH, 
a gene implicated in glutaric acidemia IIC, which features urogenital defects. Neighboring 
genes are TMEM144, RXFP1, C4orf46 and PPID. Cross-annotation with exome-wide 
collapsing analysis in 292 COU cases and 8541 controls showed evidence for enrichment in 
rare variants in BBS10 (p=3.2x10-3) and TMEM144 (p=1.2x10-2).
Conclusions: We present preliminary GWAS findings based on a relatively small 
sample size of 398 COU cases and identified 3 candidate loci. Integration with rare variants 
from an exome-wide association study permitted locus refinement and identification of 
novel susceptibility genes for follow-up studies in larger cohorts.
Funding: NIDDK Support
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A Mutation Identified in Patients with Congenital Anomalies of the 
Kidney and Urinary Tract Interrupts ROBO2-SLIT2 Association and 
Signaling Pathway
Xueping Fan,1 Tou S. Thao,2 Weining Lu.3 1Medicine, Boston University, Boston, 
MA; 2Medicine, Boston University School of Medicine, Boston, MA; 3Boston 
University Medical Center, Boston, MA.
Background: Congenital anomalies of the kidney and urinary tract (CAKUT) is 
a major cause of kidney failure in children and young adults. ROBO2 is a receptor for 
ligand SLIT2. ROBO2 and SLIT2 plays key roles in early ureteric bud outgrowth during 
kidney development and nervous system formation. There are approximately 30 ROBO2 
missense mutations identified in CAKUT patients. However, functional significances of 
these mutations are remained to be characterized. To elucidate if these mutations would 
structurally disrupt ROBO2-SLIT2 interaction and functionally compromise its signaling 
pathway, we have analyzed a missense mutation of ROBO2, p.G98W (c.292G>T), located 
in the ROBO2 first Ig domain that serves as the ligand binding site for SLIT2.
Methods: Site-directed mutagenesis was used to introduce c.292G>T point mutation 
into a human ROBO2 cDNA. Calcium phosphate transfection strategy was used to express 
ROBO2 in HEK cells. Protein expression was confirmed by Western blot analysis and 
ROBO2-SLIT2 interaction was analyzed using the ForteBio Bio-Layer Interferometry 
(BLI) system Octet RED96e. Postnatal anterior subventricular zone (SVZa) neuronal 
migration assay was performed to examine the functional impact of the mutation on 
ROBO2-SLIT2 signaling pathway.
Results: BLI binding assay showed a positive interaction between ROBO2 and SLIT2, 
however, the p.G98W mutation in ROBO2 first Ig domain hinders this binding compared 
with its wild type control. Functional assay indicates that the extracellular portion of 
ROBO2, a 153 residue peptide containing the binding domain for SLIT2, is able to block 
ROBO2-SLIT2 signaling pathway that repels neuronal migration. In contrast, after the 
p.G98W mutation was introduced, the mutated ROBO2 peptide reduces this functional 
blocking activity on neuronal migration.
Conclusions: Our results provide molecular mechanistic evidence that p.G98W in 
ROBO2 first Ig domain interrupts the ROBO2-SLIT2 receptor-ligand association, which 
may in turn disrupt their signaling pathway during early kidney development and result in 
CAKUT phenotypes in patients carrying this mutation.
Funding: NIDDK Support
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Mutations in BNC2 Lead to Autosomal-Dominant Lower Urinary Tract 
Obstruction (LUTO)
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Background: Congenital “lower urinary tract obstruction” (LUTO) is defined by 
a decrease in the free passage of urine through the urethra. About three out of 10,000 
pregnancies are affected; the etiology is so far unknown.
Methods: Whole exome sequencing (WES) in a family with 4 affected from 3 
generations was performed. 258 LUTO patients were screened for further variants in the 
identified candidate gene BNC2 using Sanger sequencing. Functional studies comprised 
in situ hybridization (ISH) studies in mouse embryos, translational knock-down (KD) in 
developing zebrafish larvae (zfl) using Morpholino oligonucleotides (MO) and ‘rescue‘ 
experiments by co-injection of human BNC2 mRNA with the bnc2-MO in zfl as well as 
overexpression of BNC2 mRNA in zfl.
Results: Filtering of WES Data revealed a nonsense mutation (c.2554C>T; p.Arg852*) 
in BNC2 (basonuclin 2). Out of 258 LUTO patients one additional family (affected father 
and son) carrying a novel missense mutation (c.2663A>G, p.H888R) in BNC2 could be 
identified. Affected members in both families presented with anatomical obstruction 
of the urethra due to posterior urethral valves (PUV), requiring surgical removal, and 
urethral stenosis with fetal presentation, requiring surgical reconstruction. Functional 
characterization of Bnc2 using ISH showed expression at E13.5 in developing mouse 
urethra. KD of bnc2 by injection MO in zfl caused cloacal obstruction with formation of 
a vesicle at the distal end of pronephric duct in 11% of zfl and cystic dilated deformed 
glomeruli and dilated pronephric ducts in 50%. Co-injection of human BNC2 mRNA with 
bnc2-MO in zfl showed rescue of the phenotype only at an amount of 100pg of mRNA. 
Already slight overexpression of human BNC2 mRNA in zfl lead to the same phenotype as 
KD, confirming the specificity of the bnc2-MO suggesting that the observed phenotypes in 
fish and human are the result of gene dosage imbalance of BNC2.
Conclusions: Human genetic and developmental biology models suggest BNC2 
mutations as the first monogenic cause of LUTO.
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Tackling Undetermined ESRD by Whole Nephrome Sequencing in Adult 
Patients Waiting for Kidney Transplantation
Isabel Ottlewski,1 Johannes Muench,1 Timo Wagner,2 Carsten Bergmann,2 
Anette Bachmann,1 Tom H. Lindner,1 Daniel Seehofer,1 Jan Halbritter.1 
1University Hospital Leipzig, Leipzig, Germany; 2Bioscientia, Ingelheim, 
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Background: End-stage renal disease (ERSD) of undetermined etiology constitutes a 
significant clinical challenge, notably in kidney transplantation (KT). In absence of renal 
histology, genetic analysis may further elucidate ESRD etiology. To date, hereditary kidney 
disease is thought to represent < 10% of ESRD patients, mainly attributed to ADPKD. In 
recent years, however, a multitude of additional rare genetic ESRD conditions have been 
discovered without being yet systematically considered in clinical routine. To tackle the 
issue of undetermined ESRD prior to KT, we aimed to broadly analyze for genetic causes 
in patients on the waitlist.
Methods: Patients on the local KT-waitlist (n=134) were stratified based on their 
presumed etiologies: i) non- hereditary (n=56); ii) hereditary, including clinically diagnosed 
ADPKD (n=29); iii) undetermined, including biopsy-proven FSGS (n=49). The latter 
patients were analyzed by whole “nephrome” sequencing, comprising more than 290 
ESRD-associated OMIM-genes.
Results: An undetermined etiology was found in 36% of individuals (49/134) on the 
waitlist, 40% of whom reported a positive family history. We detected a robust genetic 
diagnosis in 24% (12/49). The genes COL4A3/5 were found most frequently mutated in 
undetermined ESRD. Taken together, hereditary nephropathies, including ADPKD, were 
identified in 31% (41/134) of the overall cohort. By significantly increasing the proportion 
of hereditary diagnoses (from n=29 to n=41, p<0,05), the rate of undetermined ESRD went 
down from n=49 to n=37 (p<0,05).
Conclusions: By this pilot study, we demonstrate the beneficial use of whole 
“nephrome” sequencing to significantly reduce the proportion of undetermined ESRD 
prior to KT. In absence of renal histology or unspecific histological conditions, such as 
FSGS or TMA, genetic analysis may not only provide a robust diagnosis but helps 
differentiating recurrent from non-recurrent etiologies, thereby contributing to personalized 
KT management and adequate evaluation of potential living donors.
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Outcomes of Patients with Genetic Renal Disease in Regional Australia
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Background: Genetic aetiology comprises a significant proportion of adults with 
chronic kidney disease (CKD) who develop end-stage kidney disease (ESKD) and 
experience an excess of morbidity and mortality. Our aim was to evaluate the outcomes 
patients with genetic renal disease (GRD) in Tasmania, Australia.
Methods: Individuals with GRD in Tasmania were identified from AUDIT4 (renal 
unit clinical database, n=2407) and ANZDATA (Australia and New Zealand Dialysis and 
Transplantation Registry, n=361) from 1stJanuary 2012 until 1st May 2018. After discarding 
duplicates, 2434 individuals referred to tertiary renal services were reviewed.
Results: In Tasmania, GRD comprised 8.5% of the CKD population (208/2434). GRD 
patients were younger than non-GRD patients (mean 52y vs. 64y, p <0.001). There was no 
significant difference in gender or mean eGFR (in non-dialysis patients) between cohorts. 
Since 2012, GRD patients have more commonly developed ESKD, commenced renal 
replacement therapy (RRT) or received transplants than non-GRD patients (40% vs. 17%, 
p<0.001; 39.4% vs. 12.3% p<0.001; 30.3% vs. 5% p<0.001). Furthermore, GRD patients 
commenced RRT at a younger age (mean 46y vs 55y, p<0.001). Of the GRD cohort, there 
was no significant difference in gender. Cystic kidney disease was the most common GRD 
(48%), followed by Congenital Abnormalities of the Kidneys and Urinary Tract (CAKUT) 
(37%). Patients with CAKUT started RRT younger than those with cystic disease (mean 
39y vs. 55y, p<0.001). Those who received transplants did so earlier (mean 36y vs. 52y, 
p<0.001). Patients with glomerular, tubular/metabolic or other uncommon GRDs were more 
likely to be older males. Very few of the people with GRD were known to the Tasmanian 
Clinical Genetics Service, had received genetic testing or counselling.
Conclusions: Patients with GRD in Tasmania experience earlier morbidity, including 
the need for RRT and transplant. This data supports the development of a tailored genetic 
renal service to improve outcomes in affected individuals in Regional Australia.
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Yield of Atypical Hemolytic Uremic Syndrome (aHUS) Genetic Suscepti-
bility Panel Testing
Chinmayee Bhimarao Nagaraj, James Denton, D. Brian Dawson. Cincinnati 
Children’s Hospital Medical C, Loveland, OH.
Background: Hemolytic uremic syndrome (HUS) is characterized by hemolytic 
anemia, thrombocytopenia and renal failure secondary to thrombotic microangiopathy 
(TMA). 90% of HUS cases are associated with infection by Shiga toxin-producing E.coli. 
About 10% of HUS cases are associated with genetic or acquired defects in the regulation 
of the alternative complement pathway. In about 60% of individuals affected with aHUS, a 
specific genetic susceptibility variant may be identified. Clinical genetic testing in patients 
with aHUS not only informs their disease process but also provides therapeutic and 
prognostic insight for their management.
Methods: The Genetics and Genomics Laboratory at Cincinnati Children’s Hospital 
has developed an aHUS genetic susceptibility panel which includes 10 aHUS associated 
genes. We reviewed the orders we received for this panel over the last two years (June 
2016- May 2018) to assess the yield of this genetic test. We also assessed the proportion of 
pathogenic variants identified in each individual gene on this panel.
Results: Over the last two years, we have tested 338 patients suspected with genetic 
aHUS through our aHUS genetic susceptibility panel. 29.6% of the patients were 
heterozygous for the CFHR3-CFHR1 deletion, which is similar to its frequency in the 
general population. The CFHR3-CFHR1 deletion in the heterozygous state does not confer 
risk of developing aHUS. 8.3% of the patients were homozygous for the CFHR3-CFHR1 
deletion, which is associated with increased risk of developing aHUS. 10.1% of the patients 
had pathogenic or likely pathogenic sequence variants in one or more of the ten genes on the 
panel. Two of the patients were homozygous for the CFHR3-CFHR1 deletion in addition 
to pathogenic sequence variants. Three of the patients had pathogenic sequence variants in 
two different genes. Overall, about 16.9% of the patients with suspected genetic aHUS were 
found to carry genetic variations that conferred them increased risk of developing aHUS. 
The proportion of pathogenic variants identified in each individual gene on this panel are C3 
(1.6%), CFB (1.6%), CFH (16.13%), CFHR1 (4.8%), CFHR3 (11.3%), CFHR3- CFHR1 
homozygous deletion (45.2%), CFHR5 (3.2%), CFI (14.5%), DGKE (3.2%), CD46 (6.5%) 
and THBD (1.6%).
Conclusions: This study emphasizes the significance of genetic analysis in patients 
with suspected aHUS.
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Whole-Exome Sequencings Reveal Additional Extracellular Matrix Gene 
Mutations in Atypical Hemolytic Uremic Syndrome
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Medical Science, China Medical University, Taichung, Taiwan; 4Department of
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5Academia Sinica, Taipei, Taiwan.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused 
by uncontrolled activation of the alternative pathway of complement and induces 
microangiopathic hemolytic anemia, thrombocytopenia, acute kidney failure and extrarenal 
manifestations. Most of studies revealed aHUS with pathogenic loss-of-function of 
complement or gain-of-function regulators of complement. Whether patients with aHUS 
may have additional extracellular matrix gene mutations is not known at present, we did 
this study to explore this possibility.
Methods: This study used whole-exome sequencing(WES) to screen our six adult 
patients, five of them responded to anti-C5 therapy while one patient did not receive anti-C5 
treatment due to financial issue. After completing the whole-genome sequencing analyses, 
we used functional protein association network -STRING for correlation evaluation.
Results: The whole-exome sequencing analysis revealed all six patients were with 
loss-of-function of complement or gain-of-function regulators of complement (table 1). 
WES revealed a novel heterozygous mutation in AEBP1 in three aHUS patients, a novel 
heterozygous mutation in SCUBE1 in two aHUS patients, and a novel heterozygous 
mutation in WNT2B in two aHUS patients. In addition, one patient had both SCUBE1 and 
AEBP1 mutations. The STRING network revealed these mutation genes participated in 
extracellular matrix environment molecule pathways.
Conclusions: Our results demonstrate aHUS patients from Taiwan have additional 
mutations in extracellular matrix genes (e.g. AEBP1, SCUBE1, and WNT2B). The 
additional extracellular matrix gene mutations may play a role in the disease severity. We 
will further clarify the functional molecular interactions between alternative complement 
pathway and extracellular matrix genes.
Table 1
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Additional Genes Associated with Atypical Hemolytic Uremic Syndrome
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Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening, 
ultra-rare thrombotic microangiopathy. This partially penetrant genetic disease, featuring 
a characteristic triad of hemolytic anemia, thrombocytopenia and renal failure, is caused 
by complement overactivation. 50 to 80% of aHUS patients have a detectable genetic 
mutation in one of several genes that may lead to overactivation of complement. All aHUS 
sequencing assays cover a core group of complement genes: CFH, CFI, CFB, C3, MCP/
CD46. Additionally, sequencing of CFHR5, THBD, DGKE, as well as copy number to 
detect the homozygous deletion of CFHR1-CFHR3 or CFHR1-CFHR4 (but not single 
nucleotide variants within CFHR1, CFHR3 or CFHR4 alone), are often included. More 
rarely, PLG is sequenced; its inclusion is based on findings from a single publication (Bu 
(2014) J Am Soc Nephrol 25, 1) where they found several aHUS patients harboring known, 
rare pathogenic PLG variants.
Methods: Genomic DNA was extracted from patient whole blood and sequenced using 
an aHUS genetic panel. This panel comprised twelve genes (CFH, CFI, CFB, C3, MCP/
CD46, CFHR1, CFHR3, CFHR4, CFHR5, THBD, DGKE and PLG) and was sequenced 
using targeted next generation sequencing. Variants were confirmed by Sanger sequencing 
as needed.
Results: Here we describe multiple instances where we detected suspicious variants 
within PLG and CFHR3 in patients where the aHUS Genetic Panel was ordered by their 
physician. Some of the suspicious variants we found in PLG (eight cases with p.Lys38Glu 
and one case with p.Arg253His) were the same variants seen previously by Bu et al; both 
variants are also associated with plasminogen deficiency. The suspicious CFHR3 variants 
we observed were severe (splice site, nonsense, frameshift) and either exceedingly rare or 
novel.
Conclusions: These results 1) replicate the finding by Bu et al of PLG having a 
role in aHUS, and 2) suggest a potential novel contribution from CFHR3. CFHR3 has 
previously only been implicated in aHUS as part of a large homozygous deletion that also 
removes the neighboring gene CFHR1. Furthermore, it is thought that in the case of this 
large homozygous deletion, it is the absence of CFHR1 that is causitive while CFHR3 
is incidental. These results hint at the possibility that rare, dominant negative variants in 
CFHR3 may also lead to aHUS.
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Safety and Effectiveness of Eculizumab for Adult Patients with Atypical 
Hemolytic-Uremic Syndrome in Japan: Interim Analysis of Post-Market-
ing Surveillance
Hirokazu Okada,1 Hideki Kato,2 Yoshitaka Miyakawa,1 Yoshihiko Hidaka,3 
Norimitsu Inoue,4 Shuichi Ito,5 Shoji Kagami,6 Shinya Kaname,7 
Masanori Matsumoto,8 Masashi Mizuno,9 Takahisa Matsuda,12 
Akihiko Shimono,12 Shoichi Maruyama,10 Yoshihiro Fujimura,13 
Masaomi Nangaku.11 1Saitama Medical University, Saitama, Japan; 2The 
University of Tokyo Graduate School of Medicine, Bunkyo-ku, Japan; 3Shinshu 
University School of Medicine, Matsumoto, Nagano, Japan; 4Osaka 
International Cancer Institute, Osaka, Japan; 5Department of Pediatrics, 
Graduate School of Medicine, Yokohama City University, Yokohama, Japan; 
6Tokushima Unversity, Tokushima, Japan; 7Kyorin University School of 
Medicine, Mitaka, Tokyo, Japan; 8Nara Medical University, Kashihara city, 
Japan; 9Nagoya University, Nagoya, Japan; 10Nagoya University Graduate 
School of Medicine, Nagoya, Japan; 11the University of Tokyo School of 
Medicine, Tokyo, Japan; 12Alexion Pharma GK, Tokyo, Japan; 13Japanese Red 
Cross Kinki Block Blood center, Ibaraki, Japan.
Background: Eculizumab has been available for the treatment of atypical hemolytic–
uremic syndrome (aHUS) in Japan since 2013. To assess safety and effectiveness of 
eculizumab in adult aHUS patients in the real-life setting, we performed interim analysis of 
a post-marketing surveillance mandated by Japanese regulations.
Methods: This study enrolled any patient diagnosed with TMA excluding Shiga 
toxin-producing Escherichia coli-HUS or thrombotic thrombocytopenic purpura based 
on Japanese clinical guideline published in 2013 as inclusion criteria and treated with 
eculizumab. According to the guideline revised in 2016, the enrolled patients were with 
aHUS (complement-mediated HUS) and secondary TMA.
Results: Thirty-three patients with aHUS and 27 patients with secondary TMA were 
enrolled. Median treatment duration of aHUS was 24weeks. Complement genes variants 
were detected in 11 of 18 aHUS patients who underwent genetic analysis (61.1%). 
Among the 29 aHUS patients with available baseline data, platelet count (PLT), lactic 
dehydrogenase and serum creatinine (SCr) improved within 1-month after eculizumab 
initiation. TMA event–free status, complete TMA response, PLT normalization, and SCr 
decrease were achieved in 67.9% (19/28), 27.8% (5/18), 56.5% (13/23), and 57.1% (16/28) 
of patients, respectively. Thirty-three adverse reactions, i.e., hypertension, hyperuricemia, 
nasopharyngitis and edema, were observed in 13 of 33 aHUS patients.
Conclusions: This interim analysis confirmed the acceptable safety profile and 
effectiveness of eculizumab for Japanese adult aHUS patients in real-world settings.
Funding: Commercial Support - Alexion Pharma GK
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Genetic Diseases of the Kidneys: Non-Cystic - I
Genetic Analysis and Genotype-Phenotype Studies of a Cystinuria Cohort
Andrea G. Cogal,1 Sarah R. Senum,1 Ramila A. Mehta,1 Frank Modersitzki,2 
John C. Lieske,1 David S. Goldfarb,3 Peter C. Harris.1 Rare Kidney Stone 
Consortium (RKSC) 1Mayo Clinic, Rochester, MN; 2New York University School 
of Medicine, New York, NY; 3NYU Langone, New York, NY.
Background: Cystinuria is an inherited kidney stone disorder caused by mutations to 
the SLC3A1 and SLC7A9 genes. While most cases are due to biallelic mutations to either 
gene, monoallelic and digenic families have been described, with overall considerable 
disease variability. Nevertheless, clear genotype/phenotype correlations have not been 
described to date.
Methods: A next generation sequencing (NGS) panel consisting of 90 known 
and candidate kidney stone genes was developed and validated. A total of 49 unrelated, 
genetically unscreened individuals with a clinical diagnosis of cystinuria were analyzed 
using this panel. Preliminary correlations with phenotype were made with the genic groups.
Results: The baseline mean (SD) characteristics of the cohort were: age at diagnosis 
= 19.6y (12.5), number of stones = 5.8 (6.6), cystine excretion = 939.9mg (323.6), eGFR 
= 82.1ml/min/1.73m2 (24.5), with age at last follow up = 43.8y (14). A total of 34 patients 
(69.4%) had biallelic SLC3A1 and 11 (22.4%) biallelic SLC7A9 mutations. One SLC3A1 and 
two SLC7A9 cases had a single detected mutation, and one case had no mutations detected. 
Large rearrangements, detected by LOG2 ratio analysis of the sequence data and confirmed 
by Multiplex Ligation-dependent Probe Amplification (MLPA), accounted for 31.9% of 
all SLC3A1 mutations, mainly the common ex5-9 duplication. Other common mutations 
were the SLC3A1 missense change p.Met467Thr (21.7% alleles) and the nonsense mutation 
p.Arg270* (18.8%), while for SLC7A9 the missense mutation p.Gly105Arg accounted for
29.2% of pathogenic alleles. Ten novel mutations were identified for each gene. The only 
detected correlation with genotype was with baseline mean stone number, SLC3A1 = 7.1
(7.1), SLC7A9 = 2.0 (2.1; p=0.05) in this cohort.
Conclusions: This analysis shows the utility of a panel-based NGS approach in 
cystinuria populations and more broadly in patients with suspected monogenic stone 
disease. Other genetic and/or environmental factors likely also contribute to the observed 
phenotypic variability.
Funding: NIDDK Support
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A Custom Next Generation Sequencing (NGS) Panel for Kidney Stone 
Disease Resolves Diagnosis in Mutation Negative Patients Clinically 
Diagnosed with Dent Disease
Andrea G. Cogal,1 Sarah R. Senum,1 Emilie Cornec-Le Gall,2 Barbara M. Seide,1 
Carly Banks,1 Julie B. Olson,1 Tammy M. Greenwood,1 David J. Sas,1 
Dawn S. Milliner,1 Lada Beara Lasic,3 John C. Lieske,1 Peter C. Harris.1 Rare Kidney 
Stone Consortium (RKSC) 1Mayo Clinic, Rochester, MN; 2Centre Hospitalier 
Universitaire de Brest, BREST, France; 3NYU Medical Center, Pelham, NY.
Background: Dent disease is an X-linked disorder characterized by low molecular 
weight proteinuria, nephrolithiasis/nephrocalcinosis and CKD. We previously performed 
molecular screening of suspected Dent patients by Sanger sequencing of the known genes: 
CLCN5 and OCRL. The majority of cases were genetically resolved, but there remained a 
cohort with no mutations detected (NMD), which we analyze here employing a NGS panel.
Methods: A NGS panel consisting of 90 known and candidate genes related to urinary 
stone risk was developed and 61 NMD suspected Dent families screened. The phenotype of 
resolved patients was compared to the implicated gene.
Results: Likely pathogenic mutations consistent, or in one case divergent, with the 
presenting phenotype were detected in 5 (8%) of the 61 NMD families (Table). Two 
cases with SLC34A3 mutations were detected, one with a missense, an inframe deletion 
and a splicing mutation and a second homozygous for a novel frameshifting duplication. 
SLC12A1 biallelic missense mutations were found in a patient with a typical Bartter 
phenotype. A patient with a KCNJ1 frameshifting duplication and missense mutation had 
nephrocalcinosis, proteinuria, and CKD, but lacked the typical electrolyte abnormalities 
of Barrter. One subject was homozygous for a previously described CLDN16 missense 
mutation. An additional patient was found to have two large chromosomal duplications, 
confirmed by MLPA and microarray analysis, which we have categorized as possibly 
pathogenic. Three additional patients with weaker biallelic variants in candidate genes are 
being further assessed.
Conclusions: This analysis demonstrates the utility of a panel-based NGS approach in 
unresolved patients with suspected monogenic causes of nephrocalcinosis or urinary stone 
disease and is valuable since the phenotypes of these disorders can demonstrate significant 
divergence and overlap.
Funding: NIDDK Support
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SRNS-Associated MYO1E Mutations Have Differential Effects on Myo1e 
Activity and Stability
Pei-Ju Liu,1 Diana Perez,1 Jing Bi Karchin,1 Christopher D. Pellenz,1 
Sharon E. Chase,1 Maria Presti,5 Eric L. Plante,1 Claire E. Martin,4 
Svjetlana Lovric,3 Friedhelm Hildebrandt,2 Mira Krendel.1 1Cell and 
Developmental Biology, SUNY Upstate Medical University, Syracuse, NY; 
2Boston Children’s Hospital, Boston, MA; 3Hannover Medical School, Hannover, 
Germany; 4University of Guelph, Guelph, ON, Canada; 5SUNY Upstate Medical 
University, Syracuse, NY.
Background: Mutations in the MYO1E gene, encoding myosin 1e (Myo1e), are 
associated with steroid resistant nephrotic syndrome (SRNS). We set out to characterize 
novel MYO1E mutations identified in SRNS patients (Sadowski et al., JASN, 2015, 26(6): 
1279-89).
Methods: Using adenoviral transduction of EGFP-Myo1e constructs into cultured 
podocytes, we compared steady-state expression levels, protein turnover rates, and 
localization of the wild type (wt) Myo1e and several Myo1e mutants, including mutants 
with point mutations in the motor domain and a frame shift mutant d3094-7 lacking the 
C-terminal SH3 domain.
Results: We found that two mutants, the T119I motor domain mutant and the d3094-7 
frame shift mutant, had low expression levels and high turnover rates and did not localize 
to cell-cell junctions, where Myo1e is thought to aid in the assembly of the slit diaphragm 
complexes. In an attempt to restore Myo1e protein stability, we treated cells expressing these 
mutants with a proteasome inhibitor and observed accumulation of the mutant proteins. 
The restoration of protein expression in cells expressing the d3094-7 mutant resulted in a 
partial recovery of the junctional localization and dynamics of this protein. In contrast, an 
increase in the protein level of the T119I mutant achieved using proteasome inhibition was 
accompanied by formation of random, seemingly insoluble, aggregates (as determined using 
fluorescence recovery after photobleaching (FRAP)). Further investigating the properties of 
those Myo1e mutants that did not exhibit decreased protein stability, we found that the 
dynamics of one of the motor domain mutants at the junctions was decreased compared to 
the wt Myo1e. Using FRAP, we found that the mobile fraction of this mutant was lower than 
that of the wt Myo1e while the half time of fluorescence recovery was higher.
Conclusions: Overall, our findings indicate that while some SRNS-associated 
mutations affect Myo1e stability and folding, others may have more specific effects on 
motor domain activity. Furthermore, proteasome inhibition needs to be further examined 
as a potential therapeutic approach for alleviating the effects of those mutations that affect 
Myo1e stability without disrupting its motor function.
Funding: NIDDK Support, Private Foundation Support
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Quantification of Urinary 2,8-Dihydroxyadenine Excretion in Patients 
with APRT Deficiency
Hrafnhildur L. Runolfsdottir,1,2 Runolfur Palsson,1,2 Unnur A. Thorsteinsdottir,2 
Olafur S. Indridason,1 Inger M. Agustsdottir,1 Margret Thorsteinsdottir,2 
Vidar O. Edvardsson.1,2 The Rare Kidney Stone Consortium 1Landspitali - The 
National University Hospital of Iceland, Reykjavik, Iceland; 2University of 
Iceland, Reykjavik, Iceland.
Background: Adenine phosphoribosyltransferase deficiency (APRTd) is a rare 
disorder that results in renal excretion of 2,8-dihydroxyadenine (DHA) in large amounts, 
leading to kidney stones and chronic kidney disease. We have recently developed a high-
throughput ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-
MS/MS) assay for quantification of urinary DHA. The purpose of this study was to assess 
24-h urinary DHA excretion in APRTd patients, heterozygotes and healthy subjects, and the 
effect of varied purine intake in patients.
Methods: Nineteen patients in the APRT Deficiency Registry of the Rare Kidney Stone 
Consortium, 4 heterozygotes and 10 healthy volunteers not taking medications affecting 
the metabolism or excretion of purines, participated in the study. The effect of varied 
dietary purine intake was assessed in 4 patients not receiving drug treatment. Urinary DHA 
excretion was measured in 24-h urine specimens and single void urine samples, expressed 
as mg/24 h and DHA/Cr ratio (mg/mmol), respectively. Associations were examined using 
Spearman‘s correlation coefficient.
Results: The median (range) urinary DHA excretion in 28 samples from 19 patients 
with APRTd was 138.1 (63.8-291.5) mg/24 h. No DHA was detected in any 24-h urine 
samples from 4 heterozygotes and 10 healthy individuals. The DHA/Cr ratio in 42 random 
void urine samples from 19 patients was 13.1 (3.8-37.2) mg/mmol. No correlation was found 
between urinary DHA excretion and kidney function (r=0.04, p=0.816). The correlation 
between the first morning void urine DHA/Cr and the 24-h urinary DHA excretion in 
samples obtained in the same 24-h period was high (r=0.84, p<0.001). The urine DHA 
excretion was 128.6 (107.2-160.1), 135.8 (114.4-188.4) and 133.5 (102.6-159.6) mg/24 h 
on self-selected, purine enriched and purine restricted diets, respectively.
Conclusions: Patients with APRTd excrete large amounts of DHA in their urine, while 
DHA is undetectable in both heterozygotes and healthy subjects. Timed urine samples can 
be replaced with DHA/Cr ratio in first morning void urine specimens for monitoring of 
DHA excretion. Short-term changes in purine intake do not seem to affect DHA excretion.
Funding: NIDDK Support, Other NIH Support - Rare Kidney Stone Consortium 
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Diagnosis of Adenine Phosphoribosyltransferase Deficiency by  
ATR-FTIR Spectroscopy
Tzu-Ling Lin,1 Robert J. Unwin,1 Jill T. Norman,1 Vidar O. Edvardsson,2,5 
Runolfur Palsson,3,5 Peter R. Rich.4 1Centre for Nephrology, Division of Medicine, 
University College London, London, United Kingdom; 2Division of Nephrology, 
Landspital - The National University Hospital of Iceland, Reykjavik, Iceland; 
3Children’s Medical Centre, Landspitali - The National University Hospital of 
Iceland, Reykjavik, Iceland; 4Glynn Laboratory of Bioenergetics, Institute of 
Structural and Molecular Biology, University College London, London, United 
Kingdom; 5University of Iceland, Reykjavik, Iceland.
Background: Adenine phosphoribosyltransferase deficiency (APRTd) is a rare 
inherited disorder of purine metabolism characterized by renal excretion of large amounts 
of crystalline 2,8 dihydroxyadenine (DHA). Affected individuals develop kidney stones 
and progressive CKD, and eventual ESRD, secondary to renal parenchymal DHA crystal 
deposition; diagnosis is often missed and its true prevalence is uncertain. Currently, the 
primary method leading to diagnosis is the detection of DHA crystals by urine microscopy; 
however, several urinary crystalline species can easily be confused with DHA. Therefore, 
it is crucial to develop a rapid and sensitive point-of-care method for identification of DHA 
in human urine samples.
Methods: Fourier-transform infrared (FTIR) spectroscopy has been shown to be a 
straightforward and reliable technique for the diagnosis of a variety of kidney stones. We 
assessed attenuated total reflection (ATR) FTIR spectroscopy as a means of detecting DHA 
in urine.
Results: An optimal method for accurate detection and quantitation of DHA in a dried 
urine pellet was developed. Urine samples from untreated APRTd patients in whom the 
presence of DHA had been confirmed by ultra-performance liquid chromatography coupled 
to tandem mass spectrometry (UPLC-MS-MS) were assessed using ATR-FTIR. Insoluble 
DHA was detected in 17 of the 20 urine samples with concentrations ranging from 1.4 - 24.8 
μM. In 3 samples, ATR-FTIR indicated the presence of a different insoluble component
related to a form of uric acid or its salts, possibly in combination with other compounds.
Hence, this method may be useful in routine clinical screening to identify cases of APRTd. 
In addition, IR analysis of pure DHA revealed a second physical form of DHA, probably an 
amorphous state, which has not been reported before. It is unclear whether amorphous DHA 
may be involved in disease pathogenesis and/or if the lack of recognition of amorphous
DHA contributes to under-diagnosis of APRTd.
Conclusions: In conclusion, ATR-FTIR may be a useful and rapid ‘point-of-care’ 
screening tool for early diagnosis of APRTd. Both the method and instrumentation can be 
adapted easily and cheaply for clinical use. The clinical significance of the newly identified 
amorphous DHA remains to be established.
Funding: Private Foundation Support
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Development of a 2D-UPLC-MS/MS Assay for Therapeutic Monitoring in 
Patients with APRT Deficiency
Vidar O. Edvardsson,1,2 Unnur A. Thorsteinsdottir,2,3 Hrafnhildur L. Runolfsdottir,1,2 
Thorsteinn H. Bjarnason,2 Finnur F. Eiriksson,3 Margret Thorsteinsdottir,2,3 
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Consortium 1Landspital - The National University Hospital of Iceland, Reykjavik, 
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Background: Adenine phosphoribosyltransferase deficiency (APRTd) is a rare 
hereditary purine metabolism disorder resulting in accumulation and renal excretion of 
2,8-dihydroxyadenine (DHA), causing kidney stones and chronic kidney disease (CKD). 
The drugs allopurinol and febuxostat reduce urinary DHA excretion and ameliorate 
the disease manifestations. We developed a two-dimensional ultra-performance liquid 
chromatography tandem mass spectrometry (2D-UPLC-MS/MS) assay for simultaneous 
measurement of DHA and the pharmacological agents allopurinol, its active metabolite 
oxypurinol, and febuxostat in human plasma for monitoring of pharmacotherapy.
Methods: A design of experiments was used to define the optimum 2D-UPLC-MS/MS 
conditions based on the minimum number of experiments. Experimental screening of the 
variables was performed by D-optimal design to identify factors influencing retention 
time, peak height and peak area for all compounds. Variables were optimized with central 
composite face design and related to sensitivity and retention time using partial least square 
regression. Protein precipitation was carried out with 1% formic acid in methanol as a 
crash solvent. Plasma samples from APRTd patients and control specimens from laboratory 
personnel were used for the study.
Results: The plasma concentration of DHA, allopurinol, oxypurinol, and febuxostat 
was reliably achieved with the 2D-UPLC-MS/MS assay. The DHA concentrations 
in plasma from 3 APRTd patients were 456, 459 and 741 ng/mL off drug treatment 
and 130, 61 and 27 ng/mL while on allopurinol or febuxostat therapy. By contrast, 
DHA was not detected in plasma from healthy controls. The plasma allopurinol and 
oxypurinol concentration during drug treatment in the 3 patients was 802, 2391, 5089 
and 6810, 7076 and 12,510 ng/mL, respectively, and the febuxostat concentration was 
1276 ng/mL in 1 patient.
Conclusions: Our data suggest that the 2D-UPLC-MS/MS assay may be used to 
monitor the efficacy of pharmacotherapy and treatment adherence among APRTd patients. 
This method may prove useful in determining the plasma DHA concentration that must 
be attained in order to prevent new kidney stone growth and CKD progression in these 
patients.
Funding: NIDDK Support, Other NIH Support - Rare Kidney Stone Consortium 
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Safety and Efficacy Study of Lumasiran (ALN-GO1), an Investigational 
RNA Interference (RNAi) Therapeutic, in Patients with Primary 
Hyperoxaluria Type 1
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David V. Erbe,9 Dawn S. Milliner.7 1Birmingham Childrens’ Hospital, 
Birmingham, United Kingdom; 2Université ClaudeBernard Lyon1-, Bron, 
France; 3Hospital Robert Debre/Pediatric Nephrology, Paris, France; 4Rambam 
Health Care Campus, Haifa, Israel; 5Bordeaux University Hospital, Bordeaux, 
France; 6University Hospital Bonn, Bonn, Germany; 7Mayo Clinic, Rochester, 
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United Kingdom; 11Emma Children’s Hospital AMC, Amsterdam, Netherlands.
Background: In Primary Hyperoxaluria Type 1 (PH1), defective alanine:glyoxylate 
aminotransferase leads to excessive hepatic oxalate production, leading to progressive renal 
impairment and multi-organ damage from systemic oxalosis. Lumasiran, an investigational 
RNAi therapeutic suppresses hepatic glycolate oxidase, decreases the conversion of 
glycolate to glyoxylate, and results in reduced oxalate production.
Methods: ALN-GO1-001 is a randomized, placebo-controlled, single-blind, 
multicenter trial, evaluating lumasiran in patients with PH1 ≥6 years of age with urinary 
oxalate (UOx) ≥0.7 mmol/1.73m2/day and eGFR >45 mL/min/1.73m2. One of four patients 
in each dosing cohort was randomized to placebo prior to subcutaneous lumasiran. Cohorts 
1 & 2 received 3 monthly doses of 1 mg/kg or 3 mg/kg, respectively; cohort 3 received 
2 quarterly doses of 3 mg/kg lumasiran. An additional 4 patients received lumasiran in 
expansions of each of the first 2 cohorts. The primary endpoint is safety; secondary 
endpoints include change in 24-hour UOx from baseline. Eligible patients may continue 
dosing in the open-label extension (OLE) study.
Results: Patients in cohorts 1-3 had a mean age of 13.1 years (range 6-43), 7 (58%) 
female, and baseline UOx was 1.58 mmol/1.73m2/day (range 0.63-2.37). Lumasiran has 
demonstrated acceptable preliminary safety and tolerability with no treatment related 
serious adverse events or discontinuations; majority of adverse events were mild/moderate 
and unrelated to study drug. All patients treated with lumasiran in cohorts 1-3 experienced 
UOx lowering below 0.7 mmol/1.73m2/day, with a mean maximal decrease of 65%. Data 
available 85 days after initial dosing in the first 3 cohorts (n=9) showed a mean UOx 
reduction of 63% (range 49-73%). Data from patients in all cohorts (n=20), including 
quarterly dosing, expansions and OLE will be presented.
Conclusions: Preliminary results demonstrate acceptable safety data and lowering of 
UOx in patients with PH1 supporting the continued development of lumasiran as a potential 
therapeutic to alleviate pathologic overproduction and consequences of excess oxalate in 
this devastating disease.
Funding: Commercial Support - Alnylam Pharmaceuticals
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Endogenous Pentraxin 3 Inhibits Nephrocalcinosis and Protects from 
Hyperoxaluria-Induced CKD
Julian A. Marschner,1 Shrikant R. Mulay,1 Lidia Anguiano,1 Stefanie Steiger,1 
Antonio Inforzato,2 Hans J. Anders.1 1Medizinische Klinik und Poliklinik IV, 
Klinikum der Universität München, LMU München, Munich, Germany; 
2Humanitas Clinical and Research Center, Pieve Emanuele, Italy.
Background: Patients with primary hyperoxaluria type 1 have an elevated oxalate 
production leading to intrarenal calcium oxalate crystal deposition (nephrocalcinosis) and 
CKD progressing to ESRD. Pentraxin 3 (PTX3) exerts a variety of regulatory functions 
in acute and chronic tissue inflammation. Also, PTX3 acts as an opsonin for a variety of 
pathogens and endogenous particles. We hypothesized, that PTX3 would exhibit opsonin-
like functions on calcium oxalate crystals and inhibiting crystal growth and nephrocalcinosis.
Methods: Direct effects of PTX3 on calcium oxalate crystals were investigated in 
chemico using standard imaging techniques. To study the role of PTX3 in vivo, we used 
a murine model of hyperoxaluria induced nephrocalcinosis where Ptx3-deficient B6;129- 
mice or their PTX3-competent littermates were fed with a high-oxalate diet for 21 days. 
PTX3 expression was assessed by Western blot and immunohistochemistry. Phenotype 
analysis included histochemistry, flow cytometry and GFR measurement.
Results: Adding PTX3 to supersaturated calcium and oxalate in-chemico dose-
dependently inhibited crystal growth, while an isomolar albumin control did not (A). 
PTX3 protein was undetectable in the urine of healthy wildtype mice but increased within 
3 weeks of oxalate feeding. Immunhistochemistry of kidney sections indicated that urinary 
PTX3 originated from tubular epithelial cells. Testing the role of PTX3 in vivo we induced 
hyperoxaluria in Ptx3-deficient mice and their wildtype littermates. In this particular 
background, lack of PTX3 induced profound nephrocalcinosis associated with interstitial 
inflammation and fibrosis as well as a linear decline in GFR, whereas Ptx3+/+ littermates 
where protected (B-D).
Conclusions: Thus, PTX3 is an endogenous inhibitor of calcium oxalate crystallization 
even in profound hyperoxaluria. It will be interesting to look into the precise mechanism 
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of action and to develop therapeutic strategies to exploit this novel found function of PTX3 
to prevent nephrocalcinosis in primary hyperoxaluria, a disease with currently very few 
treatment options.
Funding: Government Support - Non-U.S.
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Cardiac Oxalosis in Primary Hyperoxaluria
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Background: Primary hyperoxaluria (PH) is an inherited disease characterized by 
increased hepatic production of oxalate (ox). Renal excretion of excess ox causes kidney 
stones, nephrocalcinosis, and renal damage. As GFR declines plasma ox (Pox) increases 
and can cause systemic calcium oxalate deposits (oxalosis). Cardiac involvement results 
in conduction abnormalities and infiltrative cardiomyopathy. However, epidemiology of 
cardiac oxalosis in PH is not well defined.
Methods: The PH registry of the Rare Kidney Stone Consortium was queried for 
information regarding cardiac function. Among 128 PH subjects with Pox available prior 
to transplant, 101 had type 1 (PH1), 14 PH2, and 13 PH3. ECG studies (n=433 from 52 
subjects), echocardiograms (n= 92 from 40), Pox (nl < 1.6 umol/L), and urine ox (Uox, nl < 
0.46 mmol/24 hrs) at initial evaluation and during follow-up were analyzed. E/e’ was used 
for diastolic function (nl <13). LV strain nl < -18%.
Results: At diagnosis mean (median) age was 18.6 (11.5) yrs, eGFR 75 (65) ml/
min/1.73m2, urine oxalate (Uox) 1.9 (1.7) mmol/1.73m2/day, and Pox 21.3 (6.1) umol/L. At 
diagnosis 1/52 ECGs were abnormal, with atrial fibrillation (afib) in a subject with eGFR 
66. Subjects were followed for 14.1 (11.4) yrs. Pox increased as eGFR declined (p<0.0001) 
as expected. Overall 14/52 PH subjects had 48 abnormal ECGs showing 1st degree or
variable AV block (n=6), bundle branch block (3), afib (5), and LVH (4). Abnormal ECG 
studies did not differ across eGFR groups (p=0.22). Table 1 shows clinical characteristics
and echo at last followup.
Conclusions: Using standard clinical tests, most PH subjects demonstrate good cardiac 
function, even at eGFR < 30 when Pox increases significantly. Whether more sensitive 
monitoring tools will demonstrate earlier manifestions of cardiac oxalosis remains to be 
established.
Funding: NIDDK Support, Commercial Support - OxThera, Private Foundation 
Support
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Genetic Diseases of the Kidneys: Non-Cystic - I
Blood Pressure and Biological Phenotype in Healthy-Carrier Relatives of 
Patients with Gitelman Syndrome
Rosa Vargas-Poussou,1 Laurence Dubourg,3 Marion Vallet,8 Julien Allard,2 Jean-
philippe Haymann,6 Renaud De la faille,10 Stephanie Baron,9 Pascal Houillier,7 
Ivan A. Tack,4 Anne Blanchard.5 1AP-HP Hôpital Européen Georges Pompidou, 
Paris, France; 2University Hospital Limoges, LImoges, France; 3hospices civils 
de Lyon -Université Claude Bernard Lyon 1-INSERM U 820, LYON, France; 
4Universite Paul SABATIER Toulouse III/Service Explorations Fonctionnelles 
Physiologiques, Toulouse Cedex 9, France; 5APHP, HEGP, Paris, France; 
6Sorbonne Universit?, INSERM, UMR_S 1155, AP-HP, H?pital Tenon, Paris, 
France, Paris, France; 7Paris Descartes University, Paris, France; 8Hôpital 
Rangueil, Toulouse, France; 9APHP Georges Pompidou european Hospital, 
PARIS, France; 10Hopital Pellegrin, Bordeaux, France.
Background: Gitelman syndrome (GS) is the most frequent salt-losing tubulopathy 
caused by loss of function mutations in the SLC12A3 gene, encoding for the thiazide-
sensitive NaCl cotransporter. Depending on the country, 1 to 4 % of the population is 
heterozygous carrier of pathogenic variant. Consequence of this status remains debated. 
The aim of this study was to evaluate the impact of SLC12A3 heterozygous mutations on 
blood pressure (primary outcome) and on electrolyte and glucose homeostasis.
Methods: This cross-sectional study included 239 subjects, both sex, 18-75 years 
old: 81 heterozygous carriers (HC) of class 4-5 variants (ACMG 2015), 81 non-carrier 
normotensive subjects (NC) matched to HC on age, sex and BMI and 77 patients with 
genetically proven GS. Home blood pressure (HBP) measurements were done the 
3 consecutive days before admission in hospital for blood and urine sampling and oral 
glucose tolerance test (OGTT).
Results: As compared to NC, HC had similar HBP, blood and urine concentrations of 
electrolytes (Na, K, Cl, tCO2 Mg, Ca), and values of PTH, vitamin D, renin, aldosterone and 
markers of bone remodeling as well as response to OGTT (all p>0.05, paired t test NC vs 
HC). Systolic BP increased similarly with age in both groups. GS had renal hypokalemia, 
hypomagnesemia and low urinary calcium excretion. Ten patients had known hypertension. 
GS had however lower SBP than the other groups (mean difference 4.5 (CI95 1.18; 7.78), p 
0.0087 and 4.1 mmHg (CI95 0.20; 8.07), p 0.0410; NN and HC vs GS) and higher cardiac 
frequency (mean difference 4.5 (CI95 -7.4; -1.5), p 0.0040 and -3.7 bpm (CI95 -7.0; -0.5), 
p 0.0271; NC and HC vs GS). The increase in SBP with age was blunted in GS patients. 
GS had significant higher basal glycaemia and insulin concentrations and HOMA-IR 
(homeostatic model assessment for insulin resistance) than the other groups independently 
of BMI. OGTT showed a prediabetes status in 14% of GS patients compared with 4 and 
5% in HC and NC.
Conclusions: In conclusion, we found no difference between heterozygous carriers 
and age- and sex-paired healthy controls. GS patients have a risk to develop type 2 diabetes 
pointing out the importance of body weight control in GS patients.
Funding: Government Support - Non-U.S.
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Markers of Potassium Homeostasis and Quality of Life in Salt Losing 
Tubulopathies
Zeljko Kikic, Roman Reindl-Schwaighofer, Marija Bojic, Elisabeth Darmann. 
Medical University of Vienna, Vienna, Austria.
Background: Gitelman and Barter Syndrome are the most frequent genetically 
inherited salt losing tubulopathies (SLT) with limited treatment options and quality of 
life (QOL) is reduced. Treatment options include supplementation of potassium (K+) and 
magnesium, potassium sparing diuretics. However evidence from randomized controlled 
trials indicate low efficacy of current treatments in terms of increasing K+. Morover K+ 
may not reflect the magnitude of the concommittant secondary hyperaldosteronism in 
those patients. Optimal endpoints for treatment trials should include QOL however little 
is known of optimal clinical cut-offs of laboratory values and their relation in SLT. The 
trans-tubular potassium gradient (TTKG) has been shown to be an accurate surrogate for 
hyperaldosteronism and of excellent use in other entities related to hyperaldosteronism like 
liver cirrhosis.
Methods: In this prospective cross-sectional study we included 11 patients with SLT. 
We measured laboratory parameters (K+, Mg++, Ca++, TTKG, Aldosteron) and their 
relation with QOL assessed by the RAND SF-36. The primary hypothesis was that TTKG 
may reflect QOL more accurately than K+ and serve as an end-point in future treatment 
trials. Secondary endpoints were the presence of cardiac arrhythmia in 24h ECG and cardiac 
abnormalities via ultrasound (US).
Results: The cohort consisted of mainly females with a median age of 29 years. The 
median K+ was 3.3 mmol/l and median TTKG 9.5. While there was a positive correlation 
of K+ and TTKG, we did not observe a significant correlation of TTKG with serum 
aldosterone. Comparing QOL domains we observed that TTKG showed a trend for better 
physical functioning while K+ was significantly related to emotional wellbeing and trend 
for energy and general health. Aldosterone was significantly related to role limitations 
emotional and physical. Urinary potassium with a threshold >20 mmol/l was inversely 
related with energy/fatigue and general health and a trend for emotional wellbeing while 
TTKG <10 or K+>3 mmol/l were not related to QOL. No relevant abnormalities were 
observed in either 24h ECG or cardiac US.
Conclusions: TTKG is not a suitable marker for hyperaldosteronism in SLT and K+ 
and TTKG are not sufficient endpoints for treatment trials for SLT in relation to QOL. 
Future treatment trials in SLT should include QOL assessment as well urinary parameters.
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MAP17 and SGLT2 Interaction in Cellular Models and Human Kidney 
Specimen
Joaquim T. Calado,1,2 Ana Santos,4 Ines Aires,4 Jose S. Ramalho,3 
Fernando E. Nolasco.4,1 ToxOmics 1NOVA Medical School; Faculdade de 
Ciencias Medicas, Lisbon, Portugal; 2Nephrology, Centro Hospitalar Lisboa 
Central, Lisbon, Portugal; 3NOVA Medical School, Lisbon, Portugal; 4Hospital 
Curry Cabral, Lisbon, Portugal.
Background: Mutations in SGLT2, a Na/coupled glucose transporter of the early 
proximal tubule, are responsible for Familial Renal Glucosuria (FRG), and SGLT2 
pharmacological inhibition has become a promising new therapy in type 2 Diabetes 
Mellitus. MAP17 was recently identified by means of expression cloning as an accessory 
protein for SGLT2 activity and mutations in MAP17 coding gene were found in a SGLT2 
negative FRG individual. However, the way MAP17 promotes SGLT2 activity is unknown. 
In this work we investigated the hypothesis that MAP17 is a binding partner for SGLT2 and 
that both proteins interact and dimerize.
Methods: We engineered a N-terminal V5 tagged SGLT2 plasmid and coexpressed 
together with a HA tagged MAP17 construct in HEK293 cells. We assayed the interaction 
of both proteins in vitro by immunofluorescence and immunochemistry techniques. In 
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addition, we performed histological examination and immunofluorescence observations in 
human normal kidney sections to evaluate MAP17 and SGLT2 expression in the kidney.
Results: In HEK293 cells cotransfected with both constructs, MAP17 and SGLT2 
were shown to colocalize in a perinuclear and cytoplasmic vesicular staining. In addition, 
MAP17 coimmunoprecipitated with anti V5 goat antibody only in the presence of 
V5-SGLT2 construct (fig.1). Finally, SGLT2 and MAP17 largely overlap in their abundance 
at the brush border of proximal tubule epithelial cells (fig. 2).
Conclusions: We have shown that SGLT2 and MAP17, when overexpressed, interact 
in vitro and, likewise, under constitutive expression in the kidney, they also overlap their 
abundance in the proximal tubule. This interaction provides the biochemical foundation for 
the physiological observation that MAP17 is a necessary activator of SGLT2.
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Renal Ablation of GLUT2 Leads to Intracellular Glycogen Accumulation 
and Recapitulates the Fanconi Bickel Syndrome
Anna Iervolino,1 Luigi R. De la motte,3 Federica Petrillo,1 Federica Prosperi,1 
Vincenzo Costanzo,2 Giovambattista Capasso,3 Francesco Trepiccione.3 
1Biogem, Ariano Irpino, Italy; 2University of Bologna, Bologna, Italy; 
3University of Campania Luigi Vanvitelli, Napoli, Italy.
Background: Fanconi-Bickel syndrome, also known as glycogenosis type XI, is 
characterized by hepatic glycogen accumulation and proximal renal tubular dysfunction. 
Patients mainly suffer for a typical renal Fanconi syndrome associated with fasting 
hypoglycaemia. Currently, there is no causative therapy beside fluid and electrolyte 
supplementation. Loss of function mutations of SLC2A2, encoding for GLUT2, causes 
FBS. Impairment of GLUT2 alters glucose metabolism in hepatocytes and increases 
glycogen accumulation. Since the cells of the proximal tubules share a similar glucose 
metabolism as hepatocytes, a similar mechanism could be hypothesized, but no evidences 
so far has been provided
Methods: In order to generate an experimental model of FBS, we selectively knock-
out GLUT2 expression in PAX8 expressing cells by mean of a Cre-Lox recombination 
strategy. This approach results in an efficient ablation of GLUT2 in the renal cortex
Results: GLUT2 cKO mice recapitulate the renal phenotype of FBS patients. They 
present with normo-glycaemic glycosuria and no signs of altered glucose metabolism 
when challenged with a glucose load. Glycosuria decreases, but is still detectable after 
fasting. GLUT2 cKO mice present an osmotic driven polyuria that improves by reducing 
theosmotic load. cKO mice present low molecular weight proteinuria and phosphaturia. 
This latter is sustained by a downregulation of Napi2a abundance in the cortex of GLUT2 
cKO mice. When challenged with a sodium bicarbonate load, at serum level of bicarbonate 
equal as control mice, they excrete a double amount of bicarbonate, showing that GLUT2 
ablation lead to proximal renal tubular acidosis. At histology, the proximal tubule cells 
appear hypertrophic compared with littermate controls. Quantification of renal cortical 
glycogen content shows a three fold increase abundance in cKO mice, suggesting that 
GLUT2 ablation alters significantly the intracellular glucose metabolism
Conclusions: We generate a mouse model cKO for GLUT2 recapitulating FBS. We 
show that GLUT2 is crucial for intracellular glucose metabolism in the proximal tubule 
cells since its ablation leads to a severe glycogen accumulation and loos of function. This 
model is suitable for testing novel pharmacologic approach to rescue FBS
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A Unique Mutation in the MODY1 Gene HNF4A Causes Fanconi 
Syndrome by Shifting Lipid Catabolism to Anabolism
Valentina Marchesin,1,2 Albert Perez-Marti,1,2 Matias Simons.1,2 1Institut 
Imagine, Paris, France; 2Université Paris-Descartes, Paris, France.
Background: Renal proximal tubular cells (PTCs) have the task to reabsorb most of 
water, solutes and proteins filtered by the glomerulus. To cope with their high energy demand, 
PTCs exclusively rely on fatty acid oxidation. However, lipid metabolism needs to be finely 
regulated in this tissue as recent evidence has suggested that renal lipid accumulation and 
lipotoxicity may lead to kidney dysfunction. Here, we focus on the function of the nuclear 
hormone receptor HNF4A whose mutations cause MODY1, a monogenic type of diabetes 
in humans. Only one mutation (p.R85W) in the DNA binding domain leads to additional 
PTC dysfunction (also known as Fanconi syndrome), but the reason for this is unclear.
Methods: To address the role of HNF4A in lipid metabolism and to illuminate the 
pathogenetic mechanisms underlying the R85W mutation, we made use of the Drosophila 
model. In particular, we utilized fly nephrocytes as a simplified cell model for PTCs.
Results: We show that HNF4A controls a genetic program that regulates lipid 
metabolism in nephrocytes. Silencing HNF4A causes an increase in lipid droplet size 
and number, while the overexpression of HNF4A causes depletion of lipid stores through 
brummer/ATGL-mediated neutral lipolysis. Interestingly, very high expression levels of 
HNF4A or the expression of the R85W mutation behave in a dominant-negative fashion 
by triggering a shift from lipid catabolism to lipid anabolism. In addition to a lipolysis 
block, this involves the increased DGAT1-dependent formation of lipid droplets. In both 
conditions, the lack of lipolysis leads to mitochondrial depolarization, possibly due to the 
decreased availability of free fatty acids and lack of ATP production. The mitochondrial 
damage is accompanied by the accumulation of ER fragmentation, p62- and PDI-positive 
protein aggregates and a strong induction of autophagy. Collectively, these organellar 
injuries eventually lead to nephrocyte loss and shorten the life span of flies.
Conclusions: Altogether, our data describe a novel pathogenetic mechanism for 
Fanconi syndrome with important implications for the general understanding of lipid 
metabolism in PTCs. Moreover, targeting HNF4A or one of its downstream partners could 
represent a very useful therapeutic strategy in situations with lipid overload in the PTCs.
Funding: Government Support - Non-U.S.
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Congenital Renal Glycosuria Is Associated with Healthier Weight at 
Adolescence: Nationwide Cross Sectional Study of 2.38 Million Examinees
Adi Leiba.1,2 1Division of Nephrology and Hypertension, Assuta Ashdod 
Hospital, Ben Gurion University of the Negev, Ashdod, Israel; 2Medicine and 
Medical Education, Mount Auburn Hospital, Harvard Medical School, 
Cambridge, MA.
Background: Glucose filtered in the glomeruli is normally reabsorbed by the sodium 
coupled glucose transporters (SGLTs), mostly the SGLT2, located in the renal tubules. 
Mutations in the genes coding for these transporters were shown to cause renal glycosuria. 
It was shown recently in various studies that pharmacological inhibition of SGLT2 causing 
renal glycosuria is an effective treatment for diabetic patients. Among the desirable effects 
of these medications is weight lost and reduction of blood pressure. The aim of the current 
study is to investigate whether adolescents with renal glycosuria are less likely to be 
overweight or obese
Methods: Medical and socio-demographic data on 2,385,093 adolescents examined 
for medical fitness prior to military service from 1977 to 2016 were retrieved from the 
Israeli Defense Forces conscription center database. We conducted a cross sectional study 
to evaluate the association between renal glycosucria diagnosed in the conscription center 
and the overweight (85-95 BMI percentiles) and obesity (>95 bmi percentiles). Multinomial 
regression model were used.
Results: The final study cohort comprised of 2,388,163 conscripts of whom 1069 
(0.045%) were assigned with numerical code meaning renal glycosuria not related to 
diabetes. The adjusted OR for overweight and obesity was 0.69 (95% CI, 0.54-0.89) and 
0.60 (95% CI, 0.42-0.85), respectively.
Conclusions: Congenital Glycosuria may is associated with healthier metabolic profile, 
specifically less overweight and obesity, and this effect is already seen at adolescence
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Genetic and Functional Characterization of PHEX Gene Variants in 42 
Children with X-Linked Hypophosphatemic Rickets
Aihua Zhang, Bixia Zheng, Chunli Wang, Yue Zhang, Guixia Ding, 
Songming Huang, Zhanjun Jia. Children’s Hospital of Nanjing Medical 
University, Nanjing, China.
Background: X-linked hypophosphatemia, a disorder of renal phosphate wasting and 
the most common heritable form of rickets, is caused by loss-of-function mutations in the 
gene encoding phosphate-regulating endopeptidase homolog (PHEX). The aim of this study 
was to explore the molecular basis of 42 children with HR in the Chinese population.
Methods: All patients were analyzed for the PHEX gene by direct sequencing. 
When no mutations were detected in PHEX gene, multiplex ligation-dependent probe 
amplification (MLPA) analysis was performed. PHEX non-truncating mutation and 
two truncated mutations were characterized in vitro by assessing their effects on PHEX 
expression, subcellular localization and glycosylation pattern.
Results: Among 42 patients, 40 patients (95%) harbored mutations in the PHEX gene. 
In particular, we detected 35 different mutations, including eleven indel mutations including 
nine frameshift mutations resulting from small deletions or insertions and one 3bp deletion 
mutation (31.4%), seven missense (20%), seven splice sites mutations(20%), five nonsense 
(14.2%), and five exonic deletion (14.2%). Among these mutations, 21 mutations have not 
been previously described in the literature or entered in PHEXdb and HGMD. Clinical 
presentation and disease severity did not show an evident correlation between the truncating 
and non-truncating mutation type. Like the nonsense mutaion R567X and Q714X, five of 
the six non-truncating mutation detected in our cohort also led to retention of the PHEX 
protein in endoplasmic reticulum, in an immature form, as determined by glycosylation 
pattern and proteasomal degradation analysis and immunofluorescence.
Conclusions: Our findings expand the mutation spectrum of PHEX, confirm that 
mutations in PHEX are the most frequent cause of HR, and truncating mutations is the 
most often mutation type in Chinese patients. Our clinical and experimental evidence also 
showed no correlation between the degree of disease severity and the PHEX genotypes.
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Human Gout Risk Variant ABCG2 Q141K Results in Profound Hyperuri-
cemia and Significant Changes to Kidney Function in a New Mouse Model
Owen M. Woodward, Mirajul H. Kazi, Eryn E. Dixon, Raychel M. Lewis. 
University of Maryland School of Medicine, Baltimore, MD.
Background: Gout is the most common inflammatory arthritic disease and is a 
consequence of having elevated circulating urate (UA) levels (hyperuricemia). GWAS 
studies have identified a number of key urate transporter genes that contribute to gout 
risk and are expressed in the kidney and the intestines. Yet recent work from others has 
shown individuals carrying the most common gout risk variant, Q141K ABCG2, have no 
measureable difference in their renal fractional excretion of urate (FEUA). These data beg 
the question of whether or not ABCG2 has a role in the renal urate excretion pathway.
Methods: We have made a new mouse knock-in model of the human gout risk variant, 
Q141K ABCG2 (in mice, Q140K) on a C57BL6J mouse background using CRISPR Cas9 
gene editing techniques, and have used biochemical, Immunofluorescence, and renal 
physiological measurements to described the renal phenotypes of a human risk variant 
carried by 500 million individuals world-wide.
Results: We first confirmed and localized the ABCG2 protein in the mouse and human 
tubule, confirming unambiguously that ABCG2 expression in apical membrane of the 
human proximal tubule is robust. The Q140K ABCG2 mutant male mice proved to be 
profoundly hyperuricemic, and although the mutant mice displayed both a slight decrease 
in renal protein abundance and a decrease in FEUA, it was significantly less than observed 
in the intestines, with female mice showing no defect at all. In addition to the decrease 
in FEUA, the male mutant mice exhibited other hallmarks of declining renal function 
including, reduced eGFR, signs of metabolic acidosis, impaired ammonium secretion, and 
evidence of more wide spread metabolic alterations, including increased blood glucose and 
insulin levels.
Conclusions: Our new mouse model of the common human gout risk variant, Q141K 
ABCG2, shows that a single loss of function point mutation in a single urate transporter has 
significant phenotypic effects on mammalian physiology, and this work provides evidence 
that alterations in urate homeostasis alone can effect kidney function, consistent with the 
hypothesized causal role of urate in renal and metabolic diseases.
Funding: NIDDK Support, Private Foundation Support
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Urinary MicroRNAs in Fabry Disease Patients with Mild Nephropathy
Sebastian P. Jaurretche,1,2 Graciela Venera,4 Norberto Ricardo Antongiovanni,3 
Fernando J. Perretta,5 German Perez.6 1Centro de Neurociencias Los 
Manantiales, Rosario, Argentina; 2Biophysics and Human Physiology, Instituto 
Universitario Italiano de Rosario, Rosario, Argentina; 3Nephrology, Clínica de 
Nefrología de Pergamino, Pergamino, Argentina; 4Instituto universitario 
Italiano de Rosario, Rosario, Argentina; 5Fresenius Medical Care, Escobar, 
Argentina; 6Gammalab, Rosario, Argentina.
Background: Analyze the urinary excretion profile of microRNAs (UEPmiR) regulated 
by TGF-β-SMAD. Fibrotic: miR-21;miR-192;miR-433. Anti Fibrotic: miR-29;miR-200)
Methods: microRNAs extraction from urinary cell pellet was achieved. RNAU6 was 
endogenous control. Relative miR expression levels were calculated with ΔΔCt method. 
Dependent variable: UEPmiR. Independent variables: age, gender, α-galA activity, 
genotype, CKD stage and proteinuria.
Results: Healthy subjets: 8p (4m/4f); age: 25.9±15.2ys; eGFR: 120.7±18.7 ml/
min/1.73m2. All nonalbuminuric patients. FD population: 24p (7m/17f); age: 23.7±17.3ys; 
decreased α-galA: 100% males/13.3% females; eGFR: 137.3±37.2 ml/min/1.73m2; 
microalbuminuria: 16.7% (1/7) males/35.3% (6/17) females. There were no statistically 
significant differences in age (p=0.741), eGFR (p= 0.239) and ACR (p=0.204) between 
healthy subjects and FD patients. microRNA expression in FD patients according to age, 
gender, genotype, α-galA activity, eGFR, and ACR: significant differences were found 
between sexes and normal or decreased α-galA only in miR-29 (p=0.041;0.041) and 
miR-200 (p=0.048;0.048), respectively. FD patients with normal α-galA, without clinical 
criteria to start enzyme replacement therapy (ERT)(A1 group), did not present differences 
in UEPmiR compared to healthy subjects. FD patients with more severe phenotype and 
received ERT (A2 group) did not present differences in UEPmiR compared with healthy 
subjects neither A1 group. FD patients with normal α-galA and without clinical criteria to 
start ERT (B1 group), presented a UEPmiR indicative of renal fibrosis (decrease of miR-
29 and miR-200). FD patients with decreased α-galA and clinical criteria to start ERT had 
a different UEPmiR than B1 group, finding that miR-29, in B2 group, behaves similar to 
healthy subjects.
Conclusions: FD males have a profibrotic UEPmiR. UEPmiR was similar between 
healthy subjects and two groups of FD patients, i) patients with mild FD phenotype and 
normal α-galA activity and ii) patients with normal α-galA but with a more severe phenotype 
receiving ERT. In FD patients with low α-galA activity without ERT, a profibrotic UEPmiR 
was found; compared with FD patients with low α-galA activity and severe phenotype with 
ERT, an increase of miR-29 was observed. A probable effect of ERT should be evaluated 
in longitudinal studies.
Funding: Private Foundation Support
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The Prevalence of Fabry Disease in Patients Undergoing Hemodialysis in 
the Northernmost Region in Japan
Naoki Nakagawa. Asahikawa Medical University, Asahikawa, Japan.
Background: Fabry disease, an X-linked, progressive and life-threatening genetic 
disease, is caused by abnormalities in the α-galactosidase A (α-Gal A) gene. Several studies 
in Japan reported 2-3% of males suffering from left ventricular hypertrophy were affected 
with Fabry disease, however, the prevalence of Fabry disease in patients undergoing 
hemodialysis is still unknown.
Methods: In this prospective, multicenter study, we screened 1,476 patients receiving 
dialysis from multicenter of the northernmost prefecture in Japan. Patients with a low α-Gal 
A activity were assessed using dried blood spots on filter paper, and a genetic study of the 
α-Gal A gene was performed for these patients.
Results: A total of 1,476 patients (66% male, median age 67.0 years) underwent 
screening and 52 had low α-Gal A activity; of these, two males had α-Gal A mutations. 
A 64-year-old man had the genetic mutation of p.M187V in exon 4. Another 55-year-old 
man had the genetic mutation of c.908-928del21 in exon 7, which is a new mutation not 
described before in the literature, but potentially pathogenic. Both patients had severe left 
ventricular hypertrophy and had diagnosed as having chronic glomerulonephritis without 
renal biopsy. The prevalence of Fabry disease is 0.14% in patients undergoing hemodialysis 
in the northernmost region in Japan.
Conclusions: Dried blood spot screening was considered as a simple and effective 
method for detecting the underlying patients with Fabry disease. Clinicians should be aware 
of Fabry disease as a potential cause of hemodialysis, especially in hemodialysis patients 
with severe left ventricular hypertrophy without renal biopsy.
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Bedside Assessment of the Microcirculation in Patients with Fabry Disease
Anna Bertram,1 Lisa K. Peede,1 Natalia Goldenberg,2 Jessica K. Kaufeld,3 
Hermann G. Haller.1 1Hannover Medical School, Hannover, Germany; 
2Medizinische Hochschule Hannover, Hannover, Germany; 3Medical School of 
Hannover, Hannover, Germany.
Background: Fabry disease is a hereditary lysosomal storage disease with a loss of 
α-galaktosidase A activity, in which accumulation of glycosphingolipids leads to cellular 
damage in endothelial cells and other cell types. The endothelial surface layer (ESL) 
with the glycocalyx is important for endothelial cell function. We, therefore, assessed 
the ESL as well as circulating components of the ESL in Fabry patients. Visualization 
of the microcirculation can lead to a better understanding of its contribution to the 
pathophysiological changes in Fabry disease.
Methods: 29 patients with Fabry disease and 33 healthy age- and gender-matched 
controls were analysed by intravital microscopy with the GlycoCheck™ technology (Micro 
Vascular Health Solutions) to measure ESL thickness (perfused boundary region), red blood 
cell filling velocity, and microvascular density. Circulating ESL components (syndecan-4, 
thrombomodulin), cytokines (MCP-1), and regulatory molecules (ADAM-17, VEGF-R1) 
were measured in plasma using ELISA. Patients were clinically characterized by organ 
involvement (heart, kidney, brain).
Results: Perfused boundary region was significantly decreased in patients with Fabry 
disease (1.96 ± 0.28, vs. 2.36 ± 0.27, p = 0.001). Circulating markers of the ESL were 
not different between groups. Microvascular density was significantly lower in Fabry 
patients compared to controls (median 284.50 vs. 580.83 μm/mm2, p = 0.001). The 
alterations in microcirculation were independent of the degree of organ involvement. 
MCP-1 concentration was significantly increased in Fabry patients (346.19 ± 91.82 pg/ml 
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vs. 288.13 ± 95.22 pg/ml, p = 0.018) which was pronounced in patients with cardiac 
involvement.
Conclusions: Our data suggest an increase in ESL density, and no change in glycocalyx 
breakdown in patients with Fabry disease. In addition, a rarefication of microvessels was 
observed. Our findings suggest pathophysiological changes in the microvascular structure 
of patients with Fabry disease. The enhanced inflammation is not directly related to the 
microvascular changes.
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Fabry Nephropathy: Transcriptome Sequencing of Microdissected Renal 
Compartments from Archival Kidney Biopsies at Baseline, and After 5 
and 10 Years of Enzyme Replacement Therapy
Oystein Eikrem,1,2 Philipp Strauss,1 Miroslav Sekulic,3 Camilla Tøndel,4 
Arnar Flatberg,6 Rannveig Skrunes,4 Lea Landolt,1 Janka Babickova,1 
Sabine Leh,4,1 Andreas Scherer,5 Einar Svarstad,4,1 Hans-Peter Marti.1,2 
1Department of Clinical Medicine, University of Bergen, Bergen, Norway; 
2Department of Medicine, Haukeland University Hospital, Bergen, Norway; 
3Brigham and Women’s Hospital, Boston, MA; 4Department of Pediatrics, 
Haukeland University Hospital, Bergen, Norway; 5Spheromics, Kontiolahti, 
Finland; 6Department of Clinical and Molecular Medicine, Norwegian 
University of Science and Technology, Trondheim, Norway.
Background: The present study exploited next generation mRNA sequencing from 
kidney biopsies of Fabry patients with a classical phenotype
Methods: Kidney biopsies (n=15) were obtained with a 16G needle from Fabry 
patients (n=5) from 2003-2014. Median patient age at baseline biopsy was 18 years (7-30 y). 
Control biopsies from peri-tumorous tissue of renal cancer patients (n=32). Formalin-fixed, 
paraffin-embedded (FFPE) kidney biopsies were obtained: a) baseline prior to enzyme 
replacement therapy (ERT; n=5), b) after 5y of ERT (n=5), and c) 8-10y of ERT (n=5). Total 
RNA was extracted from laser-captured, microdissected glomerular, proximal tubular, distal 
tubular and arterial cross-sections (High Pure FFPET RNA extraction kit; Roche). cDNA 
libraries were prepared using the TruSeq RNA Access Library Prep Kit® (Illumina) and 
sequenced on an Illumina HiSeq 2500/HiSeq 4000 instrument
Results: We present the results of the first 42 samples of a larger ongoing series. 
Several hundred mRNAs were differentially expressed (p-value <0.05, abs. fold change >2) 
between normal controls and Fabry baseline samples, and between the baseline samples 
and the two different treatment time points. The samples segregated completely within their 
own compartment (Fig. 1) in principle component analysis. Gene Set Enrichment Analysis 
in the glomerular compartment demonstrated enriched gene sets of extracellular matrix, 
EMT, fibrosis, and immune response in the 10 year biopsies compared to baseline (p<0.05) 
despite ERT. Several key regulatory inflammatory genes were found to be upregulated in 
all compartments
Conclusions: NGS is feasible in archival Fabry disease kidney biopsies, expanding the 
potential utility of kidney biopsies to detect markers of Fabry nephropathy, chronic kidney 
disease and therapeutic targets
Funding: Commercial Support - Sanofi Genzyme, Shire, Government Support - Non-
U.S.
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Implications of Renal Impairment on Dosing of Delayed-Release 
Cysteamine Bitartrate
Craig B. Langman,1 Saba Sile,3 Dennis M. Fisher.2 1Feinberg School of Medicine, 
Northwestern University, Chicago, IL; 2P Less Than, San Francisco, CA; 
3Clinical Development, Horizon Pharma Inc, Lake Forest, IL.
Background: Delayed Release Cysteamine Bitartrate(DRCys) is used to treat 
nephropathic cystinosis (NC) in order to prolong native kidney function and ameliorate 
other systemic effects of NC. A biomarker, WBC cystine levels (WBCCys) guides optimal 
cystine reduction. To date, there are no studies on the effects of impaired renal function, 
including hemodialysis (HD) on DRCys elimination, and Study RP103-16001 was designed 
to address these missing data.
Methods: Subjects (all without NC) with mild, moderate, or severe renal impairment, 
or ESRD requiring hemodialysis, (HD) (8 each; NKF classification based on eGFR) and 
32 matched healthy controls were studied. HD subjects received a single 200 mg dose of 
DRCys twice: 3hr before or 2hr after HD on different days. All remaining subjects received 
one 200 mg DRCys dose. Blood was sampled for 24h after each dose to detemine cysteamine 
concentrations. Pharmacokinetic analysis was conducted using mixed-effects (population) 
methods with NONMEM software (ICON Development Solutions, Hanover MD).
Results: Table 1 reports drug clearance relative to healthy controls. For subjects with 
renal impairment except those on maintenance HD, the effect on DRCys clearance is small, 
within ±20% of the values in the controls. In HD subjects, clearance fluctuates between 
successive HD treatments, being maximal post HD and then decreasing.
Conclusions: Although increasing renal impairment is associated with a decrease 
in the apparent clearance of DRCys, the magnitude is relatively small, and unlikely to 
necessitate dose reduction However, the decrease in clearance between HD sessions may 
cause DRCys efficacy to vary over that time frame. Therefore, biomarker WBCCys results 
should be interpreted in the context of when patients had the WBCCys sampled relative to 
HD. Mechanisms for HD-associated clearance changes are unknown but may involve HD 
improving CYP function.
Funding: Commercial Support - Horizon Pharmaceuticals Inc.
Factors for apparent clearance of DRCys related to residual renal function (eGFR) 
compared to healthy controls
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MAGED2 (Re)wires G-Protein Coupled Receptor Signaling in Renal 
Collecting Duct Cells
Malte P. Bartram,1 Björn Reusch,3 Bernhard Schermer,1,2 Thomas Benzing,1,2 
Bodo B. Beck,3 Markus M. Rinschen.1,2 1University Hospital Cologne, Cologne, 
Germany; 2CECAD, Cologne, Germany; 3University of Cologne Medical 
Center, Cologne, Germany.
Background: Recently mutations in MAGED2 were identified as a genetic cause 
of very severe X-linked polyhydramnios and transient antenatal Bartter syndrome. Since 
MAGED2 does not code for a transmembrane protein, the molecular mechanisms that 
contribute to the antenatal Bartter syndrome remain elusive. First results suggest that 
MAGED2 acts indirectly on ion channels and transporter expression in the kidney tubule 
system.
Methods: The role of MAGED2 in renal cell culture systems was studied by analyzing 
the proteome and phospho-proteome after MAGED2 depletion and by analyzing the 
influence of MAGED2 on vasopressin induced signaling in mouse collecting duct cells 
using Western Blot, qPCR and proteomic analyses.
Results: We show that MAGED2 ablation in HEK293T cells induced large effects on 
the phosphoproteome, without affecting protein levels. Since MAGED2 is expressed during 
development in collecting duct cells of newborn mice, we analyzed the effects of MAGED2 
knockdown on vasopressin-dependent signaling in renal collecting duct cells. We found that 
MAGED2 knockdown altered V2R-induced cAMP-generation kinetics, phosphoproteome 
rewiring, and blunted phosphorylation on downstream nodes such as phosphorylated 
CREB. V2R induced ERK inhibition and aquaporin-2 phosphorylation were not affected. 
Interestingly, these alterations resulted in a marked increase in aquaporin-2 abundance 
during long-term V2R activation, that was mediated transcriptionally, potentially through 
the mediator complex.
Conclusions: In conclusion, we show that MAGED2 is a novel modulator of G-protein 
coupled signaling, that might control important signaling events involved in ion transport 
and nephron plasticity in the distal nephron. The relevance of these findings needs to be 
recapitulated in vivo.
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Model of Megalin Trafficking in Differentiated Proximal Tubule Cells and 
Its Application in Dent Disease
Katherine Shipman, Kimberly R. Long, Youssef Rbaibi, Catherine J. Baty, 
Ora A. Weisz. University of Pittsburgh, Pittsburgh, PA.
Background: The polarized epithelial cells that comprise the proximal tubule (PT) 
have a specialized, high capacity apical endocytic pathway necessary to maintain a protein-
free urine. The multiligand receptor megalin plays an essential role in the binding and 
uptake of proteins in the ultrafiltrate. The molecular identities of the compartments involved 
in sorting of ligands and recycling of receptors in PT cells and the kinetics of megalin 
trafficking through them are unknown. Dysfunctional PT endocytosis results in tubular 
proteinuria that can progress to renal failure, as is commonly observed in Dent disease, an 
X-linked disorder caused by mutations in the Cl-/H+ exchanger CLC-5. Reduced endocytic 
uptake in Dent disease is likely due to decreased expression of megalin receptors (without 
altered mRNA levels); however, the mechanism by which this occurs is unclear.
Methods: We previously discovered that OK cells cultured under continuous fluid 
shear stress develop morphological and functional features similar to that of the PT in 
vivo, including high apical endocytic capacity and increased megalin expression. Using 
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biochemical techniques, we have estimated endocytic and recycling rates and the half-
life of surface megalin. These data were used to construct a model of megalin trafficking 
in differentiated PT cells. To study megalin trafficking in a Dent disease cell model, 
we knocked-down CLC-5 expression in these cells using siRNA. Typical knockdown 
efficiency was ~70%.
Results: We present an ordinary differential equation model of megalin trafficking 
describing surface and internalized pools of megalin with estimated kinetic parameters. 
The model is capable of achieving a steady-state with a much larger pool of internalized 
megalin compared to surface within a range of realistic parameters; this is consistent 
with observations made by our biochemical assays and by indirect immunofluorescence 
of endogenous megalin. In our Dent disease cell model, we observed decreased megalin 
expression as observed in vivo, and we are quantifying megalin trafficking kinetics in these 
cells to identify the affected step(s).
Conclusions: Our new PT cell culture model provides an ideal system in which to 
determine the organization of the apical endocytic pathway and to delineate the mechanistic 
basis of genetic diseases that cause tubular proteinuria.
Funding: NIDDK Support
TH-PO739 Poster Thursday
Genetic Diseases of the Kidneys: Non-Cystic - I
Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) Associated 
with a Mutation in GNAS
Detlef Bockenhauer,1,2 Heike Biebermann,4 Gunnar Kleinau,4 Mehul T. Dattani,8 
John W. Gregory,5 Harald Jüppner,3 Michael Mannstadt,4 Sarah Paisdzior,4 
Patrick Scheerer,4 Ian Tully,5 Louise C. Wilson,7 Annette Grueters.6 GOSH 
1University College London, London, United Kingdom; 2Nephrology, Great 
Ormond Street Hospital for Children NHS Foundation Trust, London, United 
Kingdom; 3Massachusetts General Hospital, Boston, MA; 4Charité Berlin, 
Berlin, Germany; 5Cardiff University, Cardiff, United Kingdom; 6university 
Hospital heidelberg, Berlin, Germany; 7Great Ormond Street Hospital NHS 
Foundation Trust, London, United Kingdom; 8UCL Institute of Child Health, 
London, United Kingdom.
Background: NSIAD refers to a genetic form of urinary concentration independent of 
anti-diuretic hormone (ADH). So far, it has only been shown in association with gain-of-
function mutations in AVPR2. Here, we present 2 unrelated boys with a novel syndrome 
including NSIAD.
Methods: Clinical and genetic investigations in 2 patients. The identified mutation was 
further studied in vitro.
Results: Both boys presented in the neonatal period with hyponatremia, initially 
treated with sodium supplementation and additional fludrocortisone, which was 
complicated by hypertension. Detailed investigations in one patient at the age of 3 years 
revealed clinical euvolemia, a persistently elevated urine osmolality (796-1006 mosm/kg) 
with suppressed copeptin (<3.6 pmol/l) and unresponsiveness to a tolvaptan challenge. 
Salt and mineralocorticoid supplementation was discontinued with normalization 
of blood pressure and maintenance of normonatremia with spontaneous reduction 
in fluid intake (30ml/kg/d). A subsequent transient episode of hyponatremia (128 
mmol/l) was associated with increased weight and blood pressure, suppressed copeptin 
and a urine osmolality of 1038 mosm/kg. Both patients also had complex endocrine 
abnormalities, including elevated serum PTH concentrations (66-454 pg/l), hypocalciuria 
(0.06-0.09 mol/mol) and gonadotropin-independent precocious puberty. Molecular analysis 
revealed a de novo variant in GNAS c.1126T>G; p.(F376V) on the maternally inherited 
allele in both patients. In vitro studies of mutant Gαs-F376V revealed agonist-independent 
activation of AVPR2, LHCGR and PTH1R.
Conclusions: We show a novel form of NSIAD associated with an activating mutation 
in GNAS, encoding the stimulatory G protein Gαs. In the collecting duct, Gαs associates 
with AVPR2 and activates adenyl cyclase to initiate urinary concentration. Our data indicate 
that mutant Gαs-F376V can activate independent of ADH signalling. Different mutations in 
GNAS have been previously associated with disease, including McCune-Albright Syndrome 
and Pseudohypoparathyroidism. The unique phenotype associated with this mutation can be 
explained by the differential impact on signalling with the various associated receptors, as 
well as the effect of imprinting on tissue-specific expression.
Funding: Government Support - Non-U.S.
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Whole Exome Sequencing Reveals Mutations in the Purinergic Receptors 
P2RX2 and P2RX7 as Novel Causes of Neurogenic Bladder and CKD
Nina Mann,1 Franziska Kause,1 Shirlee Shril,1 Dervla M. Connaughton,1 
Rufeng Dai,1 Caroline M. Kolvenbach,2 Friedhelm Hildebrandt.1 1Boston 
Children’s Hospital, Boston, MA; 2Harvard Medical School, Boston, MA.
Background: Neurogenic bladder is caused by disruption of the normal neural 
pathways that regulate bladder relaxation and contraction. In severe cases, neurogenic 
bladder can lead to vesicoureteral reflux, recurrent urinary tract infections, and even 
chronic kidney disease and renal failure. Animal models of bladder dysfunction suggest that 
neurogenic bladder can be caused by single gene mutations. However, to date, no mutations 
have been identified in humans.
Methods: To identify monogenic causes of neurogenic bladder, we applied 
homozygosity mapping with whole exome sequencing (WES) to our worldwide cohort of 
families with congenital anomalies of the kidneys and urinary tract (CAKUT).
Results: We identified a homozygous missense mutation (p.Gly322Arg) in the gene 
P2RX2 and a compound heterozygous missense mutation (p.Leu320Pro, p.Pro582Leu) 
in the gene P2RX7 in two families with neurogenic bladder. Both families also have 
secondary vesicoureteral reflux and chronic kidney disease. The mutations identified are 
well-conserved evolutionarily, rare in the general population, and have deleterious in silico 
prediction scores. P2RX2 and P2RX7 belong to the purinergic family of receptors, which 
are ATP-gated cation channels, and both are expressed in the urothelium and bladder smooth 
muscle. Additionally, P2rx2 knockout mice have impaired bladder reflexes (Cockayne J 
Physiol 567:621, 2005), which mimics the phenotype of our patients.
Conclusions: We identified recessive missense mutations in two purinergic receptors, 
P2RX2 and P2RX7, in families with neurogenic bladder. Purinergic signaling has been 
reported to play an important role in bladder contractility, and we therefore propose that 
mutations in these genes may be novel monogenic causes of neurogenic bladder in humans.
Funding: NIDDK Support
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Clinical Utility of Secondary Genetic Findings in CKD
Emily Groopman, Maddalena Marasa, Simone Sanna-Cherchi, 
Krzysztof Kiryluk, Ali G. Gharavi. Columbia University, New York, NY.
Background: Whole-exome sequencing (WES) is increasing utilized in nephrology. 
In addition to providing a specific etiology for nephropathy, genome-wide testing can 
detect other variants of potential clinical relevance. However, neither the prevalence of 
such secondary findings among patients with kidney disease nor their clinical implications, 
including for nephrologic care, has been assessed.
Methods: 2,187 patients with all-cause chronic kidney disease (CKD) underwent WES 
at the Columbia Institute of Genomic Medicine. 87% were adults (aged >21y) and 49% 
self-identified as non-European. We analyzed WES data for variants diagnostic for 850 
medically actionable monogenic diseases, using American College of Medical Genetics 
clinical sequence interpretation criteria. The clinical implications of secondary genetic 
diagnoses were assessed via their capacity to initiate extra-nephrologic subspecialty 
referrals and to inform key aspects of nephrologic management, such as dialysis care and 
choice of therapy.
Results: 149 (7%) patients had a secondary genetic diagnosis. Yield did not differ 
significantly between pediatric and adult cases (OR=0.70 [0.37, 1.23], P=0.25) nor 
between self-identified Europeans and non-Europeans (OR=0.83 [0.59, 1.18], P=0.31). 
The secondary genetic diagnoses spanned 78 medically actionable monogenic disorders 
and would initiate extra-nephrologic referral involving 19 different specialties. Moreover, 
in 76 (51%) of the 149 cases, the disorders found could be mistaken as secondary CKD 
comorbidities and would require disease-specific treatment. Strikingly, in each case, 
the secondary genetic diagnosis had meaningful implications for nephrologic care. 
For example, the inherited cancers found in 79 patients would inform type and dose of 
immunosuppression for renal transplantation, and, in the 45 with glomerulopathy, therapy 
for their primary renal disease as well. Similarly, the hereditary cardiac conditions noted in 
40 patients would impact dialysis and/or choice of anti-hypertensive agent.
Conclusions: WES of a large all-cause CKD cohort yielded secondary genetic 
diagnoses in 7%, with meaningful implications for nephrologic care. Our findings 
reveal a novel utility of genome-wide testing in nephrology and the associated need for 
multidisciplinary management.
Funding: NIDDK Support
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Enhance Utility of Family-Centered Diagnostic Exome Sequencing in 
Children with CKD: A Comparison of 497 Families in Trios and Singleton
Jia Rao, Qian Shen, Hong Xu. Chinese Children Genetic kidney Disease 
Database (CCGKDD) Children’s Hospital of Fudan university, Shanghai, 
China.
Background: The utility of family centered whole exome sequencing (WES) for the 
diagnosis of children with chronic kidney disease (CKD) has not been adequately studied.
Methods: Patients with CKD identified according to KDIGO guidelines were grouped 
into five phenotype categories-nephrosis, nephritis, proteinuria(non-nephrotic), congenital 
abnormalities of the kidney and urinary(CAKUT), CKD2-5 stage of unknown cause 
and miscellaneous. WES data from Chinese Children Genetic kidney Disease Database 
(CCGKDD) including 10 different renal centers in CHINA were analyzed. Singleton WES 
was performed as a first-tier sequencing test. Family-based exome sequencing included 
trio whole exome sequencing followed by family inheritance−based model filtering, 
comprehensive medical review, familial segregation analysis, and analysis of novel genes.
Results: Of 497 enrolled children with CKD, 330 received genetic diagnosis through 
singleton WES compared with 167 who underwent trios-WES. A molecular diagnosis was 
reported for 171 families (34.4%) with 78.3% of the diagnostic mutations not previously 
reported. A positive or likely positive result in a known disease causing gene was identified 
in 29.0%(89/330) of patients in singleton vs. 49.1% (82/167) of families in trios. Genetic 
diagnosis rates for each phenotypic category were 33.3% for nephrosis group, 26.6% for 
nephritis group, 43.4% for proteinuria group, 349.3% for CAKUT group, 36.6% for CKD 
2-5 stage of unknown cause group and 32.5% for miscellaneous group (Fig.1). Novel gene 
findings were identified in 4.2%(4/167) of patients in trios.
Conclusions: The multicenter cohort of WES cases demonstrate the utility of family-
based exome sequencing and analysis to obtain the highest reported detection rate in 
children with CKD.
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Fig.1 Genetic diagnosis rates for each phenotypic category in children with CKD 
comparing in singleton and trios-WES (Singleton: inner ring;Trios: outer ring)
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Novel Diagnostic and Therapeutic Approaches for Kidney Diseases: 
Potential Applications of Noncoding RNAs Associated with Regulation of 
NOTCH2 and TP53
Mohammed A. Al-Obaide, Tetyana L. Vasylyeva. Texas Tech University Health 
Sciences Center, Amarillo, TX.
Background: The NOTCH2 and TP53 genes are linked to many diseases including 
kidney diseases. In humans NOTCH2 associated with kidney developmental abnormalities 
and Alagille Syndrome. In addition to the known function of TP53 in limiting cell 
proliferation, TP53 involved in regulation of self-renewal and maintenance of the nephron 
progenitor pool. Previous studies showed excessive expression linkup NOTCH2 and 
TP53 to kidney diseases. We hypothesized that long noncoding RNA (lncRNA) which are 
tissue-specific regulators of gene expression are involved in cross-talk for tight control of 
expression of genes associated with kidney diseases, for example, the NOTCH2 and TP53. 
The genomic regions of the two genes host characterized and uncharacterized lncRNA. 
We aimed to investigate the potential interaction and cross-talk between the WRAP53 WD 
repeat containing antisense to TP53 and the uncharacterized lncRNA genes convergently or 
divergently configured to the protein-coding gene NOTCH2 in the regulation of both genes.
Methods: The search for unreported miRNA sequences in the WRAP53 WD repeat 
containing antisense to TP53 and predicted uncharacterized lncRNA LOC105378939, 
LOC111776218, LOC101929178 and LOC105378940 ncRNAs loci analyzed by the 
miRBase search tool. The microRNA recognition elements (MRE) in the NOTCH2 and 
TP53 mRNAs, identified by RNA22 v2 microRNA target detection tool. The miR binds 
to the target MRE.
Results: The lncRNAs loci are the source of various types of miRNAs. The 
analysis of the WRAP53 WD repeat containing antisense to TP53 and LOC105378939, 
LOC111776218, LOC101929178, and LOC105378940 detected several types of miRs. The 
discovered miRs bind to the target MRE of the mRNAs of the NOTCH2 and TP53. The 
miRs from WRAP53 WD repeat containing antisense to TP53 bind the MRE targets of 
NOTCH2. The miR sequences are comparable but not similar to the human (Homo sapiens) 
hsa-miR, for example, hsa-miR-6743-3p, hsa-miR-6510-5p, hsa-miR-1285-3p, and hsa-
miR-519b-3p.
Conclusions: The detected miRNAs from the investigated lncRNAs may provide novel 
approaches to delineate the complex mechanisms associated with NOTCH2 and TP53 in 
kidney diseases. The lncRNAs can act as diagnostic biomarkers and suggest therapeutic 
opportunities for the treatment of kidney diseases.
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Kidney Disease Associated Variants of ApoL1 Show Gain-of-Function in 
the pH-regulated Cation Channel Activity
John C. Edwards. St. Louis University, Saint Louis, MO.
Background: Variants in the protein ApoL1 are largely responsible for the increased 
risk of progressive kidney disease in people of African ancestry. ApoL1 is an amphitropic 
membrane protein that inserts into membranes a low pH where it confers anion-selective 
permeability. After titration to neutral pH, the anion permeability is suppressed and a non-
selective cation permeability is activated. We used vesicle based ion flux and membrane 
association assays to assess for functional difference among variants.
Methods: Recombinant ApoL1 isoforms were expressed in E. coli. KCl-loaded 
phospholipid vesicles were mixed with protein and assayed for efllux in presence of a large 
KCl gradient. Efflux was initiated by addition of selective ionophore (valinomycin to assess 
Cl permeability, or Cl ionophore 1 to assess K permeability), and detected with a chloride 
selective electrode. The initial rate of efflux after addition of ionophore minus the rate with 
control vesicles is taken as the ApoL1-dependent ion permeability. To assess membrane 
association, vesicles and protein were mixed at pH 6, then titrated to pH 7.5, stripped of 
peripherally bound protein, separated by flotation through a sucrose cushion and detected 
by western blotting.
Results: All variants show Cl-selective permease activity at low pH that is essentially 
identical. In contrast, the K-permeability of the disease-associated variants G1 and G2 is 
substantially higher than the WT (G0). All three variants were purified simultaneously, 
with assays performed on the same day with the same reagents. Three independent sets of 
purified protein showed the same pattern of activity. Combining data from the three sets, 
G1 and G2 showed 2.08 ± 0.17 and 2.03 ± 0.28 fold greater activity than G0 (mean ± SEM, 
P<0.001 for each). Membrane association experiments demonstrated consistently increased 
membrane binding by G1 and G2 compare to G0 with 3.02 ± 0.49 and 3.30 ± 0.36 fold more 
binding than G0, respectively (P<0.001 for each).
Conclusions: Kidney disease associated variants of ApoL1 show consistently greater 
cation channel activity and greater membrane insertion than the wild type protein. The data 
suggest increased membrane insertion and hence greater channel activity in kidney cells 
could be a mechanism contributing to disease progression.
TH-PO745 Poster Thursday
Bioengineering
A Quantitative 23Na-MRI Protocol to Assess Muscle Na Concentrations: 
Protocol Reliability and Na Level Heterogeneity Between the Anterolateral  
and Superficial Posterior Compartments of the Lower Leg
Hsin-Yu Fang,2 Luis M. Perez,1 Brett Burrows,2 Ryan J. Larsen,2 Ken Wilund.1 
Renal and Cardiovascular Disease Research Laboratory UIUC 1University of 
Illinois, Urbana, IL; 2University of Illinois at Urbana-Champaign, Urbana, IL.
Background: Previous sodium magnetic resonance imaging (23Na-MRI) studies 
demonstrated that sodium (Na) can be stored in muscle without thoroughly describing the 
image quantification methodology. 23Na-MRI image region of interest (ROI) analysis is a 
subjective process that depends on user experience. We sought to develop a reliable protocol 
to quantify Na concentrations in two lower leg muscle compartments. The intra- and inter-
rater reliability of our quantification protocol and the heterogeneity of Na level between two 
assessed muscle compartments were also examined.
Methods: Twenty-five 23Na-MRI (3T system) images from 21 subjects (16 healthy 
subjects/5 hemodialysis patients) were quantified for muscle Na concentrations. We 
de-identified and randomized all images into two sets for ROI analysis by two trained 
researchers. Two ROIs were designated as the anterolateral (AL) and superficial posterior 
(SP) lower leg muscle compartments. We calculated Intraclass correlation coefficient 
(ICC) estimates based on 2-way mixed-effects models to determine the intra- and inter-
rater reliability of our protocol on muscle Na concentrations of AL and SP compartments. 
Simple linear regression (SLR) analysis was used to investigate the relationship between the 
average muscle Na concentration of AL and SP (AL-SP mean) and the difference between 
AL and SP muscle Na concentrations (AL-SP difference).
Results: The ICCs of inter and intra-rater reliability for muscle Na concentrations 
of AL and SP compartments were all above 0.97, indicating excellent reliability. SP 
compartment muscle Na was higher than in the AL compartment (SP=20.32±8.69 mM, 
AL=15.57±5.92 mM, p=0.001). However, Na concentrations of the two compartments 
were strongly correlated (r=0.697, p<0.01). Linear regression of the AL-SP mean versus the 
AL-SP difference was significant (β1=-0.444, p=0.013; R2=0.232).
Conclusions: The reliability of our 23Na-MRI image analysis protocol in the 
measurement of Na concentrations in lower leg muscular compartments was high. Muscle 
Na concentrations varied between muscle compartments, suggesting a heterogenous Na 
distribution among different muscle groups. The variance of muscle Na concentrations 
between compartments increased as the total muscle Na level elevated.
Funding: Private Foundation Support
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Determination of Renal Blood Flow Based on PET/CT-Rubidium-82-Tech-
nology in Healthy Subjects
Stine Langaa,1 Thomas G. Lauridsen,1 Claire A. Fynbo,2 Jorn Theil,2 
Jesper N. Bech.1 1University Clinic of Nephrology and Hypertension, Holstebro 
Hospital, Holstebro, Denmark; 2Department of Nuclearmedicine, Herning 
Hospital, Herning, Denmark.
Background: Changes in Renal Blood Flow (RBF) play an important patophysiological 
role in the widespread diseases hypertension and kidney disease. However present methods 
for RBF-determination in humans have several disadvantages. Myocardial blood flow is 
routinely assessed with PET/CT and the perfusion tracer rubidium-82 (Rb-82). Renal PET 
with Rb-82 has shown great promise regarding determination of RBF. The purpose of the 
study is to develop a new and reliable method for determination of RBF based on PET/CT 
and Rb-82 using a 1-tissue compartment model. To minimize radiation exposure, the input 
function in the model and the kidneys have to be in the same field of view. Therefore we 
examined whether the abdominal aorta (AA) is a valid alternative as input function instead 
of the left ventricular blood pool (LVBP) which is routinely used.
Methods: 10 healthy subjects underwent dynamic PET/CT-scans with Rb-82 
as perfusion tracer in two different bed positions. Rb-82 was given as bolus injections. 
Volumes of interest were placed in the kidneys, LVBP and AA and time activity curves 
were generated. An input function was derived from both the LVBP and AA. A 1-tissue 
compartment model was used for estimation of RBF. The K1-parameter represents RBF. 
K1-values derived from the two different input functions were compared.
Results: The mean K1-value derived from LVBP was 2.14 ± 0.52 ml/min/g and 
2.11 ± 0.57 ml/min/g for the right and left kidney respectively. The mean K1-value derived 
from AA was 2.69 ± 0.40 ml/min/g and 2.77 ± 0.77 ml/min/g for the right and left kidney 
respectively. For both input functions, the mean K1-value for the right kidney was not 
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significantly different from the mean K1-value for the left kidney. For LVBP the intra-assay 
variation coefficient was 14.7% for the right kidney and 12.2% for the left kidney. For AA 
the intra-assay variation coefficient was 12.7% and 13.2% for the right and left kidney 
respectively.
Conclusions: Our preliminary results show that the PET-Rb-82 method is feasible for 
determination of RBF. Use of AA-activity as input function seems to be physiologically 
most valid because of the direct input to the renal arteries and the derived K1-values are 
significantly higher than K1-values obtained using activity from LVBP.
Funding: Government Support - Non-U.S.
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Evaluation of Renal Fibrosis Using Elastic Scattering Spectrophotometry 
(ESS)
Mostafa Belghasem,2 Ousama A’Amar,1 Daniel M. Roth,2 Nkiruka Arinze,2 
Sean Richards,3 Joshua A. Walker,2 Jean M. Francis,3 David J. Salant,3 
Vipul C. Chitalia,3 Irving J. Bigio.1 1Boston University, Dorchester, MA; 2Boston 
University School of Medicine, Boston, MA; 3Boston University Medical Center, 
Boston, MA.
Background: Interstitial fibrosis and tubular atrophy (IFTA) are hallmarks of 
progressive CKD. The standard method of assessment requires one or more biopsy cores 
and semiquantitative measurement by histology using stains such as Masson’s trichrome. 
The method is invasive, labor intensive and fraught with potential sampling error due to the 
patchy nature of IFTA. We propose an alternative, quantitative, minimally invasive method 
of fine-needle sampling at several sites using Elastic-Scattering Spectroscopy (ESS). ESS 
is a broadly applicable method that measures wavelength-dependence of optical scattering 
probability of tissue and is sensitive to the amount of fibrosis.
Methods: ESS was performed using three animal models (n=5 per model) of renal 
fibrosis (adenine-induced CKD, unilateral ureteral obstruction (UUO) and a remnant 
kidney model). The ESS spectrum was obtained using a fiberoptic probe with a 150 μm 
illumination fiber and a 100μm collection fiber, with measurements recorded from several 
points in the cortex and the medulla of the kidneys. The spectra were normalized at 
650 nm to facilitate comparison of the spectral shapes to the ESS spectra obtained from 
time = 0 (untreated controls). The ESS spectra were correlated with the amount of fibrosis 
measured by trichrome staining.
Results: All three models were associated with a rise of BUN and an increase in IFTA. 
Adenine-induced fibrotic kidneys showed a distinct spectral trend of increased scattering 
intensity in the ultraviolet region (300-400 nm) compared to normal kidneys. Similar 
spectral changes were observed in the UUO model, with the degree of spectral change 
dependent on the time after ligation. A linear correlation was observed between fibrosis as 
assessed by Trichrome stain and the ESS spectral feature.
Conclusions: The linear correlation for even this small data set is encouraging and 
bodes well for ESS as a quantitative measure of IFTA. Collectively, these data support 
further studies to explore ESS as a viable point-of-care technique to detect renal fibrosis 
quickly, offering the potential for a rapid, quantitative and objective assessment of fibrotic 
status, overcoming some of the limitations of the current method.
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Stiffness Imaging in Native Kidneys by Magnetic Resonance Elastogra-
phy: A Feasibility Study
Nayana Patel,4 Berenice Y. Gitomer,1 Diana George,4 Kristen L. Nowak,3 
Michel Chonchol.4 1Div. Renal Diseases and Hypertension, Aurora, CO; 
3University of Colorado Denver: Anschutz Medical Campus, Aurora, CO; 
4University of Colorado, Aurora, CO.
Background: Development of kidney fibrosis results in loss of kidney function among 
patients with chronic kidney disease (CKD). Kidney biopsy is the standard method for 
fibrosis detection in native or transplanted kidneys and there is not currently a non-invasive 
technique to detect kidney fibrosis. We undertook a pilot study in healthy individuals of 
different ages to explore the feasibility of performing magnetic resonance elastography 
(MRE) to determine the range of stiffness in healthy kidneys.
Methods: Six healthy subjects with eGFR > 60 ml/min/1.73m2 were included in the 
study. Kidney imaging was performed on a Siemens 3T MR scanner. Following acquisition 
of scout images for location of the kidneys, MRE was performed with patients in the prone 
position using 60Hz frequency with 2 different driver positions. In method 1 driver was 
placed in the midline overlying the spine just below the ribs and one image of both kidneys 
at the level of the hilum in the axial plane and one image through the long axis of each 
kidney obtained in the sagittal plane (3 images). In method 2 the driver was placed off 
midline on the flank to acquire images in the axial and sagittal planes a total of 4 images. 
MRE images were processed with multiple regions of interest in analysis for each kidney.
Results: Two male and 4 female subjects with age range 32 – 66 years were included. 
Kidney stiffness was heterogeneous across both kidneys and between individuals (Table 1). 
The overall mean stiffness measure for both kidneys together did not differ significantly 
between method 1 and method 2 (P = 0.4).
Conclusions: MRE of native kidneys was feasible and tolerated by all subjects. Kidney 
stiffness was heterogeneous across both kidneys. Stiffness measured by either method 
yielded similar results. However, method 1 requires acquisition of fewer images and does 
not require repositioning of the driver position thereby shortening scan time.
Funding: Private Foundation Support
Kidney Stiffness
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Understanding the Effects of Haemodialysis on Blood Flow: An Imag-
ing-Mathematical Modeling Study
Sanjay R. Kharche,2,1 Raanan Marants,1 Elena Qirjazi,2 Andrea D. Kassay,2 
Jermiah Joseph,2 Kierra D. McDougall,2 Ting Lee,1 Christopher W. McIntyre.2,1 
1University of Western Ontario, London, ON, Canada; 2Medicine, Lawson 
Health Research Institute, London ON, ON, Canada.
Background: Haemodialysis (HD) is a circulatory stress to organs. The clinical 
assessment of blood flow (BF) during HD is challenging. We are developing in silico tools 
to permit patient specific prediction of HD effects on BF, to accelerate translation. This 
study aimed to test the feasibility of creating imaging informed, patient specific simulations 
of multi-organ perfusion under the stress of HD.
Methods: We reconstructed 3D liver and kidney BF using CT images from a previous 
study, under both standard and cooled dialysate (DC). Ten patient data sets were analysed. 
Volumes of each organ were calculated. A binned histogram of blood flow distribution was 
computed for each case. Patient specific mathematical models of blood flow (Kharche et al. 
Front. Physiol. 2018) based on observed organ shape and BF distributions, known blood 
vessel morphometry, autoregulation mechanisms, and mathematically optimized spatial BF 
distribution were successfully generated for further study. Novel texture analysis based on 
fractal dimension was implemented to quantify BF heterogeneity in the images as well as 
models.
Results: One 3D reconstructed aorta-liver-kidney composite is shown in Figure 1,A. 
Histograms of BF (Figure 1, B) show that DC altered BF. In all cases, portal hepatic BF 
increased markedly due to DC. The volumes of organs were also affected by both dialysis 
and DC.
Conclusions: The development of patient specific in silico models of the multi-organ 
blood flow consequences of HD appears to be feasible and warrants further study to 
accurately predict individual treatment responses and optimize treatment parameters.
Funding: Private Foundation Support, Clinical Revenue Support
Figure 1. A. Reconstructed BF maps of aorta, liver, and kidneys. B. Histogram of BF in 
right kidney before (red) and after (green) cooling.
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Quantification of the Effects of a Haemodialysis Patient’s Cardiac 
Ejection Fraction: Towards Patient Specific Risk Prediction
Sanjay R. Kharche,2,1 Wenyao Xia,3 Andrea D. Kassay,2 Jermiah 
Joseph,2 Kierra D. McDougall,2 Terry M. Peters,3 Christopher W. McIntyre.2 
1University of Western Ontario, London, ON, Canada; 2London Health 
Sciences Centre, London, ON, Canada; 3Robarts Research Institute, London, 
ON, Canada.
Background: Hemodialysis (HD) patient hearts suffer chronic ischemia and uremia, 
leading to contractile dysfunction and arrhythmia risk. Although 2D echocardiography 
is advanced, image quality is a limiting factor. The black box nature of commercial 
software is a further challenge. To address these concerns, image analysis-computational 
tools were developed to produce patient specific structural and functional cardiac 
models to assist therapy individualisation.
Methods: Echo images from 7 patients were acquired from a previous study. 
The endocardial and epicardial borders were automatically segmented using our new 
computer codes. Using the endocardial border, 3D left ventricle chambers were 
reconstructed for each frame using the modified Simpson’s rule. Normalised chamber 
volumes were computed from the 3D geometry. Patient specific geometries were encoded 
into low parameter oblate spheroid structures to permit future assessment of arrhythmia 
risk of the uremic hearts.
Results: 3D geometry reconstruction was successfully implemented in all data sets. A 
3D endocardial surface encompassing the left ventricle chamber is shown in Fig. 1, A. The 
variation of left ventricle volume over one heart beat in one patient is shown in Fig. 1, B. 
HD reduced ejection fractions (avg. 50% to 44%).
Conclusions: Development of our own codes will permit us to customised analysis on 
a echocardiographic instrument vendor independent basis. The patient specific structural 
geometries will provide the essential basis for patient specific contractile and arrhythmia 
simulated assessment as a next generation tool for dialysis therapy optimisation.
TH-PO751 Poster Thursday
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Preliminary In Vitro Biocompatibility Test on a New Wearable/Portable 
Device for Extracorporeal Blood Ultrafiltration
Mauro Neri,2 Diego Pomare’ Montin,4 Paolo Boscariol,5 Giovanni Boschetti,7 
Massimo de Cal,1 Anna Lorenzin,4 Ilaria Palomba,6 Dario Richiedei,5 
Alberto Trevisani,5 Claudio Ronco.3 1San Bortolo Hospital, Vicenza, 
Italy; 
2University of Padova, Department of Management and Engineering, 
Vicenza, 
Italy; 3Ospedale “S. Bortolo” AZ. ULSS 6, Vicenza, Italy; 4IRRIV, Vicenza, Italy; 
5Università degli Studi di Padova, Vicenza, Italy; 6Free University of Bolzano-
Bozen, Bolzano, Italy; 7University of Padova, Vicenza, Italy.
Background: Development of a portable/wearable device for extracorporeal blood 
ultrafiltration (UF) would lead to impressive clinical, social and economic benefits for 
patients suffering of chronic kidney disease. This work presents a new prototype of a 
wearable device for blood UF, named RAP, able to remove excess fluids from fluid overload 
patients with chronic kidney disease, and a preliminary in vitro test of potential induced 
cytotoxicity by measuring apoptosis and necrosis in monocytes cell line due to indirect 
contact with the device.
Methods: The RAP has been developed as a backpack/trolley configuration. This 
original layout guarantees the best compromise between miniaturization and ergonomics, 
introducing an original positioning of many components in 3 independent panels:(a) 
disposable components,(b) non-disposable devices and (c) electronics. The device has been 
equipped with a power-bank able to last almost 6 hours and a device for remote monitoring. 
Cytotoxicity test was performed by circulating, through the RAP, complete RPMI medium. 
Monocytes were incubated for 24h in samples taken after 0’, 30’, 60’. 180’ and 360’.
Figure 1. A. Reconstructed 3D LV chamber based on an echo frame. B. LV chamber 
volume during one heart beat.
Results: RAP and its design are shown in Figure 1, where also the non-
disposable panel and the disposable one, manufactured with addictive technology, are 
shown. As shown in Figure 2, no inductions of increased necrosis or apoptosis on 
monocytes with respect to control appeared during a 6h-treatment.
Conclusions: RAP is a new, innovative wearable device for blood 
ultrafiltration. Arrangement of components can simplify the preparation of the device. 
Cytotoxic tests demonstrate no induction of cells necrosis or apoptosis. RAP is now ready 
for human trial.
Funding: Private Foundation Support
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Quantification of Internal Filtration in Hollow Fiber Hemodialyzers with 
Medium Cut-Off Membrane
Anna Lorenzin,1 Mauro Neri,1 Alessandra Brendolan,2 Claudio Ronco.2 1IRRIV, 
Vicenza, Italy; 2Nephrology, St Bortolo Hospital, Vicenza, Italy.
Background: Inadequate removal of molecules between 5 and 50KDa may cause 
long term complication in chronic hemodialysis. Medium Cut-off (MCO) is a new class 
of membranes with enhanced sieving properties and negligible albumin loss. MCO 
membrane allows to perform expanded hemodialysis (HDx), a technique based on high 
internal filtration (IF). The present study is designed to quantify IF in two MCO dialyzers 
(Theranova 400 and 500, Baxter, Deerfield, USA) using a nuclear imaging technique 
previously validated.
Methods: Blood and dialysate compartment pressure drop along with transmembrane 
pressure, were measured in a closed in vitro circuit with human blood (blood flow (QB)=300 
and 400ml/min; dialysate flow 500ml/min; net ultrafiltration rate 0ml/min). A non-diffusible 
marker molecule (albumin macro-aggregates labelled with 99Tc metastable) was injected in 
the blood compartment and nuclear emission was recorded by a gamma camera. Relative 
variations in concentration of the marker molecule along the length of the filter were used 
to calculate local cross filtration.
Results: Based on marker concentration profiles, IF was estimated (Figure 1). For 
Theranova 400, IF were 29.7 and 41.6ml/min for QB of 300 and 400ml/min. For Theranova 
500, IF were 31.6 and 53.1ml/min for QB of 300 and 400ml/min respectively.
Conclusions: MCO membrane provides significant amounts of IF due to the particular 
combination between hydraulic permeability of the membrane and reduced inner diameter 
of the fibers. High IF combined with enhanced sieving profile of MCO membrane, leads 
to improved removal of a wider spectrum of uremia retention molecules in HDx, without 
requiring complex equipment.
TH-PO753 Poster Thursday
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Direct Hemoperfusion of Protein-Bound Uremic Toxins Using Activated 
Carbon
Suguru Yamamoto,1 Yoshiharu Itoh,2 Toru Ito,1 Yoshikatsu Kaneko,1 Shin 
Goto,1 Fumitake Gejyo,1 Ichiei Narita.1 1Niigata University Graduate School of 
Medical and Dental Sciences, Niigata, Japan; 2Kureha Corp., Tokyo, Japan.
Background: Accumulation of protein-bound uremic toxins (PBUTs) is 
associated with mortality due to various systemic disorders in patients with CKD, 
especially those undergoing dialysis. The clinical outcomes of such patients could 
be improved by removing sufficient quantities of PBUTs; however, conventional 
dialysis lacks this ability. We examined the efficacy of activated carbon in adsorbing 
circulating PBUTs via direct hemoperfusion in vitro.
Methods: An in vitro blood circulating system composed of 6.5-8.5 mL 
blood circulating around a column containing activated carbon (50, 100, or 200 
mg) was constructed. Bovine blood containing PBUTs at the same concentration as 
that found in the blood of dialysis patients, as well as blood from hemodialysis 
patients (n = 8) were used. After circulation for the designated amount of time, sera were 
collected and the levels of PBUTs, such as indoxyl sulfate (IS), p-crecyl sulfate (PCS), 
indole acetic acid (IAA), phenyl sulfate (PhS), and hippuric acid (HA), were analyzed 
with mass spectrometry.
Results: Activated carbon decreased bovine blood PBUT level in a dose and 
time dependent manner (ex. reduction rate: IS 66.4%, 80.1%, and 93.8% following 60-
minute circulation in columns containing 50, 100, and 200 mg of activated carbon, 
respectively). All tested PBUTs were dramatically adsorbed by activated carbon 
from the blood of patients undergoing hemodialysis [pre vs post 4-hour circulation: 
IS median 3.01 (IQR: 2.58-3.38) vs 0.43 (0.41-0.51) mg/dL, PCS 3.34 (0.38-5.15) vs. 
0.96 (0.12-1.18) mg/dL,  IAA 0.073 (0.057-0.080) vs. 0.018 (0.016-0.019) mg/dL, PhS 
0.452 (0.240-0.651) vs. 0.008 (0.004-0.012) mg/dL and HA 1.368 (0.874-1.881) vs. 0.006 
(0.004-0.013) mg/dL] (Figure).
Conclusions: Activated carbon effectively adsorbed blood PBUTs in vitro. Direct 
hemoperfusion with activated carbon could be a promising strategy to remove circulating 
PBUTs from the blood of patients with CKD.
Scintigraphic images at steady state and marker molecule count profiles for Theranova 
400 and Theranova 500.
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Evaluation of Biocompatibility and Cytotoxic Effects of New Sorbent 
Cartridges for Blood Hemoperfusion
Diego Pomare’ Montin,1 Ghada A. Ankawi,2,1 Anna Lorenzin,1,3 Mauro Neri,3,1 
Carlotta Caprara,1 Claudio Ronco.4,1 1IRRIV, Vicenza, Italy; 2UWO, LONDON, 
ON, Canada; 3San Bortolo Hospital, Vicenza, Italy; 4Ospedale “S. Bortolo” AZ. 
ULSS 6, Vicenza, Italy.
Background: Adsorption cartridges applied in extracorporeal purification therapies, 
involve direct contact of blood with the sorbent material. The potential induced cytotoxicity 
is an important issue. The aim of this study was to investigate potential in vitro cytotoxic 
effects of sorbent cartridges HA130, HA230, HA330/380 (Jafron, China) on U937 
monocytes.
Methods: Monocytes were exposed to the sorbent material in static and dynamic 
manners. In static test, cell medium samples were collected after 24 hrs of incubation in the 
cartridges. In dynamic test, hemoperfusion modality has been carried out and samples at 30, 
60, 90 and 120 min were collected.
Results: Compared to control samples, the viability remained the same and there was 
no evidence of increased necrosis or apoptosis in monocytes exposed to the cartridges in the 
static tests (fig.1). Similarly, there was no remarkable difference in the viability, apoptosis 
and necrosis of U937 between each sample and the controls during the dynamic test (fig.2).
Conclusions: Our in vitro testing suggests that HA130, HA230, HA330/380 cartridges 
possess an optimal level of biocompatibility and their use in HP is not associated with 
adverse reactions or signs of cytotoxicity.
TH-PO755 Poster Thursday
Bioengineering
Immunomodulation Therapy Improves Cardiac Function in Chronic 
Heart Failure (CHF)
D. Buffington,1 A. Westover,1 L. Lou,1 C. Pino,1 K. Johnston,1 Hani N. Sabbah,2 H.
David Humes.1,3 1Innovative BioTherapies, Inc., Ann Arbor, MI; 2Henry Ford Health 
System, Detroit, MI; 3University of Michigan Medical School, Ann Arbor, MI.
Background: Cardiovascular disease is the leading cause of mortality in the US, 
accounting for 45% of all deaths. CHF and cardiorenal syndrome (CRS) are now understood 
to be multi-system disease processes involving not only the cardiovascular system but also 
the renal, neuroendocrine and immune systems. No effective therapy is currently available 
to treat the most severe subset of CHF patients that have progressed to acute decompensated 
HF. The Selective Cytopheric Device (SCD) is an immuno-regulating, extracorporeal, 
membrane device targeted to modulate the cardio-depressant effects that are associated with 
CHF. SCD is a platform technology focused on immunomodulation of the acute and chronic 
inflammation associated with acute and chronic organ dysfunction. SCD polysulfone fibers 
selectively sequester and immunomodulate activated systemic leukocytes as they flow 
through the fiber casing via an extracorporeal circuit and are subsequently released back 
to the systemic circulation.
Methods: 12 dogs with advanced CHF (ejection fraction (EF) <35%) were used: 5 
dogs received sham therapy (No Rx) and 7 dogs received SCD Rx sessions. 6-hour Rx 
sessions were administered every 48-72 hours for a total of 3 times over a 1-week period. 
Cardiac parameters were measured at 48 hours, 2 and 4-weeks post. Samples were taken 
to evaluate of systemic cytokines, leukocyte immune state, spleen density, and macrophage 
distribution in heart tissue and peritoneal lavage.
Results: EF% significantly increased in SCD Rx animals from 34.0±0.8 to 38.7±1.2% 
(p<0.01) measured at 48 hours post Rx and sustained through 4 weeks at 39.3±1.5% 
(p<0.005). EF% correlated with significant increases in stroke volume, end systolic volume 
and overall cardiac output. Changes were not observed in control animals. Changes in 
cardiac parameters correlated to a decrease in systemic leukocyte activation as measured 
by CD11b, decrease in macrophage density in heart, less pro-inflammatory macrophages in 
peritoneal lavage, and normalization of spleen cell density.
Conclusions: Pre-clinical study results show SCD Rx for CHF to have clinically 
relevant therapeutic benefit that was sustained over the 4-week follow-up period. A pilot 
clinical study is planned to evaluate this approach in severe CRS.
Funding: Other NIH Support - HL118792
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Mussel-Inspired Approach Towards Heparin-Immobilized Cellulose 
Hydrogel for Selective Removal of Low Density Lipoprotein from Whole 
Blood
Yupei Li,1 Baihai Su,1 Weifeng Zhao,2 Yuqin Xiong,1 Ruoxi Liao,1 Yilin Wang.2 
1Department of Nephrology, West China Hospital, Sichuan University, Chengdu, 
China; 2College of Polymer Science & Engineering, Sichuan University, 
Chengdu, China.
Background: Cardiovascular disease is the leading cause of death in most countries 
and is responsible for a significant economic and health care burden. To date, it has 
been well established that the elevated low density lipoprotein (LDL) level in serum is 
associated with the development and progression of coronary artery disease, stroke, 
heart failure and peripheral arterial disease. Although statins exhibit excellent efficacy of 
lowering LDL in most occasions, they fail to improve the outcomes of patients with familial 
hypercholesterolemia without LDL apheresis. Dextran sulfate adsorption and heparin-
induced extracorporeal LDL precipitation are commercially available at present in the 
US. However, both of them require initial separation of plasma, making it impossible to 
remove LDL from whole blood. Therefore, it is of great importance to develop a new LDL 
absorbent to overcome the drawbacks of the existing techniques.
Methods: Heparin-immobilized cellulose (HeTaCe) hydrogels were fabricated 
through a mussel-inspired approach. Fourier transform infrared spectroscopy, X-ray 
photoelectron spectroscopy, thermo-gravimetric analysis were used to characterize the 
chemical compositions of the hydrogels. The contact activation, complement activation, 
hemolysis ratio and clotting times of the hydrogels were performed to investigate the blood 
compatibility. Moreover, we conducted both statical adsorption test and dynamic simplified 
simulative column adsorption test to evaluate the adsorption clearance, capacity and 
selectivity of LDL from whole blood in vitro.
Results: Characterization of the hydrogels confirmed the successful synthesis of 
the new absorbent. HeTaCe hydrogels exhibited low hemolysis ratio (<1%), suppressed 
complement activation and contact activation, mild impact on whole blood and prolonged 
clotting times. In vitro, an ideal adsorption capacity of 79.1 mg/g with a significant 
clearance of 48.3% from 14.77 to 7.64mmol/L towards LDL was achieved and the dynamic 
adsorption test further demonstrated a selective adsorption of LDL without a significant 
reduction of HDL level in a simulative system.
Conclusions: HeTaCe hydrogels may have great potential application in safe and 
efficient LDL adsorption from whole blood, making it possible to improve the outcomes of 
patients with high cardiovasular risk.
TH-PO757 Poster Thursday
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Arteriovenous Mock Circulation Loop for Enhanced In Vitro Testing of 
an Implantable Bioartificial Kidney
Parsa Taheri-Tehrani,1 Jarrett Moyer,1 William H. Fissell,2 Sukhveer S. Sandhu,1 
Shuvo Roy.1 1University of California San Francisco, San Francisco, CA; 
2Vanderbilt University, Nashville, TN.
Background: Arterial mock circulation loops (MCL) are recognized as an appropriate 
in vitro alternative to cumbersome and cost-intensive animal studies for the development 
of blood-contacting mechanical circulatory assist devices. In contrast to an arterial pump, 
a silicon nanopore membrane (SNM)-based bioartificial kidney (BAK) is dependent upon 
arteriovenous (AV) implantation of a mechanically robust and biocompatible hemofilter. 
An MCL that mimics arteriovenous shunt physiology (pressure, flow rate and pressure-time 
curve) is an essential tool for in vitro refinement of the BAK. Here, we describe an AV-MCL 
and a corresponding bond graph mathematical model used to refine physiologic parameters 
of the physical setup.
Methods: An AV-MCL was prototyped using commercial off-the-shelf pneumatic and 
hydraulic components. Two check valves (mimicking heart valves), two vertical chambers 
(mimicking atrium and ventricle), and a pneumatic solenoid valve (mimicking the AV node) 
were used to reproduce cardiac function. Flow resistors, a compliance chamber, and venous 
reservoir were used to reproduce the circulatory system. BAK prototypes were mounted 
in the AV MCL, and surgically implanted in an adult Yucatan pig in separate experiments. 
The bond graph model was used to adjust the AV-MCL parameters to reproduce the AV 
physiologic parameters obtained experimentally in the animal.
Results: In vivo arterial, graft and venous pressures (mmHg) were 110/69 (mean 86), 
78/60 (72), and 13/6 (9), respectively. The MCL yielded arterial, graft, and venous pressures 
of 110/67 (mean 81), 79/48 (58), and 13/10 (11). The BAK hemofilter blood flow in vivo was 
1032 mL/min, compared to 940 mL/min in the MCL. The pressure waveforms measured 
from the AV-MCL were well predicted by the mathematical model.
Conclusions: An AV-MCL was developed with a corresponding bond graph 
mathematical model, and successfully replicated in vivo AV pressure and flow conditions 
through BAK prototypes. The bond graph model facilitates further refinement of AV-MCL 
physiologic parameters, such as pressure-time waveforms. Moreover, the MCL is portable, 
adjustable and reusable, allowing rapid iterative in vitro testing of BAK prototypes. This 
system offers device feedback and refinement of BAK design prior to animal trials.
Funding: Other NIH Support - NIH Funding
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Unveiling Protein-Protein Interaction of Maleic Acid-Induced AKI Using 
a Newly Developed Probe
Hugo Y. Lin,1,2 Shih-Shin Liang.3 1University of California, Irvine, Irvine, AL; 
2Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, 
Taiwan; 3Kaohsiung Medical University, Kaohsiung, Taiwan.
Background: Protein-Protein Interactions (PPIs) are important regulators of cellular 
metabolism and functions in physiology and pathology. However, it is challenging to 
decipher this complex interaction network of proteins in cells. Maleic acid (MA), an 
industrial raw material, was found to be illegally added as an emulsifier to starch-based 
food products by manufacturers in Taiwan in 2013. MA has been associated with renal 
dysfunction in many animal experiments. The goal of this study was to create a chemical 
probe that could detect MA-associated proteins in human renal proximal tubular cells that 
might be used for future detection and therapeutic targeting purposes.
Methods: Chemical probes were developed to investigate protein–protein interactions 
between MA and renal proteins. In the fabrication of these MA probes, we used silicon 
dioxide (SiO2) modified with a silanized linker (3-aminopropyl triethoxyslane, APTES) to 
generate MA with APTES–SiO2 particles. The probes were then incubated with the cell 
lysates of normal human kidney cell lines (HK-2) and subjected to MS/MS to identify 
several MA-related proteins. STITCH database was utilized to create a schematic 
illustration of the relationship among proteins associated with MA.
Results: We found nucleophosmin, neutral alpha-glucosidase AB, translocon-
associated protein subunit alpha, elongation factor 1-gamma, 60S acidic ribosomal protein 
P0-like, and heat shock protein (HSP 90-alpha and beta) to be MA-associated proteins. 
These findings suggest that MA-induced acute kidney injury may come about as a result 
of regulation of protein transportation, cell processing, endoplasmic reticulum stress, 
ribosomal modulation and protein folding and unfolding.
Conclusions: The probes developed for this study can potentially be used to identify 
and detect the target proteins and help characterize a network of MA PPIs.
TH-PO759 Poster Thursday
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Glomerular Disease Augments Kidney Accumulation of Synthetic 
Polymers
Gary Liu,1 Alexander Prossnitz,1 Diana G. Eng,2 Yilong Cheng,1,3 
Jeffrey W. Pippin,2 Stuart J. Shankland,2 Suzie Pun.1 1Bioengineering, University 
of Washington, Seattle, WA; 2Medicine, University of Washington, Seattle, WA; 
3Applied Chemistry, Xi’an Jiaotong University, Xi’an, China.
Background: Targeted polymeric drug carriers can significantly improve the solubility 
and therapeutic profiles of their drug cargoes, while minimizing side effects and toxicity. 
Physicochemical properties of the carriers drive organ accumulation and are therefore 
important in the design process. However, carrier properties such as polymer size and 
charge that are important for kidney targeting are not well understood or reported. To 
answer some of these questions, here we tested the effects of polymer charge and molecular 
weight (MW) on kidney distribution.
Methods: A panel of low-MW (LMW) polymers with fixed MW (~25 kDa) and 
increasing anionic content (0, 50, 80%) was intravenously injected into mice, and tissue 
accumulation was quantified after 7 days. A high-MW (HMW), highly anionic (47 kDa, 
80% anionic) polymer as well as mice with experimental glomerular disease were used to 
test the effects of MW and loss of filtration selectivity on polymer distribution.
Results: LMW polymers exhibited increasing kidney accumulation with increasing 
anionic content, and this trend was statistically significant (p-value < 0.0001). Confocal 
imaging of kidney sections revealed that polymers accumulated mostly in proximal tubules. 
Glomerular disease significantly augmented kidney accumulation of LMW 80%, but not 
HMW 80%, polymers. In vitro, LMW 80% polymers did not cause significant changes 
in viability in cultured proximal tubule cells, and were shown to be uptaken by active 
endocytosis. Dextran sulfate, a competitor of scavenger receptors, significantly reduced 
polymer uptake (p-value < 0.0001).
Conclusions: This study revealed important features of polymers that drive kidney 
accumulation: highly anionic polymers with MW ~25 kDa preferentially accumulate 
in the kidneys and specifically in proximal tubules, and glomerular disease enhances 
accumulation. Importantly, these polymers were not cytotoxic in vitro, and were uptaken 
by endocytosis and/or anionic scavenger receptors. These findings establish an important 
foundation in developing targeted drug carriers for kidney disease applications.
Funding: Other U.S. Government Support
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Small-Sized Cationic miRi-PCNPs Selectively Target the Kidney for 
High-Efficiency Anti-Fibrosis Treatment
Mengbi Zhang,1 Xinran Geng,2 Jianqiang Hu,2 Aiqing Li.1 1Nanfang Hospital, 
Southern Medical University, Guangzhou, China; 2Department of Chemistry, 
School of Chemistry and Chemical Engineering, South China University of 
Technology, Guangzhuo, China.
Background: MicroRNA perhaps become an innovative and effective target in the 
clinical treatment of renal fibrosis. However, the poor stability in vivo, low transfection 
efficacy, inappropriate bio-distribution and rapid renal clearance of miRNA greatly limits 
its clinical applications. In this study, we produced small-sized cationic miRi-PCNPs with 
excellent biocompatibility, high cellular uptake efficiency, selectively kidney targeting 
capacity and high efficiency anti-fibrosis treatment.
Methods: The encapsulation efficiency and drug loading efficiency of miRi was 
evaluated through measuring UV-vis absorption peak intensity of the bottom solution. 
The conjugation and stability of the miRi in PCNPs were evaluated through agarose gel 
electrophoresis. Biocompatibility was assessed using cell counting kit-8, ELISA Kits and 
HE staining. Transfection efficiency of miRi-PCNPs in vitro was evaluated by fluorescence 
microscopy and flow cytometry. In- and ex-vivo fluorescence imaging software was used to 
assess the bio-distribution of PCNPs. Western blot, pathological staining and real-time PCR 
analyses showed that therapeutic efficiency of miRi-PCNPs on kidney fibrosis in unilateral 
ureteral obstruction mice.
Results: The image of agarose gel electrophoresis showed that easily degraded miRi was 
encapsulated in PCNPs and thus prevented from degradation by ribonuclease. Cytotoxicity, 
immunotoxicity and systemic toxicity assays suggested that PCNPs had excellent 
biocompatibility. Flow cytometric assessment revealed that high transfection efficacy of miRi-
PCNPs. Ex vivo fluorescence imaging indicated that PCNPs had kidney-targeting ability. 
Western blot, pathological staining and real-time PCR analyses showed that therapeutic 
efficiency of miRi-PCNPs on kidney fibrosis was much higher than bare miRi.
Conclusions: The miRi-PCNPs possessed excellent biocompatibility, high gene 
transfection efficacy and specific kidney targeting capacity. Therefore, small-sized cationic 
PCNPs would be a promising drug deliver for RNA, which represents an innovative avenue 
of designing and developing targeting therapy system for renal fibrosis or other diseases.
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Substrate Elasticity Governs Differentiation of Renal Tubule Cells in 
Prolonged Culture
Harold D. Love,2 Mingfang Ao,2 Seiver K. Jorgensen,1 Rachel C. Evans,2 
Lindsey Swearingen,1 Nicholas J. Ferrell,2 Raymond C. Harris,2 Leslie S. Gewin,2 
Roy Zent,4 Shuvo Roy,3 William H. Fissell.2 1Vanderbilt University, Nashville, 
TN; 2Vanderbilt University Medical Center, Nashville, TN; 3UCSF, San 
Francisco, CA; 4Vanderbilt Medical Center, Nashville, TN.
Background: Primary tubule epithelial cells rapidly dedifferentiate in culture and 
form a flattened epithelium lacking the brush border essential to apicobasal transport. This 
dedifferentiation undermines the use of cultured cells for drug screening and cell-based 
therapies. We hypothesized that substrate mechanical properties have a strong influence on 
differentiation in primary renal cell culture.
Methods: We cultured primary renal tubule cells on polyacrylamide hydrogels of 
varying elasticity for 2 and 4 weeks. We measured expression of key transporter proteins 
essential to renal tubule cell function at the transcript and protein level.
Results: Primary tubule cells cultured on soft substrates for two weeks did not show 
marked differences in transcript or protein levels for NHE3 or AQP1, but after 4 weeks 
in culture, NHE3 and AQP-1 were increased on 0.5kPa gels compared with 50 kPa gels. 
Smad2 phosphorylation increased with increasing substrate stiffness, suggesting a role for 
TGF-β signaling. Indeed, addition of TGF-β to cell culture media abolished the elasticity-
dependent increase in NHE3.
Conclusions: These data support the hypothesis that scaffold elasticity is a critical 
factor in differentiation of renal tubule cells in culture.
Funding: Other NIH Support - NIBIB
NHE3 figure. (A): Expression levels of SLC9A3 (NHE3) were determined by qPCR in 
primary HREC cultured on soft (0.5 kPa), and stiff (50 kPa) hydrogels. Cells were harvested 
at short (10 days) and long (28 days) time points. (B): NHE3 protein levels were determined 
by Western Blot analysis. (C): NHE3 (Red) and F-actin (Green) staining of HREC cells 
cultured on soft (0.5 kPa) and stiff (50 kPa) hydrogels for 4 weeks. * p=0.003, ** p=0.00002.
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Gentamycin Induced Nephrotoxicity in an Artificial System of the Renal 
Proximal Tubule
Jan Sradnick,1 Florian Schmieder,2 Frank Sonntag,2 Vladimir T. Todorov,1 
Bernd Hohenstein,3,1 Christian Hugo.1 1University Hospital CGC, Technical 
University Dresden, Dresden, Germany; 2Fraunhofer Institute for Material and 
Technology IWS, Dresden, Germany; 3Nephrological Center Villingen-
Schwenningen, Villingen-Schwenningen, Germany.
Background: Mimicking proximal tubular physiology within cell-based artificial 
model systems might help to investigate pathophysiology of nephrotoxic drugs such as 
gentamycin commonly leading to acute kidney injury. We present a model system for 
transport processes along the proximal tubular barrier (TB).
Methods: Immortalized proximal tubule cells (RPTEC) and blood outgrowth 
endothelial cells (BOEC) were seeded on a transwell membrane (TW) to build a TB. 
Barrier function was measured by transepithelial electrical resistance (TEER) of the cellular 
layers on a daily basis. Gentamycin, moxifloxacin and vehicle control (CTRL) were added 
over the whole experiment (21 days) to investigate their nephrotoxic potential and disturb 
TB. The treatment influence on glucose transport through the TB was determined by 
adding fluorescent d-glucose analog (2-NBDG) to the medium above the RPTEC layer. 
Fluorescence intensity was measured after 90 min at the opposite TW side. Moreover the 
inhibition of SGLT2 by dapagliflocin (dapa) and canagliflocin (cana) and vehicle control 
(contr) during antibiotic treatment was studied.
Results: Moxifloxacin treatment increased TEER (median: 153 Ωcm2 vs control 
115 Ωcm2), while gentamycin lowered TEER (median: 73 Ωcm2). 2-NBDG concentration 
increased in the gentamycin treated group (0.79 μg/ml ±0.08 vs control 0.48 μg/ml ±0.07). 
No differences were found due to moxifloxacin. In CTRLs SGLT2 inhibition led to a 
reduction of 2-NBDG concentration in BOEC medium (CTRL: 0.5±0.07 μg/ml; ddapa: 
0.3 ± 0.03 μg/ml; cana: 0.3 ± 0.06 μg/ml)). In cell systems treated with gentamycin 2-NDBG 
concentration was reduced following SGLT2 inhibition (contr: 0.8 ±0.09 μg/ml; dapa: 
0.5 ±0.02 μg/ml; cana: 0,4 ±0.06 μg/ml). Moxifloxacin had no effect.
Conclusions: In the present study a functional renal proximal tubule cell culture model 
suitable for drug testing assays was established. TEER and direct 2-NDGB transport were 
suitable to identify nephrotoxic effects on the TB in vitro. In a next step, this system will be 
integrated in our established microfluidic system.
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Genome Engineering of Renal Epithelial Cells with Improved Function 
for an Implantable Artificial Kidney
Matthew H. Wilson,2 Wentian Luo,1 Ruth A. Veach,1 Rick C. Welch,4 Shuvo Roy,3 
William H. Fissell.1 1Vanderbilt University Medical center, Nashville, TN; 2VA 
Medical Center, Nashville, TN; 3UCSF, San Francisco, CA; 4VUMC, Nashville, TN.
Background: Development of an implantable artificial kidney (IAK) will require renal 
epithelial cells capable of reabsorption of salt and water. We used genome engineering 
to bioengineer cells for improved Na+/H+ exchange and H20 reabsorption. The non-viral 
piggyBac transposon system enables genome engineering cells to stably overexpress one 
or more transgenes simultaneously. The CRISPR/Cas9 system (dCas9-VP64) enables 
selective endogenous gene upregulation in human cells.
Methods: We generated epitope tagged human sodium hydrogen exchanger 3 (NHE3) 
and aquaporin-1 (AQP1) cDNA expressing piggyBac transposon vectors. piggyBac 
transposase expression enabled stable transposon integration and overexpression of NHE3 
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or AQP1 in cultured renal epithelial cells. The transposon system was also used to integrate 
dCas9-VP64 into human kidney cells.
Results: As a proof-of-principle, we generated renal epithelial (MDCK) cells stably 
expressing a cumate inducible NHE3 and confirmed induced overexpression via Western 
blot and immunofluorescence analysis. We also generated MDCK cells stably overexpressing 
AQP1. Cell surface delivery of NHE3 and AQP1 was confirmed using cell surface 
biotinylation assays. Importantly, MDCK cells expressing AQP1 and cumate inducible 
NHE3 demonstrated increased cellular transport. We subsequently used a high-throughput 
flow cytometry analysis to generate a library of MDCK clones with varying expression of 
AQP1 and NHE3 to determine the best ratios for optimized transport function. We tested and 
validated various guide RNAs (gRNAs) for targeted upregulation of endogenous AQP1 and 
NHE3 in human kidney cells at both the mRNA and protein level.
Conclusions: Our results reveal that genome engineering can enable improved cellular 
transport via stable overexpression of AQP1 and NHE3 in polarized kidney epithelial 
cells. We are currently attempting to extend these studies to human renal proximal tubular 
epithelial (RPTEC) cells. Additionally, the dCas9-VP64 system enables upregulation 
of endogenous AQP1 and NHE3 in human kidney cells. These studies will allow us to 
determine the optimal genome engineering approach and renal epithelial cell type for 
maximal function in the IAK.
Funding: Other NIH Support - NIBIB
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Pathophysiology of Proteinuria: Human Serum Increases Proliferation 
and Markers of AKI in an Ex Vivo Model of the Human Proximal Tubule
Ranita S. Patel,3 Kevin Lidberg,4 Catherine K. Yeung,5,2 Jonathan Himmelfarb,2,1 
Edward J. Kelly.4,2 1University of Washington, Seattle, WA; 2Kidney Research 
Institute, Seattle, WA; 3Nephrology, Seattle Children’s Hospital, Seattle, WA; 
4Pharmaceutics, University of Washington, Seattle, WA; 5School of Pharmacy, 
University of Washington, Seattle, WA.
Background: Proteinuria is a pathological cause for progressive kidney damage. 
Prolonged exposure to excess glomerular filtered protein may create tubulointerstitial 
lesions via activation of proinflammatory, proapoptotic, and profibrotic pathways in renal 
proximal tubular cells[1]. Thus the proximal tubule likely plays an important role in 
propagating the decline of renal function in proteinuric kidney disease[2].
Methods: Here, we exposed a 3D microphysiological system (MPS) of the human 
kidney proximal tubule developed in our lab[3] to human serum to explore key functional 
and structural events that may eventually lead to progressive tubulointerstitial damage. 
This is a bioengineered platform containing a tubular collagen scaffold that houses human 
proximal tubule cells. Perfusion setup allows for the delivery of media and experimental 
solutions, as well as physiological shear stress applied to the cellular tubule.
Results: Treatment with 0.5%, 1%, and 2% human serum for 48 hours led to an increase 
in kidney injury molecule 1 (KIM-1) concentrations measured from MPS effluents, with an 
average 3.55 fold increase in the 2% human serum group. The percent of cells expressing 
the proliferation marker Ki67 dramatically increased with ascending concentrations of 
human serum (8% in control vs 38% in 2 percent human serum).
Conclusions: These data demonstrate that proximal tubule cells exposed to proteins 
contained in human serum shed KIM-1 (a urinary biomarker of acute kidney injury) and 
undergo a burst of proliferation, perhaps as a compensatory mechanism or as an initiative 
to begin tubular wound healing. Future efforts will include prolonging exposure times, 
quantifying injury-associated microRNAs, and performing transcriptomic profiling 
with RNA sequencing to reveal novel biomarkers or pathways involved in proteinuric 
pathophysiology.
Funding: Other NIH Support - NCATS - National Center for Advancing Translational 
Science/CASIS - Center for the Advancement of Science in Space
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An In Vivo Vascularization Model for the Implantation of Embryonic 
Kidneys
Morgan Hamon,1,3 Peter V. Hauser,1,2 Lifu Zhao,4,1 Masaki Nishikawa,5,3 
Hiroshi Kimura,6 Naomi Yanagawa,4,1 Norimoto Yanagawa.1,3 1Greater Los 
Angeles Veterans Administration, Los Angeles, CA; 2Integrative Biology and 
Physiology, University of California Los Angeles, Los Angeles, CA; 3Department 
of Medicine, University of California Los Angeles, Los Angeles, CA; 4Sepulveda 
Research Corporation, North Hills, CA; 5GLAVAHS at Sepulveda, North Hills, 
CA; 6Tokai University, Hiratsuka, Japan.
Background: A major obstacle to implantation of ex vivo engineered 3D tissues is the 
incorporation of a functional vascular supply in order to minimize the ischemic injury and 
support the growth of the new tissue. This may be overcome in an in vivo vascularization 
model where the engineered tissues can be implanted into a pre-vascularized chamber. The 
main goal of our present study is to design such a vascularization chamber and test its 
applicability for the implantation of embryonic kidneys.
Methods: The chamber was composed of three polydimethylsiloxane (PDMS) layers: 
a base layer holding the chamber, a center layer containing the vascularization chamber with 
an opening on one side to allow the in-growth of blood vessels, and a top layer that closes 
the chamber. Pre-vascularization of the chamber was achieved by first loading the chamber 
with collagen I (C), matrigel (M) or matrigel+VEGF (MV), followed by implantation of the 
chamber between the abdominal aorta and vena cava in a mouse. After the chamber was 
pre-vascularized, mouse embryonic kidneys were placed onto the chamber. The growth and 
development of the embryonic kidneys were monitored and analyzed.
Results: We found that endothelial cells and developing vascular networks were 
detected in the chamber as early as 48h after implantation. Filling the chamber with MV 
significantly shortened the time required for pre-vascularizaion: 7 days for C loaded 
chambers, 5 days for M loaded chambers, and 2 days for MV loaded chambers. As 
compared to non-vascularized chambers, implantation of E12.5 mouse embryonic kidneys 
to pre-vascularized chambers showed significant increase in size and ureteric branching 
after 7 days.
Conclusions: We demonstrate in our present study that the in vivo vascularization 
model by using pre-vascularized chamber could be useful for the implantation of embryonic 
kidneys. Further studies are going on to optimize our system and examine the development 
and vascularization of the implanted embryonic kidneys.
Funding: Private Foundation Support
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In Silico Pharmacological Assessment of Nifedipine and Mibefradil in 
Modulating Action Potential in Guinea Pig Ureter Smooth Muscle Cells 
Chitaranjan Mahapatra. Indian Institute of Technology Bombay, Mumbai, India.
Background: Urinary stones with higher diameter are unlikely to pass in the ureter in 
most situations. Activation of muscarinic and adrenergic receptors increases the amplitude 
of ureter smooth muscle (USM) contractions. Understanding the drug effects with respect 
to various ion channels offers several possibilities for safety pharmacological assessment. 
Here our overarching objective is to utilize the computational model to simulate the effects 
of nifedipine and mibefradil on the USM cell action potential (AP).
Methods: The USM cell is described as an equivalent electrical circuit with a number 
of variable conductances representing two voltage-gated Ca2+ (T - type and L- type) 
channels, two voltage-gated potassium channels, three calcium-dependent potassium 
channels. A drug model for nifedipine and mibefradil were simulated by multiplying the 
maximal conductance of L-type and T-type Ca2+ channels with a scaling factor between  
0 and 1 to mimic the drug concentration. The maximum conductance value of the L-type 
and T-type Ca2+ channels were set to 0.00006 and 0.00002 mho/cm2 respectively.
Results: The resting membrane potential (RMP) was set at — 50mV. A current pulse 
of 2 nA for 50 ms was injected to evoke the AP. The peak amplitude of AP and total inward 
current were substantially reduced after adding nifedipine by 50% and 100 % of it’s control 
value. Adding mibefradil by 50% of it’s control value reduced the peak amplitude of AP 
and inward current. However, the addition of mibefradil by 100% resulted no AP and 
zero inward current. The results showed that both L-type and T-type Ca2+ channels play 
important roles in generating APs, although L-type calcium channel is the major contributor 
to the total inward current. This simulation showed that the activation of more T-type Ca2+ 
channels will cause higher excitability of the USM cell.
Conclusions: Our approach provides a “virtual workbench” for simulating USM cell 
AP with maximal objectivity and faithfulness with regard to recordings in experiments. 
This in silico assessment showed that while inhibition of L-type Ca2+ channel suppresses or 
eliminates APs, the RMP is left unaffected. Complete inhibition of T-type Ca2+ channel also 
reduced USM cell excitability. A compound of nifedipine and mibefradil may form a new 
pharmacological maneuver towards USM cell contraction of high amplitude.
TH-PO767 Poster Thursday
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Extracellular Matrix Stiffening by Sugars: Implications for Diabetic 
Nephropathy
Snehal Sant, Nicholas J. Ferrell. Vanderbilt University Medical Center, 
Nashville, TN.
Background: Stiffening of the extracellular matrix (ECM) contributes to a number 
of diseases including cancer and organ fibrosis. Diabetes leads to formation of advanced 
glycation end products (AGEs) that crosslink the ECM and may lead to increased matrix 
stiffness. The pathological consequences of ECM stiffening in diabetes are not fully 
understood and may be a mechanism by which AGEs contribute to disease progression 
is diabetic nephropathy. The goal of this work was to evaluate the effectiveness of AGE 
inhibitors in mitigating sugar-induced ECM stiffening of decellularized kidney ECM. AGEs 
are known to elicit receptor-mediated pathogenic effects that are independent of ECM 
stiffening. In order to evaluate the specific effects of ECM stiffening, we developed a novel 
ex vivo model to alter the mechanical properties of the ECM to evaluate effects on tubular 
epithelial cell function.
Methods: To evaluate the effects of sugar exposure on ECM stiffness, porcine kidney 
cortex was detergent decellularized and incubated in reducing sugars (glucose and ribose). 
The elastic modulus of sugar-modified ECM was measured by compression testing in the 
presence and absence of the AGE inhibitors pyridoxamine and DTPA. To evaluate cellular 
response to ECM stiffening, decellularized kidney cortical ECM was crosslinked with 
genipin. Tubular epithelial cells were cultured on genipin stiffened ECM and matrix and 
growth factor gene expression were analyzed by qRT-PCR.
Results: Sugar incubation resulted in a concentration-dependent increase in ECM 
stiffness in the presence of both glucose and ribose. Both PM and DTPA reduced ECM 
stiffening by glucose and ribose, but were most effective in the presence of glucose. Genipin 
modification of decellularized ECM resulted in a dose-dependent increase in stiffness that 
was similar to that induced by sugar modification. Tubular epithelial cells grown on genipin 
modified ECM showed upregulation of collagen IV and connective tissue growth factor 
gene expression.
Conclusions: These data show that inhibiting AGE formation mitigates sugar-induced 
ECM stiffening ex vivo. We introduce a method of evaluating cellular response to ECM 
stiffening by genipin modification of decellularized kidney ECM and show that kidney cells 
had increased expression of pro-fibrotic genes. These preliminary studies suggest that ECM 
stiffening may have pathological consequences in diabetic nephropathy.
Funding: NIDDK Support, Private Foundation Support
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Cyclosporine Induces Fenestral Injury in Bioengineered Human Kidney 
Microvessels
Ryan J. Nagao,1 Shreeram Akilesh,1 Jeffrey W. Pippin,1 Edward J. Kelly,1 
Stuart J. Shankland,1 Jonathan Himmelfarb,2 Ying Zheng.1 1University of 
Washington, Seattle, WA; 2Kidney Research Institute, Seattle, WA.
Background: The use of cyclosporine A (CsA), a potent calcineurin inhibitor and 
immunosuppressant drug, has greatly improved the survival of patients receiving organ 
transplants, but also frequently results in significant nephrotoxicity. Transplant patients 
treated with CsA have developed acute kidney injury with arteriolopathy, thrombotic 
microangiopathy (TMA) and tubulopathy. However, the mechanisms underlying human 
kidney-specific toxicological sensitivity to CsA are still poorly understood. Thus, there is 
a need to build human kidney-specific biomimetic models capable of replicating clinical 
patterns of CsA-induced kidney injury.
Methods: Here, using 2-D culture and bioengineered 3-D microvessels containing 
human kidney peritubular microvascular endothelial cells (HKMECs), we show CsA 
exposure at as little as 1 h at 1 μg/mL leads to endothelial injury not observed using human 
umbilical vein microvascular endothelial cells (HUVECs). We then analyzed clinical 
biopsies of patients who recieived CsA and expressed TMA for the presence of peritubular 
capillary dysfunction.
Results: CsA induced dysfunction in HKMECs characterized by the loss of fenestrae, 
shear stress-related changes in cell morphology, signs of vascular inflammation, erythrocyte 
adhesion to the luminal surface of the endothelium and extravasation of erythrocytes into 
the interstitial space, whereas HUVECs were unaffected. CsA disrupted the formation of the 
fenestral diaphragm protein, PV-1. Vascular endothelial growth factor (VEGF) signaling, 
which is known to be integral to support fenestrae, was also blocked by CsA, whereas adding 
VEGF partially protected HKMECs from CsA-induced morphologic changes. Integrated 
genome regulatory analyses identified key distinctions in the landscapes of HKMECs 
compared to HUVECs, particularly around genes related to formation and maintenance of 
fenestrae. Kidney transplant biopsies from patients experiencing CsA toxicity showed a loss 
of PV-1 and evidence of erythrocyte extravasation which are consistent with changes in our 
bioengineered kidney 3-D microvessels.
Conclusions: These data demonstrate that CsA directly targets human kidney 
microvascular endothelial cells, disrupting their fenestral structure and function, and 
provides novel insights into kidney-specific organotypic mechanisms of CsA-induced 
microvascular injury.
Funding: NIDDK Support, Other NIH Support - UH2/UH3 TR000504 and 1UG3 
TR002158, Other U.S. Government Support, Private Foundation Support
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Platelet Accumulated Stress Modeling Predicts Platelet Activation and 
Thrombosis
Emily Marsh,2 Joseph J. Groszek,7 Phillip E. Williams,2 David C. Laneve,6 
Mark S. Goodin,5 Steven G. Goebel,5 Amanda Buck,1 Nathan Wright,3 
Danny Bluestein,4 Rachel C. Forbes,2 Shuvo Roy,3 William H. Fissell.1 
1Vanderbilt University, Nashville, TN; 2Vanderbilt University Medical Center, 
Nashville, TN; 3UCSF, San Francisco, CA; 4Stony Brook University, Stony 
Brook, NY; 5SimuTech Group, Hudson, OH; 6Vanderbilt Medical Center, 
Brentwood, TN; 7STERIS, Lakewood, OH.
Background: Thrombosis is a dreaded complication in blood-contacting medical 
devices including implantable artificial kidneys (IAK). Fluid shear stress primes platelets to 
initiate thrombosis. We compared computational predictions of platelet accumulated stress 
(PAS), biochemichemical assays of platelet activation, and in vivo thrombosis between two 
different implanted hemofilter designs.
Methods: Platelet accumulated stress distributions under unsteady flow in two 
candidate blood conduit designs were predicted using computational fluid dynamics (CFD) 
tools. Hemofilter catrtridges were machined from polycarbonate and implanted in Class 
A dogs for 2-7 days without anticoagulation. Platelet activation was measured using a 
modified prothrombinase assay. Thrombosis was assessed by measuring cyclic variation in 
blood velocity downstream of a controlled femoral artery lesion.
Results: The two different hemofilter designs gave rise to two distinct histograms 
of PAS. In some animals, the hemofilter with the larger PAS (A) thombosed almost 
immediately while the other hemofilter (B) did not. In animals where both cartridges 
remained patent, platelet stress as measured by prothrombinase activity agreed with CFD 
predictions. Femoral artery flow was disrupted to a greater extent in animals implanted with 
hemofilter A than Hemofilter B.
Conclusions: We showed that CFD predicted biochemical measures of platelet 
activation and propensity to thrombosis in an animal model of an implanted hemofilter. 
Platelet stress is a useful tool to predict thromboembolic complications in blood contacting 
medical devices.
Funding: Other NIH Support - NIBIB
Pulsatile flow was comapred between a femoral artery with a standarized trauma (red) and a 
contralateral control artery (green). Cyclic variations in flow distinct from respiration arise 
from transient thrombosis at the arterial trauma.
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Patient-Friendly Kidney Function Monitoring
Ragwa Elsayed. San Jose State University, San Francisco, CA.
Background: Chronic Kidney Disease was ranked the 13th leading cause of Death in 
2013. Measuring the creatinine level in blood became an important biomarker to evaluate 
the kidney performance by filtering the wastes. The objective is to develop an easy low-cost 
monitoring method of the level of creatinine in blood without visiting a medical facility. It is 
an alert for individuals to check their kidney functions and communicate with a nephrologist 
when they suspect a kidney failure in the early stages.
Methods: The project is based on using paper microfluidics technology. A paper strip 
with alkaline picrate solution produces a colorimetric response upon applying a creatinine 
sample. 65 different creatinine concentrations were tested to detect the colorimetry change 
and images were captured using a smart-phone camera inside a light-box. The color 
intensity feature was extracted using different technqiues. The features extracted were used 
to train the several machine learning models for testing.
Results: The results show that the best machine learning models that gives the best 
accurate results and the lowest root mean square error is Nearest Neighbor regression model 
using the histogram of colors extraction technique.
Conclusions: We proved the feasibility and the reliability of our proposed technique. 
We are providing individuals with an affordable, reliable, and remote technology to allow 
rapid and frequent testing of kidney health. Individuals will be able to monitor their kidney 
functions without visiting a medical facility. So, we can imagine how this method would 
help patients to get early treatment, adjust medication dose, or monitor the performance 
of the transplanted kidney. Our approach is using a smart-phone for detection due to the 
accessibility of a smart-phone to any individual.
Root-mean square error for creatinine concentration prediction 0-4 (mg/dl)
Root-mean square error for creatinine prediction concentration 0-4 (mg/dl).
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Exercise Games to Improve Balance and Mobility in Diabetic Patients 
Undergoing Hemodialysis: A Randomized Controlled Trial
Fadwa S. Al-Ali,1 He Zhou,2 Abdullah Hamad,1 Rania A. Ibrahim,1 Talal Talal,3 
Bijan Najafi.2 1Hamad Medical Corporation, Doha, Qatar; 2Baylor College of 
Medicine, HOUSTON, TX; 3hamad medical corp, Doha, Qatar.
Background: Poor balance and mobility are serious problems for older adults 
undergoing hemodialysis (HD). Patients visit HD clinics multiple times a week which 
provides an optimal opportunity for intervention. We have developed an interactive foot 
and ankle exercise game (exergame) that can be played during HD to improve mobility 
and balance.
Methods: Sixty diabetic subjects receiving HD were recruited and randomized into 
an intervention group (IG: n=29, age=63.3±8years, BMI=31.2±6kg/m2, female=41%) or 
control group (CG: n=31, age=66.5±10years, BMI=32.3±8kg/m2, female=55%). Both 
groups underwent a 4-week ankle and foot exercise program (30-min per session, 2 sessions 
per week) during HD. The IG received exercise via the exergame program (Fig. 1). The 
CG received foot and ankle exercise without any technology. Balance and mobility were 
examined at baseline and conclusion of the program.
Results: All IG subjects achieved to complete all exercise tasks. No adverse event were 
reported. None of the subjects in the IG was dropped out. In balance exam under eyes-open 
condition, the IG had higher improvement in ankle stability, hip stability, and center of mass 
sway in response to exercise, when compared with the CG (58% vs. 3%, 47% vs -1%, and 
59% vs. -8%, respectively, p<0.05). Similar between-group difference was also observed 
under eyes-closed condition. From mobility standpoint, results suggested 5% reduction in 
sedentary behavior (p=0.049, Cohen’s effect size d=0.70) and 53% more vigorous activities 
in the IG compared to the CG in response to exercise.
Conclusions: This study demonstrated feasibility and effectiveness of an innovative 
game-therapy program to improve balance and mobility in HD patients. The key innovation 
of this intervention is its practicality to be done during HD, which could address the 
limitations of prior exercise interventions in HD patients.
Funding: Government Support - Non-U.S.
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Augmented Foam Sclerotherapy with Laser Treatment for Cystic Disease 
from In Vitro Sclerosant Screening Platform
Soohyun Jeong, Min hee Park, Kangwon Lee. Seoul National University, Seoul, 
Republic of Korea.
Background: Sclerotherapy has been empirically used in cyst ablation as managemental 
treatment of polycystic kidney. However valid, clinical reports and research mostly rely on 
the ex-vivo platform and desultory treatment methods. To standardize the sclerotherapy and 
minimize the complication of usage of sclerotherapy treatment to cystic disease, in vitro 
platform from which the sclerosing solution be tested and enhanced sclerosing treatment 
methods for cyst ablation must be studied.
Methods: The transwell system and collagen embedded cells were used in this study as 
the in vitro platform. The cellular membrane-disrupting effect was quantitatively measured 
in vitro by LDH assays which have been not tried before to our knowledge. Screening of 
sclerosing solution was conducted by measuring LDH level on this system. Photochemical 
tissue bonding from foam-delivered rose Bengal stains was carried out using 532nm 
green laser and two-photon laser. Sclerosing effect and degree of inflammation from the 
augmented foam sclerosant was studied in vivo.
Results: We found that the suggested in vitro platform reflect differential sclerosing 
properties from different sclerosing material than conventional cell analysis. In this study, 
we obtained the improved sclerosing foam with greater sclerosing and retention properties. 
This sclerosant was optimized with polidocanol, glycerol and rose bengal sufficient for cyst 
ablation and laser-assisted photochemical tissue bonding of the cystic membrane.
Conclusions: To our knowledge, our study is the first in suggesting sclerotherapy with 
photochemical tissue bonding combined treatment methods, along with the suggested foam 
sclerosant screening platform. We believe our research would extend possible treatment 
option for cyst management in polycystic kidney, as well as the promoting the development 
of safer, better sclerosing materials.
TH-PO773 Poster Thursday
Cellular Crosstalk in Glomerular Diseases - I
Prognosis of C1q Nephropathy Is Not Different According to the Presence 
of Segmental Sclerosis or Nephrotic Proteinuria
Ji Young Ryu,1 Hyung Eun Son,1 Ho Jun Chin.1,2 1Seoul National University 
Bundang Hospital, Seongnam, Republic of Korea; 2Department of Internal 
Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Background: C1q nephropathy is pathologically defined, however, clinical 
characteristics and prognosis of it remain poorly understood.
Methods: We collected the clinical and pathologic findings of 6413 adult patients with 
renal biopsy since 2000. We selected 29 patients followed more than 3 months after renal 
biopsy among 34 patients diagnosed as C1q nephropathy. We matched age and gender to the 
patients with FSGS and MCD and analyzed the incidence of ESRD.
Results: In patients with C1q nephropathy, estimated GFR was 83.2± 34.7 (20.1-
126.9) ml/min/1.73 m2 and UPCR was 3.30 ± 4.08 (0.05-18.53) g/g creatinine. Glomerular 
segmental sclerosis (SS) was present in 14 (48.3 %) patients. Patients with SS had higher 
level of systolic blood pressure and lower level of eGFR compared to patients without SS 
(127.0 ± 9.8 vs 114.5 ± 13.0 mmHg, p=0.010, and 67.4± 31.8 vs 98.0 ± 31.3 ml/min/1.73 m2, 
p=0.016, respectively). Other findings such as UPCR and pathologic findings except 
amount of SS were not different between groups. The levels of eGFR and UPCR at 
6 months after renal biopsy was not different in C1q patients according to the presence of 
SS. There were 17.2 % (5/29) incidence of ESRD during 94.2 ± 48.6 months. The most 
important prognostic factors were the amount of glomerular global sclerosis by Cox’s hazard 
proportional model adjusted by age, gender, eGFR, and pathologic findings. The presence 
of SS or the level of UPCR at renal biopsy were not the independent risk factors to renal 
outcome. The renal outcome was worse in C1q nephropathy compared to MCD (0/28), but, 
similar between C1q nephropathy and FSGS (6/28) (p=0.008 by Log-rank test).
Conclusions: Glomerular global sclerosis is the most important risk factor to the renal 
outcome rather than glomerular segmental sclerosis or UPCR in C1q nephropathy. The 
prognosis of C1q nephropathy was similar to that of FSGS and worse than that of MCD.
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Histopathologic and Clinical Outcomes in Idiopathic and Diabetic 
Nodular Glomerulosclerosis
Mirza M. Baig,1 Michael T. Eadon,1 Carrie L. Phillips,2 Sharon M. Moe,1 
Ranjani N. Moorthi.1 1Indiana University School of Medicine, Indianapolis, IN; 
2Pathology, Indiana University Health, Indianapolis, IN.
Background: Idiopathic nodular glomerulosclerosis (ING) is a rare form of 
glomerulopathy with an unclear pathogenesis. The hallmark of this entity is mesangial 
nodularity in the absence of diabetes mellitus or specific immune deposits on 
immunofluorescence. We hypothesized that ING and diabetic nephropathy (DN) have 
distinct histopathological features that explain their pathogenesis.
Methods: From Jan 2001 to Dec 2016, native renal biopsy interpretations were 
queried from Indiana University Health’s electronic database. Natural language processing 
followed by manual adjudication confirmed 49 cases of ING. Histopathologic features 
were compared between individuals with ING(N=49) and DN (N=770). Clinical and 
histopathological features of ING cohort were studied in detail and compared with previous 
cohorts.
Results: The mean age of ING cohort was 68 y with a Caucasian (73%) and male 
(55%) predominance. Clinical findings at presentation included renal insufficiency (81%) 
and nephrotic range proteinuria (53%). 94% had hypertension while 68% had a smoking 
history. All 49 patients had prominent diffuse mesangial sclerosis with focal or global 
nodularity. Interstitial fibrosis, tubular atrophy, and arteriosclerosis were present in >90% 
of patients. Among cases with follow up (N=25, median 616 days), 60% progressed to 
ESRD, 67% had declining renal function (creatinine increase of 0.5 mg/dL), and 38% died. 
Between the ING and DN cohorts, the only significant differences in histological findings 
were the degree of arteriosclerosis and podocyte foot process effacement, which were more 
prevalent and severe in the diabetic cohort (P<0.001).
Conclusions: In our cohort of ING, we confirmed the close association of hypertension, 
hyperlipidemia, and smoking observed in prior studies. We found minimal histologic 
differences reported between patients diagnosed with ING and DN. The histologic similarity 
of ING and DN glomerular lesions suggests there may be a common pathogenic process 
that is distinct from the presence or absence of diabetes mellitus. Future longitudinal studies 
are required to determine the pathogenesis of nodule formation in ING.
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Glomerular Basement Membrane Composition Controls Podocyte 
Morphology and Downstream Signaling
Franziska Lausecker,1 Michael J. Randles,6 Hellyeh Hamidi,3 Jon Humphries,1 
Adam Byron,5 Jeffrey H. Miner,2 Christoph Ballestrem,1 Roy Zent,4 
Martin J. Humphries,1 Rachel Lennon.1 1University of Manchester, Manchester, 
United Kingdom; 2Washington University School of Medicine, St. Louis, MO; 
3University of Turku, Turku, Finland; 4Vanderbilt Medical Center, Nashville, 
TN; 5University of Edinburgh, Edinburgh, United Kingdom; 6The University of 
Manchester, Chester, United Kingdom.
Background: Type IV collagen α3,4,5 networks are specific to the basement 
membranes in the eye, ear and the kidney. Absence of the heterotrimer leads to Alport 
syndrome, characterized by basement membrane defects and in the glomerulus by podocyte 
foot process effacement and detachment. Previous studies have shown that podocytes in 
Alport syndrome are exposed to ectopic matrix ligands as type IV collagen α1,1,2. Here, 
we investigated how exposure of podocytes to distinct matrix ligands influences molecular 
signaling events.
Methods: Human podocytes were spread on type IV collagen or laminins (511 or 521), 
and cellular morphology was assayed using light microscopy. Podocyte adhesion complexes 
were isolated and we analysed global protein levels on the different ligands using mass 
spectrometry-based proteomics. We used laser-based micropatterning to restrict cellular 
morphology and dissect the links between cell geometry and matrix ligand signalling and to 
determine how these factors regulate intracellular signaling in time and space.
Results: Matrix ligands determined distinct podocyte morphologies: podocytes on type 
IV collagen were rounded, compared to podocytes on laminin isoforms, which were more 
elongated. Proteomic analysis revealed ligand-dependent adhesion complex composition, 
with upregulation of PKCa in laminin-spread podocytes. Ratiometric imaging revealed 
increased focal adhesion signaling in podocytes spread on type IV collagen, associated with 
increased Rac1 signaling. Interestingly, when podocytes were restricted to micropatterned 
laminin circles or collagen IV lines, there was a partial rescue of the focal adhesion-
signaling phenotype.
Conclusions: We show that exposure to different basement membrane ligands results 
in altered downstream signaling and podocyte morphology. Furthermore, we suggest 
that podocyte morphology controls downstream signaling independently of the basement 
membrane ligand. Loss of the mature type IV collagen α3,4,5 network exposes podocytes 
to a range of different matrix ligands. Our data suggest that altered basement membrane 
composition may contribute to podocyte effacement in Alport syndrome through changes in 
podocyte morphology and signaling. Rescuing these defects in podocyte morphology could 
represent a new therapeutic strategy.
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Podocytic Infolding Glomerulopathy: An Indian Case Series
Sree bhushan Raju. NIMS, Hydrabad, India.
Background: Several cases of Podocytic infolding glomerulopathy (PIG) has been 
reported from Japan as a new disease entity since 2008. It is a rare glomerular abnormality 
seen predominantly among women in associaciation with membranous nephropathy 
and autoimmune diseases involving glomerular basement membrane (GBM) bubbling 
visualised by light microscopy (LM), invagination of the podocyte membrane, and the 
presence of microspheres viewable by electron microscopy (EM). The clinical features 
and pathogenesis of this condition are still unclear. We reviewed clinical, biochemical, and 
pathological features of cases of PIG at our institute.
Methods: We retrospectively analysed cases of PIG as per the diagnostic criteria 
during preceding two years
Results: Seven cases of PIG have been reported from our institute. The mean age 
of the patients was 48, (43-65) years, and all were men. Both hypertension and diabetes 
were seen in five, one each had hypertension and diabetes. Four patients had nephrotic 
range proteinuria and two had insignificant proteinuria. All had increased creatinine with a 
mean of 4.3mg%. Autoimmune workup and viral markers were negative in all. LM showed 
diabetic nephropathy (DN) in 5 cases and hypertensive changes in 1 case and secondary 
FSGS in 1 case. Microspheres were present in all but podocyte infolding was present in 1 
and cluster formation of microspheres was found in 3 cases.
Conclusions: PIG in our case series differs from that of Japan in male preponderance 
and is associated with diabetic nephropathy. The clinical significance of PIG in south Indian 
population is yet to be elucidated
TH-PO777 Poster Thursday
Cellular Crosstalk in Glomerular Diseases - I
Characterizing Renal Involvement in Hermansky-Pudlak Syndrome in a 
Zebrafish Model
Janina Müller-Deile,1 Heiko J. Schenk,1 Patricia A. Schroder,2 Mario Schiffer.3 
1MHH, Hanover, Germany; 2Mount Desert Island Biological Laboratory, 
Salisbury Cove, ME; 3Hannover Medical School, Hannover, Germany.
Background: Hermansky-Pudlak Syndrome (HPS) is an autosomal recessive genetic 
disorder, which is characterized by oculo-cutaneous albinism, a platelet storage pool 
deficiency as well as a lysosomal accumulation of ceroid lipofuscin. Impaired renal function 
and proteinuric kidney disease has been reported in some studies but we hypothesize that 
renal involvement in HPS is underestimated.
Methods: To evaluate proteinuric kidney disease in HPS we used the transgenic 
zebrafish line Tg(l-fabp:eGFP-DBP). These zebrafish express a fabp-promoter regulated 
enhanced GFP-labeled vitamin-D-binding-protein that resembles the size of human 
albumin. The loss of eGFP-DBP from the circulation indicates a dysfunction of the 
glomerular filtration barrier and can easily be assessed in the eye of the fish. We performed 
morpholino injection of different HPS isoforms at one to four cell stage of the zebrafish.
Results: Pericardial effusion and yolk sac edema were seen after knockdown of 
HPS-1, -4 and -5. Knockdown HPS-1 and -5 induced significant of proteinuria at 96 hour 
post fertilization. To determine whether edema and proteinuria resulted from glomerular 
defects, we used transmission electron microscopy of the zebrafish pronephros. Intracellular 
inclusion bodies were mainly seen in podocytes indicating that podocytes are the dominant 
glomerular cell type effected in HPS. Moreover, podocyte effacement could be detected 
after knockdown of different HPS isoforms (figure 1).
Conclusions: We established the first animal model to investigate glomerular damage 
in HPS. Understanding the renal involvement in HPS may allow the use of already existing 
therapeutic options and could prolong the life expectancy of affected patients.
(figure 1)
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A High-Power View of Renal Pathology of Sickle Cell Disease In Vivo
Balint Der, Janos Peti-Peterdi. Zilkha Neurogenetic Institute, Keck School of 
Medicine, University of Southern California, Los Angeles, CA.
Background: Sickle cell disease (SCD) is commonly associated with chronic 
kidney disease. In SCD a mutation of the β-globin chain of hemoglobin (Hbb) causes the 
sickling of red blood cells (RBC). The complexity of renal histopathology in SCD is well 
recognized, however its pathogenesis is not fully understood. The purpose of this study was 
to improve the mechanistic understanding of the renal pathology development of SCD by 
establishing an intravital imaging model of the SCD kidney for the comprehensive, high-
power quantitative visualization of renal morphology and function at the single cell and 
nephron level.
Methods: C57BL/6;129 female mice (5-8 weeks old) homozygous for both 
Hbbtm2(HBG1,HBB)Tow and Hbatm1(HBA)Tow mutations were used as a model of SCD. High resolution 
intravital multiphoton microscopy (MPM) of the intact living kidney was performed either 
in single-session or serial imaging.
Results: Compared to healthy control C57BL/6 mice, SCD mice displayed numerous 
enlarged superficial glomeruli with robust hyperdynamic vascular pathology and 
inflammation. Metabolites of hemoglobin degradation typical of the SCD environment 
(likely bilirubin) were readily detectable as green autofluorescence in the circulating 
plasma, and accumulated intracellularly in the glomerular mesangium and in tubular 
segments. Among the normally ‘doughnut’ shaped RBCs, sickled variants were also visible. 
Glomerular hyperfiltration was manifested by robustly increased glomerular diameter, and 
expanded Bowman’s space and tubular lumen. However, RBC velocity was decreased in 
glomerular capillaries, likely due to sickling and the observed numerous microthrombi, and 
the glomerulus-specific homing of different immune cell populations (CD3+ and CD44+). 
Albumin-Alexa594 uptake was visible in endothelial cells, podocytes, and proximal tubule 
cells. Over time, glomerular filtration barrier permeability increased progressively as 
evidenced by the robust filtration of albumin and 500 kDa dextran to the Bowman’s space 
by 8 weeks of age.
Conclusions: This study successfully performed in vivo MPM imaging of the SCD 
kidney, and directly visualized the impaired glomerular hemodynamics, endothelial and 
tubular injury, and chronic inflammation characteristic to SCD. MPM imaging of novel 
cellular and molecular mechanisms will help to improve our understanding of SCD kidney 
disease and to identify new targets for future therapeutic development.
Funding: NIDDK Support
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Toll Like Receptor 4 Expression in Kidney Biopsies with Adaptive FSGS
Suman Krishna Kotla, Mythili Ghanta. Internal Medicine / Nephrology, 
University of Texas Southwestern Medical Center, Dallas, TX.
Background: Adaptive focal segmental glomerulosclerosis (FSGS) is characterized 
histologically by glomerulosclerosis with progressive interstitial fibrosis and tubular atrophy 
(IFTA). This is an important cause of kidney failure in native as well as transplanted kidneys. 
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Any injury to the native or the transplanted kidney from factors such as chronic reflux, 
obesity, viral infections, rejection lead to progressive kidney failure which is histologically 
characterized by adaptive FSGS. Pathogenesis of progressive renal dysfunction in adaptive 
FSGS remains unclear and hence therapies remain ineffective at present. Toll like receptors 
are innate immune receptors that recognize molecular patterns of tissue injury termed as 
damage associated molecular proteins (DAMPs). The activation of this pathway leads to 
recruitment of inflammatory cells to the areas of injury leading to progressive fibrosis. Since 
adaptive FSGS is initiated by chronic injury we propose that DAMPs released from the 
injured kidneys lead to TLR activation and activate sterile inflammation and fibrosis leading 
to progressive disease.
Methods: Retrospective chart review was performed to identify patients with adaptive 
FSGS and clinical characteristics were obtained. Archived kidney biopsy slides of these 
cases were stained for TLR4 utilizing immunohistochemistry
Results: We analyzed expression of TLR4 in the native and transplant kidney biopsies 
of 8 patients with adaptive FSGS. 3 of the 8 biopsies showed tubular epithelial cell 
expression of TLR4. Mean Serum Creatinine at the time of biopsy and IFTA scores were 
higher in the group with TLR4 positive stain compared to the group with negative stain 
(Serum creatinine 3.7 mg/dl vs 1.16 mg/dl respectively) (IFTA 41% vs 21%).
Conclusions: This study identifies role of TLR4 activation in adaptive FSGS. Biopsies 
with advanced renal dysfunction expressed TLR4 and TLR4 expression was absent when 
the renal disease was not advanced. Findings of this study need to be verified in a large 
sample size.
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Identification of Disease-Relevant MicroRNA-Target Gene Interactions
Christopher L. O’Connor,1 Jian Shi,1 Huanqing Zhang,2 David L. Turner,2 
Markus Bitzer.1 1Medicine, University of Michigan, Ann Arbor, MI; 2Biological 
Chemistry, University of Michigan, Ann Arbor, MI.
Background: We previously determined that deletion of the miR-21 gene accentuates 
TGF-β induced, diabetic and aging-associated glomerular disease in mice. Because 
miRNA-target gene interactions are cell-type and context specific, we used independent 
methods to identify relevant in vivo target gene interactions for miR-21.
Methods: Candidate microRNA target gene interactions for miR-21 were identified by 
Pearson correlation between mRNA and microRNA abundance in micro-dissected glomeruli 
from patients undergoing nephrectomy at Michigan Medicine using Affymetrix ST2.1 
arrays and small-RNA Illumina-truseq (n=39). Genes differentially expressed in kidney 
cortex of miR-21 deficient and wildtype mice were determined using Affymetrix ST2.1 
arrays (n=8). Presence of microRNA target genes in the RNA-induced silencing complex 
(RISC) were experimentally identified using PAR-CLIP (photoactivatable ribonucleoside-
enhanced crosslinking and immunoprecipitation) and further validated using Bru-seq 
(bromouridine sequencing) in cultured human podocyte and HK2 cells. Retained candidate 
miR-21 target genes were further validated in kidney cortex of aged miR-21 deficient and 
wildtype mice (age 24-28 months; n=24) using qRT-PCR. The relevance of these genes for 
human pathology and phenotype was determined by association with clinical as well as 
glomerular and tubulointerstitial morphometric parameters as assessed through routine and 
immunohistochemical stains and quantitative image analysis in FFPE sections.
Results: 1761 and 1309 genes exhibited significant correlation with miR-21-5p or 
miR-21-3p (p<0.05; FDR<0.05: 10 and 1, respectively). 1728 genes were significantly 
different between miR-21 WT and KO mouse kidney cortex (p<0.05). PAR-CLIP identified 
752 and 687 cross-linked binding sites for miR-21-5p and miR-21-3p in 517 and 367 unique 
genes, respectively. Some genes, including Smad7, exhibited differential targeting by miR-
21 in podocytes and HK2-cells, and after exposure to TGF-β. Of these miR-21 target genes, 
15 exhibited statistically significant correlation with clinical and morphometric parameters 
in nephrectomies and two exhibited significant differential expression in kidney cortex of 
aged miR-21 mutant mice (p<0.05).
Conclusions: MicroRNA-target gene interactions are cell-type and context specific 
and require careful further investigations.
Funding: NIDDK Support
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Insertions and Deletions (InDels) in the Non-Translated Human Genome 
Upstream of ZHX2 Alter ZHX2 mRNA Expression in MCD and FSGS
Sumant S. Chugh,1 Ranjan Das,1 Maria Del Nogal Avila,1 Joubert B. Kharlyngdoh,1 
Hector Donoro blazquez,1 Eduardo Molina-Jijon,1 Lionel C. Clement,1 
Camille E. Mace,1 Carmen Avila-Casado.2 Glomerular Disease Therapeutics 
Laboratory 1Rush University Medical Center, Chicago, IL; 2University Health 
Network, University of Toronto, Toronto, ON, Canada.
Background: ZHX proteins, especially ZHX2, play a critical role as transcriptional 
regulators of human and experimental podocyte disease. Multiple groups conducting 
whole exome sequencing were unable to find significant mutations in these genes in human 
glomerular disease. We sequenced the genome upstream of ZHX2 and the intronic sequence 
looking for insertions and deletions that may induce DNA conformational changes, resulting 
in altered ZHX2 expression.
Methods: The 1.3 million bp region between the beginning of the immediate 
upstream gene HAS2 and the end of ZHX2 was sequenced in 28 patients with nephrotic 
syndrome (8 MCD, 2 FSGS tip lesion, 8 FSGS with mutations in slit diaphragm genes, 4 
recurrent FSGS,2 recurrent non-HIV collapsing glomerulopathy, and 4 Hodgkin disease 
with nephrotic syndrome) and 27 healthy controls using Agilent Custom capture and high 
throughput Illumina sequencing to obtain about 8 million sequences per sample. The 
Qiagen Biomedical Genomics Workbench software was used to identify InDels > 3 bp 
and > 20 sequences present exclusively in the patient population. One of the InDels 
identified was replicated in cultured podocytes using CRISPR Cas9 technology to study 
changes in ZHX2 expression.
Results: We identified 5 InDels (size range 6 to 67) shared by than one patient and 
40 others (size range 4 to 133) present in a single patient. These InDels were absent in 
controls and the 1000 genomes project. Patients with MCD and FSGS tip lesion had a high 
percentage of deletions (approximately 80%), whereas those with other forms of FSGS 
had mostly insertions (approximately 66%). Significance of these indels was verified by 
inserting one of these indels upstream of ZHX2 in single cell derived immortalized human 
podocytes by CRISPR-Cas9 approach. Podocytes carrying this InDel developed reduced 
ZHX2 expression.
Conclusions: Insertions and deletions upstream of the ZHX2 gene are commonly 
present in patients with MCD and FSGS patients and alter ZHX2 mRNA expression.
Funding: NIDDK Support
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Proteoglycans Play a Major Role in the Charge Selectivity of the 
Glomerular Barrier
Alina Khramova,1 Boerje Haraldsson,2,1 Kerstin Ebefors,1 Jenny C. Nystrom.1 
1University of Gothenburg, Göteborg, Sweden; 2Novartis, BASEL, Switzerland.
Background: The loss of ability to retain macromolecules is a critical step during 
kidney disease progression. The luminal surface layer of the glomerular capillary 
endothelium (ESL) is an understudied part of the filtration barrier. The ESL consist of a 
glycocalyx and an endothelial cell coat, which together form a stagnant mucosal layer – an 
additional barrier to prevent a leakage of high molecular weight proteins such as albumin.
Methods: In this study, we were guided by basic principles of ion exchange 
chromatography. In order to elute highly negatively charged proteoglycans of the ESL, we 
used 1 M NaCl solution (HS). 1 M mannitol (HO) was included to evaluate osmotic effects. 
A control fraction was eluted with normal saline solution (0,15 M NaCl) (NS). Solutions 
were introduced intraarterially to rat kidneys under anesthesia in vivo. Venous effluent was 
collected and analyzed using proteomics and mass spectrometry. Immunohistochemistry 
was used to confirm the presence of identified PGs and the thickness of the glomerular ESL 
was evaluated using intralipid droplets.
Results: We identified 9 PGs in ESL, for their contribution to the glomerular 
barrier function (presented in the order of high to low abundance): lumican, glypican-1, 
syndecan-4, perlecan, podocan, decorin, serglycan, agrin and biglycan. In general, PGs 
were more abundant in HS samples compare to NS and HO. TEM demonstrated that the 
glomerular ESL thickness was significantly reduced in HS perfused rats – 28% (p<0.05) 
compared to rats perfused with NS.
Conclusions: ESL itself is formed by PGs, glycosaminoglycans, glycoproteins and 
soluble proteins and represents a dynamic structure with significant molecular turnover. As 
a part of molecular sieving system, PGs support the characteristic permselective properties 
in kidneys by balancing the level of mentioned molecules. Thus molecular composition 
of the ESL may have a significant impact on local charge alterations which can lead to 
severe interruptions of the filtration system and, as a result, macromolecular leakage. 
These findings might be essential for understanding kidney pathology development and 
protein leakage at a molecular level as well as result in new possible targets for treatment 
of proteinuria.
Funding: Private Foundation Support, Government Support - Non-U.S.
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The Role of DDR1 in Podocyte Lipotoxicity and Progression of Alport 
Syndrome
Jin Ju Kim,1 Judith T. Molina David,1 Javier T. Varona Santos,1 
Sandra M. Merscher,1 Jeffrey H. Miner,2 Alessia Fornoni.1 1University of Miami, 
Miami, FL; 2Washington University School of Medicine, St. Louis, MO.
Background: The glomerular basement membrane (GBM) is primarily composed of 
laminin and Collagen type IV. De novo production of the α1 chain of collagen type I (Col I) 
has been observed mouse models of Alport Syndrome (AS, Col4a3KO). Discoidin domain 
receptor 1 (DDR1) is a unique receptor tyrosine kinase that is activated by collagens. 
Deletion of the DDR1 in Col4a3KO mice was shown to improve survival and renal 
function. However, how DDR1 activation by aberrant collagen production contributes to 
podocyte injury and proteinuria is poorly understood. I test the hypothesis that aberrant Col 
I induced podocyte injury via DDR1-dependent lipotoxicity.
Methods: Differentiated human podocytes were serum starved, followed by 18hrs 
treatment with 50ug/mL Col I (Corning). Following collagen treatments, podocyte lipid 
content was determined by BODIPY 493/503 and Cell Mask Blue staining. Free Fatty 
acid (FFA) uptake assessed using a fluorometric free fatty acid uptake kit (abcam). Mice 
in which exon 5 of a3 chain of collagen type IV is deleted (Col4a3KO), a model for AS, 
were obtained from the Jackson Laboratory for the determination of kidney cortex DDR1 
phosphorylation
Results: DDR1 phosphorylation was increased in kidney cortex from Col4a3KO mice 
and the degree of DDR1 phosphorylation correlated with blood urine nitrogen (BUN, R2 
=0.7, p<0.01). In vitro, DDR1 was phosphorylated by collagen type I (50μg/mL, 18hr) in 
cultured human podocytes. Increased intracellular lipid accumulation (p<0.05), Free fatty 
acid (FFA) uptake (p<0.01) and intracellular triglyceride level (p<0.01) were also observed 
in Col I treated podocytes. DDR1 dominant active (DA) transfected HEK293 cells showed 
increased expression of CD36, a protein involved in FA uptake, and increased FFA uptake 
compared to cells transfected with DDR1 WT and dominant negative (DN, p<0.05). siRNA 
knock down of CD36 reduced FFA uptake when compared to scramble siRNA control 
(p<0.05). Col I induced DDR1 activation is associated with podocyte lipotoxicity, FFA 
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uptake and intracellular lipid droplet deposition. Glomeruli isolated from Col4a3KO mice 
showed increased lipid content and increased expression of CD36.
Conclusions: Our data suggest that Col I-induced/DDR1-mediated lipotoxicity may 
represent a novel mechanism leading to podocyte injury in AS.
Funding: NIDDK Support
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Novel Parietal Epithelial Cell Subpopulations in FSGS and the Origin of 
the Glomerular Tip Lesion
Christoph Kuppe,1 Turgay Saritas,1 Victor G. Puelles,2 Bart Smeets,3 Peter Boor,1 
Mario Schiffer,7 Agnes B. Fogo,4 Hermann-Josef Groene,5 Jürgen Floege,6 
Marcus J. Moeller.1 Moeller group 1University Hospital of RWTH Aachen, 
Aachen, Germany; 2University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 3Radboud University Medical Center, Nijmegen, Netherlands; 
4Vanderbilt University Medical Center, Nashville, TN; 5German Cancer Research 
Center, Heidelberg, Germany; 6RWTH University of Aachen, Aachen, Germany; 
7Hannover Medical School, Hannover, Germany.
Background: Beside the classical flat PECs, proximal tubular epithelial like cells 
extend onto Bowman’s capsule (termed columnar PECs). In addition, a third intermediate 
PEC subgroup is identified at the junction between the flat and columnar PEC subgroups. 
Here, we have investigated the potential relevance of these PEC subgroups in focal 
segmental glomerulosclerosis (FSGS) for the first time.
Methods: The previously described transgenic mouse line PEC-rtTA labeled all 
three PEC subgroups. To allow lineage-tracing experiments, we identified the inducible 
Pax8-rtTA mouse line, which labeled specifically the two novel subgroups, columnar and 
intermediate PECs, but not flat PECs.
Results: In aging Pax8rtTA mice, cell fate mapping showed no evidence for significant 
transdifferentiation from flat PECs to columnar or intermediate PECs or vice versa. In 
glomerular disease (rapidly progressive glomerulonephritis, and FSGS), columnar PECs 
transitioned in part into the intermediate PEC phenotype. Intermediate PECs preferentially 
expressed activation markers CD44 and Ki-67, suggesting that this subgroup of PECs 
is activated more easily than the classical flat PECs. In murine FSGS, columnar and 
intermediate PECs formed sclerotic lesions contributing more than half of the cells. In 
FSGS patients, cells forming the tip lesions expressed markers of intermediate PECs.
Conclusions: In summary, columnar PECs acquire a transient phenotype termed 
intermediate PECs, which is more prone to cellular activation and proliferation compared 
to the classical flat PECs. Both novel PEC subgroups showed the capacity to form sclerotic 
lesions. We propose that in human FSGS patients tip lesions originate from this novel 
subgroup of PECs, which is located close to the tubular outlet.
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Isolation of Functional Podocytes from Urine of Alport Patients and 
Establishment of a Kidney Glomerulus Chip
Benedetta Bussolati,1 Corinne Iampietro,2 Linda Bellucci,2 Fanny O. Arcolino,3 
Elena N. Levtchenko.4 1University of Torino, Torino, Italy; 2Universita’ degli 
studi di Torino, Turin, Italy; 3KU Leuven, Leuven, Belgium; 4University 
Hospitals Leuven, Herent, Belgium.
Background: Alport syndrome (AS) is a genetic disorder characterized by mutations 
in genes of collagen IV α3α4α5 network. In AS patients, podocyte loss starts at birth and 
results in progressive reduction in podocyte number per glomerulus with time, correlating 
with renal damage. However, data on the phenotypic characteristics of human AS podocytes 
are currently limited. Our goal was to set up a novel human in vitro model representing the 
functional and molecular alterations typical of human AS glomerulus.
Methods: We generated conditionally immortalized podocytes from urine of three 
different patients (aged 16.5 ± 5.5 years) with Alport syndrome (AS podocytes). Patient 1 
showed mutation in Col4α3 gene, while Patient 2 and Patient 3 were mutated in Col4α5 
gene in heterozygosity and in hemizygosity, respectively. AS podocytes were analyzed 
for specific podocyte markers by RT-PCR and Western Blot and release of collagen IV 
chains by ELISA. Podocyte motility was tested in a wound-healing assay. We generated a 
kidney glomerulus chip using primary human glomerular endothelial cells and control or 
AS podocytes using a millifluidic device for continuous perfusion of co-culture. Passage of 
FITC-labeled albumin and inulin was measured by fluorimeter.
Results: Podocytes were immortalized with temperature-sensitive SV40T and 
telomerase reverse transcriptase. Cell showed growth at 33°C (permissive condition) and 
differentiation at 37°C, with expression of typical podocyte markers. Levels of nephrin, 
but not of podocin or synaptopodin, were significantly reduced in respect to control 
podocytes. Significant reduction of specific collagen IV chains were detected, confirm 
specific functional alterations. AS podocytes had significantly reduced motility in respect 
to control podocytes. Moreover, when co-cultured with human glomerular endothelial cells 
in an organ-on-a-chip millifluidic device, AS podocytes presented increased permeability.
Conclusions: In conclusion, we generated Alport podocytes and identified specific 
molecular and functional alterations. Moreover, we developed a human Alport glomerulus-
on-a-chip that replicates kidney disease phenotype in vitro. This will be pivotal to test 
pharmacological approaches for glomerular alterations in Alport disease.
Funding: Government Support - Non-U.S.
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β2-Adrenergic Receptor Stimulation Accelerates Podocyte Recovery from 
Injury Through Increased Mitochondrial Biogenesis
Ehtesham Arif,1 Ashish K. Solanki,1 Pankaj Srivastava,1 Judit Megyesi,3 
Michael G. Janech,1 Kenneth Kwon,1 Justin B. Collier,1 Rick G. Schnellmann,4 
Deepak Nihalani.1 1Medical University of South Carolina, Charleston, SC; 
3University of Arkansas for Medical Science, Little Rock, AR; 4University of 
Arizona, Tucson, AZ.
Background: Mitochondrial biogenesis (MB) is an adaptive response required to meet 
the metabolic and energy demand during acute injury to various organs, including kidney 
suggesting that MB plays a central role in cellular recovery from injury. In this report, we 
demonstrate that β2-AR mediated MB accelerates the recovery of podocytes from injury.
Methods: RNA-Sequencing of inured podocytes was performed to identify differential 
gene expression of mitochondrial genes. Oxygen consumption rate in response to β2-AR 
activation was measured using sea-horse approach. Effect of β2-AR agonist formoterol 
on restoring injury-induced loss of actin cytoskeleton organization and localization of 
slit-diaphragm protein Neph1 was analyzed using confocal microscopy. Additionally, 
formoterol was used to stimulate β2-AR in mice and determine its ability to restore the 
loss of glomerular filtration function. The histological, ultrastructural and immunostaining 
analysis of kidney sections was performed to assess structural and molecular changes in 
treated mice kidneys. MtDNA copy number was estimated through the qPCR analysis.
Results: Injury induced significant upregulation of β2-AR along with PGC-1α and 
several key components of the mitochondrial ETC. The activation of β2-AR by formoterol 
showed remarkable restoration of injury-induced changes in actin cytoskeleton organization 
and loss of Neph1 at the podocyte cell membrane. Importantly, in a mouse model of NTS-
induced glomerulonephritis, post NTS-injury when glomerular dysfunction was established, 
treatment with β2-AR agonist formoterol accelerated the recovery of glomerular function 
by reducing proteinuria and restoring kidney pathology. Immunoblotting and qPCR 
analysis showed that multiple proteins of the ETC were elevated and glomerular expression 
of the MB marker PGC-1α was restored. mtDNA copy number was significantly higher 
in mice treated with β2-AR agonist formoterol. Additionally, β2-AR knockdown in 
cultured podocytes significantly reduced mtDNA copy number and increased podocytes 
susceptibility to glomerular injury.
Conclusions: Overall, these results reveal β2-AR stimulation as a critical event 
required for podocyte recovery and identifies β2-AR agonist as a novel therapeutic target 
for treating podocytopathies.
Funding: NIDDK Support
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MAD2B-Medicated Cell Cycle Re-Entry of Podocytes Is Involved in the 
Pathogenesis of FSGS
Dian Bao, Hua Su, Chun Zhang. Union Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan, China.
Background: Mitotic spindle assembly checkpoint protein 2 (MAD2B), an APC/C 
inhibitor, plays a pivotal role in cell cycle control. Previously, we reported that upregulation 
of MAD2B is involved in several renal diseases. However, the role and mechanism of 
MAD2B in the pathogenesis of focal segmental glomerulosclerosis (FSGS) is not known. In 
this study, we aimed to explore the role and mechanism of MAD2B in regulation podocyte 
cell cycle re-entry during FSGS.
Methods: Mouse FSGS model and conditionally immortalized human podocytes 
(HPCs) under puromycin aminonucleoside (PAN) treatment was utilized. Expression of 
MAD2B, APC/C complex regulatory molecules Cdh1, as well as its substrates cyclinB1, 
skp2, p27 and cyclinE1 was detected by western blot and immunohistochemistry. The cell 
cycle was analyzed by flow cytometry. Ki-67 and p-H3 expression was assessed by western 
blot and immunofluorescence. Knockdown of MAD2B was carried out by lentiviral shRNA 
transfection. Ku55933, a specific inhibitor of ATM kinase, was utilized. And PYR-41 was 
applied to interfere ubiquitination. CoIP was performed to assess the interaction between 
ATM and MAD2B.
Results: Comparing to control mice, the level of MAD2B in the glomeruli of FSGS 
mice is elevated dramatically. In PAN-treated HPCs, MAD2B deficiency attenuated the 
upregulation of p-H3, cyclinB1 and reversed Cdh1 reduction, which was companied by 
less cells staying in S-stage. Furthermore, pharmacological interference of ATM kinase 
activity in vitro ameliorated the accumulation of MAD2B with the less expression of p-H3 
and Ki67 and the preservation of podocyte function presenting as increased podocin and 
CD2AP abundance. Finally, by using inhibitor targeting ubiquitinaton abolished the ATM 
kinase-mediated MAD2B regulation and subsequent cell cycle re-entry of podocytes, both 
in vitro and in vivo.
Conclusions: Overexpression of MAD2B is involved in the cell cycle re-entry and 
podocyte injury during FSGS, while ATM kinase-mediated posttranslational modification, 
especially ubiquitination is the potential upstream mechanism for MAD2B regulation.
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Characterizing Podocyte Cell Cultures and Genetic Markers of Podocyte 
Maturity
Thomas Soare, Wei Zhang, Amy D. Westerling-Bui, Hien G. Hoang, 
Adam Tebbe, Liron Walsh, Peter H. Mundel, Thomas T. Tibbitts. Goldfinch Bio, 
Cambridge, MA.
Background: Podocytes are terminally differentiated cells that are vital to kidney 
function. Injury and loss of these cells leads to the presence of protein in the urine, scarring of 
the kidney, and ultimately renal failure. Conditionally-immortalized differentiated podocytes 
provide an in vitro model to test hypotheses regarding mechanisms of disease and responses 
to treatment. However, podocytes in culture lack slit diaphragms and may lack expression of 
certain podocyte-specific proteins, leading to doubts about maturation of cultured podocytes. 
Objective: To assess cultured podocytes for maturity, we characterized transcriptomic 
changes of podocyte differentiation at the single-cell resolution.
Methods: Undifferentiated and differentiated mouse podocytes were disassociated, 
prepped with a methanol fixation protocol (10X Genomics), and sequenced on an Illumina 
HiSeq machine (26x40). To assess transcriptomic changes associated with differentiation 
and passage number, cells were clustered with principal component analysis (PCA) and 
visualized with t-Distributed Stochastic Neighbor Embedding (tSNE). Cell clusters were 
labeled by visual inspection of expression of published cell-type specific markers. We 
leveraged publicly-available scRNAseq data of mouse kidney to identify differentially 
expressed genes associated with podocyte maturation and to infer the trajectory of 
differentiation along the podocyte lineage.
Results: We analyzed 1.8e9 reads in 17467 cells, identifying marker genes expressed 
in differentiated mouse podocytes. Differentiated podocytes in culture expressed markers 
of S-shaped bodies/early podocytes (Col4a1, Col4a2, Col4a5, Pax2) as well as markers of 
mature podocytes (Synpo, Podxl, Nupr1, Plce1, Foxd1). Other markers of mature podocytes 
were not expressed in cultured podocytes (Wt1, Nphs1, Nphs2, Col4a3, Col4a4).
Conclusions: Though differentiated podocytes in culture share transcriptomic 
signatures with mature podocytes in vivo, important differences remain. Future work will 
continue to differentiate mature mouse podocytes in culture as well as mature podocytes 
in human kidney organoids. Podocytes are critical to healthy kidney function. A robust in 
vitro model of mature podocytes is vital to assessing mechanisms of kidney disease and 
responses to treatment.
Funding: Commercial Support - Goldfinch Bio
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Involvement of Alpha-Actinin-4 in Focal Adhesion Signaling in Podocytes
Hsiao-Hui Lee. National Yang-Ming University, Taipei, Taiwan.
Background: Podocytes are specialized epithelial cells that cover the outer surfaces 
of glomerular capillaries. They adhere tightly to the glomerular basement membrane and 
elaborate foot processes to form slit diaphragm for plasma ultrafiltration. Previously, we 
found that alpha-actinin-4 facilities the recruitment of Shp2 at focal adhesions (FA) that 
promotes RhoA/ROCK signaling for actomyosin contractility in cells response to matrix 
rigidity. In this study, we aim to investigate the role of alpha-actinin-4 in controlling cellular 
tension by focal adhesion signaling in podocytes.
Methods: A mouse temperature-inducible podocyte line was used as a cell model, and 
the alpha-actinin-4 gene, ACTN4, was knockout by CRISPR/Cas9 method to study its role 
in the regulation of Shp2 and ROCKII activation.
Results: Differentiated podocytes exhibited matured FAs and stress fibers accompany 
with hyperactivation of Shp2 and ROCKII that were sensitive to the puromycin 
aminonucleside-induced podocyte injury. We found that ACTN4 deficiency abolished 
adhesion-mediated Shp2 and ROCKII activation in podocytes. By Shp2 FRET biosensor, 
we also demonstrated that alpha-actinin-4 is important for Shp2 activation. Inhibition of 
Shp2 activity significantly reduced ROCKII activation, FA and stress fiber formation that 
resulted in protein leakage during filtration.
Conclusions: Our results suggest that alpha-actinin-4 is required for adhesion-mediated 
Shp2 activation. It facilitates ROCK-mediated actomyosin contractility for strengthening 
cell adhesion and cytoskeletal architecture those are crucial for podocyte filtration function.
Funding: Government Support - Non-U.S.
TH-PO790 Poster Thursday
Cellular Crosstalk in Glomerular Diseases - I
Gut Microbial Metabolite Butyrate Protects Podocytes from Damage 
Through Epigenetic-Mediated Mechanisms
Raphael F. Felizardo,1,2 Danilo C. Almeida,1 Vinicius Andrade-Oliveira,2 
Rafael L. Pereira,3 Ingrid K. Watanabe,1 Niels O. Camara.1,2 1Federal University 
of São Paulo, São Paulo, Brazil; 2University of São Paulo, São Paulo, Brazil; 
3Universidade Federal do Paraná, Curitiba, Brazil.
Background: Chronic Kidney Disease (CKD) is characterized by gradual impairment 
of renal function over a period of months or years leading to permanent kidney failure. The 
damages or loss of podocytes, specialized cells involved on filtration process, stand as one 
of the most important causes that lead to a CKD. The literature comprises a large number of 
experimental attempts that focus on mitigating the damage to the podocytes. In recent years, 
many studies point to the gut microbiota as a modulator of intestinal and extraintestinal 
diseases through the generation of short chain fatty acids (SCFA). It is already known that 
chronic kidney patients have an imbalanced gut microbiota and lower production of SCFA. 
Thus, we have explored the protective role of butyrate, an AGCC able to regulate epigenetic 
processes during the progression of experimental glomerulopathy induced by doxorubicin.
Methods: Wild type mice were induced to develop glomerulopathy by a single dose of 
doxorubicin and treated with butyrate.
Results: Wild type mice treated with butyrate showed improvement of renal function, 
associated to a preserved podocyte layer in the glomerular basement membrane and 
reduction of pro-inflammatory and pro-fibrotic markers in the kidneys. Particularly, 
butyrate modulated the activity of enzymes involved on epigenetic modifications in the 
kidneys and changed the levels of histone markers (H3K9Ac, H3K4me3 and H3K9me3) 
in the promoter region of the genes encoding synaptopodin, podocin and NEPH-1 in 
podocytes. Concomitantly, treatment with butyrate was associated with the regulations 
of small GTPases activity Rac1 and Cdc42 and maintenance of the organization of actin 
filaments in the podocytes grown in vitro.
Conclusions: Our results demonstrate that butyrate exerts relevant effects on podocyte 
homeostasis during experimental nephropathy through epigenetic mediated mechanisms. 
FAPESP grant numbers 2012/15205-4, 2012/02270-2, 2017/06222-06 and 2017/05264-7.
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Anti-PLA2R Modulation of Human Podocytes: An In Vitro Model to 
Investigate the Glomerular Basement Membrane (GBM) in Membranous 
Nephropathy (MN)
Maryline Fresquet,1 Paul E. Brenchley,2 Rachel Lennon.1 1University of 
Manchester, Manchester, United Kingdom; 2Manchester Royal Infirmary, 
Manchester, United Kingdom.
Background: 80% of MN patients have IgG autoantibodies to the phospholipase A2 
receptor (PLA2R) expressed on podocytes. IgG-PLA2R immune complexes (IC) deposit 
in the GBM which over time shows expansion with associated proteinuria and consequent 
nephrotic syndrome. “Spikes” seen on silver stained sections represent formation of new 
GBM matrix between the deposits. How anti-PLA2R modulates podocyte, IC accumulation 
in the GBM and the molecular processes that control this GBM dysregulation remain 
unclear. Hypothesis: Anti-PLA2R treatment of podocytes in vitro will alter cell signaling 
and matrix composition/deposition.
Methods: In order to identify pathways involved in extracellular matrix (ECM) 
compositional changes in MN, we performed RNA sequencing and mass spectrometry 
(MS) analysis. Differentiated human podocytes over-expressing PLA2R were treated with 
protein G purified human anti-PLA2R from 10min up to 24h. Total RNA was sequenced 
and differential gene expression analysis was performed between the treated and control 
groups (P<0.05). For the MS experiment, podocytes were daily challenged with anti-
PLA2R over 7 days. Cells were denuded and the deposited matrix analysed. Identified 
proteins were integrated with the human matrisome database and peptides quantified using 
Maxquant software.
Results: TGFβ and Hippo signaling pathways were upregulated in the treated 
podocytes. EGR1, a transcription regulator of target genes involved in inflammatory 
and tissue damage processes was significantly increased (11fold) 1 hour post treatment. 
CTGF and CYR61 genes were also upregulated (6 and 3fold) suggesting activation of the 
YAP/TAZ pathway, component of the Hippo cascade. This pathway maintains podocytes 
homeostasis, integrity of the GBM and increases expression of matrix genes. Preliminary 
MS data of the treated podocytes ECM revealed a decrease in laminin and collagen proteins 
and an increase in ECM regulators and proteoglycans.
Conclusions: Anti-PLA2R can modulate podocyte matrix production in vitro. Our 
study revealed an early activation of YAP/TAZ pathway in cultured podocytes when treated 
with anti-PLA2R and a decrease in the main proteins of the GBM at a later stage. Candidate 
pathways will need to be further validated in order to decipher the mechanism of GBM 
organisation and remodelling in MN.
Funding: Private Foundation Support
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Single Glomerular Proteomes Connect Morphology and Function in 
Proteinuric Kidney Disease
Markus M. Rinschen. CECAD, Cologne, Germany.
Background: Kidney diseases are frequently heterogenous and affect different 
glomeruli to different extents.
Methods: We use ultrasensitive sample preparation combined with quantitative 
targeted and untargeted proteomics of single glomeruli to unravel functional co-expression 
modules in glomerular populations. We analyze microdissected glomeruli of three animal 
models
Results: In single glomeruli from three different rodent models of sclerotic glomerular 
disease, we identified a coherent protein expression module consisting of extracellular 
matrix protein deposition (reflecting glomerular sclerosis), glomerular albumin (reflecting 
proteinuria) and LAMP1, a lysosomal protein. This module was associated with a loss of 
podocyte marker proteins while genetic ablation of LAMP1-correlated lysosomal proteases 
could ameliorate glomerular damage in vivo. Furthermore, proteomic analyses of individual 
glomeruli from patients with genetic sclerotic and non-sclerotic proteinuric diseases 
revealed increased abundance of lysosomal proteins, in combination with a decreased 
abundance of mutated gene products.
Conclusions: Single glomerular proteomes connect morphology and function in 
proteinuric kidney disease. Altered protein homeostasis (proteostasis) is a conserved key 
mechanism in proteinuric kidney diseases. Moreover, our technology can capture intra-
individual variability in diseases of the kidney and other tissues at a sub-biopsy scale.
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A Multi-layered Quantitative In Vivo Expression Atlas of the Podocyte 
Unravels Kidney Disease Candidate Genes
Markus M. Rinschen,1,2 Florian Grahammer,3 Thomas Benzing,4 
Tobias B. Huber.5 1CECAD, Cologne, Germany; 2The Scripps Research Institute, 
San Diego, CA; 3University Hospital Hamburg-Eppendorf, Hamburg, Germany; 
4University of Cologne, Köln, Germany; 5University Medical Center Hamburg, 
Hamburg, Germany.
Background: Damage to and loss of glomerular podocytes has been identified as 
the culprit lesion in progressive kidney diseases. The molecular identity of podocytes is 
currently not known.
Methods: We combine deep mass spectrometry-based proteomics with mRNA 
sequencing, bioinformatics, and hypothesis-driven studies to provide a comprehensive and 
quantitative map of mammalian podocytes
Results: The analyses identified unanticipated signaling pathways in podocytes. 
Comparison of the in vivo datasets with proteomics data from podocyte cell cultures showed 
a limited value of available cell culture models. Moreover, in vivo stable isotope labeling 
by amino acids uncovered surprisingly rapid synthesis of mitochondrial proteins under 
steady-state conditions that was perturbed under autophagy-deficient, disease-susceptible 
conditions. Integration of acquired omics dimensions suggested FARP1 as a candidate 
essential for podocyte function, which could be substantiated by genetic analysis in humans 
and knockdown experiments in zebrafish. FARP1 is a potentially mechanosensitive proteins 
that links the actin cytoskeleton to the membrane.
Conclusions: This work exemplifies how the integration of multi-omics datasets can 
identify a framework of cell-type-specific features relevant for organ health and disease.
Funding: Government Support - Non-U.S.
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Integrative Computational Characterization of Membranous  
Nephropathy from Genome-Wide Transcriptome Profiles
Rachel S. Sealfon,1 Laura H. Mariani,2 Viji Nair,2 Julien Funk,1 Aaron Wong,1 
Carmen Avila-Casado,3 Olga Troyanskaya,1,4 Matthias Kretzler,2 Laurence 
H. Beck.5 1Flatiron Institute, New York, NY; 2University of Michigan, Ann Arbor, 
MI; 3University Health Network, University of Toronto, Toronto, ON, Canada; 
4Princeton University, Princeton, NJ; 5Boston University Medical Center,
Boston, MA.
Background: Genome-wide expression data from kidney tissue of patients with 
nephrotic syndrome provide an opportunity to elucidate mechanisms of injury specific 
to membranous nephropathy (MN). NEPTUNE and ERCB are prospective, multicenter 
cohort studies of patients with kidney disease profiled for whole-genome transcriptomes 
from microdissected biopsy tissue. These datasets provide rich, complementary resources 
to study the molecular characteristics of MN.
Methods: We examine whole-genome expression profiles of patients with MN and 
with other causes of nephrotic syndrome (e.g. FSGS, MCD, IgAN) from the NEPTUNE and 
ERCB cohorts. We construct machine learning classifiers to distinguish patients with each 
disease based on gene expression and evaluate performance using five-fold crossvalidation. 
Using Significance Analysis of Microarrays, we identify genes differentially expressed in 
MN and common to both cohorts. To identify functional modules within the MN-specific 
gene set, we perform community clustering of these genes in a kidney functional network 
which integrates thousands of transcriptome-wide assays using tissue-specific regularized 
Bayesian integration (Greene et al. 2015; Krishnan et al. 2016).
Results: We find that glomerular gene expression can separate patients with MN from 
other nephrotic patients with high accuracy (AUC=0.9). The genes most predictive of MN 
diagnosis in NEPTUNE are also differentially expressed in MN patients in the independent 
ERCB cohort. We identify 220 genes differentially expressed in MN patients common 
to both cohorts. These genes are enriched in multiple Gene Ontology terms, including 
anatomical structure morphogenesis, biological adhesion, and basement membrane, and also 
significantly enriched in homologs of mouse podocyte markers (Park et al. 2018). Clustering 
the MN-specific genes in a kidney functional network uncovers multiple modules, including 
gene clusters enriched in ion transport and the extracellular matrix.
Conclusions: This work identifies an expression profile specific to MN patients, 
enriched in podocyte-specific genes, and shared across patients in two independent cohorts. 
Such work may facilitate transcriptome-based disease classification, insight into disease 
pathophysiology, and targeted therapeutics.
Funding: NIDDK Support, Other NIH Support - NCATS
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Urinary Lipidomics: A New Biomarker in FSGS
Elif Erkan,1 Meredith P. Schuh,2 Andrew Potter,2 Steven Potter.3 1Children’s 
Hospital of Cincinnati, CIncinnati, OH; 2Cincinnati Children’s Hospital Medical 
Center, Cincinnati, OH; 3Cincinnati Children’s Hospital, Cincinnati, OH.
Background: Primary focal segmental glomerulosclerosis (FSGS) is the most common 
glomerular pathology leading to end-stage renal disease in pediatric patient population. The 
refractory nature of FSGS and a more than 30% recurrence rate after kidney transplantation 
renders treatment of FSGS as one of the most difficult challenges in pediatric nephrology. 
A significant knowledge gap in understanding the mechanism of progression in FSGS 
hampers the development and implementation of successful treatment strategies. We 
reported an increase in urinary fatty acid (FA) and lysophosphatidylcholine (LPC) levels 
in patients with FSGS in comparison to patients with minimal change disease (MCD). We 
hypothesize that phospholipase A2 (PLA2) metabolizes phosphotidylcholine (PC) 
leading to LPC and FA accumulation causing cellular toxicity in proximal tubule 
epithelial cells and podocytes contributes to progression in FSGS.
Methods: Mouse model of FSGS was induced by mutation of Fyn and Cd2ap(Fyn–/– 
Cd2ap+/– ) in podocytes. Untrageted lipidomics of urine and kidney lysates of FSGS mice 
was analyzed by CSH-QTOF MS/MS. Cytosolic PLA2 expression in podocytes and 
proximal tubule epithelial cells was investigated by RNA sequencing. Western blotting and 
immunoflurescence staining was utilized to examine cPLA2 and PLA2 receptor expression 
in FSGS mice and human kidney biopsy sections with MCD and FSGS.
Results: Untargeted lipidomics of FSGS mice urine demonstrated increased FA and 
LPC levels reminiscent of human urine samples. Lipidomic analysis of kidney lysate of 
FSGS mice revealed increased LPC levels. Cytosolic PLA2 and PLA2 receptor expression 
was increased in the proximal tubule epithelial cells and podocytes by western blotting, 
immunofluorecence and RNA sequencing in FSGS mice. Human kidney biopsy sections 
with FSGS revealed increased cPLA2 and PLA2 receptor expression in proximal tubule 
epithelial cells and podocytes in comparison to MCD.
Conclusions: We concluded that PLA2 activity is increased in proximal tubule 
epithelial cells and podocytes in mouse and human FSGS. Moreover urinary detection of 
PLA2 by products, LPC and FA, renders urinary lipidomics a novel tool for predicting the 
diagnosis and prognosis of FSGS. We propose that increased levels of circulating PLA2 and 
cellular levels of cPLA2 leads to accumulation of toxic lipid metabolites and contributes to 
progression by inducing apoptosis and inflammation in FSGS.
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Nebulette Is a Novel Actin-Associated Protein That Stabilizes Foot Process 
Architecture in Kidney Podocytes
Xuhua Ge, Xiaoxia Yu, Jordan M. Reid, Jenny Wong, Smiti Bhattacharya, 
Christina M. Cuttitta, Kirk N. Campbell, Evren U. Azeloglu. Icahn School of 
Medicine at Mount Sinai, New York, NY.
Background: Nebulette (Nebl) is a mechanosensitive actin-associated protein 
belonging to the nebulin family that stabilizes sarcomeric structures. It has been associated 
with dilated cardiomyopathy, and it is thought to be cardiac-specific. Its role in kidney 
function is unknown. Using isobaric tagged glomarular proteomics in the puromycin-
induced rat nephropathy model, we identified nebulette as the most significant glomerular 
protein whose expression negatively correlated with proteinuria. We hypothesized that 
nebulette plays a critical role in cytoskeletal stability of kidney podocytes.
Methods: We used the NephroSeq database and immunohistochemistry to check 
for transcript and protein expression levels of nebulette in human kidneys. Primary 
podocytes isolated from global nebulette knockout mice (Nebl-KO) and their wild-type 
littermates (WT) were used to define the role of nebulette in podocyte physiology. We 
used high-content microscopy, live-cell imaging, and atomic force microscopy to quantify 
morphological characteristics, cell motility, calcium dynamics, and cytoskeletal integrity. 
We evaluated nebulette’s functional role in vivo using the adriamycin-induced nephropathy 
model in WT and Nebl-KO mice.
Results: NephroSeq database revealed that nebulette expression was enriched in healthy 
glomeruli and decreased significantly in DN and FSGS patients. Immunohistochemistry and 
immunogold electron microscopy showed localization of nebulette in human podocytes, 
specifically in foot processes. Morphologically, Nebl-KO podocytes showed significantly 
smaller spreading area, nuclear size and lower number of focal adhesions. Further, Nebl-KO 
podocytes exhibited significantly altered cellular motility and calcium dynamics. In vivo, 
there was significantly higher albuminuria and foot process effacement in Nebl-KO mice 
treated with adriamycin at two weeks.
Conclusions: Nebulette is a novel actin-associated protein that localizes to the foot 
processes of kidney podocytes, and it is associated with glomerular disease in humans. 
It plays a key role in podocyte physiology by stabilizing the cytoskeletal integrity and 
regulating focal adhesion dynamics.
Funding: NIDDK Support, Private Foundation Support
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Gadolinium-Based Contrast Agents Are Metabolic Disruptors in the 
Kidney and Exacerbate Obesity- and Diabetes-Induced Kidney Injury
Brent Wagner,1,3 Doug Y. Lee,2 Chunyan Tan,2 Catherine Do,2 Yves C. Gorin.2,1 
1Kidney Institute of New Mexico and the University of New Mexico Health 
Science Center, Albuquerque, NM; 2University of Texas Health Science Center, 
San Antonio, TX; 3Medicine Section, New Mexico Veterans Administration 
Health Care System, Albuquerque, NM.
Background: Obesity-related renal injury and diabetic kidney disease are characterized 
by activation of glomerular mesangial cells and podocyte damage with alteration of lipid 
metabolism/lipid accumulation in both cell types resulting in matrix accumulation and 
eventual progression to glomerulosclerosis with loss of renal function. We examined the 
consequences of gadolinium-based contrast agent (GBCA) treatment in the kidney from 
mice with normal kidney function and the potential interplay between obese and diabetic 
states and GBCA exposure.
Methods: GBCA was administered for 4 weeks (as previously described); 
Metabolomics was by Metabolon. Obesity and diabetes (T1D) were induced by high fat 
diet (HFD, 60% kcal saturated fat) or streptozoticin, respectively (22 week durations of 
each condition). Obese and T1D mice in the GBCA groups were treated for 4 weeks prior 
to sacrifice.
Cellular Crosstalk in Glomerular Diseases - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
327
J Am Soc Nephrol 29: 2018 Poster/Thursday
Results: GBCA caused renal fibrotic lesions and podocyte injury that correlate with 
metabolic disorders as evidenced by increased serum triglyceride/cholesterol levels and 
insulin resistance. GBCA also induced expression of fatty acid translocase FAT/CD36—an 
indicator of fatty acid uptake—and lipogenic enzymes ATP citrate lyase (ACLY) and fatty 
acid synthase (FASN), indicators of de novo lipid synthesis. Metabolomic analysis indicated 
that renal lipid metabolism and metabolic markers of collagen turnover were significantly 
altered by GBCA. HFD- and T1D-induced fibrotic and podocyte injuries are worsened 
by GBCA. GBCA exacerbated 1) HFD-mediated hyperlipidemia, 2) CD36/ACLY/FASN 
upregulation, and 3) lipid metabolism as assessed by metabolomics.
Conclusions: Our work provides the first evidence that GBCA causes significant 
metabolic disorders and kidney injury in mice without renal insufficiency. These injurious 
actions of GBCA are amplified in obese and T1D. The understanding of the functional 
interplay between GBCA and diabetes/obesity will allow the development of therapeutic 
interventions or the establishment of effective preventive measures to reduce GBCA- and 
diabetes/obesity-mediated renal pathologies. This will help break the vicious cycle in which 
GBCA exposure in patients with normal kidney function or in obese or diabetic patients that 
may be more susceptible to GBCA-mediated renal pathologies.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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KLF15 Suppress Mesangial Cell Proliferation via Increasing the 
Sumoylation of P53
Quan Hong, Ou Li, Guangyan Cai, Xiangmei Chen. Chinese PLA Genaral 
Hospital, Beijing, China.
Background: Mesangial cell proliferation is a key pathological feature in a number 
of common human renal diseases including IgA and diabetic nephropathies. Knowledge 
of MCs response to pathological stimuli is crucial to the understanding of these disease 
processes. Our previous study demonstrated Krüppel-like factor 15 (KLF15), a kidney-
enriched zinc finger transcription factor, is required for inhibiting the proliferation 
of mesangial cell. This study aims to clarify the direct target gene and the downstream 
mechanism of KLF15 regulating mesangial proliferation.
Methods: DNA of primary human glomeruli mesangial cells (HMCs) was purified 
for sequencing after the chromatin immunoprecipitation with anti-KLF15 antibody. 
Differential expression protein of cells overexpressed KLF15 were assayed by SILAC/
HPLC/MS-MS. We screened out small ubiquitin-related modifier 1 (SUMO1) as the direct 
transcriptional target of KLF15 and validated with ChIP-PCR or Luciferase assay. Finally, 
we interpreted whether SUMO1 was able to sumolyate p53 then block cell cycle and inhibit 
cell proliferation using co-IP and EDU assay in vitro. Also demonstrated these mechanisms 
on the anti-thy1 rat model.
Results: We showed that in vitro treatment with PDGF BB or high glucose induced a 
rapid decrease of KLF15 and SUMO1 expression in HMC with proliferation, also decreased 
in the renal cortex of anti-thy 1 model at the proliferated periods. SUMO1 was screened 
out and validated as one of the direct target proteins of KLF15. SUMOs are a group of 
post-translational modification proteins and participate in transcriptional regulation, 
protein stabilization, and the cell cycle. Furthermore we demonstrated overexpress KLF15 
or SUMO1 enhanced the stability of P53 (Sumolyation-p53 expression increased) that 
functioned to block the cell cycle of HMCs, therefore obliterate the cell proliferation. 
Conversely, knockdown of SUMO1, even if cultured with PDGF BB, HMCs proliferation 
rates declined along with less sumolyation-P53. Finally, results showed the level of 
sumolyation-P53 in the kidney cortex from anti-thy 1 rat model decreased at proliferation 
periods.
Conclusions: These studies manipulate the critical mechanism of KLF15 targeting 
SUMO1 in mediating the proliferation of mesangial cells. It will be a potential target for 
IgAN or diabetic nephropahty’s therapy.
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Gender Differences in the Development of Glomerulopathy in Mice with 
an EGFR Gain-of-Function Mutation
Ming-Zhi Zhang, Yan Li, Zhilian Li, Suwan Wang, Yinqiu Wang, Aolei Niu, 
Xiaofeng Fan, Raymond C. Harris. Vanderbilt University Medical Center, 
Nashville, TN.
Background: The epidermal growth factor receptor (EGFR) is widely expressed in 
the kidney in both glomeruli and tubules. Under pathological conditions, persistent and 
dysregulated EGFR activation mediates progressive glomerular and tubulointerstitial injury 
in progressive kidney diseases. Although gender differences mediating predisposition to 
kidney injury are well known, no previous studies have investigated the potential role of 
EGFR in these differences.
Methods: Dsk5 mice have a Leu863Gln mutation within a region of the kinase domain 
that stabilizes the receptor activation loop, producing a gain-of-function allele that increases 
basal EGFR kinase activity. Both male and female heterozygous Dsk5 mice on the 129 
background were used. Dsk5 mice were oopherectomized or castrated before puberty to 
investigate the effect of sex hormones on EGFR expression and glomerulopathy.
Results: In male Dsk5 mice constitutive EGFR activation was confirmed by intense 
phospho-EGFR immunostaining not seen in wild type mice. At 15 weeks of age, male 
Dsk5 mice exhibited glomerulopathy, with mesangial proliferation and segmental and 
global sclerosis. They also had increased albuminuria, loss of podocytes and increased 
tubulointerstitial fibrosis as indicated by Sirius red and Masson’s trichrome staining. 
Kidneys had increased mRNA and protein levels of profibrotic and fibrotic components, 
including TGF-β, α-smooth muscle actin, connective tissue growth factor, fibronectin, 
collagens I, III, IV and increased immune cell infiltration and proinflammatory cytokines/
chemokines, such as MCP-1, TNF-α, IL-6, and IL-1α. Unexpectedly, there was minimal 
kidney injury in female Dsk5 mice at up to 30 weeks of age. Renal mRNA and protein 
EGFR levels were significantly lower in age-matched females than males. Oopherectomy 
had no effect on renal EGFR levels and injury in female Dsk5 mice, while castration 
protected against the kidney injury seen in intact male Dsk5 mice, in association with a 
reduction in EGFR expression to levels seen in female mice.
Conclusions: These studies indicate that constitutive EGFR activation promotes 
glomerular and tubulointerstitial injury in male mice, but not in female mice, and this 
gender difference may be at least in part due to androgen-dependent higher basal levels of 
EGFR expression.
Funding: NIDDK Support, Veterans Affairs Support
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Extracellular Vesicles Derived from Amniotic Fluid Stem Cells as 
Potential Therapy for CKD
Sargis Sedrakyan,1 Valentina Villani,1 Paola Aguiari,1 Astgik Petrosyan,1 
Hasmik Soloyan,1 Corinne Iampietro,2 Benedetta Bussolati,2 Laura Perin.1 
1Children’s Hospital Los Angeles, Los Angeles, CA; 2University of Torino, 
Torino, Italy.
Background: The crosstalk between podocytes and glomerular endothelial cells 
(GEC) is vital for the maintenance of glomerular function. VEGF signaling plays a key 
role in the progression of chronic kidney disease (CKD). The discovery of safe therapeutics 
designed to specifically target the glomerular crosstalk, specifically VEGF signaling, is 
ground-breaking. We propose that extracellular vesicles derived from amniotic fluid stem 
cells (AFSC-EVs) can restore glomerular crosstalk and delay disease progression in Alport 
Syndrome, a model of CKD.
Methods: GEC were isolated from (Tek-Cre driven) tdT AS and WT mice along disease 
progression, characterized by WB and RNA-seq with specific focus on VEGF signaling and 
endothelial damage. EVs were isolated from AFSC, characterized and injected in vivo using 
our established protocols. Histology and kidney function were evaluated in injected and 
control mice.
Results: Glomeruli and GEC present with upregulated VEGF signaling before high 
level of proteinuria. RNA-seq data showed, for the first time, that AS-GEC present with 
modulation of genes involved in GBM deposition (collagen and laminin) and regulation 
(MMPs), glycocalyx component (syndecan, perlecan ect), and endothelial markers 
(VCAM1, ICAM), before the onset of proteinuria. Administration of EVs, at early stage, 
restore VEGF levels to normal by trapping excessive VEGF (EVs present VEGFR1 and 
VEGFR2 on the surface) and improve kidney function in AS mice. In light of clinical 
translation of EVs for CKD, we characterized EVs from human AFSC. We developed 
specific identity, purity and potency assays that generate EV lots with very similar 
characteristics between harvests. EVs of human origin present reno-protective activity in 
vivo in AS mice as well as capability of modulating glomerular VEGF signaling.
Conclusions: Our data suggest that VEGF-induced GEC damage might play a key 
role in the pathogenesis of AS and its progression and that administration of EVs can 
delay disease progression by preventing endothelial injury and by restoring to normal 
VEGF signaling. In sum, our work possibly will facilitate the discovery of new potential 
glomerulus-specific targeted intervention, thus possibly minimizing disease progression 
and ameliorating the life of patients affected by CKD.
Funding: Private Foundation Support
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ICOSL in Non-Immune Cells Functions as an Inducible Potent αvβ3 
Integrin-Selective Antagonist to Prevent Early Kidney Disease
Kwi Hye Koh,1 Yanxia Cao,1 Steve Mangos,1 Nicholas J. Tardi,1 
Ranadheer Dande,1 Ha Won Lee,1 Beata Samelko,1 Mehmet M. Altintas,1 
Vincent P. Schmitz,1 Hyun Lee,2 Vasil Peev,1 David J. Cimbaluk,1 Jochen Reiser,1 
Eunsil Hahm.1 1Rush University Medical Center, Chicago, IL; 2Univ. of Illinois 
at Chicago, Chicago, IL.
Background: ICOSL, the ligand for the inducible co-stimulator (ICOS), was the 
third member of the B7 superfamily discovered, is mainly expressed by antigen presenting 
cells (APCs), and functions in regulating T cell mediated immune responses. ICOSL has 
traditionally been assigned the fundamental role as an exclusive ligand for ICOS and 
was thought to be restricted to the immune system. As such, its potential function in non-
hematopoietic cells under disease conditions remains completely unexplored.
Methods: In vitro and in vivo approaches were used to conduct the following analyses: 
qPCR, immunohistochemistry, surface plasmon resonance, cellular adhesion assays, ACR 
and BUN level measurements, electron microscopy, and bone marrow transplantations. 
Available on-line databases were used for 3D-modeled homology structure analysis. Rescue 
experiments involved injection of recombinant ICOSL into ICOSL KO mice.
Results: We find that unlike other B7 co-stimulatory molecules, ICOSL contains a 
known integrin-binding motif: arginine-glycine-aspartic (RGD), and selectively binds 
to αvβ3 but not to α3β1 integrin. Indeed, this binding depends on the activation state of 
αvβ3 integrin and is largely inhibited by the presence of synthetic RGD peptide, a selective 
antagonist of αvβ3. We also find that the RGD motif present in ICOSL is functionally 
active and modulates the αvβ3 integrin-dependent adhesion of podocytes. Consistent with 
the rapid induction of podocyte ICOSL expression by inflammatory stimuli, glomerular 
ICOSL expression is greatly increased at early stages of human proteinuric kidney diseases 
such as focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). 
Furthermore, ICOSL deficiency results in an increased susceptibility to kidney injury and 
severe proteinuria in mice, and can be rescued by recombinant ICOSL injection.
Cellular Crosstalk in Glomerular Diseases - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
328
J Am Soc Nephrol 29: 2018 Poster/Thursday
Conclusions: Here we report a novel, renoprotective role for ICOSL in early kidney 
disease through its selective binding to active αvβ3 integrin. Our work identifies a novel 
role for ICOSL: protecting the kidney filter from injury by serving as a potent αvβ3-
selective antagonist, and provides new insights into various pathological diseases associated 
with aberrant αvβ3 activation.
Funding: NIDDK Support
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High Activity of Tissue Remodeling Cell Signaling Cascades in the Macula 
Densa
Urvi nikhil Shroff, Georgina Gyarmati, Janos Peti-Peterdi. University of 
Southern California, Los Angeles, CA.
Background: The macula densa (MD), a plaque of 15-20 specialized cells, sits 
at the vascular pole of the glomerulus and plays a traditional role in maintaining renal 
hemodynamics and the renin-angiotensin system. However, the new tissue remodeling 
function of MD cells is emerging. The present study aimed to examine the activity and 
role of major cell signaling pathways in MD cells, and to test if augmenting these pathways 
specifically in MD cells would alter renal tissue remodeling.
Methods: RNA seq and gene profiling was used to establish and analyze the gene profile 
of mouse MD cells under control and stimulating low dietary salt conditions. To confirm 
MD specificity of top gene candidates, immunohistochemistry (IHC) was performed on 
mouse and human kidney sections for Wnt/β-catenin, mTOR, PI3K, and MAPK signaling 
pathways that are known to regulate cell biology and tissue remodeling. To test for cell 
proliferation and rate of protein synthesis, EdU staining and a O-propargyl-puromycin 
incorporation-based assay were performed, respectively, in kidney sections of control WT 
mice and in a new genetic model of inducible MD-specific Wnt gain-of-function (gof).
Results: Combined gene profiling and IHC identified the highest activity of Wnt, 
mTOR, PI3K, and MAPK signaling in MD cells in the mouse and human kidney cortex. 
A TCF/Lef:H2B-GFP Wnt signaling reporter mouse model and activated β-catenin 
IHC showed the strongest labeling in MD cells. In MD-Wnt(gof) mice after 5 weeks of 
induction, a robust increase in MD cell proliferation, nucleus-to-cell volume ratio, and 
protein synthesis were found compared to WT control. MD-Wnt(gof) mice also featured 
enlarged glomeruli, increased PDGFRβ+ mesangial expansion and angiogenesis. Treatment 
with lithium (GSK3β inhibitor for Wnt stimulation) for 2 weeks had similar effects on MD 
cell morphology, cell biology, glomerular size and cell composition.
Conclusions: In summary, the renal cell type with the strongest Wnt, mTOR, PI3K, 
and MAPK activity is the MD, which is a chief sensor and effector of the local tissue 
environment. Wnt signaling is an important regulator of MD morphology, cell biology, and 
new function in tissue remodeling, which can be augmented in new developing regenerative 
therapeutic strategies.
Funding: NIDDK Support
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Investigating Basement Membrane Assembly
Nikki-Maria Koudis,1 William Loewenhardt,2 Michael J. Randles,3 
Rachel Lennon,1 Brian Derby.2 1Wellcome Trust Centre for Cell-Matrix 
Research, University of Manchester, Manchester, United Kingdom; 2School of 
Materials, University of Manchester, Manchester, United Kingdom; 3Faculty of 
Health and Life Sciences, De Montfort University, Leicester, United Kingdom.
Background: The glomerular basement membrane (GBM) is a specialised condensed 
network of extracellular matrix. Monocultures of podocytes and endothelial cells synthesise 
and organise a complex matrix in vitro and this has significant overlap with the components 
of the GBM in vivo. Whilst these cultures assemble type IV collagen this is predominantly 
the α1α1α2 network and not the mature α3α4α5 network, which is required for the 
long-term integrity of the GBM. We hypothesised that the combination of glomerular 
cell coculture and flow would alter the composition of matrix and lead to a more mature 
phenotype with greater similarity to the GBM in vivo.
Methods: To generate flow we utilised the QV600 bioreactor (Kirkstall) and a custom-
designed bioreactor constructed with the silicone-based polymer PDMS. Detachable 
podocyte and endothelial cell sheets were engineered and assembled into the bioreactors 
to create cocultures without the need for an intervening material for support. Cells and 
matrix were examined in static and flow conditions using light and electron microscopy and 
mass spectrometry (MS)-based proteomics. The function of this coculture system as a semi-
permeable filtration barrier was examined using fluorescently labelled dextrans.
Results: Endothelial cells and podocytes readily formed cell sheets and could be 
assembled as cocultures into bioreactors. Both cell types were viable in coculture and 
in static and flow conditions. Electron microscopy revealed the presence of basement 
membrane-like structures between cocultured cells and functional analysis confirmed 
intact barrier function. Proteomic analysis of cells under flow conditions demonstrated an 
upregulation of basement membrane proteins including altered laminin and collagen IV 
isoforms compared to static conditions.
Conclusions: Podocyte and endothelial cells are viable in direct contact and under flow 
conditions and flow influences both the composition and assembly of matrix in our system 
suggesting roles for both cell-cell cross-talk and fluid flow in the assembly of basement 
membranes. This system has utility for understanding the basic biology of GBM formation 
and glomerular cell interaction with the GBM in addition to testing compounds that could 
repair a damaged GBM in the context of glomerular disease.
Funding: Commercial Support - GlaxoSmithKline
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Podocyte Development/Function Depends on Primary Cilia and the 
Exocyst
Ashish K. Solanki,1 Ehtesham Arif,1 Matt G. Sampson,2 Deepak Nihalani,1 
Joshua H. Lipschutz.1 1Medical University of South Carolina, Charleston, SC; 
2University of Michigan, Ann Arbor, MI.
Background: Diseases affecting podocytes are leading causes of ESRD. Until recently, 
podocytes were thought not to have primary cilia, as cilia are not seen on adult podocytes; 
however, primary cilia were reported on developing podocytes in 2010. In 2014, a mutation 
in ciliary protein IFT139 was found in patients with FSGS, suggesting cilia involvement 
in GN. Our mRNA profiling of injured podocytes showed downregulation of the highly-
conserved 8 protein exocyst trafficking complex. We previously showed that the exocyst 
is necessary for ciliogenesis in kidney tubule cells, zebrafish, and mice. Exocyst members 
were also mutated in families with ciliopathies affecting the kidney. Thus, we hypothesized 
that the exocyst is critical for podocyte development/function.
Methods: We generated podocyte-specific Exoc5 knockout (KO) mice, by crossing 
Podocin-Cre and Exoc5 fl/fl mice, and studied patients in the Nephrotic Syndrome Study 
Network (NEPTUNE).
Results: Podocyte-specific Exoc5 KO mice showed massive proteinuria and 
died within 5 weeks of birth. Importantly, isolated glomeruli stained with acetylated 
alpha tubulin showed primary cilia in wild-type, but not Exoc5 KO, mouse glomeruli. 
Histological analysis showed severe defects with increased fibrosis, proteinaceous casts, 
effaced podocytes, and slit diaphragm loss in Exoc5 KO mice; while IF showed significant 
mislocalization of slit diaphragm proteins Neph1 and Nephrin. Podocyte-specific Exoc5 
KO mice phenocopied Cdc42, an exocyst regulator, KO mice reported by others. Mapping 
and Western blot analyses showed upregulation of canonical and non-canonical arms of the 
TGFβ pathway, including ERK and SMAD3 activation, in Exoc5 knockdown podocytes, 
and Exoc5 KO glomeruli. We next examined copy number variation (CNV) data derived 
from genome-wide SNP arrays from 256 patients with nephrotic syndrome enrolled in 
NEPTUNE. This dataset identified CNV that were greater than 100kb, overlapped a gene, 
and were ultra-rare or absent in control populations. Within, we identified two patients with 
qualifying CNV affecting exocyst component, EXOC4: a male toddler of Asian ancestry 
with steroid resistant minimal change, and an African-American female in her third decade 
with collapsing FSGS.
Conclusions: Our data implicate exocyst-based ciliogenic mechanisms in podocyte 
development/function, and suggest a novel target for intervention.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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A Novel Interaction Between Synaptojanin-1 and ZO-1 Indicates 
Clathrin-Mediated Turnover at the Slit-Diaphragm
Marwin Groener,1,2 Kazunori Inoue,1 Xuefei Tian,1 Christopher E. Pedigo,1 
Elizabeth Cross,1 Ying Wang,1 Shuta Ishibe.1 1Yale University School of 
Medicine, New Haven, CT; 2FAU Erlangen-Nuremberg, Erlangen, Germany.
Background: The importance of clathrin-mediated endocytosis (CME) for podocyte 
health has long been established. Deletion of Synaptojanin 1 (Synj1), which is involved in 
the uncoating of clathrin-coated vesicles (CCV), resulted in severe albuminuria and foot 
process effacement in mice. The aim of this study is to further understand the underlying 
mechanism and role of Synj1 at the slit-diaphragm (SD).
Methods: We created a mouse monoclonal antibody specific for the Synj1 isoform 
expressed in podocytes. Mass Spectrometry analysis following immunoprecipitation 
(IP) of podocyte lysate revealed tight junction protein, Zonula occludens 1 (ZO-1) as a 
binding partner. To further identify the binding domains, we transfected Cos7 cells with 
various tagged truncated ZO-1 and Synj1 plasmids and performed IP. We analyzed through 
live imaging, the temporal and spatial relationship between ZO-1 and clathrin in isolated 
control podocytes. Immunofluorescence (IF) staining with ZO-1 and clathrin light-chain 
antibodies on wild-type and Synj1 KO mouse podocytes was performed to determine ZO-1 
localization.
Results: The association of Synj1 with ZO-1 was confirmed by IP in Cos7 cells 
overexpressing Synj1 and ZO-1. Binding between the SH3 domain of ZO-1 and proline-rich 
domains of Synj1 was observed. IF staining of wild-type mouse podocytes demonstrated 
ZO-1 co-localized with clathrin-coated pits. Live cell imaging further revealed CME of 
ZO-1. However, Synj1 KO podocytes displayed ZO-1 mislocalization in the cytosol when 
compared to wild-type.
Conclusions: We identified a novel binding partner of Synj1, the slit-diaphragm 
protein ZO-1, which indicates clathrin-mediated turnover of ZO-1 similar to Nephrin likely 
occurs. IF images and live cell imaging further corroborated these findings. Furthermore, 
inhibiting uncoating of CCV in Synj1 KO podocytes resulted in mislocalization of ZO-1. 
These findings illustrate the importance of clathrin-mediated recycling of slit-diaphragm 
proteins during podocyte health and disease.
Funding: NIDDK Support
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Correlation Between Endocapillary Proliferative and Nephrotic-Range 
Proteinuria in Children with Henoch-Schönlein Purpura Nephritis
Yanjie Huang, Xiaoqing Yang. The First Affiliated Hospital of Henan University 
of Traditional Chinese Medicine, Zhengzhou, China.
Background: The endocapillary proliferative (EP) lesion is not included in ISKDC 
pathological classification of HSPN. The main objective of the study was to determine the 
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pathological importance of EP in the development of proteinuria in children with Henoch-
Schönlein purpura nephritis (HSPN).
Methods: The pathological features of 148 HSPN children with nephrotic-range 
proteinuria were investigated retrospectively. 24-hour proteinuria was measured by 
pyrogallol red-molybdate. Urinary IgG, transferrin and albumin levels were measured by 
immunonephelometry. The correlations between EP lesion and 24-hour proteinuria, urinary 
IgG, urinary transferrin and urinary albumin were analyzed. Renal biopsy specimens were 
immunohistochemically stained for nephrin and podocalyxin.
Results: Of total 581 cases of children with HSPN who underwent renal biopsy, 148 
cases (25.5%) presented with nephrotic-range proteinuria. The pathological types of HSPN 
with nephrotic-range proteinuria were categorized as IIb, IIIa, IIIb, IIIb with EP, IVb, and 
pure EP type. Among these types, pure EP type accounted for 7.4%. The levels of 24-
hour proteinuria and urinary albumin were the highest in EP type among all pathological 
types, and the percentage of EP correlated with 24-hour proteinuria and urinary albumin 
levels. 24-hour proteinuria was significantly higher in pure EP type relative to HSPN IIb 
type, and significantly higher in IIIb with EP, compared with HSPN IIIb. Nephrin, but not 
podocalyxin, was downregulated in EP segment.
Conclusions: In addition to mesangial proliferation and crescent formation, EP is an 
independent pathogenic factor in HSPN with nephrotic-range proteinuria. Downregulation 
of nephrin in EP segment is a potential molecular mechanism of nephrotic-range proteinuria. 
Albumin is the major urinary protein component in HSPN with EP.
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Immune Response to Tonsillar Microbiome Are Perturbed in the 
Development of IgA Nephropathy
Hiroki Yamaguchi, Shin Goto, Hirofumi Watanabe, Masataka Yonezawa, 
Suguru Yamamoto, Yoshikatsu Kaneko, Ichiei Narita. Division of Clinical 
Nephrology and Rheumatology, Niigata University Graduate School of Medical 
and Dental Sciences, Niigata, Japan.
Background: The aberrant immune response in palatine tonsils against commensal 
bacteria has been estimated to be involved in the development of IgA nephropathy (IgAN). 
To elucidate these mechanisms, we focused on the relationship between the expression 
of TNFSF13 (APRIL) and galactose-deficient IgA1 (Gd-IgA1) and the composition of 
bacteria in tonsillar crypts.
Methods: We enrolled 57 patients with IgAN and 27 with recurrent tonsillitis (RT) 
who were undergone tonsillectomy. Genomic DNA were extracted from the excised 
tissues of tonsillar crypts in each patient and V4 regions of the 16S-ribosomal RNA gene 
sequence were applied to assess the relative abundance of bacteria. These tissues were also 
solubilized with a lysis buffer and the concentration of extracted proteins were quantified 
with BCA methods. The levels of APRIL and Gd-IgA1 in tonsils or serum were measured 
by ELISA, and the degree of Gd-IgA1 deposition in glomerulus were evaluated by 
immunohistochemical analysis. We analyzed the correlations between the levels of APRIL, 
Gd-IgA1 and bacterial abundance, as well as the grade of glomerular injury.
Results: Immunohistochemical analysis revealed that Gd-IgA1 was localized in 
germinal center of tonsils and the degree of its stained area was correlated with tonsillar Gd-
IgA1 levels. The degree of Gd-IgA1 deposition in glomerulus was significantly correlated 
with tonsillar Gd-IgA1 levels. The levels of Gd-IgA1 in tonsil were significantly higher 
in IgAN patients with more extended glomerular damage, while tonsillar Gd-IgA1 levels 
in IgAN patients did not differ from those in RT patients. Tonsillar APRIL levels were 
significantly higher in IgAN patients than in RT patients (P < 0.01). The levels of tonsillar 
APRIL in RT were positively correlated with the relative abundance of Prevotella genus in 
tonsils, however, the upregulated levels of tonsillar APRIL in IgAN did not show any robust 
associations with 16S microbiota in tonsils.
Conclusions: Gd-IgA1 and increased APRIL expression in tonsils could be involved 
in the development of IgAN. Further analysis is needed to reveal the role of microbiome on 
the mucosal immunity in tonsils of patients with IgAN.
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Deposition of IgA and C3 on the Glomerular Loop Significantly Correlates 
with Urinary Protein in Immunoglobulin A Vasculitis with Nephritis 
(Henoch-Schonlein Purpura Nephritis)
Kazunori Karasawa, Takahito Moriyama, Kosaku Nitta. Department medicine, 
Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan.
Background: Immunoglobulin A vasculitis with nephritis (IgAVN) is considered to 
be systemic form of IgA nephropathy (IgAN). Both IgAN and IgAVN are defined by the 
presence of IgA dominant glomerular deposits. However, the pathological significance of 
the difference in glomerular location of IgA and other immunogrobulin deposits is remain 
unclear. In this study, we investigated which clinical findings and renal prognosis correlate 
with immunostaining findings in IgAVN.
Methods: We conducted a retrospective study of 33 adult patients of biopsy-proven 
IgAVN and analyzed these cases in terms of clinicopathological feature and renal prognosis. 
Especially, we evaluated renal biopsy specimens of IgAV in detail by immunostaining.
Results: 33 adults IgAVN patients (male:21, female:12) were analyzed. Averege 
age was 41.12±14.7 years old at the renal biopsy. Localization of glomeruli of IgA, IgG, 
IgM as immunoglobulin, C3, C4d, C1q as complement factor, and fibrin, fibrinogen, 
kappa chain, lambda chain as others were examined by immunostaining. IgA deposition 
was observed on glomerular loop (capillary wall) of 10 patients (30%). The average 
proteinuria was 3.60±2.61 g/day in the IgA deposited on glomerular loop group and 
1.53 ±1.63 g/day in the group with no IgA deposition on glomerular loop group. (P=0.0047) 
Furthermore, C3 deposition was also observed on glomerular loop of 10 patients (30%). The 
average urine protein was 4.04±2.64 g/day in the C3 deposited on glomerular loop group 
and 1.34±1.28 g/day in the group with no C3 deposition. (P<0.001) From these results, we 
revealed that the deposit of IgA and C3 on glomerular loop in immunostaining findings was 
positively correlated with the amount of the proteinuria. However, renal prognosis was no 
significant difference in both group in one year after treatment.
Conclusions: The deposition of IgA and C3 in the glomerular loop were significantly 
correlated with the amount of puroteinuria. These results suggested that these deposition 
may play a key role in the pathogenesis of IgAVN, and also suggested that the selection of 
therapy for IgAVN might be affected.
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GWAS-Follow-Up Study Identified Abnormal LIF Signaling Network 
Involving STAT1 and Src Family Protein-Tyrosine Kinases in IgA1- 
Secreting Cells from Patients with IgA Nephropathy
Koshi Yamada,1,2 Zhi qiang Huang,1 Milan Raska,1 Colin Reily,1 
Joshua C. Anderson,1 Hitoshi Suzuki,1,2 Krzysztof Kiryluk,3 Ali G. Gharavi,3 
Bruce A. Julian,1 Christopher D. Willey,1 Jan Novak.1 1University of Alabama at 
Birmingham, Birmingham, AL; 2Juntendo University Faculty of Medicine, 
Tokyo, Japan; 3Columbia University, New York, NY.
Background: Genome-wide association studies (GWAS) in IgA nephropathy (IgAN) 
provide insight into disease pathobiology by identifying genetic loci and mapping the 
associated molecular pathways. A GWAS locus on chr. 22q12 encompasses genes that 
include LIF that encodes leukemia inhibitory factor, an IL-6-related cytokine implicated in 
mucosal immunity and inflammation. In this study, we characterized LIF signaling pathways 
leading to overproduction of galactose-deficient IgA1 (Gd-IgA1), using IgA1-secreting cell 
lines derived from peripheral blood of patients with IgAN and healthy controls (HC).
Methods: IgA1 was determined by ELISA, Gd-IgA1 lectin ELISA with Helix aspersa 
lectin. To assess LIF signaling pathways, we used global protein-tyrosine kinases (PTKs) 
activity profiling, immunoblotting, siRNA knock-down, and a JAK2 inhibitor.
Results: LIF activated STAT1 phosphorylation (Y701) to a greater level in IgA1-
secreting cells from patients with IgAN (n=5) compared with those from HC (n=5) (p<0.01). 
LIF-mediated increase in Gd-IgA1 production by IgA1-secreting cells from patients with 
IgAN were reduced by siRNA STAT1 knock-down (p<0.05). Use of a JAK2 inhibitor 
revealed that this enhanced phosphorylation of STAT1 in IgA1-secreting cells from patients 
with IgAN was not mediated by JAK2. PTK activity profiling indicated that LIF signaling 
activated Src family of PTKs, based on highest kinase statistics (Kstat) and specificity.
Conclusions: LIF induced abnormal STAT1 signaling and enhanced production of 
Gd-IgA1 in IgA1-secreting cells from patients with IgAN, providing possible explanation 
for the phenotype associated with a GWAS locus encompassing LIF. Moreover, our 
exploratory data indicate involvement of Src family PTKs in LIF signaling that needs to 
be further explored.
Funding: NIDDK Support
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Nasal-Associated Lymphoid Tissue Is the Major Induction Site for 
Nephritogenic IgA in Murine IgA Nephropathy
Toshiki Kano, Hitoshi Suzuki, Yuko Makita, Yoshihito Nihei, Yusuke Fukao, 
Yusuke Suzuki. Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: The pathogenesis of IgA nephropathy (IgAN) is closely associated with 
dysregulation of mucosal immune system, which manifests as mesangial IgA deposition 
leading renal impairment. Several papers reported that Toll-like receptor 9 (TLR9) activated 
by exogenous pathogens is suspected in aggravation of renal injury in IgAN. However, it is 
unclear which gut-associated lymphatic tissue (GALT) or nasal-associated lymphoid tissue 
(NALT) is more involved in the pathogenesis of IgAN. Although the origin of nephritogenic 
IgA has been obscure, several studies demonstrated the efficacy of tonsillectomy and 
corticosteroid therapy, whereas the novel targeted-release formulation of budesonide 
targeting intestinal mucosal immunity reduced proteinuria in IgAN patients. In present 
study, we focused on the role of NALT and GALT using IgAN-prone ddY mice.
Methods: Levels of aberrantly glycosylated IgA and IgG-IgA immune complexes (IC) 
in serum and supernatant from cultured cells from NALT, Mesenteric lymph node (MLN) 
and spleen were measured using IgAN onset and quiescent ddY mice (each n=16) with 
or without TLR9 ligand (CPG-ODN) stimulation. Level of aberrantly glycosylated IgA 
was measured by the binding of Sambucus nigra bark lectin (SNA) and Ricinus communis 
agglutinin I (RCA).
Results: In IgAN onset ddY mice, serum levels of aberrantly glycosylated IgA and 
IC were significantly higher than those in quiescent ddY mice. However, there were no 
significant differences in the levels of aberrantly glycosylated IgA and IC produced by MLN 
between IgAN onset and quiescent mice. Serum levels of aberrantly glycosylated IgA and 
IC correlated with those in culture supernatant of splenocytes, but SNA and RCA assay 
revealed that the sugar component of IgA from MLN was different from that in circulatory 
IgA in IgAN onset ddY mice. The levels of aberrantly glycosylated IgA and IC in NALT 
and splenocytes were significantly increased by CpG-ODN, however those in MLN were 
not increased.
Conclusions: Aberrant glycosylation of IgA leading to IC formation was found in cell 
supernatant from NALT but not in MLN/GALT. The present study suggest that the NALT 
has a key role in the pathogenesis of murine IgAN
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Glomerular Diseases: Immunology and Inflammation - I
Patients with Immunoglobulin A Nephropathy Is Associated with Elevated 
Urinary Mitochondrial DNA Copy Number
Byung chul Yu,3 Hyoungnae Kim,2 Samel Park,1 Moo Yong Park,3 Soon 
hyo Kwon.2 1Soonchynhyang University Cheonan Hospital, Cheonan, Republic 
of Korea; 2Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea; 
3Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
Background: Urinary mitochondrial DNA (mtDNA) levels are considered to reflect 
mitochondrial injury in kidney. However, mitochondrial injury in IgA nephropathy (IgAN) 
remains unknown. We hypothesized that IgAN would be associated with increased urinary 
mtDNA copy numbers.
Methods: We prospectively enrolled age-sex matched healthy volunteers (HV) and 
biopsy-proven IgAN (n=30 each). Urinary copy number of the mtDNA genes cytochrome-c 
oxidase-3 (COX3) and nicotinamide adenine dinucleotide dehydrogenase subunit-1 (ND1) 
were measured by quantitative polymerase chain reaction. We measured also urinary ND-1 
and COX3 3 months after medical treatment in IgAN (n=12).
Results: The mean estimated glomerular filtration rate (eGFR) was significantly lower 
in IgAN compared with HV (75.2±28.8 vs 107.2±12.1 mL/min/1.73m2, respectively, 
p<0.001). log10ND1/nDNA and log10COX3/nDNA were significantly higher in IgAN 
compared with HV (5.70±0.36 vs 5.14±0.34, 5.68±0.37 vs 5.15±0.33 copies/μl of urine/
nDNA, respectively, both p<0.001). There was no significant relation between urinary 
mtDNA copy numbers and tranditional prognostic markers at presentation in IgAN such as 
mean arterial pressure, eGFR, and the amount of proteinuria. In the M score of the Oxford 
classification, log10ND1/nDNA and log10COX3/nDNA were significantly lower in IgAN 
patients with mesangial hypercellularity (5.61±0.39 vs 5.89±0.20, p=0.014, 5.60±0.41 vs 
5.85±0.16 copies/μl of urine/nDNA, p=0.022, respectively). Medical treatment did not 
reduced urinary mtDNA copy numbers.
Conclusions: Urinary mtDNA copy numbers were elevated in patients with IgAN. 
This suggests mitochondrial damage would be a pathogenesis in IgAN.
Relation between urinary mtDNA levels and clinical variables in patients with 
immunoglobulin A nephropathy
Data were analyzed by Spearman’s rank correlation coefficient.
COX3, cytochrome-c oxidase-3; mtDNA, mitochondrial DNA; ND1, nicotinamide adenine 
dinucleotide dehydrogenase subunit-1.
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Plasma Galactose-Deficient IgA1/C3 Ratio Is Strongly Associated with 
Disease Progression in IgA Nephropathy
Pei Chen, Gui-zhen Yu, Xue Zhang, Sufang Shi, Jicheng Lv, Hong Zhang. 
Peking University First Hospital, Beijing, China.
Background: Galactose-deficient IgA1 (Gd-IgA1) and C3 mesangial codeposition is 
a hallmark of IgA nephropathy (IgAN). In this large cohort study, we aim to evaluate Gd-
IgA1/C3 ratio in the progression of IgAN.
Methods: In this study, we included 1157 IgAN patients with a median follow-up 
period of 42 months. Plasma Gd-IgA1 was measured at the time of diagnosis using a lectin-
based ELISA. The composite kidney failure event was defined by 50% decline in eGFR 
or ESRD and renal survival was modeled using the Cox proportional hazards method and 
restricted cubic splines.
Results: Although high plasma Gd-IgA1 levels were associated with the risk of kidney 
progression events, the association was not in a linear relationship. While the correlation 
between plasma Gd-IgA1/C3 ratio and risk of kidney failure was a linear relationship. After 
adjusted for traditional risk factors, higher levels of Gd-IgA1/C3 ratio was independently 
associated with a greater risk of deterioration in renal function with a HR of 2.15 (95% 
CI=1.21–3.81, P=0.008) per ln(Gd-IgA1/C3). In reference to the first quartile, the risk of 
kidney progression event increased such that the HR for the second quartile was 1.84 (95% 
CI=1.05–3.24, P=0.034), 1.79 (95% CI=1.02–3.12, P=0.041) for the third, and 2.08 (95% 
CI=1.22–3.54, P=0.007) for the fourth quartile of the Gd-IgA1/C3 ratio.
Conclusions: Plasma Gd-IgA1/C3 ratio was an independent risk factor for kidney 
progression events.
Cox regression model associations of baseline plasma Gd-IgA1/C3 levels with incidence 
of composite end point.
Model 1 was adjusted for sex and age. Model 2 was adjusted for covariates in model 1 plus 
eGFR, proteinuria, and mean arterial blood pressure. Model 3 was adjusted for covariates 
in model 2 plus Oxford MESTC scores and steroids or other immunosuppressive agents.
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Collectin-11 Is a Recognition Molecule in Glomerular Activation of Lectin 
Pathway in IgA Nephropathy
Weiyi Guo, Li Zhu, Sufang Shi, Lijun Liu, Jicheng Lv, Hong Zhang. Renal 
Division, Peking University First Hospital, Beijing, China.
Background: Glomerular activation of lectin pathway (LP) was reported in IgA 
nephropathy (IgAN), and further associated with disease severity and therapy. Besides 
mannose-binding lectin (MBL) and ficolin, which could recognize glycans of IgA1 and 
lead to LP complement activation in IgAN, collectin-11 (CL-11) is a newly identified 
recognition molecule in LP. Here we explored the involvement of CL-11 in complement 
activation of IgAN.
Methods: We enrolled 60 IgAN patients for Immunofluorescence staining of CL-
11, MBL, ficolin, MASP2, MASP1/3, C4d, C3c and C5b-9 in renal biopsy specimens. 
Additionally, plasma samples from 10 patients with IgAN were collected for IgA1 
purification. Using jacalin affinity chromatography, Sephrcryl S300 and glycosyl hydrolysis 
treatment, monomeric IgA1 (mIgA1), polymeric IgA1 (pIgA1), as well as sialic acid 
deficient IgA1 (SAd-IgA1) and sialic acid/galactose deficient IgA1 molecules (Gd/SAd-
IgA1) were prepared and their binding with CL-11 were detected by ELISA.
Results: In our IgAN patients, 36.7% (22/60) had mesangial CL11 deposition. 
Among them, 14 also had MBL and ficolin deposition, 1 had MBL without ficolin, 4 
had ficolin without MBL, while 3 without MBL or ficolin. All of the 22 IgAN patients 
with mesangial CL-11 deposition, presented with MASP (MASP2 or MASP1/3), C4d, 
C3 and MAC deposition, which co-localized with CL-11. In vitro, pIgA1 showed a 
Ca2+-independent binding with CL-11, and the binding was in a dose-dependent manner. 
Between concentrations of 0.625-2.5 ug/ml, pIgA1 showed significantly higher binding to 
CL-11 than mIgA1, while Gd/SAd-IgA1 had significantly higher binding to CL-11 than 
SAd-IgA1 and IgA1.
Conclusions: Our results suggested collectin-11 as a recognition molecule in LP in 
IgAN. Collectin-11 prone to bind with aberrant glycosylated polymeric IgA1, which might 
contribute to the glomerular complement activation of LP in IgAN.
Funding: Government Support - Non-U.S.
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VIS649 Reduces Serum IgA Levels in NHPs Dose Dependently: PK/PD 
Exposure-Response Modeling for Translation to Treatment of IgA 
Nephropathy
Susan E. Sloan,1 Frank A. Engler,2 Kristy J. Szretter,1 James R. Myette,1 
Kristin Narayan,1 Bharathi L. Sundaresh,1 Brian J. Pereira.1 1Visterra, Inc., 
Waltham, MA; 2Certara USA Inc., Parsippany, NJ.
Background: VIS649 is a humanized IgG2 monoclonal antibody that targets 
A PRoliferation-Inducing Ligand (APRIL), a cytokine that is implicated in IgA nephropathy 
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(IgAN) pathogenesis. Targeting APRIL activity to reduce levels of aberrantly glycosylated 
circulating IgA1 may alter IgAN disease progression.
Methods: Cynomolgus monkeys (NHP; n=4/grp) were IV administered vehicle 
or VIS649 (0.5, 2.5 and 10 mg/kg) once weekly for 4 weeks, and followed for 8 weeks 
without treatment. Study endpoints included serum VIS649 and immunoglobulin (Ig) levels 
and peripheral lymphocytes (flow cytometry). Temporal changes in IgA concentration 
after VIS649 administration were described with a population pharmacokinetic/
pharmacodynamic (popPK/PD) model using an indirect response model.
Results: At the 0.5 and 2.5 mg/kg dose levels there was a ~50% reduction in serum 
IgA levels. VIS649 administration at 10 mg/kg levels resulted in a ~70% serum IgA 
reduction. This maximal effect of ~70% reduction was confirmed in parallel studies at doses 
of up to 100 mg/kg and indicates that additional mechanisms support basal levels of IgA 
production. The effect of VIS649 on reducing IgA levels was reversible and observed after 
discontinuation of VIS649 treatment during the no-dose period with dose-dependent time 
to recovery. There was a lesser effect on serum IgG/IgM levels and peripheral lymphocytes 
were not affected. In a parallel study, a reduction in IgA+ mononuclear cells in GALT and 
tonsil tissues was observed, consistent with APRILs effect on Ig class switching and plasma 
cell survival in the mucosal compartment. These data were used to develop a popPK/PD 
model. Model simulation of single dose VIS649 in humans, in the range of 1-3 mg/kg, 
predicts a maximal (~70%) reduction in IgA levels followed by a dose-dependent return to 
baseline. Model simulation of repeated monthly doses suggest dose levels in the 0.3 to 3 
mg/kg range will maintain a reduction in IgA levels below 50% of baseline.
Conclusions: VIS649 treatment reduces serum IgA levels in NHPs in a dose 
proportional manner. These data point to a clear potential therapeutic use of VIS649 in 
humans with IgAN.
Funding: Commercial Support - Visterra, Inc.
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Comparison of IgA1 Hinge-Region O-Glycoforms Between Patients with 
IgA Nephropathy and Healthy Subjects
Yukako Ohyama,1 Kazuo Takahashi,1 Hisateru Yamaguchi,2 Shoko Matsushita,1 
Kazuki Nakajima,3 Daijo Inaguma,1 Midori Hasegawa,1 Jan Novak,4 
Yoshiyuki Hiki,1 Yukio Yuzawa.1 1Fujita Health University School of Medicine, 
Toyoake, Japan; 2Institute for Comprehensive Medical Science, Fujita Health 
University, Toyoake, Japan; 3Fujita Academy, Fujita Health University, Toyoake, 
Japan; 4University of Alabama at Birmingham, Birmingham, AL.
Background: IgA1 with galactose (Gal)-deficient hinge-region (HR) O-glycans 
(Gd-IgA1) plays a key role in the pathogenesis of IgA nephropathy (IgAN). Monoclonal 
antibody (mAb) specific for Gd-IgA1 developed for detection of Gd-IgA1 was used in 
ELISA to confirm elevated serum Gd-IgA1 levels in IgAN patients. An earlier study found 
that IgAN glomerular immunodeposits were enriched for Gd-IgA1, supporting a key role 
of Gd-IgA1 in IgAN pathogenesis. To identify potentially disease-specific IgA1 HR O-
glycoforms, we profiled serum IgA1 HR glycopeptides using specimens from Japanese 
IgAN patients and healthy controls (HC) of different races.
Methods: IgA1 from sera of 20 Japanese IgAN patients and 50 HC, recruited 
from Caucasian, Black, Hispanic, Asian, and Japanese populations, was purified by 
affinity chromatography. After neuraminidase treatment and trypsin digestion, IgA1 HR 
glycosylation heterogeneity was analyzed by liquid chromatography-high-resolution mass 
spectrometry (LC-MS). Area under the peaks of extracted ion chromatogram (XIC) of 
identified IgA1 HR O-glycopeptides was calculated and expressed as relative abundance 
(RA) for each glycopeptide as percentage of all HR glycopeptides. The amount of each 
glycopeptide was then calculated by multiplying serum IgA concentration (mg/dL) by RA 
for the specific glycopeptide.
Results: Approximately 60% of HR O-glycoforms contained one to three Gal-
deficient O-glycans in IgA1 from IgAN patients as well as healthy subjects. The amount 
of Gal-deficient HR variants was increased in IgA1 from IgAN patients compared to that 
of HC (P =0.043, IgAN vs. all HC; P =0.011, IgAN vs. Japanese HC). IgA1 with single 
Gal-deficient O-glycan was notably increased in patients with IgAN compared to HC 
(P =0.043, IgAN vs. all HC; P =0.009, IgAN vs. Japanese HC).
Conclusions: Profiling of IgA1 HR O-glycoforms of IgAN patients and HC indicated 
that Gd-IgA1 glycoform with single Gal-deficient O-glycan was elevated in Japanese IgAN 
patients compared to HC. Future analysis of IgA1 HR O-glycoforms in the glomerular 
immunodeposits will allow comparison with nephritogenic Gd-IgA1 glycoforms in sera 
of IgAN patients.
Funding: Government Support - Non-U.S.
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Disease Specific Profile of Fecal Microbiome in IgA Nephropathy
Ji In Park,1 Hyunjeong Cho,2 Ji Eun Kim,3 Dong Ki Kim,3 Seung Hee Yang,4 
Jung Pyo Lee,5 Yon Su Kim,6 Hajeong Lee.6 1Kangwon National University 
Hospital, Chuncheon-si, Republic of Korea; 2Chungbuk National University 
Hospital, Cheongju-si, CHUNGCHEONGBUK-do, Republic of Korea; 3Seoul 
National University Hospital, Seoul, Republic of Korea; 4Kidney Research 
Institute, Seoul National University, Seoul, Republic of Korea; 5Seoul National 
University Boramae Medical Center, Seoul, Republic of Korea; 6Seoul National 
University College of Medicine, Seoul, Republic of Korea.
Background: The mucosal immune system plays a role in the pathogenesis of 
Immunoglobulin A nephropathy (IgAN). Previously, the gut microbiota was proved to be 
essential to develop the IgAN in mice model. However, little has been known about the 
relationship between IgAN and the intestinal microbiome in human.
Methods: We enrolled 41 biopsy-proven IgAN patients at 3 centers and collected 
fecal specimens at the time of renal biopsy. Feces from 36 patients with biopsy-proven 
membranous nephropathy (MN) or diabetic nephropathy (DMN) were used as disease 
control (DC) and from 35 healthy volunteers as healthy control (HC). The composition of 
the microbiota was analyzed using extracted metagenomic DNA from the feces by Illumina 
MiSeq system.
Results: The estimated glomerular filtration rates (eGFR), which represents the renal 
function, were 106, 74 and 71 mL/min/1.73m2 for HC, DC, and IgAN group, respectively. 
The Shannon diversity index did not differ among the 3 groups. Beta-diversity were plotted 
using principal coordinate analysis, which showed separation of IgAN from HC and DC 
groups. At phylum level, the relative abundances of Firmicutes and Acinetobacteria were 
higher, whereas those of Bacteroidetes and Proteobacteria were lower in IgAN patients than 
HC, DC groups. When we divided DC group into 21 patients with MN and 15 patients with 
DMN, the results from a comparison of 4 groups still showed IgAN specific character. At 
genus level, the number of the significantly different genus was 7 between HC and DC, 24 
between HC and IgAN, and 28 between DC and IgAN. When IgAN patients were divided 
into two groups on the basis of eGFR 60 mL/min/1.73m2 or 3g/day of proteinuria, the 
bacterial composition did not differ between groups.
Conclusions: The fecal microbiota of IgAN differed from those of healthy and disease 
control. We could tell the microbial difference of IgAN was not due to renal function but the 
IgAN-specific factor. For further investigation, shotgun metagenomic DNA sequencing is 
undergoing to characterize the functional genes of microbiota.
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The Differences in Podocyte Injury Between IgA Nephropathy and 
Membranous Nephropathy Based on Proteomics Analysis
Xizhao Chen,1 Di Wu,2 Guangyan Cai,1 Xiangmei Chen.1 1Chinese PLA General 
Hospital, Beijing, China; 2General hospital of PLA, Beijing, China.
Background: IgA nephropathy (IgAN) is the most common primary glomerular 
nephritis worldwide. Currently, the diagnosis has to depend on renal biopsy which is an 
invasive practice. The developing proteomics can provide new ideas for exploring the 
potential biomarkers and pathogenesis of IgAN.
Methods: The renal tissue of 59 patients with IgAN was obtained and screened 
for differential protein expression (DEPs) profile by a high throughput method liquid 
chromatography-mass (LC-MS). The results in IgAN were compared to those in 9 patients 
with membranous nephropathy (MN) and 19 cases of adjacent normal tissues from renal 
cell carcinoma. Specific proteins in IgAN and MN were selected. Histochemical stain and 
double-labelling immunofluorescence stain were used to locate the proteins expressed in 
IgAN and MN. siRNA and stimulus were used to establish the gene expression cell models, 
and genes and proteins were detected by RT-PCR and western blot.
Results: (1) An overall sum of 6636 proteins were identified in IgAN, MN and normal 
tissue. There were 1086 DEPs in IgAN and 392 specific DEPs in IgAN when compared 
with MN. (2) Samples from patients with IgAN and MN were clearly distinguishable 
from normal controls. (3) Specific podocyte marker proteins such as nephrin and podocin 
were down-regulated both in IgAN and MN. Specific DEP CD151, which is a membrane 
protein of podocyte, was down-regulated in IgAN and has no expression change in MN. 
Histochemical stain and double-labing IF stain showed CD151 was located in IgAN and 
its expression was lower and weaker than that in MN and normal tissue. Specific DEP 
PLA2R1, which is a specific podocyte membrane protein, was significantly up-regulated 
in MN and has no expression change in IgAN. Histochemical stain showed PLA2R1 was 
higher and stronger expressed in the podocyte of MN. (4) TNFα could suppress CD151 
expression and VEGFA could upregulate PLA2R1 expression in human primary podocyte, 
and down regulation of VEGFA in podocyte by siRNA could suppress the expression of 
PLA2R1.
Conclusions: Our study identified the differential expression of proteins in IgAN and 
MN tissues based on the proteomics analysis and detected the specific proteins CD151 
and PLA2R1. TNFα-induced CD151 down-expression and VEGFA-induced PLA2R1 
activation in podocyte might be one of the mechanisms in IgAN and MN that cause 
podocyte injury.
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Understanding the Nature of IgA Deposits in Secondary Glomerular 
Diseases
Anjali A. Satoskar,1 Ana Malvar,2 Valeria G. Alberton,2 Cherri N. Bott,1 
Tibor Nadasdy,1 Gyongyi Nadasdy,1 Brad H. Rovin.1 1Ohio State University 
Wexner Medical Center, Columbus, OH; 2HOSPITAL FERNANDEZ, Buenos 
Aires, Argentina.
Background: Galactose-deficient IgA1 (Gd-IgA1) is important to the pathogenesis 
of primary IgA nephropathy (IgAN) and Gd-IgA1 is found in the glomeruli of IgAN. 
Other glomerular diseases mimic IgAN and feature significant glomerular IgA deposits, 
but it is not clear if the IgA in these kidneys is galactose-deficient. This study was done 
to qualitatively assess IgA in the glomerular deposits of patients with Staphylococcal 
infection-associated IgAN (IA-IgAN) and cirrhosis-associated IgAN (CA-IgAN).
Methods: Double immunofluorescence staining was done on paraffin-embedded 
kidney biopsies with anti-human IgA and with the monoclonal antibody KM55, which 
specifically recognizes Gd-IgA1. Kidney biopsies were from United State (US) and 
Argentine cohorts, and included patients with primary IgAN (n=9) as positive controls, 
lupus nephritis (LN, n=11) as negative controls, IA-IgAN (n=6) and CA-IgAN (n=5). 
The Argentine cohort also included 5 additional patients who had proliferative LN with 
dominant IgA deposits before and after treatment. IgA and Gd-IgA1 were graded semi-
quantitatively based on an intensity scale of 0-3.
Results: Gd-IgA1 staining was robust in patients with primary IgAN as expected, and 
minimal in patients with LN (Table). In patients with CA-IgAN and IA-IgAN staining for 
Gd-IgA1 was positive but at about half the intensity of primary IgAN (Table). LN patients 
who had significant glomerular IgA deposits pre- and post-treatment did have detectable 
Gd-IgA1 at an intensity about half of Argentine primary IgAN. Gd-IgA1 intensity in 
primary IgAN was less in Argentine patients than US patients.
Conclusions: Galactose-deficient IgA is present in secondary glomerular diseases with 
IgA-dominant immune complexes. It is not clear if galactose-deficiency is acquired or if the 
systemic process unmasks intrinsic defects in IgA.
Funding: Clinical Revenue Support
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Activation of Toll Like Receptors 7/8 Altered IgA1 O-Glycosylation via 
Regulating Expression of O-Glycosyltransferases in IgA Nephropathy
Nuoyan Zheng,1 Xueqing Yu.2 1The Translational Medical Center, The First 
Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 2Department of 
Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 
China.
Background: IgA nephropathy (IgAN) is featured with O-glycosylation deficiency of 
IgA1 antibody, but the underlying mechanism of production of Gd-IgA1 was unknown.
Methods: The expression levels of TLRs were analyzed by real-time PCR. The 
secretion of IgA1 molecules and their O-glycan after TLR activiation were meansured by 
ELISA. The expression of O-glycosyltransferases was analyzed by Western blot.
Results: We found that gene expression levels of TLR7 and TLR8 were significantly 
increased in peripheral blood mononuclear cells (PBMCs) of IgAN patients (Figure 1A). 
Ex-vivo activation of TLR7/8 in PBMCs led to more IgA1 antibody production and higher 
O-glycan deficiency of IgA1 antibody in IgAN patients as compared with healthy donors 
(Figure 1B). Meanwhile, activation of TLR7/8 resulted in decreased expression C1GalT1
and increased GalNAcT2 expression in B cells of IgAN patients (Figure 2).
Conclusions: Thus, activation of TLR7/8 play important role in pathogenesis of IgA 
nephropathy by regulating the expression of O-glycosyltransferase and later the galactose 
deficiency of IgA molecules.
Figure 1-TLR7/8 activation led to augmented IgA1 secretion and galactose deficiency
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Figure 2-TLR7/8 activation regulates expression of O-glycosyltransferases.
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TLR9 Activation Is Involved in Aberrant IgA Glycosylation via APRIL- 
and IL-6-Mediated Pathways in IgA Nephropathy
Yuko Makita,1 Hitoshi Suzuki,1 Toshiki Kano,1 Bruce A. Julian,2 Jan Novak,2 
Yusuke Suzuki.1 1Department of Nephrology, Juntendo University Faculty of 
Medicine, Tokyo, Japan; 2Department of Microbiology, University of Alabama 
at Birmingham, Birmingham, AL.
Background: Toll-like receptors (TLRs) play a key role in the pathogenesis of IgA 
nephropathy (IgAN). Galactose-deficient IgA1 (Gd-IgA1) is involved in development of 
the disease. However, the mechanisms driving Gd-IgA1 production have not been fully 
elucidated. Although previous reports indicated a proliferation-inducing ligand (APRIL) 
and IL-6 may be involved in Gd-IgA1 synthesis in IgAN, the mechanisms leading to the 
overproduction of Gd-IgA1 and subsequent formation of Gd-IgA1 containing ICs are still 
unclear.
Methods: IgAN prone ddY mice were divided into two groups with CpG-ODN (TLR9 
ligand) immunization (n=18) or without (n=18). CpG-ODN was injected intraperitoneally 
3 times a week for 12 weeks. Renal pathology and serum levels of aberrantly glycosylated 
IgA, IgG-IgA ICs, APRIL and IL-6 were evaluated after 12 weeks. We also examined the 
mechanisms of production of Gd-IgA1 in human IgA1-secreting cells.
Results: Injection of ddY mice with CpG-ODN increased production of aberrantly 
glycosylated IgA and IgG-IgA ICs, resulting in exacerbated kidney injury (P<0.05). Serum 
levels of APRIL correlated with serum levels of aberrantly glycosylated IgA and IgG-IgA 
IC (P<0.05). CpG-ODN stimulation induced production of aberrantly glycosylated IgA in 
splenocytes of ddY mice through increase of APRIL and IL-6. In human IgA1-secreting 
cells, TLR9 activation enhanced Gd-IgA1 production via increase of APRIL and IL-6. 
Production of Gd-IgA1 was partly reduced by siRNA for APRIL and/or anti-IL-6.
Conclusions: TLR9 stimulation enhanced synthesis of nephritogenic IgA through 
overproduction of APRIL and IL-6 in IgAN. Moreover, the present study clarified the 
crosstalk between APRIL and IL-6, of note APRIL and IL-6 independently promote the 
production of aberrantly glycosylated IgA.
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T-Follicular Like Helper Cells Enhance IgA Secretion in IgA Nephropathy
Nicholas J. Steers,1 Jaclyn L. Wold,2 Maddalena Marasa,1 Ali G. Gharavi.1 
1Columbia University, New York, NY; 2Columbia University Medical Center,
New York, NY.
Background: Dysregulated IgA1 response is a central defect in the development of 
IgA Nephropathy (IgAN), but is it not clear if the altered IgA1 response is attributed to 
excessive self-proliferation of IgA+ B-cells or an imbalance in the B-cell-T-cell interactions. 
We investigated the mechanism of IgA production, focusing on the function of T-follicular 
helper (Tfh) cells, which have recently been shown to play an essential role in antibody 
response.
Methods: We studied 15 IgAN patients and 20 healthy controls (HC). IgA antibody 
secreting cells (ASC) were measured by flow cytometry. Naive B-cells, Naïve CD4+ T-cells 
and T-follicular like helper cells were sorted from the PBMC of patients, and IgA was 
measured from the B-cell-T-cell co-cultures.
Results: We detected a 3.6 fold increase in IgA ASC numbers and 1.6-fold increase 
in Tfh like cells in the peripheral blood of IgAN patients compared to HC. Both IgA ASC 
and Tfh like cell numbers were strongly correlated with the increased IgA and IgA1 levels 
in the plasma. To distinguish whether enhanced IgA production is dependent on B-cells or 
Tfh like cells, we performed co-culture experiments. Autologous co-culture experiments 
of Tfh like cells with naïve B-cells resulted in significantly increased IgA production in 
cells derived from IgAN patients (172.9 ± 60.9 ng/ml), compared to HC (58.4 ± 13.3 
ng/ml). Next, we performed co-culture experiments with cells derived from two pairs of 
monozygotic twins who are discordant for IgAN. Co-culture of Tfh like- and naïve B-cells 
from monozygotic twins with IgAN and one self-declared healthy control, and as expected 
yielded significantly higher lgA production compared to co-culture of cells from their 
corresponding healthy twins. In addition, Tfh like cells from the IgAN twins significantly 
increased IgA production from the naïve B-cells from the healthy twins (169.5 ± 31.9 ng/
ml) but Tfh like cells from the one healthy twin only elicited baseline IgA production from 
naïve B-cells from the IgAN twins (59.3 ng/ml).
Conclusions: Our data demonstrate an independent role of T-follicular like helper 
cells in enhanced generation of IgA in IgAN, identifying a new important step in IgAN 
pathogenesis. Future studies will be directed towards identification of molecular programs 
leading to enhanced Tfh like cell count and activity in IgAN.
Funding: NIDDK Support
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Urinary Galactose-Deficient IgA1 Represent a Disease-Specific Marker of 
IgA Nephropathy
Hitoshi Suzuki, Toshiki Kano, Yuko Makita, Yusuke Fukao, Yusuke Suzuki. 
Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: IgA nephropathy (IgAN) is an autoimmune disease characterized by 
IgA1-containing immune deposits in mesangium. Galactose-deficient IgA1 (Gd-IgA1) is 
recognized by anti-glycan autoantibodies, resulting in formation of pathogenic immune 
complexes. These immune complexes deposit in the kidney, activate mesangial cells, and 
induce glomerular injury. We recently elucidated that glomerular Gd-IgA1 was specifically 
detected in IgAN, but not in the other renal diseases by immunohistochemistry using Gd-
IgA1 monoclonal antibody (KM55 mAb). We hypothesized that a fraction of Gd-IgA1 from 
Glomerular Diseases: Immunology and Inflammation - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
334
J Am Soc Nephrol 29: 2018 Poster/Thursday
the glomerular deposits may be excreted into the urine and thus represent a disease-specific 
marker.
Methods: We recruited biopsy proven 129 patients with IgAN and 79 patients with 
other renal diseases (control) hospitalized from 2015 to 2017. Serum and urine samples 
collected at the time of renal biopsy were used to measure Gd-IgA1. Serum and urinary 
Gd-IgA1 were determined by KM55 mAb. Moreover, consecutive urinary Gd-IgA1 were 
measured during the course of therapy in 51 patients with IgAN.
Results: Urinary Gd-IgA1 levels were significantly higher in patients with IgAN 
compared with control (P<0.01). Even in patients with IgAN revealed trace proteinuria 
(less than 0.3g/gCr), urinary Gd-IgA1 were definitely detected. Moreover, urinary Gd-IgA1 
decreased response to therapy (P<0.001). Urinary Gd-IgA1 levels were well correlated with 
proteinuria in patients with IgAN (P<0.001), but not in control.
Conclusions: Urinary Gd-IgA1 was elevated in patients with IgAN. The fraction of 
Gd-IgA1 from the glomerular deposits may be excreted into the urine, as serum levels of 
Gd-IgA1 did not correlate with urinary Gd-IgA1. Importantly, urinary Gd-IgA1 may be an 
early biomarker compared with proteinuria in patients with IgAN. U rinary Gd-IgA1 is also 
useful to determine disease activity. Urinary Gd-IgA1 may thus represent a disease-specific 
biomarker of IgAN.
Funding: Government Support - Non-U.S.
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Circulating Autoantibodies in Lupus Nephritis Patients Target the 
Cytoskeleton Linking Protein, Moesin, and Disrupt Podocyte Actin 
Cytoskeleton
Dawn J. Caster,1 Erik Korte,4 Michael Merchant,2 Jon B. Klein,3 Shweta Tandon,4 
Kenneth R. McLeish,4 David W. Powell.4 1Medicine/Nephrology, University of 
Louisville, Louisville, KY; 2University of Louisville Medicine, Louisville, KY; 
3University of Louisville Kidney Disease Program, Louisville, KY; 4University of 
Louisville, Louisville, KY.
Background: The pathogenesis of lupus nephritis (LN) is characterized by glomerular 
deposition of immune complexes (IC) containing nucleosomes and anti-nuclear 
autoantibodies. However, proteomic studies in LN and other glomerular diseases identified 
a number of autoantibodies against tissue proteins. We used a targeted proteomic approach 
combining immunoblot analysis of human podocyte membrane proteins using sera from 
LN patients with high performance MS to identify moesin as a candidate target protein. 
We showed that autoantibodies against moesin were present in the sera of patients with 
proliferative LN and glomeruli in renal biopsies from those patients showed increased 
expression of moesin. This study tested the hypothesis that autoantibodies to moesin 
participated in IC formation in LN.
Methods: Frozen remnant kidney biopsy samples from patients with proliferative 
LN were cut into 4-6 μm sections (n= 5) and incubated with anti-moesin antibody at 1:50 
overnight followed by sequential incubation with: 1) fluorescent secondary antibody at 
1:200 2) fluorescent conjugated anti-human IgG at 1:200. Images were obtained on confocal 
microscopy. A human-derived podocyte cell line was cultured on collagen-coated glass 
bottom dishes at 37°C for 8-10 days. Cells were serum starved with 0.5% FBS medium 24 h 
before anti-moesin antibody, IgG controls, or vehicle was added for 24 h. Actin organization 
was detected by staining with rhodamine-phalloidin for 30 minutes. Rhodamine staining on 
confocal microscopy images was analyzed visually and for actin anisotropy by FibrilTool.
Results: To determine if moesin was contained in IC, renal biopsies from patients 
with proliferative LN were examined for co-localization of moesin and IgG. Confocal 
images showed minimal co-localization, indicating anti-moesin autoantibodies were not 
participating in IC formation. As moesin is a cytoskeletal linking protein, the ability of 
anti-moesin to disrupt podocyte actin organization was tested. Podocytes cultivated with 
anti-moesin antibodies, but not control IgG or vehicle, showed loss of actin cytoskeletal 
organization and decreased anisotropy.
Conclusions: We conclude that autoantibodies against moesin may participate in 
glomerular injury in LN by disruption of podocyte cytoskeletal organization.
Funding: NIDDK Support
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A Humanized Mouse Model of SLE and LN
Samia Q. Khan, Xiaobo Li, Huiting Wei, Eunsil Hahm, Meenakshi Jolly, 
Vineet Gupta. Rush University Medical Center, Chicago, IL.
Background: Lupus Nephritis (LN) is a common complication of systemic lupus 
erythematosus (SLE) with unclear etiology and limited treatment options. Single Nucleotide 
Polymorphisms (SNPs) in ITGAM (which codes for CD11b) strongly associate with disease 
pathogenesis. Yet, the role of these mutations in disease pathobiology is unclear, primarily 
because of a lack of experimental models. Additionally, while available spontaneous or 
induced mouse models of SLE have advanced our understanding of lupus, none of them 
replicate human disease very well. Here, we present a novel humanized mouse model of 
SLE and LN that better mimics the human disease and, we hope, will greatly improve 
our understanding of the cellular and genetic determinants driving lupus and aid in the 
development of novel therapeutics.
Methods: Peripheral blood mononuclear cells (PBMCs) were transferred from healthy 
donors or SLE patients into NSG mice (Healthy-NSG and SLE-NSG). Weekly blood and 
urine samples were collected and humanized mice were monitored for lupus symptoms 
until end-point at 6-weeks post engraftment when they were sacrificed and tissues, serum 
and blood were harvested for further analysis.
Results: Using our optimized protocol, the engraftment of healthy and SLE PBMCs 
was 100% successful in the NSG mice. We observed an average of 78% human CD45+ 
cells in the spleens at 6 weeks post engraftment. Interestingly, mouse CD11b+Gr1+ cells 
and human CD14+ cells were significantly elevated in vivo in SLE-NSG mice as compared 
to healthy-NSG mice. Within 1 week, SLE-NSG mice also lost whiskers and developed 
alopecia. Histopathological analysis of nasal dermis showed increased epidermal thickness 
and leukocyte density. Similar to human PBMC donors that displayed renal decline, SLE-
NSG mice also showed significantly elevated levels of serum anti-dsDNA and suPAR, and 
significantly reduced kidney function, as indicated by elevated levels of proteinuria, renal 
leukocyte infiltration, renal fibrosis and glomerular damage.
Conclusions: This novel humanized SLE/LN model exhibits several clinical 
manifestations of human lupus and is an important tool to test therapies.
Funding: Other NIH Support - R01DK106512
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Clinical Associations with Serum Syndecan-1 Level in Patients with Lupus 
Nephritis
Susan Yung, Kelvin Yu, Mel Chau, Kwok Fan Cheung, Daniel Tak Mao Chan. 
The University of Hong Kong, Hong Kong, China.
Background: Cardiovascular disease is an important long-term complication in 
patients with lupus nephritis. The endothelial glycocalyx regulates the adhesiveness of 
circulating cells to vascular endothelial cells and vascular permeability. Syndecan-1 is a 
component of the endothelial glycocalyx, and syndecan-1 shedding occurs in endothelial 
cell activation or injury.
Methods: Serial serum samples from patients with biopsy-proven Class III/IV lupus 
nephritis were obtained at intervals of 3-4 months over two years. In addition, paired 
samples with one obtained during flare and the other during remission were included. Sera 
from age- and sex-matched patients with IgA nephropathy (IgAN), SLE patients without 
nephritis, and healthy subjects were included as controls (n=25 for each group). Serum 
syndecan-1 level was determined by ELISA.
Results: Four hundred and sixty sera from 29 lupus nephritis patients (20 females 
and 9 males; age 39.0±10.2 years; disease duration 7.6±8.6 years) were studied. Serum 
syndecan-1 level was significantly higher during active lupus nephritis compared with 
remission, and also the IgAN, non-renal lupus, and healthy control groups (P<0.001, for 
all). Syndecan-1 level correlated with SLEDAI (r=0.535, P<0.001), anti-dsDNA antibody 
level (r=0.407, P=0.003), serum creatinine level (r=0.262, P=0.05), proteinuria (r=0.571, 
P<0.001), and inversely correlated with serum C3 (r=-0.443, P=0.001) and albumin levels 
(r=-0.568, P<0.001). Circulating syndecan-1 level showed a temporal relationship with 
disease activity and changes in anti-dsDNA antibody and C3 levels. ROC curve analysis 
showed that serum syndecan-1 level distinguished active lupus nephritis from healthy 
subjects with sensitivity and specificity rates of 96.3% and 96.0% respectively, from IgAN 
patients with respective rates of 85.2% and 91.3%, and from non-renal lupus patients with 
respective rates of 85.7% and 70.4% (P<0.0001, for all).
Conclusions: Active lupus nephritis is associated with increased circulating syndecan-1 
level, and thus may contribute towards the pathogenesis of cardiovascular complications in 
patients with lupus nephritis.
Funding: Government Support - Non-U.S.
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Complement Activation in Renal Thrombotic Microangiopathy Associated 
to Systemic Lupus Erythematosus: An Exploratory Analysis
Ismael A. Gómez Ruiz, Carlos Nuñez alvarez, Cristinoc Cruz, Luis E. Morales-
Buenrostro, Ricardo Correa-Rotter, Juan M. Mejia-Vilet. Instituto Nacional de 
Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background: Renal thrombotic microangiopathy (TMA) in SLE is a rare and severe 
manifestation with dismal prognosis. While complement participation in lupus nephritis 
(LN) has been studied, its role in SLE renal TMA remains lesser explored.
Methods: To study complement proteins we included patients with SLE-renal TMA 
(n=12), active biopsy-proven LN (n=12), inactive SLE patients (n=9) and living kidney 
donors (n=5). Renal TMA patients were divided into acute TMA (aTMA) or chronic 
TMA (cTMA) according to histopathology. Terminal complement pathway activation 
was evaluated by a soluble C5b-C9 ELISA. Alternative pathway urine C3d fragment was 
evaluated with a specific monoclonal antibody. Groups were compared by Kruskal-Wallis 
test and correlations obtained by Spearman’s rho.
Results: Of 12 patients with SLE renal TMA, 3 (25%) had positivity for aPL antibodies 
and 9 corresponded to aHUS. Renal TMA patients presented with higher arterial pressure, 
serum creatinine and dsDNA titers; while hemoglobin, platelets and haptoglobin levels were 
lower than in active LN. Notably, renal TMA patients had few systemic manifestations of 
microangiopathic hemolytic anemia. Renal TMA biopsies showed higher global sclerosis, 
interstitial fibrosis and tubular atrophy. Plasma and urine sC5b-C9 titers in both renal TMA 
and active LN groups were higher than in inactive LN and kidney donors. Urine sC5b-C9 
titers were higher in renal aTMA compared to cTMA (Figure A). In the Figure B we present 
the case of a patient with SLE and 2 renal TMA episodes. As shown, urine and plasma 
sC5b-C9 titers rose during the acute event and diminished after treatment. There was a 
trend for higher urine C3d fragment in aTMA compared to cTMA and active LN. There was 
a correlation between urine sC5b-C9 titers and serum creatinine (r=0.308, p=0.017) and 
proteinuria (r=0.686, p<0.001).
Glomerular Diseases: Immunology and Inflammation - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
335
J Am Soc Nephrol 29: 2018 Poster/Thursday
Conclusions: There is activation of complement pathway in renal TMA evidenced by 
the elevation of complement protein’s fragments. It should be further explored if these tests 
may be of use to follow-up the course of the disease.
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Hepcidin Modulates Macrophage Iron Metabolism to Attenuate Lupus 
Nephritis
Yogesh M. Scindia,1 Ewa U. Mandziak,1 Valentina Loi,2 Joseph T. Leeds,1 
Sundararaman Swaminathan.1 1University of Virginia, Charlottesville, VA; 2AO 
Brotzu Cagliari, Cagliari, Italy.
Background: Lupus nephritis (LN) is an end-organ manifestation of systemic 
lupus erythematosus (SLE) mostly affecting the female population. Renal inflammation, 
macrophage recruitment and proliferation are associated with worse outcome in LN. 
Hepcidin is a primary regulatory of macrophage iron metabolism and phenotype. The role 
of Hepcidin or iron transport has not been investigated in lupus. We hypothesized that 
hepcidin would mitigate LN by targeting macrophage responses.
Methods: 8-week-old femaleMRL/lpr mice (a spontaneous model of SLE) were treated 
twice a week with saline or 50 μg of hepcidin (i.p) for 10 weeks, following which outcomes 
like microalbuminuria, histopathology, and other markers of macrophage inflammation and 
proliferation were examined. In-vitro, macrophages (J774A) were treated with Hepcidin 
and stimulated with Polyinosinic-polycytidylic acid (Poly (I:C)) or M-CSF1 to evaluate 
inflammatory and proliferative response.
Results: Saline-treated mice developed severe LN by 18 weeks of age as indicated 
by high microalbuminuria, fibrosis, renal Cox-2, IL-6, CXCL-1 and M-CSF transcripts, 
immune complex deposits, iron accumulation and an infiltration of F4/80+ve macrophages. 
Hepcidin treatment significantly reduced all these manifestations of LN. There was an 
increase in renal H-ferritin and a concomitant decrease Rrm-1 and Rrm-2, iron dependent 
enzymes required for DNA synthesis. This was associated with a reduction in Ki-67 positive 
macrophages and other cells within the kidney. In-vitro hepcidin induced H-ferritin in 
macrophages and reduced their labile iron (Fe2+) content. H-ferritinhimacrophages secreted 
less IL-1bfollowing Poly (I:C) stimulation and proliferated less in response to M-CSF1.
Conclusions: We demonstrate a novel protective effect of hepcidinagainst LN which 
could open new therapeutic approaches to treat LN. Hepcidin induces H-ferritin that lowers 
labile iron and reduces inflammatory response and macrophage proliferation, two cardinal 
features of LN. Renal iron accumulation and increased Cox-2 suggest involvement of 
Ferroptosis in the pathogenesis of SLE. Further studies are required to investigate whether 
hepcidin also targets renal parenchymal cells or other immune effectors.
Funding: NIDDK Support
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Urinary Galectin-3 Binding Protein as a Predictive Marker for Lupus 
Nephritis Flare
Samir V. Parikh,1 Xiaolan Zhang,1 Roberto Bassi,2 Sneha Varghese,2 
Pramod P. Mehta,3 Wen-Rong Lie,3 Shinji L. Okitsu,4 Brad H. Rovin.1 1Ohio 
State University Wexner Medical Center, Columbus, OH; 2EMD Serono R&D 
Institute, Rockland, MA; 3MilliporeSigma, St Louis, MO; 4EMD Serono 
Research and Development Institute, Billerica, MA.
Background: Identifying predictive markers of lupus nephritis (LN) flare has been 
elusive but is necessary to improve outcomes. Serum galectin-3 binding protein (G3BP) 
is correlated with interferon signature in active SLE. We aimed to define the specificity of 
urine G3BP (uG3BP) as marker of LN flare and determine its ability to predict flare and 
response to treatment.
Methods: uG3BP protein expression was measured from urine collected at the time 
of kidney biopsy and compared across multiple glomerular diseases including active LN 
(n=97), IgA nephropathy (n=27), diabetic nephropathy (n=10), primary membranous 
nephropathy (n=10), ANCA-associated vasculitis (n=4) and healthy controls (n=20). 
Additionally, active LN expression was compared to LN remission (n=52). uG3BP levels 
were normalized for urinary creatinine (Cr). To examine uG3BP expression longitudinally, 
urine from the Ohio SLE cohort study (OSS) of 27 LN patients (44 flares) was measured 
by ELISA at 5 different time points; -4, -2, flare, +2, and +4 months post flare. uG3BP 
expression was compared between each time point to understand if uG3BP is a sensitive 
marker to predict the development and resolution of inflammation in LN.
Results: uG3BP expression was significantly increased in all tested kidney diseases, 
except ANCA compared to healthy controls (p<0.0001). The highest concentration of 
uG3BP was found in active LN (423.79±32.06 ng G3BP/mg Cr). uG3BP expression was 
significantly greater at LN flare compared to controls (423.79±32.06 vs 44.8 ng G3BP/mg cr, 
p<0.0001), IgA nephropathy (423.79±32.06 vs 138 ng G3BP/mg Cr, p<0.0001) and 
remisison LN (423.79±32.06 vs127.5 ng G3BP/mg Cr, p<0.0001). uG3BP expression 
increased incrementally from 4 months pre-flare to flare, peaked 2 months post-flare 
(p=0.02 compared to flare levels) and significantly decreased 4 months post-flare (p=0.01).
Conclusions: uG3BP, while not specific, is highly expressed at LN flare reflecting 
interferon activation. uG3BP expression may predict LN flare but due to limited samples 
size data are currently inconclusive. Further investigation is warranted. uG3BP expression 
may be a predictive marker of treatment response.
Funding: Commercial Support - Merck KGaA, Germany
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Molecular Profiling of the Kidney in Lupus Nephritis (LN) to Identify 
Heterogeneity in Different Races and Ethnicities
Isabelle Ayoub,2 Ana Malvar,1 Samir V. Parikh,2 Huijuan Song,3 John P. Shapiro,5 
Paolo Fadda,5 Lianbo Yu,3 Anjali A. Satoskar,3 Brad H. Rovin.4 1HOSPITAL 
FERNANDEZ, Buenos Aires, Argentina; 2Ohio State University Medical Center, 
Columbus, OH; 3Ohio State University, Upper Urlington, OH; 4Ohio State 
University Wexner Medical Center, Columbus, OH; 5Ohio State University, 
Columbus, OH.
Background: Black and Hispanic LN patients have worse kidney outcomes than 
white patients. Beyond socioeconomic status, we postulated that differential activation/
inactivation of molecular pathways during LN flare may contribute to this racial and 
ethnic difference. To test this hypothesis we examined the intrarenal transcript profiles of 
African American (AA), Caucasian (Cau) and Caucasian Hispanic (H) patients at their first 
“induction naïve” LN flare
Methods: Kidney biopsies were done at the first episode of class III or IV LN in 13 AA, 
11 Cau, and 8 H patients. Glomeruli were isolated by laser capture microdissection. RNA 
was analyzed using Nanostring technology. The expression of 579 genes was compared 
between groups. Transcripts with at least a 2-fold change and p <0.01 were considered 
differentially expressed
Results: Eight transcripts differentiated AA from Cau, one was upregulated. The 
expression of HLADRA was 2-fold higher and the immune-modulator HLADOB was 
2-fold lower in AA compared to Cau. IL-4, a Th2 pathway gene was downregulated in
AA compared to Cau. One hundred transcripts differentiated Cau from H. Thirty-three of
these were upregulated in Cau compared to H. The top 3 upregulated transcripts were:
fibronectin (FN1, fold change (FC) =34.82; p=1.8x10-12), osteopontin (SPP1, FC= 24.43; 
p=1.27x10-07) and FCER1G (FC 17.68; p=5.28x10-09). Pathway analysis revealed
downregulation of INF (A1, A2 and B1) and Th2 signaling in Cau compared to H. Hundred 
and nine transcripts were downregulated in AA compared to H. The main pathways affected 
were T helper cell differentiation, Th1 and Th2 activation and T/B cell signaling.
Conclusions: Molecular signatures appear to be different for the same histologic class 
of LN in different races and ethnicities. The differences in HLA, IL4 and T/B cell signaling 
genes suggest a greater propensity toward immune activation and inflammation in AA 
compared to Cau. This may partly explain why AA LN patients have more severe kidney 
injury. The molecular signature of Cau compared to H suggests more inflammatory disease 
in Cau but more T cell-mediated immune activation in H
Funding: NIDDK Support
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Podocyte Autophagy Could Protect Renal Injury in Lupus and Might Be a 
Therapeutic Target
Xujie Zhou,1 Yuan-yuan Qi,2 Wang Yanna,1 Hong Zhang.1 1Peking University 
First Hospital, Beijing, China; 21. Renal Division, Peking University First 
Hospital, 2. Peking University Institute of Nephrology, Beijing, China.
Background: More recent studies suggested that defects in autophagy contribute to 
the pathogenesis of SLE, especially in adaptive immunity. Occurrence and progression of 
lupus nephritis (LN) is the end result of complex interactions between regulation of immune 
responses and pathological process by renal resident cells, but there is still a lot of missing 
information for an establishment on the role of autophagy in pathogenesis of LN and as a 
therapy target.
Methods: Systemic and organ specific etiologies of autophagy were firsly evaluated by 
autophagy protein quantification in tissue homogenates in MRLlpr/lpr lupus prone and female 
C57BL mice. Analysis of gene expression was also adopted in human blood and urine 
sediments. Then, some key mediators of the disease, including complement inactivated 
serum, IgG from patients with LN (IgG-LN) and IFN-α were chosen to induce podocyte 
autophagy. Podocyte injuries including apoptosis, podocin derangement, albumin filtration, 
and wound healing were monitered simultaneously with autophagy steady-state and flux.
Results: Elevated LC3B in kidney homogenates and increased autophagosomes in 
podocyte from MRLlpr/lpr were observed. In humans, mRNA levels of some key autophagy 
genes were increased in blood and urinary sediments, and podocyte autophagosomes were 
observed in renal biopsies from patients with LN. Complement inactivated serum, IgG-LN 
and IFN-α could induce podocyte autophagy in a time and dosage dependent manner, and 
by reactive oxygen species production and mTORC1 inhibition, respectively. Autophagy 
inhibition aggravated podocyte damage whereas its inducer relieved the injury.
Conclusions: Podocyte autophagy could protect renal injury in lupus and might be a 
therapeutic target.
Funding: Government Support - Non-U.S.
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Urine IP-10 Increased Sensitivity in Lupus Nephritis Detection
Wonngarm Kittanamongkolchai,1,2 Api Chewcharat,1,2 Yingyos Avihingsanon.1,2 
Renal Immunology and Therapeutic Apheresis Research Unit 1Nephrology, 
Chulalongkorn University, Bangkok, Thailand; 2Maha Chakri Sirindhorn 
Clinical Research Center, Chulalongkorn University, Bangkok, Thailand.
Background: Interferon γ-inducible protein(IP-10) is an important T-helper1 
chemokine expressed locally in the kidney of lupus patients. Non-invasive test for urine 
IP-10 may improve the detection of active lupus nephritis(LN).
Methods: Since 2013, urine IP-10 has been measured in all SLE patients with clinical 
suspicion of LN at the specialized LN clinic in a tertiary care hospital in Thailand. We 
retrospectively reviewed the case records of those who underwent renal biopsy from 
October 2013 to February 2018 and had urine IP-10 measurement within 90 days from 
date of renal biopsy.
Results: Of 176 SLE patients followed at LN clinic, 47 had renal biopsy with urine IP-
10 measurement within the certain period. Urine IP-10 was positive (> 2 log copies number) 
in 42 out of 45 patients(93%) with biopsy-proven proliferative LN, while proteinuria was 
found (UPCI > 1) in 41 patients (91%). Two patients who had only renal scarring on biopsy 
had proteinuria, while urine IP-10 was negative in 1 patient(Figure 1). Four patients with 
proliferative LN who had positive urine IP-10 without proteinuria were noted for focal 
podocyte foot process effacement (Table 1). All of them had stable renal function and 
normalization of C3 without proteinuric flare after 6-month of induction therapy. There 
were 8 patients who had serial urine IP-10 measurement prior to renal biopsy. In 6 patients, 
urine IP-10 was positive before proteinuric flare (median 6 months), whereas 2 patients 
were simultaneously positive for proteinuria and IP-10.
Conclusions: Urine IP-10 enhances sensitivity of LN detection, especially in those 
without proteinuria. Its levels even increased prior to proteinuric flare in most cases. 
Combined use of urine IP-10 and conventional markers may increase early detection of LN 
and ultimately improve renal outcomes
Funding: Government Support - Non-U.S.
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Angiotensin-II Type 1 Receptor Agonist Antibodies Are Prevalent in 
Lupus Nephritis Patients But May Have Limited Clinical Impact
Juan M. Mejia-Vilet, Yesser J. López hernández, Mariedel Trujeque, Carlos 
alberto Carranza, Jesus I. Santander, Ricardo Espinosa-González, 
Norma O. Uribe-uribe, Luis E. Morales-Buenrostro. Instituto Nacional de 
Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico.
Background: Angiotensin II type 1 receptor agonist antibodies (AT1R-AA) have been 
associated with hypertension, atherosclerosis and vascular inflamation in human diseases.
Methods: The aim of the study was to evaluate the prevalence of AT1R-AA in 
lupus nephritis (LN) and their association to hypertension and vascular damage. Eighty 
LN patients were evaluated by ambulatory blood pressure monitoring (ABPM), carotid 
Doppler ultrasound and renal biopsy vessel morphometry. AT1R-AA were evaluated in 112 
kidney donors as a control group. AT1R-AA response to induction to remission therapy was 
followed for 6 months. Variables were compared by Fisher exact test or Kruskal-Wallis 
test. For correlations, serological titers were log-transformed and evaluated by Pearson test.
Results: Plasma AT1R-AA were positive in 45 (56.3%) and 23 (28.8%) had titers 
>250u/ml (Figure 1). AT1R-AA titers correlated with double-strand DNA antibodies’
(dsDNA-Ab) titer (r=+0.651,p<0.001, Figure 1) and serum complement fragments C3
(r=-0.289,p=0.009) and C4 (r=-0.451,p<0.001). 77% of patients had an abnormal ABPM
result, with 58% and 23% manifesting a diminished or absent dipping respectively. There
was no association between AT1R-AA and ABPM blood pressure levels. Abnormal carotid 
intima-media thickness was found in 7.8%, with a trend for a greater CIMT in patients
with the highest AT1R-AA titers. Subintimal fibrosis >10% was found in 46.3% of kidney 
biopsies. There was no association between AT1-AA titers and subintimal fibrosis. AT1R-
AA response to treatment was evaluated in 40 patients. AT1R-AA titers course followed that 
of the dsDNA-Ab but was not associated with the response to treatment.
Conclusions: AT1R-AA are highly prevalent in lupus nephritis patients and closely 
correlate with serological activity but their pathogenic role is questionable. AT1R-AA 
cannot be recommended to be measured routinely.
Funding: Government Support - Non-U.S.
A) AT1R-AA in kidney donors and LN patients. B) Correlation between AT1R-AA and
dsDNA antibodies.
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B Cell Subsets and Signatures in Lupus Nephritis Patients Receiving 
Mycophenolate or Azathioprine Maintenance
Desmond Y. Yap,1 Paul Lee,2 Cheryl Tam,2 Irene Yam,2 Susan Yung,2 Daniel Tak 
Mao Chan.1 1Queen Mary Hospital, Hong Kong, China; 2The University of 
Hong Kong, Hong Kong, China.
Background: Mycophenolate mofetil (MMF) and azathioprine (AZA) are standard 
maintenance agents for lupus nephritis (LN), and recent data suggested that MMF 
confers lower long-term flare risk. Aberrant B cell profiles have been implicated in LN 
pathogenesis, but the effect of MMF and AZA on B cell subsets and related signatures has 
not been investigated.
Methods: We measured the B cell subsets and serum and intracellular levels of 
relevant B cell signatures (miRNA148a, BACH1, BACH2 and PAX5) in stable LN patients 
receiving MMF or AZA (n=10 in each group), combined with low-dose prednisolone, as 
maintenance immunosuppression.
Results: The MMF group showed higher % of circulating naïve B cells and lower % of 
plasma cells (4.8±5.2% and 0.2±0.3% respectively, compared with 0.9±1.5% and 0.8±0.9% 
in AZA group, p=0.029 and 0.043), but had no difference in circulating memory B cells 
(p=0.97). The MMF group also showed lower plasma cell/naïve B and memory B/naïve B 
ratios (0.1±0.2 and 1.3±2.1 respectively, compared with 1.7±1.4 and 1.7±1.1 in AZA group, 
p=0.003 and 0.023). The MMF group showed numerically higher intracellular BACH1, 
BACH2 and PAX5 in naïve B cells (relative expression (RQ): 1.2±0.5, 1.4±0.2 and 2.6±1.7 
respectively compared with AZA group; p>0.05, for all) (Figure 1A) and in plasma cells 
(RQ: 1.3±0.1, 1.4±0.3 and 1.3±0.6 respectively compared with AZA group; p>0.05, for all) 
(Figure 1B), but showed no difference in serum and intracellular miRNA148a.
Conclusions: The alterations in B cell subsets and related signatures might contribute 
to the differential risk of relapse in patients receiving MMF or AZA maintenance.
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Figure 1. Intracellular BACH1, BACH2 and PAX5 expression in (A) naïve B cells and (B) 
plasma cells of patients receiving mycophenolate or azathioprine maintenance.
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Histologic vs Clinical Remission in Proliferative Lupus Nephritis at 6 
Months - An Experience from a State Run Tertiary Care Centre in 
Southern India
Umesh L. Institute of nephrourology, Bangalore, India.
Background: Aim and objective of this study is to describe the renal histology of the 
second biopsy and correlate histopathological remission with clinical remission at 6 months.
Methods: The study conducted in Department of Nephrology, Institute of Nephro-
Urology, Victoria Hospital Campus Bangalore, India between Oct 2015 and Nov 2017. 
A total of 50 consecutive patients with biopsy proven Proliferative Lupus Nephritis were 
included in the study. Clinical response was defined as complete (CRR), partial (PRR) 
or non-response (NRR) according to recent definitions. Histological response (HR) was 
defined as Class I, II or III/IV-C on repeat biopsies.
Results: 1/3 rd cases who were achieved complete remission clinically failed to 
achieve histological remission. Out of 19 patients 12(63%) had transformation to favorable 
class in CRR group. Out of 19 patients 12(63%) in PPR group and out of 12 patients 8(66%) 
in NRR group had unfavorable class at 6 months. Though Chronicity Index increased in all 
clinical subgroups, non responders had statistically significant increased CI.
Conclusions: The protocol renal biopsies performed at six months demonstrated an 
increase in chronicity, especially within the same histological class. 1/3rd patients with 
complete remission group had active lesions at the end of induction treatment, questioning 
the current induction therapy of 6 months which may not be sufficient. More RCTs are 
needed to test whether repeated biopsies should be considered as a part of the evaluation of 
treatment response in LN.
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The Composition of the Human Nasal Microbiome in Granulomatosis 
with Polyangiitis: A Pilot Study
Andreas Kronbichler,1,2 Ewan M. Harrison,5 Marcos Martinez del pero,9 
Beth Blane,3 Gert J. Mayer,1 Johannes Leierer,4 Seerapani Gopaluni,3 
Mark A. Holmes,3 Julian Parkhill,6 Sharon J. Peacock,7,3 David R. Jayne,3 
Josef Wagner.8 1Medical University Innsbruck, Innsbruck, Austria; 2Vasculitis 
and Lupus Clinic, Cambridge, United Kingdom; 3University of Cambridge, 
Cambridge, United Kingdom; 4Medical University Innsbruck, Int. Medicine IV, 
Nephrology & Hypertension, Innsbruck, Austria; 5Welcome Sanger Institue, 
Cambridge, United Kingdom; 6The Sanger Institute, Cambridge, United 
Kingdom; 7London School of Hyigene and Tropical Medicine, London, United 
Kingdom; 8VIDRL, Melbourne, NSW, Australia; 9West Suffolk Hospital / 
Cambridge University Hospitals, Bury St Edmunds, United Kingdom.
Background: Granulomatosis with polyangiitis (GPA, formerly Wegener’s 
granulomatosis) is a multi-system disease predominantly affecting the ear, nose and throat 
(ENT) tract, the lower respiratory tract and the kidneys. A role for Staphylococcus aureus 
nasal colonization in GPA has been proposed and thus we undertook a study to determine 
the role of the nasal microbiome in GPA.
Methods: We investigated the nasal microbiome by culture, bacterial 16S rRNA 
profiling, and shotgun metagenomic sequencing in patients with either active or inactive 
GPA, disease controls (microscopic polyangiitis or eosinophilic GPA), healthy healthcare 
professionals and healthy household controls.
Results: Presence of S. aureus as assessed by nasal culture could be detected in eight 
out of 12 active GPA patients (66.7%), which was more frequent compared to inactive 
patients (34.1%). Beta-diversity analysis revealed significant differences in the abundance 
of staphylococcal species between active GPA and healthy controls (p=0.0007) and disease 
controls (p=0.0023), while a correlation between S. aureus and active disease (p=0.0075) 
could be observed by Spearman correlation analysis. The presence of Staphylococcus 
epidermidis was associated with healthy controls (p=0.042). Staphylococcus 
pseudintermedius, generally assumed to be a dog- and cat-pathogen, showed an abundance 
of 13.01% among Staphylococci.
Conclusions: Our study offered new insights into the complex nasal microbiome 
of patients with GPA. We observed an association between active disease and S. aureus. 
Longitudinal studies are necessary to investigate the potential relationship of microbiome 
changes on the relapse rate of patients with GPA.
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Plasma Calprotectin Is a Marker of Stable Remission in ANCA Vasculitis
Elizabeth A. McInnis,1 Yichun Hu,1 Eve Wu,2 Meghan E. Free,1 Susan L. Hogan,1 
Donna O. Bunch,1 Ronald J. Falk.1 1UNC Kidney Center, Chapel Hill, NC; 2The 
University of North Carolina, Chapel Hill, NC.
Background: In ANCA vasculitis, an increase in serum calprotectin (S100A8/9) was 
implicated as a marker of relapse and inflammation, but levels did not normalize during 
remission. Serum may not allow sensitive measurement of S100A8/9. We sought to 
determine if S100A8/9 is best measured in plasma or serum and if it is a marker of disease 
activity and remission in ANCA vasculitis.
Methods: S100A8/9 was measured by ELISA (BioLegend) in 16 paired serum and 
plasma samples. Plasma levels were also tested in 31 patients during active (BVAS>3, 
15 MPO, 16 PR3) and remitting disease and in 14 age/gender matched healthy subjects. 
Additionally, 8 patients (4 MPO, 4 PR3) in long term remission off therapy (LTROT) for ≥5 
years were evaluated and compared to healthy subjects.
Results: Serum measures of S100A8/9 averaged 2.90 μg/mL higher and had a 
higher standard deviation than plasma measures (4.29 vs 4.02 respectively). Thus, plasma 
measures were used for all analyses.
Conclusions: Plasma S100A8/9 levels were elevated during active disease. Levels 
decreased during remission, but remained higher than in healthy controls. Patients in 
LTROT, however, had plasma S100A8/9 levels similar to healthy subjects. These findings 
suggest S100A8/9 is elevated during active disease and decreases, but remains slightly 
elevated, during remission, possibly due to subclinical inflammation. Levels may continue 
to decrease and normalize in long term remission off therapy. Prior studies may have 
observed artificially elevated levels of S100A8/9 due to measurements obtained in serum 
rather than plasma.
Funding: NIDDK Support
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Measurement of plasma S100A8/9 (ug/mL) in ANCA vasculitis patients and healthy 
subjects
*P value was calculated by signed rank paired test. ** P value was calculated by Wilcoxon 
two sample test.
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Myeloperoxidase-ANCA-Positive Granulomatosis with Polyangiitis Is a 
Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis 
Of 455 Patients from a Single Center in China
Dongyuan Chang, Zhi-Ying Li, Min Chen, Minghui Zhao. Renal Division, 
Peking University First Hospital, Beijing, China.
Background: Antineutrophil cytoplasmic antibody (ANCA) directed to proteinase 
3 (PR3) used to be considered the serologic marker for granulomatosis with polyangiitis 
(GPA). However, patients with myeloperoxidase (MPO)-ANCA positive GPA have been 
increasingly reported. The aim of this study was to analyze the clinical and pathological 
characteristics and outcome of Chinese patients with MPO-ANCA positive GPA.
Methods: The clinical and renal histology data, renal outcomes, response to treatment, 
relapse and mortality were compared between patients with MPO-ANCA positive GPA 
and MPO-ANCA positive microscopic polyangiitis (MPA) as well as proteinase 3 (PR3)-
ANCA positive GPA.
Results: 455 patients with ANCA-associated vasculitis (AAV) were recruited in this 
study. 276/455 patients were classified as MPO-ANCA positive MPA, 4/455 patients 
were classified as PR3-ANCA positive MPA,124/455 were MPO-ANCA positive GPA 
and 51/455 were PR3-ANCA positive GPA. Compared with MPO-ANCA positive MPA 
patients, MPO-ANCA positive GPA patients had significantly higher BVAS score and 
milder renal lesion at diagnosis. The probability of developing ESRD was significantly 
higher in patients with MPO-ANCA positive MPA than MPO-ANCA positive GPA. MPO-
ANCA positive GPA patients were likely to have relapse than MPO-ANCA positive MPA 
patients. Compared with PR3-ANCA positive GPA patients, MPO-ANCA positive GPA 
patients had significantly higher proportion of female, less constitutional symptoms and 
milder renal lesion at diagnosis.
Conclusions: Patients with MPO-ANCA positive GPA should be regarded as a unique 
subset of AAV. This subset of AAV patients had relatively milder renal injury. Although 
ANCA specificities play an important role in differentiating AAV, taking the disease type 
together to classify AAV may be more rational.
Funding: Government Support - Non-U.S.
(A) Renal survival of the three subsets of patients. (B) Relapse of the three subsets of
patients.
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A Staphylococcal Plasmid Encoded Peptide Induces Anti-Myeloperoxidase 
Nephritogenic Autoimmunity
A. Richard Kitching,1,2 Joshua D. Ooi,1 Jhih-Hang Jiang,3 Anton Y. Peleg,3,4 
Stephen R. Holdsworth.1,2 Autoimmune Kidney Disease and Vasculitis Research 
Group 1Centre for Inflammatory Diseases, Monash University, Clayton, VIC, 
Australia; 2Nephrology, Monash Health, Clayton, VIC, Australia; 3Microbiology, 
Monash University, Clayton, VIC, Australia; 4Infectious Diseases, The Alfred
Hospital, Melbourne, VIC, Australia.
Background: Loss of tolerance to MPO in ANCA-associated glomerulonephritis 
(GN) is poorly understood. It is unknown whether molecular mimicry plays any role in this 
process. We tested whether microbial peptides homologous to a dominant pathogenic MPO 
CD4+ T cell epitope (MPO409-428), relevant to several MHCII and lying within an MPO 
epitope hot spot, would induce anti-MPO autoimmunity.
Methods: Immunity to MPO and MPO409-428 was studied in microbial peptide 
immunized C57BL/6 (B/6, I-Ab), BALB/c (I-Ad/Ed) and HLA-DR15 transgenic mice 
(proliferation, IFN-γ and IL-17A ELISPOT). Anti-MPO GN and anti-MPO immunity in 
response to peptides, proteins (MPO/ovalbumin as positive/negative controls) and S.aureus 
strains with/without plasmids carrying the relevant 6-phosphogluconate dehydrogenase 
(6PGD) sequence were studied in B/6 mice (I-Ab/MPO415-428 tetramers, cytokines, MPO-
ANCA IIF/ELISA, neutrophil ROS production, MPO-ANCA transfer). Anti-6PGD 
antibodies (Ab) were measured in sera of healthy humans and patients.
Results: The 4 most homologous microbial peptides were immunogenic but did not 
induce anti-MPO autoreactivity. However, a plasmid-derived peptide from 6PGD (6PGDp) 
with similar critical binding residues for MPO409-428 in B/6, BALB/c and DR15+ mice, 
found in some S.aureus strains, induced expansion of MPO415-428 tetramer+CD4+ cells, 
anti-MPO T cell autoimmunity (to MPO408-428 and whole MPO) and bioactive MPO-ANCA 
in B/6 mice. 6PGDp induced anti-MPO autoreactivity in mice with different MHCII 
(I-Ad/Ed and DR15). Related 6PGD sequences from other S.aureus strains did not induce 
anti-MPO responses. Healthy human and vasculitis patient sera contained anti-6PGD Ab, 
demonstrating its immunogenicity in humans. 6PGDp-immunized mice developed GN when 
MPO was deposited in glomeruli by anti-basement membrane globulin. Immunization with 
S.aureus containing a plasmid with the mimic 6PGD sequence, or another S.aureus strain 
transformed with a different plasmid expressing the 6PGD mimotope, also induced anti-
MPO GN with anti-MPO cellular and humoral autoimmunity, showing that plasmids with 
this sequence induce nephritogenic anti-MPO autoimmunity.
Conclusions: A microbial plasmid encoded peptide induces anti-MPO autoimmunity 
via molecular mimicry implicating plasmids, as bacterial replicons capable of horizontal 
gene transfer, in autoimmune disease.
Funding: Government Support - Non-U.S.
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Integrated Proteomics and DNA Analysis of Pathogenic IgG from Patients 
with Anti-GBM Nephritis
Mary H. Foster,1,2 Vadim Pedchenko,3 Amy G. Clark.1 1Duke University Medical 
Center, Durham, NC; 2Medicine/Research, DVAMC, Durham, NC; 3Vanderbilt 
University Medical Center, Nashville, TN.
Background: Anti-glomerular basement membrane (anti-GBM) nephritis 
(Goodpasture’s disease) is marked by immune destruction of kidneys and lungs triggered 
by IgG autoantibodies that bind the NC1 domain of the α3 chain of collagen IV. Current 
therapy consists of toxic immunosuppression. Selective therapeutic targeting of pathogenic 
IgG and B cells is highly desirable, but precluded by the lack of information about their 
structural basis.
Methods: To address this problem, we used an innovative approach validated in 
vaccine biology. F(ab’)2 fragments were isolated by pepsin digestion from circulating 
IgG of two patients with active anti-GBM nephritis and purified on α3(IV)NC1 affinity 
columns. Antigen-binding (Ag+) and non-binding (NB) flow-through F(ab’)2 were trypsin 
digested and evaluated by liquid chromatography-tandem mass spectrometry. Peptide 
spectra were analyzed using a reference library generated from productively rearranged Ig 
heavy chains (n=11903) in the International ImMunoGeneTics database and formatted for 
use by the Mascot search engine.
Results: 826 unique spectral matches were identified. 41 peptides were identified in 
both patients’ Ag+ F(ab’)2 and absent in NB flow-through F(ab’)2. All Ag+ matches aligned 
to Ig heavy chain variable region (VH) genes, primarily in conserved framework regions. 
Notably, 32% aligned to alleles of a VH gene with an unusual highly hydrophobic heavy 
chain complementarity determining region 2 (HCDR2) that was previously associated with 
autoreactivity and reported to encode a human anti-α3(IV)NC1 collagen monoclonal Ig 
derived from a humanized immune system mouse.
Conclusions: We find evidence of shared and biased gene use among pathogenic 
IgG that bind α3(IV)NC1 collagen in patients with anti-GBM nephritis. This suggests 
that patients’ GBM-binding IgG contain unusual targetable motifs in their Ag binding 
sites. Future interrogation of the spectra using patient-specific Ig DNA reference libraries, 
generated from patients’ lymphocytes, will permit identification of non-genomic-DNA-
templated peptide sequences that are found within HCDR3, a unique region of the Ag binding 
site created in B cells during VH-DH-JH gene recombination and for which sequences are 
not present in public databases. Rare motifs will provide additional therapeutic targets for 
personalized disease management.
Funding: NIDDK Support, Other NIH Support - NIH National Center for Advancing 
Translational Sciences (NCATS) and NIEHS, Veterans Affairs Support
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Modulation of Immune Response in Kidney Lymph Node During 
Crescentic Glomerulonephritis
Vivek Kasinath,1 Osman A. Yilmam,2 Mayuko Uehara,1 Liwei Jiang,2 
Farideh Ordikhani,2 David J. Salant,3 Reza Abdi.1 1Transplantation Research 
Center and Division of Renal Medicine, Brigham and Women’s Hospital, 
Boston, MA; 2Transplantation Research Center, Brigham and Women’s Hospital, 
Boston, MA; 3Renal Section, Boston University Medical Center, Boston, MA.
Background: Crescentic glomerulonephritis (GN) is an inflammatory condition 
characterized by a rapid deterioration of renal function. Previous studies of crescentic GN 
have focused on immune activation in the kidney. However, the role of fibroblastic reticular 
cells (FRCs), the prominent cells comprising the stromal compartment of the kidney lymph 
node (KLN), has not been studied in this condition.
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Methods: We induced nephrotoxic serum nephritis (NTN), a classic experimental 
model of crescentic GN, in mice. We investigated the contribution of FRCs in the KLN 
to the activation of the immune response in crescentic GN using flow cytometry, RT-PCR, 
hematoxylin and eosin (H&E) staining, and immunofluorescence staining.
Results: Investigation of the microarchitecture of the KLN during NTN revealed 
an increase in the deposition of extracellular matrix fibers by FRCs, associated with the 
propagation of specialized blood vessels known as high endothelial venules, through 
which lymphocytes traffic into the lymph node, as well as the expansion of the lymphatic 
vasculature. The KLN contained an expanding population of pro-inflammatory CD4+ 
effector memory T cells and Th17 cells. Removal of the KLN, depletion of FRCs, and 
treatment with anti-podoplanin antibody each resulted in a reduction of renal injury.
Conclusions: The pro-inflammatory activity of FRCs in the KLN is crucial to the 
propagation of the immune response in crescentic GN. Our findings can serve as a basis 
for the development of immunosuppressive therapy for crescentic GN directed towards 
modulating the activity of FRCs.
Funding: NIDDK Support, Other NIH Support - R01AI126596
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Targeting Neutrophil Serine Proteases in ANCA-Associated Vasculitis
Uwe Jerke,1 Claudia Eulenberg-Gustavus,1 Anthony Rousselle,1 
Adrian Schreiber,1,2 Brice Korkmaz,3 Ralph Kettritz.1,2 1Experimental and 
Clinical Research Center (ECRC) Campus Buch, Berlin, Germany; 2Charite 
Berlin, Berlin, Germany; 3INSERM U-1100, Tours, France.
Background: ANCA-activated neutrophils and monocytes cause necrotizing 
vasculitis. Enzymatically active neutrophil serine proteases (NSPs) contribute to the injury. 
NSPs include neutrophil elastase (NE), cathepsin G (CatG), and proteinase 3 (PR3) that also 
provides a major ANCA antigen. NSPs are generated from inactive zymogens by cathepsin 
C (CatC) during neutrophil maturation in the bone marrow. CatC loss-of-function mutations 
prevent NSP maturation leading to zymogen degradation. We characterized NSPs in humans 
and mice and tested the hypothesis that pharmacological CatC inhibition eliminates NSPs in 
a neutrophil differentiation model and reduces PR3-ANCA induced respiratory burst as well 
as neutrophil-mediated endothelial injury.
Methods: We prepared highly purified human and murine neutrophils and monocytes. 
We assessed NSP proteins by immunoblotting and flow cytometry, and proteolytic activity 
using specific FRET substrates. We employed a reversible cyclopropyl nitrile CatC inhibitor 
(IcatC) to reduce NSPs in neutrophils differentiated from CD34+ HSC in vitro. We assessed 
superoxide production by ferricytochrome C reduction and endothelial injury by phalloidin 
staining.
Results: Human and murine neutrophils and monocytes expressed PR3, NE, and CG 
by immunoblotting and flow cytometry. All three NSPs were enzymatically active by FRET 
assays. Protein amounts and proteolytic activity were significantly higher in neutrophils 
compared to monocytes. In vitro differentiated human neutrophils progressively expressed 
active NSPs during maturation. IcatC significantly reduced NSP proteins and enzymatic 
activity. PR3 surface protein decreased by 79%±10% (p<0.01), cellular protein by 82%±4% 
(p<0.001) and PR3 enzymatic activity by 98%±1% (p<0.001). Anti-PR3 antibodies 
provoked less superoxide release (46%±6% of control, p<0.01) in neutrophils differentiated 
in the presence of IcatC compared to buffer control (n=4). In addition, supernatants from 
neutrophils that were differentiated in the presence of IcatC caused less cytoskeletal damage 
in HUVECs.
Conclusions: Pharmacological CatC inhibition down-regulates NSPs, abrogates PR3-
ANCA induced respiratory burst in an in vitro neutrophil differentiation model, and reduced 
neutrophil-mediated endothelial damage. CatC inhibition may provide a future treatment 
strategy in ANCA vasculitis.
Funding: Government Support - Non-U.S.
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Spleen Tyrosine Kinase Expression and Function in Human Neutrophils 
in ANCA-Associated Vasculitis
Maria Prendecki, Fayaz Dudhiya, Kavita Gulati, Frederick W. Tam, 
Charles D. Pusey, Stephen P. McAdoo. Imperial College London, London, 
United Kingdom.
Background: Syk is a cytoplasmic tyrosine kinase which plays an important role in 
immunoreceptor signalling. Syk is phosphorylated following ANCA-induced neutrophil 
activation, and we have previously shown that a Syk inhibitor is an effective treatment 
in experimental autoimmune vasculitis. This study aimed to investigate neutrophil SYK 
function in patients with AAV.
Methods: Neutrophils were isolated from healthy donors (n=10) and patients with 
AAV (acute presentation n=21; relapse n=10; remission n=12). Intracellular staining for 
total (T-Syk) and phosphorylated (P-Syk) was analysed using flow cytometry. Neutrophils 
were primed with TNFα 2ng/ml and stimulated with 100 μg/ml MPO-ANCA IgG (or 
control IgG). R406, a small molecule Syk inhibitor, or vehicle was added prior to addition 
of IgG. RNAscope for Syk mRNA was performed on kidney sections, and IHC for T-Syk 
on extra-renal AAV tissues including ENT, lung and skin.
Results: There were similar levels of T-Syk present in neutrophils from HC and those 
with AAV. There was increased Syk phosphorylation at both the 319 and 348 residues in 
patients with active AAV compared to HC or patients in remission (Figure 1A). When 
TNFα primed neutrophils were stimulated with MPO-ANCA IgG there was significant IL-8 
release, that was inhibited by R406 in a dose dependent manner (Figure 1B). There was 
evidence of T-Syk in infiltrating inflammatory cells in non-renal sites of AAV (Figure 1C). 
There was also evidence of Syk mRNA in infiltrating leucocytes in glomeruli from patients 
with crescentic AAV but not in patients with sclerotic lesions.
Conclusions: Syk is phosphorylated to a greater degree in patients with than in healthy 
controls indicating greater neutrophil Syk activity in patients with AAV. Syk plays a role 
in cytokine production from neutrophils which may be pathogenic, and Syk mRNA and 
protein can be identified at sites of tissue inflammation. These results suggest there may be 
a role for Syk inhibition in decreasing neutrophil mediated damage in patients with AAV.
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P2X7 Knockout Does Not Protect from Experimental Glomerulonephritis 
and Vasculitis
Maria Prendecki,1 Stephen P. McAdoo,1 Tabitha Turner-Stokes,1 
Kevin Woollard,1 Robert J. Unwin,2 H. Terence Cook,1 Jacques Behmoaras,1 
Tim Aitman,3 Charles D. Pusey,1 Frederick W. Tam.1 1Imperial College London, 
London, United Kingdom; 2University College London Medical School, London, 
United Kingdom; 3University of Edinburgh, Edinburgh, United Kingdom.
Background: P2X7 is an ionotropic receptor for extracellular ATP previously shown 
to be important in inflammation and fibrosis. It may also play a role in autoimmunity. Both 
strains of P2X7 deficient mice are incomplete knockouts and have generated conflicting 
results. Therefore we have assessed the importance of P2X7 in autoimmunity and 
glomerulonephritis (GN) using a novel P2X7 knockout (KO) rat & a small molecule P2X7 
inhibitor.
Methods: Three in vivo models, nephrotoxic nephritis (NTN), experimental 
autoimmune GN (EAG) and experimental autoimmune vasculitis (EAV) were used to 
induce disease in P2X7 KO and WKY wild type (WT) rats. P2X7 antagonist (A438079) 
or vehicle (sterile water) was administered twice daily for 6 days after induction of NTN. 
Disease severity and development of autoimmunity were assessed in each model (NTN- 
day 7 and 28, EAG- day 28, EAV- day 42).
Results: P2X7 KO rats were not protected from disease in NTN, EAG or EAV 
models. P2X7 KO and WKY WT rats had similar renal function, urinary abnormalities, 
histological disease severity, lung injury and circulating and deposited antibody. Figure 1 
shows a representative EAG experiment. However, when P2X7 antagonist (A438079) was 
administered to rats with NTN from day 0-6 both WT and P2X7 KO rats were protected 
from disease with marked improvement in urinary abnormalities, renal function and 
histological disease severity (Figure 2).
Conclusions: P2X7 KO rats are not protected from 3 distinct models of glomerular 
disease. However, the P2X7 antagonist had a marked protective effect from renal injury 
in both P2X7 KO and WKY WT rats, suggesting that its effect is unrelated to P2X7 and 
is off-target.
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Critical MPO Epitopes Drive the Adaptive Immune Response in 
MPO-ANCA Vasculitis
Meghan E. Free,1,3 Katherine G. Stember,3 Jacob J. Hess,1,4 Olivier Lardinois,5 
Carmen E. Mendoza,3 Andrew K. Le,1 Susan L. Hogan,3 Yichun Hu,1 
Mark A. Pilkinton,7 Eddie A. James,6 William W. Kwok,6 Benjamin Vincent,3 
Simon Mallal,7 J. Charles Jennette,3 Dominic J. Ciavatta,3 Ronald J. Falk.1,2 
1UNC Kidney Center, Chapel Hill, NC; 2University of North Carolina, Chapel 
Hill, Chapel Hill, NC; 3University of North Carolina at Chapel Hill, Chapel 
Hill, NC; 4Columbia University, New York, NY; 5National Institute of 
Environmental Health Sciences, Research Triangle Park, NC; 6Benaroya 
Research Institute, Seattle, WA; 7Vanderbilt University Medical Center, 
Nashville, TN.
Background: Autoimmune diseases, including ANCA vasculitis, rely on broad 
immunosuppression to treat disease. However, research to understand the interactions 
between human leukocyte antigen (HLA), autoantigen, and effector immune cells, would 
permit the development of targeted therapies to revolutionize treatment.
Methods: HLA was determined by sequence typing and peptide-HLA interactions were 
predicted and confirmed by in silico and in vitro binding studies. Class II tetramers were 
utilized to identify circulating autoreactive T cells. The clonality of anti-myeloperoxidase 
(MPO) T cells was determined by TCR sequencing. ELISA studies examined the temporal 
B cell response to MPO peptides.
Results: Patients with HLA-DPB1*04:01 and/or HLA-DRB4*01:01 exhibit CD4+ T 
cell reactivity to specific epitopes of MPO contained in tetramers. Autoreactive T cells are 
enriched for memory T cells as indicated by expression of CD25, CD45RO and CCR7. 
Additionally, autoreactive cells produce IL-17A upon stimulation. Tetramer positive cells 
are clonally restricted as evidenced by loss of TCR diversity when compared to naïve and 
memory T cell populations. Furthermore, this region of MPO is targeted by patient ANCA, 
and specific antibody reactivity is most detectable at onset of disease. These T and B cell 
epitopes are contained in a region of MPO that is buried and immune system recognition is 
dependent on secondary structure.
Conclusions: These data define the specific interactions between the autoantigen, 
MPO, and the adaptive immune system within ANCA vasculitis. Collectively, this study 
informs the development of new antigen-specific therapies in ANCA vasculitis and 
autoimmune disease.
Funding: NIDDK Support, Other NIH Support - National Center for Advancing 
Translational Sciences, National Institutes of Health, through Grant Award Number 
TL1TR001110
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Identification of PR3-ANCA MPA and MPO-ANCA GPA as Different 
Subsets of ANCA Disease
Marco A. Alba,1 Yichun Hu,2 Caroline J. Poulton,2 Lauren N. Blazek,2 J. 
Charles Jennette,1 Ronald J. Falk,2 Susan L. Hogan.2 1University of North Carolina 
at Chapel Hill, Chapel hill, NC; 2UNC Kidney Center, Chapel Hill, NC.
Background: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis 
(MPA) are two major clinicopathologic variants of ANCA vasculitis. Typically, MPA and 
GPA have been associated with MPO-ANCA and PR3-ANCA, respectively. In this study, 
we detailed the characteristics of the less common subsets PR3-ANCA MPA and MPO-
ANCA GPA.
Methods: Patients from the Glomerular Disease Collaborative Network (GDCN) 
inception cohort were analyzed. Clinicopathologic phenotype was established according 
to the Chapel Hill Consensus Conference nomenclature. Baseline manifestations, relapses, 
ESRD, and survival were studied. Fisher’s exact test and Wilcoxon rank sum test were used 
for comparisons. Proportional hazards models were used to evaluate multivariable time to 
relapse, ESRD, and death for specificity controlling for age, sex, lung and ear, nose, and 
throat (ENT) involvement, creatinine at diagnosis and induction with cyclophosphamide. 
Because the GDCN is primarily composed of nephrologist thus resulting in a cohort where 
biopsy-proven renal involvement was present in almost all patients, prevalence of kidney 
disease was not compared between groups.
Results: See Table 1. MPO-ANCA MPA vs PR3-ANCA MPA: MPA patients with MPO-
positivity were older and had lower prevalence of ENT and musculoskeletal manifestations. 
MPO-ANCA GPA vs PR3-ANCA GPA: Patients with MPO-ANCA were older, more 
likely female, and had lower prevalence of ENT and nervous system involvement. In the 
proportional hazards models, ANCA serotype was not predictive of relapse, ESRD, or death 
neither in MPA nor in GPA (Table 1).
Conclusions: PR3-ANCA MPA and MPO-ANCA GPA represent particular subsets of 
ANCA disease with distinct organ involvement. The impact of these differences on the 
clinical management warrants further evaluation.
Funding: Other NIH Support - *
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The Role of MPO, Plasma Cell, and CD20 in the Pathogenesis of Human 
MPO-ANCA-Associated Glomerulonephritis
Soko Kawashima, Shinya Kaname. First Department of Internal Medicine, 
Kyorin University School of Medicine Kyorin University School of Medicine, 
Mitaka, Japan.
Background: Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-
associated glomerulonephritis (GN) is characterized by pauci-immune necrotizing 
glomerulonephritis. We reported that MPO and immune complexes composed of MPO-
anti MPO antibody may play some direct roles in the pathogenesis of glomerular capillary 
injuries in the early phase of the disease. Previous studies have suggested involvement of 
infiltrated macrophages and lymphocytes. Here we investigated a possible role of MPO-
positive cells, plasma cells, CD20-positive B-lymphocytes in the development of MPO-
ANCA- associated GN.
Methods: Patients with ANCA-associated vasculitis (AAV) were diagnosed according 
to the definition of the 2012 Chapel Hill Consensus Conference and the 1990 American 
College of Rheumatology classification criteria. Using renal biopsy specimen including 
more than 10 glomeruli that were obtained from 20 patients with MPO-ANCA-associated 
GN, we analyzed the extent of glomerular infiltration of CD20-positive cells and plasma 
cells as well as extracellular and cellular deposition of MPO by immunohistochemistry. The 
colocalization of MPO and plasma cells / CD20 cells was also examined by double staining 
for MPO and CD20 using immunofluorescence.
Results: CD20-positive cells were found only in 5 of the 151 glomeruli (0.67%) and 
mainly located in the peritubular capillaries around the glomeruli with active lesions. In 
contrast, plasma cells were frequently observed in 124/151 glomeruli (82.1%) of the early 
phase and located mainly in the endocapillary proliferative lesions and extra-capillary 
crescentic lesions. MPO exists along the glomerular capillary walls near the infiltrated 
MPO-positive neutrophils in the early phase. No colocalization of CD20-positive cells with 
MPO-positive cells / MPO deposition was observed, but MPO was occasionally stained in 
plasma cells.
Conclusions: These results suggest that plasma cells, rather than CD-20 positive cells, 
may play some roles possibly through MPO in the pathogenesis of human MPO-ANCA-
associated glomerulonephritis.
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Chemokine Receptor 8 in Peripheral Blood Mononuclear Cells Can Be a 
Novel Diagnostic Biomarker for ANCA-Negative ANCA-Associated 
Vasculitis
Shigeto Mashiko, Satoru Sanada, Mitsuhiro Sato, Toshinobu Sato, 
Yoshio Taguma. Japan Community Health Care Organization Sendai Hospital, 
Sendai, Japan.
Background: Diagnosis of antineutrophil cytoplasmic autoantibodies associated 
vasculitis (ANCA-associated vasculitis; AAV) is based on clinical and histologic features 
with elevated serum ANCA levels, however, not all cases show ANCA positive. In such 
cases, diagnosis of AAV without histological examination is quite difficult. We have 
found that the chemokine receptor 8 (CCR8) level in peripheral blood mononuclear cells 
correlates with activity of MPO-ANCA positive AAV; CCR8 is upregulated both in mRNA 
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and protein levels, which was reported in the previous meeting. In this study, we extended 
our research of CCR8 levels in ANCA-negative AAV.
Methods: Peripheral blood mononuclear cells were collected from 81 patients 
representing rapidly progressive glomerulonephritis on their initial visit. Participants were 
categorized as ANCA-positive AAV, immune complex small vessel vasculitis, vasculitis 
associated with systemic disease, and ANCA-negative AAV according to Chapel Hill 
consensus conference criteria. CCR8 gene expression levels in each group were assessed 
retrospectively.
Results: CCR8 gene expression levels were significantly higher in patients with 
ANCA-negative AAV compared to those in healthy controls. The area under the ROC curve 
was 0.92 (95% CI: 0.76-1.00) with a sensitivity of 91.7% and a specificity of 100%. CCR8 
levels in patients with ANCA-positive AAV also showed a higher value with statistical 
significance. The area under the ROC curve was 0.83 (95% CI: 0.79-0.96) with a sensitivity 
of 75.6% and a specificity of 100%. Immune complex small vessel vasculitis and vasculitis 
associated with systemic disease did not show the CCR8 elevation. These data indicate 
that CCR8 is upregulated in pauci-immune glomerulonephritis regardless of serum ANCA 
levels.
Conclusions: CCR8 could be a useful biomarker in diagnosis of ANCA-negative AAV 
representing rapidly progressive glomerulonephritis.
TH-PO848 Poster Thursday
Glomerular Diseases: Immunology and Inflammation - I
The Emergence of Goodpasture’s Disease Following Hematopoietic Stem 
Cell Transplant: Clues to Disease Etiology?
Vadim Pedchenko,4 Paul E. Gray,1 Hugh J. Mccarthy,5 Moin Saleem,2 A. 
Richard Kitching,3 Agnes B. Fogo,4 Billy G. Hudson.4 1Immunology and 
Infectious Diseases, Sydney Children’s Hospital, Sydney, NSW, Australia; 
2University of Bristol, Bristol, United Kingdom; 3Monash University, Monash 
Health, Clayton, VIC, Australia; 4Nephrology and Hypertension, Vanderbilt 
University Medical Center, Nashville, TN; 5Syndey Children’s Hospital Network, 
Westmead, NSW, Australia.
Introduction: Goodpasture’s disease is an autoimmune disorder caused by 
autoantibodies against collagen IV in the glomerular and alveolar basement membranes. It 
has been postulated that a conformational change of the native autoantigen, the α345NC1 
hexamer of collagen IV, is imperative for the development of disease. Perturbation of the 
quaternary structure causes dissociation of the hexamer, which elicits autoantibodies against 
subunits, but not the native hexamer. This contrasts with Alport’s post-transplant nephritis, 
where the pathogenic alloantibody binds directly to native NC1 hexamer.
Case Description: We studied a patient who developed anti-GBM disease following 
allogeneic haematopoietic stem cell transplant. Autoantibody specificity was analysed 
by ELISA including binding to individual NC1 monomers of collagen IV (α1-α6), 
immunodominant epitopes of α3 chain, and native versus dissociated NC1 hexamers from 
glomerular basement membrane. Binding of autoantibody from patient serum to normal 
kidney GBM was also assessed. Anti-GBM antibodies were directed against the α3 NC1 
domain of collagen IV and developed rapidly reaching peak level in patient serum within 
5 weeks. They targeted predominantly the EA epitope of α3 NC1. Antibody binding to 
native α345NC1 hexamer was minimal; however, binding was greatly increased upon 
hexamer dissociation. None of the polymorphic genetic differences between donor and 
recipient collagen IV genes would be predicted to cause a significant NC1 conformational 
change or to provide a target for antibody binding. Both patient and donor possessed the 
Goodpasture’s susceptibility HLA-allele DRB1*1501.
Discussion: This is the first report of Goodpasture’s disease occurring post-HSCT 
where the pathogenesis has been studied from onset to recovery. The specificity and 
binding properties of the antibodies along with sequencing results indicate that this is a post-
transplant autoimmune rather than alloimmune phenomenon. This case also demonstrated 
the rapidity, in a matter of weeks, of high titres of pathogenic antibody production 
highlighting the nature of emergent Goodpasture’s disease. Our findings demonstrate the 
importance for early diagnosis of Goodpasture’s disease and timely treatment for preserving 
kidney function.
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High Glucose Promotes Macrophage Switching to M1 Phenotype via 
Down-regulating STAT-3-Mediated Autophagy
Yu Zhao,1 Xiaodong Zhu,1 Yuteng Jiang,1 Yuqiu Liu,1 Xiaoliang Zhang.2 
1Institute of Nephrology, Zhong Da Hospital, Southeast University, School of 
Medicine, Nanjing, China; 2Zhong Da Hospital, Southeast University, School of 
Medicine, Nanjing, China.
Background: Imbalance of M1/M2 macrophages phenotype activation is a key 
point in diabetic nephropathy (DN). Macrophages mainly exhibit M1 phenotype, whcih 
contribute to the inflammation and fibrosis in DN. Studies indicate that autophage plays 
an important role in M1/M2 activation. However, the mechanism of autophage regulating 
macrophage M1/M2 phenotype in DN is unknown. Thus, the aim of this study is to explore 
whether high glucose induced macrophage switch to M1 phenotype via down-regulating 
STAT-3-mediated autophagy.
Methods: In vivo, DN model rats were established by intraperitoneal injection with 
streptozocin (STZ). Rats were sacrificed respectively at 18w for histological and molecular 
analysis. In vitro, RAW264.7 cells were cultured with 30mM glucose with or without 
autophagy regulator and STAT-3 regulator intervention. Meanwhile, the classical activation 
models of M1 and M2 macrophages were established as control group. The expressions 
of autophagy-related proteins (LC3, Beclin-1, p62), M1 markers (iNOS, TNF-α) 
and M2 markers (MR, Arg-1) were detected by immunofluorescence and Western Blot.
Results: In vivo, macrophages were exhibited to M1 phenotype in DN and displayed 
a lower level of autophagy. Additionally, iNOS expression was negative correlated with 
LC3 (r=-0.619, P<0.05) and pSTAT-3 (r=-0.951, P<0.05). In vitro, electronic microscope 
analysis showed intact autophagy (Fig.1). RAW264.7 macrophages switched to M1 
phenotype under high glucose conditions. Autophagy was downregulated in such high 
glucose induced M1 macrophages. The expression of LC3 (autophagy maker) increased 
by STAT-3 activator. Meanwhile, both the STAT-3 activator and autophagy activator 
(rapamycin) promoted glucose-induced M1 macrophage translating to M2 macrophage. 
However, after inhibition of STAT-3 expression with STAT-3 siRNA, autophagy activator 
contributes to the reduction of the conversion of macrophages from M1 into M2 phenotype 
in high glucose-induced macrophage.
Conclusions: High glucose promotes macrophage switching to M1 phenotype via 
down-regulating STAT-3-mediated autophagy.
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Active Vitamin D Regulates Macrophage M1/M2 Phenotypes via the 
STAT-1-TREM-1 Pathway in Diabetic Nephropathy
Yu Zhao,1 Yuteng Jiang,1 Xiaodong Zhu,1 Xiaoliang Zhang.2 1Institute of 
Nephrology, Zhong Da Hospital, Southeast University, School of Medicine, 
Nanjing, China; 2Zhong Da Hospital, Southeast University, School of Medicine, 
Nanjing, China.
Background: Imbalance of M1/M2 macrophages phenotype activation is a key point 
in diabetic nephropathy (DN). TREM-1(Triggering Receptor Expressed On Myeloid 
Cells 1) is essential for macrophage function regulation. Signal transducer and activator 
of transcription (STAT) is a key factor that regulates the activation of macrophage M1/M2 
phenotypes. Our previous studies indicated that active vitamin D (VD) has renoprotective 
role. This study aimed to investigate whether VD suppresses macrophage transition to the 
M1 phenotype via inhibiting the high glucose-induced STAT-1 phosphorylation to reduce 
TREM-1 expression.
Methods: Pathological changes in kidney tissue were detected and the expression of 
CD68 TREM-1, STAT-1, M1 makers and M2 makers were acquired in renal tissue of DN 
patients and 18w DN rats. In vitro, RAW 264.7 cells were treated by high glucose with or 
without VD. TREM-1 siRNA, STAT-1 siRNA and high expression plasmid of TREM-1 and 
STAT-1 were explored to elucidate the underlying mechanism. The expression of TREM-
1 and STAT-1 and the changes of macrophage phenotype were examined separately by 
Western Blot, immunofluorescence stain.
Results: (1) In DN patients, the expression of M1 markers (iNOS, TNF-α) and 
TREM-1, pSTAT-1 were increased in comparation with NC group(P<0.05). Additionally, 
iNOS expression was positive correlated with the TREM-1 expression (r=0.757, P<0.05), 
pSTAT-1 (r=0.808, P<0.05). (2) In DN rats, the enlargement of glomerular surface area, 
expansion of glomerular mesangial matrix, the expression of CD68, TREM-1, pSTAT-1 
and M1 markers (iNOS) were significantly increased compared with NC group (P<0.05), 
while above changes were markedly decreased in DN+VD group (P<0.05). (3) In vitro, VD 
significantly decreased high glucose induced CD68, TREM-1, pSTAT-1 and M1 markers 
(iNOS) expression. However, above effects from VD were abolished when TREM-1 
or STAT-1 expression was overexpressed by TREM-1 or STAT-1 plasmid. Inhibition of 
STAT-1 expression with STAT-1 siRNA decreased TREM-1 expression, while, TREM-1 
regulation by TREM-1 siRNA or TREM-1 overexpression techniques did not affect STAT-1 
expression.
Conclusions: VD can inhibit macrophage transition to the M1 phenotype through the 
STAT-1/TREM-1 pathway under high glucose condition.
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Serum Amyloid A and Clinical Outcomes in Early Diabetic Kidney 
Disease
Brad Dieter,1 Sterling McPherson,2 Radica Z. Alicic,3 Pierre Jean Saulnier,4 
Robert G. Nelson,5 Matthias Kretzler,6 Katherine R. Tuttle.7 1Providence Health 
Care, Spokane, WA; 2Washington State University College of Medicine, 
Spokane, WA; 3Providence Medical Research Center, Spokane, WA; 4CHU 
poitiers, Poitiers, France; 5National Institutes of Health, Phoenix, AZ; 6U.
Michigan, Ann Arbor, MI; 7University of Washington School of Medicine, 
Spokane, WA.
Background: Risk of end-stage renal disease (ESRD) and death is increased by higher 
systemic levels of serum amyloid A (SAA) in patients with advanced diabetic kidney 
disease (DKD), but not among those with early or no DKD. The study aim was to determine 
relationships between indicators of locally-produced SAA and clinical outcomes in these 
patients.
Methods: In Pima Indians with type 2 diabetes, SAA protein was measured in urine 
(enzyme-linked immunosorbent assay, n=159) and SAA mRNA was quantified (microarray, 
n=46) in kidney tissue from research biopsies. Cox-proportional hazard models tested 
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whether urinary SAA forecasted future ESRD and all-cause death. Linear regression 
models tested for cross-sectional associations of SAA mRNA in kidney tissue with urine 
albumin-to-creatinine ratio (UACR) or estimated glomerular filtration rate (eGFR; CKD-
EPI-creatinine). Urine and blood samples for these analyses were collected within 6 months 
of the biopsies.
Results: Baseline characteristics included: age 47±11 (mean±SD) years, women 
(117/159; 74%), hemoglobin A1c 9.1±2.3%, diabetes duration 17±7 years, body mass 
index 36±8 kg/m2, renin angiotensin system inhibitor use (64/159; 40%), systolic blood 
pressure 124±16 mm Hg, UACR 39,14-209 mg/g (median, interquartile range), eGFR 
103, 91-114 mL/min/1.73m2. During a median of 12.5 years, 25 participants developed 
ESRD and 53 died. SAA-positive urine forecasted ESRD (hazards ratio [HR] 3.73, 
95% confidence interval [CI] 1.11–12.53, p=0.022), but not death (HR 1.71, 95% 
CI 0.53– 5.50). In kidney tissue, tubulointersitial SAA mRNA was associated with a 
6.3 mL/min/1.73m2 lower eGFR (p<0.001) and a 0.80 log-fold increase in UACR per log-
fold change in SAA mRNA (p<0.001). Glomerular SAA mRNA was associated with a 4.5 
mL/min/1.73m2 lower eGFR (p<0.001) and a 0.58 log-fold increase in UACR per log-fold 
change in SAA mRNA (p<0.001).
Conclusions: Urinary SAA forecasted ESRD and higher levels of SAA mRNA 
in kidney tissue correlated with lower eGFR and higher UACR. Associations between 
indicators of locally-produced SAA and clinical outcomes point to a candidate mechanism 
for DKD onset and progression in diabetic patients with early or no DKD.
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Sodium Glucose Cotransporter 2 Inhibition with Dapagliflozin Confers 
Renoprotection by Downregulating Megalin in Proximal Convoluted 
Tubules
Tomomichi Iida,2,3 Shoji Kuwahara,2 Michihiro Hosojima,4 Tomomi Ishikawa,2,3 
Eri Wada,2,1 Hideyuki Kabasawa,4 Sawako Goto,2,3 Daisuke Ugamura,2,3 
Yuta Yoshizawa,2,3 Ryohei Kaseda,3 Yoshiki Suzuki,5 Ichiei Narita,3 
Akihiko Saito.2 1Gunma University Institute for Molecular and Cellular 
Regulation, Maebashi, Japan; 2Applied Molecular Medicine, Kidney Research 
Center, Niigata University Graduate School of Medical and Dental Sciences, 
Niigata, Japan; 3Clinical Nephrology and Rheumatology, Kidney Research 
Center, Niigata University Graduate School of Medical and Dental Sciences, 
Niigata, Japan; 4Clinical Nutrition Sciences, Kidney Research Center, Niigata 
University Graduate School of Medical and Dental Sciences, Niigata, Japan; 
5Health Administration Center, Niigata University, Niigata, Japan.
Background: Megalin is an endocytic receptor expressed in the proximal tubules. We 
found that megalin mediates the endocytosis of glomerular-filtered nephrotoxic proteins, 
causing high-fat diet (HFD)-induced kidney disease in mice (JASN 2016). Thus, we 
speculate that appropriate suppression of renal megalin function may delay the development 
and progression of DKD. Sodium glucose transporter 2 (SGLT2) inhibitors are known to 
exert renoprotective actions and increase β2-microglobulin, an endocytic ligand of megalin, 
in urine of patients with type 2 diabetes. Therefore, we studied the effect of dapagliflozin, 
a widely used SGLT2 inhibitor, on megalin expression in proximal tubular epithelial cells 
(PTECs).
Methods: Eleven-week-old male C57BL/6J mice, fed a normal fat diet (NFD), were 
administered 1mg/kg dapagliflozin or vehicle via oral gavage for 7 days; or eight-week-old 
mice were fed an HFD and administered 1mg/kg dapagliflozin or vehicle for 4 weeks. The 
effect of dapagliflozin on renal megalin expression was investigated by immunoblotting, 
quantitative PCR, and immunohistochemistry. Cultured immortalized rat PTECs (IRPTCs) 
transfected with human SGLT2 cDNA (S-IRPTCs) were treated with 20 μM dapagliflozin 
or vehicle and evaluated for 2-deoxy-D-glucose uptake and megalin expression.
Results: Dapagliflozin suppressed megalin expression transcriptionally in mice fed 
either an NFD or HFD. Megalin expression was decreased in the proximal convoluted 
tubules, but not in the proximal straight tubules. In HFD-fed mice, no difference was noted 
in blood glucose levels between dapagliflozin and vehicle treatments. Urinary albumin 
and α1-microglobulin, endocytic ligands of megalin, were increased in dapagliflozin 
administered mice. In S-IRPTCs treated with dapagliflozin, the expression of both megalin 
protein and mRNA was decreased in association with decreased glucose uptake.
Conclusions: The renoprotective effect of SGLT2 inhibitors may be at least partly due 
to megalin downregulation, which would have impacts on the therapeutic strategies with 
SGLT2 inhibitors including the interpretation of megalin-associated urinary biomarkers in 
diabetes.
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SGLT2 Inhibition Relieves High Glucose-Induced Metabolic Disorders in 
Tubular Epithelial Cells Through Regulation of HIF-1α Pathway
Ting Cai,2 Yang Zhou,1 Junwei Yang.1 1Second Affiliated Hospital, Nanjing 
Medical University, Nanjing, China; 2Nanjing Medical University, Nanjing, 
China.
Background: SGLT2 inhibitor (SGLT2i) has been proved to be renoprotective by 
reducing hyperperfusion, hyperfiltration and hypertension in glomeruli of diabetic kidney. 
However, high concentration of glucose reabsorbed into proximal tubular cells induced 
consequence abnormalities in glucose and lipid metabolism seems to be detrimental in 
diabetic kidney disease (DKD). In this study, we examined whether SGLT2i dapagliflozin 
may rectify metabolic disorders and explore the possible mechanism.
Methods: Diabetic model was induced by streptozotocin injection. Losartan was 
used as hemodynamic control. Dapagliflozin and losartan were given by oral gavage for 
12 weeks. Mice were randomly assigned into six groups as follows: control + vehicle, 
control + dapagliflozin (5mg/kg), control + losartan (10mg/kg), diabetes + vehicle, diabetes 
+ dapagliflozin (5mg/kg), diabetes + losartan (10mg/kg). High glucose-incubated primary 
tubular cells (PTCs) were treated with or without dapagliflozin for indicated time periods.
Results: In both diabetic kidney and glucose-treated PTCs, metabolic abnormalities 
were notable as demonstrated by increased lactate level and lipid accumulation 
accompanied with increased expression of enzymes for glycolysis and decreased expression 
of enzymes for fatty acid oxidation. Dapagliflozin treatment decreased blood glucose level, 
attenuated the increase of kidney/body weight ratio, albuminuria excretion rate, urinary 
NGAL level and tubulointerstitial fibrosis. Furthermore, dapagliflozin treatment relieved 
the increase of lactate level and accumulation of lipid droplet in tubular cells. The increased 
expression of glycolytic enzymes and decreased expression of fatty acid enzymes were 
rectified by dapagliflozin. These metabolic benefits were not observed in losartan-treated 
group. Moreover, expression of HIF-1α, the regulator of metabolism was increased, which 
suggested the stabilization of HIF-1α in diabetic kidney. Nevertheless, dapapagliflozin 
treatment inhibited HIF-1α stabilization. HIF-1α stabilizer BAY85-3934 blocked the 
protective role of dapagliflozin on metabolism in high glucose-treated PTCs.
Conclusions: We suggested that SGLT2 inhibitor protects against metabolic 
abnormalities and relieves tubular damage in diabetes through HIF-1α pathway.
Funding: Government Support - Non-U.S.
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Renal SGLT2 mRNA Expression in Diabetic and Non-Diabetic Kidney 
Disease in Humans
Vikas Sridhar,1 Jaya P. Ambinathan,1 Matthias Kretzler,3 Petter Bjornstad,4 
Sean Eddy,3 David Cherney,1,2 Heather N. Reich.1,2 ERCB and NEPTUNE 
groups 1Nephrology, University of Toronto, Toronto, ON, Canada; 2Toronto 
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Background: In the setting of diabetes, intraglomerular hypertension is associated with 
chronic kidney disease (CKD) progression, in part through sodium-glucose cotransporter 
2 (SGLT2)-mediated suppression of tubuloglomerular feedback (TGF). Pharmacological 
inhibition of SGLT2 activates TGF and reduces CKD progression in the setting of diabetes, 
and is being examined as a renal protection strategy in non-diabetic CKD trials. Despite 
interest in this field and ongoing trials, levels of renal SGLT2 mRNA expression in human 
health and disease have not yet been fully examined. Our aim was to quantify human renal 
SGLT2 mRNA expression in healthy controls (HC), in glomerulonephritis subtypes (GN) 
and in patients with diabetic kidney disease (DKD).
Methods: SGLT2 mRNA expression was quantified and compared in HC vs. GN vs. 
DKD in the European Renal cDNA Bank (ERCB). Second, renal SGLT2 mRNA expression 
from the Nephrotic Syndrome Study Network (NEPTUNE) was analyzed using biopsies 
from patients with membranous nephropathy (MN), minimal change disease (MCD), 
focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). mRNA was 
obtained by microdissection of tubulointerstitial compartments from adult renal biopsies 
and processed using a microarray platform.
Results: In ERCB (n=166), SGLT2 mRNA expression was 9.42±0.50, 9.19±0.50 and 
8.85±0.64 in HC, GN and DKD respectively (p=0.0044). SGLT2 mRNA expression was 
higher in HC vs. DKD and GN vs. DKD (p<0.05 for both). In NEPTUNE (n=121), there 
were no mRNA expression differences across GN subtypes (MN vs. MCD vs. FSGS vs. 
IgAN). In NEPTUNE patients with GN, eGFR (r= 0.32, p<0.001) was positively correlated 
with SGLT2 mRNA expression and interstitial fibrosis was negatively correlated with 
SGLT2 expression (r=-0.23, p<0.01). No relationships were seen with proteinuria.
Conclusions: SGLT2 mRNA expression is lower in patients with DKD compared to 
HC or GN, and is related to the degree of interstitial fibrosis in GN patients. In light of 
protective effects on DKD outcomes in clinical trials despite apparently having the lowest 
SGLT2 mRNA expression, further studies are required to better understand the relationship 
between SGLT2 protein levels and/or activity and CKD outcomes in humans.
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Early B Cell Factor 1 Plays a Role in the Maintenance of Glomerular 
Filtration Barrier Integrity
Darrell C. Andrews,1 Eoin P. Brennan,1 Laura L. Beverly-Staggs,6 
Patricia A. Schroder,4 Peter J. Conlon,5 Mario Schiffer,3 Catherine Godson.2 The 
GENIE Consortium 1University College Dublin, Dublin, Ireland; 2The Conway 
Institute of Biomolecular and Biomedical, Belfield, Dublin, Ireland; 3Hannover 
Medical School, Hannover, Germany; 4Mount Desert Island Biological 
Laboratory, Salisbury Cove, ME; 5Beaumont Hospital, Dublin 9, Co Dublin, 
Ireland; 6Mount Desert Island Biological Lab, Salisbury Harbor, ME.
Background: Diabetic kidney disease (DKD) is the leading cause of end-stage renal 
disease (ESRD) and organ failure worldwide. Current therapies are inadequate and at 
best slow progression but do not arrest or reverse it. Proteinuria is associated with DKD 
progression and reflects loss of integrity of the glomerular filtration barrier (GFB). Defining 
the mechanisms underlying a compromised GFB during the progression of DKD is key 
to developing effective therapeutic strategies. We identified EBF1 as associated with 
macroalbuminuria and ESRD by our GWAS analysis in a case (n=2,861 individuals with 
T1DM) vs control (n=12,418 individuals with T1DM and no evidence of renal disease 15 
years post-diagnosis) approach. Here we investigate the contribution of EBF1 to proteinuria 
associated with DKD using a zebrafish model of GFB integrity and elaborate on its role in 
maintaining a functional GFB.
Methods: To investigate a possible causative role for EBF1 in loss of GFB integrity 
with resulting proteinuria Tg(l-fabp:DBP:EGFP) zebrafish embryos were injected with 
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control or EBF1 morpholinos. Morpholinos targeting the podocyte gene CD2AP were 
used as a positive control. Tg(l-fabp:DBP:EGFP) transgenic zebrafish express a fluorescent 
plasma protein with a molecular weight equivalent to human albumin. Compromised GFB 
integrity leading to loss of the fusion protein from the circulation can be quantified by 
fluorescence imaging of the retinal plexus. The ultrastructure of GFB was visualised using 
electron microscopy. While RNA sequencing analysis was used to map the transcriptome of 
EBF1 knockdown fish vs control.
Results: EBF1 knockdown led to a significant loss of retinal fluorescence compared 
to control and equivalent to that of CD2AP at 96hpf. Knockdown also caused generalised 
edema compared to control, further supporting a role for this gene in kidney function. 
EM analysis revealed loss of EBF1 caused pronounced podocyte foot process effacement 
and screening of a cohort of cell lines confirmed high levels of expression of EBF1 in 
podocytes. RNA sequencing analysis combined with Ingenuity Pathway Analysis revealed 
desregulated transcripts and key pathways affected by EBF1 knockdown which were 
validated by real time PCR.
Conclusions: These findings suggest that EBF1 plays a key role in maintaining GFB 
integrity.
Funding: NIDDK Support, Government Support - Non-U.S.
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Microangiography Reveals the Protective Role of Liraglutide on Renal 
Microvascular Impairment in Rats with Metabolic Syndrome
Vijayakumar Sukumaran,1 Hirotsugu Tsuchimochi,1 Takashi Sonobe,1 
Mikiyasu Shirai,2 James T. Pearson.1,3 1Department of Cardiac Physiology, 
National Cerebral and Cardiovascular Centre, Suita, Japan; 2Center for 
Advanced Medical Research for on Pulmonary Hypertension, National Cerebral 
and Cardiovascular Center, Suita, Japan; 3Department of Physiology, Monash 
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Background: Progressive renal impairment associated with metabolic syndrome 
remains a significant cause of morbidity and mortality. We investigated whether chronic 
high dose liraglutide (LIRA, GLP-1 agonist) treatment affects the metabolic profile and 
extent of renal inflammation and renal endothelial function in lean fa/+ and obese fa/fa 
(ZFDM) rats.
Methods: 8-week old lean fa/+ and obese fa/fa ZFDM rats were treated with vehicle 
or LIRA (1mg/kg/day, subcutaneous) for 8 weeks. Systolic blood pressure (SBP) was 
monitored in ZFDM rats at 0, 4 and 8 weeks using tail-cuff method. Glomerular filtration 
rate (GFR) was measured in conscious rats at 0, 4 and 8 weeks using the fluorescein 
isothiocyanate sinistrin method. X-ray microangiography was then used to investigate 
renal vascular function (vessels 70-350 μm diameter). Further, renal function parameters 
including urinary albumin, creatinine and albumin creatinine ratio were measured.
Results: We found that in comparison to the saline treated obese fa/fa rats, LIRA 
treated rats had significantly lower SBP, and restored GFR (Fig. 1A-B) due in part to an 
increase in nitric oxide-mediated vasodilation in small renal arteries and arterioles (<200 
μm diameter) (Fig. 1C-F). Further, vessel internal diameter, visible vessel number and
caliber (%) increased after LIRA treatment compared to vehicle-treated rats (Fig. 1G-I).
Moreover, the high dose LIRA treatment largely prevented the decline in renal function
seen in vehicle treated obese fa/fa rats (elevated urinary albumin and depressed creatinine).
Conclusions: These results strongly suggest that high dose LIRA treatment 
significantly improved the endothelial function of microvessels in the renal circulation, and 
greatly improved renal function.
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Possible Role of Ketone Body Metabolism in SGLT2 Inhibitor-Mediated 
Renoprotection in High Fat Diet-Fed ApoE-Knockout Mice
Tomita Issei,1 Shinji Kume,1 Norihisa Osawa,1 Kosuke Yamahara,1 
Mako Yamahara,1 Naoko Takeda,1 Masami Kanasaki,1 Eric Mayoux,2 
Tatsuroh Kaneko,3 Shin-ichi Araki,1 Hiroshi Maegawa.1 1Shiga University of 
Medical Science, Otsu, Japan; 2Boehringer-Ingelheim, Biberach an der Riss, 
Germany; 3Nippon Boehringer Ingelheim, Tokyo, Japan.
Background: A recent study showed that empagliflozin, a SGLT2 inhibitor, slowed 
renal function decline rate in diabetic patients regardless of proteinuria stage, suggesting 
that the treatment has a renoprotective property in diabetes. This animal study was aimed at 
revealing the renoprotective action of empagliflozin on atherosclerosis-related renal injury 
in diabetes, and a possible role of ketone body production in its renoprotective mechanism.
Methods: Study 1 examined the effect of oral administration of empagliflozin (30mg/
kg) for 8 weeks on atherosclerosis and renoprotection in high fat diet (HFD)-fed ApoE 
knockout (ApoE-/-) mice, an animal model for atherosclerosis. Study 2 examined the 
effect of oral administration of 1,3-butanediol, a ketone body precursor, for 8 weeks on 
atherosclerosis and renoprotection in HFD-ApoE-/- mice.
Results: In Study 1, empagliflozin treatment significantly improved atherosclerosis in 
HFD-fed ApoE-/- mice. HFD-ApoE-/- mice showed significant increases in serum cystatin 
C levels without albuminuria, and F4/80-positive macrophage infiltration and fibronectin 
deposition in renal interstitium. These renal alterations were all significantly improved 
by the empagliflozin treatment, which was accompanied by significant increases in 
serum β-hydroxybutyric acid (β-OHB) levels. In study 2, although the 1,3-BD treatment 
did not improved atherosclerosis in HFD-fed apoE-/- mice, similarly to the results from 
the empagliflozin study, the 1,3-BD treatment significantly improved serum cystatin C, 
and renal F4/80-positive macrophage infiltration and fibronectin deposition along with 
maintaining renal ATP contents in HFD-ApoE-/- mice. Finally, we confirmed that β-OHB 
supplementation inhibited apoptosis in the cultured proximal tubular cells stimulated with 
high glucose, saturated fatty acids and hypoxia.
Conclusions: Ketone body-derived energy supply to the hypoxic kidney could be a 
promising therapy for preventing renal dysfunction in diabetic kidney disease.
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Association Between MYH9 and APOL1 Gene Polymorphisms and the 
Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes in a 
Chinese Han Population
Hailing Zhao, Ping Li. China-Japan Friendship Hospital, Beijing, China.
Background: Single nucleotide polymorphisms (SNPs) in MYH9-APOL1 gene 
regions have been reported to be associated with diabetic kidney disease (DKD) in the 
American population. The susceptibility of MYH9 and APOL1 polymorphisms with DKD 
in Chinese populations has not been well studied. In this study, we examined the association 
of MYH9 rs3752462 (T>C) and APOL1 rs136161 (C>G) with DKD in a Chinese Han 
population.
Methods: MYH9 rs3752462 (T>C) and APOL1 rs136161 (C>G) were genotyped 
in 303 DKD patients and 364 type 2 diabetes mellitus (T2DM) patients without kidney 
disease using the TaqMan SNP genotyping assay. Chi-squared test and multivariate logistic 
regression were used to evaluate the association.
Results: We observed that only MYH9 rs3752462 was associated with DKD (genotype, 
P= 0.004; allele, P= 0.002). Genetic model analysis revealed that rs3752462 was associated 
with increased risk of DKD under a dominant model adjusted by age and sex (adjusted 
Odds ratio [aOR], 1.675; 95% CI 1.225-2.289; P= 0.001) and an additive model (TC vs TT: 
aOR, 1.649; 95% CI 1.187-2.290; CC vs TT: aOR, 1.817; 95% CI 0.980-3.367; P= 0.005). 
The combined effect of rs3752462 TC + rs136161 CC genotype showed a association of 
DKD adjusted by age and sex (aOR, 1.732; 95% CI 1.128-2.660; P= 0.012). After a Holm-
Bonferonni correction for multiple tests, the C allele frequencies of the rs3752462 and 
the TC + CC genotype in dominant model were considered statistically significant with a 
markedly increased risk of DKD (P<0.00208; P<0.002).
Conclusions: Our results suggest that MYH9 rs3752462 is significantly associated 
with an increased risk of DKD in Chinese Han individuals.
Funding: NIDDK Support
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Genome-Wide Association Study of Urinary and Plasma KIM-1 Levels in 
Type 1 Diabetic Subjects with Diabetic Kidney Disease
Marcus G. Pezzolesi,1 Eiichiro Satake,2 Adam Smiles,2 Christopher Simeone,2 
Julio C. Fierro,1 Bozena Krolewski,2 Stephen Rich,3 Andrzej S. Krolewski.2 
1University of Utah, Salt Lake City, UT; 2Joslin Diabetes Center, Boston, MA; 
3University of Virginia, Charlottesville, VA.
Background: Kidney injury molecule 1 (KIM-1) is a transmembrane protein primarily 
expressed at the apical membrane of proximal tubular cells following kidney damage. 
Urinary and plasma levels of this biomarker are increased in patients with non-diabetic 
chronic kidney disease and diabetic kidney disease. Here, we performed a genome-wide 
association study (GWAS) to investigate whether genetic factors influence urinary and 
plasma KIM-1 levels in type 1 diabetes.
Methods: KIM-1 levels were measured in 688 baseline urine specimens and 826 
plasma specimens from participants with type 1 diabetes enrolled in the Joslin Kidney Study. 
Genotyping was performed using Illumina’s HumanCoreExome BeadArray. Imputation 
of additional variants across the KIM-1 locus was performed using IMPUTE2 and 1000 
Genomes Phase 3 data. Association analyses between KIM-1 levels and single nucleotide 
polymorphism (SNP) data were calculated using linear regression implemented in Plink.
Results: The strongest GWAS SNP associated with urinary KIM-1 levels was a 
missense variant (rs12522248; Thr207Ala; P=6.3x10-6) located in exon 3 of the KIM1 
gene. The most strongly associated GWAS SNP with plasma KIM-1 levels was rs2436424 
(P=5.0x10-6), located 230kb downstream of KIM1. Using imputed SNPs to fine-map this 
locus, we identified 45 SNPs with P<1.0x10-5, including 2 variants approximately 50kb 
downstream of KIM1 with P<1x10-7.
Conclusions: Using a GWAS and imputation analysis of urinary and plasma KIM-1 
levels, we identified strong associations in the KIM1 gene that suggests that genetic variants 
at this locus impact KIM-1 levels in response to kidney injury. Further investigation is 
needed to fully understand the role of genetic variation on KIM-1 levels and how these 
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potentially impact the utility of this biomarker in patients with or at risk of diabetic 
kidney disease.
Funding: Private Foundation Support
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Prevalence of Angiotensin Type II Receptor (ATTR) Gene Polymorphism 
in Patients with Type 2 Diabetes with Nephropathy in India and Its Effect 
on the Antiproteinuric Efficacy of ACE Inhibitor Therapy
Om P. Kalra,1 Neerja Aggarwal,2 Parul Varshney,2 Anil K. Yadav,2 
Alpana Raizada,2 Basu D. Banerjee,2 Ashok K. Tripathi,2 Madhu V. S.2 1Pt. B.D. 
Sharma University of Health Sciences, Rohtak, Haryana, India; 2University 
College of Medical Sciences and GTB Hospital, Delhi, India.
Background: Involvement of renin angiotensin system has been implicated in the 
etiopathogenesis of diabetic nephropathy (DN). Angiotensin converting enzyme inhibitor 
(ACEI) drugs are commonly prescribed for reno-protection in patients with DN; however, 
response to ACEI therapy is not uniform in all patients. Aim of this study was to investigate 
the prevalence of ATTR A1166C gene polymorphism in North Indian patients with DN and 
its role on the anti-proteinuric efficacy of ACEI therapy.
Methods: In the present study, 270 patients having Type 2 diabetes mellitus for ≥ 5 
years with nephropathy aged between 30 to 65 (mean 52.23±6.01) years were enrolled and 
treated with ACE inhibitor (ramipril) and subsequently followed at regular intervals for 2 
years for assessment of urinary albumin/creatinine ratio (ACR) and estimated GFR. Patients 
were classified as responders if they had a decrease in urinary ACR by ≥50% at the end of 
2 years follow up. Genotyping of ATTR A1166C gene polymorphism was performed by 
primer specific polymerase chain reaction and RFLP technique.
Results: Out of 270 patients, 231 completed the follow up of 24 months. 151(65%) 
patients with DN were found to be responders following ACE inhibitor therapy. Median 
urinary ACR values declined from the baseline value of 109.9 mg/g creatinine to 
47.3 mg/g creatinine (p<0.001). At the end of 24 months, increase in serum creatinine above 
the baseline (0.28±0.3 v/s 0.61±0.2) (p=0.269) and decline in eGFR-MDRD (8.40±16.0 
v/s 12.84±15.0 mL/min/1.73m2) (p=0.058) between responders and non-responders 
respectively were not significantly different. All subjects displayed wild type allele (A) 
of this polymorphism and showed no genotypic variation; hence polymorphism of ATTR 
A1166C gene does not appear to have any role on the variability of anti-proteinuric effect 
following ACEI therapy.
Conclusions: In patients with Type 2 diabetes mellitus with nephropathy, approximately 
two third patients were found to have significant anti-proteinuric response following ACEI 
therapy. ATTR A1166C gene polymorphism is extremely rare in Northern India and does 
not appear to play any role in influencing the variation in anti-proteinuric effect following 
ACEI therapy.
Funding: Government Support - Non-U.S.
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XORs in the Genetic Susceptibility of Diabetic Kidney Disease in Mice
Haiying Qi,2 Liping Yu,1 Qin Wang,3 Ilse S. Daehn.1 1Mount Sinai School of 
Medicine, New York, NY; 2Mount Sinai school of medicine, Chatham, NJ; 3Icahn 
School of Medicine at Mount Sinai, New York, NY.
Background: Diabetic kidney disease (DKD) is the leading single cause of ESRD in the 
United States. Approximately 30% of diabetic patients develop DKD even with comparable 
blood glucose levels, indicating a significant genetic component for disease susceptibility. 
Differential susceptibilities to DKD have also been observed in well-defined strains of 
inbred mice. The underlying mechanisms that contribute to differential susceptibility to 
DKD are still poorly understood in both patients and rodent models. The glomerulus is 
the primary site of injury with glomerular hypertrophy and podocyte depletion being the 
hallmarks for progressive DKD. Our work has demonstrated that ROS and mitochondrial 
oxidative stress damage accumulation, particularly in glomerular endothelial cells (GECs), 
leads to podocyte loss via endothelial-to-podocyte crosstalk in experimental mouse models 
of DKD and focal segmental glomerulosclerosis.
Methods: We used the BXD recombinant inbred panel to map genetic loci (QTL) 
associated with number of podocytes after long-term diabetes (6 months). We used parent 
strains inbred DBA/2J (D2) mice as susceptible, and C57BL/6J (B6) mice as resistant to 
diabetes-induced podocyte depletion associated with DKD susceptibility. Genetic mapping 
identified a cis-acting regulatory of the Xdh gene encoding xanthine dehydrogenase XDH/
XO (xanthine oxidoreductase (XOR)). XORs catalyze the oxidation of purine substrates, 
xanthine and hypoxanthine, producing uric acid (UA) and are a major enzymatic source of 
cellular ROS. Both products have been demonstrated to be risk factors for cardiovascular 
diseases and DKD.
Results: Xdh expression in glomeruli and XO activity in serum were significantly 
increased in diabetic D2 mice, but not B6 resistant mice. XOR inhibition resulted in 
significantly reduced albuminuria, prevention of podocyte loss, as well as a reduction in 
DNA oxidation damage in the glomeruli of diabetic D2 mice. Using a luciferase reporter 
assay we examined if the two nucleotide variant could influence XOR activity. Our results 
show increased XOR activity of 293T cells when treated with high glucose (30mM) 
compared to controls. We have now generated mice with knock-in variants using CRISPR/
Cas9 to determine their functional role in DKD susceptibility.
Conclusions: These data suggest that the identified promoter variant regulates XOR 
activity potentially linked to genetic susceptibility to DKD.
Funding: NIDDK Support
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Tubular and Injury Marker Expression Across Nephron Subsegments in 
Diabetic Nephropathy
Daria Barwinska,2 Yinghua Cheng,2 Michael J. Ferkowicz,2 Seth Winfree,2 
Kimberly S. Collins,2 Ken Dunn,1 Katherine J. Kelly,1 Timothy A. Sutton,2 
Brad H. Rovin,5 Samir V. Parikh,3 Pierre C. Dagher,1 Tarek M. El-Achkar,1 
Michael T. Eadon.4 1Indiana University, Indianapolis, IN; 2Indiana University 
School of Medicine, Indianapolis, IN; 3Ohio State University Medical Center, 
Columbus, OH; 4Indiana University Division of Nephrology, Indianapolis, IN; 
5Ohio State University Wexner Medical Center, Columbus, OH.
Background: Laser Microdissection (LMD) allows precise separation of nephron 
structures under immunofluorescence (IF). Several markers have been identified in the 
literature that are associated with specific subsegments of a nephron. Here, we examine the 
expression of known tubular and injury markers in kidney tissue of diabetic nephropathy 
(DN) biopsies and healthy nephrectomies.
Methods: Kidney biopsies from subjects with DN as well as a wedge biopsy from a 
healthy donor kidney were obtained. Tissue was preserved in OCT for 4 years at -80° C 
and sectioned into 12 μm thick sections on LMD PPS-membrane slides. Each slide was 
subjected to a rapid staining protocol, using DAPI, FITC-Phalloidin and Na/K channel 
antibody. Each slide underwent identical antibody staining and LMD, followed by RNA 
isolation, and sequencing. Transcriptomics data were obtained using RNAseq methodology 
on Illumina platform, and analyzed using R Studio.
Results: This study revealed that LMD methodology successfully allows for accurate 
identification of specific sub segments of a nephron, as shown by presence of markers 
associated with those structures and the absence of markers associated with other regions: 
NPHS1 and NPHS2 for the glomerulus, CUBN and SLC34A1 for the S1 and S2 proximal 
tubule, LRP2 for the S3 proximal tubule, and AQP2 and SCCN1G for the collecting duct. 
In addition, the transcriptomic analysis revealed differential expression of tubular injury 
markers like LCN2 (NGAL) expressed in the S1 and S2 subsegment. In contrast, HAVCR1 
(KIM1) and TIMP2 expression was increased in the S3 subsegment.
Conclusions: LMD is an important tool that allows for accurate identification and 
isolation of tubular subsegments within renal tissue and subsequent RNA analysis. An 
increased expression of injury markers associated with different tubules was observed in 
the diseased kidney tissue samples. This suggests that specific regions of the nephron may 
respond to injury in different ways, which may further contribute to the pathogenesis and 
progression of DN.
Funding: NIDDK Support, Veterans Affairs Support
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Intraglomerular Cross-Talk Between Mesangial Cells and Podocytes 
Inhibits Normal ER-Associated Degradation Processes and Induces 
Podocyte Injury in Diabetic Nephropathy
Daisuke Fujimoto,1 Takashige Kuwabara,2 Yusuke Hata,2 Shuro Umemoto,4 
Tomoko Kanki,5 Yoshihiko Nishiguchi,3 Teruhiko Mizumoto,6 Manabu Hayata,5 
Yuichiro Izumi,5 Yutaka Kakizoe,2 Masashi Mukoyama.2 1Department of 
Nephrology, Kumamoto University, Kumamoto, Japan; 2Kumamoto University 
Graduate School of Medical Sciences, Kumamoto, Japan; 3Kumamoto 
University Hospital, Kumamoto, Japan; 4Kumamoto University Graduate 
School of Medicine, Kumamoto, Japan; 5Kumamoto University, Kumamoto, 
Japan; 6Department of Nephrology Kumamoto University Graduate School of 
Medical Sciences, Kumamoto, Japan.
Background: We previously reported that endoplasmic reticulum (ER) stress induced 
by glucolipotoxicity and homeostatic inflammation through intraglomerular cellular 
crosstalk may play an important role in the progression of diabetic nephropathy. However, 
involvement with these consequences in podocyte injury still remains unclear.
Methods: Cluster analyses were performed using cDNA microarray data set of isolated 
glomeruli from two distinct diabetic mouse models. ER stress and apoptotic responses were 
evaluated in cultured mouse podocytes MPC5 stimulated with mesangial cell-cultured 
medium (MC-sup) under high- and low-glucose conditions (HG, LG). The effects of an 
ER-associated degradation (ERAD) inhibitor Eeyarestatin I (EerI) in MPC5 and db/db mice 
were also examined.
Results: Commonly increased or decreased genes in both DM models were associated 
with apoptosis (enrichment score 3.03), inflammation (3.03), and energy metabolism (1.24), 
suggesting ER stress as a potential factor. Pathway-focused PCR array analysis revealed 
that ERAD pathway was suppressed, but apoptotic pathway was enhanced in podocytes 
stimulated with HG MC-sup. Besides, these responses were also observed in isolated 
diabetic glomeruli. In vitro, IRE1α and spliced XBP1 were suppressed in podocytes by 
HG MC-sup, although apoptosis evaluated by TUNEL-staining, Bax, ATF6 and CHOP was 
markedly increased. These results were augmented by HG MC-sup compared to LG MC-
sup. Other types of cells, such as proximal tubular cells or macrophages, did not show any 
similar responses. Of note, treatment with EerI recapitulated these results in podocytes, and 
exacerbated albuminuria in db/db mice.
Conclusions: It is recently reported that ERAD pathway may play important roles in 
the maintenance of podocytes to avoid ER stress in several glomerular diseases including 
diabetic nephropathy. In the present study, we firstly reveal that intraglomerular crosstalk 
between mesangial cells and podocytes inhibits normal ERAD processes, potentially 
causing podocyte injury in diabetic conditions.
Diabetic Kidney Disease: Basic - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
345
J Am Soc Nephrol 29: 2018 Poster/Thursday
TH-PO864 Poster Thursday
Diabetic Kidney Disease: Basic - I
Irisin, a Myokine, Ameliorates Diabetic Nephropathy by Restoring 
Autophagy in Podocytes
Dan Luo, Wenbo Zhao, Yin Li, Yang C. Lun, Hongchun Lin, Tan-qi Lou, 
Hui Peng. The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 
Guangdong, China.
Background: Moderate exercises have been demonstrated to ameliorate diabetic 
nephropathy in some clinical studies. However, the mechanism remains unknown. Skeletal 
muscle could excrete many myokines while exercises. Irisin is one of the myokines 
which could mediate the communication between muscle and other organs. Therefore, we 
hypothesis that exercised muscle-excreted irisin protects kidneys from diabetes mellitus.
Methods: We crossbred muscle-specific PGC-1α overexpression of mice (an animal 
model mimicking exercise) with db/m mice to get mPGC-1α-db/db mice. The urine 
albumin creatinine ratio (uACR) and pathologic change of kidneys were examined. 
Besides, recombinant irisin had been administrated to twelve-week-old db/db mice and 
their db/m littermates. The renal function and pathologic change were accessed to evaluate 
the protection effect of Irisin. Conditionally immortalized human podocyte cells were used 
for in vitro study to investigate how irisin protect podocytes from injury of high glucose 
(30mmol/l).
Results: There were significant accumulation of mesangial matrix, fusion of podocytes 
foot processes, widen of GBM as well as decrease of autophagy in the kidney of db/db 
mice. However, these kidney pathological injuries were remarkably improved in mPGC-
1α-db/db mice. Meanwhile, the mice also showed significant alleviation of the excretion 
of uACR than db/db mice without mPGC-1α. These results indicate that mPGC-1α could 
alleviate kidney injury induced by diabetes. Irisin was found as one of the significantly 
increased myokines in the skeletal muscles of mPGC-1α mice, then we treated db/db mice 
with irisin for eight weeks. After peritoneal injection of irisin, the kidney pathologic change 
and microalbuminuria of db/db mice were all alleviated when compared to those db/db 
mice without irisin injection. Furthermore, Irisin treatment significantly restored autophagy 
in podocytes of db/db mice. Meanwhile, in vitro study, irisin improved the expression of 
autophagy related proteins and autophagy flux in high glucose cultured podocytes.
Conclusions: Our results indicate that the myokine, irisin, prevents the progression of 
diabetic nephropathy by restoring autophagy in podocytes. Irisin is one of the myokines that 
mediate the effect of exercised-muscle prevents diabetic nephropathy, which may become a 
new strategy to protect the kidney from diabetes.
Funding: Government Support - Non-U.S.
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Astaxanthin Attenuates Diabetic Kidney Injury Through Up-Regulation 
of Autophagy
Chen Zhengyue. Ningbo Urology and Nephrology Hospital, Ningbo, China.
Background: The aim of this study was to investigate effects of astaxanthin (ATX) on 
renal injury in diabetic mice and its underlined renal protective mechanism.
Methods: Rats were randomly divided into five groups: normal, high fat diet, high fat 
+ DM, high fat + ATX treatment, high fat + DM + ATX treatment. Fasting blood glucose, 
Urinary protein / Crea were measured. Renal pathological changes were evaluated with HE 
and PAS staining. In vitro, HTECs, HMCs and Podocytes were treated with ATX in the
presence or absence of 30 mmol/L D-glucose or autophagy inducer.
Results: Diabetic rats treated with ATX had reduced 24h urinary protein excretion, 
blood glucose and lipids level as compared with those in vehicle-treated rats. The same 
as Glomerulus mesangial matrix expansion and renal tubular epithelial cell injury(Fig1,2). 
Moreover, ATX treatment markedly reduced protein levels of p62, α-SMA, FN and 
collagen IV in the kidney of diabetic rats(Fig3). In vitro, high glucose was shown to inhibit 
expression LC3-II and increase expression of p62 as compared with normal glucose while 
these changes were reversed with ATX treatment. ATX treatment also inhibited expression 
of α-SMA, collagen IV and FN in cultured kidney cells(Fig4,5).
Conclusions: The current study shows that ATX attenuates diabetes-induced kidney 
injury probably through upregulation of autophagic activity in kidney cells and anti-fibrosis 
effects.
Funding: Government Support - Non-U.S.
Figure 1. ATX treatment decrease serum glucose and urinary protein in diabetic rats. Fasting 
blood glucose, Urinary protein / Crea, H&E and PAS staining were measured. Figure 
2. ATX reduces the expression of α-SMA, FN and collagen IV in the renal of diabetic
rats.Figure 3. ATX induces autophagy in the renal of diabetic rats. Protein expression of
α-SMA and FN in renal was determined by WB. Figure 4. ATX reduce renal fibrosis factors
of HTECs, HMCs and Podocytes.Figure 5. ATX induces autophagy in HTECs A., HMCs
B., Podocytess C..
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Apelinergic System in the Kidney: Implications for Diabetic Kidney 
Disease
Tilman Müller,1 Anastasia Z. Kalea,3 Syed K. Haque2 Minghao Ye,1 
Jan Wysocki,1 Daniel Batlle.1 1Northwestern University Feinberg School of 
Medicine, Chicago, IL; 2American Laboratory Consultant LLC, Park Ridge, IL; 
3University College London, London, United Kingdom.
Background: The bioactive peptides of the apelinergic system and its receptor APJ may 
play a protective role in cardiovascular and diabetic kidney disease (DKD). We examined 
the glomerular localization of APJ in the db/db mice and the effect of hyperglycemia and 
Angiotensin II on APJ mRNA in cultured podocytes. The impact of AT1R blockade on APJ 
expression was also studied in db/db mice.
Methods: Obese db/db mice of 8wk of age were used as a model of type 2 diabetes 
and their littermates db/m served as non diabetic controls. mRNA for APJ and propreapelin 
was measured by real time PCR; protein expression for APJ was studied by western blot 
on kidney lysates. Immunohistochemistry and immunofluorescence microscopy was used 
to localize APJ in the kidney.
Results: APJ co-localized with podocyte but not endothelial cell markers. In podocytes 
stimulated with Pyr1Apelin-13 a change in the phosphorylation status of the signaling 
proteins, AKT, ERK and p70S6K, was observed with an increase 15 min after stimulation. 
Apelin-13 decreased activity of Caspase-3 in podocytes after high glucose exposure 
reflecting an anti-apoptotic effect of APJ stimulation. In podocytes, APJ mRNA was down 
regulated in high glucose, and exposure to angiotensin II led to a further significant decrease 
in APJ mRNA. APJ and propreapelin mRNA in kidneys from db/db mice were decreased 
when compared to db/m controls; treatment with the specific AT1R blocker Telmisartan 
significantly increased APJ mRNA and propreapelin levels.
Conclusions: APJ is mainly localized in podocytes and in this cell type its activation by 
Apelin-13 abolishes the proapoptic effect of high glucose, suggesting a potential therapeutic 
role of apelin and emerging agonists with extended half- life in DKD. In addition, AT1 
blockade with Telmisartan resulted in an increase in APJ mRNA and propreapelin levels in 
db/db mice suggesting a link of the apelinergic system and the AT1 receptor
Funding: NIDDK Support
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Effects of Ang-(1-7) and Its Receptor Regulating Bradykinin System on 
Podocyte Injury Induced by High Glucose
Guixiang Chen,2 Guanghui Shen,1 Jianxin Lu,2 Feng Ding.2 1Department of 
Clinical Laboratory, Shanghai Ninth People’s Hospital, Affiliated to Shanghai 
JiaoTong University, School of Medicine, Shanghai, 200011, P.R.China., 
Shanghai, China; 2Division of Nephrology, Shanghai Ninth People’s Hospital, 
Affiliated to Shanghai JiaoTong University, School of Medicine, Shanghai, 
200011, P.R.China., Shanghai, China.
Background: The mechanisms of diabetic nephropathy are still enigmatic. We 
hypothesized that RAS component Ang-(1-7) and its Mas receptor (MasR) and bradykinin 
(BK) system may play a protective role in podocyte injury induced by high glucose.
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Methods: The Podocytes cultured in vitro were respectively interfered with low 
glucose (5mM, LG), high glucose (30mM, HG), HG+Ang-(1-7), HG+HOE140 (BKB2R 
antagonist), HG+ des[Arg(9)]BK (BKB1R agonist), HG+Ang-(1-7)+A779 [Ang-(1-7) 
antagonist], HG+ Ang-(1-7)+HOE140 and HG+ Ang-(1-7)+des[Arg(9)]BK. The CCK8 
method detected the activity of podocytes and the flow cytometry detected the apoptosis 
of podocytes. The mRNA and proteinic expression of AT1R, MasR, BKB1R, BKB2R and 
podocyte-specific proteins (nephrin, podocin, WT-1) was examined by q-PCR and Western 
blot. The podocytes were also interfered with inhibitor of ERK and JNK, the expression of 
pERK/ERK, pJNK/JNK in podocytes was semi-quantificated by Western blot to investigate 
the signaling passway involved in the regulation.
Results: The CCK8 and flow cytometry results showed that the descent of podocyte 
activity and podocyte apoptosis induced by HG was rescued by Ang-(1-7) and HOE140. 
The effect presented concentration dependency. des[Arg(9)]BK and A779 displayed 
antagonistic action against Ang-(1-7), which aggratated the podocyte apoptosis and the 
descent of cell activity, moreover, the effect was most obviously at 10uM concentration. 
The results of q-PCR and Western blot indicated that HG stimulation up-regulated the 
expression of AT1R, BKB1R, BKB2R and down-regulated MasR, Nephrin, Podocin and 
WT-1. Ang-(1-7) and HOE140 could relieve the action of HG but A779 and des[Arg(9)]BK 
was the converse of Ang-(1-7) in some extent. The synergetic protective effect of HOE140 
and Ang-(1-7) was more significantly. HG and des[Arg (9)]BK activated the MAPKs 
signaling passway yet Ang-(1-7) and HOE140 inhibited it. The inhibitor of MAPKs further 
decreased the podocyte apoptosis induced by HG.
Conclusions: Ang-(1-7)/MasR may decrease the up-regulation of BKB1R and 
BKB2R induced by HG, antagonist Ang II- ACE-AT1R axis, and then inhibit the activation 
of MAPKs and podocyte apoptosis. The synergistic reaction of Ang-(1-7)/MasR and BK 
system could protect podocyte from injury induced by HG.
Funding: Private Foundation Support
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Diabetic Conditions Enhance the Phosphorylation of PACSIN2/Syndapin 
II in Podocytes
Sanna H. Lehtonen,1 Vincent Dumont,1 Sonja Lindfors,1 Carol Forsblom,2 
Hiroshi Kawachi,3 Per-Henrik Groop,4 Shiro Suetsugu.5 1University of Helsinki, 
Helsinki, Finland; 2Folkhalsan Research Center, Helsinki, Finland; 3Department 
of Cell Biology, Kidney Research Center, Niigata University Graduate School of 
Medical and Dental Sciences, Niigata, Japan; 4University of Helsinki and 
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Background: We previously found that PACSIN2/syndapin II, which regulates 
endocytosis and intracellular trafficking, is elevated in glomeruli of Zucker Diabetic Fatty 
(ZDF) rats showing aberrant localization of nephrin and severe albuminuria. We also showed 
in vitro that PACSIN2 overexpression reduces nephrin insertion at the plasma membrane. 
PACSIN2 can be phosphorylated at serine 313 (pS313-PACSIN2) by Protein Kinase C 
alpha (PKCα), which in turn regulates the endocytic activity of PACSIN2. Importantly, 
PKCα is elevated in diabetes and associated with loss of nephrin expression. The aim of 
this study was to evaluate the phosphorylation status of PACSIN2 in glomeruli in diabetes. 
We also assessed the regulation of pS313-PACSIN2 and the presence of nephrin at the 
plasma membrane after treating cultured podocytes with palmitate, elevated in patients with 
diabetes.
Methods: PKCα, total PACSIN2 and pS313-PACSIN2 levels were assessed by 
Western blotting. On-Cell Western, a 96-well plate -based surface labeling assay, was used 
to determine the insertion of nephrin at the plasma membrane. Glomeruli were isolated 
from lean and obese ZDF rats by graded sieving. Cultured podocytes were incubated with 
palmitic acid or with sera from patients with T2D having normo- or microalbuminuria.
Results: PKCα, total PACSIN2 and pS313-PACSIN2 were elevated in glomeruli of 
obese and diabetic ZDF rats compared to lean controls. Also, the level of free fatty acids 
was increased in the sera of obese ZDF rats. Increased pS313-PACSIN2 and a trend for an 
increase of total PACSIN2 were observed when human podocytes were incubated with sera 
from patients with T2D with microalbuminuria compared to normoalbuminuric patients. 
Treating podocytes with palmitic acid resulted in the time-dependent phosphorylation of 
PACSIN2 on S313. Palmitic acid treatment also resulted in the reduction of nephrin inserted 
at the plasma membrane.
Conclusions: Our results indicate that PACSIN2 and its phosphorylation at serine 313 
are elevated in glomeruli in a rat model of diabetes and diabetic kidney disease. This could 
be a consequence of elevated circulating palmitate and result in the reduction of nephrin at 
the plasma membrane, causing the destabilization of the slit diaphragm and albuminuria.
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Knockout of Heterogeneous Nuclear Ribonucleoprotein F (hnRNP F) in 
Podocytes Aggravates Podocyte Loss in Streptozotocin-Induced Diabetic 
Mice Through Alternative Splicing of Insulin Receptor Gene
Chao-Sheng Lo,1 Isabelle Chenier,1 Janos G. Filep,2 Julie R. Ingelfinger,3 Shao-
Ling Zhang,1 John S. Chan.1 1CRCHUM, Universite de Montreal, Montreal, QC, 
Canada; 2Maisonneuve-Rosemont Hosp., Montreal, QC, Canada; 3The New 
England Journal of Medicine, Boston, MA.
Background: Insulin receptor (INSR) signaling is important for podocyte integrity. 
The INSR gene encodes two isoforms via alternative splicing: INSR-A (excluding exon 11) 
and INSR-B (including exon 11). In pancreatic beta cells, INSR-A renders beta cells 
vulnerable to programmed cell death, whereas INSR-B is protective. In the present study, 
we investigated whether deletion of heterogeneous nuclear ribonuclear protein F (hnRNP F) 
in podocytes would aggravate podocyte injury in streptozotocin (STZ)-induced diabetic 
mice through modulating the alternative splicing of INSR isoforms.
Methods: Podocyte-specific hnRNP F knockout (KO) mice were generated by 
crossbreeding podocin (Pod)-Cre mice with floxed hnRNP F mice. Diabetes was induced in 
male 12-week old Pod-hnRNP F KO mice and control littermates with streptozotocin (STZ) 
(i.p., 50 mg/kg/day) for five consecutive days. Mice were euthanized 8 weeks after the STZ 
injections. Urinary ACR was assessed at 4 and 8 weeks after STZ-administration. Kidneys 
were processed for histology. Podocyte numbers were counted by p57 staining. Mouse renal 
cortex, isolated glomeruli and primary cultured podocytes were subjected to RT-PCR to 
assess INSR-A and INSR-B mRNA expression. Podocytes from control littermates and 
Pod-hnRNP F KO mice cultured in normal and high glucose media were also studied.
Results: INSR-A and INSR-B mRNA were equally expressed in the glomeruli of non-
diabetic WT mice. STZ-induced diabetes aggravated kidney injury and podocyte loss in 
Pod-hnRNP F KO mice as compared with diabetic control littermates. Diabetic Pod-hnRNP 
F KO mice exhibited lower INSR-B/A mRNA ratio in isolated glomeruli and primary 
cultured podocytes as compared to diabetic control mice. In vitro, in high glucose media, 
more cultured podocytes from Pod-hnRNP F KO were detached as compared to those from 
control littermates.
Conclusions: Deficiency of hnRNP F in podocytes aggravates podocyte loss and 
kidney injury in STZ-diabetic mice through modulation of the alternative splicing of INSR 
mRNA resulting in lower INSR-B/A mRNA ratio.
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Injury in Diabetic Kidney Disease
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Background: Diabetic kidney disease (DKD) is characterized by podocyte loss, 
altered mitochondrial oxidative phosphorylation complexes (OXPHOS), and glomerular 
lipid accumulation. We have shown that ATP Binding Cassette A1 (ABCA1)-mediated 
cholesterol efflux is impaired in clinical and experimental DKD. Here, we test the 
hypothesis that ABCA1 deficiency causes mitochondrial dysfunction in podocytes and 
contributes to injury in DKD.
Methods: Sera were obtained from Pima Indian patients with diabetes and progressive 
DKD (P, n=15) and non-progressive DKD (NP, n=16) as assessed by changes in measured 
GFR over a 10 year period. Scrambled control (siCO) and siRNA ABCA1 podocytes 
(siABCA1p) were treated with patient sera. ABCA1 expression, cholesterol efflux, 
mitochondrial OXPHOS complexes, cardiolipin (mitochondrial specific phospholipid) 
content and cytotoxicity were measured. Elamipretide (cardiolipin peroxidase inhibitor) 
was utilized for selected in vitro and in vivo experiments. BTBRob/ob (ob/ob) mice with 
podocyte specific ABCA1 deficiency (DKO) were generated and analyzed.
Results: P sera treated podocytes show reduced ABCA1 mRNA expression, and 
cholesterol efflux and increased cytotoxicity compared to NP. siABCA1p are more 
susceptible to NP and P sera induced cytotoxicity when compared to siCO. siABCA1p show 
decreased basal OCR, cardiolipin accumulation, and alterations in OXPHOS complexes. 
Elamipretide treated siABCA1p are protected from NP and P sera mediated cytotoxicity 
compared to siCO. DKO mice have increased albuminuria, mesangial expansion, 
podocyte loss, FPE and mitochondrial damage as compared to ob/ob mice. Treatment with 
Elamipretide of db/db mice is sufficient to reduce albuminuria, mesangial expansion, BUN 
and podocyte loss.
Conclusions: Our data indicate that a reduction of ABCA1 expression in podocytes is a 
susceptibility factor for DKD progression. These data also indicate that ABCA1 deficiency 
results in cardiolipin accumulation and mitochondrial dysfunction. Inhibition of cardiolipin 
oxidation prevents podocyte loss and DKD in diabetic mice. Treatment strategies to restore 
ABCA1 function may be beneficial in DKD.
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DESI-MSI Based Spatial Metabolomics and METASPACE Indicates RNA 
and Mitochondrial Dysfunction in Renal Proximal Tubules of Mice with 
Diabetes
Guanshi Zhang, Manjula Darshi, Kumar Sharma. University of Texas Health 
San Antonio, San Antonio, TX.
Background: Diabetic kidney disease (DKD) remains the largest contributor to end 
stage renal disease and insightful biomarkers are required for identifying pathways to target 
for prognosis and therapeutics. Knowledge about the spatial distribution of metabolites in 
kidney tissues of DKD patients/animals will enhance the cellular contribution of biomarkers.
Methods: In the current study, we employed an ambient desorption electrospray 
ionization - mass spectrometry imaging (DESI-MSI) approach to characterize the 
metabolome in kidney tissue sections in a model of DKD. The data output was coupled 
to a novel bioinformatics platform (METASPACE). DESI-MSI was performed for spatial 
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untargeted metabolomics analysis in kidneys of mouse models (F1 C57BL/6J-Ins2Akita 
male mice at 17 weeks of age) of type 1 diabetes (T1D, n = 5) and heathy controls (n = 6). 
MetaboAnalyst 3.0 was employed for statistical analysis, metabolic pathway analysis, and 
biomarker analysis.
Results: Mice with DKD had increased relative abundances of pseudouridine, 
accumulation of free polyunsaturated fatty acids (PUFAs), and decreased relative 
abundances of phospholipids in cortical proximal tubules when compared with 
healthy controls. In the biomarker analysis, a five-metabolite biomarker set 
(i.e., phosphatidylglycerol (PG) 32:0, pseudouridine, hexose, phosphatidylserine (PS) 34:1, 
and diphenyl disulfide) was developed for diagnosing DKD. The AUC for the ROC curve 
is 0.994 (95% CI, 0.981-1; Empirical P < 0.001), which indicates that the biomarker set has 
excellent diagnostic ability for DKD in mice.
Conclusions: In summary, this new study demonstrates that DESI-MSI can be 
successfully used to distinguish cortical proximal tubules in healthy and diabetic tissues 
based on altered relative abundance of lipid profiles. DESI-MSI technology coupled with 
the METASPACE will serve as a powerful tool to shed new light on fundamental pathways 
in DKD.
Funding: NIDDK Support
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Carrier Specific miRNA Distribution and Function in Diabetic Nephropa-
thy: A Novel Concept for Monitoring Microvascular Injury
Barend W. Florijn,1 Wendy Stam,1 Johannes H. Levels,2 Rienk Nieuwland,2 
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Background: We previously demonstrated an association between total plasma 
levels of specific microRNAs (miRs) and microvascular injury in patients with diabetic 
nephropathy (DN). However, circulating miRs are carried in exosomes, the RNA-binding 
protein Argonaute2 (AGO-2) or high-density lipoprotein (HDL). Therefore, identification 
of the carrier specificity of selected miRs could improve their biomarker potential while 
carrier-specific transfer of miRs to vascular cells could affect vascular integrity.
Methods: We assessed the plasma carrier distribution of miRs in DN (n=21), diabetes 
mellitus (DM; n=15; eGFR of ≥ 30 mL/min) patients and healthy controls (n=15). 
Exosomes, HDL and AGO-2 were isolated using size exclusion chromatography, KBr 
density gradient ultracentrifugation and immunoprecipitation, respectively. MiR expression 
was determined and validated using TaqMan® miRNA Arrays and correlated to markers 
of vascular injury, including angiopoietin-2 (Ang2), soluble thrombomodulin (sTM) and 
capillary tortuosity. In vitro studies were performed to assess transfer and function of 
specific miRNA-carrier complexes.
Results: Specific miR-carrier complexes associated with DN and vascular injury. Most 
notably, we found exosome-miR-21 and AGO-2-miR-660 levels to display a significant 
increase in both DM and DN groups compared to healthy controls and correlated with 
capillary tortuosity and Ang2, respectively. Furthermore, exosome-miR-126 levels 
increased while HDL-miR-132 levels decreased in DN and correlated with levels of Ang2. 
Mechanistically, in vitro studies demonstrated that HDL-miR-132 and exosome-miR-21 
and -126 transferred to endothelial cells, repress validated target genes and ultimately affect 
angiogenic capacity and barrier function.
Conclusions: Our data suggest that carrier specific miRs have improved sensitivity as 
biomarkers for vascular injury in DN and are not just by-products of disease progression but 
can play an active, and modifiable role in the regulation of vascular integrity.
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Transcriptome of Extracellular Vesicles Derived from In-Vitro Podocytes, 
Proximal Tubule, and Mesangial Cells
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University, Wuhan, China; 7Boehringer Ingelheim Pharma GmbH & Co. KG, 
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Background: Extracellular vesicles (EVs) are lipid-bilayer structures of variable 
sizes (30-1000nm) secreted by all cell types. They show a characteristic vesicle surface 
consisting of a variety of proteins and lipids while the intracellular content is a rich array 
of proteins and distinct RNA species. These reflect accurately the physiological state of 
their cells of origin. In diabetes, development of renal insulin resistance has a major role in 
end-organ complications like Diabetic Kidney Disease (DKD). Little is still known of the 
secreted EV repertoire of especially podocytes. Here our objective was to characterize EVs 
secreted by DKD target cells, podocytes, proximal tubular cells and mesangial cells using 
the Hydrostatic Filtration Dialysis (HFD) for EV harvesting.
Methods: We used cell culture media from podocytes, proximal tubule and mesangial 
cells in four conditions; 1) Basal 2) Insulin resistant 3) Insulin receptor transfected 
4) Insulin receptor transfected and insulin resistant. EVs were isolated from 50ml of cell
culture media, respectively using the recently described HFD. Quality of EV yield was
analyzed by negative-staining EM and by Western blotting. Vesicle concentration was 
determined by Nanoparticle Tracking Analysis (NTA). Isolated RNAs were profiled with 
Bioanalyzer Pico kit and subjected to RNAseq after cDNA library preparation using 
QIAseq miRNA Library Kit. RNAseq was performed using HiSeq 3000 (Illumina) Paired-
end (2X150) protocol.
Results: The isolated EVs appeared typical at EM and were positive for the EV-marker 
TSG101 in Western blotting. RNA yield was of high quantity and quality and thus suitable 
for RNAseq. Different treatments had distinct effect on vesiculation of the investigated 
cells. Ninety-six EV miRNAs could clearly discriminate between cell types and engineered 
cells. There were distinct EV miRNAs to reflect treatment effect within each of the 
individual cell types studied.
Conclusions: EV analysis provides a novel approach to reveal valuable 
pathophysiology, pathway and signaling information of cultured target cells. Changes in 
EV miRNAs may give insight into insulin resistance on DKD target cells and on diabetic 
nephropathy.
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Long Noncoding RNA DLX6-AS1: A Novel Biomarker of Diabetic Kidney 
Disease
Jia Guo,1,2 Yifang Hu,2 Rujun Gong,1 Zhangsuo Liu.2 1University of Toledo 
Medical Center, Toledo, OH; 2The First Affiliated Hospital of Zhengzhou 
University, Zhengzhou, China.
Background: A growing body of evidence suggests that lncRNAs act as competing 
endogenous RNAs or natural microRNA sponges and are involved in diverse human 
diseases including diabetic kidney disease (DKD). Our previous study showed that 
LncRNA DLX6-AS1 expression was increased in kidney biopsy specimens from DKD 
patients. However, whether LncRNA DLX6-AS1 expression is associated with albuminuria 
in DKD remains unknown and was explored in this study.
Methods: A total of 22 type II diabetic patients without albuminuria (diabetes mellitus 
group), 43 patients with DKD (microalbuminuria group=20,macroalbuminuria group=23) 
and 32 healthy controls were enrolled in this study. Blood samples were collected. The levels 
of LncRNA DLX6-AS1 was estimated by RT-qPCR. The correlation between LncRNA 
DLX6-AS1 levels and clinical variables was assessed by Spearman correlation analysis. 
Linear regression was applied to model the relationship between urine albumin/creatinine 
ratio as the dependent variable and other parameters. ROC analysis was performed and the 
area under the curve (AUC) was estimated to evaluate the power of LncRNA DLX6-AS1 
for predicting DKD.
Results: The four groups were comparable in sex, age and triglyceride levels. No 
significant difference was noted in duration of diabetes and incidence of diabetic retinopathy 
among subgroups of diabetes. Compared with healthy controls, the serum levels of lncRNA 
DLX6-AS1 was decreased in diabetic mellitus group (P<0.05), but was increased in 
DKD patients (P<0.05). This difference remained statistically different after adjustment 
for eGFR or HDL-C, as shown by linear regression analysis. In addition, serum LncRNA 
DLX6-AS1 levels were found to positively correlate with urine albumin/creatinine 
ratios(rs=0.626,P<0.001), but negatively correlate with eGFR(rs=-0.289,P=0.020). 
Receiver operating characteristic (ROC) curve analysis was conducted to determine the 
ability of serum LncRNA DLX6-AS1 levels to serve as biomarkers for predicting DKD. 
The area under the ROC curve (AUC) was estimated to be 0.879 (95% CI = 0.798 to 0.961), 
suggestive of an excellent sensitivity and specificity of serum LncRNA DLX6-AS1 levels 
in predicting DKD.
Conclusions: Serum levels of LncRNA DLX6-AS1 correlate with albuminuria in 
patients with diabetic kidney disease and may serve as a biomarker for predicting DKD.
Funding: Government Support - Non-U.S.
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The Leptin Receptor in Mouse Kidney: Gene Expression of Splice 
Variants and a Potential Anti-Albuminuric Role in Podocytes
Hadi Fattah, Winnie Huang, Rohit Patel, Yiling Fu, Josselin Nespoux, 
Brent Freeman, Volker Vallon. Department of Medicine, University of 
California, San Diego & VA San Diego Healthcare System, San Diego, CA.
Background: Leptin regulates food intake and metabolism primarily through leptin 
receptor splice variant B (LEPRB) in brain and liver. Little is known about LEPR splice 
variants in the kidney or their function.
Methods: A) Urinary albumin to creatinine ratios (UACR) and mRNA expression of 
renal LEPR splice variants LEPRA, LEPRB & LEPRC (by RT-qPCR, norm. to b-actin) 
were determined in non-diabetic mice (nd) and in obese/hyperglycemic mice lacking 
endogenous leptin (ob/ob) ± leptin substitution for 6 days (osmotic minipump: 4.7 μg/day 
s.c.) (all mice ~4 months of age & BTBR background)(n=5-8/group). B) C57BL6 mice 
with knockdown of LEPRs in podocytes (podocin-Cre) were generated to determine
GFR (by plasma elimination kinetics of FITC-sinistrin in conscious mice) and UACR 
(n=8/group).
Results: A) Leptin substitution restored plasma leptin levels in ob/ob (4.3±0.3 
vs 4.6±0.7 ng/ml in nd mice) and reduced hyperglycemia (275±29 vs 573±17 mg/dl in 
vehicle-treated ob/ob; P<0.05). In all 3 groups, the renal mRNA expression was higher 
for LEPRA vs LEPRB or LEPRC, and the expression of all 3 variants was higher in 
medulla vs cortex. The cortical expression of all 3 variants was lower in ob/ob vs nd, 
and not significantly affected by leptin substitution. Medullary expression was more 
variable. The transcription factor Atf3 is a newly discovered mediator of brain LEPRB. 
Atf3 mRNA was increased in kidney cortex & medulla in ob/ob vs nd and not altered by 
leptin substitution. The latter, however, reduced UACR in ob/ob (pre to post: 650±145 to 
167±45 μg/mg; P<0.05) whereas vehicle was ineffective (632±283 to 819±217 μg/mg). 
B) Ten week old male mice with LEPR knockdown in podocytes had similar blood glucose 
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(129±5 vs 117±3 mg/dl) and GFR (436±16 vs 443±18 μl/min) but enhanced UACR vs 
wild-type littermates (20.5±7.4 vs 8.8±1.5 μg/mg; P<0.05).
Conclusions: On mRNA level, LEPRA is the dominant renal splice variant of the 
LEPR, and LEPR splice variants are higher expressed in medulla vs cortex. Absence of 
leptin did not upregulate mRNA expression of LEPR splice variants in cortex or medulla, 
but enhanced mRNA of the LEPRB target gene Atf3. Functional studies were consistent 
with an anti-albuminuric effect of leptin, potentially via LEPR in podocytes.
Funding: Other NIH Support - R01DK112042, Veterans Affairs Support, Commercial 
Support - Janssen Pharmaceuticals, Inc
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Photoacoustic Ultrasound Can Non-Invasively Detect Kidney Fibrosis
Xiaolin He,2 Jiayin Dong,1 Elizabeth S. Berndl,1 Tianzhou Zhang,2 
Michael C. Kolios,1 Darren A. Yuen.2 1Ryerson University, Toronto, ON, 
Canada; 2St. Michael’s Hospital, Toronto, ON, Canada.
Background: Fibrosis is a key manifestation and driver of chronic kidney injury. 
Despite its importance, the options for measuring fibrosis are limited. The only available test 
is a needle biopsy, a time-consuming, invasive procedure that at best samples < 1% of one 
kidney, leading to the potential for sampling bias. Unlike biopsy, ultrasound can quickly and 
non-invasively image the entire kidney. While historically limited to the imaging of gross 
abnormalities, the recent combination of laser technology with ultrasound (“photoacoustic 
(PA) ultrasound”) has dramatically expanded its capabilities. Based on the principle that 
each molecule has its own unique light absorption spectrum, PA ultrasound can be used 
to non-invasively image specific molecules. We have previously demonstrated that PA 
ultrasound can specifically detect extracellular matrix in a model of ischemia-reperfusion 
injury (doi: 10.1117/12.2291199). Our goal was to test whether PA ultrasound could detect 
milder degrees of fibrosis in a clinically relevant model of diabetic nephropathy.
Methods: Diabetes was induced in renin-overexpressing, hypertensive TTRhRen 
mice using a low dose STZ injection protocol (Ren-STZ mice, n=7). Ren-STZ mice 
develop hypertension, hyperglycemia, albuminuria, and renal fibrosis (Thibodeau et al, 
PLoS ONE 2014). Kidneys were imaged in vivo using a VevoLAZR system at 21 MHz 
by Photoacoustic (PA) spectral sweep from 680 to 970 nm at 0 and 20 wks post-STZ, 
and compared with wild-type littermates injected with citrate (WT-citrate, n=9). 20 wks 
post-injection, kidneys were assessed by picrosirius red (PSR) staining to quantify fibrosis.
Results: Ren-STZ mice developed hypertension (138±7vs. 98±5 mmHg) and 
hyperglycemia (28.0±2.6 vs. 9.7±0.3 mmol/L) compared to WT-citrate mice 20 wks post-
STZ injection. As expected, Ren-STZ kidneys were more fibrotic than WT-citrate controls 
(PSR intensity: 5.4±0.1 vs. 2.8±0.1). Prior to STZ injection, the photoacoustic spectra of 
Ren-STZ and WT-citrate kidneys were similar. However, 20 wks post-STZ, Ren-STZ 
kidneys demonstrated significantly different photoacoustic spectra compared to their WT-
citrate counterparts, in line with the fibrosis observed histologically.
Conclusions: Our data suggest that photoacoustic ultrasound may enable the non-
invasive, whole organ imaging of kidney fibrosis.
Funding: Private Foundation Support
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ROCK2 Inhibitors for the Treatment of CKD
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MacFaul,1 Sara Ceccarelli,1 Kay Eckersley,1 Gary R. Pitt,2 Peter R. Bunyard,1 
Clifford D. Jones,1 Richard Armer.1 1Redx Pharma Plc, Macclesfield, United 
Kingdom; 2Walter and Eliza Hall Institute, Melbourne, NSW, Australia; 
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Background: The Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) 
serine/threonine kinases, ROCK1 and ROCK2, are central signalling proteins that regulate 
a range of cellular responses such as cell migration, contraction, proliferation, cytokine 
and growth factor expression, and integrin-mediated cell-to-cell adhesions. These processes 
are central to the aberrant wound healing response that can progress to chronic injury and 
organ fibrosis. Small molecule pan-ROCK inhibitors have been shown to be anti-fibrotic in 
a range of animal models including: bleomycin induced lung fibrosis, high fat diet induced 
liver fibrosis and models of kidney fibrosis. However, ROCK signalling is also involved in 
regulating vascular tone and pan-ROCK inhibitors have been shown to cause hyperaemia 
and hypotension, limiting their use in patients. There is significant homology between the 
ROCK1 and ROCK2 isoforms however there is evidence that ROCK2 has additional roles 
distinct from ROCK1 in both inflammation and wound healing. For example, ROCK2 is 
upregulated in diabetic kidney disease and in the diseased vascular network of patients at 
risk of chronic kidney disease (CKD).
Methods: Redx have developed a series of potent ROCK2 inhibitors, that are highly 
selective against ROCK1 and a panel of 468 kinases.
Results: Redx ROCK2 selective compounds potently suppress the release of pro-
fibrotic factors from kidney mesangial cells, cultured in high glucose. In a model of acute 
kidney injury, our selective ROCK2 tool compound reduced podocyte damage, and the 
expression of inflammatory and profibrotic genes in the kidney. In addition, in a telemetered 
rat study, no significant reduction in blood pressure or increase in heart rate was recorded, 
indicating that a selective ROCK2 inhibitor could avoid these side-effects typically 
observed with pan-ROCK inhibitors and increase the safety window at efficacious doses.
Conclusions: Highly selective ROCK2 inhibitors, therefore, could provide a novel and 
effective therapy for patients with progressive kidney fibrosis who currently have few and 
largely ineffective therapy options.
Funding: Commercial Support - Redx Pharma
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Hyperoside Alleviates the Early Glomerular Pathological Changes in 
Diabetic Kidney Disease by Inhibiting Akt/mTOR/p70S6K Signaling 
Activity
Wei Wu, Yigang Wan. Department of Traditional Chinese Medicine, Nanjing 
Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical 
School, Nanjing, China.
Background: Hyperoside (HYP), a bioactive component of Abelmoschus manihot, 
has been widely applied to clinical therapy in the early diabetic kidney disease (DKD) 
patients. However, it remains elusive whether HYP can ameliorate inchoate glomerular 
injuries in hyperglycemia. Recently the activation of phosphatidylinositol-3-kinase (PI3K)/
serine-threonine kinase (Akt)/mammalian target of rapamycin (mTOR) signaling and its 
downstream regulator, 70-kDa ribosomal protein S6 kinase (p70S6K), play important roles 
in the early glomerular pathological changes of DKD including glomerular hypertrophy, 
glomerular basement membrane (GBM) thickening and mild mesangial expansion. This 
study aimed to clarify therapeutic effects of HYP during the initial phase of DKD and its 
underlying mechanisms.
Methods: Fifteen rats were randomly divided into 3 groups: the normal, the model 
and the HYP groups. The early DKD model rats were induced by unilateral nephrectomy 
combined with intraperitoneal injection of streptozotocin, and administered with either 
HYP suspension or vehicle after modeling and for a period of 4 weeks. Changes in incipient 
glomerular lesions-related parameters in urine and blood were analyzed. Kidneys were 
isolated for histomorphometry, immunohistochemistry, immunofluorescence and Western 
blotting (WB) at sacrifice. In vitro, murine mesangial cells (MCs) were used to investigate 
inhibitory actions of HYP, on cellular hypertrophy-associated signaling pathway by WB, 
compared with rapamycin (RAP).
Results: For the early DKD model rats, HYP ameliorated micro-urinary albumin, 
body weight and serum albumin, but had no significant effects on renal function and liver 
enzymes; HYP improved renal shape, kidney weight and kidney hypertrophy index; HYP 
attenuated glomerular hypertrophy, GBM thickening and mild mesangial expansion; HYP 
inhibited phosphorylation of Akt, mTOR and p70S6K, and protein over-expression of 
transforming growth factor-β1 in kidneys. In vitro, phosphorylation of PI3K, Akt, mTOR 
and p70S6K in MCs induced by high-glucose was abrogated by treatment of HYP or RAP.
Conclusions: This study demonstrated HYP alleviates the early glomerular 
pathological changes of DKD, likely by inhibiting Akt/mTOR/p70S6K signaling activity 
in vivo and in vitro, and provided the first evidence that HYP directly contributes to the 
prevention of the early DKD.
Funding: Government Support - Non-U.S.
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Identification and Validation of Differentially Expressed Urinary 
Exosomal MicroRNAs in Type 2 Diabetic Kidney Disease
Jinnan Zang,1 David A. Simpson,2 Alexander P. Maxwell,1 Gareth J. McKay.1 
1Centre for Public Health, Queen’s University Belfast, Belfast, United Kingdom; 
2Centre for Experimental Medicine, Queen’s University Belfast, Belfast, United 
Kingdom.
Background: There is a need for improved biomarkers for the early detection of 
diabetic kidney disease (DKD). MicroRNAs (miRNAs) are short, non-coding regulatory 
RNA molecules commonly found in urinary exosomes that may be differentially expressed 
during renal dysfunction. We evaluated urinary exosomal miRNA expression in type 2 
DKD (T2DKD).
Methods: 87 previously reported human urinary exosomal miRNAs were profiled 
(Qiagen Human Urine Exosome Focus miRNA Panel) to identify differentially expressed 
miRNAs in a discovery cohort of patients with T2DKD (n= 14) and individuals with T2D 
and normal renal function, matched by age and gender (n= 15). Differentially expressed 
target miRNAs were validated in a second cohort of patients with T2DKD (n= 22) or no 
diabetes and poor renal function (n=18), and control subjects with T2D and normal renal 
function (n= 22).
Results: Quantitative expression profiles were normalised according to the 
NormFinder algorithm. Urinary miR-21-5p, let-7e-5p and miR-23b-3p were significantly 
upregulated in T2DKD cases compared to T2D controls with good renal function (P<0.05). 
Conversely, miR-30b-5p and miR-125b-5p expression were significantly lower in T2DKD 
cases compared to T2D controls (P<0.05). In a logistic regression analysis adjusted for age, 
sex and mean arterial blood pressure, only miR-21-5p remained significantly associated 
with T2DKD (odds ratio=3.28, confidence intervals: 1.14 – 9.43; P=0.03). Independent 
validation in the replication cohort confirmed up-regulation of miR-21-5p expression in 
T2DKD (2.13-fold, p<0.01) and also in patients without diabetes and poor renal function 
(1.73-fold, p<0.05). In contrast, miR-30b-5p was downregulated in T2DKD (1.22-fold, 
p<0.01) and in patients without diabetes and poor renal function (1.52-fold, p<0.005).
Conclusions: Our data identified differential expression of miR-21-5p and miR-30b-5p 
in individuals with poor renal function, although further clarification to determine if these 
are associated with general mechanisms of renal dysfunction is required.
Funding: Government Support - Non-U.S.
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Soluble cMet Levels in Urine Are a Significant Prognostic Biomarker for 
Diabetic Nephropathy
Yong Chul Kim,1 Jung Nam An,2 Chun Soo Lim,2 Yon Su Kim,3 Seung 
Hee Yang,4 Jung Pyo Lee.2 1SNUH, Seoul, Republic of Korea; 2Seoul National 
University Boramae Medical Center, Seoul, SEOUL, Republic of Korea; 3Seoul 
National University College of Medicine, Seoul, Republic of Korea; 4Kidney 
Research Institute, Seoul National University, Seoul, Republic of Korea.
Background: Hepatocyte growth factor (HGF) and its receptor, cMet, activate 
biological pathways necessary for repair and regeneration following kidney injury. 
Here, we evaluated the clinical role of urinary cMet as prognostic biomarker in diabetic 
nephropathy (DN).
Methods: A total of 218 patients with DN were enrolled in this study. We examined the 
association of urine cMet levels and long-term outcomes in patients with DN.
Results: The levels of urinary cMet were higher in patients with decreased renal 
function than in patients with relatively preserved renal function (5.17 ± 9.56 ng/ml versus 
1.86 ± 4.85 ng/ml, P = 0.001). A fully adjusted model revealed that a urinary cMet cutoff 
of 2.9 ng/mL was associated with a hazard ratio for end-stage renal disease of 2.50 (95% 
confidence interval 1.18–4.53, P = 0.007). The addition of urinary cMet to serum creatinine 
and proteinuria provided the highest net reclassification improvement. We found that in 
primary cultured human glomerular endothelial cells, TGFβ treatment induced fibrosis, and 
the protein expression levels of collagen IV, fibronectin, and αSMA were decreased after 
administration of an agonistic cMet antibody.
Conclusions: In conclusion, elevated levels of urinary cMet at the time of initial 
diagnosis could predict renal outcomes in patients with DN.
Comparison of the ROC curve, IDI and category-free NRI of the Cr vs. Cr, UPCR vs. Cr, 
UPCR, cMet/Cr in predicting ESRD
Cr, creatinine; UPCR, urine protein-to-creatinine ratio; ESRD, end stage renal disease; CI, 
confidence interval; IDI, integrated discriminatory improvement; NRI, net reclassification 
improvement
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Urinary Peptidomic Analysis Reveals Bioactive Uromodulin Peptides 
Associated with Early Type 1 Diabetes
Julie Anh Dung Van,1 Sergi Clotet-Freixas,2 Ihor Batruch,3 Xiaohua Zhou,1 
Farid H. Mahmud,4 Eleftherios P. Diamandis,5 James W. Scholey,1 
Ana Konvalinka.1 1University of Toronto, Toronto, ON, Canada; 2University 
Health Network, Toronto, ON, Canada; 3Mount Sinai Hospital, Toronto, ON, 
Canada; 4Hospital for Sick Children, Toronto, ON, Canada; 5Mount Sinai 
Hospital and University Health Network, Toronto, ON, Canada.
Background: Diabetic nephropathy is the leading cause of kidney disease worldwide. 
Yet, current treatments cannot prevent the progressive nature of the disease, exposing our 
limited understanding of the early kidney response to chronic hyperglycemia. In this study, 
we compared the urinary peptidomes of youths with type 1 diabetes without evidence of 
nephropathy and age/sex-matched healthy controls, in order to determine early changes in 
protein processing in the hyperglycemic kidney.
Methods: The study population comprises two separate cohorts: a discovery cohort 
(N = 30) and an internal validation cohort (N = 30). Urines were normalized to creatinine 
and underwent 10kDa-filter centrifugation to isolate naturally occurring peptides. In the 
discovery phase, filtered peptides were then fractionated and then injected on a Q-Exactive 
mass spectrometer. For the validation phase, parallel reaction monitoring (PRM) assays 
were developed on a Q-Exactive HFX instrument. MaxQuant and Skyline were used for 
peptide identification and quantification. Proteasix was used to predict proteases responsible 
for generating differentially excreted peptides.
Results: A total of 6349 urinary peptides from 750 proteins were quantified. Of the 
15 differentially excreted peptides (P < 0.05), five remained significant after Benjamini-
Hochberg adjustment (q < 0.05). Seven of these top 15 peptides derive from the C-terminal 
region of uromodulin, which regulates uromodulin polymerization. Out of the twelve 
predicted proteases, hepsin, granzyme A, kallikrein-6, and plasminogen were shortlisted 
because they were detected in healthy kidney tissues (Human Protein Atlas) and were 
altered at the level of gene expression in diabetic nephropathy (Nephroseq v5 database). 
Differential excretion of six uromodulin peptides was validated by PRM. Two of the 
validated uromodulin peptides induced NF-κB signaling in HK-2 cells, suggesting a 
potential role in mediating inflammation in kidney cells.
Conclusions: Differences between youths with type 1 diabetes and healthy controls 
are reflected in the urinary peptidome before the development of microalbuminuria. 
Uromodulin peptides we discovered may play a significant role in the early injury in a 
diabetic kidney and may represent a therapeutic target.
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Pirfenidone May Protect Against Diabetic Kidney Disease by Reducing 
Fumarate
Jiwan J. Kim,1 Manoj Bhattarai,1 Satoshi Miyamoto,2 Daniel Montemayor,1 
Manjula Darshi,1 Kumar Sharma.1 1University of Texas Health San Antonio, San 
Antonio, TX; 2Okayama University Hospital, Okayama, Japan.
Background: Recent studies suggest that Pirfenidone (PFD) has anti-fibrotic effect 
in various diseases including diabetic kidney disease (DKD). We previously demonstrated 
that in type 2 diabetic animal models PFD significantly reduces the expansion of mesangial 
matrix. Furthermore, in a placebo-cotrolled clinical study we found that PFD treatment 
for 54 weeks significantly improved eGFR with a low dose. In the current study we aim 
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to identify predictive metabolite biomarkers and potential mechanisms associated with 
renoprotective effects of PFD and also tested a longer acting and better tolerated version.
Methods: 1) Two types of PFD (short acting and long acting) were administered to 
16 week db/db and db/m control mice (n=8 each). After 4 weeks, 24 hr urine was collected 
and 70 urinary metabolites were quantified using GC-MS/MS. 2) Urine and plasma from 
our prior clincal trial was assessed for metabolite markers from samples collected every 3 
months. Fumarate in human urines was also assessed with a specific fumarate assay kit.
Results: Significant changes in metabolites were observed between the db/mand 
db/db, and PCA plot clustered the two groups into well-defined spaces. The db/db mice 
treated with PFD were in closer proximity to the db/db cluster with a slight trend toward 
the db/m cluster. Untreated Db/db mice had lower levels of succinate, citrate, 3-methyl 
crotonyl glycine, 2 hydroxyglutarate, and uracil, but PFD treated db/db mice had the levels 
restored either partially or completely back to the levels of db/m. Interestingly, the db/db 
mice had three fold increase in fumarate as compared to the db/m mice (p<0.0001), while 
long acting PFD treatment significantly reduced the fumarate levels below that of db/m 
mice (p<0.0001). In the human study, the baseline urine fumarate level of placebo treated 
patients showed negative correlation with the rate of change in GFR at 12 months (r=-0.89, 
p<=0.05). The correlation was not observed in subjects treated with PFD.
Conclusions: The anti-fibrotic effects of PFD in kidney has effects on several urinay 
metabolites identified to be regulated in human diabetic kidney disease. Fumarate may be 
a useful biomarker in the mouse model of diabetic kidney disease and may be a potential 
marker for anti-fibrotic therapies.
Funding: NIDDK Support
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Urinary Baseline AQP5 Is Independently Associated with eGFR Decline in 
Patients with Type 2 Diabetes and Nephropathy
Chao Gao,1 Michelle Pena,2 Hiddo J. Lambers Heerspink,2 Wenzheng Zhang.1 
1Albany Medical College, Albany, NY; 2University Medical Center Groningen, 
Groningen, Netherlands.
Background: Water channel AQP5 has been shown to be upregulated in kidney 
biopsies from patients with diabetic nephropathy, and may serve as a biomarker for tubular 
damage. Here we investigate whether urinary baseline water channel AQP5 is independently 
associated with eGFR decline in patients with type 2 diabetes and nephropathy.
Methods: Baseline urine samples (n=997) were used from the SUN-Macro 
randomized placebo controlled double blind clinical trial, which evaluated the 
renoprotective effects of sulodexide in patients with type 2 diabetes and nephropathy. 
Human AQP5-specific enzyme-linked immunosorbent assay was measured in baseline 
urine. Pearson correlation and multiple linear regression between baseline AQP5 with 
eGFR slope (calculated by ≥3 serum creatinine during follow-up) was performed, and 
association with fast renal function decline, defined as eGFR slope less than 3.0 mL/min/ 
1.73m2/year, was determined by logistic regression.
Results: Follow-up eGFR data over 1.4 years from n=700 were available for 
analysis. AQP5 was undetectable in 138 patients. Tertiles of baseline AQP5 were 0.4 
[0 – 2.2], 7.3 [5.9 – 9.1], and 16.0 [13.0 – 21.6] (ng/mL), respectively (p-value <0.01). 
Patients in the highest tertile of AQP5 had significantly higher total cholesterol, lower 
baseline eGFR, and higher levels of albuminuria compared to the lowest tertile. Baseline 
AQP5 was inversely correlated with eGFR slope (Pearson’s r = -0.12, p-value = 0.001), 
and independent of clinical risk factors age, sex, race, and baseline: SBP, DBP, HbA1c, Tot. 
Cholesterol, eGFR, and UACR (β = -0.05, p-value = 0.004). Furthermore, baseline AQP5 
was significantly associated with fast eGFR decline (OR = 1.03 (95%CI 1.003 – 1.06), 
p-value = 0.03).
Conclusions: Our data suggest that baseline AQP5, a possible marker of tubular
dysfunction, is independently associated with the progression of eGFR decline in patients 
with type 2 diabetes and nephropathy. Validation of these findings in an external cohort is 
necessary.
Funding: NIDDK Support
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PI3 Kinase/Akt Node Acts as a Driver for High Glucose-Induced miR-214 
Expression to Induce a Positive Feedback Loop via PTEN for Matrix 
Protein Expression in Proximal Tubular Epithelial Cells (PTECs)
Soumya Maity, Falguni Das, Nandini Ghosh-choudhury, 
Balakuntalam S. Kasinath, Goutam Ghosh-Choudhury. UTHSCSA, 
San Antonio, TX.
Background: We have recently shown that high glucose (HG) increased the expression 
of miR-214 to regulate renal fibrosis by directly targeting the 3’ UTR of PTEN tumor 
suppressor protein (Am J Physio Cell Physiol 313: C430, 2017). The mechanism by which 
HG regulates miR-214 expression is not known. We hypothesized involvement of PI 3 
kinase (PI 3 K)/Akt cascade in this process.
Methods: Human PTECs, activation-specific phospho-antibodies, shRNA, dominant 
negative kinases, real time qRT-PCR and immunoblotting were employed.
Results: In human PTECs, HG increased the expression of miR-214. To address the role 
of PI 3 K, we used its inhibitor Ly294002 (Ly). Ly significantly inhibited the HG-stimulated 
expression of miR-214. Similarly, expression of dominant negative PI 3 K markedly blocked 
the miR-214 expression in response to HG. Inhibition of Akt, the downstream kinase of PI 
3 K, by MK2206 significantly suppressed the HG-induced miR-214 expression. In diabetic 
renal pathology a significant role of mechanistic target of rapamycin complex 1 (mTORC1) 
has been established. Rapamycin significantly attenuated the miR-214 expression by HG. 
Furthermore, shRNA against raptor, required for mTORC1 activation, blocked the HG 
stimulated miR-214 expression, similar to rapamycin. Since miR-214 downregulates PTEN 
to drive tubular matrix protein expression, we examined the role of PI 3 K/Akt in PTEN 
protein expression. Downregulation of PTEN by HG was reversed by dominant negative PI 
3 K or Akt, which led to inhibition of mTORC1 activity as judged by phosphorylation of its 
substrate S6 kinase at Thr-389. Consequently, the HG-induced fibronectin expression was 
blocked by the dominant negative PI 3 K and Akt. Interestingly, plasmid-derived expression 
of miR-214 attenuated the increment of PTEN by the dominant negative PI 3 K or Akt in 
the presence of HG, resulting in increase in mTORC1 activity and expression of fibronectin.
Conclusions: These results are the first demonstration for a key role of PI 3 K/Akt 
signaling in HG-induced miR-214 expression. Furthermore, our data give evidence for a 
positive feedback loop involving the PI 3 K/Akt/mTORC1/miR-214 and PTEN for driving 
tubular fibrosis.
Funding: Veterans Affairs Support
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Inhibition of MicroRNA-451 Increases Metabolic Acidosis in a Mouse 
Model of Insulin Resistance and Early Diabetic Nephropathy
Maurice B. Fluitt, Narayan Shivapurkar, Carolyn M. Ecelbarger. Georgetown 
University, Washington, DC.
Background: Metabolic acidosis (MA) is a common complication of diabetic 
nephropathy (DN) and is associated with an increased risk of end-stage renal failure. MA 
has major systemic consequences which include protein wasting, inflammation, insulin 
resistance, worsened hypertension and bone disease. Several studies suggest a renal 
protective role of microRNA-451 (miR-451) in ameliorating progression of DN. The 
current study aimed to elucidate the role of miR-451 in the development of MA in a mouse 
model of insulin resistance.
Methods: Male TALLYHO/Jng mice (insulin resistant and obese) were placed on a 
high-fat diet (60% kCal) and divided into two treatment groups. Mice received 8 consecutive 
weekly intraperitoneal injections of locked nucleic acid (LNA) miR-451-inhibitor or LNA-
scramble (2 mg/kg bw; n =8/treatment). 24-hr urine was collected at 2-week intervals. Mice 
were humanely euthanized after 12 weeks and kidneys harvested.
Results: LNA-miR-451-inhibitor reduced renal expression of miR-451 6-fold in 
inhibitor treated mice (p=0.0002). Masson’s Trichrome revealed inhibition of miR-451 
increased collagen deposition by 68% (p=0.007). Blood chemistry revealed higher blood 
Na+ concentrations (2.4%; p=0.007) and anion gap (165%; p=0.01) in the mice treated with 
inhibitor versus vehicle control. There was also a strong trend for lower blood TCO2 (12.6%; 
p=0.06) and HCO3 (13.6%; p=0.06) in inhibitor-treated mice. There were no significant 
differences in serum K+ and Cl-. Western blotting analysis of cortex homogenates revealed 
significant increases in aquaporin-2 (52.8%, p=0.03), the sodium bicarbonate cotransporter 
(NBCe1) (28.3%, p=0.02) and SNAT3 (80.7%, p=0.0008) in inhibitor-treated mice. 
Additionally, there was a strong trend for an increase in the a-subunit of the epithelial 
sodium channel (ENaC) (35.5%, p= 0.05) in inhibitor-treated mice.
Conclusions: These findings suggest miR-451 may protect against the development 
of acidosis in the setting of insulin resistance and early diabetic nephropathy, further 
supporting its potential use as a therapuetic target for DN. Upregulation of transporters 
involved in proximal-tubule ammoniagenesis are likely a response to the acidosis.
Funding: Other NIH Support - NIH TL1TR001431, Private Foundation Support
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Diabetes Potentiates the Differentiation of Bone Marrow-Derived Cells 
into Glomerular Endothelium
Hiroshi Nobuta,1,2 Takahiko Nakagawa,3 Miwako Katagi,2 Shinji Kume,1 
Tomoya Terashima,2 Hideto Kojima,2 Shin-ichi Araki,1 Hiroshi Maegawa.1 
1Department of Medicine, Shiga University Of Medical Science, Otsu, Japan; 
2Department of Stem Cell Biology and Regenerative Medicine, Shiga University 
of Medical Science, Otsu, Japan; 3Department of Future Basic Medicine, Nara 
Medical University, Kashihara, Japan.
Background: Diabetes causes its complication including neuropathy and nephropathy, 
and these disorders could share a common mechanism. Recently, it has been shown that 
bone marrow-derived cells (BMDCs) play a role in the development of diabetic neuropathy. 
In particular, BMDCs expressing TNF-α reach peripheral neuronal systems to cause 
functional disorders. However, it remains unclear if BMDCs are involved in the kidney 
injury of diabetes. We thus hypothesized that BMDCs cause diabetic nephropathy (DN). To 
test our hypothesis, we examined the role of BMDCs in mice with DN.
Methods: We transplanted the total bone marrow of GFP-Tg mice into wild type mice 
and then induced diabetes by intraperitoneal injection of 55mg/kg streptozotocin (STZ) 
for five consecutive days. At 6 and 20 weeks after STZ injection, mice were sacrificed for 
analyses. Non-diabetic control mice were injected citrate buffer only.
Results: We first confirmed using FACS analysis that over 98% of BMDCs of recipient 
mice were GFP positive. Immunofluorescence study demonstrated that the number of GFP-
positive BMDCs in diabetic glomerulus was significantly higher than that in non-diabetic 
glomerulus. Most GFP-positive cells were also positive for CD31 and isolectin B4, but 
negative for podocin, α8 integrin and F4/80, suggesting BMDCs could differentiate into 
glomerular endothelial cells. Interestingly, the number of residential endothelial cells (GFP-
negative endothelial cells) were identical between diabetic and non-diabetic glomerulus. These 
data suggest that BMDCs could contribute to the development of neovascularization in DN.
Conclusions: BMDCs arrive at glomerulus and they may be involved in 
neovascularization in diabetic mice. BMDCs could play a potential role in the development 
of DN.
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Myo-Inositol Oxygenase Modulates the Progression of Renal Fibrosis in 
Diabetes via Oxidant and ER Stress
Isha Sharma,2 Fei Deng,2 Lin Sun,3 Yashpal S. Kanwar.1 1Northwestern 
University Medical School, Chicago, IL; 2Northwestern University, Chicago, 
IL; 3Second Xiangya Hospital Central South University, Changsha, China.
Background: Myo-inositol oxygenase (MIOX) is a renal tubular specific enzyme and 
its overexpression is associated with increased oxidant stress and renal fibrosis. Excessive 
ROS generation leads to accumulation of misfolded proteins in endoplasmic reticulum (ER) 
causing ER stress. How MIOX serves as a nodal molecule for regulating the progression 
of diabetic tubulopathy via oxidant and ER stress in hyperglycemia remains unexplored.
Methods: A diabetic state was induced with the administration of STZ in wild type 
(WT), MIOX transgenic (TG) and MIOX-/- (KO) mice. In addition, MIOX-/- (KO) mice 
were cross bred with Ins2 Akita mice to generate mice with double mutation (Ins2 Akita/MIOX-
KO) to assess if genetic deletion of MIOX ameliorates the progression of tubulo-interstitial 
injury in Ins2 Akita mice.
Results: The expression of GRP78/Bip, a marker of ER stress, and another ER stress 
regulator, i.e., transcription factor X-BOX binding protein-1 (XBP-1), were increased 
in kidneys of WT and MIOX-TG mice with STZ-induced diabetes and Ins2 Akita mice. 
Interestingly, by EMSA and ChiP assays MIOX expression was noted to be regulated by 
XBP-1. MIOX-KO and Ins2 Akita/MIOX-KO had reduced expression of XBP1 and GRP78/
Bip in diabetic state, and the kidneys of these mice had reduced tubulo-interstitial injury and 
fibrosis. Concomitantly, the extent of renal cellular redox was reduced in MIOX-KO and 
Ins2 Akita/MIOX-KO mice, while markedly accentuated in WT, MIOX-TG and Ins2 Akita mice, 
as indicated by perturbed NADPH:NADP ratios and increased DHE, and DCF staining 
in renal tissues. The assessment of relevant signaling molecules revealed an increase in 
the expression of p-PDK1, p-PKC in kidneys of MIOX-TG mice. Likewise, expression 
of TGF-β and Smad 3, 4 were relatively high in diabetic WT and MIOX-TG, and Ins2 Akita 
mice. The expression of the signaling molecules were marginally affected in KO mice. 
Similar results were observed in in vitro HK-2 cells studies with MIOX over-expression and 
gene disruption of MIOX as well as the XBP1, a hallmark of ER stress.
Conclusions: These findings identify a link between the biology of MIOX and oxidant 
and ER stress and delineate the role of MIOX as a nodal molecule in the pathogenesis of 
tubulo-interstitial fibrosing injury in diabetic state.
Funding: NIDDK Support
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Allogeneic “Neo-Islets,” Composed of Mesenchymal Stem and Islet  
Cells, Are Immune Protected and Control, After i.p. Administration, 
Auto-Immune Type 1 Diabetes Mellitus in Pet Dogs
Christof Westenfelder, Anna Gooch, Zhuma Hu, Ping Zhang. SymbioCellTech, 
SLC, UT.
Background: Curative T1DM therapies are needed that do not depend on potentially 
toxic anti-rejection drugs, encapsulation devices or the requirement for up to 5 pancreas 
donors per islet transplant. We demonstrated that allogeneic, ip administered “Neo-Islets” 
(NIs), aggregates of cultured islet cells (ICs) and immune- and cyto-protective Adipose 
Derived Stem Cells (ASCs), reestablished durable normoglycemia through omental 
engraftment and splenic and omental upregulation of Tregs, in autoimmune T1DM NOD 
mice without immunosuppressive agents. Comparable euglycemia was achieved with dog-
derived NIs in STZ-diabetic NOD/SCID mice (SCTM 2017;6:1631). Here we report on an 
FDA supervised pilot study (INAD 012-776) using this NI therapy in 2 insulin-dependent 
pet dogs.
Methods: Insulin dependent (≥ 6 months), diabetic pet dogs, ≤12 kg, were included, 6 
enrolled; 3 treated, and 2 (Dogs 1 and 2, male) followed for 6 months. Pre-treatment serum 
from Dog 1 and Dog 2 was tested for the presence of islet autoantibodies, and comorbidities 
and blood glucose levels were treated. 2x10e5 allogeneic NIs per kg b.wt. were then given 
i.p. Blood glucose levels, insulin requirements and formation of antibodies to allogeneic
NIs were closely monitored.
Results: Prior to treatment Dog 1 had no islet autoantibodies, suggesting insulin 
resistance, while Dog 2 had islet autoantibodies, indicating autoimmunity. Both dogs have 
improved glycemic control. Dog 2’s insulin requirements have decreased by 50% after 
6 months. Neither dog developed antibodies to the administered NIs, and no adverse events 
related to treatment were observed.
Conclusions: This ongoing pilot study in diabetic dogs demonstrates that NI therapy 
progressively reduces insulin requirements. This was achieved, without anti-rejection drugs. 
NIs, as engineered here, provide a novel therapy that, we posit, has significant translational 
relevance to clinical T1DM. We thank site PIs Drs. Rance Sellon, WSU, Pullman, WA, 
Natasha Loy Son and Julie Fisher, Veterinary Specialty Hospital, San Diego, CA, for their 
excellent collaboration.
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Effect of DsbA-L on Renal Ectopic Fat Deposition and Lipid-Related 
Kidney Damage in Diabetic Nephropathy
Xianghui Chen,1 Yachun Han,1 Ming Yang,1 Peng Gao,1 Yashpal S. Kanwar,2 
Lin Sun.1 1Second Xiangya Hospital Central South University, Changsha, 
China; 2Northwestern University Medical School, Chicago, IL.
Background: Emerging evidence suggests that ectopic fat deposition (EFD) in the 
kidney is related to the progression of diabetic nephropathy (DN), but the mechanism 
remains elusive. Disulfide-bond A oxidoreductase-like protein (DsbA-L) also known as 
Glutathione S-transferase kappa 1 (GSTK1), which has been demonstrated to regulate 
adiponectin multimerization, alleviate endoplasmic reticulum stress and prevent obesity-
induced inflammation and insulin resistance. But the role of DsbA-L in renal EFD and 
lipid-related kidney damage is unknown.
Methods: In this study, patients with DN, DsbA-L deficiency mice (DsbA-L-/- mice), 
DsbA-L overexpression mice and HK-2 cells, a human proximal tubular cells line were 
used. Differentially expressed genes were identified by transcriptome in the kidney 
tissues of mice. Oil red o staining, electron microscope and immunostaining of adipocyte 
differentiation-related protein (ADRP) were used to observe or detect the lipid depostion in 
the kidney tissues of DN patients or mice.
Results: Here, we identified decreased expression of disulfide - bond A oxidoreductase-
like protein (DsbA-L) and increased expression of adipocyte differentiation-related protein 
(ADRP) in the kidney of diabetic mice. Further, obvious lipid droplets (LDs) deposition and 
decreased DsbA-L expression were observed in the kidney of diabetic mice, accompanied 
by abnormal levels of phosphorylation of 5’AMP-activated kinase (p-AMPK), p-adipose 
triglyceride lipase (p-ATGL), p-3-hydroxy-3-methylglutaryl- CoA reductase (p-HMGCR), 
collagen I and fibronectin (FN). The above alterations were further increased in diabetic 
DsbA-L-/- mice. Overexpression of DsbA-L ameliorated high glucose (HG)-induced 
intracellular LDs deposition, whereas DsbA-L siRNA treatment aggravated it and was 
accompanied by reduced levels of p-AMPK, p-ATGL and p-HMGCR in HK-2 cells, a 
human proximal tubular cells line. Additionally, HG plus palmitic acid (PA) enhanced the 
expression of interleukin-1β and interleukin-18, which was further increased after DsbA-L 
siRNA treatment, but was alleviated by cotreatment with an AMPK activator. In the kidneys 
of DN patients, LDs deposition was negatively associated with DsbA-L expression but 
positively correlated with kidney damage.
Conclusions: Collectively, DsbA-L protects against renal EFD and lipid-related kidney 
damage via AMPK pathway.
Funding: Other NIH Support - Fund of the National Natural Sciences of China 
(81730018 and 81470960)
TH-PO890 Poster Thursday
Diabetic Kidney Disease: Basic - I
Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy 
and High-Fat Diet-Induced Renal Lipotoxicity
Yaeni Kim,1 Ji Hee Lim,2 Min Young Kim,2 Eun Nim Kim,2 Seon Deok Hwang,3 
Bumsoon Choi,4 Yong-Soo Kim,5 Cheol Whee Park.2 1Incheon St. Mary’s Hosp, 
Catholic Univ of Korea, Incheon, SEoul, Republic of Korea; 2The Catholic 
University of Korea, SEOUL, Republic of Korea; 3inha university, Incheon, 
Republic of Korea; 4Division of Nephrology, Department of Internal Medicine, 
Seoul, Republic of Korea; 5The Catholic University of Korea College of 
Medicine, Seoul, Republic of Korea.
Background: Lymphangiogenesis occurs in response to renal injury in renal proximal 
tubular epithelial cells (PTECs) and infiltrating macrophages and is correlated with the 
degree of renal interstitial fibrosis. Diabetes and high-fat diet-induced renal lipotoxicity 
causes glomerular sclerosis and tubulointersitial fibrosis, but its possible involvement with 
regard to lymphangiogenesis has not been elucidated. Peroxisome proliferative-activated 
receptor (PPAR)a plays an important role against lipotoxicity under the control of AMP-
activated protein kinase (AMPK). We evaluated whether fenofibrate has a renoprotective 
effect by ameliorating lipotoxicity-induced lymphangiogenesis.
Methods: Eight-week-old male C57BLKS/J db/db mice and spontaneously 
hypertensive rats (SHRs) were fed either a normal chow or a high-fat diet (HFD) and 
fenofibrate for 12 weeks and were evaluated for biochemical parameters and renal 
phenotypes.
Results: In db/db mice, fenofibrate inhibited the accumulation of intra-renal lipids by 
increasing the expression of PPARa and phosphorylation of AMPK. It decreased lymphatic 
growth, as represented by decreases in the expression of lymphatic endothelial hyaluronan 
receptor-1 (LYVE-1) and podoplanin, along with decreases in vascular endothelial growth 
factor-C (VEGF-C) and vascular endothelial growth factor receptor-3 (VEGFR-3). 
Consequently, fenofibrate reversed mesangial expansion, tubulointerstitial fibrosis and 
chemokine-induced inflammatory cell infiltration by improving apoptosis and oxidative 
stress. In HFD SHRs, fenofibrate attenuated renal lymphatic proliferation and inflammation 
by decreasing lipotoxicity-induced oxidative stress and apoptosis through PPARa-AMPK 
phosphorylation. In cultured HK2 cells and RAW 267 cells, fenofibrate prevented palmitate- 
and high glucose-induced expression of VEGF-C, VEGFR-3, and LYVE-1 via activation of 
PPARa-AMPK-pACC signaling and enhanced expression of M1 phenotype macrophage.
Conclusions: A causal relationship between lipotoxicity and lymphatic proliferation 
with a cellular link to macrophage activation can be speculated; pro-inflammatory M1 type 
macrophages may be primarily involved in the development of intrarenal lymphangiogenesis 
through stimulation of VEGF-C and by its transdifferentiation into lymphatic endothelial 
cells.
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Basigin/CD147 Exacerbates Diabetic Kidney Disease Dependent of 
Proteinuria
Tomoharu Watanabe,2 Tomoki Kosugi,1 Akihiro Ryuge,1 Tomohiro Masuda,1 
Kayaho Maeda,1 Sawako Kato,1 Shoichi Maruyama.1 1Nagoya University 
Graduate School of Medicine, Nagoya, Japan; 2Nagoya University, Nagoya, 
Japan.
Background: CD147/Basigin (Bsg), a glycosylated transmembrane protein, 
contributes to cell survival, migration, cancer invasion and inflammation. We have so 
far demonstrated its pathophysiological roles in the kidney diseases, ranging from the 
occurrence of acute kidney injury accompanied by ischemia to progression of renal fibrosis 
and lupus nephritis. However, the mechanism of diabetic kidney disease (DKD) involving 
Bsg remains unknown. We therefore focused on Bsg function in the development of DKD 
with proteinuria.
Methods: Two independent mice models were performed using wild-type (Bsg+/+) 
or Bsg-deficient (Bsg-/-) mice treated with streptozotocin or overloaded by bovine serum 
albumin, respectively. Primary proximal tubular epithelial cells (PTECs) derived from 
Bsg+/+ or Bsg-/- mice and human PTECs were exposed to high glucose (30mM) or albumin. 
In clinical study, DKD patients (N=52) registered with UMIN Clinical Trials Registry 
(8016) were treated with spironolactone 25 mg once daily for 8 weeks. The relationships 
between urinary Bsg values and clinical indicators were examined.
Results: While Bsg-/- mice induced by protein overload ameliorate the development 
of tubulointerstitial injury, no obvious difference in the two genotypes representing DKD 
was found. In clinical study, DKD patients showed higher plasma and urinary Bsg values 
and marked Bsg inductions in injured tubulointerstitium. Plasma and urinary Bsg levels 
showed close correlations with eGFR and proteinuria, but not HbA1c, respectively. DKD 
patients treated with spironolactone showed a striking reduction of urinary Bsg values as 
well as albuminuria. A close association between reduction rates of urinary Bsg values 
and albuminuria was observed. In in vitro study, Bsg inductions in primary PTECs after 
exposure of albumin, but not high glucose, were found in a concentration-dependent 
fashion. Bsg silencing and gene deficiency in PTECs limited inflammation-related 
chemotactic activation such as MMPs and MCP-1.
Conclusions: Bsg plays an indispensable role in the development of DKD evoked by 
proteinuria through the activation of inflammatory signaling.
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Different Renoprotective Mechanism of TMX-049, a Novel Xanthine 
Oxidoreductase Inhibitor, from Losartan: The Importance of Renal 
Tubule for Diabetic Kidney Disease Treatment
Takashi Shirakura,1 Yoshiki Tsubosaka,1 Yohei Sakamoto,2 Tsunefumi 
Kobayashi,1 Reiko Aizawa,1 Shunsuke Tsujimoto,1 Johji Nomura,1 
Chieko Matsui.1 1Pharmacology Research Department, Teijin Pharma Limited, 
Hino, Japan; 2Toxicology Research Department, Teijin Pharma Limited, 
Hino, Japan.
Background: Diabetic kidney disease (DKD) is a major renal complication of 
diabetes. Although the glomerulus has been considered as the primary site of injury, recent 
studies have suggested that renal tubule is also the prominent site. Current medications 
such as losartan (Los) exert the renoprotective effects by reducing intraglomerular 
pressure. However, there is no drug which targets tubular injury. Xanthine oxidoreductase 
(XOR) is an enzyme producing uric acid and its inhibitors have been reported to improve 
albuminuria in DKD patients. To date we found that XOR is mainly expressed in renal 
tubule in rats, suggesting the target site of XOR inhibitor may be renal tubule. To determine 
the renoprotective effect of TMX-049, a novel XOR inhibitor, and the importance of renal 
tubule as a target site for DKD treatment, we examined them using animal models of DKD 
and albumin-induced tubular injury.
Methods: 1. Male ZDF rats were orally administrated TMX-049 or Los for 13 weeks. 
2. Male unilateral nephrectomized rats were intraperitoneally injected with bovine serum
albumin and orally administrated with TMX-049 or Los for 3 weeks. Urinary albumin, and 
KIM-1 as a tubular injury marker, were measured. XOR activity in the renal cortex was
measured and histological and immunohistochemical analyses were performed.
Results: XOR, mainly expressed in renal tubule, was increased in ZDF rats, consistent 
with the increased XOR activity in renal cortex. TMX-049 but not Los inhibited XOR 
activity. In addition, TMX-049 as well as Los decreased urinary albumin and KIM-1 
excretions, and ameliorated histological damage in both glomerular and tubular region in 
ZDF rats. Albumin induced the damage in tubular region and urinary KIM-1 excretion, 
indicating tubular injury by albumin, while there were no changes in glomerular region. 
Consistent with ZDF rats, XOR activity in renal cortex was increased in albumin-treated 
rats. Importantly, TMX-049 attenuated albumin-induced tubular damages whereas 
Los failed.
Conclusions: TMX-049 attenuated renal tubular damage by inhibiting tubular XOR, 
leading to suppress renal injury. These results suggest the therapeutic potential of TMX-049 
and the importance of renal tubule as a target site for DKD treatment.
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Metabolic Differences in Diabetic Kidney Disease Patients with and 
Without Albuminuria
Stein I. Hallan,2,3 Manjula Darshi,1 Marius A. Øvrehus,2 Knut 
Asbjørn R. Langlo,2,3 Kumar Sharma.1 1University of Texas Health San Antonio, 
San Antonio, TX; 2Norwegian University of Science and Technology, Trondheim, 
Norway; 3St. Olavs Hospital HF, Trondheim, Norway.
Background: The classical paradigm describing diabetic kidney disease (DKD) as 
a linear progression with stages of glomerular hyperfiltration, progressive albuminuria, 
and subsequent declining GFR is being recently challenged. 25-50% of DKD with eGFR 
<60ml/min/1.73m2 do not have albuminuria, and the underlying pathology in this group is 
not well studied. We studied the metabolic differences in unselected well-matched DKD 
patients with (DKD A1+) and without (DKD A0) albuminuria.
Methods: 41 patients with DKD, defined as diabetes mellitus with eGFR <60mL/min/ 
1.73m2, and 60 healthy age- and sex-matched controls were randomly chosen from the 
general population (HUNT-3 study, 2006-08, Norway). Urine samples were analyzed and 
75 organic acids quantified using gas chromatography-mass spectrometry (GC-MS, 4-6 
calibration points, CV 10-20%). Kidney function was followed over 10 years.
Results: 15 of 41 DKD patients (37%) had ACR <3.0mg/mmol. Age and sex were 
similar in the healthy control, DKD A0 and DKD A1+ groups (∼ 71 years, p=0.3; and 
40% males, p=0.6). Baseline eGFR was identical in DKD A0 and A1+ (51 vs 51 ml/min/ 
1.73m2). They also had similar BMI, BP, BP medication, physical activity and education 
(p>0.4 for all), while DKD A0 had more never-smokers (p=0.002). PLS-DA analysis of the 
organic acid metabolites showed that the three groups separated moderately, with DKD A0 
positioned between controls and DKD A1+ patients (Figure 1). When comparing the two 
DKD groups, we found 22 metabolites with VIP scores ≥1.0, i.e. considered to contribute 
significantly to separation. Top metabolites were hexanol glycine, lactic acid and keto-
glucatic acid. Enrichment analysis based on these metabolites showed that citric acid cycle, 
Warburg effect, glucose-alanine, keton body metabolism, and fatty acid biosynthesis were 
the most affected pathways (p<0.05 and ∼ 5-fold enriched for all).
Conclusions: DKD patients with and without albuminuria differ substantially in their 
metabolic disturbances and could represent different clinical phenotypes
Funding: Government Support - Non-U.S.
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Haploid Deletion of TRPC1 Gene Produces Hypercalcemia, Anemia, 
Diabetes, and Renal Failure, as Diploid Deletion Causes Obesity, 
Metabolic Syndrome, Hyperparathyroidism, Liver Steatosis, and Larger 
Bone Mass
Bonnie Eby,1 Meghan M. Pantalia,2 Lindsay J. Barron,1 Alexander Lau,1 
Richard M. Atkins,3 Usman A. Khan,3 Leonidas Tsiokas,1 Kai Lau.1,4 1University 
of Oklahoma Health Sciences Center, Oklahoma City, OK; 2Columbia 
University, New York, NY; 3University of Oklahoma College of Medicine, 
Oklahoma City, OK; 4Medicine, VA Hospital & Medical Center, 
Oklahoma City, OK.
Background: The gene encoding the canonical transient recpetor potential 1 channel 
(TRPC1) is ubiquitously expressed. It is known to be involved in signal transduction by 
changing intracellular Ca, cytokine & hormone secretion, cell proliferation & differentiation. 
Gene deletion is now known to produce a myriad of abnromal but nonlethal phenotypes, 
including hypercalcemia, anemia, diabetes, renal failure, obesity, metabolic syndrome, 
hyperparathyroidism, hepatic steatosis & increased bone mass. We tested the hypothesis of 
relative gene dosge in these phenotypes by studying ♂ littermates of all 3 genotypea born 
to only +/- breeders.
Methods: Standard metabolic studies, glucose tolerance tests, & routine lab chemistry 
were done from age 1 to 22 m. Mouse ELISA were used to measure insulin, PTH, 
adipokines & FGF-23. Creatinine (Cr) was measured by HPLC & glomerular filtration rate 
(GFR) by inulin or Cr clearance.
Results: In +/- mice, like the null, we found fasting hyperglycemia at 3 m, diabetes at 
6 m, hypercalcemia at 7-12 m, anemia at 11 m, & reduced GFR of 40% at 16 m. However, 
only in null mice could we document the following phenotypes: hyperphagia, excessive 
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weight gain, obesity, hypertriglyceridemia (all at 2-4 m), reduced serum FGF 23 at 3-5 m, 
metabolic syndrome at 6 m, increased serum leptin & reduced adiponectin at 7 m, hepatic 
steatosis at 12 mon, hyperparathyroidism despite hypercalcemia & hypocalciuria [like the 
human familial hypocalciuric hypercalcemia (FHH)] at 12 m, & increased bone mass at 
19-22 m. Liver triglyceride content was elevated only in null mice. If haploid deletion
replicates the phenotypes of diploid deletion, the degree of abnormalities was uniformly
ccomparable.
Conclusions: We conclude: 1. Since haploid deficiency of TRPC1 gene produces 
anemia, diabetes, hypercalcemia & renal failure, the usual normal phenotypes would require 
both wild type alleles. 2. Since diplid deficiency is needed to produce hyperphagia, obesity, 
metabolic syndrome, FHH, hepatic steatosis & increased bone mass, the corresponding 
normal phenotypes can be maintained by 1 wild type allele. 3. Additional insights on the 
pathobiology will depend on studies in tissue-specific TRPC1 gene deletion.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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In Vivo Evidence of Role of Diabetes in Accelerating Kidney 
Tumorigenesis
Samy L. Habib.1,2 1UTHSCSA, San Antonio, TX; 2Geriatric Research, Education 
and Clinical CTR, South Texas Veterans Health System, San Antonio, TX.
Background: Our published clinical data show a strong risk of diabetes in increasing 
of renal cell carcinoma in a cohort study of kidney cancer patients whereas 25.4 % of kidney 
cancer patients have history of diabetes and our recent clinical data showed that RCC 
patients with history of diabetes increased by 33.3%. The increasing incidence of diabetes in 
our population will increase the risk of solid tumors including renal cell carcinoma (RCC). 
The mechanism by which diabetes enhances certain pathways to develop kidney tumor is 
largely unknown.
Methods: The inherited renal tumor was identified in TSC2+/- animal model, which 
is naturally heterozygous for mutation in tumor suppressor genes, Tuberous Sclerosis 
Complex (TSC). The majority of tumors observed in the kidney of TSC2+/- mice originate 
from renal proximal tubules develop around age of 12 months. We have generated a new 
mouse model of TSC2+/-/dbdb-/- by cross breed TSC2+/- and dbdb mice to investigate 
whether diabetes accelerates tumors in new mouse model at early ages.
Results: At the day of sacrificing, WT and TSC2+/- mice showed normal blood 
glucose levels (80-109 mg/dL), while db/db and TSC2+/-/dbdb mice showed ranges of 
hyperglycemia between 405-510mg/dL measured by Glucometer in overnight fasting 
animals. Our novel in vivo data showed for the first time that diabetes accelerates kidney 
tumor size to 4-fold and number to 2-fold in TSC2+/-/dbdb new mouse model compared to 
TSC2+/- mice at 10 months old. Data show that no significant difference in tumor size and 
number between TSC2+/-/dbdb and TSC2+/- mice at age of 8 months. We didn’t recognize 
any tumor in WT and db/db mice at this age. Next, we performed RNA sequencing in RNA 
isolated from kidney cortex of WT, db/db, TSC2+/- and TSC2+/-/dbdb mice at age of 10 
months. The sequencing data show different patterns of downregulation and upregulation of 
several genes between TSC2+/-/dbdb, TSC2+/- and dbdb compared to WT mice that have 
significant interest in regulation of tumorigenesis.
Conclusions: Our data provided in vivo evidence of role of diabetes in accelarting 
kidney tumorigeneis. These data suggest that short term of diabetes is not effective to 
enhance tumorigenesis in TSC2+/-/dbdb mice and longer exposure to hyperglycemia is 
required to initiate tumorigenesis. These data confirmed for the first time that diabetes is a 
major risk factor for increasing kidney cancer.
Funding: Veterans Affairs Support
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Relationship Between Endothelial Damage and Expression of Tropomyo-
sin on Peritubular Capillary During the Progression of Experimental 
Obstructive Nephropathy
Ken Kitamura,1,2 Kentaro Nakai,3,2 Hideki Fujii,2 Shinichi Nishi.2 1Kita-Harima 
Medical Center, Ono, Japan; 2Kobe University Graduate School of Medicine, 
Kobe, Japan; 3Fukuoka Red Cross Hospital, Fukuoka, Japan.
Background: Tubulointerstitial injury(TI) is a major determinant factor in progressive 
renal diseases. Although the injuries to peritubular capillary (PTC) network is crucial for the 
progression of TI, it has been few reported about marker for detecting endothelial damage 
on PTC. We investigated expression of Tropomyosin (TM), one of the actin-associated 
proteins on PTC during the progression of experimental obstructive nephropathy.
Methods: Male Wister rats (7 week old) were subjected to UUO or sham-operation, 
and kidneys were harvested on days 3, 7 and 14 post-surgery after pimonidazole infusion 
for evaluation of low oxygen area. We evaluated the expression of TM on PTC by 
immunostaining and immunoelectron microscopy. And real-time polymerase chain reaction, 
and western blot were performed. To clarify the mechanism, we assessed the expression of 
TM in human umbilical vein endothelial cells (HUVEC) exposed to hypoxia condition.
Results: The expression of TM on PTC significantly increased on day 3, reached a peak 
at day 7, and decreased on day14 by immunostaining. Also, TM was identified at cytoplasm 
of PTC by immunoelectron microscopy 7 days after operation, not identified in sham rats. 
In UUO, TM significantly expressed at low oxygen area, tended to co-express with Ki67. 
We confirmed the increased expression of TM in the whole kidney. In HUVEC, 12 hours 
hypoxia condition induced the expression of TM in immunofluorescent staining.
Conclusions: TM is a protein related to angiogenesis and increased the expression 
on PTC at the early stage of TI. This fact suggested TM might be a marker of endothelial 
damage on PTC to play a work for the protection against hypoxia damage.
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Oral Administration of Paramylon, a β-1,3-D-Glucan Isolated from 
Euglena gracilis Z Protects Against Renal Damage in CKD Rats
Yoshikuni Nagayama,1 Mizuki Yamano,1 Ayaka Nakashima,2 Kengo Suzuki,2 
Katsuyuki Matsui.1 1Teikyo University Mizonokuchi Hospital, Kawasaki, Japan; 
2euglena Co.,Ltd., Tokyo, Japan.
Background: Paramylon is a β-1,3-D-Glucan that is stored by Euglena gracilis Z and 
a large porous molecule and plays various roles in chemical storage, ion exchange, and 
as a molecular sieve. It has been demonstrated to have anti-allergy effects and enhance 
immunological functions. Now available treatments are limited in the progression of chronic 
kidney disease (CKD). The aim of this study is to investigate the effect of Paramylon in 
CKD rats.
Methods: CKD was induced in 8-week-old male Wistar rat by 5/6 nephrectomy (Nx). 
A normal diet was given for 8 weeks in Sham control or in Nx rats. A diet containing 5% 
paramylon (PAR) obtained from euglena Co., Ltd was given for 8 weeks in Nx + PAR rats.
Results: There were no significant differences of the body weight, diet intake, and 
water intake between Nx and Nx + PAR groups. Increases in serum urea nitrogen and 
urinary protein excretion in Nx were significantly suppressed in Nx + PAR. Nx + PAR 
also showed histologically milder disease when compared to Nx (glomerular sclerotic score 
1.8±0.4 vs. 0.9±0.2, means±SEM, p<0.05; tubular injury score 2.8±0.3 vs. 1.0±0.2, p<0.05; 
fibrosis area (%) 4.0±0.7 vs. 2.7±0.5, p=0.15; the number of interstitial PCNA-positive cells 
per high-power field 72±10 vs. 36±6.5, p<0.05).
Conclusions: Our data suggest that Paramylon may be a novel compound against the 
progression of renal damage in CKD rats.
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Altered Expression of the Renal Prostaglandin E2 Signaling System in 
Kidney Tissue from Patients with Hydronephrosis and Renal Fibrosis
Kirsten Madsen,1 Signe S. Tofteng,1 Amalie Kamstrup mogensen,2 Boye Jensen.1 
1University of Southern Denmark, Odense C, Denmark; 2Department of 
Cardiovascular and Renal Research, Institute of Molecular Medicine, University 
of Southern Denmark, Odense, Denmark.
Background: Renal fibrosis is the final common pathway in chronic kidney diseases 
(CKD). Increased prostaglandin E2-EP4 receptor signaling through increased EP4 receptor 
expression has been suggested to attenuate renal fibrosis in mice using the unilateral ureteral 
obstruction (UUO) model. It is unknown if patients with hydronephrosis and renal fibrosis 
show similar regulation of the renal prostaglandin E2 signaling system. We tested the 
hypothesis that hydronephrosis and renal fibrosis is associated with increased renal COX-2 
and EP4 receptor expression in humans.
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Methods: Kidney tissue was collected from patients diagnosed with hydronephrosis 
undergoing unilateral nephrectomy (n=12) at the Dept. of Urology, Odense University 
Hospital. Normal appearing kidney tissue from age- and gender matched subjects 
undergoing nephrectomy due to renal cell carcinoma (n=12) was used as control. The 
percentage of the cortical region affected by interstitial fibrosis was scored and expression 
of the prostaglandin E2 signaling system was determined by qPCR.
Results: Mean age was 54 years [range 26-78 years] in the hydronephrosis group 
and 55 years [range 28-78 years] in the control group. All patients in the control group 
showed minimal or no signs of renal fibrosis (0-10%). In the hydronephrosis group, 4 
patients showed mild (10-25%), 3 patients moderate (26-50%) and 2 patients severe 
fibrosis (50-100%). 3 patients showed minimal or no signs of renal fibrosis. No significant 
changes in COX-2, COX-1 or PTGES mRNA was detected. In kidney cortex, a significant 
upregulation of EP2 receptor mRNA was detected in the hydronephrosis group compared to 
controls and a concomitant downregulation of the EP3 receptor mRNA level. No significant 
changes in EP1 or EP4 receptor mRNAs were seen. In outer medulla, a significantly reduced 
expression of the EP3 receptor was seen in the hydronephrosis group. No changes in EP 
receptor expression were seen in the inner medulla.
Conclusions: In conclusion, hydronephrosis and renal fibrosis in humans is associated 
with altered renal EP2 and EP3 receptor expression. No changes were detected in COX-2 
and EP4 receptor expression as has been described in mice. Results suggest the EP2 and 
not the EP4 receptor to be dominant in PGE2 receptor signaling during renal fibrogenesis 
in humans.
Funding: Private Foundation Support
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Mechanisms of High Salt Intake-Increased (Pro)renin Receptor Expres-
sion in the Nephron of Dahl Salt-Sensitive Rats
Seiko Yamakoshi,1,2 Osamu Ito.3,2 1Nikko Medical Center, Dokkyo Medical 
University, Nikko, Japan; 2Tohoku University Graduate School of Medicine, 
Sendai, Japan; 3Tohoku Medical Pharmacetical University Faculty of Medicine, 
Sendai, Japan.
Background: We recently reported that high-salt (HS) intake increased the (P)RR 
expression by 3-5 fold in several nephron segments of Sprague-Dawley rats (Peptides 
63: 156-162, 2015). The present study examined the mechanisms of the HS-intake increased 
(P)RR expression in Dahl-Salt sensitive (DS) rats.
Methods: Male DS rats were fed a normal salt (NS) diet (0.6%NaCl) and a HS diet
(8%NaCl) for 4weeks. A part of the rats fed the HS diet were treated orally with xanthine 
oxidase (XO) inhibitor, febuxostat (Feb, 10mg/kg/day) or mineralocorticoid receptor (MR) 
antagonist, spironolactone (Spi, 100mg/kg/day). Additionally, deoxycorticosterone acetate 
(DOCA, 50mg/kg/week) administered to DS rats fed the NS diet for 4weeks. The (P)RR 
expression in the kidney sections and proximal tubules (PT) was examined by immunoblot 
and immunohistochemical analyses. XO activity in the CO was measured.
Results: HS intake increased the blood pressure, and Feb and Spi decreased the HS 
intake-increased blood pressure (p<0.01). HS intake increased the XO activity by 1.7 fold 
(p<0.01), and febuxostat blocked completely the activity. HS intake increased the (P)RR 
expression in the cortex by 22.6 fold (p<0.001) and the PT by 4.9 fold (p<0.01). Feb and 
Spi inhibited the HS intake-increased (P)RR expression in the cortex by 55% and 89%, 
respectively (p<0.001). Feb inhibited the HS intake-increased (P)RR expression in the PT 
by 69% (p<0.001), but Spi did not change the expression. Immunohistochemical analysis 
revealed that HS intake increased the (P)RR expression in the PT and distal tubules (DT) 
and that Feb inhibited the expression in the PT, and Spi inhibited the expression in the DT. 
In addition, DOCA increased the (P)RR expression in the cortex by 80% (p<0.001) and the 
DT, but not in the PT.
Conclusions: HS intake-increased (P)RR expression is enhanced in the PT and distal 
tubules of DS rats. The mechanisms of HS intake-increased (P)RR expression may be MR-
dependent manner in the DT and XO-dependent manner in the PT.
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Olmesartan Attenuates Kidney Injury in Experimental Alport Syndrome
Eun Hui Bae,2 Injin Kim,2 Jihong Song,2 Seong Kwon Ma,2 James W. Scholey,1 
Soo Wan Kim.2 1University of Toronto, Toronto, ON, Canada; 2Chonnam 
National University Medical School, Gwangju, Republic of Korea.
Background: As angiotensin-converting enzyme 2 (ACE2) was identified as a 
negative regulator of the renin-angiotensin-aldosterone system, there have been many 
reports concerning its role in several tissues, including kidney. We have reported that ACE2 
expression and activity in the kidney are reduced in experimental Alport syndrome (AS) and 
olmesartan has known as increased ACE2 activity.
Methods: To examine the effects of olmesartan treatment in AS, we used the Col4a3–/– 
mice. Mice were divided into three groups: saline-treated wild type mice group, saline-
treated Col4a3–/– mice, and Ang-(1-7) treated Col4a3–/– mice group. Olmesartan medoxomil 
(5 mg/kg/day) was administered from 4 to 7 weeks of age via drinking water.
Results: Treatment with olmesartan led to decreased urinary NGAL excretion in 
7-week-old Col4a3–/– mice. Pathological changes were attenuated by olmesartan treatment.
Olmesartan ameliorated kidney fibrosis as shown by decreased expression of profibrotic 
genes, less accumulation of extracellular matrix proteins, and inhibition of TGF-β signaling. 
Further, increases in proinflammatory cytokine expression, macrophage infiltration, 
inflammatory signaling pathway activation, and heme oxygenase-1 (HO-1) levels in 
Col4a3–/– mice were also reduced by olmesartan treatment. Lastly, olmesartan influenced 
the turnover of renal ACE2, as it suppressed expression of TNFα-converting enzyme
(TACE), a negative regulator of ACE2.
Conclusions: In summary, treatment with olmesartan alters angiotensin peptide 
metabolism in kidneys of Col4a3–/– mice and attenuates the progression of AS nephropathy.
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Therapeutic Targeting of GSK3β Rectifies Profibrogenic Plasticity of 
Renal Tubular Epithelial Cells in Progressive CKD
Bohan Chen,1,2 Pei Wang,1 Lance D. Dworkin,2 Zhangsuo Liu,1 Rujun Gong.2 
1The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 
2University of Toledo Medical Center, Toledo, OH.
Background: Renal tubular cells play a key role in chronic kidney injury. After a 
prolonged persistent injury beyond self-healing capacity, renal tubular cells will resort 
to maladaptive plasticity and undergo dedifferentiation, growth arrest and convertion to 
profibrogenic phenotypes that ultimately lead to renal fibrosis. Evidence suggests that 
glycogen synthase kinase (GSK) 3β is centrally implicated in kidney injury. However, its 
role in maladaptive renal tubular cell plasticity is unknown and was explored here.
Methods: In cultured renal tubular cells expressing diverse GSK3β mutants or treated 
with GSK3β inhibitors, TGFβ1-induced phenotypic changes were evaluated. In mice with 
tubular specific knockout of GSK3β or in mice treated with microdose lithium folic acid-
induced chronic kidney injury was examined.
Results: TGFβ1 treatment triggered renal tubular cell dedifferentiation, marked by 
conversion from cuboidal to dispersed spindle shape, loss of cell tight junction molecules 
like E-cadherin and ZO-1, and de novo expression of vimentin. In addition, growth 
inhibition was noted as shown by cell cycle arrest at G2/M phase. Moreover, increased 
extracellular matrix proteins like collagen I and fibronectin, as well as overproduction of 
profibrotic cytokines, such as PAI-1 and CTGF, was evident after TGFβ1 exposure. All 
these profibrogenic phenotypes were reinforced in cells expressing the constitutively active 
mutant of GSK3β, but largely abolished by ectopic expression of a dominant negative 
mutant or by GSK3β inhibitors. Mechanistically, GSK3β blockade potentiated CREB 
activity and subsequently antagonized the TGFβ1/Smad signaling, which drives tubular 
cell profibrogenic plasticity. Moreover, structural rather than transcriptional β-catenin was 
up-regulated after GSK3β inhibition, denoting a strengthened cell tight junction. So did 
cyclin D1, an essential element for cell cycle progression. In vivo, in folic acid-injured mice, 
tubular cell dedifferentiation, G2/M arrestrenal and PAI-1 and CTGF expression were all 
mitigated by GSK3β gene ablation or by microdose lithium, a standard GSK3b inhibitor, 
concomitant with attenuated tubular atrophy and renal fibrosis.
Conclusions: GSK3β is likely a pragmatic therapeutic target for correcting 
profibrogenic plasticity of renal tubular cells in CKD to improve renal fibrosis.
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Proximal Tubule ATR in Humans and Mice Is a Key Regulator of the 
DNA Repair Response Protecting the Kidney Against Maladaptive Repair 
and Fibrosis After Tubular Injury
Seiji Kishi,2,1 Craig R. Brooks,3 Takaharu Ichimura,1 Kenji Nishimura,2 
Ryuji Morizane,1 Joseph V. Bonventre.1 1Brigham & Women’s Hospital/Harvard 
Medical School, Boston, MA; 2Nephrology, Tokushima University Hospital, 
Tokushima, Japan; 3Vanderbilt University Medical Center/Division of 
Nephrology & Hpertension, Nashville, TN.
Background: Renal proximal tubular epithelial cells (RPTECs) comprise the bulk 
of the renal parenchyma and are the primary target of a variety of insults to the kidney. 
Maladaptive repair of RPTECs has been implicated in kidney fibrosis through induction 
of cell cycle arrest at G2/M. The DNA damage response (DDR) is a mechanism of DNA 
repair that is responsible for maintaining genome integrity. We hypothesize that inhibition 
of DDR, through deletion of the DNA damage sensor ataxia telangiectasia and Rad3 related 
(ATR), would worsen the fibrotic response in RPTECs.
Methods: Human kidney biopsy tissue was analyzed from 11 patients with interstitial 
fibrosis and elevated serum creatinine and 9 cases with minor glomerular abnormalities and 
good preservation of tubules. Kidney organoids were generated from human pluripotent stem 
cells. An active form of ATR and the marker of DNA damage (γH2AX) were studied by 
immunocytochemistry along with KIM-1 to evaluate whether DDR correlates with eGFR or 
fibrosis. We generated RPTC-specific conditional ATR knockout (ATRRPTC-/-) mice by crossing 
ATR floxed (ATRfl/fl) with ATR+/– and tamoxifen-inducible RPTC-CRE driver (SLC34a1-
CreERT2) mice and evaluated kidney injury, fibrosis and cell cycle arrest following ischemia/
reperfusion, cisplatin and ureteral obstruction-induced injury in these mice.
Results: Humans with chronic fibrotic kidney disease and human kidney organoids 
treated with cisplatin have activation of ATR and extensive DNA damage in proximal 
tubules with an inverse correlation between p-ATR and DNA damage marked by γH2AX 
in human biopsies. ATRRPTC-/-mice exhibited greater kidney functional impairment, DNA 
damage, and fibrosis in response to kidney injury induced by either bilateral ischemia 
reperfusion, cisplatin or unilateral ureteral obstruction. ATRRPTC-/-mice had increased G2/M 
arrested cells after these kidney injuries.
Conclusions: DDR is activated in human kidney disease and ATR plays a protective 
role against tubular cell injury, death and fibrotic response. Proximal tubule ATR activation 
is a key component of the DDR which confers a protective effect by mitigating maladaptive 
repair and consequent fibrosis that follows kidney injury.
Funding: NIDDK Support, Government Support - Non-U.S.
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Molecular Mechanisms of CKD - I
Proximal Tubule Angiotensin II Type 1 Receptor-Associated Protein 
Regulates Kidney Aging and Lifespan Through Sirtuin1-Mediated 
Pathway
Takahiro Yamaji,1 Kazushi Uneda,1 Sho Kinguchi,1 Kohji Ohki,1 Ryu Kobayashi,2 
Kengo Azushima,1 Hiromichi Wakui,1 Yoshiyuki Toya,1 Kouichi Tamura.2 
1Yokohama City University, Yokohama, Japan; 2Yokohama City University 
Graduate School of Medicine, Kanazawa-Ku, Japan.
Background: The kidney is easily affected by aging-associated changes including 
tubulointerstitial fibrosis and tubular atrophy. Angiotensin II type 1 receptor (AT1R)-
associated protein (ATRAP), which was originally identified as a molecule that binds to 
AT1R, is highly expressed in the kidney. Previously, we have shown that ATRAP suppresses 
hyper-activation of AT1R signaling, but does not affect the physiological AT1R signaling 
pathway. This time, we hypothesized that proximal tubule ATRAP suppresses aging-related 
kidney fibrosis through Sirtuin1-mediated pathway independent of angiotensin signaling.
Methods: ATRAP-knockout mice (KO mice) and their wild-type control mice 
(WT mice) were fed the standard diet and maintained until death to estimate their life spans. 
Their growth, physiological parameters and aging-related organ damages in the hearts, 
aortas and kidneys were analyzed in both groups. To further investigate the mechanism 
exacerbating aging-related kidney fibrosis in KO mice, the expression of the pro-survival 
genes was examined using human tubular epithelial cells.
Results: KO mice exhibit a normal age-associated appearance without any evident 
alterations in physiological parameters, including blood pressure and cardiovascular and 
metabolic phenotypes. However, in KO mice compared with wild-type mice, the following 
takes place: (1) age-associated renal function decline and tubulointerstitial fibrosis are more 
enhanced; (2) renal tubular mitochondrial abnormalities and subsequent increases in the 
production of reactive oxygen species are more advanced; and (3) lifespan is 18.4% shorter 
(median lifespan: 100.4 vs. 123.1 week). As a key mechanism, age-related pathological 
changes in the kidney of KO mice correlated with decreased expression of the pro-survival 
gene Sirtuin1. Furthermore, in cultured human proximal tubular epithelial cells, deletion of 
ATRAP also downregulated mRNA expression levels of Sirtuin1 under serum starvation 
condition.
Conclusions: These results indicate that proximal tubule ATRAP regulates renal 
Sirtuin1 expression and plays an important role in inhibiting aging-related kidney changes 
and protecting the normal lifespan.
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Dicer Deficiency in Proximal Tubules Exacerbates Renal Injury and 
Tubulointerstitial Fibrosis in Diabetes and UUO Models by Upregulating 
Smad2/3 Expression
Zhengwei Ma,1 Qingqing Wei,1 Zheng Dong.2 Augusta University 1Medical 
College of Georgia, Augusta University, Augusta, GA; 2Medical College of 
Georgia, Augusta, GA.
Background: Renal fibrosis is a common pathological feature in chronic kidney 
disease, including diabetic kidney disease (DKD) and obstructive nephropathy. Multiple 
microRNA species have been implicated in the pathogenesis of both DKD and obstructive 
nephropathy. Dicer is a key RNase III enzyme for microRNA biogenesis, which has been 
shown to play an important role in kidney development and renal ischemia-reperfusion 
injury. However, the role of Dicer in diabetic and obstructive kidney diseases remain 
unclear.
Methods: Dicer was specifically ablated from Kidney proximal tubules in mice by 
breeding Dicer-floxed mice with PEPCK-Cre mice. Proximal tubule Dicer knockout 
(PT-Dicer-KO) mice and wild-type (WT) mice were subjected to STZ treatment to induce 
DKD or unilateral urethral obstruction (UUO) to examine renal hypertrophy, renal injury 
and fibrosis.
Results: We found that Dicer-KO in proximal tubules deteriorated renal interstitial 
inflammation, tubular injury, and tubolointerstitial fibrosis without significantly affecing 
renal hypertrophy following STZ treatment. Dicer-KO exacerbated renal injury and 
tubolointerstitial fibrosis in the UUO model as well. At the molecular level, Dicer deficiency 
induced Smad2/3 expression in proximal tubules, which may contribute to the enhanced 
tubolointerstitial fibrosis in both STZ-diabetes and UUO models.
Conclusions: Our results provide further support for the regulatory role of Dicer and 
associated microRNA production in the development of chronic renal pathologies in DKD 
and obstructive nephropathy. Dicer deficiency may up-regulate Smad2/3 and increase renal 
apoptosis to enhance the progression of chronic kidney disease.
Funding: NIDDK Support, Veterans Affairs Support
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Lactate Induced Interstitial Fibroblasts Activation and Extracellular 
Matrix Accumulation in Folic Acid Induced AKI
Lei Jiang,2 Yan Shen,1 Junwei Yang.2 1Nanjing Medical University, Nanjing, 
China; 2Second Affliliated Hospital, Nanjing Medical University, Nanjing, 
China.
Background: Recent studies have indicated a substantial proportion of acute kidney 
injury (AKI) patients may undergo chronic kidney disease (CKD) in long term follow-
up. However, the mechanisms are still unclear. Previous evidences affirmed that interstitial 
myofibroblasts play a key role in AKI-CKD transition. In previous tests, we observed folic 
acid (FA) injection could induce extracellular matrix (ECM) deposition. Further researches 
revealed tubular epithelial and interstitial cells proliferate after FA-AKI and the later was 
significantly delayed than the former. Meanwhile, we confirmed there was active glycolysis 
in proliferative tubular epithelial cells and secreted abundant lactate after FA-AKI injury. 
Thus, we speculated the glycolysis metabolic end-product lactate secreted by injured renal 
tubular epithelial cells induced the activation of interstitial fibroblasts and led to ECM 
accumulation in folic acid AKI models.
Methods: We checked whether lactate itself could induce fibroblasts activation 
and express fibrotic proteins. In vivo, rat kidney fibroblast (NRK-49F) were exposed to 
lactate at different concentration and time interval, harvested and subjected to different 
detection methods. Secondly, different glycolytic inhibitors 2-deoxyglucose (2-DG) and 
oxamate were explored in FA treatment mice. Lactate production at acute injured phase was 
measured. We further verified whether ECM deposition was alleviated after suppressing 
lactate production. Finally, we preliminary explored the possible molecular mechanisms of 
lactate in the activation of interstitial fibroblasts.
Results: Lactate could induced NRK-49F cells activation and expressed abundant 
fibrotic proteins such as alpha-smooth muscle actin (α-SMA), fibronectin (FN). Both 2-DG 
and oxamate could inhibit the production of lactate by renal tubular epithelial cells and 
alleviated FA-AKI associated ECM deposition. The protective effects improved with the 
dose increased and 2-DG seemly more excellent. Lactate may stimulate fibroblasts via 
altering fibroblasts energy metabolism or affecting proliferative associated cells growth 
factors expression in fibroblasts.
Conclusions: Lactate secreted by injured renal tubular epithelial cells may play a key 
role in the activation of fibroblasts and ultimately led to abundant ECM accumulation in 
folic acid induced acute kidney injury.
Funding: Government Support - Non-U.S.
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Hepatic Alkaline Phosphatase Activity Is Increased in CKD and Is 
Regulated by the Intestinal Microbiota
Cassandra R. Johnson, Ogorchukwu F. Omede, Jason R. Stubbs. University of 
Kansas Medical Center, Kansas City, KS.
Background: Patients with chronic kidney disease (CKD) exhibit a pro-inflammatory 
phenotype that may partially result from intestinal dysbiosis and gut barrier dysfunction. 
A major function of liver alkaline phosphatase (ALP) is the neutralization of microbial 
toxins that enter the portal circulation from the intestine. The purpose of this study was to 
characterize expression and activity levels of liver ALP in both mice and humans with CKD, 
and explore the role of the intestinal microbiota in regulating ALP activity.
Methods: We first assessed liver ALP expression (Western blot) and function (ALP 
activity assay) in two CKD mouse models (Col4a3-/- and adenine diet) and non-CKD 
controls. Next, we confirmed the generalizability of our findings to humans by assessing 
ALP expression and function in liver samples from deceased tissue donors with advanced 
CKD or normal kidney function (n=10/group). Lastly, we performed fecal transplant studies 
to examine how repopulating the intestine of wild-type mice with microbiota from either 
CKD or control mice impacted liver ALP expression and function.
Results: CKD mice (Col4a3-/- model) exhibited a 50% higher liver ALP protein 
expression (P<0.05), that was accompanied by a 10-fold greater liver ALP activity (CKD 
3,140 vs. non-CKD 294 mU/mg protein; P<0.001). Similar findings were observed in 
mice with CKD induced by chronic adenine ingestion. Despite markedly higher liver ALP 
activity in CKD mice, serum ALP activity was equal between CKD and non-CKD mice. 
Next, we observed 3-fold higher liver ALP activity in human CKD livers (CKD 6,624,488 
vs. non-CKD 2,459,531 mU/mg protein; P=0.09), but no obvious difference in total 
protein expression. Lastly, transplantation of CKD stool into wild-type mice resulted in 
substantially higher liver ALP protein expression and ALP activity compared to wild-type 
mice transplanted with non-CKD stool (ALP activity: CKD stool 5,104 vs. non-CKD stool 
863.4 mU/mg protein; P<0.05).
Conclusions: Both mice and humans with CKD exhibit higher liver ALP activity that 
may be partially stimulated by factors derived from the CKD microbiome. We speculate 
that enhanced liver ALP activity is important for neutralizing microbial toxins that enter the 
portal circulation as a result of gut dysbiosis and barrier dysfunction in CKD.
Funding: NIDDK Support
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PI3K/Akt/NFκB Signaling Pathway Might Be the Potential Injury 
Pathway in IgG4-Related Urinary Disease
Fei Teng, Ke Zheng, Xuemei Li. Peking Union Medical College Hospital, 
Beijing, China.
Background: Diffuse lymphocytes infiltration and diverse inflammatory factors 
activation represent the inflammation status of IgG4-related disease(IgG4-RD), while 
its specific pathogenesis remains confusing, especially in IgG4-related urinary disease 
(IgG4-RUD). This study aims to preliminarily investigate the potential inflammatory and 
injury pathway of IgG4-RUD via urinary exosomes.
Methods: Four untreated biopsy proven IgG4-RUD inpatients, two IgG4-RD patients 
without urinary system involvement(disease control, DC) and two healthy controls(HC) 
were enrolled from Feb to May, 2018 in Peking Union Medical College Hospital. Disease 
activity was assessed using IgG4-RD Responder Index(RI). Urinary exosomes were 
isolated from fresh morning urine via ultracentrifugation method. Two-color Western 
blot was conducted to semi-quantify the expression of mTOR, PI3K, Akt, NFκB, Fas and 
caspase3 in urinary exosomes. Image data were analyzed using Image Studio Ver.5.2.
Results: Among the IgG4-RUD inpatients, two were diagnosed of retroperitoneal 
fibrosis, one of IgG4-related kidney disease and the other of IgG4-related ureteral lesion. 
All patients denied diabetes mellitus, other autoimmune disease and cancer history. Mean 
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disease duration was 67.5 months(6-120). For clinical parameters, mean serum IgG4 was 
12307.5mg/L(3030-17900), IgG 27.76g/L(22.02-38.06), SCr 419.1μmol/L(146-690), and 
24hUP 0.93g(0.43-1.23). Serological inflammatory markers as ESR 59.75mm/h(8-109), 
hsCRP 3.18mg/L(2.12-7.16). All patients were disease active with mean RI of 8(6-10). 
Compared with DC or HC group, the mean expression of PI3K(5300 vs 22.55 vs 437), 
Akt(22200 vs 1935 vs 2008), NF-κB(5455 vs -22.5 vs 259) and Fas(11517.5 vs 67.35 
vs 176) were all obviously higher in urinary exosomes of IgG4-RUD, and caspase3 was 
expressed only in the ureteral lesion patient. mTOR was not detected.
Conclusions: Urinary exosomes could be a noninvasive injury indicator for 
IgG4-RUD, and PI3K/Akt/NFκB signaling pathway might play a part in tissue injury.
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Multiparametric MRI for Assessment of CKD: Correlation with Histology 
and Progression
Charlotte E. Buchanan,1 Huda Mahmoud,3,2 Eleanor Cox,1 
Benjamin L. Prestwich,1 Nicholas M. Selby,3,2 Maarten W. Taal,3,2 Susan Francis.1 
1Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, 
Nottingham, United Kingdom; 2University of Nottingham, Derby, United 
Kingdom; 3Royal Derby Hospital Renal Unit, Derby, United Kingdom.
Background: Multiparametric Magnetic Resonance Imaging (MRI) allows non-
invasive assessment of renal structure and function in CKD. Here, MR results are correlated 
with biopsy and clinical measures at baseline, with repeat scanning after 1 year to assess 
progression.
Methods: 26 CKD patients (Stage 3-4, eGFR 20–59ml/min/1.73m2, 19M, 56±15yrs) 
were scanned within a median 53 days from renal biopsy, data were also collected on age-
matched healthy volunteers (HVs). At baseline, patients were scanned twice, two weeks 
apart, to assess reproducibility. Histological fibrosis quantification was performed on renal 
biopsies with sirius red staining to measure % interstitial fibrosis (IF). GFR was determined 
using Iohexol clearance and urine PCR was measured. Clinical and MRI assessments were 
repeated at 1 year. Scanning was performed on a 3T Philips Ingenia scanner and included T1 
mapping and diffusion weighted imaging as markers of fibrosis and inflammation, arterial 
spin labelling to assess perfusion, T2* mapping as a marker of oxygenation, and measures 
of kidney volume and renal artery flow. Analysis was performed using in-house software to 
create multiparametric maps. Baseline MR data were assessed against clinical measures and 
biopsy results, year 1 data was analysed to assess progression.
Results: Cortex T1 was significantly increased in CKD patients compared to HVs 
(CKD:1559±18,HV:1435±19ms, p<0.001). Cortex diffusion was reduced in CKD patients, 
but not significantly. There was no significant difference in kidney volume or T2* between 
CKD patients and HVs. Cortex perfusion (CKD:86.8±10,HV:199.5±12ml/100g/min) 
and renal artery flow (CKD:156.9±10,HV:227.4±10ml/100g/min) were significantly lower 
in CKD (p<0.001). GFR was correlated with cortex perfusion, diffusion, T1 and renal 
artery flow. The strongest MRI measure to correlate with IF score was perfusion, whilst 
glomerular sclerosis correlated with cortex T1. The mean GFR did not vary significantly 
across 1 year, however patients fell into 2 groups; those with improved (n=8) and declined 
(n=12) renal function. There was a trend for change in T1 to be associated with progression 
of disease severity.
Conclusions: This work demonstrates MRI can differentiate pathophysiological 
changes in CKD and can be used as a method to assess progression of CKD.
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SerpinA3K Is Abnormally Found in Urine of Patients with CKD from 
Different Etiologies
Andrea Sanchez-Navarro,1,2 Rosalba Pérez-villalva,1,2 Juan M. Mejia-Vilet,2 
Diego L. Carrillo Perez,2 Gerardo Gamba,1,2 Norma Bobadilla.1,2 1Molecular 
Physiology Unit, México, Mexico; 2IIB UNAM/INCMNSZ, Mexico, Mexico.
Background: We previously identified serpinA3K by high-resolution mass 
spectrometry as an early biomarker of acute kidney injury to CKD transition in rats. This 
study was designed to determine whether serpinA3K could be abnormally detected in urine 
from CKD patients and to evaluate its specificity in kidney diseases, compared with urines 
from patients with other pathologies without renal dysfunction.
Methods: We included 74 patients with CKD of different etiologies such as: FSGS, 
class III, IV or V lupus nephritis (LN), ANCA associated vasculitis (AAV), and diabetic 
nephropathy (DN) that were compared with 10 healthy volunteers. In addition, we 
included 17 patients with other pathologies and normal renal function: hepatic cirrhosis 
(HC), pancreatitis (Pan), and rheumatoid arthritis (RA). SerpinA3K was evaluated in urine 
(Western blot) and in renal biopsies (immunohistochemistry).
Results: In HC, Pan and RA patients without renal dysfunction urine serpinA3K 
was not detected. In Table 1 are the main results of the CKD patients. In addition, 
immunohistochemistry analysis showed that serpinA3K was expressed in tubular epithelial 
cells, and translocated from the cytoplasmic region to the luminal membrane in CKD 
patients.
Conclusions: Urinary serpinA3K was detected in all patients with CKD. Urine 
serpinA3K titers closely correlated with the renal fibrosis observed by histopathological 
analysis (p<0.0001). Moreover, this biomarker was able to differentiate between class 
III/IV and class V LN, in spite of severe proteinuria in these patients. These results suggest 
that urine serpinA3K comes from damaged kidney cells and could be used as a specific 
biomarker of ongoing renal inflammation, fibrosis and therefore CKD. SerpinA3K is found 
in the urine of CKD patients from different etiologies and correlates with renal fibrosis. 
SerpinA3K constitutes a specific promising CKD biomarker.
Funding: Government Support - Non-U.S.
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Levels of Biomarkers of Extracellular Matrix Turnover in Serum and 
Urine Reflect the Burden of Fibrosis in Kidney Biopsies from IgA 
Nephropathy and ANCA-Associated Vasculitis Patients
Federica Genovese,1 Nadja Sparding,1 Morten A. Karsdal,1 Doubravka Frausova,2 
Eva Honsova,3 Vladimir Tesar,4 Zdenka Hruskova.5 1Nordic Bioscience, Herlev, 
Denmark; 2Department of Nephrology, First Faculty of Medicine, Charles 
University and General University Hospital in Prague, Czech Republic, Prague, 
Czechia; 3IKEM, Prague, Czechia; 4General University Hospital in Prague, 
Prague, Czechia; 5Department of Nephrology, General University Hospital and 
First Faculty of Medicine, Charles University, Prague 2, Czechia.
Background: Renal fibrosis is a common feature of chronic kidney disease (CKD) 
and is characterized by an imbalanced turnover of extracellular matrix (ECM) components. 
It is associated with progression to end-stage renal disease, the need for dialysis or renal 
transplantation and with mortality. ECM biomarkers describing the morphological changes 
in the kidney tissue are potentially detectable in serum and urine before markers of loss of 
kidney function, such as serum creatinine, due to the fact that changes in the tissue precede 
and are the cause of changes in function.
Methods: The cohort consisted of 49 and 47 patients with IgA nephropathy (IgAN) and 
anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), respectively. 
We measured a fragment of collagen type III degradation generated by MMP-9 (C3M) and 
a fragment of type VI collagen formation, the C5 domain of the α3 chain (PRO-C6), in 
paired serum and urine samples using novel ELISAs. Renal biopsies were taken at the time 
of sample collection. Interstitial fibrosis was quantified according to the Banff classification, 
and in addition, scored according to the MEST-C classification (IgAN) or classified based 
on AAV morphology (AAV).
Results: Urinary C3M inversely correlated (r=-0.43, p<0.0001) and PRO-C6 
(in urine and serum) correlated (r=0.51, p<0.0001 and r=0.35, p=0.0009, respectively) with 
the level of histological fibrosis in the kidney. Whereas urinary C3M decreased, PRO-C6 
increased with CKD stages and Banff scores in both patients with IgAN and AAV. In IgAN 
patients, urinary C3M and PRO-C6 (in urine and serum) gradually decreased and increased, 
respectively, with interstitial fibrosis/tubular atrophy according to MEST-C. In addition, 
all three ECM markers were able to separate the AAV patients with biopsies classified as 
sclerotic from patients with biopsies classified as focal.
Conclusions: In this study, we demonstrated that C3M and PRO-C6, novel biomarkers 
of ECM turnover, not only correlated with decline in kidney function, but actually reflect the 
burden of fibrosis in the kidneys, as confirmed by the association with the extent of kidney 
fibrosis in biopsies.
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Sequential Changes of Gut Microbiota According to the Stages of CKD
Ji Eun Kim,1 Ji In Park,2 Hyunjeong Cho,3 Dong Ki Kim,1 Seung Hee Yang,4 
Jung Pyo Lee,5 Yon Su Kim,1 Hajeong Lee.1 1Seoul National University Hospital, 
Seoul, Republic of Korea; 2Kangwon National University Hospital, 
Chuncheon-si, Republic of Korea; 3Chungbuk National University Hospital, 
Cheongju-si, chungcheongbuk-Do, Republic of Korea; 4Kidney Research 
Institute, Seoul National University, Seoul, Republic of Korea; 5Seoul National 
University Boramae Medical Center, Seoul, Republic of Korea.
Background: Recent evidences suggest that the microbiome profile is altered in 
patients with end-stage renal disease (ESRD) compared to healthy population. However, 
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sequential changes of gut microbiota according to the stages of chronic kidney disease 
(CKD) have been explored rarely.
Methods: We prospectively enrolled 139 patients including CKD patients underwent 
kidney biopsy, ESRD patients waiting for kidney transplantation, and 35 kidney donors 
from three tertiary hospitals. The composition of microbiota was analyzed using extracted 
metagenomic DNA from the feces by Illumina MiSeq system. Estimated glomerular 
filtration rate (eGFR) was calculated using CKD-EPI equation.
Results: Total of 194 subjects were enrolled and divided into 4 groups according to 
their renal function as follows; 55 healthy control, 47 CKD stage 1-2, 42 stage 3-5 without 
receiving dialysis, and 50 stage 5 with maintenance dialysis. The mean eGFR of each 
groups were 103.4±15.2, 93.3±17.4, 29.6±20.4, and 7.1±2.5 mL/min/1.73 m2, respectively. 
The bacterial operational taxonomic units, diversity and richness were significantly 
different among 4 groups. Next, we compared 35 genera, which account for more than 1% 
of the sample composition in at least 1/10 of the total samples, among groups. Fourteen of 
the 35 genus groups showed significant differences among groups. Among those genera, 
Alistipes, Pseudoflavonifractor, Ruminococcus_g4 and Hungatella showed statistically 
significant increasing trend according to CKD groups and Lachnospira, Dialister and 
Haemophilus showed statistically significant decreasing trend according to the CKD groups 
with or without CKD 5D. Blautia showed an increasing trend according to the CKD group, 
but when the CKD 5D was included, the trend disappeared. Compared with CKD3-5ND 
and CKD 5D, Prevotella, Bifidobacterium and Agathobacter decreased after dialysis, 
and Clostridium and Pseudoflavonifractor increased after dialysis. The genera showing a 
change by dialysis and the genera showing a trend according to CKD stage showed different 
patterns except for Pseudoflavonifractor.
Conclusions: We found specific fecal microbiotas that changed according to the CKD 
stage, and they differed from the microbiota which was altered by dialysis. Further studies 
on the association of these microbiotas with CKD progression are needed.
TH-PO912 Poster Thursday
Molecular Mechanisms of CKD - I
Glycolysis Inhibitors Suppress Renal Interstitial Fibrosis via Divergent 
Effects on Fibroblasts and Tubular Cells in Kidneys
Qingqing Wei,1 Jennifer J. Su,3 Zheng Dong.2 1Medical College of Georgia, 
Augusta University, Augusta, GA; 2Medical College of Georgia, Augusta, GA; 
3Augusta University, Martinez, GA.
Background: Renal interstitial fibrosis is a common pathological feature of chronic 
kidney disease that may involve changes of the metabolism in kidney cells.
Methods: In this study, we first showed that blockade of glycolysis with two inhibitors 
[Dichloroacetate-DCA and shikonin] reduced renal fibrosis in the mouse model of unilateral 
ureteral obstruction (UUO).
Results: Both inhibitors evidently suppressed the induction of fibronectin and collagen 
1 in obstructed kidneys, while DCA also showed inhibitory effect on collagen IV and 
a-SMA. Histological examination also confirmed less collagen deposition in DCA treated 
kidneys. We also examined renal apoptosis by TUNEL assay and identified significant 
suppression of apoptosis after glycolysis blockage by both DCA and shikonin. We further 
examined their effects on fibrotic changes in cultured renal proximal tubular BUMPT cells
and renal NRK-49F fibroblasts (cells). While glycolysis inhibitors reduced fibronectin and 
a-SMA production in NRK-49F cells, no obvious effect or even induction of fibronectin or 
a-SMA was detected in BUMPT cells during TGF-b1 or hypoxia stimulation.
Conclusions: Altogether, these results suggest that inhibition of glycolysis may reduce 
renal interstitial fibrosis by suppressing renal apoptosis and fibrotic alterations in fibroblasts.
Funding: NIDDK Support, Veterans Affairs Support
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Uremic Toxin Decreases Intestinal Defense Peptides and Barrier Functions 
in Chronic Renal Failure Mice
Minoru Satoh,1 Seiji Itano,1 Megumi Kondo,2 Yoshihisa Wada,2 
Hiroyuki Kadoya,1 Tamaki Sasaki,1 Naoki Kashihara.1 1Kawasaki Medical 
School, Kurashiki, Japan; 2Nephrology and Hypertension, Kawasaki Medical 
School, Kurashiki, Japan.
Background: Alterations of intestinal bacterial flora and intestinal barrier function in 
chronic kidney disease (CKD) have been reported to affect on uremic toxin influx. However, 
alteration mechanisms of microbiota and intestinal barrier have not been elucidated. 
Antimicrobial peptide contributes to maintenance of microbiota. We examined whether 
uremic toxin decreases intestinal antimicrobial peptide and barrier function in chronic renal 
failure model mice.
Methods: We used male ICR-derived glomerulonephritis (ICGN) mice for renal 
failure group. Gene expression in ascending colon was analyzed by microarray analysis 
and quantitative real-time PCR (qPCR). Gene expression patterns of a whole bacterial 
flora in the intestine were analyzed by terminal restriction fragment length polymorphism 
analysis method. Fecal and serum bacteria products (phenol, para-cresol, indole/indole 
sulfateand skatole) were examined by quantitative chemical analysis. In vitro experiment, 
Caco-2 cells were exposed to indoxyl sulphate at clinically relevant concentrations 
(0.1-0.5 mM). Expressions of defensins and tight junction molecules were analyzed by 
qPCR and ELISA.
Results: Microarray analysis showed antimicrobial peptide, defensin, significantly 
decreased in ICGN mice. Defensin alfa1 and beta1 mRNA expressions in ascending 
colon were reduced in ICGN mice compared with control mice. The ratio of pathogenic 
bacteria clostridia was increased, and the ratio of opportunistic pathogen bacteroides was 
decreased in intestinal bacterial flora of ICGN mice. Fecal bacteria products phenol and 
para-cresol were increased in feces of ICGN mouse. Barrier function associated molecules, 
such as C-type lectin and tight junction, were significantly decreased in ICGN. Intestinal 
permeability in ICGN was increased compared to ICR mice. Indoxyl sulphate significantly 
decreased the expressions of C-type lectin and tight junction in Caco2 cells. Indoxyl 
sulphate also significantly decreased defensin mRNA and protein expression in Caco2 cells.
Conclusions: Uremic toxin decreases intestinal antimicrobial peptides which induce 
gut microbiome alteration in CKD. Uremic toxin also decreases intestinal barrier function 
molecules which increase Intestinal permeability in CKD. Both are combined and contribute 
to the loss of intestinal barrier function in CKD.
Funding: Government Support - Non-U.S.
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Hyperoside Diminishes Tubulointerstitial Fibrosis in Obstructive 
Nephropathy via Targeting Pericyte-Myofibroblast Transition
Yigang Wan, Wei Wu. Department of Traditional Chinese Medicine, Nanjing 
Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical 
School, Nanjing, China.
Background: Pericyte-myofibroblast transition (PMT) plays an important role 
during the progression of tubulointerstitial fibrosis (TIF) in chronic kidney disease 
(CKD). Blocking PMT has been recognized as a potential target for anti-fibrotic therapy. 
In China, hyperoside (HYP), a bioactive component of Abelmoschus manihot, has been 
frequently used to treat TIF in CKD patients. However, the therapeutic mechanisms 
in vivo of the dose-effects of HYP on TIF by targeting PMT and its signaling activation 
remained unclear.
Methods: Twenty-five rats were divided into 5 groups, the sham, the vehicle, the 
high dose of HYP, the low dose of HYP and the imatinib groups. The different doses of 
HYP, imatinib and distilled water were administrated with intraperitoneal injections or 
oral for 2 weeks before and after the induction of TIF by unilateral ureteral obstruction 
(UUO), respectively. Rat’s general status, 24 h urinary protein, urinary N-acetyl-beta-D-
glucosaminidase, blood biochemical parameters, tubulointerstitial morphological changes, 
the markers of PMT such as platelet-derived growth factor receptor (PDGFR)β, α-smooth 
muscle actin (αSMA) and vimentin, as well as the key signaling molecular expressions in 
PDGFR pathway and vascular endothelial growth factor receptor (VEGFR) pathway in the 
kidney were observed, respectively.
Results: TIF was induced in the obstructed kidneys of the UUO model rats. PMT was 
triggered, marked by the increased expressions of PMT markers in peritubular pericytes. 
In addition, TIF was aggravated by PMT and could be significantly improved by the high 
dose of HYP and imatinib in vivo, reflected by inhibiting PMT markers’ expressions in 
peritubular pericytes and attenuating ECM accumulation and collagen deposition in renal 
interstitium. HYP and imatinib could block PMT through inhibiting PDGFR and VEGFR 
signalings activation. Furthermore, the effects of HYP at the high dose were partially 
superior to those of imatinib.
Conclusions: In this study, we clarified that the high dose of HYP, superior to imatinib, 
can attenuate TIF through blocking PMT and inhibiting the key signaling molecular 
expressions in PDGFR and VEGFR pathways. These findings may partly explain the 
therapeutic mechanisms of HYP in treating CKD, and further suggest that targeting PMT 
and its signaling activation may provide new strategies for TIF treatment in CKD.
Funding: Veterans Affairs Support, Government Support - Non-U.S.
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Honokiol decreases TGF-β1 Induced Renal Fibroblast Activation by 
Regulation of TGF-β1/Smad Signaling Pathway
Woong Park, Won Kim, Kyung Pyo Kang. Chonbuk National University 
Medical School, Jeonju, Republic of Korea.
Background: In progressive renal disease, tubulointerstitial fibrosis is a final common 
feature. These fibrotic process is characterized by inflammation, excessive extracellular 
matrix deposition and organ dysfunction. Modulation of renal fibrogenesis may be one of 
the promising therapeutic targets for attenuating the progression of chronic kidney diseases. 
Honokiol is a natural biphenolic compound derived from the bark of magnolia trees and 
has anti-inflammatory, anti-oxidative, anti-tumor and neuroprotective effects. In this study, 
we investigate the effect of honokiol on TGF-β1-induced real fibroblast activation and 
unilateral ureteral obstruction (UUO)-induced renal fibrosis.
Methods: Renal fibrosis was induced by UUO in the six-week-old C57BL/6 mice for 
10 days. Honokiol (5 mg/kg) was treated by intraperitoneal injection for 7 days before 
induction of renal fibrosis and continued for 10 days. Histologic examination and Western 
blot analysis for α-smooth muscle actin (α-SMA), type I collagen and intercellular adhesion 
molecule (ICAM)-1 were performed. In vitro experiments were performed using rat renal 
fibroblast cell line (NRK-49F cells). Cell proliferation and migration were evaluated by 
XTT assay and wound healing assay. TGF-β1-induced renal fibroblast activation was 
evaluated by Western blot analysis.
Results: Treatment of TGF-β1 increased significantly proliferation and cell migration 
of NRK-49F cells compared to that of vehicle treated cells. Honokiol treatment decreased 
TGF-β1-induced renal fibroblast proliferation and activation in a dose dependent manner. 
TGF-β1 treatment increased the levels of phospho-Smad2 and 3 in NRK-49F cells, and 
honokiol significantly decreased the levels of phosphorylation of Smad2 and 3. In in vivo 
experiment, honokiol decreased UUO-induced renal tubular injury and renal fibrosis. 
Honokiol also decreased UUO-induced renal inflammation by regulation of phosphorylation 
of NFκB p65.
Conclusions: These results suggest that honokiol has a beneficial effect on UUO-
induced tubulointersitial inflammation and fibrosis by regulation of TGF-β1/Smad 
signaling pathway.
Funding: Government Support - Non-U.S.
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6-BIO Attenuates TGFβ-Induced Fibrosis by Suppression of Transcription 
Factor AP-1 and SP-1 of Plasminogen Activator Inhibitor Type-1 in the 
Human Renal Proximal Tubular Epithelial Cells
Jung Sun Park,1 Hoon In Choi,2 Donghyun Kim,3 Eun Hui Bae,3 Seong
Kwon Ma,2 Soo Wan Kim.2 1Chonnam National University, Gwangju, Republic 
of Korea; 2Chonnam National University Medical School, Gwangju, Republic of 
Korea; 3Chonnam National University Hospital, Gwangju, Republic of Korea.
Background: PAI-1 is expressed at high levels in several both acute and chronic kidney 
diseases, and leading to activation of lung, liver, kidney fibrosis. We investigated whether 
6-BIO, a glycogen synthase kinase-3β inhibitor, attenuates fibrosis by PAI-1 inhibition in 
TGFβ-induced proximal tubular (HK2) cells injury.
Methods: The effects of 6-BIO in TGFβ-induced cell fibrosis were determined using 
human renal proximal tubular epithelial (HK-2) cells. The effects of TGFβ and 6-BIO on 
cell viability were determined using EZ-CyTox assays. The protein and mRNA expression 
of PAI-1, Collagen I, Collagen IV, CTGF, SMAD, PI3K/AKT, MAPK, and NF-κB was 
determined by semiquantitative immunoblotting and RT-PCR. To study the factors that 
regulation of PAI-1 expression, we analyzed the promoter activities of transcription factors 
AP-1 and Sp-1 were determined by luciferase assays.
Results: Treatment of TGFβ increase expression of PAI-1, Collagen I, Collagen IV, and 
CTGF in HK-2 cells. Furthermore, TGFβ-treatment induces the activation of p-SMAD2/3, 
SMAD4, p-AKT, p-ERK1/2, p-p38, and p-JNK MAPK signal pathway as well as NF-κB 
nuclear transactivation. AP-1 and SP-1 promoter luciferase activity is increase by TGFβ 
treatment. 6-BIO pretreatment decreases PAI-1, Collagen I, Collagen IV, CTGF fibrotic 
protein expression in TGFβ-induced HK-2 cells. 6-BIO decreases the increased NF-κB 
nuclear transactivation, p-SMAD2/3, SMAD4, p-AKT, p-ERK1/2, p-p38, and p-JNK 
MAPK pathway in HK-2 cells. Additionally, pretreatment of 6-BIO attenuates AP-1 and 
SP-1 promoter activity.
Conclusions: Treatment of 6-BIO may exert anti-fibrotic effect by controlling SMAD, 
PI3K/AKT, MAPK, and NF-κB signal pathways via inhibition of the transcription factor 
AP-1 and SP-1 of PAI-1 in TGFβ-treated HK-2 cells.
Funding: Government Support - Non-U.S.
TH-PO917 Poster Thursday
Molecular Mechanisms of CKD - I
Lymphangiogenesis Within Kidney and Its Draining Lymph Nodes 
Mediates Renal Inflammation and Fibrosis
Pei Guangchang,2 Rui Zeng,1 Gang Xu.2 1Tongji Hospital, Huazhong Univ of 
Science and Technology, Wuhan, China; 2Tongji Hospital, Tongji Medical 
College, Huazhong 9 University of Science and Technology, Wuhan, China.
Background: Lymphangiogenesis has been reported in kidney transplant and chronic 
kidney diseases (CKD). Here, we demonstrate a crucial role for the newborn lymphatic 
vessels (LVs) within kidney and its draining lymph nodes (RDLNs) in driving intrarenal 
inflammation and fibrosis.
Methods: In the present study, we examined the lymphangiogenesis within 
kidney and RDLNs in different renal interstitial fibrosis models. Conditional 
knockdown of LVs in LYVE-1-Cre/iDTR mice and knockdown of lymphangiogenesis by 
sVEGFR3-FC or sLYVE-1-FC were adopted to observe the relationship between LVs with 
renal inflammation and fibrosis. CCR7 neutralizing antibody were used to blocking CCR7/
CCL21, to further explore the role of CCR7/CCL21 in immunocytes recruitment.
Results: Lymphangiogenesis occurs in kidney and its DLNs after renal injury, 
which mainly results from the local proliferation of pre-existing lymphatic endothelium. 
The newborn LVs like the inherent LVs essentially express C-C chemokine ligand 
21 (CCL21). The expansive LVs system play an important role in the recruitment of more 
CCR7+ dendritic cells(DCs) and lymphocytes into RDLNs and spleen, and finally inducing 
systemic lymphocyte expansion. Blocking CCR7+ cell recruitment into RDLNs and spleen 
by genetically or biologically knockdown of LVs, or inhibiting CCR7+ cell expansion using 
CCR7 neutralizing antibody, attenuated intrarenal inflammation and fibrosis.
Conclusions: We show a previously unidentified role for lymphangiogenesis in 
regulating intrarenal inflammation and fibrosis, which uncovered novel strategies for 
preventing CKD progression.
Funding: Government Support - Non-U.S.
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Inhibition of Fibronectin Polymerization Attenuates Ischemia-Induced 
Kidney Fibrosis
Stephanie L. Bowers, Stephanie Davis, Valeriia Rudomanova, Qing Ma, 
Prasad Devarajan, Burns C. Blaxall. Cincinnati Children’s Hospital Medical 
Center, Cincinnati, OH.
Background: Fibrosis is a hallmark of chronic kidney disease (CKD), regardless of 
pathophysiologic origin. After injury, activation of tissue fibroblasts leads to increased 
extracellular matrix (ECM) deposition and adverse tissue remodeling. Fibronectin (FN) 
is a vital component of the ECM that orchestrates the composition and organization of 
numerous matrix and cell surface proteins. The current study tested the hypothesis that 
treatment with the peptide pUR4, which inhibits cell-mediated FN polymerization, would 
mitigate ischemia-induced tissue remodeling and preserve renal morphology.
Methods: A mouse model of unilateral ischemia/reperfusion (UIR) injury was created 
by placement of an atraumatic clamp on the left renal artery for 30 minutes, followed by 
14 days of reperfusion. Daily IP injections of pUR4 (25mg/kg), control inactive peptide 
(III-11C; 25mg/kg) or PBS were started on the same day (concomitant), or 7-days post-
UIR (delayed). After 14 days, mice were sacrificed and both the left (injured) and right 
(uninjured) kidneys were collected; animals were assessed for evidence of injury by 
histology and immunofluorescence.
Results: Inhibition of FN polymerization with delayed (but not with concomitant) 
pUR4 treatment decreased renal FN expression and deposition following UIR (1.0 (III-
11C) vs. 0.56 (pUR4), p=0.01, n=4 each). Delayed pUR4 administration alleviated the 
characteristic UIR-induced decrease in kidney weight (5.4 vs. 6.5mg/kg body weight, 
p=0.009; n=12 for III-11C, n=14 for pUR4). Moreover, delayed pUR4 decreased cortical 
fibrosis (by picrosirius Red staining) compared to III-11C (12.1 vs. 6.0%, p=0.0009, n=12 or 
14, respectively) but not medullary fibrosis (20.2 vs. 14.4%, p=0.18). Histologic evaluation 
also revealed preserved tubule morphology with delayed pUR4 treatment.
Conclusions: Collectively, these experiments provide evidence that decreasing FN 
polymerization may attenuate the progression of CKD following renal ischemic injury.
Funding: Other NIH Support - NHLBI - T32, Private Foundation Support
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Inhibition of Fibronectin Fibrillogenesis Attenuates Progression of 
Fibrosis in Animal and Kidney Organoid Models
Cuiyan Xin,2 Navin R. Gupta,3 Amrendra K. Ajay,1 Akinwande A. Akinfolarin,1 
Edgar Garcia,1 Ryuji Morizane,1 Joseph V. Bonventre,1 Venkata Sabbisetti.1 
1Brigham and Women’s Hospital, Boston, MA; 2Brigham and Women’s Hospital, 
Harvard Medical School, Boston, MA; 3Brigham & Women’s Hospital/
Massachusetts General Hospital, Brighton, MA.
Background: Renal fibrosis is the principal pathological process underlying the 
progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD). Fibronectin 
(FN) assembly is required for collagen matrix deposition and localized activation of TGF-ß. 
We hypothesize that interfering with FN polymerization would attenuate fibrosis in in vitro 
and in vivo kidney fibrosis models.
Methods: Mice were subjected to unilateral ureteral obstruction (UUO) and treated 
with fibronectin polymerization blocking peptide (pUR4) and control peptide (CIII-11C) to 
evaluate the therapeutic benefit of blocking FN assembly in attenuating or reversing fibrosis 
progression. We evaluated the efficacy of pUR4 peptide in attenuating kidney fibrosis in 
two different treatment modalities. In parallel treatment model, we evaluated the therapeutic 
efficacy in halting or slowing the progression of fibrosis by injecting pUR4 (i.p, 100 mg/
kg) & CIII-11C (i.p, 100 mg/kg) from day 5 - day 10 post-UUO every day. In successive 
treatment model, we evaluated the efficacy of the pUR4 in halting or reversing the 
established fibrosis by giving pUR4 from day 10 – day 15 post-UUO. Mice were sacrificed 
at the end of the study and urine, blood and tissues were collected. Efficacy of pUR4 peptide 
was also evaluated in cisplatin induced kidney organoid models of fibrosis.
Results: In vivo, pUR4-treatment reduced fibrosis in both parallel and successive 
model of UUO induced fibrosis. pUR4 treated mice display reduced picrosirius red 
staining as compared to & CIII-11C treated mice in both treatment modalities. There was 
a corresponding decrease in urinary markers including KIM-1, MCP-1, IL-6, NGAL and 
microalbumin in pUR4 treated mice in both the models. Levels of collagen 1, α-SMA 
and CTGF were significantly reduced in pUR4 treated mice in both the models. In kidney 
organoids, pUR4 treatment diminished fibrilogenesis and accumulation of fibronectin and 
collagen after repetitive cisplatin injury induced fibrosis.
Conclusions: In the current study, we demonstrated that blocking fibronectin 
fibrillogenesis halts progression of kidney disease in experimental models of kidney 
fibrosis. Thus, interfering with the FN polymerization may offer a new therapeutic strategy 
for treating kidney fibrosis
Funding: NIDDK Support
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SMOC2 Mediates Renal Fibrosis by Activation of Inflammation and 
Fibroblast to Myofibroblast Differentiation
Cuiyan Xin. Vaidya Lab Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA.
Background: Fibrosis is a common end stage of nearly all chronic inflammatory 
organ diseases including chronic kidney diseases (CKD). Secreted modular calcium-
binding protein 2 (SMOC2) belongs to the secreted protein acidic and rich in cysteine 
(SPARC) family of matricellular proteins whose members are known to modulate 
cell-matrix interactions. SMOC2 has been shown to contribute to CKD by regulating 
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initiation and progression of kidney fibrosis. We therefore investigated the mechanisms 
responsible for signaling activation pathways by SMOC2 resulting in its fibrogenic effect.
Methods: To determine SMOC2 expression in CKD, three mice CKD models were 
employed: Alport nephropathy mice model (caused by a null mutation of the a3 chain 
of collagen type IV), RNA-Seq was performed to determine extracellular matrix genes 
in this model; Parabiotic aging model generated by parabiosis sugery for 4 weeks and 
unilateral ureter obstruction (UUO) surgery in 5 and 10 days, separately; Sequential 
ischemia-nephrectomy CKD model was generated by bilateral ischemia reperfusion 
(Bi-IRI) and unilateral nephrectomy surgeries time-dependently. RT-PCR and western-blot 
were employed to determine fibrotic gene mRNA and protein expression in these three 
models. To investigate the mechanism of SMOC2 triggered fibrogenesis and activation of 
fibrogenic signaling pathways, SMOC2 protein was used to stimulate interstitial fibroblasts 
and human primary proximal tubular epithelial cells.
Results: We found that SMOC2 is in the top 10 DEGs of extracellular matrix genes 
in Alport mice. SMOC2 gene and protein were highly expressed in Col4a3 knockout (KO) 
mice tissue compared to wildtype (WT) mice. Furthermore, SMOC2 over expression 
in fibrosis was also confirmed in parabiotic-UUO kidney disease model and in-house 
developed CKD model. Mechanistically, SMOC2 activates Smad and MAPK signaling 
in fibroblast and proximal tubular epithelial cells, which are both inhibited by TGFbRI 
inhibitor (SB431542) and MAPK p42/44 inhibitor (U0126). SMOC2 also promotes 
inflammatory gene expression such as IL-6 and TNFa.
Conclusions: SMOC2 is a key signaling molecule mediating fibrogenesis, and 
modulating of SMOC2 may provide a new potential therapeutic target for chronic kidney 
diseases.
Funding: NIDDK Support
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K-Cadherin Expression Regulates Activation State of Transcription 
Factors in the Presence and Absence of TGF-β1
Kameljit K. Kalsi,1 Seema Jain,1,2 Mysore K. Phanish,1,2 Mark E. Dockrell.1 
1South West Thames Institute for Renal Research, Carshalton, United Kingdom; 
2Epsom and St Helier University Hospitals NHS Trust, Carshalton, London,
United Kingdom.
Background: K-cadherin (Cadherin 6) is an atypical type I cadherin with high 
expression in the kidney where it is exclusively expressed in the proximal tubule. Unlike 
other cadherins in the tubule K-cadherin is expressed basally directly adjacent to the 
basement membrane. Disruption and loss of renal K-cadherin expression is associated 
with progressive diabetic nephropathy. Disruption of the precise cellular localisation has 
been reported in Renal Cell Carcinoma. Recently we have reported a similar disruption 
in biopsies from renal transplants. The alteration of K-cadherin expression in cancer and 
fibrosis suggests a potential role in regulating gene expression.
Methods: HKC clone 8 cells, a transformed human PTEC line which do not have 
detectable K-cadherin protein, were transfected with human K-cadherin pcDNA3.1 
expression vector (1μg). Cells were fixed and stained for K-cadherin and visualized by 
using a 3D deconvolution microscope. Primary human PTECs (K-cadherin positive), 
control HKC8 (HKC8 K-) and transfected HKC8 cells (HKC8 K+) were grown on non-
coated plastic and collagen IV coated dishes and exposed to 2.5 ng/ml TGF-β1 for 5 min 
before cells were lysed and analysed by western blot.
Results: HKC8 K+ cells showed K-cadherin expression similar to that expected in 
primary cells, localised in vesicular Golgi-type structures as well as at the cell periphery 
and was predominantly found in the basal layer. Regulation of important transcription 
factors Elk1, Erk5a & Erk5b were investigated. TGF-β1 induced an increase of phospho-
Elk1 in HKC8 K- cells grown on collagen IV but a reduction in phospho-Elk1 in HKC8 
K+ cells. The expression of K-cadherin had no effect on TGFβ-induced phospho-Elk1 in 
cells grown on plastic. In primary PTECs grown on collagen IV TGFβ1 reduced phospho-
Elk1 levels. Although TGFβ1 induces phosphorylation of Erk5a it has no effect on the 
levels of activated (phosphorylated) Erk5b. However, the expression of K-cadherin alone 
significantly increased phospho-Erk5b.
Conclusions: The basal expression of K-cadherin appears to be critical in regulating 
transcription factor activation in human primary proximal tubule cells due, at least in part, to 
its interaction with collagen IV. Disrupted expression seen in cancer and during renal injury 
will result in alteration of gene activation and cellular responses.
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Latent Transforming Growth Factor Beta Binding Protein 4 (LTBP4) 
Deficiency Attenuates the Severity of Renal Fibrosis
Chi-Ting Su,1,2 Jenq-wen Huang.1 1Renal Division, National Taiwan University 
Hospital, Taipei, Taiwan; 2Human Genetics, University of Pittsburgh, Pittsburgh, 
PA.
Background: Transforming growth factor beta (TGFβ) has been proved to be related 
to fibrosis including renal fibrosis that is characterized by the accumulation of extra-cellular 
matrix (ECM). LTBPs are recognized to direct and facilitate TGFβ action through several 
mechanisms. Moreover, the complexity of progression of renal injury remains vague. The 
intensive investigation of the mechanism will lead us understand the potential therapy for 
patients. We propose that ltbp4 can be an essential regulatory factor in renal injury because 
of its variety.
Methods: To create renal fibrosis model, we did unilateral ureteral ligation (UUO) 
in mice and check echocardiography to exam the cardiac contractility every other weeks. 
Ltbp4S-/- mice were used to investigate the potential regulatory role of ltbp4 in renal fibrosis 
related to TGFβ signaling. Protein and RNA extraction were collected for real-time PCR, 
RNA-Seq, and down-stream signaling, protein-protein interaction, and proteomics analysis.
Results: Up-regulation of ltbp4 had been noted 14 days after UUO at gene and protein 
levels. The major area of ltbp4 expression in the renal tissue was around proximal tubules 
areas and glomerular area was absent of expression. In addition, α-smooth muscle actin 
(SMA), kidney Injury Molecule-1 (KIM-1) and monocyte chemoattractant protein-1 
(MCP-1) expression at mRNA level increased significantly following the UUO surgery but 
in ltbp4S-/- mice, the expression had been drastically reduced. KIM-1, pSMAD2, pEKR 
and platelet-derived growth factor receptors beta (Pdgfrb) were increasing at protein levels 
after renal injury. Immunofluorescence staining studies revealed less expression of Pdgfrb, 
F4/80 and collagen I in ltbp4S-/- mice. TGFB receptors are speculated to be interacted with 
ltbp4, leading to abnormal down-stream signaling in ltbp4-deficient environments.
Conclusions: Reduced macrophage infiltration had been noted in renal injury tissue 
among post-UUO surgery ltbp4S-/- mice. Moreover, renal myofibroblasts expressed less 
Pdgfrb. In ltbp4-deficient environment, the severity of inflammation and renal injury 
induced by UUO can be reduced.
Funding: Government Support - Non-U.S.
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Cleavage of the Matricellular Regulators of Fibrosis, CCN2, and 3 at the 
Third Intermodular Junction
Abigail Dear,1 Mysore K. Phanish,3 Frederick W. Tam,2 Mark E. Dockrell.1 
1South West Thames Institute for Renal Research, Surrey, United Kingdom; 
2Imperial College Kidney and Transplant Institute, London, United Kingdom; 
3Epsom and St helier University Hospitals NHS Trust, Carshalton, London, 
United Kingdom.
Background: CCN proteins are modular matricellular factors with roles in cancer and 
fibrosis. Members of the family consists of 4 modules encoded by 4 exons. The strucuture 
contributes to their role regulating interactions between cells and matrix. CCN2/CTGF is 
a fibrogenic factor with actions in the lung, liver, skin and kidney. CCN3 is reported to 
counterbalance the actions of CCN2. We have previsouly described the expression and anti-
fibrotic effects of CCN3 on proximal tubule cells when we also identified a truncated form 
consisiting of just the first 3 modules. Here we investigate the enzymatic truncation of both 
CCN2 & 3 and the resultant effects.
Methods: Human primary proximal tubules were cultured on collagen IV. Protein 
expression was determined by western blotting and immunofluorescent microscopy. 
Bioinformatic analysis to identify potential cleavage sites was performed using expasy 
peptide cutter.. Mass spectrometry was carried out using 2D nano ES-MS/MS analysis after 
trypsin digestion.
Results: Enzymatic cleavage sites were identified between modules 3 & 4 of CCN2; 
two for glutamyl peptidase, and one each for HIV-1 retropepsin and MMP9. Accumualtion 
of secreted full-length CCN2 following TGFβ1 treatment dropped by 72 h following 
MMP9 induction. We hypotheised MMP9 was cleaving the protein. Co-incubation with 
the MMP9 specific inhibitor prevented the fall in full length molecule. Full length hrCCN2 
potentiated TGFβ-induced fibronectin expression while the 4th module of CCN2 reduced 
TGF β-induced fibronectin in primary PTEC in culture. Enzymatic cleavage sites were 
identified between modules 3 & 4 of CCN3 including two for cathepsin K and one for 
MMP9. Inhibition of MMP9 did not alter the amount of CCN3. Mass Spec analysis of the 
39KDa CCN3 isoform also suggrested cathepsin K.Cathepsin K is known to be induced by 
members of the TGFβ family.
Conclusions: The enxymatic cleavage of CCN2 & 3 acts a postranslational 
modiification altering the nature of the proteins..Although the potentially opposing factors 
share a putative MMP9 cleavage site the actually cleavage is performed by different 
enzymes. The induction of cleavage appears to be part of an endogenous regulatory 
process by TGFβ. Targeting the enzymatic cleavage of CCN proteins may be an alternative 
therapeutic approach in fibrosis and cancer.
Funding: Private Foundation Support
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Fibroblast-Specific p90RSK Promotes Epithelial Transdifferentiation and 
Kidney Fibrosis
Ling Lin, Chaowen Shi, Kebin Hu. Penn State University College of Medicine, 
Hershey, PA.
Background: Epithelial integrity and interactions between epithelial cells and other 
kidney cells play important roles in maintaining normal kidney structure and environment. 
p90RSK, a serine/threonine kinase, is recently shown to promote diabetic endothelial 
dysfunction and atherosclerosis, however, the role of p90RSK in chronic kidney disease 
remains largely unknown.
Methods: We generated a novel fibroblast-specific p90RSK transgenic mouse (RSK-
Tg) and established a fibroblast-epitheial coculture system using primary kidney fibroblasts 
from RSK-Tg and RSK-wt mice and human proximal tubular epithelial cells (HKC-8) to 
investigate the role of p90RSK in fibroblast-epitheial interactions and kidney fibrosis.
Results: First, we examined the expression of phospho-specific and total p90RSK 
during the course of chronic kidney injury in the classic unilateral ureter obstruction (UUO) 
model. It’s found that p90RSK is dramatically activated, largely in the interstitial FSP-
1-positive fibroblasts. We generated fibroblast-specific p90RSK transgenic mouse, RSK-
Tg, and found that this mouse has normal phenotype as the littermate control (RSK-wt).
However, after UUO injury, RSK-Tg mice display significantly worse tubular damage, 
decreased E-cadherin expression, and de novo activation of alpha-SMA, as well as increased
fibrosis, in comparison with their littermates. We further found, in our in vitro fibroblast-
epithelial coculture system, that RSK-Tg fibroblasts dramatically induced epithelial 
activation of β-catenin and its transdifferentiation into myofibroblasts, as indicated by 
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reduced E-cadherin and de novo expression of alpha-SMA. Intriguingly, blocking epithelial 
β-catenin using siRNA reversed epithelial transdifferentiation.
Conclusions: Thus, it is clear that fibroblast-specific p90RSK activation promotes 
the epithelial-to-mesenchymal transition (EMT) through activating epithelial β-catenin 
pathway.
Funding: NIDDK Support
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The Role of miR-21/Wnt in the Development of Renal Tubulointerstitial 
Fibrosis Secondary to Aristolochic Acid Induced AKI
Yi Fang,1,2 Qing Kuang,1 Sheng Wu,1 Ning Xue.1 1Zhongshan Hospital, Fudan 
University, Shanghai, China; 2Shanghai Medical Center of Kidney, Shanghai, 
China.
Background: AKI is increasingly recognized as a cumulative risk factor for 
developing advanced CKD. However, the factors governing the underlying mechanisms 
remain unclear. Previously we have found that the development of tubulointerstitial fibrosis 
after AKI was accompanied with an overwhelmed activation of miR-21 and canonical Wnt 
signaling, while inhibiting miR-21 or silencing Wnt ligands could partially attenuate AKI 
to CKD transition.
Methods: To explore the interaction between miR-21 and Wnt/β-catenin signaling, 
we exam the effects of genetic absence or pharmacologic inhibition of miR-21 on the 
expression of Wnt/β-catenin signaling pathway.
Results: In miR-21-/- mice, or in wild type mice treated with anti-miR-21 oligos, a 
significant reduction of Wnt1 and Wnt4 canonical signaling was found in the renal tissue, 
with partially reversal of renal interstitial fibrosis. Although renal abundance of miR-
21 remains unchanged either after inhibition or activation of Wnt/β-catenin signaling, 
down-regulation of β-catenin with early intervention of ICG-001, a typical β-catenin 
inhibitor was associated with significant attenuation in renal interstitial fibrosis, protein 
expression of genes coding extracellular matrix as well as the downstream genes of 
β-catenin. Moreover, inhibiting β-catenin within 24h after aristolochic acid administration, 
not at a late stage, also attenuated aristolochic acid induced apoptosis and inflammation.
Conclusions: In conclusion, these results suggest that inhibiting miR-21 and 
β--catenin signaling may be effective approaches to preventing AKI to CKD progression.
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miR-214-3p Is Activated in Fibroblasts in Progressive Renal Fibrosis
James O’Sullivan, Carolynn Cairns, Bryan Conway, Laura Denby. Denby 
University of Edinburgh, Edinburgh, United Kingdom.
Background: Renal fibrosis is referred to as the final common pathway of progressive 
kidney disease (Humphreys 2013). miR-214-3p has been demonstrated to be an important 
promoter of fibrosis in experimental renal fibrosis (Denby 2014) and may function as a 
therapeutic target. More in-depth study of miR-214’s renal cell-type specificity is needed 
in order to identify its deleterious mechanism in renal fibrosis. Gli1+ myofibroblasts in 
the kidney have recently been implicated as one of the main contributors to renal fibrosis 
(Humphreys 2015). The aim of this study was to identify which renal cell types express and 
upregulate miR-214 in response to renal injury.
Methods: Unilateral ureteral obstruction (UUO) or subtotal nephrectomy (STNx) 
was performed on mice (C57blk, SV129 or Gli1 reporter mice) and mice culled at 7 days 
(UUO), 6 or 10 weeks (STNx). During STNx model, metabolic cages were used to obtain 
urine. At cull, tissue was collected for RNA extraction, histology & FACS, and serum 
for biochemical analysis. Gene and miRNA expression was determined via qRT-PCR by 
specific primers and normalised to Ppia (gene) and U6 (miRNA).
Results: miR-214-3p expression significantly increased compared to sham in STNx 
and UUO models of renal fibrosis. This correlated with increased fibrosis histologically, 
pro-fibrotic gene expression (via qPCR) and biochemical markers of renal dysfunction (in 
STNx). Interestingly, miR-214-3p was significantly increased 6-weeks post STNx. LTL+ 
proximal tubular cells and Pdgfrb+ fibroblasts were found to be the source of miR-214 in 
UUO animals. STNx was performed on Gli1 reporter mice which revealed a significant 
increase in renal Gli1 (via FACS & qPCR). Here, miR-214 was upregulated with STNx in 
Gli1 +ve Pdgfrb -ve, Pdgfrb +ve Gli1 -ve, and dual +ve cells vs sham.
Conclusions: miR-214-3p is upregulated in proximal tubular cells, Pdgfrb+ve cells 
and Gli1+ve cells following renal injury. STNx kidneys had significantly increased miR-
214 expression, correlating with a significant increase in Gli1+ cells within the kidney. 
This expands on previous work which showed Gli1+ cells to be critical in the development 
of renal fibrosis in UUO and IRI models, demonstrating the expansion of these cells in a 
progressive model of renal fibrosis. These data will facilitate the investigation of miR-214-
3p’s mechanism and as a therapeutic target in renal fibrosis.
Funding: Commercial Support - Regulus Therapeutics, Private Foundation Support
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The Regulation of MicroRNAs on Galactose-Deficient IgA1 and Its 
Pathogenic Mechanism in IgA Nephropathy
Ludan Liang,1,2 Chunhua Weng.1,2 1Zhejiang University, Hangzhou, China; 
2Kidney Disease Center, The First Affiliated Hospital of Zhejiang University, 
Hangzhou, China.
Background: Abnormal increase of Gd-IgA1 is a recognized pathogenic factor 
of IgAN. Glycosylation of IgA1 is dependent on 3 key enzymes (C1GALT1, COSMC, 
ST6GALNAC2). Deposition of Gd-IgA1 in kidney mesangium causes IgAN, whereas 
the mechanism is not elucidated yet. This study focuses on how microRNA interfere IgA1 
glycosylation by targeting C1GALT1, and futher leading to mesangial cell malfunction, 
thereby shedding light on the mechanism of IgAN.
Methods: Part 1. 1) Screen candidate miRNAs targeting C1GALT1, verification of 
targeted regulation by Luciferase Reporter System, RT-PCR and Western Blot; 2) Change 
expression level of miRNA in DAKIKI cell, detect Gd-IgA1/IgA1 in the culture medium by 
ELISA; 3) Stimulate Human Mesangial Cells with Gd-IgA1 in vitro, analyse cell cycle by 
Flow cytometry. Part 2. 1) Analyse miRNA expression in PBMC, serum Gd-IgA1 level in 
IgAN and HC; 2) Conduct RNA-seq of glomerulus, analyse DEGs in different kidney cell 
types, especially in mesangial cells. Calculate DEGs expression change in HMC stimulated 
by Gd-IgA1.
Results: In Part 1, We screened out 6 candidate miRNAs possibly targeting 
C1GALT1. miR-152 most effecienty binds to C1GALT1 3’UTR region, inhibits 
C1GALT1 at both transcriptional and translational level. Overexpression of miR- 
152 mimics in DAKIKI obviously increases the Gd-IgA1/IgA1 in the culture medium. 
Stimulation of HMC by Gd-IgA1 drives the cell cycle towards S phase and G2/M phase, 
which possibly indicates cell proliferation. In Part 2, expression level of miR-152 was much 
higher in PBMC of IgAN than of HC. Gd-IgA1 serum concentration was obviously higher 
in IgAN than in HC. Subgroup analysis revealed that IgA1/IgA ratio is related to S-score 
in MEST-C Oxford classification system of IgAN. RNA-seq of glomerulus revealed 4 
DEGs (SERPINE1, USP2, SOX9, KLF6) closely related to mesangial cells. Stimualting 
HMC with Gd-IgA1 significantly increased the expression level of those 4 markers, among 
whom, increasement of SERPINE1 mRNA is the most remarkable, in a dose- and time-
dependent manner.
Conclusions: miR-152, which is highly expressed in PBMC of IgAN patients, 
obstructs the glycosylation process of IgA1 by targeting C1GALT1, resulting in elevation 
of Gd-IgA1, which will further stimulate kidney mesangial cells, increase the expression 
level of mesangial cell markers, especially SERPINE1, promote cell proliferation, finally 
leads to IgAN.
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Regulation of Renal Fibroblast Migration, Contraction, and  
Myofibroblast Differentiation by LPA-LPA1 Signaling via  
Specific G Proteins
Norihiko Sakai, Koichi Sato, Taito Miyake, Akihiro Sagara, Shinji Kitajima, 
Tadashi Toyama, Akinori Hara, Yasunori Iwata, Miho Shimizu, Kengo Furuichi, 
Takashi Wada. Department of Nephrology, Kanazawa University, Kanazawa, 
Japan.
Background: Renal fibrosis is a common pathway leading to end-stage renal disease 
regardless of etiologies. Pathologically, tissue fibrosis is characterized by the accumulation 
of fibroblasts/myofibroblasts and the excessive deposition and contraction of extracellular 
matrix. We have previously found the lipid mediator lysophosphatidic acid (LPA) and one 
of its receptors, LPA1, contributes to the development of renal fibrosis. However, the precise 
mechanisms by which LPA-LPA1 signaling activates renal fibroblasts (RFBs) remain to be 
determined.
Methods: In this study, we focused on the direct effects of LPA-LPA1 signaling on 
RFBs biologies, especially migration, contraction and myofibroblast differentiation. 
Cultured RFBs were used to examine cell migration, cell contraction and the expression of 
alpha smooth muscle actin (aSMA), a marker for myofibroblast differentiation, in response 
to LPA. RFBs were transfected with either LPA1 siRNA or control siRNA to determine the 
impact of LPA1 on RFBs biologies. In addition, we also investigated the involvement of G 
proteins in the LPA-LPA1 signaling-associated biologies of RFBs.
Results: RFBs treated with control siRNA were attracted by LPA in a dose-dependent 
manner, whereas LPA did not stimulate LPA1 siRNA-treated RFBs migration. In addition 
to RFBs migration, we also found that LPA directly induced cell contraction and aSMA 
gene expression by RFBs dependent on LPA1. To determine the involvement of G proteins 
in the LPA-LPA1 signaling, RFBs were transfected with siRNAs targeting G proteins. The 
chemotactic activity of LPA was significantly inhibited by siRNA treatment against Gai 
class of G proteins. In addition to that, pertussis toxin (an inhibitor of Gai) also blocked 
LPA-induced migration of RFBs. We also found that LPA-LPA1 signaling enhanced cell 
contraction and aSMA expression through Ga12/13 class of G proteins.
Conclusions: Our results suggest that LPA-LPA1 signaling directly modulates RFBs 
biologies dependent on specific G proteins in the pathogenesis of renal fibrosis.
Funding: Other U.S. Government Support
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CCN2 Module-IV Promotes Renal Fibrosis Through Activation of the 
FAK Pathway in the Tubular Epithelium
Hiroaki Amano, Tsutomu Inoue, Hirokazu Okada. Saitama Medical University, 
Saitama, Japan.
Background: CCN2 is known to mediate the profibrogenic actions of TGF-beta in the 
kidney. We previously demonstrated that CCN2 promotes renal fibrosis via its module-IV 
by using mutated-CCN2 knocked-in mice (CCN2m/m) expressing mutated CCN2 lacking 
module-IV. CCN2 was reported to use FAK, Smad2/3 and LRP6 to promote renal fibrosis. 
Among these, a significant decrease in p-FAK was found in primary skin fibroblasts derived 
from CCN2m/m compared with the wild-type cells. In this study, therefore, we examined 
possible downstream pathways through which CCN2 module-IV promotes fibrosis in the 
kidney.
Methods: Expression of candidate proteins involved in the early downstream pathways 
of CCN2 were measured by immunoblotting using kidney samples from CCN2m/m and 
wild-type mice with or without ureter obstruction (UUO). Additionally, the expression 
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and localization of other downstream proteins of the FAK pathway in those samples were 
examined by immunoblotting and immunohistochemistry.
Results: Expression levels of p-FAK, p-Smad2/3 and p-LRP6 were significantly 
higher in the fibrotic wild-type UUO kidney on day 7 in comparison with the sham-
operated control. However, p-FAK, but not p-Smad2/3 or p-LRP6, was significantly 
lower in the CCN2m/m UUO kidney compared with the wild-type UUO kidney 
(p-FAK/FAK: 1.1+/-0.1 vs. 2.6+/-0.4, p<0.01). Furthermore, mutant CCN2 showed 
significantly lower expression levels of p-Akt and total beta-catenin, which are considered 
downstream pathway proteins of pFAK, in the UUO kidney in comparison with the wild type 
(p-Akt/Akt: 0.1+/-0.1 vs. 0.6+/-0.2, p<0.03; beta catenin/GAPDH: 1.6+/-0.1 vs. 2.8+/-0.5, 
p<0.03). Immunohistochemistry revealed that FAK was activated in the tubular epithelium 
of the fibrotic wild-type UUO kidney, whereas these were significantly suppressed in the 
CCN2m/m UUO kidney.
Conclusions: CCN2 module-IV activates the FAK pathways in the tubular epithelium 
and, as a result, fibrosis is promoted in the UUO kidney. To prove this, primary tubular 
epithelial cells derived from CCN2m/m are being generated to examine the role of CCN2 
module-IV in vitro.
Funding: Commercial Support - Takeda Pharm., Chugai Pharm., Torii Pharm., 
Kyowa-Hakko Kirin, Pfizer, Boehringer Ingelheim, Astellas Pharm., Otsuka Pharm., MSD, 
Shionogi, Novartis, Sumitomo Dainippon Pharm., Mitsubishi Tanabe Pharm., Daiichi 
Sankyo Co., Government Support - Non-U.S.
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Insulin-Like Growth Factor Binding Protein 3 Specific Binding DNA 
Aptamer Attenuated Renal Tubular Fibrosis
Mi Jung Lee,1 Yubum Choi,1 Jung Tak Park,2 Tae-Hyun Yoo,3 Seung Hyeok Han,3 
Hyung Jong Kim.1 1CHA Bundang Medical Center, CHA University College of 
Medicine, Seongnam, SEOUL, Republic of Korea; 2Yonsei University Health 
System, Seodaemun-Gu, Seoul, Republic of Korea; 3Yonsei University College of 
Medicine, Seoul, Republic of Korea.
Background: Insulin-like growth factor binding protein 3 (IGFBP3) is a predominant 
IGFBP family member of six IGFBPs. Emerging evidence has indicated that IGFBP3 has 
cell- and tissue-specific effects, and it is an important mediator of fibrosis in various cell 
types and the organs. However, to date, the effect of IGFBP3 on renal fibrosis has not 
been fully evaluated. This study was to investigate whether IGFBP3 is involved in renal 
tubular fibrosis and IGFBP3 inhibition by aptamer treatment is effective for attenuating 
renal tubular fibrosis.
Methods: IGFBP3 and fibrosis-related protein expression were evaluated in 
unilateral ureteral obstruction (UUO) rats. In vitro, the proximal tubular cells (NRK-52E) 
were treated with TGF-β1 (10 ng/ml). IGFBP3 inhibition was performed by IGFBP3 
small interfering RNA (siRNA, 100 pmol/ml) and IGFBP3-binding DNA aptamer 
(200 pmol/ml) for 48 hours, respectively. Changes of fibrosis related protein expression 
were examined by real-time PCR and Western blot.
Results: IGFBP-3 and fibrosis-related protein expressions were up-regulated in the 
kidney of UUO rats. In TGF-β1-stimulated NRK-52E cells, IGFBP3 protein expression 
was increased in dose- and time-dependent manners. TGF-β1 treatment induced IGFBP3 
and fibrosis-related protein expression, including fibronectin and type I collage, in renal 
proximal tubule cell. IGFBP3 siRNA treatment significantly abrogated the increase in 
fibrosis-related protein expression induced by TGF-β1. Furthermore, the IGFBP3-binding 
DNA aptamer also significantly attenuated fibrosis-related protein expression up-regulated 
by TGF-β1 treatment.
Conclusions: This study suggests that IGFBP3 is significantly associated with 
pathogenesis of renal tubulointerstitial fibrosis. Furthermore, IGFBP3 aptamer treatment 
can be a potential therapeutic option for renal tubulointerstitial fibrosis in chronic kidney 
disease patients.
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Differences in Proximal Tubular Secretion Across Categories of CKD
Ke Wang,1 Leila R. Zelnick,2 Yan Chen,1 Andrew N. Hoofnagle,1 
Bryan R. Kestenbaum.1 1University of Washington, Seattle, WA; 2Kidney 
Research Institute, Seattle, WA.
Background: Absent a kidney biopsy, the cause of chronic kidney disease (CKD) 
is determined by clinical assessment, which includes measures of glomerular function 
(estimated glomerular filtration rate (GFR) and urinary albumin excretion). However, the 
underlying causes of CKD may also differentially impact non-glomerular tissue, including 
the proximal tubule. We quantified a set of proximal tubular secretory solutes and compared 
their clearances among varying causes of CKD.
Methods: We evaluated timed overnight urine specimens from 223 participants in 
the Seattle Kidney Study, a prospective study of CKD. We used liquid chromatography-
mass spectrometry to quantify serum and urine concentrations of ten secretory solutes and 
calculated clearance of each solute (mL/min). We abstracted CKD causes from review of 
nephrology clinic notes and categorized these causes as vascular, diabetic, glomerular, 
and tubulointerstitial kidney diseases. We used one-way analysis of variance to compare 
differences in solute clearances among the CKD causes and we advanced three solutes 
for further analyses based on meeting a 5% false discovery threshold. For each significant 
solute we used linear regression to compare the relative difference in secretory clearance 
among disease group after adjustment for age, race, gender, body mass index, estimated 
GFR, and urine albumin to creatinine ratio.
Results: Three secretory solutes met the threshold for significance across the suspected 
etiologies of CKD: isovalerylglycine, kynurenic acid, and tiglylglycine. Glomerular disease 
was associated with greater clearances of all three secretory solutes. Diabetic kidney disease 
was associated with greater isovalerylglycine clearance compared with vascular disease 
after adjustment (Table).
Conclusions: Secretory solute clearance relative to GFR is higher in CKD patients 
with glomerular disease compared to vascular disease.
Funding: NIDDK Support
*denotes statistical significance at p-value < 0.05
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Inactivation of KLHL3 Kelch Like Family Member 3 Ameliorates Renal 
Fibrosis in Unilateral Ureteral Obstructive Mice
Dae Eun Choi,1 Yoon-Kyung Chang,2 Hyunsu Choi,3 Jin young Jeong,1 Jae 
wan Jeon,4 Ki Ryang Na,5 Youngrok Ham,5 Jiwon M. Lee,1 Kang Wook Lee.5 
1Chungnam National University, Daejeon, Republic of Korea; 2The Catholic 
University of Korea, Daejeon, Republic of Korea; 3Daejeon St. Mary’s Hospital, 
Daejeon, Republic of Korea; 4Asan Medical Center, Seoul, Republic of Korea; 
5Chungnam National University Hospital, Daejeon, Republic of Korea.
Background: KLHL3 kelch like family member 3 (KLHL3) regulate some electrolyte 
in kidney tubules. In human, the mutation of KLHL3 induce hypertension, characterized by 
pseudoaldosteronism (decreasing aldosterone). We evaluated whether the KLHL3 could be 
fair target of RAAS inhibition, resulting in inhibition of renal fibrosis in unilateral ureteral 
obstructed (UUO) mice.
Methods: 10-week-old male B6 mice background KLHL3 KO mice and wild type 
mice were divided into 4 groups; wild, KLHL3 KO, wild with UUO, and KLHL3 KO with 
UUO. Mice were sacrificed at 7 days after surgery and kidney tissue were collected. Real 
time RT-PCR, western blot and immunohistochemistry for molecular study and H&E stain 
and PAS stain for histologic examination were performed.
Results: KLHL3 KO with UUO mice showed improvement of renal cell survival, 
renal function, and pathologic damage compared to wild type UUO mice. Wild type with 
UUO kidney showed decrease of renal expression of KLHL3 and WNK4, and increase of 
renin and angiotensin I receptor, compared to sham mice. However, KLHL3 KO with UUO 
reduced the renal expression of renin, angiotensin I receptor, alpha-SMA, collagen IV, and 
TGF-ß in UUO kidney, compared to wild type with UUO mice.
Conclusions: KLHL3 KO ameliorate renal fibrosis in UUO kidney via inhibition or 
renin angiotensin system.
Funding: Government Support - Non-U.S.
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Mouse Model of Progression to Chronic Kidney Injury from AKI
Jie Zhang,1 Jin Wei,1 Lei Wang,1 Ruisheng Liu.2 1USF, Tampa, FL; 2University of 
South Florida College of Medicine, Tampa, FL.
Background: There is no animal model displaying the typical characteristics of CKD 
following an episode of AKI. Thus, the aim of the present study was to develop an AKI to 
CKD animal model.
Methods: We first tested whether current AKI models can induce CKD. Bilateral 
renal ischemia reperfusion (IR) and unilateral renal IR plus uninephrectomy with stepwise 
lengths of ischemic time were performed in C57BL/6 mice. Then we developed a 
two-stage AKI to CKD model in C57BL/6 mice. In stage I, IR induced AKI was performed 
in the left kidney with stepwise lengths of ischemic time, while the right kidney was kept 
intact. In stage II, after 2 week recovery for the injured left kidney, the intact right kidney 
was removed. Kidney function and renal injury were evaluated afterwards.
Results: In current IR induced AKI models, the animals either fully recovered if the 
renal injury was moderate with <18 min bilateral or <15 min unilateral ischemic time, or died 
if the renal injury was life-threatening with >21 min bilateral or >18 min unilateral ischemic 
time. No typical CKD feature was observed in these models. In two-stage AKI to CKD 
models, after removal of the intact right kidneys, the mice with 21 min or 24 min left renal 
ischemia exhibited the characteristics of CKD, including continuous decline in GFR (from 
206.6±9.5 μl/min to 76.3±8.1 μl/min in 21 min group, from 199.2±6.7 μl/min to 49.5±11.3 
μl/min in 24 min group), gradual increase in PCr (from 0.13±0.03 mg/dl to 0.43±0.05 mg/dl 
in 21 min group, from 0.09±0.03 mg/dl to 0.65±0.09 mg/dl in 24 min group), exacerbation 
in urine albumin-to-creatinine-ratio (from 13±6 μg/mg to 3457±342 μg/mg in 21 min
group, from 9±5 μg/mg to 4841±375 μg/mg in 24 min group), histopathological changes
including tubular atrophy, interstitial fibrosis, glomerular sclerosis, collapse of glomerular 
tufts and dilated Bowman’s capsule, and transmission electron microscopy ultrastructural
alterations including peritubular interstitium expansion, collagen deposition, cellular debris
within Bowman’s space, GBM thickening, and podocyte foot process effacement. The mice 
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with 15 min or 18 min left renal ischemia had a full recovery. All mice with 27 min or 30 
min left renal ischemia died within 7 days after right kidney removal.
Conclusions: In conclusion, we successfully developed a novel mouse model with a 
direct transition from renal IRI induced AKI to subsequent progression of CKD.
Funding: NIDDK Support
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The Sulfate Moiety in Indoxyl Sulfate Is Critical for Activation of Aryl 
Hydrocarbon Receptor–Tissue Factor Axis and 3-Indole Methanol Is a 
Competitive Antagonist of Indoxyl Sulfate
Sean Richards,1 Joshua A. Walker,2 Daniel M. Roth,3 Mostafa Belghasem,2 
Norman Lee,2 Stephen A. Whelan,2 Nkiruka Arinze,4 Sung bok Yoo,2 
Jean M. Francis,1 Vipul C. Chitalia.3 1Boston University Medical Center, Boston, 
MA; 2Boston University, Boston, MA; 3Boston University School of Medicine, 
Boston, MA; 4Boston Medical Center, Boston, MA.
Background: Indolic solutes (indoxyl sulfate –IS, Indoxyl acetate -IA) are bonafide 
uremic solutes with protean systemic manifestations, including prothrombotic effect 
through activation of the Aryl hydrocarbon receptor (AHR) and tissue factor (TF). 
Despite its well-established pathogenicity, molecular determinants of IS that regulate its 
prothrombotic propensities remain unknown.
Methods: A structure activity relationship analysis was performed using a set of 
commercially available analogs. Activity was compared biochemically using validated 
AHR and TF activity assays, and visually in a transgenic zebrafish model containing a 
CYPA1 promoter tethered to a GFP reporter. A newly identified antagonist, indole- 
3-methanol (3-IM) was confirmed by using an carotid thrombosis model in mice treated 
with IS, as well as by ability to reduce TF in vascular smooth muscle cells treated with sera 
obtained from CKD patients with known concentration of IS levels.
Results: Modifying the sulfate moiety of IS altered its ability to increase AHR and 
TF activities. IA exhibited 100-fold higher AHR activation in cells and zebrafish models 
than IS. Of a total of thirteen analogs analyzed, five showed an agonistic activity in the 
presence of IS while one showed no effect. Of seven analogs with antagonistic activity 
towards IS, 3-IM significantly inhibited IS-induced AHR activation and TF with an IC50 
of 50uM. 3-IM showed a potent anti-thrombotic activity in an IS-specific mouse model of 
thrombosis. Importantly, the downregulation of TF with 3-IM was significantly higher in 
vascular smooth muscle cells treated with uremic sera compared to cells treated with control 
sera. The ability of 3IM to suppress TF inversely correlated with the levels of IS in sera of 
end stagre renal disease patients.
Conclusions: The sulfate moiety is an important determinant of activity of IS in the 
AHR-TF axis. A non-sulfated analog, 3-IM suppresses TF and thrombosis in an IS-specific 
manner. These results point to the potential of 3-IM as a new therapeutic in counteracting 
IS-mediated systemic manifestations.
Funding: Other NIH Support - R01
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Silence of Central (Pro)renin Receptor Ameliorates Salt-Induced Renal 
Injury and Oxidative Stress in CKD
Jiawen Li, Mengbi Zhang, Lishan Tan, Minzi Qiu, Aiqing Li. Nanfang Hospital, 
Southern Medical University, Guangzhou, China.
Background: High salt diet promotes renal injury and oxidative stress via the brain 
and renal RAS axis in CKD rats. (Pro)renin receptor(PRR) can mediate oxidative stress. 
However, central PRR regulates salt-induced renal oxidative stress in CKD remains 
undefined. Here we hypothesized that the reduction of central PRR expression could 
ameliorate oxidative stress and thereby prevent renal injury in high-salt-load CKD rats.
Methods: We used the lentivirus as a vector to screen out the sequences that inhibit the 
central PRR expression in mature rat hippocampal neural stem cells in vitro. Moreover, we 
investigated renal oxidative stress, renin-angiotensin system, sympathetic nerve activity and 
tissue injury in 5/6 nephrectomy CKD model rats fed high dietary salt after silence of central 
PRR expression by intracerebroventricular (ICV) lentivirus RNAi.
Results: We found that high salt diet contributes to progression of renal injury, fibrosis 
and oxidative stress in CKD; The expression of PRR in the subfornical organ was decreased 
after ICV administration of lentivirus RNAi, indicating that shRNA successfully inhibited 
the expression of PRR in the brain. The expression of tyrosine hydroxylase in neurons of 
the rostral ventrolateral medulla of the brain, and the serum, renal norepinephrine levels 
were decreased, indicating that activation of the sympathetic nerve system was prevented by 
silence of central PRR expression; while kidney H&E staining and Sirius Red staining, as 
well as Fibronectin, α-SMA, and Collagen I were down-regulated, indicating that inhibition 
of central PRR can improve renal injury and reduce renal fibrosis. In addition, renal RAS 
components such as PRR, Angiotensinogen, and Angiotensin II, and kidney NADPH 
oxidase (Nox2, Nox4) were down-regulated, while renal antioxidant enzymes (CAT, 
GP1, and SOD1) were up-regulated. These experimental data suggest that silencing PRR 
expression in the CNS may down-regulate renal RAS expression and reduce renal damage 
and oxidative stress levels.
Conclusions: Silence of central PRR expression ameliorates renal fibrosis, injury, and 
oxidative stress in CKD model fed high salt.
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Scavenging Reactive Dicarbonyls Improves Renal Injury: Role of Urinary 
Isolevuglandin-Modified Lipoproteins and Renal Lymphangiogenesis
Jianyong Zhong,1 Haichun Yang,1 Taiji Matsusaka,2 Agnes B. Fogo,1 
Macrae F. Linton,3 Valentina Kon,4 Sean S. Davies.4 1Vanderbilt University 
Medical Center, Nashville, TN; 2Tokai University School of Medicine, Isehara, 
Japan; 3Vanderbilt University School of Medicine, Nashville, TN; 4Vanderbilt 
University, Nashville, TN.
Background: The kidney has a well-developed lymphatic system and 
lymphangiogenesis occurs in diseased kidney. Our previous studies revealed that 
proteinuric injury increases urinary lipoproteins which were recently shown to regulate 
lymphangiogenesis. Isolevuglandins (IsoLG) and related reactive dicarbonyls are 
lipoxidation products that can modify lipoproteins and degrade their functions. We 
determined if scavenging dicarbonyls, including IsoLG that block protein modification, can 
modulate renal lymphangiogenesis and lessen renal injury.
Methods: Nphs1-hCD25 mice (Nep25) expressing podocyte-specific human CD25 
become proteinuric after injection of immunotoxin (LMB2). Nep25 mice were treated with 
the dicarbonyl scavenger, PPM (1g/L) or vehicle from onset of proteinuria until sacrifice 
(2 weeks). We assessed proteinuria [measured as albumin:creatinine ratio (ACR)], urinary 
apoAI, IsoLG, KIM-1 (marker of tubular injury), and the renal expression of lymphatic 
markers (LYVE-1 and podoplanin). In vitro, we assessed the effects of apoAI or modified 
apoAI (IsoLG-apoAI) ± PPM in lymphatic endothelial cells (LEC).
Results: After LMB2 injection, Nep25 mice had significantly higher urinary ACR 
(32-fold), KIM-1 (35-fold), urinary apoAI (7.3-fold), and IsoLG-protein adduct excretion 
(1.3-fold). Proteinuric kidneys showed greater immunostaining for apoAI and a denser 
lymphatic vessel network (podoplanin staining: 2.1-fold). In vitro, IsoLG-apoAI increased 
LEC viability (1.6-fold) and migration (1.1-fold) vs unmodified apoAI. These effects were 
significantly abrogated by exposure to PPM. In vivo, proteinuric Nep25 mice treated with 
PPM showed reduced lymphangiogenesis (podoplanin: 0.7-fold and LYVE-1: 0.5-fold). 
PPM treatment also significantly reduced ACR (0.8-fold), urinary KIM-1 (0.7-fold) 
together with significant reduction in IsoLG excretion (0.4-fold).
Conclusions: We conclude that dicarbonyl scavenger PPM lessens proteinuric 
renal damage through mechanisms that include preserving lymphatic endothelial cell 
functionality and diminishing urinary lipoprotein-stimulated renal lymphangiogenesis.
Funding: Other NIH Support - NHLBI
TH-PO937 Poster Thursday
Molecular Mechanisms of CKD - I
Identification of C/EBPβ-TMIGD1 as a Novel Renoprotective Pathway
Mostafa Belghasem,1 Joseph Y. Tashjian,3 Daniel M. Roth,1 Joshua A. Walker,1 
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Background: The management of chronic kidney disease (CKD) patients lacks agents 
that protects functional renal mass, which predominantly consists of tubules. We recently 
identified transmembrane and immunoglobulin domain-containing 1 (TMIGD1) as a 
novel receptor expressed predominantly in the proximal tubular epithelial cells. TMIGD1 
regulates epithelial cell adhesion and protects kidney epithelial cells from oxidative stress-
induced cell injury in cell culture. While, TMIGD1 expression changes in acute kidney 
injury and chronic CKD mouse models, depending to the stage of disease the in vivo 
renoprotective function of TMIGD1 remains unknown.
Methods: TMIGD1 transcriptional regulation and promoter were characterized using 
electrophoretic mobility shift assay (EMSA). Expression of TMIGD1 and C/EBPb were 
examined in three discrete CKD models – unilateral ureteral obstruction (UUO), Adenine-
induced CKD and remnant kidney model (RKM) model through immunofluorescence 
staining. CRSIPR/Cas9 TMIGD1 +/- mice were subjected to adenine-induced CKD model. 
Targetability of TMIGD1 was demonstrated using TMIGD1 blocking antibody.
Results: C/EBPβ strong interacts with TMIGD1 promoter and stimulates promoter 
activity of TMIGD1 in HEK-293 cells. C/EBPβ showed nuclear localization in normal 
renal tubular cells, however, it was lost with the induction of CKD and correlated with 
the downregulation of TMIGD1 in renal tubules. CRSIPR/Cas9 TMIGD1 +/-CKD mice 
showed a significantly lower kidney weight/body weight ratio suggesting a greater extent of 
renal atrophy compared to the wild type littermates. Pre-treatment of mice with a TMIGD1 
blocking antibody augmented renal tubular damage.
Conclusions: We present C/EBPβ-TMIGD1 axis as a novel renoprotective pathway, 
which can be explored further to preserve the functional renal mass in CKD.
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Use of Population Management Tools to Identify Patients at High-Risk of 
ESRD Progression
Sijie Zheng,1 Rushdy M. Al-Moomen,1 Yiann E. Chen,2 Joanna Mroz,1 
Leonid Pravoverov.3 The Permanente Medical Group 1The Permanente Medical 
Group, Oakland, CA; 2Kaiser Permanente Medical Center, Richmond, CA; 
3Kaiser Permanente, Oakland, CA.
Background: The current health care system focuses on treatment rather than 
prevention of illness. There is inadequate support for patients who are unable to adhere 
to complex medical therapies. Transition from CKD to ESRD is a perfect example: many 
patients are not engaged in renal care due to psycho-social issues such as denial, lack of 
understanding of disease, or lack of financial resources for travel and/or medications. Kaiser 
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Permanente Northern California (KPNC) is an integrated health care system providing care 
for 4.3 million members. In 2016, KPNC East Bay Nephrology department started a pilot to 
identify patients with moderate to advanced CKD who had not received Nephrology care.
Methods: We used our Electronic Medical Record (EMR) system to identify late stage 
CKD patients (eGFR less than 30 ml/min) who have not been seen by a Nephrologist. 
The patient list was monitored daily by a nurse and reviewed weekly with a Nephrologist. 
Nephrologists screened patients to determine if they were appropriate for referral to 
nephrology specialty care. Primary care providers were contacted with recommendation to 
review chart and determine if those patients may benefit from referral to nephrology care.
Results: After the implementation of the pilot, many patients who would likely have 
been “lost to follow up” were captured by this program. The Nephrology team educated 
patients about the presence of advanced CKD and developed a comprehensive plan of care 
(Figure).
Conclusions: Establishing a “safety net” by developing an automated process of 
identifying patients with elevated risk characteristics and enrolling them in a structured 
CKD care program can potentially lead to a smoother transition to ESRD in our integrated 
health care system. In addition, this program supports the development of individualized 
care pathways depending on patient-identified goals of care.
Funding: Private Foundation Support
Population Management of CKD Patients by Building a Safety Net to Identify High Risk 
Patients
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Treatment of Anemia with Oral and Parenteral Iron Leads to Bone Loss 
in Juvenile Mice with CKD
Oleh M. Akchurin,1 Edwin Patino,1 Sureshbabu Angara,1 Divya Bhatia,1 
Vidhi Dalal,1 Kelly Meza,1 Stefano Rivella,2 Mary E. Choi.1 1Weill Cornell 
Medicine, New York, NY; 2Children’s Hospital of Philadelphia, Philadelphia, PA.
Background: Anemia is common in children with CKD and is associated with 
altered iron metabolism. Thus, many children with CKD are receiving iron therapy. Iron 
sequestration due to elevated hepcidin is a concern in CKD. Iron supplementation induces 
bone loss in mice without CKD. The effects of iron on bone health in juvenile CKD remain 
poorly understood.
Methods: CKD in juvenile mice was induced by 8 weeks of a 0.2% adenine diet, post-
weaning. Bone histology and micro-CT was compared between four groups of mice: 1. 
Control (no CKD). 2. CKD without iron supplementation. 3. CKD + weekly 0.5g/kg of iron 
dextran intraperitoneally (CKD-IPFe). 4. CKD + 0.5% carbonyl iron diet (CKD-POFe). 
ANOVA was used for statistical analysis. For all reported data, pairwise comparisons 
between groups 1/2, 2/3, and 2/4 were significant (p<0.05).
Results: Renal function was reduced in all CKD groups (serum creatinine 0.22, 
0.55, 0.32, and 0.79 mg/dL in groups 1-4 respectively). As expected, mice with untreated 
CKD were anemic. Treatment with oral and IP iron resulted in improvement of Hgb 
(13.9, 11.5, 13.1, and 13.3 g/dL in groups 1-4), Hct, MCV, MCH, and RDW. Mice with 
CKD had thinner and more porous cortical bone, and lower trabecular bone mass compared 
to controls. Iron treatment resulted in further cortical thinning (Ct.Th 0.18, 0.15, 0.12, 0.10 
mm in groups 1-4), and decrease in cortical tissue mineral / apparent density, compared to 
untreated mice with CKD. Iron treatment also led to further reduction of trabecular bone 
volume (BV/TV 17.6, 12.2, 8.8, 8.6% in groups 1-4), trabecular number and increase in 
trabecular separation (Fig), compared to untreated mice with CKD.
Conclusions: Iron therapy improved anemia but was complicated by the loss of 
cortical and trabecular bone in this model of juvenile CKD. In our ongoing studies we aim 
to elucidate the underlying mechanisms. Our findings suggest a need to consider potential 
bone-related effects of iron in optimizing CKD management in children with CKD.
Cortical and trabecular bone micro-CT in four groups of mice
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Translational Medicine in CKD: Therapeutic Targeting of p-Cresyl 
Sulfate Triggered Nonspecific ROS in Uremic Lung Injury
Jia-Feng Chang. En Chu Kong Hospital, New Taipei City, Taiwan.
Background: p-Cresyl sulfate (PCS) exerts pro-inflammatory, pro-oxidant, and pro-
apoptotic effects on multi-cell systems. Nonetheless, mechanisms and therapies of PCS 
induced uremic lung injury (ULI) in chronic kidney disease (CKD) remain unclear.
Methods: We analyzed pleural effusions from CKD and non-CKD patients with 
respiratory distress for uremic toxins, hydroxyl radicals, and chemotactic cytokines. From 
bedside to bench, cell viability and inflammatory signaling pathways with reactive oxygen 
species (ROS) were investigated in PCS-treated human alveolar cell model. To mimic 
human diseases, CKD-ULI mouse model was developed with quantitative comparison of 
immunostaining and morphometric approach.
Results: Pleural effusions exhibit higher expressions of PCS/ indoxyl sulphate/ 
hydroxyl radicals/ IL-5/ IL-6/ IL-8/ IL-10/ ENA-78/ MDC/ THPO/ VEGF and leukocyte 
recruitment with proteinaceous leak in CKD patients. In vitro, PCS promotes alveolar cell 
death, cPLA2/COX-2 expression, and NADPH oxidase/mitochondria activation-related 
ROS burst. Intracellular ROS burst is abrogated by non-specific antioxidant (N-acetyl 
cysteine, NAC), inhibitors of NADPH oxidase and mitochondria-targeted superoxide 
scavenger. However, only NAC protects against PCS-induced cell death. In vivo, 
expressions of cPLA2/ COX2/ 8-OHdG, dust cells, recruited leukocytes, alveolar space, 
plasmatic leakages and interstitial edema increase in lung tissues of CKD-ULI mice, and 
NAC pretreatment ameliorates ULI and alveolar cell death.
Conclusions: PCS impairs alveolar-capillary integrity through triggering intracellular 
ROS burst, activating downstream PG pathways, cell death, and recruiting leukocytes to 
release ROS and multiplex chemoattractants. Our translational research resolves puzzling 
mechanisms of CKD-ULI, proving that PCS and nonspecific ROS serve as potential 
therapeutic targets.
Funding: Private Foundation Support
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Sucroferric Oxyhydroxide Ameliorates Glomerular Podocyte and 
Tubulointerstitial Injury in the Rat Remnant Kidney Model
Yoshikazu Nemoto,1 Takanori Kumagai,1 Takeshi Shiraishi,1 Kenichi Ishizawa,1 
Osamu Yamazaki,1 Yoshifuru Tamura,1 Makoto Kuro-o,2 Shunya Uchida,1 
Shigeru Shibata.1 1Teikyo University School of Medicine, Tokyo, Japan; 2Jichi 
Medical University, Shimotsuke, Japan.
Background: Previously, we reported that the elevation of serum phosphate can 
accelerate CKD progression in the retrospective cohort study (Plos One 2016). In this study, 
we evaluated the protective effects of sucroferric oxyhydroxide (SF), a phosphate binder, 
in a rat model of CKD.
Methods: SD rats received 5/6 nephrectomy (RK) and had a normal diet containing 
0.3% phosphate. Control rats without 5/6 nephrectomy received the same diet. A subgroup 
of RK rats received SF (50 mg/g chow; RK+SF). Renal histology was evaluated at 
8 weeks.
Results: RK rats showed increased FGF23 levels compared with control rats. Serum 
phosphate levels were also moderately but significantly increased. SF administration 
significantly decreased serum FGF23 and phosphate levels in RK rats. Urinary phosphate 
excretion was also significantly lower in RK+SF rats than RK rats. Of note, albuminuria 
in RK rats was significantly ameliorated by SF administration at 8 weeks (RK, 8.42 ± 
1.49 mg/day versus RK+SF, 2.71 ± 1.15 mg/day; P < 0.01). In the PAS-stained kidney 
sections, SF administration attenuated glomerulosclerosis and tubulointerstitial injury in 
RK rats. Consistently, gene expression of inflammatory and profibrotic cytokines were 
significantly lower in the kidney in RK+SF rats than in RK rats. In the glomeruli, we found 
that the increased expression of desmin, a marker for podocyte injury, was attenuated by SF. 
Consistently, nephrin protein expression was preserved in RK+SF rats compared with RK 
rats. The protective effects on podocytes were confirmed by morphological analysis under 
transmission electron microscope. In von Kossa staining, calcium phosphate was detected 
neither in RK nor RK+SF rats, indicating that renal injury in this model is independent of 
ectopic calcification at this stage. Plasma levels of calciprotein particles were significantly 
lower in RK+SF than RK rats, indicating the reduced mineral stress by SF.
Conclusions: These data indicate that phosphate loading to the kidney causes 
glomerular and tubulointerstitial injury in the absence of calcium phosphate deposition, and 
support the pathological role of phosphate loading in CKD progression.
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Adiponectin and Its Receptors in Peripheral Muscle and Fat Tissues of 
CKD Patients
Samantha Milanesi,1,2 Daniela Verzola,1,2 Michela Saio,1,2 Daniela Picciotto,1,2 
Giuliano Brunori,3 Chiara Venturelli,4 Giacomo Garibotto.1,2 1University of 
Genoa, Genoa, Italy; 2Policlinico S.Martino, Genoa, Italy; 3Ospedale S. Chiara, 
Trento - Italy, Trento TN, Italy; 4APSS TRENTO, Trento, Italy.
Background: Inflammation contributes to protein-energy wasting (PEW) in CKD, 
but the role of adiponectin (APN), which has anti-inflammatory properties, is not known. 
APN is secreted preferentially by adipocytes, but also by skeletal muscle. APN binds two 
receptor isoforms, adiponectin receptor 1 (AR1) and adiponectin receptor 2 (AR2). The aim 
of this study was to examine the expression of APN and its receptors in skeletal muscle and 
adipose tissue in CKD patients.
Methods: Muscle biopsies were obtained from 29 CKD (eGFR 8±3 ml/min per 1.73m2 , 
15M/14F, age 69 yrs) patients and 14 controls (C) rectus abdominis muscle samples. 
In this cohort, visceral fat samples were also obtained in 16 CKD and 10 C subjects. The 
expressions of APN, AR1 and R2 were tested by rtPCR and immunohistochemistry.
Results: Skeletal Muscle: APN gene expression and protein were up-regulated, (by 
6-3.5 folds with respect to C, p< 0.001), AR1 and R2 mRNAs were markedly downregulated 
(-90 %, p<0,001), while protein expression was unchanged in CKD vs. C. Adipose tissue: 
APN, AR1 and R2 mRNAs were upregulate (by 2-7 folds, p<0.05) in CKD vs. C. Muscle 
APN mRNA was directly related to TLR4 protein expression (r2=0.33, p=0.023); moreover, 
APN and IL-6 protein were directly related (r2=0.28, p<0.01). Only as a trend, APN protein 
was related to NF-kB pp65 (r2=0.179, p=0.056). Visceral Fat APN was directly related to
plasma CRP (r=0.62, p=0.028).
Conclusions: In conclusion, muscle and visceral fat APN and APN receptors expression 
pattern is markedly modified in CKD. The APN system appears to respond to chronic 
inflammation as a compensatory mechanism which helps to maintain body homeostasis.
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NLRP3 Inflammasome Is Activated in Skeletal Muscle of Patients with 
CKD
Daniela Verzola,1,2 Samantha Milanesi,1,2 Chiara Barisione,3,1 Silvano Garibaldi,1,2 
Michela Saio,1,2 Daniela Picciotto,1,2 Abitha Murugavel,1,2 Francesca Costigliolo,1,2 
Giuliano Brunori,4 Chiara Venturelli,5 Giacomo Garibotto.1,2 1DiMI University of 
Genoa, Genoa, Italy; 2Policlinico S.Martino, Genoa, Italy; 3University of 
Genova, Genova, Italy; 4Ospedale S. Chiara, Trento - Italy, Trento TN, Italy; 
5APSS TRENTO, Trento, Italy.
Background: Inflammation in skeletal muscle is implicated in the pathogenesis of 
insulin resistance and cachexia but why uremia upregulates muscle pro inflammatory 
cytokines is not completely understood.The NOD-like receptors (NLRs) are a group of 
pattern recognition receptors which activate the inflammasome platform. Aim of this study 
was to investigate the NLP3 role in skeletal muscle of CKD patients and the effects of 
uremic milieu on the NLRP3 pathway and mitochondria homeostasis.
Methods: Rectus abdominis muscle biopsies were collected from CKD5 patients 
(n= 25, 18M/7F, age 69±10 yrs, eGFR 8±1mL/min 1,73m2) and from 10 controls (C) 
(age 68±11 7M/3F, eGFR 100±4mL/min 1,73m2). NLRP3, IL1β expression was studied 
by immunohistochemistry, mRNA (NLRP3,IL1β,PGC1α,MFN2, NRF2) by rt-PCR. 
To assess the effects of uremic milieu, C2C12 myotubes were exposed to 10% normal 
serum (NS) or Uremic (US) Serum for 5-48 hours (h). NLRP3,IL1β,PGC1α,MFN2,NRF2 
were studied by rtPCR, caspase1 by western blot and mitochondria damage by JC1 staining.
Results: In CKD, NLRP3 mRNA and protein were overexpressed (by 16-2 folds, 
p<0.05-0.025). IL1β mRNA was upregulated (p=0.02). In vitro, 5 hour US treatment 
upregulated NLRP3 and IL1β mRNAs (by 71-12 folds p<0.01) and caspase1 (+30% 
p<0.05). TAK 242 (1μM) a TLR4 antagonist prevented these effects. In CKD muscle, 
PGC1α (a mitochondrial biogenesis regulator), MFN2 (involved in mitochondrial fusion 
and in the mitochondrial network maintenance) and Nrf2 (a player in supporting the 
mitochondria structural and functional integrity) were significantly elevated (0.05-0.01) 
respect to C. Moreover, US upregulated PGC1α, MFN2 and Nrf2 (by 2-26 folds p<0.05-
0.001) and altered mitochondrial membrane potential (p<0.05). These effects were partially 
blocked by TAK 242.
Conclusions: Our data show that NLRP3 inflammasome is activated and mitochondria 
dysregulated in CKD 5 skeletal muscle. These effects are rescued by TLR4 block, showing 
a link between TLR4 and inflammasome. TLR4/NLRP3/IL-1β blockade offers a novel 
method for reducing inflammation in muscle of CKD patients.
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Towards a Standardized Histological Identification of CINAC Patients: 
Methods and Pitfalls in Microscopic Diagnosis
Gerd Schreurs,1 Cynthia C. Nast,2 Channa Jayasumana,3 Frank Roels,5 
Chulani A. Herath,4 Swarnalata Gowrishankar,7 Christiane I. Mousson,8 
Rajeewa T. Dassanayake,6 Carlos M. Orantes,9 Patrick C. D’Haese,1 Marc E. De 
Broe,1 Benjamin A. Vervaet.1 1University of Antwerp, Antwerp, Belgium; 
2Cedars-Sinai Medical Center, Los Angeles, CA; 3Faculty of Medicine, 
Anuradhapura, Sri Lanka; 4Sri Jayawardenepura General Hospital, Colombo 
5, Sri Lanka; 5Ghent University, Gent, Belgium; 6General hospital Polonnaruwa 
Sri Lanka, Polonnaruwa, Sri Lanka; 7Apollo Hospitals, HYDERABAD, India; 
8University Hospital Dijon, Dijon, France; 9National Direction of Non-
communicable diseases of Ministry of Health of El Salvador, San Salvador, El 
Salvador.
Background: Patients with Chronic Interstitial Nephritis in Agricultural Communities 
(CINAC) demonstrate previously unidentified enlarged granules in the proximal tubular 
(PT) epithelium, first discovered and easily recognizable on Jones’ methenamine silver 
stained renal biopsies and by autofluorescence. The aim is to 1) identify the nature of 
the granules, 2) provide a standardized Jones staining protocol for granule identification, 
3) evaluate autofluorescence as a rapid diagnostic method and 4) assess EM analysis.
Methods: Formalin fixed deparaffinized renal tissue sections (4μm) of Sri Lanka and
El Salvador CINAC patients and patients with proteinuric pathologies were subjected to 
Jones staining protocols with varying silver solution incubation times. Autofluorescence 
of 4μm sections was imaged (2-7 secs shutter time), followed by standardized Jones 
staining of the same tissue section. Immunofluorescence microscopy was performed for the 
mitochondrial marker COX6c and for lysosomal markers LAMP1 and Cathepsin B. EM of 
CINAC and proteinuric renal biopsies was performed.
Results: Jones stain invariably revealed the specific PT granules only when the 
incubation in silver-solution was ≥90 min, surpassing the time (60 min) needed to visualize 
basement membranes. CINAC biopsies showed PT autofluorescent granules in a pattern 
similar to the argyrophylic granules, with nearly all autofluorescent granules also being 
argyrophylic. Most autofluorescent granules were identified as lysosomes with LAMP1 and 
Cathepsin B. In proteinuric patients, PT argyrophylic and autofluorescent granules may 
occur. However, on EM, proteinuric lysosomes were round, and did not contain dispersed 
electron dense aggregates as obseved in CINAC patients.
Conclusions: PT CINAC granules are lysosomes, identifiable by Jones staining with 
prolonged silver incubation and more rapidly by autofluorescence. EM of PT lysosomes can 
identify suspected CINAC patients, with or without proteinuria.
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Stanniocalcin-1 Inhibits ER Stress-Induced Apoptosis and Renal Fibrosis 
via Restoration of ER-Mitochondrial Calcium Communication
Eun mi Yang,1 Soo Wan Kim,1 Eun Hui Bae,2 Seong Kwon Ma,1 Jung Sun Park.3 
1Chonnam National University Medical School, Gwangju, Republic of Korea; 
2Chonnam National University Hospital, Gwangju, Republic of Korea; 
3chonnam national university, Gwang Ju, Republic of Korea.
Background: Endoplasmic reticulum (ER) stress is a common feature of several 
physiological and pathological conditions. ER stress-associated apoptosis plays a role in 
organ remodeling after insult, and overwhelming ER stress lead to renal cell apoptosis 
and subsequent fibrosis. Stanniocalcin-1 (STC-1) is a multifunctional glycoprotein which 
is targeted to the mitochondria to exert putative anti-apoptotic effects. The present study 
aimed to investigate the effects of STC-1 in ER stress-induced apoptosis and renal fibrosis 
in human renal proximal tubular (HK-2) cells.
Methods: HK2 cells pretreated with STC-1 (200 ng/ml) for 1 hours followed by 
treatment with TGF-β (10 ng/ml) for 24 hours. The protein expression of ER stress, 
apoptosis, and fibrosis markers was determined by semiquantitative immunoblotting. 
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The level of reactive oxygen species (ROS) was determined by fluorescent microscopy 
immunofluorescence. Using microscopy and immunocytochemistry, immunolabelling 
of Ca2+, calcium sensing receptor and inositol 1,4,5-trisphosphate receptor (IP3R) was 
detected.
Results: TGF-β treatment induced ER stress via upregulation of PERK-eIF2-ATF 
signaling, and suppressed cytosolic calcium concentration via downregulation of IP3R. 
Pretreatment of STC-1 attenuated the TGF-β induced up-regulation of PERK-eIF2-ATF4 
signaling and restored the cytosolic Ca concentration, thus reducing apoptosis. TGF-
β treatment induced mitochondrial ROS generation and cytosolic cytochrome c release.
STC-1 pretreatment significantly blocked mitochondrial ROS generation and cytosolic 
cytochrome C release. TGF-β treatment also induced upregulation of E-cadherin, collagen
IV and fibronectin and downregulation of N-cadherin, which was counteracted by STC-1 
pretreatment.
Conclusions: Restoration of ER-mitochondrial calcium signal by STC-1 attenuated 
ER stress induced apoptosis and fibrosis in HK2 cells. The present study suggested that the 
STC-1 may serve as a potential treatment for renal fibrotic disease.
Funding: Government Support - Non-U.S.
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Sex-Specific Renal Pathology Following 5/6 Nephrectomy Is Modulated by 
miR-146b
Mark Paterson, Alison J. Kriegel. Medical College of Wisconsin, Milwaukee, WI.
Background: Chronic kidney disease (CKD) presents a complex pathological 
landscape in both men and women. Many studies have shown miRNAs can be powerful 
mediators of pathology at the molecular level. Our work focuses on the role of miRNAs 
in CKD, utilizing the 5/6 nephrectomy (5/6Nx) rat model. We have reported a significant 
increase in the expression of miR-146b in kidney tissue following 5/6Nx. The present 
study investigates the contribution miR-146b to CKD, and the relative contribution of sex 
hormones in modulating the pathology of CKD.
Methods: Male and female Sprague Dawley (SD) rats underwent 5/6Nx or sham 
surgeries at 10 weeks of age. The 5/6Nx consists of surgical resection of 2/3 of the left 
kidney and the entire right kidney. Seven weeks later, urine and blood were collected, the 
rats were euthanized, and the kidneys harvested for downstream application. To study 
the contribution of miR-146b, wild-type SD rats (WT) were compared to miR-146b null 
mutants (KO). To study the contribution of sex hormones, intact rats were compared to 
gonadectomized rats. Histological examination of kidney tissue was performed to assess 
renal fibrosis. Metabolite and electrolyte levels were measured in blood and urine using a 
blood gas analyzer. Creatinine clearance (CrCl) and fractional excretion of sodium (FENa) 
were derived from plasma and urine concentrations and urine flow rate.
Results: Following 5/6Nx, male WT and KO rats exhibit impaired renal function 
without significant renal fibrosis; diminished CrCl (WT: 2.09 vs. 0.85 ml/min, KO: 3.28 
vs. 0.82 ml/min; sham vs. 5/6Nx) and increased FENa (WT: 0.12 vs. 0.40%; KO: 0.09 vs. 
0.40%). Female WT rats exhibited similar renal dysfunction without fibrosis; reduced 
CrCl (0.99 vs. 0.28 ml/min) and elevated FENa (0.17 vs. 0.72%). However, female KO 
rats exhibited an exacerbation of renal dysfunction and injury compared to WT after 
5/6Nx; sharply reduced CrCl (0.28 vs. 0.08 ml/min, WT vs. KO 5/6Nx), elevated FENa 
(0.72 vs. 4.43%), and significant fibrosis in the renal cortex (3.30 vs. 13.1% fibrotic area). 
Ovariectomy ameliorated nearly all structural and functional pathologies.
Conclusions: Our study suggests an important protective role for miR-146b in CKD 
which may be, in part, via modulation of estrogen signaling in the kidney. Future studies 
will address specific pathways targeted by miR-146b to elucidate its mechanism of action 
in CKD.
Funding: Other NIH Support - NHLBI
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Altering Body Temperatures Response to Heat Modulates Kidney Injury
Yuka Sato, Carlos A. Roncal-jimenez, Ana Andres-hernando, Gabriela E. Garcia, 
Miguel A. Lanaspa, Richard J. Johnson. Kidney Disease and Hypertension, 
University of Colorado Denver, Aurora, CO.
Background: Hispanic Americans may be at more risk than African Americans for 
kidney damage from heat stress due to greater mitochondrial uncoupling because of genetic 
polymorphisms. Indeed, mitochondrial uncoupling proteins (UCP) dissipate the proton 
gradient in the mitochondria, resulting in more heat generation instead of ATP synthesis. We 
therefore hypothesized that the administration of a drug that could induce a mitochondrial 
uncoupling might result in a greater increase in body temperature following heat exposure, 
and that this might lead to greater renal damage.
Methods: To test this hypothesis C57BL/6 mice were exposed to 39.5°C for 
30 minutes with subcutaneous injection of the chemical uncoupler; 2,4-dinitrophenol 
(DNP). After heat exposure, mice were returned to room temperature, and received access 
to water and food freely for one hour to avoid dehydration. The heat exposure was repeated 
twice per day for 10 days. Body temperature was evaluated with rectal probes.
Results: Body temperature immediately after the heat exposure was increased by heat 
and DNP (Table1). Albuminuria (uAlb) and BUN were increased in DNP+Heat group 
(Table1). uAlb correlated with body temperature (R=0.6, p<0.038). CPK was not increased 
in any groups, indicating an absence of rhabdomyolysis. Renal pathology showed greater 
tubular cell proliferation (proliferating cell nuclear antigen (PCNA) positive), tubular injury 
and interstitial macrophage infiltration (F4/80 positive) in the DNP+Heat group (Table1). 
HSP 70 expression was increased in Heat group and much more in Heat+DNP group.
Conclusions: Increasing body temperature for the same level of heat stress is associated 
with greater renal injury. Studies should evaluate whether individual temperature responses 
can predict renal injury in high risk subjects such as sugarcane workers.
Funding: NIDDK Support, Other U.S. Government Support, Government Support - 
Non-U.S.
Table1
*p<0.001 vs NT, **p<0.001 vs NT, DNP, Heat, †p<0.001 vs NT, DNP, p<0.01 vs Heat,
‡p<0.05 vs NT, p<0.001 vs DNP, Heat
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A Novel Conditionally Immortalized Kidney Pericyte Cell Line to Model 
Myofibroblast Transition
Benjamin D. Humphreys,1 Erinn L. Donnelly,1 Monica Chang Panesso,2 
Eoghainín O hAinmhire,3 Flavia G. Machado.4 1Washington University School 
of Medicine, Clayton, MO; 2Washington University in St. Louis, St Louis, MO; 
3Washington University, Lake St. Louis, MO; 4Washington University in St 
Louis, School of Medicine, St Louis, MO.
Background: Gli1-positive resident pericytes and perivascular fibroblasts are the 
predominant source of kidney myofibroblasts in kidney fibrosis but the study of pericyte 
to myofibroblast transition is hampered by the absence of appropriate cell culture models.
Methods: We crossed bigenic Gli1-CreERt2; R26tdTomato mice with the ‘immorto-
mouse,’ which expresses a temperature sensitive SV40 gene, and with the ‘terminator’ 
mouse, which expresses the diphtheria toxin receptor except after Cre-mediated 
recombination. After tamoxifen administration, we isolated tdTomato-positive Gli1 cells 
from kidney, and elimated all non-recombined cells by administration of diphtheria toxin. 
We characterized these cells ability to differentiate into myofibroblasts using a variety of 
methods, including scRNA-seq.
Results: Kidney Pericyte-Gli1 (KPG) cells maintain expression of appropriate pericyte 
cell markers, respond to hedgehog pathway activation and display robust myofibroblast 
differentiation upon treatment with TGFb. In support of their pericyte identity, co-culture of 
KPG with endothelium stabilizes capillary formation. Single cell RNA-sequencing analysis 
(5,000 cells) during the myofibroblast differentiation timecourse identified autocrine ligand-
receptor upregulation including the connective tissue growth factor, platelet-derived growth 
factor and transforming growth factor beta-3 pathways. Strong upregulation of genes in 
the focal adhesion pathway led us to test the serum response factor inhibitor CCG-203971 
which potently inhibited TGFb-induced pericyte to myofibroblast transition. Finally, our 
single cell analysis identified the unexpected upregulation of nerve growth factor (NGF) in 
KPG cells treated with TGFb. We confirmed strong NGF upregulation in two mouse kidney 
fibrosis models, and identified expression of the NGF receptor TrkA in VSMC cells in vivo, 
suggesting a novel role for perivascular fibroblast-derived NGF signaling to VSMC during 
kidney fibrosis.
Conclusions: KPG cells accurately model pericyte to myofibroblast transition, and we 
used them to identify a novel inhibitor of this process and the unexpected upregulation of 
the NGF pathway during renal fibrosis.
Funding: NIDDK Support
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Three Dimensional Super-Resolution Microscopy and Automatic 
Quantification of Podocyte Foot Processes in Humans, Rats, and Mice
Nadine Artelt,1 Florian Siegerist,1 Alina M. Ritter,1 Olaf Grisk,3 Rabea Schlueter,2 
Karlhans Endlich,1 Nicole Endlich.1 1Anatomy and Cell Biology, University 
Medicine Greifswald, Greifswald, Germany; 2Biology, University of Greifswald, 
Greifswald, Germany; 3Physiology, University Medicine Greifswald, Karlsburg, 
Germany.
Background: Until today, laborious and time-consuming transmission electron 
microscopy has been used to assess podocyte effacement in human and rodents. Recently, 
our group has shown that super-resolution 3D-structured illumination microscopy 
(3D-SIM) can be applied to visualize individual foot processes in human kidney biopsies. 
Furthermore, we have developed a software-based approach to quantify the structure of 
podocyte foot processes named podocyte exact morphology measurement procedure 
(PEMP). PEMP allows to quantify podocyte injury using filtration slit density (FSD), i.e. 
filtration slit length per capillary surface area, as the surrogate parameter for podocyte 
effacement in patients suffering from minimal change disease. As in basic science rodent 
models are widely distributed, we applied PEMP to mice and rats, the most used rodent 
models.
Methods: We co-stained 4 μm formalin-fixed and paraffin-embedded sections 
of healthy human, rat and mouse kidney tissue with antibodies targeted against the slit 
diaphragm protein nephrin and the actin-associated protein synaptopodin detected by Cy3 
and Alexa 488-labeled secondary antibodies, respectively. Subsequently, we imaged these 
sections by wide-field microscopy, confocal laser scanning microscopy and 3D-SIM. PEMP 
was performed by FIJI utilizing a custom-built macro that semi-automatically detects the 
filtration slit and calculates FSD.
Results: In a comparative analysis, we show that only 3D-SIM is able to clearly 
visualize the nephrin-stained slit diaphragm between synaptopodin-stained foot processes 
in all three species. Using PEMP, we determined values for FSD in healthy individuals from 
all three species. The FSD in humans was 3.106 ± 0.024 μm-1 (mean ± SEM). The FSD was 
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significantly higher in rats and mice with a mean value of 3.364 ± 0.049 μm-1 and 3.829 ± 
0.032 μm-1, respectively. Since foot process width is inversely related to FSD, the width of 
foot processes continuously increases from mice to rats and humans.
Conclusions: Taken together, we present a method for basic research which allows 
fast evaluation and quantification of podocyte foot process morphology in rodents by using 
3D-SIM on standardized histological material and tissue processing.
Funding: Government Support - Non-U.S.
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Lack of P2X7 Receptors Protects Against Pyelonephritis Associated Renal 
Fibrosis
Jacob R. Therkildsen, Mette G. Christensen, Stine Julie T. Pedersen, 
Rikke Norregaard, Helle A. Praetorius. Aarhus University, Aarhus C, Denmark.
Background: Severe urinary tract infections are regularly caused by sub-strains of 
E. coli secreting the pore-forming virulence factor α-haemolysin (HlyA). Repeated cases
of pyelonephritis can cause marked renal scarring that subsequently leads to progressive
failure. We have previously demonstrated that HlyA releases cellular ATP directly through 
its membrane pore and that acute HlyA-induced cell damage is completely prevented by
blocking ATP-signalling. Moreover, there is substantial evidence that local ATP signalling 
and P2X7 receptor activation plays a key role in the development of tissue fibrosis. This
study investigates the effect of P2X7 receptors in infection-induced renal scarring in a
murine model of pyelonephritis.
Methods: Pyelonephritis was induced by injecting 100 mill HlyA-producing, 
uropathogenic E. coli into the urinary bladder of balb/c mice. Pyelonephritis was confirmed 
by culture of the right kidney at day 5 post infection with concomitant high levels of 
proinflammatory cytokines (IL-6 and IL-1b) a response similar in both P2X7
+/+ and P2X7
-
/- mice.
Results: Lack of P2X7 receptor did not influence on the mortality in the mice exposed 
to bacteria (ntotal = 131). Fibrosis was first observed 2 weeks post infection. Our data clearly 
demonstrate that P2X7
-/- mice showed markedly less renal fibrosis following a similar degree 
of infection compared to P2X7
+/+ controls (p<0.001), reducing the renal scarring from 1.153 
± 0.0755 mm-2 to 0.296 ± 0.036 mm-2 (fibrotic areas/mm2 in the cortex). Similarly, a P2X7
antagonist BBG reduced the formation of fibrosis (p<0.001) to 0.3810 ± 0.03532 mm-2 in
the cortex. Immunohistochemistry revealed comparable degree of neutrophil infiltration in 
kidneys from P2X7
+/+ and P2X7
-/- mice, with diminished macrophage infiltration and reduced
neutrophil clearance in P2X7
-/- mice or mice treated with BBG compared to controls.
Conclusions: Hence this study suggests the P2X7 receptor to be an appealing 
antifibrotic target following renal infections.
Funding: Government Support - Non-U.S.
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Molecular Mechanisms of CKD - I
Genetic Ablation of Spermidine Oxidase Leads to Blunted Production of 
the Uremic Toxin Acrolein but Does Not Prevent CKD
Krister Bamberg,1 Charlotte Ericson,1 Lars Löfgren,1 Barbro Basta,1 
Katja Madeyski-Bengtson,1 Marcello Maresca,1 Yosuke Inui,2 Hideki Mochida,2 
Ola Fjellström.1 1AstraZeneca, Gothenburg, Sweden; 2Mitsubishi Tanabe 
Pharma Corporation, Toda, Saitama, Japan.
Background: The uremic toxin acrolein, a highly reactive aldehyde, is associated 
with cardiovascular disease and has been linked to chronic kidney disease (CKD). Sources 
of acrolein include e.g. smoking, lipid peroxidation and spermine metabolism. Spermine 
oxidase (SMOX) converts spermine to spermidine and generates acrolein.
Methods: Spermine oxidase germline deficient mice (SMOX-/-) were generated by 
CRISPR mediated gene deletion. Mice were subjected to an LPS challenge to study acute 
effects on polyamine and acrolein production. To study more chronic effects, renal ischemia 
reperfusion injury (IRI) or adenine diet induced kidney injury were elicited. 3HPMA, a 
stable metabolite of glutathione adducted acrolein, was measured in plasma and organs to 
assess acrolein production.
Results: SMOX deletion resulted in reduced circulating spermidine and acrolein 
levels. Following an LPS challenge, the acutely elevated acrolein levels, but also plasma 
creatinine levels particularly in males, were blunted in SMOX-/- animals. Both renal IRI 
and adenine diet induced chronic kidney injury led to increased circulating levels of acrolein 
in wild type but not in SMOX-/- animals. However, SMOX-/- did not prevent progression 
of kidney injury.
Conclusions: SMOX-/- animals responded with a blunted elevation of circulating 
acrolein levels after acute and chronic reduced kidney function. Reduction of this uremic 
toxin did not correlate to improved chronic kidney function in the models assessed here. It 
remains to be established whether reduction of SMOX activity and acrolein levels have a 
protective role in other cardiovascular diseases.
Funding: Commercial Support - AstraZeneca, Mitsubishi Tanabe Pharma Corporation
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Pathology and Lab Medicine: Basic
Near-Infrared Autofluorescence Is Useful for Non-Invasive Imaging of 
Injured Kidneys
Ayumi Matsumoto, Isao Matsui, Karin Shimada, Nobuhiro Hashimoto, 
Yohei Doi, Satoshi Yamaguchi, Keiichi Kubota, Tatsufumi Oka, 
Yusuke Sakaguchi, Takayuki Hamano, Yoshitsugu Takabatake, Yoshitaka Isaka. 
Osaka University Graduate School of Medicine, Suita, Japan.
Background: Tubulointerstitial injury (TI) is the final common pathway leading to 
end-stage renal disease. Because TI is an important therapeutic target in kidney diseases, 
it is indispensable to establish non-invasive strategies that enable us to evaluate the 
progression of TI.
Methods: Near-infrared autofluorescence (AF) of injured kidney was non-
invasively evaluated by IVIS imaging system. A combination of excitation 710 nm and 
emission 810-875 nm was used. Two animal models, unilateral ureteral obstruction 
and folic acid induced nephropathy, in BALB/c mice were analyzed. The origin of the 
renal AF was analyzed by confocal microscopy. Normal portions of human kidney 
tissues obtained from surgically resected kidneys owing to malignant tumors were also 
analyzed (35 patients (male 20, female 15), median age 69 (interquartile range (IQR) 
62-74), median estimated glomerular filtration rate (eGFR) 57.25 mL/min/1.73m2
(IQR 38.9-73.45)).
Results: The AF levels were positively correlated with the progression of TI in both 
animal models. Microscopic analysis of the kidney sections revealed that the AF was 
originated from the injured tubular cells. Because porphyrins are intrinsic fluorescent 
substrates that have near-infrared emission peak, we analyzed renal expression levels 
of enzymes that participate in the metabolism of porphyrin. Among 10 enzymes, only 
coproporphyrinogen oxidase (CPOX) was suppressed in the injured kidneys in both animal 
models, suggesting that coproporphrinogen III, a substrate for CPOX, and its spontaneously 
oxidized product, coproporphyrin III, were accumulated in the injured kidneys. We found 
that coproporphyrin III had identical fluorescent properties observed in the injured kidneys. 
Intraperitoneal injection of δ-aminolevulinic acid, a substrate of porphyrin synthesis, 
enhanced the AF of injured kidneys. The AF was also enhanced in BALB/c-nct/nct mice, a 
mice strain that retains only 15% of the wild type CPOX activity. Furthermore, AF levels of 
human kidney samples were inversely associated with eGFR.
Conclusions: Near-infrared AF derived from coproporphyrin III is useful for non-
invasive imaging of TI.
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Tissue-Resident Mucosal-Associated Invariant T (MAIT) Cells in Human 
Renal Fibrosis and CKD
Helen G. Healy,1,2 Becker Meng-Po Law,1,2 Xiangju Wang,1,2 Katrina Kildey,1,2 
Kurt T. Giuliani,1,2 Ray Wilkinson,1,2 Andrew J. Kassianos.1,2 1Kidney Health 
Service, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 
2Conjoint Kidney Research Laboratory, Pathology Queensland, Brisbane, QLD, 
Australia.
Background: MAIT cells are a specialised lymphocyte population associated 
with chronic inflammatory disorders in peripheral tissues. To date, MAIT cell research 
has focused primarily on mucosal tissue, with limited studies on non-mucosal organs 
such as kidneys. In this study, we evaluated MAIT cells in human native kidneys with 
tubulointerstitial fibrosis, the pathological hallmark of CKD.
Methods: MAIT cells were identified, enumerated and phenotyped from human 
kidney tissue by multi-colour flow cytometry. Localisation of MAIT cells was performed 
by immunofluorescence microscopy. MAIT cells and human primary proximal tubular 
epithelial cells (PTEC) were co-cultured under hypoxic (1% O2) conditions to examine 
mechanistic tubulointerstitial interactions.
Results: We detected significantly elevated numbers of MAIT cells (TCR-Vα7.2+ 
CD161++) in diseased biopsies with interstitial fibrosis compared with diseased 
biopsies without fibrosis and healthy kidney tissue. The increased numbers of MAIT 
cells also correlated significantly with loss of kidney function (eGFR). MAIT cells in 
fibrotic biopsies expressed cytokine receptors (IL-7Rα, IL-18Rα), activation receptor 
(NKG2D), extravasation marker (CD44) and tissue-resident markers (CD69, CD103). 
Immunofluorescent staining of fibrotic kidney tissue localised the accumulation of MAIT 
cells within the tubulointerstitial compartment, adjacent to PTEC. Notably, under in vitro 
pro-fibrotic/hypoxic conditions, PTEC induced the up-regulated expression of tissue-
resident markers on MAIT cells.
Conclusions: We provide the first characterisation of MAIT cells in human kidney 
tissue. Collectively, our data suggest that human MAIT cells are retained as tissue-resident 
lymphocytes and are positioned to contribute to the fibrotic process via complex interactions 
with PTEC. Further dissection of kidney MAIT cells is now required for the development 
of novel CKD therapeutics.
Funding: Government Support - Non-U.S.
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Pathology and Lab Medicine: Basic
RNA Seq Interrogation of a Clinical Kidney Biopsy Biobank Identifies Axl 
Kinase as an Anti-Fibrotic Target
Monica F. Tolosa,1 Lauren V. Caldwell,3 Yanling Zhang,1 Kerri Thai,1 
Anish Kirpalani,1 Adriana Krizova,1 Richard E. Gilbert,1,2 Darren A. Yuen.1,2 1St. 
Michael’s Hospital, Toronto, ON, Canada; 2Fibrocor Therapeutics, Toronto, 
ON, Canada; 3Lunenfeld Tanenbaum Research Institute, Ajax, ON, Canada.
Background: Fibrosis is a key manifestation and driver of chronic kidney injury. 
No safe and effective renal anti-fibrotic agents exist, in part because of the lack of human 
kidney tissue for study. Well annotated human kidney tissue biobanks are rare given their 
maintenance costs and the resources required to collect follow-up data. The few biobanks 
that exist have been primarily interrogated using microarrays, which while enabling 
multi-gene assessment, is limited to the probes on the array, and usually requires an extra, 
specially stored biopsy core. Here we describe the interrogation of archived remnants of 
clinical kidney biopsy tissue using a comprehensive RNA seq-based platform, enabling the 
study of clinical samples and linking to routinely obtained follow-up data.
Methods: RNA extracted from remnants of 14 frozen clinically indicated kidney 
transplant biopsies at St. Michael’s Hospital (SMH) was subjected to RNA sequencing. 
Clinical data (age, gender, Banff histologic scores, eGFR values) was collected from the 
SMH Kidney Transplant Database. Preliminary findings were confirmed in the murine 
unilateral ureteral obstruction (UUO) model of kidney fibrosis.
Results: The mean slope of eGFR change post-biopsy was -4.8 +/- 8.6 mL/min/yr. 
7 biopsies were scored as ci 1 (5 – 25% fibrosis), 6 biopsies as ci 2 (25 – 50% fibrosis), 
and 1 biopsy as ci 3 (> 50% fibrosis). In addition to known fibrosis-associated transcripts 
(collagens, TGF-beta, CTGF), we found that mRNA levels of the tyrosine kinase Axl were 
positively associated with fibrosis score (rho = 0.48, p = 0.03) and negatively with slope 
of eGFR change post-biopsy (rho = -0.52, p = 0.02). We found a similar increase in Axl 
mRNA levels in fibrotic UUO kidneys. As Axl mRNA expression was localized primarily 
to fibroblasts, we next treated NRK49F fibroblasts with an Axl inhibitor (BGB324), finding 
that Axl inhibition blocked TGF-beta-induced collagen production.
Conclusions: We describe a novel RNA seq-based platform that can interrogate 
routinely stored remnants of clinically obtained kidney biopsy tissue, enabling the use of 
archived clinical samples and their associated follow-up data. Our initial studies identified 
known fibrosis-associated transcripts, and also potential druggable targets that may lead to 
new anti-fibrotic strategies.
Funding: Private Foundation Support
TH-PO955 Poster Thursday
Pathology and Lab Medicine: Basic
The Effect of Complement 3 in Chymase Promoting Renal Interstitial 
Fibrosis
Jian-xin Wan. The First Affiliated Hospital of Fujian Medical University, 
Fuzhou, China.
Background: To investigate the effect of complement 3 (C3) on chymase promoting 
renal interstitial fibrosis.
Methods: To establish UUO model with wild type C57BL/6 mice (WT) and C3 
gene knockout mice (C3KO). WT mice were intraperitoneally injected with 10mg/Kg 
chymostatin in the first to fourteenth day after operation. All mice were sacrificed at 
fourteenth days and ipsilateral renal tissue. Masson staining was used to observe the renal 
interstitial fibrosis. The expression of C3, tryptase, chymase, rennin, AngII, TGF-β1, MMP9 
in renal interstitium were detected by immunohistochemistry or immunofluorescence or 
real time quantitative PCR or western blot. Chymase activity of renal tissue was detected by 
kit. ELISA kit was used to detect AngII, C3a, MMP9.
Results: Compared with WTcontrol group, C3, C3a, mast cells, chymase, renin, 
AngII, TGF-β1, MMP9 significantly increased in WTuuo group (P<0.001). Compared with 
WTuuo group, renal tubular injury and interstitial fibrosis were attenuated in C3KOuuo 
group (P<0.001), C3, C3a, mast cells, chymase, renin, AngII, TGF-β1, MMP9 significantly 
decreased in WTuuo group (P<0.001). Compared with WTuuo group, enal tubular injury 
and interstitial fibrosis were attenuated in WTuuo+chymostatin group (P<0.001), chymase 
activity was significantly decreased (P<0.001), the expression of AngII, TGF-β1 and 
MMP9 reduced significantly in WTuuo+chymostatin group (P<0.01).
Conclusions: Complement 3 may promote renal interstitial fibrosis by participating in 
recruitment and activation of mast cells.
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Complement 3 Mediated Macrophage Polarization Contributes to Renal 
Interstitial Fibrosis
Jian-xin Wan. The First Affiliated Hospital of Fujian Medical University, 
Fuzhou, China.
Background: To explore regulation of complement 3 (C3) on polarization of interstitial 
macrophages and related outcomes in renal fibrosis.
Methods: C57 BL/6 wild type and C3-deficient mice were created for UUO and 
sacrificed at days 3, 7, 14 after the operation. Obstructed kidneys were collected and 
assessed. Expression of C3 in kidneys was detected by immunohistochemical staining. 
Phenotypes of interstitially infiltrated macrophages, interstitial fibrosis, peritubular capillary 
density, expression of VEGF and inflammatory cytokines were compared between wild 
type and C3-deficient UUO mice. Propotion of macrophage phenotypes were identified 
by double immunofluorescence for F4/80 and iNOS or CD206, western blot for iNOS, 
Arg-1 and CD206. Paraffin sections were stained with HE and Masson’s trichrome. Score 
of tubulointerstitial injury and percent of renal interstitial fiobrotic area were obtained. 
Peritubular capillary density was detected by CD31 immunohistochemical staining. 
VEGF164, sVEGFR1, TNF-α, IL-10 were examined by real time quantitative PCR and 
western blot. Wild type and C3-deficient UUO mice were treated by liposome clodronate 
in early or late stage respectively then interstitially infiltrated macrophages and interstitial 
fibrosis were analysed.
Results: C3-deficient UUO mice had milder degree of tubulointerstitial fibrosis and 
fewer M1 but more M2 interstitial infiltration in early stage compared with wild type mice. 
This macrophage polarization shift was accompanied with decreased expression of TNF-α 
and sVEGFR1, increased expression of IL-10 and VEGF164 in kidney, as well as increased 
peritubular capillary density. Depletion of macrophages ameliorated renal fibrosis in wild 
type UUO mice but had no effect on C3-deficient UUO mice.
Conclusions: Complement 3 activation has a close relationship with renal interstitium 
infiltrating macrophages and fibrosis, and contributes to renal interstitial fibrosis by 
promotion of macrophage polarization, increasement of inflammatory cytokines, reduction 
of peritubular capillary density in kidney.
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Effect of Long-Term Tubular Overexpression of Hypoxia-Inducible 
Factor-2a on the Progressive Renal Fibrosis in a CKD Model
Kyoung Hye Kong, Hyung Jung Oh, Dong-Ryeol Ryu. Ewha Womans 
University, Seoul, Republic of Korea.
Background: Although hypoxia-inducible factor (HIF) is a key transcriptional factor 
in the response to hypoxia, and the effect of selective tubular activation of HIF-2α on renal 
fibrosis was demonstrated recently, there is no study for the effect of long-term tubular 
activation of HIF-2α on the progressive renal fibrosis.
Methods: We are mainly performed using PAX8-rtTA/tetO-Cre/HIF2dPA-HA 
transgenic mice(Tg). For the induction of renal fibrosis and CKD, the mice were 
fed a 0.2% adenine-containing diet for 2, 4, and 6 weeks with doxycycline (DOX, 
2mg/ml) administration at day 0. Moreover, isolated primary renal tubular epithelial 
cells (TECs) from Tg mice were divided into one of four groups: the control, DOX (5ug/
ml), TGF-β1(10ng/ml), and DOX+TGF-β1 groups (for 24, 48 and 72 h), in vitro. For 
renal function, Cr and BUN were measured, and real-time PCR, western blotting and 
immunohistochemical staining were performed.
Results: Serum Cr and BUN levels were significantly higher in WT and Tg CKD mice 
compared with the control mice at 2, 4 and 6 weeks. However, those levels of only 6-week 
HIF-2α activated CKD mice were significantly decreased compared to those in 6-week WT 
CKD model. The WB (fibronectin, E-cad/α-SMA, type I collagen) and IHC also showed the 
increased renal fibrosis in WT CKD mice at 2, 4 and 6 weeks compared with control mice. 
However, in only 6-week Tg CKD mice, the increased fibrosis was significantly attenuated 
compared to that in the same week WT CKD mice. In vitro, the increased fibronectin and 
type I collagen protein expressions after TGF-β1 stimulation were significantly decreased 
in the 72 h HIF-2α continuous activation except for 24 and 48 h groups.
Conclusions: These findings showed that long-term HIF-2α activation in CKD might 
inhibit the progression of renal fibrosis and improve renal function, which suggests that 
long-term renal HIF-2α activation could represent a new therapeutic way in CKD.
Funding: Other NIH Support - Natioinal Research Foundation of Korea 
(NRF-2013R1A1A2009837)
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Nrf2 Activator, RTAdh404, Attenuates Tubular Injury via Eliminating 
Mitochondrial ROS in Proteinuria Induced Renal Failure Mice
Yuji Sogawa,1 Hajime Nagasu,1 Minoru Satoh,1 Tamaki Sasaki,1 
Christian Wigley,2 Colin J. Meyer,2 Naoki Kashihara.1 1Kawasaki Medical 
School, Kurashiki, Japan; 2Reata Pharmaceuticals, Irving, TX.
Background: Severe proteinuria, including that associated with diabetic kidney 
diseases (DKD), leads to renal failure. Abundant proteinuria produces excessive reactive 
oxidative species (ROS), which trigger inflammation via mitochondrial dysfunction. 
Regulation of ROS is one of the potential therapeutic strategyies for DKD with proteinuria. 
We focused on NF-E2-related factor 2 (Nrf2), which is a master regulator for the cellular 
defense against oxidative stress. Nrf2 activator has a renoprotective effect by eliminating 
excessive ROS in ischemic-reperfusion injury. However, the mechanisms of the 
renoprotective effect of Nrf2 activator are not fully understood, especially in DKD. We thus 
investigated whether RTAdh404 attenuates proteinuria-induced renal tubular damage via 
mitochondrial protection.
Methods: Male ICR-derived glomerulonephritis mice (ICGN) were used. The mice 
were divided into three groups: ICR as a control, ICGN+Vehicle (Vehi), and ICGN+RTA 
dh404 (dh404). dh404 was administered orally for three weeks (dh404;10 mg/kg/day)). 
Serum creatinine was evaluated as a marker of a renal function. Mitochondrial function 
was assessed by COX staining and transmission electron microscope. Next, in vitro 
study, human proximal tubular epithelial cells (hPTECs) were used to determine the 
mechanism of renal protective effect by dh404. hPTEC were stimulated with bovine serum 
albumin (BSA) binding bound to free fatty acid (FFA) and treated with or without dh404 
for six hours.
Results: In ICGN+Vehi groups, renal dysfunction, based on the serum creatinine 
was significantly exacerbated. dH404 was able to treatment attenuated renal dysfunction 
in ICGN mice. Then Tubulointerstitial injury and fibrotic changes were also significantly 
worsened in ICGN+Vehi mice. Mitochondrial respiratory enzyme and the mitochondrial 
formation were injured. These damages were improved in ICGN+dh404 groups. These data 
suggest that RTA dh404 has a renoprotective effect via mitochondrial protection. In vitro 
study, hPTECs stimulated with FFA+BSA increased mitochondrial ROS and decreased 
mitochondrial membrane potential. These changes were improved with treatment of dh404.
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Conclusions: RTA dh404 attenuates proteinuria induced tubular cell injury through 
improvement mitochondrial function via eliminating mitochondrial ROS.
Funding: Commercial Support - Reata Pharmaceuticals
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Endothelial Dysfunction Exacerbates Renal Tubular Cell Injury Through 
Inflammasome Activation in a Hypertensive Mouse Model
Yuji Sogawa, Hajime Nagasu, Megumi Kondo, Yoshihisa Wada, 
Hiroyuki Kadoya, Kengo Kidokoro, Minoru Satoh, Tamaki Sasaki, 
Naoki Kashihara. Kawasaki Medical School, Kurashiki, Japan.
Background: Chronic inflammation is a common pathway of progressive kidney 
diseases. One of the mechanism in forming chronic inflammation is NLRP3 inflammasome 
activation. We reported that aldosterone induced hypertension progress tubular interstitium 
injury via NLRP3 inflammasome activation. However, it is unclear how NLRP3 
inflammasome is regulated in the kidney. On the other hand, it is reported that nitric 
oxide(NO) derived from iNOS suppress inflammasome activation in macrophage. So, we 
investigated whether or not NO derived from eNOS suppress inflammasome activation in 
hypertensive kidney disease because it is well known that endothelial dysfunction promotes 
progressive kidney disease.
Methods: Six weeks male C57BL/6 mice (WT) and eNOS deficient mice (eNOSKO) 
were used. These mice were divided into four groups (WT, WT-Ald, eNOS, and 
eNOS-Ald). Aldosterone (Ald) was continuously administered for four weeks by infusion 
pump. Next, eNOS/ASC double deficient mice (eNOS/ASC DKO) were generated to 
investigated whether inhibition of inflammasome activation can reduce kidney injury 
caused by endothelial dysfunction. Finally, we explored the molecular mechanisms 
underlying the regulation of inflammasome activation by endothelial dysfunction. Bone 
marrow-derived macrophages (BMDMs) were stimulated with ATP after priming LPS 
and simultaneously primed with S-nitrosoglutathione (GSNO) as an NO donor or 
Bay41-2272 as a sGC stimulator.
Results: NLRP3 inflammasome activation was increased in the kidneys of the 
eNOS-deficient mice, and tubulointerstitial fibrosis was accelerated. Suppression of 
inflammasome activation by knocking out ASC prevented tubulointerstitial injury in 
the eNOS knockout mice, indicating that the eNOS-NO pathway is involved in the 
development of kidney dysfunction through acceleration of NLRP3 inflammasome in 
macrophages. ATP stimulation with LPS priming caused NLRP3 inflammasome-dependent 
cell death and IL1beta secretion. While GSNO inhibited this activation, it did not affect the 
sGC stimulator. This data suggests that NO can suppress NLRP3 inflammasome activation 
directly in macrophages.
Conclusions: eNOS-NO pathway could be a therapeutic target for the treatment of 
chronic kidney disease associated with endothelial dysfunction.
Funding: Government Support - Non-U.S.
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Tenascin-C-Rich Extracellular Microenvironment Impairs Renal Tubular 
Integrity and Promotes Renal Fibrosis
Haili Zhu,1 Jinlin Liao,1 Xue Hong,1 Haiyan Fu,1 Youhua Liu.2 1Division of 
Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 
China; 2Department of Pathology, University of Pittsburgh, Pittsburgh, PA.
Background: Tenascin-C (TNC), an extracellular matrix glycoprotein, is the major 
component of fibrogenic niche that facilitates renal fibrosis through multiple mechanisms. 
We previously reported that focal expression of TNC after injury sets up a favorable 
microenvironment for fibroblast activation and proliferation. However, whether such a 
TNC-rich niche also affects tubular cell integrity and phenotype remains unclear.
Methods: Serum and biopsy specimens from CKD patients as well as various 
CKD animal models were used. TNC and its downstream signaling was manipulated or 
therapeutically inhibited in vivo. The 2-Dimensional and 3-Dimensional culture of human 
kidney proximal tubular cells (HKC-8) and mouse primary proximal tubular epithelial cells 
were applied.
Results: ELISA results demonstrated that TNC level significantly elevated in 
the serum of CKD patients, and consistently its expression was also induced in kidney 
biopsy specimens from CKD patients with different etiologies. In vitro, TNC significantly 
promoted HKC-8 cell migration and induced them to undergo epithelial-mesenchymal 
transition (EMT). Similarly, TNC also impaired the integrity of mouse primary proximal 
tubular epithelial cells by triggering EMT. Using de-cellularized kidney tissue scaffold 
(KTS) isolated from fibrotic kidneys, we found that TNC-enriched KTS facilitated tubular 
epithelial cell EMT, whereas TNC-deprived KTS inhibited it. Mechanistically, TNC 
induced integrin αvβ6, activated focal adhesion kinase (FAK), leading to the activation 
of ERK signaling. Blockade of FAK signaling abolished TNC’s ability to induce tubular 
cell EMT in vitro. In mouse models of CKD induced by unilateral ureteral obstruction or 
ischemia/reperfusion injury, knockdown TNC or specific inhibition of FAK signaling with 
small molecule inhibitor repressed partial EMT and ameliorated fibrotic lesions.
Conclusions: These studies unveil that TNC-rich extracellular niche plays a critical 
role in impairing tubular cell integrity by inducing partial EMT. Our data also indicate that 
blockade of TNC/FAK signaling is a novel strategy for therapeutic intervention of renal 
fibrosis.
Funding: NIDDK Support, Government Support - Non-U.S.
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rAAV6-Mediated miR-29b Delivery Suppresses Renal Fibrosis
Suguru Saito,1 Shinichiro Ohno,2 Masahiko Kuroda,2 Yoshihiko Kanno.1 
1Deparatment of Nephrology, Tokyo Medical University, Tokyo, Japan; 
2Deparatment of Molecular Pathology, Tokyo Medical University, 
Tokyo, Japan.
Background: Renal fibrosis is a common feature of CKD, which has no available 
specific treatment. Micro RNAs (miRNAs) are short endogenous non-coding RNAs that 
regulate various cellular processes. Previous studies showed that miR-29b inhibits renal 
fibrosis in mice models. Therefore, miR-29b replacement therapy represents a promising 
approach for treating renal fibrosis. However, an efficient method of kidney-targeted 
miRNA delivery has yet to be established. Recombinant adeno-associated virus (rAAV) 
vectors have great potential for clinical application. The distinct AAV serotypes exhibit 
different tissue tropisms. For kidney-targeted gene delivery, the most suitable AAV serotype 
has yet to be established. Here, we identified the most suitable AAV serotype for kidney-
targeted gene delivery, and determined that AAV-mediated miR-29b delivery can suppress 
renal fibrosis in vivo.
Methods: We used the normal rat kidney fibroblast cell line (NRK-49F), rat TEC 
line (NRK-52E), and human kidney proximal TECs to determine which AAV serotype is 
suitable for kidney-targeted gene delivery in vitro. To determine transduction efficiency, 
GFP-positive cells were identified by flow cytometry after the infection of rAAV serotype 
1–9 vectors containing the EGFP gene. Next, we went on to investigate the transduction 
efficiency of mouse kidney by using rAAV serotype 1–9 vectors in vivo. We injected rAAV 
vectors into the renal pelvis. To determine transduction efficiency, GFP expression was 
measured seven days after injecting rAAV vectors carrying the EGFP gene Finally, we 
investigated whether rAAV6-mediated miR-29b delivery can suppress renal fibrosis in a 
unilateral ureteral obstruction (UUO) mouse model.
Results: We found that rAAV6 vector is the most suitable for targeting kidney cells 
regardless of animal species in vitro and rAAV6 is the most suitable vector for kidney-
targeted in vivo gene delivery in mice. Intra-renal pelvic injection of rAAV vectors can 
transduce genes into kidney TECs. Furthermore, rAAV6-mediated miR-29b delivery 
attenuated renal fibrosis in UUO model by suppressing Snail1 expression.
Conclusions: In summary, our study has revealed that rAAV6 is the most suitable 
serotype for kidney-targeted gene delivery and rAAV6-mediated miR-29b delivery into 
kidney TECs can suppress established renal fibrosis. Our findings may provide novel 
information for facilitating kidney gene therapy.
Funding: Government Support - Non-U.S.
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DNM3OS Non-Coding RNA as a New Therapeutic Target in the Context 
of Renal Fibrosis
Christelle Cauffiez,1 Grégoire Savary,1 Edmone Dewaeles,1 Julie Lemaire,1 
Francois Glowacki,2,1 Nicolas Pottier.1 1University of Lille EA4483, Lille, 
France; 2CHRU de Lille, Lille, France.
Background: The study of miRNAs in fibroproliferative diseases, and in particular in 
kidney fibrosis, has underscored their involvement in the key mechanisms of fibrogenesis. 
In the context of pulmonary fibrosis, the polycistronic RNA DNM3OS, producing the three 
fibromiRs, miR-199a-5p, miR-199a-3p and miR-214-3p, has recently been described as a 
regulator of the process fibrosis. Indeed, these three miRNAs participate in TGF-β pathway 
regulation and in the differentiation of fibroblasts into myofibroblasts. The aim of this study 
was to evaluate in kidney the anti-fibrotic potential of targeting the non-coding DNM3OS 
RNA by different oligonucleotide approaches directed against DNM3OS or miR- 199a-5p.
Methods: In a first step, the oligonucleotides were selected according to their anti-
fibrotic efficacy in the 3T3 fibroblast cell line. The study then relies mainly on the use 
of a murine model of renal fibrosis induced by unilateral ureteral obstruction. After 
evaluating their safety (acute or chronic administration), oligonucleotides formulated for 
in vivo administration and directed against either miR-199a-5p or DNM3OS (Gapmer) 
were systemically injected before and after the induction of renal fibrosis. Fibrotic lesions 
was evaluated by studying the renal expression of fibronectin 1 (FN1) and Collagen 
1a1 (COL1A1) genes as well as by the histological analysis of kidney sections by 
immunohistochemistry and Sirius Red staining.
Results: Our results showed that the administration of oligonucleotides directed 
against miR-199a-5p or DNM3OS allows a significant reduction in renal fibrosis lesions 
induced by ureteral obstruction. In particular, we observed a decrease in the expression of 
extracellular matrix compounds such as FN1 and COL1A1. In addition, tolerance studies 
(single or chronic) of anti-miR-199a-5p did not reveal any renal or hepatic toxicity of the 
oligonucleotide in mice.
Conclusions: Overall, in the context of fibroproliferative pathologies, our results 
underline the interest of the therapeutic targeting of polycistronic RNA DNM3OS based 
on the modulation of the expression of this non-coding RNA or of one of the miRNAs that 
it produces using synthetic oligonucleotides. The clinical development of such molecules 
could eventually limit the progression of fibrosis.
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Therapeutic Effect of siRNA-CD40 on AKI Caused by Reversible 
Obstructive Nephropathy in Mice
Roser Guiteras,1 Alonso N. Barros,1 Anna Sola,1 Anna Manonelles,2 Joan Torras,2 
Josep M. Cruzado.2 1IDIBELL, Hospitalet de Llobregat, Spain; 2Hospital 
Universitari de Bellvitge, Barcelona, Spain.
Background: The costimulatory CD40-CD40L pathway plays a role in kidney 
inflammation. We have previously reported that renal CD40 upregulation precedes cellular 
interstitial infiltrate and fibrosis in the unilateral ureteral obstruction (UUO) model. Here we 
sought to evaluate whether the administration of siRNA anti-CD40 has a therapeutic effect 
in a reversible UUO mice model (rUUO).
Methods: Eight week-old C57BL6J male mice were divided into four groups: wild 
type (n=6); rUUO-Sham (n=8); rUUO+siRNA Scrambled, a non-specific siRNA (n=6), 
and rUUO+siRNA anti-CD40, specific siRNA anti-CD40 (n=8). Ureteral clamping was 
performed on 8 week-old C57BL6J male mice. At day 3 after surgery, the ureteral clamp 
was removed and nephrectomy of the contralateral kidney was performed. Immediately, 
PBS, siRNA SC (50μg) or anti-CD40 (50μg) was administrated via the tail vein. Mice were 
killed 48h hours after. Blood samples at days 0, 3, 4 and 5 were collected for creatinine 
analysis. Histology and kidney mRNA expression were performed.
Results: The administration of siRNA anti-CD40 was associated with a significant 
reduction of renal CD40 mRNA expression (Table 1). siRNA anti-CD40 reduced 
significantly the severity of acute renal failure associated with UUO (Figure 1). Pathologic 
analysis showed reduction of tubular dilation, F4/80 macrophage infiltration and interstitial 
fibrosis in animals treated with CD40-siRNA (Table 1). Furthermore, kidney mRNA gene 
expression analysis showed significantly lower levels of pro-inflammatory cytokines such 
IL-2 and CCL-2 and pro-fibrotic TGFβ-1 in CD40-siRNA mice.
Conclusions: The administration of siRNA-CD40 therapy at the time of ureter clamp 
removal in the UUO model reduces the severity of the acute kidney injury and promotes 
kidney repair.
TH-PO964 Poster Thursday
Pathology and Lab Medicine: Basic
Pericyte-Myofibroblast Transition Induced Tubulo-Interstitial Injury in a 
Novel Renal Venous Congestion Rat Model
Takuo Hirose,1,2 Satoshi Shimada,2 Chika Takahashi,1 Emiko Sato,2 
Satoshi Kinugasa,1,2 Sadayoshi Ito,2 Takefumi Mori.1,2 1Division of Nephrology 
and Endocrinology, Tohoku Medical and Pharmaceutical University, Sendai, 
Japan; 2Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku 
University Graduate School of Medicine, Sendai, Japan.
Background: Increased central venous pressure in congestive heart failure is 
responsible for renal dysfunction. However, the knowledge of the underlying mechanisms 
is limited. We hypothesized that renal interstitial hydrostatic pressure (RIHP) and 
expansion pressures of the vasa recta are responsible for pericyte detachment resulting renal 
congestion-mediated fibrosis. We created a novel rat renal congestion model to investigate 
the effect of renal congestion on hemodynamics and its molecular mechanisms.
Methods: The inferior vena cava (IVC) between the renal veins was ligated by suture 
in male Sprague-Dawley rats to increase upstream IVC pressure and induce congestion in 
the left kidney only.
Results: Left kidney congestion reduced renal blood flow in cortex (33.6%, 28.3 to 
16.0 mL/min) and in medulla (41.8%, 11.9 to 6.9 mL/min) and glomerular filtration rate 
(17.2%, 1.16 to 0.20 mL/min/kg BW), and increased RIHP (1.4 fold, 12.6 to 17.6 mm Hg). 
In the congestive kidneys, hypoxia was observed in the medullary thick ascending limb 
of Henle. Tubulointerstitial injury, podocyte injury, albuminuria, and reduced creatinine 
clearance were observed in the congestive kidneys. Molecules related to extracellular 
matrix expansion, tubular injury, and focal adhesion were upregulated in microarray 
analysis. Renal decapsulation ameliorated the tubulointerstitial injury (mRNA expression 
of Kim1 15.3 to 4.3 A.U., αSma 5.3 to 2.8 A.U.). Electron microscopy captured pericyte 
detachment in the congestive kidneys. Transgelin and platelet-derived growth factor 
receptors (PDGFRs), as indicators of pericyte-myofibroblast transition, were upregulated 
in the pericytes and the adjacent interstitium. Imatinib, a PDGFR inhibitor, ameliorated the 
interstitial injury.
Conclusions: Our results reveal a novel mechanism of worsening renal function 
associated with congestive heart failure, and provide a new therapeutic candidate based on 
a better understanding of the pericyte-myofibroblast transition.
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Varying AKI Types Affect Parietal Epithelial Cell Function with Different 
Impact on Tubuloglomerular Cross-Talk
Jiayi Wang,1 Xin Li,3 Ming-Zhi Zhang,1 Raymond C. Harris,1 Taiji Matsusaka,2 
Haichun Yang,1 Agnes B. Fogo.1 1Vanderbilt University Medical School, 
Nashville, TN; 2Tokai University School of Medicine, Isehara, Japan; 3The 
Medicine College of Shanghai JiaoTong University, Shanghai, China.
Background: Previously we found that mild tubulointerstitial fibrosis sensitizes the 
kidney to subsequent glomerular injury. The transition of acute kidney injury (AKI) to 
chronic kidney disease depends on the severity of AKI. In this study, we explored whether 
the type of initial proximal tubular (PT) injury impacts the glomerular response to a 
subsequent injury, and the role of parietal epithelial cells (PECs) in this response.
Methods: We induced AKI by injecting diphtheria toxin (DT) in DTR transgenic 
mice that express human DT receptor in S2 and S3 PT, or by injecting aristolochic acid 
(AA) which targets all PT and part of PECs. All mice were mated with NEP25 mice, which 
express human CD25 on podocytes, and podocyte injury can be induced by immunotoxin 
(LMB2). Mice underwent LMB2 injection at 6 wks after DT or AA injury, with control 
mice (PODO) only receiving LMB2 without preceding tubular injury, followed by 
uninephrectomy 1 wk later and sacrifice 4 wks later. In vitro, PECs were exposed to vehicle 
or AA for 24h, followed by exposure to supernatant from injured podocytes for 48 hours.
Results: Urinary KIM-1/NGAL recovered to baseline in DT while they remained high 
in AA mice at wk 6 after injury. AA+LMB2 mice had significantly higher albuminuria 
than PODO, while DT+LMB2 had no significant increase vs PODO, at 1 wk after LMB2. 
Columnar PECs may have more stem cell potential vs flat PECs, and columnar/flat 
PECs ratios were higher in PODO mice and DT+LMB2 than AA+LMB2. Expression of 
β–catenin and ILK in PECs increased in AA+LMB2, but not in DT+PODO, compared to 
PODO. WT1+ cell density was decreased in both AA+LMB2 and DT+LMB2 vs PODO. 
At 4 wks after LMB2, 0/16 PODO and 1/23 DT+LMB2 vs 8/16 AA+LMB2 mice had 
died. GFR, ACR and glomerulosclerosis were similar among groups in surviving mice. 
Both DT+LMB2 and AA+LMB2 showed more CD44+/α-SMA+ cells on the glomerular 
tuft than PODO, suggesting mesenchymal transition of activated PECs. In vitro, AA-
treated PECs expressed more ILK and CTGF vs vehicle after cells were exposed to injured 
podocyte medium.
Conclusions: Tubular injury that involves specific PT segments and PECs, which 
may serve as stem cells and participate in glomerular rescue after injury, may result in less 
recovery and increased sensitization of glomeruli to a second hit.
Funding: NIDDK Support
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IL-6 Signaling Triggers Expulsion of Uropathogenic Bacteria from Host 
Epithelial Cells to Limit UTI Chronicity
Sudipti Gupta, Christina B. Ching, Brian Becknell. Nationwide Children’s 
Hospital, Columbus, OH.
Background: Treatment of urinary tract infections (UTIs) has historically relied on the 
use of antibiotics which are limited by patient intolerance and rising bacterial resistance. 
Innate immunity represents an attractive alternative in UTI treatment and prevention; 
however, its influence on bacterial virulence is not well known. Specifically, IL-6 is induced 
during UTI, but our understanding of its role in UTI pathogenesis is limited. We sought 
to determine how IL-6 expression alters urothelial susceptibility to infection and impacts 
bacterial clearance.
Methods: 6-8 week old female wild type (WT) C57BL/6J and IL-6 knock out (KO) 
mice were transurethrally infected with uropathogenic Escherichia coli (UPEC). Bacterial 
burden was assessed by dilution plating; and intracellular bacterial communities (IBC) 
were enumerated by beta-galactosidase staining. Gentamicin protection assay quantified 
intracellular bladder bacterial burden. The impact of IL-6 neutralization and IL-6 rescue 
on IBC formation was studied in WT and IL-6 KO mice, respectively. Neutralization of 
serum IL-6 was confirmed by ELISA. In vitro gentamicin protection assay was used to 
study the impact of recombinant IL-6 on bacterial attachment, invasion, and expulsion 
in bladder epithelial cells (BECs). Results were evaluated by Mann-Whitney U test with 
p <0.05 being significant.
Results: A significant increase in IBCs was observed in IL-6 KO mice vs. WT controls 
early during infection but resolved 24 hours post infection (hpi). These findings were 
recapitulated by antibody neutralization of IL-6 in WT mice. The increase in IBCs in IL-6 
KO animals was reversed with recombinant IL-6. We confirmed an increase in bladder 
bacterial burden in IL-6 KO mice by ex vivo gentamicin protection assay, which accounts 
for increased bacteriuria in IL-6 KO compared to WT mice beginning after 24 hpi. In 
vitro experiments in BEC demonstrated that IL-6 treatment significantly increased UPEC 
expulsion but did not impact invasion or attachment.
Conclusions: IL-6 reduces UTI susceptibility by promoting UPEC expulsion from 
host epithelial cells, thereby limiting the ability of UPEC to persist intracellularly and form 
IBCs. Given that IBC formation represents a significant bottleneck event in UPEC survival, 
these findings suggest a mechanism whereby IL-6 reduces UTI chronicity.
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Mitigation of Radiation Injury by Epoxyeicosatrienoic Acid Mimetic 
Assessed by Urinary Proteomics
Ann M. Kolbach-Mandel,2 Eric P. Cohen,1,3 Neil S. Mandel,2 John D. Imig,2 
Abdul Hye Khan,2 Brian L. Fish,2 Maureen A. Kane,1 Weiliang Huang.1 
1University of Maryland, Baltimore, MD; 2Medical College of Wisconsin, 
Milwaukee, WI; 3Medicine, Baltimore VAMC, Baltimore, MD.
Background: Radiation exposure due to radionuclide cancer therapy, accident, or 
radio-nuclear attack could cause radiation induced nephropathy. Non-biased urinary 
proteomic analysis can identify novel urine biomarkers that precede tissue injury and may 
be mechanistically relevant.
Methods: 20 male WAG/RijCmcr rats underwent partial body irradiation (PBI) with 
one leg shielded to allow bone marrow reconstitution. 24 hour urine was collected four weeks 
after PBI from control (0 Gy) or irradiated (11 Gy) without or with epoxyeicosatrienoic acid 
(EET) mimetic therapy. Renal injury was assessed by urine protein and urine creatinine. 
Proteomic analysis was performed on urine (ultrafiltered > 3kDa) using standardized 
methods. Protein abundance determinations (% Extracted Ion Chromatograph, % XIC) 
were normalized to total urine protein, urine creatinine, and rat weight. Final protein 
concentrations are reported as protein/creatinine/weight (mg/g/kg).
Results: Baseline rat weights did not differ according to experimental group. 
At 4 weeks after PBI the 11 Gy rats weighed significantly less than controls. The radiated 
rats did not differ in total urine protein, urine creatinine, urine protein/creatinine, or urine 
volume. Proteinuria occurs starting at six weeks in this model. Mass spectrometry-based 
proteomics yielded 781 proteins with 99.9% overlap in all experimental groups. The 
increased abundance of proteins in irradiated rats were largely of extracellular origin and 
part of biological networks related to nucleic acid, carbohydrate, and collagen metabolism. 
The EET mimetic significantly changed select proteins related to these networks. 
Notable changes in mg/creat/body weight were: Malate dehydrogenase 0.06/0.18/0.11, 
Glyceraldehyde 3 phosphate dehydrogenase 0.05/0.20/0.12, and Lysyl Oxidase 
0.01/0.25/0.01.
Conclusions: Radiation exposure results in significant increases in urinary proteins, 
largely extracellular in origin, related to nucleic acid, carbohydrate, and collagen 
metabolism. The largest effect was on lysyl oxidase, an enzyme that increases collagen 
crosslinking which may presage tissue fibrosis in this model. This offers some insight into 
the known therapeutic benefits of the EET mimetic.
Funding: Veterans Affairs Support
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Urinary Extracellular Vesicles (uEVs) Have Unique Characteristics as 
Demonstrated by Imaging and Spectral Cytometry
Luca Musante,1 Sabrina La salvia,1 Joanne Lannigan,1 Uta Erdbruegger.2 
1University of Virginia, Charlottesville, VA; 2University of Virginia Health 
System, Charlottesville, VA.
Background: Urinary extracellular vesicles (uEVs) provide a source of valuable 
biomarkers for kidney and urogenital diseases. Analysis of uEVs is challenging due to its 
intrinsic complexity. Imaging flow cytometry (iFC) allows detection of particles that are < 
200 nm in size and has a high level of sensitivity for small particle fluorescence. In addition, 
spectral flow cytometry (sFC), which is based on whole spectrum analysis, can be used to 
further characterize the findings of the iFC analysis.
Methods: First morning void urine, blood and saliva (internal auto fluorescent control) 
were centrifuged at relative centrifugation force RCF of 4.600g for 30 minutes. The 
supernatants was further centrifuged at 20,000g to collect EVs. uEVS were stained with 
different annexin V conjugates: FITC, PE, PerCPCy5.5, Pacific Blue™, Brilliant Violet 
421, Brilliant Violet 510, APC, Alexa Fluor® 647 respectively. Gating strategy was based 
on the low scatter of the unstained uEVs and the negative control was all fluorescent probes 
alone in buffer. Stained and unstained EVs from urine, plasma and saliva were evaluated
Results: Acquisition of uEVs alone in iFC showed an interesting auto-fluorescence 
emission in channel 5 (λex 660 nm; λem 740 nm) for camera 1 and channel 11 (λex 660 nm; 
λem 740 nm) for camera 2. Auto fluorescence emission in channel 11 was caused by 
excitation from the violet laser (λex 405 nm) and red laser (λex 642 nm). Auto-fluorescence 
in Channel 5 was caused by excitation of both blue (λex 488 nm) and yellow laser 
(λex 561 nm). Spectral analysis of unlabelled uEVS, plasma EVs (pEVs), and saliva EVs 
(sEVs) showed that this auto-fluorescence was unique and specific for uEVs. Spectrum 
plots showed a distinct signature
Conclusions: While imaging flow cytometry represents a major advancement in the 
identification of uEVs, our results suggest that unexpected additional complication of the 
analysis originated from the auto-fluorescence with a peculiar spectral emission that needs 
to be taken into account when multicolor antibodies panels are planned. Likewise, choice of 
AV fluorochrome conjugate should be carefully considered.
Funding: Other NIH Support - Internal funding
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Enrichment and Identification of Ubiquitinated Proteins in Urinary 
Extracellular Vesicles
Yongqiang Li, Hequn Zou. Third Affiliated Hospital of Southern Medical 
University, Guangzhou, China.
Background: Urinary extracellular vesicles(uEVs) is widely considered to represent 
pathological events in the kidneys and the urogenital epithelium. Ubiquitin mediates 
proteolysis through the enzymatic conjugation of UB to proteins that contain primary 
degradation signals. The aim of our current study was to establish a method to enrich and 
identify ubiquitinated protein in uEVs.
Methods: After 2000g centrifugation, supernatant 2000g was obtained from 1st 
morning urine. Then supernatant 2000g was processed by Hydrostatic dialysis filter using 
dialysis membrane with a molecular weight cutoff (MWCO) of 1,000 kDa. Protein-A 
Sepharose® IgG was used to concentrate ubiquitinated proteins, which is based on the 
binding of antibodies to Sepharose beads and subsequent cross-linked by Dimethyl 
pimelimidate(DMP). Coomassie staining, western blot and mass spectrographic analysis 
were used to characterize the ubiquitinated protein in uEVs.
Results: Ubiquitinated proteins in uEVs are enriched successfully. We detected 
60 specific sites of 37 ubiquitinated proteins. These ubiquitinated proteins were mainly 
enriched in the biological process categories of cellular process. Most of the ubiquitinated 
proteins in the cellular component category occurred in the nucleus. The KEGG enrichment 
pathway analysis of these ubiquitinated proteins suggested that ubiquitination maybe play 
an indispensable role in the regulation of the mTor signaling pathway.
Conclusions: We provides a simplified method to enrich and identify ubiquitinated 
proteins in uEVs. 60 specific sites of 37 ubiquitinated proteins were discovered. Till now, 
all screening ubiquitinated proteins in urinary EVs of this study have not been previously 
reported. These method and findings allows the possibility to further chronic kidney disease 
studies in uEVs related to ubiquitinated proteins.
Funding: Government Support - Non-U.S.
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Circulating Exosomes Mediate Inter-Organ Communication in Type 2 
Cardiorenal Syndrome
Cong Wang,1 Lili Zhou,1 Youhua Liu.2 1Division of Nephrology, Nanfang 
Hospital, Southern Medical University, Guangzhou, China; 2Department of 
Pathology, University of Pittsburgh, Pittsburgh, PA.
Background: Inter-organ crosstalk plays an essential role in regulating tissue 
homeostasis, injury repair and the pathogenesis of multi-organ dysfunction. Cardiorenal 
syndrome type 2 (CRS2) is characterized by chronic abnormalities in cardiac function 
causing progressive chronic kidney disease (CKD). However, the mediators connecting 
heart and kidney are poorly characterized. In this study, we report that exosomes produced 
by injured heart plays a vital role in mediating cardiorenal connection in mouse model of 
transverse aortic constriction (TAC).
Methods: Four weeks after TAC, mice were randomized into three groups: 1) sham 
control; 2) TAC mice; 3) TAC mice injected daily with cyclopamine (CPN), a specific 
small molecule inhibitor of hedgehog signaling. At 8 weeks after TAC, all animals were 
sacrificed. Urine, blood, heart and kidney tissues were collected for analysis. Exosomes 
were isolated from mouse serum, and incubated with normal rat kidney interstitial fibroblast 
(NRK-49F) cells.
Results: At 8 weeks after TAC, cardiac hypertrophy and fibrosis were prominent, 
as evidenced by increased expression of β-myosin heavy chain, α-actin and fibronectin. 
Echocardiography also revealed an impaired cardiac function in TAC mice. These cardiac 
lesions were accompanied by an upregulation of sonic hedgehog (Shh) and increased 
production of exosomes in cardiac tissue. Blockade of Shh signaling by CPN ameliorated 
cardiac injury and restored heart function. Notably, TAC mice also developed kidney lesions 
secondary to chronic heart failure, manifested by proteinuria, kidney fibrosis and renal 
upregulation of Shh. CPN mitigated all these lesions in the kidneys. Serum derived from 
TAC mice was able to induce renal interstitial fibroblast activation in vitro, indicating the 
circulating factors as mediators of cardiorenal connection. Furthermore, exosomes isolated 
from TAC serum was sufficient to cause fibroblast activation and matrix production. 
Western blot demonstrated the presence of Shh and Smo in the isolated exosomes from 
TAC serum, but not in the exosomes from the control serum.
Conclusions: These studies demonstrate that heart-derived, circulating exosomes are a 
unique and effective vehicle to deliver Shh to the kidney after TAC. Targeted inhibition of 
Shh signaling could be a promising therapeutic strategy for protecting both heart and kidney 
in cardiorenal syndrome.
Funding: Government Support - Non-U.S.
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Renal NMDA Receptor Mediates the Amino Acid Induced Vasodilation 
Through Connecting Tubule-Glomerular Feedback (CTGF)
Cesar A. Romero,1 Hong Wang,1 Yilin Ren,2 Oscar A. Carretero.2 1Hypertension 
and Vascular Research, Internal Medicine, Henry Ford Hospital, Detroit, MI; 
2Henry Ford Hospital, Detroit, MI.
Background: The intravenous infusion of amino acids increase the renal blood flow 
and glomerular filtration rate, and it used to quantify the renal functional reserve. Similarly, 
high protein diet promotes the progression of chronic kidney diseases in part due to an 
increase in the renal blood flow, and glomerular pressure. Those glomerular effects are 
thought to be related to a vasodilation mediated by the amino acids that are released from the 
diet. However the vasodilator mechanism related to the amino acids in kidney is unknown. 
Kidney expresses the amino acid receptor N-methyl-D-aspartate (NMDA) that is activated 
by glutamate and glycine. Our lab described an intrinsic kidney feedback mechanism called 
CTGF that by sensing sodium in the connecting tubule (CNT) induces the dilation of the 
afferent arteriole (Af-Art). We hypothesize that in the kidney through the NMDA receptors 
the amino acids induce Af-Art dilation by activating CTGF.
Methods: By using double-perfusion of Af-Art and CNT technique in vitro (rabbit) 
and Stop-Flow Pressure (SFP) technique in vivo (Sprague Dawley Rat), we test the Af-Art 
dilation induced by CTGF when the CNT perfuse with glycine plus glutamate 10-3M with 
or without the NMDA blocker MK-801.
Results: In vitro, in pre-constricted Af-Arts, addition of glycine plus glutamine to the 
CNT increases the Af-Art dilation (EC50 10.7) vs. control (EC50 24.5; p<0.001), and that 
dilation is blocked by CTGF blocker benzamil, suggesting that glycine plus glutamine 
enhanced CTGF. When we add the NMDA receptor blocker MK-801 to the CNT, the 
increased CTGF response is blunted. In vivo, the intratubular infusion of the amino 
acid induces vasodilation (SFP mmHg 37.9±2.6 vs. 28.6±1.9 control; P<0.01) and that 
vasodilation is blocked by benzamil.
Conclusions: Renal vasodilation induced by amino acid is mediated by the CTGF 
through the NMDA receptor in the connecting tubule. The activation of the CTGF by amino 
acids explain the basis of the renal functional reserve test and provide potential mechanism 
to prevent the renal damage associated with high protein diet.
Funding: Other NIH Support - NHLBI
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Autophagy Protects Kidney Proximal Tubules from Phosphate-Mediated 
Mitochondrial Dysfunction
Ryuta Fujimura,1 Takeshi Yamamoto,1 Yoshitsugu Takabatake,1 Satoshi Minami,1 
Atsushi Takahashi,1 Tomoko Namba,1 Jun Matsuda,1 Shinsuke Sakai,1 
Isao Matsui,1 Fumio Niimura,2 Taiji Matsusaka,2 Yoshitaka Isaka.1 1Nephrology, 
Osaka University Graduate School of Medicine, Osaka, Japan; 2Tokai University 
School of Medicine, Isehara, Japan.
Background: Autophagy is one of the major degradation pathways in the cell and 
maintains cellular homeostasis in various settings. Hyperphosphatemia is associated with 
a faster progression of chronic kidney disease (CKD), as well as an increased risk of 
cardiovascular mortality. However, molecular mechanisms of phosphate-mediated kidney 
injury are largely unknown.
Methods: We investigated the pathogenesis of phosphate-mediated kidney injuries in 
the proximal tubular epithelial cells(PTECs) with a focus on autophagy and mitophagy, and 
the effects of autophagy deficiency and enhancement on kidney morphology and function 
during phosphate overload.
Results: In GFP-MAP1LC3 transgenic mice, high phosphate(HP) diet continuously 
stimulated autophagy in the PTECs. In novel mitophagy-reporter mice (mito-QC), HP diet 
also increased the number of mitolysosomes (mitochondria-containing autolysosomes) 
exclusively in the PTECs. High concentration of inorganic phosphate (Pi) in the medium 
increased PINK1/Parkin expression as well as autophagic activity in cultured PTECs. 
High Pi not only induced mitochondrial ROS production and mitochondrial permeability 
transition pore (mPTP) opening, but also reduced mitochondrial membrane potential, ATP 
production and oxygen consumption rate, all of which were significantly exaggerated by 
autophagy deficiency. A ROS scavenger, N-acetylcysteine (NAC), blocked mPTP opening, 
reduced PINK1/Parkin-dependent mitophagy, and successfully alleviated phosphate-
mediated cellular damages. HP diet-fed mice showed mitochondrial dysfunction, reactive 
oxygen species (ROS) production, apoptosis, and inflammasome activation in the kidney, 
which were significantly exaggerated by autophagy deficiency. Finally, HP diet-fed 
proximal tubule-specific Rubicon knockout mice, in which autophagic flux is genetically 
enhanced, ameliorated HP-mediated kidney injuries.
Conclusions: Phosphate overload induces mitophagy in PTECs, which is indispensable 
for maintaining proper mitochondrial functions. Enhancing autophagic activity could be a 
promising way to suppress CKD progression.
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A Circadian Pattern in Urine Exosome Excretion Is Not Influenced by Sex 
or Food-Water Deprivation: Implications for Biomarker Normalization
Erik H. Koritzinsky, Jonathan Street, Robert A. Star, Peter S. Yuen. National 
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
Background: Urine exosomes are extracellular vesicles released by all cells along the 
nephron and represent a promising source of non-invasive biomarkers. Many candidate 
urine exosomal biomarkers have been described, yet none have reached clinical use, in 
part because how to normalize them is unknown, as urine flow rate or concentration can 
vary by over an order of magnitude. We previously showed that urine exosome excretion 
displays a circadian pattern in male rats (peak at 21:00), but little is known about what 
factors modulate urine exosome release.
Methods: Timed urine samples from healthy rats (n=6M, 6F) were collected over 24 
hr in six 4-hr fractions. A subset of these rats (n=4) underwent a second matched 24 hr 
collection with 13 hr of food and water deprivation spanning the full dark (active) period. 
Urine exosomes were isolated by ultracentrifugation and counted by Nanoparticle Tracking 
Analysis.
Results: 24 hr urine exosome excretion varied widely between animals (CV=71%). 
To study the circadian pattern, variability was reduced by normalizing exosome excretion 
for each fraction to the peak excretion rate for each animal. Normalized urine exosome 
excretion displayed a similar circadian pattern in both male and female rats. There was no 
correlation between urine exosome excretion and urine flow rate (Male: r2=0.004, Female: 
r2=0.04). Food-water deprivation had no detectable impact on exosome excretion but 
significantly increased exosome concentration 13-17 hr after removal of food and water 
(p=0.03), likely due to decreased urine output.
Conclusions: Urine exosome excretion displays a distinct circadian pattern that 
complicates the measurement of urine exosomal biomarkers. The observed pattern in urine 
exosome excretion was neither sex specific nor affected by food-water deprivation. Spot 
urine concentration of exosomal biomarkers can be normalized by exosome concentration. 
This adjusted measure of biomarker content per exosome appears to be independent of 
time of collection, sex or food-water intake. Proper exosomal biomarker normalization will 
be essential in advancing promising candidates to clinical use and can uncover patterns 
otherwise obscured by natural biological variation, increasing their clinical utility and 
enabling the reliable use of spot urine measurements instead of timed collections.
Funding: NIDDK Support
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Tertiary Lymphoid Tissue Is a Novel Histological Marker Reflecting Local 
Injury and Inflammation in Murine and Human Kidneys
Yuki Sato,1 Peter Boor,2 Jürgen Floege,2 Motoko Yanagita.3 1Kyoto University 
Graduate School of Medicine, Kyoto, Japan; 2RWTH University of Aachen, 
Aachen, Germany; 3Department of Nephrology, Kyoto University Graduate 
School of Medicine, Kyoto, Japan.
Background: Tertiary lymphoid tissues (TLTs) are ectopic lymphoid tissues that 
are formed under various pathologic conditions such as autoimmunity and infection, and 
support priming of immune responses. We previously demonstrated that aged but not young 
mice exhibited multiple TLTs after AKI, which underlie maladaptive repair. TLTs were 
also detected in human aged and diseased kidneys, yet the comprehensive understanding is 
lacking and the clinical relevance remains controversial.
Methods: We analyzed human renal TLTs utilizing surgically resected kidneys from 
aged patients (N=69) and pyelonephritis patients (N=16) and proposed a novel staging 
scheme of TLTs. To validate this, we utilized murine TLT model utilizing aged mice subject 
to IRI. In this model, TLTs develop and expand as ischemic time or the time after IRI 
increase.
Results: TLTs in both human groups shared a perivascular, periglomerular and 
subcapsular location as well as similar components such as a homeostatic chemokine 
CXCL13, but exhibited heterogeneity in phenotype. We classified TLTs into three 
developmental stages based on the presence of follicular dendritic cells and germinal centers, 
and demonstrated in mice that the TLT stages advanced with the extent of kidney injury. 
Dexamethasone treatment after TLT formation decreased the size of TLTs, accompanied 
with improvement of renal inflammation and fibrosis, indicating the reversibility of TLTs. 
Consistently, the kidneys of aged patients with CKD exhibited more frequent and more 
advanced stages of TLTs than those without CKD, and pyelonephritis kidneys exhibited 
more frequent TLTs with more advanced stages than aged CKD kidneys.
Conclusions: Spatial and developmental similarities of TLTs in both groups indicated 
that TLT formation might not be disease-specific but rather a common pathological 
process. On the other hand, the phenotypic heterogeneity of TLTs reflected severity of 
kidney injuries, which explained the high frequency and advanced stages of TLTs in the 
kidneys with severe pyelonephritis. The reversibility of TLTs also indicated the potential 
of TLT-associated molecules as a novel candidate of biomarkers reflecting renal injury. 
Taken together, our data provide a mechanistic framework for studying TLT formation as 
a previously unappreciated pathological pathway in kidney disease progression in mouse 
and human.
Funding: Private Foundation Support, Government Support - Non-U.S.
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p90RSK Modulates Fibroblast-Epithelial Communication
Chaowen Shi, Ling Lin, Kebin Hu. Penn State University College of Medicine, 
Hershey, PA.
Background: Tubular epithelial damage is one of the prominent hallmarks of both 
acute and chronic kidney injury. Emerging evidence illuminates the fundamental role 
of intercellular communication in maintaining the integrity of kidney structure and 
environment. P90RSK is a serine/threonine kinase induced in the fibrotic kidneys. However, 
its role in kidney fibrosis remains unknown.
Methods: We examined p90RSK activation in human kidney samples. We generated a 
novel fibroblast-specific p90RSK transgenic mouse (RSK-Tg) and established a fibroblast-
epitheial coculture system using primary kidney fibroblasts from RSK-Tg and RSK-wt mice 
and human proximal tubular epithelial cells (HKC-8) to investigate the role of p90RSK in 
fibroblast-epitheial interactions
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Results: We discoved that p90RSK phosphorylation was increased in the kidney 
samples from patients with chronic kidney disease. We also found that RSK-Tg mice 
displayed enhanced renal fibrosis and increased tubular epithelial cell death after 
obstructive injury than their littermates (RSK-wt), indicating a role of p90RSK in 
fibroblast-epithelial communication. We established an in vitro fibroblast-epithelial 
coculture system using primary kidney fibroblasts from RSK-Tg and RSK-wt mice and 
human proximal tubular epithelial cells (HKC-8), and found that RSK-Tg fibroblasts 
dramatically aggregated staurosporine or H2O2-induced epithelial apoptosis. We further 
discovered that RSK-Tg fibroblasts constantly produced and released higher level of H2O2 
into the coculture medium causing epithelial oxidative stress and nuclear translocation 
of β-catenin. Intriguingly, blockade of reactive oxygen species (ROS) reduced RSK-
Tg fibroblasts-induced β-catenin and epithelial apoptosis. Moreover, knockdown of 
β-catenin by RNA silencing eliminated RSK-Tg fibroblast-induced epithelial cell death.
Conclusions: Thus, it is clear that fibroblast-p90RSK mediates epithelial cell death 
through ROS-activated β-catenin pathway.
Funding: NIDDK Support
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CMV Modifies Disease Progression in a Mouse Model of Sepsis
William Nash, Michael G. Brown, Sundararaman Swaminathan. University of 
Virginia, Charlottesville, VA.
Background: Sepsis is the leading cause of death in hospitals and accounts for around 
250,000 deaths in the U.S. anually. Despite its prominence as a global health concern, 
relatively little is understood about the mechanisms associated with survival or mortality. 
This is, in part, due to the failure of promising data from animal models to translate into 
measurable benefits during clinical trials. Hence, improving trial and animal model design 
are two main focuses in the field. We are approaching this issue by considering the effect of 
a history of infection on sepsis progression. A major difference between mice and human 
patients is their exposure to pathogens. Nearly all patients will have a latent infection of 
some kind and understanding how this may influence the septic syndrome is an important 
healthcare priority.
Methods: Cecal contents were collected from B6-background mice and processed 
into a working-stock slurry. Sepsis was induced in experimental mice via i.p. injection of 
slurry stock induce to life-threatening sepsis. Prior to sepsis, some experimental mice were 
injected with MCMV and allowed to progress to latency (60+ days). Septic mice were 
monitored frequently and survival, body weight, and clinical score were recorded. Upon 
reaching an endpoint, serum and tissue were collected for further analysis.
Results: When CMV-naive and CMV-latent male mice were given body weight-
adjusted doses of cecal slurry, all CMV-naive mice succumbed within 2 days while 
all CMV-latent mice survived out to 13 days (experimental endpoint). Upon further 
investigation, CMV-latent mice were found to have greater preservation of MHC class II on 
splenic dendritic cells which correlated with a greater representation of splenic CD3+ cells 
while CD19+ cell representation was unchanged. Analysis of mice treated with an LD50 
dose of slurry for 48 hours revealed that CMV-latent mice also trended toward lesser clinical 
scores, controlled body weight loss, and higher serum levels of IFNγ, IL-12p70, and IL-1β. 
BUN levels were elevated in the serum of all mice at 48 hours, but we did not detect any 
CMV-specific alterations.
Conclusions: The data suggest that CMV is modifying the early progression of sepsis
and favoring less severe disease. These effects appear to stem from experience of the 
immune system leading to a better regulated inflammatory response and preservation of 
specific lymphocyte populations.
Funding: NIDDK Support
TH-PO977 Poster Thursday
Pathology and Lab Medicine: Basic
Realization and Future Applications of LCM from Renal Formalin-Fixed 
Paraffin-Embedded Slices
Carlo M. Alfieri,1 Deborah Mattinzoli,2 Masami Ikehata,1 Donata Cresseri,1 
Gabriella Moroni,1 Valentina Vaira,3 Francesco Pallotti,1 Piergiorgio Messa.1,4 
1Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milan, Milan, Italy; 
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 
3University of Milan, Milan, Italy; 4Università degli Studi di Milano, Milan, Italy.
Background: Kidney transplantation(KTx) damage surveillance is relevant in clinical 
practice. Renal biopsy(RBx) is essential to guide a specific treatment. Laser capture 
microdissection(LCM) combining molecular biology and histology is a novel approach. 
Using LCM, we aim to test the expression of some pathologic markers in different renal 
compartments starting from formalin-fixed paraffin-embedded(FFPE) samples.
Methods: The principal difficulties present in LCM realization were the poor quantity 
and quality of the FFPE samples related to not RNA suitable sample procession. The 
late housekeeping Ct coupled with the uncertain RNA amount, caused by infiltrating 
inflammatory cells and by the fibrosis presence, lead us to opt for a cDNA pre-amp. Since 
RNA quality has a significant impact on reference gene stability, samples quality was 
evaluated by means of the housekeeping stability. Among the housekeeping examined, 
RPL4 had the best Ct and stability.
Results: After verifying the reliability of the selected SsoAdvanced PreAmp 
Supermix Bio-Rad kit, the method was first used in two different RBx (RBx-A: biopsy 
without histological alteration; RBx-B: biopsy from a KTx patient with initial transplant 
glomerulopathy). Then, the most promising biomarkers evidenced were validated in 
two RBx from the same KTx patient in distinct CKD progression phase (RBx-C1: no 
injuries;RBx-C2: initial chronic allograft nephropathy, associated to severe interstitial 
fibrosis) Renal fibrosis: our result suggested a DDR1-TGFβ-COLIII-COLI- chronological 
formation of the fibrotic matrix in all RBx-B compartments. The same gene expression 
trend was observed in the RBx-C1 with a later collagens protein formation in the RBx-C2. 
Predictive biomarkers: Among the biomarkers, Klotho resulted the earliest with a 
downregulation in RBx-B and RBx-C1. Periostin, although later than Klotho, showed a 
great damaged compartment discrimination capacity resulting higher in both RBx-B and 
RBx-C2 glomeruli.
Conclusions: The method presented permits to obtain reliable results in LCM from 
FPPE samples. Furthermore, it is reproducible, easy and fast. In the future, a study in KTx-
RBx of the relationship between RNA-expression at different renal sites and clinical and 
biochemical parameters and of its predictive role of KTx outcome will be possible.
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Pathological Characteristics of USAG-1 and BMP-7 Expression in Rats 
with CsA nephrotoxicity
Keisuke Sugimoto,2 Kohei Miyazaki,2 Takuji Enya,2 Tomoki Miyazawa,2 
Mitsuru Okada,2 Tsukasa Takemura.1 1Kushimoto municipality hospital, 
Wakayama, Japan; 2kindai University Faculty of Medicine, Izumi, Japan.
Background: CsA-nephrotoxicity is associated with decreased renal bone 
morphogenetic protein-7 (BMP-7) expression. Uterine sensitization-associated gene-1 
(USAG-1), a kidney-specific BMPs antagonist, plays an important role in processing renal 
damage. The study aimed to evaluate the renal expression of USAG-1 and BMP-7 induced 
by CsA in a rat model.
Methods: Eight BrlHan:WIST@Jcl (GALAS) rats were assigned to two groups: 
control (untreated) and CsA (orally received CsA 10 mg/kg body weight). After 28 days, 
the renal tissues were examined for CsA toxicity, specifically, tubulointerstitial damage 
and arteriolopathy, by light microscopy. Furthermore, the area of USAG-1 and BMP-7 
expression was scored by immunohistochemical staining.
Results: The CsA group showed mild interstitial fibrosis, but no arteriolohyalization 
and tubular atrophy. Two of the 4 rats in the CsA group presented findings similar to 
those observed during the early stage of focal segmental glomerulosclerosis (FSGS) 
development, such as enlargement of glomeruli and foam cells. In these 2 rats, high 
focal USAG expression and significantly decreased BMP-7 expression were also noted. 
In contrast, a broad area with BMP-7 expression was observed in the kidney of the 
2 rats from the CsA group that presented fewer FSGS-like findings and in the control rats 
(no CsA nephrotoxicity).
Conclusions: In this study, the characteristic histologic changes of CsA-nephrotoxicity 
were not observed, but FSGS-like findings were noted. USAG expression may contribute 
to BMP-7 suppression, resulting in FSGS-like pathology that leads to CsA-nephrotoxicity. 
Furthermore, an imbalance in USAG-1 and BMP-7 expression may also be involved in 
CsA-induced nephrotoxicity.
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Ionizing Radiation Could Cause Cellular Senescence in Kidney and 
Late-Onset Kidney Dysfunction - Experiment Using Radiation  
Nephropathy Rat Model
Sae Aratani,1 Masako Tagawa,2 Shinya Nagasaka,2 Yukinao Sakai,1 
Akira Shimizu,2 Shuichi Tsuruoka.2 1Nippon Medical School Hospital, Tokyo, 
Japan; 2Nippon Medical School, Tokyo, Japan.
Background: Cellular senescence is one of the major risk factors for chronic kidney 
disease. Cellular senescence is caused by a variety of stressors, such as ionizing radiation 
(IR). The kidney is known as radiosensitive organ, however the association between cellular 
senescence and kidney dysfunction is still unclear.
Methods: 7-8-week-old male rats received unilateral IR of 18 Gy on the left or 
right kidney (irradiated kidney) whereas normal rats received sham IR (normal kidney). 
We compared the presence of cellular senescence, kidney dysfunction, and pathological 
changes at 9 months after the IR. Cellular senescence was defined by positive staining for 
SA-β-gal and p21, increased mRNA expression level of p21, and senescence associated 
secretory phenotype (IL-6). Pathological evaluation was performed focusing on glomerular 
findings, which were evaluated in 50 glomeruli. Endothelial cell was detected by CD31 
staining. We also confirmed the endothelial senescence by vitro fashion with rat cultured 
endothelial cells received IR of 20 Gy with 25 days culturing.
Results: As shown in Table, markers of cellular senescence were elevated only in 
irradiated kidney. Regarding kidney dysfunction, irradiated rats showed higher proteinuria, 
and greater serum level of BUN. Pathological findings suggested strong endothelial cell 
injury in irradiated kidney with greater TMA and collapsing glomeruli, and reduced 
endothelial cell numbers. We confirmed endothelial cell senescence in vitro model, showing 
increased positive staining for SA-β-gal, expression level of p21 and IL-6.
Conclusions: Taken together, these data suggested IR could cause cellular senescence 
in the kidney and lead to resultant kidney dysfunction. The cellular senescence of glomerular 
endothelial cells may be associated with TMA and glomerular collapse, that lead to kidney 
dysfunction.
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Serotonin Receptor Expression in the Normal Adult Human Kidney and 
in Glomerular Diseases
Claudia R. van Roeyen,1 Jenny Vu,1 Bart Smeets,2 Marcus J. Moeller,1 
Luc Maroteaux,3 Hermann-Josef Groene,4 Jürgen Floege,1 Tammo Ostendorf,1 
Gerald S. Braun.1 1RWTH University of Aachen, Aachen, Germany; 2Radboud 
University Medical Center, Nijmegen, Netherlands; 3INSERM U839, Paris, 
France; 4German Cancer Research Center, Heidelberg, Germany.
Background: Serotonin (5-HT) is the phylogenetically oldest neurotransmitter and 
acts via specific receptors. Serotonin receptors 5-HT2A and 5-HT2B are G-protein-coupled 
and mediate vasoconstriction and hypertension. The 5-HT2A receptor is also engaged in 
blood coagulation and wound healing. Little is known about the function of 5-HT and its 
receptors 5-HT2A and 5-HT2B in the normal kidney or during renal disease.
Methods: Localization of 5-HT2A and 5-HT2B receptors was analysed by 
immunohistochemistry in the human healthy kidney and during renal disease. Serum 5-HT 
and urine 5-HT metabolite 5-HIAA concentrations were measured by HPLC. In vitro 
studies were performed to identify the role of 5-HT2A and 5-HT2B receptors in primary 
murine glomerular parietal epithelial cells (PECs). Mice with 5-HT2A and 5-HT2B deletions 
are available.
Results: In the normal human kidney (living donor biopsies), 5-HT2A and 5-HT2B 
receptors localized to PECs, proximal tubuli and the loop of Henle. In all renal diseases 
investigated, 5-HT2A- and 5-HT2B-expression in tubuli was maintained. In glomeruli, 
the number of 5-HT2B-positive cells increased significantly with disease. Serum 
5-HT concentrations were significantly reduced in patients with rapidly progressive 
glomerulonephritis (RPGN), whereas 5-HT metabolite concentrations in tendency increased 
in the urine of these patients. By immunofluorescence, glomerular 5-HT2B-positive cells
could be identified as PECs. In biopsies of patients with IgA nephropathy or RPGN, the cell 
diameter of 5-HT2B-positive PECs was significantly increased in comparison to receptor-
negative PECs. In primary PECs in vitro, removal of serotonin from culture medium
reduced the expression of activation markers. Vice versa, activation of 5-HT2A and 5-HT2B
receptors induced an overexpression of CXCR4 and VCAM.
Conclusions: In summary, we demonstrate for the first time the constitutive expression 
of 5-HT2A and 5-HT2B receptors in the adult human kidney with glomerular upregulation 
in different renal diseases. Our studies identify PECs as the primarily cell type involved 
in serotonin receptor upregulation in glomerular disease. Further in vivo studies in murine 
models of glomerular disease are currently under way in order to elucidate the potential 
pathophysiological role of these receptors.
Funding: Government Support - Non-U.S.
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What Is the Sufficient Minimum Number of Glomeruli in a Kidney Biopsy 
to Detect Nephrosclerosis?
Robert S. Niznik, Camden Lopez, Walter K. Kremers, Aleksandar Denic, 
Fernando G. Cosio, Andrew D. Rule. Mayo Clinic, Rochester, MN.
Background: The number of glomeruli present is often used to determine the 
sufficiency of a kidney biopsy sample (e.g., at least 10 glomeruli). The assumption is that 
with fewer glomeruli, the biopsy findings are too imprecise to draw inferences regarding 
the underlying pathology in the kidney. The true amount of nephrosclerosis (global 
glomerulosclerosis, fibrosis, and arteriosclerosis) is expected to not depend on the number 
of glomeruli of the biopsy.
Methods: We studied 2,915 implantation needle core kidney biopsies from living 
kidney donors at three transplant centers. The number of glomeruli, the % globally sclerotic 
glomeruli (%GSG), the amount of interstitial fibrosis (number of fibrosis foci), and the 
severity of arteriosclerosis (% intimal narrowing) were quantified on digital images of a 
single PAS-stained section. A beta-binomial model was used to estimate the mean whole-
kidney %GSG and the biological (between-kidney) variability in %GSG, number of fibrosis 
foci, and %intimal narrowing for the number of glomeruli on the biopsy section.
Results: Fewer glomeruli on biopsy correlated with both a higher mean %GSG (16% 
increase per 10 fewer glomeruli) and more between-patient variability in %GSG in the 
kidney (See figure). Because of this, the probability of the whole kidney having %GSG 
>10% with the biopsy %GSG>10% was 45% with 1-9 glomeruli and 31% with 10 or more 
glomeruli. Similar findings were seen for interstitial fibrosis and arteriosclerosis.
Conclusions: A lower number of total glomeruli correlated with increasing 
nephrosclerosis and is consistent with the concept of nephron dropout/decreased cortical 
volume. The presence of fewer glomeruli on a kidney biopsy is itself informative of 
pathology and is not always indicative of an inadequate sample. It also may represent 
cortical scarring and volume loss. Thus, requiring a minimum acceptable number of 
glomeruli should be applied cautiously when interpreting renal biopsies.
Funding: NIDDK Support
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The Clinical Features and the Expression of suPAR and ApoA-1 in Focal 
Segmental Glomerulosclerosis
Jia Lv,1 Wanwan Gao,2 Liyi Xie,1 Ping Lan.1 1Nephrology Department, First 
Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China; 2Huaihe Hospital 
of Henan University, Kai Feng, China.
Background: Our purpose is to explore whether serum and urine suPAR and ApoA-1 
can be used as markers in patients with FSGS and to evaluate the value of serum and urine 
suPAR and ApoA-1 in predicting FSGS.
Methods: Subjects were selected by inclusion and exclusion criterias, divided into four 
groups: FSGS group, MN group, IgAN group and healthy group. Serum and urine samples 
were collected. Serum and urine suPAR levels and urine ApoA-1 levels were detected in 
each group by ELISA and analyzed. Their correlations with gender, age, urea nitrogen, 
creatinine, 24h urinary protein, eGFR, serum albumin, total cholesterol, and triglyceride 
were also analyzed.
Results: Serum suPAR levels of FSGS group were higher than the MN group, 
IgAN group and healthy control group (P < 0.05); in FSGS group, serum suPAR was 
positively correlated with serum creatinine (P < 0.05), negatively correlated with eGFR 
(P > 0.05). There was no significant correlation with gender, age, urea nitrogen, 24h 
urinary protein, serum albumin, total cholesterol and triglyceride (P > 0.05). Urine suPAR 
levels of FSGS group were higher than the MN group, IgAN group and healthy group 
(P < 0.05); in FSGS group, Urine suPAR was positively correlated with 24h urinary protein 
(P < 0.05), but no significant correlation with gender, age, Urea nitrogen, serum creatinine, 
eGFR,serum albumin, total cholesterol and triglyceride (P > 0.05). Urine ApoA-1 levels of 
FSGS group, MN group and IgAN group were higher than healthy group(P < 0.05). There 
was no significant difference among FSGS group, MN group and IgAN group (P > 0.05). 
There was no significant correlation with dender, age, serum albumin, urea niteogen, serum 
creatinine, eGFR, total cholesterol and triglyceride (P > 0.05). The best predictive value of 
serum suPAR for FSGS was 3280.28 pg/ml; the area under the curve of AUC was 0.831 
(95%CI, 0.736-0.926), with sensitivity of 74.2% and specificity of 81%. The area under the 
curve of AUC for urine suPAR levels in predicting FSGS was 0.781 (95%CI, 0.673-0.890), 
with sensitivity of 71% and specificity of 77.8%. AUC for urinary APoA-1 in predicting 
FSGS was 0.483 (95%CI, 0.356-0.610) with sensitivity of 45.2% and specificity of 48.1%.
Conclusions: The value of serum suPAR level in predicting primary FSGS is higher 
than that of urine suPAR and ApoA-1. Serum suPAR is expected to be a serological marker 
for auxiliary diagnosis of FSGS.
Funding: Government Support - Non-U.S.
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The Effect of Sertraline on Reduction of Albuminuria Due to the 
Inhibition of Caveolae Pathway Through Glomerular Endothelial and 
Epithelial Cells
Takahito Moriyama, Kosaku Nitta. Tokyo Women’s Medical University, Tokyo, 
Japan.
Background: Previously, we have reported the caveolae mediated endocytosis, 
transcytosis, and exocytosis of albumin through glomerular endothelial cells as a new 
etiology of urinary albumin excretion (J Cell Biochem 116; 1065-9: 2015, J Cell Physiol 
232; 3565-73: 2017). The selective serotonin reuptake inhibitor, sertraline, inhibited the 
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dynamin which played a pivotal role for fission of caveolae from cell membrane in caveolae 
endocytosis. We hypothesized that sertraline might reduce the albuminuria by interfere the 
caveolae mediated intracellular trafficking pathway.
Methods: In this study, we analyzed whether the dynamin inhibitor sertraline interfered 
the albumin internalization through caveolae in glomerular epithelial and endothelial cells, 
and sertraline reduced the amount of albuminuria in puromycin aminonucleoside induced 
nephrotic syndrome modeled mice (PAN mice) as a novel treatment of glomerulonephritis.
Results: In vitro studies, western blotting analysis and immunofluorescence (IF) study 
showed that dose dependent (5 and 10 μM) treatment of sertraline significantly reduced the 
expression of albumin in glomerular endothelial and epithelial cells (P<0.01), though the 
Caveolin-1 (Cav-1) expression was not reduced. In vivo analysis, the electron microscopic 
findings showed that the foot process fusion and swelling of endothelial cells in dimethyl 
sulfoxide (DMSO) treated PAN mice as vehicle and also sertraline treated PAN mice, 
and the IF analysis showed the stronger Cav-1 expression on capillaries in both mice in 
comparison to normal control mice (P<0.0001). However, the amount of proteinuria was 
not increased in sertraline treated PAN mice in comparison to normal control mice (0.05 vs. 
0.02 mg/mgCre, p=0.17), though it was significantly increased in DMSO treated PAN mice 
(0.12 vs. 0.02 mg/mgCre, P=0.0027).
Conclusions: Though the foot process fusion, endothelial swelling, and caveolin-1 
expressions were occurred, albumin internalization into glomerular endothelial and 
epithelial cells and albuminuria in PAN mice were reduced by sertraline. These results 
indicated that sertraline interfered albumin internalization thorough caveolae by inhibition 
of dynamin and resulted in reduction of albuminuria. Sertraline might become the novel 
therapeutic option to reduce albuminuria in glomerulonephritis.
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Identification of Cytoplasmic Proteins Associated with Ephrin-B1 at the 
Slit Diaphragm of Podocyte: PDZ Proteins, Par6, Par3 and NHERF2 Are 
Associated with Ephrin-B1
Yoshiyasu Fukusumi, Sayuri Takamura, Ying Zhang, Hidenori Yasuda, 
Hiroshi Kawachi. Department of Cell Biology, Kidney Research Center, Niigata 
University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background: We have recently reported ephrin-B1 interacts with nephrin via their 
extracellular domains in cis form and plays an essential role at the slit diaphragm. We 
also reported the phosphorylated ephrin-B1 activates the JNK signaling independently 
of nephrin phosphorylation (JASN 2018). Because ephrin-B1 has a PDZ binding motif 
in its C-terminus, it is estimated that PDZ proteins interact with ephrin-B1. However, 
the cytoplasmic proteins interacted with ephrin-B1 in podocyte and the precise signaling 
pathways activated by the phosphorylated ephrin-B1 remain unclear.
Methods: To identify the proteins associated with ephrin-B1, we performed the gene 
expression profiling of glomerular sample of the podocyte-specific ephrin-B1 knockout (KO) 
mice. We found PDZ proteins, Par6, Par3 and NHERF2 were evidently downregulated, but 
the expressions of other PDZ proteins, ZO-1, MAGI1, CASK, which are already reported 
to be expressed at the slit diaphragm, were not changed. In this study the expression of Par6, 
Par3 and NHERF2 and their interaction with ephrin-B1 were analyzed.
Results: The decrease in mRNA expressions of Par6, Par3 and NHERF2 were 
confirmed with real-time RT-PCR (Par6, 20 ± 11%, p<0.01, Par3, 14 ± 9% to control, 
p<0.05, NHERF2, 17 ± 6%, p<0.001). The immuno-staining intensity of these proteins 
in glomeruli was decreased and their staining pattern evidently changed in the KO mice. 
Dual labeling analyses showed Par6, Par3 and NHERF2 were colocalized with ephrin-B1 
in normal glomeruli. The immunostaining of these molecules as well as ephrin-B1 were 
clearly decreased in the nephrotic state caused by PAN injection. The remaining Par3 and 
Par6 in this proteinuric state were dissociated from ephrin-B1. By contrast, the remaining 
NHERF2 was still colocalized with the remaining ephrin-B1. Immunoprecipitation 
assay showed Par3 interacted with both ephrin-B1 and nephrin, and Par6 interacted with 
ephrin-B1 but not with nephrin. It is also observed that the phosphorylation of ephrin-B1 
inhibited its interaction with Par6 and Par3.
Conclusions: Par6, Par3 and NHERF2 interact with ephrin-B1 and may contribute 
to the maintenance of the structure and the function of slit diaphragm cooperated with 
ephrin-B1.
Funding: Government Support - Non-U.S.
TH-PO985 Poster Thursday
Pathology and Lab Medicine: Basic
Chronic High-Dose Candesartan Therapy Promotes Podocyte Recruit-
ment from Glomerular Parietal Epithelial Cells Involving Suppression of 
GSK3β Signaling
Minglei Lu,1,2 Lance D. Dworkin,2 Zhangsuo Liu,1 Rujun Gong.2 1The First 
Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 2University of 
Toledo Medical Center, Toledo, OH.
Background: Evidence suggests that non-podocyte cells like glomerular parietal 
epithelial cells(PEC) contribute to podocyte repopulation and glomerular filtration 
barrier(GFB) repair in chronic kidney disease(CKD). Angiotensin blockades, as the 
standard of care for CKD, however, only exhibit a marginal effect on podocyte regeneration. 
At doses higher than recommended, angiotensin blockades are known to exert an extra anti-
proteinuric and renoprotective effect. This study aims to explore if this additional benefit is 
associated with podocyte regeneration.
Methods: After unilateral nephrectomy, spontaneously hypertensive rats received 
variable doses (standard, 5 mg/kg/d; high, 25 mg/kg/d; and ultrahigh, 75 mg/kg/d) of 
candesartan for 14 months. Renal expression of podocyte and PEC markers was evaluated.
Results: Despite a comparable effect attained by all doses on normalizing 
systemic hypertension, high and ultrahigh dose candesartan exhibited a more potent 
proteinuria-reducing effect that is independent of blood pressure control. Accordingly, 
glomerulosclerosis was improved by candesartan in a dose dependent mode. The variable 
outcomes in proteinuria is suggestive of disparity in GFB integrity. Indeed, increasing doses 
of candesartan progressively augmented the number of podocytes, marked by WT-1 staining. 
This effect seems to be attributable to new podocyte recruitment from PEC, because the 
number of cells in glomerular tufts positive for both synaptopodin and Pax2, a PEC marker, 
was increased. This coincided with a potentiated transdifferentiation of PEC to podocyte 
phenotypes in parietal epithelia. In contrast, PEC activation, probed by CD44 expression 
in glomeruli, was diminished by candesartan in a dose dependent fashion. Glycogen 
synthase kinase (GSK)3β, a multitasking serine/threonine protein kinase, has been recently 
implicated in impaired podocyte regeneration. In the diseased kidney, glomerular expression 
of GSK3β was amplified, predominantly located to PEC and podocytes. Increasing dose of 
candesartan progressively obliterated glomerular overexpression of GSK3β, concomitant 
with an improved glomerular histology and podocyte integrity.
Conclusions: Chronic high-dosage candesartan therapy is able to potentiate podocyte 
derivation from PEC via inhibition of GSK3β signaling and attenuate glomerular injury.
Funding: NIDDK Support
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DGKE Gene Variants in C3 Glomerulopathy
Ashwani Kumar,1 Raja Ramachandran,3 Ritambhra N. Duseja.2 PGIMER 
1Histopathology, PGIMER, Chandigarh, India; 2Post Graduate Institute of 
Medical Education and Research, Chandigarh, India; 3Nehru Hospital, 
Chandigarh, India.
Background: DGKE is intra-cellular lipid kinases that phosphorylate the diacylglycerol 
(DAG) to phosphatidic acid (PA). Normal expression of DGKE is found in podocytes, 
endothelium, and platelets. Evidence of some variants of DGKE is reported in association 
with glomerular microangiopathies and found to have some overlapping feature with 
membranoproliferative glomerulonephritis (MPGN). As a pilot study, we screened patients 
of C3G in addition to alternative complement pathway related gene with focus on DGKE 
gene which confirmed its involvement in aHUS.
Methods: DNA from blood (EDTA) was isolated. Whole exome sequencing, clinical 
exome sequencing and targeted sequencing (15 genes; CFH, CFHR1, CFHR2, CFHR3, 
CFHR4, CFHR5, CD46, CFI, CFB, DGKE, C3, THBD, CFD, and properdin) were 
performed in 5 cases of C3GP. Test findings were analyzed and correlated with clinical 
outcome of these five patients.
Results: In addition to CFH and CFHR5 gene variants, whole exome sequencing in 
two cases revealed two variants in DGKE gene i.e. c.1583G>A (missense variants) and 
c.183G>A (synonymous variant) in case 1 whereas in case 2, only one variant c.579A>C
(synonymous variant) was documented. Clinical exome sequencing was performed in
case 3 which showed a variant in exon 6 of DGKE gene (c.998C>G). This variant is of
undetermined significance that results in the amino acid substitution of Glycine for Alanine 
at codon 333 (p.Ala333Gly; ENTST00000284061). Targeted sequencing in other two
patients showed c.579A>C (case 4) and c183G>A (case 5) variants in DGKE gene. Of
5 cases, case 1 and 2 are from the same family with the history of renal disease in the
family. Case 1 expired and other receive a renal transplant. Case 3 had a history of UTI in
childhood followed by MPGN on renal biopsy, which rapidly progressed to end-stage renal 
disease (ESRD)/underwent transplant and had graft failure in 16 months followed by graft 
nephrectomy. Patient 4 and 5 also had rapid progression to ESRD.
Conclusions: In present pilot study, the mutation/variants found in DGKE gene 
showed that genetic defects in C3G is not only limited to alternative complement pathway-
related genes. Hence, we strongly recommend the screening of DGKE in all C3G patients. 
More data is needed to validate our findings.
Funding: Government Support - Non-U.S.
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Transcription Factor Dach1 in Podocytes
Masahiro Okabe,2,1 Yoichi Miyazaki,1 Takashi Yokoo,1 Taiji Matsusaka.2 1Jikei 
University School of Medicine, Tokyo, Japan; 2Tokai University School of 
Medicine, Isehara, Japan.
Background: Podocyte injury is crucial for the progression of chronic kidney diseases 
(CKD). Transcriptional factors, Wt1, Mafb, and Foxc2, are highly expressed in normal 
podocytes and rapidly decreased upon injury. These play important roles in maintaining 
normal podocyte function. We aim to find transcriptional factors with similar expression 
patterns, and study the function in podocytes.
Methods: We combined NEP25 mice, an immunotoxin-inducible podocyte injury 
model, with RiboTag mice, in which podocyte-specific polysome mRNAs can be yielded 
by immunoprecipitation in glomerular homogenate. We analyzed gene expression changes 
of normal and injured podocytes by microarray.
Results: We found the following 8 transcription factor mRNAs were highly expressed 
in normal podocytes and rapidly decreased after injury; Wt1, Mafb, Foxc2, Tcf21, Foxd2, 
Banp, Hoxc6, and Dach1. We focused on Dach1 because SNPs of DACH1 gene were 
associated with the progression of CKD by genome-wide association studies. RT-PCR 
analysis confirmed that Dach1 mRNA was concentrated in normal podocytes (7.33±0.68-
fold vs glomerulus) and decreased in podocytes injured by immunotoxin (0.371±0.0053-
fold vs normal podocytes). Immunostaining showed that Dach1 protein was intensely 
expressed in the nucleus of normal podocytes and decreased upon injury not only in NEP25 
model but also in adriamycin nephropathy and HIV-associated nephropathy models. 
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DACH1 protein was also expressed in human normal podocytes and the expression was 
decreased in diabetic nephropathy, lupus nephritis, and IgA nephropathy but not in minimal 
change disease. Kockdown of Dach1 by siRNA in murine primary cultured podocytes 
suppressed the proliferation and DNA synthesis of podocytes, contrasting to the growth 
inhibitory effect of DACH1 previously reported in cancer cells. The DNA binding sites 
of DACH1 are reported to co-localize with those of FOX family members. Suppression 
of Dach1 gene by siRNA in murine primary cultured podocytes decreased the expression 
of Foxc2-target genes, Podxl and Dpp4 (0.624±0.12 and 0.626±0.29-fold, respectively), 
suggesting that Dach1 may modulate or collaborate with Foxc2 in podocytes. 
Conclusions: Dach1 is highly expressed in normal podocytes and downregulated upon 
injury. This transcription factor may play a role in maintaining normal podocyte function. 
Funding: Government Support - Non-U.S.
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miR-466o-3p Promotes Podocyte Injury Through Targeting WT1
Qiyan Chen,1 Lili Zhou,1 Youhua Liu.2 1Division of Nephrology, Nanfang 
Hospital, Southern Medical University, Guangzhou, China; 2Department of 
Pathology, University of Pittsburgh, Pittsburgh, PA.
Background: Podocytes are highly specialized cells that maintain normal function of 
the glomerular filtration barrier. Dysregulation of Wnt/β-catenin signaling has been linked 
to podocyte injury; however, the underlying mechanism remains incompletely understood. 
In this study, we explored the roles of microRNA in mediating Wnt/β-catenin-triggered 
podocyte dysfunction and proteinuria.
Methods: Mouse podocytes were transiently transfected with expression vector 
encoding constitutively activated β-catenin (pDel-β-cat) or empty vector (pcDNA3). The 
differential expression of microRNA between these two groups was analyzed microarray 
assay and bioinformatics analysis. The role of miR-466o-3p in podocyte biology was 
investigated in vitro and in vivo. The BALB/c mice were randomly divided into 3 different 
groups: i) sham control; ii) ADR mice injected with empty vector pcDNA3; iii)ADR mice 
injected with miR-466o-3p plasmid. Urine, blood and kidneys were collected at 1 week 
after ADR injection.
Results: We identified multiple miRNAs whose expression was modulated by β-
catenin activation in podocytes. Real-time RT-PCR validated that miRNA-466o-3p was 
upregulated in cultured podocytes after β-catenin activation and in kidney tissues after 
adriamycin (ADR) injection. In situ hybridization demonstrated that miR-466o-3p was up-
regulated in glomerular podocytes. Bioinformatics analysis and luciferase reporter assay 
confirmed that miR-466o-3p directly targeted WT1 mRNA. Furthermore, overexpression of 
miR-466o-3p downregulated WT1 protein in vitro and promoted podocyte injury, although 
it did not affect WT1 mRNA level. Conversely, inhibition of miR-466o-3p alleviated β-
catenin induced podocyte injury. In ADR model, Overexpression of miR-466o-3p inhibited 
WT1, aggravated podocytes injury and increased proteinuria in mice.
Conclusions: These studies demonstrate that miR-466o-3p plays a critical role in 
mediating Wnt/β-catenin-triggered podocyte injury. Our findings uncover a new pathogenic 
mechanism by which Wnt/β-catenin promotes podocyte injury and proteinuria.
Funding: NIDDK Support, Government Support - Non-U.S.
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Podocyte-Specific Knockdown of PAI-1 Protects Against Podocyte Injury
Jianyong Zhong,1 Taiji Matsusaka,2 Haichun Yang,1 Agnes B. Fogo.1 1Vanderbilt 
University Medical Center, Nashville, TN; 2Tokai University School of Medicine, 
Isehara, Japan.
Background: Plasminogen activator inhibitor-1 (PAI-1) is upregulated in a variety of 
fibrotic kidney diseases. Our previous study showed systemic knockout of PAI-1 protects 
against development of glomerulosclerosis (GS) and podocyte injury in both models of 
primary podocyte injury and secondary FSGS in the 5/6 nephrectomy model. In this study, 
we investigated whether knockdown (KD) of PAI-1 only in podocytes can protect against 
podocyte and glomerular injury.
Methods: We generated inducible podocyte PAI-1 knockdown mice (PAI-1 KD, PAI-
1floxed/ rtTA/podocin Cre+) and wild type control (WT, PAI-1floxed/ rtTA/podocin Cre-). A model 
of secondary mild hypertensive podocyte injury was induced by high salt+uninephrectomy 
(uNX)+AngII. We also mated PAI-1 KD mice with Nphs1-hCD25 mice (Nep25), which 
express human CD25 just in podocytes, and develop primary podocyte injury when injected 
with immunotoxin (LMB2). Podocyte injury and GS were compared in these two models. 
In vitro, we cultured primary podocytes from these WT and PAI-1 KD mice and exposed 
cells to AngII or LMB2, respectively.
Results: In vitro primary cultured podocytes showed reduced PAI-1 after doxycycline 
induction. In vivo, double staining confirmed reduced PAI-1 in podocytes in both models, 
but increased PAI-1 expression in endothelial cells and mesangial cells. In the Nep25 model, 
PAI-1 KD in podocytes resulted in less albuminuria (ACR) and GS with more differentiated 
podocytes than WT (WT-1+ cell density, PAI-KD 27.4±1.8 vs. WT 21.8±1.9x10-4/μm2). 
In the high salt+uNX+AngII model, although podocytes expressed less desmin (PAI-KD 
0.027±0.008 vs. WT 0.051±0.008), a marker of podocyte injury, ACR and mesangial 
expansion were similar in PAI-1 KD and WT. In vitro, knockdown of PAI-1 induced more 
podocyte proliferation, adhesion and migration in both LMB2 and AngII injury models, 
with less CTGF and desmin expression vs WT. ILK was reduced in PAI-1 KD vs WT only 
in the AngII model.
Conclusions: Knockdown of PAI-1 only in podocytes protected against primary 
podocyte injury and GS, while there was less effect on GS if the injury involved multiple 
cells, as seen in the AngII model. Our data further suggest that PAI-1 upregulation of ILK 
may be one mechanism related to podocyte injury.
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Deletion of Ste20-Like Kinase SLK Induces Cytoskeletal Changes in 
Podocytes
Boyan Woychyshyn, Joan Papillon, Julie Guillemette, Andrey V. Cybulsky. 
Medicine and Physiology, McGill University, Montreal, QC, Canada.
Background: Glomerular epithelial cells (GECs; podocytes) are essential in 
maintaining glomerular permselectivity. Their function is dependent on an intact actin 
cytoskeleton. Regulation of the actin cytoskeleton, in part, relies on the assembly of a 
phospho-ezrin-NHERF2-podocalyxin complex at the apical surface of the podocyte. 
SLK is a serine/threonine kinase ubiquitously expressed in mammalian tissues, including 
GECs. SLK was reported to be involved in the arrangement of the actin cytoskeleton and in 
mediating cell cycle progression. Deletion of SLK in podocytes in mice leads to proteinuria 
and disruption of podocyte architecture as mice age. The aim of this study was to determine 
if SLK phosphorylates ezrin in podocytes and is critical in maintaining cytoskeletal integrity.
Methods: We generated a SLK knockout (KO) GEC line by transducing immortalized 
GECs isolated from mice carrying a floxed SLK allele with tamoxifen-inducible Cre 
recombinase. We also depleted SLK in GECs using siRNAs. We studied the effect of SLK 
deletion on phosphorylated ezrin, podocalyxin and F-actin using immunoblotting and 
immunofluorescence microscopy.
Results: In GECs, both KO of SLK using Cre recombinase and depletion of SLK 
with siRNAs reduced SLK protein expression and pT183 phosphorylation, which reflects 
catalytic activity (KO being more effective than siRNA). SLK KO did not affect the rate of 
proliferation of GECs. Both SLK KO and depletion markedly reduced activation-specific 
phosphorylation of ezrin, while total ezrin protein levels remained unchanged. Expression 
of podocalyxin, a protein essential to foot process integrity, was significantly reduced in the 
SLK KO cells. Levels of F-actin were markedly reduced in SLK KO cells and stress fiber 
arrangements were altered; however, total actin was unaffected. Treatment of GECs with 
erlotinib, a chemical inhibitor of SLK, showed effects on F-actin similar to KO of SLK.
Conclusions: SLK is not essential for cell cycle progression in GECs. SLK 
phosphorylates ezrin, and decreased ezrin phosphorylation due to deletion of SLK leads to 
reduction in podocalyxin and disruption of the actin cytoskeleton. The result suggests that 
SLK is important in the maintenance of the ezrin-NHERF2-podocalyxin complex and foot 
process integrity.
Funding: Government Support - Non-U.S.
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FK506 Binding Protein 12 (FKBP12) Is Highly Expressed in Glomerular 
Podocyte in Kidney: FKBP12 in Podocyte Is Co-Localized with Actin 
Cytoskeleton and Is Re-Distributed in Injured Podocytes
Hidenori Yasuda, Yoshiyasu Fukusumi, Ying Zhang, Hiroshi Kawachi. 
Department of Cell Biology, Kidney Research Center, Niigata University 
Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background: FKBP12, a 12 kDa cytoplasmic immunophilin, was identified as a 
binding protein of FK506 (tacrolimus). Tacrolimus and rapamycin bind to FKBP12 and 
exhibit immunosuppressant effect through inhibition of calcineurin and mTOR, respectively 
in T cells. FKBP12 is reported to be expressed in various organs, and the distribution 
is associated with side effects of these drugs. It is also known that FKBP12 functions 
independently of these immunosuppressants; for example, FKBP12 binds to TGF-b type 1 
receptor and inhibits its signaling. However, the localization and the physiological function 
of FKBP12 in kidney are not well elucidated.
Methods: mRNA expression of FKBP12 in several tissues and cultured podocytes 
was analyzed with RT-PCR and its precise localization was investigated with the immuno-
histochemical analyses with a specific antibody produced in a rabbit immunized with 
specific peptide. The FKBP12 expression in injured podocytes was also analyzed.
Results: FKBP12 mRNA expression in whole kidney was lower than in other organ 
materials such as cerebrum, liver, heart and lung, but the high expression was detected in 
glomeruli. The histochemical analysis with rat kidney section showed FKBP12 was highly 
expressed in glomeruli. Dual labeling staining with glomerular cell markers showed the 
FKBP12 expression in glomeruli was restricted in podocyte and the staining in podocyte 
was mainly detected at the cytoplasm close to cell membrane. FKBP12 staining in 
cultured pocoytes was colocalized with cytoskeletal actin. mRNA expression of FKBP12 
in glomeruli was downregulated at the initiation phase of nephrotic models, anti-nephrin 
antibody-induced nephropathy (20.0% to normal, P<0.001) and in PAN nephropathy, a 
mimic of MCNS (26.0% P <0.001). Immuno-staining of FKBP12 was clearly lowered when 
proteinuria peaked in PAN nephropathy (staining score, 2.7 vs 3.5 of normal, P<0.05), and 
in ADR nephropathy, a mimic of FSGS (score 2.9, P<0.05). FKBP12 staining was clearly 
decreased in the human cultured podocytes treated with ADR (67% to normal; P<0.05) and 
with serum free medium (61% P<0.05).
Conclusions: FKBP12 is mainly expressed along cytoskeletal actin in podocyte and 
its altered expression might be associated with cytoskeletal remodeling in podocyte injury.
Funding: Government Support - Non-U.S.
Pathology and Lab Medicine: Basic
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
376
J Am Soc Nephrol 29: 2018 Poster/Thursday
TH-PO992 Poster Thursday
Pathology and Lab Medicine: Basic
Transcription Factor MAFB is a New Key Regulator of Podocyte 
Autophagy
Kosuke Yamahara,1 Tillmann Bork,3 Wei Liang,4 Christoph Schell,3 
Shinji Kume,1 Mamoru Yoshibayashi,1 Shin-ichi Araki,1 Hiroshi Maegawa,1 
Tobias B. Huber.2 1Shiga University of Medical Science, Otsu, Shiga, Japan; 
2University Medical Center Hamburg, Hamburg, Germany; 3University 
Hospital Freiburg, Freiburg, Germany; 4Renmin Hospital of Wuhan University, 
Wuhan, China.
Background: Autophagy is an intracellular catabolic system with protective roles 
against fasting and cellular damage. Podocytes have high autophagy activity in basal 
condition; however, their autophagy regulating mechanisms are unclear. To reveal the 
regulating mechanism of podocyte autophagy, we focused on transcriptional regulation of 
autophagy related genes.
Methods: We searched the candidate transcription factors which regulate autophagy 
related genes with the potential to bind to transcription regulatory sites from the web 
database Motifmap. Next, we sorted the transcription factors which are strongly expressed 
in podocytes from RNA sequence data of primary culture podocytes. MAFB was extracted 
as a candidate from the results of these two analyses. To investigate the location of MAFB 
in the cell, we stained MAFB protein in mouse kidney sections and human podocyte cell 
lines. To exhibit the transcriptional role of MAFB on autophagy activation, we modified 
MAFB expression levels in human podocyte cell lines using either overexpression vector 
or siRNA, and evaluated autophagy activity by LC3-II protein expression. In addition, 
to reveal the role of MAFB for cell damage, we induced cell damage by incubation with 
palmitate and evaluated apoptosis and autophagy-related proteins using the cell line of 
tetracycline-induced overexpression/shRNA of MAFB.
Results: MAFB was localized at nuclear areas in podocytes of mouse kidney sections 
and human podocyte cell lines. LC3-II protein abundance was significantly increased in 
the MAFB overexpression group and decreased in siRNA of MAFB group. In cell damage 
experiments with palmitate, we observed suppression of apoptosis accompanied by high 
LC3-II protein abundance in the MAFB overexpression group. Phosphorylation of ULK1 
proteins, which are well known as a key autophagy regulator, was not significantly changed 
in any experiment.
Conclusions: We identified the transcription factor MAFB as a novel autophagy 
regulator independent of phosphorylation of ULK1 in podocytes. The activation of MAFB 
can be a potential therapeutic target against podocyte damages via autophagy activation.
Funding: Government Support - Non-U.S.
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Soluble Form of VCAM-1 Ameliorates Podocyte Injury by Plasma 
Membrane PTEN Recruitment
Shun Manabe,1,2 Kazuo Sakamoto,1 Naoko Ito,1 Nobuyuki Saga,1 Kosaku Nitta,2 
Michio Nagata.1 1Kidney and Vascular Pathology, Faculty of Medicine, 
University of Tsukuba, Tsukuba, Japan; 2Department of Medicine, Kidney 
Center, Tokyo Women’s Medical University, Shinjuku, Japan.
Background: Various types of stresses cause epithelial-mesenchymal transitions 
(EMTs) and detachments of podocyte that result in glomerular sclerosis. Podocyte has self-
defense mechanisms to resist against the stresses by expressing aberrant proteins. Vascular 
cell adhesion molecule-1 (VCAM-1) is a well-known protein induced by stresses that serve 
functions in membrane-bound and soluble form (sVCAM-1). However, in podocyte, the 
link between VCAM-1 and stress resistance remains unknown.
Methods: NEP25 transgenic mouse that develop podocyte-specific injury by 
immunotoxin injection were used. We assessed podocyte VCAM-1 and its ligand 
expressions by immunostaining, PCR, and western blot (WB). In vivo functions of 
sVCAM-1 were assessed by inhibiting ADAM17, the shedding enzyme of VCAM-1, by 
BB94. Immortalized podocyte were used for in vitro studies. The podocyte treated with 
H2O2, TGF-β1, sVCAM-1, and bpV were analyzed by immunostaining, real-time PCR, 
WB, and migration assay.
Results: Podocyte-specific injury of NEP25 mouse induced aberrant podocyte 
VCAM-1 and ADAM17 expression, which suggests the generation of sVCAM-1. 
Human focal segmental glomerular sclerosis also expressed podocyte VCAM-1. In 
vivoand in vitropodocyte expressed α9β1 integrin, which is the ligand of sVCAM-1.In 
vitro, sVCAM-1 ameliorated TGF-β1 induced podocyte EMT; amelioration of enhanced 
motility, maintenance of podocyte specific proteins, and inhibition of Akt phosphorylation. 
Mechanistically, sVCAM-1 recruited PTEN against plasma membrane, which was shown 
by immunostaining and WB analysis of plasma membrane fraction protein. Blockage of 
PTEN by bpV diminished the efficacy of sVCAM-1 to ameliorate podocyte EMT. Finally, 
we treated immunotoxin-injected NEP25 mouse by BB94 to inhibit sVCAM-1 generation 
that resulted in exacerbation of renal disfunction, urinary protein and glomerular sclerosis.
Conclusions: Aberrant sVCAM-1 generation recruited PTEN against plasma 
membrane to ameliorate podocyte injury by inhibiting Akt phosphorylation. VCAM-1 
expression might be one of the intrinsic self-defense mechanisms to resist against stresses 
in podocyte.
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Advanced Optical Clearing Protocols Enable Fine Analysis of Glomerulus 
Three-Dimensionally with Confocal Microscopy
Hiroyuki Yamada,1,2 Shinichi Makino,1,2 Takafumi Miyake,2,3 Motoko Yanagita,2,3 
Katsuhiko Asanuma.1,2 1Department of Nephrology, Chiba University Graduate 
School of Medicine, Chiba, Japan; 2The Laboratory for Kidney Research (TMK 
Project), Kyoto University Graduate School of Medicine, Kyoto, Japan; 
3Department of Nephrology, Kyoto University Graduate School of Medicine, 
Kyoto, Japan.
Background: In order to visualize slit diaphragm of podocyte, it is necessary to 
use an electron microscopy or super-resolution microscopy. However, there are some 
disadvantages to these approaches in terms of economics and viewable dimensions. We 
hypothesized that advanced optical clearing methods with confocal microscopy could 
enable the three-dimensional (3D) analysis of the fine structure of glomerulus and podocyte.
Methods: From among several advanced optical clearing methods, the following 
protocols were selected based on the simplicity of the technique and the number of citations: 
CUBIC, PACT, ScaleS, BABB, iDISCO and SeeDB2. Each protocol with immunostaining 
against Nephrin were applied to a 1-mm-thick slice of adult rat kidney. We investigated 
which method was most suitable for observing the fine structure of podocyte with confocal 
microscopy three-dimensionally. Next, the optimal method among them was applied to 
anti-glomerular basement membrane (anti-GBM) nephritis rats.
Results: All of these protocols could turn the rat kidney sample transparent. Although 
each protocol made it possible to visualize the 3D image of the whole glomerulus, a few 
protocols were capable of visualizing their fine structure of podocytes with confocal 
microscopy. When analyzing anti-GBM nephritis rat with 3D image, the ratio of the 
glomeruli with crescent formation in 3D analysis was significantly higher than that in the 
conventional two-dimensional histological analysis (34.1% versus 14.6%, p<0.01). High 
magnification of the 3D images showed that the meandering pattern of the slit diaphragm 
was sustained in the vehicle group while it was partially effaced in the anti-GBM nephritis 
group.
Conclusions: Advanced optical clearing methods enables a pathological 3D diagnosis 
of glomeruli and has a high sensitivity for pathological lesions. Moreover, using even 
confocal microscopy, it could visualize the fine structure of podocyte three-dimensionally. 
Optical clearing methods could make an outstanding contribution to our clinical practices 
in many aspects.
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A Deep Learning Approach for Detection of Normal and Globally 
Sclerotic Glomeruli on Whole Slide Images from Renal Biopsy Sections 
Stained with H&E
Yijiang Chen,1 Andrew Janowczyk,1 Matthew Palmer,2 John R. Sedor,3 
John F. O’Toole,3 L. Barisoni,4 Anant Madabhushi.1 1Case Western Reserve 
University, Cleveland, OH; 2University of Pennsylvania, Philadelphia, PA; 
3Cleveland Clinic, Cleveland, OH; 4U. Miami, Miller School of Medicine, 
Miami Beach, FL.
Background: Clinically useful quantitative assessment of renal biopsies requires 
robust methodologies. We demonstrated that accurate estimates of glomerular global 
sclerosis (GS) adjusted for age can predict outcomes across proteinuric diseases. However, 
visual assessment is poorly reproducible and time consuming. To increase efficiency, we 
present a deep learning-based approach for detection and segmentation (object extraction) 
of normal and globally sclerotic glomeruli (histologic primitives) digital renal biopsies.
Methods: A convolutional neural network (CNN) architecture based on Alexnext 
was trained using transfer learning to produce 3 classifiers: (i) normal glomerular tuft, (ii) 
normal glomerulus (tuft + Bowman’s capsule), and (iii) GS. We used 74 cropped images 
from whole slide images of NEPTUNE renal biopsies sections stained with H&E, divided 
into training and testing sets.
Results: The detection and pixel level segmentation results for all 3 classifiers was 
graded via the F-score (A measure of classification accuracy that considers both precision 
and recall; 1 = perfect, 0 = worst).
Conclusions: The development of these 3 CNNs represents the first step in evaluating 
renal biopsies using novel machine-human interactive protocols. The classifier “normal 
glomerulus” is a better denominator compared to “normal glomerular tuft” to estimate 
percentage of GS. Improvement in F-score for the classifier GS, however, is necessary 
before automatic assessment of GS adjusted for age can be applied in clinical research 
and practice. Future steps to implement extended machine-human interactive protocols 
will include generation of other classifiers for the annotation of additional glomerular, 
tubulointerstitial and vascular normal and abnormal histologic primitives.
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Activation of Non-MC1R-Mediated Melanocortinergic Signaling 
Ameliorates Podocytopathy and Proteinuria in Experimental Focal 
Segmental Glomerulosclerosis (FSGS)
Yingjin Qiao,1,2 Pei Wang,1 Yan Ge,3 Lance D. Dworkin,2 Zhangsuo Liu,1 
Rujun Gong.2 1The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 
China; 2University of Toledo Medical Center, Toledo, OH; 3Brown university, 
Providence, RI.
Background: The clinical effectiveness of melanocortin therapy with 
adrenocorticotropin in inducing remission of steroid-resistant nephrotic syndrome points 
to a steroidogenic-independent anti-proteinuric activity of melanocortins. However, which 
melanocortin receptor(MCR) conveys this beneficial effect is controversial. Moreover, it 
remains uncertain if a systemic or podocyte specific mechanism is involved. By harnessing 
the naturally occurring MC1R-null mice and using NDP-MSH, a potent nonsteroidogenic 
pan-MCR agonist, this study aims to validate if a podocyte-specific MC1R-mediated 
melanocortinergic signaling mediates the beneficial effect in glomerulopathy, as proposed 
recently.
Methods: FSGS was induced in wild-type (WT) and MC1R-null mice by Adriamycin, 
treated with NDP-MSH and was evaluated. Primary podocytes were injured with 
Adriamycin and cytopathy assessed.
Results: WT mice developed heavy proteinuria after Adriamycin insult, associated 
with progressive glomerulosclerosis and podocytopathy, marked by loss of podocin and 
synaptopodin, podocytopenia and extensive foot process effacement on electron microscopy. 
All these injurious effects were prominently attenuated by NDP-MSH. Surprisingly, MC1R 
deficiency in MC1R-null mice barely affected the severity of Adriamycin-elicited injury. 
Moreover, the beneficial effect of NDP-MSH was equally observed in MC1R-null mice to 
an magnitude comparable to that in WT mice, suggesting that MC1R is likely nonessential 
for the protective action. A direct podocyte effect seems to contribute, at least in part, to 
the beneficial effect of NDP-MSH, because Adriamycin-inflicted cytopathic signs in 
primary podocytes prepared from WT mice were all diminished by NDP-MSH, including 
loss of podocyte markers, apoptosis, de novo expression of podocytopathic B7-1, actin 
cytoskeleton disruption and podocyte hypermotility. Consistent with in vivo findings, 
NDP-MSH protected the MC1R-null podocytes against Adriamycin injury to a degree 
equal to that observed in WT podocytes, again suggesting that non-MC1R-transmitted 
melanocortinergic signaling is responsible for this direct podocyte protection.
Conclusions: Melanocortin therapy protects against podocyte injury and ameliorates 
proteinuria and glomerulopathy via a non-MC1R-mediated melanocortinergic signaling.
Funding: NIDDK Support
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Phospholipase A2 Receptor 1 Antibody Levels at the Time of Diagnosis 
Determine Renal Outcome in Patients with Membranous Nephropathy
Maida Mahmud,1 Hans O. Pinnschmidt,2 Linda Reinhard,1 Sigrid Harendza,1 
Thorsten Wiech,3 Rolf A. Stahl,1 Elion Hoxha.1 1III. Department of Internal 
Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 2Institute of Medical Biometry and Epidemiology, University Medical 
Center Hamburg-Eppendorf, Hamburg, Germany; 3Department of 
Nephropathology, Institute of Pathology, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany.
Background: Membranous nephropathy (MN) is an autoimmune disease caused by 
circulating antibodies against the podocyte protein phospholipase A2 receptor 1 (PLA2R1-
ab) in 80% of cases. PLA2R1-ab levels correlate with disease activity and treatment 
response. However, their significance on long-term renal outcome is not clear.
Methods: In this prospective observational multicenter study we investigated 
the predictive role of PLA2R1-ab levels for long-term renal outcome in 243 patients 
with newly diagnosed, biopsy-proven PLA2R1-associated MN, who had received no 
immunosuppressive treatment prior to study enrollment. The median follow-up time was 48 
months. The primary endpoint was defined as doubling of serum creatinine or development 
of end-stage renal disease. PLA2R1-ab levels, proteinuria and serum creatinine were 
prospectively measured every three months.
Results: 243 patients (171, 70% males; median age 55 years, IQR: 43–66 years) 
were included in the study. Thirty-six (15%) of the 243 patients reached the study 
endpoint. Multivariate Cox regression analyses adjusting for all clinical relevant 
parameters revealed that the following independent predictors significantly increased the 
risk for reaching the study endpoint: PLA2R1-ab levels (HR=1.36, 95%CI 1.11–1.66, 
p=0.003), percentage of tubular atrophy and interstitial fibrosis in the biopsy (HR=1.32, 
95%CI 1.03–1.68, p=0.030), relapse of PLA2R1-ab during follow-up (HR=3.22, 95%CI 
1.36–7.60, p=0.008), and relapse of proteinuria (HR=2.60, 95%CI 1.17–5.79, p=0.019). 
Fifty-four (22%) patients received no immunosuppressive treatment during the study. In 
41 (76%) of these patients PLA2R1-ab spontaneously disappeared during the follow-up, 29 
(54%) of them had a complete remission of proteinuria, and 19 (35%) a partial remission. 
Patients who were not treated with immunosuppressives were more often female and had 
lower PLA2R1-ab levels, proteinuria, and serum creatinine at baseline compared to patients 
receiving immunosuppression.
Conclusions: PLA2R1-ab levels are, in addition to pre-existing renal damage, a 
predictive factor for long-term outcome in patients with MN and should be considered when 
deciding on treatment of these patients.
Funding: Government Support - Non-U.S.
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Anti-PLA2R Antibodies and Outcome in Patients with Membranous 
Nephropathy
Anne-Els van de Logt,1 Joana Justino,3 Coralien Vink- van Setten,1 Jan A. van 
den Brand,1 Gerard J. Lambeau,2 Jack F. Wetzels.1 1Radboud University Medical 
Center, Nijmegen, Netherlands; 2Institute of Molecular and Cellular 
Pharmacology, CNRS and University of Nice, Valbonne, France; 3Institut de 
Pharmacologie Moleculaire et Celluleire, Sophia Abtipolis, France.
Background: Personalized treatment for patients with membranous nephropathy 
(MN) requires accurate prediction of disease course at an early stage. We evaluated the 
added value of including level of anti-PLA2R antibodies (PLA2Rab) and epitope spreading 
at baseline in prediction models.
Methods: We included untreated patients with PLA2R-related MN who were 
referred to our clinic between 1995 and 2016. Patients with nephrotic range proteinuria 
(UPCR ≥ 3 gram/10 mmol in 24-hours urine) and a creatinine level of ≤ 135 umol/l were 
included. Outcomes were progression, defined as the need for immunosuppressive therapy 
because of an increase of serum creatinine level of >30 % from baseline or severe persistent 
nephrotic syndrome, and spontaneous remission as a competing event. We fitted a Fine 
and Gray survival model to simultaneously predict the probabilities of progression and 
spontaneous remission. We included serum creatinine, UPCR and the urinary excretion of 
α1microglobulin as known prognostic markers, and added sequentially baseline PLA2Rab 
titers (ELISA) and epitope spreading. We estimated bootstrapped C-statistics and obtained 
calibration plots at twelve-month intervals during follow-up.
Results: We included 142 patients. Univariate comparison of progressors vs non-
progressors is presented in Table 1. Neither PLA2Rab titer nor epitope spreading improved 
prognostic predictions when combined with known prognostic markers. The C-statistics for 
respectively progression and remission were between 0.71 and 0.70 at 12 and 60 months 
follow-up, respectively. The model was well calibrated for both progression and remission.
Conclusions: Whereas baseline PLA2Rab titer and epitope spreading predicted 
response to treatment in patients with MN, our data from this cohort suggest that their added 
value over and beyond traditional risk biomarkers for predicting spontaneous remission 
may be limited.
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Differences in Outcome in Patients with Membranous Nephropathy with 
and Without Anti-PLA2R Antibodies
Anne-Els van de Logt,1 Joana Justino,2 Coralien Vink- van Setten,1 Jan A. van 
den Brand,1 Gerard J. Lambeau,3 Jack F. Wetzels.1 1Radboud University Medical 
Center, Nijmegen, Netherlands; 2Institut de Pharmacologie Moleculaire et 
Celluleire, Sophia Abtipolis, France; 3Institute of Molecular and Cellular 
Pharmacology, CNRS and University of Nice, Valbonne, France.
Background: The identification of autoantibodies against PLA2R1 (PLA2Rab) 
defined membranous nephropathy as an auto-immune disease. There is debate if outcome is 
different in PLA2Rab-positive and PLA2Rab-negative patients. We evaluated differences 
in the natural course of primary MN between PLA2Rab-positive and PLA2Rab-negative 
patients.
Methods: We included untreated patients with MN who were referred to our clinic 
between 1995 and 2016. Inclusion criteria were nephrotic range proteinuria (Upcr ≥ 
3 gram/10 mmol) and a serum creatinine level of ≤ 135 μmol/l. Primary outcome was 
spontaneous remission, both partial and complete, or progression, defined as the need for 
immunosuppressive therapy because of an increase of serum creatinine level > 30% or 
severe persistent nephrotic syndrome. In stored samples PLA2Rab were measured with 
ELISA (Euroimmun®). A cut-off value of < 14 RU/ml was used to define seronegativity.
Results: In total 182 patients were included. PLA2Rab were detected in 75 % of 
patients. Clinical characteristics were similar between both groups (table 1). During follow-
up, 65% of PLA2Rab-positive patients needed immunosuppressive therapy versus 48% 
of seronegative patients. At 60 months of follow-up, cumulative incidence of spontaneous 
remission was 52% vs 34% (p = 0.008) and progression was 43% vs 65% (p=0.02) for 
PLA2Rab-negative compared to positive patients.
Conclusions: The natural course of MN is more favorable in PLA2Rab-negative 
patients.
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Levels of Anti-PLA2R Antibodies Predictive of Renal Prognosis in 
Japanese Patients with PLA2R-Associated Primary Membranous 
Nephropathy
Asaka Hachiya, Shin’ichi Akiyama, Shoichi Maruyama. Nagoya University 
Graduate School of Medicine, Nagoya, Japan.
Background: Measurement of circulating levels of autoantibody against phospholipase 
A2 receptor (PLA2R) antibody at diagnosis is important for not only differentiation but also 
for prediction of renal prognosis. Recent studies suggest that a poor renal outcome mainly 
occurs in patients with PLA2R-associated primary membranous nephropathy (pMN) 
who have a high level of anti-PLA2R antibody (aPLA2R-Abs) at diagnosis. This study 
investigated the association between aPLA2R-Abs levels and renal prognosis in Japanese 
patients with PLA2R-associated pMN.
Methods: We retrospectively enrolled 53 consecutive Japanese patients with biopsy-
proven PLA2R-associated pMN (males, 38; median age, 64 [IQR 53-69] years old; 
observation period, 62 [43-91] months, urinary protein levels, 5 [4-9] g/day) admitted to 
our hospitals between January 2003 and December 2012. The primary outcome was the 
cumulative rate of 1.5-fold increase in serum creatinine and all-cause death. Sera were 
collected at the time of renal biopsy. We identified the levels of aPLA2R-Abs predictive of 
renal prognosis on the basis of C-index calculated with Cox proportional hazards models.
Results: Median levels of aPLA2R-Abs at diagnosis were 62 [IQR 32-165] RU/ml. 
Patients with ≥50 RU/ml (35 of 53) showed lower renal survival rates and more reached the 
outcomes compared to those with <50 RU/ml (17 of 35 vs. 1 of 18, p=0.01). Patients with 
≥50 RU/ml also showed significantly lower serum albumin at baseline and received more 
frequent remission-induction immunosuppressive therapies (p<0.01, p=0.01, respectively).
Cox proportional hazards models indicated that a level of ≥50 RU/ml at diagnosis predicted 
poor renal prognosis (adjusted hazard ratio by age, sex, urinary protein levels and use of
immunosuppressive agents within 1 year, 8.3 [95% confidence interval 1.1–62.5, p=0.01]).
Conclusions: APLA2R-Abs levels of ≥50 RU/ml at diagnosis could help predict poor 
renal prognosis in Japanese patients with PLA2R-associated pMN.
TH-PO1001 Poster Thursday
Glomerular Diseases: Clinical, Outcomes, Trials - I
Determination of Anti-PLA2R and Anti-THSD7A Antibodies in Brazilian 
Patients with Idiopathic and Lupus Membranous Nephropathy
Ligia C. Battaini,1 Pamela B. Larrea,1 Lia J. Marçal,2 Lectícia Jorge,3 
Leila Antonangelo,2 Denise M. Malheiros,4 Luis Yu.5 1University of Sao Paulo 
Brazil, Quito, Ecuador; 2Universidade de Sao Paulo, Sao Paulo - SP, Brazil; 
3University of São Paulo, São Paulo, Brazil; 4Univ of Sao Paulo, Sao Paulo, 
Brazil; 5University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Background: Membranous Nephropathy (MN) is a common cause of nephrotic 
syndrome in adults. In Brazil, it is the second most frequent cause of glomerulopathies. 
Incidence variations in between the various studies may reflect patterns of biopsy indication 
in different countries however, it may also be related to socioeconomical, ethnical or 
environmental characteristics. In the past years, the role of anti-phospholipase A2 (anti-
PLA2R) receptor autoantibodies and the antibody against THSD7A (thrombospondin type 
1 domain containing protein 7A) in the pathogenesis of idiopathic MN were described. The 
determination of these serum and renal tissue antibodies have not yet been performed in the 
Brazilian population.
Methods: Blood samples were collected from 26 patients diagnosed with MN and 13 
patients with Lupus Membranous Nephropathy (LMN), confirmed by renal tissue biopsy 
(OM and IF). The anti-PLA2R antibody was measured by the ELISA and IIFT techniques 
and antibodies against THSD7A by IIFT. In addition, routine tests of renal function and 
proteinuria were also collected. Patients will be followed and evaluated after 6 months and 
1 year of the initial consultation.
Results: All 13 patients with LMN were negative for anti - PLA2R and anti - THSD7. 
A total of 26 patients with MN tested negative for anti - THSD7A. Out of 26 patients, 13 
(50%) were anti-PLA2R negative by both ELISA and IIFT. On the other hand, 10 patients 
(38.4%) were positive by both methods and 3 patients were positive only by IIFT and had 
intermediate titers by ELISA method, resulting in 13 positive patients (50%). Proteinuria 
levels in ELISA and IIFT negative patients were 1.98g / vol, 6.7g / vol for ELISA and 
IIFT positive patients and 2.96g / vol for intermediate ELISA and IIFT positive patients, 
respectively. In this sample, there was a positive correlation between the anti - PLA2R titers 
and the levels of proteinuria.
Conclusions: In this Brazilian population of MN patients, there was a 50% positivity 
for anti - PLA2R. The IIFT technique was more sensitive than the ELISA test. No patient 
was positive for anti-THSD7A. All patients with LMN were negative for both antibodies. 
There was a positive correlation between the anti - PLA2R antibodies serum levels and the 
degree of proteinuria.
Funding: Government Support - Non-U.S.
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Combined Assessment of Serum Anti-PLA2Rabs and Glomerular 
PLA2Rags Deposition in Patients with Membranous Nephropathy (MN)
Pinelopi Kouki,1 Aikaterini A. Damianaki,1 Evgenia Ventouri,2 Athanasia Kapota,1 
Kostas Stylianou,3 Harikleia Gakiopoulou,2 Dimitrios I. Petras.1 1Hippokration 
Hospital of Arhens, Athens, Greece; 21st Department of Pathology School of 
Medicine University of Athens, Athens, Greece; 3University Hospital of Heraklion, 
Heraklion, Greece.
Background: MN is the most common cause of nephrotic syndrome in adults. The 
involvement of PLA2R (Ags and Abs) in the pathogenesis of the disease (idiopathic MN) 
is investigated. The purpose of the study was to correlate the glomerular deposition of 
PLA2R-antigens (Ags) and circulating serum anti-PA2R-antibodies (Abs) to renal function 
(eGFR), proteinuria and clinical outcome in patients with idiopathic MN.
Methods: Twenty patients with idiopathic MN met the study criteria. Initial eGFR and 
proteinuria were recorded at months 0 and 6 as well as the clinical outcome after treatment. 
Glomerular PLA2R-Ags deposition intensities (mild, moderate, strong) were evaluated 
with immunohistochemistry. Serum anti-PLA2R-Abs (detectable / undetectable) were 
also evaluated.
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Results: Positive PLA2R-Ags was detected at 81.25%, while detectable anti-PLA2R-
Abs in 62.5% of patients. Mean proteinuria values at months 0 and 6 were 9.1 grams and 
1.8 grams / 24 hours, respectively. Μean eGFR at months 0 and 6 was 73.1 ml / min / 1.73 m2 
and 75.83 ml / min / 1.73 m2. Strong glomerular PLA2R-Ags deposition was positively 
correlated with renal function at time 0 (p <0.05) and reduction in proteinuria at 6 months 
(p <0.01). Serum anti-PLA2R-Abs levels were not correlated with eGFR and proteinuria at 
0 and 6 months. Our results are not in accordance with the literature, probably due to early 
refferal of the patients.
Conclusions: In conclusion glomerular PLA2R-Ags deposition appears to be more 
closely correlated with renal function and the rate of proteinuria reduction than serum 
anti-PLA2R-Abs in patients with idiopathic MN. More studies are needed to prove this 
predictive role.
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Optimization of the Cutoff Value for a Commercial Anti-PLA2R ELISA to 
Diagnose PLA2R-Associated Membranous Nephropathy in Japanese 
Patients
Shin’ichi Akiyama,1 Asaka Hachiya,2 Shoichi Maruyama.1 1Nagoya University 
Graduate School of Medicine, Nagoya, Japan; 2Nagoya University, Nagoya, 
Japan.
Background: Anti-PLA2R antibodies (aPLA2R-Ab) is a potentially useful diagnostic 
and therapeutic biomarkers for PLA2R-associated primary membranous nephropathy 
(PLA2R-pMN). aPLA2R-Ab titer is easily quantified by a commercial ELISA kit. However, 
we observed more false-negative results in our experiments in Japan, when considering the 
manufacturer’s cutoff value (14 RU/ml) for ELISA than with western blot (WB) analysis 
and a commercial IIFT-CBA, indicating that the manufacture’s cutoff value is too high for 
the diagnosis of aPLA2R-Ab in Japanese PLA2R-pMN patients. Hence, it is important to 
optimize the cutoff value for ELISA in each region. This study aimed to investigate the 
optimal index cutoff value of the commercial aPLA2R-Ab ELISA kit for Japanese patients 
with PLA2R-pMN.
Methods: The aPLA2R-AB in serum samples from 117 patients with biopsy-proven 
primary membranous nephropathy (MN) were measured by WB and commercial ELISA 
(EUROIMMUN AG). WB analysis was performed under non-reducing condition and 
with diluted sera at x1/101. The ELISA was used in accordance with the manufacturer’s 
instructions. Primary MN patients were divided into an aPLA2R-Ab-positive group and a 
-negative group per the results of WB. Receiver operating characteristic (ROC) curves were 
plotted to generate the cutoff value for screening aPLA2R-Ab positive patients diagnosed
via WB analysis from among all patients with pMN. Furthermore, to confirm the absence 
of changes in specificity, disease control sera from 30 each patients with secondary MN and 
other glomerulonephritis were measured by the ELISA.
Results: WB revealed that of 117 patients with pMN, 59 were aPLA2R-Ab-positive; 
58, -negative. ROC curve analysis revealed a cutoff value of 5 RU/ml with a sensitivity 
and specificity of 50% and 93%, respectively. With a cutoff value of 5 RU/ml, none of 
the aPLA2R-Ab-positive serum samples were screened from disease control groups. The 
index cutoff value decreased from 14 to 5 RU/ml, thereby improving the sensitivity of the 
aPLA2R-Ab ELISA from 39% to 48%.
Conclusions: The optimal cutoff value of the aPLA2R-Ab ELISA for Japanese patients 
with PLA2R-pMN is 5 RU/ml. The cutoff value, thus optimized, of the ELISA enhanced 
the interpretation and confidence levels in the screening of PLA2R-pMN and eliminated the 
need for confirmation via WB analysis.
Funding: Government Support - Non-U.S.
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An Indian Experience with M-Type Phospholipase A2 Receptor (PLA2R) 
Antibody in Membranous Nephropathy
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Background: Membranous Nephropathy(MN) is one of the common cause of 
nephrotic syndrome in adults. We present our data, one of the first studies from India, on 
sensitivity of tissue and serum PLA2R in Membranous nephropathy and its association 
with disease activity.
Methods: Treatment-naïve biopsy-proven MN patients were included. Anti-PLA2R 
antibody in serum and PLA2R antigen in tissue was tested at the time of first diagnosis. 
Disease activity was assessed by measurement of proteinuria, serum albumin and renal 
function. Detailed history, examination and investigations were performed to rule out a 
secondary cause of MN.
Results: We included 38 patients in the study. Mean age was 45.09 +/- 14.29 yrs 
(27 males & 11 females). A secondary cause of MN was found in 4/38(10.5%). PLA2R (either 
serum or tissue) was positive in 25/38(65.8%) patients; 24/34(70.5%) in iMN and 1/4(25%) 
in secondary MN. Pattern of PLA2R positivity in iMN has been described in the image. 
PLA2R was associated with heavier proteinuria (11.27 ± 5.74gm/d) vs (4.08 ± 2.61gm) 
in patients negative for PLA2R(p<0.001) and significant hypoalbuminemia with serum 
albumin 2.11g/dl ± 0.7g/dl in PLA2R positive patients vs 2.93 ± 0.3g/dl in patients negative 
for PLA2R(p<0.001). No difference was found in serum creatinine between the groups 
(PLA2R positive - 1.03 ± 0.35 mg/dl vs PLA2R negative – 0.91 ± 0.29mg/dl, p - 0.3).
Conclusions: Though PLA2R is an important diagnostic tool in patients with 
Membranous nephropathy, yet it cannot replace biopsy, in view of moderate sensitivity 
as seen in our study. PLA2R is associated with heavy proteinuria and hypoalbuminemia.
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Transplacental Passage of Phospholipase A2 Receptor Antibodies from 
Maternal to Fetal Circulation and Secretion into Breastmilk
Mala Sachdeva,1,3 Fatima Sheikh,3 Laurence H. Beck,2 Steven Fishbane,3 
Llene J. Miller.4 1Donald and Barbara Zucker School of Medicine at Hofstra/
Northwell, Great Neck, NY; 2Boston University Medical Center, Boston, MA; 
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Introduction: Phospholipase A2 receptor (PLA2R) was described as the major target 
antigen in idiopathic membranous nephropathy (IMN). During pregnancy, certain maternal 
antibodies transport across the placenta. Whether PLA2R-Ab crosses over from maternal to 
fetal circulation is still unknown. We report a case of biopsy proven maternal membranous 
nephropathy where there was transfer of PLA2R-Ab from maternal to fetal circulation. We 
further report the first case where PLA2R-Ab is secreted into mother’s breast milk.
Case Description: A 33 year old female presented at 30 weeks gestation with 
nephrotic syndrome. Her initial PLA2R Ab was 57 RU/mL. At 33 weeks, her pregnancy was 
complicated by oligohydramnios and worsening of her nephrotic syndrome. Her PLA2R-
Ab titer was noted to progressively increase from 75RU/mL at 34 weeks to 111RU/mL 
at 36 weeks to 161RU/mL at the time of delivery to 506 RU/mL one month post-partum. 
At 37 weeks, a 2.29kg male was delivered. Cord blood for PLA2R-Ab was 59 RU/mL 
and infant’s serum showed PLA2R-Ab of 57 RU/mL. At 18 days, the infant’s urine spot 
protein:creatinine ratio (P:C) was 0.8 g/g, albumin was 3.5g/dL, with the PLA2R Ab 
3RU/mL (nl). At one month, the infant’s P:C normalized with serum albumin of 3.8g/dL, 
however his PLA2R-Ab rose to 25RU/mL. Mother’s breast milk was assessed by Western 
blot and IgG4 PLA2R-Abs against full-length PLA2R were detected.
Discussion: This is the first case of biopsy proven-IMN with rising PLA2R-Ab 
confirming transplacental passage of the PLA2R Ab to the fetus. PLA2R-Ab was detected in 
the cord blood and the peripheral circulation at the time of delivery which then decreased 
to normal by 18 days post-partum. Clinically, the infant had a low albumin level and 
proteinuria at 2.5 weeks post-delivery which then normalized by his one month follow 
up visit. Whether this reflects a mild case of neonatal membranous nephropathy is still 
unknown but possible. Furthermore, we have demonstrated the ability of PLA2R-Ab to 
be secreted into breastmilk, likely accounting for the rise in the infant’s one month titer. 
These findings potentially affect the future care of pregnant women with IMN as well as 
their newborns.
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108 Cases of Idiopathic Membranous Nephropathy Patients with Clinical 
and Pathological Analysis
Xin Li. Nephropathy Department, Tongji Hospital, Shanghai, China.
Background: Idiopathic membranous nephropathy is the most common cause of adult 
nephrotic syndrome. Its onset is hidden and its progress is slow. The prognosis is different. 
Analyze the clinical and pathological characteristics of the patients with IMN will help us 
to get a better understanding of the disease process. The objective was to retrospectively 
analyze the clinical and pathological features of idiopathic membranous nephropathy in 
our single center.
Methods: The clinicopathological data of 108 patients with biopsy-proven IMN from 
January 2013 to December 2017 were analyzed retrospectively. IMN patients were divided 
into NS and non-NS groups. Analyse the clinical and pathological characteristics of these 
two groups. 
Results: The average age was 57 years and 59.3% were male patients. Compared with 
patients without NS,IMN patients with NS were older,lower eGFR, higher total cholesterol, 
low density cholesterol and serum creatinine (P<0.05). The effective rate of conservative 
treatment in IMN patients without NS was 61.7%.The effective rate of immunosuppressive 
therapy in IMN patients with NS was 70.8%, and low serum albumin was an independent 
risk factor for the poor efficacy(p=0.021 OR 1.329). The effective rate of conservative 
treatment in IMN patients with NS was 47.3%,and low serum albumin was an independent 
risk factor for the poor efficacy(p=0.042 OR 1.201).
Conclusions: The remission rate of conservative treatment non-NS patients was not 
low. Hypoproteinemia may be a predictor of poor efficacy with NS patients.
Funding: Government Support - Non-U.S.
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Associations of HLA Class II Alleles with Clinical Phenotype and Outcome 
in Patients with Primary Membranous Nephropathy: A Single Amino Acid 
Makes the Difference
Huaiyu Wang, Zhao Cui, Minghui Zhao. Peking University First Hospital, 
Peking University, Beijing, China.
Background: GWAS and HLA genotyping have revealed associations between HLA 
alleles and susceptibility to primary membranous nephropathy(pMN), but the associations 
with clinical phenotypes and kidney outcome are underinvestigated.
Methods: Patients with pMN were included. Associations between HLA alleles and 
clinical variants were analyzed by Logistic regression. Risk factors for kidney outcome 
were analyzed by Kaplan-Meier curve and COX regression. Structure of HLA molecules 
were modelled.
Results: DRB1*0301 was associated with higher level of PLA2R-Ab (OR=1.58, 
95%CI 1.13-2.22, P=0.008). Although DRB1*1502 differs from DRB1*1501 by a single 
amino acid and was not risk allele for pMN, it was associated with lower eGFR both at 
baseline (OR=1.79, 95%CI 1.18-2.72, P=0.006) and last follow-up (OR=1.72, 95%CI 1.17-
2.53, P=0.006), worse renal outcome (P=0.013) and higher risk of ESRD (HR=4.52, 95%CI 
1.22-16.74, P=0.024). DRB1*1502 correlated to higher PLA2R-Ab level [161.4 (28.1, 
268.0) vs. 36.3 (2.8, 130.5) U/mL, P=0.013] and showed interaction with DRB1*0301 for 
the variable(P=0.049). Homologous modelling showed the amino acid on position 86 is a 
valine in DRB1*1501, but a glycine in DRB1*1502, the latter facilitating the formation of 
a larger pocket 1 in the binding groove.
Conclusions: Our findings show that HLA genes control PLA2R antibody production 
and pMN severity and outcome. They additionally suggest that DRB1*1502 behaves like a 
modifier gene with a strong predictor value when associated with HLA risk alleles.
Figure 1. Renal survival curves in pMN patients.
Figure 2. Structure models of pocket 1 of DRB1*1501 and DRB1*1502.
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Urine Metabolomics Analysis and Its Experimental Validation
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Background: Anti-PLA2R antibody (PLA2R Ab) is a useful biomarker in membranous 
nephropathy (MN), however, the levels of PLA2R Ab do not always predict the prognosis 
or treatment response. There are need to seek additional biomarker to predict both of 
immunosuppressive agent response and renal prognosis. Also, it is not yet known how 
PLA2R Ab-antigen reaction causes the changes in podocytes and become a pathogenicity 
of MN. We aimed to figure out biomarkers predicting the prognosis and treatment response 
using metabolomics analysis of urine samples.
Methods: The nuclear magnetic resonance-based method was used to examine the 
urine samples at the time of kidney biopsy from patients with PLA2R-associated MN and 
minimal change disease (MCD). The negative control was urine samples from healthy 
controls.
Results: Metabolites significantly higher in PLA2R-associated MN than healthy 
controls were fumarate, choline, mannitol, isoleucine, glucose, valine, leucine, tyrosine, and 
betaine. Fumarate was the only differential metabolite in PLA2R-associated MN compared 
with MCD. PLA2R-associated MN patients with high urine fumarate levels had a greater 
risk of composite renal outcome and lower likelihood of having treatment response and 
achieving remission. The in-vitro validation study was performed using primary cultured 
human podocytes treated with IgG purified from a patient with PLA2R-associated MN (MN 
IgG). PLA2R Ab-antigen interaction in MN IgG stimulated podocytes was confirmed and 
further identified increased the expression of both fibronectin and Snail, despite decreased 
fumarate hydratase, WT-1, and ZO-1 expression. Lentivirus-mediated fumarate hydratase 
activation showed improvement of fumarate hydratase, WT-1 and ZO-1, and attenuation of 
expression in fibronectin and Snail. Albumin permeability test confirmed that absorbance of 
albumin was increased in podocytes after activation of MN IgG. The fluorescence intensity 
of ZO-1 was decreased in podocytes by stimulation of MN IgG. Albumin absorbance 
and fluorescence intensity of ZO-1 in podocytes were reversed by activation of fumarate 
hydratase.
Conclusions: These findings suggest that fumarate might play an important role in the 
progression and disease activity of PLA2R-associated MN via the regulation of podocyte 
integrity and renal fibrosis.
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Serum GDH-15 Predicts the Outcome of Idiopathic Membranous 
Nephropathy
Youngrok Ham,2 Dae Eun Choi,1 Jae wan Jeon,2 Jiwon M. Lee,1 Yoon-
Kyung Chang,3 Ki Ryang Na,2 Kang Wook Lee.2 1Chungnam National 
University, Daejeon, Republic of Korea; 2Chungnam National University 
Hospital, Daejeon, Republic of Korea; 3The Catholic University of Korea, 
Daejeon, Republic of Korea.
Background: Idiopathic membranous nephropathy (IMN) is a major cause of nephrotic 
syndrome. Growth differentiation factor-15 (GDF-15) is a member of the transforming 
growth factor-β superfamily and has been associated with chronic inflammatory disease. 
It has the potential to be a useful prognostic marker in patients with renal diseases, such 
as diabetic nephropathy and IgA nephropathy. This study examined whether GDF-15 is 
associated with the clinical parameters in IMN and showed that GDF-15 can predict IMN 
disease progression.
Methods: A total of 35 patients with biopsy-proven IMN, treated at Chungnam 
National University Hospital from January 2010 to December 2015, were included. Patients 
younger than 18 years, those with secondary membranous nephropathy, and those lost to 
follow-up before 12 months were excluded. Levels of GDF-15 at the time of biopsy were 
measured using enzymelinked immunosorbent assays. Disease progression was defined as 
a ≥30% decline in estimated glomerular filtration rate (eGFR) or the development of end-
stage renal disease.
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Results: The mean follow-up was 44.1 months (range: 16–72 months). Using receiver 
operating curve analysis, the best serum GDF-15 cut-off value for predicting disease 
progression was 2.15 ng/ml (sensitivity: 75.0%, specificity: 82.1%, p = 0 007). GDF-15 
was significantly related to age and initial renal function. In the Kaplan-Meier analysis, the 
risk of disease progression increased in patients with GDF-15 ≥ 2.15 ng/ml when compared 
with those with GDF-15 < 2.15 ng/ml (50.0% versus 9.7%) (p = 0 012). In the multivariate 
Cox regression analysis adjusted for potential confounders, only GDF-15 was significantly 
associated with disease progression in IMN (p = 0 032).
Conclusions: The GDF-15 level at the time of diagnosis has a significant negative 
correlation with initial renal function and is associated with a poor prognosis in IMN. Our 
results suggest that GDF-15 provides useful prognostic information in patients with IMN.
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Novel ELISA for THSD7A Autoantibodies in Membranous Nephropathy
Christelle Zaghrini,1 Barbara Seitz-Polski,2 Joana Justino,1 Guillaume Dolla,1 
Christine Payre,1 Noemie Jourde-Chiche,3 Anne-Els van de Logt,6 
Jennie Lonnbro-Widgren,4 Jenny C. Nystrom,5 Zhao Cui,10 Jack F. Wetzels,6 
Gian Marco Ghiggeri,9 Laurence H. Beck,7 Pierre M. Ronco,8 Hanna Debiec,8 
Gerard J. Lambeau.1 1Institut de Pharmacologie Moleculaire et Cellulaire, 
University Cote d’Azur, Sophia Antipolis, France; 2Pasteur University Hospital, 
Nice, France; 3Aix-Marseille University, Marseille, France; 4Sahlgrenska 
University Hospital, Gothenburg, Sweden; 5University of Gothenburg, 
Goteborg, Sweden; 6Radboud University Medical Center, Nijmegen, 
Netherlands; 7Boston University Medical Center, Boston, MA; 8Hospital Tenon, 
Sorbonne University, Paris, France; 9G. Gaslini Children Hospital, Genoa, 
Italy; 10Peking University First Hospital, Peking, China.
Background: In 2014, THSD7A was identified as a second autoantigen for 2-5% of 
membranous nephropathy (MN) patients whereas PLA2R1 is the major autoantigen for 
70% of patients. Detection and accurate measurement of anti-PLA2R1 and anti-THSD7A 
titers provide key biomarkers to diagnose MN, monitor disease activity and predict clinical 
outcome. To date, antibodies in THSD7A-associated MN patients are only evaluated semi-
quantitatively by WB and IIFT. We aimed to develop a robust and rapid assay for the 
quantitative measurement of antibody levels in THSD7A-associated MN patients.
Methods: Screening of 1012 biopsy-proven MN patients led to the identification of 
28 THSD7A-positive patients by ELISA. Screening of additional MN patients, mostly 
PLA2R1-negative, identified 21 more cases, establishing the largest cohort of 49 THSD7A-
positive patients to date. We validated the positivity of the 49 patients by ELISA, WB, IIFT 
and biopsy staining. We analyzed the clinical parameters of this population for age, gender, 
disease activity and possible links to etiology including malignancy. We described eight 
patients double positive for THSD7A and PLA2R1 antibodies.
Results: The novel ELISA and commercial IIFT titers correlated significantly 
(p<0.0001). Among the 49 patients with anti-THSD7A antibodies, 57% were males. 
Females were younger than males (49 versus 67 years, p=0.003). Levels of anti-THSD7A 
antibodies were similar between male and female patients and correlated with disease 
activity and treatment efficacy. The double positive patients had varying antibody titers for 
both antigens and displayed no clinical difference compared to the rest of the population. 
Patients with a history of malignancy (16%) were older than others (76 versus 54 years 
old, p=0.002) and only 3 were diagnosed for malignancy within 2 years of MN diagnosis.
Conclusions: This novel ELISA assay can be used to identify patients with THSD7A-
associated MN and monitor antibodies during follow-up. Our data suggest a weak 
association between MN and malignancy in our population of THSD7A-positive patients.
Funding: Government Support - Non-U.S.
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Membranous Nephropathy at Diagnosis and Follow-Up: Comparison 
Between Elderly and Young Patients
Renata P. Brandão, Cristiane B. Dias, Lectícia Jorge, Denise M. Malheiros, 
Viktoria Woronik. University of São Paulo, São Paulo, Brazil.
Background: This study aims to evaluate the epidemiological profile between elderly 
and young patients with Membranous Nephropathy (MN) diagnosed in a single center.
Methods: This was a retrospective cohort study from 1999 to 2017, where clinical, 
epidemiological, laboratory and histological data of patients with MN accompanied by the 
Nephrology Department of the Hospital das Clinicas de São Paulo were evaluated. The only 
exclusion criterion was to have a diagnosis of Systemic Lupus Erythematosus at the time 
of the renal biopsy.
Results: In these period 219 patients had renal biopsy proving MN, presenting a 
mean age of 45.3 ± 15.7 years and 53.8% of women. Laboratory data at diagnosis were: 
serum creatinine median of 1.0 (0.8-1.7) mg/dl; median proteinuria of 6.0 (3.0-8.8) g/day 
and serum albumin median of 1.8 (1.2-2.5) g/dL. There were 48.4% of patients with 
hypertension and 35.6% with hematuria at diagnosis. A total of 44 (20%) patients were 
elderly at diagnosis and comparation with the young patients are in table 1.. Forty patients 
(18.2%) presented secondary causes, being infectious causes in 18, with hepatitis B in 4 
patients; autoimmune causes in 11, with rheumatoid arthritis in 3; and cancer in 11.
Conclusions: MN showed a different epidemiological profile among young and elderly 
patients, with a predominance of men, hypertension, and increased serum initial creatinine 
in the latter group. The secondary forms corresponded to less than 20% in these cases, 
predominating the infectious and autoimmune etiologies.
Comparison between elderly and young patients with MN
ns- not significant
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Polymorphisms in the Exon 1 of the MBL2 Gene Are Not Associated with 
a Poor Prognosis in Membranous Nephropathy
Maria Carolina R. Coêlho,1 Camila B. Oliveira,1 Carolina A. Vasconcelos,2 
Denise M. Costa,1 Gisele Vajgel,1 Maria Alina G. Cavalcante,1 Lucila 
Maria Valente.1 1Hospital das Clínicas HC - UFPE, Recife, Brazil; 2IMIP, 
Recife, Brazil.
Background: MBL2 polymorphisms may be associated with the activation of lectin 
pathway by IgG4 subclass antibodies in membranous nephropathy (MN). Studies involving 
systemic lupus erythematosus (SLE) have conflicting results, with some data sugesting 
the association between MBL2 polymorphisms with more severe forms of disease. 
We investigated whether the prognosis among patients with MN differ according to the 
presence or absence of these polymorphisms.
Methods: Polymorphisms in the exon 1 of the MBL2 gene (codons 52, 54 and 57) 
were evaluated in 59 patients with the two main etiologies of MN in our setting: idiopathic 
(35 patients) and secondary to SLE (24 patients). We divided the patients into two groups 
according to the presence or absence of the polymorphisms and analyzed proteinuria as a 
response parameter after 6 months, 1 and 5 years.
Results: The 59 patients were analysed as their baseline clinical characteristics 
(Table 1). In both genders, as in both MN etiologies, the presence of polymorphism was 
predominant. There was no distinction between groups with and without polymorphism 
with respect to age, initial LDL, serum creatinine (SCr), proteinuria, serum Albumin (SAlb) 
and blood pressure. After 6 months, 1 year and 5 years, there was no difference in relation 
to SCr and SAlb among the groups evaluated. No differences in mean and median levels 
of proteinuria were observed when we compared the patientes with and without MBL2 
polymorphisms after 6 months (4.1 x 3.8, p = 0.838), 1 year (2.1 x 1.7, p = 0.876) and 5 
years (0.2 x 1.0, p = 0.110),.
Conclusions: Our data did not support the hypothesis that MBL2 polymorphisms may be 
associated with a poor prognosis in patients with MN. Because of the small number of subjects 
studied, a larger study of MN patients would seem necessary to confirm these findings.
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Elevated Level of Urinary Angiotensinogen Is Correlated with Severity of 
Idiopathic Membranous Nephropathy (IMN)
Ziyong Tang, Yue Wang, Danxia Zheng. Department of Nephrology, Peking 
University Third Hospital, Beijing, China.
Background: The severity of IMN is a main concern for making a decision whether a 
patient should be treated with immunosuppressive agents as the treatment will predispose 
the patient to opportunistic infections. Urinary angiotensinogen (UAGT) has been shown 
highly correlated with the severity of chronic kidney disease and its relationship with 
severity of IMN was explored.
Methods: Data were collected from 48 biopsy-proven IMN, 46 minimal change 
disease (MCD), and 44 healthy controls. Urine samples were collected before the use of 
RAS inhibitors. UAGT levels were determined with a method of ELISA.
Results: UAGT levels were not different between IMN and MCD patients, but both 
of them were higher than those of normal subjects. In IMN patients, UAGT was correlated 
with serum albumin, estimated glomerular filtration rate and proteinuria. These associations 
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were not found in MCD patients. Multivariate regression showed that only proteinuria 
independently determinate the value of UAGT (β=0.649, p<0.001) in IMN patients. ROC 
curve analysis showed that proteinuria >7.8g/d was associated with higher UAGT level 
(sensitivity=55.00% specificity=89.29%, p=0.001).
Conclusions: UAGT level is one of severity markers of IMN and may serve as a 
cofactor in making a treatment decision.
Funding: Government Support - Non-U.S.
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Clinical Implications of Pathological Features of Primary Membranous 
Nephropathy
Xiao-dan Zhang,1 Zhao Cui,2 Minghui Zhao.3 1Renal Division, Peking University 
First Hospital, Beijing, China; 2Peking University First Hospital, Beijing, 
China; 3Peking University First Hospital, Peking University, Beijing, China.
Background: The clinical outcome varies considerably in primary membranous 
nephropathy (pMN). It was controversial whether the histopathological features of pMN 
could predict treatment response and kidney outcome.
Methods: A retrospective study was conducted in 371 patients with biopsy-proven 
pMN. Pathological parameters included immunofluorescence staining, membranous 
Churg’s stages, sclerosis, crescent, focal segmental sclerosis lesion, chronic and acute 
tubulointerstitial injury.
Results: We found that patients with higher intensity of C3 staining, advanced 
membranous stage, and more severe chronic tubulointerstitial injury presented with higher 
positivity rate of anti-PLA2R antibodies, higher levels of urinary protein excretion and 
serum creatinine, and lower level of serum albumin. Univariate Cox regression analysis 
showed that severe (grade=3) chronic tubulointerstitial injury was a risk factor to the kidney 
outcome of ESKD and over 50% reduction of eGFR. Multivariate analysis demonstrated it 
as an independent risk factor to ESKD.
Conclusions: We found the prognostic role of chronic tubulointerstitial injury to the 
kidney outcome of pMN. This study highlighted the value of kidney biopsy under the 
widespread usage of anti-PLA2R antibodies for diagnosis and prognosis.
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Treatment Patterns Among Adults with Membranous Nephropathy in the 
Cure Glomerulopathy Network (CureGN)
Louis-Philippe Laurin,1 Andrew S. Bomback,2 Michelle A. Hladunewich,3 
Jonathan P. Troost,4 Brenda W. Gillespie,4 Amy Kogon,8 Debbie S. Gipson,5 
Kevin C. Abbott,6 Michelle M. O’Shaughnessy.7 CureGN Membranous Epi 
Treated vs. Not Treated Work Group 1Hopital Maisonneuve-Rosemont, 
Montreal, QC, Canada; 2Columbia University, New York, NY; 3University of 
Toronto, Toronto, ON, Canada; 4University of Michigan, Ann Arbor, MI; 
5University of Michigan Mott Children’s Hospital, Ann Arbor, MI; 6The National 
Institutes of Health, NIDDK, Bethesda, MD; 7Stanford University, Palo Alto, 
CA; 8Children’s Hospital of Philadelphia, Wynnewood, PA.
Background: Patients with membranous nephropathy (MN) and risk factors for 
progressive disease may benefit from immunosuppressive therapy (IST). Most guidelines 
and expert opinion recommend a 6-12 mo observation period before initiating IST. Current 
practice patterns regarding choice and timing of IST in MN remain largely unknown.
Methods: CureGN is an ongoing 70-center prospective cohort study of children and 
adults with biopsy-proven MCD, FSGS, MN, or IgAN/IgAV. Biopsies were performed 
between 2010 and 2017. Descriptive statistics were used to assess choice and timing of 
IST after kidney biopsy. Categorical data are presented as frequencies and % and compared 
using χ2 tests; continuous data as median(IQR) and compared using the Kruskal-Wallis test.
Results: As of May 2018, 303 adult MN patients were enrolled in CureGN. Of those, 
274 were considered unexposed to IST prior to biopsy, including 267 who received no prior 
IST and 7 who received steroids alone for a maximum of 6 wks before biopsy. Characteristics 
at biopsy: age 53 yrs (42-63), 36% Female, 71% White, UP:C 5.7 g/g (3.6-8.5), 
serum albumin 2.7 g/dl (2.1-3.6), eGFR 81 ml/min/1.73m2 (57-103). 212/274 (77%) 
received IST (Table 1) for a median follow-up time of 31 mo (16-50), with 74% of IST 
treatments started in the first 6 mo after biopsy. 140/274 (51%) received RAAS blockers by 
6 mo. Patients treated with IST (vs. untreated) within the first 6 mo after biopsy had higher 
UP:C (7.1 vs. 4.0 g/g; p<0.01), lower serum albumin (2.4 vs. 3.3 g/dl; p<0.01) and lower 
eGFR (77 vs. 89; p=0.03) at time of biopsy.
Conclusions: Seventy four percent of treated patients with biopsy proven MN were 
started on IST within the first 6 mo after kidney biopsy. IST choices were heterogeneous and 
many patients were treated with steroids alone. Reasons for poor alignment with KDIGO 
guidelines regarding timing and choice of IST in MN require further exploration.
Funding: NIDDK Support
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Immunosuppressive Therapy for Children with Membranous  
Nephropathy: A Report from the Cure Glomerulopathy Network 
(CureGN)
Louis-Philippe Laurin,1,8 Isa Ashoor,10 Tarak Srivastava,2 Amira Al-
Uzri,9 Jonathan P. Troost,3 Michelle N. Rheault,4 Raed Bou Matar,5 Keisha L. 
Gibson,6 David T. Selewski,3 Debbie S. Gipson,7 Chia- Shi Wang.11 CureGN 
Membranous Epi Treated vs. Not Treated Work Group 1Hopital 
Maisonneuve-Rosemont, Montreal, QC, Canada; 2Childrens’s Mercy 
Hospital, Kansas City, MO; 3University of Michigan, Ann Arbor, MI; 
4University of Minnesota, Minneapolis, MN; 
5Cleveland Clinic, Cleveland,
OH; 6University of North Carolina Kidney Center, Chapel Hill, NC; 
7University of Michigan Mott Children’s Hospital, Ann Arbor, MI; 8University 
of Montreal, Montreal, QC, Canada; 9Oregon Health & Science University, 
Portland, OR; 10Children’s Hospital of New Orleans, New Orleans, LA; 
11Emory University School of Medicine, Atlanta, GA.
Background: Membranous nephropathy (MN) is a rare cause of nephrotic syndrome 
in children. Current practice patterns regarding choice and timing of immunosuppressive 
therapy (IST) remain largely undescribed.
Methods: CureGN is an ongoing multi-center prospective, observational cohort of 
children and adults with biopsy-proven MCD, FSGS, MN, or IgAN/IgAV. Biopsies were 
performed between 2010 and 2017. Descriptive statistics were used to assess choice and 
timing of IST after incident kidney biopsy. Categorical data are presented as frequencies 
and percentages and compared using chi-square tests; continuous data as median(IQR) and 
compared using the Kruskal-Wallis test.
Results: Forty-one children with MN were enrolled. Thirty participants without pre-
biopsy IST exposure (N=29) or exposed to steroids only within 6 weeks before biopsy 
(N=1) were treated as IST naïve and included in the analysis. Median age at time of 
biopsy was 14 yrs (12-16). 57% were female. Median urine protein to creatinine ratio 
(UP:C) was 3.8 (1.3-7.4), serum albumin was 2.2 g/dl (1.7-3.1), and estimated GFR was  
107 mL/min/1.73m2 (84-137). 21/30 (70%) of patient received IST (Table 1), with 81% 
of IST treatments started in the first 6 months after biopsy. 15/30 (50%) were treated with 
RAAS blockers by 6 months. Treated patients with IST (vs. untreated) by 6 months after 
biopsy had similar UP:C (3.8 vs. 3.4 g/g; p=0.60), serum albumin (2.4 vs. 2.1 g/dl; p=0.81) 
and eGFR (119 vs. 100; p=0.56) at time of biopsy.
Conclusions: Corticosteroids and calcineurin inhibitors were the main agents used in 
children with biopsy-proven MN. Therapies were started early within the first 6 months 
after biopsy in 81% of patients, deviating from current KDIGO practice guidelines.
Funding: NIDDK Support
Table 1. First IST used in pediatric-onset MN patients with no IST treatment before biopsy 
(n=30)
Table 1. First IST among MN adult patients with no previous exposure to IST (N=274)
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Response to Therapy Is Poor in Anti-PLA2R Positive Idiopathic 
Membranous Nephropathy Patients as Compared to Anti-PLA2R 
Negative Patients
Narayan Prasad, Akhilesh Jaiswal, Harshit Singh, Vikas Agarwal. Sanjay 
Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Background: Idiopathic membranous nephropathy (IMN) is associated with Anti-
PLA2R antibody expression on podocytes. We aimed to decipher the efficacy of tacrolimus 
(Tac) plus prednisolone, changes in anti-PLA2R level and differences in response to therapy 
in anti-PLA2R+ve and -ve patients.
Methods: In the study, total 101 (77 IMN and 24 seconday MN) patients were 
included. All secondary MN (15 diabetic, 7 lupus, 1 HBV and 1 collagen disease) were 
excluded. All IMN(n=77) patients were treated with combination of prednisolone (1mg/kg 
alternate day) and Tac 0.1mg/kg/day (target trough 6-10 ng/ml first 6 months(M) and 
4-6 ng/ml for next 3M and then tapering by 1/3 each months to stop at 12M. Anti-PLA2R 
level was estimated at baseline, 3M, 6M,12M and end of follow-up (13 to 55, median 36
months). Total remission, complete(CR) and partial (PR), relapse and side-effects were
recorded and compared between Anti-PLA2R +ve and -ve groups.
Results: Of the 77 patients, at 3M 60(77.92%) CR-37, PR-23 ; 6M 61(79.22%) CR-
53, PR-8; at12M 53(68.86%) CR-47, PR-6 achieved remission. Eight (10.38%) relapsed 
during tapering and 16(20.77%) showed no response at 12M. At the end, 68.51% remained 
in remission and 31.48% relapsed. Out of 77 patients, 51 (66.3%) were anti-PLA2R +ve. 
Remission rate was lower in anti-PLA2R+ve than -ve (36/51 vs 24/26; p=0.03) at 3M; 
(36/51 vs 25/26; p=0.009) at 6M; and (31/51 vs 22/26; p=0.03) at 12M. PLA2R level was 
decreased by 60.38% and 77.56% at 3M and 6M respectively. Relapse rate was higher 
in anti-PlA2R +ve than−ve patients(P=0.02). There was significant correlations between 
PLA2R level and 24h proteinuria at baseline (r=0.72), 3M(r=0.81) and 6M(r=0.76). During 
therapy 4 patients develop new diabetes, 4 cutaneous tinea, 1 osteonecrosis of femur head, 1 
carpal tunnel syndrome, 3 tremor and 10 upper GI symptoms. eGFR decreased significantly 
(p=0.003) by 26.5% at end, which normalized after stopping Tac. Five non-responsive 
patients had doubled of serum creatinine and progressively deteriorated eGFR. To note, 
4 females had succesful pregnancy and delivery, of them one had relapse after delivery.
Conclusions: Anti-PLA2R+ve IMN patients had poor response and more relapses as 
compared to PLA2R-ve patients. Remission with Tac and pred therapy is comparable to 
historical Ponticelli regimen with lesser side effects.
Funding: Government Support - Non-U.S.
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Treatment of Moderate and High-Risk Idiopathic Membranous Nephrop-
athy with Intravenous Cyclophosphamide Pulses and Oral Steroid
Angel C. Ortiz Bello, Luis E. Álvarez Rangel, Ida jayna I. Ruiz serrano. Instituto 
Mexicano del Seguro Social, Mexico City, Mexico.
Background: Idiopathic membranous nephropathy (IMN) is one of the most frequent 
causes of nephrotic syndrome in adults with risk of progression to end-stage renal disease. 
Proteinuria portend worse renal outcomes and is a risk factor for cardiovascular morbidity. 
The standard treatment includes oral cyclophosphamide and prednisone. Little is known 
about the efficacy of the treatment with pulse intravenous cyclophosphamide and oral 
steroid in moderate and high-risk patients and the factors associated with non-response.
Methods: A retrospective cohort study was performed on the data of patients with 
idiopathic membranous nephropathy. We included patients with biopsy-proven IMN treated 
with pulses of intravenous cyclophosphamide (750 mg/m2) and oral steroid between June 
2012 to December 2017. Continuous variables were expressed as mean ± SD. Categorical 
variables were expressed as frequencies or proportions. Comparisons of continuous 
and categorical variables were performed using Student’s t-test and the Chi.square test, 
respectively. A p value of <0.05 was considered statistically significant. The odds ratios 
(OR) with their corresponding 95% confidence intervals (CI) were estimated.
Results: Sixty-one biopsy-proven IMN patients were included. The patients were 
predominantly male (72.1%), with mean age of the sample of 47.75 ± 12.49 years. The 
average eGFR was 88.85 ± 29.92 ml/min/1.73 m2 and mean baseline proteinuria was 
12.13 ± 5.4 g/day. During the median follow-up duration of 26.52 ± 21.14 months, 
overall remission was achieved in 82% (50 cases), partial remission in 45.9% (28 cases) 
and complete remission in 36.1% (22 cases). The treatment failure was observed in 18% 
(11 cases). Adverse events related to treatment were reported in 18%. Peak proteinuria 
greater than 8 g/day (OR:1429, 95% CI:1192-1713) and non-reduction of proteinuria 
greater than 50% at month 3 (OR:3333, 95% CI:2183-5.090) were associated with the 
treatment failure.
Conclusions: Pulse intravenous cyclophosphamide and oral steroid is a therapeutic 
alternative in the treatment of idiopathic membranous nephropathy with a low incidence 
of adverse events. Peak proteinuria high-risk greater than 8 g/day and non-reduction of 
proteinuria greater than 50% at month 3 of treatment are factors associated with treatment 
failure.
Funding: Government Support - Non-U.S.
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Rituximab in Primary Membranous Nephropathy Systematic Review and 
Meta Analysis
Laila Alharbi, Michael Walsh. Mike Walsh McMaster University, Hamilton, 
ON, Canada.
Background: Primary membranous nephropathy is a kidney limited, autoimmune 
disease caused by circulating antibodies directed against phospholipase A2 receptor 
(PLA2R), a cell surface trans membrane receptor expressed on the surface of podocytes of 
the renal glomeruli. As our understanding of PMN has evolved and B cell played a major 
role in PMN, there has been paradigm shift in the treatment of PMN and Rituximab has 
emerged as a potential treatment. Objectives: to assess the effects of Rituximab in primary 
membranous nephropathy
Methods: Search methods: we searched the following databases up to January 26, 
2018: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Conferences 
organized by the following organizations: The American Society of Nephrology, Canadian 
Society of Nephrology, and International Society of Nephrology. We also search trial 
registries. Selection criteria: We included randomized controlled trials and non-randomized 
studies with a minimum follow-up duration of 12 month that have investigated the effect of 
Rituximab compared to standard of care in patients diagnosed with PMN. We assessed the 
following outcomes: proteinuria remission, AntiPLAR2 depletion and adverse events. Data 
collection and analysis: two reviewers independently extracted data from the included 
studies: The treatment effect (dichotomous variable) was assessed using risk ratio with 
95% confidence intervals (CIs). We performed meta-analyses for 6 month and 12 month 
follow-ups.
Results: Main results: two randomized trials (202 participants) were included in the 
final analysis. At six month, RR 1.01(95% CI0.42 to 2.42) of proteinuria remission with 
rituximab compared to standard of care in PMN, and at twelve months RR 1.40, (95% CI 
0.89 to 2.29). Additional data from three cohort studies showed RR 1.11(95% CI 0.70 to 
1.76) of proteinuria remission with rituximab compared to standard of care in PMN at 12 
months
Conclusions: conclusions: there is insufficient evidence to draw conclusions that 
rituximab is more effective with less adverse events than standard of care in primary 
membranous nephropathy. There is a need for further research in this area with larger 
sample size and longer term follow up.
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Five-Year Outcomes of Idiopathic Membranous Nephropathy and 
Nephrotic Syndrome After a Combination Treatment with Mizoribine and 
Low-Dose Prednisone
Yoshihiro Matsumoto,1 Yasushi Shimada,1 Youichi Nojima,1 Koichiro Iguchi,1 
Yasuo Mori.2 1Shizuoka City Hospital, Shizuoka, Japan; 2Shibukawa Clinic, 
Shizuoka, Japan.
Background: Patients with idiopathic membranous nephropathy (IMN) showing 
persistent high-grade proteinuria have the highest risk for developing end-stage renal failure. 
We previously reported the favorable short-term outcomes of treatment with mizoribine 
followed by low-dose prednisone. The purpose of the present study was to assess the long-
term efficiency of this combined treatment in a larger number of patients.
Methods: Between 2004 and 2014, 22 patients with IMN and nephrotic-range 
proteinuria were administered the combined treatment. Mizoribine was initiated at a 
dose of 150 mg/day; after 1–3 months, 20 mg/day prednisone was added. The dosage of 
prednisone or mizoribine was tapered according to the urinary protein-to-creatinine ratio 
(P/C). For some of the patients who experienced side effects, relapse, or no response (NR), 
other immunosuppressive regimens were substituted. We evaluated patient outcomes for up 
to 5 years after initiating the combination therapy. The statuses of patients who were not 
followed up after the achievement of complete remission (CR), defined as a decrease in 
urinary P/C to <0.5, were assessed through a follow-up interview
Results: Before treatment, patient urinary P/C ranged from 3.7 to 15.9 g/g. At 1, 
2, and 3 years after combination therapy, 68%, 77%, and 77% of patients attained CR, 
respectively. The 5-year actual rates for CR, partial remission, NR, two-fold Cr increase, 
and death were 82%, 14%, 5%, 5%, and 0%, respectively. Sixteen patients (73%) stopped 
treatment after 9–53 months of combination therapy. In patients who achieved at least 
one CR, the 3-year actual risk of relapse was 11%. Side effects, including fracture, were 
observed in four patients.
Conclusions: The addition of prednisone after mizoribine monotherapy resulted in fast 
and safe remission in a high proportion of patients with IMN and nephrotic syndrome. 
The risks associated with immunotherapy might be decreased by the initial prescription of 
mizoribine alone, which may act as a base for establishing therapy, followed by low-dose 
prednisone treatment.
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Mycophenolate Mofetil and Tacrolimus versus Tacrolimus Alone for the 
Treatment of Idiopathic Membranous Glomerulonephritis: A Randomised 
Controlled Trial
Aikaterini K. Nikolopoulou,1 Marie B. Condon,3 H. Terence Cook,1 
Neill D. Duncan,2 Jack W. Galliford,2 Jeremy B. Levy,2 Liz Lightstone,1 
Charles D. Pusey,1 Candice A. Roufosse,2 Tom Cairns,2 Megan Griffith.2 
1Imperial College London, London, United Kingdom; 2Imperial College 
Healthcare NHS Trust, London, United Kingdom; 3St. Helier Hospital, Surrey, 
United Kingdom.
Background: Membranous nephropathy (MN) is a common cause of nephrotic 
syndrome in adults. Tacrolimus (TAC) is effective in inducing remission of proteinuria; 
however relapses after TAC withdrawal are common. We aimed to investigate if the 
addition of mycophenolate mofetil (MMF) to TAC reduces the relapse rate of nephrotic 
syndrome in patients with MN after treatment withdrawal.
Methods: A single centre randomised controlled trial was undertaken from 2008 to 
2014; patients with biopsy proven idiopathic MN were recruited and randomly assigned to 
receive MMF and TAC or TAC alone. Treatment was for 1 year initially; once patients were 
in remission for 12 months the MMF was stopped and TAC tapered over 6 months in both 
groups. The primary outcome was the efficacy of MMF in preventing relapse of nephrotic 
syndrome on withdrawal of TAC.
Results: We randomly assigned 40 patients, 20 of whom received MMF and TAC and 
20 received TAC alone. Both groups had similar baseline characteristics. Retrospective 
anti phospholipase A2 receptor (PLA2R) biopsy staining showed similar PLA2R 
positivity in both groups. Follow up was until primary endpoint or for a minimum of 3 
years. The time to relapse after treatment withdrawal was similar in the two groups. 40% 
of patients (n=8) in the TAC/MMF group relapsed after treatment withdrawal compared 
to 35% (n=7) in the TAC group; there was no statistically significant difference in 
the relapse rate between the two groups (p=0.77). Both treatments were equivalent in 
achieving remission; 85% of patients in the TAC/MMF group and 75% in the TAC 
group reached complete remission (p=0.7). There was a trend to earlier remission in the 
TAC/MMF group; median time to remission 40 weeks compared to 54 weeks with TAC 
alone, but this was not statistically significant (p=0.46). Both treatments were well tolerated 
with similar adverse events.
Conclusions: The addition of MMF to TAC did not protect from relapse of nephrotic 
syndrome due to idiopathic MN compared to treatment with TAC alone; both groups 
showed similar remission rates and adverse events. The treatment was well tolerated 
and further studies are needed to investigate if high risk subgroups may benefit from 
combination therapy.
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Symptoms and Health-Related Quality of Life (HRQOL) in Primary 
Membranous Nephropathy
Shannon L. Murphy,1 Jill Powell,4 Adeline Dorough,4 Amy K. Mottl,1 
Bryce B. Reeve,3 Patrick H. Nachman.2 1University of North Carolina at Chapel 
Hill, Chapel Hill, NC; 2University of Minnesota, Minneapolis, MN; 3Duke 
University, Durham, NC; 4UNC Kidney Center, Chapel Hill, NC.
Background: Primary membranous nephropathy (MN) can affect patients’ HRQOL 
in profound and differing ways. Better understanding patient perspectives on disease 
experience may identify important outcomes to consider in clinical trials and facilitate 
more patient-centered care. To our knowledge, symptoms and HRQOL have not been richly 
characterized among individuals with MN. We sought to address this gap by exploring 
patient experiences with MN with a focus on symptoms and HRQOL.
Methods: We conducted 45-60 minute semi-structured interviews with 13 adults 
with primary MN. Inclusion criteria included active disease in the last 5 years and non-
dialysis dependence. We used purposive sampling to achieve heterogeneity on relevant 
demographic and clinical characteristics. Interviews were recorded and professionally 
transcribed. Transcripts were coded independently by two team members and analyzed for 
concepts and themes.
Results: Participants ranged 40-68 years old, with 46% male and 85% Caucasian. Each 
had lived with MN for 1-14 years (5.3 ± 4.4), had peak proteinuria ranging from subnephrotic 
to 23 g, and serum albumin ranging from normal to 1.5 g/dL. Treatment regimens included 
steroids (N=6), cyclophosphamide (N=6), calcineurin inhibitors (N=7), rituximab 
(N=9), and conservative management (N=2). The most common symptoms were 1) 
lower extremity edema (92%), 2) fatigue (77%), 3) pain or discomfort due to swelling 
(62%), 4) weight gain (46%), and 5) sleep changes (38%). Other reported symptoms 
included cramping, itching, and irritability. We identified 5 major themes: 1) experiencing 
sacrifice and loss, 2) feeling powerless in the face of disease, 3) navigating uncertainty, 4) 
living with constant worry, and 5) developing strategies and evolving perspective to cope. 
Overall, participants frequently struggled with the substantial physical, emotional, social, 
and/or financial effects of MN; yet, with time, many developed adaptive coping skills and 
often changed their outlook on life for the better.
Conclusions: These data shed light on the substantial burdens born by individuals with 
primary MN. Development of a MN-specific patient-reported outcomes instrument that 
captures symptoms and HRQOL is an important next step to facilitate focus on patient-
centered outcomes in research and clinical care.
Funding: Other NIH Support - T32 training grant
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Prevalence of Renal Dysfunction Among Rheumatoid Arthritis Patients in 
Jordan
Ashraf O. Oweis,1 Sameeha A. Alshelleh.2 1Jordan University Of Science and 
Technology, Amman, Jordan; 2Medicine, University of Jordan, Amman, Jordan.
Background: Rheumatoid Arthritis (RA) is an autoimmune disorder characterized by 
inflammation of multiple synovial joints, it can affect other organs such as kidneys. RA 
can affect the kidneys by direct effect of the disease itself, or secondary to the drugs used 
to treat the disease; both biological agents as well as simple analgesics like non-steroidal 
anti-inflammatory drugs(NSAIDs). Clinico-pathological correlations showed that the most 
common pathological findings on renal biopsy were secondary amyloidosis, membranous 
nephropathy, less commonly RA can cause rapidly progressive glomerulonephritis
Methods: Using our electronic records, we retrospectively evaluated RA patients in 
our tertiary referral hospital between 2010 – 2016 with at least one year follow up, renal 
dysfunction was defined as the presence of hematuria and/or at least +1 proteinuria on 
dipstick urine analysis on at least 2 occasions, and/or abnormal serum creatinine values. 
Glomerular filtration rate was calculated using CKD-EPI equation
Results: We evaluated 233 patients with a diagnosis of RA, mean age was 54.5 years, 
females were 84.9% vs. 15.1% for males, for baseline characteristics see Table 1. 44 
patients (18.8%) presented with microscopic hematuria, 16 (6.9%) with proteinuria, only 5 
(2.1%) presented with both microscopic hematuria and proteinuria. At presentation 48.2% 
were on NSAIDs, 16 (6.9%) patients treated with methotrexate, 52(22.3%) were treated 
with anti-TNF, 26 (11.1%) continued on NSAID’s. At last follow up: 32 (13.7%)patients 
had microscopic hematuria, 22 (9.4%) with proteinuria, and 7 (3%) with both microscopic 
hematuria and proteinuria. eGFR at last follow up was 93.2 ml/mi (±22.3) compared to 
97.1ml/min at presentation only 2 patients underwent renal biopsy, both had concomitant 
IgA nephropathy in their biopsies.
Conclusions: Renal dysfunction is not uncommon in RA patients, though more careful 
evaluation and attention to urine analysis and microscopy for renal dysfunction is required
Baseline characteristics
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Small Kidney Size Relative to Body Mass Is a Risk Factor for Renal 
Function Deterioration in IgA Nephropathy Patients
Yooju Nam,1 Seon yeong Lee,1 Joohwan Kim,1 Ki Heon Nam,1 Jung Tak Park,2 
Seung Hyeok Han,1 Tae-Hyun Yoo.1 1Yonsei University College of Medicine, 
SEOUL, Republic of Korea; 2Yonsei University Health System, Seodaemun-Gu, 
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Background: IgA nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide. However, identifying IgAN patients at higher risks for renal function decline is 
still a challenge. Recent investigations have proposed kidney size to be a risk factor for 
renal function decline in kidney transplantation recipients. Therefore, this study aimed to 
investigate whether kidney size has an effect on renal function deterioration rate in patients 
with IgAN.
Methods: Retrospective analysis was preformed from electronic medical records of 
516 biopsy-proven IgAN patients. Kidney length was considered as the longest longitudinal 
diameter from sonographic measurements obtained at the time of biopsy. The average length 
of both kidneys was divided by body mass index for each individual to make adjustments 
for subject size (BMI-adjusted kidney size). Renal outcome was defined as a composite of 
a ≥ 50% decline in estimated glomerular filtration rate (eGFR) from baseline or the onset 
of end-stage renal disease.
Results: The mean age of the patients was 40.4 ± 12.1 years and 211 patients 
(40.9%) were male. The mean eGFR was 79.6 ± 28.3 mL/min/1.73 m2 and the average 
kidney length was 102.8 ± 8.8 mm at baseline. The median follow-up duration was 51 
months. When the patients were grouped into tertiles based on BMI-adjusted kidney 
size, renal outcome occurred in 30 (17.0%), 25 (14.0%), and 12 (7.4%) patients in the 
1st, 2nd, and 3rd tertile groups, respectively. The amount of proteinuria was lowest and 
eGFR was highest in the 3rd tertile of BMI-adjusted kidney size group. Multivariate Cox 
proportional analysis revealed that the risk of renal outcome significantly lower in the 3rd 
tertile group as compared to the 1st tertile group (hazard ratio [HR], 0.44; 95% confidence 
interval [CI], 0.21-0.93; P = 0.031). Additionally, the risk of renal outcome significantly 
decreased as the BMI-adjusted kidney size increased (HR, 0.55; 95% CI, 0.36-0.86; 
P = 0.008). These results remained robust even after adjustments were made for confounding 
factors including baseline eGFR and proteinuria.
Conclusions: Small kidney size could be a risk factor for renal function decline in IgA 
nephropathy patients. Simple sonographic kidney size measurements may help stratifying 
progression risk in patients with IgA nephropathy.
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External Validation of the Kidney Failure Risk Equation in Biopsy Proven 
IgA Nephropathy
Rupert Major,1,2 Jorge Jesus Silva,1,4 James F. Medcalf,1 Nigel J. Brunskill,1,3 
Jonathan Barratt.1,3 The Mayer Leicester IgA Nephropathy Group 1University 
Hospitals of Leicester, Leicester, United Kingdom; 2Health Sciences, University 
of Leicester, Leicester, United Kingdom; 3Infection, Immunity and Inflammation, 
University of Leicester, Leicester, United Kingdom; 4Facultad de Medicina, 
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Background: The Kidney Failure Risk Equation (KFRE) has been externally validated 
in over 30 multi-national multiple aetiology chronic kidney disease (CKD) cohorts. It 
has high discrimination and good calibration for endstage renal disease (ESRD) events. 
However, KFRE has not been validated in IgA nephropathy (IgAN). Risk factors for IgAN 
progression to ESRD may be different to those used in KFRE. Therefore, our aim was to 
perform an independent, external validation of the 2 and 5-year 4-variable KFRE in adults 
with biopsy proven IgAN.
Methods: Using electronic records for the Leicester Renal Network, UK, we assessed 
model performance of the 2 and 5-year 4-variable KFRE. The C-statistic was used to 
assess discrimination. Calibration of the KFRE was assessed using the linear predictor’s 
calibration slope and observed versus predicted event rates plots with risk categories of 
0 to <5%, ≥5% to <25% and ≥25%.
Results: The cohort consisted of 353 individuals with biopsy proven IgAN, of whom 
166 had CKD stages 3-5 at their biopsy date. In CKD stages 3-5, mean age was 49.2 
(SD 14.4) years, 30.1% were female, mean EPI eGFR was 37.6 l/min/1.73m2 (SD 13.5) and 
median ACR was 52.2 (IQR 2.2 to 124.6) mg/mmol. 59 (35.5%) ESRD events occurred 
over median follow-up of 3.6 (IQR 1.5 to 7.7) years. For eGFR and ACR nearest to the 
date of biopsy, discrimination by KFRE was good (Harrell’s C-statistic 0.71, 95% CI 
0.62 to 0.81), although possibly inferior to the published model (Harrell’s C-statistic 0.90, 
95% CI 0.87 to 0.93). The linear predictor for calibration was 0.29 (95% CI 0.14 to 0.44). 
Calibration plots suggested that risk was over estimated at 2 and 5 years for low (<5%) 
KFRE predicted risk groups. For higher risk groups, the model was well calibrated. Results 
were similar when earliest available, instead of biopsy, eGFR and ACR were used in KFRE.
Conclusions: In an independent, external validation of KFRE in biopsy proven IgAN, 
discrimination was good but calibration was poor in lower predicted risk individuals. For 
patients with biopsy proven IgAN, the KFRE may need model adjustment, particularly for 
lower predicted risk individuals. Adjustments may be required to existing variables and/or 
inclusion of other variables, such as Oxford Classification histology findings, before KFRE 
can be used for prognostic purposes in IgAN.
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Combinatory Approach of Oxford Classification Allows a Tailored 
Prediction of Renal Death in IgA Nephropathy
Chazot Robin,2 Perrine Jullien,2 Blandine Laurent,2 Miriana Dinic,2 
Damien Thibaudin,2 Eric Alamartine,1 Christopher R. Mariat,2 Nicolas Maillard.2 
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Background: The prognostic of IgA nephropathy (IgAN) is highly heterogeneous, 
ranging from isolated hematuria to End-Stage Renal Disease (ESRD). The Oxford 
classification has been developed and recently updated to stratify patients according to the 
risk of progression considering histological elementary lesions. From a clinical standpoint, 
each patient has a proper combination of Oxford classification lesions, but the knowledge 
about the distribution and the prognostic impact of such combinations is lacking. Our 
study describes the distribution of those combinations in our population and evaluate their 
particular association with renal death.
Methods: This retrospective, monocentric cohort study included all Caucasian patients 
with biopsy-proven IgAN since 1979. Renal biopsies were scored by one pathologist 
blinded to the clinical data and according to the Oxford classification. We analyzed the 
distribution and grouped the patients according to the combination of histological MESTC 
score components to assess their risk to progress to ESRD (cox model, non adjusted and 
adjusted on proteinuria, hypertension, eGFR).
Results: A total of 695 patients were retained for analysis (mean age and proteinuria 
respectively 38.6 years and 1.04 g/day). The distribution of combinations was 
heterogenous: Most frequent lesions were M0S0E0T0C0, S1 alone, combined S1 and T1 
alone, as shown in Figure 1. M0S0E0T0 was set as the reference (Hazard Ratio (HR) for 
progression =1). The higher and significant unadjusted risk for progression was found for 
the association S1E1T1 (HR 38.14 [14.9;97.7]), S1T1 (HR 24.87 [12 ; 51.7]), S1E1C1 (HR 
8.02[3.38;19.01]), M1S1E1 (HR 7.69[2.36;25.0]), S1E1 (HR 3.88 [1.22;12.39]) as shown 
in Figure 2. Isolated S1 (HR 1.35 [0.52;3.5]), isolated M1 (HR 1,43 [0,18;11,3]), were not 
significantly associated with renal death contrary to isolated T1 (HR 14.7 [4.39;43.5]) and 
isolated E1 (HR 5.34 [1.46;19.5]).
Conclusions: This combinatory approach of Oxford classification lesions allows to 
identifying the unbalanced histological combinations with better homogeneity in renal 
outcomes prediction. Isolated M1 and S1 lesions did not seem to associate with ESRD.
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Genome-Wide Study Investigating Potential Loci Associated with Risk of 
ESRD in IgA Nephropathy Patients
Sehoon Park,1 Seung Hee Yang,2 Krzysztof Kiryluk,3 Dong Ki Kim,1 Yon 
Su Kim,4 Hajeong Lee.4 1Seoul National University Hospital, Jongno-gu, 
SEOUL, Republic of Korea; 2Kidney Research Institute, Seoul National 
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Background: End-stage renal disease (ESRD) is one of the most critical outcomes 
of IgA nephropathy (IgAN). Although genetic factor might have some effect on this 
outcome within IgAN patients, a genome-wise study regarding ESRD outcome was scarce, 
particularly in Korea which is known to have high incidence and worse prognosis of IgAN.
Methods: We performed genome-wide association and survival analyses including 
native kidney IgAN patients in Korea. Retrospectively collected 695 native IgAN patients 
were screened for inclusion. Genome-wide associations were calculated with logistic 
regression and cox regression analyses.
Results: After quality control, 691 patients and 603,128 single nucleotide 
polymorphisms (SNPs) were included in the analysis. Although an association analysis 
dealing ESRD as a binomial outcome did not show any significantly associated SNPs after 
Bonferroni correction, survival analysis including renal survival from birth revealed that 
following SNPs were significantly associated with risk of ESRD; rs655250, rs17574942, 
rs7259423, and rs5989654. When we applied less stringent threshold value, there was 
suspicious association of clusters of SNPs on chromosome 11, including rs655250 which 
showed the most significant p value, on gene coding NCAM1 (CD56). When time from 
IgAN diagnosis to ESRD was included as the survival duration, adjusted for age and sex 
at the time of IgAn diagnosis, following SNPs showed significant association with ESRD 
outcome; JHU_1.247982701, rs13095453, JHU_7.26585574, exm813062, rs2151745.
Conclusions: Potential gene loci identified in our analysis may be associated with risk 
of renal failure in IgAN patients. Further validation and expansion of our results may reveal 
association between genetic factors and IgAN prognosis.
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Association of the CMIP Gene Single Nucleotide Polymorphism with 
Serum Lipids Parameter of IgA Nephropathy
Ling Pan, Yunhua Liao, Xiaohua Li, Manqiu Mo. The First Affiliated Hospital 
of Guangxi Medical University, Nanning, China.
Background: The effect of dyslipidemia on cardiovascular complications and renal 
progression in IgAN has been confirmed. The CMIP gene was recently found to be closely 
related to TC, LDL-C and HDL-C levels. The relationship between dyslipidemia of IgAN 
and CMIP gene polymorphism has not been reported so far.
Methods: Study subjects were selected in the First Affiliated Hospital of Guangxi 
Medical University from August 2010 to December 2017. TC, TG, HDL-C, LDL-C, ApoA1 
and ApoB levels were tested. Blood samples were extracted for DNA, PCR amplification, 
electrophoresis imaging. PCR products were sent to measure genotypes. The genotypic and 
allelic frequencies were measured. We explored the relationship between CMIP gene SNPs 
and serum lipid levels, and analyzed the risk factors of dyslipidemia.
Results: The study included 543 patients, 51.7%were dyslipidemia. The genotype and 
allele frequency of CMIP rs16955379 were statistically different between the two groups 
((P < 0.05). TG, HDL, BP, tubular atrophy and interstitial fibrosis(TA/IF) were significantly 
different between CMIP rs16955379 C allele carriers and non-carriers. TC, BP, Scr, UA, 
urine protein, renal dysfunction, and TA/IF were significantly different between CMIP 
rs2925979 A allele carriers and non-carriers. TC level was associated with rs16955379 
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C allele carrier, hypertension, alcohol and UA. TG level was associated with renal 
dysfunction, rs16955379 C alleles carrier, alcohol, smoking, BMI, UA, and TA/IF. HDL 
was associated with rs16955379 C allele carrier, UA, renal dysfunction, and mesangial 
cell proliferation. LDL was associated with rs16955379 C allele carrier, hypertension, and 
UA(P < 0.05, respectively). There was a linkage disequilibra(LD) between rs16955379 and 
rs2925979, and rs2925979G-rs16955379T was the most common haplotype. The haplotype 
frequencies of CMIP SNPs were significantly different between dyslipidemia and normal 
group (P < 0.05).
Conclusions: About half of IgAN patients had dyslipidemia. The genotypic and 
allelic frequencies of rs16955379 were significant different between dyslipidemia group 
and normal group. There were significant differences in several lipid levels between CMIP 
SNPs different allele carriers. There was a LD between rs292597 and rs16955379. The most 
common haplotype was rs2925979G-rs16955379T. The related haplotypes increased the 
risk of dyslipidemia in IgAN.
Funding: Government Support - Non-U.S.
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Pathologic Tonsillar Findings Similar to Immunoglobulin A Nephropathy 
in Patients with Frequently Relapsing Nephrotic Syndrome
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Mitsuru Okada,1 Tsukasa Takemura.4 1Kindai University Faculty of Medicine, 
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Background: Several studies have reported that regulatory T (Treg) cells are of critical 
importance for maintenance of tolerance in not only immunoglobulin A nephropathy 
(IgAN) but also nephrotic syndrome (NS). The pathologic tonsillar findings in IgAN differ 
significantly from those in chronic tonsillitis. However, the pathologic tonsillar features in 
patients with NS are unclear.
Methods: Immunohistochemical staining for tonsillar CD4, CD8, HLA-DR and 
cytokeratin was performed in 8 patients with frequently relapsing nephrotic syndrome 
(FRNS) who underwent tonsillectomy for chronic tonsillitis,. The patients were in complete 
remission, and were followed on low-dose prednisolone for FRNS.
Results: In 6 of 8 patients, T-cell nodules were enlarged by infiltration of HLA-DR-
positive cells. Infiltration with both CD4-positive and CD8-positive cells was prominent 
in interfollicular areas. Cytokeratin staining showed that the layer of crypt epithelium was 
replaced by squamous epithelium.
Conclusions: The efficacy of tonsillectomy for IgAN is thought to be due to regulation 
of tolerance abnormalities. Replacement from the layer of crypt epithelium implies 
involution of lymphoepithelial symbiosis. The distribution of CD4 and CD8 is characteristic 
in the tonsils of those with IgAN. These pathologic findings in FRNS patients suggest the 
existence of a similar tolerance abnormality in the tonsils of those with NS. Our results may 
help to clarify intolerance in NS. Further studies are necessary to clarify the clinical efficacy 
of tonsillectomy for NS patients.
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The Predictive Value of Crescents in Adult Henoch-Schölein Purpura 
Nephritis
Fei Han. First Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou, China.
Background: To study the predictive value of crescents in adult Henoch-Schölein 
purpura nephritis(HSPN).
Methods: We retrospectively analyzed 275 adult patients with biopsy proven HSPN 
in the First Affiliated Hospital of Zhejiang University, and divided the patients into 
4 groups: 99 patients in none crescent croup(NC), 34 patients in segmental crescents 
group(SC), 109 patients with circumferential crescents ≤25% were categorized into 
group C1, and 33 patients with crescents >25% were categorized into group C2. Data 
including serum creatinine(Scr), evaluated glomerular filtration rate(eGFR), 24h urine 
protein and mean arterial pressure were compared, and primary outcome was defined 
as ≥50% reduction of eGFR from baseline in 2 years, doubling of serum creatinine 
(Scr), or end stage renal disease (ESRD). ESRD was defined by reaching an eGFR of 
<15ml/min/1.72m2 or requiring maintaining renal replacement therapy for more than 3 
months. Univariate analysis and multivariate analysis were used to compare the outcome.
Results: There were no significant difference in gender or age(p>0.05). Differences 
in Scr(p=0.002), eGFR(p=0.007), 24h urine protein (p<0.001)were found significant. 
The median Scr level of NC, C1,C2, SC group were 59.0(51.0, 75.0)μmol/L,66.0(52.5, 
77.0)μmol/L, 72.0 (55.0, 94.0) μmol/L, 68.0(56.5,118.0) μmol/L, respectively. Further 
analysis showed that patients with crescents (including segmental crescents) have a 
higher Scr level than those without crescents. The urine protein level of each group 
were 0.75(0.42,1.53),1.17(0.63,2.02)g, 1.60(0.86,3.00)g, 2.48(1.12,4.63) g, respectively. 
The median follow-up duration was 56(33,85) months, and 18 patients reached renal 
endpoint. Kaplan Meier analysis suggested that the renal outcomes were significantly 
different(p=0.002), the renal survival rates of NC, C1, C2, SC group were 96%, 88.1%, 
78.8%, 100%, respectively. And Cox model suggested that a crescent ratio of more than 
25% is an independent predictor of poor renal outcome.
Conclusions: A crescent ratio of more than 25% is an independent predictor of poor 
renal outcome in adult patients with Henoch-Schölein purpura nephritis.
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Crescentic Lesions in IgA Nephropathy: Impact on Outcome
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Andreia Campos,1 Carla L. Moreira,1 Jorge Malheiro,2 Josefina Lascasas.3 
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Background: Recently, IgAN Classification Working Group has published an update 
to the Oxford Classification that recommends changing the MEST to a MEST-C score, 
defending that the fraction of crescents are associated with outcome. Nevertheless, the role 
of crescentic lesions is still controversial and needs better characterization. The aim was to 
study the impact of the crescents in the outcome in our population.
Methods: A total of 88patients with biopsy-proven IgAN between January'07 and 
December'17 were re-assessed using the MEST-C, in this retrospective analysis. The 
composite outcome was defined as 50%decline in eGFR or ESRD. We compare two 
groups:with crescents(N=24,27%)and with no crescents.
Results: The baseline characteristics were similar between the groups. The patients 
with C had more proteinuria and hypoalbuminemia at presentation but had similar eGFR. 
Endocapillary hypercellularity and segmental glomerulosclerosis lesions were higher 
in patients with crescents(P<0.02). During a mean follow-up of 55.4months, 50% of the 
patients with crescents reached the composite outcome compared with27%of patients 
without(P<0.05). Survival curves are presented. ESRD were more likely in the first 
group(P<0.02) and50% decline in eGFR was more frequent but was not statistically 
significant. The independent predictors of composite outcome were eGFR at presentation, 
proteinuria, presence of crescents and moderate to severe interstitial fibrosis and tubular 
atrophy. In a multivariable Cox analysis, crescents(HR3.33, CI95%1.24-8.90, p<0.02), 
eGFR(HR0.16,p<0.001) and no immunosuppressive therapy(IST) (HR3.23,p<0.05)were 
associated with an increased risk of developing the composite outcome. IST was based on 
corticosteroid therapy, in 4cases prednisolone and cyclophosphamide were administrated. 
The survival at 96months in patients without IST was71%if they had no crescents and 42% 
if had any crescent(P=0.022). The survival among those that were treated with IST was 80% 
if had no crescents (vs51%,P=0.124).
Conclusions: Crescents, along with higher eGFR at presentation, were an independent 
prognostic factor in our population. The main histologic alterations associated with the 
outcome were severe interstitial fibrosis, tubular atrophy and crescents. Our study suggests 
that crescent have value in predicting renal outcomes in our population with IgAN.
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Urinary Soluble CD163 Level Predicts Renal Prognosis of IgA 
Nephropathy
Jiong Tian. Kidney Disease Center, the First Affiliated Hospital, College of 
Medicine, Zhejiang University, HANGZHOU, China.
Background: In IgA nephropathy (IgAN), crescent percentage was added to the 
make the new Oxford MESTC scores system recently. Macrophage is the most important 
inflammatory cell type in crescent and CD163 is a specific marker for M2c macrophage. Its 
soluble form (sCD163) is present in the bio-fluid in inflammation.sCD163 may serve as a 
biomarker for macrophage activation but its role in renal prognosis is unknown.
Methods: 115 patients of IgAN were studied. Clinical parameters including blood 
pressure, urinary protein, creatinine and eGFR at renal biopsy and the last follow-up were 
recorded. The renal end point was defined as ESRD or the eGFR declined >50% or serum 
creatinine doubled during the follow up. The serum and urinary level of sCD163 were 
determined by ELISA.
Results: The cohort were divided into three groups according to the crescent percentage. 
Urinary sCD163 in group C2 (crescents in>25% of glomeruli) were significantly elevated 
compared to that in group C1 (crescents in <25% of glomeruli) and group C0 (no crescent). 
Urinary sCD163 level was negatively correlated with eGFR and positively correlated with 
serum creatinean and proteinuria. Urinary sCD163 level was associated with M,E,S and 
C scores. There was a significantly positive correlation between urine urinary sCD163 
level and the percentage of crescents. Renal end points developed in 12 patients during the 
42.6±7.4 months of follow-up. Most importantly, our results showed that increased urinary 
sCD163 level was significantly associated with poor renal outcome.
Conclusions: The level of urinary sCD163 was closely related to clinical and 
pathological features in IgAN and it can serve as a non-invasive biomarker to reflect the 
severity of IgAN. An increased urinary sCD163 level was related with poor renal outcome 
in patients with IgA nephropathy.
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Prognostic Value of Mesangial C3 and C4d Deposition in IgA 
Nephropathy
Ki Heon Nam, Yooju Nam, Seon yeong Lee, Joohwan Kim, Tae-Hyun Yoo, 
Dae-Suk Han, Seung Hyeok Han. Yonsei University College of Medicine, Seoul, 
Republic of Korea.
Background: Activation of complement system can play an important role in the 
pathogenesis of IgA nephropathy (IgAN). C3 and C4d can be representative markers of 
alternative and lectin pathway, respectively. We studied whether mesangial C3 or C4d 
deposits can predict adverse renal outcome better than conventional risk factors and 
determined relative contribution of each pathway to disease progression.
Methods: A total of 265 patients with biopsy-proven IgAN between 2000 and 2013 
were enrolled. The degree of C3 was evaluated by immunoflurorescence staining and 
graded as 0, 1+, 2+, and 3+. We also determined C4d deposition by immunohistochemistry. 
The study endpoint was a composite of a ≥ 30% decline in estimated glomerular filtration 
rate or the onset of end-stage renal disease.
Results: During a mean follow-up of 6.8 years, 82 (30.9%) patients reached the 
composite end point. In the fully adjusted multivariable model, risk of reaching renal 
outcome was significantly higher in patients with mesangial C3 deposition of 2+ to 
3+ (HR, 1.89; 95% CI, 1.11-3.20; P = 0.019) than in those with the deposition of 0 to 
1+. In addition, patients with positive C4d deposition had a 1.9-fold increased risk 
of adverse outcome compared with those without deposition (HR, 1.90; 95% CI, 
1.07-3.40; P = 0.03). The risk was highest in patients with both C3 and C4d deposition 
(HR, 2.61; 95% CI, 1.08-6.27; P = 0.03). Adding mesangial C3 deposition to risk prediction 
model significantly increased the integrated discrimination improvement and the net 
reclassification improvement, whereas C4d-added model did not. However, adding both 
mesangial C3 and C4d deposition together significantly improved risk prediction over 
C3-added model.
Conclusions: This study showed that mesangial C3 and C4d deposition were 
independent risk factors for renal progression. In addition, predictability of C3 was superior 
to that of C4d. C4d may play an additive role in increasing predictive power.
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The Role of Expression of Toll-Like Receptors 4 and 9 in Stratification of 
Severity of IgA Nephropathy
Hana Ciferska,1 Eva Honsova,2 Zdenka Hruskova,3 Michaela Neprasova,9 
Miloslav Suchanek,4 Tomas Zima,5 Rosanna Coppo,10 Vladimir Tesar,6 
Jan Novak,7 Dita Maixnerova.8 1Institute of Rheumatology, Praha, Czechia; 
2IKEM, Prague, Czechia; 3Department of Nephrology, General University 
Hospital and First Faculty of Medicine, Charles University, Prague 2, Czechia; 
4University of Chemical Technology Prague, Prague, Czechia; 5Firts Faculty of 
Medicine, Charles University, Prague 2, Czechia; 6General University Hospital 
in Prague, Prague, Czechia; 7University of Alabama at Birmingham, 
Birmingham, AL; 8Dept. of Nephrology, Prague, Prague, Czechia; 9General 
Teaching Hospital in Prague, Dobris, Czechia; 10Fondazione Ricerca Molinette, 
Regina Margherita Hospital, Turin, Italy.
Background: The onset of IgA nephropathy (IgAN), characterized by glomerular 
deposition of IgA immune complexes, is often associated with synpharyngitic hematuria. 
Innate immune responses mediated by toll-like receptors (TLR) may play a role in IgAN 
onset and/or progression. Here, we assessed the expression of TLR 4, 7, 8, and 9 in renal-
biopsy specimens from patients with IgAN, with different degree of proteinuria and eGFR, 
compared with normal kidney specimens from cadavers and a disease controls (ANCA 
vasculitis).
Methods: Expression of TLR 4, 7, 8, and 9 was assessed using immunohistochemical 
staining of paraffin-embedded renal-biopsy tissue specimens with specific antibodies and 
evaluated semiquantitatively by light microscopy. Linear discriminant analysis (LDA) was 
used to test whether intrarenal staining of TLR 4, 7, 8, and 9 distinguished patients with 
IgAN (n=34) from controls. Moreover, patient with IgAN represented four subgroups based 
on eGFR and proteinuria. All biopsies of patients with IgAN were scored according to the 
Oxford Classification.
Results: LDA showed that TLR 4, 7, 8, and 9 staining was more intense in specimens 
from IgAN patients than in normal kidney tissues. LDA also distinguished four subgroups 
of patients with IgAN based on MEST scoring. The intensity of intrarenal staining of TLRs 
discriminated four groups of IgAN divided according severity of renal impairment and 
proteinuria.
Conclusions: Intrarenal staining of TLRs together with clinical parameters (serum 
creatinine, eGFR, and proteinuria) analyzed by LDA may be helpful in assessment of disease 
prognosis. References: Supported by the project (Ministry of Health, Czech Republic) for 
conceptual development of research organization 00023728 (Institute of Rheumatology) 
and by PROGRES Q25/LF1. JN was supported in part by grants DK078244 and DK082753 
from the National Institutes of Health.
Funding: Other NIH Support - Jan Novak supported in part by grants DK078244 and 
DK082753
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Clinical and Pathological Characteristics of Patients with HBV-Associated 
IgA Nephropathy: A Case Series
Bogdan Obrisca, Roxana A. Jurubita, Bogdan M. Sorohan, Oana C. Ion, 
Andreea Andronesi, Gener Ismail. Fundeni Clinical Institute, Bucharest, 
Romania.
Background: A higher prevalence of hepatitis B surface antigen (HBsAg) is reported 
in patients with IgA nephropathy (IgAN) from endemic areas. However, little is known 
about the clinicopathological characteristics and outcome of these patients. We sought to 
characterize a cohort of patients with IgAN and HBsAg (HBsAg-IgAN).
Methods: Medical records of 110 patients with biopsy-proven IgAN, between 1999 
and 2017, were retrospectively reviewed. Of these, 10 patients had HBsAg. Clinical and 
pathological characteristics (MEST-C score) at baseline, and outcomes were compared 
between HbsAg positive and negative IgAN patients.
Results: 10 patients (9.1%) with HBsAg-IgAN (mean age: 47 ± 20 years) 
were identified in our cohort. Mean eGFR, hematuria, and 24-hour proteinuria were 
47 ± 20 ml/min, 50 ± 60 RBC/μl and 2.3 ± 2.8 g/day, respectively. The percentage of patients 
that showed M1, E1, S1, T1 and C1 were 80%, 10%, 70%, 50% and 20%, respectively. 
By comparison to patients with HBsAg negative IgAN, there was a tendency towards a 
worse renal function at baseline with more severe features on kidney biopsy (fewer patients 
showing E lesions and more with crescents, segmental sclerosis and interstitial fibrosis). 
30% of patients had a halving of eGFR (within 27 ± 20 months), versus 14% (within 
45 ± 42 months) of patients with HBsAg negative IgAN. All patients received antiviral 
therapy, 40% having undetectable viral load at biopsy, 40% having a HBV-DNA below 
1000 IU/l (mean 264 ± 357 IU/l) and 20% having over 1000 IU/l (mean 11000 ± 8680 
IU/l). 40% of patients received additional immunosuppressive treatment (IS). There were 
no significant differences in terms of renal survival between those with high versus low viral 
replication and between those receiving antiviral therapy alone and combined antiviral/IS 
therapy. Additionally, patients receiving combined antiviral/IS therapy didn’t show any sign 
of HBV reactivation.
Conclusions: HBV-associated IgAN patients had a worse renal function at baseline, 
with more severe activity and chronicity features, both clinically and pathologically, as 
compared to HBsAg-negative IgAN patients. These characteristics determined a more rapid 
decline of renal function in our cohort of HBV-associated IgAN.
Glomerular Diseases: Clinical, Outcomes, Trials - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
389
J Am Soc Nephrol 29: 2018 Poster/Thursday
TH-PO1036 Poster Thursday
Glomerular Diseases: Clinical, Outcomes, Trials - I
Using the Oxford Classification in Assessing the Therapeutic Effects in 
IgA Nephropathy: A Secondary Analysis from a Randomized Clinical 
Trial
Shuwei Duan,1 Guangyan Cai,2 Xiangmei Chen.3 1Department of Nephrology, 
State Key Laboratory of Kidney Disease, Beijing, China; 2Chinese PLA Genaral 
Hospital, Beijing, China; 3Chinese PLA General Hospital, Beijing, China.
Background: The Oxford Classification established a consensus on pathologic 
features that could predict the risks of progression of IgA nephropathy(IgAN). Clinically, 
histopathology is essential for both evaluating the severity of the lesions and guiding 
therapeutic strategies for IgAN. It remains a challenge whether or not Oxford Classification 
can guide therapeutic strategies. The aim of the analysis was to evaluate if the oxford 
classification can predict the therapeutic effects for patients receiving telmisartan and/or 
clopidogrel with/without leflunomide.
Methods: The multicentre, prospective, double-blind, double-dummy RCT was 
conducted between July 2010 and June 2012 in Beijing, China. The results were published 
in Chinese Medical Journal in 2016. There were 162 cases, who were diagnosed in Chinese 
PLA General hospital, included in this secondary analysis. The complete or partial remission 
was defined as 24 hour proteinuria <0.3g or ≥30% reduction and stable kidney function. 
Stable kidney function was defined as increase in serum creatinine less than 26.4umol/L 
at week 24. The other was defined as ineffectiveness. The logistical regression was used 
to analyse the relationship between the character of Oxford classification and the effect.
Results: Multiple logistic regression analysis showed that both of 24 hour proteinuria≥1g 
(Odds Ratio(OR)=2.13, 95%CI 1.04-4.36) and taking leflunomide(OR=5.70, 95%CI 2.66-
12.24) were the advantage factors. Only tubular atrophy/interstitial fibrosis >50% were the 
risk factor(OR=18%, 95%CI 8%-40%). Especially, we found that there were interaction 
between mesangial hypercellularity >0.5 and leflunomide.
Conclusions: This secondary analysis supports the oxford classification for IgAN has 
capacity to predict the therapeutic effects for patients receiving telmisartan with leflunomide. 
Mesangial hypercellularity >0.5 maybe the potential character of taking leflunomide.
Funding: Government Support - Non-U.S.
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Clinical Impact of Endocapillary Proliferation with Modified Cutoff Point 
in IgA Nephropathy Patients
Ahmad B. Kaihan,2,3 Yoshinari Yasuda,4 Takahiro Imaizumi,4 Manabu Hishida,1 
Naotake Tsuboi,5 Shoichi Maruyama.5 1Nagoya University, Nagoya city, Japan; 
2Department of Nephrology/CKD, Nagoya University Graduate School of 
Medicine, Nagoya, Japan; 3Internal medicine, Balkh university/Faculty of 
medicine, Mazar-e-Sharif, Afghanistan; 4Nagoya University Graduate School of 
Medicine, Nagoya, Aichi-ken, Japan, Nagoya, Japan; 5Nagoya University 
Graduate School of Medicine, Nagoya, Japan.
Background: Predictive values of mesangial proliferation (M), endocapillary 
proliferation (E), segmental glomerulosclerosis (S), and crescents (C) among 19-validation 
studies of Oxford Classification were discrepant, in particular among Asian IgA nephropathy 
(IgAN) patients. These validation studies indicate that cutoff points of MESC score in the 
Oxford Classification may not be generalizable. Thus, we aimed to improve clinical value 
of MESC scores by modifying cutoff points.
Methods: A total of 104 IgAN diagnosed from 2001 to 2012 by renal biopsy, and 
retrospectively evaluated at Nagoya University Hospital. Cutoff point for modified 
(M′E′S′C′) was determined by receiver operating characteristic curve in association with 
renal outcome in the training cohort. Clinical value of the Oxford MESTC vs M′E′S′C′ 
cutoff points were analyzed by Kaplan-Meier and Cox regression for renal outcome in the 
validation and all cohort.
Results: Of 104 participants 12.5% of them reached renal outcome over 6.25 [4.16-
9.61] years of follow-up. The modified cutoffs were defined ≥40%, ≥10%, ≥20%, and 
≥5% in glomeruli for M′E′S′C′ respectively. In univariate analysis, E′, S′, and T were
significantly associated with renal outcome. Whereas, the Oxford MESC, M′, and C′ in the 
training and validation cohort demonstrated no significant association with renal outcome. 
By multivariate analysis in the presence of eGFR, only E′ was a significant predictive factor 
for renal outcome.
Conclusions: The E′ with modified cutoff point of 10% significantly improved 
predictive value for renal outcome in IgAN. Clinical value of modified cutoff points for 
M′E′S′C′ scores should be validated with various cohort studies in different regions.
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Steroid Responsiveness on Remission of Urinary Abnormalities According 
to the Pathological Lesions in IgA nephropathy: A Japanese Multicenter 
Prospective Cohort Study
Ritsuko Katafuchi,1 Tetsuya Kawamura,2 Akinori Hashiguchi,3 Satoshi Hisano,4 
Akira Shimizu,5 Kensuke Joh.6 The IgA nephropathy Study Group in Japan 
1National Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan; 2Jikei 
University School of Medicine, Tokyo, Japan; 3Keio University School of 
Medicine, Tokyo, Japan; 4University of Occupational and Environment Health, 
Kitakyushu, Japan; 5Nippion Medical School, Tokyo, Japan; 6Tohoku University 
Graduate School of Medicine, Sendai-city, Japan.
Background: The effectiveness of steroids on clinical course and its indication in IgA 
nephropathy (IgAN) are controversial.
Methods: 797 patients with IgAN were included. Treatment groups were defined 
by steroid (ST) and tonsillectomy (TX): group 1; ST-TX-, groups 2; TX only, group 3; 
ST only, group 4; TX+ST+. Acute lesions (AL) such as cellular or fibrocellular crescent, 
or tuft necrosis, chronic lesions (CL) such as fibrous crescent, segmental or global 
glomerulosclerosis, Japanese histological grade (HG) and Oxford classification (MEST-C) 
were evaluated. The endpoint was the remission of urinary abnormality within 24 months. 
The remission of proteinuria (UPR) was defined less than 0.3/day. The remission of 
hematuria (OBR) was defined less than 5 RBC/HPF. Clinical remission (CLR) was defined 
UPR and OBR. The effect of treatment groups, and pathological parameters on UPR, OBR, 
and CLR was analyzed by logistic model.
Results: The mean age was 38, the median of UP was 0.58, mean eGFR was 76.9. The 
median AL, CL was 3.8, and 20%. AL and CL were tertile categorized with 0 and 7.7 % 
for AL and 13.3 and 30.8% for CL as cutting values. HG1 to 4 was 61, 26, 10, and 2.8 %. 
M1, E1, S1, T1-2 and C1-2 were 24, 36, 81, 27, 62 %. The treatment group 1 to 4 was 35, 5, 
25 and 40 %. Group 3 and 4 showed significant positive effect on UPR, OBR and CLR with 
reference (ref) group 1. The effect of group 4 with ref group 3 was significant on OBR. AL3 
showed significant positive effect with ref AL1 on UPR and CLR. CL2 and CL3 showed 
significant negative effect with ref CL1 on UPR. CL3 showed significant negative effect on 
CLR. HG2 and HG3-4 showed significant negative effect on UPR with ref HG1. HG3-4 
showed significant negative effect on CLR. E1 showed significant positive effect on UPR. 
M1, S1, T1-2 showed significant negative effect on UPR with ref M0, S0, and T0. On CLR, 
C1-2 showed significant positive effect with ref C0, and T12 showed significant negative 
effect with ref T0.
Conclusions: Steroid was significantly effective on proteinuria and hematuria. 
Higher percentage of acute lesions showed significant effect of steroid on proteinuria. The 
additional effect of tonsillectomy to steroid was found on hematuria.
Funding: Government Support - Non-U.S.
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Primary Efficacy Analyses from a Phase 2 Trial of the Safety and Efficacy 
of Bardoxolone Methyl in Patients with IgA Nephropathy
Geoffrey A. Block,1 Gerald B. Appel,2 Ahmed M. Awad,9 Judith A. Betts,10 
Melanie Chin,3 Colin J. Meyer,3 Pablo E. Pergola,4 Anjay Rastogi,5 Dana Rizk,6 
Kevin Schroeder,7 Arnold L. Silva.8 1Colorado Kidney Care, Denver, CO; 
2Columbia University College of Physicians and Surgeons, Scarsdale, NY; 
3Reata Pharmaceuticals, Irving, TX; 4Renal Associates, PA, San Antonio, TX; 
5Division of Nephrology, University of California at Los Angeles Medical 
Center, Los Angeles, CA; 6University of Alabama, Birmingham, AL; 7Ohio 
Kidney Consultants, Columbus, OH; 8Boise Kidney & Hypertension Institute, 
Meridian, ID; 9Clinical Research Consultants, LLC, Kansas City, MO; 10Austin 
Kidney Associates, Austin, TX.
Background: Bardoxolone methyl (BARD) has been shown to significantly increase 
eGFR in patients with CKD and type 2 diabetes and Alport syndrome suggesting that the 
anti-inflammatory and anti-fibrotic effects of BARD may target the common pathways 
contributing to GFR loss in multiple forms of CKD. As a result, a Phase 2 trial (PHOENIX, 
NCT03366337) was initiated to test the hypothesis that BARD will improve kidney 
function in patients with IgA nephropathy (IgAN) as well as other forms of CKD.
Methods: The Phase 2 open-label, multicenter study enrolled a cohort of 26 patients 
with biopsy-confirmed IgAN. Eligible patients were 18 to 65 years of age with eGFR values 
between 30 to 90 mL/min/1.73 m2 and urine albumin to creatinine ratio (UACR) ≤ 2500 
mg/g. Patients received BARD at an initial dose of 5 mg, dose-escalated to 20 mg (for 
patients with baseline UACR ≤ 300 mg/g) or to 30 mg (for patients with baseline UACR 
> 300 mg/g) and were treated for 12 weeks. The primary efficacy endpoint was the change 
from baseline eGFR after 12 weeks of treatment. Interim results for the cohort enrolling
patients with IgAN are described herein.
Results: At data cutoff on May 15th, 2018, 5/26 (19%) of the enrolled patients with 
IgAN had completed the study. From a mean (± SE) baseline eGFR of 46.2 ± 2.5 mL/
min/1.73 m2, BARD treatment resulted in a significant increase from baseline in eGFR of 
7.8 ± 1.8 mL/min/1.73 m2 (p<0.0001) at Week 12. The improvements were consistent, and 
4 of the 5 (80%) patients had increases from baseline in eGFR > 5 mL/min/1.73 m2 at Week 
12. No patients have discontinued from the study and no serious AEs considered related to 
BARD have been reported in this ongoing trial.
Conclusions: BARD was generally well tolerated and significantly increased eGFR in 
patients with IgAN. In patients with other forms of CKD, short term eGFR increases with 
BARD are predictive of durable eGFR improvements and additional studies are needed to 
study the longer-term effects of BARD on eGFR in IgAN.
Funding: Commercial Support - Reata Pharmaceuticals
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Corticosteroid Therapy in IgA Nephropathy
Soumita Bagchi, Adarsh Barwad, Raj K. Yadav, Sandeep Mahajan, 
Dipankar M. Bhowmik, Sanjay K. Agarwal. All India Institute of Medical 
Sciences, New Delhi, India.
Background: Corticosteroid therapy is used in patients with IgA nephropathy(IgAN) 
with persistent proteinuria, but there is a lack of cosensus about its overall benefits. There is 
a paucity of data about steroid use in Indian patients who have an aggressive clinical course. 
This study aims to look at the response to steroid therapy in Indian patients with IgAN.
Methods: Patients with biopsy proven primary IgAN treated with oral corticosteroids 
from 2012 to 2017 with minimum 12 months follow up were included in the study. 
MEST-C score was assigned as per the Oxford classification to all biopsies. All patients 
received oral prednisolone 1mg/Kg/day for 8-12weeks followed by gradual tapering 
over 6-12 months. Complete remission(CR) was defined as 24-hour urine protein of 
<500 mg/d with stable eGFR and partial remission(PR) was defined as atleast 50% reduction 
in proteinuria with stable eGFR with a decline of proteinuria to <3.5g/day.
Results: Of the 94 patients included in study, 64.9% were males with mean age of 
30.4±11.9 years. Mean proteinuria was 5.2±2.6 g/day and 53.2% had gross or microscopic 
hematuria. Mean serum creatinine was 1.4±0.6 mg/dl and mean eGFR was 75. 4± 48.1 
ml/min/1.73m2. 77.7% patients had received ACEi/ARB before starting steroid therapy. 
The distribution of MEST lesions were: M1-70(74.5%), E1-7(7.5%), S1-56(59.6%), 
T1-26(27.7%) lesions and T2-7(7.5%). 9(9.6%) patients had crescents[C1-7(7.5%), C2-
2(2.1%)]. 42(44.7%) patients responded to steroid therapy (CR-22, PR-20), of whom 7 
patients had one steroid responsive relapse during the follow up and three were steroid 
dependent. On univariate analysis,S1 lesions on biopsy (p=0.011) and eGFR<30ml/
min/1.73m2(p=0.056) predicted steroid resistance. Serious adverse effects were seen 
in 16 (17.0%) patients mainly comprising of infections (13) with 4 patients developing 
Tuberculosis. One patient died due to pulmonary nocardiosis.
Conclusions: Steroid therapy reduces proteinuria in 44.7% patients with IgAN. 
However it is associated with serious infectious complications. The presence of S1 lesion 
and renal dysfunction at baseline predict poor response.
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The Global, Regional, and National State of CKD Epidemiology from 
1990 to 2016: An analysis of the Global Burden of Disease Study
Yan Xie,1 Benjamin C. Bowe,2 Hong Xian,4 Yan Yan,3 Tingting Li,5 
Geetha S. Maddukuri,1 Cheng-You Tsai,4 Tasheia A. Floyd,1 Ziyad Al-Aly.1 1VA 
Saint Louis Health Care System, Saint Louis, MO; 2Research and Development 
Service, Veterans Affairs St Louis Health Care System, St. Louis, MO; 
3Washington University Medical School, Saint Louis, MO; 4Saint Louis 
University College for Public Health & Social Justice, St. Louis, MO; 
5Washington University in St. Louis, Saint Louis, MO.
Background: The last quarter century witnessed significant population growth, aging, 
and major changes in epidemiologic trends which may have shaped the state of chronic 
kidney disease (CKD) epidemiology. The GBD study provides a detailed epidemiologic 
assessment of 333 diseases and injuries and 84 risk factors by age and sex on a global scale 
and for 195 countries and territories.
Methods: Data collected from the GBD study will be used to describe the change 
in burden of CKD from 1990 to 2016. In this work, we used the Global Burden of 
Disease (GBD) study methodologies to describe the change in burden of CKD including 
decomposition analysis to understand factors that drove change and frontier analysis that 
evaluate the relationship between burden of CKD and socio-demographic development.
Results: Globally, incidence of CKD increased by 88.76%, prevalence increased by 
86.95%, death due to CKD increased by 98.02%, and DALYs increased by 62.21%. Measures 
of burden varied substantially by level of development and by geography. Decomposition 
analyses showed that the increase in CKD DALYs was driven by population growth and 
aging; globally and in most GBD regions, age-standardized DALYs rates decreased. More 
of the CKD burden (62.96%) was in low and lower-middle-income countries; there was an 
inverse relationship between age-standardized CKD DALYs rate and healthcare access and 
quality (r=-0.52). Frontier analyses showed significant opportunities for improvement at all 
levels of the development spectrum.
Conclusions: Our results demonstrate that the global toll of CKD is significant, rising, 
and unevenly distributed; it is primarily driven by demographic expansion and in some 
regions significant tide of diabetes epidemic. Opportunities exist to reduce CKD burden at 
all levels of development.
Funding: Veterans Affairs Support
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Generalizability of SPRINT-CKD Cohort to CKD Patients Referred to 
Renal Clinics
Roberto Minutolo, Luca De Nicola. Nephrology, University of Campania, 
Naples, Italy.
Background: It is unknown whether the SPRINT-CKD sub-cohort is representative of 
CKD patients under nephrology care. We compared risk profile and outcomes of SPRINT-
CKD versus a pooled cohort of four prospective studies enrolling consecutive patients with 
CKD stage I-V under nephrology care from >6 months in 40 Italian outpatient renal clinics.
Methods: In referred cohorts, we implemented the same inclusion/exclusion criteria 
adopted in SPRINT and the same endpoints: (1) a composite of myocardial infarction, 
acute coronary syndrome, stroke, heart failure and CV death (2) all-cause mortality and 
(3) end-stage renal disease (ESRD) as a composite of chronic dialysis, transplantation
or 50% eGFR decline. Referred CKD patients were compared with those in SPRINT-
CKD randomized to standard BP arm because management in this group is comparable
to that performed in clinical practice where SBP target <140 mmHg is usually pursued.
To compare outcomes, we only considered for analysis the events occurring no later than 
4.8 years after enrolment, i.e. the maximum follow up available in SPRINT.
Results: From the initial pooled cohorts (n=3225), we deleted 338 duplicate patients, 
27 patients without data on SPRINT selection criteria and 13 subjects lost to follow-up. Out 
of the evaluable 2847 patients, only 20.1% (n=571) of the patients of the referred cohorts 
could have been potentially eligible for SPRINT trial. These patients had a worse risk 
profile at baseline (Table). At a median follow-up of 4.0 years (IQR 2.8-4.8), we registered 
85 CV events (50 fatal), 78 all-cause death with annual incidence rates higher than those 
observed in the SPRINT standard group (Table).
Conclusions: In conclusion, we suggest that the SPRINT-CKD cohort is poorly 
representative of “real-world” CKD population. Ad hoc trials are needed in referred CKD 
population.
Demographics and clinical characteristics at baseline, and incidence rates of endpoints in 
the two groups
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Explaining Racial Inequality in Albuminuria Through Multiple Mediators
Marcelo Lopes,1 Hal Morgenstern,1 Jennifer L. Bragg-Gresham,1 
Deidra C. Crews,2 Neil R. Powe,3 Nilka Rios Burrows,4 Rajiv Saran.1 1University 
of Michigan, Ann Arbor, MI; 2Johns Hopkins University School of Medicine, 
Baltimore, MD; 3Priscilla Chan and Mark Zuckerberg San Francisco Gen Hosp 
& UCSF, San Francisco, CA; 4Centers for Disease Control and Prevention, 
Atlanta, GA.
Background: Previous studies have shown that blacks have a higher prevalence of 
albuminuria than whites and that certain risk factors may account for that racial inequality. 
No research, however, has assessed the role of multiple risk factors collectively as mediators 
of the race effect.
Methods: Using cross-sectional data from the 2007-2010 National Health And 
Nutrition Examination Surveys for 6700 non-Hispanic black and white adults, ages 20+, 
we applied flexible mediation analysis (medflex, R package) to decompose the total 
effect of black race on albuminuria prevalence (albumin/creatinine ratio ≥30 mg/g) into 
direct and indirect (mediated) effects for combinations of 4 potential mediators: diabetes; 
hypertension; obesity (body mass index ≥30 kg/m2), and low vitamin D level (25[OH]D3 
<50 nmol/L). For each set of mediators, we estimated odds ratios (OR; 95% CI) for the 
direct, indirect and total effects and the percentage of the total effect that was mediated; ORs 
were adjusted for age, sex and non-mediating confounders.
Results: The weighted mean albuminuria level was 32 mg/g in blacks and 23 mg/g in 
whites; the adjusted OR for the total effect of black race on albuminuria was 1.61 (1.23, 
2.11). The % mediated by each risk factor treated separately was 50% for low vitamin D, 
44% for diabetes, 27% for hypertension, and 12% for obesity. When all 4 mediators were 
analyzed jointly, the direct-effect OR was 1.10 (0.65, 1.86), the indirect-effect OR was 1.46 
(1.23, 1.74), and 84% of the total effect was mediated by these 4 risk factors. Excluding 
low vitamin D reduced the percentage mediated to 46%; doing the same with the other 3 
mediators reduced the percentage mediated to no less than 70%.
Conclusions: The 4 risk factors treated as mediators in this study—especially low 
vitamin D and diabetes—appear to explain most of the racial difference in albuminuria 
prevalence in the United States. Although causal inference is limited by the cross-sectional 
design and possible residual confounding, the findings suggest that much of the racial 
inequality may be preventable through improvement of the risk-factor profile in blacks. As 
we learn more about how to control vitamin D level, the long-term impact on the incidence 
of chronic and end-stage renal disease could be appreciable.
Funding: Other U.S. Government Support
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Background: Disparities exist in progression of chronic kidney disease (CKD) 
across racially diverse groups. The University of California, Los Angeles Health (UCLA) 
and Providence St. Joseph Health (PSJH) systems formed a CKD and At-risk CKD Data 
Registry to inform advances in population health, individual behaviors, social and physical 
environment, and precision medicine.
Methods: CKD progression was determined across self-reported racial/ethnic groups 
in the database (>3.1 million patients) that was populated from electronic health records 
of adults treated at UCLA and PSJH from 2006 to 2016. Eligibility in the Registry was 
based on identification of CKD, and at-risk for CKD defined by hypertension, diabetes, 
or pre-diabetes. Linear regression coefficients for individual trajectories were calculated 
for patients having at least 3 eGFRs (CKD-EPI-creatinine). Individuals were classified by 
change in eGFR over time. Linear mixed models were used to assess racial differences in 
eGFR trajectories, controlling for age, gender, and time-varying measurements of systolic 
blood pressure, hemoglobin A1C, and renin angiotensin system inhibitor use.
Results: Patients with statistically significant eGFR decline (≥2-3 mL/min/1.73m2/
year; n=182,959, 16%) had a baseline of 79±26 mL/min/1.73m2 (mean±SD) versus 
81±23 mL/min/1.73m2 in non-decliners (n=980,022, 84%). Non-White were more likely 
than White patients to experience eGFR decline after adjustment for relevant covariates 
in multi-variable models. Mortality rate for patients with significant eGFR decline was >3 
times higher than in patients without eGFR decline.
Conclusions: In this large data registry from electronic health records at UCLA and 
PSJH, after multi-variable adjustment Non-White patients with CKD or at-risk for CKD are 
more likely to experience eGFR decline, which was associated with higher risk of mortality. 
Future directions include assessing eGFR decline by race/ethnicity and mortality risk in 
our unique cohort.
Funding: Private Foundation Support
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The Impact of Gender on Inpatient Mortality of Hypertensive Latino 
Patients Across CKD Stage 3 to ESRD in the United States
Mark A. Nader,1,2 Rodrigo Aguilar Campos,2 Oussama Hassan,3 
Carmen E. Cervantes,4 Ricardo Correa,6 Prabin Sharma,5 Rehan Shafique,1 
Omar Hamze,8 Hieu Q. Vo,9 Judit Gordon,7 Ping Li.7 1Kidney Care Consults, 
Memphis, TN; 2Georgetown University Hospital, Washington, DC; 3Royal London 
Hospital, Austin, TX; 4Aventura Hospital and Medical Center, Aventura, FL; 5Yale 
University Bridgeport Hospital, Bridgeport, CT; 6University of Arizona, Phoenix, 
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Consultants, Memphis, TN; 9University of Tennessee, Memphis, TN.
Background: HTN and CKD are two of the most important risk factors for CVD, a 
major cause of death in the US population. The impact of gender or menopausal age in this 
equation remains unclear on how it affects the Hispanic population. Studies comparing the 
difference in inpatient mortality between male and female with hypertension and CKD are 
sparse. Our aim was to determine if gender in Latino population affect the inpatient survival 
rate among hypertensive patients across different CKD stages.
Methods: Data was extracted from the 2005 to 2012 Nationwide Inpatient Sample 
(NIS). Using propensity score matching, female hypertensive with chronic kidney disease 
(stage 3, 4, 5 or ESRD) patients were matched with hypertensive males at a 1:1 ratio. We 
compared inpatient mortality, per CKD stage, length of stay and total hospital charges 
between male and females. Analyses were performed using SAS version 9.3.
Results: Among 227,923 hospitalized hypertensive patients, 118,132 (51.83%) were 
males and 109,791 (48.17%) females. There was 18.76% females with CKD3, 10.31% 
with CKD4, 3.85% with CKD 5 not on dialysis and 67.17% with ESRD. Similarly there 
was 19.47% men with CKD 3, 9.54% with CKD4, 3.63% with CKD5 not on dialysis and 
67.43% with ESRD on dialysis. In-hospital mortality was higher for males compared to 
females before match, (3.89 vs 3.74 p= 0.05), but non significant after matching the groups 
(3.85 vs 3.79 p= 0.48). Studying the effect of menopausal age, we find Latino women <50y 
to have less mortality risk compared to matched group of men irrespective of CKD stage 
while it is not different when comparing Men and women >50y with CKD stages 3 to 5. 
Post menopausal women with ESRD have a significantly higher mortality compared to 
men (5.15% vs 4.24%; p<0.0001). Hospitalized hispanic men had higher hospital charges 
(63,686 vs 61,667 dollars,p=0.001) even though hispanic women had a significantly longer 
mean length of stay (6.74 vs 6.70 days,p=0.001).
Conclusions: Mortality in Hispanic women with CKD 3 to 5 compared to men, is 
reduced when < 50y, comparable after >50y and increased when on dialysis. Further studies 
are needed to elucidate the possible links of menopause and sex hormones with in-hospital 
mortality of hypertensive hispanic patients.
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Impact of Kidney Function on Quality of Anticoagulation in Adults with 
Atrial Fibrillation: The CVRN WAVE Study
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Jerry H. Gurwitz.3 1Kaiser Permanente Northern California, Oakland, CA; 
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Background: Despite the development of direct oral anticoagulants, warfarin remains 
an important anticoagulation option for stroke prevention in adults with CKD. However, 
the impact of kidney function on the quality of anticoagulation for atrial fibrillation (AF) 
has not been well-defined.
Methods: Across 5 participating healthcare systems in the Cardiovascular Research 
Network (CVRN), we identified all adults with diagnosed AF who initiated warfarin and 
had ≥1 follow up international normalized ratio (INR) measurement. We used multivariable 
logistic regression, Cox regression and Kaplan-Meier curves to assess the relationship 
between estimated glomerular filtration rate (eGFR) by CKD-EPI with three metrics of 
quality of anticoagulation: patient-level %TTR, time to achieve a stable INR [between 2.0-
3.0], and early warfarin termination. Stroke and bleeding risk factors were ascertained from 
health system electronic health records.
Results: Among 24,634 eligible patients, mean age was 73 years and 44% were 
women. Baseline eGFR (ml/min/1.73 m2) was 64% for eGFR ≥60, 22% for eGFR 45-59, 
11% for eGFR 30-44, 2.5% for eGFR 15-29 and 2% for eGFR <15 or receiving dialysis. 
Patient-level %TTR ranged from 43% for eGFR <15 or dialysis to 66% for eGFR ≥60, 
with a graded increased adjusted odds of poorer anticoagulation control with lower eGFR. 
Overall, 77% reached a stable INR within the first 90 days of therapy, with only eGFR <15 
or dialysis significantly associated with a longer time to reach stable INR. There was no 
significant association of kidney function with early warfarin termination.
Conclusions: In adults with AF starting warfarin, we found graded increased odds of 
suboptimal %TTR with lower eGFR. While only eGFR <15 or dialysis was associated with 
a lower chance of reaching a stable INR within 90 days, eGFR did not appear to influence 
the likelihood of stopping warfarin within the first 12 months of treatment.
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Trends in Statin Use Among Those with CKD in the United States, 1999 to 
2014
Daniel P. Murphy, Robert N. Foley. University of Minnesota, Minneapolis, MN.
Background: Chronic kidney disease (CKD) has been recognized as a risk factor for 
cardiovascular disease (CVD). Statins have been shown to reduce CVD events in those 
with CKD not on dialysis, and CKD has been suggested as a candidate for determining 
statin therapy in cholesterol-focused guidelines. Statins have been shown to be used by a 
minority of those with CKD. Descriptions of temporal tends and disparities in statin use 
among those with CKD, identifying those who may benefit most from inclusion of CKD in 
such guidelines, are needed.
Methods: We studied trends in statin use among adult participants of the National 
Health and Nutrition Examination Survey, years 1999-2014, with creatinine-based 
estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or albumin-creatinine 
ratio ≥ 30 mg/g. Differences among racial/ethnic, other demographic, and comorbid 
characteristics were also examined.
Results: 28.9% of those with CKD used a statin. Encouragingly, statin use rose across 
the four eras studied (P < 0.001), though they may have begun to plateau after 2010: 
1999-2002, 17.1%; 2003-2006, 27.0%; 2007-2010, 33.4%, and 2011-2014, 35.6%. While 
albuminuria increased the likelihood of statin use (23.6% vs 12.2%, P < 0.001), a greater 
effect was seen among those with reduced eGFR < 60 ml/min/1.73m2 compared to those 
with preserved eGFR (41.4% vs 11.4%, P < 0.001). Those of Hispanic race/ethnicity with 
CKD received fewer statins: 15.4% compared to 32.0% for white, 26.2% for black, and 
24.6% for other race/ethnicity (P < 0.001). Statin use was more prevalent among males with 
CKD than females (32.4% vs. 26.3%, P < 0.001). In age, sex, and race/ethnicity adjusted 
models, statins were associated with: era (adjusted odds ratio (AOR) 1.77 [95% CI: 1.44-
2.17] for 2003-2006, 2.51 [95% CI: 2.04-3.08] for 2007-2010, and 2.94 [95% CI: 2.34-
3.70] for 2011-2014, vs. 1999-2002) and Hispanic race/ethnicity (AOR 0.62 [95% CI: 0.50-
0.78] vs. white). Other multivariate associations (P < 0.05) were older age, male sex, BMI 
≥ 30 kg/m2, diabetes mellitus, hypertension, myocardial infarction, heart failure, and stroke.
Conclusions: Statin use has increased over time but remains the case for the minority
in community-based CKD. Those of Hispanic race/ethnicity with CKD receive the fewest 
statins while males with CKD receive statins more often than females. Further research into 
such disparities is needed.
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Statin Use Remains Suboptimal Among US Veterans with Stage 3-5 
Non-Dialysis Dependent CKD
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Background: Statin use is one of the few interventions demonstrated in clinical trials 
to reduce cardiovascular disease (CVD) in adults with non-dialysis dependent chronic 
kidney disease (CKD-ND). KDIGO guidelines published in 2013 recommend statin use for 
adults age 50 years with CKD-ND. We previously reported suboptimal statin use during 
calendar year 2012 in U.S. Veterans with stage 3-5 CKD-ND with only 62.1% using statins 
overall and only 21.8% of Veterans with CKD-ND in absence of diabetes, clinical CVD or 
hyperlipidemia using statins. In this study, we reexamined statin use during calendar year 
2015 among U.S. Veterans age 50 years with stage 3-5 CKD-ND.
Methods: We used data from the VA Corporate Data Warehouse which includes 
demographics, inpatient and outpatient encounter diagnosis and procedure codes 
[International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification 
(ICD9/10-CM) and Current Procedural Terminology codes], outpatient pharmacy 
prescriptions reported by Veterans, and patient labs. Information on medications dispensed 
within the VA system was obtained from the Managerial Cost Accounting National Data 
Extracts which contains medications names and supply durations. Data were linked 
with the Medicare files to capture health care use and medications dispensed from non-
VA pharmacies. CKD status was based on presence of at least two estimated glomerular 
filtration rate (eGFR) values < 60 ml/min/1.73 m2 in outpatient laboratory data spaced 90+ 
days apart. Co-morbidities were defined by ICD9/10 codes.
Results: There were 242,865 Veterans age 50 years with at least two eGFR values 
<60 ml/min/1.73 m2 spaced 90+ days apart during calendar year 2014 with no history of 
dialysis or transplantation. Mean age was 76.4 years (standard deviation 9.6) and 96.7% 
were male and most were white with 14.9% reporting black race. During calendar year 
2015, 68.7% of these Veterans with stage 3-5 CKD-ND were using statins. Among Veterans 
with CKD-ND accompanied by diabetes or CVD, statin use was 75.1%. In contrast, only 
36.6% of Veterans with CKD-ND in absence of diabetes, CVD or hyperlipidemia were 
using statins.
Conclusions: Statin use appears to have increased among Veterans with stage 3-5 
CKD-ND but use still remains suboptimal, especially among those CKD-ND in the absence 
of diabetes or clinical CVD.
Funding: Veterans Affairs Support
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US Veterans with Stage 3-5 Non-Dialysis Dependent CKD Are More 
Likely to See a Cardiologist Than a Nephrologist
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Background: Nephrology care has been shown to improve outcomes and delay or 
even prevent end-stage renal disease (ESRD) in adults with established chronic kidney 
disease (CKD) but many never see a nephrologist. We examined the percentage of U.S. 
Veterans with -5 non-dialysis dependent CKD (CKD-ND) with at least one nephrology 
clinic encounter during calendar year 2015. We also examined the percentage of adults 
with CKD-ND with at least one cardiology clinic encounter during calendar year 2015 and 
examined whether referal patterns for nephrology or cardiology differed by race.
Methods: We used data from the VA Corporate Data Warehouse which includes 
demographics, inpatient and outpatient encounter diagnosis and procedure codes 
[International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification 
(ICD9/10-CM) and Current Procedural Terminology (CPT) codes], and patient labs. Since 
a percentage of Veterans receive their care from non-VA sources, we linked data from the 
Center for Medicare & Medicaid Services administrative databases to capture non-VA 
health care use. CKD status was based on presence of at least two estimated glomerular 
filtration rate (eGFR) values < 60 ml/min/1.73 m2 in outpatient laboratory data spaced 90+ 
days apart.
Results: There were 242,865 Veterans age 50 with at least two eGFR<60 ml/
min/1.73 m2 spaced 90+ days apart during calendar year 2014 with no history of dialysis 
or transplantation. Mean age was 76.4 years (standard deviation 9.6) and 96.7% were male 
and most were white with 14.9% reporting black race. In this group with stage 3-5 CKD-
ND, 16.6% saw a VA nephrologist and 6.1% saw a Medicare reimbursed nephrologist 
while 21.4% saw a VA cardiologist and 19.5% saw a Medicare reimbursed cardiologist. 
Compared to whites with stage 3-5 CKD-ND, black Veterans with stage 3-5 CKD-ND were 
more likely to see a VA or Medicare reimbursed nephrologist (31.8% vs. 20.1%, p<0.001) 
but less likely to see a VA or Medicare reimbursed cardiologist (32.3% vs. 38.7%; P < 
0.001).
Conclusions: Veterans with stage 3-5 CKD-ND are almost twice as likely to receive 
cardiology care than nephrology care although this differs somewhat by race. Increasing 
nephrology referral rates for patients with CKD-ND should be a priority for health systems 
in order to delay or prevent ESRD.
Funding: NIDDK Support, Veterans Affairs Support
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Environmental Chemical Exposures in African Children with CKD: H3 
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Background: Environmental chemical exposures are linked to oxidative stress and 
kidney injury in children and adults. This applies to short-lived organic compounds such as 
bisphenol A and phthalates and persistent synthetic chemicals such as perfluoroalkyl acids 
(PFAAs). Most investigations to date have been conducted in developed countries with few 
data about environmental chemical exposures in children living in Africa.
Methods: Clinical and laboratory data about pediatric patients enrolled in the H3 Africa 
observational cohort study including age, gender, BMI, serum creatinine, eGFR, proteinuria 
were collected. Serum samples that had been collected at enrollment were retrieved from 
the Biorepository and analyzed for PFAAs and polybrominated diphenyl ethers (PBDEs) 
and DDE presticides using established methods. Proteinuria was assessed in a first morning 
urine sample. Results are presented as mean±SD.
Results: 86 patients with CKD (41 M:45 F), age 12.6±2.6 yr old, were included in this 
nested case control study. The eGFR was 75±4 and the albumin:creatinine ratio was 65±186. 
The chemical exposures are summarized in the Table. There was no association between 
exposure (log of serum concentration) to PFAAs and proteinuria. However, controlling for 
age, gender, and BMI, there was an inverse relationship between eGFR and exposure to 
PFNA, -21.2 [95% CI:-41.6 - 0.8] and PFDA -18.3 [95% CI:-35.3 - -1.3] ml/min/log unit 
increase in exposure and a trend towards a similar effect for PFOS. PBDE/DDEs were 
detected in a small fraction of children and because of small sample size associations with 
effect markers were not made
Conclusions: PFAA exposure is substantially lower in H3 Africa participants than in 
healthy US children, age 12-19 enrolled in NHANES 2003-2010. However, even at these 
lower levels of exposure there was an adverse association between select PFAAs and GFR. 
These studies indicate the feasibility of measuring environmental chemical exposure in 
developing countries. The impact of these chemical exposures on kidney function will 
require larger cohorts of children followed for more extended periods of time.
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Risk Factors for Albuminuria and Reduced eGFR in Sub-Saharan 
Africans: Findings from the H3Africa Kidney Disease Research Network 
Project
Yemi R. Raji,1,2 Charlotte Osafo,7 Manmak Mamven,13 Timothy O. Olanrewaju,8 
Titilayo O. Ilori,10 Shikhar Kumar,12 Adebowale A. Adeyemo,11 
Rasheed A. Gbadegesin,5 Rulan S. Parekh,6 Babatunde L. Salako,9 Dwomoa Adu,4 
Akinlolu O. Ojo.3 H3Africa Kidney Disease Research Project 1University of 
Ibadan and University College Hospital, Ibadan, Oyo State, Nigeria, Ibadan, 
Nigeria; 2Medicine, University of Ibadan, Ibadan, Nigeria; 3University of Arizona 
Health Sciences, Tucson, AZ; 4University of Ghana, Accra, Ghana; 5Duke 
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Background: Chronic kidney disease (CKD) in sub-Saharan Africa (SSA) is 
among the most common non–communicable diseases ravaging the sub-continent. Data 
on comprehensive epidemiology of CKD phenotypes and genotypes are lacking from 
the region. The H3Africa Kidney Disease Research Network (H3Africa KDRN) was 
established to develop the first Pan-African study in CKD and to rapidly build capacity 
for genomic studies of kidney disease in Africa. The objective of this analysis was to 
characterize risk factors associated with albuminuria and low eGFR among the participants 
in the study.
Methods: Participants were enrolled from 8 clinical sites from 4 participating countries. 
We determined prevalent risk factors by collecting biometric that includes albuminuria and 
eGFR, the later was calculated using CKD - EPI equation. Crude and adjusted odds were 
determined for the risk factors for albuminuria of > 30mg/g and eGFR < 60 ml/min/1.73m2.
Results: Among the 3,323 participants with a median age of 45.73±15.5yrs, 57.3% 
were female. We observed that hypertension, Diabetes mellitus (DM), smoking and 
occurrence of CVD were significantly associated with albuminuria and reduced eGFR 
while gender was significantly associated with albuminuria (Table 1 and 2).
Conclusions: Hypertension, diabetes mellitus and cigarette smoking are the most 
prevalent risk factors for CKD in this study and are independently associated with 
albuminuria and low eGFR in SSA.
Funding: NIDDK Support
Risk Factors independently associated with albuminuria and Reduced eGFR
BMI-Body mass index, CI-Confidence interval eGFR-estimated glomerular filtration rate, 
CVD-Cardiovascular disease, OR-Odds ratio. * Unadjusted, ** Adjusted for age, gender, 
recruitment status and country of origin.
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CKD Epidemiology in Rural East Africa: The SEARCH-CKD Study
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Background: Little is known about CKD epidemiology among individuals living 
in Sub Saharan Africa (SSA) who may have heightened burden of kidney disease similar 
to African Americans due to shared genetic susceptibility. Non-infectious diseases and 
ongoing HIV epidemic can lead to significant CKD burden in SSA. Assessment of CKD 
burden in this region thus far has been limited by small studies or focus in urban areas. We 
sought to comprehensively ascertain the burden of CKD and its risk factors in rural areas, 
where most of the population resides.
Methods: We conducted a home-based assessment of CKD and its risk factors among 
a stratified random sub-sample of a large ongoing, population-based HIV test-and-treat 
trial in rural Uganda and Kenya (SEARCH study, NCT01864603). Prevalent CKD was 
defined as an eGFR <60 mL/min/1.73m2 or dipstick proteinuria ≥1+. Exposures of interest 
including traditional risk factors for CKD (hypertension, diabetes and HIV), were measured 
at mobile community health campaigns according to the SEARCH study protocol. We 
used household census population and sampling weights to estimate the community-based 
prevalence of CKD. To assess the association of potential risk factors with CKD, we used 
multivariable log-link Poisson models.
Results: We enrolled 5,035 participants from 30 communities (median age 41 [IQR 31-
53], 64% female). The overall CKD prevalence was 8.0% (95% CI 7.2-9.0%), and varied 
by region: Eastern Uganda, 13.0% (11.1-15.2%), Kenya, 7.1% (5.8-8.6%) and Western 
Uganda, 3.7% (2.7-5.1%). Over half (52%) of persons with CKD did not have hypertension, 
diabetes, or HIV. Independent risk factors associated with higher CKD prevalence included 
being from Eastern Uganda (prevalence ratio [PR] 1.97; 95% CI 1.50-2.60), increasing age 
(PR 1.03; 95% CI 1.02-1.04) and HIV infection (PR 1.58; 95% CI 1.28-1.97).
Conclusions: In rural East African communities, the prevalence of CKD is high and 
varies by region considerably. While HIV was associated with greater CKD prevalence, 
over half of the CKD cases could not be attributed to HIV, hypertension or diabetes. Further 
research and interventions are needed to address the burden of CKD in this vulnerable 
population where chronic dialysis and transplant are often unavailable.
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Prevalence of Proteinuria, Glycosuria, and Hypertension in a Walk-In 
Clinic in Rural Tanzania
David W. Ploth,1 Virginia Fonner,1 Michael D. Sweat,1 Jessie K. Mbwambo.2 
1Medical University of South Carolina, Charleston, SC; 2Muhimbili University 
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Background: Non-communicable diseases (NCD) including chronic kidney disease 
(CKD) and the typically comorbid conditions of diabetes mellitus (DM), hypertension 
(HTN), and cardiovascular disease represent increasing public health challenges in low- 
and middle-income countries. The present studies were conducted to explore the hypothesis 
that there are previously underappreciated and interrelated epidemics of CKD, DM, and 
HTN in rural Tanzania.
Methods: We recently reported prevalence estimates for CKD(Stages III-V) of 12.4%; 
Stage I or II HTN of 19.9% and DM(HbA1c>6.5%) of 14.8% for a random sample of 712 
residents in rural Tanzania. To assess HTN, DM, and CKD further, we obtained a single BP 
measurement and obtained random urine samples for dipstick measurement of glycosuria 
and proteinuria for individuals that voluntarily appeared at a walk-in clinic that was part of 
the overall study
Results: Table: Normal BP was reported for 33% (296/897) and prehypertension was 
reported for 35 % (317/897). Glycosuria and proteinuria were highly correlated (p≤0.001, 
Chi-Square). Glycosuria but no proteinuria was observed in 1.5%(13/833) of the samples; 
proteinuria but no glycosuria was present in 4.6%(38/833); and both proteinuria and 
glycosuria were present in 1.6%(14/833). Increasing age but was associated with HTN or 
DM but gender not. HTN was associated with overweight/obese but DM was not. DM and 
HTN were associated with each other(p≤ 0.002, Chi-square).
Conclusions: In summary, although the data are undoubtedly biased by the 
methodology available to us, we observed high prevalence of HTN, glycosuria and 
proteinuria in a community walk-in clinic that are consistent with the high rates of CKD, 
HTN, and DM observed in our earlier study. It is imperative that additional studies be 
performed to carefully asses the prevalence of these non-communicative diseases and their 
causes so that effective prevention and treatment strategies can be directed at reducing of 
the risk of kidney disease, DM, HTN and the expected cardiovascular complications that 
will follow in rural Tanzania
Funding: Other NIH Support - Funding for this project from Global Health Initiative 
Pilot Project Award, Center for Global Health, Medical University of South Carolina and 
NIMH Grant R01 MH095869.
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Trends in CKD Prevalence in the KEEP Mexico from 2008 to 2017
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Marselle Urquiza,2 Antonio Villa.2 1Sociedad de Asistencia Panamericana, 
MEXICO, Mexico; 2School of Medicine, Universidad Panamericana, Mexico 
City, Mexico.
Background: The Kidney Early Evaluation Program (KEEP) is a screening and 
educational program aimed at detecting CKD among adults with risk factors, such as DM, 
HTN, family history of these conditions or CKD. In 2008 the Mexican Kidney Foundation 
adapted KEEP; since then, 67 screening campaigns have been performed
Methods: Adults with DM, HTN, family history of DM, HTN, or CKD participated 
from 2008 to 2017. All completed a questionnaire and BP, weight, and height were 
measured. Albuminuria and serum creatinine were obtained, and GFR was estimated 
CKD: Epidemiology, Risk Factors, Prevention - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
394
J Am Soc Nephrol 29: 2018 Poster/Thursday
(CKD-EPI). Age-adjusted analyses were done to describe trends in CKD prevalence for 
almost a decade
Results: 6,885 patients with risk factors for CKD participated in a single KEEP Mexico 
program from 2008 to 2017. Mean age of participants was 49.7 ± 14.5 years, 69% were 
women. Prevalence of DM and HTN were 36.9%, and 39.5% respectively. Mean duration 
of DM and HTN were 10.1 and 8.5 years respectively. CKD prevalence was 30.2%, with 
CKD 1-2 being the most frequent stages. CKD prevalence increased over the study period, 
particularly at the expense of stage 2. Prevalence of stage 1 decreased and of stages 3, 4 & 
5 remained virtually unchanged. CKD prevalence among patients with DM, HTN, or both 
was 25.3%, 21%, and 33.2% respectively, and increased over time
Conclusions: CKD prevalence in the KEEP Mexico has increased over a decade, with 
the most significant increase in stage 2. CKD prevalence is higher in patients with both DM 
and HTN compared with those with either risk factor. Further analyses are being conducted 
to determine the factors associated with these trends. A longitudinal analysis of KEEP 
participants previously reported showed that a high proportion of patients who initially 
tested positive for CKD were eventually confirmed to have the disease
TH-PO1055 Poster Thursday
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Risk Factors for CKD Progression in the Mexican Chronic Renal 
Insufficiency Cohort (MCRIC) Study
Magdalena Madero,2 Jinsong Chen,1 Ana C. Ricardo,1 Eunice Carmona,1 
Ana P. Hernández martínez,2 Ana K. Fernández yepez,2 Esteban A. Cedillo-
Couvert,1 Mayank Kansal,1 Bernardo Moguel,2 Carlos A. Linares-Koloffon,1 
James P. Lash.1 1University of Illinois at Chicago, Chicago, IL; 2Instituto 
Nacional de Cardiología, Ciudad de México, Mexico.
Background: Chronic kidney disease (CKD) is a major public health problem in 
Mexico. However, little is known about the risk factors for progression of kidney disease 
among individuals with CKD living in Mexico.
Methods: MCRIC is an ongoing, prospective observational cohort study of adults 
with CKD recruited from a referral center in Mexico City, with entry estimated glomerular 
filtration rate (eGFR) 20-60 ml/min/1.73 m2. Using data from 257 participants who 
completed at least two study visits, we conducted Cox proportional hazards regression 
analysis to evaluate risk factors for CKD progression defined as 30% decline in eGFR from 
baseline.
Results: At study entry, mean age was 56.6 ± 0.8 years, 72.2% were male, 23% 
reported current cigarette smoking, and 53% had a diagnosis of diabetes. Mean body 
mass index (BMI) and systolic blood pressure (SBP) were 28.2 ± 4.5 Kg/m2 and 
123.4 ± 19.6 mmHg, respectively. The mean baseline eGFR was 41.1 ± 15.4 ml/min/1.73m2, 
and the median (IQR) urine protein excretion 633 (124-2460) mg/24 hours. During a median 
follow-up of 1.9 years, there were 57 CKD progression events (event rate 11.3 per 100 
person-years). In unadjusted analysis, significant predictors of CKD progression included 
diabetes (HR, 95% CI, 2.00, 1.15-3.50) and higher log-transformed urine protein (1.62, 
1.34-1.95). After adjusting for age, sex, SBP, baseline eGFR and diabetes, only proteinuria 
remained a significant predictor (1.64, 1.33-2.04).
Conclusions: This cohort of adults with CKD in Mexico experienced a high rate of 
CKD progression which was significantly associated with baseline proteinuria. Long-term 
follow-up is needed to better understand risk factors for CKD progression in this population.
Funding: NIDDK Support
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Survey of Migrant Dialysis Patients Discloses a Majority with Paraquat or 
Other Agrochemical Exposure: A Potential Etiology for CKDu
Michael Holliday,1 Jose R. Dominguez,1 Edlyn G. Bustamante,2 Ilse M. Espina,1 
Maulin Shah,1 Samaya J. Anumudu,1 Ahmed A. Awan,1 David Sheikh-Hamad.1,2 
1Baylor College of Medicine, Houston, TX; 2Harris Health System, Houston, TX.
Background: Chronic kidney disease of unknown etiology (CKDu) is a global 
epidemic of renal disease. Prior studies have reported associations of CKDu with 
Leptospira, heat and heavy metal exposures, and agricultural chemical use. From a screen 
of migrant workers with ESRD at a Houston safety net hospital, we identified Gramoxone 
(paraquat herbicide) exposure as a possible etiologic factor. Further, we found that repetitive 
administration of low dose paraquat to mice resulted in renal pathology similar to that of 
CKDu. We expanded our survey to an outpatient safety net dialysis unit that primarily 
serves migrants with ESRD.
Methods: 155 patients were screened at our outpatient dialysis unit. Of these, 38 met 
inclusion criteria and were surveyed. Exclusion criteria included known causes of primary 
or secondary renal disease (e.g. diabetes, hypertension, SLE, IgA, etc.). Included patients 
were also negative for viral hepatitis, HIV, ANA, ANCA, or monoclonal gammopathies.
Results: Average patient age at presentation was 40 (range 24-60) and 36 of 38 
surveyed patients were male. 58% (22) were from Mexico, 37% (14) from El Salvador, 
and one each from Guatemala and Honduras. Before immigration, 27 (71%) lived in a 
farm/village and 11 (29%) lived in urban area. 76% (29) reported living in hot climate 
and 74% (28 patients) had worked in agriculture for an average of 10+/-6 years prior to 
immigration. 16% (6) of patients had rare use of NSAID. 29% (11 patients) reported use 
of Gramoxone (paraquat-based herbicide) by name, while 22 (58%) patients reported prior 
herbicide and/or pesticide exposure but could not identify agents; the average duration of 
exposure was 10+/-5 years. 58% (22) consumed well water, and of patients with herbicide/
pesticide exposure, 18 (82%) consumed well water.
Conclusions: Patients with CKDu encountered at a Houston safety net hospital consist 
of migrant workers, predominantly male and young. Before immigrating to the US, most 
of the patients lived in hot mountainous climate, in a farm/village. They did not consume 
sweetened drinks and their main hydration solution consisted of well water. We found no 
clear identifiable risk factors for uCKD, except for chronic exposure to paraquat/Gramaxone 
in farm workers and consumption of well water.
Funding: Private Foundation Support
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Chronic Interstitial Nephritis in Agricultural Communities (CINAC) Is 
Strongly Associated with Pesticides
Channa Jayasumana,2 Chulani A. Herath,3 Marc E. De Broe.1 1University of 
Antwerp, Lokeren, Belgium; 2Faculty of Medicine, Anuradhapura, Sri Lanka; 
3Sri Jayawardenepura General Hospital, Colombo 5, Sri Lanka.
Background: Pesticides are hypothesized as a main etiological factor behind CINAC. 
Our aim was to see whether pesticides are associated with CINAC.
Methods: A case control study was carried out in a CINAC endemic region in Sri 
Lanka. Confirmed cases with CINAC (N=125) and controls (N=180) were recruited to the 
study. Socio-demographic and data related to usage of applying pesticides were studied. 
Participant’s urine samples were analyzed using ELISA to determine the levels glyphosate 
and paraquat.
Results: In the epidemiological study, we found CINAC is strongly associated with 
overall pesticide application (OR 2.34, 95% CI; 0.97-5.57), use of glyphosate (OR 5.12, 
95% CI; 2.33-11.26) and use of paraquat (OR 4.53, 95% CI; 1.23-10.03) adjusted for age, 
sex, education, family history of CINAC and exposure modifiers. In the analytical study it 
has been shown that creatinine adjusted values of urinary glyphosate in CINAC cases (12.7 
μg/g creatinine) was significantly higher when compared to non-endemic controls (2.4μg/g 
creatinine). Further, we found paraquat residues are still present in urine samples (Mean
1.08, Min-0, Max-11.42 μg/g creatinine) obtained from people living in CINAC endemic
regions despite parquet had been banned in 2010 in Sri Lanka. Similar association between 
CKD and pesticide usage is previously reported. In 2015 Lebov and colleagues have shown 
herbicides alachlor, atrazine, metolachlor, paraquat, and pendimethalin, and the insecticide 
permethrin are associated with end stage renal disease (ESRD) in USA among licensed
pesticide applicators.
Conclusions: Epidemiological and toxicological findings suggest CINAC is a toxic 
nephropathy associated with paraquat and glyphosate.
TH-PO1058 Poster Thursday
CKD: Epidemiology, Risk Factors, Prevention - I
Far from the “Hot Coast”: Prevalence of Mesoamerican Nephropathy 
(MeN) in a Cooler Mountain Community of Nicaragua
Stefano Bianchi, Filippo Cellai, Francesca Nistri, Andrea Grillo, Roberto Bigazzi. 
Medicine, ASLNordovest, UOC di Nefrologia e Dialisi, Livorno, Italy.
Background: MeN is an “epidemic” of chronic kidney disease (CKD) of unknown 
etiology, affecting populations of Nicaragua (N) and other pacifical coast regions wich are 
all caracterized by high temperature. Dehydration, volume depletion and heat stress are 
all risk factors for MeN commonly linked to strenuous work conditions during seasonal 
harvest. In a previous study, we have found an high prevalence of MeN (26,4%) in a general 
population (GP) sample of a costal city (Leon, N). The pecularity of our results has been a 
census based general population analysis, and not a selected group of subjects as reported 
in the majority of the previous studies published on this issue, mainly involving sugar cane 
agricoltural workers. The aim of the present study was to investigate MeN prevalence in the 
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general population of a city (Condega, N), which is located at 560 feet above sea level, very 
far from the pacific coast, with different mean temperatures (daily mean 22C° vs 30 C°of 
Leon) and farmer activities (mainly coffee).
Methods: Out of a GP population of 28.481 inhabitants, we ramdomly selected 1024 
subjects aged ≥ 18 years. The final sample of population we have studied counted 976 
subjects, mean age 41.84 ± 16.73; 457 males and 519 females. Blood and urine samples 
were collected to estimate glomerular filtration rate (eGFR-CDK-EPI, mL/min/1.73 m2) 
and urine albumin excretion (UAE, albumin mg/creatinine g).
Results: Among 976 participants to the study, 725 (74.28%; mean age 39.7; 358 males 
and 385 females) had normal eGFR; 251 (25.7 %; mean age 46.53; 106 males and 145 
females) manifested CKD (14.3 % stage 1, 16.7 % stage 2, 35.1% stage 3a, 12.4% stage 3b, 
10.8% stage 4, 10.4% stage 5). Out of 173 participants in stage 3-5 of CKD, 143 (82,7%) 
had UAE<30 mg/g, 23 (13,3%) had UAE>30 mg/g <300 mg/g and only 7 (4%) had UAE> 
300 mg/g
Conclusions: In Nicaragua, even far from the high temperatures of the pacific cost, 
the prevalence of MeN seems to be very high. The cause(s) of MeN remains still unknown. 
However, there is more than dehydration, volume depletion and heat stress.
Funding: Other NIH Support - Prevenzione, diagnosi precoce e cura dell'insufficienza 
Renale Cronica nel dipartimento di Leon. Fase 2. DGR 697 del 19/07/2016, PIR Decreto 
7722 del 05/06/2017
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eGFR, CKD Epidemiology in a Nicaraguan High Risk Area for  
Mesoamerican Nephropathy (MeN)
Antonino Sidoti,1,2 Martha Vargas,2 Maria José Sequeira Reyes,2 
Paolo Mazzacani.2 Consulta Nefrologica, Fundación Coen, Chinandega, 
Nicaragua 1Nephrology Unit Poggibonsi (Si) Italy, Pisa, Italy; 2Fundacion 
Coen, Chinandega, Nicaragua.
Background: MeN is linked with field working at sea level (mainly sugarcane) CKD 
and death in young age. Chinandega department has the two biggest sugarcane country 
plantations in El Viejo and Chichigalpa, CKD prevalence figures and etiology are unknown. 
On 2017 we enrolled age 12-22 people for a three years study to detect CKD precociously, 
assess CKD prevalence and risk factors, facilitate nephrological medical consult.
Methods: Population is 51746, by double randomization sampling 1202 record were 
completed. Plasma creatinine, blood pressure (BP), weight, height were measured; a 
questionnaire on occupation, water source, medical history, use of nSAID was administered. 
eGFR<60ml/min’ was diagnostic for CKD with Schwartz bedside for children and CKD-
EPI for adults (Schw_CKD_EPI). eGFR via combined full age spectrum formula (FAS) for 
children and CKD-EPI for adults (FAS_CKD_EPI) was calculated to choose the best suited 
formula for longitudinal eGFR follow-up and to compare different communities (Pearson 
bivariate). Schw_CKD_EPI eGFR was used for continuous and quartiles variable analyses 
by Anova and χ squared testing respectively. CI by Jeffreys method.
Results: Schw_CKD_EPI was 101±21, CKD-EPI 121±14, FAS_CKD_EPI 118±18. 
Schwartz vs FAS r=-790, p<.001. CKD prevalence was 0.75% (CI 0.31-1.36). Three 
municipalities had cases: Corinto 0,67% (CI 0.12-3.6),Chichigalpa 0.78%(CI 0.22-2.8), 
El Viejo 0.73% (CI 0.28-1.5). There was no relationship between eGFR and previous 
and actual occupation, medical antecedent i.e.dengue n=133, leptospirosis n=6, recurrent 
urinary tract infections n=209, previous episodes of dehydration n=119, frequent tonsillitis 
n=542, chikungunya n=293, malaria n=36, water source, fluid intake, frequent use of nSAID 
n=408, BP. Three communities (LM, KI, MA) were at extremes for eGFR. Differences in 
eGFR were better discriminated (p<.05) with FAS_CKD_EPI than Schw_CKD_EPI (pNS): 
LM 127±20 vs 88±18, KI 110±19vs 105±18, MA 129±12 vs. 93±17 respectively.
Conclusions: CKD prevalence is very high, well above NHANES 2011-14 age 20-39 
(0.3%). No clues about causality come from our baseline data. In the subsequent years 
of study FAS_CKD_EPI use is advisable to focus geographical areas of investigation and 
health interventions, moreover its closeness with CKD-EPI values would help eGFR follow 
up from pediatric to adult age.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Identifying CKD of Unknown Etiology in Sri Lanka
Shuchi Anand,1 Maria E. Montez-Rath,2 Dinuka M. Adasooriya,3 
Neelakanthi V. Ratnatunga,4 Neeraja Kambham,1 Zeid Badurdeen,5 
Stephen L. Schensul,6 Penny Vlahos,7 Lali (Lalarukh) Haider,8 Vivek Bhalla,1 
Adeera Levin,9 Glenn M. Chertow,2 Nishantha Nanayakkara.3 1Stanford 
University, Palo Alto, CA; 2Stanford University School of Medicine, Palo Alto, 
CA; 3Teaching Hospital, Kandy, Bamunakotuwa, Sri Lanka; 4Faculty of 
Medicine university of Peradeniya Sri Lanka, Kandy, Sri Lanka; 5University of 
Peradeniya, Sri Lanka, Kandy, Sri Lanka; 6University of Connecticut School of 
Medicine, Farmington, CT; 7University of Connecticut, Groton, CT; 8University 
of CT Health Center, West Hartford, CT; 9St. Paul’s Hospital and University of 
British Columbia, Vancouver, BC, Canada.
Background: A kidney disease of unknown cause is common in Sri Lanka’s lowland 
region. No evidence exists to inform an approach to a non-invasive clinical diagnosis.
Methods: In a prospective study to determine whether non-invasive measures can 
identify CKDu, we surveyed 600 new patients coming to nephrology clinic in a hospital 
servicing endemic regions over one year. 87 underwent kidney biopsy; 43 (49%) had a 
pathology diagnosis of tubulointerstitial disease. Using logistic regression, we tested the 
association of nine pre-selected factors with likelihood of tubulointerstitial nephritis on 
biopsy. We used bootstrap validation to calculate the model validated AUC. We tested a 
Full model and five parsimonious models.
Results: AUC for the Full model to predict CKDu was 0.82. A parsimonious model 
with age, serum albumin, and urine dipstick for protein had an AUC of 0.84 and bootstrap 
calibration slope of 0.84 (Table 1); with PPV 82.9% and NPV 80.4%. Patients with diabetes 
or hypertension recommended for kidney biopsy did not experience lower odds of a CKDu 
diagnosis.
Conclusions: We developed a standardized approach relying on non-invasive measures 
to identify probable cases of CKDu in Sri Lanka. Such an approach can strengthen CKDu 
surveillance, geographic mapping and rigorous investigations into cause via case-control 
studies.
Funding: Clinical Revenue Support
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KIM-1 as an Early Biomarker of Kidney Injury in Agricultural  
Communities in Sri Lanka
Mariana Cardenas-Gonzalez,3,1 P. mangala C. De silva,5,7 Dilini V. Ekanayake,6 
Gayani T. Wanniarachchi,6 Nandita Srayoshi,10 Sudheera Jayasinghe,8 
Ediriweera patabandi S. Chandana,7 Channa Jayasumana,2 Sisira Siribaddana,9 
Venkata Sabbisetti,3 Joseph V. Bonventre.4 1Laboratory of Systems 
Pharmacology, Harvard Medical School, Boston, MA; 2Faculty of Medicine, 
Anuradhapura, Sri Lanka; 3Brigham and Women’s Hospital, Boston, MA; 
4Brigham and Women’s Hospital, Boston, MA; 5Harvard Medical School, 
Malden, MA; 6University of Ruhuna, Sri Lanka, Matara, Sri Lanka; 7Zoology, 
University of Ruhuna, Matara, Sri Lanka; 8University of Ruhuna, Galle, Sri 
Lanka; 9Faculty of Medicine, Rajarata University of Sri Lanka, Nugegoda, Sri 
Lanka; 10Harvard Institute of Medicine, Boston, MA.
Background: Chronic kidney disease of unknown etiology (CKDu) is common 
among agricultural communities in Sri Lanka (SL), with prevalence between 10–15%. 
No definitive causes for CKDu has been identified. Early detection through community 
screening is essential for estimating true prevalence and guiding preventive management.
Methods: Inhabitants of selected villages in SL who worked in rice, sugarcane or 
vegetables farming, and a village of fishermen were recruited (647, male 61%, mean age 
44.7 y). Estimated GFR, urine albumin, and KIM-1, were measured. Logistic regression 
analysis was used to determine the odds ratios for underlying kidney proximal tubule (PT) 
injury (urinary KIM>250 pg/mg creat).
Results: Kidney disease, defined by GFR<60 ml/min and/or albuminuria >300 mg/mg, 
was present in 9% of the population. KIM-1 negatively correlated with eGFR, positively 
correlated with urine albumin (r~0.2; p<0.01, for both). KIM-1 levels were elevated in 27% 
of the population who had no defined kidney disease, indicating that these subjects have 
underlying PT injury and may be more prone to developing CKD. KIM-1 levels were higher 
in farmers than in fishermen (151±75 vs 36±21 pg/mg; p=0.01). Among farmers, vegetable 
farmers had the highest levels (310±54 pg/mg; p<0.01). Wasgamuwa, an endemic CKDu 
rice farmer community, had the highest percentage of kidney disease (24%) and higher 
levels of KIM-1 when compared to Agunukolapallassa, a non-endemic CKDu rice farmer 
community (454±93 vs 50±20 pg/mg; p<0.01). Importantly, 62% of Wasgamuwa farmers 
had KIM-1 levels >250 pg/mg, indicating that a significant fraction of this population may 
have subclinical kidney injury. Farmers have ~5 times higher risk of having underlying 
PT injury than fishermen, independent of age, sex, diabetes and hypertension (OR 4.8, 
95%CI: 2.6 to 8.9; p<0.01). Among farmers, vegetable farmers were twice at risk of 
having underlying PT injury than sugarcane farmers, after adjusting for age, sex, diabetes, 
hypertension and farming duration (OR 2, 95%CI, 1.2 to 3.9; p=0.04).
Conclusions: KIM-1 is a potential biomarker for screening populations at risk for 
underlying kidney injury in endemic and non-endemic areas of CKDu in SL.
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Prevalence and Prognosis of CKD in Italy: The Role of Demographic Shift 
Towards Older Age Groups
Fiammetta Ravaglia,1 Giuseppe L. Spatoliatore,1 Alberto Rosati,1 
Paolo Francesconi.2 1USL Toscana Centro, Florence, Italy; 2Agenzia Regionale 
di Sanità Toscana, Florence, Italy.
Background: Prevalence of chronic kidney disease(CKD) stages 3-5 in Europe 
is variable(1.0-5.9%), but lower than in United States(US)(13%). In Italy, real-world 
data is uncertain as previous studies were limited by methodological sampling and 
lack of prognostic data. To address this issue, we designed a population study based on 
administrative data, including the elderly typically under-represented. Objectives:to 
estimate CKD 3-5 stages prevalence in the resident population of a Tuscan city health 
unit(Empoli ASL), with sub-analysis in diabetic and hypertensive patients;to calculate the 
relative risk(RR) of myocardial infarction, stroke, heart failure, peripheral artery disease 
and death;to standardize data on the whole regional population.
Methods: All individuals referring to Empoli ASL were reviewed through the 
Tuscany Regional Agency for Health database. Patients>45yrs with a serum creatinine 
determination(SCr) in 2011-2013 by isotopic dilution mass spectrometry to estimate GFR 
by CKD-EPI equation were included and stratified in CKD 3a, 3b, 4-5(Renal Replacement 
Therapy patients excluded). Crude and standardised prevalence by sex, age and comorbidity 
were recorded. RR of death and cardiovascular events was assessed by Multivariate Cox 
analysis(controls=GFR>60ml/min).
Results: Of the 238,873 Empoli residents, 79,277(78%) were>45yrs and performed 
at least one SCr. 9082(11.4%) had GFR<60ml/min and 686(0.87%) had GFR<30ml/min. 
Age and sex distribution of CKD 3-5 showed higher prevalence in females and older age(p 
<0.0001)(Tab1). eGFR<60ml/min prevalence in the standardized general population>45yrs 
was 10.5%: stage 3a=7.1%, 3b=2.6%, 4-5=0.8%. Prevalence increased with age, in 45-
74yrs group was 4.4%, in the group>85yrs: stage 3=36.5%, 4-5=4.1%(Fig1). RR of death 
and cardiovascular events in Tab2.
Conclusions: This is the first Italian study to evaluate CKD prevalence with a large 
sample (238,000 inhabitants, 6.2% Tuscany population). CKD prevalence in 45-74yrs in 
Tuscany resulted 4.4% (lower than US and among the lowest in Europe), however including 
age>45yrs it reached 10.5%, highlighting the higher prevalence in the elderly, associated 
with more age-related comorbidities. The comparison of CKD prevalence between Europe 
and US, usually based on age group 45-74yrs, underestimates the real prevalence in 
European countries.
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Determinants of Intraregional Differences in Renal Function in the 
Northern Netherlands: The Lifelines Cohort Study
Qingqing Cai, Louise H. Dekker, Stephan J. Bakker, Martin H. De Borst, 
Gerjan Navis. University Medical Center Groningen, Groningen, Netherlands.
Background: Although interregional disparity in CKD prevalence has been reported 
globally, it is unclear which factors drive renal function clustering within regions. We 
studied the intraregional distribution of renal function in the Northern Netherlands and 
identified factors associated with its geographic variability.
Methods: We included 130,545 participants in LifeLines, a prospective population-
based cohort in the Northern Netherlands. Spatial analysis was performed to identify spatial 
clusters of eGFR (CKD-EPI), and multivariable logistic regression was used to identify 
demographic, clinical and environmental factors associated with 99% confidence hot vs 
cold spot clusters.
Results: Significant spatial clustering of high (hot spot) and low (cold spot) eGFR was 
found independent of age, sex and BSA (Figure). Participants in cold spot area had lower 
eGFR (95.47±15.50 vs. 98.47±14.61 ml/min/1.73 m2) and lower 24h creatinine clearance 
(126.75±35.48 vs. 130.94±33.72 ml/min) compared to those in hot spot area (p<0.05). In 
multivariable logistic regression, blood pressure (OR for being in cold spot: 1.01 [95% 
CI 1.00-1.01]), BMI (1.03[1.03-1.04]), serum potassium (0.38[0.34-0.43]), diuretics 
use (0.73[0.60-0.90]), education level (1.10[1.05-1.15]) and urbanity (2.77[2.66-2.88]) 
were all independently associated with spatial distribution of renal function (model 
R2=0.301). Subanalysis in 6,535 individuals showed that PM10 (3.67[3.07-4.39]), PM2.5 
(5.02[3.90-6.47]), NO2 (1.11[1.07-1.15]) were independently associated with renal function 
distribution, respectively.
Conclusions: Intraregional clustering of renal function was observed in the Northern 
Netherlands; determinants included blood pressure, BMI, serum potassium, diuretics use, 
education level, urbanity, and air pollution.
Funding: Government Support - Non-U.S.
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Incidence of CKD Stages 1-5 in Iceland
Arnar J. Jonsson,2,3 Sigrun H. Lund,1 Runolfur Palsson,2,1 Olafur S. Indridason.2 
1University of Iceland, Reykjavík, Iceland; 2Landspitali - The National University 
Hospital of Iceland, Reykjavik, Iceland; 3University of Iceland, Reykjavik, 
Iceland.
Background: Chronic kidney disease (CKD) is a major public health problem with a 
prevalence in the range of 5-10%, but its incidence is less clear due to lack of longitudinal 
data. The aim of this study was to estimate the incidence of CKD stages 1-5 based on serum 
creatinine (SCr) measurements, albuminuria and other markers of kidney damage.
Methods: In this retrospective study from 2008 to 2016, we obtained all standardized 
SCr and urine protein measurements from every clinical laboratory in Iceland. Information 
on age, sex, kidney-specific diagnoses and co-morbid conditions were also retrieved from 
nationwide electronic medical records. eGFR was calculated from SCr using the CKD-EPI 
equation. Incidence of CKD was defined as presence of kidney damage or eGFR <60 mL/
min/1.73m2 for more than 3 months, in individuals without CKD at study entry. Kidney 
damage was defined as albuminuria or presence of kidney-specific diagnoses including 
glomerular diseases and structural kidney abnormalities. CKD was staged according to the 
KDOQI guidelines. Incidence rates were standardized to the EU27 population.
Results: We obtained 2,049,482 SCr values for 213,011 individuals. The median 
(range) age was 63 (18–109) years; 47% were men. A total of 205,484 did not have evidence 
of CKD upon study entry, of whom 21,160 developed CKD during the study period. The 
annual age-standardized incidence of CKD 1–5 per 100,000 was 1,023 in men and 1,323 
in women. The annual age-standardized incidence of CKD per 100,000 in men was 117 for 
stage 1, 153 for stage 2, 514 for stage 3A, 184 for stage 3B, 58 for stage 4 and 16 for stage 5 
CKD. In women, the age-standardized incidence of CKD per 100,000 was 198 for stage 1, 
141 for stage 2, 678 for stage 3A, 247 for stage 3B, 63 for stage 4 and 12 for stage 5 CKD.
Conclusions: This nationwide Icelandic study comprising SCr values and other 
markers of kidney damage from the majority of the Icelandic population indicates a CKD 
incidence of approximately 1% per year, although slightly higher in women than men.
Funding: Government Support - Non-U.S.
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Association Between CKD and Socioeconomic Status: The Korea National 
Health and Nutrition Examination Survey 2010-2015
Subin Hwang,1 Kyung Don Yoo,2 Hyo Jin Kim,2 Ji In Park,3 Ho seok Koo.1 
1Department of Internal medicine, Inje University Seoul Paik Hospital, Inje 
University School of Medicine, Seoul, Republic of Korea; 2Division of 
Nephrology, Department of Internal Medicine, Dongguk University College of 
Medicine, Gyeongju, Republic of Korea; 3Department of Internal Medicine, 
Kangwon National University Hospital, Chuncheon, Republic of Korea.
Background: The prevalence of chronic kidney disease (CKD) has been increasing. 
CKD affects in the patients’ aspects regarding economic, social and emotional status. 
However, few recent studies dissecting the socioeconomic characteristics focused on CKD 
patients. We examined associations of CKD with annual income levels, education, smoking 
and alcohol consumption status, and emotional status independent of age and sex.
CKD: Epidemiology, Risk Factors, Prevention - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
397
J Am Soc Nephrol 29: 2018 Poster/Thursday
Methods: We performed a cross-sectional study of 23,701 participants with CKD, 
using data from the Korea National Health and Nutrition Examination Survey (KNHANES), 
obtained from 2010 to 2015. CKD was defined as dipstick positive proteinuria or estimated 
glomerular filtration rate<60mL/min/1.73m2. The same number of participants was 
propensity score matched by age and sex (each group n=1,952). Clinical and socioeconomic 
characteristics of two groups were analyzed.
Results: For participants with CKD versus without CKD, the estimated prevalence of 
hypertension and diabetes was 41.8% versus 32.4% and 24.3% versus 13.6%, respectively 
(each P<0.001); from the lowest to the highest, the income quartiles were 26.1%, 24.7%, 
25.2%, 24.0% versus 22.6% 24.4% 26.0%, 27.0%, respectively (P=0.038). The Education 
level was lower in patients with CKD than in normal subjects. There were more irregular 
workers in the CKD group. In CKD group, current smoker was higher than non CKD 
group (26.8% versus 21.8%, P<0.001) but case with no history of alcohol drinking in the 
past year was also higher (28.3% versus 20.6%, P<0.001). Depressive symptoms for two 
consecutive weeks and suicidal ideation were higher in CKD group (12.2% versus 8.8%, 
P<0.001; 9.8% versus 7.2%, P<0.001, respectively). In logistic regression, the risk of CKD 
was 1.21 (95% CI 1.00-1.46, P=0.393) in lowest quartile of income group, 1.25 (95% CI 
1.00-1.56, P=0.049) and 1.11 (95% CI 0.84-1.46, P=0.453), respectively, in the order of 
the quartiles based on the highest group. After adjusting, the risk of CKD was 1.17 (95% 
CI 0.97-1.42, P=0.085), 1.24 (95% CI 0.99-1.57, P=0.059) and 1.19 (95% CI 0.89-1.57, 
P=0.226), respectively.
Conclusions: Patients with CKD are associated with other chronic disease, low annual 
income, low education level, irregular workers, high smoking rate, and depressive mood 
contributing substantially to the burden for CKD.
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Recent Prevalence and Characteristic of CKD Including Diabetic Kidney 
Disease Among Participants of Nationwide Health Check Program in 
Japan
Koichi Asahi,1 Kei Nagai,2 Ryouya Tsunoda,2 Kazuhiko Tsuruya,3 
Kunitoshi Iseki,4 Kunihiro Yamagata.2 1Department of Chronic Kidney Disease 
Initiatives, Fukushima Medical University, Fukushima, Japan; 2Department of 
Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; 
3Department of Nephrology, Nara Medical University, Kashihara, Japan; 
4Nakamura Clinic, Urasoe, Japan.
Background: Diabetic kidney disease (DKD) is most important target of intervention 
for improvement of outcome of chronic kidney disease (CKD). Recent prevalence and 
characteristic of CKD including DKD among a Japanese general population are not fully 
elucidated.
Methods: Subjects were residents from 27 of the 47 prefectures in Japan who enrolled in 
national health insurance and participated in annual health check program including a CKD 
screening in 2015 (n=1,059,888; age, 40-74 years; male, 42.8%; diabetics [HbA1c≥6.5% 
or undergoing pharmacotherapy for diabetes], 12.3%). CKD was defined as estimated 
glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or dipstick albuminuria ≥1+. CKD 
comorbid with diabetics was regarded as DKD. Cross-sectional analysis of the distribution 
of GFR (G) and albuminuria (A) categories by sex/age group among participants were 
performed. (A1: <1+, A2: 1+, A3: ≥2+ by dipstick)
Results: The distribution of each G and A categories are summarized in Table. Thus, 
in this screened population, the crude prevalence of CKD was 19.7%, and those with 
reduced renal function classified between G3-5 accounted for 16.6%. Among diabetics, the 
crude prevalence of CKD was 27.7% and was higher than in non-diabetics across all age 
groups with tendency that became noteworthy in younger population. (Figure 1) As for the 
distribution of G and A category among DKD, G3a and A1 were most prevalent in the age 
groups ≥65 years. (Figure 2)
Conclusions: Recent prevalence of G3-5 might slightly increase compared with similar 
cross-sectional analysis in 2008 (Iseki K, et al. Clin Exp Nephrol 16: 244-249, 2012). The 
overwhelming majority of aged DKD remain mild to moderate renal dysfunction without 
albuminuria. Therefore, it is important for screened DKD that strategic allocation of health 
resources according to age and individual risk would be established.
Funding: Government Support - Non-U.S.
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Prevalence of CKD in the Punjab, Northern India: A Comparison with the 
United States
Jennifer L. Bragg-Gresham,1 Jarnail S. Thakur,2 Sanjay Jain,3 
Subramaniam Pennathur,1 Rajiv Saran.1 1University of Michigan, Ann Arbor, 
MI; 2PGIMER, Chandigarh, Chadigarh, India; 3PGIMER, Chandigarh, India.
Background: India is witnessing a disturbing growth in non-communicable diseases 
(NCDs), including CKD. Recently, a WHO STEPS survey was conducted in the state of 
Punjab in northern India to collect data from the adult population on NCD risk factors 
(2014-2015). We sought to compare the prevalence of CKD and its risk factors between this 
large state in northern India and the US.
Methods: Data from 1,928 participants in the Punjab survey and 5,588 in the US 
(National Health and Nutrition Examination Survey- NHANES, 2013-2014) with complete 
information on estimated glomerular filtration rate and albuminuria were examined. Both 
regions used multi-stage stratified sampling designs to collect data representative of the 
general population. All analyses used sampling weights.
Results: The average age in the Punjab sample of adults (age 20 years+) was 
significantly lower than the US (39.2 vs. 47.5 years, p<0.0001) and had a higher proportion 
of males (57.8% vs. 48.1%, p<0.0001). The US had a much higher percentage of high 
school or higher education and private health insurance coverage (p<0.0001). In the US 
body size was much larger in terms of height, weight, BMI, and waist circumference. While 
smoking and obesity were higher in the US, diabetes and hypertension were much more 
common in Punjab (39.6% vs. 10.7% and 49.5% vs. 39.8%, respectively, p<0.0001). No 
differences were seen in the prevalence of cardiovascular disease or triglyceride levels, 
although the US had higher total cholesterol. Significant differences were seen in the 
prevalence of CKD markers, with lower prevalence of eGFR < 60 ml/min/1.73m2, but 
markedly higher albuminuria (see Table).
Conclusions: We report a strikingly high prevalence of albuminuria in the Punjab (with 
well over a third of the adult population being affected!), and much higher prevalence of 
both DM and HT compared with the US. In contrast, the prevalence of eGFR <60 was 
relatively low. These findings need to be further confirmed, and if true have enormous 
public health and resource implications for a low-middle income country such as India, 
specifically in the realm of CKD, cardiovascular disease and other NCDs.
TH-PO1068 Poster Thursday
CKD: Epidemiology, Risk Factors, Prevention - I
Targeted Screening for Albuminuria in Diabetes Mellitus: A Strategy 
Worth Revisiting?
Jennifer L. Bragg-Gresham,1 Brenda W. Gillespie,1 William H. Herman,1 
Neil R. Powe,2 Tanushree Banerjee,3 Jessica L. Harding,4 Sharon Saydah,4 
Rajiv Saran.1 1University of Michigan, Ann Arbor, MI; 2Priscilla Chan and Mark 
Zuckerberg San Francisco Gen Hosp & UCSF, San Francisco, CA; 3San 
Francisco General Hospital, San Francisco, CA; 4Centers for Disease Control 
and Prevention, Atlanta, GA.
Background: Albuminuria is a risk factor for cardiovascular disease (CVD), kidney 
disease and their progression. Current guidelines recommend screening all people with 
diabetes (DM) for albuminuria to identify those at greatest risk. However, only 40% of 
DM patients currently receive albuminuria screening. We assessed patient characteristics 
associated with albuminuria in people with DM.
Methods: Associations between individual characteristics (self-reported and 
biometric) and albuminuria (albumin-to-creatinine ratio of ≥30 mg/g) were assessed 
among 4,222 individuals with DM (self-reported, or HbA1c > 7%), aged 20+ years, from 
the National Health and Nutrition Examination Survey (1999-2014), using multivariable 
survey-weighted logistic regression. We assessed model predictive ability using Harrell’s 
c-statistic.
Results: Mean age was 59 (range 20-85+) years and the prevalence of albuminuria was
30.3% (95% CI: 28.7-31.8%). Significant predictors of albuminuria are shown in the Table 
below (c-statistic = 0.67, indicating moderate prediction of albuminuria).
Conclusions: In this study several self-reported and biometric characteristics were 
independently associated with albuminuria and collectively, moderately predictive of 
albuminuria. Targeted screening of people with DM at high risk for albuminuria may 
improve albuminuria detection and in turn, may help with prevention or management of 
CVD and kidney disease.
Funding: Other U.S. Government Support
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Adjusted odds ratios and 95% confidence intervals for the association between 
characteristics and albuminuria in people with diabetes
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Population Estimates of Predicted Risk of Kidney Failure Among 
Individuals with Hypertension in Rural Bangladesh, Pakistan, and Sri 
Lanka - Health Systems Perspective
Liang Feng, Tazeen H. Jafar. Duke-NUS Medical School, Singapore, Singapore.
Background: South Asia is suffering an increasing burden of hypertension, chronic 
kidney disease (CKD) and end-stage kidney disease (ESKD). We estimated the proportion 
and number of individuals aged≥40 years with hypertension and CKD carrying a high risk 
for ESKD in rural Bangladesh, Pakistan, and Sri Lanka.
Methods: We analyzed baseline data from ongoing Control of Blood Pressure and 
Risk Attenuation (COBRA) study on 2643 hypertensives aged≥40 years recruited via door-
to-door sampling in 30 rural communities in Bangladesh, Pakistan, and Sri Lanka. Serum 
creatinine was measured, and CKD-EPI eGFR was computed. Predicted risk of kidney 
failure at five years was computed using 4-variable (age, sex, albuminuria, eGFR) Kidney 
Failure Risk Equation (KFRE) in hypertensives with CKD Stage 3 or worse (eGFR <60 ml/
min/1.73 m2). Country-level population statistics from 2016 World Bank Data were used to 
project population estimates of these conditions.
Results: See attached table
Conclusions: There is a high burden of CKD progressive to ESKD in hypertensive 
individuals in rural South Asia. There is noticeable cross-country heterogeneity in the 
proportion and number of hypertensive individuals with CKD Stage 3 or worse (highest in 
Sri Lanka), proportion at high risk of ESKD (highest in Pakistan), and the absolute number 
at high risk of ESKD (highest in Bangladesh). Countries in South Asia, need immediate 
public health measures to prevent onset and progression of CKD including establishing 
timely referrals to nephrologists, and accessible renal replacement therapy programs. 
Limitations: KFRE has not been validated for use in South Asian rural health systems. Our 
population estimates of CKD are limited to individuals with hypertension.
Funding: Government Support - Non-U.S.
Hypertensive individuals with chronic kidney disease(CKD) at high risk for end-stage 
kidney failure (ESKD) in rural communities in Bangladesh, Pakistan and Sri Lanka
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CKD and At-Risk of CKD Registry: CURE-CKD
Radica Z. Alicic. Providence Medical Research Center, Spokane, WA.
Background: Most healthcare systems have not been proactively prepared to identify 
patients with or at-risk of chronic kidney disesase (CKD) to improve care and clinical 
outcomes. The aim of this study was to classify and describe these patients in two large 
healthcare systems.
Methods: PSJH and UCLA healthcare systems collaboratively formed a registry 
(CURE-CKD) from their respective electronic health records (EHR). Participants were 
identified by a diagnosis of CKD or at-risk of CKD (diabetes, hypertension, pre-diabetes) 
by ICD-9/10 codes, guideline-based clinical criteria, and medication specific to a particular 
condition from the years 2006-2016.
Results: CURE-CKD includes 2,401,403 individuals. The table shows baseline 
characteristics by CKD (N=554,051) and at-risk of CKD (N=1,847,352) groups.
Conclusions: Real world, practice-based evidence can be used to classify patients as 
a platform for strategies to prevent CKD progression and complications as well as incident 
CKD.
Funding: Private Foundation Support
*diabetes, hypertension and/or pre-diabetes are not mutually exclusive conditions,
**identified by ICD code without CKD stage
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Baclofen Usage in Patients with Diminished Kidney Function
Alia Hasan,1 Kenar D. Jhaveri,1 Matthew A. Sparks,2 John K. Roberts,2 
Niraj R. Kothari,2 Jamil Ibrahim,1 Melissa Makar,2 Syed M. Zaidi,3 Joel Boggan,4 
Jamie S. Hirsch.1 1Nephrology, Zucker School of Medicine at Hofstra/Northwell, 
GREAT NECK, NY; 2Duke University and Durham VA Medical Centers, 
Durham, NC; 3Medical University of the Americas, Briarwood, NY; 4Durham 
VA Medical Center, Durham, NC.
Background: Baclofen, a muscle relaxant, is primarily excreted via the kidneys. As 
per pharmacy dosing guidelines, it is contraindicated in paients with eGFR <30cc/min and 
on dialysis.
Methods: We examined all orders in 2017 for baclofen across 15 hospitals in two 
large health systems. For each order, we determined the dose and frequency ordered and 
whether a dose was actually administered. Renal function was determined using the CKD-
EPI equation based upon the most proximate serum creatinine at the time of the baclofen 
order. Presence of dialysis was based upon any order for HD or PD placed during the same 
visit within 7 days prior to baclofen order. The physician notes were then reviewed from 
the start date of baclofen administration- 2 days after it was discontinued to see if any new 
neurological symptoms arose (headache, dizziness, weakness, nausea, vomiting, seizures, 
lethargy, hallucinations, agitation)
Results: Over 2652 unique orders were placed for baclofen in one health system 
informatics records. 131 orders were in patients with eGFR <30cc/min (4.9%), 93 (71%) 
resulted in at least one dose administered to the patient. Similar baclofen usage was seen 
at second institution with 1182 inpatient unique orders with 95 occurring in patients with 
eGFR <30cc/min (8%). 86% of the orders were NOT PRN orders, while remaining were 
PRN orders. Muscle spasms and hiccups were the indications for PRN orders. 46% of the 
patients- females; 58% -white vs 18% AA; 20% patients were ESKD on dialysis; 8% were 
incident dialysis patients (required initiation of HD this admission). Most baclofen orders 
were written by internal medicine (84%) services followed by surgical (7%) and others 
(4%). 80% of the orders were written by either attendings (50%) or residents (50%), and 
the remaining 20% by NP/PAs. 42% of the orders led to neurological symptoms findings.
Conclusions: Baclofen was ordered in 5-8% of patients with significantly impaired 
kidney function. Most baclofen orders were standing medications rather than PRN, and 
were ordered at high doses, increasing the toxicity risk. A significant percentage of the 
orders were written by internal medicine physicians. This study highlights the need for an 
urgent education of renal clearance of several medications such as baclofen to prescribing 
staff & pharmacists.
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The Burden of Polypharmacy in Patients with CKD: The GCKD Study
Insa M. Schmidt,2 Silvia Huebner,6 Jennifer Nadal,10 Stephanie I. Titze,13 
Matthias Schmid,11 Barbara Bärthlein,8 Georg Schlieper,12 Thomas Dienemann,11 
Ulla T. Schultheiss,1 Heike Meiselbach,7 Anna Kottgen,1 Jürgen Floege,3 
Martin Busch,5 Reinhold Kreutz,9 Jan T. Kielstein,4 Kai-Uwe Eckardt.2 1Medical 
Center - University of Freiburg, Freiburg, Germany; 2University Medicine-
Charite, Berlin, Germany; 3RWTH University of Aachen, Aachen, Germany; 
4Academic Teaching Hospital Braunschweig, Braunschweig, Germany; 
5University Hospital Jena, Jena, Germany; 6University Erlangen, Nuremberg, 
Germany; 7Nephrology and Hypertension, Erlangen, Germany; 8Medical 
Centre for Information and Communication Technology (MIK), University 
Hospital Erlangen, Erlangen, Germany; 9Charite-University Medicine Berlin, 
Berlin, Germany; 10IMBIE, Bonn, Germany; 11University of Erlangen-
Nuremberg, Erlangen, Germany; 12MVZ DaVita Karlstraße, Duesseldorf, 
Germany; 13KBV, Berlin, Germany.
Background: Patients with chronic kidney disease (CKD) bear a substantial burden 
of comorbidities leading to the prescription of multiple medications. However, data on 
medication use patterns in this population is scarce. This study uses data of a longitudinal, 
multicentre study in CKD patients to evaluate drug use trajectories as well as the prevalence 
of polypharmacy and its associated risk factors over 4 years of observation.
Methods: We analyzed data of 5217 patients aged 18– 74 years with an estimated 
glomerular filtration rate (eGFR) between 30–60 ml/min/1.73m^2 or an eGFR ≥60 and 
overt proteinuria (>500 mg/d) who participated in the German Chronic Kidney Disease 
(GCKD) study. Self-reported data on current medication use assessed at baseline (2010-
2012) and after 4 years of follow-up were used for this analysis. Prevalence and risk factors 
associated with polypharmacy (defined as the use of ≥5 drugs/d) as well as initiation or 
termination of polypharmacy were evaluated using multivariable logistic regression.
Results: The prevalence of polypharmacy at baseline and follow-up was almost 80 % 
and ranged from 62 % in patients with eGFR >90 ml/min/1.73m^2 to 86 % in those with 
eGFR 30–45 ml/min/1.73m^2. Patients took on average 7 medications per day (range 0-20), 
most frequently beta blockers, ACE-inhibitors and statins. In multivariate analysis, female 
sex and a lower educational level were independently associated with polypharmacy. 
Increasing CKD stage, age and BMI as well as diabetes mellitus, cardiovascular disease 
and a history of smoking were significantly associated with both, the prevalence of 
polypharmacy and the maintenance of polypharmacy over time. Comorbid diabetes 
mellitus was a significant risk factor for the initiation of polypharmacy in CKD patients 
(OR 2.46, p=0.003).
Conclusions: This study highlights the medication burden in CKD patients and 
strongly suggests that further research is needed to address the risks of polypharmacy in 
this vulnerable population.
Funding: Government Support - Non-U.S.
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Opiate and Non-Opiate Analgesic Use and Mortality Among CKD 
Patients Transitioning to Dialysis
Amy S. You,1 Elani Streja,2 Vanessa A. Ravel,3 John J. Sim,7 Yoshitsugu Obi,1 
Danh V. Nguyen,1 Csaba P. Kovesdy,4 Kamyar Kalantar-Zadeh,5 Connie Rhee.6 
1University of California, Irvine, Orange, CA; 2Harold Simmons Center for 
Kidney Disease Research and Epidemiology, Orange, CA; 3Harold Simmons 
Center, University of California at Irvine, Orange, CA; 4University of Tennessee 
Health Science Center, Memphis, TN; 5University of California Irvine, School of 
Medicine, Orange, CA; 6University of California Irvine, Huntington Beach, CA; 
7Kaiser Permanente Southern California, Los Angeles, CA.
Background: Population based studies show there is a high prevalence of chronic 
kidney disease (CKD) patients suffering from chronic pain. While opiates are frequently 
prescribed as analgesics, there may be toxic accumulation of metabolites, particularly 
among those with non-dialysis dependent CKD (NDD-CKD) progressing to end-stage 
renal disease (ESRD). We thus sought to examine the association of opiate vs. non-opiate 
analgesic use during the pre-ESRD (prelude) period with post-ESRD mortality risk among 
NDD-CKD patients transitioning to dialysis.
Methods: We examined a national cohort of US veterans with NDD-CKD who 
transitioned to dialysis over 2007-14. Among patients who had receipt of prescriptions in 
the Veterans Affairs (VA) Healthcare System within one year of transitioning to dialysis, 
we examined the association of pre-ESRD analgesic use (opiate analgesic, non-opiate 
analgesic, vs. no analgesic use) with post-ESRD all-cause mortality risk using adjusted 
Cox models.
Results: Among 57,764 patients who met eligibility criteria, pre-ESRD opiate use was 
associated with higher post-ESRD mortality risk (ref: no analgesic use), whereas non-opiate 
analgesic use was not associated with higher death risk in expanded case-mix adjusted 
analyses: HRs (95%CIs) 1.11 (1.08-1.13) and 1.01 (0.98-1.04), respectively. In sensitivity 
analyses, increasing frequency of opiate prescription in the one-year prelude period was 
associated with higher post-ESRD mortality risk: (ref: no analgesic use): HRs (95%CIs) 
0.99 (0.95-1.02), 1.12 (1.06-1.18), 1.15 (1.07-1.23), 1.20 (1.10-1.31), and 1.31 (1.25-1.37) 
for 1, 2, 3, 4, and ≥5 prescriptions, respectively.
Conclusions: In NDD-CKD patients transitioning to dialysis, more frequent pre-ESRD 
opiate use was associated with higher post-ESRD death risk, whereas non-opiate analgesic 
use was not associated with higher mortality. Further studies are needed to identify non-
opiate based interventions for pain management in this population.
Funding: NIDDK Support
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Polypharmacy in Older Patients Developing Advanced CKD in 6 
European Countries: Results from the EQUAL Study
Samantha J. Hayward,1 Barnaby D. Hole,3,1 Rachel Denholm,3 Polly R. Duncan,3 
Simon D. Fraser,2 James E. Morris,2 Rupert A. Payne,3 Paul J. Roderick,2 
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Kitty J. Jager,5 Fergus J. Caskey.1,3 On behalf of the EQUAL Study investigators 
1North Bristol NHS Trust, Bristol, United Kingdom; 2University of Southampton, 
UK, Southampton, United Kingdom; 3University of Bristol, Bristol, United 
Kingdom; 4University Hospital, Wuerzburg, Germany; 5Academic Medical 
Center, Amsterdam, Netherlands; 6Leiden University Medical Center, Leiden, 
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Melacrino-Morelli, Reggio Calabria, Italy.
Background: Polypharmacy is increasing in the general population. We aimed to 
describe associations with the number of prescribed medications to identify patients who 
are most likely to experience polypharmacy.
Methods: The EQUAL Study follows patients aged 65+ years from 6 European 
countries whose eGFR dropped to ≤20 ml/min/1.73m2 for the first time. Demographic, 
clinical and medication data were collected at baseline. Univariable and multivariable 
linear regression were used to determine the association between baseline factors (age, sex, 
education, eGFR, comorbidity and country) and number of medications.
Results: Recruited patients (n=1647) had a mean age of 76.4 years (SD 6.7) and 65.2% 
were male. Multimorbidity was common; the mean Charlson Comorbidity Index (CCI) was 
7 (SD 1.9). The mean number of medications was 8 (SD 3.6, range 0-21) and 75% of patients 
were on >5 medications. In the univariable analysis, all age groups except >85 years were 
on more medications than the reference group (65-70 years). Each additional CCI point was 
associated with 0.48 additional medication (p<0.001). As education attainment increased, 
people were on fewer medications. German patients were on 1.72 additional medications 
and Swedish patients were on 3.68 fewer medications when compared to the UK (both 
p<0.001). Sex and eGFR had no association with number of medications. After adjusting 
for country, education and CCI, the number of medications was only associated with age 
in the most elderly group. Those >85 years were on 1.41 fewer medications compared to 
those aged 65-70, table 1.
Conclusions: Polypharmacy was common amongst EQUAL recruits, but the 
relationship with age is complex. Unlike the general population where polypharmacy 
increases even to the oldest age groups, the oldest EQUAL recruits were on fewer 
medications. This contrast may reflect de-prescribing.
Table 1. Linear regression of number of medications by age group
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Assessing Baseline Medication Use in CKD: An Analysis of the 
SHARP-ER Study
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Background: Medication use of patients with CKD in Australia is accepted as high, 
but systematic, national data has not been available. The Pharmaceutical Benefits Scheme 
(PBS), a national program providing medication subsidies in Australia, offers a novel 
means of medication use pattern assessment in CKD based on routinely collected data. We 
assessed baseline medication use in CKD patients of the SHARP-ER study using PBS data.
Methods: Australian participants from the SHARP-ER study, a 5-year post-trial 
(2010-2015) extended follow-up of SHARP participants known to be alive at the end of 
the trial (study of cholesterol-lowering in CKD) in Australia, New Zealand and Malaysia, 
were linked to the PBS. Prescription medication dispensation in the year prior to SHARP-
ER baseline, defined as the first study visit which occurred 1.5-2 years following the final 
SHARP visit, were obtained. We examined medication use (receipt of ≥1 prescription) from 
any of the following medication groups: cardioprotective (blood pressure-lowering, lipid-
lowering, glucose-lowering, anticoagulant, antiplatelet, anaemia treatment), anti-infective, 
immunosuppressant, proton pump inhibitor (PPI) treatment and others.
Results: Of 304 participants, 86 (28.3%) were on maintenance dialysis at baseline. 
Overall, there were 11,272 unique prescriptions dispensed in the year prior to baseline which 
included those for cardioprotective (58.4%), anti-infective (9.6%), immunosuppressive 
(7.6%), PPI (12.6%) treatment and others (11.6%). On average, patients were prescribed 6 
different medications (IQR:4-8). The distributions of medication use across the medication 
groups in the 304 participants were: 92.8%, 68.4%. 25.3%, 53.3% and 54.3%, respectively. 
The proportion of patients receiving ≥3 medication groups was significantly higher among 
those on dialysis (76.7% vs. 64.7%;p=0.04) compared with non-dialysis CKD patients.
Conclusions: PBS data in patients with moderate-to-severe CKD suggests a high 
medication burden primarily directed at cardiovascular risk mitigation. Further longitudinal 
assessments of cardioprotective and anti-infective medication use according to patient 
characteristics are needed.
Funding: Government Support - Non-U.S.
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Retrospective Cohort Study
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Background: Sleeping disorder has long been connected with chronic kidney 
disease (CKD). But the correlation between sleeping pills and CKD has not been in-depth 
exploration. This study aimed to evaluate the potential harm of sleeping pills on the risk for 
CKD and CKD progression to dialysis-requiring end-stage renal disease (ESRD).
Methods: In a population-based cohort study of 204,176 sleeping pill users within 
989,753 individuals, after exclusion criteria (those with sleeping pills use less than 3 
months, with acute kidney injury, CKD and ESRD diagnosis before sleeping pills use, 
with obstructive sleep apnea and non-apnea sleep disorder, with age less than 18 years 
and gender unkown), a total of 183,321 sleeping pills users were compared to 366,642 
individuals without sleeping pills use followed up for 13 years after been diagnosed as 
CKD (ICD-9-CM). Using propensity score matching, we analyzed the type of sleeping 
pills related to risk of CKD and CKD progression to ESRD by Cox proportional hazards 
regression with adjustment for sex, age, and comorbidities.
Results: Sleeping pills use was associated with increased risk for CKD after adjusting 
underlying comorbidities (aHR 2.002, 95% CI 1.790-2.333, p <0.001). Despite high social 
economic status (insured premium more than 35,000 Taiwanese dollars) and those with 
hyperlipidemia, those with sleeping pills use among most comorbidities are correlated with 
risk of CKD. Persistent use of sleeping pills after CKD also increased the risk of concurrent 
ESRD (aHR 7.981, 95% CI 5.117-10.986, p <0.001). After subgroup analyzing for sleeping 
pill use, flurazepam (p=0.198), lorazepam (p=0.051) and triazolam (p=0.125) are the drugs 
with no significance in correlation to CKD risk increasing.
Conclusions: Sleeping pills use was associated with increased risk of CKD and ESRD. 
Further studies are warranted to confirm these findings.
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The Economic Burden of CKD Progression Among Patients with and 
Without Major Adverse Cardiac Events (MACE) in the US
Tony Okoro,1 Yong Chen,1 Linda Casillas,1 Shan Zheng,1 Daniel C. Parks,1 
Csaba P. Kovesdy.2 1GlaxoSmithKline, Collegeville, PA; 2University of Tennessee 
Health Science Center, Memphis, TN.
Background: Little is known about the costs of CKD progression among patients with 
cardiovascular disease. The objective of this study was to assess the economic burden of 
CKD progression among CKD patients with and without MACE.
Methods: Optum claims data were used to identify patients with baseline non-dialysis 
dependent CKD (stages 3a, 3b, 4 and 5) in 2013 using estimated glomerular filtration rate 
(eGFR) based on the Kidney Disease Outcomes Quality Initiative (KDOQI) diagnosis 
criteria. Patients were followed through 6/30/2017 to assess CKD progression defined as 
worsening CKD stage from baseline. Annualized all-cause costs were assessed between 
patients with and without defined CKD stage progression and then stratified by the presence 
or absence of follow-up MACE.
Results: 57,597 CKD patients were identified in 2013, among which 35,975, 16,982, 
4,340 and 299 had CKD stages 3a, 3b, 4 and 5, respectively. Among those without MACE 
(n=47,004), mean annualized all-cause costs increased from stage 3a ($8,398) to 5 ($12,711) 
in those without stage progression and from stage3a ($12,062) to 5 ($79,093) in those 
with stage progression. Mean annualized all-cause costs among patients with ≥1 MACE 
(n=10,593) were from $35,924 for stage3a to $42,479 for stage5 without stage progression 
and from $40,687 (stage 3a) to $97,013 (stage 5) with stage progression. Overall, CKD 
progression costs for the entire cohort increased from stage3a ($6,010) to stage5 ($66,737) 
(P for trend < 0.001). The trends were consistent among those with and without MACE.
Conclusions: Progression of CKD increases the economic burden in patients regardless 
of MACE status but healthcare costs are higher in those with MACE compared to those 
without MACE. Preventing renal function decline could reduce economic burden seen in 
patients with advanced CKD stages and MACE.
Funding: Commercial Support - GlaxoSmithKline
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Prior Military Service Associated with CKD: Analysis of the Behavioral 
Risk Factor Surveillance System
Ian J. Stewart,1,2 Eduard Poltavskiy,1 Jeffrey T. Howard,3 Lauren Walker,1 
Jud C. Janak.3 1Clinical Investigation Facility, David Grant USAF Medical 
Center, Travis AFB, CA; 2Medicine, Uniformed Services University of the 
Health Sciences, Bethesda, MD; 3Department of Defense Joint Trauma System, 
Fort Sam Houston, TX.
Background: While military service is associated with health promoting and 
compromising factors, prior work shows that veterans report poorer overall health and 
higher prevalence of many health compromising behaviors compared to the civilian 
population. Although some evidence suggests that veterans may be at higher risk for 
cardiovascular disease, there is a paucity of evidence regarding other medical conditions, 
such as chronic kidney disease (CKD). We sought to determine if CKD is more common 
among veterans by analyzing data from the Centers for Disease Control and Prevention 
Behavioral Risk Factor Surveillance System (BRFSS).
Methods: We performed a cross-sectional study of BRFSS from 2011 to 2016. The 
presence of CKD and prior military service were determined by self-report. Standard 
statistics were used to compare demographic data and health behaviors between groups 
with and without prior military service. Weighted univariate and multivariable logistic 
regression analyses were performed to compare the odds of CKD development based on 
military status. A priori subgroup analyses stratified by race were also examined.
Results: Our search yielded a total of 2,861,628 subjects for analysis, 14.8% 
(n=369,844) of whom had prior military service. Individuals with prior service were 
more likely to have CKD (3.9% vs 2.6%; p<0.001). On univariate analysis, military 
service was associated with CKD development [odds ratio (OR) 1.55, 95% confidence 
interval (CI) 1.50-1.61; p<0.001). While attenuated, this difference remained significant 
in the multivariable model (OR 1.12, 95% CI 1.07-1.17; p<0.001). On analysis of racial 
subgroups, white subjects with prior military service were more likely to report CKD 
compared to those without prior military service (OR 1.15, 95% CI 1.09-1.21; p<0.001) in 
the multivariable model. No significant difference was observed in black (OR 1.07, 95% CI 
0.92-1.25; p=0.40) or Hispanic (OR 1.15, 95% CI 0.93-1.41; p=0.20) subjects.
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Conclusions: While differences seem to exist across racial strata, these results from a 
nationally representative sample support an association between prior military service and 
CKD. Further research is needed to determine why veterans are at a higher risk for CKD to 
guide treatment and prevention efforts.
Funding: Other U.S. Government Support
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Housing Insecurity and Risk of Kidney Disease in an Urban Population
Tessa K. Novick,3 Dingfen Han,3 Alan B. Zonderman,1 Michele K. Evans,2 
Deidra C. Crews.3 1Intramural Research Program, NIA, NIH, Baltimore, MD; 
2National Institutes of Health/National Institute on Aging, Baltimore, MD; 
3Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Housing insecurity is characterized by high housing costs or unsafe 
living conditions that prevent general self-care and threaten independence. It is associated 
with decreased healthcare access, and increased risk for chronic diseases and medical 
complications. The objective of this study was to examine the association between housing 
insecurity, incident chronic kidney disease (CKD) and rapid kidney function decline.
Methods: Data from the Healthy Aging in Neighborhoods of Diversity across the Life 
Span (HANDLS) study (Baltimore, MD) was used for this longitudinal analysis. Housing 
insecurity was defined as answering yes to the question, “Can you afford a suitable home?” 
at the HANDLS wave 3 visit. We used multivariable logistic regression to compare risk 
of rapid kidney function decline (loss of > 5ml/min/1.73m2 eGFR per year over a median 
of 3.5 years), incident reduced eGFR (< 60 ml/min/1.73m2) and incident albuminuria 
(albumin-creatinine ratio [ACR] > 30mg/g), between participants with and without housing 
insecurity.
Results: Of the 1354 HANDLS participants included, mean age was 48 years, 
40% were male and 57% were African American. A total of 443 (32.7%) were housing 
insecure. After a median of 3.5 years follow up, rapid kidney function decline, incident 
reduced eGFR and incident albuminuria occurred in 213 (15.7%), 68 (5.2%) and 80 (6.6%) 
participants respectively. After multivariable adjustment, housing insecurity was associated 
with increased odds of incident albuminuria but there were no statistically significant 
associations between housing insecurity and rapid kidney function decline or incident 
reduced kidney function (Table).
Conclusions: Housing insecurity was associated with increased risk for incident 
albuminuria in an urban population. The prevalence of housing insecurity among persons 
with CKD and its impact on kidney outcomes is worthy of further study.
Funding: Other NIH Support - National Institute on Aging
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Association Between Religiosity and Risk of End-Stage Kidney Disease 
(ESKD) Among Blacks and Whites in the Southeastern United States
Devika Nair,1 Kerri L. Cavanaugh,1 Ken Wallston,1 Aihua Bian,2 
Thomas G. Stewart,1 William J. Blot,1 Talat Alp Ikizler,1 Loren Lipworth.1 
1Vanderbilt University Medical Center, Nashville, TN; 2Vanderbilt University, 
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Background: Religiosity is associated with improved outcomes in chronic illnesses 
via healthy behaviors and is prevalent among blacks as a means to cope with health-related 
stress. No study of religiosity in kidney disease has examined its association with objective 
measures of physical health such as progression to ESKD.
Methods: The Southern Community Cohort Study is a large prospective cohort 
of low socioeconomic status blacks and whites in the southeastern U.S. Using a case-
cohort design, we examined the association between religiosity and ESKD among 737 
incident ESKD cases ascertained by USRDS linkage and a probability sampled subcohort 
(n=4,238). Religiosity was recorded at enrollment via three self-reported items: frequency 
of church service attendance; degree of spirituality; and degree of comfort from religion. 
We constructed Cox regression models, accounting for sampling weights, of time to ESKD 
in relation to each religiosity item, and adjusted for demographic, psychosocial (social 
support, depressive symptoms), and clinical variables (including diabetes, hypertension, 
estimated glomerular filtration rate). Interaction between each religiosity item and race was 
statistically significant (p<0.01).
Results: Overall, 24% of blacks, compared to 18% of whites, reported the highest 
frequency of service attendance (>once/week); 57% and 72% of blacks reported very high 
spirituality and high degree of comfort from religion, respectively, compared to 51% and 
56% of whites. Among blacks, hazard ratios (HR) and 95% confidence intervals (CI) for 
ESKD associated with the highest vs. lowest categories of service attendance, spirituality, 
and comfort from religion were 0.74 (0.57-0.97), 0.66 (0.54 to 0.80), and 0.23 (0.15-0.36), 
respectively. Among whites, the corresponding estimates were 0.28 (0.16-0.50), 1.08 (0.66-
1.77), and 1.11 (0.44-2.78).
Conclusions: Frequent attendance at religious services is associated with a decreased 
risk for ESKD among socioeconomically-disadvantaged black and white adults. Among 
blacks, spirituality and comfort from religion are also associated with decreased ESKD risk. 
Engaging blacks in faith-based community settings may be a culturally-relevant way to 
facilitate healthy behaviors to decrease kidney disease progression.
Funding: NIDDK Support
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CKD Self-Management in Older Adults
Sarah J. Schrauben,1 Julie A. Wright Nunes,9 Michael J. Fischer,2 
Anand Srivastava,3 Thida C. Tan,4 Ana C. Ricardo,5 James P. Lash,5 Myles Wolf,6 
Amanda H. Anderson,7 Jing Chen,8 Harold I. Feldman.7 1Department of Medicine, 
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2University of Illinois Hospital and Health Sciences Center, Chicago, IL; 
3Northwestern University Feinberg School of Medicine, Chicago, IL; 4Kaiser 
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Background: Chronic kidney disease (CKD) patients are asked to engage in self-
management behaviors in order to manage the disease and mitigate its sequelae. However, 
an examination of self-management behaviors and their association with clinical outcomes 
in older adults has not been well characterized.
Methods: Data from the Chronic Renal Insufficiency Cohort were analyzed using 
latent class analysis (LCA) to identify behavior patterns among those <65 and ≥65 years of 
age. LCA was based on body mass index, diet, physical activity, blood pressure, smoking, 
and hemoglobin A1c. Logistic regression assessed association of select factors to behavior 
patterns. Cox proportional hazards models were used to examine association of behavior 
patterns with cardiovascular events, CKD progression, and death. Results stratified by 
diabetes.
Results: Three behavior patterns (healthy, obese/sedentary, non-obese/smoking) were 
identified separately among age groups. Less healthy patterns included those with more 
depression, lower education, and self-efficacy. In older adults, less healthy patterns were 
associated with inadequate health literacy, less social support, and physical functioning. 
Among <65 years, the obese/sedentary pattern had increased hazard of death, CKD 
progression (diabetics), and cardiovascular events (non-diabetics), and the non-obese/
sedentary pattern had an increased hazard of death (diabetics), and cardiovascular events 
(non-diabetics). Among 65+ years, the obese/sedentary and non-obese/smoking patterns 
were associated with increased death and CKD progression (non-diabetics), see Table.
Conclusions: Self-management behavior engagement patterns are associated with risk 
of important outcomes among CKD patients. These patterns may be able to identify high-
risk groups and be targeted for aggressive management.
Funding: NIDDK Support
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Markers of Modifiable Health Behaviors, Cardiovascular Events, Death, 
and CKD
Sarah J. Schrauben,1 Sandra Amaral,4 Amanda H. Anderson,3 Harold I. Feldman,3 
Laura M. Dember.2 1Department of Medicine, University of Pennsylvania 
Perelman School of Medicine, Philadelphia, PA; 2University of Pennsylvania 
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Background: Chronic kidney disease (CKD) guidelines focus on modifiable health 
behaviors in the effort to decrease the risk of death and atherosclerotic events, both of which 
are increased in CKD. However, the effectiveness of these recommendations is relatively 
unknown since they were based largely on general population research. We examined the 
relationship of markers of modifiable health behaviors and clinical outcomes among those 
with and without CKD.
Methods: Data pooled from Atherosclerotic Risk in Communities Study, Multi-Ethnic 
Study of Atherosclerosis, and Cardiovascular Health Study. CKD defined as estimated 
glomerular filtration rate (eGFR) <60 ml/min/1.732. Markers of modifiable behaviors: 
physical activity, blood pressure, smoking, diet, body mass index, and fasting blood 
glucose. Multivariable adjusted Cox proportional hazards models estimated risk of death 
and a composite of atherosclerotic events. Effect modification was explored for age.
Results: Those with CKD (n = 8,542): mean 59.7 yrs, eGFR 54.7; without CKD 
(n=19,188): mean 60.2 yrs, eGFR 77.3. There was evidence of an interaction by age with 
behaviors for both outcomes. Results reported by <65 and 65+ yrs (see Table). Overall, 
CKD: Epidemiology, Risk Factors, Prevention - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
402
J Am Soc Nephrol 29: 2018 Poster/Thursday
recommended markers of health behaviors were associated with decreased death and 
atherosclerotic events. Particularly, controlled BP had a stronger association in CKD.
Conclusions: Markers of modifiable behaviors were associated with reduced risk of 
death and atherosclerotic events in CKD and without CKD. Blood pressure control had a 
stronger association among those with CKD.
Funding: NIDDK Support
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Health Literacy and Rapid Kidney Function Decline
Rekha Kambhampati,5 Marie Kuczmarski,1 Mara McAdams-DeMarco,5 
Dingfen Han,2 Alan B. Zonderman,3 Michele K. Evans,4 Deidra C. Crews.5 
1University of Delaware, Newark, DE; 2Johns Hopkins, Baltimore, MD; 
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Background: Health literacy is the ability to understand basic health information. 
Cross-sectional studies have revealed an association between limited health literacy and 
lower eGFR in those with CKD. The association of health literacy and kidney function over 
time has not been described, therefore, we conducted a prospective analysis of this question.
Methods: We studied 1,603 Healthy Aging in Neighborhoods of Diversity across the 
Life Span study participants with preserved kidney function (eGFR ≥ 60 mL/min/1.73 m2). 
A Rapid Estimate of Adult Literacy in Medicine test score of ≤ 60 indicated limited health 
literacy. We used multivariable logistic regression to assess the association of health literacy 
with rapid kidney function decline (eGFR loss ≥ 3 mL/min/1.73 m2 per year over median 
of 5 years).
Results: Participants’ mean age was 48 years. The prevalence of limited health literacy 
was 29.7% (n=476). Participants with limited health literacy were more likely to be male 
(50.4% vs 37.1%), African American (74.8% vs 52.4%), living in poverty (51.9% vs 
31.2%), have less educational attainment (mean 11.3 vs 13.3 years of schooling), and be 
current smokers (53.1% vs 41.5%) than persons with adequate health literacy (p<0.05 for 
all). Both literacy groups had similar baseline levels of eGFR, systolic BP, self-reported 
hypertension, and diabetes. A total of 218 (13.6%) participants had rapid kidney function 
decline at follow-up. The unadjusted odds of rapid kidney function decline among those with 
limited health literacy compared to adequate health literacy was 1.20 (95% CI: 0.81-1.77). 
After adjusting for age, sex, race, poverty status, education, smoking status, BP, and 
diabetes, there was still no association (OR 0.99, 95% CI: 0.67-1.47). A series of alternate 
outcomes (rapid eGFR decline of ≥3% decrease per year, eGFR decrease of ≥25% over a 
median of 5 years, incident eGFR<60, and incident albuminuria) revealed results consistent 
with the primary outcome.
Conclusions: There was no association between health literacy and various measures 
of kidney function decline in this cohort. Although previous cross-sectional analyses have 
shown an association between health literacy and kidney function, this finding was not 
present in this prospective analysis. Factors other than health literacy may have more 
influence over early loss of kidney function.
Funding: NIDDK Support
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Moderate or Advanced CKD: Findings from the French CKD-Renal 
Epidemiology and Information Network (CKD-REIN) Study
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VILLEJUIF Cedex, France; 2CHRU Nancy, Vandœuvre les Nancy, France; 
3Paris Descartes University, Boulogne Billancourt, France; 4University Hospital 
of Nancy, Vandoeuvre les Nancy, France; 5CHU de Bordeaux, Bordeaux, 
France.
Background: Social support is associated with higher well-being in chronic kidney 
disease (CKD), but has only been explored in ESRD patients. We describe family profiles 
and their associations with self-reported quality of life and depression in patients with 
moderate or advanced CKD.
Methods: Four questionnaires were administrated to 3,033 adult patients with CKD 
stage 3-5 under nephrology care: the 12-item Family Relationships Index (FRI) to assess 
family relationships through 3 subscales [family cohesion (degree of support within the 
family), family expressiveness (extent to which family members express feelings) and 
family conflict (amount of conflict among family members), the KDQoL scale to measure 
CKD effects, burden, and symptoms, the SF-12 to assess mental and physical composite 
scores (MCS, PCS), and the CES-D scale for depression symptoms. Comparisons between 
profiles were adjusted for age, sex, and living status.
Results: Based on 2,004 patients (median age 68, 68% men, 20% living alone, 56% 
stage 3 CKD) with complete data for the FRI, cluster analysis yielded 3 family profiles 
(Upper Figure). Patients with profile 3 (the highest family cohesion and expressiveness, 
and the lowest conflict) had the best patient-reported outcomes. In comparison, patients 
with profile 1 (the lowest family cohesion and expressiveness, and intermediate conflict) 
had significantly lower KDQoL and SF-12 scores (p<.001) (Lower Figure), and a higher 
prevalence of self-reported depression symptoms, 9% vs 6% (p<.001). Patients with profile 
2 (high family cohesion, intermediate expressiveness, and highest conflict) did not differ 
significantly from those with profile 3.
Conclusions: Family environment plays a crucial role in patients’ adaptation to CKD. 
Accounting for it could allow health professionals to better assist their patients.
TH-PO1085 Poster Thursday
CKD: Epidemiology, Risk Factors, Prevention - I
Association of Social Support with CKD Among African-Americans
Rasheeda K. Hall,1 Clemontina A. Davenport,1 Mario Sims,3 Cathleen Colon-
emeric,1 Tiffany R. Washington,4 Jennifer St. Clair Russell,1 Jane F. Pendergast,1 
Nrupen A. Bhavsar,1 Julia J. Scialla,1 Crystal C. Tyson,1 Nancy Min,3 
Bessie A. Young,2 L. Ebony Boulware,1 Clarissa J. Diamantidis.1 1Duke University 
School of Medicine, Durham, NC; 2Uniiversity of Washington, Seattle, WA; 
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Background: Low social support (LSS) negatively affects health behaviors. Because 
disease self-management and lifestyle modifications improve outcomes in chronic kidney 
disease (CKD), we sought to examine the independent association of LSS with CKD 
prevalence or rapid renal functional decline (RRFD) in African Americans at risk of CKD 
incidence or progression in the Jackson Heart Study (JHS).
Methods: The JHS is a prospective cohort of African Americans within the Jackson, 
MS metropolitan area. At baseline (2000-2004), social support was assessed using the 
Interpersonal Support Evaluation List (ISL); a 16-item survey with four subscales: 
appraisal, belonging, self-esteem, and tangible support. ISL scores < 32 indicate LSS. CKD 
was defined as an estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2 or a urine 
albumin/creatinine ratio (ACR) ≥30mg/g in those with an eGFR ≥ 60ml/min/1.73m2. We 
conducted multivariable logistic regression to evaluate the association between LSS and 
CKD prevalence in the general JHS cohort, as well as the association of LSS and RRFD 
(defined as a > 30% decrease in eGFR over a 10 year period) among JHS participants 
with diabetes, hypertension, or CKD at baseline. Models were adjusted for baseline 
sociodemographics, comorbidities and ACR.
Results: Of 5301 JHS participants, 4015 (76%) completed the ISL. 843 (21%) had LSS. 
Participants with LSS (vs. high) were more likely to have lower income (47% vs. 28%), be 
current or former tobacco users (39% vs. 30%), have diabetes (25% vs. 21%), and CKD 
(14% vs. 12%) (all p<0.05). After multivariable adjustment, LSS was not independently 
associated with prevalent CKD or with RRFD. However, a low self-esteem subscale score 
was associated with increased odds of prevalent CKD [OR 1.06 (95% CI 1.01-1.12)].
Conclusions: Overall, LSS was not independently associated with CKD outcomes 
among African Americans in the JHS, but low-self-esteem was associated with CKD. Self-
esteem may have a role in CKD management and warrants further study.
Funding: Other NIH Support - Kl2TR001115, R03AG050834, P30AG028716, Private 
Foundation Support
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Tele-Nephrology to Provide Efficient and Patient-Centered Ambulatory 
Care
Charuhas V. Thakar,1,2 Nicole Piero,3 Cristy A. Goodall,4 Anthony C. Leonard.1 
1University of Cincinnati, Cincinnati, OH; 2Renal Section, Cincinnati VAMC, 
Cincinnati, OH; 3VA Medical Center, Milford, OH; 4Cincinnati VA Medical 
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Background: Subspecialty referrals in ambulatory care in the U.S. have doubled in the 
last decade. According to an AAMC-commissioned study in 2017, there will be a projected 
a shortage of up 61,800 nonprimary care specialists by 2030. We evaluated whether the 
incorporation of tele-nephrology within ambulatory care could improve efficiency and 
patient-centeredness.
Methods: In a large Veteran’s Affairs health system, we assessed outpatient utilization 
of tele-nephrology via e-Consults (e-C), defined as either electronic, telephonic or video 
communication with the referring provider and/or the patient. We implemented a pilot 
to pro-actively triage eligible renal consults in patients 75 or older (Grp I) to be initially 
addressed via e-Consults compared to those < 75 (Grp II). e-C assessments and ability 
to completely address the consult without need for in-person (IP) visit were compared by 
Chi-square or Fishers tests.
Results: In FY 2016-17, of the 1,803 consults, inital e-C assessments were peroformed 
on 172 (9.5%), leaving 1,631 IP visits. Since the pilot, between 1/1/18 and 5/29/18, 249 
renal consults were received of which, 9% (22/249) patients were Grp I. 86% (19/22) in 
Grp I underwent initial e-C assessments compared to 14% (33/227) in Grp II (p < 0.001). 
Of the initial e-C assessments 26% (5/19) in the Grp I were completed by avoiding IP visit; 
whereas 42% (14/33) in Grp II were completed without IP visit (p = 0.37). Pilot Grp I was 
100% male (mean age of 81.3; mean serum creatinine 1.84 mg/dl); 78% were diabetic and 
78% hypertensive. They resided between 2 and 42 miles from the clinic, and 20% were 
receiving home-based primary/hospital care. The mean time to complete an e-C assessment 
was 1.43 days from date of referral, as compared to > 30 day wait for IP visit. Along with 
comprehensive medical review, 93% received renal-specific diagnostic assessments (lab 
tests, radiology tests, medication review management). Overall, initial e-C (52/249) created 
21% efficiency; and created 8% capacity (19/249) by avoiding the need for IP visits, with 
same resources.
Conclusions: e-Consults reduced time to initial renal assessment, allowed prompt 
diagnostic testing, medication management, and avoided travel burden for patients and 
relatives. Tele-nephrology models of ambulatory care delivery can improve efficiency, 
enhance patient-safety, and reduce real and opportunity costs.
Funding: Clinical Revenue Support
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CKDApps: A Systematic Evaluation of Patient-Facing Smartphone Apps 
for CKD by Patients and Nephrologists
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Background: Many aspects of chronic kidney disease (CKD) management rely 
heavily on patient self-care, including medication and dietary adherence, self-monitoring 
of blood pressure, and daily physical activity. There is growing evidence that incorporating 
technology, specifically smartphone-based applications (apps), can help support self-care in 
CKD and chronic disease more generally.
Methods: We identified apps targeting CKD patients by conducting a search of the 
Apple App Store (iOS) and Google Play Store (Android) using the following 4 phrases: 
“kidney disease,” “renal,” “dialysis,” and “kidney transplant.” We considered the first 50 
apps for each search term on each app store. We modified a previously described framework 
for assessment of mobile health apps to account for kidney disease-specific content areas 
and evaluated apps on their clinical focus, types of patient engagement, quality, usability, 
safety, and cost. Engagement and quality were assessed by both a patient and a nephrologist, 
usability was assessed by patients, and safety was assessed by nephrologists.
Results: Our search strategy identified 174 unique apps on Android and 165 unique 
apps on iOS. After excluding apps that were not related to kidney disease, not patient-
facing, or were last updated prior to 2014, 12 Android-only apps, 11 iOS-only apps, and 5 
dual-platform apps remained. Patient and nephrologist ratings showed a positive correlation 
that was not statistically significant (p = 0.063, see Figure). Consumer ratings on the app 
stores did not correlate with patient ratings (p = 0.177).
Conclusions: Only a small subset of CKD apps are highly rated by both patients and 
nephrologists. Patients’ impressions of app quality are not directly linked to consumer app 
ratings or nephrologist impressions. Efforts to develop and disseminate apps for CKD self-
care should involve direct patient input.
Funding: NIDDK Support
Relationship between (A) nephrologist and patient ratings and (B) consumer and patient 
ratings.
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Attitude, Motivation, and Barriers to Exercise in Patients with CKD: A 
Focus Group Study
Jessica B. Kendrick,1 Emily Andrews.2 1University of Colorado School of 
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Background: Physical activity is remarkably low in patients with chronic kidney 
disease (CKD). Data suggests that exercise is beneficial for patients with CKD. The adjusted 
risk of death and end stage renal disease is lower in CKD patients who are physically active 
compared to those who are inactive. Despite the benefits of exercise in patients with CKD, 
the majority of patients remain sedentary. The purpose of this formative evaluation was to 
identify CKD patient attitudes, beliefs and barriers to exercise.
Methods: Adult individuals from the Denver Metro area with CKD stage 3 and 
4 who were not currently physically active were recruited for 10 focus groups (3 in 
English speaking males, 3 in English speaking females, 2 in Spanish speaking males and 
2 in Spanish speaking females) from May 2016 to December 2016. Focus groups were 
transcribed verbatim and transcripts were coded and thematically analyzed.
Results: A total of 41 individuals participated in the study. 51.2% were female and 
44% were Hispanic. The majority of the participants held a CKD diagnosis for 1-7 years. 
Participants recognized the benefits of physical activity on both physical and mental health 
but physical activity was not viewed to have a significant impact on CKD. Social support 
was a strong motivational factor to physical activity. Social support was preferred from 
friends, family, or peers with similar health conditions. Spanish speaking participants saw 
family as a barrier if the family member was not directly participating in physical activity. 
Additional barriers to physical activity included poor health, fatigue, a fear of worsening 
their disease and lack of guidance from their nephrologist. Spanish speaking participants in 
particular expressed frustration with their nephrologist’s lack of advice regarding exercise.
Conclusions: Barriers and motivators to physical activity were similar amongst male 
and female participants with CKD. Lack of advice from nephrologists regarding exercise 
was a significant barrier. Physical activity interventions in patients with CKD should 
include not only increased patient self-efficacy and social support but also counseling and 
prescribing of exercise by nephrologists.
Funding: Other NIH Support - NHLBI
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Quality of Life of Patients with CKD: A Cross Sectional Analysis from the 
ICKD Cohort
Ashok K. Yadav,1 Vivek Kumar,2 Sishir D. Gang,3 Sreejith Parameswaran,4 
Narayan Prasad,5 Santosh Varughese,8 Krishan Lal L. Gupta,6 Vivekanand Jha.7 
ICKD study Investigators 1Nephrology, PGIMER, Chandigarh, India; 
2Postgraduate Institute of Medical Education and Research, Chandigarh, India; 
3Muljibhai Patel Urological Hospital, Nadiad, India; 4JIPMER, Ponidcherry, 
India; 5SGPGIMS CAMPUS, Lucknow, India; 6Postgraduate Institute of Medical 
Education & Research, Chandigarh, India; 7George Institute for Global Health, 
New Delhi, India; 8Nephrology, CMC, Vellore, India.
Background: Improving symptoms and function in daily life are important patient 
centered outcomes in chronic diseases. Health-related quality of life (QOL) is an important 
key indicator of how a condition affects the patient’s life, and QOL has been expressed as 
the subjective assessment of the impact of disease and its treatment across the physical, 
psychological and social domains of functioning. We report QOL in patients with early 
stages of CKD who have been enrolled in the ICKD study.
Methods: All subjects, who had been enrolled in the on-going, multi-centric ICKD 
cohort study and had KDQOL-36TM survey data recorded at baseline, were eligible for the 
present study. We assessed QoL by KDQOL-36TM. Raw scores are converted to subscale 
scores using the Microsoft Excel tool (KDQOL-36TM Scoring Program, v 2.0). These 
subscales are Mental Component Summary (MCS), Physical Component Summary (PCS), 
Symptoms, Effect and Burden. Each subscale category is scored between 0-100, with 
higher scores indicating better quality of life. demographic and socioeconomica as well 
as clinical parameter were studied for association with QOL. Low QOL was defined as 
subscale score that was 1 SD less than the mean for the respective subscale.
Results: The mean scores for KDQOL-36TM subscales were 48.81±9.93, 44.17±9.49, 
65.29±31.40, 81.31±24.70 and 86.68±21.43 for PCS, MCS, burden, effects and symptoms, 
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respectively. Urban residence, non-vegetarian dietary pattern, education below high school, 
occupational exposure and lower income were associated with lower scores across all 
KDQOL-36 subscales (p<0.05). Professional workers had high score across all KDQOL-36 
subscales compared to farmers, housewife and unemployed subjects (p<0.01). Increasing 
quartile of annual income ws associated with higher scores in all subscales (p<0.01). Urban 
residence, occupational exposure and housewife status were associated with low QOL 
across all KDQOL-36TM subscales (p<0.05). Education below high school, lower eGFR, 
low annual income and BMI <18 kg/m2 were associated with low QOL in all subscale 
scores (p<0.01) except in symptoms subscale.
Conclusions: We identified the association between a number of clinical and socio-
economic variables related and one or more KDQOL-36TM subscales.
Funding: Government Support - Non-U.S.
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A Worrisome Explosion: Time Series Analysis of Kidney Cancer Incidence 
in the United States
Achintya Ray,1 Bhabendra Putatunda.2 1Tennessee State University, Nashville, 
TN; 2Nephrology Associates PC, Murfreesboro, TN.
Background: With over 500,000 adults in the US suffering from kidney & renal pelvis 
cancer and 65,000 new cases are estimated to be diagnosed in 2018 (representing 3.8% of 
all new cancer cases), kidney cancer poses a major public health challenge and remains a 
significant source of healthcare cost and mortality. Between 1975-2015, national incidence 
of kidney cancer more than doubled from 7.1 to 15.7 per 100,000 population.
Methods: Annual time series data covering 1975-2015 is collected from NCI’s SEER. 
Level and smoothed (moving average, 3-year and 5-year) time series plots are obtained 
(details in Figure 1). Autocorrelation and partial autocorrelation functions obtained from 
the time series data point to a long memory in the data generating process and help us in 
understanding the magnitude of rising in renal cancer incidence during the last half-century. 
Augmented Dickey-Fuller (ADF) tests are performed to check the stationarity in the time 
series data.
Results: ADF tests using the standard estimation equation rejected stationarity of the 
incidence data for lag lengths 1, 3, and 5 points to the presence of strong non-stationarity in 
longitudinal incidence in kidney cancer. The results pointing to non-stationarity hold even 
after controlling for trend, and random walk with or without drift.
Conclusions: Analysis of 41 years of kidney cancer incidence data strongly establishes 
that kidney cancer incidences have been increasing statistically significantly over time. 
The incidence has more than doubled in the last half-century. Current evidence does not 
support any immediate possibility of a reversal in that increasing trend. Results point to a 
strong need for urgent interventions and robust public health awareness campaigns aimed at 
slowing or perhaps reversing the explosive trend in kidney cancer incidence.
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Referral to Nephrology Care and Mortality Risk in People with Stage 4 
CKD: A Population-Based Study
Ping Liu,1 Robert R. Quinn,1 Mohammad E. Karim,3 Aminu K. Bello,2 
Paul E. Ronksley,1 Robert G. Weaver,1 Helen Tam-Tham,1 Brenda Hemmelgarn,1 
Braden J. Manns,5 Marcello Tonelli,1 Giovanni F. Strippoli,4 Pietro Ravani.1 
1University of Calgary, Calgary, AB, Canada; 2University of Alberta, Edmonton, 
AB, Canada; 3University of British Columbia, Vancouver, BC, Canada; 
4University of Bari, Bari, Italy; 5Foothills Medical Center, Calgary, AB, Canada.
Background: Guidelines recommend referral for specialist kidney care when 
estimated glomerular filtration rate (eGFR) is <30 ml/min/1.73m2 (stages 4-5 CKD). These 
recommendations are largely based on studies in people treated with dialysis showing 40% 
lower mortality with predialysis care of at least 4 months vs. shorter or no predialysis care. 
The effects of nephrology referral for the broader population of CKD patients are unknown. 
We examined the association between referral to nephrology care and mortality risk in 
people with stage 4 CKD.
Methods: Using population-based administrative and laboratory data, we identified all 
adults, residing in Alberta, with at least two consecutive outpatient measurements of eGFR 
≥15 to <30 ml/min/1.73m2 spanning more than 90 days between 2002 and 2014. Patients
were followed from date of the first eGFR after the 90-day qualifying period (study entry) 
until the earliest of death, out-migration from the province, or March 31, 2015. We used 
outpatient nephrology visit for at least once as a proxy for referral to nephrology care. We 
estimated hazard ratios (HRs) and confidence intervals (CIs) for all-cause mortality with 
nephrology referral (vs. no referral) and whether this effect varied by age, adjusting for
baseline demographics and key laboratory and clinical characteristics, and using methods
that address immortal time bias and time-varying confounding potentially affected by
previous exposure status.
Results: Of the 15,315 study participants, 78% were ≥75 years old; 35% were referred 
to a nephrologist (median time-to-referral 8 months); and 67% died (median time-to-death 
2.6 years). People who were referred were younger and had less comorbidity. Compared to 
non-referral, referral at any time during follow-up was independently associated with 12% 
lower mortality (HR 0.88; 95% CI, 0.83-0.93). The association was stronger in people aged 
<70 years (HR 0.80; 95% CI, 0.68-0.95) and absent in people aged ≥90 years (HR 1.05; 
95% CI, 0.88-1.24).
Conclusions: Among people with stage 4 CKD meeting the criterion for nephrology 
referral, most of them are very old and the survival benefit of nephrology referral may be 
smaller than expected and become smaller with older age.
Funding: Government Support - Non-U.S.
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Decline in Glomerular Filtration Rate Before and After Multidisciplinary 
Care Referral in Moderate to Advanced CKD
Makoto Hirakawa. Iizuka Hospital, Iizuka, Japan.
Background: The multidisciplinary care (MDC) model has been used in our hospital 
for years. We investigated whether the outpatient chronic kidney disease (CKD) treatment 
by the MDC contributed to the inhibition of the progression of renal failure.
Methods: This study provides a retrospective review of the individual rates of 
estimated glomerular filtration rate (eGFR) decline (ml/min/1.73m2/year) for the 6 months 
before and after referral in 40 referrals with stages 3–5 CKD to one renal unit between 
March 2010 and June 2012. The MDC team consisted of a nephrologist, nurses, dieticians, 
and other professionals.
Results: The Age and eGFR at the time of referral was 66 ± 12 and 14.7 ± 6.6 ml/
min/1.73m2 (mean ± SD), and the mean observation period was 395 days (172 to 862 days). 
The decrease in the eGFR before and after the referral was significantly improved from 
-8.0 ± 8.0 ml/min/1.73m2/year to -1.3 ± 5.9 ml/min/1.73m2/year (P<0.01). Blood pressure
also reduced significantly (139/80 to 133/73mmHg, P<0.05).
Conclusions: The outpatient renal failure treatment by using multidisciplinary care 
might contribute to the suppression of renal failure.
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Comparing Glomerular Filtration Rate Measured by Radionuclide 
Imaging with Creatinine Based Equations
Camilo A. Gonzalez,2,1 Alejandro Durán,3 María T. Vargas,3 Paola Garcia,2,3 
Patricia Rodriguez,2,3 Kateir Contreras.2,3 1Nefrology, Clinica Universitaria 
Colombia, Bogotá, Colombia; 2Nefrology, Hospital Universitario San Ignacio, 
Bogota, Colombia; 3Pontificia Universidad Javeriana, Bogota, Colombia.
Background: Glomerular filtration rate (GFR) is the best index of kidney function. 
Creatinine based equations (CBE) are recomended by guidelines. In Colombia sometimes 
we use radionuclide imaging(RI) with 99mTc-DTPA to measure GFR thinking that it could 
be better. The aim of this study is to estimate correlation and concordance between this 
method and eGFR with CBE.
Methods: We included patients who had standarized creatinine and GFR meassured 
with 99mTc-DTPA RI in the same week from 4 institutions in Bogota, Colombia between 
November 2008 and October 2017. We excluded patients with expected source of error in 
CBE and RI. CBE used were CKD-EPI, MDRD4 and Cockcroft Gault adjusted to body 
surface (CGa). We estimated the correlation with Spearman coefficient and concordance 
with kappa coefficient for CKD diagnosis (<60ml/min/1.73m2) and CKD grades. We 
considered p<0.05 as statistically significant.
Results: We included 421 patients. Mean age 54 years (± 17.1), 46.8% female, mean 
eGFR 75.9 (± 26.6), 76.3 (± 28.8), 77.1 (± 31.6) and 77.9 (±28.4) ml/min/1.73m2 with 
CKD-EPI, MDRD4, CGa and RI respectively; 29.4% had eGFR less than 60. There were 
no differences of mean. In the graph, we show the distribution by grades of CKD. The 
correlation was good between equations, but acceptable when comparing CBE with 99mTc-
DTPA RI. Weighted kappa concordance between CBEs was good but for 99mTc-DTPA RI 
compared to all CBE was fair.(Table)
Conclusions: GFR with 99mTc-DTPA RI had a low correlation and fair concordance 
compared with CBE. There are no reasons to consider RI as a better tool. And also, is an 
expensive test with limited availability.
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Spearman coeficiente and weighted Kappa coefficient by CKD grades 1 to 5.
All p<0.00001
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Improved Time to eGFR Decline Outcomes in Glomerular Disease
Sarah Mansfield,1 Jarcy Zee,1 Laura H. Mariani,2,1 Brenda W. Gillespie.2 1Arbor 
Research Collaborative for Health, Ann Arbor, MI; 2University of Michigan, 
Ann Arbor, MI.
Background: The standard method of using two estimated glomerular filtration rate 
(eGFR) measures to calculate time to a percentage decline in eGFR may result in inaccurate 
event times due to eGFR variability and restriction of events to study visit times. We 
propose fitting a regression line to all observed eGFR measures to improve accuracy and 
power of time to percentage decline in eGFR outcomes.
Methods: Using data from the Nephrotic Syndrome Study Network (NEPTUNE) of 
patients with minimal change disease, focal segmental glomerulosclerosis, or membranous 
nephropathy, we compared time to 40% decline in eGFR using both event time calculation 
methods. We also used computer simulations to assess power and accuracy of event times 
under both methods. Parameters for the simulations, such as eGFR variability, percent 
missing eGFR observations, and correlation between successive eGFR measurements, 
imitated NEPTUNE data.
Results: 380 NEPTUNE patients with a mean of 6.5 eGFR measurements over a mean 
of 33 months of follow-up were included in the analysis. Among these patients, 91 had a 
40% decline in eGFR using the two-point method, while 68 had a 40% decline in eGFR 
using our proposed linear regression method. For patients who had an event under both 
methods (n=64), the two-point method estimated earlier event times compared to the linear 
regression method (Figure 1). Under simulated data conditions, the standard two-point 
method was less accurate in estimating event times than our proposed regression method, 
particularly with high eGFR variability or more missingness. The two-point method was 
also less powerful in detecting time-to-event differences between groups.
Conclusions: Using our proposed regression method to estimate time to a percentage 
decline in eGFR increases accuracy and power. Reducing noise in outcome estimation with 
our proposed method increases the ability to discover treatment or biomarker effects.
Funding: NIDDK Support
Kaplan-Meier estimates of the probability of a 40% decline in eGFR using NEPTUNE data.
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Validation of the Kidney Risk Failure Equations (KFRE) in Patients with 
CKD in Singapore
Ian tatt Liew,1 Wanting Weng,1 Yee Ang,2 Chun wei Yap,2 Peng Shen,1 Xi 
yan Ooi,1 Regina Lim,1 Adrian Liew.1 1Tan Tock Seng Hospital, Singapore, 
Singapore; 2National Healthcare Group, Singapore, Singapore.
Background: Accurate identification of patients with CKD at risk of progressing 
to require renal replacement therapy (RRT) would allow optimal care. Tangri et al 
developed models to predict progression in patients with CKD stages 3-5 (eGFR 
10-59ml/min/1.73m2) to kidney failure using data from Canadian cohorts. The aim of our
study is to validate the 4-variable and 8-variable KFREs in the multiethnic population in
Singapore.
Methods: Demographics, clinical and laboratory data of patients with CKD stages 3-5 
referred from primary care physicians to TTSH Renal Department between 1 January 2009 
to 31 December 2012 were collected. Kidney failure was defined as the initiation of chronic 
dialysis or kidney transplant. The 2 year and 5 year kidney failure risks were predicted using 
the 4-variable(age, sex, albuminuria and eGFR) and 8-variable(4-variable and calcium, 
phosphate, bicarbonate and albumin) models. This was compared with actual kidney failure 
rate at 2 and 5 years of follow up. Patients who died before kidney failure were excluded. 
Model performance was evaluated using the area under the receiver operating characteristic 
curve (ROC-AUC) and by comparing the observed and predicted risks of kidney failure.
Results: The KFRE models were validated using 2,238 and 1,845 patients for the 2 
and 5 year kidney failure risks respectively. 158 (7.1%) and 355 (15.9%) patients developed 
kidney failure at 2 years and 5 years respectively. ROC-AUC for the 4-variable KFRE 
at 2 and 5 years are 0.921 (95% confidence interval [CI] 0.899-0.943) and 0.866 (CI 
0.844-0.887) while those for the 8-variable KFRE are 0.925 (CI 0.905-0.945) and 0.862 
(CI 0.840-0.883) respectively. The mean differences between the observed and predicted 
kidney failure risk was lower for the 4 variable equation compared to the 8 variable equation 
at 2 and 5 years.
Conclusions: Discrimination of the 4-variable and 8-variable KFRE were similar and 
were able to predict the progression to kidney failure in our patients. To further improve the 
accuracy of the KFRE, we would need to recalibrate the 8-variable equation for our local 
multiethnic population
Mean difference between observed and predicted risks
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Lower Diastolic Blood Pressure Increases the Risk of Mortality and 
Progression to ESRD – Multicenter Large Cohort Study
Do Hyoung Kim,1 Yong Chul Kim,3 Jung Nam An,2 Dong Ki Kim,3 Yon 
Su Kim,4 Chun Soo Lim,2 Dong Ho Shin,5 Jung Pyo Lee.2 1Hallym University 
Hangang Sacred Heart Hospital, Seoul, Republic of Korea; 2Seoul National 
University Boramae Medical Center, Seoul, SEOUL, Republic of Korea; 3Seoul 
National University Hospital, Seoul, Republic of Korea; 4Seoul National 
University College of Medicine, Seoul, Republic of Korea; 5College of Medicine, 
Hallym University, Seoul, Republic of Korea.
Background: Higher systolic blood pressure (BP) is known to be associated with an 
increased risk of cardiovascular events and mortality in chronic kidney disease (CKD) 
patients. However, the clinical impacts of diastolic BP and the ideal diastolic BP target in 
Asian elderly CKD patients have not been well studied.
Methods: A multicenter CKD cohort from 2001 to 2016 was used. We examined the 
associations of systolic and diastolic BP with all-cause mortality and progression to end-
stage renal disease (ESRD) using multivariate Cox proportional hazards regression models.
Results: A total of 13,700 patients with complete data for multivariable analysis were 
enrolled. Systolic BP showed a U-shaped association with mortality and a linear association 
with progression to ESRD. Systolic BP greater than 140 mmHg or diastolic BP less than 
50 mmHg was significantly associated with higher mortality, regardless of the presence 
of diabetes or hypertension. In subgroup analysis of age, the patients with diastolic BP 
< 60 mmHg and aged < 50 years, or diastolic BP < 50 mmHg and aged < 70 years had a 
higher risk of mortality compared to those with diastolic BP 70-79 mmHg after adjusted 
systolic BP (age < 50, hazard ratios [HRs], 4.46; 95% confidence interval [95% CI], 2.38 
to 8.35; age 50-59, HRs, 2.92; 95% CI, 1.33 to 6.38; age 60-69, HRs 2.84; 95% CI, 1.49 to 
5.43). However, there was no association in those aged ≥ 70 years. The risk for progression 
to ESRD was also increased with diastolic BP < 60 mmHg (HRs 1.20; 95% CI, 1.01 to 
1.43). The risk for mortality and progression to ESRD was also increased with diastolic BP 
< 60 mmHg in patients with diabetes (HRs 2.65; 95% CI, 1.67 to 4.22; HRs 1.43 95% CI 
1.01-1.89).
Conclusions: In the CKD patients, lower diastolic BP was significantly associated with 
mortality and progression to ESRD; however, the effects were reduced in elderly patients 
(≥ 70 years).
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Prevalence and Clinical Outcome of Apparent Treatment Resistant 
Hypertension in CKD in Korea: Korean Cohort Study for Outcome in 
Patients with CKD (KNOW-CKD)
Young jin Kim,1 Hong sang Choi,1 Chang Seong Kim,1 Eun Hui Bae,1 Seong 
Kwon Ma,1 Kook-Hwan Oh,2 Curie Ahn,2 Soo Wan Kim.1 1Department of 
Internal Medicine, Chonnam National University Medical School, Gwangju, 
Republic of Korea; 2Department of Internal Medicine, Seoul National University, 
Seoul, Republic of Korea.
Background: It is not well defined the prevalence and clinical outcome of apparent 
treatment resistant hypertension(ATRH) in Korean CKD patients. The present study was 
aimed to investigate the prevalence of ATRH, and its effects on the renal and cardiovascular 
outcomes and all-cause mortality.
Methods: We collected data of 1878 patients with hypertension in the Korean Cohort 
Study For Outcome in Patients with Chronic Kidney Disease(KNOW-CKD) to understand 
ATRH. The definition of ATRH is; 1) systolic blood pressure(BP)≥140mmHg or diastolic 
BP≥90mmHg with 3 classes of antihypertensive agents, 2) any BP with 4 antihypertensives, 
at baseline.
Results: 374(19.9%) patients revealed ATRH. Presence of ATRH was associated with 
baseline renal function, sex, diabetes, severity of proteinuria, BMI, and prior history of 
myocardial infarction. Patients with ATRH showed higher risk of adverse renal outcome 
than non-ATRH patients. The adjusted renal event hazard ratio(HR) was 1.362[95% 
CI 1.079-1.719], p=0.0093. Cardiovascular outcome and all-cause mortality were not 
statistically different (0.884[0.528-1.481], 1.731[0.898-3.338]). The risk of renal events 
increases with lower baseline renal function. Patients with eGFR<30 ml/min/1.73m2 and 
eGFR 30~60 showed higher HR than patients with eGFR≥ 60(24.547[12.082-49.875], 
4.278[2.072-8.833]). In subgroup analysis, patients used loop diuretics at baseline had 
higher HR (1.361[1.076-1.720]). Patients who didn’t achieved BP goal(140/90mmHg) with 
4 antihypertensives showed higher risk of renal event risk(2.189[1.469-3.269]).
Conclusions: Our study shows that ATRH is associated with high risk of adverse renal 
outcome in patient with chronic kidney disease. Especially patients with ATRH and CKD 
stage III~V need more careful approach and management to prevent worsening of renal 
function.
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The Interactions Between Proteinuria, Activity of Fibroblast Growth 
Factor 23, and Serum Phosphate on Renal Progression in Patients with 
CKD: A Result from the KNOW-CKD Study
Hyoungnae Kim,1 Ki Heon Nam,2 Seung Hyeok Han,2 Tae-Hyun Yoo.2 
1Soonchunhyang University Hospital, Seoul, Republic of Korea; 2Yonsei 
University College of Medicine, Seoul, Republic of Korea.
Background: Both of proteinuria and hyperphosphatemia are well known risk factors 
of CKD progression. Recent experimental study reported that proteinuria increases serum 
phosphate by decreasing biologic activity of fibroblast growth factor 23 (FGF-23). We 
examined this relationship in a large chronic kidney disease (CKD) cohort and evaluated 
combined effect of proteinuria, FGF-23 activity, and serum phosphate on CKD progression.
Methods: This prospective longitudinal study was conducted with 1909 patients from 
CKD stage 1 to 5. The activity of FGF-23, measured by fractional excretion of phosphate 
(FEP)/FGF-23 ratio, was compared according to the degree of proteinuria. Primary 
outcome was CKD progression defined as ≥50% decline of estimated glomerular filtration 
rate (eGFR), doubling of serum creatinine, start of dialysis, or kidney transplantation.
Results: The patients with more proteinuria had significantly higher serum phosphate 
levels from CKD stage 2 to 5 than those with less proteinuria. In addition, there was a 
negative relationship between 24 hour urine protein (24h UP) and FEP/FGF-23 ratio 
(γ, -0.07; P = 0.005). In addition, after matching variables associated with serum phosphate, 
patients with more proteinuria had higher serum phosphate (P < 0.001) and FGF-23 
(P = 0.012), and lower FEP/FGF-23 ratio (P = 0.007) compared to those with less 
proteinuria. In the matched cohort, low FEP/FGF-23 ratio was a risk factor of CKD 
progression (hazard ratio, 0.86 per 1 log increase; 95% confidence interval, 0.79-0.94; 
P = 0.001), and there was significant interaction between 24h UP and FEP/FGF-23 ratio 
(P = 0.027). Furthermore, 24h UP and serum phosphate also had a significant interaction on 
CKD progression (P < 0.001).
Conclusions: Proteinuria is associated with decreased biologic activity of FGF-23 and 
serum phosphate. Furthermore, diminished activity of FGF23 is an independent risk factor 
for renal progression in proteinuric CKD patients.
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Association Between Serum Lipid Profiles and Progression of CKD: 
KNOW-CKD Study
Ki Heon Nam, Yooju Nam, Seon yeong Lee, Joohwan Kim, Tae-Hyun Yoo, 
Dae-Suk Han, Seung Hyeok Han. Yonsei University College of Medicine, 
Seodaemun-gu, SEOUL, Republic of Korea.
Background: Dyslipidemia has been linked to an increased risk of cardiovascular 
morbidity and mortality in patients with chronic kidney disease (CKD). However, the role 
of individual lipid parameter in the development of in the progression of CKD is not well 
established.
Methods: Among 2,238 patients with non-dialysis CKD enrolled in the KoreaN 
cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD), 1,939 
patients who measured total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), 
high density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were included in 
the analysis. Study endpoint was a composite of a ≥ 50% decline in estimated glomerular 
filtration rate or the onset of end-stage renal disease.
Results: The mean age was 53.8 ± 12.2 years and 1,192 (61.5%) patients were males. 
The mean serum concentrations of TC, LDL-C, HDL-C, and TG were and 174.1 ± 38.9, 
96.9 ± 31.3, 49.3 ± 15.5, and 156.6 ± 96.9 mg/dl, respectively. During a median follow-up 
of 3.0 years, 421 patients (21.7%) reached the composite end point. In the fully adjusted 
multivariable Cox models, HDL-C was significantly associated with increased risk of CKD 
progression (HR, 1.11 per 10 mg/dl increase; 95% CI, 1.01-1.22; P = 0.03), while TC (HR, 
0.99 per 10 mg/dl increase; 95% CI, 0.95-1.03; P = 0.53), LDL-C (HR, 1.01 per 10 mg/dl 
increase; 95% CI, 0.97-1.06; P = 0.68), and TG (HR, 0.99 per 10 mg/dl increase; 95% CI, 
0.98-1.01; P = 0.35) were not. However, areas under the curve of these 4 lipids were similar 
and none of the parameters did not improve the net reclassification improvement and the 
integrated discrimination improvement for the progression of CKD.
Conclusions: HDL-C only was significantly associated with CKD progression. 
However, all lipid parameters had limited roles in improving risk stratification for adverse 
renal outcome.
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Serum Bilirubin Is a Significant Prognostic Marker for Renal Progression 
and Mortality in Patients with CKD
Young Lee Jung,1 Eunjeong Kang,2 Jung Nam An,3 Chun Soo Lim,3 Yun 
Kyu Oh,4 Jung Pyo Lee.3 1Seoul National unioversity Hospital, Bucheon, 
Republic of Korea; 2Seoul National University Hospital, Seoul, Republic of 
Korea; 3Seoul National University Boramae Medical Center, Seoul, SEOUL, 
Republic of Korea; 4Department of Internal Medicine, Boramae Medical Center, 
Seoul, Republic of Korea.
Background: Mildly elevated bilirubin could protect kidney damage by reducing 
oxidative stress. However, it is still unclear that serum bilirubin level can predict clinical 
outcomes in the patients with CKD. The aim of our study is to investigate the association of 
serum bilirubin and clinical outcomes in CKD patients.
Methods: A total of 5479 patients who visited nephrology clinic at Seoul National 
University Boramae Medical Center between 2006 and 2016 were enrolled. Patients were 
divided 4 groups according to different baseline serum total bilirubin levels. Primary 
outcome was ESRD and secondary outcome was all-cause mortality. We conducted Cox 
analysis to evaluate the association between all-cause mortality and ESRD progression. 
Age, sex, eGFR, hypertension, and diabetes were included as covariates.
Results: Mean serum bilirubin level was 0.7±0.5 mg/dL. A total of 1029patients 
were a group with the lowest serum bilirubin level (0.5 mg/dL<Bb) and 1723patients 
had bilirubin level between 0.5mg/dL and 0.7mg/dL.1658patients had bilirubin level 
between 0.7 g/dL and 1.0mg/dL, 1069 patients with more than 1.0 mg/dL bilirubin. Low 
bilirubin groups were older and had more hypertension and diabetes. Also, eGFR of low 
bilirubin groups was lower than that of high bilirubin group. During the follow-up period 
of 79.4±10.3 months, 412 patients developed ESRD and 691 patients were dead. In the 
multivariate cox analysis, the higher serum bilirubin level groups had significantly lower 
risk of ESRD progression, while the group with the lowest mortality rate was not the group 
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with highest bilirubin level but the group with mildly elevated bilirubin(0.7≤Bb<1.0mg/dL) 
representing reverse J shaped curve.
Conclusions: The lower serum total bilirubin level was significantly related with 
ESRD progression and mortality. Total serum bilirubin can be used as early biomarker for 
predicting ESRD development and survival in CKD patients.
Figure 1. Survival curves showing ESRD risk and mortality according to bilirubin 
levels.
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The Relationship Between Body Mass Index (BMI) and Outcomes in 
Health and CKD
Jochen G. Raimann,1 Peter Kotanko,1 Levi D. Waldron.2 1Renal Research 
Institute, New York, NY; 2Waldron Lab, CUNY Graduate School of Public 
Health and Health Policy, New York, NY.
Background: In the general population the relationship between BMI and mortality 
is U-shaped, while in the hemodialysis (CKD 5D) population lower risk at higher BMI 
was observed. Pathophysiologic explanations exist, but disease may also act as a statistical 
collider creating a “selection bias by death”. We studied the relationship across CKD stages 
and in various subpopulations.
Methods: We studied healthy subjects, CKD patients at various stages (NHANES 
1999 to 2010), and CKD5D patients dialyzing in Renal Research Institute (RRI) clinics. 
We constructed Cox proportional hazard models and depicted hazard ratios over a wide 
BMI range using spline functions and evaluated differences between subsets stratified by 
age (</>= 55 years), gender, race, and ethnicity. We also constructed polynomial models to 
test for an interaction between CKD stage and BMI in the Cox models. Akaike Information 
Criterion (AIC) was computed to determine the most accurate model.
Results: We studied 21569 healthy subjects, 8621 CKD stage 2 patients, 2507 CKD 
stage 3-5 patients, and 4351 CKD5D patients. We found consistently an inverse association 
between BMI and mortality in CKD5D patients and variations in the other subsets. While 
the interaction between CKD stage and BMI were significant in all constructed models, 
the final model with the lowest AIC value include only an interaction between CKD5D 
and BMI.
Conclusions: Our data show a consistent U-shaped relationship between BMI and 
all-cause mortality in the general population, but an “obesity paradox” in CKD5D. While 
the biological reasons are elusive, the consistency of the observation across all analyses 
suggests a pathophysiological relationship in concert with CKD acting as a statistical 
collider.
Spline function of hazard ratio of all-cause mortality over a 3-year follow-up period as a 
function of body mass index (BMI).
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Race, Gender, and the Participation Gap: Evaluation of Clinical Trials in 
Kidney Disease
Krishna A. Agarwal,1 Nayan Agarwal,2 Pranav S. Garimella,3 Tushar Chopra,4 
Michelle M. Wong,5 Rakesh Malhotra.3 1UMass Medical School-Baystate, 
Springfield, MA; 2University College of Medical Sciences and GTB Hospital, 
Delhi, New Delhi, India; 3University of California, San Diego, CA; 4University 
of Virginia, Charlottesville, VA; 5University of British Columbia, Vancouver, BC, 
Canada.
Background: Disparities in kidney disease by race, ethnicity, and sex are well 
documented. However, the representation of these groups in randomized controlled trials 
(RCTs) is largely unknown. Here, we aim to determine differences in gender and race 
participation in kidney disease RCTs.
Methods: The ClinicalTrials.gov electronic database was searched from January 1, 
1970 to January 1, 2018, with the following keywords: “kidney disease,” “chronic kidney 
disease” (CKD), “acute kidney injury” (AKI), “hemodialysis” (HD), “peritoneal dialysis”, 
“glomerulonephritis” (GN), “kidney stones”, “kidney transplant”, or “polycystic kidney 
disease” (ADPKD). RCTs that were registered as completed and which reported results 
were eligible for inclusion. We limited our search to studies which were conducted in United 
States and published in the English language. Two reviewers independently extracted race 
and gender data onto standardized extraction forms.
Results: The initial search provided 2436 citations with 339 studies (CKD 109; HD 75; 
AKI 44; GN 40; Transplant 33; ADPKD 19; Misc. 19) potentially eligible for inclusion. Of 
the 339 trials (n=102,361, mean age 56±12 years), sex was reported for 98% (n=100,452) of 
trial participants. Women accounted for 43% of participants overall, with similar percentages 
in non-dialysis CKD RCTs and dialysis RCTs. Race was reported for 60% (n= 61, 697), 
of which 78.5% were Caucasians, 15.6 % African American (AA), 3.7% Hispanics, 1.5% 
Asians, 0.6% American Indians and 0.1% were Native Hawaiian. In HD RCTs, Caucasian 
(44.9%) and AA (42.0%) were equally represented, and Hispanics accounted for 9.6% of 
trial participants. Low recruitment of AA (3.2% and 11.6%, respectively) and Hispanics 
(5.8% and 0.7%, respectively) was observed in both transplant and AKI RCTs.
Conclusions: Our findings suggest that racial minorities, especially AA and Hispanics, 
and women are less likely to be enrolled in clinical trials. Future studies should focus on 
addressing the barriers to recruitment of women and minorities in RCTs, in order to achieve 
representative RCT populations.
TH-PO1103 Poster Thursday
CKD: Clinical, Outcomes, Trials - I
Sex and Racial Differences in Pre-Dialysis Hospitalization in Incident 
ESRD Patients
Silvi Shah, Karthikeyan Meganathan, Annette Christianson, Anthony C. Leonard, 
Charuhas V. Thakar. University of Cincinnati, Cincinnati, OH.
Background: Pre-dialysis hospitalization is an independent predictor of mortality, and 
significant contributor to health care costs in patients with end stage renal disease. Sex 
and racial differences in the pre-dialysis hospitalizations has not been studied for incident 
dialysis patients.
Methods: We evaluated 165,452 adult patients who initiated dialysis between 1/1/2010 
and 12/31/2014 from the United States Renal Data System with linked claims for Medicare 
Part A and Part B or Medicare Primary Other as the primary payer for the entire two 
years prior to dialysis initiation. Using case-mix adjusted logistic regression models, we 
examined the impact of race and sex on the two year pre-dialysis hospitalization as the 
primary outcome identified using ICD-9 codes.
Results: Mean age was 73 ± 11 years. In the study sample, 54.3% were men. 65% were 
Whites, 21.6% were Blacks, 8.9% were Hispanics, 3.5% were Asians, and 0.9% were Native 
Americans. Overall, 77% of patients had at least one pre-dialysis hospitalization. Among 
the causes of pre-dialysis hospitalization, 28.6% of patients experienced cardiovascular 
hospitalization, 12.4% had infection hospitalization, 11.5% had both cardiovascular and 
infection hospitalization and 24.5% had neither cardiovascular nor infection hospitalization. 
Overall, one-year all-cause mortality was 30.7%. Women had higher odds of pre-dialysis 
hospitalization as compared to men (odds ratio [OR], 1.17; 95% confidence interval [CI], 
1.14-1.20]). In adjusted analyses, as compared to Whites patients, odds of pre-dialysis 
hospitalization was lower among Asians (OR, 0.55; 95% CI, 0.52-0.59]), and Hispanics 
(OR, 0.80; CI, 0.77-0.84); and was not statistically significant for Black patients or Native 
Americans.
Conclusions: Among dialysis patients, women have 17% higher odds of pre-dialysis 
hospitalization as compared to men. As compared to White patients, Asians have 45% lower 
odds and Hispanics have 20% lower odds of pre-dialysis hospitalizations. Process of care 
and biological factors need to be explored further to understand the reasons behind these 
disparities associated with pre-dialysis hospitalization.
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Pregnancy Outcome Predictors Among Japanese Patients with CKD
Satoshi Kumakura,1 Takashi Nakamichi,1 Tasuku Nagasawa,1 Tae Yamamoto,1 
Masatoshi Saito,2 Mariko Miyazaki,1 Hiroshi Sato,1 Sadayoshi Ito.1 1Department 
of Nephrology, Endocrinology and Vascular Medicine, Tohoku University 
Hospital, Sendai, Japan; 2Department of Obstetrics and Gynecology, Tohoku 
University Hospital, Sendai, Japan.
Background: Studies on pregnant patients with chronic kidney disease (CKD) have 
been performed worldwide; however, data on the size of the study population, race, as 
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well as information on CKD are limited. On account of limited data rendering the studies 
non-generalizable, some of the guidelines remain controversial, thereby restricting their 
application in clinical practice. We conducted a retrospective cohort study to address this 
problem by clarifying the association between CKD status and pregnancy outcomes.
Methods: Patients with CKD who gave birth or miscarried at our institution between 
January 1, 2010, and December 31, 2017 were selected as the study population. Clinical 
data were collected from medical records. We analyzed the correlations between CKD 
status (age, body mass index, estimated glomerular filtration rate [eGFR], urinary protein-
creatinine ratio [UP], mean blood pressure [MBP], and antihypertensive drug use [HTND]) 
at the time of referral and severe adverse events (SAE). We also focused on the incidence of 
small-for-gestational-age (SGA) infants and birth weight (BW).
Results: The study included 113 pregnancies among 88 patients. Median age was 32 
years (interquartile range [IQR]: 29-36). Median eGFR was 101.8 ml/min/1.73 m2 (IQR: 
80.9-120.3). Median UP was 0.17 g/gCr (IQR: 0.04-1.1). Of the 88 patients, most were 
Japanese, 28 had IgA nephropathy, 15 had nephrotic syndrome. SAE in 34 cases included 
severe pregnancy-induced hypertension, preterm delivery, emergency cesarean section, 
neonatal intensive care unit admission, low BW, and fetal death. Multivariate logistic 
regression analysis showed that SAE was correlated with age (odds ratio [OR]=1.14, 
p=0.025), eGFR (OR=0.98, p=0.013), MBP (OR=1.05, p=0.033), and HTND (OR=4.00, 
p=0.025). BW was correlated with age (t=-2.20, p=0.03), UP (t=-2.05, p=0.043), and 
HTND (t=-2.36, p=0.021) according to multivariate linear regression analysis (R-squared 
=0.20). However, UP alone was a predictor for SGA (OR=1.42, p=0.021) according to 
multivariate logistic regression analysis.
Conclusions: As in previous reports, eGFR was found to be a predictor of SAE. 
However, we found that it was UP rather than kidney function that might affect child 
growth. Therefore, the mechanism of SAE development and the effect on child growth 
might be different among CKD pregnancies.
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Anti-Mullerian Hormone in Women with CKD
Kate Wiles,1,2 Emma Wayman,6 Catherine Nelson-piercy,5 Liz Lightstone,3 
Lucy C. Chappell,1 Kate Bramham.4 1King’s College London, London, United 
Kingdom; 2Guy’s and St. Thomas’ NHS Foundation Trust, London, United 
Kingdom; 3Imperial College London, Hammersmith Hospital, London, United 
Kingdom; 4King’s College Hospital, London, United Kingdom; 5Guy’s & St 
Thomas’ Foundation Trust, London, United Kingdom; 6Guys and St Thomas’ 
trust, London, United Kingdom.
Background: Although CKD is recognised to impact female fertility, underlying 
pathophysiological mechanisms are poorly understood. Serum concentrations of anti-
Mullerian hormone (AMH) are used in women without CKD as a marker of ovarian 
reserve, which is a key component of female fertility. There are limited data on the utility of 
serum AMH quantification in women with CKD.
Methods: Serum AMH was quantified by Roche Elecsys AMH assay in 163 women 
with CKD (30 CKD stage 1, 37 Stage 2, 26 Stage 3a, 31 Stage 3b, 21 Stage 4, 18 Stage 5) 
seeking pregnancy advice. Values were compared to assay-specific percentiles.
Results: In women with CKD there was no correlation between eGFR and age-
corrected AMH centile (r=-0.001, p=0.98). There was a strong correlation between 
AMH and age (r=-0.5, p<0.0001). Women with CKD had a lower age-corrected AMH 
concentration compared to women without CKD across all CKD stages (p=<0.0001 to 
0.007). The effect of CKD on AMH was greatest for women <35 years (p=0.002-0.03).
Conclusions: Women with CKD have lower levels of serum AMH compared to 
women without CKD, across all stages of CKD. This suggests that women with CKD have 
reduced ovarian reserve. The clinical significance of a lower serum AMH, especially in 
women with CKD <35 years, warrants further investigation. There is no evidence that renal 
clearance modifies serum AMH concentration.
Funding: Government Support - Non-U.S.
Age-specific serum AMH concentrations (median ± IQR) in women with CKD (black) 
compared to controls (grey)
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The Impact of Gender on Inpatient Mortality of Hypertensive Patients 
with CKD3 to ESRD in the US
Mark A. Nader,1,2 Rodrigo Aguilar Campos,2 Oussama Hassan,3 
Carmen E. Cervantes,7 Ricardo Correa,4 Prabin Sharma,9 Rehan Shafique,1 
Hieu Q. Vo,5 Omar Hamze,1 Ping Li,6 Judit Gordon.8 1Kidney Care Consultants, 
Memphis, TN; 2Georgetown University Hospital, Washington, DC; 3Royal 
London Hospital, Austin, TX; 4University of Arizona, Phoenix, AZ; 5Nephrology 
and Hypertension, university of Tennessee, Memphis, TN; 6George Washington 
University, Washington, DC; 7Aventura Hospital and Medical Center, Aventura, 
FL; 8Medstar Georgeotown University Hospital, Washington, DC; 9Yale 
University Bridgeport Hospital, Bridgeport, CT.
Background: HTN and CKD are 2 of the most important risk factors for CVD in 
the US population.The impact of gender or race in this equation remains unclear. Studies 
comparing the inpatient mortality between males and females with HTN and CKD are 
sparse. Our aim was to determine if gender in the US population and menopausal age, affect 
the inpatient survival rate of hypertensive patients across CKD stages.
Methods: Data was extracted from the 2005-2012 Nationwide Inpatient Sample (NIS). 
Using propensity score matching, hypertensive female with CKD (stage3-5 + ESRD) 
patients were matched with hypertensive males at a 1:1 ratio. We compared inpatient 
mortality per CKD stage, menopausal age and race. Analyses were performed using SAS9.3.
Results: Among 2,121,750 hospitalized hypertensive patients, 51.5% were males and 
48.5% females. There was 32.1% females with CKD3, 14.7% with CKD4, 3.4% CKD5 and 
54% with ESRD. Similarly, 32.7% of males have CKD3, 13.2% CKD4, 3.2% CKD5 and 
50.9% with ESRD. In-hospital crude mortality was significantly higher for males compared 
to females at CKD stages 3 (3.1 vs 3.3% p<0.0001), CKD4 (4.1 vs 4.4%p=0.0004) and 
ESRD (5.1 vs 5.2%p=0.0039) but was non-significant in CKD5 not on dialysis (4.7 vs 
4.8%p=0.45). Factoring menopausal age for each race group, we find women<50y old to 
have significantly less mortality than men, across all CKD stages and races. Women> 50y 
have similar mortality rate to men with CKD 3,4 or 5; while women>50y with ESRD have 
a significantly higher mortality than ESRD men of similar race group (fig1).
Conclusions: Inpatient mortality risk of women compared to men through stages 
of CKD 3 to ESRD, appears to be reduced in pre-menopausal women, comparable after 
menopause and increased when on dialysis, irrespective of the race group. Further studies 
are needed to elucidate the possible links of menopause and the effect of gender with 
mortality in patients with hypertension and CKD and to assess if this holds true in outpatient 
settings.
TH-PO1107 Poster Thursday
CKD: Clinical, Outcomes, Trials - I
Impact of Thyroid Hormones on Kidney Function in Patients with a Renal 
Transplant – A Retrospective Data Analysis
Benjamin Schairer, Georg Punzengruber, Wolfgang Winnicki, Harald Herkner, 
Gurkan Sengoelge. Medical University of Vienna, Vienna, Austria.
Background: High levels of thyroid-stimulating-hormone (TSH) correlate with 
reduced estimated glomerular filtration rate (eGFR) and an increased risk of developing 
chronic kidney disease (CKD), even in euthyroid patients. Thyroid-hormone-replacement-
therapy has been shown to delay progression of end-stage renal disease in sub-clinically 
hypothyroid patients with CKD. However, the presence of such a link after kidney 
transplantation (NTX) has not been previously investigated. This study tested whether TSH 
levels are associated with eGFR in patients with a renal transplant.
Methods: 398 patients who received an NTX between 2003 and 2016 in Vienna, 
Austria, were included in this retrospective study. Thyroid and kidney function parameters 
were collected at 12 and 24 months post NTX. Linear regression models estimated the 
association between thyroid- and renal function. Functional variables at both time-points 
or their differences over time were used to avoid within-individual correlations in a 
longitudinal setting. Multivariable linear regression models were employed to adjust main 
effect estimates due to potential confounding factors: BUN/creatinine ratio, tacrolimus 
plasma levels, CRP, BMI, gender, age.
Results: A linear regression analysis comparing the changes in eGFR and TSH 
between months 12 and 24 post NTX showed a significant inverse correlation (p=0,0183). 
For every 1-unit increase in the change of TSH over 12 months eGFR decreased by 
1,39 ml/min in the same time frame. The strongest confounder in this comparison was 
BUN/creatinine ratio. TSH had no impact on eGFR when values 12 and 24 months post 
NTX were compared: p=0,6296 or p=0,8578, respectively.
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Conclusions: Normothyroid renal graft recipients with increasing TSH values between 
the months 12 and 24 post NTX had less stable, even decreasing eGFR levels. The single 
thyroid and kidney function values at selected time-points did not show a correlation. 
Prospective randomized placebo-controlled studies are underway to clarify whether 
treatment with thyroid hormones reaching low-normal TSH levels could enhance eGFR of 
patients with a kidney graft.
TH-PO1108 Poster Thursday
CKD: Clinical, Outcomes, Trials - I
Creating Axes of Kidney Tubule Health: A Factor Analysis of Biomarkers  
in SPRINT
Alexandra K. Lee,1 Ronit Katz,2 Vasantha Jotwani,1 Pranav S. Garimella,3 
Joachim H. Ix,3 Michael Shlipak.4 1Kidney Health Research Collaborative, UCSF 
& VA, San Francisco, CA; 2University of Washington, Seattle, WA; 3UCSD, San 
Diego, CA; 4San Francisco VA Medical Center, San Francisco, CA.
Background: Several biomarkers of kidney tubule function and injury associate 
with cardiovascular disease (CVD) and mortality risks, but associations are weakened by 
their physiological overlap and inter-correlation. Factor analysis is an agnostic method to 
condense information by analyzing covariance of measurements. We hypothesized that 
factor scores would represent underlying physiology and be associated with outcomes 
independently of eGFR and albuminuria.
Methods: Among 2,376 SPRINT participants with eGFR <60, we measured urine 
levels of kidney tubule injury (IL-18, NGAL, KIM-1, MCP-1, YKL-40) and function 
(α-1 microglobulin, β-2 microglobulin, uromodulin), and serum levels of PTH and FGF23. 
Factor analysis utilized principal-component factor estimation and promax rotation. We 
used Cox models to evaluate associations of factor scores with composite CVD, heart 
failure (HF), and all-cause death.
Results: Mean age was 73±9, 40% female, and mean eGFR 46±11. Factor scores 
reflected biology: there were two injury factors, Factor 1 comprised by IL-18, NGAL, and 
YKL-40; Factor 2 by MCP-1 and KIM-1; one factor of proximal tubule reabsorption, Factor 
3, α-1 and β-2; and one factor of renal reserve: Factor 4, uromodulin, PTH, and FGF23. 
After adjusting for eGFR, albuminuria, and CVD risk factors, Factors 1, 3, and 4 were 
associated with CVD risk (Table), and Factor 1 was associated with HF. Factors 1 and 4 
were associated with higher mortality risk. In participants without prior CVD or HF, Factor 
3 was more strongly associated with CVD (HR 1.28, 95%CI 1.08-1.52) and HF (1.36, 1.02-
1.81) (p-for-interaction=0.03, 0.04).
Conclusions: Combining biomarkers into factors may be an efficient method to create 
biologically plausible axes of kidney tubule health that have important associations with 
CVD risk, independently of glomerular markers.
Funding: NIDDK Support
Adjusted Associations of Factor Scores (per SD) with CVD, HF, and Death in SPRINT-
CKD Participants
Adjusted for age, sex, race, randomization arm, eGFR, ACR, history of CVD/HF, number 
of hypertensive agents, SBP, DBP, HDL, total cholesterol, triglycerides, statin use, smoking.
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Plasma TNF Receptor Concentrations After Hospitalization with AKI and 
Long-Term CKD and Mortality
Steven G. Coca,1 Dennis G. Moledina,2 Mark M. Wurfel,3 Edward D. Siew,4 
Amit X. Garg,5 Chi-yuan Hsu,6 James S. Kaufman,7 Paul L. Kimmel,8 
Chirag R. Parikh.9 ASSESS-AKI 1Icahn School of Medicine at Mount Sinai, New 
York, NY; 2Yale School of Medicine, New Haven, CT; 3University of Washington, 
Seattle, WA; 4Vanderbilt University School of Medicine, Nashville, TN; 5London 
Health Sciences Centre, London, ON, Canada; 6University of California San 
Francisco, San Francisco, CA; 7VA New York Harbor Healthcare System, New 
York, NY; 8National Institute of Diabetes and Digestive Kidney Diseases 
(NIDDK), Bethesda, MD; 9Yale University and VAMC, New Haven, CT.
Background: Plasma tumor necrosis factor receptor (TNFR)1 and TNFR2 provide 
prognostic information in ambulatory patients with diabetic kidney disease, but their utility 
in patients after an episode of AKI is unknown.
Methods: Hospitalized adults with and without AKI were enrolled in a parallel, 
matched cohort from 4 centers between 2009-2015 and had plasma TNFR1 and TNFR2 
measured at the outpatient baseline visit within 3 months post-discharge. We tested for 
associations between biomarkers, expressed continuously and by quartiles, with time until 
the composite kidney outcome (CKD incidence, CKD progression, or ESRD) and death via 
a multivariable Weibull regression model that accounted for (1) the 1:1 matching of adults 
and (2) competing risk. We adjusted for demographics, comorbidities, AKI status during 
hospitalization, and concurrent eGFR, UACR, and CRP at the baseline visit.
Results: Among 1377 participants, median concentrations of TNFR1 and TNFR2 
decreased from 3976 [IQR 2791-5936] and 8485 [IQR 5865-12774] pg/mL during 
hospitalization, to 2829 [IQR 2064-4162] and 6661 [IQR 4758-9692] pg/mL at the post-
discharge baseline visit, respectively. The composite CKD outcome occurred in 257 (19%) 
and death before CKD occurred in 212 (15%) over a median follow-up of 4.2 years, 
and these events occurred more frequently in those with higher concentrations of each 
biomarker. After adjustment for a comprehensive panel of covariates, plasma TNFR1 and 
TNFR2 were independently associated with both the CKD outcome and death (Figure).
Conclusions: In hospitalized patients that survived at least 3 months, plasma TNFR1 
and TNFR2 provide additional risk-stratification for kidney outcomes and death, even 
after accounting for concurrent measures of kidney function, albuminuria, and systemic 
inflammation.
Funding: NIDDK Support
Association of Plasma TNFR1 and TNFR2 with Outcomes in the ASSESS-AKI Study
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Elevated Soluble ST2 Levels but Not Galectin-3 Is Associated with Renal 
Progression and Adverse Clinical Outcomes in Non-Dialysis Patients with 
CKD
Ae jin Kim, Kayeong Chun, Han Ro, Jae Hyun Chang, Hyun Hee Lee, 
Wookyung Chung, Ji Yong Jung. Division of Nephrology, Department of 
Internal Medicine, Gachon University Gil Medical Center, College of Medicine, 
Gachon University, Incheon, Republic of Korea.
Background: Soluble ST2 (sST2) and Galectin-3, novel biomarkers of heart failure 
and cardiovascular stress, predict cardiovascular event and mortality. However, the 
relationships with renal function and adverse outcomes are less certain. The purpose of this 
study was to determine whether sST2 and Galectin-3 associated with chronic kidney disease 
(CKD) progression and adverse clinical outcomes.
Methods: We measured baseline sST2 and Galectin-3 concentrations in CKD patient 
cohort at our institution included between October 2013 and December 2014. The primary 
outcome was CKD progression (≥50% reduction in estimated GFR [eGFR] from the 
baseline or reach to the end-stage renal disease [ESRD]). The secondary outcome was the 
composite of CKD progression, cardiovascular event, or death. We used Cox proportional 
hazards model to evaluate associations between sST2 and Galectin-3 level with renal and 
composite outcomes.
Results: A total of 312 patients were enrolled in this study. At baseline, sST2 was 
directly associated with serum creatinine (r = 0.492, P < 0.001) and urine protein-to-
creatinine ratio (UPCR) (r = 0.309, P < 0.001). Galectin-3 was also directly associated with 
serum creatinine (r = 0.164, P = 0.004) and UPCR (r = 0.136, P = 0.027). Cox regression 
analysis showed that baseline sST2 level was independently predicted the CKD progression 
(hazard ratio [HR] per SD increase in log-transformed sST2 concentration, 16.383; 95% 
confidence interval [CI], 3.362 – 79.836; P = 0.001) and composite outcome (HR, 5.430; 
95% CI, 1.459 – 20.213; P = 0.012) after adjustment for confounding factors. However, 
baseline Galectin-3 level was associated with CKD progression and composite outcome 
only in crude analysis, lost its statistical significance after adjustment for confounding 
variables.
Conclusions: In conclusion, elevated levels of sST2 are significantly associated with 
renal progression and adverse clinical outcomes in non-dialysis patients with CKD.
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Serum Metabolomic Biomarkers Associated with Neurocognitive 
Dysfunction in Youth with CKD
Celina Brunson,1 Lu Huang,2 Justine Shults,1,2 Susan L. Furth,1,2 
Michelle Denburg,1,2 Erum A. Hartung.1,2 1Children’s Hospital of Philadelphia, 
Philadelphia, PA; 2Perelman School of Medicine University of Pennsylvania, 
Philadellphia, PA.
Background: CKD is linked to worse neurocognitive (NC) outcomes, possibly related 
to effects of uremic toxins on the brain. Aims of this study are (1) to compare serum 
metabolomic profiles of children and young adults with CKD to healthy controls and (2) to 
evaluate the association between serum metabolite levels and NC outcomes in individuals 
with CKD.
Methods: Serum untargeted metabolomic profiling (Metabolon, Inc.) was performed 
in individuals aged 8-25 years with CKD Stage 2-4 (n=65) and matched healthy controls 
(n=69). Metabolite levels in CKD vs. control groups were compared by multivariable 
linear regression, with metabolite level as the outcome variable and CKD vs. control as 
the explanatory variable, adjusted for age, gender, obesity and race. Using the subset of 
metabolites that differed in CKD vs. controls after Bonferroni correction (threshold 
p=5.7x10e-7), the relationship of metabolite level and NC outcome within the CKD group 
was analyzed by multivariable linear regression, with NC composite score as the outcome 
variable and metabolite level as the explanatory variable, adjusted for estimated glomerular 
filtration rate (eGFR), glomerular vs. non-glomerular disease, maternal education, income, 
age, gender, obesity and race. The NC composite score was calculated using the mean 
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of z-scores within 4 domains: intelligence, attention regulation, working memory and 
executive function.
Results: 233 of the 876 metabolites identified differed significantly between CKD and 
control groups after Bonferroni correction, including metabolites previously found to be 
associated with CKD and NC dysfunction such as those within the kynurenine/tryptophan 
and glutamate pathways. Within the CKD group, 6 of the 233 metabolites examined were 
associated with NC composite score (raw p values <0.05), but the association was not 
significant after Bonferroni correction.
Conclusions: Youth with CKD have significantly different metabolomic profiles than 
healthy controls. We did not find an association between metabolite levels and composite 
NC outcome in the CKD group. However, use of a composite NC score may mask 
differences in individual NC domains, and adjusting for eGFR may mask associations with 
renally-cleared metabolites. Future analyses will include examining the relationships of 
metabolite levels with individual NC domains.
Funding: NIDDK Support
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Robotic Technology Quantifies Cognitive Deficits in Multiple Domains for 
ESRD Patients
Jessica Vanderlinden, Stephen H. Scott, Rachel M. Holden, J. gordon G. Boyd. 
Queen’s University, Kingston, ON, Canada.
Background: Cognitive impairment is highly reported among chronic kidney disease 
(CKD) patients, particularly in stage 5 CKD. Lack of validated assessments for quantifying 
cognition in CKD patients can lead to difficulty in determining the prevalence and degree of 
this impairment. Robotic technology, such as the KINARM, may be able to detect cognitive 
deficits associated with CKD, particularly because the KINARM has been shown to identify 
subtle neurocognitive deficits in ischemic stroke patients. Importantly, these subtle deficits 
may correlate better with quality of life assessments than routine clinical testing. Objective: 
To quantify the neurocognitive deficits of patients with stage 5 CKD.
Methods: Recruitment was performed at a CKD clinic in a tertiary medical centre. 
Eligible patients were stage 5 CKD patients with no history of neurodegenerative disease 
or stroke. Consented patients performed a neuropsychological battery that included: the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and a 
robotic assessment (KINARM, BKIN Technologies, Kingston ON). The RBANS measures 
5 cognitive domains along with giving an overall composite score, whereas the KINARM 
Standard Tests quantifies sensorimotor and neurocognitive control of the upper limb.
Results: From July 2015-April 2018, 30 patients were recruited. On the RBANS, 
only 3/30 patients scored outside the normative range (defined as >1.96 SD, representing 
the 95% performance of healthy controls) on the composite total score which measures 
global impairment. There was variability of impairment across domains, ranging from 0/30 
on language to 8/30 on the visuospatial domain. In contrast, compared to age and gender 
matched controls, approximately one-third of patients were impaired on six of the nine tasks 
performed. These tasks correspond to deficits in: attention (10/30), sensorimotor (9/30), 
visuospatial (13/30), visuomotor (11/30), overriding of automatic response (10/13), and 
executive function (11/30).
Conclusions: Robotic technology can detect cognitive impairments in a higher 
proportion of patients with stage 5 CKD compared to a traditional neuropsychological 
assessment tool. The clinical relevance of these cognitive impairments needs further 
investigation.
Funding: Government Support - Non-U.S.
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Inflammatory Biomarkers Improve Prediction of Sertraline Treatment 
Response in CKD
L Parker Gregg,1,2 Thomas Carmody,1 Dustin Le,1 Madhukar Trivedi,1 
Susan Hedayati.1 1University of Texas Southwestern, Dallas, TX; 2VA North 
Texas Healthcare System, Dallas, TX.
Background: Inflammation may mediate depression, and CKD is associated with 
elevated inflammatory markers and depression prevalence. We studied whether baseline 
inflammation predicts treatment response to sertraline in individuals with CKD and 
depression.
Methods: In 193 participants with stage 3-5 CKD and depression randomized 
to sertraline or placebo in the double-blind Chronic Kidney Disease Antidepressant 
Sertraline Trial (CAST), we measured baseline albumin, pre-albumin, interleukin-6 (IL-6), 
and high sensitivity C-reactive protein (hsCRP). Outcomes were a ≥3-point decrease 
(improvement) and ≥50% decrease (response) in depressive symptoms, assessed by the 
Clinician-Rated 16-Item Quick Inventory of Depression Symptomatology (QIDS). Logistic 
regression measured associations of inflammatory markers with outcomes after covariate 
adjustment. Inflammatory marker x treatment interaction P<.1 was considered significant. 
The areas under the curve (AUC) for nested models predicting response were compared 
using non-parametric tests.
Results: Mean age was 58±13 years, 58% were Black, 42% White, and 18% Hispanic. 
HsCRP correlated with baseline QIDS score (r=.19, P<.05). In the sertraline group, hsCRP 
was higher in those who did vs. did not achieve improvement, median (IQR): 5.0 (1.7-8.6) 
mg/L vs. 1.4 (0.6-3.7), P=.005, and response, 5.0 (2.0-14.6) vs. 2.7 (0.8-6.0), P=.03. A 1 
log-unit increase of hsCRP independently predicted a differential degree of improvement 
and response to sertraline vs. placebo (Table). Baseline QIDS, eGFR, age, diabetes, site, 
and hsCRP (highest tertile) predicted sertraline response, AUC (95% CI) .71 (.58, .85). 
Addition of albumin and pre-albumin (lowest tertile) and IL-6 (highest tertile) improved the 
AUC to .82 (.72, .92), P=.02 (Figure).
Conclusions: Higher baseline hsCRP was independently associated with depressive 
symptom improvement and response to sertraline. Inflammatory biomarkers may identify 
CKD patients more likely to benefit from sertraline.
Funding: NIDDK Support, Other NIH Support - National Center for Advancing 
Translational Sciences, Veterans Affairs Support, Private Foundation Support
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Expression of MMPS and TIMPS Is Differentially Regulated in Cataract 
Tissue of Patients with CKD and Diabetes Mellitus (DM) or Both
Calum W. Chong,1 Minas T. Coroneo,2 Ian C. Francis,3 Zoltan H. Endre,1,2 
Jonathan H. Erlich.2,1 1Prince of Wales Hospital, Bellevue Hill, NSW, Australia; 
2UNSW, Randwick, NSW, Australia; 3Prince of Wales hospital, Randwick, NSW, 
Australia.
Background: Cataract is a common preventable cause of blindness particularly 
amongst diabetics and recent reports suggest an increased incidence in patients with CKD. 
Matrix metalloproteinases MMPS and their regulators, including tissue inhibitors of MMPS 
(TIMPS) are variably expressed in lens tissue and may play a role in the genesis of cataract 
formation. This may result from direct modulation of extracellular matrix or be secondary 
to cell cycle events or other pathways
Methods: We prospectively evaluated 270 patients (age range, 46-93 years; mean, 71 
years) who had phacoemulsification cataract surgery with intraocular lens implantation. 
Cataracts were graded at time of surgery, noting the presence of renal impairment 
(eGFR<60ml/min), type 2 diabetes mellitus and use of hypolipidemic drugs. For analysis, 
subjects were categorized according to presence of absence of diabetes mellitus and the 
presence or absence of CKD. mRNA was extracted from 123 patients, and real time PCR 
performed for MMPs 1,2,3,9,14 and 15 and TIMPS 1,2,3 and 4. All samples were corrected 
for the housekeeper gene 18S
Results: Age and CKD but not DM were associated with higher grade cataracts. 
MMPs 1,3,14 and TIMPS 1,2, and 3 were readily quantifiable by RT PCR. Only low 
levels of MMP 2 and 9 were observed and could only be quantified as present or absent. 
MMP15 and TIMP 4 were not detected. Non-diabetic patients with CKD EGFR < 60 ml/ml 
had relatively increased expression of MMP1,3,14 and TIMPs 1,2, and 3. There were no 
detectable differences in MMP 2 and 9. The presence of DM eliminated many differences, 
with higher levels of MMP 14 and TIMPs 2 and 3 in patients without CKD compared to 
those with CKD and DM. Hypolipidemic agents modified MMP and TIMP expression in 
patients with eGFR> 60 ml/min but not CKD. In non-diabetic patients, the product of TIMP 
1 or 2 and MMP-3 alone were highly predictive of renal impairment with ROCs of 0.88 and 
0.89 respectively. In patients with DM and CKD only TIMP-2 x MMP3 was predictive of 
CKD with an AUC of 0.74
Conclusions: CKD, diabetes and hypolipidemic agents differentially regulate the 
expression of MMPS and TIMPs in cataracts. These regulators may be important in 
the pathogenesis and relevant to potential therapeutic interventions for slowing cataract 
formation
Funding: Clinical Revenue Support
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Type III Collagen Turnover Is Associated with Disease Progression and 
Mortality in CKD Patients from the Renal Impairment in Secondary Care 
Cohort
Daniel Guldager Kring Rasmussen,1 Anthony Fenton,2 Federica Genovese,1 
Morten A. Karsdal,1 Charles Ferro,2 Mark D. Jesky,2 Paul Cockwell.3 1Nordic 
Bioscience, Herlev, Denmark; 2University Hospital Birmingham NHS Trust, 
Birmingham, United Kingdom; 3Queen Elizabeth Hospital Birmingham, 
Birmingham, United Kingdom.
Background: Renal fibrosis is a major underlying pathological feature in patients 
with chronic kidney disease (CKD) and strongly predicts progression to end-stage renal 
disease. We hypothesized that non-invasive assessment of the development and remodeling 
of fibrosis may have utility for linking dynamic in situ pathology with clinical outcomes. We 
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focused on type III collagen (COL III), one of the most abundant collagens in renal fibrosis, 
utilizing PRO-C3 to assess COL III formation and C3M for COL III degradation.
Methods: We measured serum (S)-PRO-C3 and S-C3M and urine (U)-PRO-C3 and 
U-C3M in 499 patients from the Renal Impairment In Secondary Care (RIISC) study.
RIISC is a prospective, observational cohort of patients with moderate to advanced CKD. 
One-year disease progression was defined as a decline in eGFR >30% or commencing renal 
replacement therapy within 12 months. Results were adjusted for potential confounders
including age, gender, pulse pressure, eGFR, and urinary albumin:creatinine ratio. Median 
follow-up was 46 months (range 0–72).
Results: U-PRO-C3 and S-PRO-C3 levels increased significantly with increasing CKD 
stage (p<0.0001), but were very weakly correlated (rho=0.1, p=0.03). Conversely, U-C3M 
levels decreased with increasing CKD stage (p<0.0001); there was no change in S-C3M 
levels with increasing CKD stage. The odds ratio (OR) for one-year disease progression for 
a doubling in U-C3M was 0.29 (95% CI 0.17-0.51, p<0.0001) and 0.47 (95% CI 0.23-0.96, 
p=0.04) in the adjusted model. Interestingly, the levels of U-C3M divided by S-C3M gave 
rise to a hazard ratio for development of end-stage renal disease of 0.79 (95% CI 0.63-0.99, 
p=0.04) in the adjusted model. S-PRO-C3 levels at baseline was able to predict mortality 
with hazard ratios per-doubling of S-PRO-C3 of 2.03 (95% CI 1.31-3.16, p=0.002) in the 
adjusted model.
Conclusions: In conclusion, we have found a dysregulated balance between COL 
III formation and degradation in patients with CKD, and show that this is associated 
with an increased risk of adverse outcomes. These findings need urgent replication in an 
independent cohort; if confirmed they have implications for pathotyping and therapeutic 
targeting in patients with CKD.
Funding: Commercial Support - Nordic Bioscience
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Neutrophil/Lymphocyte Ratio in Prediction of Disease Progression in 
Patients with Stage 1-4 CKD in China: Results from the Chinese Cohort 
Study of CKD (C-STRIDE)
Qiongjing Yuan,1 Jinwei Wang,2 Hui Xu.3 the C-STRIDE study group 1Xiangya 
Hospital, Central South University, Changsha, China; 2Renal Division, Department 
of Medicine, Peking University First Hospital; Peking University Institute of 
Nephrology, Beijing, China; 3Nephrology Department, Xiangya Hospital, Central 
South University, Changsha, Hunan, China, ChangSha, China.
Background: Chronic kidney disease (CKD) leads to end-stage renal failure and 
cardiovascular events. An attribute to these progressions is abnormalities in inflammation, 
which can be evaluated using the neutrophil/lymphocyte (N/L) ratio. We aimed to 
investigate the association of N/L ratio with the progression of ESKD, CVD and all-cause 
mortality in Chinese patients with stages 1-4 CKD.
Methods: A total of 1341 stages 1-4 CKD (18–74 years of age) patients with complete 
N/L and other relevant clinical variables were included in the current analysis.. Patients 
were divided according to the median of baseline N/L ratio (≥2.26 or <2.26). ESKD was 
defined at time to start hemodialysis, peritonal dialysis or renal transplantation. CVD risk 
was determined with onset of new CVD events. All-cause mortality was recorded at time of 
decease. The follow-up was censored at June 30, 2017. Cox regression analysis was used in 
estimating the association between N/L and the outcomes.
Results: Baseline N/L ratio was related to anemia rate, total serum cholesterol, eGFR, 
blood pressure, uric acid, CKD-MBD rate, cardiovascular disease, ACR and metabolic 
acidosis. The study duration was 4.35 year(IQR 2.86-5.26). Patients with N/L ratio ≥2.26 
were at risk of developing ESKD (HR 1.687(95% CI:1.288,2.209))and all-cause mortality 
(HR 3.220(95% CI:1.174,8.834))compared to patients with N/L ratio <2.26 (P<0.05); We 
did not observe a significant association between abnormal N/L and CVD risk in the multi-
variable adjusted model.
Conclusions: Our results suggest that N/L ratio other than hs-CRP is associated with 
the risk of ESKD and all-cause mortality in Chinese patients with stage1-4 CKD. N/L ratio 
is an easily accessible and useful marker for monitoring CKD patients in clinical practice.
Funding: Government Support - Non-U.S.
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Endothelial Cell Injury Marker CD146 Evaluates Disease Severity and 
Predicts Renal Outcomes of Early Diabetic Nephropathy
Ying Fan,1 Yang Fei,1 Yiyun Wang,1 Jiejun Wen,1 John C. He,2 Niansong Wang.1 
1Shanghai 6th People’s Hospital affiliated to Shanghai Jiaotong University, 
Shanghai, China; 2Mount Sinai School of Medicine, New York, NY.
Background: Glomerular endothelial cell injury plays a crucial role in the development 
of diabetic nephropathy (DN). CD146, an endothelial marker, was shown to increase in 
chronic kidney disease (CKD), but its role in DN remains unknown.In the current study, 
we examined the circulating levels of sCD146 in plasma and renal expression of CD146 
in kidney biopsies of DN patients at different CKD stages. We evaluated whether CD146 
could be used to assess the severity of disease and predict renal outcomes in DN at early 
stages.
Methods: 159 non-dialysis type 2-DN patients from 2008 to 2015 were enrolled to 
measure the plasma concentration of soluble CD146 (sCD146). 94 diabetes mellitus (DM) 
patients without DN and 100 healthy subjects were used as controls. The patients with 
CKD stage 1-3 were referred as early stages. Another independent cohort of 48 patients 
with biopsy-proved DN was used for the immunohistochemistry study of CD146. Renal 
outcomes were defined as doubling of serum creatinine, progression to end-stage renal 
disease or death.
Results: The plasma levels of sCD146 was upregulated in patients with DN compared 
to those without DN. Elevated plasma sCD146 was inversely associated with renal function 
and proved to be a more optimal marker than urine albumin creatinine ratio (UACR) to 
evaluate disease severity in these DN patients. Staining of kidney sections showed that 
CD146 was co-localized with endothelial marker CD31 and its expression increased in DN 
when compared with minimal change disease (MCD) and normal controls. The positive 
area of CD146 staining in kidney was correlated with the severity of pathological changes 
in these DN patients. Survival analysis suggested that both plasma levels of sCD146 and the 
biopsy expression of CD146 were correlated with the renal outcomes.
Conclusions: Plasma CD146 levels and its renal expression are associated with kidney 
injury and renal function and could be potentially developed as a marker to predict renal 
outcomes in patients with early stages of DN.
Funding: Government Support - Non-U.S.
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Expression of CPT1α in Human Kidney Biopsy Samples Predicts the 
Deterioration of Renal Function and Progression of Tubulointerstitial 
Fibrosis
Yi Fang,2 Qi Yuan,1 Junwei Yang.2 1Nanjing Medical University, Jiangsu 
Nanjing, China; 2Second Affiliated Hospital, Nanjing Medical University, 
Nanjing, China.
Background: Fatty acids are the preferred energy source for proximal tubule cells, 
defective fatty acid oxidation (FAO) leads to intracellular lipid accumulation, which plays 
an important role in the pathogenesis of kidney fibrosis. CPT1α is the rate limiting enzyme 
for FAO. In this study, we investigated whether expression of CPT1α in human biopsy 
samples predicts the progression of renal disease.
Methods: This was a retrospective cohort study enrolled 30 patients in our hospital 
from May 2015 to December 2015. The clinical data were collected and renal biopsy 
samples were immunhistochemically stained with CPT1α. Lipid droplets accumulation was 
detected by Oil Red O staining. Interstitial fibrosis was evaluated by Masson’s trichrome 
staining. The association of CPT1α with lipid droplets accumulation, degree of renal 
fibrosis and decline rate of eGFR was investigated.
Results: In kidney biopsy samples, lipid droplets accumulation suggested damage in 
fatty acid metabolism. Expression of CPT1α was decreased in fibrosis area. Moreover, 
CPT1α level was negatively correlated to area of lipid droplet deposition and the area of 
fibrosis (fig. 1). Furthermore, expression of CPT1α is negatively correlated with the decline 
of eGFR per year.
Conclusions: These results suggest that expression of CPT1α in human kidney biopsy 
samples may predict the decline of renal function and progression of renal interstitial 
fibrosis. CPT1α may service as a novel biomarker for prognosis of renal disease.
Funding: Government Support - Non-U.S.
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Urinary Mitochondrial DNA Level as a Biomarker of Tissue Injury in 
Non-Diabetic CKD
Zhongping Wei, Cheuk-Chun Szeto. The Chinese University of Hong Kong, Sha 
Tin, China.
Background: Chronic kidney disease (CKD) is a global public health issue and an 
important economic burden to the health care system. However, the underlying mechanism 
of progressive renal function loss in CKD, it still remains incompletely understood. 
Emerging evidence shows that mitochondrial dysfunction plays an important role in the 
pathogenesis and progression of chronic kidney disease (CKD). We study the relation 
between urinary mitochondrial DNA (mtDNA) levels and renal dysfunction in non-diabetic 
CKD.
Methods: We recruited 102 non-diabetic CKD patients, 43 of them had kidney biopsy 
that showed non-specific nephrosclerosis. Urinary mtDNA level was measured by digital 
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polymerase chain reaction, and compared to baseline clinical, biochemical, histological 
parameters as well as renal function decline in the subsequent 48.3 ± 31.8 months.
Results: Urinary mtDNA was easily detectable. The median urinary mtDNA level 
was 1519.4 (501.61 – 3131.23) million copy/mmol creatinine. There were modest 
but statistically significant positive correlations between urinary mtDNA level and 
baseline estimated glomerular filtration rate (GFR) (r = 0.427, p < 0.001) and proteinuria 
(r = 0.376, p < 0.001). For patients with kidney biopsy, urinary mtDNA level also inversely 
correlated with the severity of glomerulosclerosis (r = -0.537, p < 0.001), tubulointerstitial 
fibrosis (r = -0.309, p = 0.029). Urinary mtDNA level predicts renal event-free survival by 
univariate analysis (unadjusted hazard ratio [HR] 0.685, p = 0.033), but the predictive value 
of urinary mtDNA level fell short of statistical significance ((adjusted hazard ratio [HR] 
0.808, 95%CI 0.331 – 1.968, p = 0.638) after adjusting for confounding factors.
Conclusions: Urinary mtDNA levels correlate with baseline renal function, 
proteinuria, and the severity of histological damage in non-diabetic CKD. Our result 
suggests that urinary mtDNA level may be a surrogate marker of the degree of permanent 
renal parenchymal damage in non-diabetic CKD.
Funding: Government Support - Non-U.S.
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Reassessment of Native and Transplant Renal Biopsy Complications and 
Risk Factors as Performed by Nephrologists from a Large Australian 
Renal Unit
Jamie X. Cheong, Paul J. Champion de Crespigny. The Royal Melbourne 
Hospital, Parkville, VIC, Australia.
Background: Renal biopsies are the gold standard for diagnosis for many renal 
conditions. Approximately 250 renal biopsies per million population are performed 
in Australia per annum, 75 per million in the USA. In Australia biopsies are performed 
percutaneously under ultrasound guidance with spring loaded needles predominantly by 
nephrologists. Worldwide minor complications (5-30%) and major complications (1-7%) 
have been reported. Risk factors include hypertension, acute kidney injury, aspirin use, 
gender, BMI. There remains limited high quality data on biopsy complications and risk 
factors. We conducted a single centre audit of percutaneous renal biopsies with the aim to 
clarify complication rates and identify risk factors.
Methods: We retrospectively reviewed 997 native and transplant renal biopsies 
performed by nephrologists or trainees at our large tertiary renal and transplant centre 
between October 2015 to April 2018. Risk factors were recorded on a regulated form and 
review of the medical records. Major bleeding was defined as transfusion, embolisation 
or surgical management. Minor complications included macroscopic haematuria, urinary 
retention, non-diagnostic sample and pain.
Results: We report a total of 58 (5.8%) complications with 12 (1.1%) major 
complications and 46 (4.7%) minor complications. No nephrectomies or deaths were 
recorded. Macroscopic haematuria and pain were the most common. We found a 
significant increase in complications with systolic blood pressure >160 mmHg but 
no difference with diastolic blood pressure >90 mmHg. Of the 197 patients on aspirin, 
17 (29.3%) had complications compared to those not on aspirin (5.1%, p=0.06). Urea ≥ 
20 mmol/L had increased complications compared to Urea < 20 mmol/L(7.9% vs 5.3%, 
p=0.232). Males were more likely to have complications than females (10.2% v 3.2%, 
p<0.001). There were no increase in complications from BMI or gauge. 38(3.4%) patients 
recorded an incidental decrease in haemoglobin of > 10g/L but only 2 of these had 
documented complications.
Conclusions: Complication rates following percutaneous renal biopsies have markedly 
improved. Ongoing collection of prospective data and increase size of study is required. 
Detailed data will help provide further insight into the risks of renal biopsies and potential 
modifiable risk factors.
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Pre-Renal Biopsy (PRB) Ultrasound (US) Assessment: Does It Count?
Haridian Sosa Barrios,1 Paola M. Villabón ochoa,2 Victor Burguera,1 
Laura V. Blanco,1 Melissa Cintra Cabrera,1 Milagros Fernandez lucas,1 
Maite Rivera.1 1Hospital Universitario Ramón y Cajal, Madrid, Spain; 2Hospital 
Universitario de Guadalajara, Madrid, Spain.
Background: PRB is an important technique providing relevant information to guide 
diagnosis and treatment in renal disease. As an invasive procedure it has complications, 
mainly bleeding related. At present, routine US assessment post PRB is recommended to 
diagnose haemorrhagic and/or vascular complications. In our centre a PRB drill (SimPRB) 
is done routinely by the same nephrologists who will perform the procedure to evaluate its 
feasibility and rule out any anomalies that could prevent the patient from being biopsied.
Methods: We retrospectively analyzed all SimPRB done by Interventional Nephrology 
in our centre from January 2014 until December 2017. Our aim was to assess SimPRB 
findings and their influence on PRB technique. During SimPRB we evaluate each 
patient’s position and apnea tolerance, kidney US anatomy, previous renal abnormalities 
(like hydronephrosis and congenital deffects) and renal depth. This enables our team to 
avoid renal lesions and select needle size, puncture area and trajectory. Also, it allows 
interventional nephrologists to assess risks and benefits of PRB technique.
Results: Of 277 SimPRB done in the study period, 163 were male, 88 kidney 
transplants (KT) and 151 native kidneys (NK, 91% left sided). In 37 cases (13,3%) SimPRB 
found abnormalities and modified the technique: 7 patients were considered unsuitable for 
PRB and 30 had a relevant anomaly that modified the PRB procedure. SimPRB findings 
that contraindicated PRB were: hydronephrosis (n=2), bladder cancer (n=1), patient refusal 
(n=1), patient unable to tolerate apnea (n=1) and thinned parenchymal thickness (n=2 NK). 
In 30 cases SimPRB modified PRB technique changing the selected puncture area: cysts 
in usual puncture area (n=11), severe scoliosis (n=2), prone position intolerance (n=3), 
inaccesible KT pole (n=1) and right NK biopsy (n=13).
Conclusions: The SimPRB offers a first PRB approach for both patient and 
interventional nephrologist, reducing the number of failed procedures, anxiety and 
uncertainty about the technique. Also, SimPRB minimises complications and unnecessary 
hospital stays, thus improving patient safety and care. We suggest SimPRB should be 
included as a routine part of pre PRB protocols.
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Transient Hypotension After Renal Biopsy Did Not Predict Major 
Bleeding Complication
Yoichi Takeuchi, Tasuku Nagasawa, Mariko Miyazaki, Sadayoshi Ito. Tohoku 
University Hospital, Sendai, Japan.
Background: The vasovagal reflex during the renal biopsy is likely to be considered 
less serious. We revealed that the reflex was one of the uncomfortable complications that 
impair QOL of the patients (Yoichi T et al. Clin Exp Nephrol., 2018). Here, we aimed 
to examine the association between the transient hypotensive events and the amount of 
retroperitoneal bleeding, accurately quantified by computed-tomographic (CT) images 
of all patients after the renal biopsy. And, we conducted a risk assessment of the major 
complication.
Methods: This is a single-center retrospective observational study. A total of 454 
Japanese patients underwent ultrasound-guided renal biopsy at our hospital from 2013 
through 2017. Demographic factors, eGFR, hemoglobin concentration, platelet counts, 
and renal volume were included as covariates. Renal and bleeding volumes were 
3D-reconstructed from CT images. Major complications (blood transfusion, angiographic 
intervention and bladder obstruction) were defined as primary outcome and peritoneal 
bleeding volume as secondary outcome. Logistic regression analysis was used to control 
the possible confounders related to bleeding complications.
Results: Accurately measured by using the CT images, the retroperitoneal bleeding of 
total 454 patients had median amount of 40.3 mL (IQR: 19.6 - 88.2). Transient hypotensive 
events occurred in 26 patients (5.7%), with major bleeding complications occurring in 18 
patients (3.9%). Significant difference was found in the retroperitoneal bleeding between 
the groups with and without transient hypotensive event (median 237.6 mL [IQR: 2.34 - 
638.4] vs. median 38.9 mL [IQR: 1.00 - 974.0], P = 0.0011). A transient hypotensive event 
was associated with retroperitoneal bleeding of 100 mL or more by using logistic regression 
model (adjusted odds ratio 4.9 [95%CI: 2.12 - 11.30], P < 0.001). The hypotensive events, 
however, did not associated with major bleeding complications, and the risk factors for the 
complications were observed in lower eGFR and lower hemoglobin concentration before 
the biopsy, consistent with previous reports.
Conclusions: The vasovagal reflex after renal biopsy predicted substantial amount of 
retroperitoneal bleeding, but it had no association with the major bleeding complications. 
Major complication would develop owing to the other potential etiologies besides the 
absolute amount of bleeding.
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Optimising Renal Perfusion Measurement with Arterial Spin Labelling
Keith Gillis,1 Alastair J. Rankin,1 Sarah Allwood-Spiers,2 Aleksandra Radjenovic,1 
Giles Roditi,2 Rajan Patel,1 Patrick B. Mark.1 Glasgow Renal Research Group 
1University of Glasgow, Glasgow, United Kingdom; 2NHS Greater Glasgow and 
Clyde, Glasgow, United Kingdom.
Background: Arterial spin labelling is a magnetic resonance imaging technique, 
allowing measurement of renal perfusion without a contrast agent. The optimal manner 
of image analysis is not known, and we sought to determine which ASL measurement 
correlates with measured glomerular filtration rate (GFR).
Methods: Healthy volunteers underwent measurement of glomerular filtration rate 
(GFR) by technetium-99m dimercaptosuccinic acid (DMSA) renography; CKD-EPI 
eGFR was calculated from serum creatinine. Renal anatomy was evaluated on HASTE 
imaging whilst ASL was performed using flow sensitive alternating inversion recovery 
(FAIR) labelling and true fast imaging with steady state precession (True-FISP) acquisition. 
Perfusion was measured in regions of interest in cortex and whole kidney. The perfusion of 
each kidney was calculated as a factor of renal volume and whole kidney perfusion, whilst 
total kidney perfusion was the sum of right and left kidney perfusion.
Results: 12 healthy volunteers were recruited with an age of 50.8±13.7 years, and eGFR 
of 100.9±13.3 ml/min/1.73m2, DMSA GFR was 97.3±23.4 ml/min/1.73m2, mean cortical 
perfusion was 259.3±56 ml/min/100g, mean whole kidney perfusion was 215.6±35.4 
ml/min/100g, and total kidney perfusion was 766.5±186.5 ml/min. In an analysis of 24 
kidneys, there was significant correlation between single kidney GFR and kidney perfusion 
(r=0.6, p=0.0018) but not cortical (r=-0.041, p=0.85) or whole kidney perfusion (r=0.091, 
p =0.67). In an analysis of each individual, there was significant correlation of total GFR 
with total kidney perfusion (r=0.71, p=0.01).
Conclusions: Assessment of renal physiology using ASL MRI may be best expressed 
by measurement of total renal perfusion.
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Functional MRI Defined-Renal Cortex Hypoxia Is a Proteinuria- 
Independent Predictor for Progression of CKD
Kei Sugiyama,1 Tsutomu Inoue,1 Eito Kozawa,4 Masahiro Ishikawa,2 
Hiroaki Amano,1 Akira Shimada,3 Naoki Kobayashi,2 Junji Tanaka,4 
Hirokazu Okada.1 1Nephrology, Saitama Medical University, Iruma-gun, 
Saitama, Japan; 2School of Clinical Engineering, Saitama Medical University, 
Hidaka-shi, Japan; 3Endocrinology and Diabetes, Saitama Medical University, 
Saitama, Japan; 4Radiology, Saitama Medical University, Iruma-gun, Japan.
Background: Progression of chronic kidney disease (CKD) is characterized by 
tubulointerstitial fibrosis and glomerulosclerosis. Chronic hypoxia followed by inflammation 
may be key to this process. Until now, however, there has been no means of evaluating this 
noninvasively. Here, we employed blood oxygen level-dependent (BOLD) and diffusion-
weighted (DW) magnetic resonance imaging (MRI) to assess renal tissue oxygenation and 
fibrosis, respectively, and evaluated their correlation with clinical parameters in a single-
center, longitudinal, retrospective observational study over five years.
Methods: We examined the prognostic significance of the T2* values of BOLD MRI 
and apparent diffusion coefficient (ADC) values on DW MRI at the cortex and medulla as 
well as diabetes mellitus, mean blood pressure, estimated glomerular filtration rate, serum 
urate levels, and proteinuria. Rate of decline in eGFR was calculated by linear regression 
analysis using changes in estimated glomerular filtration rate (eGFR) during the observation 
period. MRI was performed with a 1.5 T Imager (Sonata®; Siemens, Erlangen, Germany) 
and a six-channel body coil. Both T2* and ADC maps were generated using software in 
the MRI scanner.
Results: A total of 91 patients were enrolled. Participants, male = 51 (56.0%), were 
aged 55.8 ± 15.6 years. Thirty-eight (41.8%) had diabetes mellitus, and the eGFR was 
49.2 ± 28.9 mL/min/1.73 m2 at the time of enrollment. ADC values, but not T2* values, of 
renal cortex were well correlated with eGFR at the start point. Neither the ADC nor T2* 
values of the renal medulla showed significant correlation with clinical parameters due to 
large variations. The rate decline in eGFR per year (ΔGFR) during the observation period 
was -1.92 ± 3.00 mL/min/1.73 m2. Multiple linear regression analysis revealed that ΔGFR 
was significantly correlated with eGFR at the start point, the amount of proteinuria, and the 
T2* values (t=2.980, p=0.004), but not with the ADC values.
Conclusions: Hypoxia as determined by low T2* values using functional MRI is a 
clinically valuable parameter that affords a proteinuria-independent predictor of CKD 
progression.
Funding: Private Foundation Support
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Magnetic Resonance Measurements of Intra-Renal Oxygenation and 
Fibrosis and Change in Kidney Function: COMBINE Trial
Tamara Isakova,1 Cynthia A. Kendrick,2 Brett Larive,2 Jennifer J. Gassman,2 
Kalani L. Raphael,3 Dominic S. Raj,5 Linda F. Fried,6 Kevin C. Abbott,8 
Stuart M. Sprague,13 Myles Wolf,7 Geoffrey A. Block,10 Alfred K. Cheung,4 
Joachim H. Ix,11 John P. Middleton,7 Susan R. Mendley,9 Pottumarthi V. Prasad.12 
CKD Optimal Management with Binders and NicotinamidE (COMBINE) 
Investigators 1Feinberg School of Medicine, Northwestern University, Chicago, 
IL; 2Cleveland Clinic, Cleveland, OH; 3VA Salt Lake City Health Care System, 
Salt Lake City, UT; 4University of Utah, Salt Lake City, UT; 5GWU Medical 
Faculty Associates, Washington, DC; 6VA Pittsburgh Healthcare System, 
Pittsburgh, PA; 7Duke University, Durham, NC; 8The National Institutes of 
Health, NIDDK, Bethesda, MD; 9NIDDK/NIH, Bethesda, MD; 10Colorado 
Kidney Care, Denver, CO; 11UCSD, San Diego, CA; 12NorthShore University 
HealthSystems, Evanston, IL; 13NorthShore University HealthSystem University 
of Chicago Pritzker School of Medicine, Chicago, IL.
Background: Prior studies report differences between health and CKD in intrarenal 
oxygenation and fibrosis, as measured by MRI. Data on longitudinal relationships of MRI 
biomarkers with change in eGFR are limited.
Methods: We obtained baseline and follow up renal MRI in 87 of 205 participants of 
the COMBINE trial, which was a randomized, double-blinded, 12-month, 4-group parallel 
study of nicotinamide and lanthanum carbonate vs. placebo in individuals with CKD stages 
3-4. Relaxation rate R2* was the BOLD MRI index; higher values of R2* may represent
decreased oxygenation. Apparent diffusion coefficient (ADC) was the diffusion MRI index; 
lower values of ADC may be due to greater fibrosis. We evaluated longitudinal data from 
all 87 participants to test the hypotheses that higher R2* values and lower ADC values are 
associated with decline in eGFR.
Results: The mean baseline eGFR was 32.6±7.58 and the mean subject-specific eGFR 
slope was -2.1±4.15 ml/min/1.73 m2/year. We observed minimal changes in R2* and ADC 
values over 12 months. Baseline R2* and ADC did not correlate with eGFR slope (R2* 
cortex: r=0.03; p=0.76; ADC cortex: r=0.17, p=0.12). However, change in ADC from 
baseline to end of study correlated with eGFR slope (r=0.22; p=0.04). Participants with 
diabetes and rapid eGFR decline (>3 ml/min/1.73 m2/year) had the lowest baseline and 
follow up ADC values and individuals without diabetes and without rapid eGFR decline 
had the highest values (Table).
Conclusions: R2* and ADC remained stable during 12 months. While R2* did not 
correlate with change in eGFR, change in ADC correlated with faster decline in eGFR, and 
individuals with diabetes and rapid loss of eGFR had the lowest baseline and follow up 
ADC. Larger studies with longer duration are needed to further test BOLD and diffusion 
MRI measurements as possible imaging biomarkers of kidney function.
Funding: NIDDK Support
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Use of Multi-Parametric Functional MRI to Identify Progressive CKD
Luping Li,1,2 Wei Li,1,2 Bradley K. Hack,1 Orly F. Kohn,2 Stuart M. Sprague,1,2 
Pottumarthi V. Prasad.1,2 1NorthShore University HealthSystem, Evanston, IL; 
2Pritzker School of Medicine, University of Chicago, Chicago, IL.
Background: Only a quarter of those with stage 3 CKD will progress to end stage 
kidney disease over 10 years [PMID: 22545920]. Hence, there is a need for novel markers 
to identify individuals at risk of progressive CKD. The chronic hypoxia hypothesis 
suggests that progressive CKD involves loss of peritubular capillaries leading to hypoxia 
which results in development of fibrosis [PMID: 25401039]. MRI can evaluate perfusion, 
oxygenation and fibrosis using arterial spin labeling, blood oxygenation level dependent 
(BOLD) and diffusion MRI respectively. We evaluated a cohort of diabetic patients with 
CKD stage 3 using these three techniques to determine whether we can identify patients at 
risk of progressive CKD.
Methods: 41 patients (median eGFR = 49 (40 to 62) mL/min/1.73m2) participated in 
this IRB approved study. MRI data were acquired using 3T scanner. Following baseline MRI, 
each individual received 20 mg furosemide iv, and BOLD MRI scans repeated. R2* was 
used as BOLD MRI parameter, higher values of which indicate lower tissue oxygenation. 
Lower values of apparent diffusion coefficient (ADC) suggest higher levels of fibrosis. 
Annual loss of renal function (eGFR_slope) was estimated using eGFR measurements 
obtained from electronic medical records over a period of 2-7 years. MRI data and their 
associations with baseline eGFR, eGFR_slope were analyzed using Spearman correlation 
and linear regression analyses using SPSS.
Results: R2* was not associated with eGFR or eGFR_slope. Medullary response 
to furosemide (ΔR2*_Medulla) (ρ = 0.401, p= 0.014) and cortical perfusion (ρ= 0.441, 
p = 0.009) showed positive association with annual loss of eGFR. Cortical ADC was 
associated with cortical perfusion; but not with eGFR or eGFR_slope. The association for 
ΔR2*_Medulla (but not the cortical perfusion) vs. eGFR_slope remained significant even 
after adjusting for baseline eGFR, age, BMI, gender, systolic blood pressure and blood 
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glucose. In those individuals (n=9) with > 3 ml/min annual loss of eGFR, ΔR2*_Medulla 
(1.90 ± 2.53 vs. 5.39 ± 3.65 s-1; p = 0.007) and cortical perfusion (88.99 ± 30.31 vs. 117.11 
± 34.76 ml/min/100gm; p = 0.045) were lower compared to the rest.
Conclusions: Quantitative functional MRI measurements may be useful in identifying 
individuals with moderate but progressive CKD. Larger prospective studies should be 
performed to confirm these associations.
Funding: NIDDK Support
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Diffusion Weighted Imaging for Quantification of Cyst Volume in ADPKD
Anna Caroli,1 Paolo Brambilla,3 Sandro Sironi,5,3 Giuseppe Remuzzi,4 
Andrea Remuzzi.2,1 1Mario Negri Institute, Bergamo, Italy; 2Engineering 
Department, University of Bergamo, Dalmine, Italy; 3ASST Papa Giovanni 
XXIII, Bergamo, Italy; 4IRCCS - Istituto di Ricerche Farmacologiche Mario 
Negri, Bergamo, Italy; 5University Milano-Bicocca, Milano, Italy.
Background: In autosomal dominant polycystic kidney disease (ADPKD), kidney 
enlargement is mainly due to cyst growth and associates with renal function decline. Whilst 
total kidney volume is quite easy to be quantified, total cyst volume (TCV) is difficult and 
time consuming. In the last decades a number of different magnetic resonance imaging 
(MRI) modalities have been proposed to investigate renal structure, microstructure, and 
function. This study proposes a novel method to automatically quantify TCV in ADPKD 
patients using diffusion weighted MRI (DWI).
Methods: T2-weighted MRI and DWI (Figure 1A) were performed in 15 patients 
with ADPKD enrolled in the EuroCYST Initiative in Bergamo Hospital (Italy). TCV was 
quantified on each T2-weighted MRI using an accurate semi-automated method assumed 
as reference [Caroli et al. Lancet 2013]. Each DWI was processed using a bi-exponential 
model. The histogram of the pure diffusion component (D) was thresholded using the Otsu 
method, to separate cyst from non-cystic renal parenchyma, and TCV was automatically 
computed based on this threshold. DWI-computed TCVs were finally compared with the 
reference values.
Results: Fluid-filled kidney cysts were denoted by higher D values than non-cystic 
volume (Figure 1B). DWI-computed TCV highly and significantly correlated with TCV 
quantified on T2-weighted MRI (rho = 0.99, p <0.001)(Figure 1C), despite the former 
consistently underestimating TCV (DWI-computed TCV = 1144±1068 mL; reference T2-
weighted TCV = 1356±1256 mL).
Conclusions: Current findings suggest that our method can be used to automatically 
quantify TCV on DWI to accurately estimate the extension of renal structural changes in 
ADPKD. The proposed method may be useful to monitor disease progression as well as to 
evaluate the effect of pharmacological intervention. Acknowledgements. This study was 
funded in part by ERA – EDTA (EuroCYST Initiative).
Funding: Private Foundation Support
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Implications of ADPKD Diagnosis at Young Age: A Post Hoc Analysis of 
the TEMPO 3:4 Trial
Peter Janssens,2 Stephanie L. De Rechter,5 Bert Bammens,5 Franziska Grundmann,6 
Francois Jouret,9 Max Liebau,8 Roman-Ulrich Mueller,7 Ronald D. Perrone,4 
Franz S. Schaefer,3 Christina Pao,1 Djalila Mekahli.2 1Otsuka Pharmaceutical 
Development and Commercialization, Princeton, NJ; 2KULeuven, Leuven, 
Belgium; 3University of Heidelberg, Heidelberg, Germany; 4Tufts Medical Center, 
Boston, MA; 5University Hospitals Leuven, Leuven, Belgium; 6University of 
Cologne, Cologne, Germany; 7Dept. 2 of Internal Medicine, University of Cologne, 
Koeln, Germany; 8University Hospital Of Cologne; Children’s Hospital, Koeln, 
Germany; 9University of Liege Hospital (ULg CHU), Liege, Belgium.
Background: In ADPKD, there is currently limited information whether early 
diagnosis and management improve outcomes. We studied the implications of early 
diagnosis on outcome.
Methods: A post hoc analysis of TEMPO 3:4, a prospective, double-blind RCT in 
adults with ADPKD, with eCr ≥60 mL/min and TKV ≥750 mL. Comparison between 
patients diagnosed at age ≤18 years (childhood diagnosis [CD]) and >18 years (adult 
diagnosis [AD]).
Results: Patients were classified as CD in 20%, AD in 76% (Table 1), and unknown 
age at diagnosis in 4% (not shown) of the cases. At time of TEMPO 3:4 inclusion, CD were 
younger and had better eGFR than AD (Table 1). There were no significant differences 
in TKV, hypertension or RAASi use. Rates of TKV growth and eGFR changes by age at 
diagnosis are shown in Table 2.
Conclusions: The characterization of CD patients in TEMPO 3:4 shows that these 
participants were more severely affected based on a larger age-adapted TKV. Despite 
this fact, yearly TKV increase and loss of eGFR in the placebo arm of the study showed 
a tendency (NS) to be milder in the CD cohort. These data suggest the need for further 
evaluation of early intervention in the treatment of ADPKD.
Funding: Commercial Support - Otsuka Pharmaceutical Development and 
Commercialization Inc.
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Integrase Strand Transfer Inhibitor and Progression to CKD in an 
Outpatient Cohort of HIV-Infected Patients
Nora Franceschini. UNC Center for AIDS Research University of North 
Carolina Chapel Hill, Chapel Hill, NC.
Background: Recently introduced integrase strand transfer inhibitor (INSTI)-based 
regimens are highly effective in suppressing HIV viral load and have increased long-
term survival of people living with HIV. The kidney outcomes among patients on INSTI 
regimens have not been compared.
Methods: The study included Center of AIDS Research (CFAR) HIV Clinical Cohort 
participants initiating an INSTI-based regimen (raltegravir [RAL], dolutegravir [DTG] 
and cobicistat-boosted elvitegravir [EVG/c]). Changes in eGFR over time were modelled 
using linear regression with restricted cubic splines. Multivariable Cox proportional hazards 
models were used to assess time to the first occurrence of low eGFR (<60 mL/min/1.73m2) 
in the full sample and in a sample restricted to tenofovir (TDF) users. Multivariable models 
were controlled for baseline age, sex, race, injection drug use as a mode of transmission, 
CD4 cell count, history of AIDS-defining illness, cardiovascular disease, hypertension and 
its pharmacological treatment, and diagnosis of diabetes and its pharmacological treatment. 
Patients were censored at death, lost to follow-up or October 1st, 2016.
Results: The anchor-agents for the 920 patient-regimens consisted of RAL (n= 156, 
17%), DTG (n= 360, 39%) and EVG/c (n=404, 44%). eGFR remained relatively stable over 
time on all three INSTI-based agent treatment, following some minimal variation over the 
first few months on the regimen. Compared to EVG/c, RAL was not associated with a faster 
progression to low eGFR (overall sample, hazard ratio [HR]: 1.08; 95% Confidence Interval 
[C.I.]: 0.65, 1.77 and TDF-restricted sample, HR: 0.98; 95% C.I. 0.55, 1.72). Compared to 
EVG/c, DTG was associated with a faster progression to low eGFR in the TDF-restricted 
sample (HR 1.75; 95% C.I. 1.00, 3.06), but not in the full sample (HR 1.33; 95% C.I. 0.79, 
2.25).
Conclusions: The changes in eGFR over time observed for DAG regimen may be due 
to tubular creatinine secretion inhibition rather than kidney injury, although progression to 
low eGFR might be accelerated with DTG use among TDF users.
Funding: NIDDK Support, Other NIH Support - NIHMD, NHLBI
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Effect of Treatment of Chronic Hepatitis C Virus (HCV) Infection with 
Glecaprevir/Pibrentasvir (G/P) on Renal Biomarkers in Patients with 
CKD Stage 3b, 4, or 5
Meghan E. Sise,1 Raymond T. Chung,4 Marwan O. Kaskas,5 Neddie Zadeikis,2 
Manal Abunimeh,2 Zhenyi Xue,2 Federico Mensa,2 Marcello Persico.3 
1Department of Medicine, Division of Nephrology, Massachusetts General 
Hospital, Boston, MA; 2AbbVie Inc., North Chicago, IL; 3Internal Medicine and 
Hepatology Unit, University of Salerno, Fisciano, Italy; 4Department of 
Medicine, Division of Gastroenterology, Massachusetts General Hospital, 
Boston, MA; 5Northwest Louisiana Nephrology, Shreveport, LA.
Background: Chronic HCV infection is associated with CKD development and 
progression to end-stage renal disease (ESRD). HCV elimination may reduce risk of CKD 
progression. G/P, an all-oral pangenotypic HCV direct-acting antiviral (DAA) regimen, has 
minimal renal excretion. G/P is approved for patients (pts) with compensated liver disease 
and any degree of renal impairment, including ESRD, with high cure rates. Here we explore 
the impact of G/P on renal biomarkers in pts with CKD stage 3b, 4, or 5.
Methods: EXPEDITION-5 was a Phase 3b trial evaluating efficacy and safety of G/P 
for 8, 12, or 16 weeks (wks) in pts with CKD stage 3b, 4, or 5. Pre- and posttreatment 
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C-reactive protein, tumor necrosis factor-α, urine protein/creatinine ratio (PCR), urine
albumin/creatinine ratio, and urine neutrophil gelatinase-associated lipocalin concentrations
will be evaluated.
Results: 101 pts enrolled. Baseline characteristics are shown (table). 83% of pts 
received 8 wks of G/P. Sustained virologic response at posttreatment wk 12 (SVR12) 
was 97% with no virologic failures. There were no DAA-related serious adverse events 
(AEs) or clinically relevant lab abnormalities. 2 predialysis pts discontinued due to AEs. In 
predialysis pts (N=24), eGFR (mean±SD, mL/min/1.73 m2) did not change from screening 
(27.1±9.2) to posttreatment wk (PTW) 4 (27.4±11.6); mean PCR was 2.7 g/g at baseline and 
2.6 g/g at PTW4/12; 41% of pts had ≥30% improvement in PCR after G/P.
Conclusions: G/P for 8–16 wks was not associated with eGFR deterioration in 
predialysis pts. Preliminary data suggest G/P may improve PCR in a substantial number of 
pts. Other renal biomarker analyses will be presented.
Funding: Commercial Support - AbbVie
Baseline Characteristics in EXPEDITION-5
*4 pts were receiving peritoneal dialysis; all other pts were receiving hemodialysis.
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Effect of Ledipasvir and Sofosbuvir (LDV/SOF) on Kidney Function and 
Urinary Biomarkers in Patients (Pts) with Proteinuric CKD
Meghan E. Sise,1 Donald F. Chute,1 Jenna L. Gustafson,1 Sushrut S. Waikar,2 
Raymond T. Chung.1 1Massachusetts General Hospital, Boston, MA; 2Harvard 
Medical School, Boston, MA.
Background: HCV infection is associated with CKD incidence and progression. HCV 
may lead to immune-complex mediated glomerulonephritis, however HCV also promotes 
atherosclerosis, insulin resistance and chronic inflammation. We sought to determine 
whether HCV treatment improves kidney function, as assessed by biomarkers of kidney 
disease.
Methods: NCT02503735 was an investigator-initiated pilot trial that used SOF/
LDV to treat pts with HCV genotype 1 or 4 and proteinuria (>300mg proteinuria/g Cr). 
Baseline proteinuria, cystatin-c, and creatinine were compared to on treatment values and 
post-therapy values. Insulin resistance (IR) was calculated by HOMA-IR. Urine biomarkers 
were measured by Luminex. The primary outcome was change in natural log proteinuria-to-
creatinine (UPC) ratio from baseline to 12-weeks post SOF/LDV compared by paired t-test.
Results: 10 pts began 12-weeks of LDV/SOF mean age 64 (SD 10), 70% male, 60% 
White, 30% Black, 10% Native American. 4/10 had cirrhosis. 8/10 were cured of HCV, 2 
relapsed. Baseline eGFR was 63.2 mL/min/1.73m2 (SD 26.2), baseline proteinuria was 
1.05g/g (SD 0.95). Baseline to post-treatment values are in Table 1. Non-diabetic pts cured 
of HCV (pts 1-4) all had improvement in proteinuria: 1.8g/g, (SD 1.6) to 0.69g/g (SD 
0.7g/g) (p=0.01). Diabetic pts and pts with HCV relapse had worsening proteinuria 0.77g/g, 
(SD 0.3) to 2.2g/g (SD 1.4) (p=0.05). Complement and cryoglobulins normalized in the 
majority, IR decreased slightly.
Conclusions: Non-diabetic pts with HCV-associated CKD had substantial improvement 
in proteinuria when HCV was eradicated with SOF/LDV.
Funding: Commercial Support - Gilead Sciences
Abbreviations: Pt = patient, UPC = urine protein to creatinine, CRP = c-reactive protein, 
HOMA-IR = homeostatic model assessment of insulin resistance
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Ankle Brachial Index Is Associated with Cardiovascular and Renal Events 
in Patients with CKD: Result from the KNOW-CKD Study
Chang Seong Kim,1 Hong sang Choi,1 Eun Hui Bae,1 Kook-Hwan Oh,2 
Curie Ahn,2 Soo Wan Kim.3 1Chonnam National University Hospital, Gwangju, 
Republic of Korea; 2Seoul National University Hospital, Seoul, Republic of 
Korea; 3Chonnam National University Medical School, Gwangju, Republic of 
Korea.
Background: Vascular calcification of the media is an independent and strong predictor 
of cardiovascular risk in patients with chronic kidney disease (CKD). Ankle brachial index 
(ABI) is a useful tool for diagnosis of medial calcification as well as peripheral artery 
disease. However, few studies are reported its relation to the renal progression and risk 
of cardiovascular events in patients with CKD. We examined this relationship in a large 
CKD cohort.
Methods: In this prospective longitudinal study, we enrolled 2115 patients from the 
KoreaN cohort study for Outcome in patients with CKD (KNOW-CKD). The patients 
were categorized into low ABI (≤ 0.9), borderline ABI (0.9−1.1), normal ABI (1.1−1.3), 
or high ABI (≥ 1.3). The relationship between ABI and cardiovascular events (myocardial 
infarction, stroke, cerebral hemorrhage, or congestive heart failure), renal progression (as ≥ 
50% decline of estimated glomerular filtration rate (eGFR), doubling of serum creatinine, 
or start of dialysis) was analyzed using Cox regression.
Results: Renal progression and cardiovascular events were occurred 330 (15.6%) 
and 86 (4.3%) in patients, respectively, during the median follow-up of 26.9 months. 
Compared to patients with high ABI, patients with low ABI had a lower prevalence of 
renal progression (low ABI: 17.5% vs. high ABI: 24.7%), whereas had a higher risk of 
cardiovascular events (low ABI: 17.3% vs. high ABI: 7.2%). In Cox regression model, 
patients with low ABI were at higher risk of cardiovascular events even after adjustments 
(hazard ratio [HR], 4.41; 95% confidence interval [CI], 1.63−11.9; P = 0.003), but high 
ABI had no significant risk of cardiovascular events (HR, 1.18; 95% CI, 0.46−3.07; 
P = 0.731) than those with normal ABI. However, there was no significant association 
between patients with low or high ABI and a risk of renal progression after adjustment.
Conclusions: Low ABI (≤ 0.9) is related to higher risk of cardiovascular events in 
patients with CKD. Measuring ABI might serve as a useful tool for predicting cardiovascular 
events in Korean CKD patients.
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Association Between Serum Lipid Profiles and Cardiovascular Outcomes 
in CKD Patients: KNOW-CKD Study
Arum Choi, Yooju Nam, Seon yeong Lee, Joohwan Kim, Ki Heon Nam, Tae-
Hyun Yoo, Dae-Suk Han, Seung Hyeok Han. Yonsei University College of 
Medicine, Seodaemun-gu, SEOUL, Republic of Korea.
Background: Dyslipidemia has been linked to an increased risk of cardiovascular 
morbidity and mortality in patients with chronic kidney disease (CKD). However, the role 
of individual lipid parameters in the development of cardiovascular events in the CKD 
population is not well established. Here, we analyzed the relative contribution of 4 lipid 
profiles such as total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high 
density lipoprotein cholesterol (HDL-C), and triglycerides (TG) to the risk of cardiovascular 
morbidity and mortality in patients with non-dialysis CKD.
Methods: Among 2,238 patients with non-dialysis CKD enrolled in the KoreaN cohort 
study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD), 1,728 patients 
who measured TC, LDL-C, HDL-C, and TG and were not previously diagnosed with 
cardiovascular disorders were included in the analysis. Study endpoint was a composite of 
major cardiovascular events or death.
Results: The mean age was 52.9 ± 12.1 years and 1,023 (59.2%) patients were males. 
The mean serum concentrations of TC, LDL-C, HDL-C, and TG were and 175.5 ± 38.5, 
98.0 ± 31.2, 49.8 ± 15.6, and 156.9 ± 96.6 mg/dl, respectively. Among 1,728 patients, 860 
(49.7%) patients were treated with lipid-lowering drugs. During the median follow-up 
duration of 3.0 years, 105 patients (6.1%) reached the composite end point. In the fully 
adjusted multivariable Cox models, HDL-C (HR, 1.05 per 10 mg/dl increase; 95% CI, 0.92-
1.12; P = 0.50), TC (HR, 1.03 per 10 mg/dl increase; 95% CI, 0.98-1.09; P = 0.23), LDL-C 
(HR, 1.03 per 10 mg/dl increase; 95% CI, 0.97-1.10; P = 0.36), and TG (HR, 1.00 per 
10 mg/dl increase; 95% CI, 0.98-1.02; P = 0.75) were not associated with increased risk 
of cardiovascular events or death. Furthermore, areas under the curve of these 4 lipids 
were similar and none of these parameters improved net reclassification improvement and 
integrated discrimination improvement for the prediction of cardiovascular morbidity and 
mortality.
Conclusions: This study showed that four lipid profile parameters did not predict the 
future adverse outcomes nor improved cardiovascular risk stratification in patients with 
CKD.
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Kidney Function Decline Affects Endothelial Dependent Flow Mediated 
Dilation Independently of HDL, LDL, and HsCRP
Victoria Whitfield,2 Elvis A. Akwo,2 Edward D. Siew,3 Talat Alp Ikizler,2 
Adriana Hung.1 1Vanderbilt University, Nashville, TN; 2Vanderbilt University 
Medical Center, Nashville, TN; 3Vanderbilt University School of Medicine, 
Nashville, TN.
Background: Patients with CKD have a significant cardiovascular morbidity 
& mortality. Endothelial function is the earliest manifestation in the continuum of 
atherosclerosis. We investigated the relationship between glomerular filtration rate (GFR) 
and endothelium-dependent vascular function in a nondiabetic population.
Methods: Participants were 89 CKD patients and 22 with normal GFR who underwent 
brachial artery flow-mediated dilation (FMDBA) by high resolution ultrasound. Clinical 
evaluation, renal function tests, lipid profile and high sensitivity C-reactive protein (hsCRP) 
assays were performed on all study participants. Multivariable linear regression models 
with robust standard errors were used to investigate the dose-response relationship between 
FMD% and estimated GFR (eGFR) – modeled as a restricted cubic spline with 4 knots. 
Covariates were age, sex, race, body mass index (BMI), systolic blood pressure (SBP), 
hsCRP, HDL and LDL cholesterol. Skewed variables were log transformed.
Results: Over 71% of participants were male, 21% were African-American. The mean 
(SD) age was 63.2 (13.7) years. Median (25th, 75th) FMD% was lower among CKD patients 
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compared to controls [4.2 (2.9, 6.3) vs. 8.5 (4.8, 10.4); p = 0.0004] (figure 1). After full 
adjustment for baseline covariates, CKD patients had a significant 3.2% (95% CI: 0.7, 5.7, 
p = 0.01) lower FMD%. Percent FMD had a significant inverse correlation with age (r = 
-0.36, p = 0.001). In a minimal model adjusted for age, sex, race and BMI, eGFR had a
significant (p = 0.0006) positive nonlinear relationship with FMD% with a trough on the 
dose-response curve occurring at an eGFR ~ 60mL/min/1.73m2 (figure 1). The association
remained significant (p = 0.0005) after further adjustment for SBP, log hsCRP, log HDL 
and log LDL.
Conclusions: Endothelium-dependent vascular function diminishes across the kidney 
function continuum, independently of traditional CVD risk factors. Further investigation 
into the underlying mechanisms involved maybe warranted.
Funding: Veterans Affairs Support
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Insulin Sensitivity, Systemic Inflammation and GFR as Key Determinants 
of Arterial Stiffness
Elvis A. Akwo,1 Aseel Alsouqi,1 Victoria Whitfield,1 Lori Wanko,1 Talat 
Alp Ikizler,1,2 Adriana Hung.2,1 1Vanderbilt University Medical Center, Nashville, 
TN; 2Veterans Affairs CSR&D, Nashville, TN.
Background: Patients with chronic kidney disease (CKD) are at increased risk of 
cardiovascular disease (CVD). The underlying mechanisms of the burden of CVD in CKD 
remains poorly understood. We investigated the relationship of GFR, aortic arterial stiffness 
and the mediating effects of systemic inflammation and insulin sensitivity.
Methods: We studied 136 patients: 50 CKD and 86 normal GFR. Aortic pulse wave 
velocity (aPWV) was measured via transcutaneous tonometry. Insulin sensitivity index (ISI) 
was measured by hyperinsulinemic euglycemic clamp; high sensitivity C-reactive protein 
(hsCRP) and eGFR were measured at baseline. Sequential multivariable linear regression 
with robust standard errors was used to study determinants of aPWV and perform mediation 
analyses.
Results: Median age was 54 years; 51% were female and 38% African-American. 
Patients with CKD had significantly higher aPWV [10.7±2.2 vs. 7.7±1.4, p < 0.0001] 
compared to controls. Log aPWV was inversely correlated with eGFR (r = - 0.65, 
p < 0.0001) and log ISI (r = -0.38, p < 0.0001); and was positively correlated with age 
(r = 0.73, p < 0.0001), BMI (r = 0.17, p = 0.02) and log hsCRP (r = 0.23, p <0.0001). In the 
model adjusted for: age, sex, race, BMI and smoking, a 10 ml/min decrease in eGFR was 
associated with a 2.1% increase (95% CI: 0.8, 3.3, p = 0.001) in aPWV. Further adjustment 
for log ISI and log hsCRP attenuated the eGFR effect (percent increase in PWV = 1.4%, 
95% CI: - 0.2, 3.0, p = 0.1). GFR had a significant (p = 0.01) inverse nonlinear association 
with CPP that became insignificant when adjusting for hsCRP and/or ISI [Figure 1].
Conclusions: Declining GFR is associated with increased aPWV and CPP. These 
adverse vascular outcomes in CKD are partly mediated by systemic inflammation and 
insulin resistance. Targetting both IS an/or inflammation could reduce CVD risk in CKD 
patients.
Funding: Veterans Affairs Support, Private Foundation Support
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Association of Serum Uromodulin with Mortality and Cardiovascular 
Disease in the Elderly – The Cardiovascular Health Study
Dominik Steubl,1 Petra Buzkova,8 Pranav S. Garimella,2 Joachim H. Ix,2 
Prasad Devarajan,3 Michael R. Bennett,6 Paulo H. Chaves,7 Michael Shlipak,4 
Mark J. Sarnak.5 1Tufts Medical Center, Tufts University, Boston, MA; 2UCSD, 
San Diego, CA; 3Cincinnati Children’s Hospital, Cincinnati, OH; 4San Francisco 
VA Medical Center, San Francisco, CA; 5Tufts Medical Center, Boston, MA; 
6Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 7Florida 
International University, Miami, FL; 8UW, Seattle, WA.
Background: Uromodulin is released by renal tubular cells into the serum (sUMOD) 
and urine. Lower urine UMOD has been linked to mortality and cardiovascular disease but 
much less is known about sUMOD. We evaluated the association of sUMOD with those 
outcomes in community-dwelling older adults.
Methods: We measured sUMOD in a random subcohort of 933 participants enrolled 
in the Cardiovascular Health Study. The association of sUMOD with all-cause mortality, 
incident heart failure (HF) and incident CVD (myocardial infarction, stroke and mortality 
due to coronary disease or stroke) were evaluated using multivariable Cox regression, 
adjusting for study participants’ demographics, estimated glomerular filtration rate (eGFR), 
albuminuria and CVD risk factors. Generalized additive models with splines were used to 
address the functional form of sUMOD with outcomes. Due to non-linear associations of 
sUMOD with all outcomes, 2.5% of the values on either end of the sUMOD distribution 
were excluded from the analyses, limiting the range of sUMOD to 34.3 - 267.1 ng/ml.
Results: The mean age was 78±5 years, 40% were male, and 15% were non-white. 
Mean sUMOD level was 127±64 ng/ml, eGFR was 63 ml/min/1.73 m2 and 42% had CKD 
defined as eGFR<60 ml/min/1.73 m2. Patients in the lower sUMOD ranges had lower eGFR 
and higher albuminuria. During a median follow-up of 9.9 years, 805 patients died, 283 
developed HF and 274 CVD. In multivariable analysis higher sUMOD was independently 
associated with lower mortality and CVD, and a trend for HF (Table).
Conclusions: Low sUMOD is independently associated with mortality and CVD in 
the elderly.
Funding: Other NIH Support - This work was supported by grants from the National 
Institute of Diabetes Digestive and Kidney Diseases (NIDDK) R01 DK098234 (to JHI and 
MGS) and from the National Institutes of Aging (NIA) R01AG 027002 (to MJS and MGS). 
The Cardiovascular Health Study was supported by contracts HHSN268201200036C, 
HHSN268200800007C, and N01HC-85079 through N01HC-85086, N01HC-35129, 
N01HC-15103, N01HC-55222, N01HC-75150, N01HC-54133, and N01-HC85239 and 
grant U01 HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with 
additional contributions from the National Institute of Neurological Disorders and Stroke. 
Additional support was provided by R01AG023629 from the NIA. PD was supported by 
National Institutes of Health grant P50 DK096418. PSG is supported by National Institutes 
of Health training grant 5 T32 DK007777-13.
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Kidney and Cardiac Parameters – Which Are More Important in 
Predicting Circulatory Congestion and Mortality Risk in CKD? Insights 
from a 5-Year Prospective Analysis
Angela Yee Moon Wang,1 Henry H. Wu,1 Qizhe Cai,3 Hoi Kei S. Wong,2 
Xiuzhang Lu.3 1Queen Mary Hospital, University of Hong Kong, Hong Kong, 
China; 2University of Hong Kong, Hong Kong, China; 3Beijing Chao-Yang 
Hospital, Beijing, China.
Background: Chronic kidney disease (CKD) patients are frequently complicated 
with circulatory congestion (CC). However, factors predicting the risk of CC are poorly 
understood.
Methods: 300 CKD stage 3-5 subjects (Mean age, 60±10yrs, 56.3% men) were randomly 
recruited from a University Teaching Hospital. All underwent 2D-echocardiography & 
tissue Doppler imaging (TDI) to assess cardiac structure & function, bloods & first void 
urine collection for eGFR & urine protein to creatinine ratio (UPCR), & blood pressure 
measurement.
Results: eGFR (mean±SD): 33 ± 17ml/min per 1.73m2. Urine UPCR: 139 ± 202mg/mmol 
creatinine. All subjects were followed prospectively for a median of 68 (IQR, 30, 70) 
mths, 25% were complicated with CC or died from other causes. In the multivariable 
Cox regression analysis considering clinical, hemodynamic, biochemical, echo & TDI 
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parameters, eGFR (P=0.002) & UPCR (P=0.006) exhibited independent significance in 
predicting the risk of CC & mortality. Additional adjustment for cardiovascular medications 
including renin-angiotensin system blockers, beta-blockers, & diuretics did not change 
the significance of eGFR & UPCR in predicting CC & mortality. In a receiver-operator-
characteristics curve analysis, UPCR showed the largest area under the curve (AUC) (0.78, 
95% confidence intervals [CI], 0.72 - 0.84) in predicting the composite endpoint of CC & 
mortality, followed by eGFR (0.75, 95% CI, 0.69 - 0.81) & the ratio of early mitral inflow 
velocity to peak mitral annulus velocity (E/Em ratio, a marker of left ventricular [LV] filling 
pressure) (0.74, 95% CI, 0.67 – 0.80). The AUC of LV mass index & ejection fraction was 
0.72 (95% CI, 0.65 - 0.79) & 0.50 (95% CI, 0.42 – 0.58), respectively.
Conclusions: Both proteinuria & eGFR exhibited independent significance & were 
more powerful than cardiac structural & functional parameters in predicting CC & 
mortality risk in CKD. Among the cardiac parameters, diastolic dysfunction outweighed 
systolic dysfunction in predicting CC & mortality risk. Further intervention study is needed 
to evaluate whether retarding proteinuria & CKD progression may effectively lower the 
incidence of CC and improve clinical outcomes of CKD patients.
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Effect of Fructooligosaccharide on Endothelium Function in CKD 
Patients: A Randomized Controlled Trial
Rachel G. Armani, Christiane I. Ramos, Lilian Cuppari, Maria 
Eugenia F. Canziani. Division of Nephrology - Federal University of São Paulo, 
Sao Paulo, Brazil.
Background: Microbiota-derived uremic toxins have been associated with increased 
cardiovascular risk in chronic kidney disease (CKD). This has encouraged the investigation 
of alternative paths to modulate gut environment with ensuing reduction of toxin production, 
inflammation and endothelial dysfunction. This trial aimed to evaluate the effect of the 
prebiotic fructooligosaccharide (FOS) on endothelial dysfunction in CKD non-dialysis 
patients.
Methods: The 3-month double-blind randomized controlled trial included 46 non-
diabetic CKD patients [52% men; 57.6±14.4 years; eGFR: 21.3±7.3 mL/min/1.73m]. 
Intervention and placebo consisted in 12g/day of FOS or maltodextrin, respectively. 
P-cresyl sulfate (PCS), indoxyl sulfate (IS), Interleukin 6 (IL6) were evaluated. Endothelial 
dysfunction was assessed through stroma derived factor 1 alfa (SDF1α), serum nitric oxide 
(NO) and flow-mediated dilatation (FMD).
Results: Aside for the intervention group being older (53.4±16.0 vs 61.9±11.4,p=0.04) 
the groups were homogeneous. During the study, renal function, electrolytes, remained stable 
in both groups. A downward trend in PCS serum levels (52.86±30.68 vs 43.06±32.43mg/
L,p=0.07) was observed in the treated group. Regarding inflammation, IL6 decreased in this 
group (3.14±2.22 vs 2.65±1.37 pg/mL, p=0.04). There was no difference in NO, SDF1α 
levels and FMD (Figure 1). In an exploratory analysis, including only patients with less 
damaged endothelium at baseline (FMD≥2.2% median), we observed that treated group had 
significant greater values of FMD after 3 months (p=0.04).
Conclusions: There was no effect of FOS on endothelial function in the studied 
population. Nonetheless, in patients with less damaged endothelium at baseline, we could 
observe an improvement of endothelial dilatation in the treated group, which could suggest 
a potential impact of FOS in the recovery of endothelial function.
Funding: Government Support - Non-U.S.
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Representation of Kidney Disease in Peripheral Artery Disease Therapy: 
A Systematic Review of Randomized Controlled Trials
Yumeng Wen,2 O. Alison Potok,1 Rakesh Malhotra,1 Lili Chan,2 
Ioannis Konstantinidis,2 Girish N. Nadkarni,2 Steven G. Coca,2 
Pranav S. Garimella.1 1University of California San Diego Medical Center, San 
Diego, CA; 2Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Kidney disease (KD) patients have a higher risk of peripheral artery 
disease (PAD) with worse outcomes than the general population. We assessed the inclusion 
of KD patients in randomized controlled trials (RCT) of PAD therapy.
Methods: We searched PubMed for RCTs of PAD therapy that reported clinical 
outcomes, randomized ≥ 50 subjects and were published in English from 01/2000 to 
04/2018. Two independent reviewers selected studies and extracted data, including trial 
characteristics, criteria for KD patients’ exclusion, proportion of KD patients and number of 
subgroup analyses by non-renal or renal parameters.
Results: We included 228 trials randomizing 122924 subjects. KD patients were 
excluded in 98 (42.6%) trials with 29 (29.6%) of these not reporting kidney specific 
exclusion criteria. The remainder excluded KD patients based on varied cutoffs for 
creatinine, glomerular filtration rate and need for dialysis. Trials assessing ACC/AHA 
class I or II recommendations were less likely to exclude KD patients (38.4 % vs 51.2%, 
p=0.04). Characteristics associated with a higher likelihood of KD patient exclusion were 
multicenter studies (47.4% vs. 33.8% in single center studies, p=0.04), industry funding 
(53.5% vs. 35.0% in academic grant or government-funding, p=0.02) and smaller patient 
samples (43.2% of studies with <100 subjects, vs 10.0% of studies with ≥1000 subjects, 
p=0.04). Only 9.6% (22/228) of the trials reported kidney function and 1.3% (3/228) 
reported subgroup analyses based on it. Exclusion of KD patients by diagnostic category 
and therapeutic class is depicted in the Figure.
Conclusions: Numerous PAD trials exclude KD patients, a majority uses non-specific 
renal criteria. Including KD patients in PAD trials is needed to improve the quality of 
evidence for interventions in this vulnerable population.
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CKD and Incident Hearing Loss
Shruti Gupta,3 Karen J. Cruickshanks,1 Gary C. Curhan,2 Sharon Curhan.4 
1University of Wisconsin School of Medicine and Public Health, Madison, WI; 
2Channing Division of Network Medicine, Brigham and Women’s Hospital, 
Boston, MA; 3Brigham and Women’s Hospital, Boston, MA; 4Brigham and 
Women’s Hospital/Harvard Medical School, Boston, MA.
Background: There is a strikingly high prevalence of sensorineural hearing loss 
among patients with chronic kidney disease (CKD), with estimates ranging from 36 to 77%. 
However, the etiology of hearing loss in CKD is not well-understood. In the only prior 
longitudinal study, estimated glomerular filtration rate (eGFRCysC) <60 mL/min/1.73 m
2  
was significantly associated with a 50% higher 20-year cumulative incidence of hearing 
impairment. We assessed whether lower baseline eGFR calculated using serum creatinine 
(SCr) was associated with incident hearing loss, and whether rapid decline in eGFR over 
time was associated with an evenhigher risk.
Methods: SCr was measured in 1843 individuals without hearing loss at the start of the 
Epidemiology of Hearing Loss Study in 1993. Follow-up SCr assessments were conducted 
at 5 (n=1500) and 10 (n=1086) years. The eGFRCr was estimated using the CKD-EPI 
equation. Hearing tests were conducted at baseline, and at 5, 10, and 15 year follow-up 
visits. The risk of hearing loss was assessed as a function of baseline eGFRCr, as well as a 
function of a 20% decline in eGFRCr between baseline and 5 years, and between 5 and 10 
years. Incident hearing loss was defined as pure-tone average >25 dB for thresholds at 0.5, 
1, 2, and 4 kHz. Cox proportional hazards regression was used to adjust for sex, cholesterol, 
smoking, waist circumference, schooling, NSAIDs, loop diuretics, hypertension, and 
diabetes.
Results: During 15,676 person-years of follow up, there were 802 cases of incident 
hearing loss (Table 1). There was no significant association between lower baseline eGFRCr 
and incident hearing loss. There was also no association after stratifying by sex or age. 
Decline in eGFRCr was not associated with incident hearing loss.
Conclusions: There were no significant associations between baseline eGFRCr or 
decline in eGFRCr and risk of incident hearing loss.
Funding: NIDDK Support, Other NIH Support - Shruti Gupta (F32DC017342), Gary 
Curhan (DK091417), Karen Cruickshanks, EHLS (AG11099)
Table 1: Multivariate-Adjusted Hazard Ratios for Risk of Hearing Loss by Baseline eGFR 
and eGFR Decline, EHLS 1993-2010
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Factors Influencing Approval Rates of Peripherally Inserted Central 
Catheters (PICCs) in Patients with Kidney Disease
Irene Chernova,1,2 Corey J. Cavanaugh,1,2 Ravi Kodali,1,2 Ngozi Okoba,1,2 
Sarthak Virmani,1,2 Justin M. Belcher.2,1 Yale Nephrology Fellows 1Yale New 
Haven Hospital, New Haven, CT; 2Yale University, New Haven, CT.
Background: Current guidelines recommend against placement of peripherally 
inserted central catheters (PICCs) in stage 3-5 CKD without nephrology consultation in an 
attempt to preserve veins for future arteriovenous fistula access creation for hemodialysis. 
In many instances, nephrology input is also required for PICC placement for patients with 
acute kidney injury (AKI). With no official guidelines delimiting patients appropriate 
for PICCs, the consult burden on renal fellows can be significant. Here we attempted to 
determine medical and demographic factors influencing our practice patterns for approving 
PICC placement to develop objective guidelines identifying patients who unanimously are 
or are not appropriate for PICCs to potentially reduce the burden of consults.
Methods: We identified over 100 patients in whom a PICC consult was placed to 
nephrology over 10 months at 3 separate hospitals. We evaluated the PICC approval rate 
accounting for age, gender, serum creatinine at time of consult and baseline, CKD stage, 
AKI stage, diabetes, hypertension and end-stage comorbidities (cirrhosis, heart failure, 
malignancy, dementia, hospice). PICC placement decision for the initial 51 patients was 
adjudicated by the first year class of clinical fellows and 1 attending nephrologist in a 
blinded manner.
Results: Of the 51 adjudicated patients, 24/51 (47%) had universal agreement between 
both the original consulting fellow and the adjudicating fellows and attending. Presence 
of end-stage diagnosis, hospice status and advanced age were the major factors predictive 
of universal agreement for PICC placement while stage 4-5 CKD in younger patients 
correlated highly with nephrology recommending against PICC placement.
Conclusions: These preliminary data suggest that certain patient characteristics (such 
as an end-stage diagnosis) correlate highly with PICC approval including in patients with 
CKD stage 3-5 who may otherwise be excluded from PICC placement based on strict 
guidelines. Further analysis is currently underway to facilitate the development of an 
objective criteria list which can be used to standardize decision-making regarding PICC 
placement amongst nephrology practitioners and provide guidance to practitioners as to 
when a nephrology consult is indicated.
Funding: Clinical Revenue Support
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Optimal Treatment for Prevention of Recurrent Thrombosis After 
Idiopathic Renal Infarction
Maurice I. Khayat,2 Stephen W. Olson,1 Robert Nee.2 1Nephrology, Walter Reed 
National Military Medical Center, Bethesda, MD; 2Walter Reed National 
Military Medical Center, Vienna, VA.
Background: Idiopathic renal infarction (iRI) is rare but associated with significant 
morbidity. Recurrent episodes of systemic thrombosis have been reported after diagnosis. 
Anticoagulation and antiplatelet therapy have been previously described, but no prior 
studies have established an optimal treatment regimen following iRI.
Methods: We performed a retrospective cohort study of 104 iRI cases (2003-2018) 
confirmed by review of the military electronic medical record (EMR). iRI was defined by 
the absence of cardioembolic, hypercoagulable or vasculopathy risk factors. The cases were 
divided into groups receiving (n=48) and not receiving (n = 56) anticoagulation therapy. 
The non-anticoagulation group was further divided into antiplatelet (n=37) and no therapy 
(n=19) subgroups. All cases were reviewed for evidence of the primary outcomes of 
recurrent arterial thrombosis, de novo venous thrombosis, and bleeding events over the 
maximum duration of follow up available in the EMR.
Results: Median follow up was 53 months (IQR 27-99) following iRI. There was 
no significant difference in the incidence of recurrent arterial thrombosis between the 
anticoagulation group and the non-anticoagulation group [4% (2/48) vs. 0% (0/56), 
p =0.21] or between the anticoagulation group and the antiplatelet subgroup [4% (2/48) vs. 
0% (0/37), p =0.50]. There was also no significant difference in the incidence of de novo 
venous thrombosis (different cases than arterial thrombosis) between the anticoagulation 
group and the non-anticoagulation group [4% (2/48) vs. 0% (0/56), p =0.21] or between 
the anticoagulation group and the antiplatelet subgroup [4% (2/48) vs. 0% (0/37), p =0.50]. 
More iRI patients in the anticoagulation group had a bleeding event than both the non-
anticoagulation [13% (6/48) vs. 0% (0/56), p=0.008] and antiplatelet [13% (6/48) vs. 0% 
(0/37), p=0.03] subgroups.
Conclusions: Anticoagulation after iRI is not associated with a reduction in either 
recurrent arterial thrombosis or de novo venous thrombosis, but is associated with an 
increased risk of bleeding. This study suggests that antiplatelet agents may be the best 
treatment option following iRI, but further evaluation is warranted in a randomized study.
Funding: Other U.S. Government Support
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Acute Pancreatitis (AP) in CKD5 and Kidney Transplant (Tx) Recipients: 
Results of a US Nationwide Analysis
Paul T. Kroner,3 Massimo Raimondo,3 Karl Mareth,1 Ali Alsaad,1 Nabeel Aslam,2 
Hani Wadei.2 1Department of Medicine, Mayo Clinic, Jacksonville, FL; 
2Department of Medicine, Division of Nephrology, Mayo Clinic, Jacksonville, 
FL; 3Department of Medicine, Division of Gastroenterology, Mayo Clinic, 
Jacksonville, FL.
Background: The prevalence of AP in CKD5 has not been clearly defined. The aim 
of this study was to compare the prevalence, etiology and outcomes of AP in CKD5 and 
kidney tx recipients with those without CKD using a large national database
Methods: Using the Nationwide Inpatient Sample (NIS) database, 433,805 patients 
hospitalized in 2014 with ICD-9 admission code for AP were identified. All patients 
were >18 yrs old and had no history of pancreas tx. Patients with AP and CKD5 not on 
dialysis (n=690), CKD5 on dialysis (n=11,415) and kidney tx recipients (n=1,320) were 
identified and were propensity-matched in a 1:1 fashion and regressed against gender, age, 
ethnicity and Charlson Comorbidity Index to patients with AP and no CKD (n=13,425). 
A multivariate logistic regression was constructed to adjust for other variables such as 
patients’ median income, hospital region, hospital size and teaching status
Results: Results are presented in Table 1. Adjusted prevalence of AP was comparable 
between the non-CKD, CKD5, and kidney tx populations. Crude and adjusted mortality was 
higher in CKD5 and kidney tx patients. CKD5 patients were more likely to develop shock 
and require ICU than the non-CKD group. Alcoholic and gall stone AP were more common 
in non-CKD group while hypercalcemia AP was more common in the CKD5 group
Conclusions: 1)The adjusted prevalence of AP is comparable between non-CKD 
patients, CKD5 and kidney tx recipients. 2)Adjusted mortality is more than double in CKD5 
and kidney tx recipients comapred to non-CKD patients. 3)Dialysis-dependent CKD5 
patients hospitalized with AP had highest rate of shock and ICU stay compared to non-CKD 
patients. 4)Hypercalcemia is the main cause of AP in the CKD5 population irrespective of 
dialysis need
Prevalence, mortality and etiology of AP in patients without CKD, with CKD5 and in 
kidney tx recipients
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Surprise Question and Time-to-Hospitalization in Advanced CKD
Nicolas Baddour,1 Cassianne Robinson-Cohen,2 Loren Lipworth,2 Aihua Bian,2 
Thomas G. Stewart,2 Khaled Abdel-Kader.2 1Vanderbilt University School of 
Medicine, Nashville, TN; 2Vanderbilt University Medical Center, Nashville, TN.
Background: Hospitalization is a common and high-risk event for patients with CKD. 
The surprise question (SQ) is a provider-based subjective health measure (i.e., “Would you 
be surprised if this patient died in the next 12 months?”) that associates with mortality in 
advanced CKD; however, the association with hospitalization has not been examined.
Methods: We enrolled 488 ambulatory patients with stage 4 or 5 CKD who were ≥ 60 
years of age and followed in nephrology clinic. Providers were asked the SQ using a binary 
and 5-point Likert scale following each office visit. Hospitalizations were determined 
by linkage to a statewide health database. Death was determined through linkage with 
national or local public health records as well as obituary searches. Other covariates were 
abstracted by chart review using structured forms. We determined hazard ratios for time to 
first hospitalization using cox proportional hazards regression. In addition to the SQ Likert 
scale, our multivariable model included age, gender, race, marital status, insurance status, 
diabetes, hypertension, cardiovascular disease, heart failure, malignancy, liver disease, 
chronic lung disease, number of hospitalizations in the prior year, number of medications, 
BMI, eGFR, serum albumin, and hemoglobin.
Results: 293 (60%) patients were hospitalized. Median time to first hospitalization was 
591 days in patients with SQ binary ‘surprised’ answer versus 277 days in ‘not surprised’ 
counterparts. 16 (3.3%) patients died before a hospitalization. The Likert SQ response was 
significantly associated (p = 0.01) with time to hospitalization with hazard ratios (95 % CI) 
of 1.67 (0.88 – 3.17), 2.25 (1.46 – 3.5), 1.60 (1.08 – 2.37), and 1.51 (1.01 – 2.26) for 1 (not 
at all surprised), 2, 3, and 4, respectively (versus reference: 5 very surprised).
Conclusions: Provider response to the SQ is associated with time-to-hospitalization 
in older adults with Stage 4 and 5 CKD. Future studies should examine whether the SQ is 
useful in identifying patients with high healthcare utilization.
Funding: Private Foundation Support
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Determinants of Renal Function After Nephrectomy for Renal Cell 
Cancer in Ethnic Minorities
Albert M. Osei,1,2 Ankit M. Mangla,1 Edwin Okyne,1 Chimezie U. Mbachi,1 
Peter D. Hart.1,2 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL; 
2Rush University Medical Center, Chicago, IL.
Background: Renal cell cancer, unless metastasized at the time of diagnosis, is 
treated by partial or radical nephrectomy. Nephrologists are often consulted to predict renal 
function outcome especially for those with CKD. There is paucity of data on this subject 
for ethnic minorities.
Methods: Electronic medical records of all patients who underwent partial or radical 
nephrectomies from 2007 to 2017 in a large inner-city public teaching hospital were 
reviewed. Inclusion criteria included pathologic confirmation of renal cell cancer. Patients 
who had repeat nephrectomy of the contralateral kidney were excluded. Demographics, co-
morbidity, preoperative and up to two years of postoperative laboratory data were reviewed. 
CKD was defined as eGFR < 60ml/min/1.73m2and acute kidney injury was staged by AKIN 
criteria (KDIGO, Kidney Int. (suppl) 2012)
Results: 422 patients met the criteria for the analysis. Percentage of African Americans, 
Hispanics and Caucasians was 36, 31, 29 respectively. Males: Females-62% vs 38% with 
no ethnic differences. African Americans were older-mean age of Hispanics, Caucasians 
and African Americans was 51, 53, 56 respectively (P<0.001). Diabetes was present in 24% 
with no ethnic difference. Hypertension was present in 49% with disproportionate 51% of 
these being African Americans. 11% had baseline CKD with majority (63%) being African 
Americans. Partial nephrectomy was performed in 40% compared to radical nephrectomy 
in 60% with no group differences. Postoperative AKI developed in 54% of patients and 
was significantly higher with radical nephrectomy than partial nephrectomy (68% vs 39% 
P< 0.001). At 3 months, postoperative CKD increased to 34%, remained about this level 
at 2 years and African Americans, Caucasians, Hispanics constituted 52, 24, 16 percent 
(P=0.001) respectively. Associations with postoperative CKD were African American 
ethnicity, preexisting CKD, radical nephrectomy, diabetes mellitus, and postoperative AKI 
(P<0.001 for all)
Conclusions: African Americans compared to other ethnic groups have 
disproportionately increased risk of chronic kidney disease following nephrectomy and this 
is partly explained by the higher baseline CKD.
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Hypoglycemia Is Common in Patients with Type 2 Diabetes and CKD
Susana Hong, Steven Fishbane, Kenar D. Jhaveri, Vipulbhai Sakhiya, 
Meng Zhang, Yael T. Harris. CGM Study Department of Medicine, Zucker 
School of Medicine at Hofstra/Northwell, Great Neck, NY.
Background: It is unclear what the incidence of hypoglycemia is among patients with 
type 2 diabetes mellitus (T2DM) and non-dialysis chronic kidney disease (n-CKD). The 
magnitude of the problem remains largely unknown, as previous studies have generally 
relied on random laboratory blood testing to define hypoglycemia in this population. The 
purpose of our study was to use continuous glucose monitoring (CGM) to determine the 
frequency and severity of hypoglycemia in stable outpatients with T2DM and n-CKD.
Methods: We studied 60 patients with T2DM and n-CKD defined as eGFR 
0-45 ml/min. Patients wore the CGM (Abbott FreeStyle Libre Pro) for 14 days, with glucose 
recorded every 15 minutes, with a maximum of 1,344 glucose measurements. Blood tests
were performed in the fasting state at the end of the 14 day CGM. Hypoglycemia was
defined as plasma glucose below 70 mg/dL.
Results: All 60 patients had analyzable data, having worn the CGM for a mean of 
12.7±2.9 days. Mean age was 72.4±10.4 years, 75% of patients were men, 15% were black, 
and mean eGFR 25.6±10.5. The mean glucose concentration was 152.2±56.6 mg/dL. 
47/60 (78.3%) patients had at least one hypoglycemic episode. The mean number of 
episodes was 7.8±9.6, with a range of 0-53 episodes. The mean number of minutes of 
hypoglycemia was 1574±2350. This represents a mean of 7.8±11.0% of total measurement 
time being hypoglycemic (figure), compared to studies in T2DM without CKD where the 
number is closer to 1.5%.
Conclusions: Hypoglycemia is very common among patients with T2DM and CKD. 
Extra glucose monitoring is advisable to avoid adverse events.
Funding: Clinical Revenue Support
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T Cell-Derived Cytokines in Urine as Biomarkers for Clinical Diagnosis of 
Acute Interstitial Nephritis
Dennis G. Moledina,1 Randy L. Luciano,1 Francis P. Wilson,1 Wassim Obeid,1 
Michael B. Kuperman,2 Gilbert W. Moeckel,1 Michael Kashgarian,1 
Jordan S. Pober,1 Mark A. Perazella,1 Lloyd G. Cantley,1 Chirag R. Parikh.1 1Yale 
School of Medicine, New Haven, CT; 2Arkana Laboratories, Little Rock, AR.
Background: The current clinical diagnosis of acute interstitial nephritis (AIN) is 
challenging as it relies on combining a high-index of clinical suspicion with subsequent 
biopsy confirmation. We hypothesized that AIN is a T cell-mediated process and tested 
urine for cytokines associated with T cell immunity as biomarkers for clinical diagnosis 
of AIN
Methods: We enrolled consecutive participants who underwent a kidney biopsy for 
evaluation of acute kidney disease at 2 academic hospitals from 2015 to 2017. We measured 
6 cytokines associated with T cell-mediated inflammation (TNFα, IFNγ, IL2, IL4, IL5, and 
IL13) in urine samples collected before the biopsy. We established AIN diagnosis through 
adjudication of histological images by 3 independent renal pathologists. We considered 
univariable and multivariable associations of clinical variables and biomarkers with AIN to 
develop a clinical diagnostic model
Results: Of the 154 participants, 35 (23%) had AIN and 119 had other diagnoses including 
acute tubular injury (n=37), diabetic kidney disease (n=15), arterionephrosclerosis (n=18), 
glomerular disease (n=40), and others (n=9). Patients with AIN had higher levels of TNFα 
and IL2 (Figure). The AUC for AIN diagnosis based on clinicians’ pre-biopsy diagnosis 
was 0.59 (0.50-0.69). The AUC of a model containing urinary markers of inflammation 
(pyuria) and glomerular injury (hematuria and proteinuria) was 0.72 (0.62-0.81), 
which increased on addition of TNFα and IL2 to 0.82 (0.73-0.90; P<0.001) and 0.76 (0.67-
0.85; P=0.009), respectively
Conclusions: Urine cytokines associated with T cell immunity were higher in patients 
with AIN as compared with those who had other diagnoses. These biomarkers significantly 
improved discrimination for AIN compared to clinicians’ prebiopsy suspicion of AIN
Funding: NIDDK Support, Private Foundation Support
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The Association of Plasma Inflammatory Mediators with CKD and 
Mortality After AKI: The ASSESS-AKI Study
Dennis G. Moledina,1 Chirag R. Parikh,1 Edward D. Siew,3 Mark M. Wurfel,4 
James S. Kaufman,5 Paul L. Kimmel,6 Alan S. Go,7 Thida C. Tan,7 
Vernon M. Chinchilli,9 Steven G. Coca,8 Kathleen D. Liu.2 ASSESS-AKI 1Yale 
School of Medicine, New Haven, CT; 2University of California at San Francisco 
School of Medicine, San Francisco, CA; 3Vanderbilt University School of 
Medicine, Nashville, TN; 4University of Washington, Seattle, WA; 5VA New York 
Harbor Healthcare System, New York, NY; 6National Institute of Diabetes and 
Digestive Kidney Diseases (NIDDK), Bethesda, MD; 7Kaiser Permanente 
Northern California, Oakland, CA; 8Icahn School of Medicine at Mount Sinai, 
New York, NY; 9Penn State College of Medicine, Hershey, PA.
Background: Inflammation contributes to development and progression of chronic 
kidney disease (CKD) after acute kidney injury (AKI) in preclinical studies. We evaluated 
the association of plasma inflammatory mediators with clinical outcomes in the longitudinal 
cohort of the ASSESS-AKI study
Methods: The ASSESS-AKI study is a multicenter, prospective cohort of participants 
hospitalized with AKI and matched non-AKI controls (n=769 pairs). We collected plasma 
samples collected during the index hospitalization and 3-months after discharge. We 
measured 10 inflammatory mediators [interferon (IFN)γ, tumor necrosis factor(TNF)α, 
interleukin (IL)1β, IL2, IL4, IL6, IL8, IL10, IL12p70, and IL13] using a MesoScale 
multiplex assay. We tested the independent association of these mediators with (a) chronic 
kidney disease (CKD) composite outcome, which included CKD incidence, progression, 
and end-stage kidney disease, and (b) death using a multivariable trivariate Weibull 
regression model
Results: The CKD composite outcome occurred in 297 (19%) participants and 309 
(20%) died after 4.8 (3.4, 5.9) years of follow-up. Participants with AKI were more likely 
to experience CKD outcome than non-AKI participants [207 (27%) vs. 90 (12%)]. In a 
multivariable analysis controlling for eGFR, albuminuria, smoking, body mass index, 
and AKI status, TNF-α levels at both hospitalization and 3-months after discharge were 
associated with higher risk of CKD (Figure), whereas none of the other biomarkers were 
associated with CKD. At 3 months after hospital discharge, IL6 and IL8 levels were 
associated with an increased risk of death, which remained significant after controlling for 
C-reactive protein.
Conclusions: Among the plasma inflammatory biomarkers, TNFα levels measured
during hospitalization and 3-months after discharge were independently associated with 
CKD, whereas IL6 and IL8 at 3-months after discharge were associated with increased 
mortality.
Funding: NIDDK Support
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Kidney Biopsy-Related Complications in Hospitalized Patients with Acute 
Kidney Disease
Dennis G. Moledina,1 Randy L. Luciano,1 Lidiya Kukova,1 Lili Chan,2 
Aparna Saha,2 Girish N. Nadkarni,2 Francis P. Wilson,1 Mark A. Perazella,1 
Chirag R. Parikh.1 1Yale School of Medicine, New Haven, CT; 2Ichan School of 
Medicine, New York, NY.
Background: We used data from the Yale biopsy cohort and Nationwide Inpatient 
Sample (NIS) to evaluate rates and risk factors of biopsy-related complications including 
adjudicated procedure-related bleeding requiring blood transfusions or angiographic 
interventions and death
Methods: We used data from the Yale biopsy cohort and Nationwide Inpatient 
Sample (NIS) to evaluate rates and risk factors of biopsy-related complications. We 
looked at complications including adjudicated procedure-related bleeding requiring blood 
transfusions or angiographic interventions and death
Results: Between 2015-2017, 159 hospitalized patients underwent a kidney biopsy 
at Yale for AKD evaluation. Median age of participants was 59 (47-68) years, 68 (43%) 
were women, 80 (51%) had stage 1 AKI, and 42 (27%) had stage 2 or higher AKI. Of 
these, 12 [9 (5-15)%] required a blood transfusion for biopsy-related bleeding and 3 [2 (1-
5)%] required an intervention. Of the 4 [3 (1-6)%] deaths during hospitalization, none were 
related to the biopsy. We identified lower hemoglobin and platelet levels, female sex, trainee 
as proceduralist, and larger needle gauge as risk factors of post-biopsy transfusion (Table). 
Higher blood urea nitrogen was associated with higher rates of transfusion in patients who 
did not receive desmopressin [n=32 (20%)], but not in those who received desmopressin 
(interaction P=0.008). Among the 53,315 hospitalizations with kidney biopsies between 
2012-2014 in the NIS, 925 (2%) required an intervention, similarly to the Yale cohort 
(P=0.88).
Conclusions: Hospitalized patients experience higher risk of post-biopsy complications 
and several risk factors such as lower hemoglobin and platelet count, female sex, and larger 
needle gauge are associated with this risk.
Funding: NIDDK Support, Private Foundation Support
Risk factors for post-biopsy bleeding requiring blood transfusion
*All risk factors with P<0.05 shown. ^Interaction P=0.008
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Assessment of Utility of Urine Sediment Microscopy in Hepatorenal AKI
Maria Soledad Rivera,1,2 Ayman M. Alghamdi,1 Juan Carlos Q. Velez.1,2 
1Ochsner Clinic Foundation, New Orleans, LA; 2Ochsner Clinical School, The 
University of Queensland, New Orleans, LA.
Background: Microscopic examination of the urinary sediment (MicrExUrSed) is a 
useful diagnostic tool in acute kidney injury (AKI). However, its performance has not been 
examined in AKI in patients with end-stage liver disease (ESLD). Hepatorenal syndrome 
type 1 (HRS-1), a type of AKI in ESLD, is difficult to diagnose despite the existence of the 
International Club of Ascites (ICA) criteria. We hypothesized that MicrExUrSed improves 
accuracy of diagnosis of acute tubular injury (ATI) in ESLD patients with AKI.
Methods: MicrExUrSed was performed in patients with AKI stage ≥ 2 with or without 
ESLD over a 6-month period. HRS-1 was defined by the ICA criteria. Urine Na <20 mEq/L, 
urine volume <500 ml, mean arterial pressure <75 mmHg and serum Na <135 mEq/L 
were supportive criteria. Definite HRS-1 was defined as: ICA + supportive criteria were 
met. Possible HRS was defined as: only ICA criteria were met. No HRS was defined as: 
≥1 ICA criteria was not met. Urinary cast scores (based on Chawla et al and Perazella 
et al) were assigned to each specimen. Chawla scores (CS) 3-4 and Perazella scores (PS) 2-3
were deemed consistent with ATI and not HRS-1.
Results: Distribution of casts (>25% lpf with ≥1 cast) differed between the ESLD 
(n=35) and non-ESLD (n=44) groups. Hyaline casts (HC), renal tubular epithelial cell casts 
(RTECC) and waxy casts (WC) were identified more often in ESLD compared to non-ESLD 
[57 vs 29% (p<0.05); 26 vs 5% (p<0.01) and 20 vs 5% (p<0.05) for HC, RTECC and WC], 
but not granular casts [43 vs 61%]. In the ESLD group, total bilirubin was significantly 
higher for those with RTECC [35.9 vs. 6.4 mg/dL (p<0.0001)] suggesting pathogenesis 
of bile cast tubulopathy. A diagnosis of Definite HRS-1 was assigned to 6 (17%), Possible 
HRS-1 to 14 (40%) and No HRS-1 to 15 (43%) patients. Addition of MicrExUrSed changed 
the diagnosis in 11 (31%) patients: Definite HRS-1 was changed to No HRS-1 in 2 and 
Possible HRS-1 was changed to No HRS-1 in 9, changing the final No HRS-1 count to 26 
(74%) and HRS-1 to 9 (26%). Nonetheless, vasoconstrictor therapy to treat HRS-1 was 
given to 23 (66%) patients.
Conclusions: MicrExUrSed can aid in the diagnosis of AKI in ESLD by identifying 
those with evidence of ATI, i.e., not consistent with HRS-1, with potential implications on 
the use of vasoconstrictor therapy and/or dialysis decisions.
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Impact of Porto-Pulmonary Hypertension in the Course of Hepatorenal 
AKI
Maria Soledad Rivera,1,2 Alaa E. Mohammed,1 Juan Carlos Q. Velez.1,2 1Ochsner 
Clinic Foundation, New Orleans, LA; 2Ochsner Clinic School, University of 
Queensland, New Orleans, LA.
Background: Porto-pulmonary hypertension is prevalent in cirrhotic patients. 
However, its impact on the clinical course of hepatorenal acute kidney injury (AKI) has 
not been previously investigated. We hypothesized that echocardiographic evidence of 
pulmonary hypertension affects the interplay between change in mean arterial pressure 
(MAP) and course of hepatorenal AKI during vasoconstrictor therapy as well as the overall 
renal outcome.
Methods: We conducted a prospective observational study of hospitalized patients 
with AKI stage ≥ 2 (AKIN) and cirrhosis over a 4-month period. Daily MAP and serum 
creatinine (sCr) values were collected, as well as pulmonary arterial pressure (PAP) 
estimated by echocardiography at the time of AKI. Patients were divided into PAP tertiles: 
1st ≤30, 2nd 31-40, 3rd >40 mmHg. Daily change in MAP (ΔMAP) and daily change in 
sCr (ΔsCr) from baseline were computed. Renal outcome chosen was need for renal 
replacement therapy (RRT).
Results: Among 52 patients, 19 (37%) were female, mean age was 56 (range 25-75). 
Baseline values were median MAP 76 (IQR 71–84) mmHg, median sCr 2.3 (IQR 1.7–3.7) 
mg/dL, median serum albumin 2.3 (IQR 1.8–3) g/dL and median total bilirubin 4.1 (IQR 
1.8–27.2) mg/dL. A significant inverse correlation was found between ΔMAP and ΔsCr on 
the following day (r = -0.20, p=0.0003) throughout the course of AKI. PAP was obtained 
in 36 patients. The correlation between ΔMAP and ΔsCr within each PAP tertile were: 
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≤30: r = 0.08 (p=0.37), 31-40: r = -0.36 (p=0.002) and >40: r = -0.40 (p=0.0006). Thus,
as PAP increases, a negative correlation between ΔMAP and ΔsCr on the following day
strengthens. Furthermore, there was a trend for an increased need for RRT within those
in the highest tertile of PAP (need for RRT: 28.6%, 33%, and 70%, for the 1st, 2nd, and 3rd
tertiles, respectively (p=0.0511, chi-square for trend).
Conclusions: Cirrhotic patients with more severe pulmonary hypertension exhibit a 
significantly stronger negative correlation between ΔMAP and ΔsCr, suggesting that those 
with higher PAP may display increased sensitivity to improved kidney function upon 
optimization of MAP with vasoconstrictors. Moreover, higher PAP is associated with 
greater need for RRT, adding complexity to the pathogenesis of hepatorenal AKI.
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Angiopoietin-2 Predicts Mortality and Kidney Outcomes in  
Decompensated Cirrhosis
Andrew S. Allegretti,1 Xavier F. Parada,1 Guillermo Ortiz,6 Joshua Long,1 
Scott Krinsky,1 Sophia Zhao,1 Bryan C. Fuchs,1 Dongsheng Zhang,3 
S. Ananth Karumanchi,2 Sahir Kalim,4 Sagar U. Nigwekar,1 Ravi I. Thadhani,5 
Samir M. Parikh,3 Raymond T. Chung.1 1Massachusetts General Hospital,
Boston, MA; 2Cedars-Sinai Medical Center, Los Angeles, MA; 3Beth Israel
Deaconess Medical Center, Boston, MA; 4Massachusetts General Hospital/
Harvard Medical School, Cambridge, MA; 5Cedars-Sinai, Los Angeles, CA; 
6Medicine, St. Elizabeth’s Hospital, Boston, MA.
Background: AKI in decompensated cirrhosis has limited therapeutic options 
and novel mechanistic targets are urgently needed. Angiopoietin-2 is a context-specific 
antagonist of Tie2, a receptor that signals vascular quiescence. Considering the prominence 
of vascular destabilization in decompensated cirrhosis, we evaluated Angiopoietin-2 to 
predict clinical outcomes.
Methods: Serum Angiopoietin-2 was measured in a prospective cohort of hospitalized 
patients with decompensated cirrhosis and AKI. Clinical outcomes were examined over 
a 90-day period and analyzed according to Angiopoietin-2 levels. Primary outcome was 
90-day mortality.
Results: We analyzed 191 patients (median Angiopoietin-2 level 18.2 [IQR 11.8, 26.5] 
ng/mL). Median MELD score was 23 [17, 30] and 90-day mortality was 41%. Increased 
Angiopoietin-2 was associated with increased mortality (died 21.9 [13.9, 30.3] ng/mL vs. 
alive 15.2 [9.8, 23.0] ng/mL; p <0.001), higher AKIN stage (stage I 13.4 [9.8, 20.1] ng/mL 
vs. stage II 20.0 [14.1, 26.2] ng/mL vs. stage III 21.9 [13.0, 29.5] ng/ml; p = 0.002) and 
need for renal replacement therapy (16.5 [11.3, 23.6] ng/mL vs. 25.1 [13.3, 30.3] ng/mL; 
p = 0.005). The association between Angiopoietin-2 and mortality was significant 
in unadjusted and adjusted Cox regression models (p ≤ 0.001 for all), and improved 
discrimination for mortality when added to MELD score (integrated discrimination 
increment 0.067; p = 0.001).
Conclusions: Angiopoietin-2 was associated with mortality and other clinically 
relevant outcomes in a cohort of decompensated cirrhotic patients with AKI. Further 
experimental study of Angiopoietin/Tie2 signaling is warranted to explore its potential 
mechanistic and therapeutic role in this population.
Funding: NIDDK Support, Private Foundation Support
90-day survival by Angiopoietin-2 tertile. Low (<13.5 ng/mL), Mid (13.5-23 ng/mL), High
(> 23 ng/mL)
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Post-Discharge Long-Term Outcomes of the Dialysis-Requiring AKI 
During the Perioperative Period of Liver Transplantation
Soojin Lee,1 Sehoon Park,1 Yaerim Kim,1 Chun Soo Lim,2 Kwon Wook Joo,1 
Dong Ki Kim.1 1Seoul National University Hospital, Seoul, Republic of Korea; 
2Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Background: Patients undergoing liver transplantation (LT) are prone to acute kidney 
injury (AKI), which is known to decrease patient survival, and considerable portion of AKI 
patients require renal replacement therapy (RRT) during the perioperative period of LT. 
Nevertheless, long-term outcomes among the patients requiring RRT are not thoroughly 
evaluated yet.
Methods: The nationwide, population-based cohort study was conducted. Adult 
patients received LT in tertiary hospitals of Korea between 2006 and 2015 were considered. 
Patients who underwent RRT or received LT prior to the index admission were excluded. 
The RRT group consisted of the patients received RRT during the perioperative period of LT 
and the control group included the patients who did not underwent RRT.
Results: Of 8,421 patients underwent LT, 5,911 received RRT. Among the patients 
received RRT, 802 underwent continuous renal replacement therapy (CRRT). All-cause 
mortality [adjusted hazard ratio (HR) 1.52 (1.26-1.83), P<0.001] and progression to end-
stage renal disease (ESRD) [adjusted HR 2.93 (2.34-3.66), P<0.001] were increased in RRT 
patients (Table 1). However, the risk of MACE [adjusted HR 1.17 (0.80-1.70), P=0.430] 
were similar between the two groups. Among the patients who received RRT, all-cause 
mortality [adjusted HR 2.92 (1.48-5.76), P=0.002] was worse in CRRT group, compared 
to intermittent renal replacement therapy (IRRT) group. ESRD progression [adjusted HR 
0.36 (0.24-0.52), P<0.001] was improved with CRRT application and the risk of MACE 
[adjusted HR 1.11 (0.42-2.94), P=0.832] was comparable between the two groups.
Conclusions: Requirement of RRT during the perioperative period of LT had worse 
long-term mortality and ESRD progression compared to the patients who did not receive 
RRT. The risk of MACE in patients underwent RRT was comparable to the control groups.
Funding: Commercial Support - Baxter (LSO-18-70260)
Table 1. Prognosis of patients underwent RRT
HR = hazard ratio, CI = confidential interval.
Model 1 was an unadjusted simple model.
Model 2 was adjusted for age, sex, comorbidities, and the etiology of liver disease.
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Cisplatin-Induced Kidney Injury Is Transient and Associated with 
Short-Term Elevation of Urine Interleukin-18 in Patients with Testicular 
Cancer
Kelly McMahon,1 Alan C. Cameron,2 Jeff D. White,3 Paul Welsh,2 
Michael Zappitelli,4 Rhian Touyz,2 Patrick B. Mark,2 Ninian N. Lang.2 1McGill 
University, Montreal, QC, Canada; 2University of Glasgow, Glasgow, United 
Kingdom; 3Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 
4Toronto Hospital for Sick Children, University of Toronto, Toronto, ON, 
Canada.
Background: Cisplatin causes acute kidney injury (AKI) but changes in urinary AKI 
biomarkers are not well defined in clinical practice. We investigated short- and medium-
term AKI using novel biomarkers over 9 months in patients with testicular cancer treated 
with cisplatin.
Methods: Prospective observational study of men with testicular cancer in 3 groups 
following orchiectomy: 1) surveillance; 2) adjuvant cisplatin (1-2 cycles); 3) metastatic 
disease with high dose cisplatin (3-4 cycles). Blood/urine was collected at 6 visits: baseline, 
24h, 6 weeks, 3, 6 and 9 months for renal injury markers.
Results: 27 men (median age 34y [IQR 31-40y]) were recruited: surveillance (N=10); 
adjuvant cisplatin (N=7); metastatic cisplatin (N=10). Urine tubular injury markers 
(interleukin-18 [IL-18], neutrophil gelatinase-associated lipocalin [NGAL], vascular 
endothelial growth factor [VEGF], kidney injury molecule-1 [KIM-1]), urine albumin/
creatinine ratio (ACR) and serum cystatin C (CysC) were elevated at 24h and 6 weeks (KIM-
1) post cisplatin in adjuvant and metastatic groups (all: P<0.05 vs. baseline). These normalized
by 6 weeks (IL-18, NGAL, VEGF, ACR, CysC) and 3 months (KIM-1). eGFR was within
normal range throughout. Urine IL-18 rose in both cisplatin groups at 24h (median [IQR]: 
adjuvant 24h 22.8 [16.4-34.7] vs. baseline 6.8 [5.7-15.9]; metastatic 24h 23.7 [20.1-36.1] vs.
baseline 9.2 [7.2-11.9] pg/mg, P<0.05) and returned to baseline by 6 weeks.
Conclusions: Cisplatin nephrotoxicity is reversible over 3 months and is evident with 
use of novel biomarkers. Elevation of IL-18 supports a major inflammatory renal insult. 
This provides evidence to support investigation of anti-inflammatory drugs to prevent 
cisplatin toxicity.
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Role of Plasma Cystatin C and Urine NGAL in Prediction of  
AKI and Mortality in Patients with Acutely Decompensated Cirrhosis:  
A Prospective Cohort Study
Sang-Kyung Jo, Jihyun Yang, Junyong Lee, Sewon Oh, Myung-Gyu Kim. 
Korea University Anam Hospital, Seongbuk-Gu, SEOUL, Republic of Korea.
Background: Acute kidney injury (AKI) is the most frequent and devastating 
complication in cirrhotic patients. Emerging evidence suggests that novel biomarkers could 
predict AKI earlier than conventional markers and better predict prognosis in these patients.
Methods: To determine the incidence and prognosis of AKI in acutely decompensated 
cirrhotic patients and also test whether plasma cystatin C, urine neutrophil gelatinase-
associated lipocalin (NGAL) or tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-
like growth factor 7 (IGFBP7) could predict the development of AKI and prognosis.
Results: Of 111 patients, 45 (40.5%) developed AKI during hospitalization. Although 
53.3% of AKI episodes were transient, stage 1 AKI, overall mortality was significantly 
higher compared to those without AKI (25% vs. 46.5%, p=0.02). Although initial BUN 
and serum creatinine were not different, plasma cystatin C and urine NGAL at the time 
of admission were significantly increased in patients who developed AKI and also death. 
Plasma cystatin C and urine NGAL were independently associated with the development 
of AKI after adjusting for clinical variables including age, co-morbidity, and Child-Pugh 
score. [plasma cystatin C, odds ratio (OR) 2.09; 95% confidence interval (CI), 1.01-4.35), 
urine NGAL, OR 1.04, CI 1.01-1.05]. Although these biomarkers failed to predict mortality 
independent of clinical variables, urine NGAL significantly improved the accuracy of 
MELD in predicting mortality.
Conclusions: The incidence of AKI is high and even minor increase in serum creatinine 
is associated with high mortality in decompensated cirrhosis. Novel biomarkers including 
plasma cystatin C or urine NGAL might be useful in the earlier diagnosis of AKI and also 
in predicting mortality in acutely decompensated cirrhotic patients.
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Utility of Serum Cystatin C (SCysC) to Assess AKI and Day 90 (D90) 
Major Kidney Adverse Events (MAKE90) Following Cardiac Surgery 
(CS) in Subjects Treated with QPI-1002
Lukas J. Lehner,1 U. Schwertschlag,6 Matthias Thielmann,2 Andre Lamy,3 
David Corteville,4 D. P. Cafaro,6 A. Patel,6 Madhav Swaminathan,5 
D. J. Odenheimer,6 P. Chan,6 Gabor Szabo,7 Yuval Mathews,8 D. Rothenstein,8 
Elizabeth C. Squiers.6 The Quark AKI Study Team 1Charité Universitätsmedizin 
Berlin, Berlin, Germany; 2West-German Heart and Vascular Center Essen,
University Duisburg-Essen, Essen, Germany; 3McMaster University, Hamilton, 
ON, Canada; 4McLaren Northern Michigan, Petoskey, MI; 5Duke University
Medical Center, Durham, NC; 6Quark Pharmaceuticals, Inc., Fremont, CA; 
7University of Heidelberg, Heidelberg, Germany; 8Quark Pharmaceuticals, Nes 
Ziona, Israel.
Background: QPI-1002 (QPI), a siRNA targeting p53, is being developed for acute 
kidney injury (AKI) following CS. KIDGO guidelines recommend assessment of renal 
function based on SCysC in settings where serum creatinine (SCr) may be unreliable (e.g. 
decreasing muscle mass).
Methods: Initial results from a global Phase 2 double-blind study with QPI for AKI 
(N=341: QPI=165, Placebo (PL)=176) (NCT#02610283) (presented at ASN 2017: SA-
OR124). SCr and SCysC levels were both measured.
Results: QPI significantly reduced (↓) AKI (35.4 % QPI vs 50.6% PL; p=0.0047), 
↓AKI severity across all grades (p=0.002), and ↓ AKI duration (p=0.0016) assessed by 
SCysC similarly to SCr (ASN 2017). In a higher risk subpopulation [proteinuria, low 
baseline eGFR, and/or insulin dependent diabetes, (N=241)], QPI ↓MAKE (Death, RRT or 
a ↓in eGFR by 25%) at D90 using eGFRCys (37% QPI vs 51% PL; RRR=29%; p=0.024), 
but not using eGFRCr. To determine the cause of the divergence of SCr and SCys eGFRs at 
D90, subjects were grouped by the discordance of SCr and SCys after the method of Grubb 
using the differences of eGFRs between baseline and D90. Groups were as per Figure 
1. The Concordant population (N=114) also had a treatment effect in favor of QPI using
eGFRCr for MAKE90 (RRR23%). The largest discordant group, Discordant 1 (N=55),
compared to Concordant population, had longer ICU stays (6 vs 4.4 days), more MACE
events (10.9 vs. 6.2 %) and had muscle mass loss expressed as ↓sarcopenia index (Kashani 
et al 2018) with a 28% decrease.
Conclusions: SCr and SCys post CS (D1-D5) were concordant and QPI-1002 
significantly reduced the incidence, severity and duration of AKI by either analyte. QPI 
significantly ↓MAKE 90 in a subpopulation of higher risk subjects when evaluated by SCys. 
Consistent with other reports, SCr appeared to overestimate eGFR at D90 as compared to 
SCys in a subset of subjects at risk for decreased SCr production.
Funding: Commercial Support - Quarkpharma Fremont, CA
Figure 1
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Improving the Kinetic GFR by Taking Volume Changes into Account
Sheldon Chen. MD Anderson, Houston, TX.
Background: The kinetic glomerular filtration rate (GFR) equation was developed to 
estimate the kidney function even as the serum creatinine is changing. One shortcoming 
of the equation is that it assumes a constant volume of distribution for the creatinine. 
The volume in hospitalized patients can fluctuate quickly and drastically. For example, 
in hypotension and multiorgan failure, aggressive volume resuscitation would dilute the 
creatinine concentration, slowing down a rise in creatinine and making the acute kidney 
injury (AKI) appear milder.
Methods: To undo the confounding effects of volume change, we improved the kinetic 
GFR model by introducing variables to describe the ongoing influence of volume change. 
In the upgraded model, we solved its differential equation to yield a formula that predicts 
how the serum creatinine would evolve, as determined by the creatinine generation rate, 
creatinine clearance rate (~GFR), and now a volume change rate. Clinically, the starting 
and ending creatinines are measured by the lab, so the equation is rearranged to solve for 
the kinetic GFR.
Results: The new kinetic GFR equation was tested in multiple patients, some of whom 
had extreme changes in volume. In all cases, incorporating volume information resulted in 
the calculated GFR being correctly adjusted, concordant with: 1) Volume Gain → A) AKI 
looks less severe; GFR is actually lower, or B) renal recovery looks very robust; GFR is 
actually not as high, and 2) Volume Loss → A) AKI looks quite severe; GFR is actually not 
as impaired, or B) renal recovery looks unimpressive; GFR is actually higher than believed. 
Case: a 66-year-old woman has ischemic lactic acidosis and hypotension (87/53 mm Hg). 
She was given normal saline at 300 mL/h. NS plus the many intravenous drips (pressors 
and antimicrobials) added up to a net volume gain of 5 liters in 12 hours. With oliguria, her 
serum creatinine rose from 0.84 to 1.25 mg/dL over a 16-hour period, encompassing the 
above 12 hours. The old equation would calculate a kinetic GFR of 48.3 mL/min. The new 
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equation would calculate a kinetic GFR of 38.6 mL/min. The difference of 9.7 mL/min was 
due to massive volume gain, which masked the true severity of her AKI.
Conclusions: Body volume changes can significantly affect creatinine kinetics. The 
new volume-adjusted equation improves the precision of kinetic GFR estimation, which 
could aid in diagnosis and medication dosing.
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Evaluation of Finger-Stick Point of Care Creatinine Assay for Early 
Diagnosis of AKI in the Community
Joshua Storrar, James Ritchie, Denise Darby, Khalid Alshawy, Smeeta Sinha, 
Dimitrios J. Poulikakos. Renal Medicine Department Salford Royal NHS 
Foundation Trust, Salford, United Kingdom.
Background: Acute kidney injury (AKI) is a major health problem which occurs in 
the context of infection in more than 50% of cases. Recent guidance for sepsis mandates 
the delivery of a sepsis bundle within one hour of presentation in patients with suspected 
infection and AKI. However, the majority of these cases arise in the community. Primary 
care physicians need to make a decision for hospital referral at the first assessment. The aim 
of this study was to evaluate finger-stick capillary point of care (POC) creatinine (Cr) testing 
for real time diagnosis of AKI and evaluate its role in the clinical decision making process 
during the assessment of sepsis in nursing home residents.
Methods: The precision of the POC Cr assay was measured as coefficient of variation 
(CV) ie the ratio of the standard deviation to the mean over 5 repeated measurements.
Correlation, reliability and agreement were estimated by using Pearson’s correlation,
Intraclass Correlation Coefficient calculation and the Bland-Altman method respectively. 
POC Cr from finger-stick capillary samples, along with concurrent serum Cr samples 
measured by Siemens Advia 2400 Jaffe in our laboratory, were collected from nursing home 
residents and A&E patients.
Results: Mean CV from 9 samples with 5 repeated measurements was 0.044±0.018 
(min=0.018, max=0.081). There were 70 paired samples from 66 patients aged 78±17. 
POC Cr was 116±64umol/L and Serum Cr 84±41umol/L. Pearson correlation was 0.804 
(p=0.000), Figure 1A. Average Intraclass Correlation Coefficient was 0.843 (confidence 
interval 0.748-0.903, p=0.000). Bland-Altman plot is presented in Figure 1B. Mean 
difference between POC Cr and Serum Cr was 32±39, 4 values were outside the limits of 
agreement defined as mean difference ±1.96 SD (95% confidence interval) and 3 of 4 were 
above 200.
Conclusions: Finger-stick POC Cr has good agreement with laboratory method and 
may be used to assist clinical decision making. It can reliably detect severe AKI stages 2 
and 3. POC Cr tends to overestimate serum Cr and has decreased agreement in Cr values 
above 200 umol/L.
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Leucine Rich α-2 Glycoprotein Is a Novel Urinary and Serum Biomarker 
for AKI
Tomohiro Eguchi, Yoshio Terada, Yoshinori Taniguchi, Hirofumi Nishikawa. 
Kochi University, Nankoku city, Japan.
Background: Leucine-rich α-2 glycoprotein (LRG) is one of serum glycosylated 
proteins with 347 amino acids, and reported that serum LRG is a novel disease activity 
biomarker for rheumatoid arthritis and inflammatory bowel disease. However, little is 
known about the role of LRG in acute kidney injury (AKI) pathogenesis. We examined 
renal LRG expression and urinary LRG level using mice AKI model and clinical samples.
Methods: We evaluated LRG mRNA and protein expression in kidney in the 
bilateral renal ischemia-reperfusion injury (IRI) mice AKI model. We also examined 
immunohistological examination of LRG localization by confocal microscopy, and 
measured serum and urinary LRG levels. We evaluate the mechanism of LRG regulation 
using cultured renal tubular cells (NRK-52E cells). In clinical study, we measured urinary 
LRG in contrast media-induced AKI patients using ELISA, and immunohistological 
examination of LRG in AKI and minimal change renal biopsy samples.
Results: In mice with IRI-induced AKI, renal mRNA and protein expression of LRG 
were induced from 6 h and 12 h and peaked at 24 h and 48 h after IRI, respectively. In 
control mice kidney, only a very few expression of LRG was observed. Immunohistological 
examination showed that LRG expression was observed mainly on renal tubular cells in 
AKI mice. The LRG positive tubular cells are mainly co-stained with AQP1 using confocal 
microscopy. We also find that serum and urinary LRG levels were up-regulated in IRI-
induced AKI from 12h. In NRK-52E cells, TNF-alpha and LPS stimulated LRG expression. 
Notably, in contrast media-induced AKI patients, urinary LRG levels were increased from 
6 h. LRG staining were enhanced in AKI renal-biopsy samples mainly at proximal tubules. 
In contrast, only a few LRG staining was observed in minimal change renal biopsy samples.
Conclusions: Our results demonstrate that LRG is up-regulated in renal tissues in both 
mice and human AKI, and that urine and serum LRG are increased in early phase of AKI. 
Inflammatory cytokines such as TNF-alpha stimulates expression of LRG in renal tubular 
cells. Thus, urine and serum LRG could serve as a potential early biomarker in AKI.
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Performance of Urinary Osteopontin for the Prediction of AKI Prognosis 
and Clinical Outcomes in Critically Ill Adults
Lynn Redahan,2 Stephen Duff,2 Sebastian Vencken,1 Peter P. Doran,1 
Patrick T. Murray.2 The Dublin Acute bioMArker Group Evaluation (DAMAGE) 
Study Group 1University College Dublin, Dublin, Ireland; 2UCD School of 
Medicine and Medical Science, Dublin 7, Ireland.
Background: Osteopontin (OPN) is a secreted phosphoprotein whose expression 
is upregulated in several experimental models of acute kidney injury (AKI). Due to the 
localisation of its expression, it has been suggested to be a marker of injury to the ascending 
limb of the loop of Henle. OPN expression is increased in regenerating proximal tubular 
cells following injury and it may play a role in renal repair and regeneration. The full extent 
of the role of OPN in human AKI is incompletely understood. We hypothesised that OPN 
levels may predict adverse outcomes, such as AKI progression and mortality, in critically 
ill patients.
Methods: The Dublin Acute Biomarker Group Evaluation (DAMAGE) Study is 
a prospective multicenter observational study investigating the utility of several urinary 
biomarkers for the diagnostic and prognostic assessment of AKI in critically ill adults. We 
conducted a subgroup analysis of this cohort to evaluate whether urinary OPN levels could 
predict which patients would develop progressive AKI and other adverse clinical outcomes.
Results: The final analysis included a total of 33 patients with a mean age of 59.3 years 
(S.D. 17.5). Urinary OPN levels normalised to urinary creatinine on Day 1 and on the day 
of AKI diagnosis did not differ significantly between survivors to day 30 and non-survivors. 
There was no statistically significant difference in urinary OPN levels between those who 
met the criteria for progression (a composite of progression to a higher KDIGO AKI 
stage, renal replacement therapy or death) and those who did not. There was a significant 
difference in the distributions of urinary OPN levels in patients who survived to the time of 
ICU discharge and those who did not (p=0.043).
Conclusions: In conclusion, although the sample size for this subset analysis is small, 
the lack of major difference in estimated risks between groups (odds ratios: ~0.99-1.01 per 
100 mg/g OPN/creatinine), even when adjusted for study centre, appears to show that OPN 
levels measured on Day 1 or on the day of AKI diagnosis is unlikely to be a predictor of 
AKI progression or survival.
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Biomarkers of Kidney Injury and Repair and Risk for Future Kidney 
Events: The ASSESS-AKI Study
Jeremy Puthumana,3 Kathleen D. Liu,2 Edward D. Siew,4 William B. Reeves,5 
Jonathan Himmelfarb,6 Steven G. Coca,7 Alan S. Go,8 Chi-yuan Hsu,9 Talat 
Alp Ikizler,13 Mark M. Wurfel,15 Amit X. Garg,10 James S. Kaufman,14 
Paul L. Kimmel,11 Vernon M. Chinchilli,12 Chirag R. Parikh.1 ASSESS-AKI 
Study Investigators 1Yale University and VAMC, New Haven, CT; 2University of 
California at San Francisco School of Medicine, San Francisco, CA; 3Yale 
School of Medicine, New Haven, CT; 4Vanderbilt University School of Medicine, 
Nashville, TN; 5University of Texas Health Science Center San Antonio, San 
Antonio, TX; 6Kidney Research Institute, Seattle, WA; 7Icahn School of Medicine 
at Mount Sinai, New York, NY; 8Kaiser Permanente Northern California, 
Oakland, CA; 9University of California San Francisco, San Francisco, CA; 
10London Health Sciences Centre, London, ON, Canada; 11National Institute of 
Diabetes and Digestive Kidney Diseases (NIDDK), Bethesda, MD; 12Penn State 
College of Medicine, Hershey, PA; 13Vanderbilt University Medical Center, 
Nashville, TN; 14VA New York Harbor Healthcare System, New York, NY; 
15University of Washington, Seattle, WA.
Background: Acute kidney injury (AKI) is a complex disorder associated with 
increased risk of CKD and mortality. While kidney function may improve after an episode 
of AKI, subclinical kidney damage may remain that connotes propensity for GFR decline 
over time. We sought to examine the utility of biomarkers associated with renal injury and 
repair during and after AKI.
Methods: In a prospective longitudinal parallel cohort study, we enrolled 769 adults 
hospitalized with AKI and 769 hospitalized adults without AKI from 4 centers in North 
America. Interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), 
kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), 
uromodulin (UMOD), and YKL-40 were measured in urine samples collected during index 
hospitalization and outpatient follow-up at 3 months. We followed patients for a median of 
4.2 years and assessed the association of the biomarkers with a composite renal outcome 
(CKD incidence, CKD progression, or ESRD) and death.
Results: Urinary biomarkers at the time of index hospitalization were not significantly 
associated with the composite renal outcome or death. As shown in Figure, urinary IL-18, 
NGAL, KIM-1, MCP-1, and YKL-40 at 3 months were independently associated with risk 
of renal events in adjusted analyses. In addition, higher urinary NGAL and YKL-40 levels 
at 3 months were independently associated with increased risk of mortality.
Conclusions: Urine biomarkers were detectable at 3 months, suggesting ongoing 
inflammation, repair, and fibrosis even after clinical AKI has resolved. Biomarker levels at 
3 months identify patients at risk for renal events and death.
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Early increase in Renal Injury Urinary Biomarkers Associated with AKI 
Development in Major Elective Non-Vascular Abdominal Surgeries
Lia J. Marçal,2 Graziela R. de Souza,2 Veronica Torres,2 Flávia B. Azevedo,2 
Dirce M. Zanetta,1 Luis Yu,2 Leila Antonangelo,2 Emmanuel A. Burdmann.2 
1University of São Paulo, S Paulo, Brazil; 2University of Sao Paulo Medical 
School, Sao Paulo, Brazil.
Background: There are few data on the incidence of acute kidney injury (AKI) 
diagnosed by KDIGO criteria and the role of renal injury urinary biomarkers (uBMs) 
for predicting AKI in patients (pts) submitted to major elective non-vascular abdominal 
surgeries (MENVAS).
Methods: A total of 225 pts were evaluated, peri-operatively and from the ICU 
admission up to 7 days. Serum Creatinine (SCr) was assessed before surgery and once a 
day up to 7d or until ICU discharge. Hourly Urinary Ouput (ml/kg/h) was measured daily. 
AKI was diagnosed using either SCr or/and urinary output (UO) according to KDIGO 
definitions. Urine sample was collected 1 day before surgery (baseline), 30 min, 12 and 24h 
after ICU admission. Five uBMs were assessed: monocyte chemotactic protein 1 (MCP-1), 
interleukin 18 (IL-18), kidney injury molecule-1 (KIM-1), microalbuminuria (μalb) and 
neutrophil gelatinase-associated lipocalin (NGAL) by Luminex x-MAP method. Data are 
presented as median (first and third quartiles) or frequency. Statistical significance was 
p<0.05.
Results: Overall, age was 55±15y, 58,2% were female, hospital LoS was 17,7±16.9d, 
ICU LoS was 3.2±3.2d and mortality was 6,7%. A total of 126 pts (56%) developed AKI 
- majority KDIGO I (77,8%). Those developing AKI KDIGO II and III had significantly 
higher BMs values compared to pts AKI KDIGO I or non-AKI in all studied times, but the 
SCr didn’t rise at the same period (IMAGE 1). UO has the best performance: 77,6% pts
(KDIGO I) and 89,3% (KDIGO II and III) in 6h; NGAL showed a good performance 24h 
after ICU admission.
Conclusions: We found a strikingly high incidence of MENVAS-associated AKI 
diagnosed by KDIGO criteria in patients admitted ICU. Those who developed more severe 
AKI showed significantly higher uBMs in all times studied, including the preoperative 
period. uBM increase earlier and before SCr.
Funding: Government Support - Non-U.S.
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Diagnostic Utility of Serial Microscopic Examination of the Urinary 
Sediment in AKI
Ayman M. Alghamdi,1 Maria Soledad Rivera,2 Juan Carlos Q. Velez.1,2 1Ochsner 
Clinic Foundation, New Orleans, LA; 2Ochsner Clinical School, The University 
of Queensland, New Orleans, LA.
Background: Urine microscopy is a clinical tool of diagnostic and prognostic value 
in acute kidney injury (AKI). However, the natural history and timing of cast formation 
remains underexplored. A single inspection of a urine specimen during the course of AKI is 
a mere snapshot that depends on the day of inspection. We hypothesized that longitudinal 
inspection of the urinary sediment provides additional diagnostic information otherwise not 
identified in a single inspection.
Methods: Microscopic examination of the urinary sediment (MicrExUrSed) +/- 
Sternheimer-Malbin stain was undertaken in all patients with AKI stage ≥ 2 who were seen 
on consultation in an inpatient nephrology service during a 6-month period. MicrExUrSed 
were done on the day of consult (day 1), 48 hours later (day 3) and 96 hours later (day 5). 
Urinary cast scores (based on Chawla et al and Perazella et al) were assigned to each 
specimen. Chawla scores (CS) 3-4 and Perazella scores (PS) 2-3 were categorized as 
consistent with acute tubular injury (ATI), whereas CS 1-2 and PS 0-1 were categorized as 
non-diagnostic for ATI (non-ATI). Worsening AKI was defined as a rise in serum creatinine 
(sCr) ≥ 0.3 mg/dL at either day 3 or 5.
Results: At least 2 serial specimens were collected in 60 patients (mean age 58, 32% 
women, mean sCr at day 1 3.8 mg/dL). Overall, CS and PS category changed over time in 
16 (27%) patients, and the change was observed at day 3 in almost all cases (15 of 16). On 
day 1, a CS and PS consistent with non-ATI was assigned to 31 (52%) patients. Among 
those 31 patients, CS and PS changed from non-ATI category to ATI in 9 (24%) at day 3. 
Those 9 patients accounted for 32% of the total 38 with ATI score. Patients with worsening 
AKI were more likely to change their score from non-ATI to ATI compared to those with 
stable or improved AKI [relative risk 3.3 (CI: 1.0 – 10.9) for CS (p = 0.047); 8.3 (CI: 1.1 – 
63.1) for PS (p = 0.041)].
Conclusions: Serial MicrExUrSed reveals diagnostic findings of ATI otherwise not 
identified in a single examination, particularly in specimens of patients with worsening 
AKI. A repeat MicrExUrSed within 48 hours may be warranted in cases of worsening AKI 
with unclear etiology.
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Serum Procalcitonin as a Predictor for the Development of AKI in 
Critically Ill Patients
Kayeong Chun, Ae jin Kim, Han Ro, Jae Hyun Chang, Hyun Hee Lee, 
Wookyung Chung, Ji Yong Jung. Division of Nephrology, Department of 
Internal Medicine, Gachon University Gil Medical Center, College of Medicine, 
Gachon University, Incheon, Republic of Korea.
Background: Procalcitonin (PCT) has been recognized as one of useful markers 
for the diagnosis of systemic inflammatory response syndrome. In addition, it has been 
reported that PCT is affected by renal function. However, there are few studies regarding the 
relationships between PCT and the development of acute kidney injury (AKI). Hence, we 
investigated whether serum PCT levels at the time of admission can predict the development 
of AKI and clinical outcomes.
Methods: We retrospectively analyzed data of 790 patients in whom PCT were 
measured on admission to the intensive care unit. We attempted to investigate that the 
serum PCT level at the time of admission could be as a predictor for development of AKI 
according to the groups classified in to the septic and the non-septic patients and risk factor 
for all-cause mortality.
Results: The serum PCT levels were significantly higher in patients with AKI than in 
those without AKI (P < 0.001). After adjustment of confounding factors, PCT still remained 
an independent risk factor for AKI (odds ratio [OR], 2.096; 95% confidence intervals [CI], 
1.378–3.190; P = 0.001). The OR (95% CI) for AKI development among those with and 
without sepsis were 2.620 (1.230–5.582, P = 0.013) and 1.928 (1.119–3.321, P = 0.018), 
respectively.
Conclusions: Serum PCT level could be used as a marker to predict the possibility of 
AKI in critically ill patients admitted to the ICU.
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Endogenous Ouabain (EO) as Predictor of AKI and Post-Operative 
Outcomes
Marco Simonini,1 Elena G. Bignami,2 Paola Casanova,1 Roberta Meroni,1 
Chiara Lanzani,1 Elisabetta Messaggio,1 Simona Delli carpini,1 Lorena Citterio,1 
Paolo Manunta.1 1San Raffaele Scientific Institute, Milan, Italy; 2University of 
Parma, Italy, Parma, Italy.
Background: AKI is a frequent complication of cardiac surgery. A large number of 
novel postoperative biomarkers have been proposed to assess the risk of AKI. However, 
there are neither preoperative biomarkers nor robust validated risk models that predict 
AKI. EO is an adrenal stress hormone with hemodynamic and renal effects. Our group 
have already reported that higher pre-operative EO levels are associated with a worse renal 
outcome after cardiac surgery. Our aim is to confirm levels of EO as predictive biomarker 
of AKI in a larger population.
Methods: EO preoperative level was measured in 1097 patients admitted for elective 
cardiac surgery. For the analysis, patients were grouped according to EO preoperative levels: 
1st group EO<133 pmol/L; 2nd EO 133-210 pmol/L; 3rd EO>210 pmol/L. According to 
the 3 groups, it was evaluated 1) incidence of AKI, 2) requirement of RRT and 3) total in-
hospital mortality (IHM).
Results: In this extended population, we confirmed our previous observations for the 
great impact of preoperative EO level in the development of post-operative AKI. Patients 
with the highest EO values (>210 pmol/L) had highest postoperative AKI incidence (28.9% 
vs. 24.3% vs. 15.6%, p<0.0001, fig 1) and required more RRT (p=0.006) postoperatively. 
Moreover, we observed a relationship between EO and total In Hospital Morality (IHM 
occurred in 3.2% of patients presenting the highest levels of EO; p=0.028). All results were 
corrected for main clinical variable associated to post-operative AKI (as age, sex, EF, basal 
eGFR, surgery type, history of hypertension/diabetes; re-intervention).
Conclusions: These results confirmed preoperative EO level as predictive for the 
outcomes in patients undergoing cardiovascular surgery: subjects with the highest level of 
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preoperative plasma EO experienced the worst outcomes (increased incidence of AKI, use 
of RRT and IHM).
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Optimization of a Novel 5-Plex Panel for AKI
Candace M. Adamo,1 Eibhlin M. McCole,2 Ciaran Richardson,2 
Timothy H. Carlson,1 Grainne Donnellan,2 Amar Sethi.1 1Pacific Biomarkers, 
Seattle, WA; 2Randox Teoranta, Dungloe, Ireland.
Background: Since creatinine is a lagging index of AKI progression, studies are now 
underway to qualify a new set of biomarkers for detecting drug-induced kidney injury 
(DIKI). Here, following optimization, we present performance data for a novel multiplex 
composed of urine AKI biomarkers.
Methods: The AKI multiplex panel quantifies KIM-1, cystatin C, clusterin, OPN 
and NGAL levels in urine. Multiplex results were compared to those from ELISA using 
urine from one cohort (n=60) treated with a preservative prior to freezing, and urine from 
a second cohort (n=122) left untreated. Cross reactivity for each analyte with non-panel 
related proteins was tested. Interfering substances were tittered to determine non-interfering 
concentrations (within ± 10%). Potential interferents assessed included human albumin 
(HA), hemoglobin, bilirubin, pH, glucose, sodium chloride and creatinine.
Results: Comparison of preserved urine biomarkers obtained using the two analytical 
methods provided correlations (r2) of 0.816, 0.970, 0.842, 0.718, and 0.741 for KIM-1, 
NGAL, cystatin C, clusterin and OPN, respectively. Slopes were 0.32, 0.87, 1.33, 0.53, 
and 1.06, respectively. The methods were poorly correlated for unpreserved urine with r2  
ranging from 0.203 to 0.705. Cross reactivity was <1% for all tested non-panel, related 
proteins. Interfering concentration for HA was <0.5 mg/mL for clusterin and was 
insignificant for remaining biomarkers. Hemoglobin interference was <62.5 μg/mL for 
clusterin and insignificant for all other biomarkers. Bilirubin, glucose, sodium chloride and 
creatinine interferences were insignificant for all biomarkers.
Conclusions: All five biomarkers tested with the novel panel and predicate ELISA 
methods correlated well when preserved urine was used. Recovery of some urinary AKI 
biomarkers is susceptible to variability, which can be controlled with preservative. No 
clinical significant interference was observed for several substances known to be present 
in urine and cross-reactivity for non-panel proteins was not significant. Previously reported 
performance of this multiplex combined with the present data demonstrate good multiplex 
selectivity, and document an in vitro diagnostic that fills the need for a robust and cost-
effective approach to diagnosis and monitoring of DIKI.
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Histopathological Features of Acute Tubular Necrosis in Native Kidney 
Correlate with Clinical Outcomes
Joy C. Chen,1 Aishwarya Ravindran,2 Sanjeev Sethi,2 Kianoush Kashani.3,4 
1Internal Medicine, Mayo Clinic, Rochester, MN; 2Laboratory Medicine and 
Pathology, Mayo Clinic, Rochester, MN; 3Nephrology and Hypertension, Mayo 
Clinic, Rochester, MN; 4Pulmonary and Critical Care Medicine, Mayo Clinic, 
Rochester, MN.
Background: Acute kidney injury (AKI) is a life-threatening complication of critical 
illnesses and is associated with increased morbidity and mortality. Acute tubular necrosis 
(ATN) is a frequent cause of AKI; however, few studies have examined the histopathological 
features of ATN as prognostic factors of kidney function recovery in native kidneys. Our 
aim is to describe histopathological features of ATN systematically and correlate with 
clinical outcomes.
Methods: Analyses included adult patients who underwent kidney biopsy for AKI 
unrelated to kidney transplantation at Mayo Clinic Rochester from January 1st, 2000 through 
December 31st, 2015 and ATN was the primary histological diagnosis (n = 46). Biopsies 
were reviewed by a kidney pathology consultant (SS) semi-quantitatively. Features of 
ATN included vacuolization, the presence of tubular debris, tubular distension, tubular cell 
flattening, and the extent of interstitial fibrosis and tubular atrophy (IFTA). To evaluate the 
factors associated with kidney recovery, patients were divided into two groups: recovery (n 
= 28, serum creatinine (SCr) level at 30 days decreased by 0.3 mg/dL and renal replacement 
therapy (RRT) liberated) vs. no recovery (n = 18).
Results: The median age at time of biopsy was 67 [IQR 58, 75] years old; of which 
50% were males, 91% Caucasian, with Charlson comorbidity index of 5 [IQR 4, 7], and SCr 
3.9 mg/dL [IQR 2.2, 5.2] at the time of biopsy. 35 (76%) patients were inpatient, 9 (20%) 
required intensive care unit (ICU) admission, and 10 (22%) required RRT at time of biopsy. 
Twenty eight (61%) patients recovered kidney function within 30 days of biopsy. The 
presence of 3+ debris on biopsy was associated with a higher chance of recovery (Figure 1).
Conclusions: Among patients with AKI with biopsy-confirmed ATN, 61% recovered 
kidney function within 30 days of biopsy and recovery was associated with increased 
presence of tubular debris.
Figure 1 Histopathologic features of ATN in patients with and without recovery. *P-value 
<0.05.
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A Furosemide Excretion Stress Test (FEST) Predicts AKI Progression and 
Mortality After Sepsis
Jonathan Street,1 Tiffany R. Bellomo,1 Erik H. Koritzinsky,1 Hiroshi Kojima,1 
Lakhmir S. Chawla,2 Peter S. Yuen,1 Robert A. Star.1 1NIDDK/NIH, Bethesda, 
MD; 2University of California, San Diego, San Diego, CA.
Background: The furosemide stress test (FST) has been shown to be a sensitive 
and specific predictor of progression to AKIN stage III in the ICU. FST measures the 
volume of urine produced after a furosemide bolus. Furosemide is actively excreted by 
the proximal tubules into the lumen where it inhibits NKCC2 in the thick ascending limb. 
We hypothesize that furosemide excretion (FEST) will be a more direct measure of tubule 
health than diuresis (FST). We developed a protocol for FST and FEST in mice and tested 
this hypothesis in a murine model of septic-AKI and in a human cohort.
Methods: Sepsis was induced in male and female CD-1 mice by cecal ligation and 
puncture (CLP). The FST/FEST started at 42 hours post-CLP. 1 mg/kg furosemide s.c. 
was given and urine collected for 12 hours. The mice were monitored until 7 days post-
CLP. Furosemide concentration was determined by a new reverse phase HPLC assay in the 
mouse urine samples and urine samples from 49 patients in the PASSKI cohort.
Results: In the mouse model a moderate severity of sepsis was used and similar 
mortality was seen in the males and females. In the male group, from 79 mice 32 survived 
to 42 hours and underwent FST/FEST with 19 mice surviving to 7 days compared 
to 60/23/14 in the females. Urine production during the 12 hour collection varied from 
0.08 to 2.62 ml. Urine production post-challenge and the fraction of furosemide recovered 
predicted mortality [AUC ROC values of 0.92 for FST in males, 0.95 for FST in females, 
0.87 for FEST for males, and 1.00 for FEST in females]. Both FST and FEST predicted 
time of death in males (R2 = 0.30 and 0.75), males and females combined (R2 = 0.26 and 
0.74) but not females alone. FST and FEST correlated with kidney NKCC2 mRNA levels 
(R2 = 0.35 and 0.46), and weakly with BUN, ALT and CK. In the human cohort, FST and 
FEST were comparable in predicting progression to KDIGO stage III (AUC ROC values of 
0.864 for FST and 0.848 for FEST).
Conclusions: In both the mouse model and human cohort the furosemide stress test and 
furosemide excretion stress test perform similarly with FST slightly superior in predicting 
mortality or progression. The furosemide excretion stress test predicted time to death in the 
mouse model.
Funding: NIDDK Support
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Loop Diuretic Challenge to Predict the Need for Renal Replacement 
Therapy Among Patients with Stage III AKI
Ankit Sakhuja, Erin F. Barreto, Robert C. Albright, Kianoush Kashani. Mayo 
Clinic, Rochester, MN.
Background: A poor response to a high dose loop diuretic challenge (LDC) predicts the 
progression of stage I and II acute kidney injury (AKI). Performance of this diagnostic test 
in stage III AKI is unknown. The objective of this study was to determine if poor response 
to LDC among patients with stage III AKI predicted the need for renal replacement therapy 
within 24-hours (dialysis24h).
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Methods: We included adults (≥18 years) admitted or transferred to medical or 
general surgical ICUs at Mayo Clinic, Rochester, MN between Jan 1, 2004, to Dec 31, 
2016. Patients with stage III AKI were identified by an electronic surveillance tool using 
AKIN criteria. We then identified patients who received LDC, defined as at least 1mg/kg 
intravenous bolus dose of furosemide or equivalent intravenous bolus dose of bumetanide 
after the diagnosis of stage III AKI. We excluded patients with the end-stage renal disease, 
organ transplantation or who died within 24 hours of LDC. We modeled post-LDC urine 
output as a restricted cubic spline and compared the area under the curve (AUC) for urine 
output (mL) at 2h (UOP2h) and 6h (UOP6h) after LDC to predict dialysis24h.
Results: We included 687 patients with stage III AKI who received LDC. The patients 
who received dialysis24h were younger (63.9 ± 14.5 years vs. 67.6 ± 15.6 years, p= 0.008), 
had lower Charlson comorbidity indices (4.9±2.4 vs. 5.8±2.7, p< 0.001) and higher SOFA 
scores on the day of LDC (10.4±3.9 vs. 8.2±3.4, p< 0.001). Both median total 2 hours 
(UOP2h) and 6 hours (UOP6h) urine output after LDC were lower in patients who needed 
dialysis24h (UOP2h 48ml vs. 138ml, p<.001; UOP6h 210ml vs. 616ml, p< 0.001) but UOP6h 
was better in predicting dialysis24h (Area under the curve 0.71 vs. 0.67, p= 0.02). The 
sensitivity and specificity of a UOP6h cutoff of ≤600ml to predict dialysis24h was 80.9% & 
50.5% and for a cutoff of ≤300cc was 64.2% & 68.2%.
Conclusions: Among patients with AKI stage III the UOP6h after loop diuretic 
challenge had a modest discriminant capacity to identify dialysis initiation within the next 
24 hours. Though its predictive power seems better in earlier stages of AKI, LDC may be a 
useful adjunct to assess dialysis needs in patients with advanced AKI.
Funding: Other NIH Support - This publication was made possible by CTSA Grant 
Number UL1 TR002377 from the National Center for Advancing Translational Sciences 
(NCATS), a component of the National Institutes of Health (NIH). Its contents are solely 
the responsibility of the authors and do not necessarily represent the official view of NIH.
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The Effect of Serum Neutrophil Gelatinase-Associated Lipocalin on 
Discontinuation of Continuous Renal Replacement Therapy in Critically 
Ill Patients with AKI
Ling Zhang. West China Hospital of Sichuan University, Chengdu, China.
Background: To determine the optimal time for discontinuing continuous renal 
replacement therapy (CRRT) for critically ill patients with acute kidney injury (AKI) by 
evaluating serum Neutrophil gelatinase-associated lipocalin (NGAL).
Methods: Patients treated with CRRT at least 24 hours for AKI in ICUs were divided 
into “success” and “failure” groups according to their renal replacement therapy requirement 
within 7 days after the initial discontinuation of CRRT.
Results: 80 AKI patients were divided into the success (n = 57) and failure groups 
(n = 23). The patients in failure group was associated with higher mortality compared 
with successful group (39% vs.14%, p = 0.017). There were significant differences in 
serum NGAL, creatinine level and urine output at discontinuation between two groups. In 
patients without sepsis (n = 55), serum NGAL and urine output were found as significant 
predictors of successful cessation. The area under receiver operating characteristic 
(AUROC) to predict successful discontinuation of CRRT was 0.85 for NGAL and 0.82 
for urine output. NGAL of 403 ng/ml had highest sensitivity (71%) and specificity (85%), 
as well as urine output of 695 ml/d with highest sensitivity (86%) and specificity (72%). 
However, in septic patients (n = 25), urine output, but not serum NGAL (OR, 0.990, 
p =0.43), was a significant variable (OR, 1.005, p =0.044), and the AUROC was 0.861 
(p = 0.003), with a cutoff of 793.5 ml (sensitivity 75%, specificity 100%).
Conclusions: Serum NGAL was a significant factor to predict successful CRRT 
discontinuation in non-septic patients. However, urine output, rather than serum NGAL, 
was a significant predictor in septic AKI patients.
Funding: Clinical Revenue Support
AUROC and cutoff of NGAL, creatinine and urine output for successful CRRT 
discontinuation in all included patients
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Different Roles of Functional and Structural Markers Measured at 
Discontinuation of Renal Replacement Therapy for AKI
Teruhiko Yoshida,1,2 Ryo Matsuura,1 Yoshihisa Miyamoto,1 Yohei Komaru,1 
Takuya Isegawa,1 Yoshifumi Hamasaki,3 Eisei Noiri,3 Masaomi Nangaku,4 
Kent Doi.3 1The University of Tokyo Hospital, Tokyo, Japan; 2National Institute 
of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 3University of 
Tokyo, Tokyo, Japan; 4the University of Tokyo School of Medicine, Tokyo, Japan.
Background: Severe acute kidney injury (AKI) which requires renal replacement 
therapy (RRT) has been reported to show unacceptably high mortality of 50% or more. 
Successful discontinuation of RRT is supposed to be associated with better outcomes. 
Although functional and structural markers have been evaluated in AKI, little is known 
about their roles in predicting outcomes when measured at the time of RRT discontinuation.
Methods: We performed a prospective single-center cohort study. Patients received 
continuous RRT (CRRT) for AKI between August 2016 and March 2018 in the intensive 
care unit of The University of Tokyo Hospital (Tokyo, JAPAN) were analyzed. Clinical 
parameters and urine samples were obtained at CRRT discontinuation. Successful CRRT 
discontinuation was defined as neither resuming CRRT for 48 hours nor receiving 
intermittent hemodialysis during 7 days from the CRRT termination. Major adverse kidney 
events (MAKEs) was defined as death or dialysis requirement or more than 25% reduction 
of eGFR from the baseline at day 90.
Results: 73 patients who received CRRT for AKI were analyzed. 59 discontinued 
patients and 14 un-discontinued patients were identified. Among kinetic eGFR, urine 
volume, urinary NGAL and urinary L-FABP, urine volume had the highest AUC [95%CI] 
0.91 [0.80-0.96] with the cut-off value of 740 ml/day. For predicting MAKEs at day 90, 
urinary NGAL had the highest AUC 0.76 [0.62-0.86], whereas kinetic GFR and urine 
volume failed to show statistical significance (kinetic eGFR AUC 0.49 [0.35-0.63], urine 
volume AUC 0.59 [0.44-0.73]).
Conclusions: Our prospective study revealed functional marker of urine volume could 
predict successful weaning of RRT, on the other hand, structural maker of urinary NGAL 
could predict long-term renal outcomes. This indicates different roles of functional and 
structural makers in predicting the outcomes of severe AKI requiring RRT.
Funding: Government Support - Non-U.S.
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Urinary Biomarkers and Renal Recovery at 4 Months After Community 
Acquired AKI: A Prospective Study in a Tertiary Care Hospital
Krishan Lal L. Gupta,1 Vinod Nagesh,1 Vivek Kumar,1 Ravindra L. Mehta.2 
1Postgraduate Institute of Medical Education & Research, Chandigarh, India; 
2University of California San Diego Medical Center, La Jolla, CA.
Background: Acute kidney injury (AKI) in developing countries is most commonly 
community acquired. Despite advances in the epidemiology of AKI, prognostication 
remains a significant challenge. We studied the ability of urinary biomarkers to predict renal 
recovery at four months after community-acquired AKI
Methods: We studied 78 patients with community-acquired AKI (AKIN stage 1 to 3) 
at the Department of Nephrology, PGIMER, Chandigarh. Serum and urine samples were 
collected at admission, discharge and, at 1 and four months after discharge. Renal recovery 
was defined as eGFR (CKD EPI)>60 ml/min/1.73m2 and urine protein to creatinine ratio 
<500 mg/g at four months after discharge. We investigated whether urinary biomarker 
(uL-FABP, uNGAL, uKIM-1) at hospital discharge could predict failure to recover renal 
function at four months after discharge
Results: 75(96%) patients had AKIN stage 3 AKI and other 3 patients had AKIN stage 
2 AKI. 21(27%) patients had failed to recover renal function at four months of discharge. 
Median urinary NGAL and urinary KIM-1 were significantly lower in patients with renal 
recovery (n=57) compared to those with persistent renal dysfunction (n=21). However, 
the differences in the median urinary L-FABP was not statistically different between the 
two groups (p-value = 0.55). Urinary NGAL and uKIM-1, individually predicted failure to 
recover renal function at four months after community-acquired AKI with AUCs of 0.71 
(95% CI, 0.26 to 0.55) and 0.68 (95% CI, 0.52 to 0.84), respectively.
Conclusions: This is the first prospective study to evaluate urinary biomarkers as an 
outcome-specific biomarker in patients with community-acquired AKI cohort. The results 
of this study indicate that urine NGAL and uKIM-1 are an independent predictor of failure 
to recover renal function after community-acquired AKI
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Kinetic eGFR Can Predict AKI Recovery Earlier, Especially in Patients 
with CKD
Keita Uehara, Takahito Uema, Tadashi Miyara. Department of Internal 
Medicine, Naha City Hospital, Naha, Okinawa, Japan.
Background: The kinetic estimated glomerular filtration rate eGFR (KeGFR) obtained 
via consecutive serum creatinine (sCr) values is reportedly useful for predicting renal 
recovery after acute kidney injury (AKI). However, no studies have determined which 
patients can benefit using the KeGFR model. We predicted recovery from AKI with 
consecutive KeGFR and sCr values, comparing the usefulness of KeGFR.
Methods: This retrospective cohort study included patients admitted to our intensive 
care unit (ICU) from April 2014 to March 2016 and diagnosed with AKI after ICU 
admission. We defined renal recovery day as the first day when increasing consecutive 
sCr values turn to decrease or decreasing consecutive KeGFR values turn to increase, 
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comparing each recovery length from AKI. We examined patient characteristics when the 
KeGFR model was superior in predicting recovery from AKI.
Results: During the study period, 972 patients were admitted to our ICU and 74 were 
finally studied. On admission, median age was 75.5 (IQR: 64.0-83.0) years, median baseline 
sCr was 0.81 (IQR: 0.63-1.04) mg/dL, and median baseline eGFR was 65.0 (IQR: 51.1-
77.6) mL/min/1.73 m2. AKI recovery length was statistically shorter in KeGFR model 
than sCr model (median [IQR], 1.0 [1.0-2.0] vs 1.0 [1.0-2.0], p<0.01). In 17 (23.0%) 
patients, using the KeGFR model predicted AKI recovery earlier than when using the 
sCr model. Among those whose AKI recovery was predicted better than when using the 
sCr model, the baseline sCr was likely higher (median [IQR], 0.80 [0.61-0.93] vs 0.97 
[0.79-1.42], p<0.01), baseline eGFR was likely to be lower (median [IQR], 68.0 [54.2-
80.9] vs 51.6 [35.8-64.1], p=0.01), and the proportion of patients with CKD was higher 
(n [%], 18 [31.6] vs 13 [76.5], p<0.01). Other factors such as age, sex, mean blood pressure, 
sequential organ failure assessment score, infusion volume, and body weight were not 
associated with predicting early AKI recovery using the KeGFR model.
Conclusions: KeGFR can predict recovery from AKI earlier, especially in patients with 
a higher baseline sCr, lower baseline eGFR, and CKD. Using the KeGFR model, we can 
confirm the efficacy of our AKI therapy early, which would enable prompt and accurate 
management of patients with CKD.
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Post-AKI eGFR and ACR and Future Risk of Kidney Disease Progression
Chi-yuan Hsu,1 Vernon M. Chinchilli,5 James S. Kaufman,7 Paul L. Kimmel,3 
Steven G. Coca,2 Mark M. Wurfel,6 Edward D. Siew.4 1University of California 
San Francisco, San Francisco, CA; 2Icahn School of Medicine at Mount Sinai, 
New York, NY; 3National Institute of Diabetes and Digestive Kidney Diseases 
(NIDDK), Bethesda, MD; 4Vanderbilt University School of Medicine, Nashville, 
TN; 5Penn State College of Medicine, Hershey, PA; 6University of Washington, 
Seattle, WA; 7VA New York Harbor Healthcare System, New York, NY.
Background: Some have advocated routine post-dischage nephrology follow-up for 
hospitalized patients who experienced AKI. We hypothesize that post-hospitalization eGFR 
and proteinuria levels risk stratify patients bettter than presence or severity of AKI.
Methods: We studied 1603 adult ASSESS-AKI study participants (PMID: 20799966). 
ASSESS-AKI prospectively enrolled hospitalized patients with and without AKI in a 
parallel, matched cohort. All participants had an outpatient baseline research study visit 3 
months post-discharge when eGFR, ACR and comorbitidies were ascertained. Cox models 
were used to examine predictors of kidney disease progression, defined as time to halving 
of eGFR or ESRD.
Results: Median age of the study population was 66 (IQR 56-74) yrs; eGFR 69 (51-90) 
ml/min/1.73m2, ACR 14 (7-56) mg/g. 38% were female, 13% black, 3% Hispanic, and 41% 
had diabetes mellitus (DM). 772 participants had AKI and 831 did not. Most cases of AKI 
were mild to moderate in severity (72% stage 1, 15% stage 2). 139 participants had kidney 
disease progression after a median follow-up of 4.8 yrs. Severity of AKI was associated 
with kidney disease progression in simple and multivariable Cox models (Table). However, 
taking into account AKI severity did not materially improve risk stratification beyond a 
Cox model which contained basic demographics, DM status, SBP, BMI, eGFR and ACR 
(C-statistic 0.83 vs. 0.82). A Cox model with post-AKI ACR alone had a C-statistic of 0.81. 
(Similar results were seen when AKI was captured as presence or absence rather than staged 
by severity.)
Conclusions: Post-hospitalization levels of eGFR and ACR should guide triaging for 
implementation or intensification of reno-protective measures more so than presence or 
severity of AKI during hospitaliation. Patients who have preserved eGFR and low ACR 
after hospitalization have good renal prognosis and may not need referral to nephrology, 
regardless of whether AKI occured or not.
Funding: NIDDK Support
*adjusted for center, demographics, SBP, BMI
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Recovery and Survival at Three Months Following Dialysis-Dependent 
AKI
Isabela V. Bertoni,1 Doreen Zhu,1 Michael P. Turner,2 Richard Haynes.2 1Oxford 
Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, 
United Kingdom; 2University of Oxford, Oxford, United Kingdom.
Background: Recovery from dialysis-dependent AKI is desirable because long-
term dialysis is associated with significant morbidity and mortality. We examined how 
previous CKD stage, aetiology of AKI and co-morbidities influenced survival and dialysis 
dependence at three months after initial presentation.
Methods: 245 consecutive cases of AKI requiring RRT were identified from a tertiary 
referral centre in the UK, treated between 2008 and 2018. Baseline demographic and 
comorbidity data were extracted and logistic regression was used to assess the association 
of these characteristics with the primary outcome of renal recovery and survival at three 
months, in uni- and multi-variate models.
Results: Median age was 66 years (IQR 56.5-75). The most common diagnosis 
was ATN (60%) followed by vasculitis (9%) and myeloma (8%). At three months after 
presentation, 187 (76%) individuals were dialysis independent and 30 (12%) had died. 
Unadjusted and adjusted odds ratios (OR) are shown in table one. (Odds >1 means factor 
was associated with worse outcome).
Conclusions: This single centre study demonstrated that prior CKD stage and a history 
of cancer and higher were of the strongest predictors of renal recovery and survival at three 
months. This could assist clinical decision making and information given to patients.
Table 1: Unadjusted and adjusted odds ratios (OR) for association of patient characteristics 
with dialysis dependence and/or mortality at three months post presentation
*not included in final model
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AKI Followed by Complete Recovery Is Associated with Higher Risk of 
Upper Gastrointestinal Bleed
Asad Shafiq,2 Zhiying You,3 Benjamin Griffin,2 John R. Holmen,4 Titte Srinivas,5 
Michel Chonchol,2 Sarah Faubel,6 Anna J. Jovanovich.1,2 1Denver VA, Denver, 
CO; 2University of Colorado, Aurora, CO; 3UC Denver, Aurora, CO; 
4Intermountain Healthcare, Murray, UT; 5Intermountain Medical Center, 
Murray, UT; 6University of Colorado Denver, Denver, CO.
Background: Recovery from dialysis dependent AKI is associated with future risk 
of upper gastrointestinal bleed (UGIB). To date, no studies have explored the association 
between complete recovery from non-dialysis dependent AKI and future risk of UGIB. We 
aim to determine the long-term risk of UGIB after a hospital admission complicated by non-
dialysis dependent AKI followed by complete recovery of kidney function in a propensity 
score-matched cohort of cases and controls.
Methods: We identified 1140 AKI cases (AKI Network definition) with complete 
kidney function recovery at the time of discharge (serum creatinine <1.10 times the pre-
admit baseline value) during hospital admission between January 1, 1999 and December 
31, 2009 from an integrated health care delivery system. We matched 1140 controls (no 
AKI during index admit) based on a propensity score including: age, sex, race, prior 
inpatient visits, all components of the Charlson Comorbidity index, baseline creatinine, and 
admission season. The primary outcome was time to UGIB, defined by ICD-9 codes. Cox 
proportional hazards models were adjusted for prior UGIB, liver disease, and peptic ulcer 
disease (PUD) and censored for death.
Results: Baseline characteristics among the cases and controls were similar: age 62±17 
years, 46% female, 92% white, baseline creatinine 0.9 ± 0.2 mg/dL. During a median post-
discharge follow-up of 13 months, 646 (57%) cases and 470 (41%) controls had an UGIB. 
The risk of UGIB was 1.6 times higher among patients with AKI followed by complete 
recovery compared to controls (Hazard Ratio 1.65 [95% CI, 1.46 – 1.86]; p <0.0001). After 
adjusting the model for prior UGIB, liver disease, and PUD, the risk of UGIB was still 
higher among the patients with AKI followed by complete recovery compared to control 
group (Hazard Ratio 1.50 [95% CI, 1.32 – 1.69]; p <0.0001).
Conclusions: In this cohort, non-dialysis dependent AKI during a hospital admission, 
despite complete recovery of kidney function, was associated with future UGIB compared 
to patients without AKI. Future studies are needed to further investigate this relationship.
Funding: Veterans Affairs Support
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AKI Followed by Complete Recovery Is Associated with Greater Risk of 
Subsequent Venous Thromboembolism
Benjamin Griffin,2 Neil R. Shah,2 Zhiying You,3 John R. Holmen,4 Titte Srinivas,5 
Michel Chonchol,2 Sarah Faubel,6 Anna J. Jovanovich.1,2 1Denver VA, Denver, 
CO; 2University of Colorado, Aurora, CO; 3UC Denver, Aurora, CO; 
4Intermountain Healthcare, Murray, UT; 5Intermountain Medical Center, 
Murray, UT; 6University of Colorado Denver, Denver, CO.
Background: Acute kidney injury (AKI) is associated with long-term morbidity 
including chronic kidney disease and heart disease. Recent data suggest that AKI is 
associated with increased long-term event rates such as sepsis, cancer, and venous 
thromboembolism (VTE). A prior study included patients with dialysis-requiring AKI with 
recovery but the degree of kidney function recovery was unclear. We aim to determine the 
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risk of VTE following a hospital admission complicated by AKI with complete recovery in 
a propensity score-matched cohort of cases and controls.
Methods: We identified 1139 AKI cases (AKI Network definition) with complete 
kidney function recovery by the time of discharge, defined as serum creatinine <1.10 
times the pre-admit baseline value, during a hospitalization between January 1, 1999 and 
December 31, 2009 from an integrated health care delivery system. We matched 1139 
controls (no AKI during index admit) based on a propensity score including age, sex, 
race, number of prior inpatient visits, baseline creatinine, season of admission, and all co-
morbidities in the Charlson Comorbidity index. The primary outcome was time to VTE. 
Cox proportional hazards models were adjusted for history of prior VTE and cancer and 
censored for death.
Results: Baseline characteristics among the cases and controls were similar: age 
62 ± 17 years, 46% female, 92% white, serum creatinine 0.9 ± 0.2 mg/dL. During a median 
[IQR] post-discharge follow-up of 65 [9-89] months, 246 cases (22%) and 73 controls (6%) 
developed new VTE. In the unadjusted Cox model AKI with complete recovery was with 
a nearly four-fold increase in hazard ratio for subsequent VTE (HR 3.99 [95% CI, 3.06 – 
5.18]; p <0.0001). This association did not change after adjusting for prior VTE and cancer 
diagnosis (HR 3.82 [95% CI, 2.94 – 4.97]; p <0.0001).
Conclusions: AKI with complete recovery is associated with increased risk of VTE. 
These data further support the idea that AKI is associated with long-term events dysfunction 
independent of decreased kidney function. Future research is needed to determine the 
mechanism of long-term changes following AKI.
Funding: Veterans Affairs Support
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The Risk of Major Adverse Kidney Events After AKI: A Systematic 
Review and Meta-Analysis
Emily J. See,1 Kushani C. Jayasinghe,2 David W. Johnson,1 Kevan Polkinghorne,3 
Nigel D. Toussaint.4 1Princess Alexandra Hospital, Greenslopes, QLD, 
Australia; 2Monash Health, Clayton, NSW, Australia; 3Monash Medical Centre 
and Monash University, Melbourne, VIC, Australia; 4The Royal Melbourne 
Hospital, Parkville, VIC, Australia.
Background: Acute kidney injury (AKI) is a common consequence of acute illness and 
is associated with high morbidity and mortality. Robust estimates of the long-term outcomes 
of AKI, using consensus definitions of exposure, are needed to inform clinical practice and 
guide optimal allocation of healthcare resources.
Methods: A systematic search was performed through EMBASE, MEDLINE, and 
grey literature sources to identify cohort studies reporting an association between AKI 
and chronic kidney disease (CKD), end-stage kidney disease (ESKD) or death. All studies 
published between 2004 and 2018 involving hospitalised adults were eligible if they defined 
AKI according to consensus definitions (RIFLE, AKIN, or KDIGO), included a non-AKI 
control group, and followed patients for at least 1 year. Risk of bias was assessed using 
the Newcastle-Ottawa Scale. Random effects meta-analysis was used to combine adjusted 
hazard ratios between studies. Subgroup, sensitivity and meta-regression analyses were 
performed to investigate potential sources of heterogeneity.
Results: The systematic search retrieved 6369 citations, of which 81 studies comprising 
more than 2 million participants were eligible for inclusion. One-third of studies were in 
cardiovascular surgery patients and one-third were performed in Europe. Reporting of 
methods was incomplete in many studies. The most common sources of bias were poor 
representativeness of patient cohorts, and insufficient duration and completeness of follow 
up. Funnel plot asymmetry reflected a lack of small studies with negative effects. AKI was 
associated with a significantly increased risk of death across all subgroups: angiography 
(HR 3.07, 95%CI 2.12-4.46), cardiovascular surgery (HR 1.75, 95%CI 1.55-1.98), intensive 
care (HR 1.47, 95%CI 1.32-1.65), and hospital (HR 1.41, 95%CI 1.26-1.56). The risk of 
death increased from stage 1 (HR 1.35, 95%CI 1.27-1.44) to stage 3 (HR 2.76, 95%CI 2.28-
3.35). AKI was associated with increased risks of CKD (HR 2.86, 95%CI 2.09-3.91) and 
ESKD (HR 4.81, 95%CI 3.04-7.62). Heterogeneity between studies was high.
Conclusions: AKI was associated with inferior long-term survival and an increased 
risk of adverse renal outcomes. The risk of a poort outcome increased with greater AKI 
severity. Patients undergoing angiography and cardiovascular surgery were at greatest risk.
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Contrast-Induced AKI and Adverse Clinical Outcomes Risk in Acute 
Coronary Syndrome Patients Undergoing Percutaneous Coronary 
Intervention: A Meta-Analysis
Yi Yang,1 Shuwang Ge,2 Gang Xu.3 1Tongji hospital affiliated to Tongji medical 
college, Huazhong University of Science and Technology, Wuhan, Hubei, China, 
Wuhan, China; 2Tongji Hospital, Tongji Medical College, Huazhong University 
of Science and Technology, Wuhan, China; 3Tongji hospital affiliated to Tongji 
medical college, Huazhong University of Science and Technology, Wuhan, 
China.
Background: Recent studies have shown associations between contrast-induced acute 
kidney injury (CI-AKI), in patients undergoing percutaneous coronary intervention (PCI) 
for acute coronary syndrome (ACS), and increased risk of adverse clinical outcomes in ACS 
patients undergoing PCI; however, the estimates are inconsistent and vary widely.
Methods: EMBASE, PubMed, Web of ScienceTM and Cochrane Library databases were 
systematically searched from inception to December 16, 2016 for cohort studies assessing 
the association between CI-AKI and any adverse clinical outcomes in ACS patients treated 
with PCI. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CI) of 
these outcomes. Heterogeneity was explored by subgroup analyses.
Results: We identified 1857 articles in electronic search, of which 23 (n=33080) were 
included. Our meta-analysis revealed that CI-AKI significantly increased the risk of all-
cause mortality (18 studies; n= 28367; RR=3.16, 95% CI 2.52–3.97; I2 =56.9%), short-
term all-cause mortality (9 studies; n=13895; RR=5.55, 95% CI 3.53–8.73; I2 =60.1%), 
major adverse cardiac event(7 studies; n=19841; RR=1.49, 95% CI: 1.34–1.65; I2=0), major 
adverse cardiovascular and cerebrovascular event (3 studies; n=2768; RR=1.86, 95% CI: 
1.42–2.43; I2=0) and stent restenosis (3 studies; n=130678; RR=1.50, 95% CI: 1.24–2.81; 
I2=0), respectively, in ACS patients undergoing PCI. Subgroup analyses showed the study 
design, sample size and prevalence of CI-AKI might have effect on pooled RR.
Conclusions: CI-AKI may be a prognostic marker of adverse outcomes in ACS patients 
undergoing PCI. More attention should be paid to diagnosis and management of CI-AKI.
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Post-Trans-Catheter Aortic Valve Implantation AKI Stage 3 Requiring 
Renal Replacement Therapy and Mortality in Patients with Severe Aortic 
Stenosis and High Surgical Risk
Juan C. Duque Ballesteros, Manuel Rivera-Maza, Gabriel Contreras. University 
of Miami, Miami, FL.
Background: Trans-catheter aortic valve implantation (TAVI) is an established 
treatment for severe symptomatic aortic stenosis (AS) in high surgical risk patients. 
However, post TAVI complications affect outcomes. Acute kidney injury (AKI) stage 3 
requiring renal replacement therapy (RRT) after TAVI has been associated with high 
hospital mortality. Efforts to understand the factors that contribute to increase morbidity 
and mortality in patient undergoing TAVI are needed in order to decrease their morbidity 
and mortality.
Methods: The data of patients who underwent TAVI between 2012 and 2014 from the 
nationwide inpatient sample database was analyzed in this investigation. ICD-9-CM codes 
were used to identify hospital admissions for TAVI (procedure codes: 35.05 and 35.06) and 
new AKI stage 3 requiring RRT post-TAVI (diagnostic codes 584.5 to 584.9 plus procedure 
code 39.95). The primary outcome was AKI stage 3 requiring RRT post-TAVI. Stata/IC 
14.2 was used to identify predictors of the primary outcome using multivariable regression 
analysis.
Results: An estimated total of 41,050 patients underwent TAVI during the pre-specified 
study period. Patient mean age was 81.1 years, 47.7 were women and 81% were white. 685 
(1.7%) patients developed AKI stage 3 requiring RRT after TAVI. Hospital mortality was 
30.7% in this subgroup. Multivariable regression analysis identified trans-apical approach 
(OR [95%CI], 1.67 [1.13-2.46]), preexisting chronic kidney disease (CKD) (OR [95%CI], 
1.84[1.30-2.61]), non-elective TAVI (OR [95%CI], 2.24[1.58-3.18]), heart failure (OR [95% 
CI], 2.48 [1.58-3.90]], and procedural or post-procedural mechanical circulatory support 
(MCS) use (OR [95%CI], 3.39[1.77-6.50]) as predictors for AKI stage 3 requiring RRT.
Conclusions: Patients complicating with AKI stage 3 requiring RRT after TAVI have 
a high hospital mortality. Preexisting CKD, trans-apical approach, non-elective TAVI, 
development of heart failure and the need for MCS were significantly associated with AKI 
stage 3 after TAVI.
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AKI After Non-Cardiac Surgery as an Independent Predictor of Infection 
and Malignancy During Long-Term Follow-Up
Miho Tagawa,1 Masatoshi Nishimoto,1 Maiko Kokubu,4 Takayuki Hamano,5 
Masaru Matsui,2 Ken-ichi Samejima,3 Masahiro Eriguchi,1 Yasuhiro Akai,1 
Kazuhiko Tsuruya.1 1Nara Medical University, Kashihara, Japan; 2Nara 
Prefecture General Medical Center, Nara, Japan; 3First Department of Internal 
Medicine, Nara Medical University, KASHIHARA, Japan; 4nara medical 
university, NARA, Japan; 5Osaka University Graduate School of Medicine, 
Suita, Japan.
Background: Previous studies showed that acute kidney injury (AKI) was an 
independent predictor of all-cause mortality and cardiovascular events. However the 
associations between AKI and non-cardiac outcomes have not been studied.
Methods: This is a retrospective observational study. Inclusion criteria were adults 
who underwent non-cardiac surgery under general anesthesia from 2007 to 2011. 
Exclusion criteria were urologic and obstetric surgeries, subjects missing creatinine values 
perioperatively, or subjects on dialysis preoperatively. Exposure of interest was AKI within 
7 days of surgery by KDIGO criteria. Outcome variables were admission for infection and 
diagnosis with malignancy (including recurrence). When the outcome was malignancy, 
subjects who underwent palliative resection of malignancy were excluded. Statistical 
analyses were performed using Kaplan-Meier curve and Cox regression analyses.
Results: Among 3,939 subjects, there were 289 events of AKI (7.3%). During median 
follow-up of 4.0 years, there were 291 admissions for infection and 668 were diagnosed with 
malignancy. Event-free survival among subjects with AKI was significantly lower. After 
adjustments for potential confounders, AKI was significantly associated with admission 
for infection and the diagnosis of malignancy (HR 1.73 [1.21-2.47] and 1.50 [1.17-1.92], 
respectively). Subgroup analyses stratified by age, sex, or history of malignancy yielded 
similar results. Among subjects with AKI, 11.4 % did not recover renal function during 
index admission for the surgery. Analyses excluding subjects without recovery of renal 
function did not change the results.
Conclusions: AKI was an independent predictor of infection and malignancy during 
long-term follow up after non-cardiac surgery, irrespective of recovery of renal function. 
There is a possibility that AKI predisposes patients to long-term immunosuppressed state.
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AKI: Clinical, Outcomes, Trials - I
Renal Dysfunction and In-Hospital Mortality Among Critically Ill Patients 
with Stroke
Katsuhito Ihara,1 John Danziger,2,3 Murray Mittleman.1,2 1Harvard T.H. Chan 
School of Public Health, Boston, MA; 2Harvard Medical School, Boston, MA; 
3Nephrology, Beth Israel Deaconess Medical Center, Boston, MA.
Background: The interplay between baseline renal function and acute kidney injury 
(AKI) on in-hospital mortality among critically ill patients hospitalized for stroke is largely 
unknown.
Methods: We used the multicenter eICU Collaborative Research Database to identify 
4,736 adult non-dialysis patients admitted to ICU with acute stroke between 2013 and 
2015. Baseline renal function was defined as estimated glomerular filtration rate (eGFR) 
calculated by the MDRD equation based on the first serum creatinine within 24 hours 
of ICU admission. AKI was defined based on the Kidney Disease: Improving Global 
Outcomes guidelines. We used a multivariable logistic regression with a restricted cubic 
spline of eGFR and an interaction with AKI to estimate the probability of in-hospital 
mortality according to baseline eGFR among patients who did and did not develop AKI.
Results: The mean age of the patients was 68.6 ± 14.8 years, 48.6% were male, and 
80.8% were Caucasian. The mean eGFR on admission was 72.5 ± 30.7 ml/min/1.73m2 
with 18.0% (n = 852) presenting with an eGFR between 90 and 120 ml/min/1.73m2 
and 40.6% (n = 1,922) between 60 and 90 ml/min/1.73m2. Patients with lower eGFR 
were older, more likely to have diabetes, require intubation, and have lower Glasgow 
coma scales. There were 460 deaths (9.8%) during hospitalization. After adjusting for 
confounding, both reduced (eGFR <45, odds ratio (OR), 1.83; 95% confidence interval 
(CI), 1.20-2.79) and highly elevated eGFR (≥120, OR, 1.37; 95% CI, 0.69-2.74) 
were associated with increased mortality when comparing to eGFR between 75 and 
90 ml/min/1.73m2. The figure shows that AKI was associated with higher in-hospital 
mortality and the relationship between eGFR at baseline and mortality was significantly 
different among those with and without AKI.
Conclusions: Both eGFR on admission and AKI are strong predictors of in-hospital 
mortality and the impact of eGFR is stronger among patients who develop AKI.
FR-PO037 Poster Friday
AKI: Clinical, Outcomes, Trials - I
AKI in Patients with Acute Exacerbation of Chronic Obstructive 
Pulmonary Disease Necessitating Hospitalization
Dawei Chen, Xin Wan. Nanjing First Hospital, Nanjing, China.
Background: Acute kidney injury (AKI) on patients with acute exacerbations of 
chronic obstructive pulmonary disease (AECOPD) remained unknown, and little is known 
about the differences between community-acquired AKI (CA-AKI) and hospital-acquired 
AKI (HA-AKI) in patients with AECOPD. Thus, we compared prevalence, risk factors, and 
outcomes for these patients with CA-AKI and HA-AKI.
Methods: Between January 2014 and January 2017, data from adult inpatients with 
AECOPD were analyzed retrospectively. In all, 1768 patients were included.
Results: Prevalence of CA-AKI was 15.8% and that of HA-AKI was 5.5%, giving 
an overall AKI prevalence of 21.3%. Comparing with patients without AKI, patients 
with AKI were more likely to require mechanical ventilation (38.7% versus 19.1%; 
P < 0.001), non-invasive mechanical ventilation (20.4% versus 16.0%; P = 0.044), invasive 
mechanical ventilation (18.3% versus 3.1%; P < 0.001), and intensive care unit (ICU) 
admission (33.7% versus 12.9%; P < 0.001). Patients with AKI had a longer duration 
of ICU stay (9 days versus 8 days; P = 0.033), a longer hospitalization (13 days versus 
10 days; P < 0.001), and a higher inpatient mortality (18.0% versus 2.7%; P < 0.001). 
Patients with CA-AKI had a higher prevalence of chronic kidney disease (CKD) and 
lower prevalence of chronic cor pulmonale than patients with HA-AKI. Risk factors for 
developing HA-AKI and CA-AKI were similar: being elderly, requirement for mechanical 
ventilation and a history of coronary artery disease and CKD. Patients with HA-AKI were 
more likely to have stage-3 AKI and worse short-outcomes. In comparison with CA-AKI, 
patients with HA-AKI were more likely to require non-invasive mechanical ventilation 
(31.3% versus 16.8%; P = 0.003), and had a longer duration of mechanical ventilation 
(11 days versus 8 days; P = 0.020), longer hospitalization (14 days versus 12 days; 
P = 0.038), and higher inpatient mortality (32.0% versus 13.2%; P < 0.001). Those with 
HA-AKI had worse (multivariate-adjusted) inpatient survival than patients with CA-AKI 
(hazard ratio, 1.7 [95% CI, 1.03–2.81; P = 0.038] for the HA-AKI).
Conclusions: AKI was common in patients with AECOPD requiring hospitalization, 
and had a worse prognosis. CA-AKI was more common than HA-AKI but otherwise 
demonstrated similar demographics and risk factors. Nevertheless, patients with HA-AKI 
had worse short-term outcomes.
FR-PO038 Poster Friday
AKI: Clinical, Outcomes, Trials - I
In-Hospital Mortality of AKI in Those with and Without HIV at a Tertiary 
Hospital in South Africa: A 2-Year Retrospective Cohort Study
Nikash N. Ramsunder,3 Mogamat-Yazied Chothia.1,2 1Medicine, Tygerberg 
Academic Hospital, Cape Town, South Africa; 2Nephrology, Stellenbosch 
University, Cape Town, South Africa; 3University of Stellenbosch, Durban, 
South Africa.
Background: Acute kidney injury (AKI) in HIV patients in Sub-Saharan Africa is 
a common cause for hospitalisation and is associated with high morbidity and mortality. 
There is a paucity of comparative epidemiological data regarding the outcome of AKI 
in those with and without HIV from the African continent. The primary outcome was to 
determine the overall in-hospital mortality of AKI.
Methods: This was a single centre study of all consecutive adult patients with AKI 
referred to the renal unit at Tygerberg Hospital for the period from 1 January 2015 to 31 
December 2016. AKI was defined as a recent normal serum creatinine (< 3 months) and/or 
normal kidney sizes on ultrasound examination (> 100 mm length). Those with proteinuria 
> 3.0 g/day were excluded. Kaplan Meier curves and logistic regression were used to assess
survival and identify factors predicting mortality.
Results: We identified a total of 291 patients with AKI of which 116 (39.9%) were HIV 
positive. Overall, 91 (31%) patients died of which 40 (34.5%) were HIV positive and 51 
(29.1%) were HIV negative (P = 0.34). At hospital admission, more HIV positive patients 
had tuberculosis (81.5% vs. 18.5%, P < 0.01) and had higher admission serum creatinine 
(551.1 umol/L vs. 190 umol/L, P < 0.01). Of those that died, the HIV positive patients were 
younger (41 years vs. 52 years, P < 0.01), were predominantly Black (87.5% vs. 23.5%, P 
< 0.01) and were predominantly admitted to medical wards (92.5% vs. 41.2%, P < 0.01). 
There was no difference in mortality regardless of renal replacement therapy (P = 0.50). 
Logistic regression identified Mixed race (OR 2.47, P = 0.02), HIV (OR 2.69, P < 0.01) and 
surgical ward admission (OR 2.05, P = 0.03) as strong predictors for death.
Conclusions: Overall in-hospital mortality of AKI was high. HIV was associated with 
a greater risk of death that may be the result of late presentation of both the AKI as well 
as the HIV.
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AKI: Clinical, Outcomes, Trials - I
Incidence and Outcomes of Acute-on-CKD - The French CKD-REIN 
Cohort Study
Aghiles Hamroun,1 Luc Frimat,2 Maurice Laville,3 Marie Metzger,1 
Celine Lange,4 Christian Combe,5 Denis Fouque,3 Jarcy Zee,6 Ziad Massy,7 
Benedicte Stengel.1 1CESP U1018, INSERM, Villejuif, France; 2Nancy 
University Hospital, Vandoeuvre les Nancy, France; 3Université de Lyon, 
Pierre-Bénite, France; 4Biomedicine Agency, La Plaine Saint-Denis, France; 
5CHU de Bordeaux, Bordeaux, France; 6Arbor Research Collaborative for 
Health, Ann Arbor, MI; 7Ambroise Pare University Hospital and Inserm U1018 
Eq5, Boulogne Billancourt/ Paris cedex, France.
Background: Incidence and outcomes of de novo acute kidney injury (AKI) are well 
documented, but less is known about acute-on-chronic kidney disease (ACKD).
Methods: We estimated ACKD incidence rate over 1-year follow-up in 2375 patients 
with any type of CKD stages 3-4, but without past AKI at baseline. AKI events were defined 
and classified according to KDIGO 2012, and validated by an expert committee. Cause-
specific Cox regression models identified factors associated with full renal recovery, defined 
by <10% increase in post AKI serum creatinine as compared with baseline creatinine, 
during the year post-AKI. We estimated cumulative incidences for the competing risks 
of end-stage kidney disease (ESKD) and death after ACKD. The hazard ratios [HR, 95% 
confidence intervals] of these outcomes associated with ACKD during the first year of 
follow-up were estimated by cause-specific Cox regression models, adjusted for sex, age, 
eGFR, and albuminuria.
Results: Overall, 142 patients (mean age 70 years, 69% men, mean eGFR 29mL/
min/1.73m2, 50% with severely increased albuminuria -A3 range-) experienced a first AKI-
event (25% outpatient) at a rate of 6 per 100 person-years: 73% were staged 1, 12% staged 
2, and 13% staged 3. One hundred patients (70%) achieved full renal recovery, within 
a mean time of 4 months after AKI. Pre-renal AKI (HR=2.54 [1.42;4.54]), dehydration 
(HR=1.76 [1.00;3.17]) and drug-related AKI (HR= 2.04 [1.11;3,75]) were significantly 
associated with full renal recovery. The cumulative incidences of ESKD and death 
after ACKD reached 13.1% and 15.7% at 12 months, respectively (Figure). ACKD was 
significantly associated with increased ESKD risk (adjusted HR=2.13 [1.32; 3.46]) and 
mortality (adjusted HR=2.07 [1.11; 3.83]).
Conclusions: ACKD is common and, despite a high rate of full renal recovery, it is 
associated with very high risks of both ESKD and death.
Post-ACKD outcomes.
FR-PO040 Poster Friday
AKI: Clinical, Outcomes, Trials - I
Renal Outcomes of Laparoscopic versus Open Surgery in Patients with 
Rectal Cancer: A Propensity Score Analysis
Jin hyuk Paek,1 Ji Young Ryu,2 Hyung Eun Son,2 Ho Jun Chin,2 Sejoong Kim.2 
1Internal Medicine, Keimyung University School of Medicine, Daegu, Republic 
of Korea; 2Internal Medicine, Seoul National University Bundang Hospital, 
Seongnam, Republic of Korea.
Background: The laparoscopic approach in abdominal surgery is widely used and has 
many advantages over open surgery (OS). However, the renal outcomes of laparoscopic 
surgery (LS) are still not proven in rectal cancer. Thus, we compared the renal outcomes 
between LS and OS in patients with rectal cancer.
Methods: We conducted a retrospective cohort study of 1633 patients who underwent 
rectal cancer surgery between 2003 and 2017. Postoperative acute kidney injury (AKI) was 
determined according to the serum creatinine criteria of the Kidney Disease: Improving 
Global Outcomes classification. AKI stage 2 or 3 were classified as severe AKI and AKI 
recovery was defined as return of serum creatinine to < 1.2 times the baseline level.
Results: Among 1633 patients, 1072 patients (65.6%) underwent LS. The incidence 
of postoperative AKI in LS was significantly lower than in OS (9.3 vs. 17.3%, p < 0.001, 
respectively). After matching propensity scores (1:1), 395 patients were included in each 
group. LS group still demonstrated a significantly lower incidence of postoperative AKI 
than OS group (9.9 vs. 15.9%, p = 0.011, respectively). The operation time (p < 0.001), 
estimated blood loss (p < 0.001), incidence of transfusion (p < 0.001) in LS group were 
significantly lower than in OS group. However, there were no differences in incidence of 
severe AKI (p = 1.000), AKI recovery (p = 0.962) and in-hospital mortality (p = 0.249) 
between two groups. Cox proportional hazard models revealed that LS group had lower 
incidence of postoperative AKI than OS group (HR, 0.599; 95% CI, 0.402-0.893; 
p = 0.012). In subgroup analysis, LS had much lower incidence of postoperative AKI 
than OS in patients with American Society of Anesthesiologists (ASA) score ≤ 2 (HR, 
0.516; 95% CI, 0.314-0.850; p = 0.009) and in patients who did not receive neoadjuvant 
chemotherapy (HR, 0.519; 95% CI, 0.295-0.912; p = 0.023).
Conclusions: This study showed that LS may reduce postoperative AKI in patients 
with rectal cancer and that its beneficial effect may be associated with operation time or 
intraoperative bleeding events and be dominant in patients with low ASA score and no 
neoadjuvant chemotherapy.
FR-PO041 Poster Friday
AKI: Clinical, Outcomes, Trials - I
Postoperative Blood Transfusion Predicts AKI in Patients with Rectal 
Cancer
Ji Young Ryu,1 Jin hyuk Paek,2 Sejoong Kim,1,3 Ho Jun Chin,1,3 Ki Young Na.1,3 
1Seoul National University Bundang Hospital, Seongnam, Republic of Korea; 
2Keimyung University School of Medicine, Daegu, Republic of Korea; 
3Department of Internal Medicine, Seoul National University College of 
Medicine, Seoul, Republic of Korea.
Background: Preoperative anemia and perioperative transfusion are associated with 
postoperative acute kidney injury in cardiovascular surgery, but little is known about 
their relationship in patients with rectal cancer surgery. Thus, we investigated whether 
postoperative blood transfusion may predict postoperative acute kidney injury in patients 
with rectal cancer.
Methods: We collected 1328 patients who underwent rectal cancer surgery from a 
single-center prospective cohort between 2003 and 2017. Postoperative acute kidney injury 
(AKI) was determined according to the serum creatinine criteria of the Kidney Disease: 
Improving Global Outcomes classification.
Results: Among 1328 patients, 134 patients (10.1%) received blood transfusions 
and 1194 patients (89.9%) did not receive. American Society of Anesthesiologists 
(ASA) score (p < 0.001), preoperative hemoglobin (p < 0.001), albumin, operation time 
(p < 0.001), amount of intraoperative bleeding (p < 0.001) showed differences in the 
two groups. Overall AKI incidence was 12.6% and severe AKI incidence was 1.2%. The 
incidence of postoperative AKI in the transfused group was significantly higher than in 
no blood transfusions group (10.2% vs 2.3%, p < 0.001, respectively) and similar result 
was observed in severe AKI (1.1% vs 0.4%, p=0.007, respectively). Cox proportional 
hazard models revealed that the AKI incidence was different according to preoperative 
hemoglobin concentration (HR, 0.894; 95% 0.827-0.968; p=0.05) and transfusions (HR, 
2.692; 95% 1.822-3.976; p < 0.001). But, there was no difference in perioperative changes 
in hemoglobin. Two of category of preoperative hemoglobin concentrations (>12 and 10.1-
12.0) were associated with a risk of postoperative AKI, whether patients was received 
transfusions or not (OR, 3.676; 95% 1.703-7.933; p=0.01 and OR, 2.589; 95% 1.209-5.545; 
p=0.014, respectively).
Conclusions: This study showed that postoperative blood transfusions may increase 
postoperative AKI in patients with rectal cancer. It is also possible that close monitoring of 
blood transfusions after surgery may improve AKI outcomes in patients with rectal cancer.
FR-PO042 Poster Friday
AKI: Clinical, Outcomes, Trials - I
Association of Dietary Intakes with the Incidence of AKI During 
Chemoirradiation Using High-Dose Cisplatin in Patients with Head and 
Neck Cancer
Akihiko Kato,1 Soichiro Nagata,2 Tomoyuki Fujikura,2 Naro Ohashi,2 
Hideo Yasuda.2 1Blood Purification Unit, Hamamatsu University Hospital, 
Hamamatsu, Japan; 2Internal Medicine 1, Division of Nephrology, Hamamatsu 
University School of Medicine, Hamamatsu, Japan.
Background: Cisplatin (CDDP)-based chemotherapy and radiotherapy can impact 
on nutrition intake because of reduction of eating ability. However, it remains to be fully 
clarified whether changes of nutritional status is associated with the development of CDDP-
induced acute kidney injury (AKI). So, we aimed this study to clarify the nutritional impact 
on incident AKI in head and neck cancer patients with chemoradiotherapy.
Methods: We assessed nutritional parameters and dietary intakes just before and 
during the chemoradiotherapy including 66-70 Gy with CDDP 80 mg/m2 on Days 1, 22 
and 43 in 84 head and neck cancer patients (age: 61±10 years old, male/female=72/12). 
Nutritional intervention was conducted to reach the recommended intake of energy 
(30 kcal/kg/day) and protein (1.0-1.2 g/kg/day), considering with enteral, parenteral 
nutrition and oral intake. Adjustments were made during treatment, aiming to maintain 
stable or improving nutritional indicators.
Results: Thirty-three episodes of AKI developed in 30 patients (35.7%) during 
the 3 courses of CDDP administration (stage 1, N=28; stage 2; N=2, stage 3; n=3). 
Serum creatinine increased at the end of chemo-radiotherapy to a greater extent in AKI 
(0.79±0.19 to 1.16±0.38 mg/dL) than in non-AKI patients (0.73±0.18 to 0.87±0.51 mg/dL). 
No difference was found in basal energy (1,345±538 vs. 1,356±537 kcal/day) and protein 
intakes (53±21 vs. 53±22 g/day) between AKI and non-AKI patients. CDDP-based 
chemoradiotherapy decreased body weight (BW) by -5.6±6.4% during the therapy. A 
significantly greater decrease of BW was observed in AKI than in non-AKI patients 
(-7.5±5.9 vs. -4.6±6.4%, p<0.05). There was also a significantly lower intake of energy 
(909±392 vs. 1,166±421 kcal/day, p<0.05) and protein (37±0.7 vs. 46±17 g/day, p<0.05). 
A stepwise regression analysis revealed that energy and protein intakes and % decrease of 
BW at the end of treatment were significantly associated with the incident AKI (p<0.05).
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Conclusions: The findings suggest that poor dietary intake during the platinum-based 
chemoradiation was associated with acute kidney toxicity. A more aggressive dietary 
support may be required to mitigate the onset of CDDP-induced AKI in patients with head 
and neck cancer.
FR-PO043 Poster Friday
AKI: Clinical, Outcomes, Trials - I
Effects of Obesity on Mortality in Critically Ill Patients with AKI
Sophia L. Ambruso,1 Benjamin Griffin,2 Zhiying You,3 Jessica B. Kendrick,4 
Paul M. Palevsky,5 Anna J. Jovanovich,6 Sarah Faubel.1 1University of Colorado 
Denver, Denver, CO; 2University of Colorado, Aurora, CO; 3UC Denver, Aurora, 
CO; 4University of Colorado School of Medicine, Aurora, CO; 5University of 
Pittsburgh/VA Pittsburgh Healthcare System, Pittsburgh, PA; 6Denver VA / 
University of Colorado, Denver, CO.
Background: The prevalence of obesity is rising in the critically ill population, but 
little data exists on outcomes in critically ill obese patients with acute kidney injury (AKI) 
requiring renal replacement therapy (RRT). In this study, we assessed the impact of obesity 
on rates of mortality in patients with AKI initiated on RRT.
Methods: We conducted a secondary analysis of the Acute Renal Failure Trial Network 
(ATN) database, which compared less-intensive to more-intensive RRT dosing strategies 
in critically ill patients. Weights >128.5 kg, exceeding the max dose capabilities of the 
Prisma machine at the time, were excluded. Modalities used were CVVHDF and HD, often 
with cross-over during the admission. In the overweight patients who received CVVHDF, 
88% received a dose reduction. The overweight group was defined as ‘actual weight 30% 
greater than ideal body weight’. We categorized patients into an overweight group and a 
standard weight group (all other patients). A subgroup analysis looked separately at those 
who received CVVHDF at some point during the admission (CVVHDF group) and those 
who received no CVVHDF (HD only group). Our primary outcome was 60-day mortality. 
We used logistic regression to adjust for demographics, SOFA score and Charlson score.
Results: In the combined CVVHDF and HD cohort, the 60-day mortality rate was 45% 
(n=235, mean BMI 35.1) in the overweight group and 55% (n=633, mean BMI 25.7) in the 
standard weight group. Compared to the standard weight group, the overweight group had a 
45% improved odds of survival, which persisted after illness severity adjustments (OR 0.55 
[95% CI, 0.32-0.90]; p=0.016). Among patients receiving HD only, the overweight group 
had improved odds of survival (OR 0.42 [95% CI 0.21-0.84]; p=0.015). In contrast, there 
was no survival benefit in the overweight patients receiving CVVHDF (OR 0.83 [95% CI 
0.52-1.21]; p=0.3).
Conclusions: Overweight patients with AKI had improved survival compared to the 
standard weight group. However, the survival benefit was only observed in overweight 
patients who received HD only, not CVVHDF. This benefit seems to parallel the protective 
effect of obesity seen in outpatient HD populations. Loss of benefit in the CVVHDF group 
is likely multifactorial. More outcomes studies in overweight and obese patients with AKI 
in the ICU are needed.
FR-PO044 Poster Friday
AKI: Clinical, Outcomes, Trials - I
Cannabis Use and Its Association with Incidence of AKI in Advanced 
CKD Patients Transitioning to ESRD
Praveen Kumar Potukuchi,1 Keiichi Sumida,2 Miklos Z. Molnar,1 
Abduzhappar Gaipov,1 Frank Park,1 Cameron M. Kaplan,1 Hamid Moradi,4 
Fridtjof Thomas,1 Justin Gatwood,1 Elani Streja,3 Kamyar Kalantar-Zadeh,4 
Csaba P. Kovesdy.1 1University of Tennessee Health Science Center, Memphis, 
TN; 2Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan; 
3Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Orange, CA; 4University of California Irvine, School of Medicine, Orange, CA.
Background: Cannabinoid receptors are expressed in the kidneys and their stimulation 
may have both harmful and beneficial effects. Synthetic cannabinoid use is associated with 
acute kidney injury (AKI) in case reports, but the effects of cannabis use on the incidence of 
AKI in patients with advanced CKD is unknown.
Methods: We examined 2,416 US veterans who transitioned to dialysis during 2007-
2014 and had undergone urine toxicology tests up to one year prior to dialysis, and had 
serial serum creatinine levels measured within 7 days after the test. We compared patients 
whose toxicology tests were positive for cannabis alone (primary exposure group, PEG, 
N=76) with those whose tests were negative (negative control group, NCG, N=1,138). AKI 
was defined according to KDIGO creatinine–based criteria. We examined the association 
of cannabis use with AKI using logistic regression adjusted for sociodemographics, 
comorbidities, medications, and vital signs.
Results: The mean (SD) age of the cohort was 60.6 (9.3) years; 97% were male, 46.7 % 
were African American and 76.4% were diabetic. AKI occurred in 58.6% of the cohort. 
Cannabis use was not associated with the odds of AKI in crude or in multivariable adjusted 
models (multivariable adjusted odds ratios (and 95%CI) in PEG vs. NCG: 0.75 (0.45-1.24); 
Figure 1).
Conclusions: Cannabis use in advanced CKD patients is not associated with the 
incidence of AKI.
Funding: NIDDK Support, Veterans Affairs Support
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Role of Sweat and Core Body Temperature in AKI During Marathon
Sherry Mansour,1 Yaqi Jia,1 Wassim Obeid,2 Thomas Martin,4 Rachel W. Pata,4 
Karen M. Myrick,4 Lanxin Jiang,6 Heather Thiessen Philbrook,5 Lidiya Kukova,5 
Chirag R. Parikh.3 1Yale University, New Haven, CT; 2Yale, New Haven, CT; 
3Yale University and VAMC, New Haven, CT; 4Quinnipiac University, Hamden, 
CT; 5Yale University, New Haven, CT; 6Yale University, New Haven, CT.
Background: The strenuous physical activity of marathons is associated with AKI in 
runners. Given the increasing participation in marathons, it is important to understand the 
etiology behind runners’ AKI to allow for future preventative measures. We hypothesized 
that sodium loss from sweat along with a rise in core body temperature during the race will 
be associated with AKI via thermoregulatory vasodilation and shunting of blood away from 
kidneys to muscles and skin. To test this hypothesis we conducted a prospective study of 22 
runners participating in the 2017 Hartford Marathon.
Methods: Vital signs, blood and urine samples were collected 24 hours pre-marathon, 
and immediately post-marathon. We measured conventional and novel biomarkers. We also 
measured continuous core body temperature using Zephyr® technology and sweat volume 
and sodium using PharmChek® patches during the race. We performed linear regression 
analyses to determine the association between sweat sodium and core body temperature 
with kidney injury.
Results: Runners ranged from 22 to 63 years of age, had 2 to 25 years of running 
experience and 52% were males. Runners lost an estimated median range of 2.34 (0.50 to 
7.21) grams of sodium, 2.47 (0.36 to 6.81) liters of volume via sweat and had temperatures 
of 101.12 (96.44 to 105.8)°F during race. The change in weight ranged from 1.81 (0.18 to 
5.08) kg. 56% developed AKI based on creatinine definition and 83% had a positive urine 
microscopy for acute tubular injury. Runners with AKI and higher sweat sodium had higher 
increases in several injury, inflammatory and repair biomarkers (Figure). Sweat sodium 
and temperature were not associated with change in creatinine or urine microscopy during 
the race.
Conclusions: Runners have substantial rise in core body temperature and extensive 
weight loss mainly via sweat sodium and volume losses. The mechanisms associated with 
thermoregulatory vasodilation and associated reduced blood flow to the kidney may provide 
insights into the pathophysiology of runners’ AKI.
Funding: NIDDK Support
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AKI: Clinical, Outcomes, Trials - I
Phenotypes of Volume Status in AKI Patients and Their Association with 
Intradialytic Hypotension
Rogerio Passos,1,2 Etienne Macedo,3 Mauricio Teixeira,4 Fernanda O. Coelho,1 
Érica B. Melo,5 Juliana R. Caldas,6 Michel P. Ribeiro,7 Joao G. Ramos,1 Paulo 
benigno P. Batista.8 SAPIENS MI 1Hospital Sao Rafael, Salvadir, Brazil; 
2Hospita Portugues, Salvador, Brazil; 3University of California San Diego, San 
Diego, CA; 4USP, Salvador Bahia, Brazil; 5Hospital Português da Bahia, 
Salvador, Brazil; 6HSR, Salvador, Brazil; 7Hospital SÃo Rafael, Salvador, 
Brazil; 8Hospital São Rafael, Salvador, Brazil.
Background: Intradialytic hypotension (IDH) is a common complication during 
intermittent dialysis (IHD) in hospitalized patients. It is associated delay in organ failure and 
renal recovery, and a common reason for modality change and continuous renal replacement 
therapy (CRRT) initiation.. Knowledge of patient volume status could help tailor the 
ultrafiltration rate and prevent episodes of IDH This study aim to evaluate the association 
of volume status based on sonographic profiles before IHD and occurrence and severity of 
IDH. Intradialytic hypotension (IDH) is a common complication during intermittent dialysis 
(IHD) in hospitalized patients. It is associated delay in organ failure and renal recovery, and 
a common reason for modality change and continuous renal replacement therapy (CRRT) 
initiation.. Knowledge of patient volume status could help tailor the ultrafiltration rate and 
prevent episodes of IDH This study aim to evaluate the association of volume status based 
on sonographic profiles before IHD and occurrence and severity of IDH.
Methods: We conducted a prospective observational study including all consecutive 
AKI patients requiring IHD in the intensive care unit. Bedside sonography to evaluate 
inferior Vena Cava Colapsability (cIVC) measurement and B lines were assessed by two 
different trained attending physicians. Volume status profile was classified into 4 groups: 
(1) B Lines (+) cIVC (-); (2) B lines (+), cIVC (+); (3) B lines (-) cIVC (-); (4) B lines (-)
/ iICV (+)
Results: Of 248 patients 42% were classified as G1; 22% G2, 20% of group (3) and 
16% of group (4). (55%) had at least one episode of hypotension during therapy, with 
different frequency among the groups (p < 0.001). Hypotension was more frequent in group 
(4) (85%), p < 0.001 versus others, and less frequent in group (1) (22%, p <0.001 versus
others). In the multivariate adjusted analysis, the risk of IDH remained different among
the groups (p< 0.001) and group (4) exhibited the highest hazard ratio (HR = 6.58. 95%
CI 3.22- 8.24).
Conclusions: Bedside sonography assessing B lines determination and cIVC can be 
used to define volume status profile in critically ill patients and risk of hypotension during 
IHD. Further studies are needed to design adequate targeted treatments
FR-PO047 Poster Friday
AKI: Clinical, Outcomes, Trials - I
Hyperchloremia Is Associated with AKI in Pediatric Patients with Septic 
Shock
Erin K. Stenson,1 Natalie Z. Cvijanovich,2 Neal J. Thomas,3 Michael T. Bigham,4 
Julie C. Fitzgerald,5 Michael W. Quasney,6 Mark W. Hall,8 Rainer Gedeit,9 
Robert J. Freishtat,10 Jeffrey E. Nowak,11 Riad Lutfi,12 Shira J. Gertz,13 
Jocelyn R. Grunwell,14 Hector R. Wong,15 Parag N. Jain.7 1Cincinnati Children’s 
Hospital Medical Center, Cincinnati, OH; 2UCSF Benioff Childrens Hospital, 
Oakland, CA; 3Penn State, Hershey, PA; 4Akron Children’s Hospital, Akron, OH; 
5Children’s Hospital of Philadelphia, Philadelphia, PA; 6University of Michigan, 
Ann Arbor, MI; 7Texas Children’s Hospital, Houston, TX; 8Nationwide Children’s 
Hospital, Columbus, OH; 9Medical College of Wisconsin, Milwaukee, WI; 
10Children’s National Health System, Washington, DC; 11Children’s Respiratory 
and Critical Care Services, P.A., Minneapolis, MN; 12Riley Hospital for 
Children, Indianapolis, IN; 13Saint Barnabas Medical Center, Livingston, NJ; 
14Emory University/Children?s Healthcare of Atlanta, Atlanta, GA; 15Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH.
Background: Hyperchloremia is associated with increased mortality in pediatric septic 
shock patients, and associated with increased rate of acute kidney injury (AKI) in adults. It 
is unknown whether hyperchloremia is associated with AKI in pediatric patients.
Methods: We tested the hypothesis that hyperchloremia is associated with increased 
rates of severe AKI in pediatric patients with septic shock. We performed a retrospective 
analysis of a pediatric septic shock database that included 619 children with septic shock 
from 29 PICUs in the U.S. We considered the minimum, maximum, and mean chloride 
values as separate hyperchloremia variables within the first 7 days of PICU admission. 
We considered hyperchloremia as a dichotomized variable defined a priori as a serum 
concentration ≥110mmol/L. We used multivariable logistic regression to determine the 
association between these hyperchloremia variables and outcomes, after adjusting for 
illness severity and age. Our primary outcome variable was day 3 AKI, defined as KDIGO 
stage 2 or 3.
Results: There were 125 subjects with AKI and 494 subjects with no AKI. Subjects 
with AKI were younger (1.7 years; IQR 0.7-5.4 v. 3.5 years; IQR 1.3-7.1; p <0.001) and had 
higher PRISM-III scores (15; IQR 9-24 v. 11; IQR 7-16; p <0.001). There were 42 subjects 
with a minimum chloride ≥110mmol/L, 117 subjects with a mean chloride ≥110mmol/L, 
and 359 subjects with a maximum chloride ≥110mmol/L. A minimum chloride ≥110mmol/L 
was associated with increased odds of AKI (odds ratio, 2.4; 95% CI, 1.2-4.9; p = 0.014). 
A mean chloride ≥110mmol/L was associated with increased odds of AKI (odds ratio, 1.8; 
95% CI, 1.1-2.9; p = 0.014).
Conclusions: Hyperchloremia is independently associated with severe AKI in pediatric 
patients with septic shock. Further evaluation of the optimal fluid to be used in resuscitation 
of these patients is warranted.
Funding: Other NIH Support - National Institutes of Health Grants R35GM126943 
and R01GM108025
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Chloride Abnormalities Are Independently Associated with Mortality in 
Critically Ill Children
Matthew Barhight,4 John T. Brinton,5 Danielle Soranno,4 Sarah Faubel,2 
Benjamin Griffin,3 Jens W. Goebel,4 Peter Mourani,6 Katja M. Gist.1 1University 
of Colorado, Children’s Hospital Colorado, Aurora, CO; 2University of Colorado 
Denver, Denver, CO; 3University of Colorado, Aurora, CO; 4Children’s Hospital 
Colorado, Aurora, CO; 5University of Colorado Denver School of Medicine, 
Aurora, CO; 6University of Colorado School of Medicine, Aurora, CO.
Background: Chloride disturbances in critically ill adults are associated with mortality. 
The impact of chloride disturbances on outcomes in critically ill children is unknown. The 
purpose of this study was to determine if there is an association between mortality and 1) 
admission chloride levels and 2) changes in the chloride level following initial resuscitation 
in critically ill children.
Methods: We retrospectively studied all PICU patients (01/2014 – 12/2015) at 
Children’s Hospital Colorado, excluding those 1) aged < 90 days or > 25 years, 2) without 
admission laboratory tests, 3) end stage renal disease, 4) a disorder of chloride transport and 
5) admitted for diabetic ketoacidosis. Patients were stratified based on admission chloride 
levels (hypochloremia, <100 mEq/L; normochloremia, 100-109 mEq/L and hyperchloremia 
≥110 mEq/L). Additionally, they were dichotomized based on the change in chloride (ΔCl) 
in the first 24 hours (< 5 mEq/L, ≥ 5 mEq/L). Multivariate logistic regression and analysis of 
covariance were performed to determine the impact of chloride derangements on mortality
and length of stay respectively.
Results: 2022 patients were included; overall mortality was 4% (n = 77) and day 2 
AKI occurred in 18% (n = 318). Hypochloremia, hyperchloremia, and ΔCl ≥ 5 mEq/L 
occurred in 7%, 21%, and 12% respectively. Hypochloremia and ΔCl ≥ 5 mEq/L were 
independently associated with a 4.57 (95% CI: 1.65 - 12.66) and a 3.17 (95% CI: 1.61 - 6.26) 
greater odds of mortality respectively, after adjusting for confounders. In ANACOVA 
models, hypochloremia and hyperchloremia were associated with an estimated increase in 
the expected length of hospital stay of 1.2 days (95% CI: 1.0 - 1.5; p=0.03), and 1.2 days 
(95% CI: 1.0 - 1.4 p=0.02) respectively. ΔCl ≥ 5 mEq/L was associated with an estimated 
increase in the expected time on mechanical ventilation of 1.3 days (95% CI: 1.0 - 1.4; 
p = 0.02).
Conclusions: Hypochloremia and ΔCl ≥ 5 mEq/L in the first 24 hours of admission are 
common and independent risk factors for mortality in critically ill children after adjusting 
for confounders. Further studies are needed to address the mechanism by which chloride 
disturbances increase mortality in critically ill children.
FR-PO049 Poster Friday
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Subclinical AKI Is Associated with Adverse Outcomes in Critically Ill 
Neonates and Children
Yanhong Li. children hospital of Soochow University, Suzhou, China.
Background: Acute kidney injury (AKI) is associated with adverse outcomes. 
Research in AKI has focused on identifying early biomarkers capable of detecting kidney 
injury before the rise in serum creatinine. However, whether AKI could be diagnosed in 
the absence of the classic signs of clinical AKI, and whether the condition of subclinical 
AKI, identified by using structural or functional biomarkers in the absence of oliguria 
or increased serum creatinine levels, is clinical significant, remained to be elucidated in 
critically ill children. The aims of the study were to investigate the association of urinary 
cystatin C (uCysC) level and mortality, and determine whether uCysC-positive subclinical 
AKI was associated with adverse outcomes in critically ill neonates and children.
Methods: In this prospective cohort study, uCysC levels were serially measured during 
the first week after intensive care unit (ICU) admission in a heterogeneous group of patients 
(n=510) presenting to a tertiary neonatal (n=239) and pediatric (n=271) ICU. The term 
of “uCysC(−)” or “uCysC(+)”, indicating the absence or presence of tubular injury, was 
defined by the optimal cut-off value of the peak uCysC to predict ICU mortality.
Results: The initial and peak uCysC levels had odds ratios of 1.19 and 1.26 (per 
10,000 ng/mg uCr increase), and achieved the area under-the-receiver-operating-
characteristic curve of 0.76 and 0.81, respectively, for predicting ICU mortality. At the 
optimal cut-off value of 1,260 ng/mg uCr, the peak uCysC displayed sensitivity of 79.2% 
and specificity of 72.3% for predicting mortality. Among all patients, 130 (25.5%) developed 
uCysC(+)/AKI(−) status during the first week after admission. The adjusted odds ratio for 
patients with uCysC(+)/AKI(−) status being associated with an increased risk of mortality 
was 9.34 (P<0.001), compared to those with uCysC(−)/AKI(−). Patients with uCysC(+)/
AKI(−) spent 2.8 times as long in ICU compared to those with uCysC(−)/AKI(−).
Conclusions: Both initial and peak uCysC levels are independently predictive of 
mortality in critically ill neonates and children. Subclinical AKI may occur without 
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detectable loss of kidney function, and uCysC-positive subclinical AKI was associated with 
worse clinical outcomes in this population.
FR-PO050 Poster Friday
AKI: Clinical, Outcomes, Trials - I
The Relationship Between Statin Use and 1-Year Mortality After Severe 
AKI
Chia-Lin Wu,1,2 Chih-cheng Hsu,3 Der-Cherng Tarng.4 1Division of Nephrology, 
Department of Medicine, Changhua Christian Hospital, Changhua, Taiwan; 
2Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; 
3Institute of Population Health Sciences, National Health Research Institutes, 
Miaoli County, Taiwan; 4Taipei Veteran’s General Hospital, Taipei, Taiwan.
Background: The potential survival benefits of statin use in patients with dialysis-
requiring acute kidney injury (AKI) are still not known. We examined the association 
between statin use and 1-year mortality in patients with dialysis-requiring AKI.
Methods: This nationwide population-based retrospective cohort study included 6091 
hospitalized patients with dialysis-requiring AKI (1271 statin users and 4820 statin non-
users) retrieved from the National Health Insurance Research Database of Taiwan between 
January 1, 2000, and December 31, 2012. All patients were followed up until December 
31, 2013. Primary outcome was 1-year mortality after dialysis-requiring AKI. All primary 
analyses were performed using the intention-to-treat approach.
Results: During the 1-year follow-up period, 492 of 1271 (38.7%) statin users and 
2365 of 4820 (49.1%) statin non-users died after dialysis-requiring AKI. Statin use was 
independently associated with lower risks of 1-year all-cause mortality (hazard ratio [HR], 
0.81; 95% confidence interval [CI], 0.73-0.91; p<0.001) and in-hospital all-cause mortality 
(HR, 0.82; 95% CI, 0.72-0.94; p=0.004). The survival benefit of statin treatment was dose-
dependent and consistent across subgroups based on sensitivity analyses.
Conclusions: Statin use was independently associated with reduced risks of 1-year and 
in-hospital mortality in patients with dialysis-requiring AKI. However, further clinical trials 
are warranted to confirm our results.
Incidence and risk of 1-year mortality in patients with dialysis-requiring AKI
Incident rate: 1000 person-years
Kaplan-Meier curves for the cumulative incidences of all-cause mortality in statin 
users and non-users. cDDD = cumulative defined daily dose.
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The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup 
of Participants in the ACCORD Trial
Neha Debnath,1 Kinsuk Chauhan,1 Girish N. Nadkarni,1 Amit X. Garg,2 
Chirag R. Parikh,3 Steven G. Coca.1 1Icahn School of Medicine at Mount Sinai, 
New York, NY; 2London Health Sciences Centre, London, ON, Canada; 3Yale 
University and VAMC, New Haven, CT.
Background: In ACCORD, 48% of those randomized to fenofibrate demonstrated a 
≥20% increase in the concentration of serum creatinine within 4 months, a finding consistent 
with other trials. The effect of fibrates on markers of kidney tubular injury is unknown.
Methods: We obtained stored urine samples from a subgroup of 571 ACCORD 
participants randomized to either placebo (n= 329) or fenofibrate (n=242) where all 
patients also received statins. Our outcome was 2-year changes in the concentration of 
two urine biomarkers of injury: kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), 
and 2 urine biomarkers of repair: YKL-40 and monocyte chemoattractant protein (MCP-1), 
along with the changes in eGFR and urine albumin to creatinine ratios (UACR) measured 
from random samples. We adjusted for clinical variables and randomization arm and 
compared the changes in the markers via analysis of covariance (ANCOVA).
Results: Baseline clinical characteristics and measures of eGFR (88 ml/min/1.73m2), 
UACR (12 mcg/mg), and all 4 biomarkers were similar in the 2 groups. At 24 months, 
eGFR was 14.2 ml/min/1.73m2 lower with fenofibrate vs. placebo and serum creatinine was 
0.18 mg/dl higher. In contrast, UACR and all 4 urine biomarkers of kidney injury or repair 
were similar or decreased from baseline in fenofibrate vs. placebo (Figure). In a stratified 
analysis, even participants with the highest quintile 24-month decrements in eGFR with 
fenofibrate (-30.4 to -73.5 ml/min/1.73 m2) still had lower or unchanged UACR and urine 
biomarkers.
Conclusions: These findings indicate the increase in the concentration serum creatinine 
with fibrates is not due to intrinsic damage to kidney tubule cells.
Funding: NIDDK Support
24-month change in eGFR, Serum Creatinine, UACR and Urinary Kidney Injury and 
Repair Biomarkers in ACCORD Participants Randomized to Fibrates vs. Placebo
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The LncRNA Profile in Control and Ischemically Injured Kidneys of Old 
Mice
Tamás Kaucsár, Peter Hamar. Semmelweis University, Budapest, Hungary.
Background: The expression profile of lncRNA is hardly known in the control and 
injured kidneys of old mice. We investigated the influence of aging on the lncRNA profile 
after renal ischemia-reperfusion (IR) injury in mice.
Methods: The left renal pedicle of adult (9.4±0.3 months, n=7) and old (28.5±1.2 
months, n=8) C57BL/6N mice was clamped for 20 min. The right kidney was left intact. 
Plasma urea and urine NGAL (uNGAL) were measured prior to and 7 days after reperfusion. 
On day 7 tubular injury was evaluated by histology (PAS, HE) and KIM1 mRNA (qPCR) 
expression. The extent of fibrosis (FN1) and senescence (p21) was analyzed with qPCR. 
Long non-coding RNA profile (90 lnc) was examined with qPCR array.
Results: Older mice had higher baseline uNGAL (old: 285.7±93.8 ng/mg Crea vs. 
adult: 78.0±9.1 ng/mg Crea, p<0.05) and milder kidney injury (p<0.05). KIM1 (8.3x; 
p<0.001), FN1 (2x; p=0.05) and p21 (3.8x; p<0.05) mRNA levels were higher in their non-
ischemic kidneys relative to the adult group. There was no significant difference in baseline 
plasma urea levels between the two groups (old: 75.9±10.2 mg/dl vs. adult: 57.6±5.3 mg/
dl). Following IR tubular injury increased in both groups (p<0.05) with KIM1 (adult: 202x, 
old: 19.5x, p<0.0001) and FN1 (adult: 8.5x, old: 3x, p< 0.001) mRNA compared to the 
contralateral control kidneys. uNGAL level was higher after IR compared to the baseline 
(old: 3817±1975 ng/mg Crea, p<0.0001; adult: 2833±1201 ng/mg Crea, p<0.001). p21 
mRNA increased only in the ischemic kidneys (4.5x, p<0.01), compared to the contralateral 
control. The plasma urea concentration increased only in the old group following 7 days of 
reperfusion (140.7±25.6 mg/dl, p<0.01). From the 81 measureable lncRNAs 8 increased 
and 1 decreased only by IR. Old age only influenced 1 lncRNA expression. Further 12 
lncRNA expression was influenced by both IR and old age.
Conclusions: Our results demonstrated significant tubular damage and decreased renal 
function in the kidneys of old mice, in accordance with the literature. We have also found 
that several lncRNAs were differentially expressed in old and adult mice in both the control 
and ischemic kidneys. New National Excellence Program (Human Resources Department)
Funding: Government Support - Non-U.S.
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miR-146a Targeted to Splenic Macrophages Prevents Sepsis-Induced 
Multiple Organ Injury Including AKI
Yoshio Funahashi, Noritoshi Kato, Naotake Tsuboi, Shoichi Maruyama. 
Department of Nephrology Nagoya University Graduate School of Medicine, 
Nagoya, Japan.
Background: To date, additional pathophysiology and new drug concept need to be 
provided in patients with multiple organ injury due to sepsis. microRNAs (miRNAs) have 
garnered attention as potent oligonucleotide therapeutics. The aim of the present study is 
to investigate the pathophysiological role of exogenous miR-146a in sepsis-induced acute 
kidney injury (AKI).
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Methods: In vitro study, RAW264.7 cells were transfected with miR-16, miR-126, 
miR-146a, miR-200b, or a negative control, then treated with 1 mg/ml lipopolysaccharide 
(LPS) for 6 hours. In vivo study, young C57BL/6 mice were intravenously injected a mixture 
of miR-146a-expressing plasmid and polyethyleneimine (PEI). 7 days after transfection, 
sepsis was induced via cecal ligation and puncture (CLP).
Results: Among tested miRNA, miR-146a showed the best suppressive efficacy, 
whereby transcriptional activity of NF-κB was decreased by targeting IRAK-1 and TRAF6 
in RAW264.7 cells. Treatment with the miR-146a-expressing plasmid/PEI complex 
significantly decreased the level of serum inflammatory cytokines, attenuated organ injury 
including kidney injury, and led to increased survival in CLP-induced polymicrobial sepsis. 
miR-146a-expressing plasmid was abundantly distributed in splenic macrophages, but not 
in kidney cells. The miR-146a-treated CLP mice also showed a significant decrease in NF-
κB activation and apoptosis in splenocytes. Splenectomy diminished the anti-inflammatory 
effects of miR-146a.
Conclusions: The induction of miR-146a in splenic macrophages prevents excessive 
inflammation and sepsis-induced multiple organ injury, including AKI. This study provides 
a pathophysiological breakthrough in the relationship between splenic macrophages and 
sepsis-induced AKI.
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MicroRNA-219c Dependent Mincle Is Critical for Maintaining  
Proinflammatory Phenotype of Macrophage in Renal Inflammation
Linli Lv,1 Zuolin Li,3 Ye Feng,2 Xin Zhong.4 1Southeast University, Institute of 
Nephrology, Nanjing, China; 2Zhongda hospital, Southeast university, Nanjing, 
China; 3Zhong Da Hospital, Southeast University, Nanjing, China; 4Institute of 
Nephrology, Zhongda Hospitial, Southeast University School of Medicine, 
Nanjing, China;, Nanjing, China.
Background: Macrophages are a key inflammatory cell that plays a critical role 
in renal inflammation and fibrosis. Our previous study demonstrated that the pattern 
recognition receptor, Mincle is essential for maintaining inflammatory phenotypes of M1 
macrophages in acute renal inflammation. However, the mechanism through which Mincle 
expression was regulated and its relation with different macrophage phenotypes remains 
largely unknown.
Methods: Unilateral urethral obstruction model of renal injury was established at day 
1, 3, 7 to observe the dynamic change of Mincle expression and its relation with macrophage 
phenotype. For in vitro study, LPS and IL4 was used to induce M1, M2 polarization to 
explore Mincle expression in the process of phenotype switching. The regulatory effects 
of microRNA-219c in Mincle expression and kidney inflammation were also determined.
Results: During progression of renal inflammation in UUO model, Mincle+ 
macrophage significantly increased at day 1 while it decreased rapidly with theincreasing 
M2 macrophage infiltration. During macrophage phenotype switch, Mincle mRNA and 
protein was enhanced in LPS-primed M1 macrophage, while its expression decreased in 
M2 macrophage. Interestingly, Mincle overexpression induced proinflammatory phenotype 
polarization and also reversed the phenotype switching to M2 macrophage from either M0 
or M1 macrophages. Bioinformatic analysis showed that Mincle was a potential target of 
microRNA-219c. Interestingly, microRNA-219c was reduced in injured kidney of UUO 
model when Minlce was upregulated at day1. Mincle protein was reduced in RAW264.7 
with microRNA-219c mimic treatment. And the luciferase reporter gene assay confirmed 
that microRNA-219c was a novel regulator of Mincle expression. To explore the effect of 
microRNA-219c in renal inflammation, microRNA-219c was overexpressed in mice via 
lentivirus injection. Impressively, Mincle and inflammatory cytokines CCL2, IL6 mRNA 
was remarkably reduced in UUO kidney compared to empty vector group.
Conclusions: MicroRNA-219c was a novel regulator of Mincle which is critical for 
maintaining proinflammatory macrophage phenotype and contribute to renal inflammation. 
Targeting microRNA-219c-Mincle may represent as a novel therapy for macrophage-
dependent kidney injury.
Funding: Government Support - Non-U.S.
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MicroRNA-132 Mediates Tubular Cell Sensitivity and Increases Kidney 
Injury in Mice
Cory V. Gerlach,1,2 Jia-Ren Lin,1 Robert A. Everley,1 Joseph V. Bonventre,2,1 
Vishal S. Vaidya.2,1 1Harvard Program in Therapeutic Science, Harvard Medical 
School, Boston, MA; 2Renal Division, Brigham and Women’s Hospital, Boston, MA.
Background: MicroRNAs regulate multiple signaling pathways that can affect disease 
progression. We previously reported that miR-132 was upregulated in kidney tubular 
epithelial cells following injury with nephrotoxic chemicals and was positively correlated 
with kidney injury in mice and humans.
Methods: MiR-132 knockout (KO) mice and wild-type (WT) littermate controls were 
subjected to folic acid (FA) nephropathy (250 mg/kg, ip). Kidney structure and function 
was assessed by widely established methods. Cyclic immunofluorescence was conducted 
to evaluate 21 proteins representing inflammation, proliferation and DNA damage on the 
same fixed kidney tissue. For mechanistic investigations, tandem mass tag proteomics was 
conducted and targeted pathways were probed using Human Proximal Tubular Epithelial 
Cells (HPTECs) transfected with miR-132 mimics or inhibitors.
Results: In miR-132 KO mice, FA injections resulted in 37% less tubular injury and 
64% lower levels of blood urea nitrogen after 2 days compared to WT mice (p<0.05). At 
day 2, tubular cell proliferation, DNA damage and inflammation were also decreased in 
miR-132 KO mice relative to WT. Interestingly, miR-132 KO and WT mice had similar 
kidney damage at day 1, demonstrating that miR-132 KO mice recovered more quickly 
despite less tubular cell proliferation. On the other hand, proteomics revealed that miR-
132 overexpression in HPTECs upregulated proteins involved in promoting cell cycle 
progression. Out of the 9 proteins predicted to be miR-132 targets, RASA1 (inhibitor of 
Ras) and SOD2 (detoxifier of mitochondrial reactive oxygen species) were confirmed. In 
HPTECs, overexpression of miR-132 increased cell count by 69% while miR-132 inhibition 
decreased cell count by 33% (p<0.05). Testing the functional importance of these data in an 
injury setting, when HPTECs overexpressing miR-132 were treated with cisplatin there was 
~2.5-fold increase in cell death (p<0.05).
Conclusions: Upregulation of miR-132 following kidney injury increases the 
sensitivity of the kidney to further damage. Therefore, inhibition of miR-132 may offer a 
therapeutic benefit for acute kidney injury and limit the extent of kidney damage.
Funding: Other NIH Support - Outstanding New Environmental Sciences 524 (ONES) 
award from NIH/NIEHS (ES017543)
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Effect of NLRP3 on Rhabdomyolysis-Induced AKI Model
Suk jong Song,1 Sangho Lee,1 Ju young Moon,3 Yang gyun Kim,1 
Kyung-hwan Jeong,4 Dong-Jin Kim,2 Su-Mi Kim,2 Seo Jung-Woo,2 
Su Woong Jung,1 Yu ho Lee.5 1Division of Nephrology Department of internal 
medicine Kyung Hee University College of Medicine, Seoul, Republic of Korea; 
2Kyung Hee University, Seoul, Republic of Korea; 3Kyung Hee University, 
College of Medicine, Seoul, Republic of Korea; 4Kyung Hee University, School 
of Medicine, Seoul, Republic of Korea; 5Kyung Hee University Hospital at 
Gangdong, Seoul, Korea, Seoul, Republic of Korea.
Background: Recent studies suggested NOD-like receptor, pyrin domain containing-3 
(NLRP3) inflammasome contribute renal injury in rhabdomyolysis. However, a role of the 
inflammasome-independent tubular epithelial NLRP3 in rhabdomyolysis-induced acute 
kidney injury (RAKI) has not clarified yet. We investigated the role of both inflammasome-
independent tubular NLRP3 and inflammasome-dependent NLRP3 in RAKI and evaluated 
the possibility of NLRP3 as the treatment target of RAKI.
Methods: HK-2 cells and THP-1 cells were treated with myoglobin to mimic the 
rhabdomyolysis environment in vitro. A glycerol-induced rhabdomyolysis animal model 
was used to generate RAKI model in NLRP3 knock-out (KO) and wild-type (WT) mice.
Results: Apoptosis increased by myoglobin-induced injury in HK-2 cells; however, 
the number of apoptotic cells significantly decreased in siNLRP3 treated HK-2 cells. The 
increase of inflammatory cytokines, IL-1β and IL-18, by myoglobin-induced injury in THP-
1 cells attenuated by siNLRP3 treatment. The RAKI NLRP3 KO mice showed a marked 
decrease in serum creatine levels, renal KIM-1, and histologic renal injury scores than in 
RAKI WT mice. Apoptotic markers such as PARP and cleaved caspase-3 in the kidney 
decreased in NLRP3 KO mice compared with WT. Also, inflammatory cytokines such as 
IL-6, TNF-α, and IL-1β decreased in RAKI NLRP3 KO.
Conclusions: In conclusion, the deficiency of NLRP3 protected kidneys from RAKI 
by both inflammasome-independent and -dependent ways. The depletion of NLRP3 directly 
reduced the renal tubular cell apoptosis and blocked the NLRP3 inflammasome activation 
of the macrophage after RAKI. Our results suggest that NLRP3 could play the essential role 
in RAKI and be a candidate as a treatment target.
Funding: Government Support - Non-U.S.
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A New Mouse Model for Septic AKI with Vasopressor Support
Brianna C. Halasa,1 Jonathan Street,1 Peter S. Yuen,2 Robert A. Star.2 1National 
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 
2National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), 
Bethesda, MD.
Background: Sepsis, a common cause of acute kidney injury (AKI), is a dysregulated 
host response to infection that leads to multiple organ dysfunction. Currently, there is no 
specific therapy for sepsis/AKI. Patients with sepsis-induced AKI are treated with supportive 
care including fluids and vasopressors to manage hypotension. While blood pressure 
maintenance in sepsis patients is routine, blood pressure measurement and management is 
notoriously absent in small animal models. We established a mouse model of septic-AKI 
with conscious hemodynamic monitoring and vasopressor treatment. We hypothesize that 
stabilizing blood pressure with norepinephrine (NE) will partially mitigate the severity of 
sepsis-AKI, perhaps changing the responsiveness to specific treatments.
Methods: In CD-1 mice (n=22), we inserted a telemetry device into the left carotid 
artery to monitor blood pressure, and catheterized the right jugular vein for IV drug delivery. 
After recovery, sepsis-AKI was induced by cecal ligation and puncture (CLP). NE was 
administered IV via an osmotic minipump. Hemodynamics were recorded by telemetry 
from 24 hr before to 24 hr post-CLP. Glomerular filtration rate (GFR) was measured by loss 
of transcutaneous fluorescence of IV injected FITC-sinistrin.
Results: Surgical anesthesia caused transient 1 hr hypotension and bradycardia. 
Despite variability, septic NE-treated mice fell into 2 groups. In the first group (n=8), the 
effect of NE was short. The blood pressure increased for ~4 hr then dropped to septic-
shock levels (<65mmHg). In the second group (n=12), NE effect lasted longer. The blood 
pressure rose to normal (90-110 mmHg) and remained constant for ~20 hr. In 2 outliers, the 
blood pressure fluctuated over 24 hr. The heart rate was consistent in all groups; returning 
to normal (650-750 bpm), then decreasing 3-5 hr later. We measured GFR in mice that 
survived to 24 hr; 2 mice from the second group had a normal GFR of 742 and 871 uL/
min/100gBW.
Conclusions: We successfully delivered intravenous NE and monitored hemodynamics 
in septic mice. We found substantial mouse to mouse variability in blood pressure, making 
it crucial to monitor individual NE responses. NE had the expected hemodynamic response 
in blood pressure stability in over half of the mice.
Funding: NIDDK Support
FR-PO058 Poster Friday
AKI: Tubules, Metabolism, New Models
A Novel Contrast-Induced AKI Mouse Model Based on Low-Osmolar 
Contrast Medium
Jianxiao Shen, Zhaohui Ni. Renji Hospital, Shanghai, China.
Background: The contrast-induced acute kidney injury (CI-AKI) has been becoming 
the third common cause of hospital-acquired acute kidney injury. An ideal animal model is 
essential for understanding the pathophysiology of CI-AKI. This study provides a novel, 
efficient and reproducible CI-AKI model which was developed in mouse by administrating 
a low-osmolar contrast medium (LOCM).
Methods: First, we applied the frequently-used pretreatments (uninephrectomy and 
water deprivation), which combined with HOCM on rats could induce CI-AKI, on mice 
with LOCM. Secondly,we attempted to find a novel preatment suitable for mouse and 
LOCM by combining two classic pretreatments(uninephrectomy, water deprivation and 
furosemide administration). Finally, we evaluate the kidney damage of the novel model.
Results: This mouse model possessed a significant reduction in renal function, severe 
renal tissue damage, and increased renal tubular cells apoptosis, indicating that LOCM is a 
feasible inducer for CI-AKI mice model.
Conclusions: We found that uninephrectomy(UPHT) combined with 24h water 
deprivation and furosemide administration 20 min before LOCM (iohexol, 10 ml/kg) 
application is a feasible pretreatment to establish a novel CI-AKI mouse model.
Funding: Other NIH Support - National Natural Science Foundation of China
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Neonatal AKI in a Juvenile Rabbit Model Results in Reduced Nephron 
Number Assessed by MRI
Jennifer R. Charlton,1 Edwin Baldelomar,2 Sejin Nam,2 Kevin M. Bennett.3 
1University of Virginia, Charlottesville, VA; 2University of Hawaii at Manoa, 
Honolulu, HI; 3University of Hawai’i, Honolulu, HI.
Background: Acute kidney injury (AKI) affects 30% of preterm neonates. Preterm 
neonates develop AKI during nephrogenesis conferring a risk for chronic kidney disease. 
Current monitoring practices cannot detect microstructural changes in the kidney. Our 
objective was to assess if the renal microstructure, number (Nglom) and volume (Vglom) of 
the glomeruli, is affected by AKI during nephrogenesis using cationic ferritin enhanced 
MRI (CFE-MRI).
Methods: New Zealand rabbits were used as nephrogenesis occurs for 3 postnatal 
weeks. The AKI group received indomethacin and gentamicin at week #1 for four days. 
At six weeks, the AKI and control groups (5/grp) were injected with cationic ferritin, 
euthanized and kidneys were imaged (7T ClinScan GRE pulse sequence:TR:80/TE:20, 
thickness 0.17, FOV 29, 448*448 matrix, FA 25o). Nglom and Vglom were determined by 
threshold guiding with a watershed transformation.
Results: Body and kidney weights were significantly lower in the AKI group. The 
kidney/body weight and renal function measured by serum creatinine was not different 
between the groups. Nglom and Vglom were lower in the AKI group (Nglom: 86387 vs 178093, 
p=0.01; Vglom: 319044 vs. 425029 μm
3, p=0.01), Fig 1. AKI kidneys had a layer of glomeruli 
which were not labeled and undetectable by MRI. On histological assessment, the glomeruli 
in the undetectable region were shrunken, immature and lacked tubules (Fig 2).
Conclusions: Neonatal AKI from gentamicin and indomethacin causes permanent 
glomerular reduction without glomerular hypertrophy. Tools such as CFE-MRI that allow 
us to visualize and quantify renal microstructure to detect early CKD and evaluate the 
nephrotoxic potential of medications during nephrogenesis.
Funding: Private Foundation Support
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Experimental Aristolochic Acid Nephropathy: A Model to Study 
AKI-to-CKD Transition
Inès Jadot,1 Florian Juszczak,2,1 Olivia Botton,1 Joelle L. Nortier,3 Anne-
Emilie Decleves,2 Nathalie Caron.1 1University of Namur, Namur, Belgium; 
2Laboratory of Molecular Biology, University of Mons, Belgium, NIMY (MONS), 
Belgium; 3Hospital Erasme, Brussels, Belgium.
Background: Even though impaired kidney function is classified into two distinct 
categories, the acute (AKI) and the chronic (CKD) kidney disease, recent epidemiologic 
and mechanistic studies demonstrated that AKI and CKD are interconnected. Indeed, AKI is 
a risk factor for the development of CKD. In this regard, molecular and cellular mechanisms 
underlying the AKI-to-CKD transition are unclear, mainly due to a lack of appropriate 
experimental models. In the present study, we aim to highlight the benefit of using the 
experimental aristolochic acid (AA) nephropathy (AAN) model to further delineate the 
progression of CKD from an AKI episode.
Methods: C57BL/6J male mice were randomly subjected to daily ip injection of 
vehicle or AAI solution (3,5mg/kg) for 4 days. Mice were then euthanized at different time-
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points to determine key biological markers of the AKI-to-CKD transition using urine and 
plasma assays, histological and molecular analyses.
Results: AA-treated mice developed a biphasic evolution of renal dysfunction and 
morphological alterations. First, an AKI phase (day 5) was demonstrated as attested by a 
significant increase in plasma creatinine along with PTEC necrosis as well as proteinuria. 
Later, during the progression of AKI to CKD, increased in oxidative stress and inflammatory 
cell infiltration (macrophages and lymphocytes) were characterized. Finally, chronic phase 
(day 20) was characterized by an extensive tubular atrophy and a massive tubulo-interstitial 
fibrosis as attested by Red Sirius staining and increased in pro-fibrotic gene expression.
Conclusions: AKI-to-CKD transition has clinical importance since patients surviving 
an episode of AKI present a significant risk of progression to CKD. However, the 
mechanisms by which AKI might initiate the CKD onset have not been fully defined. A 
better understanding of these mechanisms could lead to identify key biomarkers as well as 
new therapeutic strategies to prevent and treat AKI or impede progression to CKD. In this 
regard, animal models of AAN could represent a useful tool to provide important insights 
into the underlying mechanisms of AKI-to-CKD transition.
Funding: Government Support - Non-U.S.
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Low Nephron Endowment-Induced Compensatory Nephron Hypertrophy 
Causes ER Stress Making the Nephrons More Susceptible to Injury
Hongxia Zhang,2,1 Jinxian Xu,2 Caihong Dai,2 Shijun Lv,1 Jian-Kang Chen.2 
1Department of Clinic Medicine, Weifang Mecial College, Weifang, China; 
2Medical College of Georgia, Augusta University, Augusta, GA.
Background: Functioning nephrons respond to nephron deficits by increases in size 
and mass but not in number. Such a growth response is called compensatory nephron 
hypertrophy (CNH), which can occur in many situations. However, the pathogenic role of 
CNH in determining the susceptibility and severity of AKI and the underlying molecular 
mechanisms remain poorly understood.
Methods: We generated an mVPS34 gene-floxed mouse and crossed it with a HoxB7.
Cre mouse. Utilizing a long-term selective breeding strategy for a low HoxB7.Cre activity, 
we established a stable sub-strain of renal collecting system-specific mVPS34 knockout 
(KO) mice with a genotype of mVPS34flox/flox;HoxB7.Cre(+). These KO mice were challenged 
with bilateral renal ischemia/reperfusion (I/R) insults at 8 weeks of age. Gender-matched 
littermates with a genotype of mVPS34flox/flox;HoxB7.Cre(-) were used as controls (Ctrl).
Results: The KO mice appear healthy, with normal levels of BUN, serum creatinine, 
and blood pressure (measured by telemetry). Using the newly developed accurate 
glomerular counting method, we found that KO mice have a 60% congenital nephron 
deficit, compared to Ctrl littermates: 11066 ± 776.5 (N=8 mice) vs. 27915 ± 1293 (N=11 
mice) nephrons/mouse, with both left and right kidneys containing similarly lower nephron 
numbers. The mean renal glomerular and tubular areas of KO mice were significantly larger, 
with a 38% increase in single nephron GFR, confirming congenital nephron deficit-induced 
CNH. A 15-minute ischemia followed by 24 hours of reperfusion caused markedly more 
severe ischemia-reperfusion injury (IRI) and significant increases in both serum creatinine 
(Scr) and BUN in KO mice while Ctrl mice exhibited minimal structural damage but had 
no increase in either Scr or BUN. A 30-minute I/R also caused IRI in both KO mice and 
Ctrl mice, with significantly more severe morphological and functional damage in KO mice 
than in Ctrl mice. Mechanistic studies revealed markedly higher levels of Bip and C/EBP 
homologous protein (CHOP) in the KO mice, indicating the elevation of ER stress.
Conclusions: The congenital CNH caused by mVPS34 deletion in collecting duct 
is more susceptible and severe to ischemic nephron injury, which is likely mediated by 
elevated ER stress.
Funding: NIDDK Support, Government Support - Non-U.S.
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Repetitive Ischemic Injuries to the Kidneys Result in Lymph Node 
Fibrosis and Impaired Healing
Omar H. Maarouf,1 Mayuko Uehara,2 Vivek Kasinath,2 Zhabiz Solhjou,7 
Naima M. Banouni,2 Baharak Bahmani,4 Liwei Jiang,2 Osman A. Yilmam,2 
Indira Guleria,6 Scott B. Lovitch,4 Jane L. Grogan,8 Peter Sage,4 
Jonathan Bromberg,5 Martina M. McGrath,3 Reza Abdi.2 1Thomas Jefferson 
University Hospital, Philadelphia, PA; 2Medicine/Renal, Brigham and Women’s 
Hospital, Boston, MA; 3Harvard University, West Roxbury, MA; 4Brigham and 
Women’s Hospital, Boston, MA; 5University of Maryland, Baltimore, MD; 
6Children’s Hospital Boston, Boston, MA; 7University of Central Florida, 
Kissimmee, FL; 8Genentech, South San Francisco, CA.
Background: The contribution of the kidney-draining lymph node (KLN) to the 
pathogenesis of ischemia-reperfusion injury (IRI) of the kidney and its subsequent recovery 
has not been explored in depth. In addition, the mechanism by which repetitive IRI 
contributes to renal fibrosis remains poorly understood.
Methods: Transgenic mice were used. Ischemia Reperfusion Injury (IRI) surgeries on 
mice were performed using clamps. Aseptic techniques were used to culture cells. Protein 
and mRNA were extracted according to generally accepted techniques. Light and electron 
microscopy were used in addition to immunofluorescence staining.
Results: Herein, we have found that IRI of the kidney is associated with expansion 
of high endothelial venules (HEVs) and activation of fibroblastic reticular cells (FRC) 
in the KLN, as demonstrated by significant expansion in the extracellular matrix. The 
lymphotoxin α signaling pathway mediates activation of FRCs. Chronic blockade of 
the LTα –LTβr axis with lymphotoxin β receptor immunoglobulin (LTβr-Ig) resulted 
in marked alteration of the KLN as well as augmentation of renal fibrosis. In the acute 
setting, depletion of FRCs reduced T cell activation in the KLN and ameliorated renal injury 
2 days post-IRI. Repetitive renal IRI was associated with senescence of FRCs, fibrosis of 
the KLN, and renal scarring. FRC administration promoted repair of the kidney and KLN
Conclusions: Our study is novel in emphasizing the critical role of FRCs in KLN in 
both the initiation and repair phases of injury following IRI of the kidney. We also highlight 
the potential of FRCs as a cellular therapy to control inflammation and promote renal repair 
following IRI important in the progression of renal fibrosis.
Funding: Other NIH Support - National Institute of Allergy and Infectious Disease, 
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Interferon Regulatory Factor 4 in Macrophages Promotes Renal Fibrosis 
Following Severe AKI
Zhilian Li,1,2 Jessica M. Overstreet,1 Sungjin Chung,1,3 Yinqiu Wang,1 Ming-
Zhi Zhang,1 Raymond C. Harris.1 1Vanderbilt University Medical Center, 
Nashville, TN; 2Guangdong General Hospital, Guangdong Academy of Medical 
Sciences, Guangzhou, China; 3The Catholic University of Korea College of 
Medicine, Seoul, Republic of Korea.
Background: Acute kidney injury (AKI) is characterized by abrupt and reversible 
kidney dysfunction, and incomplete recovery from AKI leads to chronic kidney injury. 
Macrophage proliferation and polarization to an M2 phenotype plays a key role in recovery 
from AKI. However, M2 macrophages can produce profibrotic factors such as TGF-β and 
FIZZ1/RELMα, and their persistence may contribute to interstitial fibrosis when recovery 
from AKI is incomplete. Interferon regulatory factor 4 (IRF4) plays an important role in 
macrophage M2 polarization. The present study examined the potential role of macrophage 
IRF4 in recovery from AKI.
Methods: Wild type (WT, IRF4f/f) or macrophage IRF4-/- (LysM-Cre; IRF4f/f) mice 
(male, 3 months old, C57BL/6) were uninephrectomized, immediately followed by 
unilateral I/R with renal pedicle clamping for 32 min. Mice were sacrificed after 4 weeks.
Results: The effectiveness of macrophage IRF4 deletion was confirmed by qPCR 
in isolated renal macrophages. In cultured bone marrow monocytes, IRF4 deletion led 
to significant increases in LPS/IFN-γ-induced proinflammatory cytokines/chemokines. 
Macrophage IRF4-/- mice had delayed functional recovery during the first five days of 
recovery and more histologic injury at 5 days post I/R. At four weeks post-severe AKI, 
kidneys of IRF4-/- mice had marked decreases in M2 markers, IL-4Rα, CD206, FIZZ1/
RELMα, CD209, and B7-H4 as well as decreases in proinflammatory cytokines/
chemokines, IL-1α, IL-1β, IL-6, IL-23, CCL3, iNOS, TNF-α, and IFN-γ. Surprisingly, 
macrophage IRF4-/- mice had less severe kidney injury, as indicated by fewer protein casts 
and dilated tubules and less tubular atrophy. Sirius red and Masson’s Trichrome staining 
showed less renal interstitial fibrosis and decreased mRNA and protein levels of profibrotic 
and fibrotic components, TGF-β1, TGF-β2, CTGF, α-SMA, fibronectin, collagens I, III, IV 
as well as decreased immune cell infiltration in macrophage IRF4-/- mice.
Conclusions: Macrophage IRF4 facilitates functional and structural recovery of 
kidneys from AKI, possibly due to inhibiting proinflammatory cytokines/chemokines. 
When recovery from AKI is incomplete, IRF4-mediated pro-fibrotic, M2 polarization of 
macrophages/dendritic cells may contribute to development of fibrosis.
Funding: NIDDK Support, Veterans Affairs Support
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Hydrodynamic Isotonic Fluid Delivery Following Renal I/R Reduces 
Inflammation Associated with the AKI-to-CKD Transition
Purvi Mehrotra,1 Jason A. Collett,2 Riley P. O’Shaughnessy,2 David P. Basile.2 
1Indiana School of Medicine, Indianapolis, IN; 2Indiana University School of 
Medicine, Indianapolis, IN.
Background: AKI represents a significant risk factor for CKD. T cells, most notably, 
Th17 cells, play an important role in the transition from AKI to CKD. We’ve previously 
shown that retrograde hydrodynamic delivery of isotonic fluid (HIFD) improved renal 
function in established AKI between 24-48 hours following ischemia and reperfusion 
injury. This improvement was associated with decreased inflammation and vascular 
congestion. However, it is unknown whether HIFD manifests sustained effects on renal 
function, inflammation and secondary development of CKD.
Methods: S.D. rats underwent left unilateral I/R: 35 min with right Unx to induce 
AKI. 24 hours later, renal function was evaluated (serum creatinine; SCre) and rats received 
either HIFD into the renal vein or 0.5ml of saline into the vena cava (VC) as control. 
The animals were then allowed to recover for 20 weeks while regularly monitoring renal 
function. Inflammatory cells were evaluated in kidney 20 weeks post-surgery.
Results: Rats were stratified into either moderate (SCre <3.0 mg/dl) and severe 
(SCre >3.0 mg/dl) injury groups based upon serum creatinine at 24 hours post I/R. In the 
severe injury group, sCre tended to be reduced between 24 to 48hrs by HIFD treatment 
relative to VC-treated rats (HIFD: -0.34 vs. VC: +0.03 mg/dl); HIFD had no effect on SCre 
between 24-48 hours in the mild injury group. At 20 weeks post I/R, the number of renal 
mononuclear cells were significantly reduced by HIFD treatment in both moderate (41%) 
and severe (54%) injury as compared to VC-treated rats. In addition, there was a significant 
reduction in Th17 cells (CD4+IL17+) following HIFD in both the moderate (HIFD: 889.7 
vs. VC: 2480 cells/gram kidney; p<0.05) and severe groups (HIFD: 1351 vs. VC: 3838 
cells/gram kidney; p<0.05). HIFD-treated rats also demonstrated significant reductions in 
CD4+IFNy+ T cells (HIFD: 477.4 vs. VC: 1529 cell/gram kidney; p<0.05) compared with 
VC-treated rats in the severe group.
Conclusions: Renal vein HIFD treatment following established AKI reduces 
inflammation associated CKD progression. HIFD treatment improved chronic renal 
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inflammation despite the lack of improvement in renal function in moderately injured 
animals. Therefore, HIFD represent a novel therapeutic strategy for prevention of CKD 
following AKI.
Funding: NIDDK Support
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Significance of Pax2 Reactivation After Kidney Injury
Keisuke Sako, Shohei Makiishi, Yuta Yamamura, Yasunori Iwata, 
Norihiko Sakai, Miho Shimizu, Kengo Furuichi, Takashi Wada. Kanazawa 
University, Kanazawa, Japan.
Background: Pax2 is a transcription factor necessary for kidney development. It has 
been reported that homozygous mutation of Pax2 is embryonic lethal. On the other hand, 
Pax2 expression in the mature kidney is almost diminished. However, it has been reported 
that Pax2 is reactivated in the proximal epithelial tubular cells at the recovery phase of the 
injury. It has also been reported that Pax2 is involved in stimulation of cell proliferation. In 
this study, we examined the effect of reactivating Pax2 on kidney injury.
Methods: To determine the function of Pax2 reactivation in mouse proximal tubules of 
kidneys, we generated kidneyproximal tubule-specific Pax2 conditional knockout (K/O) mice. 
We generated a transgenic mouse that expresses Cre recombinase under the control of the 
promoter of the kidney androgen-regulated protein (KAP) gene (Pax2 flox/flox; KAP-Cre+male 
mouse). Kidney ischemia was induced in male mice of 6-week-old C57BL/6J (B6) male mice 
and conditional K/O mice. The left renal artery and vein of these mice were clamped for 60 min 
to induce ischemia -reperfusion (I/R) injury. Kidney tissues were removed for examination 2, 4, 
7 or 14 days after I/R. We evaluated cell proliferation (immunohistochemical staining of Ki-67 
and BrdU), inflammation (immunohistochemical staining of F4/80 and CD3) and fibrosis (sirius 
red staining and hydroxyproline assay). We also conducted similar experiments on Pax2 hetero 
K/O mice and Pax2 siRNA induction mice.
Results: In B6 male mice, the number of Pax2 positive cells and mRNA expressions 
increased after I/R. Immunohistochemical analysis of CD3 and F4/80 showed at increasing 
number of the in inflammatory cell infiltration in conditional K/O mice (p<0.05). In analysis 
of interstitial fibrosis, the area ratio of sirius red staining and the hydroxyproline assay were 
higher in conditional K/O mice at day 14 after I/R (p<0.05). The number of Ki-67 positive 
cells was decreased in conditional knockout mice at day 2 after I/R (p<0.01). Almost of all 
the Ki 67-positive cells were co-positive with BrdU. In addition, the area ratio of sirius red 
staining was also higher in Pax2 hetero K/O mice and Pax2 siRNA induction mice at 14 
days after I/R (p<0.05).
Conclusions: Reactivation of Pax2 after ischemia reperfusion injury may be involved 
in cell proliferation and interstitial fibrosis suppression in the injured kidney.
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Loss of Proximal Tubular Krüppel-Like Factor 15 Exacerbates Renal 
Injury
Ahmed A. Attallah,1 Xiangchen Gu,3 Yiqing Guo,1 Sian Piret,1 Monica P. Revelo 
Penafiel,4 John C. He,5 Sandeep K. Mallipattu.2 1Stony Brook University, Stony 
Brook, NY; 2Stony Brook Medicine, Stony Brook, NY; 3Yueyang hospital of 
integrated Traditional Chinese and Western Medicine, Shanghai University of 
Traditional Chinese Medicine, Shanghai, China; 4University of Utah, Murray, 
UT; 5Mount Sinai School of Medicine, New York, NY.
Background: Although several causes contribute to the development of kidney fibrosis 
and eventual CKD, repeated bouts of acute tubular injury secondary to DNA damaging 
tubular toxins remains a major cause. Krüppel-Like Factor 15 (KLF15), a zinc-finger 
transcription factor that is expressed in renal stromal and proximal tubule (PT) cells was 
recently shown as a potential mediator of kidney fibrosis. KLF15 expression is reduced 
in early and late stages of human kidney fibrosis as compared to healthy control subjects. 
We sought to determine the mechanism by which tubular KLF15 serves a key mediator of 
DNA-damage induced PT injury leading to AKI and CKD.
Methods: PT-specific Klf15 knockout mice (Klf15ΔPepck) were generated by crossing 
Klf15fl/fl mice with Pepck-Cre mice. We utilized low-dose Aristolochic Acid I (AAI) to 
model DNA-damage induced PT injury, 3 mg/kg every three days for 2 weeks (active 
phase), followed by 2 weeks for remodeling (chronic phase), with DMSO as control. RNA-
Seq was performed in active and remodeling phase samples.
Results: Klf15ΔPepck mice demonstrated worse renal function (elevated serum urea 
nitrogen and creatinine), increased PT injury (AQP1 & lotus lectin redistribution and 
reduced expression) and changes in fibrotic markers compared to AAI-treated Klf15fl/fl  
mice in the acute and chronic phase. RNA-seq analysis showed that integrin signaling 
and focal adhesion pathways were upregulated in AAI-treated Klf15fl/fl mice. In the active 
phase a subset of 36 genes in metabolic & oxidative stress pathways were downregulated 
in Klf15ΔPepck but not in Klf15fl/fl and have KLF15 predicted binding sites (BS). In the 
chronic phase versus DMSO a subset of 13 genes including additional members of Focal 
adhesion, Regulation of actin cytoskeleton, integrin signaling and Inflammation pathways 
were upregulated in Klf15ΔPepck but not in Klf15fl/fl and have KLF15 BS. In the active to 
chronic transition a subset of 55 genes including additional members of Cell adhesion, Cell 
differentiation and Integrin signaling pathways were upregulated in Klf15ΔPepck but not in the 
Klf15fl/fl and have KLF15 BS.
Conclusions: These data suggest that the loss of tubular KLF15 exacerbates AAI-
induced AKI and CKD, which is mediated by metabolic, focal adhesion and integrin 
signaling pathways.
Funding: NIDDK Support
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Identifying the Target of Pro-Regenerative Compound, PTBA, to Improve 
Post-AKI Repair
Hwa I. Han, Amanda Crunk, Neil A. Hukriede. University of Pittsburgh, 
Pittsburgh, PA.
Background: Despite the high prevalence of AKI, no approved therapeutic directly 
repairs renal tubular epithelial cells (RTEC). We discovered a small molecule, phenyl-
thio butanoic acid (PTBA), which improves post-AKI survival, RTEC dedifferentiation 
& proliferation, & attenuates fibrosis in various models of AKI. In vitro studies suggest 
histone deacetylase 8 (HDAC8) as a PTBA target. We utilize hdac8 mutant zebrafish 
to investigate loss-of-function in a nephrotoxin model of AKI. HDAC8 deacetylates 
structural maintenance of chromosomes 3 (SMC3), a subunit of cohesin involved in sister 
chromatid cohesion & subsequent segregation. Without HDAC8, there is a perturbance of 
SMC3 acetylation resulting in G1/S delay. G1/S arrest has been reported as a protective 
mechanism to allow RTEC proliferation, while G2/M arrest produces pro-fibrotic factors. 
We hypothesize HDAC8 inhibition dysregulates the SMC3 acetylation cycle, thereby 
promoting G1/S delay rather than G2/M arrest in RTECs, acting as a protective mechanism.
Methods: We utilized hdac8 null mutant fish to investigate changes in the repair 
response. To analyze injury response at a cellular level, we utilized immunohistochemistry 
to characterize cell cycle phases: EdU (S), PCNA (S), & Phospho-Histone H3 (pH3) 
(G2/M). We compared Smc3Ac changes, a potential downstream target of Hdac8, in wild 
types & hdac8-/- by western blot & profiled the acetylome in wildtype, mutant, & compound 
treated zebrafish larvae.
Results: Upon gentamicin induced AKI, hdac8-/- fish exhibited increased survival as 
compared to genetically wildtype larvae. In assessing cell cycle changes, we identified 
an increased number of PCNA+ & EdU+ RTECs in hdac8-/-. However, hdac8-/- showed a 
lower number of pH3+ RTECs, a marker of G2/M. Upon investigating SMC3Ac levels, we 
observed increased SMC3Ac in hdac8-/- larvae.
Conclusions: HDAC8 inhibition & SMC3 acetylation is a potential mechanism for 
increasing post-AKI repair. Genetic ablation of hdac8 shows enhanced post-AKI survival. 
Cell cycle analysis suggests absence of Hdac8 activity increases PCNA & EdU, S-phase 
markers, while lowering G2/M arrest. This increase in S phase & decrease in G2/M may be 
attributed to the lack of interaction between Hdac8 & Smc3. Overall, we identified a target 
for HDAC8 & SMC3 as a potential molecular pathway for RTECs to prefer G1/S delay, 
rather than G2/M as a protective mechanism during AKI.
Funding: NIDDK Support, Other U.S. Government Support
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Senescence Associated Secretory Phenotype: Role of Plasminogen 
Activator Inhibitor-2 (PAI-2) in Acute and Chronic Kidney Disease
Payel Sen, Alexandra Helmke, Sibylle Von Vietinghoff, Song Rong, 
Jan H. Braesen, Hermann G. Haller, Anette Melk, Roland Schmitt. Hannover 
Medical School, Hannover, Germany.
Background: One of the important mechanisms that play a role in age-related kidney 
disease is cellular senescence and the senescence associated secretory phenotype (SASP), 
which activates fibroblasts and causes immune cell infiltration. We identified plasminogen 
activator inhibitor-2 (PAI-2) as an upregulated secreted protein in senescent primary tubular 
epithelial cells (PTEC). PAI-2 is best known for its expression by macrophages, which are 
integral in post-injury kidney repair. Therefore, we intended to study the role of PAI-2 in the 
renal tubular SASP and immune surveillance in AKI and CKD.
Methods: Microarray was used for SASP analysis in PTEC. PAI-2 mRNA expression 
was tested in PTECs after treatment with Phorbol and γ-irradiation. HEK cells transduced 
with PAI-2 were co-cultured with fibroblasts. PTEC and bone marrow derived macrophages 
(BMDM) were extracted from wild type (WT) and PAI-2 knock out (KO) mice. To assess 
differences in post-injury repair, PAI-2 WT and KO mice were subjected to ischemia/
reperfusion (I/R) and unilateral ureteral obstruction (UUO).
Results: PTEC derived from PAI-2 KO mice showed higher proliferation and lower 
expression of senescence marker p16INK4a after Phorbol treatment. In co-culture assays 
secreted PAI-2 activated fibroblasts. BMDMs extracted from WT mice had a stronger 
inflammatory phenotype after activation with LPS and IFNγ. While in acute phase post I/R 
PAI-2 KO kidneys had a reduced damage load, PAI-2 KO was associated with enhanced 
chronic damage during the later phase of I/R. In UUO, the KO kidney had more damage 
in acute as well as chronic phase. WT kidneys compared to KO showed steady decline in 
classically as well as alternatively activated macrophages in the later time points in both 
forms of injury.
Conclusions: PAI-2 is produced and secreted by tubular cells upon stress and during 
senescence. In the peritubular milieu, PAI-2 plays a heterogeneous role by promoting 
senescence and activating fibroblasts. It also strongly affects macrophage polarization and 
infiltration. While PAI-2 might have damaging effects during early renal injury our results 
indicate that PAI-2 is needed for long-term adaptation. In summary, PAI-2 is a novel renal 
SASP component which has an important impact on kidney adaptive repair.
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Tubular Epithelial Proliferation Accelerates Tubular Atrophy After 
Kidney Injury Through Its Contractile Capacity
Noriyuki Yamashita, Tetsuro Kusaba, Keiichi Tamagaki. Department of 
Nephrology, Graduate School of Medical Science, Kyoto Prefectural University 
of Medicine Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Tubular atrophy is a common pathological finding in kidney fibrosis and 
is characterized by flattened tubular epithelia surrounded by thickened tubular basement 
membrane (TBM). After injury, neighboring epithelia exert strong mechanical forces on 
the area surrounding the damaged site in order to close the wound. We hypothesize that the 
regeneration of tubular epithelia during repair itself drives the TBM to shrink, resulting in 
tubular atrophy.
Methods: In order to mimic the mechanical effects of tubular epithelia during repair 
on the TBM in vitro, tubular epithelial cells (NRK52E) were cultured on a thin floating 
collagen gel, and its changes by various stimuli were assessed. In in vivo experiments, we 
performed a clonal analysis of solely labeled tubular epithelia using bigenic mice with the 
proximal tubule-specific tamoxifen-inducible Cre gene (SLC34a1GCE) and tdTomato 
reporter gene. We then investigated the role of focal adhesion kinase (FAK), a key molecule 
in the mechanosensing of focal adhesion and the modulation of actin polymerization, during 
kidney injury and repair.
Results: An in vitro analysis showed that the active proliferation of NRK52E caused 
the floating gel to shrink and become thick, similar to the TBM of atrophic tubules. The 
TGFβ treatment accelerated gel contraction, whereas the inhibition of actin polymerization 
by a FAK or ROCK inhibitor suppressed it. An in vivo clonal analysis after severe ischemia 
reperfusion injury (IRI), together with upregulation of TGFβ, showed that tubules containing 
a larger clone number were more likely to be atrophic and lose terminally differentiated 
tubular markers. In contrast, tubules containing a large clone number were not atrophic in 
mild IRI kidneys, and differentiated tubule markers were preserved. Based on the active 
phosphorylation of FAK in the tubular epithelia and interstitial fibroblasts in IRI kidneys, 
an in vivo clonal analysis showed that the administration of a low dose of the FAK inhibitor 
ameliorated the atrophy of tubules with a larger clone size and interstitial fibrosis.
Conclusions: The present in vitro andin vivo results indicate that tubular atrophy after 
severe kidney injury is associated with the active proliferation of tubular epithelia through its 
contractile capacity induced by upregulation of TGFβ and subsequent actin polymerization.
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Nephrectomy Induced Renal Repair After AKI Prevents Progression to 
CKD by an Early Immunosuppressive Action
Lies Moonen,1 Bart Cuypers,3 Pieter Meysman,1 Kris Laukens,2 
Patrick C. D’Haese,4 Benjamin A. Vervaet.4 Laboratory of Pathophysiology, 
University of Antwerp 1University of Antwerp, Wilrijk, Belgium; 2Universiteit 
Antwerpen, Antwerpen, Belgium; 3University Of Antwerp, Antwerp, Belgium; 
4University Antwerp, Edegem, Belgium.
Background: Enhanced renal repair is defined as the remarkable repair of an acutely 
injured kidney upon removal of the healthy contralateral kidney. If the latter kidney is left 
in place, repair is only marginal and the injured kidney turns fibrotic. It is yet unclear to 
which extent and by which molecular mechanism a nephrectomy is able to alter the fate of 
injured kidney cells.
Methods: Acute kidney injury was induced by left ischemia/reperfusion (I/R) after 
which either right nephrectomy (Nx) or mock-Nx was performed 3 days later. Wild type 
C57BL/6J mice underwent 21 min of ischemia at 36°C. Control mice underwent mock-I/R 
and mock-Nx surgery. Mice were euthanized at either 7 days or 6 weeks after I/R. Kidneys 
were weighed and qPCR analysis of the profibrotic genes Col1, Col4, TGFbeta and CCN2 
was performed. Masson/H&E stain was used to microscopically evaluate histopathology 
and the extent of collagen deposition. RNA-sequencing was used to compare differential 
gene expression.
Results: In the I/R without Nx group the median left kidney-to-body weight ratio 
(mg/g) at week 6 was 2.8 (range 2.1-3.1), whereas that of its right healthy kidney was 6.7 
(range 6.4-7.0), indicating severe atrophy in the injured left kidney. In the Nx group, left 
kidney-to-body ratio was 6.9 (range 6.0-7.3) and that of its right kidney at the time of Nx 
6.5 (range 5.9-7.5). When no Nx was performed, Col1, Col4, TGFbeta and CCN2 were 
upregulated 18-, 5-, 7- and 3-fold compared to controls at week 6, respectively. In case of 
Nx, this decreased to 5-, 2-, 2-, and 0-fold upregulation. On a histological level, Nx strongly 
attenuated cortical atrophy and tubulo-interstitial fibrosis. Preliminary whole transcriptome 
RNA-seq analysis at day 7 showed differential expression of 534 genes (257 up, 277 down) 
of which immune response and MAPK pathways were most significantly downregulated 
upon Nx.
Conclusions: In conclusion, Nx performed 3 days after I/R has an early 
immunosuppressive action and attenuates renal atrophy and fibrosis in C57BL/6J mice. 
This murine model is a useful alternate tool to further study the mechanism of physiology-
driven enhanced renal recovery.
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Pannexin1 Regulates Intracellular ATP in a Cisplatin Model of AKI
Jakub Jankowski,1 Junlan Yao,1 Shuqiu Zheng,1 Amandeep Bajwa,1 
Diane L. Rosin,1 Brant Isakson,2 Kodi S. Ravichandran,3 Mark D. Okusa.1 
1University of Virginia, Charlottesville, VA; 2University of Virginia School of 
Medicine, Charlottesville, VA; 3University of Virginia, Carter Immunology 
Center, Charlottesville, VA.
Background: Pannexin1 (Panx1) is a membrane channel that can release ATP upon 
injury, thereby exacerbating inflammation. We reported that Panx1 deficiency protects 
kidneys from ischemia-reperfusion injury (IRI). We found significant differences in kidney 
ATP between Panx1 KO and control kidneys after injury and hypothesized that retention of 
ATP is a universal protective mechanism in AKI, including the cisplatin model.
Methods: Global Panx1 KO and WT mice (n=4) were subjected to 26min bilateral 
kidney ischemia and 24h of reperfusion. Global (n=8) and proximal tubule (PT, n=4) 
Panx1 KO mice and appropriate controls (n=6 and 4, respectively) were given cisplatin 
(20 mg/kg, ip). Injury was assessed 72 h later by plasma creatinine (PCr), blood urea 
nitrogen (BUN) and weight loss. Whole kidney ATP was obtained by chloroform extraction 
of kidney homogenates. CRISPR/Cas9 was used to generate stable Panx1 KO in murine 
proximal tubule cells (TKPTS). Cells were treated with 20 μM cisplatin overnight or 
20 μM antimycin A for 1 hour to induce injury. Intracellular ATP concentration was 
measured using luminescent assay.
Results: At baseline, global Panx1 KO had less ATP (normalized to tissue weight) in 
whole kidney homogenates than WT mice (n=8 and 9; 0.59 vs. 1.00; p<0.05). Following 
IRI kidney ATP was higher (2.9 vs. 1.0; p<0.05) and PCr was lower (0.48 vs. 1.45 mg/dL; 
p<0.01) in Panx1 KO than in WT mice. After cisplatin, BUN was higher in Panx1 KO than 
WT mice (81.74 vs. 58.46 mg/dL; p=0.07) but there was no difference in kidney ATP (0.89 
vs. 0.92; p=0.879). Similarly, after cisplatin, BUN (113.8 vs. 61.49 mg/dL; p<0.05) and 
body weight loss (21.76 vs. 17.37%; p<0.05) was higher in PT-specific Panx1 KO than WT 
mice. Kidney ATP was not greater in PT-Panx1 KO than WT mice (1.31 vs. 1.00; p=0.34) 
after cisplatin treatment. Cultured Panx1 KO cells retained more ATP than controls after 
cisplatin (54 vs. 36%, p<0.0001) or antimycin A (66 vs. 49%, p<0.001) treatment.
Conclusions: These results show that Panx1 influences ATP balance in cisplatin 
injury setting. PT-specific Panx1 deletion is sufficient to exacerbate injury, contrary to 
in vitro observations that Panx1 knockout tubules retain more ATP after antimycin A or 
cisplatin stimulation. The complex role of intracellular ATP homeostasis in AKI will require 
additional investigation.
Funding: NIDDK Support
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Paricalcitol Ameliorates Cisplatin-Induced AKI by Inhibiting Cell 
Pyroptosis
Hao Zhang,1 Siqing Jiang,2 Bin Yi,1 Zhaoxin Hu.3 1The Third Xiangya Hospital 
of Central South University, Changsha, China; 2The third Xiangya Hospital, 
Central South University, CHANGSHA, China; 3Central South University, 
CHANGSHA, China.
Background: Cisplatin is a classic and effective chemotherapeutic agent, but its kidney 
toxicity has restricted its application. Vitamin D receptor (VDR), as an important nuclear 
receptor, is involved in the pathogenesis of acute and chronic kidney diseases. The VDR 
agonist paricalcitol exerts a protective effect on a variety of acute kidney injury. In this 
study, we investigated the protective effect and mechanism of paricalcitol in cisplatin-
induced acute injury.
Methods: Eight week old male VDR KO mice and WT mice were randomly divided 
into 6 groups (n=6): (A) WT+Control, (B) WT+Cisplatin, (C) WT+Cisplatin+Paricalcitol, 
(D) KO, (E) KO+Cisplatin, (F) KO+Cisplatin+Paricalcitol. Pretreatment of paricalcitol
(0.2mg/kg, intraperitoneally injected) was performed for five consecutive days. On the sixth 
day, cisplatin (20 mg/kg) was intraperitoneally injected to induce acute kidney injury (AKI). 
Samples were collected 72 hours after cisplatin injection. Real-time PCR and Western blot 
were used to detect the expressions of renal apoplexy-associated proteins such as NLRP-3, 
caspase-1 and IL-1β. Renal pathological specimens were subject to HE staining to assess
the degree of renal tubular injury.
Results: 1. 72 hours after cisplatin injection, mice in groups B, C, E and F became 
depressed and ate less. The levels of Cr, BUN and CysC were significantly higher in groups 
B, C, E and F (p<0.05), as compared with those in groups A and D, while mice in group 
E showed the most serious renal damage (p<0.05). 2. The mRNA and protein levels of 
NLRP-3, caspase-1 and IL-1β in groups B, C, E and F were significantly higher than those 
in group A and D (p<0.05). The increase of the three mRNAs/proteins in group E was most 
significant (p<0.05), and the expression of the three proteins in group C was lower than 
that in group B. 3. HE staining indicated that the renal tubular injury index in group C was 
significantly lower than that in group B (p<0.05). The renal tubular injury index was highest 
in group E (p<0.05).
Conclusions: VDR plays an important role in cisplatin-induced AKI. The VDR agonist 
paricalcitol possibly reduce cisplatin-induced AKI by inhibiting cell pyroptosis.
Funding: Government Support - Non-U.S.
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Retinoic Acid Alleviates Cisplatin Induced Kidney Injury Through 
Activation of Autophagy
Junxia Wu,1,2 Xin Wan.3 1Department of Nephrology, Nanjing First Hospital, 
Nanjing Medical University, Nanjing, Nanjing, China; 2Charles and Jane Pak 
Center for Mineral Metabolism and Clinical Research, University of Texas 
Southwestern Medical Center, Dallas, TX; 3Nanjing First Hospital, Nanjing, 
China.
Background: Retinoic acid (RA) reduces injury, inflammation, and fibrosis in models 
of acute renal injury, including toxin and ischemia reperfusion AKI, but little is known 
about its effect on cisplatin induced kidney injury.
Methods: We examine the effects of RA on cisplatin induced kidney injury in vivo 
and introduce a murine model of cisplatin induced kidney injury by retro-orbital injection 
of cisplatin both in WT and autophagy-related gene 5–knockout mice. Renal function test, 
LDH test, HE staining, PCR, immunoblots and immunofluorescence were used in the study. 
And in vitro, NRK cells were treated with and without cisplatin and were transfected with 
GFP-LC3 plasmid. Data are representatives of at least three experiments and expressed 
as means ± SD. Statistical analysis was conducted using the GraphPad Prism software. 
Statistical differences in multiple groups were determined by multiple comparisons with 
ANOVA followed by homogeneity test for variance. P<0.05 was considered as significantly 
different.
Results: Cisplatin group mice exhibited typical features of clinical cisplatin induced 
kidney injury including renal histology changes, higher level of NGAL and plasm creatinine. 
In WT mice, RA alleviated cisplatin induced dilation and necrosis of renal tubular epithelial 
cells and improved renal function and upregulated autophagy. Knockout mice showed more 
severe kidney injury as was indicated by worsening renal function, more tissue damage. 
And the protective effect of retinoic acid was not significant in knock out mice as autophagy 
was blocked. In vitro, RA protected proximal tubular epithelial cells from cisplatin induced 
injury, inhibited apoptosis and promote the proliferation of epithelial cells after cisplatin 
induced injury and upregulated autophagy which were confirmed by higher level of LC3 
-II / LC3 -I ratio, lower level of P62 by immunoblots and more autophagy punctae after
transfection of GFP-LC3 plasmid.
Conclusions: RA alleviates cisplatin-induced kidney injury via upregulating autophagy.
Funding: Other NIH Support - George M. O’Brien Kidney Research Center Grant , 
Pak Center Innovative Research Support Program
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Cisplatin-Induced AKI: Preconditioning Protects by mRNA-Independent 
Proteome Alterations
Martin Späth,1 Malte P. Bartram,1 Nicolàs Palacio-Escat,2 Karla J. Hoyer,1 
Bernhard Schermer,1 Thomas Benzing,1 Volker R. Burst,1 Julio Saez-Rodriguez,2 
Pitter F. Huesgen,3 Roman-Ulrich Mueller,1 Markus M. Rinschen.1 1Department 
2 of Internal Medicine, Renal Division; University of Cologne, Cologne, 
Germany; 2RWTH Aachen, Aachen, Germany; 3Forschungszentrum Juelich, 
Juelich, Germany.
Background: Acute kidney injury is one of the most common kidney diseases, 
resulting in significantly increased morbidity and mortality. Unfortunately, strategies for 
prevention or causal treatment are lacking in routine clinical practice. During the last years 
it has been shown in animal models, that a number of preconditioning protocols have a 
protective effect.
Methods: We characterized two of these strategies - calorie restriction and hypoxic 
preconditioning - in a mouse model of cisplatin-induced acute kidney injury. To investigate 
the underlying mechanisms, we used multi-layered omic data (transcriptome, proteome, 
and N-degradome for measuring proteolytic activity) and functional parameters of 
preconditioned and non-preconditioned cisplatin-treated animals. These parameters were 
generated from identical animals and integrated bioinformatically.
Results: Both protocols significantly reduced cisplatin-induced acute kidney injury. 
Bioinformatic analysis revealed mRNA-independent proteomic changes affecting the 
extracellular compartment, mitochondrial function and tubular transporters. Interestingly, 
our analyzes showed a strong dissociation of protein and mRNA expression after cisplatin 
treatment. In the animal cohort, the degree of mRNA-protein dissociation showed a strong 
correlation (R> 0.95) with the degree of damage. N-degradome analysis revealed that most 
post-transcriptional changes were determined by Arg-specific proteolytic processing. This 
involved a characteristic cisplatin-induced complement activation, which was prevented 
by preconditioning. In addition, amyloid and acute phase proteins accumulated within 
the cortical parenchyma. Extensive analyzes of damage-associated molecular patterns 
(DAMPs) suggest that the transcription-independent deposition of serum amyloid P could 
play a key role in the contribution of the microenvironment to renal damage.
Conclusions: This study provides new insights into the pathogenesis of cisplatin-
induced acute kidney injury and the molecular mechanisms that underly organ protection 
through preconditioning through multi-omic phenotype correlations.
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Celastrol Ameliorates Cisplatin Nephrotoxicity by Inhibiting NF-κB and 
Improving Mitochondrial Function
Xiaowen Yu, Yue Zhang, Guixia Ding, Aihua Zhang, Zhanjun Jia, 
Songming Huang. Children’s Hospital of Nanjing Medical University, Nanjing, 
China.
Background: Celastrol (CE) is an active ingredient of Chinese medicine Tripterygium 
wilfordii which is clinically used to treat immune diseases. Currently, celastrol is 
documented as a potent agent for treating cancer and inflammatory disorders. The present 
study was to investigate the effects of celastrol on cisplatin (Cis) nephrotoxicity and the 
underlying mechanisms.
Methods: In vivo, C57BL/6 mice were treated with cisplatin (20 mg/kg) with or without 
celastrol administration (1 mg/kg/day). After 3 days treatment, mice were sacrificed and the 
kidney and blood samples were collected for analysis. In vitro, renal tubular epithelial cells 
(RTECs) were treated with cisplatin (5 μg/ml) with or without celastrol treatment (50 nM).
Results: Pretreatment with celastrol markedly ameliorated cisplatin-induced kidney 
injury as shown by the improved renal function (BUN: Cis group 75.2±10.7 vs. Cis+CE 
group 31.1±10.9mmol/L, p<0.001; serum creatinine: Cis group 1.2±0.3 vs. Cis+CE 
group 0.37±0.18 mg/dl, p<0.001; and cystatin C: Cis group 16.0±1.68 vs. Cis+CE group 
11.3±1.89 ng/ml, p<0.001), kidney morphology (PAS), and oxidative stress (MDA) in line 
with a robust blockade of renal tubular injury markers of KIM-1 (-86.97%) and NGAL 
(-82.09%). Meanwhile, renal apoptosis and inflammation were also strikingly attenuated 
in celastrol-treated mice. In vitro, celastrol inhibited cisplatin-induced cell apoptosis 
(-34.31%), suppressed NF-κB activation (-54.53%), and improved mitochondrial function 
shown by the restored mtDNA copy number (+29%), mitochondrial membrane potential 
(+61.09%), and OXPHOS activity (+1.67 folds) in cisplatin-treated renal tubular cells.
Conclusions: Our study suggested that celastrol could suppress NF-κB and improve 
mitochondrial function to protect against cisplatin nephrotoxicity. Celastrol serves as a 
promising drug for the treatment of AKI.
FR-PO076 Poster Friday
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Lactate Improves Survival in Mice with Sepsis Through HCA2 Activation
Ayumi Takakura,2 Kambiz Zandi-Nejad.1 1BIDMC/HVMA-Harvard Medical 
School, Boston, MA; 2Brigham and Women’s Hospital, Boston, MA.
Background: Sepsis is characterized by systemic inflammation due to infection and is 
the most common cause of acute kidney injury (AKI) in critically ill patients. During sepsis, 
activation of pro-inflammatory pathways results in dysfunction of mitochondria and cells, 
leading to multi-organ failure.
Methods: Wild-type and Hca2-/- mice were undergone cecal ligation and puncture 
(CLP) to induce sepsis. For survival study, we monitored the mice for 2 weeks after CLP. 
For treatment study, we administered either normal saline or lactated Ringer’s solution once 
a day for total of 3 injections. The isolated peritoneal fluid or cells were subjected to ELISA 
assay and real time RT-PCR analyses.
Results: Here we show that: 1) in peritoneal immune cells from mice undergone 
cecal ligation and puncture (CLP), hydroxycarboxylic acid receptor 2 (HCA2) expression 
increased in parallel with pro-inflammatory cytokines; 2) survival rates for Hca2-/-mice after 
CLP were lower than for wild-type mice (~40% vs. ~80%) 2 weeks after CLP-induced 
sepsis, suggestive of a protective role for HCA2 in sepsis; 3) early mortality of Hca2-/-mice 
were associated with higher pro-inflammatory cytokine production in Hca2-/-peritoneal fluid 
compared to wild-type; 4) administration of lactated Ringer’s (LR) has beneficial effects on 
mortality in wild-type mice (but not Hca2-/-mice) during sepsis; 5) unlike normal kidneys, 
kidneys in the setting of sepsis expressed Hca2; 6) LR administration attenuated sepsis-
associated AKI, partly restored expression of the key regulator of mitochondrial biogenesis, 
peroxisome proliferator-activated receptor gamma coactivator-1-a(PGC1a), and reduced 
pro-inflammatory cytokine production. Our data suggest that lactate-induced activation 
of HCA2 regulates a negative feedback loop during sepsis to decrease the inflammatory 
response.
Conclusions: The data further suggest that fluid resuscitation with LR solution may 
benefit patients with sepsis, particularly those with sepsis-associated AKI treated with 
potentially lactate-depleting renal replacement therapies (RRT).
Funding: Clinical Revenue Support
FR-PO077 Poster Friday
AKI: Tubules, Metabolism, New Models
Preconditioning Mice with a Pharmacologic Activator of AMPK 
Ameliorates Ischemic AKI by Activating Akt
Wilfred Lieberthal,1,2 Mersema Abate,3,1 Jerrold S. Levine.5,4 1Nephrology, Stony 
Brook University Medical Center, Stony Brook, NY; 2Medicine, Northport VA, 
Northport, NY; 3Stony Brook University Hospital, Stony Brook, NY; 4Department 
of Medicine, Jesse Brown Veterans Affairs Hospital, Chicago, IL; 5Department 
of Microbiology and Immunology, University of Illinois, Chicago, IL.
Background: We have reported that preconditioning renal tubular cells (RTCs) with 
A-769662 (a novel small molecule activator of AMPK), reduces the death of renal tubular 
cells (RTCs) induced by metabolic stress in vitro and ameliorates the severity of ischemic
AKI in mice. (Liebertal, W. et al: American J Phyiol Renal Physiol 311:F731-739, 2016). 
Our objective in this study was to determine whether Akt plays a role in mediating these
effects of A-769662.
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Methods: We knocked down expression of the beta-domain of AMPK by > 85% using 
shRNA (“KD” RTCs). In control RTCs a “scrambled” shRNA was used. Ischemic AKI was 
induced by subjecting the kidneys to ischemia-reperfusion injury (IRI).
Results: Preconditioning control cells with A-769662 increased the phosphorylation 
(activity) of AMPK, and reduced the death of these cells induced by exposing them to 
metabolic stress. However, in KD cells A-769662 had no measurable effects on the 
activation of AMPK or on their survival after stress. These data show that the activation 
of AMPK by A-769662 is profoundly impaired in KD RTCs. A-769662 activated Akt 
in control but not in KD RTCs. These findings demonstrate that the activation of Akt by 
A-7609662 is AMPK-dependent, and not the result a nonspecific “off target” kinase. It 
also shows that AMPK acts upstream of Akt. We show, that inhibiting Akt with a specific 
Akt inhibitor in control cells during the preconditioning period, reduced the pro-survival
effect of A-769662 by ~50%. These findings suggest that Akt contributes to the pro-survival 
effects of A-7698662 in vitro. We next evaluated the role of AMPK and Akt in modulating
the severity of ischemic AKI in vivo. We show that preconditioning mice with A-769662 
activated AMPK and Akt in the renal cortex, and that inhibiting Akt, while having no
effect on the activation of AMPK, reduced the activation of Akt. Finally, we provide novel 
evidence, that A-769662 ameliorates the severity of ischemic AKI, and that Akt contributes 
to this effect.
Conclusions: ) A-769662 activates AMPK and Akt in control RTCs and in the kidneys 
of mice; ii) the activation of Akt by A-760662 is mediated by AMPK; iii) The activation 
of Akt contributes to the pro-survival effects of A-769662 in vitro, and to the beneficial of 
A-769662 in ischemic AKI in vivo; iv) the mechanisms responsible for the activation of Akt 
by AMPK remain to be elucidated
Funding: Commercial Support - Dialysis Centers Incorporated, Private Foundation 
Support
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Metabolic Alterations Following Renal Ischemia Reperfusion in Rats
Christina Bracken,1 Jeff H. Stanwix,1 Katelyn Pulito,1 Mahati Krishna,2 
Effie Tozzo.1 1Mitobridge, an Astellas company, Cambridge, MA; 2Syngene 
International Pvt. Ltd., Bangalore, India.
Background: Acute kidney injury (AKI) is a major health issue, associated with high 
morbidity, mortality, fibrosis and CKD. Ischemia reperfusion injury (IRI) during surgical 
procedures such as coronary artery bypass grafting or transplantation can cause AKI. In this 
study, we sought to characterize the timecourse of molecular and cellular pathophysiological 
consequences of IRI in the rat.
Methods: Sprague-Dawley rats underwent 45-minute bilateral ischemia followed by 
reperfusion for 1, 4, 8, 12, 24, 48, 72 hours (hr) or 14 days. We characterized renal injury by 
measuring plasma and urine biomarkers at all timepoints. We also evaluated tubular injury/
repair and subsequent development of renal fibrosis. To delineate IR-induced metabolic 
changes, we examined gene expression of metabolic pathways including pyruvate handling, 
fatty acid oxidation, oxidative stress, and mitochondrial homeostasis. We also evaluated 
NAD+ utilization and biosynthesis using mass spectrometry and ELISA based methods.
Results: IR-AKI resulted in varying kinetics of plasma and urinary biomarkers. 
Plasma creatinine and NGAL were elevated 4hr post AKI, and peaked at 24hr, whereas 
BUN increase was slightly delayed. Urinary NGAL and KIM-1 had similar time-dependent 
profiles peaking at 24-48hr, whereas urinary FABP-1 excretion peaked at 4hr, then rapidly 
declined. Tubular and vascular injury were evident 4hr post AKI with proliferation occurring 
from 24 - 72hr. Gene expression analysis revealed downregulation of proximal tubular 
cell-specific genes, which suggests loss or de-differentiation. By day 14 post injury, there 
was clear biochemical and histological evidence for fibrosis despite normal GFR. Renal 
IRI negatively affected the expression of genes regulating oxidative stress, mitochondrial 
function, pyruvate handling and fatty acid metabolism through the reperfusion phase. 
Furthermore, data revealed reduced gene expression of NAD+ biosynthetic enzymes 
concomitant with a drop of NAD+, increased NAD+ utilization and breakdown products.
Conclusions: Together, our data reveal dysregulation of metabolic processes that 
contribute to the pathophysiology of IR-induced AKI and may allow for investigation of 
previously unexplored therapeutic avenues.
Funding: Commercial Support - Astellas
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GSK3β-Mediated Keap1-Independent Regulation of Nrf2 Antioxidant 
Response: A Molecular Rheostat of AKI-to-CKD Transition
Minglei Lu,1,2 Lance D. Dworkin,2 Zhangsuo Liu,1 Rujun Gong.2 1The First 
Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 2University of 
Toledo Medical Center, Toledo, OH.
Background: How acute kidney injury(AKI) is transformed to chronic kidney 
disease(CKD) remains elusive. Evidence suggests that glycogen synthase kinase(GSK)3β, 
a pivotal mediator of Keap1-independent regulation of Nrf2 defense, contributes to kidney 
injury. Whether GSK3β-mediated Nrf2 regulation is involved in AKI to CKD transition is 
unknown and was explored here.
Methods: Mice with renal tubule-specific GSK3β knockout and control mice were 
injured with folic acid. Nrf2 response and CKD transition were evaluated. In cultured renal 
tubular cells expressing GSK3β mutants, hydrogen peroxide-elicited chronic injuries and 
Nrf2 response were examined.
Results: Following folic acid injury, mice developed AKI with ensuing CKD transition, 
characterized by variable degrees of tubular cell atrophy, growth arrest and interstitial 
fibrosis. This lingering injury of renal tubules was parallelized by sustained oxidative 
stress that coincided with an impaired Nrf2 antioxidant defense, marked by mitigated Nrf2 
nuclear accumulation and blunted induction of its target antioxidant enzymes. The initiation 
of Nrf2 signaling, however, seems unaffected since cytoplasmic Nrf2 in injured tubules was 
persistently elevated. Moreover, renal expression of Keap1, a key repressor of Nrf2, was 
barely associated with the magnitude of CKD transition. In contrast, GSK3β was persistently 
overexpressed and hyperactive in renal tubules during CKD transition. Likewise, in patients 
who developed CKD following AKI related to diverse etiologies, GSK3β overexpression 
was evident in renal tubules and concomitant with impaired Nrf2 response and oxidative 
damages. Mechanistically, Nrf2 defense agaisnt oxidative stress was sabotaged in renal 
tubular cells expressing a constitutively active mutant of GSK3β in a Keap1-independent 
mode, in parallel with an exacerbated cell cycle arrest, dedifferentiation, apoptosis and 
extracellular matrix overproduction. Conversely, ectopic expression of dominant negative 
GSK3β reinforced Nrf2 response and diminished cytopathic changes. In vivo in folic acid-
injured mice, targeting GSK3β in renal tubules via gene knockout or by microdose lithium 
reinstated Nrf2 response and hindered CKD transition.
Conclusions: GSK3β-regulated of Nrf2 may serve as a pragmatic therapeutic target for 
modifying the long-term sequelae of AKI.
Funding: NIDDK Support
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Efficacy of Low Intensity Pulsed Ultrasound on an AKI Mouse Model via 
the Prevention of Endoplasmic Reticulum Stress and Apoptosis
Shing-Hwa Liu,1 Kuan-yu Hung,3 Chih-Kang Chiang.1,2 1Graduate Institute of 
Toxicology, National Taiwan University, Medical College, Taipei, Taiwan; 
2Department of Integrated Diagnostics & Therapeutics, National Taiwan 
University Hospital, Taipei, Taiwan; 3Department of Internal Medicine, National 
Taiwan University Hospital, TAIPEI, Taiwan.
Background: Acute kidney injury (AKI) is associated with high mortality rates and 
often predisposes patient to development of chronic kidney disease. Renal ischemia/
reperfusion injury (IRI) is a major cause of AKI. The mechanisms of IRI have been found 
to be included endoplasmic reticulum (ER) stress, inflammatory responses, hypoxia, and 
generation of reactive oxygen species. Low intensity pulsed ultrasound (LIPUS), which 
is a kind of therapeutic ultrasound, has been shown to exert therapeutic effects on bone 
healing and accelerate the healing process. The effect and mechanism of LIPUS on AKI 
still remain unclear. Here, we investigated the therapeutic effect and possible mechanism 
of LIPUS on IRI.
Methods: We use a mouse model of unilateral IRI with nephrectomy of the 
contralateral kidney in the presence or absence of LIPUS treatment (3 MHz, intensity 
0.1 W/cm2, 20 mins, 50% duty factor) 5 day before and 1 day after surgery.
Results: The results showed that renal function markers (e.g. BUN, creatinine), ER 
stress-related molecules (e.g. GRP78, eIF2-α, CHOP) and apoptotic markers (e.g. Bax, 
caspase-3) were significantly increased in the kidneys of mice with IRI for 24 h, which 
could be significantly reversed by LIPUS treatment. The histopathological examination 
showed that the lesser renal tubular injury and inflammation were observed in IRI+LIPUS 
mice than in IRI alone mice.
Conclusions: Taken together, LIPUS treatment showed the benefits for renal protection 
in IRI mice. These findings suggest that LIPUS therapy may be used to serve as an auxiliary 
tool for management of AKI.
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UCP2-Dependent Improvement of Mitochondrial Dynamics Preserves 
AKI
Yang Zhou,1 Nan Qin,2 Xiaoming Mao,2 Junwei Yang.1 1Second Affiliated 
Hospital, Nanjing Medical University, Nanjing, China; 2Nanjing Medical 
University, Nanjing, China.
Background: Acute kidney injury (AKI) is a public health concern with high 
morbidity and mortality rate in hospitalized patients and the survivors have increased risk 
of progression to chronic kidney disease. Mitochondrial damage is the critical driver of 
AKI-associated dysfunction and loss of tubular epithelial cells; however, the pathways that 
mediate these events are poorly defined.
Methods: AKI was induced by ischemia/reperfusion injury. We generated proximal 
tubular cells specific uncoupling protein 2 (UCP2) knockout mice to investigate the role of 
UCP2 on AKI. Primary tubular epithelial cells were cultured under normoxia or hypoxia 
conditions. Mitochondrial dynamics were evaluated by electron microscopy, western blot 
analysis and immunofluorescent staining.
Results: Here, in murine ischemia/reperfusion-induced (I/R-induced) AKI model, 
we determined that mitochondrial damage is associated with the level of renal UCP2. 
In hypoxia-damaged proximal tubular cells, a disruption of mitochondrial dynamics 
demonstrated by mitochondrial fragmentation and disturbance between fusion and fission 
was clearly indicated. Ucp2-deficient mice suffered I/R injury experienced more severe 
AKI and mitochondrial fragmentation than wild-type (WT) mice. Moreover, Genetic or 
pharmacologic treatment increased UCP2 expression, improved renal function, reduced 
tubular injury and limited mitochondrial fission. In cultured proximal tubular epithelial cells, 
hypoxia-induced mitochondrial fission was exacerbated in Ucp2-/- cells, while increase of 
UCP2 improved hypoxia-induced disturbance between mitochondrial fusion and fission. 
Furthermore, modulation of UCP2 suggested its role in preserving mitochondrial integrity 
by preventing loss of membrane potential and reducing subsequent mitophagy.
Conclusions: Together, our results indicate that UCP2 is protective against AKI and 
suggest that enhancing UCP2 to improve mitochondrial dynamics has potential as a strategy 
for improving outcomes of renal injury.
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AATF/Che-1 Controls Ribosomal Biogenesis Through Direct Binding of 
Ribosomal RNA and R-Protein Encoding mRNAs
Rainer Kaiser,1 Michael Ignarski,1 Constantin Rill,1 Eric Van nostrand,3 
Markus M. Rinschen,1 Bernhard Schermer,1 Thomas Benzing,1 Katja Hoepker,2 
Francesca Fabretti,1 Roman-Ulrich Mueller.1 1Dept. 2 of Internal Medicine, 
University of Cologne, Koeln, Germany; 2University of Cologne, Köln, 
Germany; 3UCSD, La Jolla, CA.
Background: AATF/Che-1 (Apoptosis Antagonizing Transcription Factor) is an RNA 
Pol II binding transcription factor that has been shown to play crucial roles in multiple 
essential cellular pathways - e.g. DNA damage response and mTOR signaling. It further has 
been linked to acute kidney injury. However, the exact molecular function of this protein 
is not known.
Methods: We have identified AATF as a putative RNA binding protein (RBP) in 
murine kidney cells. Here, we use Enhanced Crosslinking and Immunoprecipitation 
(eCLIP) as well as RNA editing followed by sequencing (TRIBE) techniques to identify 
both coding and non-coding RNAs bound by AATF. Binding of RNA as well as validation 
of specific targets was done by PNK assays and RIP-qPCR. Using TALEN-mediated 
genome engineering, we have created a set of transgenic cell lines that express GFP-tagged 
WT AATF or AATF mutant proteins. In addition, we perform MS/MS studies to uncover 
proteins interacting with AATF.
Results: Here we validate AATF as an RNA binding protein and identify hundreds 
of RNA targets bound by AATF. Analysis of transcripts bound by AATF were enriched 
for ribosomal and other non-coding RNA biotypes. More specifically, the 45S rRNA 
precursor was one of the most enriched transcripts bound to AATF. Moreover, both 
structural constituents of the RNP and components of the ribosome biogenesis machinery 
were strongly overrepresented among the mRNA transcripts. Both the 45S pre-ribosomal 
precursor and its product, 18S rRNA, were depleted upon knockdown of AATF. However, 
AATF did not only interact with RNA molecules associated with ribosomal function and 
integrity, but also with a large number of protein components of the rRNP and other RNA 
binding proteins.
Conclusions: Our study validates AATF as an RNA binding protein and reveals yet 
another link between rRNA metabolism, nucleolar integrity and other essential pathways 
such as the DNA damage response. An impact on ribosome abundance and functionality 
mediated by RNA binding could be an important feature of the role of AATF in 
carcinogenesis and may open new ways to address its role as a potential therapeutic target. 
To this end, a better understanding of its molecular function is of great importance.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO083 Poster Friday
AKI: Tubules, Metabolism, New Models
The mRNA Interactome of Ciliated Renal Cells and Its Modulation by 
Hypoxia
Rainer Kaiser,1 Constantin Rill,1 Michael Ignarski,1 Ilian Atanassov,2 
Bernhard Schermer,1 Thomas Benzing,1 Francesca Fabretti,1 Roman-
Ulrich Mueller.1 1Dept. 2 of Internal Medicine, University of Cologne, Koeln, 
Germany; 2Max Planck Institute for Biology of Aging, Cologne, Germany.
Background: RNA-binding proteins (RBPs) are fundamental regulators of cellular 
biology and affect every step in processing RNA-biology. The scale of their impact has been 
shown by recent studies that have linked RBPs to a number of human pathologies, ranging 
from neurological disorders and ischemia reperfusion injury to tumor growth. Despite this 
central role in cell biology, the global effect of RBPs in the kidney has not been assessed 
until now. Here, we identify the first set of RBPs in ciliated renal epithelial cells under both 
hypoxic and normoxic growth conditions.
Methods: Using Oligo(dT) beads to precipitate mRNA-protein complexes on ciliated 
mIMCD-3 cells, we aimed to identify the kidney-specific mRNA interactome using mass 
spectrometry. Cells were either exposed to hypoxia or grown under normoxic conditions. 
In parallel, the proteome of whole cell lysates was identified to assess the abundance of 
total protein in comparison to RBPs detected using the same conditions. Using TALEN-
generated transgenic human cell lines, specific candidates were validated as RNA binding 
protein with the Polynukleotide (PNK) assay, showing RNA bound directly to the proteins 
of interest. Localization of the RBPs was analyzed using immunofluorescence.
Results: Our data revealed over 350 significant mRNA interactors and more than 300 
candidate RBPs, 84 of which have not been described as RBPs in common data bases. 
We define these proteins as the renal epithelial cell mRNA interactome. The PNK assay 
validated all chosen candidates as RBPs and indeed showed direct binding to RNA. Since 
the whole cell proteome did not show these RBPs to be differentially expressed upon 
exposure to hypoxia, we hypothesize that the increased detection of RBP candidates in the 
hypoxic samples is indeed due to differential binding to their target transcripts.
Conclusions: Our data identify the first set of RBPs specific to ciliated renal epithelial 
cells and show that hypoxia can modulate RNA-binding, adding another regulatory layer 
to the diverse biology of the kidney. Using established human transgenic cell lines, we are 
now aiming for functional studies of individual candidates in order to address their impact 
on hypoxia signaling and their impact of preconditioning-mediated increase of viability 
both in vitro and in vivo.
Funding: Private Foundation Support, Government Support - Non-U.S.
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AICAR, an AMPK Activator, Protects Against Cisplatin-Induced AKI 
Through JAK/STAT/SOCS Pathway
Tsogbadrakh B. Bodokhsuren, Jinho Lee, Sohyun Yun, Curie Ahn, Kook-
Hwan Oh. Division of Nephrology, Department of Internal Medicine, Seoul 
National University Division of Nephrology, Department of Internal Medicine, 
Seoul National University, Seoul National University Hospital, Seoul, Republic 
of Korea.
Background: Cisplatin causes acute kidney injury (AKI) through proximal tubular 
injury. We investigated protective effect of the adenosine monophosphate protein kinase 
(AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) against 
cisplatin induced AKI. We investigated whether AMP-kinase activator AICAR ameliorates 
cisplatin induced AKI and through JAK/STAT/SOCS pathway.
Methods: Male Sprague-Dawley rats were randomly divided into four groups: 
control, AICAR, cisplatin and cisplatin + AICAR groups. On day 1, SD rats were injected 
with single dose of cisplatin (7 mg/kg, i.p.). From day 1 to 5, AICAR was administered 
to rats at 100mg/kg i.p. daily. Blood urea nitrogen (BUN) and the serum creatinine were 
measured. The kidneys were harvested on the day 5. Renal damage was analyzed in 
sections stained with Hemotoxylin and Eosin (H&E). Renal tissues were also examined 
for immunohistochemistry and western blot for p-AMPK, KIM1, cleaved caspase 3 and 
JAK/STAT/SOCS. For in vitro studies, NRK-52E normal rat kidney cells were treated with 
cisplatin and/or AICAR. By western blot, we also confirmed the expressions of p-AMPK 
and JAK/STAT/SOCS pathway in NRK-52E cells.
Results: A single injection of cisplatin caused marked increase of the serum creatinine 
and BUN levels on day 5. Peak BUN and serum creatinine levels were decreased by 
treatment with AICAR. As compared to the cisplatin group, acute tubular necrosis (ATN) 
score was improved in rats treated with cisplatin + AICAR. AICAR was protective against 
cisplatin induced acute tubular injury by up-regulating p-AMPK expression and down-
regulating KIM-1 and cleaved caspase 3. JAK2/STAT1/SOCS1 pathway was down-
regulated by AICAR treatment in our in vivo and in vitro study. AICAR was protective 
against cisplatin induced acute tubular injury by up-regulating p-AMPK expression in 
NRK-52E cells. Protein expression levels of JAK2/STAT1 were markedly ameliorated in 
NRK-52E cells by AICAR.
Conclusions: Thus, the present study demonstrates the protective effect of AICAR in 
cisplatin-induced ATN and shows a new renoprotective mechanism through JAK2/STAT1/
SOCS1 pathway and apoptosis inhibition. This study suggests that activation of AMPK 
activator, AICAR might ameliorate the cisplatin induced AKI.
FR-PO085 Poster Friday
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NAD+ Augmentation Improves Cell Survival Against Cisplatin via 
Enhanced Mitophagy
Matthew R. Lynch, Mei T. Tran, Samir M. Parikh. Beth Israel Deaconess 
Medical Center, Boston, MA.
Background: Cisplatin nephrotoxicity is a common cause of acute kidney injury. 
Activation of autophagy in the renal tubule may be protective against cisplatin. We previously 
reported that nicotinamide adenine dinucleotide (NAD+) precursor treatment ameliorated 
cisplatin nephrotoxicity in mice. Given the role of NAD+ in mitochondrial function and 
homeostasis, we investigated if the protection afforded by NAD+ augmentation against 
cisplatin involved the induction of mitochondrial autophagy, i.e., mitophagy. Mitophagy has 
been traditionally difficult to quantify, requiring co-staining of cells with mitochondrial and 
lysosomal dyes which can be cytotoxic, non-specific, or both. Recently, a pH-sensitive non-
toxic biosensor protein, mtKeima, has been developed to track the fraction of mitochondria 
that undergo autophagy and breakdown in the acidic lysosome.
Methods: We developed a stable renal tubular cell line expressing mtKeima, which 
we treated with cisplatin (10 mM) or vehicle. Another set of cells were pre-treated with 
the NAD+ precursor nicotinamide mononucleotide (NMN, 1 mM) 30m prior to cisplatin 
or vehicle. General autophagy was assessed by Western Blot for LC3 and p62. Cells were 
imaged 24h after treatment on a confocal microscope with two sequential excitations 440 
nm and 559 nm and a 570 to 695 nm emission range. A mitophagy index was calculated 
by determining the ratio between the area of the red (acidic) and green (basic) emission.
Results: LC3 and p62 revealed no differences in response to cisplatin or NMN. 
However, cisplatin markedly inhibited mitophagy (p<0.05, 2-fold change). Conversely, 
NMN enhanced basal mitophagy (p<0.001, 4-fold change). Pre-treatment of cisplatin-
exposed cells with NMN abrogated the decline in mitophagy induced by cisplatin (p<0.001, 
6-fold change). Finally, application of the lysosome inhibitor, chloroquine, enhanced
cisplatin toxicity.
Conclusions: Whereas traditional measurements of autophagy were uninformative, 
use of mtKeima illuminated a specific reduction in mitophagy triggered by cisplatin. This 
effect was abrogated with the addition of NMN. Our results indicate that preservation of 
mitophagy with its safe mitochondrial disposal, rather than generalized autophagy, may 
be critical for renal tubular cells to resist cisplatin. Further, NAD+ supplementation may 
represent a therapeutic option for the treatment of cisplatin nephrotoxicity.
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Nrf2 Attenuates Tubular Epithelia Cell Transdifferentiation in Response 
to Hypoxia Through Regulating CTGF Secretion
Weiwei Kong,1 Jingqi Fu,1 Junjun Luan,1 Congcong Jiao,1 Huimeng Qi,2 
Yanqiu Wang,1 Detian Li,1 Jingbo Pi,2 Hua Zhou.1 1The Affiliated Shengjing 
Hospital of China Medical School, Shenyang/China, China; 2China Medical 
University, Shenyang, China.
Background: Nuclear factor erythroid 2-related factor 2 (Nrf2) is a well-known 
regulator of oxidant and xenobiotic metabolism. We previously reported that Nrf2 
ameliorates renal tubular transdifferentiation in mice on day 5 after unilateral ureteral 
obstruction (UUO); however, the mechanism of attentuation remains unclear. We aimed to 
clarify whether Nrf2 regulates the connective tissue growth factor (CTGF)/WNT pathway, 
which is a key pathway in tubular epithelia cell transdifferentiation.
Methods: Normal rat kidney-52E (NRK52E) tubular cells were divided into four 
groups: scramble control, Nrf2-knockdown (Nrf2-KD) control, scramble hypoxia (5%), and 
Nrf2-KD hypoxia groups. Expression levels of CTGF and WNT signaling pathway (p-Lrp6 
and β-catenine) were detected by western blotting. Then, we used siRNAs to silence CTGF 
and Nrf2 simultaneously and to measure WNT signaling and vimentin, a transdifferentiation 
marker. We also investigated the expression of c-fos, a known transcription regulator of 
CTGF, and the expression of a group microRNAs as post transcription factors of CTGF. In 
addition, we evaluated the expression of CTGF in the kidneys of Nrf2+/+ and Nrf2−/− mice 5 
days after UUO by immunostaining and western blotting.
Results: We found that Nrf2 deletion significantly increased CTGF expression 
in response to 5% of hypoxia in NRK52E cell line. In hypoxia treated NRK52E cells, 
deletion of Nrf2 promoted expression of p-Lrp6 and β-catenine as well as vimentin. 
The overexpression of p-Lrp6, β-catenine and vimentin due to only silencing Nrf2 was 
decreased by double silencing Nrf2 and CTGF. Nrf2 knockdown increased expression of 
c-fos and p-c-fos in NRK52E cells. However, Nrf2 knockdown showed no regulation of
post-transcription factors such as miR-26a, miR-26b, miR-30a and miR-133. Similarly,
expression of CTGF and activity of WNT signaling were increased in Nrf2−/− mice
compared to those in Nrf2+/+ mice on the 5th day after UUO operation.
Conclusions: Nrf2 attenuated tubular epithelial cellular transdifferntiation may be 
mediated by downregulating WNT signaling pathway through inhibiting CTGF secretion in 
tubular epithelial cells. This suggests that Nrf2 activator might be a potential agent to slow 
down the progression from acute renal tubular damage to chronic tubulointerstitial fibrosis.
Funding: Government Support - Non-U.S.
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Nrf2 Interactions with the HIF System May Determine Long Term 
Outcomes After AKI
Corry D. Bondi, Brittney M. Rush, Roderick J. Tan. University of Pittsburgh, 
Pittsburgh, PA.
Background: Acute kidney injury (AKI) affects up to 1 in 5 hospitalized patients and 
is associated with an increased risk of developing chronic kidney disease. AKI is commonly 
caused by ischemia and proximal tubular epithelia are particularly vulnerable to injury. HIF-
1α (Hypoxia-inducible factor-1α) and Nrf2 (Nuclear factor erythroid 2-related factor 2) 
are transcription factors with protective effects against AKI. Studies suggest an association 
between HIF system activation and Nrf2 activity but this has not been extensively studied 
in the kidney.
Methods: C57BL/6 mice were subjected to kidney ischemia-reperfusion to induce 
AKI. Ischemia times were titrated to induce mild to severe injury and kidneys were 
harvested at various acute and chronic timepoints post-reperfusion. To simulate mild and 
severe injury conditions in vitro, proximal tubular HK-2 cells were exposed to either nutrient 
replete or nutrient deficient conditions, respectively, in the presence of HIF activation with 
cobalt chloride (CoCl2). Immunoblotting, qPCR, RNA interference, serum creatinine, and 
histologic methods were used.
Results: Kidneys obtained 24 h after mild injury had elevated protective Nrf2 activity, 
as evidenced by expression of the Nrf2 target gene Nqo1, and this was associated with 
minimal histologic injury at late timepoints. Kidneys exposed to severe injury failed to 
upregulate Nqo1, and this was associated with the development of chronic injury and 
fibrosis. Similarly, HK-2 cells exposed to mild stress conditions using nutrient replete media 
with CoCl2 led to Nqo1 upregulation, but cells exposed to nutrient deficient conditions with 
CoCl2 did not show Nqo1 induction. HIF-1α appeared to exert a negative effect on Nrf2 
since HIF-1α knockdown enhanced Nqo1 expression. HIF-1α activation also suppressed 
Nrf2 nuclear localization in nutrient deficient conditions.
Conclusions: Our data suggest there is a threshold of severity at which AKI leads to 
the development of progressive CKD, and disparate outcomes may be partly determined by 
Nrf2 activity. Also, we demonstrate differential regulation of Nrf2 by HIF activation in mild 
and severe injury conditions. Overall, our results show that there is an association between 
Nrf2 and the HIF system that may determine the long-term outcome of the kidney.
Funding: Other NIH Support - NIH T32 DK061296; NIH P30 DK079307, Private 
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Nrf2 Deficiency Aggravates Folic Acid-Induced AKI Through  
Upregulation of Renal Ferroptosis in Mice
Shiwen Zhang,1 Junjun Luan,1 Jingqi Fu,2 Weiwei Kong,1 Yanqiu Wang,1 
Detian Li,1 Jingbo Pi,2 Hua Zhou.1 1Department of Nephrology, The Affiliated 
Shengjing Hospital of China Medical University, Shenyang, China; 2Program of 
Environmental Toxicology, School of Public Health, China Medical University, 
Shenyang, China.
Background: The role of nuclear factor erythroid 2-related factor 2 (Nrf2) in folic 
acid (FA)-induced acute kidney injury (AKI) remains unstudied so far. Ferroptosis is 
demonstrated to be involved in FA-induced AKI. We aim to verify whether Nrf2 deletion 
aggravated FA-induced AKI in mice and to investigate the corresponding mechanism.
Methods: Male Nrf2+/+ and Nrf2−/−mice were injected FA (100 mg/kg) intravenously 
to induce AKI. NaHCO3 was used as the vehicle. AKI was evaluated by serum creatinine 
(Scr), blood urea nitrogen (BUN), and tubular damage on PAS staining 48h after FA 
injection. Meanwhile, we examined four types of tubular cell death including tubular 
necrosis, apoptosis (TUNEL staining), pyroptosis (Caspase1, Pycard, and Txnip-1/2), and 
ferroptosis (Gpx4 and Acsl4). We also examined the renal expression of Nrf2-associated 
genes such as pro-inflammatory cytokines (Il6 and Tnfα) and antioxidative factors (Nqo1, 
Gclc, and Gclm) in Nrf2−/−mice compared to that in Nrf2+/+ mice. In addition, we explored 
the influence of Nrf2 deletion on the activity of methylenetetrahydrofolate dehydrogenase 
(MTHFD), which is an enzyme involved in FA systemic metabolism.
Results: AKI occurred in both Nrf2+/+ and Nrf2−/− mice. AKI features such as Scr, BUN, 
tubular damage degree on PAS staining, and tubular necrosis scores were more severe in 
Nrf2−/− mice than in Nrf2+/+ mice. The number of TUNEL positive nuclei in kidneys of Nrf2−/− 
mice was higher than that in Nrf2+/+ mice. However, the above four pyroptosis biomarkers 
showed no difference in the kidneys of both Nrf2+/+ and Nrf2−/− mice. Interestingly, renal 
anti-ferroptosis gene Gpx4 expression was downregulated while pro-ferroptosis gene Acsl4 
was upregulated. In addition, renal pro-inflammatory Il6 and Tnfα genes were increased 
and antioxidative Nqo1, Gclc, and Gclm genes were decreased in Nrf2−/− mice compared 
to in Nrf2+/+ mice. Further, we found FA increased the activity of MTHFA; however, no 
difference of this enzyme was seen in Nrf2−/− mice compared to Nrf2+/+ mice.
Conclusions: Nrf2 deficiency aggravates FA-induced AKI in mice. Acute tubular 
protective roles of Nrf2 may be mediated by a combination of mechanisms such as anti-
inflammation, antioxidative response, anti-apoptosis, and anti-ferroptosis.
Funding: Government Support - Non-U.S.
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The Protective Role of Nrf2 Against Aristolochic Acid (AA)-Induced Renal 
Tubular Epithelial Cell Injury
Xuan Huang, Juan Wu, Haishan Wu, Xinhui Liu, Xueqing Yu, Xiao Yang. 
Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, 
Guangzhou, China.
Background: Aristolochic acid nephropathy(AAN) is a rapidly progressive 
tubulointerstitial disease induced by aristolochic acid(AA) and there are currently no 
effective treatments for it. Nrf2, as a major regulator of antioxidant response, has been 
proven by numerous studies to be protective in acute kidney injury and chronic kidney 
disease progression. However, its role in AA-induced kidney injury has not been elucidated 
yet. We previously demonstrated that Bardoxolone methyl(BARD) ameliorates AA-
induced acute kidney injury through Nrf2 pathway. In this study, we further assessed the 
role of Nrf2 in AA-induced renal tubular epithelial cell injury.
Methods: NRK-52E cells were incubated with different concentrations of AA for 0-24 
hours to evaluate cell viability, Nrf2 signaling pathway protein levels, ROS production, 
and cell apoptosis/necrosis. The role of Nrf2 in AA-induced ROS production and cell 
apoptosis/necrosis was determined through Nrf2 knockdown by its specific siRNA or Nrf2 
overexpression by Nrf2 plasmid, respectively. Cell viability was evaluated by MTT. Cells 
were labeled with DCFH-DA for detection of ROS by flow cytometry. The cells also doubly 
labeled with Annexin V and propidium iodide(PI) for measurement of cell apoptosis/
necrosis by flow cytometry. Expression of Nrf2 and its downstream protein HO-1 and 
NQO1 was analyzed by western blotting.
Results: AA increased intracellular ROS production and cell apoptosis/necrosis in a 
time-dependent manner. Meanwhile, the cell viability and the expression of Nrf2 signaling 
pathway proteins (Nrf2, HO-1, NQO1) were significantly decreased. Downregulation of Nrf2 
by its specific siRNA further increased ROS levels(25.2±12.5 vs 8.5±2.5, P<0.05) and cell 
apoptosis/necrosis(50.21±5.65% vs 35.81±0.97%, P<0.05), and reduced the expression of 
Nrf2 signaling pathway proteins(P<0.05). Conversely, overexpression of Nrf2 significantly 
decreased AA-induced ROS production and cell apoptosis/necrosis(24.12±1.61% vs 
32.61±0.81%, P<0.01). The expression of Nrf2 and its downstream protein HO-1 were 
significantly upregulated compared with non-Nrf2 transfected group(P<0.05).
Conclusions: Impaired Nrf2 signaling pathway is one of the mechanisms of AA-
induced renal tubular epithelial cell injury, and activation of Nrf2 can ameliorate the cell 
injury by its antioxidant effect.
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The Effect and Mechanism of Leptin in Ischemia Reperfusion Induced 
AKI
Siyao Li, Jing Xi, Yi He, Junxiang Chen. Second Xiangya Hospital Central 
South University, Changsha, China.
Background: Ischemia-reperfusion (IR)-induced acute kidney injury (AKI) is one of 
the most common causes of AKI, but the underlying pathogenesis is poorly understood. 
And there are little reports about the role of leptin in IR-induced AKI.
Methods: Bilateral renal ischemia (30 min)/reperfusion (48hrs) injury (IRI) model was 
performed using ob/+ mice (wild type) and ob/ob mice (Leptin deficient). Blood samples 
were collected for renal function evaluation and the kidneys were removed for histological 
examination and protein detection.
Results: Compared with the sham groups, both of the I/R groups showed significantly 
higher levels of serum urea nitrogen and creatinine, which were even much higher in 
the ob/ob/I/R group than those in the ob/+/I/R group. No obvious tubular damage and 
TUNEL positive cells were observed in the sham groups, but severe tubular lysis, loss 
of brush border, sloughed debris in tubular lumen space and TUNEL-positive cells were 
observed in the I/R groups and were much more obvious in the ob/ob/I/R group than those 
in the ob/+/I/R group. Significantly increased Caspase3, Caspase9 and LC3 II protein 
expression and decreased p-mTOR protein expression were detected in both of the I/R 
groups comparing with the sham groups, these changes were more significantly in the 
ob/ob/I/R group than in the ob/+/I/R group. P-AMPK,P-PTEN,P-AKT,P-ERK protein 
were significantly down-regulated and PTEN protein was significantly up-regulated in both 
of the I/R groups compared with the sham groups, these changes were were much more 
remarkable in the ob/ob/I/R group than in the ob/+/I/R group.
Conclusions: After IRI, Mice showed impaired renal function, damaged kidney tubules 
and increased apoptosis and autophagy, which were significantly more obvious in the ob/
ob/I/R group than in the ob/+/I/R group. The ob/ob/I/R group showed remarkably increased 
PTEN protein and decreased P-AMPK,P-PTEN,P-AKT,P-ERK protein than the ob/+/I/R 
group. All the above results suggests that leptin may participates in the pathogenesis of 
I/R-induced AKI by regulating autophagy via a complicated network composed of mTOR 
dependent pathways, as well as by regulating apoptosis.
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A Single Dose of Lithium Attenuates Rhabdomyolysis-Associated AKI
Maria H. Shimizu, Ana Carolina de Braganca, Daniele Canale, Rildo A. Volpini, 
Antonio C. Seguro. Faculty of Medicine - University of Sao Paulo, São Paulo, 
Brazil.
Background: Acute kidney injury (AKI) is the most severe complication of 
rhabdomyolysis. Evidence suggests that glycogen synthase kinase 3β (GSK3β) inhibition 
protects against AKI. Treatment with a single dose of lithium, a selective inhibitor of 
GSK3β, accelerated recovery of renal function in models of cisplatin and ischemia/
reperfusion- induced AKI. The aim of this study was to evaluate the efficacy of a single 
dose of lithium in the treatment of rhabdomyolysis-induced AKI in rats.
Methods: Male Wistar rats aged 3 months were allocated to four groups: 1- Control: 
received saline 0.9% intraperitoneal (IP); 2- Lithium: rats treated with a single IP 
injection of lithium chloride 80 mg/Kg body weight (BW) ; 3- Glycerol (50%, 5 ml/kg 
intramuscular,IM); 4- Glycerol plus Lithium: glycerol 50%, 5 ml/kg IM + lithium chloride 
80 mg/kg IP injected 2 hours after glycerol administration. After 24 h the animals were 
anesthetized to measure inulin clearance (GFR, ml/min/100g BW). At the end of the 
clearance experiments the rats were euthanized, blood and kidney were collected to evaluate 
plasma levels of creatine phosphokinase (CPK), expression of GSK3β in renal tissue and 
kidney histological damage score.
Results: As described in the table below, glycerol-injected rats showed markedly 
reduction of GFR, increase of CPK levels, exaggerated increase of GSK3β renal expression 
and higher kidney injury score. A single dose of lithium administration ameliorated all these 
alterations.
Conclusions: Lithium treatment attenuated renal dysfunction in a model of 
rhabdomyolysis-associated AKI by improving inulin clearance and reducing kidney 
injury score. These therapeutic effects were due to an inhibition of renal GSK3β and were 
associated with a decrease in muscle injury. This may represent a new therapeutic approach 
for rhabdomyolysis-induced AKI. (FAPESP 2015/11933-3; 2015/05513-1)
Data are expressed as mean±SEM. a p<0.001, c p<0.05 vs Control; d p<0.001, e p<0.01 vs 
Lithium ;f p<0.001, g p<0.05 vs Glycerol.
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Stress Granule Plays a Protective Role in Renal Proximal Tubular Cells
Shixuan Wang,1,2 Zheng Dong.1,2 1Medical College of Georgia, Augusta, GA; 
2Charlie Norwood VA Medical Center, Augusta, GA.
Background: Stress granule (SG) is one type of cytoplasmic structures formed 
in eukaryotic cells upon certain types of stress. Further study disclosed that SG mainly 
contains RNA-binding proteins (RBPs) and mRNAs. SGs are widely regarded as one 
mechanism for cells to survive a harsh insult. However, little is known about SG biogenesis 
in renal tubular cells.
Methods: To explore how tubular cells form SGs to a series of interventions, we 
applied different kinds of stressors to cultured mouse (BUMPT) and rat (RPTC) proximal 
tubular cells as well as a short period of ischemia/reperfusion to mouse kidneys.
Results: It was found that glycolytic inhibitors such as 2DG (2-deoxy-D-glucose) and 
3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) can induce SG formation within 30 
minutes in cultured BUMPT and RPTC cells. Similarly, SGs are induced by inhibitors for 
the respiratory chain of mitochondria such as sodium azide and CCCP (carbonyl cyanide 
m-chlorophenyl hydrazone). Interestingly, cisplatin, a common chemotherapy drug for
many types of cancers, hardly induces SG formation. Ischemia/reperfusion to mouse
kidneys can induce SG formation in renal proximal tubular cells. To further test the role of 
SGs in renal tubular cells, we stably knocked down G3BP1, a SG core protein, in BUMPT 
and RPTC cells by shRNA viral transduction. As expected, knockdown of G3BP1 partially 
disrupts the assembly of SGs. After azide or cisplatin treatment, more dead cells were found 
morphologically in knockdown cells in comparison to controls, accompanied by increment 
in cleaved caspase-3 expression. Re-introduction of exogenous G3BP1 into knockdown
cells can rescue the cell death phenotype.
Conclusions: All taken together, SGs can form in cultured renal proximal tubular cells 
at certain conditions and kidneys after ischemia/reperfusion. Intervention on SG biogenesis 
may provide an approach to lessen the severity of a series of renal diseases.
Funding: NIDDK Support, Veterans Affairs Support
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Upregulation of Hypothalamic Arginine Vasopressin by Bilateral 
Nephrectomy in Transgenic Rats Expressing Arginine Vasopressin- 
Enhanced Green Fluorescent Protein
Kenya Sanada, Hiromichi Ueno, Tetsu Miyamoto, Kenichiro Bando, 
Yoko Fujimoto, Yoichi Ueta, Yutaka Otsuji, Masahito Tamura. University of 
Occupational and Environmental Health, Japan, Kitakyushu-shi, Japan.
Background: Acute loss of kidney function is a critical internal stressor. The 
paraventricular nucleus (PVN) of the hypothalamus is an integrative site of the 
neuroendocrine and autonomic nervous systems that deals with a variety of aversive 
stressors. Hypothalamic arginine vasopressin (AVP) and corticotropin-releasing hormone 
(CRH) in the parvocellular division of the paraventricular nucleus (pPVN) play important 
roles in the regulation of stress responses. However, hypothalamic AVP dynamics after 
acute kidney injury remain unclear.
Methods: We generated transgenic rats that express the AVP-enhanced green 
fluorescent protein (eGFP) fusion gene. Since eGFP fluorescent intensity is a quantitative 
indicator of AVP synthesis in the transgenic rats, we evaluated AVP-eGFP fluorescence in 
the hypothalamus after the rats had undergone bilateral nephrectomy. We then examined 
AVP gene expression by in situ hybridization histochemistry. Finally, we quantified Fos-
Like immunoreactivity (IR) cells, which are used as a marker of neural activity, in several 
brain regions which modulate biological responses to severe stressors by controlling AVP 
synthesis.
Results: After bilateral nephrectomy, eGFP fluorescent intensities were significantly 
increased in the pPVN, but not in the magnocellular PVN. The mRNA levels of eGFP, AVP, 
and CRH in the pPVN were significantly increased after bilateral nephrectomy. Bilateral 
nephrectomy also caused a marked increase in Fos-IR in the locus coeruleus, nucleus of 
the solitary tract, area postrema, and rostral ventrolateral medulla, which are responsible for 
modulating sympathetic nervous system activity.
Conclusions: Bilateral nephrectomy caused upregulation of AVP synthesis and 
neuronal activity. Further studies are needed to identify the neural and/or humoral factors 
that activate the central AVP system after bilateral nephrectomy.
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Recognition of Apoptotic Cells by Viable Proximal Tubular Epithelial 
Cells (PTEC) Induces Death Receptor (DR)-Dependent Death of PTEC, 
but in a Ligand-Independent Manner
Michael E. Dietrich,2 Jerrold S. Levine,2,1 Joyce Rauch,3 Lanfei Feng.2 1Jesse 
Brown VAMC, Chicago, IL; 2University of Illinois at Chicago College of 
Medicine, Chicago, IL; 3Research Institute of the McGill University Health 
Centre, Montreal, QC, Canada.
Background: We have shown that mouse kidney PTEC have distinct non-competing 
receptors for apoptotic and necrotic targets. Receptor-mediated recognition of apoptotic, but 
not necrotic, targets induces apoptotic death of PTEC responders.
Methods: Responder cells were BU.MPT cells, a conditionally immortalized PTEC 
line. Target cells, induced to undergo apoptosis or necrosis, were homologous (BU.MPT) or 
heterologous (DO11.10 lymphocytes) cells.
Results: Apoptotic target-induced death of PTEC responders is profound (~100% 
by 48-72 h). Target-induced apoptotic death appears to involve death receptors (DRs), as 
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supported by the following data. First, death is associated with signaling events typical of 
DR-mediated apoptosis in type II epithelial cells, including cleavage of caspase-8, cleavage 
of the pro-apoptotic Bcl-2 family member BID to tBID, and activation of caspase-3. 
Second, PTEC constitutively express the DRs DR5, Fas, and TNFRI, as assessed by flow 
cytometry, and DR expression is significantly decreased following exposure to apoptotic 
targets, consistent with receptor activation and internalization. A fourth DR, DR3, is not 
expressed constitutively by PTEC, but is induced following exposure to apoptotic targets. 
Third, decreased DR expression correlates with activation of caspase-3 and induction of 
apoptosis. Surprisingly, DR activation appears to occur in a ligand-independent manner. No 
DR ligand (DR-L) expression (TRAIL, FasL, or TNF) is seen in responder PTEC by flow 
cytometry (surface or intracellular) or by ELISA (secreted into media). Moreover, target-
induced apoptosis of PTEC responders was not prevented by inhibitors of DR-L, nor was it 
induced by addition of soluble DR-L.
Conclusions: Exposure of viable PTEC to apoptotic (but not necrotic) targets induces 
PTEC apoptosis via DR-dependent mechanisms. Surprisingly, target-induced apoptosis 
occurs in a ligand-independent manner, with recognition of apoptotic (but not necrotic) 
targets leading to DR-L-independent egagement of DRs. We hypothesize that PTEC injury 
in vivo is characterized by two distinct waves of cell death. In the 1st, PTEC death is the 
direct result of ischemic or other injury. In the 2nd, PTEC death is independent of injury, and 
the result of DR activation by recognition of adjacent dead or dying cells.
Funding: Clinical Revenue Support
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Dynamin Regulates Membrane Tension in Renal Epithelial Cells by 
Establishing Architecture of Actin Cortex
Changkyu Gu,1 Henning Hagmann,2 Agnieszka Collins,1 Kamalika Mukherjee,1 
Monica H. Stevens,1 Paul T. Brinkkoetter,2 Sanja Sever.1 1Massachusetts 
General Hospital/Harvard Medical School, Charlestown, MA; 2University 
Hospital Cologne, Cologne, Germany.
Background: The GTPase dynamin is essential for podocyte structure and function as 
it plays a role in regulating endocytosis and the actin cytoskeleton. Previously, we showed 
that dynamin can directly bind to actin and regulate actin polymerization. Importantly, our 
studies demonstrated that pharmacological targeting of dynamin with a small molecule, 
Bis-T-23 that promotes formation of dynamin oligomerization (DynOLIGO), ameliorated 
kidney injury in animal models of human kidney disease by recovering functional actin 
structures in injured podocytes. Recently, dynamin is also reported to orchestrate the global 
actomyosin cytoskeleton that underlies renal epithelial cell polarity independent from its 
role in endocytosis. Here, we expand the role of DynOLIGO to include regulation of membrane 
tension, and thus endocytosis in renal epithelial cells by establishing architecture of actin 
cortex.
Methods: Polarized renal epithelial cells (Inner Medular Collecting Duct) were used 
for this study. Atomic force microscopy was utilized to determine membrane tension. Actin 
polymerization assays were performed with cell lysates from IMCD cells. The structure 
of actin filaments was evaluated by electron microscopy of negatively stained specimens. 
Endocytosis was examined in IMCD cells stably expressing eGFP-clathrin light chain by 
Total Internal Reflection Fluorescence Microscopy, followed by computer-based image 
analysis.
Results: Using a combination of distinct dynamin mutants and Bis-T-23 we show that 
DynOLIGO defines the length of actin filaments in conjunction with gelsolin. In addition, we 
show that dynamin crosslinks actin filaments into distinct structures in conjunction with its 
oligomerization state and the length of the actin filaments. Importantly, our data demonstrate 
that DynOLIGO regulates membrane tension most likely by defining and crosslinking cortical 
actin. Furthermore, dynamin’s effect on cell surface tension indirectly influences the speed 
of clathrin coated pit maturation in polarized renal epithelial cells.
Conclusions: Our study defines a novel role for DynOLIGO cycle as a direct regulator 
of membrane tension and indirect regulator of endocytosis by orchestrating actin cortex 
architecture in polarized renal epithelial cells.
Funding: NIDDK Support
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Mucin 1 Prevents Accelerated Shedding of Kidney Injury Molecule-1 
Following Ischemic Renal Injury
Mohammad M. Al-bataineh,1 Carol L. Kinlough,3 Zaichuan Mi,1 
Edwin K. Jackson,1 Rebecca P. Hughey.2 1University of Pittsburgh, Pittsburgh, 
PA; 2Dept Medicine-Renal Electrolyte Division, Pittsburgh, PA; 3Department of 
Medicine University of Pittsburgh, Pittsburgh, PA.
Background: Kidney injury molecule-1 (KIM-1) is a type I transmembrane 
glycoprotein that is rapidly induced after kidney injury in the proximal tubule (PT). The 
ectodomain of KIM-1 is cleaved and thereby constitutively shed into the urine providing 
a sensitive biomarker for kidney injury. It was reported recently that a transcription factor 
STAT3 is phosphorylated by extracellular signal-regulated kinases 1 and 2 (ERK1/2) and/
or checkpoint kinase 1 (ChK1) following kidney injury and thereby upregulates KIM-1. 
KIM-1 also has anti-inflammatory role as it mediates phagocytosis of apoptotic and necrotic 
cells (efferocytosis) following kidney injury. However, the accelerated shedding of KIM-1 
regulated by p38 MAPK blocks efferocytosis as the excess soluble KIM-1 acts as a decoy to 
cell-associated KIM-1. Mucin 1 (Muc1) is a transmembrane glycoprotein found primarily 
in the distal nephron that is also induced in the PT following kidney injury. We previously 
published data showing that Muc1 plays a protective role during ischemia-reperfusion 
injury (IRI) by stabilizing both HIF-1a and b-catenin.
Methods: More recently, using our hanging-weight protocol of 20 min ischemia and 
48 h recovery, we observed a significant two-fold higher level of urinary KIM-1 as well as 
more severe kidney injury in Muc1 KO mice when compared to wild-type (WT) littermates. 
There was no significant difference in the levels of neutrophil gelatinase-associated lipocalin 
(the distal tubule injury biomarker NGAL) between Muc1 KO and WT littermates. Based 
on these findings, we tested the hypothesis that Muc1 plays a protective role during IRI by 
modulating the pathways known to regulate PT KIM-1 activity.
Results: Immunoblots of kidney tissue revealed that levels of both ERK1/2 and 
ChK1 were significantly higher in Muc1 KO mice when compared to WT littermates. 
Furthermore, the cytoplasmic and nuclear levels of active STAT3 were significantly higher 
and thus KIM-1 levels in Muc1 KO mice when compared to WT littermates. Moreover, 
levels of phosphorylated p38 MAPK are significantly higher in Muc1 KO mice when 
compared to WT littermates which enhances KIM-1 shedding, and consequently more 
severe kidney injury.
Conclusions: These results support the likelihood that Muc1 regulates KIM-1 function 
by regulating both its expression and shedding following kidney injury.
Funding: NIDDK Support
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Gene Deletion of the Na-Glucose Cotransporter SGLT2 Does Not Affect 
Kidney Injury or Recovery in a Murine Model of Severe AKI
Josselin Nespoux, Rohit Patel, Winnie Huang, Brent Freeman, Volker Vallon. 
Department of Medicine, University of California, San Diego & VA San Diego 
Healthcare System, San Diego, CA.
Background: In normoglycemia, the renal Na-glucose cotransporter SGLT2 reabsorbs 
~97% of filtered glucose in the early proximal tubule, while SGLT1 reabsorbs the remaining 
glucose in the downstream S3 segment. Pretreatment with an SGLT2 inhibitor appeared 
protective at 24 hrs after ischemia-reperfusion (IR)-induced acute kidney injury (AKI) in 
mice (PLoS ONE 11(7):e0160478, 2016). Here we determined whether gene knockout of 
SGLT2 (KO) affects kidney injury or recovery following IR.
Methods: Male KO and wild-type (WT) mice (C57BL/6J) underwent sham surgery 
(Sham) or IR (25 min of bilateral renal artery clamping) under ketamine/xylazine anesthesia, 
while body temperature was maintained at 36-37°C (n=7-15/group). Urine and blood were 
collected at several time points. GFR was measured 14 days after IR by plasma elimination 
kinetics of FITC-sinistrin in conscious mice. Kidneys were harvested 23 days after IR for 
renal gene expression analysis by RT-qPCR.
Results: On day 1 after IR, plasma creatinine (by LC-MS-MS) increased to similar 
levels in KO-IR and WT-IR (1.96±0.19 vs 1.87±0.25 mg/dL, NS) vs Sham groups 
(0.14±0.01 vs 0.11±0.01 mg/dL, NS); fractional urinary glucose excretion (based on 
creatinine) increased from 27 to 62% in KO-IR and from 0.1 to 20% in WT-IR. IR reduced 
urine osmolality and increased plasma osmolality to a similar extent in KO-IR and WT-IR; 
this was associated with a similar increase in urinary KIM-1 to creatinine ratio, a marker 
of proximal tubule injury. On day 14, GFR was similarly reduced in KO-IR and WT-IR 
(2.4±0.2 vs 2.8±0.3 μL/min/g BW, NS) vs Sham groups (12.0±0.8 vs 11.9±0.9 μL/min/g  
BW, NS). On day 23, plasma creatinine (0.28±0.03 vs 0.32±0.03 mg/dL, NS) and plasma 
osmolality were partially restored in KO-IR and WT-IR, and urine osmolality and renal 
mRNA expression of Na-2Cl-K cotransporter NKCC2 were reduced at similar levels 
vs. Sham groups. Moreover, renal mRNA expression of markers of injury, fibrosis, 
inflammation and oxidative stress (KIM-1, type 1 collagen, TGFB1, MCP-1, NOX2) was 
significantly and similarly increased in KO-IR and WT-IR versus Sham groups.
Conclusions: Absence of SGLT2 did not affect the initial injury and impairment of 
kidney function or the subsequent partial kidney function recovery in a mouse model of 
IR-induced severe AKI.
Funding: NIDDK Support, Veterans Affairs Support
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Urinary Symmetric Dimethylarginine Reflects Mild Renal Damage After 
Cisplatin Treatment in Rats
Yuji Hotta,1 Aya Naiki-Ito,2 Ayae Kitagawa,1 Natsumi Tomita,1 Masahiro Kondo,3 
Tomoya Kataoka,4 Yasuhiro Maeda,1 Satoru Takahashi,2 Kazunori Kimura.1,4 
1Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya 
City University, Nagoya, Japan; 2Experimental Pathology and Tumor Biology, 
Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan; 
3Pharmacy, Nagoya City University Hospital, Nagoya, Japan; 4Clinical 
Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, 
Nagoya, Japan.
Background: Serum symmetric dimethylarginine (SDMA) correlates with renal 
function, but the usefulness of measuring urinary SDMA levels is unclear. Here, we studied 
if urinary SDMA levels reflected mild nephropathy after cisplatin (CDDP) treatment that 
failed to increase serum creatinine (SCr) in rats.
Methods: [Single CDDP treatment] Eight-week-old male Wistar-ST rats were divided 
into control and CDDP groups, treated with saline and CDDP 1 mg/kg intraperitoneally, 
respectively. SCr, blood urea nitrogen (BUN), and urinary and serum SDMA levels were 
measured before and 5 days after treatment. SDMA was measured by ultra performance 
liquid chromatography-tandem mass spectrometry. Damage to proximal tubules (PTs) was 
evaluated by H&E staining. mRNA expression levels of organic anion transporter1 (Oat1) 
which transports SDMA were measured by real-time PCR. [Multiple CDDP treatment] We 
formed groups that were treated with saline and CDDP 1 mg/kg every 7 days (day 0, 7, 
14, and 21) to study the effects of multiple CDDP treatment cycles. SCr, BUN and serum 
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and urinary SDMA levels were measured at day 0 and day 5 in each cycle. Damage of PTs 
were studied 28 days after treatment. Statistical analysis was performed by Welch’s t-test.
Results: [Single CDDP treatment] SCr and BUN unchanged 5 days after treatment 
between control and CDDP groups. However, necrosis of PTs was partly observed in the 
CDDP group. Urinary SDMA levels in the CDDP group significantly increased on day 5 
(P<0.01); serum SDMA levels did not change. mRNA expression levels of Oat1 unchanged 
between control and CDDP group. [Multiple CDDP treatment] SCr and BUN did not 
change even after 3 CDDP treatment cycles compared with control group. In CDDP group, 
heteromorphic regenerating endothelium was observed. Urinary SDMA in CDDP group 
was significantly increased compared with control group from day 5 until the endpoint 
(P<0.01).
Conclusions: Urinary SDMA levels reflect the mild damage of PTs after CDDP 
treatment, which SCr and BUN could not reflect. Thus, urinary SDMA may be a better 
biomarker than SCr and BUN.
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Involvement of Acid-Sensing Ion Channels in Ischemia/Reperfusion 
Induced Kidney Injury
Nana Song. Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Acidic microenvironment is commonly observed in ischemic tissue. In 
the kidney, extracellular pH dropped from 7.4 to 6.5 within 10 min initiation of ischemia. 
Acid-sensing ion channels (ASICs) represent a family of H+-activated Na+ channels. 
Among six ASICs subunits, ASIC1a and ASIC3 are high proton sensitive, which can be 
activated by pH drops from 7.4 to 7.0 or lower. However, ASIC1a is the only one that is 
permeable to Ca2+ besides Na+. Thus, activation of ASIC1a can mediate the intracellular 
Ca2+ accumulation and play crucial roles in apoptosis of neuron. The aim of the present 
study was to test the hypothesis that extracellular acidosis caused by ischemia increases 
renal epithelia cell apoptosis through ASIC1a-mediated calcium entry.
Methods: Immunofluorescence double staining and confocal analysis were applied 
to observe the co-localization of ASICs with AQP1 (proximal tubule marker), THP (thick 
ascending limbs and distal tubule marker) and Synaptopodin (podocyte marker). ASIC1a 
inhibitor PcTx-1 and ASIC3 inhibitor APETx-2 was injected previously to IR operation. 
After that, the pathological and functional injury of the kidney was assessed by PAS 
staining and serum creatinine, and the apoptosis of kidney epithelia cells was measured 
by TUNEL staining and immunohistochemical reaction of caspase3. To demonstrate the 
underlying mechanism of ASICs induced renal IRI, HK-2 cells was pretreated with PcTx-
1 before hypoxia, the intracellular concentration of Ca2+, mitochondrial transmembrane 
and apoptosis was measured by Fluo-4/AM, JC-1 and AnnexinV/PI and analyzed by flow 
cytometry.
Results: ASIC1a was found to be co-localized with AQP1 and Synaptopodin. ASIC3 
was detected majorly in podocyte and mesenchyma. IRI up-regulated the expression of 
ASIC1a, however, had little effect on ASIC3, both in vivo and in vitro. Additionally, 
blocking ASIC1a by administration of PcTx-1 protects kidney from ischemia/reperfusion 
injury. Inhibition of ASIC3 by APETx2 had no significant effect on renal ischemia/
reperfusion injury. Moreover, Blocking ASIC1a attenuated ischemia/reperfusion induced 
Ca2+ overflow, loss of mitochondrial transmembrane potential and apoptosis in HK-2 cells.
Conclusions: The results revealed that ASIC1a localized in the kidney proximal tubular 
and contributed to ischemia/reperfusion induced kidney injury. Consequently, targeting the 
ASIC1a may prove to be a novel strategy for AKI patients.
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Mechanisms of Sex-Dependent Development of Acute Renal Failure -  
Insights from Preconditioning Experiments
Karla J. Hoyer, Martin Späth, Torsten Kubacki, Marc Johnsen, Thomas Benzing, 
Bernhard Schermer, Volker R. Burst, Roman-Ulrich Mueller. University of 
Cologne, Koeln, Germany.
Background: Experimental work on acute kidney failure in mice shows a clear sex 
distribution - the severity of renal failure in females is significantly lower than in males, 
however, the mechanisms are not clear. Interestingly, preconditioning (caloric restriction, 
hypoxia) prevents acute kidney injury (AKI) reliably. The aim of the work is to evaluate 
sex-specific mechanisms of the protective effect of caloric preconditioning.
Methods: 14 week old male and female C57Bl6 wild-type mice underwent no 
preconditioning serving as a control group or four weeks of a calorie-restricted diet as a 
method of preconditioning prior to ischemia-reperfusion-injury (IRI). Afterwards, we 
compared control animals with animals after CR and males and females by phenotyping 
(histology, urea).
Results: IRI led to a pronounced kidney damage in males compared to a significantly 
lower damage in females. CR can completely prevent kidney failure in males. There is no 
significant improvement in the female mice compared to the untreated females. For further 
investigations, we performed a transcriptome analysis after preconditioning and were able 
to demonstrate the downregulation of a cytochrome P450 enzyme, Cyp4a12a, which is 
predominantly expressed in male mice. Cyp4a12a is necessary for the enzymatic production 
of 20-HETE, a derivative of arachidonic acid, which has an influence on renal regulation 
of blood pressure and volume retention. After the treatment of preconditioned animals 
with 20-HETE, the protective effect of caloric restriction can be abrogated. This suggests 
a possible relationship between the effect of preconditioning, sex, and a reduction of the 
concentration of 20-HETE.
Conclusions: The fact that female animals show a significant reduction of damage 
compared to males emphasizes the importance of the sex-specific analysis of the 
development of acute renal failure. In addition, we can report on the effect of caloric 
restriction and sex depending on the concentration of 20-HETE for the first time.
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Selective Vasopressin V1a Receptor Antagonism Improves Renal 
Oxygenation and Perfusion in AKI
Hana Cernecka, Karoline Droebner, Thomas Mondritzki, Marie-Pierre L. Collin, 
Frank Eitner, Peter Kolkhof. Bayer AG, Wuppertal, Germany.
Background: Vasopressin (AVP) is a neurohormone with a well understood role in 
urinary volume control via activation of V2 receptors expressed in the collecting duct. The 
function of renal V1a receptors, which are broadly expressed on vascular smooth muscle 
cells throughout the medullary vasa recta, in mesangial as well as in macula densa cells, is 
less well understood. Since reduced blood supply and tissue hypoxia are frequent findings in 
kidney diseases, we aimed to investigate the potential benefit of selective V1a antagonism 
(using relcovaptan, SR 49059) in rat models of acute kidney injury (AKI).
Methods: The effects of relcovaptan on renal blood flow (RBF) and tissue oxygenation 
were investigated in isolated perfused rat kidneys as well as in anesthetized rats (n=7 per 
group) via Laser Doppler Flowmetry in settings of increased AVP levels induced by either 
infusion of AVP or renal ischemia/reperfusion injury (I/RI).
Results: Relcovaptan (0.3–300 nM; p<0.001) significantly improved the AVP-mediated 
(50 nM) reduction of perfusate flow in concentration-dependent manner while having no 
effect on urine excretion. In vivo, infusion of AVP (50 ng/kg/min i.v.) significantly increased 
mean arterial pressure (137±3; mean±SEM) which was normalized by relcovaptan in a 
dose-dependent manner (108±3; p<0.01). Infusion of AVP reduced both renal perfusion and 
tissue oxygenation (pO2; 7.5±4). Relcovaptan dose-dependently restored renal perfusion 
and significantly increased pO2 (30.7±6.4; p<0.01). Systemic hemodynamic parameters 
remained stable under I/RI conditions and concomitant infusion of relcovaptan. Fifteen 
minutes of ischemia resulted in decreased levels of both RBF and pO2 after reperfusion in 
comparison with basal levels. In contrast, selective V1 a receptor antagonism significantly 
improved pO2.
Conclusions: Selective V1a inhibition exerts beneficial effects on renal oxygenation 
under different pathological settings and might be a promising therapeutic approach to 
improve kidney hypoxia and subsequently kidney function in conditions of increased AVP 
levels, such as AKI and CKD.
Funding: Commercial Support - Bayer AG
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Partitioning Defective Par1a Deletion Attenuates Renal Fibrosis in Mice
Estefany Maria,2 Abhijeet Pal,4 Zhongfang Du,3 Kimberly J. Reidy.1 1Pediatrics/ 
Nephrology, Children’s Hospital at Montefiore/ Albert Einstein College of 
Medicine, Bronx, NY; 2Albert Einstein College of Medicine, Bronx, NY; 3Albert 
Einstein College of Medicine, Children’s Hospital at Montefiore, Bronx, NY; 
4The Children’s Hospital at OU Medical Center, Oklahoma City, OK.
Background: Chronic kidney disease (CKD) affects 1 in 7 U.S. adults; CKD leads to 
both increased morbidity and mortality. CKD progression correlates with tubulointerstitial 
fibrosis. As shown in mouse models, fibrosis is driven by Notch and Wnt activation. 
Notch and Wnt are important renal developmental pathways. In prior work from our 
laboratory focused on the developing kidney, Notch signaling pathway expression was 
decreased in Par1a/b mutant mice (Par1a+/-:Par1b-/-). Par1a and 1b are serine threonine 
kinases: they regulate protein trafficking, cell-cell adhesion, cell-matrix adhesion and the 
actin cytoskeleton. Par1a and 1b are paralogues and compensate for one another: while 
Par1a+/-:Par1b-/- mice die after birth, individual Par1a or 1b knockout mice have no renal 
developmental phenotype. We hypothesized: Loss of Par1a or 1b would attenuate Notch 
signaling and renal fibrosis.
Methods: To examine the expression of Par1a/b and Notch signaling components 
in renal injury, immunoflorescence (IF) staining was performed; Par1a and 1b paralogue 
specific antibodies were used. For acute kidney injury, mice were injected with 20 mg/kg 
cisplatin injection i.p. For chronic kidney injury, folic acid nephropathy and unilateral 
ureteral obstruction were used. To test the role of Par1a in renal fibrosis, folic acid injection 
(250 mg/kg dissolved in 300 mM NaHCO3) was performed in Par1a-/- and Par1a+/+ 
mice. Vehicle injected mice served as controls. To detect renal fibrosis, Picrosirius red 
staining of collagen was performed. Quantification of 20x images was performed using 
Image J.
Results: Par1b expression increased in acute kidney injury, while Par1a expression 
increased predominantly in chronic kidney injury models. Consistent with other studies, 
Notch signaling component expression also increased following kidney injury. Folic acid 
injected Par1a-/- mice had decreased renal fibrosis: as quantified by sirius red staining, 
percent area of fibrosis was 12 +/- 6.8 % in folic acid treated Par1a+/+ vs 3 +/- 2.2% in 
Par1a-/- kidneys. (p-value <0.01)
Conclusions: Par1a and Notch signaling pathway member expression are increased in 
renal fibrosis mouse models. In mice, Par1a deletion was protective against fibrosis. Par1a 
is a potential modifier of Notch activation during renal fibrosis.
Funding: NIDDK Support
Molecular Mechanisms of CKD - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
446
J Am Soc Nephrol 29: 2018 Poster/Friday
FR-PO103 Poster Friday
Molecular Mechanisms of CKD - II
A Downstream Molecule of 1,25-Dihydroxyvitamin D3, Alpha-1-Acid 
Glycoprotein, Protects Against Mouse Model of Renal Fibrosis
Jing Bi,1,2 Hiroshi Watanabe,3 Rui Fujimura,4 Kento Nishida,5 Ryota Nakamura,3 
Shun Oshiro,6 Tadashi Imafuku,6 Masako Miyahisa,6 Toru Maruyama.3 1Dept of 
Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto 
University, Kumamoto, Japan; 2Program for Leading Graduate Schools “HIGO 
(Health life science: Interdisciplinary and Glocal Oriented) Program”, 
Kumamoto University, Kumamoto, Japan; 3School of Pharmacy, Kumamoto 
University, Kumamoto, Japan; 4Kumamoto university, Kumamoto-shi, Japan; 
5Department of Biopharmaceutics, School of Pharmacy, Kumamoto University, 
Kumamoto-shi, Japan; 6Kumamoto University, Kumamoto, Japan.
Background: Renal fibrosis, the central feature of the progression of chronic kidney 
disease, is associated with unremitting renal inflammation. 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), the active form of vitamin D, has been reported for its anti-renal fibrotic 
effect in model of unilateral ureteral obstruction (UUO), but its molecular mechanism is 
still unknown.
Methods: ICR mice (male, 4-week-old) were randomized and anaesthetized before 
the abdomen was opened, then the left ureter was ligated with 4-0 silk and the abdomen 
was closed with sutures. 1,25(OH)2D3 was administered i.p. daily from day 0 to day 6 
of the UUO treatment. Alpha-1-acid glycoprotein (AGP) was administered i.v. daily from 
day 1 to day 6 of the UUO treatment. Mice were sacrificed on day 7 after surgery. Phorbol 
12-myristate 13-acetate (PMA)-treated THP-1 cells or HepG2 cells were treated with
1,25(OH)2D3 or AGP and incubated for 48 hr. LPS were incubated for 48 hr. Real-time
PCR, immunofluorescence and Picrosirius Red staining were performed.
Results: Renal fibrosis and inflammation observed in the kidney of the UUO mice 
were attenuated by the treatment of 1,25(OH)2D3. Interestingly, the plasma protein level of 
AGP, a downstream molecule of 1,25(OH)2D3, was increased following the administration 
of 1,25(OH)2D3 to healthy mice. Additionally, the increase of ORM1, an AGP gene, was 
observed in 1,25(OH)2D3-treated HepG2 cells and THP-1-derived macrophages. To 
investigate the involvement of AGP, exogenous AGP was administered to the UUO mice, 
resulting in attenuated renal fibrosis and inflammation. Regarding the mechanism, we found 
the mRNA expression of CD163, a monocyte/macrophage marker with anti-inflammatory 
potential, was increased in THP-1-derived macrophages under 1,25(OH)2D3 or AGP 
stimulus, respectively. Moreover, AGP prevented lipopolysaccharide-induced macrophage 
activation.
Conclusions: We found for the first time that AGP could be a key molecule in the 
protective effect of vitamin D against renal fibrosis. AGP may function as an important 
immune regulator, replacing vitamin D to offer therapeutic strategy for renal inflammation 
and fibrosis.
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Reduction of Excess Renal Iron Acquisition Diminishes Tubular Injury in 
Experimental Focal Segmental Glomerulosclerosis
Rachel Van swelm,2 Sanne Beurskens,1 Henry Dijkman,1 Jack F. Wetzels,1 
Erwin Wiegerinck,1 Rian Roelofs,1 Johan Van der vlag,1 Bart Smeets,1 
Dorine W. Swinkels.1 1Radboud University Medical Center, Nijmegen, 
Netherlands; 2Radboud University Medical Centre, Nijmegen, Netherlands.
Background: Renal iron accumulation as a result of proteinuria is suggested to play 
a role in progression of chronic kidney disease (CKD). Here, we studied the molecular 
mechanisms of renal iron loading in experimental focal segmental glomerulosclerosis 
(FSGS; Thy-1.1 mouse model) and investigated if reduction in renal iron loading decreased 
tubular injury.
Methods: Thy-1.1 mice were injected with a monoclonal anti-Thy-1.1 antibody (mAb) 
or saline as control and sacrificed immediately after injection (D1), day 8 (D8) or day 22 
(D22).
Results: Injection of mAb resulted in immediate and persistent albuminuria (p<0.01). 
Renal injury in mAb-injected mice was confirmed by standard histology, increased urinary 
kidney injury markers KIM1 (p<0.05) and NGAL (p<0.01) and elevated renal mRNA 
expression of IL-6 (p<0.001) and HO-1 (p<0.01). Increased distal tubular iron accumulation 
was observed with increasing renal injury in mAb-treated mice. QPCR analysis indicated 
distal iron accumulation via the NGALR and not transferrin receptor-1 (TfR1). In vivo 
silencing of renal NGALR resulted in significantly reduced HO-1 and L-ferritin mRNA 
levels at D8 (both p<0.05), indicating reduced iron accumulation and injury. Systemic 
iron depletion by iron-deficient diet reduced renal iron accumulation and urinary KIM1 
and NGAL on D8 (both p<0.05), but not D22. Interestingly, the iron-deficient diet did not 
reduce renal IL-6 mRNA, whereas an iron-rich diet diminished IL-6 (D22, p<0.001) and 
urinary KIM1 (p<0.05) and NGAL (p<0.001) on D8 and D22, despite concurrent increased 
iron deposition and oxidative stress as indicated by HO-1 immunostaining and mRNA 
expression (p<0.001). Alternatively, we aimed to prevent excess renal iron deposition by 
reducing glomerular protein filtration (captopril; CA) or iron chelation (deferoxamine; 
DFO) for 7 days after mAb injection. Both CA and DFO reduced renal iron accumulation, 
and urinary KIM1 and NGAL (p<0.05) on D8, which did not last until D22, suggesting 
requirement for continuous treatment.
Conclusions: In conclusion, our results indicate that prevention of excess renal iron 
accumulation could be useful to halt progression of tubular injury in CKD. However, 
disturbances in systemic iron balance are not feasible, warranting a targeted renal approach.
Funding: Private Foundation Support
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TRPM7 Is a Potential Therapeutic Target in Progressive Renal Disease
Sayuri Suzuki.1,2 1Queen’s Center for Biomedical Research, The Queen’s 
Medical Center, Honolulu, HI; 2University of Hawaii Cancer Center, John A. 
Burns School of Medicine, University of Hawaii, Honolulu, HI.
Background: Unilateral Ureteral Obstruction (UUO) is a representative model 
of nephritis with progressive tubulointerstitial injury and renal fibrosis occurring by 
inflammation that is suitable for investigating the cellular and molecular events that occur 
during progressive renal fibrosis associated with cell proliferation and apoptosis. Blocking 
tubular epithelial cell proliferation is crucial to preventing the renal tubule dilation and 
the progression of kidney damage. TRPM7 belongs to the Transient Receptor Potential 
Melastatin family of ion channels. Our work shows that TRPM7 is a Ca2+- and Mg2+-
conducting ion channel fused with a functional kinase. TRPM7 plays a key role in a variety 
of diseases, including malaria invasion, neuronal death in ischemia, cancer and cardiac 
fibrillation. TRPM7 is aberrantly over-expressed in lung, liver and heart fibrosis. It is also 
overexpressed after renal ischemia-reperfusion, an event that induces kidney injury and 
fibrosis. However, the role of TRPM7 is unclear in kidney fibrosis.
Methods: We created UUO mouse model, compared the expression level of TRPM7 
in UUO kidneys and control kidneys at Day7 using qRT-PCR, western blotting assay and 
immunohistochemistry. Our lab’s drug screening efforts have identified waixenicin A that is 
the currently only specific and potent TRPM7 inhibitor. Using NRK49F and NRK52E cells, 
we investigated the inhibitory efficacy of waixenicin A on MTT cell growth assay.
Results: The expression levels of TRPM7 mRNA and protein in UUO kidneys were 
higher than control kidneys, TRPM7 particularly increased on tubular epithelial cells. The 
TRPM7 positive cell number increased twice on both of renal tubular epithelial cells and 
tubulointerstitial cells in UUO kidneys compared to control kidneys. Waixenicin A inhibited 
the cell growth of renal epithelial cells and fibroblasts in vitro.
Conclusions: TRPM7 up-regulated in progressing inflammatory renal damage, 
waixenicin A could be capable of inhibiting kidney cell proliferation and fibrosis in renal 
disease.
Funding: Private Foundation Support
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Apolipoprotein L1 Is Associated with Larger HDL Particles in CKD
Andrew N. Hoofnagle,1 Michael L. Andrews,2 Zsuzsanna Kuklenyik,2 Ian H. de 
Boer,1 Bryan R. Kestenbaum.1 1University of Washington, Seattle, WA; 2Centers 
for Disease Control and Prevention, Atlanta, GA.
Background: Apolipoprotein L1 (ApoL1) is a potential mediator of inflammatory 
kidney injury and disease progression. Two polymorphisms in the APOL1 gene 
(G1 and G2) increase the risk of chronic kidney disease (CKD) in Blacks. The mechanism 
of injury may involve ApoL1 expressed within the kidney (e.g., in podocytes) and/or ApoL1 
secreted by the liver (i.e., in plasma). We have previously demonstrated that ApoL1 is 
depleted from the HDL2/3 fraction of plasma in patients with lower eGFR. In this study, we 
aimed to quantify the distribution of ApoL1 within plasma to help clarify the biochemistry 
of ApoL1.
Methods: We determined ApoL1 phenotype and plasma concentrations using targeted 
mass spectrometry (MS) among 424 participants from the Seattle Kidney Study, a racially 
diverse, well-characterized cohort of patients with CKD. For 20 participants, we used 
asymmetric flow field-flow fractionation (AF4) to fractionate plasma into 40 fractions, 
which were each analyzed using MS to determine relative concentrations of ApoL1.
Results: Plasma concentration of ApoL1 was associated with age, race, and ApoL1 
phenotype (Table 1). In addition, both plasma concentration of ApoL1 and the ratio of 
the amount of ApoL1 in HDL to total plasma ApoL1 were directly correlated with eGFR. 
However, only the ratio of ApoL1 in HDL to total ApoL1 was significantly associated with 
eGFR, after controlling for age, race, and phenotype, which suggested that ApoL1 is located 
in a different fraction of plasma in CKD. We then used AF4 and MS to determine that 
ApoL1 is associated with larger particles (similar to HDL1 particles containing ApoE) in 
participants with lower eGFR, after controlling for race and genotype (p<0.01).
Conclusions: These results demonstrate that plasma ApoL1 is biochemically different 
in patients with reduced eGFR, which may be related to the role ApoL1 plays in the 
progression of CKD.
Funding: NIDDK Support, Other NIH Support - NHLBI
1White or G0/G0 individuals as comparator. 2Model with age, race, number of risk alleles, 
and eGFR included.
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Inhibiting ApoL1 Translocation to Mitochondrial Matrix Can Protect 
Against Risk Variant Mediated Cytotoxicity
Shrijal Shah,1 Herbert F. Lannon,1 Leny Dias,1 Martin R. Pollak,2 
David J. Friedman.2 1Beth Israel Deaconess Medical Center, Boston, MA; 2Beth 
Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Background: African Americans with two copies of ApoL1 risk variants (G1 and G2) 
are at high risk of developing chronic kidney disease. The subcellular localization of ApoL1 
based on imaging studies has been a subject of conflicting reports.
Methods: HEK293 stable cells that express G0, G1, G2 in the presence of tetracycline 
were made using the T-Rex system. Cells were transfected with siRNA for specific outer 
mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM) translocase 
machinery components and then ApoL1 expression was induced with tetracycline. After 
ApoL1 induction, mitochondrial and cytosolic fractions were prepared by differential 
centrifugation and presence of ApoL1 in each fraction was determined by immunoblotting. 
We also measured oxygen consumption rate using a Seahorse assay and measured 
cytotoxicity after knocking down specific OMM and IMM components.
Results: Using a biochemical approach to study ApoL1 localization, we found 
a large fraction of G0 as well as G1 and G2 in the mitochondria. Protease digestions of 
isolated mitochondria demonstrated that ApoL1 protein had been translocated into the 
mitochondrial matrix. siRNA knock-down of OMM protein TOMM20, which is involved 
in recognizing matrix-targeting presequences on nuclear-encoded proteins, reduces ApoL1 
levels in mitochondria. TOMM20 knockout also rescues G1 and G2 mediated mitochondrial 
dysfunction as measured by oxygen consumption rate and reduces cell death. Knock-down 
of TIMM23/TIMM17 complex components, which are essential for translocating matrix-
targeted proteins, rescues G1- and G2-mediated cytotoxicity whereas knock-down of 
TIMM22, which is essential for protein insertion into the IMM, has no effect.
Conclusions: G1 and G2 need to translocate to mitochondrial matrix to induce toxicity. 
Since both G0 and risk variants are translocated to the mitochondrial matrix, elucidating 
different behavior of these variants after mitochondrial translocation will be important for 
understanding why only the risk variants cause kidney injury.
Funding: Other NIH Support - National Institute on Minority Health and Health 
Disparities, Other U.S. Government Support, Commercial Support - Vertex Pharmaceuticals
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Combined Effects of GSTM1 Deficiency and Podocyte-Specific APOL1 G0 
and G2 Transgene on Blood Pressure and Albuminuria in a Mouse Model 
of CKD
Shirin Pourafshar, Sylvia Cechova, Behnam Keshavarz, Rosa Chan, Thu H. Le. 
University of Virginia, Charlottesville, VA.
Background: We reported that GSTM1 null allele (GSTM1(0)) is associated with 
accelerated kidney disease progression in the African Americans Study of Kidney Disease 
(AASK) participants, and those carrying both GSTM1(0) and APOL1 risk variants had the 
worst composite outcomes. This suggests a potential interaction between these 2 genes in 
CKD. Transgenic mice expressing the human APOL1 high risk variants in podocytes did 
not show kidney disease at baseline; however, females developed preeclampsia during 
pregnancy. The objective of this study was to investigate whether GSTM1 interacts with 
APOL1 to influence hypertension (HT) and kidney disease development in a mouse model 
of CKD.
Methods: We generated Gstm1 deficient mice on the FVB background. We crossed the 
FVB Gstm1-/- mice with FVB podocyte specific APOL1 G0 or G2 Transgenic mice (TgG0 
and TgG2), respectively. The offspring were subjected to subtotal nephrectomy (Nx). Wild-
type FVB were used as controls. After a 10-day training period, baseline systolic blood 
pressure (SBP) and SBP 6-8 weeks after Nx were measured using tail-cuff method. Urinary 
albumin and creatinine were measured using commercially available ELISA kits. Data are 
reported as means ± SD.
Results: There were no significant differences in albumin/creatinine ratios among 
groups. However, Gstm1-/-/APOL1TgG2 mice had significantly higher SBP compared to 
other groups and also higher than Gstm1-/-/APOL1TgG0 (P < 0.05) (see graph).
Conclusions: In experimental CKD, mice carrying podocyte specific APOL1 G2 Tg 
and deficient of GSTM1 enzyme have worst HT, independent of albuminuria. These results 
suggest a potential interaction between these two genes in the development of HT in CKD.
Gstm1-/-/APOL1TgG2 mice had significantly higher SBP compared to other groups.
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Glomerular Endothelial Cell Senescence Drives Aged-Related Glomerulo-
sclerosis via PAI1
Camille Cohen,1 Océane Le goff,1 Frederic Soysouvanh,4 Lucile Amrouche,1 
Alexandre Karras,2 Dominique Nochy,2 Fabien Milliat,3 Fabiola Terzi.1 
1INSERM U1151 mechanisms and therapeutic strategies of chronic kidney 
disease, Hopital Necker, Paris, France; 2Hopital Europeen Georges Pompidou 
- Assistance Publique Hopitaux de Paris, Paris, France; 3IRSN, Fontenay-aux
Roses, France; 4Institute for Radioprotection and Nuclear Safety, Fontenay-
aux-Roses, France.
Background: Chronic kidney disease (CKD) is a major public health problem with 
a prevalence that dramatically increases with age. One of the most frequent histological 
lesions observed in elderly is glomerulosclerosis. However, its pathophysiology is still 
unclear. A recent study indicated that cellular senescence may be implicated since targeted 
apoptosis of senescent cells in aging murine models delays glomerulosclerosis. However, 
how cellular senescence triggers the development of glomerulosclerosis is unknown. 
Elucidating this issue was the aim of our study.
Methods: In this aim, we used several murine models including wild type and 
transgenic mice experiencing physiological and accelerated aging.
Results: As expected, 24 months-old mice developed sclerotic glomeruli as 
compared to 4 months-old mice. Beta-galactosidase and 53BP1 staining revealed 
increased glomerular cell senescence with age. Interestingly, colocalization experiments 
demonstrated that senescence interested almost exclusively endothelial cells. Consistently, 
we observed that endothelial glomerular cells were blocked in G1. This phenotype was 
associated with an increased expression of several components of the senescence associated 
secretory phenotype (SASP). Among these, plasminogen activator inhibitor 1 (PAI1), a 
senescence inducer and mediator, was particularly interesting, since its expression increased 
in endothelial cells. These results were confirmed in an experimental mouse model of 
accelerated aging (sublethal irradiation at 8 weeks and sacrifice 12 months later) as well as 
in patients treated with genotoxic. Interestingly, specific deletion of PAI1 in endothelial cells 
prevented cell senescence and the development of glomerulosclerosis during physiological 
aging in transgenic VECad-CreXPAI1flox/flox mutant mice. Podocytes loss was also decreased 
in transgenic mice, suggesting a cross-talk between endothelial cells and podocytes.
Conclusions: In conclusion, our study uncovers the critical role played by endothelial 
senescence in the development of glomerulosclerosis and podocyte rarefaction in aging 
and identified PAI1 as a novel promising therapeutic target for preventing age-related CKD 
progression.
Funding: Government Support - Non-U.S.
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The Roles of Uremic Toxin Early Elimination on AKI to CKD Transition
Jia-Huang Chen, Chih-Kang Chiang. National Taiwan University, College of 
medicine, Taipei, Taiwan.
Background: The post-AKI fibrosis is emerging as a major driver of progressive CKD. 
However, the cause of abnormal renal recovery after AKI is multifactorial and still poorly 
understood. Indoxyl sulfate (IS) is a protein-bound uremic toxin produced by bacterial 
metabolism of the amino acid tryptophan, which excreted through organic anion transporter 
on renal tubular epithelial cells into urinary and generally accumulates in patients with 
CKD. Although the adverse effects of IS on CKD progression have been well documented, 
its impacts on post-AKI fibrosis are still unknown. Accordingly, we investigated whether 
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AKI induces an increased level of serum IS and its role in AKI to CKD transition. Also, the 
therapeutic potency of early elimination of uremic toxins by absorbent Kremezin (AST-
120) was tested.
Methods: In animal study, the two-step unilateral ischemia reperfusion injury with
contralateral nephrectomy (hereafter abbreviated as UIRI) was used as a post-AKI fibrosis 
model. Briefly, C57BL/6 mice were subjected to 30 minutes unilateral ischemia reperfusion 
injury and contralateral nephrectomy were conducted at day10, and then sacrificed at day 
15. All mice are randomly divided into: (1) Sham, (2) UIRI, (3) UIRI + indole, (4) UIRI
+ indole+ AST-120, and (5) UIRI + AST-120. For in vitro investigation, HK-2 cells were
treated with 1mM IS for 48 h, followed by 12 hours of hypoxia and 24 hours of reperfusion
(H/R) to explore the underlying mechanism.
Results: In our animal studies, we observed an increased serum IS levels without 
simutaneous accumulation of small uremic toxin molecules following 10 days of UIRI. 
Furthermore, AST-120 administration actually reduced deterioration of renal function caused 
by UIRI combined with high protein intake. We also revealed the possible mechanisms 
underlying the IS-enhanced proximal tubule damage after AKI. IS exposure potentiated 
H/R-induced G2/M cell cycle arrest, which also aggravated ER stress-mediated epithelial 
mesenchymal transition (EMT) as demonstrated by 4-PBA-treated rescue experiments.
Conclusions: Our results support the pathological role of uremic toxins in post-
ischemic AKI fibrosis, and low protein diets would be recommended to prevent advanced 
kidney disease progression. Furthermore, elimination of IS by AST-120 is likely to prove 
useful for the prevention/treatment of post-AKI renal impairment.
Funding: Government Support - Non-U.S.
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Kidney Genome Atlas: A Whole-Genome Landscape of More Than 2,000 
Kidney Disease Patients
Wei Zhang,1 Thomas Soare,1 Adam Tebbe,1 Liron Walsh,1 Matthias Kretzler,2 
Girish N. Nadkarni,3 Rasheed A. Gbadegesin,4 Jamie L. Wenke,5 Peter H. Mundel,1 
Thomas T. Tibbitts.1 1Goldfinch Bio, Cambridge, MA; 2U.Michigan, Ann Arbor, 
MI; 3Ichan School of Medicine, New York, NY; 4Duke University Medical Center, 
Durham, NC; 5Nashville Biosciences, Nashville, TN.
Background: Chronic kidney disease (CKD) is a heterogeneous disease affecting more 
than 30 million people in the US, which is about 10% of the US population. Despite the 
urgent need for targeted therapeutics, the understanding of the mechanistic basis of CKD 
including the genetic variants that potentially drive it has lagged other diseases (e.g. cancer) 
for decades.
Methods: Here we report the generation and initial analysis of the Kidney Genome 
Atlas (KGA), the world’s largest whole-genome landscape of individuals with molecularly 
defined kidney diseases. Focusing initially on focal segmental glomerulosclerosis 
(FSGS), related disorders, and diabetic kidney disease (DKD), KGA contains whole 
genome sequences (>30X coverage) from more than 2,000 patients and 2,500 matched 
healthy controls. Each genome is linked to longitudinal clinical records and for a subset 
of 500 patients, the atlas also includes matched transcriptomic data from microdissected 
glomerular and tubulointerstitial samples.
Results: The KGA has enabled the discovery of genetic variants associated with kidney 
disease and the integration of genomic and transcriptomic data to identify kidney disease-
specific expression quantitative trait loci (eQTLs). The atlas also provides the foundation 
for establishing the relationships between genetic variants, histologic diagnoses, and 
quantitative clinical phenotypes of kidney function and disease progression. Computational 
integration of these datasets will enable the prioritization of candidate variants with putative 
disease modulating effect. Investigating and validating biological pathways derived from 
these analyses can also be used to stratify patients into subtypes most likely to respond to 
specific targeted therapies.
Conclusions: The KGA is a valuable resource fueling our understanding of the 
molecular mechanisms of kidney diseases at the whole genome scale.
Funding: Commercial Support - Goldfinch Bio.
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Sodium and Phosphate Dietary Additives Exacerbate Progression of CKD 
and Lead to Early Mortality
Claire Gerber,1 Samantha Neuburg,1 Corey Dussold,1 Lixin Qi,1 
Guillaume Courbon,1 Maralee Capella,1 Connor Francis,1 Xueyan Wang,1 
Myles Wolf,2 Aline Martin,1 Valentin David.1 1Northwestern University - 
Feinberg School of Medicine, Chicago, IL; 2Duke University, Durham, NC.
Background: Fibroblast growth factor 23 (FGF23) increases in response to high 
phosphate diets and states of impaired phosphate excretion, such as chronic kidney disease 
(CKD). Excess FGF23 hasemerged as a novel and powerful risk factor for cardiovascular 
disease (CVD) and death in patients with CKD and in the general population. Multiple 
studies have shown that excess FGF23 is often due to high consumption of processed foods, 
enriched in phosphate and sodium additives, that stimulate FGF23 production and increase 
risks of death. We hypothesized that consumption of excess phosphate stimulates FGF23 
production, and that presence of CKD and simultaneous consumption of excess sodium 
exacerbates FGF23 negative outcomes.
Methods: To investigate the effects of dietary intake of phosphate and sodium on 
cardiovascular and CKD disease progression, 5 week old wild-type (WT) and Col4a3KO 
(CKD) mice were fed a control (Ctr), high sodium (HN), high phosphate (HP), or a high 
sodium-high phosphate (HPN) diet for 18 weeks. We assessed survival, renal function and 
serum FGF23 in 23 week old mice.
Results: Phosphate and/or sodium did not impact renal function or overall survival 
in WT mice. In contrast, HP, HN and HPN diets further impaired renal function in CKD 
animals compared to CKD-CTR mice. HP and HN diets decreased survival in CKD mice, 
CKD-HN and CKD-HP mice showing an average survival of 26 and 22 weeks, repectively, 
compared to CKD-CTR mice that live in average 34 weeks (p<0.05). Interestingly, 
phosphate and sodium in HPN diet did not show additive effects on the overall survival of 
CKD mice (27 weeks). Consumption of phosphate in HP and HPN diets increased (p<0.05) 
FGF23 in WT mice, by 20 fold in WT-HP and by 3 fold in WT-HPN compared to WT-
CTR mice, whereas HN did not affect FGF23 levels in WT mice. CKD-CTR mice showed 
increased FGF23 (3 fold) compared to WT-CTR mice. HP, HN and HPN diets all increased 
FGF23 in CKD groups, with the highest increase found in CKD-HP mice (20-fold) while 
CKD-HN and CKD-HPN animals showed only 3 and 5 fold increase respectively, in FGF23 
(p<0.05 vs CKD-CTR).
Conclusions: Overall, our data suggest that consumption of high phosphate rather than 
high sodium raises FGF23 in CKD, exacerbates decline in kidney function, and leads to 
early mortality.
Funding: NIDDK Support, Private Foundation Support, Government Support - Non-
U.S.
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Translational Profiling and RNA-Seq of Proximal Tubule Reveals 
Gender-Specific Transcriptional Patterns, Tubulointerstitial Signaling, 
and lncRNA Regulation During Kidney Fibrosis
Chun-Fu Lai,1,2 Haojia Wu,1 Monica Chang Panesso,1 Benjamin D. Humphreys.1 
1Division of Nephrology, Department of Medicine, Washington University in St. 
Louis School of Medicine, St. Louis, MO; 2Department of Internal Medicine, 
National Taiwan University Hospital, Taipei, Taiwan.
Background: Proximal tubule epithelial cells (PTEC) are central mediators of 
interstitial fibrosis in CKD. We applied Translating Ribosome Affinity Purification (TRAP) 
followed by RNA-seq to precisely measure the gene expression landscape of PTEC during 
renal fibrosis.
Methods: Bigenic Slc34a1GFPCreERT2; R26eGFP-L10a mice received tamoxifen to activate 
expression of eGFP-L10a in PTEC with subsequent unilateral ureteral obstruction (UUO) 
surgery. Kidneys were harvested at day 5 or 10. Each group included three female and four 
male mice. PTEC-specific polysomal mRNA was isolated by affinity purification, and each 
sample sequenced to a depth of 30 million reads. Extensive informatic analysis identified 
critical genes and pathways, which were validated by in situ hybridization.
Results: Unexpectedly, we identified a group of genes with sexually dimorphic 
expression patterns including neuronal regeneration related protein (Nrep), interleukin 34 
and nuclear factor interleukin-3-regulated protein (Nfil3). For both sexes, serpin family A 
member 10 (Serpina10), vascular cell adhesion molecule 1 (Vcam1), SRY-box 9 (Sox9), 
and nerve growth factor (Ngf) top the list of PTEC-specific highly upregulated genes after 
UUO. Functional annotations transcriptional changes in PTEC implicate the interleukin-
1β and tumor necrosis factor signaling pathways in mediating tubule-interstitial crosstalk. 
Contrary to published reports, PTEC strongly upregulated Indian hedgehog (Ihh), not Sonic 
hedgehog (Shh), during renal fibrosis. All results were validated by quantitative PCR and 
in situ hybridization. Finally, two long intergenic noncoding RNAs (Snhg18 and predicted 
gene 20513) and microRNA 6358 were strongly upregulated in injured PTEC, suggesting 
novel regulatory roles in fibrosis. None of these genes have been described in kidney 
previously.
Conclusions: This is the first comprehensive RNA-seq-based transcriptional profile 
of PT cells during fibrosis. We reveal unexpected gene expression differences in male vs. 
female PT, validate novel pathways mediating tubule-interstitial crosstalk and identify 
novel lncRNA upregulation not previously associated with kidney.
Funding: NIDDK Support
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BION-1301: A Novel Fully Blocking APRIL Antibody for the Treatment of 
IgA Nephropathy
John Dulos, Paul Vink, Hans Van eenennaam, Andrea Van elsas. Aduro Biotech 
Europe, Oss, Netherlands.
Background: A PRoliferation Inducing Ligand (APRIL, TNFSF13) is a ligand for the 
receptors B cell maturation antigen (BCMA) and Transmembrane activator and CAML 
interactor (TACI). APRIL serum levels were found to be enhanced in patients diagnosed 
with IgA Nephropathy (IgAN) and treatment with an anti-mouse APRIL antibody reduced 
serum IgA and proteinuria increase in an IgAN mouse model (Kim Y.G. et al. PLOS one 
Sep 8, 2015). Altogether suggesting that the APRIL-axis is important in IgAN pathology 
and strongly supporting the development of our anti-APRIL antibody, BION-1301 to treat 
IgA nephropathy (IgAN).
Methods: BION-1301 affinity, binding to APRIL and blocking capacity to BCMA 
and TACI was characterized using Biolayer Interferometry and ELISA. A sinlge-dose non-
human primate (NHP) PK and tolerability study was performed administering intravenous 
(i.v.) BION-1301 at 0.3, 3 and 30 mg/kg. Preclinical safety was assessed in a 4-week repeat-
dose NHP study using weekly i.v. doses of 10, 30 and 100 mg/kg. In human primary B-cell 
cultures the effect of (anti-)APRIL on IgA production, BCMA and TACI expression was 
assessed.
Results: We developed a novel humanized high-affinity anti-APRIL antibody BION-
1301 (KD 0.4 ± 0.15 nM, EC50 0.29 ± 0.05 nM). Its epitope was mapped to the BCMA 
and TACI binding site conferring fully blocking capacity to BION-1301. Blocking potency 
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(IC50) was 1.61± 0.78 nM (BCMA) and 1.29 ± 0.89 nM (TACI) respectively. The mouse 
anti-human parental antibody hAPRIL.01A inhibited APRIL-dependent B-cell proliferation 
and IgA production in vitro and in vivo (Guadagnoli et al. Blood Jun 23;117, 2011). In 
B-cell cultures, hAPRIL.01A reduced IgM, IgA and IgG-secreting cells after CpG pulse
and APRIL stimulation. Following administration of a single-dose of BION-1301 to
NHP, PK parameters typical for human IgG4 antibodies were observed, and confirmed a 
lack of tolerability issues. In a 4-week repeat dose NHP study BION-1301 demonstrated
a favorable safety profile (No Observed Adverse Event Level was 100 mg/kg). 
Chronic exposure to BION-1301 led to a significantly reduced IgA level vs baseline of 
-50±14, -52±14, -59±7 % at 10, 30 and 100 mg/kg respectively.
Conclusions: Here, we report the in vivo and in vitro mechanism of action of a novel 
humanized APRIL neutralizing antibody modulating IgA, support the development of
BION-1301 for the treatment of IgAN.
Funding: Commercial Support - Aduro Biotech
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Follistatin as a Novel Therapeutic Agent in CKD
Neel Mehta,1 Dan Zhang,2 Richard Van krieken,1 Juehua He,1 Bo Gao,2 
Joan C. Krepinsky.1,2 1McMaster University, Hamilton, ON, Canada; 2St. 
Joseph’s Hospital, Hamilton, ON, Canada.
Background: Chronic kidney disease (CKD), characterized by progressively 
worsening glomerular and interstitial fibrosis accompanied by declining kidney function, 
is a major cause of morbidity and mortality. Follistatin (FST) is a glycoprotein which 
neutralizes members of the TGFβ superfamily, most prominently the activins. It does not 
directly inhibit TGFβ1. Recent studies have shown an increase in activin A in serum of mice 
with CKD. Here we assess the therapeutic efficacy of FST in a mouse model of CKD with 
reduced renal mass and proteinuria.
Methods: Male CD1 mice underwent either a 5/6 nephrectomy or sham surgery, after 
which 5μg human recombinant FST (PB01, Paranta Biosciences Ltd) or vehicle was given 
intraperitoneally every other day for 9 weeks. At endpoint, blood pressure, renal function, 
albuminuria and renal pathology were assessed.
Results: Activin A was significantly upregulated in the serum and kidneys of mice with 
CKD. Activation of Smad3, a downstream mediator of activin A signaling, was increased 
in CKD kidneys. This was inhibited by FST. Mice with CKD had elevated blood pressure, 
a significantly diminished glomerular filtration rate (GFR) and severe albuminuria. 
Pathologically, mice with CKD had prominent glomerulosclerosis and tubulointerstitial 
fibrosis, assessed using trichrome and picrosirius red staining. Immunoblotting showed 
increases in the profibrotic cytokine CTGF and the matrix proteins fibronectin, collagen 
Iα1 and collagen 4α1. Clinically, FST improved blood pressure, GFR and albuminuria, 
and pathologically both glomerulosclerosis and tubulointerstitial fibrosis were significantly 
attenuated.
Conclusions: Our data support a prominent pathologic role for the TGFβ family 
member activin A in CKD. We show that administration of the activin neutralizing 
protein FST is effective in preserving kidney structure and function and in attenuating 
the progression of CKD. These data highlight the promising role of FST as a novel 
renoprotective agent in CKD.
Funding: Government Support - Non-U.S.
FR-PO116 Poster Friday
Molecular Mechanisms of CKD - II
miR299a-5p Is a Pathogenic Driver of Renal Fibrosis in CKD
Neel Mehta,1 Dan Zhang,2 Juehua He,1 Bo Gao,2 Joan C. Krepinsky.1,2 1McMaster 
University, Hamilton, ON, Canada; 2St. Joseph’s Hospital, Hamilton, ON, 
Canada.
Background: Chronic kidney disease (CKD) is a major cause of morbidity and 
mortality. It is characterized by glomerular and interstitial fibrosis. Glomerular mesangial 
cells (MCs) are a major contributor to glomerular fibrosis. Previously, we identified that 
caveolin-1 (cav-1) is required for basal and TGFβ1-induced MC synthesis of matrix proteins. 
The protective phenotype of cav-1 knockout (KO) MCs against fibrosis is associated with 
increased expression of a TGFβ family member neutralizing protein, follistatin (FST). To 
better understand the mechanism of FST upregulation and identify novel therapeutic targets, 
we performed a quantitative screen in cav-1 wild-type (WT) and KO MCs to identify 
differentially regulated miRNAs that bind to and regulate the 3’UTR of FST.
Methods: In vitro studies were carried out in primary MCs isolated from cav-1 WT and 
KO mice using standard molecular biology techniques. For in vivo studies, a 9-week 5/6 
nephrectomy (5/6 Nx) mouse model of CKD was used.
Results: Expression and activity of miR299a-5p was significantly decreased in KO 
MCs which express high levels of FST. We confirmed that miR299a-5p regulates the 3’UTR 
of FST. In KO cells, FST downregulation increased TGFβ1-induced matrix synthesis. We 
thus examined whether miR299a-5p regulated this process. In WT MCs, TGFβ1 increased 
miR299-5p expression and downregulated FST, while exogenous FST reduced TGFβ1-
induced matrix synthesis. Importantly, downregulation of miR299a-5p increased FST 
expression and decreased TGFβ1-induced matrix synthesis. Conversely, in KO cells, 
overexpression of miR299a-5p decreased FST expression and enhanced TGFβ1-induced 
matrix synthesis. These data demonstrate that miR299a-5p suppression of FST expression 
augments ECM production in response to TGFβ1, a key contributor to the pathogenesis 
of CKD. In the 5/6 Nx mouse model of CKD, we further identified significantly elevated 
expression of both TGFβ1 and miR299a-5p.
Conclusions: miR299a-5p expression is increased in the kidneys of mice with CKD. 
miR299a-5p augments TGFβ1-induced ECM production in glomerular MCs through 
downregulation of the antifibrotic protein FST. These data suggest that miR299a-5p plays 
a pathogenic role in the development and progression of renal fibrosis. Its inhibition thus 
represents a potential novel therapeutic target for the treatment of CKD.
Funding: Government Support - Non-U.S.
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Cyclophilin D Deficiency Is Not Protective in Aristolochic Acid 
Nephropathy
Khai Gene Leong,1,2 Elyce Ozols,1,2 John Kanellis,1,2 David J. Nikolic-
Paterson,1,2 Frank Y. Ma.1,2 1Department of Nephrology, Monash Health, Clayton, 
VIC, Australia; 2Centre for Inflammatory Diseases, Monash University, Clayton, 
VIC, Australia.
Background: Cyclophilins are a family of enzymes which regulate protein folding. 
Of these enzymes, cyclophilin D (CypD) facilitates mitochondrial-dependant cell death 
during pathological conditions. CypD-/- mice are protected from acute kidney injury (AKI) 
following renal ischaemia/reperfusion injury, and exhibit less renal fibrosis in the unilateral 
ureteric obstruction model. However, the contribution of CypD in the transition of AKI to 
chronic kidney disease (CKD) is not known. The aim of this study was to determine the role 
of CypD in promoting the transition of AKI to CKD using the aristolochic acid-induced 
nephropathy (AAN) model.
Methods: Groups (n=10) of wild type (WT) and CypD-/- mice on the C57BL/6J 
background were given intraperitoneal injections of 2mg/kg aristolochic acid every 2nd day 
for 28 days. Mice were killed on day 28. Controls were untreated.
Results: AAN caused >2.5-fold rise in serum creatinine (sCr) in WT mice 
(34.3±9.9mmol/L vs 13.5±2.3mmol/L in controls; P<0.0001), with evidence of tubular 
damage (KIM-1 & α-Klotho mRNA levels; P<0.0001), increase in tubular cell death 
(cleaved caspase-3+ cells; P<0.0001), and significant renal fibrosis (collagen IV 
immunostaining, and collagen I & α-SMA mRNA levels; all P<0.0001 vs controls). CypD-
/- mice were not protected from AA-induced renal dysfunction (sCr 37.0±14.3 mmol/L; 
P=N.S.), and showed no reduction in tubular damage, cell death or renal fibrosis. Further 
analysis showed that AAN in WT mice caused loss of peritubular CD31+ capillaries 
(P<0.0001), and infiltration of macrophages (CD68 & CD206 mRNA levels; P<0.0001) 
and T-cells (CD3 & IL-2 mRNA levels; P<0.0001). CypD-/- mice were not protected from 
peritubular capillary loss or macrophage infiltration in AAN. However, CypD-/- mice 
showed reduced T-cell infiltration and activation (CD3 & IL-2 mRNA levels; P<0.0001), 
including Th1 cells (T-bet mRNA levels; P<0.05).
Conclusions: CypD does not contribute to the transition of AKI to CKD in experimental 
AAN.
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Polymyxin and Neomycin (P+N) Attenuates Inflammation and Fibrosis in 
Unilateral Ureteral Obstructed (UUO) Kidney by Altering Macrophage 
Phenotype
Siddhartha S. Ghosh,1 Austin J. Gonzalez,2 Richard Krieg,3 Todd W. Gehr,2 
Shobha Ghosh.3 1VCU Medical Ctr, Richmond, VA; 2Virginia Commonwealth 
University, Fredericksburg, VA; 3VCU, Richmond, VA.
Background: Gut bacteria have been shown to modulate inflammation in both acute 
and chronic kidney injury. P+N are non-absorbable antibiotics that are used to sterilize the 
gut. UUO mice develop acute inflammation in one kidney after surgery which progresses 
to fibrosis within 7 days. We wanted to investigate if gut sterilization by P+N can affect 
inflammation and fibrosis in UUO mice.
Methods: UUO surgery was done by the method adapted from Vanderbilt O’Brien 
Center. One group of mice was treated with P+N 7 days before UUO. One group was 
untreated (UT). Control mice did not receive surgery or treatment (C). Mice were sacrificed 
3 days (n=5/group) and 10 days (n=5/group) after UUO. Macrophage (Mo) and macrophage 
phenotype M1 and M2 were determined by flow cytometry. Inflammation markers MCP1, 
IL1β, and fibrosis marker α-smooth muscle actin (SMA) were assessed by immunoblot. 
Lipopolysaccharide (LPS) was measured by LAL assay.
Results: 3 Days post UUO: P+N treatment did decrease Mo influx in kidney but not 
Mo phenotype (Table). Only MCP1 increased in UT kidney compared to C, and P+N 
significantly lowered it (p<0.05). 10 Days post UUO: Although Mo in the kidneys of both 
groups was significantly higher, UT had more M1 and less M2 compared to P+N (Table). 
High levels of MCP1, IL-1β and SMA were lowered by P+N. Average plasma LPS in 5 
normal mice (C) was 0.8 EU/ml. LPS of UT mice was 3.7±0.32 EU/ml, 3 days after UUO 
and remained high (3.1±0.3 EU/ml) even after 10 days of UUO. In contrast, LPS levels of 
P+N group (1.1±.3 EU/ml) after 10 days was not different from group C.
Conclusions: LPS is known to modulate inflammation and Mo phenotype. M1 and 
M2 phenotypes are known to modulate fibrosis and inflammation respectively. Increased 
inflammation and fibrosis in UT (10 days) can be attributed to increased M1 and decreased 
M2. A decrease in inflammatory markers and fibrosis in P+N corresponds to the increased 
M2 and decreased M1 in this group. P+N can only act at the intestinal level and reduction 
of systemic LPS by this treatment implies that the gut might be a source of kidney 
inflammation.
Table
*p<0.05 compared to UT
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Molecular Mechanisms of CKD - II
Breast Regression Protein-39 (BRP-39) Promotes Fibrosis Following AKI 
by Inducing Matrix Expression by PDGFRβ+ Myofibroblasts
Amirtha Chinnadurai,1 Leyuan Xu,2 Lloyd G. Cantley.1 1Yale University School 
of Medicine, New Haven, CT; 2Yale University, New Haven, CT.
Background: Maladaptive repair after unilateral ischemia-reperfusion injury (U-IRI) 
leads to sustained low-level mRNA expression of chitinase-3-like1(Chi3l1, protein name 
BRP-39). We have recently shown that persistent expression of BRP-39 promotes interstitial 
fibrosis following maladaptive kidney repair. At the whole kidney level, PDGFRβ+ 
myofibroblast accumulation was not significantly different in the injured wild-type (WT) 
and Brp-39 knockout. However, there was a significant decrease in the expression of 
collagen 1α1(Col1a1), collagen 3α1(Col3a1) and fibronectin(Fn1) by myofibroblasts in 
the injured kidney of BRP-39 knockout compared to the WT kidney. Here,we investigated 
the role of BRP-39 in PDGFRβ+ myofibroblast matrix gene expression during the acute 
kidney injury(AKI) to chronic kidney disease transition.
Methods: Male WT mice (9–11 weeks) subjected to U-IRI for 30 minutes. The injured 
kidney was removed on day 14 after U-IRI, and primary renal myofibroblasts were isolated 
via magnetic activated cell sorting using PE-tagged PDGFRβ antibody. Purity of the 
PDGFRβ+ myofibroblasts assessed by qPCR for PDGFRβ mRNA. Primary myofibroblasts 
were grown for 4 days in culture (~70% confluence), then stimulated with recombinant 
BRP-39 (0.5 μg/ml) or vehicle control for 24-hour followed by qPCR for Col1a1, Col3a1 
and Fn1.
Results: Primary PDGFRβ+ myofibroblasts were enriched 5.7fold compared to the 
initial population(n=7,p=0.04) and were also enriched for expression of the postulated 
BRP-39 profibrotic receptor, Crth2 (n=7, p=0.004). The expression level of Pdgfrb and 
Crth2 in these cells were 9.1 and 3.7fold higher than in immortalized fibroblast cell lines 
(NRK49 and NIH3T3). Stimulation of PDGFRβ+ myofibroblasts with BRP39 resulted in 
3.4fold in Fn1 expression(p=0.038,n=6) with no significant effect on Col1a1 or Col3a1. 
Preliminary findings (n=2, pooled from 8 kidneys) show with the addition of TGFβ1 
(20 ng/ml) and PDGFβ (10 ng/ml) with BRP39 resulted in a further increase in fibronectin 
expression (dct = 8.489±5.22 vs 3.34±4.62)
Conclusions: We show that freshly isolated myofibroblasts express high levels of 
the profibrotic receptor,crth2 and directly respond to BRP39 by increasing fibronectin 
expression. These in-vitro findings suggest that BRP39 and/or the crth2 receptor may serve 
as therapeutic targets to limit fibrosis after AKI
Funding: NIDDK Support
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AMPK Activation Improves Tissue Oxygenation in CKD
Zhi Zhao Liu,2 Prabhleen Singh.1 1UC San Diego & VA San Diego Healthcare 
System, San Diego, CA; 2University of California, San Diego, San Diego, CA.
Background: Progressive intra-renal hypoxia is implicated in the pathogenesis 
of CKD. However, effective therapies to target intra-renal hypoxia are very limited. We 
have previously reported early alterations in renal oxygenation and oxygen demand-
supply mismatch leading to hypoxia in subtotal nephrectomy (STN), a well-established 
experimental model of CKD. AMP-activated protein kinase (AMPK) is an important 
cellular metabolic sensor and regulator, which is dimished in CKD. In this study, we 
evaluated the quantitative changes in renal tissue oxygenation and the impact of AMPK 
activation by metformin (MET) on hypoxic and metabolic stress adaptation in STN.
Methods: Male Wistar rats were randomly divided into four groups/two time points: 
sham, sham+MET (250 mg/kg/day oral gavage), STN, STN+MET, and 1-week or 4-week 
treatment. Rats were anesthetized and placed on a temperature-controlled table. Left 
jugular vein, left femoral artery, and urinary bladder were cannulated. Intrarenal oxygen 
tension (pO2) was measured in the renal cortex and medulla by a Clark-type microelectrode 
(Unisense) after 60-min equilibration period.
Results: At 1-week post-STN, renal cortical pO2 declined in STN (33±10 vs. 
52±7 mmHg in shams, p<0.0001). MET treatment improved the STN-induced decreased 
cortical pO2 (47±6 mmHg) (p<0.0001). At 4-week time point, renal cortical pO2 continued 
to be lower in STN (40±11 vs. 52±6 mmHg in shams, p=0.0008). MET prevented the STN-
induced decrease in cortical pO2 (49±7 mmHg) (p=0.0031). However, in the renal medulla, 
the STN-induced decreased pO2 was not rescued by MET at both time points.
Conclusions: Our findings demonstrate that tissue oxygen tension is reduced in 
the STN kidneys in early and late stages. This was prevented by AMPK activation with 
metformin treatment in the renal cortex. Impact of AMPK activation on tubular transport 
and metabolism in STN is being investigated.
Funding: NIDDK Support, Veterans Affairs Support
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PGE2 EP1 Receptor Deletion Worsens Hypertensive Kidney Disease in 
TTRhRen Mice, Promoting Glomerular Podocyte and Endothelial Cell 
Injury
Rania Nasrallah,2,1 Susan J. Robertson,3 Jamie Ghossein,1 Fengxia Xiao,4 
Dylan Burger,2 Richard L. Hébert.2,1 1University of Ottawa, Ottawa, ON, 
Canada; 2Kidney Research Centre, Ottawa, ON, Canada; 3The Ottawa Hospital, 
Ottawa, ON, Canada; 4Ottawa Hospital Research Institute, Ottawa, ON, 
Canada.
Background: Prostaglandin E2 (PGE2) regulates glomerular hemodynamics, renin 
secretion, and tubular transport. PGE2 EP1 receptors promote renal injury in diabetes, and 
EP1 deletion improves hyperfiltration, albuminuria, and fibrosis in several diabetic models. 
The role of PGE2/EP1 in hypertension remains controversial. The purpose of this study was 
to examine the contribution of PGE2/EP1 to long-standing hypertensive kidney disease.
Methods: Male FVB EP1-/- mice were bred with hypertensive TTRhRen mice (Htn) 
to evaluate kidney function and injury at 24 wks of age in 4 groups: wild-type (WT), EP1-
/-, Htn, HtnEP1-/-. Blood pressure was measured by tail vein, and glomerular filtration 
rate (GFR) was estimated by FITC-inulin clearance. Urine was collected over 24 hrs in 
metabolic cages, and urine albumin was measured by ELISA. Total RNA was isolated from 
renal cortex for quantitative PCR analysis. Ultrastructural injury was assessed by electron 
microscopy. Urine microparticles were characterized by flow cytometry.
Results: Systolic blood pressure was elevated in Htn mice (150 mmHg) compared to 
WT mice (110 mmHg), but unchanged by EP1 deletion. However, EP1 deletion resulted 
in significantly increased albuminuria (>10-fold WT and >3-fold Htn) and reduced FITC-
inulin clearance (50% of WT) in HtnEP1-/- mice, independent of blood pressure changes. 
Cyclooxygenase (COX)-2 mRNA was increased in all mice lacking EP1. Ultrastructural 
injury to podocytes and glomerular endothelium was prominent in HtnEP1-/- mice 
compared to Htn and WT mice: including widened subendothelial space, subendothelial 
lucent zones and focal lifting of endothelium from the glomerular basement membrane 
with focal subendothelial cell debris. This injury was associated with increased podoplanin-
positive urine microparticles indicative of podocyte damage.
Conclusions: EP1 deletion increases albuminuria and reduces GFR in Htn mice, 
due to significant injury to podocytes and glomerular endothelium. Taken together, the 
data suggests that EP1 receptors play a protective role in hypertensive kidney disease. 
Highlighting the importance of carefully examining disease context (eg. diabetes vs 
hypertension) when characterizing underlying disease processes.
Funding: Government Support - Non-U.S.
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Superiority of ACF-TEI, a Novel Uremic Toxin Adsorbent, to Classical 
Oral Adsorbent in In Vitro and In Vivo Adsorption Profiles
Takashi Shirakura, Hiroshi Shimoyama, Yasumi Nishiwaki, Kumiko Hase, 
Yoshimasa Takahashi, Johji Nomura, Tsunefumi Kobayashi. Pharmacology 
Research Department, TEIJIN Pharma Limited, Hino, Japan.
Background: Uremic toxins (UTs) such as indoxyl sulfate (IS) accumulate in the blood 
of patients with impaired renal function. Since several observation studies have demonstrated 
a link between serum UT levels and clinical outcomes, UTs have much attention as key 
factors in the progression of chronic kidney diseases (CKDs) and cardiovascular diseases. 
Spherical activated carbon (AST-120) adsorbs UTs and those precursors such as indole in 
the intestinal tract and excretes them out of the body with feces, leading to reduce serum 
UT levels. Therefore AST-120 is effective in improving symptoms of uremia and delaying 
the introduction to dialysis in CKD patients. However, the oral adsorbents comprising AST-
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120 have insufficient adsorption performance and need to be taken at high daily doses. To 
improve their compliance and efficacy, we focused on activated carbon fiber (ACF) and 
have identified a novel and potent oral UT adsorbent, ACF-TEI. In this study, we analyzed 
in vitro adsorption profiles of ACF-TEI and compared in vivo efficacy of ACF-TEI and 
AST-120 on serum IS levels. We also evaluated the effects of ACF-TEI on renal fibrosis in 
rat model of kidney injury.
Methods: As for the in vitro adsorption profiles, we examined the adsorption of 
precursors including indole and p-cresol, and digestive enzymes. In in vivo studies, we 
compared the effects of ACF-TEI and AST-120 on serum IS concentrations in rat model of 
CKD and dog model treated with tryptophan, a precursor of indole. To evaluate the effects 
on renal fibrosis, cisplatin-induced nephrotoxicity (CDDP) model were used.
Results: Compared with AST-120, ACF-TEI showed more potent capacity and speed 
in adsorbing the UT precursors. ACF-TEI had a low capacity to adsorb digestive enzymes 
and the capacity was comparable to that of AST-120. In rats and dogs, ACF-TEI reduced 
serum IS levels more potent than AST-120. ACF-TEI decreased serum and renal IS levels, 
urinary excretion of KIM-1, and a-SMA expression in CDDP model.
Conclusions: The adsorption capacity and efficiency of ACF-TEI were superior to 
AST-120. In addition, ACF-TEI reduced the serum IS levels more potent than AST-120 in 
in vivo models. Thus, ACF-TEI is expected to show more beneficial effects than AST-120 
in clinical.
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Megalin Deletion Prevents Long-Term Loss of Glomerular Filtration Rate 
After Rhabdomyolysis
Katsuyuki Matsushita,2 James A. McCormick,2 Kiyoshi Mori,4 Motoko Yanagita,3 
Michael Hutchens.2,1 1Portland VA Medical Center, Portland, OR; 2Oregon 
Health & Science University, Portland, OR; 3Department of Nephrology, Kyoto 
University Graduate School of Medicine, Kyoto, Japan; 4School of Pharmaceut 
Sci, University of Shizuoka, Shizuoka, Japan.
Background: Rhabdomyolysis, caused by injury, physical training, or medication, 
causes acute kidney injury and can lead to chronic kidney disease. Treatment is limited to 
supportive care and urinary alkalization, which is controversial. No specific therapy exists, 
but myoglobin-induced tubular epithelial apoptosis is a mechanism. Myoglobin undergoes 
tubular endocytosis via megalin, therefore we hypothesized that proximal tubule-specific 
megalin deletion would ameliorate chronic loss of glomerular filtration rate (GFR) caused 
by rhabdomyolysis.
Methods: Proximal tubule-specific inducible megalin deletion mice (iMegKO, 
LRP2 fl/fl NDRG1-CreERT2) were generated by breeding megalin floxed mice 
(a gift of Professor T. Willnow, Max Delbruck Institut) with NDRG1-CreERT2 (a gift 
of M. Yanagita, Kyoto University). Tamoxifen (150 mg/kg body weight) was injected 
intraperitoneally to 7 iMegKO and 7 cre- littermate control mice (all 8-12 week-old 
males) for 5 days, 2 weeks before rhabdomyolysis was induced by 50% glycerol injection 
(6.5 ml/kg). Before glycerol and 2, 30, and 60 days after injection, glomerular filtration rate 
(GFR) was measured by FITC-sinistrin transcutaneous clearance. After injection, all GFR 
measurements were expressed as %baseline. Statistical analysis was by repeated measures 
2-way ANOVA.
Results: Tamoxifen only induced deletion of megalin in cre+ mice. Megalin deletion
reduced GFR (745±42mL/min/100g body weight in iMegKO vs 872±35 μL/min/100g 
body weight in control, P<0.05). iMegKO mice did not demonstrate reduced GFR on day 
2, maintaining baseline GFR to 60 days (102% baseline, ns), whereas in controls, glycerol 
injection induced significant, sustained decline in GFR at 30 and 60 days (76±7% baseline, 
p=0.005 compared with baseline, p=0.02 compared with KO).
Conclusions: Proximal tubule-specific deletion of megalin ameliorates chronic renal 
functional loss caused by experimental rhabdomyolysis.
Funding: Veterans Affairs Support
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Estimating the Health Economic Outcomes of Serum 25-Hydroxyvitamin 
D and Intact Parathyroid Hormone Levels in Stage 3-4 CKD: The Impact 
of Treatment Timing
Matthew Gitlin,1 Kamyar Kalantar-Zadeh,2 Christopher S. Hollenbeak,3 
Sophie Snyder,1 Akhtar Ashfaq.4 1BluePath Solutions, Los Angeles, CA; 
2University of California Irvine, School of Medicine, Orange, CA; 3Penn State 
College of Medicine, Hershey, PA; 4OPKO Health, Inc., Miami, FL.
Background: Serum 25-hydroxyvitamin D (25D) and intact parathyroid hormone 
(iPTH) levels in patients with Chronic Kidney Disease (CKD)are associated with 
meaningful clinical outcomes, including cardiovascular (CV) events, fractures, CKD 
progression, and death. This study estimated differences in outcomes (CV events, fractures, 
and CKD progression) and costs due to changes in 25D and iPTH levels associated with 
vitamin D (vit D) therapy among patients with CKD not on dialysis.
Methods: A cost-consequence model taking a Medicare payer perspective was 
developed to estimate the economic and clinical consequences of increasing 25D and 
lowering iPTH in stage 3-4 CKD patients. The base case Markov model assumed a 
1000-patient cohort with 1-year cycles and a 5-year time horizon. Correction of 25D and 
iPTH level and associated clinical events were based on published meta-analyses. Costs of 
clinical events were based on data from national public databases.
Results: Across a 1,000-person cohort, increasing 25D and lowering iPTH may avert 
about 202 CV events, 6 fractures and 230 patient-years in the CKD stage 5/dialysis state. 
The estimated offsets total about $25 million (Figure 1). The analysis is sensitive to the cost 
inputs and the effectiveness of correcting 25D and iPTH. Under scenario analysis, when 
excluding the stage 5/dialysis, the total savings over a 1,000-person cohort is about $4.7 
million, mainly attributable to averted CV events.
Conclusions: Vit D therapy in stage 3-4 CKD appears to be cost-saving by offsetting 
CV events, fractures, and CKD progression, although it may also be associated with such 
adverse events (AE) as hypercalcemia, hyperphosphatemia, and increased FGF23; further 
research is warranted to assess whether vit D treatment with extended-release calcifediol 
results in improved outcomes without these AEs.
Funding: Commercial Support - OPKO
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Multiple, Systemic Effects of PHD Inhibitors Signify an Anti-Fibrotic and 
Anti-Inflammatory Impact on Cardiovascular Complications in the 
Remnant Kidney
Lisa Uchida,1 Tetsuhiro Tanaka,1 Hisako Saito,1 Mai Sugahara,1 Kenji Fukui,1,2 
Takeshi Wakashima,1,2 Masaomi Nangaku.1 1Division of Nephrology and 
Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, 
Japan; 2JT CPRI, Osaka, Japan.
Background: Hypoxia plays a crucial role in the progression of chronic kidney 
disease(CKD) which is associated with fibrosis, inflammation and oxidative injury. 
Previous studies suggest that prolyl hydroxylase inhibitors(PHD inhibitors), stabilizers 
of hypoxia-inducible factors (HIFs), could be applied in acute organ injuries like renal 
ischemia-reperfusion and myocardial infarction. However, the effect of PHD inhibitor on 
CKD and its cardiovascular consequences remains unknown.
Methods: Male Sprague-Dawley rats underwent 5/6 nephrectomy (remnant kidney: 
RK). Rats were divided into three groups: (1)sham operation rats (2)RK rats with normal 
diet (3) RK rats with 0.005% enarodustat(PHD inhibitor) diet since 1 week before 5/6 
nephrectomy. L-NNA(20 mg/L), NO synthase inhibitor, was supplemented in drinking 
water to accelerate the CKD model. At 6 weeks after 5/6 nephrectomy, kidney and heart 
were harvested after the echocardiography.
Results: Systolic blood pressure was lower in RK-Enarodustat group than in the RK 
group, but the difference did not reach statistical significance. Blood urea nitrogen and 
serum creatine levels at 2, 4, 6 weeks were reduced in the RK-Enarodustat group, whereas 
there was no difference in urinary protein excretion between the two groups. The number 
of ED-1-positive cells was significantly less in the RK-Enarodustat group (43.7±7.7 per 
×200 field) than in the RK group (100.8±14.2, P<0.01). And, the number of infiltrated 
CD206 macrophages, the M2 macrophages, was also less in the RK-Enarodustat group. 
Immunohistochemical analysis revealed a significant decrease in nitrotyrosine accumulation 
in tubules in the RK-Enarodustat group(7.6±1.3 vs 11.5±0.9, p=0.036). In heart, the number 
of ED-1, CD206-positive infiltrating macrophages and picrosirius red staining showed 
significant reductions in the RK-Enarodustat group. Anterior and posterior wall thicknesses, 
markers for cardiac hypertrophy, were markedly less in the RK-Enarodustat group than in 
the RK group, whereas there was no difference in fractional shortening, ejection fraction 
and E/A.
Conclusions: These data show that PHD inhibitors significantly improve inflammation, 
oxidative stress and fibrosis in remnant kidney and may also mediate beneficial effects in 
cardiovascular complications.
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Targeted Ablation of Distal Cerebrospinal Fluid-Contacting Nucleus 
Alleviated Renal Fibrosis in CKD
Minzi Qiu, Jiawen Li, Lishan Tan, Aiqing Li. Nanfang Hospital, Southern 
Medical University, Guangzhou, China.
Background: The distal cerebrospinal fluid-contacting nucleus (dCSF-CNs) is thought 
to be a linkage between the cerebrospinal fluid and brain. The potential function of dCSF-
CNs in development of CKD is poorly understood. We hypothesized that dCSF-CNs 
might exert a signaling transmission effect on the cascade reaction of renin-angiotensin 
system (RAS) in the progression of kidney injury, and that ablation of the dCSF-CNs might 
alleviate the local RAS and renal fibrosis in five-sixths nephrectomied (5/6Nx) rat model.
Methods: Rats were subjected to intracerebroventricular (icv) administration of 
artificial cerebrospinal fluid (aCSF) followed by five-sixths nephrectomied or sham 
operation, or icv administration of Cholera toxin subunit B conjugated with saporin 
(CB-SAP) for dCSF-CNs lesion before five-sixths nephrectomied. The effect of CB-
SAP treatment on ablation of dCSF-CNs was confirmed via double immunofluorescence 
staining. The expression levels of RAS components, NOX2 and c-fos in SFO, PVN and 
hippocampus, as well as the numbers of Tyrosine Hydroxilase and c-fos positive cells in 
RVLM were detected. The expression levels of RAS components (AGT, ACE, AT1R, 
ACE2, Mas receptor), NADPH oxidase (NOX2, catalase), inflammatory cytokines (MCP-1, 
IL-6), fibrotic readouts (fibronectin, collagen I) in kidney were compared.
Results: Compared with 5/6Nx rats, the number of CB-labelled neurons in dCSF-CNs 
decreased in CB-SAP treated rats. Treatment with CB-SAP down-regulated the expression 
levels of RAS components (AGT, Ang II, AT1R), NADPH oxidase (NOX2, catalase), 
inflammatory cytokines (MCP-1, IL-6), fibrotic readouts (fibronectin, collagen I) in rats, 
and up-regulated the protein levels of ACE2 and Mas receptor, compared with CKD rats. 
Increased numbers of Tyrosine Hydroxilase and c-fos positive cells were observed in the 
RVLM of 5/6Nx rats, but that were decrease under the influence of ablation of dCSF-CNs.
Conclusions: Targeted ablation of the dCSF-CNs might alleviate renal inflammation 
and fibrosis in the development of chronic kidney injury through inhibiting activation of 
inhibit the cerebral and renal RAS/ NADPH oxidase.
Funding: Government Support - Non-U.S.
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A Novel, Selective TRPC6 Antagonist Reduces Renal Interstitial Fibrosis 
in the Mouse Unilateral Ureteral Obstruction Model
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Magdalene M. Moran.3 1Boehringer Ingelheim Pharmaceuticals, Ridgefield, 
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Background: A role for dysregulation of the non-selective cation channel TRPC6 in 
the development of FSGS is well-established based on the identification of multiple gain-of-
function mutations in humans which cause disease by cytoskeletal alterations in podocytes, 
leading to impairment of the glomerular filtration barrier. Despite the strong evidence 
linking elevated TRPC6 activity to CKD, no inhibitors have advanced to clinical testing 
due to challenges associated with achieving selectivity against related ion channels and 
identifying compounds with a suitable pharmacokinetic profile for oral dosing.
Methods: A novel TRPC6 antagonist, BI 749327, was characterized with in vitro 
electrophysiology measurements using HEK293 cell transfectants and in vivo in the mouse 
unilateral ureteral obstruction (UUO) model of renal fibrosis.
Results: BI 749327 has a manual patch-clamp IC50 value of 13 nM against TRPC6 and 
85- and 42-fold selectivity against TRPC3 and TRPC7, respectively. Oral gavage dosing
with BI 749327 produced plasma exposures predicted to provide potent 24 hour inhibition. 
Treatment of mice undergoing UUO surgery with BI 749327 inhibited the development of 
fibrosis as measured by hydroxyproline incorporation. TRPC6 dependent inhibition was 
confirmed as mice lacking TRPC6 had a similar reduction in fibrosis in the UUO model 
when compared with BI 749327 treated wild-type mice and by the demonstration that the
compound had no further effect on fibrosis development in this model when administered 
to TRPC6 deficient mice.
Conclusions: The opportunity for treatment with a TRPC6 antagonist to inhibit 
renal fibrosis in addition to restoring podocyte calcium homeostasis further highlights the 
therapeutic potential of this mechanism for the treatment of CKD. These results are the 
first demonstration of in vivo benefit in a disease model with TRPC6 pharmacological 
inhibition, and BI 749327 provides a tool for further evaluating TRPC6 inhibition for the 
treatment of CKD.
Funding: Commercial Support - Boehringer Ingelheim Pharmaceuticals, Hydra 
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Cerebral Microvasculature Impairments Induced Dementia in CKD
Jen Xu,1 Hugo Y. Lin,2 Li-lun Ho,5 Kenneth Lim,4 Thomas F. Hiemstra,6 
Joseph V. Bonventre,3 Tzongshi Lu.3 1Harvard College, Cambridge, MA; 
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Background: Structural and functional impairments of brain microvasculature result in 
white matter hypo-perfusion and ischemia are major causes of Cerebral small vessel disease 
(CSVD). Recently, chronic kidney disease (CKD) has been identified as a significant risk 
factor for stroke and dementia as well as CSVD. Interestingly, both kidney and cerebral 
microvasculature share similar anatomical and physiologic characteristics particular in their 
endothelium. The goal of this study was to elucidate the molecular mechanisms of CKD 
induced cerebral microvasculature dysfunction and consequences neurological diseases.
Methods: CKD mice model was generated by 5/6 nephrectomy on C57BL/6 mice. 
Transcriptomic profiling of calcification medium (CM) and hyperglycemia medium (GM) 
treated primary human brain microvascular endothelial cells (HBMECs), in vitro, and 
human arteries collected from CKD (n=20), CAD (n=15) and healthy donors (n=20) were 
subjected to RNA sequencing, ex vivo. In addition, incidence and risk of dementia in CKD 
from a population-based study using the Taiwan National Health Insurance database with 
1,000,000 subjects from 2000 to 2009.
Results: Our results showed that CKD mice had decreased myelinated nerve fibers 
in the corpus callosum and cerebral cortex and loosening myelinated fibers in the corpus 
callosum. Collagen IV accumulation in brain microvasculature and serum phosphate 
levels were significant increased in CKD mice compared to control mice. Tight junction 
(TJ) proteins occludin, claudin-5, and ZO-1 were down-regulated in both CM/GM-treated 
primary HBMECs. In human arteries, both claudin-5 and ZO-1 genes were down-regulated 
in CKD group together with anti-apoptotic gene Bcl2. Furthermore, cell viability decreased 
and caspase-3 mediated apoptosis increased as well as Collagen IV expression in CM 
treated HBMECs. The subsequent risks of dementia were 2.208-fold (Diabetes + CKD); 
1.638-fold (CKD); 1.527 fold (Diabetes) higher in comparison with healthy cohort.
Conclusions: Our data show for the first time that TJ dysfunction in cerebral 
microvascular dysfunction occurs in CKD may play a role in dementia. It provides a 
potential mechanism for the development of CSVD in CKD patients. Our results may 
benefit CKD patients to reduce the following CSVD and dementia through controlling 
blood phosphate levels and maintain TJ’s function.
Funding: Private Foundation Support
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Evaluation of Allostatic Load as a Mediator of Sleep and Kidney 
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Background: Poor sleep associates with adverse chronic kidney disease (CKD) 
outcomes yet the biological mechanisms underlying this relation remain unclear. One 
proposed mechanism is via allostatic load (AL) – a cumulative biologic measure of stress. 
Using data from the Jackson Heart Study (JHS), we examined the potential mediating effect 
of AL on the relation between sleep patterns and kidney outcomes
Methods: We examined the association of self-reported sleep duration: very short, 
short, recommended, and long (≤5, 6, 7-8, or ≥9 hours per 24 hours, respectively) and 
self-reported sleep quality: high (excellent/very good) vs. good vs. low (poor/fair) with 
prevalent baseline CKD (Exam 1), estimated glomerular filtration rate (eGFR) decline, 
and incident CKD at follow-up (Exam 3). CKD was defined as eGFR <60ml/min/1.73m2 
or urine albumin-to-creatinine ratio ≥30mg/g. Models were adjusted for demographics, 
comorbidities and kidney function. We further evaluated AL (quantified at baseline using 
11 biomarkers from neuroendocrine, metabolic, autonomic, and immune domains) as a 
mediator of these relations.
Results: Among 5177 JHS participants, 40% slept the recommended 7-8 hours; 25%, 
29% and 6% reported very short, short and long sleep duration, respectively. Participants 
with very short sleep duration (vs. 7-8 hours) had greater odds of prevalent CKD (odds ratio 
[OR] 1.31, 95% confidence interval [CI] 1.03-1.66) after adjustment. Very short, short or 
long sleep duration (vs. 7-8 hours) were not associated with any other kidney outcomes over 
a median follow-up of 8 years. Low sleep quality (vs. high) associated with greater odds 
of prevalent CKD (OR 1.26, 95% CI 1.00-1.60) and 0.18 mL/min/1.73m2 (95% CI 0.00 to 
0.36) faster eGFR decline per year over follow-up. AL did not mediate the associations of 
sleep duration or sleep quality with kidney outcomes.
Conclusions: Very short sleep duration and low sleep quality were associated with 
adverse kidney outcomes in this all black cohort, but AL did not appear to mediate these 
associations. Future work should investigate the role of other biologic mediators in the 
relation between sleep and CKD outcomes in blacks.
Funding: Other NIH Support - National Heart, Lung, and Blood Institute; and the 
National Institute for Minority Health and Health Disparities
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Chemokine Ligand 14 Could Be a Possible Biomarker of CKD 
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Background: Chemokine ligand 14 (CCL14), a ligand for CCR1, has been known 
as a M2 polarizing marker and chemotactic cytokine, which is expressed by fibroblast, 
monocyte, etc. Although it was first isolated from the hemofiltrate of chronic renal failure 
patients, its expression pattern in chronic kidney disease have never been investigated.
Methods: To elucidate concentration change of CCL14 in chronic kidney disease, 
we performed urine proteomic analysis using three patients’ random urine per each CKD1 
and 5. For validating tissue expression of CCL14, kidney biopsy tissues of three normal, 
nine CKD 3, and eight CKD 5 patients were evaluated by immunohistochemistry. Among 
CKD 3 group, patients with GFR decrease more than 5 ml/min/1.73 m2 within a year were 
considered to have rapid progression. We also evaluated kidney tissue expression of CCL14 
in acute tubular necrosis that is a well-known etiology of chronic kidney disease if it recurs 
frequently. For in vitro study, primary cultured human tubular epithelial cells (hTECs) and 
glomerular endothelial cells (GECs) were treated with rTGFβ for inducing fibrosis, and 
CCL14 expression level was measured using western blotting.
Results: In urine proteomics analysis, we discovered CCL14 showed a 122-fold 
increase in CKD 5 patients’ urine comparing to CKD 1 (p<0.001). In other hands, in human 
kidney biopsy tissue, CKD 3 patients with rapid progression showed higher expression 
level of CCL14 (17.33±4.13) compared to non-progressive CKD 3 (10.12±3.60) (p=0.032), 
control (12.48±2.49) (p=0.019), and CKD 5 (9.63±5.52) (p=0.049). CRP was adversely 
lower in progressive CKD 3 patients compared to others (p=0.017), and interstitial 
inflammation or fibrosis pattern was not different (p=0.861). In kidney tissue of patients 
with acute tubular necrosis, CCL14 expression level was 1.6-fold higher than those of 
normal cases (p=0.015). In in vitro assay, CCL14 expression was increased 2 folded by 
treating rTGFβ in GEC cells.
Conclusions: CCL14 expression tends to increase in patients with progressive CKD 
or acute tubular necrosis. Moreover, its expression is increased by a rTGFβ-enriched 
fibrotic environment. Our results suggest CCL14 could be a possible biomarker of CKD 
progression that pre-existing inflammatory marker or pathologic variables could not predict.
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Neto, Simone C. Arias, Antonio C. Seguro, Denise M. Malheiros, 
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Background: Subjects recovering from acute kidney injury (AKI) may develop renal 
fibrosis and chronic kidney disease (CKD) by unclear mechanisms that may involve innate 
immunity (InIm). In rats exposed to nephrotoxic agents, AKI is followed by mild fibrosis. 
Whether this process proceeds to CKD later on has not been examined. Here we investigated 
1) whether renal injury resulting from treatment with Gentamicin (G) progresses to CKD in 
the long run by; 2) the role of InIm in this process.
Methods: Male Munich-Wistar rats received daily sc injections of G, 80 mg/kg, during 
9 days. Control rats (C) received vehicle only. Rats were studied at 1, 30 and 180 days after 
G, to assess:Creatinine Clearance (ClCr, mL/min), Albuminuria (ALB, mg/24h), Glomerular 
ischemia (%GI), Cortical Collagen 1 (%Coll) and Fibronectin (%FN), Macrophages (Mø) 
and AngII+ cells (/mm2), as well as renal KIM1 and IL1β (pg/mg), αSMA, TLR4, NFkB 
(nuclear p65) and IL6 (xC)
Results: At Day 10, GI, tubular injury, ALB and low ClCr were associated with marked 
inflammation and InIm activation. Partial reversal of these changes was seen at Day 30, 
along with incipient fibrosis. At Day180, worsened ALB was seen along with prominent GI 
and renal fibrosis, although inflammation was attenuated.
Conclusions: G leads to AKI, strong inflammation and InIm activation. In the long 
run, glomerular injury develops along with renal fibrosis. Since InIm activation and 
inflammation abate with time, the mechanisms of these late effects might involve other 
mechanisms, such as direct participation of tubular cells. FAPESP/CNPq
Funding: Government Support - Non-U.S.
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Background: Apabetalone, an oral small molecule BET inhibitor, reduced the incidence 
of major adverse cardiac events (MACE) in patients with CVD and improved eGFR in a 
subgroup with CKD in phase 2 trials. Because vascular calcification (VC) is associated with 
MACE, effects of apabetalone on processes associated with VC were examined.
Methods: Plasma proteomics was conducted in CVD patients receiving apabetalone 
in the 3 month (ASSERT) and 6 month (SUSTAIN & ASSURE) phase 2 trials, as well as 
patients with stage 4/5 CKD that received a single 100mg dose. Coronary artery VSMCs 
were used to examine effects of apabetalone on transdifferentiation & calcium deposition.
Results: Apabetalone significantly reduced circulating levels of VC markers in CVD 
patients in phase 2 trials, including alkaline phosphatase, osteopontin and osteoprotegerin. 
Plasma proteomics of CKD patients (n=8) indicated activation of molecular pathways 
driving VC including IL-6 signaling, BMP-2 signaling & RANK signaling in osteoclasts. 
Downregulation of these pathways by apabetalone was predicted in the CKD cohort 12hrs 
post-dose. In VSMCs cultured in osteogenic conditions, apabetalone opposed induction 
of transdifferentiation markers & inhibited calcium deposition. BRD4 is a transcriptional 
regulator & target of apabetalone. ChIP-seq showed transdifferentiation of VSMCs to a 
calcifying phenotype promoted re-distribution of BRD4 on chromatin, resulting in fewer 
BRD4-rich enhancers (118 in osteogenic, 288 in basal). 38 genes were uniquely associated 
with BRD4-rich enhancers in osteogenic vs basal conditions; several of the genes have 
been linked to calcification. Apabetalone reduced BRD4 on many of these enhancers, which 
correlated with decreased gene expression. Bioinformatics indicated BRD4 may cooperate 
with specific transcription factors to promote calcification.
Conclusions: Involvement of BRD4 in VSMC transdifferentiation & calcification is a 
novel discovery. Further assessment of apabetalone as a therapeutic for VC is warranted. 
The impact of apabetalone on biomarkers, renal function & CVD outcomes in patients with 
impaired kidney function is being evaluated in a subgroup of the phase 3 BETonMACE 
trial.
Funding: Commercial Support - Resverlogix Corp.
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The Role of Periostin in Aging Process
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Background: Periostin, a matricellular protein, has been reported in diverse processes 
and pathologies in tissue remodeling through the promotion of adhesion, cell survival, 
cellular dedifferentiation, and fibrogenesis. However, its role in aging process is unknown.
Methods: We analyzed tissues from 2-months and 24-months old wild-type and Postn 
null (Postn-/-) mice and performed high throughput RNA-Sequencing of kidney tissue in 
aged mice. The genes showing altered expression were confirmed by qRT-PCR analysis.
Results: At 24-months old Postn null mice had preserved kidney tissue and less 
markers of senescence than wild-type mice. The gross appearance and the kidneys of aged 
WT mice were bigger and heavier than young WT mice. Serum creatinine levels were 
also higher in the aged WT mice compared to those in the young WT mice. However, 
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all these changes were diminished in the aged Postn null mice; serum creatinine levels 
were considerably lower in aged Postn null mice than in aged WT mice. Apparent tubular 
atrophic changes, interstitial fibrosis, and collagen fiber deposition which were prominent 
in the aged WT mice than in the young WT mice, were remarkably alleviated in aged Postn 
null mice. Furthermore, the expressions of periostin were also attenuated in aged Postn 
null mice compared to in aged WT mice. Also, we found that many of the changes in gene 
expression that occur during the aging process by periostin.
Conclusions: The data obtained in this study should expand our knowledge on the 
periostin mediated aging and provide molecular mechanism. Periostin inhibition could have 
protective effects in aging process.
FR-PO134 Poster Friday
Molecular Mechanisms of CKD - II
Diverse Associations Between Oxidative Stress and Thromboxane A2 in 
Hypertensive Glomerular Injury
Yukihito Nakano, Yoshihisa Nakatani, Masahiro Takami, Shuji Arima. Kindai 
University Faculty of Medicine, Osaka-Sayama, Japan.
Background: In addition to lowering blood pressure, therapeutic strategies to 
ameliorate hypertensive renal injury need to be established. In this study, we studied the 
possible contribution of thromboxane A2 (TXA2) which contributes to impaired renal 
hemodynamics under pathological conditions and potently stimulates reactive oxygen 
species generation, to the development of regional heterogeneity in hypertensive glomerular 
injury. We examined the impact of the inhibition of TXA2 synthesis in relation to its 
antioxidant effects on regional glomerular injury.
Methods: Experiments were performed using male stroke-prone spontaneously 
hypertensive rats (SHRSP) and Wistar–Kyoto rats (WKY) at 5, 10 and 15-week age, 
respectively. We investigated systolic blood pressure (SBP), the degree of glomerular injury 
(glomerular sclerosis index: GSI), urinary albumin excretion (UAE), serum creatinine 
concentration (Cr), urinary 8-OHdG excretion, thromboxane synthase (TXAS) and heme 
oxygenase-1 (HO-1) gene expression. We also evaluated difference in GSI and each gene 
expression between superficial and juxtamedullary glomeruli. Then we investigated the 
effect of tempol (an intracellular antioxidant) and ozagrel (TXAS inhibitor).
Results: Juxtamedullary glomeruli showed higher GSI after 10 weeks of age in both rats. 
TXAS and HO-1 mRNA expression was enhanced in both superficial and juxtamedullary 
glomeruli in SHRSP compared with that in age-matched WKY. Notably in juxtamedullary 
glomeruli, TXAS expression was progressively enhanced as rats grow. Neither tempol nor 
ozagrel had any effect on SBP or Cr in SHRSP. Ozagrel but not tempol improved GSI 
in both superficial and juxtamedullary glomeruli. Tempol significantly increased TXAS 
expression in superficial but not juxtamedullary glomeruli, whereas ozagrel suppressed it.
Conclusions: Under the established severe hypertension, the glomerular injury as well 
as TXAS expression was augmented. Since these changes were attenuated by ozagrel but 
not tempol, the TXA2–TPR pathway and oxidative stress participate and interact together 
to promote hypertensive glomerular injury. Moreover, our results indicated that TXA2 
inhibition may be a better therapeutic target than ROS inhibition to inhibit the aggravation 
of hypertensive glomerular injury at an advanced stage.
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Upregulation of a Urea Transporter in Uremic Heart Promotes Cardiac 
Fibrosis and Increases Vimentin
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Background: Cardiac abnormalities are linked to increased morbidity and mortality in 
chronic kidney disease (CKD) patients. CKD induces hypertension and retention of water, 
urea, and salt within the body. These are strongly related with the cardiovascular disease 
known as uremic cardiomyopathy. Uremic cardiomyopathy consists of left ventricular 
hypertrophy and interstitial fibrosis. Urea transporters (UT) are mainly involved with the 
urine concentrating mechanism in the kidney medulla. There is an isoform of UT-A in heart, 
but its role is not well known. We investigated the role of UT in mouse heart with a focus 
on the uremic heart.
Methods: To create a CKD model, C57BL6 mice underwent a 5/6 nephrectomy 
(5/6Nx), and were given 0.45-1% NaCl water to drink. Mice were sacrificed at 8 weeks after 
surgery. Heart tissue and blood were harvested. Mouse blood pressure measurements were 
determined by the tail cuff method. Cell culture studies were performed using mIMCD3 
cells that were stably transfected with UT-A1. Immunohistochemistry was performed on 
paraffin sections. Protein expression levels were detected by western blot.
Results: BUN was 28.9 mg/dL (sham) and 56.6 mg/dL (5/6Nx) (P <0.05) proving 
success of the CKD model. In mouse heart, cardiac fibrosis of CKD mice was confirmed 
by Masson’s Trichrome staining of paraffin-sections. The protein abundance of UT-A was 
increased 1.4-fold and the pro-fibrosis marker vimentin was increased 1.7-fold in CKD 
mice vs. sham mice. Using immunohistology, we found that vimentin was also increased 
in CKD heart. In vitro, the amount of vimentin protein was increased 3.7-fold in UT-A1 
overexpressing cells compared with empty vector control mIMCD3 cells. Both systolic 
blood pressure (129 mmHg (5/6Nx) vs 116 mmHg (sham)) and heart to body weight ratio; 
(7.18 mg/g (5/6Nx) vs 4.73 mg/g (sham)) were increased (P <0.05) in CKD mice 8 weeks 
after surgery.
Conclusions: The upregulation of UT-A in uremic heart was associated with an 
increased vimentin protein level, which could be related with increased cardiac fibrosis in 
chronic kidney disease.
Funding: NIDDK Support
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CKD Mediates Cardiac Dysfunction by Recruiting Monocyte Derived 
Inflammatory Macrophages
Kevin Woollard, Ana Isabel Garcia Diaz, James A. Tomlinson, Charles D. Pusey. 
Imperial College London, London, United Kingdom.
Background: The relationship between chronic kidney disease (CKD) and accelerated 
cardiac disease is complex and not fully explained by traditional cardiovascular risk factors. 
Macrophages have critical roles in both kidney and cardiovascular disease, however a 
mechanistic link is not well described.
Methods: Using the folate induced nephropathy and 5/6 nephrectomy mouse models 
of CKD, we show that monocyte derived macrophages infiltrate heart tissue in large 
numbers but not other organs.
Results: We show using monocyte/macrophage transgenic reporters, with flow 
cytometry, imaging and qPCR, that the cardiac macrophage pool switches phenotype 
to a pro-inflammatory state during CKD. This cellular infiltrate was associated with an 
increase in cardiac remodeling through changes in extracellular matrix gene expression, 
cardiomyocyte enlargement and decrease in cardiac function, as shown by reduced ejection 
fraction. This phenotype was rescued by global knockout of C-C chemokine receptor type 
2 (CCR2-/-), associated with monocytopenia, during folate nephropathy. Measurement of 
specific chemokine expression in heart and plasma identified a unique chemokine axis, 
involving overexpression of CXCL10 that was also present in the plasma of CKD patients.
Conclusions: This work uncovers a novel pathway via CXCL10 that mediates 
cardiac inflammatory monocyte derived macrophage infiltration in the context of CKD, 
thus identifying new biological targets for improved diagnosis, prognosis and treatment of 
cardiomyopathy risk in CKD patients.
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Background: The primary cilium is an organelle, present at the cell surface and plays 
a role as an antenna. The primary cilium mediates cell proliferation, differentiation, death, 
and planar cell polarity. Recently, it has reported that transforming growth factor (TGF)-β 
receptors are localized and concentrated within the primary cilium in human mesenchymal 
stem cells. Also, the primary cilium regulates the transdifferentiation into myofibroblast 
of human adipose progenitor cells. We investigated a role of the primary cilium in renal 
fibroblast-myofibroblast transdifferentiation through regulating TGF-β1 receptors and the 
modulating cilia would attenuate interstitial fibrosis in unilateral ureteral obstruction (UUO) 
model.
Methods: NRK-49F cells were differentiated into myofibroblasts with TGF-β1. Using 
immunocytochemistry staining and western blot, the primary cilium and the fibroblast-
myofibroblast transdifferentiation in NRK-49F cells were studied. UUO was performed to 
evaluate the interstitial fibrosis.
Results: The primary cilium is crucial for the maintenance of the myofibroblasts 
phenotype and for TGF-β1-induced Smad phosphorylation. Knock-down of cilia proteins 
such as SMO, Arl13b, and IFT88 decreased the expression of α-SMA and Smad signaling. 
TGF-β receptors localized to the primary cilium in NRK-49F cells, especially when the 
cells are cytokinesis cycle. Colchicine, an inhibitor of microtubule polymerization, and 
HPI-4, ciliogenesis inhibitor, attenuates cilia growth and TGFβ1-induced fibrosis. In 
addition, colchicine treatment attenuates interstitial fibrosis in UUO mice kidney.
Conclusions: We provide the evidence that the primary cilium is indispensable for the 
transdifferentiation from fibroblast into myofibroblast by modulating TGF-β1 receptors. 
The cilia targeted therapy could be a promising option for attenuating renal fibrosis.
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The Dual Blockade Losartan/Erlotinib Attenuates Inflammation and 
Fibrosis Formation in Vitamin D Deficiency Rats Submitted to 5/6 
Nephrectomy
Janaina G. Goncalves, Ana Carolina de Braganca, Daniele Canale, 
Maria H. Shimizu, Antonio C. Seguro, Rildo A. Volpini. Faculty of Medicine - 
University of Sao Paulo, Sao Paulo, Brazil.
Background: 5/6 nephrectomy (N) is a classical experimental model of chronic 
kidney disease (CKD). Some studies have been linking vitamin D deficiency (VDD) to 
inflammatory process and renal fibrosis formation (RFF). Besides the beneficial effects 
of AII type I receptor antagonists, many efforts have been made to investigate alternative 
pathways related to RFF and inflammation. We evaluated the effects of the dual blockade 
including losartan (L) and erlotinib (E), an inhibitor of the epidermal growth factor receptor 
(EGFr) activity on CKD in rats under VDD.
Methods: Male Wistar rats received a vitamin D free (D) diet for 90 days. On day 30, 
rats were submitted to N surgery. Four groups were studied: D+N; D+N+L (50 mg/Kg/day 
in drinking water for 53 days); D+N+E (6 mg/Kg/day intraperitoneally for 53 days); 
D+N+L+E (dual treatment). We measured serum levels of 25(OH)D and aldosterone by 
ELISA; inulin clearance (Cin); mean arterial pressure (MAP); proteinuria; immunoblotted 
for TGF-β1, TGF-α and p-EGFr; performed IHC for CD206 and CD68; and evaluated 
interstitium enlargement by fraction interstitial area (FIA).
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Results: All animals had untedectable levels of 25(OH)D. L+E treatment improved 
renal function and decreased MAP and proteinuria. L+E treatment reduced the expression 
of TGF-β1, TGF-α and p-EGFr, attenuating the expansion of FIA. Also, L+E mitigated the 
inflammatory profile of macrophages.
Conclusions: The dual blockade L+E ameliorated the course of CKD by retarding 
RFF and modulating the inflammatory phenotype of macrophages. (FAPESP 2015/05513-
1; 2015/11933-3)
Funding: Government Support - Non-U.S.
Data are expressed as mean±SEM. BW, Body weight. a p<0.001, b p<0.01, c p<0.05 vs 
N+D; d p <0.001, e p<0.01, f p<0.05 vs. N+D+L; g p<0.001, i p<0.05 vs N+D+E.
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Molecular Mechanisms of CKD - II
Proteinuric Renal Injury Modulates Intestinal Lymphangiogenesis and 
Functionality of Plasma and Lymphatic HDL
Tadashi Otsuka, Haichun Yang, Babak Banan, Valentina Kon. Vanderbilt 
University Medical Center, Nashville, TN.
Background: Evidence suggests that in addition to plasma, critical changes in 
lipoprotein metabolism occur in the lymphatic circulation. Proteinuric renal injury changes 
lipoprotein levels and homoeostasis. Liver is a major regulator of lipoprotein metabolism, 
however, intestines also play a role, including synthesis of apolipoprotein AI (apoAI), the 
major protein in HDL. We examined how proteinuric renal injury affects intestinal handling 
of apoAI and functionality of HDL.
Methods: We studied Sprague-Dawley rats injected with puromycin aminonucleoside 
(PAN) or saline (C). Lymph was collected in conscious animals by indwelling mesenteric 
lymph duct cannulation. Lymphatic vessels were identified by immunohistochemistry (IHC) 
and RT-qPCR of podoplanin (PD). Functionality of HDL was assessed by cytokine response 
(TNFa, IL-6, Il-12 and iNOS/Arg1 ratio) in macrophages exposed to apoB-depleted HDL 
fractions isolated from plasma and lymph by RT-qPCR. HDL-cholesterol (HDL-C)/apoA1 
ratio served as a HDL-particle size marker.
Results: PAN significantly increased urinary albumin creatinine ratio vs C. Intestines 
of PAN had significant increase in PD+lymphangiogenesis and enlargement of lacteals 
accompanied by higher mesenteric lymph flow (6.3±1.7 vs 0.8±0.4ml/h). VEGFA was 
significantly elevated in PAN lymph and plasma (2.8-fold and 2.2-fold, respectively). 
Plasma HDL of PAN caused significantly greater macrophage inflammatory response 
[TNFa, IL-6, Il-12 (3.5-fold, 5.1-fold, 6.4-fold, respectively)] vs C. By contrast, HDL from 
mesenteric lymph of PAN was not pro-inflammatory and rather significantly decreased 
iNOS/Arg1 vs controls (0.5-fold). Although PAN did not change intestinal expression of 
apoA1 mRNA and IHC showed lower ileal apoAI than C, hepatic apoAI mRNA expression 
was significantly higher (3.9-fold). However, total output of apoAI in mesenteric lymph 
(apoAI quantity over time) was significantly higher in PAN (59.4±24.7 vs 11.2±6.5μg/h). 
Although HDLC/apoA1 ratio in lymph was similar, this ratio doubled in plasma of PAN 
(129.2±45.2 vs 60.0±21.1).
Conclusions: PAN renal injury increases intestinal lymphangiogenesis, mesenteric 
flow, composition and functionality of lymphatic HDL which is distinct from functionality 
of plasma HDL.
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Measurement Characteristics of Proximal Tubular Secretory Solutes
Yan Chen,1,2 Andrew N. Hoofnagle,1,2 Leila R. Zelnick,2 Ke Wang,1,2 
Jessica O. Becker,1 Bryan R. Kestenbaum.1,2 1University of Washington, Seattle, 
WA; 2Kidney Research Institute, Seattle, WA.
Background: Reliable measurements of proximal tubular solute clearance, a vital 
kidney function, have been elusive. We developed targeted liquid chromatographic-tandem 
mass spectrometric methods to quantify 16 endogenously produced secretory solutes 
in serum and urine. We tested diurnal variation of each solute, determined their kidney 
clearances, and assessed associations with the estimated glomerular filtration rate (GFR) in 
studies of healthy subjects and those with chronic kidney disease (CKD).
Methods: Among healthy controls, we measured plasma concentrations of each 
solute at 7 time points throughout the day. We calculated 24-hour urinary clearances from 
timed urine collections using the weighted 24-hour mean plasma value of each solute. We 
determined the diurnal within-subject coefficient of variation (CV) of plasma concentration 
for each solute. We investigated associations of derived clearances with estimated GFR in 
239 participants from the Seattle Kidney Study, a cohort study of CKD.
Results: Three of the 16 solutes had implausible kidney clearance values and 4 
exhibited high diurnal variation (Table). Nine solutes demonstrated reasonable diurnal 
stability and plausible clearance values. The clearances of these solutes correlated with GFR 
among CKD patients.
Conclusions: We identified 9 solutes that show promise for estimating proximal tubular 
secretory clearance - cinnamoylglycine, indoxyl sulfate, p-cresol sulfate, isovalerylglycine, 
kynurenic acid, pantothenic acid, pyridoxic acid, tiglylglycine, and xanthosine.
Funding: NIDDK Support
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Deubiquitinase Inhibitor PR-619 Reduces Smad4 Expression and 
Suppresses Renal Fibrosis in Mice with Unilateral Ureteral Obstruction
Kotaro Soji,1,2 Shigehiro Doi,1 Ayumu Nakashima,1 Takao Masaki.1 1Hiroshima 
University Hospital, Hiroshima, Japan; 2Hiroshima Red Cross Hospital & 
Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Background: Deubiquitinating enzymes (DUBs) remove ubiquitin from their 
substrates and, together with ubiquitin ligases, play an important role in the regulation of 
protein expression. Although transforming growth factor (TGF)-β1-Smad signaling is a 
central pathway of renal fibrosis, the role of DUBs in the expression of TGF-β receptors 
and Smads during the development of renal fibrosis remains unknown.
Methods: In this study, we investigated whether PR-619, a pan-DUB inhibitor, 
suppresses fibrosis in mice with unilateral ureteral obstruction (UUO) and TGF-β1-
stimulated normal rat kidney (NRK)-49F cells, a rat renal fibroblast cell line. Either the 
vehicle (dimethyl sulfoxide) or PR-619 (100 μg) was intraperitoneally administered to mice 
after UUO induction once a day for 7 days.
Results: Administration of PR-619 attenuated renal fibrosis with downregulation of 
mesenchymal markers, extracellular matrix proteins, matrix metalloproteinases, apoptosis, 
macrophage infiltration, and the TGF-β1 mRNA level in UUO mice. Although type I TGF-
β receptor (TGF-βRI), Smad2, Smad3, and Smad4 protein expression levels were markedly 
increased in mice with UUO, administration of PR-619 suppressed only Smad4 expression 
but not TGF-βRI, Smad2, or Smad3 expression. PR-619 also had an inhibitory effect on
TGF-β1-induced α-smooth muscle actin expression and reduced Smad4 levels in NRK-
49F cells.
Conclusions: Our results indicate that PR-619 ameliorates renal fibrosis, which is 
accompanied by the reduction of Smad4 expression.
Funding: Private Foundation Support
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Regulating Hyaluronan Deposition Attenuates Tubulointerstitial Fibrosis 
in Ureteral Obstruction
Xinyi Wang,1,2 Swathi Balaji,3 Emily Steen,3 Hui Li,3 Alexander Blum,3 
Paul Austin,4 Paul L. Bollyky,5 Thomas N. Wight,6 Jizhong Cheng,3 
Sundeep G. Keswani.3 Laboratory for Regenerative Tissue Repair 1Surgery, 
Baylor College of Medicine, Houston, TX; 2Pediatric Surgery, Texas Children’s 
Hopsital, Houston, TX; 3Baylor College of Medicine, Houston, TX; 4Texas 
Children’s Hospital, Houston, TX; 5Stanford University, Stanford, CA; 6Benaroya 
Research Institute, Seattle, WA.
Background: Renal fibrosis is an end-stage outcome of chronic kidney disease(CKD) 
without foreseeable cure. However, we recently found that interleukin-10 (IL-10) can 
abrogate dermal fibrosis by regulating hyaluronan(HA), an abundant glycosaminoglycan 
in the extracellular matrix (ECM). Here, we hypothesize that promoting the expression 
of the high molecular weight(MW) HA form attenuates renal fibrosis by regulating ECM 
remodeling and reducing inflammation.
Methods: in vivo: we used the UUO model in the presence or absence of IL-10 to 
assess the HA role. UUO/sham kidneys were collected at d3,7,14&21 for RNA, ELISA, 
and/or IHC analyses. HA synthases(HAS1-3) and hyaluronidases(HYAL1-2) enzyme levels 
were determined by qPCR and immunoblotting (IB), while HA MW was confirmed by gel 
electrophoresis. To test loss of function effects, we fed mice with 4-methylumbelliferone(4-
MU,5%), a HA synthesis inhibitor, and evaluated the outcomes.in vitro: renal fibroblasts(FB) 
were isolated from C57BL/6J mice to measure total HA by pericellular matrix assays. α-
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SMA, HAS1, 2 and p-STAT3 expression were also assessed by IB at 48h. Mean ±SD; 
p-values by ANOVA.
Results: in vivo: HAS1 & HAS2 expression was upregulated in normal and 4MU-
fed UUO mice compared to control mice from d3 onwards. ELISA showed that total HA 
levels steadily increased from d3-14 for UUO mice, and up to d21 for IL-10-treated UUO 
mice. In normal diet mice, lenti-IL-10 resulted in decreased kidney fibrosis and preserved 
tubular integrity in comparison to controls. IL-10-treated 4-MU diet mice did not attenuated 
fibrosis. HA gel electrophoresis showed that unlike control/sham kidneys, d3&7 UUO 
kidneys had a previously unreported 1.5x106D HA form. in vitro: A 1.88-fold increase in 
HA-rich matrix formation was shown with 24h of IL-10 stimulation, and the effect was 
abrogated by HYAL. Significant increased HAS2, α-SMA, & p-STAT3 in the IL-10-treated 
FBs after 48h. p<0.05
Conclusions: Our study provides the first evidence that injured mouse kidney expresses 
increased levels of an ultra-high MW HA variant not found in normal kidneys. This 
suggests that HA is critical for kidney function, homeostasis, and architectural integrity. 
Understanding the mechanisms behind HA-mediated in renal fibrosis could lead the design 
and application of innovative therapeutics.
Funding: Other NIH Support - NIGMS, Clinical Revenue Support
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A Critical Role of Histone Methyltransferase EZH2 in Mediating Renal 
Epithelial-Mesenchymal Transition and Renal Fibrogenesis
Xiaoxu Zhou,2 Chongxiang Xiong,2 Shougang Zhuang.1 1Department of 
Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, 
Providence, RI; 2Rhode Island Hospital, Brown University, Providence, RI.
Background: EZH2 (Enhancer of Zeste Homolog 2) is a methyltransferase that 
induces histone H3 lysine 27 trimethylation (H3K27me3) and functions as an oncogenic 
factor in many cancer types. Its role in renal epithelial-mesenchymal transition (EMT) 
remains unknown.
Methods: In this study, we examined the effect of EZH2 inhibition on EMT and renal 
fibrosis in the kidney following unilateral ureteral obstruction (UUO).
Results: We found that EZH2 and H3K27me3 were highly expressed in the kidney 
of mice with and cultured mouse kidney proximal tubular cells (TKPT) undergoing EMT. 
Inhibition of EZH2 with 3-deazaneplanocin A (3-DZNeP) attenuated renal fibrosis, which 
was associated with preserving E-cadherin expression and inhibiting vimentin upregulation 
in the obstructed kidney. Treatment with 3-DZNeP or transfection of EZH2 siRNA also 
inhibited TGF-β1-induced EMT of TKPT. Injury to the kidney or cultured TKPT resulted 
in upregulation of Snail1 and Twist, two transcription factors, and downregulation of 
PTEN, a protein tyrosine phosphatase associated with inhibition of PI3K-AKT signaling; 
EZH2 inhibition or silencing reversed all those responses. 3-DZNeP was also effective in 
suppressing epithelial arrest at G2/M phase and dephosphorylating AKT and β-catenin in 
in vivo and in vitro.
Conclusions: These data indicate that EZH2 activation contributes to renal EMT and 
fibrosis through activation of multiple signaling pathways and suggest that EZH2 would be 
a novel therapy for treatment of renal fibrosis.
Funding: NIDDK Support, Government Support - Non-U.S.
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Molecular Mechanisms of CKD - II
Single Nephron Dynamics in Patients with Obesity-Related 
Glomerulopathy
Yusuke Okabayashi,1,2 Nobuo Tsuboi,1 Takaya Sasaki,1 Kotaro Haruhara,1 
Go Kanzaki,1 Kentaro Koike,1 Akira Shimizu,2 Takashi Yokoo.1 1The Jikei 
University School of Medicine, Tokyo, Japan; 2Nippion Medical School, Tokyo, 
Japan.
Background: The etiologies and mechanisms underlying the progression of obesity-
related glomerulopathy (ORG) remain largely unknown, and the urinary protein excretion 
(UPE) level is the only predictive factor for renal outcome. ORG is characterized by renal 
histopathological findings of low glomerular density with glomerulomegaly, related to 
glomerular hyperfiltration. In this study, we estimated total nephron number and related 
factors in patients with ORG at different stages of the disease.
Methods: The total nephron number was calculated using a simplified method based on 
combined use of unenhanced computed tomography and non-sclerotic glomerular density 
in renal biopsy. Single-nephron glomerular filtration rate (snGFR) and single-nephron UPE 
(snUPE) were calculated by dividing eGFR or UPE by total nephron number, respectively. 
The glomerular volume (GV) was estimated from the measured mean glomerular area. 
Obese kidney transplantation donors were included in the study as a control group.
Results: Among the 30 Japanese ORG patients included in the study, total nephron 
number ranged from 153000 to 1061000 per kidney and was inversely correlated with 
GV (r = –0.366, p = 0.047). The snGFR was correlated with GV (r = 0.631, p < 0.001), 
and snUPE was correlated with the degree of glomerulosclerosis (r = 0.633, p < 0.001). 
None of these parameters associated with total nephron number showed a correlation with 
body mass index (BMI). Patients with advanced renal impairment were characterized by 
diminished snGFR and markedly elevated snUPE level (Figure). Among the ORG patients 
with preserved renal function (eGFR  45 mL/min/1.73 m2, n = 22), total nephron number 
was identified as a factor associated with UPE at diagnosis, independent of eGFR and BMI.
Conclusions: There is a close relationship between difference in total nephron number 
and severity of ORG, in relation to changes in the single nephron dynamics. Compensatory 
failure of glomerular hyperfiltration may be a characteristic of advanced ORG.
FR-PO145 Poster Friday
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Analysis of the Peritubular Capillaries and Lymphatics in a Model of 
Renal Injury and Repair
Marie-Louise Monaghan, Carolynn Cairns, Gary Borthwick, Laura Denby, 
Jeremy Hughes, Bryan Conway. University of Edinburgh, Edinburgh, United 
Kingdom.
Background: Chronic kidney disease has a diverse range of aetiologies, but all are 
associated with alterations in the renal interstitial microvasculature. We hypothesised that 
renal injury promotes loss of peritubular capillaries leading to tubular cell hypoxia, but 
conversely lymphatic vessel density may increase as a compensatory response to reduce 
inflammation and facilitate repair.
Methods: C57Bl/6 mice underwent unilateral ureteric obstruction (UUO) or sham 
surgery. After 7 days of UUO, 8 mice were culled while in the remaining mice the ureter 
was re-implanted into the bladder to relieve obstruction (R-UUO) for 1, 2 and 4 weeks 
(n=6-8). Kidneys were harvested and analysed by flow cytometry, immunostaining, 
RNAseq, qPCR and electron microscopy.
Results: Flow cytometry demonstrated a 16-fold increase in the proportion of 
dead DAPI+/CD31+ endothelial cells (ECs) in UUO kidney v sham (p=<0.001). CD31 
quantification by IHC revealed a doubling in areas of capillary rarefaction in UUO v sham 
(p=<0.001), with the degree of rarefaction falling by 31% following R-UUO (p=<0.001). 
Electron microscopy analysis demonstrated a reduction in peritubular capillary fenestrations 
and an increase in EC vacuolation, which partially reversed following R-UUO. While the 
density of Lyve-1+ lymphatic vessels remained similar in UUO kidney v sham, there was a 
doubling of lymphatic vessels after 4 weeks of relief of obstruction (p<0.05). RNAseq and 
qPCR analysis of renal cortex revealed a reduction in Vegfa in UUO v sham, which partially 
reversed following R-UUO. Conversely there was a significant up-regulation of Vegfc and 
Vegfd, most notably following R-UUO. Gene expression of Vegfr3 increased in UUO 
compared with sham (p<0.01), and this persisted through to week 4 after R-UUO. Dual 
immunofluorescence for VEGFR3 and LYVE-1 determined that the increase in VEGFR3 
staining occurred largely in CD31+/Lyve1- vessels, most likely peritubular capillaries. This 
was confirmed by flow cytometry with the proportion of CD31+/podoplanin- cells that co-
expressed VEGFR3 increasing from 7% in sham to 36% in UUO kidney.
Conclusions: Our data suggest that peritubular capillary rarefaction occurs following 
renal injury and only partially improves following cessation of injury. Therapies that 
prevent capillary rarefaction may reduce secondary renal injury and augment repair.
Funding: Private Foundation Support
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The Role of Complement C1r and C1s Serine Proteases in Kidney Fibrosis 
Sandhya Xavier,1 Ranjit K. Sahu,2 Didier Portilla.3 1University of Virginia/
Department of Medicine, Charlottesville, VA; 2University of Virginia, 
Charlottesville, VA; 3University of Virginia Health System, Charlottesville, VA.
Background: We previously reported increased expression of C1q in kidney cells 
as a pathophysiologic mechanism leading to kidney fibrosis. The classical pathway of 
complement activation is initiated by the assembly of the C1 complex which consists of 
C1q and serine proteases C1r and C1s. We hypothesize that activation of classical pathway 
in kidney cells contributes to tubulointerstitial fibrosis, and tested this idea in mice with 
global deletion of C1r.
Methods: We performed real time-PCR, immunohistochemistry, in situ hybridization, 
western blotting and microarray based gene expression analysis in wild type (WT) and in 
C1r-/- mice subjected to unilateral ureteral obstruction (UUO) or folic acid injury (FA). We 
overexpressed human C1r in human tubular epithelial cells
Results: Administration of FA or UUO injury in WT mice led to upregulation 
of C1r and C1s mRNA and protein in whole kidney tissue. In situ hybridization and 
immunohistochemistry localized increased expression of these proteases to distal tubular 
epithelial cells. C1r deletion reduced fibrosis in both animal models. While kidney 
inflammation and complement activation measured by increased expression of C3 
fragments were significantly reduced in the FA model, C3 formation and inflammation 
were not affected in the UUO mice, despite the reduction in fibrosis. While C1r-/- mice 
had reduced C1s expression, stable transfection of human C1r in renal epithelial cells 
led to increased expression of both C1r and C1s. Gene expression arrays corroborated 
downregulation of probe sets representing C1r and C1s in kidney tissue of C1r-/- mice, as 
well as downregulation of genes associated with connective tissue and collagen. C1r-/- mice 
treated with FA had reduced expression of genes associated with increased inflammation.
Conclusions: In conclusion our studies support the role of classical complement 
pathway activation during fibrosis via increased expression of C1r in distal tubular epithelial 
cells and identify C1r as a novel potential therapeutic target for the treatment of progressive 
kidney disease.
Funding: NIDDK Support, Veterans Affairs Support
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Loss of C5aR1 in Foxd1+ Stromal Cells Reduces Kidney Fibrosis
Ranjit K. Sahu,2 Sandhya Xavier,1 Didier Portilla.3 1University of Virginia/
Department of Medicine, Charlottesville, VA; 2University of Virginia, 
Charlottesville, VA; 3University of Virginia Health System, Charlottesville, VA.
Background: Recent studies have identified a population of perivascular mesenchymal 
cells in the kidney that express the transcription factor Foxd1. These cells are called resident 
fibroblasts or pericytes. Fate-mapping studies have identified these pericytes and resident 
fibroblasts as the major precursor population of interstitial myofibroblasts in animal models 
of kidney disease. We previously reported increased synthesis of complement components 
including anaphylatoxin receptor C5aR1 in PDGFβR-positive pericytes isolated from 
murine models of fibrosis. Reduced expression of C5aR1 using global deletion of C5aR1 
ameliorates renal fibrosis. We hypothesize that deletion of C5aR1 in Foxd1-expressing cells 
can lead to reduced myofibroblast production, reduced inflammation, and reduced kidney 
fibrosis.
Methods: C5aR1GFPfl/fl mice were generated by inserting LoxP sites flanking exon 
2 as previously reported. C5aR1GFPfl/fl mice were crossed with mice expressing Cre-
recombinase under control of the Foxd1 promoter to generate Foxd1-Cre-C5aR1GFPfl/fl  
mice. Eight week old Foxd1-Cre-C5aR1GFPfl/fl mice and C5aR1GFPfl/fl (control mice) 
received intraperitoneal injections of either vehicle (sodium bicarbonate) or folic 
acid+sodium bicarbonate (FA). Two weeks later kidney tissue was harvested for analysis. 
Primary mouse pericytes were isolated from the kidneys of Foxd1CreC5aR1GFPfl/fl and 
C5aR1GFPfl/fl following FA-injury as previously reported
Results: Immunohistochemical analysis, flow cytometry, quantitative RT-PCR and 
western blots demonstrated reduced inflammation and reduced fibrosis in whole kidney 
tissue from Foxd1CreC5aR1GFPfl/fl mice treated with FA when compared to control mice. 
Cytokine production measured by Luminex assays in cell supernatants from cultured 
PDGFβR+ cells isolated from kidneys of FA-treated mice demonstrated that the absence of 
C5aR1 receptor in cultured pericytes reduces inflammatory cytokine production including 
IL6, TNFalpha, and MIP2.
Conclusions: The loss of C5aR1 in Foxd1 stromal cells reduces kidney fibrosis and 
reduces inflammatory response of kidney pericytes. These results support the role of 
increased expression of pericyte C5aR1 in the pathogenesis of kidney fibrosis.
Funding: NIDDK Support, Veterans Affairs Support
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Study of the Expression of Renal PCSK9 in the Rrm2b Mouse Model of 
Nephrotic Syndrome
Eduardo Molina-Jijon,1 Stephanie Gambut,1 Camille E. Mace,1 Carmen Avila-
Casado,2 Lionel C. Clement.1 Glomerular Disease Therapeutics Laboratory 
1Rush University Medical Center, Chicago, IL; 2University Health Network, 
University of Toronto, Toronto, ON, Canada.
Background: 85% of American chronic disease patient presenting nephrotic syndrome 
(NS) have high levels of low density lipoprotein cholesterol (LDL-c), compared to only 
31.5% in the American general population. A factor from the kidney might be responsible 
for the increased susceptibility for high levels of LDL-c in NS patients. Proprotein 
convertase subtilisin/kexin type 9 (PCSK9) was shown to play an important role in the 
regulation of LDL-c levels in the liver. PCSK9 is expressed in the kidney at a lower level 
of expression compared to the liver, but its role in this organ is not clear. We decided to 
study the expression and the role of PCSK9 in NS in the Rrm2b mouse, a model collapsing 
glomerulopathy.
Methods: Male Rrm2b Control (+/+) and knock-out (-/-) mice (6 mice/group) were 
studied every week between the age 5 and 12 weeks. Albuminuria, PCSK9 and cholesterol 
serum levels were assessed. PCSK9 gene and protein expression in liver, kidney, intestine 
and serum were studied by RealTime PCR, Western blot, and confocal microscopy.
Results: Rrm2b+/+ mice do not develop albuminuria, hypercholesterolemia, or high 
levels of serum PCSK9. Compared to controls, Rrm2b-/- develop albuminuria from the 
age of 7 weeks (from 425±239 μg/18h at 7 weeks to 3895±381 at 10 weeks (P<0.001)). 
Serum PCSK9 levels significantly increase from the age of 8 weeks (from 19.75±5.21 ng/ml 
at 8 weeks (P<0.05) to 55.54±13.07 at 10 weeks (P<0.01)). Serum total cholesterol levels 
significantly increase from the age of 8 weeks (from 124.16±10.27 mg/dl at 8 weeks 
(P<0.05) to 567.58±72.96 at 10 weeks (P<0.001)). PCSK9 gene expression is relatively 
unchanged as animal age. PCSK9 protein expression was shown by Western blot to increase 
in the renal cortex from the age of 9 weeks, and decrease in the liver from the age of 
7 weeks. By confocal microscopy, PCSK9 was shown to co-localize with Aquaporin-2, 
indicating expression in the collecting duct where its expression is increased from the age 
of 7 weeks.
Conclusions: As Rrm2b-/- mice age and develop NS, PCSK9 protein levels increase 
in the kidney and serum, and decrease in the liver. Collecting duct expressed PCSK9 may 
play an important role in the initiation of hypercholesterolemia in NS in the Rrm2b mouse 
model, as a link between the kidney and the liver.
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Nephron Loss Reduces Excretion of Urinary Extracellular Vesicles
Charles J. Blijdorp,1 Thomas Hartjes,1 Bart J. Kramers,2 Martin E. Van royen,1 
Ron T. Gansevoort,3 Robert Zietse,1 Ewout J. Hoorn.1 1Erasmus Medical Center, 
Rotterdam, Netherlands; 2Harvard, Groningen, Netherlands; 3University 
Medical Center Groningen, Groningen, Netherlands.
Background: Urinary extracellular vesicles (uEVs) are emerging as non-invasive 
biomarkers for various kidney diseases. We previously showed that the uEV-marker CD9 
decreases with disease progression in autosomal dominant polycystic kidney disease 
(ADPKD; Salih et al., J Am Soc Nephrol 2016). Therefore, here, we hypothesize that 
nephron loss decreases uEV excretion.
Methods: We quantified uEVs in two different settings of nephron loss, including 
donor nephrectomy and ADPKD with progressive decline of estimated glomerular filtration 
rate (eGFR). We obtained spot and 24-hour urine samples from 20 kidney donors the day 
prior and 3 months after nephrectomy, and from 27 ADPKD patients at baseline and after 
a median follow-up time of 3 years. uEVs were quantified using 3 techniques, including 
EVQuant (a novel technique which counts individual fluorescently labeled EVs after 
immobilization in a matrix), nanoparticle tracking analysis (NTA), and a time-resolved 
fluorescence immunoassay (TRFIA) capturing CD9+ uEVs.
Results: Baseline kidney function correlated with uEV excretion in both healthy 
donors (EVQuant vs. eGFR: R2 0.41, P = 0.01) and ADPKD patients (CD9-TRFIA vs. 
mGFR: R2 0.23, P = 0.02). Donor nephrectomy reduced eGFR by 32 ml/min/1.73m2 or 38% 
after 3 months. uEV excretion decreased by 18% as analyzed by EVQuant (95%CI: 6-31%), 
21% by NTA (95%CI: 7-34%) and 22% by TRFIA (95%CI: 3-42%). In the ADPKD cohort 
the average loss in eGFR was 4.1 ml/min/1.73m2/year (95%CI 2.9-5.2), or 18% after 3 years 
(95%CI 13-23%). In this period, the number of uEVs reduced by 22% (95%CI: 9-36%, as 
analyzed by TRFIA).
Conclusions: Nephron loss reduces uEV excretion both after donor nephrectomy 
and in progressive ADPKD. Therefore, it is important to adjust for uEV excretion when 
performing cross-sectional or longitudinal analyses of uEVs in patients with reduced kidney 
function.
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Deconvolving Bulk Disease Expression Datasets Using Markers Identified 
from Single-Cell Sequencing Data Defines CKD Associated Cell Types
Rachel S. Sealfon,1 Rajasree Menon,2 Evren U. Azeloglu,3 Edgar A. Otto,2 
Paul J. Hoover,6 Olga Troyanskaya,4,1 Matthias Kretzler.5 1Center for 
Computational Biology, Flatiron Institute, New York, NY; 2University of 
Michigan, Ann Arbor, MI; 3Icahn School of Medicine at Mount Sinai, New York, 
NY; 4Princeton University, Princeton, NJ; 5U.Michigan, Ann Arbor, MI; 6Broad 
Institute, Cambridge, MA.
Background: Elucidating changes in cell type composition across diseases can provide 
insight into pathology-related alterations in kidney tissue. Single-cell data from tumor 
nephrectomy tissue allows the identification of cell type markers in the adult human kidney. 
By integrating this information with bulk expression data from 223 biopsies from the 
European Renal cDNA Bank cohort (ERCB), we identify cell type proportion alterations 
across 9 diverse glomerular diseases.
Methods: We first identify cell type specific genes in an unbiased, data-driven 
manner from eight adult kidney single cell 10X Genomics expression datasets from tumor 
nephrectomy tissue. We extract markers from the single-cell expression data using the Seurat 
R package (Butler et al., 2018). We then expand these cell type specific marker sets by 
identifying additional cell type specific marker genes using computational nanodissection 
(Ju et al., 2013) and perform pathway enrichment analysis. Using our expanded set of 
marker genes, we deconvolve microdissected glomerular bulk expression data from the 
ERCB cohort using CellCODE (Chikina et al., 2015) to identify differences in cell type 
composition across patients with diverse kidney diseases.
Results: Both the cell type specific marker genes identified from single-cell data and 
the additional cell type marker genes identified by nanodissection show relevant functional 
enrichments. Consistent with prior knowledge, we find that podocyte markers are lost in 
diseased patients compared to living donors, monocyte markers are elevated in immune-
mediated diseases such as lupus nephritis relative to other kidney diseases, and mesangial/
vascular smooth muscle cell markers are elevated in diabetic nephropathy. Multiple cell 
type markers are correlated with GFR, with podocyte markers positively correlated and 
parietal epithelial cell markers negatively correlated
Conclusions: Integrating single-cell and bulk expression data provides insight into 
cell composition changes across diverse kidney diseases. Our approach illustrates the 
power of leveraging and integrating multimodal data types to understand the molecular 
underpinnings of disease processes.
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MicroRNA-34a Induces Renal Aging by Regulating SIRT1/p53/p21 
Pathway and Promoting the Expression of Senescence-Associated 
Secretory Phenotype (SASP)
Fanfan Gao,1 Hongli Jiang.2 Dialysis Department of Nephrology Hospital, First 
Affiliated Hospital of Medicine School, Xi’an Jiaotong University, Xi’an 
710061, Shaanxi, China 1Dialysis Department of Nephrology Hospital, First 
Affiliated Hospital of Medicine School, Xi’an Jiaotong University, Xi’an, China; 
2First Affiliated Hospital of Medicine School, Xi?an Jiaotong University, 
Xi’an, China.
Background: An increasing number of investigations suggest that small non-coding 
microRNAs play an important role in the regulation of genes involved in various kidney 
disease. MicroRNA-34a (miR-34a) has been recently implicated in cardiac, endothelial, 
endothelial progenitor cell, vascular smooth muscle cell senescence, however, its 
contribution to the aging process of kidney has not been explored so far. The aim of the 
present study was to analyze miRNA expression profiles and the rule of miR-34a in mice 
kidney during the aging process.
Methods: The kidneys of male C57BL/6 mice at different ages (3 months, 12 months 
and 24 months, n=5 per group) were used. Total RNA was extracted using Trizol reagent 
following the manufacturer’s procedure. The total RNA quantity and purity were analysis 
of Bioanalyzer 2100 with RIN number >7.0. Approximately 1 ug of total RNA were used to 
prepare small RNA library according to protocol of TruSeq Small RNA Sample Prep Kits. 
And then we performed the single-end sequencing (36bp or 50bp) on an Illumina Hiseq 
2500 at the LC-BIO following the vendor’s recommended protocol. In addition, the results 
were assessed by real-time PCR and western blotting in kidneys of mice.
Results: Several up- and downregulated miRNAs were identified in the mice kidneys 
at 3 different ages. We observed the upregulation of miR-26a, miR-214, miR-34a, miR-
34c, miR-29c, miR-199a, miR-21a, miR-27a, miR-195a and miR-23a, whereas miR-335, 
miR-200b, miR-378a, miR-151, miR-486a, miR-615, miR-378 were downregulated in 
the aging mice kidneys. We found that miR-34a was highly expressed in kidneys isolated 
from old mice. Moreover, its well-known target, the longevity-associated protein SIRT1, 
was significantly downregulated during aging in both kidney tissue and HK-2 cells. miR-
34a overexpression in HK-2 cells caused cell cycle arrest along with enhanced p21 and 
p53 protein levels and reduced SIRT1 protein expression. Furthermore, miR-34a ectopic 
expression induced the expression of SASP, including TNF-α, IL-1α, IL-6, plasminogen 
activator inhibitor-1 and monocyte chemoattractant protein-1.
Conclusions: In conclusion, our findings suggest that aging-associated increase of 
miR-34a expression plays an important role in renal aging by inhibition of SIRT1 and 
activation of p53/p21 pathway as well as the induction of SASP.
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Weekly Subcutaneous Mutated Human Angiopoietin – Like 4 (8520) 
Improves CKD in Diabetic Rats via an Anti-Endothelial Apoptosis 
Mechanism
Sumant S. Chugh,1 Maria Del Nogal Avila,1 Ranjan Das,1 Joubert B. Kharlyngdoh,1 
Hector Donoro blazquez,1 Eduardo Molina-Jijon,1 Lionel C. Clement,1 
Camille E. Mace,1 Carmen Avila-Casado.2 Glomerular Disease Therapeutics 
Laboratory 1Rush University Medical Center, Chicago, IL; 2University Health 
Network, University of Toronto, Toronto, ON, Canada.
Background: We previously showed that single intravenous dosing of recombinant 
mutated human Angptl4 (8520) reduces proteinuria for over 2 weeks in diabetic rats 
(Clement L, Mace C, et al Nature Medicine Jan 2014). We now tested whether subcutaneous 
doses in diabetic rats would reduce CKD.
Methods: We treated male ZSF1 rats (n = 5 rats / group) with 8520 or rat albumin once 
a week subcutaneously in declining doses, starting with 500 μg per dose on Week 0 (W0) to 
125 μg on Week 9, to 100 μg on Week 15 and 50 μg on Week 16, after which the treatment 
was stopped and rats sacrificed on W20. Food and water intake, proteinuria, blood glucose, 
plasma human Angptl4 levels and serum parameters were measured periodically.
Results: Pharmacokinetic assessment of plasma human Angptl4 (8520) levels 
showed elevated levels between W1 and W15 at dose ranges between 500 μg and 100 μg 
subcutaneously per week. Plasma levels were statistically similar at doses between 500 μg 
and 125 μg. Plasma creatinine was significantly lower in the treatment group (P < 0.01 to P 
< 0.001) between doses 500 and 125 μg, and BUN between 500 and 100 μg (P < 0.05). 18-
hour proteinuria was mostly similar between treatment and control groups, and as were the 
plasma glucose and triglyceride levels. Histological improvement revealed very significant 
improvement morphometric parameters in the treatment compared to control group. 
TUNEL staining for apoptosis revealed very significant reduction in interstitial capillary 
endothelial apoptosis in the treatment Vs. the control group (P < 0.001).
Conclusions: Weekly subcutaneous doses of mutated human Angptl4 in ZSF1 rats 
improves GFR at doses between 500 and 125 μg. Despite sub-therapeutic doses and 
stopping treatment towards the end, morphology was significantly improved, suggesting a 
memory effect. The absence of effects on proteinuria and the highly significant difference in 
interstitial capillary endothelial apoptosis suggests that the beneficial effects of subcutaneous 
dosing are mediated by preserving interstitial capillaries and presumably promoting repair 
in the treatment group.
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miRNA Profiling of Kidney Disease Indicates a Conserved Role for 
miRNA99 Family
Archana Raman,1 Verónica Miguel,2 Chengxiang Qiu,1 Jihwan Park,1 
Shizheng Huang,1 Katalin Susztak.1 Susztaklab 1University of Pennsylvania, 
Philadelphia, PA; 2CBMSO, Madrid, Spain.
Background: MicroRNAs (miRNAs) are short non-coding RNA molecules that play 
a crucial role in cellular homeostasis by regulating gene expression. Lately, miRNAs have 
become important therapeutic targets. To determine consistently altered miRNAs that could 
causally affect chronic kidney disease (CKD) development, we sought to define miRNA 
profiles in kidneys of five different CKD models and validated these results in patient 
samples.
Methods: miRNA fraction was isolated from the kidneys of wildtype mice or 
mice with CKD induced by 1) unilateral ureteral obstruction (UUO), 2) folic acid (FA) 
administration, 3) transgenic expression of Notch intracellular domain in tubule cells, 4) 
transgenic expression of PGC1α in podocytes and 5) transgenic expression of APOL1 
risk allele in podocytes. Small RNA sequencing was followed by miRNA alignment and 
abundance quantification. qPCR analysis and in situ hybridization were used to validate 
candidate miRNAs differentially expressed in CKD. We used microRNA mimics and 
inhibitors to understand the role of miRNA in cultured renal tubule cells.
Results: We detected differences in levels of 457 miRNAs among all analyzed models 
of kidney disease. miR-99 family consisting of 99a, 99b and 100, were significantly 
downregulated in all five models. In situ hybridization for miR-99 family on wildtype, 
UUO, and FA kidney sections showed that these miRNAs were expressed widely in 
normal tubules but absent or significantly downregulated in injured/dedifferentiated 
tubules. Importantly, human renal biopsy sections also showed significant downregulation 
in the expression of the miR-99 family in CKD patients, compared to healthy volunteers. 
Furthermore, transfection of HKC8, a human proximal tubule cell line, with miR-99a and 
100 mimics improved epithelial characteristics and reduced proliferation. We identified 
IGF1 and mTOR as likely targets of miR-99 family in kidney tubule samples.
Conclusions: We found that miR-99a, 99b and 100 are significantly downregulated 
across all examined CKD models and human subjects, implying a causal role in disease. 
Upregulation of miR-99 family in vitro significantly decreased expression of mTOR, IGF-
1, cell proliferation and improved epithelial characteristics, suggesting a crucial regulatory 
function. In summary, miR-99 family could be potential therapeutic targets for CKD.
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The Effect of Autophagic Flow in the Phenotype Transformation of 
Macrophage M1/M2
Yuqiu Liu,1 Yuteng Jiang,1 Yu Zhao,1 Xiaodong Zhu,1 Beibei Wu,1
Xiaoliang Zhang.2 1Institute of Nephrology, Zhong Da Hospital, Southeast 
University School of Medicine, Nanjing, China; 2Zhong Da Hospital, Southeast 
University, School of Medicine, Nanjing, China.
Background: Macrophage infiltration is an important histopathological feature 
of kidney disease, and its activation state in the microenvironment is the main factor 
determines disease prognosis. Autophagy is a process in which lysosomes degrade their 
own damaged and excess proteins. It’s highly dynamic, also known as autophagic flow. In 
this study, macrophages were cultured in vitro to fully observe the levels of autophagic flow 
and the effects on the M1/M2 phenotype transformation.
Methods: The macrophages RAW264.7 were stimulated with IFN-γ+LPS and IL-4 for 
24h to induce M1 and M2 activation. Use of autophagosome-generating activator (RAPA), 
autophagosome production inhibitor (3-MA), autolysosome fusion inhibitor (BAFA) and 
autolysosome degradation inhibitor (CQ) to intervene M1/M2 for 24h. The expression 
levels of M1 markers, M2 markers and autophagy markers were detected by western blot 
and immunofluorescence. Then using an electron microscope to observe autophagic flow.
Results: 1. The expression of M1 markers (iNOS, TNF-α) increased with IFN-γ+LPS. 
Instead, IL-4 stimulated activation of M2 that the levels of MR and Arg-1 increased. 2. 
Autophagy-related proteins LC3 and Beclin-1 had higher level in M2 cells with the level 
of autophagy specific degradation protein p62 decreased, suggesting the autophagy level 
of M2 cells was higher than that of M1 cells. 3. The autophagosome formation, fusion of 
autophagosomes with lysosomes, autolysosome formation, and substrate degradation were 
observed by EM. 4. For M1 cells, RAPA increased the expression of LC3, Beclin-1 and 
p62, while those decreased with 3-MA. After BAFA intervention, the expression of LC3 
and Beclin-1 decreased, when p62 was significantly increased. But the expression of LC3-
II, Beclin-1 and p62 showed a tendency to increase after CQ intervention. 5. Activation of 
autophagy induced the transformation of M2 cells, while inhibition of autophagy induced 
M1 activation.
Conclusions: Autophagic flow can regulate the mutual transformation of macrophage 
M1/M2 phenotype. But changes in a single marker can’t confirm the level of autophagy in 
the cell, the dynamic changes in autophagy flow need to be evaluated.
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Molecular Magnetic Resonance Imaging of Allysine to Quantify Renal 
Fibrogenesis
Bryan C. Fuchs, Yinching I. Chen, Diego Dos santos ferreira, Gunisha Arora, 
Ricard Masia, Ivy Rosales, Robert B. Colvin, Peter Caravan. Massachusetts 
General Hospital, Boston, MA.
Background: Chronic kidney disease (CKD), most commonly caused as result of type-
2 diabetes or ischemic/hypertensive nephropathy, currently affects 12% of all adults in the 
US. The fibrotic deposition and remodeling of extracellular matrix proteins to form cross-
linked collagen fibers is a characteristic feature of CKD and eventually results in end stage 
renal disease. Critical to fiber formation is the enzymatic production of allysine on collagen, 
which facilitates fibril cross-linking through condensation reactions with neighboring 
allysine and lysine residues. We have developed a novel Gd-based MRI probe, GdOA, 
designed to target allysine for noninvasive imaging of active fibrogenesis in kidney disease.
Methods: The ability of GdOA to detect fibrogenesis was evaluated in two animal 
models of CKD - nephrotoxic serum nephritis (NTN) and Col4a3-/- Alport mice. For the 
NTN model, 129/SvEv mice were dosed at day 0 with 250 μg Sheep IgG and then with 
125 μL sheep anti-rat GBM serum on day 5. Control animals received PBS injections. 
Animals were imaged 7 days post GBM serum injection. For the Alport model, wild type 
and Col4a3-/- mice were imaged at 6-10 weeks of age to assess mild and advanced stages 
of disease. Following MRI, kidneys were collected and assessed for hydroxyproline (HYP) 
content and tissue histology.
Results: The NTN model resulted in diffuse tubular injury, glomerulosclerosis, and 
mild fibrosis. GdOA resulted in a 6.9 fold increase in ΔR1 (probe relaxivity) in the cortex 
of the NTN group compared to control mice (p = 0.048). Hydroxyproline content in tissue 
was 1.88 fold higher for NTN animals compared to control animals (p = 0.0004) and 
ΔR1 showed positive correlation with increasing HYP concentrations (r = 0.625). In the 
Col4a3-/- mice, Gd-OA was able to detect early stages of disease and also correlated with 
increasing HYP concentrations.
Conclusions: The requirement of allysine for the crosslinking of ECM proteins makes 
it a valuable biomarker of fibrogenesis. GdOA is an oxyamine derivative of GdDOTA 
designed for targeted binding to allysine, with minimal off-target accumulation and rapid 
renal excretion. GdOA MRI demonstrated a strong correlation with the extent of disease in 
two animal models of CKD and therefore might provide a novel means to quantify early 
stages of renal fibrosis in patients.
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Nicorandil Plays a Protective Role Against Renal Fibrosis in Unilateral 
Ureteral Ligation Models via Reducing TGF-β1/Collagen Expression and 
Improving Energy Metabolism
Yingying Chen, Lan Chen, Yisheng Ling, Tianjun Guan. Department of 
Nephrology, Zhongshan Hospital, Xiamen University, Xiamen, China.
Background: As one of most important metabolic sensors, ATP-sensitive potassium 
channels (KATP) could regulate cellular activity to meet energetic demands. It has also 
been demonstrated that KATP plays a protective role on several ischemia-associated 
diseases. However, there are few studies to clarify whether KATP opener could directly 
improve renal function or renal fibrosis in unilateral ureteral ligation (UUO) models. 
This experimental study was designed to clarify the effect and mechanism of nicorandil 
(a KATP opener) on renal dysfunction, extracellular matrix expression and ATP generation 
in mice renal fibrosis model caused by unilateral ureteral ligation.
Methods: Mice UUO models were developed and observed at 7th and 14th day 
after operation. There were three groups in our study: sham-operation (n=12), UUO 
(n=12), UUO+nicorandil (n=12). In nicorandil treatment group, nicorandil was injected 
intraperitoneally daily (20mg/kg/d) for 12 days from the third day of UUO operation. Renal 
function and ATP synthesis (using an ATP assay kit, FLAA, Sigma, USA) were detected 
at 7th and 14th day after operation. Masson trichrome staining was performed to analyze 
collagen generation. TGF-β1 and Smad3 were detected by Western blot.
Results: Compared with sham-operation group, UUO groups had a significantly 
higher serum level of creatinine (7th day: 55.9±4.8 vs. 35.7±3.2μmol/L, P<0.01; 14th 
day: 82.0±7.8 vs. 35.2±6.2μmol/L, P<0.01). Nicorandil treatment not only reduced serum 
creatinine level (7th day: 45.7±3.6 vs. 55.9±4.8μmol/L, P<0.05; 14th day 64.3±5.5 vs. 
82.0±7.8μmol/L, P<0.01), but also reduced collagen volume fraction (7th day: 10.5±2.8% 
vs. 17.6±3.8%, P<0.01; 14th day: 16.4±3.8% vs. 34.2±5.2%, P<0.01). We also found 
that TGF-β1 and Smad3 expression were significantly reduced in nicorandil treatment 
group. Furthermore, renal ATP synthase was also improved significantly (sham operation 
group: 8.55±2.74 nmol/L; UUO group: 2.92±1.96 nmol/L; UUO+nicorandil group: 
4.88±1.48 nmol/L, P<0.05).
Conclusions: KATP opener nicorandil protected against UUO-induced renal fibrosis, 
which were associated with TGF-β1/collagen expression and energy metabolism recovery.
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Vitamin D Receptor (VDR) Expression Determines Initiation and 
Progression of Renal Lesions in HIV-Transgenic Mice with Variable 
Angiotensinogen (Agt) Copies
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Background: Agt transgenic mice have been shown to carry higher serum and cellular 
levels of Angiotensin II levels and associated downstream effects. Since Ang II has been 
shown to play a role in the progression of HIVAN, we hypothesized that mice with enhanced 
expression of Agt would display a rapid progression of renal lesions in a mouse model of 
HIVAN. We evaluated the effect of different copies of Agt in the initiation and progression 
of HIVAN in genetically engineered HIVAN mice (Tg26) expressing variable copies of Agt.
Methods: Control and Tg26 mice with 2 (Tg26/Agt-2) and 4 (Tg26/Agt-4) copies 
of Agt were evaluated for severity of renal lesions, arteriosclerosis and hypertension at 8 
weeks and 16 weeks. Renal cortical sections were stained with Sirus red and PAS. RNA 
was extracted from renal tissues and probed for AT1, AT2, VDR, and molecules involved 
in profibtotic and epithelial-mesenchymal transition (EMT) pathways. Renal lesions were 
graded for their severity.
Results: Tg26/Agt-4/8wks showed lower blood pressure (P<0.01) vs. Tg26/
Agt-2/8 wks, while Tg26/Agt-4/16wks displayed higher blood pressure vs. Tg26/Agt-
2/16wks. Tg26/Agt-4/8wks displayed attenuated expression of PAI-1 vs. Tg26/Agt-
2/8wks; however, Tg26/Agt-4/16wks showed 3-fold greater PAI-1 expression than to 
Tg26/Agt-2/16wks. Tg26/Agt-2/8wks displayed attenuated expression of VDR and 
enhanced production of Ang II vs. Tg26/Agt-4/8wks; however, this pattern reversed at 
16 wks. Tg26/Agt-4/8wks displayed attenuated expression of AT1 and AT2 and down-
regulation of Tert, TGF-β, Snail, and vimentin when compared to Tg26/Agt-2/8wks. 
Nonetheless, all these markers were comparable between these groups at 16 wk of age. 
Tg26/Agt-2/8wks developed renal lesions which were more advanced than Tg26/Agt-
4/8wks. Conversely, Tg26/Agt-4/16wks displayed more advanced renal lesions vs. Tg26/
Agt-2/16wks
Conclusions: Tg26/Agt-4 displayed slower progression of HIVAN initially at 8 
weeks associated with enhanced renal tissue VDR expression and attenuated expression 
of AT1, TGB-β, PAI-1, Tert and EMT markers. However, Tg26/Agt-4 at 16 wks displayed 
accelerated growth due to attenuated VDR expression leading to high blood pressure, 
upregulation of EMT and profibrotic molecules.
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Sodium-Glucose Cotransporter 2 Inhibition Does Not Ameliorate Renal 
Progression in Adriamycin-Induced Nephropathy
Jin Joo Cha,1 Jeong-Taek Lim,1 Ji ae Yoo,1 Jungyeon Ghee,1 Hye sook Min,2 
Dae R. Cha,1 Young Sun Kang.1 1Korea University, Ansan, Republic of Korea; 
2Wonkwang University Gunpo Hospital, Gunpo-si, Republic of Korea.
Background: Sodium-glucose cotransporter 2(SGLT2) inhibitors target SGLT2 
in renal proximal tubules and promotes glycosuria in type 2 diabetic mellitus, resulting 
in lowering blood glucose. Clinical studies have shown that SGLT2 inhibitors attenuate 
the progression of diabetic nephropathy, which results were not merely associated with 
improved glucose control. To understand the related mechanisms, we investigated the 
effects of SGLT2 inhibitior dapagliflozin (DAPA) in a mouse model of adriamycin (ADX)-
induced nephropathy.
Methods: ADX induced nephropathy model resulted in severe proteinuria and 
progressive glomerulosclerosis. Seven week old Balb/c mice were divided in five groups;1) 
control with vehicle, 2) control with DAPA 3mg, 3) ADX(11.5mg/kg) with vehicle, 4) 
ADX(11.5mg/kg) with DAPA 1mg, 5) ADX(11.5mg/kg) with DAPA 3mg. With ADX 
injection, DAPA was administered via gavage for 2 weeks. Molecular analyses using RT-
PCR, western blot and immunohistochemistry were performed.
Results: DAPA administration was associated with decreased systolic blood pressure 
(SBP) in control group, but not among ADX injected groups. DAPA administration did 
not alleviate proteinuria, glomerular sclerosis and interstitial fibrosis in the ADX-induced 
nephropathy. Also, there were no differences in the expressions of TGF-β, Smad2 and 
collagen IV in the renal cortex of ADX with DAPA groups compared to ADX control group. 
Expression of macrophage marker ED1 was significantly increased in the kidney of ADX 
control group. DAPA administration in ADX groups decreased macrophage infiltration 
in the renal medulla, whereas no significant difference was observed in the renal cortex. 
SGLT2 expressions in the kidney were decreased in DAPA groups as expected. Strangely, 
the expressions of SGLT2 increased in the medulla of ADX with DAPA groups.
Conclusions: SGLT2 inhibition with dapagliflozin had no effect on reduction in 
proteinuria and inflammatory changes in renal cortex of ADX-induced nephropathy. Our 
study suggest that SGLT2 inhibition may modulate inflammation in the renal medulla, 
which effect may have been masked by massive insult of cortex. More experimental studies 
on renal injury model is needed to clarify the underlying mechanisms.
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Comprehensive Transcriptomic Mapping of Baseline and Pathological 
Human Kidneys at Single-Cell Resolution
Ayshwarya Subramanian,1 Katherine A. Vernon,3 Michal Slyper,1 Julia Waldman,1 
Keith H. Keller,3 Yiming Zhou,3 Danielle Dionne,1 Lan T. Nguyen,1 Astrid Weins,3 
Orit Rosen,1 Aviv Regev,1 Anna Greka.2 HCAKidney 1Broad Institute, 
Cambridge, MA; 2Harvard Medical School, Boston, MA; 3Brigham and Women’s 
Hospital, Boston, MA.
Background: The heterogeneity of cell types and states in human tissues pose 
challenges for precision medicine and targeted therapeutics as not all patients present 
the same disease phenotype or treatment response. Most of our current understanding of 
cell-types comes from comprehensive histological observations of surface proteins and 
other molecules, gathered over the decades. However, recent advances in single cell and 
spatial genomics, such as single-cell RNA-Seq, now allow us to classify large numbers of 
individual cells by their profiles. In this study, as part of the Human Cell Atlas initiative, 
we aim to catalog cell-types in human kidney specimens obtained from healthy donors and 
patients with kidney diseases.
Methods: Discarded tissue from tumor nephrectomies was subjected to single-cell 
dissociation or single-nucleus isolation, the latter applicable to frozen tissue as well. Droplet-
based single-cell or single nucleus RNA-Seq libraries were prepared, PCR amplified and 
sequenced. Single-cell profiles were clustered, and clusters were annotated post hoc based 
on known marker genes.
Results: We identified over 10 known cell-types, from around 2,000 cells from 
discarded healthy tissue. Recovered cell-types included both renal parenchymal and 
immune cells. Heterogeneity was observed in collecting duct and proximal tubular cells. 
Data-driven markers were inferred for the cell-types.
Conclusions: We have established working single-cell dissociation protocols optimized 
specifically for human kidney specimens with paired reproducible analyses and insights. 
Proportions of cell-types will be reported with more confidence as we gather more samples, 
and in comparison with specific disease phenotypes.
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The Impact of Carbon Monoxide Poisoning on Long-Term Risk of CKD: 
A Nationwide, Population-Based Study in Taiwan
Kuangyu Wei, Chen-Yi Liao, Chia-chao Wu. Tri-service general hospital, 
National defense medical center, Taipei, Taiwan.
Background: Risk of chronic kidney disease (CKD) in patients with carbon monoxide 
poisoning (COP) and the hyperbaric oxygen (HBO) therapeutic effect had not been 
investigated.
Methods: Patients that survived after COP during index hospitalizations from 2000 to 
2013 were identified in nationwide administrative registries. In a cohort study of 989,753 
patients, we enrolled 8,616 COP patients and matched 34,464 comparison cohort as the 
non-COP group by propensity scores. Using this adjusted data, a possible association 
between COP and the risk of developing CKD was estimated using a Cox proportional 
hazard regression model. We further compared cumulative risk of CKD among COP 
patients stratified by HBOT with Kaplan-Meier analysis and the log-rank test.
Results: After a mean follow-up period of 4.28 years, the incident CKD rate was 261 
per 10000 person-years. The COP group had higher risk (adjusted hazard ratio: 6.150; 
P < 0.001) than the non- COP group when measured over 4 years after CKD diagnosis. 
After stratification, the risk of CKD remarkably increased independent of status regarding 
sex, age, season and comorbidities (hypertension, diabetes mellitus, congestive heart 
failure, stroke, chronic obstructive pulmonary disease, liver cirrhosis, coronary artery 
disease, arrhythmia or hyperlipidemia) in the COP cohort. Age-specific COP to non-COP 
hazard was the greatest in the youngest group (18-29 years) (adjusted HR=34.18, 95% 
CI = 29.47–39.653). Additionally, HBOT did not result in statistically significant reduction 
in the risk of CKD in the COP cohorts (P=0.188, long-rank test).
Conclusions: The patients that survived after COP had a higher incidence of developing 
CKD. The results suggest that clinicians should enhance postdischarge follow-up of kidney 
function among COP patients
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The Presence of Simple Renal Cyst Is Associated with Increased Risk of 
Albuminuria in Young Adults
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Background: It is well-known that the prevalence of simple renal cyst increases with 
age. However, simple cysts are occasionally found in adults younger than 40 years of age. 
This cross-sectional study evaluated the clinical significance of simple renal cysts in young 
adults, focusing on the associations with hypertension and albuminuria.
Methods: Adults younger than 40 years who received comprehensive medical checkup 
from January 2005 to December 2013 were included. Simple renal cysts were identified by 
ultrasonography.
Results: Among 5832 young adults, renal cysts were found in 276 subjects (4.7%). 
Subjects diagnosed with polycystic kidney disease (n=5) or medullary sponge kidney 
(n=1) were excluded from the analyses. A single cyst and multiple cysts were found in 
234 (4.0%) and 42 (0.7%) subjects, respectively. The locations of single cyst were cortex 
in 187, medulla in 26, and parapelvic region in 21. In univariate logistic regression 
analyses, age, male sex, body mass index, waist circumference, systolic blood pressure 
(SBP), hypertension, current smoking, high-density lipoprotein cholesterol, and uric acid 
levels were associated with a higher prevalence of simple cysts. Multivariate analyses 
of cysts showed that age (OR, 1.07; CI, 1.02-1.12), SBP (OR, 1.01; CI, 1.00-1.02), and 
hypertension (OR, 1.85; CI, 1.24-2.76) had independent associations with the presence of 
simple cysts. The subjects with cysts had a higher prevalence of albuminuria (defined as 
a urine albumin to creatinine ratio > 30μg/mg) than those without cysts (11.2% vs. 4.5%, 
P <0.001). Multivariate analyses of albuminuria revealed that the presence of simple 
renal cysts was associated with a 2.32-fold increase in the risk of albuminuria (95% CI, 
P <0.001). The location of the cysts was not related to the prevalence of albuminuria.
Conclusions: Age, SBP, and hypertension history were independently associated 
with simple renal cyst in adults younger than 40. The presence of the renal cyst was an 
independent risk factor of albuminuria.
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Renal Prognosis Evaluation with Contrast-Enhanced Ultrasound
Yao Xu,1 Shan Mou.2 1Ren Ji Hospital, school of Medicine, Shanghai Jiao Tong 
University Shanghai, PR China, Shanghai, China; 2Renji Hospital, Shanghai, 
China.
Background: The purpose of this initial study was to confirm the ability of contrast-
enhanced ultrasound (CEUS) to detect and predict renal function changes in chronic kidney 
disease (CKD) patients. The prognostic efficacy of CEUS parameters was compared with 
that of the renal pathology.
Methods: Patients with biopsy-proved CKD and received CEUS were enrolled in 
this study. CEUS was performed after an intravenous bolus injection of 1.5 ml SonoVue 
(BR1; Bracco Milan, Italy). Time-intensity curves (TICs) and quantitative indexes were 
created using QLAB quantification software. All biopsies were analyzed with α-SMA 
immunohistochemistry. The Cox proportional hazards model retrospectively investigated 
risk factors on kidney survival.
Results: A total of 140 patients were followed for a median period of 22.0 months. In 
total, 18 (13%) patients exhibited CKD progression. Lower derived peak intensity (DPI)
and higher resistance index (RI) was noted in CKD progression group. Multivariate Cox 
regression analysis revealed that the DPI associated with progression of kidney disease. 
Based on which, linear predictor score (LP) was made. Kaplan-Meier curve showed that 
DPI had the similar ability as fibrosis to estimate the risk of kidney progression for each 
CKD patient. Patients with a LP-DPI≥0 were less likely to recover from CKD progression. 
The area under the receiver operating characteristic (ROC) curves for the model of DPI 
was 0.82 (95%CI, 0.60-0.96, P<0.001) with a sensitivity of 82% and a specificity of 78%.
Conclusions: This study demonstrated that the DPI might be the most valuable CEUS 
parameter for the evaluation of renal function deterioration risk. The DPI could serve as an 
independent predictor of the long-term prognosis of CKD patients.
Kaplan-Meier plots showing renal survival stratified by linear predictor score (LP) from the 
multivariate Cox proportional hazards model included DPI and α-SMA.
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Doppler Indexes of the Renal Cortex Are Independently Related to Renal 
Perfusion in Hypertensive CKD Patients
Arkadiusz Lubas, Stanislaw Niemczyk. Military Institute of Medicine, Warsaw, 
Poland.
Background: In many studies, Resistive Index measured in segmental or interlobular 
intrarenal arteries has been used interchangeably as an equivalent of renal perfusion. Due 
to the diverging region of measurement, achieved indexes are significantly different. 
However, they were not compared to the renal perfusion estimated in the independent 
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method. The study aimed to investigate relations between different renal Doppler indexes 
(segmental renal Resistive Index (sRI), cortical renal Resistive Index (cRI), cortical renal 
Pulsatility Index (cPI)) and Renal Perfusion (RP) measured in contrast-enhanced computed 
tomography.
Methods: In fifteen patients (6F, 9M; age 61.5 ±19.3) with unilateral renal artery 
stenosis, ultrasound examination (GE Logic P6) with the estimation of sRI (a mean of 3 
measurements using a Pulsed Wave Doppler); cRRI and cRPI (3-5 seconds movie of Color 
Doppler with PixelFlux software [Chameleon Software, Germany]) was performed. Then 
contrast-enhanced multidetector computed tomography (GE Discovery 750 HD) of renal 
and intrarenal arteries was completed, and a Renal Blood Flow in a whole cortex (cRBF, 
[mL/s/100g]) was measured. The data from 15 kidneys without a stenotic artery were 
considered for statistics. Based on creatinine, estimated glomerular filtration rate (eGFR) 
was calculated using MDRD formula.
Results: Values of intranenal indexes were estimated: sRI = 0.710 ±0.107; 
cRI = 0.751 ±0.185; cPI = 1.515 ±0.614, whereas mean RP = 206.8 ±64.9 ml/s/100g and 
eGFR = 54.8 ±29.6 ml/min/1.73m2. All intrarenal Doppler indexes correlated significantly 
with age, eGFR, and with each other. In addition, cRI and cPI correlated with RP 
(r = -0.547, p < 0.05 and r = -0.655, p < 0.05, respectively). The multivariable regression 
analysis adjusted to age and eGFR showed independent connection between cRI and RP (b 
= -0.55; R2 = 0.30, p < 0.035). In the same regression model, cPI independently related to 
RP (b = -0.65; R2 = 0.43, p < 0.008). However, relation to RP was not significant for sRI 
(p < 0.112).
Conclusions: Doppler indexes measured in renal cortex area are independently related 
to the renal perfusion. Renal Resistive Index in segmental arteries should not be considered 
as a marker of renal cortical blood flow
Funding: Government Support - Non-U.S.
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Oral Bisphosphonate Use and Renal Function Decline in Patients with 
CKD
Fergus J. Caskey,1 Danielle E. Robinson,2 Victoria Y. Strauss,2 M sanni Ali,3 
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Andrew Judge,2,7 Muhammad K. Javaid,2 Daniel Prieto-Alhambra.2 1UK Renal 
Registry, Southmead Hospital, Bristol, United Kingdom; 2NDORMs, University 
of Oxford, Oxford, United Kingdom; 3London School of hygiene and tropical 
medicine, London, United Kingdom; 4MRC Lifecourse Epidemiology Unit, 
University of Southampton, Southampton, United Kingdom; 5School of Social 
and Community Medicine, University of Bristol, Bristol, United Kingdom; 
6University of Southern Denmark, Odense, Denmark; 7Translational Health 
Sciences,University of Bristol, Bristol, United Kingdom.
Background: Oral bisphosphonates (BP) are contraindicated in patients with 
moderate-severe chronic kidney disease (CKD) due to concerns regarding their effects on 
renal function. The aim of this study was to assess the effect of BP use on CKD stage 
worsening and annual changes in estimated glomerular filtration rate (eGFR) over time.
Methods: Patients aged 40+ with an eGFR<45 in UK primary care (CPRD) linked 
to hospital records. Followed for up to 10 years. BP users censored 210 days after the last 
BP prescription. Unexposed patients could become exposed; 10-year follow up re-started. 
Users were matched to up to 5 non-users using propensity scores (PS), stratified by the 
number of years of follow-up. Cox regression was used to estimate the hazard ratio (HR) of 
stage worsening. The rates of annual eGFR changes were estimated by the slopes of a mixed 
effect model with cubic splines and an interaction between BP use and time.
Results: 31275 patients (6309 BP users) were included in the PS matched analyses. 
3,978 (13%) patients moved to a later stage. The HR for BP users was 1.69 (95% confidence 
interval (CI): 1.58, 1.80). Annual eGFR changes were different for BP users and non-users 
(Figure). In the first three years, the mean eGFR increased at the rate of 2.58 (2.50, 2.66) 
and 0.91 (0.65, 1.17) mL/min/1.73 m^2 per year for non-users and users, respectively. They 
were followed by slow decline slopes of -0.80 (-0.89, -0.70) and -0.24 (-0.55, 0.08) per year. 
No significant difference in mean eGFR after 8 years.
Conclusions: BP use has a 70% higher likelihood of worsening in CKD stages. Further 
research is needed to understand the longitudinal changes in eGFR trajectories.
Funding: Government Support - Non-U.S.
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Proton Pump Inhibitor Use and Progression to Major Adverse Renal 
Events: A Competing Risk Analysis
Christopher H. Grant,2 Keith Gillis,1,2 Jennifer S. Lees,1,2 Jamie P. Traynor,2 
Patrick B. Mark,1,2 Kathryn K. Stevens.2 1University of Glasgow, Glasgow, 
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Background: Proton pump inhibitors (PPIs) are commonly prescribed in primary 
and secondary care. PPIs are associated with acute tubulointerstitial nephritis, but their 
association with chronic kidney disease (CKD) is uncertain. We aimed to determine if PPI 
use is associated with adverse renal outcomes or survival in patients with CKD.
Methods: We conducted a retrospective observational cohort study comprising patients 
with CKD attending a secondary referral renal clinic between 01/01/2006 and 31/12/2016. 
Baseline exposure variables at start of PPI (PPI group) or study inception (control group) 
were derived for relevant clinical, socio-demographic and biochemical data. The primary 
outcome was a composite measure of doubling baseline creatinine or end stage renal disease 
(ESRD) denoted Major Adverse Renal Events (MARE). We defined tubular dysfunction 
as potassium or magnesium below laboratory normal range. A competing risks survival 
analysis evaluated the association between PPI exposure and MARE, with the competing 
risk of death.
Results: There were 7765 patients referred to a secondary care renal clinic during 
the study period: 6734 were included in the analysis of which 2928 were prescribed a 
PPI. The PPI group had more men (51.3 vs 48.7%, p=0.04) with higher GFR (35.6 vs 
32.0, p<0.001), but similar burden of cardiovascular disease (69.2 vs. 67.4, p=0.13) and 
diabetes (61.8 vs 63.9%, p=0.09), and the same age (68.5 vs 68.0 years, p= 0.02). There 
was more tubular dysfunction in the PPI group (59.2 vs. 54.2%, p<0.001). In a competing 
risks survival analysis, there was no difference between progression to death (p=n/s), but 
greater progression to MARE in the PPI group (log rank p<0.001). After adjustment for 
the competing risk of death, the factors associated with progression to MARE were tubular 
dysfunction (SHR 2.33, 95% CI 20.80-2.60, P<0.001), diabetes (SHR 1.39, 95% CI 1.26-
1.54, P<0.001) and hypereosinophilia (SHR 1.71, 95% CI 1.53-1.92, P<0.001). PPI use was 
not associated with increased risk of progression to MARE on multivariable adjustment.
Conclusions: PPI use may not be associated with progression to MARE in patients 
with renal impairment. Tubular dysfunction, hypereosinophilia and diabetes were 
associated with MARE regardless of PPI use. Further prospective analysis is required to 
validate these findings
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Discontinuation of Proton Pump Inhibitors in Patients with CKD
Amanda Mertz,1 Danielle N. Cooney,1 Mahboob Rahman,2,1 
Chirstopher S. Lacey,1 Christopher J. Burant,1 Niraj Desai.2,1 1Northeast Ohio VA 
Healthcare System, Cleveland, OH; 2Case Western Reserve University, 
Cleveland, OH.
Background: Proton pump inhibitors (PPIs) are commonly used medications in the 
US and are historically well tolerated. Recent studies have linked PPI use to development 
of chronic kidney disease (CKD) and end-stage renal disease (ESRD). We investigated 
whether discontinuation of PPIs in patients with CKD results in slower kidney disease 
progression compared to patients who continued PPIs.
Methods: This is a retrospective chart review of patients with established CKD taking 
a PPI from January 1, 2014 to December 31, 2014. Patient’s eligible for inclusion were 
those with established CKD, defined as 2 eGFR measurements of < 60 ml/min/1.73m2 at 
least 90 days apart, who were on a PPI from January 1, 2014 to December 31, 2014, with 
a medication possession ratio (MPR) of ≥70%. Patients were excluded if they were on 
dialysis at baseline and did not have baseline and final eGFR measurements. We compared 
baseline eGFR to a final eGFR after at least 6 months of discontinuation or continuation 
of a PPI.
Results: 100 patients in the PPI discontinuation group and 97 patients in the PPI 
continuation group met study inclusion criteria. Baseline renal function in the PPI 
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continuation group was eGFR of 47.9 ml/min/1.73 m2 and 50.7 ml/min/1.73 m2 in the PPI 
discontinuation group. Final eGFR in the PPI continuation group was significantly higher 
at 51.1 ml/min/1.73m2 (p=0.01). Final eGFR in the PPI discontinuation group was 51.8 ml/
min/1.73m2 (p=0.3). The average time between baseline and final eGFRs was 270 days in 
the PPI continuation group and 301 days in the PPI discontinuation group. There was no 
statistically significant difference in the change in eGFRs between groups (95% CI -5.48-
2.03; p=0.37).
Conclusions: Discontinuing a PPI after one year of continuous use in patients with 
CKD did not impact change in renal function after one year.
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Determining the Association of Allopurinol Prescription on Progression of 
Renal Dysfunction and Progression to Renal Replacement Therapy in 
Patients with CKD
Andrew J. Mallett,1,2 Andrew S. Jeyaruban,1,2 Anne Cameron (Salisbury),2 
Jianzhen Zhang,2 Helen G. Healy,1,2 Wendy E. Hoy.2 on behalf of the CKD.QLD 
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Background: Reports in the literature link hyperuricaemia with incident chronic kidney 
disease CKD. However, the relationship between allopurinol prescription and progression 
of renal dysfunction is not well understood. We aimed to determine the association of 
allopurinol prescription and changes in kidney function amongst patients with CKD.
Methods: A retrospective cohort study of 1,123 patients of a tertiary teaching hospital 
registered in the CKD.QLD registry between January 2011 and August 2017 (minimum of 2 
years follow-up). Subject demographics (age), health data (BMI, comorbidities, laboratory 
test results) and allopurinol prescription were extracted from integrated medical records. 
Delta eGFR (CKD-EPI)was calculated as the difference between latest eGFR and initial 
eGFR. Subjects were stratified into two groups based on prescription of allopurinol.
Results: Subjects prescribed allopurinol were older (70.7 vs 65.8; p<0.01), had higher 
BMI (32.3kg/m2 vs 30.5kg/m2; p<0.01), worse renal function (35.2mL/min/1.73m2 vs 
43.6mL/min/1.73m2; p<0.01), higher urate level (0.47mmol/L vs 0.42mmol/L; p<0.01) 
as well as higher proportion of diabetes (54% vs 46%; p=0.04), dyslipidaemia (54% vs 
41%; p<0.01), hypertension (84% vs 72%, p<0.01) and gout (54% vs 11%; p<0.01). The 
proportion of subjects treated with allopurinol increased with CKD stage; stage 1:1.5%, 
stage 2:7.1%, stage 3: 21.7%, stage 4: 21.4% stage 5:17.3%. Prescription of allopurinol did 
not have a significant association with delta eGFR in patients with hyperuricaemia (1.8mL/
min/1.73m2/yearvs 1.6mL/min/1.73 m2/year; p=0.2) or gout (2.2mL/min/1.73m2/year vs 
1.8mL/min/1.73m2/year; p=0.5). Nor was allopurinol prescription in the subgroup with 
serum urate level < 0.36mmol/L associated with a significant change in delta eGFR (3.5mL/
min/1.73m2/year vs 1.6mL/min/1.73m2/year;p=0.17). Multivariate analysis adjusting for 
age and comorbidities found no significant association of allopurinol prescription with 
either delta eGFR or progression to kidney replacement therapy (p>0.05).
Conclusions: Allopurinol prescription was more prevalent in advanced CKD. However, 
it did not appear to be independently associated with deterioration of kidney function.
FR-PO168 Poster Friday
CKD: Epidemiology, Risk Factors, Prevention - II
Association Between Plasma Myostatin Levels and Loop Diuretic Use in 
Non-Dialysis-Dependent CKD Patients
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Background: Myostatin (MSTN) is mainly synthesized in skeletal muscles and acts 
as a negative regulator of skeletal muscle mass. It is up-regulated in patients with chronic 
kidney disease (CKD) and considered to be associated with the development of sarcopenia. 
Recently, we have reported that loop diuretics, commonly used in patients with advanced 
CKD, suppress skeletal muscle differentiation (Mandai S. Sci Rep. 2017). So far, the 
association between serum MSTN (sMSTN) levels and loop diuretic use is unknown.
Methods: We conducted a cross-sectional study comprised of 362 non-dialysis-
dependent CKD patients over 20 years of age. The primary outcome was sMSTN levels. 
Multiple linear regression analyses were conducted to assess the associations between 
sMSTN levels (logarithmically transformed) and baseline characteristics including skeletal 
mass index (SMI). Interaction between loop diuretic use and SMI to sMSTN levels was 
estimated after stratifying patients by loop diuretic use. We calculated SMI as follows: Total 
body skeletal muscle mass measured by DEXA was divided by height squared.
Results: Median age was 71 years, 64.4% were male, mean SMI was 6.49 kg/m2, mean 
eGFRcysC was 39.0 ml/min/1.73m2, median sMSTN level was 1130 pg/ml, and 14.6% 
were treated with loop diuretics. Multivariate analysis showed that sMSTN levels were 
positively correlated with SMI (β=0.128, P<0.001), and negatively with eGFRcysC and 
loop diuretic use (β=-0.004, P=0.005 and β=-0.231, P<0.001, respectively). When stratified 
by loop diuretic use, adjusted coefficient β of SMI for sMSTN was higher in patients treated 
with loop diuretics than in patients not treated with loop diuretics (β=0.237, P=0.001 and 
β=0.118 P<0.001), respectively).
Conclusions: Loop diuretic use was independently associated with lower sMSTN 
levels. This result indicates that loop diuretics serve as negative regulator of skeletal muscle 
mass and therefore sMSTN levels may be attenuated by negative feedback. However, the 
increase of sMSTN level associated with SMI among the patients treated with loop diuretics 
was larger than those without loop diuretics. Other potential factors which elevate sMSTN 
levels in patients treated with loop diuretics are suggested to affect the relationship between 
sMSTN levels and SMI.
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Circulating ADAM17 Activity as a Marker of CKD Progression
Vanesa Palau,1 Maria Jose Soler,1,2 David Benito,1 Jose M. Valdivielso,3 
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Background: Several substrates for ADAM17 have been identified, including TNF-α, 
EGFR ligands, L-selectin, VCAM-1 and angiotensin converting enzyme(ACE)2. We have 
studied circulating ADAM17 in chronic kidney disease(CKD) patients from the NEFRONA 
cohort study.
Methods: 2032 patients without history of CV disease from an observational and 
multicenter study (NEFRONA project) divided into two groups: non-dialysis CKD stage 
3-5 patients and control patients were studied. Baseline circulating ADAM17 activity was 
analyzed using a fluorimetric assay in plasma samples. Increased serum creatinine and 
dialysis requirement after 24months of follow-up depending on basal circulating ADAM17 
activity were studied. Logistic regression analyses were used to identify predictors of
increasing serum creatinine and risk of dialysis requirement.
Results: Circulating ADAM17 activity was significantly increased in CKD3-5 patients 
as compared to CONT(p<0.05). Baseline circulating ADAM17 activity was higher in 
patients with a 30% increase in serum creatinine levels after 2 years(p<0.05). Circulating 
ADAM17 activity was also higher in patients that needed dialysis in comparison with 
patients that maintained kidney function(p<0.05). After multivariate logistic regression 
analysis we found an interaction between sex and sADAM17 activity for increasing 30% 
serum creatinine, dialysis requirement and composite renal outcome(p<0.05). Therefore, 
we decided to perform the analysis stratifying by sex. Increased ADAM17 activity was 
independently associated with CKD progression regarding 30% increase in serum 
creatinine, dialysis requirement and composite renal end point but only in males. In females, 
ADAM17 activity was not associated with CKD progression.
Conclusions: Circulating ADAM17 activity was increased in CKD patients. 
Circulating ADAM17 activity was increased in patients that doubled serum creatinine and/
or patients that need dialysis therapy being an independent predictor of worsening renal 
function in males.
Funding: Government Support - Non-U.S.
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Association of Serum Uromodulin with ESRD and Kidney Function 
Decline in the Elderly – The Cardiovascular Health Study
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Background: Uromodulin is released by tubular epithelial cells into the serum 
(sUMOD) and low levels are associated with tubular atrophy and interstitial fibrosis (IF/
TA). However, little is known about the association of sUMOD with long-term kidney 
outcomes in the elderly, a population with a high prevalence of IF/TA.
Methods: We assessed the association of sUMOD with end-stage-renal-disease (ESRD) 
in a random subcohort (n=933) plus all additional cases of ESRD in the Cardiovascular 
Health Study using a modified Cox regression analysis. We also evaluated the association 
of sUMOD with kidney function decline (≥30% decline of estimated glomerular filtration 
rate (eGFR) at 10 years of follow up) using logistic regression. Sampling for the latter 
was from the random subcohort as well as all additional cases. Models were adjusted for 
demographics, eGFR, albuminuria and other risk factors.
Results: Mean age of the random subcohort was 78 years, 40% were male, and 15% 
were non-white. Mean±SD sUMOD level was 127±64 ng/ml and eGFR was 63±19 ml/
min/1.73 m2. 53 participants experienced ESRD during a median follow-up 9.9 years. 
Higher sUMOD was associated with lower hazard for ESRD in univariate analysis (Figure). 
In multivariable analysis each 1 SD higher sUMOD was associated with a 63% lower risk 
of ESRD (HR 0.37 (95%-CI 0.14-0.95)). 179 participants experienced kidney function 
decline. In demographic adjusted analyses, higher sUMOD was associated with lower 
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odds of kidney function decline (OR 0.75 (0.60-0.95)); after multivariable adjustment, the 
association was attenuated and no longer significant (OR 0.88 (0.68-1.14)).
Conclusions: Low levels of sUMOD may identify persons at increased risk for ESRD.
Funding: NIDDK Support, Other NIH Support - This work was supported by 
grants from the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK) 
R01 DK098234 (to JHI and MGS) and from the National Institutes of Aging (NIA) 
R01AG 027002 (to MJS and MGS). The Cardiovascular Health Study was supported 
by contracts HHSN268201200036C, HHSN268200800007C, and N01HC-85079 
through N01HC-85086, N01HC-35129, N01HC-15103, N01HC-55222, N01HC-75150, 
N01HC-54133, and N01-HC85239 and grant U01 HL080295 from the National Heart, 
Lung, and Blood Institute (NHLBI), with additional contributions from the National Institute 
of Neurological Disorders and Stroke. Additional support was provided by R01AG023629 
from the NIA. PD was supported by National Institutes of Health grant P50 DK096418. 
PSG is supported by National Institutes of Health training grant 5 T32 DK007777-13.
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Monocyte as a Marker of Renal Damage in Patients with Glomerular 
Hyperfiltration and Early CKD
Sewon Oh,1 Junyong Lee,2 Jihyun Yang,2 Myung-Gyu Kim,1 Sang-Kyung Jo.1 
1Korea University Anam Hospital, Korea University College of Medicine, Seoul, 
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Background: Experimental studies have shown that monocyte/macrophages play 
an important role in progression of chronic kidney disease (CKD). Recent epidemiologic 
study also suggests a significant association between higher monocyte count and risk of 
incident CKD in humans. Glomerular hyperfiltration (GH) is known as an early marker 
of progressive CKD in diverse clinical conditions. However, not all patients with GH 
progressed to CKD and monocyte may be associated with renal injuries caused by GH. The 
purpose of this study is to examine whether higher monocyte count is associated with GH 
and progressive kidney disease.
Methods: A longitudinal observational cohort study was performed using data from 
regular health checkup examinations in tertiary hospital during 2004-2017. We analyzed 
56,258 adults at initial examination and selected 16,695 adults who had initial estimated 
glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2 with at least two tests of eGFR in 
follow-up analysis. Monocyte count was categorized into sex-specific quartiles. GH was 
defined as the upper 2.5 percentile of eGFR in the total population.
Results: The monocyte count showed a U-shaped association with eGFR. The 
monocyte count was significantly higher in participants with eGFR ≥ 120, 60-74, 45-59, 
30-44, and <30 ml/min/1.73m2 compared with those with eGFR 90-104 ml/min/1.73m2
at initial examination (N=56,258, P≤0.025). The highest quartile of monocyte count was
independently associated with GH in multivariate analysis compared with the lowest
quartile (OR, 1.278; 95% CI, 1.070-1.525). In participants without GH, the highest quartile 
of monocyte count was associated with the higher risk of ≥ 25% eGFR decline (RR, 1.859; 
95% CI, 1.254-2.755) and the development of proteinuria (RR, 1.377; 95% CI, 1.135-
1.671) compared with lowest quartile. In participants with GH, the highest quartile was
also associated with increased risk for the development of proteinuria (RR, 5.833; 95% CI,
1.196-28.453), but was not associated with ≥ 25% eGFR decline.
Conclusions: Higher monocyte count is associated with progressive CKD. In addition, 
monocyte count could be a marker to identify patients at risk for progression of kidney 
disease in GH.
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The Plasma Growth Differentiation Factor-15 Levels as Useful Biomarker 
for Renal Impairment in the Elderly: Korean Frailty and Aging Cohort 
Study
Hyung-seok Ihm, Jin sug Kim, Su Woong Jung, Chun-Gyoo Ihm, Kyung-
hwan Jeong, Tae won Lee, Ji yung Lee, Hyeon Seok Hwang. Kyung Hee 
University, School of Medicine, Seoul, Republic of Korea.
Background: Growth differentiation factor-15 (GDF-15) expression has been reported 
to increase in response to tissue damage, and has recently emerged as a useful biomarker for 
various diseases. Although accumulating evidence supports the prognostic value of GDF-
15 in renal impairment, few studies have analyzed it in the elderly. Thus, we conducted a 
cross-sectional study to investigate the association between plasma GDF-15 level and renal 
function in the elderly.
Methods: The present study was based on the baseline data of the Korean Frailty and 
Aging Cohort Study (KFACS), a nationwide cohort study that began in 2016. Of the 1,559 
participants assessed in the first year, 443 with available plasma GDF-15 data were enrolled 
in this study. We investigated the association of plasma GDF-15 level with clinical and 
biochemical parameters. The study population was divided into two groups according to 
renal function (chronic kidney disease [CKD] and non-CKD groups) to analyze diagnostic 
predictive value for CKD.
Results: In a simple regression analysis, the level of plasma GDF-15 was negatively 
correlated with the estimated glomerular filtration rate (eGFR; r = -0.383, p < 0.001). In 
multiple linear regression analysis, GDF-15 level was still significantly correlated with 
eGFR, even after adjusting for other parameters (r = -0.259, p < 0.001). Plasma GDF-
15 level was significantly higher in the elderly with CKD than in those with non-CKD 
(2364.025 ± 1052.23 ng/L and 1451.23 ± 835.79 ng/L, respectively, p < 0.001). The optimal 
cut-off value for CKD-predicting GDF-15 level was 1699.4 pg/mL (76.5% sensitivity and 
76.0% specificity), as determined by receiver operating characteristic curve. The area under 
the curve was 0.793 ± 0.033 (95% CI 0.729-0.857, p < 0.001).
Conclusions: Our results suggest that plasma GDF-15 level can be a useful biomarker 
for renal impairment in the elderly. Further large and prospective studies of extended 
duration are needed.
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Wide Pulse Pressure as a Risk Factor for Kidney Dysfunction
Tadashi Toyama,2 Shinji Kitajima,2 Akinori Hara,2 Kiyoki Kitagawa,1 
Yasunori Iwata,2 Norihiko Sakai,2 Miho Shimizu,2 Kengo Furuichi,2 
Takashi Wada.2 1Kanazawa Medical Center, Kanazawa, Japan; 2Division of 
Nephrology, Kanazawa University Hospital, Kanazawa, Japan.
Background: The risk of kidney dysfunction due to hypertension has been drawing 
attention especially for people who have the characteristics of advanced arteriosclerosis. 
However, the relationships from the aspect of systemic arteriosclerosis were not well 
known. Pulse pressure (PP) is a routinely measured vital sign and is thought to reflect 
the arteriosclerosis of elastic arteries. The aim of this study is to clarify the relationships 
between pulse pressure for development of kidney dysfunction. Risks related to systolic 
blood pressure (SBP) according to wide pulse pressure was also studied.
Methods: People aged 40 years or older who had a medical checkup in Kanazawa city 
were included in the analysis. Kidney dysfunction was defined as a decline of eGFR by 30% 
from baseline. PP was classified as normal (40–60 mmHg) and wide (>60 mmHg). Cox 
proportional hazard model was used to estimate the risks for kidney dysfunction associated 
with wide PP and SBP.
Results: A total of 36,134 people was included in the analysis. The mean age was 69 
years. Incidence rates of kidney dysfunction for people with normal and wide PP were 
8.1 and 15.2 (per 1000 person-years), respectively. After multivariable adjustments, hazard 
ratio for the kidney dysfunction associated with wide pulse pressure compared with normal 
pulse pressure was 1.40 (95% CI 1.25 – 1.57). In the stratified analysis by baseline PP, 
hazard ratios related to higher SBP (+10 mmHg) in normal and wide PP group were 1.14 
(95%CI 1.07 – 1.22) and 1.12 (95%CI 1.06–1.19), respectively. Among the people with 
wide PP, people with baseline SBP ≥160 mmHg showed significant risk (HR 1.52 [95%CI 
1.03–2.24]) compared with the people with SBP 120 – <130 mmHg (reference), whereas 
SBP 130 – 160 mmHg was not related to significant risks.
Conclusions: Wide PP was associated with higher risks for kidney dysfunction. More 
studies are needed regarding the risks related to mild hypertension accompanied by wide PP.
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Trends in Angiotensin Converting Enzyme Inhibitor and Angiotensin II 
Receptor Blocker Use Among Those with CKD in the United States
Daniel P. Murphy, Robert N. Foley. University of Minnesota, Minneapolis, MN.
Background: Angiotensin converting enzyme inhibitors or angiotensin II receptor 
blockers (ACE/ARB) are first-line anti-hypertensives in chronic kidney disease (CKD). 
Even though evidence-based treatment of hypertension has changed considerably, and 
hypertension is common in CKD, nationally-representative, contemporary information 
regarding ACE/ARB use in CKD is lacking.
Methods: We examined ACE/ARB trends and racial/ethnic and other demographic 
disparities among adult National Health and Nutrition Examination Survey participants 
from years 1999 to 2014 with creatinine-based estimated glomerular filtration rate (eGFR) 
< 60 ml/min/1.73m2 or albumin-creatinine ratio (ACR) ≥ 30 mg/g.
Results: 33.9% of participants with CKD used ACE/ARB. Although ACE/ARB use in 
CKD rose across the four eras studied (P < 0.001), estimates changed little in the last 3 eras: 
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1999-2002, 24.1%; 2003-2006, 33.0%; 2007-2010, 38.0%; and 2011-2014, 38.7%. ACE/
ARB use was greater in those of non-Hispanic white (35.3%) and black (37.0%) and lower 
in those of Hispanic (25.4%) and other (28.7%) race/ethnicity. In models that adjusted for 
age, sex and race/ethnicity, ACE-ARBs were associated (P < 0.05) with: era (adjusted odds 
ratios (AOR) 1.52 [95% CI: 1.21-1.92] for 2003-2006, 1.94 [95% CI: 1.56-2.41] for 2007-
2010, and 2.07 [95% CI: 1.64-2.62] for 2011-2014, vs. 1999-2002) and non-Hispanic black 
race/ethnicity (AOR 1.41 [95% CI: 1.18-1.68], vs. non-Hispanic white). Other multivariate 
associations included older age, male sex, BMI ≥ 30 kg/m2, diabetes mellitus, hypertension, 
cardiac failure, and myocardial infarction.
Conclusions: ACE/ARB use is the exception in community-based CKD. Although 
use increased early in the current millennium, subsequent estimates remained static. When 
age and sex are considered, disparities against participants from racial/ethnic minority 
subgroups were not apparent.
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Kidney Function Outcomes Following RAAS Inhibition in Patients with 
Heart Failure
Wendy I. McCallum,1 Hocine Tighiouart,1 Elaine Ku,2 Deeb N. Salem,1 
Mark J. Sarnak.1 1Tufts Medical Center, Boston, MA; 2University of California 
San Francisco Medical Center, San Francisco, CA.
Background: Blockade of the renin-angiotensin-aldosterone system (RAAS) is 
beneficial for cardiovascular outcomes in patients with heart failure with reduced ejection 
fraction (HFrEF), but is also associated with decline in estimated glomerular filtration rate 
(eGFR). Long-term kidney outcomes after RAAS inhibition remain unclear in HFrEF.
Methods: We performed a retrospective analysis of the Studies Of Left Ventricular 
Dysfunction (SOLVD) trials, in which participants with HFrEF were randomized to 
enalapril vs placebo in the Treatment Trial (n=2423) if symptomatic, and in the Prevention 
Trial (n=4094) if asymptomatic. Joint models were used to estimate rate of decline in eGFR. 
Multivariable Cox models were used to evaluate the association of enalapril vs placebo for 
the following 3 outcomes at any timepoint: 1) ≥0.3 mg/dl increase in serum creatinine, 2) 
≥30% decline in eGFR, and 2) incident CKD Stage 4 or 5 as defined by new eGFR ≤30 
ml/min/1.73m2.
Results: A total of 6,517 participants randomized to enalapril (n=3254) or placebo 
(n=3263) were included in this analysis. Mean baseline eGFR was higher in Prevention vs 
Treatment (76.2±18.6 vs 69.5±19.8 ml/min/1.73m2, p<0.01). Over a median follow-up of 
24 months, mean eGFR declined at similar rates, -1.6 (95% CI -1.8,-1.4) for Prevention vs 
-1.7 ml/min/1.73m2/year (95% CI -2.0, -1.5) for Treatment (p=0.51) (Figure). Only 1.4%
in Prevention Trial and 4.5% in Treatment Trial reached CKD stage 4 or 5. In adjusted
analyses, randomization to enalapril was associated with a higher hazard of increase in
creatinine by ≥0.3 mg/dl (HR of 1.32, 95% CI 1.18, 1.47), decline in eGFR by ≥30% (HR 
1.33, 95% CI 1.18, 1.50) and CKD Stage 4 or 5 (HR 1.43, 95% CI 1.05, 1.95).
Conclusions: GFR decline on average was slow in both trials and only a small 
percentage of patients with HFrEF reached incident CKD Stage 4 or 5 over a median of 
2 years. Randomization to enalapril carried a higher risk of reaching all kidney function 
endpoints but it remains to be determined whether these differences are of clinical 
importance.
Funding: Other NIH Support - T32 grant: 1T32DK07777
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Long-Term Incense Use and the Risk of ESRD
Tingting Geng,1 Tazeen H. Jafar,2 Jian-Min Yuan,3 Woon-puay Koh.2 1National 
University of Singapore, Singapore, Singapore; 2Duke-NUS Graduate Medical 
School, Singapore, Singapore; 3University of Pittsburgh, Pittsburgh, PA.
Background: Animal study suggests exposure to incense burning has deleterious 
effects on kidney function and architecture. However, the association between domestic 
incense burning and risk of end-stage renal disease (ESRD) has not been reported previously.
Methods: We investigated this association in the Singapore Chinese Health Study, a 
prospective population-based cohort of 63,257 Chinese men and women of 45-74 years of 
age in Singapore at recruitment during 1993-1998. Information on the practice of incense 
burning at home, diet, lifestyle and medical history was collected at baseline interviews. 
ESRD cases were identified through linkage analysis with the nationwide Singapore Renal 
Registry through 2015. We used Cox proportional hazards regression analysis to estimate 
hazard ratio (HR) and 95% confidence interval (CI) of ESRD associated with domestic 
incense burning.
Results: Among cohort participants, 76.9% were current incense users. After an 
average 17.5 years of follow-up, 1,217 (1.92%) ESRD cases were documented. Compared 
to never users, the multivariable-adjusted HR for ESRD was 1.05 (95% CI, 0.80 to 1.38) 
for former users and 1.26 (95% CI, 1.02 to1.57) for current users of incense. The ESRD risk 
was restricted only to current daily users with a history of more than 20 years; HR was 1.25 
(95% CI, 1.07 to 1.46), compared with non-current users. Conversely, those who did not use 
incense daily or those who had used daily for ≤ 20 years had no increased risk.
Conclusions: Our findings demonstrate that long-term daily exposure to domestic 
incense burning could be associated with a higher risk of ESRD in Singapore Chinese.
Funding: Other NIH Support - National Institutes of Health, USA (R01 CA144034 and 
UM1 CA182876), Government Support - Non-U.S.
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The Association Between Lead and Cadmium Co-Exposure and the Renal 
Dysfunction
Xiao Chen, Jing Chen. Department of Nephrology, Zhongshan Hospital Fudan 
University, Shanghai, China.
Background: Cadmium (Cd) and lead (Pb) exposure both can induce kidney damage. 
However, the effects of combined exposure to Cd and Pb on renal function at environmental 
levels have not been fully clarified. In this study we investigate the renal function in a 
Chinese population co-exposed to Cd and Pb.
Methods: A total of 331 subjects (215 women and 116 men), living in either a control 
or a polluted area, were included in this study. Cd and Pb in blood and urine (BCd, BPb, 
UCd, and UPb), and kidney effect markers including urinary N-acetyl-β-D-glucosaminidase 
(UNAG) and estimated glomerular filtration rate (eGFR), were determined, and the 
association between exposure markers and renal effects biomarkers were analyzed.
Results: The exposure levels in the polluted area were significantly higher than in 
the control area (all p < 0.01). The eGFR of subjects in the polluted area was decreased 
compared with that in the control area (p < 0.01). The subjects with high BCd/BPb 
(BCd ≥ 2 μg/L, BPb ≥ 100 μg/L) or high UCd/UPb (UCd ≥ 3 μg/g creatinine, UPb ≥ 10 
μg/g creatinine) showed higher UNAG and UALB levels compared with other subgroups 
(p < 0.01). The probability of having elevated UNAG in subjects with high BCd/BPb was 
greater than those for with low BCd/BPb [odds ratio (OR) = 2.6, 95% CI: 1.4-4.7], low 
BCd/high BPb (OR =3.1, 95% CI: 1.4-6.6), and high BCd/low BPb (OR = 1.7, 95% CI: 
0.9-3.2). The OR of subjects with low UCd and high UPb, high UCd and low UPb, and high 
UCd/UPb were 2.9 (95% CI: 1.4-5.7), 3.3 (95% CI: 1.5-7.2), and 7.7 (95% CI: 4.0-14.7), 
respectively, compared with those with low UCd/UPb. The risk of decrease in eGFR was 
also higher in subjects with high UCd/UPb than for those with low UCd/UPb (OR =7.2, 
95% CI: 0.8-62.2).
Conclusions: Our data demonstrate that Cd and Pb exposure, alone or in combination, 
are associated with renal impairment. In addition, co-exposure to Pb and Cd propagates the 
renal tubular dysfunction compared with Cd or Pb exposure alone.
FR-PO178 Poster Friday
CKD: Epidemiology, Risk Factors, Prevention - II
Association of Hyperuricemia to Mesoamerican Nephropathy
Ramon Garcia-Trabanino,1,2 Joel E. Romero alejo,5,2 Maria V. Rodriguez,3 
Emmanuel Jarquin,4 Juan J. Vindell.3 1Centro de Hemodialisis, San Salvador, El 
Salvador; 2Emergency Social Fund for Health, Tierra Blanca, El Salvador; 
3Universidad de El Salvador, San Salvador, El Salvador; 4AGDYSA, San 
Salvador, El Salvador; 5Instituto Salvadoreño del Seguro Social, Jiquilisco, El 
Salvador.
Background: Mesoamerican nephropathy (MeN) is considered a new entity among 
chronic kidney diseases (CKD), but still of uncertain etiology (CKDu). Some risk factors 
and characteristics identified through previous cross-sectional studies are: agriculture 
work -mainly sugar cane work-, hot environment, hyperuricemia and dysuria. The aim of 
our study was to reassess the role of hyperuricemia in adult subjects with altered kidney 
function (AKF) and without diabetes mellitus (DM) and hypertension (HTN), traditional 
risk factors of CKD.
Methods: The studied sample came from 10 communities in a known hotspot of MeN 
in El Salvador (Bajo Lempa region). We used a cross sectional design where incoming 
participants were grouped depending on different exposures: Group 1: previous diagnose 
of DM and/or HTN, and agriculture work; group 2: DM/HTN without agriculture; 
group 3: agriculture without DM/HTN, and group 4: non-DM/HTN without agriculture. 
They were included independent of previous diagnosis of CKD or hyperuricemia. Our 
primary outcomes were: AKF, defined by elevated serum creatinine (SCr) or eGFR 
<60 mL/min/1.72m2 (MDRD equation), and hyperuricemia, defined by elevated serum uric 
acid (male: >7 mg/dL, female: >6 mg/dL) or daily intake of allopurinol prescribed by a 
physician.
Results: 681 subjects were included: 58.4% female, mean age 42 years (SD ± 17.291) 
with the following distribution: group 1: 14 subjects, group 2: 20 subjects, group 3: 282 
subjects, and group 4: 365 subjects. Frequency of AKF for each corresponding group: 
78.5%, 45%, 23.40%, and 18.63%, p=0.000. The frequency of hyperuricemia in subjects 
without AKF was 15.68%, and with AKF 43.27%, p=0.000. Comparing all subjects with 
AKF and hyperuricemia we found that working in agriculture presented higher frequency 
(62.2%, p=0.006). Comparing those in groups 2 and 3 with AKF for hyperuricemia we 
found a frequency of 44.44% and 54.44%, respectively. With a multivariate analysis, DM, 
HTA, dysuria, and hyperuricemia were statistically associated to AKF (p<0.0001) but not 
agriculture work (p=0.094) or ever working in sugar cane culture (p=0.252).
Conclusions: More research with stronger design is needed to study this factor as it 
might seem that uric acid has a role in AKF in this region, mostly in those without traditional 
risk factors (CKDu).
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The Impact of Hyperuricemia on Kidney Failure and Mortality in a 
Multi-center CKD Cohort: An Instrumental Variable Analysis
Yong Chul Kim,1 Jung Nam An,2 Dong Ki Kim,3 Chun Soo Lim,2 Yon Su Kim,4 
Jung Pyo Lee.2 1SNUH, Seoul, Republic of Korea; 2Seoul National University 
Boramae Medical Center, Seoul, SEOUL, Republic of Korea; 3Seoul National 
University Hospital, Seoul, Republic of Korea; 4Seoul National University 
College of Medicine, Seoul, Republic of Korea.
Background: Hyperuricemia is an independent risk factor for mortality, cardiovascular 
disease, and renal disease in general population. However, the relationship between 
hyperuricemia with kidney failure and death in chronic kidney disease (CKD) remains 
controversial.
Methods: The study investigated the association between uric acid with all-cause 
mortality, end stage renal disease (ESRD) in 42,253 CKD patients in a multi-center cohort 
from 2001 to 2016. We used the regional prevalence of hyperuricemia (uric acid ≥ 6.8 mg/dL) 
as an instrument to test our hypothesis that hyperuricemia is associated with ESRD and 
mortality.
Results: In all subjects, the mean uric acid level was 5.4 ± 1.8 mg/dL. During a median 
year follow-up, there were 3,556 (8.42%) of renal failure and 5,094 (12.06%) of death 
in this cohort. Using an instrumental variable analysis after adjusting confounders such 
as age, diabetes, hypertension and estimated GFR (eGFR), we found evidence suggesting 
a causal relationship between hyperuricemia and increased risk of all-cause mortality 
(HR 3.131, 95% CI 2.043-4.797, P < 0.001). This tendency was consistent regardless of 
gender (male: HR 2.270, 95% CI 1.338-3.851, P = 0.002, female: HR 2.656, 95% CI 1.459-
4.834, P = 0.001). On the contrary, higher uric acid concentrations were independently 
associated with reduced risk for kidney failure in the entire participants (HR 0.539, 95% CI 
0.318-0.915, P = 0.022), especially in patients with reduced renal functions (eGFR below 
30, HR 0.189, 95% CI 0.098-0.366, P < 0.001).
Conclusions: Instrumental variable analysis supports that uric acid concentration is an 
independent risk factor for all-cause mortality, while hyperuricemia might have protective 
effect for ESRD, especially in reduced renal function.
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Physical Activity Is Associated with the Incident CKD in Subjects with 
Normal Renal Function: Community Based Prospective Cohort Study
Jimin Park, Yooju Nam, Seon yeong Lee, Joohwan Kim, Ki Heon Nam, Seung 
Hyeok Han, Tae-Hyun Yoo. Yonsei University College of Medicine, Seoul, 
Republic of Korea.
Background: Physical exercise has a beneficial effect on the prevention of 
cardiovascular disease and diabetes via improvement in the cardio-metabolic disturbances 
and is associated with better survival in patients with various chronic diseases as well as 
general population. However, the effects of physical activity on renal outcomes remains 
unclear. We aimed to investigate the association between daily physical activity and the 
development of chronic kidney disease (CKD) in relatively healthy population with normal 
renal function.
Methods: Data were retrieved from the Korean Genome and Epidemiology Study, a 
prospective community-based cohort study. Daily physical activity was estimated by semi 
quantitative daily activity questionnaire. The eGFR calculated by the CKD-EPI equation 
from a total of 8,261 subjects were followed up biennially from 2001 to 2014. The primary 
endpoint was incident CKD, defined as a composite of eGFR <60 mL×min-1×1.73 m-2 and/
or the development of proteinuria during the follow up period.
Results: The mean age of study subjects was 52.0 years and 3,953 (47.9%) participants 
were male. At baseline, the mean eGFR was 94.16 ± 14.16 mL×min-1×1.73 m-2. And 
the average daily physical activity was 1443.3 ± 896.5 MET*h. During a mean follow-
up duration of 119.2 (79.1 – 159.3) months, CKD newly developed in 1,518 (18.4%) 
subjects. The incidence of proteinuria and eGFR decline lower than 60 mL×min-1×1.73 m-2 
were 288 (3.5%) and 1,319 (15.9%) subjects, respectively. When divided into quartiles 
according to daily physical activity, Kaplan-Meier analysis revealed that the risk of CKD 
development in the highest quartile (Q4) was significantly lower than that of the lowest 
quartile (Q1) (P <0.001). This association was remained significant even after adjustments 
were made for confounding factors by multivariable Cox proportional hazards model. (HR 
[95% CI] = 0.75 [0.65–0.87], P < 0.01).
Conclusions: High physical activity is independently associated with decreased risk of 
incident CKD in healthy population with normal renal function.
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Effect of Exercise Intensity on Autoregulation of GFR in Patients with 
CKD Stage 2
Kazuko Koutoku,1 Tetsuhiko Yasuno,2 Syotaro Kawakami,6 Kanta Fujimi,3 
Takuro Matsuda,3 Shihoko Nakashima,1 Yoshinari Uehara,4 Takao Saito,5 
Yasuki Higaki.4 1Fukuoka Univercity, Nanakuma, Johnan-ku, Fukuoka, Japan; 
2Fukuoka university, Fukuoka, Japan; 3Fukuoka University Hospital, Fukuoka, 
Japan; 4Fukuoka University, Fukuoka, Japan; 5Sanko Clinic, Fukuoka, Japan; 
6Fukuoka University Chikusa Hospital, Fukuoka, Japan.
Background: Several studies have showed that aerobic exercise improves 
cardiovascular function in patients with CKD. On the other hand, glomerular filtration rate 
(GFR) significantly decreased during severe exercise in healthy young men (Kawakami 
S, et al. 2018). The purpose of this study was to determine the association of GFR with 
intensity of exercise in patients with CKD stage 2.
Methods: Renal blood flow (RBF) was assessed by Duplex ultrasound. GFR was 
estimated by serum cystatin-C (eGFRcys). FF was calculated with eGFRcys/RBF 
(1-hemtocrit). Eight males with CKD stage 2 (eGFRcys: 60-89/min/1.73m2) participated in 
the study, consisting of three separate trials using a cycle ergometer. The first is a maximal 
graded exercise test. The second is a multi-stage exercise test to determine their lactate 
threshold (LT). The third is a multi-stage exercise test (4 minutes/stage) at intensities of 
60%, 80%, 100%, 120%, and 140% of LT.
Results: eGFRcys significantly decreased and FF significantly increased (eGFRcys: 
73±14min/1.73m2, FF: 0.44±0.17) after strenuous exercise (p< 0.01). eGFRcys did not 
decrease until 100% of LT was attained, and showed slight reduction at 120% of LT and 
140% of LT (eGFRcys: 76±10min/1.73m2 and 72±9min/1.73m2) relative to its resting 
value. FF was significantly higher at 100% of LT (FF: 0.46±0.16), compared to its resting 
value (p< 0.01). Heart rate (HR) and the norepinephrine level (NE) also increased with the 
intensities of LT (HR: p< 0.01, NE: p< 0.05). (Fig. 1)
Conclusions: Our results demonstrate that GFR does not change during exercise until 
the LT is attained, although FF increases. These findings suggest that patients with CKD 
stage 2 might be able to maintain their GFR during exercise up to 100% of LT.
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Concomitant Acute Pyelonephritis and Obstruction Duration Affects 
Renal Outcome in Obstructive Uropathy by Urolithiasis
Seongyup Yeo, Jin Ho Hwang. Department of Internal Medicine, Chung-Ang 
University Hospital, Seoul, Republic of Korea.
Background: Urolithiasis related obstructive uropathy is one of increasing causes 
of CKD, which commonly encountered in clinical field. Obstruction release from 
urolithiasis can be easily delayed with a lack of suggested golden time to prevent renal 
function deterioration. Here, we investigated the clinical significance and renal outcomes of 
urolithiasis related obstructive uropathy.
Methods: This is a study of 1646 from 2315 patients in urolithiasis related obstructive 
uropathy cohort which is recruited between Jan. 2005 and Dec. 2015. Clinical outcomes 
were evaluated with respect to obstruction duration, acute kidney injury (AKI), and acute 
pyelonephritis (APN) accompanied by obstructive uropathy.
Results: Median duration of obstruction (elapsed time to release obstruction) was 6 
days and APN was accompanied in 14.3% of patients. Patients with HT, DM, and CKD 
had significantly higher rates of APN accompanied by obstructive uropathy. In the patients 
whose obstruction was relieved within 2 days from the symptom onset, 8.7% showed 
spontaneous release of obstruction. There was a significant increase in the number of APN 
(P=0.008) and AKI (P=0.002) patients who underwent early treatment of obstruction within 
6 days from the symptom onset. People with Grade 1 or 2 hydronephrosis tended to release 
obstruction earlier, and those with Grade 3 or 4 had a higher rate of obstruction release after 
7 days. In the patients with concomitant APN, mean age was older (59.4 vs 51.9 years-
old, P<0.001), AKI occurred more frequently (73.7% vs 32.9%, P<0.001), estimated GFR 
(eGFR) at the last follow-up visit was lower (80.9 vs. 86.9 ml/min/1.73m2, P=0.024), and 
the use of NSAIDs were lower (49.3% vs. 74.9%, P<0.001). The AKI grades by KDIGO 
showed worse renal outcome in advanced stage (P=0.001). When we adjusted gender, age, 
HT, DM, use of NSAIDs, APN, AKI grades, and obstruction release over 2 days for a 
multivariate analysis, APN (HR 2.2, CI 1.01-4.65; P=0.047) and the obstruction release 
after 2 days (HR 3.55, CI 1.34-9.38; P=0.011) were independently associated with eGFR 
decrease of >30%.
Conclusions: In urolithiasis related obstructive uropathy patients, concomitant APN 
was strongly associated with renal function deterioration after obstruction release. The 
elapsed time to release obstruction also affected to renal function.
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IgG4-Related Kidney Disease (IgG4-RKD) a Large Single-Institution 
Study
Alessia Buglioni, Mariam P. Alexander, Loren P. Herrera hernandez, 
Mary E. Fidler, Samih H. Nasr, Sanjeev Sethi, Samar M. Said, Joseph P. Grande, 
Marie C. Hogan, Lynn D. Cornell. Mayo Clinic, Rochester, MN.
Background: IgG4-related disease (IgG4-RD) is an immune-mediated condition that 
can involve any organ, often by mass-forming inflammatory lesions. The kidney is usually 
affected in a pattern of tubulointerstitial nephritis (TIN); membranous glomerulonephritis 
(MGN) is another recognized pattern.
Methods: A retrospective biopsy (bx) - and nephrectomy-based study from a single 
institution with clinicopathological correlation was performed in cases of IgG4-RKD 
diagnosed between 1/2001 and 5/2018.
Results: 101 patients (80 M, 21 F) were identified with IgG4-RKD on bx (n= 96) or 
nephrectomy (n= 5), with a histologic pattern of TIN (94%) and/or MGN (15%). Race/
ethnicity included white non-Hispanic (65%), African-American (11%), Asian (11%), 
Hispanic (11%), and American Indian (3%). The mean age was 62 years (range 20-84). 
Mean creatinine (SCr) at bx was 3.4 mg/dl (median 2.6 mg/dl, range 0.9-11.0 mg/dl). 
The primary indication for bx or nephrectomy was acute or chronic renal failure (68%), 
proteinuria (9%), or abnormal imaging (23%). Overall, 39% had renal masses. Extra-renal 
involvement was present in 85%. Serum IgG and/or IgG4 was increased in 88%. 29% 
had positive antinuclear antibody. Serum complement (C3 and/or C4) was decreased in 
63%. Plasma cell-rich TIN was present in all cases of TIN and 93% showed an increase 
in IgG4+ plasma cells (focal >10 cells/40x field). Interstitial fibrosis was severe in 65% 
of cases, moderate in 15%, mild in 20%. 15% had MGN; of those with MGN, 71% 
also had a component of TIN. None showed granulomatous inflammation. 70% showed 
tubular basement membrane immune complex deposits by IF or EM. Follow-up was 
available in 49 patients (49%), with a mean length of 17 months. 98% were treated with 
immunosuppression (prednisone in 64%, rituximab in 6%, both 10% and other in 19%). 
80% of patients with elevated SCr responded to therapy.
Conclusions: In our study, the most common manifestation of IgG4-RKD is TIN with 
functional impairment rather than mass lesions. MGN is not uncommon. Clinical features 
of IgG4-KRD included a higher prevalence of hypocomplementemia. Notably, 15% of 
patients have renal-limited disease. Immunosuppressive therapy improves renal function 
in the majority of patients.
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and Albuminuria with ESRD and All-Cause Mortality in the GCKD 
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Background: Chronic kidney disease (CKD) is classified according to cause of kidney 
disease, estimated glomerular filtration rate (eGFR) and albuminuria, but risk prediction 
mainly relies on eGFR and albuminuria. We investigated the impact of kidney disease 
etiology on the association of kidney disease measures with adverse outcomes.
Methods: We studied 5,214 patients with CKD in the German Chronic Kidney Disease 
(GCKD) study, where the treating nephrologists assessed the cause of kidney disease. We 
grouped causes according to the KDIGO guideline with sensitivity analyses for alternative 
classifications. We analyzed the relative hazard of end-stage renal disease (ESRD) and all-
cause mortality as a function of eGFR and urinary albumin-creatinine-ratio (UACR) using 
age, sex, German origin, systolic blood pressure, smoking, diabetes, BMI and history of 
cardiovascular disease as covariates. We tested for interaction between eGFR and UACR 
with cause of kidney disease in a Cox proportional hazards model.
Results: We observed 237 ESRD events and 418 deaths over 4.5 years of follow-
up. Risk of ESRD and mortality increased with lower eGFR and higher UACR in each 
of the CKD causes where sample size was adequate. In the ESRD model, interaction of 
CKD cause was only present for eGFR with cystic or congenital diseases (p=0.004, see 
Table), although power to detect modest interactions is limited. For all-cause mortality, no 
significant interaction was observed between CKD cause and eGFR or UACR.
Conclusions: KDIGO staging of ESRD and mortality risk by eGFR and albuminuria 
is valid across different causes of CKD, although the eGFR relationship to ESRD risk is 
stronger in cystic or congenital kidney disease.
Funding: Private Foundation Support, Government Support - Non-U.S.
Prevalence of CKD causes, incidence and HRs for ESRD associated with lower eGFR or 
higher UACR and p-values of the interaction between cause and eGFR/UACR, adjusted 
for age, sex, German origin, systolic blood pressure, smoking, diabetes, BMI, CVD history
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Background: Hydrophobic uremic toxins accumulate in patients with chronic kidney 
disease, contributing to a highly increased cardiovascular risk. The clearance of these uremic 
toxins by current hemodialysis techniques is limited due to their high binding affinity to 
plasma proteins, which prevents their removal through the pores of dialysis membranes. 
Adsorber techniques may be an appropriate alternative and/or additional technique to 
increase hydrophobic uremic toxin removal.
Methods: We developed an extracorporeal adsorber particle for efficient adsorption 
of these uremic toxins. The whole blood adsorber particle consists of a porous, activated 
charcoal core with a hydrophilic surface coating of cross-linked polyvinylpyrrolidone. 
The adsorption capacity of the particles was quantified by analytical chromatography after 
incubation or perfusion of the particles with an aqueous serum albumin solution or blood, 
each containing mixtures of hydrophobic uremic toxins.
Results: The particle hemocompatibility was assessed by quantifying the production 
of thrombin-antithrombin III complex (TAT) and complement component 5a (C5a) as well 
as leukocyte and thrombocyte counts in blood. A time-dependent increase in hydrophobic 
uremic toxin adsorption was depicted and all tested toxins showed a high binding affinity 
to the adsorber particles. Further, the particle showed a good hemocompatibility without 
significant effects on C5a, TAT or thrombocyte concentration, although leukocyte counts 
were slightly reduced
Conclusions: In conclusion, the whole blood adsorber particle is hemocompatible 
and shows a high adsorption capacity towards hydrophobic uremic toxins. Thus, it is an 
interesting candidate for further in vivo studies with the aim to increase the efficiency of 
conventional dialysis techniques and reduce mortality in CKD patients.
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Background: CKD and periodontal disease (PD) disproportionately affect poor and 
minority populations. Observational studies suggest PD may be a modifiable CKD risk 
factor. The KAPD study (NCT01802216) was a pilot RCT to assess the feasibility of 
recruiting and retaining patients from a diverse, public hospital setting and to determine the 
variability of kidney and inflammatory biomarkers in response to PD treatment.
Methods: We randomly enrolled 51 adult patients with moderate/severe PD and 
CKD to immediate PD treatment (whole mouth deep cleaning + local minocycline to 
deep pockets, n=34) or delayed treatment with rescue (deep cleaning for worsening tooth 
sites, n=17) every 4 months for a 12-month protocol, with biomarkers assessed at baseline, 
4-month, and 12-month study visits.
Results: Of enrolled patients, 82% were non-white; 47% had seen a dentist within
the last 2 years; and 80% completed all 4 visits of the 12-month protocol (28 intervention, 
13 rescue). 6 delayed treatment patients (35%) required rescue treatment. For intervention 
group, biomarkers of vascular injury (ADMA), and inflammation (IL-6) improved; tubular 
injury (urine NGAL) worsened; and UACR improved while serum NGAL worsened 
(markers of glomerular injury). Changes among UACR and serum NGAL in the rescue 
group were opposite, but similar otherwise.
Conclusions: KAPD demonstrated enrolling and retaining patients from a diverse, 
public hospital setting in a 12-month trial is feasible. There was variability in kidney 
and inflammatory biomarkers in response to PD treatment. Rescue treatment may have 
obscured decisive treatment effect. A larger trial is needed to determine the extent to which 
PD treatment may slow CKD progression.
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Background: Patients with chronic kidney disease (CKD) are often unaware of their 
diagnosis. Doctors may be hesitant to inform patients of a CKD diagnosis and may use 
heterogeneous terms when doing so. We examined patients’ experiences and preferences 
about being informed of a CKD diagnosis.
Methods: 202 adults with CKD Stages 1-5 completed a cross-sectional survey between 
April 2015-May 2016. Survey questions focused on: patient experiences being informed 
about a CKD diagnosis, preferences about verbiage patients use to describe their CKD 
diagnosis (“Which of the following words or phrases do you use to talk about your kidney 
problem?”), and when patients thought they should have been told about their diagnosis (“If 
you had the choice, when would you have wanted to know that you had kidney disease?”).
Results: Mean (SD) age was 59 (16) years. 48% were male, 78% Caucasian, 17% 
African American, 73% had CKD Stage 3-5, 51% had an annual income > $50K, and 
95% had ≥ H.S. education. Most patients were first told they had CKD by a kidney doctor 
(n=87, 47%) in an outpatient setting (n=138, 72%). Others learned of their diagnosis from 
primary care doctors (33%), ER doctors (7%), and “others,” e.g. inpatient providers (9%). 
Other settings included the hospital (15%), ER (7%), and at home via phone call (6%). 
Thirty percent of patients reported DM and/or hypertension as the cause of their CKD, and 
49% did not recall being told or did not know the cause. Most patients preferred multiple 
terms to refer to their diagnosis; the majority used “kidney disease” (82%) and “chronic 
kidney disease” (65%), followed by “decreased kidney function” and “elevated creatinine” 
(both 61%). Least used terms were “kidney injury” (12%) and “renal insufficiency” 
(18%). Ninety-six percent felt patients should be informed of their CKD diagnosis upon 
identification by their doctor. Only 4% felt it was acceptable for the doctor to determine if 
informing the patient mattered or to not inform patients at all.
Conclusions: Most patients were not told about their CKD diagnosis until they saw a 
kidney doctor in an outpatient setting. Nearly half did not know the cause of their CKD. 
Preferred verbiage is largely congruent with current guidelines. In contrast to doctors’ 
perspectives, patients feel they should be informed of their CKD diagnosis as soon as it is 
identified by a doctor.
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Background: Identifying CKD patients is an essential step for surveillance, research 
recruitment and quality improvement (QI). Using diagnostic codes to identify CKD patients 
is challenged by widespread under-diagnosis of CKD. An electronic CKD phenotype based 
on data widely available in the electronic health record could facilitate identification of 
patients likely to have CKD.
Methods: A working group of patients, nephrologists, primary care providers and 
informaticists developed the ePhenotype. Five clinical sites implemented the ePhenotype. 
Each site collected study population demographics (age, race, sex), labs (eGFR, UACR, 
UPCR, UA) and dialysis/transplant status. The ePhenotype determined CKD status 
(eGFR <60 ml/min/1.73m2, UACR ≥30 mg/g), CKD stage and chronicity (prior lab value 
indicative of CKD 90+ days prior). Four sites conducted a blinded, manual validation on a 
random subsample of the population across CKD status. Diagnostic accuracy (proportion of 
patients with correctly identified CKD stage) and sensitivity/specificity of the ePhenotype 
for identifying CKD, dialysis and transplant were calculated for each site and overall.
Results: The validation population included 1,680,334 patients across 4 sites with 
average age 49.8±18.5. Of these, 58.7% were female, 10.4% were black, 59.3% had at 
least 1 eGFR and 40.6% had any proteinuria measurement. The proportion of patients with 
any proteinuria measurement varied across sites (20.2% to 52.1%) and increased as eGFR 
decreased. The ePhenotype was successfully implemented at all sites. Diagnostic accuracy 
for identifying CKD stage was 98%. Sensitivity and specificity, respectively, across the 
validation sites were 99.3% and 98.5% for CKD, 94.5% and 90.7% for dialysis and 97.3% 
and 91.1% for transplant (Table 1).
Conclusions: The ePhenotype was successfully implemented at multiple sites with a 
high degree of accuracy and has the potential to facilitate identification of patients with 
CKD for surveillance, research and QI.
Funding: NIDDK Support
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Developing Incident CKD
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Background: Chronic Kidney Disease (CKD) is an under-identified condition and 
current methodology for identifying patients at risk of developing incident CKD is limited. 
Identifying patients who are high risk for CKD can improve awareness while delaying onset 
and progression of CKD. Machine learning algorithms can be used to stratify risk of those 
likely to develop incident CKD. Previous work has defined CKD using ICD codes or a 
limited number of eGFR readings.
Methods: Data from 1,780,262 patients with no baseline CKD in the Veterans Affairs 
healthcare system was analyzed. We used a random forest classifier to 1) predict incident 
CKD (eGFR >90 progressing to eGFR <60) and 2) predict the development of advanced 
CKD (eGFR >60 progressing to eGFR <45) utilizing information on patient demographics, 
comorbidities, laboratory values, and medication use. We excluded eGFR values during an 
AKI episode using an algorithm and selected sustained eGFR periods using slope-based 
analyses. One, two, and five-year prediction models were generated.
Results: The performance of the prediction models are summarized in Table 1. As 
models predict on outcomes across longer time ranges the lab values become less important 
while the comorbidities rise in importance. At the top risk quartile, our one year incident 
CKD model has an AUC of 0.839, a sensitivity of 0.754, and a specificity of 0.751, and our 
one year development of advanced CKD model has an AUC of 0.871, a sensitivity of 0.825, 
and a specificity of 0.751.
Conclusions: We demonstrate the ability to leverage advanced machine learning 
models to predict CKD incidence using longitudinal data commonly available in EHR 
systems. Future studies should validate our model in a clinical setting.
Funding: Veterans Affairs Support, Commercial Support - pulseData
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Background: Little is known about chronic kidney disease CKD progression among 
rural versus urban dwelling patients. The study aim was to determine associations of 
residential location with estimated glomerular filtration rate (eGFR) over time in patients 
with and at-risk for CKD.
Methods: Providence and UCLA healthcare systems collaboratively formed a CKD 
and at-risk CKD registry from electronic health records (n=3,118,853). Participants were 
identified by diagnosis of CKD, at-risk for CKD (diabetes, pre-diabetes, or hypertension) by 
ICD-9/10 codes and condition-specific criteria from 2006-2016. The primary outcome was 
eGFR (CKD-EPI-creatinine) including ≥3 values over ≥90 days, and the main covariate 
of interest was rural versus urban dwelling defined by Rural-Urban Commuting Area 
codes. Other pre-specified covariates in the random effects regression model included: age, 
gender, race; and time-varying covariates: HbA1c, systolic blood pressure, and angiotensin 
converting enzyme inhibitor/angiotensin receptor blocker (ACE/ARB) usage.
Results: Baseline characteristics: 59±17 years of age, 56% female, 10% rural 
dwelling, 86% White, 6% Black or African American, and 7% Asian. Baseline eGFR 
was 60.6±22.5 mL/min/1.73m2 in the CKD cohort and 90.0±18.3 mL/min/1.73m2in the 
at-risk cohort. For both the CKD and at-risk cohort, patients dwelling in a rural versus 
an urban location experienced a nearly 4 mL/min/1.73m2greater annual decline in eGFR 
(B = -3.81, 95% CI: -4.21 - -3.42, p<0.001) over a median of 5 years, controlling for other 
covariates. eGFR decline significantly varied across race and was inversely associated with 
age, time, and ACE/ARB usage. eGFR decline was positively associated with female sex 
and systolic blood pressure. HbA1c was not associated with eGFR change.
Conclusions: In patients with CKD and at-risk for CKD, rurality independently 
associated with faster loss of kidney function compared to urban dwelling. Facilitators and 
overcoming barriers to better care are needed for these patients in rural locations.
Funding: Private Foundation Support
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Background: Monitoring quality of CKD care and understanding geographic variation 
in care quality are important for improving patient outcomes; however this topic has 
received limited attention. We examined quality of care measures for CKD and geographic 
variation in elderly Medicare beneficiaries in the United States.
Methods: We analyzed the 5% sample of the Medicare fee-for-service population 
linked with Part D medication claims data from 2007 to 2015. We selected elderly 
(65 years) patients with diagnosed CKD (by ICD-9 codes) and examined their care in 
repeated annual crossections. We assessed 4 key CKD quality indicators including urine 
albumin testing, renin-angiotensin (RAS) inhibitors use, not receiving (i.e., <14 days per 
month prescription) of non steroidal anti-inflammatory drugs (NSAIDs), and receiving 
nutritional consultation. Variation in these practices by age, sex, race, comorbidities 
(diabetes, hypertension and history of cardiovascular disease) and county of residence, were 
examined. A multivariate logistic model identified factors associated with urine albumin 
testing and RAS inhibitor use.
Results: Of the total 2,162,085 elderly CKD patients, 43.1% were 80 years or older, 
44.8% had diabetes, and 86.4% had hypertension. We observed steady increase in urine 
testing (from 21.5% in 2007 to 29.5% in 2015) and RAS inhibitor use (31.8% in 2007 
to 40.6% in 2015) (each p for trend <0.01). During the same follow-up years, nutritional 
guidance was received in under 2%, but NSAIDs avoidance was observed in over 95%. 
County-level variation (Figure) in urine testing and RAS inhibitor use ranged widely from 
0 to >50%, and increased over time. Age <80 years, diabetes, and hypertension, were 
associated with higher odds of urine testing and RAS inhibitor use.
Conclusions: Significant practice gaps and variations exist across the US for selected 
quality indicators of CKD care in older adults. More research into this area is vital as quality 
of care monitoring has potential to inform policy and practice improvements for this patient 
population..
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Background: Tubular atrophy on biopsy is a strong predictor of kidney disease 
progression, but tubular health is poorly quantified by traditional measures including 
estimated glomerular filtration rate (eGFR) and albuminuria. We hypothesized that urinary 
biomarkers of tubule dysfunction would be associated with faster kidney function decline 
in persons with chronic kidney disease (CKD).
Methods: We measured baseline urine concentrations of α1-microglobulin (α1m), 
β2-microglobulin (β2m), and uromodulin among 2,428 participants of the Systolic 
Blood Pressure Intervention Trial who had an estimated glomerular filtration rate (eGFR) 
<60 ml/min/1.73 m2. We used linear mixed models to evaluate biomarker associations with 
annualized relative change in eGFR.
Results: At baseline, the mean age was 72±9 years and eGFR was 48±11 ml/
min/1.73m2. Over a median follow-up of 3.8 years, higher concentrations of urine α1m 
and β2m and lower concentrations of urine uromodulin were independently associated with 
faster annualized eGFR decline (Table). There were no statistically significant interactions 
by intervention arm (p>0.3 for all biomarkers).
Conclusions: Among hypertensive, nondiabetic patients with CKD, urinary biomarkers 
of tubular dysfunction were independently associated with subsequent declines in kidney 
function.
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Associations of urinary biomarkers with annualized relative change in eGFR among 
SPRINT participants with CKD at baseline (N = 2,428)
β coefficient represents % eGFR change in ml/min/1.73m2/year per doubling of the 
biomarker. Demographic-adjusted model includes age, sex, race, intervention arm and
urine creatinine. Multivariable-adjusted model additionally includes baseline eGFR, urine
albumin, smoking status, history of cardiovascular disease, number of antihypertensive
medications, systolic blood pressure, diastolic blood pressure, body mass index, high-
density lipoprotein, and total cholesterol.
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Background: Novel urine biomarkers have enabled earlier detection of kidney tubular 
damage, but their prognostic value for adverse cardiovascular outcomes is uncertain. We 
hypothesized that urinary biomarkers of tubular injury would be associated with higher 
risks for cardiovascular events and mortality in persons with chronic kidney disease (CKD).
Methods: We measured urine concentrations of interleukin-18 (IL-18), kidney injury 
molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), monocyte 
chemoattractant protein-1 (MCP-1), and chitinase-3-like protein-1 (YKL-40) among 2,377 
participants of the Systolic Blood Pressure Intervention Trial who had an eGFR<60 ml/
min/1.73 m2. We used Cox proportional hazards models to evaluate biomarker associations 
with CVD events and all-cause mortality.
Results: At baseline, the mean age was 72±9 years and eGFR was 48±11 ml/
min/1.73m2. Over a median of 3.8 years, 305 CVD events (3.6% per year) and 233 all-
cause deaths (2.6% per year) occurred. After multivariable adjustment, including baseline 
eGFR and albuminuria, higher urine IL-18 and YKL-40 concentrations were independently 
associated with higher mortality risk (Table). The biomarkers did not have statistically 
significant associations with CVD events. Associations were similar when stratified by 
randomization arm.
Conclusions: Among hypertensive, nondiabetic patients with CKD, urine IL-18 and 
YKL-40 were independently associated with higher mortality risk but not with CVD events. 
The remaining markers were not associated with CVD or mortality risk.
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Associations of urine biomarkers with CVD events and mortality among SPRINT 
participants with CKD at baseline (N = 2,377)
Hazard ratios per doubling in biomarker. Models adjust for age, sex, race, intervention arm, 
baseline eGFR, urine albumin, urine creatinine, smoking status, history of CVD or heart 
failure, number of antihypertensive medications, statin use, systolic and diastolic blood 
pressures, body mass index, and lipid profiles.
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Background: Small molecules that associate with subsequent GFR decline in patients 
with CKD may help uncover novel pathophysiological mechanisms of disease or treatment 
targets.
Methods: Among 960 participants in the African American Study of Kidney Disease 
and Hypertension (baseline mGFR 47 +/- 15 ml/min/1.73 m2), we evaluated the associations 
of 961 named and unnamed serum metabolites identified through untargeted metabolomic 
profiling with decline in measured GFR over time using linear mixed models and a median 
of 11 measures of mGFR over 4.1 years. We selected metabolites associated with mGFR 
decline (p<0.05) and subsequently assessed their associations with ESRD over a median 
of 8.9 years using Cox models (Bonferroni-corrected p<0.05). Analyses were adjusted for 
study arm, age, sex, smoking, heart disease, body-mass index, systolic blood pressure, log-
transformed proteinuria, and, in the Cox model, baseline measured GFR.
Results: There were 112 metabolites associated with change in mGFR over time in 
AASK (p<0.05). Fourteen were also associated with ESRD after correcting for multiple 
comparisons (p<0.0004). All 14 metabolites were negatively associated with baseline 
mGFR. The top three metabolites associated with ESRD were 1-methylhistidine, 
erythronate, and O-sulfo-L-tyrosine. Six of the 14 were in the phosphatidylethanolamine 
pathway.
Conclusions: Several metabolites, including six in the phosphatidylethanolamine 
pathway, may relate to ESRD risk. Further studies are needed to determine if these 
associations are causal.
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Solene M. Laville,1 Marie Metzger,1 Benedicte Stengel,1 Christian Jacquelinet,2 
Maurice Laville,3 Luc Frimat,4 Denis Fouque,5 Christian Combe,6 Valérie Gras,7 
Ronald L. Pisoni,8 Ziad Massy,9 Sophie Liabeuf.7 1CESP U1018, INSERM, 
Villejuif, France; 2Agence de la biomedecine, Saint-Denis La Plaine, France; 
3Université de Lyon, Pierre-Bénite, France; 4Nancy University Hospital, 
Vandoeuvre les Nancy, France; 5University Claude Bernard, Pierre Benite, 
France; 6CHU de Bordeaux, Bordeaux, France; 7CHU Amiens, Amiens, France; 
8Arbor Research Collaborative for Health, Ann Arbor, MI; 9Ambroise Pare 
University Hospital and Inserm U1018 Eq5, Boulogne Billancourt/ Paris cedex, 
France.
Background: Little is known about the burden of adverse drug events (ADEs) in 
chronic kidney disease (CKD). We assess the incidence rate of ADEs and describe the 
suspected prescribed drugs associated with the main reported ADEs in the CKD-REIN 
cohort.
Methods: The CKD-REIN study includes 3033 outpatients (65% men) with CKD 
(estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2). ADEs were identified 
from medical records, hospital discharge reports, or patient interviews. All reported ADEs 
were reviewed by pharmacist experts who coded the type of events and the associated 
suspected drugs. Incidence rates were estimated by Poisson regression, overall and by 
patient characteristics.
Results: At baseline, patients’ median age was 69(IQR, 60-76), median eGFR 
was 32(IQR, 23-41)mL/min/1.73m2 and the median number of medications was 8 per 
day. During a median follow-up of 2.3 years, 777 ADEs were reported in 545 patients, 
27% of whom had at least two. The overall incidence rate of ADEs was 10.7[95%CI, 
9.9-11.4] per 100 person years, with significantly higher rates in women than men, and in 
patients with diabetes, lower eGFR, cardiovascular history and with a higher number of 
medications at baseline; it did not differ significantly according to age. Renin-angiotensin 
system inhibitors (RASi) (15%), antithrombotic agents (13%) and diuretics (9%) were 
the drug classes most frequently associated with ADEs. As expected, main ADEs were 
increased serum creatinine and hypotension with RASi and diuretics, hemorrhage with 
antithrombotic agents, and cough with RASi. Of note, 71% of ADEs led to discontinuing 
treatment and 16% to modifying treatment dose. Among the 777 evaluated ADEs, 161 
(21%) were reported among inpatients, either as a cause of hospitalization or an incident 
event, 2.2[95%CI, 1.9-2.6] per 100 person years, four of which were linked with death. 
The drugs most frequently involved in ADEs associated with hospitalization or death, were 
vitamin K antagonists (n=39) and heparin (n=7).
Conclusions: The burden of ADEs is high in patients with CKD and led to discontinuing 
drugs prescribed to slow CKD progression and reduce cardiovascular complications. The 
impact of ADEs and resulting prescription changes on CKD outcomes need to be evaluated.
Funding: Government Support - Non-U.S.
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Urine Markers of Kidney Tubule Cell Injury and Kidney Function 
Decline: Results from SPRINT Trial
Rakesh Malhotra,1 Ronit Katz,2 Vasantha Jotwani,3 Michael Shlipak,4 Joachim H. Ix.1 
1UCSD, San Diego, CA; 2University of Washington, Seattle, WA; 3UCSF, San 
Francisco, CA; 4San Francisco VA Medical Center, San Francisco, CA.
Background: Tubulo-interstitial fibrosis and atrophy are important risk markers for 
chronic kidney disease (CKD) progression on kidney biopsy, but are not evaluated in clinical 
testing. We examined the association between urinary kidney tubule injury biomarkers with 
subsequent loss of kidney function in persons with non-diabetic CKD who participated in 
The Systolic Blood Pressure Intervention Trial (SPRINT).
Methods: Among 2428 SPRINT participants with CKD (eGFR <60 ml/min/1.73m2) 
at baseline, we measured urine concentrations of markers of injury (interleukin-18 [uIL-
18], kidney injury molecule-1[uKIM-1], and neutrophil gelatinase-associated lipocalin 
[uNGAL]), inflammation (monocyte chemoattractant protein-1 [uMCP-1]) and repair 
(human cartilage glycoprotein-40 [uYKL-40]). We used linear mixed models to evaluate 
the associations of each biomarker with annualized change in eGFR; and used proportional 
hazards regression to evaluate the renal composite outcome of 50% eGFR decline, 
transplant or end-stage renal disease.
Results: At baseline, the mean age was 73±9 years and mean eGFR was 46±11 ml/
min/1.73m2; 60% were men and 66% were white. During 3.8 years mean follow-up, there 
were 87 composite renal events. In adjusted continuous models, higher uIL-18, uNGAL and 
uYKL-40 concentrations were associated with faster eGFR decline (Table). Associations 
with the renal composite endpoint appeared non-linear, with heightened risk in the highest 
quartile. The high quartiles of uKIM-1 (hazard ratio 2.84 [95% CI 1.31 to 6.17), uYKL-40 
(1.95 [1.08 to 3.51]) and uMCP-1 (2.43 [1.13 to 5.23]) were each associated with risk of 
the renal composite outcome relative to the lowest quartiles. Associations were similar in 
the two randomization arms.
Conclusions: Urine markers of tubule cell injury provide information about risk of 
subsequent loss of kidney function independent of eGFR and albuminuria. Future studies 
are required to determine if dynamic changes in urine tubule injury markers provide 
information on subsequent risk of CKD progression.
Funding: NIDDK Support
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Markers of Kidney Tubule Function and Risk of Cardiovascular Disease 
Events and Mortality in the SPRINT Trial
Pranav S. Garimella,1 Alexandra K. Lee,2 Walter T. Ambrosius,3 Udayan Y. Bhatt,4 
Alfred K. Cheung,5 Michel Chonchol,6 Timothy Craven,3 Amret T. Hawfield,3 
Vasantha Jotwani,2 Anthony A. Killeen,7 Henry A. Punzi,8 Mark J. Sarnak,9 
Michael Shlipak,10 Joachim H. Ix.11 1University of California San Diego, San 
Diego, CO; 2Kidney Health Research Collaborative, UCSF & VA, San Francisco, 
CA; 3Wake Forest School of Medicine, Winston-Salem, NC; 4The Ohio State 
University, Dublin, OH; 5University of Utah, Salt Lake City, UT; 6University of 
Colorado, Aurora, CO; 7University of Minnesota, Minneapolis, MN; 8Punzi 
Medical Center, Carrollton, TX; 9Tufts Medical Center, Boston, MA; 10San 
Francisco VA Medical Center, San Francisco, CA; 11UCSD, San Diego, CA.
Background: Biomarkers of tubule injury, inflammation and fibrosis have emerged as 
prognosticators of kidney and cardiovascular disease (CVD) outcomes. However, markers 
of tubular function have not been adequately evaluated as risk factors for CVD.
Methods: Using a sample of 2,377 persons with CKD at the baseline SPRINT 
visit, we evaluated the association of three urinary markers of tubular function; alpha-1 
microglobulin (α1m), beta-2 microglobulin (β2m) and uromodulin with CVD events, heart 
failure and all-cause mortality using Cox regression over 3.7 years of follow up. Markers 
were log-transformed given skewed distributions.
Results: Mean age was 73 years, 40% were woman, 26% black, and mean glomerular 
filtration rate (GFR) was 46±11 ml/min/1.73m2. In multivariable analyses, each two-fold 
higher α1m was associated with a 33%, 31%, 61% and 85% greater risk of composite CVD, 
mortality, CVD death and acute coronary syndromes (ACS), respectively [table]. There 
was no association of β2m with any of the outcomes. Each two-fold higher uromodulin 
was associated with a 22%, 30% and 31% lower adjusted risk of composite CVD, HF 
and CVD death, respectively. These associations were not modified by baseline CVD or 
intervention arm.
Conclusions: Among non-diabetic persons with CKD, biomarkers of tubular function 
are associated with incident CVD and mortality independent of GFR and albuminuria.
Funding: NIDDK Support, Other NIH Support - "The Systolic Blood Pressure 
Intervention Trial is funded with Federal funds from the National Institutes of Health (NIH), 
including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), 
and the National Institute of Neurological Disorders and Stroke (NINDS), under Contract 
Numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, 
HHSN268200900048C, HHSN268200900049C, and Inter-Agency Agreement Number 
A-HL-13-002-001. It was also supported in part with resources and use of facilities
through the Department of Veterans Affairs. The SPRINT investigators acknowledge the
contribution of study medications (azilsartan and azilsartan combined with chlorthalidone)
from Takeda Pharmaceuticals International, Inc. All components of the SPRINT study
protocol were designed and implemented by the investigators. The investigative team
collected, analyzed, and interpreted the data. All aspects of manuscript writing and revision 
were carried out by the coauthors. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the NIH, the U.S. Department of 
Veterans Affairs, or the United States Government. For a full list of contributors to SPRINT, 
please see the supplementary acknowledgement list: https://www.sprinttrial.org/public/
dspScience.cfm We also acknowledge the support from the following CTSAs funded 
by NCATS: CWRU: UL1TR000439, OSU: UL1RR025755, U Penn: UL1RR024134& 
UL1TR000003, Boston: UL1RR025771, Stanford: UL1TR000093, Tufts: UL1RR025752, 
UL1TR000073 & UL1TR001064, University of Illinois: UL1TR000050, University of 
Pittsburgh: UL1TR000005, UT Southwestern: 9U54TR000017-06, University of Utah:
UL1TR000105-05, Vanderbilt University: UL1 TR000445, George Washington University: 
UL1TR000075, University of CA, Davis: UL1 TR000002, University of Florida: UL1
TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM103337
COBRE Award NIGMS, Wake Forest University: UL1TR001420.
Association of tubular function biomarkers with clinical outcomes among SPRINT 
participants with CKD
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Urinary PTH1R: Novel Predictor of Mineral Metabolism Disorder and 
Renal Outcome of CKD
Dandan Qiu,1 Yu Pan,4 Jingsong Shi,1 Minlin Zhou,2 Feng Xu,5 Zhihong Liu,3 
Song Jiang.2 1National Clinical Research Center of Kidney Diseases, Jinling 
Hospital, Nanjing University School of Medicine, Nanjing, China; 2National 
Clinical Research Center of Kidney Diseases Jinling Hospital, Nanjing, China; 
3National Clinical Research Center of Kidney Diseases, Nanjing, China; 
4National Clinical Research Center of Kidney Diseases, Research Institute of 
Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 
China; 5Research Institute of Nephrology, Jinling Hospital, Nanjing University 
School of Medicine, Nanjing, China.
Background: There is short of early predictor of mineral metabolism disorder and renal 
outcome in patients with chronic kidney disease (CKD). This study aimed to explore the 
association of urinary parathyroid hormone 1 receptor (PTH1R) with mineral metabolism 
markers, and the predictive value for renal outcome in CKD.
Methods: 29 healthy controls and 140 diabetic nephropathy (DN) patientswere 
enrolled as discovery cohort and 200 general CKD patients were enrolled as an independent 
validation cohort. All patients were followed up for at least 1 year and measured the intact 
PTH (iPTH), fibroblast growth factor 23 (FGF23) in baseline serum and PTH1R in baseline 
urine. Urinary PTH1R was normalized to urine creatinine and log transformed [uPTH1R/
Cr(log10)].The composite renal endpoint was defined as end-stage renal disease (ESRD) or 
30% reduction of baseline eGFR during follow-up.
Results: In discovery cohort, DN patients had a significantly higher mean uPTH1R/
Cr(log10) level compared with healthy control (2.53±0.61 pg/mg versus 1.89±1.14 pg/mg, 
P<0.01). uPTH1R/Cr(log10) was significantly increased in DN patients with eGFR of 60~75 
ml/min/1.73m2, which was earlier than serum FGF23 and iPTH. Baseline uPTH1R/Cr(log10) 
was associated with serum calcium (r=-0.224, P<0.01), serum FGF23 (r=0.232, P<0.05), 
and eGFR slope (r=0.318, P<0.001). 59 patients in discovery cohort entered into composite 
renal endpoint during follow-up. Cox regression analysis showed that higher uPTH1R/
Cr(log10) had a significantly higher risk for renal outcome [HR=2.190; 95%CI(1.048,4.575), 
P<0.05]. Validation cohort confirmed that uPTH1R/Cr(log10) was an independent risk factor 
for renal outcome [HR=1.573; 95%CI(1.094,2.263), P<0.05] in general CKD patients. 
Addition of uPTH1R/Cr(log10) to eGFR and proteinuria could significantly improve the 
prediction value for renal outcome (likelihood ratio test, P<0.001).
Conclusions: Urinary PTH1R was an independent risk factor for renal outcome in 
CKD patients, and was a novel biomarker of disordered mineral metabolism.
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The Association of Blood Urea Nitrogen to Creatinine Ratio with Renal 
and Cardiovascular Outcomes in CKD: The CRIC Study
Georges Saab,1 Edward J. Horwitz,1 Wei Yang,2 Jing Chen,3 Jiang He,4 
Ana C. Ricardo,5 James H. Sondheimer,9 Nidhi Sukul,10 Xiaoming Zhang,8 
Mahboob Rahman,6 Sankar D. Navaneethan.7 1MetroHealth Medical Center, 
Cleveland, OH; 2University of Pennsylvania, Philadelphia, PA; 3Tulane School 
of Medicine, New Orleans, LA; 4Tulane School of Public Health and Tropical 
Medicine, New Orleans, LA; 5University of Illinois at Chicago, Chicago, IL; 
6Case Western Reserve University, Cleveland, OH; 7Baylor College of Medicine, 
Sugar Land, TX; 8University of Pennsylvania School of Medicine, Philadelphia, 
PA; 9Wayne State University School of Medicine, Detroit, MI; 10University of 
Michigan, Ann Arbor, MI.
Background: Above a traditional cutoff point of 20, a blood urea nitrogen to creatinine 
ratio (BUN/Cr) has been suggested to be a marker of neurohormonal activation (NHA) 
which could contribute to progressive chronic kidney disease (CKD), cardiovascular 
disease (CVD) and higher mortality. We therefore examined the association of baseline 
BUN/Cr with these outcomes among persons with CKD.
Methods: 2 We examined 3908 adult participants in the Chronic Renal Insufficiency 
Cohort (CRIC) Study. Cox regression was used to examine BUN/Cr as a categorical 
predictor (< 20, 20-<25, 35-<30, and >=30) and a continuous predictor using splines. 
Outcomes included time to end-stage renal disease (ESRD), congestive heart failure (CHF), 
atherosclerotic events (stroke, myocardial infarction, and peripheral artery disease), atrial 
fibrillation, and all-cause mortality. Cox models were adjusted demographics, clinical and 
laboratory characteristics.
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Results: Among the 3908 participants included in the analysis, mean age and eGFR 
was 57.7 (11.0) years and 44.9 (16.9) ml/min/1.73m2 respectively. Participants were 41.6% 
white and 45.2% female. Higher BUN/Cr was associated with increased risk of CHF, 
atherosclerotic events, atrial fibrillation, and overall mortality, but not with ESRD when 
examined as a continuous (Figure 1) or categorical predictor (Table 1)
Conclusions: Higher BUN/Cr is associated with an increased CVD risk and mortality 
but not ESRD among persons with CKD.
Funding: NIDDK Support
Table 1
Figure 1
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Urine Citrate Excretion Non-Invasively Verifies Reduced Acid Retention 
in Response to Dietary Acid Reduction in CKD 2 Patients Without 
Metabolic Acidosis
Nimrit Goraya,1,2 Jan Simoni,3 Lauren N. Sager,4 Nicolaos E. Madias,5 
Donald E. Wesson.6,2 1Internal Medicine, Baylor Scott and White Health, 
Temple, TX; 2Medicine, Texas A&M HSC, Temple, TX; 3Surgery, Texas Tech 
University Health Sciences Center, Lubbock, TX; 4Biostatistics, Baylor Scott & 
White, Temple, TX; 5Medicine, Tufts University School of Medicine, Boston, 
MA; 6Baylor Scott and White Health and Wellness Center, Dallas, TX.
Background: Some CKD stage 2 (eGFR=60-89 ml/min/1.73 m2, CKD 2) patients 
without metabolic acidosis (defined as plasma total CO2 <22 mM) nevertheless have 
acid (H+) retention and decreasing H+ retention with dietary H+ reduction slows eGFR 
decline. Current methods to verify a decrease in H+ retention and thereby establish clinical 
effectiveness of dietary H+ reduction require cumbersome and invasive methods with 
limited clinical utility. We explored the utility of urine citrate excretion to non-invasively 
verify decreased H+ retention in response to dietary H+ reduction in CKD 2 patients without 
metabolic acidosis.
Methods: We measured H+ retention and 8-hour urine citrate excretion (UcitrateV) in 
macroalbuminuric, non-diabetic CKD 2 (n=40) and CKD stage 1 (eGFR >90 ml/min/1.73 m2, 
CKD 1, n=26) patients with hypertension-associated nephropathy but without metabolic 
acidosis (mean plasma total CO2 25.9±0.8 and 26.4±0.6 mM, respectively). H
+ retention 
was measured before and after dietary H+ reduction with 30 days of base-producing fruits 
and vegetables (F+V) by comparing observed to expected increase in plasma [HCO3] 
in response to retained HCO3 (dose minus UHCO3V) 6 hours after oral NaHCO3 bolus 
(0.5 mmol/kg bw), assuming 50% body weight HCO3 apparent space of distribution.
Results: H+ retention was higher in CKD 2 than CKD 1 (28.1±9.4 vs. 5.2±12.0 mmol, 
respectively, p<0.01) but UcitrateV was lower in CKD 2 than CKD 1 (187±40 vs. 335±125 mg, 
respectively, p<0.01). F+V did not decrease H+ retention in CKD 1 (p=0.88) but did so in 
CKD 2 (to 18.4±17.4 mmol, p<0.01 vs. baseline) and increased UcitrateV (to 245±70 mg, 
p<0.01 vs. baseline) in CKD 2. Overall Pearson Correlation for UcitrateV with H
+ retention 
after F+V was -0.71 (p<0.001). A mixed effects regression model showed UcitrateV to be 
strongly predictive of H+ retention (p<0.001) so that for every 1 mg increase in UcitrateV, H
+ 
retention decreased 0.096 mmol.
Conclusions: UcitrateV non-invasively verifies decreased H+ retention in response to 30 
days of F+V in CKD 2 patients without metabolic acidosis. It should be further explored 
as a method to establish clinical effectiveness of dietary H+ reduction in CKD patients with 
comparatively well-preserved eGFR and no metabolic acidosis, but who are at risk for 
nephropathy progression.
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Urine Citrate Excretion Non-Invasively Identifies Changes in Acid 
Retention over Time in CKD 2 Patients Without Metabolic Acidosis
Nimrit Goraya,1,2 Jan Simoni,6 Lauren N. Sager,3 Nicolaos E. Madias,4 
Donald E. Wesson.5,2 1Internal Medicine, Baylor Scott and White Health, Temple, 
TX; 2Texas A&M HSC College of Medicine, Temple, TX; 3Biostatistics, Baylor 
Scott & White, Temple, TX; 4Medicine, Tufts University School of Medicine, 
Boston, MA; 5Baylor Scott and White Health and Wellness Center, Dallas, TX; 
6Surgery, Texas Tech University Health Sciences Center, Lubbock, TX.
Background: Some CKD stage 2 (eGFR=60-89 ml/min/1.73 m2, CKD 2) patients 
without metabolic acidosis (conventionally defined as plasma total CO2 <22 mM) 
nevertheless have acid (H+) retention that appears to exacerbate nephropathy progression, 
increases as eGFR decreases over time (Goraya et al, AJP, 2018), and this increase in H+ 
retention might be ameliorated with chronic oral NaHCO3. Current methods to measure H
+ 
retention are cumbersome and invasive so we explored the utility of urine citrate excretion 
to non-invasively identify changes in H+ retention over time.
Methods: We measured H+ retention and 8-hour urine citrate excretion (UcitrateV) in 
macroalbuminuric, non-diabetic CKD 2 patients with hypertension-associated nephropathy 
without metabolic acidosis (plasma total CO2 >24 mM) given 0.5 meq/kg bw/day 
NaHCO3 (HCO3, n=40), 0.5 meq/kg bw/day NaCl (NaCl, n=40), or usual care (UC, 
n=40) and assessed them yearly for 10 years. H+ retention was measured at baseline and 
10 years by comparing observed to expected increase in plasma total CO2 in response to 
retained HCO3 (dose minus UHCO3V) 2 hours after oral NaHCO3 bolus (0.5 mmol/kg bw), 
assuming 50% body weight HCO3 apparent space of distribution.
Results: Baseline H+ retention and UcitrateV were not different among groups. The 
10-year vs. respective baseline value in HCO3 was not different for H
+ retention (15.7±12.6
vs. 18.1±14.9 mmol, p=0.90) or UcitrateV (204±43 vs. 195±49 mg, respectively, p=0.30).
By contrast, the 10-year vs. respective baseline value in NaCl was higher for H+ retention
(27.5±15.2 vs. 19.2±16.7 mmol, respectively, p<0.01) and lower for UcitrateV (158±47 vs.
193±52 mg, respectively, p<0.01). Similar to NaCl, 10-year vs. respective baseline value in 
UC was higher for H+ retention (22.1±11.2 vs. 17.4±9.9 mmol, respectively, p<0.01) and
lower for UcitrateV (164±42 vs. 187±40 mg, respectively, p<0.01). A generalized linear model 
for repeated measures, adjusted for time, showed that UcitrateV was a predictor of H
+ retention
overall (p<0.01) and within each of the 3 groups (p<0.05).
Conclusions: UcitrateV non-invasively identifies changes in H+ retention over time in 
CKD 2 patients without metabolic acidosis. It should be further explored to follow clinical 
effectiveness of dietary H+ reduction in CKD patients without metabolic acidosis.
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Urine Chloride levels Are Associated with CKD Progression in CKD 
Patients
Boyoung Nam, Joohwan Kim, Yooju Nam, Ki Heon Nam, Tae-Hyun Yoo, 
Seung Hyeok Han. Yonsei University College of Medicine, Seoul, Republic of 
Korea.
Background: Tubuloglomerular feedback is the physiologic mechanism responsible 
for autoregulation of GFR and renal blood flow. This response is mainly driven by chloride 
level in the distal tubules, thus prevents glomerular hypertension. Here, we studied the 
relationship between urinary chloride level and CKD progression.
Methods: Data were retrieved from the KoreaN Cohort Study for Outcome in Patients 
With Chronic Kidney Disease cohort. Among 2,238 participants, a total of 2,019 patients 
were eligible for the analysis after excluding patients with missing data. Patients were 
categorized into 3 groups according to baseline tertiles of random urinary chloride excretion 
: < 76, 76-115, and ≥ 116 mEq/L. The study endpoint was a composite of >50% decrease 
in eGFR, or ESRD.
Results: The mean age was 53.7 ± 12.1 years, and 1234 (61.2%) patients were male. 
During a median follow-up of 2.8 years, 436 (21.6%) participants reached the renal 
endpoint. CKD progression occurred in 236 (34.8%), 159(24.1%), and 41(6.0%) patients 
in the lowest, middle, and highest tertile groups (P < 0.001), respectively. Compared to the 
lowest tertile, the middle (HR, 0.811; 95% CI, 0.660-0.997; P=0.047) and highest (HR, 
0.619; 95% CI, 0.434-0.882; P=0.008) tertiles were significantly associated with decreased 
risk of adverse renal outcome in multivariable models after adjustment of confounding 
factors. This association was consistently observed in adjusted multivariable model where 
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urinary chloride was entered as a continuous variable (HR per 10 mEq/L increase, 0.961; 
95% CI, 0.931-0.993; P=0.016) There was a significant interaction between urinary chloride 
level and eGFR (P=0.009) and the significant association between urinary chloride level 
and CKD progression was evident particularly in patients with eGFR < 60ml/min/1.73m2; 
HR in the highest tertile was 0.444 compared to the lowest tertile (95% CI, 0.287-0.686; 
P < 0.001).
Conclusions: This hypothesis generating study showed that higher urinary chloride 
level is associated with the progression of CKD.
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Serum Chloride Associates with CKD Progression
Minesh Khatri,1 Josh P. Zitovsky,2 Melissa J. Fazzari,2 Candace D. Grant.2 
1Medicine, NYU Winthrop, Mineola, NY; 2NYU Winthrop Hospital, Mineola, NY.
Background: Chloride is the predominant extracellular anion in the body, serving 
important functions including maintenance of electroneutrality, modulation of renin 
secretion, and regulation of renal sodium transport. Limited data suggest it may predict 
mortality in heart failure, chronic kidney disease (CKD), and pulmonary arterial 
hypertension. Recent randomized trials in hospitalized patients have also shown that 
administration of crystalloid intravenous fluids with lower chloride concentration may have 
better renal outcomes than fluids with higher chloride concentration. However, chloride has 
not been studied longitudinally for CKD progression.
Methods: 536 subjects with predominantly stage 3 and 4 CKD were recruited into 
a prospective cohort study from a nephrology clinic at a single academic medical center. 
Renal function was re-assessed longitudinally. Logistic and Cox regression models were 
created for outcomes of upper quartile of annualized estimated glomerular filtration rate 
(eGFR) decline and > 30% decline in eGFR, respectively. Baseline chloride was modeled 
continuously as an independent variable, and models were adjusted for potential confounders 
including co-morbidities, proteinuria, and relevant serum labs and medications.
Results: Median follow-up time was 1.7 years. At baseline, median age was 73, 62% 
were male, 52% diabetic, 91% hypertensive, and median eGFR was 36 mL/min. Median 
serum chloride at baseline was 105 mEq/L (interquartile range 102-107 mEq/L). In fully 
adjusted models, higher serum chloride significantly associated with greater likelihood 
of upper quartile of annualized eGFR decline (OR 1.09 per 1 mEq/L increase in serum 
chloride, p = 0.031), and greater hazard of > 30% eGFR decline (HR 1.06 per 1 mEq/L 
increase in serum chloride, p = 0.036).
Conclusions: In this cohort of CKD patients, higher serum chloride levels associated 
with increased risk of eGFR decline. Chloride may be a useful, readily available biomarker 
to aid in predicting CKD progression. Further studies are needed to determine if there is 
causality, and if so to elucidate pathophysiology and delineate possible treatment strategies.
Funding: Clinical Revenue Support
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Association of Serum Bicarbonate Levels with Kidney Function Decline in 
Patients with Polycystic Kidney Disease
Roshini Yapa,2 Zhiying You,3 Berenice Y. Gitomer,4 Michel Chonchol,2 
Jessica B. Kendrick.1 1University of Colorado School of Medicine, Aurora, CO; 
2University of Colorado, Denver, CO; 3UC Denver, Aurora, CO; 4Div. Renal 
Diseases and Hypertension, Aurora, CO.
Background: Lower serum bicarbonate levels are associated with kidney disease 
progression in patients with chronic kidney disease. Whether serum bicarbonate levels 
are associated with kidney disease progression in patients with polycystic kidney disease 
(PKD) is unknown. We tested the hypothesis that lower bicarbonate levels are associated 
with kidney function decline in patients with PKD.
Methods: We included 774 patients from the HALT-PKD Study A (N=395) and B 
(N=379) with baseline serum bicarbonate levels and at least three measurements of 
estimated glomerular filtration rate (eGFR). Bicarbonate was examined as a continuous 
variable and in categories (≤ 24, 25-28 and >28 mEq/L, with 25-28 mEq/L as the reference 
group). The outcome was yearly change in slope of eGFR. Linear regression models were 
used to examine the association between serum bicarbonate and change in eGFR.
Results: The mean (SD) age was 43 ± 10 years. The mean (SD) serum bicarbonate 
and eGFR at baseline was 26.7 ± 2.4 mEq/L and 70 ± 26 ml/min/1.73m2, respectively. 
Participants with serum bicarbonate ≤ 24 mEq/L had lower eGFR, higher body mass index 
(BMI) and systolic blood pressure (SBP) than those with bicarbonate levels >24 mEq/L. In 
the fully adjusted model, each 1 mEq/L increase in serum bicarbonate level was associated 
with a 0.1 ml/min/1.73m2 increase in annual slope of eGFR (β 0.1 ml/min/1.73m2, 95% CI 
0.002 to 0.15, p=0.04). A serum bicarbonate level ≤ 24 mEq/L was associated with a yearly 
decline in eGFR slope in unadjusted analysis and in partially adjusted analysis, but only 
trended towards significance in the fully adjusted model (p=0.09).
Conclusions: Lower serum bicarbonate levels are associated with an increased risk of 
decline in eGFR in patients with PKD.
Funding: Other NIH Support - NHLBI
β Estimate (95% CI)
Model 1: adjusted for age, gender, race, treatment randomization
Model 2: adjusted for model 1 plus smoking, cardiac history, BMI, SBP, baseline eGFR and 
urine albumin to creatinine ratio
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Association Between Changes in Pre-Transition Sodium with Post- 
Transition Mortality and Hospitalization Among Patients Transitioning  
to Dialysis
Maria V. Marroquin,1 Ekamol Tantisattamo,1 Jui-Ting Hsiung,1 Christina Park,1 
Carola-Ellen Kleine,1 Melissa Soohoo,1 Connie Rhee,1 Csaba P. Kovesdy,2 
Kamyar Kalantar-Zadeh,1 Elani Streja.1 1Harold Simmons Center for Kidney 
Disease Research and Epidemiology, Division of Nephrology and Hypertension, 
University of California, Irvine, Orange, CA; 2University of Tennessee Health 
Science Center, Memphis, TN.
Background: Disturbances in the serum sodium metabolism are common in advanced 
chronic kidney disease (CKD) and end-stage renal disease (ESRD). Additionally, CKD 
patients transitioning to dialysis-dependent ESRD have a particularly high mortality risk 
within the first month of transition. Thus, we examined the relationship between pre-ESRD 
change in sodium and post-ESRD outcomes.
Methods: We retrospectively examined a cohort of 22,644 veterans transitioning 
to ESRD between 2007-2015. Patients were grouped into three categories according to 
their change in sodium. Changes in sodium from 6 to 3 months prior to ESRD transition 
were calculated by using a mixed-effects model. We explored the association between 
change in sodium levels, with post-ESRD transition overall all-cause mortality using Cox 
proportional hazard models, and hospitalization incident rate ratio (HIRR) with Poisson 
regression. Associations were examined across multiple levels of adjustments including 
case-mix variables, markers of malnutrition and inflammation, glucose and medications.
Results: Mean age of the total cohort was 67±11 years and median change in sodium 
level was 0.4 (-1.1,2.0) mEq/L. Both, increasing and decreasing sodium levels were 
associated with a higher all-cause mortality risk in the fully adjusted model (HR 1.10, 
95%CI 1.05-1.15) [figure 1A]. A similar pattern was observed for HIRR across hierarchical 
adjustments; however the association was attenuated for increasing sodium levels in the 
fully adjusted model (HR 1.06 95%CI 1.01-1.10) [figure 1B].
Conclusions: Changes in pre-ESRD serum sodium are associated with post-transition 
death risk and HIRR. Monitoring pre-transition sodium levels may help identify patients at 
risk for adverse outcomes after ESRD transition.
Funding: NIDDK Support
FR-PO206 Poster Friday
CKD: Epidemiology, Risk Factors, Prevention - II
Effect of Dietary Salt Intake on Renal Outcomes in Advanced CKD 
Patients
Minjung Kang, Eunjeong Kang, Hyunjin Ryu, Curie Ahn, Kook-Hwan Oh. 
Seoul National University Hospital, Seoul, Republic of Korea.
Background: The present study analyzed the effect of dietary salt intake on renal 
outcome for Asian CKD patients. The study is conducted on large number of CKD patients 
at stages G3a, G3b and G4, with long term follow-up. This study suggests the optimal 
amount of salt intake for advanced CKD patients.
Methods: Our data were extracted from The KoreaN cohort study for Outcome in 
patients With CKD (KNOW-CKD). A total of 1,409 CKD patients at stages G3a, G3b and 
G4, who were enrolled in the KNOW-CKD from 2011 to 2016 were included in the analysis. 
After excluding 413 patients with incomplete data to define 24-hour urine sodium excretion, 
996 non-dialysis CKD patients were finally analyzed. Dietary salt intake, assessed by 24-
hour urine sodium excretion, was divided into quartile groups. Second quartile (Q2, 6.72 
~9.14 g salt/day) was regarded as the reference group. Estimated glomerular filtration 
rate (eGFR) was assessed by CKD-EPI (Cr) equation based on isotope dilution mass 
spectrometry (IDMS)-traceable creatinine measured at a central laboratory. eGFR slope was 
analyzed by mixed model from the subjects who repeatedly measured the serum creatinine 
level more than 4 times at 6- to 12-month interval. Composite renal event is defined either 
as eGFR halving or as initiation of renal replacement therapy (RRT). Each component of 
composite renal event was also analyzed.
Results: During the mean 45.6 months of follow-up, 225 subjects developed the 
composite renal event. After adjustment for confounders including baseline eGFR, multiple 
Cox regression showed that the risk of composite renal outcomes is significantly higher in 
the highest quartile group (Q4, salt intake > 11.89 g/day, HR 1.86, p<0.024). Multiple linear 
regression showed that eGFR slope was not independently associated with daily salt intake 
(b=-0.02, P=0.23).
Conclusions: High salt intake, assessed by 24 hour urine sodium excretion, is 
associated with increased risk of CKD progression in advanced CKD.
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Effect of Aldosterone-Renin Level on Glomerular Filtration Rate Slope in 
Patients with Primary Aldosteronism: A Retrospective, Multi-Center 
Cohort Study
Hiroki Kobayashi,2,1 Masanori Abe,2 Masayoshi Soma,5 Katsutoshi Takahashi,3 
Mitsuhide Naruse.4 JPAS group 1Section on Genetics and Epidemiology, Joslin 
diabetes center, Harvard medical school, Boston, MA; 2Division of Nephrology, 
Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, 
Japan; 3Showa General Hospital, Kodaira, Japan; 4NHO Kyoto Medical Center, 
Kyoto, Japan; 5Division of General Medicine, Nihon University School of 
Medicine, Tokyo, Japan.
Background: Primary aldosteronism (PA) is recognized as renin-independent 
aldosterone overproduction, leading to glomerular hyperfiltration. Recent studies 
demonstrated higher morbidity of renal damage in PA patients compared with essential 
hypertension. In this study, we aimed to investigate the association of renin-aldosterone 
levels with adrenalectomy-induced estimated glomerular filtration rate (eGFR) decrease. 
Furthermore, we also sought to investigate whether renin-aldosterone level affect eGFR 
slope in PA patients who did or didn’t undergo adrenalectomy.
Methods: This is a multicenter retrospective cohort from the Japan Primary 
Aldosteronism Study. In a total of 2,814 patients with PA, we identified three groups, A) 487 
patients who underwent adrenalectomy, B) 284 patients who did not undergo adrenalectomy 
with follow-up data, and C) 106 patients who underwent adrenalectomy with follow-up 
data. In group A, we evaluated the predictors of adrenalectomy-induced eGFR decrease for 
aldosterone producing adenoma by linear regression model. In groups B and C, we analyzed 
associations between renin-aldosterone levels and annual eGFR decline (mL/min/1.73 m2/
year) by partial spearman correlation analysis, and the association was also assessed using 
ordinal logistic regression models adjusted for clinical cofounders.
Results: In group A, suppressed plasma renin activity (PRA) was an independent 
predictor for adrenalectomy-induced eGFR decrease. In group B, suppressed PRA was 
significantly correlated with higher annual eGFR decline (r = -0.13, P = 0.036). Furthermore, 
quartiled PRA was also associated with annual eGFR decline in ordinal logiostic regression 
model (adjusted cumulative odds ratio = -0.087, P = 0.019), although these associations 
could not be identified in group C.
Conclusions: Our study demonstrated that excess aldosterone levels with renin 
suppression affects eGFR slope, and glomerular hyperfiltration is one of the explanation 
of this association. Furthermore, suppressed PRA which indicate the inadequate 
mineralocorticoid receptor blockade might be a marker for steeper eGFR slope in patients 
with PA.
Funding: Government Support - Non-U.S.
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High Renin-Aldosterone Ratio and Lateralization Index Are Associated 
with Adverse Renal Outcomes in Primary Aldosteronism Patients Who 
Underwent Adrenalectomy
Sukyung Kang, Yooju Nam, Seon yeong Lee, Joohwan Kim, Ki Heon Nam, 
Seung Hyeok Han, Tae-Hyun Yoo. Yonsei University College of Medicine, 
Seoul, Republic of Korea.
Background: Previous studies reported that renal impairment develop in PA patients 
after adrenalectomy. However, aldosterone-induced glomerular hyperfiltration can lead to 
masked preoperative renal dysfunction in PA patients. We aimed to elucidate risk factors for 
renal impairment after adrenalectomy in these subjects.
Methods: In this retrospective study, total 109 PA patients and 193 pheochromocytoma 
patients as control, who underwent adrenalectomy between January 2006 and November 
2017 at Yonsei University Severance Hospital, were enrolled. Acute kidney injury (AKI) 
after adrenalectomy was defined as increase in serum creatinine >0.3 mg/dL or decrease in 
eGFR >30% from preoperative baseline values. Postoperative chronic kidney disease (CKD) 
was defined as eGFR <60mL/min/1.73m2 for more than 3 months post-adrenalectomy. In 
all PA patients, adrenal vein sampling was performed to evaluate aldosterone and cortisol 
levels in each adrenal glands.
Results: Study patients, mean age was 49.6 years and 140(46.4%) were male. 
Among 109 PA patients, the incidence of AKI and CKD were 28 (25.7 %) and 34 (31.2 
%). Meanwhile, among 193 pheochromocytoma patients, the incidence of AKI and CKD 
were 21(10.9%) and 6(3.1%). Multivariable regression analysis showed high relation of PA 
patients resulting in CKD compared to pheochromocytoma (Odds ratio 64.8). Univariable 
regression analysis identified coexisting diabetes mellitus (DM), duration of hypertension, 
high adrenal venous sampling (AVS) aldosterone-cortisol ratio and lateralization index as 
risk factors for development of postoperative CKD in PA patients. The AVS aldosterone-
cortisol ratio in non-CKD and CKD patients were 84.93 and 113.86. Also lateralization 
index in non-CKD and CKD patients were 10.33 and 19.80.
Conclusions: Present study demonstrated incidence of CKD was more frequent in 
PA patients compared to pheochromocytoma patients post-adrenalectomy. Also, high AVS 
aldosterone-cortisol ratio and lateralization index are independent risk factors for adverse 
renal outcomes in PA patients post-adrenalectomy.
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Urinary Angiotensinogen Predicts Progressive CKD After an Episode of 
AKI
Wei Cao. Division of Nephrology, Nanfang Hospital, Southern Medical 
University, Guangzhou, China.
Background: One of the major obstacles to prevent AKI-CKD transition is the lack of 
effective methods to follow and predict the ongoing kidney injury in AKI survivors.
Methods: In this study, we test the utility of urinary angiotensinogen (UAGT) for 
dynamically evaluating renal structural changes and predicting AKI-CKD progression by 
using both mild and severe bilateral renal ischemia/reperfusion injury mice. Furthermore, 
we evaluated the value of UAGT in predicting AKI-CKD progression in patients with acute 
tubular necrosis.
Results: UAGT returns to pre-ischemic levels 14 days after mild AKI followed by 
kidney architecture restoration, whereas sustained increase in UAGT accompanies by 
ongoing renal fibrosis after severe AKI. UAGT at day 14-42 correlates with renal fibrosis 
84 days after AKI. For predicting fibrosis at day 84, the area under receiver operating 
characteristics curve of UAGT at day 14 is 0.81. Persistent elevation in UAGT correlates 
with sustained activation of intrarenal renin-angiotensin system (RAS). Abrogating RAS 
activation markedly reduced fibrosis, consistent with a role of kidney RAS activation in 
AKI-CKD progression. Moreover, RAS intervention early in the course of AKI-CKD 
transition is more beneficial than late intervention in reducing renal fibrosis. Similar 
changes in the UAGT were observed in patients with AKI-CKD transition.
Conclusions: Our study suggests the potential use of UAGT in motoring renal 
structural recovery over time and the beneficial effect of early RAS intervention in reducing 
fibrosis after renal function recovery from AKI.
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Estradiol and Renal and Cardiovascular Outcomes in Women with CKD: 
The Chronic Renal Insufficiency Cohort (CRIC) Study
Ana C. Ricardo,1 Catherine Kim,5 Jesse Y. Hsu,2 Eunice Carmona,1 
Amanda H. Anderson,2 Jing Chen,3 Mirela A. Dobre,4 John W. Kusek,6 
Marie Krousel-wood,7 Nikhil A. Parikh,1 Susan P. Steigerwalt,5 Xue Wang,2 
Harold I. Feldman,2 James P. Lash.1 1University of Illinois at Chicago, Chicago, 
IL; 2University of Pennsylvania, Philadelphia, PA; 3Tulane School of Medicine, 
New Orleans, LA; 4Case Western Reserve University, Cleveland, OH; 5University 
of Michigan, Ann Arbor, MI; 6NIDDK, Bethesda, MD; 7Ochsner Clinic 
Foundation, New Orleans, LA.
Background: The incidence of end-stage renal disease (ESRD) and cardiovascular 
disease is lower in women than men. This observation may be explained by the protective 
effect that endogenous estrogens may have on vascular function. We evaluated the 
association of estradiol levels with renal and cardiovascular outcomes in women with 
chronic kidney disease (CKD).
Methods: Prospective, longitudinal study of 1125 women with measured plasma 
17b-estradiol by electrochemiluminescent immunoassay at the second annual CRIC 
visit. We used multivariable mixed-effects and Cox models to examine the association of 
estradiol with estimated glomerular filtration rate (eGFR) slope, incident ESRD (dialysis or 
transplantation), atherosclerotic events (myocardial infarction/revascularization, stroke or 
peripheral arterial disease) and all-cause mortality.
Results: Overall mean (SD) age was 59.6 (10.9) years, and median (IQR) estradiol 
level 15.8 (8.5-30.2) pg/mL. Compared with women in the highest estradiol quartile (Q4), 
women in the lowest quartile (Q1) were more likely to be older (63.0 vs. 50.0 years), non-
Hispanic white (56.8 vs. 37.4%), and post-menopausal (96.5 vs. 44.2%); and less likely to 
have diabetes (36.8 vs. 45.9%) and obesity (39.6 vs. 54.1%). Mean eGFR in ml/min/1.73m2 
was higher in Q1 (46.9) compared with Q4 (45.9). Median urine protein-creatinine ratio 
was similar in the two quartiles (0.09 vs. 0.10). Over a median follow-up of 6.9 years, 
189 women developed ESRD, 121 had an atherosclerotic event, and 165 died. In mixed 
effects models adjusted for relevant demographic and clinical characteristics, the difference 
in eGFR slope between Q1 and Q4 was 0.34 ml/min/1.73m2/year (p=0.5). We found no 
significant association between estradiol (Q1 vs. Q4) and ESRD (HR 0.61, 95% CI 0.35-
1.09), atherosclerotic events (HR 0.59, 95% CI 0.29-1.19) or death (HR 0.75, 95% CI 0.4-
1.41). The results were unchanged in analyses stratified by menopausal status.
Conclusions: In this cohort of women with CKD, estradiol levels were not associated 
with renal outcomes, cardiovascular events or death.
Funding: NIDDK Support
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Association of Thyroid Function with Prevalence and Development of 
CKD
Akiko Toda, Hiroshi Tsuji, Shigeko Hara. Toranomon Hospital, Tokyo, Japan.
Background: Previous cross-sectional studies indicated an association between 
hypothyroidism and kidney dysfunction, but few studies have investigated aboutthyroid 
dysfunction and chronic kidney disease (CKD), especially whether thyroid dysfunction is a 
risk factor for CKD development.
Methods: Using the data of annual health check-ups, we evaluated a relationship 
of thyroid dysfunction with CKD prevalence and development by a multivariate logistic 
regression analysis. In cross-sectional and longitudinal studies, 16,390 subjects and 7,609 
subjects were analyzed, respectively. We categorized the subjects into four groups based 
on their serum thyroid-stimulating hormone (TSH) concentrations;below-normal (TSH 
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<0.54 mU/L), lower-normal (0.54–2.40 mU/L), higher-normal (2.40–4.26 mU/L) and 
above-normal (>4.26 mU/L). As covariate factors, age, gender, obesity, hypertension, 
dyslipidemia, hyperuricemia, diabetes mellitus, proteinuria, and hematuria were adjusted in 
cross-sectional study. In longitudinal study, the baseline eGFR was added to the covariate 
factors of the cross-sectional study.
Results: The cross-sectional study revealed a positive correlation between the TSH 
concentration and CKD prevalence. Compared with the lower-normal TSH group, the 
odds ratios (ORs) and 95% confidence intervals (CI) of CKD prevalence were 0.609 
(0.452–0.821, p= 0.001) for the below-normal group, 1.492 (1.332–1.672, p<0.001) for 
the higher-normal group, and 1.900 (1.568–2.302, p<0.001) for the above-normal group. 
The longitudinal study revealed that the risk of CKD development within three years was 
significantly higher in the above-normal TSH group compared with the lower-normal TSH 
group: OR 1.578, 95% CI 1.016–2.451, p= 0.042. However, no significances of CKD 
development risk in the below-normal TSH group and the higher-normal TSH group were 
observed.
Conclusions: Our data indicated that a higher TSH concentration has a positive 
correlation with CKD prevalence, and that a high TSH concentration is a risk factors 
for CKD development. These results suggest thatthyroid function screening might be 
informative in patients whose eGFR declines without a clear cause, and thyroid hormone 
replacement therapy for hypothyroidism patients could have an effect on preventing CKD 
development.
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Thyroid Hormones and CKD in the German CKD (GCKD) Study
Ulla T. Schultheiss,2,5 Inga Poguntke,2,5 Peggy Sekula,2,5 Kai-Uwe Eckardt,3 
Seema Baid-Agrawal,4 Elke Schaeffner,1 Anna Kottgen.2,5 1Institute of Public 
Health - Charite, Berlin, Germany; 2Medical Center - University of Freiburg, 
Freiburg, Germany; 3University Medicine-Charite, Berlin, Germany; 
4Sahlgrenska University Hospital, University of Gothenburg, Gothenburrg, 
Sweden; 5Institute of Genetic Epidemiology, Freiburg, Germany.
Background: Clinical and translational research support a connection between 
kidney and thyroid function, e.g. hypothyroidism and low triiodothyronine (FT3) levels 
in combination with normal thyroid stimulating hormone (TSH) levels (= Euthyroid Sick 
Syndrome: ESS) and CKD. The relationship between these conditions and CKD progression 
is understudied. We evaluated the longitudinal association of TSH, free thyroxine (FT4), 
FT3, and thyroid diseases with a composite endpoint of renal events.
Methods: Thyroid markers were measured at baseline using standard laboratory 
methods. GFR was estimated using the CKD-EPI formula. Over four years of follow-up, 
449 renal events occurred among 4,391 GCKD participants. Renal events included ESRD 
(dialysis, transplantation), acute kidney injury, or renal death abstracted from hospital 
records by trained personnel. Cox proportional hazard models of time to the composite 
outcome adjusted for age, sex, study site, smoking, BMI, history of cardiovascular disease, 
diabetes mellitus, and proteinuria were evaluated for continuous thyroid markers as well as 
for thyroid diseases (hypothyroidism: TSH>3.29, FT4≥9.8-18.8 or TSH>3.29, FT4<9.8; 
ESS: TSH≥0.49-3.29, FT3<3.3).
Results: Mean age was 60 years, with 59.4% males. Medians were TSH: 1.2 mIU/L, 
FT4: 14.3 pmol/L and FT3: 4.2 pmol/L; hypothyroidism and ESS were present in 5.0% and 
5.4%. Thyroid hormone substitution was 21.0%. No association was observed for TSH and 
FT4, FT3 was significantly associated (HR 0.8, 95%CI 0.7-0.9). Compared to euthyroid 
patients, hypothyroid patients had a 1.6-fold higher risk and patients suffering from ESS 
had a 2.0-fold higher risk of reaching the composite endpoint (Table 1). Excluding patients 
on thyroid medication: the associations with FT3 and ESS remained (FT3: HR 0.7, 95%CI 
0.7-0.9; ESS: HR 1.9, 95%CI 1.3-2.7), the association with hypothyroidism disappeared.
Conclusions: Lower FT3 levels, hypothyroidism and ESS were associated with a 
higher risk of a composite renal endpoint in a population with CKD stage 3 and at risk for 
thyroid dysfunction.
Funding: Government Support - Non-U.S.
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A Dose Dependent Relationship Between Hypothyroidism and CKD 
within a Real-World Clinical Environment
Cheng-Wei Huang,1 Bonnie H. Li,2 Connie Rhee,3 John J. Sim.4 1Department of 
Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los 
Angeles, CA; 2Department of Research and Evaluation, Kaiser Permanente 
Southern California, Pasadena, CA; 3University of California Irvine Medical 
Center, Orange, CA; 4Division of Nephrology and Hypertension, Kaiser 
Permanente Los Angeles Medical Center, Los Angeles, CA.
Background: Whether hypothyroidism (HT) engenders chronic kidney disease (CKD) 
is unknown. We sought to determine whether HT and different thyroid states are associated 
with CKD among a large diverse population.
Methods: A cross sectional study was performed among individuals with concurrent 
thyroid stimulating hormone (TSH) and creatinine measurements within Kaiser Permanente 
Southern California health system (1/1990-12/2017). Rates of CKD across different 
thyroid states were compared. Multivariable logistic regression analysis adjusted for 
age, sex, race, and comorbidities was performed to estimate odds ratios (ORs) for CKD 
by thyroid state. HT was defined as TSH>4mcIU/mL and/or receipt of thyroid hormone 
replacement. HT was further categorized into 1) hypothyroid state (HS): TSH>4mcIU/mL 
regardless of thyroid hormone replacement, and 2) attenuated-hypothyroid state (AS): 
TSH<4mcIU/mL and on thyroid hormone replacement. Euthyroid (ET) was defined as 
TSH<4mcIU/mL and on no thyroid hormone replacement. The primary outcome was CKD 
defined as eGFR<45mL/min/1.73m2.
Results: A total of 378,101 individuals were identified. Among 114,872 (30.4%) 
meeting criteria for HT, 31,242 (27.2%) were HS and 83,630 (72.8%) were AS. Compared 
to ET individuals, multivariable OR (95% confidence interval) for CKD (eGFR<45mL/
min/1.73m2) were 1.59 (1.52-1.66) and 1.12 (1.08-1.16) for HS and AS respectively when 
compared to ET (Table 1).
Conclusions: Within a real-world clinical environment, there is a greater likelihood of 
CKD associated with HT. A stronger association was seen among those with HS compared 
to those with AS. Our findings suggest that there may be a dose dependent relationship 
between thyroid function and CKD. Whether treatment of hypothyroidism among CKD 
patients may improve and alter the course of CKD is an area warranting future investigation.
Table 1. Odds ratios of CKD (eGFR<45mL/min/1.73m2) across each thyroid state
1Adjusted for demographics including age, sex, and race
2Additionally adjusted for hypertension and diabetes
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Prevalence of CKD, Xanthine Oxidase Inhibitor Treatment, and Serum 
Uric Acid Control in US Adults with Gout: NHANES 2007–2014
Jean J. Lim, An-Chen Fu, David S. Reasner, Douglas C. Taylor. Ironwood 
Pharmaceuticals, Inc., Cambridge, MA.
Background: Gout is the most common form of inflammatory arthritis, mainly caused 
by elevated serum uric acid (sUA). The American College of Rheumatology recommends 
lowering sUA to <6 mg/dL for gout patients, most commonly achieved by lifestyle changes 
and xanthine oxidase inhibitor (XOI) treatment. Elevated sUA is also associated with the 
prevalence of chronic kidney disease (CKD). This study aims to estimate the prevalence of 
CKD among US adults (age ≥20 years) with gout, stratified by XOI treatment status and 
sUA control (<6 mg/dL).
Methods: This cross-sectional study was conducted using the National Health and 
Nutrition Examination Survey (NHANES) 2007–2014 including patients who had ever 
been told by a doctor that they had gout. CKD was categorized based on 2012 Kidney 
Disease: Improving Global Outcomes using estimated glomerular filtration rate (eGFR; 
CKD-EPI equation) and urine albumin-creatinine ratio. Descriptive analyses were 
performed accounting for the survey’s complex sampling design.
Results: Of 20,880 participants (representing an estimated 207 M US non-
institutionalized adults), 899 (representing 7.8 M) had gout. Among the gout population, 
4.9 M (63%) had uncontrolled sUA, 2.8 M (36%) had moderate or higher risk of CKD, and 
2.2 M (28%) were taking an XOI. Of the gout population who were not taking an XOI, the 
majority were uncontrolled regardless of CKD risk (Table).
Conclusions: Among gout patients, more than one third have moderate or higher risk 
of CKD, and less than one third are currently treated with XOI and of those, 43% have 
uncontrolled sUA. Therefore, gout patients may benefit from sUA-lowering treatment 
options that are consistent with their renal function.
Funding: Commercial Support - Ironwood Pharmaceuticals, Inc.
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Urate-Lowering Therapy for Asymptomatic Hyperuricemia in Patients 
with CKD: Controversial Role of Renal Outcome
Dong Ho Shin,1 Do Hyoung Kim,2 Chaehoon Han,4 Jung-woo Noh.3 1College of 
Medicine, Hallym University, Seoul, Republic of Korea; 2Hallym University 
Hangang Sacred Heart Hospital, Seoul, Republic of Korea; 3Hallym University, 
Seoul, Republic of Korea; 4kangnam secred heart hospital, Seoul, Republic of 
Korea.
Background: Because serum uric acid increases as the glomerular filtration rate (GFR) 
falls, hyperuricemia has also been associated with chronic kidney disease (CKD). Although 
there are plausible evidences that hyperuricemia represents a risk factor for the progression 
of CKD, causal role of uric acid is still controversy in CKD patients with asymptomatic 
hyperuricemia.
Methods: We performed a retrospective single center study, enrolling 935 
asymptomatic hyperuricemia patients with stage 3 - 4 CKD, between 2006 and 2018. By 
using propensity score matching, we matched 290 patients with and without urate-lowering 
therapy pairs from 935 patients. CKD progression was defined as a >30% reduction in GFR 
over 2 years. The changes in GFR over time compared between patients with and without 
urate-lowering therapy using a linear mixed model.
Results: In matched patients, the mean age was 63.2 ± 12.7 years, and 561 patients 
60% was diabetic nephropathy. Mean estimated glomerular filtration rate (eGFR) was 
44 ± 11 ml/min/1.73 m2. Serum uric acid level was significantly higher in treatment group 
8 ± 2 vs 12 ± 3 mg/dL). During the mean follow-up of 120 ± 48 months, the proportion of 
CKD progression was not different between treatment group and no treatment group (41.5% 
vs. 39.5%, p = 0.34). In addition, the overall rate of decline in GFR was also comparable 
between two group (p = 0.45).
Conclusions: Uric acid-lowering therapy may be controversy in delaying the 
progression of CKD. Therefore, further randomized controlled trials should be performed 
to confirm the effect of urate-lowering therapy on the progression of CKD.
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Stage of CKD Does Not Affect the Velocity of Tophus Reduction in 
Patients with Chronic Refractory Gout Treated with Pegloticase
Brian F. Mandell,1 Michael Pillinger,2 N. L. Edwards,3 Richard J. Johnson,4 
Anthony Yeo,5 Peter E. Lipsky.6 1Cleveland Clinic, Cleveland, OH; 2NYU 
School of Medicine, New York, NY; 3University of Florida College of Medicine, 
Gainesville, FL; 4University of Colorado Denver, Aurora, CO; 5Horizon 
Pharma, Lake Forest, IL; 6AMPEL BioSolutions, Charlottesville, VA.
Background: Impaired renal function is a recognized comorbidity of gout and gouty 
tophi may be more frequent in those with renal dysfunction. It is not known however, 
whether the velocity of resolution of tophi in response to urate lowering therapy is affected 
by renal insufficiency.
Methods: This analysis used results from two 6-month randomized controlled trials 
of pegloticase in patients with chronic refractory gout to address this issue. The velocity of 
tophus resolution was determined in 18 patients with chronic gout refractory to oral urate 
lowering therapy who responded to pegloticase administered at a dose of 8 mg every 2 
weeks (q2w) with sustained serum urate reductions (<6 mg/dL) over 6 months. eGFR was 
determined at baseline and after 3 and 6 months of treatment. Tophi were photographed 
at baseline, 3, 4.5, and 6 months and measured using Computer-Assisted Photographic 
Evaluation technology. At baseline, the mean area of photographed tophi was 585.8 mm2.
Results: Complete resolution of all tophi photographed was achieved by 34.8% of 
the patients. Using linear regression analysis, the velocity of tophus resolution for all the 
patients was calculated to be 60.1 mm2 per month. There was no significant relationship 
between baseline eGFR and velocity of tophus resolution (p=0.5). In addition, there were no 
significant differences in the velocity of tophus resolution for patients with Stage 1 chronic 
kidney disease (CKD) vs Stage 2 CKD (P=0.7), Stage 3 CKD (P=0.9), or Stage 4 CKD 
(P=0.7).
Conclusions: The results from this analysis thus indicate that renal impairment does 
not compromise the ability of pegloticase to resolve tophi rapidly in patients who respond 
with sustained reductions in serum urate.
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Association of Renal Dysfunction and Development of Tophi in Subjects 
with Chronic Refractory Gout
Richard J. Johnson,1 N. L. Edwards,2 Michael Pillinger,3 Anthony Yeo,4 
Peter E. Lipsky.5 1University of Colorado Denver, Aurora, CO; 2University of 
Florida College of Medicine, Gainesville, FL; 3NYU School of Medicine, New 
York, NY; 4Horizon Pharma, Lake Forest, IL; 5AMPEL BioSolutions, 
Charlottesville, VA.
Background: Many, but not all patients with chronic gout develop tophi, and the 
factors that govern tophus formation are not fully understood. Several studies have 
suggested impairment of renal function increases the risk for development of tophi, but 
others have not.
Methods: This analysis addressed the relationship between estimated glomerular 
filtration rate (eGFR) and the presence of tophi in patients with chronic refractory gout, as 
well as effects of tophus resolution on eGFR using results from two randomized controlled 
trials of pegloticase in chronic gout patients.
Results: Overall, 73% of the 212 subjects in these trials had clinically apparent tophi 
at baseline and 27% did not. Subjects with tophi were significantly older than those without 
tophi (56.7 vs 51.9 years, P=0.034) and had a significantly longer disease duration (16.3 
vs 11.7 years, P=0.0072). Subjects with tophi also had a significantly lower eGFR than 
those without tophi (59.8 vs 67.9 mL/min/1.73 m2, P=0.0495). Subjects with advanced renal 
disease were also more likely to have tophi. Persistent serum urate lowering and resolution 
of tophi in subjects treated with pegloticase had no significant effect on eGFR despite a 
significant decrease in the urinary uric acid:creatinine ratio.
Conclusions: These results indicate that chronic refractory gout patients may present 
with or without clinically apparent tophi and that there is a significant association between 
the presence of renal dysfunction measured by eGFR and the frequency with which chronic 
refractory gout patients manifested tophi. However, persistent serum urate lowering and 
tophus resolution had no significant effect on eGFR over the period of observation in this 
group of subjects.
Funding: Commercial Support - Horizon Pharma
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Evaluation of the Effects of Allopurinol on Metabolic Acidosis in Patients 
with CKD
Maryam Miri. Kidney transplantation complications research center, Mashhad 
University of Medical Sciences, Mashhad, Islamic Republic of Iran.
Background: Chronic kidney disease(CKD) is a disabling disease with multiple 
complications. Increased serum level of uric acid due to glomerular filtration rate (GFR) 
impairment is an importance and the lack of a similar study In Iran, this study was designed 
to evaluate the effect of allopurinol on metabolic acidosis in patients with renal failure.
Methods: In this randomised controlled trial (RCT) study, 50 patientswithCKDstage 
II-IV, who referred to Ghayem Hospital, were selected and randomly divided into two
equal groups of 25 subjects. In addition to standard treatments, the intervention group
received 100 mg allopurinol tablet for 3 months and the control group received placebo.
Demographic data were obtained from each subject. Serum uric acid level, creatinine, pH
blood and bicarbonate levels were obtained at the initiation of treatment and at the end of
the third month.
Results: The mean age of subjects was 54.04±12.62 years. The most common cause 
of CKD was Diabetes Mellitus (36.0%). Allopurinol administration resulted in a significant 
increase bicarbonate and PH(p<0.001 each) compared to control group. A significant 
reduction in uric acid (p<0.05) and increase in GFR (p<0.05) was observed in both groups.
Conclusions: Allopurinol may ameliorate metabolic acidosis, glomerular filtration and 
uric acid in patients with CKD
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Post-Discharge Readmission Outcomes Following Hyperkalemia-Related 
Hospitalization
J. Michael Woolley,4 Keith Betts,1 Fan Mu,2 Yao Wang,3 Sneha S. Kelkar,1 
Eric Wu.2 1Analysis Group, Inc., Los Angeles, CA; 2Analysis Group, New York,
NY; 3Analysis Group, New York, NY; 4AstraZeneca, Wilmington, DE.
Background: The objective of this study was to compare post-discharge outcomes, 
including hospital readmission rates, lengths of stay (LOS) per readmission, and total 
inpatient days, between hospitalizations in patients with and without hyperkalemia (HK).
Methods: Adults with available potassium lab results and at least one hospitalization 
were identified from a large US claims database (1/1/2010-12/31/2014). Hospitalizations 
with an HK diagnosis (ICD-9 276.7) were defined as case hospitalizations (cases), and 
hospitalizations from patients without HK (no HK diagnosis, no potassium lab tests 
above 5.0 mEq/L, and no sodium polystyrene sulfonate use) were defined as control 
hospitalizations (controls). Cases and controls were required to have continuous enrollment 
from 6 months prior to admission to 12 months after discharge from the hospitalization. 
Controls were matched 1:1 to cases on age, chronic kidney disease (CKD) stage, dialysis 
treatment, heart failure (HF), renin-angiotensin-aldosterone system inhibitor (RAASi) use, 
major diagnostic categories, and selected diagnosis-related groups. Readmission rates, 
LOS per readmission, and total inpatient days during the 1-year post-discharge period were 
assessed using Wilcoxon signed-rank and McNemar tests. Analysis was repeated in patients 
with CKD and/or HF.
Results: A total of 5,377 hospitalizations with HK (cases) were matched to 
hospitalizations without HK (controls). Compared with controls, cases had higher rates of 
readmission (30-day: 12.5% vs. 8.4%; 60-day: 18.3% vs. 12.7%; 90-day: 24.3% vs. 16.8%). 
Cases also had longer LOS per readmission (8.1 vs. 7.1 days) and more total inpatient days 
(10.5 vs. 5.8 days) during the 1-year post-discharge period (all p<0.001). In patients with 
CKD and/or HF, cases had higher rates of readmission (30-day: 13.8% vs. 9.4%, 60-day: 
19.8% vs. 14.3%, 90-day: 26.5% vs. 19.2%), longer LOS per readmission (8.4 vs. 7.4 days), 
and more total inpatient days (12.4 vs. 7.2 days) during the 1-year post-discharge period 
compared with controls (all p<0.001).
Conclusions: Post-discharge, hyperkalemia-related hospitalizations were associated 
with higher readmission rates, longer lengths of stay per readmission, and higher total 
inpatient days.
Funding: Commercial Support - AstraZeneca
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What Characterizes the Patients Who Develop Repeated or Persistent 
Hyperkalemia? A Population-Based Laboratory Study of Potassium 
Trajectories in Patients with CKD
Reimar W. Thomsen,1 Sia Kromann Nicolaisen,1 Eirini Palaka,2 Pål Hasvold,3 
Lars Pedersen,1 Kasper Adelborg,1 Henrik T. Sorensen.1 1Department of Clinical 
Epidemiology, Aarhus University Hospital, Aarhus N, Denmark; 2Global Health 
Economics, AstraZeneca, Cambridge, United Kingdom; 3Medical Department, 
AstraZeneca Nordic, Etterstad, Oslo, Norway.
Background: Hyperkalemia (HK) (defined as blood potassium (K+) >5.0 mmol/L) is 
common among patients with chronic kidney disease (CKD) and associated with adverse 
outcomes. Little is known about the characteristics of patients with repeated and persistent 
HK.
Methods: Observational laboratory study of all patients with CKD in Northern 
Denmark, 2000-2012. For all CKD patients with an incident HK event, we examined K+ 
trajectories over 6 months. We described patient characteristics associated with persistent 
HK (2 or more elevated K+ tests >5.0 mmol/L with ≤1 normal K+ test in between) and 
repeated HK (2 or more elevated K+ tests separated by ≥2 normal K+ tests).
Results: In 157,283 patients with CKD (median age 73 years, 59% females, median 
number of annual K+ tests =4), 28% (n=43,845) had a subsequent HK event detected. 
Within 6 months after the first HK, 29% had died, 45% had no additional high K+ 
value, while 26% (n=11,390) fell into persistent or repeated HK pattern. FIGURE shows 
K+ trajectories for patients with persistent (A:2 high K+ tests, n=3,936; B:3 high tests, 
n= 1,236; C:≥4 high tests, n=974) or repeated HK (D, n=5,244). Important baseline 
predictors for persistent or repeated HK include low eGFR (prevalence ratio (PR)=2.40 
(95% CI 1.91-3.01) for eGFR <15), severity of first HK event (PR=3.98 (95% CI 3.05-
5.18) for K+ 6.0-6.5 mmol/L), and use of ACE-inhibitors (PR=1.32 (95% CI 1.23-1.41)) or 
spironolactone (PR=1.59 (95% CI 1.43-1.78)).
Conclusions: Repeated HK and persistently elevated K+ levels are common in CKD 
patients. The use of readily identifiable clinical predictors can help identify patients at 
highest risk, who can benefit most from effective K+ management.
Funding: Commercial Support - AstraZeneca
FIGURE. Median K+ before and after a first HK event in 11,390 CKD patients with 
persistent or repeated HK trajectories over 6 months
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Assessing the Impact of Hyperkalemia on Patient-Reported Quality of 
Life: A Global Analysis of the KDQOL-36 in a Real-World CKD Patient 
Population
Susan Grandy,1 James Jackson,2 Lei Qin,1 Rebecca Moon,2 Megan Scott,2 
Eirini Palaka.3 1Astrazeneca, Gaithersburg, MD; 2Adelphi Real World, 
Macclesfield, United Kingdom; 3AstraZeneca, Cambridge, United Kingdom.
Background: Hyperkalemia (HK), defined as abnormally high serum potassium 
(K+>5mmol/L), is common in patients with chronic kidney disease (CKD) because of the 
effects of kidney disease on K+ homeostasis. Management of HK includes strict adherence 
to a low K+ diet which can be unhealthy and an added burden to patients. Evidence 
describing the impact of HK on patient reported outcomes is limited. The objective of this 
analysis was to assess the impact of HK on the Quality of Life (QoL) of non-dialysis (ND) 
CKD patients using the Kidney Disease Quality of Life Instrument (KDQOL), a validated 
CKD-specific questionnaire.
Methods: Data from the 2015 and 2018 Adelphi CKD Disease Specific Programmes 
were pooled to create a cross-sectional dataset of unique patients, including global data from 
physicians and their ND CKD patients across EU-5, China and USA. Patients completed 
the KDQOL, a disease specific self-report measure targeted at the particular concerns of 
individuals with kidney disease. CKD ND patients with HK (K+ >5.0 mmol/L) and without 
HK (i.e. those with normal K+ levels 3.5-5.0 mmol/L) were stratified to study the association 
between HK and QoL. Multivariate analysis was used to identify the association between 
HK and QoL, adjusting for age, sex, eGFR levels, and presence of heart failure and diabetes.
Results: Results of the KDQOL analysis showed that ND patients with HK (n=216) 
had significantly lower mean QoL scores compared to those without HK (n=933) for 3 of 
the 5 KDQOL domains: burden of kidney disease (54.9 vs. 60.8; p=0.011), effects of kidney 
disease (69.6 vs. 76.1; p=<0.001) and physical health (39.1 vs. 41.6; p=0.001). Additionally, 
patients with HK had numerically lower scores for the remaining 2 KDQOL domains 
compared to patients without HK, namely symptoms/problems (80.1 vs. 82.1; p=0.134) and 
mental health (45.3 vs. 46.8; p=0.073).
Conclusions: This study highlights the negative impact of HK on the quality of 
life of CKD ND patients globally. HK contributes to the overall CKD disease burden, 
leading to further decrements in quality of life compared to patients without HK. Effective 
management of hyperkalemia may improve quality of life in this patient population.
Funding: Commercial Support - AstraZeneca
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Quality of Life in CKD Patients with Hyperkalemia in the US: Results 
from the KDQOL-36
Susan Grandy,1 James Jackson,2 Lei Qin,1 Rebecca Moon,2 Megan Scott,2 
Eirini Palaka.3 1Astrazeneca, Gaithersburg, MD; 2Adelphi Real World, 
Macclesfield, United Kingdom; 3AstraZeneca, Cambridge, United Kingdom.
Background: Hyperkalemia (HK), defined as abnormally high serum potassium 
(K+ >5mmol/L), is common among patients with Chronic Kidney Disease (CKD) and is 
associated with increased risk of mortality and hospitalization. Over 6% of CKD patients 
in the US have HK, four times the corresponding rates in the general US population. The 
Kidney Disease Quality of Life Instrument (KDQOL) is a 36-item survey specifically 
targeting concerns of individuals with CKD, to identify the disease burden on quality of life 
(QoL). Limited real-world data exist on the impact of HK on the QoL of CKD patients in 
the US. While low K+ diet is key for HK management, the established poor dietary habits 
of the US population together with the lack of universal health coverage and limited social 
support increase the importance of better understanding the impact of HK on the QoL of 
US CKD patients.
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Methods: Real-world data of unique CKD non-dialysis (ND) patients from the 2015 
and 2018 US Adelphi CKD Disease Specific Programmes were pooled and analyzed. 
Patients completed the KDQOL questionnaire, while physicians reported information on 
patient demographics, disease characteristics and comorbidities. Patients with and without 
HK (normal K+ 3.5-5.0 mmol/L) were compared. The association between HK and QoL 
was measured using multivariate analysis adjusting for age, sex, eGFR level, and presence 
of heart failure and diabetes.
Results: Based on the results from US CKD ND patients with HK (n=64) and without 
HK (n=312), HK patients had significantly lower QoL scores across four of the five 
KDQOL domains, compared to those without HK: burden of kidney disease (54.4 vs. 66.0; 
p=0.023), effects of kidney disease (69.7 vs. 80.2; p=0.010), physical health (38.7 vs. 42.2; 
p=0.020) and mental health (44.8 vs. 48.9; p=0.018). US patients with HK also had a lower 
score on the fifth symptoms/problems domain compared to those without HK, without this 
difference being statistically significant (83.2 vs. 85.2; p=0.455).
Conclusions: CKD ND patients with HK in the US experienced a greater negative 
impact on their QoL compared to patients without HK, as they experienced higher disease 
burden, and a greater physical and mental impact. Effective management of K+ levels has 
the potential to maintain or improve QoL in this patient population.
Funding: Commercial Support - AstraZeneca
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Secondary Hyperparathyroidism Is Associated with Erythropoietin 
Deficiency and Endogenous Erythropoietin Resistance in Patients with 
CKD
Il Young Kim,1 June hyun Kim,1 Dong Won Lee,1 Soo Bong Lee,1 Miyeun Han,2 
Harin Rhee,2 Sang Heon Song.2 1Pusan National University Yangsan Hospital, 
Yangsan, Republic of Korea; 2Pusan National University Hospital, Busan, 
Republic of Korea.
Background: Erythropoietin (EPO) deficiency and resistance to endogenous EPO 
is an important pathophysiological feature in anemia of chronic kidney disease (CKD). 
Secondary hyperparathyroidism is known to contribute to anemia of CKD. We aimed 
to investigate the associations between parathyroid hormone (PTH) and anemia, EPO 
deficiency, and endogenous EPO resistance in patients with CKD.
Methods: This study included 409 patients with CKD [glomerular filtration rate 
(GFR) < 60 ml/min/1.73m2] who were not on dialysis therapy. Patients on exogenous EPO 
therapy and patients with iron deficiencies were excluded. Endogenous EPO resistance was 
assessed by calculating the ratio of endogenous EPO to hemoglobin (Hb) (endogenous 
EPO/Hb ratio). The associations of Hb level, endogenous EPO level, and the endogenous 
EPO/Hb ratio with clinical and laboratory variables were investigated by univariate and 
multivariate analyses.
Results: In univariate analysis, intact PTH level was correlated negatively with the 
Hb level (r = -0.403, P < 0.001) and endogenous EPO level (r = -0.108, P = 0.029). The 
intact PTH level was correlated positively with the endogenous EPO/Hb ratio (r = 0.139, 
P = 0.005). Multiple regression analysis revealed that the intact PTH level remained 
significantly associated with the Hb level (β = -0.136, P = 0.006), endogenous EPO level 
(β = -0.148, P = 0.016), and the endogenous EPO/Hb ratio (β = 0.131, P = 0.021), even after 
adjusting for other confounding factors, including the levels of the inflammatory marker 
C-reactive protein.
Conclusions: Secondary hyperparathyroidism exhibited significant associations 
with anemia, EPO deficiency, and endogenous EPO resistance in CKD patients. These 
associations were independent of inflammation status.
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Fibroblast Growth Factor 23 and Adiposity in Patients with CKD Stages 3 
and 4
Elvis A. Akwo,1 Cassianne Robinson-Cohen,1 Victoria Whitfield,1 
Edward D. Siew,1,3 Talat Alp Ikizler,1,3 Adriana Hung.2,1 1Vanderbilt University 
Medical Center, Nashville, TN; 2Veterans Affairs CSR&D, Nashville, TN; 
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Background: Adiposity has been associated with higher Fibroblast Growth Factor 23 
(FGF23) levels in patients with normal kidney function. If this relationship is observed 
in patients with moderate chronic kidney disease (CKD) is unknown. We investigated the 
relationship between adiposity and FGF23 in a cohort of patients with stages 3-4 CKD.
Methods: This was a cross-sectional investigation of 71 CKD patients who underwent 
body composition and anthropometric assessments. Dual energy x-ray absorptiometry 
(DEXA) scans were used to measure total fat mass and body mass index (BMI) was 
computed using baseline weight and height measurements. Biomarkers included estimated 
glomerular filtration rate (eGFR), serum leptin, FGF23, high sensitivity C-reactive protein 
(hsCRP) and serum lipids. Ordinary least squares regression with the sandwich estimator of 
variance was used to investigate the relationship between FGF23 and measures of adiposity 
(BMI, total fat mass) and the pro-atherogenic adipocytokine leptin. Log-transformation was 
performed for variables with considerable skewness.
Results: Mean (SD) age was 66 (12) years, 26% of participants were female, 23% 
were African-American. Median eGFR was 46.9 ml/min/1.73m2 (IQR 41.9, 52.8), median 
BMI was 31(IQR: 27, 35). Log FGF23 had a significant positive correlation with BMI 
(r = 0.27, p = 0.02), total fat mass (r = 0.30, p = 0.01) and serum leptin (r = 0.43, 
p < 0.0001). After full adjustment for age, sex, race, eGFR, log hsCRP, log HDL and 
log triglycerides, a 50% increase in FGF-23 was associated with 1 unit [95% I: 0.1, 1.9; 
p = 0.03] increase in BMI, 2.5 kgs [95% CI: 0.2, 4.8; p = 0.03] increase in total fat mass and 
a 6.7 ng/mL [95% CI: 1.0, 12.4; p = 0.02] increase in serum leptin.
Conclusions: We report in patients with stage 3 & 4 CKD a cross-sectional association 
between higher FGF23 and higher adiposity (BMI, total fat mass and the pro-atherogenic 
adipocytokine, leptin). The causes and the implications of these associations need to be 
further investigated. Particularly in bone and vascular health.
Funding: Veterans Affairs Support
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Elevated Serum Osteoprotegerin Associates with Microbiota-Derived 
Phenylacetylglutamine and Vascular Calcification in CKD
Lu Dai,1 Abdul Rashid T. Qureshi,1 Bengt Lindholm,1 Olof Heimburger,5 
Peter F. Barany,1 Magnus Soderberg,2 Pieter Evenepoel,3 Peter Stenvinkel.4 
1Division of Renal Medicine and Baxter Novum, Karolinska Institutet, 
Stockholm, Sweden; 2Pathology, Drug Safety and Metabolism, IMED Biotech 
unit, AstraZeneca, Molndal, Sweden; 3Department of Immunology and 
Microbiology, Laboratory of Nephrology, University Hospitals Leuven, Leuven, 
Belgium; 4Division of Renal Medicine and Baxter Novum, Karolinska Institutet, 
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Background: Increasing evidence indicate that a complex interplay between reduced 
renal function, altered bone metabolism and increased levels of metabolites produced by 
the gut microbiota drives vascular calcification (VC) which causes considerable morbidity 
and mortality in patients with chronic kidney disease (CKD). Here we investigated if 
osteoprotegerin (OPG), an osteocyte-derived inhibitor of bone formation, is associated with 
phenylacetylglutamine (PAG), a gut microbial metabolite, and VC in CKD stage 5 patients.
Methods: In 112 living donor kidney transplant (LD-Rtx) recipients (63% males; 
median age 47 years), associations between severity of VC (score 0 to 3; evaluated by 
histological examination of epigastric artery specimens collected at LD-Rtx), and serum 
OPG and PAG were investigated. Patients with VC grade 0 (n=17) and 1 (n=51) were 
combined into Group 1, representing no or minimal VC (n=68), and those having moderate 
(score 2; n= 29) or extensive (score 3; n= 15) VC were combined into Group 2 (n=44).
Results: Group 2 patients had significantly higher OPG levels than Group 1 patients 
with no or minimal VC. In Spearman’s rank correlations, OPG was positively associated 
with age, bone specific alkaline phosphatase, PAG, high-sensitive C-reactive protein and 
percentage calcification. Multivariate regression analyses showed that after adjustments 
for age, sex, diabetes and smoking habits, 1-SD higher level of PAG (β=0.35 P<0.001) 
was independently associated with 1-SD higher OPG level (adjusted r2=0.44). OPG was 
significantly associated with VC score after adjustments for age, sex, diabetes, smoking 
habits and PAG (OR [95% CI]: 2.05 [1.08, 3.89]; p=0.03).
Conclusions: While gut microbiome assessed by PAG is closely related with bone 
metabolism as assessed by OPG in CKD patients, serum OPG is a strong predictor of 
biopsy-verified VC, independent of gut microbiota status as assessed by PAG.
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Serum Procalcitonin Level May Predict Secondary Hyperparathyroidism 
Resistance Among CKD Patients
Mahmoud H. Imam, Mohammed Shawki. Internal Medicine Department, 
Faculty of medicine,Benha University, Benha, Egypt.
Background: Secondary hyperparathyroidism (SHPT) is common among CKD 
patients stage 3-5D. Frequently, patients reveal resistance to the conventional medications 
including vitamin D and oral cinacalcet. Inflammation was postulated as a potential cause 
of such resistance. The aim of this study is to assess if serum procalcitonin (PCT) level may 
be useful to predict SHPT resistance among CKD patients.
Methods: In this prospective study, 516 CKD patients attending nephrology clinic 
at a tertiary hospital were recruited. Inclusion criteria included: (1) eGFR < 60 ml/min 
for more than 3 months or patients were on regular hemodialysis. (2) serum intact 
parathormone (iPTH) level ≥ 300 pg/ml. Exclusion criteria included: (1) patients who had 
a kidney transplant, (2) patients had an evident infection at the time of the initial visit, and 
(3) patient was already receiving either vitamin D supplementation or oral cinacalcet. PCT 
and C reactive protein (CRP) levels were measured for each patient during the initial visit. 
iPTH was measured monthly. Resistance was defined as less than 30% reduction in initial 
iPTH level despite three months of maximally tolerated cinacalcet and vitamin D therapy. 
Multiple regression analysis and ROC curve tests were performed to assess the causality
between PCT level and SHPT resistance.
Results: 482 patients completed the study. The mean age of patients was 61.4 ± 11.2 
years. Female patients were 49%. Mean eGFR was 38 ± 17 ml/min/1.73 m2. Mean baseline 
iPTH was 845 ± 314 pg/mL. Serum PCT level was significantly higher among patients with 
resistance to SHPT therapy (mean PCT was 0.90 ± 0.28 vs 0.42±0.16 ng/mL; 95% CI: - 
0.5316, -0.4284; p .001). The area under the ROC curve for PCT, CRP, and age were 0.89, 
0.71 and 0.65 respectively.
CKD: Clinical, Outcomes, Trials - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
478
J Am Soc Nephrol 29: 2018 Poster/Friday
Conclusions: Serum procalcitonin level may be useful to predict resistance to therapy 
for secondary hyperparathyroidism among chronic kidney disease patients.
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The Oxidized Form of Serum Albumin, Non-Mercaptalbumin Is 
Significantly Associated with Renal Function and Anemia in CKD Patients
Shinya Nakatani,1 Eiji Ishimura,2 Keiko Yasukawa,4 Norikazu Toi,1 
Hideki Uedono,1 Akihiro Tsuda,3 Shinsuke Yamada,1 Katsuhito Mori,1 
Hitoshi Ikeda,4 Yutaka Yatomi,4 Masaaki Inaba.1 1Osaka City University 
Graduate School of Medicine, Osaka, Japan; 2Meijibashi Hospital, Matsubara-
shi, Japan; 3Department of Nephrology, Endocrinology, Metabolism, and 
Molecular Medicine, Osaka City University Graduate School of Medicine, 
Osaka, Japan; 4The University of Tokyo Hospital, Tokyo, Japan.
Background: Human mercaptalbumin (HMA; reduced form of serum albumin) and 
non-mercaptalbumin (HNA; oxdized form of serum albumin) have been known to be an 
indicator for evaluating oxidative stress in the systemic circulation, including patients with 
end stage renal disease.
Methods: We investigated factors associated with fraction of HNA (f(HNA)) in 112 
pre-dialysis CKD patients (age 63.6±14.0 years; 59 males and 53 females), using a newly 
established, anion-exchange column packed with a hydrophilic polyvinyl alcohol gel, along 
with high performance liquid chromatography.
Results: The means f(HNA) in CKD patients was 30.0 ±6.13%, whose value 
was higher than that reported in healthy subjects f(HNA) 25.1±3.0%. Age, estimated 
glomerular filtration rate (eGFR), blood urea nitrogen, hemoglobin, sodium-chloride, 
phosphate, intact parathyroid hormone (PTH), and fibroblast growth factor (FGF)-
23 levels correlated significantly with plasma f(HNA) (ρ=0.302, p〈0.001;ρ=-0.436, 
p〈0.001; ρ=0.457, p〈0.001;ρ=-0.382, p〈0.001;ρ=-0.324, p〈0.001;ρ=0.265, p=0.001; 
ρ= 0.367, p=0.001;ρ= 0.419, p〈0.001;respectively). In multiple regression analyses, age 
(β=0.200, p=0.014), eGFR (β=-0.238, p=0.009), hemoglobin (β=- 0.346, p<0.001), and 
ferritin (β=0.200, p=0.019), were associated significantly and independently with f(HNA) 
(R2=0.356, p<0.001). In addition, concerning factors related to CKD-mineral and bone 
disorder(CKD-MBD), intact-PTH (β=0.218, p=0.049) and 1,25-dihydroxyvitamin D 
(1,25(OH)2D) levels (β=-0.178,p<0.001) were significantly and independently associated 
with serum f(HNA) (R2=0.339, p<0.001), although fibroblast growth factor-23 were not.
Conclusions: We demonstrated that impaired renal function and renal anemia were 
strongly associated with oxidization of serum albumin. We also demonstrated that, intact 
PTH and 1,25(OH)2D are significant factors associated with the redox states of serum 
albumin. Our findings suggest the importance of management of hemoglobin and ferritin 
levels, and appropriate control of CKD-MBD factors in regard to better redox state of 
albumin in CKD patients.
Funding: Commercial Support - Keiko Yasukawa, Hitoshi Ikeda and Yutaka Yatomi 
disclosed receipt of the following financial support by by JSPS KAKENHI (25253040) 
and The Nakatani Foundation for Advancement of Measuring Technologies in Biomedical 
Engineering.
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Bortezomib in the Treatment of Kidney Light Chain Amyloidosis
Nan Chen. Ruijin Hospital, Shanghai, China.
Background: Light-chain amyloidosis is a clonal plasma cell disorder. It can cause 
kidney injury including proteinuria and abnormal renal function. This study is in order to 
evaluate the efficacy of Bortezomib in the treatment of Kidney Light Chain Amyloidosis
Methods: This is a retrospective study. All participants were recruited from Department 
of Nephropathy, Shanghai Ruijin Hospital between February 2013 to February 2018. The 
diagnosis of Kidney light chain amyloidosis(KAL) was based on kidney biopsy. All the 
patients were given BD therapy per month (Bortezomib 1.3mg/m2 BSA on day 1,4,8,11, 
Dex on day 1-4 and 8-11). The primary outcome was kidney complete response(CR) 
defined as at least 50% reduction in 24-hour urinary protein(24hUP) compared to baseline, 
plus the decrease of estimated GFR(calculated by EPI-Creatinine equation) was less than 
25% compared to baseline. Partial response(PR) was defined as 24hUP reduction within 
20%~50%. Non response was defined as 24hUP reduction less than 20% or the decrease of 
eGFR more than or equal to 25%.
Results: Thirty patients were diagnosed as KAL in this study. Of all the patients, 18 
(60%) were male and mean age was 56 (35-69) years old. Totally, 24 (80%) patients were λ 
type KAL, 6 (20%) patients were κ type KAL. Nineteen patients (63.3%) were CKD stage 
1, 8 patients (26.7%) were CKD stage 2 and 3 patients (10%) were CKD stage 3~5. The 
mean frequency of BD therapy was 3.8 (1-12) times and the mean follow-up period was 
8.21 (3-28) months after advanced remission or treatment. Finally, 12 of 30 patients (40%) 
reached CR,4 reached PR (13%). After BD therapy, the 24hUP was significantly decreased 
compared to baseline (3.6 vs 5.2 g/24h, P<0.05), serum albumin was increased (23.9 vs 
28.13g/L, P<0.005)and there was no decrease of eGFR(83.9 vs 87.9, p=0.228).(Figure 1)
Conclusions: Bortezomib was effective in the treatment of patients with KAL and the 
renal remission rate of our study was 53%.
Bortezomib in the Treatment of Kidney Light Chain Amyloidosis
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Treatment of Multiple Myeloma Related Kidney Disease by Bortezomib
Nan Chen. Ruijin Hospital, Shanghai, China.
Background: Only few evaluate the efficacy and safety of bortezomib in the treatment 
of multiple myeloma(MM) related kidney disease.
Methods: It is a retrospective cohort study. All the eligible patients were enrolled from 
Department of Nephropathy, Shanghai Ruijin Hospital between Sep 2009 and Aug 2017. 
Patients diagnosed MM with renal insufficiency were enrolled while patients with relapsed 
MM were excluded. All the subjects were given a bortezomib based treatment, including 
PD(bortezomib, dexamethasone)/PAD(bortezomib, adriamycin, dexamethasone)/
PCD(bortezomib, cyclophosphamide, dexamethasone). The primary outcome was clinical 
remission. Definition of hematological remission and renal response were according to the 
criterion made by IMWG(International Myeloma Working Group).
Results: Totally, 53 patients with MM related kidney diseases were recruited in 
this study. Of the 53 cases, 34M & 19F, mean age 59(35-86)y/o, median urinary protein 
4.2g/24h, serum albumin 30g/L, EPI-eGFR 19ml/min, 10 cases received dialysis therapy. 
The MM type included 11 IgA,5 IgD,16 IgG,21 Light chain. Of 28 cases with renal biopsy, 
6(21%)amyloidosis, 14(50%) cast nephropathy, 6(21%) tubulointerstitial lesions, 2(8%) 
light chain deposition disease(LCDD). The medium follow-up time was 7(3-47)months. 
Of 32 cases that taken at least 4 cycles of bortezomib treatment, hematological remission 
showed that 14(44%) achieved CR,9(28%)achieved PR,7(22%)were stable, 2(6%) were 
relapsed;23/32 baseline eGFR<60ml/min, renal response showed that 5(22%) achieved 
CR,1(4%)achieved PR,12(52%)achieved MR,5(22%)were stable. Of 10 cases that dialysis 
dependent, 5 got rid of dialysis. After treatment, patients showed improvement in clinical 
features.(Fig 1&2)
Conclusions: Bortezomib can significantly reduce urinary protein, increase EPI-eGFR 
and improve prognosis of MM related kidney disease, which means making patients benefit.
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Direct Oral Anticoagulants vs Warfarin Across CKD Stages: Mortality 
Outcomes in US Veterans
Alissa Dratch,3,1 Drake A. Edgett,3,1 Elani Streja,3,1 Ekamol Tantisattamo,1 
Kamyar Kalantar-Zadeh,3,1 Csaba P. Kovesdy,2 Wei Ling Lau.1 1University of 
California, Irvine School of Medicine, Orange, CA; 2University of Tennessee 
Health Science Center, Memphis, TN; 3Harold Simmons Center for Kidney 
Disease Research and Epidemiology, Orange, CA.
Background: For over 50 years warfarin was the only oral anticoagulant available 
and was shown to prevent stroke and improve survival in the general population. However, 
evidence to support use of anticoagulation in patients with advanced CKD has been 
controversial. Direct Oral Anticoagulants (DOACs) became available in the past decade 
but outcomes data in CKD is limited. In this project we examined mortality outcomes 
associated with DOACs vs. warfarin therapy in the Veterans Affairs (VA) database.
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Methods: In a national cohort of US veterans, we identified patients who were initiated 
on warfarin or DOAC treatment between 1/1/2012-12/31/2013. Cox models were used 
to calculate mortality hazard ratios across stages of kidney disease (or no kidney disease) 
with multivariable adjustment for age, gender, race and baseline comorbidities (diabetes, 
hypertension, heart failure, myocardial infarction, prior stroke, antiplatelet medications).
Results: The cohort included 27,787 patients of which 73% were non-CKD, 15% were 
CKD stage 3a, 5% were CKD stage 3b, and 1% were CKD stage 4. There were no CKD 
stage 5 patients on DOACs. Patients had a mean±SD age of 69±10 years and included 
19% diabetics, 15% African-Americans and 2% Hispanics. Patients on warfarin were more 
likely to be older, African-American, and have pre-existing comorbidities. Compared to 
warfarin, patients initiated on DOAC medication had a lower risk of death in non-CKD and 
CKD stage 3a groups; however associations were attenuated and trended toward a reverse 
association in later stage CKD [Figure].
Conclusions: In a national cohort of US veterans DOACs were associated with a lower 
mortality risk in non-CKD and early stage CKD. Further studies with larger patient numbers 
are warranted to evaluate outcomes of DOACs vs. warfarin therapy in later stage CKD.
Funding: Veterans Affairs Support
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The Bleeding Risk of Adding Pentoxifylline to Aspirin in Patients with 
CKD
Chia-Chun Wu,1,2 Tzongshi Lu,3 Jui-Yi Chen.1 1Chi Mei Medical Center, Tainan, 
Taiwan; 2Pharmacy, Chia Nan University of Pharmacy and Science, Tainan, 
Taiwan; 3Brigham and Women’s Hospital, Harvard Medical School, Natick, MA.
Background: Pentoxifylline (PTX) is found renoprotective in chronic kidney disease 
(CKD) by the effects of antiinflammation, antifibrosis and improvement on hemorheology. 
CKD is a risk factor of cardiovascular disease, therefore many patients with CKD are under 
antiplatelet treatment to prevent it. CKD is also known associated with a greater risk of 
bleeding. Herein, we want to know if adding on PTX in CKD patients who already under 
aspirin therapy will increase the risk of bleeding.
Methods: The National Health Insurance Research Database in Taiwan was used to 
identify patients who had diagnosis of CKD and under aspirin treatment longer than 3 
months after CKD diagnosed. The exclusion criteria were having major bleeding events 
within one year prior the CKD diagnosed, liver cirrhosis, thrombocytopenia and history 
of hospitalization within three months before study index date. Patients who received PTX 
after aspirin were selected as study group (PTX group), the remaining patients who without 
PTX treatment and matched on age, gender and years of CKD diagnosis were selected 
as control group. The study outcome was any event of intracranial hemorrage (ICH) or 
gastrointestinal(GI) bleeding after using PTX. A conditional logistic regression model was 
used to estimate the risk of bleeding in PTX treated patients.
Results: A total 607 patients in PTX group and 1214 in control group were analyzed. 
The mean age of both groups was 65.7+/-12.4 yeas old. PTX group had higher percentage 
of diabetes mellitus (DM)(44.48% vs 35.91%, p<0.001) and stroke history (18.29% vs 
14.33%, p=0.029). The percentage of ICH and GI bleeding events was 1.48% and 14.83% 
in the PTX group; 1.89% and 11.86% in the control group, without significant difference. 
The risk of having a bleeding event was not significant different between PTX group and 
control group after adjusting the comorbidities of DM, hypertension, hyperlipidemia, 
stroke history and end stage renal disease. (Adjusted Odds Ratio(AOR) of ICH: 0.78, 95% 
Confidence Interval(CI): 0.38-1.62; AOR of GI bleeding: 1.4, 95%CI :0.98-1.72).
Conclusions: Add-on PTX in CKD patients who under aspirin treatment would not 
increase the risk of ICH and GI bleeding.
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Is the Use of Opioids and Benzodiazepines Among Patients with CKD 
Stages 3-5 Associated with Postoperative Outcome?
Thorir E. Long,1,2 Dadi Helgason,1,2 Martin I. Sigurdsson,3 Gisli H. Sigurdsson,1,2 
Runolfur Palsson,1,2 Olafur S. Indridason.1 1Landspitali - The National University 
Hospital of Iceland, Reykjavik, Iceland; 2University of Iceland, Reykjavik, 
Iceland; 3Duke University Medical Center, Durham, NC.
Background: Preoperative use of opioids and benzodiazepines (BZDs) has been 
associated with adverse outcomes following surgery. The aim of this study was to examine 
the use of opioids and BZDs among individuals with chronic kidney disease (CKD) in 
association with postoperative outcomes.
Methods: This was a retrospective study of adult patients who underwent non-cardiac 
surgery at the University Hospital in Reykjavik in 2006-2015. Clinical data was obtained 
from electronic medical records. CKD stages 3-5 was defined according the the KDIGO 
classification system. Patients were considered to be using opioids or BZDs if they had filled a 
prescription within six months prior to surgery and a daily defined dose (DDD) was determined 
for all patients. Survival of CKD patients using opioids and BZD was compared to propensity 
score-matched (PSM, 1:1) control group of CKD patients not using these medications.
Results: A total of 42,600 patients underwent non-cardiac surgery during the 10-
year study period, of whom 6973 (16.4%) had preoperative CKD 3-5, with 3877 (9.1%), 
1845 (4.3%), 578 (1.4%) and 673 (1.6%) having stages 3A, 3B, 4 and 5, respectively. 
Preoperatively there were 8008 (19%), 3327 (8%), 2888 (7%) individuals taking opioids, 
BZDs and both opioids and BZDs, respectively. CKD patients were more often treated with 
BZDs (10.5% vs. 7.3%) and both opioids and BZDs (8.6% vs. 6.4%) than patients without 
CKD (p<0.001). CKD patients received a median (interquartile range, IQR) of 47 (20-112) 
DDD of opioids and BZDs over the 6 month period, compared with 33 (13-93) DDD in 
those without CKD (p<0.001). Preoperative use of opioids or BDZs among CKD patients 
was not associated with worse 30-day (97% vs. 96%, p=0.1) or one-year survival (86% vs. 
86%, p=0.66) compared to the PSM control group. In an analysis limited to individuals with 
CKD stage 3B or higher, who were prescribed >90 DDD in the six months preoperatively, 
30-day (96% vs. 97%) and one-year survival (84% vs. 84%) was similar to controls.
Conclusions: In this surgical cohort we found that patients with CKD were more
commonly prescribed opioids, BZDs or both, but quantity of prescribed medications was 
modest. With this prescription pattern, adverse effect on postoperative survival was not 
observed.
Funding: Government Support - Non-U.S.
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Marijuana Use and Kidney Outcomes in the ASSESS-AKI Cohort
Joshua L. Rein,1 Lindsay Texter,2 Mark M. Wurfel,3 Edward D. Siew,4 
Amit X. Garg,5 Thida C. Tan,6 Paul L. Kimmel,7 James S. Kaufman,8 
Vernon M. Chinchilli,2 Steven G. Coca.1 on behalf of the Assessment Serial 
Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) 
Study Investigators 1Icahn School of Medicine at Mount Sinai, New York, NY; 
2Pennsylvania State College of Medicine, Hershey, PA; 3University of 
Washington, Seattle, WA; 4Vanderbilt University School of Medicine, Nashville, 
TN; 5London Health Sciences Centre, London, ON, Canada; 6Kaiser Permanente 
Northern California, Oakland, CA; 7National Institute of Diabetes and Digestive 
Kidney Diseases (NIDDK), Bethesda, MD; 8VA New York Harbor Healthcare 
System, New York, NY.
Background: Legal recreational and medicinal use of marijuana (MJ) is increasing 
worldwide. Animal kidney injury models show that activation of the cannabinoid receptor 
CB1 can exacerbate kidney disease while activation of CB2 may be protective. Whether 
these effects apply to whole plant MJ remains to be determined.
Methods: We conducted a post-hoc analysis of MJ usage as a risk factor for kidney 
function decline and albuminuria in the ASSESS-AKI parallel matched cohort study that 
enrolled hospitalized adults with and without AKI from 4 US centers between 2009-2015, 
with a median of 4.1 years of follow-up. MJ usage was defined as responding yes to “have 
you used MJ since your last study visit?” at least once on any study visit questionnaire. 
Nonusers were defined as always responding no to this question. Kidney function decline 
was defined according to the parent study protocol. Association between MJ usage and the 
categorical and continuous outcomes were determined using multivariable Cox regression 
and linear mixed models, respectively.
Results: MJ users represented 113 of 1599 (7%) participants, were younger (mean 
age 54 vs. 65 years), mostly white (78%), men (78%), and were more likely to be heavy 
tobacco users (≥20 cigarettes/day; 26% vs. 8%). Baseline eGFR was higher in users vs. 
non-users (87 +/- 30 mL/min/1.73 m2vs. 69 +/- 26 mL/min/1.73 m2), while baseline UACR 
was similar (120 +/- 80 in users vs. 99 +/- 72 in nonusers). In those with baseline eGFR ≥60 
mL/min/1.73 m2, MJ use was not associated with incident CKD (adjusted HR 0.93; 95% 
CI, 0.5-1.8) or differences in eGFR slope over time (mean difference -0.12 mL/min/1.73 m2/
year, P=0.7). In contrast, in those with baseline eGFR <60 mL/min/1.73 m2, MJ users had 
more rapid eGFR decline vs. nonusers (-3.2 vs -1.4 mL/min/1.73 m2/year,P=0.002) and had 
a strong trend towards higher risk for CKD progression (adjusted HR 2.7; 95% CI, 0.83 to 
8.5). MJ usage was not associated with the rate of change in UACR over time in those with 
(P=0.4) and without CKD (P=0.2).
Conclusions: MJ usage was associated with more rapid eGFR decline in those with 
baseline CKD, but not in those without CKD, nor was it associated with changes in 
albuminuria over time in those with or without CKD. Reasons for the effect modification by 
CKD status regarding MJ and kidney function should be explored.
Funding: NIDDK Support
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Cannabis Use and Its Association with eGFR Decline in Advanced CKD 
Patients Transitioning to ESRD
Praveen Kumar Potukuchi,1 Keiichi Sumida,2 Miklos Z. Molnar,1 
Abduzhappar Gaipov,1 Frank Park,1 Cameron M. Kaplan,1 Hamid Moradi,4 
Fridtjof Thomas,1 Justin Gatwood,1 Elani Streja,3 Kamyar Kalantar-Zadeh,4 
Csaba P. Kovesdy.1 1University of Tennessee Health Science Center, Memphis, 
TN; 2Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan; 
3Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Orange, CA; 4University of California Irvine, School of Medicine, Orange, CA.
Background: The renal safety of cannabis use in patients with advanced CKD is 
unknown.
Methods: We examined 6,788 US veterans who transitioned to dialysis during 2007-
2014 and had undergone urine toxicology tests within a year before the dialysis initiation. 
We compared patients whose toxicology tests were positive for cannabis alone (primary 
exposure group, PEG, N=195) with those whose tests were negative (negative control 
group, NCG, N=3,266). We estimated slopes of eGFR and the effect of inter-individual 
cannabis use on intraindividual slopes in multilevel mixed-effects models with random 
intercepts and slopes adjusted for sociodemographics, comorbidities, medications, and vital 
signs.
Results: The mean (SD) age of the cohort was 60.5 (9.6) years; 97% were male, 46 % 
were African American and 72% were diabetic. The median (IQR) eGFR slope was -10.9 
(-17.2, -6.1) ml/min/1.73m2/year. Cannabis use was associated with significantly steeper 
eGFR slopes in the unadjusted model (Figure 1, estimated slope in the PEG compared 
to NCG group (95% CI) -3.55 (-6.58, -0.51) ml/min/1.73m2/year, P=0.02) However, after 
multivariable adjustments cannabis use was not associated with steeper slopes.
Conclusions: Cannabis use is not associated with more rapid loss of kidney function 
in patients with advanced CKD.
Funding: NIDDK Support, Veterans Affairs Support
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Efficacy and Safety of Endothelin Receptor Antagonist on Renal 
Outcomes
Muh Geot Wong,1,2 Edmund Chung,2 Sunil V. Badve,3 Meg J. Jardine,1 
Brendon L. Neuen,1 Min Jun,1 Hiddo J. Lambers Heerspink,4 Dick de Zeeuw,4 
John McMurray,5 Vlado Perkovic.1,2 1Renal and Metabolic Division, The George 
Institute for Global Health, Newtown, NSW, Australia; 2Renal Medicine, Royal 
North Shore Hospital, St Leonards, NSW, Australia; 3Department of Renal 
Medicine, St George Hospital, Kogarah, NSW, Australia; 4University Medical 
Center Groningen, Groningen, Netherlands; 5University of Glasgow, Glasgow, 
United Kingdom.
Background: Preclinical studies suggest that blockade of the endothelin receptor 
reduces proteinuria and may confer renal protection. The aim of this systematic review 
and meta-analysis was to summarize evidence from randomized controlled trials (RCT) 
concerning the benefits and risks of ERA on renal outcomes.
Methods: MEDLINE, Embase and Cochrane Central Register of Controlled Trials 
were searched for RCTs evaluating ERAs in adults that reported renal outcomes. The 
primary outcome was kidney failure (end-stage kidney disease, renal failure, or doubling 
of creatinine, or as reported by the authors). The secondary outcomes were change in 
kidney function (estimated glomerular filtration rate or creatinine clearance), albuminuria 
and systolic blood pressure from baseline to last measurement, all-cause mortality, 
cardiovascular mortality and adverse events. Treatment effects were summarized using 
random-effects meta-analysis.
Results: Six RCTs (3963 participants, median sample size 333, median follow-up 
15 weeks) met eligibility criteria. There was substantial heterogeneity in baseline kidney 
function and study population. Compared to placebo, ERA significantly reduced the risk 
of kidney failure (2 trials, risk ratio [RR] 0.75, 95%CI 0.56, 0.93). Compared to placebo, 
ERA significantly reduced albuminuria (3 trials, SMD -1.19, 95%CI -1.86, -0.53), and 
systolic blood pressure (weighted mean difference [WMD] -5.86, 95%CI -10.62, -1.09 
mm Hg). ERA treatment was associated with a short term decrease in kidney function 
(5 trials, standardized mean difference [SMD] -0.11, 95%CI -0.22, 0.00). ERA had uncertain 
effect on all-cause mortality (4 trials, RR 1.62, 95%CI 0.62, 4.29), and pulmonary edema 
(2 trials, RR 2.07, 95%CI 0.65, 6.59); but increased the risk of systemic edema (6 trials, RR 
1.90, 95%CI 1.29, 2.79).
Conclusions: Short-term trials suggest that ERA treatment may reduce the risk of 
kidney failure and reduce albuminuria. Adequately powered RCTs with long-term follow-
up are required to evaluate whether ERA treatment improves renal outcomes.
FR-PO236 Poster Friday
CKD: Clinical, Outcomes, Trials - II
Effect of a Carbonaceous Adsorbent on the Progression of CKD
Hiroko Yamagishi, Hitoshi Suzuki, Yusuke Suzuki. Nephrology, Juntendo 
University Faculty of Medicine, Tokyo, Japan.
Background: AST-120 (Kureha Chemical, Tokyo, Japan) is an oral spherical 
carbonaceous adsorbent, which was approved for use in delaying the initiation of dialysis 
and ameliorating the symptoms of uremia in patients with progressive chronic kidney 
disease (CKD). It adsorbs the precursor of indoxyl sulfate in the intestines and prevents 
indoxyl sulfate production. Indoxyl sulfate, initially identified as a major uremic toxin 
that causes uremic symptoms, contributes to CKD progression. Although international 
multicenter prospective trials of AST-120 did not slow progression of CKD in patients with 
moderate to severe CKD, present study evaluated the efficacy of AST-120 in preventing the 
progression of CKD and its indication in our Japanese cohort.
Methods: Antihypertensive therapy using renin-angiotensin-aldosterone inhibitor 
(RAS-i) and a low-protein diet is conventionally used to treat patients with CKD. We 
retrospectively recruited 218 patients with CKD treated with AST-120 from 2014 to 2015. 
Changes of serum levels of blood urea nitrogen (BUN) and eGFR were analyzed for 4 
years, from 1 year before medication. Moreover, we elucidated the recommended timing of 
initiation of AST-120 administration.
Results: The mean eGFR and BUN at the baseline were 24.1 ml/min/1.73m2 and 35.9 
mg/dL, respectively. Decline of eGFR before AST-120 treatment was -4.9 ml/min/1.73m2/
year. After 1-year and 3-year medication with AST-120, the decline of eGFR was 
significantly improved to -0.7 and -0.9 ml/min/1.73m2/year, respectively. Increase slope 
of BUN also improved +4.7 to +1.9 mg/dl/year after 3-year administration with AST-120. 
We next divided patients into 3 groups depending on baseline eGFR, i.e., >50 eGFR ≥40, 
>40 eGFR ≥30 and eGFR<30 ml/min/1.73m2 groups. The effect of AST-120 to prevent
progression of CKD was the highest in >50 eGFR ≥40 group in which decline of eGFR was
-9.9 to -1.2 ml/min/1.73m2/year during intervention period.
Conclusions: Present study suggests that treatment with AST-120 may delay
progression of CKD. Especially, AST-120 administration is recommended to initiate
relatively maintained renal function (>50 eGFR ≥40). Those findings provided insight into 
management of CKD patients.
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Improvement in Kidney Function upon Discontinuation of Fenofibrate in 
Outpatient Nephrology Consultations for CKD
Rafael A. Justiniano Magraner,3 Manuel E. Gonzalez,3 Juan Carlos Q. Velez.1,2 
1Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA; 
2Ochsner Clinical School, The University of Queensland, New Orleans, LA; 
3Ochsner Clinic Foundation, Metairie, LA.
Background: It has been noted in observational and interventional trials that individuals 
exposed to fenofibrate can exhibit a rise in serum creatinine (sCr) concentration. However, 
it is not known to what extent this phenomenon impacts kidney function in patients who are 
referred to a nephrology clinic for consultation for chronic kidney disease (CKD).
Methods: We prospectively collected data in patients referred to a nephrology clinic for 
new evaluation of a recent rise in sCr or CKD who underwent discontinuation of fenofibrate 
to assess the effect of that intervention on kidney function, i.e., sCr and estimated glomerular 
filtration rate (eGFR). Fenofibrate was discontinued when no other cause for a recent rise in 
sCr or CKD was identified at the time of consultation.
Results: A total of 16 patients (69% women, 75% white, 56% type 2 diabetes, 31% 
peripheral arterial disease, 19% NASH) were captured over 1.5 years, median baseline 
sCr 1.9 (1.1 – 2.4) mg/dL and eGFR 34 (22 – 57) ml/min; proteinuria was absent in 13 
(81%) patients. At 3 months (n = 16), median sCr decreased to 1.4 (0.9 – 2.2) mg/dL 
(p < 0.01) and median eGFR increased to 45 (27 – 71) ml/min (p < 0.05). At 6 months 
(n = 14), median sCr decreased to 1.5 (0.9 – 2.2) mg/dL (p < 0.05) and median eGFR 
increased to 42 (26 – 71) ml/min (p = 0.08). A ≥ 30% rise in eGFR was observed in 50% 
of patients at 3 months and it persisted in 46% and 50% of patients at 6 and 12 months, 
respectively. Median relative change in eGFR was +29% (+7 to +83), +24% (-13 to +68) 
and +29% (0 to +78) at months 3, 6 and 12, respectively. Triglyceride level increased by 
> 2-fold in 4 patients during follow up, whereas it remained within the same range in the
remaining 12 patients (only 3 required gemfibrozil).
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Conclusions: Discontinuation of fenofibrate in patients referred for CKD evaluation 
can result in sustained improvement in kidney function. There is a need to raise awareness 
among primary practitioners about this phenomenon that prompts consultations to 
nephrology. Furthermore, these proof-of-concept pilot data may serve as rationale for a 
prospective controlled study
FR-PO238 Poster Friday
CKD: Clinical, Outcomes, Trials - II
Ketosteril Effects on Advanced CKD: Implications from Taiwan 
Population-Based Study
Fan Pei-Chun. Chang Gung Memorial Hospital, Linkou Medical Center, 
Taoyuan, Taiwan, Taoyuan, Taiwan.
Background: Chronic kidney disease (CKD) is a risk factor for mortality and morbidity. 
Many clinical studies to investigate whether lowering protein intake with ketoacid analogue 
(LPD-KA) supplement can attenuate the progression of CKD which were unable to have 
a definite conclusion. This study aims to evaluate the benefit of LPD-KA in patients with 
advanced CKD.
Methods: The study analyzed encrypted datasets from Taiwan’s National Health 
Insurance Research Database. The exposure group was the LPD-KA which fulfilled the 
medication possession rate > 90% during the first 90 days of follow up and the comparison 
group was non-users. Outcomes included mortality, dialysis, cardiovascular event, sepsis 
and blood transfusion at 2-year follow up. Diabetes mellitus (DM) was a stratum variable 
of interest.
Results: The data of 2654 patients in the LPD-KA group and 5308 propensity score 
matched patients in the LPD-KA naive group between January 1, 2001 and December 31, 
2013 were analyzed. Patients on LPD-KA had lower mortality (8.1% vs. 11.5%; hazard ratio 
[HR] 0.69, 95% confidence interval [CI] 0.59-0.81) and lower composite cardiovascular 
events (10.1% vs. 12.5%; HR 0.78, 95% CI 0.68-0.90). When stratifying analyses by DM, 
LPA-KA had beneficial effects on composite cardiovascular events and dialysis in patients 
without DM, but not in patients with DM (P for interaction < 0.05). The LPD-KA prolonged 
the dialysis for a median of 1.8 months (P < 0.001) in the non-DM group, but not in the DM 
group (0.2 month, P = 0.515).
Conclusions: LPD-KA might be a effective therapy for patient of CKD especially in 
patients without DM. Cardiovascular and infective event is less in LPD-KA group. Further 
investigation with earlier treatment to improve the outcome is warranted.
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Effects of Brazilian Green Propolis Extract on Proteinuria in CKD 
Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Marcelo D. Silveira,1 Flavio Teles de Farias Filho,3 Andresa Berretta,2 
Camila E. Rodrigues,1 Talita R. Sanches,1 Antonio C. Seguro,1 Lucia Andrade.1 
1University of Sao Paulo School of Medicine, Sao Paulo, Brazil; 2Apis Flora 
Indl. Coml. Ltda., Ribeirao Preto, Brazil; 3Federal University of Alagoas, 
Maceio, Brazil.
Background: Chronic kidney disease (CKD) is a public health problem of global 
proportions, and proteinuria is associated with disease progression. Brazilian green propolis 
(GP) is a natural resin that bees collect from plant sap, presenting anti-inflammatory, 
immunomodulatory and anti-oxidant properties. We tried to determine whether GP extract 
can reduce proteinuria and alter the estimated glomerular filtration rate (eGFR).
Methods: This was a randomized, double-blind, placebo-controlled study including 
32 patients with diabetic or non-diabetic CKD; between 18 and 90 years of age; with 
an eGFR of 25-70 ml/min/1.73m2; and with proteinuria (>300mg/day) or micro- or 
macro-albuminuria (urine albumin-to-creatinine ratio >30mg/g uCr or >300mg/g uCr, 
respectively). The patients were randomly assigned to receive GP (n=18) or placebo (n=14) 
at a dose of 500 mg/day and were followed for 12 months.
Results: Proteinuria (mg/24h) was significantly lower in the GP group than in the 
placebo group—695 (95% CI: 483-999) vs. 1403 (95% CI: 1031-1909)—(p=0.004). This 
finding was independent of variations in eGFR and systemic hemodynamics, which did not 
show differences between the groups during the follow-up. There was also a significant 
reduction of the urinary monocyte chemoattractant protein-1 (pg/mg uCr) was also 
significantly lower in the GP group than in the placebo group—58 (95% CI: 36-95) vs. 98 
(95% CI: 62-155)—(p=0.038). At the dose used, GP was found to be safe and well tolerated.
Conclusions: Our findings broaden the perspectives for the use of GP as a natural 
adjuvant in reducing proteinuria in CKD. (ClinicalTrials.gov identifier: NCT02766036; 
Supported by FAPESP)
Funding: Government Support - Non-U.S.
* P = 0.023; † P = 0.006; ‡ P = 0.004; Propolis vs. Placebo.
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Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase 
Inhibitor, and Vascular Endothelial Growth Factor in Patients with CKD
Tadao Akizawa,1 Iain C. Macdougall,2 Jeffrey S. Berns,3 Nobuyuki Takakura,4 
Thomas Bernhardt,7 Megumi Taguchi,5 Eriko Ogura,5 Kazuma Iekushi.6 1Showa 
University School of Medicine, Tokyo, Japan; 2King’s College Hospital, London, 
United Kingdom; 3University of Pennsylvania School of Medicine, Philadelphia, 
PA; 4Osaka University, Suita-shi, Japan; 5Bayer Yakuhin, Ltd., Osaka, Japan; 
6Bayer Yakuhin, Ltd, Osaka, Japan; 7Bayer AG, Berlin, Germany.
Background: Hypoxia-inducible factor (HIF) transcriptionally upregulates a large 
number of genes including erythropoietin (EPO) and vascular endothelial growth factor 
(VEGF). EPO gene upregulation is helpful in treating anemia, whereas VEGF upregulation 
could potentially exacerbate conditions such as diabetic retinopathy or malignancy. We 
studied whether molidustat is linked to changes in VEGF concentrations and related adverse 
events (AEs) in patients with chronic kidney disease (CKD).
Methods: Three Phase 2b studies (A: 16 weeks, placebo-controlled, fixed-dose; B: 
16 weeks, darbepoetin-controlled, variable-dose; and C: up to 36 months, darbepoetin-
controlled, extension) were conducted in anemic subjects with CKD who were not on 
dialysis. Plasma VEGF concentrations were compared between baseline and last visit. We 
also assessed adverse events (AEs) of diabetic retinopathy (DR), macular degeneration 
(MD) and malignancy as these may potentially be influenced by VEGF. Subjects with 
proliferative diabetic retinopathy and previous or concurrent cancer at baseline were
excluded from the studies.
Results: The results of VEGF concentrations are shown in Table 1. DR and MD as AEs 
were reported in none of 101 subjects in (A), in 1 of 92 subjects (1.0%) in (B), and in 2 of 
103 subjects (1.9%) in (C) in molidustat group. None were reported in comparator groups 
in the three studies. Malignancy as AEs were reported in 1 of 101 subjects (1.0%) in (A), in 
1 of 92 subjects (1.0%) in (B), and in 3 of 103 subjects (2.9%) in (C) in molidustat group. 
In 2 of 41 subject (4.9%) AE was reported in darbepoetin group (C).
Conclusions: No notable differences in changes of VEGF from baseline to last visit 
between molidustat and comparator groups were observed. Comparable numbers of 
subjects with an AE of DR, MD and malignancy in molidustat and comparator groups were 
identified. Due to the small number of treated patients the findings will need to be confirmed 
in larger Phase3 studies.
Funding: Commercial Support - Bayer AG
Table1. VEGF concentrations at baseline and last visit
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CKD: Clinical, Outcomes, Trials - II
Primary Efficacy Analyses from a Phase 2 Trial of the Safety and Efficacy 
of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic 
Kidney Disease
Pablo E. Pergola,1 Gerald B. Appel,8 Ahmed M. Awad,9 Judith A. Betts,11 
Geoffrey A. Block,2 Melanie Chin,7 Lesley Inker,3 Colin J. Meyer,7 
Anjay Rastogi,4 Dana Rizk,5 Kevin Schroeder,10 Arnold L. Silva.6 1Renal 
Associates, PA, San Antonio, TX; 2Colorado Kidney Care, Denver, CO; 3Tufts 
Medical Center, Boston, MA; 4Division of Nephrology, University of California 
at Los Angeles Medical Center, Los Angeles, CA; 5University of Alabama, 
Birmingham, AL; 6Boise Kidney & Hypertension Institute, Meridian, ID; 7Reata 
Pharmaceuticals, Irving, TX; 8Columbia University College of Physicians and 
Surgeons, Scarsdale, NY; 9Clinical Research Consultants, LLC, Kansas City, 
MO; 10Ohio Kidney Consultants, Columbus, OH; 11Austin Kidney Associates, 
Austin, TX.
Background: Bardoxolone methyl (BARD) has been shown to significantly increase 
eGFR in patients with CKD and type 2 diabetes or Alport syndrome suggesting that the 
anti-inflammatory and anti-fibrotic effects of BARD may target common pathways 
contributing to GFR loss in multiple forms of CKD. Inflammation seems to correlate with 
disease initiation and progression in polycystic kidney disease (PKD). As a result, a Phase 2 
trial (PHOENIX, NCT03366337) was initiated to determine if BARD will improve kidney 
function in patients with autosomal dominant PKD (ADPKD).
Methods: The open-label, multicenter study enrolled 31 patients with ADPKD with 
genetic confirmation of PKD1 mutation. Eligible patients (18 to 65 years of age) had eGFR 
values between 30 to 90 mL/min/1.73 m2 and urine albumin to creatinine ratio (UACR) 
≤ 2500 mg/g. Patients received BARD at an initial dose of 5 mg, dose-escalated up to 20
mg (for patients with baseline UACR ≤ 300 mg/g) or up to 30 mg (for patients with baseline 
UACR > 300 mg/g) and were treated for 12 weeks. The primary efficacy endpoint was the 
change from baseline eGFR after 12 weeks of treatment. Interim results are described herein.
Results: At data cutoff on May 15th, 2018, all 31 of the patients had completed 
Week 4 and 8/31 (26%) had completed the study. From a mean (±SE) baseline eGFR of 
47.7 ± 2.4 mL/min/1.73 m2, BARD treatment resulted in a significant increase in eGFR 
of 6.6 ± 0.9 mL/min/1.73 m2 (n=31; p<0.0001) at Week 4 and 12.0 ± 1.4 mL/min/1.73 m2  
(n=8; p<0.0001) at Week 12. The improvements were consistent, all 8 (100%) of the patients 
had increases in eGFR at Week 12. UACR was not significantly different from baseline. No 
patients have discontinued from the study and no serious AEs considered related to BARD 
have been reported in this ongoing trial.
Conclusions: BARD was generally well tolerated and significantly increased eGFR in 
patients with ADPKD. In patients with other forms of CKD, short term eGFR increases with 
BARD are predictive of durable eGFR improvements and additional studies are needed to 
study the longer-term effects of BARD on eGFR in ADPKD.
Funding: Commercial Support - Reata Pharmaceuticals
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One-Year Data Report from “CARDINAL”: A Phase 2/3 Study of 
Bardoxolone Methyl in Patients with Alport Syndrome
Geoffrey A. Block,1 Pablo E. Pergola,2 Bernard V. Fischbach,9 Lesley Inker,3 
Peter A. McCullough,4 Melanie Chin,5 Colin J. Meyer,5 Michelle N. Rheault,6 
Clifford E. Kashtan,6 David G. Warnock,8 Oliver Gross.7 1Colorado Kidney 
Care, Denver, CO; 2Renal Associates, PA, San Antonio, TX; 3Tufts Medical 
Center, Boston, MA; 4Baylor University Medical Center, Dallas, TX; 5Reata 
Pharmaceuticals, Irving, TX; 6University of Minnesota, Minneapolis, MN; 
7University Medicine Goettingen, Goettingen, Germany; 8Medicine, University 
of Alabama Birmingham, Birmingham, AL; 9Dallas Nephrology Associates, 
Fort Worth, TX.
Background: A Phase 2/3 trial (CARDINAL, NCT03019185) was initiated to 
determine if bardoxolone methyl (BARD) will improve eGFR in patients with Alport 
syndrome (AS). Primary efficacy analyses from the Phase 2 portion of the trial previously 
showed that BARD increased eGFR by 13.4 mL/min/1.73 m2 (n=30, p<0.0001) after 12 
weeks of treatment. Interim results for patients who have completed 48 weeks of treatment 
are described herein.
Methods: The Phase 2 open-label portion of the trial enrolled patients on stable RAAS 
blockade, ages 12 to 60 years, with confirmed diagnosis of AS, eGFR values from 30 to 90 
mL/min/1.73 m2, and urinary albumin to creatinine ratio (UACR) ≤ 3500 mg/g. Patients 
received once-daily doses of BARD at 5 mg and dose-escalated to 20 mg or 30 mg (for 
patients with baseline UACR > 300 mg/g), as tolerated. Following the Week 48 visit, 
patients stopped receiving BARD during a 4-week withdrawal period before completing 
the Week 52 visit.
Results: As of May 15, 2018, 13/30 (43%) of the enrolled patients had received 48 
weeks of treatment, and 8 patients had Week 52 data. Treatment with BARD produced 
mean increases in eGFR of 14.0 mL/min/1.73 m2 at Week 48 (n=13; 95% CI: 9.5 to 18.5; 
p<0.0001). Moreover, after one year of treatment with BARD and withdrawal of drug, 
eGFR remained above baseline with mean increases in eGFR of 5.6 mL/min/1.73 m2 at 
Week 52 (n=8; 95% CI: 0.3 to 10.9, p=0.04). Geometric mean UACR also increased, but 
log UACR/eGFR ratios were unchanged from baseline. The most commonly reported AE 
was muscle spasms, which were generally mild to moderate in severity, with no evidence of 
muscle toxicity. No drug-related serious AEs or discontinuations had been reported in the 
ongoing Phase 2 portion of the trial at the time of data cutoff.
Conclusions: In patients with AS, BARD was generally well tolerated and produced 
improvements in kidney function that were sustained for up to one year and remained 
significantly above baseline following treatment withdrawal. The Phase 3 double-blind, 
randomized, placebo-controlled portion of the trial that will enroll up to 150 patients is 
underway.
Funding: Commercial Support - Reata Pharmaceuticals
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A Randomized Trial of Ferric Citrate in Advanced CKD: Safety
Geoffrey A. Block,1 Martha Persky,5 Rupal Mehta,2 Tamara Isakova,2 
Myles Wolf,3 Glenn M. Chertow.4 1Colorado Kidney Care, Denver, CO; 
2Feinberg School of Medicine, Northwestern University, Chicago, IL; 3Duke 
University, Durham, NC; 4Stanford University School of Medicine, Palo Alto, 
CA; 5Denver Nephrology Research Division, Denver, CO.
Background: We hypothesized that provision of fixed dose ferric citrate (FC), 
independent of serum phosphate (P) or degree of anemia, would improve multiple 
biochemical manifestations of advanced chronic kidney disease and reduce associated 
complications.
Methods: Patients with eGFR ≤ 20 ml/min (50% eGFR ≤ 15 ml/min), P ≥3.0 mg/dL, 
hemoglobin (Hb) >8.0 g and who were not anticipated to start dialysis within 8 weeks were 
randomized 2:1 to received fixed dose FC, (two per meal) or standard of care treatment 
(SOC). 199 patients (133 FC, 66 SOC) attended at least 1 follow-up visit. Patients were 
seen monthly for 9 months, or, for individuals who started hemo- or peritoneal dialysis, for 
3 months thereafter.
Results: Baseline characteristics were similar with the exception of diabetes, which 
was more common in the SOC arm. Mean baseline eGFR was 14 ml/min. Table 1 shows 
the proportion of patients with any AE and serious AEs by treatment arm. “Gastrointestinal” 
(GI) was the only SOC in which related AE’s occurred in ≥ 5% of FC patients: discolored 
feces (28%), constipation (12%) and diarrhea (9%). No related serious adverse events 
occurred. Annualized admission rates were lower with FC than with SOC (median (10%, 
90% range), 0 (0,1.9) versus 0 (0,5.2), Wilcoxon Rank Sum p=0.001). After adjusting for 
age, race, sex, baseline eGFR and diabetes, treatment with FC significantly reduced hospital 
admissions (p=0.002) and hospital days (p=0.0006).
Conclusions: In this randomized, unblinded trial in patients with advanced CKD, 
treatment with fixed-dose FC resulted in an increase in GI AEs and a reduction in annualized 
hospital admission rates and hospital days. Larger, placebo-controlled trials of FC in this 
patient population are warranted to determine the reproducibility of these findings.
Funding: Commercial Support - Keryx
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Effects of Renal Denervation in Patients with Versus Without CKD: Results 
from the Global SYMPLICITY Registry with Follow-Up Data of 3 Years
Roland E. Schmieder,1 Felix Mahfoud,2 Giuseppe Mancia,5 
Krzysztof Narkiewicz,9 Luis M. Ruilope,6 Markus P. Schlaich,3 Bryan Williams,4 
Michael Böhm,7 Christian Ott.8,10 1University Hospital Erlangen, Erlangen, 
Germany; 2University of the Saarland, Homburg, Germany; 3The University of 
Western Australia, CRAWLEY, WA, Australia; 4University College London, 
London, United Kingdom; 5University of Milan-Bicocca, Milan, Italy; 6National 
Instituto of Health, Spain, Madrid, Spain; 7Kardiology, Saarland University 
Medical Center, Homburg, Germany; 8Friedrich-Alexander University 
Erlangen-Nürnberg, Erlangen, Germany; 9Medical University of Gdansk, 
Gdansk, Poland; 10Department of Nephrology and Hypertension, Paracelsus 
Medical University, Nuremberg, Germany.
Background: Activity of the sympathetic nervous system (SNS) is increased in 
hypertensive patients with chronic kidney disease (CKD). We tested the hypothesis that 
hypertensive patients with CKD enrolled in the Global Symplicity Registry (GSR) show 
different patterns in blood pressure (BP) outcomes in the short- and long-term follow-up.
Methods: The GSR (NCT 01534299) is a prospective, open-label, international, 
multicentre observational study for assessment of safety and effectiveness of renal 
denervation (RDN) among real-world patients treated with the Symplicity™ RDN system 
(Medtronic, Santa Rosa, CA, USA). Inclusion criteria are age ≥18 years and eligibility 
for RDN. 24-h ambulatory BP was assessed at pre-specified time-points (6, 12, 24 and 
36 months). For the current analyses, enrolled patients (N=1600) were stratified based 
on baseline estimated glomerular filtration rate in <60 vs. ≥60ml/min/1.73m2 into with 
(N=383) and without (N=1217) CKD groups.
Results: Patients with CKD were significantly older (p<0.0001) and were treated with 
more antihypertensive medications (p<0.0001) compared to patients without CKD. 24-h 
ambulatory diastolic (but not systolic) BP was lower in patients with compared to without 
CKD (152.9±19/81.3±13 vs. 153.2±18/87.2±14 mmHg, p=0.6380/<0.0001), resulting in 
an increased pulse pressure. In patients with and without CKD, 24-h ambulatory BP was 
reduced after RDN compared to baseline values at all time-points (all p<0.01). There was 
no difference in 24-h ambulatory systolic BP reduction after RDN in favor of patients with 
compared to without CKD, even after adjustment (Table).
Conclusions: Hypertensive patients with CKD did not show a greater short-term or 
long-term decrease in 24-hour ambulatory BP.
Changes in ambulatory BP (mmHg)
*adjusted for baseline 24-h ambulatory BP, age and gender
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Meta-Analysis on the Effects of Intensive (INT) Blood Pressure (BP) 
Control on Incident CKD and ESRD
Srinivasan Beddhu,1 Robert E. Boucher,1 Adhish Agarwal,1 Terrence S. Bjordahl,1 
Debra L. Simmons,1 Linda F. Fried,2 Sankar D. Navaneethan.3 1University of 
Utah School of Medicine, Salt Lake City, UT; 2VA Pittsburgh Healthcare System, 
Pittsburgh, PA; 3Baylor College of Medicine, Sugar Land, TX.
Background: We examined the hypothesis that the effects of INT BP control on kidney 
outcomes could differ by the level of baseline kidney function.
Methods: We performed a literature search and included studies that met one of the 
following criteria: 1. included participants without CKD at baseline and data for incident 
CKD were available and 2. included participants with stage 3/ 4CKD and data for ESRD 
available. We excluded BP studies that randomized by medications but not a BP goal, 
lifestyle intervention studies, with follow-up < 1 year or did not report the above outcomes. 
The estimates were pooled using a random effects model.
Results: Of the 3470 potentially relevant studies, 30 studies were extracted and 8 
studies were included for analysis. There were 625 incident CKD events in 6560 non-CKD 
participants in 3 studies (Fig 1). Compared to the standard BP goal, intensive BP lowering 
had higher risk of incident CKD (RR 2.08, 95% CI 1.41 to 3.05). There were 210 ESRD 
events in 2759 CKD participants during the trial phase in 7 studies (Fig 2, panel A) with 
a RR of 0.94 (95% CI 0.79-1.12) for intensive vs. standard BP control. Two (MDRD and 
AASK) studies reported legacy folllow-up ; including these there were 483 ESRD events 
with a RR of 0.91, 95% CI 0.82-1.01 (Fig 2, panel B).
Conclusions: While INT BP lowering has higher risk of incident CKD in non-CKD, 
it might potentially reduce the risk of ESRD in CKD. Further RCTs of INT BP lowering in 
CKD participants are warranted to establish the risk-benefit ratio.
Effects of intensive BP control on incident CKD in non-CKD participants
Effects of intensive BP control on ESRD in participants with CKD in main trial phase (panel 
A) and entire legacy follow-up (panel B)
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Effects of Alkali Therapy on Renal Outcomes: A Systematic Review and 
Meta-Analysis
Sebastian O. Hultin, Christopher J. Hood, Nigel D. Toussaint, David W. Johnson, 
Sunil V. Badve. Australasian Kidney Trials Network, Sydney, NSW, Australia.
Background: Preclinical studies suggest that treatment of metabolic acidosis may slow 
the progression of chronic kidney disease (CKD). The aim of this systematic review is to 
summarize evidence from randomized controlled trials (RCTs) concerning the benefits and 
risks of alkali therapy on renal outcomes.
Methods: Medline, Embase and Cochrane Central Register of Controlled Trials were 
searched for RCTs with at least 3 months of follow-up in patients with CKD defined as 
eGFR <60mL/min/1.73m2 or the presence of albuminuria that reported renal outcomes. 
Treatment effects were summarized using random-effects meta-analysis.
Results: Eight trials involving 679 participants (median sample size 80, median 
follow-up 12 months) evaluating sodium bicarbonate treatment were eligible for inclusion. 
Of these, 3 trials were a placebo-controlled studies. Overall, risk of bias was unclear or 
high risk. Compared to no study medication or placebo, treatment with sodium bicarbonate 
resulted in slower decline in kidney function (7 trials, standardized mean difference [SMD] 
for change from baseline in glomerular filtration rate or creatinine clearance 0.29 [95%CI 
0.11, 0.48]. Sodium bicarbonate abrogated increases in serum creatinine from baseline (4 
trials, weighted mean difference [WMD] -0.07 [95%CI -0.12, -0.03] mg/dL) and reduced 
the risk of end-stage kidney disease (4 trials, risk ratio [RR] 0.44 [95%CI 0.22, 0.88]). 
Sodium bicarbonate had uncertain effects on proteinuria (3 trials, SMD -0.27 [95%CI -0.59, 
0.05]) and systolic blood pressure (6 trials, WMD 0.27 [95%CI -3.01, 3.56] mm Hg). Data 
for effects of sodium bicarbonate on death and adverse events were scant.
Conclusions: Alkali therapy with sodium bicarbonate may slow the progression of 
CKD. Adequately powered RCTs are required to evaluate the benefits and risks of alkali 
therapy in CKD.
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Are Treatment Effects on eGFR Decline Greater in Patients with Faster 
Underling Disease Progression? A Report from an NKF FDA Workshop
Tom Greene. CKD-Epidemiology Collaboration University of Utah, Salt Lake 
City, UT.
Background: Analyses at the individual and trial level support the validity of eGFR 
slope as a surrogate endpoint in chronic kidney disease (CKD) RCTs. The gain in statistical 
power for eGFR slope vs. the clinical endpoint of doubling serum creatinine or kidney 
failure is limited if treatments reduce the rate of eGFR decline proportionally to the rate 
of CKD progression (attenuating slopes of fast more than slow progressors), rather than 
uniformly (attenuating slopes independent of progression rate) [Greene et al, this meeting]. 
By definition, proportional effects, but not uniform effects, attenuate the standard deviation 
(SD) as well as mean of eGFR slopes. We describe the effects of treatments on the slope SD 
in past RCTs to inform selection of endpoints in future RCTs.
Methods: We used mixed effects analyses to estimate treatment effects on the mean 
and SD of eGFR slopes after 3 months follow-up (chronic slopes) for 47 CKD RCTS 
(59074 patients), and used meta-regression to relate the ratio of the chronic slope SDs to 
the ratio of mean chronic slopes between treatment and control groups while accounting for 
random error in each RCT.
Results: The figure shows that treatments that reduce the mean chronic slope also often 
reduce the SD, indicating that effective treatments tend to slow progression more in faster 
than in slower progressors. The slope of the meta-regression line is 0.45 ± 0.13, about half 
way between 0 (corresponding to uniform effects) and 1 (corresponding to proportional 
effects), suggesting treatment effects are usually intermediate between uniform and 
proportional.
Conclusions: Effective treatments usually reduce CKD progression by effects that are 
intermediate between uniform and proportional. For intermediate effects, our simulation 
studies demonstrate that slope-based endpoints can substantially reduce required sample 
sizes and follow-up times when there is no acute effect and baseline eGFR is high [Greene 
et al, this session].
Funding: Private Foundation Support
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Optimizing Patient Enrollment in Clinical Trials Based on Albuminuria 
Inclusion Criteria
Simke W. Waijer,1 Skander Mulder,1 Michele Provenzano,3 Vlado Perkovic,2 
Hiddo J. Lambers Heerspink.1,2 1University Medical Center Groningen, 
Groningen, Netherlands; 2The George Institute for Global Health, Newtown, 
NSW, Australia; 3Second University of Naples, Naples, Italy.
Background: Clinical trials in CKD enroll patients with elevated urinary 
albumin:creatinine ratio (UACR) levels to enrich the population for high renal risk patients. 
Screen failure rates are often high due to high intra-individual variability in UACR. We 
tested whether a screening approach with more flexible UACR thresholds would decrease 
screen failure rate without adversely impacting on overall study duration.
Methods: We performed a post-hoc analysis on data from the ALTITUDE trial. We 
selected patients randomized to placebo treatment with a baseline UACR >300 mg/g and 
eGFR between 30 and 60 ml/min/1.73m2 at the first visit (pre-screening). We then used 
stepwise lower UACR cut-offs at the next qualifying visit (e.g. 300 (base scenario), 210, 
150, 30 mg/g) as inclusion criteria. For each scenario we calculated the number of eligible 
patients and number of renal endpoints (ESRD/ doubling serum creatinine/ renal death). 
Based on these data we performed simulations for a future trial. We calculated the duration 
of enrollment and total duration of the clinical trial to accrue 961 endpoints, which provided 
90% power to detect a 20% risk reduction assuming a renal event rate of 5.6% (base 
scenario).
Results: 848 patients (median UACR 1239 mg/g; median eGFR 44 ml/min/1.73m2) 
were eligible for the base scenario. Lowering the UACR qualification threshold increased 
the number of eligible patients (thus decreasing screen failures) and resulted in only a 
modest decrease in average renal event rate. In simulations, lowering the UACR cut-off 
accelerated enrollment and did not increase overall trial duration to reach 961 events.
Conclusions: Relaxing UACR based inclusion criteria in a population with 
documented UACR levels in the protocol required range decreases screen failure rates 
without prolonging trial duration. This approach may increase recruitment feasibility and 
site investigators’ motivation.
Table 1
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Using E-Consults in Nephrology to Improve Renal Care: A 5-Year 
Experience in the Miami VAMC
Antonio A. Armstrong,2 Lumen A. Mendez Castaner,2 Emilian A. Cristea,3 
Lorena Cuebas-Rosado,4 Daniel J. Soberon,4 Vasuki N. Venkat,4 
Marco A. LadinoAvellaneda.1 1Miami VA Medical Center/University of Miami/ 
Jackson Memorial Hospital, Plantation, FL; 2Jackson Memorial Hospital, Orlando, 
FL; 3University of Miami, Lauderhill, FL; 4Miami VA Hospital, Miami, FL.
Background: Electronic consultations (E-consults) are defined as asynchronous, 
consultative, provider-to-provider communications within a shared electronic health record 
or web-based platform. The primary objective of an E-consult is to expedite and improve 
patient care by increasing access to specialty knowledge and expertise without the need for 
a face-to-face visit. E-consults provide a virtual clinical discussion by the specialist after the 
information is reviewed and returned with suggestions and recommendations. Our review 
study evaluates our 5-year experience using this consultative method.
Methods: This is a retrospective study that evaluated 745 E-Consults for the 
Nephrology section at the Miami VAMC during a 5-year period (2013-2018). Data was 
obtained and included the following: gender, age, reason for the consult, time to answer 
the consult and improvement of the patient’s condition after the consult. A simple survey 
was given to the referring health care provider to evaluate the quality of the E-consult and 
their satisfaction.
Results: The nephrology section answered the consult in an average of 40 hours. 95% 
were male patients (N=708), median age was 62.3 years old. The reasons for consulting: 
Chronic Kidney Disease 54% (N=401), proteinuria workup and co-management 16% 
(N=118), uncontrolled hypertension 12% (N=90), recommendations and clearance to 
use medications in patients with CKD grades III, IV and V 7% (N=52), electrolyte and 
metabolic disorder management 6% (N=43), contrast-induced nephropathy prevention 
5% (N=41). 82% (N=611) of the E-consults resolved the referral, 18% (N=134) of the 
E-consults needed the patient to have a face-to-face encounter. In a scale from 1-5, where 
5 is the highest and 1 lowest, health care providers satisfaction was 4.5, quality of the
E-consult was 4.7, consult answer their concerns was 4.4. All health care providers (N=22) 
stated that they will continue to use E-consults.
Conclusions: E-consults improve the care of patients with renal conditions. They 
decrease waiting times and facilitate the access and evaluation of patients that need 
evaluation of a nephrologist. Referring health care providers were satisfied with the 
outcome of the E-consult and will continue to use in the renal care of their patients.
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The Effect of Integrated Care on the Rate of GFR Decline: A Community 
Hospital Approach
Teerawat Thanachayanont,1 Kriang Tungsanga.2 1Nephrology, 
Bhumirajanagarindra Kidney Institute, Bangkok, Thailand; 2King Chulalong 
Memorial lHospital, Bangkok, Thailand.
Background: Due to limited amount of nephrologists in Thailand, most of CKD 
patients are taking care by primary care physicians especially in the rural area. To improve 
the quality of CKD care in the community hospital level, we had designed the integrated care 
model which composed of 2 main components including hospital-based multidisciplinary 
team (MDT) and community care network (CCN) at village level. In our previous study, 
integrated care model was effective in slowing progression of CKD. It is challenging if this 
model could be implemented in routine practice.
Methods: We are conducting a quasi experimental study. Patients aged 18-70 years old 
with stage 3 or 4 CKD were enrolled from 5 district hospitals. All patients were managed 
by integrated care teams. Hospital-based MDT provided group education, individual 
counselling in addition to standard CKD care. CCN team performed individual counseling 
and monitoring on proper lifestyle modification, protein and salt intake assessment. All 
patients will have hospital visit every 3 months and will receive home visit by CCN twice 
a year.
Results: 914 stage 3 and 4 CKD patients were enrolled. Mean age was 62±6.13 years. 
37.2%,43.7%,19.1% of the cohort were in CKD stage 3A, 3B and 4, respectively. Diabetic 
kidney disease was the leading cause of CKD. Mean eGFR at baseline were 40.38±10.26 ml/
min/1.73 m2. Baseline SBP and DBP were 128±17.07 and 73±10.56 mmHg, respectively. 
79.9% of the study cohort had negative proteinuria by urine dipstick. The rate of eGFR 
change at 1 year of follow-up was – 0.838±10.06 ml/min/year. Patients with baseline BP 
less than 140/90 mmHg had a slower rate of eGFR decline when compared with patients 
with baseline BP 140/90 mmHg or more [-0.554±10.53vs-1.62±8.50 ml/min/year;P=0.04]. 
Patients with baseline proteinuria 1+ or more had greater rate of eGFR decline than those 
with negative proteinuria [-2.35±11.26vs-0.401±9.77 ml/min/year;P=0.001].
Conclusions: Our study revealed that this integrated care model has a beneficial 
effect on slowing the rate of eGFR decline in CKD stage 3-4 patients. Baseline BP and 
degree of proteinuria are 2 main factors that were significantly associated with greater rate 
of eGFR decline. Our study shows that the integrated care model could be successfully 
implemented at the community hospital level. It seems promising this integrated care could 
be implemented in another developing countries.
Funding: Private Foundation Support
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Cost Analysis of a Virtual Monitoring System to Reduce Suboptimal 
Initiation of Dialysis
Drew Hager,1 Thomas W. Ferguson,1 Navdeep Tangri,1 Paul Komenda,2 
Stewart Nadurak,1 Claudio Rigatto.3 1Seven Oaks General Hospital, Winnipeg, 
MB, Canada; 2University of Manitoba, Winnipeg, MB, Canada; 3Chronic 
Disease Innovation Centre, Winnipeg, MB, Canada.
Background: Patients with kidney failure require renal replacement therapy in the 
form of dialysis or kidney transplant to survive. Optimal initiation of dialysis includes 
outpatient, elective implementation of a patient’s chosen modality once clinical indications 
for dialysis are met. Despite interdisciplinary nephrology care teams, suboptimal initiation 
requiring hospitalization occurs in approximately 30% of patients and is estimated to cost 
Canadians $33 million per year. Virtual monitoring in high-risk chronic kidney disease 
(CKD) patients may decrease the rate of suboptimal initiations and therefore decrease 
hospitalization expenses. The objective of this study is to evaluate the cost savings of a 
virtual monitoring program in high-risk CKD patients.
Methods: We constructed a decision analytic Markov model from the perspective 
of the Canadian health payer. A virtual monitoring strategy was compared with the status 
quo. Costs of a suboptimal initiation, CKD multidisciplinary clinic care, and for receiving 
dialysis were taken from a review of the literature. Probability of kidney failure was 
calculated based on the Kidney Failure Risk Equation (Tangri et al, JAMA, 2011), and 
risks of mortality on dialysis and with late stage CKD were taken from national dialysis 
registries. Effectiveness of the intervention was assumed to be similar to other virtual 
monitoring interventions in chronic disease patients and evaluated in sensitivity analyses 
(baseline relative risk reduction (RRR) of a suboptimal dialysis start 0.39).
Results: Compared with the status quo the virtual monitoring system was associated 
with a cost savings of $762.29 per patient enrolled in the intervention. With threshold 
analysis we found that the RRR of a suboptimal dialysis start afforded by the intervention 
would have to be reduced to 0.255 to reach cost neutrality. In univariate sensitivity analyses 
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the most influential variables included the probability of kidney failure per month, the 
relative risk reduction afforded by the intervention, the hospitalization cost of a suboptimal 
dialysis initiation, and the proportion of kidney failure starts that are assumed to be 
suboptimal.
Conclusions: Allocation of funds toward implementation of a virtual monitoring 
system with the potential to decrease rates of suboptimal dialysis initiation can produce 
significant cost savings.
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The End of the CKD Journey - Who Starts Renal Replacement Therapy 
and Who Dies Without It Among CKD Patients in Public Renal Speciality 
Practices in Queensland, Australia
Wendy E. Hoy,2,1 Jianzhen Zhang,2,1 Zaimin Wang,1 Anne Cameron (Salisbury),2,1 
Helen G. Healy,2,1 Andrew J. Mallett,2,1 Sree Krishna Venuthurupalli.3 NHMRC 
CKD.CRE and CKD.QLD Collaborative 1The University of Queensland, 
Brisbane, QLD, Australia; 2NHMRC CKD.CRE & CKD.QLD, Brisbane, QLD, 
Australia; 3Toowoomba Hospital, Toowoomba, QLD, Australia.
Background: Persons with CKD who start renal replacement therapy (RRT) in 
Australia are well characterised, but the characteristics and outcomes of those who do not 
start RRT are less well understood. We examined the fate of patients with CKD in selected 
public renal specialty clinics in Queensland (in the CKD.QLD registry) and compare those 
who started renal replacement therapy (RRT) with those who died without RRT.
Methods: 6,371 patients in CKD.QLD (54% males, mostly CKD stages 3b, 4 and 5), 
were followed from date of informed consent until the start of RRT, death, or a censor date 
of June 30, 2016. Outcomes and causes of death were ascertained from Queensland Health 
records. Median follow-up (IQR) was 2.8 (3) years, with a total of 15,714 person years.
Results: By the censor date, 605 (9.5%) patients had started RRT, at a median (IQR) 
age of 63 (20) years and 837 (13.1%) had died without RRT, at median (IQR) age 78 years 
(14). RRT incidence rates per 100 person years for males and females respectively were 
3.8 vs 2.7, p=0.001, and death rates were 5.8 vs 4.8, p=0.001. Among deaths without RRT, 
377 (45.5%) mentioned terminal ESKF or chronic renal failure, an additional 193 (23.3%) 
mentioned CKD, and 57 (6.9%) mentioned AKI, with no gender differences.
Conclusions: Most of these patients with relatively advanced CKD experienced a 
“renal death” (started RRT or died with ESKF). Rates were higher for males. More died 
without RRT than started RRT. They were relatively distinct populations: average ESKF-
free survival was 15 years longer for patients who did not start RRT (78 vs 63 years). About 
half the deaths without RRT were ESKF deaths, while another 30% mentioned a renal 
diagnosis. Ascertainment renal failure and CKD in death certificates was very good.
Funding: Government Support - Non-U.S.
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Developing a System to Track and Reinstate Kidney Patients Lost to 
Follow-Up
Lowell J. Lo. UCSF Nephrology & Hypertension Faculty Practice Clinic Team 
Medicine, UCSF, San Francisco, CA.
Background: In the care of chronic diseases, reducing the patients lost to follow-up 
(LTFU) is an important way to improve outcomes. At our tertiary academic center, we 
identified that approximately 24% of patients seen over six months had been instructed 
to follow-up in the clinic but did not within the recommended time frame. We designed 
a method to trigger an alert for these patients and contact them to schedule appointments.
Methods: Leveraging alerts from our electronic medical record (EMR), we generated 
an LTFU report that identifies patients who did not return to the clinic as requested by 
the providers. The alerts were dependent on physician participation in an EMR follow-up 
trigger. Clinical staff called these patients and classified them into three groups: scheduled 
(appointment made successfully), no need to return (patients transitioned to dialysis, 
transferred to another nephrologist, or died), or call back (unable to reach or refused 
appointment). We also recorded individual conditions that could contribute to LTFU.
Results: Physician participation in the EMR trigger system was 76.5%. Over nine 
months, using our EMR alert and calling system, we reduced the percentage of LTFU 
patients from 24% to 3.8%. Of the 418 LTFU patients, we successfully scheduled 225 
(54%) patients, identified 34 (8.1%) no need to return patients, and continued to reach out 
monthly to 157 (38%) patients. Among patients LTFU, a majority did not provide a reliable 
method to be contacted.
Conclusions: Retention in care is associated with improved outcomes. Our study 
identified a method by which patients LTFU were identified. Majority of the patients were 
able to have appointments successfully scheduled. Vulnerable patients may benefit from 
early identification of risk of LTFU. A limitation of our study is that we lack outcome data 
on patients who were LTFU and the development and implementation of the system is 
time-intensive.
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Longitudinal Kidney Care Program and Its Impact on Decreasing 
Hospitalizations and Increasing Home Dialysis as the First Choice for 
Dialysis
Saravanan Balamuthusamy,1 Aruna Govindaraju,2 Manonmani Ellappan,3 
Ranjit K. Dhelaria,5 Alagarsamy l Reddi,4 Roshni Veerappan ganesan,6 
Balamurugan P. Sankarapandian.5 1Research, PPG healthcare, Fort Worth, TX; 
2PPG Health, Fort Worth, TX; 3PPG Health/ TRI, Fortworth, TX; 4Texas 
Research Institute and PPG Healthcare PA, Fort Worth, TX; 5PPG Healthcare, 
Fort Worth, TX; 6Texas Research Institute, Fort Worth, TX.
Background: The economic and morbidity burden of kidney disease has substantially 
increased in the past decade. With innovations on the pipeline for novel dialysis modalities, 
there is a lack of system-based practice applications in patients with kidney disease to 
decrease hospitalizations. We have initiated a systematic approach in educating patients 
with renal failure based on risk of progression to end stage kidney disease and assessed its 
efficacy in decreasing hospitalizations.
Methods: Retrospective analysis of patients in our nephrology practice who 
were hospitalized between January 2017 to January 2018. Also the rates of early home 
dialysis initiation were analyzed. ESRD patients were not included in the analysis for 
hospitalizations. The reason for hospitalizations were based on the admission diagnosis.
Results: The database included 4367 patients at low risk of progression and 1954 
patients at a higher risk of progression based on the NKF heat map. The aggregate episode 
rate for hospitalization per 100 patients was calculated. The rate of hospitalizations was 
computed for three years. The first year serves as a control as the LKCP was not initiated at 
that time. The 2 years after that is when the program was actively implemented. The results 
are shown in Figures 1 and 2.
Conclusions: There is a significant reduction in hospitalizations and early initiation of 
home dialysis with a well-structured kidney care program that includes a multidisciplinary 
approach. These methods need to be validated in a much larger cohort for mortality risk and 
cost savings calculated with real time data from payors.
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Improving Patient and System Outcomes Through Integrated Care for 
CKD
Monica C. Beaulieu,1,2 Mark Canney,3,2 Dilshani Induruwage,2 Adeera Levin.1,2 
BC Kidney Care Committee 1St. Paul’s Hospital and University of British 
Columbia, Vancouver, BC, Canada; 2BC Provincial Renal Agency, Vancouver, 
BC, Canada; 3University of British Columbia, North Vancouver, BC, Canada.
Background: In British Columbia Canada, patients with Chronic Kidney Disease not 
on dialysis (CKD-ND) are cared for by interprofessional kidney care clinics (KCC’s) using 
an integrated chronic disease model of care within a system which includes decision support 
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and clinical pathways, a single information system, feedback and audit systems, process 
and outcomes measures, provincial education of health care providers, policy makers, and 
patients, and dedicated patient focused funding. The BC-KCC’s are integrated into a larger 
province wide renal network, with accountability for patient and system outcomes.
Methods: We describe the impact of a series of initiatives in KCC’s to standardize 
education and support decision making and access for home- based therapies (HBT), 
conservative care (CC) and pre-emptive transplantation (Tx) over time. Initiatives were 
introduced sequentially, using change management and adult education principles, 
with materials developed by a diverse group of health care professionals and supported 
administratively with provincial dissemination.
Results: In March 2018, the cohort has 10,979 pts; mean age 71, median GFR 33 ml/
min/1.73m2 at registration; 54% are male, 50% DM and 43% have CVD. 1285 new pts and 
1017 pts exited KCC. Table 1 describes the 6 monthly prevalence of key outcomes over 
time. Documented treatment decisions for those with GFR <20 have increased slightly, as 
has formal symptom assessments, and numbers of pts choosing and starting on HBT and 
following conservative care pathways.
Conclusions: An integrated approach based on fundamentals of chronic care models 
has led to improved patient outcomes systemwide in BC.
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Emerging Treatment Options for Anemia Associated with CKD: Success 
of Online Medical Education at Improving Knowledge and Confidence of 
Nephrologists
Amy Larkin,1 David R. Anderson,3 Karen Badal.2 1Medscape Education, 
Nicholasville, KY; 2WebMD, New York, NY; 3Medscape LLC, New York, NY.
Background: As emerging therapies hold promise to improve treatment of anemia in 
patients with CKD, clinicians are in need of updates on development of new drugs that 
may ultimately influence their practices. We sought to assess baseline knowledge related to 
emerging treatments for CKD-related anemia and determine if online continuing medical 
education (CME) activities could improve the clinical knowledge and confidence of 
nephrologist in the area of Hypoxia-Inducible Factor Prolyl Hyproxylase Inhibitors (HIF-
PHIs).
Methods: The effect of two online, CME-certified, roundtable video discussion 
activities were analyzed to determine efficacy of online education. Three multiple-choice 
knowledge/competence questions and 1 self-efficacy confidence question were presented 
both before and immediately after each activity. A repeated pairs pre-/post-assessment 
study design was used and McNemar’s chi-squared test (5% significance level, P <.05) 
assessed educational effect for each activity. The activities launched November 18, 2016 
and December 21, 2016, and data were collected through December 20, 2016 and February 
1, 2017, respectively.
Results: In total, 264 nephrologists answered all pre-/post-assessment questions and 
were included in the study. Overall improvements were seen after participation in both 
CME activities: 10% more nephrologists (P=.035) correctly identified safety and efficacy 
data for an emerging HIF-PHIs 38% more nephrologists (P<.001) accurately characterized 
recently released data from a Medicare population of CKD patients On the 2 activities, 43% 
(n=126) and 38% (n=138) reported increased confidence in understanding of new therapies 
in development for the treatment of iron deficiency anemia in patients with CKD Continued 
educational gaps: About a third of nephrologists did not recognize new data presented at a 
major medical conference related to emerging HIF-PHIs
Conclusions: This study demonstrates the success of online, video-based roundtable 
discussion on improving knowledge and confidence of nephrologists related to emerging 
treatments for anemia associated with CKD. Continued knowledge gaps were identified for 
future educational targets.
Funding: Commercial Support - Developed through an independent educational grant 
from AstraZeneca
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A Streamlined Electronic Decision Support for the Management of 
Patients with CKD
Abraham W. Aron,1 Stewart H. Lecker,2 Martin R. Pollak,2 Ali Poyan-Mehr.2 
1Department of Internal Medicine, Beth Israel Deaconess Medical Center, 
Boston, MA; 2Division of Nephrology, Beth Israel Deaconess Medical Center, 
Boston, MA.
Background: Caring for patients with CKD requires the management of multiple 
medical conditions and is highly complex, data-driven and difficult to consolidate. 
Increased time spent on electronic health records (EHRs) is frequently perceived as an 
impediment to patient-centered care and has been shown to increase physician burnout. We 
have created a streamlined, electronic dashboard and decision support tool to consolidate 
CKD management, enhance efficiency and improve the clinician’s work experience.
Methods: A total of 6 core content areas, 14 decision support notifications and over 90 
data elements were systematically arranged into a single dashboard within our institution’s 
EHR. This was further enriched by links to professional literature and patient handouts. To 
assess the impact of this decision support tool, we conducted a survey amongst providers at 
our single tertiary care center.
Results: We received over 300 responses. 12% were Nephrology attendings/fellows, 
24% were primary care physicians and 64% were medical residents. Amongst responders, 
60% used the tool in their clinical practice. It is used primarily in the outpatient setting 
(69%), and most frequently for the assessment of CKD etiology/stage (48%), management 
of mineral and bone disorders (29%) and anemia management (22%). The streamlined 
CKD dashboard and decision support tool was considered by 56% of respondents as helpful 
in preventing physician burnout.
Conclusions: While EHRs are frequently cited as a major source of physician burnout, 
an enhanced user interface can lead to an improved work experience. The widespread 
voluntary adoption of our CKD dashboard and electronic decision support suggests 
opportunities for EHRs to impact CKD management, enhance efficiency, and improve 
the clinician’s work experience. Our data further suggests benefits of augmenting decision 
support and automated guidance while caring for patients with CKD.
Figure 1. User deomgraphics of the decision support tool.
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Implementation of a CKD Panel Management Tool for Resident 
Physicians
Frederick M. Howard, James J. Connolly, William Ackley, Kaoru Harada, 
Steffne J. Kunnirickal, Naseema B. Merchant, Mark A. Perazella. Yale School of 
Medicine, Cheshire, CT.
Background: Chronic kidney disease (CKD) affects approximately 1 in 7 adults and 
over one million Veterans served by the Veterans Health Administration (VHA). These 
patients are at increased risk for numerous adverse sequelae, including anemia, metabolic 
acidosis (MA), proteinuria, mineral bone disease (MBD), and hypertension. Clinical practice 
guidelines have been published by the Kidney Disease: Improving Global Outcomes work 
group to assist clinicians in managing the sequelae of CKD, but guideline compliance was 
low in a test cohort of patients cared for by residents working at a VHA Medical Center.
Methods: We designed a panel management tool to provide an automated summary of 
guideline-based interventions relevant to each patient seen in clinic. Residents received up 
to 16 recommendations per patient – eight focusing on work-up of anemia, five on MBD, 
and one each on uncontrolled hypertension, evaluation for albuminuria, and correction of 
MA. Guideline compliance, both overall and for specific domains of care, was compared 
pre- and post-intervention using a two-sided t-test.
Results: We identified 365 encounters with patients with at least stage III CKD (eGFR 
< 60 ml/min/1.73 m2) during the six months prior to intervention, and 272 encounters in the 
first four months of our intervention. Guideline compliance increased from 53.5 ± 1.3% pre-
intervention to 61.0 ± 2.5% post-intervention (p < 0.01). In a subgroup analysis, there were 
significant improvements in MBD testing (40.0 ± 2.4% vs 53.0 ± 2.9%) and albuminuria 
screening (25.6 ± 2.0% vs 42.1 ± 3.3%).
Conclusions: Implementation of a panel management tool achieved significant 
improvement in overall guideline compliance, with particular efficacy in the domains of 
MBD and albuminuria screening. The short time course of the intervention may have limited 
our ability to assess for improvement in blood pressure control and MA. This effective tool 
could be universally applied to improve the management of CKD by VHA providers.
Funding: Veterans Affairs Support
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eGFR in the Emergency Department as a Predictor of In-Hospital 
Mortality in Pneumonia
Chung-te Liu.1,2 Division of Nephrology, Department of Internal Medicine, Wan 
Fang Hospital, Taipei Medical University 1Division of Nephrology, Department 
of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, 
Taiwan; 2Graduate Institute of Clinical Medicine, College of Medicine, Taipei 
Medical University, Taipei, Taiwan.
Background: Pneumonia is a global leading cause of mortality. Severity-assessment 
scores in pneumonia are crucial for guiding the treatment. Community-based studies have 
demonstrated the association between pre-existing low estimated glomerular filtration rate 
(eGFR) and outcomes in pneumonia. However, whether a single eGFR measurement in 
the emergency department can predict in-hospital mortality in pneumonia remains to be 
investigated.
Methods: This hospital-based, retrospective cohort study was conducted at Wan Fang 
Hospital and included 1554 patients hospitalized with pneumonia between January 2013 
and December 2015. Patients under 20 years of age were excluded. The main predictor 
was eGFR in the emergency department calculated according to the equation suggested by 
Chronic Kidney Disease Epidemiology Collaboration. The outcomes included in-hospital 
mortality, intensive care unit (ICU) admission, need for ventilator, durations of hospital and 
ICU stay, and ventilator use. Receiver operating characteristic (ROC) curve and Youden 
criteria for determining the optimal cut-off value of eGFR to predict in-hospital mortality 
were used and confirmed using a multivariate logistic regression model.
Results: Of 1554 patients, 263 (16.9%) had chronic kidney disease (CKD) and 
demonstrated higher C-reactive protein (CRP) levels and SMART-COP score and more 
events of multilobar pneumonia, acute kidney injury, ICU admission, and in-hospital 
mortality. Patients with higher pneumonia severity scores tended to have lower eGFR. eGFR 
of 55.89 mL/min/1.73m2 was the optimal cut-off value for predicting in-hospital mortality. 
Multivariate logistic regression analysis adjusted for sex, co-morbidities, CRP, liver 
function tests, and SMART-COP score demonstrated that eGFR <55.89 mL/min/1.73m2 
had odds ratio of 3.2 (95% confidence interval: 2.3–4.4) for in-hospital mortality.
Conclusions: Low eGFR in the emergency department is associated with higher 
pneumonia severity. eGFR <55.89 mL/min/1.73m2 is an independent predictor of in-
hospital mortality in patients hospitalized with pneumonia.
FR-PO260 Poster Friday
CKD: Clinical, Outcomes, Trials - II
The Effect of Peer Mentoring on Active Engagement Among Patients with 
Advanced CKD
Said Al Zein, Mo’Tasem Alkhasoneh, Tara Liaghat, Nasrollah Ghahramani. 
Penn State College of Medicine, Hershey, PA.
Background: Peer mentoring is an effective strategy in patient education and has been 
proposed as an effective model for active patient engagement. This study compares the 
effect of peer mentoring (face-to-face and online) with usual care on active engagement 
among patients with chronic kidney disease (CKD).
Methods: Patients with stage 4 or stage 5 CKD were randomly assigned either to face-
to-face (FTF) peer mentoring, online peer mentoring, or usual care (control). For the FTF 
group, the frequency of contact by a mentor was weekly by phone and monthly FTF visit. 
For the online mentorship, the frequency of contact by mentor was weekly by the online 
platform, and more frequently as initiated by the mentee. The mentorships were maintained 
for at least 6 months. Usual care participants received a printed copy of an information 
handbook and were encouraged to discuss questions with their care team. We used the 13-
item validated Patient Activation Measure® (PAM) at baseline and at 12 months to assess 
change in level of engagement. Univariate and multivariate analyses were used to compare 
the change in PAM scores from baseline to 12 months.
Results: A total of 130 patients completed the 12 month assessment. Baseline PAM 
score and demographic characteristics (mean age, educational attainment, gender and race 
distribution) were similar among the 3 groups. There was a significant improvement in the 
mean PAM score for the online peer mentoring group (69.7±15.6 vs. 76.44 ± 13.96; p=0.02). 
There was a slight (non-significant) improvement in PAM among the FTF group and no 
change in PAM among the control group. Improvements in PAM stage (by at least one 
level) were seen among 33% of the FTF, 48.7% of the online and 22.7% of the control 
group. PAM was decreased by at least one stage among 36% of the FTF, 12.8% of online 
and 31.8% of control group.
Conclusions: Compared with face-to-face mentoring and information only education, 
online peer mentoring is associated with improved scores in Patient Activation Measure and 
PAM stage among patients with advanced CKD. Funding: PCORI
Funding: Other U.S. Government Support
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The Effect of Peer Mentoring on Caregiver Burden Among Caregivers of 
Patients with CKD
Mo’Tasem Alkhasoneh, Said Al Zein, Tara Liaghat, Nasrollah Ghahramani. 
Penn State College of Medicine, Hershey, PA.
Background: Caregivers play a fundamental role in the treatment and management of 
patients with chronic kidney disease (CKD). Caregiver burden may result from providing 
care to patients with CKD and is often overlooked by clinicians. Peer mentoring is an 
effective educational strategy which may result in improvement in caregiver burden. This 
study compares the effect of peer mentoring (face-to-face and online) with usual care on 
caregiver burden among caregivers of patients with CKD.
Methods: A 16-hour structured program trained CKD patients and their caregivers 
to become peer mentors to newly diagnosed patients with CKD and their caregivers. 
Caregivers of patients with stage 4 or stage 5 CKD were randomly assigned either to face-
to-face (FTF) peer mentoring, online peer mentoring, or usual care (control). For the FTF 
group, the frequency of contact by a mentor was weekly by phone and monthly FTF visit. 
For the online mentorship, the frequency of contact by mentor was weekly by the online 
platform, and more frequently as initiated by the mentee. The mentorships were maintained 
for at least 6 months. Usual care participants received a printed copy of an information 
handbook about care of the patient with CKD. We used the Zarit Burden Interview (ZBI) 
to measure caregiver burden at baseline and at 12 months. The ZBI is a self-administered 
questionnaire of 22 items, which measures the impact of caregiving in psychological, 
physical and social domains. The items are ranked on a five-point Likert scale and the total 
score is calculated; higher scores indicating heavier burden. Univariate and multivariate 
analyses were used to compare the change in ZBI scores from baseline to 12 months.
Results: A total of 61 caregivers completed the 12 month assessment. Baseline ZBI 
score and demographic characteristics (mean age, highest grade of education, gender and 
race distribution) were similar among the 3 groups. There was a significant decrease in the 
mean ZBI score for the online mentoring group (23.9±10.7 vs. 12.8 ± 12.3; p=0.03). There 
was a slight (non-significant) improvement in ZBI among the FTF group and among the 
control group.
Conclusions: Compared with face-to-face mentoring and information only education, 
online peer mentoring is associated with improved scores in caregiver burden among 
caregivers of patients with advanced CKD. Funding: PCORI
Funding: Other U.S. Government Support
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Optimizing the Utility of Patient Experience Surveys to Advance the 
Quality of Renal Care
Helen Chiu,1,2 Gloria T. Freeborn,1 Ognjenka Djurdjev,1 Sushila Saunders,1 
Adeera Levin.3 1BC Renal Agency, Vancouver, BC, BC, Canada; 2Providence 
Health Care Research Institute, Vancouver, BC, Canada; 3St. Paul’s Hospital 
and University of British Columbia, Vancouver, BC, Canada.
Background: Patient experience is an essential indicator for advancing person-
centred care. Although many patient experience measures are validated in chronic disease 
populations, how they can be utilized in guiding improvement in renal care is understudied. 
Thus, we verified how results of a validated patient experience survey can be used to guide 
improvement in the continuum of renal care.
Methods: A validated 20-item instrument, Patient Assessment of Chronic Illness 
Care (PACIC), was mailed out to >13,000 eligible patients receiving non-dialysis and 
dialysis care in British Columbia, Canada. The responses were descriptively analyzed by 
subscale (five dimensions in PACIC) and modality of care. Priority matrix analysis was also 
performed to identify specific areas of improvement.
Results: Nearly 4,000 patients responded (30% response rate). More than 75% of 
respondents rated the overall quality of kidney services as “excellent” or “very good.” 
Based on the survey responses, the area of highest satisfaction was the overall organization 
and delivery of care, and areas of improvement included “goal setting” and “follow-up.” 
Priority matrices by modality identify unique improvement opportunities (Fig 1) not 
otherwise apparent from conventional analysis by highlighting aspects of care highly 
associated with overall perception of the renal services quality.
Conclusions: Measuring patient experience across a diverse renal population yields 
important insights. When analyzed with respect to the overall perception of quality of 
kidney services, the utility of PACIC results is enhanced in that it can guide strategic action 
planning specific to each modality of renal care, with a greater potential for positively 
impacting those living with kidney disease.
Funding: Government Support - Non-U.S.
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Fig 1. Priority matrices by modality
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Impact of a Phone App on the Referral to Nephrology
Nestor Oliva-Damaso,1 Elena Oliva-Damaso,2 Francisca Lopez,1 
Maria M. Castilla,1 Jose C. Rodriguez-Perez,3 Juan Payan Lopez.1 1Hospital 
Costa del Sol, Marbella, Spain; 2Hospital General Universitario de Gran 
Canaria Dr Negrin, Las Palmas, Spain; 3University Hospital, Las Palmas Gran 
Canaria, Spain.
Background: Several factors might influence nephrology referral decisions by 
clinicians, including lack of training about guidelines regarding timing or indications. In the 
21st century tools as phone apps can make knowledge more accessible.
Methods: Prospective quasi-experimental study. We studied referral to nephrology in 
the Hospital Costa del Sol of 2015. In 2016 we perform formative lectures to the principal 
departments that refer patients to nephrology of phone “Nefroconsultor” that recommends 
referrals attending to KDIGO criteria. We studied referral of 2017 after intervention.
Results: 628 patients with a mean age of 68 years-old, 63% were male, a 
mean creatinine at time of referral of 1,5mg/dL and a glomerular filtration rate of 
46 ml/min/1,73m2 (CKD-EPI). Comparing before and after intervention, previous 
implantation of phone app 333 patients were referred while after 295 patients were referred, 
a 10,1% less (p=0,001). There were no differences in age (p=0,13); gender (p=0,197); serum 
creatinine (p=0,59) and glomerular filtration rate CKD-EPI (p=0,41). In 2015, 132 patients 
of 333 met stablished KDIGO criteria of referral (39,8%) while in 2017 200 patients of 
295 (60,2%) and considered well referred (p=0,001). The increase of intervention success 
was of a 28,8% (binomial effect size display with Cohen’d effect size of 0,751). Previous 
the app 208 patients of 333 (63,2%) were referred with data of albuminuria while after 
258 of 295 patients (89% p=0,001). The increase of intervention success was of a 25,7% 
(Cohen’d effect size of 0,744). Referral including urine sediment improved from a 69,3% 
to 87,2% (p=0,001) with an increase of intervention success of 12,2% (Cohen’d 0,28). 
Multivariate regression analysis using referral meeting KDIGO criteria as dependent 
variable and adjusting by age, sex and department of provenance, 2017 was associated 
with a correct referral with a odds ratio of 3,57 (IC 95%: 2,52-5,05) compared to 2015 
(p=0,001). Proteinuria as the reason of referral to nephrology also increased from a 24% 
to a 34,8% (p=0,004).
Conclusions: The use of a tool as phone app (Nefroconsultor) improves the referral 
to nephrologist a 28,8% attending to referral stablished criteria. The app also increases the 
study of albuminuria and urine sediment at the moment of referral, increasing proteinuria as 
reason of referral. UNDER REVIEW CJASN.
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Evaluation of the Efficacy of CKD Support Decision-Making Application: 
How It Changes Home Blood Pressure and Kidney Functions
Shiho Kosaka,1 Junichi Hoshino,2 Yoshifumi Ubara,2 Masami Hamada,3 
Masayuki Yamanouchi,2 Akinari Sekine,2 Keiichi Sumida.4 1Graduate school of 
Health Sciences, Tokyo Medical and Dental University, Tokyo, Japan; 
2Toranomon Hospital, Tokyo, Japan; 3Nagoya university, Nagoya, Japan; 
4Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Background: Disease management in patients with chronic kidney disease (CKD) is 
complicated. Appropriate information provision and daily self-monitoring of parameters 
such as blood pressure are required. Therefore, this study aimed to evaluate how a chronic 
kidney disease support decision-making application (CKD-SDM) app in patients with CKD 
affects the blood pressure, kidney functions, and disease-management knowledge at home.
Methods: This study was a randomized, controlled trial involving 54 patients with 
stage 3, 4, or 5 non-dialysis CKD. The intervention group was provided with a tablet 
equipped with the CKD-SDM app. An automated sphygmomanometer for home blood 
pressure monitoring (HBPM) was used in both groups for 8 weeks. The primary outcome 
measure is change in HBPM data from baseline to 8 weeks. Secondary outcomes are 
changes in renal functions and self-management knowledge level on CKD.
Results: The mean (SD) age, eGFR, and HBPM (morning and evening) of participants 
were 70.7±11.0 years, 37.0±14.4 ml/min per 1.73 m2, and 133.7±11.5/78.3±8.9 and 
130.5±13.4/76.0±8.9 mmHg, respectively. No significant differences between groups 
were observed at baseline. After 8 weeks, HBPM reduction in both groups were -5.8/-
1.5 vs. -3.1/-0.7 mmHg in the morning and -6.1/-3.3 vs. -4.0/-1.5 mmHg in the evening, 
with no significant differences between the two groups. In the female intervention group, 
the morning systolic blood pressure (SBP) difference significantly decreased, -7.7 vs. 
-2.6 mmHg (p<0.05). All kidney functions were not significantly different. Similarly, 
the self-management knowledge level on CKD was not significantly improved in the 
intervention group.
Conclusions: Eight weeks of intervention with CKD-SDM app did not reduce the 
overall HBPM, despite the improved SBP observed in the female intervention group. In 
the future, we have to plan larger and long-term studies to evaluate HBPM reduction and 
kidney functions in patients with CKD. Trial Registration: This study is registered in the 
UMIN Clinical Trial Registry (000025792).
Funding: Government Support - Non-U.S.
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CKD: Clinical, Outcomes, Trials - II
Patient Language and Guideline-Concordant Care Among Individuals 
with CKD in Primary Care
Sarah Rosenwohl-Mack,1 Anna Rubinsky,2 Leah Karliner,1 Lenny Lopez,1 
Carmen A. Peralta.2 1University of California, San Francisco, San Francisco, 
CA; 2University of California San Francisco/SFVAMC, San Francisco, CA.
Background: Patients with a language barrier are at risk for poor communication and 
inadequate management of chronic conditions. We assessed the quality of Chronic Kidney 
Disease (CKD) management in primary care for non-English speakers compared to English 
speakers.
Methods: Using EHR data (2014-2015), we evaluated the association of non-English 
language preference with guideline-concordant care among adults with CKD in a primary 
care clinic in San Francisco where interpreters are available. Outcomes included: testing for 
albuminuria (all) and A1c (patients with diabetes); prescription of ACEi/ARB and statins; 
BP at goal < 140/90 and A1c<7 (patients with diabetes). We used multivariate modified 
Poisson regression to estimate relative risks of each outcome.
Results: Among 1,726 patients, mean age was 66 ±10, 26% were Asian, 14% Black and 
7% Hispanic. 88% had Medicare and 10% Medicaid. Compared to English speakers, non-
English speakers had higher prevalence of comorbidities (cerebrovascular disease, 16% vs. 
12%; diabetes, 57% vs. 41%; and hypertension, 89% vs. 81%) and more frequent primary 
care visits, but similar eGFR (49 vs. 48 ml/min/1.73m2). In unadjusted comparisons, non-
English speakers were more likely to be tested for albuminuria and have a prescription for 
statins, but there were no differences in ACEi/ARB prescription, BP or A1c control. After 
adjustment, differences were mostly attenuated.
Conclusions: Overall, most guideline measures were sub-optimally met. However, 
there was consistent care across language preference: in a single clinic with access to 
professional interpreters, non-English language preference was not associated with 
differences in guideline-concordant processes of care for CKD.
Funding: NIDDK Support
Rates of Guideline-Concordant Care by Language Preference
*Fully adjusted (age, sex, race, insurance type, number of PC visits in the study period,
CKD stage, count of comorbid conditions if applicable)
FR-PO266 Poster Friday
CKD: Clinical, Outcomes, Trials - II
Evaluation of CKD Symptom Management Algorithms and Patient 
Information Sheets in Two Kidney Care Clinics
Puneet Vashisht,4 Judith G. Marin,1 Nadia Y. Zalunardo,2 Monica C. Beaulieu,3 
Hilary Wu.5 1Providence Health, North Vancouver, BC, Canada; 2Gordon & 
Leslie Diamond Health Care Ctr., Vancouver, BC, Canada; 3University of 
British Columbia, North Vancouver, BC, Canada; 4Lower Mainland Pharmacy 
Services, Vancouver, BC, Canada; 5Vancouver General Hospital, Vancouver, 
BC, Canada.
Background: As renal function declines, symptoms related to chronic kidney disease 
(CKD) become more prevalent and impact quality of life. To address symptom management 
systematically in patients with eGFR ≤ 15 mL/min not on dialysis, the British Columbia 
Provincial Renal Agency (BCPRA) developed 8 symptom management algorithms and 
patient information sheets. The objectives of this project are to assess patients’ symptom 
burden before and after implementation of these tools and to assess patient and staff 
satisfaction.
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Methods: We conducted a prospective quantitative and qualitative study at 2 Kidney 
Care Clinics (KCCs). Five patients who were followed with the symptom management 
algorithms for nausea, low appetite, pruritis, and fatigue/insomnia were interviewed to 
assess satisfaction with care received via the algorithms and patient information sheets. 
Symptom burden was assessed pre and post algorithm use using a validated symptom 
assessment tool (Edmonton Symptoms Assessment Score (ESAS)). Next, focus groups with 
renal nurses (RNs) and renal dieticians (RDs) were conducted to assess provider satisfaction 
with the tools.
Results: Following assessment of 5 patients, ESAS score improved for 4 patients after 
a mean (SD) follow up of 80 (13) days. Patients reported that recommendations provided 
were somewhat helpful for symptom and quality of life improvement and that the patient 
information sheets were helpful and easy to use. Of the 13 RNs and RDs in the focus 
groups, 12/13 were satisfied or very satisfied with the algorithms and 13/13 were satisfied 
or very satisfied with the patient information sheets. Major themes identified by patients and 
providers included their satisfaction with the ability to improve standardized care, patient 
education, patient-centered care, accountability, and follow-up.
Conclusions: Following implementation of BCPRA symptom management 
algorithms, we were able to show a reduction in symptoms for patients with a GFR 
≤ 15 mL/min not on dialysis using validated symptom management tools. Patients and 
providers found the information sheets/algorithms helpful and easy to use.
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CKD: Clinical, Outcomes, Trials - II
The Prevalence of Uremic Symptoms and Their Association with Adverse 
Outcomes in CKD
Tariq Shafi,1 Eugene P. Rhee,2 James P. Lash,3 Chi-yuan Hsu,4 Dominic S. Raj,5 
Jonathan J. Taliercio,6 Bernard G. Jaar,7 Jing Chen,8 John W. Kusek,10 
Jeffrey C. Fink,11 James H. Sondheimer,12 Harold I. Feldman,9 Eliseo Guallar.13 
CRIC Study 1Johns Hopkins University, Baltimore, MD; 2Massachusetts 
General Hospital, Newton, MA; 3University of Illinois at Chicago, Chicago, IL; 
4University of California San Francisco, San Francisco, CA; 5George 
Washington University, Washington, DC; 6Cleveland Clinic, Cleveland, OH; 
7Johns Hopkins University, Baltimore, MD; 8Tulane School of Medicine, New 
Orleans, LA; 9University of Pennsylvania, Philadelphia, PA; 10NIDDK, 
Bethesda, MD; 11University of Maryland, Baltimore, MD; 12Wayne State 
University School of Medicine, Detroit, MI; 13Johns Hopkins Bloomberg School 
of Public Health, Baltimore, MD.
Background: Fatigue, anorexia, and pruritus are important patient-reported symptoms 
of CKD. Their prevalence and association with adverse outcomes in patients with non-
dialysis dependent CKD have not been well established or characterized.
Methods: Among 3,639 participants of the ongoing Chronic Renal Insufficiency 
Cohort Study (CRIC), we assessed fatigue, anorexia, and pruritus using the KDQOL-36, 
administered at baseline and then annually. We calculated a uremic symptom score 
(U-Score) by averaging the 3 symptom scores for each person. We determined the time-
varying association of each symptom and the U-Score with the risk of CKD progression 
(50% reduction in eGFR or ESRD), death and first cardiovascular disease (CVD) events, 
using Cox models adjusted for demographic, clinical, and laboratory variables, including 
eGFR and albuminuria.
Results: At baseline, mean age was 58 yrs and eGFR was 45 ml/min/1.73m2. The 
prevalence of fatigue was 52%, anorexia, 21%, and pruritus, 42%; each were associated 
with lower eGFR (p<0.001). During a median follow-up of 6.1 yrs, a higher U-Score (more 
symptoms) was significantly and positively associated with all outcomes (Table). Each 
individual symptom was associated with the risk of CKD progression; anorexia and fatigue 
were associated with death; none of the individual symptoms was associated with first CVD 
event.
Conclusions: A uremic symptom score, derived from three commonly reported 
symptoms, is associated with adverse outcomes in patients with non-dialysis dependent 
CKD. Our findings highlight the importance of patient-reported symptoms and underscore 
the need for unraveling their pathogenesis.
Funding: NIDDK Support
Association of Uremic Symptoms with Outcomes
1HR per 10-point higher score (more symptoms). 
2HR for presence vs. absence of symptoms. 
Adjusted: age, sex, race, income, education, marital status, smoking, alcohol use, DM, 
HTN, CVD, BMI, eGFR, BUN, albumin, cholesterol, urine albumin
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Perceived Significance of Engagement in CKD Research Priority Setting 
Among Stakeholders: A Qualitative Study
Meghan J. Elliott,1 Zahra S. Goodarzi,1 Joanna Sale,4 Linda A. Wilhelm,3 
Brenda Hemmelgarn,1 Sharon Straus.2 1University of Calgary, Calgary, AB, 
Canada; 2Li Ka Shing Knowledge Institute, Toronto, ON, Canada; 3Canadian 
Arthritis Patient Alliance, Midland, Kings County, NB, Canada; 4St. Michael’s 
Hospital, Toronto, ON, Canada.
Background: Patients and other stakeholders are increasingly engaging as partners 
in research, although how they perceive such experiences, particularly over the long term, 
is not well understood. We sought to characterize how participants from a chronic kidney 
disease (CKD) research priority-setting project conducted two years previously perceived 
the significance of their involvement.
Methods: This was a qualitative study involving participants across Canada from a 
prior CKD research priority-setting project. We purposively sampled across stakeholder 
roles (i.e. patients with non-dialysis CKD, caregivers, healthcare professionals, and 
policymakers) and engagement types (i.e. involvement on the project’s steering committee 
and/or final prioritization stage). We conducted individual, in-depth Interviews, which we 
analyzed using an inductive, thematic analysis approach.
Results: We conducted 23 interviews across all stakeholder roles and engagement 
types, and characterized three themes. Participants identified research engagement as 
an opportunity to facilitate integration of distinct CKD stakeholder communities (i.e. 
patients/caregivers and healthcare professionals/researchers). All participants appreciated 
the experiences that stakeholders, and particularly patients, brought to research, which 
furthered their understanding of the CKD lived experience and the value of patient-oriented 
research. Stakeholders suggested that their involvement in the project helped re-focus their 
commitment CKD research and care, which encompassed a subsequent interest in research 
engagement and patient-centered care approaches.
Conclusions: When reflecting on their of experience engaging in CKD research 
prioritization, stakeholders viewed the significance of their involvement in relation to the 
integration of different CKD communities, an appreciation of the CKD experience, and a re-
focusing of their commitment to research and CKD care. Findings highlight considerations 
for future health research that engages stakeholders, and in particular those living with CKD 
or other chronic illnesses, as research partners.
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Accurate Estimation of Arterial pH from Venous pCO2 and Venous CO2: 
An Easy Solution to an Old Problem
Sheeba H. Ba aqeel, Daniel Batlle. Northwestern University Feinberg School of 
Medicine, Chicago, IL.
Background: Plasma CO2 from venous blood (vTCO2 or vCO2) is often used as a 
surrogate for arterial bicarbonate (aHCO3). Arterial PCO2 (aPCO2) can be estimated from 
the venous PCO2 (vPCO2) using regression equations derived from correlative studies. If 
the pH is recalculated using vPCO2, the HCO3 (numerator in the Henderson Hasselbalch 
equation) is also impacted thereby limiting the accuracy of the corrected pH. We reasoned 
that with proper validations of vCO2 as a surrogate for aHCO3 and vPCO2 corrected to 
reflect aPCO2, the arterial pH (apH) can be readily estimated from venous blood and the 
venous pH will not be needed. Here we tested this concept.
Methods: We analyzed a de-identified database of venous and arterial blood gases 
performed in the clinical lab of Northwestern Medicine, Chicago, USA. ABG, VBG and 
electrolyte panel were examined in 113 samples obtained simultaneously. Additionally, 
concurrent data for arterial and venous PCO2 obtained from 3911 samples and collected 
from various hospital departments was used for a regression equation to calculate aPCO2 
from vPCO2. Pearson correlations and Bland-Altman analysis were done to examine the 
limits of agreement.
Results: vCO2 was in close agreement with the aHCO3 (R2=0.93 P<0.001; 95% 
limits of agreement were 2.89 to -2.89 mmol/L, mean bias= -0.2 ±1.59). aPCO2 was 
estimated from vPCO2 to yield corrected PCO2 (cPCO2) using a regression equation, 
cPCO2=2.3+0.82*vPCO2. The apH was then calculated using this cPCO2 and vCO2 
as follows: apH = 6.1 + log vCO2 / 0.03 x cPCO2. The corrected apH showed a close 
correlation and agreement with measured apH (R2=0.81 P<0.001 (fig1) and 95% limits of 
agreement 0.46 to -0.39, mean bias 0.04±4.4)
Conclusions: 1)CO2 values in venous blood are in close agreement with aHCO3 
calculated from the ABG. Accordingly, vCO2 can substitute for aHCO3 to recalculate the 
pH 2)The corrected vPCO2 and the measured vCO2 allow for an accurate calculation of 
apH which is close to measured apH. Moreover, this avoids altogether the measurement of 
venous pH which is not a good reflection of apH.
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Anion Gap (AG) Improves the Prediction of Ionized Hypocalcemia (HC) 
in Critical Care
Ernie Yap,3 Andrea Roche-Recinos,1 Philip Goldwasser.2 1Danbury Hospital, 
Danbury, CT; 2VA New York Harbor, Brooklyn, NY; 3SUNY Downstate, 
Brooklyn, NY.
Background: The physiologically active form of total serum calcium (sCa) is ionized 
(iCa). It is reported in arterial (ABG) and venous (VBG) gas panels. The rest of sCa is 
bound, mainly to albumin (ALB), or chelated by small anions. Low ALB and high chelating 
anion levels are common in critical care patients (pts). A popular adjustment of sCa for 
ALB alone (BMJ 1977) yields a corrected value (cCa) that doesn’t detect abnormal iCa 
well in such pts, perhaps because it ignores the chelating anions. AG reflects the levels of 
both such anions and ALB, and has been shown to correlate with iCa (Nordin 1989). We 
tested whether the diagnosis of HC in critical care could be improved by accounting for 
both AG and ALB.
Methods: In 769 critical care pts, simultaneous values of sCa (units: mg/dL), ALB (g/
dL), and AG (mEq/L) were paired retrospectively with closely-timed (<20 min. apart) values 
of iCa (mM) derived from 309 ABGs (mean pH=7.390) or 460 VBGs (mean pH=7.363). 
We defined HC as iCa <1.10 in ABGs and, to adjust for the mean pH difference, as <1.11 
in VBGs. The prevalence of HC was 28% (86/309) in ABGs and 21% (95/460) in VBGs. 
A model to predict HC in the ABG cohort was generated by multiple logistic regression 
with sCa, ALB, and AG as candidate predictors. Next, this model was validated in the VBG 
cohort. Areas under the ROC curve (AUC) of the model and of cCa were compared. Data 
are summarized as means [95%CI].
Results: sCa (p<10-10), ALB (p<.004), and AG (p<10-5) were each significant 
independent predictors of HC in the ABG cohort, with odds ratios of 0.064 [.029-.142], 2.87 
[1.40-5.87], and 1.19 [1.11-1.28], respectively. The overall odds were 6,853,807×0.064sCa× 
2.87ALB×1.19AG. This model had a better AUC than cCa in both the ABG cohort (0.89 
[.84-.93] vs 0.82 [.77-.88]; p<.005) and the VBG cohort (0.89 [.86-.93] vs 0.82 [.77-.87]; 
p=.0002). The predicted HC rate and the observed rate showed good agreement in the VBG 
cohort, divided into 4 prediction subgroups, each 25% wide (Table).
Conclusions: Adjusting sCa for both AG and ALB improves the diagnosis of HC. The 
absolute probability estimates of the logistic model are intuitive and may help clinicians 
decide when to obtain an ABG.
Funding: Veterans Affairs Support
Predicted and Observed HC Rates in the VBG Cohort
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Etiology of the Elevated ΔAG/ΔHCO3 Ratio in Lactic Acidosis: Time for 
Another Delta?
Richard M. Treger,1,2 Tristan Grogan,3 Scott Rudkin.4 1Nephrology, Veterans 
Affairs, Los Angeles, CA; 2Nephrology, UCLA, Los Angeles, CA; 3UCLA, Los 
Angeles, CA; 4UCI, Orange, CA.
Background: The ratio of delta anion gap and delta bicarbonate (ΔAG/ΔHCO3) is 
used to detect co-exisiting acid-base disorders in patients with high AG metabolic acidosis. 
The ΔAG/ΔHCO3 ratio in lactic acidosis (LA) is 1.6-1.8, most commonly postulated to 
result from lactate anions remaining in the extracellular space while protons are buffered 
intracellularly. Others have proposed that hypochloremia, resulting from extrusion of 
cellular cations and resultant expansion of the extracellular compartment during the 
buffering process in LA, accounts for the increment in AG. This study examined the 
etiology of the elevated ΔAG/ΔHCO3 seen in LA.
Methods: Data were obtained prospectively from adult trauma patients at a level 1 
trauma center. Venous samples were drawn prior to administration of intravenous fluids. The 
associations between ΔLactate and ΔAG, arterial pH and ΔAG/ΔHCO3, and serum chloride 
and ΔAG/ΔHCO3 were examined using Pearson’s correlations and linear regression models.
Results: 108 patients were included. 63 patients had normal serum lactate levels 
(≤ 2.1 mM) with a mean AG of 7.1 and a mean lactate level of 1.5 mM, the values used 
to calculate subsequent ΔAG and ΔLactate values. ΔAG/ΔHCO3 was calculated for 
45 patients who had elevated serum lactate levels (>2.1 mM). The mean ΔAG/ΔHCO3 
was 1.86. The mean ΔLactate/ΔHCO3 ranged between 0.95-1.21 and the ΔLactate only 
explained 24.6% of the observed variance in the ΔAG (Figure). There was no statistically 
significant association between arterial pH or serum chloride and the ΔAG/ΔHCO3 ratio 
(p = 0.52 and 0.33, respectively).
Conclusions: The high ΔAG that results in an increased ΔAG/ΔHCO3 ratio does not 
appear to be primarily a result of increased extracellular lactate, pH-dependent contribution 
of anions or cations to the AG, or hypochloremia. Therefore, the high ΔAG/ΔHCO3 seen 
in lactic acidosis is likely a result of unmeasured organic anions, possibly including Krebs 
cycle intermediates. Further work to identify them needs to be carried out.
Funding: Veterans Affairs Support
Figure. Correlation between ΔLactate and ΔAG. r = 0.496, p = 0.001.
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Genotype, Not Lactic Acidosis, Predicts Disease Progression in a Cohort of 
MELAS Patients
Krishna rekha Moturi,4 Jifu Jin,2 Jiangtao Li,3 Ralitza H. Gavrilova,1 Qi Qian.5 
1Genetics, Mayo Clinic, Rochester, MN; 2Nephrology, Zhongshan Hospital, 
Shanghai Medical College, Fudan University, Shanghai, China; 3Nephrology, 
Tongji Hospital, Tongji University School of Medicine, Shanghai, China; 4John 
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Hypertension, Mayo Clinic School of Medicine, Rochester, MN.
Background: The clinical features of MELAS (mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes) are heterogeneous. The role of 
lactic acidosis and MELAS genotypes in disease severity and progression has not been 
clarified. This study investigated MELAS phenotype in relation to the presence/severity of 
lactic acidosis and to the MELAS genotypes (classic [m.3243A>G] and other non-classic 
mutations).
Methods: MELAS patients in the North American Mitochondrial Disease Consortium 
(NAMDC) database, hospitalized in the Mayo Clinic for MELAS-related symptoms (up to 
Jan. 2018), were enrolled. Demographics, disease course, laboratory results, neuroimaging 
and muscle biopsies were obtained.
Results: Twenty-four (24) participants (15 female) were studied. Total follow-up was 
170 person-years (median follow-up, 7.2 [IQR 1.3-11.6] years). The median age of disease 
onset was 6.5 (IQR 1.0-35.2) years. Headache, confusion, and ↓cognition were the most 
common initial presentations. 16.7% of the subjects died during the follow-up. Lactic 
acidosis, defined by serum lactate >2.2 mmol/L, was present in 83.3% of the patients with 
an average serum level 3.3±1.0 mmol/L. No significant association was found between the 
presence and severity of lactate levels and MELAS disease presentation and progression. 
33.3% and 66.7% of the subjects harbored m.3243A>G and non-classic mutations, 
respectively. Patients with m.3243A>G mutation had a higher % occurrence of diabetes, 
hearing loss, cognitive dysfunction, migraine, seizures and stroke-like episodes and a lower 
% occurrence of skeletal myopathy than the patients with non-classic mutations, 50 vs 6.3; 
100 vs 25; 87.5 vs 31.3; 75 vs 31.3; 100 vs 56.3; 75 vs 12.5; 12.5 vs 68.8, respectively (all 
P<0.05). Despite more aggressive treatment with antiepileptic, L-arginine and CoQ/Q10, 
cardiac functional and cognitive deterioration were more rapid and severe in patients with 
m.3243A>G mutation (all P<0.05). More diagnostic tests (CSF lactate, muscle biopsy and 
MRS) were performed for patients with non-classic mutations (P<0.05).
Conclusions: In this cohort of MELAS patients, the m.3243A>G mutation, not 
the presence or severity of lactic acidosis, was associated with a more severe MELAS 
phenotype.
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Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review 
and Meta-Analysis
Sankar D. Navaneethan,1 Jerry M. Buysse,3 Jun Shao,2 Dawn Parsell,4 
David A. Bushinsky.5 1Baylor College of Medicine, Sugar Land, TX; 2Tricida, 
Inc., South San Francisco, CA; 3Tricida, Inc, South San Francisco, CA; 4Parsell 
and Otto Consulting, Inc., Cedar Park, TX; 5University of Rochester Medical 
Center, Rochester, NY.
Background: Metabolic acidosis is an important risk factor for disease progression in 
chronic kidney disease (CKD) that also has significant adverse effects on muscle and bone. 
We conducted a systematic review and meta-analysis to evaluate the benefits and risks of 
treatment of metabolic acidosis with oral alkali supplements or reduction of acid load with 
dietary intervention.
Methods: We searched MEDLINE, Embase, and Cochrane Central Register of 
Controlled Trials for clinical trials (with a control group) of oral alkali supplementation or 
low acid-producing dietary intervention in stage 3-5 CKD patients for a minimum of 4 weeks. 
Data were pooled in a meta-analysis with results expressed as weighted mean difference 
(intervention versus control; WMD) for continuous outcomes and relative risk (RR) for 
categorical outcomes with 95% confidence intervals (CI) using a random effects model.
Results: Fourteen clinical trials were included (n=1810 participants). Both oral alkali 
supplementation and dietary intervention increased serum bicarbonate levels (Table). 
Treatment resulted in a slower decline in eGFR and a reduction in urinary albumin excretion, 
along with a reduction in the risk of progression to ESRD (4 trials; n=434; RR 0.32, 95% 
CI 0.18, 0.56). Important exclusions noted in the oral alkali studies were CKD patients 
with sodium-sensitive comorbidities (edema, heart failure, uncontrolled hypertension). 
Oral alkali supplementation was associated with significantly increased urinary sodium 
excretion, and trends of elevated diastolic blood pressure and increased antihypertensive 
therapy, although these trends were not statistically significant. Dietary intervention was 
associated with a significant reduction in systolic blood pressure. Included studies were of 
moderate quality.
Conclusions: In patients with CKD and metabolic acidosis, an increase in serum 
bicarbonate concentration induced either by oral alkali supplementation or reduction in 
dietary acid intake slows the rate of kidney function decline and reduces urinary albumin 
excretion.
Funding: Commercial Support - Tricida
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Serum Chloride and All-Cause Mortality in CKD
Sankar D. Navaneethan,1 Wolfgang C. Winkelmayer,1 Susana Arrigain,2 
Joseph V. Nally.2 1Baylor College of Medicine, Sugar Land, TX; 2Cleveland 
Clinic, Cleveland, OH.
Background: We studied the associations of serum chloride with all-cause mortality in 
non-dialysis dependent CKD.
Methods: We included 62,643 patients with eGFR 15-59 ml/min/1.73 m2 (twice 90 days 
apart) and had serum chloride measured using the same assay in a single health care system 
in this analysis. Cox proportional hazards model (including time-dependent) were used to 
study the associations between hypochloremia (<98 mmol/l, n=5246) and hyperchloremia 
(>110 mmol/l, n=702) with all-cause mortality while adjusting for demographics, comorbid 
conditions including heart failure, use of diuretics and kidney function.
Results: During a median follow-up of 3.8 years, 18,181 patients died. In the Cox 
proportional hazards model using baseline serum chloride levels, hypochloremia (but not 
hyperchloremia) was associated with higher risk of death. Analysis of chloride as continuous 
measure yielded similar results. Restricting the analysis to those with normal serum sodium 
(n=59,964) yielded similar results. In the model with time dependent repeated measures 
of serum chloride, both hypochloremia (HR 2.54, 95% CI 1.44, 2.65) and hyperchloremia 
(HR 1.39, 95% 1.24, 1.55) were associated with higher risk of death. Presence or absence of 
CHF didn’t modify the observed associations.
Conclusions: Among non-dialysis dependent CKD population, hypochloremia is 
associated with higher risk of death. Further studies examining the potential mechanisms 
for the observed associations are warranted.
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Chloride Increase Following Continuous Renal Replacement Therapy 
(CRRT) Initiation Is Associated with Mortality
Benjamin Griffin,1 Nigel Arruda,1 Isaac Teitelbaum,2 Anna J. Jovanovich,3 
Muhammad Aftab,4 Matthew Barhight,5 Katja M. Gist,6 Sarah Faubel.7 
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Background: Hyperchloremia is common in critically ill patients, and recent studies 
are increasingly linking elevated serum chloride with mortality. CRRT can rapidly shift 
chloride levels, and it is unclear what impact these changes have on patient outcomes. In this 
study we examined the association between changes in chloride following CRRT initiation 
and mortality.
Methods: We conducted a retrospective analysis of adult patients initiated on CRRT 
at the University of Colorado Hospital between July 2015 and September 2016. The main 
exclusion criterion was death within 24 hours of CRRT initiation. Chloride levels were 
measured upon admission to the ICU, prior to CRRT initiation, and every 8 hours thereafter 
until CRRT was discontinued. Changes in chloride were calculated from admission value 
to CRRT initiation. Changes after CRRT initiation were calculated from the first value 
following CRRT initiation to the highest value while on treatment. The primary outcome 
was in-hospital mortality. Logistic regression was used to adjust for SOFA score, body mass 
index, and gender.
Results: A total of 127 cases were included in the analysis. Average chloride on 
admission was 102 ± 6.7 mEq/L and 106 ± 8.3 mEq/L at CRRT initiation. After adjusting 
for all covariables, chloride on admission, though not at CRRT initiation, predicted 
mortality: for every 1 mEq/L increase in admission chloride there was an 8% increased 
risk of mortality. Mean changes in chloride from admission to CRRT initiation and from 
CRRT initiation to end of therapy were 3.6 ± 7.4 mEq/L and 2.8 ± 3.5 mEq/L respectively. 
Change in chloride from admission to CRRT initiation was not significantly associated with 
in-hospital mortality. Notably, change in chloride of 1 mEq/L following CRRT initiation 
was associated with a 15% increased risk of mortality.
Conclusions: Hyperchloremia upon ICU admission is associated with increased 
mortality. Increases in chloride levels following CRRT initiation are also associated with 
mortality, even after adjusting for illness severity. The role of chloride in critical illness, 
particularly in those requiring CRRT, warrants further investigation.
Funding: Other NIH Support - T32 DK 007135
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Phosphorous and Magnesium Nadirs Following Continuous Renal 
Replacement Therapy (CRRT) Initiation Are Associated with Mortality
Benjamin Griffin,1 Nigel Arruda,1 Sophia L. Ambruso,1 Joao P. Teixeira,1 
Anna J. Jovanovich,2 Sarah Faubel.3 1University of Colorado, Aurora, CO; 
2Denver VA / University of Colorado, Denver, CO; 3University of Colorado 
Denver, Denver, CO.
Background: Severe acute kidney injury (AKI) requiring continuous renal 
replacement therapy (CRRT) is common in the intensive care unit, complicating 5% of all 
admissions. As CRRT therapy fluids typically contain no phosphorus and low magnesium 
concentrations, CRRT is known to rapidly deplete these electrolytes, and their repletion 
during CRRT is often required. Studies examining the impact of these electrolyte losses 
on patient mortality have been inconclusive. The purpose of this study was to examine the 
impact of phosphorous and magnesium levels on mortality in the setting of CRRT.
Methods: We conducted a retrospective analysis of adult patients initiated on CRRT at 
the University of Colorado Hospital between July 2015 and September 2016. Patients were 
excluded if they died within 24 hours of CRRT initiation. Phosphorous and magnesium 
levels were collected at CRRT initiation and every 8 hours thereafter. The primary outcome 
was in-hospital mortality. Logistic regression was used to adjust for SOFA score, body mass 
index, and gender.
Results: A total of 155 cases were included in the analysis. Mean phosphorous and 
magnesium levels at the time of CRRT initiation were 5.4 ± 2.7 mg/dL and 2.28 ± 0.58 mg/dL, 
respectively. Neither baseline levels nor changes from baseline were associated with 
mortality. However, higher nadir levels of both phosphorous and magnesium were 
independently associated with mortality, even after adjusting for confounders.
Conclusions: While baseline phosphorous and magnesium values were not associated 
with mortality, nadir levels were. We expected lower nadir levels to be associated with 
mortality, but observed the opposite. Lower nadir levels may have been indicative of 
higher dose or higher quality of CRRT. The frequency and quantity of electrolyte repletion 
were not evaluated in this study. Further investigation into the role of phosphorous and 
magnesium in AKI requiring CRRT is warranted.
Funding: Other NIH Support - T32 DK 007135
Table 1. Final multivariate models for in-hospital mortality
* Final model was adjusted for SOFA score, body mass index, and gender
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Comparison of Indicators of Fluid Overload in Hemodialysis Patients
Erik Yarmey, Proma Mazumder, Jordan Brown, Frances Shofer, Anthony J. Dean, 
Nova Panebianco, Nathaniel C. Reisinger. University of Pennsylvania, 
Philadelphia, PA.
Background: Fluid overload (FO) contibutes to mortality in hemodialysis (HD) 
patients and is often undiagnosed. FO is determined by physical exam including systolic 
and diastolic blood pressure (SBP, DBP), lung crackles (rales), lower extremity edema 
(LEE), and jugular venous distention (JVD). Other signs of FO include serum n-terminal 
pro-BNP (BNP) and findings on chest x-ray (CXR) or thoracic computed tomography (CT). 
Point-of-care ultrasound is a as powerful tool for determination of FO via measurements of 
the inferior vena cava (IVC) and quantitative 28-point lung ultrasonography for B-line score 
(BLS). We present a cohort study of HD patients comparing indicators of FO.
Methods: Patients with ESRD on HD were enrolled from a large urban emergency 
department at a referral center. Patients were excluded if they were unable to consent. 
Indicators of FO were obtained prior to first HD including BLS (0-280). IVC size and 
collapse was graded by 2 independent observers on a 4-point scale. 10 indicators of FO 
(BLS, IVC, CXR, CT, BNP, rales, LEE, JVD, SBP, DBP) were compared against presence 
or absence of FO as determined by the treating nephrologist or on chart review.
Results: Of 101 patients enrolled, median age was 60, 51% were male, 84% identified 
as Black or African American. Comorbidities included 65% diabetic, 27% coronary artery 
disease, 33% airways disease, 40% had systolic heart failure, 75% diastolic heart failure. 
Median dialysis vintage was 33 months. Access type was 54% arteriovenous fistula, 29% 
graft, and 17% catheter. ESRD vintage was 33 months. Residual renal function was minimal. 
62% of patients had FO on arrival and 27% of visits were for FO. BLS was available for 
101 patients with median score of 34. Area under the receiver-operator characteristic curve 
(AUC) was 0.95 for BLS [95% CI 0.92-0.99] with optimal cutoff of 30. AUC was 0.60 for 
edema [0.53-0.68], 0.60 for rales [0.54-0.66], 0.53 for JVD [0.50-0.56], 0.53 for SBP [0.41-
0.65], 0.49 for DBP [0.38-0.61]. IVC was obtained on 37 patients AUC 0.78 [0.61-0.95]. 
BNP was obtained on 39 patients AUC 0.80 [0.63-0.98]. CXR was obtained on 76 patients 
AUC 0.71 [0.61-0.80]. CT was available on 20 patients AUC 0.91 [0.81-1.00].
Conclusions: Quantitative BLS outperforms conventional physical exam, serologic, 
and other imaging indicators in determination of FO in HD patients.
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Fluid Overload Is Associated with Major Adverse Kidney Events in 
Critically Ill Patients with AKI Requiring CRRT
Connor W. Woodward,1 Ye Li,2 Joshua Lambert,2 Marice Ruiz-Conejo,3,1 
Andrew Kelly,2 Brittany D. Bissell,1 Victor M. Ortiz-Soriano,1 Lenar T. Yessayan,4 
Peter Morris,1 Javier A. Neyra.1 1University of Kentucky, Lexington, KY; 
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Pines, FL; 4University of Michigan, Ann Arbor, MI.
Background: Fluid overload (FO) has been associated with adverse outcome. The 
purpose of this study was to examine the association between FO and major adverse kidney 
events (MAKE) in critically ill patients with AKI requiring CRRT.
Methods: This was a single-center, retrospective, cohort study of ICU patients that 
suffered from AKI requiring CRRT. Patients with ESRD, kidney transplant or baseline 
eGFR <15 were excluded. FO was defined as cumulative fluid balance (from hospital 
admission to CRRT initiation) expressed as a percent of admission body weight. MAKE 
was determined up to 90 days following hospital discharge and consisted of the composite 
of mortality, RRT dependence and failure to recover at least 50% of baseline eGFR if not 
on RRT. A secondary outcome of ventilator-free days was also examined. Multivariable 
logistic regression and linear regression models were conducted.
Results: A total of 481 patients were included in the study. The median (IQR) FO was 
9.9% (2.8 – 20.2%). FO ≥10% (clinical cut-off reportedly associated with adverse outcome) 
was found in 238 (49.5%) of patients on the day of CRRT initiation. MAKE was more 
frequent in patients with FO ≥10% vs <10% (79.4% vs 71.6%, p=0.047). After adjustment 
for demographics, comorbidity, acuity of illness, time from ICU admission to CRRT 
initiation, and baseline eGFR, FO ≥10% was independently associated with MAKE (OR, 
1.60, 95% CI, 1.02 – 2.52). Furthermore, for each one-day increment from ICU admission 
to CRRT initiation, there was a 3% increase in the adjusted odds of MAKE (p=0.02). FO 
≥10% was also associated with less ventilator-free days in adjusted models (p<0.01).
Conclusions: FO ≥10% on the day of CRRT initiation was independently associated
with major adverse kidney events and less ventilator-free days in critically ill patients that 
suffered from AKI requiring CRRT. FO should be a clinical parameter routinely included in 
the evaluation of CRRT need in critically ill patients.
Funding: Other NIH Support - Early Career Pilot Grant from NCATS/NIH
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Background: Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is 
common in the intensive care unit (ICU) and has a mortality rate of >50%. Fluid overload 
(FO) >10% of body weight has been shown to be deleterious in ICU patients, but studies 
specifically evaluating patients with severe AKI requiring continuous renal replacement 
therapy (CRRT) remain limited. Furthermore, the effects of volume removal following 
CRRT initiation are not well described. The purpose of this study was to examine the impact 
of (1) FO at CRRT initiation and (2) fluid removal on in-hospital mortality.
Methods: We conducted a retrospective analysis of adult ICU patients who underwent 
CRRT for a minimum of 24 hours at University of Colorado Hospital from September 
2015 to July 2016. Patients were characterized by fluid balance at initiation of CRRT and 
total volume removed by CRRT during their hospitalization. The primary outcome was 
in-hospital mortality. Logistic regression was used to adjust for Sequential Organ Failure 
Assessment (SOFA) score, gender, and body mass index.
Results: A total of 87 patients were included in the final analysis, of which 41 (47.1%) 
patients had FO >10% of body weight at the time of CRRT initiation. Negative fluid balance 
on CRRT was achieved in 64 (73.5%) patients. The adjusted odds ratio for mortality in those 
with >10% FO was 2.69 (Table 1). There was no association between mortality and negative 
fluid balance on CRRT.
Conclusions: Our study adds to prior studies showing that fluid overload is 
independently associated with increased mortality in ICU patients requiring CRRT. 
However, we found no significant association between fluid balance during CRRT and 
mortality. The effect of fluid balance on mortality in ICU patients requiring RRT, both 
before and after RRT initiation, merits further investigation.
Funding: Other NIH Support - T32 DK 007135
Table 1. Final multivariate model for in-hospital mortality
* Comparison group is Fluid Overload < 0%
^ Comparison group is Positive Fluid Balance on RRT
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Liver Stiffness Reflecting Renal Congestion Predicts Renal Outcome in 
Patients with Congestive Heart Failure
Tatsufumi Oka,1 Takayuki Hamano,2 Satoshi Yamaguchi,1 Yohei Doi,1 
Yusuke Sakaguchi,2 Isao Matsui,1 Yoshitaka Isaka.1 1Nephrology, Osaka 
University Graduate School of Medicine, Suita, Japan; 2Inter-Organ 
Communication Research in Kidney Disease, Osaka University Graduate 
School of Medicine, Suita, Japan.
Background: Renal congestion is one of the underlying mechanisms for acute kidney 
injury in congestive heart failure (CHF). Reportedly, ultrasonographic liver stiffness (LS), 
originally developed for assessment of liver cirrhosis, reflects right atrial pressure (RAP) 
with great accuracy in CHF without liver cirrhosis. However, its association with renal 
congestion and its clinical relevance remain uncertain.
Methods: In this prospective cohort study (JACC Cardiovasc Imaging 2018), we 
enrolled inhospital patients with acute heart failure in an educational hospital. LS was 
evaluated in all participants. Using longitudinal inhospital data, we investigated the 
association between time-dependent LS and kidney length. High-LS was defined as 
≥9 kPa (75 percentile, corresponding to RAP of ≥8.9 mmHg). Exposures were LS levels at 
discharge and changes in its levels during hospitalization. An outcome was eGFR change
over time after discharge. We employed a multivariable mixed effects model with time-
dependent eGFR as a dependent variable. In sensitivity analyses, we used coarsened exact 
matching to balance the baseline clinical characteristics.
Results: Among the 251 patients, median eGFR, BNP, LS at discharge, and follow-up 
were 54.7 mL/min/1.73m2, 188.7 pg/mL, 6.3 kPa, and 12.0 months, respectively. During 
hospitalization, in patients with eGFR>30 mL/min/1.73m2, LS decrease was observed 
in parallel with decrease in kidney length (P=0.01), suggesting a rationale to use LS as a 
proxy of renal congestion. After adjustment for 16 factors including BNP, ejection fraction, 
and blood pressure, patients with high-LS at discharge had lower eGFR over time than the 
rest of the patients (P=0.03) (Figure 1). In patients with LS improvement from high- to 
normal-LS during hospitalization, eGFR trajectory was higher than that in patients without 
improvement (P<0.01) and comparable to that in patients with normal-LS on admission 
(P=0.81) (Figure 2).
Conclusions: LS reflecting renal congestion predicts worse renal outcome in CHF. 
Renal function should be followed up carefully in patients with a high LS value at discharge.
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Simplified, Simulated Sodium Kinetic Modeling for Correction of 
Hyponatremia by Continuous Venovenous Hemofiltration
Junior Uduman, Naushaba Mohiuddin, Gerard Zasuwa, Jerry Yee, 
Stanley Frinak. Division of Nephrology and Hypertension, Henry Ford Hospital, 
Detroit, MI.
Background: Management of hyponatremic, oliguric patients is challenging using 
conventional dialytic therapy. Osmotherapy, targeted plasma sodium concentration [Na] 
elevation, delivered by continuous renal replacement therapy (CRRT), must be safely 
achieved without overcorrection of [Na], i.e., >6 to 8 mmol/L in 24 hours. Predictive 
modeling of controlled osmotherapy requires an appreciation of CRRT and ongoing Na 
kinetics. Utilizing an approach based on near-equivalence of Na dialysance and urea 
reduction ratio (URR), we developed a model that calculates [Na] elevations precisely using 
predilution continuous venovenous hemofiltration (CVVH), and contrasts the conventional 
strategy of using replacement fluid [Na] as the post-treatment goal [Na].
Methods: The model defines the post-treatment [Na] (NaPost) at time (t), thereby 
defining ΔNa, the difference between pre-therapy [Na] (NaPre) and NaPost. A [Na] 
gradient (,Na = NaRF – NaPre) is defined by URR, derived from Na dialysance (D). 
Because D approximates KUrea, URR is derived from Watson volume, treatment 
time, and D, determined by QB (hematocrit-adjusted blood flow rate), QRF (RF rate), 
and QUF (ultrafiltration rate). URR represents the time-varying decrease of ,Na, i.e., 
Napost = [(1 − URR) × NaPre + (URR × NaRF)] and NaRF = NaPre + (ΔNa/URR).
Results: The model calculates, tabulates, and plots time-varying NaPost. Panel 1 of 
figure displays model input and output parameters for a hypothetical scenario of an anuric 
hyponatremic patient with tabulated data and graph in panel 2. Model extensions permit 
simultaneous initial targeting of NaPost, URR, or effluent dose. Integrated calculations 
determine RF dilutions or infusion rates of parallel hypotonic solutions when RF solutions 
cannot be adjusted.
Conclusions: We conclude that safely controlled osmotherapy of oligoanuric, 
hyponatremic patients by predilution CVVH is feasible, and can determine time-varying 
NaPost. Validation of the model in various clinical scenarios of hyponatremia is required to 
support utility.
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Continues Renal Replacement Therapy: A Simple Approach for Treating 
Hyponatremia
Pooja D. Amarapurkar,1 Jiny Olickal,2 Daniel J. Watford,1 Daniel J. Soberon,3 
Vasuki N. Venkat,3 Marco A. LadinoAvellaneda.4 1Jackson Memorial Hospital/
University of Miami, Miami, FL; 2Jackson Memorial Hospital, Miami Beach, 
FL; 3Nephrology, Miami VA medical Center, Miami, FL; 4Miami VA Medical 
Center/University of Miami/ Jackson Memorial Hospital, Plantation, FL.
Background: Severe hyponatremia (serum sodium(Na) <125) is frequently seen in 
critically ill patients. Often, this is unresponsive to fluid restriction, diuretics or 3% saline. 
The combination of hyponatremia and acute kidney injury (AKI) needing continuous 
renal replacement therapy (CRRT) makes management of hyponatremia challenging. 
Indication for CRRT include acidosis, volume overload & electrolyte abnormalities. 
Dialysate/replacement fluid solutions used during CRRT have a standard Na concentration 
of 140 meq/L. When dosed at 25-30 ml/kg/hr there is a risk of rapid correction of Na 
level & osmotic demyelination syndrome. There is limited data for CRRT in correcting 
hyponatremia. Few complex formulas help to calculate the appropriate CRRT dose for Na 
correction, providing adequate clearance. We report our experience of managing 33 cases 
with severe hyponatremia using CRRT.
Methods: Out of 33 patients with severe hyponatremia, 28 had AKI stage III needing 
CRRT & 5 had ESRD. 30 patients required vasopressor support. CRRT was initiated in all 
for correction of Na at 15-25 ml/kg/hr. Pre-pump infusion of D5W was added to dilute the 
replacement fluid. All the patients had the serum Na level checked every hour for the first 3 
hours and then every 3-4 hours once a Na 125 mmol/l was reached.
Results: A steady 6-8 mmol/day rise in serum Na level was obtained along with the 
correction of other abnormalities & no complications.
Conclusions: This case series highlights the applicability of a simplified practical 
approach without using complex formulas to safely manage severe hyponatremia using 
CRRT despite a standard Na concentration in the dialysate/replacement solution. Close 
serum Na monitoring is imperative to adjust the delivered CRRT and D5W infusion doses.
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Sodium Fluctuations and Mortality in a General Hospitalized Population
Gianmarco Lombardi, Pietro Manuel Ferraro, Luca Calvaruso, Silvia D’Alonzo, 
Alessandro Naticchia, Giovanni Gambaro. Fondazione Policlinico Universitario 
A. Gemelli, Rome, Italy.
Background: Aim of our study was to describe the association between natremia (Na) 
fluctuation and hospital mortality in a general population admitted to a tertiary medical 
center.
Methods: We performed a retrospective observational study on the patient population 
admitted to the Policlinico A. Gemelli Hospital between January 2010 and December 2014 
with inclusion of adult patients with at least two Na values available on the biochemistry 
database and with a normonatremic condition at hospital admission. Patients were 
categorized according to all Na values recorded during hospital stay in the following 
groups: hyponatremia, normonatremia, hypernatremia, mixed dysnatremia. The difference 
between the highest or lowest Na value reached during hospital stay and the Na value read 
at hospital admission was used to identify the maximum Na fluctuation. Cox proportional 
hazards models was used to estimate adjusted HRs for hospital mortality with the group of 
dysnatremia and with quartiles of Na fluctuation. Covariates assessed were age, sex, highest 
and lowest Na level, Charlson-Deyo index score, cardiovascular diseases, cerebrovascular 
diseases, dementia, congestive heart failure, kidney disease, eGFR.
Results: 57,156 admissions matched inclusion criteria. Incident dysnatremia was 
independently associated with in-hospital mortality (incident hyponatremia HR 2.55, 95% 
CI 2.14, 3.04, p<0.001; incident hypernatremia: HR 5.71, 95% CI 4.69, 6.95, p<0.001; mix-
dysnatremia: HR 4.44, 95% CI 3.23, 6.10, p<0.001). We found a higher risk of in-hospital 
death by linear increase of quartile of Na fluctuation (p trend <0.001) irrespective of severity 
of dysnatremia (HR of 1.60, CI 95% 1.17, 2.20, p=0.004, in the 4th percentile Na fluctuation 
compared with the first one; Figure).
Conclusions: Fluctuation of natremia during hospital stay is a prognostic marker for 
hospital death independently by dysnatremia severity.
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Maintaining Sodium Homeostasis During Liver Transplant - A Novel 
Approach
Courtney Jones, Charuhas V. Thakar, Taranpreet Kaur. University of Cincinnati, 
Cincinnati, OH.
Introduction: Following two cases of osmotic demyelination syndrome (ODS) in 
patients with near-normal serum sodium (Na) levels (134 mEq/L) at the start of orthotopic 
liver transplantation (OLT) at our institution, we sought a systems approach for minimizing 
ODS. Many patients presenting for OLT with hyponatremia have concomitant renal 
dysfunction necessitating intraoperative continuous renal replacement therapy (CRRT). 
Intraoperative CRRT using standard dialysate with a Na concentration of 140mEq/L could 
pose a risk due to rapid Na rise. A multi-disciplinary approach was taken with anesthesiology, 
nephrology, transplant surgery, and pharmacy to create a pathway for low Na dialysate 
with a Na concentration of 130mEq/L for OLT patients with hyponatremia that also need 
intraoperative RRT. Commercially available low Na dialysate does not contain calcium 
(Ca), which requires frequent replacement at baseline during an OLT. Pharmacy presented 
the data along with a failure modes and effects analysis (FMEA) to the hospital’s drug 
policy committee and gained approval for compounding calcium into our commercially 
available low Na dialysate.
Case Description: Following implementation of our system change, a patient 
presented for OLT with a MELD-Na of 30, hepatorenal syndrome, acidosis, hyperkalemia, 
and hyponatremia (Na 124). This patient was admitted to the ICU preoperatively and 
initiated on CRRT with low Na dialysate compounded with Ca while waiting for the liver 
to arrive. Intraoperative fluid administration, transfusion, electrolytes, and acid-base status 
were managed in standard fashion plus the addition of low Na dialysate. At the end of 
the OLT, the Na had only risen to 126 over 14 hours. The low Na dialysate continued 
three additional days postoperatively in the ICU to allow the Na to gradually normalize. 
Four days after presentation, the Na was 135 and the patient was transitioned to standard 
dialysate and never developed ODS. He is currently off dialysis with an eGFR of 33.
Discussion: ODS occurs in approximately one percent of OLT patients with 
associated high morbidity and mortality. The rate of Na rise is strongly correlated with 
the development of neurologic changes and standard dialysate can contribute to that. A 
multi-disciplinary system based approach achieved patient safety and allowed a platform 
for broader implementation to hyponatremic patients without renal dysfunction.
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Hyponatremia Associated with Development of Sepsis
Win Kulvichit,1,4 Cassandra L. Formeck,1,2 Priyanka Priyanka,1 Emily L. Joyce,1,2 
Shashank Badavanahalli Rajashekar,1 Michael L. Moritz,2 Juan Carlos Ayus,3 
John A. Kellum.1 1Center for Critical Care Nephrology, CRISMA, Department 
of Critical Care, University of Pittsburgh School of Medicine, Pittsburgh, PA; 
2Department of Nephrology, Children’s Hospital of Pittsburgh, Pittsburgh, PA; 
3Renal Consultants of Houston, Houston, TX; 4Division of Nephrology, 
Department of Medicine, Faculty of Medicine, Chulalongkorn University, 
Bangkok, Thailand.
Background: Hyponatremia is a common electrolyte imbalance in critically ill patients 
and is associated with increased mortality and morbidity. Experimental evidence suggest 
that hyponatremia may compromise immune cell function. Thus, we sought to determine 
whether an association between hyponatremia and sepsis was present in critically ill adults 
and children.
Methods: Data was obtained from databases of 46,329 adult and 12,806 pediatric 
patients from the ICUs of UPMC hospitals. We included patients with a Na value measured 
within 6 hours of ICU admission and excluded patients with sepsis on admission. We 
analyzed the association between hyponatremia by severity (serum Na <135 mEq/L, mild; 
130-134 mEq/L, moderate; 125-129 mEq/L, severe <125 mEq/L) and the development of
sepsis over 7 days following the occurrence of hyponatremia.
Results: A total number of 39,403 adults and 3,977 children were included in the 
analysis. 40% of adult patients and 14% of pediatric patients had hyponatremia with rates 
of sepsis of 24% and 33% respectively. Critically ill patients with hyponatremia were at 
increased risk of developing sepsis (RR 2.43 for adult, RR 1.34 for pediatric patients). Risk 
for developing sepsis increased with the severity of hyponatremia in adults.
Conclusions: Critically ill patients with hyponatremia are at increased risk for 
developing sepsis. Further analysis is required to understand the nature of this relationship 
and to better control for confounding.
Unadjusted Relative Risk of Developing Sepsis within 3 days Following Exposure to 
Varying Degrees of Hyponatremia in Adult and Pediatric ICU Patients
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Communication of Hyponatremia and Outcomes
Kirsten Salline,2 Jeffrey I. Silberzweig,1,2 Vesh Srivatana,1,2 Clara Oromendia,3 
Stephanie Tsai.3 1The Rogosin Institute, New York, NY; 2Weill Cornell Medical 
College, New York, NY; 3Weill Cornell Medicine, New York, NY.
Background: Prior literature documents the prognostic importance of hyponatremia 
but it is commonly treated as a peripheral issue during hospital admissions. We seek to 
quantify the degree to which hyponatremia is reported to outpatient providers and to 
evaluate factors associated with communication and associations between communication 
and important clinical outcomes.
Methods: With IRB approval, we conducted a retrospective cohort study of patients 
admitted to the Weill Cornell Campus of the New York-Presbyterian Hospital in January 
2014 with corrected serum sodium <130 mEq/L who survived the index hospitalization. 
Discharge summaries were reviewed for mention of hyponatremia; charts were reviewed 
for pertinent clinical data. Patients who did and did not have hyponatremia mentioned in 
the discharge summary were compared using chi-square (or Fisher’s Exact) and Kruskal-
Wallis tests for categorical and continuous variables, respectively. Statistical significance 
was determined be at the 0.05 alpha level.
Results: Hyponatremia was mentioned in 34% of 127 discharge summaries; patients 
with communicated hyponatremia were older (mean 72 vs 63 years; p=0.003) and had 
lower nadir (125 vs 128 mEq/L; p<0.001) and discharge sodium (132 vs 135 mEq/L, 
p=0.002). Communication was associated with diagnosis of hyponatremia within 24 
hours of admission (p=0.006) and admission to general medicine (47% communicated) 
versus other hospital service (27%) (p=0.02). The cause of hyponatremia was more often 
SIADH (p<0.001) or hypovolemia (p=0.005) in the communication group. Communication 
of hyponatremia was not associated with improved one-year mortality, readmission or 
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readmission with hyponatremia. Patients with communicated hyponatremia were less likely 
to follow up with outpatient providers in our system (60% vs. 81%, p=0.03); of those who 
followed up in our system, hyponatremia was mentioned in an outpatient provider’s note 
only twice.
Conclusions: Our results suggest that hyponatremia is infrequently communicated 
to outpatient providers. Higher rates of communication were associated with severity and 
timing of hyponatremia and hospital service. The lower rate of follow up in patients with 
communicated hyponatremia and outpatient providers’ response may explain the lack of 
difference in clinically important outcomes. Alternatively, communication may be less for 
patients planning to follow up internally.
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Hyponatremia and Mortality Among Very Elderly Residents in a 
Geriatric Health Service Facility
Tamayo Naka,2 Kentaro Kohagura,1 Masako Kochi,3 Yusuke Ohya.3 1Dialysis 
Unit, University of the Ryukyus Hospital, Nishihara-cho, Japan; 2Nishizaki 
Hospital, Itoman city, Japan; 3University of the Ryukyus, Nishihara-cho, Japan.
Background: Hyponatremia is common among elderly patients. This study aimed to 
examine the prognostic value of hyponatremia among elderly residents in a geriatric facility.
Methods: We retrospectively examined the association between serum sodium levels 
and mortality among 118 residents (82% female, mean age 85.5 years) in a single geriatric 
health service facility. We defined hyponatremia as Na <135 mEq/L. On the basis of single 
measurements of serum sodium at periodic examinations, the patients were divided into 
hyponatremia and non-hyponatremia groups. Multivariable Cox proportional hazards 
models were used to evaluate the effect of hyponatremia on mortality from May 2005 to 
April 2007.
Results: Thirty-three patients (28%) had hyponatremia. Over a 1-year follow-up 
period, the cumulative survival rate was significantly lower in patients with hyponatremia 
than in those without hyponatremia. In a multivariate analysis, including traditional risk 
factors for death, hyponatremia was associated with an increased mortality risk (adjusted 
hazard ratio, 2.73; 95% confidence interval, 1.01–5.16; p = 0.047).
Conclusions: Hyponatremia is common and is a predictor of mortality in the near 
future among very elderly residents of a geriatric facility.
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Clinical Significance of Serum Sodium in Insomnia Patients
Eunjin Bae,1 Tae won Lee,2 Ha nee Jang,1 Hyun Seop Cho,2 Se-Ho Chang,1 
Dong Jun Park.3 1Gyeongsang national university hospital, Jinju, Republic of 
Korea; 2Gyeongsang National University Hospital, Changwon-si, 
Gyeongsangnam-do, Republic of Korea; 3Gyeongsang National University 
Changwon Hospital, Changwon, Republic of Korea.
Background: Hyponatremia is thought to be associated with attention deficits, 
cognitive decline, gait disturbances, and fracture even if it is asymptomatic. However, 
there is no study of hyponatremia and its clinical effects in patients with insomnia. We 
investigated the prevalence of hyponatremia and the clinical relevance of serum sodium 
concentration in patients with insomnia.
Methods: We retrospectively enrolled patients with a diagnosis of insomnia from 
January, 2011 to December 2012. Among these, we excluded patients who were being 
treated with cancer or not cured, or had renal replacement treatment. Hyponatremia was 
defined as a serum sodium concentration of less than 135 mmol/L. We divided into 3 
groups according to serum sodium: tertile 1 (<138 mmol/L), tertile 2 (138.0-140.9 mmol/L), 
and tertile 3 (≥141.0 mmol/L). Multivariable logistic regression was used to evaluate the 
association between serum sodium level and all-cause mortality, acute kidney injury (AKI).
Results: A total of 443 patients with insomnia were included, of which 14.9% (n=67) 
had hyponatremia. Patients with lower serum sodium concentration tended to have lower 
hemoglobin, calcium, phosphorus and albumin level and older age. During median follow 
up 48.5 months, 19.8% (n=33), 8.4% (n=12), 2.3% (n=3) patients died in tertile 1, 2, and 3. 
Twenty one percent (n=35), 11.9% (n=17), 11.3% (n=15) patients experience AKI in tertile 
1, 2, and 3. Tertile 1 was significantly associated with all-cause mortality (reference tertile 2 
group, Hazard ratio 1.96; 95% confidence interval 0.66 – 5.80; P=0.006) even after adjusted 
co-variates. However, there was no significant relationship between tertile 1 and AKI.
Conclusions: In patients with insomnia, lower serum sodium is significantly associated 
with all-cause mortality and thus we should have continuous interest in hyponatremia, and 
we need to identify the cause of hyponatremia and correct the correctable factors.
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No Added Salt…The Epidemiology of Severe Hyponatraemia in a Tertiary 
Referral Hospital
Susan Mcgrath,1,3 Brona Moloney,1,3 Dean S. Moore,1,3 Yvonne M. O’Meara,1,4 
Aisling O’Riordan,1 Peadar McGing,2 Denise M. Sadlier.1,4 1Nephrology, Mater 
Misericordiae University Hospital, Dublin, Ireland; 2Clinical Chemistry, Mater 
Misericordiae University Hospital, Dublin, Ireland; 3RCPI, Dublin 8, Ireland; 
4University College Dublin, Dublin, Ireland.
Background: Severe hyponatremia is defined as a serum sodium concentration less 
than or equal to 120mmol/L and can be associated with mild symptoms (e.g. decreased 
concentration) to more severe life-threatening symptoms (e.g. seizures and coma). Patients 
with severe symptomatic hyponatraemia should be managed with hypertonic saline to 
correct their serum sodium and reduce the morbidity and mortality associated with this 
condition. In this retrospective study, the aetiology, management and outcomes of severe 
hyponatraemia were examined over a 5-year period
Methods: All patients admitted to a tertiary referral hospital with serum sodium 
≤120mmol/L were identified through the biochemistry laboratory database from January 
2013 – December 2017 inclusive. Patient data was extracted from hospital records and
included age, gender, presenting complaint, co-morbidities, medications, clinical exam
findings, treatment received, laboratory results, length of stay, nephrology consult and in-
hospital mortality.
Results: A total of 592 patients met the inclusion criteria, 46.7% (n=277) were male, 
24.8% (n=147) were aged >80years. The commonest causes were hypovolaemia (30%, 
n=178), hypervolaemia (15%, n=89), Syndrome of Inappropriate ADH secretion (13.7%, 
n=81) and medication induced (15%, n=89), of which thiazides were the most common. 
The most common symptoms were falls (17.2%, n = 102), confusion (11.6%, n=69) and GI 
upset (9.7%, n=58). 7.2% (n=43) presented with seizures. Hypertonic saline was indicated 
in 26.2% (n=155) of cases, but of these only 19.4%(n=30) have it documented as part of 
their treatment, 5% of total cases. Of the patients who presented with seizure, only 16.3% 
(n=7) received hypertonic saline. Average length of stay for these patients was 25days. 
Mortality for an admission complicated by severe hyponatremia was 14% (n=84), with a 
one year mortality of 27.4% (n=162).
Conclusions: Severe hyponatraemia is associated with significant symptoms, length 
of stay and 1-year mortality. Hypertonic saline is indicated in the treatment of severe 
symptomatic hyponatraemia and is proven to be a safe therapy, but only a minority of 
patients received this important treatment. Further education is required in order to improve 
the management and outcomes in this patient group.
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Optimal Cut-Off Level of Urine Sodium in Differentiating Hypovolemic 
Hyponatremia and SIADH
Raku Son,1 Masahiko Nagahama,1 Yasuhiro Komatsu,2 Masaaki Nakayama.1 
1St. Luke’s international hospital, Tokyo, Japan; 2Gunma University, Graduate 
School of Medicine, Maebashi, Gunma, Japan.
Background: The European clinical guideline recommends using 30 mEq/L as the 
cut-off level of urine sodium (U-Na) to differentiate hypovolemic hyponatremia (hypo-Na) 
from others. However, due to the complexity of hyponatremia, we frequently encounter the 
patients whose U-Na are not completely suppressed and wonder the accuracy of this cut-off 
level. This study is to examine the diagnostic performance of U-Na and other parameters, 
and clarify optimal cut-off level of U-Na in patients with hyponatremia.
Methods: In this single-center, retrospective cohort study, we collected data of 
hospitalized patients with profound hypotonic hyponatremia evaluated by nephrology 
consultants, defined by serum Na (S-Na) % 120 mEq/L and serum osmolality (Osm) % 280 
mOsm/kg H2O from April 2011 to September 2017. The final diagnosis of hyponatremia 
was categorized into either hypo-Na or SIADH based on nephrologist evaluation through 
the hospital course. Patients with urine Osm % 100 mOsm/kg H2O or diagnosis of 
polydipsia, adrenal insufficiency and hypervolemia were excluded. The diagnostic accuracy 
of U-Na, fractional excretion of sodium (FENa), FE urea, and FE uric acid for hypo-Na 
were evaluated by receiver-operating characteristic (ROC) curves and the areas under the 
ROC curves (AUC).
Results: Of 130 patients (age 75.7 ± 13.1, 51% of males, minimal S-Na 115 ± 4.1 
mEq/L), 97 patients (75%) were diagnosed as hypo-Na. In the ROC curves, U-Na showed 
the best diagnostic utility in differentiating hypo-Na and SIADH with AUC of 0.79 compared 
to FENa, FE urea and FE uric acid (AUC of 0.39, 0.44 and 0.50, respectively) (Figure). The 
optimal cut-off level of U-Na was 56 mEq/L with sensitivity of 64% and specificity of 90%, 
which was not significantly changed when assessed in patients with diuretics use (n=40) or 
not (n=90) with cut-off levels of 64 mEq/L and 56 mEq/L, respectively.
Conclusions: U-Na performed the best in differentiating hypo-Na and SIADH in 
hyponatremic patients with a cut-off level of 56 mEq/L, higher than that recommended in 
the current guidelines. The diagnostic accuracy was not influenced by diuretics use.
ROC curves of diagnostic parameters for hypo-Na
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Safety and Efficacy of Tolvaptan in Lung Cancer with Hyponatremia Due 
to the Syndrome of Inappropriate Antidiuretics Hormone
Hyun Seop Cho,1 Ji-Hye Kwak,1 Ha nee Jang,1 Tae won Lee,2 Dong Jun Park,2 
Se-Ho Chang.1 1Internal medicine, Gyeongsang national university hospital, 
Jinju, Gyeongsangnam-do, Republic of Korea; 2Internal Medicine, Gyeongsang 
National University Changwon Hospital, Changwon, Gyeonsangnam-do, 
Republic of Korea.
Background: Hyponatremia is the most common electrolyte disorder in lung cancer 
patients and has been associated with poor prognosis. We investigated the safety and 
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efficacy of tolvaptan in lung cancer with the syndrome of inappropriate antidiuretics 
hormone(SIADH).
Methods: We reviewed medical record database for all lung cancer patients with 
SIADH treated with tolvaptan. All patients received 7.5mg/day as an initial dose. 
Overcorrection of serum sodium was defined as an increased of serum sodium exceeding 
12 mmol/L over 24 hours or 8 mmol/L over 8 hours.
Results: 41 patients (32 male patients, aged 67.61 ± 10.1 years) with lung cancer 
treated with tolvaptan were enrolled. Serum sodium increased significantly from baseline 
during the first 24 hours (122.68 ± 4.54 vs 132.05 ± 4.27 mmol/L, p=0.03), and then 
plateaued until day 14(134.27 ± 6.11 mmol/L). There was no difference in baseline sodium 
level according to a type of lung cancer(121.97 ± 3.47 vs 123.68 ± 5.26 mmol/L, p=0.223). 
In small cell lung cancer, the change was significantly higher (11.09 ± 2.83 mmol/L) than 
in non-small cell lung cancer (7.36 ± 6.07 mmol/L, P= 0.029). But, there was no difference 
in the rate of correction between severe hyponatremia(<125 mmol/L) and moderate 
hyponatremia (p=0.48). Also, there was no difference in the rate of correction according 
to BMI (p=0.057). No serious adverse events were reported, but in 36.6 % of patient 
hyponatremia was overcorrected and in 14.6% of patients a slight increase in liver function 
test was observed.
Conclusions: In patients with lung cancer patient with SIADH, initial dose 7.5 mg 
tolvaptan was well-tolerated, relatively safe and effective.
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Non-Osmotic Sodium Storage Capacity in Patients with  
Glycosaminoglycan Alterations
Stijn Besseling,1 Eliane Wenstedt,1 Rik H. Olde Engberink,2 Nienke M. Rorije,1 
Liffert Vogt.1 1Amsterdam Cardiovascular Sciences, Amsterdam Medical Center, 
University of Amsterdam, Amsterdam, Netherlands; 2Academic Medical Center, 
Amsterdam, Netherlands.
Background: In the 2-compartment model the kidneys are believed to be solely 
responsible for matching Na+ intake and excretion. Recent observations that Na+ can 
accumulate in the body without concurrent water retention, via binding to negatively 
charged glycosaminoglycans (GAG), challenge this model. Type 1 diabetic (DM1) patients 
are characterized by acquired GAG loss while hereditary multiple exostosis (HME) patients 
have defective heparan sulfate GAG polymerization due to mutations in either EXT1 or 
EXT2 genes. We questioned whether non-osmotic sodium storage is impaired in DM1 and 
HME patients as compared to healthy controls (HC).
Methods: Eight DM1, 7 HME patients and 11 HC were included, all non-smoking 
males with normal kidney function, BMI and blood pressure. Non-osmotic storage capacity 
was estimated after acute infusion of 0.54±0.1L hypertonic saline (2.4±0.2%) by measuring 
plasma [Na+] and urinary Na+ and K+ excretion at various time points during 4-hr follow-up. 
We compared the observed changes in plasma [Na+] with the expected changes that were 
estimated by Adrogue-Madias (AM) and Nguyen-Kurtz formulas, which are based on the 
2-compartment model.
Results: Maximum increase (mean (SE)) of plasma [Na+] was reached 5 minutes after 
infusion in all 3 groups (DM1, 5.4±0.6; HME, 4.1±0.5, HC 3.5±0.4 mmol/L). The plasma 
[Na+] rise 5 minutes after infusion in DM1 was significantly higher than in HC (p=.01), 
without differences between HC and HME patient (p=.42). The formulas poorly predicted 
plasma [Na+] 5 minutes after infusion, with observed changes in plasma [Na+] exceeding 
expected changes. When using AM, DM1 showed the biggest discrepancy between 
observed and expected change in plasma [Na+] (DM1, -1.98±0.6, p=.01; HME, -0.87±0.5, 
p=.12; HC -0.31±0.4 mmol/L, p=.46). In all groups, the observed Na+ and K+ excretion were 
significantly lower compared to the expected excretion, but no differences between groups 
were observed. Blood pressure was not affected by infusion.
Conclusions: DM1 patients have reduced ability for non-osmotic sodium storage, 
possibly due to a reduced amount of GAGs. HME patients do not show a reduced ability for 
non-osmotic sodium storage, perhaps by compensatory synthesis GAGs other than heparan 
sulfate.
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Expression of Sodium Renal Transporters in Urinary Exosomes from 
Patients with Edema Associated with Cirrhosis, Heart Failure, or 
Nephrotic Syndrome
Ivonne Hurtado,1 Silvana Bazua-Valenti,2,1 Lorena L. Rojas,1 Fabiola Gallardo,1 
Diego L. Carrillo Perez,1 Braulio A. Marfil-Garza,1 Pablo E. Galindo,4 Tomas 
Alexis Becerra-Gamba,3 Magdalena Madero,3 Gerardo Gamba.1,2 1INCMNSZ, 
MEXICO, Mexico; 2IIB, UNAM, Mexico City, Mexico; 3INCICH, Mexico City, 
Mexico; 4Instituto Nacional de ciencias medicas y nutrición salvador Zubiran, 
CUERNAVACA, Mexico.
Background: The formation of edema requires sodium retention along the nephron. 
The molecular pathways in humans leading to salt retention in edematous states remain 
elusive. The use of urinary exosomes (UE) is a non-invasive powerful tool to study the 
pathophysiology of renal diseases. Here we analyzed the expression of a variety of renal 
sodium transporters in UE from patients with and without edema diagnosed with chronic 
failure of the liver or heart, as well as from patients with nephrotic syndrome.
Methods: We conducted a prospective and observational study. We obtained clinical 
and biochemical data, as well as urinary samples from adult patients with liver cirrhosis 
(LC), heart failure (HF) or nephrotic syndrome (NS) (N=9 with, N=9 no-edema for each 
group) and 5 healthy volunteers as controls. UE from 8 ml of urine were obtained by 
ultracentrifugation for western blot analysis of SGLT2, NHE3, NKCC2, NCC and ENaC. 
The amount of UE used per patient was adjusted to urinary creatinine.
Results: Clinical and biochemical data from edema and non-edema patients were 
similar, except for mild hyponatremia and lower MAP in LC and HF patients with edema, 
respectively. Analysis of UE of patients with LC showed a significant increase in NHE3 
and SGLT2 only in the edema group, while there was decreased NCC expression in the 
non-edema group. Conversely, NS and HF patients showed increased proximal tubule 
transporters even in the non-edema group. These patients were also characterized by 
increased ENaC expression. NKCC2 was only increased in HF patients with or without 
edema. Interestingly, NCC did not increase in any of the groups.
Conclusions: Our observations suggest that in edematous patients, regardless of the 
underlying syndrome, the proximal tubule transporters are upregulated and may be the most 
important cause of sodium retention. Interestingly, NKCC2 was increased in HF patients, 
but not in LC or NS patients. Down regulation of NCC in some groups suggests that the 
distal nephron is trying to compensate proximal reabsorption. These results suggest that 
diuretic therapy in patients with edema could be revisited to explore the use of proximal 
tubule inhibitors.
Funding: Government Support - Non-U.S.
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Kidney Functional MRI: A Potential Noninvasive Assessment of Early 
Change and NCC Function in Chinese Gitelman Syndrome Patients
Xiaoyan Peng, Gu-Mu-Yang Zhang, Dongli Tian, Hao Sun, Limeng Chen. 
Peking Union Medical College Hospital, Beijing, China.
Background: Gitelman syndrome (GS) is an inherited salt-losing tubulopathy with 
Na+-Cl-cotransporter (NCC) dysfunction. Diffusion kurtosis imaging (DKI) and inteavoxel 
incoherent motion imaging(IVIM) MRI are functional MRI(fMRI) which could disclose 
more precise tissue structure and water diffusion. Recently, we observed fMRI associated 
well with the pathologic changes in IgA nephropathy. In this study we first applied the novel 
technique in the kidney of GS patients.
Methods: Twenty patients with genetically confirmed GS and 24 age and gener 
matched healthy volunteers were enrolled. DKI and IVIM were performed at a clinical 3T 
MR scanner. The DKI parameters (K=mean kurtosis, D=mean diffusivity, ADC=apparent 
diffusion coefficient) and IVIM parameter(fP=microvascular perfusion fraction, 
DP=pseudodiffusion, D=diffusion coefficients) were generated by a post-processing 
software. The association between parameters and clinical data were investigated. The in 
vivo NCC function of patients were evaluated by thiazide test using ΔFECl(the increment 
of fractional excretion of Cl-).
Results: The mean age of GS patients was 28.4±10.2y and 45.8% were male with a mean 
onset age of 22.2±11.7y. At admission, the mean serum K+and Mg2+ was 3.22±0.55 mmol/L 
and 0.68±0.16 mmol/L. GS patients showed decreased reaction to thiazide test. Compared 
to controls, lower DKI-ADC (1.45±0.19 vs 1.55±0.12,P=0.048), which indicating greater 
diffusion restriction, was observed in the renal medulla of GS. Lower IVIM-DP (117.8±46.0 
vs. 151.3±56.3,P=0.039) indicating less microvascular perfusion, was observed in the renal 
cortex of GS. Among GS patients, in DKI the cortex ADC was associated well with plasma 
upright renin activity and blood pressure. The D value and K value correlated well with 
serum Cl-(D: r=-0.670, P=0.001; K: r=-0.470, P=0.037) and HCO3
-(D: r=0.709, P<0.001; 
K: r=0.469,P=0.037). In the kidney medulla, only K value associated well with serum Cl-
(r=-0.514,P=0.020). In IVIM, both the cortex D (r=0.702,P=0.035) and medulla DP(r=-
0.683, P=0.048) correlated well with ΔFECl.
Conclusions: DKI and IVIM MRI potentially provides a novel method for examining 
microvascular perfusion and diffusion in the kidney of GS patients and can serve as a 
noninvasive assessment of early change and NCC function in Chinese Gitelman syndrome 
patients.
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Hyponatremia and Renal Dysfunction in Acute Heart Failure
Masaaki Yamada, Karthikeyan Meganathan, Silvi Shah, Hassane Amlal, 
Charuhas V. Thakar. University of Cincinnati, Cincinnati, OH.
Background: Acute heart failure (HF) is a common cause of hospitalization and risk 
factor for hyponatremia (hypoNa) as well as renal dysfunction. Although renal function 
influences both HF and sodium (Na) regulation, this interrelationship is not studied in acute 
care settings. Moreover, effect of Na correction in HF during acute care is not known.
Methods: We examined all adults, >18 years of age, requiring 24 or more hours of 
hospitalization for HF from a national multicenter sample derived from Cerner Health 
Facts between 1/2010 and 6/2016. Admission Na levels in mEq/L were classified as severe 
hypoNa (<130), moderate hypoNa (130-134), mild hypoNa (135-139), normal (140-144), 
or hypernatremia (≥145). By logistic regression adjusted for major confounders, with 
normal as a reference group, risk of all cause hospital mortality/hospice (primary outcome) 
or 30-day readmission was modeled for other Na groups. We further assessed effect of 
correction of Na at discharge relative to admission on the primary outcome as well.
Results: Sample included 109,906 HF patients with median age of 74 years (Q1, 
Q3, 63, 84); 49% female; 19% Black; median serum Cr 1.2 mg/dL (Q1, Q3, 0.9, 1.7). Na 
classes were 5% (<130), 13% (130-134), 41% (135-139), 36% (140-144), and 5% (≥145). 
Overall hospital mortality was 5%; crude mortality rate showed a “U”-shaped relationship 
by Na classes (p <0.001). Compared to the normal class, adjusted odds ratio (aOR); 95% 
confidence interval (CI) were 2.3 (2.1-2.6) in Na <130; 1.7 (1.6-1.9) in Na 130-134; 1.2 
(1.1-1.3) in Na 135-139; and 1.8 (1.6-2.0) in Na ≥145. Renal dysfunction defined as 
Cr ≥1.3 mg/dL on admission was associated with increased mortality independent of Na 
(aOR 1.6; 95% CI, 1.5-1.7) compared to others. Among the 5,130 severe hypoNa patients, 
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compared to those who corrected from <130 to 130-139, the risk of mortality in patients 
who remained <130; corrected to normal (140-144); or over corrected (≥145) was aOR 2.1 
(95% CI, 1.7-2.6), 2.5 (95% CI, 1.7-3.5), and 10.5 (95% CI, 6.0-18.5) respectively. Overall, 
30-day readmission rate was 15%; compared to normal group (14%) it was higher in severe 
hypoNa (18%, p <0.001) and aOR 1.4 (95% CI, 1.3-1.5).
Conclusions: Management of hypoNa, in concert with level of renal function, is 
necessary to improve key HF outcomes. However, correcting severe hypoNa to normal or 
above normal may be harmful in acute HF.
Funding: Commercial Support - Otsuka
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Acetazolamide Therapy in Patients with Heart Failure: A Meta-Analysis
Janewit Wongboonsin,1 Charat Thongprayoon,2 Wisit Cheungpasitporn.3 
1Medicine, Univeristy of Minnesota, Minneapolis, MN; 2Bassett Medical Center, 
Cooperstown, NY; 3Nephrology, University of Mississippi, Jackson, MS.
Background: Fluid overload and central sleep apnea are highly prevalent in patients 
with heart failure (HF). Acetazolamide, although used as one of the first diuretics for heart 
failure, has not been readily added on as a therapy for diuretic resistance. In addition, its use 
in sleep apnea disorder has shown promising results, at least in the setting of high altitude 
conditions. We performed this meta-analysis to assess effects of acetazolamide therapy on 
1) fluid and/or electrolytes, and 2)apnea indexes in heart failure patients.
Methods: A literature search was conducted using MEDLINE, EMBASE and
Cochrane Database from inception through June 2017 to identify studies evaluating the 
use of acetazolamide in HF patients. Study results were pooled and analyzed using a 
random effects model. The protocol for this meta-analysis is registered with PROSPERO 
(International Prospective Register of Systematic Reviews; no. CRD42017065401).
Results: 9 studies (3 randomized controlled trials and 6 cohort studies) with a total 
of 229 HF patients were enrolled. After acetazolamide treatment, there were significant 
decreases in pH (mean difference [MD] of -0.04 [95% CI, -0.06 to -0.02]), pCO2 (MD 
of -2.06 mmHg [95% CI, -3.60 to -0.53 mmHg]) and serum bicarbonate levels (MD of 
-6.42 mmol/L [95% CI, -10.05 to -2.79 mmol/L]). Compared with placebo, acetazolamide 
significantly increased natriuresis (standardized mean difference [SMD] of 0.67 [95% CI, 
0.08 to 1.27]), and decreased the apnea-hypopnea index (AHI) (SMD of -1.06, [95% CI, 
-1.75 to -0.36]) and central apnea index (CAI) (SMD of -1.10, [95% CI, -1.80 to -0.40]), 
respectively. We found no publication bias as assessed by the funnel plots and Egger’s 
regression asymmetry test with p= 0.20, 0.75 and 0.59 for analysis of the changes of 
pH, pCO2, and serum bicarbonate levels with the use of acetazolamide in HF patients, 
respectively.
Conclusions: Our study demonstrates significant reduction in pH, increase in 
natriuresis, and improvements in apnea indexesamong HF patients with acetazolamide.
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Carbonic anhydrase Inhibitors (CAI) Use in Patients with Respiratory 
Failure and Metabolic Alkalosis: A Systematic Review and Meta-Analysis 
of Randomized Controlled Trials
Bassem Y. Tanios,1 Maryam O. Omran,2,3 Carlos Noujeim,4,5 Tamara Lotfi,6,3 
Samir G. Mallat,1 Pierre K. Boukhalil,4 Elie A. Akl,7,6 Houssam S. Itani.8 
1Division of Nephrology and Hypertension, American University of Beirut 
Medical Center, Beirut, Lebanon; 2Nursing Department, American University of 
Beirut Medical Center, Beirut, Lebanon; 3Faculty of Health Sciences, American 
University of Beirut, Beirut, Lebanon; 4Division of Pulmonary and Critical 
Care, American Universtiy of Beirut Medical Center, Beirut, Lebanon; 5Division 
of Pulmonary and Critical Care, Keserwan Medical Center, Ghazir, Lebanon; 
6Department of Clinical Research Institute, American University of Beirut, 
Beirut, Lebanon; 7Internal Medicine, American University of Beirut Medical 
Center, Beirut, Lebanon; 8Division Nephrology and Hypertension, Makassed 
General Hospital, Beirut, Lebanon.
Background: Metabolic alkalosis is common in patients with respiratory failure and 
may delay weaning in mechanically ventilated patients. The objective of this systematic 
review is to assess the benefits and harms of CAI therapy in patients with respiratory failure 
and metabolic alkalosis
Methods: We conducted a comprehensive literature search for relevant randomized 
clinical trials(RCTs) assessing at least one of the following outcomes:mortality, duration of 
hospital stay, duration of mechanical ventilation(MV), blood gas parameters, and adverse 
events. Teams of two review authors independently and in duplicate selected eligible trials 
then abstracted data, and assessed risk of bias of the included trials. The primary meta-
analysis used a random-effects model
Results: We identified 6 eligible RCTs with a total of 564 participants. The synthesized 
data did not exclude neither a reduction or an increase in mortality or in duration of hospital 
stay with the use of CAI(Table). There was a decrease in the duration of MV of 27(95% 
CI -50; -4) hours with CAI use(Figure). CAI therapy resulted in an increase in PaO2, and 
a decrease in PaCO2, serum bicarbonate and pH. There was an increased risk of adverse 
events in the CAI group(Table). Quality of evidence was judged to be low for most outcomes
Conclusions: In patients with respiratory failure and metabolic alkalosis, results of our 
systematic review suggest that CAI therapy has a favorable effect on blood gas parameters. 
In mechanically ventilated patients, the evidence suggests that CAI therapy may decrease 
duration of MV. Therefore, this clinically important outcome should be confirmed by future 
larger RCTs
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24-Hour Urine Magnesium Excretion in a Multi-Ethnic Asian Population 
of CKD and Healthy Participants
Umer F. Khan,1 Titus W. Lau,3 Boon Wee Teo.2 1National University Hospital
Singapore, Singapore, Singapore; 2Yong Loo Lin School of Medicine, National
University of Singapore, Singapore, Singapore; 3National University Health
System, Singapore, Singapore.
Background: Magnesium (Mg) is implicated in bone metabolism, vascular tone, 
cardiovascular risk, and immunity. Its homeostasis is affected by diet, gut absorption, and 
kidney filtration, reabsorption, and excretion. Previous studies demonstrated an increase in 
serum Mg and urine fractional excretion of Mg (FEMg) in chronic kidney disease (CKD). 
The 24-hour urinary Mg (24UMg; mmol) excretion in a multi-ethnic Asian population of 
CKD and healthy participants without kidney disease is unknown. We aim to characterize 
serum Mg, 24UMg, and FEMg in a multi-ethnic Asian population.
Methods: Out of 335 (51% male) consenting participants, 232 (69%) were patients 
with CKD, and 103 (31%) were healthy individuals without kidney disease, diabetes, 
or hypertension. Following a 24-hr urine collection, participants underwent glomerular 
filtration rate (GFR; mL/min/1.73m2) measurement using Tc99mDTPA, and provided a spot 
urine and blood. No patients were on Mg supplementation. Data were analyzed on SPSS 
V23 using standard statistical tests, where appropriate.
Results: Of the 232 patients with CKD, 72 (31.0%) had GFR >60, 99 (42.7%) had GFR 
30-60, and 61 (26.3%) had GFR <30; 51.3% were diabetic, and 82.8% were hypertensive. 
Mean 24UMg values were lower in patients with CKD (2.50±1.25) than healthy participants
(2.93±1.45) [p=0.006]. Patients with GFR <30 had lower mean 24UMg values (2.00±1.10) 
compared to groups 30-60, and >60 (2.64±1.20, 2.75±1.34, respectively) [p=0.001]. Group 
with GFR <30 had a higher mean serum Mg (p=0.005) and an increased FEMg (p<0.001). 
24UMg is associated with GFR (24UMg=2.032+0.009×GFR, p=0.002], which persists 
after excluding patients on diuretics. 24UMg and GFR is positively correlated in CKD
patients with hypertension but not in non-hypertensives and diabetic patients.
Conclusions: Healthy participants have higher 24UMG excretion than CKD patients. 
With reduced GFR, serum Mg is higher, and 24UMg is lower, and is associated with an 
increased FEMg in Asian CKD patients.
FR-PO299 Poster Friday
Fluid and Electrolytes: Clinical
Tacrolimus Trough Levels and Risk of Hypomagnesemia in Renal 
Transplant Recipients
Antonio Gomes Neto, Joëlle C. Schutten, Michele F. Eisenga, Jan-
Stephan Sanders, Stefan P. Berger, Martin H. De Borst, Gerjan Navis, 
Stephan J. Bakker. University Medical Center Groningen, Groningen, 
Netherlands.
Background: Magnesium (Mg) is the 2nd most abundant intracellular cation essential 
to neurochemical transmissions and many enzyme activities. Hypomagnesemia (hypoMg) 
is a risk factor for cardiovascular and mineral bone disease and in renal transplant recipients 
(RTR), Tacrolimus (Tac) use is associated with higher risk of hypoMg. However, it is 
unknown whether Tac trough levels further contributes to the risk of hypoMg. We aimed to 
investigate the association between Tac use and hypoMg in a large cohort of RTR.
Methods: For this study, we used data from the Transplantlines Biobank and Cohort 
Study comprising RTR with a functioning graft ≥1 year post-transplantation. Plasma Mg 
and Tac trough levels were measured using routine laboratory procedures. HypoMg was 
defined as a Mg level <1.7 mg/dL. Linear and logistic regression were used to assess the 
association of Tac use with plasma Mg and hypoMg, respectively. In additional analyses, 
we analyzed whether Tac trough levels were associated with plasma Mg and hypoMg in 
Tac users.
Results: We included 614 RTR (mean age 56±13 years; 59.2% male) at a median of 
4.7 [1.0 - 11.7] years posttransplantation. Mean eGFR was 50±17 ml/min/1.73m2 and mean 
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plasma Mg was 1.8±0.2 mg/dL. Of the total population, 170 (28%) RTR had a hypoMg 
and 378 RTR used Tac with a mean trough level of 5.8±1.8 ug/L. In linear regression 
analysis, Tac use was associated with lower plasma Mg (β -0.17 [95%CI -0.21;-0.12], 
p < 0.001), independent of age, sex, time after transplantation and eGFR. Similarly, 
in logistic regression analysis Tac use was independently associated with higher risk of 
hypomagnesemia (OR 4.5 [95%CI 2.6;7.8], p < 0.001). Within Tac users, Tac trough 
levels were strongly associated with lower plasma Mg (β -0.04 [95%CI -0.05 ; -0.03], 
p < 0.001) and higher risk of hypoMg (OR 1.4 [95%CI 1.2 ; 1.6], p < 0.001), independent 
of potential confounders.
Conclusions: HypoMg occurs in approximately 28% of RTR. Tac use is associated 
with a > 4 times greater risk of hypoMg. Importantly, we identified a dose-response effect 
between higher Tac trough levels and lower plasma Mg in Tac users. These results suggest 
that reducing Tac trough levels may be an effective treatment strategy for hypoMg in RTR 
treated with Tac.
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Association Between Use of Proton Pump Inhibitors and Hypomagnesemia: 
A Meta-Analysis
Paweena Susantitaphong,1 Thawin Srinutta,1 Api Chewcharat,1 
Kullaya Takkavatakarn,2 Kearkiat Praditpornsilpa,1 Bertrand L. Jaber,3 
Somchai Eiam-Ong.1 1Chulalongkorn University, Bangkok, Thailand; 2Division 
of Nephrology, King Chulalongkorn Memorial hospital, Bangkok, Thailand; 3St. 
Elizabeth’s Medical Center, Boston, MA.
Background: Hypomagnesemia is associated with an increased risk of cardiac 
arrhythmia and mortality. The use of proton pump inhibitors (PPIs) has been inconsistently 
associated with development of hypomagnesemia. To shed more light on this controversy, 
we performed a meta-analysis to examine the association between use of PPIs and 
hypomagnesemia.
Methods: The literature search was conducted in MEDLINE, Scopus, and Cochrane 
Central Register of Controlled Trials (through December 2017) to identify observational 
studies that examined the association between use of PPIs and development of 
hypomagnesemia. Random-effects model meta-analysis was used to compute the pooled 
odds ratio (OR) with 95% confidence interval (CI).
Results: Thirteen cohort studies were identified, totaling 125,280 patients. 38.7% (95% 
CI 29.5-48.7%) of patients were PPI users. The baseline prevalence of diabetes mellitus 
and diuretic use was not significantly different between PPI users and non-users. By meta-
analysis, use of PPIs was associated with a higher odds for development of hypomagnesemia 
(pooled odds ratio 1.83; 95% CI 1.26, 2.67; P = 0.002; I2 = 97%).
Conclusions: The use of PPIs is significantly associated with development of 
hypomagnesemia. As a result, serum magnesium levels should be monitored in patients 
receiving long-term PPIs.
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Efficacy and Safety of Patiromer in Participants with Diabetes: A Pooled 
Analysis
Patrick Rossignol,1 Coleman Gross,2 Martha Mayo,2 Suzette Warren,2 
Jinwei Yuan,2 Jeffrey J. Budden,2 George L. Bakris.3 1Clinical Investigation 
Center-INSERM-CHU of Nancy, VANDOEUVRE LES NANCY, France; 
2Relypsa Inc., a Vifor Pharma Group Company, Redwood City, CA; 3The 
University of Chicago Medicine, Chicago, IL.
Background: The purpose of this post-hoc pooled analysis was to assess the efficacy 
and safety of patiromer (PAT) for treatment of hyperkalemia in participants with and 
without diabetes mellitus (DM+ and DM-).
Methods: We analyzed pooled data through Week 4 (Wk4) from 3 trials of PAT. Study 
participants who took ≥1 PAT dose and had ≥1 post-baseline (BL) serum potassium (sK) 
measurement were included. Participants were stratified according to DM+ and DM-, and 
assessed for: sK change from BL at Wk4, sK over time, and % with any sK measurement 
in target range (3.8–5.0 mEq/L).
Results: 653 participants were included; 82% DM+ (mean BL HbA1c and DM 
duration: 7.4% and 14 years, respectively). Mean BL sK and eGFR were 5.4 mEq/L 
and 40.3 mL/min/1.73m2 in DM+, and 5.5 mEq/L and 34.8 mL/min/1.73m2 in DM-. At 
Wk4, overall mean (SE) sK change from BL was -0.72 (0.02) in DM+ and -0.88 (0.06) 
in DM- (Figure). In participants with BL sK ≥5.5 mEq/L, mean (SE) sK changes at Wk4 
were -1.01 (0.05) in DM+ and -1.21 (0.10) in DM-, and -0.52 (0.03) and -0.51 (0.08), 
respectively, in DM+ and DM- participants who had BL sK <5.5 mEq/L. Regardless of 
BL sK status, >95% of all DM+ and DM- participants achieved any sK measurement 
in the target range through Wk4. The presence or absence of heart failure or eGFR 
<45 mL/min/1.73m2 did not impact these results. At least 1 adverse event (AE) was reported 
in 31% of DM+ and 38% of DM- participants, most commonly (≥2%) constipation, diarrhea, 
hypomagnesemia (hypoMg), and nausea. AEs of hypoMg were reported in 2% of both DM+ 
and DM- participants. Lab values of Mg <1.4 mg/dL occurred in 5% and 1% of DM+ and 
DM- participants, respectively. Use of proton pump inhibitors and/or loop diuretics was 
common (43%) in those who experienced low serum Mg.
Conclusions: In this post-hoc analysis of pooled data, PAT was equally effective and 
well-tolerated in DM+ and DM- participants.
Funding: Commercial Support - Relypsa Inc., a Vifor Pharma Group Company
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The Association of Sodium Polystyrene Sulfate (Kayexelate™) Use and 
Adverse Gastrointestinal Events
Ariana Noel,2 William Petrcich,3 Sarah E. Bota,3 Ziv Harel,4 Manish M. Sood.1,3 
1Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2University of 
Ottawa, Ottawa, ON, Canada; 3Institute for Clinical Evaluative Sciences, 
Ottawa, ON, Canada; 4University of Toronto, Toronto, ON, Canada.
Background: Sodium Polystyrene Sulfate (SPS, Kayexelate™) is a commonly 
prescribed medication for the treatment of hyperkalemia. Case reports implicate the 
possibility of intestinal injury with SPS with or without sorbitol. In this regard, we set 
out to assess the risk of GI adverse events (intestinal ischemia, ulceration and perforation, 
abdominal surgery) with SPS use.
Methods: Population-based, retrospective cohort study of 1,853,866 eligible adults of 
advanced age (> 66 years) between 1995 and 2015 in Ontario, Canada. A high dimensional 
propensity score was used to match adults with a SPS prescription to no SPS prescription. The 
primary outcome was a composite of adverse gastrointestinal outcomes (intestinal ischemia, 
ulceration/perforation, abdominal survey) within 1-year of initial SPS prescription. Secondary 
outcomes included each component of the composite primary outcome. Cox proportional 
hazards were used to examine the association of SPS and a composite of GI adverse events. 
Additional sensitivity analyses limited to patients with laboratory values (eGFR, serum 
potassium) and a unrelated dummy outcome (cataracts) were performed. Pre-specificed 
subgroups of interest were examined using interaction terms.
Results: From 1, 853, 866 eligible adults, 20,020 were prescribed SPS (mean age 78.5 
SD 7.7 years, 46% female) and matched. The risk of any adverse GI event was higher 
with SPS use compared to non-use (n=370 events, HR 1.26 95%CI 1.03-1.55). Among the 
individual types of GI adverse injury, gastrointestinal ulceration and perforation (HR 1.56 
95%CI 1.08-2.25) events were higher with SPS whereas intestinal ischemia and abdominal 
surgery were similar. Among SPS-users with laboratory values (n= 7557, mean eGFR 44.8 
SD 20.3 ml/min/1.73m2, mean serum potassium 5.6 SD 0.7 mEq/L), the risk of any adverse 
GI event was similarly elevated (HR 1.44 95%CI 1.09-1.90). The findings were consistent 
after additional adjustment for living in a rural residence or a long-term care home and there 
was no association with SPS use and the dummy outcome (cataracts). The results were 
consistent across all prespecified subgroups.
Conclusions: The use of SPS is associated with a higher risk of adverse gastrointestinal 
events. Our findings suggest caution with the use of SPS and alternative treatments for 
potassium lowering be considered.
Funding: NIDDK Support
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Acid-Base and Electrolyte Disturbances in Severe Hyperemesis 
Gravidarum
Maria Soledad Rivera,1,2 Luis Estremadoyro,4 Juan Carlos Q. Velez.1,3 1Ochsner 
Clinical School, New Orleans, LA; 2School of Medicine, University of 
Queensland, Brisbane, QLD, Australia; 3Department of Nephrology, Ochsner 
Clinic Foundation, New Orleans, LA; 4Universidad Peruana Cayetano Heredia, 
Lima, Peru.
Background: Hyperemesis gravidarum (HG) is a complication of pregnancy 
characterized by incessant vomiting and reduced oral intake. However, the effect of severe 
HG on acid-base and electrolyte balance has not been previously examined.
Methods: A cross-sectional study was conducted to assess for acid-base and electrolyte 
abnormalities in pregnant women with symptoms of HG that were severe enough to lead to 
a visit to an emergency room.
Results: A total of 22 women [9 (41%) primigravida] were included over a 6-month 
enrollment period in a large city hospital. Median age was 25 (17 – 38) and median 
gestational age was 10 (5 -16) weeks. Median duration of HG prior to arrival was 
24 (3 – 63) days. Vomiting episodes per day were 6 (3 – 12) and ketonuria was found in 
16 of 22 women (73%). Dehydration was clinically evident in 18 of 22 (82%) and the 
mean change in body weight was –12%. The mean arterial pH was 7.41 (7.30 - 7.50), 
mean bicarbonate was 19 mEq/L (14 – 28) and mean pCO2 was 29 mmHg (19 - 39). 
Physiological respiratory alkalosis was found in 17 of 22 (77%), metabolic alkalosis 
from vomiting was present in 10 of 22 (45%) and high anion-gap metabolic acidosis from 
starvation ketosis in 12 of 22 (55%) patients. Among them, 8 of 22 (36%) presented with 
a triple acid-base disorder, i.e. simultaneous respiratory alkalosis, metabolic alkalosis and 
metabolic acidosis. Only 2 (9%) patients exhibited no acid-base disorder. The presence 
of high anion gap metabolic acidosis was associated with a greater degree of weight loss 
(p < 0.05) and a lower age (p < 0.05). In addition, 9 of 22 (41%) patients were hypokalemic 
[mean K 3.5 mEq/L (2.4 – 4.2)], 7 of 22 (32%) were hyponatremic, and only 1 patient was 
hypernatremic [mean Na 139 mEq/L (128 – 148)].
Conclusions: Triple acid-base disorder of respiratory alkalosis, metabolic acidosis and 
metabolic alkalosis is the most common diagnosis in severe HG. Lower age and a greater 
degree of reduction in body weight are associated with high anion gap metabolic acidosis. 
Hypokalemia and dysnatremia can also occur. Acid-base/electrolyte assessment in HG is 
warranted.
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Electrolyte-Related Events Among US Veterans with Hyperkalemia
Csaba P. Kovesdy,1 Elvira Gosmanova,2 Steven D. Woods,3 Jeanene Fogli,3 
Christopher G. Rowan,4 Jared Hansen,5 Brian C. Sauer.5 1University of Tennessee 
Health Science Center, Memphis, TN; 2Stratton VA Medical Center and Albany 
Medical College, Albany, NY; 3Relypsa, Inc., a Vifor Pharma Group Company, 
Redwood City, CA; 4COHRDATA, LLC, Santa Monica, CA; 5Salt Lake City VA 
Medical Center (IDEAS), Salt Lake City, UT.
Background: Patiromer is a novel sodium-free potassium-binding polymer for treating 
hyperkalemia. The real-world impact of patiromer and sodium polystyrene sulfonate (SPS) 
on clinical outcomes is unclear.
Methods: Using the VA Informatics and Computing Environment (VINCI) database, 
we assessed the percentage of patients with electrolyte-related hospitalizations and 
emergency department (ED) visits 1, 3, and 6 months before and after the first patiromer 
and SPS dispensing (index date). Follow-up exposure was classified as of the index date and 
followed for 6 months (ITT) or censored at discontinuing/switching (continuous exposure, 
CE).
Results: 193 and 8492 patients initiated patiromer and SPS, respectively. All patients 
had a pre-index serum potassium ≥5.1 mEq/L and heart failure, diabetes, or renal disease. 
The percentage of patients with electrolyte-related ED visits and hospitalizations in the ITT 
population are shown in Figure. Although patient numbers were small in the CE population, 
decreases in electrolyte-related outcomes at months 1, 3, and 6 post-index were observed 
for ED visits (-2.9%, -9.6%, and -23.1%, respectively, for patiromer, and -4.1%, -4.1%, and 
-5.7%, respectively, for SPS) and hospitalizations (-1.2%, -3.8%, and -7.7%, respectively,
for patiromer, and -0.5%, -0.9%, and -0.4%, respectively, for SPS).
Conclusions: The greatest reduction in electrolyte-related events was observed post-
patiromer initiation. Given the limited number of patiromer users in this database, these 
findings merit additional study.
Funding: Commercial Support - Relypsa, Inc., a Vifor Pharma Group Company
Figure. Difference in % of Patients with Electrolyte-Related ED Visits & Hospitalizations 
Pre-Index vs. Post-Index in the Patiromer and SPS Cohorts (ITT Analysis)
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Mortality Associated with Hyperkalemia in Medicare Patients
J. Michael Woolley,3 Keith Betts,1 Fan Mu,2 Yao Wang,2 Akanksha Dua,2 
Eric Wu.2 1Analysis Group, Inc., Los Angeles, CA; 2Analysis Group, Los Angeles, 
CA; 3AstraZeneca, Wilmington, DE.
Background: The objective of this study was to compare all-cause mortality between 
patients with and without hyperkalemia in the U.S. Medicare population.
Methods: Adult patients with and without hyperkalemia (cases vs. controls), were 
selected from a 5% random sample from the Medicare population (1/1/2010-12/31/2014). 
Hyperkalemia was defined as having at least one diagnosis of hyperkalemia (ICD-9-CM 
276.7). The index date was a randomly selected claim date with a hyperkalemia diagnosis 
for cases and a randomly selected claim date for controls. Continuous enrollment for at least 
6 months before the index date (baseline period) was required and patients were followed 
from the index date to death or the end of data availability (study period). Controls were 
exactly matched one-to-one to cases on age group, chronic kidney disease (CKD) stage, 
dialysis, and heart failure (HF). Mortality outcomes were analyzed at 36 months. Time 
to death was estimated with Kaplan-Meier analysis and compared using the log-rank test. 
Hazard ratios (HRs) were estimated using univariate and multivariate Cox proportional 
hazards (PH) models.
Results: A total of 157,441 cases were matched to 157,441 controls. Compared with 
controls in the overall population, cases had higher 3-year mortality rates (47.5% vs. 33.7%) 
and lower median time to death (40.3 months vs. median not reached). Among the 79,327 
matched pairs of patients with CKD and/or HF, the 3-year mortality was higher (59.6% 
vs. 48.7%) and the median time to death was lower (22.7 vs. 38.4 months) (p for log-
rank test<0.001) in cases compared with controls. In univariate Cox PH models, the risk of 
mortality was significantly higher for cases compared with controls overall (HR: 1.67, 95% 
CI: 1.65, 1.69) and among patients with CKD and/or HF (HR: 1.44; 95% CI: 1.42, 1.46) 
(all p<0.001). After adjusting for age, gender, region, diabetes, hypertension, and Charlson 
Comorbidity Index, the risk remained higher for cases compared with controls in the overall 
population (HR: 1.49, 95% CI: 1.48, 1.51) and among patients with CKD and/or HF (HR: 
1.37, 95% CI: 1.35, 1.39) (all p<0.001).
Conclusions: In this study of Medicare patients, hyperkalemia was associated with 
increased mortality.
Funding: Commercial Support - AstraZeneca
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Association of Potassium Level and Mortality in Massive Health Record 
Databases
Christos Argyropoulos,1 Cristian G. Bologa,1 V. Shane Pankratz,2 
Mark L. Unruh,1 Maria-Eleni Roumelioti,1 Vallabh O. Shah,3 Saeed K. Shaffi.1 
1University of New Mexico, Albuquerque, NM; 2UNM Health Sciences Center, 
Albuquerque, NM; 3University of New Mexico Health Science Center, 
Albuquerque, NM.
Background: Dyskalemias have been associated with mortality in studies of small 
to moderate samples. However the association of potassium (K) with mortality across the 
spectrum of renal function (est. glom. filtration rate, eGFR) remains poorly defined. Our 
aim was to characterize this relation in the Cerner Healthfacts database which abstracts 
data from 1/3 of US healthcare facilities over a period of 10 years.
Methods: Serum K levels, demographics, eGFR (CKD-Epi) and comorbidity 
(Charlson) collected within 24 hours of all adult patient encounters in Healthfacts were 
analyzed after excluding patients on dialysis. The most recent K level was associated 
with each death recorded in Healthfacts. Relative mortality risks (RR) were calculated by 
Poisson Generalized Estimating Equations, that accounted for the repeated measures of K 
levels in the same individual. Cubic splines were used to model the relation of K with death 
in fully adjusted models.
Results: We analyzed 20,697,035 K measurements in 15,376,693 individuals. Patients 
with CKD were more likely to be older, non-white and have higher K levels (Table). The 
RR of death with K level was U-shaped; the lowest RR was observed for K: 3.5-4.5 meq/l 
(Fig A). Hyperkalemia (K>5.5 meq/l) was associated with higher RR in those with low 
eGFRs (Fig B, p<0.001 for the interaction between eGFR and K).
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Conclusions: The RR for hyperkalemia was higher relative to hypokalemia.The 
interaction between eGFR and K level reflects the variable causes of high K in patients with 
CKD & the inability of the kidneys to rapidly excrete the K load. Further studies are needed 
to understand this complex relationship.
Funding: Commercial Support - Dialysis Clinic, Inc
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Course and Outcomes of Hyperkalemia in Hospitalized Patients
Etienne Macedo,2 Linda Awdishu,1 Euyhyun Lee,2 Ravindra L. Mehta.2 1UCSD 
Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; 
2University of California San Diego Medical Center, La Jolla, CA.
Background: Hyperkalemia (High K) is a common complication among hospitalized 
patients contributing to increased hospital stay and costs. In this study, we determined the 
incidence and severity of hyperkalemia and characterize its recognition, treatment, and 
complications in different hospital settings and patient populations.
Methods: Data regarding patient location, comorbidities, medications in use before/
after High K detection and outcomes were extracted from the EMR of all adult patients with 
at least 2 consecutive K>5mEq/L during a hospital stay at an academic medical center. Need 
for ICU admission, dialysis, number of drugs to treat HighK, land ength of ICU/hospital 
stay were assessed during hospitalization. Mortality was recorded for the duration of the 
observation period.
Results: From January 1, 2013, to November 30, 2015, 133,807 hospitalized patients 
had at least one potassium assessment. Of these patients, 13,748 (10.3%) had at least one 
K≥ 5mEq/L, and 2,150 (1.6%) had two consecutive values, within 7 days, ≥ 5 mEq/L. 
Almost half of the highK episodes were present at hospital admission, and the majority of 
these cases were from the emergency room (ER) 497 (23%), ward 1318 (62.9%), and ICU 
280 (13.4%). Of 1,815 patients with hyperkalemia diagnosis in the ward or ER, 225 (12%) 
were transferred to the ICU within 24 hours of hyperkalemia diagnosis. 126 (6%) patients 
that were dialyzed during hospital admission: 78 (61%) were ESRD, 22 (3.4%) AKI, and 
104 (6.9%) AKI on CKD. The median length of hospital stay was 9 days and was higher in 
AKI patients 11 (4-22) vs. 9 (4-17) days in no AKI. Overall, the in-hospital mortality rate 
in patients with hyperkalemia diagnosis was 12%. Patients with AKI had a higher mortality 
rate (AKI; 122 (17%) vs. 159 (10%) no AKI). Within the study period interval, 29% of 
patients with a hyperkalemia episode died. Patients with no previous renal dysfunction 
showed a greater in-hospital mortality rate 179 (15%) than those with CKD stage 3-5 and 
ESRD, 67(11.3%) and 25 (6.8%), respectively.
Conclusions: HighK in hospitalized patients is associated with a high mortality rate 
and increases significantly over the period of observation. Presence of CKD and ESRD 
is not associated with worse outcomes, whereas development of AKI is associated with 
increased length of stay and mortality.
Funding: Commercial Support - Relypsa, Inc., a Vifor Pharma Group Company
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Predicting Complicated Hyperkalemia in Hospitalized Patients
Etienne Macedo,2 Linda Awdishu,1 Euyhyun Lee,2 Ravindra L. Mehta.2 1UCSD 
Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; 
2University of California San Diego Medical Center, La Jolla, CA.
Background: Hyperkalemia (HighK) is common in hospitalized patients and can be 
life-threatening. Patient-related factors and process of care, including drugs, are known 
to be associated with the development of hyperkalemia. In order to prevent hyperkalemia 
complications, it is fundamental to identify the cause and provide early treatment. In this 
study, we evaluated risk factors for complicated hyperkalemia (CK) during hospitalization.
Methods: Data regarding patient location, comorbidities, medications in use before 
and after HighK detection and outcomes were extracted from the EMR of all adult 
patients at an academic medical center with at least 2 consecutive K > 5mEq/L during a 
hospital stay. CK was defined as: (1) maximum K level ≥ 6.5 mEq/L, (2) need for ICU 
admission within 24h of HighK diagnosis, (3) need for dialysis, if not ESRD, (4) death with 
K ≥ 5 mEq/L, (5) more than 3 drugs for hyperkalemia treatment initiated after hyperkalemia 
diagnosis, and (6) more than 8 days for potassium normalization. We divided the cohort into 
derivation (n= 1,165), and validation (n=985) cohorts, to build and evaluate the performance 
of the model. The Least absolute shrinkage and selection operator (LASSO) with 10-fold 
cross-validation was used to build the model.
Results: From January 1, 2013, to November 30, 2015, 133,807 hospitalized patients 
had at least one K assessment. Of these patients, 13,748 (10.3%) had one K value higher 
than 5 mEq/L, and 2,150 (1.6%) had two consecutive values, within 7 days, more than 5 
mEq/L. CK occurred in 822(38%) of patients; 488(42%) derivation and 334(34%) in the 
validation cohort. The majority of the patients, 1,193 (55%) had eGFR > 60ml/min, and 
1310 (61%) fulfilled criteria for AKI during the admission, 192 (9%) were ESRD. Mortality 
in CK was significantly higher, 200(24.3%) vs. 71(5.3%) HighK group (p<0.001). Presence 
of hypotension, cardiopulmonary diagnosis, fluid overload, infection and ICU location were 
independently associated with CK. ESRD, myopathy and HIV diagnosis were protective 
factors. The model AUC was 0.70 in the derivation and 0.64 in the validation dataset.
Conclusions: HighK is common in hospitalized patients and associated with high 
mortality. A model based on clinical information and process of care may help identify 
patients with HighK who are at highest risk for complications and require surveillance.
Funding: Commercial Support - Relypsa, Inc., a Vifor Pharma Group Company
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Timing Is Everything: Decreasing Mortality in Severe Hyperkalemia
Sayee Sundar Alagusundaramoorthy,1 Andrew Gregory,3 Laura J. Maursetter,2 
Tripti Singh.1 1University of Wisconsin, Madison, WI; 2University of Wisconsin 
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Background: Hyperkalemia is a modifiable risk factor for sudden cardiac death; a 
leading cause of mortality in hemodialysis patients. There is lack of data in literature guiding 
the treatment of hyperkalemia in hospitalized end stage renal disease (ESRD) patients. 
The goal of this study was to determine if time to dialysis after severe hyperkalemia will 
influence mortality in hospitalized ESRD patients.
Methods: We conducted a retrospective study of all adult ESRD patients admitted to the 
hospital who had hemodialysis for severe hyperkalemia between January 2011- June 2017. 
Chart review was conducted to determine patient and treatment characteristics. Logistic 
regression analysis was performed to determine the factors that influenced mortality.
Results: 346 ESRD patients on hemodialysis admitted at our center had severe 
hyperkalemia during the study period. Mean serum potassium was 7mEq/L. In-hospital 
mortality in ESRD patients with severe hyperkalemia was 6.9%. Median time to dialysis 
after serum potassium result was 2.13 hours (25, 75 IQR 0.98, 4.9 hours). Time to dialysis 
after serum potassium result was associated with a significantly increased risk of mortality 
in this population (HR 1.007, 95% CI 1.002-1.012, p <0.0045) (Table 1). Logistic regression 
analyses also determined age, length of stay, serum creatinine and serum albumin level as 
significant predictors of in-hospital mortality (Table 1). Sex, race, history of diabetes and 
hypertension, serum potassium level and serum CO2 level did not influence in-hospital 
mortality in this cohort.
Conclusions: We conclude that early dialysis after serum potassium result in 
hospitalized ESRD patients with severe hyperkalemia is associated with decreased in 
hospital mortality.
Table 1: Risk factors for mortality in hospitalized ESRD patients with severe hyperkalemia
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Fluid and Electrolytes: Clinical
Changes in Nephrologists’ Understanding and Management of Hyperkale-
mia from 2015 to 2018
Amy Larkin,1 Donald Blatherwick,2 Teresa S. Marshall,2 George Boutsalis.2 
1Medscape Education, Nicholasville, KY; 2Medscape, Medford, NJ.
Background: Identifying clinical gaps related to hyperkalemia and its management 
can inform the development of tools to advance best practices for nephrologists
Methods: Medscape conducted surveys in 2015, 2016, and 2018. The first two 
were CME-accredited activities consisting of 25 multiple choice, knowledge- and case-
based questions aboout hyperkalemia assessment and management. These online surveys 
were available without compensation or fee. The third online, 14-question, survey 
was incentivized for nephrologists with monetary compensation for completion. In all 
surveys, respondents’ confidentiality was maintained and responses were de-identified 
and aggregated prior to analyses. Data collection occurred in 9/22 - 11/22/2015, 11/21 – 
12/21/2016, and 4/20 – 4/26/2018.
Results: Participation by nephrologists: 394 in 2015, 131 in 2016, and 50 in 2018 
Significant Changes: Competence related to management of hyperkalemia rose 
significantly (P =.018) from 44% in 2016 to 66% in 2018* Competence regarding clinical 
use of potassium binders grew significantly (P <.001), from 63% to 92% (2016 to 2018, 
respectively) Nephrologists who reported being very confident increased significantly 
(P =.04), from 35% to 45% to 60% (2015, 2016, and 2018, respectively)* Modest 
Changes: Hyperkalemia risk assessment understanding grew (58% to 72%, P =.083) as 
well as recognition of strategies to minimize hyperkalemia risk with RAAS inhibitors (25% 
to 30%, P =.381) from 2016 – 2018* Knowledge of the mechanism of action of patiromer 
trended upward each year, 46% to 50% to 56% (2015, 2016, and 2018 respectively, 
P=.377) * Ongoing Gap: Confusion remains around the mechanism of action of ZS9, 49% 
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(2015), 39% (2016), and 44% 2018, P =.046)* Understanding related to the physiology of 
hyperkalemia and potassium excretion remains low (55% vs 54%, P - .885) from 2015 to 
2018* * results indicate a need for further education
Conclusions: These surveys demonstrate some improvement in clinical knowledge, 
competence, and confidence by nephrologists related to hyperkalemia from 2015 to 2018, as 
well as continued gaps that need to be addressed to improve patient care. Future education 
in the area of hyperkalemia should focus on improving risk assessment for hyperkalemia, 
understanding available treatment options, management of hyperkalemia, and also reinforce 
important points to further increase confidence.
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Calcium-Phosphate Product and Its Impact on Mortality in Hospitalized 
Patients
Michael A. Mao,1 Charat Thongprayoon,2 Wisit Cheungpasitporn,3 
Stephen B. Erickson.1 1Nephrology and Hypertension, Mayo Clinic, Rochester, 
MN; 2Bassett Medical Center, Cooperstown, NY; 3Nephrology, University of 
Mississippi Medical Center, Jackson, MS.
Background: Calcium-phosphate product (CaP) of >55 mg2/dL2 is associated with 
acute or subacute calcification of vascular, cardiac, and other soft tissues. However, the 
relationship between admission CaP and in-hospital mortality in all hospitalized patients 
is unclear.
Methods: All adult hospitalized patients who had both admission serum calcium and 
phosphate levels available between years 2009 and 2013 were enrolled. Admission CaP 
was categorized based on its distribution into six groups (<21, 21-<27, 27-<33, 33-<39, 
39-<45 and ≥45 mg2/dL2). The odds ratio (OR) of in-hospital mortality by admission CaP, 
using the CaP category of 27-<33 mg2/dL2 as the reference group, was obtained by logistic 
regression analysis.
Results: 14,772 patients were studied. The lowest incidence of in-hospital mortality 
was associated with an admission CaP within 27-<33 mg2/dL2. A U-shaped curve emerged 
demonstrating higher in-hospital mortality associated with both CaP <27 and ≥33 mg2/dL2. 
After adjusting for potential confounders, both CaP <21 and ≥39 mg2/dL2 were associated 
with an increased risk of in-hospital mortality with ORs of 1.60 (95% CI 1.07-2.37), 1.53 
(95% CI 1.07-2.18) and 3.46 (95% CI 2.51-4.79) when CaP were within <21, 39-<45 and 
≥45 mg2/dL2, respectively. Among a subgroup of patients with available serum albumin,
the lowest incidence of in-hospital mortality was associated with corrected CaP within
33-<39 mg2/dL2. After adjusting for potential confounders, corrected CaP 39-<45 and 
≥45 mg2/dL2 were associated with an increased risk of in-hospital mortality with ORs of
2.15 (95% CI 1.39-3.33) and 3.90 (95% CI 2.60-5.94) when CaP were within 39-<45and
≥45 mg2/dL2, respectively.
Conclusions: CaP levels on admission are associated with in-hospital mortality. Highest 
mortality risk is observed in hospitalized patients with admission CaP ≥45 mg2/dL2.
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A Structural Equation Model on Regulatory Network of Phosphate 
Metabolism in Healthy Individuals
Guoxin Ye,1 Mengjing Wang,2 Jiaying Zhang,2 Weisheng Chen,3 Jing Chen.3 
1Division of Nephrology, Huashan Hospital, Shanghai Medical College, Fudan 
University, Shanghai, China; 2Huashan hospital, Fudan University, Shanghai, 
China; 3Huashan Hospital, Shanghai, China.
Background: Basic and clinical studies reveal that the homeostasis of phosphate is 
maintained by a regulatory network. The factors in the network may change along with 
the dietary intake of phosphate. The aim of our study was to explore the variation of 
phosphatoninin with the change of diet.
Methods: A cross-over trial of 6 healthy volunteers was conducted. Each of them 
was given diet strictly: regular Pi diet (1500 mg/d), low Pi diet (LPD, 500 mg/d) and 
high Pi diet (HPD, 2300 mg/d), with a wash out period after diet intervention. The data 
were traditionally detected by ANOVA. In order to overcome limitations of the traditional 
correlation analysis, we used structural equation model (SEM) as a general framework for a 
new paradigm of analysis of multiple correlations.
Results: Pi was significantly higher in HPD. In contrast, Ca was lower in HPD. 
Meanwhile, LDP increased 1,25(OH)D and 25(OH)D. HPD leaded to increasing level of 
iPTH. With the gradual escalation of Pi intake, the FGF23 were upward trend. However, 
klotho didn’t appear to be affected by dietary intervention by ANOVA. With the traditional 
comparison, it was difficult to reveal the overall phosphate network regulation. By SEM, 
we developed 3 networks for phosphate regulation. When healthy individual with regular 
Pi diet, Ca, Pi, iPTH, FGF23 and klotho formed a precise regulatory network. When HPD 
or LPD, vitamin D was closely associated with other phosphatonin, suggesting vitamin D 
played a prominent role in HPD or LPD. FGF23 and klotho had a close relationship in the 
network, especially in high Pi loads.
Conclusions: By SEM, the importance of klotho in phosphate regulation is revealed 
with the network diagrams. Meanwhile, the network demonstrates the importance of 
vitamin D in abnormal phosphate metabolism which need further investigation.
Funding: Government Support - Non-U.S.
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Recurrent GATM Mutations Causing Autosomal Dominant Renal 
Fanconi Syndrome with Progressive Renal Failure
Ming-Tso Yan,1,2 Shih-Hua P. Lin.3,1 1National Defense Medical Center, Taipei, 
Taiwan; 2Cathay General Hospital, Taipei, Taiwan; 3Tri-Service General 
Hospital, Neihu, Taiwan.
Background: Inherited renal Fanconi syndrome without extrarenal manifestations, 
described as Fanconi renotubular syndrome (FRTS), have been reported to be caused 
by genetic defects in uncertain loci of chromosome 15 (type I), SLC34A1 (type II) and 
EHHADH (type III). In Type I characterized by autosomal dominant inheritance with late 
onset FRTS and progressive renal failure, its causative gene mutation is just reported to 
be caused by GATM encoding arginine-glycine aminotransferase (AGAT), an enzyme 
catalyzing rate-limiting step of creatine biosynthesis.
Methods: A Chinese family with typical autosomal dominant FRTS and progressive 
renal failure was enrolled. The affected father (age 60 and serum creatinine 6.1 mg/
dl with eGFR 12 ml/min) and daughter (age 31, and serum creatinine 1.3 mg/dl, eGFR 
50 ml/min) exhibited severe hypophosphatemia and hyperchloremic metabolic acidosis 
with distinctively osteomalacia as well as hypokalemia despite potassium, alkali, and 
vitamin D therapy. Sanger’s sequencing demonstrated no pathogenic mutations in SLC34A1 
and EHHADH. Whole exome sequencing was performed in this family.
Results: Whole exome sequencing discovered a possible culprit missense mutation 
(p.Thr336Ile) in GATM, which mutation was identical to recent report, supporting the 
pathogenic role of GATM mutation in this unique type of FRTS. Localization of T336I 
mutation on 4th β-sheet was suggested to transform 4th β-sheet into a novel additional 
interaction surface, resulting in formation of linear AGAT multimer rather than physiological 
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homodimer by interaction between 2nd β-sheet. Because biallelic mutations in GATM causes 
cerebral creatine deficiency syndrome (CCDS) with neurological symptoms but not FRTS, 
the role of diminished total AGAT activity in pathogenesis of FRTS is unlikely.
Conclusions: Uniallelic GATM mutation clustering to a specific region may play a 
role in pathogenesis of autosomal dominant FRTS. Generation of GATM T336I knock-in 
mice is warranted to elucidate the mechanism of FRTS and assess the therapeutic role of 
creatine administration.
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Intrapartum PDE-5 Inhibition Lowers Blood Pressure and Renal Injury 
in Young Adult Offspring of Preeclamptic Dahl S Rats
Hannah R. Turbeville, Sean Didion, Michael R. Garrett, Jennifer M. Sasser. 
University of Mississippi Medical Center, Jackson, MS.
Background: Up to 10% of pregnancies are complicated by preeclampsia, and up 
to 15 million Americans are offspring of preeclamptic pregnancies. The Developmental 
Origins of Health and Disease hypothesis proposes that an adverse intrauterine environment 
programs the fetus to develop high blood pressure (BP) from early childhood, and evidence 
shows that offspring of preeclamptic pregnancies have increased risk of hypertension and 
CKD. Animal models of hypertension in pregnancy have shown that sildenafil citrate, a 
phosphodiesterase-5 (PDE-5) inhibitor that prolongs NO-cGMP signaling, improves the 
maternal syndrome of preeclampsia; however, the effects of perinatal use on long term fetal 
outcomes have not been reported. Here, we test the hypothesis that PDE-5 inhibition during 
preeclamptic pregnancy improves long-term BP and renal injury in the offspring.
Methods: Female Dahl S rats (n=16) on a 0.3% salt diet, a previously characterized 
model of preeclampsia, were mated and treated orally with sildenafil (50 mg/kg/day) or 
vehicle from gestational day 10 to delivery. Lactating dams and offspring were on normal 
chow for the duration of the study, and measurements were made at 11 weeks of age.
Results: Systolic BP (n=5-9/group, tail cuff) was greater in Dahl S rats of untreated 
mothers compared to offspring of sildenafil treated dams (VEH: 177±4 mmHg; SLD: 
158±2 mmHg; p=0.0001). BP data were pooled due to lack of significant sex differences 
between treated groups. Tubulointerstitial fibrosis (n=3/group) was measured in kidney 
sections stained with Masson’s trichrome. Tubulointerstitial fibrosis is increased in male 
Dahl S offspring of untreated mothers as compared with offspring of sildenafil treated dams 
(Area: VEH: 9.0 ±0.6%; SLD: 5.0 ±0.6%, p=0.006), but no differences were observed in 
female rats (VEH: 5.3 ±0.7%; SLD: 6.0 ±0.6%). Urine was collected for measurement 
of urinary protein (Bradford assay), but no significant differences in proteinuria were 
observed (VEH male: 87 ±23 mg/day; SLD male: 138 ±18 mg/day; VEH female: 
64 ±9 mg/day; SLD female: 53 ±7mg/day).
Conclusions: These data support the hypothesis that use of a PDE-5 inhibitor during 
preeclamptic pregnancy improves the long-term BP and renal injury in the offspring.
Funding: NIDDK Support, Other NIH Support - NHLBI R01, Private Foundation 
Support
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The Role of Renal Claudin-4 Protein in Salt-Induced Hypertension of 
Spontaneous Hypertensive and Dahl Salt Rats
Gheun-Ho Kim, Sua Kim, Chor ho Jo. Hanyang University, Seoul, Republic of 
Korea.
Background: Claudin proteins in the kidney act as Na+ barrier or Cl- channel, and 
hypotension was reported from renal claudin-4 knockout mice due to urinary Cl- loss. Our 
previous study showed that salt-sensitive hypertension was associated with upregulation 
ofclaudin-4 in Dahl salt rats (DSR). Here we extended our work to see if any changes 
in renal claudin proteins precede the development of salt-sensitive hypertension in 
spontaneous hypertensive rats (SHR) and DSR.
Methods: Time course studies were undertaken over two weeks for SHR and one week 
for DSR. SHR were randomly divided into normal salt-loaded (SN, n=4) and high salt-
loaded (SH, n=4) rats at each time point. High salt was offered with 8% NaCl diet. Wistar 
Kyoto rats (WKR) served as controls and were given normal salt diet. DSR were classified 
into salt-resistant (SR, n=6) and salt-sensitive (SS, n=6) rats, and both groups were given 
8% NaCl diet. Systolic blood pressure (SBP), urine sodium excretion, and renal protein 
expression of claudin-2, claudin-4, claudin-7, claudin-8, and claudin-10 were serially 
followed.
Results: At baseline, SBP was higher in SHR than in WKR (137 ± 1 vs. 118 ± 1 mmHg, 
P<0.05). SBP was not different between SN and SH at Day 7, but was higher in SH than in 
SN (162 ± 1 vs. 156 ± 1 mmHg, P<0.05) at Day 14. WKR had lower SBPs throughout the 
period (114 ± 1 mmHg at Day 14). At baseline, claudin-4 (123 ± 1 vs. 100 ± 2%, P<0.05) 
expression increased in SHR compared with WKR. The expression of claudin-4 was not 
different between SN and SH at baseline, but increased in SH compared with SN from Day 
7 (185 ± 4 vs. 130 ± 2%, P<0.05) to Day 14. In DSR, SBP was not significantly different 
between SR and SS through Day 3, but increased in SScompared with SR (141 ± 2 vs. 
119 ± 1 mmHg, P<0.05) at Day 7. From baseline (174 ± 3 vs. 100 ± 3%, P<0.05) to Day 3 
(240 ± 4 vs. 100 ± 3%, P<0.05), claudin-4 expression increased in SS compared with SR. 
Immunofluorescence localization of claudins in the kidney was compatible with the results 
of immunoblot analysis.
Conclusions: In response to high salt intake, the increase in renal claudin-4 protein 
preceded the elevation of SBP in both SHR and DSR. Claudin-4 expression also increased 
in SHR compared with WKR. These findings suggest the contributory role of renal 
claudin-4 in salt-sensitive hypertension.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - I
Role of Na/K-ATPase Signaling in Susceptibility to Hypertension in 
Salt-Sensitive Animal Models
Yanling Yan,1 Muhammad A. Chaudhry,2 Ying Nie,8 Shuyan Sun,7 Fang Bai,3 
Rebecca Pratt,2 Cameron Brickman,4 Komal Sodhi,5 Jung Han Kim,2 
Deepak K. Malhotra,6 Zi-jian Xie,8 Joseph I. Shapiro,2,6 Jiang Liu.3 1Marshall 
University, Joan C. Edwards School of Medicine, Huntington, WV; 2Marshall 
University School of Medicine, Huntington, WV; 3Marshall University JCE 
School of Medicine, Huntington, WV; 4Marshall University JCESOM, 
Huntington, WV; 5Marshall University Joan C. Edwards School of Medicine, 
Huntington, WV; 6The University of Toledo, Toledo, OH; 7Shijiangzhuang 
Medical School, Proctorville, OH; 8Marshall University, Huntington, WV.
Background: Previous studies from our and our collaborative laboratories have 
indicated that Na/K-ATPase acts as a receptor for reactive oxygen species (ROS), 
regulating renal Na+ handling and blood pressure (JBC, 2011; JAHA, 2016). In the present 
work, the Na/K-ATPase signaling was investigated in the animal models of salt-sensitive 
hypertension.
Methods: Studies were conducted with tissues from rats and mice made hypertensive 
by the salt administration. Na/K-ATPase signaling including phosphorylation of c-Src 
and ERK1/2 and protein carbonylation (DNP, commonly used as a marker for ROS) 
was assessed by Western blot(WB). Renal function curve was constructed with high salt 
diets (HS, 2, 4, and 8% NaCl). Urinary and plasma Na+ levels were measured by flame 
photometry.
Results: In the Dahl salt-sensitive hypertensive rat (S), the renal proximal tubules 
(RPTs) contained significantly more protein carbonylation than did the control (Dahl 
salt-resistant rat, R) RPTs (Fig. A. NC, Normal chow). Qualitatively similar effects were 
observed on the Na/K-ATPase signaling from the kidney cortex of three obese rat and mouse 
models (Fig. B-D). As did Dahl S rat, (Fig. A and in JBC, 2011), Na/K-ATPase signaling 
was not able to be stimulated by HS (Fig. D), leading to blunted urinary Na+ excretion 
and salt-sensitive hypertension in obese TALLYHO/JngJ (TH) mice. More importantly, 
pNaKtide as an antagonist of Na/K-ATPase signaling attenuated protein carbonylation and 
c-Src phosphorylation stimulated by a high-fat diet (HF, Fig. C).
Conclusions: All four forms of salt-sensitive hypertension showed significant elevation 
of baseline Na/K-ATPase signaling when compared to their respective controls, indicating 
that this aberration in Na/K-ATPase signaling may represent a common signaling defect 
fundamental to the salt-sensitive hypertensive syndrome irrespective of etiology.
Funding: Other NIH Support - Research reported in this abstract was supported by 
the National Institute Of General Medical Sciences of the National Institutes of Health 
under Award Number 1P20GM121299-01A1 Sub-Project ID: 8359 (to Y. Yan), NIH R15 
1R15DK106666-01A1 (to J. Liu), and NIH RO1 HL071556 (to J.I. Shapiro).
FR-PO317 Poster Friday
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Tubulo-Glomerular Feedback Independent Hypertension and Kidney 
Interstitial Fibrosis in DOCA-Salt Mice
Xiaoxiao Shi, Xiaoyan Peng, Dongli Tian, Peng Xia, Yubing Wen, Limeng Chen. 
Peking Union Medical College Hospital Kidney Lab Peking Union Medical 
College Hospital, Beijing, China.
Background: Sodium transporters and tubulo-glomerular feedback (TGF) play 
important roles in sodium balance and blood pressure maintanence. Renal adenosine-A1 
adenosine receptor (A1AR) pathway, which is mediated by Na-K-Cl cotransporter 2 
(NKCC2), is involved in the classic TGF mechanism. This study was to observe the role of 
sodium transporters and A1AR in salt-sensitive hypertension and associated kidney injury.
Methods: Deoxycorticosterone acetate (DOCA)-salt hypertensive mouse model 
was established by removal of left kidney, implantation of a DOCA pellet (200mg, 60-
day release), and feeding with high salt diet (8%NaCl). Arterial blood pressure and urine 
electrolyte excretion were determined. Pathological changes, protein and mRNA expression 
of sodium transporters and adenosine-A1AR pathway were measured in mice kidney.
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Results: DOCA-salt and uni-nephrectomy treatment in wildtype C57BL/6J mice led 
to continuous higher blood pressure, accompanied by obvious tubulo-interstitial injury 
and interstitial fibrosis at different ages (4w, 8w). In DOCA-salt wildtype mice, the Na+-
Cl- cotransporter (NCC) and NKCC2 upregulation (1.6-1.75 times) were observed in 
kidney, with activation of adenosine-A1AR pathway (mRNA expression of adenosine 
synthetase CD73 and A1AR about 2-3 times increased). DOCA-salt mice also showed 
signs of glomerular hyperperfusion and hyperfiltration, which included polyuria, increased 
urine sodium excretion and kidney enlargement. Compared with DOCA-salt wildtype 
mice, the DOCA-salt A1AR-/- mice presented more severe glomerular hyperperfusion 
and hyperfiltration (including polyuria and increased urine sodium excretion). However, 
DOCA-salt A1AR-/- mice showed the same degree of hypertension (4w: 125.7±7.4 vs. 
127.4±18.8 mmHg; 8w: 135.3±5.2 vs. 141.7±9.5 mmHg; P>0.05 both) and renal interstitial 
fibrosis (4w: 2.05±1.73% vs. 1.52±1.44%; 8w: 10.35±4.86 vs. 9.42±5.95%; P>0.05 both), 
which were compliant with the change of NCC protein expression (4w 1.65 ± 0.19 vs. 
1.70 ± 0.18; 8w 1.47 ± 0.21 vs 1.00 ± 0.34, P>0.05 both).
Conclusions: DOCA-salt treatment in mice induced hypertension and kidney interstitial 
fibrosis. The mechanism may lie in NCC activation, instead of NKCC2 associated TGF.
Funding: Government Support - Non-U.S.
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In Obese ZSF1 Rats Salt-Sensitivity of Blood Pressure Is Positively 
Related to Free Sodium in Skin and Negatively to Bound Sodium in Skin
Isabel T. Nguyen,1 Anne-Maj Samuelsson,2 Jaap A. Joles,1 Marianne C. Verhaar.1 
1University Medical Center Utrecht, Utrecht, Netherlands; 2University of 
Bergen, Bergen, Norway.
Background: Last year we reported that blood pressure in Zucker fatty/spontaneously 
hypertensive heart failure F1 hybrid (ZSF1) rats exposed to deoxycorticosterone acetate 
(DOCA) and fed a high salt diet is more salt-sensitive in obese than in lean ZSF1 rats 
(p<0.0001). Moreover, obese females were even more salt-sensitive than obese males 
(p<0.01). Only male obese ZSF1 were hyperglycemic and manifested glycosuria (Nguyen 
et al. ASN 2017). This follow-up study dissects the role of free and bound sodium in the skin 
on the differences in salt-sensitivity between female and male obese ZSF1 rats.
Methods: Male and female ZSF1 rats, lean (N=4-6/subgroup) and obese (N=6-8/
subgroup), were either implanted with a DOCA pellet and fed a high salt diet (6% NaCl) or 
with a placebo pellet and fed a normal salt diet from 19 weeks of age. Every two weeks, from 
18 (i.e prior to pellet implantation) to 26 weeks of age, systolic blood pressure (SBP) and 
24-hours urine was collected. To further elucidate the diverging natriuresis-pressure relations 
in the obese ZSF1, skin sodium content was determined at 26 weeks (N=2-4/group).
Results: On placebo, obese male ZSF1 showed more free sodium in skin than obese 
females (p=0.03). However, on DOCA+salt, obese females showed higher free sodium 
compared to obese males (p=0.053). The interaction between sex and DOCA+salt on free 
sodium in skin was very significant (p=0.002). For bound sodium in skin changes were in 
the reverse direction (interaction: p=0.036). Overall (N=6), the increase in blood pressure/
natriuresis on DOCA+salt from week 18 to week 26 correlated positively with free sodium 
in skin (r=0.91, P=0.01; Figure 1A) and tended to correlate negatively with bound sodium 
in skin (r=0.69, P=0.13; Figure 1B).
Conclusions: Our results indicate that in obese ZSF1 rats inverse relations exist 
between salt sensitivity of blood pressure and free versus bound sodium in the skin. 
Compartmentalization of sodium in the skin is influenced by sex, which in this model may 
be associated with differences in glycemia.
Funding: Private Foundation Support
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Deletion of SPAK (Stk39) Reduces Hypertension, NKCC2 Phosphorylation 
and NKCC2 Activity in Dahl Salt-Sensitive Rats
Jose A. Garcia-Pedraza,1,2 Tang-Dong Liao,1 Pablo A. Ortiz.1 1Henry Ford 
Hospital, Detroit, MI; 2University of Salamanca, Salamanca, Spain.
Background: The Na/K/2Cl cotransporter NKCC2 mediates the NaCl reabsorption in 
the thick ascending limb (TAL), playing a crucial role in blood pressure regulation. NKCC2 
can be phosphorylated by the SPAK kinase (Stk39) at Thr96,101 and this is thought to activate 
NKCC2. We found that NKCC2 phosphorylation was 5-fold higher in TALs from Dahl 
salt-sensitive (DSS) rats. However, the role of SPAK in NKCC2 function and salt-sensitive 
hypertension remain unclear. We hypothesized that SPAK is involved in salt-sensitive 
hypertension in part by increasing NKCC2 phosphorylation and activity.
Methods: To test this, we generated SPAK knockout (KO) rats in a DSS genetic 
background via Crispr/Cas9 targeting. We used telemetry to measure systolic blood 
pressure (SBP) on normal (0.22% Na) or high salt diet (4% Na).
Results: At baseline, SPAK-KO had lower SBP than wild-type DSS (WT) rats 
(SPAK-KO: 139±1, WT: 153±2 mmHg; p<0.05). After 4 weeks on high salt, SBP rose 
reaching 162±3 in SPAK-KO and 183±3 mmHg in WT rats (p<0.05). The increase in SBP 
after feeding a high salt diet was lower in SPAK-KO than WT rats at 7 days (10±1 vs  
15±1 mmHg, p<0.05), 14 days (14±2 vs 19±2 mmHg, p<0.05), and 28 days (22±3 vs  
30±2 mmHg, p<0.05). We measured total and phospho-NKCC2 in isolated TALs. On 
normal salt diet, phospho-NKCC2 (Thr96,101) over total NKCC2 was 61±25% lower in 
SPAK-KO (p<0.05), whereas total NKCC2 was not different. After 4 weeks on high salt, 
phospho-NKCC2 was 62±13% lower in SPAK-KO (p<0.05) whereas total NKCC2 was not 
different. SPAK-KO rats had a decreased bumetanide-induced natriuresis while on a normal 
salt diet (UNa WT: 1271±55; UNa SPAK-KO: 843±80 μmol/12h; p<0.05). Lymphocyte 
infiltration (CD3+) into the kidney after 4 weeks on high salt diet was not different between 
strains, whereas CD68+ macrophages were lower in SPAK-KO (WT: 266±35, SPAK-KO: 
150±6 CD68+/mm2, p<0.05).
Conclusions: We conclude that SPAK-KO DSS rats exhibit lower SBP at baseline and 
reduced salt-sensitivity in part caused by lower NKCC2 phosphorylation and activity. In 
addition, decreased macrophage infiltration in SPAK KO rats supports a potential role for 
SPAK in renal inflammation during salt-sensitive hypertension.
Funding: NIDDK Support
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Exogenous Mineralocorticoid Administration and Acute Salt Loading 
Effects on NCC Expression and Activity in Hypertensives with Raised 
Aldosterone/Renin Ratio (ARR)
Aihua Wu,2 Martin Wolley,2,1 Diane Cowley,2 Richard Gordon,2 Robert Fenton,3 
Michael Stowasser.2 1Department of Nephrology, Royal Brisbane and Women’s 
Hospital, Brisbane, QLD, Australia; 2Endocrine Hypertension Research Centre, 
The University of Queensland Diamantina Institute, Greenslopes and Princess 
Alexandra Hospitals, Brisbane, QLD, Australia; 3Department of Biomedicine, 
Aarhus University, Aarhus, Denmark.
Background: Primary aldosteronism (PA) is a common form of hypertension (HTN) 
caused by autonomous aldosterone (Aldo) production. Aldo is the major endogenous 
mineralocorticoid regulating sodium (Na) reabsorption by stimulating the Na-Cl 
cotransporter (NCC) and the epithelial Na channel (ENaC) in the renal distal tubule. 
Potassium (K) may also regulate NCC. Exogenous mineralocorticoid and salt loading 
suppress plasma Aldo, and affect differently NCC and ENaC in human and murine studies.
Methods: Urine samples were collected before and after fludrocortisone suppression 
testing (FST; fludrocortisone administration and orally salt loading for 4 days) from 13 
subjects (10 with HTN and raised ARR and 3 cured of PA by unilateral adrenalectomy); and 
saline suppression testing (SST; 2L saline infusion over 4h) from 9 subjects (5 with HTN 
and raised ARR and 4 cured of PA). Urinary exosomes were analysed by immunoblotting.
Results: Significant increases in abundances of NCC (mean 2.97 fold, p=0.04) and 
pNCC (mean 2.06 fold, p=0.03) by day 4 of FST were observed in 10 with HTN and raised 
ARR, yet no clear trends of NCC and pNCC were observed in the 3 cured of PA. There were 
no significant changes in abundance of prostasin, cleaved γ-ENaC and NKCC2 post FST 
in all 13 subjects, but cleaved γ-ENaC rose post FST (mean 1.17 fold, p=0.05) among the 
10 with HTN and raised ARR. There were trends observed towards decreases in abundance 
of NCC (p=0.09) and pNCC (p=0.07) in 5 with HTN and raised ARR undergoing SST, but 
not in 4 cure of PA where NCC and pNCC were already low at baseline. The abundances of 
cleaved γ-ENaC and NKCC2 were unchanged. Plasma Aldo droped in both subjects with 
HTN and raised ARR (from 328.6 to 180.8 pM, p=0.07) and subjects cured of PA (from 
153.75 to 57.25 pM, p=0.05) after SST, but plasma K was unchanged.
Conclusions: Variation of NCC abundance and phosphorylation during FST and SST 
is detectable in human urinary exosomes. Exogenous mineralocorticoid administration is 
associated with increases in exosomal NCC and pNCC. The decreases in NCC and pNCC 
abundance during SST in HTN with raised ARR suggest acute salt loading may induce 
salt excretion by reducing NCC expression and activity, which may relate to a reduction in 
plasma Aldo but is independent of plasma K.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - I
Stimulatory Effects of NaCl on Tonic Highly Sensitive Cultured Neurons 
with Renal Afferents
Kristina Rodionova,2,1 Amelie Dietz,2 Martin Hindermann,2 Tilmann Ditting,2,1 
Christian Ott,2,1 Roland E. Schmieder,2 Kerstin U. Amann,3 Roland Veelken.2,1 
1Medical Department 4, Paracelsus Private Medical School, Nuremberg, 
Germany; 2Dept. of Nephrology, Friedrich-Alexander-University Erlangen-
Nuremberg, Erlangen, Germany; 3Dept. of Nephropathology, Friedrich-
Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Background: An important regulatory role of afferent nerve fibers from the kidney has 
been postulated for a while especially in developing hypertension and counterregulation 
of salt loading. However, it is not known how salt will act on renal afferent nerves. Hence 
we wanted to test the hypothesis that even short exposure to low NaCl concentrations will 
already induce significant action potential generation in cultured neurons with renal axons.
Methods: Over 180 cultured dorsal root ganglion neurons (Th11-L2) of rats with renal 
afferents in vitro were investigated in current clamp mode to asses action potential (AP) 
generation and classify neurons as tonic (high AP generation upon stimulation) and phasic 
(AP ≤ 5 upon stimulation). Furthermore, experiments in voltage clamp mode to assess 
inward currents have been performed. Cultured neurons were exposed to short periods of 
superfused boli with increasing NaCl concentrations (0.3%, 3%, 4.5%, 10%).
Results: Renal neurons exhibited significant production of action potentials to NaCl 
superperfusion that was impaired with increasing concentrations of NaCl (0.3%: 36+/-
Hypertension and CVD: Mechanisms - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
504
J Am Soc Nephrol 29: 2018 Poster/Friday
9.6 APs/10s; 3%: 14.5+/-3.6 APs/10s; 4.5%: 7.8+/-0.7 APs/10s; p<0.05; mean+/-SEM). 
Superfusion with 10 % NaCl increased AP generation in tonic neurons (15.9+/-3.1 APs/10s, 
p<0.05; mean+/-SEM) likely due to unspecific e.g. osmotic effects. Phasic neurons were not 
affected by NaCl. Classification of renal neurons according to their firing pattern (tonic or 
phasic) revealed the majority of renal neurons to be tonic as previously described.
Conclusions: Superfusion with NaCl in a low concentration led to marked increases of 
action potential production in tonic, highly active neurons (a characteristic feature of renal 
innervation) that was impaired with higher superpefused NaCl concentrations in a dose-
dependent manner. Hence, NaCl likely influences renal sympathetic nerve activity via the 
stimulation of renal afferents. However, this effect might be not uniform for all forms and 
stages of salt loading and hypertension.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - I
Neurogenic SP Facilitates Action Potential Production in Tonic Highly 
Sensitive Cultured Neurons with Renal Afferents
Kristina Rodionova,1,3 Tilmann Ditting,1,3 Johannes Schätzl,1 Martin 
Hindermann,1 Christian Ott,1,3 Roland E. Schmieder,1 Kerstin U. Amann,2 
Roland Veelken.1,3 1Dept. of Nephrology, Friedrich-Alexander-University 
Erlangen Nürnberg, Erlangen, Germany; 2Dept. of Nephropathology, Univestiy 
of Erlangen-Nuremberg, Erlangen, Germany; 3Medical Department 4, 
Paracelsus Private Medical School, Nuremberg, Germany.
Background: Release of the proinflammatory peptide SP from afferent nerves 
has been shown to influence local inflammation. But SP is also involved in a powerful 
sympathoinhibitory afferent renal nerve pathway with a long time-constant. Hence we 
wanted to test the hypothesis that SP also influences action potential production related 
to TRPV1 receptor stimulation in cultured neurons with afferent axons from the kidney 
in vivo.
Methods: Cultured dorsal root ganglion neurons (Th11-L2) of rats with renal 
afferents in vivo were investigated in current clamp mode to asses action potential (AP) 
generation and classify neurons as tonic (high AP generation upon stimulation) and phasic 
(AP ≤ 5 upon stimulation). Furthermore experiments in voltage clamp mode to assess 
inward currents. For stimulation of TRPV1 receptors acid of pH 6 was used with and 
without the addition of SP (0.5 μmol) or CGRP (0.5 μmol).
Results: More than 92 DRG neurons with renal afferents were tested. Addition of SP 
did not change action potential generation nor inward currents. Proton stimulation (pH 6) 
of TRPV1 significantly increased action potential production in tonic neurons (0 APs/10s 
vs. 9.57+/-1.89 APs/10s, p<0.05, mean+/- SEM) and augmented long-term inward currents 
(baseline -361.7 +/- 89.6 pA vs. -1393.3+/-337.3 pA, p<0.05, mean +/- SEM). The co-
stimulation of renal neurons with protons (pH 6) and SP increased the number of action 
potentials per 10 seconds in tonic neurons (9.57 +/-1.89 APs/10s vs. 16.86+/2.3 APs/10s, 
p<0.05, mean+/- SEM) as compared to a co-stimulation with CGRP, that was not effective 
in this respect (13.19+/-1,62 APs/10s vs. 9.57 +/-1.89 APs/10s).
Conclusions: SP in contrast to CGRP facilitated action potential production in 
tonic, highly active neurons with axons from the kidney (a characteristic feature of renal 
innervation). Hence, SP might increase the sensitivity of afferent renal nerve pathways thus 
influencing renal sympathetic nerve control.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - I
Increased Renal Protein Expressions of SLC4A4 and SLC4A5 in 
Salt-Sensitive C57Bl/6J Mice
Xiaoyan Wang, Xiaobo Ma, Laureano D. Asico, Pedro A. Jose. Hypertension & 
Renal Diseases George Washington University School of Medicine, Washington, DC.
Background: C57Bl/6J mice are salt-sensitive caused, in part, by the dysfunction of 
the renal dopamine D1 receptor. However, the role of renal ion transporters in salt-sensitive 
mice is not well understood.
Methods: Therefore, we studied the effect of varying amounts of sodium intake on the 
blood pressure (BP) and renal expression of exchanger/transporters/channels for sodium 
and other ions in salt-sensitive C57Bl/6J mice and salt-resistant BALB/c mice.
Results: We found that 4% NaCl diet given for 1 wk increased the BP (ΔBP=+20 mm 
Hg) of C57Bl/6J (male, 3 months old, n=5) but not of sex-and age-matched BALB/c mice 
(n=5). C57Bl/6J mice on high NaCl intake (1.6%, 4%, 6%) had higher BP (ΔBP=+20 mm Hg) 
relative to when they were on low or normal NaCl intake (<0.09%, 0.6%, 0.8%). The dietary 
salt-induced increase in BP was observed in anesthetized and conscious, unanesthetized 
mice, measured by telemetry. There were no differences in water/food intake, urinary 
excretion, and serum concentrations of Na+, K+, and Cl- between the two mouse strains. 
However, high salt intake (4%NaCl) increased the renal protein expressions of SLC4A5 
(NBCe2) (162±8% vs. 100±5%) and SLC4A4 (NBC1) (163±12%) compared with normal 
salt diet in C57Bl/6J mice, which was not observed in BALB/c mice. By contrast, the 4% 
NaCl diet increased renal SLC26A6 (Pendrin L1) in both C57Bl/6J (190±1%) and BALB/c 
(161±8%) mice. Increased NaCl intake did not affect the renal protein expression of NHE3 
in either mouse strain. Renal protein expressions of NCC and αENaC, but not of NKCC2 
and γENaC, were decreased by high salt diet in BALB/c, but not in C57Bl/6J mice.
Conclusions: We conclude that the salt sensitivity of BP in C57Bl/6J mice is associated 
with increased renal protein expressions of SLC4A4 and SLC4A5 and impaired salt-
mediated down-regulation of NCC and αENaC.
Funding: NIDDK Support, Other NIH Support - HL68686, HL23081, HL074940, 
HL092196, Private Foundation Support
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Hypertension and CVD: Mechanisms - I
Up-regulation of SGLT-5 as a Cause of Fructose-Induced Volume- 
Dependent Hypertension
Hiroaki Hara,1 Kaori Takayanagi,1 Yuka Kitamura,1 Takatsugu Iwashita,1 
Taisuke Shimizu,1 Masaaki Terao,1 Ryo Yamamoto,1 Yoshimi Okada,1 
Tomonari Ogawa,1 Koichi Kanozawa,1 Hajime Hasegawa.2 Department of 
Nephrology & Hypertension, Saitama Medical Center, Saitama Medical 
University 1Saitama Medical Center, Saitama Medical University, Kawagoe, 
Japan; 2School of Medicine, Saitama Medical University, Kawagoe, Japan.
Background: Excessive intake of fructose causes a variety of adverse conditions 
including obesity, hepatic steatosis, insulin resistance, uric acid overproduction and 
hypertension which is the most common and significant pathological setting. Cause of 
the hypertension is not known at present. This study aimed to elucidate the underlying 
mechanism of fructose-induced hypertension by rat model.
Methods: Male SD rats (7 weeks old) were fed by food containing 60% glucose (GLU) 
and 60% fructose (FRU) for 3, 6 and 12 weeks. Histological, immunohistological and 
molecular biological analysis, and gene chip study were applied. No difference of calorie 
and salt intake of individual animal was daily checked by the measured weight of remaining 
food.
Results: Mean blood pressure and fractional sodium excretion (FENa) of FRU were 
both significantly higher (BP 12w-GLU: 94.8±3.4 vs 12w-FRU: 103.7±1.2 mmHg; FENa 
12w-GLU: 0.084±0.011 vs 12w-FRU: 0.059±0.08%), suggesting that fructose caused ECF 
volume-dependent hypertension. Glomerular expansion in FRU (glomerular surface area 
in 12w-GLU: 7495±181 vs 12w-FRU: 9831±164 μm2) was agreed with the increase in 
the ECF volume. The expression of GLUT-5, fructose entry pathway, and ketohexokinase, 
phosphatase of fructose, in the proximal tubule were both up-regulated by fructose. As a 
candidate of fructose-induced salt reabsorption pathway, NHE3 was focused first because 
it is principal salt reabsorption pathway of proximal tubule. However, gene expression 
analysis, immunohistochemistry and immunoblotting of whole and phosphorylated NHE3 
indicated negative results. To explore salt transporting molecules responding to fructose, 
gene chip analysis was conducted, and Slc5a10, corresponding to SGLT-5, showed 
significant up-regulation. The result was confirmed by RT-PCR (12w-GLU: 75.0±5.8% 
vs 12w-FLU: 230.1±16.0%), and SGLT-1 mRNA was also confirmed to be up-regulated 
(12w-GLU: 127.9±15.1% vs 12w-FLU: 214.8 ±37.4%).
Conclusions: Excess intake of fructose caused volume-dependent hypertension due to 
increased salt reabsorption through fructose-induced up-regulation of SGLT-1 and 5.
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Hypertension and CVD: Mechanisms - I
Sympathetic Nervous System Regulation of the NCC Is Mediated by 
α1-Adrenoceptors and OxSR1 to Drive Hypertension
Franco J. Puleo, Alissa Frame, Richard D. Wainford. Boston University, Boston, MA.
Background: Recent studies suggest that Sympathetic nervous system (SNS) release 
of norepinephrine (NE) mediates acute sodium chloride cotransporter (NCC) upregulation 
via synergistic α1 and β adrenoceptor pathways and oxidative stress responsive 1 
(OXSR1) signaling in NCC regulation. Hypothesis: NE increases NCC activity via an 
α1-adrenoceptor and OxSR1 pathway to drive neurogenic or salt sensitive hypertension 
(HTN, SSH).
Methods: Male Sprague-Dawley (SD) rats receiving a continuous s.c. saline, NE 
(600ng/min), or NE + terazosin (α1 antagonist, 10mg/kg/day) infusion were fed a 0.6% 
(NS) or 4% NaCl (HS) diet for 14 days. Naïve or 14 day s.c. terazosin infused spontaneous 
hypertensive rats (SHR) and Wister Kyoto (WKY) rats were also assessed (N=4/gp). On 
day 14 basal MAP and NCC activity (peak natriuresis to hydrochlorothiazide [HCTZ]; 
2mg/kg) were assessed. NCC, phosphoNCC, and OXSR1 protein levels were assayed via 
immunoblotting. Expression of adrenoceptor mRNA (α1A-D, β1, β2) was assessed via 
qPCR using kidney samples from separate groups of rats (N=6/gp).
Results: SD rats remain normotensive on a HS diet and NCC expression and activity is 
downregulated. NE infusion prevents HS-evoked NCC downregulation, leads to increased 
OXSR1 expression, and drives SSH. The SHR model of neurogenic HTN shows increased 
NCC activity and high BP. SHR and NE-infused SD rats show increased expression of α1-
adrenoceptor-1D mRNA (SHR: 1.4±0.1 fold increase vs. WKY rats, NE-infused SD rats on 
NS: 2.2 ±0.5 fold increase, on HS: 2.2±0.4 fold increase vs. respective SD rat diet group). 
Antagonism of α1-adrenoceptors 1) abolishes SSH and restores HS evoked downregulation 
of NCC activity in NE-infused SD rats, 2) reduces NCC activity and BP in SHR.
Conclusions: SNS release of NE can modulate NCC activity via an α1-adrenoceptor 
pathway to evoke SSH and neurogenic HTN. Taken together, we propose a model whereby 
SNS release of NE activates a linear α1-adrenoceptor pathway that stimulates OxSR1-
mediated NCC regulation. Thus, sympathetically driven increases in renal expression of 
α1-adrenoceptors may contribute to SSH and HTN by driving increases in NCC mediated 
sodium reabsorption and BP.
Funding: Other NIH Support - R01HL139867, R01HL141406, R01HL107330, 
K02HL112718, F31DK116501, 17GRNT33670023
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Hypertension and CVD: Mechanisms - I
Increased Proximal Tubule Sodium Avidity Among African Americans vs 
Whites with CKD Correlates with Blood Pressure
Anna L. Zisman,1 Brianna Lambert,1 Stuart M. Sprague,2 Fredric L. Coe,1 
Elaine M. Worcester.1 1University of Chicago, Chicago, IL; 2NorthShore 
University HealthSystem University of Chicago Pritzker School of Medicine, 
Chicago, IL.
Background: Since African Americans (AA) adapt to higher sodium (Na) intake 
mainly with a fall in Na reabsorption in the distal nephron and whites (W) via a fall in 
the higher capacity proximal tubule (PT), AA might be less efficient in adaptation to Na 
loads. This could lead to greater fluid and Na retention and hypertension both with high Na 
diet and chronic kidney disease (CKD), which has not been previously studied. We sought 
to compare patterns of nephron segment Na reabsorption using endogenous lithium and 
iohexol clearances in individuals across race and levels of kidney function.
Methods: 17 subjects (7 male; 10 AA, 9 of the total with CKD with mean GFR 55 ml/min) 
were recruited. Subjects with CKD, if treated for hypertension, were weaned off all 
medication for at least one week prior to study date using a low sodium diet. Subjects could 
participate in the study day only if their blood pressures (BP) remained <150/90 during the 
washout. All subjects were placed on an 80 meq/day sodium diet for 1 week prior to study 
date. Subjects were admitted to the CRC and continuous iohexol infusion (with bolus) was 
initiated. Urine and serum laboratory measurements including basic chemistries and lithium 
were collected at baseline and during six 40-minute clearance periods, with a standardized 
meal served after the 3rd clearance period. BPs were measured with each blood draw.
Results: Fractional excretion of lithium (FELi) was markedly higher in CKD (0.28 
vs. 0.15, p<0.0001) and in W (0.27 vs. 0.17, p<0.0001) (Figure). This correlated to mean 
systolic BP (CKD AA 135 mmHg vs control AA 116 mmHg, p<0.05, and vs W CKD 
115 mmMg p<0.001).
Conclusions: PT sodium avidity is significantly higher in AA subjects in health and in 
CKD and directly correlates with BP.
Funding: NIDDK Support
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Hypertension and CVD: Mechanisms - I
Mineralocorticoid Receptor Antagonism by Finerenone Improves 
Diastolic Dysfunction Induced by CKD in Mice
Benjamin Bonnard,1 Marie Pieronne-Deperrois,2 Zoubir Djerada,2 Soumaya El 
moghrabi,1 Peter Kolkhof,3 Antoine Ouvrard-Pascaud,2 Paul Mulder,2 
Frederic Jaisser,1,4 Smail Messaoudi.1 1Cordeliers Institute, Paris VI-University, 
INSERM U1138, Paris Cedex 13, France; 2Normandie Univ, UNIROUEN, 
FHU- REMOD-VHF, INSERM 1096, Paris, France; 3Cardiology Research, 
BAYER AG, Wuppertal, Germany; 4Clinical Investigation Centre 1433, 
INSERM, Vandoeuvre-lès-Nancy, France.
Background: Managing the cardiovascular complications of renal failure is a major 
therapeutic challenge in clinical practice. Mineralocorticoid Receptor (MR) blockade is a 
highly effective strategy for the management of heart failure, but the use of MR antagonists 
(MRA) is limited by their side effects rendering them contraindicated in patients with 
renal failure. Finerenone is a new non-steroidal MRA that has demonstrated in more than 
2000 patients with heart failure and additional chronic kidney disease (CKD) as well as in 
patients with diabetic kidney disease that neither hyperkalemia nor reductions in kidney 
function were limiting factors to its use. The aim of this study is to characterize the effects of 
finerenone on the cardiac complications of renal failure in a mouse model of CKD.
Methods: CKD was induced by subtotal nephrectomy (Nx), and finerenone was 
administered at a low dose (2.5 mg/kg/d) from week 4 to week 10 post-Nx. Cardiac function 
was assessed by echocardiography and invasive hemodynamic while cardiac fibrosis was 
measured by Sirius Red staining.
Results: Renal failure induced cardiac systolic and diastolic dysfunctions as well as 
minor changes on cardiac structure in untreated CKD mice. We also observed alterations in 
the phosphorylation of proteins playing key roles in the calcium handling (phospholamban, 
calmodulin kinase II) in these mice. Finerenone prevented most of these lesions without 
interfering with renal dysfunction.
Conclusions: The benefits of finerenone suggest that MR plays a key role in the 
development of diastolic dysfunction induced by CKD, thus providing a rationale for 
further clinical studies with MRAs in patients with CKD.
Funding: Commercial Support - BAYER
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Hypertension and CVD: Mechanisms - I
Systemic Succinate Homeostasis and Local Succinate Signaling Control 
Blood Pressure and Modify Risks for Calcium Oxalate Lithogenesis
Ehud Ohana, Ahlam Khamaysi, Liana Shimshilashvili. Ben Gurion university of 
the Negev, Beer Sheva, Israel.
Background: Succinate and citrate are important metabolic signaling molecules. In 
the kidney, low urinary citrate increases the risk for developing kidney stones, while an 
elevation of luminal succinate in the juxtaglomerular apparatus increases renin secretion 
and can cause hypertension. Although the association between kidney stone formation 
and hypertension is well established in humans, the molecular mechanisms that link these 
pathophysiologies remain elusive.
Methods: We have utilized electrophysiological measurements, fluorescent imaging 
and radiolabeled molecules to monitor transport rptoein activity in live cells. In addition 
we utilized biochemical assays to monitor protein expression and interaction. Finally, 
slc26a6-/- mice were utilized to test the physiological effects of impaired succinate and 
citrate homeostasis.
Results: Here, we reveal an intimate relationship between succinate and citrate/oxalate 
in vivo and study the molecular mechanism of this association. Deletion of the succinate/
citrate transport inhibitor, the slc26a6 transporter, in male mice resulted in 40% decrease in 
urinary excretion of succinate, elevated plasma renin and activity-dependent hypertension. 
Structural modeling confirmed by mutational analysis identified the NaDC-1/slc26a6 
interacting surfaces that mediate inhibition of the succinate/citrate transporter, NaDC-1, by 
slc26a6. This interaction is regulated by the scaffolding protein IRBIT, which interacts with 
the NaDC-1/slc26a6 complex and is released upon stimulation of the succinate receptor, 
SUCNR1 to inhibit succinate transport by NaDC-1.
Conclusions: These findings reveal a succinate/citrate homeostatic pathway regulated 
by IRBIT that controls blood pressure and biochemical risk of calcium-oxalate stone 
formation and provides a novel potential molecular link between these syndromes. This may 
have significant clinical implications for stone formation and the associated hypertension.
FR-PO329 Poster Friday
Hypertension and CVD: Mechanisms - I
Succinate Transport Is Mediated and Regulated by the slc26a6/NaDC-1 
Transporters
Ahlam Khamaysi, Ehud Ohana. Department of Clinical Biochemistry and 
Pharmacology, Ben Gurion university of the Negev, Beer Sheva, Israel.
Background: The slc26a6/NaDC-1 system controls citrate absorption from the urinary 
lumen. Urinary citrate chelates free Ca2+ thus protecting against Ca2+-oxalate crystallization. 
Since the slc26a6/NaDC-1 complex mediates and regulates both citrate and succinate 
transport, a major question that we asked here is whether the same mechanism controls 
succinate homeostasis and which molecular determinants mediate slc26a6-NaDC-1 
interaction and regulation.
Methods: We monitored protein-protein interaction by coimmunoprecipiatation. 
Succinate transport was monitored using electrophysiological measurements.
Results: Our structural modeling confirmed by mutational analysis identified the 
slc26a6/NaDC-1 interacting surfaces that mediate regulation of NaDC-1 by slc26a6. To 
test our model, we monitored the effects of slc26a6 (E613A) and NaDC-1(K107A, R108A) 
on NaDC-1–slc26a6 interaction by co-immunoprecipitation (coIP). The slc26a6(E613A) 
mutant showed reduced interaction with NaDC-1 and reduced inhibition of NaDC-1 
activity, assayed as Na+-dependent succinate currents. Although expression of slc26a6 
was not affected by the (E613A) mutation, slc26a6(E613A) had ~30% lower Cl-/oxalate 
exchange activity. The role of NaDC-1(K107) and NaDC-1(R108) in the NaDC-1–slc26a6 
interaction is shown. While NaDC-1(R108A) was inactive (not shown), NaDC-1(K107A) 
retained its activity. Importantly, however, the interaction between NaDC-1(K107A) and 
slc26a6 was reduced and NaDC-1(K107A) was not inhibited by slc26a6, which strongly 
inhibits WT NaDC-1.
Conclusions: These results suggest that NaDC-1-mediated succinate transport is 
controlled by the interaction between the two transporters, and that their interaction is 
mediated by E613 at the slc26a6-STAS domain and K107 at the NaDC-1 H4c region.
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Hypertension and CVD: Mechanisms - I
Succinate Signaling Regulates Succinate Transport
Liana Shimshilashvili,1 Ahlam Khamaysi,2 Ehud Ohana.3 1Clinical biochemestry 
and pharmacology, Ben Gurion University of the Negev, Beer sheva, Israel; 
2Clinical biochemestry and pharmacology, Ben Gurion University of the Negev, 
Beer sheva, Israel; 3Clinical biochemestry and pharmacology, Ben Gurion 
university of the Negev, Beer sheva, Israel.
Background: The SUCNR1 acts as an extracellular succinate sensor and is widely 
expressed in a variety of epithelial tissues namely the kidney, liver and the intestine. 
SUCNR1 is a Gq coupled receptor which regulates renin secretion when stimulated in the 
macula densa. In general, Gq coupled receptors elevate intracellular IP3, that subsequently 
binds the IP3 receptor (IP3R) and releases IRBIT. IRBIT is the master transport regulator, 
interacting and modulating the NBC, Slc26a6 and succinate transporters. Here we asked 
whether succinate receptor stimulation regulates succinate transport via the IP3- IRBIT 
pathway.
Methods: We monitored SUCNR1 and NaDC-1 mediated succinate transport using 
fluorescent ion imaging and electrophysiological measurements, respectively. Protein 
expression was monitored using biochemical techniques.
Results: We found that SUCNR1 activity in transfected human embryonic kidney 
cells (HEK293) results in intracellular Ca2+ release, which is abolished by PLC inhibitor. 
Moreover, SUCNR1 activity is desensitized by succinate overstimulation. SUCNR1 
is expected to result in IRBIT release. We found that IRBIT interacts with the succinate 
transporter NaDC-1 and regulates succinate transport.
Conclusions: Together, our results suggest that succinate signaling may regulate 
succinate transport across cellular membranes.
FR-PO331 Poster Friday
Hypertension and CVD: Mechanisms - I
Low Doses of Intrarenal Bradykinin Induce a Monophasic Sympathoin-
hibitory Response
Martin Hindermann,3 Tilmann Ditting,3,2 Kristina Rodionova,3,2 Christina Forray,3 
Christian Ott,3,2 Roland E. Schmieder,3 Kerstin U. Amann,1 Roland Veelken.3,2 
1Dept. of Nephropathology, University of Erlangen-Nürnberg, Erlangen, 
Germany; 2Medical Department 4, Paracelsus Private Medical School, 
Nuremberg, Germany; 3Dept. of Nephrology, Friedrich-Alexander-University 
Erlangen-Nürnberg, Erlangen, Germany.
Background: As recently reported intrarenally administered bradykinin induced a 
biphasic renal sympathetic nerve response (RSNA) with increases and decreases of RSNA 
but not uniform sympathoexcitation as previously assumed. The high doses necessary to 
evoke this biphasic response to bradykinin did not suggest a major physiological role of this 
observation in renal salt and water handling. Hence, we wanted to test the hypothesis that 
significantly lower doses of intrarenal bradykinin as previously used will induce a merely 
monophasic renal sympathoinhibition.
Methods: Groups of anesthetized SD rats (n=6-12) were equipped with femoral 
catheters (blood pressure (BP) & heart rate (HR) recording, drug application), a renal 
arterial catheter for one time intrarenal administration (IRA) of Bradykinin (BK 5 nM, 5 μl) 
or Capsaicin (CAP 1 nM, 10 μl) and a bipolar electrode for RSNA recordings; eventually an 
intravenous (iv) bolus of the NK1-receptor blocker RP67580 (10*10-3M, 15 μl) was given
Results: IRA Bradykinin and IRA CAP decreased RSNA from baseline 
3.8±1.2 μV*sec to 1.3±0.7 μV*sec (5 μl, 5 nM BK, p<0.05) and 4.0±0.6 μV*sec to 
1.6±0.4 μV*sec (10 μl, 1 nM CAP, p<0.01). After reaching the lowest point of RSNA 
activity at 95 min, both groups showed a slight re-increase of RSNA within the following 
55 min (from 1.3±0.7 μV*sec up to 2.4±1.3 μV*sec (BK) and from 1.6±0.4 μV*sec up to 
1.9±0.4 μV*sec (CAP)). Suppressed RSNA in both groups could be unmasked by systemic 
(i.v.) administration of the NK1-blocker (1.4±0.4 μV*sec to 5.0±1.9 μV*sec; p<0.05 (BK); 
3.5±0.6 μV*sec to 9.7±1.7 μV*sec; p<0.01 (CAP)).
Conclusions: Bradykinin is able to reduce renal sympathetic nerve activity in doses 
that are significantly lower than doses inducing a biphasic sympathoexcitatory/-inhibitory 
response suggesting a physiological role of bradykinin in renal sympathetic nerve control 
and hence in neurogenic salt and water handling.
Funding: Government Support - Non-U.S.
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NAD(P)H Oxidase 4 Modulates Generation of Hydrogen Peroxide in Rat 
Aorta and Kidney Glomerulus During High Salt Intake
Xingsheng Li,1,2 Wei-zhong Ying,1,2 Paul W. Sanders.1,2 1University of Alabama 
at Birmingham, Birmingham, AL; 2Birmingham Veterans Affairs Medical 
Center, Birmingham, AL.
Background: NAD(P)H Oxidase 4 (Nox4) is a unique member of a family of 
oxidoreductases, because it is a constitutively active enzyme that produces specifically 
hydrogen peroxide (H2O2). The purpose of present study is to test the hypothesis that high-
salt intake increases H2O2 generation in the aorta and kidney glomerulus through Nox4.
Methods: Sprague-Dawley rats were randomly assigned to receive a low-salt (LS, 
0.3% sodium chloride) or high-salt (HS, 8% sodium chloride) diet for 7 days. Additional 
groups of rats on the LS and HS diets received a Nox4 inhibitor (GKT136901, 60mg/g BW) 
by gavage in the final two days. Fresh aortic rings and kidney glomeruli were prepared for 
H2O2 measurement using Amplex Red ELISA or C2DCF fluorescence staining for confocal 
microscopy. Expression of kidney Nox4 protein was accessed by immunohistochemistry 
in fixed kidney tissue.
Results: Compared with animals maintained on the LS diet, HS enhanced H2O2 
generation in the aorta (P=0.019); animals that received the HS diet had a 47.4% higher 
H2O2 production than animals on the LS diet. Serial scanning using confocal microscopy 
of aortic specimens stained with C2DCF demonstrated that intracellular levels of H2O2 in 
both endothelial and smooth muscle layers of the HS-treated animals were higher than 
the LS group. Treatment of rats with the Nox4 inhibitor reduced intracellular H2O2 levels 
remarkably in both low- and high-salt treated animals. Production of H2O2 by kidney 
glomeruli in rats that received HS was also higher than LS animals (P<0.001), and co-
incubation with the Nox4 inhibitor (50μM) inhibited H2O2 generation in glomeruli of 
animals receiving both the LS and HS diets (P<0.001). Immunohistochemistry of kidney 
sections showed that Nox4 protein expression was increased in animals that received HS 
diet, particularly in outer cortex and medulla. CONCLUSION: In summary, rat aortae and 
kidney glomeruli from rats on a HS diet showed enhanced H2O2 generation, which was 
attenuated by introducing the Nox4 inhibitor. We conclude that Nox4 participated in the 
modulation of the salt-dependent increase in H2O2.
Conclusions: In summary, rat aortae and kidney glomeruli from rats on a high-salt 
diet showed enhanced H2O2 generation, which was attenuated by introducing the Nox4 
inhibitor. We conclude that Nox4 participated in the modulation of the salt-dependent 
increase in H2O2.
Funding: Veterans Affairs Support, Other U.S. Government Support
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Peroxisome Proliferator-Activated Receptor α Attenuates Hypercholesterolemia- 
Induced Serum Sulfatide Abnormalities
Yuji Kamijo, Daiki Aomura, Shigekazu Kurihara, Takayuki Nimura, 
Makoto Harada. Department of Nephrology, Shinshu University School of 
Medicine, Matsumoto, Japan.
Background: As chronic kidney disease (CKD) patients often develop accompanying 
cardiovascular disease (CVD), an understanding of the developmental mechanisms of 
CVD is important for nephrologists. Our past studies have demonstrated that serum levels 
of sulfatides, which belong to glycosphingolipids regulated by peroxisome proliferator-
acitvated receptor α (PPARα) and exert anti-platelet and anticoagulation activities, 
were decreased in end-stage CKD patients and that serum levels of sulfatides in CKD 
patients with CVD were lower than in those without. Thus, reduced serum sulfatides in 
CKD patients is potentially related to CVD development. It is also unknown whether 
hypercholesterolemia, an important CKD risk factor, affects serum levels of sulfatides with 
or without PPARα involvement.
Methods: We fed a high-cholesterol (HC) diet to wild-type (WT) and Ppara-null 
(KO) mice and examined the serum level changes of cholesterol and sulfatides, sulfatide 
metabolism, and oxidative stress, another important factor influencing serum sulfatide 
levels.
Results: The HC diet caused identical levels of hypercholesterolemia in WT and KO 
mice. Serum levels of sulfatides and the expression level of CST, a major sulfatide synthase, 
were significantly decreased in both groups due to cholesterol overload, with significantly 
lower levels in the KO group. On the other hand, oxidative stress was significantly increased 
in both groups by cholesterol overload, with significantly higher levels in KO mice.
Conclusions: Hypercholesterolemia via cholesterol overload induced a reduction of 
serum sulfatide levels, suppression of sulfatide synthase expression, and an increase in 
oxidative stress. PPARα attenuated serum sulfatide abnormalities by maintaining sulfatide 
synthesis and reducing oxidative stress. PPARα activation therapy may therefore be useful 
for preventing CVD in CKD patients with hypercholesterolemia.
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Macrophage Myeloperoxidase Deficiency Attenuates CKD Accelerated 
Atherosclerosis
Anna V. Mathew, Lixia Zeng, Vetalise K. Cheofor, Nancy F. Roeser, Jaeman Byun, 
Subramaniam Pennathur. University of Michigan, Ann Arbor, MI.
Background: Increased myeloperoxidase (MPO) expression and activity are associated 
with cardiovascular disease in chronic kidney disease (CKD). We recently demonstrated 
the presence and catalytic activity of myeloperoxidase in vascular lesions of CKD mice. 
However, it is not known if modulation of MPO alters development and progression of 
exaggerated atherosclerosis in CKD.
Methods: Male and female LDL receptor-deficient mice were subjected to sham or 5/6 
nephrectomy surgery (CKD). These mice were then irradiated and transplanted with bone 
marrow from MPO knock-out (MPOKO) mice to induce macrophage MPO deficiency. The 
mice were then maintained on a high-fat diet for 16 weeks. The extent of atherosclerosis 
was then assessed with oil red O staining of en face aortic sections.
Results: As anticipated, the CKD mice had significantly higher plasma creatinine, 
lower hematocrit, and decreased body weight when compared to the sham animals within 
the same group. After radiation, the MPOKO mice have decreased hematocrit and body 
weight but did not have any change in renal function compared to non-irradiated mice. 
Quantification of aortic oil red O stained lesional area revealed that CKD MPOKO mice 
had significantly decreased aortic plaque area compared to CKD mice with normal MPO 
expression. Both sham mice and CKD mice with MPOKO marrow showed decreased 
atherosclerosis compared to their wildtype counterparts and had no significant change in 
atherosclerosis when compared with each other.
Conclusions: Our studies demonstrate attenuation of atherosclerosis with macrophage 
MPO deficiency in CKD mouse model of atherosclerosis. These results strongly implicate 
macrophage-derived MPO in the pathogenesis of CKD accelerated atherosclerosis.
Funding: NIDDK Support, Other NIH Support - NHLBI K08HL130944
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Interleukin-11 Expression Correlates with Hypertensive Kidney Injury in 
Rat Renovascular Hypertension
Karl F. Hilgers,1 Roland Veelken,1 Kerstin U. Amann,2 Andrea Hartner.3 
1University of Erlangen, Erlangen, Germany; 2University Hospital Erlangen, 
Erlangen, Germany; 3University Hospital of Erlangen, Erlangen, Germany.
Background: Interleukin-11 (IL-11) was recently identified as a crucial determinant of 
cardiovascular fibrosis (Schafer et al. 2017, Nature 552:110). We examined IL-11 expression 
in the heart and the kidney exposed to high blood pressure in renovascular hypertensive rats.
Methods: Two-kidney, one-clip renovascular hypertension (2K1C) was induced in 
rats; controls (CON) were sham operated. IL-11 expression was measured by RT-PCR in 
the left ventricle and the right kidney (exposed to high blood pressure). The correlation of 
renal IL-11 expression with several biomarkers of kidney injury was assessed. We further 
investigated IL-11 expression in 2K1C rats grouped into rats with malignant versus non-
malignant hypertension (based on weight loss, and the number of typical fibrinoid necrosis 
and onion skin lesions per kidney section of the nonclipped kidney).
Results: At 35 days after clipping, mean arterial pressure was 207±4 mmHg in 2K1C 
versus 113±3 mmHg in CON (p=0.004). IL-11 expression in the right kidney was elevated 
19.6±3.3-fold in 2K1C (N=17) compared to CON (N=8, p<0.001). In left ventricular tissue 
there was only a non-significant trend towards higher IL-11 expression in 2K1C compared 
to CON (2-fold, p=0.121). IL-11 in the right kidney in 2K1C correlated with the expression 
of TGFβ (r=0.72, p=0.001), TIMP-1 (r=0.71, p=0.001), collagen 1 (r=0.68, p=0.001), 
PDGF (r=0.81, p<0.001) as well as with serum creatinine (r=0.52, p=0.036). There were 
also correlations with parameters of inflammation including MCP-1 expression (r=0.78, 
p<0.001) and macrophage infiltration (ED-1 staining, r=0.73, p=0.001) but no correlation 
with mean arterial pressure (p=0.299). Rats with malignant 2K1C (N=8) had the highest 
levels of IL-11 expression in the kidney (28.3±3.7-fold versus 11.9±4.1-fold in non-
malignant 2K1C, N=9; p<0.01 by ANOVA and Bonferroni; CON N=6).
Conclusions: Expression of IL-11 in the kidney of renovascular hypertensive rats is 
markedly increased and correlates with parameters of fibrosis, inflammation and loss of 
function.
Funding: Government Support - Non-U.S.
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Dysregulation of a Pro-Inflammatory Signaling Pathway Exacerbates 
Vascular Calcification Induced by Saturated Fatty Acids
Audrey L. Keenan,1 Shohei Kohno,2 Yuji Shiozaki,2 Shinobu Miyazaki-anzai,3 
Makoto Miyazaki.3 1University of Colorado AMC, Aurora, CO; 2University of 
Colorado Denver, Aurora, CO; 3University of Colorado-Denver, Aurora, CO.
Background: Vascular calcification is closely associated with cardiovascular mortality 
in patients with chronic kidney disease (CKD). We previously reported that saturated fatty 
acids (SFAs) such as stearic acid promote osteoblastic differentiation and mineralization 
of vascular smooth muscle cells (VSMCs). We recently found that profound activation 
of aortic IKKb and NFkB-mediated inflammation occurs in mouse models of vascular 
calcification such as SMC-specific SCD1/2 knockout mice. However, the pathological 
relevance of a pro-inflammatory signaling pathway to SFA-mediated vascular calcification 
in CKD is unknown. In this study, we investigated the role of the IKKb-NFkB pathway in 
the development of vascular calcification induced by SFAs.
Methods: We generated several in vitro models of IKKb-NFkB pathway activation or 
suppression using a mouse VSMC line, including VSMCs overexpressing constitutively 
active IKKb (IKKbCA) and IkBa (IKKb deficient) VSMCs (IkBaKO). For in vivo study, we 
generated SMC-specific IKKb knockout mice by crossing IKKb floxed mice with an SMC-
specific Cre transgenic mouse line, SMMHC-Cre(ER)T2, to generate SMC-IKKbKO mice.
Results: IKKbCA significantly increased levels of phosphorylated (active) p65, 
and reduced levels of IkBa protein, a negative regulator of NFkB, resulting in increased 
expression of NFkB target genes, including IL-6, MCP-1 and iNOS. Importantly, IKKb 
activation increased the matrix calcium of VSMCs. In addition to IKKbCA, IkBaKO 
significantly increased expression of NFkB target genes and matrix calcium induced by 
stearate treatment compared with wild type VSMCs. We next examined whether IKKb 
inhibition inhibits calcification of VSMCs. shIKKb inhibited stearate-induced up-regulation 
of NFkB target genes. Unexpectedly, however, IKKb knockdown significantly accelerated 
stearate-induced vascular calcification. Consistent with the in vitro study, SMC-IKKbKO 
mice had significantly larger calcified medial lesions under 5/6 nephrectomy.
Conclusions: This study suggests that the IKKb-NFkB pathway positively and 
negatively regulates mineralization of VSMCs.
Funding: NIDDK Support, Other NIH Support - NHLBI
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New Myeloid-Derived Cells Attributing to Cardio-Renal Syndrome
Akihiro Sagara,1 Norihiko Sakai,1 Yasunori Iwata,1 Kengo Furuichi,1 
Yasuhiko Yamamoto,2 Takashi Wada.1 1Nephrology, Kanazawa University 
Hospital, Kanazawa, Japan; 2Kanazawa University Graduate School of Medical 
Sciences, Kanazawa, Japan.
Background: Cardiovascular disease is connected to chronic kidney disease (CKD), 
which is well-known as cardio-renal syndrome (CRS). Dysregulation of tissue repair is 
a pathological process leading to the end stage of organ failure characterized by tissue 
fibrosis. However, it remains unknown how fibrosis occurs in CRS under CKD.
Methods: To identify bone marrow (BM)-derived cells responsible for the development 
of CRS, continuous angiotensin II (AII) infusion plus unilateral ureteral obstruction (UUO) 
(AII+UUO) CRS model was employed using CAG-GFP mice and Col1a2 (Col)-GFP mice, 
with procedures of parabiosis and bone-marrow transplantation. Flow cytometry was used 
to identify recruited and migrated cells into the hearts or kidneys and gene expression 
analyses were followed by cell sorting. We also used immunohistochemistry and co-culture 
system of sorted cells with mouse embryonic fibroblasts (MEFs) from Col-Luciferase mice.
Results: We newly identified a cluster of myeloid cells, CD45+Sca1+ cells, in the hearts 
as well as kidneys of the CRS model. The cell type was a globular and mononuclear and this 
population was significantly increased in number along with the exacerbation of fibrosis. 
The CD45+Sca1+ cells had an activating potential for collagen production of the cultured 
MEFs and an ability of producing type 1 collagen by themselves. GeneChip analyses and 
flow cytometry showed the subpopulation of the CD45+Sca1+ cells, which expressed CCR8.
Conclusions: We could find a new population of myeloid-derived fibrosis-inducing 
cells, which were associated with cardiac and kidney fibrosis using our CRS model. Further 
studies are needed to elucidate the full role of this cell population in CRS under CKD.
Funding: Government Support - Non-U.S.
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Renin-Angiotensin System Mediates Renal Vasoconstriction Induced by 
Acute Renal Venous Pressure Elevation in Rats
Xiaohua Huang,1 Shereen M. Hamza,1 Wenqing Zhuang,3 William A. Cupples,2 
Branko Braam.1 1University of Alberta, Edmonton, AB, Canada; 2Simon Fraser 
University, Burnaby, BC, Canada; 3Univ. of Alberta, Edmonton, AB, Canada.
Background: Combined cardiac/renal dysfunction is characterized by elevated renal 
venous pressure (RVP). Renin-angiotensin system (RAS) is presumably an important 
mediator of worsening kidney function at a high RVP. In the present study, our hypothesis 
is that acute RVP elevation increases vascular tone leading to decreased renal vascular 
conductance (RVC) can be abolished when endogenous angiotensin II (ANG II) is 
inhibited. Our objective is to evaluate RVP induced renal hemodynamic response during 
ANG II inhibition.
Methods: Male Lewis rats (350-450g) received a regular sodium diet were randomized 
as time control or subjected to RVP increase to 20 mmHg. EndogenousANG II was blocked 
using Enalapril infusion and mean arterial pressure (MAP) was restored by continuous, 
constant ANG II (ANG II “clamped”, n=18) or vasopressin (AVP)(n=11) infusion. To 
increase RVP, the left renal vein was partially occluded for 120 min following 60 min 
baseline. MAP, renal blood flow (RBF) and GFR were continuously monitored.
Results: When ANG II was clamped, elevating RVP (0.4±0.3 to 19.6±0.3 mmHg) 
induced a reduction of MAP by experiment end (Δ -22±4 mmHg, P<0.05). The RVP-
induced RVC reduction previously observed in intact rats was completely inhibited 
(Δ 0.011±0.005 ml/min. mmHg). ANG II clamp did not prevent the decrease of both
RBF (Δ -1.9±0.4ml/min, P<0.05), and ipsilateral GFR (Δ -0.77±0.18 ml/min, P<0.05).
In AVP-infused animals, RVP increase (0.1±0.4 to 19.6±0.6 mmHg) did not impact MAP 
(Δ -5.6±4.0 mmHg). Although RBF decreased (Δ -1.3±0.7ml/min, P<0.05), RVC did
not decrease (Δ 0.022±0.011 ml/min. mmHg) and the reduction of GFR was attenuated 
(Δ -0.45±0.15 ml/min).
Conclusions: RVP induced renal vasoconstriction was abolished and reduction in RBF
and GFR was attenuated when ANG II was fixed or inhibited. This suggests a primary role 
for the RAS in the vasoconstriction induced by increased RVP.
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Hypertension and Proteinuria After Antiangiogenic Drugs: Role of the 
Renin-Angiotensin-Aldosterone System
Roman A. Shingarev,1 Sheron Latcha,1 Insara Jaffer Sathick,1 Minolfa C. Prieto,2 
Edgar A. Jaimes.1 1Memorial Sloan Kettering Cancer Center, New York, NY; 
2Tulane University, New Orleans, LA.
Background: Antiangiogenic drugs (AAD) are an effective treatment for many 
cancers. Hypertension (HTN) and proteinuria (PTN) are frequent side effects of AAD and 
are common reasons for therapy discontinuation. These effects are thought to be due at 
least in part to blockade of VEGF in the vasculature and podocytes, but the mechanisms 
involved are not well understood. Renin-angiotensin-aldosterone system (RAAS) blockade 
is commonly used for treatment despite the lack of evidence of RAAS activation in 
this setting. Here, we examine the link bewteen the development of HTN and PTN and 
intrarenal (IR) RAAS activation.
Methods: Urine albumin/creatinine ratio (ACR) and blood pressure (BP) were 
measured in 28 prospectively enrolled patients before AAD and on subsequent follow-
up visit. Urine angiotensinogen (uAGT) was used as marker of IR RAAS activation and 
quantified by ELISA, corrected for urine creatinine and assessed for association with HTN 
and PTN. HTN was defined as BP ≥ 140/90. PTN was defined as > “trace” on urinalysis.
Results: HTN was present in 8 patients at the study start with 50% developing 
worsening HTN. New HTN developed in 12 patients (60%) and PTN in 10 patients (36%). 
Mean fold uAGT increase was significantly correlated with fold increase in urine ACR 
(r=0.39, p=0.04). A 6-fold increase in uAGT was associated with development of HTN 
and/or PTN, RR= 1.5 (95% confidence interval, 1.1-2.02). Mean fold uAGT increase was 
greater in patients with incident HTN vs non-HTN and with incident PTN vs non-PTN; 
however, this trend did not reach statistical significance. Mean baseline uAGT was not 
predictive of subsequent HTN or PTN.
Conclusions: This study suggests that IR RAAS activation after AAD drugs is 
responsible at least in part for the development of HTN and PTN in these patients. Larger 
studies will be needed to better determine whether IR RAAS activation mediates the 
development of isolated HTN without PTN after AAD.
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ReninNull Cells Synthesize Osteopontin, a Likely Cause of Concentric 
Renal Arteriolar Hypertrophy
Hirofumi Watanabe, Maria Luisa S. Sequeira Lopez, Roberto Ariel Gomez. 
Department of Pediatrics, Child Health Research Center, University of Virginia 
School of Medicine, Charlottesville, VA.
Background: Ren1c gene knockout (Ren1KO) mice develop renal failure and a 
characteristic renal vascular lesion consisting of concentric arteriolar hypertrophy. Recently, 
we discovered that in Ren1KO mice, the cells programmed for the renin phenotype (Reninnull 
cells) survive and increase in numbers along the renal arterial tree, maintain the molecular 
program of the renin phenotype, and integrate in a chaotic, disorderly manner inside the 
vessel wall, thus contributing to the vascular abnormality. However, how Reninnull cells are 
involved in vascular hypertrophy remains to be elucidated.
Methods: We performed transcriptome analysis of renin cells. To isolate renin cells, 
we generated mice that express yellow fluorescent protein (YFP) under the control of 5 Kb 
of the 5’ regulatory region of the Ren1c gene. YFP-positive cells sorted from the kidneys of 
Ren1KO mice were processed for single-cell RNA sequencing (scRNA-seq) and compared 
to cells similarly processed from wild type mice kidneys. RNAs differentially expressed 
were verified by in situ hybridization using digoxigenin-labeled RNA probes. Plasma 
osteopontin (OPN) level was examined by ELISA.
Results: Differential expression analysis of scRNA-seq showed 364 genes significantly 
upregulated in Ren1c wild type cells and 1395 genes significantly upregulated in Ren1KO 
cells. We identified transcripts of 107 genes corresponding to putative secreted proteins 
whose expression were found to be enhanced in the cells from Ren1KO mice. Using in situ 
hybridization, the expression of the several identified genes was detected in the hypertrophic 
arterioles at higher level in Ren1KO mice than control mice. Spp1 gene that encodes OPN is 
one of the most significantly upregulated genes in Reninnull cells. With ELISA, we found that 
plasma OPN level was elevated in Ren1KO mice than control mice.
Conclusions: Reninnull cells in the hypertrophic arterioles in Ren1KO mice express 
secreted protein genes including Spp1 gene. Further study for the function of these genes 
may elucidate the mechanisms of vascular hypertrophy.
Funding: NIDDK Support
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Mitochondrial NADP+ Dependent Isocitrate Dehydrogenase (IDH2) 
Deficiency Aggravates High Fat Diet-Induced Hypertension
Mi Ra Noh,1 Min Jung Kong,2 Jee in Kim,3 Kwon Moo Park.4 1Department of 
Anatomy and BK21 Plus, School of Medicine, Kyungpook National University, 
Daegu, Republic of Korea; 2Kyungpook Nationcal University, Daegu, DaeJeon, 
Republic of Korea; 3Keimyung University, Daegu, Republic of Korea; 
4Kyungpook National University, Daegu, Republic of Korea.
Background: Obesity is a major risk factor for essential hypertension. Oxidative stress 
is an important pathogenic mechanism of obesity-induced hypertension. Mitochondrial 
NADP+-dependent isocitrate dehydrogenase (IDH2) plays as a major antioxidant system 
by production of NADPH, which is an essential player in the glutathione (GSH) and 
thioredoxin systems for peroxide detoxification antioxidant system. Here, we investigated 
the role of IDH2 in high fat diet (HFD)-induced hypertension using Idh2 gene-deleted 
(Idh2–/–) mice and wild-type (Idh2+/+) littermates.
Methods: Eight-week-old Idh2–/–and Idh2+/+ mice were fed a normal diet (ND) or a 
HFD for 12 weeks.
Results: HFD accelerated the increase in body weight and mean blood pressure (MBP) 
compared to those in the ND group in both mice. MBP was higher in Idh2–/– mice than 
in Idh2+/+. Also, the level of cholesterol was greater in Idh2–/– mice than in Idh2+/+ mice. 
Whereas, the lipid accumulation in the kidney was greater in Idh2+/+ HFD mice than in 
Idh2–/– HFD mice. mRNA levels of renin, angiotensinogen, angiotensin converting enzyme, 
and angiotensin II receptor type I increased in the HFD mouse kidneys and these increases 
were higher in Idh2–/– mouse kidneys than in Idh2+/+ mouse kidneys. However, there were 
no differences in this renin angiotensin system between ND groups. Mitochondrial damage 
was observed after HFD feeding in both mice and this damage was more severe in the 
Idh2–/– mice than Idh2+/+ mice.
Conclusions: These results indicate that HFD-induced hypertension is worsened 
by IDH2 gene deletion with greater oxidative stress in the kidneys, suggesting that 
mitochondrial redox balance is associated with obesity-induced hypertension.
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A New Role of Sox6 in Blood Pressure Regulation
Mohammad Saleem,1 Conrad Hodgkinson,2 Jose Gomez.1 1Vanderbilt University 
Medical Center, Nashville, TN; 2Medicine, Duke University, Durham, NC.
Background: Hypertension afflicts about 50% of the U.S. adult population, of 
which half are unresponsive to treatment. As such, new therapies to treat this disease 
and its complications are necessary. Renin catalyzes the rate limiting step in the renin 
angiotensin aldosterone system (RAAS) and is produced and stored by Juxtaglomerular 
(JG) cells in the kidney. The transcriptional mechanisms that govern renin expression are 
of great importance to develop new treatments for hypertension. Gene expression profiling 
indicated that the transcription factor Sox6 is highly expressed in JG cells compared to 
renal Mesenchymal Stromal Cells (MSCs) in the adult kidney. Moreover, in vitro Sox6 
knockdown decreased the differentiation of renal MSCs into renin producing cells. These 
results support a previously undefined role for Sox6 in blood pressure control. Several 
human genetic studies associate Sox6 with hypertension. We hypothesized that Sox6 is a 
new transcription factor involved in renin expression control.
Methods: Ren1dCre/Sox6fl/fl (Sox6KO mouse), in which Sox6 is deleted specifically 
in renin expressing cells was used. In vivo: JG cell expansion was induced by 10 days 
of low sodium diet (0.01% Na) and furosemide (0.1 mg/g body weight). Plasma renin 
concentration measured by elisa. Expression of genes involved in vasoconstriction, calcium 
(Ca2+) and sodium (Na) metabolism was measured by qRT-PCR.
Results: In vivo, at base line specific Sox6 knock-out animals did not alter plasma 
renin concentration (575±492 ng/mL Sox6-wt vs 984±400 ng/mL Sox6-KO, N=7-11). 
However, the expression of several genes involved in vasoconstriction, Ca2+ and Na 
metabolism were solely expressed in the Sox6-KO mice. In contrast to the basal state, 
Sox6 knockout had a dramatic effect during JG cell expansion. As expected, in wild-type 
mice plasma renin concentration increased during JG cell expansion. Interestingly, there 
was a concomitant increase in Sox6 expression. In contrast, specific knock out of Sox6 
in renin expressing cells halted the increase in the amount of plasma renin concentration 
during JG cell expansion (186±123 ug/mL Sox6-wt vs 135±68 ug/mL Sox6-KO, N=17-18, 
P<0.05).
Conclusions: These results support a novel role of Sox6 in renin cell fate and thereby 
in renal development and blood pressure regulation. This opens new possibilities of renin 
regulation and the development of new therapeutic targets for hypertension.
Funding: Other NIH Support - NHLBI
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The Effect of Microgravity on Central Aortic Blood Pressure
Felix S. Seibert,1 Fabian Bernhard,1 Ulrik Stervbo,1 Benjamin Rohn,1 
Nikolaos Pagonas,1 Frederic Bauer,1 Nina Babel,1 Joachim Jankowski,2 
Timm H. Westhoff.1 1Ruhr-University Bochum, Germany, Herne, Germany; 
2RWTH Aachen, Aachen, Germany.
Background: Blood pressure has been traditionally measured at peripheral arteries. 
In the past decade evidence has grown, that central aortic blood pressure may be a more 
powerful predictor for cardiovascular events, but data on its regulation are rare. The present 
work examines the impact of microgravity on central blood pressure for the first time.
Methods: We performed seven parabolic flights with 22 seconds of weightlessness in 
each parabola. Hemodynamic parameters including central systolic blood pressure were 
measured non-invasively in a free-floating position in 20 healthy subjects (19-43 years of age).
Results: Arterial elasticity at rest was normal in all participants (augmentation index 
14% [interquartile range IQR 10-22], pulse wave velocity 5.2 m/s [IQR 5.0-5.4]). Transition 
of 1g to 0g led to a significant increase of central systolic blood pressure from 124 (IQR 
118-133) to 127 (IQR 119-133) mmHg (p=0.017). Cardiac index augmented significantly 
from 2.5 (IQR 2.2-2.8) to 2.7 (IQR 2.3-3.0) l/min/m2 (p<0.001), whilst peripheral vascular 
resistance showed a decrease from 1.30 (IQR 1.14-1.48) to 1.25 (IQR 1.15-1.40) s*mmHg/ml 
(p=0.037). Peripheral systolic blood pressure did not change significantly (p>0.05).
Conclusions: Whereas there is a multitude of studies on the effects of microgravity 
on peripheral blood pressure, this study provides first data on central aortic blood pressure. 
An acute loss of gravity leads to a central blood volume shift with an augmentation of 
cardiac output. In healthy subjects with normal arterial stiffness the compensatory decrease 
of peripheral resistance does not outweigh this effect resulting in an increase of central 
blood pressure.
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Hypertension and CVD: Mechanisms - I
MicroRNAs May Predict End-Organ Damage in Severe Hypertension: An 
Experimental Animal Model
Knut Asbjørn R. Langlo,2,1 Gustavo J. Silva,3 Tina S. Overrein,4 Ulrik Wisloff,5,6 
Natale Rolim,7 Stein I. Hallan.8,1 1Department of Nephrology, Clinic of Medicine, 
St. Olavs Hospital HF, Trondheim, Norway; 2K.G. Jebsen Center of Exercise in 
Medicine, Department of Circulation and Medical Imaging, Faculty of Medicine 
and Health Sciences, Norwegian University of Science and Technology, 
Trondheim, Norway; 3K.G. Jebsen Center of Exercise in Medicine, Department of 
Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, 
Norwegian University of Science and Technology, Trondheim, Norway; 4Division 
of Pathology and Medical Genetics, Department of Laboratory Medicine, St. 
Olavs Hospital, Trondheim, Norway; 5K.G. Jebsen Center of Exercise in Medicine, 
Department of Circulation and Medical Imaging, Faculty of Medicine and Health 
Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 
6School of Human Movement & Nutrition Sciences, University of Queensland, 
Brisbane, QLD, Australia; 7NTNU, Trondheim, Norway; 8Department of Clinical 
and Molecular Medicine, Faculty of Medicine, Norwegian University of Science 
and Technology, Trondheim, Norway.
Background: Severe hypertension is a potentially life-threatening condition if 
complicated by vital organ failure. The clinical challenge is to differentiate patients in risk 
of these serious complications from those with solely severely elevated blood pressure. 
Therefore, we aimed to investigate how hypertension-induced end-organ damage altered the 
level of circulating microRNAs (miRs) in an experimental model of severe hypertension.
Methods: Dahl salt-sensitive rats were randomized in low-salt (LS, N=20: 
0.3% NaCl) or high-salt (HS, N=60: 8% NaCl) diet. Mean systolic blood pressure was 152 
mmHg (SD 18,2) in the LS group and 205 mmHg (SD 19,9) in the HS group (p<0,001). 
Hypertensive encephalopathy (HE) and thrombotic microangiopathy (TMA) were accessed 
by histology, heart failure with preserved ejection fraction (HFpEF) by echocardiography 
and endothelial dysfunction (ED) by acetylcholine-induced relaxation.
Results: Partial least squares discriminant analysis (PLS-DA) analysis (VIP-score cut-
off at 1.2) predicted 28 miRs for ED, 29 miRs for HE, 30 miRs for HFpEF, and 24 miRs for 
TMA. ROC curve further identified the miRs that better separate disease from non-disease 
animals: miR-28-5p for ED (AUC=0.778), miR-151-5p for HE (AUC=0.779), let7c-5p 
for HFpEF (AUC=0.897), and miR-21-5p for TMA (AUC=0.971). Additionally, we have 
identified a common signature of circulating miRs using (PLS-DA VIP-score above 1,0) 
for all 4 outcomes (let-7b-5p, miR-21-5p, miR-484, let-7a-5p, miR-130b-3p, let-7e-5p, and 
miR-342-3p). Interestingly, KEGG analysis revealed an enrichment of pathways related 
to TGF-beta signaling (p=3.58E-08), adherens junction (p=6.62E-08), HIF-1 signaling 
(p=4.43E-04), p53 signaling (p=3,280E-03), and ECM-receptor interaction (p=8.11E-03).
Conclusions: This shows that miRs may serve as biomarkers to identify serious end-
organ failure in severe hypertension. Analysis also show that different hypertension induced 
end-organ failures may be caused by common pathways.
Funding: Government Support - Non-U.S.
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Circulating Extracellular miRNAs in Early Pregnancy and Preeclampsia 
in Women with Chronic Hypertension
Line Malha,1 Klaas E. Max,2 Thangamani Muthukumar,1 Hua Yang,1 
Phyllis August,1 Thomas Tuschl,2 Manikkam Suthanthiran.1 1Weill Cornell 
Medical College, New York, NY; 2Rockefeller University, New York, NY.
Background: Women with chronic hypertension (cHTN) are at an increased risk for 
developing preeclampsia (PE). Development of biomarkers that foretell PE is an unmet 
objective. We aim to investigate the hypothesis that circulating extracellular miRNA 
profiles are predictive of PE in women with cHTN.
Methods: Circulating miRNAs in 57 cell-free EDTA plasma samples collected during 
9 to 19 weeks of pregnancy from women with cHTN (RO1 HL 48846. PI: P. August), 
were characterized by small RNA-derived barcoded cDNA sequencing. 39 samples had 
>1 million reads (30 samples from women who did not develop PE [No PE group] and 
9 samples from women who subsequently developed PE [PE group]). We performed 
differential expression analysis to identify miRNAs discerning the two groups. Criteria for 
the selection of predictive miRNA included a base mean >5, an absolute fold change (FC) 
between groups >2, and an unadjusted P <0.05.
Results: Age, gestational age, race, parity, body mass index and baseline blood 
pressure were not different between the two groups. The PE group was more likely to have 
a previous history of PE (6/10 vs. 3/24, P<0.001). Differential gene expression analysis 
identified 19 miRNAs in agreement with the above criteria (Table 1).
Conclusions: Validation that circulating levels of 19 miRNAs in plasma may predict 
the development of PE in women with cHTN may inform pathogenesis and help design 
prophylactic strategies.
Funding: Other NIH Support - RO1 HL 48846. PI: P. August
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Long-Lasting RNAi Therapeutics Targeting Angiotensinogen Induces a 
Robust and Durable Antihypertensive Effect
Estrellita Uijl,1 Katrina M. Mirabito Colafella,3 Ewout J. Hoorn,2 Jae B. Kim,4 
Donald J. Foster,4 Alexander H. Danser.2 1Erasmus Medical Center, Rotterdam, 
Netherlands; 2Erasmus Medical Center, Rotterdam, Netherlands; 3Monash 
University, Clayton, NSW, Australia; 4Alnylam Pharmaceuticals, Cambridge, MA.
Background: All angiotensin stems from angiotensinogen (AGT). A single dose of 
small interfering ribonucleic acids (siRNA) targeting AGT may provide long-lasting blood 
pressure reductions, as it would abolish angiotensin generation. Here we assessed efficacy 
of AGT siRNA in spontaneously hypertensive rats (SHRs).
Methods: SHRs were treated for 4 weeks with vehicle, siRNA (10 mg/kg; s.c. every 2 
weeks), valsartan (31 mg/kg/day; oral), captopril (100 mg/kg/day; oral), valsartan+siRNA, 
or captopril+valsartan (all groups n=8). Mean arterial pressure (MAP) was measured via 
radiotelemetry.
Results: Baseline MAP was 137±2 mmHg. ΔMAP was largest after valsartan+siRNA 
(-67±3 mmHg; P<0.01 vs. captopril+valsartan), followed by captopril+valsartan, captopril, 
siRNA and valsartan (-55±4, -24±2, -14±1, and -9±2 mmHg, respectively). Valsartan+siRNA 
reduced cardiac hypertrophy the most (P<0.05 vs. captopril+valsartan). No treatment 
affected glomerular filtration rate or albuminuria. After 4 weeks, siRNA lowered AGT by 
98.6%, which increased to 99.9% in combination with valsartan. All treatments increased 
renin, the highest rise occurring after valsartan+siRNA. Yet, only valsartan+siRNA lowered 
angiotensin II. No treatment altered aldosterone. Plasma K+ tended to increase in all groups, 
significance being reached only in the valsartan+siRNA group. Both types of dual blockade 
attenuated normal growth from the second week of treatment onwards.
Conclusions: In conclusion, due to renin upregulation, circulating angiotensin II 
remained intact even with only 1.4% of AGT left, relative to pretreatment. Consequently, 
AGT siRNA caused a similar antihypertensive effect as valsartan and captopril. Importantly, 
when combining siRNA+valsartan, angiotensin II collapsed, and blood pressure decreased 
synergistically. Given the potential for a low dosing frequency, this novel treatment may 
address medication adherence problems in patients with resistant hypertension and further 
development is warranted.
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Impact of Dialysis Access on Right Heart Function
Jamie L. Kennedy, Laura Holsten, Idil Aktan, Andrew D. Mihalek, 
Sula Mazimba, Brendan T. Bowman, Alden M. Doyle, Thu H. Le. University of 
Virginia, Charlottesville, VA.
Background: Arteriovenous shunts (AVS) are the preferred hemodialysis (HD) 
access over central venous catheters (CVC) due to lower rates of infection and venous 
complications. However, AVS may be associated with a higher prevalence of pulmonary 
hypertension (PH), which is linked to poor kidney transplant outcomes. We assessed the 
relationship between dialysis access and right heart (RH) function (RHF) in a cohort of 
patients referred to our center for kidney transplantation.
Methods: We conducted a retrospective analysis of patients who underwent 
transthoracic echocardiogram (TTE) evaluation. We assessed the frequency of PH with 
estimated pulmonary artery systolic pressure (PASP) ≥ 50 mmHg, right ventricular (RV) 
dysfunction, and moderate or greater tricuspid regurgitation (TR). Analyses were performed 
with SAS, using either chi square, ANOVA, or Fisher’s exact test.
Results: We identified 448 patients with TTE and known dialysis access: 69.2% AVS, 
19.4% CVC, and 11.4% peritoneal dialysis (PD). Demographics and comorbid conditions 
were similar across access groups, with the exception of gender and dialysis duration (See 
Table). The prevalence of RH dysfunction (PH, TR, and RV dysfunction) was lowest in 
PD patients. Among HD patients, TR was significantly more common in CVC than AVS 
patients, whereas PH and RV dysfunction were not different. Linear regression modeling of 
estimated PASP found access, age, and diabetes as significant predictors, and again favored 
PD over CVC and AVS.
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Conclusions: PD patients were less likely to have RH dysfunction than HD patients. 
The effect of CVC vs AVS was less clear; TR was more common in CVC patients while 
there was no difference in PH and RV dysfunction. Dialysis access decisions are not 
randomized, possibly leading to differences unaccounted for in our analysis.
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Carotid Intima-Media Thickness Is a Risk Factor to Cognitive  
Impairment in Dialysis Patients
Ke Zheng,1 Qian Yujun,2 Haiyun Wang,1 Xuemei Li.1 1Peking Union Medical 
College Hospital, Beijing, China; 2Peking Union Medical College Hospital, 
Chinese Academy of Medical Sciences, Beijing, China, Beijing, China.
Background: Carotid atherosclerosis is closely related to cardiovascular and 
cerebrovascular disease. Carotid intima-media thickness (cIMT) measurement by ultrasound 
is the most widely used noninvasive imaging method to assess carotid atherosclerosis, and 
was considered as a risk factor and predictor of CV disease. With growing concern about 
the cognitive impairment (CI) and cerebral small vascular disease (CSVD) problem in 
ESRD 5D patients, some studies were designed to explore the risk factors of them, without 
convincing conclusion. In this study, we evaluated the relationship between CIMT and 
CSVD, CI.
Methods: In this retrospective studies, we analyzed the carotid artery ultrasound results 
of our dialysis cohort of 2013~2014 CSVD/CI study in which the CSVD were assessed 
by magnetic resonance imaging and cognitive function were assessed by a cognitive test 
battery (including: global cognitive function, verbal memory, language ability and executive 
function). According to cIMT measurement, patients were divided into normal cIMT group 
(cIMT<1mm) and increased cIMT group (cIMT≥1mm). Multivariable analysis was used to 
explore the relevance between cIMT and CSVD, CI.
Results: 73 dialysis patients (HD and PD) of our CSVD/CI study cohort of 4 received 
carotid artery ultrasonography. 54.8% (40/73) was diagnosed as increased cIMT. Compared 
with normal cIMT group, increased cIMT group, was older (62.4yr vs 52.5yr, p<0.001), with 
lower serum albumin level (37.4g/Lvs39.4g/L,p=0.046) and lower SCr level (860.7umol/L 
vs 1007.8umol/L, P=0.010). There were no difference of the prevalence of 3 typical features 
of CSVD (lacunes, CMBs, and WMHs) between two groups. After multivariable analysis, 
patients with increased cIMT had a 1.27 fold risk of MMSE score reduce, 2.30 fold risk of 
MoCA score reduce, 23.53 fold risk of Trails A time delay and 61.56 fold risk of Trails B 
time delay, but cIMT was not relative to CSVD.
Conclusions: Increased cIMT was an independent risk factor of impairment of global 
cognitive function, executive function,and the impact of cIMT was not induced by CSVD. 
Carotid artery ultrasonography may be a useful tool of screening high risk of impaired 
cognitive function patients.
Funding: Government Support - Non-U.S.
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Impact of Hybrid Therapy with Peritoneal Dialysis and Hemodialysis on 
Cardiac Events
Masataka Banshodani, Misaki Moriishi, Sadanori Shintaku, Shinichiro Tsuchiya, 
Hideki Kawanishi. Tsuchiya General Hospital, Hiroshima, Japan.
Background: The impact of hybrid therapy with peritoneal dialysis (PD) and 
hemodialysis on cardiac events in PD patients remains unclear.
Methods: PD patients, who underwent the hybrid therapy for at least 3 years, were 
divided into low cardiac function (LCF, left ventricular ejection fraction [LVEF] < 60%) 
and normal cardiac function (NCF, LVEF ≥ 60%) groups by cardiac function at the initiation 
of the hybrid therapy. In these patients, emergency hospitalization rate for cardiovascular 
diseases (CVDs) (hospitalizations/patient-dialysis years) and echocardiographic parameters 
(mean ± standard deviation) were evaluated.
Results: The mean age and PD vintage at the initiation of the hybrid therapy in 
both groups were the followings: LCF group (n = 29), 57.0 ± 11.8 and 3.6 ± 3.3 years; 
NCF group (n = 64), 58.0 ± 10.8 (P = 0.7) and 4.5 ± 3.2 (P = 0.2) years. The 1-year 
emergency hospitalization rate for CVDs significantly decreased after the initiation of 
the hybrid therapy in both groups: LCF group, 0.36 to 0.11 (P = 0.02); NCF group, 0.45 
to 0.09 (P < 0.001). In longitudinal analyses for 3 years after the initiation of the hybrid 
therapy using generalized linear mixed models, in LCF group, LVEF (44.1 ± 15.0%) 
significantly improved 1 (53.2 ± 18.2%), 2 (55.5 ± 16.7%), and 3 (57.7 ± 17.0%) years 
after the initiation (every P < 0.05), whereas, in NCF group, LVEF (68.4 ± 5.5%) was 
maintained at the same level 1 (67.1 ± 7.9%), 2 (66.9 ± 8.7%), and 3 (68.1 ± 9.0%) years 
after the initiation (every P > 0.05). Moreover, in LCF group, LV mass index (LVMI) 
(189.1 ± 41.2 g/m2) decreased 1 (177.7 ± 35.3 g/m2, P = 0.8), 2 (159.5 ± 44.8 g/m2, 
P = 0.008), and 3 (166.4 ± 46.8 g/m2, P = 0.05) years after the initiation, whereas, in NCF 
group, LVMI (156.8 ± 44.7 g/m2) was maintained at the same level 1 (152.8 ± 40.4 g/m2), 
2 (154.6 ± 54.4 g/m2), and 3 (158.5 ± 52.2 g/m2) years after the initiation (every P > 0.05).
Conclusions: The hybrid therapy may decrease CVDs and improve cardiac function 
in PD patients with LCF.
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No Association Was Observed Between Aortic Arch Calcification and 
Mortality in Hemodialysis Patients
Toma Hamada. Team Yokochi Division of Nephrology, Kanto rosai hospital, 
Kanagawa prefecture Nakahara ward kizuki sumiyoshicho 1-1, Japan.
Background: Vascular Calcification (VC) is common in end-stage renal disease. 
Previous reports have shown that Aortic Arch Calcification (AoAC) score is associated with 
poor outcomes in general population. We assessed the utility of AoAC score at initiation 
of hemodialysis.
Methods: In this study, 115 patients who initiated Hemodialysis in our facility from 
January 2010 to December 2013 were retrospectively analyzed. The follow-up period was 
3 years, and we excluded patients who underwent renal transplantation, transfered to other 
hospital, and lost to follow up. Two nephrologists retrospectively reviewed chest X-rays to 
count AoAC score. Using specific scale, we counted the calcification parts from 0 to 16. 
Patients were classified into 2 groups based on AoAC score : High AoAC score (HC) group 
(AoAC score  7) and Low AoAc score (LC) group (AoAC score < 7), and we compared 
clinical characteristics and outcomes among both groups. Analyses were performed using 
JMP.
Results: Overall 155 patients were included in the study, 66 % of them were male, 
mean age was 70.0 ± 10.6 years, mean AoAC score was 6.5 ± 3.6. There was highly 
significant correlationship between the two nephrologist’s AoAC score (r = 0.95, 
p < 0.05). AoAC score was correlated with age (r = 0.42, p < 0.05) and alkaline phosphatase 
(ALP) (r = 0.21, p < 0.05), was not correlated with serum phosphate (p = 0.75) and calcium 
(p =0.50). Kaplan-Meier analysis showed that all-cause mortality rates were significantly 
higher in HC group compared with LC group (p < 0.05). Logistic regression analysis 
revealed that HC group patients were significantly high to die within 3 years after initiation 
of hemodialysis (unadjusted odds ratio 2.90; 95 % CI 1.16 – 7.78; p < 0.05). But, after 
adjustment for age, sex, presence of diabetes, serum phosphate, calcium, ALP, HC group 
did not have higher mortality compared with LC group (adjusted odds ratio 1.71; 95 % CI 
0.61 – 4.99; p = 0.30).
Conclusions: These results suggested that the severity of Aortic Arch Calcification at 
initiation of hemodialysis was not an independent risk factor for mortality. But it is well-
known, the progression of calcification is associated with poor outcomes, further studies are 
needed to solve the mechanism of this mysterious discrepancy.
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A Systematic Review of Interventions Targeting Arterial Stiffness in 
ESRD
Rosendo A. Rodriguez,2 Richard Hae,3 Matthew Spence,3 Beverley J. Shea,4 
Mohsen Agharazii,5 Kevin D. Burns.1 1Medicine, Kidney Research Centre, 
Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada; 
2Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, 
ON, Canada; 3Ottawa Hospital Research Institute, University of Ottawa, 
Ottawa, ON, Canada; 4Ottawa Hospital Research Institute, University of 
Ottawa, Ottawa, ON, Canada; 5CHUQ-HDQ, Quebec City, QC, Canada.
Background: Increased carotid-femoral pulse wave velocity (cf-PWV) in end-stage 
renal disease (ESRD) patients is indicative of both increased arterial stiffness and high risk 
for cardiovascular and overall mortality. Several strategies have been studied to decrease 
arterial stiffness in ESRD, using cf-PWV as a monitoring tool. We conducted a systematic 
review to explore the effect of these interventions on cf-PWV in ESRD patients.
Methods: MEDLINE, EMBASE and EBM databases were searched for all randomised 
and observational studies that evaluated interventions to improve arterial stiffness in adults 
with ESRD. The primary outcome was a reduction of cf-PWV and secondarily, the effects 
on blood pressure (BP). Study screening, selection, data collection and assessment of 
methodological quality were performed by two independent reviewers. Study-level effect 
estimates and pooled estimates were provided by computing the mean differences (MD) and 
95% confidence intervals (CI) using the DerSimonian and Laird method and the random 
effects model.
Results: From 6,607 citations identified, 68 studies met eligibility criteria (randomised: 
29; observational studies: 39), and 33 studies were suitable for meta-analysis of 7 
interventions (Table). Bio-electrical impedance-guided ultrafiltration (UF), low calcium 
dialysate, intra-dialytic exercise and calcium channel blockers (CCB) effectively reduced 
cf-PWV, but only UF and CCB decreased BP compared to standard care. Cholecalciferol 
or cinacalcet did not affect cf-PWV or BP. Kidney transplantation decreased BP but not 
cf-PWV compared to dialysis.
Conclusions: Bio-impedance guided UF, low calcium dialysate, exercise and CCB 
reduce arterial stiffness in ESRD patients. The effectiveness of combining these strategies 
in decreasing adverse cardiovascular events in ESRD patients requires further study in 
randomised clinical trials.
Funding: Government Support - Non-U.S.
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Leucine-Rich a-2-Glycoprotein 1 Predicts Cardiovascular Diseases in 
ESRD Patients
Feng-Jung Yang.2,1 1Graduate Institute of Clinical Medicine, College of 
Medicine, National Taiwan University, Taipei, Taiwan; 2Internal medicine, 
National Taiwan University Hospital Yulin Branch, Douliu, Taiwan.
Background: Plasma Leucine-Rich a-2-Glycoprotein 1 leucine rich α-2 glycoprotein 
(LRG-1) as a novel serum biomarker for various inflammatory diseases such as rheumatoid 
arthritis and inflammatory bowel disease. Patients with end-stage renal disease (ESRD) 
are associated with several health-related adverse outcomes including inflammation, 
atherosclerosis and premature mortality in individuals. Whether level of Plasma Leucine-
Rich a-2-Glycoprotein 1may associate with the clinical status of hemodialysis patients is 
unknown.
Methods: The immunity in ESRD study (iESRD) recruited 169 hemodialysis 
patients from southern Taiwan. By history taking and detailed chart reviews, baseline co-
morbidities were recorded. Peripheral blood was sampled before hemodialysis session and 
processed immediately. Plasma levels of LRG1 and high-sensitivity C reactive protein were 
determined by ELISA. Peripheral blood monocyte and T cell differentiation subsets were 
determined by multicolor flow cytometry.
Results: Among these patients, 100% were LRG-1-seropositive. In the univariate 
analysis, log level of LRGwas independently associated with the existence of cardiovascular 
diseases including stroke and peripheral arterial occlusive disease (OR=111.9 95% CI=2.3-
5283.3, p=0.016). In a multivariate-adjusted logistic regression model, log level of LRG 
was independently associated with the existence of cardiovascular diseases including 
stroke and peripheral arterial occlusive disease (OR=150.9 95% CI=2.3-9684.8, p=0.018) 
afteradjusting for gender, hemoglobin, DM, hypertension and hs-CRP. Level of LRG-1 
positively correlated with both IL-6, CRP and WBC, indicating the accumulation of these 
cytokines participate in the progression of atherosclerosis.
Conclusions: LRG-1positively correlates with the existence of cardiovascular diseases 
in ESRD patients. Role of LRG-1 and the associated inflammation response should be 
further investigated in the pathogenesis of atherosclerosis in this patient population.
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Prognostic Value of Left Atrial Volume Index (LAVi) in ESRD Patients
Shahbaz Sarwar, Sidra Saleem, Haris Naveed, Afshan Ittifaq, Asad Mahmood, 
Abeera Mansur. DHMC, Lahore, Pakistan.
Background: Cardiovascular Disease is the leading cause of death in End Stage Renal 
Disease (ESRD) patients. Echocardiographic estimation reveals that left atrial volume Index 
(LAVi) is increased in diastolic dysfunction of left ventricle, hypertensive heart disease 
and chronic kidney disease patients. LAVi is an established independent risk predictor for 
mortality in atherosclerotic heart disease. However, LAVi has not been extensively studied 
in ESRD population. The aim of this study is to assess the impact of LAVi on cardiovascular 
mortality in hemodialysis patients.
Methods: From January 1, 2013, through April 30, 2018, we evaluated 
echocardiographic findings of 91 ESRD patients on maintenance hemodialysis. LAVi was 
categorized as 1 and 2 (1 < 40 mL/m2 and 2 ≥40 mL/m2). All patients had an ejection 
fraction of greater than 40%. Patient information was collected and data analysed using 
SPSS version 22 for windows software package.
Results: Out of 91 patients, 34 patients(37.4%) had LAVi greater than 40 ml/m2. 
Among 34 patients with LAVi greater than 40ml/m2, 64.7% encountered death. The 
proportion of death was significantly more in LAVi group 2 than in LAVi group 1 (P=0.007). 
Unadjusted logistic regression analysis revealed that cardiovascular mortality in LAVi group 
2 was 3.4 times higher as compared to LAVi 1 (OR=3.39; 95%CI: 1.39-8.25). In survival 
analysis the patients with increased LAVi (group 2) were at a greater risk of mortality. 
Although this group also showed an observable difference in survival and a hazard ratio of 
1.5 it was not significant(p=0.197).
Conclusions: Increased LAVI is an independent predictor of cardiovascular mortality 
in End Stage Renal Disease patients.
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Higher Hemodialysis Product Is Associated with Lower Systolic Blood 
Pressure in Home Hemodialysis Patients
Eric D. Weinhandl,1,2 Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Emerging data has clarified that 24-hour ambulatory blood pressure is 
linearly associated with risk of cardiovascular events. Randomized clinical trials consistently 
show that increasing hemodialysis (HD) frequency reduces systolic blood pressure (SBP). 
Thus, the HD prescription may be calibrated to target blood pressure and corresponding 
cardiovascular risk. We assessed whether Scribner and Oreopoulous’ hemodialysis product 
(HDP) is associated with pre-dialysis SBP in a cohort of home hemodialysis (HHD) patients.
Methods: We analyzed data from US patients who have undergone HHD with the 
NxStage System One and used Nx2me Connected Health. Data regarding HD frequency, 
session duration, and pre-dialysis SBP were organized into calendar weeks. We retained all 
calendar weeks with ≥3 HD sessions. For each calendar week, we calculated the HDP as 
equal to (mean session duration, in hours) × (number of HD sessions)2. We fit generalized 
estimating equations to model separately the associations of pre-dialysis SBP with HDP, 
HD frequency, and HD hours per week, with adjustment for age and sex.
Results: We analyzed data from 769 patients, 34,340 calendar weeks, and 142,210 HD 
sessions. Mean age was 54.3 years; 66.4% of calendar weeks were accumulated in male 
patients. Mean treatment frequency was 4.1 sessions per week, mean (standard deviation) 
HDP was 56 (28) points, and mean HDP with 3, 4, 5, 6, and 7 sessions was 32, 52, 75, 
97, and 122 points, respectively. Mean (standard deviation) pre-dialysis SBP was 135.1 
(22.6) mmHg. In a multivariate model, each 10-point increment in the HDP was associated 
with a 1.5-mmHg decrement (95% confidence interval, 1.1-2.0) in pre-dialysis SBP. 
Each 5-year increment in age was associated with a 0.4-mmHg increment in pre-dialysis 
SBP (P = 0.25), and male versus female sex was associated with a 4.8-mmHg increment 
(P = 0.004). Goodness of fit was best with HDP, moderate with HD frequency, and worst 
with HD hours per week.
Conclusions: The HDP is a simple-to-use formula that be used to calibrate both 
treatment frequency and session duration to target a specific change in pre-dialysis SBP. 
Increased HDP is associated with decreased pre-dialysis SBP, implying that schedules of 
3 sessions/week × 3.5 hours/session and 6 sessions/week × 8 hours/sessions are associated 
with highest and lowest SBP, respectively.
Funding: Commercial Support - NxStage Medical, Inc.
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Effect of Coronary Revascularization on the Association of Elevated 
Troponin with Post-Dialysis Mortality in Patients with Advanced CKD
Santhosh K. Koshy,2,1 Lekha K. George,1 Miklos Z. Molnar,1 Praveen 
Kumar Potukuchi,1 Abduzhappar Gaipov,1 Manyoo Agarwal,3 Koshy K. George,4 
Kamyar Kalantar-Zadeh,5 Csaba P. Kovesdy.6,1 1University of Tennessee Health 
Science Center, Memphis, TN; 2Regional One Health - University of TN Health 
Sciences Ctr, Memphis, TN; 3University of Tennessee Health Science Center, 
Memphis, TN; 4University of Queensland, Memphis, TN; 5University of 
California Irvine, School of Medicine, Orange, CA; 6Memphis VA Medical 
Center, Memphis, TN.
Background: Coronary revascularization (CR), supported by its long-term mortality 
benefit, is indicated for high risk acute coronary syndrome as evidenced by elevated 
troponin. Patients with CKD often present with higher and sustained levels of troponin 
due to reduced clearance, causing diagnostic uncertainty and potentially resulting in fewer 
patients receiving CR. The incidence of CR and its benefits on long-term mortality in 
patients with advanced CKD and elevated troponin levels is unclear.
Methods: We examined 16,759 US veterans who had troponin measured during the 
3 years prior to start of dialysis. We examined the association between troponin level and 
future CR, and whether or not future CR modifies the association between troponin levels 
and subsequent mortality. We modelled the risk of mortality associated with the highest 
recorded troponin level in time-dependent Cox models including the interaction between 
troponin and future CR, while adjusting for demographics, comorbidities, smoking status, 
blood pressure, BMI and baseline eGFR.
Results: Patients were 66±10 years old, 97% male, 37% African-American and 77% 
diabetic. CR was performed in only 326 patients (2%) following a troponin measurement, 
and higher troponin was associated with future CR (multivariable adjusted hazard ratio and 
95%CI in fourth [>0.25 ng/ml] vs. first quartile [<0.03 ng/ml] of troponin: 6.35 [4.26-9.46]). 
Death occurred in 11,315 patients (67%). Higher troponin was associated with linearly 
higher mortality in patients who did not undergo CR (Figure). Patients who underwent CR 
experienced numerically lower risk of death associated with troponin levels compared to 
those without CR (Figure), but the interaction was not statistically significant.
Conclusions: CR may be associated with lower post-dialysis mortality in patients with 
advanced CKD and elevated troponin. The potential benefit of CR in this population needs 
to be explored further in large prospective studies.
Funding: NIDDK Support, Veterans Affairs Support
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Hypertension and CVD: Clinical, Outcomes, Trials
Effects of a Comprehensive Volume Reduction Protocol on Hydration 
Status and Blood Pressure Control in Hemodialysis Patients
Ken Wilund,1 Luis M. Perez,2 Brett Burrows,1 Alana P. Harris,1 Jennifer 
L. Barnes,3 Lauren Chan.4 1University of Illinois at Urbana-Champaign,
Urbana, IL; 2University of Illinois, Urbana, IL; 3Illinois State University,
Normal, IL; 4Oregon State University, Tigard, OR.
Background: Chronic volume overload remains one of the most vexing problems 
in hemodialysis (HD) therapy. The purpose of this study was to investigate the impacts 
of comprehensive volume reduction protocol focused on reducing dietary sodium intake, 
blood pressure medications, and post-dialysis weight, on HD patient’s hydration status and 
blood pressure.
Methods: Twenty-three maintenance HD patients (age = 56 ± 13.3y, 48% female) 
completed a 6-month comprehensive volume control protocol consisting of: 1) weekly 
intradialytic counseling to reduce dietary sodium intake and interdialytic weight gain 
(IDWG); 2) persistent reductions in post-dialysis weight; and 3) reductions in prescribed 
blood pressure (BP) medications. The primary outcome was volume overload (VO) 
measured by bioelectrical impedance spectroscopy. Secondary outcomes included: IDWG, 
estimated dry weight (EDW), BP, BP medication prescriptions, and dietary sodium intake.
Results: From baseline (BL) to 6 months (6m), significant improvements were noted in 
VO (BL 3.9 ± 3.9L (BL) vs 6m 2.6 ± 3.4L, p=0.003), post-dialysis weight (BL 89.4 ± 23.1 kg 
vs 6m 87.6± 22.2 kg; p = 0.012), and EDW (BL 89.0 ± 23.2 vs 6m 86.7 ± 22.5 kg., 
p=0.009). There was also a trend for a reduction in monthly averaged IDWG (p = 0.053), 
and dietary sodium intake (BL 2.9 ± 1.6 vs 6m 2.3 ± 1.1 g/day, p=0.13). Neither systolic 
BP (BL 160 ± 25 vs. 6m 156 ± 23 mmHg, p=0.56) nor diastolic BP (BL 81 ± 20 vs 6m 
79 ± 15 mmHg, p= 0.73) changed, though there was a significant reduction in the total 
number of BP medications prescribed (BL 3.0 ± 1.0 vs 6m 1.5 ± 1.0 BP meds; p<0.01).
Conclusions: Our comprehensive volume reduction protocol significantly improved 
HD patient’s hydration status. While BP did not change, the reduction in prescribed BP 
medication number suggests improved BP control. Despite these overall positive findings, 
the magnitude of change in most variables was modest, and cultural changes in hemodialysis 
clinics may be necessary to realize more robust results.
Funding: Commercial Support - Renal Research Institute
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Trajectories of Adherence to Thienopyridines After Coronary Stenting in 
Patients on Dialysis
Benjamin Lidgard,1 Tara I. Chang,2 Maria E. Montez-Rath,2 Wolfgang 
C. Winkelmayer,3 Jenny I. Shen.4 1Harbor UCLA Medical Center, Carson, CA;
2Stanford University School of Medicine, Palo Alto, CA; 3Baylor College of
Medicine, Houston, TX; 4LaBiomed at Harbor-UCLA, Torrance, CA.
Background: Adherence to medications often fluctuates over time. We identified 
distinct trajectories of adherence to thienopyridines after percutaneous intervention (PCI) 
with stenting in patients on dialysis and hypothesized that better adherence would be 
associated with lower risk of cardiovascular events.
Methods: Using the U.S. Renal Data System, we identified all adult patients on dialysis 
who underwent PCI with stenting from July 2007 to December 2012, filled a discharge 
prescription for a thieneopyridine, and survived the following 6 months. We applied group-
based trajectory modeling to categorize patients into patterns of thienopyridine adherence 
in the 6 months after discharge. We used Cox regression to estimate the hazard ratios for 
the composite outcome of myocardial infarction, revascularization, and death associated 
with each trajectory.
Results: Among 8,296 patients, we identified 4 distinct trajectories of adherence: 1) 
consistently high adherence, 2) high adherence with gradual decline, 3) moderate adherence 
with gradual improvement, and 4) moderate adherence with rapid decline (Figure). The 
unadjusted risk of the composite outcome was significantly lower for those with consistently 
high adherence (Table).
Conclusions: Consistently high adherence to thienopyridines was associated with a 
lower unadjusted risk of cardiovascular events than other trajectories of adherence. Further 
work to identify correlates of these trajectories may help inform interventions to improve 
adherence and potentially reduce adverse outcomes.
Funding: NIDDK Support
Hazard Ratios for CV Outcomes
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The Safety and Efficacy of Clonidine in Hemodialysis Patients: A 
Systematic Review and Meta-Analysis
Gwendolyn Derk,1 Amy B. Pai,2 Ruopeng An,3 Ken Wilund.1 Renal and 
Cardiovascular Disease Research Laboratory UIUC 1University of Illinois, 
Urbana, IL; 2University of Michigan, Ann Arbor, MI; 3Univresity of Illinois at 
Urbana-Champaign, Champaign, IL.
Background: The United States Renal Data System data shows that 20% of 
hemodialysis (HD) patients are prescribed clonidine to treat hypertension. Clonidine is a 
centrally acting alpha 2 adrenergic agonist, and the balance between potential efficacy and 
its known adverse effects is unknown in HD patients. This study systematically reviewed 
existing evidence and performed a meta-analysis on the safety and efficacy of clonidine in 
HD patients.
Methods: Keyword and reference search was conducted through February 2018 in 
PubMed Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov databases. 
Inclusion criteria were - study design: randomized controlled trials, cohort studies, 
prospective studies, retrospective studies or case series; subjects: adult HD patients; main 
outcome: blood pressure and safety; language: English; and article type: peer-reviewed 
publications.
Results: Eight studies met the inclusion criteria, including two prospective pre-post 
studies, one double-blind controlled trial, one single blinded placebo-controlled trial, one 
crossover open-label clinical trial, one retrospective analysis, and two case report series. 
Study durations ranged from 2 to 8 weeks, with a total sample size of 23. Risk of bias 
was high for all included studies. Significant side effects and adverse events include 
hypotension, lightheadedness, drowsiness, dry mouth, and rebound hypertension for oral 
clonidine, as well as contact dermatitis for patch application. Meta-analysis (random effect 
model) found short-term clonidine use to be associated with significant improvement in 
systolic blood pressure (pooled effect: -12.985, 95% CI[7.878, 18.092], p<0.001) while 
changes in diastolic blood pressure were not statistically significant (-11.119, 95% CI[-
22.725, 0.487], p=0.060). There is currently no data on the long-term efficacy of clonidine 
in dialysis patients.
Conclusions: Despite its widespread use, there is no evidence supporting the long-term 
use of clonidine in the HD population and significant safety concerns. There is low-quality 
evidence demonstrating the efficacy of clonidine in lowering blood pressure in HD patients 
in the short term. Clonidine is poorly tolerated and has a potentially dangerous adverse 
effect profile. Future studies on anti-hypertensives with known cardiovascular benefits 
should be studied more rigorously in the HD population.
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Arterial Stiffness as a Risk Factor for Subclinical Coronary Artery 
Calcification in Predialysis CKD: From the KNOW-CKD Study
Young Youl Hyun,1 Su Ah Sung,4 Seung Hyeok Han,2 Soo Wan Kim,3 Kook-
Hwan Oh,5 Curie Ahn.5 KNOW-CKD Study Investigators 1Kangbuk Samsung 
Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of 
Korea; 2Yonsei University College of Medicine, Seoul, Republic of Korea; 
3Chonnam National University Medical School, Gwangju, Republic of Korea; 
4Eulji Medical Center, Seoul, Republic of Korea; 5Seoul National University 
Hospital, Seoul, Republic of Korea.
Background: Both arterial stiffness and coronary artery calcification (CAC) are 
important predictors of cardiovascular disease (CVD) in the general population and 
in chronic kidney disease (CKD) patients. Recent studies on arterial stiffness and CAC 
in subjects with preserved renal function have verified the association between the two. 
However, the relationship is not well evaluated in CKD patients.
Methods: This cross-sectional study analyzed 1,385 predialysis CKD patients from 
the KNOW-CKD cohort. Participants were divided into four groups according to brachial-
ankle pulse wave velocity (baPWV) quartile. Coronary artery calcium score (CACS) were 
assessed using cardiac computed tomography and CAC was defined as a CACS >100.
Results: CAC prevalence was higher in the higher baPWV groups (6.4%, 9.8%, 
23.7%, and 43.8% for the 1st to 4th quartiles of baPWV, respectively, P<0.001). In Tobit 
regression analyses (Table) that were fully adjusted for traditional and renal cardiovascular 
risk factors, the CACS ratio comparing the highest and lowest baPWV quartiles was 3.03 
(95% CI, 1.59–6.87). Similarly, the OR for CAC in the highest baPWV quartile compared 
to the lowest quartile was 1.98 (95% CI, 1.09–3.60) in a fully adjusted multivariate logistic 
model. Results were consistent across analyses with different cutoffs for CAC or with 
different clinically relevant subgroups.
Conclusions: Increased arterial stiffness measured by high baPWV was associated 
with CAC in a predialysis CKD cohort. Further studies are required to explore the role of 
arterial stiffness in the development of CAC and cardiovascular disease in CKD.
Funding: Government Support - Non-U.S.
Multivariate-adjusted CACS ratios according to baPWV
Model 1: Adjusted for age and sex; 
Model 2: Adjusted for model 1 + WHR, systolic blood pressure, diabetes, eGFR, LDL 
cholesterol, hsCRP, urine protein to creatinine ratio, and current smoking; 
Model 3: Adjusted for model 2 + calcium, phosphorus, 25-OH-vit D, and intact PTH
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Vascular Abnormalities in CKD Patients
Nina Hojs,1,2 Joey Junarta,6 Robin Ramphul,3 Racquel M. Lowe-Jones,7 Juan 
carlos Kaski,5 Debasish Banerjee.4 1University Clinical Centre Maribor, 
Maribor, Slovenia; 2Faculty of Medicine, University of Maribor, Maribor, 
Slovenia; 3St. George’s University Hospitals NHS Foundation Trust, Worthing, 
United Kingdom; 4St Georges Hospital and St Georges University of London, 
Wimbledon, United Kingdom; 5SGUL, LONDON, United Kingdom; 6St. 
George’s, University of London, London, United Kingdom; 7St George’s 
University Hospital, London, United Kingdom.
Background: CKD patients suffer from excess vascular events. The exact nature of 
vascular abnormalities and their progression is unknown. The aim of our study was to 
compare vascular abnormalities and its progression in 3-6 months in different CKD groups 
and healthy controls.
Methods: A detailed vascular assessment was performed in clinically stable patients 
(21 CKD stage 2-4, 14 haemodialysis (HD), 22 transplant (TX)) and 21 healthy controls in 
a quiet, temperature controlled vascular laboratory; at baseline and 3-6 months. Data were 
analysed with SPSS version 25, P value <0.05 was considered significant.
Results: The carotid intima media thickness (CIMT) differed significantly between 
all groups at baseline and after 3-6 months. As expected, the lowest values were present in 
healthy controls and the highest in CKD2-4 and HD patients. Ankle brachial index (ABI) 
significantly differed between groups at baseline, but not after 3-6 months. Brachial flow 
mediated dilatation (FMD) didn’t differ between groups at baseline or on follow up. Pulse 
wave velocities (PWV) were significantly different between different groups, with the 
highest values in HD and CKD2-4 patients and the lowest values in healthy controls. During 
3-6 months CIMT increased significantly only in TX patients. ABI significantly decreased 
in 3-6 months in the CKD2-4 patients. FMD decreased in 3-6 months in TX patients. PWV 
didn’t change significantly in 3-6 months in all groups.
Conclusions: CKD2-4, HD, TX patients and healthy controls differ significantly in 
CIMT, ABI and PWV, with the most abnormal values present in HD patients. Progression 
of cardiovascular disease in this short term follow up was variable, with worsening of FMD 
and CIMT in TX patients.
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The Make-Up of Cardiovascular Disease as Kidney Function Declines: 
Results from a Population-Based Australian Cohort Study (EXTEND45)
Louisa Sukkar,1,2 Brendan Smyth,1 Amy Kang,1 Min Jun,3 Celine Foote,1 
Kris Rogers,1 Brendon L. Neuen,1 Martin P. Gallagher,1 Alan Cass,6 
Carol A. Pollock,4 Germaine Wong,4 John Knight,1 David Peiris,1 Meg J. Jardine.5 
EXTEND45 Steering Committee 1The George Institute for Global Health, 
Sydney, NSW, Australia; 2School of Public Health, The University of Sydney, 
Sydney, NSW, Australia; 3The George Institute for Global Health, UNSW Sydney, 
Newtown, NSW, Australia; 4The University of Sydney, St. Leonards, NSW, 
Australia; 5The George Institute for Global Health, UNSW, Newtown, NSW, 
Australia; 6Menzies School of Health Research, Darwin, NT, Australia.
Background: The pathophysiological process behind cardiovascular morbidity differs 
between people with Chronic Kidney Disease and the general population. We aimed to 
examine the relative contributions of myocardial and endoluminal disease to cardiovascular 
morbidity as kidney function declined.
Methods: Based on data from the EXTEND45 study (the 45 and Up Study linked 
to hospital and community pathology datasets by the Centre for Health Record and 
Linkage[CHeReL]), we identified a population-based cohort (2006-2014) of 41,099 people 
aged ≥45 years who had a measure of kidney function(estimated glomerular filtration 
rate[eGFR]). Cardiac hospitalisations were identified using ICD-10 codes and classified into 
endoluminal (all coronary artery diseaxse including complications), myocardial (all cardiac 
failure and arrhythmias) or other (all valvular disease and infective cardiac processes). We 
compared the proportion of endoluminal, myocardial and other causes of hospitalisation by 
KDIGO stage using the Chi-squared test and the trend in proportions between endoluminal 
and myocardial causes using the Cochran-Armitage trend test.
Results: Of 41,099 participants 3,177 experienced ≥1 hospitalised cardiac event(1901, 
837, 439 endoluminal, myocardial and other respectively) over a median follow-up of 
1.9 years. Endoluminal causes as a total proportion of cardiac hospitalisation decreased 
as kidney function declined(64.5%, 61.8%, 57.2%, 53.1%, 50% for Stages 1, 2, 3a, 3b, 
and 4-5, respectively) while myocardial(26.7%, 25.5%, 27.0%, 28.1%, 29.6% respectively) 
causes increased(P-value 0.0005) and this trend was significant(P= 0.02). Other causes were 
also found to increase(8.8%, 12.7%, 15.9%, 18.8%, 20.5% respectively, P-value 0.0005).
Conclusions: The trend towards a decrease in the proportion of endoluminal and 
an increase in myocardial causes of hospitalisation with kidney function decline was 
significant. Understanding risk factors that lead to this divergence in cardiovascular 
morbidity may help reduce the burden.
Funding: Commercial Support - The EXTEND45 Study is funded through peer-
reviewed (NSW Cardiovascular Research Network Collaborative Project Grant) and 
unrestricted industry (from MSD, Amgen and Eli Lilly) research grants.
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Vascular Endothelial Growth Factor C Is Associated with Atherosclerotic 
Change in Kidney Arteries
Kei Takahashi, Satoru Sanada, Mitsuhiro Sato, Toshinobu Sato, Yoshio Taguma. 
Japan Community Health Care Organization Sendai Hospital, Sendai, Japan.
Background: Vascular endothelial growth factor (VEGF) contains five members 
in humans. Among them, VEGF-C is known to has a crucial role in lymphangiogenesis, 
however, some studies have shown that the VEGF-C is associated with atherosclerosis as 
well. In this study, we observed the VEGF-C expression in kidney arteries using kidney 
biopsy samples.
Methods: VEGF-A, B and C expressions on arteries greater than intralobular artery 
were assessed by immunofluorescence histochemistry using 185 kidney biopsy specimens 
obtained at Japan Community Health Care Organization Sendai Hospital. Atherosclerotic 
change was scored semi quantitatively. Results were compared with patients’ baseline 
characteristics.
Results: One hundred sixty three specimens which contained more than one 
interlobular artery were eligible for the study. The age of participants ranged from 14 to 
85 and biopsy result included various diseases such as glomerulonephritis, diabetes and 
hereditary disorders. VEGF-A was positive, and VEGF-B was negative in all arterial 
samples, whereas VEGF-C was positive in 87 and negative 76 samples. VEGF-C positive 
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group was older (61.0±14.1 vs 46.6±19.9, p<0.001), showed higher cardio-ankle vascular 
index (8.39±1.36 vs 7.45±1.43, p<0.001) and higher prevalence of hypertension (72.4 vs 
40.8%, p<0.001) compared to that of negative group. Body mass index, serum HbA1c level 
and serum cholesterol level did not show a statistical significance between the two groups.
Conclusions: VEGF-C expression on the artery could be associated with atherosclerosis 
in the kidney. This new finding is enabled by kidney biopsy which can obtain arterial 
samples from a wide age range.
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Fibroblast Growth Factor 23 Is Associated with Biomarkers of Cardio-
myocyte Stress/Injury in Patients with CKD
Ana Coloma,1,2 Pedro Azcarate,3 Jose M. Valdivielso,4 Enrique Ramalle-
Gomara,5 Emma H. Loza,1 Javier Diez.6 1Nephrology, Hospital San Pedro, 
Logroño, Spain; 2Nephrology, Hospital Universitari de Bellvitge, Hospitalet de 
Llobregat, Spain; 3Cardiology, Hospital San Pedro, Logroño, Spain; 
4IRBLLEIDA, Lleida, Spain; 5La Rioja Regional Authority - Logroño - Spain, 
Logroño, Spain; 6Centre of Applied Medical Research, University of Navarra, 
Pamplona, Spain.
Background: High levels of fibroblast growth factor 23 (FGF23) has been related with 
left ventricular hypertrophy (LVH) in adults with CKD. In this cross-sectional study, we 
aimed to determinate the associations between c-terminal FGF23 (ctFGF23), intact FGF23 
(iFGF23), serum αKlotho, cystatin C, high sensitive troponin T (hsTnT), prothormone 
brain natriuretic peptide (NT-proBNP) levels and structural and functional cardiac changes 
in patients with chronic kidney disease (CKD).
Methods: We enrolled patients with CKD and left ventricular ejection fraction (LVEF) 
>50%. Patients with atrial fibrillation, history of heart failure, myocardial infarction, 
pulmonary hypertension, cardiomyopathies, LVEF <50% or parathyroidectomy were
excluded. Laboratory parameters including serum creatinine, 24h-proteinuria, mineral
bone disorder (calcium, parathormone (PTH), phosphate, tubular reabsorption of phosphate 
(TRP), phosphate clearance), iFGF23, ctFGF23, serum αklotho, hs-TnT, NT-proBNP were 
measured. Echocardiographic parameters including LV mass index, relative wall thickness 
(RWT), volume end-diastolic (VTD), early diastolic mitral annulus velocity (e’ velocity), 
E/e’, left atrial volume index (LAVI) and global longitudinal strain (GLS) were measured
by the same cardiologist at the same day of blood extraction. The cardiologist was blind for 
the stage of CKD in each patient.
Results: 120 patients were included. FGF23 was related with 2 biomarkers of 
cardiomyocyte stress/injury: hsTnT (p<0.05) and NT-proBNP (p<0.05), without finding an 
association with structural and functional cardiac parameters. However, cystatin C, hsTnT 
and NT-proBNP were associated with LV mass (p<0.05), RWT (p<0.001), VTD (p<0.001), 
e’velocity (p<0.001), E/e’ (p<0.001), LAVI (p<0.001). We also found that FGF23 was 
associated with αKlotho (p<0.05), creatinine based-estimated glomerular filtration rate 
(p<0.001), 24h proteinuria (p<0.001), cystatin C (p<0.001), PTH (p<0.001), TRP (p<0.05).
Conclusions: FGF23 was not associated with structural and functional cardiac 
changes, but it was associated with two biomarkers of cardiomyocyte stress/injury: hsTnT 
and NT-proBNP. This finding suggests a relation between FGF23 and remodeling of cardiac 
tissue in patients with chronic kidney disease.
Funding: Government Support - Non-U.S.
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Longitudinal Changes of Cardiac Structure and Function in Mild to 
Moderate CKD: Results from the Korean Cohort Study for Outcomes in 
Patients with CKD (KNOW-CKD)
Eunjeong Kang,1 Hyunjin Ryu,1 Minjung Kang,2 Curie Ahn,1 Kook-Hwan Oh.1 
1Seoul National University Hospital, Seoul, Republic of Korea; 2Seoul National 
University Hospital, Seoul, Republic of Korea.
Background: Abnormal left ventricular (LV) structure and function are associated with 
increased risk of adverse outcomes among patients with chronic kidney disease (CKD). 
However, little is unknown regarding the natural longitudinal changes in cardiac structure 
and function especially in early CKD patients.
Methods: This was a longitudinal study of a subset of participants of the KoreaN 
Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) 
who were enrolled from 2011 to 2012. Patients with CKD at stages from G1 to G3b were 
included if they had serial echocardiograms performed at baseline and again after 4 years. 
Age, sex, diabetes, CKD stages, hemoglobin, albumin, lipid profile, systolic blood pressure, 
and baseline LV mass index were included as covariates in the multivariable analysis for 
risk factors of de novo LV hypertrophy (LVH).
Results: A total of 378 patients (57.7% male) were enrolled. The numbers of patients 
with diabetes and hypertension were 65 (17.2%) and 360 (95.2%), respectively. During 
the follow-up period for 4 years, mean (SD) estimated glomerular filtration rate was 
declined from 64.1±27.1mL/min/1.73m2 to 54.8±30.8 mL/min/1.73m2. Over 4 years, 
there was no significant change of LV structure and function among overall subjects. Our 
subjects were divided into two subgroups based on the baseline eGFR; subgroup I (eGFR 
≥60 ml/min/1.73m2) and subgroup II (30 < eGFR <60 ml/min/1.73m2). Mean age (SD) was
46.5±11.2 years in subgroup I, and 55.4±10.8 years in subgroup II (P<0.001). In subgroup
analysis, the prevalence of LVH for subgroup I was similar between baseline and follow-up 
(18.5% vs. 19.9%). However, for subgroup II, LVH increased from 26.2% at baseline to
52.3% at 4 years. There was no significant change over time in the prevalence of systolic 
and diastolic dysfunction according to CKD stage. In multivariable logistic regression
analysis, only age was associated with development of de novo LVH (odds ratio 1.602; 95%
confidence interval 1.021-1.105, P=0.003).
Conclusions: In conclusion, LV structure and function of mild to moderate CKD 
patients (eGFR >30ml/min/1.73m2) did not change significantly over 4 years.
Funding: Other U.S. Government Support
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Lanosterol Synthase and Endogenous Ouabain Cooperate in Blood 
Pressure Control
Chiara Lanzani,1,2 Simone Fontana,1,2 Marco Simonini,1,2 Elena Brioni,1,2 
Elisabetta Messaggio,1,2 Ermira Cuka,1,2 Simona Delli carpini,1,2 
Lorena Citterio,1,2 Laura Zagato,1,2 John Hamlyn,3 Paolo Manunta.1,2 1Genomics 
of Renal Diseases and Hypertension, IRCCS San Raffaele Scientific Institute, 
Milan, Italy; 2Chair and School of Nephrology, Università Vita Salute San 
Raffaele, Milan, Italy; 3University of Maryland, Baltimore, Baltimore, MD.
Background: Endogenous Ouabain (EO) is stress hormone secreted from the adrenal 
glands in response to hemodynamic stimuli. Long term body sodium has been shown to 
modulate plasma EO levels according to Lanosterol synthase gene polymorphisms. The 
present study explores the effect of acute saline load according to LSS Gene variants and 
circulating EO levels in a large cohort of naïve hypertensive patients (NHPs).
Methods: Basal EO was measured in 713 NHPs for acute saline test phenotypes. For 
the analysis, patients were divided in groups according to tertile distributions of basal EO 
: 1st group EO <167 pmol/L; 2nd group EO >167 pmol/L and < 268 pmol/L; 3rd group EO 
>268 pmol/L. In the three groups, we evaluated 1) changes in EO, 2) interaction with LSS
variants and 2) blood pressure effects.
Results: Circulating EO was higher among Salt Sensitive NHPs, (geometric mean 
224.04 vs 199.81 pM/L,p =0.005) no significant modification was observed during acute 
maneuvers. However, a significant modulation (p=0.044) was observed between elevated 
circulating EO and the LSS A variant, and the DBP rise after saline infusion.
Conclusions: These results confirm the role of EO in salt sensitive hypertension. 
Patients carrying at least one LSS A variant in the presence of elevated EO show an 
modulatory effect on diastolic BP. The higher affinity of the LSS A variant at tissue levels 
may account for the enhanced vascular response in these patients. The present findings 
support a role for LSS and EO in salt adaptation.
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Pharmacologic Control of Arterial Hypertension and Risk of All-Cause 
Mortality in Older Adults
Antonios Douros,1 Markus van der Giet,1 Natalie Ebert,1 Jens Gaedeke,2 
Martin K. Kuhlmann,3 Alice Schneider,1 Elke Schaeffner.1 Berlin Initiative 
Study (BIS) Team 1Charite Universitätsmedizin Berlin, Berlin, Germany; 2Dept. 
of Nephrology, Charité, Berlin, Germany; 3Vivantes Klinikum im Friedrichshain, 
Berlin, Germany.
Background: Hypertension is highly prevalent in older adults and can increase the risk 
of mortality. Real world data on the effects of disease control in this age group are scarce. 
Thus, the objective of this population-based analysis was to assess whether pharmacologic 
control of hypertension has an impact on the risk of all-cause mortality in patients ≥70 yrs.
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Methods: All patients were participants in the Berlin Initiative Study (BIS). 
Demographics, lifestyle factors, medication use, and comorbidities were ascertained 
in face-to-face interviews. Mortality was assessed using health insurance data including 
the exact date of death. Cox prop. hazards models yielded adjusted hazard ratios (HRs) 
with 95% confidence intervals (CIs) of all-cause mortality associated with systolic blood 
pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg (‘good’ disease 
control) compared to SBP ≥140 mmHg and/or DBP ≥90 mmHg (‘poor’ disease control). In 
secondary analyses we assessed the risk of all-cause mortality after stratifying by age (70-79 
vs ≥80 yrs) and previous cardiovascular (CV) events.
Results: Among the 2069 participants of the BIS, 1628 (79%) were treated with 
antihypertensive drugs at baseline. Of those, 636 (39%) showed good disease control 
(mean age 81 yrs, 51% female) and 992 (61%) poor disease control (mean age 81 yrs, 53% 
female). Baseline characteristics were comparable between patients with good and poor 
disease control except for previous myocardial infarction (23% vs 15%) and albuminuria 
(23% vs 33%). During a follow-up of 8853 person-yrs, 469 patients died. Compared with 
poor disease control, good disease control was associated with an increased risk of all-cause 
mortality (HR, 1.27; 95% CI, 1.04-1.55). This effect was augmented in patients ≥80 yrs 
(HR, 1.41; 95% CI, 1.13-1.76) and patients with previous CV events (HR, 1.68; 95% CI, 
1.19-2.38) (Figure).
Conclusions: Reducing BP below 140/90 mmHg could increase the risk of mortality 
in older adults, in particular among octogenarians and patients with previous CV event.
Funding: Private Foundation Support
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Influence of Pre-Diabetes Status on the Effects of Intensive Systolic Blood 
Pressure (SBP) Lowering in the Systolic Blood Pressure Intervention Trial 
(SPRINT)
Naveen Rathi, Guo Wei, Robert E. Boucher, Tom Greene, Srinivasan Beddhu. 
University of Utah, Salt Lake City, UT.
Background: Intensive lowering of SBP increased the risk of incident CKD in 
people with type 2 diabetes mellitus. Hence, we examined the hypothesis that pre-diabetes 
increases the risk of incident CKD with intensive SBP lowering in persons without diabetes.
Methods: SPRINT tested the effects of intensive (<120 mm Hg) versus standard 
(<140 mm Hg) SBP goals on CVD outcomes. Diabetes was an exclusion criteria. Based on 
fasting blood glucose (FBG), we defined normoglycemic group as FBG < 100 mg/dl and 
pre-diabetes group as FBG ≥ 100 mg/dl in SPRINT participants without CKD at baseline. 
We defined incident CKD as ≥ 30% decline in eGFR to < 60 ml/min/1.73 m2 with a second 
confirmatory value. We examined in Cox regression models whether the risk for incident 
CKD with intensive SBP lowering differed by pre-diabetes status.
Results: Of the 6678 non-CKD SPRINT participants, 2829 (42.3%) had prediabetes. 
The baseline characteristics are summarized in the Table. Over 21155 total years of follow-
up, there were 164 incident CKD events. The incidence of CKD was higher in the intensive 
arm compared to standard SBP arm within normoglycemia and pre-diabetes group (Fig 1), 
with similar hazard ratios (interaction p = 0.47).
Conclusions: Intensive SBP lowering increased the risk of incident CKD in persons 
with normoglycemia and prediabetes. There was no evidence that the presence of pre-
diabetes modified the risk of incident CKD with intensive SBP lowering.
Funding: NIDDK Support
Relative risk differences of incident CKD by intervention arms and prediabetes status
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Hypertension and CVD: Clinical, Outcomes, Trials
Associations of Early Decline in eGFR with Cardiovascular Disease (CVD) 
Events in the Systolic Blood Pressure Intervention Trial (SPRINT)
Srinivasan Beddhu,1 Paul L. Kimmel,2 Glenn M. Chertow,3 Alfred K. Cheung,1 
Guo Wei,1 Robert E. Boucher,1 Michel Chonchol,4 Barry I. Freedman,5 
Joachim H. Ix,6 Michael V. Rocco,5 Paul K. Whelton,7 Tom Greene.1 1University 
of Utah, Salt Lake City, UT; 2National Institute of Diabetes and Digestive 
Kidney Diseases (NIDDK), Bethesda, MD; 3Stanford University School of 
Medicine, Palo Alto, CA; 4University of Colorado, Aurora, CO; 5Wake Forest 
School of Medicine, Winston-Salem, NC; 6UCSD, San Diego, CA; 7Tulane 
University School of Public Health and Tropical Medicine, New Orleans, LA.
Background: SPRINT examined the cardiovascular effects of intensive (INT) vs. 
standard (STD) SBP goals (<120 vs. <140 mm Hg). INT SBP lowering resulted in early ↓ 
in eGFR but the clinical implications are unclear.
Methods: In a post-hoc analysis, based on % change in eGFR from baseline to 6 
months, we defined four ΔeGFR groups (Table). Using -5 to +5% group as the reference, 
we related ΔeGFR groups to CVD events that occurred after 6 months in Cox regression 
models.
Results: 15% in the STD vs. 26% in the INT SBP arms (p<0.001) had >10% ↓ in 
eGFR. Key baseline characteristics are summarized in the Table. Unadjusted Kaplan-Meier 
plots suggested higher incidence of CVD events in the group with >10% ↓ in eGFR within 
the STD SBP arm, which attenuated in an adjusted Cox regression model (Fig 1). There 
was no evidence that ΔeGFR groups associated with CVD events in the INT arm (Fig 2).
Conclusions: INT SBP lowering resulted in a higher proportion of persons with >10% 
↓ in eGFR but there is no clear evidence that greater ↓ in eGFR was associated with worse 
CVD outcome in either arm during the trial. Further investigation of the implications of 
early eGFR ↓ on CVD is warranted.
Funding: NIDDK Support, Other NIH Support - NHLBI, NIA, NINDS
Baseline characteristics by ΔeGFR groups in STD and INT arms
ΔeGFR groups and CVD events in STD arm
ΔeGFR groups and CVD events in INT arm
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Hypertension and CVD: Clinical, Outcomes, Trials
Ambulatory Blood Pressure (ABP) Is More Important Risk Factor to 
Renal Outcome in CKD Patients Than Office Blood Pressures
Hyung Eun Son,1 Ho Jun Chin.1,2 1Internal medicine, Seoul National University 
Bundang Hospital, Seongnam, Gyeong-gido, Republic of Korea; 2Medicine, 
Seoul National University, Seoul, Republic of Korea.
Background: The prognosis of CKD is strongly associated with blood pressure. 
However, there are few clinical data suggesting which methods is better for measuring 
blood pressure and what is the target level of blood pressure to prevent CKD progression.
Methods: We enrolled 387 hypertensive CKD patients from three tertiary referral 
hospitals in Korea who underwent ABP monitoring and followed for 38.0 months. The 
primary renal outcome was an incident end stage renal disease (ESRD) which data was 
collected from the ESRD registry of the Korean Society of nephrology.
Results: The mean office blood pressure was 131.9/79.4 mmHg and the mean ABPs 
was 131.9/79.4 mmHg. The estimated glomerular filtration rate (GFR) and urine protein 
to creatinine ratio (UPCR) was 45.0 ± 21.6 ml/min/1.73 m2 and 1.545 ± 2.278 mg/mg 
creatinine, respectively. There were 13.4 % (52/387) incident ESRD. The risk factors for an 
incident ESRD were age, GFR, UPCR, product of calcium by phosphorous at renal biopsy 
and parameters of blood pressures, such as ambulatory systolic blood pressure (ASBP), 
ambulatory diastolic pressure (ADBP), ABP grouped by the criteria of 120/80, 130/80, and 
140/90 mmHg. The rate of incident ESRD in patients with ABP < 120/80 mmHg was 1.2 
%, with ABP 120/80-129/79 mmHg, 12.0 %, with 130/80-139/89 mmHg, 10.2 %, and, with 
ABP  140/90 mmHg, 25.4 % (p<0.001). The risk ratios of an incident ESRD in patients 
with ABP 120/79-129/79, 130/80-139/89, and ABP  140/90 mmHg were 10.643 (95% 
CI: 1.032-86.980, p=0.027), 7.489 (95% CI: 0.928-60.408, p=0.059), and 13.518 (95% CI: 
1.792-101.952, p=0.012) compared to the risk of ESRD in patients with ABP < 120/80 
mmHg, respectively (p for trend=0.002), adjusted by risk factors using the Cox’s hazard 
proportional model.
Conclusions: Office blood pressure was not appropriate measurement to guide 
BP control in CKD patients. Lower criteria of ambulatory blood pressure would be 
recommended for prevention of ESRD in CKD patients.
FR-PO370 Poster Friday
Hypertension and CVD: Clinical, Outcomes, Trials
Effect of Chronotherapy on BP Pattern and Renal Function in CKD 
III-IV: A RCT
Vaibhav Tiwari,1 Raju K. Sahu.2 1nephrology, ipgmer, Kolkata, India; 
2IPGME&R Kolkata, Kolkata, India.
Background: There is higher prevalence of non dipping pattern in antihypertensive 
CKD patients. we studied the effect of shifting antihypertensives to night time on blood 
pressure profile of CKD III-IV patients
Methods: Study Design: single centre, prospective, RCT Setting and participants: 
CKD III-IV with non dipping pattern on ABPM Intervention: the intervention group 
received all the antihypertensives in the night time, control group continued to take 
medication in the morning. Both groups were followed for 1 year Outcomes: primary 
outcome was the reversion to dipper status. Secondary outcomes were changes in eGFR 
and cardiac structure.
Results: 39 patients in bedtime group and 36 patients in awakening group were 
analysed. 10 patients (24%) reverted to dipping pattern in bedtime group as compared to 
none in the awakening group. Mean eGFR decrease from 34.59±12.43 to 34.41±11.82 
ml/min/1.73m2 in Bedtime group (p=0.5), in awakening group eGFR decrease from 
32.46±13.42 to 29.91±9.97 ml/min/1.73m2 (p=0.03). Between group difference in eGFRs 
was significant at 1 year (5.22 [95% CI,4.3-6.1]ml/min/1.73m2; p= 0.02). Cardiac structure 
changes showed no significant changes in either group.
Conclusions: Bedtime administration of antihypertensives reverted non dippers to 
dippers and slowed the decline in eGFR in CKD III-IV compared to morning administration 
of antihypertensives.
Baseline Characteristics
Flow diagram
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Hypertension and CVD: Clinical, Outcomes, Trials
Non-Dipping Blood Pressure Profile Does Not Predict a Risk for 
Developing CKD in Normotensives
Tomoharu Ida, Tetsuro Kusaba, Keiichi Tamagaki. Kyoto Prefectural University 
of Medicine, Kyoto, Japan.
Background: Lack of nocturnal blood pressure (BP) fall (non-dipper), a potent risk of 
future kidney dysfunction, is frequently observed in chronic kidney disease (CKD) patients. 
However, whether non-dipping pattern of BP profile in normotensive CKD patients is still a 
risk for progression of kidney disease is unknown. The aim of our retrospective cohort study 
is to elucidate the impact of non-dipping BP profile with normotensives on the incidence of 
ESRD and the CKD progression.
Methods: 1198 CKD patients (age:68.6 ± 12.0, eGFR:33.1 ± 18.2 ml/min/1.73m2, avg 
± SD) who underwent ambulatory BP monitoring (ABPM) were enrolled into our analysis. 
According to their nocturnal BP dipping pattern (>10%: dipper or <10%: non-dipper) and 
the average 24hr BP (>130/80 mmHg: hypertensive or <130/80 mmHg: normotensive),
the patients were divided into 4 groups. Primary composite outcomes including 40%
reduction of eGFR from baseline or reaching ESRD were assessed. We also performed the 
multivariate regression analysis of the factors considered to have significant relationship for 
the incidence of primary outcomes.
Results: 86.3% of patients were non-dipper and half of them were normotensive. 
The average observation period was 4.76 ± 2.75 (avg ± SD) years. Overall, the composite 
outcomes occurred in 45.6% of patients and it was highest in hypertensive non-dipper group 
(60.0%). In normotensive patients, there was no difference in the incidence of primary 
outcome between non-dipper (32.0%) and dipper (29.6%). Multivariate regression analysis 
showed that amount of urinary protein (95% CI 0.74-0.91) and 24hr BP (95% CI 0.67-
0.81), not BP dipping rate (95% CI 0.98-1.01), were relevant for the incidence of primary 
outcomes.
Conclusions: ABPM based analysis demonstrated that non-dipping pattern of BP does 
not predict the risk for the kidney disease progression in normotensive CKD patients.
Hypertension and CVD: Clinical, Outcomes, Trials
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Hypertension and CVD: Clinical, Outcomes, Trials
Association of Major Adverse Cardiac Events in Patients Taking Direct 
Oral Anticoagulants (DOACs) in Patients with CKD
Justin M. Ashley,7 Eric McArthur,2 Marisa Battistella,3 Amber O. Molnar,4 
Min Jun,5 Amit X. Garg,6 Thomas Mavrakanas,8 Manish M. Sood.1 1Ottawa 
Hospital Research Institute, Ottawa, ON, Canada; 2Institute for Clinical 
Evaluative Sciences, London, ON, Canada; 3University Health Network, 
Toronto, ON, Canada; 4McMaster University, Hamilton, ON, Canada; 5The 
George Institute for Global Health, UNSW Sydney, Newtown, NSW, Australia; 
6London Health Sciences Centre, London, ON, Canada; 7The Ottawa Hospital, 
Ottawa, ON, Canada; 8McGill University, Montreal, QC, Canada.
Background: Clinical trials provide conflicting evidence for the use of DOACs in the 
prevention of major adverse cardiac events (MACE). Patients with chronic kidney disease 
(CKD) are at an exceptionally high risk for MACE. We set out to assess the association of 
DOAC use compared to no oral anticoagulant or warfarin, and MACE, hemorrhage and 
all-cause mortality in patients with CKD.
Methods: Population-based retrospective cohort study of 241, 045 eligible adults 
of advanced age (≥ 66 years) in Ontario, Canada from 2009-2016. A high dimensional 
propensity score was used to match new DOAC use to either no anticoagulant or 
warfarin. The study outcomes were major cardiac events (MACE), hemorrhage requiring 
hospitalization and all-cause mortality. DOAC exposure was modeled using Cox and 
Fine & Gray sub-distribution hazards models to examine the association with outcomes. 
Outcomes by level of kidney function, albuminuria and DOAC type were also examined.
Results: We matched 6,039 DOAC (mean [SD] age, 77.2 [7.0] years; 44.9% women), 
users with a high dimensional propensity score to non-anticoagulant users. There were a 
total of 560 (46% DOAC users) MACE, 178 hemorrhages (47% DOAC users) and 768 
(31.3% DOAC users) deaths during the follow-up time. DOAC use, compared to no 
anticoagulant use, was associated with a higher risk of MACE (sHR 1.20 95%CI 1.04-1.39) 
and hemorrhage requiring hospitalization (sHR 1.36 95%CI 1.03-1.80) whereas all-cause 
mortality was lower (sHR 0.74 95%CI 0.61-0.91). Among DOAC and non-anticoagulant 
use, the risk of hemorrhage and all-cause mortality differed by DOAC type whereas all-
cause mortality differed by eGFR. We further matched 5,581 DOAC to warfarin users. 
There were a total of 460 (56% DOAC users) MACE, 177 hemorrhages (49% DOAC users) 
and 581 (61% DOAC users) deaths during the follow-up time. DOAC use, compared to 
warfarin use, was associated with a comparable risk of MACE, hemorrhage and all-cause 
mortality. Among DOAC and warfarin users, the risk of all-cause mortality but not MACE 
or hemorrhage differed by eGFR.
Conclusions: DOACs did not lower the risk of major cardiac events compared to no 
DOAC use or warfarin in patients with or without CKD. Further studies to determine if 
specific DOAC dosages reduce MACE in CKD are required.
FR-PO373 Poster Friday
Hypertension and CVD: Clinical, Outcomes, Trials
Duration of Dual Antiplatelet Therapy in Patients with CKD and 
Drug-Eluting Stents: A Meta-Analysis
Thomas Mavrakanas,1,2 Yiannis Chatzizisis,7 Karim Gariani,11 
Dean J. Kereiakes,10 Giuseppe Gargiulo,4 Fausto Feres,6 Marie claude Morice,12 
Jean-Louis Georges,8 Marco Valgimigli,9 Deepak L. Bhatt,5 Laura Mauri,5 
David M. Charytan.3 1Brigham & Women’s Hospital, Boston, MA; 2Geneva 
University Hospitals, Geneva, Switzerland; 3Brigham and Women’s Hospital/
Harvard Medical School, Brookline, MA; 4Bern University Hospital, Bern, 
Switzerland; 5Brigham and Women’s Hospital, Newton, MA; 6Instituto Dante 
Pazzanese de Cardiologia, São Paulo, Brazil; 7UNMC, Omaha, NE; 8Centre 
Hospitalier de Versailles, LE CHESNAY, France; 9University Hospital Bern, 
Bern, Switzerland; 10The Christ Hospital, Cincinnati, OH; 11Geneva University 
Hospital, Geneva, Switzerland; 12Générale de Santé - Institut Cardiovasculaire 
Paris Sud, MASSY, France.
Background: Whether prolonged dual antiplatelet therapy (DAPT) is more protective 
in chronic kidney disease (CKD) patients with drug-eluting stents (DES) compared with 
shorter DAPT is uncertain. This meta-analysis examined whether shorter DAPT in patients 
with DES and CKD is associated with lower mortality or major adverse cardiovascular 
event rates compared with longer DAPT.
Methods: A Medline literature research was conducted to identify randomized trials 
in patients with DES comparing different DAPT duration strategies. The primary outcome 
was a composite of all-cause mortality, myocardial infarction, stroke, or stent thrombosis 
(definite- probable). The secondary outcome was major bleeding. A random-effects model 
was used.
Results: Five randomized controlled trials were included (1,902 CKD patients). 
Short DAPT (≤6 months) was associated with a similar incidence of the primary outcome, 
compared with 12-months DAPT among patients with CKD (Figure). Twelve-months 
DAPT was also associated with a similar incidence of the primary outcome compared with 
extended DAPT (≥30 months) in the CKD subgroup (Figure). Numerically lower major 
bleeding event rates were detected with shorter vs. 12-month DAPT (RR 0.68, 95% CI 
0.29-1.60, p=0.38) and 12-month vs. extended DAPT (RR 0.82, 95% CI 0.34-1.94, p=0.65) 
in CKD patients.
Conclusions: Short DAPT may be preferred to longer DAPT in CKD patients with 
DES.
Forest plot showing the impact of short (≤6 months), 12-month, and extended (>=30 
months) dual antiplatelet therapy on the composite primary outcome, a composite of all-
cause mortality, myocardial infarction, stroke, and stent thrombosis (definite or probable) in 
patients with chronic kidney disease.
FR-PO374 Poster Friday
Hypertension and CVD: Clinical, Outcomes, Trials
Direct Oral Anticoagulants vs Warfarin: Stroke Outcomes in CKD 
Patients
Drake A. Edgett,1,2 Alissa Dratch,1,2 Elani Streja,1,2 Ekamol Tantisattamo,2 
Kamyar Kalantar-Zadeh,1,2 Wei Ling Lau.2,3 1Harold Simmons Center for Kidney 
Disease Research and Epidemiology, Orange, CA; 2University of California, 
Irvine School of Medicine, Orange, CA; 3Visiting Fellow at OptumLabs, San 
Francisco, CA.
Background: CKD patients are at higher risk of ischemic and hemorrhagic stroke. 
For over 50 years warfarin was the only oral anticoagulant available for stroke prevention. 
Direct Oral Anticoagulants (DOACs) became available in the past decade but outcomes 
data in CKD is limited. In this project we examined ischemic stroke outcomes associated 
with warfarin vs. DOAC therapy in the OptumLabs® Data Warehouse (OLDW).
Methods: This was a retrospective analysis of de-identified claims and electronic health 
record data for privately insured and Medicare Advantage enrollees in a large, private, U.S. 
health plan. Adults aged ≥18 years with claims data between 10/1/2010-11/30/2017 were 
included. Stroke events were captured between index prescription date and censor date 
(earliest date of index medication stopped, death, or end of follow up). Cox models were 
used to calculate hazard ratios of time to first stroke. Poisson models were used for stroke 
incident rate ratios. Associations were evaluated with multivariable adjustment for age, 
gender, race and baseline comorbidities (diabetes, hypertension, heart failure, myocardial 
infarction, prior stroke, antiplatelet medications).
Results: The cohort included 340,732 patients of which 90% were non-CKD, 9% were 
CKD stage 3-4, and 1% were CKD stage 5/ESRD. Patients had a mean±SD age of 67±13 
years, and included 30% diabetics, 10% African-Americans and 6% Hispanic. Patients on 
warfarin were more likely to be older, African-American, ESRD, and have pre-existing 
comorbidities. Across all strata, patients on warfarin had a faster time to first stroke and a 
higher incidence of stroke events [Table].
Conclusions: In a large nationwide database, DOACs were associated with a lower 
risk of ischemic stroke as compared to warfarin therapy. Randomized controlled trials 
are warranted to further investigate this observed superiority of the newer anticoagulant 
therapies.
FR-PO375 Poster Friday
Hypertension and CVD: Clinical, Outcomes, Trials
Kidney Failure and Mortality in Older Live Kidney Donors with 
Hypertension
Fawaz Al Ammary,1 Xun Luo,1 Allan Massie,1 Macey L. Henderson,1 
Deidra C. Crews,1 Jacqueline Garonzik wang,1 Daniel C. Brennan,1 
Alexander C. Wiseman,2 Dorry L. Segev.1 1Johns Hopkins University, Baltimore, 
MD; 2University of Colorado at Denver and Health Sciences Center, Denver, CO.
Background: Hypertension in otherwise healthy, screened older live kidney donor 
candidates has been viewed as safe. However, hypertension guidelines have evolved and 
long-term outcomes for these donors have not been explored, which may bring this practice 
into question.
Methods: We used a US cohort of 24,533 older donors (≥50-year-old), including 2265 
with predonation hypertension, to quantify the 15-year end-stage renal disease (ESRD) 
and mortality risk in donors with hypertension vs. those without hypertension. From 
2004-2016, hypertension was defined as documented predonation use of antihypertensive 
therapy, regardless of systolic/diastolic blood pressure (SBP/DBP); from 1999-2003, when 
there was no documentation of antihypertensive therapy, hypertension was defined as 
predonation SBP≥140 or DBP≥90 mmHg.
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Results: Older donors were 88.1% white, 5.6% Hispanic, and 6.3% black. Estimated 
15-year ESRD risk was 77 per 10,000 (95%CI:38-155) for donors with hypertension (mean 
SBP=137.7 mmHg) vs. 21 per 10,000 (95%CI:12-37) for donors without hypertension
(mean SBP=123.4 mmHg); (adjusted hazard ratio [HR] 3.04; 95%CI:1.28-7.22; P=.01).
In the years when predonation use of antihypertensive therapy was available, risk of ESRD
was 6.21-fold higher (95%CI:1.20-32.17; P=.03) for donors using antihypertensive therapy
(mean SBP=131.9 mmHg) vs. those not using antihypertensive therapy (mean SBP=123.9 
mmHg); this inference remained similar after further adjustment for SBP<125. There was 
no evidence of association between donor hypertension and 15-year mortality risk (HR
1.18; 95%CI:0.84-1.66; P=0.34).
Conclusions: Older kidney donor candidates with hypertension may be viewed as 
potentially high-risk for ESRD. These findings may help inform discussion with older 
candidates considering kidney donation; long-term monitoring is warranted. .
Funding: NIDDK Support
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Hypertension and CVD: Clinical, Outcomes, Trials
High Variability of Initial 24-Hour Systolic Blood Pressure After ICU 
Admission Is Associated with Mortality
Soon hyo Kwon,1 Moo Yong Park,2 Hyoungnae Kim,2 Hyunjin Noh.2 
1Soonchunhyang University, Seoul, Republic of Korea; 2Soonchunhyang 
University Hospital, Seoul, Republic of Korea.
Background: Increased blood pressure variability predicts long-term outcomes in 
cardiovascular and kidney disease. This study aimed to determine whether variability of 
initial 24-hour systolic blood pressure (SBP) affects mortality in critically ill patients.
Methods: In a retrospective study, we enrolled patients who had been admitted to 2 
adult intensive care units (ICU) in a single center between Nov. 2015 and Oct. 2017. All 
patients were under active treatment. Variability of patients’ blood pressure was assessed by 
initial 24-hour SBP coefficient of variation (CV) after ICU admission. CV was measured 
as standard deviation of SBP divided by mean of SBP. Patients were categorized into two 
groups based on SBP CV. The effect of SBP variability on 90 day mortality was analyzed.
Results: Of the 451 patients (male 56 %) were analyzed, 25.7% of patients died within 
90 days. The mean SBP CV was 7.6 ± 1.4 % in low CV group (n=225) and 13.6 ± 3.2 % in 
high CV group (n=226). In Kaplan-Meier survival analysis, 90 day mortality of high CV 
group was higher than that of low CV group (p = 0.001) (Figure 1). A Cox analysis showed 
that high CV in SBP was an independent risk factor for death compared to low CV in SBP 
(HR 1.87; 95% CI, 1.26-2.77; p = 0.002) after adjust of age, sex, comorbidities, inotropic 
agents and SBP.
Conclusions: Higher SBP variability in critically ill patients was associated with high 
mortality. This suggests that variability of blood pressure would be helpful for prediction of 
prognosis and treatment in ICU patients.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Clinical, Outcomes, Trials
AKI Followed by Complete Recovery Is Associated with Higher Stroke 
Risk
Joao P. Teixeira,2 Zhiying You,3 Benjamin Griffin,2 John R. Holmen,4 
Titte Srinivas,5 Michel Chonchol,2 Sarah Faubel,6 Anna J. Jovanovich.1,2 1Denver 
VA, Denver, CO; 2University of Colorado, Aurora, CO; 3UC Denver, Aurora, 
CO; 4Intermountain Healthcare, Murray, UT; 5Intermountain Medical Center, 
Murray, UT; 6University of Colorado Denver, Denver, CO.
Background: Acute kidney injury (AKI) has been shown to be associated with a future 
increased risk of adverse cardiovascular events. However, there are fewer data specifically 
analyzing the risk of stroke after AKI and they have been somewhat mixed. While severe 
(stage III) AKI has been shown to be independently associated with an increased risk of 
future stroke, the effects of less severe AKI or AKI with recovery are unclear. We aim to 
determine the risk of stroke following an admission complicated by AKI with complete 
recovery in a propensity score-matched cohort of cases and controls.
Methods: We identified 1139 AKI cases (AKI Network definition) with complete 
kidney function recovery at the time of discharge, defined as serum creatinine <1.10 
times the pre-admit baseline value, during a hospitalization between January 1, 1999 and 
December 31, 2009 from an integrated health care delivery system. We matched 1139 
controls (no AKI during index admit) based on a propensity score including age, sex, race, 
prior inpatient visits, season of admission, baseline creatinine, and all components of the 
Charlson Comorbidity index. The primary outcome was time to post-discharge stroke, as 
defined by ICD-9 codes. Cox proportional hazards models were adjusted for history of prior 
stroke and atrial fibrillation and censored for death.
Results: Baseline characteristics among the cases and controls were similar: age 62 
± 17 years, 46% female, 92% white, serum creatinine 0.9 ± 0.2 mg/dL. During a median
[IQR] post-discharge follow-up of 68 [17-92] months, 99 cases and 36 controls had a stroke. 
In the unadjusted model, AKI with recovery was associated with a greater than 3-fold
increased risk of stroke (HR 3.08 [95% CI, 2.10 – 4.52]; p <0.0001). This association did 
not change after adjusting for prior stroke and atrial fibrillation (HR 3.27 [95% CI, 2.21 – 
4.2]; p <0.0001).
Conclusions: Among patients from an integrated health care delivery system, AKI 
followed by complete recovery was independently associated with an increased risk of 
incident stroke. These data add to prior studies linking AKI with an increased long-term 
risk of cardiovascular events.
Funding: Veterans Affairs Support
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Hypertension and CVD: Clinical, Outcomes, Trials
Health Plan Coverage Duration and Annualized Healthcare Costs in 
Patients with ADPKD in a Managed Care Population
Myrlene Sanon,1 Robert A. Stellhorn,1 Efstathios N. Michalopoulos,2 
Christina Pao,1 Dorothee Oberdhan.2 1Otsuka Pharmaceutical Development & 
Commercialization, Inc., Princeton, NJ; 2Otsuka Pharmaceutical Development 
& Commercialization, Inc., Rockville, MD.
Background: ADPKD is a rare inherited systemic disease characterized by progressive 
kidney enlargement and worsening of kidney function leading to end stage renal disease, and 
transplant. Hypertension occurs in 70% of patients and contributes to disease progression, 
and cardiovascular morbidity and mortality. Even for long-term progressive diseases, US 
health plans often focus on short-term outcomes rather than prevention due to patients’ short 
retention in health plans. This study assesses health plan retention rates and direct healthcare 
costs of ADPKD patients with hypertension.
Methods: Patients diagnosed with ADPKD were selected from the Optum 
Clinformatics 2007-2017 US research database. ADPKD was identified using ICD9/10 
codes: 753.12, 753.13, Q61.2, and Q61.3. Patients were required to have continuous 
medical and pharmacy benefits for 6 months pre- index date (baseline period) and ≥6 
months post-index date. The index date was the date of ADPKD diagnosis. Duration of plan 
coverage was reported for the overall population and annual healthcare costs reported in 
patients with and without hypertension.
Results: A total of 9,361 patients met inclusion criteria, of whom 85% had 
hypertension. Mean enrollment duration was 36.5 months with a median of 28.1 months. 
Forty-three percent of patients had 1-2 years coverage, 18% 2-3 years coverage, 12% 3-4 
years coverage, 8% 4-5 years coverage, and 18% greater than 5 years coverage. Mean 
annual direct healthcare costs were higher for patients with ADPKD and hypertension 
($50,850) compared with ADPKD only ($16,135), p<0.001. In patients with ADPKD and 
hypertension, outpatient costs were the primary source of costs with a mean of $18,025, 
followed by inpatient costs ($15,957), pharmacy costs ($8,022), emergency room visits 
($1,476), office visits ($993), and home health costs ($504).
Conclusions: The study findings indicate that most patients with ADPKD retain their 
health plan coverage for a relatively long period, including those with the most prevalent 
comorbid condition in this population. Direct healthcare costs were higher among patients 
with comorbid hypertension. Since these patients incur higher healthcare cost, health plans 
and decision makers may benefit from earlier disease management strategies for ADPKD.
Funding: Commercial Support - Otsuka Pharmaceutical Development & 
Commercialization, Inc.
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Hypertension and CVD: Clinical, Outcomes, Trials
Clinical Feature and Diagnosis of Primary Hyperaldosteronism
Ryotaro Shioda, Hitoshi Suzuki, Yasuhiko Kanaguchi, Tomohito Gohda, 
Yusuke Suzuki. Nephrology, Juntendo University Faculty of Medicine, Tokyo, 
Japan.
Background: Primary aldosteronism(PA) is the most common form of secondary 
hypertension, with an estimated prevalence of 10% of hypertensive patients. Patients with 
PA have higher cardiovascular morbidity and mortality than age- and sex-matched patients 
with essential hypertension and the same degree of blood pressure elevation. Early checkup 
is extremely important to prevent cardiovascular event, stroke and renal dysfunction.
Methods: We retrospectively analyzed the clinical features of the patient with PA who 
were diagnosed from 2014 to 2018.
Results: We analyzed 36 cases with PA who were not treated with RAS inhibitor or 
diuretic drug at the time of screening test for PA. The average age was 49 years old. The 
cases of serum K < 3.5 were only 20%, and adrenal adenoma detected by CT scan was 
42.9%. The median of aldosterone-to-renin ratio (ARR) was 841.9 (206-4370), however, 
in cases with adrenal adenoma, the median ARR was significantly high level with 1299.4 
(300-4370). The correct diagnostic rate of diagnoses of saline test, furosemide test and 
captopril test was 77.1, 71.4 and 65.7%, respectively. There was a trend that the accuracy of 
captopril test was low in patients with low eGFR. The correct diagnostic rate of combination 
of saline and furosemide tests would be the best. The 90 percentile of the serum potassium 
in patients with PA was 4.4 mEq/L, however, those in patients with over 40 years old were 
4.5 mEq/L.
Conclusions: Present study suggested that screening test for PA should be performed 
in cases with serum potassium was less than 4.3 mEq/L in hypertensive patients. Especially, 
in cases with over 40 years old, the screening of the PA with ARR should be performed. In 
addition, the correct diagnostic rate of diagnoses of captopril test was low compared with 
other screening test. Combination of salin and furosemide tests suggested to be proposed 
in present study.
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A Cross-Talk Between TGFbeta Receptor (TGFbR) and PDGF Receptor- 
Beta (PDGFRb) Controls mTORC1-Mediated Mesangial Cell (MC) 
Hypertrophy and Fibrotic Protein Expression
Soumya Maity,3 Falguni Das,4 Nandini Ghosh-choudhury,4 
Meenalakshmi M. Mariappan,1 Balakuntalam S. Kasinath,1 Goutam Ghosh-
Choudhury.2 1University of Texas Health Science Center, San Antonio, TX; 
2Medicine, UT Health San Antonio, San Antonio, TX; 3University of Texas 
Health Science Center at San Antonio, San Antonio, TX; 4UTHSCSA, SAN 
ANTONIO, TX.
Background: TGFb induces MC hypertrophy and matrix protein expression via 
noncanonical mTORC1 during the progression of diabetic nephropathy. The mechanism 
of mTORC1 activation is not clear. Since its activation requires tyrosine kinase activity, 
we considered a cross-talk between TGFb serine-threonine kinase and PDGFRb tyrosine 
kinase in this process.
Methods: Human glomerular MCs in culture and OVE 26 diabetic mice were 
used. PDGFRb inhibitor, activation/inactivation-specific phospho-antibodies, siRNA 
and plasmid-derived expression vector transfection, 35S-Methionine incorporation and 
immunoblotting were used.
Results: In MCs, TGFb increased the activating phosphorylation of PDGFRb in a 
time-dependent manner. This phosphorylation was inhibited by the TGFbRI and PDGFRb 
inhibitors SB431542 and JNJ, respectively. Importantly, JNJ did not have any effect on 
TGFb-stimulated phosphorylation of receptor-specific Smad 3 while SB inhibited its 
phosphorylation. JNJ also inhibited the phosphorylation of PDGFRb at Tyr-751, the PI 3 
kinase binding site, in response to TGFb, resulting in inhibition of Akt phosphorylation at 
both Thr-308 and Ser-473. Transfection of siRNA against PDGFRb confirmed these results. 
Importantly, JNJ and siRNA targeting PDGFRb blocked the phosphorylation of the Akt 
substrate PRAS40, a negative regulator of mTORC1 activation. To determine the mTORC1 
activity, we measured the phosphorylation of S6 kinase and rps6. Inhibition of PDGFRb as 
well as its siRNA mitigated TGFb-induced mTORC1 activity that resulted in attenuation 
of MC hypertrophy. Similarly, JNJ and siPDGFRb inhibited TGFb-stimulated fibronectin 
expression in MCs. Finally, in the renal cortex of OVE 26 diabetic mice, expression of 
TGFb was significantly increased concomitant with phosphorylation of PDGFRb, which 
were associated with increased Akt phosphorylation and mTORC1 activation that lead to 
increased fibronectin expression.
Conclusions: Our results provide the first evidence for a functional role of PDGFRb 
downstream of TGFbR to activate Akt/mTORC1 axis for MC hypertrophy and matrix 
protein expression. We propose to test PDGFRb-specific inhibitor in preclinical models of 
diabetic nephropathy.
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Quercetin Ameliorates Podocytes Injury via Inhibition of Oxidative Stress 
and TGF-β1/Smad Pathway in DN Rats
Fanfan Gao,1 Hongli Jiang.2 Dialysis Department of Nephrology Hospital, First 
Affiliated Hospital of Medicine School, Xi’an Jiaotong University, Xi’an 
710061, Shaanxi, China 1The First Affiliated Hospital of Xi’an Jiaotong 
University, Xi’an, China; 2First Affiliated Hospital of Medicine School, Xi?an 
Jiaotong University, Xi?an, China.
Background: An increasing number of investigations revealed that podocytes 
play a crucial role in the development and progression of diabetic nephropathy (DN). 
The bioflavonoid quercetin, an antioxidant, may be a potential alternative to ameliorate 
podocytes injury in DN rats. The aim of this study was to investigate the protective effect and 
underlying mechanism of quercetin on podocyte injury in rats with diabetic nephropathy.
Methods: SD rats (180-220g) were randomly divided into four groups: normal control 
(NC), diabetic nephropathy (DN), DN treated with low-dose quercetin (DN+LQ) and DN 
treated with high-dose quercetin (DN+HQ). All diabetic rats were induced by a single 
intraperitoneal injection of streptozotocin at concentration 60 mg/kg, and quercetin was 
administered daily with an oral dose of 50 mg/kg (DN+LQ) or 100 mg/kg (DN+HQ) 1 week 
after STZ injection, NC and DN rats were administered vehicle only. Blood glucose and 
body weight were measured every 2 weeks, and albuminuria was measured every 4 weeks. 
All animals were sacrificed after 12 weeks of treatments. Then HE, PAS staining and electron 
microscope were performed to observe kidney tissue and podocytes. Immunohistochemical 
stainig and western blotting were performed to explore the expression of podocin, nephrin, 
desmin, TGF-β1, p-Smad2, and p-Smad3 and Smad7. The contents of SOD, GSH and 
MDA were examined by ELISA.
Results: In the present study, quercetin markedly decreased blood glucose levels, 
kidney-to-body weight ratio, albuminuria, creatinine clearance rate, blood urea nitrogen, 
triglycerides and significantly attenuated oxidative stress compared with the DN group. 
Moreover, quercetin was observed to inhibit podocyte effacement and decrease the 
thickness of glomerular basement membranes. Mechanistically, quercetin significantly 
increased the expression of podocyte-specific markers nephrin and podocin and decreased 
expression of the podocyte injury marker desmin in DN rats. Quercetin also inhibited 
activation of the TGF-β1/Smad signaling pathway in DN rats by decreasing expression of 
TGF-β1, p-Smad2, and p-Smad3, and increasing Smad7 expression.
Conclusions: Quercetin administration ameliorated podocytes injury in DN rats, 
possibly by inhibiting oxidative stress and the TGF-β1/Smad signaling pathway. Thus, 
quercetin may be manipulated to act as a potential drug for prevention of early diabetic 
nephropathy.
Funding: Government Support - Non-U.S.
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TGF-β1 Increases LTBP-2 via RelA, and Elevated LTBP-2 Stimulates 
TGF-β1 Secretion via ERK, Forming a Positive Feedback Vicious Loop 
and Resulting in the De-Differentiation of Proximal Tubules
Kazuhiro Hasegawa, Shu Wakino, Hiroshi Itoh. Keio University, Tokyo, Japan.
Background: Latent transforming growth factor-β-1 binding protein-2 (LTBP-2) 
does not bind to transforming growth factor-β1 (TGF-β1) unlike other LTBPs. Reportedly, 
serum LTBP-2 levels were elevated statistically; thus, it is considered as a potential 
prognostic marker in the progressive stages of diabetic kidney disease. Although LTBP-2 
seems to regulate the TGF-β1 bioactivity, except direct bindings, the effect of LTBP-2 in 
the kidneys is unclear.
Methods: We evaluated the regulatory mechanism of the LTBP-2 expression and 
primary function of LTBP-2.
Results: In wild-type mice, LTBP-2 is expressed only in proximal tubules (PTs). 
Diabetic nephropathy, such as STZ and db/db mice, demonstrated remarkably upregulated 
LTBP-2 in PTs. UUO models also marginally increased LTBP-2 immunostaining in 
collecting tubules but not in PTs. By treating humoral factors that are considered crucial 
mediators in the pathogenesis of diabetic renal injury or renal fibrosis, such as high glucose, 
AGE, angiotensin II, TGF-β1, TNF-α, and interleukin 6, only the TGF-β1 administration 
markedly elevated the LTBP-2 mRNA and protein expression in time- and dose-dependent 
way in cultured PTs. TRANSFAC analysis, luciferase assays, and EMSA revealed that the 
promoter region spanning −1666 to −1436, especially the RelA binding site, was essential for 
the basal LTBP-2 gene promoter activity and TGF-β1–induced LTBP-2 gene upregulation. 
Erk phosphorylation was markedly elevated by the transfection of LTBP-2 cDNA vector 
into HK-2 cells, resulting in the de-differentiation of PTs such as reducing E-cadherin 
expression, increasing fibronectin expression, and TGF-β1 secretion. Conversely, LTBP-2 
siRNA administration under TGF-β1 treatment silenced Erk phosphorylation, resulting in 
blocking the de-differentiation of PTs. When cells were treated with Erk inhibitor, these 
phenotypic changes were prevented.
Conclusions: Renal fibrogenetic changes in diabetic nephropathy were attributed to 
the upregulation of LTBP-2 via the RelA activation by TGF-β1. Elevated LTBP-2 triggers 
the stimulation of TGF-β1 secretion via Erk signaling, forming a positive feedback vicious 
loop and resulting in the de-differentiation of PTs. Overall, silencing LTBP-2 is a novel 
therapeutic target for blocking diabetic tubulopathy or fibrotic changes.
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Smad3 Regulates Cell Fate Through Silencing of Enhancer and  
Superenhancer Elements During the Specification of iPSC Derived  
Kidney Organoids
Jessica L. Davis, Thomas K. Dodd, Ciarán Kennedy, Shane Clerkin, 
Darrell C. Andrews, Catherine Godson, John Crean. University College Dublin, 
Dublin, Ireland.
Background: Critical pathological features of diabetic nephropathy are now accepted 
to include dysregulation of epigenetic processes as evidenced by the observed differential 
methylation in patients with or without progressive disease. We recently demonstrated a 
novel direct interaction between Smad3 and EZH2, the enzymatic component of the PRC2 
complex, during cell fate specification and TGFβ mediated epithelial dedifferentiation. 
Targeting this interaction in iPSC derived renal organoids protected against TGFβ mediated 
tubular epithelial dedifferentiation. Here we further delineate the molecular mechanism 
underlying this interaction.
Methods: Co-localisation of Smad3 and EZH2 was analysed and visualised using 
ChIP-Atlas (www.chip-atlas.org). Putative superenhancers (SE) were identified using the 
Illumina BaseSpace platform. Differential expression of SE target genes in healthy and 
CKD kidney samples were analysed using Nephroseq (www.nephroseq.org). Target genes 
were further analysed during the specification of iPSC derived kidney organoids and during 
TGFβ mediated epithelial dedifferentiation using quantitative real-time PCR.
Results: ChIP-seq identified Smad3 and EZH2 co-localisation at specific loci in 
human ESCs, and newly occupied enhancers in ESCs and iPSCs treated with activin A. 
Bioinformatic analysis of these sites identified 243 putative SEs potentially regulated by 
Smad3/EZH2. Further analysis identified a number of these putative SE target genes that 
are silenced in normal adult kidney but whose expression is significantly increased during 
disease. These included critical determinants of cell fate including ZIC3, ZIC5, and DPPA4. 
Further analysis by RT-PCR indicated a TGFβ dependent downregulation of genes within 
this cohort suggesting a novel mechanism of gene repression during both development 
and disease. Functional analysis of enhancer reporter activity verified a Smad3/EZH2 
dependent mechanism.
Conclusions: We propose that this complex forms a molecular switch that regulates 
enhancer and/or promoter access through epigenetic mechanisms and controls gene 
silencing, informing the fundamental mechanisms through which subsets of genes are 
switched on and off during fate specification and during the pathogenesis of diabetic 
nephropathy.
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LRG1 Promotes DN Progression by Enhancing TGF-β-Induced 
Angiogenesis
Quan Hong,1,2 Lu Zhang,1,4 Jia Fu,1 Wenjun Ju,3 Xiangmei Chen,2
Steven G. Coca,1 Detlef O. Schlondorff,1 John C. He,1 Kyung Lee,1 
Matthias Kretzler.3 1Icahn School of Medicine at Mount Sinai, New York, NY; 
2Chinese PLA General Hospital, Bei Jing, China; 3University of Michigan, Ann 
Arbor, MI; 4Xiamen University Affiliated The First Hospital, Amoy, China.
Background: Glomerular endothelial dysfunction and neoangiogenesis have long 
been implicated in pathogenesis of diabetic nephropathy (DN). However, specific 
molecular pathways contributing to these processes in the early stages of DN injury 
is not well understood. Our recent transcriptomic profiling of isolated glomerular 
endothelial cells identified number of pro-angiogenic genes that were upregulated in the 
diabetic mice, including leucine-rich alpha-2 glycoprotein-1 (LRG1). LRG1, a secreted 
glycoprotein belonging to a leucine-rich repeat family, was previously shown to promote 
neovascularization in models of ocular disease by potentiating the TGF-β/ALK1 signaling 
in endothelial cells. However its role in kidney cells, particularly in the setting of DN, was 
not known.
Methods: We analyzed the expression pattern of LRG1 in murine and human diabetic 
kidneys in comparison to normal kidneys by utilizing the RNA-sequencing data of isolated 
glomeruli and by RNA in situ hybridization. We examined the effects of high glucose 
conditions on LRG1 cultured murine glomerular endothelial cells (mGECs) in vitro. We 
then examined the effects of genetic ablation of Lrg1 in DN progression in diabetic mice at 
12 weeks and at later time point of 20 weeks post diabetes induction.
Results: We found that LRG1 mRNA expression is significantly increased in glomeruli 
of mouse and human diabetic kidneys and that its expression localizes predominantly with 
the glomerular endothelial cells (GECs). High glucose conditions led to the upregulation 
of LRG1 expression in cultured mGECs, and shRNA-mediated knockdown of Lrg1 led to 
reduction in endothelial tube formation in vitro. Genetic ablation of Lrg1 in mice markedly 
attenuated diabetes-induced angiogenesis, albuminuria and glomerulopathy at 12 and 20 
weeks of diabetes. These improvements were associated with reduced ALK1-Smad1/5/8 
activation and with reduced number of GECs in glomeruli of diabetic mice. Moreover, we 
found that plasma LRG1 levels were associated with worsened renal outcome in type 2 
diabetic patient cohort from BioMe Biobank.
Conclusions: Together, our results identify LRG1 as a potential novel pathogenic 
mediator of glomerular angiogenesis in diabetic kidneys and a risk factor of DN 
progression, and suggest that LRG1 may be a promising therapeutic target against the 
disease progression.
Funding: NIDDK Support
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Mesangial Matrix Expansion Attenuated by All-Trans Retinoic Acid 
Through Direct Suppression of Bone Morphogenetic Protein 4 in Mouse 
Diabetic Nephropathy
Masanori Tamaki, Tatsuya Tominaga, Yui Fujita, Seiji Kishi, Taichi Murakami, 
Kojiro Nagai, Hideharu Abe, Toshio Doi. Department of Nephrology, Tokushima 
University, Tokushima, Japan.
Background: Diabetic nephropathy (DN) leads to mesangial matrix expansion, 
resulting in glomerulosclerosis and renal failure. Collagen IV (COL4), a major component 
of the mesangial matrix, is positively regulated by bone morphogenetic protein 4 (BMP4)/
suppressor of mothers against decapentaplegic (Smad1) signaling. All-trans retinoic acid 
(atRA) treatment has a beneficial effect on several kidney disease models, although the 
effect on mesangial matrix expansion in DN remains unclear. AtRA is a representative 
ligand for retinoic acid receptor (RAR), which heterodimerizes with retinoid X receptor 
(RXR). Because RAR/RXR heterodimer binds to RA response element (RARE) and 
regulates various gene transcriptions, the therapeutic effect of atRA on DN through BMP4 
regulation by RAR/RXR–RARE was investigated in the present study.
Methods: Streptozotocin was given to male ICR mice at 12 weeks old for diabetes 
induction. Both control mice and diabetic mice were given all-trans retinoic acid (atRA, 
15 μg/gBW) intraperitoneally thrice weekly from 16 weeks old to 24 weeks old. Animal 
kidneys were harvested at 24 weeks. AtRA or specific agonists for each subtype of RAR 
were added to cultured mouse mesangial cells for 24 h (from 1 nM to 1 μM). The RAR 
binding capacity to RARE, suggested by genome analysis, was confirmed by ChIP analysis. 
The functional role of the putative RARE was confirmed by a reporter assay.
Results: Mesangial matrix expansion worsened in diabetic mice and was associated 
with increased BMP4, phosphorylated Smad1, and COL4. These levels were attenuated 
after atRA administration. In cultured mesangial cells, BMP4 and COL4 expression levels 
were significantly decreased by atRA or low concentrations (1 nM) of RARα agonist but 
not by 1 nM of RARβ or γ agonists. Two putative regions with significant homology to 
RARE were identified around the mouse Bmp4 gene. ChIP analysis and subsequent reporter 
assays indicated the binding of one putative RARE of the Bmp4 gene to RARα and RXR, 
resulting in suppression of BMP4 expression.
Conclusions: AtRA directly suppressed BMP4 via RARα/RXR heterodimer binding 
to a unique RARE, resulting in amelioration of mesangial matrix expansion in diabetic 
mice. These findings provide a novel regulatory mechanism for treatment of DN.
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The Hippo Pathway in the Regulation of the Epithelial-to-Mesenchymal 
Transition of Renal Proximal Tubular Epithelial Cell in Diabetic 
Nephropathy
Chenyang Qi, Zhigang Zhang, Huijuan Wu. Department of Pathology, School of 
Basic Medical Sciences, Fudan University, Shanghai, China.
Background: Diabetic nephropathy (DN) is a major cause of end-stage renal disease in 
the world. Epithelial-to-mesenchymal transition (EMT) of renal proximal tubular epithelial 
cells (PTECs) is an important mechanism in the progression of interstitial fibrosis in DN. 
Recently, Hippo pathway was recognized as a regulator of cell proliferation, differentiation 
and apoptosis and may be potential therapeutic targets in many kidney diseases.
Methods: In order to study whether the Hippo pathway regulate EMT of PTECs in DN, 
we cultivated the db/db type 2 diabetic model mice and normal or high glucose stimulated 
HK-2 cells (human PTECs). We detected the levels of Hippo pathway and EMT of HK-2 
cells and PTECs in db/db mice. We administrated verteporfin, a YAP inhibitor, and detected 
the change of EMT.
Results: Compared with the littermates, db/db mice developed microalbuminuria at 
the age of 20 weeks and showed obvious kidney hypertrophy from the 4th week. Then, 
we found that the expression of phosphorylated YAP at serine 127 (p-YAP-S127) in 
PTECs was obviously increased. While, the total YAP level did not change significantly. 
We also found that the protein levels of epithelial markers (Ecadherin, ZO-1, and CK-18) 
were significantly decreased in db/db mice, while the mesenchymal markers (Vimentin, 
α-SMA) was elevated and these changes were consistent with EMT. Similar changes 
have been found in HK-2 cells. In high glucose stimulated HK-2 cells, p-YAP-S127/
total YAP ratio was increased, epithelial markers were decreased and the mesenchymal 
markers was elevated (i.e., the onset of EMT). At the same time, we extracted the nuclear 
and cytoplasmic fraction in normal or high glucose stimulated HK-2 cells. The total YAP 
level in the cytoplasm was increased, while that in the nucleus was decreased. In addition, 
administration of verteporfin, which could reduce the level of p-YAP, elevated the epithelial 
markers and decreased mesenchymal markers (i.e., reversed the EMT) in high glucose 
stimulated HK-2 cells.
Conclusions: In conclusion, high glucose reduced the YAP nuclear translocation, thus 
more p-YAP was anchored in the cytoplasm and induced EMT of PTECs. Verteporfin could 
reverse the EMT, which suggested that Hippo pathway can regulate the EMT in PTECs. 
This study would provide a new potential therapeutic target for DN.
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Blockade of RIPK3 Alleviates Renal Fibrogenesis Through TLR2/4 
Signalling in Streptozotocin-Induced Diabetic Model
Ying Shi, Chunling Huang, Xinming Chen, Carol A. Pollock. University of 
Sydney, Sydney, NSW, Australia.
Background: Current therapies for renal fibrosis are largely ineffective. Therefore, 
identification of novel therapeutic targets is essential. RIPK3 is identified as a crucial 
regulator of TLRs signalling activation, which has been well recognised to be involved in 
renal fibrogenesis. To date, the function of RIPK3 in renal fibrosis remains unclear.
Methods: C57BL/6 wild-type mice and C57BL/6 RIPK3 gene knock out (RIPK3-/-) 
mice were used in the study. streptozotocin (55 mg/kg/day) was administrated to induce 
diabetic model by i.p. for 5 consecutive days. After 24 weeks treatment, mice were 
sacrificed and urinary albumin creatinine ratio (UACR) was measured by ELISA. Kidney 
histological change and ECM deposition were assessed by PAS, picrosirius red staining 
and immunohistochemistry. Collagen IV, Fibronectin, α-SMA, TGF-β, TNF α, IL-1 β, 
TLR2. TLR4, MCP-1, F4/80 mRNA expression level were assessed by quantitative RT-
PCR analysis.
Results: RIPK3 deletion reduced UACR compared to the increased level of diabetic 
group. Both Immunohistochemical staining and PCR revealed that the absence of RIPK3 
decreased the diabetic induced collagen IV and Fibronectin within kidney cortex. In 
addition, diabetes induced the TLR2/4 signalling activation and resulted in an increase of 
MCP-1 and F4/80 gene expression. However, genetic ablation of RIPK3 decreased TLR2/4 
mRNA expression levels and the downstream TNF α and IL-1 β transcription associating 
with less MCP-1 and F4/80 gene expression. Moreover, diabetes upregulated TGF-β and α-
SMA mRNA expression within kidney, whereas this effect was blocked by RIPK3 deletion.
Conclusions: RIPK3 is crucial in renal fibrosis by mediating TLR2/4 signalling. Our 
data suggest that RIPK3 blockade may be a potential novel target in renal fibrosis.
Funding: Government Support - Non-U.S.
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Grem1 Plays a Vital Role in Nicotine Exacerbated Diabetic Nephropathy
Hongxiu Wen,2,1 Xiqian Lan,2,1 Vinod Kumar,3 Seyedeh Shadafarin Marashi 
Shoshtari,4 Rukhsana Aslam,5 Ali Hussain,6 Ashwani Malhotra,7 
Pravin C. Singhal.8 1Feinstein Institute for Medical Research, Manhasset, NY; 
2Key Laboratory for Aging and Regenerative Medicine, School of Pharmacy, 
Southwest Medical University, Luzhou, China; 3Fienstine Institute for Medical 
Research, NEW YORK, NY; 4The Feinstein Institute for Medical Research, 
Manhasset, NY; 5Feinstein Institute for medical research, Glenoaks, NY; 
6Feinstein Institute of Medical Research, New York, NY; 7Feinstein Institute 
Medical Research and NSLIJ, MANHASSET, NY; 8North Shore LIJ Health 
System, Great Neck, NY.
Background: Increasing evidences have demonstrated that cigarette smoking promotes 
the progression of diabetic nephropathy (DN), but the underlying molecular mechanisms 
are far from clear. Nicotine, a major component for smoking addiction, has been reported 
to be an independent component to cause kidney cell injury to accelerate the progression of 
DN. This study has been designed to evaluate the role of nicotine in DN and to explore the 
underlying molecular mechanisms.
Methods: In vivo studies, diabetic mice were developed through the administration of 
three doses of streptozotocin (STZ, 50 mg/kg body weight, intraperitonelly). These mice 
were fed with either nicotine (100 μg/ml) or vehicle (PBS) in their drinking water for 5 
months. At the end of the experimental period, kidney function biomarkers (proteinuria, 
blood urea nitrogen [BUN]) were collected and kidneys were harvested for histological 
changes and molecular analysis (immunohistochemistry, real-time PCR, and Western 
blotting). The kidney transcriptomes of these mice were compared through RNA seq 
analysis, and the results were further confirmed by real-time PCR, Western blotting, and 
immunohistochemical studies. In vitro studies, human podocytes were treated with high 
glucose (30 mM) with or without nicotine (10 μM), followed by morphologic assay for 
apoptosis. The effect of high glucose with or without nicotine was also evaluated on 
podocytes-silenced for specific genes.
Results: In vivo studies, STZ-receiving mice displayed a higher level of blood 
glucose and associated kidney injury, however, nicotine further exacerbated this effect of 
hyperglycemia. Interestingly, nicotine alone didn’t cause an over kidney injury. RNA seq 
analysis revealed that nicotine dramatically exacerbated the expression of Grem1, a DAN 
family member, which has been demonstrated to play a vital role in the pathogenesis of 
DN. In vitro studies, combined use of nicotine and high glucose displayed an increase in 
podocyte apoptosis as well as the expression of Grem1; while silencing of Grem1 decreased 
the number of cells with apoptosis.
Conclusions: Grem1 might play an important role in nicotine-exacerbated DN. Our 
study has highlighted novel molecular targets for the therapy and prevention of smoking 
boosted DN.
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Grem2 Mediates Podocyte Apoptosis in High Glucose Milieu
Hongxiu Wen,2,1 Xiqian Lan,2,1 Vinod Kumar,1 Abheepsa Mishra,1 
Rukhsana Aslam,1 Seyedeh Shadafarin Marashi Shoshtari,1 Ali Hussain,1 
Ashwani Malhotra,1 Pravin C. Singhal.1 1The Feinstein Institute for Medical 
Research, Northwell Health, MANHASSET, NY; 2Key Laboratory for Aging and 
Regenerative Medicine, School of Pharmacy, Southwest Medical University, 
Luzhou, China.
Background: The DAN family members (Grem1, Grem2, Grem3, Cerberus, 
NBL1, SOST, and USAG1) are highly expressed during development where they have 
an important role in kidney formation and morphogenesis; in adults, however, increased 
DAN protein levels are often associated with severe disease-states, including renal fibrosis. 
Grem1, SOST, and USAG1 have been demonstrated to be upregulated and play a critical 
role in the progression of diabetic nephropathy (DN); other DAN family members have 
not been reported to be related to renal disease, and their expression in DN kidneys has not 
be yet investigated. In this study, we investigated the expression and the role of Grem2 in 
type 2 DN mice.
Methods: In vivo studies, 14-weeks-old BTBR ob/ob (a type 2 diabetic mouse 
model) and control (BTBR, wild-type) mice were evaluated for renal function biomarkers 
(proteinuria and blood urea nitrogen [BUN]). Kidneys were harvested and renal tissues 
were analyzed by real-time PCR, Western blotting, and immunohistochemistry studies. In 
vitro studies, human podocytes transfected with Grem2 plasmid were evaluate for apoptosis 
(morphologic assay and Western blotting). To evaluate the Grem1-mediated downstream 
signaling, the phosphorylation status of Smad2/3 and Smad1/5/8 was assessed; additionally, 
SIS3, an inhibitor for Samd3, and BMP-7, an agonist for Smad1/5/8 were used to treat the 
cells.
Results: In vivo studies, the diabetic mice showed elevated levels of and proteinuria 
BUN. Real-time PCR and Western blotting analysis showed an increased expression of 
Grem2 in diabetic kidneys. Immuno-histochemical studies showed enhanced Grem2 
expression both by tubular and glomerular cells. In vitro studies, high glucose increased 
Grem2 expression in cultured human podocytes, and silencing of Grem2 partially 
suppressed high glucose-induced apoptosis. Overexpression of Grem2 promoted podocyte 
apoptosis morphologically as well as by an increased Bax/Bcl2 ratio. Overexpression 
of Grem2 increased the phosphorylation of Smad2/3 and decreased the phosphorylation 
of Smad1/5/8, while addition of SIS3 or BMP-7 attenuated Grem2-induced podocyte 
apoptosis.
Conclusions: High glucose increases Grem2 expression in kidney cells. Grem2 
mediates podocyte apoptosis through Smads. Grem2 plays an important role for the 
progression of DN.
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Activation of Pro-Fibrotic Genes by Nicotine in a Mouse Model of 
Diabetes: Implications for Diabetic Nephropathy in Smokers
Wenguang Feng,2 Edgar A. Jaimes.1 1Memorial Sloan-Kettering Cancer Center, 
New York, NY; 2University of Alabama at Birmingham, Birmingham, AL.
Background: Tobacco use is a well-recognized, preventable risk factor for CKD 
progression, especially in diabetics; however, the mechanisms involved are not completely 
understood. We and others have demonstrated that nicotine acetylcholine receptors 
(nAChR) are present in rat, mouse, and human kidneys, and that the systemic administration 
of nicotine worsens the severity of renal injury in animal models of CKD. In these studies 
we hypothesize that siganling via the α7-nAChR promotes the gene expression of pro-
fibrotic pathways in diabetic mice receiving nicotine.
Methods: Diabetes (DM) was induced by low dose STZ injection in male eNOS-/- mice 
(n=6 per group). After confirmation of diabetes nicotine was admnistered in the drinking 
water (Nic, 100 μg/mL) for 10 weeks. A group of mice was treated with the specific 
α7nAChR blocker IC200610 (NB, 2 mg/kg IP) 5 days a week for 10 weeks. An additonal 
group of mice double knockout for eNOS and α7nAChR was also made diabetic (DKDM) 
and treated with nicotine (Nic, 100 μg/mL). After euthanasia renal cortex mRNA expression 
for genes involved in fibrosis and inflammation was determined by RT-PCR.
Results: Diabetes resulted in increased expression of genes linked to fibrosis and 
inflammation (table). The administration of nicotine increased the expression of CTGF, 
COL1 and MMP2 three genes that have been linked to progression of CKD. The 
administration of a specific α7nAChR blocker or genetic deletion of α7nAChR reduced the 
expression of these genes suggesting that these effects are mediated via signaling activated 
by this receptor.
Conclusions: The administration of nicotine to diabetic mice results in increased 
expression of CTGF and MMP2 two genes involved in the pathogenesis of progressive 
CKD including diabetic nephropathy. In addition these effects appear to be mediated by the 
α7nAChR which could potentailly be a therapeutic target for diabetes with CKD who use 
nicotine containing tobacco products.
Funding: Other NIH Support - NIEHS
Gene expression in diabetic mice on nicotine
* P <0.05 vs Control, ** P <0.05 vs DM and DM+Nic, # P<0.05 DM (N=6 per group)
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Modulation of GSK-3β Expression by AMPK Ameliorates Diabetic 
Kidney Injury by Promoting IR Phosphorylation Cascade
Bo Zhang, Suyan Duan, Yanggang Yuan. The First Affiliated Hospital of Nanjing 
Medical University, Nanjing, China.
Background: Insulin resistance is a systemic disorder that affects many organs and 
insulin-regulated pathways. Insulin signaling to the glomerular podocyte is important for 
normal kidney function and is implicated in the pathogenesis of diabetic nephropathy (DN). 
It has recently been found that GSK-3β may play a role in the pathogenesis of diabetes and 
DN; however, the specific mechanism is still unknown. We aimed to investigate whether 
GSK-3β has a role in the amelioration of podocyte injury and insulin resistance, thus 
suppressing the progression of DN. Moreover, the molecular mechanisms responsible for 
the effects were examined.
Methods: Podocyte insulin responses were investigated with western blotting, 
cellular glucose uptake assays and fluorescent imaging of the insulin receptor signalling. 
Quantitative (q)RT-PCR was employed to investigate changes in mRNA. Cell viability 
and motility were detected by CCK-8 and wound healing assay. Db/db mice injected with 
different treatment were also generated. ELISA measurements were also used.
Results: Our results demonstrated that AMPK modulates podocyte IR level and 
enhances insulin-stimulated phosphorylation of PI3K/Akt cascades in high-glucose 
condition and diabetic db/db mice. Plus, AMPK prevented hyperglycemia-induced increase 
of GSK3β phosphorylation, ameliorated glucose uptake into podocytes, and impaired 
podocyte viability and motility. Moreover, treatments for modulation of key proteins in 
AMPK- PI3K/Akt -GSK3β signalling results in a reduction of proteinuria and significant 
improvement in renal function and pathological damage in db/db mice.
Conclusions: These findings evoke a novel therapeutic concept for DN, implying that 
the pharmacologic activation of AMPK might suppress the progression of DN and podocyte 
injury, also rescue podocyte insulin resistance. AMPK-PI3K/Akt- GSK3β pathway may be 
exploited as a therapeutic target for protection against podocyte injury and insulin resistance 
in DN.
Representative HE staining of diabetic kidney in each group
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Circulating Soluble Nogo-B Ameliorates Diabetic Glomerulopathy Partly 
by Modulating GSK3β/βcatenin Signaling
Carlo alberto Ricciardi,1 Ivan Hernandez,1 Georgia E. Fouli,1 Anthea E. Hayward,1 
David A. Long,2 Luigi Gnudi.1 1King’s College London, London, United 
Kingdom; 2University College London, London, United Kingdom.
Background: Early diabetic glomerulopathy (DG) is characterised by albuminuria, 
endothelial cell (EC) proliferation, EC glycocalyx disruption and podocyte loss. Nogo-B, 
expressed in glomerular EC and podocytes, is downregulated in diabetes. A 200-aminoacid 
N-terminus soluble Nogo-B (sNogo-B) is found in the circulation and (as Nogo-B) binds
to its receptor NgBR promoting vascular integrity. Activation of GSK3β/βcatenin pathway 
promotes vascular stability; conversely, inactivation of GSK3β with βcatenin cellular
accumulation, as seen in diabetes, promotes VEGFR2 signaling and ECs proliferation/
vascular permeability. We investigated whether, in diabetes, sNogo-B overexpression 
modulates GSK3β/βcatenin and VEGFA signaling towards a stable glomerular capillary.
Methods: Adult DBA2J male mice were made diabetic with streptozotocin; sNogo-B 
overexpression was initiated after induction of diabetes by adeno-associated vector (AAV)
(AAV driving the expression of green fluorescent protein-GFP served as control). Mice with 
glycemia >22 mM were considered diabetic. Mice were killed after 12-14 weeks of diabetes 
and kidney tissue collected for electron microscopy and immunofluorescence, respectively 
for podocyte number and EC proliferation/glycocalyx determination; renal cortex lysate was 
utilised for VEGFA/VEGFR2 phosphorylation levels (ELISA), and AKT, GSK3β/βcatenin 
signaling (western immunoblotting). Abuminuria was measured by ELISA.
Results: Diabetes (D) resulted in albuminuria, glomerular EC proliferation, EC 
glycocalyx disruption and podocyte loss when compared to non-diabetic (ND) mice 
(ND-GFP vs D-GFP, p<0.01); sNogo-B overexpression ameliorated diabetes-mediated 
albuminuria and vasculature anatomical alterations and was paralleled by inhibition of 
diabetes-mediated AKTser473 and GSK3βser9 phosphorylation (D-GFP vs D-sNogo-B, 
p<0.05). βcatenin was highly expressed in kidney cortex lysate of D-GFP mice (ND-GFP 
vs D-GFP, p<0.001) and was downregulated in D-sNogo-B mice (D-GFP vs D-sNogo-B, 
p<0.01), an event paralleled by a normalisation of diabetes-mediated VEGFA/VEGFR2 
receptor system activation (D-GFP vs D-sNogo-B, p<0.04).
Conclusions: sNogo-B overexpression in diabetic mice promotes a healthy vasculature 
via activation of GSK3β/βcatenin pathway; sNogo-B could represent a targetable pathway 
for the treatment of DG.
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Deacetylation of S6 Kinase (S6K) by High Glucose Drives Mesangial Cell 
(MC) Hypertrophy and Matrix Expansion in Diabetic Nephropathy (DN)
Falguni Das, Nandini Ghosh-choudhury, Balakuntalam S. Kasinath,
Goutam Ghosh-Choudhury. UTHSCSA, SAN ANTONIO, TX.
Background: Hyperglycemia increases mTORC1-dependent S6K Thr-389 
phosphorylation/activation to induce glomerular MC hypertrophy and matrix protein 
expansion in DN. S6K is acetylated in the C-terminal lysines (K484/485/493). We 
investigated the mechanism of S6K acetylation in relation to MC hypertrophy and 
fibronectin expression.
Methods: Human MCs in culture and streptozotocin (STZ)-induced diabetic rats were 
used. Activation/inactivation-specific phospho-antibodies, siRNA and plasmid-derived 
expression vector transfection and immunoblotting were employed.
Results: In MCs, 25 mM glucose (HG) decreased acetylation of multiple proteins 
including S6K concomitant with its increase in phosphorylation/activation. Consequently, 
HG increased phosphorylation of the S6K substrates rps6 and eEF2 kinase that resulted 
in dephosphorylation of eEF2. To determine the mechanism of S6K deacetylation, we 
considered the class I histone deacetylase-1 (HDAC1). Trichostatin-A (TSA), a pan HDAC 
inhibitor, blocked all of the HG-stimulated effects. HG increased the association of S6K 
with HDAC1. Expression of HDAC1 decreased the acetylation of S6K and increased the 
phosphorylation of S6K, rps6, eEF2 kinase, and dephosphorylation of eEF2, resulting 
in MC hypertrophy and expression of fibronectin, similar to HG. In contrast, siRNA 
against HDAC1 prevented these effects induced by HG. To study the precise mechanism, 
an acetylation mimetic triple mutant (TKA) was used. Expression of TKA blocked HG-
stimulated phosphorylation of S6K, rps6, eEF2 kinase and inhibited the dephosphorylation 
of eEF2 resulting in attenuation of MC hypertrophy and fibronectin expression. In contrast, 
acetylation deficient mutant S6K (TKR) induced above phosphorylation events, and MC 
hypertrophy and fibronectin expression, similar to HG. Finally, in the renal glomeruli 
of STZ-induced diabetic rats, acetylation of S6K was significantly reduced concomitant 
with increased HDAC1, S6K activation, phosphorylation of rps6 and eEF2 kinase, 
dephosphorylation of eEF2, renal hypertrophy and fibronectin expression.
Conclusions: Our data for the first time show a role of S6K deacetylation in MC 
hypertrophy and matrix expansion, two pathologic features of DN. The results also furnish 
a molecular basis underlying the association between S6K and HDAC1 in DN.
Funding: Veterans Affairs Support
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DcR2 Interacts with Peroxiredoxin 1 and Accelerates Senescence of Renal 
Tubular Epithelial Cell in Diabetic Nephropathy
Jia Chen, Yani He. Daping Hospital, Chongqing, China.
Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease 
(ESRD). The extent of tubulointerstitial lesions ultimate determines the rate of attrition of 
renal function, and premature senescence of RTECis a prominent renal histological change 
in DN. Decoy receptor 2 (DcR2) is a transmembrane receptor of cellular senescent marker, 
but the interaction proteins and the role of DcR2 are not clear.
Methods: 139 DN patients which diagnosed by renal biopsy were enrolled. Renal 
DcR2 and senescent markers, P16 and SA-β-gal were detected with immunostaining. 
The degree of cell senescence were evaluated after regulation of DcR2 expression. Co-IP 
combining with LC-MS/MS were screened the interaction proteins for DcR2 in renal tissue 
and high glucose (HG) induced-proximal tubular epithelial cells (PTECs). The interaction 
of DcR2 and PRDX1 was detected by Co-IP and pull down assay. Peroxidase activity of 
PRDX1 was assessed by the kits of ROS and specific 2-cys peroxidase activity. The level of 
PRDX1 phosphorylation was detected through WB.
Results: DcR2 was primarily expressed in renal proximal tubules, and co-expression 
with senescent markers P16 and SA-β-gal. Overexpression of DcR2 accelerate whereas 
knockdown inhibited the expression of P16 and SA-β-gal. Quantitative proteomics 
identified 135 differentially expressed proteins (DEPs) in renal tissue and 59 DEPs in HG. 
Peroxiredoxin 1 (PRDX1), an enzyme of oxidative stress, was screened not only in renal 
tissue but also in HG-induced cells. The interaction of DcR2 and PRDX1 was verified in 
vivo and in vitro. DcR2 can inhibited the peroxidase activity of PRDX1 through promote 
the phosphorylation of PRDX1.
Conclusions: DcR2 accelerates tubular cell senescence through interacting with a new 
partner PRDX1, and DcR2 can affect the peroxidase activity of PRDX1 through regulating 
the phosphorylation of PRDX1 in DN.
Funding: Government Support - Non-U.S.
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SMPDL3b Modulates Insulin Signaling in Lipid Raft Domains and 
Interferes with Diabetic Kidney Disease
Alla Mitrofanova,1 Shamroop Kumar Mallela,1 Gloria Michelle Ducasa,1 Tae-
Hyun Yoo,2 Judith T. Molina David,3 Mengyuan Ge,3 Jin Ju Kim,3 
Christopher E. Pedigo,7 Christian Faul,4 Yu Ishimoto,5 Reiko Inagi,6 Sandra 
M. Merscher,3 Alessia Fornoni.3 1University of Miami School of Medicine,
Miami, FL; 2Yonsei University College of Medicine, Seoul, Republic of Korea; 
3University of Miami, Miami, FL; 4The University of Alabama at Birmingham,
Birmingham, AL; 5Tokyo University, Hongo, Japan; 6The University of Tokyo
Graduate School of Medicine, Bunkyo-ku, Japan; 7Yale University, New Haven, CT.
Background: SMPDL3b is a recently identified phosphodiesterase localized in lipid 
raft domains that regulates lipid composition and plasma membrane fluidity. As SMPDL3b 
is upregulated in diabetes while insulin receptor signaling is impaired, our study was aimed 
at testing the hypothesis that SMPDL3b affects the generation of sphingolipids involved in 
the regulation of insulin receptor signaling.
Methods: For in vitro studies, control and SMPDL3b overexpressing human podocytes 
were used. Cells were treated with insulin (0.1 and 1 nM, 30 min) or ceramide-1-phosphate 
(C1P; 100 uM, 1h) and analyzed by Western blotting or PCR. Lipidomic analysis was 
performed using LC-MS analysis and TLC plates. Co-immunoprecipitation experiments 
were performed using HEK293 cells. For in vivo studies, podocyte-specific Smpdl3b 
deficient diabetic db/db mice were produced using Cre-LoxP technology. Starting at 4 
weeks of age, vital parameters (weight, glycemia, urine) were measured bi-weekly. For C1P 
replacement therapy, diabetic mice were IP injected with 30 mg/kg C1P daily for 28 days. 
Mice from all experiments were sacrificed for in-depth phenotypical analysis. All animal 
studies were performed in accordance with the NIH IACUC Guide. For statistical analysis 
One-Way ANOVA followed by Bonferroni’s posttest or Student t-test were used.
Results: SMPDL3b binds to both IR isoforms (IRA and IRB) and, when in excess, 
competes with the binding of IRB to caveolin-1 and alters pro-survival insulin signaling in 
podocytes. In vivo, we demonstrated that kidneys of diabetic db/db mice are characterized 
by SMPDL3b excess and C1P deficiency, whereas podocyte-specific Smpdl3b deficient 
diabetic db/db mice show a normal C1P content and are protected from the development 
of diabetic kidney disease (DKD). Exogenous administration of C1P is sufficient to restore 
proper IR signaling in vitro and to protect from DKD in vivo.
Conclusions: Taken together, we identified new sphingolipid modulator of insulin 
signaling and demonstrated that replacement of deficient active sphingolipid species such 
as C1P may represent a novel approach to treat diabetic complications such as DKD.
Funding: NIDDK Support
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LXR/mTOR/Nox4 Signaling Axes: Novel Therapeutic Targets in Diabetic 
Nephropathy
Sahar Alkhansa,2 Stephanie A. Eid,2 Christopher El mouhayyar,3 
Neamah Mahjoub,2 Rasha Barakat,4 Assaad Antoine Eid.1 1American University 
of Beirut/Faculty of Medicine, Beirut, Lebanon; 2American University of Beirut, 
Beirut, Lebanon; 3American Univeristy of Beirut, Naccache, Lebanon; 
4Universite Paris Descartes, Amioun, Lebanon.
Background: Podocyte injury has emerged as a key mediator in the initiation of 
Diabetic Nephropathy (DN). The molecular mechanism by which hyperglycemia induces 
podocyte injury is multi-factorial and not well defined. Recent studies have described the 
potentiality of defective autophagy mechanisms on the onset and development of diabetes. 
Our lab has described the importance of renal NADPH Oxidases (Noxs) in the progression 
of podocyte injury. Yet, a mechanistic pathway between Nox-induced ROS production and 
the alteration in autophagy has yet to be clarified. Liver-X-receptor (LXR) and the mTOR 
pathway have recently been linked to autophagy and oxidative stress. In this study we aim to 
assess the role of Nox/LXR/mTOR axes on autophagy and their possible links to podocyte 
depletion and injury.
Methods: Pharmacological means were utilized to alter the expression of Noxs, LXR 
and the mTOR signaling pathways, while podocyte depletion/loss, autophagy alteration and 
glomerular injury were assessed as the corresponding biological output both in vitro and 
in vivo.
Results: Our results reveal that high glucose (HG) induces defective autophagy in 
both podocytes and isolated glomeruli of type 2 diabetic mice. HG reduces LXR mRNA 
levels and protein expression and activates the mTORC1/p70S6kinase pathway. HG also 
increases the levels of Nox4 and Nox activity and induces ROS production. Activation of 
the LXR pathway using an LXR activator T0, decreases HG-induced Nox4 expression, 
Nox activity, inactivates the mTORC1 pathway, and restores autophagy protein levels. In 
parallel, inactivation of the mTORC1 pathway using low dose rapamycin, mimicked the 
effect of T0 on ROS production and podocytes injury but did not alter the LXR pathway, 
suggesting that mTORC1 is downstream of LXR and Noxs are the final common pathway 
altered in our experimental model. More importantly, our results display the role of Nox4 
in autophagy, where inactivation of Nox4, using GKT, a potent Nox1 and Nox4 inhibitor, 
restores homeostatic autophagy levels, and reduces podocytes and glomerular injury.
Conclusions: Thus, LXR activation, mTOR and/or NADPH oxidase inhibition may 
represent a therapeutic modality for diabetic kidney disease.
FR-PO397 Poster Friday
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High Glucose–Induced Apoptosis and Necroptosis in Podocytes Is 
Regulated by UCHL1 via the RIPK1/RIPK3 Pathway
Yuyin Xu,1 Chenyang Qi,2 Huijuan Wu,2 Zhigang Zhang.2 1Departmen of 
pathology, School of basic medical science, Fudan University, Shanghai, China; 
2Department of Pathology, School of Basic Medical Sciences, Fudan University, 
Shanghai, China.
Background: Depletion of podocytes plays a critical role in the pathogenesis of 
diabetic nephropathy (DN). Many investigations suggested its close association with 
apoptosis. However, the complex mechanism of podocyte loss in DN remains unclear. 
Recently, necroptosis has emerged as an important cell death model in cell injury related 
to many pathological conditions, which is regulated through the receptor interacting kinase 
1/3 (RIPK1/RIPK3) pathway. It has been revealed that the molecular pathways to regulate 
apoptosis and necroptosis are closely related. Therefore, it is speculated that apoptosis and 
necroptosis may occur simultaneously during the process of podocyte injury in DN.
Methods: Immunofluorescence staining, trypan blue staining, Hoechst staining, 
TUNEL and ELISA were used to detect apoptosis and necroptosis of podocytes in vitro 
and in vivo. The ultrastructures of the two cell death patterns were observed under scanning 
electron microscope (SEM). After stimulation of podocytes with high glucose (HG), the 
expression of UCHL1 and RIPK1/RIPK3 pathway and the regulation effect of UCHL1 
on apoptosis and necroptosis of podocytes were detected by western blot. The endogenous 
binding of UCHL1 with RIPK1 or RIPK3 and the ubiquitination of RIPK1 and RIPK3 
proteins was detected by IP experiment.
Results: The present study demonstrated that necroptosis was involved in HG-induced 
podocyte injury both in vitro and in vivo. HG could induce both apoptosis and necroptosis 
in podocytes, which was dependent on HG concentration and treatment duration. This 
novel study explored the explicitly different morphological characteristics of apoptotic and 
necroptotic cells using SEM examination with TUNEL and Trypan blue double staining. 
The inhibition of apoptosis by z-VAD-fmk could enhance the necroptosis process, which 
was inhibited by Necrostatin-1(Nec-1). The present study also showed that ubiquitin 
carboxyl-terminal hydrolase L1 (UCHL1) had a central role in regulating the two modes of 
cell death via mediating the ubiquitination states of the RIPK1/RIPK3 pathway.
Conclusions: These data suggested that necroptosis might be a major contributor to 
podocyte loss rather than apoptosis in HG treatment. The discovery of the novel function of 
UCHL1 may assist in developing strategies for treating podocyte damage induced by HG.
Funding: Government Support - Non-U.S.
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Amodiaquine and Chloroquine Attenuate Mitochondrial Abnormalities in 
Diabetic Tubulopathy Presumably by AMPK Phosphorylation
So-young Lee,1 Dong Ho Yang,2 Jun mo Kang,2 Min ji Sung,2 Yubum Choi,2 
Wooyeol Ahn,3 Su Woong Jung,4 Soonchul Lee.5 1Internal Medicine, CHA 
Bundang Medical Center, CHA Univ., Seongnam, Gyeonggi-do, Republic of 
Korea; 2Internal Medicine, Bundang CHA medical center, CHA university, 
Seongnam, Gyeonggi-do, Republic of Korea; 3CHA University, Seongnam, 
Gyeonggi-do, Republic of Korea; 4Internal Medicine, Kyung Hee University 
Hospital at Gangdong, Kyung Hee University, Seongnam, Gyeonggi-do, 
Republic of Korea; 5Orthopaedic Surgery, CHA Bundang Medical Center, CHA 
university, Seongnam, Gyeonggi-do, Republic of Korea.
Background: The activity of 5’ AMP-activated protein kinase (AMPK), the major 
energy-sensing enzyme, was recently observed to be reduced in the kidneys of both diabetic 
mice and humans. Several previous studies showed that AMPK activators attenuate diabetic 
nephropathy, resulting in decreased albuminuria in diabetic mice. Chloroquine (CQ), an 
antimalaric drug, has also been considered an essential therapy in patients with systemic 
lupus erythematosus (SLE). It was reported that withdrawal of amodiaquine (AQ), a 
derivative of chloroquine is related to lupus flares after medication cessation. Although the 
mechanisms by which these agents act on SLE are unclear, a recent study reported that 
chloroquine increased AMPK phosphorylation in myotube cells. We investigated the effects 
of CQ and AQ on AMPK phosphorylation in renal tubular cells in a diabetic environment 
in vivo and in vitro. We also examined whether CQ- or AQ-mediated AMPK activity 
restoration attenuated diabetic tubulopathy by normalizing mitochondrial fragmentation.
Methods: Human renal proximal epithelial cells (HKC8) were incubated in high-
glucose conditions. Diabetes was induced with streptozotocin in male C57/BL6J mice.
Results: Treatment with CQ or AQ abolished high-glucose-induced phospho-
AMPK and phosph-PGC1α down-regulation in HKC8 cells. Improvements in functional 
mitochondrial mass and balanced fusion/fission protein expression were observed in HKC8 
cells after treatment with CQ or AQ in high-glucose conditions. Moreover, decreased 
mitochondrial ROS production and reduced apoptotic and fibrotic protein expression were 
noted in HKC8 cells after treatment with CQ or AQ, even in high-glucose conditions. CQ 
and AQ treatment effectively mitigated albuminuria and renal histopathologic changes and 
increased AMPK activity in the kidneys of diabetic mice. Electron microscopy analysis 
showed that mitochondrial fragmentation was decreased, and 8-OHdG content was low 
in the renal tubular cells of the CQ and AQ treatment groups compared with those of the 
diabetic control group.
Conclusions: Our results suggest that CQ and AQ may be useful treatments for patients 
with diabetic kidney disease. This work was supported by a National Research Foundation 
grant of Korea (NRF-2016R1C1B1013814) funded by the Korea government.
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Sirt6 Protects Podocytes from High Glucose-Induced Mitochondrial 
Dysfunction and Apoptosis Through AMPK Activation
Guohua Ding, Yanqin Fan. Division of Nephrology, Renmin Hospital of Wuhan 
University, Wuhan, Hubei, China Renmin Hospital of Wuhan University, Wuhan, 
China.
Background: Previous studies have shown that mitochondrial dysfunction plays 
an important role in podocyte injury. Sirt6 has been revealed with essential roles in the 
regulation of mitochondrial function. However, the pathological features and molecular 
mechanism of mitochondrial damage in podocytes under high glucose (HG) condition 
remains unknown. The present study aims to observe the changes of podocyte mitochondria 
under HG and to evaluate whether Sirt6 contributes to HG-induced podocytes apoptosis 
through modulating mitochondrial function.
Methods: In vivo study, transmission electron microscope (TEM) was used to 
identify ultrastructure changes of podocyte mitochondria in diabetic mice. Co-localization 
expression of Sirt6 and WT-1 was evaluated in glomeruli by double immunolabeling. 
Western blot was performed to assess Sirt6 and p-AMPK expression in glomeruli. In 
vitro study, conditionally immortalized human podocytes were exposed to HG (30mM) 
for 24 h. Mitochondria ultrastructure was observed by TEM. Mitochondrial number and 
ROS production were respectively evaluated by Mito Green and MitoSox Red staining. 
Mitochondrial membrane potential was determined by JC-1 staining. Flow cytometry 
was used to assess podocyte apoptosis. Western blot was performed to evaluate Sirt6 and 
p-AMPK expression.pcDNA3.1 SIRT6 was transfect to podocytes to evaluate the effect
of Sirt6 over-expression on mitochondrial function and podocyte apoptosis under HG
stimulation.
Results: Ultrastructural changes of podocytes in diabetic mice included mitochondria 
swelling, vacuoles formation, and mitochondrial cristae fracture. Double immunolabeling 
of Sirt6 and WT-1in glomeruli was obviously decreased in diabetic animals. In addition, 
p-AMPK expression was reduced in diabetic mice compared with controls. In cultured
podocytes, TEM studies showed mitochondria swelling and cristae fracture under HG
treatment. HG induced decrease in mitochondrial number and increase in mitochondrial
ROS production. Furthermore, HG induced decreased mitochondrial membrane potential.
All these changes were significantly alleviated by pcDNA3.1 SIRT6 transfection. Sirt6 
overexpression also stimulated p-AMPK expression and alleviated HG-induced podocyte
apoptosis.
Conclusions: These results indicate that Sirt6 could protect podocytes from high 
glucose-induced mitochondrial damage and apoptosis via AMPK activation.
Funding: Government Support - Non-U.S.
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Renoprotective Function of Liver Type Fatty Acid Binding Protein 
(L-FABP) in Diabetic Kidney Disease via Activation of Mitochondrial 
Function
Shiika Watanabe,1 Takeshi Sugaya,1 Daisuke Ichikawa,1 Kenjiro Kimura,2 
Yugo Shibagaki,1 Atsuko Ikemori.1 1St. Marianna University School of Medicine, 
Kawasaki, Japan; 2Tokyo Takanawa Hospital, Tokyo, Japan.
Background: Tubulointerstitial damage (TID) in diabetic kidney disease (DKD) is 
one feature of histopathology observed in the diabetic patients with early progressive renal 
decline. Therefore, TID is a therapeutic target in order to prevent the progression of DKD. 
Recently, TID in DKD is reported to be associated with renal mitochondrial injury. Renal 
liver type fatty acid binding protein (L-FABP) has an anti-oxidant effect as a scavenger of 
reactive oxygen species. However, the interaction between renal L-FABP and mitochondrial 
function has not been investigated yet. Therefore, the aim of this study is to reveal the 
renoprotective potential of renal L-FABP via activation of mitochondrial function in 
streptozotocin-induced DKD.
Methods: To evaluate the role of renal L-FABP, we used human L-FABP chromosomal 
transgenic (Tg) mice because L-FABP is not expressed in the kidneys of wild-type (WT) 
mice. The (Tg) mice and wild-type (WT) mice were divided into two groups: diabetic 
mice were injected with STZ; control mice were injected with a citrate buffer alone. At 19 
weeks after these injections, the mice were killed and the kidney, and urine were isolated 
for analysis.
Results: The expression of renal L-FABP and the level of urinary L-FABP increased 
significantly in diabetic Tg mice compared to control Tg mice. Urinary albumin levels, the 
expression of α-smooth muscle actin in the interstitium and the level of renal oxidative 
protein were significantly lower in diabetic Tg kidneys compared with diabetic WT 
kidneys. The expression of mitochondrial superoxide dismutase 2 was significantly higher 
in diabetic Tg kidneys compared with diabetic WT kidneys. In the diabetic Tg kidneys, 
the expression of PPARγ co-activator 1α(PGC-1α) was significantly higher than that of 
diabetic WT kidneys.
Conclusions: In conclusion, renal L-FABP could activate mitochondrial function by 
acceleration of mitochondrial biogenesis due to rise of PGC-1α expression, and attenuate 
renal oxidative stress, and consequently, the renal fibrosis were prevented. Increase in renal 
L-FABP expression may be a promising treatment against TID in DKD.
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Disruption of Renal Tubular Mitochondrial Quality Control by KCa3.1 in 
Diabetic Nephropathy
Chunling Huang, Hao Yi, Ying Shi, Qinghua Cao, Xinming Chen, 
Carol A. Pollock. kolling institute, the University of Sydney, St. Leonards, NSW, 
Australia.
Background: Mitochondrial dysfunction is involved in the pathogenesis of diabetic 
nephropathy. Mitochondrial quality control is characterized by repairing of mitochondrial 
damage through mitophagy and fission/fusion. It has been shown that blockade of KCa3.1, 
a potassium channel, ameliorates diabetic renal fibrosis and KCa3.1 activation contributes 
to dysfunctional tubular autophagy in diabetic nephropathy through PI3K/Akt/mTOR 
signaling pathways. However, the role of KCa3.1 in mitochondrial quality control is not yet 
known. Therefore, the aim of the study is to identify the role of KCa3.1 in mitochondrial 
quality control in diabetic nephropathy.
Methods: In vitro human proximal tubular cells (HK2 cells) transfected with scrambled 
siRNA or KCa3.1 siRNA were exposed to TGF-β1 for 48h. Mitochondrial function and 
mitochondrial ROS (mtROS) production were assessed. In vivo, diabetes was induced 
in KCa3.1+/+ and KCa3.1-/- mice by streptozotocin injection. The pro-fission protein 
dynamin-related protein 1 (Drp1) and pro-fussion protein mitofusin 2 (Mfn2) as well as 
BCL2 interacting protein 3 (BNIP3) (a mitophagy regulator) were examined by western 
blotting in HK2 cells and mice kidneys.
Results: The in vitro results showed that TGF-β1 significantly inhibited mitochondrial 
ATP production rate, compared to the controls, which were significantly reversed by KCa3.1 
siRNA in HK2 cells. KCa3.1 gene silencing inhibited TGF-β1-induced significant increase 
in MitoSOX Red fluorescence in HK2 cells. TGF-β1 significantly increased the expression 
of Drp1 and BNIP3 in HK2 cells, which were attenuated by KCa3.1 gene silencing. The 
expression of Mfn2 was not overtly apparent on TGF-β1 stimulation. Consistently, the in 
vivo results showed significantly increased Drp1 and BNIP3 expression in diabetic KCa3.1 
+/+ mice, which were significantly reduced in diabetic KCa3.1-/- mice.
Conclusions: KCa3.1 mediates dysregulation of mitochondrial quality control in 
diabetic nephropathy.
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Urothelial-Specific Insulin Receptor Deletion Suppresses Host Defenses of 
the Kidney and Bladder
Matthew J. Murtha,2 Laura Schwartz,3 Kristin Bender,5 Birong Li,6 Tad Eichler,4 
John D. Spencer.1 1The Research Institute at Nationwide Children’s, Columbus, 
OH; 2Ohio State University Hospital, Columbus, OH; 3Nationwide Children’s 
Hospital, Columbus, OH; 4The Research Institute at Nationwide Childrens 
Hospital, COLUMBUS, OH; 5The Research Institute at Nationwide Children’s 
Hospital, Columbus, OH; 6Nationwide Children’s Hospital, Columbus, OH.
Background: In people with diabetes mellitus (DM), urinary tract infection (UTI) is 
more common and has worse outcomes. With DM, UTI is more likely to cause acute kidney 
injury, which increases the risk of chronic and end-stage kidney disease. The mechanisms 
that predispose diabetics to UTI remain elusive. To investigate the significance of insulin 
signaling on kidney and urothelial host defense, we genetically deleted the insulin receptor 
(IR) in murine urothelium.
Methods: Urothelial-specific IR knock-out mice (IRKO) were generated by breeding 
homozygous mice for the floxed Insr gene (insulin receptor gene) with transgenic mice 
that have tamoxifen-inducible Cre recombinase under the Uroplakin 2 (Upk2) promoter. 
Littermates lacking the Upk2-Cre transgene served as controls (IRflox). To determine if 
urothelial-specific IR deletion impacts host defense, female mice were transurethrally 
infected with uropathogenic E. coli (UPEC). At 24, 48, and 72 hrs post infection, UPEC 
burden was enumerated in urine, bladder, and kidney. To assess why IRKO mice have 
increased UTI susceptibility, human urothelial cells were assayed in vitro using siRNA to 
silence IR and investigate if silencing IR disrupts urothelial barrier formation.
Results: PCR confirmed urothelial-specific Cre-LoxP recombination and IR transcript 
deletion in bladders of IRKO mice. Compared to IRflox, IRKO mice exhibit normal 
development, no evidence of hyperglycemia, and normal bladder/kidney histology. 
Following transurethral UPEC infection, the bladders of IRKO mice developed significantly 
pronounced and prolonged inflammation and edema. This was accompanied by significantly 
greater UPEC burden in the urine, bladder, and kidneys at all time points. siRNA-mediated 
INSR silencing in human bladder cells in vitro resulted in marked differences in urothelial 
proliferation and migration.
Conclusions: These results suggest that intact insulin signaling is critical for UTI 
defense. Also, they indicate that hyperglycemia alone does not explain increased UPEC 
susceptibility. Finally, they indicate that abnormal bladder defenses, including a reduced 
ability to regenerate an impermeable urothelial barrier, increases the likelihood for 
significant bladder and kidney infection. Additional studies are warranted to identify how 
IR deletion impacts urothelial defenses.
Funding: NIDDK Support
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Genetic Regulation of Diabetic Kidney Disease Traits and Transcriptome 
Signature in Mice
Xiuju Wu,2 John M. Basgen,3 Daria Merkurjev,4 Aldons J. Lusis,5 
Susanne B. Nicholas.1 1Medicine, David Geffen School of Medicine at UCLA, 
Los Angeles, CA; 2Human Genetics, David Geffen School of Medicine at UCLA, 
Los Angeles, CA; 3Charles Drew University, Minnetonka, MN; 4Human Genetics, 
David Geffen School of Medicine at UCLA, Los Angeles, CA; 5Human Genetics, 
David Geffen School of Medicine at UCLA, Los Angeles, CA.
Background: Diabetic kidney disease (DKD) is the leading cause of chronic kidney 
disease and end-stage renal disease. Thus far, the genetic factors contributing to hallmark 
features of DKD remain poorly understood. Our goal was to assess DKD and associated 
molecular markers in an intercross between two strains of mice differing in albuminuria on 
the background of the diabetes-inducing Ins2Akita mutation.
Methods: We generated F2 mice from a cross between maternal CBA/J and paternal 
C57BL/6J-Ins2Akita mice. We measured albumin-to-creatinine ratio (ACR) on 24-h urine 
from F2 mice at age 7 and 20 weeks. Kidney morphometry was quantified by light and 
electron microscopy at 20 weeks. We performed RNA sequencing on kidney cortex to 
identify transcripts associated with physiologic and structural traits. Linkage analysis 
identified causal loci of physiologic and molecular traits.
Results: We observed 20-fold variation in ACR among 87 diabetic F2 mice at age 
20 weeks. Plasma glucose (p=1.7×10-6), kidney weight (p=1.0×10-6), glomerular volume 
(p=2.1×10-11), glomerular basement membrane width (p=2.2×10-5), total mesangial cell 
(1×10-2) and total mesangial matrix (p=1.5×10-4) increased significantly in diabetic F2 
mice versus non-diabetic mice. We detected a significant quantitative trait locus for ACR 
on chromosome 4 (LOD=3.79, p=0.030) and a locus for volume fraction of mesangial cell 
and total mesangial cell on chromosome 14, LOD=3.79, p=0.031. We identified regulatory 
pathways enriched for oxidative stress (p=1.23×10-14), fatty acid metabolism (p=6.86×10-11) 
and mitochondrial function (p=4.51×10-12) associated with ACR.
Conclusions: The study identified a genetic basis for increases in volume fraction of 
mesangial cell, total mesangial cell and ACR, and regulatory pathways associated with 
oxidative stress, fatty acid metabolism and mitochondrial function in DKD. The study 
provides further insight to the genetic determination of DKD traits.
Funding: Other NIH Support - NIMHD, NIDDK
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Integrated Epigenetic Analysis for Kidney Function and Functional 
Decline Defines Novel Biological Pathways for Patients with Diabetic 
Kidney Disease
Xin Sheng,1 Chengxiang Qiu,2 Caroline A. Gluck,3 Raymond R. Townsend,4 
Katalin Susztak.2 1university of pennsylvania, Philadelpiha, PA; 2University of 
Pennsylvania, Philadelphia, PA; 3Nemours/AI DuPont Hospital for Children, 
Wilmington, DE; 4University of Pennsylvania School of Medicine, Villanova, PA.
Background: Poor metabolic control induces epigenetic changes, which play an 
important role in development and progression of diabetic kidney disease (DKD). Prior 
studies failed to integrate epigenetic information with genotype and transcriptomic data. 
Here we performed an integrated epigenetic, genetic and transcriptomic analysis in CRIC 
(Chronic Renal Insufficiency Cohort).
Methods: We analyzed genome wide cytosine methylation changes in blood samples 
of 473 patients with DKD from the CRIC. Subjects were matched for baseline features but 
showed differences in their kidney function decline. We adopted linear regression model 
adjusted for age, sex, batch, genetic background, hypertension, cell type heterogeneity 
and glucose control for eGFR and eGFR slope. To distinguish between genetically 
or environmentally driven methylation differences, we catalogued genotype-driven 
methylation changes by performing mQTL (methylation quantitative trait) analysis. To 
define genetically driven gene expression changes, we performed expression of quantitative 
trait analysis (eQTL). Bayesian co-localization analysis was adopted to identify causal 
genes by integrating GWAS, mQTL and eQTL datasets.
Results: We identified that methylation level of 2 probes significantly associated with 
baseline kidney function (eGFR). Methylation level of 9 probes significantly association 
with kidney function decline. We were able to replicate the association for 3 of the 11 
probes in the ARIC (Atherosclerosis Risk in Communities Study) and FHS (Framingham 
Heart Study) cohorts. We found that methylation of 6 of the 11 loci were driven by genetic 
variation (mQTL SNP). To understand functional consequences of methylation changes, 
we integrated the results with RNA-seq data using expression of quantitative trait (eQTL) 
analysis. We found that the expression of (Lyzosome) LYZ significantly associated with the 
genetic variation and methylation differences. Transcript level of LYZ in the kidney also 
strongly correlated with kidney function.
Conclusions: We identified and replicated significant methylation changes 
associated with kidney function and functional decline. Integrated genetic, epigenetic and 
transcriptomic analysis defines genetically and potentially environmentally driven changes 
and novel biological mechanisms for DKD.
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Inhibition of P2X7 Receptor Delays the Progression of Diabetic Nephropa-
thy and Represses Klotho Expression
Elisa M. Higa,1 Maria jose D. Fernandes,2 Robson S. Serralha,1 Deyse Lima,1 
Giovana Punaro,1 Adelson Rodrigues.1 Laboratory of Nitric Oxide and Oxidative 
Stress 1Medicine, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; 
2Neurology, Neurosurgery and Neuroscience, Universidade Federal de Sao 
Paulo, Sao Paulo, Brazil.
Background: Previous studies in our laboratory have suggested that P2X7 could 
contribute to the progression of diabetic nephropathy and modulate klotho expression. 
Aim of this study was to investigate the role of P2X7 knockdown in the onset of diabetic 
nephropathy and its possible relationship with klotho, in rats.
Methods: Seven-week-old male Wistar rats weighing 210g were all uninephrectomized; 
two-thirds were induced to diabetes with 60mg/kg streptozotocin i.v., and one-third received 
its vehicle (control rats). At 4th day of the fifth week of the protocol, half of the diabetic rats 
received a small interfering RNA targeting for P2X7 mRNA, and the other half received its 
vehicle. Euthanasia was made at the eighth week.
Results: Diabetic animals reproduced all classic symptoms of the disease; besides, they 
showed reduced renal function and low NO bioavailability; also SOD1, SOD2 and catalase 
were increased, probably due to the oxidative stress factors which were elevated in this 
situation. Metabolic data of diabetic rats did not change by silencing P2X7 receptor. For 
the other hand, silencing P2X7 was able to increase plasma and membrane forms of klotho, 
which in turn could have contributed to balance oxidative and nitrosative profile, ultimately 
improving the renal function.
Conclusions: These findings suggest that the management of P2X7 receptor can benefit 
the kidneys or perhaps even other organs involved in diabetic nephropathy. Maneuvers 
like silencing P2X7 can be used as an adjuvant therapy in diabetes mellitus, improving the 
quality of life of these patients.
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Effects of Chronic Renal Impairment on Glucose Homeostasis: Role of 
Class II PI3K-C2β
Samira Alliouachene, Julius E. Kieswich, Muhammad M. Yaqoob. Diabetic 
Kidney Disease group Queen Mary University, London, United Kingdom.
Background: Chronic kidney impairment may result in multiple metabolic 
derangements leading to insulin resistance and Type 2 diabetes. However the underlying 
mechanisms involved in the crosstalk between the kidney and insulin target tissues remains 
unknown. Therefore to help elucidate this we studied the effect of reduced kidney mass on 
whole-body glucose homeostasis in lean and obese mice.
Methods: Mice underwent unilateral nephrectomy (UniNX) or sham operation at 
7-week old followed by either normal chow or high fat diet (HFD). 16 weeks after surgery, 
glucose homeostasis was assessed.
Results: Unexpectedly, despite mild proteinuria and uremia, glucose tolerance and 
insulin sensitivity were improved in UniNX animals both on normal and HFD without 
enhanced insulin secretion. This correlated with a significant increase in in vivo insulin 
stimulated-Akt signaling in metabolic tissues (liver, muscle and adipose tissue) both under 
normal and HFD in UniNX conditions. Furthermore, we observed a significant decrease 
of HFD-induced liver steatosis in UniNX animals. Taken together this unanticipated data 
show a beneficial impact of UniNX on glucose homeostasis. To get greater insight into the 
molecular mechanisms involved, we investigated the role of the class II PI3K-C2β, a lipid 
kinase previously reported as a potential drug target for insulin sensitization. We observed 
that class II PI3K-C2β inactivation positive effect was accentuated by UniNX with a 
significant improvement of glucose metabolism and a complete protection against HFD-
induced obesity and hepatic steatosis. In conclusion this study highlights an unexpected 
beneficial synergistic effect of PI3K-C2β inactivation and UniNX to protect against obesity, 
insulin resistance and hepatic steatosis.
Conclusions: Taken together this data reveal the possibility that kidney donors 
taking PI3K-C2β inhibitors could be fully protected against obesity, insulin resistance and 
diabetes. This study could encourage living kidney donations in addition to improving our 
understanding of the molecular mechanisms involved in the crosstalk between the kidney 
and insulin target tissues.
Funding: Government Support - Non-U.S.
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Proximal Tubular Uptake of Free Fatty Acid (FFA) by Kidney Injury 
Molecule-1 (KIM-1) Mediates Tubulointerstitial Disease in Diabetic Mice
Yutaro Mori,1 Jae Hyung Chang,1 Shan Mou,1,2 Huiping Zhao,1,4 Jiahua Li,1 
Pierre Galichon,1 Craig R. Brooks,1 Sheng Xiao,3 Venkata Sabbisetti,1 
Suetonia Palmer,1 Vijay K. Kuchroo,3 Takaharu Ichimura,1 Joseph V. Bonventre.1 
1Renal Division, Department of Medicine, Brigham and Women’s Hospital, 
Harvard Medical School, Brookline, MA; 2Renal Division, Renji Hospital, 
Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3Center 
for Neurologic Disease, Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA; 4Department of Nephrology, Peking University People’s 
Hospital, Beijing, China.
Background: Diabetic kidney disease (DKD) is associated with tubulointerstitial 
damage which predicts progression of chronic kidney disease. KIM-1, a scavenger 
receptor, is the most upregulated proximal tubule protein in many forms of kidney injury. 
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Dysregulated lipid metabolism is a primary feature of DKD. We hypothesized that KIM-1-
mediated uptake of FFAs contributes to tubulointerstitial damage in DKD.
Methods: Renal epithelial cells expressing KIM-1 (LLC-PK1 cells and mouse primary 
renal epithelial cells) were exposed to palmitate followed by measurement of FFA uptake, 
cell death and pro-inflammatory and pro-fibrotic effects in vitro. In vivo, two animal models 
were used to evaluate the role of KIM-1-mediated FFA uptake. A DKD model induced 
by unilateral nephrectomy, streptozotocin and high fat diet (UNx-STZ-HFD DKD) was 
studied in wild-type or KIM-1Δmucin (functional knockout of KIM-1 lacking a mucin domain) 
mice. A second new model was created whereby KIM-1 or KIM-1Δmucin was upregulated by 
aristolochic acid and the effect of subsequent injection of FFA was determined (AA-FFA 
model).
Results: FFA was taken up by the wild-type KIM-1 expressing cells but not by control 
or KIM-1Δmucin expressing cells, leading to cell death in cells expressing wild-type KIM-1. 
mRNAs of IL-1β and NLRP3 were increased after FFA treatment only in cells expressing 
wild-type KIM-1 but not controls. Conditioned media harvested from FFA-treated cells 
expressing wild-type KIM-1 stimulated greater αSMA expression in mouse fibroblasts, 
compared to media from KIM-1Δmucin cells. In the UNx-STZ-HFD DKD model, wild-
type mice showed greater proximal tubular atrophy, macrophage infiltration, fibrosis and 
albuminuria when compared with KIM-1Δmucin mice. In the AA-FFA model, wild-type mice 
showed more macrophage infiltration, αSMA expression and loss of brush border when 
compared with KIM-1Δmucin mice.
Conclusions: KIM-1 mediates the proximal tubular uptake of FFA, which leads to 
cell death and pro-inflammatory and pro-fibrotic responses in diabetic mice. Our findings 
support the role of KIM-1 as a therapeutic target for DKD.
Funding: NIDDK Support
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Diabetic Condition Induces Hypertrophy and Apoptosis in Parietal 
Epithelial Cells Through Mitotic Catastrophe
Takahisa Kawaguchi, Kazuhiro Hasegawa, Shu Wakino, Hiroshi Itoh. Keio 
University, Tokyo, Japan.
Background: Podocyte hypertrophy and apoptosis are two hallmarks of diabetic 
glomeruli; however, little information is available about changes in parietal epithelial cells 
(PECs). We hypothesized that diabetes induces hypertrophy and apoptosis in PECs in a 
similar manner and causes damage. This study aimed to elucidate the effects of a diabetic 
condition on PECs in vitro and in vivo.
Methods: Conditionally immortalized mouse PECs were exposed to 5 mmol/L glucose 
(NG), 30 mmol/L glucose (HG), and angiotensin-II (AT-II) at the dosage of 10−6 mol/L 
or aldosterone at 10−7 mol/L. Hypertrophy and cell cycle analysis were assessed by flow 
cytometry. Podocyte apoptosis was ascertained by Annexin V/PI staining, Hoechst 33342 
staining, and caspase 3/7 staining. For in vivo studies, streptozotocin-induced diabetic 
mice, db/db diabetic mice, and BTBR ob/ob mice were used as diabetic mouse models. 
Histomorphology of the renal tissue was observed using light microscopy and transmission 
electron microscopy (TEM). PEC apoptosis was assessed using the TUNEL assay and 
cleaved caspase-3 staining.
Results: In cultured PECs, HG induced hypertrophy, whereas AT-II and aldosterone 
failed to induce hypertrophy. Flow cytometry revealed that HG also induced PEC apoptosis 
in a dose-dependent manner and S-phase arrest of PECs, suggesting mitotic catastrophe 
of PECs. In TEM, PECs exhibited enlargement of both the cytoplasm and nucleus at the 
ultrastructural level in all diabetic mouse models. PAX 8 staining revealed PEC nuclear 
hypertrophy in diabetic mice, whereas the cell number of PECs remained unaltered, 
suggesting that PECs in diabetic condition underwent DNA replication with a mitotic 
defect. However, an increase in apoptotic PECs was not observed in diabetic glomeruli.
Conclusions: PECs in diabetic condition are in a state of dysregulation of proliferation 
similar to mitotic catastrophe. As PECs are considered a precursor of podocytes, this injury 
to PECs might impair glomerular regeneration. Nevertheless, further studies are warranted 
to elucidate the potential pathological role of morphological changes in PECs in diabetic 
kidney disease.
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ENaC and MARCKS Proteolysis in Diabetes Associated Hypertension
Kubra M. Tuna,1 Zinah M. Ghazi,2 Qiang Yue,2 Douglas C. Eaton,4 Abdel A. Alli.1 
1University of Florida, Gainesville, FL; 2Emory University, Atlanta, GA; 4Emory 
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Background: The majority of T2DM patients present with hypertension and diabetic 
nephropathy progresses more rapidly in hypertensive diabetic patients compared to those 
without hypertension. Thus, there is an urgent need to better understand the mechanisms 
contributing to diabetes associated hypertension in order to reduce morbidity and mortality 
in these patients. Proteolysis of both the epithelial sodium channel (ENaC) and the 
myristoylated alanine-rich C-kinase substrate (MARCKS) is necessary for high levels of 
ENaC activity.
Methods: Here we use salt-loaded db/db mice and control mice to test the hypothesis 
that increased proteolysis of ENaC and MARCKS plays an essential role in the pathogenesis 
of hypertension secondary to diabetes. Cleaved ENaC and MARCKS was assessed by 
Western blotting. Protease activity was measured by zymography and fluorometric assays. 
ENaC activity was assessed by electrophysiology. Blood pressure was measured by 
telemetry.
Results: Western blots using validated antibodies showed both ENaC and MARCKS 
proteolysis is increased in the diabetic db/db kidneys compared to kidneys from C57B6 
wild-type mice. Western blot and zymography analyses showed increased expression 
and activity of proteases including cathepsins in the diabetic db/db kidneys compared to 
controls. ENaC activity was increased in split-open tubules from salt-loaded diabetic db/db 
mice compared to controls. Telemetry studies showed mean arterial pressure was increased 
in these diabetic db/db mice after salt-loading and the blood pressure was restored by daily 
injections with amiloride.
Conclusions: This project will contribute to our understanding of the protease-
dependent regulation of ENaC and MARCKS in the development of diabetes associated 
hypertension and potentially lead to novel drug targets and therapeutics.
Funding: NIDDK Support
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RNA Binding Proteins Tristetraprolin and Human Antigen R Mediate 
Diabetic Tubulopathy via Modulation of Inflammation and Apoptosis of 
Renal Tubular Epithelial Cells
Jia Guo,1,2 Fei Cheng,3 Rujun Gong,4 Zhangsuo Liu.5 1The university of Toledo, 
medical center, Toledo, OH; 2The first affiliated hospital of Zhengzhou 
University, Zhengzhou, China; 3The First Affiliated Hospital of Zhengzhou 
University, ZhengZhou, China; 4University of Toledo Medical Center, Toledo, 
OH; 5The first affiliated hospital of zhengzhou university, Zhengzhou, China.
Background: Inflammatory components have been involved in diabetic tubulopathy, 
a key constituent of diabetic nephropathy (DN) pathology, with undefined molecular 
mechanisms. RNA binding proteins Tristetraprolin (TTP) and Human antigen R (HuR) 
have been implicated in inflammatory response in a variety of diseases and exert opposite 
modulatory effects on a number of inflammatory mediators. Nevertheless, their role in 
diabetic tubulopathy remains unknown. Evidence suggests that the expression and activity 
of TTP and HuR are regulated by phosphorylation that is catalyzed by a number of kinases, 
including GSK3β, a cell signaling transducer with a nephropathic action. The aim of this 
study was to examine the role of GSK3β -regulated TTP and HuR in diabetic tubulopathy 
by using an in vitro model of renal tubular epithelial cells (HK-2).
Methods: The mRNA or protein expressions were measured by qRT-PCR or 
immunoblotting. Apoptosis was analyzed by TUNEL staining. The subcellular localization 
of TTP, HuR and GSK3β was determined by immunofluorescence staining. GSK3β was 
silenced by RNA interference to examine the modulatory effect on TTP and HuR expression.
Results: After exposure of HK-2 cells to high ambient glucose (HG, 30Mm glucose), 
both mRNA and protein expressions of TTP were decreased, while those of HuR were 
increased, associated with an up-regulation of KIM-1 and TNF-α, loss of E-cadherin and 
augmented cellular apoptosis, implying that TTP and HuR were oppositely regulated upon 
high glucose-induced renal tubular cell injury. Tubular cell injury coincided with GSK3β 
hyperactivity, marked by GSK3β overexpression and suppressed phosphorylation of 
GSK3β at serine 9. Dual color fluorescent immunocytochemistry staining demonstrated 
that GSK3β is co-localized with TTP and HuR respectively in different subcellular 
compartments of HK-2 cells. Moreover, GSK3β seems to be essential for high glucose-
induced TTP and HuR dysregulation, because silencing of GSK3β substantially reinstated 
TTP expression and offset HuR overexpression, concomitant with an improved cellular 
injury and apoptosis.
Conclusions: The GSK3β regulated RNA binding proteins TTP and HuR play a crucial 
role in mediating inflammation and apoptosis renal tubular cell injury in diabetes.
Funding: Government Support - Non-U.S.
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The Effects of Modulating Autophagy on Macrophages Adhesion and 
Migration in Diabetic Nephropathy
Yuteng Jiang, Xiaodong Zhu, Yu Zhao, Yuqiu Liu, Beibei Wu, Xiaoliang Zhang. 
Institute of Nephrology, Zhong Da Hospital, Southeast University, School of 
Medicine, Nanjing, China.
Background: Macrophage infiltration is an important histopathological feature of 
various chronic renal diseases including diabetic nephropathy. This study aims to investigate 
the impact of macrophages adhesion and migration by modulating autophagy.
Methods: In vivo, rats were randomly distributed into control (NC) and diabetic 
nephropathy (DN) groups. The pathological changes in renal tissue were assessed, and 
expression of CD68, LC3, P62 were analysed. In vitro, RAW264.7 cells were divided 
into normal and high glucose (HG, 30mM) groups. The capacity for macrophage adhesion 
and migration and the expression of autophagy markers were observed with and without 
autophagy modulators (rapamycin, 3-methyladenine, chloroquine, and bafilomycin 
A1 for RAPA, 3-MA, CQ, BAFA). The numbers of autophagosomes and the process of 
degradation and fusion of autophagosome-lysosome were observed by electron microscopy.
Results: In vivo, renal injury is aggravated in diabetic rat compared with NC 
group. The expression levels of CD68 and P62 of renal tissues increased in DN group, 
while expression level of LC3 decreased. In vitro, HG or 3-MA reduce the numbers of 
autophagosomes with less expression of LC3 and Beclin-1, but increase expression of P62. 
HG or 3-MA promote the adhesion and migration capacity of macrophages. Moreover, CQ 
and BAFA inhibit the process of degradation and fusion of the autophagosome-lysosome as 
well as the expression of LC3 and Beclin-1. We notice an increase expression of P62 by CQ 
and BAFA stimulaion. These effects further facilitate the adhesion and migration capacity 
of macrophages. However, RAPA increases the numbers of macrophage autophagosomes, 
resulting in an increase expression of LC3 and Beclin-1, whereas a reduction expression of 
P62, which lead to inhibition of adhesion and migration of macrophages induced by HG 
(P<0.05).
Conclusions: Modulating the function of autophagy can affect the adhesion and 
migration capacity of macrophages in diabetic nephropathy.
Funding: Government Support - Non-U.S.
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The Possible Mechanisms of Effects of NF-κB Inhibitor Parthenolide on 
Promoting Renal Tubules Albumin Reabsorption in Type 2 Diabetic 
Nephropathy
Qiufa Hao,1 Xuemei Li.2 1Peking Union Medical College Hospital, Chinese 
Academy of Medical Sciences, Beijing, China, Beijing, China., Beijing, China; 
2Peking Union Medical College Hospital, Beijing, China.
Background: Increased albuminuria caused by albumin reabsorption reduction 
of renal tubules is highlighted as the cause of early stage of diabetic nephropathy. The 
underlying mechanism has not been fully figured out. We aimed to observe whether 
reducing inflammation thereby remodeling impaired insulin signaling could improve renal 
tubules albumin uptake in diabetic nephropathy.
Methods: 1)8-weeks db/m and db/db mice were used as control(C group) and diabetic 
nephropathy model(DN group). Parthenolide(PTN 1mg/kg) was used intraperitoneally 
every other day to db/db mice as treatment group(DN+PTN group). After 8-weeks treatment, 
urine, blood and kidney samples were collected. Expressions of NF-κB, insulin signaling 
protein pAKT/AKT and albumin receptors amnionless(AMN) and cubilin in kidneys were 
detected by immunohistochemistry and immunoblotting. 2)HKC cells were treated with 
TNF-α(25ng/ml), PTN(5μM) and insulin(100nM). Albumin uptake and expressions of NF-
κB, pAKT/AKT, AMN and cubilin were tested by fluorometric assay and immunoblotting.
Results: 1)Compared with DN group, DN+PTN group showed decreased insulin 
resistance index levels(P<0.05) and slightly reduced urine albumin creatinine ratio 
levels(P>0.05). 2)NF-κB expression increased and phosphorylation of AKT decreased 
in DN group compared with C group (P<0.05). PTN reduced NF-κB expression and 
ameliorated decline of AKT phosphorylation(P<0.05). Compared with C group, AMN 
and cubilin expressions decreased in DN group(P<0.05), and PTN attenuated reduction of 
cubilin expression(P<0.05). 3)Insulin promoted AMN and cubilin expressions and albumin 
uptake of HKC cells(P<0.05). In TNF-α group, NF-κB expression increased and AKT 
phosphorylation decreased compared with insulin group(P<0.05). In TNF-α+PTN group, 
PTN reduced NF-κB expression and AKT phosphorylation(P<0.05). AMN and cubilin 
expressions decreased in TNF-α group(P<0.05), and PTN attenuated reduction of cubilin 
expression(P<0.05).
Conclusions: The study observed in diabetic nephropathy PTN could ameliorate insulin 
resistance and slightly reduce albuminuria. We found albuminuria with albumin receptors 
reduction was induced by inflammation impaired insulin signaling in renal tubules. PTN 
could reduce inflammation, remodel impaired insulin signaling, and then increase albumin 
uptake by ameliorating albumin receptors expressions.
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PKC-δ Reduced DUSP4 Expression Causing NOX4 and Progressive 
Diabetic Nephropathy
Marina Rousseau,1 Benoit Denhez,1 Farah Lizotte,1 Pedro M. Geraldes.2 
1University of Sherbrooke, Sherbrooke, QC, Canada; 2University of Sherbooke, 
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Background: Diabetic nephropathy is characterized by the loss of an important 
epithelial cell called podocytes. Podocytes are specialized cells that have a critical role 
in maintaining the integrity of the glomerular filtration barrier. A promising insight in the 
initiation of glomerular pathology begins with the loss of expression of the dual specificity 
phosphatase 4 (DUSP4), known for its role in MAPK inhibition. We have observed that 
cultured podocytes exposed to high glucose (HG; 25 mM) concentrations and glomeruli of 
diabetic (Ins2+/C96Y) mice exhibited significant reduction of DUSP4 which complied with 
glomerularsclerosis, podocyte foot process effacement and podocyte cell death. However, 
the exact mechanism of diabetes-induced DUSP4 reduction remained unknown but protein 
kinase C (PKC) activation has been shown to regulate DUSP expression in macrophages.
Methods: Non-diabetic (NDM) and diabetic (DM) mice with the deletion of DUSP4 
(D4KO) and PKC-δ (Prckd-/-) were used after 6 months of diabetes. Mouse podocytes 
were exposed to normal (NG; 5.6 mM) or high (HG; 25 mM) glucose levels for 72 hours 
with or without the overexpression of DUSP4 and PKC-δ adenoviral vector to evaluate 
the oxidative stress pathway. Human blood and kidney sample were collected to measure 
DUSP4 mRNA levels and estimated glomerular filtration rate using the CKD-EPI formula.
Results: By overexpressing the dominant negative form of PKC-δ specifically, we 
were able to reestablish DUSP4 expression levels in podocytes. In addition, decreased 
DUSP4 expression observed in renal cortex of DM mice were not seen in DM mice that 
did not possess the PKC-δ gene. Podocytes exposed to HG concentrations showed a 52% 
increase of NOX4 expression which was prevented with the overexpression of DUSP4. DM 
mice had a 30% increase in NOX4 expression in the glomeruli, which was exacerbated by 
31% in DM mice with a specific deletion in DUSP4. Interestingly, in humans, decreased 
mRNA expression of DUSP4 in the renal cortex of diabetic patients correlated with eGFR 
level decline.
Conclusions: Reduction of DUSP4 expression induced by PKC-δ activation increased 
NOX4 expression and podocyte dysfunction in diabetic nephropathy.
Funding: Government Support - Non-U.S.
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Parkin Inhibits Accelerating Senescence of Renal Tubular Cells by 
Promoting GATA4 Degradation in Diabetic Nephropathy
Kehong Chen,1 Yani He.2 1Daping hospital, Chongqing, Chongqing, China; 
2Daping Hospital, Chongqing, China.
Background: Accelerating senescence of renal tubular epithelial cell (RTEC) plays 
a fundamental role in the pathogenesis of diabetic nephropathy (DN). Parkin, as an E3 
ubiquitin ligase, can promote protein ubiquitination and degradation. Parkin gene mutation 
can accelerate neuron senescence in several neuropsychiatric disorders. GATA binding 
factor 4 (GATA4), as a substrate of E3 ubiquitin ligase, is a key regulatory factor for 
senescence phenotype. We investigated the role of Parkin in accelerating senescence of 
RTEC and its mechanism.
Methods: 149 cases of patients with DN diagnosed by renal biopsy were recruited in 
our study. Renal Parkin expression was detected by immunohistochemistry. In vivo, we 
generated Parkin overexpressed streptozotocin-induced DN mice. In vitro, knockdown and 
overexpression experiments were performed by parkin siRNA or Parkin overexpressed 
adenovirus in high glucose (HG) stimulated mouse primary RTEC.
Results: Expression of parkin was gradually decreased with development of 
tubulointerstitial injury and negatively correlated with renal tissue injury scores (tubular 
atrophy and interstitial fibrosis, renal interstitial inflammation score), renal function injury 
parameter Scr. Parkin positive tubular epithelial cell did not express senescent marker P16. 
Compared to wild type DN mice, parkin overexpressed DN mice had lower renal tissue 
injury scores and better renal function. P16 and GATA4 expression of renal tubules were 
inhibited in parkin overexpressed DN mice. In vitro, parkin overexpression inhibited HG-
induced GATA4 expression and RTEC senescence, whereas parkin knockdown enhanced 
GATA4 expression in RTECs under HG conditions. Furthermore, we found parkin co-
immunoprecipitated with GATA4. Parkin overexpression increased GATA4 ubiquitination 
under HG conditions, whereas parkin knockdown decreased GATA4 ubiquitination.
Conclusions: Parkin may inhibit HG-induced RTEC senescence by promoting 
GATA4 ubiquitination and degradation. Parkin is a potential anti-senescence factor in the 
development of DN.
Funding: Government Support - Non-U.S.
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ARF6: A Possible Molecular Target for Diabetic Kidney Disease?
Jamie Lin,2 Nathanael Green,1 Daniel L. Galvan,2 Jianyin Long,2 Benny 
B. Chang,1 Farhad R. Danesh.2 1Baylor College of Medicine, Houston, TX; 2The 
University of Texas MD Anderson Cancer Center, Houston, TX.
Background: Podocytes are key target cells that determine the progression of diabetic 
kidney disease (DKD), the leading cause of renal failure in the U.S. It is now clear that 
small GTPase proteins have quintessential roles that govern podocyte health – too much 
or too little GTPase activity can make the podocyte more susceptible to injury. We recently 
discovered that ADP-ribosylation factor 6 (ARF6), a Ras-family small GTPase protein, is 
present in human podocytes and involved in podocyte response to in vivo glomerular injury 
models; however, its role in DKD is unknown. Since ARF6 is involved in diverse cellular 
events (e.g. actin rearrangement or endocytic trafficking), we postulate that alterations 
in ARF6 activity might have injury-specific effects on kidney function and that glucose-
induced activation of ARF6 in podocytes contributes to the progression of DKD.
Methods: We used an integrated genetic and pharmacologic approach by taking 
advantage of the CRISPR-Cas9 system to generate an ARF6-gene deleted mouse podocyte 
line as well as a selective ARF6 inhibitor, NAV2729 (R&D Systems). Mouse podocyte 
cell lines were cultured under normal glucose (NG, 5mM) or high glucose (HG, 25 mM) 
conditions for 48 hours.
Results: Podocytes cultured under HG conditions expressed significantly higher Arf6 
mRNA and protein levels compared to podocytes cultured under NG conditions. Isolated 
podocytes from diabetic (Leprdb/db) mice had increased ARF6 expression compared to 
control (Leprdb/+) mice. Furthermore, we generated an ARF6-gene deleted mouse podocyte 
cell line in which we found that ARF6 knockout podocytes had augmented mitochondrial 
ROS production. To determine whether ARF6 might serve as a molecular target for 
pharmacologic inhibition in DKD, diabetic and control mice were treated with an ARF6 
inhibitor (NAV2729) or vehicle (DMSO) at a dose of 60 mg/kg starting at 8 weeks of age. 
NAV2729-treated diabetic mice demonstrated significant improvement in the urine albumin 
to creatinine ratio (UACR) compared to diabetic mice treated with vehicle suggesting a 
nephro-protective effect of ARF6 inhibition.
Conclusions: These results suggest that ARF6 is an important protein involved in 
podocyte health. ARF6 expression is increased under diabetic conditions. Inhibition of 
ARF6 might prevent podocyte injury and DKD progression.
Funding: Private Foundation Support
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Inhibition of Vascular Endothelial Growth Factor Receptor-2  
Phosphorylation by Calcium Dobesilate Requires Interaction  
with Heparan Sulfate Binding Site
Florence Njau,1 Nelli Shushakova,2 Hermann G. Haller.1 1Hannover Medical 
School, Hannover, Germany; 2Nephrology and Hypertensiology, Hannover, 
Germany.
Background: Inhibition of vascular endothelial growth factor (VEGF) is a therapeutic 
option in diabetic microangiopathy. However, VEGF is needed at physiological 
concentrations for the maintenance of glomerular integrity. Since VEGF exerts its effects 
on endothelial cells via binding to (1) the VEGF-receptor and (2) to heparan-sulfate (HS) as 
co-receptor partial blockade of VEGF may be a possible strategy. We tested the hypothesis 
that the small molecule calcium dobesilate (CaD) (1) inhibits VEGF signaling in endothelial 
cells, (2) that this effect is mediated via interference between CaD and heparan-sulfate (HS) 
binding sites and (3) CaD ameliorates diabetic nephropathy (DN) in a diabetic mouse model 
via inhibition of VEGF.
Methods: In vitro, the effect of CaD on VEGF signaling in endothelial cells (EC) 
together with the role of heparin was analyzed by Western blotting. EC function was 
assessed by migration, proliferation and permeability assays. Streptozotocin-treated mice 
(STZ) were treated with CaD and functional parameters as well as renal histology and 
inflammatory cells infiltration (immunohistochemistry) were measured at 6 and 12 weeks 
of hyperglycemia.
Results: CaD inhibited VEGF165-induced phosphorylation of VEGFR-2 kinase 
and suppressed the activity of VEGFR-2 mediated signaling cascades both in vitro and 
in diabetic animals. The effects of CaD in vitro were abrogated by exogenous heparin, 
suggesting the involvement of heparin-like domain in the interaction with CaD. VEGF121, 
which does not bind to heparin, was not inhibited by CaD. CaD restored tight junction 
protein expression and decreased VEGF-induced migration, proliferation and permeability 
in endothelial cells. CaD ameliorated glomerular pathology, reduced albuminuria and 
inflammatory cells infiltration in STZ-treated mice and reduced VEGF signaling in diabetic 
kidneys.
Conclusions: Our results suggest that CaD inhibits VEGFR-2 phosphorylation through 
the interaction between CaD and HS binding sites both in cultured endothelial cells and 
in vivo. CaD is a partial VEGF inhibitor without the negative effects of complete VEGF 
blockade and could be useful as therapeutic strategy in diabetic nephropathy.
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The Use of Type 2 Hypoglycemic Agents in Type 1 Diabetic Animals: 
Unveiling Novel Signaling Pathways
Batoul Dia,2 Patricia Bou assi,2 Christopher El mouhayyar,3 Rasha Barakat,4 
Neamah Mahjoub,2 Assaad Antoine Eid.1 1American University of Beirut/
Faculty of Medicine, Beirut, Lebanon; 2American University of Beirut, Beirut, 
Lebanon; 3American Univeristy of Beirut, Naccache, Lebanon; 4Universite 
Paris Descartes, Amioun, Lebanon.
Background: Diabetic nephropathy (DN) is the leading cause of end stage renal disease. 
The AMPk activator, metformin, or the GLP1-agonist, liraglutide are hypoglycemic agents 
that are typically prescribed to type 2 diabetic patients. With their distinct mechanisms of 
action, these hypoglycemic drugs are utilized in our study to dissect the molecular pathway 
through which DN may ensue in type1 diabetes. Oxidative stress is known to be the 
unifying mechanisms that mediates the pathogenesis of DN, however, the role of the DUOX 
subfamily of enzymes, a poorly studied cellular source of reactive oxygen species (ROS), 
and their mechanism of action has not been previously characterized in DN. In this study, 
we aim to examine the expression of DUOXs in the diabetic renal system and reveal their 
crosstalk with AMPK/GLP-1 signaling in type 1 diabetic animals.
Methods: Monotherapy and combination therapy of metformin and liraglutide 
were used to assess their effects on glomerular injury in STZ-induced type-1 diabetic 
animals. ROS production, proteins and mRNA levels of DUOX, AMPK, mTOR, and 
autophagy markers were examined and correlated with morphological alterations observed 
histologically in addition to albuminuria.
Results: Our results showed that metformin or liraglutide monotherapy or 
their combination did not affect glycaemia. However, a decrease in albuminuria, 
glomerulosclerosis, and tubulointerstitial fibrosis was evident, especially when the drugs 
were used in combination. Elevated ROS production correlated with NADPH oxidase 
activity in diabetic animals compared to non-diabetic animals. The administration of the 
metformin or liraglutide was shown to partially reverse DUOX-derived ROS production, 
the expression of fibronectin, COL IV, nephrin, DUOX1, DUOX2, AMPK, mTOR and 
autophagy markers LC3A and LC3B in the type 1 diabetic animals. An effect that was more 
pronounced when the drugs were used in combination.
Conclusions: These findings shed light on the crosstalk between the AMPK and GLP1 
signaling pathways with the NADPH-oxidases and their role in restoration of autophagy, a 
potential reno-protective mechanism in DN.
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Renin Producing Cells in the Diabetic Kidney
Jeannette Tang,1 Mina Shirazi,1 Minghao Ye,1 Jan Wysocki,1 Patricia G. Vallés,2 
Maria Luisa S. Sequeira Lopez,3 Roberto Ariel Gomez,3 Daniel Batlle.4 
1Northwestern University, Chicago, IL; 2Notti Pediatric Hospital School of 
Medicine, Mendoza, Argentina; 3University of Virginia, Charlottesville, VA; 
4Northwestern University Feinberg Medical School, Chicago, IL.
Background: Urinary renin is increased in patients with diabetes and models of 
diabetic kidney disease but its source is not clear. The intensity of renin staining in the 
collecting tubule is increased in the STZ model of diabetes and in Angiotensin (Ang) II-
induced hypertension which could lead to RAS activation locally at this site. We examined 
the distribution of renin expressing cells using a renin reporter mouse made diabetic by STZ 
to trace the localization of renin lineage cells (RLC).
Methods: The Ren1d-Cre; mT/mG, a double transgenic reporter mouse model, 
expresses both Cre-recombinase from the endogenous renin locus (Ren1D) and the 
mT/mG cassette from the Rosa26 locus (mRenCre-mT/mG). The membrane-directed 
tomato protein (mT) is expressed ubiquitously and fluorescents in red, while the membrane-
targeted green fluorescent protein (mG) is found only in those cells undergoing Cre-
recombination. In RLC the mT/mG construct switches from red fluorescent to green 
fluorescent (mG), while all non-RLC remain mT positive. Ren1d-Cre;mT/mG were made 
diabetic using STZ. Animals were studied 11-12 weeks after STZ injection.
Results: In WT mice made diabetic by STZ, renin staining by immunohistochemistry 
was increased in the collecting tubule and by immunofluorescence aquaporin 2 (AQP2), 
a marker of principal cells, co-localized with renin protein. In the renin reporter mice 
AQP2 co-localized with green fluorescent protein (GFP+) reflecting that renin producing 
cells are or had been present at this site. A quantitative comparison of this GFP+ cells 
between kidney sections of STZ treated and untreated reporter mice, however, revealed no 
significant differences. Within the glomerulus, RLC were strongly present in parietal areas 
and within the glomerulus but no significant differences were found between diabetic and 
non-diabetic renin reporter mice.
Conclusions: In collecting tubules from diabetic mice there is an increased expression 
of renin which cannot be attributed to increased number of renin producing cells at that 
site. Alternative explanations such as increased uptake of filtered renin and impaired 
reabsorption mainly in the proximal tubule need to be considered as the source of collecting 
tubule renin.
Funding: NIDDK Support
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Inhibition of Glucose Transporters Ameliorates Fibrogenic Signaling in a 
Cellular Model of Diabetic Nephropathy
Xinlu Pan,3,2 Deborah L. Baines,2 Mysore K. Phanish,1 Mark E. Dockrell.3,2 
1Epsom and St Helier University Hospitals NHS Trust, London, United 
Kingdom; 2St George’s, University of London, London, United Kingdom; 3South 
West Thames Institute for Renal Research, London, United Kingdom.
Background: Diabetic Nephropathy (DN) is the leading cause of kidney failure. 
Prolonged exposure to elevated glucose strongly facilitates the progression of DN. 
Tubulointerstitial fibrosis is a key prognostic marker of DN. Approximately 90% of glucose 
in the glomerular ultra-filtrate is reabsorbed by the low affinity Na+/glucose co-transporter 
SGLT2. Following the advent of therapeutics targeting glucose uptake at this specific site, 
we propose a role for SGLT2 in regulating DN.
Methods: Primary PTEC were grown on collagen IV coated/uncoated culture 
dishes. On reaching 80% confluence, they were treated with D-Glucose at either 5.5 mM 
(normoglycaemic control), 25mM (hyperglycaemia) or 5.5 mM D-Glucose + 19.5 mM 
L-Glucose (osmotic control). Cells were treated with TGFβ1, 0.75ng/ml or vehicle. After 24 
h, cells were lysed. Heparin pull down was applied to the media to isolate heparin-binding 
proteins. Dapagliflozin (0.1, 1 & 10μm) was administered to cells treated with high glucose 
in combination with TGF-β1. Western blot was then used to detect the level of Connective 
Tissue Growth Factor (CTGF) and EDA fibronectin protein.
Results: There was no obvious cytotoxic effect of any of the treatments. Western 
blotting demonstrated that primary PTEC secreted CTGF, mwt 36 & 38kDa. Neither 
TGF-β1 alone nor raised glucose induced a significant increase in CTGF; however the 
combination of both did (p<0.05 compared to all other treatments) at 24h. EDA+ fibronectin 
protein was unchanged. Dapagliflozin at all three concentrations significantly attenuated 
CTGF protein secretion, reducing the expression to approximately basal levels.
Conclusions: A combination of raised D-Glucose and TGF-β1, similar to that 
expected in DN, induced a significant increase in CTGF, an important pro-fibrotic marker. 
Dapagliflozin successfully reduced this outcome, thus confirming SGLT2 function. 
Interestingly, high glucose and TGF-β1 alone under these conditions did not produce a 
significant increase in CTGF, suggesting an additive effect in the upregulation of CTGF. 
Glucose-induced CTGF expression in vascular smooth muscle cells is associated with 
cellular damage and death. These phenomenon were not observed in our primary renal cells. 
This suggests a more precise controlled mechanism for glucose-induced CTGF in PTEC.
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Endoglin as Potential Target to Slow Down Progressive Diabetic 
Nephropathy via Inhibition of Fibrosis Formation
Tessa Gerrits,1 Malu Zandbergen,1 Jan A. Bruijn,2 Hans J. Baelde,3 
Marion Scharpfenecker.3 1LUMC, Leiden, Netherlands; 2Leiden University 
Medical Center, Dept.Pathology, Leiden, Netherlands; 3Leiden University 
Medical Center, Leiden, Netherlands.
Background: Diabetic nephropathy (DN) is a complication of diabetes, resulting in 
progressive decline of renal function and proteinuria. Progressive DN is histologically 
characterized by glomerular matrix expansion and interstitial fibrosis, in which TGF-β 
plays an important role. Endoglin, a co-receptor of TGF-β, mostly known for regulating 
endothelial cell functions, is also described in human fibrotic tissues such as liver, heart 
and intestine. To investigate the role of endoglin in progressive DN, we measured endoglin 
expression in biopsies of patients with DN and characterized the endoglin-expressing 
cell type in the interstitium. We also investigated the effect of endoglin knockdown on 
extracellular matrix production in kidney fibroblasts in vitro.
Methods: Kidney biopsy material of 11 patients with DN was collected. As control, 
tumor free tissue of 7 patients with a renal tumor was used. Sequential sections were stained 
for endoglin and Sirius Red. The positively stained interstitial area was quantified using 
ImageJ. Immunofluorescent double stainings for endoglin and CD31, CD68, vimentin or 
a-SMA were performed on biopsy material from a patient with and without DN. A human 
kidney fibroblast cell line (TK173) was transduced with a lentiviral vector expressing an 
shRNA against endoglin.
Results: Endoglin was significantly upregulated in patients with DN compared 
to controls (p<0.001). Also, the Sirius red-positive area was significantly increased in 
patients with DN (p<0.001). Immunofluorescence showed co-expression of endoglin with 
the endothelial marker CD31. Endoglin also co-localized with the myofibroblast marker 
a-SMA. Co-localization with fibroblast (vimentin) or macrophage (CD68) markers was 
not observed. In cell culture, endoglin knockdown in fibroblast resulted in reduced PAI-1, 
CTGF and fibronectin expression after stimulation with TGF-β (p<0.05).
Conclusions: Endoglin is upregulated in the interstitium of DN patients and is 
expressed in myofibroblasts. In vitro, endoglin is involved in TGF-β dependent matrix 
production. Therefore, endoglin might play a role in the development of fibrosis and thus 
the progression towards end-stage renal disease in DN.
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Inhibitor of Growth 2 Regulates the High Glucose Induced Cell Cycle 
Arrest and Epithelial-to-Mesenchymal Transition in HK-2 Cells
Wei Xin,1 Ruijuan Yan,3 Yuan Ma,2 Tingting Lv,2 Liyong Chen,1 Qiang Wan.3 
1Shandong Provincial Hospital affiliated to Shandong University, Jinan, China; 
2Medical school, Shandong University, Ji’Nan, China; 3Shandong Provincial 
Qianfoshan Hospital affiliated to Shandong University, Jinan, China.
Background: Cell cycle dysregulation has been linked to various kidney injuries in 
recent years; however, its involvement in the fibrosis of diabetic kidney disease (DKD) is 
far from being clarified. ING2 (inhibitor of growth 2) is the second member of the inhibitor 
of growth family and participates in the regulation of many cellular processes, yet the role 
of ING2 in the process of DKD remains largely unknown. In the present study, we aimed to 
investigate the involvement of ING2 in the cell cycle arrest and epithelial-to-mesenchymal 
transition (EMT) process in diabetic conditions and the underlying mechanism for it.
Methods: The human proximal tubular epithelial cells (HK-2) were stimulated 
with high glucose and diabetic mice were generated by streptozotocin injection. ING2 
expression was detected by western blotting and immunofluorescent staining in vitro and 
immunohistochemistry staining in vivo. The expression of ING2 was silenced by siRNA 
transfection. Cell proliferation was analyzed by CCK-8 and EdU assay. Cell cycle arrest 
was measured by flow cytometry. The EMT markers were detected by qPCR and western 
blotting. The p53 activation by high glucose was proved by chromatin immunoprecipitation 
(ChIP) and the downstream p21 expression was detected by qPCR and western blotting.
Results: We first revealed that the expression of ING2 was increased both in 
diabetic mouse kidney in vivo and in high glucose stimulated HK-2 cells in vitro. ING2 
downregulation ameliorated the reduced proliferation and cell cycle arrest induced by 
high glucose in HK-2 cells. Moreover, p53 was activated under hyperglycemia condition 
and ING2 knockdown suppressed p21 expression by reducing p53 acetylation and finally 
alleviated the expression of EMT markers in the high glucose stimulated HK-2 cells.
Conclusions: Our study demonstrated that cell cycle regulation is bound up with 
the EMT of high glucose cultured HK-2 cells, suggesting a novel function of ING2 as a 
potential therapeutic strategy targeting cell cycle arrest for the kidney fibrosis in DKD.
FR-PO422 Poster Friday
Diabetic Kidney Disease: Basic - II
Role of CD13 in Renal Proximal Tubular Handling of Albumin
Robin H. Lo, Claire Gerber, Emily R. Shearier, Mallika Ghosh, Linda H. Shapiro. 
Center for Vascular Biology, University of Connecticut School of Medicine, 
Farmington, CT.
Background: Albuminuria, a complication of disease states that damage glomerular 
function such as diabetic nephropathy (DN), promotes renal damage by triggering 
pro-inflammatory and pro-fibrotic pathways leading to chronic kidney disease (CKD). 
Understanding how the kidney handles urinary albumin may thus be beneficial for 
identifying therapeutic mechanisms to limit disease progression. Urinary proteins are 
normally efficiently resorbed via the Megalin-Cubilin receptor complex and the neonatal 
Fc Receptor (FcRn) in the proximal tubule. CD13, a multifunctional cell surface molecule, 
negatively regulates clathrin-dependent endocytosis in various cell types. Like the albumin 
endocytic receptors, CD13 is expressed abundantly on the apical surface of proximal tubule 
epithelial cells. Here, we examined the role of CD13 in renal proximal tubular handling of 
albumin in two murine models of albuminuria as well as in unchallenged mice.
Methods: WT and CD13 KO C57/B16 mice were used for both a streptozotocin 
(STZ) induced DN model (50 mg/kg daily for 5 days) and albumin overload (AO) model 
(bovine serum albumin; increasing daily doses from 2 mg/g to 10 mg/g on day 5, final 
10 mg/g dose on day 8). Urine and serum were collected at basal, 8, 12, 16, and 20 weeks 
post STZ-treatment in the DN model and day 8 in the AO model for ELISA analysis. 
Kidneys were collected for immunofluorescence, flow cytometry, and electron microscopy 
analysis. Relationship of CD13 to Megalin, Cubilin, and FcRn was analyzed by co-
immunofluorescence of kidney sections and western blotting of brush border membrane 
fractions.
Results: Compared to WT, CD13 KO mice exhibited significantly decreased 
albuminuria in both 20 week STZ-induced DN and AO models, as well as increased cellular 
uptake of albumin in the proximal tubules even in unchallenged conditions. Furthermore, 
we identified possible mechanisms by which CD13 regulates albumin endocytosis, 
including 1) co-localization of CD13 and FcRn, 2) elevated levels of cubilin at the brush 
border of CD13 KO proximal tubules, and 3) maintenance of cristae integrity in CD13 KO 
mitochondria after 20 week STZ-induced DN.
Conclusions: Our results suggest that CD13 serves as a key mediator for albumin 
endocytosis in the proximal tubule and may be a potential therapeutic target for preventing 
albuminuria-induced damage in renal disease.
Funding: Other NIH Support - R01-HL127449, R01-HL125186
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The iBEAT MRI Biomarker Panel: Prognostic Imaging Biomarkers for 
DKD
Kanishka Sharma,1 Fotios Tagkalakis,1 Irvin Teh,1 Virva Saunavaara,5 
Dmitry Kuznetsov,6 Michael W. Mansfield,1 Mark Gilchrist,3 Roberto De blasi,7 
Mark Ibberson,6 Anil K. Karihaloo,2 Nicolas Grenier,4 Steven Sourbron.1 BEAt-
DKD Work Package 4 1University of Leeds, Leeds, United Kingdom; 2Novo 
Nordisk, Seattle, WA; 3Royal Devon and Exeter Hospital, Devon, United 
Kingdom; 4Pellegrin Hospital, Bordeaux, France; 5Turku PET centre c/o Turku 
University Hospital, Turku, Finland; 6SIB, Lausanne, Switzerland; 7Pia 
Fondazione Panico, Tricase, Italy.
Background: Advances in functional Magnetic Resonance Imaging (MRI) have 
provided novel renal imaging biomarkers that inform on parenchymal perfusion, 
oxygenation, filtration, fibrosis, inflammation, and tissue composition. We present a novel 
panel of MRI biomarkers designed to help predict DKD progression. The panel has been 
developed for iBEAT, a new cohort study in 500 patients with T2 diabetes and eGFR>30 
mL/min, starting mid 2018. iBEAT is part of the BEAt-DKD project (www.beat-dkd.eu) 
funded by IMI-JU (No 115974).
Methods: iBEAT will collect MRI in 5 sites at 3 Tesla scanners of 2 vendors; studies 
will be uploaded into a central database. QC and MRI post-processing will be performed 
centrally, and MRI biomarkers will be integrated with clinical data, demographics, blood-, 
urine-, and biopsy biomarkers, endothelial function, and nuclear medicine gold-standards. 
The MRI protocol was developed through a 6-month process involving measurements on 
volunteers and a reference object developed by NIST.
Results: The iBEAT MRI panel characterizes both kidney parenchyma and general 
body composition. The latter includes liver fat (%, insulin resistance), pancreatic fat (%, 
insulin secretion), liver iron (mg/g, diabetes risk), visceral fat (mL, diabetes risk). Renal 
biomarkers cover three groups: (1) Anatomical biomarkers include kidney volume (mL, 
increased in hyperfiltration), renal sinus fat (mL, predictor of albuminuria), cortical 
volume (mL, surrogate for nephron number); (2) Microstructure biomarkers include 
T2* (ms, oxygenation), T1 (ms, fibrosis), T2 (ms, inflammation, oedema), blood volume 
(%, glomerular hypertrophy), tubular volume (%, tubular obstruction), fractional anisotropy 
(%, tubular dilatation, glomerulosclerosis); (3) Dynamic biomarkers include cortical and 
medullary perfusion (ml/min/g), filtration fraction (%, hyperfiltration), tubular flow 
(ml/min/g, concentrating capacity), GFR density (ml/min/g).
Conclusions: The iBEAT MRI biomarker panel is designed to capture DKD 
progression on the level of renal tissue dynamics, microstructure and anatomy, as well 
as broader risk factors for diabetes. The iBEAT study will determine the utility of these 
biomarkers for DKD prognosis, and whether they may become part of the clinical endpoint 
in future trial designs.
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Prognostic Imaging Biomarkers for Diabetic Kidney Disease (iBEAT): A 
BEAt-DKD Study
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Maria F. Gomez.3 1University of Leeds, Leeds, United Kingdom; 2Novo Nordisk, 
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Background: BEAt-DKD (Biomarker Enterprise to Attack DKD) is a public-private 
partnership committed to deliver more effective patient stratification, DKD prevention and 
management (www.beat-dkd.eu; IMI-JU No 115974). We report here on an early milestone 
in BEAt-DKD, the design and setup of a clinical study (iBEAT) to explore the utility of 
imaging biomarkers.
Methods: iBEAT was developed as a collaborative project with central coordination 
between sept 2016 and June 2018. iBEAT will be run by 7 core sites including 5 recruiting 
centres, one of whom is the coordinating site (Leeds), a central biobank (Lund), a data 
management centre (Lausanne), and an image processing and QA centre (Leeds)
Results: iBEAT is a 4-year prospective observational cohort study in 500 patients 
with Type 2 diabetes and eGFR>30mL/min, aiming to identify MRI & Ultrasound (US) 
biomarkers that can improve DKD prognosis. MRI and US will be collected at baseline 
only. Demographics, clinical, family and medication history, blood (70mL) and urine will 
be collected annually. Additional data will be collected by four sites to address ancillary 
objectives (100 patients per site): Kidney biopsies, digitalized and characterized by histology 
and EM (Bari); PET-based renal blood flow (Turku); glycocalyx and microvascular 
assessments (Exeter); 2-year follow-up MRI and US (Bordeaux). Biopsies and biofluids 
including urinary vesicles and sediment will be used for biomarker discovery using state of 
the art omics, and stored for validation studies. A parsimonious set of baseline biomarkers 
associated with eGFR (primary) and eGFR slope over time (secondary) will be identified.
Conclusions: iBEAT is the largest functional imaging biomarker study in DKD 
performed to date. The study will test the utility of imaging biomarkers for DKD prognosis, 
and may also help improve our understanding of disease pathogenesis.
Funding: Commercial Support - European Federation of Pharmaceutical Industries 
and Associations
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Magnetic Resonance Elastography (MRE) with Arterial Spin Labeling 
(ASL) Kidney Blood Flow for Noninvasive Evaluation of Diabetic 
Nephropathy
Robert S. Brown,1 Maryellen Sun,3 Isaac E. Stillman,1 Teresa L. Russell,1 
Sylvia E. Rosas,2 Jesse L. Wei.1 1Beth Israel Deaconess Medical Center, Boston, 
MA; 2Joslin Diabetes Center, Boston, MA; 3Lowell General Hospital, Lowell, MA.
Background: Noninvasive quantitative measurement of fibrosis in chronic kidney 
disease (CKD) would be advantageous diagnostically and therapeutically but standard 
radiologic imaging is too variable for clinical usage. Using MRE, by applying a vibratory 
force, shear waves are generated that can measure kidney parenchymal shear stiffness that 
may correlate with tissue fibrosis.
Methods: We used novel 3-dimensional MRE with ASL kidney blood flow rates to 
study 30 diabetic patients with stage 0 to 5 CKD compared to 13 control individuals without 
CKD.
Results: MRE cortical shear stiffness at 90 Hz was surprisingly decreased significantly 
below normal in diabetic nephropathy (DN) of stages 3-5 CKD. Likewise, cortical 
ASL blood flow decreased progressively from 480±136 ml/min/100g tissue in controls 
to 152±32 ml/min/100g in stage 5 CKD. Calculation of a surrogate filtration fraction 
(sFF = eGFR/ASL) decreased progressively from 0.21±0.07 in controls to 0.10±0.02 in 
Stage 4-5 CKD. To account for the effect of decreased blood flow which has been shown to 
decrease MRE kidney shear stiffness, we calculated a novel shear stiffness index normalized 
to blood flow (SSI = MR shear stiffness/ASL blood flow, Pa/ml/min/100g cortical tissue). 
The SSI increased progressively from 12±3 in the controls to 26±4 in stage 5 CKD. This 
significant increase of the SSI also correlated with the grade II-V interstitial fibrosis in DN 
graded ‘blindly’ by biopsy in 5 patients.
Conclusions: MRE coupled with ASL blood flow rates can noninvasively measure 
kidney tissue perfusion, quantitate a sFF proportional to measured filtration fractions, and 
calculate a novel shear stiffness index that correlates with the degree of kidney fibrosis in 
worsening diabetic nephropathy.
Funding: NIDDK Support, Other NIH Support - Harvard Catalyst Subaward
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Functional Magnetic Resonance Imaging (MRI) Is Promising in 
Predicting the Prognosis of Diabetic Kidney Disease (DKD): Confirmed by 
the Cohort Study
Jing Li, Huizhen Wang, Jianteng Xie, Tiantian Liang, Yifan Zhang, Yanhui Wang, 
Wenjian Wang. Division of Nephrology, Guangdong General Hospital, 
Guangdong Academy of Medical Sciences, Guangzhou, China.
Background: DKD, the major cause of CKD and ESRD globally, which prognosis is 
determined by tissue hypoxia or fibrosis. However, assess the two aspects noninvasively 
is difficult. Whether functional MRI is available for predicting outcomings has not been 
proven.
Methods: we performed a corhort study in 67 DKD patients, measuring their renal 
oxygenation by blood oxygenation level-dependent(BOLD) MRI and fibrosis by intravoxel 
incoherent motion (IVIM) diffusion weighted imaging (DWI). 10 diabetes mellitus were 
recruited as control. The correlation were caculated by pearson linear analysis. Student’s 
t-test and one-way ANOVA were used to assess the difference among groups. the area under 
the curve (AUC) were built to assess the discriminative accuracy of MRI values with GFR. 
finally, Kaplan-Meier analysis was used to evaluate the prognosis after follow up.
Results: Differences were discovered in MRI values between DKD groups and 
controls. There is strong positive corelation between cortex ADC (p<0.0001)or D value 
(p<0.0001)and GFR, but negative correlation found in cortex R2* (p=0.0008). AUC 
(identify with eGFR) of cortex D, was 0.86 (95% CI 0.79–0.93) stronger than the AUC 
of the cortex ADC (AUC: 0.84, 95% CI 0.77–0.92) or cortex R2* (AUC: 0.67, 95% CI: 
0.57–0.77). A further increase in the AUC was obtained taking ECT-GFR as a standard. 
Follow-up period was 22.4±12.7 months, Kaplan-Meier curve according to cortex D over 
time showed a significantly different prognosis(Log-rank=23.26; P<0.0001), in contrast, 
that cortex R2* value is less accurate(Log-rank=16.7; p=0.001).
Conclusions: Cortex D value is in good agreement with the decline of renal function, 
Thus, cortex D value is an ideal biomarker for predicting the prognosis, cortex R2* is less 
accurate than cortex D but also helpful in judging prognosis.
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Magnetic Resonance Imaging Allows a Novel Non-Invasive Functional 
and Pathophysiologic Assessment of CKD in Diabetic Nephropathy
Kianoush Makvandi,1 Gert Jensen,1 Paul Hockings,2 Tim Unnerstall,3 
Henrik Leonhardt,3 Lisa Jarl,2 Anna Frödén löwenmark,2 Camilla Englund,2 
Susan Francis,4 Johannes Hulthe,2 Seema Baid-Agrawal.1 1Department of 
Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden; 2Antaros 
Medical, Molndal, Sweden; 3Department of Radiology, Sahlgrenska University 
Hospital, Gothenburg, Sweden; 4Sir Peter Mansfield Imaging Centre, 
Nottingham, United Kingdom.
Background: Magnetic resonance imaging (MRI) has great potential to non-invasively 
assess functional and morphologic changes in the kidney that may improve diagnosis, 
prognosis and treatment in patients with chronic kidney disease (CKD). We investigated 
in diabetic nephropathy (DN) patients if non-contrast MRI using multiple techniques could 
differentiate a) CKD3-4 stages from healthy controls and b) CKD3 from CKD4 stages.
Methods: An interim analysis of the ongoing study evaluated 18 CKD4, 10 CKD3 
patients with DN staged using measured GFR and 20 age- and gender-matched healthy 
controls. The MRI session included following techniques: R2* for assessment of renal 
hypoxia, apparent diffusion coefficient (ADC) for fibrosis, arterial spin labelling (ASL) 
for cortical perfusion, renal artery blood flow (peak velocity maximum and minimum, 
mean arterial flow [MAF], renal artery resistive index [RARI), PC perfusion (MAF/kidney 
volume), and kidney volume corrected for body surface area (BSA).
Results: Several of these parameters (highlighted in the table) were highly sensitive 
and specific to differentiate healthy vs CKD3-4 and CKD3 vs CKD4. By multivariate 
analysis, the combination of mean arterial flow and R2* medulla showed a strong predictive 
ability to separate healthy from CKD patients.
Conclusions: A comprehensive non-contrast MRI protocol was developed, which as a 
single non-invasive tool could improve our understanding of the function and underlying 
pathophysiology of CKD including DN, obviating potential user-dependent errors and 
risky use of contrast agents. Longitudinal follow-up will assess whether these findings can 
identify patients at risk for progression of CKD.
Funding: Commercial Support - Antaros Medical AB, Astra Zeneca
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High Repeatability and Sensitivity of MR Imaging Biomarkers of CKD
Paul Hockings,1 Kianoush Makvandi,2 Tim Unnerstall,3 Henrik Leonhardt,3 
Anna Frödén löwenmark,1 Lisa Jarl,1 Camilla Englund,1 Susan Francis,4 
Gert Jensen,2 Fredrik Erlandsson,5 Anna K. Sundgren andersson,5 
Johannes Hulthe,1 Seema Baid-Agrawal.2 1Antaros Medical, Molndal, Sweden; 
2Department of Nephrology, Sahlgrenska University Hospital, Gothenburg, 
Sweden; 3Department of Radiology, Sahlgrenska University Hospital, 
Gothenburg, Sweden; 4Sir Peter Mansfield Magnetic Resonance Center, 
Nottingham, United Kingdom; 5AstraZeneca, Gaithersburg, MD.
Background: New drug development tools are needed for monitoring response to 
therapy in chronic kidney disease (CKD) with increased precision and repeatability. We 
evaluated 18 CKD4 and 10 CKD3 subjects with type 2 diabetic nephropathy, and 20 age- 
and sex-matched healthy volunteers with a wide range of non-contrast magnetic resonance 
Imaging (MRI) techniques. Measured GFR (mGFR) was assessed using iohexol clearance. 
Half of the subjects were re-scanned after 2-4 weeks to assess repeatability.
Methods: MRI techniques included R2* for assessment of renal hypoxia, apparent 
diffusion coefficient (ADC) for fibrosis, R1for interstitial water balance, arterial spin 
labelling (ASL) for cortical perfusion, renal artery blood flow (peak systolic velocity, 
end diastolic velocity, mean arterial flow, and renal artery resistive index (RARI)), global 
perfusion (mean arterial flow/kidney volume), and kidney volume corrected for body 
surface area.
Results: see Table
Conclusions: Several MR parameters correlate strongly with mGFR indicating that 
these biomarkers are biologically relevant while providing additional information on 
pathophysiology. Given the known relationship between MRI biomarkers and mGFR plus 
the intra-subject CoV, the number of subjects needed to detect, e.g. a 2 ml/min/1.73m2 
change in mGFR can be calculated. To conclude, a 30 min non-contrast MRI protocol 
characterising important aspects of CKD with a high repeatability and sensitivity was 
identified. Repeatability data allows future CKD intervention studies to be correctly 
powered.
Funding: Commercial Support - Antaros Medical; AstraZeneca
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Myocardial Flow Reserve Assessed by Cardiac 82Rb PET/CT Is 
Associated with Albumin Excretion in Patients with Type 1 Diabetes
Emilie Hein Zobel,1 Signe Abitz Winther,3 Bernt Johan Von Scholten,2 
Lene Holmvang,5 Andreas Kjaer,4 Peter Rossing,3 Tine Hansen.1 1Steno Diabetes 
Center, Gentofte, Denmark; 2Novo Nordisk A/S, Soborg, Denmark; 3Steno 
Diabetes Center Copenhagen, Gentofte, Denmark; 4Rigshospitalet, Copenhagen, 
Denmark; 5Rigshopitalet, Copenhagen Ø, Denmark.
Background: To evaluate myocardial flow reserve (MFR) and coronary artery 
calcium (CAC) in persons with type 1 diabetes with or without albuminuria and in non-
diabetic controls. MFR reflects the function of large epicardial arteries and myocardial 
microcirculation. CAC represents structural aspects of atherosclerosis. In addition we 
evaluated the association of MFR and CAC with retinopathy, another microvascular 
complication
Methods: Cross-sectional study in type 1 diabetes, stratified by normoalbuminuria 
(n=30) and macroalbuminuria (n=30), and in non-diabetic controls (n=30). MFR 
(pharmacological stress flow/rest flow) was evaluated by cardiac 82Rb positron emission 
tomography/computed tomography.
Results: MFR was similar in patients with normomalbuminuria (NORMO) and 
controls (3.1 ± 0.8 vs. 3.0 ± 0.79; p=0.74). Patients with macroalbuminuria (MACRO) 
had lower (impaired) MFR compared to NORMO (2.1 ± 0.9 vs. 3.1 ± 0.8; p < 0.0001). 
The CAC score (median[IQR]) was higher in NORMO compared to controls (72[22-
247] vs. 0[0-81], p=0.018), and comparable between MACRO and NORMO. MFR was
comparable in patients with diabetes and simplex or no retinopathy (n=24 and n=12, 
2.8 ± 0.84 vs. 3.3 ± 0.77, p=0.11), but lower in proliferative (n=24) compared to simplex
retinopathy (2.1 ± 0.97 vs. 2.8 ± 0.84, p=0.02). The CAC score was comparable between
groups of retinopathy.
Conclusions: Myocardial microvascular function was comparable in non-diabetic 
controls and patients with type 1 diabetes and normoalbuminuria; but impaired in the 
presence of microvascular complications (macroalbuminuria and proliferative retinopathy). 
Coronary calcification was elevated in diabetes, however not explained by albuminuria.
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Pulse Wave Velocity Is an Independent Risk Factor for Cardiovascular 
Events, Mortality and Decline in Renal Function in Patients with Type 1 
Diabetes
Marie Frimodt-Moller,1 Simone Theilade,1 Signe Abitz Winther,1 Nete Tofte,1 
Tarunveer S. Ahluwalia,1 Peter Rossing.1,2 1Steno Diabetes Center Copenhagen, 
Gentofte, Denmark; 2University of Copenhagen, Copenhagen, Denmark.
Background: The prognostic significance of carotid-femoral pulse wave velocity 
(cfPWV), the gold standard measure of arterial stiffness, remains to be determined in 
patients with type 1 diabetes (T1D). We investigated the predictive value of cfPWV for 
development of cardiovascular events (CVE), mortality and decline in renal function in 
T1D.
Methods: At baseline cfPWV was measured using the SphygmoCor device in 652 
patients with T1D and various degrees of albuminuria, ranging from normo- (<30 mg/24h), 
micro- (30-299 mg/24) to macroalbuminuria (≥300 mg/24h. Endpoints were traced through 
National Registers and patient records until 31st December 2016 comprising: composite 
CVE, mortality, progression from normo- to micro/macroalbuminuria or from micro- to 
macroalbuminuria, and decline in estimated glomerular filtration rate (eGFR) ≥30%. 
Median follow-up ranged from 5.2 to 6.2 years. Slope estimates of eGFR and urinary 
albumin creatinine rate (UACR) were calculated for a median of 5.5 years. Adjustment 
included sex, age, mean arterial pressure, LDL cholesterol, smoking, HbA1c, UACR and 
eGFR at baseline. Hazard ratios (HR) were calculated per 1 standard derivation (SD) 
increase in cfPWV.
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Results: Of the 652 participants (56% male); mean±SD age was 54±13 years, cfPWV 
10.5±3.38 m/s and eGFR 81±26 ml/min/1.73m2. Median numbers of eGFR and UACR 
measures during follow-up were 6.0 and 17.0, respectively. After adjustment, higher 
cfPWV remained significantly associated with all endpoints: composite CVE (n=81; 
HR:1.31; p=0.045); mortality (n=48; HR:1.39; p=0.033); progression in albuminuria 
(n=31; HR:1.16; p=0.012); and decline in eGFR ≥ 30% (n=90; HR: 1.39; p=0.015). Higher 
cfPWV was associated with a steeper decline in eGFR and a steeper increase in UACR after 
adjustments (p≤0.009).
Conclusions: In patients with T1D, higher arterial stiffness was consistently associated 
with a higher risk of CVE, mortality and decline in renal function, independent of other risk 
factors. Measurement of cfPWV may have a promising role in risk stratification in T1D.
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Exome Wide Association Study Identifies a Rare Coding Variant in 
Cubilin Gene and Suggestive Variants in Additional Genes Associated with 
Albuminuria Among 33,985 Europeans with and Without Diabetes
Tarunveer S. Ahluwalia,1,11 Christina-Alexandra Schulz,2 Tea Skaaby,3 
Niina Sandholm,4 Jette Bork-Jensen,11 Natalie R. Van zuydam,8 Peter Almgren,2 
Betina H. Thuesen,3 Marit E. Jørgensen,1 Ivan Brandslund,5 Cramer 
K. Christensen,9 Allan Linneberg,3 Emma Ahlqvist,2 Per-Henrik Groop,6,4 
Samy Hadjadj,7 Leif Groop,2 Niels Grarup,11 Marju Orho-Melander,2 
Mark McCarthy,8 Olle Melander,2 Peter Rossing,1,10 Tuomas O. Kilpelainen,11 
Torben Hansen.11 1Steno Diabetes Center Copenhagen, Gentofte, Denmark; 
2Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden; 
3Center for Clinical Research and Prevention, Bipebjerg and Frederiksberg
Hospital, The Capital Region, Copenhagen, Denmark; 4Folkhalsan Institute of
Genetics, Folkhalsan Research Center, Helsinki, Finland; 5Lillebaelt 
hospital,University of South Denmark, Vejle, Denmark; 6University of Helsinki
and Helsinki University Hospital, Helsinki, Finland; 7CHU Poitiers, CIC and
Endocrinology Department, Poitiers, France; 8Wellcome Center Human
Genetics, University of Oxford, Oxford, United Kingdom; 9Lillebaelt Hospital,
Horsens, Denmark; 10University of copenhagen, Copenhagen, Denmark; 11Novo 
Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic 
Genetics, University of Copenhagen, Copenhagen, Denmark.
Background: Identification of rare coding variants associated with albuminuria may 
provide new options for preventing chronic kidney disease (CKD) and end-stage renal 
failure, especially in diabetic patients. With the increasing burden of CKD reaching about 
15% in the US, efforts to identify underlying genetic factors for albuminuria have been 
limited, majority focusing just common variants.
Methods: We performed an exome-wide association study to identify coding variants 
in a two-phase (discovery and replication) approach employing 33,985 individuals of 
European ancestry (15,872 with and 18,111 without diabetes). Additive genetic models 
using linear regression on natural log transformed Albuminuria levels was performed for 
263,894 single nucleotide polymorphisms (SNPs), adjusted for age, sex, and population 
substructure. Meta analyses conducted using fixed effects inverse variance method.
Results: We identify a rare (MAF: 0.8%) missense variant in Cubilin gene (CUBN, 
p=1.3 × 10-11) associated with albuminuria in the combined European (EUR) meta-
analyses. The rare CUBN variant had 3 times stronger effect in individuals with diabetes 
compared to those without (pinteraction: 5.4 × 10
-4, βDM: 0.69, βnonDM: 0.20) in the discovery 
meta-analyses. This CUBN rare variant is an independent signal for albuminuria after 
conditional analyses with the previously known albuminuria common SNP (LD: 
r2 = 0.0002, D’ = 1.0, pcondition: 8.5 × 10
-7). Gene-aggregate tests based on rare (MAF<0.01) 
and common variants suggest three additional genes associated with albuminuria (HES1, 
CDC73, and GRM5) after correction for multiple testing (p_bonferroni<2.7 × 10
-6).
Conclusions: The current study identifies a rare coding variant in the CUBN locus 
and suggestive variants in 3 other genes associated with albuminuria in individuals with 
and without diabetes, implicated in renal dysfunction. These highlight novel genes and 
pathways as potential targets towards diabetes related kidney disease prevention.
Funding: Private Foundation Support, Government Support - Non-U.S.
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TCF7L2 and ACE Polymorphisms Confer Genetic Susceptibility to 
Diabetes Mellitus Type 2/Diabetic Nephropathy in Chilean Patients
Paola Krall,1 Natalia C. Peralta,1 Daniela P. Nualart,1 Carolina Lavoz,1 
Osvaldo A. Elgueta,2 Leopoldo G. Ardiles,1 Claudio A. Flores,1 
Sergio A. Mezzano.1 1Universidad Austral de Chile, Valdivia, Chile; 2Cesfam 
Externo Valdivia, Valdivia, Chile.
Background: Diabetes mellitus type 2 (DMT2) is a chronic disease that is the leading 
cause of end-stage renal disease due to diabetic nephropathy (DN). A role in DN has been 
described for Gremlin (GREM1) and for an indel (I/D) in the Angiotensin-converting-
enzyme (ACE) gene. Chile has the highest prevalence of DMT2 in Latin America, but the 
genetic susceptibility to develop DMT2 or DN remains undetermined. The aim of this work 
is to explore in a cohort of Chilean subjects, the association of polymorphisms in genes 
related to GREM1 and ACE with DMT2 or DN.
Methods: A retrospective case-control study was performed in 140 control subjects 
and DMT2 patients without DN (n=80) or with DN (n=101), categorized as those with 
early DN (1-7 yrs after DMT2 diagnosis) and late DN (8-15 yrs after DMT2 diagnosis). 
The genotype in the following polymorphisms was determined: rs1129456 (GREM1), 
rs7903146 (TCF7L2), rs34231037 (VEGFR2), rs4819554 (IL-17RA), indel (18 pb) in the 
VEGF gene and the indel (~300pb) in the ACE gene. Allelic and genotypic frequencies were 
analyzed to determine Odds ratio (OR).
Results: The analysis showed that the T allele (TCF7L2) was associated with 
DMT2 (OR=1.53, IC 95%=1.08-2.18, p=0.009). Additionally, a significant association 
was identified between the D allele (ACE) and the development of DN (OR=1.62, 
IC 95%=1.06-2.47, p=0.01), as well as with an early development of DN (OR=2.22, 
IC 95%= 1.10- 4.46, p=0.01).
Conclusions: Our results demonstrate that particular variants in TCF7L2 (T allele) 
and ACE (D allele) are highly prevalent in the study cohort (30-50%) and present a 
potential clinical value as risk alleles for DMT2 and DN of early development. TCF7L2 is 
a transcription factor controlling the GREM1 expression. Although the SNP in GREM1 was 
not associated with DMT2/ DN, further studies are required to determine if the TCF7L2 
genotype is associated with GREM1 expression in the diabetic kidney. A larger study with 
multi-center individuals’ recruitment is required to validate TCF7L2 and ACE as genetic 
markers of susceptibility in the Chilean population, in order to consider them as input to 
design more effective strategies to prevent DMT2 and DN. Grant FONDECYT Regular 
116-0465
Funding: Government Support - Non-U.S.
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Genome-Wide DNA Methylation Analysis for Diabetic Kidney Disease
Laura J. Smyth, Jill Kilner, Chris C. Patterson, Christopher J. Wooster, 
Gareth J. McKay, Alexander P. Maxwell, A.J. Mcknight. Epidemiology and 
Public Health Research Group Queen’s University Belfast, Belfast, United 
Kingdom.
Background: Diabetic kidney disease (DKD) is a serious complication of diabetes, 
characterised by progressive development of proteinuria and loss of renal function. 
Increasing evidence suggests that epigenetic alterations, including DNA methylation, 
are involved in the development and progression of DKD. This investigation compared 
methylation profiles from individuals with type 1 diabetes (T1D) and DKD to individuals 
with T1D and no evidence of renal failure, to identify potential methylation-based 
biomarkers of DKD.
Methods: Using the Zymo EZ DNA methylation kit to bisulphite treat the DNA and 
the Infinium HD Methylation Assay, MethylationEPIC BeadChips from Illumina, the 
methylation status of >850,000 CpG sites, gene bodies, promoters and CpG islands have 
been determined for 106 individuals with T1D. Of these, 66 individuals had DKD and 40 
controls had no evidence of renal disease. Cases and controls for this analysis were matched 
carefully for ethnicity, sex, age (≤1 year), and duration of diabetes. We also considered 
192 individuals with Illumina’s HumanMethylation27K array data and 250 individuals 
with HumanMethylation450K array data for DKD. DNA obtained from each individual 
was treated consistently, with standard quality control applied.
Results: Methylation data was analysed using Genome Studio and Partek Genomics 
Suite v7.0. From the EPIC array, 891 CpG sites were identified as having significantly 
different levels of methylation in cases compared with controls, 9 of which had a significance 
level of p≤9.75x10-08. Among the genes identified, several including BCL2, CUX1, FKBP5, 
FBXO5, PRKAG2 and PSD3 have been linked with T1D. High concordance (R2=0.994) 
between duplicate samples (n=7) was observed. Across data from all arrays, top-ranked 
genes with differential methylation profiles included CUX1, FKBP5 and PRKAG2.
Conclusions: We have previously reported CUX1, FKBP5, and PRKAG2 genes 
associated with CKD, supported by changes in gene expression using RNA-Seq (Smyth et 
al., Epigenetics, 2014). This project supports meta-analysis of independent cohorts across 
arrays and demonstrates blood-derived methylation signatures may serve as minimally 
invasive biomarkers of DKD.
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Gene Expression Profiles of Hyperfiltration in Early Diabetic Kidney 
Disease
Vidar T. Stefansson,1 Viji Nair,2 Laura H. Mariani,2 Toralf Melsom,1,4 
Bjorn O. Eriksen,1,4 Robert G. Nelson,3 Matthias Kretzler.2 1UiT The Arctic 
University of Norway, Tromso, Norway; 2University of Michigan, Ann Arbor, 
MI; 3National Institutes of Health, Phoenix, AZ; 4University Hospital of North 
Norway, Tromso, Norway.
Background: Hyperfiltration (HF) is a state of high glomerular filtration rate (GFR) 
seen in early diabetic kidney disease. Prolonged HF damages glomeruli, eventually leading 
to a vicious cycle of fibrosis and an increased filtration load for remaining glomeruli. 
Previous definitions of HF based on GFR cut-points have not convincingly captured 
microstructural and gene expression signatures in individuals. We used novel methods of 
capturing individual HF to elicit morphometric and gene expression profiles from kidney 
biopsies.
Methods: 111 Pima Indians with type 2 diabetes had a research kidney biopsy between 
2002-2007 and 9-29 iothalamate GFR and albumin-creatinine ratio (ACR) measurements 
between 1989 and 2017. Those with mean GFR <60ml/min/1.73m2 or ACR >300mg/g 
around the time of biopsy were excluded. Subjects who had their highest ever recorded GFR 
measurement within two years of biopsy were categorized as having HF. Eigengene-based 
weighted gene co-expression network analysis modules were constructed from glomerular 
transcriptomes. Pathway analyses and downstream targets were identified.
Results: The interquartile range of GFR among HF subjects was 138.1-203.5. One 
module uniquely associated with HF. Individual genes of interest included KDR, ICAM2 
and PECAM1. Main pathways included Hepatic Fibrosis and the Th2 Pathway. Downstream 
targets included angiogenesis and endothelial cell proliferation.
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Conclusions: A new method of capturing individual HF in early diabetic kidney 
disease correlated with clinical and morphological data and yielded novel findings in 
gene expression analyses. These pathways may be potential targets for further research on 
diagnosis and treatment of HF.
Funding: NIDDK Support, Government Support - Non-U.S.
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Genes Related to the Different Stages of Diabetic Kidney Disease: A 
Clariom™ D Assay in Patients with Biopsy Proven Diabetic Nephropathy
Suyan Duan,2 Bo Zhang,1 Yanggang Yuan.3 1The first affiliated hosptial of 
Nanjing Medical University, Nanjing, China; 2The First Affiliated Hospital of 
Nanjing Medical University, Nanjing, China; 3the First Affiliated Hospital of 
Nanjing Medical University, Nanjing, China.
Background: Diabetic kidney disease (DKD) is the leading cause of end-stage renal 
disease. A great number of metabolites, cytokines, proteins and transcription factors 
play a role in the accumulation of extracellular matrix and mesangial proliferation in the 
glomerulus. The integrative analysis of the proteomic and transcriptomic features of bioptic 
samples among different categories of patients affected by diabetic nephropathy, especially 
based on the accurate classification of the histopathological changes in the glomerular and 
tubulointerstitial compartment, could lead to the identification of new early biomarkers.
Methods: Microarray data obtained from glomeruli isolated from normal kidneys 
(n = 2) and kidneys from patients with DN (n = 4) were used for the Clariom™ D Assay.
Results: Two patients were diagnosed as type IIb stage DN with moderate proteinuria, 
while other two patients were diagnosed as type IV stage DN with massive proteinuria. 
In the present study, differentially expressed genes (DEGs) between healthy controls 
and patients with different stages of DN were also analyzed. To investigate the function 
changes in the course of DN progression, GO enrichment and KEGG pathway analyses 
were performed for both up- and down-regulated DEGs. GO provides 3 structured networks 
of de ned terms to describe gene product attributes: cellular compartment (CC), biological 
process (BP) and molecular function (MF). Results show that signaling pathways are 
altered by the up-regulated DEGs (Fig1,2).
Conclusions: In conclusion, our transcriptome based analysis suggests that the 
association between gene expression and renal pathology is mediated by structural changes 
and that there may be differences in pathways that lead to protenuria.
GO term
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Integrating Plasma Proteomic with Tissue Transcriptomic Profiles in 
Early Diabetic Kidney Disease Identifies IFNG Activation as a Predictor 
of Disease Progression
Viji Nair,1 Helen C. Looker,4 Robert G. Nelson,3 Wenjun Ju,1 Matthias Kretzler.2 
1University of Michigan, Ann Arbor, MI; 2U.Michigan, Ann Arbor, MI; 3National 
Institutes of Health, Phoenix, AZ; 4NIH, Phoenix, AZ.
Background: Circulating proteins may act through their downstream signaling 
pathways in the kidneys to promote intrarenal impairment and progression to end-stage 
renal disease (ESRD) in persons with diabetic kidney disease (DKD).
Methods: Targeted plasma proteomics (SOMAscan) were obtained in (n=162) Pima 
Indians with type 2 diabetes and early DKD and compared to subsequent genome-wide 
transcriptomics of protocol kidney biopsies performed on average 2.3 years (n=74) and 
11.2 years (n=57) later.
Results: 317 out of 550 plasma proteins were differentially expressed between 56 
patients who progressed to ESRD and those who did not after a median follow up of 11 
years (FDR<0.2). 114 genes in the glomeruli (Glom) (13 ESRD vs 54 of non-ESRD) and 
182 in the tubulointerstitium (TI) (7 ESRD vs 40 non-ESRD) were differentially expressed 
(FDR<0.2). Interferon gamma (IFNG) was identified as the top ESRD-associated plasma 
cytokines and the top up-stream regulator of intrarenal ESRD-associated genes in both 
Glom and TI. An activation score (Z score) was generated for the IFNG signaling pathway 
based on the expression of IFNG downstream genes (Glom and TI). IFNG Z-scores in 
Glom and TI were inversely associated with measured GFR decline (r=-0.55 and -0.59, 
p<0.0001 respectively). Patients who progressed to ESRD had a significantly higher 
Z-score than those who did not (Figure). Circulating IFNG was associated with intrarenal 
IFNG pathway score in biopsies obtained 11.2 years later (r= 0.47 and 0.40, p<0.002, glom 
and TI respectively).
Conclusions: Increased circulating IFNG early in DKD precedes intrarenal IFNG 
pathway activation and subsequent clinical outcome a decade later, providing a strong 
rationale for targeting systemic inflammatory pathways in DKD progression.
Funding: NIDDK Support, Commercial Support - Boehringer Ingelheim
Intrarenal IFNG pathway Z scores in Glom (A) and TI (B) are significantly higher in ESRD/
progressors compared to non progressors (median FU 11 ± 2.5 Years). Progressors were 
defined as measured GFR slope more than -3 mL/min
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Circulating MicroRNA Profiles and Risk of ESRD in Patients with 
Diabetes and CKD: An RNA-Sequencing Based Study
Eiichiro Satake,3 Marcus G. Pezzolesi,2 Christopher Simeone,1 Zaipul I Md 
Dom,3 Hiroki Kobayashi,3 Adam Smiles,1 Monika A. Niewczas,3 
Andrzej S. Krolewski.3 1Joslin Diabetes Center, Boston, MA; 2University of 
Utah, Salt Lake City, UT; 3Joslin Diabetes Center, Harvard Medical School, 
Boston, MA.
Background: MicroRNAs (miRNAs) are endogenous, short non-coding RNA 
molecules that are involved in gene regulation and play important roles in the pathogenesis 
of various diseases including diabetic kidney disease (DKD). However, miRNA signatures 
associated with DKD has not been fully established.
Methods: Using High Throughput Genomics (HTG) edge sequence platform, the 
expression of 2,083 mature miRNAs were examined in baseline plasma specimens from 
239 patients with type 1 diabetes (T1D) and CKD stages 3 & 4 to find miRNAs associated 
with progression to ESRD during 7-15 years of follow-up. The findings in T1D were 
validated using the same technology in the replication panel of 136 patients with type 2 
diabetes (T2D) and the same CKD stages.
Results: Cox proportional hazard model analysis revealed that 15 miRNAs were 
strongly associated with renal function decline and time to ESRD in both T1D and T2D. 
Using Spearman’s rank test, 3 candidate miRNAs were significantly associated with 
declining renal function after adjusting for age, sex, type of diabetes, duration of diabetes, 
HbA1c, eGFR and ACR (p<0.05). In pathway analysis, 6 KEGG pathways (Endocytosis, 
FoxO signaling, mTOR signaling, Neurotrophin signaling, Rap1 signaling and Ras 
signaling) were significantly enriched by genes targeted by all 3 miRNAs (P<0.01).
Conclusions: We investigated plasma miRNA profiles associated with ESRD in 
patients with diabetes using RNA-sequencing based platform. Our results suggest that these 
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miRNAs are associated with declining renal function in patients with diabetes and have 
potential to serve as circulating biomarkers, and possibly therapeutic targets for DKD.
Funding: NIDDK Support, Commercial Support - Novo Nordisk
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Urinary Exosomal CCL21 mRNA as Biomarker of Diabetic Nephropathy
Ye Feng, Linli Lv, Xin Zhong, Bi-Cheng Liu. Zhong Da Hospital, Southeast 
University Medical School, Nanjing, China.
Background: Diabetic nephropathy (DN) is one of the common complications of diabetes 
characterized by variable histological changes and clinical course. Currently, renal biopsy and 
pathological assessment remains the standard approach in the diagnosis and prognosis of DN. 
Given the invasive procedures and unpredictable post-operative complications of biopsy, novel 
and noninvasive biomarkers are needed. We aimed to find noninvasive biomarkers reflecting 
the histological injury and progression of renal function in DN.
Methods: A screening cohort of 4 biopsy-proven DN patients and 4 diabetic patients 
with normal renal function(DM) and a validation cohort of patients with 28 biopsy-proven 
DN patients and 24 DM patients were enrolled in our study. We isolated exosomes from 
urine samples at the time of renal biopsy. Urinary exosomes was identified by Western 
blotting (using Alix, CD63 and CD9 as exosomal markers). Kidney histological damage 
of DN patients was scored according to Tervaet standard. Urinary exosome profile of the 
packing inflammatory response related genes were assessed and its correlation with clinic 
and histological injury parameters were analyzed.
Results: Known exosome markers including Alix, CD63 and CD9 were identified 
by Western blotting. Profile of the packing inflammatory related mRNA revealed CCL-
21 was remarkably upregulated in urinary exosomes of DN patients compared with DM 
patients(p<0.05). Validation study confirmed the findings and found the correlation of CCL-
21 with levels of proteinuria (r=0.590, p<0.05) and eGFR (r=0.591, p<0.05). Furthermore, 
CCL21 was positively correlated with tubulointerstitial damage. DN patients with severe 
tubulointerstitial damge showed the highest expression of CCL-21 compared with DN 
patients with mild and moderate damage. Impressively, CCL21 showed good performance 
in discriminating patients with different levels of tubulointersitial inflammation.
Conclusions: In summary, urinary exosomal CCL-21 mRNA may be promising 
noninvasive biomarkers of diabetic nephropathy reflecting renal histological injury and 
renal function deterioration.
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Urine Synaptopodin Predicts Progression of Diabetic Nephropathy in 
Patients with Type 2 Diabetes
Nam-Jun Cho,1 Eun-Young Lee,1 Choon Hee Chung,2 Minhwan Kang.1 
1Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea; 
2Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Background: Synaptopodin, a protein that plays an important role in the maintenance 
of the structure of podocyte, is known as a marker that reflects the damage of glomerulus. 
Although some studies reported that urine synaptopodin was elevated in diverse kidney 
diseases, the clinical role of urine synaptopodin in the diabetic patients remains unclear. 
We hypothesized that urine levels of synaptopodin would be associated with severity and 
prognosis of diabetic nephropathy.
Methods: A total of 145 patients with type 2 diabetes and 25 healthy control subjects 
were enrolled. They were followed up with estimated glomerular filtration rate (eGFR), 
urine albumin-to-creatinine ratio (UACR) and urine protein-to-creatinine ratio. The 
participants with baseline eGFR less than 60 mL/min/1.73 m2 were excluded. Urine levels 
of synaptopodin were assessed by enzyme-linked immunosorbent assays.
Results: The mean age of the study participants was 56.2 ± 10.5 years and their 
median follow-up was 36 (24–40) months. Urine synaptopodin levels, presented as urine 
synaptopodin-to-creatinine ratio, were significantly higher in patients with diabetes (256.0 
[142.0–481.7] pg/mg) than healthy control (129.2 [96.5–289.1] pg/mg). Among diabetic 
patients, urine synaptopodin levels were increased according to albuminuria stages 
(normoalbuminuria, 234.3 [140.1–470.7] pg/mg; microalbuminuria, 258.3 [143.8–424.6] 
pg/mg; and macroalbuminuria, 341.8 [178.7–570.6] pg/mg). Urine synaptopodin in diabetic 
patients was not significantly correlated with baseline eGFR. However, urine synaptopodin 
was negatively correlated with changes of eGFR (R = 0.209, p = 0.023). Moreover, in the 
normoalbuminuric subgroup of diabetic patients, urine synaptopodin was significantly 
associated with changes of UACR (R = 0.272, p = 0.045). This finding was also valid after 
adjusting for age, sex, body mass index, glycated hemoglobin level, eGFR, and follow-up 
duration.
Conclusions: Our study presented that urine synaptopodin in patients with type 2 
diabetes reflected the severity of diabetic nephropathy and predicted progression of the 
disease. These results suggest that urine synaptopodin would be a useful early biomarker 
for diabetic nephropathy.
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Urinary Excretion of Podocyte mRNA as a Risk Prediction Biomarker for 
Progression of Diabetic Nephropathy: 2-Year Follow-Up Study
Akihiro Fukuda,1,2 Yuji Sato,2 Akihiro Minakawa,2 Masao Kikuchi,2 
Shouichi Fujimoto.2 1Oita University, Yufu, Japan; 2University of Miyazaki, 
Kiyotake, Japan.
Background: Recent studies suggest that podocyte injury has already occurred at the 
early stage of diabetic nephropathy. Podocyte cell lineage-specific mRNA can be recovered 
from urine pellets. We previously reported that urinary excretion of podocyte mRNA could 
be an early diagnostic biomarker for diabetic nephropathy. Here, we examine whether it can 
be used as a risk prediction biomarker for progression of diabetic nephropathy.
Methods: For our previous study, outpatients at various stages of diabetes (n=83, 
normoalbuminuria group, n=31, microalbuminuria group, n=31, macroalbuminuria group) 
were enrolled from January to June 2015 and spot urine samples were collected. For the 
present study, we performed a prospective observational cohort study of these participants 
using data from a 2-year follow-up period (2015–2017). Renal outcome was defined as a 
decrease in the estimated glomerular filtration rate (eGFR) of >4% per year. Predictors used 
were baseline urinary excretion of podocyte mRNA (podocin/aquaporin 2 mRNA ratio), 
podocin mRNA/creatinine ratio (UPodCre), podocin/nephrin mRNA ratio, and albumin/
creatinine ratio (UAlbCre). A logistic regression analysis was used to calculate the odds 
ratios (ORs) for eGFR decrease, with adjustments made for age, sex, duration of diabetes, 
body mass index, systolic blood pressure, eGFR, low density lipoprotein cholesterol, serum 
albumin, glycated hemoglobin, and usage of insulin or a renin-angiotensin system inhibitor.
Results: Of the 145 patients, 31 were excluded because of lack of follow-up or data. 
UPodCre and UAlbCre were significantly associated with decreased eGFR in univariable 
analysis [OR, 2.95 (95% CI, 1.18–7.34) and OR, 2.70 (95% CI, 1.67–4.36), respectively], 
and remained significantly associated with decreased eGFR in multivariable analysis 
adjusted for the above confounding factors [OR, 2.97 (95% CI, 1.07–8.27) and OR, 3.98 
(95% CI, 1.94–8.15), respectively].
Conclusions: Urinary excretion of podocyte mRNA was independently associated 
with eGFR decline in addition to albuminuria in diabetic patients. Results from this and 
our previous study suggest that urinary excretion of podocyte mRNA could be used as early 
diagnostic and risk prediction biomarker for progression of diabetic nephropathy.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Identification of New Protein Biomarkers for Diabetic Kidney Disease by 
Proximity Extension Assays
Anja Thorenz,1 Berthold Hocher,2,3 Oleg Tsuprykov,2,4 Mira Pavkovic.1 1Bayer 
AG, Wuppertal, Germany; 2University of Potsdam, Potsdam, Germany; 3Key 
Laboratory of Study and Discovery of Small Targeted Molecules of Hunan 
Province, Hunan Normal University, Changsha, China; 4IFLB, Institute for 
Laboratory Medicine, Berlin, Germany.
Background: Diabetic kidney disease (DKD) is a complication of diabetes and the 
leading cause of kidney failure in developed countries. To treat DKD more effectively, it is 
essential to identify new drug targets and to judge the success of such developments using 
reliable markers. The olink proximity extension assay (PEA) allows measuring 92 proteins 
across 96 samples per panel simultaneously using only 1μl of plasma. To identify novel 
protein biomarkers for DKD the olink PEA was selected and evaluated in this study.
Methods: Plasma from DKD patients with different CKD stages (0,2,4) (n=62,mean age 
70y) as well as healthy controls (n=9,mean age 62y) were used for protein profiling with the 
olink PEA. Plasma was obtained from informed and consenting donors. Here, two antibodies 
labeled with unique, partially complementary oligonucleotides bind pair-wise to the target 
protein. The formed double-stranded sequence is detected and quantified using RT-PCR. 
Relevant proteins were verified with ELISA for evaluation of the olink PEA.
Results: The CKD marker FGF23 showed higher expression in plasma of CKD4 
patients (n=36,mean age 74y) than in CKD2 patients (n=20,mean age 69y) and CKD0 
(n=6, mean age 61y) when measured with olink PEA. This was also seen in the FGF23 
ELISA. Also markers as VCAM1 and PECAM1 had similar expression patterns in the 
olink PEA and ELISA measurements. Correlation analysis showed significant correlation 
between the 2 methods when FGF23 (p<0.001,r=0.922), VCAM1 (p<0.001,r=0.84) 
and PECAM1 (p<0.001,r=0.851) were compared. The olink PEA also identified other 
differentially expressed proteins in the observed groups. Even differences between CKD 
stages were detected. 48 proteins out of 192 proteins were significantly different among the 
groups (panel CV2 and 3). Stem cell factor (SCF) which contributes to renal fibrosis was 
significantly upregulated in plasma of CKD2 patients compared to CKD0 patients and even 
higher in CKD4 patients.
Conclusions: The olink PEA and ELISA showed similar patterns and correlated 
significantly for FGF23, VCAM1 and PECAM1 in plasma of DKD patients. Moreover, 
other proteins which were different between DKD patients with different CKD stages 
and control groups were identified. Therefore, the olink PEA might be a promising tool to 
identify novel biomarkers for possible new drug targets and treatment evaluation for DKD.
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High-Throughput Proteomic Search Reveals Novel Plasma Biomarkers of 
Time to ESRD in Type 1 Diabetes Patients with Persistent Proteinuria and 
CKD Stage 1-2
Jan Skupien,1 Adam Smiles,2 Andrzej S. Krolewski.2 1Jagiellonian University 
Medical College, Krakow, Poland; 2Joslin Diabetes Center, Boston, MA.
Background: The risk of end-stage renal disease (ESRD) reaches 30-50% in 
patients with type 1 diabetes and persistent proteinuria. An intensive research effort is 
needed to identify and evaluate interventions that improve prognosis in these patients. To 
better understand the disease process, identify novel drug targets and improve end-point 
definitions in clinical trials new biomarkers of renal function decline and ESRD risk are 
desperately needed.
Methods: We assayed baseline plasma specimens using an Olink proteomic platform 
(Uppsala, Sweden) in a group of 82 patients with type 1 diabetes and CKD stage 1-2 from 
Joslin Proteinuria cohort and replicated the findings in an additionally ascertained sample of 
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76 patients with similar baseline characteristics. Using an accelerated failure time survival 
regression model we sought association of 454 proteins with time to ESRD. Association 
was considered significant if false discovery rate-adjusted p-value <0.01 and a p-value 
<0.01 in the replication set.
Results: We identified 31 plasma proteins significantly associated with time to ESRD. 
The largest number of them represented tumor necrosis factor signaling pathway. All 
markers were associated with increased risk of ESRD, i.e. their higher concentration was 
associated with shorter time to ESRD. Most proteins were highly correlated and redundant 
as biomarkers. Three of them were independently associated with time to ESRD and are 
shown in the Table. Using these three proteins we estimated patients’ time to ESRD. The 
median predicted time in patients with ESRD was 9.7 years (observed 8.2 years) and in 
those without ESRD the median predicted time was 15.8 years.
Conclusions: There are multiple novel biomarkers of fast progression to ESRD in 
patients with type 1 diabetes and proteinuria. These proteins should be further investigated 
for their biologic role and therapeutic potential. They may serve in the future for predicting 
time to ESRD in diabetic kidney disease.
Funding: NIDDK Support, Private Foundation Support
Multivariate predictive model of time to ESRD
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Pre-ESRD Determinants of Post-ESRD Mortality in Patients with Type 1 
Diabetes (T1D)
Adam Smiles,1 Jan Skupien,2 Alessandro Doria,3 Andrzej S. Krolewski.1 1Joslin 
Diabetes Center, Boston, MA; 2Jagiellonian University Medical College, 
Krakow, Poland; 3Joslin Diabetes Center - Harvard Medical School, Boston, 
MA.
Background: We reported that in T1D patients the patterns of estimated glomerular 
filtration rate decline (eGFR slopes) preceding the onset of ESRD were linear but varied 
greatly among individuals. The slopes could be grouped to fast, moderate and slow 
(Skupien et al. Diabetes Care). In this study we investigated in the same cohort whether 
post-ESRD mortality was influenced by the pre-ESRD eGFR slopes. In addition we sought 
whether plasma concentrations of 568 proteins during pre-ESRD period were associated 
with post-ESRD mortality.
Methods: A cohort of 206 T1D patients who developed ESRD while attending the 
Joslin Clinic were matched against the United States Renal Data System and National Death 
Index registries to ascertain dates of starting dialysis, renal transplant and mortality. Plasma 
samples obtained from these patients when they had had CKD stage 2-4 were assayed on the 
SOMAscan proteomics platform. Relative concentrations of 568 proteins were measured. 
Cox proportional hazard model for time to mortality was used, and proteins with a p value 
of <0.005 were selected.
Results: There were 75 deaths while on dialysis during 441 person-years (py) 
of follow-up (17.0 deaths/100 py) and 40 deaths after transplant during 1204 person-
years (3.3 deaths/100 py). Total mortality was 115 deaths during 1644 person-years 
(7.0 deaths/100 py) Patients with fast (< -10 ml/min/yr) and moderate (-5 -10 ml/min/
yr) renal decline had a two times higher post-ESRD mortality than in those with slow 
(> -5 ml/min/yr) renal decline. This pattern was similar for mortality during time spent on 
dialysis and after receiving renal transplant (see Table). We identified 4 plasma proteins 
whose elevated level was associated with increasing risk of post-ESRD mortality: CCL3L1, 
CCL18, IL5RA, PRSS22 and 3 plasma proteins whose higher levels were associated with 
decreasing risk of post-ESRD mortality: VIP, IL11 and IFNL1.
Conclusions: Disease processes that determine post-ESRD mortality begin long before 
the onset of ESRD. The candidate proteins identified should be investigated further for their 
potential role as predictors and determinants of post-ESRD mortality.
Funding: NIDDK Support, Private Foundation Support
Mortality Rates (Deaths/100 Person-Years)
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DUPDN - Diagnostic Urinary Panel for Diabetic Nephropathy: A Model to 
Predict Progressive CKD
Mysore K. Phanish,2 Mark E. Dockrell.1 1South West Thames Institute for Renal 
Research, Surrey, United Kingdom; 2Epsom and St helier University Hospitals 
NHS Trust, Carshalton, London, United Kingdom.
Background: CKD in patients with diabetes is detected and monitored using eGFR 
and albuminuria. Both have limitations and a significant proportion of patients with type2 
diabetes have CKD without albuminuria. We tested a panel of urinary biomarkers that reflect 
areas of injury and pathogenic mechanisms to develop a model to predict progressive CKD.
Methods: 400 patients with diabetes and CKD were recruited and 388 included in 
analysis. 50% of patients had ACR <3. A random urine sample was collected at baseline 
and analysed for a panel of biomarkers - ACR, inflammatory cytokines-IL1β, IL6, MCP1, 
Markers of proximal tubular injury/damage- NAG and RBP, NGAL, Fibronectin (Fn). 
Patients were followed for 5y. Logistic regression analysis was done to test the association 
of individual and combination of biomarkers with presence of CKD stage 3 or 4 aand 
progression to CKD st 3 or 4. ROC AUC results were obtained for each combination of 
biomarkers to measure their sensitivity and specificity to CKD stages and progression. A 
mixed model was used for the association of biomarkers with the trajectory of eGFR over 
5y. Models with the same numbers of observations were compared using the AIC goodness-
of-fit measure.
Results: Comparisons between CKD stages demonstrated significant differences in 
urinary RBP, NAG, MCP1, IL6. In multivariate analysis, at all levels of ACR, urinary RBP 
demonstrated better correlation with CKD stage 3 and 4 compared to ACR but this effect 
was not seen after adjusting for age, sex and race. Adjusted ACR predicted CKD stage 3 
as well as any other combination of markers with AUC of 83%. For progression to stage 3 
or 4 CKD, unadjusted and adjusted ACR was a poor predictor (With an AUC of 62-67%). 
Addition of RBP and MCP1 as covariates with adjustment for age, sex and race in patients 
with ACR of <3 improves the ROC AUC to 75%. Urinary Fn was raised in diabetic patients 
with early CKD compared to healthy controls. Using 1,243 observations of eGFR over 5y 
we arrived at 2 models with best AIC values: 1. where the eGFR gradient against time in 
yrs is associated with baseline ACR and RBP/Cre: 2. where the eGFR gradient against time 
in yrs is associated with baseline MCP1/Cre and RBP/Cre. This final model showed best 
AIC value.
Conclusions: Our study suggests that models that include RBP and MCP1 in addition 
to or instead of ACR improve prediction of future eGFR.
Funding: Private Foundation Support
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Plasma Lipids Are Associated with Diabetic Kidney Disease: A Study of 
Plasma Lipidomics in Type 1 Diabetes
Nete Tofte,1 Tommi Suvitaival,1 Linda Ahonen,1 Simone Theilade,1 Signe 
Abitz Winther,1 Marie Frimodt-Moller,1 Tarunveer S. Ahluwalia,1 Peter 
Rossing.1,2 1Steno Diabetes Center Copenhagen, Copenhagen, Denmark; 
2University of Copenhagen, Copenhagen, Denmark.
Background: The pathophysiology of diabetic kidney disease (DKD) is incompletely 
understood. The study aim was to perform lipidomics analyses to evaluate associations 
between plasma lipids and measures of DKD.
Methods: In total, the study comprised 668 patients with T1D with varying albuminuria 
status. Non-targeted lipidomics analyses were performed on plasma samples using ultra-
high performance liquid chromatography quadrupole time-of-flight mass spectrometry. 
Cross-sectional associations between single lipid species and low eGFR or albuminuria 
were analysed. Longitudinal data on urinary albumin excretion (UAE) and estimated 
glomerular filtration rate (eGFR) were obtained from electronic records over a median of 
5.5 years. eGFR slopes and hazard ratios for progression in albuminuria status (progression 
from normo- to micro/macroalbuminuria or from micro-to macroalbuminuria) were 
calculated. Adjustments included age, gender, HbA1c, systolic blood pressure, smoking, 
BMI, statin treatment, plasma triglycerides, total plasma cholesterol and baseline eGFR 
and/or UAE, where appropriate. Results were corrected for multiple testing.
Results: A total of 121 lipids from 4 different lipid classes (phosphatidylcholines (PCs), 
lysophosphatidylcholines (LPCs), triacylglycerols (TGs), and sphingomyelins (SMs)) were 
included in the analyses. In a crude model adjusted for baseline eGFR, PC(36:4) had the 
strongest association to eGFR decline (p<0.01) and 10 medium-and-short-chain TGs were 
weakly associated to eGFR decline (p<0.10). Among these lipids, the association between 
PC(36:4) and eGFR decline remained significant after adjusting for clinical variables (β=-
0.08360; p=0.0004). Similar associations were seen in the cross-sectional analyses between 
lipids and eGFR. In cross-sectional analyses of macro- vs normoalbuminuria, PC, SMs and 
medium-chain-length TGs were decreased (p<0.05), however, no lipids were significantly 
associated with change in albuminuria status in longitudinal analyses.
Conclusions: Alterations in the plasma lipid levels were associated with decreased 
eGFR and macroalbuminuria in this T1D study cohort, indicating broad changes in 
the lipidome in individuals with DKD. Further, the PC(36:4) was discovered to have a 
significant association to future eGFR decline.
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Plasma Metabolomics Identifies Markers of Impaired Kidney Function: A 
Meta-Analysis of 1,984 Europeans with Type 2 Diabetes
Nete Tofte,1 Tarunveer S. Ahluwalia,1 Nicole Vogelzangs,2 Dennis O. Mook-
Kanamori,3 Adela Brahimaj,7 Jana Nano,5 Ko Willems van dijk,3 Marie Frimodt-
Moller,1 Carla J. Van der kallen,2 Ilja C. Arts,2 Joline Beulens,8 Amber A. Van der 
heijden,6 Giel Nijpels,9 Marleen V. Greevenbroek,2 Coen Stehouwer,4 
Peter Rossing,1 Leen M. ’t Hart.3 1Steno Diabetes Center Copenhagen, 
Copenhagen, Denmark; 2Maastricht University, Maastricht, Netherlands; 
3Leiden University Medical Center, Leiden, Netherlands; 4University Hospital 
Maastricht, Maastricht, Netherlands; 5Erasmuc Medical Center, Rotterdam, 
Netherlands; 6VUMC, Amsterdam, Netherlands; 7Erasmus MC, Rotterdam, 
Netherlands; 8VUmc, Amsterdam, Netherlands; 9VU University, Amsterdam, 
Netherlands.
Background: There is a need for novel biomarkers and better understanding of the 
pathophysiology of diabetic kidney disease. The aim was to investigate the associations 
between plasma metabolites and measures of kidney function.
Methods: Blood metabolites (n=235) were measured by nuclear magnetic resonance 
spectroscopy (NMR) in 1,984 type 2 diabetes (T2D) cases among three independent Dutch 
studies (the Hoorn Diabetes Care System (DCS, n=995) cohort, the Maastricht Study 
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(MS, n=848) and the Cohort of Diabetes and Atherosclerosis Maastricht study (CODAM, 
n=141)) with mean ± SD age 59.7 ± 8.8. Linear regression based associations were tested 
between single plasma metabolites and estimated glomerular filtration rate (eGFR) and 
urinary albumin-to-creatinine ratio (UACR) in each study. Covariate adjustments included 
age, sex, systolic blood pressure, body mass index, medication (lipid-lowering, glucose-
lowering, anti-hypertensive), smoking, diabetes duration, HbA1c, and eGFR or UACR, 
where appropriate. A fixed effect meta-analysis of the 3 study sets was performed. A 
Bonferroni’s correction of pbonferroni = 1.0 × 10
-4 was considered significant.
Results: After adjustment for multiple testing, 82 metabolites associated significantly 
with eGFR while two with UACR. Alteration of several lipoprotein subclasses of VLDL 
and HDL as well as amino acids (phenylalanine, isoleucine and glutamine) and glycoprotein 
acetyls were associated with lower eGFR. Higher UACR levels were significantly 
associated with glycoprotein acetyls and cholesterol esters in very small VLDL.
Conclusions: The current study identifies plasma metabolites associated with 
decreased eGFR and albuminuria among T2D cases of European origin. These findings 
implicate an involvement of lipid and amino acid metabolism in the pathogenesis of DKD.
Funding: Government Support - Non-U.S.
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A Biomarker of Type VI Collagen Formation Is Associated with Diabetic 
Kidney Disease and Is a Risk Factor for Mortality in Elderly Women
Federica Genovese,1 Nadja Sparding,1,2 Morten A. Karsdal,1 Cecilie liv Bager.1 
1Nordic Bioscience, Herlev, Denmark; 2Biomedical Sciences, Faculty of Health 
and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Background: Diabetic kidney disease (DKD) is the leading cause of chronic dialysis 
and accounts for at large proportion of all cases of chronic kidney disease (CKD). Renal 
fibrosis is the hallmark of CKD and is caused by changes in the balance of extracellular 
matrix (ECM) remodeling. Type VI collagen is a crucial ECM molecule for the control of 
tissue organization. In this study, we investigated the association of PRO-C6 (collagen type 
VI formation) with DKD and with mortality in patients with DKD.
Methods: The study population included 5855 postmenopausal women from the 
Prospective Epidemiological Risk Factor Study (PERF) cohort. The women were examined 
at baseline (BL year, 2000) and serum PRO-C6 were measured. The dialysis, diagnosis and 
mortality information were extracted from Danish Health Registries at end of study (2015). 
DKD was defined as eGFR <60 ml/min/1.73m2, dialysis, or a renal diagnose (ICD10). 
Healthy women were defined as women with no history of chronic diseases (ICD10 chapter 
II, IX, X, XI, XIII, XIV). Women with DKD were stratified into quintiles based on BL 
PRO-C6 levels and compared with an ANOVA test. Cox regression was used to explore the 
association with all-cause mortality with 15 years of follow-up.
Results: A total of 75 and 308 women were diagnosed with DKD and diabetes at BL, and 
450 were healthy. Serum PRO-C6 levels were higher in women with DKD (mean=10.7 ng/ml 
(SD=3.7), p<0.0001) and diabetic (mean=8.7 ng/ml (SD=2.7), p=0.004) compared to the 
healthy group (mean= 8.0 ng/mL (SD=3.0)). Levels of PRO-C6 were higher in women 
with DKD compared to the diabetic group (p<0.0001). The women with DKD were older 
(age, 74.6) than the diabetic women (age, 71.3) (p<0.0001), but the effect of age did not 
affect the independent association of PRO-C6 with DKD. Finally, DKD women in the 5th 
quintile of PRO-C6 had an increased risk of all-cause mortality compared to women in the 
3th quintile (HR=2.6 (95% CI=0.9-7.3), p=0.08). The borderline-significance was probably 
due to lack of power.
Conclusions: In this study, we demonstrated that PRO-C6, a biomarker of collagen 
type VI formation, was increased in serum of post-menopausal women with DKD 
compared to women with diabetes without kidney involvement and healthy women. In 
addition, PRO-C6 was associated with mortality in women with DKD.
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The Implications of Immunoglobulin G and Complement 3 in Differentiating 
Nondiabetic Renal Disease from Diabetic Nephropathy in Patients with 
Type 2 Diabetes Mellitus: A Single-Center Study in China
Junlin Zhang. Nephrology, West China Hospital of Sichuan University, Chengdu, 
China.
Background: Heavy proteinuria caused by nondiabetic renal disease (NDRD) is 
common in type 2 diabetes mellitus (T2DM). The aim of this study was to investigate 
specific predictors for NDRD in addition to traditional indicators in T2DM.
Methods: A total of 341 patients with T2DM who underwent renal biopsy were 
retrospectively included. Eligible patients were divided into a nephrotic-range group 
(n=194) and a non-nephrotic-range group (n=147) based on proteinuria level. Risk factors 
for NDRD were evaluated using logistic regression, and the diagnostic implications of these 
variables were assessed by subgroup.
Results: Multivariate logistic regression indicated that reduced serum IgG (OR, 
0.762; 95%CI, 0.628–0.924; p=0.006) was an independent predictor of NDRD in the 
nephrotic-range group. However, in the non-nephrotic-range group, increased C3 level 
was an independent risk factor for NDRD (OR, 1.313; 95%CI, 1.028–1.678; p=0.029). 
In the nephrotic-range group, the optimal cutoff value of IgG for predicting NDRD was 
734.0 mg/dl, with 67.8% sensitivity and 74.8% specificity, and IgG ≤734.0 mg/dl was the 
best predictor of NDRD. In the non-nephrotic-range group, the optimal cutoff value of C3 
for predicting NDRD was 122.0 mg/dl with low sensitivity (30.9%) but high specificity 
(97.8%).
Conclusions: At different levels of proteinuria, reduced IgG and increased C3 levels 
were independent indicators of NDRD in T2DM. Insights into these factors will help to 
advance the clinical management of NDRD.
FR-PO449 Poster Friday
Diabetic Kidney Disease: Clinical - I
Cathepsin D: A Potential Biomarker for Diabetic Kidney Disease
Viktor Drel,1 Tomas Vaisar,2 Jiwan J. Kim,1 Erkka A. Valo,3 Jing Zhang,4 
Tarunveer S. Ahluwalia,5 Janet Snell-Bergeon,6 Peter Rossing,5 Per-
Henrik Groop,3 Loki Natarajan,4 Andrew N. Hoofnagle,2 Ian H. de Boer,2 
Manjula Darshi,1 Kumar Sharma.1 1University of Texas Health San Antonio, San 
Antonio, TX; 2University of Washington, Seattle, WA; 3Folkhälsan Research 
Center, Helsinki, Finland; 4University of California San Diego, La Jolla, CA; 
5Steno Diabetes Center Copenhagen, Gentofte, Denmark; 6University of 
Colorado Denver, Aurora, CO.
Background: Cathepsins are lysosomal proteases that play important roles in a 
wide range of physiological and pathological processes. Recent studies have suggested 
that dysregulation of cathepsin D (Cat D) can lead to development of fibrosis and induce 
apoptosis in the podocytes and tubular cells in acute kidney injury murine models. In the 
current study we analyzed if changes in Cat D are associated with the development and 
progression of diabetic kidney disease (DKD) in type I diabetic mouse models and in 
humans.
Methods: Cat D protein levels in urine were measured by liquid-chromatography mass 
spectroscopy in four diverse cohorts (CACTI, EDC, Finn-Diane, and Steno) with long-
standing type I diabetes and normal kidney function (eGFR≥60ml/min/1.73m2). Subjects 
were classified into slow decliners/controls with eGFR decline ≤1ml/min/1.73m2/yr 
or rapid progressors/cases with eGFR decline of ≥3ml/min/1.73m2/yr. Cat D activity in 
urine samples of patients with established kidney disease (eGFR<40ml/min/1.73m2) and in 
type 1 DKD mouse model (Akita) was measured biochemically. Immunohistochemistry in 
mouse kidney tissues were performed with FFPE embedded kidney sections.
Results: Baseline mean eGFR and median ACR in controls (n=351) and cases (n=270) 
were 91.97 (sd 18.68) and 9.44 (IQR 30), and 98.37 (sd 25.44) and 33.49 (IQR 283.01), 
respectively. Cat D protein levels in urine were significantly elevated in cases as compared 
to controls [mean 1.18 au (1.07-1.3) in controls vs 1.56 au (1.37 to 1.57) in cases, p<001, 
FDR q=0.01). Immunohistochemical analysis identified predominant localization of Cat D 
to tubules in akita kidney sections and increased as compared to controls. Cat D activity was 
significantly elevated in urine (p<0.001) samples of of akita mice (n=6 each WT and akita, 
p<0.001) and in patients with established DKD (n=10 each control and DKD, p<0.0001). 
Cat D activity also correlated significantly (R2: 0.855, p<0.0001) with albumin/creatinine 
in akita mouse urine.
Conclusions: The current data indicate that Cathepsin D may play vital role in the 
pathogenesis of diabetic kidney disease and its level as well as activity in urine can serve as 
biomarker of the diabetic nephropathy.
Funding: Private Foundation Support
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Plasma Endostatin and Kidney Outcomes in Patients with Type 2 Diabetes
Kinsuk Chauhan,1 Girish N. Nadkarni,1 Lili Chan,1 Chirag R. Parikh,2 
Steven G. Coca.1 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Yale 
University and VAMC, New Haven, CT.
Background: Additional biomarkers are needed for prognostication of kidney function 
decline in patients with type 2 diabetes. There are limited data on the association of markers 
of endothelial dysfunction with longitudinal kidney function decline. We assessed the 
association of plasma endostatin, an inhibitor of angiogensesis, and kidney outcomes in two 
settings: a clinical trial and a contemporary clinical cohort.
Methods: We used banked plasma specimens from a nested matched case-control 
study (187 cases:187 controls) in the Action to Control Cardiovascular Disease (ACCORD) 
trial and a diverse cohort of patients with type 2 patients from the EMR and USRDS-linked 
Mount Sinai BioMe Biobank (n=871). We measured endostatin in plasma specimens 
banked from the time of enrollment in ACCORD and BioMe and examined its association 
with a composite kidney outcome of sustained 40% decline in eGFR or ESRD, as well as 
the clinical utility.
Results: Baseline eGFR was 90 ml/min/1.73 m2 in ACCORD and 66 ml/min/1.73 
m2 in BioMe. Baseline plasma endostatin levels were higher for participants that achieved 
the composite kidney endpoint (median 42 ng/ml in 187 ACCORD cases and 45 ng/ml 
in 121 participants reaching the endpoint in BioMe) vs. those without the CKD endpoint 
in both cohorts (median 36 and 38 ng/ml, respectively). Each log2 increment in plasma 
endostatin was independently associated with the kidney outcome in both cohorts (adjusted 
OR 2.5; 95% CI 1.5-4.3 in ACCORD and adjusted HR 2.6; 95% CI 1.8-3.8). Participants 
in the highest quartile (>48 ng/ml in both cohorts) vs. lowest quartile of plasma endostatin 
(< 32 ng/ml in ACCORD and < 31 ng/ml in BioMe) had approximately 4-fold higher risk 
for the kidney outcome (adjusted OR 3.6; 95% CI 1.8-7.3 in ACCORD and adjusted HR 
4.4; 95% CI 2.3-8.5 in BioMe). In BioMe, at a predicted probability threshold of 30% 
using clinical variables (age, sex, BMI, history of CVD,CHF, baseline eGFR, baseline 
mean arterial pressure, and ACEi/ARB usage) plus endostatin, the NPV was 0.90 (95% CI 
0.89-0.91) and the PPV was 0.45 (95% CI 0.37-0.54) for the outcome of composite kidney 
endpoint.
Conclusions: Higher baseline plasma endostatin associated with kidney outcomes 
during follow-up in patients with type 2 diabetes from two diverse cohorts.
Funding: NIDDK Support
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Serum Soluble Tumor Necrosis Factor Receptor 1 (sTNFR1) Associates 
with Decline in Estimated Glomerular Filtration Rate (eGFR) Slope in a 
Phase 2 Study of Selonsertib in Diabetic Kidney Disease (DKD)
Jacqueline Tarrant,1 Andrew Billin,2 Yuanyuan Xiao,1 Matthew Peach,2 
Fang Chen,1 Scott D. Patterson,2 John Sundy,5 Uptal D. Patel,2 Pablo E. Pergola,3 
Glenn M. Chertow.4 1Gilead Sciences, Foster City, CA; 2Gilead Sciences, Inc., 
Foster Cuty, CA; 3Renal Associates, PA, San Antonio, TX; 4Stanford University 
School of Medicine, Palo Alto, CA; 5Gilead Sciences, Inc, Belmont, CA.
Background: Circulating sTNFR1 is a promising biomarker of DKD severity and risk 
of progression. We investigated the disease associations and predictive effect of sTNFR1 
in a Phase 2 study of selonsertib (SEL), a small molecule inhibitor of apoptosis signal-
regulating kinase 1 (ASK1), in DKD.
Methods: In this study, 333 patients with moderate-to-advanced DKD (UACR 600 
mg/g for stage 3a, UACR 300 mg/g for stage 3b, UACR 150 mg/g for stage 4) were 
randomized 1:1:1:1 to receive SEL (2, 6, or 18 mg) or matching placebo (PBO) orally once 
daily for 48 weeks (W48). The analysis population (full analysis set) excluded 2 sites for 
technical deviations and patients with baseline eGFR 20 mL/min/1.73m2. Serum sTNFR1 
was measured at baseline (BL) and W48 by ELISA. Spearman correlation was used to 
assess association between markers, and a random slope model for differences in chronic 
eGFR slope (W4-W48) between treatments.
Results: Serum sTNFR1 was inversely correlated with eGFR at BL (N=261; r=-0.74; 
p<0.001) and at W48 (N=215; r=-0.75; p<0.001), in addition to change of sTNFR1 and 
change of eGFR at W48 (N=215; r=-0.35; p=0.0016). There was no significant relation 
between sTNFR1 and UACR at BL (N=261; r=0.12). We found a trend for a relatively 
lower increase in sTNFR1 from BL to W48 in the 18mg SEL group (median=0.12 ng/
mL, Q1-Q3: -0.43 to 0.53 ng/mL; N=49) compared to PBO (median=0.31 ng/mL, Q1-Q3: 
-0.17 to 0.66 ng/mL; N=49). Applying a BL 4.3 ng/mL sTNFR1 cutpoint retrospectively
(identified by Yamanounchi M, et al. Kidney Int 2017), 51% of our overall population were
potentially at high risk for progression to end stage renal disease. The subgroup >4.3 ng/mL 
sTNFR1 had an apparent therapeutic benefit from SEL 18 mg compared to PBO when 
comparing eGFR chronic slope (W4 to 48) difference (p=0.029), however this was no 
different from the benefit shown overall (p=0.036).
Conclusions: Serum sTNFR1 was directly correlated with eGFR at BL and change at 
W48 in patients with moderate-to-advanced DKD. The subgroup with BL sTNFR1>4.3 ng/
mL had similar treatment benefit to SEL compared to the overall trial population
Funding: Commercial Support - Gilead Sciences
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Serum Soluble CD163 Associates with Estimated GFR and History of 
Ischemic Heart Disease in Adults with Diabetes
Tomas P. Griffin,1,2 Daniel Dempsey,3 Aisling Morrin,3 Md Nahidul Islam,2,4 
Sarah M. Moran,3 Paula M. O’Shea,4 Jason Wyse,3 Mark A. Little,3 
Matthew D. Griffin.2,5 1Centre for Endocrinology, Diabetes and Metabolism, 
Saolta University Health Care Group (SUHCG), Galway University Hospitals, 
Galway, Ireland; 2Regenerative Medicine Institute, at CÚRAM SFI Research 
Centre, School of Medicine, National University of Ireland Galway (NUIG), 
Galway, Ireland; 3Trinity Health Kidney Centre, Trinity College Dublin, Dublin, 
Ireland; 4Department of Clinical Biochemistry, Saolta University Health Care 
Group (SUHCG), Galway University Hospitals, Galway, Ireland; 5Department 
of Nephrology, Saolta University Health Care Group (SUHCG), Galway 
University Hospitals, Galway, Ireland.
Background: CD163 is a scavenger receptor for haptoglobin-haemoglobin complexes 
that is expressed by monocytes/macrophages and undergoes ectodomain shedding into 
blood as soluble CD163(sCD163) in an inflammatory milieu. Activation of monocytes/
macrophages is implicated not only in the pathophysiology of diabetes but also in the 
development of glomerular injury in diabetic kidney disease. The aim of this study was to 
determine the relationships between serum sCD163 and clinical/biochemical parameters in 
a cohort of diabetic patients with a broad range of renal functional parameters.
Methods: A total of 201 adults with diabetes (eGFR[CKD-EPI] range 10-143mL/
min/1.73m2) were recruited to a prospective cohort study. Subjects had serum collected 
at 1-4 timepoints(stored at -80oC). Clinical, anthropometric and biochemical data were 
recorded at each timepoint. Serum sCD163 concentration was quantified using R&D 
ELISA(DY1607). To analyse the longitudinal relationships between relevant clinical/
laboratory parameters and sCD163, a linear mixed model was fitted in R.
Results: Of 23 parameters included in the model, there were significant associations 
between serum sCD163 and eGFR, ALT, diuretic use and history of ischaemic heart 
disease(IHD). The highest value coefficients of association with serum sCD163 were for 
eGFR(negative) and IHD(positive) (Fig 1). Parameters for which no significant association 
was observed included BMI, HbA1c, urine ACR and lipids.
Conclusions: In adults with diabetes, serum sCD163 associated most closely with 
eGFR and IHD. Thus, variation in serum sCD163 among adult diabetic patients may 
reflect, in part, the role of monocyte/macrophage activation in renal and cardiovascular 
complications of diabetes.
Funding: Government Support - Non-U.S.
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Soluble Urokinase Plasminogen Activator Receptor Predicts Kidney 
Function Decline and Mortality in Patients with Type 1 Diabetes
Viktor Rotbain Curovic,1 Simone Theilade,1 Signe Abitz Winther,1 Nete Tofte,1 
Jesper Eugen-Olsen,3 Frederik Persson,1 Tine Hansen,1 Jørgen L. Jeppesen,2 
Peter Rossing.1,2 1Steno Diabetes Center Copenhagen, Gentofte, Denmark; 
2University of Copenhagen, Copenhagen, Denmark; 3Clinical Research Center, 
Hvidovre Hospital, Copenhagen, Denmark.
Background: Soluble urokinase plasminogen activator receptor (suPAR) is an 
important inflammatory biomarker. The predictive qualities of suPAR in relation to 
complications in patients with type 1 diabetes (T1D) are unknown. We investigated the 
prognostic ability of suPAR for the development of decline in renal function, end stage renal 
disease (ESRD), progression in albuminuric status and mortality in T1D.
Methods: 667 patients with T1D and various degrees of diabetic kidney disease 
were included in a prospective study. suPAR was measured with commercial ELISA kits. 
Patients were traced through the National Death Register, the National Health Register and 
electronic laboratory records. Endpoints were: eGFR-decline ≥30%, development of ESRD, 
progression to higher albuminuric status and mortality. Follow-up ranged from 5.2 to 6.2 
years. Results were adjusted for sex, age, LDL cholesterol, HbA1c, systolic blood pressure, 
BMI, smoking status, urinary albumin excretion rate, eGFR, prescribed renin-angiotensin-
aldosterone system inhibitors, and CRP. Hazard ratio (HR) is shown per doubling of suPAR 
and presented with 95% confidence interval (CI). Relative integrated discrimination (rIDI) 
was calculated to assess predictive contribution of suPAR to known risk factors.
Results: Of 667 participants, 368 (55%) were male; mean±SD age was 55±13 years and 
eGFR 88±25 ml/min/1.73m2. Median (interquartile range) of suPAR was 3.4 (2.7-4.5) ng/
ml. There were 93 cases of eGFR-decline ≥30%, 26 cases of ESRD, 36 cases of progression 
in albuminuria and 58 deaths. Adjusted HR (95% CI) for the respective endpoints were
2.96 (1.70-5.16, p<0.001), 2.99 (0.75-11.9; p=0.12), 1.41 (0.60-3.35; p=0.43) and 4.42
(2.05-8.62, p<0.001). rIDI analysis showed contribution of 18.6% (p=0.009) for eGFR-
decline, 5.5% (p=0.29) for ESRD, 1.1% (p=0.68) for progression in albuminuria and 23.8% 
(p<0.001) for mortality.
Conclusions: Higher suPAR level is independently associated with an increased risk of 
eGFR-decline and mortality in patients with T1D. In addition, it is a sizeable contributor in 
the risk stratification of the same based on rIDI. Our results suggest that suPAR may have an 
important role in identifying T1D patients at early risk of kidney function decline and death.
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Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, 
Cardiovascular Event, and Mortality in Patients with Type 1 Diabetes
Sascha Pilemann-lyberg, Tine Hansen, Nete Tofte, Signe Abitz Winther, 
Simone Theilade, Tarunveer S. Ahluwalia, Peter Rossing. Steno Diabetes Center 
Copenhagen, Gentofte, Denmark.
Background: Previous studies have provided inconclusive results to the role of uric 
acid (UA) for risk prediction. Here we aimed to improve power and precision of the 
predictive value of UA for risk of decline in kidney function, cardiovascular event (CVE) 
and mortality in patients with type 1 diabetes (T1D).
Methods: UA was measured in 670 patients with T1D and various degrees of 
albuminuria, ranging from normo- (<30 mg/24 h) to macroalbuminuria (≥300 mg/24 h). 
Patients were traced through national registers to gather data on CVE and mortality. 
Endpoints: mortality, CVE and eGFR-decline of ≥30%. Median follow-up ranged from 
5.1 to 6.2 years. Slope estimates of eGFR and urinary albumin excretion rate (UAER) were 
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calculated for a median of 5.5 years. We applied Cox regressions and linear regression 
models. Adjustment included sex, age, body mass index, HDL cholesterol, smoking, HbA1c, 
mean arterial pressure, UAER, treatment with RAAS blockers and eGFR. Hazard ratio 
(HR) were calculated per doubling of UA and presented with 95% confidence interval (CI). 
Relative integrated discrimination (rIDI) was calculated to assess predictive contribution of 
UA to known risk factors.
Results: Of the 670 patients, 372 (55%) were male, mean ± SD age was 55±13 years 
and eGFR 82±26 ml/min/1.73m2. Median (IQR) uric acid was 5.04 (3.87-6.22) mg/dl. 
Higher UA was associated with higher risk of decline in eGFR of ≥30% (n=89; HR: 3.14 
(1.69-5.82), p<0.001), CVE (n=94; HR: 2.43 (1.31-4.52), p=0.005) and mortality (n=58; 
HR: 2.81 (1.23-6.43), p=0.014) in adjusted analyses. Adding UA to the adjusted model 
including conventional risk factors improved the rIDI by 12.8% for decline in eGFR of 
≥30% (p<0.001), 8.7% for CVE (p=0.008) and 10.8% (p=0.040) for mortality. Higher UA 
was also associated with steeper decline in eGFR (p<0.0014) and steeper increase in UACR 
(p<0.0016) in adjusted analysis.
Conclusions: In T1D, higher UA is associated with higher risk of decline in kidney 
function, CVE and mortality, independently of other risk factors. Our results suggest that 
UA have a promising role in risk stratification among T1D.
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Diagnostic Efficacy of sPLA2R-Ab for Membranous Nephropathy in 
Diabetes Kidney Disease
Qian Wang, Zheyi Dong, Xiangmei Chen, Xiaomin Liu, Weiguang Zhang. 
Chinese PLA General Hospital, Beijing, China.
Background: The pathological types of diabetes kidney disease (DKD) are 
various, among which, membranous nephropathy(MN) accounts for a large proportion 
of non-diabetic renal diseases (NDRD). Serum anti-phospholipidase A2 receptor 
antibody(sPLA2R-Ab) is used for the diagnosis of MN, the diagnostic efficacy of sPLA2R-
Ab for MN in DKD need to be further verified.
Methods: Screened on patients with type 2 diabetes mellitus who underwent a renal 
biopsy and had a valid sPLA2R-Ab test results, hospitalized in the general hospital of the 
people’s liberation army of China between May 1st, 2016 and January 30th, 2018. Eligible 
patients were divided into two groups according to the pathological results: MN group and 
non-MN group. Patients’clinical characteristics and laboratory datas were collected.
Results: The study included 252 patients:59 (23.4%) in the MN group and 193 (76.6%) 
in the non-MN group. The baseline were compared between the two groups: age, history 
of diabetes, creatinine, GFR and blood pressure were statistically significant. MN group 
was older, lower blood pressure, shorter history of diabetes and better renal function than 
non-MN group. The positive value of SPLA2R-Ab was defined respectively as≥20, > 12, 
> 2: sPLA2R-Ab achieved a good diagnostic efficiency with sensitivity of 59.3%, 66.1% 
and 83.1%, specificity of 100%, 98.96% and 93.26%, positive predictive values of 100%, 
95.12% and 79.0%, negative predictive values of 88.9%, 90.52% and 94.74%, and accuracy 
of 90%, 91.27% and 90.87% for MN in DKD respectively.
Conclusions: SPLA2R-Ab has a good diagnostic accuracy for MN in DKD, and the 
positive threshold may be reduced to 12, which can increase the accuracy of diagnosis.
Table1 The diagnostic efficacy of sPLA2R-Ab for MN in DKD
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Urinary Biomarkers of Tubular Injury Predict Renal Progression and 
ESRD in Type 2 Diabetes Mellitus: A Prospective Cohort Study
Pimanong Pooluea,2 Pamila Tasanavipas,2 Amnart Chaiprasert,2 
Theerasak Tangwonglert,1 Naowanit Nata,1 Ouppatham Supasyndh,2 
Bancha Satirapoj.1 1Phramongkutklao hospital, Bangkok, Thailand; 
2Phramongkutklao Hospital, Bangkok, Thailand.
Background: Diabetic kidney disease (DKD) typically evolves over many years. The 
diagnosis, evaluation and treatment are based mainly on biomarkers that assess kidney 
function. New potential tubular biomarkers in DKD could improve risk stratification and 
prediction.
Methods: A prospective cohort study, a total of 257 type 2 diabetic patients were 
included. The baseline values of urine albumin creatinine ratio (UACR), urine Cystatin-C 
to creatinine ratio (UCYS), urine angiotensinogen to creatinine ratio (UANG), urine NGAL 
to creatinine ratio (UNGAL) and urine KIM-1 to creatinine ratio (UKIM) were measured. 
The composite outcome was a rapid glomerular filtration rate (GFR) decline or incident of 
ESRD at 3 year follow-up.
Results: The median follow-up period was 40.8 monthsand the composite outcome 
were noted in 26.1%. Urine tubular biomarkers of UCYS, UANG, UNGAL and UKIM 
were significantly higher among patients with rapid GFR decline or new onset of ESRD. 
Using univariate followed by multivariate COX proportional hazard regression analysis, 
the number of patients reached the composite renal endpoint was higher among those in the 
highest quartiles of UCYS (HR 3.86, 95% CI, 1.95-7.66), UANG (HR 3.93, 95% CI, 1.95- 
7.88) UKIM (HR 3.41, 95% CI, 1.66-7.01) and UNGAL (HR 3.25, 95% CI, 1.58-6.71) than 
in those in the lowest quartiles. In addition, the highest quartile of UCYS, UANG, UKIM 
and UNGAL were associated with a 2.53 to 2.96-fold increased risk of rapid GFR decline 
or ESRD compared with the lowest quartile in adjusted models. All biomarkers predicted 
composite outcome with ROC for UACR = 0.731; 95% CI 0.65-0.81, UCYS = 0.64; 95% 
CI 0.56-0.72, UANG = 0.635; 95% CI 0.55-0.72, UKIM = 0.611; 95% CI 0.53-0.69 and 
UNGAL = 0.598; 95% CI 0.52-0.68. Highest ROC for integrated with UACR, UANG and 
UNGAL = 0.751; 95% CI 0.68-0.82.
Conclusions: The study supported that type 2 diabetic patients with high levels of urine 
tubular biomarkers (Cystatin-C, angiotensinogen, KIM-1 and NGAL) had more incidence 
of ESRD and rapid GFR decline. These tubular biomarkers may be independent predictors 
of the renal progression in DKD.
Funding: Government Support - Non-U.S.
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Clinical Value of Urinary C5b-9 Complement Complex in Overt Diabetic 
Nephropathy
Karyne Pelletier,1 Arnaud Bonnefoy,2 Hugo Chapdelaine,3 Matthieu Lejars,2 
Vincent Pichette,5 Francois Madore,1 Soumeya Brachemi,4 Stephan Troyanov.1 
1Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada; 2CHU Sainte-
Justine, Montréal, France; 3Institut de Recherches Cliniques de Montréal, 
Montreal, QC, Canada; 4Service de néphrologie, CHUM, Montreal, QC, 
Canada; 5Université de Montréal, Montreal, QC, Canada.
Background: Experimental studies support a role of complement activation through 
the lectin pathway in diabetic nephropathy (DN). We evaluated urinary levels of C5b-9 
membrane attack complex (MAC) in patients with overt DN, tested associations with eGFR 
decline, proteinuria and inflammatory biomarkers.
Methods: This is a prospective observational cohort study of patients with overt DN 
followed for 2.1 years (1.6-2.8) from hospitals affiliated with the University of Montreal. 
We obtained repeated measurements of proteinuria, urinary MAC and inflammatory 
biomarkers expressed as urinary creatinine ratios. We also compare levels to patients with 
MGN, FSGS, AAV and IgAN.
Results: The diabetic cohort (n=83) was 80% male. The initial eGFR was 25 ± 9 mL/
min/1.73m2 with an eGFR decline of 2.9 ± 3.0 mL/min/1.73m2/year. The median MAC-to-
creatinine ratio was 1.89 (0.48-10.37) mg/mmol. The highest quartile was associated with 
a rate of decline in renal function of -5.1 ±mL/min/1.73m2/year compared to -2.2 ± 2.6 
(p < 0.001) (Figure 1). Urinary C5b-9 was also associated with inflammatory biomarkers 
and with the proteinuria (Spearman’s rho 0.80, p<0.001). Furthermore, at comparable levels 
of proteinuria, the patients with DN in this study had similar or higher levels of urinary 
MAC than patients with other immunologic glomerulonephritis (n=62).
Conclusions: Complement MAC is present in the urine of patients with overt DN 
and higher levels correlate with a more rapid rate of renal function decline. At similar 
proteinurias, patients with DN had similar or higher levels compared to those with MGN, 
FSGS, AAV and IgAN. These findings support that urinary C5b-9 excretion in DN is not 
solely caused by a passive filtration of plasma C5b-9, but is locally expressed and implicated 
in the pathogenesis of DN.
Funding: Government Support - Non-U.S.
Figure 1. Rate of renal function decline according to urinary C5b-9 quartiles
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Associations of Urinary NGAL and RBP with Nephropathy and Their 
Roles in Normoalbuminuric Renal Insufficiency in T2DM
Hao Zhang,2 Aimei Li,1 Bin Yi,2 Wei Zhang.1 1the Third Xiangya Hospital, 
Central South University, Changsha, China; 2The Third Xiangya Hospital of 
Central South University, Changsha, China.
Background: Diabetic nephropathy(DN)is an important complication of diabetes 
mellitus and has become the leading cause of end-stage renal disease (ESRD) worldwide. 
At present, the diagnosis of DN mainly depends on glomerular filtration rate (GFR) and 
albuminuria, but both of them have limitations. In addition, some patients follow a non-
albuminuric pathway to renal impairment. The aim of this study was to investigate novel 
biomarkers in urine to reflect renal damage in T2DM.
Methods: This is a cross-sectional study recruiting 269 type 2 diabetic patients and 
30 control subjects. Urinary neutrophil gelatinase-associated lipocalin (NGAL), retinol 
binding protein (RBP), plasminogen activator inhibitor-1(PAI-1), vascular cell adhesion 
molecule-1 (VCAM-1), E-cadherin, as well as urinary albumin excretion were measured in 
urine. Glomerular filtration rate (GFR) was estimated via CKD-EPI combined creatinine–
cystatin C equation. The patients were further categorized based on urine albumin/
creatinine ratio (UACR) or eGFR. Their correlations with UACR and eGFR were analyzed. 
Plasma TNF-α, IL-6, ET-1 and 8-OHdG was tested in patients with normoalbuminuria. 
The associations of TNF-α, IL-6, ET-1 and 8-OHdG with eGFR and urinary biomarker 
were analyzed. Sensitivity, specificity, and area under the curve (AUC) were calculated as 
measures of diagnostic accuracy.
Results: It was observed that the levels of urinary NGAL, RBP and PAI-1 were 
significantly elevated and correlated with UACR and eGFR in T2DM. In T2DM patients 
with UACR<30mg/g, plasma TNF-α, IL-6 and 8-OHdG were increased in patients with 
renal insufficiency, and plasma TNF-α and 8-OHdG were negatively correlated with eGFR. 
Urinary NGAL and RBP were statistically elevated in patients with renal insufficiency and 
inversely correlated with eGFR. In addition, urinary NGAL showed a positive correlation 
with plasma TNF-α and 8-OHdG, and urinary RBP showed a positive correlation with 
plasma 8-OHdG.
Conclusions: In conclusion, the results indicate that urinary NGAL, RBP and PAI-1 
may serve as novel biomarkers for the diagnosis of nephropathy in T2DM and urinary 
NGAL and RBP may be promising biomarkers for diagnosing renal impairment in T2DM 
patients with normoalbuminuric.
Funding: Government Support - Non-U.S.
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Urine Metabolites Predict Kidney Function Decline in Type I Diabetic 
Subjects
Manjula Darshi,1 Erkka A. Valo,2 Jing Zhang,3 Jiwan J. Kim,1 Rintaro Saito,4 
Daniel Montemayor,1 Tarunveer S. Ahluwalia,5 Janet Snell-Bergeon,6 
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Background: Diabetes is the most common cause of chronic kidney disease (CKD) 
and end-stage renal failure. Albuminuria and eGFR are widely approved biomarkers to 
identify kidney disease progression. However, due to considerable heterogeneity not 
all subjects progress at the same rate. In the current study, we evaluated a set of urinary 
metabolites toward prediction of rapid progression of CKD in patients with type I diabetes.
Methods: We used a nested case-control study in four diverse cohorts (CACTI, EDC, 
FinnDiane, and Steno) with long-standing type I diabetes and normal kidney function. 
Subjects were classified into slow decliners/controls with eGFR decline ≤1ml/min/1.73m2/
yr or rapid progressors/cases with eGFR decline of ≥3ml/min/1.73m2/yr. Thirty four urine 
metabolites were measured by gas chromatography-mass spectrometry. Logistic regression 
and Random Forest models were used to predict rapid eGFR decline. Area under the curve 
(AUC) were used to assess model performance.
Results: Baseline mean eGFR and median ACR in controls (n=340) and cases 
(n=212) were 91.97 (sd 18.68) and 9.44 (IQR 30), and 98.37 (sd 25.44) and 33.49 (IQR 
283.01), respectively. Analysis with clinical variables revealed age, baseline ACR, and 
baseline eGFR to be significant predictors of rapid decline. Among the metabolites, three 
were univariately associated with rapid decline (FDR p=0.015, 0.025, 0.025). A model to 
predict eGFR decline using clinical variables had an AUC of 0.71 (95% CI 0.63-0.79); no 
significant improvements in AUC were observed with added metabolites. In a stratified 
analysis of eGFR≥60 ml/min/1.73m2 and combined micro- and macroalbuminuria (MA+) 
group, metabolites significantly improved the AUC from 0.69 with clinical variables (0.45-
0.84) to 0.76 (0.61-0.89) when combined with metabolites. Random Forest selected 6 
metabolites as top 7 variables and the metabolites significantly improved the AUC from 
0.61 (0.44-0.76) to 0.75 (0.61-0.89), 95% CI.
Conclusions: In subjects with albuminuria and normal eGFR (≥60 3ml/min/1.73m2) 
clinical variables are not optimal to predict kidney function decline and urine metabolites 
may be useful as prognostic biomarkers for loss of renal function.
Funding: Other NIH Support - Juvenile Diabetic Research Foundation
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Developing Prognostic Models for Kidney Function Decline Based on 
Clinical and Metabolite Profiles in an Albuminuria-Stratified Analysis in 
the CRIC Cohort
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Kumar Sharma,4 Loki Natarajan.1 1Department of Family Medicine and Public 
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Background: There is significant heterogeneity in the rate of kidney function decline 
among Type 2 diabetics, signaling a critical need to better identify patients at high risk of 
rapid kidney function decline. We previously identified a metabolomic signature of chronic 
kidney disease (CKD) using cross-sectional analysis. Metabolomic analysis combined 
with novel statistical methods could provide clinically useful signatures of CKD using 
longitudinal cohorts.
Methods: We studied 1003 Type 2 diabetics with up to 10 years of follow-up. The 
median eGFR decline per year (-1.84 ml/min/1.73m2/yr) cutoff delineated fast vs slow CKD 
progression. An untargeted flow-injection mass spectrometry method was used to assay an 
a priori 16-metabolite set, implicated in mitochondrial dysfunction in CKD. Models for 
fast vs slow decline were built with the 16-metabolite subset and standard clinical variables 
(e.g. age, race, HbA1c, MAP) as predictors. The accuracy (i.e. % of fast and slow decliners 
correctly identified by the model) of clinical-only, metabolite-only, and clinical-metabolite 
statistical models were compared using 5-fold cross-validation. Analyses were stratified by 
albumin/creatinine ratio (ACR): normal (ACR <30 mg/g), microalbuminuria (ACR 30-300 
mg/g), macroalbuminuria (ACR >300 mg/g).
Results: There were significant differences in eGFR decline (p <0.001) between 
albuminuria groups: mean eGFR slopes (ml/min/1.73m2/yr) were -0.43 in normo-, -1.47 in 
micro-, and -3.03 in macro-ACR groups. As expected, study entry eGFR, diabetes control 
(HbA1c) and blood pressure (MAP) were worse (p <0.001) as albuminuria increased. 
Predictive accuracy of models was 84% normo-, 64% in micro-, 82% in macro-groups. 
Given the high accuracy, we further investigated the models for the normo- and macro-
groups. After adjusting for clinical variables, prognostic metabolites were (i) 2-methyl 
acetoacetate for normo-ACR and (ii) pyruvic and homovanillic acids for the macro-ACR 
groups.
Conclusions: The accuracy of the models differed by ACR level. Several a priori 
metabolites predicted CKD progression, and interestingly, prognostic metabolites varied by 
ACR status. Our findings suggest that metabolites may offer insights into CKD progression 
in Type 2 diabetes within albuminuria groups.
Funding: NIDDK Support, Other U.S. Government Support
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Validation of a Systems Biology Derived Urinary Metabolite Panel for 
Prediction of Albuminuria Response to Spironolactone Therapy in Type 2 
Diabetes
Skander Mulder,1 Hiddo J. Lambers Heerspink,1 Paul Perco,2 Robert D. Toto,3 
Michelle Pena.1 1University Medical Center Groningen, Groningen, 
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Background: The mineralocorticoid receptor antagonist spironolactone significantly 
reduces albuminuria in patients with diabetic kidney disease, albeit with a large between 
individual variability. We previously identified a panel of systems biology derived urinary 
metabolites for prediction of albuminuria response to spironolactone therapy.1 Here we 
validate this metabolite panel in an external cohort.
Methods: Data and samples were used from a randomized placebo controlled double 
blind clinical trial.2 Patients with diabetes, hypertension, and albuminuria (urine albumin-to-
creatinine ratio ≥300 mg/g) who all received lisinopril 80 mg/day were randomly assigned 
to placebo (n=23) or spironolactone 25 mg/day (n=20) for 48 weeks. Urine samples were 
obtained at baseline, 24 and 48 weeks, and LC-MS metabolomics measurements were 
performed on the baseline samples. We used leave-one-out cross-validated optimism 
corrected ridge regression to predict albuminuria response to spironolactone.
Results: After 12 weeks of therapy, spironolactone reduced UACR relative to placebo 
by median -57%, with large variability (5th to 95th percentile -136% to +4%). A clear 
separation between the spironolactone and placebo arms was observed in the predicted 
treatment effect by the metabolite panel (Figure). The metabolite panel was able to predict 
albuminuria response to spironolactone (R2 = 0.30, p-value <0.01).
Conclusions: We validated a previously identified panel of 18 urinary biogenic 
amines and organic acids to predict albuminuria response to spironolactone. These results 
suggest that this urinary metabolite panel may be used as a tool to tailor optimal therapy 
in diabetes and move in the direction of personalized medicine. References 1. Pena et al. 
Urinary Metabolomics Predict Albuminuria Response to Spironolactone Therapy in Type 
2 Diabetes. J Am Soc Nephrol 27, 2016: 557A 2. Mehdi et al. J Am Soc Nephrol. 2009 
Dec;20(12):2641-50
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Horizon 2020 research and innovation programme and EFPIA., Government Support - 
Non-U.S.
Diabetic Kidney Disease: Clinical - I
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
540
J Am Soc Nephrol 29: 2018 Poster/Friday
FR-PO462 Poster Friday
Diabetic Kidney Disease: Clinical - I
Increasing Baseline Albuminuria Is Associated with a Continuously 
Increased Risk of Cardiovascular (CV) and Renal Outcomes in the 
LEADER Trial
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Groningen, Groningen, Netherlands; 4KfH Kidney Center, and Friedrich 
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Background: Albuminuria is a known risk factor for CV disease, but the lower limit 
from which it is a risk factor is not well defined.
Methods: We assessed CV and renal outcomes by increasing levels of baseline 
urinary albumin-to-creatinine ratio (UACR) in the LEADER trial. LEADER was a 
randomized, double-blind, placebo-controlled CV outcomes trial of liraglutide up to 
1.8 mg/day vs placebo added to standard care for 3.5–5 years in 9340 patients with type 2 
diabetes and high risk for CV disease. We analyzed the risk of major adverse CV events 
(MACE), expanded MACE, all-cause death, and adjudicated renal events (doubling of 
serum creatinine and estimated glomerular filtration rate ≤45 ml/min/1.73 m2; the need 
for continuous renal-replacement therapy; or death from renal disease) by baseline UACR 
irrespective of treatment group; UACR < lower limit of quantification (LLoQ) (G0; 
n=1598), 0 to <15 mg/g (G1; n=2905), 15 to <30 mg/g (G2; n=1196), 30 to <100 mg/g (G3; 
n=1609), 100 to <300 mg/g (G4; n=845), and ≥300 mg/g (G5; n=960).
Results: The risk of MACE, expanded MACE, all-cause death and renal events 
increased with increasing baseline UACR (Figure), statistically significant for all subgroups 
with UACR ≥30 mg/g compared to G0. Interestingly, in patients at the higher part of the 
normoalbuminuric range (G2), a trend towards increased risk for CV events and all-cause 
death was observed.
Conclusions: In LEADER, baseline UACR≥30 mg/g was associated with increased 
risk of death, and CV and renal events, emphasizing the importance of albuminuria as a 
modifiable risk factor.
Funding: Commercial Support - Novo Nordisk
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Association of Anthropometric Measures of Obesity and CKD in Elderly 
Women Admitted in a Tertiary Care Government Teaching Hospital
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Background: There is growing evidence which suggests that obesity is an important 
contributor to the development of CKD. However, the relationship between obesity and 
CKD is complex and not completely understood, and the best anthropometric index of 
obesity in predicting CKD is controversial. We carried out this study to determine the 
best anthropometric index of obesity in predicting CKD in a population of elderly women 
admitted in RCSM Government Medical College and CPR General Hospital, the only 
tertiary care government teaching hospital in the city of Kolhapur, India.
Methods: We carried out this study for the duration of 3 years from May 2015 to 
April 2018 at our institute. Anthropometric indices of obesity including body mass index 
(BMI), waist circumference (WC), waist-to-height ratio (WheiR) and waist-to-hip-ratio 
(WHR), were obtained in 1706 selected females. Biochemical measurements including 
blood glucose, lipid profile, and 2-h postprandial blood glucose were performed. GFR was 
estimated by using CKD-EPI equation. Adequate statistical tests were carried out and for all 
tests, a p-value <0.05 was considered statistically significant.
Results: The prevalence of CKD stage ≥ 3 was 36.64%. Overweight and obesity was 
found in 54.16% and 34.88% of participants, respectively. Increased central fat distribution, 
as defined by WheiR, WC and WHR, was found in 84.34%, 89.86% and 86.52% 
individuals, respectively. Univariate linear regression analysis showed positive correlations 
between CKD and age (p<0.001), BMI (p<0.0001), WC (p<0.0001), WHR (p<0.005), 
WheiR (p<0.0001), diabetes (p<0.005), as well as triglicerydes (p<0.003); however there 
was a negative correlation between CKD and HDL level (p=0.025). Multivariable analysis 
demonstrated that hypertension, diabetes, WC and WheiR were independent predictors 
of CKD. The area under the receiver operating characteristics curve was best for WheiR 
(0.638), followed by WC (0.619), BMI (0.603), and WHR (0.598).
Conclusions: Abdominal obesity is an important predictor of CKD. Of commonly used 
anthropometric parameters of obesity, WheiR ≥ 0.6 is particularly associated with CKD in 
elderly females. However, the value for these obesity indices is limited in screening CKD 
and further research in this regard is highly encouraged.
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Diabetic Retinopathy Is Associated with Renal Function Deterioration in 
Korean Population with Type 2 Diabetes
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Background: Although both retinopathy and nephropathy are major diabetic 
microvascular complications, a few studies have examined the relationship between retinal 
structural changes and renal functions in patients with diabetes. We investigated whether 
diabetic retinopathy (DR) status has adverse effects on kidney function in patients with 
type 2 diabetes.
Methods: We enrolled 2,139 patients with type 2 diabetes who had undergone fundus 
exam and serial renal function evaluation from August 2006 to February 2014. DR status 
was classified to no DR, non-proliferative DR (NPDR), and proliferative DR (PDR). 
Cox regression analysis was used to evaluate the hazard ratio for renal function decline 
according to DR status.
Results: The mean age of the study participants was 58.3±11.3 years and 1,124 
(52.5%) were women. The mean follow-up period was 3.1±2.9 years. DR was associated 
with the change in estimated glomerular filtration rate (eGFR) and the development of renal 
dysfunction (decreased eGFR〉20%) (no DR group 2.23±24.51; NPDR group -2.82±24.11; 
PDR group -4.82±46.63 mL/min/1.73m2/year, P〈0.001). After adjustments for other risk 
factors, DR was an independent predictor for renal function deterioration (HR 1.917, 95% 
CI 1.470–2.498, P〈0.001). In addition, the progression of DR (new-onset DR or progression 
of DR status) was associated with the change in eGFR (no DR progression group 
0.86±19.77, DR progression group -1.75±14.24 mL/min/1.73m2/year; P〈0.001). After 
adjustments for risk factors, however, DR progression was not an independent predictor 
for renal function deterioration (HR 1.374, 95% CI 0.748–2.523, P=0.305). On the other 
hands, DR was associated with the development of proteinuria during follow-up periods 
(no DR group 6.2%; NPDR group 17.5%; PDR group 30.1%, P〈0.001). Progression of 
DR was also associated with the development of proteinuria during follow-up periods (no 
DR progression group 9.1%; DR progression group 17.1%, P=0.013). Multivariate analysis 
demonstrated that the status of DR as well as eGFR and HbA1c is an independent predictor 
for development of proteinuria.
Conclusions: Our findings showed a strong association between DR and progressive 
renal dysfunction after adjustment for traditional and non-traditional risk factors in Korean 
patients with type 2 diabetes.
Funding: Government Support - Non-U.S.
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Impact of Diabetic Retinopathy and Diabetic Kidney Disease on All-Cause 
and Cardiovascular Mortality
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Background: The relationship between diabetic microvascular complications 
including diabetic retinopathy (DR), and diabetic kidney disease (DKD), and mortality in 
populations are not clear.
Methods: We examined the association between DR, DKD and mortality among 2880 
Chinese, Malay and Indian adults (aged 40-80 years) with diabetes who participated in 
the Singapore Epidemiology of Eye Diseases study (baseline, 2004-2011). Information on 
mortality was obtained by linkage with National Death Registry until May 2017. DR was 
ascertained from retinal photographs and DKD from estimated glomerular filtration rate 
(≤60 ml/min/1.73 m2). Associations of DR and DKD with each outcome separately and 
jointly were examined using multivariate Cox proportional hazards regression models.
Results: Over a median follow-up of 8.8 years, 580 deaths occurred (20.1%) of which 
254 (8.8%) were due to CVD. DR and DKD were significantly associated with all-cause 
and CVD mortality separately and jointly. In joint models including both DR and DKD, 
58.9% had neither DR nor DKD (DR-DKD-), 11.8% had DKD alone (DKD+ DR-), 21% 
had DR alone (DR+ DKD-), and 8.3% had both DR and DKD (DKD+DR+). Beyond the 
background risk (12% and 4.2% in DR-DKD-), excess risk of absolute all-cause and CVD 
mortality were 27.1%, 12.6% in DKD+ DR-, 6.5%, 5.2% in DR+DKD- and 5% and 5.3% in 
DKD+DR+. In multivariable models, compared to DR-DKD-, hazard ratio (95% confidence 
interval) of all-cause and CVD mortality were 1.89 (1.40-2.57), 2.26 (1.42-3.61) for DKD+ 
DR-, 1.38 (1.03-1.86), 1.64 (1.06-2.56) for DR+DKD-; 2.76 (2.05-3.72), 3.41 (2.19-5.32) for 
DKD+DR+. No significant interaction was observed between DR and DKD on additive or 
multiplicative scale for either outcome (all p>0.1).
Conclusions: Our results suggest that risks of all-cause and CVD deaths were 
significantly higher in those with DKD and DR, but DKD largely contributed to the excess 
risk. Our findings emphasize the need for assessing the presence of DR and DKD in diabetic 
populations to assess mortality risk associated with type 2 diabetes.
Funding: Government Support - Non-U.S.
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Masayuki Yamanouchi,1,2 Kengo Furuichi,3 Junichi Hoshino,2 Yoshifumi Ubara,2 
Takashi Wada.1,3 1Department of Nephrology and Laboratory Medicine, Faculty 
of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, 
Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan; 
2Nephrology Center, Toranomon Hospital, Tokyo, Japan; 3Division of 
Nephrology, Kanazawa University, Kanazawa, Japan.
Background: Several cross-sectional studies have recently shown that a proportion 
of patients with type 2 diabetes mellitus develop loss of renal function without overt 
proteinuria or even without microalbuminuria, suggesting the existence of non-proteinuric 
phenotype of diabetic nephropathy. Their clinicopathological characteristics and renal 
prognosis, however, are scarce.
Methods: We retrospectively assessed patients with type 2 diabetes mellitus, who 
underwent clinical renal biopsy from Jan 1, 1985 to Dec 31, 2016 and had follow-up data 
until Dec 31, 2017, from the Japan’s nationwide multicenter renal biopsy registry. Among 
795 patients, we restricted 526 patients with reduced renal function (defined as estimated 
glomerular filtration rate <60 mL/min/1.73m2) and had a pathological diagnosis of diabetic 
nephropathy as the only glomerular disease diagnosis. 88 were non-proteinurics (urine 
albumin to creatinine ratio (UACR) <300 mg/gCre), and 438 patients were proteinurics 
(UACR ≥300 mg/gCre). For comparative analyses, we derived one-to-one paired cohorts 
of those without proteinuria versus those with proteinuria using propensity-score matching 
(matched by age, gender, and baseline eGFR). The primary endpoint was progression of 
CKD defined as new-onset ESRD, decrease of eGFR by ≥ 50%, or doubling of serum 
creatinine.
Results: In the matched analyses (82 patients in each group), patients with non-
proteinuric diabetic nephropathy had lower systolic blood pressure and total cholesterol 
level, higher serum albumin level, and less frequent typical pathological lesions. After a 
median follow-up of 3.0 years (IQR 1.0-6.6) from the date of renal biopsy, 65 (40%) of the 
164 matched patients had renal events. The 5-year CKD progression-free survival for all 
patients was 63.3% (95% CI, 53.3-71.7): 86.7% (95% CI, 72.5-93.8) for the non-proteinuric 
diabetic nephropathygroup and 43.2% (95% CI, 30.2-55.6) for the proteinuric diabetic 
nephropathygroup (log-rank test p<0.001). The lower renal risk in non-proteinuric diabetic 
nephropathy group was consistent across all subgroup analysis.
Conclusions: Patients with non-proteinuric diabetic nephropathy had lower blood 
pressure and less typical morphological changes, and were at lower risk of CKD progression.
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Background: Regardless of the causes of renal diseases, proteinuria is the strongest 
predictor of renal prognosis among clinical parameters. Diabetic kidney disease (DKD) 
patients are rarely examined by renal biopsy. Determination of the histological lesions that 
are responsible for proteinuria in DKD will be useful for the future research to identify the 
intervention to the specific lesions.
Methods: This is a serial cross-sectional study of 347 adults with biopsy-proven 
diabetic nephropathy (DN) from 1981 to 2014. Predictors were histological findings in 
renal pathology and outcome variable was proteinuria. DN was evaluated by two renal 
pathologists according to 9 glomerular lesions; mesangial expansion, exudative lesion, 
nodular sclerosis, microaneurysm, duplication of the basement membrane, perihilar 
neovascularization, glomerulomegaly, global sclerosis, and segmental sclerosis, 2 
tubulointerstitial lesions; interstitial fibrosis tubular atrophy (IFTA) and inflammatory cell 
infiltration, and 2 vascular lesions; arteriolar hyalinosis and intimal thickening of large 
artery. In addition to histological findings, age, sex, body mass index, estimated glomerular 
filtration rate (eGFR), systolic blood pressure and use of renin-angiotensin system blockers 
were used for adjustment. Statistical analyses were performed using multivariate general 
linear model and two-way analyses of covariate and variance.
Results: Hypertension and diabetic retinopathy were observed in 65% and 46% of 
patients, respectively, with mean age of 58 ± 11. Median level of proteinuria at the time 
of renal biopsy was 0.50 g/day (25th and 75th percentile: 0.20 and 2.7 g/day) and mean 
eGFR was 62.4 ± 32.6 mL/min/1.73m2. Twelve out of thirteen histological lesions were 
significantly correlated with each other and proteinuria levels. However, after multivariate 
adjustment nodular sclerosis and IFTA remained significant predictors for proteinuria levels. 
Two-way analyses of covariate and variance showed that IFTA and glomerular lesions had a 
synergetic effect on increased multivariate adjusted proteinuria levels.
Conclusions: Nodular sclerosis and IFTA were significant predictors of proteinuria 
levels and had a synergetic effect on increased proteinuria in DN patients. These two lesions 
might be relevant targets for developing new therapy in DKD patients.
Funding: Government Support - Non-U.S.
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Comparison of Renal Outcomes Between Diffuse and Nodular Diabetic 
Nephropathy: A Meta-Analysis
Qiqi Feng,1 Jialing Rao,2 Weiyan Lai.1 1The Third Affiliated Hospital of Sun Yat-
sen University, Guangzhou, China; 2The Third Affiliated Hospital of Sun Yet-sen 
University, Guangzhou, China.
Background: The diffuse (DIF) type and the nodular (NOD) type of glomerulosclerosis 
have long been recognized as the pathological characteristics of diabetic nephropathy (DN). 
However, the relationship between pathological changes and renal outcomes is not fully 
elucidated so far. The present meta-analysis was designed to compare the renal outcomes 
between the two pathological types of DN.
Methods: We reviewed relevant studies that compared the renal outcomes between 
DIF and NOD in Medline, Embase, Cochrane Library, CNKI and other sources from 1950 
to 2015.
Results: Of 3615 citations identified, only four retrospective cohort studies involving 
596 patients were included in the meta-analysis. Pooled analysis of relative risk (RR) in 
the fixed-effects model showed that NOD had higher risk for developing ESRD than DIF 
did (RR 1.86, 95%CI 1.28-2.70, P = 0.001, P for heterogeneity = 0.12, I2 = 48%). The 
sensitivity analysis showed that the heterogeneity among studies was decreased when 
studies with type 1 diabetic patients were excluded (P for heterogeneity = 0.34, I2 = 0%).
Conclusions: The present meta-analysis revealed that renal outcomes were closely 
related to pathological changes of DN, and NOD had higher risk for developing ESRD 
than DIF.
Fig. 1 Comparison of renal outcomes between the diffuse (DIF) type of diabetic nephropathy 
and the nodular (NOD) type
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Assessment of the Relationship Between the 2010 Pathologic Classification  
and Renal Outcomes in Patients with Diabetic Nephropathy: A 
Meta-Analysis
Qiqi Feng,1 Tan-qi Lou.2 1The Third Affiliated Hospital of Sun Yat-sen University, 
Guangzhou, China; 2The Third Affiliated Hospital of Sun Yat-Sen University, 
Guangzhou, China.
Background: The pathologic classification for diabetic nephropathy (DN) established 
by the Renal Pathology Society in 2010 has received extensive attention. However, its 
relationship with renal prognosis requires further study.
Methods: Original cohort studies were identified by searching PubMed, Embase, the 
Cochrane Library, CNKI and other resource. Hazard ratios (HRs) were pooled using the 
RevMan 5.3 software.
Results: Of the 1549 relevant articles, six retrospective or prospective cohort studies 
with a total of 803 participants were finally included in the meta-analysis. The pooled HRs 
revealed that the risks for renal end-points of Class I and IIa were obviously lower than 
those of Class IIb, III and IV, and in turn, the risks of Class IIb and III were lower than that 
of Class IV. But there were no significant differences between Class I and IIa, and between 
Class IIb and III. The pooled HRs for tubular, interstitial and vascular changes showed 
that interstitial fibrosis and tubular atrophy (IFTA) and interstitial inflammation were 
significantly correlated to renal outcomes while arteriolar hyalinosis and arteriosclerosis 
were not (Table 1). Subgroup analyses and sensitivity analyses indicated that different types 
of diabetes generated heterogeneity.
Conclusions: The present meta-analysis revealed that 1) the glomerular classes were 
not completely associated with renal prognosis in that the renal outcomes were benign in 
Class I and IIa, moderate but similar in Class IIb and III and severe in Class IV; 2) the 
tubular and interstitial lesions were independent variables associated with renal outcomes 
while vascular changes were not.
Table 1 Results of statistical pooling
Note: interstitial fibrosis and tubular atrophy, IFTA; *P<0.05, **P<0.01.
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Diabetic Fibrillosis, Not an Uncommon Entity: A Case Series
Sree bhushan Raju. NIMS, Hydrabad, India.
Background: Diabetic Fibrillosis (DF) is a rare glomerular abnormality detected in 
electron microscopy as random nonbranching fibrillary deposits in mesangium. There are 
few case reports available related to this entity and we report a case series of this interesting 
association.
Methods: We reviewed all the cases of type 2 diabetic patients who underwent renal 
biopsy for various indications in last one year (April 2017 to march 2018). Cases which 
were reported as DF in electron microscopy were collected. Clinical course, investigation 
reports and biopsy findings were analysed.
Results: DF was reported in 5 (3.7 %) out of 134 cases of diabetic nephropathy. The 
mean age was 55.6±.6 years (46-65). All five had both hypertension and diabetes. Mean 
duration of diabetes was 12± 2.7years. All five had increased serum creatinine with mean 
of 6.9±3.5 mg/dl. Three patients had nephrotic and two had subnephrotic range proteinuria 
(mean 3±1.3 g/day). Autoimmune and myeloma workup was negative. Light microscopy 
showed diabetic nephropathy class IV with arteriolar hyalinosis in all 5 cases. The 
Immunofluorescence and congo red stain was negative in all. GBM thickening is seen in all 
cases with mean thickness ranging from 426 to 714 nm. Random non branching fibrillary 
deposition is seen in mesangium of all cases. No spherular microparticles or tubuloreticular 
inclusions were seen.
Conclusions: diabetic fibrillosis is not an uncommon entity with a prevalence of 3.7 % 
in our case series. The clinical significance of this entity is yet to be determined. The 
observations made in this series needs to be elicited with a larger series of cases to know the 
impact on long term kidney function.
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Renal Biopsy in Diabetic Patients: Preliminary Results of the Spanish 
Multicenter Study BIODIAB-GLOSEN-GEENDIAB
Sheila Bermejo,1,2 Noemí Esparza,4 Marian Goicoechea,5 Meritxell Ibernon,6 
Tania Linares,7 Ana Coloma,3 Adoración Martin,8 Rosa Garcia Osuna,9 
Montserrat M. Diaz Encarnacion,10 Nuria Garcia-Fernandez,11 Nadia Martin 
Alemany,12 Katia Lopez-Revuelta,13 Sandra Elias,14 Irene Agraz,15 Julio Pascual,16 
Manuel Praga,17 Xavier Fulladosa,18 Maria Jose Soler.19 GLOSEN, GLOMCAT, 
GEENDIAB 1Parc de Salut Mar, Barcelona, Spain; 2Fundació Althaia, Manresa, 
Spain; 3Hospital San Pedro, Logro?o, Spain; 4Hospital Universitario Insular de 
Gran Canaria, Las Palmas, Spain; 5Hospital General Universitario Gregorio 
Marañon, Madrid, Spain; 6Hospital Sant Joan Despí Moises Broggi, Sant Joan 
Despí, Spain; 7Hospital Gregorio Marañón, Madrid, Spain; 8Agencia Sanitaria 
Hospital de Poniente, Ameria, Spain; 9Hospital De Dalamos, Palamos, Spain; 
10Fundación Pugvert, Barcelona, Spain; 11Clinica Universidad de Navarra, 
Pamplona, Spain; 12University Hospital Dr. Josep Trueta, Girona, Spain; 
13Hospital Universitario Fundación Alcorcón, Alcorcon - Madrid, Spain; 
14Hospital Universitario Ramón y Cajal, Madrd, Spain; 15Hospital valle 
d’Hebron, Barcelona, Spain; 16Hospital del Mar, Parc de Salut Mar, Barcelona, 
Spain; 17Hospital 12 de Octubre, Pozuelo De Alarcon, Spain; 18Hospital 
Universitari De Bellvitge, L’Hospitalet de Llobregat, Spain; 19Parc de Salut Mar. 
Fundació IMIM, Barcelona, Spain.
Background: The diabetic patient with kidney disease has a high prevalence of non-
diabetic nephropathy(NDN) and the renal and patient survival in relation to the presence 
of diabetic nephropathy(DN) or NDN has not been widely studied. The objectives of the 
study are: to determine the capacity of the clinical and analytical data in the prediction in 
the histological result(DN or NDN) and to find differences in renal and patient survival.
Methods: Spanish retrospective descriptive multicenter study of the pathological result 
of biopsies performed in diabetic patients in 2002-2014.
Results: 16 centers participated including 692 patients:511 men(73.8%), 
mean age of 62±12years, evolution of diabetes mellitus 10.5(3.7-15.3)years, serum 
creatinine 2,8±2,2mg/dl, glomerular filtration rate MDRD-4 of 37,7±26.8mL/
min/1,73m2, glycosylated hemoglobin 7±1,7% and proteinuria of 3.91(1.1-5)gr/24h. 
40.6% of patients had DN,48.6%NDN and 10.8%ND plus NDN. The most frequent 
NDN was nephroangiosclerosis(12.7%). Multivariate logistic regression analysis: 
age(OR1,026,1,003-1,033,p=0.021), microhematuria(OR 1.523,1.047-2.214,p=0.028), 
creatinine(OR:1,149,1,045-1,164,p=0.004) and diabetic retinopathy (DR)(OR0.434,0.311-
0.604p<0.001) were independently associated with NDN. We obtained the ROC curve 
model:(95% CI):0.683(0.636-0.731). 35.2%(n=184) of patients needed renal replacement 
therapy(RRT),47.3% of them presented DN,38.6% NDN and 14.1% DN and NDN. The 
overall mortality of the studied patients was 18.7%(n=98), of them 42% presented DN,46% 
NDN and 12% DN and NDN. In the analysis of survival with Kaplan-Meier curves: Patients 
with DN or DN+NDN presented worse renal prognosis than NDN patients(p<0.001). In the 
multivariate analysis of Cox adjusted by confusing variables, DN was confirmed as a risk 
factor for RRT.
Conclusions: The most frequent NDN is nephroangiosclerosis. Elder patients with 
microhematuria, worse renal function and absence of DR are high risk for NDN. DN has 
worse renal prognosis than NDN. The histological diagnosis of renal involvement in the 
diabetic can facilitate an effective treatment and an improvement in the renal prognosis.
Funding: Government Support - Non-U.S.
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Activation of the Free-Fatty Acid Receptor GPR40 Improves Anemia in 
Mouse Models of Kidney Disease via a Novel EPO-Independent Mecha-
nism of Action
Jean-Francois Thibodeau,1,3 Chet E. Holterman,3 Pierre Laurin,1 
Richard L. Hébert,2,3 Chris R. Kennedy,2,3 Brigitte Grouix,1 Lyne Gagnon.1 
1Prometic Biosciences Inc., Laval, QC, Canada; 2Department of Cellular and 
Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, 
Canada; 3Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, 
ON, Canada.
Background: The prevalence of anemia increases with the progression of chronic 
kidney disease (CKD) and leads to reduced quality of life and increased cardiovascular risk. 
Yet, the use of erythropoiesis stimulating agents is associated with negative outcomes in 
CKD patients. Here we present an alternative pathway for the treatment of anemia secondary 
to kidney disease through activation of GPR40, in mediating in vitro stimulation of bone 
marrow cells, particularly the colony-forming-unit-erythrocytes (CFU-E) generation; and 
the anti-anemic effects of PBI-4050 in models of renal injury.
Methods: In vitro, murine bone marrow cells were assayed for CFU-E in the presence 
or absence of PBI-4050 (agonist of GPR40) and/or GW1100 (GPR40 antagonist). PBI-
4050 was tested in ischemia-reperfusion (IR) AKI in WT mice. In addition, we used an 
adenine-induced CKD model whereby male wild type (WT) and GPR40-/- mice were fed 
a diet supplemented with 0.25% adenine for one week and treated for three weeks with 
PBI-4050 (200 mg/kg).
Results: PBI-4050 increased the formation of CFU-E in a GPR40 dependent manner 
as GW1100 blocked this increase. In addition, GPR40 antagonism led to a significant 
decrease in CFU-E counts. Furthermore, PBI-4050 showed comparable activity to EPO 
regarding CFU-E count. After 14 days following IR-AKI, PBI-4050 maintained hematocrit. 
In adenine-CKD mice, Hct, Hb and mean corpuscular volume were significantly decreased 
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in CKD-mice, while PBI-4050 maintained these levels and led to significantly higher 
plasma erythropoietin levels. In parallel, signs of anemia were present to similar degrees 
in both untreated WT and GPR40-/- mice. Interestingly, PBI-4050 treatment in adenine-fed 
GPR40-/- mice failed to improve Hct levels.
Conclusions: Taken together, our data suggest treatment of anemia through a novel 
alternative pathway which is EPO-independent. Treatment with PBI-4050 may provide 
therapeutic benefit by maintaining adequate Hct and Hb levels, while also improving renal 
and cardiovascular outcomes.
Funding: Commercial Support - Prometic Life Sciences Inc.
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Fludrocortisone Stimulates Erythropoietin (Epo) Protein Expression in 
the Distal Tubules of Mouse Kidney
Yukiko Yasuoka,3 Tomomi Oshima,3 Yuichiro Izumi,2 Yuichi Sato,4 
Noriko Takahashi,3 Hiroshi Nonoguchi,1 Katsumasa Kawahara.3 1Kitasato 
University Medical Center, Kitamoto, Japan; 2Kumamoto University, Kumamoto, 
Japan; 3Kitasato University, School of Medicine, Sagamihara, Japan; 4Kitasato 
University, School of Allied Health Sciences, Sagamihara, Japan.
Background: Although normal plasma Epo concentration is very low, Epo mRNA was 
expressed in the kidney tubules under normal condition (Nagai, Yasuoka, et al, 2014). We 
further showed that fludrocortisone, an aldosterone receptor agonist, stimulated Epo mRNA 
expression in the distal nephron (Yasuoka, et al, ASN 2017). In this study, we investigated 
the localization of Epo protein-producing cells in the kidney and liver after fludrocortisone 
injection.
Methods: Fludrocortisone (2.5 mg/100 g BW) or Angiotensin II (0.5 μg/100 g BW) 
was once applied to mice (C57BL/6J, male, 10 weeks). After 2, 4, 6 and 72 hr, kidneys were 
examined by Western blot and immunohistochemistry using anti-Epo antibodies.
Results: Under normal (basal) conditions, Epo staining was widely found along the 
nephron (proximal tubules < thick ascending limbs < collecting ducts). Fludrocortisone 
significantly increased Epo production in the medullary thick ascending limb, and cortical 
and outer medullary collecting ducts, particularly in type A of intercalated cells after 4-6 hr. 
Western blot showed that Epo protein expression was increased by 5-fold in the kidney but 
not changed in the liver. Angiotensin II stimulated Epo mRNA expression in proximal and 
distal tubules but not in the interstitial cells. Epo staining decreased to the basal level after 
72 hr, but was not detected in the interstitial cells.
Conclusions: Renin-angiotensin-aldosterone system regulates Epo production by the 
nephron.
Funding: Government Support - Non-U.S.
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Enarodustat (JTZ-951), an Oral HIF-PH Inhibitor, Stabilizes HIF-α 
Protein and Induces Erythropoiesis with Hardly Influence the Function of 
Vascular Endothelial Growth Factor
Kenji Fukui, Yuichi Shinozaki, Hatsue Kobayashi, Katsuya Deai, 
Hiromi Yoshiuchi, Akira Matsuo, Mutsuyoshi Matsushita. Biological and 
Pharmacological Research Laboratories, Central Pharmaceutical Research 
Institute, Japan Tobacco Inc., Osaka, Japan.
Background: Renal anemia is principally caused by decreased erythropoietin (EPO) 
production in the kidney due to renal dysfunction. The production of EPO cannot be 
increased in response to hypoxia in the chronic kidney disease (CKD) kidney. The EPO 
production is regulated by hypoxia-inducible factor (HIF) -α, and it was hydroxylated by 
HIF-prolyl hydroxylase (PHD) and degradated by the ubiquitin-proteasome system. Several 
PHD inhibitors, including enarodustat are under clinical trials as treatment for renal anemia.
Methods: The enzyme inhibitory activity in human PHD enzymes was investigated 
by HTRF assay system. The expression of HIF proteins, EPO mRNA levels, and EPO 
proteins were evaluated by Western blotting, qPCR, and ELISA, respectively. Normal rats 
and 5/6-nephrectomized rats were used in in vivo experiment.
Results: Enarodustat had inhibitory effects on human PHD 1-3, but had no inhibitory 
effects on various receptors or enzymes. In Hep3B cells, enarodustat increased HIF-1α 
and HIF-2α protein levels, EPO mRNA levels, and EPO production. In normal rats, after 
a single oral dose of enarodustat, the plasma concentrations of enarodustat reached Cmax 
by one hour after administration, and then decreased rapidly. The liver and kidney EPO 
mRNA levels and plasma EPO concentrations also increased, and then both decreased 
by 24 hours. In 5/6-nephrectomized rats, repeated oral doses of enarodustat once daily 
showed the erythropoiesis stimulating effect in proportion to the doses from 1 mg/kg. The 
administration of enarodustat at the high dose (over 30 mg/kg) increased plasma vascular 
endothelial growth factor (VEGF), however, retinal VEGF mRNA levels and the retinal 
vascular permeability were not changed. Finally, we evaluated the effect of enarodustat in 
the colorectal cancer cell-inoculated mice model. Although enarodustat dosing at the high 
dose increased the plasma VEGF, it showed no effect on the tumor growth.
Conclusions: Enarodustat stabilizes HIF-α protein and induces erythropoiesis with 
hardly influence the unexpected function, and it is expected to become a new orally drug 
that can maintain the hemoglobin concentrations in CKD patients with renal anemia.
Funding: Commercial Support - Japan Tobacco Inc.
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A Dose-Dependent Biphasic Effect of HIF Stabilizer (MK-8617) on Renal 
Fibrosis
Zuolin Li,1 Linli Lv,1 Jialing Ji,2 Tao-Tao Tang,1 Cao Jingyuan,1 Bi-Cheng Liu.1 
1Zhong Da Hospital, Southeast University, Nanjing, China; 2Nanjing Medical 
University, Nanjing, China.
Background: HIF stabilizer is a novel drug for renal anemia. Previous clinical trials 
have demonstrated HIF stabilizer could elevate hemoglobin (Hb) levels effectively in CKD 
patients. As a critical transcription factor, HIF has been involved in regulating hundreds of 
genes, which raised too much concern by clinician for its potential adverse effect. Here we 
firstly demonstrated the dose dependent biphasic effect of MK-8617(HIF stabilizer, Selleck) 
on renal fibrosis.
Methods: CKD-anemia model was induced by in mice undergoing 5/6 nephrectomy 
(5/6Nx). 5/6Nx mice were treated with MK-8617 orally at low dose (1.5mg/kg/d, group 
A), middle dose (5mg/kg/d, group B) and high dose (12.5mg/kg/d, group C) for 12weeks 
respectively. The 5/6Nx mice not treated with MK-8617 served as Ctrl group.
Results: Hb level was significantly elevated in all three groups with MK-8617 
treatment for 12 weeks compared with that in Ctrl group. However, Hb level in group C 
was lower than that of the other two groups. Compared with the Ctrl group, the Scr and 
BUN were significantly decreased in group A and B respectively. It is of note that there 
was no significant reduction of Scr and BUN in group C. The VEGF mRNA and protein 
expression were significantly increased in both remnant kidney and liver in mice with 
Group C, but not in group A & B. However, the number of glomerular endothelial cells was 
significantly decreased in group C. More impressively, mice in group C showed a serious 
renal fibrosis with macrophage infiltration, but in contrast, mice in group A & B showed the 
attenuation of renal fibrosis compared to the Ctrl group. Furthermore, we identified there 
was a transdifferention of macrophage to myofibroblast in group C.
Conclusions: Although the significant improvement of renal anemia with MK-8617 
in 5/6Nx mice, the dose dependent biphasic effect on renal fibrosis has been found, which 
implied that cautious should be taken when long term use this kind of drug to treat renal 
anemia, specifically when the dose is high. And the exact mechanism is also to be clarified.
Funding: Government Support - Non-U.S.
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Hypoxia Increases Erythrocyte Death Rate and Oxidative Stress Induced 
by Indoxyl Sulfate
Andrea N. Moreno-Amaral,1 Gabriela F. Dias,1 Sara S. Tozoni,1 Natalia Borges 
Bonan,4 Roberto Pecoits-Filho,2 Peter Kotanko.3 CARe - CKD Anemia Research 
Group 1Pontifícia Universidade Católica do Paraná, Curitiba, Brazil; 
2Pontificia Universidade Catolica do Parana, Curitiba, Brazil; 3Renal Research 
Institute, New York, NY; 4PUC-PR, CURITIBA, Brazil.
Background: Prolonged intradialytic hypoxemia has been associated with higher 
erythropoietin requirements and poor clinical outcomes in dialysis patients. We analyzed 
the erythrocyte (RBC) response to indoxyl sulfate under hypoxic conditions.
Methods: RBC from 10 healthy subjects were incubated for 24h with buffer (CON-
RBC) or IS (0.01; 0.09; and 0.17 mM) in normoxia (22% O2) or hypoxia (5% O2) 
conditions. Flow cytometry was used to determine: a) Eryptosis by phosphatidylserine 
exposure (PS) (by Annexin-Phycoerythrin) and intracellular Ca2+influx (by Fluo-3AM), b) 
reactive oxygen species (ROS) production (by DCFH-DA probe) and reduced glutathione 
(GSH) content (by ThiolTracker Violet).
Results: Eryptosis increased in an IS dose-dependent manner in both normoxia and 
hypoxia, but the effect was more pronounced with hypoxia (Table 1). Similarly, IS exposure 
increased ROS production and decrease GSH content in an IS dose-dependent manner, and 
the response was also amplified by hypoxia (Table 1).
Conclusions: IS exposure increased eryptosis and oxidative stress and, this effect 
was amplified by hypoxia. These results suggest that the eryptotic effect of uremia may 
be aggravated by hypoxia. This may represent a novel mechanism in the development of 
renal anemia.
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Inflammation Contributes to Anemia of CKD Through Both Iron and 
HIF/EPO-R Pathways
Daniel Landau,1,2 Inbar Bandach,4 Yael Segev.3 1Tel Aviv University, Petach 
Tikva, Israel; 2Pediatrics B, Schneider Children’s Medical Center, Petach Tikva, 
Israel; 3Ben Gurion University, Beer-Sheva, Israel; 4Microbiology and 
Immunology, Ben Gurion University, Beer Sheva, Israel.
Background: Anemia of chronic kidney disease (CKD), originally thought to be due 
to impaired renal erythropoietin (EPO) synthesis as well as iron malabsorption, may also be 
due to EPO resistance, clinically associated with inflammation. The key pro-inflammatory 
cytokine Interleukin (IL-1) is normally controlled by a receptor antagonist (IL1Ra). IL1Ra-
KO (RaKO) mice show arthritis and excessive inflammation. The aim of this study was to 
characterize the anemic state of RaKO mice with adenine induced-CKD.
Methods: Wild-type (WT) and RaKO mice were fed with 0.2% adenine or control 
diets, leading to 4 groups: WT, WT-CKD, RaKO, RaKO-CKD. Mice were sacrificed after 
10 weeks. For a control model of anemia (CA), WT mice were bled every two days for a 
week.
Results: Higher levels of S-creat and histologic kidney inflammation were seen in 
RAKO-CKD Vs WT-CKD. Kidney IL-6 and phospho-STAT3 were increased in both CKD 
groups, especially in RAKO-CKD. Arthritis, associated with increased liver CRP, was 
more accentuated in RAKO-CKD Vs RaKO. Hct levels were decreased in CKD groups, 
especially in RAKO-CKD. The response to bleeding induced anemia (CA) included: no 
evidence for inflammation, low liver hepcidin, elevated renal HIF2 and increased EPO 
controlled bone marrow (BM) EPO-R and transferrin receptor (TFR). Serum iron and MCV 
levels were significantly reduced in both CKD groups and were even lower in RAKO-CKD 
Vs WT-CKD. Liver hepcidin mRNA levels were increased in RAKO-CKD in comparison 
to all other groups. Serum EPO levels were not increased. Renal HIF2 and BM EPO-R 
mRNA levels were significantly decreased in both CKD groups, especially in RAKO-CKD.
Conclusions: Exaggerated arthritis and inflammation were associated with higher 
degree of renal insufficiency and anemia in RAKO-CKD Vs WT-CKD. In addition to the 
well-known hepcidin mediated decreased iron absorption, the normal response to anemia 
induced hypoxia is deranged in CKD and even more accentuated when inflammation is 
increased in CKD-RaKO: renal HIF2 and EPO, BM EPO-R and TFR are not upregulated, 
which further exacerbate anemic tendency. Altogether, this supports the key role of 
inflammation in CKD-associated anemia. Novel treatments to reduce inflammation may 
attenuate the anemic state or increase the response to exogenous EPO.
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Hypervitaminosis A Contributes to Abnormal Iron Metabolism in CKD
Serina Kabutoya,1 Masashi Masuda,2 Yuichiro Adachi,2 Yilimulati Yimamu,1 
Hisami Okumura,3 Hironori Yamamoto,4 Yutaka Taketani.3 1Tokushima 
university, Tokushima, Japan; 2Tokushima University, Tokushima, Japan; 
3University of Tokushima, Tokushima, Japan; 4Dept. of Health and Nutrition, 
Jin-ai University, Echizen city, Fukui, Japan.
Background: Anemia is the major features of chronic kidney disease (CKD). Hepcidin 
(HAMP) is the principal iron regulatory hormone and its overproduction contributes to 
anemia. HAMP blocks iron fluxes to the blood by degradation of the iron exporter ferroportin 
(FPN) at the plasma membrane of macrophages. It has been reported plasma vitamin A 
and its metabolites, all-trans retinoic acid (ATRA), are increased in CKD patients. Several 
reports showed both hypervitaminosis A and vitamin A deficiency (VAD) results in iron 
deposition in the liver and reduces serum iron levels in rats, which suggests an inappropriate 
vitamin A levels may affect iron metabolism disorder. However, the molecular mechanism 
behind the regulation of iron metabolism by ATRA have been unclear. In this study, we 
investigated whether hypervitaminosis A can be involved in abnormal iron metabolism in 
CKD and its molecular mechanism.
Methods: Five-week-old male C57BL/6J mice were treated 5/6 nephrectomy 
operation to induce CKD and they were fed VAD diet for nine weeks. Iron deposition of 
tissues was evaluated by Berlin blue stain. Gene expressions were evaluated by RT-PCR, 
Western blotting.
Results: Berlin blue stain showed VAD diet did not affect hepatic iron deposition, 
but reduced hepatic HAMP protein levels in CKD mice. Furthermore, VAD decreased 
the expression of hepatic p-STAT3 protein, transcription factor which activates HAMP 
transcription, in CKD mice. In spleen, VAD inhibited iron deposition and increased FPN 
mRNA levels in CKD mice. To understand the more detailed mechanism of abnormal iron 
metabolism by hypervitaminosis A, we evaluated iron-related gene expression in response 
to ATRA in vitro. The expression of HAMP mRNA and protein were increased by ATRA 
in HepG2 cells. Ro 41-5253, RAR antagonist, reduced HAMP mRNA levels increased by 
ATRA in HepG2 cells. Both ATRA and TTNPB, RAR agonist, increased p-STAT3 protein 
levels in HepG2 cells. Finally, we investigated whether VAD-increased splenic FPN mRNA 
expression in CKD was not only via HAMP action but also a direct action of ATRA. 
Interestingly, ATRA reduced the levels of FPN mRNA and protein in Raw264 cells.
Conclusions: We suggest CKD-induced hypervitaminosis A may contribute to 
abnormal iron metabolism through the indirect regulation of hepatic HAMP and the direct 
regulation of splenic FPN.
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Ferric Carboxymaltose Restores Iron Status and Transiently Increases 
FGF23 in a Mouse Model of Iron Deficiency
Maralee Capella,1 Claire Gerber,1 Guillaume Courbon,1 Samantha Neuburg,1 
Connor Francis,3 Corey Dussold,1 Xueyan Wang,1 Lixin Qi,1 Myles Wolf,2 
Aline Martin,1 Valentin David.1 1Northwestern University - Feinberg School of 
Medicine, Chicago, IL; 2Duke University, Durham, NC; 3University of Florida 
College of Medicine, Gainesville, FL.
Background: Iron deficiency stimulates FGF23 transcription and cleavage, resulting 
in high circulating levels of total FGF23 (tFGF23) due to increased FGF23 fragments 
but relatively normal levels of biologically active intact FGF23 (iFGF23), and hence 
no hypophosphatemia. While this suggests that treating iron deficiency will decrease 
circulating levels of FGF23, recent publications have shown transient asymptomatic 
hypophosphataemia secondary to iFGF23 increase, in response to certain intravenous iron 
preparations such as ferric carboxymaltose (FCM).
Methods: We investigated whether treatment with FCM could impact FGF23 
production in a mouse model of dietary iron deficiency. To induce iron deficiency, we fed 
3 week-old C57BL6 mice an iron deficient diet (ID) for 3 weeks or a diet containing an 
adequate amount of iron (Ctr). Subsequently, six week old ID mice were treated with a 
single iv dose of 30mg/Kg FCM or saline vehicle (Veh). We then performed biochemical 
analyses of urine and serum from mice collected at different time points up to 2 weeks post 
injection.
Results: Compared to Ctr mice, six-week old ID animals showed evidence of iron 
deficiency anemia including low serum iron (23±6 vs 53±18 μg/dL), low red blood cells 
(7.9 ±0.3 vs 8.4±0.3 M/μL), and hemoglobin (10.0±0.2 vs 13.2 ±0.6 g/dL) (p<0.05, ID vs 
Ctr). FCM treatment rapidly increased serum iron levels 6 hours post-injection (290±21 
vs 28±20 μg/dL) and hemoglobin (11.6±0.4 vs. 10.0±0.4 g/dL) after 48 hours (p<0.05, 
FCM vs Veh). As shown previously, tFGF23 was increased in ID animals (1013±143 vs 
202±14 pg/mL) while iFGF23 was only slightly elevated (132±8 vs 82±5 pg/mL) (p<0.05, 
ID vs Ctr). FCM administration, led to a transient increase in tFGF23 (2448±269 vs 
1343±256 pg/mL) and iFGF23 (193±13 vs 124±8 pg/mL) compared to iron deficient 
vehicle mice (p<0.05, FCM vs Veh). However, one week after FCM treatment, tFGF23 
(378±76 vs 1142±186 pg/mL) and iFGF23 (112±7 vs 163±6 pg/mL) levels were corrected 
(p<0.05, FCM vs Veh), likely due to partial correction of iron deficiency.
Conclusions: Our data show that FCM administration to iron deficient mice corrects 
iron deficiency anemia and transiently increases iFGF23. The causes of this increase remain 
to be elucidated.
Funding: NIDDK Support, Commercial Support - Vifor Pharma
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Role of Reduced [Ca2+]i in the Denser Bone Phenotype of Mouse Familial 
Hypocalciuric Hypercalcemia (FHH) Induced by Deleting the Gene 
Encoding Canonical Transient Receptor Potential 1 (TRPC 1) Channel
Bonnie Eby,2 Marta Onopiuk,5 Marybeth Humphrey,4,6 Leonidas Tsiokas,3 
Kai Lau.1,6 1University of Oklahoma Health Science Center, Oklahoma City, OK; 
2University of Oklahoma Heath Sciences Center, Oklahoma City, OK; 
3University of Oklahoma Health Sciences Center, Oklahoma City, OK; 
4University of Oklahoma, Oklahoma City, OK; 5OUHSC, Oklahoma City, OK; 
6Medicine, VA Hospital & Medical Center, Oklahoma City, OK.
Background: In reporting the 80% increased bone mass in FHH, we noted +/- mice 
have similar hypercalcemia (11 vs 10.7 mg %), calcitriol, & calcitonin as null, but no 
hyperparathyroidism (HPT) or hypocalciuria. We asked if gene dosage causes these & the 
bone phenotype. In parathyroid gland (PTG), renal cells & osteocytes from null mice, we 
found lower [Ca2+]i & blunted response to CaSR agonists, shifting right Ca set point for 
PTH release. We tested the hypothesis that reduced [Ca2+]i alters secretion of cytokines & 
phosphatonins to produce greater renal Ca & P retention & more bone mineral accretion.
Methods: We did metabolic studies in ♂ littermates of all 3 genotypes & measured 
blood chemistry as published & cytokines by mouse ELISA.
Results: At 6.5 mon, plasma leptin in null (2.34), but not +/- (1.78), was 75% higher 
than wild-type (wt) (1.3 ng/ml), compatible with known increased leptin secretion by low 
[Ca2+]i in adipocytes. Given published positive feedback between PTH by PTG & leptin by 
adipocytes, the data suggest leptin could aggravate the HPT in null mice. Plasma adiponectin 
was reduced in null (5.36 vs 6.17 in +/- vs 6.39 μg/ml in wt), consistent with its known 
inhibition by low [Ca2+]i & with the published hypocalciuric effects if downregulated. 
Indeed, despite hypercalcemia, urine Ca (50 in null vs 79 in +/- vs 84 μg/d in wt) & Ca 
clearance (0.68 vs 1.08 vs 1.25 μl/min) were lower in null. Consistent with the low [Ca2+]i 
we found in osteocytes, FGF-23 was down in null (51% at 4 mon & 32 % by 5 mon). At 8 
mon, P clearance was reduced in null (48 vs 60 in +/- vs 67 μl/min in wt). Thus, serum P 
was elevated in null (7.4 vs. 6.2 in +/- vs 6.3 mg % in wt). At 12 mon, urine P stayed 50% 
lower in null, consistent with the anti-phosphaturia of reduced FGF-23.
Conclusions: Our data support this model of bone phenotype in null mice. 1. Disturbed 
[Ca2+]i homeostasis from losing both alleles shifts Ca set point to cause HPT. 2. Reduced 
[Ca2+]i in adipocytes triggers leptin, aggravates HPT, & inhibits adiponectin. 3. Reduced 
[Ca2+]i in osteocytes inhibits FGF-23. 4. In concert, these hypocalciuric & anti-phophaturic 
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factors promote renal Ca & P retention to favor bone formation, independent of any other 
renal & skeletal effects of TRPC1 deficiency.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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Cross-Talk Between Vascular and Bone Tissues: Does Vascular  
Calcification Induce Bone Loss?
Maria L. Mace,1 Eva Gravesen,3 Anders Nordholm,1 Marya Morevati,3 
Patrick C. D’Haese,2 Klaus Olgaard,3,4 Ewa Lewin.1,4 1Herlev Hospital, Herlev, 
Denmark; 2University Antwerp, Edegem, Belgium; 3Rigshospitalet, Copenhagen, 
Denmark; 4University of Copenhagen, Copenhagen, Denmark.
Background: Disturbances in bone homeostasis have been associated with 
development of vascular calcification. Results of epidemiological studies in general 
population and in CKD patients showed more severe progressive vascular calcifications 
were associated with greater bone loss and fractures. Our question was whether the presence 
of severe vascular calcification may have an impact on bone metabolism.
Methods: A novel model of isogenic aorta transplantation was used (ATX). Severe 
uremic vascular calcifications were induced in DA rats by 5/6 nephrectomy, high P diet and 
calcitriol. After 14 weeks the calcified abdominal aorta of the uremic rat was transplanted 
into a normal DA rat (n=16). Control groups were ATX of a normal aorta to normal rat 
(n=9) and age-matched rat (n=6). Rats were sacrificed 4 weeks after ATX and plasma 
biochemistry, bone and vessels were analyzed.
Results: The uremic donor rat suffered from severe kidney disease with disturbed 
mineral balance and its aorta had a high calcium content of 15.7±0.8 μg Ca/mg vs. none in 
the normal aorta. Control, normal ATX and calcified ATX rats had same levels of creatinine, 
Ca2+, phosphate, PTH, FGF23 and sclerostin. The calcified ATX rats had significant changes 
in mRNA of several bone markers compared to normal ATX and control rats such as alkaline 
phosphatase (3.26±0.29 vs. 1.56±0.32 & 0.86±0.12, both p<0.001), sclerostin (3.60±0.68 
vs. 1.41±0.34 & 1.04±0.27, both p<0.01), RUNX2 (1.53±0.09 vs. 0.80±0.18 & 0.44±0.11, 
p<0.01, p<0.001), Osteocalcin (0.54±0.06 vs. 0.92±0.14 & 1.19±0.06, p<0.05, p<0.001), 
RANKL (0.40±0.05 vs. 1.91±0.36 & 2.43±0.30, p<0.01, p<0.001), cathepsin K (2.36±0.24 
vs. 1.19±0.23 & 1.01±0.07, p<0.01, p<0.001), beta catenin (3.15±0.25 vs. 1.28±0.26 & 
1.03±0.13, both p<0.001), collagen I (8.50±0.93 vs. 4.06±2.02 & 3.25±0.88, p<0.05, 
p<0.001), osteopontin (1.46±0.18 vs. 0.69±0.17 & 0.49±0.06, both p<0.01). Finally, bone 
mineral density (BMD) was significantly lower in calcified ATX rats compared to normal 
ATX and control rats (1576±5 vs. 1592±5 & 1613±6 mg/cc, both p<0.05).
Conclusions: These novel findings indicate the existence of a tissue crosstalk between 
vessels and bone. The presence of vascular calcifications has an impact on several pathways 
in bone and decrease BMD. Vascular calcification does induce bone loss.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO482 Poster Friday
Bone and Mineral Metabolism: Basic
The Phosphate Binding Therapy Fermagate Attenuates Vascular 
Calcification in Experimental Adenine-Induced CKD
Cynthia M. Pruss, Paul S. Jeronimo, Kimberly J. Laverty, Emilie C. Ward, 
Mandy E. Turner, Bruno A. Svajger, Martin P. Petkovich, Rachel M. Holden, 
Michael A. Adams. Queen’s University, Kingston, ON, Canada.
Background: Hyperphosphatemia, common in chronic kidney disease (CKD), is 
linked to vascular calcification (VC), which further increases cardiovascular risk. Some 
evidence suggests oral magnesium (Mg) inhibits VC. Fermagate is a calcium-free, 
magnesium-releasing phosphate binder that controls hyperphosphatemia. This study 
determined if fermagate treatment compared to untreated control could impact VC in the 
adenine-induced CKD rat model.
Methods: Male Sprague Dawley rats were fed a 0.25% adenine, 0.5% phosphate 
(PO4) diet to induce CKD (creatinine >250 uM) over 4-5 weeks, then fed 0.5% PO4 
without adenine diet. At 6 weeks CKD, two dietary PO4 regimens were tested: moderate 
PO4 (0.75%P) diet (5g 8AM and 4PM ±fermagate (FER n=9) untreated control (CON 
n=6), 10g diet overnight, or a combination of high and low PO4 (1-0.5%P): high (1%P 5g 
8AM, 4PM ±fermagate) and 10g low (0.5%P) PO4 diet overnight (FER n=8, CON n=10) 
with the same amount of daily dietary PO4. Serum calcium (Ca), magnesium (Mg), PO4, 
FGF-23, parathyroid hormone (PTH), vitamin D metabolome, and tissue Ca and PO4 were 
determined.
Results: In both studies, fermagate increased serum Mg (203% 0.75%P, p<0.0001; 
163% 0.5-1%P, p<0.0001, % control, 2-way ANOVA) and had lower levels of serum PO4 
(67% 0.75%P, p<0.001; 64% 0.5-1%P, p<0.001), and PTH (31% 0.75%P, p<0.001; 16% 
0.5-1%P, p<0.001). The proportion of VC was significantly reduced in arterial tissues with 
fermagate treatment (79%/65% in CON vs. 35% FER(0.75%P) and 13% FER(0.5-1%P), 
respectively, p<0.001). This inhibition was also evident on a per animal basis (100%/70% 
CON had VC vs. 33% FER(0.75%P) and 13%(FER 0.5-1%P), p<0.05, respectively). 
Fermagate treatment did not significantly alter Mg levels in the vasculature tissue, serum 
Ca, FGF-23, or serum vitamin D metabolome.
Conclusions: These results demonstrate that fermagate effectively reduces the 
bioavailability of dietary PO4, decreases serum PO4, increases serum Mg, and effectively 
limits the development and progression of CKD-induced vascular calcification.
Funding: Commercial Support - OPKO Health: Renal Division
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TNAP Inhibition: A Novel Strategy to Prevent the Development of 
Vascular Calcification?
Britt Opdebeeck,1 Anja Verhulst,2 Patrick C. D’Haese,1 Ellen Neven.2 1University 
Antwerp, Wilrijk, Belgium; 2University of Antwerp, Wilryk, Belgium.
Background: Vascular media calcification (VC) is frequently seen in chronic kidney 
disease patients. Pyrophosphate (PPi) is a well-known calcification inhibitor that binds to 
nascent hydroxyapatite crystals and prevents further incorporation of inorganic phosphate 
(Pi) into these crystals. However, the enzyme tissue non-specific alkaline phosphatase 
(TNAP), which is highly expressed in calcified arteries, degrades extracellular PPi into Pi 
ions, by which PPi loses its ability to block VC. Here, we aimed to evaluate whether a 
TNAP-inhibitor is able to prevent the development of arterial calcification in a rat model 
of warfarin-induced VC.
Methods: To induce VC, rats received a diet containing 0.30% warfarin and 0.15% 
vitK1 throughout the entire study and were subjected to the following daily treatments: (i) 
vehicle (n=10) or (ii) 10 mg/kg/day TNAP-inhibitor (n=10) administered via an i.p. catheter 
from start of the study until sacrifice at wk7. Calcium (Ca) and phosphorus (P) levels were 
determined in serum and urine samples being important determinants of VC. To evaluate 
osteo/chondrogenic switch of vascular smooth muscle cells (VSMCs), aortic mRNA 
expression of runx2, TNAP, SOX9, collagen1 and 2 was analyzed by qPCR. At sacrifice, 
VC was evaluated by measurement of the total Ca content in the arteries and quantification 
of the area % calcification on Von Kossa stained aortic sections.
Results: No difference in serum Ca and P levels was observed between both study 
groups. Warfarin exposure resulted in distinct calcification in the aorta and peripheral 
arteries in vehicle treated rats. Importantly, daily treatment with a TNAP-inhibitor 
significantly reduced VC as indicated by a significant decrease in calcium content in the 
aorta (mean ± SEM; vehicle 3.84±0.64 mg Ca/g wet tissue vs TNAP-inhibitor 0.70±0.23 
mg Ca/g wet tissue) and peripheral arteries and a distinct reduction in area % calcification 
on Von Kossa stained aortic sections as compared to vehicle condition. TNAP-inhibitor 
treatment did not alter the mRNA expression of osteo/chondrogenic marker genes runx2, 
TNAP, SOX9, collagen1 and 2.
Conclusions: Treatment with a TNAP-inhibitor significantly reduced the development 
of VC in the aorta and peripheral vessels of warfarin exposed rats most probably by directly 
interfering with the apatite formation rather than promoting osteo/chondrogenic conversion 
of VSMCs.
Funding: Government Support - Non-U.S.
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Protein Bound Uremic Toxins Promote Vascular Calcification by Glucose 
Mediated Activation of Inflammation and Coagulation Pathways
Britt Opdebeeck,1 Annelies De maré,2 Bjorn Meijers,4 Anja Verhulst,2 
Pieter Evenepoel,4 Patrick C. D’Haese,3 Ellen Neven.2 1Laboratory of 
Pathophysiology, University of Antwerp, Wilrijk, Belgium; 2University of 
Antwerp, Wilryk, Belgium; 3University Antwerp, Edegem, Belgium; 4University 
Hospitals Leuven, Leuven, Belgium.
Background: Protein-bound uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate 
(PCS) have been associated with cardiovascular morbidity and mortality in patients with 
chronic kidney disease (CKD). We aimed to provide direct evidence for a role of these 
toxins in CKD-related vascular calcification.
Methods: To induce CKD, rats were orally dosed with adenine sulfate for 10 days and 
continuously exposed to either vehicle, IS or PCS (150 mg/kg/day) until 7 weeks after CKD 
induction. Vascular calcification was assessed by measurement of arterial calcium content 
and through histochemical evaluation of Von Kossa stained sections. Quantitative mass 
spectrometric proteomics was further employed to investigate the mechanistic pathways 
underlying IS and PCS-mediated vascular calcification.
Results: IS and PCS exposure did not worsen renal function, fibrosis, or inflammation. 
Calcification in the aorta, carotid and femoral arteries was significantly increased by 
exposure to both toxins, for which serum levels similar to CKD patients were reached. 
Arterial calcification was not associated with changes in bone metabolism inherent to CKD. 
Unbiased proteomic analyses of arterial samples coupled to functional bioinformatics 
annotation analysis revealed that calcification events were likely associated with acute phase 
response signaling, coagulation and glucometabolic signaling pathways, while escape from 
calcification was linked with liver X receptors and farnesoid X/liver X receptor signaling 
pathways. Further metabolic linkage to these pathways also revealed that IS/PCS exposure 
engendered a pro-diabetic state, evidenced by elevated resting glucose and reduced glucose 
transporter (Glut1) transcript expression.
Conclusions: We demonstrate that both IS and PCS directly promote vascular 
calcification via activation of inflammation and coagulation pathways in the arterial wall 
which was strongly associated with impaired glucose homeostasis.
Funding: Government Support - Non-U.S.
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Calcium-Sensing Receptor Signal Modulation: Identification of  
CaRS875 as a Novel Phosphorlyation Site and the Contribution  
of Both Intracellular Domains to Homodimer Signaling
Lenah S. Binmahfouz,2 Arthur D. Conigrave,3 Donald T. Ward.1 Ward 1The 
University of Manchester, Manchester, United Kingdom; 2The University of 
Manchester, Manchester, United Kingdom; 3University of Sydney, Sydney, NSW, 
Australia.
Background: The calcium-sensing receptor (CaR) controls parathyroid hormone 
secretion and renal Ca2+ reabsorption and its function is inhibited by protein kinase C (PKC) 
phosphorylation on CaRT888. However, the equivalent PKC site in metabotropic glutamate 
receptor-5 aligns instead to CaRS875, not previously considered a PKC site. Thus, we 
examined whether a) CaRS875 represents a novel PKC site, b) mutation of CaRT888 can rescue 
loss-of-function (LOF) CaR mutants and c) whether one or both intracellular domains 
(ICD) of the CaR homodimer contribute to signaling.
Methods: The non-phosphorylatable mutation CaRS875A was introduced into both wild-
type human CaR and CaRT888A to test whether this heightens signaling. Then CaRT888A was 
introduced into two loss-of-function (LOF) mutants, CaRS170A (extracellular domain, ECD) 
and CaRF801A (intracellular domain, ICD) to determine a) whether it can rescue their lost 
function and b) whether its addition to both monomers enhances the benefit. If so then this 
would indicate that both ICDs of the dimer contribute to signaling.
Results: In HEK-293 cells, CaRS875A exhibited significantly enhanced signaling 
vs wild-type CaR (EC50, 3.4 ± 0.2 mM WT vs. 1.6±0.1 S875A; P<0.001) while the 
phosphomimetic CaRS875D mutant reduced Ca2+o potency (4.7±0.2 mM S875D vs 3.4±0.2 
WT; P<0.01). When combined with T888A, the Ca2+o responsiveness of the double mutant 
CaRS875A/T888A was further left-shifted relative to CaRT888A alone (2.1±0.4 S875A/T888A 
vs. 2.6±0.1 T888A; P<0.01) demonstrating the sites’ additive effects. Next, the LOF 
homodimers CaRS170A (ECD) and CaRF801A (ICD) exhibited no Ca2+o responsiveness up to 
40mM, whereas co-mutation with T888A significantly rescued their Ca2+o responsiveness. 
It is known that heterodimerisation of CaRS170A and CaRF801A permits partial rescue of their 
function. However, additional co-mutation with T888A not only enhanced the rescue but 
gave maximal rescue when present on both monomers.
Conclusions: Thus, CaRS875 is a novel PKC site that, together with CaRT888, shapes 
the CaR signalling that underpins Ca2+o homeostasis. Furthermore, removal of inhibitory 
signaling at CaRT888 can rescue both ECD and ICD loss-of-function mutants, and, both ICDs 
of the dimer contribute to CaR signalling.
Funding: Government Support - Non-U.S.
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INS-3001 Efficiently Inhibits Severe Vascular Calcifications by Direct 
Interference with Vessel Wall Calcification
Anja Verhulst,1 Mattias E. Ivarsson,3 Roberto Maj,4 Ellen Neven,5 
Patrick C. D’Haese.2 1Pathophysiology, University of Antwerp, Antwerp, 
Belgium; 2University Antwerp, Edegem, Belgium; 3Inositec Inc., Zurich, 
Switzerland; 4Inositec AG, Zurich, Switzerland; 5University of Antwerp, Wilryk, 
Belgium.
Background: Prevention/treatment of vascular calcification currently is based on 
controlling its most important risk factors. A new therapeutic approach with potential higher 
efficacy consists in the administration of molecules directly interfering with the calcification 
process in the vessel wall, such as INS-3001. This abstract reports about the administration 
of INS-3001 in a rat model of vitamin D-warfarin induced vascular calcifications (pooled 
data of 3 independent studies).
Methods: Calcification was induced in male rats (8 weeks) by warfarin (3mg/g diet) 
administration during 6 days and by 4 consecutive daily administrations of vitD3 (100.000 
IU/kg) starting on day 1 of the warfarin administration. Rats were randomly assigned to 
different groups: vehicle, and INS-3001 groups of 12, 25, 2x25, 50 and 2x50 mg/kg/day. 
Treatment was administrated sc. for 7 days (starting together with vitD). Animals were 
sacrificed on the 8th day. Vascular calcification was evaluated on Von Kossa stained tissue 
sections of the thoracic/abdominal aorta and by measurement of the total Ca content 
of the thoracic/abdominal aorta and the carotid/femoral arteries by atomic absorption 
spectrometry.
Results: Mortality rate was 38% (15/40) in the vehicle group, similar -33% (4/12) and 
44% (5/12)- in the 1x25 and 1x12.5 mg/kg/day dose groups, numerically lower -15% (3/19), 
21% (4/19)- in the 2x50, 1x50 mg/kg/day dose groups and significantly lower 0% (0/18) 
in the 2x25 mg/kg/day dose group. In the abdominal aorta, significantly lower Von Kossa 
positivity (area%) was measured in the INS-3001 groups compared to the vehicle group 
(3±5%, 6±4%, 8±7%, 15±3%, 20±3% and 28±10% in respectively the 2x50, 50, 2x25, 
25, 12.5 mg/kg/day and the vehicle group). Total Ca content of the abdominal aorta was 
also significantly lower in the INS-3001 (not the 12.5 and 25 mg/kg/day) groups compared 
to the vehicle group (2.8±3.7, 6.1±5.0, 7.4±6.9, 14.9±7.0, 15.6±9.4 and 14.9±7.5 mg/g 
tissue in respectively the 2x50, 50, 2x25, 25, 12.5 mg/kg/day and the vehicle group. Similar 
reductions in area% Von Kossa positivity and total Ca content were seen in the thoracic part 
of the aorta, and the arteria femoralis and carotis.
Conclusions: In conclusion, INS-3001 is a promising molecule for the treatment of 
CKD and non-CKD induced vascular calcifications.
Funding: Commercial Support - Inositec AG, Switzerland
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Identification and In Vitro Characterisation of a Novel Inhibitor of 
Vascular Calcification
Antonia E. Schantl,1 Mattias E. Ivarsson,2 Bastien Castagner,3 Jean-
Christophe Leroux.1 1ETH Zurich, Zurich, Switzerland; 2Inositec Inc., Zurich, 
Switzerland; 3McGill University, Montreal, QC, Canada.
Background: Vascular calcification (VC) is the pathological deposition of calcium 
and phosphate minerals in the walls of the cardiovascular system. At present, there is 
no approved pharmacological treatment and affected individuals are left at great risk of 
experiencing cardiovascular events and death. Herein, we describe a new class of inhibitors 
of VC based on the previously reported inhibitor myo-inositol hexaphosphate (IP6), with 
improved drug-like properties.
Methods: Multi-step syntheses, starting from protected myo-inositol species, via 
selective PEGylation, phosphorylation or sulfation were employed to afford a library of 
novel IP6 derivatives. Activity was compared in a serum calcification propensity assay, and 
stability was monitored in serum. In vitro efficacy experiments were performed on primary 
human vascular smooth muscle cells (VSMCs), treated with either calciprotein particles 
(CPPs) (50 μg/mL) or calcification medium (2.7 mM calcium and 2.5 mM phosphate, CaP), 
respectively. Subsequently, calcification of the cell monolayer, cell viability and expression 
of cell markers were assessed.
Results: Synthesis and screening of twelve monodispersed PEGylated IP6 derivatives 
revealed IP4-di-PEG2 (INS-3001) to be almost 10-fold more potent than IP6 in delaying 
serum calcification propensity, with activity in the low μM range. This activity was retained 
following 4 h incubation in fresh human serum. VSMC calcification was largely abolished 
by 1 μM INS-3001 in the CaP setup (Figure 1), and 30 μM INS-3001 in the CPP setup, 
respectively.
Conclusions: INS-3001 was superior to natural IP6 with regard to serum calcification 
propensity, in vitro stability and efficacy in cell culture models. Thus, the presented in vitro 
data provides support for the further development of INS-3001 as an inhibitor of vascular 
calcification.
Funding: Commercial Support - Janssen AG, Clariant International AG, Givaudan 
Schweiz AG, Government Support - Non-U.S.
Figure 1 Reduction of VSMC calcification by INS-3001.
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Hyperphosphatemia Is a Negative Modulator of the Calcium-Sensing 
Receptor
Patricia Pacios centeno,3 Chia-Ling Tu,5 Amanda L. Herberger,6 Wenhan Chang,4 
Arthur D. Conigrave,2 Donald T. Ward.1 Ward 1University of Manchester, 
Manchester, United Kingdom; 2University of Sydney, Sydney, NSW, Australia; 
3The University of Manchester, Manchester, United Kingdom; 4Endocrine Unit, 
SF-VAMC, University of California San Francisco, San Francisco, CA; 5San 
Francisco VA Medical Center, San Francisco, CA; 6University of California, 
San Francisco/ San Francisco Veterans Affairs Medical Center, San Francsicso, 
CA.
Background: Chronic kidney disease (CKD) is associated with hyperphosphataemia 
and secondary hyperparathyroidism (SHPT). The key controller of parathyroid hormone 
(PTH) secretion is the calcium-sensing receptor (CaSR), whose crystallised extracellular 
domain has revealed four putative phosphate-binding sites in its inactive conformation. Our 
aim was to determine whether extracellular phosphate, at concentrations found in CKD, can 
inhibit CaSR and increase PTH secretion, and thus potentially contribute to the aetiology 
of SHPT.
Methods: CaSR activity was measured as Ca2+i mobilisation (Fura-2) and extracellular 
signal-regulated kinase (ERK) phosphorylation in HEK-293 cells stably transfected 
with human CaSR. The HEPES buffer contained 0.5mM CaCl2 with phosphate added as 
Na2HPO4 and KH2PO4 in a 4:1 ratio (pH 7.4). PTH secretion was measured in dispersed 
human parathyroid cells obtained ethically following neck surgery and in cultures of intact 
mouse parathyroid glands.
Results: Raising phosphate concentration from 0.8 mM (physiological) to 2 mM (CKD-
like) inhibited CaSR-induced Ca2+i mobilisation (-52 ± 4%; P<0.001) and ERK activation 
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(-18 ± 3%; P<0.01). Raised phosphate concentration (2 mM) inhibited the maximal (Emax) 
Ca2+o response suggesting non-competitive antagonism (-32 ± 3%; P<0.001). Further, 
phosphate attenuated CaSR activity with an IC50 of 1.2 mM (95%CI 1.0 to 1.4). Mutation of 
CaSRR62 (a putative phosphate-binding site) to alanine ablated this inhibitory effect. Finally, 
pathophysiologic phosphate concentrations elicited rapid (within minutes) and reversible 
increases in PTH secretion in freshly-isolated human parathyroid cells (+39 ± 10%, 0.8 
vs 2mM, P<0.05; +58 ± 15%, 0.8 vs 3mM; P<0.001) consistent with a receptor-mediated 
action (with thanks to Ryan Mun). Similarly, in cultures of mouse parathyroid glands 
phosphate again elicited rapid, concentration-dependent increases in PTH secretion (by up 
to 180%, 3 vs 0.8mM).
Conclusions: Therefore CaSR is able to sense pathophysiologic deviations in phosphate 
concentration apparently via non-competitive antagonism at CaSRR62 resulting in increased 
PTH secretion. This mechanism may help explain the contribution of hyperphosphatemia 
to SHPT.
Funding: Other NIH Support - NIAMS, Veterans Affairs Support, Government 
Support - Non-U.S.
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Impact of Modifying Calcitriol Dosing on the Vitamin D Metabolome and 
Vascular Calcification in Experimental CKD
Bruno A. Svajger,1 Cynthia M. Pruss,1 Kimberly J. Laverty,1 Jason Zelt,1 
Emilie C. Ward,2 Mandy E. Turner,3 Glenville Jones,4 Martin P. Petkovich,1 
Rachel M. Holden,1 Michael A. Adams.1 1Queen’s University, Kingston, ON, 
Canada; 2Queen’s University, Kingston, ON, Canada; 3Queen’s University at 
Kingston, Kingston, ON, Canada; 4Queens University, Kingston, ON, Canada.
Background: Calcitriol (CAL) and other vitamin D analogs are used to manage 
SHPT in CKD although treatment can result in PTH over-suppression and lead to vascular 
calcification (VC). This study sought to determine whether modifying CAL dosing 
frequency and magnitude could provide a better treatment profile (PTH, FGF23, VC) in 
experimental CKD.
Methods: Experimental CKD (e-CKD) was induced by 0.25% dietary adenine in 
adult male Sprague-Dawley rats (n=42). At 4 weeks (W), e-CKD rats were divided into 
5 groups and treated with oral CAL as follows: 0ng/kg (e-CKD control, n=8), 5ng/kg x 4, 
q6h (n=9), 20ng/kg once daily (n=8), 20ng/kg x 4, q6h (n=9), or 80ng/kg once daily (n=8). 
After 3W treatment, rats were sacrificed, tissues and blood were collected and assessed for 
vitamin D metabolome, PTH, FGF-23 and VC. Sub-analysis according to PTH level: (i) 
over suppressed (OS), (ii) target, and (iii) mildly suppressed (MS) was performed.
Results: CAL treatment in e-CKD rats markedly increased the levels of 1,25-(OH)2D3 
in a dose-dependent manner (4-6X). In contrast, both circulating 25-OH-D3 and 
24,25-(OH)2D3 fell significantly (10-30%), particularly at the higher CAL dose. Sub-
analysis based on PTH suppression revealed a greater fall in 25-OH-D3 and 24,25-(OH)2D3 
levels in Target and OS groups compared to the MS and untreated e-CKD. Overall, in 
e-CKD, the CAL treatment induced markedly increased VC (94% in Tx vs. 29% of vessels 
in unTx) and FGF-23 (8-20 X increase in Tx vs. unTx) regardless of treatment profile.
Conclusions: CAL suppressed PTH early in e-CKD treatment as expected, but PTH 
became progressively refractory over the 3 weeks of treatment. Even in the absence of overt 
PTH over suppression, all animals in the CAL treatment group had significant vascular 
calcification. All CAL treatment groups induced similar changes in the circulating vitamin 
D metabolome, with increased 1,25-(OH)2D3 but decreased 25-OH-D3 and corresponding 
24,25-(OH)2D3. The CAL treatment induced varying alterations in the vitamin D 
metabolome which were reflected, in part, on how PTH levels were modified in response to 
CAL. These findings suggest that how calcitriol is administered as well as the level of PTH 
suppression should be re-examined to minimize VC in CKD.
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Significant Differences Exist in Intestinal Phosphate Absorption Between 
Species
Yasuhiro Ichida,1 Naoto Hosokawa,1 Ryushi Takemoto,2 Takafumi Koike,2 
Tasuku Nakatogawa,2 Mayumi Hiranuma,2 Hitoshi Arakawa,2 Yukihito Miura,2 
Hiroko Azabu,2 Shuichi Ohtomo,1 Naoshi Horiba.1 1Chugai Pharmaceutical Co. 
Ltd., Gotemba, Shizuoka, Japan; 2Chugai Research Institute for Medical 
Science, Inc., Gotemba, Japan.
Background: The efficacy of a NaPi-IIb specific inhibitor was recently reported 
to be different between rat and human. In addition, intestinal phosphate absorption was 
previously reported to be different between rat and mouse. This study analyzed intestinal 
phosphate absorption in dog, monkey, and rat and also investigated the concentrations of 
phosphate and related hormones in serum. The results showed significant differences in the 
intestinal phosphate absorption between the three species.
Methods: Fecal and urinary phosphate excretion were compared in dog, monkey, and 
rat after paired feeding. Phosphate uptake by intestinal brush border membrane vesicles 
(BBMV) and the mRNA expression of NaPi-IIb, PiT-1, and PiT-2 were also evaluated 
in duodenum, jejunum, and ileum of each species. In addition, the ALP activity in each 
intestinal segment and the concentration of serum phosphate and FGF23 were measured.
Results: The intestinal phosphate absorption rate, as calculated from food intake and 
fecal excretion, was highest in dog out of the three species, as were urinary fractional 
excretion of phosphate and serum concentration of FGF23. Accordingly, phosphate uptake 
with BBMV and mRNA expression of NaPi-IIb were also highest in dog. Surprisingly, 
urinary phosphate excretion was lowest in monkey, and the intestinal phosphate absorption 
rate in monkey was by far the lowest out of the three species. Dog and rat showed positive 
correlations between phosphate uptake with BBMV and mRNA expression of NaPi-IIb in 
each intestinal segment. Although phosphate uptake in BBMV was high in monkey, mRNA 
expression of NaPi-IIb was not detected in any of the intestinal segments, and intestinal 
ALP activity was low.
Conclusions: These results suggest that, whereas NaPi-IIb is the major contributor to 
intestinal phosphate absorption in dog and rat, monkey phosphate degrades only slightly 
in the intestine, and its contribution to intestinal phosphate absorption might be through 
a sodium-dependent phosphate transporter other than NaPi-IIb. In conclusion, there are 
significant differences in intestinal phosphate absorption between dog, monkey, and rat. 
Further analysis is needed to elucidate the phosphate absorption in human.
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Oxidative Stress and Autophagy Are Involved in Matrix Vesicles 
(MV)-Induced Calcification of Recipient Vascular Smooth Muscle Cells 
(VSMC)
Neal X. Chen,1 Kalisha O’Neill,1 Sharon M. Moe.1,2 1Indiana University School of 
Medicine, Indianapolis, IN; 2Roduebush VA Medical Center, Indianapolis, IN.
Background: Oxidative stress is increased in patients with CKD and is associated 
with vascular calcification. Oxidative stress can also increase autophagy. We have 
previously demonstrated that cellular derived MV, but not media derived MV, increase 
calcification of recipient normal rat VSMC when endocytosed, in association with increased 
intracellular calcium and NOX production. We hypothesize that this increased oxidative 
stress in recipient VSMC cells may lead to inappropriate autophagy that induces vascular 
calcification and thus extends calcification lesions.
Methods: Cellular or media derived MV were co-cultured with recipient VSMC in 
the calcification inducing media (high phosphorus) and alteration of oxidative stress (ROS 
production) and autophagy were examined by confocal microscopy and Western blot, 
respectively. Calcification was determined by biochemical assay. In some experiments, 
inhibitors for autophagy (3-MA) and oxidative stress (NOX1/4 inhibitor GKT137831) were 
added to the MV-VSMC cultures.
Results: The addition of cellular MV, but not media MV, to recipient normal VSMC 
increased ROS production by 95% at 24 h and increased the expression of autophagy 
markers LC3II and Atg5 at 1 and 3 days during calcification. Pretreatment with GKT137831 
significantly blocked cellular MV-induced ROS production in recipient VSMC. 
Furthermore, inhibition of autophagy with 3-MA decreased MV-induced calcification of 
recipient VSMC by 425%, a magnitude similar to the inhibition induced by blockade of 
NOX1/4 activity.
Conclusions: Cellular derived MV induced ROS production and increased autophagy 
in recipient VSMC during calcification (high phosphorus media). These results suggest that 
normal VSMC may endocytose cellular MV from calcifying VSMC leading to increased 
ROS and autophagy in the recipient VSMC, resulting in increased calcification.
Funding: Other NIH Support - NIAMS, Veterans Affairs Support
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Effect of Advanced Glycation End-Products (AGE) Lowering Drug 
ALT-711 on a Rat Model of CKD-Mineral Bone Disorder (CKD-MBD)
Neal X. Chen,1 Shruthi Srinivasan,1 Loretta O. Aromeh,1 Kalisha O’Neill,1 
Keith Avin,2 Matthew R. Allen,1 Tom Nickolas,4 Joseph M. Wallace,5 
Sharon M. Moe.1,3 1Indiana University School of Medicine, Indianapolis, IN; 
2Indiana University-Indianapolis, Indianapolis, IN; 3Roudebush VA Medical 
Center, Indianapolis, IN; 4Columbia University Medical Center, New York, NY; 
5Indiana University Purdue University Indianapolis, Indianapolis, IN.
Background: Reduced bone quality is a key determinant of skeletal fragility in CKD. 
We hypothesized that the increased formation of AGEs that occur in advanced CKD due to 
oxidative stress may be responsible for the impaired bone fragility. To test this hypothesis, 
we evaluated the efficacy of an AGE breaker (ALT-711) on CKD-MBD and bone AGEs in 
a slowly progressive rat model of CKD, the Cy/+ rat.
Methods: We compared five groups of animals [1: Normal (NL); 2: CKD; 
3:CKD+ALT-711; 4: CKD+ 3% calcium in drinking water (Ca, lowering PTH and reducing 
bone remodeling); and 5: CKD+ALT-711+Ca]. Treatment was started at 25 weeks of age 
(~50% kidney function) and ended at 35 weeks (~15% function). Blood, kidney weight, and 
heart weight were examined at sacrifice and aorta calcification determined biochemically. 
Bone AGE content was determined in demineralized femur shaft using fluorescence plate 
reader, normalized by collagen (hydroxyproline) content.
Results: As expected, there was progressive decline in kidney function over time in all 
4 CKD groups compared to NL. The serum levels of calcium and FGF23 were higher, and 
phosphorus and PTH lower in CKD animals treated with calcium consistent with resolution 
of secondary hyperparathyroidism. The administration of ALT did not alter BUN, calcium, 
PTH or FGF23 levels but did reduce serum phosphorus levels in CKD animals. Heart 
weight and left ventricular mass index (LVMI) increased in all of the CKD animal groups 
compared to NL. Treatment with ALT-711, calcium, or ALT+Ca all reduced the heart 
weight and LVMI in CKD animals. There was increased vascular calcification in all of the 
CKD animal groups but no effect of ALT-711 treatment. Serum 8-OHdG levels (marker of 
DNA oxidation) was elevated in CKD compared to NL and not lowered by ALT-711. Bone 
AGE levels were increased in CKD compared to NL but not reduced by ALT treatment.
Conclusions: In a progressive rat model of CKD, there is increased AGE accumulation 
in bone. Starting treatment with an AGE breaker early in the course of CKD failed to 
improve bone AGE levels, but did reduce heart weight. Interestingly, there was also an 
interaction with secondary hyperparathyroidism in the pathogenesis of AGEs and response 
to ALT. Bone biomechanical testing is in progress.
Funding: Other NIH Support - NIAMS, Veterans Affairs Support
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Specific Knockdown of WNT8b Expression Protects Against  
Phosphate-Induced Calcification in Vascular Smooth Muscle  
Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway
Li Yao, Zitong Sheng, Tianhua Xu, Pengzhi Wan, Tian Binyao. The First 
Affiliated Hospital of China Medical University, Shenyang, China.
Background: In the last 10 years, the prevalence, significance, and regulatory 
mechanisms of vascular calcification have gained increasing recognition. The aim of this 
work is to study the action of WNT8b on the disease development of phosphate-induced 
vascular calcification through its effect on vascular smooth muscle cells (VSMCs) in vitro 
by inactivating the Wnt/β-catenin signaling pathway.
Methods: In order to find out the effect of WNT8b on the Wnt/β-catenin signaling 
pathway and vascular calcification in vitro, β-glycerophosphate (GP) induced T/G 
HA-VSMCs were treated with siRNA against WNT8b, LiCl (Wnt agonists), and both, 
respectively. The mRNA and protein levels of WNT8b, α-SMA, calcification associated 
molecules, the Wnt signaling pathway related molecules were determined by reverse 
transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. 
TOP/FOP-Flash reporter assay was performed to detect transcription activity mediated by 
β-catenin.
Results: si-WNT8b reduced calcium deposition and activity of ALP, increased α-
SMA level, and dropped BMP2, Pit1, MSX2, and Runx2 levels, while stimulation of LiCl 
worsened β-GP-induced calcium deposition, increased activity of ALP, reduced α-SMA 
expression level. si-WNT8b resulted in reductions in WNT8b, Fzd4, β-catenin, p-GSK-
3β, and cyclin-D, whereas enhancement of p-β-catenin and GSK-3β, indicating si-WNT8b 
could alter the Wnt/β-catenin signaling pathway thus to hamper the vascular calcification in 
T/G HA-VSMC, which further demonstrated by TOP/FOP FLASH assay and detection of 
β-catenin expression level in the nucleus.
Conclusions: Taken together, we conclude that WNT8b knockdown abolishes 
phosphate-induced vascular calcification in VSMCs by inhibiting the Wnt/β-catenin 
signaling pathway.
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High Phosphate Diet Before Pregnancy Dysregulates Phosphate  
Metabolism in Neonatal Offspring Mice
Mayu Hayashi,1 Shiori Fukuda,1 Maki Kishimoto,1 Hironori Yamamoto,2 
Masashi Masuda,1 Yutaka Taketani.1 1Tokushima University, Tokushima, Japan; 
2Dept. of Health and Nutrition, Jin-ai University, Echizen city, Fukui, Japan.
Background: Excess intake of dietary phosphate (Pi) increases fibroblast growth factor 
23 (FGF23) and parathyroid hormone (PTH) to maintain plasma Pi level. FGF23, is a potent 
phosphaturic factor, binds to α-klotho / FGFR complex in the kidney to promote excretion 
of Pi into urine. In addition, excess intake of dietary Pi also decreases in renal α-klotho 
expression. Downregulation or lack of α-klotho induces a premature aging-like phenotype 
such as ectopic calcification and osteoporosis resulted from hyperphosphatemia. Recent 
the theory of developmental origins of health and disease indicates that early exposure of 
dietary or environmental factors determines the risk of various diseases in adulthood. Thus, 
excess intake of dietary Pi during or before pregnant period may affect the gene expression 
of α-klotho or other Pi regulating factors related to future health risks in offsprings.
Methods: To investigate that, we used C57BL/6J female mice aged 8 weeks old. Mice 
were fed with either control Pi (CP) or high Pi (HP) diet for 21 days before pregnancy. At 
the end of diet control, they were mated with male mice and become pregnant. After the 
delivery, both groups were fed with CP diet. Neonatal offspring mice (at 3 weeks old when 
they were weaning) were subjected to analysis.
Results: As a result, although the no difference of Pi and calcium levels in breast 
milk between two groups, the offspring mice in HP diet group revealed plasma FGF23 
concentration was significantly elevated, urinary Pi excretion tended to increase and urinary 
calcium excretion tended to decrease. Renal α-klotho mRNA expression level was not 
changed in the both groups. But interestingly, renal mRNA expression level of NaPi2c and 
CYP27B1, which are known to be suppressed by the FGF23/α-klotho signal was decreased 
in HP diet group. Femur mRNA expression level of Phex, which is known to FGF23 
secretory suppression factor at the bone was increased in HP diet group. In addition, femur 
mRNA expression level of DNA methyltransferase (DNMT1) was significantly increased 
in HP diet group.
Conclusions: In conclusion, excessive dietary Pi intake before pregnant causes 
abnormal Pi metabolism, and it may be due to epigenetic modification through DNA 
methylation at bone.
Funding: Government Support - Non-U.S.
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Nox1 Induces Osteoblastic Transition of Vascular Smooth Muscle Cells 
and Contributes to Vascular Calcification in Early CKD Rats with Normal 
Serum Phosphorus
Hui Xu. Nephrology Department, Xiangya Hospital, Central South University, 
Changsha, Hunan, China, ChangSha, China.
Background: Vascular calcification (VC) is a major cause of mortality in patients with 
chronic kidney disease (CKD). While higher levels of serum phosphorus contribute to VC, 
but in early CKD patients with normal phosphorus have VC, and reduction of serum P by 
using various P binder is not effective in preventing VC progression in patients with CKD. 
So, we think some other factors contribute to VC, especially in Early CKD.
Methods: In CKD dialysis patients with VC (n=11) and dialysis CKD patients without 
VC (n=13), serum 8-OHdG was measured. We use CKD5 and early CKD rats to test the 
Vascular calcification and Nox1, we also use the serum of early CKD patients to incubate 
primary VSMCs , SM22α expression and RUNX2 expression, calcium deposition in 
primary rat VSMCs and Nox1 are measured.
Results: In a rat model for the stage 5 CKD (CKD5), robust increases of VC and 
8-OHdG, significant reductions of smooth muscle 22 alpha (SM22α) expression, and
an upregulation in RUNX2 expression in vascular smooth muscle cells (VSMCs) were
demonstrated. Inhibition of 8-OHdG using MnTMPyP dramatically reduced these events
without normalization hyperphosphatemia. In CKD patients with VC (n=11) but not in
CKD patients without VC (n=13), 8-OHdG was significantly elevated. While the serum 
levels of calcium and phosphate were not altered in animal models in the early stage CKD
(ECKD), 8-OHdG, VC, SM22α downregulation, RUNX2 upregulation, and NADPH
oxidase 1 (NOX1) expression in VSMCs were all significantly changed. More importantly 
serum (10%) derived from patients with ECKD (n=30) or CKD5 (n=30) significantly 
induced SM22α downregulation, RUNX2 upregulation, NOX1 upregulation along with a
robust 8-OHdG, and calcium deposition in primary rat VSMCs. These alterations were all 
reduced by MnTMPyP and a specific NOX1 inhibitor (ML171).
Conclusions: Collectively, we provide evidence for an important role of Nox1 in 
promoting VC development in early CKD patients, which was at least in part through 
induction of osteoblastic transition in VSMCs.
Funding: Government Support - Non-U.S.
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Polymer Characterization of VS-505, a Novel Non-Absorbed,  
Calcium- and Aluminum-Free Phosphate Binder
J. Ruth Wu-Wong,1 Yung-wu Chen,1 Tony Zhang,2 Jin Tian.2 1Vidasym, Chicago, 
IL; 2Alebund, Shanghai, China.
Background: Inadequate control of phosphate in chronic kidney disease can lead to 
pathologies of clinical importance. VS-505 is a novel phosphate binder, which has been 
evaluated in hemodialysis subjects with hyperphosphatemia for 8 weeks (ClinicalTrials.gov 
Identifier #: NCT02469467) with the following results: (1) significantly reduced plasma 
phosphorus (Pi) in the treatment group (median Pi change -2.40 mg/dl), (2) no changes of 
iron parameters, and (3) no change of Ca levels, but a significant reduction in iPTH and 
CaxPi over the treatment period.
Methods: In this study, VS-505 was characterized by FT/IR spectroscopy (Fourier 
Transform Infrared), XPS (X-ray Photoelectron Spectroscopy), and 57Fe Mössbauer 
spectroscopy. VS-505 is not soluble in regular NMR solution/solvent, and thus was 
analyzed by a 750 MHz solid-state NMR spectroscopy. In 5% EDTA, VS-505 was partially 
solubilized, and the solubilized material was analyzed by size exclusion chromatograph.
Results: VS-505 has a high density (1.95 vs. 1.27 g/cm3 for sevelamer, by helium 
pycnometer) with a reduced pill size. When exposed to simulated gastric fluid, VS-505 
exhibits a low swell volume (0.4 vs. 4 cm3/ml/0.1 g for sevelamer), and low iron release 
(<3% Fe+3 vs. 53% for sucroferric oxyhydroxide) after 2 hr of incubation at 37°C. FTIR 
spectrum of VS-505 conforms with that of gum Arabic, indicating that gum Arabic is the 
main component in VS-505. Results from XPS show the presence of Fe, C and O in VS-
505, devoid of chloride and other impurities. Mössbauer spectroscopy results indicate 
that all Fe atoms in VS-505 are in the high-spin Fe+3 state. Solid-state NMR results show 
significant differences in chemical shifts between gum Arabic and VS-505, implicating the 
presence of tight complex between iron ion and gum Arabic. Results from the size exclusion 
chromatograph with solubilized material in 5% EDTA indicate that gum Arabic in VS-505 
maintains its original molecular weight with chelated iron ion.
Conclusions: The characterization shows that VS-505 is a stable complex with 30% 
iron ion chelated to 70% gum Arabic (by weight). While effectively binding phosphate, VS-
505 releases <3% of its iron content in gastric fluid, and doesn’t significantly affect blood 
iron parameters in both pre-clinical and clinical studies.
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Discovery of a Novel NPT2b Inhibitor That Inhibits Intestinal Phosphate 
Absorption in Mice and Rats
Xiaojun Wang, Yanping Xu, Xiaohong Yu, Asim B. Dey, Hong Y. Zhang, 
Charity Zink, Dariusz Wodka, Gina Porter, William F. Matter, Leah L. Porras, 
Charles A. Reidy, Jeffrey A. Peterson, Brian Mattioni, John Wetterau. Eli Lilly 
and Company, Indianapolis, IN.
Background: Hyperphosphatemia in CKD and ESRD contributes to bone, kidney 
and CV diseases. Inhibition of the intestinal phosphate (Pi) transporter, NPT2b, may be an 
approach to augment current therapies for hyperphosphatemia.
Methods: Utilizing radiolabeled Pi uptake assays in CHO cells over-expressing various 
Pi transporters, and a mouse model, we discovered a novel NPT2b inhibitor, LY3358966. 
Due to the insoluble nature of the compound at acidic and neutral pH, the sodium salt of 
the compound was formulated in PVP-VA for further characterization. An amorphous solid 
dose formulation suitable for clinical development was prepared by spray dry dispersion 
and incorporated into a capsule and further tested for activity in mice.
Results: LY3358966 inhibited Pi uptake in CHO cells over-expressing human, mouse 
and rat NPT2b with an IC50 of 32.4, 43.9, and 26.8 nM, respectively. Formulated in PVP-
VA and dosed in water, the compound has desirable PK properties for a drug target found on 
the luminal surface of the small intestine, with low bioavailability, and very low serum free 
drug concentrations. LY3358966 acutely (15 min) inhibited Pi absorption in mice with an 
ED50 of 0.15 mg/kg and Emax of 73%. Four hours after dosing the inhibitor, the ED50 was 
1.12 mg/kg and Emax was 79%. In contrast, it acutely inhibited Pi absorption with an ED50 
of 0.051 mg/kg and an Emax of only 19% in rats. Importantly, a solid dose formulation of 
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LY3358966 incorporated into a capsule effectively inhibited Pi uptake in mice. Following 
three 10 mg/kg doses of LY3358966 and radiolabeled Pi, mouse feces were collected for 48 
hours. Compared to placebo treated animals, there was a significant increase in radiolabeled 
Pi recovered in feces (8.6% of the dose, p < 0.0001).
Conclusions: LY3358966 is a potent NPT2b inhibitor with desirable PK properties 
that inhibits Pi absorption in mice when dosed in a solid dose formulation acceptable for 
clinical development. Using a pharmacological approach, we achieved an inhibition of Pi 
absorption in mice comparable to that reported in NPT2b knockout mouse models. The 
NPT2b inhibitor had less effect on acute Pi absorption in rats.
Funding: Commercial Support - Eli Lilly Co
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Stronger Phosphate Lowering Effects of a Novel PiT-1/PiT-2/NaPi-IIb 
Triple Inhibitor EOS789 in Hyperphosphatemia Than a NaPi-IIb 
Inhibitor
Shuichi Ohtomo,1 Yoshinori Tsuboi,1 Yasuhiro Ichida,1 Hitoshi Hagita,2 
Manami Iida,1 Naoshi Horiba.1 1Chugai Pharmaceutical Co. Ltd., Gotemba, 
Shizuoka, Japan; 2Chugai Research Institute for Medical Science, Inc., 
Gotemba, Japan.
Background: EOS789 is a novel inhibitor of the sodium-dependent phosphate co-
transporters PiT-1, PiT-2, and NaPi-IIb, which play central roles in intestinal phosphate 
absorption.
Methods: The in vitro inhibitory activity and the in vivo potency of EOS789 were 
evaluated.
Results: The in vitro IC50 values of EOS789 on human or rat NaPi-IIa, NaPi-IIb, 
NaPi-IIc, PiT-1, and PiT-2 were between 1 and 10 μM, and its IC50 value on sodium-
dependent phosphate uptake in rat small intestinal brush border membrane vesicles was 
3.1 μM. The inhibitory effect of EOS789 on intestinal phosphorus uptake was evaluated 
in healthy rats by fecal phosphorus excretion rate. EOS789 dose-dependently increased the 
fecal phosphorus excretion rate and inversely decreased the urinary phosphorus excretion 
rate. The effects of EOS789 on serum phosphorus, FGF23, and intact PTH concentrations 
were evaluated in a hyperphosphatemia model of adenine-induced nephritis rats. After 14 
days food admixture dosing of EOS789 with a dose between 0.015% and 0.5%, the serum 
phosphorus, FGF23, and intact PTH concentrations were decreased dose-dependently. 
Notably, EOS789 at the highest dose decreased these serum parameters to below their 
values in normal control rats. In addition, EOS789 exhibited a more potent effect on serum 
phosphorus than a NaPi-IIb-selective inhibitor in hyperphosphatemia rats. The effect of 
EOS789 on the progression of chronic kidney disease was also evaluated in chronic anti-
Thy1.1 nephritis rats. During the experimental period, dietary dosing of EOS789 provided 
a sustained suppression of serum phosphorus, FGF23, and intact PTH. After 16 weeks of 
dosing, EOS789 significantly decreased serum creatinine concentration in parallel with 
suppression of fibrosis-related mRNA and pro-inflammatory cytokine mRNA expressions. 
In addition, EOS789 significantly ameliorated ectopic calcification of the thoracic aorta.
Conclusions: This series of data suggests that EOS789 has a robust lowering effect on 
serum phosphorus under hyperphosphatemic conditions, and that EOS789 treatment can 
ameliorate renal function deterioration and protect the cardiovascular system from ectopic 
calcification.
FR-PO499 Poster Friday
Bone and Mineral Metabolism: Basic
Combination Treatment with Tenapanor and Sevelamer Synergistically 
Reduces Urinary Phosphate Excretion in Rats
Andrew J. King, Jill N. Kohler, Cyra Fung, Zhengfeng Jiang, Allison Quach, 
Padmapriya Kumaraswamy, David P. Rosenbaum. Ardelyx, Fremont, CA.
Background: Many chronic kidney disease (CKD) patients on dialysis fail to 
achieve target serum phosphate (P) levels, despite treatment with available P binding 
agents. Tenapanor is a first-in-class, minimally absorbed small molecule NHE3 inhibitor 
that reduces intestinal P absorption and is under investigation as a novel treatment for 
hyperphosphatemia in CKD patients on dialysis. This study evaluated the effect of 
tenapanor and varying doses of sevelamer carbonate administered alone and in combination 
on urinary P excretion, an index of intestinal P absorption, in rats.
Methods: Male Sprague Dawley rats were assigned to groups dosed orally with 
vehicle or tenapanor (0.3 mg/kg/day) and provided with a diet containing varying amounts 
of sevelamer (0-3% w/w) for 11 days. 24-hour urinary P excretion was measured over the 
final 4 days. The effect of the addition of tenapanor (0.3 mg/kg/day) or vehicle for 7-days on 
24-hour urinary P excretion in rats (n=6/group) already on a stable dose of sevelamer (1.5% 
w/w) for 6 days was also assessed.
Results: In combination with tenapanor, sevelamer dose-dependently decreased urinary 
P excretion such that the combination effect was significantly greater than either tenapanor 
or the equivalent dose of sevelamer alone across all sevelamer dose levels (Figure). The 
BLISS statistical model of independence indicated that the drug combination interaction 
between tenapanor and sevelamer was synergistic. On a stable sevelamer dose (1.5% w/w) 
that reduced urinary P excretion by 42 ± 3% (P<0.001), the addition of tenapanor reduced 
residual urinary P excretion by 37 ± 6% (P<0.05).
Conclusions: The combination of tenapanor and sevelamer results in greater reductions 
in intestinal P absorption than when either agent is administered alone. Clinical evaluation 
of the potential for the combination of tenapanor and sevelamer to more effectively achieve 
serum P target levels in hyperphosphatemic CKD patients on dialysis is warranted.
Funding: Commercial Support - Ardelyx
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Effects of Ferric Citrate on Phosphate Metabolism in Alport Mice with 
CKD
Komuraiah Myakala,1 Xiaoxin Wang,2 Moshe Levi.2 1Biochemistry, Georgetown 
University, Washington, DC; 2Georgetown University, Washington, DC.
Background: The maintenance of phosphate (Pi) homeostasis depends on the 
absorption of Pi across the intestine, reabsorption by the kidney and resorption by the 
bone. The mechanisms however still remain unknown and the role of intestinal Pi transport 
is subject of ongoing debate. Hyperphosphatemia is a common occurrence and plays 
important roles in cardiovascular and metabolic bone disease. Normalizing the serum Pi 
by reducing the dietary Pi intake can resolve the biochemical changes which may improve 
the clinical outcomes in CKD. To investigate the role of intestinal Pi absorption, we studied 
the effects of the Pi-binder Ferric Citrate (FC) on reducing intestinal absorption of Pi in a 
mouse model of progressive CKD
Methods: 4-week old wild type (WT) and Col4a3 knockout (Alport, CKD) mice (n=6 
to 8 per group) were fed with control diet (0.9% Pi, 0.6% Ca2+) or control diet supplemented 
with 2% or 3% ferric citrate (FC) for 5 to 6 weeks. Tissues were harvested and serum 
biochemistry was measured at 9-10 weeks old mice. To determine the intestinal Pi transport 
mechanism in CKD, we isolated apical brush border membrane vesicles (BBMVs) from 
the ileum and studied sodium gradient dependent Pi (Na+/Pi) transport and NaPi-2b protein 
abundance.
Results: Serum BUN and Pi were increased significantly in Alport CKD mice 
compared to WT. In parallel to Pi, serum FGF23 levels were markedly increased in CKD 
mice. Dietary FC administration in CKD mice significantly reduces the serum Pi levels 
along with a significant decrease in intact FGF23. In addition, serum calcium (Ca2+) was 
reduced significantly in CKD mice compared to WT. FC diet improved Ca2+ levels in CKD 
mice. The excretion of Pi in the urine was increased in CKD mice compared to WT mice 
and in contrast, urinary Pi was reduced in both wild type and CKD mice fed with FC. 
BBMV Na+/Pi cotransport activity was comparable between WT and CKD mice fed with 
control diet. However, BBMV Na+/Pi transport activity was increased in both WT and CKD 
mice fed with FC diet. This was associated with a 2-fold increase in BBMV NaPi-2b protein 
abundance.
Conclusions: Our data indicates that, the administration of FC improved the 
dysregulated Pi metabolism in CKD. However, the resultant increase in NaPi-2b protein 
abundance suggest that FC or any other Pi binder needs to be administered at all times 
with the diet.
Funding: Commercial Support - Keryx Biopharmaceuticals Inc.
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Effects of Low-Dose Ferric Citrate on Hematologic and FGF23  
Parameters in High-Hepcidin Murine Models with and Without CKD
Mark R. Hanudel, Maxime Rappaport, Victoria R. Gabayan, Isidro B. Salusky, 
Elizabeta Nemeth, Tomas Ganz. UCLA, Los Angeles, CA.
Background: Ferric citrate (FC) is an effective phosphate binder and iron supplement 
in CKD patients. FC-delivered iron is enterally absorbed, despite high hepcidin levels, but 
the specific absorption mechanism and its regulation remain unknown. We assessed the 
effects of FC in Tmprss6 knockout (TKO) mice, a model characterized by high hepcidin 
levels and resultant iron-refractory iron-deficiency anemia, without or with the addition of 
adenine-induced CKD, which exacerbates anemia and iron restriction.
Methods: Wild-type (WT) and TKO mice were fed diets with or without 0.2% adenine 
for 6 weeks (to induce CKD), with or without 0.1% FC for the last 3 of the 6 weeks 
(corresponding to an adult human FC dose of ~2 tablets thrice daily). Blood and tissues 
were then collected for analysis.
Results: In the absence of CKD, TKO mice compared to WT mice had significantly 
higher serum hepcidin, lower liver iron, lower serum iron, lower hemoglobin, higher serum 
erythropoietin (EPO), higher bone and marrow Fgf23 mRNA, and higher plasma C-terminal 
(total) FGF23, but no difference in circulating intact FGF23. In TKO mice, despite high 
serum hepcidin, FC administration significantly decreased serum phosphate, increased liver 
iron, increased serum iron, increased hemoglobin, decreased serum EPO, decreased bone 
and marrow Fgf23 mRNA, and decreased plasma total FGF23. With adenine-induced CKD, 
TKO mice had the highest hepcidin levels. FC treatment caused no significant changes in 
serum phosphate, liver iron, or serum iron, but significantly increased hemoglobin, with a 
trend towards lower serum EPO. FC therapy significantly decreased bone Fgf23 mRNA, 
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marrow Fgf23 mRNA, and plasma total FGF23, but not intact FGF23. Despite the very 
high hepcidin levels, FC increased duodenal ferroportin protein in the CKD TKO mice.
Conclusions: In the high-hepcidin TKO mice, low-dose FC was sufficient to increase 
enteral iron absorption and ferroportin expression, improve the anemia of both iron 
deficiency and CKD, and decrease FGF23 expression. FC may decrease FGF23 expression 
through decreased enteral phosphate absorption, improved iron status, and/or decreased 
EPO levels. Although murine FC dosing needs to be optimized, the models of FC absorption 
despite high hepcidin levels will facilitate examination of the mechanisms involved.
Funding: Commercial Support - Keryx
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Vitamin D Increases Bone FGF23 Expression by Increasing Numbers of 
Early Osteocytes
Renata C. Pereira,2 Kathleen Noche,5 Barbara Gales,4 Isidro B. Salusky,3 
Katherine Wesseling-Perry.1 1David Geffen School of Medicine at UCLA, Los 
Angeles, CA; 2University of California, Los Angeles, CA; 3Mattel Children’s 
Hospital, Los Angeles, CA; 4University of California Los Angeles, Los Angeles, 
CA; 5UCLA, Los Angeles, CA.
Background: Vitamin D directly stimulates osteoblast maturation and FGF23 
expression. FGF23 is expressed in early osteocytes at the trabecular periphery. Whether the 
vitamin D-mediated increase in bone FGF23 expression reflects increased numbers of early 
osteocytes or an increase in per-osteocyte expression is unknown.
Methods: We evaluated markers of osteocyte maturity and FGF23 expression by 
immunohistochemistry (IH) and immunofluorescence (IF) and osteocyte apoptosis by 
TUNEL staining in iliac crest of 11 dialysis pts age 15.8±0.8 years who underwent bone 
biopsy before and after 8 mos of doxercalciferol (D) therapy. Bone protein expression was 
evaluated by Ariol scanning of IH. Numbers of FGF23-expressing osteocytes were counted 
and normalized by bone area. RNA was extracted from cores and evaluated by qRT-PCR.
Results: FGF23 co-localized with e11/gp38, a marker of early osteocytes (Fig 1A). 
Numbers of FGF23-expressing osteocytes correlated with FGF23 protein expression 
(r=0.83, p<0.001). Numbers of FGF23-expressing osteocytes increased by 226 (83, 440)% 
and FGF23 mRNA increased by 226 (124, 320)% in response to D. Expression of sclerostin, 
a mature osteocyte marker, increased in cortical bone in response to D (p<0.05). Osteocyte 
apoptosis was low at baseline but increased with D (Fig 1B).
Conclusions: The co-localization of FGF23 with e11/gp38 suggests that increased 
numbers of FGF23-expressing osteocytes reflect a D-mediated increase in early osteocytes. 
The tight relationships between FGF23 RNA message, FGF23 protein, and numbers of 
FGF23-expressing osteocytes suggest that D-mediated increases in FGF23 expression 
are due to increased numbers of FGF23-expressing osteocytes in CKD bone. Increased 
osteocyte apoptosis suggests that D is associated with increased osteocyte turnover. Further 
studies into altered osteocyte maturation, the effects of medications on osteocyte biology, 
and their implications for clinical bone disease in CKD patients are warranted.
Funding: Other NIH Support - NIAMS
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Primary CKD Osteoblasts Are Resistant to the Pro-Maturation Effects of 
1,25D In Vitro
Renata C. Pereira,2 Isidro B. Salusky,3 Anne M. Delany,4 Katherine Wesseling-
Perry.1 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2University 
of California, Los Angeles, CA; 3Mattel Children’s Hospital, Los Angeles, CA; 
4University of Connecticut Health Center, Farmington, CT.
Background: Osteoblast maturation and bone mineralization are integrally linked 
processes. Pediatric CKD patients have a high prevalence of skeletal mineralization defects 
in vivo and primary CKD osteoblasts demonstrate intrinsic impairments in maturation in 
vitro. 1,25D simultaneously stimulates osteoblast maturation and bone FGF23 expression 
while overexpression of FGF23 in primary rodent osteoblasts impairs their maturation 
and mineralization. However, the independent effects of 1,25D and FGF23 on osteoblast 
differentiation in CKD are unknown.
Methods: To investigate this, primary osteoblasts from 6 adolescent dialysis patients 
and 3 healthy adolescent controls were grown to confluence and stimulated to mineralize in 
differentiation media for 2 weeks. Mineralization was quantified by staining cultures with 
1% Alizarin Red S; gene expression was evaluated by qPCR in parallel cultures.
Results: Mineralization was greater in healthy control than in CKD osteoblasts. 1,25D 
increased mineralization of CKD osteoblasts (Fig A). FGF23 did not affect mineralization 
in either CKD or healthy control cultures (Fig B). Runx2 (early osteoblast marker) 
expression was similar in healthy control and CKD osteoblasts at baseline and increased in 
both groups with time. 1,25D increased Runx2 in control, but not CKD, osteoblasts (Fig C). 
Osteocalcin (Bglap) (mature osteoblast marker) expression was higher in control than in 
CKD osteoblasts at baseline. 1,25D stimulated Bglap in both groups (Fig D). FGF23 did 
not affect Runx2 or Bglap.
Conclusions: These data suggest that CKD osteoblasts are resistant to the pro-
maturation effects of 1,25D. This 1,25D resistance may contribute to the mineralization 
defects that persist in pediatric CKD patients despite current renal osteodystrophy therapies. 
The mechanism behind CKD osteoblast maturation resistance, which appears unrelated to 
exogenous FGF23, requires further evaluation.
Funding: Other NIH Support - NIAMS
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1,25-Dihydroxyvitamin D Stimulation Increases FGF23 Expression in 
Calcified Vessels Under High Phosphate Condition
Masaki Ohya, Kazuki Kawakami, Tomohiro Sonou, Mitsuru Yashiro, 
Toru Mima, Shigeo Negi, Takashi Shigematsu. Wakayama Medical University, 
Wakayama, Japan.
Background: Elevated fibroblast growth factor 23 (FGF23) is observed in patients with 
end stage renal disease (ESRD) or chronic kidney disease (CKD). Vascular calcification 
is also a commonly observed in patients with ESRD or CKD, which leads to increased 
cardiovascular events and mortality. Expression of FGF23 in bone is elevated by the factors 
as serum Pi, parathyroid hormone (PTH), and 1,25-Dihydroxyvitamin D, and is suppressed 
by dentin matrix protein-1 (DMP1). We hypothesized that 1,25-Dihydroxyvitamin D 
stimulates FGF23 expression in Pi-induced calcified vessels.
Methods: We performed aortic tissue culture in the medium with normal phosphate 
(0.9mM), high P (3.8mM)i, and high Pi with 1,25Dihydroxyvitamin D (1,25D) for 10 days, 
subsequently von kossa staining, quantification of calcium contents and gene expression of 
Fgf23, Dmp1, and other osteocyte/osteoblast marker; alkaline phosphatase (Alp), dickkopf-
related protein 1 (Dkk1), and screlostin, and immunostaining of FGF23 and DMP1 in the 
cultured aorta.
Results: Aortic ring cultured in the medium with high Pi and high Pi+1,25D showed 
calcium deposition and increased calcium contents significantly. Quantitative PCR 
demonstrated that increasedAlpand Dkk1expression and unchanged Sost expression in 
high Pi+1,25D medium. Expression of FGF23 in aorta ring is not altered under the high Pi 
condition, but is increased under the high Pi+1,25D condition. DMP1 expression in aorta is 
increased under the high Pi condition while the up-regulation is attenuated under the high 
Pi+1,25D condition.
Conclusions: These results suggest that 1,25Dihydroxyvitamin stimulation increases 
FGF23 expression in calcified vessels under high phosphate condition.
Funding: Government Support - Non-U.S.
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A. Quantification of Fgf23gene expression. B. Immunoblot image of FGF23 protein. C.
Immunohistochmical images of FGF23 expression. Normal Pi; 0.9 mmol/L phosphate,
High Pi; 3.8 mmol/L phosphate, High Pi+1.25D; 3.8 mmol/L phosphate and 100 nmol/L 
1,25-Dihydroxyvitamin D3.
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Osteocytes Are the Major Source of Circulating FGF23 During Acute 
Inflammation
Guillaume Courbon,1 Claire Gerber,1 Samantha Neuburg,1 Maralee Capella,1 
Corey Dussold,1 Xueyan Wang,1 Lixin Qi,1 Wenhan Chang,2 Myles Wolf,3 
Aline Martin,1 Valentin David.1 1Northwestern University - Feinberg School of 
Medicine, Chicago, IL; 2Endocrine Unit, SF-VAMC, University of California 
San Francisco, San Francisco, CA; 3Duke University, Durham, NC.
Background: Inflammation is a novel mechanism that stimulates fibroblast growth 
factor (FGF) 23 production in bone cells and extraosseous tissues, however the contribution 
of osteocytes to circulating FGF23 levels during acute inflammation is unknown.
Methods: To investigate the effects of inflammation on FGF23 production, wild-type 
(WT) mice and mice with a conditional deletion (cKO) of Fgf23 in osteocytes (Fgf23fl/
fl;DMP1-Cre+) received a single injection of interleukin-1β (IL-1β) or saline (Ctr). We 
measured FGF23 mRNA and circulating intact and total protein (cFGF23 which includes 
intact and cleaved proteins) up to 6 hours post injection.
Results: In WT mice, injection of IL-1β increased circulating levels of intact and total 
FGF23 (12-fold and 62-fold, respectively, p<0.001 vs Ctr). IL-1β increased Fgf23 mRNA 
expression by 60 fold in bone, 7 fold in spleen and by 300 fold in kidney (p<0.05 vs. Ctr), 
suggesting that extraosseous production of FGF23 may contribute to circulating FGF23 
levels. In line with these findings, cKO-Ctr mice did not show a significant reduction 
in circulating FGF23 compared to WT-Ctr mice, suggesting that extraosseous FGF23 
production is sufficient to maintain relatively normal circulating FGF23 levels. However, 
cKO mice showed a markedly reduced FGF23 secretion in response to IL-1β injection 
compared to WT- IL-1β mice for both intact (-80%) and total FGF23 (-92%, p<0.001). 
Consistent with these data, bone Fgf23 mRNA and protein expression levels were also 
dramatically reduced by 80% (p<0.01) in cKO- IL-1β mice compared to WT- IL-1β. Finally, 
IL-1β treatment of primary osteocytes cultures from WT and cKO animals increased Fgf23 
mRNA expression and protein secretion by 10 fold in WT mice (p<0.05 vs. Ctr) but failed 
to increase FGF23 in cKO cultures.
Conclusions: These results suggest that Fgf23 expression is increased in bone and 
extraskeletal tissues during acute inflammation, however osteocytes are the major secretory 
source for the circulating FGF23 protein.
Funding: NIDDK Support
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Soluble Klotho Regulates TRPC6 Calcium Signaling via Lipid Rafts and 
Independently of FGFR-FGF23 Pathway
Jian Xie, Sung Wan An, Chou-Long Huang. Carver school of Medicine, 
University of Iowa, Iowa City, IA.
Background: Membranous Klotho interacts with fibroblast growth factor receptor 
(FGFR) to form coreceptors for FGF23. The ectodomain of membranous klotho is shed 
(soluble klotho, sKL) and functions as a circulating endocrine or local paracrine factor. sKL 
protects the heart by inhibiting growth factor-stimulated, PI3K-dependent TRPC6-mediated 
Ca entry. Lipid rafts are membrane microdomain important in many cellular processes 
including growth factor signaling and membrane trafficking. We have shown that sKL binds 
to sialogangliosides of membrane lipid rafts to inhibit cardiac Ca signaling. Regulation of 
lipid raft formation and function may underlie pleiotropic actions of sKL. A recent X-ray 
crystal structure of sKL in ternary complex with FGFR and FGF23 suggests that function 
of sKL is mediated by FGFR and FGF23. The physiological circulating levels of sKL and 
FGF23 are ~30 pM and 2 pM (50 pg/ml), respectively. Yet many in vitro assays examining 
the function of sKL, FGF23, and FGFR based on formation of the ternary complex utilize 
supraphysiological levels of sKL and FGF23. For example, in cell proliferation assay 
based on sKL-FGF23-FGFR ternary complex, 100 fold higher sKL (3 nM) and 4,000 fold 
higher FGF23 (200 ng/ml = 4 nM) are commonly used. Here, we examine whether sKL can 
function independently of FGFR-FGF23.
Methods: Computer modeling of sKL structure with and without FGFR-FGF23. 
Whole-cell patch-clamp recording of TRPC6 channels in L6 myoblast cell line lacking 
endogenous FGF receptors.
Results: Computer modeling of sKL structure suggests potential binding sites for sialic 
acids of gangliosides in the absence of FGFR-FGF23. sKL inhibits TRPC6 channel in L6 
cells. We identified amino acid sequence unrelated to sKL but structurally conserved for 
binding sialic acid known as carbohydrate binding motif (CBM). Purified recombinant 
CBM inhibits TRPC6 expressed in L6 cells and in HEK293 cells.
Conclusions: Our results support the hypothesis that sKL protects the heart by 
downregulating TRPC6-mediated calcium signaling in lipid rafts. sKL can exert actions 
independently of FGFR-FGF23 signaling pathway.
Funding: NIDDK Support
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Valsartan Mitigated CKD-MBD in Uremic Rats by Activation Klotho
Ao Cheng. Department of Neprology, The Fist Affiliated Hospital of Xiamen 
University, Xiamen, China.
Background: Valsartan as the most commonly one of ARB drugs, can effectively 
lower blood pressure and remit the progression of chronic kidney disease. In addition, we 
also observed that the ARB drugs could ameliorate the calcium and phosphorus metabolism 
in patients. The main purpose of this experiment is to explore whether valsartan could 
mitigate calcium and phosphorus metabolism and secondary hyperparathyroidism and seek 
the underlying signal pathway in uremic rats.
Methods: Animal Experiment: The rats were divided into three groups: sham 
group, 5/6 nephrectomy group, 5/6 nephrectomy + calcitriol group. 1) Through serum 
biochemical tests, to detect the levels of BUN, Creatine, Ca and P in various groups and 
determine expression of Klotho, TGFβ1, iPHT in serum. 2) By HE, Masson staining of 
renal tussues, Observation of fibrosis and collagen deposition in parathyroid tissue and 
renal tissue. 3) Detection expression of Klotho, TGFβ1, iPHT in parathyroid tussue by 
Immunohistochemical staining. 4) Detection expression of AT1, Klotho, TGFβ1, iPHT, 
E-cadherin and α-SMA in renal tussue by Immunohistochemical staining. 5) Using PCR
and Western-Bloting detect expression of Klotho, TGFβ1, E-cadherin and α-SMA in renal 
tussues.
Results: (1) Valsartan could effectively reduce the elevated creatinine, BUN, improve 
the calcium and phosphorus metabolism and lessen iPTH in the 5/6 nephrectomy rats; (2) 
Valsartan can distinctly reduce parathyroid hyperplasia and iPTH expression, increased 
Klotho expression in parathyroid tissue; (3) Valsartan might ameliorate kidney injury 
and fibrosis by light microscopy; (4) In renal tissue, Valsartan may induce Klotho and 
E-cadherin expression and reduce iPTH, TGFβ1 and α-SMA expression.
Conclusions: Valsartan could suspress parathyroid hyperplasia and ameliorate kidney 
injury and fibrosis in uremic rats. Valsartan might delay the progression CKD-MBD in 
ESRD by increasing the expression of Klotho, reducing iPHT, improving calcium and 
phosphorus metabolism.
Funding: Government Support - Non-U.S.
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Comparison of Four Commercially Available ELISA Kits for Serum and 
Urinary Klotho in Mice
Naoto Hamano,1 Hirotaka Komaba,1,2 Takehiko Wada,1 Masafumi Fukagawa.1 
1Division of Nephrology, Endocrinology and Metabolism, Tokai University 
School of Medicine, Isehara, Japan; 2The Institute of Medical Sciences, Tokai 
University, Isehara, Japan.
Background: Klotho is a transmembrane protein that serves as a co-receptor for 
fibroblast growth factor 23 (FGF23). Klotho is cleaved and released into body fluids, 
including serum, urine, and cerebrospinal fluid. Soluble Klotho has been implicated in 
diverse of biological activities and an increasing number of studies measured serum or 
urinary soluble Klotho levels using commercially available ELISA kits. However, the 
sensitivity and specificity of these kits have been poorly studied.
Methods: We assessed the diagnostic accuracy of 4 commercially available ELISA kits 
for soluble Klotho using serum and urine from 3-week-old Klotho homozygous knockout 
(Klotho-/-), heterozygous knockout (Klotho-/+), and wild type littermate mice. We measured 
serum soluble Klotho with 4 kits and urinary soluble Klotho with 2 kits following the 
instructions of manufacturers.
Results: Klotho-/- mice showed hyperphosphatemia, high 1,25-dihydroxyvitamin D, 
low PTH, increased fractional excretion of phosphate, and markedly elevated FGF23, as 
described previously. All 4 kits for serum soluble Klotho measurements appeared to be 
inaccurate, with false positive results with sera from Klotho-/- mice. As for urinary soluble 
Klotho measurements, we found that only a kit from Immuno-Biological Laboratories 
Co., Ltd. provided reasonable results. With this assay, mean±SD creatinine-adjusted 
urinary soluble Klotho levels in Klotho-/- mice, Klotho-/+ mice, and wild type mice were 
5±2, 218±38, and 290±149 pg/g creatinine, respectively (P <0.001).
Conclusions: These results indicate that appropriate choice of the assay is important 
for accurately measuring soluble Klotho levels. For validating the function of ELISA 
kits, measurement of target elements with specimens of knockout animals would provide 
valuable information.
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Sclerostin, a Potential Mediator in the Bone-Vascular Axis
Annelies De maré,1 Britt Opdebeeck,2 Ellen Neven,1 Patrick C. D’Haese,2 
Anja Verhulst.1 1University of Antwerp, Wilrijk, Belgium; 2University Antwerp, 
Wilrijk, Belgium.
Background: The Wnt/β-catenin signaling, one of the most important bone anabolic 
pathways, might also be a major player in the crosstalk within the bone-vascular-
axis. When pathologically disturbed, this axis results in the concomitant occurrence of 
disturbed bone metabolism and vascular calcification (VC). A hallmark of these VCs is 
the transdifferentiation of vascular smooth muscle cells (VSMCs) towards bone-forming 
(osteochondrogenic) cells. In the current study we investigated parameters related to the 
Wnt/β-catenin signaling cascade and its inhibitor sclerostin.
Methods: Rats were given 0.3mg warfarin/g diet to induce VC. Rats not receiving 
warfarin were included as controls. Rats were sacrificed at different time-points, i.e. 
after 4, 6, 8 and 10 weeks of warfarin treatment, to follow up the development of VC. At 
sacrifice; VC, aortic mRNA expression and immunohistochemistry, bone status and serum 
biochemistry were analyzed.
Results: Results showed a time-dependent increase in VC in warfarin-treated rats. 
Aortic calcium concentration significantly differed from controls in 4-wk treated rats 
(p=0.0286), reaching a 50-fold increase in 10-wk treated rats (p=0.0061). Furthermore, 
aortic mRNA levels of osteochondrogenic transdifferentiation markers (Sox9, p=0.0317 
and Cbfa1, p=0.0635) and β -catenin (regulating target gene transcription, p=0.0159) were 
upregulated. Interestingly, this went along with an upregulation of aortic mRNA expression 
(p=0.0159) and protein levels of sclerostin, as well as serum levels of this protein which 
became significant (p=0.0381) in 10-wk treated rats compared to controls. Finally, a mild 
but significant (p= 0.0095) decrease in bone formation parameters was observed in 10-wk 
treated warfarin rats.
Conclusions: Our results support the hypothesis that VSMCs transdifferentiate 
towards osteochondrogenic cells and thereby also express genes/proteins associated with 
the Wnt/β-catenin signaling, including its inhibitor sclerostin. The latter thereby may act 
as a negative feedback protein to prevent excessive (vascular) calcifications, similar to its 
function in bone. Sclerostin might also spillover from the vessels to the circulation (high 
serum sclerostin levels) causing mild inhibition of bone formation.
Funding: Government Support - Non-U.S.
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Accumulation of Activated β-Catenin in Uremic Hyperparathyroid 
Glands
Ping Wen, Dawei Hou, Jinlong Cao, Junwei Yang. Second Affiliated Hospital, 
Nanjing Medical University, Nanjing, China.
Background: Parathyroid proliferation may become nodular mainly in cases of 
advanced uremic hyperparathyroidism. The ubiquitously expressed multifunctional 
protein β-catenin displays important functions in the canonical Wnt signaling pathway by 
regulating cell proliferation and differentiation. Activation of Wnt/β-catenin pathway leads 
to stimulate aerobic glycolysis, called Warburg effect, which is validated the dominant 
metabolic style in tumor tissue. While hyperplasic parathyroid glands display similar 
pathology characteristics of tumor, the aim of this study is to evaluate whether the Wnt/β-
catenin signaling pathway is activated in hyperplastic glands from sHPT patients and if 
Warburg effect is activated by β-catenin pathway.
Methods: Serum iPTH levels were measured by radio-immunity method. Hyperplastic 
parathyroid glands from sHPT patients (n=36) were acquired from patients during the 
operation. Normal parathyroid tissue (n=3) was obtained from glands inadvertently removed 
in conjunction with thyroid surgery. Real time RT-PCR and immunohistochemistry were 
performed to detect PCNA and activated β-catenin, and glycolytic enzymes.
Results: 1. The average serum iPTH level was 1264.59±576.29 pg/ml of sHPT patients 
and 42.0±20.95 pg/ml of normal controls respectively. 2. HE staining revealed 5 diffuse 
hyperplasic glands and 31 nodular hyperplasic glands. 3. The mRNA and protein expression 
of PCNA was dramatically up-regulated compared to normal controls. 4. The expressions 
of activated β-catenin were increased in hyperplastic glands compared to normal glands. 
There was no difference between diffuse hyperplasic and nodular hyperplasic glands. 
Semiquantitative analysis didn’t reveal association between β-catenin and iPTH level. 
5. The expressions of glycolytic enzymes: HK2, PFK and LDH were not up-regulated in
hyperplasic glands compared to the normal glands. Semiquantitative analysis didn’t reveal
associations between expressions of glycolytic enzymes and iPTH level.
Conclusions: Our results strongly suggest that modifications in the Wnt/β-catenin 
signaling pathway may be involved in the development of sHPT. However, aerobic 
glycolysis was not activated by β-catenin in hyperplasic glands. The precise mechanism 
is needed to be explored.
Funding: Government Support - Non-U.S.
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In Silico Model of PTH-Induced Self-Limiting Anti-Apoptotic Signaling 
Pathways in Osteoblasts
Alhaji Cherif,1 Doris H. Fuertinger,2 Stephan Thijssen,1 Peter Kotanko.1,3 1Renal 
Research Institute, New York, NY; 2Fresenius Medical Care, Bad Homburg, 
Germany; 3Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Cyclical and continuous stimulations of cell receptors result in 
differential responses with important clinical and therapeutic implications. An example of 
such differential response is seen in the anabolic and catabolic outcomes of intermittent and 
continuous elevations of parathyroid hormones (PTH), respectively, where chronic level of 
PTH, as seen in hyperparathyroidism, leads to catabolic effects on bone, whereas cyclical 
administration of PTH or analogs, as seen in osteoporotic therapy, stimulates osteoblastic 
activities resulting in anabolic gains. The goal is to develop an in silico model describing the 
proteasomal proteolysis mechanism limiting the anti-apoptotic effect of PTH in osteoblasts, 
in order to understand quantitatively the differential clinical responses.
Methods: We develop a model to describe the underlying PTH-induced intracellular 
osteoblastic signaling pathway, namely, Runx-2-CREB-Bcl-2 signaling pathway. The 
model incorporates multiple scale to capture scale differences between the anti-apoptotic 
and degradative enzymatic activities. The model is used to evaluate apoptotic activities 
under the conditions of continuously and intermittently elevated PTH, respectively.
Results: In silico result shows that continuously elevated PTH increases degradative 
enzymatic activities and blunt the anti-apoptotic effects associated with the Runx-2-
CREB-Bcl-2 signaling pathway. The directional difference between CREB and Runx-
2 equilibrates Bcl-2 level, thereby nullifying its anti-apoptotic effects on osteoblasts. 
Consequently, PTH-mediated osteoclastic activities via RANK-RANKL-OPG pathway 
exert catabolic loss. The model also predicts that intermittency of PTH increases CREB 
while only intermittently decreasing Runx-2, resulting in a net increase in Bcl-2. This, in 
conjunction with downstream inhibition of cytokine-mediated osteoblastic apoptosis, leads 
to anabolic gains. Employing global sensitivity analysis, different anti-apoptotic therapeutic 
directions are outlined.
Conclusions: There is a great need to understand the mechanisms underlying 
differential osteoanabolic and catabolic responses induced by intermittent and continuous 
levels of PTH, respectively, in order to provide new therapeutic options for patients. With 
our model, we can demonstrate importance of Runx-2-CREB-Bcl-2 signaling in limiting 
the osteoblastic apoptosis.
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Severe CKD, Even Without a High-Phosphorus Diet, Affects the 
Expression of Only CaSR, VDR, and Gcm2 in the Parathyroid Glands in 
Rats but Not of Other Key Genes Involved in Parathyroid Function
Taketo Uchiyama,1 Ichiro Ohkido,1 Sahoko Kamejima,2 Akio Nakashima,3 
Takashi Yokoo.4 1Division of Nephrology and Hypertension, Department of 
Internal Medicine, Jikei University School of Medicine, Tokyo, Japan; 2Jikei 
University School of Medicine, Tokyo, Japan; 3Division of Kidney and 
Hypertension, Department of Internal Medicine, The Jikei University School of 
Medicine, Tokyo, Japan; 4The Jikei University School of Medicine, Tokyo, 
Japan.
Background: Secondary hyperparathyroidism (SHPT) is a common complication 
of chronic kidney disease (CKD), which disrupts mineral homeostasis. It occurs during 
the early course of progressive renal insufficiency, and is associated with mortality and 
cardiovascular events. Downregulation of calcium-sensing receptor (CaSR) and vitamin 
D receptor (VDR) occurs throughout this process. Previously, we reported that glial 
cells missing 2 (Gcm2), which directly regulates CaSR and is related to hyper- and 
hypoparathyroidism, may be responsible for the reduction in mRNA and protein levels of 
CaSR (ASN 2017). However, as many other important genes regulate parathyroid function, 
we aimed to investigate the role of these genes in SHPT progression.
Methods: CKD was induced in rats with 0.75% adenine-containing diet. CKD and 
control rats were maintained for 2 weeks on diets with 0.7% (normal; NP) or 1.3% (high; 
HP) phosphorus. For gene expression analysis, quantitative real-time polymerase chain 
reaction (PCR) was performed with TaqMan probes. Protein expressions was analyzed by 
immunohistochemistry and Western blotting. DNA methylation analysis was performed by 
restriction digestion and quantitative PCR.
Results: VDR mRNA and protein expression levels were reduced in CKD rats fed NP 
and HP diets. There was no significant difference in the DNA methylation status of VDR 
promoters among the four groups (Figure 1) as same as CaSR (ASN 2017). There were no 
significant differences in the gene expression levels of MafB, GATA3, Eya1, Tbx1, Pax1, 
Pax9, Six1, Six4 (Figure 2), although the Gcm2 gene and protein expression levels were 
significantly decreased.
Conclusions: CKD NP and HP rats showed significant reductions in CaSR, VDR and 
Gcm2 gene and protein expressions. Our data suggested that compared with CaSR and 
VDR, Gcm2 plays a major role in SHPT progression and may be an important therapeutic 
target for SHPT.
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Effect of Ovariectomy on the Progression of CKD-Mineral Bone Disorder 
(CKD-MBD) in Cy/+ Rats
Colby Vorland,1 Pamela Lachcik,1 Courtney N. Nelson,1 Neal X. Chen,2 
Sharon M. Moe,2 Kathleen M. Hill Gallant.1,2 1Purdue University, West Lafayette, 
IN; 2Indiana University School of Medicine, Indianapolis, IN.
Background: There is increasing interest in sex as a biologic variable, yet studies 
have generally not examined the role of sex in the pathogenesis of CKD-MBD despite 
experimental and epidemiological evidence suggesting that estrogen is protective to 
kidney function and bone and thus CKD-MBD. In the Cy/+ rat model of CKD-MBD, a 
spontaneous genetic mutation causes progressive kidney function decline in males prior to 
20 weeks of age, but kidney function is maintained in females past 80 weeks of age making 
it impractical to study these females as a model of CKD. Therefore, ovariectomy to mimic 
a post-menopausal state may accelerate the initiation of the CKD-MBD phenotype and 
enable the use of female Cy/+ rats in research.
Methods: Sixteen female Cy/+ rats were randomized to either ovariectomy (OVX) 
(n=8) or sham surgery (n=8) at 15 weeks of age. A casein-based diet was initiated at 24 
weeks of age to promote kidney function decline as is done in studies with male Cy/+ rats. 
Blood was sampled at 10, 20, 25, 30, and 35 weeks of age, and analyzed for BUN, plasma 
phosphorus, and plasma calcium.
Results: Data collected on all n=16 through 25 weeks show that OVX rats have higher 
body weights (p<0.0001) (and lower uterine weights for n=4 that completed the 35 weeks 
of the study) confirming the success of the OVX procedure. Plasma phosphorus decreased 
over time in both groups (p<0.0001), but was not different between groups (p=0.46). 
Plasma calcium was not different between groups (p=0.38) and did not change over time 
(p=0.57). Plasma BUN decreased slightly over time in both groups (p<0.01) but remained 
in normal ranges, and there is no difference between OVX and sham (p=0.23). In n=2 OVX 
and n=2 sham that have completed the 35 weeks of the study, preliminary analysis shows no 
appreciable difference in BUN, phosphorus, or calcium between groups.
Conclusions: Analyses will continue through 35 weeks, however at 25 weeks of age, 
there is currently no indication that OVX accelerates kidney function decline in female 
Cy/+ rats. This is in contrast to Cy/+ male rats which can be phenotyped based on elevated 
BUN as early as 10 weeks of age, and by 25 weeks of age exhibit a ~50% reduction in 
kidney function (Moe et al. 2011).
Funding: NIDDK Support, Other NIH Support - Funded in part by Award Number 
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Advanced Glycation End-Products (AGEs) Accumulation and Skeletal 
Complications in CKD Patients
Noemi A. Roza,3,1 Kelcia R. Quadros,3,1 André B. Esteves,3,1 Renata A. Franca,3,1 
Cynthia M. Borges,3,1 Cinthia E. Carbonara,3,1 Fabiana S. Antonialli,3,1 
Luciene dos Reis,2 Vanda Jorgetti,2 Rodrigo B. de Oliveira.3,1 Laboratory for 
Evaluation of Mineral and Bone Disorder in Nephrology (LEMON) 1State 
University of Campinas, Campinas, Brazil; 2University of Sao Paulo - Medical 
School - Nephrology Division, Sao Paulo, Brazil; 3School of Medical Sciences, 
Campinas, Brazil.
Background: Chronic kidney disease (CKD) has high rates of mortality related to 
uremic toxins and bone complications. Fractures risk is higher in CKD patients than general 
population and is dependent of cortical bone quality. We aim to investigate the relationships 
between advanced glycation end-products (AGEs) and bone in a cohort of patients at 
different stages of CKD.
Methods: 86 CKD patients (stages 3-4, N=26; hemodialysis, N=32; peritoneal 
dialysis, N=28) were included. AGEs levels were measured in serum (for glycated 
hemoglobin and pentosidine), skin (through AGE-Reader device), and cortical bone 
(by immunohistochemistry). Fracture risk was predicted using FRAX tool. Bone 
histomorphometry was performed to measure cortical porosity, thickness and volume.
Results: Age was 51±13 yrs., 48 (56%) male, 41 (48%) Caucasian and 16 (19%) 
diabetics; GFR was 6 (5-17) mL/min, body mass index (BMI) was 26±5 kg/m2 and 
waist circumference 92±12 cm. AGEs levels in skin were 3.0±0.7 AU (reference: < 2.0 
AU) and were positively correlated with age (R=0.68; P=0.001), glycated hemoglobin 
(R=0.28; P=0.04), risk for major osteoporotic fracture (R=0.54; P=0.001), hip fractures 
(R=0.53; P=0.001), Framingham risk (R=0.53; P=0.001). AGEs deposition in cortical 
bone were positively correlated with major osteoporotic fracture risk (R=0.50; P=0.001). 
Cortical thickness were negatively correlated with serum pentosidine (R=-0.30; P=0.04) 
and glycated hemoglobin levels (R=-0.31; P=0.03), Framingham Risk (R=-0.33; P=0.02), 
age (R=-0.43; P=0.03), BMI (R=-0.43; P=0.03), waist circumference (R=-0.38; P=0.01), 
and LDL-cholesterol (R=-0.34; P=0.02). Cortical porosity were positively correlated with 
cholesterol levels (R=0.30; P=0.04) and Framingham Risk (R=0.32; P=0.03).
Conclusions: AGEs were detected in cortical bone of CKD patients at different stages 
and correlates with their risk for major osteoporotic fractures; this risk was also related 
with AGEs accumulation in skin. Serum levels of pentosidine and glycated hemoglobin 
were associated to low thickness of cortical bone. Finally, there seems to be a relationship 
between poor quality of cortical bone and factors linked to cardiovascular disease.
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PTH Suppression Normalizes CKD-Induced Elevations in Cortical Bone 
Perfusion in an Animal Model of Progressive CKD
Mohammad W. Aref,1 Elizabeth A. Swallow,2 Neal X. Chen,3 Sharon M. Moe,3 
Matthew R. Allen.3 1IU School of Medicine, Indianapolis, IN; 2Indiana 
University, Indianapolis, IN; 3Indiana University School of Medicine, 
Indianapolis, IN.
Background: Patients with chronic kidney disease (CKD) have accelerated bone loss, 
vascular calcification and abnormal biochemistries, together contributing to an increased risk 
of cardiovascular disease and fracture-associated mortality. Despite evidence of vascular 
pathologies and dysfunction in CKD, our group has shown that cortical bone tissue perfusion 
is higher in a rat model of high-turnover CKD. The goal of this experiment was to test the 
hypothesis that suppression of high turnover through calcium-induced suppression of PTH 
would normalize cortical bone vascular perfusion in the setting of CKD.
Methods: 35-week-old animals in one of three groups: normal (NL), Cy/+ (CKD), and 
Cy/+ treated with 3% calcium water (CKD+Ca) for 10 weeks (n=6/group) underwent intra-
cardiac fluorescent microsphere injection to assess bone tissue perfusion.
Results: CKD animals had serum blood urea nitrogen (BUN) and PTH levels 
significantly higher than NL (+182% and +958%; p<0.05). CKD+Ca animals had BUN 
levels that were similar to CKD, while PTH levels were significantly lower and comparable 
to NL. Dynamic bone histomorphometry of the proximal tibia demonstrated that active 
remodeling surfaces were significantly increased in the CKD animals compared to normal 
(+88%); levels were normalized to NL levels by calcium supplementation. MicroCT 
analysis of the proximal tibia cortical porosity showed a trend toward higher values in 
CKD (+401%; p=0.0962) but not CKD+Ca (+111%; p = 0.3787) compared to NL. Both 
femoral cortex (+220%, p=0.0083) and tibial cortex (+336, p=0.0009) tissue perfusion were 
significantly higher in CKD animals when compared to NL; perfusion was normalized to 
those of NL in CKD+Ca animals.
Conclusions: These data demonstrate that the combination of bone remodeling 
suppression and serum PTH reduction normalizes cortical bone perfusion in the setting 
of CKD. Further work will focus on uncoupling the effects of PTH reduction and turnover 
suppression on cortical bone perfusion in the setting of CKD.
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Inflammation and Bone Loss in Patients with New Onset of Lupus 
Nephritis: The Pathways to Increased Osteoclastogenesis
Ana P. De Lima,3 Wagner Dominguez,4 Cristiane B. Dias,5 Luciene dos Reis,4 
Vanda Jorgetti,2 Viktoria Woronik.1 1Nephrology, University of São Paulo, São 
Paulo, Brazil; 2Universidade de Sao Paulo, Sao Paulo, Brazil; 3Universidade de 
São Paulo, São Paulo, Brazil; 4University of Sao Paulo - Medical School - 
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Background: The pathogenesis of lupus nephritis (LN) comprises immune complexes 
deposition, abnormalities of complement system,T,B and regulatory cells-TREG, unbalance 
of Th1/Th2 subsets and IL17. Bone loss is present in newly diagnosed LN patients 
without an expressive dose of corticosteroids. Some evidences indicate an increased 
osteoclastogenesis as the main disturb of the remodeling process. Although the pathways 
that lead to bone loss are not completely understood, some systems are involved such as 
RANK-L/OPG, Wnt/βcatenin and Th17/IL17. In this context osteoblasts seems to play a 
remarkable role in mediating the crosstalk between bone and immune systems as well as 
osteoclast response. Vitamin D (VitD) is well-known for its role in bone mineralization 
but studies have been revealing its anti-inflammatory actions such as redirecting Th1 to 
Th2 response, suppressing Th17 and stimulating TREG. This study aimed to determine the 
pathways involved in abnormal osteoclastogenesis observed in women at the diagnosis of 
proliferative LN as well as evaluating if vitD can reverse this response.
Methods: We cultured the human osteoblastic cell line hFOB 1.19. Once mature, we 
divided cultures into those supplemented with serum from healthy controls (n=15) and LN 
patients (n-15) instead of fetal bovine serum. Then 1,25-dihydroxyvitaminD was added in 
two subgroups at 10-9M e 10-7M while vitD was absent in one subgroup in both healthy and 
LN women. After 48h of vitD addition, hFOB cultures were trypsinized. Flow Cytometry 
and multiplex assays were performed to test CD166, CD54, RANK-L, OPG, CD14, TLR4, 
NFκB, SOST, DKK1, βcatenin, IL6, IL1β, TNFα, IL2, IL17A, IL17F, IL21 and IL22.
Results: There was a tendency of DKK1 to be higher in LN patients than healthy 
controls at baseline without vitD (668.6x460.4pg/mg, p0.07) but at vitD 10-7M the 
difference became significant (673.0x456.6pg/mg, p0.02). Without vitD, OPG was higher 
in the healthy group than LN (298.7x 178.8pg/mg, p0.003).
Conclusions: Osteoblasts cultured with LN serum tend to have lower levels of OPG, 
which can corroborate to increased osteoclastogenesis by inhibition of RANK-L action. 
Although DKK-1, an inhibitor of wnt/βcatenin pathway, tend to be higher in osteoblasts 
cultured with LN serum, no difference was observed in βcatenin levels among the groups.
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Validation of a Small Caliber Bone Biopsy for the Diagnosis of Renal 
Osteodystrophy
Etienne Novel-Catin,1 Solenne Pelletier,1 Denis Fouque,1 Jean-Paul Roux,3 
Roland Chapurlat,3 Tom Nickolas,2 Marie-helene Lafage-proust.4 1University 
Center Hospital - Lyon Sud, Saint Priest, France; 2Columbia University Medical 
Center, New York, NY; 3inserm UMR 1033, lyon Cedex 08, France; 4INSERM 
U1059-CHU, SAINT-ETIENNE, France.
Background: Histomorphometric analysis of a transiliac bone biopsy is the gold 
standard for the diagnosis of renal osteodystrophy (ROD). This procedure is usually 
performed with an 8mm-diameter trephine. However, this procedure is progressively 
forgone due to its invasiveness and cost as well as to the increasing lack of experts able 
to carry it out. Our objective was to validate ROD diagnosis on halved bone samples, 
mimicking those obtained with a 4mm Jamshidi needle, a procedure of increasing popularity 
that has not been endorsed yet.
Methods: Fifty two bone biopsies performed in CKD patients with 8mm Meunier-
Bordier trephines were included. Quantitative histomorphometric analysis of the 
complete bone samples was performed including assessment of bone mass (Bone volume, 
BV/TV,%), turnover (Bone Formation Rate, BFR, μm3/μm2/d, mineralizing surface, MS/
BS,%, and Mineral Apposition Rate, MAR, μm/d), resorption (TRAP positive osteoclastic 
surface, OcS/BS, %), mineralization (osteoid surface, OS/BS %, osteoid thickness OTh, 
μm and Mineralization Lag Time, MLT, days). Each histological section was then divided 
lengthwise in two 4mm-wide hemi-biopsies. Histomorphometric analysis was repeated
this time on one randomly chosen hemi-biopsy for each sample, blind form initial results. 
Diagnoses were classified as Osteitis Fibrosa (OF), Adynamic bone disease (ABD), Mixed 
uremic bone disease (MUO), Osteomalacia (OM) or other. Correlation of each parameter
between the whole biopsy and the corresponding hemi-biopsy was studied using Pearson’s 
test. Concordance between the ROD diagnosis obtained from the whole biopsy and the
hemi biopsy was analyzed.
Results: Fifty two biopsies were analyzed including 39 OF, 3 ABD, 3 MUO, 3 OM 
and 4 Other. Correlations between whole 8mm-wide biopsies and the corresponding hemi-
biopsies was for BV/TV, r=0.97, p<0.001, OS/BS, r=0.98, p<0.001, Oc.S/BS, r=0.98, 
p<0.001, and BFR/BS, r=0.93, p<0.001. Final diagnosis was concordant between the whole 
biopsy and the hemi-biopsies in 97% of cases.
Conclusions: Four mm wide bone biopsies allow for an accurate assessment of ROD 
in CKD patients. The replacement of Meunier/Bordier trephines with disposable Jamshidi-
type needles could improve the procedure’s feasibility at the patient’s bedside, as well as 
decrease both its invasiveness and cost.
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Multiple Lower Doses of Zoledronate Reduces Skeletal Accumulation in 
the Setting of CKD
Elizabeth A. Swallow,1 Mohammad W. Aref,2 Spencer Sacks,3 
Demi R. Lehmkuhler,1 Neal X. Chen,4 Sharon M. Moe,4 Matthew R. Allen.4 
1Indiana University, Indianapolis, IN; 2IU School of Medicine, Indianapolis, IN; 
3Marian University, Indianapolis, IN; 4Indiana University School of Medicine, 
Indianapolis, IN.
Background: Chronic Kidney Disease (CKD) results in a dramatic increase in skeletal 
fracture risk. Bisphosphates (BP) are an effective and common treatment for reducing 
fracture risk but they are not recommended in advanced CKD. We have recently shown 
higher skeletal accumulation of zoledronate (ZOL) in the setting of CKD. This study aimed 
to test the hypothesis that more frequent, lower dose administration of ZOL would alter 
skeletal accumulation profiles in CKD.
Methods: At 25 weeks of age, normal (NL) and CKD (Cy/+) rats were divided into 
control groups (no dosing), a single dose of a fluorescent-tagged ZOL (FAM-ZOL), or 
ten weekly doses of FAM-ZOL each at 1/10th the dose of the single dose group. A subset 
of CKD animals were provided 3% calcium (Ca) in drinking water to lower PTH and 
bone remodelling. At 35 weeks of age, serum, tibia, ulna, radius, vertebra, femora, and 
mandible were collected. Bulk fluorescence levels were assessed using Spectral CT and data 
compared using 2-way ANOVA.
Results: At 35 weeks of age, all CKD groups had significantly higher blood urea 
nitrogen (BUN) compared to NL. Parathyroid hormone (PTH) levels were 10-fold greater 
in CKD animals compared to NL; Ca supplementation normalized PTH levels to those of 
NL. At all skeletal sites assessed CKD and CKD+Ca animals had higher FAM-ZOL levels 
compared to NL (+89 to +167%). The vertebra, radius, and ulna all showed significant 
dosing effects with the multiple dosed animals accumulating 20-32% less FAM-ZOL than 
those given a single dose. At the distal femur, there was a significant interaction between 
factors, with CKD+Ca animals having a 40% reduction in FAM-ZOL retention with 
multiple FAM-ZOL doses versus a single dose.
Conclusions: More frequent, lower dose administration result in significantly less 
zoledronic acid accumulation compared to a single dose at multiple skeletal sites.
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Effects of Fetuin-A-Containing Calciprotein Particle (CPP) on  
Posttranslational Modifications of Fetuin-A in HepG2 Cells
Hideki Uedono,1 Akinobu Ochi,1 Shinya Nakatani,1 Akihiro Tsuda,1 
Katsuhito Mori,1 Masanori Emoto,1 Masaaki Inaba,1 Tetsuo Shoji.2 1Osaka City 
University Graduate School of Medicine, Osaka, Japan; 2Osaka City University 
Graduate School, Osaka, Japan.
Background: Fetuin-A is a liver-derived circulating glycoprotein that has potent 
calcification-inhibitory capacity. Under calcification stress such as CKD, fetuin-A prevent 
ectopic calcification by forming colloidal complexes that comprise calcium, phosphate 
and fetuin-A, termed fetuin-A-containing calciprotein particle (CPP). Recent reports 
suggest that CPP may have physiological and pathological functions including induction of 
inflammation. The objective of this study was to investigate the effects of CPP on fetuin-A 
expression in hepatocytes.
Methods: Synthetic CPP was prepared as previously reported. Because fetuin-A 
is posttranslationally modified, the molecular weight (MW) of fetuin-A is known to be 
approximately 60 kDa (fully modified fetuin-A: FM-Fet), which is much higher than 
deduced MW based on amino acid sequence. We focused on the effects of synthetic CPP on 
FM-Fet expression using the human hepatoma HepG2 cell line.
Results: CPP increased protein expression of FM-Fet in dose- (462% increase by 
100 μg/mL CPP for 24hr) and time-dependent manner. However, CPP did not affect the 
mRNA expression of fetuin-A. Although we focused on the effects of CPP on degradation 
pathways of fetuin-A such as the lysosome and the ubiquitin-proteasome system, these 
pathways were not involved in CPP-induced FM-Fet expression. Since FM-Fet contains 
N-linked and O-linked glycosylation sites, cell lysates containing CPP-induced FM-
Fet were incubated with N-glycosidase PNGase F (peptide-N-glycosidase F) and/
or O-glycosidase. Treatment with N-glycosidase and/or O-glycosidase increased the
considerable mobility of 60 kDa form of FM-Fet, suggesting that CPP modulate N- and
O- glycosidations of fetuin-A. After HepG2 cells were pretreated for 30 min with or without 
1 μg/mL brefeldin A, which blocks the transport of proteins from the endoplasmic reticulum 
to the Golgi complex, cells were incubated in 100 μg/mL CPP for 24 hr. Treatment with 
brefeldin-A inhibited CPP-induced FM-Fet expression concomitant appearance of 
approximately 50-55 kDa form.
Conclusions: CPP could upregulate posttranslational modifications of fetuin-A in 
HepG2 cells. These findings suggest a positive feedback loop between increased CPP which 
may reflect fetuin-A deficiency in advanced CKD and up-regulation of secreted fetuin-A.
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PPARγ Mediates Impaired Circadian Rhythmicity of Human Vascular 
Smooth Muscle Cells Cultured Under High Phosphate Environment
Ningning Wang,1 Qingting Wang,2 Ying Cui.1 1Department of Nephrology, The 
First Affiliated Hospital with Nanjing Medical University, Nanjing, China; 
2Nephrology, the First Affiliated Hospital of Nanjing Medical University, 
Nanjing, China.
Background: The onset of cardiovascular disease (CVD) in chronic kidney 
disease(CKD) patients often vary by time-of-day. Peroxisome proliferator-activated 
receptor γ (PPARγ) has been confirmed to play an important role in vascular smooth muscle 
cells (VSMC) by acting as a peripheral factor participating in regulation of cardiovascular 
circadian rhythms. It has been reported that hyperphosphatemia plays a vital role in 
abnormal cardiovascular circadian rhythms. Here we aim to investigate the role of PPARγ 
in the biorhythm regulation of human aortic vascular smooth muscle cells (HASMCs) under 
high phosphate environment in vitro.
Methods: The HASMCs were divided into (1) normal control group (1.0 mmol/L 
phosphorus), (2) high phosphorus group (2.5 mmol/L phosphorus), (3)PPARγ activator 
rosiglitazone group (10 μmol/L), and (4) high phosphorus(2.5 mmol/L phosphorus) + 
rosiglitazone group (10 μmol/L) (n=3). The timing of the beginning stimulated was counted 
as time 0. Thereafter, cells were collected every 4 hours for a total of 28 hours. The mRNA 
expressions of PPARγ, Bmal1, Per2 and Rev-erbα in different groups of cells at different 
time points were detected by quantitative polymerase chain reaction (qRT-PCR).
Results: The mRNA expressions of PPARγ and clock genes Bmal1, Per2, Rev-erbα 
showed circadian rhythm in control group of HASMCs. A high-phosphorus environment 
could inhibit the expression of above genes, thereby destroying the normal biorhythm of 
HASMCs. After activating PPARγ by rosiglitazone, the expression of clock genes were 
up-regulated, and the inhibited biorhythm of HASMCs by high-phosphorus environment 
could be reversed(Fig1).
Conclusions: Expression of PPARγ and clock genes Bmal1, Per2, Rev-erbα in 
HASMCs has circadian rhythm. High phosphorus environment destroys their normal 
biological rhythms by inhibiting PPARγ. We uncovered a vital role of PPARγ in vascular 
rhythms disorders under high phosphate environment, suggesting the new treatment target 
of CVD in CKD patients.
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NMR Metabolomic Profiling in Distinguishing Kidney Stone Formers 
from Controls
Aleksandar Denic, Ivan Vuckovic, Lisa E. Vaughan, Felicity T. Enders, 
Slobodan Macura, John C. Lieske, Andrew D. Rule. Mayo Clinic, Rochester, MN.
Background: NMR-based urine metabolomics has shown considerable potential in 
biomarker discovery. It is not fully understood why some individuals develop kidney stones 
and others do not. We hypothesized that certain urine metabolites can distinguish kidney 
stone formers from controls.
Methods: We used high resolution NMR spectroscopy to study urines of 255 adult 
first-time incident symptomatic stone formers (SF), and 255 age and sex-matched controls. 
This was split into a training dataset (2/3, n=171 SF/control each) and a test dataset (1/3, 
n=84 SF/control each). NMR spectra were normalized by total spectrum area. Sex and 
metabolites from NMR data were used in PLS discrimination analysis to fit a model that 
distinguishes stone formers from controls in the training dataset. Variables with VIP>0.8 
were selected for inclusion and cross-validation was used to determine number of 
components in the final model.
Results: Among the 108 metabolites included in the final model, those with the 
strongest positive association with SF were 1,6-Anhydro-D-glucose, glucuronate, lactose 
and an unknown compound, while those with the strongest negative association were 2 
unknown compounds and scyllo-inositol. The area under the curve for detecting stone 
formers with the metabolite panel was 0.66 in the training dataset and 0.57 in the validation 
dataset (Figure). Sensitivity and specificity were 78%/50% and 76%/36% in the training 
and validation sets, respectively.
Conclusions: This study found that a panel of urine metabolites could potentially 
discriminate those at risk for symptomatic kidney stones. Further studies are needed to 
identify the unknown compounds. Understanding the differential expression of these 
metabolites could shed new insights into the biology of kidney stone formation.
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Matrix Protein Differences Between Various Stone Types
Jeffrey Wesson. VA Medical Center, Milwaukee, WI.
Background: Enrichment of highly anionic and highly cationic proteins was observed 
in calcium oxalate monohydrate (COM) stone matrix, but ittle is known about protein 
distributions other stone types. In this study, stone matrix proteins have been quantitatively 
identified in other stone types, including uric acid (UA), calcium oxalate dihydrate (COD), 
and basic calcium phosphate (BCP) using a previously reported method.
Methods: Stone matrix proteins were isolated from 11 COM stones (>60% COM 
content), 6 UA stone samples (>95% UA content), 6 COD stones (>50% COD content), 
and 5 BCP stones (>50% BCP content) by dissolution in sequential washes with an EDTA/
SDS solution at pH=8 with dithiothreitol added. The solubilized proteins from each stone 
were concentrated and desalted by ultradiafiltration. Proteomic analysis was performed 
at the Medical College of Wisconsin Innovation Center using non-labelled, quantitative 
mass spectrometry methods and reported as spectral counts (SC), including only proteins 
with 2 or more peptide matches at >85% confidence, after removing keratin and redundant 
proteins.
Results: All samples contained >1,000 SC, but the total protein signal was slightly 
smaller in COM compared to other stone types. More than 400 unique proteins were 
identified in each stone type, but a smaller subset were both frequent and abundant in each 
stone type: 69 proteins in ≥7 of 11 COM stones (89% SC); 126 proteins in ≥4 of 6 COD 
stones (85% SC); 108 proteins in ≥3 of 5 BCP stones (92% SC), and 51 proteins in ≥4 of 
6 UA stones (67% SC). Most abundant proteins were common between the different stone 
types, and all stone types were enriched in strongly cationic proteins. Calcium containing 
stones were also enriched in strongly anionic proteins, more prominently in COM compared 
to COD or BCP. UA stones exhibited a markedly different proteome compared to calcium 
stones, with fewer nuclear proteins and more inflammatory components.
Conclusions: Stone matrix proteins exhibit distinctly different patterns in each stone 
type, implying that unique crystal interactions with proteins and/or cell surfaces control their 
pathogenesis. The prominence of strongly anionic proteins in calcium stones, particularly 
in COM suggests that polyanion-polycation aggregation is a plausible mechanism for COM 
stone formation. Conversely, UA stone formation may be more dependent on inflammatory 
pathways, but the link to crystal aggregation is unkown.
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Common CLDN2 Variants Are Associated with Kidney Stone Risk and 
Reduced Claudin-2 Expression in Human Tissue
Joshua N. Curry,1 Chizu Tanikawa,3 Yoichiro Kamatani,4 Koichi Matsuda,3 
Alan S. Yu.2 1University of Kansas School of Medicine, Kansas City, KS; 
2University of Kansas Medical Center, Kansas City, KS; 3The University of 
Tokyo, Minato-ku, Tokyo, Japan; 4RIKEN Center for Integrative Medical 
Sciences, Yokohama, Japan.
Background: The majority of calcium reabsorption in the proximal tubule (PT) 
occurs by an unknown route, although many studies suggest it is a passive process. The 
claudin family of proteins are tight junction proteins that in part modulate paracellular 
permeability and passive reabsorption in the kidney. The isoform claudin-2 forms cation-
selective pores in vitro and is highly expressed in the PT. We previously showed that Cldn2-
/y mice exhibit hypercalciuria and nephrocalcinosis, both of which are major risk factors for 
the development of kidney stones. We hypothesized that CLDN2 polymorphisms would 
associate with susceptibility for nephrolithiasis. To date, genome-wide association studies 
of nephrolithiasis have excluded CLDN2 from their analyses due to its location on the X 
chromosome.
Methods: Twelve SNPs in the CLDN2 locus passed our inclusion criteria and were 
assessed by logistic methods for disease association in two separate patient populations. 
Meta-analysis of the 2 studies was subsequently conducted using METAL with a total of 
11,130 kidney stone cases and 187,639 controls. Using the dataset from the Genotype-
Tissue Expression (GTEx) project, we analyzed cis-acting eQTLs in the CLDN2 locus. 
GTEx has insufficient kidney samples for eQTL analysis, but human kidney cortex and 
pancreas both exclusively express the same transcript (ENST00000540876.1). Thus, we 
analyzed pancreatic claudin-2 expression in association with CLDN2 risk variants.
Results: Our findings show that 9 CLDN2 SNPs were associated with nephrolithiasis 
with p-values of 0.0462-0.0055. Given our findings in Cldn2-/y mice, we predicted that 
CLDN2 risk variants for kidney stones would lead to reduced claudin-2 expression. In 6 
of the 7 CLDN2 SNPs available for eQTL analysis using GTEx, nephrolithiasis risk alleles 
were strongly associated with decreased pancreatic claudin-2 expression.
Conclusions: Our present findings suggest that common CLDN2 variants lead 
to reduced claudin-2 expression and thereby increase the risk for human kidney stone 
formation.
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Urinary Stone Forming Crystals Activate Renal Medullary Epithelial 
Cells to Shed Extracellular Vesicles Containing Specific MicroRNAs and 
Proteins
Guotao Chen,4 Muthuvel Jayachandran,1 Jing jing Han,2 Zejfa Haskic,3 
John C. Lieske.1 1Mayo Clinic, Rochester, MN; 2Mayo Clinic College of 
Medicine (Rochester), Rochester, MN; 3Mayo clinic, Rochester, MN; 
4Department of Nephrology, The Bishan Hospital, Chongqing City, P.R. China, 
Chongqing city, China.
Background: The majority (~80%) of urinary stones are comprised of calcium oxalate 
(CaOx) and/or hydroxyapatite (HA). Our previous studies suggest that populations of 
urinary extracellular vesicles (EVs) and their contents differ in stone formers. This study 
was designed to examined whether CaOx or HA crystals activate human renal medullary 
epithelial cells (HRMdEC) to shed EVs containing specific microRNAs (miRNAs) and 
their target proteins.
Methods: HRMdEC grown in 6-well tissue culture plates were synchronized by 
incubation in RenaLife Basal Medium without fetal bovine serum for one hour before 
exposure to CaOx monohydrate (COM) or HA crystals (100μg/mL). Aliquots of medium 
(250μL) were collected at 0, 0.5, 1, 3, 6, 12, and 24 hour (h). Populations of EVs in 
medium were analyzed by digital flow cytometer. Cells were harvested at 24h to determine 
expression of miRNAs identified previously in the urinary EVs of stone formers and their 
target proteins using qPCR and Western blotting, respectively. Data were analyzed by 
Student’s t-test or Wilcoxon rank sum test.
Results: The total number of EVs (exosomes and microvesicles) in the medium was 
significantly increased (P<0.05) by 3h and progressively increased out to 24h after addition 
of COM or HA crystals. Cellular expression of preselected miR-1299, miR-146b-5p and 
miR-483-5p were increased whereas miR-532-5p and 664a-3p were decreased significantly 
(P<0.05) in response to COM crystals. Expression of miR-146b-5p was increased whereas 
miR-532-3p was decreased significantly (P<0.05) in response to HA crystals. Cellular 
expression of miR-146-5p and miR-532-3p targeted matrix matalloproteinase-16 was 
increased significantly (P<0.05) following COM crystal treatment.
Conclusions: Exposure of cultured renal medullary epithelial cells to urinary stone 
forming crystals activates them to shed EVs and express specific miRNAs and target 
proteins. The response to COM crystals was more robust that to HA. Further analysis of 
intra- and inter-cellular signaling pathways via EVs and miRNAs could elucidate novel 
cellular mechanisms in early urinary stone pathogenesis.
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Specific Inflammatory and Renal Cellular Injury Markers Are  
Found in Urinary Extracellular Vesicles and Proteins Associated with 
Nephrocalcinosis and Stones in Type 1 Primary Hyperoxaluria Patients
Muthuvel Jayachandran, Stanislav Yuzhakov, Andrew D. Rule, Dawn S. Milliner, 
John C. Lieske. Mayo Clinic, Rochester, MN.
Background: Our previous study showed that specific inflammatory (MCP-1) and 
renal cell injury (NGAL) molecule associated urinary extracellular vesicles (EVs) were 
significantly lower in calcium oxalate (CaOx) stone formers compared matched controls. 
Primary hyperoxaluria type 1 (PH1) can cause nephrocalcinosis (NC), CaOx stones, and 
chronic kidney disease but specific populations of urinary EVs contribution in these disease 
processes are not well known.
Methods: Bio-banked urine from PH1 patients without (n=10) and with 
nephrocalcinosis (n=6) or stones (n=9) and age-/sex-matched (± 5 years) living kidney 
donors (n=25) was studied. All patients had an eGFR > 40 and no prior kidney or liver 
transplantation. Urinary EVs were analyzed by digital flow cytometry and analyzed as 
EVs/μL urine or EVs /mg creatinine. A customized protein array was used to identify 
specific proteins in urine.
Results: Compared to healthy controls, PH1 patients excreted significantly greater EVs 
and EVs with surface biomarkers of inflammation (ICAM-1, MCP-1, tissue factor, VCAM-
1), renal injury (β2-microglobulin (β2-M), clusterin, KIM-1, Laminin α-5, NGAL), of 
glomerular origin (juxtaglomerular, mesangial, podocyte, and parietal cells), and of tubular 
origin (proximal and distal tubule, collecting duct) (all P<0.05). PH1 patients with NC 
had fewer total EVs than PH1 patients without NC or stones (P<0.05). PH1 patients with 
kidney stones had fewer total EVs, and subgroups of EVs with biomarkers of inflammation, 
renal injury, glomerular origin, specific renal tubular and papillary origin compared to PH1 
patients without NC or stones (all P<0.05). Excretion of soluble urinary MCP-1, CRP, and 
osteopontin were all significantly lower in PH1 patients with NC compared to PH1 patients 
without either NC or stones, or patients with stones alone (P<0.05). A similar trend for 
decreased urinary excretion of soluble CD14, endoglin, E-selectin, ICAM-1, PDGFRβ, and 
osteoprotegrin was observed in PH1 patients with NC compared to the other groups.
Conclusions: This study suggests that inflammation-associated EVs and proteins 
released from specific populations of renal parenchyma of PH1 patients may contribute 
nephrocalcinosis and stone pathogenesis.
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Characterization of Oxalobacter Formigenes-Derived Factors as Potential 
Novel Therapeutic Agents for Hyperoxalemia, Hyperoxaluria, and Related 
Kidney Stones
Hatim A. Hassan,1 Donna L. Arvans,4 Changsoo Chang,2 Christine Tesar,5 
Gyorgy Babnigg,2 Altayeb Alshaikh,1 Mark W. Musch,3 Eugene B. Chang,1 
Andrzej Joachimiak.2 1University of Chicago, Chicago, IL; 2Argonne National 
Laboratory, Argonne, IL; 3U Chicago, Chicago, IL; 4University of Chicago, 
LEMONT, IL; 5Argonne National Lab, Argonne, IL.
Background: Most kidney stones are composed of calcium oxalate, and small 
increases in urine oxalate significantly enhance the risk for stone formation. Hyperoxaluria 
is a major risk factor for calcium oxalate kidney stones (COKS) and it has no specific 
therapy. The gut bacterium Oxalobacter formigenes (Of) induces colonic oxalate secretion 
and reduces urinary oxalate excretion via an unknown secretagogue. Given the difficulties 
with recolonization, Of alone is not therapeutically feasible and underscores the need to 
identify the secretagogue inducing colonic oxalate secretion. We previously identified Of-
derived factors secreted in its culture conditioned medium (CM) that stimulate (>2.8-fold) 
oxalate transport by human intestinal Caco2-BBE (C2) cells, and reduce (>32.5%) urinary 
oxalate excretion in hyperoxaluric mice by stimulating (>42%) distal colonic oxalate 
secretion. The in vivo retention of biologic activity reflects the therapeutic potential of these 
factors and support the pursuit of their characterization.
Methods: Using Mass spectrometry we identified multiple protiens in a family of 
a regulatory protein as the major Of-derived factors, and we have obtained the crystal 
structures for 5 of these proteins.
Results: The identified proteins closely recapitulate the effects of the Of-derived 
factors and stimulate (1.4-2.4-fold) oxalate transport by C2 cells via PKA and stimulation 
of the oxalate transporters SLC26A6 and SLC26A2 similar to CM. We also identified 
35-amino acid peptides (P8+9) within one of these proteins that significantly stimulate 
(>2.4-fold) oxalate transport by C2 cells. P8+9 peptides also stimulated oxalate transport by 
human sigmoid colon (1.8-fold) and ileum (2-fold) organoids (ex vivo intestinal epithelia
models fully mimicking the in vivo physiological responses), strongly suggesting that P8+9
peptides will stimulate oxalate transport in human colonic and ileal epithelia in vivo.
Conclusions: We identifed Of-derived peptides with singificant potential to stimulate 
oxalate transport in human colonic and ileal epithelia in vivo. Future studies will evaluate 
the therapeutic potential of these peptides in reducing urine and plasma oxalate levels in 
hyperoxaluric and hyperoxalemic mice, respectively.
Funding: NIDDK Support, Other NIH Support - Grants GM094585 and GM115586 
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The Combination of Chlorthalidone and Potassium Citrate Is More 
Effective Than Either Agent Alone in Decreasing Calcium Oxalate Stone 
Formation in Genetic Hypercalciuric Stone-Forming Rats
Nancy S. Krieger,1 John R. Asplin,2 Ignacio Granja,4 Evan Multala,6 
Courtney A. Flotteron,7 Luojing Chen,5 David A. Bushinsky.3 1Univ. of Rochester 
Medical Center, Rochester, NY; 2Litholink Corp, Chicago, IL; 3Univ. of 
Rochester Medical Center, Rochester, NY; 4Litholink Corp, Chicago, IL; 5Univ. 
of Rochester Medical Center, Rochester, NY; 6Univ. of Rochester Medical 
Center, Rochester, NY; 7Univ. of Rochester Medical Center, Rochester, NY.
Background: To study human idiopathic hypercalciuria (IH) we developed an animal 
model, genetic hypercalciuric stone-forming (GHS) rats, whose pathophysiology parallels 
that of human IH. All GHS rats spontaneously form calcium phosphate (CaP) stones while 
there is no stone formation in the founder rats. When the oxalate precursor, hydroxyproline, 
is added to the diet, only calcium oxalate (CaOx) stones form. Previously, we demonstrated 
that chlorthalidone (CTD) alone was superior to potassium citrate (KCit) alone or in 
combination with CTD, in reducing CaP stone formation. In the current study we tested the 
hypothesis that CTD and KCit combined would effectively reduce CaOx stone formation 
in GHS rats.
Methods: 113th generation GHS rats were fed a fixed amount of a normal Ca 
(1.2%) and P (0.65%) diet with 5% hydroxyproline added, housed in metabolic cages and 
divided into four groups. Diets were supplemented with KCl (4 mmol/d) as control, KCit 
(4 mmol/d), CTD (4-5mg/kg/d)+KCl, or KCit+CTD. Urine (u) was collected at 6,12, and 
18 wks for analyses and kidney stone formation was determined by X-ray at 18 weeks.
Results: Compared to the KCl control, KCit reduced uCa (KCl= 17.2±0.3 mg/d, 
KCit=14.4±0.3), CTD reduced it further (CTD=13.0±0.6) and KCit+CTD reduced it even 
further (KCit+CTD=9.3±0.4). The combination of KCit+CTD decreased uOx compared to 
all other groups (KCl=3.4±0.2 mg/d, K Cit=3.5±0.2, CTD=3.5±0.1, KCit+CTD= 2.7±0.1). 
Compared to KCl (108.7±2.2 mg/d), KCit and CTD+KCit increased uCit (KCit=146.6±2.6, 
KCit+CTD=129.9±3.3). There were no significant differences in CaOx supersaturation (ss) 
in any group. CTD did not change uCaP ss (KCl= 4.3±0.3, CTD=2.3±0.2), while KCit 
alone, or in combination with CTD, increased it (KCit=10.3±0.6, KCit+CTD=11.5±0.9). 
Compared to KCl (stone formation with a range of 0-4: KCl=2.1±0.1), KCit did not alter 
stone formation (2.0±0.3), while there was less stone formation in rats fed CTD alone 
(CTD=1.6±0.2). The combination of KCit+CTD (0.8±0.2) resulted in significantly fewer 
stones than KCl, CTD or KCit alone.
Conclusions: Thus in GHS rats fed a diet that results solely in CaOx stone formation, 
the combination of KCit+CTD prevented stone formation better than either agent alone.
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Neutrophil Infiltration and NETosis in the Pathogenesis of Human Kidney 
Brushite Stones
Mohammad S. Makki,4 Seth Winfree,4 Frank Witzmann,3 Elaine M. Worcester,2 
James Williams,4 Tarek M. El-Achkar.1 1Indiana University, Indianapolis, IN; 
2University of Chicago, Chicago, IL; 3Indiana University School of Medicine, 
Indianapolis, IN; 4Indiana University School of Medicine, Indianapolis, IN.
Background: The pathogenesis of kidney stones in humans is poorly understood. 
There are multiple types of kidney stones, and the role of inflammation in promoting 
specific stone types is not well established. Here, we applied a combination of unbiased 
omics and quantitative large-scale 3D imaging on kidney stones and papillae from two 
types of stone forming patients: calcium oxalate and brushite. Our goal was to uncover a 
specific inflammatory signature that could differentially associate with a specific type of 
stone disease and infer how they are formed.
Methods: Kidney stones were obtained from a well-characterized cohort of patients 
in a high volume clinic. Stones were further processed for label free quantitative mass 
spectrometry to quantify differentially expressed proteins. Papillary biopsies were obtained 
at the time of percutaneous nephrolithotomy and processed for histology and large scale 3D 
imaging. 3D tissue cytometry and analysis was done using Volumetric Tissue Cytometry 
and Analysis Software (VTEA).
Results: Brushite stones have differentially increased neutrophil proteins such as 
myeloperoxidase and elastase compared to calcium oxalate evaluated by LC/MS. To 
determine if this observation is driven by changes in the kidney papillae, we confirmed 
that the number (6.91 ±1.19% vs. 1.35 ± 0.28%; p=3.2x10-5) and the density of neutrophils 
(10.1x103 ±6.2x103/mm3 vs. 0.91x103 ±0.67x103/mm3; p<0.05) were increased in the 
papillae from brushite vs. calcium oxalate patients, respectively. To explain how neutrophil 
proteins are transitioning from the tissue to the stone matrix, we investigated whether 
Neutrophil Extracellular Trap (NET) formation, whereby neutrophils expel their DNA and 
their cytoplasmic content, is more common in brushite stones. Indeed, histone citrullination 
of neutrophils, a marker of NETosis, was increased in brushite compared the calcium 
oxalate papillae (1.3 ± 0.28% vs. 0.07 ±0.04%; p<0.05).
Conclusions: Our work supports that increased neutrophil infiltration and NETosis may 
be an important factor in the pathogenesis of brushite stones. We propose that metabolic 
changes or ascending infections could trigger a hyper-inflammatory response that leads to 
the release of NET proteins in the urine, which promote brushite stone formation.
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Inositol Phosphate Analogs as Inhibitors of Renal Calcium Oxalate 
Crystallization
Anna Kletzmayr,1 Mattias E. Ivarsson,2 Bastien Castagner,3 Jean-Christophe 
Leroux.1 Drug Delivery and Formulation 1ETH Zurich, Zurich, Switzerland; 
2Inositec Inc., Zurich, Switzerland; 3McGill University, Montreal, QC, Canada.
Background: Nephrocalcinosis and nephrolithiasis can be triggered by calcium oxalate 
(CaOx) crystallization, a main symptom in different forms of hyperoxaluria. To date, 
treatment options for pathologies involving renal CaOx crystallization are scarce, mostly 
aiming at slowing down disease progression, rather than directly targeting crystal growth 
and deposition. Inositol hexaphosphate (IP6) was previously shown to inhibit crystallization 
of calcium salts. Its clinical use, however, may be hampered by its low urine exposure 
following parenteral dosing. In this project, we aim at developing inhibitors against renal 
CaOx crystallization, based on IP6 analogs.
Methods: Potency of compounds to inhibit CaOx crystallization was assessed by light 
scattering measurements. Effects on the CaOx crystal morphology were characterized by 
light microscopy, followed by an automated image analysis and machine learning approach 
to classify different CaOx hydrate forms. In vitro cell experiments were performed using 
RPTEC human proximal tubular cells. Adhesion of CaOx crystals to a cell monolayer was 
determined by light microscopy and CaOx induced cellular toxicity in vitro was measured 
with a viability stain.
Results: In the initial screening of a small library of IP6 analogs, a subgroup of 
compounds that included IP5-mono-PEG2 (INS-2001), showed inhibitory potential in 
the low micromolar range. Light microscopy experiments performed in human urine, 
confirmed the dose-dependent reduction in size of CaOx monohydrate crystals upon the 
addition of INS-2001. This compound also significantly reduced CaOx adhesion to renal 
epithelial cells at submicromolar concentrations. Additionally, protective effects of INS-
2001 on CaOx induced cellular toxicity in vitro were observed.
Conclusions: The data generated with INS-2001 provide a starting point for further 
optimization of the IP6 analogs for treatment of renal CaOx crystallization. In subsequent 
steps, inhibitory effects of INS-2001 and related compounds on CaOx-induced fibrosis and 
inflammation in vitro, and in vivo efficacy will be characterized in depth.
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Effect of Alanine Supplementation on Oxalate Synthesis
Sonia Fargue,1 Ross P. Holmes,2 John Knight.3 1Urology, University of Alabama 
at Birmingham, Birmingham, AL; 2UAB, Birmingham, AL; 3University of 
Alabama at Birmingham, Birmingham, AL.
Background: Alanine:glyoxylate aminotransferase (AGT) is the enzyme deficient in 
type 1 primary hyperoxaluria, which are a group of severe inherited kidney stone disorders 
characterized by an excessive endogenous synthesis of oxalate. The high Km of AGT for 
alanine (30 mM) and the lower level of alanine in human plasma (200-600 μM) suggest 
that AGT metabolic function, and therefore oxalate synthesis, could be improved by alanine 
supplementation. In support of this hypothesis, cells expressing normal or pathogenic 
variants of AGT and supplemented with L-alanine, have decreased synthesis of oxalate 
when incubated with an oxalate precursor, glycolate. In order to test whether L-alanine 
could improve AGT metabolic efficiency in vivo, we investigated the effect of L-alanine 
supplementation on the urinary excretion of oxalate in normal mice and mice deficient in 
AGT or Glyoxylate reductase (GR, deficient in primary hyperoxaluria type 2).
Methods: Wt, Gr Ko and Agt Ko mice were fed a low oxalate diet. Three 24 hr urines 
were collected in metabolic cages at baseline and after 1 week of equilibration with the low 
oxalate diet supplemented with 5-10% alanine. Plasma and liver alanine were measured 
by high-pressure liquid chromatography after extraction of the tissues. Urine oxalate was 
measured by ion chromatography coupled with mass spectrometry, urine creatinine was 
measured on a chemical analyzer. Statistical analysis was done with Student’s paired t-test.
Results: Urinary oxalate was higher in Gr and Agt Ko compared with Wt mice at 
baseline (152 ±35, 215 ± 13 compared with 48 ± 5 μg oxalate/day, in GR KO, Agt Ko 
and Wt, respectively, p<0.005). Supplementation with L-alanine in the diet resulted in a 
20-30% decrease in urinary oxalate in both Gr Ko and Wt animals (106 ± 20 and 36 ± 2 μg 
oxalate/day after supplementation, p<0.002 and p<0.001, respectively). There was no
significant change in urinary excretion of oxalate in Agt Ko mice.
Conclusions: The urinary excretion of oxalate was decreased by dietary L-alanine 
supplementation in Wt and Gr Ko mice, which express functional Agt. These results suggest 
that L-alanine could prove useful as an adjunct therapy in PH2 and PH3, for which no 
specific treatment is currently available, and potentially idiopathic hyperoxaluria.
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The Role of the Microbiota in Mammalian Oxalate Metabolism
Lama Nazzal,1 Menghan Liu,1 Melody Ho,1 Ignacio Granja,2 John R. Asplin,2 
David S. Goldfarb,1,3 Martin J. Blaser.1 1New York University School of Medicine, 
New York, NY; 2Litholink Corporation, Chicago, IL; 3New York Harbor VAMC, 
Hastings on Hudson, NY.
Background: Kidney stones represent a disease of worldwide prevalence with 
significant public health implications. About 60–80% of stones are composed of calcium 
oxalate (CaOx); hyperoxaluria is a major risk factor for CaOx stones. Oxalate is an end-
product of mammalian digestion and as with urea, must be excreted. We obtain oxalate from 
diet, or from endogenous production. Certain intestinal bacteria have the ability to degrade 
oxalate, protecting against oxalate nephropathy, including nephrolithiasis. To understand 
the role of the gut microbiome in oxalate metabolism, we compared conventional mice 
with germ-free mice (that lack a microbiota). In addition to the stress of endogenous oxalate 
production, we challenged groups with dietary and metabolic (via hydroxyproline (Hyp)
supplementation) oxalate loads.
Methods: Conventional (CO) and germ-free (GF) mice were fed normal chow 
diets supplemented with either 1% Oxalate (Ox), 1% Hydroxyproline (Hyp) or were 
unsupplemented (NC) for 6 weeks (n=3-4/mice group). After 6 weeks, we obtained 48-hour 
urine collections for measurement of the oxalate/creatinine ratio (Uox/cr).
Results: In CO mice, Uox/cr increased with the Ox diet compared with NC (0.57 + 0.17 
vs 0.16 + 0.05, p= 0.03 by Student’s t test), but not with the Hyp diet (0.14 +0.03 vs 0.16 
+0.05, p=ns). However, in germ-free mice, both dietary Hyp and Ox led to increased Uox/
cr compared to NC diet (0.50 ± 0.04, 0.85 ± 0.11, vs. 0.31± 0.06, p<0.05 by ANOVA,
respectively). Uox/Cr was lower in CO mice than GF mice when receiving Hyp (p=0.01, by 
Student’s t test), Ox (p=0.06), and NC diets (0.06).
Conclusions: In conclusion, oxalate excretion was higher in the germ-free than in 
the conventional mice under all three dietary conditions (Ox, Hyp, NC), providing direct 
evidence that the normal gut microbiome plays a protective (symbiotic) role in oxalate 
metabolism. With the metabolic stress of the Hyp diet, the CO mice but not the germ-
free mice could compensate. Since mice are not colonized with O. formigenes, this work 
indicates that other members of their microbiota have the functional capacity to alter oxalate 
metabolism.
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Intermuscular Fat in Patients with CKD Inversely Correlates with 
Physical Activity and Mitochondrial Function
Jorge Gamboa,1 Chad A. Keller,4 Baback Roshanravan,2 Talat Alp Ikizler.3 
1Vanderbilt University, Nashville, TN; 2University of Washington - Kidney 
Research Institute, Seattle, WA; 3Vanderbilt University Medical Center, 
Nashville, TN; 4Vanderbilt University, Nashville, TN.
Background: Patients with chronic kidney disease (CKD) have higher prevalence of 
sarcopenia, defined as reduction in muscle mass and/or muscle strength. Muscle quality 
(in particular, fat infiltration) may provide insight into the links between muscle metabolic 
health and physical functioning beyond traditional muscle mass assessment. We hypothesize 
that intermuscular fat is increased in patients with chronic kidney disease and it is inversely 
associated with physical activity and mitochondrial function.
Methods: In a cross-sectional study, we evaluated 51 subjects (20 with CKD stage 3-4, 
15 with CKD stage 5 on hemodialysis, and 16 matched controls with no history of CKD). 
Intermuscular fat was evaluated in the quadriceps muscle using sequential thigh magnetic 
resonance images. Physical performance was measured using the six-minute walk test. 
Mitochondrial function was evaluated by measuring phosphocreatine (PCr) recovery after 
exercise using 31phosphorus magnetic resonance spectroscopy (31P-MRS). A longer PCR 
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recovery results in a greater time constant tau (τ), which indicates worsening mitochondrial 
function.
Results: Groups were matched by gender, body mass index, and history of diabetes and 
hypertension. Patients with CKD stage 5 were younger than patients with CKD stage 3-4 
(47.7±11.7 vs. 63.6±9.0) but had similar age compared to controls (46.9±9.5). Intermuscular 
fat was greater in patients with CKD stage 5 compared to patients with CKD stage 3-4 
and controls (Figure 1A). We also found a negative correlation between quadriceps 
intermuscular fat and physical performance (Figure 1B). In addition, mitochondrial 
dysfunction (greater time constant τ) was associated with increased intermuscular fat 
(Figure 1C).
Conclusions: CKD is associated with greater intermuscular fat which associates with 
poor physical performance and impaired mitochondrial function. Future studies should 
evaluate the effectiveness of interventions that not only increase muscle mass but also 
improve muscle quality in patients with CKD.
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Impaired Muscle Mitochondrial Energetics Is Associated with Poor 
Physical Performance and Reduced Objective Physical Activity in CKD
Baback Roshanravan,1 Sophia Liu,3 Kushang V. Patel,3 Jorge Gamboa,2 
Amir S. Ali,3 Jonathan Himmelfarb,1 Ian H. de Boer,1 Kevin Conley,3 
Bryan R. Kestenbaum.1 1University of Washington - Kidney Research Institute, 
Seattle, WA; 2Vanderbilt University, Nashville, TN; 3University of Washington, 
Seattle, WA.
Background: Persons with chronic kidney disease (CKD) are at increased risk 
of impaired mobility function that is central to living independently. The abnormal 
uremic milieu of CKD may contribute to reduced ambulatory physical performance and 
sedentarism by impairing skeletal muscle mitochondrial metabolism.
Methods: We performed a cross-sectional analysis of 48 participants (37 with CKD 
not treated with dialysis and 11 matched, clinic-based controls without CKD) from the 
Muscle Mitochondrial ENergetics and Dysfunction (MEND) study. Persons were excluded 
from MEND if they used medications that influenced mitochondrial metabolism or had 
mobility disability. We measured mitochondrial capacity during the recovery from exercise 
of the tibialis anterior leg muscle as ATPmax using 31Phosphorus magnetic resonance 
spectroscopy. We assessed ambulatory physical performance by the 6-minute walk 
and timed up and go tests and we quantified usual physical activity levels using digital 
accelerometry over a two-week period. Results were adjusted for age, sex, weight, diabetes, 
and leg muscle size.
Results: Among persons with CKD, the mean GFR was 36 ±15 ml/min; mean age was 
62 ±15yr; 50% were female, and 30% had diabetes. After adjustment, patients with CKD 
had a 0.181mM/sec (1SD) lower muscle ATPmax compared with controls (95% CI 0.06-
0.297 lower; P=0.003). Among those with CKD greater muscle ATPmax was associated 
with greater 6 minute walk distance (A), faster timed up and go performance (B) and greater 
usual physical activity (C) (Figure).
Conclusions: CKD is associated with lower muscle mitochondrial capacity measured 
by ATPmax manifesting as poor ambulatory physical performance. Among CKD patients, 
mitochondrial capacity is associated with objective measurements of physical performance 
and activity.
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Factors Associated with Functional Impairment in Mild to Moderate CKD
Natasha J. McIntyre,1 James E. Morris,2 Simon D. Fraser,2 Scott Harris,2 
Adam Shardlow,1 Paul J. Roderick,2 Christopher W. McIntyre,3 Richard J. Fluck,4 
Maarten W. Taal.1 1University of Nottingham, Nottingham, United Kingdom; 
2University of Southampton, Southampton, United Kingdom; 3London Health 
Sciences Centre, London, ON, Canada; 4Royal Derby Hospital, Derby, United 
Kingdom.
Background: Chronic kidney disease (CKD) is associated with functional impairment 
(reduced physical ability to perform normal activities and independently self-care) and 
may impact on quality of life. Additional factors related to functional impairment in CKD 
are less well described and may help identify those needing assessment and intervention. 
This study explored factors associated with functional impairment in people with mild to 
moderate CKD and comorbidities.
Methods: Data were analysed from 1013 patients at 5y follow up in the Renal Risk in 
Derby cohort study, comprising patients with CKD stage 3 at recruitment in primary care 
(baseline n=1741). Data included: age, sex, socioeconomic status (SES) based on index of 
multiple deprivation (IMD); comorbidities; renal function (estimated glomerular filtration 
rate (eGFR)); Karnofsky Performance Status (KPS). Functional impairment was defined 
as KPS score ≤70 (at best, unable to do active work or normal activities but can self-care; 
possible KPS score 0-100 in intervals of 10, lower score represents lower function). Binary 
logistic regression analyses assessed associations with functional impairment.
Results: Cohort characteristics were: median age 77y, 62% female, mean eGFR 54 ml/
min/1.73m2. 23% scored ≤70 on the KPS indicating low levels of functional impairment. 
On univariable analysis, functional impairment was associated with older age, lower SES, 
multiple comorbidities, and lower eGFR. In a multivariable model, these factors remained 
independently associated, and female sex became associated, with the outcome.
Conclusions: In addition to lower eGFR, older age, female sex, lower SES and multiple 
comorbidities were independent risk factors for clinician-assessed functional impairment in 
mild to moderate CKD. Persons with these risk factors should be considered for further 
functional status assessment and interventions to improve impairment.
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Association of Subjective Health Assessments with Frailty, ADLs, and 
iADLs in Advanced CKD
Nicolas Baddour,1 Cassianne Robinson-Cohen,2 Loren Lipworth,2 Aihua Bian,3 
Thomas G. Stewart,2 Khaled Abdel-Kader.2 1Vanderbilt University School of 
Medicine, Nashville, TN; 2Vanderbilt University Medical Center, Nashville, TN; 
3Vanderbilt University, Nashville, TN.
Background: Subjective health measures (i.e., patient self-rated health (SRH) and 
the provider surprise question (SQ)) predict key outcomes such as mortality. How these 
measures relate to frailty and functional status has not been studied in chronic kidney 
disease (CKD).
Methods: We approached 293 and enrolled 271 outpatients ≥ 60 years of age with non-
dialysis dependent CKD stage 4 or 5. Patients were assessed with the SRH questionnaire: 
“In general, would you say your health is: excellent, very good, good, fair, or poor.” 
Providers completed patient assessments with the SQ using a 5-point Likert scale: “Would 
you be surprised if this patient died in the next 12 months?” Frailty was measured using 
Fried Frailty phenotype and the Clinical Frailty Scale. Activities of daily living (ADLs) and 
instrumental ADLs (iADLs) were assessed using Katz and Lawton measures. Correlations 
were evaluated using Spearman’s rank correlation. We used cutoff responses of ‘poor’ or 
‘fair’ for SRH and 1 or 2 (i.e., not surprised) for the SQ to determine test-characteristics.
Results: About 15% of patients were frail by both Fried Frailty phenotype and Clinical 
Frailty Scale and 8% and 29% of patients had at least 1 ADL or iADL deficit, respectively. 
Both SRH and SQ were fairly to moderately correlated with clinical frailty score, Fried 
Frailty phenotype, iADLs, and weakly correlated with ADLs [Table 1]. SRH (of excellent, 
very good or good) had a negative predictive value (95% confidence interval) of 0.92 (0.86 
to 0.96), 0.92 (0.87 to 0.96), 0.96 (0.91 to 0.98), and 0.83 (0.76 to 0.89) for Fried Frailty 
phenotype, Clinical Frailty scale, ADL deficiency, and iADL deficiency respectively. SQ 
had a negative predictive value of 0.87 (0.82 to 0.91), 0.90 (0.86 to 0.94), 0.79 (0.73 to 
0.84), and 0.95 (0.92 to 0.98) for Fried Frailty, Clinical Frailty, ADL deficiency, and iADL 
deficiency respectively.
Conclusions: Single question patient or provider subjective health measures are 
correlated with frailty and functional status. These measures also may serve as useful tools 
to rule out frailty and disability in this population.
Funding: Private Foundation Support
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Physical Activity, Body Composition, Metabolism: Clinical
Profiles of Physical Activity in Hemodialysis Patients Randomized into the 
HDFIT Trial
John W. Larkin,1,2 Priscila B. Gonçalves,1 Hao Han,2 Jochen G. Raimann,3 
Maggie Han,3 Carlos E. Poli de Figueiredo,4 Americo L. Cuvello neto,7 Ana 
Beatriz L. Barra,5 Len A. Usvyat,2 Peter Kotanko,3 Maria Eugenia F. Canziani,6 
Roberto Pecoits-Filho.1 HDFIT Study Investigators 1Pontifícia Universidade 
Católica do Paraná, Curitiba, Brazil; 2Fresenius Medical Care North America, 
Waltham, MA; 3Renal Research Institute, New York, NY; 4Pontifícia Universidade 
Católica do Rio Grande do Sul, Porto Alegre, Brazil; 5Fresenius Medical Care, 
Rio de Janeiro, Brazil; 6Universidade Federal de São Paulo, Sao Paulo, Brazil; 
7Hospital Alemão Oswaldo Cruz, Sao Paulo, Brazil.
Background: Profiles of physical activity (PA) are poorly understood in dialysis 
patients. We characterized granular profiles of PA in hemodialysis (HD) patients.
Methods: PA was measured with the Actigraph (www.actigraphcorp.com) monitor 
over 1 week in patients treated with high-flux HD during the baseline period of the HDFIT 
randomized controlled study, which is a 6-month study of the impacts of modality (HDF vs 
HD) on PA levels (ClinicalTrials.gov: NCT02787161). Granular PA levels were captured 
in blocks including a HD period (Block A), 2-hour (hr) post-HD period (Block B; includes 
30min data slices), and 2-to-24hr post-HD period (Block C; includes 4.5hr data slices) 
captured over 24hr periods relative to the start time of HD on dialysis days, and concurrent 
periods on non-HD days and the long interdialytic day.
Results: We recruited 195 HD patients from 13 sites during October 2016 to 2017. 
Patients were: age 53±15 years, 71% male, 59% white race, post-HD weight 76±16 Kg, 
29% with diabetic nephropathy, 26% with hypertensive nephrosclerosis, and 16% with 
chronic glomerulonephritis. Patients took a mean of 4,725 steps/24hrs. On non-HD days 
and the long interdialytic day, patients took 1,387 and 1,105 more steps/24hrs vs HD days 
respectively (both p<0.001). During concurrent times to the HD session on non-HD days 
and the long interdialytic day, patients performed 1,351 and 1,082 more steps respectively 
(both p<0.001). Surprisingly, on HD days patients performed more steps in each 30 min 
slice during the 2hr post-HD period vs concurrent times on non-HD days and the long 
interdialytic day (all p<0.05). On non-HD days, patients performed more steps during the 2 
to 6.5hr post-HD period (p<0.05).
Conclusions: Findings revel PA levels tend to be lower on HD days primarily due to 
sitting/lying during HD treatments, albeit patients had higher post-HD PA levels compared 
to concurrent times on non-HD days that may be related to transportation from the clinic. 
Offering intradialytic exercise programs could help increase PA during HD, potentially 
above sedentary levels (i.e. >5,000 steps/day or equivalents) with potential benefits as 
observed in the general population.
Funding: Commercial Support - Fresenius Medical Care and Pontificia Universidade 
Catolica do Parana
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Decline in Functional Status and Mortality in Patients on Hemodialysis: 
Results from the Japan Dialysis Outcome and Practice Patterns Study 
(J-DOPPS)
Ryota Matsuzawa,1 Tsukasa Kamitani,2 Baback Roshanravan,3 Shingo Fukuma,4 
Nobuhiko Joki,5 Masafumi Fukagawa.6 J-CLIP 1Kitasato University Hospital, 
Sagamihara, Japan; 2Kyoto university, Kyoto, Japan; 3University of Washington 
- Kidney Research Institute, Seattle, WA; 4Kyoto University, Kyoto, Japan; 
5TOHO University Ohashi Medical Center, Tokyo, Japan; 6Tokai University
School of Medicine, Isehara, Japan.
Background: Poor functional status — the limitation in activities of daily living 
(ADL) — is strongly associated with adverse clinical outcomes among end-stage renal 
disease (ESRD) patients treated with hemodialysis (HD). Little is known in regard to the 
association of change in functional status and adverse clinical outcomes in this population. 
The current investigation tests the association of decline in functional status with all-cause 
mortality among HD patients using data from the Japan Dialysis Outcome and Practice 
Patterns Study (J-DOPPS).
Methods: We studied 817 ESRD patients on HD with repeat measures of functional 
status enrolled in the J-DOPPS. Information on age, sex, body mass index, smoke, 
dialysis vintage, comorbidities and laboratory data was collected. The assessments of 
functional status were conducted twice over a one-year baseline period (2012-2013), and 
functional status score was calculated based on Katz index and Lawton-Brody instrumental 
ADL scale. We classified patients into 2 groups based on having or not at least 1 point 
declined in functional status score during the baseline period. A Cox regression analysis 
was conducted to evaluate the association between the decline in functional status and the 
all-cause mortality during the follow-up period (2013-2015) with adjustment for potential 
confounders.
Results: Over this period, 163 (20.0%) patients showed decline in functional status 
score, and 44 (5.4%) patients died. Using Cox regression analysis adjusting for potential 
confounders including baseline functional status, the declined in functional status score was 
significantly associated with higher mortality (adjusted hazard ratio, 2.68; 95% confidence 
interval, 1.31-5.50).
Conclusions: Decline in functional status was strongly associated with mortality 
among patients treated with HD. These findings underscore the importance of interventions 
directed at preventing deterioration in functional status over time among HD patients.
Funding: NIDDK Support, Commercial Support - Kyowa Hakko Kirin, Government 
Support - Non-U.S.
Association between decline in functional status score and all-cause mortality
HR: hazard ratio; CI: confidence interval.
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Predictors of Mobility Impairment over Time in Incident Dialysis Patients
Ranjani N. Moorthi,1 William F. Fadel,4 Alissa A. Cranor,1 Judy Hindi,4 
Kathleen A. Lane,1 Ravi I. Thadhani,3 Keith Avin,2 Sharon M. Moe.1,5 1Indiana 
University School of Medicine, Indianapolis, IN; 2Indiana University-
Indianapolis, Indianapolis, IN; 3Cedars-Sinai, Los Angeles, CA; 4Indiana 
University, Indianapolis, IN; 5Roudebush VAMC, Indianapolis, IN.
Background: Sarcopenia involves loss of muscle strength and/or mass that leads to 
loss in physical function (mobility impairment). Mobility impairment can be quantified by 
gait speed measures. In CKD, mobility loss is associated with hospitalizations, functional 
dependence and mortality. The trajectory of mobility over time in new dialysis patients is 
not well-characterized. We hypothesized that there are decreases in mobility over time in 
incident dialysis patients, independent of changes in muscle strength.
Methods: Gait speed was assessed in 195 subjects who were incident to outpatient 
dialysis by the 4-meter walk test at baseline, 6, 12 and 24 months. Maximum handgrip 
strength of 3 trials in both upper limbs was recorded at similar time points. Appendicular 
lean mass/ ht2 was measured by DXA. Mixed effects models were used to analyze 
changes in gait speed and identify predictors of change among covariates which included 
demographics, walking aids, self-reported health status, ESRD cause, time-varying muscle 
strength, baseline lean mass and physical activity.
Results: The mean age of the cohort was 54.3+/-13 years, with 53.3% male, 72.4% 
black and with a median of 93.7+/-72 days since dialysis start. There was an average 
decrease in gait speed of 0.023 m/s/yr. Lower grip strength at baseline was associated 
with lower gait speed trajectory over time (Figure). Age, use of walking aids, lower grip 
strength, diabetic nephropathy as cause of ESRD, self-reported poor ambulation and lower 
health utility were significantly associated with poor mobility over time in the adjusted 
mixed effects model (all p<0.05). Baseline lean mass or step counts did not affect these 
relationships.
Conclusions: There is loss of mobility with time in patients relatively new to dialysis. 
Loss of muscle strength is an independent risk factor for mobility impairment over time. 
Identifying risk factors for mobility loss may be used to target interventions like physical 
therapy, gait training and exercise.
Funding: NIDDK Support
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The Effect of Exercise Intervention on Physical Activity in Patients with 
Non-Dialysis-Dependent CKD: A Systematic Review
Naohiko Fujii. The NDD-CKD Team of the Committee of the Guideline for 
Renal Rehabilitation Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, 
Japan.
Background: As the population of chronic kidney disease (CKD) grows larger 
and older worldwide, frailty has become one of emerging problems that may affect the 
prognosis of patients with CKD and their quality of life. Many observational studies 
suggest that frailty should be a clinically-relevant mortality risk in both dialysis-dependent 
and non-dialysis-dependent (NDD) CKD. However, it is not well understood whether this 
vulnerable state is modifiable by lifestyle intervention, or exercise, in patients with NDD-
CKD independent of diet and drug therapy. We performed a systematic review to evaluate 
the benefits and limitations of exercise intervention among patients with NDD-CKD on 
exercise tolerance.
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Methods: We searched PubMed and the Japanese medical publication library 
“Ichushi” databases for randomized controlled trials (RCTs) or intervention trials targeting 
patients with NDD-CKD published until April 2017. Outcomes of interest included 
indices of exercise tolerance, such as VO2 peak and 6-min walking test (6MWT). Two 
or three reviewers independently screened the title and abstract of extracted papers from 
the databases and reviewed the full-text of articles that met the prespecified inclusion and 
exclusion criteria. Data quality and risk of bias were evaluated by GRADE system. Any 
disagreements between the reviewers were resolved by discussion. Data syntheses and 
meta-analyses were performed using Review Manager version 5.3.
Results: After the full-text review of 50 selected articles, 14 RCTs and two intervention 
trials were included in meta-analysis. Four of them conducted resistance exercise, and others 
did aerobic exercise or exercise with reduced workload. Nine studies reported changes in 
VO2 peak, six in 6MWT, and the rest measured other indices. Overall, VO2 peak and 6MWT 
were significantly improved by 3.2 [inter quartile range (IQR): 1.5 – 5.0] mL/kg/min (N = 
296, I2 = 0.67) and 51 [22 - 80] m (N = 241, I2 = 0.27), respectively. There was no report on 
adverse event regarding exercise intervention.
Conclusions: Moderate exercise intervention among patients with NDD-CKD is 
beneficial for exercise tolerance measured by VO2 peak and 6MWT. These results should 
be verified by other objective indices for mobility and in other CKD populations especially 
with frailty.
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Physical Performance in Nocturnal Hemodialysis Patients: Systematic 
Review of the Literature
Manouk Dam, Peter J. Weijs, Frans J. van Ittersum, Brigit C. van Jaarsveld. VU 
University Medical Center, Amsterdam, Netherlands.
Background: Hemodialysis (HD) pts have poor physical performance, leading 
to a diminished quality of life (QOL) and overall health. This low activity level can be 
explained by lack of energy due to insufficient metabolic clearance and shortage of time 
by time-consuming HD sessions. Nocturnal hemodialysis (NHD) improves metabolic 
control and results in largely increased spare time. Whether NHD stimulates pts to a more 
active lifestyle and increased muscle mass and strength, is unclear. Our aim is to investigate 
whether physical performance improves when pts switch from conventional HD to NHD.
Methods: A systematic literature search, with help of a specialized librarian, was 
conducted in multiple databases: MEDLINE, Embase, CINAHL, PhycInfo and Web of 
Science. Databases were searched until January 2018. Primary outcomes of interest were 
physical performance, activity, strength and muscle mass in NHD, either at home or in-
center. Two reviewers performed data extraction and assessment of methodological quality 
independently, with the Newcastle-Ottawa scale.
Results: The search yielded 10 studies meeting the inclusion criteria including 2 RCTs. 
A total of 526 NHD pts were evaluated with a mean follow-up duration of 15,3 months. 
Physical performance was assessed with objective measurements in 7 studies: short-physical 
performance battery (1x), exercise spirometry (1x), 6-min walk test (6MWT, 1x), (skeletal) 
muscle mass using dual-energy X-ray absorptiometry (2x) and bioelectrical impedance 
analysis (BIA, 2x). In 5 studies physical performance was assessed subjectively, with a 
physical component score (PCS) of a QOL questionnaire. Of the objective outcomes, 3 
studies found significant improvements in physical performance using exercise spirometry, 
6MWT and BIA. Of the subjective outcomes, 2 studies showed a better PCS. The remaining 
6 studies showed no improvement in physical performance nor PCS.
Conclusions: A limited amount of studies investigate whether physical performance 
improves after switching from CHD to NHD and a minority of these assess physical 
performance with objective measurements. As current literature regarding physical 
performance emphasizes the importance of physical activity on clinical outcomes, it is 
essential to conduct better research in larger study groups, to investigate whether NHD can 
improve physical performance of pts with ESRD.
Funding: Commercial Support - Baxter
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Physical Activity and Sedentary Behaviour in Hemodialysis: Preliminary 
Data from a Pilot Study
Keigan More,1 Alec Cranston,2 Chris M. Blanchard,3 Olga Theou,3 
Amanda J. Vinson,4 Christine Dipchand,4 Karthik K. Tennankore.4 1Department 
of Medicine, Dalhousie University, Halifax, NS, Canada; 2Nova Scotia Health 
Authority, Halifax, NS, Canada; 3Dalhousie University, Halifax, NS, Canada; 
4Dalhousie University/NS Health Authority, Halifax, NS, Canada.
Background: Dialysis patients have reduced moderate to vigorous physical activity 
(MVPA), defined as activities that use ≥3 metabolic equivalents (METS). This has been 
shown in both self-reported surveys and objective accelerometer studies. Less attention 
has been directed towards sedentary behavior (SB), which is characterized by low energy 
expenditure (≤ 1.5 METS). Furthermore, locations where MVPA or SB occur are largely 
unknown for dialysis patients. Objective: To determine the number of minutes per day of 
MVPA and SB for in-center hemodialysis patients using accelerometers and to identify 
locations where MVPA and SB occur using global positioning software (GPS).
Methods: We analyzed a cross-section of adult in-center hemodialysis patients at 
tertiary care dialysis program, recruited over a three-month period. Patients were fit with the 
Actigraph GT3X accelerometer and Qstarz BT-Q1000X GPS receiver and were instructed 
to wear these devices for ≥10 hours/day for ≥4 days/week. Minutes of physical activity at 
various intensities and SB were described as was time spent at each activity level across 
different locations.
Results: Overall, 50 patients consented to participate in the study; 47 were fit with both 
devices, and 37 met the minimum accelerometer wear time of ≥4 days/week. Mean age 
of the cohort was 61±15 years. Diabetes (46%), coronary artery disease (34%), and heart 
failure (21%) were highly prevalent. Among those who fulfilled valid days, median wear 
time was 755 minutes/day (IQR 720-794), median sedentary time was 544 minutes/day 
(IQR 487-583), and median MVPA time was 2 minutes/day (IQR 1-9). The cohort spent 
73% (IQR 64-78) of their wear time in a sedentary state, and only 0.3% (IQR 0.1-1.2) in 
MVPA. Only three patients met Canadian guidelines for weekly MVPA (≥150 minutes/
week in bouts of ≥ 10 minutes). The majority of SB occurred in the home, hospital, and 
during transport, whereas most MVPA occurred at home.
Conclusions: Hemodialysis patients exhibit substantial SB and minimal MVPA 
across a multitude of locations. The home environment may represent an ideal location for 
behavior interventions as the majority of SB and MVPA occurs at home. Further studies 
are needed to determine the effects of these behaviors on clinical outcomes as well as to 
determine barriers to MVPA and facilitators of SB.
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The Effect of Intradialytic and Home-Based Exercise on Physical Function 
and Quality of Life in Hemodialysis Patients
Brett Burrows,1 Luis M. Perez,1 Lauren Chan,2 Alana P. Harris,1 
Jennifer L. Barnes,2 Ken Wilund.1 1University of Illinois at Urbana-Champaign, 
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Background: It’s well established that hemodialysis (HD) patients are less active and 
have greater muscle atrophy compared to healthy people. Previous research has associated 
lack of physical activity with reduced physical function (PF) and quality of life (QOL) and 
increased mortality. Preceding research also states that HD patients’ QOL may be negatively 
influenced by significant increases in intradialytic weight gain thus increasing the likelihood 
of a hypotensive event. HD patient’s specifically cite sleep problems and fatigue as negative 
effects of hemodialysis on QOL. The aim of this study was to determine the effect of a 
6-month physical exercise program on HD patients’ PF and QOL.
Methods: HD patients (n=22) were enrolled in a larger volume control (VC) pilot
trial with assessments at baseline (BL) and 6-months (6m). Nine HD patients were 
randomized into a volume control and exercise group (VCE). During regularly scheduled 
HD treatments, over the 6-month trial, VCE performed thrice weekly moderate intensity, 
progressive intradialytic cycling for 15-30 min per session. Additionally, VCE was given 
a progressive individualized home exercise prescription that consisted of total body 
resistance exercises and balance exercises, which the HD patients were asked to complete 
twice a week. Thera-bands of various resistance were given to perform the exercises at 
home. Before randomization, BL assessments were taken including; BP, short physical 
performance battery (SPPB), and self-reported Kidney Disease Quality of Life (KDQoL).
Results: SPPB total score did not improve BL to 6m between groups (VCE 9.4 to 10.1, 
VC 8.5 to 8.9; p=.71). The symptoms and sleep subsets, of the KDQoL, were significantly 
different between groups from BL to 6m (symptoms: VCE 73.2 to 85.0, VC 71.1 to 67.1; 
p=0.02, sleep: VCE 60.8 to 71.4, VC 58.5 to 50.9; p=0.02). Fatigue, part of the symptoms 
subset, was found to be reduced in VCE from BL to 6m (VCE 54.2 to 75.0, VC 51.7 to 
40.0; p=0.05).
Conclusions: Despite no improvement in the SPPB between groups, specific QOL 
parameters such as sleep and fatigue improved significantly. These findings suggest novel 
benefits in QOL from an intradialytic cycling and home-based exercise program in HD 
patients.
Funding: Private Foundation Support
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Feasibility of Intradialytic Exercise in a Rural Community Hemodialysis 
Unit: Mixed Methods Analysis of Implementation
Malgorzata E. Kaminska,1 Robin K. Roots,2 Anurag Singh.3 1University Of 
Northern British Columbia, Prince George, BC, Canada; 2University of British 
Columbia, Prince George, BC, Canada; 3Department of Internal Medicine, 
Division of Nephrology, University Hospital of Northern British Columbia, 
Prince George, BC, Canada.
Background: The use of leg cycle ergometers (LCEs) during hemodialysis (HD) has 
been shown to have a number of benefits including improved adequacy of HD and blood 
pressure reduction while also improving exercise capacity, physical function and quality 
of life in patients with end stage kidney disease. LCEs have been implemented at several 
dialysis centres in major Canadian cities, however no known location in British Columbia. 
Furthermore, a gap exists in the literature with respect to the feasibility of implementing 
such programs in small or rural HD centres. We examined the feasibility of implementing 
LCEs concurrent with HD in a rural community centre.
Methods: Study participants included patients and clinical care providers (CCPs) 
recruited from a remotely located community HD unit in northern British Columbia. 
Descriptive statistics were used to indicate frequency, intensity and length of cycle 
utilization. Barriers and facilitators to participation were captured in individual semi-
structured interviews conducted with patient and CCPs at the end of the study period. 
Transcribed interviews were coded and analyzed using a theoretical framework scaffolded 
by constructs of acceptability and feasibility of implementation (O’Cathian et al. 2015).
Results: Of 14 eligible patients, 9 enrolled of which 6 actively participated in the study. 
Over 1 to 4 months patients used LCEs an average of 85% (63%-100%) of their dialysis 
sessions. Duration of LCEs use increased over time from a low of 15 minutes to an average 
of 1 hour (15-120 minutes) at an “easy” rate on the Perceived Exertion Scale with no 
adverse events reported. Thematic analysis of 14 interviews (9 patients; 5 CCPs) identified 
key elements for successful implementation: patient and CCP orientation and a structured 
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support process aided in acceptability, resulting in minimal disruption to workflow and 
generating motivation to participate and a positive patient and CCP experience.
Conclusions: Exercising during HD is acceptable, feasible, and safe when implemented 
in a rural community HD unit using a structured team-based approach. It does not add 
workload for clinical staff and can be incorporated in the workflow. Patients reported an 
overall positive experience and recommended the creation of an education tool to aid in 
recruitment.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Effect of Acute and Chronic Intradialytic Bicycle Ergometer Exercise on 
Nrf2 mRNA Expression in Hemodialysis Patients
Denise Mafra,1 Jessyca S. Brito,2 Greicielle S. Da silva,2 Drielly V. Reis,2 Bruna 
kelly S. Souza,4 Ludmila F. Cardozo,3 Natalia A. Borges.2 1Federal University 
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Background: Hemodialysis (HD) patients have a constant state of oxidative stress, 
which results from an imbalance between reactive oxygen species production and 
endogenous antioxidant defense mechanisms, leading to increased cardiovascular risk. 
Physical exercise may reduce cardiovascular risk through its beneficial effects on nuclear 
factor erythroid 2-related factor 2 (Nrf2) expression that regulates several antioxidant genes. 
The aim of the present study was to verify the effect of acute and chronic intradialytic 
bicycle ergometer exercise on Nrf2 mRNA expression in HD patients.
Methods: Eleven HD patients were studied (7 men, 47.5 ± 6.7 yrs, 25.4 ± 12.3 months 
of dialysis, BMI of 23.7 ± 2.2 Kg/m2). The physical exercise program was individualized 
and performed on an adapted stationary bicycle, consisting in heating (5 minutes), 35 
minutes of aerobic training at target heart rate, and cool down (load reduction for 5 minutes). 
The acute effect (single session) was assessed after the first exercise session and the chronic 
effect after 3 months of the exercise program with 3 sessions per week. Peripheral blood 
mononuclear cells were isolated and processed for the evaluation of expression of Nrf2 and 
NAD(P)H:quinoneoxidoreductase 1 (NQO1) by quantitative real-time polymerase chain 
reaction.
Results: No significant changes were observed after a single exercise session in Nrf2 
mRNA expression [from 0.38 (0.15 - 2.84) to 1.92 (0.65 - 2.48), p=0.21] or NQO1 mRNA 
expression [from 0.31 (0.16 -1.20) to 0.85 (0.43 - 1.98), p=0.17]. After 3 months of the 
exercise program there was a significant increase in Nrf2 mRNA expression [from 0.38 
(0.15 -2.84) to 1.63 (0.64 - 3.25), p=0.04] and no significant change in NQO1 mRNA 
expression [from 0.31(0.16 -1.20) to 1.97 (0.45 - 3.88), p=0.17].
Conclusions: These results suggest that acute intradialytic bicycle ergometer exercise 
was unable to change Nrf2 but three months exercise program seems to modulate this 
transcription factor which could improve long-term endogenous antioxidant defense in HD 
patients.
Funding: Government Support - Non-U.S.
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Effect of Resistant Starch Supplementation on the Indole-3-Acetic Acid 
Levels and Aryl Hydrocarbon Receptor Expression in Hemodialysis 
Patients
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Background: Researchers have investigated the role of the gut microbiota in the 
pathogenesis of chronic kidney disease (CKD) and cardiovascular disease (CVD). The 
gut microbiota imbalance favors bacterial growth producing uremic toxins, such as indole-
3-acetic acid (IAA). This toxin leads to inflammation and, the aryl hydrocarbon receptor 
(AhR) has been pointed as an important ligand of IAA, triggering inflammatory signaling 
responses. Thus, the use of prebiotics, such as resistant starch (RS), may be an effective
non-pharmacological strategy to restore gut microbiota balance, reducing IAA levels and
AhR expression, and consequently decreasing inflammation in CKD. The aim of this 
study was evaluate the effect of RS supplementation on IAA levels and AhR expression in 
hemodialysis patients (HD).
Methods: Randomized, double-blind, placebo-controlled clinical trial including 
43 HD patients (53.4% male, 58.2 ± 9.5 years, 25.7 ± 3.8 kg/m2, 37.5 ± 26.9 months of 
HD). The patients were supplemented with 16g/day of RS (HI-MAIZE 260) or placebo 
in the form of cookies (for consumption on the day of dialysis) and sachet (for daily 
consumption without dialysis) for 4 weeks. Blood samples were collected before and after 
the supplementation period. IAA plasma levels were measured by high performance liquid 
chromatography and, peripheral blood mononuclear cells were isolated and analyses of 
quantitative real time polymerase chain reaction was performed to evaluate the AhR mRNA 
expression.
Results: Thirty one patients completed the study, 15 in the RS group and 16 in the 
placebo group. No differences were found in IAA levels (2329.5 (1112-3451)mg/L vs 
1667 (1191 - 2934)mg/L; p=0.16) or in AhR mRNA expression (1.08 ± 0.5 vs 1.12 ± 0.45, 
p=0.81) after RS supplementation. However, there was a positive correlation (r=0.48; 
p=0.03) between IAA and AhR at the baseline.
Conclusions: Although RS supplementation did not influence IAA levels or AhR 
expression, the positive association between this toxin and the AhR confirm a possible 
interaction between them. Future therapeutic strategies can be discovered in the sense of 
modulating this complex pathway.
Funding: Government Support - Non-U.S.
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Presarcopenia and Sarcopenia as Predictors of Hospitalization-Free 
Survival in Patients with CKD
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Background: Sarcopenia is defined as the degenerative loss of skeletal muscle mass, 
and strength associated with aging. In this article, we compared prevalence of sarcopenia 
using three different skeletal muscle mass indices in predialysis and dialysis patients with 
chronic kidney disease (CKD), and sought to the relationship with clinical outcomes.
Methods: 179 patients were recruited (114 male, 65 female, 103 predialysis, 76 
dialysis) and followed prospectively for up to 3 years. Appendicular skeletal muscle mass 
(ASM) was measured by bioimpedance analysis (Inbody 620, In-body, Seoul, Korea). 
Weight (wt) adjusted, height square (ht2) adjusted, or body mass index (BMI) adjusted ASM 
were assessed in all subjects. Hand grip strength and walking speed were measured. Frailty 
phenotypes were examed in all subjects. Sarcopenia was considered present when subjects 
had low handgrip strength accompanied by low adjusted ASM. Those who showed only low 
hand grip or muscle volume loss were categorized as presarcopenia.
Results: 9.5%, 4.5%, or 2.8% of the patients had sarcopenia, while 55.9%, 57.5%, or 
58.7% of the patients were categorized as presarcopenic status according to three different 
indices (ASM/wt, ASM/ht2, or ASM/BMI respectively). ASM/wt index showed significant 
correlation with age, handgrip strength, HOMA-IR and frailty score. During follow-up, 56 
patients were hospitalized (cardiovascular 30.3%; infectious disease 23.2%). Multivariate 
cox proportional hazards models also demonstrated that the risk of hospitalization was 
significantly higher for CKD patients who were categorized as sarcopenic (hazard ratio 
[HR], 9.11 ; 95% confidence interval [CI], 2.295 – 25.182; P < 0.001) or presarcopenic (HR, 
2.48 ; 95% CI, 1.180 – 5.230; P = 0.017) than normal status according to ASM/wt index
Conclusions: ASM/wt index showed best relationship with age, muscle strength, 
insulin resistance and frailty. Sarcopenia and presarcopenia defined using ASM/wt index 
predicted poorer hospitalization-free survival in patients with CKD. This work was 
supported by a National Research Foundation grant of Korea (NRF-2016R1C1B1013814) 
funded by the Korea government.
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Relative Sarcopenia and Mortality and the Modifying Effects of CKD and 
Adiposity
Susan Ziolkowski,1 Jin Long,3 Glenn M. Chertow,1 Mary B. Leonard.2 1Stanford 
University School of Medicine, Palo Alto, CA; 2Stanford School of Medicine, 
Stanford, CA; 3Stanford University, Palo Alto, CA.
Background: Conventional definitions of sarcopenia based on lean mass may fail to 
capture low lean mass relative to higher fat mass, i.e., relative sarcopenia. The objective 
of this study is to determine the associations of sarcopenia and relative sarcopenia with 
mortality independent of co-morbidities, and whether chronic kidney disease (CKD) and 
adiposity alter these associations.
Methods: Dual energy X-ray absorptiometry (DXA)-derived appendicular lean mass 
index (ALMI, kg/m2) and fat mass index (FMI, kg/m2) were assessed in 14,850 NHANES 
participants from 1999-2006 and were linked to death certificate data in the National 
Death Index with follow up through 2011. Sarcopenia was defined using sex and race/
ethnicity-specific standard deviation scores compared with young adults (T-scores) as an 
ALMI T-score < −2 and relative sarcopenia as fat-adjusted ALMI (ALMIFMI) T-score < −2. 
Glomerular filtration rate (GFR) was estimated using creatinine- (eGFRCr) and cystatin 
C- (eGFRCys) based regression equations.
Results: Three (3.0) percent of NHANES participants met criteria for sarcopenia
and 8.7% met criteria for relative sarcopenia. Sarcopenia and relative sarcopenia were 
independently associated with mortality (HR sarcopenia 2.89, 95% CI, 2.17 to 3.86; HR 
relative sarcopenia 2.62, 95% CI, 2.14 to 3.20). The corresponding population attributable 
risks were 6.2% (95% CI, 4.3% to 7.5%) and 25.8% (95% CI, 17.3% to 31.2%), respectively. 
The risk of mortality associated with relative sarcopenia was attenuated among persons 
with higher FMI (p for interaction <0.01) and was not affected by CKD status for either 
sarcopenia or relative sarcopenia.
Conclusions: Sarcopenia and relative sarcopenia are significantly associated with 
mortality regardless of CKD status. Relative sarcopenia is nearly 3-fold more prevalent 
amplifying its associated mortality risk at the population level. The association between 
relative sarcopenia and mortality is attenuated in persons with higher FMI.
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CKD and the Adiposity Paradox: Valid or Confounded?
Susan Ziolkowski,3 Jin Long,2 Glenn M. Chertow,3 Mary B. Leonard.1 1Stanford 
School of Medicine, Stanford, CA; 2Stanford University, Palo Alto, CA; 3Stanford 
University School of Medicine, Palo Alto, CA.
Background: Obesity is associated with decreased mortality risk in in patients 
with end-stage renal disease and mild to moderate chronic kidney disease (CKD), a 
phenomenon termed the obesity paradox. Indices of obesity, including Quételet’s (body 
mass) index (BMI, kg/m2) and % body fat (%BF) are confounded by muscle mass, while 
DXA derived fat mass index (FMI, kg/m2) overcomes this limitation. We aimed to compare 
the associations between adiposity and mortality in persons with CKD using alternative 
estimates of adiposity, and to determine whether muscle mass, inflammation and recent 
weight loss modify these associations.
Methods: DXA-derived FMI, BMI, and %BF were calculated in 2,852 NHANES 
participants with CKD from 1999-2006, used to define obesity according to established 
cut-offs, and linked to death certificate data in the National Death Index with follow up 
through 2011. Cox proportional hazards models assessed associations between mortality 
and estimates of adiposity. Sequential models adjusted for percent weight change since 
the maximum reported weight and interactions with measures of inflammation and muscle 
mass.
Results: In adjusted models, obesity based on FMI (obeseFMI) was associated with 
lower mortality (HR 0.82, 95% CI, 0.70 to 0.97). As continuous variables, higher FMI, BMI 
and %BF were associated with lower mortality. The protective effect of obesity was less 
pronounced among those with higher lean mass. The prevalence of >10% weight loss was 
20% in obeseFMI participants, compared with 40.4% in the non-obeseFMI participants. Prior 
weight loss was strongly associated with mortality, and the protective effect of obesity was 
no longer significant after adjustment for prior weight loss. Inflammation did not modify 
these associations.
Conclusions: These data demonstrated an apparent protective effect of high fat mass 
in CKD, particularly among persons with low muscle mass. The prevalence of prior weight 
loss was two-fold less among obese compared to non-obese persons and confounded these 
associations.
Funding: NIDDK Support
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Pre-ESRD 24 Hour Urine Creatinine Changes and Post-ESRD Mortality
Csaba P. Kovesdy,2,1 Praveen Kumar Potukuchi,1 Chi-Yang Chiu,1 Adnan Naseer,2 
Oguz Akbilgic,1 Fridtjof Thomas,1 Melissa Soohoo,3 Elani Streja,3 
Miklos Z. Molnar,1 Kamyar Kalantar-Zadeh.3 1University of Tennessee Health 
Science Center, Memphis, TN; 2Memphis VA Medical Center, Memphis, TN; 
3University of California at Irvine, Orange, CA.
Background: Protein-energy wasting (PEW) is common in CKD and ESRD. The 
temporal dynamics of PEW in patients with progressive loss of kidney function, and its 
association with future outcomes, is unclear.
Methods: We examined changes in 24-hour urine creatinine (24hrUC; a surrogate of 
muscle mass) over the last 3 years prior to renal replacement therapy in a national cohort 
of 701 incident ESRD US veterans with 2 or more 24hrUC measurements. We estimated 
24hrUC slopes in mixed effects models, and we examined their association with post-
dialysis all-cause mortality using Cox models adjusted for confounders. To assess the 
temporal dynamics of pre-ESRD changes in 24hrUC and its association with changing 
eGFR, we separately fitted in mixed effects models penalized spline regressions of 24hrUC 
on time and on eGFR.
Results: Patients were 63±10 years old, 97% male, 35% African-American. Mean 
baseline eGFR and 24hrUC were 26±16 ml/min/1.73m2 and 1294±290 mg, respectively. 
The mean slope of 24hrUC vs. time was -77±45 mg/year. Decline in 24hrUC started to 
accelerate in the last 2 years prior to ESRD, and once eGFR was <25 ml/min/1.73m2 
(Figure). 444 patients died (mortality rate 191/1000 patient-years, 95%CI: 174-209) over a 
median follow-up time of 3 years. More severe decreases in 24hrUC were associated with 
higher mortality (Figure).
Conclusions: Patients with advanced CKD lose an average of 6% of their muscle 
mass each year. Loss of muscle mass starts to accelerate once eGFR falls below 
25 ml/min/1.73m2, and more loss of muscle mass is associated with higher mortality after 
ESRD transition.
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Change in Body Composition over Time and Its Association with Survival 
Among Patients on Hemodialysis
Cynthia Delgado,1 Janet Chiang,4 Barbara A. Grimes,3 George A. Kaysen,5 
Mark Segal,3 Kirsten L. Johansen.2 1Veterans Affairs Medical Center, San 
Francisco, CA; 2University of California, San Franicsco, San Francisco, CA; 
3UCSF, San Francisco, CA; 4University of California, San Francisco, San 
Francisco, CA; 5University of California, Davis, Davis, CA.
Background: Patients with ESRD who have a higher body mass index have better 
survival, a phenomenon known as the obesity paradox. Accounting for body composition 
and for changes over time may help to elucidate this paradoxical association.
Methods: We leveraged repeated measures of body composition (at baseline, 12, and 
24 months) by whole-body bioimpedance spectroscopy (BIS) from 286 prevalent ESRD 
patients from 7 dialysis facilities in the USRDS ACTIVE/ADIPOSE study to examine the 
obesity paradox. We performed BIS to estimate intracellular water as a proxy for muscle 
mass (ICW/m2), extracellular water (ECW/m2), and fat mass (FM/m2). Death data were 
ascertained through linkage with the USRDS through June 2016. We used linear mixed 
models to examine change in body composition over time and Cox models with BIS-derived 
estimates as time-varying predictors to examine survival after adjusting for covariates.
Results: Results: Participants’ mean age was 59 ± 15, and 66% were male. Over time, 
only ICW/m2 declined (-0.08 95%CI -0.13, -0.04 L/m2/year) and neither ECW/m2 (0.02 
95%CI -0.03, 0.06 L/m2/year) nor FM/m2 (-0.07 95%CI -0.20, 0.05 L/m2/year) changed 
significantly. In survival analysis with body composition parameters as time-varying 
predictors, ICW/m2 was associated with lower mortality (HR 0.67, 95%CI 0.49, 0.93). 
Higher ECW/m2 was associated with higher mortality (HR 1.75 95%CI 1.19, 2.60). Fat 
mass was not associated with survival (HR 0.99 95%CI 0.93, 1.06).
Conclusions: In this cohort of participants with repeated measures of body composition, 
muscle mass declined over time. Higher muscle mass was associated with better survival, 
but higher fat mas was not associated with survival independent of muscle mass.
Funding: NIDDK Support, Veterans Affairs Support
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Abdominal Obesity in Normal Weight versus Overweight and Obese 
Hemodialysis Patients: Associations with Nutrition, Inflammation, Muscle 
Strength, and Quality of Life
Ilia Beberashvili,1 Ada Azar,2 Ramzia Abu hamad,1 Inna Sinuani,3 
Leonid Feldman,1 Shai Efrati.1 1Nephrology Division, Zerifin, Israel; 2Nutrition 
Department, Zerifin, Israel; 3Department of Pathology and Cytology, Assuta 
Ashdod Medical Center, Ashdod, Israel.
Background: The biological basis of abdominal obesity leading to more severe 
outcomes in maintenance hemodialysis (MHD) patients with normal body mass index 
(BMI) is unclear. We compared the phenotype of abdominal obesity in different BMI 
categories of MHD patients.
Methods: We performed a cross-sectional study of 188 MHD patients (52.7% women; 
mean age, 69.4±11.5 years) with abdominal obesity in different BMI groups using WHO 
criteria. Appetite and dietary intake, body composition, handgrip strength, malnutrition-
inflammation score (MIS), inflammatory biomarkers, adipokines and health-related quality 
of life (QoL) questionnaires were studied.
Results: According to multivariable analyses, abdominally obese patients with normal 
BMIs consumed less protein per day (p=0.04), had lower measurements of surrogates 
of lean (p<0.001) and fat mass (p<0.001), higher total cholesterol, TNF-α (p<0.05), and 
adiponectin to leptin ratios (p=0.003) compared to overweight and obese patients with 
abdominal obesity. Multivariable analyses showed no differences in handgrip strength 
among the study groups. The abdominally obese study participants with normal weight 
had significantly lower scores in role-physical (p=0.003) and pain (p=0.04) scales after 
multivariable adjustments.
Conclusions: Normal weight MHD patients with abdominal obesity exhibit a more 
proatherogenic profile in terms of inflammatory markers and adipokines expression, lower 
body composition reserves and lower physical ability compared to abdominal obesity 
patients with overweight and obesity. This at least partially explains the abdominal obesity 
paradox in MHD population in which worse clinical outcomes are seen in abdominally 
obese patients with normal BMIs, as opposed to overweight and obese patients who are 
also abdominally obese.
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Effects of Body Fat Accumulation During PD on Mortality and Technique 
Failure: Is There a Difference by PD Duration?
Jwa-kyung Kim,1 Narae Joo,2 Youngsu Kim,3 Sung gyun Kim.1 1Hallym 
University, Seoul, Republic of Korea; 2Halyym University Sacred Heart 
Hospital, AnYang, Republic of Korea; 3Hallym Univ. Sacred Heart Hospital, 
Angyang, Republic of Korea.
Background: Significant body fat accumulation is an inevitable but potentially serious 
problem in maintenance peritoneal dialysis (PD) patients. Whether excessive fat gain 
predicts long-term outcomes in these patients is still unknown.
Methods: In this prospective observational study of 296 patients, the association 
between excessive fat accumulation and patient survival and PD failure rates was analyzed. 
Patients were classified by dialysis duration at time of study enrollment into short- (<2years) 
and long-term (>2years) groups. Body weight (BW) and body composition analysis were 
measured twice, 12.8 ± 4.6 months apart. Excessive fat accumulation was defined as a 
1-year change in body fat percentage (ΔPBF) over the highest quartile (5.0% for men, 5.4%
for women).
Results: A substantial 1-year increase in BW and PBF were only observed in the 
short-term group (p<0.001, 0.027), whereas, in the long-term group, the changes were 
insignificant. In the short-term group, the ΔPBF was closely associated with unfavorable 
baseline metabolic profiles, including old age, diabetes, obesity, elevated blood pressure 
and edema. Accordingly, mortality rate in patients with excessive fat accumulation was 
significantly higher than in those without (P=0.007). The risk of technical failure was also 
increased with excessive fat gain. After adjusting for diabetes, obesity, and fluid status, it 
increased the incident risk of PD failure by 2.22-fold (95% CI 1.08–4.54). However, in the 
long-term group, fat gain did not impact on prognosis.
Conclusions: Excessive fat accumulation occurring primarily during the early period 
of PD was associated with baseline unhealthy metabolic profiles, higher mortality and PD 
failure rate independent of baseline obesity and fluid status.
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The Association Between Obesity and CKD in the Human Hereditary and 
Health in Africa Kidney Disease Research Network
Titilayo O. Ilori,1 Charlotte Osafo,2 Shikhar Kumar,5 Rulan S. Parekh,3 
Dwomoa Adu,7 Rasheed A. Gbadegesin,6 Akinlolu O. Ojo.4 H3Africa Kidney 
Disease Study 1Nephrology, University of Arizona, Tucson, AZ; 2University of 
Ghana Medical School, ACCRA, Ghana; 3The Hospital For Sick Children, 
Toronto, ON, Canada; 4University of Arizona Health Sciences, Tucson, AZ; 5The 
university of arizona, Tucson, AZ; 6Duke University Medical Center, Durham, 
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Background: There is very little existing data on the relationship between obesity 
and CKD in Africans. We estimated the prevalence of obesity among cases (eGFR<60ml/
min/1.73m2) and controls (eGFR>60ml/min/1.73m2) in the Human Hereditary and Health 
in Africa Kidney Disease Research Network (H3A-KDRN) and determined the association 
between obesity (measured by body mass index (BMI) and waist circumference) and CKD.
Methods: In this case-control study, we estimated the prevalence of obesity in cases 
and controls using BMI ≥30kg/m2 and waist circumference ≥88cm in women and ≥102cm 
in men as definitions for obesity. Using logistic regression, we estimated crude and adjusted 
prevalence odds ratios and 95% confidence intervals for CKD in the entire cohort.
Results: The prevalence of obesity using BMI was 28.2% in the cases vs 21.5% in the 
controls (p<0.0000001) while the prevalence of obesity by waist circumference was 22.8% 
in cases and 26.2% in controls (p<0.01). Cases with a higher BMI were more likely to have 
higher eGFR (p<0.001) while controls with a higher BMI had a lower eGFR (p<0.0001). 
Compared to those with normal BMI, underweight individuals were 1.43 times more likely 
to have CKD, OR=1.43 (95% CI 1.11, 1.83). Overweight OR =0.87 (0.77,0.99) and obesity 
class I OR=0.81 (95% CI 0.68,0.95) were both associated with lower odds of CKD in the 
crude analyses. After adjusting for age, gender, country, hemoglobin and ACR underweight 
OR=1.61(95% CI 1.31, 1.98), overweight OR=0.85 (95% CI 0.74,0.97) and class I obesity 
OR=0.82 (95% CI 0.68, 0.99) remained associated with CKD. Compared to those with a 
normal waist circumference (80-87.9cm in women and 94-101.9cm in men), individuals 
with a waist circumference of <80cm in women and <94cm in men were more likely to 
have CKD (OR=1.24, 95% CI 1.05,1.48) in the crude and some adjusted models OR=1.20 
(95% CI 1.01, 1.44). No other waist circumference categories were associated with CKD.
Conclusions: The findings in this stud mimics the risk factor paradox for obesity. 
Underweight individuals were more likely to have CKD but obese and overweight were 
less likely to have CKD. We will need further prospective studies to determine if higher 
BMI is protective of CKD in Africans or if these findings are reflective of reverse causality.
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Effect Modification of GFR and BMI on Insulin Sensitivity Among 
Nondiabetic Patients
Elvis A. Akwo,1 Aseel Alsouqi,1 Victoria Whitfield,1 Talat Alp Ikizler,1,2 
Adriana Hung.2,1 1Vanderbilt University Medical Center, Nashville, TN; 
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Background: Insulin resistance (IR) is highly prevalent in patients with CKD. The 
reason for this phenomenon is unknown. We studied the interaction between estimated 
glomerular filtration rate (eGFR) and body mass index (BMI) as determinants of peripheral 
and central insulin sensitivity (IS).
Methods: In a cross-sectional study of 150 patients, 56 CKD and 94 with normal 
GFR, we used hyperinsulinemic euglycemic glucose clamp to measure IS (peripheral or 
skeletal muscle IS) as insulin sensitivity index (ISI) and the homeostasis assessment of 
insulin resistance (HOMA-IR) (central or liver IS). eGFR estimated by CKD-EPI and 
body mass index (BMI) were estimated at baseline. Linear regression models with robust 
standard errors (to relax homoscedasticity assumptions) and interaction terms were used to 
investigate GFR and BMI as predictors of IS.
Results: The mean age was 53.9 (14.5) yrs; 50.7% were female and 36.7% African-
American. Log ISI was positively correlated (r = 0.39, p < 0.0001) with eGFR and 
inversely correlated (- 0.30, p < 0.0001) with BMI. In multivariable models adjusted for 
age, sex and race, a 10 ml/min/1.73m2 increase in eGFR was associated with a greater 
increase in ISI among non-obese (0.48; 95% CI: 0.25, 0.70) compared to obese participants 
(0.18; 95% CI: 0.02, 0.35) (p-interaction = 0.04). Patients with low GFR had lower ISI 
(insulin resistant) even with normal BMI (Fig. 1a). Log HOMA-IR was inversely correlated 
with eGFR (r = - 0.49, p < 0.0001) and positively correlated with BMI (r = 0.52, p < 0.0001). 
HOMA-IR was higher for persons with lower GFR compared to higher GFR, at any BMI 
value. For example, at a BMI of 30 and a GFR of 30 ml/min/1.73m2, HOMA-IR was 4.8 
compared to 1.2 at a GFR of 120 ml/min/1.73m2 (Fig. 1b).
Conclusions: GFR and BMI are both predictors of IS but the magnitude of the effect 
of BMI on IS varies across GFR levels and type of IS (peripheral versus central). The effect 
of BMI on central or liver IS (HOMA-IR) is more pronounced at lower GFR with small 
changes in BMI translating into greater variations in IS. Conversely, at low GFR, skeletal 
muscle IS is less affected by BMI.
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Density of Brown Adipose Tissue in Japanese Hemodialysis Patients: 
Association with Protein-Energy Wasting
Yoshihiko Kanno,1 Miho Nagai,1 Yuko Kurosawa,1 Sayuri Fuse,1 Takashi Ishizu,2 
Takafumi Hamaoka.1 1Tokyo Medical University, Tokyo, Japan; 2Tsukuba 
Central Hospital, Ushiku, Japan.
Background: Patients receiving chronic hemodialysis are on catabolic status in energy-
consuming cycle, according to complex factors due to the pathogenesis of original disease, 
renal failure and dialysis therapy. Nutritional disorder in CKD patients with decreases of 
skeletal muscle and body fat has proposed to be called as Protein-Energy wasting (PEW) 
by International Society of Renal Nutrition and Metabolism (ISRNM). On the other hand, 
the pathogenesis of PEW is still unknown. In recent years, the importance of energy 
metabolism control via brown adipose tissue (BAT) gathers attraction, despite the difficulty 
in measuring its density. We have developed its portable measuring system, and investigated 
BAT densities and nutritional states in Japanese HD patients.
Methods: We assessed BAT densities in Japanese HD patients (66.5 ± 10.4 years) 
and healthy adults (65.3 ± 10.4 years) based on total hemoglobin concentrations in the 
supraclavicular region measured with near-infrared time-resolved spectroscopy. We also 
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assessed correlation between BAT densities and bioelectrical impedance analysis for the 
evaluation of body composition in HD patients.
Results: The BAT density in 33 HD patients was 75.6 ± 31.4 μM, which tended to be 
higher (p = 0.059) compared with 61.1 ± 4.3 μM in healthy subjects of the matched age 
over 40 years old. Furthermore, BAT density and body fat mass were negatively correlated 
in HD patients. BAT in healthy subjects were negatively correlates visceral fat area in 
previous studies. But in our study, despite the fact that the visceral fat area was significantly 
higher in HD patients, BAT tended to be higher in HD patients. The stimulation by cold and 
consequently increase in sympathetic nerve activity directly to BAT causes an increase in 
BAT density. It is known that muscle sympathetic nerve activity is elevated in patients with 
CKD complicated hypertension. It may be involved as a cause of increase in BAT density.
Conclusions: BAT may be one of the principal factors for malnutrition with energy-
consuming cycles in HD patients.
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Glucose (Glu) Disposal in Diabetic (D) and Non-Diabetic (ND) Patients 
During Hemodialysis (HD)
Longin Niemczyk,1 Stanislaw Niemczyk,2 Anna Wojtecka,2 
Katarzyna Szamotulska,3 Daniel Schneditz.4 1Medical University of Warsaw, 
Warszawa, Poland; 2Military Medical Institute of Warsaw, Warsaw, Poland; 
3National Research Institute of Mother and Child, Warsaw, Poland; 4Medical 
University of Graz, Graz, Austria.
Background: It was the purpose to examine whether intra-venous (iv) Glu administered 
during HD caused a characteristic response suitable to detect impaired Glu tolerance in HD 
patients (pts) during routine treatment.
Methods: About 30 min into treatment (baseline T0), a 40% Glu solution (100.1±22.0 mL) 
was directly injected into the venous line of the extracorporeal circulation at a dose of 0.5 g/kg 
dry weight. Blood samples were drawn from the arterial line at T0, and 5, 10, 20, 30, 60 
min after injection (T5, T10, T20, T30, T60). Glu (mmol/L) and insulin (Ins; mU/L) levels 
were measured. In addition, relative blood volume (RBV; %) was continuously measured 
by ultrasonic technique for quantification of osmotic volume effects.
Results: 25 ND and 9 D pts were studied (61±13 years, dry weight 80.6±17.6 kg, 
UF volume 2.47±0.92 L, 12 female). The increase and time course in Glu was largely 
comparable between D and ND pts; Ins significantly increased in ND pts only (Tab. 1). 
The RBV effect of Glu peaked around 6 min after injection and was 105.16±1.30 vs. 
105.90±1.52% in ND and D pts, respectively, and also showed a comparable time course 
(Fig. 1).
Conclusions: In spite of significant difference in Ins secretion, infusion of Glu amount 
comparable to that of an iv Glu tolerance test did not produce major differences in Glu 
disposal during HD. It appears that Glu is removed faster by HD than it can be disposed in 
the large but slowly perfused Ins-dependent muscle and skin compartment. This may have 
implications for iv nutrition during extracorporeal treatments.
Funding: Clinical Revenue Support
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Lipoprotein Subfraction Analyses in a Cohort of the Palm Tocotrienols in 
Chronic Hemodialysis Study (PATCH)
Eno Latifi, Dina A. Tallman, Deepinder Kaur, Pramod Khosla. The PATCH 
Investigators Wayne State University, Detroit, MI.
Background: Dyslipidemia (D) is one of the characteristics of end-stage renal 
disease patients who develop cardiovascular disease (CVD). The PATCH clinical trials 
[NCT02358967, NCT02913690] are double-blind one-year intervention trials (300 mg 
tocotrienols or placebo daily) in hemodialysis patients in USA, Malaysia and Bangladesh 
(currently some 400 patients are enrolled). A pilot study showed improvement in D with 
tocotrienols. The aim of this preliminary analysis is to evaluate and characterize lipoprotein 
subfractions in the PATCH Michigan cohort.
Methods: The Michigan cohort includes 138 patients enrolled across various dialysis 
clinics in Michigan (recruitment ends Dec 2018). Subject are 95% African Americans (Age 
59 ± 13 yrs., 64% men, dialysis vintage 65±63 months). Blood was collected at baseline 
and plasma isolated for lipid determination and lipoprotein subfraction analyses using a 
gel-electrophoresis method (Quantimetrix LipoprintTM).
Results: Baseline plasma lipids (n=124) revealed HDL-C, LDL-C and Triglyceride 
(TAG) values (mg/dL) of 49±18, 79±39 and 95±51, respectively. The values were 
not influenced by the dialysis shift during blood collection. The percentage of large, 
intermediate and small HDL particles were 39.4±15.6, 46.9±9.5 and 13.6±8.4, respectively. 
The percentage of large, intermediate and small LDL particles were 15.0±4.3, 8.1±3.9 and 
2.4±3.3, respectively. Eight percent of subjects were D (TAG 201±54, HDL-C 33±5, LDL-C 
133±17 mg/dL), 48% were normolipemic [N] (TAG 64±25, HDL-C 61±18, LDL-C 55±23 
mg/dL), while the rest had mixed D (TAG 110±36, HDL-C 40±11, LDL-C 96±38 mg/dL). 
Dyslipidemic subjects had significantly greater proportion of small HDL particles than N 
subjects (22.5%±4.5% vs 9.1%±6.9%), while large HDL (24.6%±8.9% vs 48.3%±13.9%) 
and intermediate HDL (52.9%±6.6% vs 42.4%±8.7%) were significantly lower. D subjects 
had significantly smaller LDL particle sizes compared to N subjects.
Conclusions: Changes in circulating lipoproteins reflect alterations in LDL and HDL 
particle sizes that can be readily detected. The role of these compositional changes in 
CVD in HDL patients is as yet, unresolved. (Supported by the Malaysian Palm Oil Board/
Government of Malaysia)
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Glycosylated Hemoglobin A1c as a Predictive Marker of Poor Sleep in 
ESRD Population
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Background: Patients on dialysis experience higher rates of sleep disorders compared 
to general population. Self-directed questionnaires can help to diagnose sleep disorders. We 
aim in this study to describe the epidemiology of sleep disorders in ESRD population and 
determine the clinical and laboratory biomarkers that can predict it.
Methods: We conducted a prospective cross-sectional study in ESRD patients on 
dialysis in the main dialysis unit in the state of Qatar. All adult patients on dialysis for at 
least one month were eligible. Enrolled patients underwent sleep disorder screening using 
the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire to measure the quality 
and patterns of sleep in adults. PSQI score ≥5 indicates poor sleep. Logistic and regression 
models were employed to evaluate the association between poor sleep scores and different 
commonly used clinical and laboratory markers.
Results: 253 patients on dialysis (62% on hemodialysis and 38% on peritoneal dialysis) 
were enrolled. 115 (44.6%) were male. Median PSQI score was 10 (interquartilerange(IQR): 
6-18). Diabetic patients had significantly higher median score of PSQI of 10 (IQR: 7-18.75) 
compared to non-diabetics (Median 9, IQR: 5-16.5) (P=0.02). 84% of diabetics had PSQI ≥ 5 
compared to 73% in non-diabetic (P=0.03). Using univariate linear regression model, PSQI
scores correlated significantly with Hb1AC levels (β1= 0.9, P=0.006) (even after adjusting 
for BMI (β1= 0.6, P=0.03)). For every 0.9 unit increase in Hb1AC, the PSQI increases by 1. 
The receiver operating characteristic (ROC) using Hb1AC as a predictor for sleep disorder 
showed AUC of 0.65. Utilizing a cut-off value of 5.1, the predictive diagnostic utility of
Hb1AC was 80% for sensitivity and 89% specificity. Univariate analysis of other clinical 
markers including hemoglobin level, anemia, PTH, KT/v, hypertension, and phosphorus
revealed no statistical correlation with PSQI scores.
Conclusions: Our data shows high prevalence of sleep disorders in ESRD population 
and diabetic patients are at higher risk. Utilizing Hb1AC in diabetics with ESRD can predict 
patients at increased risk of sleep disorder. Our statistical models suggest that controlled 
diabetes is associated with better sleep quality, however, further investigational work is 
needed.
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Intra-Individual Variability in High Density Lipoprotein Cholesterol and 
Risk of ESRD: A Nationwide Population-Based Study
Eun Sil Koh, Seok Joon Shin, Cheol Whee Park, Sungjin Chung. The Catholic 
University of Korea College of Medicine, Seoul, Republic of Korea.
Background: Recent studies demonstrated an association between low high density 
lipoprotein – cholesterol (HDL-C) and progression of chronic kidney disease (CKD). 
However, some of the results showed the inconsistencies between HDL-C and renal 
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function outcomes. We investigated the association between HDL-C variability and the risk 
of end-stage renal disease (ESRD).
Methods: Using nationally representative data from the Korean National Health 
Insurance System, 3 718 355 subjects who were free of ESRD and who underwent ≥3 health 
examinations during 2005 to 2010 were followed to the end of 2015. HDL-C variability was 
measured using the coefficient of variation (CV), standard deviation (SD) and the variability 
independent of the mean (VIM). The primary outcome was the development of ESRD, 
defined as a combination of the relevant disease code and the initiation of renal replacement 
therapy.
Results: There were 2095 cases of ESRD during a median follow up of 4.8 years. There 
was a graded association between a higher HDL-C variability and incident ESRD. In the 
multivariable adjusted model, the hazard ratios and 95% confidence intervals comparing 
the highest versus lowest quartiles of VIM of HDL-C were 1.60 (95% confidence interval, 
1.39–1.84). The results were consistent when the variability of HDL-C was modeled using 
SD and CV and were independent of preexisting CKD.
Conclusions: Increasing HDL-C variability was associated with an increasing 
incidence of ESRD. This findings suggest that HDL-C variability is an important risk factor 
of CKD progression in the general population.
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The Impact of Onset Age on Metabolic Disorders in Urolithiasis
Wen Wen, Yuehong Li, Qi Chen. Beijing Tsinghua Changgung Hospital, 
Medical center, Tsinghua University, Beijing, China.
Background: Urolithiasis is related with metabolic disease, such as hyperuricemia, 
diabetes, dyslipidemia and hypertension. We aim to explore the association between the 
metabolic diseases and the stone type, clinical and laboratory features, the onset age with 
urolithiasis patients.
Methods: Clinical data were retrospectively collected from 707 patients with 
urolithiasis surgery in Beijing Tsinghua Changgung Hospital from December 2015 to 
August 2017. Their demographic data, clinical manifestations, laboratory tests and 
examinations were analyzed retrospectively.
Results: (1) 446 males and 261 females (18 to 94 years old) from 28 provinces in 
China were included in our study. The urolithiasis patients with onset age > 30 years old are 
more likely common to diabetes mellitus, hypertension, gout, hyperlipidemia and metabolic 
syndrome. (2) The onset age of urolithiasis is positively associated with BMI (r=0.100, 
P=0.011), iPTH (r=0.089, P=0.049), TG (r=0.083, P=0.033), globulin (r=0.077, P=0.046) 
and IgG (r=0.077, P= 0.040), while it is negatively related to urine phosphorous (r=-0.109, 
P=0.027) and HDL-C (r=-0.099, P=0.010). (3) Correlation analysis showed that the level of 
TC and LDL-C were both positively associated with serum calcium, phosphorus, alkaline 
phosphatase (ALP), globulin and white blood cell (WBC) (P<0.05). The level of TG is 
positively associated with serum calcium, magnesium, 25-OH-VitD3, while negatively 
associated with urine PH (P<0.05). HDL-C was negatively associated with urine uric acid 
(P<0.05). Fast glucose was positively associated with serum ALP, globulin and the count of 
urine bacterium (P<0.05). Serum uric acid was positively associated with serum calcium, 
phosphorous and urine phosphorus (P<0.05). (4) The incidence of urinary infection 
(70.3% vs. 62.2%, P=0.025) and amorphous calcium phosphate (1% vs. 0%, P=0.043) is 
significantly higher in patients with hyperlipidemia.
Conclusions: The urolithiasis patients with onset age > 30 years old are more likely 
associated with metabolic disorders and urinary infections. Elevation of serum lipid, glucose 
and urate acid may add risks to urolithiasis by impacting urine PH, calcium-phosphorus 
metabolism and infectious status.
Funding: Private Foundation Support
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Exosomal MicroRNAs Profiling in Obese Patient Using 
MicroRNA-Sequencing
Soon hyo Kwon, Hyoungnae Kim, Moo Yong Park, Hyunjin Noh. 
Soonchunhyang University Hospital, Seoul, Republic of Korea.
Background: Exosomal micro RNAs (miR) are valuable biomarker and regulate 
biological process of obesity. Bariatric surgery has beneficial effect on obese patients. 
However the mechanisms of this surgery are not clear. We investigated to identify exosomal 
miR signature associated with obesity and examine exosomal miR changes after bariatric 
surgery.
Methods: Healthy volunteers (HV, n=18) and non-diabetic obese patients (n=16) 
were enrolled prospectively. We assessed the miR profile of serum exosome from HV and 
obese patients using RNA sequencing (RNA-seq) cross sectionally. To evaluate the effect 
of bariatric surgery, we conducted exosomal miR analysis in 12 obese patients 6 months 
after surgery.
Results: RNA-seq analysis showed 224 obesity-related microRNAs. Using >2 and 
<-2-fold changes as cut-offs, we identified that the expression of 72 (up-regulation=57, 
down-regulation=15) exosomal miR in obese patients compared to HV (table 1). Biological 
pathway analysis was suggestive of modulation of signaling pathways including the Wnt 
pathway, fatty acid biosynthesis, AMPK signaling, p38 MAPK signaling, and AMPK 
signaling in exosome from obesity patients. Bariatric surgery induced weight reduction led 
to a marked change in the Wnt pathway and fatty acid biosynthesis pathway.
Conclusions: Obesity leads a different miR pattern in serum exosome compared 
to healthy volunteers. Weight loss after bariatric also induces changes in exosomal miR 
profiles.
Funding: Government Support - Non-U.S.
Top 5 list of exosomal micro RNAs from obesity compared to healthy volunteers
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Cognitive Impairments in Renal Transplant Recipients: Impact on Daily 
Life Functioning
Aaltje L. Ziengs, Antonio Gomes Neto, Anne M. Buunk, Michele F. Eisenga, 
Coby Annema, Stephan J. Bakker, Gerjan Navis, Joke M. Spikman. University 
Medical Center Groningen, Groningen, Netherlands.
Background: After kidney transplantation, there is a heavy demand on the cognitive 
capacities of kidney transplant recipients (KTR) in order to increase survival chance with 
the donor organ. However, until now, it has been insufficiently examined to what extent 
cognitive functioning is affected in KTR. In this study, we aimed to examine the prevalence 
of cognitive impairment in KTR in the chronic stage. In particular, we assessed to what 
extent cognitive impairments affects daily life functioning post-transplant.
Methods: This study was conducted as part of the Transplantlines Biobank and Cohort 
Study at the University Medical Center Groningen. We included 120 KTR and 85 age, 
sex and education matched healthy controls (HC). Cognitive functions were assessed with 
tests measuring memory (15 Words Test (15WT), Wechsler Adult Intelligence Scale subtest 
Digit Span (Forward and Backward; DS FW, DS BW), Word Fluency (WF)), attention and 
mental speed (Trail Making Test part A (TMT-A)) and executive functioning (Trail Making 
Test part B (TMT-B), Dutch version of the Controlled Word Association Test (COWAT)). A 
questionnaire was used to examine participation in daily life (Utrecht Scale for Evaluation 
of Rehabilitation - Participation).
Results: Mean age of KTR was 56.9 ± 12.4 years, 69 were male, at a median time 
of 11 [1-41] years post-transplantation. KTR performed significantly worse on tasks 
measuring memory (p < 0.01 (15WT); p < 0.001 (WF); p < 0.05 (DS BW)), attention 
and mental speed (p < 0.01 (TMT-A) and executive functioning (p < 0.001 (TMT-B); 
p < 0.001 (COWAT)), compared to HC. Furthermore, daily life participation was 
significantly correlated with mental speed (r = -0.36, p < 0.001) and working memory 
(r = 0.21, p < 0.05).
Conclusions: This study shows cognitive impairments in multiple domains in KTR 
post-transplantation. Moreover, cognitive dysfunctioning interferes negatively with 
participation in everyday life. Administering early neuropsychological assessment in 
KTR is clinically highly relevant to detect cognitive impairments and to allow for timely 
counselling or treatment.
FR-PO563 Poster Friday
Physical Activity, Body Composition, Metabolism: Clinical
Health-Related Hope, Disease Stage, and Disease Self-Management over a 
Very Wide Range of CKD Severity
Noriaki Kurita,1 Takafumi Wakita,5 Yoshitaka Ishibashi,2 Tomo Suzuki,4 
Hiroo Kawarazaki,3 Yugo Shibagaki,4 Masahiko Yazawa.4 1Department of Innovative 
Research and Education for Clinicians and Trainees, Fukushima Medical University 
Hospital, Fukushima, Japan; 2Japanese Red Cross Medical Center, Tokyo, Japan; 
3Inagi Municipal Hospital, Tokyo, Japan; 4Division of Nephrology and Hypertension, 
Department of Internal Medicine, St.Marianna University School of Medicine, 
Kawasaki, Japan; 5Kansai University, Suita, Japan.
Background: Disease experience varies at different stages of CKD. Patients who 
experience hope might more effectively adjust to their health condition. The aims of this 
study were to quantify the associations of health-related hope with disease stage, and with 
psychological and medical indices of CKD self-management.
Methods: Data were collected from 461 adult CKD patients in Japan. The range of 
disease severity was very wide: Included were patients at stage 2-3 who were not receiving 
dialysis (ND stage 2-3) and those at ND stages 4 and 5. Also included were patients receiving 
dialysis. Health-related hope (HR hope) was measured with a recently developed 18-item 
scale focusing on how people experience their health and how healthcare affects hope. 
General linear models were used to examine the associations of HR hope with CKD stage, 
blood pressure (BP), and serum levels of phosphorus and potassium. The burdens of water 
and diet restriction were measured with the Kidney Disease Quality of Life questionnaire. 
Generalized ordered logit models were used to examine the associations of HR hope with 
the likelihood of reporting that water or diet restriction was burdensome.
Results: Patients at ND stages 4 and 5 had lower levels of HR hope than those at ND 
stage 2-3 (Figure). With ND stage 2-3 as the reference, patients at all further stages had 
lower levels of HR-hope. The lowest level of HR-hope was among patients with disease at 
ND stage 5. Higher levels of HR hope were significantly associated with lower likelihoods 
of reporting that water and diet restrictions were burdensome (adjusted OR 0.53 and 0.57 
for water restriction and diet restriction, respectively). Higher levels of HR hope were also 
significantly associated with lower systolic BP (adjusted mean difference -5.8 mmHg). 
HR hope levels were not associated with diastolic BP or with serum levels of phosphorus 
or potassium.
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Conclusions: Among CKD patients, higher HR hope is associated with less-severe 
disease, lower systolic BP, and lower perceived burden of water restriction and diet 
restriction.
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Exploring Beliefs about Treatment in Advanced CKD and Relationship 
with Well-Being and Outcome
Zoe C. Pittman,1 Maarten W. Taal,1 Christopher W. McIntyre.2 1Royal Derby 
Hospital, Derby, United Kingdom; 2London Health Sciences Centre, London, 
ON, Canada.
Background: The beliefs that individuals hold about treatments affect treatment 
adherence. We aimed to examine this in both dialysis and non-dialysis dependant CKD 
patients and to include reference to other aspects of a treatment.
Methods: The Beliefs about Medicines Questionnaire (BMQ) explores individuals’ 
beliefs about the necessity and concerns of treatments. We adapted the BMQ for beliefs 
about dialysis, fluid restriction, medicines and dietary restrictions. Individuals from 
HD (29), PD (10), CKD 4/5 (5) and transplant (13) clinics completed all relevant BMQ 
questionnaires and the illness intrusiveness ratings scale (IIRS), PHQ-9 (cut point 
PHQ ≥ 10 for depression screening in dialysis), dialysis recovery time (DRT) and measures 
of treatment tolerability (TT) and burden (TB). BMQ outputs are reported as mean ± 
SD, necessity score (max 25) and necessity minus concerns score (N-C) (range ±20, 0 = 
balanced beliefs).
Results: Dialysis: necessity 11.2 ± 4.8 and N-C -3.7 ± 4.7. N-C correlated with renal 
replacement therapy vintage (r=0.332 p=0.045) and TT (r=0.478, p=0.003) but not with TB, 
DRT, IIRS or PHQ-9 or age. Dietary restriction: necessity 15.2 ± 4.7 and N-C -1.2 ± 4.0. 
N-C correlated with serum potassium (r=0.376 p=0.015) and phosphate (r=0.332 p=0.040) 
but not with number of phosphate binders. Medicines: necessity 12.5 ± 4.3 and N-C -4.5 ± 
4.8. N-C correlated with serum phosphate (r=0.384, p=0.005) but not with total number of 
medications or binders prescribed. Fluid restriction: necessity 13.3 ± 4.1, N-C -1.3 ± 4.0. 
No correlations were seen, including with interdialytic weight gains or systolic blood
pressure. There was variable but significant correlation between all N-C scales; Dialysis: 
Medicines (r=0.718), Diet (r=0.550), Fluid (r=0.588); Medicines: Fluid (r=0.416), Diet
(r=0.601); Fluid: Diet (r=0.601).
Conclusions: Individuals have a sophisticated way of thinking about the treatments that 
they are prescribed. These beliefs are not dependent on knowledge but impact on behaviours 
that affect measurable outcomes such as serum potassium and phosphate. The variation in 
correlation between some scales suggest that these thought processes are related, however 
they are not fixed character traits, and therefore may be amenable to education that takes 
into account individual beliefs in order to address them directly.
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Illness Perceptions in Renal Disease Correlate with Well-Being Markers
Zoe C. Pittman,1 Maarten W. Taal,1 Christopher W. McIntyre.2 1Royal Derby 
Hospital, Derby, United Kingdom; 2London Health Sciences Centre, London, 
ON, Canada.
Background: Individuals’ perception of their illness correlates with both mortality and 
quality of life in dialysis patients. Improved understanding of illness perception and its 
relationship with outcomes will allow improved targeting of information and education. We 
therefore examined illness perceptions in both advanced CKD and dialysis, and how these 
relate to other markers of wellbeing.
Methods: The revised illness perceptions questionnaire (IPQr) offers a robust 
mechanism for examining individual’s perception of illness. Persons from HD (29), PD 
(10), CKD 4/5 (5) and transplant (13) clinics were recruited for a study of understanding 
and illness perceptions. Questionnaires included the IPQr, illness intrusiveness ratings scale 
(IIRS), PHQ-9 (cut point PHQ ≥ 10 for depression screening in dialysis), dialysis recovery 
time (DRT) and measures of treatment tolerability (TT) and burden (TB), including number 
of tablets (total (NT) and phosphate binders (NB)). Additional background data were 
collected.
Results: Mean±SD values for individual IPQr subscales (max allowed) were 
Chronicity (30) 17.15±2.74, Cyclical (20) 9.91±3.97, Consequences (30) 19.11±3.59, 
Personal Control (30) 17.95±3.83, Treatment Control (25), 14.98±3.24, Understanding 
(25) 12.98±3.95, Emotional response (30) 15.54±4.98. Subscale analysis did not show
any effect from dialysis status, gender or dialysis vintage. There were no correlations
with chronicity, treatment control or understanding. However, subscales did demonstrate
correlation with: 1)Perception of negative consequences; Age (r=-0.411), PHQ-9
(r=0.289), IIRS (r=0.550), TT (r=0.376), TB (r=0.331) 2)Emotional response; Age 
(r=-0.305), PHQ-9 (r=0.476), IIRS (r=0.476), TT (r=0.419), TB (r=0.450), NB (r=0.292).
3)Increased perception of the cyclical nature of the condition; PHQ-9 (r=0.308), IIRS
(r=0.359), TT (r=0.395), TB (r=0.298). 4)Perception of treatment control correlated with
age (r=0.282).
Conclusions: This study shows that individuals’ perceptions of the consequences and 
emotional burdens of kidney disease are high and correlate with depressive symptoms and 
measures of consequence such as illness intrusiveness, treatment tolerability and treatment 
burden. Perceptions did not differ with dialysis status or dialysis vintage, suggesting that 
this is not a treatment effect. Further work will look at other predictors and outcomes.
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Cancer Screening in ESRD Patients
Anusha Sundararajan, Deepak Kana kadayakkara, Gregory K. Buller. Internal 
Medicine, Yale New Haven Health Bridgeport Hospital, Bridgeport, CT.
Background: As primary care physicians, we order health maintenance investigations 
as part of preventive work up which include cancer screening tests. ESRD patients form 
a special subset of population where regular cancer screening guidelines should not be 
applied as mortality is higher. The 2012 ASN ‘choosing wisely’ campaign recommended 
against regular cancer screening in ESRD patients. We initiated a project in our institution 
to assess the frequency of cancer screening tests- with focus on colorectal cancer screening 
in our ESRD population.
Methods: We did a retrospective study which included ESRD patients on hemodialysis 
(based on ICD codes) from a single center from 2012-2017 and excluded patients who had 
already received transplant or had prior malignancy. We had a total of 298 patients.
Results: Among the total 298 patients, 188 patients were between 45-75 year age 
group- out of which 96 patients (51%) underwent colonoscopy; out of 96 patients who 
underwent colonoscopy, 36 (37.5 %) were not transplant candidates and 16 (16.6%) died 
within the next 5 years. We also calculated Charlson comorbidity index of the patients to 
assess their 10 year survival likelihood.
Conclusions: Although patients who were undergoing transplant evaluation and patients 
with higher life expectancy had higher screening probability, the above numbers suggest 
that overscreening is still present. Hence, more individualized decision making including 
transplant likelihood and overall comorbidities of patients have to be considered before 
ordering cancer screening tests to avoid unnecessary cost and patient burden. These results 
can also help modify current practice- Providers can be alerted by EMR in ESRD population 
before ordering cancer screening tests to check if they will really benefit from them.
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Relationships Between Satisfaction Scores and Outcomes in Dialysis 
Patients
Yue Jiao, John W. Larkin, Marta Reviriego-Mendoza, Amy Barry, Judy L. Green, 
Len A. Usvyat, Jeffrey L. Hymes, Angela McClure, Franklin W. Maddux. 
Fresenius Medical Care North America, Waltham, MA.
Background: Patient satisfaction is an important aspect of the quality of care provided, 
yet the associations to outcomes are unknown. We determined correlations between Net 
Promoter Score (NPS) satisfaction survey scores and clinical outcomes in hemodialysis 
(HD) patients.
Methods: We used clinic level data from a large dialysis provider in 2015 and 2017. 
NPS index assesses consumer satisfaction with a company’s services via their willingness 
to recommend it to others; scores range from -100 to 100. We calculated Pearson’s 
correlation coefficient (R) between annual NPS and end-of-year quality metrics that include 
readmission and hospital day rates per patient year, as well as the percent (%) of patients: 
nonadherent with HD treatments, with arteriovenous fistula (AVF), with hemoglobin 
(HgB) ≥10.0 to ≤11.0g/dL, with albumin (Alb) ≥4.0g/dL, and with calcium (Ca) 
≤10.0mg/dL & phosphate ≥3.0 to ≤5.5mg/dL & parathyroid hormone ≥150 to ≤600pg/mL 
for a composite mineral bone disorder (MBD) measure. NPS was further compared to an
overall composite quality score that aggregated the above metrics and others (e.g. Kt/V). We 
also calculated R between changes in NPS and changes in quality metrics.
Results: We analyzed data from 2,287 in-center HD clinics. Mean NPS scores were 
49.0 in 2015 and 61.3 in 2017. We found higher NPS was related to: a lower % of patients 
nonadherent with HD treatments (R= -0.19 in 2015 & -0.18 in 2017; both p<0.001), a 
higher % of patients with AVF (R= 0.11 in 2015 & 0.12 in 2017; both p<0.001), a higher % 
of patients with HgB ≥10.0 to ≤11.0g/dL (R= 0.09 in 2015 & 0.10 in 2017; both p<0.001), a 
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higher % of patients with MBD laboratories in goal range (R= 0.14 in 2015 & 0.16 in 2017; 
both p<0.001), and a higher overall composite quality score (R= 0.13 in 2015 & 0.15 in 
2017; both p<0.001). NPS was not related to readmission and hospital day rates, or the % of 
patients with Alb ≥4.0g/dL. The 12.3-point increase in NPS from 2015 to 2017 was related 
to improvements in the overall composite quality score (R= 0.06; p=0.01).
Conclusions: NPS scores were related, albeit weakly, to several quality metrics 
including treatment nonadherence, AVF use, anemia and MBD laboratories, and overall 
composite quality scores. Increases in NPS over time were weakly related to better overall 
composite quality scores.
Funding: Commercial Support - Fresenius Medical Care North America
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Depressive Disorders Are a Risk Factor for Falls and Fall-Related Injuries 
Among Adults with Kidney Disease
Brandon Kistler,1 Jagdish Khubchandani,1 Paul N. Bennett,2 Ken Wilund,3 
Jacob J. Sosnoff.4 1Ball State University, Muncie, IN; 2Satellite Healthcare, San 
Jose, CA; 3University of Illinois, Urbana, IL; 4University of Illinois at Urbana-
Champaign, Urbana, IL.
Background: Depressive disorders are common among patients with chronic kidney 
disease (CKD) and especially those who have advanced to end stage kidney disease 
(ESKD). In addition, depression and pharmacotherapy for depression have been associated 
with impaired gait and increased propensity for falls in older adults. Therefore, the purpose 
of this study was to determine the relationship between depressive disorders, falls, and fall-
related injuries in a large cohort of US adults with CKD.
Methods: We analyzed the 2016 US Behavioral Risk Factor Surveillance System data 
using complex sample survey data analysis procedures in STATA software accounting for 
the multistage cluster study design.
Results: Among 354,829 adults, 16,675 (4.5%) reported CKD, 61,543 (16.8%) 
reported a history of a depressive disorder, 102,456 (28.5%) reported a fall, and 38.7% of 
those who fell reported a fall-related injury. Compared to adults without CKD or depression, 
adults with depression (OR=2.88, 95% CI=2.76-2.99), adults with CKD (OR=1.74, 
95%CI=1.60-1.90), and adults with both CKD and depression (OR=4.17, 95%CI=3.69-
4.71) had increased odds of suffering a fall. These results remained significant after 
accounting for demographic characteristics and comorbidities commonly associated with 
falls such as diabetes, arthritis, asthma, and cardiovascular conditions. Similarly, adults 
with depression (OR=2.02, 95%CI=1.90-2.14), CKD (OR=1.37, 95%CI=1.19-1.57), and 
CKD with depression (OR=2.89, 95%CI=2.47-3.38) had a higher risk of suffering an injury 
from a fall. Among only CKD patients, those who had been diagnosed with depression 
had higher odds of falling (OR=2.39, 95%CI=2.08-2.76) and suffering an injury (OR=2.11, 
95%CI=1.72-2.59) even after adjusting for demographics and comorbidities commonly 
associated with falls.
Conclusions: Among adults with a self-reported diagnosis of CKD, depression is a risk 
factor for suffering a fall and fall-related injury. It is unknown if this increased propensity for 
falling is related to medications, depression, or an interplay of these and other factors. Given 
the high prevalence of depression within the CKD population, this relationship warrants 
further examination in order to prevent and decrease fall-related injuries in this population.
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Hospital Admission Rates Are Associated with Depressive Affect and 
Antidepressant Use in Dialysis Patients
Billy Kim,1 Marissa A. Lee,1 Sheetal Chaudhuri,2 Hao Han,2 Marta Reviriego-
Mendoza,2 John W. Larkin,2 Len A. Usvyat,2 Terry L. Ketchersid,2 
Franklin W. Maddux.2 1Fresenius Rx, Nashville, TN; 2Fresenius Medical Care 
North America, Waltham, MA.
Background: Depression is a common mental health disorder and the leading cause 
of disability worldwide (WHO 2017). In the general population, antidepressant use has 
been associated with adverse drug events and frequent emergency room visits (Shehab 
N, et al. 2016). Little is known about the effects of antidepressant use, drug dialyzability, 
and associated outcomes in hemodialysis (HD) patients. We aimed to determine if 
hospitalization rates differ in HD patients by use of antidepressants and the presence of 
depressive affect (DA).
Methods: We analyzed data from a large dialysis provider on HD patients treated during 
2016 to 2018. We stratified patients by antidepressant use and compared hospitalization 
rates per patient year (ppy). Furthermore, we captured data on patients who completed DA 
screening via the patient health questionnaire-2 (PHQ2) and compared hospitalization rates 
for those who were DA positive (PHQ2 score ≥3) or negative, and using an antidepressant 
or not.
Results: In a population of 268,443 HD patients, 26% of patients were using an 
antidepressant. Hospitalization rates were higher in those using an antidepressant versus 
patients not taking any antidepressants (2.18 vs 1.41 admissions ppy, respectively). Overall, 
there was a 75% response rate to the PHQ2 survey. Among those who completed the PHQ2, 
9% were DA positive. Antidepressants were used by 41% of DA positive patients and 
22% of DA negative patients. In DA positive patients, hospitalization rates were higher 
for those using an antidepressant versus patients not using antidepressants (2.66 vs 2.29 
admissions ppy, respectively). Similarly, DA negative patients using antidepressants had 
higher hospitalization rates versus those not using antidepressants (2.4 vs 1.9 admissions 
ppy, respectively).
Conclusions: Findings indicate that patients taking antidepressants may have higher 
hospitalization rates when compared to those not taking any medication, irrespective of 
DA. Antidepressant-related hospitalization rates may be due to drug adverse events and 
could in part be confounded by indication. Treatment adherence and the presence of major 
depressive episodes are not addressed in this analysis. Further analyses are warranted.
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Association of Chronic Insomnia with Protein Energy Wasting in CKD
Jun Ling Lu,1 Amado X. Freire,1 Miklos Z. Molnar,1 Kamyar Kalantar-Zadeh,2 
Csaba P. Kovesdy.3,1 1University of Tennessee Health Science Center, Memphis, 
TN; 2University of California Irvine, School of Medicine, Orange, CA; 3Memphis 
VA Medical Center, Memphis, TN.
Background: Chronic insomnia is highly prevalent. Its effects on the sympatho-
adrenal system could potentially cause multi-systems abnormalities. It is unknown if 
chronic insomnia plays a role in the development of protein energy wasting (PEW) in 
patients with chronic kidney disease (CKD).
Methods: In a national cohort of 229,236 CKD patients, we examined associations 
between chronic insomnia (defined as the presence of ICD9 codes 307.42, 307.49 and 
780.52 and long-term use of insomnia medications) and PEW defined as the concomitant 
presence of serum albumin <3.8 g/dl or serum cholesterol <100 mg/dl, weight loss of 5% 
or more over 3 months, and neutrophil-to-lymphocyte ratio (NLR) >4.0. Associations 
were examined in crude logistic regression models (Model 1) and after adjustments for 
age, gender, race (Model 2), BMI, blood pressure, eGFR, chronic pain (Model 3), and 
comorbidities and socio-economic status (Model 4).
Results: 13,215 patients (5.8% of the cohort) had chronic insomnia and 1,412 (0.6% 
of the cohort) had PEW. 152 chronic insomnia patients (1.2%) vs. 1,260 patients in control 
group (0.6%) had PEW. Insomnia was associated with higher odds of PEW events in both 
unadjusted (Model 1) and in multivariable adjusted models (odds ratio in Model 4: 1.5 
[95%CI: 1.3, 1.9], p<0.001), Figure 1. Results were consistent in subgroup analyses.
Conclusions: Chronic insomnia is associated with higher risk of PEW in CKD patients. 
Further studies are needed to determine underlying mechanisms of action and the effects 
of interventions.
Funding: NIDDK Support
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Hypokalemia: A Diagnostic Challenge
Smitha R. Anam,1,2 James I. McMillan,1,2 Zhiwei Zhang.1 1Nephrology, VA Loma 
Linda Healthcare system, Loma Linda, CA; 2Nephrology, Loma Linda University 
Medical Center, Loma Linda, CA.
Introduction: Hypokalemia, a very common clinical problem is generally due to 
decreased oral intake, urinary loss, gastrointestinal loss or transcellular shifts. Here we 
present a challenging case of refractory hypokalemia.
Case Description: A 72-year-old man with new diagnosis of prostate adenocarcinoma 
not yet on treatment presented with hematuria, new hypertension and hypokalemia. He 
denied poor oral intake, vomiting or diarrhea. He denied medications or herbal, dietary 
supplements. There was no family history of hypokalemia or hypertension. Laboratory: 
Serum Na 145mmol/L, K 2.0mmol/L, HCO3 34mmol/L, Plasma Renin 0.62ng/ml/hr, 
Aldosterone< 1ng/dl, Cortisol 38.8mcg/dl, ACTH 81pg/ml, Urine K 88.5mmol/L. 
Cystoscopy: large friable prostate, likely the cause of hematuria so palliative TURP 
was performed. Androgen deprivation therapy (Bicalutamide) was begun. Refractory 
hypokalemia persisted despite aggressive potassium replacement.
Discussion: In our patient, inappropriately high urine K, Hypokalemia and Chloride-
resistant metabolic alkalosis and Hypertension suggested mineralocorticoid excess. 
However low plasma renin and aldosterone indicated pseudohyperaldosteronism. 
Differential diagnosis included Liddle’s, Gellers syndromes, Syndrome of apparent 
mineralocorticoid excess or chronic licorice use, Cushing syndrome and Congenital 
adrenal hyperplasia. Patient’s age and pertinent history excluded several of these leading 
us to a diagnosis of ACTH-dependent Cushing’s syndrome. This was further confirmed by 
overnight dexamethasone suppression test. ACTH-dependent Cushing’s syndrome could 
be due to Cushing’s disease but MRI of brain was negative, making this unlikely. Ectopic 
ACTH producing tumor was felt more likely. A high grade prostatic adenocarcinoma 
with a neuroendocrine component was found in prostate tissue. The basic mechanism for 
hypokalemia is mineralocorticoid receptor (MR) activation by excess cortisol, leading 
to sodium reabsorption via ENaC. Treatment strategies focus on decreasing tumor 
burden and inhibition of MR or ENaC. Since some reports indicated spironolactone may 
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potentially promote prostate cancer, we instead recommended ENaC inhibitor triamterene. 
Chemotherapy (Etoposide/Carboplatin) was then initiated with resolution of hypokalemia 
after 5 days of treatment. He was off triamterene and potassium replacement by the end of 
3rd cycle of chemotherapy.
FR-PO572 Poster Friday
Trainee Case Reports - III
Hypokalemia as the Smoking Gun of Paraneoplastic Syndrome
Katherine M. Scovner,1 Li Li,2 Joseph V. Bonventre.2 1BWH/MGH, Boston, MA; 
2Brigham and Women’s Hospital, Brookline, MA.
Introduction: Ectopic secretion of ACTH (EAS) is commonly associated with small 
cell lung cancer but rare with other lung cancers. The present case is that of an individual 
with EAS leading to hypokalemia in the setting of lung adenocarcinoma.
Case Description: A 66-year-old woman presents with metastatic lung 
adenocarcinoma (poorly differentiated) diagnosed 2 years prior to admission. She had been 
treated with carboplatin and taxol. She presents with hypokalemia (K 2.6mmol/L despite 
K supplementation of 80meq per day). Hypokalemia was noted at the time of carboplatin 
therapy but resolved following its discontinuation. Hypokalemia was noted again at the time 
of the diagnosis of brain metastasis. Other labs were notable for Mg 1.8mg/dL, bicarbonate 
33mmol/L, pH 7.51, and WBC 34.4K/uL with neutrophil predominance. Urine K was 
92mmol/L and transtubular K gradient ((urine K/plasma K)/(urine osm/plasma osm)) was 
26.2. Plasma cortisol was 46.5ug/dL at 7pm when ACTH was 67pg/mL. Morning cortisol 
after 1mg and 8mg dexamethasone were 38.1ug/dL and 32.9ug/dL respectively. Urine 
free cortisol was 650mcg/24 hours. Renin and aldosterone levels were both below lower 
limits of assay detection. Brain MRI showed no pituitary pathology to suggest Cushing 
disease. She was thus diagnosed with EAS. The patient underwent bilateral laparoscopic 
adrenalectomy, and potassium normalized. She then pursued hospice care as there were no 
more chemotherapeutic options.
Discussion: Although rare among non-small cell lung cancer patients, 13 cases of 
EAS with non-small cell lung cancer had been reported as of 2012. Hypokalemia due to 
platinum-based chemotherapy tends to coexist with hypomagnesemia (platinum decreases 
Mg, which inhibits the Na+K+ATPase and K is lost in urine through potassium channels 
in the thick ascending limb). The patient had hypokalemia as well as leukocytosis at the 
time of diagnosis of brain metastasis. Trends in K and WBC over time may help predict 
progression of malignancy in the setting of EAS. Bilateral adrenalectomy represents an 
option for control of EAS, but expected survival post-operatively should be considered 
before proceeding.
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Abiraterone Induced Hypokalemia in Treatment of Castration Resistant 
Prostate Cancer
Waleed Asfar, Milos N. Budisavljevic, Andrew B. Elliott. Medical University of 
South Carolina, Charleston, SC.
Introduction: Abiraterone was approved in combination with prednisone for the 
treatment of metastatic Castration Resistant Prostate Cancer (CRPC) who recieved 
chemotherapy. In 2018 FDA expanded the indication to include chemotherapy naive 
patients. Most common side effects associated with abiraterone include fatigue, diarrhea, 
hypertension, elevated liver enzymes, and hypokalemia. Abiraterone inhibits CYP17A1, the 
rate limiting hydroxylase in androgen and steroids synthetic pathway. This causes ACTH 
level to increase, leading to secondary excess in mineralocorticoids. This secondary excess 
manifests as hypertension, hypokalemia, and fluid overload. Prednisone is co-administered 
to suppress the hypothalamic-pituitary-adrenal axis and diminish the symptoms of 
mineralocorticoid excess.
Case Description: We Describe a case of a 65 year old male with history of 
hypertension, dyslipidemia, hypothyroidism and prostate cancer. He was diagnosed with 
Prostate cancer in 2005 and recieved total prostatectomy. In 2012 he developed biochemical 
relapse and recieved radiation and androgen depreviation therapy. In 2015 he was found 
to have bone metastasis and recieved radiation therapy to the cervical spine and started 
on abiraterone and prednisone therapy early 2016. He was later found to have avascular 
necrosis of the left femoral head and decided to stop prednisone as he was worried about his 
bone health. He was found to have Hypokalemia and worsening control of blood pressure 
on follow up with primary care, his serum potassium was 2.5 with a serum bicarb of 25. He 
was started on oral potassium supplementation but his Hypokalemia persisted. He was seen 
by nephrology as an outpatient, his exam was significant for elevated BP and trace lower 
extremity edema. serum aldosterone to renin was low at 2.9. He was started on aldactone 
with improvement in his serum potassium on follow up.
Discussion: With the recent expansion of the FDA approval more prostate cancer 
patients will be treated with abiraterone, understanding the mechanism of action of 
abiraterone and resulting side effects is crucial as it can prevent dangerous arrhythmias 
and outcomes. Nephrology input is needed in manging these patient along with primary 
care. Patient with contraindications to steroids should be started on eplerenone or aldactone 
therapy.
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A Rare Mutation Causing Hypertension and Hypokalemia During 
Pregnancy
Meghana Chalasani,1 Laith Al-Rabadi,2 Josephine Abraham.1 1University of 
Utah, Salt Lake City, UT; 2University of Utah hospital, Salt Lake, UT.
Introduction: Geller syndrome is a rare autosomal dominant condition characterized 
by severe early-onset hypertension and hypokalemia in pregnancy due to a gain-of-function 
mutation that causes upregulated mineralocorticoid activity.
Case Description: A 42-year old woman presented to her obstetrician during her 29th 
week of pregnancy (G1P0) and was found to be hypertensive (172/109 mm Hg). Patient 
was diagnosed with hypertension in her late thirties which she initially managed with 
exercise but later required hydrochlorothiazide and atenolol for 3 years. Both were stopped 
when she became pregnant and she did not require initiation of any other agents. At week 
29, patient presented to her obstetrician with hypertension. She was also noted then to 
have hypokalemia (2.9 mmol/L) and hypomagnesemia (1.4 mmol/L) both of which were 
repleted intravenously. Repeat labs three days later revealed a potassium of 2.9 mmol/L 
and a magnesium of 1.4 mmol/L. Nephrology was consulted for further evaluation. Patient 
denied using diuretics or any over-the-counter supplements. Lab work was notable for a 
trans-tubular potassium gradient (TTKG) of 6.7 consistent with renal potassium wasting. 
Extensive chart review was conducted including patient’s routine labs prior to pregnancy. 
Potassium levels pre-partum were consistently around 4 mmol/L. Patient was treated 
with oral potassium and magnesium supplements with frequent labs and instructions to 
discontinue supplements after delivery of fetus. Repeat labs four weeks post-partum 
revealed potassium of 3.8 mmol/L and magnesium of 2.0 mmol/L. Blood pressure also 
improved to 144/86 mm Hg.
Discussion: Geller syndrome is a rare autosomal dominant condition in which a gain-
of-function mutation causes upregulation of mineralocorticoid activity by progesterone 
during pregnancy. The progesterone-high environment of pregnancy, particularly in the 
second and third trimesters, is likely the reason our patient suddenly developed hypertension 
and hypokalemia at 29 weeks. Although genetic testing is still pending, we are fairly 
confident in our diagnosis particularly because our patient’s blood pressure and potassium 
levels improved post-partum. It is important that clinicians are aware of this rare entity as 
treatment with aldosterone antagonists which theoretically sound ideal to treat hypertension 
with hypokalemia can in fact exacerbate the hypertension.
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Supratherapeutic Posaconazole: An Emerging Cause of Apparent 
Mineralocorticoid Excess (AME)
Narisorn Atsava-Svate,1 Alkesh Jani.2 1University of Colorado Denver, Denver, 
CO; 2University of Denver Colorado, Aurora, CO.
Introduction: Apparent mineralocorticoid excess (AME) causes severe hypertension 
accompanied by metabolic alkalosis with hypokalemia. Substances which are well known to 
cause AME include glycyrrhizic and glycyrrhetinic acid found in licorice. These compounds 
competitively inhibit the enzyme called 11 Beta Hydroxysteroid Dehydrogenase type 2 (11β- 
HSD2). Lack of 11β- HSD2 caused higher cortisol available to bind the mineralocorticoid 
receptor, and results in ENaC-mediated Na reabsorption. Posaconazole, the broad-spectrum 
azole group antifungal agent, is commonly used for prophylaxis in patients with AML and 
severe neutropenia. Literature review revealed that posaconazole at supratherapeutic level 
can also inhibit 11β- HSD2 and cause apparent mineralocorticoid excess (AME).
Case Description: A 37 years old Caucasian female with refractory acute myelogenous 
leukemia (AML) with normal baseline blood pressure(100-120/65-80mmHg). She had 
neutropenia after third re-induction chemotherapy with G-CLAM regimen. She was then 
started on oral posaconazole 300 mg daily for fungal prophylaxis. One month later she then 
developed refractory hypokalemia with metabolic alkalosis and new onset hypertension 
(180/110mmHg). We were giving her potassium replacement 60-80 mEq/day, but her 
serum potassium level remained less than 3.3 mEq/L. Her serum cortisol level was 18.2 
mcg/dL, plasma renin activity <0.167 ng/mL/h, plasma aldosterone level < 1ng/dL. Serum 
posaconazole level was 1800 ng/mL. Discontinuation of posaconazole, with documented 
normal therapeutic posacoanzole level, resulted in improvement of hypertension, refractory 
hypokalemia and metabolic alkalosis. All clinical features resolved within 2 weeks after 
discontinuation of posaconazole.
Discussion: We suggest that posaconazole level should be part of laboratory 
investigations in patients who are treated with posaconazole and have new onset of 
hypertension, hypokalemia and metabolic alkalosis. Posaconazole, at supratherapeutic 
level, inhibits 11 Beta Hydroxysteroid Dehydrogenase type 2 and causes apparent 
mineralocorticoid excess (AME).
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Trainee Case Reports - III
Urinary Exosome Analysis in a Case of Licorice-Induced 
Pseudoaldosteronism
Shinichiro Asakawa,1 Osamu Yamazaki,1 Yuto Hayama,1 Masaki Yamanaka,1 
Emiko Kuribayashi-Okuma,1 Yoshihide Fujigaki,2 Shigeru Shibata.1 Teikyo 
University School of Medicine 1Teikyo University School of Medicine, Tokyo, 
Japan; 2Teikyo University School of Medicine, Department of Internal Medicine, 
Tokyo, Japan.
Introduction: Excessive licorice intake can cause a syndrome mimicking 
hypermineralocorticoidism. Glycyrrhizin, the active metabolite of licorice, inhibits 
11bHSD2 that converts cortisol to inactive cortisone, resulting in epithelial Na+ channel 
(ENaC) activation in principal cells. However, the contributions of other Na and Cl 
transporters including Na-Cl cotransporter (NCC) in distal convoluted tubules and the Cl/
HCO3 exchanger pendrin in intercalated cells remain unknown.
Case Description: A 74-year-old woman with type 2 diabetes was referred for muscle 
weakness, leg edema, and polyuria. She reported that she had been taking herbal medicine 
containing licorice (6 g/day). Her BP was 162/78 mmHg and work up revealed severe 
hypokalemia (1.9 mEq/L), mild hypernatremia (147 mEq/L), and metabolic alkalosis 
(pH 7.513, and HCO3 43.2 mmol/L). Urinary potassium level was 84.0 mEq/gCr, 
indicating the urinary potassium loss. Serum magnesium level was 1.9 mg/dL. Her serum 
aldosterone level was below the detection limit (< 10 pg/mL) with low plasma renin activity 
(0.3 ng/mL/hour). Serum cortisol and adrenocorticotropic hormone were normal. 
Abdominal CT scan and Doppler ultrasound of renal arteries revealed no abnormality. 
She stopped taking licorice and received KCl 40 mmol of DIV and 24 mmol oral in first 
24 hrs. However, hypokalemia persisted, and the patient received 25mg of spironolactone 
orally from day 3. On day 10, serum potassium returned to normal, and was discharged 
on day 13. To address the contribution of Na and Cl transport mechanisms in the distal 
nephron, we isolated exosomes from pre- and post-treatment urine samples. Comparison 
of the pre- and post-treatment samples revealed that active, cleaved form of ENaCγ was 
markedly increased, whereas uncleaved form was undetectable in the pre-treatment sample, 
consistent with the increased activity of ENaC. Of note, both pendrin and NCC levels were 
profoundly increased in the pre-treatment sample, and were reduced after the treatment. In 
contrast, NKCC2 levels were lower in the pre-treatment sample than in the post-treatment 
sample.
Discussion: These data indicate that not only ENaC but NCC and pendrin are involved 
in licorice-induced fluid and electrolyte abnormalities.
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Hypokalemic Tetraparesis as First Manifestation of MGRS
Nicola Lepori,1 Matteo Floris,1 Andrea Angioi,1 Riccardo Cao,1 Alice Atzeni,1 
Anna Maria Asunis,2 Doloretta Piras,1 Gianfranca Cabiddu,1 Antonello Pani.1 
1Nephrology, Ospedale Brotzu, Cagliari, Italy; 2Anatomic Pathology, Ospedale 
Brotzu, Cagliari, Italy.
Introduction: Renal potassium wasting is a frequent cause of hypokalemia; it can be 
consequence of medications, endogenous hormone production, inherited or acquired renal 
tubular defects
Case Description: A 50 y/o woman was admitted to our Hospital with limb weakness, 
muscle cramps progressing to tetraparesis, associated with severe hypokalemia (1,6 
mEq/L). She denied diarrhea or vomiting; pharmacologic and past medical history were 
unremarkable. Labs showed normal renal function, hyperchloremic metabolic acidosis, 
urinary potassium wasting (88 mmol/24h) and alkaline urine. A diagnosis of hypokaliemic 
tetraparesis due to distal renal tubular acidosis (type 1 RTA) was made. IV NaHCO3 
and KCl replacement resolved the tetraparesis. Further investigations were made: SPEP 
showed a IgMK monoclonal protein, ANA (1:640) and ENA-SSA were positive (689 U/ml) 
while antiDNAds were negative. At that time, she rejected a renal biopsy and any 
follow-up. Two months later, she was admitted to our Department with hypertension 
(170/90 mmHg) and swelling. Labs showed normal kidney function, hypokalemia, 
slightly increased CRP levels. Urinalysis revealed microscopic hematuria and proteinuria 
(3.6 g/24h). Serology revealed very low C3 and C4, positive ANA (1:320), ENA-SSA 
(314 U/ml), type 1 cryoglobulins (IgMk). Suspecting an MGRS, a renal biopsy was 
performed: light microscopy showed an MPGN pattern with coarse pseudothrombi and a 
diffuse interstitial infiltration of lymphomonocytes, kappa+. IF was coherent with serology, 
showing IgMK (+++) and C3 (++) subendothelial deposits, and kappa+ cytoplasmic 
droplets in proximal tubules. Type 1 cryoglobulinemia and kappa light chains induced 
chronic tubular interstitial nephritis (resulting in type 1 RTA) was diagnosed. After three 
courses of dexamethazone, rituximab and cyclophosphamide, microscopic hematuria 
disappeared, proteinuria improved to 0,15 g/24h and serum potassium levels persisted 
steady without potassium supplements
Discussion: We described an unusual presentation of MGRS, with severe hypokalemia 
due to diffuse tubular injury mediated by kappa light chain, followed by a full blown 
type 1 cryoglobulinemia. Searching for a monoclonal protein should be an essential part 
investigating an acquired tubular disfunction
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Neck Down Paralysis in a Young Male Triggered by High-Dose Steroids
Sohaib Zahid, Swathi Lavudi, Tina Y. Ko, Khaled Nashar, 
Kalathil K. Sureshkumar. AGH Nephrology Nephrology, Allegheny Health 
Network, Pittsburgh, PA.
Introduction: Derangements in electrolyte homeostasis can result in a variety of 
clinical manifestations. Herein we present a unique case of sudden severe symptomatic 
hypokalemia in an otherwise healthy young male triggered by high dose steroid.
Case Description: A 30 year old caucasian male with no significant medical history 
was given intravenous high dose steroids for allergic skin rash in the ER. The next day 
he presented with sudden onset of bilateral upper and lower extremity weakness and 
palpitations. Vitals were normal except for tachycardia. Physical examination confirmed 
bilateral upper and lower extremity weakness with diminished reflexes. CBC and BMP 
were unremarkable except for potassium (K) 1.4 meq/L. EKG revealed atrial fibrillation. He 
was given IV and oral K replacement. Further workup showed TSH of 0.007mcU/ml(0.4-
4.0) with free T4 of 4.28 ng/dl(0.7-1.9) and free T3 of 11.19 pg/ml(1.76-3.68). He was 
started on propranolol and methimazole. His symptoms completely resolved within twelve 
hours of treatment and he was discharged home in a stable condition.
Discussion: Hypokalemic periodic paralysis (HPP) is a rare autosomal dominant 
neuromuscular disorder with prevalence of 1 in 100,000. Male to female ratio is 
approximately 4:1. Genetic mutations have been identified that affect skeletal muscle 
sarcolemma calcium and sodium channels, resulting in inadequate depolarization. Acquired 
HPP has been described in association with hyperthyroidism and can be precipitated by 
administration of intravenous steroids as in our patient. Thyroid hormones increase tissue 
responsiveness to beta-adrenergic stimulation, resulting in increase sodium-potassium 
ATPase activity on skeletal muscle membrane resulting in hypokalemia. High dose steroid 
likely modulated the K lowering effect of thyroid hormones in our patient. It is important 
to differentiate thyrotoxic periodic paralysis (TPP) from HPP as the former requires 
administration of non selective beta blocker along with K replacement to ameliorate the 
acute attack whereas the latter corrects with K replacement alone.
FR-PO579 Poster Friday
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Symptomatic Hypophosphatemia from Parenteral Iron Administration
Sohaib Zahid, Swathi Lavudi, Kalathil K. Sureshkumar, Tina Y. Ko. AGH 
Nephrology Nephrololgy, Allegheny Health Network, Pittsburgh, PA.
Introduction: Fibroblast growth factor 23 (FGF23) plays a crucial role in phosphate and 
vitamin D homeostasis. Herein we present a case of severe symptomatic hypophosphatemia 
following the administration of intravenous (IV) ferric carboxymaltose likely triggerred by 
inappropriate FGF23 activity.
Case Description: A 31 year old female received two doses of IV ferric 
carboxymaltose for iron deficiency anemia. Four days later, she presented with numbness, 
tingling and muscle cramps. Evaluation revealed severe hypophosphatemia with serum 
phosphorus level of 1.0 mg/dl. Serum potassium, calcium, iPTH, 25 hyrdoxy, and 1,25 
dihydroxyvitamin D levels were normal. A 24 hour urine collection revealed calcium of 
27 mg (100 -250mg) and phosphorus of 1.8 g (0.4- 1.3 g) with a high fractional excretion 
of phosphorus >5%. Serum FGF23 level was inappropriately elevated at 97 RU/ml 
(44-215) for the degree of hypophosphatemia. Patient was given IV and oral phosphorus 
supplementation repeatedly without clinically significant improvement. Serum phosphorus 
levels were normalized with resolution of symptoms three weeks later.
Discussion: FGF23 is secreted primarily by bone, thymus, heart, brain and, in 
low levels, by several other tissues. It reduces serum phosphorus levels by decreasing 
expression of type IIa sodium/phosphate cotransporters, resulting in decreased renal 
phosphate reabsorption. It also down regulates the gene transcription of 1α-hydroxylase 
thereby reducing the bioactive 1,25-dihydroxy vitamin D (1,25-2OH-VitD) further 
decreasing the phosphate reabsorption in the gut. Ferric carboxymaltose is a newer iron 
formulation increasingly prescribed due to its effectiveness and shorter infusion time. 
There have been reports of hypophosphatemia associated with use of IV iron preparations 
including saccharated ferric oxide and ferric citrate hydrate. Studies have shown that IV 
iron may reduce peripheral degradation, secretion, and clearance of FGF23 resulting in 
inappropriately elevated FGF23 levels. Data is scarce with use of IV ferric carboxymaltose 
and hypophosphatemia. Our case highlights the importance of understanding the side effect 
profile of commonly administered medications and formulations so that an early diagnosis 
could be established.
FR-PO580 Poster Friday
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A Case of Diabetic Ketoacidosis Concurrently with Severe Hypokalemia 
Induced by Distal Renal Tubular Acidosis Due to Toluene Intoxication
Kazuki Aihara,1 Yosuke Nakagawa,1 Naoto Hamano,1 Masahiro Koizumi,1 
Takehiko Wada,2 Masafumi Fukagawa.1 Division of Nephrology, Endocrinology 
and Metabolism, Tokai University School of Medicine, Isehara, Japan 1Tokai 
University School of Medicine, Isehara, Kanagawa, Japan; 2Tokai University, 
Isehara, Japan.
Introduction: Diabetic ketoacidosis (DKA) is a high anion gap metabolic acidosis due 
to excessive blood concentration of ketone bodies. Hyperkalemia is often accompanied with 
DKA because of extracellular potassium shift caused by lack of insulin action as well as 
reduced renal potassium excretion caused by acute prerenal kidney injury. Here, we report a 
case of DKA complicated by severe hypokalemia resulting from distal renal tubular acidosis 
type 1 (RTA-1) due to toluene intoxication.
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Case Description: A 37-year-old male who had been treated with basal supported 
oral therapy for type 2 diabetes mellitus for 7 years experienced appetite loss. He took 
only isotonic drinks for 5 days and nausea and vomiting developed, followed by muscle 
weakness and difficulty of walking. He was referred to our hospital with his laboratory 
findings of hyperglycemia and high anion gap metabolic acidosis with ketonemia, which 
was diagnosed as DKA. In the meantime, normal anion gap metabolic acidosis was thought 
to be exist as well. In addition, he had severe hypokalemia and inappropriately high urinary 
excretion levels of potassium despite acute kidney injury due to volume depletion. He was 
treated with fluid resuscitation and continuous venous insulin infusion plus a large amount 
of potassium supplementation (Figure 1). After his general status improved, he stayed out 
of the hospital for trial. However, he came back in a haze with an odor of organic solvent 
and urinalysis revealed elevated levels of potassium and urinary hippuric acid concentration 
(23.65 g/L). Finally, he confessed to abuse of toluene for more than 20 years.
Discussion: It is known that toluene intoxication can be the cause of RTA-1 which 
gives rise to normal anion gap metabolic acidosis and hypokalemia. We should take toluene 
intoxication account if severe hypokalemia is accompanied with DKA.
FR-PO581 Poster Friday
Trainee Case Reports - III
Use of Patiromer for Long-Term Management of Hyperkalemia in an 
ESRD Patient
Sylvester Barnes,1,2 Julia Schneider,1,2 David J. Leehey.1,2 1Hines VA, Hines, IL; 
2Loyola University Medical Center, Maywood, IL.
Introduction: Hemodialysis patients generally undergo dialysis with a dialysate 
potassium concentration of either 2 or 3 mEq/L. Use of lower dialysate potassium 
concentrations (< 2 mEq/L) may lead to post-dialysis hypokalemia and an increased risk 
of arrhythmia. This leads to a dilemma when pre-dialysis hyperkalemia is not controlled 
despite use of a 2 mEq/L potassium dialysate. A possible solution is the use of potassium 
binding agents in order to decrease pre-dialysis serum potassium concentrations.
Case Description: A 60-YOM with ESRD due to IgA nephropathy was being 
maintained on hemodialysis on a MWF schedule for 4h each treatment using an AVF. He 
was very compliant with dialysis and with dietary restrictions. However he had persistent 
pre-dialysis hyperkalemia (peak K of 7 mEq/L and average around 5.5 mEq/L) despite use 
of a 2 mEq/L potassium dialysate. His Kt/V was 1.6. No access recirculation was present. 
He did not take RAAS inhibitors or other medications known to cause hyperkalemia. He 
had previously been prescribed maintenance sodium polystyrene sulfonate which was 
poorly tolerated. In February 2017 he was scheduled for laparoscopic cholecystectomy, and 
assistance was requested in lowering his serum potassium levels pre-operatively. He was 
begun on patiromer 8.4g every Saturday and Sunday which resulted in a marked decrease 
in his pre-dialysis serum potassium concentrations. He was subsequently maintained on 
patiromer for over one year (until March 2018) with no further episodes of hyperkalemia 
(see Figure; arrow depicts duration of patiromer therapy). At the patient’s request the drug 
was then stopped, leading to an increase in pre-dialysis serum potassium level.
Discussion: Hyperkalemia can be a persistent problem for patients on chronic 
hemodialysis. Most guidelines recommend that very low potassium dialysates 
(< 2 mEq/L) be avoided. In this patient, use of patiromer twice weekly resulted in a long-
term stable lowering of the pre-dialysis potassium concentration. To our knowledge this is 
the longest reported use of scheduled patiromer in a dialysis patient.
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Loquat Induced Severe Hyperkalemia Presenting as Secondary Hyperka-
lemic Paralysis and Cardiac Conduction Abnormalities
Raja M. Rashid,1 Zahid Nabi.2 1CPSP, Islamabad, Pakistan; 2KRL Hospital, 
Islamabad, Pakistan.
Introduction: Severe hyperkalemia is attributed to 3-5% deaths and a quarter 
of emergency dialysis sessions in ESRD patients. It generally manifests as cardiac 
abnormalities and rarely as secondary hyperkalemic paralysis. Missed dialysis sessions and 
dietary indiscretions to known potassium rich food are common causes. Loquat (Nispero, 
Eriobotrya japonica) is an often overlooked fruit for having moderate to high potassium 
content (266mg/100gram) that caused life threatening hyperkalemia in our patient.
Case Description: 27 year old male with ESRD secondary to diabetic nephropathy on 
thrice weekly maintenance hemodialysis for past 1.5 years presented in ER with restlessness, 
feeling of unease and weakness in limbs and inability to walk. There was no history of 
current or preceding fever and any such episode in the past. Examination revealed an alert 
yet restless individual, afebrile with pulse of 62 bpm and blood pressure of 90/60mmhg, 
flaccid paraparesis, hypotonia and diminished reflexes. His immediate EKG is shown in 
Fig. 1. Calcium gluconate was infused, transcelluar shifting measures were instituted and 
dialysis session of 4 hours was carried out within 30 minutes of presentation with constant 
cardiac monitoring. EKG changes necessitated repetition of calcium gluconate, thrice over 
an hour, changing serum calcium from 8.8 mg/dl pre-dialysis to 9.4mg/dl afterwards. Non 
hemolized and repeated samples confirmed pre dialysis serum potassium of 9.6mmol/L 
and post dialysis concentration of 5.2mmol/L. His symptoms improved after 80 mins of 
dialytic therapy. Patient was not on Beta blockers, ACE inhibitors or NSAIDs. The family 
and patient denied taking any unusual substance except for repeated large servings of loquat 
since his last dialysis session.
Discussion: Context specific and dietary education curtailing multicultural cuisines can 
prevent potassium catastrophes. In the ER, secondary hyperkalemic paralysis should be 
considered in differentials of acute paralysis. IV Calcium for myocardial stability is to be 
repeated judiciously unless pressing EKG changes vanish. Unambiguous EKG changes in 
pertinent clinical setting are sufficient in dialysis population to warrant urgent hemodialysis 
administration.
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Trainee Case Reports - III
SIADH as the Initial Presentation in Guillain Barre Syndrome
Nicholas Fuca,1 Divya Asti,2 Bindu Mudduluru,2 Elie El-Charabaty.1 SIUH 
Internal Medicine / Nephrology 1Staten Island University Hospital, Staten 
Island, NY; 2Northwell Health, Staten Island, NY.
Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune disease damaging 
the peripheral nervous system that commonly presents as rapidly progressive symmetrical 
motor weakness. Autonomic dysfunction occurs in about 70% of GBS patients. Although 
there is a known association of SIADH in GBS patients, it usually occurs late in the disease 
course when there is maximal motor deficit. SIADH as an initial finding in patients with 
GBS is rare which is reported in this case.
Case Description: 72-year old female with history of dyslipidemia presented with 
subjective complaints of bilateral lower extremity weakness and difficulty ambulating. 
Her initial neurological exam was normal, with no deficits. She was found to have 
hyponatremia at 128 mEq/l that continued to drop to 115 mEq/l despite normal saline. Her 
serum Osmolality was 245 Osm/L, with elevated Urine Osmolality 702 Osm/L, suggestive 
of SIADH. Fluid restriction 1L daily was initiated, and her sodium continued to decline to 
113 mEq/l. By day 6 she was found to have lower extremity weakness with strength 1/5. 
CSF analysis showed an albuminocytologic dissociation (total protein 288 & WBC 3) – 
suggestive of GBS. Therapeutic Plasmapheresis Exchange and oral Tolvaptan was initiated. 
Her sodium stabilized 134-137 mEq/l. With aggressive treatment and physical therapy, she 
regained her strength and walked without assistance at discharge.
Discussion: GBS commonly presents as progressive symmetrical muscle weakness 
with absent/decreased deep tendon reflexes. Incidence of SIADH in GBS is ~4.8%. 
Pathogenesis of SIADH in GBS is hypothesized to be: (1) Resetting of the osmoreceptor 
(2) Increased sensitivity of ADH at renal tubules. Hyponatremia in our case was present
on admission prior to motor deficits from GBS. Urine and serum studies confirmed 
SIADH requiring tolvaptan. Her GBS was treated with plasmapheresis and her sodium
stabilized only after treatment of the underlying GBS. Only 2 cases of GBS with SIADH
at presentation have been reported. Observational and prospective studies have shown
hyponatremia in GBS is associated with poor outcomes and increase mortality. Our case
report emphasizes that SIADH may precede the development of profound motor deficit in 
GBS. Physicians should be aware of this rare presentation to prevent delays in treatment.
Further studies are necessary to understand the cause behind SIADH in GBS and its impact 
on prognosis.
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Trainee Case Reports - III
Hyponatremia Due to Nivolumab-Induced Sequential Primary Adrenal 
Insufficiency and Hypothyroidism
Raku Son, Masahiko Nagahama, Masaaki Nakayama. St. Luke’s international 
hospital, Tokyo, Japan.
Introduction: Hyponatremia is the most common electrolyte disorders in lung cancer 
patients. Here we present a case of hyponatremia due to both primary adrenal insufficiency 
and hypothyroidism in a patient treated by nivolumab, a novel and increasingly used 
immune checkpoint agent.
Case Description: A 77-year old Asian man diagnosed as Stage IV non-small cell lung 
cancer on 6 courses of nivolumab for 4 months presented with 1-week general malaise. 
Laboratory test showed serum sodium (S-Na) 122 mEq/L. Cortisol, renin, aldosterone 
were 1.31 microg/dL, 1.1 ng/ml/hr and 23 pg/ml, respectively. Brain MRI denied 
hypophysitis. Positron emission tomography (PET) scan showed no adrenal metastasis but 
raised suspect of thyroiditis, though TSH was within normal limit. After treatment with 
hydrocortisone for primary adrenal insufficiency, S-Na was improved to 136 mEq/L. One 
month after discharge, laboratory follow-up revealed TSH of 62.7 micro IU/ml with low 
free T4 and T3. Levothyroxine was started but TSH remained high at 99.9 micro IU/ml. 
Two months after discharge he again presented with S-Na 121 mEq/L accompanied with 
loss of appetite. Laboratory test revealed cortisol 23.23 microg/dL, renin 7.5 ng/ml/hr and 
aldosterone 115 pg/ml. We increased both levothyroxine and hydrocortisone and S-Na 
returned to 135 mEq/L.
Discussion: Hyponatremia in lung cancer patients is commonly attributed to SIADH 
or hypovolemia. However, immune checkpoint agent including nivolumab can cause 
hypophysitis, primary adrenal insufficiency and hypothyroidism, or even more than one as 
in our patient. Any patient on a checkpoint inhibitor presenting with hyponatremia should 
undergo full work-up of endocrine disorders.
FR-PO585 Poster Friday
Trainee Case Reports - III
A Rare Case of Hypophysitis Induced Hyponatremia
Alia Hasan, Mala Sachdeva, Rimda Wanchoo, Kenar D. Jhaveri. Nephrology, 
Zucker School of Medicine at Hofstra Northwell, GREAT NECK, NY.
Introduction: Immune checkpoint inhibitors are associated with a few electrolyte 
disorders. CTLA-4 antagonists are known to cause hypophysitis and as a result 
hyponatremia with an incidence of 3.2%. PD-1 inhibitors are not commonly associated 
with hyponatremia from hypophysitis. We report a case of hyponatremia associated with 
hypophysitis secondary to pembrolizumab therapy.
Case Description: A 69 year old male was diagnosed with non small cell lung 
cancer with metastatic lesions. Given the tumor was PDL1 positive, the patient was 
initiated on pembrolizumab therapy. 4 months into therapy, the patient was noted to have 
orthostatic hypotension and presented with a blood pressure of 90/50 mmHg and a sodium 
concentration of 125mmol/L. A trial of normal saline lead to improvement in blood pressure 
but worsening of hyponatremia to 123mmol/L. Serum osmolarity was 260mosm/Kg and 
urine osmolarity of 475mosm/Kg. Urine Na was 45mmol/L. An am cortisol repeated 3 times 
showed a very low value. ACTH was also suppressed. A thyroid panel revealed a low TSH 
and a low T4 level. FSH, LH and other hormones were in normal limits. An MRI of the 
brain did not show any pituitary lesions and a CT scan of the adrenals revealed no new 
findings. Given the hormonal abnormalities, a diagnosis of hypophysitis was made. This led 
to secondary adrenal insufficiency, hypotension and hyponatremia. The patient responded to 
corticosteroid therapy and Na improved to 133 mmol/L on discharge. The patient was also 
started on fludrocortisone and levothyroxine therapy.
Discussion: In contrast to CTLA4 antagonists, PD1 and PDL1 inhibitors are more 
commonly assocaited with thyroid and adrenalitis causing hyponatremia. Hypophysitis 
with PD-1 inhibitors is rare occuring <1% of patients. The mean onset of endocrine 
side effects is 9 weeks after initiation (range 5-36 weeks) of immunotherapy. Since the 
endocrine effects of immune checkpoint inhibitors are classified as toxic adverse events, it 
is recommended both discontinuation of the immune checkpoint inhibitor medication and 
‘high-dose’ glucocorticoid treatment as in our patient. Our case highlights the potentially 
life threatening complication of checkpoint inhibitors and the urgent need for awareness 
amongsts hospitalists, nephrologists and oncologists for prompt recognition and treatment.
FR-PO586 Poster Friday
Trainee Case Reports - III
Hyponatremia in Pregnancy and the Role of Renal Biopsy
Nathaniel Pedley, Pietro A. Canetta, Russell J. Crew, Michael B. Stokes, 
Pascale Khairallah. Columbia University Medical Center, New York, NY.
Introduction: Preeclampsia is a serious pregnancy complication that may mimic 
nephrotic syndrome. Severe hyponatremia in preeclampsia is rare and presents a unique 
clinical challenge as it increases the risk of seizures, mimicking eclampsia. It can also lead 
to several maternal and fetal adverse events.
Case Description: We report the case of a 35yo G1P0 female who presented at 
21 weeks of gestation with anasarca and vomiting. The pregnancy was conceived via 
in vitro fertilization and was uneventful until the day of presentation. She was found to 
be hypertensive to 152/84mm Hg with 4+ proteinuria on urine dispstick. Her labs were 
significant for creatinine of 0.7 mg/dL, serum albumin of 2.5 g/dL, Na of 117 mmol/L, and 
proteinuria of 12.5 g/g. Serum osmolality was 233 mOsm/Kg, UNa was <20 mmol/L and 
UOsm was 235 mOsm/Kg. Severe hyponatremia was secondary to low effective circulating 
volume from hypovolemia in the setting of vomiting and anasarca, and improved with 
albumin infusions. The combination of severe hyponatremia and proteinuria prompted a 
renal biopsy to identify the underlying cause of nephrotic syndrome. The biopsy showed 
diffuse severe glomerular thrombotic microangiopathy with endotheliosis, consistent with 
preeclampsia. The pregnancy was terminated with normalization of Na levels within 3 days 
postpartum and reduction in proteinuria to 2 g/g within 2 weeks postpartum.
Discussion: This case is the earliest by gestational age at which preeclampsia-induced 
hyponatremia has been reported. The rarity of this complication, combined with the early 
gestational age of preeclampsia onset and the desire of the patient to maintain her pregnancy, 
necessitated a definitive diagnosis to explain her clinical picture. The renal biopsy proved 
critical in determining the diagnosis and best course of therapeutic action.
FR-PO587 Poster Friday
Trainee Case Reports - III
Evaluating Preeclampsia as a Rare Cause of Severe Hyponatremia
Shreemayee De,1 Aimen Liaqat.2 1Newark Beth Israel Medical Center, Edison, 
NJ; 2Saint Barnabas Medical Center, West Orange, NJ.
Introduction: During normal pregnancy, resetting of osmostat can take place resulting 
in decrease of plasma osmolality by about 10 mOsm/kg, and mild decrease in serum 
sodium concentration by 4-5 meq/L. This phenomenon has been associated with increased 
production of hCG. Preeclampsia is a multisystem disorder defined by hypertension and 
proteinuria, but not classically associated with severe hyponatremia. However, there are 
rare incidences where severe hyponatremia is a complication of preeclampsia that can result 
in serious complications such as convulsions and cerebral edema.
Case Description: The first case is about a 32-year old female of 27-week gestation 
who presented with preeclampsia with severe features. Due to worsening epigastric pain, 
HELLP syndrome and elevated blood pressure, patient had emergent C-section at 28-week 
gestation. Patient was also found to have severe hyponatremia with lowest serum sodium 
concentration of 120 meq/L on the day of C-section. She was initially treated with fluid 
restriction and diuretics; this resulted in overcorrection of sodium by 10 meq/L that was 
treated with hypotonic fluid and one dose of desmopressin. Gradually the correction of 
sodium slowed down and eventually corrected to 142 meq/L on the day of discharge. The 
second case is about a 29-year old female of 33-week gestation who also presented with 
preeclampsia with severe features. Due to breech presentation of the fetus and preeclampsia, 
patient had C-section at 34-week gestation. Patient initially had normal serum sodium 
concentration. Overtime sodium concentration decreased to 126 meq/L one day prior to 
C-section. Gradually, sodium improved appropriately with diuretics and fluid restriction to 
136 meq/L 2 days after C-section.
Discussion: The pathogenesis of preeclampsia associated severe hyponatremia has 
been widely postulated. It is important to understand the etiology of severe hyponatremia 
based on history and physical exam, which can help guide treatment. The main mechanism 
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is yet to be understood. There is a theory that preeclampsia can stimulate non-osmotic 
release of ADH. Another theory suggests that defective placenta in preeclamptic patients is 
unable to produce enough vasopressinase that would rapidly inactivate ADH. Although the 
incidence of preeclampsia associated severe hyponatremia is reported rarely, it is a serious 
complication that needs to be addressed soon and managed promptly.
FR-PO588 Poster Friday
Trainee Case Reports - III
Correction of Hyponatremia Using D5W Pre-Blood Pump on Patients on 
Continuous Renal Replacement Therapy: A Case Series
Cassiopia L. Lippold, Ami Patel. University of Baltimore, Baltimore, MD.
Introduction: Patients with severe hyponatremia and renal failure who require 
continuous renal replacement therapy (CRRT) are at risk of overcorrection of their sodium 
(Na) level. Herein, we present three cases of using a calculated amount of dextrose 
5% solution (D5W) pre-filter as pre-blood pump (PBP) to prevent overcorrection of 
hyponatremia.
Case Description: Case 1: 53 year old female with end-stage liver disease secondary to 
alcohol and lupus presented with abdominal pain and vomiting with serum Na level of 114 
mEq/L, which was overcorrected to 138 mEq/L by day 2. She was initially treated with free 
water flushes via a nasogastric tube and peripheral D5W, which improved her serum Na to 
129 mEq/L. On day 4, she was started on continuous venovenous hemofiltration (CVVH) 
for oliguric renal failure with replacement rate around 1.5 L per hour, and added D5W PBP 
at 35 ml/hr, to keep her serum sodium at 135 mEq/L on the following day. Achieved Na 
was around 135-137 mEq/L. Case 2: 39 year old male presented with alcohol withdrawal 
and hemorrhagic shock due to a variceal bleed. His admitting Na was 100 mEq/L, which 
corrected to 119 mEq/L by day 2. Patient was started on CVVH for acidosis, oliguric renal 
failure, and volume overload. Initial prescription was 2 L per hour replacement rate, D5W 
500 ml per hour as PBP to aim for a goal Na of 112 mEq/l. The patient’s Na level improved 
to 112-115 mEq/L by day 3-4. Subsequently, D5W PBP was slowly titrated downward to 
aim for slow correction of hyponatremia. Case 3: 45 year old male presented with acute 
alcoholic hepatitis, oliguric renal failure, and hyponatremia of 124 mEq/L. Patient was 
started on CVVH with D5W 100 ml per hour as PBP to achieve a goal Na of 131 mEq/L. In 
the next 24 hours, his Na was 127 mEq/L, and D5W was titrated downward with eventual 
slow correction of his hyponatremia.
Discussion: Slow correction of hyponatremia can safely be accomplished with the 
above calculation in patients with renal failure requiring CRRT using D5W PBP.
FR-PO589 Poster Friday
Trainee Case Reports - III
Syndrome of Inappropriate Antidiuresis (SIAD) in a Patient with Systemic 
Sclerosis: Cyclophosphamide (CYC) Use and Scleroderma Renal Crisis 
(SRC)
Marcelo D. Silveira, Victor F. Seabra, Marcia Fernanda Arantes de Oliveira, 
Camila E. Rodrigues, Bernardo V. Reichert, Antonio C. Seguro, Lucia Andrade. 
University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Introduction: Hyponatremia is the most common electrolyte disorder and is often 
caused by SIAD, which can in turn be caused by the use of CYC, especially at moderate 
or high doses. To our knowledge, there has been only one reported case of hyponatremic 
hypertensive syndrome caused by SRC. The proposed mechanism is alteration of the 
osmoregulatory system, involving release of antidiuretic hormone (ADH) secondary to 
peripheral hyperstimulation of the renin-angiotensin system (RAS). We describe a case of 
SIAD associated with the use of low-dose CYC and aggravated after SRC.
Case Description: A 50-year-old male patient with a 2-year history of systemic 
arterial hypertension (controlled with losartan, 100 mg/day) presented with pulmonary 
interstitial disease and a 1-year history of progressive skin thickening. Skin biopsy showed 
sclerosing dermatitis, consistent with scleroderma. A mixed nucleolar and cytoplasmic 
reticular pattern of antinuclear antibodies was found. After an initial dose of CYC (500 mg), 
he developed asymptomatic hyponatremia (plasma sodium, 125-130 mEq/L). His condition 
was aggravated during an episode of hypertensive crisis and acute kidney injury, suggestive 
of SRC. During the hypertensive crisis, he presented to the emergency room with 
hypertension (200/120 mmHg), worsening of renal function (creatinine increasing from 1.0 
to 1.5 to 2.5 mg/dl), and hyponatremia (Na, 121 mEq/L), as well as the following: plasma 
osmolality, 270 mOsm/kg; urine osmolality, 419 mOsm/kg; ADH, 1.5 pg/ml (reference: 
1.0-13.3 pg/ml); schizocytes 0.6% (reference: absent); and lactate dehydrogenase, 259 U/L 
(reference: 135-220 U/L). Plasma sodium levels improved after blood pressure control with 
captopril (200 mg/day), fluid restriction and increased protein intake. There was also partial 
improvement of renal function (creatinine decreasing from 2.5 to 1.5 mg/dl).
Discussion: In this case, low-dose CYC use led to SIAD, with worsening of 
hyponatremia and increased plasma ADH, inconsistent with a hypo-osmolar state, in 
a patient whose condition was consistent with SRC. There was a significant increase 
in plasma renin activity, suggesting peripheral hyperstimulation of the RAS, which can 
deregulate the central osmoregulatory system.
FR-PO590 Poster Friday
Trainee Case Reports - III
Osmotic Demyelination Syndrome Associated with Acute Severe 
Hypernatremia and Hyperglycemia
Fumiaki Tanemoto, Masahiko Nagahama, Yugo Ito, Masaaki Nakayama. St. 
Luke’s International Hospital, Tokyo, Japan.
Introduction: The association between hyponatremic osmotic disturbance and osmotic 
demyelination syndrome (ODS) are well-established and studied. It has been increasingly 
recognized that ODS can occur in the setting of hypernatremia. In case of hypernatremic 
ODS, there is no consensus on how rapid or slow to correct plasma sodium. We report a case 
of ODS accompanied by acute hypernatremia and hyperglycemia.
Case Description: A 63-year-old female with a history of hypertension and dementia 
was brought to the ER with coma. Laboratory data were significant for plasma sodium 
of 189 mEq/L, plasma glucose of 629 mg/dL, serum bicarbonate of 22 mEq/L, BUN 
of 63 mg/dL, and plasma osmolality of 412 mosmol/kg. Head CT did not reveal any 
abnormalities. She was diagnosed with hyperosmolar hyperglycemic syndrome (HHS) 
and hypernatremia, and was admitted to ICU. Since there were 2 target components of 
hypertonicity simultaneously, hypernatremia and hyperglycemia, a great attention was paid 
to lower the tonicity appropriately to avoid cerebral edema. The upper limit of a correction 
rate of plasma tonicity during correction of hyperglycemia was set as 3 mosmol/kg per 
hour and that of plasma sodium was 10 mEq/L per day according to clinical guidelines. 
Although those correction rates were strictly kept, her neurological symptoms were not 
improved significantly. Brain MRI was performed to ascertain more precise information 
on day 6, which was consistent with ODS. With continuation of those correction rates of 
plasma tonicity and plasma sodium, her neurological symptoms as well as ODS findings in 
MRIs were improved gradually. The patient was sent to a rehab facility with good condition 
on day 65.
Discussion: ODS usually occurs in patients with overly rapid correction of chronic 
hyponatremia. However, ODS also results from a rapid increase in tonicity in patients with 
acute hypernatremia or HHS. Since onset of hypernatremia is unclear in most of the cases, 
serial imaging with different modalities may be warranted for detecting subtle neurological 
findings associated with hypernatremia, such as cerebral edema or even ODS. Although the 
appropriate correction rate of plasma sodium with hypernatremic ODS is not known, this 
case suggests that adhering to clinical guidelines may improve the prognosis of it.
FR-PO591 Poster Friday
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Central Diabetes Insipidus in a Patient with Newly Diagnosed AML
Osama El Shamy,1 Siddhartha Kattamanchi,3 Steven G. Coca.2 1Mount Sinai 
Hospital, Hasbrouck Heights, NJ; 2Icahn School of Medicine at Mount Sinai, 
New York, NY; 3Mount Sinai Medical Center, New Rochelle, NY.
Introduction: Central diabetes insipidus (CDI) has been reported as both a rare 
complication of AML that may precede its diagnosis, and a may be a manifestation of 
its relapse. The exact mechanism by which diabetes insipidus and AML are connected 
remains elusive. The prevalence of cytogenic abnormalities in AML has been implicated 
as a possible cause. Here we describe a case of AML-induced CDI with monosomy 7 and 
without evidence on imaging of pituitary infiltration
Case Description: A 28 y/o woman was transferred from an outside hospital with 
significant leukocytosis (WBC 163,000) in the setting of a non-healing dental extraction 
and worsening odynophagia. She was found to have a new diagnosis of AML (diagnosed by 
peripheral blood smear and a deletion of D7S522 (7q31) locus via FISH) and a left neck soft 
tissue infection. The patient was started on the 7+2 chemotherapy protocol (Cytarabine and 
Idarubicin) on 4/17/18. The renal service was consulted for AKI in the setting of polyuria 
(approximately 2.5 to 3 liters per day). Labs were notable for a serum creatinine of 2.1 
mg/dL, serum sodium of 152 meq/L, and urine osm of 190 mosm/L. She was started on 
ddAVP, and was continued for several days, over which time her urine output decreased, 
urine osmolality increased, with concomitant improvements in serum sodium and serum 
creatinine. Re-induction chemotherapy for persistent blasts was started 2 weeks later with 
clinical response over the next 10 days as evidenced by only 0.3% blasts. ddAVP was able 
to be discontinued as well at this point, as the resolution of the CDI coincided with the 
re-induction chemotherapy and subsequently confirmed low blast count and undetectable 
B cells
Discussion: A review of the literature reveals that CDI is a rare complication of 
AML, which can occur anytime during the course of AML. Although the exact mechanism 
connecting AML and CDI is unknown, some proposed theories include infiltration of 
hypothalamic pituitary stalk and abnormal expression of GP130 on neutrophils and platelets 
in patients with deletions on chromosome 7 or monosomy 7. The deficient GP 130 leads to 
abnormalities in glycosylation of neutrophils and platelets which can lead to CDI via two 
mechanisms: 1) decreased pre-pro-vasopressin which results in less active ADH production 
and 2) the dysfuctional platelets may affect ADH function and transport. Successful 
treatment of AML can rapidly reverse CDI.
FR-PO592 Poster Friday
Trainee Case Reports - III
X-Linked Recessive Nephrogenic Diabetes Insipidus Cured with Bilateral 
Native Nephrectomy Following Living Donor Renal Transplant
Gautam Rangavajla,2 Juan Pablo Arroyo,1 Anthony J. Langone.1 1Nephrology, 
Vanderbilt University Medical Center, Nashville, TN; 2Vanderbilt University
School of Medicine, Nashville, TN.
Introduction: X-linked recessive nephrogenic diabetes insipidus (X-NDI) is the most 
common subtype of congenital nephrogenic diabetes insipidus (CNDI) and is caused by 
mutations in the AVPR2 gene. This results in dehydration which increases the risk of urinary 
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tract damage. Current treatment for CNDI aims to reduce free water loss through low-
solute diets, HCTZ and potassium-sparing diuretics, as well as NSAIDs. Diuretics enhance 
sodium and water reabsorption in the proximal nephron, and NSAIDs inhibit prostaglandin-
meditated free water excretion. However, this treatment only reduces urine output by 25-
50%, leaving a considerable aquaresis that impacts quality of life.
Case Description: A 19 year-old man with X-NDI with an AVPR2 mutation and 
neurogenic bladder underwent a Mitrofanoff procedure for neurogenic bladder at age 6. 
Despite intermittent catheterization several times a day, he developed recurrent UTIs, and 
eventually CKD IV secondary to chronic hydronephrosis. He had poor quality of life given 
need for q1-2 hr catheterizations with aprox. 600 cc of urine each time. Pre-transplant 
his creatinine baseline was 8.5 mg/dL. His medications included amiloride, HCTZ, and 
oxybutynin. He underwent a living related kidney transplant and was discharged on 
standard immunosuppression and antibiotics, amiloride, and HCTZ. He continued urinary 
catheterizations following discharge, with Cr stabilizing to a baseline of 1.7. His urine 
output continued at above 3L per day. He then underwent bilateral native nephrectomy 
in an attempt to cure his X-NDI and improve his quality of life. Labs following bilateral 
nephrectomy showed normal serum (289 mOsm) and urine (528 mOsm) osmolality with a 
urine output of 1.6L per day, and his Cr decreased to 1.1 mg/dL on discharge.
Discussion: Current research into new therapeutic strategies for X-NDI focuses on 
AVPR2 chaperones, methods to biochemically bypass the AVPR2 receptor, and existing 
drugs that affect AVPR2’s signaling pathway. This case represents, to our knowledge, the 
first X-NDI patient cured with bilateral native nephrectomy following living related donor 
transplant for X-NDI complications. This suggests a role for renal transplantation and 
native nephrectomy as a definitive treatment of X-NDI and possibly CNDI, with a marked 
improvement in patients’ quality of life.
FR-PO593 Poster Friday
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Hypophosphatemia and Phosphate Wasting Due to Oncogenic Osteomala-
cia in a Patient with Natural Killer T-Cell Lymphoma
John P. Canterbury, Juan Carlos Q. Velez. Ochsner Clinic Foundation, Jefferson, 
LA.
Introduction: Hypophosphatemia is common electrolyte disorder in hospitalized 
patients. Urinary phosphate wasting can be caused by oncogenic osteomalacia (OncOsteom), 
en entity characterized by production of phosphatonins, like fibroblast growth factor 23 
(FGF-23). Mesenchymal tumors are the most common cause of OncOsteom and other 
malignancies are rarely associated. Here we present an unusual case OncOsteom in a patient 
with Natural Killer T-cell (NKT) lymphoma.
Case Description: A 33 year-old woman was admitted to the hospital with fever, 
chills, productive cough and myalgias. She had a remote history of mycobacterium avium 
complex infection and was actively being treated for hepatitis B virus with tenofovir and 
for hemophagocytic lymphohistiocytosis with etoposide. Upon arrival, the patient was 
normotensive but in respiratory distress. Examination showed sinus tachycardia and diffuse 
rales on lung auscultation. Laboratory data revealed serum electrolytes (mEq/L): Na 137, 
K 3.7, Cl 106, and CO2 23. Others serum chemistries (mg/dL): creatinine 0.4, urea nitrogen 
16, calcium 7.7 (serum albumin was 1.6 g/dL, corrected calcium 9.6) and phosphorus 
1.5. Intravenous sodium phosphate was aggressively supplemented. Urine phosphate 
was 63 mg/dL, no glucosuria. Discontinuation of tenofovir did not lead to resolution of 
hypophosphatemia and the patient continued to require constant IV phosphate replacement 
for 12 additional days. A diagnosis of OncOsteom was entertained and a FGF-23 level was 
obtained and found to be elevated at 1940 RU/mL. A 1,25 (OH) vitamin D level was 48 ng/
mL and 25 (OH) vitamin D was 8 ng/mL. A bone marrow biopsy was performed and the 
patient was diagnosed with NKT lymphoma. She continued to deteriorate clinically and 
expired 1 week later.
Discussion: Hypophosphatemia secondary to OncOsteom is an ominous disorder 
associated with significant morbidity. It is typically encountered in patients with 
mesenchymal tumors. Our case is the first reported in a patient with NKT lymphoma. 
The teaching point is that OncOsteom should be considered in cases of refractory urinary 
phosphate wasting in the presence of a lymphoproliferative disorder and measurement of 
FGF-23 level should be considered in those cases to reach a diagnosis.
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Case Report and Literature Review of Fanconi Syndrome Induced by 
Deferasirox in a Patient with Beta Thalassemia
Akika Ando, Santosh Saraf, Frances F. Tian, James P. Lash, Ana C. Ricardo. 
Division of Nephrology, Division of Hematology/Oncology, Department of 
Medicine, University of Illinois at Chicago University of Illinois at Chicago, 
Chicago, IL.
Introduction: Deferasirox (DFRA) is an oral iron chelating agent used to treat 
transfusion-related iron overload. Fanconi syndrome has been reported in less than 1% 
of patients receiving DFRA. There is a limited number of cases of Fanconi syndrome 
reported among patients with beta thalassemia treated with DFRA. Therapy with DFRA 
was permanently discontinued in all of the reported cases, except one in whom DFRA 
therapy was resumed after improvement of renal tubular function, resulting in recurrence of 
Fanconi syndrome. We report the case of a patient who developed Fanconi syndrome while 
receiving DFRA therapy who was rechallenged with the medication but has no signs of 
renal dysfunction after 6 months of therapy.
Case Description: A 25-year-old woman with medical history of beta thalassemia 
major and transfusion-related iron overload requiring iron chelation therapy, presented 
to the emergency department with generalized pain, nausea, and headaches for 24 hours. 
The patient had been receiving DFRA for 12 months prior to presentation. On admission, 
she was found to have hypophosphatemia (<1.0 mg/dL), hypokalemia (2.7 mEq/L), and 
non-anion gap metabolic acidosis (serum bicarbonate level 15 mEq/L). She was also found 
to have a urine pH of 5.5, glucosuria without hyperglycemia, and 100 mg/dL proteinuria 
based on urine disptick. Based on her clinical presentation, the patient was diagnosed with 
Fanconi syndrome. Her symptoms resolved within 1 week of discontinuing DFRA. Due 
to intolerance to alternative chelating agents, DFRA was restarted 1 year after Fanconi 
syndrome was diagnosed at 50% of the recommended dose and 3 months later, increased 
up to the full recommended starting dose. After 6 months of therapy, the patient has no 
symptoms or signs of Fanconi syndrome recurrence.
Discussion: As demonstrated in our case and prior reports in the literature, DFRA-
induced Fanconi syndrome is reversible once DFRA therapy is discontinued. Plasmapheresis 
was attempted in one case, but did not significantly impact recovery time. Recovery can 
usually take several weeks to months. One case demonstrated the development of mild 
tubular damage after DFRA was restarted. Based on our case report, rechallenge with 
DFRA may be safe with close monitoring.
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Patiromer Associated Hypercalcemia
Adil Ghaffar,1 Hemant Magoo,1,2 Ashish Verma.1,2 1Internal Medicine, Saint 
Vincent Hospital, Worcester, MA; 2Renal and Transplant Associates of New 
England, Worcester, MA.
Introduction: Patiromer calcium sorbitex is a non-absorbable cation exchange 
polymer approved for management of chronic hyperkalemia in patients with chronic kidney 
disease. We report a case of hypercalcemia in a patient with chronic kidney disease stage 5 
(CKD 5) treated with patiromer.
Case Description: A 75-year-old Caucasian male had Hypertension and CKD 5 (GFR 
of 10 ml/min/1.73m2) secondary to biopsy proven Focal Segmental Glomerulosclerosis. 
He had chronic hyperkalemia despite discontinuation of RAAS inhibition. Patient was 
initiated on patiromer 8.4 grams daily. This has been continued for over a year now. Prior to 
patiromer’s introduction, corrected calcium was in the 8.5 to 8.9 mg/dl range. Eight months 
into treatment with patiromer, calcium was between 10.5 to 11.1. iPTH was 23-29 pg/ml. 
25-hydroxy vitamin D was low at 9ng/ml. TSH was normal and serum immunofixation was 
negative. Patient had been taking prn TUMS (calcium carbonate) otc for reflux symptoms
that was discontinued upon discovery of hypercalcemia. However, hypercalcemia has
persisted several months after discontinuation of TUMS.
Discussion: Patiromer binds free potassium and magnesium ions in the gut and 
releases calcium ions in exchange. This helps correct hyperkalemia in these patients 
without sodium loading, a problem with sodium polysterene sulfonate. Though 10% of the 
patients did develop hypomagnesemia (below 1.4mg/dL), significant hypercalcemia has 
not been reported in any clinical study or subsequently. The amount of calcium released 
from patiromer that may be systemically absorbed is modest and did not lead to significant 
hypercalcemia in clinical studies. However, patients with advanced CKD may be more 
vulnerable due to their limited ability to excrete calcium in the urine. Prolonged treatment 
with Patiromer may increase the risk of hypercalcemia as noted in our patient and should be 
monitored for, besides hypomagnesemia.
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SPECT/CT with Technetium 99m-Methyl Diphosphonate for the 
Diagnosis of Severe Symptomatic Hypercalcemia After Rhabdomyolysis 
Induced AKI in 2 Patients with Cirrhosis
Silvia Ramirez,1 Ismael A. Gómez Ruiz,2 Abraham Cohen-Bucay,3 
Ricardo Correa-Rotter.4 1Instituto Nacional de Ciencias Medicas y Nutricion 
Salvador Zubiran, Mexico City, Mexico; 2Instituto Nacional de Ciencias 
Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; 3Boston University 
Medical Center, Boston, MA; 4Institutor Nacional de la Nutricion, Mexico City, 
Mexico.
Introduction: Rhabdomyolysis induced acute kidney injury (RI-AKI) is often 
complicated by multiple electrolyte abnormalities. Hypercalcemia (HC) due to soft tissue 
mobilization of calcium deposits in the recovery phase of RI-AKI has been described yet 
severe HC is rare. We present two patients with cirrhosis who developed RI-AKI and severe 
HC, both with SPECT/CT deposit images
Case Description: Case 1: 56-yr-old female, primary biliary cholangitis Child-Pugh 
B cirrhosis who developed exertional RI-AKI that required hemodialysis (HD). She was 
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hypocalcemic during the oliguric phase; during the recovery phase developed severe HC 
(peak of 16.2 mg/dl) with neurological symptoms. She required intermittent 13 sessions of 
HD in addition to volume replacement, diphosphonates, and diuretics and recovered in 8 
weeks. Plasma levels of 25-OH and 1-25(OH)2 vitamin D were low, iPTH appropriately 
suppressed. A SPECT/CT with 99Tcm-methyl diphosphonate (99Tcm-MDP) demonstrated 
extensive soft tissue tracer accumulation (Fig1). Case 2: 65-yr-old female, Child-Pugh B 
cirrhosis secondary to hepatitis C, who developed exertional RI-AKI that required HD. 
Normocalcemic during the oliguric phase yet during the recovery phase developed severe 
symptomatic HC (peak 14.7 mg/dl), requiring 3 intermittent HD sessions. HC lasted for 2 
weeks. Plasma levels of 25-OH and 1-25(OH) vitamin D were low, iPTH level appropriately 
suppressed and a SPECT/CT with 99Tcm-MDP demonstrated soft tissue tracer accumulation. 
The evolution of serum calcium, phosphorus, and creatinine levels are showed in Fig1. Both 
patients had full renal and neurological recovery.
Discussion: SPECT/CT with 99Tcm-MDP is a useful tool to identify soft tissue calcium 
deposits in patients with HC after RI-AKI. Intermittent HD is an effective treatment for 
severe HC. Since both of our patients were cirrhotic, we postulate that cirrhosis might be a 
risk factor for HC during the recovery phase of RI-AKI.
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Hypercalcemia in ESRD Patients Secondary to Immobilization: A Case 
Series
Sanjeev Gupta, Yorg Al Azzi. Westchester county medical center, White Plains, 
NY.
Introduction: Immobilization is a well-known cause of hypercalcemia. However, 
there is scarce data available about hypercalcemia secondary to immobilization in end-
stage renal disease (ESRD) patients as ESRD is often associated with hypocalcemia. We 
are presenting 3 cases of hypercalcemia in ESRD patients due to prolonged immobilization.
Case Description: 1: A 59-year-old man with the history of diabetes mellitus admitted 
for liver and heart transplant. Hospital course was complicated by sepsis, ventilator 
dependent respiratory failure (VDRF) and renal failure requiring hemodialysis (HD). He 
was initially hypocalcemic with elevated PTH and calcitriol was started. However, later 
he developed hypercalcemia with highest serum calcium level being 12.7mg/dl. Calcitriol 
was withheld and low calcium bath was used but hypercalcemia didn’t resolve. Work-up 
came back negative [PTH-28 pg/ml, 25(OH)D-7 pg/ml and 1,25(OH)2 D-22 pg/ml]. 2: 
A 61-year-old man with the history of CHF and ESRD secondary to polycystic kidney 
disease on HD admitted with pericardial effusion. Hospital stay was complicated by 
hemothorax and VDRF. A few months later he became hypercalcemic with calcium level 
elevated up to 11.6 mg/dl. Work-up was negative [PTH-28 pg/ml, 25(OH)D-44 pg/ml and 
1,25(OH)2 D-40 pg/ml]. 3: A 59-year-old lady with the history of atrial fibrillation, dilated 
cardiomyopathy, chronic heart failure and CKD admitted with CHF exacerbation. Hospital 
course was complicated by V. fibrillation arrest requiring AICD, renal failure requiring HD 
and VDRF. The patient remained ventilator dependent and developed hypercalcemia with 
a serum calcium of 11.2 mg/dl while on HD. Again, work-up was negative [PTH-74 pg/ml, 
25(OH)D-26 pg/ml and 1,25(OH)2 D-24 pg/ml]. All of our patients had the extensive 
workup to rule out malignancy as a part of renal transplant evaluation and hypercalcemia 
was attributed to immobilization.
Discussion: Hypercalcemia due to immobilization is a result of diminished bone 
formation and increased bone resorption. Immobilization could be a common cause of 
hypercalcemia in ESRD patients than in the general population as ERSD is a low bone 
turnover disease and patients tend to be sicker. Immobilization should be considered a cause 
of hypercalcemia in ESRD patients especially when they are bed-bound and a conservative 
approach can be considered rather than an invasive or expansive approach of excluding 
malignancy.
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Successful Treatment of Tuberculosis-Associated Hypercalcemia with 
Denosumab in a Liver Transplant Patient with AKI
Aldo E. Torres Ortiz, Prakrati C. Acharya, Wisit Cheungpasitporn. Nephrology, 
University of Mississippi Medical Center, Jackson, MS.
Introduction: Denosumab, a human monoclonal antibody that inhibits RANKL, 
has recently been approved for treatment of malignancy-related hypercalcemia. To our 
knowledge, we present the first case of successful treatment of tuberculosis (TB)-associated 
hypercalcemia with denosumab.
Case Description: A 65-year-old African-American woman was admitted to 
the hospital with a 5-day history of vomiting. She also had a 3-month history of 
nonproductive cough. She underwent orthotopic liver transplantation for HCV-associated 
cirrhosis 8 months prior to admission and was maintained on tacrolimus, prednisone and 
mycophenolate mofetil. At presentation, she was found to have AKI with serum Cr 4.7 mg/dL 
(baseline Cr 2.2 mg/dL). Physical exam revealed bilateral crackles. Laboratory testing 
showed high serum Ca of 13 mg/dL. Phos was 4.4 mg/dL and PTH was suppressed at 
7.8 pg/mL. She had elevated 1,25(OH)2 VitD (113 pg/mL) with low 25-OH-VitD level 
(14 ng/mL). Work-up confirmed the diagnosis of TB by demonstration of AFB in BAL. 
Liver biopsy also showed granulomas containing AFB. HyperCa showed only transient 
response to IV 0.9% NaCl. A high dose of steroids was not considered due to active 
TB. Zolendronic acid was not given due to potential AKI side effect. Thus, denosomab 
120 mg SC injection was given. Ca started to decrease within 48 hours and normalized 
(Ca 10.2 mg/dL) on day 7 post-treatment with improvement in Cr of 2.1 mg/dL. However, 
asymptomatic hypoCa occurred on day 16 and reached nadir on day 27 (Ca 7.6 mg/dL). 
HypoCa subsequently improved with up-titration of Ca and active vitamin D supplements. 
At 4 months F/U, she remained normocalcemic (without Ca or Vit D supplement). PTH 
(47 pg/mL) and 1,25(OH)2 VitD (41 pg/mL) levels were normalized. 25-OH-VitD level 
increased to 19 ng/mL. Her Cr continued to improve (1.7 mg/dL).
Discussion: We report on the first experience in treatment of granulomatous 
disease-associated hypercalcemia with denosumab. Our patient had an improvement 
in hypercalcemia, however, hypocalcemia can occur following denosumab injection 
and requires close monitoring and treatment. Our patient developed asymptomatic 
hypocalcemia, which subsequently improved with up-titration of Ca and Vit D supplements. 
Further studies are needed to evaluate safety and efficacy in similar clinical scenarios.
FR-PO599 Poster Friday
Trainee Case Reports - III
22q11.2 Deletion Syndrome Presenting with Chronic Hypocalcemia
Xiangling Wang,1 Maren T. Scheuner,2 Enrica Fung.3 1Loma Linda University, 
Loma Linda, CA; 2VA Greater Los Angeles Healthcare System, Los Angeles, CA; 
3Loma Linda VA, Redlands, CA.
Introduction: 22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a 
genetic disorder characterized with distinguishing facial features and congenital anomalies. 
Hypocalcemia can be seen in up to 50% of patients. However, it can be challenging to 
reach the diagnosis in adult patients who have no or mild congenital anomalies. Here we 
report one female who was diagnosed with 22q11.2 deletion syndrome after symptomatic 
hypocalcemia for more than 40 years.
Case Description: The patient was a 66 years old Caucasian female who was the 
product of an uncomplicated twin pregnancy. She had frequent ear infections and nasal 
speech requiring speech therapy during childhood. She completed a college education and 
denied history of developmental delay. She experienced seizures and muscles spasms at the 
age of 22 while in the military service. Hypocalcemia was diagnosed and she was treated 
with calcium and vitamin D supplementation. Since then, she has only had episodes of 
muscle spasms. Family history was significant for one son with hypocalcemia and another 
son who died from congenital heart disease at age 6 weeks. Since her transfer to our facility 
in 2016, she had fluctuating levels of total serum calcium (Figure 1A) with normal range 
intact PTH (Figure 1B). Urine calcium excretion was low. On physical exam, she had short 
stature with mild facial dysmorphism, including hypertelorism and square nasal root (Figure 
1C and 1D). Chromosomal microarray showed 22q11.2 deletion (Figure 1E). Diagnosis 
was established and she received genetic counseling about the mode of inheritance and 
the possibility that her son had the same diagnosis. In follow up, she continues to have 
intermittent asymptomatic hypocalcemia despite supplementation of calcium.
Discussion: This case highlights the importance to consider 22q11.2 deletion syndrome 
in chronic hypocalcemia patients who have inappropriately normal or low levels of PTH. 
Chromosomal microarray is available to establish the diagnosis in most cases.
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A Case of Pseudohypoparathyroidism Presenting with Symptomatic 
Hypocalcemia After Acute Hepatitis Due to Epstein-Barr Virus
Ritsuko Itayama, Yosuke Nakagawa, Yudai Isozaki, Hiroo Takahashi, 
Hirotaka Komaba, Masahiro Koizumi, Takehiko Wada, Masafumi Fukagawa. 
Tokai University School of Medicine, Isehara, Japan.
Introduction: Pseudohypoparathyroidism (PHP) type 1b is characterized by 
isolated resistance to parathyroid hormone without the features of Albright hereditary 
osteodystrophy (AHO). In PHP type 1b, most cases are sporadic and the timing of 
development of symptomatic hypocalcemia is quite variable. The initial manifestations of 
hypocalcemia such as tetany, muscle cramps and convulsion usually occur in childhood or 
adolescence, but they may be delayed until adulthood. Here, we report a young adult case 
of PHP type 1b which presenting with hypocalcemic tetany after acute hepatitis due to 
Epstein-Barr virus infection.
Case Description: A 24-year-old man who had been previously healthy was admitted 
to the hospital because of nausea and appetite loss followed by tetany for three days. He 
had been well until two weeks prior to the admission, when he got a febrile pharyngitis 
with lymphadenopathy. The symptoms were improved by taking some antipyretics and 
antibiotics, however, general fatigue and appetite loss steadily developed with tetany and 
weakness. Laboratory test revealed significantly elevated transaminases which indicated 
acute hepatitis, as well as hypocalcemia, hyperphosphatemia and increased level of intact 
PTH. Head computed tomography showed bilateral basal ganglia calcification. On the basis 
of PTH-resistant hypocalcemia without the features of AHO, he was given diagnosis of 
PHP type 1b and started on calcium and calcitriol. He was symptomatically improved with 
treatment and his laboratory findings returned to normal range. At the same time, acute 
hepatitis, which had been proved to be caused by primary Epstein-Bar virus infection, 
recovered spontaneously.
Discussion: It is unknown what factor triggers symptomatic hypocalcemia in PHP type 
1b. In our case, it was considered that decreased synthesis of 25-OH vitamin D in the liver 
due to acute hepatitis provoked PTH resistance followed by symptomatic hypocalcemia. 
PHP type 1b might be overlooked and should be taken into account if asymptomatic 
hypocalcemia is identified.
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A Rare Case of Hypoparathyroidism Complicating Pregnancy
Elliott Antman,2 Anip Bansal,2 John M. Carson.1 1NYU Winthrop Hospital, 
Mineola, NY; 2University of Colorado School of Medicine, Denver, CO.
Introduction: Heterozygous activating mutations in the calcium sensing receptor 
(CaSR) which increase CaSR sensitivity to extracellular Ca cause autosomal dominant 
hypocalcemia (ADH). ADH results in hypocalcemia with low-normal parathyroid hormone 
(PTH) levels and is often diagnosed as hypoparathyroidism. This case describes the 
complicated course of a pregnant woman with ADH.
Case Description: A 31 year old female was diagnosed with autoimmune 
hypoparathyroidism at age 22 when she presented with paresthesias and cramping in both 
hands with a serum Ca of 5.5mg/dL, phosphate of 6.1mg/dL and PTH of 10pg/mL. Genetic 
testing for DiGeorge syndrome was negative. She had no family history of calcium or other 
electrolyte disorders. Her symptoms improved with oral Ca supplementation and calcitriol. 
Three years later a renal sonogram demonstrated medullary nephrocalcinosis. Her 24 
hour urine Ca ranged 300 to 700mg and a thiazide (HCTZ) was added. Due to persistent 
hyperphosphatemia, the calcitriol was replaced by recombinant PTH. After starting HCTZ 
and recombinant PTH she developed symptomatic hypomagnesemia which persisted after 
stopping HCTZ. A 24hr urine magnesium (Mg) was 204mg. Her 24hr urine potassium was 
140mEq while hypokalemic and off HCTZ. At age 29 she had a pregnancy complicated by 
exacerbation of hypomagnesemia and unexpected intrauterine fetal demise (IUFD) at 35 
weeks. At the time, her serum Mg level was 1.3mg/dL. Other electrolyte levels were normal. 
A fetal ultrasound 10 days prior showed mild polyhydramnios and otherwise normal fetus. 
The cause of IUFD was uncertain but attributed to the hypomagnesemia. A year later she 
became pregnant again with exacerbation of hypomagnesemia. ADH was suspected and 
genetic testing was sent midterm. At 34 weeks she developed polyhydramnios, was induced, 
and delivered uneventfully. Two days post-partum, her newborn became bradycardic and 
seized with a serum Ca of 5.9mg/dL. PTH was 12pg/mL. Soon after, the mother’s genetic 
testing confirmed a CaSR activating mutation consistent with ADH type 1.
Discussion: ADH should be considered in the differential for hypoparathyroidism 
as its diagnosis has significant genetic/family planning implications. Treatment of ADH 
(thiazides, recombinant PTH) may exacerbate renal Mg wasting associated with this 
disease, as does pregnancy. Calcilytics, allosteric antagonists of the CaSR, are an emerging 
therapy that may benefit patients with ADH.
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IV Iron Therapy Induced Acute Hypophosphatemia in CKD Patients
Annise Chung,1 Ping Li.2 1Internal Medicine - Nephrology, Medstar Georgetown 
University Hospital, Washington, DC; 2Nephrology, DC VA Medical Center, 
Washington, DC.
Introduction: Intravenous (IV) iron-induced hypophosphatemia is a well-documented 
side effect in iron deficient patients. Single dosing studies suggest that decreases in serum 
phosphate are asymptomatic and fully reversible with phosphate repletion. Long term 
complications such as arrhythmias, muscular weakness, osteomalacia and bone fractures 
have also been documented. We report a case of hypophosphatemia with a newer formulation 
of IV iron: ferric carboxymaltose (FCM) induced severe acute hypophosphatemia.
Case Description: A 97 year old male with past medical history of atrial fibrillation, 
iron deficient anemia, hypothyroidism, chronic kidney disease III, and hypertension was 
referred to renal clinic for acute hypophosphatemia. The patient had been on oral iron 
supplementation for iron deficient anemia and it was not effective. He received IV FCM for 
iron deficient anemia twice in the previous month. The patient was sent to the emergency 
department after he was found to have a phosphate level of 0.8 mg/dL by routine lab work. 
Patient initially received both oral and intravenous phosphate repletion in the emergency 
department and subsequently received oral phosphate supplementation. However, the 
hypophosphatemia persisted in the presence of oral phosphate supplementation. Laboratory 
data showed calcium was 7.9 mg/dl, phosphate 1.5mg/dl, magnesium 2.1 mg/ml, 
intact parathyroid hormone 295pg/ml and 25-OH, vitamin D 30.8 ng/ml. His serum 
creatinine was at his baseline of 1.5-1.8 mg/dL. In addition, intact FGF23 level was 
found to be 1424 RU/ml (reference range < 180). Parathyroid scan showed no adenoma 
in parathyroid glands. Based on the above temporal association, patient was suspected 
of FCM induced, FGF23 mediated renal phosphate wasting. IV FCM was stopped and 
patient received oral active vitamin D, calcium and phosphate supplementation. The acute 
hypophosphatemia improved.
Discussion: This case highlights the association between FCM and low serum 
phosphate levels. Although there has been a growing body of literature on the association, 
many nephrologists may not be aware of the hypophosphatemic side effects of FCM. In the 
recently published phase 3 study of IV ferumoxytol versus FCM, hypophosphatemia was 
seen in 38.7% of the FCM group 2 weeks after treatment. In patients who receive IV FCM 
for iron deficient anemia, serum phosphate levels should be monitored.
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Hypomagnesemia: Beware of Zebras
Mohammad wisam Baqdunes, Kalathil K. Sureshkumar. Allegheny General 
hospital, Wexford, PA.
Introduction: Hypomagnesemia can be the initial and predominant manifestation of 
the rare17q12 deletion syndrome.
Case Description: A 62 year old male with 17 years history of severe hypomagnesemia 
of unclear etiology requiring daily IV and oral magnesium replacement and recent 
diagnosis of type 2 diabetes mellitus presented to our clinic for further evaluation. Patient 
experienced weakness, myalgia and cognitive deficits. Physical examination revealed 
macrocephaly along with brachydactyly of the hands and feet. He was found to have severe 
hypomagnesemia, hypocalcemia and hypokalemia with evidence for renal magnesium 
wasting requiring aggressive replacement with preserved renal function. Computed 
tomography scan of abdomen and pelvis showed bilateral kidney cysts. Because of the 
morphological and electrolyte abnormalities, chromosomal micro array was performed 
which showed a 1.5 mega-bases loss at chromosome 17q12 involving 20 genes. Per genetic 
analysist, patient’s history, clinical findings and genetic analysis were consistent with17q12 
deletion syndrome.
Discussion: Hypomagnesemia can be a presenting manifestation of 17q12 deletion 
syndrome also known as autosomal dominant tubulo-interstitial kidney disease sub type 
HNF-IB caused by a mutation in hepatocyte nuclear factor 1 beta. Classic features of 
17q12 deletion syndrome are variable combinations of the following findings: structural or 
functional abnormalities of the kidney and urinary tract (80-85%), maturity onset diabetes 
of the young type 5 (MODY5) from beta-cell dysfunction (40%), and neurodevelopmental 
or neuropsychiatric disorders (50%). Renal abnormalities include tubular interstitial disease, 
characterized by reduced urine concentrating ability, hyperuricemia, hypomagnesemia, 
hypokalemia with bland urine sediment and tubular interstitial fibrosis on renal histology. 
Family members should be tested because of the autosomal dominant inheritance.
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Severe Hypomagnesemia as the Initial Indicator of HNF1β-Associated 
Renal Disease
Nina Mann,1 Michael A. Ferguson,1 Deborah R. Stein.2 1Boston Children’s 
Hospital, Boston, MA; 2Children’s Hospital Boston, Boston, MA.
Introduction: Mutations in HNF1β (hepatocyte nuclear factor-1-beta) are known to 
cause Renal Cysts and Diabetes Syndrome (RCAD), so-named for two common clinical 
manifestations, maturity-onset diabetes of the young (MODY) and renal cystic disease. 
However, it has become increasingly recognized that HNF1β-associated disease can lead to 
a wide spectrum of clinical manifestations affecting multiple organ systems, with varying 
degrees of renal involvement. Due to the clinical heterogeneity, a high index of suspicion is 
required in making the diagnosis. Here, we present a case in which severe hypomagnesemia 
led to a diagnosis of RCAD.
Case Description: A 13-year-old Caucasian girl with newly diagnosed insulin-
dependent diabetes mellitus presented with one month of intermittent lower abdominal 
pain, dysuria, and urinary frequency, and one day of paresthesias. On initial assessment, 
she appeared tired, but otherwise had an unremarkable physical examination. Laboratory 
studies revealed severe hypomagnesemia (0.6 mg/dL (normal range 1.5 to 2.2 mg/dL)) and 
hypocalcemia (ionized calcium of 0.75 mmol/L (normal 1.14 to 1.29 mmol/L)), as well as 
mild acute kidney injury (Creatinine 1.0 mg/dL) and metabolic alkalosis (bicarbonate 31 
mmol/L and venous pH 7.5). Urinalysis revealed 3+ protein and 2+ glucose. Fractional 
excretion of magnesium was inappropriately elevated at 11%, and urinary calcium was 
undetectable. A renal ultrasound demonstrated a single 1.3 cm simple cyst in the right 
kidney. The patient received IV calcium and magnesium supplementation, and was 
ultimately transitioned to enteral magnesium oxide supplements. Subsequent genetic testing 
revealed a large deletion of chromosome 17q12. Upon retrospective chart review, it was 
found that at the time of her initial presentation with diabetes mellitus one month prior, the 
patient had mild hypomagnesemia and, unusually, a metabolic alkalosis.
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Discussion: Mutations in HNF1β can lead to impaired magnesium handling in the 
distal convoluted tubule, but hypomagnesemia remains an under-recognized manifestation 
of HNF1β-associated disease. This case highlights that hypomagnesemia should be an 
indicator to test for mutations in HNF1β, particularly if present in conjunction with early-
onset diabetes or urinary tract malformations.
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A Puzzling Case of Metformin (MF) Associated Lactic Acidosis (MALA)
Rhea Thurston, Bassem B. Ibrahim, Jacques A. Durr, Hansang Park. University 
of South Florida Morsani College of Medicine, Tampa, FL.
Introduction: MF, a biguanide used to treat type 2 diabetes mellitus, increases intestinal 
glucose utilization and lactate production. It inhibits the mitochondrial respiratory chain 
complex 1, which clears lactate by the liver and kidney. MF is highly cationic, not protein-
bound and is eliminated unchanged by the kidneys. Its apparent volume of distribution 
(AVD) is enormous (up to 1000 L). MALA can occur with overdose or in cases associated 
with reduced kidney or liver function. The incidence of MALA without acute overdose is ~ 
6.3 cases per 100,000 patient years. Normal therapeutic MF levels are 1-2 μg/mL and rarely 
exceed peak levels of 5 μg/mL, above which MF can cause MALA.
Case Description: A 70 year old female with a history of hypertension, type 2 diabetes 
mellitus and cerebral vascular accident, presented to the emergency room (ER) with a two 
day history of abdominal pain, nausea and vomiting. She was confused with Kussmaul 
breathing. Among her medications was MF/Januvia 1000/50 mg BID. Blood pressure 
was 98/59, pulse 96, RR 27, and temperature 89.40F. Initial arterial blood gas analysis 
revealed a pH of 6.88. Her serum bicarbonate was < 5 mmol/L, serum glucose 115 mg/
dL and potassium 5.4 mmol/L. Initially her anion gap could not be calculated, but when 
her bicarbonate could be measured, it was as high as 52 mmol/L. Her admission serum 
creatinine was 8.1 mg/dL with a normal baseline (1 mg/dL). Her serum lactate was elevated 
at 33.8 mmol/L. A CT of her abdomen and pelvis did not show any acute pathology. She was 
immediately intubated, started on pressor support and bicarbonate infusion with continuous 
renal replacement therapy (RRT). Emergent exploratory laparotomy ruled out ischemic 
bowel. The patient had only 2-3 hrs of RRT because of repeat dialysis line clothing. In spite 
of this, her acid-base and electrolyte abnormalities spontaneously improved and RRT was 
discontinued. The patient was managed only with IV fluids, including dextrose/insulin, as 
a presumed enzymatic defect could not be excluded. Although the MF level was toxic (37 
μg/mL), a prompt recovery ensued.
Discussion: Mortality from MALA is ~ 50%, and given MF’s large AVD, an extended
dialysis time (preferably hemodialysis) is required. Our patient had virtually no dialysis and 
her massive lactic acidosis corrected spontaneously over 2 days with only IV fluid therapy. 
The role of dextrose/insulin is unknown.
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Treatment of Severe Metformin-Associated Lactic Acidosis (MALA) with 
Continuous High Flux Hemodialysis and Tris-Hydroxymethyl Amino-
methane (THAM)
Abhinav K. Tiwary,1 Daniel L. Landry,3 Marat Abdullin,3 Bogdan Tiru,2 
Kostas Papamarkakis,2 Gregory L. Braden.3 1Nephrology, UMMS-Baystate,
Springfield, MA; 2Baystate Medical Center, Springfield, MA; 3Kidney Care and
Transplant Services of New England, Springfield, MA.
Introduction: Hemodialysis is the preferred modality for severe lactic acidosis due to 
MALA. We report a case of ingestion of 480 grams of metformin. After 33 hours of high 
flux hemodialysis (HFHD) his severe MALA was reversed by THAM. This is the first case 
report of the use of THAM to treat severe MALA not responding to HFHD alone.
Case Description: A 43-year-old suicidal man with type 2 diabetes ingested the 
largest reported dose of metformin, 480000 mgs. Initial serum potassium was 4.9 mmol/L, 
bicarbonate (HCO3) 16 mmol/L, anion gap 22, serum lactate 6.2 mmol/L, & an ABG 
showed a ph 7.16, pCO2 36, PO2 247 & HCO3 12 mmol/L. He was intubated for airway 
support & activated charcoal & polyethylene glycol given by NG tube. Repeat labs showed 
a potassium of 7.4 mmol/L, lactate of 6.6 mmol/L, & pH of 7.06. Emergent high flux HFHD 
was initiated. After 12 hours of dialysis the metformin dialyzer clearance was 416 ml/min 
which is significantly better than earlier reports of 68-228 ml/min. Due to a persistent lactate 
of 22.6 - 31.4 mmol/L we continued HFHD for a total of 33 hours. The next day the serum 
ph was only 7.11 and the serum HCO3 10’ mmol/L. A dose of THAM was calculated as 
follows: THAM (ml of 0.3 mol/L solution) = lean body weight (kg) x base deficit (mmol/L). 
We chose 3 times the usual base deficit to increase serum HCO3 by 15 mmol/L rather than 
the usual 5. We gave 1280 ml of THAM over 12 hours, enough to increase the serum HCO3 
by 15 mmol/L. Levophed & vasopressin for hemodynamic support were rapidly weaned. 
The serum lactate corrected dramatically after THAM from 31.4 to 6.2 mmol/L. In fact, 
over the next 24-hours, the serum lactate normalized along with pH & HCO3 levels.
Discussion: Our study is the first successful use of THAM with continuous HFHD in 
a patient with severe MALA complicated by anuria. THAM rapidly equilibrates into the 
intracellular space of liver, muscle & intestine. We hypothesize that the rapid increase in 
tissue pH inhibits lactate dehydrogenase & increases the activity of pyruvate dehydrogenase 
& pyruvate carboxylase leading to rapid inhibition of lactate production & enhanced 
metabolism of lactate. Our case supports the use of THAM to augment continuous HFHD 
for the correction of severe acidemia associated with MALA.
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Severe Lactic Acidosis in a Patient with Advanced Hepatic Malignancy 
Due to Warburg Effect
Avinash G. Adiga, Kumar Rohit. Nephrology, NYU Langone Medical Center, 
New York, NY.
Introduction: Lactic acidosis is one of the most common cause of metabolic acidosis 
in hospitalized pateints and is either due to overproduction or reduced metabolism of 
lactate. Impaired tissue oxygenation, either from decreased oxygen delivery or a defect 
in mitochondrial oxygen utilization usually causes increased lactate production. Causes of 
lactic acidosis can be divided into those associated with impaired tissue oxygenation as 
type-A and those without obvious systemic impairment in oxygenation as type B lactic 
acidosis. We report a case of severe type B lactic acidosis in a patient with extensive hepatic 
malignancy most likely from Warburg effect.
Case Description: 62 years old male with history of hypertension, hypothyroidism and 
advanced hepatic metastatic gall bladder cancer admitted to the hospital due to failure to 
thrive. On examination BP was 128/80mmhg, HR 90/min, temperature was 95.3F. Patient 
was lethargic, abdomen was soft, distended and multiple bulky masses were appreciated in 
the right upper quadrant. Labs revealed Na:134, K: 4.2, Cl: 94, bicarb <10, BUN 53mg/dl, 
creatinine 3.0mg/dl, anion gap 24. ABG showed pH 7.11, pCO2:9.7, HCO3: 3, lactate >22 
suggesting severe high anion gap metabolic acidosis due to lactate. He also had evidence 
of tumor lysis syndrome with LDH 2331, uric acid 14.1, phosphorus 9.1. CAT scan of 
abdomen showed infiltrative tumor replacing majority of both hepatic lobes with some 
sparing of superior right hepatic lobe.
Discussion: Metabolic modifcation is a typical hallmark of cancer cells, despite 
presence of adequate oxygen, tumor cells generate energy from aerobic glycolysis instead 
od mitochondrial oxidative phosphorylation. This phenomenon is defined as “Warburg 
effect”, this leads to increased glycolysis, accumulation of ATP and lactate production by 
tumor cells. Warburg effect confers advantage to cell growth by providing carbon sources 
that are required for rapid cell proliferation and also by decreasing reactive oxygen species. 
This effect is more commonly seen in hematologic malignancies like lymphoma and 
leukemia, but can rarely be seen in solid malignancies. Our patient had features of tumor 
lysis and severe type B lactic acidosis, by excluding other causes of type B lactic acidosis 
it was attributed most likely due to Warburg effect. In addition impaired hepatic and renal 
clearance of lactate contributed to very high lactate levels.
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Severe Chloride Deficiency Metabolic Alkalosis from Excessive Sweating
Himabindu Yerneni,1 Martin Sedlacek,2 Tomonori A. Oyadomari.3 1Dartmouth 
Hitchcock medical center, Hanover, NH; 2Dartmouth-Hitchock Medical Center, 
Lebanon, NH; 3Dartmouth Hitchcock Medical Center, Lebanon, NH.
Introduction: Most cases of chloride deficiency metabolic alkalosis are due to 
chloride loss from the gastrointestinal tract or the urine and secondary hyperaldosteronism 
contributes to hypokalemia.We are presenting a case of chloride deficient metabolic 
alkalosis from an unusual source.
Case Description: A 32 y/o man presented with generalized weakness, fatigue and 
failure to thrive since several days. He was severely volume depleted with hypotension 
and orthostatic BP changes, subjective weight loss and decreased skin turgor. Laboratory 
testing revealed a severe hypokalemic metabolic alkalosis with CO2 50 mmol/L, Chloride 
70 mmol/L, sodium 126 mmol/L, potassium 2.1 mmol/L, magnesium 0.78 mmol/l BUN 18 
mg/dl creatinine 0.7 mg/dl. A spot urine sodium was 10 mmol/L, Chloride <10 mmol/L and 
potassium 26 mmol/L. The patient had no nausea, vomiting or diarrhea and denied any use 
of diuretics. He had a history of multi substance abuse and incarceration and recently started 
working as a painter. The patient reported that painting under the hot roof in summer” was 
killing him”. He had previous care in our institution because of cystic fibrosis. The patient’s 
symptoms and metabolic abnormalities resolved with saline and the patient was discharged.
Discussion: Cystic fibrosis is an inherited disorder characterized by excessive chloride 
content in sweat with resulting pulmonary and gastrointestinal complications. Chloride 
deficiency metabolic alkalosis is a rare complication of cystic fibrosis precipitated by 
environmental stressors leading to excessive sweating, in this case by painting under a hot 
roof in summer.
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CVVH as Therapy for Severe Metabolic Alkalosis
Harish Shanthanu Seethapathy, John Y. Choi, Andrew Z. Fenves. Massachusetts 
General Hospital, Boston, MA.
Introduction: Untreated severe metabolic alkalosis (pH>7.6) can lead to devastating 
clinical consequences such as seizures and coma. We describe the use of continuous veno-
venous hemofiltration (CVVH) in the management of a patient with severe metabolic 
alkalosis.
Case Description: A 51-year-old male with advanced diffuse large B-cell Lymphoma 
was admitted for high-dose methotrexate infusion as part of his 6th cycle of chemotherapy 
(R-CHOP plus methotrexate). He received oral and intravenous sodium bicarbonate 
to maintain high urine flow rates (>100cc/hour) and a urine pH>7.5 to aid methotrexate 
excretion. He sustained an AKI (peak Cr of 2.5mg/dL; baseline 0.8mg/dL) two days after 
the infusion. Serum methotrexate levels, which were followed q12h were persistently high 
(>6umol/L) and isotonic sodium bicarbonate (250cc/hour) was continued. A week later, 
he developed altered mental status and respiratory failure requiring ventilator support. An 
arterial blood gas showed a pH of 7.60, pCO2 of 51mmHg and his HCO3 was 46mmol/L. 
He had received a total of 20L of isotonic sodium bicarbonate. His pH worsened to 7.69 on 
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the ventilator and we were consulted. We initiated CVVH on a citrate bath with a blood flow 
of 150mL/min and a replacement fluid rate at 800mL/min. Our aim was slow and steady 
correction of alkalosis - we achieved that over the next 12 hours with a drop in his pH from 
7.69 to 7.52. CVVH was terminated after 24 hours. In the next few days, he was extubated 
and his mental status and renal function returned to baseline.
Discussion: Metabolic alkalosis has traditionally been treated with an acid such as 
hydrochloric acid (HCl) or an acid precursor such as ammonium chloride (NH4Cl). Issues 
with availability and the need for reconstitution and specific guidelines for administration 
(in the case of HCl) limit their use. CVVH is readily available and most ICUs can initiate 
CVVH within a few hours. There are no specific prescription guidelines to treat metabolic 
alkalosis. While conventional hemodialysis has been described as a treatment modality, 
effects of rapid correction of pH are unknown. We successfully achieved a gradual 
correction of alkalosis using a bicarbonate free bath with slow clearance parameters and 
constant monitoring. To our knowledge, this is one of the first cases describing the use of 
CVVH for correction of metabolic alkalosis in the setting of AKI.
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Autosomal Recessive Polycystic Kidney Disease (ARPKD) Presenting in 
Adulthood
Ravi Kodali, Neera K. Dahl. Yale University Yale School of Medicine, 
Madison, CT.
Introduction: ARPKD is characterized by multiple renal cysts arising from the 
collecting ducts, variable degree of progressive renal failure and congenital hepatic fibrosis. 
It is caused by mutations in PKHD1 gene located on chromosome 6p21. It is mostly 
diagnosed in infancy or childhood with only few cases being diagnosed as adults. Here we 
present a case of ARPKD that was diagnosed in adulthood.
Case Description: A 37-year-old female with past medical history significant for 
congenital hepatic fibrosis is referred to polycystic kidney disease clinic for evaluation of 
cystic kidney disease. Family history is significant for cystic kidney disease in two of her 
cousins (both on the paternal side). Neither of her parents had a history of kidney cysts. 
Her renal function was normal. Abdominal MRI revealed a cirrhotic liver with extensive 
fibrocystic changes and splenomegaly. It also showed several sub-centimeter cysts in both 
kidneys (Figure 1). Whole exome sequencing showed compound heterozygous variants of 
PKHD1; one, c.3761_3762delCCinsG is known to be pathogenic. The other, c.9107T>G, 
is a variant of unknown significance (VUS). This is a rare variant (2/100,000) which has 
previously been detected in at least 2 ARPKD patients, with clinical presentations of hepatic 
fibrosis.
Discussion: There are more than 750 different mutations described in PKHD1 gene. 
Most common amongst these is a missense mutation in exon 3. Our patient has a compound 
heterozygous mutation. The first allele had a mutation in exon 32. This involves deletion of 
two nucleotides and addition of a third nucleotide leading to a frameshift mutation which 
leads to a premature stop codon. This is a known pathogenic mutation. Less is known about 
the second variant, c.9107T>G although it has been described in ARPKD patients presenting 
with hepatic fibrosis and normal kidney function. Adult onset ARPKD is rare, and notable. 
The combination of hepatic fibrosis, splenomegaly and kidney cysts are consistent with 
ARPKD, although in this patient the liver findings dominate.
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Gastrointestinal Bleed in ESRD: An Unexpected Cause
Ravi Kodali, Eric Chang, Ursula C. Brewster. Yale University Yale University 
School of Medicine, New Haven, CT.
Introduction: ESRD patients have a fivefold higher risk of gastrointestinal (GI) bleed 
compared to those without CKD. Common causes include angiodysplasia, peptic ulcer 
disease, diverticular disease, ischemic colitis. A lesser known causes of GI bleed in this 
population is sevelamer induced GI ulcer.
Case Description: A 59-year-old African American man with type 2 diabetes mellitus, 
HTN, ESRD on hemodialysis, presented with severe headache and right sided weakness. 
He had intraventricular hemorrhage from severe hypertension. Routine labs showed 
hyperphosphatemia, so he was continued on sevelamer. On hospitalization day 20, he had 
multiple episodes of dark tarry stools with hemoglobin drop. Upper GI endoscopy revealed 
a large ulcer in the duodenum; he was started on pantoprazole. GI bleed recurred over the 
next weeks. A colonoscopy revealed a 3-5 cm segment of ulcerated and friable mucosa in 
the ascending colon. Biopsy of the colonic ulcer revealed presence of “fish scale” crystals 
previously associated with sevelamer, with inflammatory changes (Fig 1). A diagnosis of 
sevelamer induced colonic ulcer was made and sevelamer was stopped.
Discussion: Here we report 6 cases from our institution of GI ulcerations with 
deposition of sevelamer (Table 1). This is an underappreciated association and should be 
suspected in the right clinical scenario. Given the continued increase in use of sevelamer 
as a phosphate binder, it is important for the nephrologists to be cognizant of this entity.
Table 1
Sevelamer crystals in biopsy from colon
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A Case of Early Onset Autosomal Dominant Polycystic Kidney Disease 
Caused by GANAB Mutation
Elizabeth Waldrop, Mohammed A. Al-Obaide, Tetyana L. Vasylyeva. Texas 
Tech University Health Sciences Center, Amarillo, TX.
Introduction: Autosomal Dominant Polycystic Kidney Disease (ADPKD) typically 
results from mutations in the PKD1 and PKD2 genes, which code for polycystin 1 and 
polycystin 2 respectively. Mutations in these genes promote renal cystic dysplasia and 
are a significant cause of End-Stage Kidney Disease (ESKD). PKD3 is related to GANAB 
gene mutation and represents mid- and late adulthood. We report a description of a case 
of ADPKD in a 12-year-old female with dual mutations in PKD1 and GANAB genes and 
presented bilateral renal cysts in adolescence.
Case Description: A 12-year-old female presented to the local emergency room 
with persistent intense left flank pain. Dipstick showed large blood and abdominal CT 
showed 4 mm obstructing calculus in proximal left ureter, nephrolithiasis with minimal 
scaring in upper pole of left kidney, multiple bilateral renal cysts with the dominant on 
the left kidney at 2.8 mm. Non-calcified 2 mm right lower lobe pulmonary nodules was 
also identified. Renal function was preserved with BUN of 11 mg/dl and creatinine of 
0.6 mg/dl, electrolytes were within normal range. The patient was treated with pain control 
medications and hydration with improvement and was referred to a nephrologist. Renal 
ultrasound (RUS) showed multiple bilateral cysts. The right kidney measured 10.5 cm x 
4.9 cm x 4.8 cm and the left kidney measured 9.8 cm x 4.7 cm x 5.0 cm. Renal cysts 
were present bilaterally with some displaying thick internal septation. The largest cyst was 
present in the left kidney, measuring 3.3 mm. Using genomic DNA from the submitted 
specimens, the exonic regions and flanking splice junctions captured and sequenced by 
NGS and compared to the human genome build of non-mutated genes of interest. The 
results returned positive for GANAB, variant p.R61X generated nonsense mutation; and 
PKD1, variant p.P61L generated missense mutation. The GANAB mutation classified as 
pathogenic variant and the PKD1 mutation classified as a variant of uncertain significance.
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Discussion: The presented case is the first reported pediatric case with dual mutation 
(PKD1 and GANAB) and nephrolithiasis. The data present unreported novel GANAB 
mutations to expand the mutation spectrum reported by Porath et al., 2017. Knowledge 
of spectrum variety in pediatric patients with cystic kidney disease might direct early 
diagnostic and open prospective for gene therapy.
FR-PO613 Poster Friday
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Long Term Effect of High Dose Tolvaptan Treatment for Autosomal 
Dominant Polycystic Kidney Disease Patient
Yuri Machiba,1 Shinya Nakatani,1 Eiji Ishimura,2 Hideki Uedono,1 
Ayumi Nakatani,1 Akihiro Tsuda,1 Katsuhito Mori,1 Masaaki Inaba.1 1Osaka City 
University Graduate School of Medicine, Osaka, Japan; 2Meijibashi Hospital, 
Matsubara-shi, Japan.
Introduction: Based on the results of Tolvaptan Efficacy and Safety in Management 
of Autosomal Dominant Polycystic Kidney Disease and Its Outcome (TEMPO) 3:4 trial, 
tolvaptan was firstly approved by regulatory authority in Japan (March, 2014), as a therapy 
for Autosomal dominant polycystic kidney disease (ADPKD) patients. However, to date, 
the long term efficacy and safety of high dose tolvaptan is unknown. Here, we present a 
Japanese case with ADPKD, who have continued a high dose of tolvaptan (a total daily dose 
of 120 mg) for 9 years from the beginning of the TEMPO 3:4 trial.
Case Description: A 36-year-old man was diagnosed with ADPKD in 2008. His 
estimated glomerular filtration rate was 57.3 mL/ min/1.73 m2 calculated as Japanese 
formul, and the total kidney volume (TKV) was 1499 mL.Tolvaptan was started at a dose 
of 60 mg/day (with 45 mg given in the morning and 15 mg in the evening), with weekly 
increase by 30mg/day, and finally to 120 mg/day divided into 90 mg in the morning and 
30 mg in the evening. The rate of eGFR decline during tolvaptan treatment was - 3.01 
mL/min/1.73 m2 per year (57.3 mL/ min/1.73 m2 before the treatment of tolvaptan; and 
34.4 mL/ min/1.73 m2 9 years later). The TKV increased by 6.17 %/year (1499mL before 
the treatment; and 2328 mL 9years later). During 9-year period, the patient has showed 
no tolvaptan-related adverse events, such as liver dysfunction, and hypernatremia, which 
were more common adverse events in tolvaptan group of the TEMPO 3:4 trial9. Tolvaptan 
treatment is continuing in this patient, and his condition is stable now.
Discussion: The post hoc exploratory analysis of the TEMPO3:4 trial also revealed 
that tolvaptan decrease the rate of eGFR by - 3.70 mL/min/1.73m2 /year (n=151, 95% 
confidential interval:- 4.04 to - 3.36 mL/min/1.73m2 /year) in the tolvaptan group and - 5.36 
mL/min/1.73m2 year (n=84, 95% confidential interval:- 6.19 to - 4.53 mL/min/1.73m2 /
year) in the placebo group, in ADPKD patients with CKD stage 33. In our patient, during 
9-year period, the rate of eGFR decline was -3.01ml/min/1.73 m2 /year, which was similar
to the results of the previous study. Thus, high dose of tolvaptan treatment for the protection 
of kidney function could be maintained in longer term, even in patients with CKD stage 3.
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A Case of Autosomal Dominant Alport Syndrome Diagnosed by a Second 
Renal Biopsy
Tomohiko Asakawa,1 Kandai Nozu,2 Makoto Araki.1 1Suwa Central Hospital, 
Chino, Japan; 2Kobe University, Kobe, Japan.
Introduction: Typically, Alport syndrome is diagnosed by a renal biopsy and is 
characterized by Alport symptoms, including kidney disease, hearing loss, and eye 
abnormalities. However, symptoms and signs are characteristic of X-linked Alport 
syndrome that are not applicable to the autosomal dominant condition.
Case Description: A male patient experienced asymptomatic hematuria since 
childhood. His mother had chronic hemodialysis because of unknown renal disease. He 
received a renal biopsy at the age of 16 years; however, light and electron microscopic 
findings revealed minor abnormalities and the immunofluorescence staining of type 
IV collagen α5 chain was normal. Since then, he received conservative treatment ; 
however, hematuria and proteinuria tended to increase over time. Therefore, he received 
a second renal biopsy at the age of 23 years. While light microscopy revealed focal 
glomerulosclerosis in some glomeruli, electron microscopy revealed irregular thickening 
and thinning with a reticulated change in the glomerular basement membrane. Although 
renal biopsy findings suggested Alport syndrome, he reported no hearing loss or visual 
impairment. Therefore, genetic analysis revealed a single-base deletion of type IV collagen 
a3 chain [exon26 c.1826delC, p(Pro 609Leufs*138)], which, along with a family history, 
confirmed the diagnosis of autosomal dominant Alport syndrome. Currently, the patient is 
receiving conservative treatment, including renin–angiotensin system inhibitors.
Discussion: A renal biopsy cannot diagnose Alport syndrome at an early stage because 
of an unclear change in the basement membrane. Besides, autosomal dominant Alport 
syndrome lacks eyes and ears abnormalities, which delays the diagnosis unless positive 
suspicion. Recent advancements in sequence technology have revealed autosomal dominant 
Alport syndrome to be a relatively frequent disorder (19%–31% of Alport syndrome cases). 
Thus, in patients with family history of renal impairment, we should consider the possibility 
of autosomal dominant Alport syndrome, even if absence of Alport symptom except 
hematuria.
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A Case Report of a Novel Variant of X-Linked Alport Syndrome
Robert M. Gaeta, Christina M. Yuan, Robert Nee, John S. Thurlow. Walter Reed 
National Military Medical Center, Bethesda, MD.
Introduction: X-linked Alport syndrome is a rare hereditary disorder caused by 
COL4A5 gene variants. We describe a case of a 28 year old Caucasian male with a family 
history of end-stage renal disease (ESRD) presenting with episodic gross hematuria and 
nephrotic range proteinuria. Renal biopsy showed focal segmental glomerulosclerosis 
with non-diagnostic ultrastructural findings. Next Generation Sequencing showed a 
COL4A5 missense likely pathogenic variant, substituting adenine for guanine at nucleotide 
901(c.901G>A) of coding DNA predicting a glycine to serine substitution at amino acid 
301 (p.Glyc301Ser).
Case Description: A 28 year-old Caucasian male with recent diagnosis of hypertension 
and a family history of ESRD presented with episodic gross hematuria and nephrotic 
range proteinuria (7.7g/g). Blood pressure was 146/92 mmHg. Physical examination 
was unremarkable with no lower extremity edema. All other laboratory testing and 
renal ultrasound was unremarkable. Renal biopsy showed FSGS with non-diagnostic 
ultrastructural findings (figure 2). NGS and Sanger Sequencing revealed a COL4A5 
missense variant, substituing adenine for guanine at nucleotide 901(c.901G>A) of coding 
DNA predicting a glycine to serine substitution at amino acid 301 (p.Glyc301Ser).
Discussion: The pathogenicity for this novel missense variant is strongly suspected 
based on its location in a conserved GLY-Xaa-Yaa triple helical domain in the COL4A5 
gene. Knebelmann et al first reported a similar missense variant substituting arginine 
for glycine at position 325 in a large kindred of X-linked Alport syndrome. The variant 
genotype has implications for individual prognosis. A study of 175 X-linked AS families 
showed that rate of progression of renal and extra-renal manifestations was associated 
with mutation type. Those with Gly-Xaa-Yaa variants reached ESRD at a median of 33 
years versus 25 years for truncating mutations. Correct diagnosis allowed for appropriate 
genetic counseling and treatment, including ACE inhibitor therapy and the avoidance of 
immunosuppression. The views expressed in this presentation are those of the authors and 
do not necessarily reflect the official policy or position of the Department of the Navy, the 
Department of the Army, the Department of Defense, nor the US Government.
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A New Pathogenic Stop Codon Variant in the COL4A5 Gene
Claudio Perez-Ledezma,1 Asif A. Sharfuddin,2 Carrie L. Phillips,3 
Michael T. Eadon.1 1Indiana University School of Medicine, Division of 
Nephrology, Indianapolis, IN; 2Division of Transplant Nephrology, Indiana 
University School of Medicine, Indianapolis, IN; 3Pathology, Indiana University 
School of Medicine, Indianapolis, IN.
Introduction: X-linked Alport syndrome (AS) is a progressive form of renal failure 
caused by pathogenic variants in the COL4A5gene. More than 702 variants have been 
described and a further 400 are estimated to be known to individual laboratories but have 
not been published.
Case Description: We present the case of a 30 year-old man with a history of AS 
diagnosed at age 8 years (hearing loss, vision deficit, and proteinuria) who presented for 
discussion of inheritance patterns of his disease as part of family planning with his current 
partner. AS was biopsy-proven at age 14 years, which showed thinned and multi-laminated 
glomerular basement membranes. He experienced an acute decline in renal function at age 
22 years, requiring dialysis for 2 years before undergoing a living-related renal transplant. 
He and his significant other have no known family history of chronic kidney disease. 
He notes a history of hypertension in his maternal grandfather. Since a pedigree was not 
possible, it was unclear whether he had X-linked, autosomal recessive, or autosomal 
dominant inheritance. Thus, the patient underwent sequencing of COL4A3, COL4A4, 
COL4A5, and COL4A6 genes to determine his specific mutation. A hemizygous stop codon 
variant was found in exon 52 of the COL4A5 gene, designated c.4829C>A, resulting in 
premature protein termination (p.Ser1610*) after TCA to TAA conversion. He was referred 
for genetic counseling.
Discussion: About 65% of AS cases are caused by COL4A5mutations and are inherited 
in an X-linked pattern. The patient’s variant c.4829C>Aappears to be pathogenic in this 
given clinical context and has never been previously reported. The description and reporting 
of COL4A5 variants and clinical associations help to predict phenotype and understanding 
of collagen type IV biochemistry, which may ultimately inform therapy.
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Biallelic PKD1 Mutations in a Child with Aggressive Autosomal Dominant 
Polycystic Kidney Disease and Congenital Hepatic Fibrosis
Rosanna Fulchiero,1 Callie Diamonstein,5 Catherine S. Chao,4 Haresh Mani,3 
Natalie S. Hauser,3 Patricia Seo-Mayer.2,1 1Inova Fairfax Children’s Hospital, 
Falls Church, VA; 2Pediatric Specialists of Virginia (Inova-CNMC) and 
Georgetown University School of Medicine, Fairfax, VA; 3Inova Fairfax 
Hospital, Falls Church, VA; 4Pediatric Specialists of Virginia, Oak Hill, VA; 
5Inova Translational Medicine Institute, Falls Church, VA.
Introduction: Autosomal recessive polycystic kidney disease (ARPKD) is generally 
characterized by neonatal detection of enlarged kidneys and pulmonary hypoplasia. 
Autosomal dominant PKD (ADPKD) usually manifests in adulthood with hypertension 
and nephromegaly. Both have gastrointestinal manifestations - congenital hepatic fibrosis 
(CHF) is common in ARPKD, while ADPKD patients more typically have polycystic liver 
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disease. CHF has been rarely reported in cases of ADPKD, but specific modifier genes have 
not been identified. We report the case of a child with aggressive ADPKD and CHF in the 
context of a biallelic mutation of PKD1.
Case Description: We report the case of a term male infant of African descent 
presenting with neonatal nephromegaly, pulmonary hypoplasia and hypertension. ARPKD 
was suspected initially, but genetic testing did not identify a pathogenic mutation in PKD2 
or PKHD1. Instead, two variants on the PKD1 gene were identified (c.11249G>A and 
c.6395T>G), one of which was previously unreported. His course was complicated by
anemia, hypertension, respiratory insufficiency and progressive CKD. At 20 months of 
age, he became acutely ill with fever, ascites, and worsening abdominal distension and
was diagnosed with spontaneous bacterial peritonitis. Liver imaging showed hepatomegaly 
with normal liver function tests. Renal function deteriorated, requiring hemodialysis and
ultimately, nephrectomies. Kidney biopsy showed diffuse cysts involving all segments of
the nephron, complete obliteration of the cortex and glomerulocystic changes. Liver biopsy 
demonstrated CHF, with diffuse ductal plate malformation, tortuous peripheral ductal
profiles and expanded portal tracts. Doppler ultrasound did not reveal portal hypertension.
Discussion: Our patient has a previously unreported variant of PKD1, and biallelic 
or “double dominant” ADPKD. This case is significant due to his neonatal presentation, 
early deterioration of renal function, and CHF, all of which are unusual in ADPKD. This 
suggests that biallelic ADPKD has unique clinical characteristics. This case emphasizes 
the importance of considering a wider differential diagnosis when evaluating children with 
nephromegaly and cystic kidney disease; and the importance of monitoring for CHF and 
related sequelae, even in the context of ADPKD.
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Mutation in NOTCH2 Gene Causing Liver and Renal Failure in Newborn
Thu Tran, Rasmey Chhin, Tetyana L. Vasylyeva. Pediatrics, Texas Tech 
University Health Sciences Center, Amarillo, TX, Amarillo, TX.
Introduction: Alagille syndrome is an autosomal dominant disorder known to cause a 
multi-organ dysfunction and often presents as neonatal liver disease. The majority of cases 
are related to the mutation of the JAG1 gene and only a small percentage, <1%, is due to 
mutation of the NOTCH2 gene. We present a patient who was diagnosed with neonatal giant 
cell hepatitis and renal tubular dysgenesis later found to have NOTCH2 gene mutation.
Case Description: The patient delivered at 39 weeks gestation via cesarean section 
due to being large for gestational age and appeared “swollen” on ultrasound. At 6 weeks 
of life, he was found to have elevated transaminases, hyperbilirubinemia, clay colored 
stools, rust colored urine and ascites. A liver biopsy was done and read as neonatal giant 
cell hepatitis with marked hemosiderosis, bile duct paucity, and acute microabscess. At 
5 months of life, he was admitted for acute kidney failure when found to have oliguria, 
hyperkalemia, rising creatinine levels and coagulation levels indicative of disseminated 
intravascular coagulation. He underwent orthotopic liver transplantation at that time. A 
biopsy was done on the explanted liver and found hepatocellular necrosis with syncytial 
giant cell transformation and diffuse fibrosis with marked hemosiderosis which was highly 
concerning for possible embryonal hepatoblastoma versus neonatal hemochromatosis. 
He required a prolonged period of continuous renal replacement therapy and dialysis 
which prompted a fine needle biopsy of the kidneys revealing renal tubular dysgenesis. 
Repeated biopsy at the age of 4 years showed glomeruli with podocyte hypertrophy and 
fetal glomerular appearance. Whole exome sequencing was later done and revealed he had 
an unclassified variant detected of phenotype H2032N which is found in the NOTCH2 gene 
and known to be linked to Alagille syndrome.
Discussion: Alagille syndrome is characterized by bile duct paucity but has the 
classical involvement of 5 main systems including: liver, dysmorphic facies, congenital 
heart disease, skeletal anomalies, and ophthalmic defects. Both the JAG1 gene and the 
NOTCH2 genes are involved with the Notch receptors. JAG1 gene is responsible for up to 
95% of cases while the NOTCH2 gene is involved in <1% of cases. This case highlights the 
extensive multisystem involvement that can be seen in Alagille syndrome and the extremely 
rare presentation of the NOTCH2 gene mutation.
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C3 Gene Mutation Abnormality Associated with Atypical Hemolytic 
Uremic Syndrome in a Patient With Polycystic Kidney Disease
Vineet K. Jassal, Tushar Chopra, Negiin Pourafshar. University of Virginia Div. 
of Nephrology, Charlottesville, VA.
Introduction: Atypical HUS (aHUS) is a disorder involving dysregulation of the serum 
complement system, resulting in endothelial cell injury and has been effectively treated with 
blockade of the complement system. The optimal therapy remains unknown, but advances 
in genetic testing help determine which patients would benefit from complement system 
blockade. We report a case of an aHUS patient that benefited from genetic testing after 
being on dialysis.
Case Description: 35-year-old female with a past medical history of obesity, 
gestational hypertension, history of a miscarriage, diabetes mellitus, and polycystic kidney 
disease presented with diarhea, acute renal failure, and uremic symptoms after eating 
uncooked meat. Her serum creatinine (sCr) was 11 mg/dL, platelet count 82 k/μL and 
labs concerning for microangiopathic hemolytic anemia. A kidney biopsy showed severe 
acute thrombotic angiopathy; extensive endothelial cell injury and prominent fibrinoid 
necrosis of vascular walls. There were mild chronic changes in the parenchyma including 
focal glomerulosclerosis, tubular atrophy and interstitial fibrosis. Genetic testing revealed a 
variant of unknown significance in the C3 gene. She required hemodialysis, and started on 
eculizumab, along with prednisone and plasmapheresis. A month later, her kidney function 
improved to be off dialysis and one year later her sCr is stable 3.0 mg/dl with continued 
use of eculizumab.
Discussion: Our case highlights the difficulty in recognition of mutations of 
complement cascade that can be trigged to cause thrombotic microangiopathy. We herein, 
present a case of atypical hemolytic uremic syndrome that is uncommonly associated 
with C3 gene mutation. Genetic susceptibility to aHUS has been well recognized with 
mutations in genes involving complement factor I, membrane cofactor protein, and CFH 
(complement factor H). These mutations affect the binding regions of C3b that interrelate 
with CFH, CD46, and complement receptor 1, with resultant dysregulation of the 
alternative complement pathway. Patients with C3 mutations usually progress to severe 
disease and ESRD within the first year following presentation. Therefore proper diagnosis 
and management (including the use of eculizumab) in this group of patients would have a 
great impact on prognosis of their renal disease.
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Atypical Hemolytic Uremic Syndrome (HUS): DGKE and Other 
Mutations in West Virginia Children’s Hospital
Kayla Duvall,1 Oulimata K. Grossman.2 1WVU School of Medicine, Morgantown, 
WV; 2West Virginia University Health Sciences, Morgantown, WV.
Introduction: HUS is a thrombotic microangiopathy (TMA) presenting with 
thrombocytopenia, anemia, and end organ involvement with normal ADAMTS13. 
Microvascular injury, platelet consumption and intravascular hemolysis lead to end organ 
damage. Renal biopsy is pathognomonic. Typical HUS presents acutely after E. coli (STEC) 
related bloody diarrhea with good prognosis despite severity. Atypical HUS (aHUS) has 
incidence projected at 0.53 per million. Here we focus on etiologies related to complement 
dysregulation. AHUS is a chronic and progressive disease leading to acute kidney injury 
(AKI), end stage renal disease (ESRD), and even death. Early treatment with complement 
blockade (Eculizumab) has improved prognosis. Although a rare disease, this reports 3 
cases managed in our institution to highlight the varied presentation and management.
Case Description: Patient A had TMA at 8 months old with proteinuria and progressed 
to ESRD at 19 years. Renal biopsy showed chronic TMA. This patient received Eculizumab 
for 4 months after renal transplant. Patient B was diagnosed at 3 years old with acute 
gastroenteritis, neurologic symptoms, and nephrotic syndrome. Renal biopsy showed acute 
TMA. Symptoms resolved with Eculizumab. Patient C presented at 10 years old with 
abdominal pain, gross hematuria, and proteinuria. Renal biopsy showed IgA nephropathy 
and no TMA lesions. This patient improved without Eculizumab.
Discussion: Despite similarities in presentation, it is vital to differentiate aHUS from 
HUS as early treatment with Eculizumab is recommended in aHUS to prevent morbidity. 
Genetics will determine who benefits from this treatment. Mutation in CFH gene is a major 
cause in up to 25% of cases, has poor prognosis, and requires plasma treatment. Patient 
B had such treatment and did have a secondary mutation on CFH compared to patient C 
who did not require treatment. MCP mutations are generally known to be associated with 
glomerulopathies and have better prognosis. DGKE, a rarely reported mutation, presents in 
infancy with ESRD by age 20 years and is not known to respond to Eculizumab without a 
secondary mutation. Extending our review on prior and future cases will give more insight 
to this very rare disease.
Genetics of Cases
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A Case of Familial Infantile Nephrotic Syndrome Secondary to  
Membranous Nephropathy
Ashley E. Rawson,1 Amy C. Wilson,1 Anne Kouri,1 Myda Khalid,1 
Corina Nailescu,1 Carrie L. Phillips,2 David S. Hains.1 Indiana University School 
of Medicine Pediatric Nephrology 1Indiana University School of Medicine 
Pediatric Nephrology, Indianapolis, IN; 2Indiana University School of Medicine, 
Indianapolis, IN.
Introduction: Infantile nephrotic syndrome (NS) is defined as NS onset between 3-12 
months of life. It is often caused by genetic alterations of proteins involved in forming 
the podocyte slit diaphragm and glomerular basement membrane. Over 95% of cases are 
autosomal recessive and can be attributed to mutations in NPHS1, NPHS2, NPHS3, WT1, 
and LAMB2. Biopsy findings are usually negative for immune deposition. In very rare 
cases membranous nephropathy causes infantile NS; however, there are no documented 
cases of dominant inheritance. We describe a case of familial infantile NS with a variable 
histologic phenotype and atypical inheritance pattern.
Case Description: A 9-month-old male presented with 2 weeks of diffuse swelling. He 
had massive proteinuria with a urine protein: creatinine ratio of 22.18. His renal function, 
complement levels, metabolic work-up and ANA were unremarkable. Family history 
included a half-brother (same mother) with steroid resistant NS who presented at 1 year 
of age and died of sepsis at 2 years of age 8 years prior to this case. The half-brother had 
a kidney biopsy revealing type III membranoproliferative glomerulonephritis but genetic 
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evaluation was not sent. Genetic evaluation on our current patient is pending; however, 
because of the biopsy findings of the half-brother, a biopsy was performed and consistent 
with membranous nephropathy. Immunofluorescence was positive for glomerular labeling 
of IgG (3+), IgA (2+), and C3 (4+). Additionally, glomerular capillary loops diffusely 
labeled with PLA2R (3+) antibody and tubular basement membranes labeled with IgG in a 
granular pattern. Patient currently maintains normal albumin levels on albumin infusions, 
furosemide, and ACE-inhibition.
Discussion: Infantile membranous nephropathy with tubular basement membrane 
antibodies is not currently reported in the literature. Some pediatric case reports exist but 
staining of the tubular basement membranes with IgG is typically in a linear pattern. The 
granular pattern seen in our patient is very unusual and usually seen in patients with SLE. 
Familial cases of these findings have not been reported. The presence of NS in half-brother 
suggests a dominant inheritance pattern and may suggest a novel gene mutation for infantile 
NS. The half-brother with a different histological pattern suggests a variable phenotype.
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Renal Manifestation in a Patient with Seckel Syndrome:  
An Interdisciplinary Challenge
Henrike Stopfkuchen, Anja K. Büscher, Ilja Finkelberg, Peter F. Hoyer, 
Rainer Büscher. Paediatric Nephrology, University Hospital Essen, Essen, 
Germany.
Introduction: Seckel syndrome (SCKL) ist the extremly rare manifestation of an 
proportionate dwarfism, presenting with microcephaly, osteodysplasia, bird head-like 
appearance and psychomotorical retardation. Approximately 20 cases worldwide are 
described. This genetically heterogeneous syndrome ist inherited autosomal-recessive 
and the gene located on chromosomal region 3q22.1-q24 (OMIM no. 210600). A renal 
manifestation is not described so far.
Case Description: We present the case of a 34 years old Lebanese woman diagnosed 
with Seckel syndrome in early childhood. Parents are first degree relatives. Intrauterine 
growth retardation was observed, several other family members are diagnosed with 
unclear dwarfism, but nobody else with Seckle syndrome. Birth weight was 1500 g 
(< 3rd percentile, gestational age 36 weeks). Besides the typical stigma of the syndrome, the 
patient did well and the family doctor in Lebanon was not seen on a regular basis. A chronic 
Hepatitis B infection remained clinically unapparent and was not treated. The family moved 
to Germany when the girl was 16 years old. The patient was first seen in our hospital at the 
age of 34 years presenting with a first transitorily ischemic attack and dexter hemiparesis. 
Further laboratory results revealed a so far unapparent chronic renal failure. Kidneys were 
dysplastic with volumina of 17 and 23 ml. Due to the low weight of 15.0 kg and a height 
of 107.6 cm, peritoneal dialysis was initiated by the paediatric dialysis department. Besides 
several internal, neurological and gynecological ailments such as progessive heart failure 
and dysmenorrhea, the patient remained under paediatric care due to the habit. Continuous 
cyclic peritoneal dialysis was continued for 5 years, the patient did well and was listed as 
kidney recipient with Eurotransplant. A second ischemic attack and severe heart failure with 
shortening fraction < 10% occured in April 2018 and the patient passed away few days later.
Discussion: Take-away lesson: Regardless the age, treatment of multi-morbid patients 
with rare diseases is an enormous interdisciplinary challenge. Preservation of quality of life 
has highest priority and needs individual definitions and solutions.
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A 5-Month-Old Female with One Week of Anuria
Angelina M. Dixon,1 Hannah R. Lively-Endicott,2 Samir S. El-Dahr.1 1Tulane 
University School of Medicine, New Orleans, LA; 2University of Queensland/
Ochsner Clinical School, New Orleans, LA.
Introduction: Anuric AKI is typically associated with worse outcomes than AKI with 
preserved urine volume. Anuria usually suggests obstruction, but it can also be seen in 
ATN or AIN. Acute vascular catastrophe can also cause anuria; however, it must affect both 
kidneys or a single functioning kidney.
Case Description: We present the case of a 5-month-old, ex-24-week female 
transferred to our PICU from an outside hospital NICU with anuria. Ten days prior to 
transfer the patient’s creatinine had risen from 0.3 to 2.0 in five days with oliguria, and 
seven days prior to transfer the patient was noted to be anuric. A renal US demonstrated 
obliteration of the renal venous flow suggestive of thrombosis of the IVC and bilateral 
(BL) renal veins as well as high resistive flow in the main renal artery. Upon admission, 
the patient had a BUN of 219 mg/dl and creatinine of 6.8 mg/dl. She was placed on CRRT. 
A repeat US confirmed IVC and BL renal vein thrombi, so a heparin drip was started. 
Subsequent catheterization demonstrated BL renal artery thrombi as well, so the patient 
underwent mechanical thrombectomy of her IVC and right renal vein in addition to site-
directed TPA to her IVC, renal veins, and renal arteries. Ultimately, anticoagulation was 
not sustainable due to the development of severe coagulopathy, so the decision to withdraw 
support was made. The etiology of this patient’s BL renal artery thrombi is still unclear. 
Our patient had a normal hypercoagulability workup; however, she had multiple central 
venous lines placed, including a catheter placed immediately before her creatinine began to 
drastically rise. In addition, she had a known PFO. Therefore, the most likely etiology of in 
this patient was central-line associated thrombus formation.
Discussion: Renal vascular occlusion leads to renal infarct in hours as collateral 
vasculature can only maintain adequate perfusion for a short period of time. Therefore, 
early diagnosis and treatment is imperative. Treatment is controversial and depends on the 
acuity of the situation. Most patients are treated with systemic anticoagulation. In recent 
reports, supportive care is recommended for unilateral vascular occlusion without extension 
into the IVC where thrombolytic agents were used for bilateral cases. The long-term benefit 
of this approach is still unclear.
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LOANing a Kidney: Role of Whole Exome Sequencing (WES) in 
Diagnosis of Microscopic Hematuria in Potential Kidney Donors
Sarthak Virmani, Neera K. Dahl. Yale School of Medicine, New Haven, CT.
Introduction: Kidney donors with microscopic hematuria present a particular 
challenge to transplant clinics, with some advocating for donor kidney biopsies. Only those 
with no glomerular lesions by biopsy are deemed to be suitable donors. We used WES 
instead of a more invasive kidney biopsy to determine a donor’s eligibility for transplant. 
Subsequent confirmatory testing in her sibling, the recipient, led to an unexpected finding.
Case Description: A 62-year-old French Canadian woman was referred to our 
transplant center for evaluation as a potential kidney donor to her 60-year-old younger 
sister with ESRD from biopsy proven FSGS. Years earlier, their mother had also developed 
ESRD of unknown etiology. Routine evaluation of the donor showed microscopic 
hematuria. Further inquiry revealed a long-standing history of microscopic hematuria in 
at least 3 other first degree family members. This prompted WES of the potential donor. 
An autosomal recessive homozygous variant (cA740G) in the INVS gene, associated with 
nephronophthisis was found. This variant was classified a variant of unknown significance 
(VUS). Her sister, the potential recipient, was also found to have the same homozygous 
mutation. However, in addition to his mutation, a likely pathogenic frameshift variant in 
the COL4A4 gene (P1235fs) was also found to be present. This led to a reformed diagnosis 
of autosomal dominant Later Onset Alport Nephropathy (LOAN) in the proposed recipient 
and cleared her sister for donation.
Discussion: COL4A4 mutations can differentiate the patients with familial microscopic 
hematuria into benign familial hematuria or LOAN presenting histologically as FSGS. 
About 25 % of patients above the age of 50 with COL4A3/A4 mutation, who are labelled 
as having thin basement membrane nephropathy, have been found to have proteinuria, 
hematuria, hypertension and progression to ESRD making this differentiation imprortant. 
This case highlights the importance of WES in differentiating various familial microscopic 
hematuria syndromes and helps obviate the need for renal biopsies, especially in patients 
being considered for transplant.
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The Clinical Impact of Whole-Exome Sequencing by Japan’s Initiative on 
Rare and Undiagnosed Diseases (IRUD) Project on Renal Genetic 
Diseases
Akira Ishii,1 Kanna Shinkawa,1 Atsushi Fukatsu,2 Naoko Nakagawa,3 
Takahito Wada,3 Naoya Kondo,1 Kaoru Sakai,1 Shuichiro Endo,1 Hideki Yokoi,1 
Takeshi Matsubara,1 Shinji Kosugi,3 Kenjiro Kosaki,4 Motoko Yanagita.1 
1Department of Nephrology, Kyoto University Graduate School of Medicine, 
Kyoto, Japan; 2Fukatsu Medical Clinic, Anjo, Japan; 3Department of Medical 
Ethics/Medical Genetics, Kyoto University School of Public Health, Kyoto, 
Japan; 4Center for Medical Genetics, Keio University School of Medicine, 
Tokyo, Japan.
Introduction: There exist many patients who are suffering from rare, undiagnosed 
kidney diseases. In 2015, the Japan Agency for Medical Research and Development 
(AMED) launched the Initiative on Rare and Undiagnosed Diseases (IRUD). IRUD is a 
national project to analyze whole-exome sequence by using next-generation sequencer.
Case Description: Case 1: A 30-year-old woman, who was diagnosed with Retinitis 
Pigmentosa, developed renal dysfunction (serum creatinine level, 4.8 mg/dl). She had 
hypokalemia and metabolic acidosis, and her 31-year-old brother also had same symptoms 
and was receiving hemodialysis. Her brother was suspected of having Nephronophthisis 
and the genetic examination was performed but could not find the NPHP gene mutation. 
Therefore, we examined exome sequencing by IRUD. By genetic analysis, she had 
compound heterozygous missense variants in ALMS1 gene c.[4331A>T];[7973C>G] which 
were also found in her brother, but it seemed atypical presentations as Alstrom syndrome 
because they did not show neither obesity nor type 2 diabetes. Case 2: A 57-year-old 
man, who was diagnosed with hematuria 37 years ago, developed proteinuria and renal 
dysfunction (serum creatinine level, 3.5 mg/dl). Her mother and younger sister also had 
hematuria and proteinuria and his three sons also had hematuria. From his family history 
of renal disease including women, Alport syndrome which is probably due to COL4A3 or 
COL4A4 mutation was suspected. Exome sequencing found deletion and missense variants 
in COL4A4 gene c.[1323_1340del]; [2045A>G] in the patient. These mutations had not 
been reported so far as responsible genes in Alport syndrome.
Discussion: These genetic mutations found in the two cases were predicted to cause the 
phenotypes of diseases. Whole-exome sequencing by IRUD is a powerful tool for diagnosis 
of rare and atypical renal genetic diseases. Sharing and accumulating the genetic data of 
diseases will be important for further elucidation of the pathology.
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Proximal Tubule Histopathologic Variability in Renal Tubular Dysgenesis:  
A Case Report
Seon Lee, Nirupama Gupta, William L. Clapp, Lawrence R. Shoemaker. 
University of Florida- College of Medicine, Gainesville, FL.
Introduction: Renal tubular dysgenesis (RTD) is a rare autosomal recessive disorder 
that presents with antenatal oligohydramnios and anuric renal failure, despite normal renal 
sonography. Mutations of 4 genes that code for integral proteins of the renin-angiotensin 
system (RAS) are responsible for RTD. The function of these proteins is necessary for 
proper fetal renal tubular development. The pathologic hallmarks of RTD include a 
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paucity of proximal tubules (PT) with aberrant developmental features, detectable by light 
microscopy and immunohistochemistry (IHC).
Case Description: A 32-week gestational age neonate delivered by urgent C-section 
for prolonged rupture of membranes and oligohydramnios had anuric renal failure since 
birth and severe hypotension refractory to vasopressors. Imaging revealed a normal renal 
sonogram and a large anterior skull ossification defect. Blood tests revealed markedly low 
renin activity, but normal cortisol, aldosterone, and angiotensin converting enzyme levels. 
Review of renal biopsy performed on DOL 20 revealed a paucity of PT. In contrast to prior 
reports, several developmentally mature PT were detected that stained positive with IHC 
targeted for PT-specific markers CD10 and CD15. Genetic confirmation was sought on 
DOL 23. The patient had a homozygous nonsense mutation in the REN gene, c.127C>T, 
which results in termination of coding of transcripts at the level of the pro-peptide of renin. 
This pathogenic mutation, which prevents any renin production, was previously identified 
and described in another patient with RTD.
Discussion: This case brings to question whether there exists a meager degree of 
biological redundancy in the fetal RAS that may obscure correlation of genotype and 
phenotype. For example in this case, might there be alternate enzymes (other than renin) 
capable of activating RAS? Recognition of the mild histopathologic variability in these 
rare cases supports early genetic testing for RTD in neonates with unexplained anuria. 
Furthermore, the finding of relatively mature PT in this case, associated with a mutation 
that prevents any renin production, suggests a greater complexity of the biology of the fetal 
RAS than currently appreciated.
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A Surprise Diagnosis: Oxalate Nephropathy
Deep Shah, Kim Jordan. Ohiohealth Riverside Methodist Hospital, Columbus, 
OH.
Introduction: Hyperoxaluria can cause acute kidney injury (AKI) or chronic kidney 
disease (CKD) from oxalate crystal deposition. We present a surprising diagnosis of oxalate 
nephropathy in an elderly female.
Case Description: A 75-year-old female presented with dyspnea, weight gain, and 
edema. She had diastolic heart failure, CKD stage 3 attributed to insulin-requiring diabetes, 
and prior partial colectomy for ulcerative colitis. Furosemide was increased two weeks 
prior because of symptoms, but no other medication changes were noted. Admission 
serum creatinine was 8.1 mg/dl, (1.6 mg/dl baseline). AKI was attributed to cardiorenal 
syndrome, but she failed to improve with intravenous furosemide, and hemodialysis was 
started. Echocardiography showed mild left ventricular hypertrophy and atrial dilation, 
EF 60-65%, and grade 2 diastolic dysfunction. Protein and moderate blood were noted on 
urinalyis, but casts and crystals were not reported. Renal ultrasound found mild asymmetry 
in kidney size, few simple renal cysts, and hyperechoic cortices. Serum complement 
levels, anti-GBM, ANA, ANCA, urine protein electrophoresis and serum immunofixaton 
studies were normal. Kidney biopsy revealed acute tubular necrosis with prominent oxalate 
crystals, urine eosinophils, mild fibrosis, and interstitial changes consistent with oxalate 
nephropathy. The patient reported consumption of one gallon of iced tea daily for 20 years. 
While on hemodialysis, plasma oxalate was 15.4 micromol/L (normal <11) with urinary 
oxalate excretion of 11.4 mg/24 h (normal <40 mg/24 h). Calcium supplementation was 
started and she was instructed to maintain high water intake, avoid iced tea consumption, 
and begin a low oxalate, low vitamin C, calcium-enriched diet. The patient remains on 
hemodialysis post-discharge.
Discussion: Hyperoxaluria can be primary from enzymatic deficiency, or secondary 
from gastrointestinal disease, malabsorption syndromes, excessive vitamin C ingestion, and 
ethylene glycol toxicity. However, ingestion of oxalate-rich foods, including spinach, beets, 
rhubarb, peanuts, star fruit, and iced tea should also be considered. Despite documented 
excess dietary oxalate intake in individuals in the United States, reports speculate that 
oxalate nephropathy is under-recognized. Physicians should consider oxalate nephropathy 
in the right clinical scenario, in this case, excessive iced tea and underlying gastrointestinal 
disease.
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ESRD Secondary to Oxalate Nephropathy Post Whipple’s Procedure: A 
Report of an Interesting Case
Azka Arif,6,1 Ahmad Hassan,3 Leena Syed,4 Muhammad Moosa Niazi,3 
Talal A. Khan.5,2 1Internal Medicine, Freeman Health System, Joplin, MO; 
2Nephrology, Kansas City University of Biomedical Sciences, Joplin, MO; 
3Rawalpindi Medical College, Rawalpindi, Pakistan; 4Quaid-e-Azam Medical 
College, Bahawalpur, Pakistan; 5Nephrology, Freeman Health System, Joplin, 
MO; 6Internal Medicine, Kansas City University of Biomedical Sciences 
Graduate Education Program, Joplin, MO.
Introduction: HTN & DM are the two most common causes of ESRD. Secondary 
Oxalate Nephropathy is one of the rare causes of ESRD, We present an interesting case of 
ESRD secondary to oxalate nephropathy resulting from Pancreatic Exocrine deficiency.
Case Description: 77-year-old male with recently diagnosed HTN, presented to 
ER with generalized weakness, nausea, vomiting & swelling. Initial labs showed BUN 
of 109mg/dl, creatinine of 14.8 mg/dL. No recent IV contrast exposure, no NSAIDs 
use, no evidence of hematuria, had 0.5 g of proteinuria & negative urine eosinophils. 
Immune workup was negative. Renal ultrasound was negative for hydronephrosis. He was 
urgently dialyzed & later on underwent kidney biopsy which showed evidence of oxalate 
nephropathy & significantly advanced fibrosis. Patient had history of Whipple’s procedure 
in 1996, he was not on any pancreatic enzyme supplementation. He had history of chronic 
recurrent diarrhea. His serum lipase was <10 U/L & serum Albumin was 2.8mg/dl. He was 
deemed ESRD & continued hemodialysis. He was started on pancreatic enzymes and his 
diarrhea improved.
Discussion: Our case represents one of the rare complications of pancreatic exocrine 
insufficiency resulting from Whipple’s procedure. Pancreatic insufficiency is associated 
with fat malabsorption causing calcium chelation. Resulting Hyperoxaluria causes oxalate 
nephropathy. Our case presents a rare yet unfortunate long-term complication of pancreatic 
insufficiency post Whipple’s procedure. Patients especially after Gut related surgeries 
should be monitored for any hyperoxaluria which can result in lifelong morbidity.
Oxalate Crystals Under Polarized Light in Renal Biopsy specimen
Mechanism of Oxalate Nephropathy
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Oxalate Nephropathy in Patient with Diabetic Kidney Disease
Hristo Shivarov,1 Maria V. DeVita.2 1Lenox Hill Hospital - Northwell Health 
System, New York, NY; 2Lenox Hill Hospital- Northwell Health System, New 
York, NY.
Introduction: Secondary oxalate nephropathy is an uncommon condition that causes 
acute kidney injury with the potential for progression to end-stage renal disease. The 
diagnosis is based on high clinical suspicion and the findings from kidney biopsy.
Case Description: 54 year old female with significant past medical history for Diabetes 
mellitus type I since age of 10, proliferative diabetic retinopathy, diabetic kidney disease, 
CKD stage 3b, HTN. She presented into the ED with abdominal pain, nausea and vomiting 
for less than 1 week. Laboratory work showed severe deterioration of her kidney function 
BUN 129 mg/dl and serum creatinine of 10.4 mg/dl and severe anemia – hemoglobin 6.6 
g/dl. Baseline creatinine of 1.82 mg/dl, eGFR 31 ml/min one month prior. Furosemide 
and Enalapril were discontinued, rehydration therapy was initiated in the next two days 
without significant improvement in renal function, The evaluation for secondary causes 
for worsening of the renal function were negative: C3 and C4, hepatitis status, free light 
chains, UA – bland sediment <5 RBC, 5-10 WBC, no casts, proteinuria +, 34 mg/24 h. 
The patient was started on hemodialysis. Because of relatively fast progression of the 
renal failure inconsistent with diabetic nephropathy a renal biopsy was performed. The 
histological findings were consistent with widespread tubular oxalate crystal deposition, 
diffuse and nodular diabetes glomerulosclerosis and severe arterial sclerosis. After that a 
detailed history of her dietary habits was taken. The patient acknowledge for recent change 
Trainee Case Reports - IV
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
582
J Am Soc Nephrol 29: 2018 Poster/Friday
in her diet habits including increased intake of green leafy vegetables, copious amount of 
green tea and almonds.
Discussion: A diet rich of oxalate can cause irreversible acute oxalate nephropathy, 
which can lead to ESRD in a patient with impaired renal function. Patients with predisposing 
conditions such as CKD and diabetic kidney disease are particularly at risk. Heightened 
awareness of the potential for acute oxalate nephropathy following a high green diet in 
susceptible individuals is needed to reduce the incidence of this preventable condition
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Acute Renal Failure Due to Dietary Hyperoxaluria
Prerna Kumar, Youness Hussein, Douglas L. Somers. University of Iowa, Iowa 
City, IA.
Introduction: We present a case of rapid drop in GFR attaining CKD stage 5 from 
CKD stage 3 caused by excessive dietary oxalate intake.
Case Description: A 51-year-old male with the PMH of chronic kidney disease 
stage 3b, benign prostatic hypertrophy and kidney stones was admitted in February 2018 
for unintentional weight loss, abdominal discomfort, and a creatinine of 6.9. Patient 
reportedly lost 14 lbs over 4 months. Detailed interviewing revealed a recent change in 
his diet. He was on a “Microbiome-intense diet” for two months in December 2017 to 
accompany his wife in her weight loss regimen. This diet included whole meals of raw fruits 
and vegetables, and later included eggs and cheese, as well as a lot of almonds, spinach, 
kale and berries. Pertinent positives on physical exam included BP of 100/60 mm Hg and 
dry mucous membranes. Labs: BUN 111, Creatinine 6mg/dL (baseline 2.0) and eGFR 
8 mL/min/1.73m2. Chart review revealed a history of oxalate kidney stones in 2014 with 
high oxalate excretion. Prior CT abdomen/pelvis without contrast showed bilateral non-
obstructing renal stones. Patient denied taking any herbal products, over the counter drugs 
including NDSAIDs, or any “diet pills”. Family history was negative for renal stones. 24-
hour urine collection for stone analysis demonstrated high urinary oxalate excretion. Renal 
biopsy showed chronic interstitial nephritis, with intraparenchymal deposition of oxalate 
and phosphate He was discharged with recommendations to stop the microbiome diet and 
restart potassium citrate.
Discussion: Oxalate is widely found in both plants and animals and is normally 
excreted by the kidneys.. Increased oxalate excretion in the urine causes supersaturation 
and deposition of calcium oxalate crystals in the renal tissue. The most common cause 
of hyperoxaluria is excessive oxalate absorption from the gastrointestinal tract, enteric 
hyperoxaluria from fat malabsorption or excessive endogenous oxalate production (primary 
hyperoxaluria). The diagnosis of dietary hyperoxaluria in this patient was suggested by the 
patient’s extreme diet which altered the gut flora and consequently, the oxalate homeostasis. 
Most commonly implicated vegetables and fruits are peanuts, celery, carrots, parsley, beets, 
spinach, nuts and rubarb. As patient’s GFR fell, his serum oxalate increased leading to more 
deposition.
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Gastrointestinal Bleeding Secondary to Gastric Mucosal Calcinosis in an 
ESRD Patient
Anum Malik,1 Jonathan J. Taliercio,2 Laura Ferreira Provenzano.1 1Cleveland Clinic, 
Beachwood, OH; 2Glickman Urological and Kidney Institute, Cleveland, OH.
Introduction: Gastric mucosal calcinosis (GMC) is a pathological process of 
calcium salt deposition in normal tissues from prolonged periods of hypercalcemia 
or hyperphosphatemia. The gastric mucosa, kidneys and lungs are preferred sites for 
deposition. We describe a rare case of upper gastrointestinal bleeding (UGIB) secondary to 
GMC in a peritoneal dialysis (PD) patient.
Case Description: A 21 year old male with a history of ESRD secondary to anti-
glomerular basement membrane disease on PD was transferred to our facility for work 
up of an UGIB. He has a complex cardiac history including congenital transposition of 
the great arteries requiring surgical repair in childhood and left ventricular thrombus 
on warfarin. He was listed for a combined heart-kidney transplant. He presented to the 
emergency department due to a syncopal episode which was attributed to hemorrhagic 
shock upon discovery of a hemoglobin 5.2g/dL from a baseline 9 g/dL and guaiac positive 
stools. His INR was 5.9 and his coagulopathy was reversed and transfused blood. An EGD 
demonstrated non-bleeding gastric ulcers which were biopsied. Pathology revealed diffuse 
calcification of the lamina propria with a mononuclear inflammatory infiltrate diagnostic of 
GMC. On review of his dialysis and bone mineral disease (BMD) history he a low average 
transporter without residual renal function on PD for 3 years. PD prescription was 10 hours 
of CCPD with 8 exchanges, fill volume of 1.8L of 2.5% dextrose dialysate per exchange, 
with a last fill of 1.5L of 2.5% dextrose. His last Kt/V was consistently > 1.7 for the last year. 
His serum calcium levels have been within goal but he has been hyperphosphatemic with 
average level of 8-9mg/dL and PTH 501 pg/ml attributable to noncompliance with multiple 
calcium and non-calcium binders. He had no signs of calciphylaxis. Despite these findings, 
he continues to do well post discharge.
Discussion: We report a unique case of GMC in the setting of hyperphosphatemia in 
an ESRD patient with a dialysis vintage of only 3 years and an adequate Kt/V. On literature 
review, there is no other reported cases of GMC in a PD patient and only one reported case 
in a hemodialysis patient. Our case also highlights the importance of recognizing GMC as 
an possible etiology of UGIB in ESRD patients, especially those with poorly controlled 
BMD.
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Spontaneous, Non-Traumatic Rupture of an Acquired Renal Cyst in 
ESRD Patient with Large Retroperitoneal Hemorrhage - A Case Report
Abbas Raza,1 Sandeep Aggarwal,2 Muhammad O. Hanif.1 1Drexel University, 
Philadelphia, PA; 2Drexel University College of Medicine, Philadelphia, PA.
Introduction: Acquired Cystic Kidney Disease (ACKD) is asymptomatic in most 
patients. However, the renal cyst may be associated with back pain, infection, and malignant 
transformation. Cyst rupture and bleeding secondary to ACKD are considered unlikely 
because of reduced renal parenchymal blood supply in atrophic kidneys. We present a 
case of an End Stage Renal Disease (ESRD) patient with a previously unrecognized cystic 
condition who presented with extensive retroperitoneal hemorrhage.
Case Description: A 31-year-old male with the medical history of ESRD for 5 years 
due to hypertension and no history of smoking presented with acute onset of left flank 
pain. Patient denies any traumatic event prior to the onset of pain. Blood work showed 
a hemoglobin of 9.5 g/dl with normal coagulation profile and platelets. Imaging showed 
large heterogeneously attenuating, ruptured left renal/perinephric hematoma measuring 
10x12x27 cm occupying most of the left retroperitoneal space and extending across the 
midline. There were multiple foci of active extravasation and no normal renal parenchymal 
tissue was visualized. (Figure-1). The patient had an emergent fluoroscopy guided coil and 
Gelfoam embolization of the superior and inferior pole left renal arteries with successful 
hemostasis. The patient remained hemodynamically stable for the rest of the stay.
Discussion: To our knowledge, it is the first reported case of ACKD associated massive 
hemorrhage. Although rare, hemorrhage due to ruptured renal cyst should be suspected 
when an ESRD patient presents with acute back pain and symptoms of shock. Screening for 
ACKD has been proposed but larger scale trials are required for consensus and guideline 
development.
Figure 1: CT scan image. Red asterisk on the left of the patient indicating the area of 
retroperitoneal hemorrhage. Note right atrophic kidney (yellow asterisk).
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A Concrete Cause of Abdominal Pain
Jimmy D. Gentry, Peter Hanna, Rishi Naik, Lori Wanko, Edward Gould. 
Vanderbilt University Medical Center, Nashville, TN.
Introduction: Sevelamer hydrochloride is a non-calcium based phosphate binder 
routinely used in the treatment of hyperphosphatemia in patients with impaired renal 
excretion of phosphorus. Sevelamer is commonly associated with mild gastrointestinal (GI) 
symptoms - most commonly, constipation, nausea and bloating. Here we describe a case 
of a more serious sevelamer concretion masquerading as a gastric malignancy in a patient 
presenting with abdominal pain.
Case Description: Our patient is a 48 year-old female with a history of hypertension, 
DM2, morbid obesity, and ESRD on hemodialysis three times a week, who presented with 
sharp left flank pain of two weeks duration as well as nausea and early satiety. A contrasted 
CT scan raised concern for invasive gastric malignancy. She underwent endoscopy with 
biopsy for diagnostic purposes. Visual examination revealed a discolored infiltrative mass. 
Histologic examination revealed irregularly shaped “fish-scales” consistent with sevelamer 
crystals and other debris all consistent with sevelamer concretion. After multidisciplinary 
discussion the decision was made to forego surgical removal and treat conservatively. 
Prior to presentation, she had been on 3200mg three times daily of sevelamer; this was 
discontinued with plan for repeat EGD to ensure resolution of the gastric mass and healing 
of the gastric ulcer.
Discussion: Resin-based phosphate binders such as sevelamer can crystallize leading 
to the formation of concretions. Since the first description of this in 2013 there have been 
seventeen reported cases of GI lesions attributable to sevelamer. Eighty-one percent of these 
were in the intestine and the most frequent presentation is GI bleeding. Pathology ranges 
from acute inflammation to chronic mucosal injury, strictures, ulcerations, and necrosis, 
many of which show sevelamer at least in close proximity to inflammation or ulceration 
on histology. Gastric involvement is rare, and when present is usually in the form of an 
ulceration. We could not identify previous reports of a gastric mass due to sevelamer. 
Given the frequency of sevelamer use, it is critical for clinicians to remain attentive to the 
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possibility of sevelamer concretions as a cause for GI symptoms and pathology in patients 
using it for phosphorous elimination.
FR-PO634 Poster Friday
Trainee Case Reports - IV
Normohormonal Primary Hyperparathyroidism Presenting as Fracture 
Non-Union
Amita Maibam, Madhumathi Rao. University of Kentucky, Lexington, KY.
Introduction: Primary hyperparathyroidism (PHPT) is a rare cause of poor 
fracture healing. We present a patient with osteopenia and fracture non-union with mild 
hypercalcemia in the setting of hydrochlorthiazide (HCTZ) treatment and normal intact 
parathyroid hormone (iPTH) level.
Case Description: A 54-year-old Caucasian female with history of hypertension, 
hypothyroidism and depression presented with progressive pain and deformity of the left 
forearm, 8 months after open reduction and internal fixation of fractures of left radius and 
ulna. X-ray showed fracture non-union (Figure:1, left); laboratory evaluation revealed 
mild hypercalcemia (10.5 mg/dl), non-suppressed iPTH (41 pg/ml), and elevated serum 
creatinine (1.3 mg/dl). Repeat serum calcium after stopping HCTZ, remained 10.5 mg/dl 
though iPTH increased to 64 pg/ml (range 14-66) Urine calcium was 851 mg/d and bone 
densitometry showed osteopenia of lumbar spine. A right inferior parathyroid adenoma 
was demonstrated on nuclear scan establishing a diagnosis of PHPT. The remainder of the 
work up for hypercalcemia was also significant for a diagnosis of monoclonal gammopathy 
of undetermined significance (MGUS) confirmed by bone marrow aspiration. Patient 
underwent parathyroidectomy with prompt reversal of biochemical abnormalities. At 4 
weeks after surgery, repeat calcium was 9.6 mg/dl and iPTH level 27 pg/ml; bone pain was 
improved, and forearm X-ray showed evidence of healing with new bone formation and 
reversal of cystic changes (Figure:1, right).
Discussion: Normohormonal PHPT accounts for about 5 % of parathyroid explorations 
and should be considered in patients with fracture non-union and should be corrected before 
any further orthopedic intervention is undertaken. Mild hypercalcemia in the setting of 
thiazide treatment and normal iPTH levels may confound the diagnosis and require a high 
degree of suspicion. The reported association between PHPT and MGUS was also notable 
in this patient.
Left Forearm XRAY showing fracture site before (left) and after (right) parathyroidectomy.
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Lytic Lesions in A Dialysis Patient: It’s Not Always Cancer
Victoria Gutgarts,1,5 David L. Epstein,3 Narasimhan P. Agaram,2 Juliet N. Barker,4 
Insara Jaffer Sathick.1 1Nephrology, Memorial Sloan Kettering Cancer Center, 
New York, NY; 2Pathology, Memorial Sloan Kettering Cancer Center, New York, 
NY; 3Nephrology, The Rogosin Institute, New York, NY; 4Hematology/Oncology, 
Memorial Sloan Kettering Cancer Center, New York, NY; 5Nephrology, Weill 
Cornell Medical Center, New York, NY.
Introduction: Secondary hyperparathyroidism is a known complicaiton of end stage 
renal disease (ESRD). Increased production of parathyroid hormone (PTH) leads to excess 
osteoclast activity and fibroblast proliferation. In severe cases, patients are at risk of 
developing bone lesions called brown tumors.
Case Description: A 31 year old female with history of Hodgkins lymphoma 
treated with umbilical cord transplant and ESRD due to hypertension on dialysis for six 
years, presented for kidney transplant evaluation. She had no systemic complaints and 
an unremarkable physical exam. Laboratory values were significant for elevated PTH 
1874 pg/ml. As part of her transplant evaluation, she underwent CT scan showing multiple 
bony lesions concerning for malignancy. PET scan confirmed FDG avid lytic lesions 
(Figure 1a). Biopsy of the right iliac crest (Figure 1b) revealed a giant cell rich lesion with 
osteoclasts and hemosiderin pigment deposition. Despite being medically managed with 
cinacalcet and doxercalciferol, the patient developed diffuse lytic bone lesions consistent 
with brown tumor of hyperparathyroidism.
Discussion: Brown tumor is a rare finding in ESRD patients and has an estimated 
incidence of 1.7 %. Clinically, they can be silent unless there is compression of surrounding 
structures. CT or PET imaging reveals the lesions, but histopathology is necessary to 
identify the giant cell granulomas with brown colored hemosiderin deposits from which 
the tumor gets its name from. Treatment begins with pharmacologic therapy to lower PTH, 
but can be ineffective, and parathyroidectomy and evaluation for kidney transplantation 
should be considered. This case underlines the importance of recognizing Brown tumor 
as a complication and important differential diagnosis of a patient with imaging showing 
lytic lesions. Prevention and early diagnosis are essential to reduce the prevalence of high 
turnover bone disease.
Figure 1
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A Case Report of Early Calciphylaxis Based on Single Cutaneous 
Erythema and Literature Review
Yuqiu Liu, Haifeng Ni, Xiaoliang Zhang. Institute of Nephrology, Zhong Da 
Hospital, Southeast University School of Medicine, Nanjing, China.
Introduction: We analyzed the clinical information of a patient with single cutaneous 
erythema leading to calciphylaxis, and reviewed literatures. Improve clinical understanding 
of calciphylaxis to reduce the occurrence of missed diagnosis and misdiagnosis.
Case Description: A 36-year-old male patient with hemodialysis for 5 years had focal 
purple-black skin changes in the left leg recently(Fig. A). Then the wound was enlarged 
and ulcerated with mild pain(Fig. B). X-rays showed the large vessel calcification(Fig. D). 
There was multiple subcutaneous small vessel calcification by further plain CT scanning 
of suspicious vessel calcification area. In particular, small blood vessels deep in the skin 
lesions were significantly calcified(Fig. E). Imaging evidence strongly suggests a diagnosis 
of calciphylaxis. A skin biopsy was performed on the rough skin of the patient’s left lower 
leg. The pathology showed extensive calcium deposits in the subcutaneous soft tissue with 
calcification of the small vessel wall(Fig. F). The calciphylaxis was diagnosed and was still 
in the early stage of disease. After comprehensive treatment based on sodium thiosulfate 
for three months, the necrosis area was gradually scabbed and the wound healed(Fig.C).
Discussion: Calciphylaxis is a fatal vascular disease characterized by systemic arteriole 
calcification with endothelial destruction and thrombosis, resulting in peripheral tissue 
ischemic necrosis. This patient presented with a single, early-onset skin lesion and lacked 
typical skin lesions. Imaging examinations have a high guiding significance in the diagnosis 
of calciphylaxis in this case. Recently, the prevalence of calciphylaxis in dialysis patients 
has been increasing, and a combination of diagnostic techniques has helped early detection. 
Skin biopsy helps diagnose early and atypical patients, while imaging is a non-invasive test 
that can be used as an early screening and efficacy monitoring tool.
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Dramatic Improvement in Dialysis Related Tumoral Calcinosis Following 
Renal Transplantation
Win Win Moe, Kamal Nayyar, Ruby Zhao, Nobuyuki (Bill) Miyawaki, 
James Drakakis. NYU Winthrop Hospital, Mineola, NY.
Introduction: Tumoral calcinosis (TC) is an uncommon and serious complication 
of dialysis. It is usually associated with high serum calcium and phosphorus product. 
Management of this ectopic calcification syndrome involves dietary phosphorus restriction, 
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non-calcium based binders, low calcium dialysis, and parathyroidectomy. Here, we present 
a case of extensive TC which failed to respond to conservative measures in a patient on 
long-standing dialysis, only clinically and radiographically improved after a successful 
renal transplant.
Case Description: A 56 year old male with history of HIV on HAART therapy with 
resultant end-stage-renal-disease (ESRD) on dialysis for 8 years, presented with hip pain 
and difficulty ambulating. CT scan revealed abundant metastatic calcium deposition within 
the adductor compartment of the right thigh, enlarging within the vastus intermedius 
and iliopsoas tendon and invading the femur. Biopsy revealed benign fibrous tissue and 
marked granular calcification. He was initially on hemodialysis (HD) but later switched to 
peritoneal dialysis (PD) due to limited vascular access. While on PD, clearances were sub-
optimal and phosphorus ranged 8-10 mg/dL. PTH was elevated (300-400 pg/mL) despite 
attempts to suppress with calcimimetic. He then switched back to an intense HD regimen 
via a femoral dialysis catheter and was given low calcium dialysate and sodium thiosulfate. 
However, he did not improve and a request for medical urgency to receive compassionate 
points on the deceased donor wait list was filed. Shortly after, he received a functioning 
kidney transplant and imaging began to show resolution. In fact, a CT scan done 3 years 
later revealed the deposition to be 2.9 x 1.0 x 3.2 cm, compared with14 x 14 x 10 cm at 
time of initial diagnosis.
Discussion: There is known morbidity associated with extraosseous tumoral 
calcification associated with ESRD, often carrying with it a poor prognostic significance. 
Several medical and surgical (i.e, parathyroidectomy) treatment options are available, but 
responses may be limited. Renal transplantation has been described as being useful to 
treat TC and several cases of complete dissolution have been reported. This case similarly 
illustrates success after kidney transplantation and highlights the need for awareness in 
diagnosis and urgency to help facilitate an effective treatment strategy.
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Calciphylaxis Patient Characteristics and Outcomes: Case Series of 7 
Patients
Mariam Zakher,1 Loay H. Salman,1 Swati Mehta,1 Sabrina Daoui,2 Rachid Daoui,3 
Rafia I. Chaudhry.1 1Albany Medical College, Albany, NY; 2363, Saratoga 
Springs, NY; 3Nephrology, Saratoga Hospital, Saratoga, NY.
Introduction: Calcific uremic arteriolopathy (CUA) also known as calciphylaxis 
is a rare, life-threatening ischemic small-vessel vasculopathy, primarily a complication 
of advanced CKD or ESRD. The pathogenesis involves intimal hypertrophy and medial 
calcification, resulting in endovascular fibrosis and thrombosis of small arteries and 
arterioles. We reviewed historical cases to assess patient characteristics, treatment 
modalities employed and clinical outcomes.
Case Description: We present 7 cases of calciphylaxis diagnosed between 2013 
and 2017. Median age at time of diagnosis was 57.7 (42-76), 57% were male, 57% were 
Caucasian, 71% smokers, and 100% obese. Patients had been on dialysis for an average 
of 5.2 years prior to diagnosis. Only 1 patient was on peritoneal dialysis; the rest were on 
in-center hemodialysis (3 days/week). Comorbid conditions included DM (4/7), HTN (4/7), 
concomitant anticoagulation with warfarin (2/7), vitamin D analogue (4/7), oral calcium 
supplements (2/7), and calcitriol (2/7). Calciphylaxis was confirmed by skin biopsy in 7 
cases. Mean calcium, phosphorus and PTH levels were 9.15, 5.6, and 322.9, respectively. 
All patients received sodium thiosulfate 25 mg 3 days/ week, along with increased daily 
dialysis (average of 5.2 treatments/ week for 4.3 hours over 7.2 months). 5/7 patients were 
reported to have complete resolution after an average of 7.64 months. One patient continues 
to receive treatment. Two patients died, including one patient who chose to discontinue 
dialysis 3.8 years after diagnosis, and the second patient did not tolerate sodium thiosulfate 
(metabolic acidosis and hypotension) and died from sepsis 8 days after diagnosis. 
Complications of sodium thiosulfate included metabolic acidosis (6/7), hypotension (4/7), 
and hypocalcemia (2/7).
Discussion: Previously reported risk factors include high BMI, female sex, DM, PD, 
higher serum calcium, phosphorus, and parathyroid hormone, and combined therapy with 
calcium salts and vitamin D, cinacalcet, warfarin and calcitriol. Mortality rate is reported at 
27% at 6 months after CUA diagnosis, and 45% at 12 months. Data on the dose and duration 
of increased intensity dialysis as well as treatment are lacking, and while CUA is associated 
with a high rates of mortality, we have a 71% survival rate with emphasis on maximizing 
dialysis (daily).
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Penile Calciphylaxis: A Clinico-Radiologic Diagnosis
Gajapathiraju Chamarthi,2 Abhilash Koratala.1 1Nephrology, University of 
Florida, Gainesville, FL; 2University of Flroida, Gainesville, FL.
Introduction: Calciphylaxis, also known as calcific uremic arteriolopathy (CUA) is a 
rare and serious disorder typically seen in ESRD patients that presents with skin ischemia 
and necrosis and histologically characterized by calcification of dermal arterioles. While 
most lesions occur on the lower extremities followed by the lower abdomen, rare sites such 
as breast and penis have been reported. Herein, we present a case of penile calciphylaxis 
that was diagnosed clinically.
Case Description: A 34-year-old man with end-stage renal disease (ESRD) secondary 
to diabetes mellitus, on hemodialysis for 2 years was seen for worsening pain and blackening 
of the skin in the penile region that started a month ago. He denied having any fever, painful 
urination, discharge from the urethra or unprotected sexual intercourse in the recent past. 
Physical examination revealed mild edema and superficial necrosis of the foreskin and glans 
penis [Figure 1A]. Laboratory data demonstrated a high blood urea nitrogen of 100 mg/
dL, serum creatinine 12.2 mg/dL, parathyroid hormone (PTH) 400 pg/mL and calcium-
phosphorus product of 111 mg/dL. He was not on therapeutic anticoagulation and work up 
for hypercoagulable disorders was negative. Plain radiographs of the pelvis demonstrated 
widespread vascular calcification [Figure 1B], suggestive of CUA.
Discussion: High calcium-phosphate product, elevated PTH, hypoalbuminemia, 
diabetes, obesity, warfarin use, female sex and protein C or S deficiency are among the risk 
factors for CUA and skin biopsy is the gold standard of diagnosis. However, biopsy is not 
typically recommended for penile lesions because of the risk for progression of necrosis 
and therefore, penile CUA essentially remains a clinico-radiologic diagnosis. Treatment 
includes aggressive risk factor control, intensification of hemodialysis regimen, supportive 
wound care and administration of intravenous sodium thiosulfate with dialysis, all of which 
we instituted in our patient. The prognosis remains poor despite treatment and the main 
cause of mortality in these patients is sepsis.
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Non-Uremic Calciphylaxis: Early Diagnosis of a Rare Entity and 
Successful Treatment with Sodium Thiosulfate
Rocio Eleid,1 Gautam M. Phadke.2 1University of North Dakota, Fargo, ND; 
2University of North Dakota School of Medicine, Fargo, ND.
Introduction: Calciphylaxis is a rare cutaneous disease, with varied lesions: from 
bullae to necrotic ulcers. Pain out of proportion to clinical examination is a distinct finding. 
Key finding is Vitamin K deficiency, contributing to progressive microvascular calicifcation 
and microthrombi. Diabetes, liver cirrhosis and patients on warfarin are Vitamin K deficient.
Case Description: A 64 yo male with DM2, HTN and cirrhosis was referred to 
the Nephrology Clinic for evaluation of AKI, hematuria, nephrotic range proteinuria. 
Kidney biopsy showed Nodular Diabetic Nephropathy, secondary IgA nephropathy 
(liver cirrhosis) and ATN. His Ca was 9.6 mg/dl, Phos 4.1 mg/dl, vitamin D 15ng/dl, 
and PTH 129 pg/ml. Three months after initial evaluation, measured GFR (Iohexol) was 
19 ml/min/1.73m2 and he presented with left lower extremity, painful, necrotic ulcers. 
Despite surgical debridement, lesions increased in size and he developed new lesions on 
the right leg. Skin biopsy via telescoping technique showed intraluminal occlusion of small 
and medium sized vessels with calcified appearing material consistent with calciphylaxis. 
Sodium thiosulfate was started at 12.5 g twice/week, it was increased to 25 g twice/week and 
that dose was kept for 7months. Patient lesions improved and thiosulfate was discontinued.
Discussion: This illustrates the importance of an early diagnosis and treatment of non 
uremic calciphylaxis with attention to “at risk” patients: liver cirrhosis, in our case. The 
patient is currently been referred for simultaneous liver-kidney transplantation.
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Top Left: Lesion at presentationTop Right: Lesion resolved
Bottom: H&E, shows calcification and fibrointimal hyperplasia
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A Case of Delayed Onset Hungry Bone Syndrome After Subtotal 
Parathyroidectomy in ESRD Patient with Secondary 
Hyperparathyroidism
Samer Kareem, Aromma Kapoor, Michael D. Klein. Nephrology, Westchester 
Medical center, Valhalla, NY.
Introduction: Hungry bone syndrome (HBS) is an important postoperative 
complication of parathyroidectomy done for severe hyperparathyroidism of renal origin; 
occuring in 27.8 to 72% of cases. It is marked by hypocalcemia (most severe in the first 
24-48 hrs) associated with hypophosphatemia, hypomagnesemia and elevated Alkaline
phosphatase. We are reporting a case where hungry bone syndrome is seen to develop 
more than one week post-op, and did not respond to standard management despite normal 
magnesium and Phosphorus levels.
Case Description: 52 yr old male with ESRD on HD underwent subtotal 
parathyroidectomy for management of severe secondary hyperparathyroidism (PTH 2024 
pg/ml) in spite of high dose of cinacalcet and calcitriol. Post -op PTH dropped to 63.5 pg/ml. 
The lowest reading of Ca was 8.2mg/dl in the immediate post-op period and was treated 
with Ca and vitamin D analogs as per standard guidelines. Two weeks later patient reported 
symptoms of tetany on dialysis and serum Ca was 6.8 mg/dl. Serum Phos remained 
3.3 -4.5mg/dl range and ALP 282 u/l with a normal Magnesium. Calcium was persistently 
low despite treatment with IV calcium ; requiring a prolonged hospital stay.
Discussion: HBS is characterised by prolonged and severe postoperative hypocalcemia 
and hypophosphatemia as a result of extensive and accelerated remineralisation of bone 
following sudden decrease of parathyroid hormone. This syndrome should be anticipated 
when there is evidence of severe parathyroid bone disease with marked elevation of serum 
ALP and PTH levels. Other factors that predict the development of HBS include old age, 
high BMI, and high pre-op BUN. HBS is seen within 24 hrs of a total parathyroidectomy in 
patients with SHPT. The post operative fall in serum calcium has been strongly correlated 
with the severity of bone disease which can be diagnosed only with pre-operative bone 
biopsy not by serum chemistries. This case shows that patients might develop severe 
hypocalcemia in the later time despite a normal serum calcium postoperatively. We 
recommend, patients undergoing total parathyroidectomy should have their serum calcium 
and phosphate levels closely monitored in the following 2 weeks to safeguard against the 
development of severe and symptomatic hypocalcemia and to provide guidance on the 
intensity of calcium supplementation.
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Hyperparathyroidism Induced Erythropoietin Resistance After Successful 
Renal Transplantation
Juan Pablo Arroyo,1 Laura Binari,2 Anthony J. Langone.1 1Nephrology, 
Vanderbilt University Medical Center, Nashville, TN; 2Vanderbilt University 
Medical Center, Nashville, TN.
Introduction: Resistance to erythropoietin (EPO) in the CKD-ESRD population is 
pervasive. Common causes include iron deficiency, chronic inflammation, medications 
and hyperparathyroidism. Most if not all of these conditions resolve after successful 
renal transplant. Post-transplant anemia can occur due to multiple factors including 
immunosuppressant medications, dapsone, TMP-SMX, RAAS antagonists, and viral 
infections (CMV, Parvovirus). We report a case of hyperparathyroidism-induced EPO 
resistance in a patient which was successfully treated with subtotal parathyroidectomy 
three-years after her transplant.
Case Description: A 36-year-old woman with a history of ESRD secondary to 
hypertension underwent a successful deceased donor kidney transplant managed with 
tacrolimus, mycophenolate mofetil and prednisone complicated by refractory anemia 
and hyperparathyroidism. Three years post transplantation with baseline creatinine of 
1 mg/dL, she continued to require 40,000 units of subcutaneous epoetin alfa twice weekly 
for refractory anemia. Her hemoglobin oscillated between 6 – 7 g/dL during this time. She 
underwent an extensive workup that included: multiple iron panels all with >20% saturation, 
negative parvovirus PCR, and a bone marrow biopsy that showed mild hypocellularity. Her 
blood pressure management did not include ACEi/ARBs. Her initial immunosuppressive 
regimen included sirolimus; her anemia, however, persisted after switching to tacrolimus. 
Her NT-PTH was noted to be consistently above 1750 pg/mL and subsequently referred for 
parathyroidectomy following a sestamibi scan demonstrating multigland hyperplasia. One 
month following her parathyroidectomy, her anemia resolved completely and was able to 
stop epoetin alfa injections.
Discussion: Although hyperparathyroidism is a known cause of EPO resistance in the 
CKD-ESRD population, it is thought to contribute minimally to the overall burden of EPO 
resistance. This case highlights that isolated hyperparathyroidism in the absence of other 
common causes for EPO resistance (iron deficiency, medications, infection/inflammation) 
can cause severe EPO resistance, and must be addressed when evaluating anemia in renal 
transplant patients despite stable creatinine.
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Laparoscopic Gastric Sleeve Surgery in a Patient on Peritoneal Dialysis
Anthony Nguyen,2 Farshid Yazdi,1 Mihran V. Naljayan.2 1Louisiana State 
University Health Sciences Center New Orleans, New Orleans, LA; 2LSUHSC 
School of Medicine, New Orleans, LA.
Introduction: The high prevalence of obesity along with its potential resulting 
conditions make obesity a major public health concern. Morbid obesity is a limiting factor for 
a dialysis patient to obtain a kidney transplant. While an obese patient may elect to undergo 
bariatric surgery to induce weight loss, there is little data on this type of surgery involving a 
PD patient. We present a rare case of a patient with end-stage kidney disease (ESKD) on PD 
who underwent laparoscopic gastric sleeve surgery while maintained on PD.
Case Description: A 66-year-old morbidly obese female patient with ESKD on PD 
underwent laparoscopic gastric sleeve surgery. Prior to her surgery, she was 124 kg and 
was on continuous cyclic peritoneal dialysis (CCPD) for 9 hours with 4 cycles of 3000 mL 
2.5% dextrose solution with 500 mL icodextrin last fill. Her adequacy prior to surgery 
was residual renal (RR) Kt/V 0.45 and PD Kt/V 1.56 for a total of 2.01. She cycled the 
night before her surgery and did not do a last fill. She received clindamycin 600 mg IV 
perioperatively (allergy to cefazolin) and post operatively, she held PD the first night, then 
initiated 1000 mL 2.5% dextrose for 6 cycles over 12 hours. At day 5 post operatively, it was 
increased to 1500 mL for 6 cycles over 12 hours due to low drain alarms. After 3 weeks, it 
was increased to 2500 mL alternating 1.5% and 2.5% dextrose for 4 cycles over 9 hours. 
Her adequacy 4 weeks postoperatively was RR Kt/V 1.03, PD Kt/V 1.11, and total 2.15. 
Two months postoperatively she was 113 kg.
Discussion: One particularly interesting observation regarding this case is the fact 
that the patient’s RR Kt/V improved after her surgery also leading to an increase in her 
total adequacy. This case illustrates how PD patients undergoing bariatric surgery can 
successfully be maintained on PD post-operatively without having to transition temporarily 
to hemodialysis and without sacrificing renal adequacy. Being allowed to continue PD as 
opposed to hemodialysis allows for the patient to avoid potential complications involved 
with a catheter and leads to a goal weight suitable for transplantation.
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Rapid Diagnosis of Fungal Peritonitis in a Peritoneal Dialysis Patient 
using a Multiplex PCR-based Identification Panel
Divya Shankaranarayanan,1 John R. Lee,1 Lars Westblade,2 Stephen G. Jenkins,2 
Vesh Srivatana.1,3 1Department of Nephrology, Weill Cornell Medicine, New 
York CIty, NY; 2Department of Microbiology, Weill Cornell Medicine, New York 
City, NY; 3The Rogosin Institute, New York, NY.
Introduction: Fungal peritonitis can be difficult to detect using conventional culture 
methods and delayed diagnosis can lead to significant morbidity and mortality. The 
FilmArray® blood culture identification panel (BCID; BioFire Diagnostics, LLC.) is an 
US FDA approved test for rapid identification of common bacterial and fungal pathogens 
in positive blood culture broths. We present a case of peritoneal dialysis (PD) peritonitis 
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with Candida albicans that was detected using the BCID panel prior to conventional fungal 
culture results.
Case Description: The patient is a 50-year-old female with history of end stage renal 
disease (ESRD) secondary to membranoproliferative glomerulonephritis on PD for 7 years. 
She was admitted with abdominal pain and cloudy PD fluid concerning for peritonitis. She 
had been discharged ten days prior after being treated for Clostridioides difficile colitis. She 
reportedly had a breach in aseptic techniques while performing PD exchanges since her 
hospital discharge. On presentation, her PD effluent had 5,150 white blood cells (WBC/μL) 
with 94% polymorphonuclear (PMN) cells. She was started on empiric intraperitoneal 
antibiotics as well as oral fluconazole for prophylaxis for fungal peritonitis. Initially, her 
WBC count in the PD fluid and clinical condition improved and PD fluid cultures were 
negative. However, on the 5th hospital day she had worsening symptoms and increasing 
WBC count in the PD fluid. The BCID panel was able to detect Candida albicans on a 
PD fluid sample that was saved at the time of her presentation. Treatment was escalated 
to intraperitoneal antifungal therapy, and subsequent PD fluid cultures confirmed Candida 
Albicans peritonitis. Her PD catheter was eventually removed on the 7th day of her 
hospitalization and she was switched to hemodialysis.
Discussion: Rapid diagnosis of fungal peritonitis in PD patients can lead to life 
saving therapy and definitive PD catheter removal. In this case, initial conventional PD 
fluid cultures were non diagnostic, but the BCID enabled rapid identification of a Candida 
albicans infection. This case illustrates a potential use and supports future studies on rapid 
PCR based diagnostic techniques for diagnosing PD peritonitis.
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A Rare Presentation of an Unusual Fungus: Trichoderma Peritonitis
Jeremy Carlson, Peter P. Staiano, Leighton R. James. UF Health, Jacksonville, FL.
Introduction: Peritoneal Dialysis (PD) can be an attractive modality for end stage 
renal disease (ESRD) patients. It does, however, require patients be responsible enough to 
safely perform their own dialysis care, otherwise they can develop peritonitis. Often there 
is a bacterial source, however, in rare cases fungal infections are seen and in these cases, 
mortality is higher. Trichoderma is an opportunistic fungus normally found on decaying 
wood, and it’s presence in humans is especially rare and mainly limited to case reports, 
most of which surfacing in the last 10 years. This likely reflects the increasing number 
of relatively immunocompromised patients on PD and recent improvements in identifying 
pathogens. Presented is a rare case of PD associated Trichoderma peritonitis.
Case Description: A 48 year old Hispanic male with past medical history of diabetes 
mellitus, hypertension, and 1.5 years of PD presented to his nephrologist’s office with 
decreased appetite, abdominal pain, and cloudy effluent from his PD catheter. He was on 
his 3rd week of treatment with vancomycin and meropenem for gas gangrene diabetic 
foot ulcer infection. Intraperitoneal vancomycin was initiated for presumed PD peritonitis. 
PD effluent studies showed 1984 WBCs and mold culture growth, indicating fungal 
infection. He was immediately admitted for PD catheter removal, anti-fungal therapy with 
amphotericin B, and hemodialysis preparation with a tunnel catheter. Cultures finalized 
during his admission showed Trichoderma species susceptible to voriconazole, which he 
was switched to and discharged with a 1 month course.
Discussion: Peritonitis is a feared complication in PD patients as it can permanently 
ruin PD access as well as quickly develop into florid sepsis and death. This is especially 
true in fungal peritonitis cases, where all cause mortality is worse compared to bacterial 
counterparts. Nephrologists must remain vigilant in monitoring for signs and symptoms 
of peritonitis (mainly abdominal pain, fever, and cloudy effluent) at every office visit and 
maintain a low threshold for treatment and admission. Risk factors specifically for fungal 
peritonitis include: HIV co-infection, recent treatment with antibiotics, or recent abdominal 
surgery/peritonitis. It is imperative when fungal peritonitis is diagnosed the catheter is 
removed and strong antifungals are started until susceptibilites are returned.
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Spontaneous Rupture of Peritoneal Dialysis Catheter with No Drainage 
Problem
Ricardo Rodriguez-Santos,1 Shweta Bansal,2 Ashley Garcia-Everett.1 
1UTHSCSA, Helotes, TX; 2University of Texas Health Science Center at San 
Antonio, San Antonio, TX.
Introduction: Background: Spontaneous rupture of the intraperitoneal portion of 
peritoneal dialysis (PD) catheter is a rare complication and usually presents with drainage 
failure and PD related infection. Here we present a case of PD catheter rupture who presents 
with peritonitis; however, intact out- and in-flow.
Case Description: Case report: A 32-year female with end stage renal disease due to 
hypertension on PD for 5 years presented with 2 days of mild grade fever, nausea, abdominal 
pain and cloudy peritoneal fluid. She was managed on CCPD with a two-cuff coiled 
Tenckhoff catheter. She practiced daily exit site care using topical exsept and alternative 
gentamicin/bactroban cream. She had 2 episodes of exit site infections with pseudomonas 
and coagulase negative staphylococcus, respectively 3 years prior to presentation but no 
peritonitis. On examination, she was afebrile, tachycardiac and had diffuse abdominal 
tenderness; however, no findings of exit site infection. PD fluid revealed 12,000 WBC/μl 
with 98% neutrophils and culture grew Pseudomonas aeuroginosa. CT scan done for 
abdominal pain showed discontinuity of the PD catheter within the anterior abdominal 
wall soft tissue. Later, fluoroscopic study with gastrograffin confirmed the fracture site 
in subcutaneous fat with pooling of contrast around the site and drainage of a portion of 
contrast into peritoneal cavity suggestive of a track. Of note, the patient had an episode of 
exit site trauma with mild bleeding 8 months prior to the presentation but no infection. Since 
then she had intermittent issues with long drain time (about 30 minutes) which improved 
somewhat with laxatives. In addition, she maintained good solute and volume clearance 
throughout this period. Finally, she underwent surgical removal of the fractured catheter 
and found to have abscess around the fracture site which was evacuated. The patient had 
an uneventful recovery and PD was resumed successfully with a new catheter after few 
months.
Discussion: Conclusion: This is a rare case of PD catheter rupture which likely 
occurred slowly over time allowing the formation of a soft tissue track and uninterrupted 
PD therapy but with long drain time. This case highlights the need to be vigilant about these 
rare events even with mild catheter flow issues.
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Physical Examination of the Hemodialysis Vascular Access: An  
Unforgettable Tool
Jessita singh natasha Albert messiah dhas,1 Jason C. George,1 Steven 
R. Bonebrake,2 Luis L. Nadal,3 Ion D. Bucaloiu.1 1Geisinger Medical Center,
Danville, PA; 2Geisinger, Danville, PA; 3Geisinger Health System, Danville, PA.
Introduction: Hemodialysis (HD) access failure is an important cause of morbidity 
and mortality in HD patients. We present a case of false-negative fistulography in an end 
stage renal disease patient presenting with life-threatening hyperkalemia.
Case Description: A 66-year-old man on chronic HD for 5 years via right 
brachiocephalic fistula presented with one day of profound weakness. There were no 
missed HD sessions and no major dietary indiscretions by history. Initial labs showed serum 
potassium of 8.7 mmol/L (non-hemolyzed), serum bicarbonate 23 mmol/L, glucose 98 mg/
dL. EKG showed widened QRS complex and he promptly received intravenous calcium 
gluconate and insulin. On physical exam his fistula was well-developed and had a harsh, 
pulsatile bruit. He underwent an emergent, 4-hour HD session with 2K dialysate, blood 
flow of 400 mL/minute, and dialysate flow of 800 mL/min. Labs 4 hours after HD showed 
serum potassium 6.1 mmol/L. Reflux fistulography showed no stenosis at the anastamotic 
segment. Given recurrent hyperkalemia despite an additional 3.5 hours of HD the following 
day, the case was reviewed with Interventional Radiology and variable contrast densities 
were noted along different fistula segments. Repeat fistulography via retrograde access was 
obtained, during which a wire and catheter were advanced across the anastomosis, placing 
the catheter retrograde in the brachial artery prior to infusing contrast. A hemodynamically 
significant anastomotic and juxta-anastomotic narrowing was identified and successfully 
treated with angioplasty. Back pressure generated by reflux angiography masked the 
stenoses that were apparent when retrograde approach was utilized. After another 4-hour 
HD session, the patient’s hyperkalemia resolved.
Discussion: Thorough assessment of the HD vascular access includes both physical 
and radiological data. Retrograde arterial catheterization and angiography in a dialysis 
access circuit provides better physiologic imaging when stenosis is suspected at the 
anastomosis and/or juxta-anastomotic segment. This case illustrates the importance of 
correlating clinical and physical examination data with subtle angiographic findings and 
raises awareness among nephrologists of potential pitfalls in the diagnosis and management 
of HD access failure with important patient safety implications.
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Arteriovenous Fistula (AVF) Pseudo-Stenosis
Robert Valleau,1,2 David J. Leehey,2 Mohamed A. Rahman,3 Aparna Natarajan,1,2 
Julia Schneider.1,2 1Nephrology, Loyola University Medical Center, Maywood, 
IL; 2Hines VA Hospital, Hines, IL; 3Nephrology Associates of Northern IL, Elk 
Groove Village, IL.
Introduction: Pseudo-stenosis of an AVF has not yet been described in the literature, 
though it has been noted in the coronaries. It is the false visual appearance of stenosis seen 
during interventions involving the use of guidewire.
Case Description: Patient 1. 81-year-old male with a brachio-basilic AVF was 
referred for a fistulogram for high venous pressures noted during dialysis. A fistulogram 
with guidewire insertion and contrast injection showed multiple areas of apparent stenosis 
of the basilic vein. After retraction of the guidewire and repeat contrast injection, these 
areas of apparent stenosis were no longer observed. Patient 2. 83-year-old male with a 
brachio-cephalic AVF was referred for a fistulogram because of arm pain. A fistulogram 
with guidewire insertion and contrast injection showed high-grade stenosis at the cephalic 
arch which was sucessfully dilated with a balloon. Distal to the area of stenosis, the cephalic 
vein appeared tortuous with multiple areas of stenosis seen while the guidewire was in place 
(Fig1). Once the guidwire was removed and contrast re-injected, these areas of apparent 
stenosis were absent (Fig2).
Discussion: Pseudo-stenosis (accordion effect) is well-described in the coronary 
arteries and is characterized by pseudo-narrowing of the coronary vessels which disappears 
after guidewire withdrawal. Although the exact mechanism is unclear, the theory is that 
advancing a guidewire, thereby shortening a tortuous artery, induces folds of the vessel 
wall which creates the false impression of narrowing. This phenomenon has not previously 
been reported in an AVF. It is important to recognize this phenomenon to avoid unnecessary 
interventions.
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Airway Compromise and Failed Extubation Due to Central Venous 
Stenosis in a Hemodialysis Patient
Karthik Kovvuru. Nephrology, University of Mississippi Medical Center, 
Jackson, MS.
Introduction: Central Venous Stenosis (CVS) in hemodialysis (HD) patients is 
common and is not always easy to manage. We encountered a patient who presented with a 
unique complication of central venous stenosis.
Case Description: 57 Yr old Female pt with HIV and ESRD on HD for more than 
eight years via left AV fistula presented to the hospital for large bloody bowel movement 
and hypotension (80/50). She was given a liter of fluid and three units of red blood cells 
with improvement of blood pressure to (110/70). She was admitted to floor and started on 
maintenance IV fluids at 75cc/hr. Dialysis was held for two days due to stable labs, clinical 
euvolemia and borderline blood pressures. Pt developed shortness of breath, difficulty 
breathing and got intubated. During intubation it was noted that pts airway was swollen, 
angioedema was clinically diagnosed and started on Rx. Chest x ray did not show any fluid 
in the lungs and she continued to remain clinically euvolemic other than swollen face and 
left arm. No precipitant for angioedema could be found and the swelling did not resolve with 
medical treatment. CT scan of the chest was performed which showed subcutaneous edema 
throughout the neck bilaterally (left greater than right), subcutaneous edema of upper chest 
wall, mucosal edema of base of tongue and supraglottic larynx, Extensive collateral venous 
vessels in left anterior upper chest with narrowing of brachiocephalic vein. Angiogram 
showed occlusion at the level of left brachiocephalic vein which was difficult to open. Left 
arm AV fistula doppler showed wide patency with flow of 2.4 Liter per min. Pt was trached 
and weaned off ventilator after aggressive removal of volume with help of midodrine and 
cold dialysate. However she could not be decannulated due to persistence of edema from 
CVS. After 8 months of hospital stay she was sent to hospice care.
Discussion: Our patient developed upper airway edema secondary to CVS and high 
flow AV fistula on the same side. The volume resuscitation she received for GI bleed 
resulted in worsening airway edema leading to intubation. Once intubated the positive 
pressure in the chest cavity will decrease venous return worsening the airway edema leading 
to failed extubation. CVS should be considered as potential cause of airway edema and 
failing extubation in hemodialysis patients.
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Potential Anaphylactic Shock Related to Tunneled Hemodialysis Catheter 
Material
Andrew B. Elliott,1 Fredrik Jenssen,1 Neville R. Dossabhoy,2 Tibor Fulop,1 
Waleed Asfar.1 1Medical University of South Carolina, Charleston, SC; 
2LSUHSC-Shreveport, Shreveport, LA.
Introduction: We report a most concerning case of likely allergic reaction related to 
tunneled dialysis catheter (TDC) polyurethane material, manifesting with anaphylactic 
shock and culminating in the patient’s death.
Case Description: The index case of a 57-year-old male veteran with end-stage 
renal disease, diabetes mellitus, obesity, and sleep apnea had been receiving in-center 
maintenance hemodialysis for nine years. Due to an interval left arterio-venous upper 
extremity fistula malfunction, he received a tunneled dialysis catheter (TDC) [major 
manufacturer; 23 cm, 14.5 French dual-lumen catheter] in the right internal jugular position. 
Of note, this was his first catheter access. Shortly after TDC placement, he complained 
of diffuse and severe itching; however, no hives or respiratory difficulties were observed. 
Approximately 12 hours after TDC placement, he presented for his scheduled chronic 
dialysis. Immediately after start (1-2 min), he complained of intolerable whole body itching 
and requested termination of treatment; blood was not returned. Diffuse swelling of the 
tongue and face was observed with almost immediate full-blown hemodynamic collapse 
and cardiovascular arrest. A prolonged resuscitation attempt failed. Subsequent autopsy 
revealed severe cardiomegaly and atherosclerosis, but no clear or competing immediate 
cause of death. An extensive investigation of dialysis machine and water supply ruled out 
bacterial or chemical contamination. No other patients experienced any problems in the 
unit. Aside from the catheter use in this patient, there was no technological change in the 
facility (filter, sterilization) and his dialysis prescription was unchanged. An institutional 
Root Cause Analysis was also performed, which failed to disclose any other competing 
cause for cardiovascular arrest.
Discussion: To our knowledge, this is the first report of possible anaphylactic shock 
related to TDC polyurethane material. Diffuse itching soon after TDC placement (not 
related only to insertion site) should raise clinical suspicion and may indicate risk of 
hemodynamic collapse after blood starts flowing through the catheter. Also it is important 
to consider other entities that may cause allergic reaction that has not been discovered in 
this setting and possible differences in cleaning of VA dialysis machines vs other outpatient 
units to see differences arise.
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Volume of Distribution in a Severely Underweight Female Is Better 
Approximated by Ideal Body Weight Than Actual Body Weight
Benjamin Griffin,1 Joao P. Teixeira,1 Sophia L. Ambruso,1 Stuart L. Linas,1 
James F. Dylewski.2 1University of Colorado, Aurora, CO; 2University of 
Colorado Hospital, Aurora, CO.
Introduction: Guidelines recommend that patients treated with continuous renal 
replacement therapy (CRRT) be delivered an effluent dose of 20-25 mL/kg/hr. There is 
debate, especially at the extremes of BMI, as to whether actual, adjusted, or ideal body 
weight (IBW) should be used in these dose calculations.
Case Description: The patient is a 50 year-old woman with a history of anorexia who 
was admitted with altered mental status. Initial vital signs were significant for weight of 27 
kg, BMI 10.1 kg/m2, and BP 70/34 mmHg. Labs showed lactate 21 mg/dL, bicarbonate 
(HCO3
-) 2 mmol/L, and creatinine 2.1 mg/dL. Arterial blood gas (ABG) showed an initial 
pH 6.55, PCO2 32 mmHg, and calculated HCO3
- 3 mg/dL. Protocolized sepsis management 
was initiated, and she was intubated. Shortly thereafter, she became anuric and was 
initiated on CRRT. The initial dialysate dose, prescribed using actual weight, was 800 ml/
hr. Labs 2 hours later revealed pH 6.84, pCO2 10 mmHg, and calculated HCO3
- 3 mg/dL. 
 The dialysate dose, recalculated using her IBW of 58 kg, was increased to 1750 ml/hr. 
Six hours later, pH was 6.83 with calculated HCO3
- 3 mg/dL. Lactate remained elevated at 
20 mg/dL. Her CRRT prescription was changed to 1500 mL/hr of dialysate with 250 mL/hr 
of post-filter concentrated bicarbonate solution (6 ampules in 1 L of water or 300 mEq/L of 
sodium bicarbonate). After 4 hours, pH was 7.39, pCO2 was 15 mmHg, and measured serum 
HCO3
- was 9 mg/dL. Sodium had risen from 143 to 147 mmol/L. Notably, lactate remained 
elevated at 18 mg/dL. When using appropriate formulas to estimate the expected rate of 
change in sodium and bicarbonate and comparing to the observed changes, the effective 
volumes of distribution were those of a typical patient with a weight in the range of 55 – 
70 kg, in line with her IBW. Ultimately the patient was found to be surreptitiously taking 
metformin (later confirmed with serum testing). Her acidosis resolved with 48 hours of 
CRRT and she was transferred to the floor the next day.
Discussion: This case illustrates the challenges of dosing CRRT in severely 
underweight patients and suggests that IBW, rather than actual body weight, gives a better 
approximation of the volumes of distribution of sodium or bicarbonate and therefore may 
be more appropriate for dosing of CRRT.
FR-PO652 Poster Friday
Trainee Case Reports - IV
Does a Very High Nephrocheck Level (Above 10) Predict the Need of 
Early RRT?
Sanjeev Gupta,1 Anastasios Papanagnou,2 Savneek S. Chugh.3 1Westchester 
county medical center, White Plains, NY; 2Westchester Medical Center, Bayside, 
NY; 3New York Medical College, Hartsdale, NY.
Introduction: Studies have shown that elevated levels of TIMP-2 (tissue inhibitor of 
metalloproteinase) and IGFBP7 (insulin-like growth factor binding protein) predict AKI 
early on compared to other biomarkers, and early intervention can prevent AKI or its 
progression. It is, however, unknown if elevated levels of these biomarkers can predict the 
need for RRT. We present two cases of high Nephrocheck levels (above 10) who required 
RRT within 24 hours.
Case Description: (1) 51 y/o woman with a PMH of DVT and DM-2 was transferred 
to our hospital with complaints of nausea, dizziness, and abdominal pain. She was found 
to have wide complex tachycardia; she was subsequently cardioverted and started on 
amiodarone, as well as lidocaine drip. 2D Echo showed an EF of 10% with SBP in the 
80s. Emergent cardiac catheterization did not reveal any CAD; an IABP was placed and 
the patient was transferred to our facility for ECMO placement. Her BUN/Cr initially was 
20/0.91 which increased to 33/3.3. Nephrocheck was performed showing a level of more 
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than 10; her Cr worsened the following day and the patient became anuric; CVVHD was 
started. (2) 52 y/o woman with a PMH of sickle cell disease and asthma was transferred to 
our hospital for further management of septic shock. On admission, her Cr was 1.5 which 
worsened to 2.3. Nephrocheck was done showing a level of more than 10; the patient was 
placed on HD shortly thereafter.
Discussion: Nephrocheck has a high negative predictive value, ruling out potential AKI 
if the value is negative; however, it has a low positive predictive value. A high Nephrocheck 
level is indicative of significant kidney injury; however, no studies have been done, thus far, 
examining the correlation between a high Nephrocheck level predicting the need for early 
or late RRT. Both of our patients with Nephrocheck levels above 10 required RRT within 
24 hours of admission. Therefore, Nephrocheck can be used an early surrogate marker of 
kidney injury, seen prior to elevations in serum Cr; this data can be helpful to triage the 
patients with severe AKI requiring RRT.
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Hemodialysis for Urea Cycle Disorder Associated Hyperammonemia -  
Does It Have a Role?
Angel F. Delgado Garrastegui,1 Agustin G. Velazquez perez,2 Apoorva Cheeti,4 
Bharat Sachdeva,3 Neeraj Singh.5 1LSU Health Shreveport, Shreveport, LA; 
2LSU health shreveport, Shreveport, LA; 3Lousiana State University - Shreveport, 
Amritsar, India; 4Willis-Knighton Health System, Shreveport, AL; 5LSU Health 
Sciences Center, Shreveport, LA.
Introduction: Hemodialysis for hyperammonemia is rarely performed. We report a 
patient who presented with acute encephalopathy, nausea and vomiting associated with 
elevated levels of serum ammonia and normal hepatic workup and responded only to 
hemodialysis.
Case Description: A 20 year old Caucasian male with no significant past medical 
history presented with nausea, vomiting and altered mental status of one day duration. 
On admission, his vitals were stable and examination was unremarkable except for 
disorientation. Laboratory work-up revealed normal CBC and BMP and liver function tests 
except for elevated serum ammonia at 144 mmol/L (normal11-32mmol/L): Head CT, EEG 
and CSF fluid analysis were negative. Further liver work up including hepatitis panel, HIV 
screen, alfa-feto-protein, calcinoembrionic antigen, smooth muscle ab, alpha-1 antitrypsin, 
anti-mitochondrial ab, antinuclear ab, ceruloplasmin level, hemochromatosis panel, liver 
ultrasound and a liver biopsy was normal. On admission, patient was started on intravenous 
fluids, vitamin B12, lactulose, rifaximin and protein restriction, but failed to respond and 
serum ammonia levels trended up to 275 mmol/L on day 3. He was initiated on hemodialysis 
and underwent a total of 2 dialysis sessions with reduction in ammonia levels to <9umol/L 
and improvement in mentation by day 5. The urine organic acid gas chromatography test 
showed highly elevated orotic and uracil levels suggesitive of a urea cycle defect, possibly 
OTC (ornithine transcarbamylase deficiency), citrullinemia, argininosuccinic aciduria, 
argininemia or Hyperammoninemia-Hyperornithinemia-Homocitrullinuria syndrome. 
Genetic testing was negative for the most common mutations but did not rule out a urea 
cycle defect. The patient was discharged on L carnitine, lactulose and a low protein diet and 
has not had a recurrent episode of hyperammonemia till last follow-up.
Discussion: Serum Ammonia is a small molecule, with a molecular weight less than 
that of urea and as such its clearance by a dialyzer membrane is greater than the clearance 
rate for urea. Hemodialysis can be effectively utilized to treat hyperammonemia associated 
with urea cycle defect in medically refractory cases.
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Back from the Cold!
Sandeep Padala, Muhammad O. Saleem, Azeem Mohammed. Augusta 
University, Augusta, GA.
Introduction: Continuous Renal replacement therapy (CRRT) can modulate core body 
temperature through modulation of the replacement fluid temperature. Although this has 
been theorized to be helpful in hypotension, there are no guidelines for a temperature setting 
during CRRT. We present a case where maintaining an optimal temperature during CRRT 
was of paramount importance to the overall patient management.
Case Description: A 32-year-old African American male presented to the emergency 
room with recurrent syncope and was notably pale and lethargic on arrival. Lab tests revealed 
hemolytic anemia with hemoglobin of 3.3 g/dL, LDH of 991 U/L, haptoglobin of 1 mg/dL, 
positive C3 and total bilirubin of 4.3 mg/dL. A peripheral smear showing severe anemia, 
prominent agglutination and several granulocytes containing intracytoplasmic cryoglobulins 
was conclusive for cold agglutinin disease. Although steroids and plasmapheresis were 
started, patient’s condition worsened with the development of multiorgan failure, shock 
and oliguric renal failure from acute tubular necrosis. We instituted emergent initiation of 
CRRT for correction of malignant hyperkalemia and acidosis in the setting of hemodynamic 
instability. Patient underwent 5 days of CRRT with concomitant plasmapheresis. To assist 
with the overall therapeutic warming strategy, the Replacement fluid was heated on an 
external heating device and via the CRRT machine to the maximum temperature of 38 C. 
He improved significantly with resolution of acidosis, and electrolyte derangements; he 
ultimately required rituximab to truncate the autoimmune hemolytic anemia. A repeat cold 
agglutinin assay confirmed IgG+ cold agglutinin disease with a positive Mycoplasma IgM 
thought to be the likely trigger of the autoimmune hemolytic anemia.
Discussion: This case provides a unique perspective on temperature control during 
CRRT. Typically, cooling of dialysate or replacement fluid is used to bolster blood pressure 
in times of hemodynamic shock. In this setting, the reverse was utilized as a therapeutic 
benefit. While often overlooked as a part of the routine CRRT order set, this case highlights 
the important impact that temperature modulation can have on overall patient management, 
and should be carefully considered when approaching the CRRT prescription.
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Emergent Hemodialysis: Not Only for AKI
Emmanuelle Cordero Torres, Loay H. Salman, Rafia I. Chaudhry, 
Mauricio Monrroy. Albany Medical Center Nephrology and Hypertension 
Albany Medical College, Albany, NY.
Introduction: Severe hypothermia, i.e. core body temperature <28°C, is associated 
with a mortality rate of 50% despite optimal medical care. Commonly used external and 
internal rewarming techniques may not be effective in achieving the desired core body 
temperature, and more invasive rewarming modalities i.e. extra corporeal membrane 
oxygenation (ECMO) and cardiopulmonary bypass (CPB) are not available in all 
institutions. Hemodialysis (HD) is a safe, effective, and readily available option for the 
emergent management of hypothermia when conventional techniques have failed.
Case Description: A 78-year-old woman found unconscious, was airlifted to our 
institution with severe hypothermia (core body temperature of 28°C). She was unresponsive, 
requiring intubation for airway protection. Initial vital signs included BP 167/87 HR 40 RR 
18 T 28°C. External rewarming with thermal blankets, and internal rewarming with 40 °C 
NS infusion resulted in increase in core body temperature from 28°C to 31°C over 5 hours. 
The patient remained unresponsive and bradycardic. Nephrology was consulted for role 
of extracorporeal renal replacement therapy in the setting of persistent hypothermia. We 
initiated hemodialysis via a right femoral HD catheter, with HD blood flow (Qb) of 300 
ml/min, dialysate flow (Qd) 600 ml/min, and dialysate temperature of 37°C. The achieved 
Qb was 250 ml/min. The patient’s core body temperature was monitored via bladder probe, 
and rose from 32°C to 36.5°C after 3 hours of treatment i.e. hourly increase of 1.5°C. She 
regained consciousness soon after HD was completed, and was extubated. Frostbite lesions 
were evident in fingers and toes, although no other sequela of hypothermia persisted. No 
further complications, including electrolyte abnormalities, developed during, and after 
rewarming with HD.
Discussion: Hemodialysis is an effective therapeutic option to improve core body 
temperature, after external and internal rewarming techniques have failed. The rate of core 
body temperature increase can be closely monitored, and the ability to adjust the dialysate 
temperature offers the advantage to achieve a safe rate of correction (0.5 to 2°C). Timely 
rewarming can minimize duration and severity of adverse events including bradycardia and 
QT prolongation, which may result in a cardiac arrest if untreated. Furthermore, possible 
electrolyte derangements are simultaneously addressed with HD.
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Adverse Events During Hemodialysis in HeartWare LVAD Recipients
Tapati Stalam. University of Maryland Medical Center, BALTIMORE, MD.
Introduction: Over the past decade, implantable left ventricular assist devices have 
become an acceptable alternative to support patients with advanced heart failure, either 
as a bridge to transplantation or as destination therapy for patients who are not candidates 
for heart transplantation. As the number of LVAD implantation increases, greater number 
of LVAD recipients requiring long term renal replacement therapy, usually chronic 
hemodialysis (HD), will be seen. This is due to common simultaneous chronic kidney 
disease in patients with heart failure, but more frequently due to irreversible acute kidney 
injury occurring in the peri-implantation period. We looked at 92 HD sessions in HeartWare 
LVAD recipients between 2015 and 2017 and assessed adverse events requiring early 
termination of HD sessions.
Case Description: Between 2015 and 2017 at the University of Maryland Medical 
Center, 7 patients required HD after LVAD implantation. These 7 patients had a total of 
92 HD sessions during their hospitalizations. The average age of the patients was 46 +/- 
11.9 years old. Two patients had ESRD and were on HD prior to LVAD implantation. The 
remaining 5 patients had CKD but were not on HD. The pre-LVAD creatinine average for 
all 7 patients was 2.55 +/- 1.8. After LVAD implantation, all of the patients were initially 
on continuous renal replacement therapy before being transitioned to HD. During HD all 
patients were on midodrine, vasopressors, or fludrocortisone to help increase blood pressure. 
There were 7 HD sessions that required early termination due to symptomatic hypotension 
(3), asymptomatic hypotension (2), sinus tachycardia and cramping and discomfort. The 
average duration of all HD sessions was 172 minutes and the average duration of HD 
sessions that were terminated early was 148 minutes.
Discussion: 7 out of 92 sessions required early termination and the most common 
reasons (5 out of 7) were related to hypotension. Complications related to blood pressure 
was also found to be the most common reason for termination of HD in a previous study 
of HD sessions in Heartmate LVAD patients. As a result of continuous-flow technology, in 
most LVAD recipients, there is an absence of pulse, precluding the standard assessment of 
blood pressure and making assessment of blood pressure during dialysis difficult. There 
needs to be more research on how to address this in addition to how to optimize and change 
LVAD settings during HD sessions.
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Full Vessel and Empty Chambers: Volume Management in a Patient with 
Total Artificial Heart
Maria Andrievskaya, Stanley Frinak, Jerry Yee, Junior Uduman. Division of 
Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI.
Introduction: Total Artificial Heart (TAH) is a pulsatile device that is FDA approved 
as a bridge to transplant among individuals with biventricular failure. Renal failure 
requiring renal replacement therapy (RRT) is seen in 15 to 20% of these patients. Given the 
mechanical constraints of these devices, volume management in dialysis dependent patients 
is challenging as they are prone to deleterious effects of volume overload and contraction. 
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We describe the use of blood volume monitor as a tool to guide ultrafiltration management 
in a patient with TAH.
Case Description: A 50 year-old male with non-ischemic cardiomyopathy was 
admitted with decompensated biventricular failure and acute kidney injury (AKI) requiring 
RRT. He was evaluated for advanced heart failure therapies. His hospital course was 
prolonged with multiple cardiac and medical complications warranting percutaneous 
cardiac support devices. He was eventually listed for heart-kidney transplantation and 
underwent TAH implantation as a bridge to transplant. The ventricular chambers of the 
TAH have limited pre-load capability, thus 6 to 7 days a week of dialysis therapy has been 
a requirement to avoid volume overload. Similarly, excess ultrafiltration can also lead to 
unstable hemodynamics. Four months post-operatively the patient remained on a step-down 
inpatient unit, without invasive hemodynamic monitoring capabilities, while awaiting organ 
transplantation. It was difficult to maintain an adequate fluid balance without additional 
hemodynamic monitoring. In addition to fill volumes reported on the patient’s TAH 
monitor, (Companion 2 Driver- SynCardia) blood volume monitoring with the Crit-line 
IIITM was utilized for real time fluid management. Each dialysis treatment was 3-3.5 hours 
duration with ultrafiltration of 2-3 liters per session. The average blood volume change was 
between -7 to 8%, allowing safe ultrafiltration without untoward hemodynamic instability.
Discussion: A clinical trial for TAH as destination therapy is currently underway 
and more widespread adoption of TAH is likely. Understanding the mechanics and 
hemodynamic effects of TAH is important for nephrologists caring for dialysis dependent 
patients. This index case describes the feasibility and utility of employing a blood volume 
monitor to assist in safe volume management.
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Intraperitoneal Filling Transiently Decreases Hepato-Splanchnic 
Perfusion During Regular Peritoneal Dialysis
Werner Ribitsch, Thomas A. Lehner, Notburga Sauseng, Alexander 
R. Rosenkranz, Daniel Schneditz. Medical University of Graz, Graz, Austria.
Background: Peritoneal dialysis (PD) is considered a hemodynamic more tolerable
treatment mode compared to hemodialysis (HD). However, during PD intra-abdominal 
pressure (IAP) reaches values close to intra-abdominal hypertension (IAH, defined as 
IAP>12 mmHg) known to cause local venous congestion. It was the aim to investigate 
whether a standardized PD filling reduced hepato-splanchnic blood flow (Qh).
Methods: Measurements were done during a peritoneal equilibration test (PET) with 
2L of 2.27% glucose dialysate. Subjects remained fasting and assumed a supine body 
position throughout the duration of the study. Data were obtained in the drained state at 
baseline (T0), immediately after instillation of dialysate (T1), as well as 2 h after instillation 
(T2). IAP was measured by Durand’s approach. Qh was determined from kinetics of 
indocyanine-green (ICG) dye venously injected and transcutaneously measured by pulse-
dye-densitometry (DDG-2001, Nihon-Kohden, Japan). Mean arterial pressure (MAP) and 
total peripheral resistance (TPR) were derived from continuous arterial pulse analysis 
(Finometer, Finapres Medical Systems, The Netherlands). Plasma glucose (G) and insulin 
(I) concentrations were measured by standard techniques. Variables obtained at T0, T1, and 
T2 were compared by non-parametric Friedman-test.
Results: Ten patients (58.6±14.8 years; 87.5±18.8 kg dry body mass; 172±9 cm; 8 
male; 8 non-diabetics) were studied after a 13.9±4.3 h fasting period. IAP increased after 
filling and remained elevated (Tab. 1). Qh fell by about 13.4±17.6% at T1 but returned close 
to baseline values at T2. MAP increased at T1 and T2. TPR (in peripheral resistance units, 
PRU) remained unaffected.
Conclusions: The increase in IAP during PD causes a small and transient decrease in 
Qh. The subsequent rebound coincides with the absorption of glucose and is likely due to 
the vasodilatory effects of glucose and insulin which appears to compensate for the pressure 
induced flow congestion in the splanchnic circulation.
Table 1
*p<0.05, **p<0.01, ***p<0.001
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Prevalence and Prognosis of Coexisting Frailty and Cognitive Impairment 
in Continuous Ambulatory Peritoneal Dialysis Patients: A Prospective 
Cohort Study from a Single Center in China
Chunyan Yi, Xiao Yang, Xueqing Yu. Nephrology, The First Affiliated Hospital, 
Sun Yat-sen University, Guangzhou, China.
Background: The aim of this study was to investigate the prevalence of coexisting 
frailty and cognitive impairment as well as its association with clinical outcomes in 
continuous ambulatory peritoneal dialysis (CAPD) patients.
Methods: Patients on CAPD from January 1, 2014 and December 31, 2016 were 
recruited. Frailty was assessed by clinical frailty scale (CFS), and cognitive function was 
assessed by the Montreal Cognitive Assessment (MoCA). All patients were followed up 
until cessation of PD or December 31, 2017.
Results: A total of 880 CAPD patients were recruited, with a median vintage of 
PD 24.9 (6.0-52.4) months. The mean age was 48.5±14.6 years, 352 (40%) patients 
were female and 147 (26.7%) patients with diabetic nephropathy. Coexisting frailty and 
cognitive impairment was present in 205 (23.3%) patients. Pathway models showed that 
CFS score was negatively associated with MoCA score (β=-0.14, P<0.001); diabetes 
mellitus and cardiovascular disease are positively associated with CFS score (β=0.14, 
p<0.001; β=0.12, P<0.001) while negatively associated with MoCA score (β=-0.14, 
p<0.001; β=-0.08, P<0.01); serum albumin was negatively associated with CFS score 
(β=-0.09, P<0.01) while positively associated with MoCA score (β=0.05, P<0.05). 
Coexisting frailty and cognitive impairment was associated with increased mortality (HR 
2.34; 95% CI 1.16-4.72; P<0.05) and had higher peritonitis rate (0.22 vs. 0.11 episodes per 
patient year, P<0.05).
Conclusions: Coexistence of frailty and cognitive impairment was common in CAPD 
patients, which increased the risk of adverse outcomes. A significant relationship between 
frailty and cognitive impairment was demonstrated.
Funding: Government Support - Non-U.S.
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Peritoneal Dialysis in the Elderly: An Opportunity Not to Miss
Jakob D. Ohman, Vivian Gama, Tripti Singh, Brad C. Astor, Sana Waheed. 
University of Wisconsin School of Medicine and Public Health, Madison, WI.
Background: End Stage Renal Disease (ESRD) prevalence is steadily increasing in 
the United States with 700,000 patients currently requiring some form of renal replacement 
therapy, with a steeper increase in prevalence in the older population (age > 65 years). The 
rate of peritoneal dialysis (PD) utilization in the US is low at 7% of the ESRD population. 
The aim of this study is to find the rate of utilization of PD in older patients and examine 
the outcomes of PD compared to hemodialysis (HD) in old patients segmented into 
chronological age groups in order to study modality-based survival as age advances.
Methods: We utilized the United States Renal Data System (USRDS) to track the 
survival of patients with ESRD who started dialysis between 2001-2014. Survival of 
patients on PD and HD was compared in three age groups: age 65-74, age 75-84, and age 
>85. Comparisons of PD and HD were adjusted for sex, year of initiation of dialysis and
number of comorbidities, and mortality rates were calculated.
Results: A total of 743,229 patients were analyzed in the 3 different age categories. 
Prevalence of PD use was lower as age progressed, with 6%, 4%, and 3% of patients 
using PD in the three age groups: 65-74 (N=21,776), 75-84 (N=11,978), >85 (N=2,426), 
respectively, (Table 1). PD was associated with lower mortality compared to HD across all 
age groups after adjustment for sex, race and number of comorbidities, (Table 2).
Conclusions: PD is underutilized in the older population but overall is associated with 
a lower mortality in these patients. Despite comorbidity adjustments, it is possible that PD 
patients are inherently healthier than HD patients. However, the results of this study should 
encourage providers to strongly consider PD as an option in older patients.
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Prevalence and Outcome Impact of Depression and Frailty Among 
Peritoneal Dialysis Population in a Local Dialysis Centre
Gordon C. Chan,2 Cheuk-Chun Szeto.1 1The Chinese University of Hong Kong, 
Shatin, China; 2Prince of Wales Hospital, Hong Kong, China.
Background: Depression and frailty are increasingly being recognized as contributing 
factors to the adverse clinical outcome of peritoneal dialysis (PD) patients. Depressed patients 
have multiple physical and psychological symptoms, and have poor adherence to dialysis 
and medical therapy. Frailty refers to a state of increased vulnerability caused by decline 
in physical reserve and function, and is caused by malnutrition, chronic inflammation, and 
repeated infection. However, the interaction between depression and frailty in PD patients 
remains uncertain. We determine the prevalence of depression and frailty in prevalent PD 
patients. We further dissect the internal relationship between depression and frailty, and 
their relative contribution to the adverse clinical outcome in PD patients.
Methods: This is a prospective observational study. We recruited 267 prevalent PD 
patients between 2015 and 2016. Depression was identified by Patient Health Questionnaire 
(PHQ-9). Frailty was identified by a validated Frailty Score. All cases were followed for one 
year. Outcome measures included number and duration of hospitalisation, peritonitis rate, 
and all-cause mortality.
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Results: Of the 267 patients, 197 patients (73.8%) were depressed, and 157 (58.8%) 
were frail. There was a substantial overlap between depression and frailty. Although 
depression and frailty were associated the number and duration of hospitalisation by 
univariate analysis, the association became insignificant after adjusting for confounding 
factors by multivariate analysis. Both depression and frailty were associated with one-year 
mortality by univariate analysis, but only frailty was an independent predictor of patient 
survival by multivariate analysis (adjusted hazard ratio 1.424, 95% confidence interval 
1.011-2.005. p = 0.043).
Conclusions: Depression and frailty were common among Chinese PD patients. 
Frailty, but not depression, was an independent predictor of one-year mortality. Further 
studies are needed to determine the benefit of treatment for frailty in PD patients.
Funding: Government Support - Non-U.S.
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Factors Affecting Selection of Dialysis Modality in Elderly Patients with 
CKD: Prospective Cohort Study of Korea
Jang-Hee Cho,1,2 Hee-Yeon Jung,1,2 Ji-Young Choi,1,2 Sun-Hee Park,1,2 Chan-
Duck Kim,1,2 Se-Hee Yoon,3,2 Yong-Lim Kim.1,2 Clinical Research Center for 
End Stage Renal Disease (CRC for ESRD) Investigators 1Kyungpook National 
University Hospital, Daegu, Republic of Korea; 2Clinical Research Center for 
End Stage Renal Disease, CRC for ESRD, Republic of Korea; 3Konyang 
University Hospital, Daejeon, Republic of Korea.
Background: Several factors associated with dialysis modality selection have been 
reported in many studies. However, the factors affecting selection of dialysis modality in 
elderly patients with chronic kidney disease is not known. We investigated which factors 
are associated with selection of dialysis modality in elderly patients compared to younger 
patients.
Methods: This study included 2,238 incident dialysis patients from a multicenter 
prospective cohort study in Korea from August 2008 to July 2015 (NCT00931970). We 
surveyed demographic, referral, dialysis planning, socioeconomic, and clinical data. Using 
multivariate regression analyses, variables significantly associated with the chosen dialysis 
modality were analyzed. The differences in the factors were compared between elderly (≥65 
years) and younger (<65 years) groups.
Results: Of the enrolled patients, 1,537 (68.7%) and 701 (31.3%) selected hemodialysis 
(HD) and peritoneal dialysis (PD) respectively. The percentage of HD was higher in elderly 
patients compared to younger patients (82.3% vs. 62.2%, p<0.001). In elderly group, 
patients choosing PD was younger than patients choosing HD (70.4±4.4 vs. 72.2±5.4, 
p<0.001). Patients with planned dialysis (p<0.001), employed status (p=0.042), married 
status (p=0.023), and congestive heart failure (p=0.003) were more common in elderly 
PD patients. However, patients with tumor were more common in elderly HD patients. 
Multivariate analysis showed that planned dialysis (p<0.001) and congestive heart failure 
(p=0.003) were independent factors for selecting PD and tumor (p=0.01) was for selecting 
HD in elderly group. In younger group, planned dialysis (p<0.001), employed status 
(p<0.001), and independent economic status (p=0.043) were revealed as the independent 
factors for choosing PD whereas peripheral vascular disease (p=0.019) and tumor (p=0.02) 
were independent factors for choosing HD.
Conclusions: As age of patients with chronic kidney disease increases, HD was more 
frequently selected modality than PD. Dialysis planning and specific comorbidities were 
associated with selection of dialysis modality in elderly patients. However, elderly patients 
were less affected by socioeconomic status compared to younger patients.
FR-PO663 Poster Friday
Dialysis: Peritoneal Dialysis - II
Barriers and Facilitators to Home Dialysis in Older Veterans: Perspectives 
from Patients and Caregivers
Michael J. Fischer,1,6 Lindsey A. Jones,3 Cindi Fiandaca,6 Timothy P. Hogan,4 
Bridget M. Smith,5 Elisa J. Gordon.2 1Jesse Brown VAMC, Chicago, IL; 
2Northwestern University, Chicago, IL; 3Department of Veterans Affairs, Hines, 
IL; 4Veterans Health Administration, Bedford, MA; 5Hines VA Hospital, Hines, 
IL; 6Edward Hines Jr. VA Hospital, Hines, IL.
Background: Home-based dialysis - hemodialysis (HD) or peritoneal dialysis (PD) 
– often confers greater survival and quality of life, and lower morbidity than in-center
hemodialysis for patients with end-stage renal disease (ESRD). However, home dialysis
is underutilized, especially among older adults. To understand this underutilization, we
assessed barriers and facilitators to home dialysis from the perspectives of older Veterans
and their caregivers.
Methods: Semi-structured telephone interviews were conducted and audio-recorded 
separately with Veterans receiving home dialysis through VA and their informal caregivers 
in five VA facility-based programs during 2017-2018. Transcribed interviews were analyzed 
using content analysis to identify themes emerging from the data.
Results: Out of 82 Veterans on home dialysis (78 PD, 4 HD), 63 (77%) had informal 
caregivers. We interviewed 20 Veterans (24% participation rate) and their 20 caregivers 
(32% participation rate). Most Veterans were male (100%), white (77%), with an average 
age of 64 years. Most caregivers were female (95%), white (78%), with an average age of 63 
years. Most Veterans (54%) believed that they needed their caregiver to assist in performing 
home dialysis. Key patient-level barriers included unsuitable home environment, lack of 
self-efficacy in administering home dialysis treatments, and physical disability. Important 
facilitators included having sufficient space at home, knowledge/training on performing 
home dialysis, and caregiver support. Significant caregiver-level barriers included 
unsuitable home environment, lack of self-efficacy in administering home dialysis 
treatments, and competing job duties. Common facilitators included personal devotion 
to the Veteran, knowledge/training of the home dialysis procedure, and VA dialysis staff 
support. Veterans and caregivers similarly supported interventions to foster home dialysis, 
including telemedicine applications and paid stipends for caregivers.
Conclusions: Informal caregivers play a key role in supporting home dialysis for older 
adults. Interventions should address both patient and caregiver barriers to increase use of 
home dialysis.
Funding: Veterans Affairs Support
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Association Between Receiving Public Assistance and Long-Term 
Peritoneal Dialysis Outcomes in Adults
Daisuke Komukai,1 Yutaka Nakajima,2 Hiroshi Kashiwaba,1 Takeshi Suzuki,1 
Ai Kato,1 Susumu Uda,1 Kanji Shishido.2 1Department of nephrology, Kawasaki 
Saiwai Hospital, Kawasaki, Japan; 2Kawasaki Clinic, Kawasaki, Japan.
Background: Public assistance (PA) in Japan is available as part of the financial support 
system for the poor. With the increasing number of elderly people living in households, 
the number of elderly people receiving PA has increased. Although the role of peritoneal 
dialysis (PD) is substantial in the treatment of end-stage renal disease (ESRD) in the elderly, 
the effects of the long-term PD on PA recipients remain unknown.
Methods: We reviewed medical records for 147 patients who had initiated PD between 
2005 and 2018 at Kawasaki Saiwai Hospital and had remained in care at a related facility. 
We examined patient characteristics, including age, sex, ESRD etiology, and serum 
creatinine and albumin levels at the PD induction. Data on PD prescription and the method 
of connection were also collected. The long-term technical survival and peritonitis-free 
survival rates were calculated using Kaplan–Meier method, and predictors of technical and 
peritonitis-free survival were determined using Cox regression analysis.
Results: PD was initiated in 88 males and 59 females, of which 18 received PA. At the 
induction, mean patient age was 63.1 years and mean estimated glomerular filtration rate 
(eGFR) was 5.9 ml/min/1.73m2. In the Kaplan–Meier analysis, the overall median time 
for technical survival was 1158 days: 806 days for the recipients and 1357 days for non-
recipients. Although there was no statistical difference in the technical survival rate between 
the two groups, the outcome appeared to be unfavorable in the PA recipients. The peritonitis-
free survival was significantly shorter in the PA recipients than in the non-recipients. In Cox 
regression analysis, PA was associated with short technical [HR 2.16; 95%CI 1.06–4.40] 
and peritonitis-free survival [HR 3.13; 95%CI 1.55–6.34] after adjustments for age, sex, 
estimated GFR at the induction, the presence of diabetes, connection method, and the 
presence of people living together.
Conclusions: Receiving PA was associated with unfavorable technical survival 
outcomes and significantly poor peritonitis-free survival outcomes.
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Quality of Life and Emotional Distress Changes Between Peritoneal 
Dialysis Patients Versus Hemodialysis Patients and Their Families
Takeyuki Hiramatsu, Shota Okumura, Yuko Asano, Masatsuna Mabuchi, 
Katsuhiko Suzuki, Daiki Iguchi, Shinji Furuta. Konan Kosei Hospital, Konan 
Aichi, Japan.
Background: In Japan, hemodialysis (HD) is the most popular modality for the 
end stage renal disease (ESRD) patients. While, the number of peritoneal dialysis (PD) 
patients accounts for 2.8%. We investigated the reason of low PD penetration through the 
prospective assessment of quality of life(QOL) and emotional distress(ED) of patients and 
their families.
Methods: Fifty one incident patients (31 PD, 20 HD) were recruited. The SF-36 and 
CES-D were assessed in all patients and their families at the start of dialysis and every year 
for 2 years.
Results: The background characteristic was similar between two groups. The CES-D 
in PD was not changed, but was significantly increased in HD at 2 years. As for families, the 
CES-D results showed the same trend as patient’s. Summary of physical components and 
role of social components (RS) in SF-36 at 2 years in PD but not in HD revealed significant 
improvement,. The summary of mental components (MC) were not changed in both groups. 
But MC in PD were significantly higher than that in HD at 2 years. The summary of RS was 
significantly improved at 2 years in PD and retained higher than that in HD. In the family’s 
test, all SF-36 scores were not changed in PD, but MC was decreased in HD, followed 
significant lower at 2 years than in PD.
Conclusions: In this study, PD provided better QOL and ED due to preservation of 
residual renal function and lesser hospital visiting. However, HD is more prevalent in Japan 
instead of burdening the families. It might be considered that most Japanese tend to or 
depend on others and select HD modality. Moreover, ESRD patients were not well educated 
according to PD. Finally, it is important to inform patients of PD where PD provides better 
QOL and better effect on emotional change.
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table 1: QOL and ED change
*: p<0.05 vs at baseline, †: P<0.05 vs group HD
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Estimating Total Small Solute Clearance in Patients Treated with 
Continuous Ambulatory Peritoneal Dialysis Without Urine and Dialysate 
Collection
Li Fan,1 Dominik Steubl,2,11 Lesley Inker,2 Hocine Tighiouart,2 Amy B. Karger,6 
John H. Eckfeldt,7 Hao Zhang,8 Jing Hu,3 Yunhua Liao,9 Tariq Shafi,4 Wei Chen,10 
Xueqing Yu,5 Andrew S. Levey.2 1Department of Nephrology, The First Affiliated 
Hospital of Sun Yat-sen University; Key Laboratory of Nephrology, Ministry of 
Health; Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, 
China; 2Tufts Medical Center, Boston, MA; 3The third Xiangya hospital of 
Central South Univercity, Changsha, China; 4Johns Hopkins University School 
of Medicine, Baltimore, MD; 5Department of Nephrology, The First Affiliated 
Hospital, Sun Yat-sen University, Guangzhou, China; 6University of Minnesota, 
Minneapolis, MN; 7University of Minnesota Medical School, Minneapolis, MN; 
8The Third Xiangya Hospital of Central South University, Changsha, China; 
9The First Affiliated Hospital of Guangxi Medical University, Nanning, China; 
10The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 
11Nephrology, Klinikum rechts der Isar, Technische Universitaet Munich, 
Munich, Germany.
Background: Higher total (kidney plus dialysis) clearance of small solutes is associated 
with lower mortality in peritoneal dialysis (PD) patients. Measurement of total clearance 
(mCL) is recommended to monitor and adjust dialysis dose, but is difficult and prone to 
errors due to the requirement for timed fluid collections. We hypothesized that equations 
(eCl) could be developed to estimate mCl using serum concentrations of endogenous 
filtration markers.
Methods: Using 2/3 of the participants in the Guangzhou PD Study (N=980), we used 
linear regression to develop eCl equations. Reference tests were mCl for urea nitrogen 
(mClUN, ml/min) and average mCl for UN and creatinine (mClUN-cr, ml/min/1.73 m
2). 
Index tests were various eCl equations using UN, creatinine, low-molecular-weight-
proteins (LMWP) [beta-trace-protein (BTP), beta-2-microglobulin (B2M), cystatin C], 
demographic variables and body size. We validated the equations in the remaining 1/3 of the 
cohort (n=322) and refitted equations in the combined dataset. We analyzed the predictive 
value of the equations to detect a weekly total standard Kt/V (mClUN per week indexed for 
total body water) >1.7 using receiver-operating-characteristic curve.
Results: Mean age of the cohort was 50±15 years, 53% were male; mClUN was 6.9±1.8 
ml/min, mClUN-cr 7.5±2.8 ml/min/17.3 m
2. Creatinine but not UN contributed to eCl (Table). 
LMWP did not improve accuracy for mClUN (range 87.6-88.6%). BTP and B2M improved 
accuracy for mClUN-cr (range 81.6-82.0 vs. 79.7%), however, differences were small. The 
area-under-the-curve for predicting a weekly kt/V >1.7 was similar for all equations (range 
0.791-0.802).
Conclusions: Total small solute clearance can be estimated moderately well [TMC1] in 
CAPD patients from serum concentration of creatinine and demographic variables without 
urine and dialysate collection. Equations to estimate total clearance need to be evaluated 
in other cohorts.
Funding: Commercial Support - Siemens, Dialysis Clinic Inc., Private Foundation 
Support
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Factors Associated with Peritoneal Membrane Permeability in Patients 
Starting Peritoneal Dialysis
Paraskevi Tseke,1 Emilios Andrikos,3 Konstaninos Perrakis,9 Olga Balafa,6 
Vassilios Liakopoulos,2 Christine Melexopoulou,8 Chrhstos Katsinas,13 
Vasileios Margellos,4 Marios Theodoridis,11 Chrysostomos Dimitriadis,10 
Evangelia Dounousi,12 Theofanis Apostolou,4 Ploumis S. Passadakis,7 George 
I. Tsirpanlis.5 1General Hospital “Alexandra”, Athens, Greece; 2Nephrology, 
AHEPA, University Hospital, Thessaloniki, Greece; 3G.Hatzikosta General 
Hospital, Ioannina, Greece; 4“Ant. Mpilis” Nephrology Department 
Evaggelismos Hospital, Athens, Greece; 5Nephrology, G. Genimatas General 
Hospital, Athens, Greece; 6University Hospital, Ioannina, Greece; 7Democritus
University of Thrace, Alexandroupolis, Greece; 8Laiko Hospital, Ethniko
Kapodistriako University, Athens, Greece; 9University Hospital of Hrakleio,
University of Crete, Hrakleio, Greece; 10Ippokrateio Hospital of Thessaloniki,
Thessaloniki, Greece; 11Univesity Hospital of Alexandroupolis, Alexandroupolis, 
Evros, Greece; 12University of Ioannina, Ioannina, Greece; 13“Bodosakio”
General Hospital, Ptolemaida, Greece.
Background: Peritoneal membrane transport characteristics vary in peritoneal dialysis 
(PD) patients and have been related to patient and technique survival.
Methods: Data from PD patients from 10 PD units in Greece were retrospectively 
analyzed. Patients with a history of early catheter dysfunction or leakage were excluded. 
163 patiens (100 male and 63 female) were finally included, whose first PET test was 
performed within 2 months after PD catheter insertion. Patients were divided into 4 sub-
groups according to 4 hr D/P creatinine ratio; fast as 1SD above mean, average fast as 
between mean and mean+1SD, average slow as mean-1SD and slow as below 1SD from 
the mean. Ordinal regression analysis was performed to identify risk factors for faster 
membrane permeability.
Results: The median age of the study group was 58.2 (range 21-88) years. The etiology 
of ESRD was unknown in 26.5%, diabetes mellitus in 19.5%, hypertension/nephrosclerosis 
in 18%, glumerolonephritis in 17.2%, polycystic kidney disease in 10.5%. Gender and BMI 
did not differ significantly between sub-groups of patients (p>0.05). In univariate analysis 
age (p=0.02), the history of diabetes mellitus (p=0.03) and lipidemia (p=0.03), as well as 
hemoglobin (p=0.03) and albumin concentrations (p=0.01) were significantly different 
among the four sub-groups. In multivariate analysis only the presence of diabetes mellitus 
(OR=1.98, p= 0.045) and hemoglobin levels (OR: 0.76, p=0.01) were independently 
associated with higher membrane permeability.
Conclusions: Diabetes mellitus and anemia are independent predictors of membrane 
transport characteristics in patients starting PD.
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Risk Factors for Loss of Residual Renal Function During the First Year of 
Chronic Automated Peritoneal Dialysis (APD) in Children
Qian Shen.1,2 1Department of Nephrology, Children’s Hospital of Fudan 
univeristiy, Shanghai, China; 2Shanghai Kidney Development & Pediatric 
Kidney Disease Research Center, Shanghai, China.
Background: In chronic dialyzed patients, preservation of residual renal function is 
associated with better survival, lower morbidity, and greater quality of life. The aim of this 
study was to assess risk factors for loss of residual renal function (RRF) in children during 
the first year of chronic automated peritoneal dialysis (APD).
Methods: The study group included 56 children (33 boys and 23 girls, median 
age 9.58 years) with end-stage renal disease (ESRD) at Children’s Hospital of Fudan 
University from Jan 2008 to Dec 2015 who commenced APD as the initial method of renal 
replacement therapy for at least 12 months with significant initial residual renal function 
(daily diuresis more than 100ml/m2/day). Patient characteristics and potential risk factors 
of developing oligoanuria (under 100 ml/m2/day) including gender, BMI and age at APD, 
etiology of ESRD, baseline daily diuresis and residual glomerular filtration rate (rGFR), 
PD fluid volume, glucose load, ultrafiltration, peritoneal permeability, dialysis adequacy, 
blood pressure, biochemical parameters, medications used and dialysis-related peritonitis 
frequency were analyzed.
Results: 1. Mean diuresis before initiation of APD was 692.0±315.9 (mL/m2/day) and 
mean rGFR was 7.48±2.93 (mL/min/1.73 m2). An average decline of daily urine volume 
was 376.2±354.6 (mL/m2/day) in the first year of APD and 23 (41.14%) children became 
oligoanuria. 2. Risk factors associated with loss of RRF: Children who lost RRF during 
the first year frequently exhibited a lower baseline rGFR (P=0.02), were exposed to higher 
dialysate glucose (P<0.001), higher PD fluid volume (P=0.002) and achieved higher daily 
ultrafiltration volume (P<0.001). The use of RAS antagonists (ACEI/ARB) tended to 
increase the risk of becoming oligoanuria (P=0.003).
Conclusions: The important risk factors for rapid RRF loss in children during the first 
year of chronic APD include lower baseline rGFR, higher glucose load, higher PD fluid 
volume, higher ultrafiltration and administration of RAS antagonists.
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Dialysis: Peritoneal Dialysis - II
Simultaneous Optimization of Ultrafiltration and Solute Transport in 
Automated Peritoneal Dialysis (APD)
Karin E. Bergling,1 Anders P. Wieslander,2 Carl M. Öberg.1,3 Renal Physiology 
& Peritoneal Dialysis Group 1Department of Clinical Sciences, Lund University, 
Lund, Sweden; 2Baxter, Lund, Sweden; 3Lund University Hospital, Department 
of Nephrology, Lund, Sweden.
Background: In a recent study we found that the treatment with APD could be 
improved in terms of shorter treatment times and markedly (> 20%) lower glucose 
absorption using optimized bi-modal treatment regimens, combining cycles with a high 
glucose concentration and cycles using low or no glucose.
Methods: We further explored this novel concept in silico by using a sparse linear 
regression model with constraints to find the shortest possible treatment time given a set 
of clinical treatment goals. We created optimal regimes giving the same Kt/V urea and/or 
weekly creatinine clearance and UF as a standard (6 × 2 L 1.36%) and an adapted (2 × 1.5L 
1.36% + 3 × 3L 1.36%) regime.
Results: Compared to the non-optimized (standard and adapted, see Figure A) regimes, 
optimized regimes for creatinine (35 L/week; see Figure B and C) and UF (0.5 L/day) 
demonstrated marked reductions (up to 40%) in glucose absorption (G abs), having a 
similar sodium and phosphate removal (see Table). Optimizing for urea Kt/V (1.40 /
week; PD-only; see Figure A) and UF (0.5 L/day) leads to a slightly lower creatinine and 
phosphate removal but leads to a shorter treatment time. Larger fill volumes of 1200 mL/m2 
(UF cycles) and 1400 mL/m2 (Clearance cycles) can be applied to shorten the total treatment 
time.
Conclusions: These simulations suggest that great reductions in treatment time and in 
glucose absorption are possible using a novel optimization technique for APD prescription. 
Further studies are needed to evaluate the feasibility of these novel regimens.
Funding: Private Foundation Support
† PD only. ‡ optimized for urea Kt/V and UF, see text. * optimized for creatinine clearance 
and UF, see text.
Optimized APD
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A Time-Varying Analysis: The Relationship Between Serum Uric Acid and 
Residual Renal Function Loss in CAPD Patients
Yang C. Lun. zhong-shan university, Guangzhou, China.
Background: Residual renal function(RRF) is significantly associated with mortality 
and quality of life in peritoneal dialysis(PD) patients. A number of studies demonstrated 
that pre-dialysis serum uric acid(UA) was predictor of RRF loss in PD patients. However, 
the relationship between serum uric acid and RRF loss in patients over time are unknown.
Methods: This is a single-center, retroperspective cohort study. Total 201 CAPD 
patients who started PD between January1, 2008 and April 30, 2016 at the third affiliated 
hospital of Sun-Yat Sun University were eligible for the study with follow-up through 
December 31, 2016. Urine volume, biochemical and therapeutic information was collected 
within 1 month of PD commencement and at every 3-month intervals thereafter. Cox 
proportional hazard regression models and penalized splines analysis were employed to 
analyze the association between uric acid and RRF loss and to identify independent risk 
factors of RRF loss.
Results: During the period of first five years in PD, 86 patients became anuria. 
Multivariate Cox regression analysis showed that uric acid, 5-year peritonitis rate, 
ultrafiltration and phosphorous were independent risk factors of RRF loss while KT/V urea 
was a protective factor. Using Cox proportional hazard regression models and penalized 
splines analysis, when compared to patients with UA 403-455umol/L, patients with 
UA>455umol/L (HR=1.99, 95%CI 1.021-3.345; p<0.05) or UA<403umol/L (HR=2.12, 
95%CI 1.005-3.611; p<0.05), UA levels conferred a higher risk of RRF loss, while it 
showed a U-shaped relationship between continuous UA levels and RRF loss.
Conclusions: A U-shaped relationship between UA levels and RRF loss was found in 
patients over time. Uric acid, 5-year peritonitis rate, ultrafiltration, phosphorous, and KT/V 
urea were independent risk factors for RRF loss in CAPD patients.
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Early Complications of Urgent-Start Peritoneal Dialysis
Ying Wang, Haiyun Wang, Ying Ma, Yang Li, Bingyan Liu, Zijuan Zhou, 
Wei Yang, Xuemei Li, Limeng Chen. Peking Union Medical College Hospital, 
Beijing, China.
Background: Urgent-start peritoneal dialysis (PD) would be an effective option for 
patients need unplanned dialysis. However, the early catheter-related complications in 
urgent-start PD have not been well investigated and the previous results were inconsistent.
Methods: In this retrospective study, end stage renal disease (ESRD) patients were 
included if they were over 18 years old and received regular PD in our PD center between 
1 March 1996 and 30 September 2016. Urgent-start PD was defined as initiation of PD 
within 2 weeks of catheter insertion. The time from placement-to-PD was determined by the 
nephrologists based on the clinical condition of each patient. Patients were divided into two 
groups according to whether PD was started urgently or not. The outcome was mechanical 
and infectious complications and technique survival in the first 6 months.
Results: A total of 667 patients (203 urgent-start, 464 conventional-start) were included. 
The mean age of the study patients was 59.6±15.4 years old, and 49.8% of the patients 
were female. Diabetes was the primary cause of ESRD (36.1%) and was followed by 
glomerulonephropathy (25.6%) and hypertension (20.5%). The time from catheter insertion 
to PD initiation was 8.1±4.5 and 18.6±12.7 days in urgent-start and conventional-start PD 
group, respectively. Compared with conventional-start patients, urgent-start patients had 
lower serum albumin, Kt/v, Ccr and eGFR levels at the start of PD, and otherwise there was 
no significant difference between the two groups. The rate of mechanical complications at 
1 month, 3 months, and 6 months after PD commencement was 9.4%, 16.7%, and 18.2% 
in the urgent-start PD group, respectively. The rate of infectious complications at the same 
time points was 11.8%, 13.8%, and 20.7% in the urgent-start group. Technique survival was 
96.9% and 98.4% in urgent-start and conventional-start PD group, respectively. There was 
no difference in the rate of mechanical and infectious complications and technique survival 
between urgent- and conventional-start PD patients at either time point.
Conclusions: Urgent-start PD patients had similar rates of catheter-related 
complications and technique survival compared with conventional-start PD patients.
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Low-Volume Tidal Peritoneal Dialysis Is a Preferable Mode in Patients 
Initiating Urgent-Start Automated Peritoneal Dialysis
Jianteng Xie, Huizhen Wang, Jing Li, Tiantian Liang, Yanhui Wang, Yifan Zhang, 
Wenjian Wang. Division of Nephrology, Guangdong General Hospital, 
Guangdong Academy of Medical Sciences, GuangZhou, China.
Background: To evaluate the safety of low-volume tidal peritoneal dialysis (TPD) and 
intermittent peritoneal dialysis (IPD) in end-stage renal disease (ESRD) patients initiating 
automated peritoneal dialysis (APD) after an acute catheter insertion.
Methods: Clinical outcomes of patients who received either TPD or IPD using an APD 
system were compared in a randomized, open-label, prospective control study in a single-
center setting. From May 2011 to May 2013, 49 patients were enrolled and 27 patients 
received low-volume TPD treatment whereas 22 patients underwent low-volume IPD 
right after Tenckhoff catheter insertion. The incidence of complications during the 14-day 
APD treatment were observed. After APD treatment, all the patients were transferred to 
continuous ambulatory peritoneal dialysis (CAPD) and followed up for 2 years.
Results: The IPD group demonstrated a significantly high incidence of catheter-related 
complications than the TPD group after adjusting for age, gender, baseline diabetes, systolic 
blood pressure, and body mass index. However, the short duration of APD treatment with 
either IPD or TPD mode did not affect the long-time technical survival.
Conclusions: In patients immediately after catheter insertion, low-volume TPD 
mode demonstrated a lower incidence of catheter-related complications compared to 
IPD. However, definitive conclusions about TPD benefit cannot be made, owing to early 
termination of the trial.
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Patient characteristics at baseline.
The incidence of complications during 2-week APD treatment.
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Clinical Outcomes Associated with Peritoneal Dialysis Catheter Placement 
by Interventional Radiology
Gabrielle Côté,1 Yannick Begin,1 Mathieu Rousseau-Gagnon,2 Mohsen 
Agharazii,2 Fabrice Mac-Way.2 1Université Laval, Québec, QC, Canada; 2CHU 
de Quebec, Hotel-Dieu de Quebec Hospital, Quebec, QC, Canada.
Background: Fluoroscopy-guided peritoneal dialysis (PD) catheter insertion by 
interventional radiologist (IR) has been reported as an appropriate alternative to surgical 
insertion to increase access to PD. The objective of this study was to report clinical 
outcomes and complications associated with PD catheter insertion by IR.
Methods: We conducted a single-center retrospective study of all patients who had PD 
catheter insertion by IR from January 2014 to January 2018. The primary outcomes were 
to report the complications related to catheter insertion within the first 3 months and the 
number of active PD patients at 3 months. Secondary outcomes were to evaluate the impact 
on the prevalent number of PD patients and on the waiting time for PD catheter insertion.
Results: 56 patients with a median age of 55 years old (20-85) were included in this 
study. Patients with severe obesity (IMC>35), polycystic kidney disease and previous major 
surgery were not eligible for IR and were referred for laparoscopic insertion. Among these 
56 patients, 1 had kidney transplantation, 1 had renal recovery and 2 were deemed unable 
to learn the procedure. Therefore, 52 completed the training and began PD. Among these 
52 patients, 49 (94%) were on active PD at 3 months (catheter removed due to an acute 
intestinal perforation post-insertion (n=1), refractory peritonitis (n=1) and a pleural leak 
(n=1)). Within 3 months, catheter malposition occurred in 12 (21%) patients but only 3 of 
them needed surgical or IR repositioning. Three patients (5%) experienced peri-catheter 
leaks where PD was successfully restarted after temporary cessation for 4 weeks. Finally, 1 
patient developed peritonitis and 1 had exit site infection that were successfully treated with 
antibiotics. Since the introduction of this technique, the number of prevalent PD patients 
in our center increased from 60 to 84 while the average time for PD catheter insertion has 
decreased from 4.5 to 1.5 months.
Conclusions: Insertion of PD catheter by IR is associated with a low complication 
rate while it improves access to PD therapy. Its use should therefore be encouraged as an 
alternative to surgical placement in most patients.
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Peritoneal Dialysis After Renal Transplant Failure: A Different Beast 
Altogether
Vivian Gama,1 Jakob D. Ohman,1 Tripti Singh,1 Brad C. Astor,2 Sana Waheed.3 
1University of Wisconsin School of Medicine and Public Health, Madison, WI; 
2University of Wisconsin, Madison, WI; 3University Of Wisconsin School Of 
Medicine and Public Health, Madison, WI.
Background: The number of patients starting dialysis after graft failure (DAGF) 
has been steadily increasing in the United States. This population differs significantly 
from those with native End Stage Renal Disease (ESRD) and little is known about the 
outcomes of DAGF patients on peritoneal dialysis (PD). We undertook this study to 
examine characteristics and survival of DAGF patients on PD compared to the native ESRD 
population on PD.
Methods: We analyzed the United States Renal Data System (USRDS) to assess 
characteristics and survival of DAGF and native ESRD patients on PD. Mortality rates 
were compared after adjustment for age, sex, number of comorbidities, and year of dialysis 
initiation.
Results: A total of 7.46% of DAGF and 7.09% of native ESRD patients used PD 
(p=0.01) and a total of 108,194 patients on PD were analyzed (Table 1). The mean age for 
DAGF patients on PD was significantly lower than native ESRD patients on PD (p<0.001). 
DAGF patients on PD were more likely to be employed than their counterparts with native 
ESRD (p<0.001). Those with DAGF had higher mortality than those with native ESRD 
(Table 2). This trend was even more significant after adjustment for age, sex, number of 
comorbidities, and year of dialysis initiation (p<0.001).
Conclusions: DAGF patients on PD have much worse outcomes compared to their 
native ESRD counterparts. The results of this study should encourage providers to consider 
DAGF PD patients as a high risk group and focus on risk reduction. Further research 
regarding the timing and cause of mortality in DAGF population on PD is needed.
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Bedside Peritoneal Dialysis Catheter Repositioning - A Novel Technique
Santosh Varughese,1 Suceena Alexander,2 Anna T. Valson,2 Shibu Jacob,3 
Shailesh T. Kakde,4 Anjali Mohapatra,3 Vinoi G. David.5 1Nephrology, Christian 
Medical College, Vellore, India; 2Christian Medical College, Vellore, India; 
3Christian Medical College, Vellore, Vellore, India; 4Christian medical college, 
Vellore. Tamil Nadu, India; 5Royal Adelaide Hospital, Adelaide, SA, Australia.
Introduction: Malfunction of peritoneal dialysis (PD) catheters usually need surgical 
repositioning, requiring anaesthesia, operating time, longer hospital stay and surgical 
expertise. This novel technique obviates need for surgical intervention.
Case Description: The abdomen is scrubbed and cleaned. PD catheter distal to exit 
site is meticulously cleaned, titanium adaptor and transfer set removed, the former soaked 
in povidone-iodine. A guidewire is passed through catheter into peritoneal cavity. A 5mm 
incision is made over previous healed incision scar. Soft tissue is dissected until deep cuff 
is visible. With blunt dissection, cuff is gently separated from subcutaneous tissue where 
it had become anchored. Taking care to retain guide wire’s position inside peritoneum, 
intra-peritoneal part of PD catheter is removed. External portion of guidewire is advanced 
through PD catheter till free from catheter. Proximal end of guidewire is in peritoneum 
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and distal end free. PD catheter is searched for occluding clots, and if present, are gently 
milked out and catheter flushed with saline. A dilator is advanced along guidewire to ensure 
adequate space for PD catheter at linea alba. Peel-away sheath and dilator are then advanced 
into peritoneum. The dilator and guide wire are removed leaving only sheath in place. The 
catheter is then re-introduced into peritoneum through the sheath, which is separated leaving 
catheter in place. Peritoneal cavity is filled with PD fluid and good inflow and outflow are 
ensured. Subcutaneous tissue and skin are closed in layers. In the 18 patients so far. we 
have had an immediate technical success of 100% and a month later 12 catheters were 
functioning well (66.67%). Six months later, the catheters remained functional except in 
one patient who died due to heart disease.
Discussion: This novel technique allows for preservation of the catheter, exit site and 
tunnel. This reduces costs and duration of hospital stay and does not require specialized 
surgical expertise, operating room time or a dedicated anaesthetist.
Steps of repositioning
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Percutaneous Re-Positioning of Peritoneal Dialysis Catheter Accidentally 
Placed in the Pre-Peritoneal Subcutaneous Space Leaving the Tunnel and 
Exit-Site Intact - A Novel Idea
Santosh Varughese. Nephrology, Christian Medical College, Vellore, India.
Introduction: Percutnaeously placement of peritoneal dialysis (PD) catheters may be 
accidenatly be placed in the pre-peritoneal subcutanous space if the introducer needle does 
not pierce the peritoneal membrane in the initial part of the procedure. If this happens, the 
catheter insertion has to be redone either percutaneously or surgcially. The catheter often 
has to be replaced as part of it has been externalized and is unsterile.
Case Description: 70 year old man with end stage renal disease underwent bedside PD 
catheter insertion. Unfortunately, the cathteter was accidetally placed in the pre-peritoneal 
subsutaneous space. The inflow and outflow of PD fluid was present as the pre-peritoneal 
subcutaneous space had expanded with the PD fluid, but was slow. The problem was 
identified on CT scan and PD catheter re-insertion was planned. A week later, a novel 
technique was attempted in which the exit site and tunnel were untouched. The skin and 
subcutanousl sutured over the origical catether insertion site were undone and the deep cuff 
of the catheter was dissected and the intrabdominal part of the cathteter was exteriorized. 
A veress needle was advanced till it reached the peritoneal space, the position of which 
was confirmed using a guidewire. The track was dilated using a peel-away sheath-dilator 
assembly. The dilator was removed and the intra-abdomina portion of the catheter was 
slid in. The wound was closed in layers after ensuring good inflow and outflow. Peritoneal 
dialysis exchanges were begun the same day.
Discussion: Compared to using a new PD catheter and tunnel, this novel technique 
allows for a simple bedside repositioning technique, saving time, operating room time, 
reducing hospital stay and possibly avoiding unnecessary hemodialysis.
Steps of procedure
FR-PO677 Poster Friday
Dialysis: Peritoneal Dialysis - II
Long-Term Outcomes in Peritoneal Dialysis Patients Who Initiated 
Immediately After Catheter Insertion Using Percutaneous Catheter 
Placement Method
Young kyung Ko,2 Young-Il Jo.1 1Nephrology, Konkuk University Medical 
Center, Seoul, Republic of Korea; 2Nephrology, Konkuk University Medical 
Center, Gwangjin-gu, seoul, Republic of Korea.
Background: The aim of this study was to evaluate the long-term outcomes in 
peritoneal dialysis (PD) patients who initiated immediately after catheter insertion using 
percutaneous catheter placement method without a break-in procedure.
Methods: We conducted a retrospective study including all incident PD patients in our 
hospital who began PD therapy between January 2002 and December 2017. PD catheter 
(swan neck or non-swan neck) were used and inserted by a nephrologist using percutaneous 
catheter placement method with guidewire. PD therapy initiated immediately after 
catheter insertion without a break-in procedure. Demographic and clinical data including 
ESI, peritonitis, pericatheter leakage, and catheter dysfunction during the study period 
were collected. Event-free survival rates of clinical events and patient survival rates were 
calculated using Kaplan-Meier analysis.
Results: One-hundred thirty seven patients began PD during the study period, and 
127 of these patients were included in the final analysis. During the follow-up period, 
83 patients were withdrawn from PD. Reasons for discontinuing PD were transfers 
to hemodialysis(42.3%), kidney transplantation (18.8%), follow-up loss(21.7%), or 
death(17.6%). The survival rates were 96.7%, 94.3%, 91.3%, 91.3% and 86.8% at 1, 2, 3, 4 
and 5 years after PD initiation, respectively [Fig. 1]. In the Cox multivariate model, DM was 
related to patient survival. The technique survival rates were 90.9%, 83.7%, 81.2%, 73.5% 
and 69.6% at 1, 2, 3, 4 and 5 years after PD initiation, respectively [Fig. 1]. The risk factor 
for technique survival was catheter migration (95% CI 0.113-0.701, p=0.006). Event-free 
survival rates of variable clinical events were shown in Fig 1.
Conclusions: Our study showed that long-term outcomes including patient survival 
rates and event-free survival rates were comparatively high in PD patients who initiated 
immediately dialysis after catheter implantation using percutaneous method
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Laparoscopic Peritoneal Dialysis Catheter Insertion Using Nitrous Oxide 
Under Conscious Sedation
Nalinee Saiprasertkit, Joanne M. Bargman. Toronto General Hospital, Toronto, 
ON, Canada.
Background: The conventional laparoscopic peritoneal dialysis catheter implantation 
using carbon dioxide (CO2) for peritoneal insufflation necessitates general anesthesia (GA) 
due to CO2-induced peritoneal pain. However, end stage kidney disease (ESKD) patients 
are not generally ideal candidates for GA. Using nitrous oxide (N20) as an insufflation 
agent offers several advantages, including PD catheter insertion under regional anesthesia.
Methods: We performed a retrospective cohort study in ESKD patients who underwent 
laparoscopic PD catheter insertion with N2O under regional anesthesia from Jan 1, 2008 
to May 31, 2018. Patient demographics, treatment outcomes and adverse events were 
collected from our electronic databases.
Results: There were 152 patients, mean age was 68.2 ± 13.2 years; 41.5% women. 
Most common cause of ESKD was diabetic nephropathy (25.6%). Only 2 patients had 
unsuccessful catheter insertion due to extensive intra-abdominal adhesions. One patient 
required unexpected hospitalization due to intraoperative bleeding requiring a blood 
transfusion. Mean follow up was 26.6±23.1 months. One-year and 2-year catheter survival 
rates were 90.1% and 84.9%. Mean catheter survival was 51.0 ± 7.6 months.
Conclusions: Laparoscopic implantation of PD catheter with N2O insufflation and 
local anesthesia is feasible and can be performed safely in end-stage renal failure patients.
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Bedside Peritoneal Dialysis Catheter Insertion Program at the University 
Health Network – An Improvement Initiative to Grow PD Prevalence
Ali Z. Ibrahim, Rory F. McQuillan. University of Toronto, Toronto, ON, Canada.
Background: Peritoneal dialysis (PD) is underutilized in many jurisdictions, despite 
known societal and individual benefits, cost efficiency, and safety. One identified cause is 
lack of timely access to PD catheter insertion, which lends itself to quality improvement 
and innovation.
Methods: At the University Health Network at the University of Toronto, we sought to 
initiate a nephrologist-led bedside PD catheter insertion program directed at late presenting 
ESKD patients, beginning in January 2013, with appropriate support from a nursing 
education and infrastructure perspective. This included the implementation of a “Dialysis 
Start Unit” for patients needing Intermittent Peritoneal Dialysis while waiting for training 
with a nursing educator, as well as a dialysis catheter coordinator who was involved in both 
the bedside and surgical PD insertion programs. Specifically, the program aimed to help 
grow the PD program, while maintaining literature standards for catheter function, adverse 
events, and technique survival.
Results: The nephrology division at UHN has been able to create sustainable growth 
at a rate of 35% in its PD population using a safe, resource conscious, and effective 
way. This growth has come with no cost by way of patient adverse events or sacrifice of 
technique survival. Indeed, PD catheter failure rates have been consistently falling with 
more experience within the program, and within the last 2 years have been well below the 
accepted literature standards of 25%, at a rate of 5-7%. This is in keeping with available 
evidence that operator expertise, experience and interest have a large bearing on the success 
of any insertion technique. The rise in PD population was also accompanied by stability of 
home hemodialysis (HHD) and in-centre intermittent hemodialysis (IHD) numbers, while 
continuing to have a sustained rise in PD patient numbers.
Conclusions: Using a well-coordinated multi-disciplinary initiative to insert PD 
catheters at the bedside, the nephrology division at UHN was able to increase PD prevalence 
in a safe manner, which can be replicated in a similar context using similar resources and 
planning
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Abdominal Rectus Thickening as a Predictor of Peritoneal Catheter 
Primary Dysfunction
Pablo Maggiani, Guillermo Navarro Blackaller, Jonathan Chavez, Maria de la 
luz Alcantar Vallin, Guillermo Garcia-Garcia, Elsa edith Carreon bautista. 
Hospital Civil De Guadalajara, University of Guadalajara, Zapopan, Mexico.
Background: Percutaneous insertion of peritoneal dialysis (PD) catheters by 
nephrologists are an effective alternative to open surgical techniques. Complications 
following PD catheter insertion requiring manipulation or replacement are about 20%. 
Previous studies show that ultrasound measurements of skin depth to the peritoneum with 
values> 5.5 cm (p <0.001) are associated at percutaneous DP catheter dysfunction.
Methods: We conducted a cross-sectional study of 46 patients who had their first 
percutaneous peritoneal dialysis (PD) catheter and had a primary PD catheter dysfunction 
(PDC) defined as PD catheter removal when the PDC never worked due to a problem 
related to the catheter. They were divided into 2 groups: Group A patients who presented 
DPC dysfunction (20 patients) and Group B without DPC dysfunction (26 patients). We 
perform ultrasound measurement of the abdominal wall to all patients after DPC was 
inserted. We mesured distance from the surface of the skin to the parietal peritoneum (SPP) 
and the thickness of the rectus abdominis (RAT) in centimeters (cm) in the sagittal plane, on 
the medial border of the rectus abdominus muscle at the level of the umbilicus, just above 
the scar of the procedure. Body mass index (BMI), central obesity (CO) was calculated.
Results: The mean age was 44.3 years (SD +/- 13.6). The BMI of Group A 24.9 kg / m2 
(SD +/- 5.5) and Group B 24.4kg / m2 (SD +/- 4.1), central obesity (OC) of group A 93.6cm 
(SD +/- 16.8) and Group B 90.5 cm (SD +/- 11.2), SPP Group A 2.7 cm (SD +/- 0.94), 
Group B 2.2 cm (SD +/- 0.7), Group A RAT 1,005 cm (SD +/- 0.2), Group B 0.7cm (SD 
+/- 0.15). Of the 46 patients, 43% (20) had primary PDC dysfunction (group A). The RAT ≥ 
1 cm was the only variable that was significantly associated with the primary dysfunction of 
the PD catheter (RR: 6.8, IC 95% 2.7-16.0) OR: 100, (IC 95% 10.23 .977.1, p <0.0001), a 
sensitivity of 80%, specificity 96%, PPV of 94% NPV of 86%, with an AUC 0.86.
Conclusions: It was also observed that 94.4% (17) of patients with CO who did not 
have primary PDC dysfunction had a RAT <1 cm. No significant association was observed 
between primary PDC dysfunction and other risk factors, such as age, BMI, CO and SPP. 
The RAT ≥ 1cm is an very good predictor of the risk of primary dysfunction of the PD 
catheter.
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Comparison of Different Techniques for Peritoneal Dialysis Catheter 
Insertion: A Systematic Review and Network Meta-Analysis
Lichuan Yang. West China Hospital of Sichuan University, Chengdu city, China.
Background: Peritoneal dialysis (PD) is one of the important treatment methods of 
end-stage renal disease (ESRD). Various techniques had been applied to the PD catheter 
insertion, including open surgery, laparoscopy and percutaneous techniques. However, the 
best technique, regarding both the catheter survival and catheter related complications, 
is still controversial. Previous studies did not compare the three techniques at the same 
time. Therefore, we did a systematic review and network meta-analysis to identify the best 
insertion method.
Methods: We systematically searched PubMed, Embase, Cochrane library, CNKI, 
WanFang and VIP database for randomized controlled trial, case-control study and cohort 
study until December 2017. Quality assessment and data extraction were conducted by 
two reviewers independently. We performed a direct meta-analysis and Bayesian network 
meta-analysis to pooled odds ratios (OR) or weighted mean differences (WMD) with 95% 
credible intervals (CrI) with random effects model. The node-splitting method was used to 
assess the inconsistency. We estimated the potential ranking probability of treatments by 
calculating the surface under the cumulative ranking curve for each intervention. Meta data 
is analysed by Addis software version 1.16.5.
Results: Forty studies involving 6494 patients were included (10 RCTs and 30 
retrospective studies). The surface under the cumulative ranking curve (SUCRA) ranking 
from the network analysis showed that laparoscopy had the lowest occurrence of PD 
catheter displacement and obstruction, followed by percutaneous insertion and open 
surgery. Percutaneous insertion had the lowest occurrence of hernia, exit-site and tunnel 
infections. Open surgery had the lowest incident of bleeding.
Conclusions: Considering about the dysfunction of PD catheter, laparoscopy may be 
the best technique for PD catheter insertion. Different technique has the advantage of their 
own and more RCTs with larger sample size, comparing laparoscopy and percutaneous 
insertion directly are needed in the further.
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Stakeholder Priorities for Remote Management in Peritoneal Dialysis
Lalita Subramanian,1 Tony Cuttitta,1 Rosalind H. Kirk,5,1 Rachel Perlman,2,1 
Yanko Restovic,4 Allison D. Jeter,2,4 Rachel Tocco,1 Kimberly Fox,1 
Nicholas W. Moore,1 Jeffrey Perl,3,1 Ronald L. Pisoni.1 1Arbor Research 
Collaborative for Health, Ann Arbor, MI; 2UM Health Center, Ann Arbor, MI; 
3University of Toronto, Toronto, ON, Canada; 4RM4PD project, Stakeholder 
Advisory Panel, Ann Arbor, MI; 5Independent Qualitative Research Consultant, 
Edinburgh, United Kingdom.
Background: Remote management (RM) technologies alert and enable health care 
providers to manage a range of health-related changes including remote follow-up, where 
appropriate. In this study, an Advisory Group including patients, social workers, nurses, 
nephrologists, alongside researchers, developed and reviewed interviews and responses 
from patients, care partners and clinicians on using remote management (RM) technologies 
that may influence priorities for patient care and engagement in peritoneal dialysis (PD) 
treatment for kidney failure.
Methods: Thirty semi-structured phone interviews were conducted in the United States 
and United Kingdom between October 2017 and January 2018. These aimed to assess effects 
of RM on PD treatment from patients’, care partners’ and clinicians’ perspectives. NVivo11 
was used to organize and analyze the data to identify remote management priorities. Sample 
quotes illustrating the variations in perspectives among the three groups are shown in Table
Results: Sample quotes illustrating the variations in perspectives among the three 
groups are shown in the Table. Clinicians tended to view RM as a tool with the potential to 
significantly change management and delivery of PD care while patients and care partners 
frequently perceived RM as having some benefits but not necessarily addressing some of 
the more immediate needs with their care.
Conclusions: There were variations in aspects of RM that were most valued by 
patients, care partners and clinicians. Opportunities for further technological innovations 
might exist in addressing patient and care partner priorities for PD care.
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Comparison of Hospitalization Rate in Automatized Peritoneal Dialysis 
Patients with and Without Remote Management Program in Colombia
Angela S. Rivera,3 Mauricio Sanabria,2 Jasmin Vesga,1 Adriana M. Suarez,1 
Alfonso Bunch.1 1RTS, Bogota, Colombia; 2RTS Baxter, Bogota, Colombia; 
3Baxter, Bogota, Colombia.
Background: The remote monitoring technology specifically designed to be integrated 
into APD systems (such as ShareSourceä, Baxter Healthcare) gives both patients and 
their clinical team a powerful tool that can enhance communication, potentially improve 
adherence to the treatment, optimize fluid balance; and address potential complications of 
therapy in near real-time. The purpose of this study was to compare the hospitalization 
rate in incident adult patients in Automated Peritoneal Dialysis (APD) with and without 
HomeChoice Claria® & Shaaresource®.
Methods: Multicenter observational retrospective cohort study in incident adult patients 
in Automated Peritoneal Dialysis (APD) with HomeChoice Claria and Sharesource®, 
enrolled between October 1st, 2016 to October 31th, 2017 with follow up of 1 year, in 46 
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renal clinics of the Renal Therapy Services (RTS) Colombia network. For the analysis, 
descriptive statistics and incidence rate were used
Results: 954 patients were evaluated, 56.6% were men, the mean age was 59.63 
years (SD = 16.12). See table 1 We found a decrease statistically significant in days and 
hospitalization rate with the monitoring program for APD patients. Details are presented 
in table 2 y 3
Conclusions: A remote monitoring program for APD patients may be easily and 
efficiently implemented in healthcare settings improving clinical outcomes.
Funding: Commercial Support - Baxter Healthcare Corporation
Table1. Baseline clinical and demographic characteristics
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Impact of Peritoneal Dialysis (PD) Remote Monitoring on PD Services
Heidy Hendra, Georgina J. Pharro, Sarah Lewis, Tina Mccornack, 
Gowrie Balasubramaniam. Southend University Hospital NHS Foundation 
Trust, Chelmsford, United Kingdom.
Background: Remote monitoring to manage renal patients is increasing. HomeChoice 
Claria with Sharesource™ (Baxter Healthcare Ltd) is a web-based, two-way connectivity 
platform enabling remote monitoring of automated peritoneal dialysis (APD). We 
introduced it in 10/2015 and reviewed it’s impact after 12-months.
Methods: 48 patients were studied; median age 62.8 years (24 – 90), 30 males. 
Patients and clinical information were identified from the electronic patient records system 
and medical records. We investigated the number of patient on PD, months on treatment, 
outpatient attendances, remote consultations, home visits and staff travel. We also looked 
at take-up/ drop-off rates. Continuous variables were analysed by the independent samples 
t-test.
Results: Average number of patients on active PD increased by 14%, patient months
on treatment increased by 12% as patients spent 4 months longer on treatment on average. 
Outpatient attendances increased by 34%. 60 remote consultations were performed,
averaging 0.2 remote consultations/ patient/ month. The number of home visits per month 
increased by 41% and the visits per patient increased by 29%. The mean nurse mileage/
month increased by 57% and mileage/ patient/ month increased by 43% in 2015/16 (Results 
shown in Table 1). There was a net loss of 9 patients 12 months prior to implementation and 
a net gain of 2 patients 12 months after implementation.
Conclusions: More service was delivered with the same number of nursing staff. There
was a rise in PD-related OP attendances per patient, mean home visits/ month and mileage/
patient in 2015/6; this may be due to increased visit for educational purposes during system 
exchange as data collected across the year showed a reduction. Further study involving
longer period of observation is needed to validate the result.
Summary of results
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Cost Consequence Analysis of a Remote Monitoring Program to Improve 
Clinical Practice of Automatized Peritoneal Dialysis in Colombia
Juan G. Ariza,1 Alfonso Bunch,2 Mauricio Sanabria,3 Angela S. Rivera,4 
Jasmin Vesga.2 RTS Renal Therapy Services 1BAXTER, BOGOTA, Colombia; 
2RTS, Bogota, Colombia; 3RTS Baxter, Bogota, Colombia; 4Baxter, Bogota, 
Colombia.
Background: To estimate from the payer perspective, the cost and clinical 
consequences of a Remote Monitoring (RM) standardized program, supported in Claria 
Sharesource technology, to improve the clinical practice and control of incident patients 
in automatized peritoneal dialysis (APD) currently treated in the Renal Therapy Services 
(RTS) setting in Colombia.
Methods: A one year Markov analytic model, structured in five health states, was 
used to project costs and clinical outcomes from a cohort of 100 APD patients with and 
without RM. Real world outcomes required as model inputs such as rates of hospitalization, 
peritonitis, technique failure and mortality were estimated from retrospective patient level 
registries and RTS medical records. Renal care ambulatory costs were estimated from 
referent national tariffs. Inpatient care costs were obtained from administrative database in 
a referent health care provider. Model results were reported as the RM incremental effect in: 
overall direct costs, patient months in control, one year persistence in APD, hospitalization 
episodes, days of hospitalization, peritonitis episodes, technique failure episodes and death 
episodes. Both deterministic and probabilistic sensitivity analyses were done to analyze the 
effect of information uncertainty in the model results.
Results: In comparison with APD without RM, the implementation of a standardized 
RM program in 100 APD patients during one year resulted in: Overall savings USD $ 
16,169; 73 additional patient months in control; 25 hospitalization episodes avoided; 243 
hospitalization days avoided; 17 peritonitis episodes avoided; 7 technique failure episodes 
avoided; 7 death episodes avoided and 13 additional patients persisted in APD technique 
after one year. Deterministic sensitivity analysis: RM tariff, hospitalization rate and 
hospitalization episode costs were the most sensitive drivers of model results. Probabilistic 
sensitivity analysis: With 66% of chance, the RM standardized program was a cost-saving 
dominant intervention.
Conclusions: From the payer perspective, RM is a cost saving dominant alternative, 
improving patient time in control, burden of hospitalization, risk of complications, 
persistence in APD technique and mortality.
Funding: Clinical Revenue Support
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Associations Between Use of a Patient Portal with Hospitalization Rates 
and Modality Failure in Peritoneal Dialysis Patients
Carlos Muchiutti, Bryan Fore, Sheetal Chaudhuri, Sophia Rosen, Hao Han, 
Marta Reviriego-Mendoza, John W. Larkin, Len A. Usvyat, Franklin W. Maddux. 
Fresenius Medical Care North America, Waltham, MA.
Background: Peritoneal dialysis (PD) patients often have their clinical status assessed 
monthly, which limits the clinicians view of the patients’ health state. A large dialysis 
provider has recently constructed a connected health program for PD patients to enter their 
clinical parameters or complaints daily. This portal provides automated alerts to clinicians 
for abnormal findings, as well as non-adherence with reporting. We analysed outcomes for 
hospital admission rate and modality failure in patients who were using the portal versus 
those who were not.
Methods: We included data from 5549 active PD patients who were introduced to the 
patient portal prior to Sep 30, 2017 and had <=10 hospitalizations days in Sep 2017. Patients 
who documented data for ≥20 treatments during Sep 2017 were considered “the engaged 
group” (n=1199). The remaining 4350 patients who did not document any treatment data 
on the portal were considered “the non-engaged group.” Patients who documented data on 
>0 and <20 treatments were not included in this analysis. Patients were followed 6 months 
starting Sep 30, 2017 up until the earliest of discharge from the clinic (including death),
switch from PD to hemodialysis (HD) or end of follow-up. We compared the percent of 
patients who switched modality from PD to HD using Chi-square test without accounting
for the length of follow-up. We compared the hospital admission rate during follow-up 
period using Poisson regression model adjusted for prior hospitalizations.
Results: We observed that patients in “the engaged group” had a 20% lower risk of 
hospitalization compared to the “non-engaged group” (Relative Risk=0.8, p<0.001). We 
found no significant difference in modality changes from PD to HD between groups (11% 
engaged patients vs 13% non-engaged patients, p=0.11).
Conclusions: Consistent documentation of treatment data in the patient portal was 
associated with lower hospital admission rates among PD patients suggesting that better 
patient engagement as well as more real-time clinician involvement may impact patients’ 
hospitalization rates. However, observations may be confounded by indication of portal 
use, which could represent a more adherent group of patients. Further analysis is needed to 
confirm these findings.
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Role of Peritoneal Phosphorus Transport in Peritoneal Dialysis Regimen 
for the Management of Hyperphosphatemia
Elena Guillen,1 Marc Xipell Font,1 Enrique Montagud,1 Raquel Ojeda lopez,2 
Lida M. Rodas Marin,1 Francisco Maduell,1 Manel Vera.1 Peritoneal Dialysis 
Department, Hospital Clínic 1Hospital Clinic, Barcelona, Spain; 2University 
hospital, Córdoba, Spain.
Background: The ratio D/P-Creatinine (DP-Cr) obtained by the peritoneal equilibrium 
test (PET) is the most widely used parameter to characterize the type of peritoneal 
membrane transport, and it is used to determine the dialysis regimen for ultrafiltration 
(UF). It has been suggested that net UF influences the final clearance of solutes, so guiding 
ultrafiltration by D/P-Phosphorus (DP-P) instead of DP-Cr could have some added value in 
the management of hyperphosphatemia. The objective of this study is to define if there is a 
correlation between DP-P and DP-Cr, and if these are related to the clearance of phosphorus 
(P) and creatinine (Cr).
Methods: Retrospective analysis of PET performed in our center in 2016-2017.
DP-Cr and DP-P were calculated, and in patients with 24h effluent sample the day of the 
PET, it was also analyzed weekly Kt/V-urea, and peritoneal Cr and P clearance (CrCl and 
PCl). Statistical analysis was done using t-Student test for independent data and Pearson 
correlation coefficient, establishing a significance level of p<0.05.
Results: 68 PET were analyzed in 54 patients, mean age 60.4 years (SD 17), 
predominantly men (69% vs 31%). The mean plasma P, DP-Cr and DP-P were respectively 
4.5 mg/dL (SD 1.2), 0.74 (SD 0.12) and 0.71 (SD 0.17). The correlation coefficient DP-P/
DP-Cr showed a significant relationship (r=0.84, p<0.001), which was maintained when 
analyzing patients according to phosphorus levels: DP-P/DP-Cr with P<5 mg/dL (r=0.81); 
and P≥5 mg/dL (r=0.93) (p<0.001). Patients in DP-P ≥50th percentile had P levels of 4.2 
(± 1.05), and those in <50th percentile had levels of 4.88 (± 1.38) (p <0.031). Moreover, 
in patients with 24h effluent analyzed the day of the PET (n=35), the average PCl and 
CrCl was 4.1 and 2.85 ml/min, with statistical significant correlation (r=0.92, p<0.001). 
However, in these patients no relationship was found between DP-Cr and CrCl (r=0.068, 
p=0.7), nor between DP-P and PCl (r=0.052, p=0.7).
Conclusions: The DP-P/DP-Cr high correlation suggests that both parameters could be 
useful to classify the type of peritoneal transport. However, although patients with higher 
DP-P had better control of hyperphosphatemia, thus suggesting a direct positive relationship 
between DP-P and PCl, our data showed no correlation between them.
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Tissue Sodium Stores in Peritoneal Dialysis Patients
Supisara Tintara,1 Aseel Alsouqi,2 Serpil muge Deger,5 Aihua Bian,3 
Thomas G. Stewart,2 Jens Titze,4 Talat Alp Ikizler.2 1Vanderbilt University 
School of Medicine, Nashville, TN; 2Vanderbilt University Medical Center, 
Nashville, TN; 3Vanderbilt University, Nashville, TN; 4Duke - National 
University of Singapore, Singapore, Singapore; 5Vanderbilt University Faculty 
of Medicine Department of Nephrology, Nashville, TN.
Background: A remarkable amount of sodium (Na+) is stored in the tissue without 
commensurate water retention, particularly in the skin and muscle. Using 23Na-magnetic 
resonance imaging (MRI), elevated tissue Na+ content was found in hemodialysis patients. 
Peritoneal dialysis (PD) patients generally have higher residual kidney function than HD 
patients, yet the effectiveness of PD in tissue Na+ removal has not been evaluated.
Methods: We examined tissue Na+ levels in 10 PD patients. PD patients were matched 
with healthy controls by age, race, gender and body mass index (BMI). All study subjects 
underwent 23Na-MRI to quantify Na+ levels in lower leg muscle and skin.
Results: We studied 10 PD patients and 41 controls. PD patients had significantly 
higher skin and muscle Na+ levels compared to controls (figure 1). In PD subjects, skin Na+ 
level was inversely correlated to ultrafiltration volume, a marker of Na+ removal adequacy 
(figure 2).
Conclusions: Our data suggest that PD patients have elevated tissue Na+ stores. The 
mechanisms by which this abnormality develops and its consequences should be further 
examined.
Funding: Commercial Support - Baxter Healthcare Corporation
Characteristics of the study population
Continuous variables are presented as median [interquartile range], categorical variables 
are presented as n (%).
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Comparison of Low and Standard Dose Adrenocorticotropic Hormone 
(ACTH) Stimulation Test in the Diagnosis of Adrenal Insufficiency in 
Peritoneal Dialysis Patients
Yun Jung Oh,1 Su mi Lee,2 Jiwon Ryu,1 Chungsik Lee.1 1Internal Medicine, 
Cheju Halla General Hospital, Jeju, Republic of Korea; 2Internal medicine, 
Dong-A University hospital, BUSAN, Republic of Korea.
Background: Adrenocorticotropic hormone (ACTH) stimulation test is the 
current standard for diagnosing adrenal insufficiency (AI). The low dose (1 μg) ACTH 
stimulation test (LDT) has been introduced to detect incomplete impairment of adrenal 
function with partial corticotropin deficiency, which might be masked by the conventional 
supraphysiological dose (250 μg) of ACTH employed in the standard dose ACTH 
stimulation test (SDT). Indeed, several studies have shown an increased sensitivity of 
LDT over SDT in chronic ill patients with secondary AI. This study aims to investigate 
the diagnostic value of low and standard dose ACTH stimulation tests for identifying AI in 
patients on peritoneal dialysis (PD).
Methods: A total of 60 prevalent PD patients were enrolled and underwent LDT and 
SDT using doses of 1 μg and 250 μg synthetic ACTH, respectively. The two tests were 
performed in random sequence with minimum one week interval and a cut-off level of peak 
serum cortisol for AI was <18 μg/dL in both tests. Surveys of AI-associated symptoms and 
laboratory test were performed.
Results: Overall, 22 (36.7%) patients in the LDT and 8 (13.3%) patients in the SDT 
showed an insufficient increase of cortisol to ACTH stimulation and were categorized as 
having AI. In the LDT, no remarkable difference in presence of symptoms associated with 
AI was observed between the AI patients and non-AI patients. Laboratory findings were not 
different between the two groups, either. However, the patients who were diagnosed with 
AI by the SDT complained fatigue (62.5% vs. 15.4%, P=0.009) and constipation (50.0% 
vs. 13.5%, P=0.031) more frequently compared with the patients without AI. The adequacy 
of dialysis (Kt/V) was significantly lower in patients diagnosed with AI by the SDT than 
non-AI patients (1.64±0.21 vs. 1.99±0.37, P=0.019).
Conclusions: Adrenal response to ACTH was diminished in low dose compared with 
standard dose and the use of LDT diagnosed more adrenal abnormalities than SDT in PD 
patients. However, the clinical significance of identifying AI patients using the LDT was 
not observed in those patients.
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Hyperosmolality in Peritoneal Dialysis Increases Plasma Arginine 
Vasopressin Levels
Hiromichi Ueno,1 Tetsu Miyamoto,3 Kenya Sanada,2 Yoko Fujimoto,1 
Kenichiro Bando,4 Yoichi Ueta,1 Yutaka Otsuji,1 Masahito Tamura.5 1University 
of Occupational and Environmental Health, Kitakyushu, Japan; 2University of 
Occupational and Environmental Health, Japan, Kitakyushu-shi, Japan; 
3Second Department of Internal Medicine, Kitakyushu, Fukuoka, Japan; 
4University of occupational and environmental health, Kitakyushu, Japan; 
5University of Occupational & Environmental Health, Kitakyushu, Japan.
Background: Fluid retention is common in peritoneal dialysis (PD) patients. Arginine 
vasopressin (AVP), an antidiuretic hormone, promotes fluid retention and stimulates thirst. 
Consequently, AVP is important for fluid management in PD patients. Although several 
studies have reported an increase in plasma AVP levels in hemodialysis patients, the 
dynamics of plasma AVP levels in PD patients has not yet been clarified.
Methods: We measured plasma AVP levels and osmolalities in 20 PD patients aged 
48-79 years-old over 2-145 months of PD duration. Blood volumes were evaluated by
bioelectrical impedance analysis.
Results: Plasma AVP levels (5.5 ±0.6 pg/mL) and osmolality (303.4 ±1.6 mOsm/kgH2O) 
increased significantly in PD patients. In addition, a positive correlation was observed 
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between plasma AVP levels and osmolality, and a small increase in plasma glucose levels 
(138.5 ±11.0 mg/dl) was observed in PD patients.
Conclusions: Several studies have shown that PD solution increases plasma glucose 
levels. Therefore, we considered that PD-induced hyperglycemia may cause an increase 
plasma osmolality and AVP levels. To the best of our knowledge, this is the first report to 
demonstrate an increase in plasma AVP level in PD patients. These findings provide novel 
insights into the fluid management of PD patients.
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Use of Raman Spectroscopy Analysis to Evaluate the Molecular Composi-
tion of Spent Peritoneal Dialysate and Urine over Time
James L. Pirkle,1 John L. Robertson.2 1Wake Forest School of Medicine, Winston 
Salem, NC; 2Virginia Tech, Blacksburg, VA.
Background: Common indices to assess peritoneal dialysis (PD) adequacy – Kt/V urea 
and creatinine clearance – may not reflect clearance of other small and middle-molecular 
weight molecules that may be more important in the pathogenesis of uremia and patient 
outcomes. These indices may not reflect changes in residual renal function, peritoneal 
membrane integrity, local/systemic inflammation, patient metabolism, or mineral/electrolyte 
balance. Identification of other potentially important molecules in both spent dialysate (SD) 
and urine (UR) may provide better measures of treatment adequacy. However, analysis 
of these potentially-important molecules, with current technology (chromatography, mass 
spectroscopy), is time-consuming, expensive, and unlikely to be widely available in clinical 
settings.
Methods: We used novel methods, based on Raman spectroscopy and computational 
analysis, to study the molecular composition of SD and UR collected periodically from 
15 PD patients over a two-year period of observation. Raman spectra were generated by 
irradiation of SD and UR samples at 785 nm, corrected for incident (background) radiation 
and then computationally normalized. The spectra of SD and UR samples from PD patients 
were compared to analytical standards, to unused dialysate fluid (SD samples) and urine 
(UR) collected from consented, healthy volunteers. Quantification of prominent spectral 
peaks (urea, creatinine, glucose, for example) was achieved by comparison with analytical 
standard calibration curves.
Results: As expected, spectra of SD and UR differed significantly. Of note, SD spectra 
among 15 patients also differed significantly from one another, as did UR spectra. For 
individual patients, both SD and UR spectra varied over time, reflecting changes in types 
of molecules being dialyzed and/or excreted in urine. Variations in either SD or UR spectra 
were not well-correlated to Kt/V urea or creatinine clearance. Prominent spectral peaks 
representing collagen and nucleic acids in some SD specimens may signal changes in 
peritoneal membrane integrity; this requires further analysis.
Conclusions: Changes in the molecular composition of peritoneal dialysate and urine 
over time can be identified using computational Raman spectroscopy. This method may 
yield a viable tool for assessing the clinical effectiveness of the peritoneal dialysis therapy.
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Time-Course Changes in the Levels of Biomarkers in Peritoneal Dialysis 
Effluent Among Patients Using New Neutral Fluids
Risa Terashima, Yudo Tanno, Nanae Matsuo, Yukio Maruyama, Ichiro Ohkido, 
Keitaro Yokoyama, Takashi Yokoo. The Jikei University School of Medicine, 
Tokyo, Japan.
Background: Recently, new neutral peritoneal dialysis fluid (PDF) contained 
bicarbonate 25mEq/L and lactate 10mEq/L (Bic/Lac PDF), instead of lactate 40mEq/L 
contained neutral fluid (Lac PDF), was available in Japan. The levels of biomarkers in PD 
effluents are used as the indexes of peritoneal deterioration associated with PD. However, 
there are few reports evaluating time-course changes in biomarker levels according to dwell 
time using Bic/Lac PDF.
Methods: Six stable PD patients were included (72±6 y/o, male 83%, PD duration 
52.8±32.8 months). We compared the levels of CA125, IL-6, FDP, VEGF, and TNF-α in 
PD effluents between Bic/Lac PDF and Lac PDF after a dwell time of 2, 4, 6, and 8 hours.
Results: The levels of CA125 and IL-6 after the dwell time of 2, 4, 6, and 8 hours were 
as follows; CA125: Bic/Lac PDF, 13.2±6.5, 21.3±10.9, 26.8±14.2, and 33.6±19.1 U/mL; 
Lac PDF, 10.5±3.6, 16.6±5.6, 21.5±8.0, and 27.4±10.5 U/mL, and IL-6: Bic/Lac PDF, 
10.1±7.8, 16.9±9.0, 23.4±10.3 and 33.2±11.9 pg/mL; Lac PDF, 12.1±6.9, 21.1±11.6, 
29.4±16.2, and 43.2±23.6 pg/mL, respectively. The levels of FDP also showed increasing 
trends over time. The levels of VEGF and TNF-α in some samples were below the detection 
limits up to a dwell time of 6 hours.
Conclusions: The levels of biomarkers in PD effluents are greatly affected by PDF 
dwell time. Time-course changes in the levels of biomarkers are similar between two PDF.
Funding: Commercial Support - Baxter Healthcare
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T Regulatory Cells in Peritoneal Dialysis: Effect of the First Dialysis 
Session
Carlotta Caprara,1 Rahul Sharma,2 Anna chiara Frigo,3 Diego Pomare’ Montin,1 
Valentina Corradi,4,1 Massimo de Cal,4,1 Claudio Ronco.4,1 1IRRIV, Vicenza----, 
Italy; 2University of Virginia, Charlottesville, VA; 3University of Padova, 
Padova, Italy; 4San Bortolo Hospital, Vicenza, Italy.
Background: T Regulatory (Treg) cells are a subpopulation of T cells that modulate 
the immune system, maintain tolerance to self-antigens, prevent autoimmune disease 
and regulate key immune responses across a variety of disease settings. In the literature, 
contrasting results have been reported about the influence of dialysis on Treg cells, in 
chronic kidney disease stage G5 patients that show activated but impaired immune system. 
Moreover the influence of dialysis on T cells needs further investigation. The aim of this 
study is to evaluate the influence of the first peritoneal dialysis (PD) treatment on Treg cells 
subset.
Methods: A total of 13 patients that have to start PD were enrolled. Treg were studied 
by flow cytometry with: CD3(PerCP); CD4(FITC); CD25(PECy7); CD127(PE) and 
FOXP3(APC) antibodies. Time point: T0 (before the first dialysis treatment); T1 (after 
1 month). We performed Wilcoxon for dependent samples to compare the mean delta 
percentage difference between T0 and T1(100*(T1-T0)/T0).
Results: Treg cells (either considered as CD25+FoxP3+ or as Foxp3+) analyzed 
as percentage of lymphocytes showed a statistically significant increase during time 
(median=35.92; p=0.0425 for CD25+FOXP3+ and median=30.85; p=0.0479 for FOXP3+); 
Splitting Foxp3+ cells into CD25Hi, CD25Int and CD25Lo, showed an increment during 
time of Foxp3+CD25hi population (median=53.85; p=0.0215) while the other two 
populations remained unchanged (median=23.81 and median=15.38 respectively; p>0.05), 
as well as T lymphocytes (median=-6.58; p>0.05).
Conclusions: The study analyzed for the first time T cells variation before and after 
the first PD treatment. PD treatment improves T cells status by increasing Treg percentage, 
and Treg expressing CD25 after one month of treatment, while it does not influence other 
cells populations.
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miRNAs and Hyalinizing Vasculopathy in Peritoneal Dialysis Patients
Rafael Selgas,1,2 Raúl R. Rodrigues díez,2 Ricardo Ramos-Ruiz,5 Gloria Del 
peso,6 Maria A. Bajo,1 Marta Ruiz-Ortega,2 Manuel Lopez-Cabrera,4 
Carlos Llorens.3 Peritoneal Studies Group in Madrid 1Hospital University La 
Paz, Madrid, Spain; 2Universidad Autonoma, Madrid, Spain; 3Biotechvana, 
Paterna, Spain; 4Consejo Superior de Investigaciones Cientificasn, Madrid, 
Spain; 5parque científico de madrid, MADRID, Spain; 6Hospital Universitario 
La Paz, Madrid, Spain.
Background: Peritoneal membrane is conditioned by lesions appearing at long-term 
for dialysis purposes. Among these lesions, Hialynazing Vasculopathy has received less 
attention than others, and mechanisms causing this damage are incompletely studied 
although it is regularly found at advanced peritoneal stages. miRNAs are important 
regulators of cell biology. A miRNA transcriptomic study is an appropriate approach to 
independently (non-hypothesis driven) explore molecular mechanisms involved in this 
pathology.
Methods: We studied 7 patients affected by peritoneal vasculopathy and 4 patients 
without it. Total RNA was extracted from FFPE peritoneal tissue, small RNA libraries were 
prepared and sequenced.
Results: 20 miRNAs differentially expressed between groups were found (Table, up/
down in vasculopathy). Remarkably, 9 of them belong to a cluster of miRNA loci separated 
by less than 10 kb in chromosome 14 (marked in Table). We also detected messenger RNAs 
which were differentially expressed, and positive correlations between miRNAs and these 
messenger RNAs were found
Conclusions: GO enrichment performed based on coding genes shown as differentially 
expressed, revealed differential enrichment in proteins with hydrolase activity and proteins 
with RNA and protein binding functions. Differential enrichment was also observed 
in proteins involved in translation processes with sub-localizations mainly exosomal 
vesicles and extracellular space besides of cytosol sub-localisations probably related with 
translational processes. Enrichment analysis of metabolic pathways reveals enrichment 
in enzymes involved in three pathways; Aminoacyl-tRNA biosynthesis, N-Glycan 
biosynthesis and Galactose metabolism. The impact of these new findings in terms of gene 
function will be discussed.
Funding: Government Support - Non-U.S.
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Predictors of Icodextrin Induced Hyponatremia
Ankur Gupta,2 Susan D. Lavoie,1 Swapnil Hiremath,3 Pierre-Antoine Brown,4 
Brendan Mccormick.1 Kidney Research Centre, University of Ottawa 1Ottawa 
Hospital, Ottawa, ON, Canada; 2TOH, OTTAWA, AB, Canada; 3University of 
Ottawa, Ottawa, ON, Canada; 4The Ottawa Hospital, Ottawa, ON, Canada.
Background: Icodextrin (ICO) is a polyglucose peritoneal dialysis (PD) solution 
used in the long dwell. It is known to produce a mild dilutional hyponatremia due to its 
absorption and metabolism to maltose. In our program, many patients are treated with 
a single ICO dwell overnight as part of an incremental PD approach. We hypothesized 
that these patients are more likely to develop ICO induced hyponatremia due to decreased 
peritoneal clearance of maltose.
Methods: We performed a cross sectional analysis of our prevalent PD patients treated 
with ICO to determine the predictors of a significant (≥ 5 mmol/L) drop in serum sodium 
(Na) after ICO initiation. From our electronic database, demographic and biochemical 
information was abstracted. Serum Na values immediately before and a minimum of two 
weeks post ICO initation were compared.
Results: 107 of 193 prevalent patients had at least once ICO exposure and 98 patients 
had pre/post Na values and were included. Predictors of a significant drop in Na are shown 
in the table. When age and modality were entered into a regression model, the adjusted OR 
for hyponatremia with single ICO exchange was 1.88 (CI 1.16 to 3.13, P=0.01) compared 
with a single ICO and full CAPD or CCPD.
Conclusions: We conclude that use of a single overnight ICO exchange is associated 
with a significantly higher risk of hyponatremia than when ICO is used as part of a full 
CAPD or CCPD regime. This suggests that peritoneal clearance of maltose is important in 
attenuating the apparent drop in serum sodium with ICO. Further prospective studies are 
needed to validate this concept.
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Body Mass Index Trends in Patients Undergoing Peritoneal Dialysis for 
Decades and Their Effect on Patient Survival: Analysis of Data from an 
ESRD Registry (1985–2014) in Korea
Seon Deok Hwang,1 Jin ho Lee,2 Woo Yeong Park,3 Jeong Ho Kim,4 Jong 
Hyun Jhee,1 Seoung Woo Lee.5 1Inha University College of Medicine, Incheon, 
Republic of Korea; 2Bong Seng Memorial Hospital, Busan, Republic of Korea; 
3Dongsan Medical Center, Daegu, Republic of Korea; 4Daejeon St. Mary’s 
Hospital, Daejeon, Republic of Korea; 5Inha University Hospital, Inchon City, 
Republic of Korea.
Background: Significant increases in the prevalence of obesity have been observed 
among patients with end-stage renal disease (ESRD). However, the changes in body mass 
index (BMI) status in prevalent Korean patients undergoing peritoneal dialysis (PD) over 
the recent decades and their impact on patient survival remains unknown.
Methods: Among 80,674 patients from the ESRD registry of the Korean Society 
of Nephrology. Prospective cases for Our analysis were outpatients ≥ 18-years-old who 
underwent maintenance peritoneal dialysis between 1985 and 2015. Among the possible 
(10,495) cases identified, cases with sufficient data was not measured were excluded. After 
screening, our analysis was based on the data of 6,095cases. BMI divided the entire patient 
population into quartiles. As a result, BMI was divided into <21.19 in group 1, 21.19 to 
23.18 in group 2, 23.18 to 25.71 in group 3, and >25.70 in group 4. Among the 6,095 cases 
included in our analysis, 2,229 (36.7%) all-cause deaths was recorded over the follow-
up period, Kaplan-Meier survival curves confirmed increase in all-cause mortality among 
BMI. We additionally analyzed these patients by dividing them into diabetic and non-DM 
patients.
Results: The log rank of the Kaplan-Meier survival curves according to the BMI 
Group was 19.53 and the P-value was 0.001. Cox proportional hazards model, Even 
after adjustment for potential confounders, the all-cause mortality HR was 1.29 (95% CI, 
1.10–1.551; P = 0.001) in quartile 3 and 1.36 (95% CI, 1.14–1.59; P< 0.001) in quartile 4 
respectively. However, There was no statistical significance between quartile 1 and quartile 
2(HR, 1.17; 95% CI, 0.99–1.37; P = 0.055). In diabetic patients which were adjusted for 
several parameters that was important to mortality, meaningful values were seen in group 4 
and mortality was 1.45 times higher in patients with BMI 25.7 or higher in diabetic patients 
1.45 (95% CI 1.20-1.76 p-value<0.001).
Conclusions: In the Korean PD patients BMI elevation is significantly correlated with 
increased mortality of CAPD patients. In particular, the high BMI of DM CAPD patients 
increases mortality
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A Single Center Validation Study of a Korean Version of the SARC-F for 
Patients on Peritoneal Dialysis
Joonhyuk Seo, Seok hui Kang, Kyu-hyang Cho, Jong-Won Park, Jun-Young Do. 
Devision of Nephrology, Department of Internal Medicine, Yeungnam University 
Medical Center, Daegu, Republic of Korea.
Background: The SARC-F is a simple screening tool for sarcopenia, consisting of 
5 questions covering strength, assistance in walking, rising from a chair, climbing stairs, 
and falls. Given most of those on peritoneal dialysis (PD) have low muscle mass and poor 
physical function, it is worth examing an usefulness of SARC-F for them. This study aimed 
to validate the Korean version of SARC-F for patients on PD.
Methods: The Korean version of SARC-F, which was introduced from a previous 
study validating it in community-dwelling older adults, was tested in regular visiting 127 
outpatients on PD (men 52.8%, women 47.2%). Validity was analyzed by standard 
criteria based on the Foundation for the National Institutes of Health, Asian and 
European Working Group. The subjects were divided into two groups according to 
SARC-F score (<4 and ≥4) and its correlation with multiple factors including age, KT/V, 
residual renal function, skeletal muscle mass, handgrip strength, etc. was inspected by sex.
Results: The prevalence of sarcopenia in men and women according to SARC-F was 
14.9% and 31.6%, respectively. For men, SARC-F showed low sensitivity and low positive 
predictive value (PPV) [33.3%-66.7%, 10.0%-20.0%, respectively], but high specificity 
and high negative predictive value (NPV) [85.9%-87.5%, 94.7%-98.2%, respectively]. 
Similary, for women, SARC-F showed low sensitivity, low PPV and high NPV [50.0%-
80.0%, 5.3%-21.1%, 97.6%, respectively], although specificity was relatively lower than 
men [69.0%-72.7%]. The SARC-F<4 group had less muscle mass and poorer hand grip 
strength.
Conclusions: As the specificity and NPV of Korean version of SARC-F were high, 
it is useful, particularly for men on PD, to rule out sarcopenia in a simple way. Regarding 
the lower specificity for women, it is suggestive that applying a different cut-off value 
according to sex is necessary. The sensitivity was too low to screen the sarcopenic patient 
on PD, and hence, further attention for screening sarcopenia would be required.
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Comparison of the Risk of Fracture in Peritoneal Dialysis Patients with 
Sarcopenia Using the FRAX
Heeryong Lee, Jeongmyung Ahn, Dong Ryeol Lee. Nephrology, Maryknoll 
Medical center, Busan, Republic of Korea.
Background: For chronic patients with chronic diseases such as peritoneal dialysis, 
the rate of sarcopenia is high. This sarcopenia increases the risk of dying by causing heart 
failure, fractures, infection, frailty, and resistance to insulin. This study was initiated 
because of the lack of evidence of a risk of fractures in patients with peritoneal dialysis.
Methods: : We studied 146 patients on peritoneal dialysis. For the diagnosis of 
sarcopenia, we measured muscle mass (measured using a bioimpedance analysis), muscle 
strength (measured using a handgrip strength), and physical performance (measured using 
a gait speed). Sarcopenia was diagnosed on the basis of the European Working Group on 
Sarcopenia in Older People (EWGSOP). The risk of fracture was measured using the fracture 
risk assessment tool (FRAX) after measuring the femoral neck bone mineral density. The 
FRAX is computerized algorithm that determines fracture probability in individuals by 
integrating important individual clinical risk factors for fracture and mortality.
Results: The mean age was 57.7 ± 11.8; There are 63 men and 83 women. There were 
101 patients with continuous ambulatory peritoneal dialysis and 45 patients with automated 
peritoneal dialysis. A total of 45 patients were sarcopenia (30.8 %), of which 21 were men 
and 24 were women. There was no difference between the two groups of dialysis duration 
(1713.4 ± 1621.6 days vs 1804.3 ± 1917.4 days, p=0.761). Differences in values of the 10-
year probability of fractures were seen depending on the presence of sarcopenia. The risk of 
10-year of major osteoporotic fractures was low in a group that did not have sarcopenia (4.3
± 3.0 % vs. 6.9 ± 5.9, p = 0.021). And the risk of 10-year of hip fractures was also lower in
the group without sarcopenia (1.3 ± 2.0 vs 2.3 ± 1.5, p=0.022).
Conclusions: In peritoneal dialysis patients, the risk of fractures increases if they have 
sarcopenia. In peritoneal dialysis patients, it is desirable to reduce the risk of fractures by 
preventing sarcopenia.
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A Study Based on Bioelectrical Impedance Analysis on the Weight Gain in 
Peritoneal Dialysis: Fat or Muscle?
Guilherme P. Santa Catharina, Fernanda T. Ferreira, Erica A. Guimarães, 
Gabriel C. Barsotti, Lilian Cordeiro, Bruno C. Silva, Benedito J. Pereira, 
Hugo Abensur, Rosilene M. Elias. University of São Paulo, São Paulo, Brazil.
Background: Patient weight gain after the beginning of Peritoneal Dialysis (PD) is a 
well-known phenomenon, yet whether this is resultant from increased overhydration, fat 
or muscle mass is not well established. Bioelectrical Impedance Analysis (BIA) can assess 
both nutritional status and tissue hydration in these patients.
Methods: This is a cross-sectional study that included 44 incident patients on PD. A 
subset of 20 patients underwent BIA at baseline and 6 months after PD initiation for the 
following variables: fat mass (FM), muscle mass (MM), phase angle (PA), extracellular/
total body water ratio (ECW/TBW). Weight, body mass index, fasting glucose, total and 
HDL cholesterol, albumin, creatinine and FM/MM behavior during study period were also 
evaluated.
Results: Patients aged 52±17 years (43% men, 30% diabetic). There was an increase 
in weight gain (p<0.001), with no significant increase in fasting glucose, total and HDL 
cholesterol. Serum albumin reduced from 3.7±0.5 to 3.5±0.6g/dl (p=0.024). Fat increased 
from 19±6 to 21±7kg (p=0.041), with no increase in MM (from 23±4 to 24±5kg p=0.142), PA 
(from 4.4±2.5 to 3.5±5.6° p=0.914), and ECW/TBW (from 0.40±0.01 to 0.40 ±0.02, 
p=0.667). There were 3 distinct behaviors: Group 1: increased FM/decreased MM (N=7); 
Group 2: decreased FM/increased MM (N=6); Group 3: increased FM and MM (N=6). 
Groups were similar by age, gender, albumin and presence of diabetes, albeit group 2 
presented higher HDL cholesterol at 1 year (p=0.049), independent of statin prescription. 
[Figure 1]
Conclusions: PD is associated with weight gain, which is mostly due to a FM 
component. Intriguingly, some patients presented reduced FM and increased MM, and 
exhibited high levels of HDL cholesterol. Further studies are necessary to establish a link 
between weight gain, body composition and cardiovascular risk in PD patients.
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Elevated Serum Uric Acid Is Associated with Greater Skeletal Muscle 
Mass in Patients on Peritoneal Dialysis
Xi Xiao,3 Xiao Yang,1 Chunyan Yi,3 Yuan Peng,3 Haishan Wu,3 Meiju Wu,3 
Xuan Huang,3 Xueqing Yu.2 1The First Affiliated Hospital, Sun Yat-sen 
University, Guangzhou, China; 2Department of Nephrology, The First Affiliated 
Hospital, Sun Yat-sen University, Guangzhou, China; 3The First Affiliated 
Hospital, Sun Yat-sen University, Guang Zhou, China.
Background: Serum uric acid (UA) has been identified as a good nutritional marker in 
hemodialysis patients, but was little investigated in patients on peritoneal dialysis (PD). The 
aim of this study was to investigate the relationship between uric acid and skeletal muscle 
mass (SMA) in PD patients.
Methods: This is a cross-sectional study. The patients who performed multi-frequency 
bioelectrical impedance (BIA) from January 1, 2013 to December 31, 2016, and with SUA 
values were enrolled. Collected data included demographic characteristics, clinical and 
laboratory measurements. Skeletal muscle mass was measured by BIA. The relationship 
between SUA and the skeletal muscle mass was tested by multiple linear regression models.
Results: A total of 734 prevalent PD patients (57.4%male) were enrolled, with a mean 
age of 48.3±14.2 years, a mean SMA of 27.0±5.5kg and a mean serum UA of 6.8±1.3mg/
dl. Compared with participants in lowest quartile of UA, those participants in highest
quartile showed a higher SMA(28.22±5.88 vs. 25.97±4.70, p =0.015). When examined
as a continuous variable in multiple linear regression models, serum UA was positively
associated with skeletal muscle mass in total patients [standardized coefficients (β) 0.453; 
95% confidence interval(CI) 0.145 - 0.760, p = 0.004]. And gender-stratified analysis shows 
that the association exists both in male (β 0.433; 95% CI 0.010 - 0.856, p= 0.045) and
female patients (β 0.486; 95% CI 0.032 to 0.940, p= 0.036). Furthermore, a significant
association was found between the highest or the second highest quartiles of UA and
skeletal muscle mass in fully adjusted models in PD patients(β 1.952; 95% CI 0.801 -3.102, 
p= 0.001; β 1.453; 95% CI 0.305-2.600, p= 0.013, respectively).
Conclusions: The elevated serum UA was associated with a greater skeletal muscle 
mass in PD patients, and uric acid could be a potential nutritional marker in PD patients.
Funding: Government Support - Non-U.S.
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Home-Based Aerobic and Resistance Exercise Training on Peritoneal 
Dialysis Patients: A Randomized Controlled Trial
Kiyotaka Uchiyama,1 Shu Wakino,1 Naoki Washida,1,2 Kohkichi Morimoto,1 
Takahiro Kasai,2 Hiroshi Itoh.1 1Division of Endocrinology, Metabolism and 
Nephrology, Keio University, School of Medicine, Tokyo, Japan; 2Department of 
Nephrology, International University of Health and Welfare School of Medicine, 
Chiba, Japan.
Background: Muscle wasting, common and progressive in uremic patients, is 
associated with a high probability for morbidity, lower health-related quality of life 
(HRQOL), and mortality. However, potential effect of aerobic and resistance training on 
peritoneal dialysis (PD) patients has not been fully elucidated. This randomized, controlled 
study investigated whether a home-based exercise program for PD patients would improve 
their physical function, PD-related parameters and HRQOL.
Methods: 47 PD participants (mean age, 64 years; mean PD vintage, 3.8 years; 35 men) 
were randomly assigned to home-based training (n = 24) or usual care (n = 23). Participants 
were included if they started PD more than 3 months prior to baseline assessment. Patients 
were excluded if they had unstable medical conditions. Home-based-exercise patients were 
instructed to perform aerobic exercise at 40–60% of the peak oxygen uptake (VO2peak) thrice 
weekly, and resistance training at 70% one-repetition maximum twice weekly for 12 weeks. 
Exercise capacity was assessed by VO2peak estimated from incremental shuttle walking test 
and handgrip and quadriceps strength. In addition to evaluation of PD-related parameters, 
HRQOL was assessed by the Kidney Disease Quality of Life-Short Form questionnaire.
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Results: 44 participants completed the study (home-based training, n = 22; usual 
care, n = 22). Analyses of covariance, adjusted for baseline values, revealed significant 
differences between home-based training and usual care in VO2peak (12.5 ± 3.6 to 13.1 ± 
4.2 mL/kg·min versus 11.9 ± 2.8 to 11.2 ± 3.1 mL/kg·min; P = 0.02) and serum albumin 
(3.46 ± 0.49 to 3.51 ± 0.44 g/dl versus 3.55 ± 0.41 to 3.42 ± 0.47 g/dl; P = 0.03). Moreover, 
compared to usual care group, exercise group showed significant improvements in 
HRQOL scores of physical role functioning (P = 0.02) and role/social component summary 
(P < 0.01), as well as non-significant improvements in kidney disease component summary 
(P =0.06), bodily pain (P = 0.07), and vitality (P = 0.06). There were no reported adverse 
events as a result of the intervention.
Conclusions: A 12-week home-based aerobic and resistance exercise improved aerobic 
capacity, serum albumin and HRQOL in PD patients. The present study demonstrated for 
the first time, the efficacy of home-based training in PD patients.
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Roles of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Arteriovenous  
Fistula (AVF) Development
Yan-Ting Shiu,1 Ha D. Le,1 Yuxia He,1 CS Jason Tey,1 Isabelle D. Falzon,1 
Yanhang Zhang,5 Michael Allon,2 Timmy C. Lee,2 Scott A. Berceli,3 
Karl A. Nath,6 Edgar A. Jaimes,4 Alfred K. Cheung.1 1University of Utah, SALT 
LAKE CITY, UT; 2University of Alabama at Birmingham, Birmingham, AL; 
3University of Florida, Gainesville, FL; 4Memorial Sloan-Kettering Cancer 
Center, New York, NY; 5Boston University, Boston, MA; 6Mayo Clinic, Rochester, 
MN.
Background: Collagen is one of the most abundant vascular extracellular matrix 
components, and collagenolytic MMP-2 and MMP-9 are key regulators of vascular 
remodeling. MMP-2 and MMP-9 are known to stimulate the proliferation of vascular 
endothelial cells (ECs) and smooth muscle cells (SMCs) and cause collagen disruption. 
These properties may respectively promote the formation of neointimal hyperplasia (NH) 
and alter the ability of the AVF wall to expand in patients with chronic kidney disease 
(CKD). Thus, we investigated the effect of CKD on MMP-2 and MMP-9 expression, and 
their roles in AVF development.
Methods: Human vascular ECs and SMCs were cultured in serum obtained from CKD 
patients or non-CKD control subjects and then quantified for MMPs by western blot. We 
used a modified low-dose adenine diet to induce CKD in Wistar rats. Baseline femoral 
venous MMPs were quantified and femoral AVFs were created in CKD rats and non-CKD 
rats. Baseline vascular compliance was measured and carotid-jugular AVFs were created in 
global MMP-2 or MMP-9 knockout (KO) mice on C57BL/6 background, with C57BL/6 
mice serving as wild-type (WT) controls. AVFs from both animal models were harvested 
for histology.
Results: Compared to non-CKD serum, CKD serum enhanced MMP-2 (1.3-fold) and 
MMP-9 (20-fold) protein expression in cultured ECs. Similar trends were found for SMCs. 
When compared to non-CKD rats, CKD rats had higher baseline venous MMP-2 (3-fold) 
and MMP-9 (4-fold), and smaller AVF vein lumen area 4 weeks after creation. Baseline 
carotid arteries from the MMP-2 KO mice and MMP-9 KO mice had higher compliance 
when compared to WT mice. The percent open lumen area of the AVF veins at 1 week after 
creation was larger in the MMP-2 KO mice (39% ± 6%) and MMP-9 KO mice (47% ± 3%) 
vs. the WT mice (11% ± 2%).
Conclusions: Our animal studies showed that MMP-2 and MMP-9 were strong 
impediments to AVF development. Therapeutic approaches of inhibiting these molecules 
may enhance AVF maturation in CKD patients.
Funding: NIDDK Support
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Preexisting venous Medial Matrix Metalloproteinase (MMP)-2  
and Arteriovenous Fistula (AVF) Maturation: Findings from the  
Hemodialysis Fistula Maturation (HFM) Consortium Study
Yan-Ting Shiu,1 Ha D. Le,1 Michael Allon,2 Michelle L. Robbin,2 Kelly 
L. Hudkins,3 Charles E. Alpers,3 Tom Greene,1 Alfred K. Cheung.1 1University of 
Utah, SALT LAKE CITY, UT; 2University of Alabama at Birmingham,
Birmingham, AL; 3University of WA, Seattle, WA.
Background: AVF maturation requires adequate outward remodeling (luminal 
expansion) and limited inward remodeling (neointimal hyperplasia) to facilitate increases 
in AVF diameter and blood flow. MMP-2 and MMP-9 are critical for vascular remodeling in 
other settings. Inhibition of MMP-2 and MMP-9 reduces neointimal hyperplasia following 
vascular injury or graft implantation in animals with normal renal function. However, 
the clinical relevance of MMP-2 and MMP-9 in AVF diameter (a net result of luminal 
expansion and neointimal hyperplasia) and blood flow remains unclear.
Methods: We prepared histological slides of venous samples from 100 randomly 
selected patients at the time of AVF creation in the HFM Study. The protein expression 
levels of MMP-2 and MMP-9 were quantified by immunohistochemistry and ImageJ, 
and reported as a percentage of the total medial area. We then investigated the statistical 
associations of MMP-2 or MMP-9 levels with AVF diameter and blood flow assessed using 
duplex ultrasound at 6 weeks after AVF creation.
Results: Venous medial MMP-2 (Fig. 1) and MMP-9 expression varied widely among 
patients. We found a negative association of venous medial MMP-2 with the 6-week AVF 
diameter (Δ diameter = –0.23 mm; 95% CI, –0.44 to –0.02; p=0.029) and a trend for AVF 
blood flow (Δ flow = –39 ml/min; 95% CI, –106 to –29; p=0.26), per 10% increase in MMP-
2. No association was found between MMP-9 and the 6-week AVF diameter or blood flow.
Conclusions: Preexisting venous medial MMP-2 expression was associated with 
impaired AVF maturation in this subset of HFM patients. More rigorous validation of this 
observation using a larger cohort is necessary.
Funding: NIDDK Support
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Transcriptomics of Human Arteriovenous Fistula Failure Uncovers an 
Unexpected Source of Inflammation
Laisel Martinez,2 Marwan Tabbara,2 Juan C. Duque Ballesteros,2 Guillermo 
Selman,1 Angela Paez,2 Loay H. Salman,1 Roberto I. Vazquez-Padron.2 1Albany 
Medical College, Albany, NY; 2University of Miami, Miller School of Medicine, 
Miami, FL.
Background: Improving arteriovenous fistula (AVF) outcomes requires a better 
understanding of the biology underlying maturation or failure. Unfortunately, our current 
knowledge of the biological processes associated with maturation relies on assumptions 
and extrapolation from other vascular pathologies, which overlooks the uniqueness of AVF 
remodeling.
Methods: In this study, we used an unbiased “omics” approach based on high-
throughput RNA sequencing of human pre-access veins and fistulas to uncover novel 
molecular targets associated with nonmaturation. We obtained native vein and juxta-
anastomotic AVF tissues from patients undergoing two-stage upper arm AVF surgeries at a 
single center. Paired venous samples from both stages were used to study the vein to AVF 
transformation at the transcriptomics level.
Results: We discovered a unique molecular signature of pro-inflammatory genes 
(CSF3R, FPR1, S100A8, S100A9, and VNN2) that was upregulated in native veins that 
failed vs. matured (FDR<0.05), and whose expression co-localized to smooth muscle cells 
in the media. Furthermore, expression of S100A8 and S100A9 was significantly associated 
with postoperative intimal hyperplasia (IH) and the product of medial fibrosis x IH (R2 
0.10-0.15, P<0.05). We revealed the drastic vascular transformation that occurs during 
early remodeling at the molecular level, with >9,500 genes differentially expressed between 
native veins and AVFs in paired tissue samples.
Conclusions: In conclusion, this work demonstrates the importance of the subclinical 
inflammatory status of the pre-access vein in AVF nonmaturation, and identifies 
calprotectin (S100A8/A9) as a potential therapeutic target to prevent this complication. Our 
transcriptomics data underscores the complexity and uniqueness of vascular remodeling 
after fistula creation.
Funding: NIDDK Support
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Endothelial-to-Mesenchymal Transition in Neointimal Hyperplasia of a 
Mice Model of Arteriovenous Fistula
Chung-te Liu. Division of Internal Medicine, Wanfang Hospital, Taipei Medical 
University, Taipei, Taiwan.
Background: To date, arteriovenous fistula (AVF) is the preferred vascular access for 
hemodialysis. However, for the matured AVF, the 2-year patency without intervention was 
only 30-50%. In addition, frequent interventional procedures were required to maintain 
AVF patency, which causes immense suffer to patients. As such, medical treatment to 
prevent AVF stenosis is desired. Stenosis of AVF resulted from the process of neointimal 
hyperplasia, signifying thickening of subintima caused by proliferation of cells express α-
smooth muscle actin (α-SMA) and vimentin. The pathogenic role of neointimal hyperplasia 
in AVF stenosis has been confirmed by multiple studies, however, understanding of its 
molecular mechanism is still suboptimal. Endothelial-to-mesenchymal transition (EndMT) 
is the process that endothelial cells transform to mesenchymal cells, which had been 
demonstrated in pathogenic fibrogenesis of cardiovascular diseases. This study tries to 
demonstrate EndMT in a mice AVF model.
Methods: Chronic kidney disease (CKD) in mice is induced by diet containing 0.2% 
adenine. After 10 days of adenine diet, CKD was confirmed by elevated serum creatinine 
and surgical creation of AVF was performed. Murine AVF model is created by aortocaval 
puncture to form AVF between abdominal aorta and inferior vena cava (IVC). The 
successful creation of AVF was confirmed by doppler ultrasound during surgery. Six weeks 
after AVF creation, the mice were sacrificed and AVF was resected. The specimens were 
stained for α-SMA and vascular endothelial-cadherin (VE-cadherin) to show the expression 
of both endothelial and mesenchymal features of the proliferated intima.
Results: After 10 days of adenine containing diet, serum creatinine increased 
significantly from 0.25 mg/dL to 0.73 mg/dL. Immediately after AF creation, doppler 
ultrasound showed increased blood flow and exaggerated pulsation wave form of the IVC 
proximal to AVF site. The IVC wall adjacent to AVF site showed proliferated intima, which 
stains positive for α-SMA. Co-staining the same area showed that the proliferated intima 
expressed both α-SMA and VE-cadherin, which indicated possible EndMT.
Conclusions: This pilot study provided preliminary evidence of the presence of EndMT 
in AVF mice model, which may underly the pathogenic stenosis of human AVF. However, 
more evidence is still required to confirm EndMT in AVF and its molecular pathway.
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The Role of PDE5A Inhibition in Arteriovenous Fistula Remodeling
Maheshika S. Somarathna, Tatyana Isayeva Waldrop, Jessica N. Redmann, 
Timmy C. Lee. The University of Alabama at Birmingham, Birmingham, AL.
Background: Impaired outward vascular remodeling along with neointimal 
hyperplasia (NH) are thought to be the major underlying causes of arteriovenous fistula 
(AVF) maturation failure. We hypothesize that a selective phosphodiesterase type 5A 
(PDE5A) inhibitor, sildenafil, administered before and after AVF creation can be used to 
improve vascular outward remodeling. The aims of this study are to evaluate in a rat AVF 
model, the effect of PDE5A inhibition on: 1) venous and arterial diameter 2) venous blood 
flow and 3) venous NH formation.
Methods: Sildenafil was administered to 12-16-week-old Sprague-Dawley rats two 
weeks prior to AVF (Femoral vein to artery) creation and continued until sacrifice at 7 
days. Venous blood flow was measured using transonic perivascular flow probes and the 
diameters of the AVF venous and arterial segments were measured at a point proximal and 
a point distal to the anastomosis using the microscopic ocular micrometer (Fig. 1A), at the 
time of sacrifice. Morphometric analysis of the AVF vein was also carried out to assess the 
changes in NH development.
Results: When compared to control group, a significant increase in venous and arterial 
diameter was observed in the sildenafil treated group in proximal and distal regions, at 
7days after AVF creation. Furthermore, increased venous blood flow was also observed 
in sildenafil treated AVFs. However, no significant difference in the NH development was 
observed between the two groups.
Conclusions: Sildenafil administered before and after AVF creation, improves venous 
blood flow and the outward expansion in AVF vessels without affecting the level of NH 
at 7 days. These observations suggest that, outward expansion of venous limb of the AVF 
can preserve the luminal caliber and allow proper maturation of AVF, in the presence of 
NH formation. Therefore, targeting mechanisms that enhance outward vascular remodeling 
could be a potential therapeutic approach for treating AVF maturation failure.
Funding: Veterans Affairs Support
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Neutrophil Activation Status Was Associated with the Degree of  
ºArteriovenous Fistula Stenosis in Chronic Hemodialysis Patients
Hye Min Choi,1 Young Eun Kwon,2 Dong-jin Oh.2 1Internal medicine, Myongji 
Hospital, Goyang-si, Republic of Korea; 2Myongji Hospital, Koyang, Republic 
of Korea.
Background: Although arteriovenous fistula (AVF) dysfunction is a major cause of 
morbidity in hemodialysis (HD) patients, detailed pathogenesis of AVF stenosis is still under 
investigation. Leukocytes have been shown to play an important role in the development 
AVF stenosis. However, prior reports have focused on monocyte lineage cells, and little is 
known about the possible role of neutrophils. We aimed to evaluate the association between 
AVF stenosis and neutrophil activation status by measuring circulating levels of neutrophil 
elastase (NES), lactoferrin, and angiogenin, which are markers of neutrophil activation and 
inhibition, respectively.
Methods: A total of 69 patients were included who received HD with native AVF 
for more than 3 months. Patients with recent history of infection, antibiotics, or AVF 
intervention were excluded. Degree of AVF stenosis was expressed by the percent of the 
greatest stenotic diameter to the widest adjacent vessel diameter by ultrasound
Results: The pre-dialysis circulating NES and lactoferrin levels were not significantly 
different between HD patients and control (healthy and CKD stage 3), although angiogenin 
level was significantly higher in HD population. The degree of AVF stenosis was positively 
correlated with NES (r=0.360, p=0.002) and lactoferrin (r=0.352, p=0.003) levels. Patients 
with AVF stenosis (stenosis > 50%) were older (65.9±9.7 vs 58.0±13.7, p=0.004), had longer 
duration of AVF use (52.9±45.8 vs 39.5±46.0 month, p=0.019), higher hsCRP (0.34±0.35 vs 
0.15±0.17 mg/dl, p=0.029), and higher NES (421.0±254.2 vs 192.2±136.3 ng/ml, p<0.001) 
and lactoferrin (279.4±127.4 vs 144.0±68.9 ng/ml, p=0.001) levels compared with the other 
group. There was no significant difference in gender, presence of diabetes, angiogenin, 
and other biochemical measurements including albumin, calcium, phosphorus, iPTH, and 
cholesterols according to the degree of AVF stenosis. In multivariable analysis, however, 
only age and duration of AVF use were statistically significant factors for AVF stenosis.
Conclusions: Circulating levels of NES and lactoferrin, indirect markers of neurophil 
activation, were associated with the degree of AVF stenosis. Larger scales of long-term 
prospective studies are needed to show whether they could be used as independent 
predictors of at-risk AVF.
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The Role of Heme-Degrading and Heme-Binding Proteins in Decreasing 
Thrombosis
Meryl C. Nath,1 Anthony J. Croatt,1 Joseph P. Grande,1 Allan W. Ackerman,1 
John D. Belcher,2 Raymond F. Regan,3 Gregory M. Vercellotti,2 Karl A. Nath.1 
1Mayo Clinic, Rochester, MN; 2University of Minnesota, Minneaplis, MN; 
3Thomas Jefferson University, Philadelphia, PA.
Background: Induction of the heme-degrading enzyme, heme oxygenase-1 (HO-1), 
protects against dysfunction and closure of an arteriovenous fistula (AVF) and other types 
of vascular injury. Thrombosis contributes to AVF dysfunction and closure, and to certain 
types of vascular and renal injury. The present study examined whether HO-1 induction or 
administration of its products reduces thrombosis in vivo.
Methods: We employed the murine clot model induced by infra-renal ligation (L) of 
the inferior vena cava (IVC). Clot size is assessed in this model by determining the clot 
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weight/clot length ratio. Our prior studies in this model demonstrated that HO-1 is induced, 
and that clot size is increased in HO-1-/- mice as compared with HO-1+/+ mice.
Results: Clot size in the IVCL model was significantly reduced in mice treated with 
hemin (an inducer of HO-1) as compared with saline on day 1 (1.13±0.54 vs 2.92±0.21), 
day 2 (1.72±0.26 vs 3.58±0.36), and day 3 (1.70±0.47 vs 3.29±0.24) after IVCL. These 
beneficial effects of hemin were accompanied by reduced expression of proinflammatory 
and thrombogenic genes. We confirmed marked induction of HO-1 mRNA and protein and 
HO activity in the IVC in hemin-treated mice. HO-1 upregulation in the IVC by adeno-
associated viral delivery also reduced clot size in the IVCL model. Biliverdin, a product of 
HO activity, reduced clot size on day 2 after IVCL, as did another product of HO activity, 
carbon monoxide, delivered as CORM-3. The constitutive HO isoform, HO-2, did not 
exhibit the anti-thrombotic efficacy of HO-1 as clot size was not increased in HO-2-/- mice 
as compared with HO-2+/+ mice. Analysis of the clot model further demonstrated that the 
heme-binding protein, hemopexin (HPX) was induced in the IVC, and that clot size was 
increased in HPX-/- mice as compared with HPX+/+ mice.
Conclusions: HO-1 and its products are markedly effective in inhibiting thrombosis, 
whereas such efficacy is not exhibited by HO-2. The beneficial effect of HO-1 in reducing 
AVF closure and vascular injury likely reflects, at least in part, its inhibitory effect on 
thrombogenesis. HPX is identified as a novel inhibitor of thrombogenesis in the IVCL 
model.
Funding: NIDDK Support
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Role of Mevalonate Pathway on Vascular Access Failure in Maintenance 
Hemodialysis
Manabu Kanda, Satoru Sanada, Mitsuhiro Sato, Toshinobu Sato, Yoshio Taguma. 
Japan Community Health Care Organization Sendai Hospital, Sendai, Japan.
Background: We have reported the effectiveness of statins against vascular access 
(VA) dysfunction. Despite statin administration, there was no difference in serum 
cholesterol levels between the statin users and the non-users, suggesting that the VA 
protective role of statin is different from the cholesterol lowering effect. In recent years, 
Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif 
(TAZ) were found as a new pathway associated with arteriosclerosis. The turbulence of 
intravascular blood flow triggers the YAP/TAZ pathway, which enhances gene expressions 
correlated with inflammation and fibrosis, resulting in arteriosclerosis. Mevalonate acid 
(MA) activates this pathway and statins are known to inhibit the MA production. Therefore, 
we hypothesized that VA protective effect of statin could be inhibition of YAP/TAZ pathway 
via MA reduction.
Methods: Patients on maintenance hemodialysis and people with stage 4 or 5 chronic 
kidney disease were enrolled in this study. The serum MA levels were measured using an 
enzyme cycling method. Gene expressions of connective tissue growth factor (CTGF) and 
cysteine-rich angiogenic inducer 61 (CYR61) in the peripheral blood mononuclear cells 
were evaluated using real-time PCR.
Results: Serum MA levels in patients with CKD and maintenance hemodialysis 
increased compared to healthy subjects (6.6±0.7, 8.8±0.6, and 4.6±0.8 μg/dL, respectively). 
Among hemodialysis patients, serum MA levels were higher in patients with VA dysfunction 
than without dysfunction (9.2±0.6 vs 6.6±0.7 μg/dL, p=0.07). Moreover, serum MA levels 
in patients who required VA angioplasty more than a year showed a higher value than those 
without repeated angioplasty (9.4±0.9 vs 8.7±0.7 μg/dL, p=0.60). These data suggest that 
serum MA levels associate with an increased risk of VA dysfunction. Serum MA levels were 
lower in statin users compared to non-users (7.4±1.1 vs 9.4±0.6 μg/dL, p=0.10), indicating 
that statin could decrease serum MA levels. Lastly, CTGF and CYR61 gene expressions 
were decreased in statin users compared to non-users (0.13±0.02 vs 0.17±0.01, 0.48±0.05 
vs 0.67±0.11, respectively), implying that statin inhibits the YAP/TAZ pathway.
Conclusions: Statin treatment could be effective on VA dysfunction through lowering 
MA and YAP/TAZ suppression.
Funding: Private Foundation Support
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Zinc Deficiency Is a Risk for Vascular Access Failure in Hemodialysis 
Patients
Yukiko Hasuike,1 Naoto Kakita,2 Masayoshi Nanami,1 Kosuke Mizusaki,1 
Wataru Fukao,1 Aritoshi Kida,1 Mana Yahiro,1 Yasuyuki Nagasawa,1 
Takahiro Kuragano,1 Masaharu Ishihara.1 1Internal Medicine, Division of Kidney 
and Dialysis, Nishinomiya, Japan; 2Mitsubishi Kobe Hospital, Kobe, Japan.
Background: Vascular access (VA) is essential for the hemodialysis (HD) patients. 
Percutaneous transluminal angioplasty (PTA) is an effective therapy against VA failure, 
however, re-failure of VA is often occurred even after PTA. Zinc plays a role in endothelial 
cell function, and Zinc deficiency can effect vascular dysfunction. To investigate the 
association of Zinc deficiency with VA failure, serum Zinc and the patency of VA following 
PTA were examined.
Methods: Blood samples were taken from 337 HD patients at PTA against VA failure. 
Serum Zinc, factors related to mineral-bone metabolism (Ca, iP, PTH-intact [iPTH], ALP), 
8-hydroxy-2’-deoxyguanosine (8OHdG) as a maker of oxidative stress, inflammation (CRP, 
interleukin-6, tumor necrosis factor-α), and uremia (BMI, albumin, urea nitrogen, Hb) were 
measured. The end point of study was VA failure (re-vascularization or re-operation) during 
the observational period after PTA. Cox proportional hazards models for the end point was 
used.
Results: During follow-up period (median 367 days), re-vascularization was 
performed in 67 participants and re-operation in 69. The median of serum Zinc was 
63 pg/ml (IQR 56 to 74), and 130 (38.6%) participants had Zn deficiency (<60 pg/ml). The 
participants with VA failure had lower Zn (p=0.03), higher iPTH, and a tendency to high 
8OHdG compared with the participants without VA failure. There was no difference in the 
other factors. The Kaplan-Meier analysis showed that the participants with Zn deficiency 
was associated with higher incidence of VA failure (Figure 1). Cox regression analysis also 
revealed that Zn deficiency (adjusted hazard ratio 1.51, 95% CI 1.06 to 2.13, p=0.022) was 
a risk for VA failure.
Conclusions: Zinc deficiency was an independent risk for VA failure. Zinc might be 
associated with the maintenance of VA patency in HD patients.
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Increased Monocyte-to-High-Density Lipoprotein Ratio Is Associated with 
Recurrent Vascular Access Stenosis
Yaeni Kim,1 Hye Eun Yoon,2 Seok Joon Shin.3 1Incheon St. Mary’s Hosp, 
Catholic Univ of Korea, Incheon, SEoul, Republic of Korea; 2The Catholic 
University of Korea, Incheon, INCHEON, Republic of Korea; 3Incheon St. 
Mary’s Hospital, The Catholic University of Korea, Incheon, Incheon, Republic 
of Korea.
Background: Previous studies indicate that increased monocyte count and decreased 
high-density lipoprotein (HDL) cholesterol levels are associated with chronic kidney 
disease, and increased risk for cardiovascular diseases, indicating its possible role in 
pro-inflammatory and pro-oxidant states. We tried to investigate the clinical significance 
of circulating monocyte count-to-serum HDL cholesterol ratio (M/H ratio) in predicting 
recurrent vascular access stenosis after angioplasty in hemodialysis patients.
Methods: M/H ratio at access creation and prior to angioplasty was measured in a total 
of one-hundred and fifty hemodialysis patients in Incheon St. Mary’s hospital from July, 
2006 to September, 2017. The impact of M/H ratio in predicting recurrent access stenosis 
was evaluated retrospectively by using Kaplan-Meier, Cox regression, and ROC curve 
analyses.
Results: The patient group comprised of 67% male and 58% diabetes, aged 62±14 
years old (n=150). Baseline M/H ratio at access creation was not different between those 
with vascular access stenosis (n=71) and those without stenosis (n=79) (10.74 vs. 12.42, p = 
0.11). Among patients with vascular access stenosis, there also was no difference in baseline 
M/H ratios between those with recurrent stenosis (n=33) and those without recurrence 
(n=38) (9.98 vs. 11.4, p = 0.24). However, pre-angioplasty M/H ratio increased significantly 
when compared to that of baseline (10.75 vs. 17.95, p < 0.001). Delta M/H ratio, as defined 
by a difference between baseline and pre-angioplasty ratios was calculated and mean delta 
M/H ratio was 1.9. Increased delta M/H ratio (delta M/H ratio greater than or equal to 
1.9) was associated with recurrent stenosis (HR 4.16, CI 1.43-12.12, p = 0.009). Moreover, 
increased delta M/H ratio was clinically significant in predicting recurrent vascular access 
stenosis (AUC 74%, p = 0.001).
Conclusions: Increased delta M/H ratio may play a role in pro-inflammatory and pro-
oxidant environment and predispose vascular access for recurrent stenosis after angioplasty.
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Artery to Fistula Diameter Ratio as a Predictor of Early Re-Occlusion of 
Immature Arteriovenous Fistulas After Percutaneous Transluminal 
Angioplasty
Hong jin Bae,3 Chang hun Song,4 Youngrok Ham,2 Dae Eun Choi,1 Kang 
Wook Lee,2 Jiwon M. Lee,1 Ki Ryang Na.2 1Chungnam National University, 
Seoul, Republic of Korea; 2Chungnam National University Hospital, Daejeon, 
Republic of Korea; 3Chung Nam National University hospital, Daejeon, 
Republic of Korea; 4Chungnam national university, Daejeon, Republic of Korea.
Background: Percutaneous transluminal angioplasty (PTA) is widely performed for 
arteriovenous fistula (AVF) that fails to mature after initial formation. We observed that 
some immature AVFs re-occlude earlier than others. We sought to investigate the predictors 
for early post-intervention failure of immature fistulas after the primary PTA.
Methods: We retrospectively reviewed the records and angiographic images of patients 
who had immature fistulas and thereby received PTA between years 2013 to 2017 at our 
center. We investigated the short-term post-intervention outcomes of the patients within 90 
days post PTA. Patients who had re-occlusion within the period were defined as early failure 
group and the rest as patent group. We investigated factors associated with early failure.
Results: There were 80 eligible patients with 22 brachiocephalic (BC) and 58 
radiocephalic (RC) AVFs. The median age of the patients was 64 years [range, 38-87]. 
There were 51 (63%) males and 29 (36%) females. Among the 58 RC AVFs, 10 (17%) 
patients had early failure. Logistic regression analysis showed that larger artery to fistula 
(A/F) diameter ratio was the sole independent predictor of early failure after primary PTA 
(odd ratio 2.29 [1.023-5.147], P= 0.044).
Conclusions: Although further studies in a larger scale are required to confirm the 
clinical significance, larger A/F diameter ratio was a potential predictor of early re-occlusion 
in immature fistulas after primary PTA.
Funding: Government Support - Non-U.S.
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Comparison of the Outcomes of Upper Arm Arteriovenous Fistula and 
Forearm Arteriovenous Graft
Xueqin Bian, Yuan Luo, Hong Ye, Junwei Yang. Second Affiliated Hospital, 
Nanjing Medical University, Nanjing, China.
Background: Forearm arteriovenous graft (AVG) and upper arm arteriovenous fistula 
(AVF) are secondary choices when forearm AVF fails or the vascular quality is poor because 
of the increased hemodialysis duration or primary disease, such as diabetes. In this study, we 
compared the outcomes of upper arm AVF and forearm AVG in our dialysis center.
Methods: Patients underwent upper arm AVF or forearm AVG in our hospital from 
October 2014 to December 2017 were enrolled. The primary and secondary patency, 
complications were compared between the two groups. Kaplan-Meier survival curves and 
univariate Cox proportional hazard models were used.
Results: There were 116 (55.2%) patients underwent AVF and 94 (44.8%) patients 
underwent AVG, respectively. The characterizations of the patients, including age, gender, 
primary renal disease, comorbidities, hemodialysis duration and previous fistulation history 
were similar between the two groups. The primary patency of AVG vs. AVF were 83.5% 
vs. 93.1%, 75.8% vs. 91.4%, 60.3% vs. 75.3%, 42.1% vs. 56.6%, 31.6% vs. 57.1% at 3, 6, 
12, 24, 36 month after the surgery, respectively; however, no significant differences were 
observed between the two groups (P=0.13). Compared with AVF, AVG has higher secondary 
patency (P=0.03), which were 94.7% vs. 93.1%, 95.6% vs. 91.4%, 85.7% vs. 80.4%, 73.6% 
vs. 66.0%, 68.4% vs. 57.1% at 3, 6, 12, 24, 36 month after the surgery, respectively. The 
incidences of complications were higher in AVG than AVF, including thrombosis (23.3% 
vs. 13.4%), stenosis (50.0% vs. 21.2%), infection (2.4% vs. 0.5%) and steal syndrome (2.4% 
vs. 1.7%). In all kinds of comorbidities, fistulation history was correlated with reduction of 
primary patency (HR: 0.42; 95% CI: 0.26 to 0.67) and secondary patency (HR: 0.44; 95% 
CI: 0.28 to 0.69) in AVF group but not in AVG group.
Conclusions: Forearm AVG has superiority in secondary patency than upper arm AVF. 
AVG has more complications than AVF. Upper arm AVF may be recommended to increase 
primary patency and reduce complications.
Funding: Government Support - Non-U.S.
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Use of Smaller Vessels to Create an AVF Increases the Need for  
Interventions to Promote Its Maturation
Crystal A. Farrington,1 Michelle L. Robbin,1 Timmy C. Lee,2 Michael Allon.1 
1University of Alabama at Birmingham, Birmingham, AL; 2Univ of Alabama at 
Birmingham, Birmingham, AL.
Background: Preoperative vascular mapping using ultrasound (US) is often used to 
aid in the creation of an arteriovenous fistula (AVF). Current vascular access guidelines 
recommend minimal arterial and venous diameters of 2.0 mm and 2.5 mm, respectively, 
to optimize overall (assisted and unassisted) AVF maturation. However, the relationship of 
preoperative US measurements with unassisted AVF maturation (successful use without a 
prior intervention) has not been evaluated.
Methods: We reviewed the clinical, demographic, and preoperative mapping ultrasound 
information of 189 hemodialysis patients from a large dialysis center who received new 
upper extremity AVFs from 2010-16. We then evaluated the association of preoperative US 
measurements of venous diameter, arterial diameter, and brachial blood flow with two AVF 
outcomes: unassisted AVF maturation and overall AVF maturation.
Results: The mean age of the study population was 53 years. 58% of the patients were 
male, 81% were black, 57% were diabetic, and 48% were obese. 74% of the AVFs were 
located in the upper arm. Progressive increases in preoperative arterial diameter, venous 
diameter and brachial artery blood flow were each associated with corresponding increases 
in unassisted AVF maturation. Incremental increases in preoperative arterial diameter and 
blood flow were likewise associated with progressive increases in overall AVF maturation. 
In contrast, there was no significant association between preoperative venous diameter 
and overall AVF maturation (Table 1). Finally, the proportion of AVFs requiring assisted 
maturation was 52, 32, 31, and 22% when the preoperative arterial diameter was < 3, 3-3.9, 
4-4.9, and ≥ 5 mm, respectively.
Conclusions: Preoperative arterial diameter and blood flow are associated significantly 
with both unassisted and overall AVF maturation. Preoperative venous diameter is 
associated with unassisted, but not with overall, AVF maturation. Use of smaller vessels to 
create an AVF increases the need for interventions to promote its maturation.
Funding: NIDDK Support
Table 1. Preoperative arterial diameter, venous diameter, and brachial artery blood 
flow and their associated AVF outcomes.
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Sirolimus Treated AV Fistulae: Maturation Profile and Impact of 
Processes of Care
Sriram Iyer,1 Nelson P. Kopyt,2 Nirav Gandhi,3 Naveen K. Atray,4 
Thomas D. Wooldridge,5 Joseph J. Lee,6 Kendra S. Hendon,7 William D. Paulson,8 
Osman S. Khawar,9 Robert I. Lynn,10 Prabir Roy-Chaudhury,11 Maria V. DeVita.12 
on behalf of the ACCESS Trial investigators 1Vascular Therapies, Cresskill, NJ; 
2Lehigh Valley Hospital, Bethlehem, PA; 3Southern California Kidney Consultants, 
Anaheim, CA; 4Capitol Nephrology, Sacramento, CA; 5Nephrology & Hypertension 
Associates, LTD, Tupelo, MS; 6Nephrology Associates Medical Group, Riverside, 
CA; 7Knoxville Kidney Center, Knoxville, TN; 8Augusta University, Augusta, GA; 
9Balboa Nephrology Medical Group, Escondido, CA; 10Albert Einstein College of 
Medicine, Bronx, New York, NY; 11University of Arizona, Tucson, AZ; 12Lenox Hill 
Hospital- Northwell Health System, New York, NY.
Background: An arteriovenous fistula (AVF) is clinically mature if it can be 
reproducibly cannulated with 2 large-bore needles and has enough blood flow to support 
adequate hemodialysis. This analysis relates to AVF maturation data from patients (pts) 
who received intraoperative sirolimus delivered perivascularly at and around the AVF 
anastomosis from a collagen membrane (Drug product Vascular Therapies, Cresskill, NJ). 
The 7 center Hemodialysis Fistula Maturation (HFM) Study (n=602) recently reported 
impact of care processes on AVF maturation outcomes (Allon AJKD 2018)
Methods: Data for sirolimus treated AVF is from 30 Phase 2 + 22 open label pts. (from 
an ongoing US multicenter Phase 3 study NCT 02513303) undergoing surgery for a first, 
single stage upper extremity AVF. Mature AVF is defined as ability to use the AVF for 3 
consecutive 2-needle dialysis sessions with a mean flow of ≥300 mL/min for pts on dialysis 
or vein diameter of 6 mm and blood flow of ≥500 mL/min on ultrasound for patients not 
on dialysis.
Results: 52 pts; 51 ESRD, 1 CKD, 67% Male, mean, age 56±17y, 42% diabetic; 65% 
forearm AVF. Table compares metrics of AVF that matured without (Gp1) and with (Gp 2) 
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supplementary procedures (SP) which included balloon PTA, vein elevation and exclusion 
of collateral vein(s)
Conclusions: 1. Excluding the 6 AVF that thrombosed early, all (100%) remaining 
46 sirolimus treated AVF matured into a useful fistula (HFM: 77.6%) 2. 38/46 (83%) of 
sirolimus treated AVF matured after a median of 48 days (HFM: 125 days) 3. The median 
time of 121 days to maturation for the 8/46 (17%) AVF which required supplementary 
procedure(s) for maturation was roughly 2.5 times > than Gp 1. 4. For 83% of sirolimus 
treated AVF’s (Gp1) the ONLY metric influencing use of the AVF for dialysis was the 
anatomical and functional readiness of the fistula for cannulation. 5. For the 17% AVF that 
required supplementary interventions (Gp2), optimizing processes of care should help in 
reducing time to first AVF use.
Funding: Commercial Support - Vascular Therapies, Inc. Cresskill, NJ
Table
* 6/52 (11.5%) AVF thrombosed within 2 weeks and are excluded from this analysis
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Risks and Benefits of Antiplatelet Agents and Anticoagulants on  
Preventing Vascular Access Dysfunction in Hemodialysis Patients
Hsin-Hsu Wu.1,2 1Nephrology Department, Chang-Gung Memorial Hospital, 
Taipei, Taiwan; 2Chang Gung University, Taoyuan, Taiwan.
Background: Dialysis adequacy is one major determinant of survival for patients with 
end-stage renal disease. Good vascular access is essential to achieve adequate dialysis. This 
study evaluated the impact of different drugs on the vascular access dysfunction rate of an 
arteriovenous fistula or arteriovenous graft and the rate of major bleeding in hemodialysis 
patients
Methods: Patients with end-stage renal disease registered in the Taiwan National 
Health Insurance program from January 1, 1997 to December 31, 2012. A total of 95,992 
patients were enrolled in our study. Vascular access dysfunction, defined as the need 
of thrombectomy or percutaneous angioplasty. Major bleeding, defined as emergent 
department visits or hospitalization with a primary diagnosis of gastrointestinal bleeding 
or intracerebral hemorrhage. Adjusted odds ratio between person-quarters with or without 
antiplatelet or oral anticoagulant using were calculated using logistic regression and inverse 
probability treatment weighting.
Results: The odds ratio of vascular access dysfunction was 0.17 (0.10-0.28) for aspirin, 
0.69 (0.67-0.71) for clopidogrel, 0.62 (0.55-0.71) for dipyridamole, 0.62 (0.50-0.77) for 
Aggrenox, and 0.86 (0.81-0.90) for warfarin. The highest odds ratio for intracerebral 
hemorrhage was 2.55 (1.36-4.79) in patients using Aggrenox. The odds ratio for 
gastrointestinal bleeding was 1.53 (1.28-1.83) for clopidogrel, 1.11 (0.09-13.4) for aspirin, 
0.90 (0.38-2.17) for dipyridamole, 1.22 (0.29-5.16) for Aggrenox, and 1.27 (0.79-2.03) for 
warfarin.
Conclusions: Antiplatelet and anticoagulant agents might reduce vascular access 
dysfunction rate. The gastrointestinal bleeding rate was increased in clopidogrel using 
group. Aggrenox might increase the intracerebral hemorrhage rate and should be used with 
caution.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
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Effect of Aspirin Resistance and Mean Platelet Volume on Vascular Access 
Failure in Hemodialysis Patients
Jung-woo Noh,3,1 Hayne C. Park,1 Chaehoon Han.2 1Hallym University Kidney 
Research Institute, Seoul, Republic of Korea; 2kangnam secred heart hospital, 
Seoul, Republic of Korea; 3Dr. Chun & Cho Medical Clinic & Dialysis Center, 
Seoul, Republic of Korea.
Background: Maintaining patency of vascular access in hemodialysis patients is 
important because it is a life-saving vessel. We investigated the effect of aspirin resistance 
and mean platelet volume (MPV) on vascular access(VA) failure in hemodialysis (HD) 
patients.
Methods: We enrolled 163 maintenance HD patients. Aspirin resistance was defined 
as aspirin resistance unit (ARU) >550. VA failure was defined as thrombosis or a decrease 
of greater than 50% of normal vessel diameter which was angiographically documented 
reduction with ≥ 50 % luminal diameter accompanied by abnormal clinical findings.
Results: 163 patients showed a mean age of 57.6 ±12.0 years and 79 were male (48.5 %). 
Mean dialysis duration was 50.1 ± 52.1 months. Aspirin resistance was observed in 17 
out of 109 patients who measured the value. During a follow-up period of 34 months, 65 
VA failures occurred out of all subjects while 41 events among the failures occurred in a 
patient group who measured aspirin resistance. There was no significant difference between 
the two groups according to aspirin resistance in the cumulative event rate of VA failures 
(57% vs. 38.2%, log-rank test, p=0.051). Mean MPV was 9.15 ± 0.05 fl. The 163 patients 
were grouped according to half-tile values of MPV (9.08 fl) at baseline and ones with 
higher MPV levels (n=82) had exhibited lower levels of platelet count (p=0.002), albumin 
(p=0.009). The Kaplan-Meier curve showed significant difference between two groups 
in cumulative events of VA failure (54.1% vs 35.3%, p=0.018). In multivariate analysis, 
MPV (HR 1.794; 95% CI1.066-3.020; p=0.028), platelet count (HR 1.003; 95% CI 1.001-
1.006; p=0.01) and smoking (HR 1.894; 95% CI 1.019-3.519; p=0.043) were independent 
predictive factors of VA failure.
Conclusions: High MPV was associated with increased risk of VA failure. However, 
aspirin resistance showed a weak relationship with VA failure. MPV may be a potential 
marker for prediction of VA survival in HD patients.
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Intermittent Pneumatic Compression Devices Assists in Vascular Access 
Selection: A Hierarchical Regression Model Study
Tej M. Singh. Fist Assist Research Team Vascular Surgery, El Camino Hospital, 
Los Altos Hills, CA.
Background: Arteriovenous fistulas (AVF) are the preferred type of vascular access 
for hemodialysis patients. Among AVF, radiocephalic fistulas (RCF) are recommended. 
RCF placement has dropped in the USA to low rates. The aim of the present study is to 
determine if the use of a novel intermittent compression device can assist in vascular acces 
fistula selection.
Methods: After AVF creation, an intermittent pneumatic compression device enabling 
60 mm Hg of cyclic compression was worn proximal to AVF intermittently for 6 hours daily 
for 3 months. Patients in the treatment group (n=41) wore the device. Twenty-four (n=24) 
had BCF, while seventeen (n=17) had RCF. Controls (n=12) used a sham device. Vein size 
was measured at baseline and at 3 months by duplex. Percentage increase was tested for 
significance. Hierarchical regression models were developed to model vein size dilation 
based on factors such as patient group, fistula type (BCF or RCF), the interaction between 
patient group and fistula type, and patient demographics.
Results: The interaction effect between patient group and fistula type was found to be 
significant. In a stepwise regression procedure, the first term enteresd in the model is the 
interaction between patient group and AVF type. At a proximal distance of 5 cm and 10 cm, 
the interaction term was highly significant (p <.01). Vein size increase is affected by patient 
group (treatment vs. control) as well as the type of fistula created for vascular access. The 
type of fistula created for vascular access, has an interaction effect with patient-group type 
(treatment vs. control) in affecting vein size dilation
Conclusions: The use of a novel, pneumatic compression device has significant impact 
on the recommended guidelines for vascular access selection. For patients who use the non-
invasive device, a larger vein size dilation is achieved with a radiocephalic fistula. Novel, 
pneumatic devices may assist in RCF placement in the future.
Hierarchical regression modeling at 5 cm of fistula
FR-PO719 Poster Friday
Dialysis: Vascular Access - I
Correspondence of Low Wall Shear Stress and Cephalic Arch Stenosis in 
Brachiocephalic Arteriovenous Fistula Access
Mary S. Hammes,1 Kevin Cassel,2 Brian Funaki,1 Fredric L. Coe.1 1University of 
Chicago, Chicago, IL; 2Illinois Institute of Technology, Chicago, IL.
Background: An arteriovenous fistula (AVF) is the optimal access for hemodialysis. A 
brachiocephalic fistula (BCF) is often placed, but cephalic arch stenosis (CAS) commonly 
develops leading to failure. We hypothesized that a contribution to AVF failure is low wall 
shear stress (WSS) (less than 0.076 Pa), resulting in neointimal hyperplasia and venous 
stenosis. The aim of this study was to determine the correspondence of low WSS and the 
development of CAS in a large cohort followed longitudinally.
Methods: 39 subjects with ESRD and a primary BCF were followed from time of 
placement for three years or until the time of CAS. A venogram, Doppler, and blood 
viscosity were performed at time of AVF maturation (3 months), then annually up to three 
years or to time of CAS. Geometric measurements of venous diameter, radius of curvature, 
and arch angle were made. Computational modeling determined the location and percent 
low WSS in the arch. The relationship between WSS at three months and location of CAS 
was estimated by correlating computational modeling and quadrant location of CAS. 
Correspondence was examined using Chi-square.
Results: 32 subjects developed CAS by three years as shown by dots in the Figure. 
Of these, 25 subjects (red dots) displayed correspondence between low WSS at three 
months and CAS, whereas 7 subjects did not (blue dots) (p=0.0015). Most subjects with 
correspondence had low WSS areas evident in greater than 20% of the arch (p=0.0006). 
Venous diameter, radius of curvature and arch angle at three months did not predict 
CAS(p>0.05).
Conclusions: The presence and magnitude of low WSS in the cephalic arch is a factor 
associated with the development of CAS. Determination and attenuation of low WSS at 
3 months may help to prevent the development of CAS which is difficult to treat once it 
develops.
Funding: NIDDK Support
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A Computational Fluid Dynamics (CFD) Approach to Optimize  
Arterio-Venous Fistula (AVF) Anastomotic Hemodynamics with  
Ôan External Support Device (VasQ™)
Dirk M. Hentschel. Brigham and Women’s Hospital, Boston, MA.
Background: The complex AVF geometry induces hemodynamic changes in the juxta-
anastomotic region (JAR). Multidirectional flow and oscillating wall shear stress (WSS) 
along the venous wall invoke undesirable inward vein remodeling through aggressive 
development of neointimal hyperplasia. A CFD model was utilized to study the effect of 
geometric parameters on hemodynamic profiles to inform optimal design of the VasQ™ 
device.
Methods: A fully developed 3D end-to-side AVF CFD model was evaluated 
through a range of artery and vein diameters (2.9-8mm) and flow volumes (40–1100 ml/
min) assuming steady, laminar, Newtonian flow. 2D velocity streamline patterns were 
analyzed. Geometric parameters controllable by external scaffold were optimized for 
minimizing multidirectional flow along the venous wall (A1) and maximizing its distance 
from anastomosis (P1). Parameters included anastomotic angle (20°-60°), Proximal Vein 
(PV)/Distal Vein (DV) diameter ratio (conical shape) (1.2-2) and conical segment 
length(CSL) (15-25mm). Each parameter was analyzed by fixing all model values 
excluding the tested one.
Results: Improved flow patterns (small mean λ value; λ =A1/P1) were observed 
for anastomotic angle between 40°-50° (0.92±0.2) compared to angle between 20°-30° 
(2.3±1.7) and 60° (1.74±1.3). Optimal PV/DV (conical shape) was 1.5 (0.23±0.07) with 
higher λ values for PV/DV lower or higher than 1.5. λ values of 0.2±0.8, 0.27±0.05 and 
0.35±0.06 for CSL of 25mm, 20mm and 15mm accordingly.
Conclusions: Improved unidirectional flow pattern directly correlated to uniform WSS 
in the JAR were observed for anastomotic angle between 40°-50°, conical vein shape with 
1.5 PV/DV and CSL of 25mm in multiple configurations. These conclusions were the basis 
for designing VasQ™.
Funding: Commercial Support - Laminate Medical Technologies
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Tested geometrical parameters
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New Approach for Assessing Vascular Stiffness in Patients with 
Hemodialysis
Dong Ho Shin,1 Do Hyoung Kim,2 Jung-woo Noh,3 Chaehoon Han.4 1College of 
Medicine, Hallym University, Seoul, Republic of Korea; 2Hallym University 
Hangang Sacred Heart Hospital, Seoul, Republic of Korea; 3Hallym University, 
Seoul, Republic of Korea; 4kangnam secred heart hospital, Seoul, Republic of 
Korea.
Background: It is known that increased vascular stiffness, as measured by pulse 
wave velocity (PWV), can predict cardiovascular events in hemodialysis (HD) patients. 
Additionally, the measurement of static intra-access pressure ratio (SIAPR), using 
transducer on HD machines, is preferred vascular access surveillance method. However, 
little is known about the clinical usefulness of SIAPR in predicting the degree of vascular 
stiffness.
Methods: A total of 209 patients on maintenance hemodialysis were evaluated 
between January 2014 and February 2018 at three hospitals. Brachial-ankle pulse wave 
velocity (baPWV) and SIAPR were measured in HD patients. After that, we performed 
echocardiography at study enrollment and investigated cardiovascular (CV) events after 
study enrollment, respectively.
Results: Patients with arteriovenous (AV) graft and AV fistula was 172 and 37, 
respectively. Among AV fistula group, SIAPR was significantly negative correlation with 
baPWV (ß = - 0.16, p =0.04). The area under the receiver operating (ROC) curve for 
SIAPR value to predict CV events was 0.09 (95% confidence interval [CI]; 0.86 - 0.95, 
p < 0.001). A SIAPR value of 0.09 was selected as the cut-off value for CV events. baPWV 
(222.7 ± 418.1 vs. 2010.2 ± 511.4 cm/s, P = 0.04) and the proportion of left ventricular 
diastolic dysfunction (86% vs. 25%, p = 0.01) was significantly higher in patients with 
a SIAPR value ≤ 0.09 than with a SIAPR value > 0.09. Kaplan-Meier analysis revealed 
that cumulative incidence of CV events was significant higher in patients with a SIAPR 
value ≤ 0.09 (p.= 0.04). Among AV graft group, there were significantly negative correlation 
between SIAPR and baPWV. When a SIAPR value of 0.15 was selected as the cut-off value 
for CV events, similar trends were observed.
Conclusions: SIAPR was significantly associated with baPWV and left ventricular 
diastolic dysfunction in HD patients. Additionally, lower value of SIAPR could predict 
cardiovascular events.
FR-PO722 Poster Friday
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Adjunctive Use of Color-Coded Digital Subtraction Angiography During 
Percutaneous Transluminal Intervention of Hemodialysis Vascular Access
Swee Ping Teh, Ru Yu Tan, Suh Chien Pang, Kian Guan Lee, Alicia H. Ong, Tze 
tec Chong, Apoorva Gogna, Chieh-suai Tan. Singapore General Hospital, 
Singapore, Singapore.
Background: Parametric color-coding of digital subtraction angiography (DSA) 
has been successfully used in interventional neuroimaging and diagnostic imaging 
for peripheral arterial disease. We aimed to examine the utility of color-coded DSA for 
quantitative hemodynamic analysis in percutaneous transluminal angioplasty (PTA) of 
hemodialysis access.
Methods: This is a prospective, single center study. DSA acquisitions were post-
processed into color-coded images. Regions of interest (ROI) were selected for each image. 
Hemodynamic parameters including time-to-peak (TTP) contrast opacification, contrast 
transit time (TT) and contrast decay time were obtained. These parameters were compared 
pre-and post-PTA.
Results: DSA of 16 patients who underwent PTA were included. 9 interventions were 
performed on arteriovenous fistulas and 7 on arteriovenous grafts with median access age 
of 3.5 ± 3.1 years (interquartile range 1.8-6.7). All patients had improvement in percentage 
of stenosis post PTA with a mean difference of 39.71 ± 16.25% (p<0.01). TTP improved 
significantly following PTA, with mean reduction of 0.35 ± 0.65 seconds (s) (p<0.01) 
and 0.60 ± 0.83s (p<0.01) for pre- and post- stenosis ROIs respectively. Mean reduction 
in contrast transit was 0.23 ± 0.53s (p=0.04). Receiver operator characteristics analysis 
showed that 10% contrast decay time at 0.05s correlated with access flow of 800cc/min 
with sensitivity of 0.91 and specificity of 0.5 (area under the curve 0.89, 95% confidence 
interval 0.71 – 1.0).
Conclusions: Adjunctive usage of parametric color-coded DSA could provide 
hemodynamic information, which may be useful for decision-making during PTA of 
hemodialysis access.
FR-PO723 Poster Friday
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Timing of Vascular Access Creation in Hemodialysis Patients
Annemiek Borsje, Daan M. Van velzen, Willem A. Bax, Karina de Groot, 
Erik L. Penne. Northwest Clinics Alkmaar, Alkmaar, Netherlands.
Background: Late referral for vascular access creation in Chronic Kidney Disease 
(CKD) patients who opted for hemodialysis (HD) may lead to high central venous catheter 
(CVC) rates. In contrary, too early referral potentially leads to unnecessary vascular access 
interventions. The aim of the present study was to analyze timing of vascular access creation 
in patients starting HD.
Methods: We conducted a retrospective, observational study in stage 4 and 5 CKD 
patients from a single center in the Netherlands, referred for first vascular access creation 
between 2009 until 2011. Patients were divided in three groups: (too) early, optimal or 
(too) late vascular access creation. Early was defined as vascular access surgery ≥6 months 
prior to start HD. Optimal was defined as starting HD with an adequate vascular access and 
surgery was within 6 months prior to start. Late was defined as starting HD with a CVC. 
Patient characteristics as well as vascular access interventions were recorded.
Results: Forty-two patients were included (age 68±11y; 50% male; eGFR 11±3ml/
min/1.73m2). Mean time from vascular access surgery to initiation of HD was 338±470 
days. Vascular access creation was early in 60% (n=25), optimal in 29% (n=12) and late 
in 12% (n=5). Forty-four percent of the patients in the early group (n=11; 26% of all 
included patients) never started HD after a mean follow-up of 8 ±0.7 years (7 patients died, 
2 had stabilized kidney function, 1 underwent pre-emptive kidney transplantation, and 1 
was lost to follow up). Overall, in 45% (n=19) of patients a surgical and/or endovascular 
intervention was performed before initiation of HD. Of the 11 patients that never started HD 
an intervention was performed in 36% (n=4). All patient in the early and optimal group had 
an adequate vascular access at start of HD. Higher age and high eGFR were associated with 
late vascular access creation.
Conclusions: In this study, the majority of patients started HD with an adequate 
vascular access. However, in a substantial proportion of patients interventions were needed 
prior to start HD, also in the subgroup of patients that never started HD during follow up. 
More studies are warranted to investigate the optimal timing of vascular access creation 
aiming at adequate vascular access at time of start HD on the one hand and avoiding too 
early referral resulting in unnecessary interventions on the other hand.
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Evolution of Vascular Access in the First Year of Dialysis in the Irish 
Health System: A National Cohort Study
Gasim Ahmed,1,2 Leonard Browne,2 Wael F. Hussein,2,1 Liam Plant,3 
Austin G. Stack.2,1 1Nephrology, University Hospital Limerick, Liimerick, 
Ireland; 2Graduate Entry Medical School, University of Limerick, Limerick, 
Ireland; 3Cork University Hospital, Cork, Ireland.
Background: Although the arteriovenous fistula (AVF) confers superior benefits over 
central venous catheters (CVC), utilisation rates remain low among prevalent haemodialysis 
(HD) patients. The goal of this study was to determine the type and frequency of vascular 
access provision in the first year of dialysis and identify factors associated with conversion 
to AVF.
Methods: Data was obtained from the National Kidney Disease Clinical Patient 
Management System which tracks all patients with end stage kidney disease (ESKD) 
in Ireland. All adult patients who began HD in 2015 and 2016 and treated for at least 90 
days were included. Data was captured on demographics factors, primary cause of ESKD 
(P-CKD), comorbid conditions, and biochemical indicators at day 90 (D90). Univariable and 
multivariable Cox regression quantified the risk of conversion from CVC to AVF with follow-
up to D360 expressed as hazard ratios (HR), censored at change in modality and death.
Results: The study cohort included 610 patients, mean age 61.7yr (±15.8), 65% 
men and 76.7% were using a CVC for dialysis at D90. At D90, the likelihood of CVC 
varied significantly across HD centres (from 63 % to 91%, P<0.001) and these differences 
persisted when adjusting for case-mix. From D90 to D360, rates of AVF increased modestly 
from 23% to 41%, P<0.001 with a corresponding fall in CVC rates from 77% to 59%, 
P<0.001. Factors associated with conversion from CVC to AVF included age [HR, 0.45, 
(0.21- 0.96) for age > 78 vs < 60 years (ref)]; P-CKD-hypertension [HR, 0.19 (0.05- 0.72) 
and P-CKD-unknown [HR 0.25, (0.10- 0.61) vs P-CKD-polycystic kidney disease (ref)], 
increasing BMI, [HR1.05 (1.02- 1.08)] per unit increase, and HD centre (Figure 1).
Conclusions: CVCs remain the major type of vascular access in Irish HD patients 
with only a modest rise in AVF provision observed during the first year. Substantial centre 
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variation exists at dialysis initiation and continues throughout the first year which is not 
fully explained by patient-level factors.
Funding: Government Support - Non-U.S.
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Improving Rate of Access Placement for Inpatients with eGFR Less Than 
20 mL/min/1.73 m2
Peter Burke,1 Goni Katz Greenberg,2 Yasmin G. Brahmbhatt.1 1Thomas Jefferson 
University Hospital, Philadelphia, PA; 2Thomas Jefferson University and 
Hospital, Philadelphia, PA.
Background: The most common form of renal replacement therapy in the US is 
hemodialysis (HD) which requires Arterio-Venous (AV) access placement. Challenges 
with obtaining timely permanent AV access include late referral to nephrology and vascular 
surgery, patient non-compliance, and lack of effective patient pathways. Baseline data at our 
institution for inpatients with eGFR < 20 ml/min, revealed there was a greater prevalence 
of patients without permanent AV access for HD initiation compared to national data. Using 
Quality Improvement (QI) methodology and interventions, we aimed to improve AV access 
creation in this population.
Methods: Over a three month period on five medicine teaching services, residents were 
given a protocol to order venous mapping, consult nephrology and vascular surgery for 
all patients with an eGFR<20 ml/min. The vascular team established care and scheduled 
outpatient appointments for permanent HD access. The nephrology fellows scheduled 
follow up appointments and conducted post-discharge physician phone calls. Baseline data 
was collected on patients with an eGFR< 20 ml/min who were discharged without initiation 
of HD including readmitted patients over a 3 month period.
Results: The study population had a greater rate of AVF/AVG present at 62% compared 
to the baseline data at 23% and did not significantly alter the length of stay (Table 1).
Conclusions: Hospitalizations are stressful and making decisions regarding long 
term care can be difficult. Follow-up physician phone calls allowed care teams to speak to 
patients when they were more receptive and motivated to make healthcare decisions. This 
improved patient compliance and follow-up rates, and resulted in timelier AV access rates 
without adversely affecting length of stay. Study limitations included the time-intensive 
nature of care coordination, lack of a transitions of care coordinator and the structure 
of patient capture. We conducted a successful QI intervention in a limited pilot project. 
Creating an effective patient pathway for inpatients with advanced CKD can increase rates 
of AV access placement without significantly increasing length of stay.
Vascular Access Rate and Length of Stay
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Outcomes of Coordinated Late Vascular Access Creation
Robin Shah, Nabil J. Haddad, Khaled Boobes, Sharon Vancleef, Anil K. Agarwal. 
Division of Nephrology, The Ohio State University Wexner Medical Center, 
Columbus, OH.
Background: Guidelines recommend timely pre-dialysis access creation to reduce 
incident catheter utilization which is associated with higher risk of hospitalization, 
procedures, mortality and cost. The process to achieve this goal is ambiguous and access 
coordination could be valuable, especially if the creation is late. Our program utilizes a 
hemodialysis (HD) access coordinator working closely with nephrologists and surgeons. 
This study analyzes how this system affects the outcomes of late access creation in our 
patient population.
Methods: Prospectively collected data from an electronic access database and the 
medical records of patients undergoing HD access creation between 2011-2017 prior to HD 
initiation from a single hospital system were analyzed.
Results: A total of 130 patients between the age of 22 to 89 years at the time of access 
placement had 146 accesses created. Seventy-eight (60%) were male, 52 (40%) female, 
52% Caucasian and 42% African American. At time of access creation, median age was 
60.5 and 56.5 years and median eGFR was 13.5 and 15.5 ml/min per 1.73 m2 in the AVF and 
AVG group, respectively. A total of 131 AVF and 15 AVG were created. Seventy six patients 
started HD with a median time after creation of 109 and 131 days for non-diabetics and 
diabetics, respectively. At this time, 54 (42%) patients remain pre-HD-18 (33%) with failed 
access and 6 (11%) have died with a functioning access. Access success rate in those who 
initiated dialysis was 63%. HD was initiated with a catheter in 36% (46% in females vs. 
30% in males). The average time to an interventional procedure after creation was shorter 
in non-diabetics (153 days) vs diabetics (197 days) and shorter in AVF (184 days) vs AVG 
(219 days). Interestingly, non-diabetics and patients under the age of 70 had a higher rate 
of access failure.
Conclusions: Nationally, 60-80% of incident HD patients have a catheter with fewer 
than 15% access placed less than 3 months prior to HD initiation. In our program, access 
placement occurred 3.5-4.5 months prior to dialysis initiation, later than recommended 6 
months and at a very low eGFR. Despite that, our incident catheter rate was about half the 
national average. Our data emphasizes the importance of access coordination in order to 
reduce the incident catheter use and unnecessary access creations.
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Patient Centered Care: The Effect of an Integrated Nephrology-Vascular 
Surgery-Ultrasound Clinic on Arteriovenous Fistula Use
Teresa Kuo,1 Sumie Iwasaki,2 Jessica B. Lapasia,2 Liisa Lyon,3 Aaron C. Baker,4 
Hong T. Hua,4 Aida Shirazi,3 Tracy Y. Jonelis.2 1Department of Medicine, Kaiser 
Permanente, San Francisco, CA; 2Department of Nephrology, Kaiser 
Permanente, San Francisco, CA; 3Division of Research, Kaiser Permanente, 
San Francisco, CA; 4Department of Vascular Surgery, Kaiser Permanente, San 
Francisco, CA.
Background: Arteriovenous fistula (AVF) is the preferred form of vascular access 
for hemodialysis due to their association with lower rates of complication and lower cost 
of maintenance. Multiple teams are involved throughout the course of AVF creation but 
they are often not seeing the patient simultaneously. We hypothesize that an integrated, 
multidisciplinary clinic including nephrologists, vascular surgeons, and an ultrasonographer 
will improve initiation of hemodialysis using AVF.
Methods: The study population included adults at least 18 years old who received an 
AVF between March 2013 and March 2016 at Kaiser Permanente San Francisco (KPSF), 
during which an integrated clinic was formed. This cohort was retrospectively compared to 
KPSF patients who received an AVF between March 2009 to March 2012. Subjects were 
excluded if they had a prior AVF placed in the previous 12-24 months, history of renal 
transplant, death before AVF use, or lost to follow up. The final analytic cohort included 
233 patients. Chi-square tests and t-tests were used to compare the demographic (age, 
race, gender) and clinical characteristics (diabetes mellitus, HbA1c, estimated glomerular 
filtration rate, peripheral vascular disease, and tobacco smoking status) by integrated vs the 
non-integrated clinic. Chi-square tests and logistic regression were used to compare clinical 
outcomes of patients in integrated clinic compared to patients in the non-integrated clinic.
Results: There were 118 patients in the integrated clinic (mean age 70.4±13.7 years, 
30.5% women) and 115 patients in the non-integrated clinic (mean age 66.2±13.1 years, 
40.9% women). Enrollment in the integrated clinic significantly improved initiation of 
dialysis using an AVF (48.3% versus 33.9%; odds ratio, OR, 1.8; p=0.03). The integrated 
clinic also significantly decreased initiation of dialysis using a central venous catheter 
(CVC) (35.6% versus 51.3%; OR 0.5, p=0.02).
Conclusions: An integrated, multidisciplinary AVF surveillance clinic increases 
initiation of hemodialysis using AVFs and decreases initiation of hemodialysis using CVCs.
FR-PO728 Poster Friday
Dialysis: Vascular Access - I
Clinical Outcomes and Economic Impact of Starting Hemodialysis with a 
Catheter (CVC) vs a Permanent Access After Pre-ESRD Arteriovenous 
Fistula (AVF) Creation
Saad Mohammed Shariff,1 Alian Albalas,2 Michael Allon.1 1University of 
Alabama at Birmingham, Birmingham, AL; 2UAB, Birmingham, AL.
Background: Patients progressing to ESRD frequently have an AVF placed pre-
ESRD, but may initiate HD with a CVC if the access is not yet suitable for use. Little is 
known about the clinical outcomes and economic impact of such patients initiating HD with 
a CVC vs a permanent access.
Methods: We identified 205 patients who received an AVF pre-ESRD between 2006 
and 2012, and started hemodialysis within 2 years. Of these, 91 initiated HD with a CVC and 
114 with a permanent access. We compared these two groups in terms of demographics, co-
morbidities, the frequency of percutaneous access procedures, surgical access procedures, 
total access procedures, hospitalizations due to catheter related bacteremia (CRB), and 
annual cost of vascular access management from ESRD to the end of patient follow-up.
Results: The groups initiating HD with a CVC vs a permanent access were similar in 
terms of age, sex, race, diabetes, vascular disease, and heart failure. As compared to patients 
initiating HD with a permanent access, those initiating with a CVC had a 61% greater 
annual frequency of percutaneous access procedures, a 41% greater frequency of surgical 
access procedures, a 55% greater frequency of total access procedures, and a 5-fold higher 
frequency of CRB hospitalizations (Table 1). Patients initiating HD with a CVC incurred a 
median annual cost of access management that was $2,930 higher ($5,478 [2,011-12,497) 
vs $2,548 [924-6717], p<0.001).
Conclusions: Among patients with pre-ESRD AVF creation, those initiating HD with 
CVC had substantially more frequent percutaneous, surgical, and total access procedures, 
as well as CRB hospitalizations. The annual cost of access management was substantially 
higher in those initiating HD with a CVC vs a permanent access.
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Frequency of post-ESRD access procedures and CRB hospitalizations in patients starting 
HD with permanent access vs a CVC after pre-ESRD AVF surgery.
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Incremental Costs of Arteriovenous Fistula (AVF) Non-Use Among US 
Hemodialysis Patients
Mae Thamer,1 Timmy C. Lee,3 Monnie Wasse,4 Marc H. Glickman,5 
Joyce Z. Qian,6 Daniel Gottlieb,7 Scott Toner,7 Timothy A. Pflederer.2 1MTPPI, 
Bethesda, MD; 2Illinois Kidney Disease and Hypertension Center, Peoria, IL; 
3Univ of Alabama at Birmingham, Birmingham, AL; 4Rush University Medical 
Center, Chicago, IL; 5Hancock Jaffe Labs, Virginia Beach, VA; 6Johns Hopkins 
University, Potomac, MD; 7Proteon Therapeutics, Waltham, MA.
Background: Despite the importance of vascular access (VA) for adequate hemodialysis 
(HD), few studies have examined the real world costs related to AVF maturation and use. 
We used national Medicare claims data to examine per patient VA costs over a 3 year period 
based on AVF use for dialysis among a cohort of dialysis patients.
Methods: We conducted a retrospective observational study using USRDS data for 
all incident Medicare patients who initiated dialysis from 2010-2011 and initiated dialysis 
with a mature AVF (n=2,704) or initiated dialysis with a CVC and underwent AVF creation 
in the next 6 months (n=3,901). Using a multidisciplinary expert panel, we identified VA-
related diagnostic, imaging, endovascular, surgical, infection, hospitalization and anesthesia 
codes to calculate total VA costs paid by Medicare. Annualized per patient per year (PPPY) 
costs were calculated from the AVF creation date with costs censored at death or change 
in renal replacement modality. VA costs were calculated from the AVF creation date and 
were compared based on whether the AVF was successfully used for dialysis, as defined 
by the presence of at least one monthly ESRD billing claim in which AVF was recorded 
as the VA in use.
Results: Regardless of timing of fistula insertion, AVFs that were not successfully used 
for dialysis resulted in incremental VA-related costs to Medicare of more than $20,000 
PPPY in the first year after AVF creation, compared to AVFs that were successfully used. 
Incremental VA-related costs were also observed in the second and third year following 
AVF creation. In aggregate, annualized VA costs for three years after AVF creation are more 
than three times as high for patients whose fistula does not mature compared to those whose 
fistula matures.
Conclusions: Improvements in processes of care and technologies to enhance AVF 
maturation and use for dialysis as well as better patient selection should result in less 
morbidity with the potential for significant cost-savings.
Funding: Commercial Support - Proteon Therapeutics Inc
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Procedural Burden Following Arteriovenous Graft Placement Among 
Incident Hemodialysis Patients in the United States
Kenneth J. Woodside,1 Kaitlyn Repeck,2 Purna Mukhopadhyay,2 
Douglas E. Schaubel,1 Vahakn Shahinian,1 Rajiv Saran,1 Ronald L. Pisoni.2 
1University of Michigan, Ann Arbor, MI; 2Arbor Research Collaborative for 
Health, Ann Arbor, MI.
Background: We previously reported that half of patients required interventional 
procedures for successful maturation of arteriovenous fistula (AVF), with additional 
post-maturation burden of 0.40 and 0.52 procedures per person-year (ppy) for those with 
natural and assisted maturation, respectively (p<0.0001). Herein, we sought to determine 
the procedural burden during ‘maturation’ and maintenance phases of newly placed 
arteriovenous grafts (AVG).
Methods: Using data from the United States Renal Data System (USRDS), patients 
new to HD from 7/1/12 to 12/31/14 with initial billing codes for AVG placements (since 
HD start) from 7/1/12 to 12/31/15 were included. Successful maturation was defined as first 
documentation of AVG use in CROWNWeb monthly data. Patients were followed until 
12/31/2016, or 1 year post-AVG placement.
Results: Among 258,731 incident HD patients, there were 23,629 first-time AVG 
placements. Of these, 59.9% were successfully utilized, 28.7% had no recorded use, 
and 11.3% were lost to follow-up (Table). Of successfully utilized AVG, 18.2% required 
interventions during the maturation phase, for 0.31 procedures per person (pp), while 43.3% 
of unsuccessful AVG underwent intervention, for 1.03 pp (p<0.0001). Following successful 
first use, those with assisted maturation underwent 2.05 ppy, while those without assistance 
demonstrated 1.59 ppy (p<0.0001).
Conclusions: Surprisingly, AVG utilization following placement was lower than 
anticipated. Interventions on AVG were common for both maturation and maintenance. 
While the maturation procedural burden for AVG compares favorably with AVF, the 
maintenance phase procedural burden is much higher, implying potential logistic and cost 
advantages of AVF over AVG.
Funding: NIDDK Support
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The Repeatability of AVF Mean Blood Flow in Temperate and Sub 
Saharan Environments
David H. King,1 Abdelgalil A. Ali,1 Mo Al-Qaisi.2 1Broomfield Hospital, 
Chelmsford, United Kingdom; 2Imperial College London, London, United 
Kingdom.
Background: We have previously demonstrated a 70% difference between Dialysis 
AVF blood flow in the UK and Sudan, the Sudan mean being greater than the UK mean 
(1). The study has recently been extended to 4 renal centres in Sudan.. A recent 7 centre 
study in the USA has published the mean AVF blood flow at 6 weeks maturation (2),. We 
have characterised UK and USA environments as temperate and the Sudan environment 
as sub Saharan.
Methods: AVF blood flow was measured with a Duplex device in all centres. Clinical 
indications were used in the USA study to eliminate failing or failed AVF from the study 
of mature fistulae.. The incidence of failing AVF in each cohort in the UK and Sudan was 
studied using a new device Bluedop ™ (1)
Results: The results are tabulated below. Additional data was recorded including 
patient Age, Gender and AVF location.
Conclusions: Conclusion: A number of explanations for the elevated Sub Saharan 
mean Blood Flow results have been explored. Mean annual temperature appears to be a 
possible cause, Published values for minimal seasonal ambient temperatures show Khartoum 
is approximately 14 degrees C warmer than London thoughout the year. USA ambient 
temperatures have not been studied. Deep Infra Red studies have been shown to speed 
AVF maturation. It should also be noted that although AVF failure rates were comparable 
in Sudan and the UK, that active intervention was not available in Sudan. (1) Environmental and Patient 
Specific Factors associated with AVF Blood Flow. ASN Abstracts New Orleans, November 3rd 2017 (2) Relationship Between Clinical Processes and 
Arteriovenous Fistula Cannulation and Maturation: A MultiCenter Cohort Study, AJKD, published online, doi: 10.1053/j.akjd.2017.10.027
Funding: Commercial Support - Bluedop Medical Ltd
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Outcomes of Expanded Polytetrafluoroethylene Vascular Grafts as 
Dialysis Access in Chinese Population: A Retrospective Study
Yuan Luo, Xueqin Bian, Hong Ye, Junwei Yang. The second affiliated hospital 
of nanjing medical university kidney centre in China, Nanjing, China.
Background: With the increased prevalence of end stage renal disease and extended 
life expectancy of hemodialysis patients, more and more patients had limited quality 
and availability of superficial vessels for fistula. It is recommended to apply expanded 
polytetrafluoroethylene (ePTFE) vascular grafts if native fistula is not possible. The aim 
of our study is to analysis the outcomes of arteriovenous graft (AVG) in our dialysis center.
Methods: It was a retrospective study enrolled all the patients who underwent 
AVG from October 2014 to December 2017 in our dialysis center. The demographic 
characteristics, dialysis duration, laboratory tests, location and configuration of AVG, 
operation outcome,as well as the patency rate were analyzed.
Results: A total of 222 patients with the mean age of 60.5±13.9 were included in this 
study. 56% of the study population was female. The most common comorbidities were 
hypertension (84%) and diabetes (49%). All the grafts were successfully implanted. The 
follow-up period ranged from 3 to 40 months. The configurations of the grafts were 
73% loop and 27% straight, and 57% of them were implanted in forearms. There was no 
operation-related mortality. However, 3 early failure were noted. The primary and secondary 
patency rates were 81% and 98%, 63% and 92%, 49% and 82%, 30% and 63%, at 6, 12, 
24, 36 months after the surgery, respectively. The primary and secondary patency of grafts 
in forearm was markedly better than those in upper arm. Comorbidities and configurations 
were not correlated with patency. There were 160 postoperative complications developed in 
96 patients during the study period, including thrombosis (74), proximal vein stenosis (72), 
infection (11), bleeding with hematoma (1), steal syndrome (1), and pseudoaneurysm (1).
Conclusions: AVGs implanted in forearm has superior primary and secondary patency 
than in upper arm. We recommended using ePTFE grafts as an alternative in patients with 
poor autogenous vascular conditions.
Funding: Government Support - Non-U.S.
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Dialysis: Vascular Access - I
A Prospective Outcome Analysis of the Early Cannulation Graft 
ACUSEAL® versus the Standard Expanded Polytetrafluoroethylene 
(ePTFE) Graft in Hemodialysis (HD) Patients
Ioannis E. Giannikouris,1,2 Giovanni Giordano,3 Periklis P. Kyriazis,4 
Dimitra Bacharaki,5 Giuseppe Bacchini.6 1Medifil SA, Athens, Greece; 2Thriasio 
General Hospital of Elefsina, Elefsina, Greece; 3Vanvitelli L. Hospital, Tramonti, 
Italy; 4Internal Medicine, Baystate Medical Center/University of Massachusetts, 
Springfield, MA; 5University Hospital Attikon, Chaidari, Greece; 6Alessandro 
Manzoni Hospital Lecco, Lecco, Italy.
Background: Our objective was to prospectively compare survival, assisted primary 
(APR) and secondary (SEC) patency rates of the early cannulation ACUSEAL® and 
standard ePTFE arteriovenous grafts (AVG) for HD access.
Methods: Incident patients requiring implantation of an AVG for HD initiation or 
therapy continuation were enrolled between December 2014 and December 2017. Outcome 
measures were APR, SEC survival, APR and SEC patency rates of these AVG.
Results: A total of 146 HD patients had AVG implanted, 63 were ACUSEAL® and 
83ePTFE. For ACUSEAL® APR survival was 190 days and APR patency rate was 31%, 
12%, 6% in 12, 24 and 36 months. For ePTFE grafts APR survival was 537 days(p=0.001) 
and APR patency rate 56%, 43% and 30%. Whereas, SEC survival was 596 days for 
ACUSEAL® and 1,365 days for ePTFE(p=0.04) while SEC patency was 72%, 49%, 34% 
and 80%, 70% και 57% in 12, 24 and 36 months, respectively. Wall destruction and lumen 
stenosis were common findings in removed ACUSEAL®AVG.
Conclusions: The advantage of early cannulation of ACUSEAL® AVG seems to be 
partly neutralized by the inferior clinical outcomes seen by this graft compared to those of 
ePTFE AVG. Prospective randomized trials are needed to confirm these preliminary results
Foreign-body giant and mononuclear cell Inflammatory infiltrate penetrating the inner and 
intermediate graft layers
Polypoid granulation tissue causing wall, layer separation and luminal stenosis
FR-PO734 Poster Friday
Dialysis: Inflammation and Infection
The Effect of Citrate Dialysate on Clot Formation and Anemia in 
Hemodialysis Patients
Thananda Trakarnvanich. Hemodialysis Nurses team at Vajira Hospitl,Ruenrudee 
Clinic and Bangpai Hospital Vajira Hospital, Bangkok, Thailand.
Background: Citrate anticoagulation in renal replacement therapy is increasingly 
becoming a favorite choice to prevent extracorporeal circuit clotting. The use of citrate 
rendered the reduction of heparin in conventional hemodialysis. This is a study to test the 
effect of citrate on heparin avoidance and other parameters such an ESA dose, anemia, 
adequacy of dialysis, and inflammatory cytokines compared to acetate dialysate.
Methods: Sixty one chronic HD patients were switched from acetate to citrate 
dialysate and treated in 3 phases, with each phase lasting for four weeks. These phases 
comprised 50% and 25% heparin reduction and heparin free treatments. Visual clotting 
score, as graded by a visual analog scale, ESA doses and laboratory data including pre- and 
post-HD ionized calcium levels,IL-6 and hs-CRP were measured
Results: Except for two episodes of clotting, the dialyzers could be used thoroughly 
throughout the citrate phases. The mean visual clotting scores for all three study periods 
were comparable. Hemoglobin decreased slightly in phase 2 (9.68±1.88 VS 9.06±1.60 g/dL, 
p=0.001, pre and post protocol) despite constant ESA dose. There were no significant 
differences in electrolytes, adequacy of dialysis, and inflammatory cytokine levels, as 
measured by IL-6 and hs CRP between acetate and citrate dialysis. The post protocol level 
of iCa 2+ paradoxically rose after HD in most sessions. We observed no adverse events 
during citrate dialysis.
Conclusions: During periods of citrate dialysis in chronic HD patients, heparin can 
be avoided while maintaining balanced electrolyte levels and adequacy of dialysis and 
hemoglobin. No significant adverse events, including hypocalcemia, were found.
Funding: Government Support - Non-U.S.
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Dialysis: Inflammation and Infection
The Total IV Iron Burden and Insulin Sensitivity in ESRD
Monique E. Cho,1,2 Jared Hansen,2,1 Iran Lavasani,1 Ranganath Muniyappa.3 
1University of Utah, Salt Lake City, UT; 2Veterans Health Administration, Salt 
Lake City, UT; 3NIDDK, NIH, Bethesda, MD.
Background: Systemic iron overload has been strongly associated with increased 
incidence of diabetes in non-CKD patient populations. Despite the high prevalence iron 
overload in hemodialysis (HD) patients due to frequent IV iron infusion, there are no studies 
to evaluate the association between total accumulative IV iron dose and insulin sensitivity.
Methods: We performed an observational pilot study of prevalent hemodialysis 
patients at University of Utah (N=16). Patients with history of dementia, chronic hepatitis, 
steroid use, malignancy, thalassemia, hemochromatosis, sickle cell disease, hospitalization 
or IV antibiotic use within one month of screening were excluded. The total accumulative 
dose of IV iron for the entire duration of dialysis was calculated for each participant. All 16 
participants underwent 3-hour oral glucose tolerance test to calculate whole-body insulin 
sensitivity (Matsuda Index, MI). The total accumulative IV iron dose was log transformed 
to enable parametric analysis with Pearson correlation coefficient to evaluate its association 
with MI.
Results: The study group was diverse (8 Hispanics, 4 Whites, 1 Asian, and 3 mixed), 
with 9 men and 7 women. Half of the group had diabetes. The mean±SD values for age, 
dialysis duration, systolic blood pressure, hemoglobin, and albumin were 52±14 years, 
7.4±5.8 years, 142±28 mmHg, 10.6±1.9 g/dL, and 3.9±0.2 mg/dL, respectively. The median 
(IQR) transferrin saturation and ferritin were 28 (21, 39)% and 652 (300, 971) ng/mL. The 
median (IQR) total IV iron dose over the mean HD duration was 10,825 (6,986, 16675) 
mg (range of 2,400 to 29,748 mg). The insulin sensitivity as assessed by MI showed a 
significant inverse relationship with the total IV iron dose (r = -0.50, Figure 1).
Conclusions: This is the first study to evaluate the association between IV iron therapy 
and insulin sensitivity and to suggest a possible role of IV iron therapy in metabolic risk in 
HD patients. Larger studies are required to confirm the result and to further investigate the 
underlying mechanisms.
Funding: Private Foundation Support
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Dialysis: Inflammation and Infection
Comparison of Measured and Prescribed Dialysate Sodium in Three 
Brands of Dialysate Acid Concentrate
Ambreen Gul,1 Dana Miskulin,2 Serena Cumber,3 S. Paine,1 N. Trujillo,1 
Joseph J. Anaya,4 Huan Jiang,1 Philip Zager.1 1Dialysis Clinic, Inc., Albuqerque, 
NM; 2Tufts Medical Center, Boston, MA; 3Dialysis Clinic, Inc., Albuquerque, 
NM; 4Dialysis Clinic, Inc., Albuquerque, NM.
Background: There is ongoing controversy regarding the optimal dialysate sodium 
concentration (DNa). This issue is further complicated by differences between prescribed 
and measured DNa. These differences are higher in facilities utilizing Fresenius K2 
dialysate delivery machines, dialysate concentrates mixed on site, and a centralized 
delivery system. These differences may reflect errors in the DNa acid dialysate concentrate, 
abnormal pressures in the distribution loop, or machine malfunction. The present study was 
conducted to assess the measured DNa in three brands of dialysate acid concentrate.
Methods: We measured DNa in two lots of Diasol, NaturaLyte and Rockwell acid 
concentrates, delivered from individual jugs by Fresenius T-machines. We used a single lot 
of pre-mixed bicarbonate concentrate. The prescribed DNa was 140 mEq/L. We sampled 
acid concentrates on a single day. We measured DNa on three consecutive days by both 
direct and indirect ion selective electrode method. We computed least square means of 
measured DNa concentrations from linear mixed models.
Results: The least square mean DNa concentrations are shown in the Table. There were 
no statistically significant differences between prescribed and measured DNa observed 
with different brands of dialysate acid concentrates, measurement method, lot and day of 
measurements (p=0.3 for each).
Conclusions: There were no significant differences between the prescribed and 
measured DNa in any of the three pre-mixed dialysate acid concentrates. The significant 
differences between prescribed and measured DNa previously reported may reflect errors in 
mixing dialysate concentrates on-site or pressure abnormalities in the delivery loop.
Funding: Clinical Revenue Support
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Dialysis: Inflammation and Infection
Effect of a Hemodialysis Treatment on Platelet Function Using PFA-100
Komal Patel,1 Jordan L. Rosenstock,1 Maria V. DeVita,2 Warda Zaman.3 
1Northwell Health Lenox Hill Hospital, Paramus, NJ; 2Lenox Hill 
Hospital- Northwell Health System, New York, NY; 3Northwell Lenox Hill 
Hospital, New York, NY.
Background: Platelet dysfunction is well known to be present in patients with end-
stage renal disease (ESRD). Various tests have been used to assess platelet function in 
patients with ESRD, but few studies involve the platelet function analyzer (PFA-100). PFA-
100 is more accurate in assessing platelet function compared to prior methods such as skin 
bleeding time and platelet aggregation. The purpose of this study was to show the effect of 
a hemodialysis (HD) session on platelet function in a patient with ESRD on chronic HD.
Methods: The study enrolled 16 patients undergoing chronic HD three times a week 
from a single unit. Exclusion criteria were hemoglobin < 9 mg/dL, thrombocytopenia 
and the use of antiplatelet agents. Blood was drawn prior to and after HD after the long 
interdialytic period, and sent for PFA-100 analysis. Heparin was held during the treatment. 
PFA -100 measured both the collagen /epinephrine (COL/EPI) and collagen/ ADP (COL/ 
ADP) closure times in seconds.
Results: Pre-HD, 11 (69%) started with an abnormal COL/EPI of which none 
normalized. Of the 5 patients that started with a normal COL/EPI, 1 developed an abnormal 
COL/EPI post-HD. Pre-HD, 11 (69%) started with an abnormal COL/ADP of which one 
normalized. Of the 5 patients that started with a normal COL/ADP, 4 patients developed an 
abnormal COL/ADP post-HD. Overall post-HD, there was an increase in COL/EPI closure 
time in 11 (69%), no change in 2 (12%), and decrease in 3 (19%) patients. There was 
an increase in COL/ADP in 12 (75%), no change in 1 (6%), and decrease in 3 (19%) of 
patients. Only one patient who originally had an abnormal PFA test, had normalization of 
the PFA- 100 after a HD treatment.
Conclusions: This study found that the majority of regularly dialyzed patients in our 
population had abnormal platelet function as measured by the PFA -100 analyzer after the 
long interdialytic interval. Only one patient had normalization a abnormal PFA-100 after a 
HD treatment. Most patients appeared to have worsening of platelet function as indicated 
by a longer closure time. This could be due to an interaction with the dialyzer membrane. 
Our findings don’t support a common practice of performing a HD treatment prior to 
surgical procedures in order to help avoid bleeding complications. This study involved a 
small cohort of patients from a single HD unit, a larger multi-centered trial is warranted to 
confirm results.
FR-PO738 Poster Friday
Dialysis: Inflammation and Infection
Hemodialysis (HD) Using Molecular Hydrogen-Enriched Dialysate 
Generates Greater Amount of Exhaled Hydrogen Than Conventional HD, 
Decreases Plasma Glucose, and Increases Serum LDL-C in One Session
Hirotsugu Iwatani, Yuta Asahina, Shintaro Koizumi, Masafumi Yamato. 
Nephrology, Osaka National Hospital, Osaka, Japan.
Background: Novel hemodialysis using molecular hydrogen-enriched dialysate 
(Hydrogen HD) is reported to improve the prognosis of patients on chronic dialysis. To 
investigate whether or not this effect is derived from the hydrogen infused through dialysate, 
we aimed to investigate the difference of exhaled hydrogen concentration between novel 
Hydrogen HD and conventional HD. We also investigated the effect of Hydrogen HD on 
glucose and lipid metabolism.
Methods: We investigated the exhaled hydrogen concentration (ppm) of patients 
undergoing Hydrogen HD and conventional HD and compared the concentrations between 
the two groups. The subjects are eight adult HD inpatients in our hospital that gave written 
informed consent to go through Hydrogen HD and conventional HD. Exhaled hydrogen 
concentration were monitored at 0h, 0.5h, 1h, 2h after the start of HD, at the end of HD, 
and 0.5h after the end of HD (6 points). Exhaled hydrogen was calculated as AUC. Plasma 
glucose and lipid profile were also investigated before and after the each session of HD. 
Statistical analyses were performed by Wilcoxon signed rank test using JMP. The ethics 
committee in our hospital approved this study.
Results: The patients’ characteristics were as follows; age 74 (63-79) y.o., sex F/M 
3/5. Total exhaled hydrogen in Hydrogen HD was 502 (261-1541) ppm*hour and that in 
conventional HD was 45 (11-149) ppm*hour (p=0.0078). Serum LDL-C changes from 75 
(39-102) to 78 (43-105) in Hydrogen HD significantly (p= 0.0156) and from 79 (45-105) to 
78 (49-103) in conventional HD (n.s.). Plasma glucose changes from 142 (111-168) to 117 
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(99-144) in Hydrogen HD significantly (p=0.0078) and from 144 (111-184) to 129 (105-
166) in conventional HD (n.s.).
Conclusions: Exhaled hydrogen in hemodialysis treatment using molecular hydrogen-
enriched dialysate is significantly greater in amount than that in conventional HD. 
Overflowed molecular hydrogen from exhaled gas is the clue that the beneficial effect of 
this novel HD is based on the infused molecular hydrogen from dialysate. Hydrogen HD 
decreases plasma glucose and increases serum LDL-C in one session.
Funding: Commercial Support - Otsuka pharmaceutical Co.
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Dialysis: Inflammation and Infection
Effect of Statins on Life Prognosis in Japanese Patients Undergoing 
Hemodialysis
Yuki Ota,1 Mineaki Kitamura,1 Kumiko Muta,1 Hiroshi Yamashita,1 Yoko Obata,1 
Takashi Harada,2 Satoshi Funakoshi,2 Tomoya Nishino.1 1Nagasaki University 
Hospital, Nagasaki, Japan; 2Nagasaki Renal Center, Nagasaki, Japan.
Background: Although large-scale studies have not proved the benefits of statin use in 
patients undergoing maintenance hemodialysis, recent studies suggest that statins could be 
useful to reduce the risk of cardiovascular events and all-cause mortality in specific groups 
of patients undergoing hemodialysis. The aforementioned large-scale studies included 
a small percentage of Asians, and few studies have investigated the effects of statins in 
Asians undergoing dialysis. We investigated the benefits of statins in patients undergoing 
maintenance hemodialysis at a large single center in Japan.
Methods: We obtained demographic, clinical, and hemodialysis data pertaining to all 
patients who underwent maintenance hemodialysis at the Nagasaki Renal Center between 
July 2011 and June 2012. Data were based on the patients’ birth month. Patients were 
followed-up until September 2017.
Results: We studied 339 patients among which 51 (15.0%) were prescribed statins. 
The mean duration of observation was 3.7±2.0 years, 43% were women, and the mean 
hemodialysis vintage was 90±96 months. During the follow-up, 194 patients (57%) died. 
Among those who died, 43% (n=23) had been prescribed statins and 61% (n=171) had 
not been prescribed statins. After propensity score matching based on age, gender, dialysis 
vintage and time, diabetes mellitus, ischemic heart disease, dry weight, left ventricular 
ejection fraction, and serum albumin, an intergroup comparison between those who received 
statins and those who did not (44 patients in each group) showed significant differences in 
the survival rate based on the log-rank test, P=0.03. Although causes of death did not differ 
between groups, there were fewer causes of death from cardiovascular events, infections, 
and cancer in the group prescribed statins.
Conclusions: Our results suggest that statins may improve life prognosis in Japanese 
patients undergoing maintenance hemodialysis. Although potential residual confounders 
could not be excluded, statins may have an effect in reducing cardiovascular events, 
infections, and cancer. Further studies are required to prove this hypothesis.
FR-PO740 Poster Friday
Dialysis: Inflammation and Infection
Erythropoietin-Stimulating Agent Dose Not Associated with Patient 
Transition to Nocturnal In-Center Hemodialysis
Adam S. Wilk,1 Courtney E. Hoge,1 Laura Plantinga,2,1 Janice P. Lea.2 1Rollins 
School of Public Health, Emory University, Atlanta, GA; 2Emory University 
School of Medicine, Atlanta, GA.
Background: Nocturnal dialysis (ND) can support longer sessions with better 
clearances of uremic toxins, compared to traditional in-center hemodialysis (HD). It has 
been suggested that patients with improved clearances may have improved responses to 
erythropoietin-stimulating agents (ESAs). We compared use of ESAs for ND patients 
before and after they initiated ND treatment.
Methods: We identified ND patients at a medium-sized dialysis organization to be 
those HD patients for whom ≥80% of dialysis sessions were ND sessions—starting at 
6:30pm or later and lasting ≥5 hours—over the 3 months after their first ND session (≥20 
sessions total) during 2010-16. Outpatient dialysis session and administered ESAs data 
were extracted for these patients within 12 months of ND transition (pre and post). Epogen 
units administered per month before December 2012 (when the organization switched to 
Aranesp) were converted to approximately equivalent Aranesp mcg/month dosages to 
support a single measure of ESA use per patient-month. Descriptive analyses of ESA use 
were performed for all months with ≥7 sessions (i.e., still in care). The effects of post-
transition ND care status on ESA use were estimated using a generalized linear model 
(GLM) with a Gaussian distribution and random intercepts and slopes; standard errors were 
clustered at the patient level.
Results: We identified 64 ND patients (4.7% of 1,357 eligible patients in care), 
with 354 pre-transition patient-months (3,974 sessions) and 496 post-transition patient-
months (5,841 sessions). Across descriptive analyses and GLM analyses accounting for 
patient-level clustering, we found no statistically significant differences in ESA use post-
transition. We estimated ESA use levels of 158.3 mcg/month post-transition versus 147.1 
pre-transition (p=0.24) in descriptive analyses, and our GLM point estimate associated with 
post-transition was +5.5 mcg/month (p=0.69).
Conclusions: After transitioning to ND, patients may not experience any change in 
their ESA use. Further studies are needed to more fully assess any changes in patients’ 
anemia management, including iron use; these analyses should also account for potential 
differences in Kt/V, hemoglobin, and other lab results.
FR-PO741 Poster Friday
Dialysis: Inflammation and Infection
Effects of Glucose-Containing Dialysate During Hemodialysis
Mijung Yoo,1 Yang Wook Kim,4 Bongsoo Park,2 Sihyung Park,2 Yoo jin Lee.3 
1Inje University Haeundae Paik Hospital, ULSAN, Republic of Korea; 2Inje 
University, Haeundae Paik Hospital, BUSAN, Republic of Korea; 3Haeundae 
Paik Hospital, BUSAN, Republic of Korea; 4Haeundae Paik Hospital, inje 
university, BUSAN, Republic of Korea.
Background: When hemodialysis is performed using glucose-free dialysate, 
glucose is released into the dialyzer and hypoglycemia may occur. Repeated occurrence 
of hypoglycemia increases the risk of cognitive decline and reduces the quality of life of 
patients. In this study, we aimed to compare the incidence of hypoglycemia and biochemical 
changes in patients with hemodialysis using glucose-containing dialysate and glucose-free 
dialysate.
Methods: All patients were dialyzed with glucose-free dialysate and changed to 
glucose-containing dialysate. We measured the levels of albumin, BUN, creatinine, total 
cholesterol, triglyceride, C-reactive protein, calcium, phosphorus, SPKt/V and URR 
3 months before and after dialysate change. Two hours after the start of dialysis, blood 
glucose level was measured. When the blood glucose level was less than 90 mg/dl, 100 ml 
of 50% dextrose fluid was administered and the number of times was recorded.
Results: A total of 53 patients participated in the study. When comparing before 
and after dialysis solution change, no statistically significant differences were found 
in albumin(g/dl)(3.53±0.36 vs 3.54±0.34; p-value 0.87), BUN(mg/dl)(60.02±19.07 vs 
60.46±16.26; p-value 0.87), creatinine(mg/dl)(9.42±2.66 vs 9.36±2.68; p-value 0.95), 
total cholesterol(mg/dl)(148.83±33.39 vs 147.19±30.44; p-value 0.56), triglyceride(mg/dl) 
(113.57±75.55 vs 117.34±78.40; p-value 0.65), C-reactive protein(mg/dl)(0.38±0.63 
vs 0.37±0.60; p-value0.61), calcium(mg/dl)(9.63±9.31 vs 8.35±0.58; p-value 0.61), 
phosphorus(mg/dl)(4.77±1.43 vs 5.03±1.31; p-value 0.18), SPKt/V(1.57±0.23 vs 
1.59±0.24; p-value 0.40) and URR(71.74±10.36 vs 73.26±5.01; p-value 0.49). The 
mean number of dextrose fluid administration was statistically significant(0.16±0.27 vs 
0.03±0.08; p-value 0.00).
Conclusions: Hyperglycemia is known to increase the production of free radials and 
to induce oxidative stress. However, in our study, with glucose-containing dialysate, the 
deterioration of inflammatory markers associated with oxidative stress was not observed, 
the incidence of hypoglycemia was reduced, and the dialysis efficiency remained similar. It 
is believed that the use of glucose-containing dialysate will be more beneficial to the patient.
FR-PO742 Poster Friday
Dialysis: Inflammation and Infection
Accuracy of Dialysate Sodium from Dialysate Conductivity Compared to 
Measured Sodium: A Quality Assurance Study
Pierre-Antoine Brown,3,2 Rayees Y. Sheikh,1 Edward G. Clark,3,2 Ayub Akbari,3,2 
Swapnil Hiremath.3,2 1The Ottawa Hospital, Ottawa, ON, Canada; 2The Ottawa 
Hospital and Kidney Research Centre - Ottawa Hospital Research Institute, 
University of Ottawa, Ottawa, ON, Canada; 3University of Ottawa, Ottawa, ON, 
Canada.
Background: Dialysate sodium is traditionally set at a constant with the intention of 
providing isonatric dialysis. A dialysate sodium higher than plasma levels can result in 
transfer of sodium to the patient, while a lower sodium can lead to cramps and hypotension. 
Modulations of dialysate sodium are done by changing dialysate conductivity, since sodium 
is the primary driver of conductivity. Recent studies have suggested that the agreement 
between dialysate conductivity and measured dialysate sodium is imperfect. This quality 
assurance study was designed to examine the bias between machine reported conductivity 
and measured dialysate sodium and determine the factors associated with the bias, if present.
Methods: We conducted patient-free dialysis sessions using 3 different dialysis 
machines (Gambro Artis, Bellco Formula and Fresenius 4008) with varying sodium and 
potassium baths. Machine reported conductivity was recorded at time 0, 1hour, 2 hour, and 
4 hours. Concurrently, dialysate samples were sent for measurement of sodium (indirect 
ion selective [ISE] method) and other electrolytes. A total of 46 sessions with different sets 
of dialysate sodium (135 mEq/L or 140 mEq/L) and K baths (2 mEq/L or 3mEq/L) were 
analyzed.
Results: At all 4 time points, the measured dialysate sodium was significantly higher 
than the set dialysate sodium. At T0, the difference was 6.11 ± 1.62 mEq/L (mean +/- SD) 
with similar results noted for all time points. The difference between measured and set 
dialysate sodium was higher for 3K (6.48 ± 1.85 mEq/L) bath than 2K bath (5.58 ± 1.07 
mEq/L) (p=0.003), but not different whether set sodium was 135 or 140 (p = 0.80). There 
also was a difference between the 3 models of HD machines tested; model one: 6.23 ± 1.36 
mEq/L; two: 4.80 ± 1.93 mEq/L; three: 7.10 ± 1.10mEq/L; p=0.0035.
Conclusions: Our analysis shows that, for 3 common dialysis machine models, there 
is a significant difference between the ordered dialysate sodium (I.e. conductivity) and 
the measured dialysate sodium. The bias persists throughout session time, and a range of 
common sodium and potassium baths. It is large enough to have clinical implications.
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Dialysis: Inflammation and Infection
Evaluation of Albumin Loss During Hemodialysis with Theranova® 
Medium Cut-Off (MCO) Dialyzer: Six Months Follow-Up
Nicola Marchionna,1 Sara Samoni,1 Mauro Neri,2 Anna Lorenzin,2 
Alessandra Brendolan,1 Monica Zanella,1 Claudio Ronco.1 1S Bortolo Hosp, 
Vicenza, Italy; 2IRRIV, Vicenza, Italy.
Background: Theranova® medium cut-off (MCO) dialyzer is an innovative membrane 
designed to expand the spectrum of medium molecules removal, beyond standard high-flux 
dialysis, using conventional hemodialysis (HD) infrastructure. It represents a novel method 
to remove uremic toxins in an increased range of molecular weight (MW).
Methods: The purpose of this observational study was to evaluate the safety of 
treatment in terms of albumin removal, evaluating the albumin concentrations in plasma 
and dialysate. Six patients on chronic HD were observed for a period of six months. Each 
patient was treated with Theranova® 400 filter (PAES/PVP membrane, 1.7 m2 surface 
area, Baxter) in dialysis bicarbonate 4 h Qd 500 ml/min. Pre-treatment patient albuminemia 
and protein loss at the end of the treatment (dialysate sample) were assessed at the first 
treatment, one week, one month, three and six months after.
Results: Serum levels of predialitic albumin remained constant throughout the 
observation period (figure). Protein loss in each hemodialysis session was similar or lower 
than in HD bicarbonate treatments with high flux membranes, previously tested (3.7 ± 2.2 g).
Conclusions: In addition to a high efficiency in low and medium MW uremic toxins 
removal, in this study Theranova medium cut-off filters demonstrated not to cause an 
increased protein loss in comparison with a standard high flux dialyzer
FR-PO744 Poster Friday
Dialysis: Inflammation and Infection
The Role of Neutrophil/Lymphocyte Ratio as a New Paradigm to 
Determine Hemodialysis Initiation
Tae won Lee,1 Ha nee Jang,2 Ji-Hye Kwak,2 Eunjin Bae,1 Hyun Seop Cho,2 
Hyun-Jung Kim,4,3 Se-Ho Chang,2,3 Dong Jun Park.1,3 1Department of Internal 
Medicine, Gyeongsang National University Changwon Hospital, Changwon-si, 
Gyeongsangnam-do, Republic of Korea; 2Department of Internal Medicine, 
Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, 
Republic of Korea; 3College of Medicine, Gyeongsang National University, 
Jinju-si, Gyeongsangnam-do, Republic of Korea; 4School of Medicine, 
Gyeongsang National University, Jinju, Republic of Korea.
Background: There are still much controversies about the timing of initiation of the 
dialysis in patients with chronic kidney disease (CKD) although absolute and relative 
indications have been well established. This study underwent to evaluate whether 
neutrophil/lymphocyte ratio (NLR) could be used as an important index of dialysis initiation 
by comparing the other clinical presentations and biochemical findings.
Methods: We retrospectively evaluated the medical records of patients to start chronic 
maintenance hemodialysis from January 2011 to December 2016 in our institutions. We 
compared laboratory findings of the last 3 months with those of just before timing of 
dialysis initiation. Patients with acute infection, using steroid or immunosuppressive agent 
use, and undergoing acute hemodialysis for acute kidney injury were excluded.
Results: Total 300 patients were included. The mean age was 61 years old. The mean 
estimated glomerular filtration rate (eGFR) by MDRD was 5.93 ± 2.78 (ml/min/1.73m2) 
at the time of hemodialysis, whereas it was 7.86 ± 3.28 (ml/min/1.73m2) 3 months before 
hemodialysis (p<0.001). The mean NLR significantly increased from 2.50 ± 1.02 to 
4.32 ± 2.08 (p<0.001) in this duration. We found significant correlations between NLR 
and hemoglobin (r=-0.523, p<0.001), serum albumin level (r=-0.685, p<0.001), serum 
phosphorus level (r=0.465, p<0.001), total CO2 level (r=-0.361, p<0.012), and CRP level 
(r=0.458, p<0.001). In addition, patients undergoing planed dialysis through prepared arm 
vascular access showed significantly lower NLR than those of emergency dialysis requiring 
Perm-cath or temporary catheter (3.58 ± 1.55 vs.4.75 ± 2.23, p<0.001) although eGFR 
was not different between two groups. Lower hemoglobin, total CO2, albumin, sodium 
and calcium level was shown in patients undergoing emergency dialysis, compared with 
patients using planned arm vascular access (p<0.001, p=0.002, p<0.001, p=0.006, and 
p=0.002, respectively).
Conclusions: In conjunction with many other components, NLR might be used 
valuable marker in CKD patients when clinician consider the initiation of renal replacement 
therapy or prepare vascular access.
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Quantification of Lipoteichoic Acid, Biofilm Morphology, and  
Microbiology in Hemodialysis (HD) Patients with Catheters
Amy B. Pai, Lenar T. Yessayan, Michael Heung, Karen N. Davidge, 
Michael Dean, Gabrielle M. Costello. University of Michigan, Ann Arbor, MI.
Background: Lipoteichoic acid (LTA) is a Gram-positive bacteria cell wall component 
that is shed and induces inflammation through toll-like receptor 2. Currently, there are no 
non-invasive approaches to assess biofilm burden within a dialysis access. The purpose 
of this study was to characterize LTA concentrations in HD patients with central venous 
catheters (CVCs) compared to arterio-venous grafts (AVGs), and arterio-venous fistulas 
(AVFs) and to evaluate biofilm distribution and microbiology in pulled CVCs.
Methods: Eligible patients were adults with indwelling CVC, AVG or AVF being used 
for HD at the time of sample collection with no concurrent treatment for infection. Venous 
blood samples were collected prior to dialysis initiation, at 30 minutes, 2 hours and end of 
treatment (EOT). Catheter aspirate was also collected. LTA concentrations were measured 
by ELISA. In an ongoing sub-study, catheters that were pulled by clinical decision were 
evaluated by scanning electron microscopy (SEM) for biofilm surface area and the tip, mid-
section and hub were cultured and bacterial species determined by MALDI-TOF.
Results: LTA profiles were measured in 17 CVC, 15 AVG and 16 AVF patients. 
Unexpectedly, LTA was detectable in serum from all access types at baseline and increased 
significantly over the dialysis session at each time point measured compared to baseline 
(p<0.012 for all comparisons). Catheter aspirate LTA concentration significantly correlated 
with serum concentrations at 2 hours and EOT (r2 0.34 and 0.30, respectively p=0.02) 
The rate of change from baseline to EOT was highest in patients with CVCs but was not 
statistically significantly different from AVF and AVG. Among catheters pulled (n=4) large 
plaques of biofilm were observed on all sections examined by SEM. Staphylococcus sp. 
including epidermidis, caprae, hominis, lugdenisis were most abundant, however, Candida 
albicans was also cultured from some external hub and external/internal tip sections.
Conclusions: LTA was detectable in the serum of HD patients across access types and 
large increases during dialysis sessions were observed. Further study of the relationship 
of serum LTA to biofilm surface area and biomarkers of inflammation are warranted to 
understand the extent to which access type contributes to inflammation in HD patients.
Funding: Private Foundation Support
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Calcium Mass Balance During Hemodialysis: A Comparison of Different 
Dialysate Calcium Concentrations Including Citrate-Acid Calcified 
Dialysate
Karlien J. ter Meulen,1 Frank van der Sande,1 Constantijn Konings,3 
Marijke J. Dekker,1 Bernard J. Canaud,2 Jeroen Kooman.1 1Maastricht University 
Medical Centre, Maastricht, Netherlands; 2FMC Deutschland GmbH, Bad 
Homburg, Germany; 3Catharina Hospital, Eindhoven, Netherlands.
Background: Bone and mineral disorders are still cause of morbidity and mortality 
among chronic kidney diseases, even though adjustments made in therapy and techniques. 
The optimal dialysate calcium (dCa) and magnesium (dMg) is debated in hemodialysis 
as international guidelines differ. Citric-acid dialysate may affect Mg and Ca removal 
during dialysis. The aim of this study was to compare the mass balances in calcium 
(CaMB) and magnesium (MgMB) between bicarbonate/acetic-acid dialysate with dCa1.50 
(dAcetCa1.50) and dCa1.25 (dAcetCa1.25), as well with citric-acid dialysate with dCa1.50 
(dCitCa1.50) and dMg of 0.5 mmol/l.
Methods: Twenty patients were enrolled in this 4-week prospective multicenter 
randomized cross-over trial where they received a baseline week (dAcetCa1.50), followed 
by the randomized sequence of dAcetCa1.25 or dCitCa1.50 for one week and the alternate 
treatment was provided after a washout week with dAcetCa1.50. Spent dialysate was 
collected from the outlet of the dialysis machine in a fractionated way.
Results: Eighteen patients completed the study, one session was excluded due to 
unclear dialysate. CaMB was in general positive during dAcetCa1.50 and negative during 
dAcetCa1.50 and dCitCa1.50. MgMB was negative during all different treatments There 
was an inverse correlation for pre-dialytic serum ionized calcium (iCa) with CaMB in 
dAcetCa1.50 (r; p-value) (-0.687; 0.002) and in dCitCa1.50 (-0.725; 0.001). This was also 
found for total calcium in dAcetCa1.50 (-0.579; 0.012) and dCitCa1.50 (-0.708; 0.001), 
and corrected total calcium in dAcetCa1.50 (-0.687; 0.002) and dCitCa1.50 (-0.725; 0.001).
Conclusions: Our study shows that whereas dAcetCa1.50 leads to net gain of calcium 
by the body during dialysis, net loss occurs during dCitCa1.50, with levels comparable to 
dAcetCa1.25. Given the strong dependence of CaMB on pre-dialytic iCa, the introduction 
of dCa solution with 1.375 mmol/l may be relevant for individualizing CaMB during 
dialysis. Major losses of Mg occur during the use of conventional dialysis solutions.
Funding: Commercial Support - Fresenius Medical Care
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Reduction in Mean Patient Body Weights and Blood Pressures Were 
Observed During a Fluid Management Quality Improvement (QI) Project 
Utilizing Relative Blood Volume Monitoring (RBV-M)
Paul Balter,1,2 Yisha Li,3 Claudy Mullon,3 Robert J. Kossmann,3 Linda Ficociello.3 
1Nephrology Associates of Northern Illinois and Indiana (NANI), Oak Brook, 
IL; 2Renal Research Institute, New York, NY; 3Fresenius Medical Care Renal 
Therapies Group, Waltham, MA.
Background: A one-year fluid management QI project utilizing RBV-M was conducted 
at 20 Renal Research Institute clinics. A retrospective database analysis of the QI project 
was conducted to assess changes in body weight and blood pressure in hemodialysis (HD) 
patients.
Methods: Patients included in this analysis received HD in the month before QI 
initiation (Pre-QI) and QI end. RBV-M was used to monitor relative blood volume during 
hemodialysis with Crit-Line® Monitors (CLM-III, CLM-IV, or CLiC). All available 
PreHD- and PostHD- body weights (wt) and PreHD- and PostHD- systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) values were averaged monthly for each patient. 
A subgroup analysis of patients with Pre-QI hypertension was conducted for patients with 
PreHD-SBP ≥ 140 mmHg and/or PreHD-DBP ≥ 90 mmHg during Pre-QI. Paired t-tests 
were utilized to test for difference between Pre-QI and QI month 12 (M12).
Results: In total, 651 patients were included in the analysis and 473 had Pre-QI 
hypertension. Mean PreHD-wt decreased from 84.06 to 83.27 kg (-0.79 kg, p<0.0001) and 
PostHD-wt from 81.71 to 80.96 kg (-0.75 kg, p<0.0001) from Pre-QI to M12. Mean PreHD-
SBP decreased from 152.04 to 149.92 mmHg (-2.12 mmHg, p=0.005) and mean PostHD-
SBP decreased from 139.32 to 137.09 mmHg (-2.23 mmHg, p=0.003) from Pre-QI to M12. 
Mean PreHD-DBP decreased from 80.07 to 78.70 mmHg (-1.37 mmHg, p=0.002) and 
PostHD-DBP decreased from 73.69 to 72.41 mmHg (-1.28 mmHg, p=0.001) from Pre-QI 
to M12. On average, in the subgroup of patients with hypertension during Pre-QI, PreHD-
SBP decreased from 161.54 to 156.55 mmHg (-4.99 mmHg, p<0.0001) and PostHD-SBP 
decreased from 145.56 to 141.56 mmHg (-4.00 mmHg, p<0.0001).
Conclusions: A QI project on fluid management utilizing RBV-M was associated 
with reductions in patient body weights and blood pressures. Most patients had Pre-
QI hypertension (73%). These patients had an average decrease in PreHD-SBP of 4.99 
mmHg and may be a population that could particularly benefit from a QI initiative on fluid 
management.
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
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Impact of PEAK Methodology on Interdialytic Weight Gain: A  
Multi-center Experience
Atef Z. Altaher, Marta C. Bento, Janet Cowperthwaite. DaVita-Saudi Arabia, 
Riyadh, Saudi Arabia.
Background: Hemodialysis (HD) patients who experience larger interdialytic weight 
gains (IDWG) are at increased risk of cardiovascular and all-cause mortality. Diastolic 
dysfunction, associated with fluid overload is reported in a significant numbers of dialysis 
patients directly reducing survival. In addition reports suggest that IDWG > 4% increases 
the risk of death substantially. This risk prompted us to focus quality improvement activities 
on the IDWG of chronic patients on HD.
Methods: PEAK methodology based on six sigma and lean processes was introduced 
incrementally into each of the 15 DaVita KSA clinics included in this study. During the 
implementation period the teams were provided with education about PEAK and supported 
to hold daily reviews of the current status, then to discuss ideas and action plans to implement 
patient centered strategies to promote compliance. The percentage of patients showing 
≥ 4% IDWG on each treatment day during the 9 month study period was counted. The 
data included all prevalent and incident patients with valid data reported in the electronic
medical records system (n=1472). Average data were calculated for each treatment week
and month. Results were compared at 3, 6 and 9 months using Chi2 test.
Results: The percentage of patients not achieving IDWG in each of the clinics at the 
start of the study period ranged from 20.5%-66.1%. Improvement in IDWG was observed 
in 11 of 15 and 12 of 15 clinics after 3 and 6 months, respectively. After 9 months, the 
percentage of patients not achieving target IDWG ranged from 15.6%-63.7% and had 
decreased by 36% of the initial value for the whole population. At the end of the study the 
percentage of patients not achieving target had decreased in all 14 clinics.
Conclusions: By implementing the PEAK methodology and encouraging team focus 
on this defined outcome, all clinics that implemented the program achieved a decrease in 
average IDWG in their patient populations.
Funding: Commercial Support - DaVita
Percentage of patients with IDWG ≥ 4% over 9 months observation period (whole 
population)
FR-PO749 Poster Friday
Dialysis: Inflammation and Infection
The Swelling of the Median Nerve Is the Independent Risk Factor for 
Carpal Tunnel Syndrome in Patients with Short-Term Hemodialysis
June hyun Kim,1 Soo Bong Lee,1 Il Young Kim,1 Dong Won Lee,1 Sang 
Heon Song,2 Harin Rhee,2 Miyeun Han.2 1Pusan National University Yangsan 
Hospital, Yangsan, Republic of Korea; 2Pusan National University Hospital, 
Busan, BUSAN, Republic of Korea.
Background: A carpal tunnel syndrome (CTS) is a frequent complication of long-term 
hemodialysis. 20% to 50% of the patients dialyzed for 10 years or longer are reported to 
have CTS. However, risk factors for CTS in short-term hemodialysis have been less known. 
In this study, we investigated whether the swelling of median nerve could be a risk factor 
for CTS in patients with relatively short-term hemodialysis (mean duration of hemodialysis: 
4.03 years).
Methods: The study included 43 patients (23 male & 20 female) on maintenance 
hemodialysis and 97 healthy controls. We diagnosed the CTS by nerve conduction study 
(NCS) and clinical symptom. The cross-sectional area (CSA) of median nerve was 
measured at the wrist (CSA–W) and forearm (CSA-F) by ultrasonography. The wrist to 
forearm ratio (WFR; CSA-W/CSA-F) was calculated for each arm. The degree of swelling 
of median nerve was assessed by the WFR.
Results: The mean duration of hemodialysis (n=43) was 4.02 ± 3.30 years. The 
WFRs in hemodialysis patients were higher than those in healthy controls (1.37 ± 0.45 vs. 
1.21 ± 0.25, P = 0.021). We classified into patients with CTS (n=19) and without CTS 
(n=24). There were no significant differences in age, sex, duration of hemodialysis, the 
cause of renal failure, β2-microglobulin, and adequacy of dialysis (Kt/V) between patients 
with CTS and without CTS. The WFRs in patients with CTS were higher than those in 
patients without CTS (1.5 ± 0.5 vs. 1.2 ± 0.2, P = 0.001). We performed ROC analysis to 
investigate the best cut-off value of WFR for predicting the CTS in all study subjects (n=43). 
The AUC of the WFR was 0.825 (95% CI: 0.678-0.923). The best cut-off value of the WFR 
was > 1.25 with a sensitivity of 84.2% and specificity of 70.8%. In multivariate analysis, 
the patients with WFR > 1.25 were 6.3 times more likely to have the CTS compared with 
patients WFR (HR: 6.30, 95% CI: 1.45-27.5, P = 0.014)
Conclusions: This study demonstrated that the swelling of median nerve was the 
independent risk factor for the CTS in patients with relatively short-term hemodialysis.
FR-PO750 Poster Friday
Dialysis: Inflammation and Infection
Development of a Microparticle-Based Bio-marker of Hemodialysis 
Induced Vascular Injury
Janice Gomes,1,2 Claire Grant,2 Elena Qirjazi,1,2 Christopher W. McIntyre.1,2 
1University of Western Ontario, Toronto, ON, Canada; 2Lawson Health Research 
Institute, London, ON, Canada.
Background: Hemodialysis (HD) is a treatment option that is associated with 
complications such as microvascular dysfunction and damage to vulnerable vascular beds. 
This damage has been observed through gold standard imaging techniques such as Echo, 
CT, MRI, and PET, however there are no reliable blood based bio-markers available to 
identify this injury that might be suitable to use in general clinical practice. We therefore 
investigated the use of blood vessel and circulating blood cell derived microparticles as an 
indicator of vascular damage in a cohort of HD patients under standard treatment condition 
and a state of reduced circulatory stress (using dialysate cooling).
Methods: An assay was created to assess the level of endothelial, platelet, erythrocyte, 
and leukocyte derived microparticles. By utilizing Nanoscale Flow Cytometry (Apogee 
A50), we measured microparticle levels within plasma samples obtained from patients 
receiving standard hemodialysis treatment (36.5 degrees Celsius, n=31) and 16 of the same 
patients receiving cooled dialysate treatment (35 degrees Celsius). Microparticles were 
enumerated at pre, during, and post treatment.
Results: CD31+/CD62E+ microparticles (derived from activated endothelium) 
correlated with ultrafiltration rate (as the primary driver of HD-based circulatory stress) 
(R2=0.1720, p<0.05). There was no relationship between erythrocyte, leukocyte, and 
platelet derived microparticles and ultrafiltration rate. Furthermore, we observed that 86% 
of patients experienced a reduction in CD62E+ (e-selectin) microparticle levels when 
administered cooled dialysate treatment in comparison to standard treatment (Figure, 
**p<0.01).
Conclusions: The use of microparticles as a bio-marker of HD induced ischemic 
injury shows promise and warrants further refinement and investigation to identify and risk 
assess patients receiving HD, as well as monitoring response to efforts to individualize and 
optimize HD treatment.
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Hospitalizations for Cryptococcal Meningitis in End-Stage Kidney Disease 
(ESKD) Patients Without HIV: National Estimates 2006-15
Ahmed A. Awan,1 Samaya J. Anumudu,2 Sankar D. Navaneethan,2 
Wolfgang C. Winkelmayer,2 Carl P. Walther.1 1Baylor College of Medicine, 
Houston, TX; 2Baylor College of Medicine, Houston, TX.
Background: While cryptococcal meningitis (CM) has been reported in HIV-negative 
persons with ESKD, its epidemiology is poorly described
Methods: Using the National Inpatient Sample, a national all-payer database, we 
estimated CM hospitalizations among persons with ESKD from 2006-15. Using ICD9 codes, 
we identified patients with ESKD on dialysis (CKD-G5D), and transplanted (CKD-T), CM 
(in first 5 discharge diagnoses, to improve specificity), and HIV. We evaluated in-hospital 
mortality in CKD-G5D and CKD-T patients without HIV using logistic regression models, 
adjusted for demographics and a priori comorbidities (age, sex, diabetes, liver disease, heart 
failure, lung disease, rheumatic disease).
Results: We estimated 1855 hospitalizations of ESKD patients with non-HIV CM 
from 2006-15, with409 (95% CI:317-502) on dialysis, and 1446 (95% CI:1212-1680) with 
kidney transplant. The number of hospitalizations increased from 2006-2007 to 2008-2009, 
especially in the CKD-T population, and has remained steady since then (Figure). In-
hospital mortality was higher for patients with CKD-G5D compared to CKD-T:21% (95% 
CI 12.3-29.9%) vs. 9% (95% CI 2.0-16.0%), respectively. Adjusted odds -ratio for death in 
CKD-T vs.CKD-G5D was 0.39 (95% CI [0.16-0.96]).
Conclusions: ESKD patients without HIV are at risk for cryptococcal meningitis, and 
nephrologists should be aware of this risk. Mortality among those on dialysis is significantly 
higher than among those with a kidney transplant, perhaps reflecting underlying severe 
comorbidities causing the immune suppression among affected dialysis patients.
Figure.
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Hemodialysis Transportation Modality and Their Effects on Treatment 
Adherence
Candace D. Grant, James Drakakis, Naveed N. Masani, Nobuyuki 
(Bill) Miyawaki. NYU Winthrop Hospital, Mineola, NY.
Background: A common reason for nonadherence to hemodialysis (HD) treatments is 
difficulty with transportation. Health disparities occur in groups of people that experience 
suboptimal health care based on their social, economic, and/or environmental disadvantage. 
The modality used for transportation is dependent on a patient’s socioeconomic status 
and can be related to health disparities. Identifying how transportation modality affects 
adherence to HD regiments can hopefully lead to improved strategies in HD transportation 
and improve clinical outcomes for all HD patients. We examined transportation modality 
and HD treatment adherence.
Methods: We reviewed the electronic charts of patients enrolled at our outpatient HD 
units. We identified 306 eligible patients that had documented transportation modality as 
well as health insurance information. HD compliance was calculated for the group between 
April 2014 to April 2018. The modes of transportation were designated as self/family (SF), 
ambulance/ambulette (AMB) and Taxi/AbleRide (TX). Health insurance was divided into 
three groups: Medicare (MCR), Medicaid (MCD) and private insurance/self-pay (PVT).
Results: The study population was 53% white, 57% male with a median age of 66 years. 
59%, 18% and 23% of the patients had MCR, MCD, or PVT for insurance respectively. 
Patients with more than one mode of transportation (n=20) had an average compliance of 
91.27% versus 90.95% with only one mode (n=286). Of the patients with only one mode 
of transportation, the average compliance was 91.78%, 90.39%, and 88.21% for travel by 
SF, AMB, and TX, respectively. HD compliance by primary insurance varied at 92.3%, 
91.8% and 86.7%, for PVT, MCR and MCD, respectively (P<0.01). When comparing 
compliance of different transportation modes within the designated insurance groups, there 
was a significant difference between the modes of transportation at 90.3% and 85% for SF 
and combined AMB/TX respectively, (p<0.05).
Conclusions: Our findings suggest that health insurance and transportation modality 
both play a significant role in HD treatment compliance. Patients on MCD experience more 
health disparities that can interfere with HD regiment complaince. Further prospective 
studies are required to explore this relationship and why MCD insured patients would 
experience lower HD compliance when relying on commercial sources for transportation.
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Screening for Obstructive Sleep Apnea in Hemodialysis Patients Using the 
Crit-Line Monitor
Ohnmar Thwin, Xia Tao, Mirell Tapia, Priscila Preciado, Stephan Thijssen, 
Peter Kotanko. Renal Research Institute, New York, NY.
Background: Obstructive sleep apnea (OSA) is common among end-stage renal 
disease patients. The absence of airflow leads to a decrease in arterial and peripheral blood 
oxygen saturation (SO2). A saw-tooth pattern of SO2 is considered as a sign of OSA. The 
Crit-Line monitor (CLM) is being used in hemodialysis (HD) centers. Our goal was to 
investigate if CLM can be used to identify sleep-related breathing disorders
Methods: Prosprective, observational study done in chronic HD patients. Subjects 
were studied twice and equipped with a WatchPAT device (FDA approved device for OSA) 
and videotaped and CLM data was recorded. The degree of simililarity between SO2 from 
WatchPAT and CLM was determined by cross-correlation analysis
Results: We studied 14 patients (age 55.4±10 yrs, 64% males, BMI 25.6±6.8 kg/m2) 
with a total of 27 visits. We identified a saw-tooth pattern in the SO2 signals in 9 sessions (Fig 
1). The cross-correlation coefficient between CLM and WatchPAT for SO2 was 0.93±0.11 
for 9 visits. Prolonged desaturation (>3% points from baseline) episodes occurred in 5 
visits, with 4 showing SO2 saw-tooth patterns. Fig.2 shows the SO2 signals from CLM 
and WatchPAT for one of these visits. Cross-correlation coefficient is 0.89±0.10 for these 5 
visits, and 0.53±0.23 for visits without saw-tooth pattern
Conclusions: While there was a high degree of correlation between the SO2 from the 
CLM and the WatchPAT device, the CLM captures a higher-resolution. CLM provides 
richer information and reveals SO2 nuances (such as the signature SO2 saw-tooth patterns) 
better than the WatchPAT device. It is ought to be possible to use the CLM for screening for 
sleep apnea as well as other blood oxygenation disorders. Further validation is required (e.g. 
comparison to polysomnography)
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Determination of Calf Normalized Resistivity at 50 kHz in the General 
Population
Fansan Zhu,1 Samer R. Abbas,1 Laura Rosales,1 Nathan W. Levin,1,2 
Peter Kotanko.1,3 1Renal Research Institute, New York, NY; 2Mount Sinai School 
of medicine, New York, NY; 3Icahn School of Medicine at Mount Sinai, New 
York, NY.
Background: We have developed 5 kHz calf normalized resistivity (CNR5) method to 
identify degrees of fluid status in dialysis patients. However, the 50 kHz BIA method have 
been used in clinical studies for many years. The aim of this study was to evaluate whether 
50 kHz CNR (CNR50) could be used to determine fluid status by comparing CNR5 and 
CNR50 chosen randomly from a general population.
Methods: Subjects from a general population were studied once. Calf multi-frequency 
bioimpedance spectroscopy measurements (Hydra 4200) was performed in the supine 
position. Further measurements included body height, weight and calf circumference. 
Resistances at 5 kHz (R5) and at 50 kHz (R50) respectively were extracted from the raw data. 
Calf resistivities (Rho5 and Rho50) were calculated based on resistances and average cross-
sectional areas over a calf length measurement of 10 cm. CNR5 and CNR50 were obtained 
by normalizing calf resistivities with body mass index (BMI).
Results: Ninety-one subjects (sex: 49 f, age: 57±10 year, BMI: 27.9± 4.7 kg/m2) 
were evaluated. Although calf R50 (R
2=0.89, p<0.0001), Rho50 (R
2=0.9, p<0.0001) and 
CNR50 (R
2=0.91, p<0.0001) highly correlated with CNR5, Rho5 and CNR5 respectively, 
the values of R50 (36.6±6.0, Ohm), Rho50 (352.9±60.6, Ohm*cm) and CNR50 (13.0±2.5, 
10-2 *Ohm*m3/kg) were significantly lower than in R5 (48.1±7.2, Ohm), Rho5 (464.9±79,
Ohm*cm) and CNR5 (17.1±3, 10
-2 *Ohm*m3/kg) respectively (Fig.1 and Fig.2). Bland-
Altman analysis showed that the differences between CNR5 and CNR50 was 4.08±0.95 10
-2
*Ohm*m3/kg (Fig.3). The difference between CNR5 and CNR50 was weakly (R
2=0.13) but 
significantly (p<0.001) associated with subject age (Fig.4).
Conclusions: Values of 50 kHz data R50, Rho50 and CNR50 were lower than that of 5 
kHz data with BIA respectively, presumably because a 50 kHz current passes into part of the 
intracellular space, while this does not occur measurably with 5 kHz current. This difference 
offers the practicability of using the CNR50 range in healthy subjects, as a criterion of 
normal fluid status.
Figures
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Effects of Medium Cut-Off (Theranova) Dialyzer on Hemodialysis 
Patients: A Prospective, Cross-Over Study
Mario Cozzolino. Department of Health Sciences, University of Milan, Milan, Italy.
Background: Recent data suggest that expanded hemodialysis (HDx) enabled by 
middle cut-off membrane promotes greater clearance for large middle molecules implicated 
in inflammation and immune function modulation.
Methods: In prospective, open-label, controlled, crossover pilot study, 20 prevalent 
hemodialysis (HD) patients were studied for 6 months in two dialysis treatments as follows: 
one MCO (Theranova) dialyzer and one high-flux dialyzer.
Results: In table 1, we present the baseline characteristics of HD patients. Hemoglobin, 
ferritin, transferrin, calcium, phosphate, parathyroid hormone and 25(OH) vitamin D levels 
were similar with MCO and high-flux HD. In addition, we did not find any albumin loss in 
the two treatment groups. Also, dialysis adequacy was similar in MCO and high-flux HD 
treated patients. Interestingly, the cumulative number of episodes of infection, confirmed 
clinically and treated with antibiotics) was significantly lower in HDx (# 6), compared with 
high-flux HD patients (# 20) (Figure 1), while number of hospitalizations did not change.
Conclusions: In conclusion, our pilot study demonstrates that Theranova dialyzer has 
a good tolerance profile and, intriguingly, reduces the cumulative number of infections in 
HD patients.
Funding: Commercial Support - Baxter
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Impact of Bemiparin, a Low Molecular Weight Heparin, in the Oxidative 
Stress of Patients in Chronic Hemodialysis
Elba O. Medina,1 Rafael Valdez-Ortiz,2 L. M. Perez-Navarro,3 Josue W. Tapia 
Lopez.4 1Hospital General de Mexico “Dr. Eduardo Liceaga”, Mexico City, 
Mexico; 2Hospital General de Mexico, Mexico City, Mexico; 3Hospital General 
de México Dr. Eduardo Liceaga, México, Mexico; 4ISSSTE, Estado de Mexico, 
Mexico.
Background: Patients in hemodialysis (HD) has increased oxidative stress (OS), 
what it produces endothelial damage secondary to the generation of reactive oxygen 
species (ROS), and consequently progression of cardiovascular disease (CVD). It has been 
observed, that the use of low molecular weight heparin (LMWH) could decrease the OS 
in this patients. We evaluated the effect of bemiparine a LMWH on the OS of patients in 
chronic HD.
Methods: Randomized, open, single-blind controlled clinical trial in chronic HD 
patients: group with UFH (n=19) as standard anticoagulation during HD and group 
with LMWH (n= 19). The OS markers were measured basal, at 4 and at 8 weeks: 
malondialdehyde (MDA), total antioxidant capacity (TAC), Superoxide Dismutase (SOD), 
Nitric Oxide synthase (NOS), Catalase (CAT) and Peroxidase (POD). Student’s t-test, one-
way ANOVA were performed.
Results: The mean age of the study groups was 33.5± 4.4 years. The comparison 
between groups did not present statistically significant differences in markers of OS. While, 
the intragroup comparison group with LMWH, was statistically significant differences in 
the levels of TAC (basal vs intermediate and, basal vs final); CAT (Intermediate vs final) 
and POD (intermediate vs final); while, the group with UFH showed statistically significant 
differences (p≤ 0.05) in the levels of POD (basal vs final), see Figure 1. None of the groups 
presented events of thrombosis or hemorrhagic complications.
Conclusions: There was a prospective increase in the concentration of OS markers in 
the LMWH group, what it demonstrates that the continuous use of LMWH participates in 
the antioxidant defense against the generation of ROS and the OS of patients with CKD in 
HD. It is necessary to evaluate the long-term use of LMWH on oxidative stress markers and 
evaluate the possible benefit of it use in the reduction of cardiovascular mortality.
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Safety and Efficacy of Heparin During Dialysis in the Context of Systemic 
Anticoagulant and Antiplatelet Medications
Steven M. Brunelli,1,2 Dena E. Cohen,1,2 Gilbert Marlowe,1,2 Daniel Liu,2 
Levi Njord,2 David B. Van Wyck,2 George R. Aronoff.3 1DaVita Clinical 
Research, Minneapolis, MN; 2DaVita Institute for Patient Safety, Denver, CO; 
3DaVita Kidney Care, Denver, CO.
Background: Heparin is widely used to prevent coagulation during hemodialysis 
(HD). Although systemic anticoagulants and antiplatelet agents are commonly prescribed 
in the HD population, the safety and efficacy of heparin in the presence versus absence of 
these medications is unclear.
Methods: This retrospective, longitudinal, time-updated cohort study considered 
adult patients receiving in-center HD (Aug 2015 – Jul 2017). Study data were derived 
from deidentified patient electronic health records. For each calendar month, patients 
were ascribed a 3-part exposure status (use of heparin, systemic anticoagulant, systemic 
antiplatelet agent). Outcomes included anemia measures, peri-treatment bleeding and 
clotting, and hospitalization for gastrointestinal (GI) bleeding. Within each systemic 
medication exposure category, associations of heparin use (vs. non-use) were examined 
using adjusted general linear, negative binomial, or Poisson models.
Results: Across all systemic medication exposures, heparin use (vs. non-use) was 
associated with significantly lower erythropoiesis stimulating agent (ESA) dose and higher 
hemoglobin values; slightly lower intravenous (IV) iron dose; and similar serum ferritin 
and transferrin saturation. Heparin use was also associated with lower rates of clotting 
during treatment. Heparin use was not associated with excess risk of hospitalization for GI 
bleeding, or with peri-treatment bleeding episodes. Associations with respect to ESA, IV 
iron, hemoglobin, and clotting were approximately 2-fold more potent in the absence of a 
systemic anticoagulant; the presence of a systemic antiplatelet agent did not impact these 
associations. Neither systemic medication type influenced associations between heparin use 
and peri-treatment or GI bleeding.
Conclusions: Heparin use was safe and effective regardless of systemic anticoagulant 
and antiplatelet agent status. Clinical judgment must be applied to assess bleeding risk in 
individual patients; however, the decision to withhold heparin should not solely be based 
upon the concurrent use of systemic anticoagulant or antiplatelet agents.
Funding: Commercial Support - This was a research project conducted by the DaVita 
Institute for Patient Safety and supported by DaVita Kidney Care
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Decreasing the Incidence of Catheter-Related Blood Stream Infections in 
Hemodialysis Patients: A Quality Improvement Program
Wisam H. Al-Badr, Mahmoud M. Shaheen, Hany A. Salama, 
Mahmoud A. Ahmed, Hany Elshiekh, Ibrahim A. Jubran, Saad S. Alobaili, 
Abdulkareem Alsuwaida. DaVita-Saudi Arabia, Riyadh, Saudi Arabia.
Background: Hemodialysis patients dialyzing with a central venous catheter are at risk 
for developing catheter-related bloodstream infections (CRBSI), which are associated with 
substantial morbidity. In 2009, the US Centers for Disease Control and Prevention (CDC) 
sponsored a collaborative project to reduce CRBSIs in outpatient hemodialysis facilities. 
The aim of our study was to evaluate the impact of applying the CDC program on the 
occurrence of CRBSI in an outpatient hemodialysis population.
Methods: All cases of CRBSI that occurred among patients treated at 20 outpatient 
dialysis centers operated by DaVita-Saudi Arabia (Oct. 2015 to Dec. 2017) were recorded. 
The quality improvement project, which involved adopting the CDC Dialysis BSI 
Prevention Collaborative Interventions was initiated in April 2016. Interventions used 
included the CathAway protocol, ideal catheter lock, standardization of antibiotic therapy, 
training protocols, closed audits for catheter care, and maximal barrier precautions at the 
time of catheter insertion. The rate of CRBSI was calculated monthly as the incidence of 
CRBSI per 1000 catheter-days.
Results: During the studied period, the monthly CRBSI incidence decreased from 
5.6 per 1000 catheter-days in the first quarter 2016 to a nadir of 1.8 during the last quarter 
2017. There was also a substantial decrease in the mean monthly incidence of CRBSI from 
5.1 ± 3.8 among 1477 patients in 2016 to 2.7 ± 0.86 among 2255 patients in 2017.
Conclusions: The most effective strategy for prevention of CRBSIs is reducing the use 
of catheters. However, given the reality that catheter use cannot be eliminated, adoption of 
CDC-recommended programs may reduce the rate of CRBSI.
Funding: Commercial Support - DaVita
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Characteristics of Hospital Acquired Central Line Associated Bloodstream 
Infection (CLABSI) in Hemodialysis (HD) Patients in a Single Tertiary 
Medical Center in Hawaii
Nattawat Klomjit,1 Ekamol Tantisattamo.2,3 1John A. Burns School of Medicine. 
University of Hawaii, Honolulu, HI; 2University of California, Irvine School of 
Medicine, Orange, CA; 3Division of Nephrology, Department of Internal 
Medicine, William Beaumont Hospital, Oakland University William Beaumont 
School of Medicine, Multi-Organ Transplant Center, Royal Oak, MI.
Background: Hospital acquired CLABSI is one of an important complication of 
dialysis catheter and is associated with high morbidity and mortality in HD patients. We 
studied baseline characteristics of HD patients who developed hospital acquired CLABSI 
as part of our institutional quality improvement project.
Methods: We identified index patients through the hospital database based on CDC 
definition of CLABSI. We studied the hospital acquired CLABSI patients who had HD 
catheter presented at the time of CLABSI diagnosis between 1/1/12 and 12/31/17. We 
studied baseline characteristics, hospital-related factors, and mortality rate associated with 
CLABSI.
Results: Of the 13 patients, 46% were male and median± SD age was 66±11.28 
years old. Asian is the most prevalent (46%) followed by mixed race (31%). There were 
no Caucasian patients in the cohort. More than half had diabetes. Infection (46.2%) was 
the most common admitting diagnoses followed by cardiovascular diseases (30.1%). The 
majority of patients had ESRD (69.2%) followed by AKI on CKD (23.1%), and AKI (7.7%) 
and two-third of the patients infected tunneled HD catheter (TDC) and the remaining one-
third had non-TDC. A quarter of patients (23%) was in ICU when CLABSI was diagnosed. 
Only 38% of blood cultures were drawn from peripheral sites and central line. Up to 31% 
had an early CLABSI occurred within 7 days after HD catheter placement. Gram positive 
cocci is the most common pathogens (54%), followed by gram negative bacilli (31%), 
anaerobe (8%), and fungus (7%) and 85% of cases were managed by infectious disease 
physicians. Median length of hospital and ICU stays were 21 and 17 days, respectively. 
In-hospital mortality rate was 15.4%.
Conclusions: Our patients are elderly with diabetes mellitus being the major co-
morbidities. There are unexplained racial disparities of races given no Caucasian patients in 
our cohort. The majority of hospital acquired CLABSI occurred in ESRD patients and the 
prevalence of infected TDC was greater than that of non-TDC. A third of patients developed 
CLABSI within 7 days of HD catheter placement therefore strict measures should be 
employed during this phase to prevent early HD catheter infection.
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ESRD and a Risk of Tuberculosis: A Nationwide Population-Based Cohort 
Study
Soon Kil Kwon,1 Hye-Young Kim,1 Sun Moon Kim,2 Hyunjeong Cho.2 
1Nephrology, Chungbuk National University College of Medicine, Cheongju, 
Chungbuk, Republic of Korea; 2Chungbuk National University Hospital, 
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Background: The converging epidemics of tuberculosis (TB) and end-stage renal 
disease (ESRD) have generated a significant public health burden and difficulties in 
controlling TB, although the relationship between these conditions remains poorly 
understood. This nationwide propensity score-matched cohort study aimed to assess the 
rateof developing TB among patients receiving dialysis for ESRD.
Methods: The Korean national health insurance database was used to identify 
patients receiving dialysis for new-onset ESRD during 2004–2013, who were matched to 
an equivalent number of non-dialysis subjects. We also collected data from the KNHIS 
National Sample Cohort (NSC), which is stored in the same database. The KNHIS-NSC 
included approximated 1,000,000 individuals (2.2% of the total Korean population) and 
was created by sampling the records of the National Health Information database. The 
incidences of active TBin the dialysis and control cohorts during 2004–2013 were identified 
using International Classification of Disease, tenth revision (ICD-10) codes (A15–19, U88). 
The diagnosis of active TBwas then confirmed based on simultaneous prescriptions for ≥2 
anti-tuberculosis drugs during a 30-day period. The incidences of TB in the ESRD and 
control cohorts were calculated for 2004–2013, and multivariable Cox proportional hazards 
modelwas used to evaluate the ESRD-related risk of developing TB.
Results: During 2004–2013, 59,584 patients received dialysis for newly diagnosed 
ESRD, which was associated with a significantly higher risk of TB than among the controls 
(incidence rate ratio: 4.80). The cumulative TB incidence was significantly higher in the 
dialysis cohort than in the control cohort (p<0.0001; log-rank test), and subgroup analyses 
revealed similar results for both hemodialysis and peritoneal dialysis (both p<0.0001; 
log-rank test). However, there was no significant difference in the risk of TB between the 
hemodialysis and peritoneal dialysis subgroups(p= 0.67; log-rank test). The ESRD cohort 
had an independently elevated risk of TB (hazard ratio: 4.39, 95% confidence interval: 
3.60–5.37).
Conclusions: Similar to the findings of previous studies, we found that patients 
receiving dialysis for ESRD had an elevated risk of TB. These results highlighted the need 
of detailed and well-organized guidelines for TB screening among patients with ESRD.
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Effect of Vancomycin on Plasma Concentration of Uremic Solutes
Leland R. Soiefer,2,4 Michelle Chang,2,3 Farah Tamizuddin,2 Daria Schatoff,2 
Lucas Cofer,2 Albert Matalon,2 Lama Nazzal,2 Bjorn Meijers,1 Robert Holzman,2 
Jerome Lowenstein.2 1University Hospitals Leuven, Leuven, Belgium; 2New 
York University School of Medicine, New York, NY; 3NYP Hosp-Columbia 
University Medical Center, New York, NY; 4New York- Presbyterian Weill 
Cornell Medical Center, new York, NY.
Background: Many uremic retention solutes are products of gut bacterial metabolism. 
Protein-binding renders these solutes poorly dialyzable. In a prior study we observed that 
a single dose of 250 mg of vancomycin, given by mouth, resulted in a significant (40%) 
decrease in the plasma concentration of indoxyl sulfate and p-cresyl sulfate over a period 
of one week. In this study we compared the changes in plasma concentration of a panel of 
protein-bound uremic retention solutes in response to the once-weekly oral administration 
of 250 mg of vancomycin or placebo over a period of 8 weeks.
Methods: Eight subjects with chronic, stable ESRD on thrice-weekly hemodialysis via 
AV fistula in the River Renal Dialysis Unit in Bellevue Hospital, were randomized to two 
groups, utilizing a single-blinded procedure. Baseline plasma samples were collected prior 
to the initial dose of vancomycin or placebo and at weeks one, two, three, four, and eight. 
Uremic retention solutes were measured by MS-HPLC.
Results: Six of the eight uremic retention solutes (Table 1) demonstrated a significant 
decline in concentration over the eight week period of once-weekly vancomycin 
administration. The magnitude of the decline makes it more likely that gut production was 
reduced rather than renal excretion increased. Solute concentrations remained unchanged 
over the same period of placebo administration.
Conclusions: The significant decline in the plasma concentrations of multiple uremic 
retention solutes provides evidence of the importance of the gut microbiome in the 
generation of these solutes. The reduction in concentrations of indoxyl sulfate, p-cresyl 
sulfate, and kynurenic acid, recognized as likely uremic toxins, suggests that altering the 
gut microbiome might provide a valuable therapeutic strategy in the management of ESRD.
Funding: Private Foundation Support
Linear Trends in Solute Concentrations Over 8 Weeks
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The Amino Acid Losses Are Equal Between Pre and Post On-line HDF 
Under the Same Dialysis Dose (Kt/V)
Shunichiro Urabe,1 Motoko Kato,1 Emi Hiyama,1 Asami Kurii,1 Toru Hyodo,2 
Makoto Kitamura,3 Miho Hida,3 Yasuhisa Kurata,3 Kenichi Kokubo.4 1Eijin 
Clinic, Hiratsuka, Japan; 2Eijin Clinic and Cambodian Association of 
Nephrology, Hiratsuka, Japan; 3Kurata Hospital, Hiratsuka, Kanagawa, Japan; 
4Kitasato University School of Allied Health Sciences, Sagamihara, Japan.
Background: We analyzed the amino acid losses that occur on performing pre-dilution 
on-line HDF (Pre-HDF) and post-dilution on-line HDF (Post-HDF) because the amino acid 
kinetics of HDF has been unknown until now.
Methods: We compared the total amino acid, total non-essential/essential/branched-chain 
amino acid amount into the total waste fluid, and Kt/V (urea) between 9 patients undergoing 
Pre-HDF (7 males, 4 diabetic, mean age: 72.4±2.1 years) and the same patients receiving 
Post-HDF. The mean blood flow rate in the former and latter was 222.2±24.8 and 200.0±0.0 
mL/min, respectively. The dialysate flow rate was 328.7±48.6 and 556.0±0.0 mL/min, 
respectively. The replacement fluid flow rate was 251.3±27.4 and 44.0±0.0 mL/min, 
respectively. The replacement fluid volume was 56.7±6.2 and 10.0±0.0 L, respectively.
Results: In the Pre-HDF group, the total and total non-essential amino acid losses 
(4814.3±1055.6 and 3058.4±632.0 mg, respectively) were not significantly different from 
in the Post-HDF group (5257.3±698.9 and 3421.9±446.8 mg, respectively) (p = 0.180 and 
0.116, respectively). In the former, the total essential amino acid (1755.9±503.3 mg) was 
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not significantly different from in the latter (1835.3±351.0 mg) (P=0.401) and also in the 
former, the branched-chain amino acid (780.2±224.2 mg) was not significantly in the latter 
(816.4±210.1 mg) (P=0.139). In the Pre-HDF group, the urea and Cr reduction rates were 
69.5±7.4 and 63.2±6.7%, respectively. In the Post-HDF group, the values were 70.9±4.4 
and 64.8±3.9%, respectively. The values showed no significant differences between the 
Pre-HDF and Post-HDF group (Urea: P=0.354, Crea: P=0.309). The Kt/V (urea) values in 
the former and latter were 1.46±0.28 and 1.45±0.19, respectively; there was no significant 
difference (p=0.862).
Conclusions: Under the same dialysis dose of Kt/V for urea, the amino acid losses 
were same between Pre-HDF and Post-HDF, suggesting that the moderate volume Post-
HDF (replacement fluid volume: around 10.0 L) is as favorable as the Pre-HDF as a blood 
purification method from the viewpoint of nutrition.
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Safety and Effectiveness of Sucroferric Oxyhydroxide in Dialysis Patients: 
24-Month Interim Analysis of the VERIFIE Study
Markus Ketteler,8 John Boletis,9 Angel Luis M. De Francisco,11 Marc G. Vervloet,1 
Philip A. Kalra,2 Denis Fouque,3 Piergiorgio Messa,7 Manuela Stauss-Grabo,13 
Anja Derlet,13 Viatcheslav Rakov,4 Sebastian Walpen,4 Linda Ficociello,6 
Jacques B. Rottembourg,12 Christoph Wanner,5 Jorge B. Cannata-Andia.10 1VU
university medical centre, Overveen, Netherlands; 2Salford Royal Hospital NHS 
Trust, Salford, United Kingdom; 3University Claude Bernard, Pierre Benite,
France; 4Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland; 
5Nephrology, University Hospital, Wuerzburg, Germany; 6Fresenius Medical
Care Renal Therapies Group, Waltham, MA; 7Nephrology, Maggiore Hospital,
Milan, Italy; 8Klinikum Coburg GmbH, Coburg, Germany; 9Laiko University
Hospital, Athens, Greece; 10Medicine, Hospital Universitario Central de
Asturias, Oviedo, Spain; 11Hospital Univ. Marques de Valdecilla, Santander, 
Spain; 12Nephrology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; 
13Clinical Research, Fresenius Medical Care, Bad Homburg, Germany.
Background: Sucroferric oxyhydroxide (SFOH) is an iron-based phosphate binder 
(PB) for the treatment of hyperphosphatemia in dialysis patients (pts).
Methods: VERIFIE is a non-interventional prospective, multicenter, European cohort 
study evaluating the real-world safety and effectiveness of SFOH. This interim analysis was 
performed 24 months after first-patient, first-visit.
Results: 1075 pts (mean age 61.5 yrs; 66.7% male) were included in the safety analysis 
set, with 1023 pts in the full analysis set to evaluate SFOH effectiveness. Prior PB use was 
reported for 58.9% of pts at study entry, while 40.1% received concomitant PBs during the 
study. The mean observation period was 186 days. In total, 378 (35.2%) pts reported ≥1 
adverse drug reaction, the vast majority of which were gastrointestinal-related (Panel A). 
263 (24.5%) pts withdrew from the study during the observation period. No statistically 
significant changes in serum ferritin, TSAT or hemoglobin were observed from baseline 
(BL) to Month 18. Mean daily dose of SFOH during observation period was 1144.3 mg (2.3 
pills/day). Overall, serum phosphorus (sP) levels decreased significantly from 6.3 mg/dL 
at BL to 5.4 mg/dL at Months 6, 12 and 18 with SFOH therapy (p≤0.0001). The % of pts 
achieving sP control (≤5.5 mg/dL) from BL to Month 6 increased across all participating 
countries (Panel B).
Conclusions: The safety profile of SFOH was comparable to that observed in the Phase 
3 study; no new safety signals were identified. SFOH effectively reduced and maintained sP 
levels, with a relatively low pill burden.
Funding: Commercial Support - Vifor Fresenius Medical Care Renal Pharma
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Changes in Serum Magnesium During Hemodialysis in Three Facility 
Settings
Eduardo K. Lacson,1,2 Gideon N. Aweh,3 Dwayne J. Bergeaux,6 Deana Fontenot,2 
Bhabendra Putatunda,4 Nand K. Wadhwa.5 1Tufts University School of Medicine, 
Boston, MA; 2Dialysis Clinic Inc., Nashville, TN; 3Dialysis Clinic, Inc., 
Nashville, TN; 4Nephrology Associates PC, Murfreesboro, TN; 5Stony Brook 
Medicine, Stony Brook, NY, East Setauket, NY; 6DCI, Crowley, LA.
Background: A quality improvement project monitored serial serum magnesium 
(sMg) after a manufacturer changed dialysate magnesium (dMg) content. Three Medical 
Directors decided to order facility-wide post-dialysis sMg in addition to pre-dialysis sMg. 
Only 60-75% of sMg diffuse during hemodialysis (HD) due to sequestration by albumin 
a.k.a. the Gibbs-Donnan effect.
Methods: All maintenance HD patients in three outpatient units were included and
sMg were tested with the monthly blood draws for December, 2017. Facility A utilized a
dMg of 1.0 mEq/L which is most commonly used by DCI, a non-profit dialysis provider. 
Facility B also utilized dMg of 1.0 mEq/L but routinely gave oral magnesium supplements 
to target pre-dialysis sMg of ~2.0 mEq/L. Facility C utilized a dMg of 1.6 mEq/L with a
citrate-based bath for over three years.
Results: The facilities (A-B-C) had varying levels of pre-dialysis sMg with A having
levels consistent with other DCI facilities at ~1.8 mEq/L.; B had higher pre-dialysis sMg of 
~2.0 mEq/L consistent with its target; and C also had elevated pre-dialysis sMg consistent 
with prior reports at dMg ~1.5 mEq/L. At dMg = 1.0 mEq/L A (representing usual care)
had ~10% decline of sMg post-dialysis compared to ~17% decline in B, which started with 
higher pre-dialysis sMg. The sMg was unchanged in C with no net removal at dMg of 1.6 
mEq/L. Results are summarized in the table.
Conclusions: Serum magnesium did not fully equilibrate with dialysate consistent with
the Gibbs-Donnan effect. Net sMg removal increases with higher sMg levels at dMg of 1.0 
mEq/L; At dMg of 1.6 mEq/L, sMg is maintained at ~2.1 to 2.2 mEq/L with no net dialytic 
magnesium removal. These findings illustrate what could be expected in a comparative 
effectiveness study comparing dMg at 1.0 vs. 1.5 mEq/L.
Pre- & Post-HD Magnesium Under 3 Different Settings
Mg = Magnesium; Note: Pre-HD & Post-HD serum magnesium shown as mean +/- 
standard deviation, in mEq/L.
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High Risk of Pyogenic Spondylitis in CKD Patients: Its Characteristics 
and Incidence
Rikako Oki, Hidekazu Moriya, Yasuhiro Mochida, Kunihiro Ishioka, 
Sumi Hidaka, Takayasu Ohtake, Shuzo Kobayashi. Shonan Kamakura General 
Hospital, Kamakura, Japan.
Background: Pyogenic spondylitis is a rare but life- threatening disease. Mortality 
has been reported to be approximately up to 11% with the incidence of 2.5 - 7.4/100,000 
population per year, particularly more in elderly people or compromised hosts. CKD 
patients often have infectious complications. However, little information is available 
regarding the incidence of this disorder in CKD patients. In this study, we examined to 
clarify the incidence and characteristics of pyogenic spondylitis in CKD patients.
Methods: A retrospective observational study was conducted in our hospital. Fifty-
seven patients (45 CKD patients without HD (eGFR < 60ml/min/1.73m2) [ND] and 12 
HD patients [HD]) were diagnosed to have pyogenic spondylitis between January 2012 
and October 2016. We investigated age, disease background, affected site, causative 
microorganism, therapy, hospitalization period, mortality rate, causes of death in ND group 
and HD group.
Results: Median of age in all patients was 79 years old (IQR: 72-86): 54% were male, 
30% had diabetes and 21% were HD patients. In-hospital mortality was 23%, and average 
hospitalization period was 55 days. Staphylococci species were the most frequent pathogen 
(49%). Comorbidities are diabetes (30%), ischemic heart disease (17.5%), peripheral 
vascular disease (11%), and cerebral vascular disease (10%). There was no significant 
difference in hospitalization period and mortality rate between ND and HD group. The rate 
of pyogenic spondylitis caused by Staphylococci tended to be higher in HD group(P=0.056). 
Fifty percent of pyogenic spondylitis developed due to infection of AV fistula (AVF), and 
the causative microorganism of all cases due to infection of AVF was Staphylococci.
Conclusions: Mortality of pyogenic spondylitis is high in CKD patients. Bacteremia 
caused by blood access infection is a risk factor of pyogenic spondylitis and more attention 
should be paid to infection of AVF.
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Long Term Effects of Expanded Hemodialysis (HDx) on Clinical and 
Laboratory Parameters in a Large Cohort of Dialysis Patients
Alfonso Bunch,1 Lars-Goran Nilsson,2 Jasmin Vesga,1 Freddy Ardila,1 
Eduardo Zuniga,1 Juan Alarcon,1 Adriana M. Suarez,1 Ricardo Sanchez,3 
Mauricio Sanabria.4 1RTS, Bogota, Colombia; 2Baxter International Inc., Lund, 
Sweden; 3Universidad Nacional de Colombia, Bogotá, Colombia; 4RTS Baxter, 
Bogota, Colombia.
Background: Expanded hemodialysis (HDx) enabled by medium cut off membrane 
provides clearance of large middle molecules which have been linked to inflammation, 
immune modulation and atherosclerosis. The long term effects of HDx on serum levels of 
small solutes and albumin has not been investigated in large cohort of patients.
Methods: Multicenter prospective study in prevalent hemodialysis patients, older 
than 18 years old; enrolled from September 1 to November 30 of 2017, and converted 
to HDx using Theranova 400 (3 sessions per week, 4 hours per session, same heparin 
dose). Albumin assay used was bromocresol blue with laboratory reference values between 
3,5 gr/dl – 5,1 gr/dl Measurements were done at baseline, week 2, and month 1,2,3,4,5,6; 
descriptive statistics and ANOVA were used.
Results: We analyzed data on 524 patients, 61.6% (n=323) men, mean age 60.1 
years (SD=15.3), dialysis vintage was 5.4 years (SD=5.01). We did not observe clinically 
significant differences in laboratory variables after 6 months of intervention with expanded 
hemodialysis; details are presented in Table 1. We found an initial small decrease in serum 
albumin level which stabilized and within the normal range per our laboratory references. 
See Table 1 Dialysis performans adequacy (Kt/V) was achieved. No clinically significant 
differences in laboratory values at 6 months with HDx was observed (Table 2).
Conclusions: The expended hemodialysis (HDx) shows a very good safety and 
performance profile during the first three months of use.
Funding: Commercial Support - Baxter Healthcare Corporation
FR-PO767 Poster Friday
Dialysis: Inflammation and Infection
In-Vivo Dialysis Kinetics of 300 mL/min and 500 mL/min Dialysate Flows
Dimitri A. Augustin,1 Leslie A. Spry,2 Sarah S. Prichard,3 Glenn M. Chertow,1 
Luis Alvarez.4 1Stanford University School of Medicine, Palo Alto, CA; 
2Unafilliated, Lincoln, NE; 3Unafilliated, Montreal, QC, Canada; 4Palo Alto 
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Background: Conventional dialysate flow rates (QD) are typically 500-800ml/min with 
the intent to maximize urea removal during hemodialysis. We previously conducted kinetic 
modeling of 300 ml/min compared to 500 ml/min (QD) and concluded that lower QD would 
be expected to provide adequate hemodialysis. Little is known about the kinetics of dialysis 
with a 300 ml/min (QD) since the bulk of literature focuses on (QD) above 500ml/min. We 
present in-vivo kinetic testing of hemodialysis patients with 500ml/min and 300ml/min 
(QD) and evaluate the differences in kinetic curves.
Methods: The study group included 6 patients undergoing chronic hemodialysis via a 
fistula (n=4) or graft (n=2). Mean age was 58 years; mean weight was 85kg. We performed 
a prospective, open label, randomized, cross-over evaluation of in-vivo kinetics of serum 
urea, phosphorus, and other solutes at variable (QD). All patients participated in 2 complete 
dialysis sessions in each of 3 treatment conditions: 1. 500ml/min (QD), 2. 300ml/min (QD), 
and 3. 300ml/min (QD) with extended time.
Results: The mean urea kinetic curves with (QD) 300ml/min and 500ml/min mirrored 
each other in all 6 patients. The figure displays data for the 3 patients with 240 minutes 
prescriptions. The inverted curves include an initial steep decline and gradual trough at the 
end of hemodialysis treatment; the curves conclude with a slight rebound curve within an 
hour post treatment. Mean serum beta2 microglobulin, bicarbonate, potassium, phosphate, 
and sodium all followed similar kinetic curves during QD 300ml/min and 500ml/min.
Conclusions: With a fixed dialyzer size and blood flow rate, solute kinetics of 300 ml/min 
(QD) are similar to those of a 500 ml/min (QD).
Funding: Commercial Support - Outset Medical, Inc
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Neutrophils to Lymphocytes Ratio Prior to Death in Hemodialysis 
Patients: Results from the Global MONDO Initiative
Xiaoling Ye,1 Dalia E. Yousif,1 Jochen G. Raimann,1 Yuedong Wang,6 
Jeroen Kooman,2 Frank van der Sande,2 Stefano Stuard,3 Bernard J. Canaud,4 
Adrian M. Guinsburg,3 Len A. Usvyat,5 Peter Kotanko.1 The MONDO Initiative 
1Renal Research Institute, New York, NY; 2Maastricht University Medical 
Centre, Maastricht, Netherlands; 3Fresenius Medical Care, Bad Homburg, 
Germany; 4FMC Deutschland GmbH, Bad Homburg, Germany; 5Fresenius 
Medical Care North America, Melrose, MA; 6University of California - Santa 
Barbara, Santa Barbara, CA.
Background: Among patients(pts) with end stage renal disease (ESRD), chronic 
inflammation is highly prevalent and associated with adverse clinical outcomes including 
CVD and death. Understanding the dynamics of readily available inflammatory markers 
(NLR,CRP,WBC) across different survival time is an essential way to explore patient- and 
process-related factors that contribute to adverse outcomes.
Methods: MONDO Initiative is a global retrospective cohort study that contained data 
of 150k+ pts with in-center HD from 41 countries&6 continents. Adult pts who died within 
the first 36 months (mos) on HD were stratified into 6 groups, pts died from 0-6, 6-12,12-
18,18-24,24-30 and 30-36 mos after HD initiation. Pts who survived 36+ mos were chosen 
as the control group. Monthly average of NLR, CRP, Neutrophils, Lymphocytes, WBC 
were obtained, cubic spline function were applied to access the trends and rate of changes 
for each of the parameters of interest. Additionly, subgroup analysis were performed to 
explore the sex and regional differences.
Results: 18,276 incident HD pts were included, 2,068 died within 6 mos,1,231 died 6 
-12 mos,971 died 12 -18 mos,792 died 18-24 mos,721 died 24-30 mos, 648 died 30-36 mos, 
and 12,295 survived 36+ mos. For pts who with shorter survival time, NLR, Neutrophils,
Lymphocytes, WBC&CRP were observed to be higher at HD initiation. Additionaly, all the 
inflammatory markers were declined after the HD initiation and reached nadir from 3-0 mo, 
vary by pts’ survival time. All the markers with an accrelated trend mos before death. For 
pts who survived 36+ mos, NLR, CRP and WBC seem to be stable after they reached the 
nadir. No sex and regional differences were observed.
Conclusions: Understanding the dynamics of readily available inflammatory markers 
is an important way to explore patient- and process-related factors that contribute to 
outcomes. NLR variations over survival time may have a prognostic impact.
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Are Cytokines and Body Composition Surrogate Markers for Outcomes 
in Hemodialysis Patients?
Ana Rita M. Martins,1,2 Inês C. Moreira,1 Andre L. Weigert.1,2 1Davita, Óbidos, 
Portugal; 2Pharmacology Department, Medical School; Lisbon University, 
Lisbon, Portugal.
Background: Obesity has been linked to better outcomes in hemodialysis (HD) 
patients (pts). Persistent inflammation, an important contributor to wasting, is associated 
with increased levels of tumor necrosis factor-alpha (TNF-α), hepcidin (Hpc) and soluble 
CD-163 (sCD163). TNF-α is a pro-inflammatory adipokine, sCD163 is a marker of 
macrophage activation and Hpc is the main regulator of hepcidin-ferroportin axis, all
relevant inflammatory mediators. Our aim was to identify potential targets to minimize 
inflammation in HD pts.
Methods: Prospective cohort study with 160 prevalent HD pts. Baseline demographic 
data, blood biochemistry, serum inflammatory markers, comorbidities, anthropometric 
parameters and multifrequency bioimpedance were evaluated.
Results: In our cohort, 91 pts were male, mean age was 67 years, 40% had diabetes 
(DM) and average time on HD was 92 months. During the follow up (39±16 months), 38 
pts died of cardiovascular (CV) events. Charlson comorbidity score was 4.4±2.3 and body 
index mass was 26.3±4.6 kg/m2. Pts were divided in two groups, according to their lean 
mass (LM): 51% had LM≥27%; no differences seen in age and time on HD between the two 
groups. Pts with LM≥27% had lower TNF-α (p=0.004), sCD163 (p=0.047), Hpc (p=0.038), 
hospital admissions (p=0.048) and had higher serum albumin (p=0.008). In a Kaplan Meier 
test, pts with higher LM had a better survival (139 vs 117 months; log rank 5.1; p=0.024). 
TNF-α was positively correlated with ferritin (p=0.005); sCD-163 was negatively correlated 
with serum albumin (p=0.02) and positively with CV events (p=0.025). Hpc was positively 
correlated with ferritin (p=0.018) and with cardiac failure (p=0,005) and negatively with 
triglycerides (p=.005). In a Cox hazards model, LM <27% was an independent predictor of 
mortality (HR=2.82; p=0.021; IC 95% 1.2-6.8), adjusted for age and DM.
Conclusions: We observed an association between a higher LM and better clinical 
outcomes and attenuation in inflammatory markers. Further studies of whether interventions 
that optimize body composition and interfere with the inflammatory profile of HD pts will 
improve survival are warranted.
Funding: Commercial Support - Davita
FR-PO770 Poster Friday
Dialysis: Inflammation and Infection
Immunogenicity and Safety of a Single Booster Dose of Heplisav-B in 
Patients Undergoing Hemodialysis
Randall N. Hyer, Robert Janssen. Dynavax Technologies, Berkeley, CA.
Background: Patients with end-stage renal disease (ESRD) undergoing hemodialysis 
have a greater risk of hepatitis B virus (HBV) exposure, a lower seroprotection response 
to primary HBV vaccination, and experience a more rapid decline in antibody to HBV 
surface antigen (anti-HBs) levels compared with healthy subjects. Anti-HBs levels should 
be assessed annually, and a booster provided if levels decline to <10 mIU/mL. Heplisav-B® 
is a TLR9-agonist-adjuvanted HBV vaccine with higher protection rates than commonly 
used alum-adjuvanted HBV vaccine (Engerix-B®), particularly in populations known to be 
hyporesponsive. This phase 3, randomized, open-label study assessed the immunogenicity 
of a single booster dose of Heplisav-B in patients with ESRD receiving hemodialysis who 
had previously received HBV vaccinations.
Methods: Adult patients with or without seroprotection from at least 1 HBV vaccine 
series (prior responders and prior nonresponders, respectively) and with anti-HBs levels 
<10 mIU/mL were randomized 1:1:1 to receive a booster vaccination of Heplisav-B, 
Engerix-B, or Fendrix (not available in the US). Seroprotection rates (SPRs) (proportion 
of patients with anti-HBs ≥10 mIU/mL) were assessed at week 4. Here we report the 
comparison between Heplisav-B and Engerix-B.
Results: A total of 76 prior nonresponders (Heplisav-B, n=38; Engerix-B, n=38) and 
28 prior responders (Heplisav-B, n=16; Engerix-B, n=12) were enrolled. Among prior 
nonresponders, a single dose of Heplisav-B induced a higher SPR at week 4 compared 
with a double dose of Engerix-B (42.1% vs 18.9%); treatment difference was 23.2% (95% 
CI: 1.4, 43.1). Among prior responders, SPRs at week 4 were comparable (Heplisav-B: 
80.0% vs Engerix-B: 90.9%; treatment difference: –10.9% [95% CI: –41.3, 23.5]). In a post 
hoc analysis based on criteria established in prior phase 3 trials, the SPR at week 4 with 
Heplisav-B group was significantly higher than with Engerix-B among prior nonresponders. 
Adverse events (AEs), serious AEs, and deaths were comparable between groups.
Conclusions: A single booster of Heplisav-B provides better protection against HBV 
than a double dose of Engerix-B with a comparable safety profile in patients undergoing 
hemodialysis who were nonresponders to prior HBV vaccination. Acknowledgement: 
Writing assistance, funded by Dynavax Technologies, provided by Caroline Walsh Cazares, 
PhD, of JB Ashtin.
Funding: Commercial Support - Dynavax Technologies
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Successful Hepatitis B Seroconversion Using Intradermal Engerix-B in 
Hemodialysis Patients Unresponsive to Two Courses of Standard 
Double-Dose Intramuscular Vaccine - Real World Experience
Daniel L. Landry,2,1 Gregory L. Braden,2,1 Spencer Hodgins,2 Jeffrey Mulhern.1 
1Kidney Care and Transplant Services of New England, Springfield, MA; 
2Baystate Medical Center, Springfield, MA.
Background: Double dose intramuscular (DDIM) hepatitis B vaccination of 
nonimmune incident hemodialysis patients remains standard of care. Given best case 
reported seroconversion rates of only 70 percent in this population following a standard 
DDIM regimen, a significant number of hemodialysis patients are deemed non-responders, 
remain at risk for infection and ultimately require cohorting away from isolation rooms 
when an actively infected patient is present. Multiple protocols have been recommended 
to convert these non-responders including administration of a single DDIM booster dose, 
repetition of an entire DDIM series or conversion to an intradermal delivery protocol. We 
report our experience with short-term intradermal hepatitis B vaccination in 28 patients who 
failed to respond to two courses of standard DDIM hepatitis B vaccination.
Methods: Non-responder patients were defined as those with an anti-HBsAg 
titer < 10 mIU/mL 30 days after receiving two DDIM series consisting of Engerix-B 
(GlaxoSmithKline) 40 mcg at months 0, 1, 2 and 6. All non-responders subsequently 
received 5-10 mcg intradermal Engerix-B every two weeks for a total of 8 doses. An 
anti-HBsAg titer > 10 mIU/mL at one year after completion of intradermal dosing was 
considered a successful response.
Results: Twenty-five of 28 (89%) patients unresponsive to two courses of DDIM 
Engerix-B responded to intradermal dosing with a mean anti-HBsAg titer of 258 mIU/mL 
at 1 year. Twenty of the 25 patients who seroconverted responded with a titer > 30 mIU/mL. 
No significant differences in age, race, gender, dialysis access type, comorbidities, 
nutritional parameters, bone mineral markers, dialysis adequacy, or dialysis vintage were 
noted between the two groups. There were no reports of adverse events associated with 
intradermal dosing.
Conclusions: Intradermal dosing of Engerix-B to hemodialysis patients unresponsive 
to two courses of DDIM vaccination is highly effective in achieving a sustained serologic 
response. The practice of administering a second DDIM vaccination series to non-responder 
hemodialysis patients should be abandoned and replaced with an intradermal Engerix-B 
dosing regimen.
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HCV in Hemodialysis Patients: Where Is the Difference?
Adrian M. Guinsburg,1 Marcelo D. Ferder.2 1Fresenius Medical Care, Moron, 
Argentina; 2Fresenius Medical Care Argentina S.A., Buenos Aires, Argentina.
Background: Several authors have described worst outcomes in HCV patients (pts) 
due to cardiovascular (CV) diseases, cirrhosis and hepatocarcinoma. Though, outcomes in 
HD pts are controversial. The aim of this study was to identify HCV+ pts characteristics 
affecting long term survival in HD.
Methods: Pts from Fresenius Medical Care Argentina database were included and 
classified as HCV+ when HCV antibodies were detected by ELISA and then followed until 
death, transplant or lost to follow-up. Differences in baseline labs were compared and all-
cause, CV and liver mortality were analyzed using uni and multivariate Cox models.
Results: 35,707 incident pts were included. Age 57.1±16.9 yrs, gender 57.7% male, 
DBT 16.5%, CVD 12%, neoplasia 1.1%. HCV+ prevalence 5.9% (2121). Mean follow-up 
time 3.45 ± 3.2 yrs CI [3.42 - 3.48]. HCV+ pts were younger (52.3 ± 15 vs 57.4± 17 yrs), had 
higher Hb (9.98 ± 2.1 vs 9.28 ± 1.9 mg%), higher ferritin (543 ± 646 vs 469 ± 521 ng/ml), 
higher Ca (8.94 ± 1.1 vs 8.59 ± 0.9 mg%), higher albumin (3.69 ± 0.5 vs 3.61 ± 0.6 g/dl), 
lower CRP (11.9 ± 21 vs 18.8 ± 36 mg/l), higher liver enzymes (AST 32.5 ± 28 vs 
21.4 ± 24, ALT 34.6 ± 41 vs 22.2 ± 58, ALP 377.7 ± 438 vs 256 ± 236 IU/l) and lower total 
cholesterol (163.5 ± 44 vs 172.8 ± 51 mg%). Surprisingly, unadjusted Cox models showed 
advantage in HCV+ for all-cause mortality (n=35,707, events 15,839 RR 0.87 p < 0.0001, 
CI [0.82-0.93]) and CV mortality (n=35,707, events 2,545 RR 0.31 p < 0.0001, CI [0.24-
0.39]) but no difference for liver mortality. After adjustment to case-mix, nutritional and 
inflammation markers, survival advantage disappears for all-cause (n=4,283, events 1,227 
RR 1.17 pNS) and CV mortality (n=4,283, events 470 RR 1 pNS).
Conclusions: In our study HCV+ pts showed lower CRP and higher Hb levels, as well 
as lower all-cause and CV mortality. Lower CRP levels were previously reported associated 
with disturbance in production of CRP[1]. Higher Hb levels were published related to 
increased production of EPO in the liver[2]. Even paradoxical unadjusted effect of HCV+ 
was reported[3], it’s not in accordance with several studies and may be related to ameliorated 
inflammatory response. In fact, adjusting to inflammatory markers vanished this effect. 
Prospective, controlled trials may be needed to identify HCV effect on HD patients [1]Braz J 
Med Biol Res. 2005;38:783-8 [2]Blood Purif 2011;32:69–74 73 [3]J Bras Nefrol 2010;32(4): 
335-339
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Procalcitonin as a Predictor of Sepsis in Patients with ESRD
Raman Dhillon,1 Shideh Doroudi,2 Puja Patel.1 1St. Joseph’s University Medical 
Center, Clifton, NJ; 2Family Medicine, St. Joseph’s University Medical center, 
Clifton, NJ.
Background: Procalcitonin is a helpful biomarker in the diagnosis of sepsis in critically 
ill patients, especially in identifying occult bacterial infections. Procalcitonin levels rise 3-6 
hours after onset of sepsis, and peak at 24-48 hours. It has been found that renal clearance 
of procalcitonin is low, and the use of procalictonin in kidney disease has not been widely 
studied.
Methods: A Retrospective chart review of patient admitted with diagnosis of Sepsis 
and End Stage Renal disease was reviewed for 57 months. All patients with end stage renal 
disease and sepsis with procalcitonin measured at admission or during hospitalization 
were included. We used two-way ANOVA table to explore the relationships between 
procalcitonin, lactic acid levels, hemodialysis, and cultures.
Results: Of 362 patients, 190 were male and 172 were female with ages ranging from 
30-100 years. 158 of 362 patients were on hemodialysis. 210 of 362 had procalcitonin
levels measured during hospitalization. Procalcitonin of these patients ranged from less
than 0.05 to 235.94 ng/mL. 148 of 362 patients had lactic acid measured, with 62 having
lactic acid ≥ 2 mmol/L. Of the 362 patients, 41 had positive cultures. By using our method 
of statistical analysis, we found that only age was statistically significant, with a P-value 
0.0107, meaning that procalcitonin levels were increased with increasing age. We also 
found that lactic acid and culture growth when compared with procalcitonin levels, were
not statistically significant, with P-values of 0.4095 & 0.9148, respectively.
Conclusions: Procalcitonin’s role has not been well studied in patients with end stage 
renal disease on hemodialysis, although it has been found that it is the best predictor of 
infection in hemodialysis patients. Previous studies have found that higher cutoff levels of 
procalcitonin should be used to rule in or rule out infection, and it has been found that a 
procalcitonin of ≥0.5 ng/mL can be used to rule in infection in patients on hemodialysis. Our 
study looked at patients with end stage renal disease on hemodialysis and sepsis comparing 
procalcitonin, lactic acid and culture growth. We found that lactic acid and culture results 
were not statistically significant, meaning that those values may be negative despite positive 
procalcitonin levels. Therefore, clinical judgment should be used when a patient has sepsis.
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Analysis of Infection Rate According to Natural Killer Cell Activity in 
Hemodialysis Patients
Seok-hyung Kim,1 Jung eun Lee,2 Hyung Jong Kim,3 Hoon Young Choi,1 
Hyunwook Kim,1 Tae hoon Kim,1 Mirae Lee,1 Taeyeon Kim,1 Hyeong 
cheon Park.1 1Gangnam Severance Hospital, Yonsei University College of 
Medicine, Seoul, Republic of Korea; 2Yongin Severance Hospital, Yongin-si, 
Republic of Korea; 3Bundang CHA Medical Center, CHA University, Seongnam, 
GYEONGGI-DO, Republic of Korea.
Background: Natural killer (NK) cells are lymphocytes of innate immune system that 
play a key role in host defense against diverse range of pathogens. NK cell deficit has 
been suggested in patients undergoing hemodialysis (HD) with conflicting results regarding 
their activity and impaired antimicrobial activity in host defense. Aim of this study was to 
determine the susceptibility to bacterial infection according to NK cell cytotoxic activity 
in HD patients.
Methods: Clinically stable HD patients without active malignancy or 
immunosuppressive medications were enrolled (N=204). NK Vue™ assay (ATGen Co. 
Seoul, Korea), that uses serum of ex vivo stimulated whole blood to detect interferon (IFN)-
γ secreted from NK cells, was used to assess NK cell activity. This NK cell activity was
consecutively assessed at six-month intervals from 2015 to 2017. We further investigated 
the incidence of major infections requiring intravenous antibiotics or hospitalization
according to NK cell activity during the study period.
Results: Mean patient age was 61.4 ± 13.8 years and 58.8% were male. During the study 
period, a total of 214 major infections occurred. Mean baseline NK cell activity was 586.2 ± 
540.7 pg/mL. Decreases in NK cell activity were significantly correlated with incidence of 
major infections. Furthermore, mean changes in NK cell activity were significantly different 
between periods at which infections have occurred and those periods free of infections, 
-71.7 ± 875.7 pg/mL and 110.5 ± 846.0 pg/mL, respectively (P=0.016). In univariate
logistic analysis, older age [odds ratio (OR): 1.018; 95% CI, 1.004-1.032, P=0.010], higher 
serum C-reactive protein (CRP) [OR: 1.052; 95% CI, 1.010-1.096, P=0.014] and decreased 
NK cell activity [OR: 0.975; 95% CI, 0.955-0.995, P=0.017] were associated with higher 
incidence of infection. After adjusting for age, sex and CRP, decreased NK cell activity was 
independently associated with higher incidence of infection. [OR: 0.976; 95% CI, 0.956-
0.996, P=0.019] Increases in CRP was not significantly correlated with decreases in NK cell 
activity (R=-0.056, P=0.189).
Conclusions: Our results show higher incidence of infection during period of greater 
decrease in NK cell activity from baseline. NK cell activity could thus be a useful marker to 
predict risk of infection in HD patients.
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Short-Chain Fatty Acids Increase CD25HighCD127Low-Regulatory 
T-Cells in Patients with ESRD
Fabian Meyer,2 Ulrik Stervbo,2 Felix S. Seibert,2 Frederic Bauer,2
Benjamin Rohn,1 Mikalai Nienen,2 Timm H. Westhoff,2 Nina Babel.2 1Marien 
Hospital Herne, Herne, Germany; 2University Hospital Marien Hospital Herne, 
Herne, Germany.
Background: Patients with End Stage Renal Disease (ESRD) suffer from an elevated 
systemic inflammation, which can lead to an increased morbidity and mortality. Previous 
data obtained from the EAE mouse model of MS, revealed the potential of disease 
amelioration by short-chain fatty acids. This clinical improvement was accompanied by 
increased frequency of regulatory T-cells (Treg). We hypothesized that the elevated systemic 
inflammation of patients with ESRD could be reduced though a dietary supplement with a 
short-chain fatty acid.
Methods: ESRD patients and healthy volunteers supplemented their diet with a daily 
dose of 2 x 500 mg propionic acid (PA) for 30 days. PBMCs were isolated at day 0, 15, 
and 30 of the PA supplement and 60 days later for a follow-up after PA supplementation. 
The baseline status and possible physiological oscillations in cell numbers were assessed 
through sampling at days -60, -45, and -30. We established a 12 color flow cytometry 
panel to quantify Tregs, and characterized them with respect to their developmental and 
gut homing phenotype through expression of CCR7/CD45RA and CCR9/β7 integrin, 
respectively. We also analyzed changes in functional activity of antigen-specific memory/
effector T cells by stimulation with recall antigens. Here, we used stimulation with Tetanus/
Diphteria vaccine and subsequent evaluation by 13 parameter flow cytometry.
Results: We observed a gradual and significant expansion in the frequencies of 
CD25highCD127low Tregs in the ESRD patients and healthy volunteers already at day 15 
of PA supplementation. At day 30, an increase of 20-35% as compared to Treg baseline 
counts was observed in both study groups. Treg numbers returned to baseline values after 
discontinuation of the PA supplement. Despite significant expansion of Tregs during PA diet, 
the responsiveness and functionality of effector T cells remained stable as demonstrated by 
the stable frequencies of antigen-specific T effector cells upon ex vivo stimulation.
Conclusions: Our data revealed that dietary supplements with short-chain fatty acids 
might have a beneficial effect on the elevated systemic inflammation of ESRD patients. 
The effect can be achieved through an expansion of circulating Tregs without affecting the 
antigen-specific memory response.
Funding: Government Support - Non-U.S.
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HBV Vaccination Non-Responders with ESRD Demonstrate Available 
Cellular Memory Immunity Against Hepatitis B Vaccine
Gounwa Awad, Mikalai Nienen, Ulrik Stervbo, Frederic Bauer, Felix S. Seibert, 
Timm H. Westhoff, Nina Babel. University Hospital Marien Hospital Herne, 
Herne, Germany.
Background: In the compromised immune system of patients with end-stage renal 
disease (ESRD) undergoing hemodialysis, the adequacy of host protection upon hepatitis 
B vaccination is crucial. Whereas seroconversion rates to hepatitis B (HBV) vaccine in 
this population is known to be lower than the general population, the cellular immune 
response to the vaccine in hemodialysis patients remain under study. Here, we functionally 
analyze and quantify HBV surface antigen (HBsAg)-specific T cells in patients with ESRD 
vaccinated against HBV with HBsAg vaccine. Cellular immunity against HBsAg and its 
correlation with humoral response were explored in 35 patients with ESRD undergoing 
hemodialysis and 13 healthy controls (HC).
Methods: Patients were divided according to their Hepatitis B vaccine titers into 
three groups: High responders (HR), Low-responders (LR), Non-responders (NR). Using 
multi-parameter flow cytometry HBsAg-specific T cells were quantified and functionally 
analyzed according to expression of activation markers CD40L and/or CD137 and cytokine 
release upon stimulation with HBsAg overlapping peptide pools. We also performed 
immunophenotyping of B cells, dendritic cells and regulatory T cells.
Results: HBsAg-specific CD4+T cells were detected not only in LR (88.8%) and HR 
(100%) but also in almost all NR; 78.6% of NR demonstrated HBsAg-specific memory 
T-cell response. Counts of HBsAg-specific CD4+CD40L+ T cells were significantly higher 
in HR compared to NR (p<0.001). No difference in cytokine release between the groups
was. A correlation between vaccine-specific CD4+ T cell response and humoral response 
was identified (r=0.7537, p=0.0021). No significant difference was found in the number 
of myeloid and plasmacystoid dendritic cells between patients with ESRD of different
titer groups. Interestingly, they were significantly higher in HR than in HC (p<0.05). A 
significantly larger Naïve B cell (IgD+CD27-) population was found in HR and HC 
compared to NR (p<0.05).
Conclusions: Our results show that HBV-specific memory T cells producing effector 
cytokines are detectable in humoral non-responders and might provide antiviral effects in 
case of HBV exposure in ESRD patients.
Funding: Government Support - Non-U.S.
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The Clinical Utility of Routine Screening of Multi-Drug Resistant 
Organisms in Hemodialysis Outpatients
Elizabeth S. Lee,1 Adeera Levin,2 Jacek Jastrzebski,1 Mercedeh Kiaii,1 
John E. Antonsen.3 1University of British Columbia, Vancouver, BC, Canada; 
2St. Paul’s Hospital and University of British Columbia, Vancouver, BC, 
Canada; 3Vancouver Island Health Authority, Victoria, BC, Canada.
Background: Hemodialysis (HD) outpatients are routinely screened for Methicillin 
Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE) 
despite limited information on effective MRSA/VRE control in outpatients. Yet, MRSA/
VRE colonized patients are not subject to different care in the community. HD patients 
would be empirically treated for MRSA if clinically appropriate, regardless of their 
colonization status. Patients may have negative experiences from swab collection +/- cohort.
Methods: We aimed to assess the clinical utility of the current practices by evaluating 
a) the MRSA/VRE infection rates and b) the estimated costs of such practice for the local 
HD patients. We evaluated the 12-month-data on access related infection (bacteremia 
and exit site infection) in the two typical HD units, using a provincial renal database. We 
reviewed 1) the prevalence of MRSA/VRE access infections, 2) the relationship between
colonization and infection in this cohort, and 3) the costs of routine screening and contact 
precaution practices for the provincial HD cohort.
Results: There were 52 access related infections (among 43/410 HD patients) (2016). 
40/52 (77%) infections were not caused by MRSA or VRE (Figure 1). The prevalence rates 
for MRSA and VRE were 10-25% and 3-5% in both units. There was poor correlation 
between colonization and infection. The annual cost of provincial screening practice (2,200 
prevalent and 600 incident HD patients) was estimated to be over 120,000 Canadian dollars.
Conclusions: We provide additional evidence demonstrating little clinical utility for 
routine MRSA/VRE screening in HD outpatients, which leads us to advocate for practice 
re-evaluation.
Figure 1. Number of MRSA/VRE infections among the 52 access related infections in the 
study HD units
FR-PO778 Poster Friday
Dialysis: Inflammation and Infection
Routine Screening for Staphylococcus aureus in Haemodialysis Patients 
– Is It Worthwhile?
Tayeba Roper,1 James Scuffell,2 Maggi Steele,1 John Clark,3 David Makanjuola.3 
1Epsom & St Helier NHS Trust, Surrey, United Kingdom; 2Epsom and St Helier 
University Hospitals NHS Trust, Surrey, United Kingdom; 3St. Helier Hospital, 
Surrey, United Kingdom.
Background: Staphylococcus aureus (S. aureus) is common in haemodialysis (HD) 
patients, with manifestations varying from asymptomatic colonisation to bacteraemia. 
This has led to the development of guidelines for routine screening for both methicillin-
sensitive and methicillin-resistant S. aureus (MSSA and MRSA). We aimed to establish 
the effectiveness of screening and de-colonisation for S. aureus in a cohort of HD patients.
Methods: We screened all HD patients at a UK satellite unit between September 2009 
and July 2010 for S. aureus carriage. Screening was at 0, 1, 2, 3, 6 and 9 months with nasal, 
groin and HD line site swabs, cultured on chromogenic agar. Isolates were characterised by 
antibiogram. Eradication with Chlorhexidine solution was given to all carriers. A further 
course of eradication therapy was given to those in whom repeat swabs were positive. Due 
to limited capacity, not all patients with MRSA were isolated in side rooms. Universal 
precautions were used in all cases. Clinical and demographic data were collected from 
patient records.
Results: 82 patients were included. 68% were male; median age was 68.5 years (range 
57-78). 42% were carriers of S. aureus; 80% had MSSA, 20% had MRSA. 15/28 MSSA 
carriers underwent successful eradication; of these 8/15 re-acquired MSSA. 3/7 MRSA
carriers underwent successful eradication, all three re-acquired the same strain of MRSA.
MRSA antibiograms were identical in 2/7 patients. These patients dialysed on separate
days, making transmission between them unlikely. All other MRSA strains had different
antibiograms.
Conclusions: Our data show that S. aureus colonisation is common in HD patients. We 
found that, despite treatment, eradication is often short-lived or unsuccessful. We believe 
that S. aureus is often re-acquired from non-clinical areas such as hospital transportation, the 
home environment and perhaps close relatives/friends. We question the benefit of routinely 
screening for S. aureus, given the poor de-colonisation and high re-acquisition rates. The 
antibiotic resistance profile showed that there was no evidence of cross-transmission within 
the unit and in the absence of facilities to segregate colonised patients, we have shown 
that universal infection control measures are sufficient to prevent spread between patients.
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Vitamin D and Risk of Infection in Long-Term Dialysis Patients: A 
Systematic Review and Meta-Analysis
Guobin Su,1,2 Zhuangzhu Liu,2 Xindong Qin,2 Hong Xu,1 Xusheng Liu,2 
Zehuai Wen,2 Bengt Lindholm,1 Juan J. Carrero,1 David W. Johnson,3 
Nele Brusselaers,1 Cecilia S. Lundborg.1 1Karolinska Institutet, Stockholm, 
Sweden; 2The Second Affiliated Hospital, Guangzhou University of Chinese 
Medicine, Guanghzou, China; 3Princess Alexandra Hospital, Brisbane, QLD, 
Australia.
Background: Infections are common and can be fatal in patients undergoing long-term 
dialysis. Current studies have shown conflicting evidence associating infection with vitamin 
D, which have not been systematically reviewed in this population
Methods: We searched PubMed, Web of Science, Cochrane Library, Embase databases 
and three Chinese databases, from inception through December 2017, for interventional 
(non-randomized or randomized controlled trials, RCTs), cohort and case-controlled studies 
on levels of serum 25-hydroxy vitamin D (25(OH)D); or use of vitamin D [supplemental 
nutritional vitamin D or vitamin D receptor activator (VDRA)] and infection (any infection, 
infection-required hospitalization or infection-related death, or composite), in long-term 
dialysis patients. We conducted a meta-analysis on the relative risk of infection and level of 
25(OH)D or use of vitamin D.
Results: Of 2,440 reports identified, 17 studies met inclusion criteria, all with moderate 
quality, with 6 cohort studies evaluating 25(OH)D serum concentrations (N=5,714) and 11 
(2 RCTs and 9 observational studies) evaluating the use of vitamin D (N=92,309). The risk 
of composite infection was 39% lower (relative risk [RR] 0.61, 95% CI 0.41-0.89) in those 
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with high/normal levels of 25(OH)D than in those with low levels. Compared to those who 
did not use vitamin D, the pooled adjusted risk for composite infection was 41% lower in 
those who used vitamin D (RR 0.59, 95% CI 0.43-0.81).
Conclusions: High/normal serum levels of 25(OH)-vitamin D and use of vitamin D, 
particularly VDRA, were each associated with a lower risk of composite infection in long-
term dialysis patients.
Funding: Government Support - Non-U.S.
Figure: Forest plot depicting the meta-association between use and non-use of Vitamin 
D, and high/normal vs. low level of 25(OH)D, and risk for infection-related outcomes
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Dialysis: Inflammation and Infection
Vaccinations for Patients with ESRD: Crossroads Between Nephrology 
and Primary Care
Samuel Phen, Maryam Sattari, Shahab Bozorgmehri, Tezcan Ozrazgat-baslanti, 
Amir Kazory. University of Florida, Gainesville, FL.
Background: A subset of patients with end-stage renal disease (ESRD) who receive 
maintenance hemodialysis consider their nephrologist as their primary care provider (PCP). 
Preventive measures such as vaccinations markedly reduce mortality among these patients, 
yet their vaccination rates fall far below recommended. We aimed to (1) determine whether 
there is a difference in rates of compliance with recommended vaccinations between ESRD 
patients with PCPs (PCP group) and those without PCPs (No PCP group), and (2) identify 
differences in the characteristics between the PCP and No PCP groups.
Methods: We performed a cross-sectional survey of adult patients with ESRD in two 
outpatient dialysis centers affiliated with the University of Florida. A survey instrument was 
used to conduct one-to-one interviews. We used the Advisory Committee on Immunization 
Practices (ACIP) guidelines to determine eligibility for various vaccinations. We used X2 or 
t-test to compare various characteristics.
Results: The mean age of the 132 study participants was 57.8 ±14.7 years. Sixty-six
(50%) were male, 81 (61.3%) were African American, and 118 (89.4%) reported having
a PCP. The PCP group had significantly higher rates of influenza vaccination (89.8% vs. 
71.4%, p=0.046), pneumonia (75% vs. 42.9%, p=0.012), and tetanus (Tdap) (96.4 vs.
78.6%, p=0.006). The rates of vaccination for human papillomavirus (HPV), hepatitis B,
and shingles were also higher among the PCP group but did not reach statistical significance. 
The PCP group was older than the no PCP group (mean age 58.9 vs. 47.9 years, p=0.008) 
with higher education level; none of the patients without PCP had higher education while
54.2% of those with PCP had undergraduate or graduate education; p<0.001). Men were
more likely not to have a PCP (p=0.024), but no difference was observed among races.
Conclusions: This study suggests that among ESRD patients receiving hemodialysis, 
having a PCP is associated with higher rates of recommended vaccinations and that female 
gender, advanced age, and higher education level are associated with higher likelihood
of having a PCP. These findings could have important implications for optimizing the 
preventive care of these patients. Future studies are needed to explore whether increasing
the number of patients with a PCP will portend salutary impact on their care.
FR-PO781 Poster Friday
Dialysis: Hospitalization and Mortality
Recent Trends in Emergency and Observation Room Admissions Among 
Medicare Dialysis Patients
Eric D. Weinhandl,1,2 Debabrata Ray,1 Kristine Kubisiak,1 Allan J. Collins.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Among dialysis patients, emergency room (ER) and observation room 
(OBS) admissions - excluding those resulting in transfer to inpatient care - may reflect 
several factors, including morbidity and insufficient availability of outpatient clinic 
appointments. We assessed trends in ER/OBS admissions among Medicare dialysis patients 
in 2014-2016.
Methods: We analyzed Medicare limited data sets. For each calendar week (Monday 
to Sunday) in 2014-2016, we identified all Medicare Parts A and B beneficiaries with ≥1 
outpatient dialysis treatment. We excluded patients hospitalized on Sunday and not 
discharged before the end of the day. During the next week, we calculated the percentage 
of patients with ≥1 ER/OBS admission not resulting in transfer to inpatient care. We fit 
an ARIMA(1,0,0)x(0,1,0) model to the time series of admission percentages and used a 
likelihood ratio test to assess whether a secular trend remained after accounting for serial 
correlation and seasonality. We analyzed the aggregate population and strata defined by 
age, race, sex, concurrent Medicaid enrollment, US Census Division, and dialytic modality 
(hemodialysis, peritoneal dialysis).
Results: The average number of Medicare dialysis patients per week was more 
than 286,000. As displayed in the figure, the mean percentage of dialysis patients with 
≥1 ER/OBS admission each week was 2.97% in 2014, 3.04% in 2015, and 3.12% in
2016 (P < 0.001, from test of secular trend). The percentage of dialysis patients with ≥1 
ER/OBS admission each week increased significantly (P < 0.05) in every stratum. Strata
with the highest mean percentages of dialysis patients with ≥1 ER/OBS admission each
week in 2016 were ages 20-34 years (5.14%), ages 35-44 years (4.04%), and Medicaid
enrollees (3.83%).
Conclusions: Utilization of emergency and observation room care is increasing among 
Medicare dialysis patients.
Funding: Commercial Support - NxStage Medical, Inc.
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Dialysis: Hospitalization and Mortality
Discrepant Associations of Hemodialysis Intensity and Survival in the 
Facility and at Home
Eric D. Weinhandl,1,2 Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Incremental hemodialysis (HD) has recently garnered interest. Mathew 
et al (Kidney Int, 2016) reported that in US incident patients on in-center HD, adjusted 
hazard ratios (AHRs) of death for 2 vs. 3 and ≥4 vs. 3 sessions/week were 0.88 (95% 
confidence interval, 0.72-1.08) and 1.56 (1.21-2.03), respectively. These data may reflect 
either the relative efficacy of twice-weekly HD as an initial prescription or residual 
confounding. We assessed whether these associations could be replicated among in-center 
hemodialysis (IHD) and home hemodialysis (HHD) patients.
Methods: We used data from the United States Renal Data System. We identified 
adult patients who initiated HD in 2011-2015, and we retained patients with an initial HD 
prescription of 2 to 7 sessions/week and 2-8 hours/session, according to form CMS-2728. 
We followed patients until death, but for a maximum of one year. Using Cox regression, we 
assessed associations of HD frequency, HD hours per week, and HD product (frequency2 × 
hours/session) separately among IHD and HHD patients, with adjustment for demography, 
vascular access type, and disease severity, including estimated glomerular filtration rate.
Results: We identified 503,678 IHD patients and 2849 HHD patients. With IHD 
(vs. HHD), the percentage of patients prescribed 2 sessions/week was 1.1% (vs. 1.1%), 
the percentage of patients prescribed ≥4 sessions/week was 0.5% (vs. 59.7%), mean HD 
hours per week were 11.4 (vs. 14.0), and mean HD product was 34 (vs. 62) points. With 
IHD, the AHRs of death for 2 vs. 3, ≥4 vs. 3, and ≥4 vs. 2 sessions/week were 0.84 (0.80-
0.89), 1.05 (0.96-1.14), and 1.24 (1.12-1.38), respectively; with HHD, the AHRs were 0.83 
(0.39-1.76), 0.63 (0.52-0.75), and 0.76 (0.36-1.61), respectively. With IHD, the AHR of 
death for each additional HD hour per week was 1.012 (1.008-1.016); the corresponding 
AHR for HHD was 0.967 (0.943-0.993). Finally, with IHD, the AHR of death for each 
10-point increment in HD product was 1.039 (1.028-1.051); the corresponding AHR for
HHD was 0.946 (0.915-0.979).
Conclusions: Associations of HD frequency, HD hours per week, and HD product 
are almost entirely discrepant with IHD and HHD. In the facility, lower HD frequency 
and fewer HD hours are associated with better survival. In the home, higher frequency and 
greater HD hours are associated with better survival.
Funding: Commercial Support - NxStage Medical, Inc.
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Dialysis: Hospitalization and Mortality
Predictors of Hyperkalemia-Related Emergency Department Encounters 
Among Patients Receiving Hemodialysis Care
Paul E. Ronksley, James Wick, Meghan J. Elliott, Robert G. Weaver, 
Jennifer M. MacRae. University of Calgary, Calgary, AB, Canada.
Background: Almost 10% of emergency department (ED) visits among dialysis 
patients are for conditions that could potentially be managed in an outpatient setting such 
as hyperkalemia. We used population-based data to identify factors that place hemodialysis 
patients at increased risk of hyperkalemia-related ED events.
Methods: We identified all chronic hemodialysis patients age ≥18 years from March 
2009–March 2015 within southern Alberta, Canada. We used a nested case-control design 
to identify differences between patients with and without hyperkalemia-related ED events 
(defined by ICD-10 related codes and/or serum K+ ≥6mmol/L). Cases were matched to 
controls based on dialysis site type (satellite or in-centre) and time period. Clinical and 
dialysis-specific variables were measured 2-4 weeks prior to outcome dates. We assigned 
a random date within each control’s period on hemodialysis to serve as a proxy for an 
outcome date. Potential predictors included demographic/clinical characteristics, prior 
health system use, and dialysis run sheet variables. Conditional logistic regression models 
were used to identify significant predictors of hyperkalemia-related ED events.
Results: Of 2012 patients on chronic hemodialysis, 129 had 180 hyperkalemia-related 
ED events (cases) within the study timeframe. Controls were matched to cases at a ratio 
of ~3-to-1 (508 controls). In bivariate analysis, cases were younger, had higher levels of 
comorbidity, higher acute care use in the prior 6 months, and received more intensive 
dialysis treatment (e.g. higher ultrafiltration (UF) volume, cumulative duration of dialysis) 
in the weeks prior to an ED event. Multivariate modeling identified the following predictors 
of hyperkalemia-related ED events: ED use in prior 6 months (OR: 2.70; 95% CI: 1.69-
4.33), dialysate potassium concentration ≤3.0mmol/L (2.95; 1.28-6.77), average UF 
volume>2.5L per dialysis session (2.73; 1.59-4.71), >15 hours of cumulative dialysis time 
in the prior week (5.84; 2.32-14.70), dialysis access via fistula (1.79; 1.20-2.66).
Conclusions: We identified a number of predictors that place patients at greater risk 
of presenting to the ED with hyperkalemia. Identification of such patients may allow for 
targeted strategies for preventive care, thus avoiding unnecessary acute care use and cost 
while improving patient quality of life.
FR-PO784 Poster Friday
Dialysis: Hospitalization and Mortality
Predicting Who Needs Urgent Dialysis Prior to Ambulance Transport to 
the Emergency Department
Karthik K. Tennankore,1 Amanda J. Vinson,1 John E. Bartolacci,2 
Judah Goldstein,2 David Clark.3 1Dalhousie University/NS Health Authority, 
Halifax, NS, Canada; 2Dalhousie University, Halifax, NS, Canada; 3London 
Health Sciences Centre, London, ON, Canada.
Background: Chronic hemodialysis patients who require ambulance transport to the 
emergency department (ambulance-ED) may subsequently need urgent dialysis. However, 
little is known about predictors of urgent dialysis based on patient factors identified prior 
to ED transport. The purpose of this study was to develop a risk prediction model for 
urgent dialysis after ambulance-ED based on patient characteristics identified at the time 
of paramedic assessment.
Methods: We analyzed a cohort of incident thrice-weekly hemodialysis patients 
between 2009-2013 (last follow-up of 2015) who experienced one or more ambulance-ED 
events. Chief complaint, vital sign parameters and time from last dialysis to ambulance 
dispatch was assessed for all patients at the time of paramedic assessment prior to 
ED transport. Urgent dialysis was defined as a need for dialysis within 24 hours of an 
ambulance-ED in a monitored setting or among patients with an initial ED potassium of 
>6.5 mmol/L. Associations with urgent dialysis were analyzed using logistic regression. A 
risk prediction model was created and internally validated.
Results: Among 197 patients, there were 624 ambulance-ED events and 87 episodes 
of urgent dialysis. Weakness as a presenting complaint (OR 4.62, 95% CI 1.23-17.29), >24 
hours since last dialysis (OR 2.09, 95% CI 1.15-3.81), and triage vitals (heart rate <60 
beats/minute (OR 3.06, 95% CI 1.09-8.61), systolic blood pressure >160 mmHg (OR 2.37, 
95% CI 1.32-4.25), respiratory rate ≥20 breaths/minute (OR 2.00, 95% CI 1.06-3.75) and 
oxygen saturation <90% (OR 3.04, 95% CI 1.55 – 5.94)) were associated with an increased 
need for urgent dialysis after ambulance-ED. A risk prediction model incorporating these 
variables had very good discrimination (C-statistic: 0.81, 95% CI 0.76-0.86). The negative 
predictive value for not needing urgent dialysis was 93.6% using the optimal cut point 
(≥15% predicted probability). Of the patients who were predicted to need urgent dialysis 
but were transported to a dialysis incapable facility, 31% required a second transport for 
urgent dialysis.
Conclusions: We created a risk prediction model for urgent dialysis after ambulance-
ED based on patient characteristics at the time of paramedic assessment. This model has 
the potential to guide dialysis patient transport to dialysis-capable facilities when needed.
FR-PO785 Poster Friday
Dialysis: Hospitalization and Mortality
Cumulative Time in Hospital After Initiation of Dialysis: A Cohort Study
Karthik K. Tennankore,1 David Clark,2 Kara Matheson,3 Amanda J. Vinson.1 
1Dalhousie University/NS Health Authority, Halifax, NS, Canada; 2London 
Health Sciences Centre, London, ON, Canada; 3Nova Scotia Health Authority, 
Halifax, NS, Canada.
Background: Chronic dialysis patients are at risk for frequent and prolonged 
hospitalizations. Less is known about predictors of cumulative time in hospital after 
initiation of dialysis, including each subsequent hospitalization. Having an awareness of the 
predictors of cumulative hospital time is important for informed decision making between 
patients and providers prior to initiation of dialysis.
Methods: We analyzed a cohort of incident, chronic dialysis patients from 2009-
2014 (last follow-up of 2015) at a tertiary care center. Baseline characteristics including 
demographics, comorbidities, frailty status (assessed using the clinical frailty scale; CFS 
rated from 1: very fit to 7: severely frail) and laboratory parameters were captured in 
all patients at dialysis initiation. The primary outcome was cumulative time in hospital 
(proportion of time in hospital/total follow-up time and inclusive of the time in hospital after 
dialysis initiation for inpatient dialysis starts). Generalized linear models were used to fit a 
negative binomial distribution of cumulative time with total time of followup as the offset.
Results: A total of 647 patients were included in the study. Mean age was 62 ± 15 
years, 90% were caucasian and the majority (63%) were male. Diabetes (48%), coronary 
artery disease (30%), congestive heart failure (22%), and cancer (11%) were prevalent at 
dialysis initiation; a smaller proportion (5%) had underlying liver disease. The median CFS 
score was 4 (IQR 2.5) corresponding to “vulnerable but not frail”. Median days in hospital 
for the cohort was 13 (IQR 41) and cumulative hospital time was 3% of total follow-up 
time (48/1704 years). In an adjusted model, the percent change in the incident rate of 
cumulative days in hospital was 22% for each 1 point increase in frailty severity. Other 
factors associated with higher cumulative time included age (IRR 1.02, 95% CI 1.01-1.03 
per year), liver disease (IRR 2.07, 95% CI 1.07-4.02), malignancy prior to dialysis initiation 
(IRR 1.78, 95% CI 1.09-2.90) and low albumin (IRR 0.93, 95% CI 0.91-0.96 per each g/L 
decrease in albumin).
Conclusions: Demographics, comorbidities, frailty status and laboratory parameters 
are associated with a higher cumulative time in hospital after dialysis initiation. This 
information may be used to better inform patients of their risk of hospitalization after 
starting chronic dialysis.
FR-PO786 Poster Friday
Dialysis: Hospitalization and Mortality
B-Line Score Is Predictive of Repeat Acute Care Utilization in 
Hemodialysis Patients
Nathaniel C. Reisinger, Jordan Brown, Proma Mazumder, Erik Yarmey, 
Frances Shofer, Anthony J. Dean, Nova Panebianco. University of Pennsylvania, 
Philadelphia, PA.
Background: ESRD is burdensome both for patients and healthcare systems because 
of high acute care utilization. Hemodialysis (HD) patients present to an emergency 
department (ED) an average of 3 times per year and are hospitalized an average of twice 
per year with readmission rates of 30%. Readmissions are particularly taxing on hospitals 
as they are not reimbursed by Medicare. Cardiovascular disease, due in large part to visits 
for fluid overload (FO), drives these high rates of acute care utilization. The standard of 
care for assessment of FO remains physical exam despite its poor accuracy. 28-point B-line 
score (BLS) has emerged as a quantitative marker of FO, outperforming the physical exam. 
The goal of this study was to determine if BLS is predictive of hospital readmissions or 
ED revisits.
Methods: A convenience sample of patients with ESRD presenting to a large urban 
tertiary care ED was enrolled consecutively. Patients were excluded if they were not 
chronically on HD or were unable to consent. BLS was obtained after enrollment, prior to 
their first HD session at our center. The patients were followed for 30 days to determine the 
rate of readmissions and 60 days to determine the rate of ED revisits. Presence of FO was 
determined by the treating nephrologist or on chart review. Visits for FO were determined 
by discharge diagnosis.
Results: Of 101 patients enrolled, median age was 60, 51% were male, 84% identified 
as Black or African American. Comorbidities included 65% diabetic, 27% coronary artery 
disease, 33% airways disease, 40% systolic heart failure, 75% diastolic heart failure. Median 
dialysis vintage was 33 months. Access type was 54% arteriovenous fistula, 29% graft, and 
17% catheter. ESRD vintage was 33 months. Residual renal function was minimal. 62% of 
patients had FO on arrival and 27% of visits were for FO. 45% of patients had an ED revisit 
within 60 days. Median BLS for patients with a 60-day ED revisit was significantly higher 
than those without (64 vs 29, p=0.001). Median BLS for patients with a 30-day readmission 
was also higher (57 vs 32, p=0.12).
Conclusions: BLS for patients with a 60-day ED revisit or 30-day readmission was 
higher than patients without revisits or readmissions. BLS is a useful metric in the ED for 
determining whether patients with ESRD on HD are likely to have repeat visits.
FR-PO787 Poster Friday
Dialysis: Hospitalization and Mortality
Correspondence Between Causes of Recurrent Hospitalizations Among 
Hemodialysis Patients
Scott Sibbel, Adam G. Walker, Francesca Tentori, Steven M. Brunelli. DaVita 
Clinical Research, Minneapolis, MN.
Background: Despite targeted efforts, hospitalizations represent a major burden for 
end-stage kidney disease patients, with an average of 1.7 admissions per patient-year and 
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30.7% of patients being readmitted to the hospital. There is a need to identify factors that 
drive hospitalization risk in this population. We evaluated cause of initial admission and 
readmission among patients receiving in-center hemodialysis at a large dialysis organization 
(LDO) in the US.
Methods: Using Medicare claims we identified all patients with at least one index 
hospitalization ≥ 1 day during 2014. Readmissions were defined as hospitalizations that 
occurred within 30 days after index admission. Cause of hospitalizations were determined 
by primary ICD-9 diagnosis code and were classified using the clinical classification system 
(CCS). The relationship between causes of index hospitalization and readmission were 
determined through cross-tabulation of the percent difference between observed (O) and 
expected (E) readmissions accounting for background admission rate (O-E/E*100).
Results: During the study period the overall probability of readmission was 31.5%. 
Diseases of the circulatory system were the most common cause for both hospitalizations 
and readmissions. Overall, the probability of readmissions did not vary greatly by cause of 
index admission (28.8%-35.8%) and the leading cause of readmission was the same as that 
of the index hospitalization.
Conclusions: We found that the cause of readmission was closely related to the 
cause of prior hospitalization in a large sample of US dialysis patients. Despite potential 
misclassification of readmission cause, these results raise the possibility that the clinical 
issue was not fully addressed during the index admission. Further studies are needed to 
identify clinical practices that may help reduce readmission rates.
Funding: Commercial Support - DaVita Inc
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Dialysis: Hospitalization and Mortality
Lower Rates of Hospital Admissions During a Fluid Management Quality 
Improvement (QI) Project Utilizing Relative Blood Volume Monitoring 
(RBV-M) - A Retrospective Database Analysis
Paul Balter,1,2 Panduranga S. Rao,3 Yisha Li,4 Claudy Mullon,4 
Robert J. Kossmann,4 Linda Ficociello.4 1Nephrology Associates of Northern 
Illinois and Indiana (NANI), Oak Brook, IL; 2Renal Research Institute, New 
York, NY; 3University of Michigan Health System, Ann Arbor, MI; 4Fresenius 
Medical Care Renal Therapies Group, Waltham, MA.
Background: Hemodialysis (HD) patients experience high rates of hospitalization and 
mortality, especially in the first 90 days of dialysis. A clinic-wide fluid management QI 
project was conducted at 9 dialysis facilities utilizing RBV-M. The aim of this retrospective 
analysis was to assess hospital admissions among incident HD patients during the QI 
project compared to incident HD patients not participating in the QI project.
Methods: Incident patients in their first 90 days of HD were analyzed. The analysis 
included 3 periods: before the QI start (Pre-QI); during the QI project (QI); and following 
the end of the QI project (Post-QI). RBV-M was conducted using Crit-Line® monitors. 
Hazard ratios were modeled using all hospital admissions during the first 90 days of 
dialysis. Poisson regression was used to compare hospital days across 3 periods.
Results: 1068 adult incident HD patients (Pre-QI: 501, QI: 376, Post QI: 191) who 
started HD between 2009 and 2017 were analyzed. There was a difference in hospital 
admission rates among the 3 periods (P=0.02). Compared to the QI period, the Pre-QI 
period had a 20% increased rate of hospitalization (HR= 1.2, 95%CI: [0.99,1.47]) and the 
Post-QI period had a 40% increased rate (HR= 1.4, 95%CI: [1.11,1.84]). Fewer hospital 
days were observed for the QI period (P=0.04) compared with the non-QI groups, with 5.84 
(P=0.01) less hospital days per person-year (PPY) and 4.7 (P=0.12) less hospital days PPY 
compared with Pre-QI and Post-QI, respectively (Figure).
Conclusions: The use of RBV-M as part of a QI on fluid management was associated 
with a decreased rate of hospital admissions and fewer hospital days among incident HD 
patients during the first 90 days of dialysis.
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
FR-PO789 Poster Friday
Dialysis: Hospitalization and Mortality
Early Readmissions Are More Common After Long Hospitalizations 
Among Hemodialysis Patients
Adam G. Walker, Scott Sibbel, Francesca Tentori, Steven M. Brunelli. DaVita 
Clinical Research, Minneapolis, MN.
Background: Approximately one-third of dialysis patients who are hospitalized will be 
readmitted post discharge. In this study, we characterized patterns of readmissions by length 
of index hospitalizations.
Methods: Patients included in this analysis were Medicare beneficiaries, receiving 
in-center hemodialysis at a large dialysis organization (LDO,) and had a qualifying 
index hospitalization lasting ≥ 1 day during the study period (2014). Hospitalizations 
were considered readmissions if they occurred ≤ 30 days post-discharge from the index 
admission. Causes of hospitalizations were determined by primary ICD-9 diagnosis code.
Results: The mean length of stay for index admissions was 7.1 ± 9.5 days (median 
4 days). The longest index hospitalizations were those due to infectious and parasitic 
disease and the shortest were related to endocrine, nutritional, metabolic diseases and 
immunity disorders. The overall probability of readmission was 31.5%; 27.6% and 52.4% 
of all readmissions occurred within 6 (“early readmissions”) and 12 days post-discharge, 
respectively. Patients with index hospitalization duration > 7 days had a higher probability 
of readmission overall (34.7% vs. 30.3 %) and of early readmission (30.0% vs. 26.1%) 
compared to those with shorter index hospitalizations.
Conclusions: These results suggest that patients with longer hospitalizations are more 
vulnerable to readmissions overall and to early readmissions, likely due to the severity 
of disease. This was particularly common among patients admitted for infections. These 
results raise the possibility that the clinical issue was not fully addressed during the index 
admission or shortly after discharge. There is a need to identify clinical practices that may 
help reduce readmission rates.
Funding: Commercial Support - DaVita Inc
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Dialysis: Hospitalization and Mortality
Recent Trends in Hospital Admissions Among Medicare Dialysis Patients
Debabrata Ray,1 Kristine Kubisiak,1 Allan J. Collins,1,2 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Hospital admissions not only reflect the morbidity of dialysis patients, 
but also account for more than one-third of Medicare Parts A and B expenditures among 
patients (USRDS Annual Data Report, 2017). We assessed trends in hospital admissions 
among Medicare dialysis patients in 2014-2016.
Methods: We analyzed Medicare limited data sets. For each calendar week (Monday 
to Sunday) in 2014-2016, we identified all Medicare Parts A and B beneficiaries with ≥1 
outpatient dialysis treatment. We excluded patients hospitalized on Sunday and not 
discharged before the end of the day. We calculated the percentage of patients with ≥1 
hospital admission during the next week. We fit an ARIMA(1,0,0)x(0,1,0) model to the time 
series of admission percentages and used a likelihood ratio test to assess whether a secular 
trend remained after accounting for serial correlation and seasonality. We analyzed the 
aggregate population and strata defined by age, race, sex, concurrent Medicaid enrollment, 
US Census Division, and dialytic modality (hemodialysis, peritoneal dialysis).
Results: The average number of Medicare dialysis patients per week was over 
286,000. As displayed in the figure, the mean percentage of dialysis patients who were 
newly hospitalized each week was 3.09% in 2014, 3.07% in 2015, and 3.10% in 2016 
(P = 0.90, from test of secular trend). This percentage increased significantly (P < 0.05) 
among ages 20-34 years (3.47%, 3.58%, and 3.70% in 2014, 2015, and 2016, respectively), 
ages 35-44 years (2.93%, 2.98%, and 3.09%), Medicaid enrollees (3.33%, 3.33%, and 
3.39%), and West South Central residents (2.91%, 2.92%, 3.00%). In other strata, secular 
trends were not significant (P > 0.05).
Conclusions: Between 2014 and 2016, the risk of hospital admission among all 
Medicare dialysis patients was stable, although a secular trend of increasing risk was 
evident in young adult and dual-eligible patients.
Funding: Commercial Support - NxStage Medical, Inc.
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Dialysis: Hospitalization and Mortality
Using Artificial Intelligence to Help Predict Imminent Hospitalizations in 
Patients with ESRD
Andrew Long,2 Tommy C. Blanchard,2 Joanna Willetts,2 Hao Han,2 
Michael R. O’Connell,2 Amanda K. Ward,1 Lisa Reighter,1 Scott Braverman,1 
Kendra N. Smith,1 Annette L. Baker,1 Gamaela D. Brown,1 Greg S. Garza,1 
Cara Gallagher,1 Jodi Conti,1 Sheetal Chaudhuri,2 Len A. Usvyat,2 
Terry L. Ketchersid,2 Franklin W. Maddux.2 1Fresenius Health Partners, Austin, 
TX; 2Fresenius Medical Care North America, Waltham, MA.
Background: Patients with end-stage renal disease are hospitalized two times per year 
on average; approximately 35% have a re-admission within 30 days of discharge (USRDS 
2017). The cost of hospitalizations represents about one-third of the total Medicare spending 
for patients on dialysis. We developed a model to predict which patients treated at a large 
dialysis provider are at imminent risk of hospitalization to highlight patients who might 
benefit from additional interventions.
Methods: We built a machine learning model using over 1500 variables to predict the 
probability that a patient would be admitted within 7 days of the current outpatient dialysis 
treatment. Some of the variables in the model include treatment vital signs, administered 
medications, lab values, prior hospitalizations, demographics, comorbidities, lifestyle, and 
free-text clinical notes. Training data was extracted from patients treated at a large dialysis 
provider between January 2016 through May 2017. The results shown below are from un-
seen test data with 200,000 patients in June 2017.
Results: Approximately 2.7% of patients are hospitalized weekly. Results from the 
test data show the model has an area under the receiver operating curve (AUROC) of 0.78, 
sensitivity of 69%, and specificity of 72%. The confusion matrix for test data is shown in 
Table 1. Top variables for predicting hospitalization are related to prior hospitalizations, the 
content of free-text clinical notes, serum albumin, blood pressure, interdialytic weight gain, 
and hemoglobin.
Conclusions: This work demonstrates that data routinely collected during dialysis 
treatments can be used to predict imminent hospitalization. We are currently pilot-testing 
this model to determine if surfacing the results of these real time artificial intelligence-based 
machine learning algorithms to the local care team can help patients avoid hospitalizations 
and lead to improved patient outcomes.
Funding: Commercial Support - Fresenius Medical Care North America
Confusion matrix for test data (n = 200000)
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Prior Hospitalization Burden and the Relatedness of 30-Day  
Readmissions in Patients Receiving Hemodialysis
Eugene Lin,1 Jay Bhattacharya,1 Glenn M. Chertow.2 1Stanford University, Palo 
Alto, CA; 2Stanford University School of Medicine, Palo Alto, CA.
Background: Thirty-day readmissions are common in patients receiving hemodialysis 
and costly to Medicare. Because patients on hemodialysis have a high background 
hospitalization rate, thirty-day readmissions might be less likely related to the index 
hospitalization or to the quality of post-discharge care than in patients with other conditions.
Methods: We evaluated whether prior hospitalization burden was associated with 
increased 30-day readmissions unrelated to the index hospitalization in adults with Medicare 
receiving hemodialysis in the United States from 1/1/2012-12/31/2013. We categorized a 
hospitalization, 30-day readmission pair as “related” if the principal diagnoses came from 
the same organ system. Using multinomial logistic regression, we estimated the likelihood 
that an index hospitalization was followed by a related or unrelated 30-day readmission.
Results: The adjusted probability of an unrelated 30-day readmission after any index 
hospitalization was 19.1% (95% CI: 18.9%, 19.3%) in patients with 0-1 hospitalizations 
in the prior year, 22.6% (95% CI: 22.4%, 22.8%) in patients with 2-4 hospitalizations, and 
31.2% (95% CI: 30.8%, 31.5%) in patients with 5 or more hospitalizations. Cardiovascular 
index hospitalizations had the highest adjusted probability of a related 30-day readmission: 
10.4% (95% CI: 10.2%, 10.7%), 13.6% (95% CI: 13.4%, 13.9%), and 20.8% (95% CI: 
20.2%, 21.4%) respectively. Conversely, renal index hospitalizations had the lowest 
adjusted probability of a related 30-day readmission, 2.0% (95% CI: 1.8%, 2.3%), 3.9% 
(95% CI: 3.4%, 4.4%), and 5.1% (95% CI: 4.3%, 5.9%) respectively.
Conclusions: High prior hospitalization burden increases the likelihood that a 
patient receiving hemodialysis experiences a 30-day readmission unrelated to the index 
hospitalization. Healthcare payers such as Medicare should consider incorporating clinical 
relatedness into 30-day readmission quality measures.
Funding: NIDDK Support, Other NIH Support - National Institute of Aging
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Hospital-Acquired Anemia in Hemodialysis Patients: Opportunities for 
Improvement
Marta Christov,1,2 Anastasios Papanagnou,2 Michael D. Klein.2,1 1New York 
Medical College, Valhalla, NY; 2Westchester Medical Center, Bayside, NY.
Background: Anemia is a significant comorbidity in end-stage renal disease (ESRD) 
patients. Hospital-acquired anemia (HAA) is well-described in non-ESRD patients, where 
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it correlates with increased morbidity and mortality. Little is known about the development 
of HAA in hospitalized ESRD patients and potential modifiable factors.
Methods: We used retrospective chart review to compare hemoglobin (Hgb) on 
admission, at its lowest (nadir) and on discharge in 52 adult patients with ESRD admitted 
over a three month period to our medical center. Inclusion criteria were age > 18 years 
and admission between December 1st 2016 and February 28th 2017, as well as a billing 
code of ESRD (N18.6). Exclusion criteria were: bleeding-related admission, multiple 
admissions over the observation period, admission longer than 30 days, peritoneal dialysis. 
We analyzed change in hemoglobin from admission to discharge or admission to nadir and 
factors that were associated with the changes. Total diagnostic blood volume refers to the 
total amount of blood drawn by phlebotomy during the stay.
Results: The mean Hgb on admission was 10.6 (+/-1.5) g/dL and the mean discharge 
Hgb was 9.6 (+/-1.7) g/dL. The mean lowest Hgb was 9.0 (+/- 1.6) g/dL. Total diagnostic 
blood volume for the admission was significantly correlated with Hgb change from 
admission to lowest (0.578, p<0.001); 23% of patients required blood transfusions. Age, 
sex, comorbidities, admission diagnosis and access type were not associated with the 
change in Hgb, while length of stay and total diagnostic blood volume were associated 
with a Hgb drop from admission to nadir. We propose a definition of HAA for the ESRD 
population to include a Hgb decrease from admission to discharge of 1.5 g/dL or greater or 
need for transfusion.
Conclusions: Hospitalized ESRD patients showed significant decrease in hemoglobin 
during inhospital stay that correlated most closely with length of stay and total diagnostic 
blood volume. Strategies to minimize phlebotomy volume in this vulnerable population 
need to be tested.
Funding: NIDDK Support, Private Foundation Support
FR-PO794 Poster Friday
Dialysis: Hospitalization and Mortality
Determinants of Dialysis Facility Hospital Readmissions
Ziad M. Ashkar. Lafayette General Health, Lafayette, LA.
Background: Hospital readmissions are common, costly, and potentially avoidable. In 
ESRD, factors including anemia, CHF, cardiovascular disease, malignany, vascular access 
and low albumin were associated with readmissions. No studies have looked into dialysis 
units specific determinants of dialysis facility readmission rate. The purpose of this study is 
to identify unique dialysis facility determinants of hospital readmissions.
Methods: Observational retrospective, cross-sectional design. Data are obtained from 
CMS Dialysis Facility Compare, release date April 2018. Dialysis facility readmission rate 
was used as outcome variable. (defined as a percentage of hospital discharges). Multilinear 
regression with cluster by network was then done, with number of dialysis stations, % of 
patients with hemoglobin<10g/dl, % with KT/V>=1.2, % with AV Fistula in use, % with 
catheters more than 90 days, % with Calcium > 10.2mg/dl, phosphorus < 3.5 mg/dl and 
>7mg/dl
Results: For each increase in number of dialysis stations, there is a 6.3 % increase in
dialysis facility readmission rate (DFR). For each increase in % patients with Hb < 10g/dl, 
there is a 3.8 % increase in DFR. Each increase in % with KT/V>=1.2 is associated with
13.5 % decrease in DFR. There are no associations with the other variables.
Conclusions: Using data from dialysis facility compare, hemodialysis clinics with
KT/V>=1.2 are associated with significant decrease in dialysis facility readmission rates. 
Increase in dialysis stations and increase in percent with hemoglobin < 10g/dl are associated 
with increase in readmission rates. Strategies targeting adequate clearance and anemia
management will likely have significant impacts towards decreasing hospital readmissions 
in individual dialysis facilities. More studies are needed to understand drivers behind
increase in station numbers and readmissions in dialysis.
Multilinear regression determining Dialysis Facility Readmission Rate.
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Post Hoc Ergo Propter Hoc: A Multilevel Strategy to Reduce 30-Day 
Readmissions in Patients on Dialysis
Frank J. O Brien,1 Sadaf N. Sheikh,2 Anitha Vijayan.3 1Washington University in 
St. Louis, St. Louis, MO; 2Washington university St Louis MO, Valley Park, MO; 
3Washington University in St. Louis, St. Louis, MO.
Background: Patients with end-stage renal disease (ESRD) requiring dialysis are twice 
as likely as the general population to be readmitted within 30 days of hospital discharge. 
Inpatient care costs account for approximately 40% of total Medicare expenditures for 
dialysis. As of 2017, outpatient dialysis facilities have been penalized by the Centers of 
Medicare and Medicaid (CMS) for excessive readmissions as the standardized readmission 
ratio (SRR) became part of the ESRD quality incentive program. Our study examines the 
effect of a multi-level strategy to reduce readmission rates.
Methods: Washington University owns and operates 2 out-patient ESRD facilities in 
the city of St. Louis, with a census of approximately 400 patients. Using 2014-2017 data 
as our benchmark, we examine the impact of a dedicated transitional care nurse (TCN) 
and communication improvements (between the inpatient nephrology service and dialysis 
facilities) on readmission rates. The role of the TCN is to reconcile patient’s hospitalization 
with their outpatient care plan and bridge the gap from hospital to home. The TCN 
commenced work in the 3rd quarter of 2017.
Results: Admission and 30 day readmission data are outlined below in table 1. 
Admissions and readmissions have been decreasing over the past 3 years. 30 day 
readmissions reduced since introduction of readmission prevention strategy. An influenza 
outbreak was responsible for the increased number of admissions in the first quarter of 
2018. The TCN was able to see approximately 50% of patients within 48 hours of discharge 
and the patient’s nephrologist saw 90% of patients within one week of discharge.
Conclusions: This study highlights the ongoing difficulty dialysis units have with 
reducing readmission rates. We show that increased patient engagement with a TCN in the 
first 48 hours post discharge and improved structured communication between in patient 
nephrology services and dialysis facilities has led to reduced rates of readmissions.
Funding: Private Foundation Support
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In-Hospital Hemodialysis Services Provided by Tele-Nephrologists Using 
the NxStage System One S
Janice P. Lea,1 Tahsin Masud,1 James T. Someren,1 Jason Cobb,2 
Jerome S. Tannenbaum.3 1Emory University, Atlanta, GA; 2Emory University 
School of Medicine, Atlanta, GA; 3Sanderling Healthcare, LLC, Nashville, TN.
Background: Telemedicine has recently permeated into the nephrology space allowing 
ESRD patients in rural hospitals without access to traditional hemodialysis (HD) to receive 
dialysis care without transfer to larger healthcare systems. We report 5 months of experience 
using non-traditional dialysis machines (Nxstage System One S) in providing hemodialysis 
to patients remotely monitored by tele-nephrologists in rural hospitals.
Methods: A retrospective, descriptive study of patients receiving tele-nephrology 
consultation and chronic dialysis services between January 2018 and May 2018 in rural 
community hospitals across the U.S. Consultations were requested by the on-site physicians 
and were performed by reviewing the patient’s hospital EMR and performing a real-time 
history and physical exam with audio-video technology and Littman electronic stethoscope. 
Tele-nephrologists ordered HD using Nxstage System One S technology and Certified 
Clinical HD Technicians per standard nephrology practice. Hemodialysis treatment data 
was captured electronically and extracted into Excel for analysis
Results: A total of 6 rural hospitals across the U.S, provided 145 HD treatments to 
51 ESRD patients (25 females, 26 males; average age 64.9 (22-88 years) during the first 5 
months of 2018. HD prescription details with average blood flow (Qb), dialysate flow (Qd), 
dialysate volume, duration, flow fraction, and fluid removal (UF) rates are listed in Table 
1. Average pre-systolic BP (SBP) was 134 and post- SBP -131 with low SBP- 109. For
those with pre- SBP 100-130, and pre-SBP>130, 18% and 3% respectively had intradialytic 
drop to SBP<90. 7% of treatments utilized a 1 K bath, 44% - 2 K bath, and 48% - 3K bath. 
Average hours in between subsequent HD sessions was 47.
Conclusions: Hemodialysis services provided by NxStage System One S in ESRD 
patients in rural hospitals is effective and safe. This low dialysate volume platform is 
performed at similar frequencies and UF rates as traditional dialysis platforms (high 
dialysate volume) without high rates of hypotension.
Table 1 HD NxStage prescription
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Factors Affecting Sudden Death in Hemodialysis Patients: Ten-Years 
Outcome of the Q-Cohort Study
Hiroto Hiyamuta,1 Shigeru Tanaka,2 Masatomo Taniguchi,3 Toshiaki Nakano,1 
Masanori Tokumoto,4 Kazuhiko Tsuruya,5 Takanari Kitazono.6 1Kyushu University, 
Fukuoka, Japan; 2Fukuoka Dental College, Fukuoka, Japan; 3Fukuoka Renal 
Clinic, Fukuoka, Japan; 4Department of Internal Medicine, Fukuoka Dental 
College, Sawara-ku, Japan; 5Nara Medical University, Kashihara, Japan; 
6Department of Medicine and Clinical Science, Fukuoka, Japan.
Background: Sudden death is a serious problem in hemodialysis patients. However, 
the precise incidence rate of sudden death and its risk factors remain unclear.
Methods: A total of 3,506 Japanese HD patients aged ≥18 years were prospectively 
followed for 10 years. Sudden death was defined as sudden and unexpected natural death 
within 24 hours. Multivariate-adjusted hazard ratios (HR) with 95% confidence intervals 
(95% CI) of each risk factor of sudden death were calculated using a Cox proportional 
hazards model.
Results: During a follow-up period, 1,748 patients died from any causes and 227 of 
them (13%) were attributed to sudden death. In multivariable-adjusted Cox analysis, male 
sex (hazard ratio [HR] 1.65; 95% CI 1.19–2.30), age (HR 1.44; 95% CI 1.26–1.65 for 
every 10-years increase), presence of diabetes (HR 2.45; 95% CI 1.82–3.29), history of 
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cardiovascular events (HR 1.85; 95% CI 1.38–2.46), cardiothoracic ratio in chest X-ray 
(HR 1.21; 95% CI 1.07–1.39 for every 5-percentage-point increase), serum levels of 
phosphate (HR 1.15; 95% CI 1.03–1.30 for every 1-mg/dL increase), and C-reactive protein 
(HR 1.11; 95% CI 1.03–1.20 for every 1-mg/dL increase) were independent predictors for 
developing sudden death. In subgroup analysis, shorter dialysis session length (<5 hours) 
was associated with an increased risk of sudden death in male group (HR 1.51; 95% CI 
1.03– 2.21; p for interaction 0.01) or elderly group (≥ 65 years) (HR 2.45; 95% CI 1.82–
3.29), and lower serum calcium level was a significant predictor for sudden death in female 
group (HR 1.88; 95% CI 1.36–2.63 for every 1mg/dL decrease; p for interaction <0.001).
Conclusions: The present study demonstrated the lower occurrence rate of sudden 
death compared to previous reports, but elucidated its specific risk factors, related 
to atherosclerosis, vascular calcification, left ventricular hypertrophy, and chronic 
inflammation, in hemodialysis patients.
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Characteristics of Sudden Cardiac Death in Our Hemodialysis Unit
Carmen Mon, Milagros Ortiz, Olimpia Ortega, Aniana Oliet, Maria Sanchez, 
Rosa E. Camacho, David Arroyo, Jessica Urdaneta, Diego Navazo, Juan 
Carlos Herrero. Hospital Severo Ochoa, Madrid, Spain.
Background: In hemodialysis (HD) patients sudden cardiac death (SCD) accounts for 
one out of every four deaths. It is complicated to determine how unexpected death is on 
ESRD patients whose illness is chronic and have a high comorbidity. Our aim was to study 
mortality in our dialysis unit, focusing on SCD.
Methods: Retrospectively, we collected mortality data for ten years. Clinical, 
biochemical (analytical closer to the date of death) and causes of death were analyzed. SCD 
was defined as an unexpected circulatory arrest or an unwitnessed, unexpected death in 
patients known to be well within the past 24 h.
Results: 215 deaths were reviewed. First cause of death was cardiovascular disease 
(CVD) (54 p, 25%), the second SCD (42p, 19%). Risk factors for SCD at univariate study 
are showed in Table 1. In the logistic regression analysis, SCD was associated with: lack of 
AF (p0,05, HR0,27,CI 0,107-0,67), higher potassium levels (p0,02, HR1,64,CI 1.0,7- 2,4), 
higher albumin levels (p0,02,HR2,CI 1,1-3,8) and lower CRP levels (p:0,01 HR0,99,CI 
0,98-0,99).
Conclusions: SCD was the second cause of death in our HD patients and was not 
associated to traditional risk factors. There was no relationship between SCD and previous 
diagnosis of CVD, malnutrition and inflammation nor structural heart disease (AF). High 
value of serum potassium was the only risk factor associated to SCD that we can modify.
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Plasma Syndecan-1 in Hemodialysis Patients Associates with Survival and 
Reduced Volume Status
Josephine Koch,1 Nienke Idzerda,2 Wendy Dam,3 Solmaz Assa,2 Jacob van den 
Born,4 Casper F. Franssen.2 1University of Groningen, Groningen, Netherlands; 
2University Medical Center Groningen, Groningen, Netherlands; 3University 
medical center groningen, Groningen, Netherlands; 4Univ. Med. Center 
Groningen, Groningen, Netherlands.
Background: Syndecan-1, a transmembrane heparan sulfate proteoglycan, associates 
with renal and cardiovascular functioning. We earlier reported syndecan-1 to be involved 
in renal tubular regeneration. We now examined plasma values of syndecan-1 in a 
hemodialysis cohort and its association with volume, inflammatory and endothelial markers 
in addition to outcome parameters.
Methods: Eighty-four hemodialysis patients were evaluated for their plasma 
syndecan-1 levels by ELISA before, 60, 180 and 240 minutes after starting dialysis. Patients 
were divided into sex-stratified tertiles based on predialysis plasma syndecan-1 levels. We 
studied the association between plasma levels of syndecan-1 and volume, inflammation and 
endothelial markers and its association with cardiovascular events and all-cause mortality 
using Kaplan-Meier curves and cox regression analyses with adjustments for gender, age, 
diabetes and dialysis vintage.
Results: Predialysis syndecan-1 levels were two-fold higher in males compared 
to females (P=0.0003). Patients in the highest predialysis plasma syndecan-1 tertile had 
a significantly higher ultrafiltration rate (P=0.034) and lower plasma values of BNP 
(P=0.019), pro-ANP (P=0.024) and endothelin (P<0.0001) compared with the two lower 
predialysis syndecan-1 tertiles. No significant associations with inflammatory markers 
were found. Cox regression analysis showed that patients in the highest syndecan-1 tertile 
had significantly less cardiovascular events and better survival compared with the lowest 
syndecan-1 tertile (P=0.02 and P=0.005, respectively).
Conclusions: In hemodialysis patients, higher plasma syndecan-1 levels were associated 
with lower concentrations of BNP, pro-ANP and endothelin, and with better patient 
survival. This may suggest that control of volume status in hemodialysis patients allows 
an adaptive tissue regenerative response as reflected by higher plasma syndecan-1 levels.
Funding: Government Support - Non-U.S.
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Gender Differences in Three-Year Clinical Outcomes in Japanese Dialysis 
Patients
Takatoshi Morinaga,1 Atsushi Fukatsu,2 Daijo Inaguma,3 Hirofumi Tamai.1 
1Nephrology, Anjo Kosei Hospital, Aichi prefecture Anjo city, Japan; 2Fukatsu 
Medical Clinic, Anjo, Japan; 3Nephrology, Fujita Health University School of 
Medicine, Toyoake, Japan.
Background: A recent Dialysis Outcomes and Practice Patterns Study (DOPPS) has 
shown a male-to-female mortality ratio one-to-one, notwithstanding women’s statistically 
longer life expectancy in the general population (Hecking et al., 2014). This finding 
contrasts with the recent report that Japanese women on dialysis treatment have more 
favorable longevity (Jap. Soc. Dial. Ther., 2009). Accordingly, we further investigated 
clinical procedures and outcomes in order to clarify the gender differences in Japanese 
patients on chronic dialysis treatment in order to establish an optimal dialysis modality.
Methods: Subjects were patients in 17 centers participating in the Aichi Cohort Study 
of Prognosis in Patients Newly Initiated into Dialysis (AICOPP) from October 2011 to 
September 2013. We excluded 129 from the study because their three-year outcome data 
was unavailable. Thus, 1,395 subjects were enrolled in the study. Three-year mortality was 
analyzed by multivariate logistic regression model adjusted by age, gender, body mass 
index (BMI), diabetes mellitus, C-reactive protein, serum albumin, use of statin, history of 
cardiovascular disease (CVD) and malignancy. Three-year mortality and CVD events were 
studied separately in women and men with or without CVD at baseline.
Results: Overall, 458 (32.4%) of 1,395 test subjects were women. Women had lower 
rates of diabetes mellitus (Women 49.8% vs Men 56.0: P=0.028) and history of CVD 
(38.2% vs 49.8: P<0.001). Age (mean ± SD, 68.2 year ± 12.7 vs 67.7 ± 12.8: P=0.51) and 
BMI (23.3 ± 5.3 vs 23.5 ± 3.9: P=0.30) were similar in both sexes. Female gender (adjusted 
odds ratio 0.66: 95% CI 0.47-0.91) was a positive and history of CVD (OR 1.85: 1.37-2.51) 
was a negative independent predictor of three-year mortality.
Conclusions: Women on chronic dialysis treatment had a lower mortality risk than 
men. However, women with CVD comorbidity had a higher mortality rate which cancelled 
out the survival advantage. These data suggest that the dialysis modality for women with a 
risk of CVD needs to be modified.
Three-year outcome in subgroups (N=1395)
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Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to 
Potentially Modifiable Risk Factors: Results from the DOPPS
Bruce M. Robinson,1 Hal Morgenstern,2 Angelo Karaboyas,1 Yun Li,2 
Brian Bieber,1 Raymond M. Hakim,5 Takeshi Hasegawa,7 Michel Y. Jadoul,6 
Elke Schaeffner,3 Raymond C. Vanholder,4 Ronald L. Pisoni,1 Friedrich K. Port.1 
1Arbor Research Collaborative for Health, Ann Arbor, MI; 2University of 
Michigan, Ann Arbor, MI; 3Charite, Berlin, Germany; 4University Hospital 
Gent, Gent, Belgium; 5Vanderbilt University, Franklin, TN; 6Cliniques Saint-
Luc, University of Louvain Medical School, Brussels, Belgium; 7Showa 
University, Yokohama, Japan.
Background: Despite recent improvements in survival on chronic hemodialysis (HD), 
mortality soon after HD start remains high. We aimed to identify potentially modifiable risk 
factors with the greatest impact on early HD mortality.
Methods: The analysis included 15,891 incident HD patients (<60 days on HD) from 
21 countries in phases 1-5 (1996-2015) of the Dialysis Outcomes and Practice Patterns 
Study (DOPPS). Using adjusted Cox regression, we estimated the fraction of deaths in 
the first year of HD attributable to potentially modifiable risk factors at study entry (the 
attributable fraction, AF) by comparing predicted survival based on risk factors observed 
vs. counterfactually set to reference levels.
Results: Of 12 risk factor chosen based on known mortality associations, the highest 
AFs were observed for catheter use (22%), serum albumin <3.5 g/dL (19%), and serum 
creatinine <6 mg/dL (12%). Risk factors with an AF of 5-9% were lack of pre-HD nephrology 
care, lack of residual urine volume, SBP out of range 130-160 mm Hg, phosphorus 
out of range 3.5-5.5 mg/dL, hemoglobin out of range 10-12 g/dL, and WBC count 
>10,000/μL. The AFs for ferritin >800 ng/mL, serum calcium out of range 8.4-9.5 mg/dL 
and PTH out of range 150-300 pg/mL were <3%. Overall, 65% (95% CI 59-71%) of deaths 
were attributable to these 12 risk factors. The AF for CRP was 21% in facilities where it is 
routinely measured.
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Conclusions: A substantial proportion of first-year HD deaths could potentially 
be reduced by successfully modifying a few risk factors. Highest priority targets should 
include decreasing catheter use and avoiding or treating malnutrition/inflammation 
whenever possible.
Funding: NIDDK Support, Commercial Support - The DOPPS Program is supported 
by Amgen, Kyowa Hakko Kirin, Baxter Healthcare. Additional support for specific 
projects and countries is provided by AstraZeneca, European Renal Association-European 
Dialysis & Transplant Association (ERA-EDTA), Fresenius Medical Care Asia-Pacific Ltd, 
Fresenius Medical Care Canada Ltd, German Society of Nephrology (DGfN), Janssen, 
Japanese Society for Peritoneal Dialysis (JSPD), Keryx, Kidney Care UK, MEDICE 
Arzneimittel Pütter GmbH & Co KG, Proteon, and Vifor Fresenius Medical Care Renal 
Pharma. Public funding and support is provided for specific DOPPS projects, ancillary 
studies, or affiliated research projects by National Health & Medical Research Council 
(NHMRC) in Australia, Cancer Care Ontario (CCO) through the Ontario Renal Network 
(ORN) in Canada, French National Institute of Health and Medical Research (INSERM) 
in France, Thailand Research Foundation (TRF), Chulalongkorn University Matching 
Fund, King Chulalongkorn Memorial Hospital Matching Fund, and the National Research 
Council of Thailand (NRCT) in Thailand, National Institute for Health Research (NIHR) 
via the Comprehensive Clinical Research Network (CCRN) in the United Kingdom, and 
National Institutes of Health (NIH) in the US. All support is provided without restrictions on 
publications. All grants are made to Arbor Research Collaborative for Health and not to Dr. 
Robinson directly., Private Foundation Support, Government Support - Non-U.S.
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Poor Immune Response to Influenza Vaccine Is Associated with Increased 
Mortality in Hemodialysis Patients
Jaromir Eiselt,1 Daniel Rajdl.2 1Internal Dept. 1, Charles University, Plzen, 
Czechia; 2Dept. of Biochemistry, Plzen, Czechia.
Background: Immune response reflects an individual’s immune status. Hemodialysis 
(HD) and renal transplantation (TX) are associated with the state of immune dysfunction. 
The aim of our study was to assess natural levels of pneumococcal IgG (pne-IgG, patients 
unvaccinated against pneumococcus) and hemagglutination-inhibition antibodies (HIA, 
post influenza vaccine) in HD and TX patients. We tried to determine the factors influencing 
the immune status and the relationship of the immune response to mortality.
Methods: A total of 99 HD and 64 TX patients who have never received a pneumococcal 
vaccine were vaccinated against influenza in seasons 2015/16 and 2016/17. Their pne-IgG, 
pre- and post-vaccine HIA titre, iron status, C-reactive protein (CRP), albumin and 25-OH 
vitamin D were measured at baseline and after one year. Total follow-up was 30 months. 
To identify variables associated with mortality, univariate Cox regression analyses were 
performed with mortality as a dependent variable, and age, gender and the above mentioned 
markers as predictors. Markers with p<0.1 (post-vaccine rise in HIA, CRP, albumin, age) 
were subsequently included into a multivariate Cox regression model.
Results: Pneumococcal IgG levels and percentage of seroprotective HIA were 
comparable in HD and TX groups and between the two consecutive years (Table 1). 
Mortality was higher in the HD, in which 30 patients died, while only one death was 
recorded in TX. According to the multivariate Cox regression model (adjusted R2 0.246, 
p<0.0001), the predictors of death were low postvaccination HIA titre (p=0.019), and high 
CRP (p=0.003).
Conclusions: The immune response to the influenza vaccine and the natural production 
of pne-IgG are comparable in HD and TX patients. Besides dependence on HD, significant 
independent predictors of mortality in HD population are low antibody response to influenza 
vaccine and high CRP.
Funding: Government Support - Non-U.S.
Data are medians (interquartile ranges), unless stated otherwise; Mann-Whitney and χ2 test; 
A H1N1, A H3N2, B are influenza virus strains, SPpost is post-vaccine seroprotection rate; 
differences among groups were not statistically significant.
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Association of Fruit and Vegetable Intake with All-Cause Mortality in 
Hemodialysis Patients (DIET-HD): A Prospective Cohort Study
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Background: Higher fruit and vegetable intake is associated with lower vascular 
and all-cause mortality for the general population. However, whether fruit and vegetable 
consumption benefits patients treated with haemodialysis is uncertain. We evaluated the 
association of fruit and vegetable intake with mortality outcomes in adults on hemodialysis.
Methods: The DIET-HD study was a prospective cohort study involving 9757 adults 
treated with hemodialysis. Fruit and vegetable intake was measured using the GA2LEN 
food frequency questionnaire. Cox regression analyses adjusted for sociodemographic and 
clinical variables and clustered by country were conducted.
Results: During a median follow up of 2.7 years (18,666 person-years), there were 
2087 deaths, of which 958 were vascular deaths. Overall, higher combined intake of fruit 
and vegetables was associated with lower risks of non-vascular and all-cause mortality. The 
risk for vascular mortality was lower with the highest tertile of intake although the 95% 
confidence interval included the possibility of a null effect. With reference to the lowest 
tertile of intake (0 to 5.5 servings per week), the adjusted hazards ratios (95% confidence 
interval) for the middle (5.6 to 10 servings per week) and highest (>10 servings per week) 
tertiles were 0.88 (0.76-1.02) and 0.77 (0.66-0.91) for non-vascular mortality; 0.90 (0.81-
1.00) and 0.80 (0.71-0.91) for all-cause mortality ; and 0.95 (0.81-1.11) and 0.84 (0.70-
1.00) for vascular mortality.
Conclusions: Higher consumption of fruit and vegetables is associated with lower risk 
of mortality in hemodialysis patients.
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Background: Variability of laboratory parameters and serum sodium (SNa) observed 
to associated with adverse physical conditions in chronic hemodialysis (HD) patients (pts) 
[Nakazato Y et al]. SNa, the main determinant of plasma osmolality, play a key role in 
fluid shifts between the extra-& intracellular compartments. Variability SNa, denoted as the 
measured-to-measured variation, affects the stability of cell volume.
Methods: All adult incident pts with more than 5 SNas during the first year on HD 
were included, outcomes were recorded over a 2 yrs period. Average baseline SNa as well 
as variabilities were computed by standard deviation (SD) of the residual, SD, relative 
range (the difference between the largest and smallest), average real variability (ARV). Cox 
proportional models with bivariate spline functions were applied to study the joint effects of 
SD of residual, SD, ARV and relative range of SNa, respectively. Cox proportional models 
with multiple adjustments were also used to further evaluate the adverse effect of SNa 
variability.
Results: Out of 30,174 pts (EU:15,660, Asia:8,749,US:2,691,UK:2,282, South 
America:791) were included, 7,021 (23.3%) died. Hyponatremia (SNa<=135) was the most 
prominent predictor of increase mortality. For pts with SNa>135, we didn’t observe an 
association between SD residual and mortality. Increased risk of death with higher SD and 
ARV appeared to be present at all levels of SNa. A more pronounced effect of relative range 
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was observed compared to SD and ARV. More significant effect was observed with the 
maximal SNa happened before the minimal SNa [Figure 1]. Cox proportional model with 
adjustments also yield the same results.
Conclusions: Given the positive association between mortality and hiher SNa range,S, 
ARV regardless of the SNa level, these measures constitute novel prognostic indicators in 
HD therapy.
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Background: Patients with end-stage renal disease (ESRD) have a higher-than-normal 
cancer risk. However, the incidence and mortality of cancers in ESRD patients receiving 
hemodialysis (HD) or peritoneal dialysis (PD) have been rarely studied for Korean 
populations.
Methods: We analysed data from the National Health Insurance Service (NHIS) of 
Korea to identify the incidence and mortality of cancers in ESRD patients receiving HD 
or PD. The study population was all ESRD patients starting maintenance dialysis between 
2006 and 2014. They were followed from initiation of dialysis until death, discontinuation 
of dialysis, or the end of 2015. Cox proportional hazard regression models was used to 
identify the risk factors for cancer in ESRD patients.
Results: Of 17,140 ESRD patients, 4,258 (24.8%) had been newly diagnosed with 
cancer. The incidence of any cancer was higher for certain subgroups: older age, DM, 
hypertension, stroke, and coronary artery disease. In age-, gender-, and 1:2 propensity 
score-matched general population, 24.7% had been newly diagnosed with cancer. Rate of 
cancer in HD patients was 1.06 times higher than in the general population (95% CI 1.025-
1.110, p=0.0014), while PD patients did not differ from general population (HR 0.897, 
95% CI 0.765-1.051, p=0.1782). There were no significant differences in rates of cancer 
(HD vs. PD, 24.9% vs. 21.7%), the time from start dialysis to diagnosis of cancer (HD 
vs. PD, 4.49±3.00 vs. 3.68±2.92 years), and mean age at diagnosis of cancer (HD vs. PD, 
64.44±12.14 vs. 60.23±13.20 years) between patients on HD and PD. Figure-1 showed 
the overall survival curves of cancers after newly diagnosed in ESRD patients and general 
populations.
Conclusions: These results suggested that the frequency of cancer is higher in ESRD 
patients on HD, not PD, than in the Korean general population.
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Background: An increased risk of early mortality exists for patients (pts) starting 
chronic hemodialysis (HD) therapy. In the French NephroCare (NC) centers a Specific 
Oriented Care for HD Incident Patients (SOCHIP) program has been implemented.
Methods: The SOCHIP program started in October 2015. One nurse was in charge 
to recover monthly the Key Performance Indicators (KPIs) for all incident HD pts during 
the first 4 months. The prescriptions of pts out of target were reviewed monthly. We have 
retrospectively calculated monthly the % of pts in target before and after the implementation 
of the SOCHIP program.
Results: Respectively, 816 (SOCHIP-) and 666 (SOCHIP+) pts have been analyzed 
(age:68,4 and 68,7 yo; % females: 35 and 31,3; Charlson Index:5,1 and 5,2). At M4 the 
% of pts in target has been significantly increased for effective treatment time (≥720 
minutes/week; 33 versus 43%, p=0,0007), the processed blood volume (240 liters/week; 
20,0 versus (vs) 43,8%, p<0,0001), KT/V (≥1.4; 37,5 vs 56,4%, p<0,0001) the HyS (<13% 
(females) and <15% (males); 38,7 vs 65,9%, p<0,0001), the hemodynamic status (BCM® 
+ predialysis systolic blood pressure <160 mmHg; 53,2 vs 65,7%, p<0,0001), albuminemia 
(≥35g/l; 51,6 vs 59,4, p=0,094). There was no significant changes of the % of patients 
in target for the vascular access (AV fistula; 54,0 vs 49,2%), hepatitis-B protection (Ac 
antiHbs+ or complete immunization record in E5; 96,7 vs 98,0%), Hemoglobine (≥10g/
dl ou between 10 et 12g/dl if EPO; 52,8 vs 54,8%) and mid-week phosphatemia (<1,65
mmoles/l or >0,75 mmoles/l if Pi-binders prescription; 67,9 vs 69,4%). The crude mortality 
has significantly decreased from 30,1 to 22,4 for 100 patient/years p=0.0002).
Conclusions: These data show that the SOCHIP program has allowed to improve the % 
of pts in target for 6 out of 10 usual KPIs. The KPIs improvement parallels the improvement 
of the early mortality. Other parameters included in the SOCHIP program have not been 
evaluated (early access to cardiologist and diabetologist). Moreover, the significant increase 
of pts in target for albuminemia suggests that the early access to the dietitian has been 
improved by the SOCHIP program. We can conclude that a specific program for incident 
HD patient improves the % of pts in target of most of the KPIs and may improve the early 
mortality in this setting.
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Background: The results of the Initiating Dialysis Early and Late (IDEAL) study 
suggested that patients with stage V CKD, randomized to late initiation of Hemodialysis 
(HD) had similar mortality to those who started early. However, more than 3/4th of patients 
assigned to the late arm received dialysis earlier than planned. Moreover, IDEAL study 
population was very different from that of the United States and had close nephrology 
followup. We used a propensity score based analysis of the USRDS database to examine 
how the eGFR at the time of initiation of dialysis affects total and cardiovascular (CV) 
mortality in the US population in a real word setting.
Methods: Patients ≥18 years old who initiated in-center HD between 2006 and 2014 
were included. 676,196 patients were categorized based on the tertiles of MDRD eGFR 
levels prior to initiation of HD, into late (eGFR <8.7), intermediate (eGFR 8.7 to <13.0) 
and ≥ and early start (eGFR >13.0 ml/min) groups. Associations between eGFR groups and 
10-year all-cause and CV mortality were assessed using KM curves and multivariable Cox 
proportional hazards models with propensity-score weighted regression.
Results: Mean age was 64±15 years. Elderly, Caucasians, males and those with 
diabetes or heart failure were more likely to be initiated on HD early. Compared to the 
late start group, the intermediate and early start had a 42% and 93% increased risk of 
10-year all-cause mortality, respectively (HR=1.42; 95%CI: 1.41-1.43 and HR=1.93;
95%CI: 1.91-1.94 respectively). This association was attenuated, but remained significant 
when adjusted for multiple covariates (adjusted HR=1.13; 95%CI:1.12-1.14 for
intermediate and HR=1.37; 95%CI: 1.36-1.39, for early start respectively). The 10-year CV 
mortality was similarly increased with early dialysis (adjusted HR=1.13; 95%CI: 1.12-1.15 
and HR=1.40; 95%CI: 1.38-1.42, for late and early start respectively). This association was 
robust and consistent across multiple sub-groups and sensitivity analyses.
Conclusions: Our results demonstrate that early initiation of dialysis is associated 
with increased toal and cardiovascular mortality. This increased mortality is not completely 
accounted for by co-morbidities in the early initiation group. The mechanistic basis of these 
observation requires further study.
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Background: Since the discovery of initial survival disadvantage of hemodialysis 
(HD) over peritoneal dialysis (PD), selection bias has been questioned when making this 
comparison. To minimize the bias, patients with planned initiation of HD have previously 
been chosen for comparison, but the results were inconclusive. Here, with a different 
definition for planned initiation, we tested the hypothesis that the dialysis modality had no 
effect on the one-year mortality rate in incident dialysis patients.
Methods: A total of 45,825 incident dialysis patients with maintenance dialysis for 
more than 3 months in Taiwan between 2007 and 2011 were enrolled. Planned initiation of 
HD was defined as the initiation of HD through peripheral vascular access at an outpatient 
clinic (planned-HD), and the one-year mortality rate was compared between HD and PD 
groups in cohorts by planned initiation of HD and propensity score matching using Cox 
model.
Results: In all, 39,635(age 64±14y, F:48%, DM:60%), 9,184(age 65±13y, F:46%, 
DM:57%), and 6,190(age 55±15y, F:51%, DM:44%) incident dialysis patients were enrolled 
in HD, planned-HD, and PD groups, respectively. During the observation period, the death 
was reported for 4,453, 812, and 342 patients, respectively. HD group had a higher one-
year mortality rate than PD group after either adjusting the baseline clinical characteristics 
(age, sex, socioeconomic status, urbanization, hypertension, diabetes, cardiac disorder, 
ischemia stroke, gout, peripheral vascular diseases, and Charlson score) [adjusted hazards 
ratio (95% confidence interval) 1.17 (1.04–1.30)] or propensity score matching [1.23 (1.07–
1.42)]. However, this survival disadvantage disappeared when the planned-HD group was 
compared with the PD group after either adjusting the baseline clinical characteristics [0.96 
(0.85–1.10)] or propensity score matching [0.99 (0.85–1.16)].
Conclusions: The initial survival disadvantage of HD over PD can be alleviated by 
planned initiation of HD in the dialysis population in Taiwan.
Funding: Government Support - Non-U.S.
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Background: Nutritional status and inflammation are significant markers for mortality 
and morbidity, especially in hemodialysis patients. While there is much evidence to support 
the association between albumin levels and nutritional status and inflammation, less is 
known about the associations between globulin levels and mortality risk in hemodialysis 
patients.
Methods: We retrospectively examined a cohort of 104,164 incident hemodialysis 
patients treated by a large dialysis organization from 2007 to 2011 whose first patient 
quarter (dialysis start + 91 days) globulin measurements were obtained during treatment. 
Patients were grouped into 9 globulin categories. Using Cox models, we explored the 
association between serum globulin levels and all-cause mortality from the time of dialysis 
initiation with adjustments for case-mix variables and laboratory markers of malnutrition 
inflammation complex syndrome (MICS), including albumin.
Results: Mean patient age was 63±15 years; 44% were female, 31% were African 
American, and 58% were diabetic. Mean globulin level was 1.16±0.31 g/dL. Compared to 
the reference group of 3.0-<3.2 g/dL, patients with lower globulin (<2.8 g/dL) and higher 
globulin (≥3.8 g/dL) had higher mortality risk in the unadjusted model. After case-mix 
adjustment, compared to the referent, patients with lower globulin had lower mortality risk 
while higher globulin still had higher mortality risk. After adjustment for MICS covariates, 
the associations were attenuated; however, patients with globulin >3.8 g/dL still had a 
higher mortality risk compared to the referent [figure1].
Conclusions: Among incident hemodialysis patients, higher globulin level is associated 
with higher mortality risk, independent of other markers of malnutrition and inflammation, 
including albumin.
Funding: NIDDK Support
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Background: Mortality risk is high in dialysis patients. Yet, the mortality risk in 
dialysis compared to other diseases like cancer is poorly understood. We conducted a 
population-based cohort study using healthcare databases from Ontario, Canada, to examine 
survival probabilities for all-cause mortality in maintenance dialysis patients compared to 
patients with common cancers (women: breast, colorectal, lung, or pancreas; men: prostate, 
colorectal, lung, or pancreas) from 1997 to 2015.
Methods: We used the Kaplan-Meier product limit estimator to determine the 
cumulative probability of survival for all-cause mortality. Additional analyses examined the 
risk of mortality adjusting for clinical characteristics and trends in survival probability using 
Cox proportional hazards regression.
Results: 33,500 maintenance dialysis patients and 532,452 cancer patients (median 
follow-up 4.4 years). In males, dialysis had worse 5-year survival (50.8%, 95% confidence 
interval [CI]: 50.1, 51.6%) compared to prostate (83.3%, 95% CI: 83.1, 83.5%) and 
colorectal cancer (56.1%, 95% CI: 55.7, 56.5%) but better survival than lung (14.0%, 95% 
CI: 13.7, 14.3%) and pancreas cancer (9.1%, 95% CI: 8.5, 9.7%). In females, dialysis had 
worse 5-year survival (49.8%, 95% CI: 48.9, 50.7%) compared to breast (82.1%, 95% 
CI: 81.9, 82.4%) and colorectal cancer (56.8%, 95% CI: 56.3, 57.2%) but better survival 
than lung (19.7%, 95% CI: 19.4, 20.1%) and pancreas cancer (9.4%, 95% CI: 8.9, 10.0%). 
After adjusting for clinical characteristics, similar results were found. Survival significantly 
improved across eras (1997-2001, 2002-2006, 2007-2011, 2012-2015) for all cancer types 
(P<0.01) but no significant change was observed in dialysis patients (females, P=0.89; 
males, P=0.48) (Figure).
Conclusions: Survival in dialysis patients was lower than patients with several types 
of common cancers. Unlike cancer patients, the prognosis of patients on dialysis has not 
improved over time. Results highlight the need to develop and test interventions to improve 
survival in maintenance dialysis patients.
Figure. 5-year survival probabilities for all-cause mortality by era of cohort entry for 
women (A) and men (B)
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A Simple Vitality Question, Its Correlates, and Clinical Outcomes in 
Patients Receiving Hemodialysis: The Japanese Dialysis Outcomes and 
Practice Pattern Study
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Background: The lack of an assessment of vitality in daily practice may be partially 
due to inadequate understanding of lack of vitality and the lack of a concise method of 
assessing it. The aim of this study was to examine the predictability of a simple 1-item 
vitality question and its correlates.
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Methods: This was a cohort study involving hemodialysis patients who participated 
in the Japan Dialysis Outcomes and Practice Pattern Study (phase 3 to 4 [2005–2011]). 
Predictor was one-item vitality measured via the 12-item Medical Outcomes Study Short 
Form survey version 2.0, using a 5-level Likert scale. Outcomes were all-cause mortality 
and a composite of multiple cardiovascular hospitalization and all-cause mortality. A 
pooled ordered logit model was fitted to examine correlates of 1-item vitality. Cox and 
mixed-effects Poisson regression models were fitted for mortality and composite outcomes, 
respectively.
Results: 3,667 patients were analyzed. Decrease in vitality category was associated 
with tachycardia (≥ 100 vs. 60 to < 70 beats/min) and benzodiazepine, hypnotics, or 
antidepressant use. In contrast, increase in vitality was associated with increase in single-
pool Kt/V, serum albumin, and BMI. Compared with the lowest vitality category, the second 
highest and middle categories were negatively associated with all-cause mortality (Figure; 
adjusted hazard ratio [AHR] 0.66, 95% confidence interval [95% CI] 0.47–0.93 and AHR 
0.75, 95% CI 0.59–0.96, respectively). A one-category increase in vitality was consistently 
associated with lower mortality (AHR 0.86, 95% CI 0.78–0.96). The associations between 
1-item vitality and multiple cardiovascular hospitalization and mortality were similar to
those between vitality and mortality.
Conclusions: 1-item vitality predicted all-cause mortality and a composite of multiple 
cardiovascular hospitalization and all-cause mortality, and correlates with some modifiable 
factors, including vital signs. Dialysis staff should consider asking this simple question in 
daily practice to improve patient quality of life and outcomes.
Funding: Commercial Support - Kyowa Hakko Kirin
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Background: Despite the long-appreciated association of seizures with uremia, 
there are few national data regarding the prevalence and outcomes of ESRD patients with 
epilepsy compared to those without epilepsy.
Methods: We assessed claims-based diagnoses of epilepsy, baseline characteristics, 
anticonvulsant drug prescriptions and outcomes by comparing ESRD patients with and 
without epilepsy in the USRDS. Study population comprised of prevalent US ESRD 
patients with continuous Medicare Part A, B, and D coverage from Jan. 1, 2013 to Dec. 
31, 2014. Epilepsy was defined as one claim with an International Classification of 
Disease-9th Revision-Clinical Modification (ICD-9-CM) code for epilepsy or two claims 
with ICD-9-CM codes for seizures at least 30 days apart from Jan. 1, 2013 to Dec. 31, 
2014. The outcome was all-cause mortality from Jan. 1, 2015 to July 31, 2016. We used 
modified Poisson regression with a robust variance estimator to estimate risk ratios and 
95% confidence intervals for the association between epilepsy status and mortality. Final 
models were adjusted for sociodemographics, ESRD treatment history, and comorbidities.
Results: Of 195,319 ESRD patients in the cohort, 15,233 patients (7.8%) were classified 
as having epilepsy. Of ESRD patients with a claims-based diagnosis of epilepsy, 80.4% 
filled an anticonvulsant or hydantoin prescription compared to 31.6% of patients without 
epilepsy. 19 anticonvulsant medications were prescribed. Levetiracetam and Phenytoin 
were the most commonly prescribed anticonvulsant drugs without another indication such 
as pain. 20.1% of patients died during the 19-month follow-up period: 27.9% of patients 
with epilepsy and 19.4% of patients without epilepsy (p <0.0001). After adjustment for 
confounders, the estimated mortality risk among those with epilepsy was 1.14 (95% CI: 
1.11, 1.18) times that among those without epilepsy.
Conclusions: ESRD patients have a high prevalence of epilepsy and many are treated 
with anti-convulsant drugs such as Levetiracetam and Phenytoin. ESRD patients with 
epilepsy had an increased risk of death compared to those without epilepsy. Given the high 
epilepsy prevalence among the ESRD population, continued efforts are needed to identify 
appropriate treatment/medication selection and to prevent premature mortality among 
ESRD patients with epilepsy.
Funding: NIDDK Support
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Background: Relative blood volume (RBV) and central venous oxygen saturation 
(ScvO2) monitoring is increasingly adopted. We previously identified that at higher ScvO2 
levels, that RBV had only a small effect on mortality risk, whereas at lower ScvO2 levels, 
RBV tends to drive mortality risk. In this study, we further explored the association between 
RBV and ScvO2 values on all-cause mortality.
Methods: This is a retrospective multicenter cohort study of HD patients with central-
venous catheter (CVC) as vascular access from 17 Renal Research Institute clinics from 
January 2012 to June 2017 where the Crit-Line® Monitor (CLM) is used. The CLM allows 
for monitoring of extracorporeal hematocrit (Hct) and ScvO2. The patients were stratified 
into 2 groups depending on their RBV and ScvO2 at 3 hours (mean values between minutes 
170 and 190) into HD.
Results: We included 151 patients with a total of 3,937 HD treatments. The median 
follow-up time was 2.8 years. The patients were stratified into 2 groups, 52 patients with 
their RBV larger than 91.74% and ScvO2 lower than 56.72% at 3 hours into HD were 
labeled right corner patients (based on the position from our last study [1]). The results 
indicate a significantly increased mortality in patients with lower ScvO2 and higher RBV 
levels compared to others (Figure 1 KM plot). Multivariate Cox analysis with different 
levels of adjustments corroborated the higher hazards ratios for all-cause mortality in these 
patients.
Conclusions: We found that patients with lower ScvO2 and higher RBV levels had 
higher mortality. These findings may be related to patients’ volume status and cardiac 
function. References Hanjie Zhang et. al. Association of intradialytic relative blood volume 
and central-venous oxygen saturation with mortality among hemodialysis patients. ERA 
EDTA 2018 abstract.
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Association Between Reduction of Extracellular Volume by In-Center 
Short Daily Hemodialysis and Survival
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Background: Overhydration (OH) is associated with a higher mortality risk in 
maintenance hemodialysis. A better management of OH through daily hemodialysis (DHD) 
could improve survival.
Methods: Retrospective analysis of patients on hemodialysis 3 sessions/week for >3 
months who shifted to in-center short DHD (≥ 5 sessions / week) between 2012 and 2016 
at 23 dialysis units in Brazil. Hydration status was evaluated before and 6 months after 
initiating DHD by bioimpedance spectroscopy. Pre-dialysis hydration state was considered 
adequate when OH ≤15% of extracellular volume. For survival analysis, data were censored 
2 years after initiating DHD.
Results: A total of 208 patients were included in the analysis (56±16 years old, 64% 
males, 38% diabetics, 56% on dialysis 6 sessions/week, treatment time was 12.5±1.8 h/week. 
After 6 months on DHD, 177 patients were re-evaluated. OH was reduced from 13.9% 
(IQR 5.4 – 22.3%) to 8.9% (IQR 0.4 – 15.9%), P<0.0001, the rate of patients with OH>15% 
dropped from 47% to 29% (P= 0.0005) and pre-dialysis systolic blood pressure fell from 
139±21 mmHg to 134±21 mmHg (P= 0.029). The 2-year survival rate was 76%, with no 
difference according to the OH status before DHD initiation (P= 0.92). However, survival 
was higher for patients reached OH ≤15% after the beginning of DHD than those with 
OH >15% (83% vs. 70%; P= 0.02). In a Cox regression model, after adjustment for 
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demographic, clinical and laboratory variables, OH ≤15% persisted associated with a lower 
mortality risk (hazard ratio 0.40 [95% confidence interval 0.18 – 0.90]).
Conclusions: Moving from standard hemodialysis to short DHD was associated with 
a better control of excessive extracellular volume and blood pressure. Patients who reached 
OH ≤15% after initiating DHD presented a lower risk of death.
FR-PO815 Poster Friday
Dialysis: Hospitalization and Mortality
Weight loss Increases Risk of Cardiovascular Events and Mortality in 
Incident Dialysis Patients
Sawako Kato,1 Bengt Lindholm,2 Yukio Yuzawa,3 Shoichi Maruyama.1 1Nagoya 
University Graduate School of Medicine, Aichi, Japan; 2Karolinska Institutet, 
Stockholm, Sweden; 3Fujita Health University School of Medicine, Toyoake, 
Japan.
Background: Protein-energy wasting is a common and established risk of 
cardiovascular events and mortality in dialysis patients, while obesity is associated with a 
greater survival as well known “reverse epidemiology”. Recent study suggested that short-
term weight loss was more associated with worse outcome. Here we explored if weight loss 
just before initiation of dialysis could predict CVD events and mortality among incident 
dialysis patients.
Methods: In an ongoing prospective cohort study, 175 incident Japanese dialysis 
patients (113 males, age 59 ±11 years) were enrolled and followed for a median of 55.2 
months (range 1-112 months). Laboratory biomarkers were determined at baseline. We 
defined [dry weight of the first month of start dialysis therapy] – [body weight at 6 months 
before start dialysis therapy] as the delta body weight (DBW), patients with over 5kg weight 
loss during this term as weight loss and patients with under 5kg weight loss or weight gain 
as stable weight, respectively.
Results: In Spearman rank test, DBW negatively correlated with body weight 
(rho=-0.15, P=0.042), abdominal circumference (rho=-0.21, P=0.007), serum CRP 
(rho=-0.17, P=0.032) and cardiothoracic ratio (rho=-0.20, P=0.013), while there was no 
correlation between DBW and body mass index (BMI). In Kaplan-Meier curves, the CVD 
death was associated with weight loss (Log rank 5.91, P = 0.015). And the duration from 
start of dialysis therapy to the first CVD events was significantly shorter in patients with 
weight loss (Log rank 10.74, P = 0.001). In Cox hazard model, after adjustments for age, 
gender, and BMI, the weight loss had a significantly increased relative risk of CVD deaths 
(2.89, 95% CI; 1.05-9.22, P = 0.0385).
Conclusions: In Japanese incident dialysis patients, short-term weight loss just before 
initiation dialysis therapy associated with increased risk of CVD deaths and events. These 
results may suggest that we should pay attention to lean losing weight rather than physical 
status.
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Association of White Blood Cell Count with Survival in Incident 
Hemodialysis Patients
Tiffany Zai,1 Christina Park,1 Jui-Ting Hsiung,1 Melissa Soohoo,1 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh,1 Elani Streja.1 1Harold Simmons 
Center for Kidney Disease Research and Epidemiology, Division of Nephrology 
and Hypertension, University of California, Irvine, Orange, CA; 2University of 
Tennessee Health Science Center, Memphis, TN.
Background: Higher white blood cell counts (WBC) have been shown to be strongly 
and independently associated with all-cause mortality in maintenance hemodialysis (HD) 
and incident peritoneal dialysis patients; however, the association between WBC count and 
mortality in incident HD patients has been understudied.
Methods: We retrospectively examined a cohort of 109,767 incident HD patients 
receiving treatment within a large dialysis organization from 2007-2011, with available 
WBC measurements during the first 91-days of dialysis. Patients were grouped into 6 
WBC categories. Using Cox models, we examined the association between WBC count 
and all-cause mortality with hierarchical adjustments for case-mix variables, albumin and 
additional laboratory markers of malnutrition and inflammation (MICS).
Results: Mean patient age of the cohort was 63±15 years; 44% of patients were female, 
32% were African American, and 58% were diabetic. Mean WBC count was 7.82±2.68 
x103/mm3. Compared to the reference group of WBC 7.0-<8.0 x103/mm3, we observed 
a J-shaped association between WBC and mortality. Patients with low WBC (<6.0 x103/
mm3) had a higher risk of mortality (hazard ratio (HR): 1.04 [95% CI: 1.00, 1.08]), and 
patients with greater WBC (>9.0 x103/mm3) had the highest risks of mortality in case-mix 
adjusted models. After further adjustment for albumin and MICS covariates, associations 
were modestly attenuated; however, patients with WBC >9.0 x103/mm3 still had a higher 
mortality risk compared to the referent [figure1].
Conclusions: Among incident HD patients, higher WBC count is associated with 
higher mortality risk, independent of other markers of malnutrition and inflammation, 
including albumin. These data suggest that WBC count may need closer monitoring in 
patients who are new to dialysis, but further studies are needed to examine this relationship.
Funding: NIDDK Support
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Intradialytic Relative Blood Volume Changes and All-Cause Mortality 
Among Hemodialysis Patients
Priscila Preciado,1 Hanjie Zhang,1 Stephan Thijssen,1 Jeroen Kooman,2 
Frank van der Sande,2 Peter Kotanko.1 1Renal Research Institute, New York, NY; 
2Maastricht University Medical Centre, Maastricht, Netherlands.
Background: Adequate volume control is a major challenge in hemodialysis (HD) 
patients, as both fluid overload and depletion are associated with increased mortality. 
Ultrafiltration is the only means for fluid removal in anephric patients. Whenever the 
ultrafiltration rate (UFR) exceeds the plasma refilling rate, the blood volume declines and 
hypotension may ensue. Relative blood volume (RBV) monitoring during HD is used as a 
means to tailor UFR. Our goal was to explore the association between intradialytic RBV 
levels and all-cause mortality in maintenance HD patients
Methods: We conducted a retrospective analysis of data from HD patients dialyzed 
in 17 Renal Research Institute clinics between 1/2012 and 12/2016. A 6-months baseline 
period preceded a follow-up. Censoring events were change in treatment modality, transfer 
to another clinic, and study end. RBV was measured using the Critline monitor. RBV was 
assessed after 25%, 50%, 75% and 100% of the elapsed treatment time. The relationship 
between mortality and RBV at these four time points was analyzed using Cox proportional 
hazards models with spline terms
Results: We studied 842 patients with a total of 28,119 HD treatments (mean age 
61.0±14.8 years, 50% whites, 62% males, 56% had diabetes mellitus, 22% had congestive 
heart failure). Median follow-up time was 30.8 months. The mortality rate was 11.5/100 
patient years. We identified specific intradialytic RBV levels after 25%, 50%, 75% and 
100% of the elapsed dialysis treatment time that were associated with a significantly lower 
all-cause mortality [Fig 1].
Conclusions: We showed in a large cohort of HD patients that specific RBV levels 
are associated with better outcomes. These findings corroborate the notion that RBV 
monitoring has the potential to improve outcomes. Prospective studies are warranted to 
explore if active attainment of these RBV levels translates into improved patient outcomes.
Fig 1. Intradialytic RBV ranges associated with hazard ratios significantly below 1.0 for 
all-cause mortality.
Dialysis: Hospitalization and Mortality
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
635
J Am Soc Nephrol 29: 2018 Poster/Friday
FR-PO818 Poster Friday
Dialysis: Hospitalization and Mortality
Synergic Impact of BMI, Diabetes, and Age on Long-Term Mortality in 
Incident Japanese Hemodialysis Patients: A Cohort Study of the Large 
National Dialysis Registry
Tatsunori Toida,1,2 Yuji Sato,3 Satoshi Ogata,4 Atshushi Wada,4 Ikuto Masakane,4 
Shouichi Fujimoto.1 1Department of Hemovascular Medicine and Artificial 
Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; 
2Department of Internal Medicine, Nobeoka Hospital of Miyazaki Prefecture, 
Nobeoka city, Japan; 3Dialysis Division, University of Miyazaki Hospital, 
Miyazaki, Japan; 4Committee of Renal Data Registry, The Japanese Society for 
Dialysis Therapy, Tokyo, Japan.
Background: In general Japanese with diabetes, leanness has been associated with an 
increased risk of all-cause mortality. However, it currently remains unclear whether BMI 
and age influence the prognosis of diabetic patients who start hemodialysis.
Methods: Study design: Cohort study. Participants: Data from the national dialysis 
registry in 2007, including 35,415 patients on incident hemodialysis and 6,061 patients 
aged ≥20 years with BMI data. Predictor: Patients were divided into 6 categories according 
to baseline BMI levels (Leanness: <18.5, Normal: 18.5-25, Obesity: ≥25) and the 
presence or absence of diabetes. Outcomes: All-cause mortality during a 5-year follow-
up. Measurements: Hazard ratios were estimated using Cox’s model for the relationships 
between diabetes, BMI categories, and all-cause mortality, and adjusted for potential 
confounders including sex, age, systolic BP values, a previous history of cardiovascular 
disease, and so on. Patients with normal BMI levels without diabetes were set as our 
reference category. We also examined the effects of age on these relationships.
Results: Among 3239 and 2822 patients with or without diabetes, 993 and 887 patients 
died of all-cause mortality, respectively. Cox’s regression analysis showed that leanness, 
but not obesity, was independently associated with an increased risk of all-cause death in 
patients with and without diabetes. When patients were divided into two groups: younger 
and older than 60 years, the risk of all-cause death in the younger group was markedly 
increased among lean diabetic patients as well as among those with a normal BMI and 
diabetes, but not obesity. However, in the older group, the risk of death among diabetic 
patients with a normal BMI was not significantly different from that among those without 
diabetes. In diabetic patients of the older group, only leanness was associated with an 
increased risk of mortality.
Conclusions: Among incident Japanese hemodialysis patients, leanness, but not 
obesity, increases the risk of all-cause mortality. Particular attention must be paid to the 
markedly high mortality rate in lean diabetic patients regardless of age. Furthermore, 
diabetes may be associated with mortality in patients younger than 60 years with a normal 
BMI.
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A Higher Mortality Rate in Afebrile Bacteremia in Chronic Hemodialysis 
Patients
Keun-hoi Park, Wonhak Kim, Soon Bae Kim. Seoul Asan Medical Center, 
Seoul, Republic of Korea.
Background: Body temperature (BT) has received little attention as a prognostic factor 
in hemodialysis patients. Some previous studies reported that fever in initial bacteremia is 
associated with better survival. Therefore, we aimed to analyze the difference in hospital 
mortality between febrile and afebrile chronic hemodialysis (CHD) patients with bacteremia 
and investigated positive blood culture rate according to the C-reactive protein (CRP) level.
Methods: The blood culture data in CHD patients from 2006 to 2014 were collected 
and the bacteremic events were assigned to either “febrile group” or “afebrile group” 
based on the BT measured on the day of blood culture. Fever was defined as a tympanic 
temperature > 37.5 degrees Celsius or an axillary temperature > 37.0 degrees Celsius. 
Empirical antibiotics were administered immediately after blood culture. Laboratory values 
were considered only for the day of blood culture sampling. The primary outcome was in-
hospital mortality rate, the length of ICU stay and the length of hospitalization.
Results: From a total of 1556 blood cultures, 190 bacteremias were identified excluding 
cases of immunosuppressive agents or anti-cancer drug use and cases of delayed blood 
culture. Both the febrile group (n=162) and afebrile group (n=28) showed no difference 
in baseline characteristics. With regard to primary outcome, in-hospital mortality rate was 
higher in the afebrile group (41.4% vs. 6.1%) and the interval from admission to blood 
culture was longer in the afebrile group (3 hours v. 1 hour). The major reason for blood 
culture in the afebrile group was a high CRP level. Assessing the positive blood culture 
rate according to the CRP level in all the 1556 cultures, we found that the rate was 5.7 % 
(34/600) in patients with CRP levels <5mg/dL, 15.1 % (44/292) in those with CRP levels 
between 5 and 10 mg/dL, and 23.8 % (158/664) in those with CRP levels >=10 mg/dL.
Conclusions: An afebrile state with bacteremia in CHD patients was associated with a 
higher in-hospital mortality rate. Therefore, a prompt blood culture and empirical antibiotics 
administration should be considered in CHD patients with high CRP levels irrespective of 
fever.
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Dialysis: Hospitalization and Mortality
Long-Term Blood Pressure Variability Better Predicts All-Cause Mortality 
in Hemodialysis Patients than Intradialytic Blood Pressure Variability
Ruoxi Liao,1 Li P. Lin,1 Jiameng Li,3 Yuqin Xiong,2 Yupei Li,1 Baihai Su.3 1West 
China Hospital, Sichuan University, Chengdu, China; 2West China Medical 
School, West China Hospital, Sichuan University, Chengdu, China; 3West China 
Hospital of Sichuan University, Chengdu, China.
Background: Blood pressure variability (BPV) is a potential prognostic predictor 
for all-cause mortality. Here we conducted a retrospective cohort study to compare 
the affecting factors and prognostic ability of long-term BPV with intradialytic BPV in 
hemodialysis(HD) patients.
Methods: We included 611 HD patients, collected their baseline characteristics 
including one-year blood pressure, and followed up for 40 months. Long-term BPV was 
assessed by pre-dialysis SBP residual metric, while intradialytic BPV was assessed by 
intradialytic absolute SBP residual.
Results: Long-term BPV showed a correlation with intradialytic BPV (Spearman r from 
0.5997 to 0.6883). According to logistic regression, both long-term and intradialytic BPV 
were associated with age, vascular access type, dialysis time, dialysis vintage, pre-dialysis 
blood pressure and serum albumin(Alb), while only intradilytic BPV was affected by body 
mass index (Fig 1 A-D). High long-term BPV but not intradialytic BPV was associated 
with high all-cause mortality (p= 0.0047 and 0.3682, respectively)(Fig 1 E-F). According to 
receiver operating characteristic (ROC) curve with mortality as dependent variable, long-
term SBP residual metric showed a stronger prognostic ability than intradialytic BPV (area 
under curve [AUC] 0.679 vs. 0.568, p=0.0381), which was more significant in patients with 
blood pressure≥140/90mmHg (AUC 0.713 vs. 0.556, p=0.0191)(Fig1 G-H). After complete 
adjustments, long-term BPV remained significantly associated with all-cause mortality 
(hazard ratio 1.628 per quartile; 95% confidence interval, 1.086 to 2.441).
Conclusions: Our results implied an advantage of long-term BPV in predicting all-
cause mortality in HD patients, suggesting long-term BPV as an additional target of blood 
pressure management.
Funding: Government Support - Non-U.S.
Fig 1. Affecting factors and prognostic ability of intradialytic and long-term BPV
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Predialysis Hyponatremia and Post-Dialysis Elevation in Serum Sodium 
Concentration During Hemodialysis as Significant Predictors of Mortality 
in Patients Undergoing Hemodialysis
Kiichiro Fujisaki,1 Nobuhiko Joki,2 Shigeru Tanaka,3 Eiichiro Kanda,4 
Takayuki Hamano,5 Ikuto Masakane,6 Kazuhiko Tsuruya.7 1Kyushu University 
Hospital, Fukuoka, Japan; 2TOHO University Ohashi Medical Center, Tokyo, 
Japan; 3Fukuoka Dental College, Fukuoka, Japan; 4Kawasaki Medical School, 
Kurashiki, Japan; 5Osaka University Graduate School of Medicine, Suita, 
Japan; 6Honcho-Yabuki Clinic, Yamagata, Japan; 7Nara Medical University, 
Kashihara, Japan.
Background: Previous studies have reported that hyponatremia is associated with 
increased mortality in hemodialysis (HD) patients. However, there have been few reports on 
studying the fluctuation of serum sodium (Na) concentration during HD (ΔNa: postdialysis 
Na – predialysis Na) in HD patients. We conducted this cohort study using a nation-wide 
registry of patients with end-stage renal disease in Japan to examine the association of 
predialysis hyponatremia and ΔNa during HD with mortality.
Methods: We identified 178,114 patients from a nation-wide database of HD patients 
receiving thrice-weekly HD in Japan. The study outcome was 2-year all-cause mortality and 
baseline Na levels were categorized into quintiles. We examined the association of serum 
Na concentration and ΔNa with the mortality using a Cox proportional hazards model.
Results: During a 2-year follow-up period, 25928 patients died from any cause. Each 
1-mEq/L decrement in pre-dialysis Na concentration was associated with increased risk
of all-cause death (Hazard ratio [HR], 1.05; 95% confidence interval [Cl], 1.05-1.06). 
In contrast, higher ΔNa level was associated with higher all-cause mortality (HR for 1
mEq/L increment in ΔNa, 1.02; 95% Cl, 1.01-1.02). The combined association of tertiles
of predialysis Na concentration and ΔNa with all-cause mortality showed the highest
mortality (HR 1.09, 95% CI 1.05–1.13) in subjects with the lowest Na concentration (Na
≤136 mEq/L) and the highest ΔNa level (ΔNa >4 mEq/L) compared with those (reference) 
with intermediate predialysis Na concentration (137–140 mEq/L) and the lowest ΔNa level 
(ΔNa ≤2 mEq/L).
Conclusions: Lower predialysis Na concentration and higher ΔNa are associated with 
an increased risk of death in HD patients.
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Blood Pressure Variability along Hemodialysis: Is It Related to Mortality?
Eduardo Baamonde,1 Elena Oliva-Damaso,1 Nicanor Vega-diaz,1 
Roberto Gallego Samper,2 Nestor Oliva-Damaso,3 Silvia Marrero- Robayna,1 
Jose C. Rodriguez-Perez.1 1Hospital General Universitario de Gran Canaria Dr 
Negrin, Las Palmas, Spain; 2Hospital Universitario de Gran Canaria Dr 
Negrin, Las Palmas de Gran Canaria, Spain; 3Hospital Costa del Sol, Marbella, 
Spain.
Background: Recent studies, link Hemodialysis systolic blood pressure (BP) variability 
and mortality. However BP variability can be seen with different (BP) components, 
including systolic and diastolic as well as predialysis, intradialytic, and postdialysis BP. 
Aims: To analyze BP variability in different measurements along Hemodialisys (HD) 
session and verify which of them predict mortality in incident patients.
Methods: Retrospective analysis of 277 incidents patients on conventional HD. 
BP records were collected throughout the hemodialysis sessions from the beginning 
of treatment. BP variability was calculated using the coefficient of variation (CV). 
Demographic and clinical data were analyzed during a 24 month follow-period as well as 
mortality rate. Survival analisys (Cox proportional hazards) was carried out by stratifying 
patients in tertiles of BP variability.
Results: 277 incident HD patiens (186 M, 91 F). Age (yr): 65,1 ± 13,1. Sex (%men): 
67,1. Diabetes (%): 45,8. Hypertension (%): 95. Systolic preHD BP (mmHg): 137,6 ± 
14,5 CV: 11,5 ± 3,7, Diastolic preHD BP (mmHg): 73,3 ± 6,8. CV:12,1 ± 7,7. Systolic 
postHD BP(mmHg) : 137,2 ± 14,7. CV: 11,2 ± 3,05. Diastolic postHD BP: 73,5 ± 6,5. CV: 
13,5 ± 14,5. We observed 51 deaths (18,4%) during the follow-up period. Higher Diastolic 
post hemodialisys blood pressure variability (DBPV) was associated with an increased 
risk of death, as shown in the table below (Fig1). Survival analysis (Kaplan-Meyer) shows 
significative differences between tertiles of DBPV (p<0.009) (Fig2).
Conclusions: In our study we observed and increased risk of mortality in patients with 
higher diastolic blood pressure variability, especially those with greater variability post 
hemodialysis.
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The Impact of Sunlight Exposure on Mortality of ESRD Patients: A 
Bi-Directional Case-Crossover Study in the Korean Nation-Wide ESRD 
Cohort
Yong Chul Kim,1 Soie Kwon,2 Jung Nam An,3 Dong Ki Kim,4 Chun Soo Lim,3 
Jung Pyo Lee.3 1SNUH, Seoul, Republic of Korea; 2Seoul national university, 
Seoul, Republic of Korea; 3Seoul National University Boramae Medical Center, 
Seoul, SEOUL, Republic of Korea; 4Seoul National University Hospital, Seoul, 
Republic of Korea.
Background: Recent data suggest that reduced sunlight exposure is associated with 
increased mortality in the general population. To date, the association between sunlight 
exposure and mortality in dialysis patients has not been examined.
Methods: Among 134,478 dialysis patients in the Korean end-stage renal disease 
(ESRD) cohort from 2001 to 2014, 31,291 patients were enrolled from seven metropolitan 
cities, and data were analyzed using bi-directional case-crossover design. We examined 
the association between short-term sunlight exposure and mortality in ESRD patients. We 
adjusted for temperature, humidity, and daily concentrations of nitrogen dioxide (NO2), 
sulfur dioxide (SO2), ozone (O3), carbon monoxide (CO), and particle matter (PM10) as 
confounders.
Results: The characteristics of the study population included age (65.6 ± 12.26 (mean 
± standard deviation [SD]) years), sex (male, 59.96%; female, 41.04%), comorbidity 
(diabetes, 53.58%; hypertension, 40.5%), and kidney dialysis type (hemodialysis, 73.02%; 
peritoneal dialysis, 26.98 %). The mean ± SD follow-up time was 4.68 ± 4.37 years. The
daily sunlight exposure was significantly decreased in the case group compared with the 
control group (P=0.004). Sunlight exposure was associated with all-cause death overall
(ORs [95%CI]: 0.99 [0.98-0.99], P=0.042) in a fully adjusted model. Patients with diabetes 
(ORs [95%CI]: 0.98 [0.97-0.99], P=0.016) or aged higher than 75 years (ORs [95%CI]; 
0.97 [0.96 – 0.99], P=0.020) had higher risks of mortality than patients without diabetes or 
aged below 75 years, respectively.
Conclusions: These findings suggest that sunlight exposure is inversely correlated with 
all-cause mortality in dialysis patients, especially in high-risk patients with diabetes and 
older adults.
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Association Between Endothelin-1 Levels and Mortality Among Hemodi-
alysis Patients
Ping Li,1,2 Finnian R. McCausland,1 Sushrut S. Waikar.1 1Harvard Medical 
School, Boston, MA; 2Department of Nephrology, State Key Laboratory of 
Kidney Disease, 2011DAV00088, National Clinical Research Center for Kidney 
Disease, 2013BAI09B05, Chinese PLA General Hospital, Beijing, China.
Background: Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor 
peptide implicated in the pathogenesis of hypertension, heart failure, and CKD. The 
association of endothelin with adverse outcomes in individuals with end stage renal disease 
on hemodialysis is unclear.
Methods: We measured pre-dialysis plasma levels of ET-1 in 794 individuals with 
ESRD on maintenance hemodialysis from the DaVita BioReg Biorepository, a prospective 
cohort study of prevalent hemodialysis patients. ET-1 was measured with a commercially 
available ELISA, with CV’s of 7.3% from blind split replicate samples. Unadjusted and 
adjusted proportional hazards regression models were fit to exam the association of ET-1 
with all- cause mortality.
Results: Mean age was 60, 41.4% were women, and median vintage was 37.2 months. 
Median (IQR) endothelin-1 concentration was 2.02 (1.56 – 2.71) pg/mL. ET-1 levels were 
positively correlated with pre-dialysis blood pressure (r=0.13, p<0.001), weight difference 
before and after dialysis (r=0.119, P<0.001) and longer dialysis vintage (r=0.084, P=0.019). 
In multivariable proportional hazards models adjusted for age, race, sex, BP, BMI, vintage, 
laboratory variables, and dialysis access, higher ET-1 levels were associated with a 37% 
higher risk of all-cause mortality (hazard ratio 1.37; 95% confidence interval, 1.23 to 1.53; 
P < 0.001) during median 27.8 months of follow-up time.
Conclusions: Higher pre-dialysis plasma ET-1 levels are associated with an increased 
risk of death. The mechanisms underlying this association and its potential therapeutic 
relevance merit further investigation.
FR-PO825 Poster Friday
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Beta-2 Microglobulin Levels and All-Cause Mortality: Results from the 
Dialysis Outcomes and Practice Patterns Study (DOPPS)
Jeffrey Perl,1 Daniel G. Muenz,2 Brian Bieber,2 Aleix Cases,3 Eiichiro Kanda,4 
Francesco Locatelli,5 Hal Morgenstern,6 Friedrich K. Port,2 Bruce M. Robinson.2 
1St. Michael’s Hospital, Toronto, ON, Canada; 2Arbor Research Collaborative 
for Health, Ann Arbor, MI; 3Nephrology Department, Hospital Clinic, Barcelona, 
Spain; 4Kawasaki Medical School, Kurashiki, Japan; 5Ospedale Alessandro 
Manzoni, Azienda Socio Sanitaria Territoriale, Lecco, Italy; 6University of 
Michigan, Ann Arbor, MI.
Background: Dialysis-related amyloidosis due to beta-2 microglobulin (β2M) 
accumulation among hemodialysis (HD) patients is now uncommon due to HD delivery 
improvements. The impact of β2M levels and other middle molecules on other adverse 
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events among HD patients remains unclear. We sought to identify patient factors that may 
affect β2M level and estimate the effect of β2M on mortality.
Methods: Facilities in DOPPS phases 4-6 were included in this study if ≥50% of 
patients had β2M levels reported in ≥50% of follow-up rounds. Cox regression was used to 
estimate the association (hazard ratio [HR]; 95% CI) between β2M, categorized in tertiles, 
and all-cause mortality, adjusting for demographic factors, comorbidities, HD treatment 
factors, and stratified by study phase and region (Japan vs. Europe).
Results: We identified 5366 patients from 77 HD facilities in Japan (n=3837), France, 
Italy, and Spain (n=1529). Median (IQR) values of β2M (mg/dL) were 2.58 (2.17-3.00) in 
Japan and 2.55 (1.98-3.21) in Europe. In cross-sectional, unadjusted analysis, patients in the 
upper β2M tertile had longer dialysis vintage, greater likelihood of urine volume <200mL/
day, lower prevalence of diabetes, higher serum phosphorus, and higher C-reactive protein, 
relative to the lower β2M tertile. Little association was observed between β2M and HD 
treatment time. Compared with the lower β2M tertile, the adjusted HR for mortality was 
1.20 (0.98-1.48, 95% CI) for the middle tertile and 1.44 (1.17-1.75, 95% CI) for the upper 
tertile (Figure).
Conclusions: β2M is positively associated with mortality, controlling for several 
potential confounders. Interventions targeting greater β2M clearance during HD therapy 
may be an effective therapeutic strategy to improve outcomes among these patients.
Funding: NIDDK Support, Commercial Support - The DOPPS Program is supported 
by Amgen, Kyowa Hakko Kirin, Baxter Healthcare. Additional support for specific 
projects and countries is provided by AstraZeneca, European Renal Association-European 
Dialysis & Transplant Association (ERA-EDTA), Fresenius Medical Care Asia-Pacific Ltd, 
Fresenius Medical Care Canada Ltd, German Society of Nephrology (DGfN), Janssen, 
Japanese Society for Peritoneal Dialysis (JSPD), Keryx, Kidney Care UK, MEDICE 
Arzneimittel Pütter GmbH & Co KG, Proteon, and Vifor Fresenius Medical Care Renal 
Pharma. Public funding and support is provided for specific DOPPS projects, ancillary 
studies, or affiliated research projects by National Health & Medical Research Council 
(NHMRC) in Australia, Cancer Care Ontario (CCO) through the Ontario Renal Network 
(ORN) in Canada, French National Institute of Health and Medical Research (INSERM) 
in France, Thailand Research Foundation (TRF), Chulalongkorn University Matching 
Fund, King Chulalongkorn Memorial Hospital Matching Fund, and the National Research 
Council of Thailand (NRCT) in Thailand, National Institute for Health Research (NIHR) 
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Polyvascular Disease and Cardiovascular Risk in Hemodialysis Patients: 
Ten-Year Outcomes of the Q-Cohort Study
Shigeru Tanaka,1 Toshiaki Nakano,2 Hiroto Hiyamuta,2 Masatomo Taniguchi,3 
Masanori Tokumoto,4 Hiroaki Ooboshi,1 Kazuhiko Tsuruya,5 Takanari Kitazono.6 
1Fukuoka Dental College, Fukuoka, Japan; 2Kyushu University, Fukuoka, 
Japan; 3Fukuoka Renal Clinic, Fukuoka, Japan; 4Department of Internal 
Medicine, Fukuoka Dental College, Sawara-ku, Japan; 5Nara Medical 
University, Kashihara, Japan; 6Department of Medicine and Clinical Science, 
Fukuoka, Japan.
Background: Patients with polyvascular disease (PVD), which indicates co-existing 
arteriosclerotic disease on multiple vascular beds, have been identified to be a high-risk 
group of recurrent ischemic events in a community setting. However, the impact of PVD 
on the risk of cardiovascular events has not been evaluated previously in a hemodialysis 
population.
Methods: A total of 3,504 hemodialysis patients were prospectively followed for 
10 years. PVD were defined as prior cardiovascular disease plus co-existing vascular 
diseases in one or more vascular beds. We examined the relationship between PVD and 
the occurrence of composite end point of ischemic events, including cardiovascular death, 
non-fatal coronary artery disease, stroke, and critical limb ischemia.
Results: The proportion of participants with PVD was 5.7% (n=200) at baseline. 
During follow-up period (median: 106.6 months, interquartile range: 50.1–121.8 months), 
1,316 patients experienced at least 1 or more events of cardiovascular death (n=620), non-
fatal coronary artery disease (n=456), stroke (n=524) or critical limb ischemia (n=257). In 
multivariable analysis, PVD was the most powerful predictor for ischemic events exceeding 
the contribution of presumed risk factors such as diabetes, aging and hypertension. 
Compared to the group without injured vascular beds, the risk of the events significantly 
elevated with the increase in the number of injured vascular beds (hazard ratio [HR] 1.71, 
95% confidence interval [CI] 1.52–1.92 in the group of single vascular bed lesions, and HR 
2.16, 95% CI 1.78–2.67 in the group of polyvascular bed lesions).
Conclusions: This study clearly demonstrates that PVD is the most powerful predictor 
for future incidences of ischemic events in hemodialysis patients.
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An Inverse Association of Proteinuria with Mortality in Incident 
Hemodialysis Patients
Manabu Hishida,1 Tariq Shafi,2 Lawrence J. Appel,3 Daijo Inaguma,4 
Kunihiro Matsushita.5 1Epidemiology, Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD; 2Johns Hopkins University School of Medicine, 
Baltimore, MD; 3Johns Hopkins Medical Institutions, Baltimore, MD; 
4Nephrology, Fujita Health University, Nagoya, Japan; 5Johns Hopkins 
Bloomberg School of Public Health, Baltimore, MD.
Background: Proteinuria is a potent predictor of mortality. However, in patients with 
severely reduced kidney function, a few studies from the CKD Prognosis Consortium and 
Veterans Affairs showed a J-shaped association between proteinuria and mortality. To our 
knowledge, no studies have explored this association in incident dialysis patients.
Methods: We examined data from 1380 Japanese incident dialysis patients (mean age 
67 years). Baseline data were collected just before or during the hospitalization at which 
dialysis was initiated. The associations of dipstick proteinuria (negative/trace, 1+, 2+ and 
≥3+) with all-cause mortality and cardiovascular disease (CVD) mortality were quantified 
in Cox models after accounting for potential confounders such as age, cause of CKD, and 
history of CVD.
Results: Proteinuria ≥3+ was the most prevalent category (n=765 [55.4%]), followed 
by 2+ (430 [31.2%]), 1+ (137 [9.9%]), and negative/trace (48 [3.5%]). Patients with lower 
proteinuria were likely to be older and have a history of CVD, compared to the patients with 
higher proteinuria. During a mean follow-up of 3.3 years, there were 352 deaths (129 due 
to CVD). Patients with lower proteinuria had a higher risk of mortality, with unadjusted 
hazard ratios 3.86 (2.55-5.85) for negative/trace, 1.62 (1.16-2.26) for 1+, and 1.35 (1.07-
1.71) for 2+ (Model 1 in Table). Although attenuated, this pattern remained significant after 
accounting for potential confounders (p for trend ≤0.001 and adjusted hazard ratio 2.60 
[1.62-4.17] for negative/trace in Model 4 in Table). This association was consistent for CVD 
and no-CVD mortality, even when restricting to adults aged ≥70 years, or further adjusting 
for cardiac ejection fraction.
Conclusions: We documented a progressive inverse trend of proteinuria with mortality 
among incident dialysis patients, with a strikingly high risk of mortality in persons with 
negative/trace proteinuria. Our study highlights the prognostic value of predialysis data 
and suggests that absence of proteinuria as a potential indicator of the highest postdialysis 
mortality risk.
Funding: Private Foundation Support
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Low Eosinophil Count and Decrease in Eosinophil Count During the First 
6 Months After Hemodialysis (HD) Are Associated with High Mortality
Duk-Hee Kang,1 Yong kyu Lee,1 Carola-Ellen Kleine,1 Connie Rhee,1 
Csaba P. Kovesdy,2 Elani Streja,1 Kamyar Kalantar-Zadeh.1 1Harold Simmons 
Center for Kidney Disease Research and Epidemiology, Division of Nephrology 
and Hypertension, University of California, Irvine, Orange, CA; 2University of 
Tennessee Health Science Center, Memphis, TN.
Background: Eosinophilia has been recognized to occur in HD patients, however its 
causes and clinical significance are still uncertain. Eosinophils are traditionally known as 
the moderator of allergic reactions, however they have now emerged as one of the most 
important immune-regulating cells, and an increase in eosinophil count is also reported 
to be a predictor of vascular disease in the general population. Associations of eosinophil 
count (EOS) and its changes with mortality in dialysis patients are still unknown.
Methods: In a cohort of 107,056 incident HD patients treated by a large dialysis 
organization during 2007-2011, we examined the relationships of baseline EOS (Q1-
average within 3 months of HD transition) and 6-month changes in EOS (Q2-Q1) with 
mortality using Cox proportional hazards models. Three adjustment models were used 
including case-mix variables and markers for malnutrition and inflammation.
Results: Baseline EOS and fraction during Q1 were 231 (interquartile range: 155-339) 
/mm3 and 3.2% (2.2-4.6). Eosinophilia (>350/mm3) was observed in 23.4% of patients. 
There was a gradual increase in mean EOS after the initiation of dialysis. The 6-month 
mean and percent changes in EOS were 5.1 (-53 to 199) /mm3/quarter and 0.11 (-0.22 to 
0.28) %/quarter, which did not parallel with the changes in WBC count. In fully adjusted 
models, mortality risk was highest in subjects with lower baseline EOS (<150/mm3), and 
also slightly higher in patients with higher levels (>550/mm3) resulting in a reverse J-shaped 
relationship. Compared to the group with stable EOS (change: -50 to <50/mm3/quarter), 
both decrease or increase in EOS was associated with higher all-cause mortality risk. Case-
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mix-adjusted HR [95% CI] 2.05 [1.93-2.18] in the decrease group and 1.25 [1.19-1.32] in 
the increase group, respectively. [Figure]
Conclusions: Low baseline EOS and a 6-month EOS decrease following dialysis 
initiation were associated with higher all cause mortality risk.
Funding: NIDDK Support
FR-PO829 Poster Friday
Dialysis: Hospitalization and Mortality
Syncope and Collapse Is Associated with an Increased Risk of Cardiovas-
cular Disease and Mortality in Patients Undergoing Dialysis
Tung-Min Yu. Taichung Veterans General Hospital, Taichung ---, Taiwan.
Background: Patients undergoing dialysis have a higher risk of cardiovascular 
disease and mortality than the general population. Syncope and collapse (SC) is often 
observed in patients before and after dialysis sessions. However, the epidemiology of SC 
is undetermined and the association between SC and cardiovascular outcomes in a dialysis 
population has not been discussed. This study explored the impact of SC on cardiovascular 
events and mortality.
Methods: This study retrospectively examined data of patients undergoing dialysis 
from population-based medical registries between 1998 and 2011. Patients undergoing 
dialysis who have SC (N = 3876) were selected as the study cohort and those without SC 
who were propensity score-matched at a 1:1 ratio were included as controls. Major adverse 
cardiovascular events (MACEs), included acute coronary syndrome (ACS), arrhythmia or 
cardiac arrest, stroke, and overall mortality, were evaluated and compared in both cohorts.
Results: In 2011, the incidence and prevalence rates of SC were 7.05% and 10.8%, 
respectively, in the dialysis population. The mean follow-up periods until the occurrence 
of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality in the SC cohort were 
3.51 ± 2.90, 3.43 ± 2.93, 3.74 ± 2.97, and 3.76 ± 2.98 years, respectively. Compared with 
the patients without SC, those with SC had higher incidence rates of ACS (30.1 vs. 24.7 
events/1000 people/year), arrhythmia or cardiac arrest (6.75 vs. 3.51 events/1000 people/
year), stroke (51.6 vs. 35.7 events/1000 people/year), and overall mortality (127.7 vs. 77.9 
deaths/1000 people/year). The SC cohort also had higher risks of ACS, arrhythmia or 
cardiac arrest, stroke, and overall mortality (adjusted hazard ratios: 1.28 [95% confidence 
interval (CI) = 1.11–1.46], 2.05 [95% CI = 1.50–2.82], 1.48 [95% CI = 1.33–1.66], and 1.79 
[95% CI = 1.67–1.92], respectively) than did the non-SC cohort.
Conclusions: SC was significantly associated with cardiovascular events and overall 
mortality in the patients on dialysis. SC may serve as a prodrome for cardiovascular 
comorbidities, thereby assisting clinicians in identifying high-risk patients.
FR-PO830 Poster Friday
Dialysis: Hospitalization and Mortality
Elevated Levels of Soluble ST2 but Not Galectin-3 Are Associated with 
Increased Risk of Mortality in Patients with Hemodialysis
Ae jin Kim, Kayeong Chun, Han Ro, Jae Hyun Chang, Hyun Hee Lee, 
Wookyung Chung, Ji Yong Jung. Division of Nephrology, Department of 
Internal Medicine, Gachon University Gil Medical Center, College of Medicine, 
Gachon University, Incheon, Republic of Korea.
Background: Soluble ST2 (sST2) and galectin-3 has been proposed as novel 
biomarkers of cardiac fibrosis and heart failure, and may also predict cardiovascular 
event and mortality. However, there are limited data on the association between sST2 and 
galectin-3 and clinical outcomes in patients with end-stage renal disease. To determine 
this, we examined associations of sST2 and galectin-3 with all-cause mortality and 
cardiovascular events in patients with hemodialysis (HD)
Methods: This study included maintenance HD patients 18 years or older who consent 
to preserve their serum to the Bio Bank at our institution between March 2014 and March 
2015. The primary outcome was all-cause mortality. The secondary outcome was composite 
of the cardiovascular event (CVE) and mortality. We used Cox proportional hazards 
regression analysis to evaluate associations between sST2 and galectin-3 levels and clinical 
outcomes. Patients were followed for CVE and mortality through March 2018.
Results: A total of 296 patients were analyzed in this study. Mean age was 57 ± 13 
years, 52.9% were male. The mean serum level of sST2 was 24.81 ± 12.43 ng/ml and 
mean serum level of galectin-3 was 35.50 ± 9.91 ng/ml. Serum sST2 concentration was 
significantly associated with higher mortality (hazard ratio [HR], 1.043; 95% confidence 
interval [CI], 1.017 – 1.070; P = 0.001) and composite outcome including CVE and 
mortality (HR, 1.022; 95% CI, 1.003 – 1.040; P = 0.022) after adjustment for confounding 
factors. However, serum galectin-3 level was not independently associated with mortality 
nor composite outcome after adjustment.
Conclusions: Elevated levels of sST2 is independently associated with increased risk 
of adverse clinical outcomes in patients with HD.
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Racial and Sex Disparities in Mortality in Incident ESRD Patients
Silvi Shah, Anthony C. Leonard, Karthikeyan Meganathan, Annette Christianson, 
Charuhas V. Thakar. University of Cincinnati, Cincinnati, OH.
Background: End Stage Renal Disease (ESRD) is a global public health problem; and 
is characterized by high morbidity and mortality. Although mortality in patients is highest 
during the first year of dialysis, differences in mortality across five different races among 
men and women is not well studied.
Methods: We evaluated 944, 650 adult patients who initiated dialysis between 1/1/2005 
and 12/31/2014 from the United States Renal Data System (USRDS). Using adjusted 
logistic multivariate regression models adjusted for major cofounders, we examined the 
effect of race and sex on all cause mortality after dialysis initiation.
Results: Mean age of the study population was 65±14 years. Of the study cohort, 56% 
were male. 53% were White, 28% were Black, 14% were Hispanic, 4% were Asian, and 
1% were Native American. Of those who started dialysis, 77% initiated with a catheter. 
Overall, 30% did not receive pre-dialysis nephrology care. One-year mortality was 24% 
and 90-day mortality was 9%. In adjusted analyses, as compared to Whites, one-year 
mortality was lower among Blacks (odds ratio [OR], 0.73; 95% confidence interval [CI], 
0.72-0.74]), Hispanics (OR, 0.64; CI, 0.63-0.65), Asians (OR, 0.55; CI, 0.53-0.56), and 
Native Americans (OR, 0.67; CI, 0.63-0.71). Females were less likely to die within one 
year after initiating dialysis than were males (OR, 0.98; CI, 0.97-0.99). Other significant 
predictors of mortality included absence of predialysis nephrology care, use of central 
venous catheter as dialysis access, older age, poor functional status, serum albumin 
< 3.5 mg/dl, and comorbidities (congestive heart failure, cancer, and chronic obstructive 
pulmonary disease).
Conclusions: Among incident dialysis patients; as compared to White patients, Black 
patients are 27% less likely, Hispanic patients 36% less likely, Asians patients 45% less 
likely, and Native Americans are 33% less likely to die within one year. Females have 
lower mortality than males. Biological factors associated with these disparities need to be 
explored further to understand the reasons behind the survival advantage among minorities 
and women.
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Impact of Transferrin Saturation on All-Cause Mortality in Patients on 
Maintenance Hemodialysis
Kosaku Nitta. Tokyo Women’s Medical University, Shinjuku-ku, Japan.
Background: To evaluate iron status, transferrin saturation (TSAT) and serum ferritin 
levels are commonly used. TSAT provides an assessment of how much transferrin has 
bound iron, whereas serum ferritin is a marker used to reflect body iron storage. Our aim 
was to evaluate the prognostic importance of TSAT in Japanese patients on maintenance 
hemodialysis (MHD).
Methods: A total of 398 MHD patients were recruited and divided into 3 groups 
according to baseline TSAT of <20%, 20–40%, and >40%. The mean duration of the study 
was 52.2 ± 16.3 months. The primary endpoint was all-cause mortality, and the secondary 
endpoint was cardiovascular (CV) mortality.
Results: A total of 130 patients died during a mean follow-up duration of 52.2 ± 16.3 
months. There were no differences in the proportion of patients on erythropoiesis-
stimulating agents or iron supplements among the 3 groups. During a mean follow-up 
duration of 52.2 ±1 6.3 months, 130 patients died of CV causes (n = 63, (15.8%) and 
infection (n = 47, 11.8%). Compared with the reference group (TSAT 20–40%), patients 
with TSAT <20% had significantly higher all-cause mortality rates (6.44 vs. 9.55 events per 
100 patient-year, p = 0.0452). Kaplan-Meier analysis also showed that all-cause mortality 
rates were significantly higher in patients with TSAT <20% compared to the other two 
groups (p =0.0353).
Conclusions: Low TSAT was a significant independent risk factor for all-cause 
mortality in a cohort of Japanese MHD patients. These findings suggested that the adverse 
clinical outcomes in patients with low TSAT can be partly attributed to iron-deficiency 
anemia.
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Modelling Survival in Dialysis Patients to Improve Their Access to Life 
Insurance for Loan
Christian Jacquelinet.1,2 on behalf the REIN Registry 1Agence de la biomedecine, 
Saint-Denis La Plaine, France; 2CESP-U1018, INSERM, Villejuif, France.
Background: “AERAS convention” (Access to Loan for People with Increased 
Health Risk Agreement) aims in France to provide insurance companies with evidence-
based data to improve their assessment of risk for patients with chronic diseases.Data from 
the French REIN registry were used to predict survival for ESRD patients who frequently 
face the highest difficulties to borrow money due to high (often precluding) life insurance 
premiums, especially for those under dialysis.
Methods: The study included a cohort of 27952 patients who started a replacement 
therapy between 2002-1-1 and 2016-12-31 at the age of 25 to 60 yo. We focus here on 
10-years survival conditionally on being alive and not previously transplanted at 1, 3 or
5 years. A Cox model was used to build multivariate risk functions for each conditional
time points, taking into account updated data from the closest annual follow-up. A 10-year 
survival threshold significantly greater than 90% with an unilateral alpha risk of 2.5% was 
considered as a proxy for considering a potential access to loan without major life insurance 
premiums.
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Results: Age, albuminemia, diabetes, number of cardio-vascular comorbidities, 
respiratory insufficiency, dialysis modalities and placement on the waiting list were 
significant and independent predictors of 10-years survival, with varying HRs and ß 
coefficients with conditional time points (e.g. 1, 3 or 5 years from dialysis start). C-indexes 
were greater than 0.6 and discrimination was good, as illustrated by quartile-stratified 
10-years survival conditionally on being alive and not previously transplanted at 5 years
(Figure 1). More than a quarter of patients who were 25 to 65 yo at start of dialysis and
respectively alive after 1, 3 and 5 years of dialysis are predicted with 10-year survival
greater than 90%.
Conclusions: ESRD registries indeed provide useful personalized tools to improve 
access to loan for many patients with ESRD, thus contributing to their social and 
professional integration of these patients, and finally to their quality of life.
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Cause of Death in Patients on Renal Replacement Therapy Varies Across 
Australia, New Zealand, and Malaysia - Results from the Study of Heart 
and Renal Protection-Extended Review (SHARP-ER)
Ben Talbot,1 Louisa Sukkar,1,3 Brendan Smyth,1,3 Min Jun,1 Meg J. Jardine,1 
Alan Cass,4 Robert J. Walker,2 Christina A. Reith,5 Hooi L. Seong,6 
Martin P. Gallagher.1 1The George Institute for Global Health, The University of 
New South Wales, Sydney, NSW, Australia; 2University of Otago, Dunedin, New 
Zealand; 3Sydney School of Public Health, The University of Sydney, Sydney, 
NSW, Australia; 4Menzies School of Health Research, Darwin, NT, Australia; 
5CTSU, Nuffield Department of Population Health, University of Oxford, 
Oxford, United Kingdom; 6Sultanah Aminah Hospital Johor Baru, Malaysia, 
Johor Bahru, Malaysia.
Background: The mortality rate among dialysis patients is high with regional 
variability. The Study of Heart and Renal Protection-Extended Review (SHARP-ER) 
comprised extended 5-year follow up of eligible participants in Australia, New Zealand and 
Malaysia alive at the end of SHARP (a randomised double-blind trial of simvastatin and 
ezetimibe vs. placebo in chronic kidney disease). We compared survival and cause of death 
between countries in dialysis patients in the SHARP-ER cohort.
Methods: Eligible participants in Australia, New Zealand and Malaysia alive at the 
end of SHARP were identified and extended 5-year follow up data collected. Cause of 
death was determined using registry data (national death index in Australia and New 
Zealand and national death registry in Malaysia) for participants receiving chronic dialysis 
(haemodialysis or peritoneal dialysis) at the beginning of the extended review period. 
Multivariate survival analysis and multinomial logistic regression were conducted to assess 
for differences.
Results: The cohort comprised 1136 participants in total. Of these, 526 were receiving 
chronic dialysis and were included in the analysis. During the 5 year follow up 203 died 
(38.6%). Median age was lowest in Malaysia (56.2 years [50.4-63.8]), followed by New 
Zealand (60.4 years [55.5-67.3]) and Australia (66.1 years [55.3-75.8]). Treating country 
did not significantly affect survival following adjustment for age, gender and dialysis 
modality. Cardiovascular disease was the most common cause of death (New Zealand 
52.4%, Australia 43.2%, Malaysia 32.6%). Infectious causes of death were significantly 
more common in Malaysia versus Australasia (Australia and New Zealand combined; RR 
4.56, p=0.002, 95% CI 1.75-11.85) following adjustment. Crude rates of infectious death 
by country were: Malaysia 31.8%, New Zealand 9.5%, Australia 6.8%. Peritoneal dialysis 
was also associated with an increased risk of infectious death (RR 3.64, p=0.017, 95%CI 
1.26-10.48) following adjustment.
Conclusions: In the SHARP-ER cohort, survival on dialysis was comparable between 
Australia, New Zealand and Malaysia but causes of death differed. This suggests a need for 
region specific interventions.
Funding: Government Support - Non-U.S.
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Prevalence of Oral Mucosal Lesions in Hemodialysis Patients and 
Association with Mortality: A Prospective Cohort Study
Marinella Ruospo, Marietta Török, Marco A. Murgo, Anna Bednarek, 
Domingo Del castillo caba, Amparo Bernat, Paul Stroumza, Charlotta Wollheim, 
Jorgen B. Hegbrant. Oral-D investigators: M Ruospo, S Palmer, P Natale, V 
Saglimbene, G Graziano, G Wong, J Craig, M Petruzzi, M De Benedittis, E 
Celia, R Gelfman, M Leal, M. Torok, A Bednarek-Skublewska, J Dulawa, D del 
Castillo, A Bernat, P Stroumza, L Frantzen, J Hegbrant, C Wollheim, L Gargano, 
S Schon and GFM Strippoli Diaverum Medical Scientific Office, Lund, Sweden.
Background: Oral mucosal lesions are highly prevalent and frequently severe for 
adults treated with longterm hemodialysis. We aimed to evaluate the prevalence of mucosal 
lesions and association with mortality among hemodialysis patients.
Methods: The ORAL-D study was a multinational cohort study that involved a 
comprehensive, standardized oral and dental examination among 4726 patients with 
ESKD disease treated with haemodialysis in Europe and South America. We evaluated 
oral mucosal lesions assessed by trained dentists according to standard WHO guidelines. 
The association between mucosal lesions and all-cause and cardiovascular mortality was 
estimated using a Cox proportional hazard regression model. Analyses were adjusted for 
sociodemographic and clinical variables. The primary outcome was all-cause mortality.
Results: 70 participants (1.7%) had mucosal ulceration, 147 (3.5%) presented white 
stain, 169 (4%) red stain, 85 (2%) neoformation, and 331 (7.9%) had petechial lesions. 
Overall, 207 (4.9%) had geographical tongue and 450 (10.7%) had a fissured tongue. 
Oral candidiasis was observed in 192 (4.6%) participants and 21 had oral herpetic lesions. 
401 participants (9.5%) had a cancer-related mucosal lesion and 213 participants (5%) an 
infection-related lesion. During a median 3.47 (1.55-5.78) months of follow-up, there were 
2114 deaths including 1013 cardiovascular deaths. In unadjusted survival analyses, the 
proportion of patients who died was higher among those with red stain, fissured tongue, and 
petechial lesions. Similarly, the estimated proportion of patients who had a cardiovascular 
death was higher among those with red stain, fissured tongue, petechial lesions, neoformation 
and oral candidiasis. When adjusting for clinical and sociodemographic factors, only the 
presence of oral candidiasis was significantly associated with an increased risk of all cause 
(adj HR 1.37, 95% CI 1.00-1.86) and cardiovascular mortality (adj HR 1.64, 95% CI 1.09-
2.46). This association was confirmed in competing risks analysis and using a shared frailty 
model to account for clustering by country.
Conclusions: There is generally limited evidence of an independent association 
between oral mucosal lesions and mortality outcomes among hemodialysis patients.
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Outcomes of Treatment of Myeloma in Patients Requiring Renal 
Replacement Therapy – A Single Centre Experience
Aruni Ratnayake, Mukunthan Srikantharajah, David Makanjuola, 
Simon C. Stern. Epsom and St Helier University Hospitals NHS Trust, London, 
United Kingdom.
Background: Renal impairment is a complication of multiple myeloma (MM). The 
incidence of renal impairment at diagnosis of MM is 20-50%; about 10% of these present 
with acute kidney injury requiring renal replacement therapy (RRT). Treatments including 
Bortezomib have improved prognosis with full or partial recovery of renal function; 
however they cause side effects e.g. peripheral neuropathy. We reviewed outcomes of MM 
treatments in patients requiring RRT over an 11 year period.
Methods: Patients diagnosed with MM requiring RRT between January 2007 - 
December 2017 were identified. Patient data was obtained from electronic records.
Results: 29 patients met the inclusion criteria. Median age 64 years (range 45-86); 
59% were male; 72% were Caucasian. Median follow up time was 33 months (range 8-96 
months). 65% (N=19) were treated with first line chemotherapy including Bortezomib; of 
these 84% showed complete (21%), or partial (63%) response to therapy. 1 year survival 
was 89% (N=19), 5 year survival 71% (N=14). Complications were thrombosis (11%), 
neuropathy (53%) and infection requiring hospital admission (42%). 37% recovered 
enough renal function to cease RRT. 35% (N=10) did not have Bortezomib as part of 
initial treatment. Of these 50% responded to therapy; all with partial response, none with 
complete response. 1 year survival was 90% (N=10), 5 year survival was 50% (N=10). 
Complications were thrombosis (20%) and infection requiring hospital admission (20%). 
No patient experienced neuropathy. Only 10% recovered sufficient renal function to stop 
RRT. Patients who gained dialysis independence had significant reduction of free light 
chains after 2 chemotherapy cycles (median 85%, range 61%-99%). Those who were still 
on RRT had more variation in change in free light chains ranging from -99% to +63%.
Conclusions: Our study coincides with the introduction of Bortezomib as first-line 
treatment in 2010. In our cohort, Bortezomib resulted in increased rates of response to first 
line therapy, greater likelihood of dialysis independence and improved overall survival. 
However, more side effects were associated with Bortezomib. As has been shown in 
patients with renal amyloid (Rezk et al, Kidney International 2017), reduction of free light 
chains post chemotherapy can be used as a predictor for dialysis independence and our 
results support this.
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End-of-Life Care Among Patients with ESRD Who Undergo a Lower 
Extremity Amputation
Catherine Butler,1 Susan M. Hailpern,4 Margaret Schwarze,6 Ronit Katz,1 
Manjula Kurella Tamura,3 Maria E. Montez-Rath,5 Yoshio N. Hall,7 
William Kreuter,1 Ann M. O’Hare.2 1University of Washington, Seattle, WA; 2VA 
Puget Sound Health Care System, Seattle, WA; 3Stanford University, Palo Alto, 
CA; 4Medicine, University of Washington, Kidney Research Institute (retired), 
Seattle, WA; 5Stanford University School of Medicine, Palo Alto, CA; 6UW 
School of Medicine and Public Health, Madison, WI; 7University of Washington-
Kidney Research Institute, Seattle, WA.
Background: Patients with ESRD have a high incidence of lower extremity amputation 
and limited post-operative long-term survival, but little is known about the relationship 
between amputation and patterns of their end-of-life care.
Methods: We used Medicare claims to compare patterns of amputation and health 
care utilization in the last year of life among 754,762 patients with ESRD registered in 
the USRDS and 958,412 Medicare beneficiaries without ESRD who died between 2002 
and 2014.
Results: During the last year of life, 8.2% of Medicare beneficiaries with, and 0.9% of 
those without ESRD underwent at least one lower extremity amputation. After adjustment 
for differences in patient characteristics, patients with ESRD were more likely to have 
undergone at least one amputation (relative risk (RR) 2.30, 95% confidence interval (CI) 
2.24-2.35) and multiple amputations (RR 3.65, 95% CI 3.36-3.97) within a year of death. 
During their last year of life, patients with ESRD who underwent amputation were more 
likely to be admitted to the hospital, ICU, and/or to a SNF and less likely to be enrolled 
in hospice than other patients (figure). During this time, they spent a median of 58 days 
admitted to a hospital (vs. 35 days for patients without ESRD who underwent amputation, 
29 days for patients with ESRD who did not undergo amputation, and 13 days for patients 
without ESRD who did not undergo amputation), 12 days admitted to an ICU (vs. 
8, 9, and 5), 54 days admitted to a SNF (vs. 56, 39, and 32), and 5 days enrolled in hospice 
(vs. 10, 6, and 17).
Conclusions: Almost one in ten patients with ESRD undergo an amputation in the 
last year of life. These patients spend prolonged periods of time in acute and subacute care 
settings towards the end of life, but receive relatively little hospice care. These findings 
argue for more work to understand the end-of-life experience of these patients and suggest 
opportunities to improve care.
Funding: NIDDK Support
Percentage of patients admitted and median days spent in each care setting in the last year 
of life
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Dialysis: Hospitalization and Mortality
Regional Factors Associated with Hospice Use in the US Hemodialysis 
Population
Jessica Cruz Whitley,1 Heejung Bang,2 Andrew I. Chin.3 1UC Davis, Sacramento, 
CA; 2UC-Davis, Davis, CA; 3University of California Davis, Sacramento, CA.
Background: Hospice use remains underutilized in the US ESRD population. We 
explored patient, hospice, and community factors at the county level for hospice use in a 
contemporary cohort of hemodialysis (HD) patients.
Methods: All deaths in patients on HD from 2014-2015 in the USRDS database 
were obtained. Hospice use was based on the death form hospice indicator or at least one 
Medicare hospice charge the year of death. Number of Medicare-certified hospices, their 
profit status, and regional characteristics at the County level were obtained from publically 
available databases and linked to the patient by County. Univariate comparisons and 
Multivariables Logistic Regression models were used.
Results: Of 140,729 deceased patients, 25% utilized hospice at the time of death. 
Those who utilized hospice were older at the time of death, predominantly White (74%), 
and non-Hispanic (89%). In logistic regression analyses, men were 11% less likely to utilize 
hospice than women, Hispanics were 12% less likely to use hospice than non-Hispanics, 
and Blacks were 33% less likely to utilize hospice than Whites. Those who utilized hospice 
were 3% more likely to have a Medicare certified hospice within their county. The number 
of hospices within county of residence and non-profit status were positively associated 
with hospice use. Residing in the Northeast region of the US and higher % of Medicare 
recipients eligible for Medicaid in the county were negatively associated with hospice use. 
Other socio-economic factors and intensity of care measures did not appear to be associated 
with hospice use.
Conclusions: Patient demographics associated with hospice use are consistent with 
published research. We also found that the region in the US, number of hospices in the 
county of residence and the composition of Medicare recipients in the county appear to also 
be associated with hospice use in a contemporary HD cohort.
Characteristics of patients by hospice status at time of death
All p-values <0.0001. 
* row % within each region; all others are column %.
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Dialysis: Hospitalization and Mortality
Postoperative Outcomes in Chronic Dialysis Patients: A Meta-Analysis of 
37 Studies and 75,428 Patients
Dharmenaan Palamuthusingam,1,3 Arun Nadarajah,1 David W. Johnson,1,3 
Jonathan C. Craig,2 Elaine M. Pascoe,3 Carmel M. Hawley,1,3 Magid Fahim.1,3 
1Princess Alexandra Hospital, Brisbane, QLD, Australia; 2University of Sydney/
Children’s Hospital, Sydney, NSW, Australia; 3The University of Queensland, 
Brisbane, QLD, Australia.
Background: Chronic dialysis patients frequently undergo major surgery, but their 
absolute and relative risk of postoperative complications is unclear. The aim of this study 
was to estimate the risks of fatal and non-fatal postoperative outcomes in chronic dialysis 
patients undergoing non-transplant surgery.
Methods: Two authors performed a systematic review of observational studies indexed 
in Embase and MEDLINE till July 2017 that reported postoperative outcomes in chronic 
dialysis and non-dialysis patients undergoing major, non-transplant surgery. Summary 
level data on study characteristics, type of surgical procedure, patient demographics 
and comorbidity were extracted. The primary outcome was death(30-day or in-hospital 
mortality); secondary outcomes were myocardial infarction and sepsis. Random effects 
meta-analysis was performed to derive summary risk estimates and meta-regression was 
performed to explore heterogeneity.
Results: 37 studies involving 75,428 chronic dialysis and 9,624,178 non-dialysis 
patients undergoing orthopedic, vascular, cardiothoracic, general and urological procedures 
were included. Summary, unadjusted risk estimates showed increased risks of postoperative 
mortality (7.2% vs. 0.2%, OR 5.61, 95%CI 4.5-7.0, I290%), myocardial infarction (1.1% 
vs. 0.3%, OR 3.3, 95% CI 2.3-4.7, I274%) and sepsis (6.3% vs. 0.6%, OR 3.6, 95% CI 2.4-
5.3, I296%) in dialysis patients compared to non-dialysis patients irrespective of discipline. 
Adjustment for age and comorbidity attenuated the risks of postoperative death (OR 3.1, 
95% CI 2.9-3.3 I290%), myocardial infarction (OR 1.8, 95% CI 1.3-2.3, I20%) and sepsis 
(OR 2.6, 95% CI 2.3-2.9, I270%). Weighted univariate metaregression showed a significant 
association between individual study reported mortality odds ratios and differences in 
age (slope 0.099, p<0.01), cardiac disease prevalence (slope 0.002, p<0.01) and diabetes 
prevalence (slope 0.49, p<0.01) between dialysis and non-dialysis patients.
Conclusions: Chronic dialysis patients have substantially increased risks of both fatal 
and non-fatal postoperative complications across all surgical disciplines. This heightened 
risk is attributable not only to their dialysis dependency, but also to their older age and 
higher comorbid illness burden.
Funding: Government Support - Non-U.S.
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Dialysis: Hospitalization and Mortality
The Association Between Race/Ethnicity and Mortality Is Modified by 
BMI
Carola-Ellen Kleine,1 Hamid Moradi,1 Christina Park,1 Jui-Ting Hsiung,1 
Connie Rhee,1 Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh,1 Elani Streja.1 
1Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Division of Nephrology and Hypertension, University of California, Irvine, 
Orange, CA; 2University of Tennessee Health Science Center, Memphis, TN.
Background: African-Americans (AA) and Hispanics have better survival rates once 
on hemodialysis (HD). This phenomenon is known as “racial paradox”. Besides, obese HD 
patients might have a survival benefit, too. Therefore, we aimed to examine if BMI is an 
effect modifier of the race/ethnicity-mortality association.
Methods: We retrospectively examined a cohort of 140,817 HD patients from a large 
dialysis organization in 2007 to 2011 who had known race/ethnicity and recorded BMI 
value. Patients were grouped according to their self-identified race/ethnicity. We explored 
the effect modification of BMI on the association between AA vs White, Hispanic vs. 
White, Asian vs. White and White vs non-White and all-cause mortality with adjustments 
for case-mix variables and laboratory markers of malnutrition and inflammation by using 
restricted cubic spline models, which splined the impact over continuous BMI.
Results: The cohort consisted of 29% AAs, 3% Asians, 14% Hispanics, 50% Whites 
and 3% others with a mean age of 64±15 years and mean BMI value of 28.2±7.3 kg/m2. We 
found a survival benefit of both AA and Hispanic patients when compared to White patients. 
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This survival benefit was more observed in those with higher BMI and attenuated for low 
BMI patients. We observed a similar trend for Asians (reference Whites), however it did not 
reach statistical significance for higher BMI values. For Whites, the mortality association 
mirrored the findings in non-Whites. [figure1].
Conclusions: Among HD patients, BMI is an effect modifier of the race/ethnicity-
mortality association.
Funding: NIDDK Support
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Normothermic Ex-Vivo Kidney Perfusion Restores the Gene Expression 
Profile of Marginal Kidney Grafts Subjected to Warm Ischemia
Peter Urbanellis,1,2 Caitriona M. McEvoy,3 Ivan Linares,4 Dagmar Kollmann,5 
Sujani Ganesh,4 Istvan Mucsi,2 Darius Bagli,6 Ana Konvalinka,7 Lisa Robinson,8 
Markus Selzner.5 1University of Toronto, Toronto, ON, Canada; 2Multi-Organ 
Transplantation, University Health Network, Toronto, ON, Canada; 3University 
Health Network, Toronto, Toronto, ON, Canada; 4University Health Network, 
Toronto, ON, Canada; 5Toronto General Hospital, Toronto, ON, Canada; 
6Hospital for sick children / univ of Toronto, Toronto, ON, Canada; 7University 
Health Network, University of Toronto, Toronto, ON, Canada; 8The Hospital for 
Sick Children, Toronto, ON, Canada.
Background: Normothermic ex-vivo kidney perfusion (NEVKP) results in improved 
marginal renal graft function compared to static cold storage (SCS) post-transplantation. To 
determine the mechanisms responsible for the beneficial effects of NEVKP, we investigated 
gene expression profiles of donation-after-cardiac-death (DCD) grafts stored with NEVKP 
or SCS to that of unmanipulated naïve-kidneys.
Methods: Kidneys from Yorkshire pigs were removed following 30-min of warm 
ischemia modelling DCD. Grafts were stored in SCS or NEVKP for 8hr prior to heterotopic 
autotransplantation. On POD3, grafts were collected and microarray analysis was 
performed.
Results: During NEVKP storage, DCD-grafts demonstrated favorable perfusion 
characteristics including lactate clearance, decreasing intra-renal resistance, and urine 
production. NEVKP resulted in improved graft function compared to SCS post-transplant 
with decreased peak serum creatinine (POD1: 4.0+/-1.15mg/dL vs POD3: 12.0+/0.78mg/
dL, n=5, p<0.01) and higher creatinine clearance (POD3: 39.6+/-11.8mL/min vs 2.6+/-
0.9mL/min, n=5, p<0.01). Transcriptomic analysis demonstrated significant differences in 
the expression of 27 genes in NEVKP grafts compared to naïve-kidneys (Table 1, ≥±2-fold 
change, n=3, FDR q<0.20). In contrast, 668 genes were differentially expressed between 
grafts stored with SCS and naïve-kidneys (Table 2, ≥±2-fold change, n=3, FDR q<0.20).
Conclusions: NEVKP of DCD kidney grafts resulted in a gene expression profile 
more closely resembling naïve kidneys. Conversely, grafts stored with SCS demonstrated 
increased expression of genes related to inflammation, apoptosis, and repair.
FR-PO842 Poster Friday
Transplantation: Basic
Dextran-Based and Albumin-Based Perfusates in Normothermic Ex Vivo 
Kidney Perfusion
Yilun Wu,1 Xiuhua (sue) Wang,2 Darren Freed.1,2 1Department of Physiology, 
University of Alberta, Edmonton, AB, Canada; 2Department of Surgery, 
University of Alberta, Edmonton, AB, Canada.
Background: Kidney transplantation is the definitive treatment for end-stage renal 
disease. Transplantation is superior to the alternative, dialysis, in survival, quality of 
life, and cost-savings. However, the gap between kidney donation and demand for donor 
kidneys is growing, and improved utilization of renal grafts, especially extended criteria 
donors, is necessary. Normothermic ex vivo kidney perfusion (NEVKP) is a novel method 
for graft preservation; it maintains metabolism, allows assessment, and allows therapeutic 
interventions. Currently many NEVKP systems use perfusates composed of a combination 
of physiological saline, red blood cells, and supplemental source of oncotic pressure and 
nutrients. Our study examines the effect of dextran-40 based perfusate compared to albumin 
based perfusates in NEVKP.
Methods: We establish a NEVKP model using porcine kidneys extracted with 10 
minutes of warm ischemia perfused using cardiopulmonary bypass equipment. Donor 
kidney is perfused at normothermia and 60mmHg arterial pressure. Perfusate is composed 
of donor whole blood and a modified plasmalyte solution containing either 8% dextran-40 
or 8% bovine serum albumin. Glucose and insulin are infused.
Results: Dextran and albumin produced similar intra-renal resistance during 12 hours 
of perfusion. However, dextran based perfusate shows improved urine production rates 
and urine quality (lower pH, lower/undetectable glucose and calcium) and lower plasma 
and tissue inflammatory markers (plasma interleukin-6 2.45±0.88ng vs 5.24±0.52ng, 
plasma tumor necrosis factor-α undetectable in dextran perfusates vs 0.55±0.14ng, tissue 
expression of toll like receptor-4 77% higher in albumin perfusate group tissues). Neither 
perfusate groups significantly increase plasma kidney injury molecule-1 (KIM-1), however 
both perfusate groups show lower tissue KIM-1 compared to tissue from start of perfusion.
Conclusions: With improved perfusion characteristics and reduced inflammatory 
profile, we believe a dextran based perfusate is superior to albumin based perfusates in 
NEVKP and that our system provides a viable platform for ex vivo preservation of porcine 
kidneys and further study of different interventions during ex vivo kidney perfusion.
Transplantation: Basic
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
642
J Am Soc Nephrol 29: 2018 Poster/Friday
FR-PO843 Poster Friday
Transplantation: Basic
Proteomics Analysis Reveals Novel Molecular Mechanisms Associated 
with Normothermic Ex-Vivo Perfusion
Caitriona M. McEvoy,1 Shelby Reid,6 Peter Urbanellis,2 Moritz Kaths,7 
Lisa Robinson,3 Markus Selzner,4 Ana Konvalinka.5 1University Health Network, 
Toronto, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada; 
3The Hospital for Sick Children, Toronto, ON, Canada; 4Toronto General 
Hospital, Toronto, ON, Canada; 5University Health Network, University of 
Toronto, Toronto, ON, Canada; 6Institute of Medical Science, University of 
Toronto, Toronto, ON, Canada; 7University Hospital Essen, Essen, Germany.
Background: Normothermic ex-vivo perfusion (NEVKP) is associated with 
significantly improved graft function following transplantation in comparison to static 
cold storage (SCS); however, the molecular mechanisms underpinning this improvement 
remain unclear. We hypothesized that NEVKP induces key alterations in the renal proteome 
compared to SCS, enabling us to characterize the molecular mechanisms that lead to 
superior graft function in this setting.
Methods: Porcine kidneys were removed following 30 minutes of warm ischemia, 
before being subjected to either SCS or NEVKP (n=5, each group) for 8 hours prior to 
autotransplantation. Kidney biopsies were collected at time zero, upon reperfusion, and 
at POD3. We conducted an unbiased proteomics analysis by LC-MS/MS on Q-Exactive-
Plus mass spectrometer. Subsequent analyses were performed using MaxQuant, Perseus, 
pathDIP, mirDIP, NaVIGaTOR and Cytoscape.
Results: Renal function was significantly improved with NEVKP in comparison to 
SCS with decreased peak serum creatinine on POD1, and higher creatinine clearance on 
POD3. We detected 6354 proteins in total (FDR <0.01), with 71 proteins identified as 
significantly differentially expressed between experimental groups and time points (2-
way ANOVA, p<0.05). Pathway enrichment analysis demonstrated that proteins increased 
in SCS compared to NEVKP kidneys mediated inflammation, antigen presentation, 
extracellular matrix production and fibrosis (e.g. THBS1, XRCC6, TMCO1, JUN, CD40). 
We identified microRNAs predicted to regulate these SCS-dominant proteins (e.g. miR-
129, miR-206). In contrast, proteins increased in NEVKP compared to SCS were mostly 
metabolic, mediating energy production through TCA cycle (ACO2, COX4I1, ATP5J2, 
ETFB, MPC2, NDUFAF7). These proteins were predicted to be regulated by miR-203 and 
miR-199, and the transcription factor ZNF143.
Conclusions: NEVKP may thus repair grafts by diminishing inflammatory/fibrotic 
signals and altering metabolism via the TCA cycle. Conversely, proteins enriched in SCS 
kidneys are associated with fibrogenic and inflammatory pathways. Our findings may yield 
novel therapeutic targets to attenuate injury associated with warm ischemia.
Funding: Private Foundation Support
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RNA-Seq Analysis of Human Renal Allograft Biopsies Reveals Key 
Mediators of Interstitial Fibrosis/Tubular Atrophy
Caitriona M. McEvoy,1 Eoin P. Brennan,4 Denise M. Sadlier,4 Peter J. Conlon,3 
Ana Konvalinka,5 Catherine Godson.2 1University Health Network, Toronto, 
Toronto, ON, Canada; 2The Conway Institute of Biomolecular and Biomedical, 
Belfield, Dublin, Ireland; 3Beaumont Hospital, Dublin 9, Co Dublin, Ireland; 
4University College Dublin, Dublin, Ireland; 5University Health Network, 
University of Toronto, Toronto, ON, Canada.
Background: Interstitial Fibrosis/Tubular Atrophy(IFTA) is the final common pathway 
of most progressive renal diseases and is a potent predictor of renal outcome in both native 
and transplanted kidneys. IF/TA is a major cause of late allograft loss; however, our 
understanding of the molecular mechanisms underpinning this complex process remains 
incomplete.
Methods: We performed RNA-Seq gene expression profiling on renal tissue 
from transplanted patients undergoing a clinically indicated biopsy (n=21). IF/TA was 
determined from the renal biopsy report, and by quantitative morphometric analysis. 
Bioinformatic analysis was performed by DESeq2 to obtain differentially expressed (DE) 
genes. Ingenuity Pathway Analysis and MatInspector were employed to identify the key 
pathyways & transcription factors related to the dysregulated genes. NetworkAnalyst was 
used to generate a gene-protein interaction network.
Results: We identified 671 DE genes (381 upregulated, 236 downregulated; FDR<0.1) 
between severe and mild/moderate IF/TA in our cohort. Pathway analysis revealed that 
B-Cell development, NRF2-mediated oxidative stress response & superoxide radical 
degredation comprise the top canonical pathways associated with the perturbed genes in our 
dataset. Pivotal upstream regulators are associated with lymphoid cell development (SPI1), 
proteasomal degradation (BACH1,LONP1) & regulation of antioxidant proteins (NFE2L2). 
In silico cell-type enrichment analysis reveals enhanced transcriptional signatures from
CD19+ B-Cells, Dendritic cells & CD4+ T-cells in the expression profiles of patients with 
severe IF/TA. DE genes were validated using external datasets prior to generating a gene-
protein interaction network. Zero & first order interactions were examined. Significant gene 
modules detected in the networks relate to oxidative stress and mitochondrial function, T & 
B-Cell signalling, ECM-Receptor interaction, scaffolding proteins & chemokine signalling 
pathways.
Conclusions: Our dataset reveals novel molecular signatures and transcriptional 
regulators central to IF/TA using systems biology tools. These data underscore a prominent 
role of inflammation and oxidative stress in the development of IF/TA and reveal novel 
potential mediators of this process.
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Proteomics of Microdissected Glomeruli and Tubulointerstitium Reveals 
Compartment-Specific Alterations in the Extracellular Matrix of Kidney 
Allografts with Antibody-Mediated Rejection
Sergi Clotet-Freixas,1 Caitriona M. McEvoy,1 Ihor Batruch,3 Max Kotlyar,1 
Chiara Pastrello,1 Julie Anh Dung Van,2 Andrea Bozovic,1 Vathany Kulasingam,1 
Andrzej Chruscinski,1 Rohan John,1 Ana Konvalinka.1,2 1University Health 
Network, Toronto, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, 
Canada; 3Mount Sinai Hospital, Toronto, ON, Canada.
Background: Kidney transplantation is the optimal treatment for end-stage 
kidney disease, but most grafts fail prematurely. Antibody-mediated rejection (AMR) is 
responsible for >50% of graft loss. AMR is caused by antibodies against HLA and non-HLA 
antigens, which are directed against proteins in the two main compartments of the kidney: 
glomeruli and tubulointerstitium (TI). We hypothesized that renal AMR is associated with 
compartment-specific proteome alterations that may uncover the mechanisms of early 
antibody-mediated injury.
Methods: We performed laser capture-microdissection to isolate glomeruli and TI 
from paraffin-embedded kidney biopsies, and subjected samples to proteome analysis on 
Q-Exactive mass spectrometer. We compared 8 biopsies with pure AMR with 23 matched 
‘non-AMR’ biopsies with cellular rejection (ACR) or acute tubular necrosis (ATN). 
Biopsies were for-cause and scored using Banff criteria-2017.
Results: Biopsies were performed early post-transplant; none of them had marked 
fibrosis. AMR biopsies were C4d+ and had no chronic lesions. We identified 2026 proteins 
in glomeruli and 2426 in TI. Podocyte-specific proteins were exclusively found in the 
glomeruli (NPHS1, PTPRO), and tubular proteins were found only in TI (CUBN, UMOD), 
indicating compartment-specific enrichment. 141 proteins were differentially expressed in 
AMR vs. non-AMR glomeruli (73 up- and 68 downregulated) and 123 in TI (15 up- and 108 
downregulated). Proteins involved in HLA-mediated antigen presentation were increased 
in both AMR compartments. Interestingly, proteins significantly decreased in both 
compartments in AMR (e.g.LAMC1, COL1A1, NID1) belong to basement membranes and 
processes such as integrin signaling, collagen, extracellular matrix (ECM) and cytoskeleton. 
Levels of collagens, laminins, and other ECM proteins directly correlated (R>0.7; p<0.05), 
suggesting co-regulation in renal AMR.
Conclusions: Basement membranes are often remodeled in late chronic AMR and are 
the targets of non-HLA antibodies, suggesting that these proteomic changes may represent 
early, important alterations in AMR. Targeting early ECM remodeling in AMR may 
represent a new therapeutic opportunity.
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The Difference of IgA1 O-Glycosylation Between IgA Nephropathy 
Transplant Recipients and IgA Deposition Donors
Shigeaki Nakazawa,1 Toyofumi Abe,2 Ryoichi Imamura,1 Taigo Kato,3 
Norio Nonomura.4 1Osaka University Graduate School of Medicine, Suita, 
Japan; 2Urology, Oska University Graduate School of Medicine, Suita, Japan; 
3Osaka University, Suita, Japan; 4Department of Urology, Osaka University 
Graduate School of Medicine, Osaka, Japan.
Background: IgA nephropathy (IgAN) is most common primary glomerulonephritis, 
and recurrence of IgAN after renal transplantation is frequent. On the other hand, IgA 
deposition (IgAD) from donor kidney without any manifestation of renal disease is often 
observed. The reason why IgA depositionD does not progress to IgA nephropathyN is not 
clear. In this study, we firstly analyzed the frequency of IgAD in living renal transplant 
donors, and we secondarily evaluated the IgA1 O-glycan structure in IgAN recipients, 
IgAD donors, and non-IgAD healthy donors (healthy donors).
Methods: We investigated O-glycan structure of IgA1 hinge region in 25 IgAN 
recipients, 17 IgAD donors, and 26 normal healthy donors matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF MS).
Results: In O-glycans analysis using MALDI-TOF-MS, GalNAc and Gal content in 
HR of IgAN recipients were significantly decreased than IgAD donors and healthy donors. 
However, in all patterns of O-glycans, there was no significant difference between IgAD 
donors and healthy donors.
Conclusions: This is first report to compare the O-glycans structure in IgAN recipients 
and IgAD donors using MALDI-TOF-MS. Our result indicated that the decreased number 
of GalNAc and Gal content in HR could play pathogenic role in IgAN.
Funding: Government Support - Non-U.S.
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Kynurenine 3-Monooxygenase Is a Key Mediator in the IDO Signaling 
Pathway for Prevention of Rejection in Experimental Kidney 
Transplantation
Youli Wang,2 Todd D. Merchen,1 Randi Lassiter,2 Xuexiu Fang,2 
Daniel T. Kleven,2 Chak-Sum Ho,3 N. Stanley Nahman.1 1Medical College of 
Georgia at Augusta University, Augusta, GA; 2Augusta University, Evans, 
Colombia; 3Gift of Life Michigan, Ann Arbor, MI.
Background: Indoleamine 2,3-dioxygenase (IDO) degrades tryptophan to kynurenine 
(KY), and the IDO-transprotein prevents rejection (RJX) in rat kidney transpants (KTx). 
KY is the substrate for KYnurinase (KYase), KYamiotransferase II (KAT), and KY 
3-monooxygenase (KMO), each of which may generate immunosuppressive KYs, 
including the product of KMO, 3HK. Thus, in pig KTx we showed loss of graft KMO
expression in RJX. 3HK is toxic to Tcells and neurons, yet tubular cells with elevated KMO
appear normal, suggesting lineage specificity to 3HK toxicity. In this work, we further 
gauged the effect of RJX on enzymes degrading KY and studied the in vitro effects of 3HK 
on cultured kidney and Tcells.
Methods: Yorkshire pigs underwent allogeneic (Allo) or auto renal transplants (Auto 
[control for ischemia]) as we described (Trans Immun, 42:40, 2017). Allos had SLA testing 
and received mismatched kidneys. All pigs had R UNx before closure (control tissue). 
72 hr post-op all grafts were taken and probed for IDO and tandem enzymes (qPCR, 
immunohistochemistry (IHC), and HPLC for IDO activity). 3HK cytotoxicity and cell 
proliferation was assessed using human primary kidney cortical endothelial (Endo) and 
epithelial (Epi) cells, and human peripheral blood Pan-T cells (Tcells).
Results: Allografts showed acute RJX (Banff 1-3), a 6X increase in IDO mRNA and 
19.5X increase in IDO activity vs Auto. When compared to R UNx, KMO, KYase and KAT 
all showed a near 50% reduction in Autos, a change attributed to ischemia. However in 
rejecting Allos vs Autos, there was an over 90% reduction in KMO mRNA with no additive 
effect on KYase or KAT. IHC of kidney showed dramatic reductions in KMO protein in 
Epi and Endo cells. 3HK inhibited proliferation of active Tcells and promoted Tcell injury 
and death. The same and higher concentrations of 3HK had no effect on cortical Epi and 
Endo cells.
Conclusions: The loss of KMO, KYase and KAT from ischemia may partially explain 
RJX in the face of elevated IDO levels. The dramatic decline in KMO in RJX vs the other 
enzymes may exacerbate the process. 3HK destroys Tcells without affecting Epi or Endo 
cells. These data suggest that KMO is a key player mediating RJX in the IDO pathway and 
that the loss of 3HK from reductions in KMO may favor Tcell proliferation and promote 
RJX.
Funding: Private Foundation Support
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Dimethyl Fumarate Ameliorates Tacrolimus-Induced Nephrotoxicity in 
Rats
Akihiro Shimomura, Shiri Li, Donald C. Dafoe, Hirohito Ichii. University of 
California, Irvine, Orange, CA.
Background: Tacrolimus (TAC) is an important maintenance immunosuppressive 
drug that is widely used for organ transplant. However, patients treated with TAC are at high 
risk of developing organ injuries such as kidney and pancreas, especially kidney is more 
susceptible to TAC. TAC causes renal dysfunction or failure not only on donor kidneys 
but also on native kidneys. The incidence is 52%, 40% and 59% in patients after kidney, 
liver and heart transplants, respectively. Despite the tremendous efforts to reduce TAC-
induced kidney injury, satisfactory therapies have not been established because the exact 
pathogenesis has remained unclear. There are increasing evidences that oxidative stress is 
involved in both TAC-induced kidney and pancreas injuries. Dimethyl fumarate (DMF), 
which has recently been approved by FDA for the treatment of relapsing forms of multiple 
sclerosis (MS) and relapsing-remitting MS patient, is a modifier of the nuclear factor-2-
keap1 pathway that induces antioxidative and antiapoptotic effects. In the present study, we 
investigated the effects of DMF on TAC-induced kidney and pancreas injuries.
Methods: Male Sprague-Dawley rats at 9 weeks of age were divided randomly into 
four groups; low-salt (LS) diet (group LS), LS+DMF (group DMF), LS+TAC (group 
TAC), or LS+TAC+DMF (group TAC+DMF). DMF at a dose of 50 mg/kg·BW or vehicle 
was gavaged once a day. TAC at a dose of 1.5 mg/kg·BW or vehicle was subcutaneously 
injected once a day.
Results: At 15 weeks of age, significantly elevated levels of serum creatinine and urea 
nitrogen were detected in group TAC. Group TAC+DMF showed significantly lower levels 
of them than group TAC. Both Masson’s Trichrome staining and immunohistochemical 
collagen1 staining of rat kidney showed consistent results with renal function. On the other 
hand, intraperitoneal glucose tolerance test, HOMA-IR and HOMA-β showed significantly 
impaired glucose tolerance and β cell function in group TAC, which could not be improved 
by DMF.
Conclusions: DMF ameliorated kidney injury but not pancreas injury in the 
TAC-induced rat model. This provides a novel approach for preventing TAC-induced 
nephrotoxicity in patients after organ transplant. Our data also indicates that TAC-induced 
kidney and pancreas injuries may have different pathogenic mechanisms. We expect to 
further investigate the pathogenic mechanisms of TAC-induced organ injuries.
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The Potential Role of IL-33/ST2 Pathway in Renal Allograft Rejection
Mi-yeon Yu,1 Jae Wook Lee,6 Yong Chul Kim,3 Sunhwa Lee,3 Un Sil Jeon,2 
Hajeong Lee,4 Dong Ki Kim,3 Yon Su Kim,4 Seung Hee Yang.5 1Seoul national 
university hospital, Seoul, Republic of Korea; 2Sheikh Khalifa Specialty 
Hospital, Ras Al Khaimah, United Arab Emirates; 3Seoul National University 
Hospital, Jongno-gu, Seoul, Republic of Korea; 4Seoul National University 
College of Medicine, Seoul, Republic of Korea; 5Kidney Research Institute, 
Seoul National University, Seoul, Republic of Korea; 6National Cancer Center, 
Seoul, Republic of Korea.
Background: Interleukin (IL)-33 is one of IL-1 family cytokine that has pleiotropic 
effects, such as inflammation promotion and immune response regulation. Recent studies 
showed that IL-33 and its receptor, growth stimulation gene-2 (ST2) are biomarkers in heart 
allograft rejection. However, there is no studies about their role in renal allograft rejection. 
Moreover, its response according to rejection type remain unclear. We that IL-33 and ST2 
expression differently express according to rejection type in renal allograft rejection.
Methods: Serum and kidney biopsy tissue were obtained from healthy controls and 
kidney transplanted recipients with acute antibody mediated rejection (AAMR), acute 
cell mediated rejection (ACMR), and chronic antibody mediated rejection (CAMR). We 
compared the expression of IL-33 and ST2 between 4 groups. To test the suppressive 
effect of anti-ST2 monoclonal antibody (anti-ST2 Ab), mixed lymphocyte reaction and 
chemotaxis assays by Boyden chambers were performed. We also evaluated the change of 
expression of IL-33/ST2 in dose of the anti-ST2 Ab (0.5 and 1 μg/ml).
Results: In comparison with the ELISA, ST2 level was higher in rejection group than 
in control group. The level of IL-33 was too low to be analyzed. Immunohistochemical 
analysis demonstrated that IL-33 and ST2 elevate in kidney tissue with rejection, especially 
in acute rejection. However, the expressions of IL-33/ST2 were no difference between 
AAMR and ACMR. In response to anti-ST2 Ab, primary human renal proximal tubular 
epithelial cells, which was stimulated by recipients’ serum, showed a decrease in fibronectin 
and IL-33/ST2. IL-8, pro-inflammatory cytokine, was also decreased after treatment 
with anti-ST2 Ab by each group. In vitro validation, anti-ST2 Ab caused decreases in 
proliferation of lymphocyte and the level of IL-8. These decreases were significantly at high 
concentrations. We found that anti-ST2 Ab was able to significantly decrease chemotaxis.
Conclusions: Expressions of IL-33 and ST2 are higher in acute rejection than chronic 
rejection. Pro-inflammatory cytokines associate with IL-33/ST2 pathway during rejection. 
Blocking of the IL-33/ST2 axis may contribute to protect the allograft rejection.
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Effect of Klotho on Autophagy Clearance in Tacrolimus-Induced Renal 
Injury
Sun Woo Lim,1 Yoo-Jin Shin,2 Kang Luo,3 Yi Quan,4 Eun jeong Ko,5 Byung 
ha Chung,6 Chul Woo Yang.6 Seoul St. Mary’s Hospital, The Catholic University 
of Korea 1The Catholic University of Korea, Seoul, Republic of Korea; 2College 
of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; 3The 
Catholic University of Korea, Seoul, Korea., Seoul, Republic of Korea; 4Seoul 
St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of 
Korea; 5Seoul St.Mary’s Hospital, Seoul, Republic of Korea; 6Seoul St. Mary’s 
Hospital, Seoul, Republic of Korea.
Background: Recently, we showed that tacrolimus-induced renal injury is closely 
associated with impairment of autophagy clearance, and Klotho deficiency aggravates 
tacrolimus-induced renal injury. In this study, we evaluated the effect of Klotho treatment 
on autophagy clearance in tacrolimus-induced renal injury.
Methods: We evaluated the effect of Klotho on tacrolimus-induced renal injury in an 
experimental mouse model and in vitro by treatment with tacrolimus and/or recombinant 
mouse Klotho.
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Results: In vivo and in vitro studies showed that tacrolimus treatment impaired 
lysosomal acidification and decreased cathepsin B activity, expression of lysosome-
associated membrane protein 2, and transcription factor EB (TFEB), a master regulator 
for lysosomal biogenesis. These results were improved by Klotho treatment. Moreover, 
addition of bafilomycin A1, an inhibitor of lysosomal function, abolished the protective 
effect of Klotho, indicating that the protective effect of Klotho was closely associated with 
lysosome function. Klotho induced nuclear translocation of TFEB through inhibition of 
phosphorylation of glycogen synthase kinase 3β (GSK3β) by confirming using CHIR99021, 
a GSK3β inhibitor.
Conclusions: Collectively, our data suggest that Klotho improves autophagy clearance 
via activation of lysosomal function in tacrolimus-induced nephrotoxicity.
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Self In Vivo Production of a Synthetic Biological Drug, Anti-IL-2Rα/IL-10 
Fusion Protein Using Minicircles in Skin Allograft Model
Sun Woo Lim,1 Yoo-Jin Shin,6 Kang Luo,3 Yi Quan,4 Eun jeong Ko,5 Byung 
ha Chung,2 Chul Woo Yang.2 Seoul St. Mary’s Hospital, The Catholic University 
of Korea 1Transplant Research Center, The Catholic University of Korea, Seoul, 
Republic of Korea; 2Seoul St. Mary’s Hospital, Seoul, Republic of Korea; 3The 
Catholic University of Korea, Seoul, Korea., Seoul, Republic of Korea; 4Seoul 
St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of 
Korea; 5Seoul St.Mary’s Hospital, Seoul, Republic of Korea; 6College of 
Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background: Anti-IL-2Rα monoclonal antibodies are typically used to prevent acute 
rejection in patients after transplantation. Minicircle DNA, one of the most remarkable gene 
therapy technologies of late, has the advantage of being small in size, non-viral, and free of 
unwanted immune responses such as no bacterial backbone. The aim of this study was to 
investigate the therapeutic effects of anti-IL-2Rα and IL-10, anti-inflammatory cytokine, in 
vitro and in vivo using a minicircle vector system.
Methods: Minicircle DNA was prepared by inserting the sequences for Basiliximab 
(anti-IL-2Rα) and IL-10 into the parental plasmid and removing the bacterial backbone. 
After minicircle DNA administration, protein production for anti-IL-2Rα and IL-10 was 
determined in HEK293T cell line and mice, and the therapeutic effect was evaluated in skin 
allograft rejection model.
Results: Minicircle DNA was transfected into the HEK293T cells and observed up 
to 30 days and detected the protein production in the conditioned media. In mice, in vivo 
imaging was used to confirm that DNA expression persists for up to 30 days after single 
administration. The produced protein was maintained in the blood for up to 10 days. Anti-
IL-2Rα/IL-10 fusion protein increased survival effect more than single protein expressing 
anti-IL-2Rα or IL-10 in the skin allograft rejection model.
Conclusions: Anti-IL-2Rα/IL-10 fusion protein, which is synthesized in the body using 
minicircle DNA, has demonstrated an effective therapeutic effect on acute rejection after 
transplantation. We also demonstrated the potential of the minicircle DNA as a powerful 
biological agent to induce immune tolerance of grafts by combining various therapeutic 
target designs.
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Accelerated Cellular Senescence Associated with CFHR3-1 Variants 
Influences Graft Survival in IgA Nephropathy Transplanted Patients
Francesco Pesce,1 Chiara Divella,1 E. D. Stea,1 Matteo Accetturo,2 
Francesca Cianciotta,3 M. Rossini,4 Giulia Fontò,1 G. Lucarelli,1 
Loreto Gesualdo,1 Giuseppe Castellano.5 1University of Bari, Bari, Italy; 
2University of Bari - Dept. Emergency and Organ Transplants, Bari, Italy; 
3Università di Bari, Bitetto, Italy; 4University of Bari, Department of Emergency 
and Organ Transplantation, Nephrology Unit, Bari, Italy; 5UNIVERSITA STUDI 
BARI, BARI, Italy.
Background: The deletion of complement factor H-related genes 1 and 3 (CFHR3-
1Δ) has been associated with a decreased risk of IgA nephropathy (IgAN) and is in linkage 
disequilibrium (LD) with the SNP rs6677604 (“A” allele), which can be used as a proxy to 
detect it. We hypothesized that CFHR3-1Δ is also implicated in the processes that influence 
graft survival in recipients with IgAN and tested whether cellular senescence is involved in 
mediating the damage.
Methods: A total of 67 biopsy-proven IgAN patients who received a renal transplant at 
the Kidney Transplant Center of the Department of Emergency and Organ Transplantations 
(D.E.T.O), University of Bari between 1993 and 2017 where included in the study. The 
region in CFHR3-1 encompassing the SNP rs6677604 was amplified using PCR and 
sequenced by Sanger. Immunohistochemical expression of p16INK4A was performed on 
paraffin-embedded kidney transplant biopsies of 8 patients (4 with rs6677604-AA vs 4 with 
rs6677604-GA), and quantified using the Aperio Positive Pixel Count Algorithm. Masson’s 
trichrome staining and quantification of positive area was performed. Clinical data at 
baseline and during the follow-up were recorded. An eGFR < 60mL/min/1.73m2 (MDRD 
equation) was considered as main outcome at a univariate and multivariate analyses.
Results: The rs6677604-A allele was found in 22 (32.8%) patients (genotype 
rs6677604-AG) whereas 45 (67.2%) carried the GG genotype. These two groups had no 
difference as for demographic features, donor and transplant-related variables (incidence of 
delayed graft function and acute rejection episodes). Patients with the rs6677604-GG had a 
worse outcome during a mean follow-up of 69 ± 62 months at univariate (P=5.81E-05) and 
multivariate analysis (HR 30.8; 95% IC 3.3-285.5; P=0.003). Graft biopsies in this group 
featured a significantly higher expression of the senescence marker p16INK4a (P=0.001) in 
tubular epithelial cells showing increased levels of fibrosis (P=0.005).
Conclusions: These findings suggest that CFHR3-1Δ and its proxy rs6677604 are 
associated with long term graft function in transplant recipients with IgAN nephropathy 
through mechanisms involving accelerated cellular senescence.
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Extracellular Vesicles (EVs) Induce Tubular Epithelial Cells (TEC) 
Inflammaging in Antibody-Mediated Rejection (AMR)
Chiara Divella,1 Alessandra Stasi,1 Rossana Franzin,1 Fabio Sallustio,1,2 
Claudia Curci,1 Guido Merlotti,3 Marco Quaglia,5 Loreto Gesualdo,1 
Vincenzo Cantaluppi,4 Giuseppe Castellano.1 1University of Bari, BARI, Italy; 
2Department of Basic Medical Sciences, Neuroscience and Sense Organs, 
University of Bari, Bari, Italy; 3University of Piemonte Orientale, Novara, Italy; 
4University of Piemonte Orientale (UPO), Novara, Italy; 5Università del 
Piemonte Orientale, Torino, Italy.
Background: Recent data suggest a strong correlation between chronic kidney disease 
development and activation of accelerated senescence processes known as “inflammaging” 
in tubular epithelial cells (TEC). However, the role of TEC inflammaging and its mediators 
in kidney transplantation remains incompletely understood.
Methods: Renal biopsies of 10 transplanted patients with Acute and Chronic AMR 
were collected. Serum samples (5% for 24h) and EVs isolated from the same patients 
(5E+4EVs/cells target for 24h) were incubated with primary culture of TEC (3th passage); 
p21 and p53 gene levels were measured by qPCR to assess TEC senescence. IHC staining 
for markers of inflammaging (p16INK4a and Klotho) were performed on paraffin tissue of 
the same patients.
Results: Pre-implantation biopsies did not showed signs of TEC Inflammaging. 
TEC from patients with Chronic AMR expressed significant levels of p16INK4a indicating 
occurrence of senescence phenotype, compared with Acute AMR (p<0.05). In vitro, the 
exposure of TEC to serum of Acute and Chronic AMR patients induced senescence by up-
regulating of p21 and p53 gene levels, compared to basal condition (p<0.05). Interestingly, 
EVs isolated from the AMR patients induced senescence in vitro promoting a significant 
increase in p21, p53 and cyp1b1 gene level, and a down-regulation of klotho gene (p<0.05).
Conclusions: Our data demonstrated that TEC inflammaging induced by EVs might 
represent a new pathogenetic mechanism involved in acute and chronic AMR and could 
be identified as a potential new therapeutic target to counteract accelerated aging in kidney 
transplantation.
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The (R)-Enantiomer of the 6-Chromanol Derivate SUL-121 Counteracts 
Renal Vasoconstriction by Antagonism of the Α1-Adrenoceptor
Dalibor Nakladal,1,3 Hendrik Buikema,1 Atilio Reyes romero,2 Guido Krenning,4 
Robert H. Henning,1 Leo E. Deelman.1 1Department of Clinical Pharmacology, 
University of Groningen / University Medical Center Groningen, Groningen, 
Netherlands; 2University of Groningen, Groningen, Netherlands; 3Department 
of Pharmacology & Toxicology, Comenius University in Bratislava, Bratislava, 
Slovakia; 4Pathology and Medical Biology, University Medical Center 
Groningen/ University of Groningen, Groningen, Netherlands.
Background: In kidney transplantation, impaired graft perfusion associates with 
decreased graft survival. Disturbed adrenergic signal transduction during rewarming is an 
important factor limiting renal perfusion. Recently, we developed a class of 6-chromanol 
based SUL-compounds which maintain mitochondrial function and limit reactive oxygen 
species (ROS) during cooling and metabolic stress. Here, we investigate the effects of SUL-
121 on vascular function of porcine kidneys.
Methods: Porcine kidneys were collected at a local slaughterhouse and immediately 
flushed with UW with heparin, placed on ice and transported to the laboratory. The effects 
of SUL-121 and its enantiomers (R)-SUL-150 and (S)-SUL-151 on renal perfusion pressure 
was assessed in an isolated kidney perfusion system. In addition, rings from isolated 
intrarenal arteries were used to measure constriction responses to various agonists after 
pre-incubation with SUL-compounds. Receptor binding and intracellular calcium transients 
were assessed in α1 adrenoceptor transgenic CHO cells. Molecular docking simulation was 
performed in an α1 adrenoceptor flexible homology model using Induced Fit software.
Results: Addition of SUL-121, SUL-150 but not SUL-151 caused a decrease (-11±1, 
-13±2 and -1±1 mmHg, respectively) in renal perfusion pressure. Pre-incubation with SUL-
121 and SUL-150 competitively inhibited contraction responses to the α1 adrenoceptor
agonist phenylephrine (pA2 5.37±0.03). SUL-151, other 6-chromanols and their metabolites
were without effect. Contraction responses to histamine and U46619 were not influenced 
by SUL-150. Phenylephrine-induced calcium signalling was similarly inhibited by SUL-
150 in transgenic CHO cells (pA2 5.31±0.03). SUL-150 effectively displaced radiolabelled
prazosin in a competitive binding assay. Simulation of molecular docking demonstrated
shared binding characteristics of SUL-150 and prazosin.
Conclusions: SUL-150, the (R)-enantiomer of SUL-121, is an antagonist of the 
α1 adrenoceptor with ligand-receptor interactions similar to prazosin. Considering the 
improvement of renal perfusion through adrenergic antagonism in addition to previously 
reported beneficial effect on mitochondrial function and ROS production, we propose SUL-
150 as a novel and unique protectant in kidney transplantation.
Funding: Commercial Support - Sulfateq B.V., Groningen, Netherlands
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Effect of Deceased Donor Inflammatory Pathways on Chronic Renal 
Graft Dysfunction
Montserrat M. Diaz Encarnacion,5 Elena Guillen-gomez,1 Iara Dasilva Santos,2 
Irene Silva,3 Lluis Guirado,4 Nuria Serra.6 1Fundación Puigvert, Barcelona, 
Spain; 2Fundacio Puigvert, BARCELONA, Spain; 3FUNDACION PUIGVERT, 
BARCELONA, Spain; 4Fundació Puigvert, Barcelona, Spain; 5Fundación 
Pugvert, Barcelona, Spain; 6Fundació puigvert, Barcelona, Spain.
Background: In deceased donor (DD) renal transplantation an inflammatory activity 
is established prior to nephrectomy. It produces macrophage infiltration and has been 
associated with the onset of fibrosis. Adenosine exerts its anti-inflammatory activity 
mainly through the A2A receptor. Monocytes and macrophages release TNF-α which 
induces A2A activity and mediates renal interstitial fibrosis through an increase in TGF-
β1 and macrophage M2 switching. The aim of this study is to determine the effect of DD 
inflammation on chronic renal graft dysfunction.
Methods: Samples of pre-implantation renal tissue, 17 from living donor (LD) and 40 
from DD were analyzed by Real-time PCR with the TaqMan® OpenArray® and western-
blot.
Results: Infiltration of macrophages in DD kidneys was significantly greater than in 
LD. The expression of TNF-α, TGF-β1 and A2A was also higher than in LD and correlated 
positively with each other. A2A receptor also correlated with: pro-fibrotic markers such as 
α-SMA, fibronectin, vimentin, and collagen; the enzyme adenylate cyclase and the M2 
macrophage marker CD163, C/EBPβ and IL-10, which are most expressed in DD kidneys. 
Western-blot results show PKA and CREB activation and increased CD163 and A2A 
protein translation.
Conclusions: TNF-α-mediated inflammation in DD kidneys is associated with the 
increase/activation of anti-inflammatory factors such as TGF-β1 and adenosine receptor 
A2A. Our results indicate that the activation of this pathway induces PKA-mediated 
CREB phosphorylation, which in turn stimulates transcription of C/EBPβ and promotes 
the induction of factors that could lead to fibrosis in the renal graft via M2 macrophages.
Funding: Government Support - Non-U.S.
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Tacrolimus Results in Increased CTGF Expression by Human Proximal 
Tubule Cells and Is Associated with Donor ABCB1 3435C>T Genotype
Noel Knops,1 Yasaman Ramazani,3 Elena N. Levtchenko,1 Tri Q. Nguyen,2 
Dirk R. Kuypers.1 1University Hospitals Leuven, Leuven, Belgium; 2UMC 
Utrecht, Utrecht, Netherlands; 3KU Leuven, Leuven, Belgium.
Background: Clinical studies have demonstrated the importance of genetic variation 
in CYP3A5 and ABCB1 for tacrolimus disposition and suggested a role in the development 
of renal fibrosis associated with long-term tacrolimus treatment. Our aim was to explore the 
implications of tacrolimus exposure in a model of human proximal tubule cells incorporating 
genetic variation in CYP3A5 and ABCB1 on the expression of profibrotic cytokine CTGF 
and correlate these findings with CTGF expression in kidney allograft biopsies.
Methods: We selected 8 clones of human conditional immortalized PTC (ciPTC) with 
4 different combinations of CYP3A5 (rs776746) and ABCB1 (rs1045642) genotypes. Cells 
were incubated with vehicle, 50 ng/ml and 300 ng/ml tacrolimus (in vivo concentration 
range). Quantitative RT-PCR and western blot were performed to study CTGF 
expression. In addition, CTGF staining was performed on protocol biopsies with a known 
pharmacogenetic background derived from 21 allograft recipients over a period of 2 years.
Results: CTGF mRNA and protein expression increased with tacrolimus concentration 
(CTGF vs. β-actin vs. vehicle at 50ng/ml: + 34.1% (95% CI: 22.3 - 45.9) and at 300 ng/ml: 
+45.0% (95% CI: 35.2 - 54.8); p<0.001). Subgroup analysis demonstrated 46% higher
protein expression in CYP3A5 *3/*3 allele carriers vs. *1 allele carriers (p=0.047) and 
more than 2-fold higher CTGF expression in ABCB1 3435 TTs, while in the genetic CC/
CT counterparts CTGF expression decreased (p=0.01). Immunohistochemical studies of 
protocol biopsies demonstrated a 37.1% increase in tubular cell CTGF staining between 3 
to 24 months in kidneys from 3435 TT genotype donors, while in CC/CT donor grafts the 
percentage of CTGF positive tubuli remained stable (p=0.015).
Conclusions: Tacrolimus exposure in human PTCs results in a concentration-dependent 
increase in CTGF expression. Tacrolimus exposure for 72 hours resulted in increased CTGF 
expression in PTC derived from CYP3A5 *3/*3 allele carriers, and in particular with the 
ABCB1 3435TT genotype. Immunohistochemical studies on protocol biopsies confirm 
increasing CTGF expression over time in donor kidneys with the ABCB1 3435TT genotype.
Funding: Government Support - Non-U.S.
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A Biomarker of Collagen Type VI Formation Is Associated to Allograft 
Outcome in Kidney Transplant Recipients
Federica Genovese,1 Nadja Sparding,1 Daniel Guldager Kring Rasmussen,1 
Morten A. Karsdal,1 Henrik Birn,2 Bente Jespersen,3 Rikke Norregaard.4 1Nordic 
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Background: A careful evaluation of kidney transplant recipients is important for a 
successful allograft outcome. Non-invasive biomarkers are needed to predict immediate 
and long-term kidney function after transplantation. Preliminary findings have identified 
PRO-C6, a non-invasive biomarker of collagen type VI formation related to burden of 
kidney fibrosis, as a good prognostic marker for kidney function loss and mortality in 
chronic kidney disease patients.
Methods: Here we evaluate the prognostic potential of PRO-C6 in kidney transplant 
recipient by measuring PRO-C6 in plasma of 219 patients before transplantation, and 1 day, 
3 months and 12 months after transplantation, by means of an ELISA developed at Nordic 
Bioscience.
Results: Levels of the serum PRO-C6 decreased significantly from baseline (median, 
95% CI: 50.7, 46.7-53.5) to day 1 (median, 95% CI: 34.8, 31.1-38.3) and further decreased 
at month 3 (median, 95% CI: 14.2, 12.7-14.5), but not significantly from month 3 to month 
12 (median, 95% CI: 13.5, 12.7-14.5). PRO-C6 correlated with plasma creatinine before 
transplantation (rho =0.43, p<0.0001), 1 day after rho for PRO-C6 vs plasma creatinine was 
0.67, p<0.0001, at 3 months after rho for PRO-C6 vs measured GFR was -0.58, p<0.0001, 
and at 12 months after rho for PRO-C6 vs measured GFR was -0.57, p<0.0001. PRO-C6 
measured either before transplantation and at day 1 after transplantation could identify 
patients who required dialysis one week after transplantation (delayed graft function) 
(AUC: 0.679, p<0.0001; and AUC: 0.860, p<0.0001, respectively). PRO-C6 measured 
1 day after transplantation identified patients who still required dialysis three months 
after transplantation (AUC: 0.789, p<0.0001). Plasma creatinine measured one day after 
transplantation did not have any prognostic ability to identify patients with no graft function 
after 3 months. PRO-C6 measured 1 day after transplantation was also associated to the 
time needed to reach a 50% reduction in plasma creatinine after transplantation (HR per 
doubling of PRO-C6: 0.659 (0.548-0.792), p<0.0001).
Conclusions: PRO-C6 measured in plasma was associated with delayed graft function 
and no function at 3 months after transplantation and it can potentially be used to identify 
the patients at risk of graft function loss.
Funding: Commercial Support - Nordic Bioscience
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Liposomal Delivery Improves the Efficacy of Prednisolone to Reduce 
Renal Inflammation in a Mouse Model of Acute Renal Allograft Rejection
Carla van Alem,1 Schmidbauer Martina,5 Song Rong,4 Jan H. Braesen,3 
Anja Thorenz,4 Rongjun Chen,4 Jurjen Ruben,1 Elizabeth M. Winter,1 
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Netherlands; 2Institute for Animal Science, Hannover Medical School, 
Hannover, Germany; 3Pathology, Hannover Medical School, Hannover, 
Germany; 4Nephrology, Hannover Medical School, Hannover, Germany; 
5Radiology, Hannover Medical School, Hannover, Germany; 6Enceladus 
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Background: Allograft rejection remains one of the main obstacles in kidney 
transplantation. Although treatment with high doses of corticosteroids is often efficacious, 
systemic exposure and activation of the glucocorticoid receptor (GR) results in substantial 
side effects. In this study we used a mouse model of acute renal allograft rejection to 
investigate whether liposomal encapsulation could facilitate local delivery of prednisolone 
to the allograft and enhance its therapeutic effect.
Methods: Male BalbCHanZtm recipients received a kidney transplant from male 
C57BL/6JHanZtm donors (n=10 per group). Recipients were injected daily with 5 mg/kg 
cyclosporine A and received either 10 mg/kg prednisolone (P), or liposomal prednisolone 
(LP) intravenously on day 0, 3, and 6, or no additional treatment (NA). Functional MRI was 
performed at day 6 (N=6) to study graft perfusion and organs were harvested at day 7 for 
FACS- and qPCR analysis.
Results: MRI analysis revealed better allograft perfusion upon LP treatment, as 
compared to NA treatment (428.3±114 vs 218.5±117 ml/min*100g, p<0.05) while P vs 
NA treatment showed no significant improvement. FACS analyses of allografts revealed 
a reduced number of CD45+ leukocytes in LP vs P or NA treatment (5,3 and 6,6 fold 
decrease, p<0.05), less CD3+ T cells in LP vs NA (3,7 fold decrease, p<0.05), and less 
F4/80+ macrophages in LP vs P and NA (4,3 and 4,2 fold decrease, p<0.05). Upon LP 
treatment, the expression of the GR responsive gene Fkbp5 was upregulated in the allograft, 
as compared to P and NA treatment (3,7 and 4,4 fold change, p<0.05). This was also 
observed in the spleen, but not in the heart, a non-target organ.
Conclusions: Liposomal delivery results in a higher local bioavailability of 
prednisolone, increased perfusion and a reduced cellular infiltrate in the transplanted 
kidney, compared to conventional prednisolone. Future clinical studies should reveal if 
treatment with LP results in improved efficacy and reduced side effects in patients with 
renal allograft rejection.
Funding: Commercial Support - Enceladus Pharmaceuticals B.V., Private Foundation 
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Variability in Outcome in Patients with DSAs Is Modulated by the 
Expression of HLA Antigens on the Allograft Endothelium
Stephanie Beland, François Bouchard-Boivin, Olivier Desy, Sacha A. De Serres. 
University Health Center (CHU) of Quebec, Laval University, Quebec, QC, 
Canada.
Background: The development of de novo donor-specific antibodies (DSAs) is 
associated with antibody-mediated rejection and allograft failure. However, some patients 
with DSAs escape graft rejection. We hypothesized that DSA-mediated injury is modulated 
by 1) the variability in expression of HLA-II antigen subtypes (DR, DP and DQ) on a 
within-patient basis and 2) the variability in HLA antigen expression on a between-patient 
basis.
Methods: We measured in vitro HLA-I and II (DR, DP and DQ subtypes) antigen 
expression on 2 glomerular endothelial cell lines and on blood outgrowth endothelial cells 
(BOEC) from patient’s collected PBMCs (n=12). Endothelial cells were treated following 
a time-course of IFN-g for 10 days to induce HLA-II expression. HLA antigen expression 
was assessed by flow cytometry over time. Unstimulated cells were used as controls.
Results: Across all individuals, the maximal percentage and the standard deviation of 
HLA-positive cells varied substantially (97±3 vs. 96±3 vs. 89±9 vs. 44±37% for HLA-I 
vs. –DR vs. –DP, vs –DQ respectively, p<0.001) as well as the time of incubation to reach 
maximal expression (5±2 vs. 4±1 vs. 6±2 vs. 9±1days, p<0.001). Maximal MFI also varied 
between HLA subtypes (98±49 vs. 12±8 vs. 10±6 vs. 4±3x103, p<0.001) as well as the time 
to reach this maximum (4±1 vs. 6±2 vs. 8±2 vs. 10±1days, p<0.001). Repeated experiments 
on the same individuals showed little variation between experiments (mean SD 12±8 vs. 
7±5 vs. 6±4 vs. 1±1, p<0.07), indicating that the variability was not due to inter-assay 
variation.
Conclusions: Among HLA-II subtypes, the DR antigen seems to be the most inducible, 
whereas DQ has a lower and more variable expression. The use of BOEC is breaking new 
in the analysis of HLA antigen expression in vitro. A better understanding of the expression 
of DSA ligand could be instrumental in our understanding of antibody-mediated rejection.
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MHC Class II Ligation on Glomerular Endothelial Cells Upregulates 
Adhesion Molecules and Chemoattractants
Sarah E. Panzer,1 Nancy A. Wilson,1 James F. Dylewski,2 Arjang Djamali,1 
Judith Blaine.3 1University of Wisconsin Madison, Madison, WI; 2University of 
Colorado Hospital, Aurora, CO; 3University of Colorado Denver, Aurora, CO.
Background: Microvascular injury and leukocyte margination across endothelial cells 
are key pathologic processes in kidney allograft rejection. The mechanisms of glomerular 
endothelial cell injury and leukocyte infiltration remain unclear. We hypothesize MHC class 
II ligation on glomerular endothelial cells will result in upregulation of adhesion molecules 
and chemoattractants.
Methods: A Bl/6 mouse glomerular endothelial cell (MGEC) line was stimulated with 
IFNγ to upregulate MHC class I and II; then incubated with anti-MHC class II antibodies 
or plasma from balb/c mice sensitized with Bl/6 splenocytes. Expression of adhesion 
molecules were assessed by flow cytometry. Gene expression was measured by RT2 
profiler and Taqman RT PCR. Cytokine expression was analyzed in culture supernatants 
with LegendPlex.
Results: MGEC stimulated with IFNγ upregulated gene expression of TRAIL, 
RANTES, MCP-1, caspase1, beta2microglobulin, Vcam1, IL-6 and Icam1 (A). IFNγ 
stimulation of MGEC increased surface expression of MHC class I, MHC class II, 
VCAM1, and ICAM1; but not P-selectin (B). Subsequent ligation with MHC class II 
antibody transiently increased surface expression of P-selectin at 6 hours; while sensitized 
plasma resulted in a greater increase in P-selectin, which persisted at 24 hours (C). MGEC 
secretion of chemoattractants (MCP-1 and RANTES) increased with IFNγ stimulation and 
was further enhanced with MHC II ligation (D). Adhesion molecules and MHC co-localize 
on the cell surface (E).
Conclusions: MHC II crosslinking on MGEC resulted in an upregulation of P-selectin 
as well as chemoattractants. MHC molecules and adhesion molecules are co-localized 
on the endothelial cell surface. Future studies will examine therapeutic targets, such as 
inhibitors of mTOR (inhibition of ICAM1 clustering) and Nox4 (TRAIL pathway).
Funding: Other NIH Support - This project was supported by the Clinical and 
Translational Science Award (CTSA) program, through the NIH National Center for 
Advancing Translational Sciences (NCATS), grant UL1TR000427, and the KL2 training 
Award (KL2TR000428)., Clinical Revenue Support
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Transplantation: Basic
B Cell Deficiency in a Rat Kidney Transplant Model Reduces Glomerular 
Basement Membrane Duplication in Early Transplant Glomerulopathy
Sarah E. Panzer, Yabing Huang, Weixiong Zhong, Arjang Djamali. University of 
Wisconsin Madison, Madison, WI.
Background: B cells play core roles in the humoral response and are able to contribute 
to cellular immunity, but the specific role of B cells in early transplant glomerulopathy (TG) 
remains unclear. We hypothesize B cell deficiency will attenuate the pathology of TG.
Methods: A rat kidney transplant model was used with 4 treatment groups: Syngeneic 
(Lewis to Lewis), Allogeneic (Fisher to Lewis), Sensitized (Fisher to Lewis 3 weeks 
following donor blood transfusion), or Allogeneic B cell deficient (B-/-) recipients (Fisher 
to B-/- Lewis). All animals were harvested at 3 or 6 months. The following 5 parameters 
were measured by electron microscopy: duplication of glomerular basement membrane 
(GBM), total length of GBM, diameter of endothelial cell (EC), height of EC, and layers 
of peritubular capillary basement membrane (PTCBM). The ratio of GBM injury and mean 
data was determined among these groups.
Results: At 3 months after transplant, GBM duplication was reduced between B-/-
 recipients and sensitized recipients (10.2±0.8% versus 6.5±0.7%; p=0.01). The percent 
of GBM with duplication was reduced at 6 months after transplant in B-/- recipients 
compared to allogeneic and sensitized recipients (B-/-:8.5±1.1%, allogeneic:17.2±0.8%, 
sensitized:32.6±3.3%; p<0.001) (Figure 1). The mean maximum diameter and the mean 
height of EC demonstrated no differences among allogeneic, sensitized, and B-/- recipients 
in both 3 and 6 months samples. PTCBM multilayering was also similar among allogeneic, 
sensitized, and B-/- recipients in both 3 and 6 months samples.
Conclusions: B cell deficiency in this model reduces the duplication of GBM in early 
TG. The GBM injury occurs before obvious EC injury and PTCBM multilayering. Future 
studies of B cell directed interventions are needed in TG.
Funding: Other NIH Support - This project was supported by the Clinical and 
Translational Science Award (CTSA) program, through the NIH National Center for 
Advancing Translational Sciences (NCATS), grant UL1TR000427, and the KL2 training 
Award (KL2TR000428).
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Transplantation: Basic
An Optimized Protocol to Quantify Signaling in Human Transitional B 
Cells by Phospho Flow Cytometry
Nicholas Zwang,1 Kim Cardenas,2 Anita S. Chong,3 Patricia W. Finn,4 
David L. Perkins.5 1Nephrology, The University of Illinois at Chciago, Chicago, 
IL; 2BioLegend, Chicago, IL; 3University of Chicago, Chicago, IL; 4University 
of Illinois at Chicago, Chicago, IL; 5University Illinois Chicago, Chicago, IL.
Background: Phospho flow cytometry is a powerful technique to analyze signaling 
in rare cell populations. This technique, however, requires harsh conditions for cell 
fixation and permeabilization, which can denature surface antigens or antibody-conjugated 
fluorochromes. These are among several technical limitations which have been a barrier to 
quantify signaling in unique B cell subsets. One such immature subset, transitional B cells 
(TrBs), may play a role in suppressing solid organ transplant rejection, graft-versus-host 
disease, autoimmunity, and even the immune response to malignancy. Here we sought to 
optimize a protocol for quantification of signaling in human TrBs compared with mature 
B cell subsets.
Methods: TrBs were defined by surface marker expression as CD19+CD24hiCD38hi. 
Key parameters optimized included antibody clone selection, sequence of surface 
epitope labeling in relation to paraformaldehyde-based fixation and methanol-based 
permeabilization, photomultiplier tube (PMT) voltages, and compensation. Special 
attention was paid to labeling of CD38 with regard to these parameters, and an optimized 
protocol enabled reliable identification of TrBs, naïve (CD24+CD38+), early memory 
(CD24hiCD38-), and late memory (CD24-CD38-) B cells.
Results: Phospho flow cytometry enabled simultaneous quantification of 
phosphorylation among at least three different signaling molecules within the same sample. 
Among normal donors, transitional B cells exhibited diminished mitogen activated protein 
kinase/extracellular signal-regulated kinase and Akt phospho signaling upon nonspecific 
stimulation with phorbol 12-myristate 13-acetateand ionomycin stimulation.
Conclusions: We optimized an effective protocol to quantify B cell subset signaling 
upon stimulation. Such a protocol may ultimately serve as the basis for assessing 
dysfunctional B cell signaling in disease, predict clinical outcomes, and monitor response 
to B cell-directed therapies.
FR-PO863 Poster Friday
Transplantation: Basic
Utility of Immunoglobulin/T-Cell Receptor Gene Rearrangements As a 
Tool for Early Detection and Monitoring of Post-Transplant Lymphopro-
liferative Disorder in Renal Transplant Recipients
Wee Song Yeo,1 Chang-Yien Chan,1 Hui Kim Yap.2 1National University of 
Singapore, Singapore, Singapore; 2National University Hospital, Singapore, 
Singapore.
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is a well-known 
complication post-transplant and contributes significantly to the morbidity and mortality 
seen in transplant recipients. A key limitation in the management of this dreaded disease 
involves its early detection and subsequent monitoring. A potential solution involves 
Ig/TCR gene rearrangement analysis. This molecular clonality analysis technique is 
based on the principle that, all cells of a malignancy have a common clonal origin and 
demonstrate clonally rearranged Ig or TCR genes. The diagnosis of malignant B- and T-cell 
proliferations is therefore supported by the finding of Ig/TCR gene clonality, whereas 
reactive lymphoproliferations show polyclonally rearranged Ig/TCR genes. We report 
our experience with two renal transplant recipients with PTLD whereby Ig/TCR gene 
rearrangements may play a role in the surveillance of this lymphoproliferative disorder.
Case Description: The 2 patients reported underwent cadaveric renal transplantation 
with subsequent development of PTLD. Both had reduction in immunosuppressants with 
rituximab therapy, following diagnosis of PTLD. One of the patients went on to CHOP 
chemotherapy and even lost her renal allograft secondary to PTLD involvement. Both 
patients were in clinical, hematological and radiological (PET scan) remission at the point 
of performance of Ig/TCR gene rearrangements. In these two pediatric renal transplant 
recipients with PTLD, it was noticed that there were Ig/TCR gene rearrangements detectable 
in their peripheral blood suggestive of clonal remnant of their PTLD.
Discussion: Lymph node/tissue biopsies remain the gold standard for the diagnosis 
of PTLD. Transplant recipients could not and should not be subjected to infinite repeated 
biopsies or expensive imaging studies (e.g. PET-CT scans) for the purpose of monitoring 
for the development of PTLD in view of inherent risks associated with biopsies and 
radiation risks, respectively. Our case report suggests the potential utility of Ig/TCR gene 
rearrangements as a non-invasive tool for early detection and monitoring of PTLD. Further 
large prospective trials are required to validate the above proposal.
FR-PO864 Poster Friday
Transplantation: Basic
Multiplexed Immunofluorescence to Investigate the Immune Response to 
BK Virus in Kidney Transplant Recipients
Cecile Fajardo,1 Paul C. Grimm,2 Neeraja Kambham.3 1Stanford University, 
Stanford, CA; 2Stanford University Medical Center, Stanford, CA; 3Stanford 
University, Stanford, CA.
Background: BK virus nephropathy is a complication in renal transplant that leads to 
allograft dysfunction or failure. Acute inflammation, tubular atrophy, and interstitial fibrosis 
are seen in both BKVN and acute rejection making it challenging to differentiate. Previous 
studies have characterized the immune response on histology, but the identification 
and characterization of infiltrating cells was limited due to constraints of traditional 
immunohistochemistry. Multiplexed immunofluorescence allows a more comprehensive 
understanding of the spatial relationships of immune cell phenotypes and ongoing signals 
within the kidney microenvironment.
Methods: Using CO-detection by inDEXing (CODEX), the expression of 50 markers 
for identifying renal structural elements, immune cell subsets, and immune function were 
evaluated on a single tissue section of a pediatric kidney transplant recipient.
Results: See images and caption for results.
Conclusions: CODEX is a novel technique in characterizing the immune repertoire in 
BKVN and visualizing renal histology. Predominant immune infiltrate in BKVN consists 
of T cells, plasmacytoid and myeloid dendritic cells, and sparse NK cells, which have not 
been previously described. A majority of CD3 T cells in BKVN appear to be activated 
and a minority expressing markers of exhaustion and inhibition. Comparing the immune 
repertoire of BKVN and acute rejection is an important and clinically significant future 
direction.
A) Renal tubules with cytokeratin, endothelial cells and blood vessels using CD31, and
glomerular podocytes using podocin. B) Co-localization of CD3 T cells (green), CD1c
myeloid dendritic cells (white), CD16 NK cells (yellow). C) Infiltration of interdigitating 
plasmacytoid dendritic cells (green) and myeloid dendritic cells (blue) in a cluster of T
cells (red).
D) Functional analysis of CD3 T cells (blue) show co-expression of markers of inhibition
with CD152/CTLA4 (green), exhaustion with CD279/PD1 (yellow), activation with CD69 
(red), D4 shows a merge of all markers.
FR-PO865 Poster Friday
Transplantation: Basic
Inhibition of Cyclophilin A and Large T Antigen Interaction Reduces 
Polyomavirus BK Replication
Ya-chung Tian. Linkou Kidney Research Center Chang-Gung Memorial 
Hospital, Taipei County, Taiwan.
Background: Specific treatment for polyomavirus BK (BKV) infection in kidney 
transplant recipients remains unsolved. We previously demonstrated that cyclophilin A 
(CypA) was crucial for BKV replication. The aim of this study was to assess the impact of 
interaction of CypA and BKV large T antigen (TAg) on BKV replication.
Methods: HRPTEC or HK-2 were used in this study.
Results: The immunoprecipitation (IP) revealed an interaction between TAg and 
CypA. Similarly, the ELISA assays using purified TAg and CypA confirmed a binding 
between CypA and TAg. Atomic force microscope (AFM) revealed a binding between TAg 
and CypA. This binding was reduced if the TAg-coated probe was pretreated with anti-
TAg blocking antibody. Immunocytochemistry (IHC) also verified nuclear colocolization 
of CypA and TAg expression. Both N-terminus (DN-CypA) and C-terminus (DC-CypA) 
failed to colocalize with nuclear TAg expression. The IP assay confirmed a failure of DN-
CypA binding to TAg. Overexpression of DN-CypA in the CypA-knockdown cells reduced 
BKV replication, confirming that the N-terminus of CypA binding to TAg is crucial for viral 
replication. Overexpression of CypA but not DN-CypA enhanced TAg-induced promoter 
activity of BKV. Overexpression of CypA in the NFATc3-knockdown cells still enhanced 
viral replication, indicating a NFATc3-independent pathway. Addition of Debio-025 caused 
a reduction in BKV replication. IHC showed that Debio-025 caused a reduction of nuclear 
CypA expression. Immunoblotting assay confirmed a dramatic reduction of CypA in the 
nuclear fraction by addition of Debio-025. Mutant CypA proteins at six different functional 
residues in the enzyme pocket of CypA (possible functional sites of Debio 025) did not 
affect TAg and CypA interaction detected by the IP assay and the ELISA assay. In vivo, 
following BKV injection, BKV copies in the kidneys were reduced in the CypA-knockout 
mice or in the Debio-025-treated mice, when compared with those in the wild-type mice or 
non-treatment controls.
Conclusions: Nuclear translocation of CypA and interaction with nuclear TAg, both of 
which depends on N-terminus of CypA is essential for BKV replication. Blockade of the 
CypA-dependent NFAT-independent pathway by Debio-025 suppressed BKV replication. 
As no anti-BKV treatment is satisfactory so far, alisporivir that has no immunosuppressive 
effect can be potentially applied for anti-BKV treatment.
Funding: Government Support - Non-U.S.
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Transplantation: Translational and Transplant Pathology
Efficacy and Safety According to Dose of Valganciclovir for Cytomegalovi-
rus (CMV) Prophylaxis in Transplantation: Network Meta-Analysis Using 
Recent Data
Jin ho Lee,1 Seon Deok Hwang,3 Seoung Woo Lee,4 Woo Yeong Park,7 Jeong 
Ho Kim,8 Hee yeoun Kim,2 Seong min Kim,5 Joon Seok Oh,6 Dongyeol Lee,1 
Yong hun Sin,9 Joong Kyung Kim.1 1Bong Seng Memorial Hospital, Busan, 
Republic of Korea; 2Bongseng hospital, Busan, Republic of Korea; 3Inha 
University College of Medicine, Incheon, Republic of Korea; 4Inha University 
Hospital, Inchon City, Republic of Korea; 5Dongrae Bongseng Hospital, Busan, 
Republic of Korea; 6Bong Seng Hospital, Korea, Dong-gu, Busan, Republic of 
Korea; 7Dongsan Medical Center, Daegu, Republic of Korea; 8Daejeon St. 
Mary’s Hospital, Daejeon, Republic of Korea; 9Bong Seng Hospital, Busan, 
Republic of Korea.
Background: Valgancivlovir is used to prevent post-transplant CMV infection 
among kidney transplantation patients. However, the dose of drug being used still remains 
controversial since the continuous use of such drug decrease kidney functions and induces 
leukopenia in some of the cases. Accordingly, the purpose is to measure the appropriate 
dose of the drug required for preventing CMV using network Meta analysis
Methods: We searched the Cochrane Central Register, OVID MEDLINE, EMBASE, 
and Pubmed until April 15, 2017. We reviewed the reference lists of relevant reviews, 
registered trials, and relevant conference proceedings. Definition of low dose valganciclovir 
group is 450mg and standard dose one is 900mg. Studies evaluating among valganciclovir 
900 mg, 450 mg and controls were evaluated. We performed direct and indirect network 
meta-analysis using Bayesian models and generated rankings of the different dose of 
valgaciclovir agents by generation mixed treatment comparison (GeMTC).
Results: Twenty-four studies involving 3,730 participants were eligible. As a result of 
analyzing among three groups, following completion of the research, the analysis revealed 
that the glomerular filtration rate, graft loss, tacrolimus level, antibody mediated rejection, 
fungal, and Candida infection rates were not different among groups. Compared with 
control, there was no difference between low dose 0.79 [95% Crl, 0.50-1.40] and standard 
dose 1.0 [95% Crl, 0.61-1.60] groups when CMV incidence was compared. In the Rank 
probabilities table, the best order for lowering the CMV event was as high as dose of 
450mg (71.1%). Incidence of leukopenia showed a significant difference, but there was 
no statistical significance in the low dose group 1.5 [95% Crl, 0.99-2.20] compared with 
the control group, but 4.3 times higher in the high dose group 4.3 [95% Crl, 2.69-7.10], 
which was 2.9 times higher in the low dose group and the high dose group 2.9 [95% Crl, 
1.88 -4.67].
Conclusions: The use of valganciclovir did not show any difference in other side 
effects, but the use of low doses of leukopenia significantly reduced side effects. The 
incidence of CMV was not different among the three groups, but the tendency was also 
decreased at low dose.
FR-PO867 Poster Friday
Transplantation: Translational and Transplant Pathology
Cytomegalovirus Serostatus and Living Donor Kidney Transplant 
Outcomes in the Era of Routine CMV Prophylactic and Preemptive 
Therapy
Napat Leeaphorn,1 Natanong Thamcharoen,2 Neetika Garg,3 Woojin 
James Chon,1 Lee S. Cummings,1 Martha Pavlakis.2 1Renal Transplant Program, 
University of Missouri-Kansas City School of Medicine/Saint Luke’s Health 
System, Kansas City, MO; 2Transplant Institute, Beth Israel Deaconess Medical 
Center, Boston, MA; 3University of Wisconsin-Madison, Madison, WI.
Background: The impact of CMV serostatus on living donor kidney transplant 
outcomes in an era when CMV prophylactic and preemptive strategies are used routinely 
has never been examined.
Methods: Using UNOS/OPTN data, adult patients with first living donor kidney 
transplant between 2010 and 2015 were stratified into 4 groups: D-/R-, D+/R-, D+/R+, 
and D-/R+. Death-censored graft survival, all-cause mortality and cumulative incidence of 
rejection at 1-year were examined using D-/R- as a reference group.
Results: A total of 28,730 recipients were included: 4,972 (17.3%) in D+/R-, 7,404 
(25.8%) in D-/R-, 10,233 (35.6%) in D+/R+, and 6,121 (21.3%) in D-/R+ group. In the 
multivariable analysis, D+/R- was associated with an increased risk of graft failure 
(HR=1.18, P=0.049) when compared to D-/R-. There was also an increased risk of graft 
failure in D+/R+ when compared to D-/R- (HR=1.09, P=0.021). CMV serostatus did not 
have any statistically significant effects on all-cause mortality or acute rejection at 1 year.
Conclusions: In living donor kidney transplantation, CMV mismatch (D+/R-) is not 
an independent risk factor for patient mortality in the era of effective prophylactic and 
preemptive strategies. D+/R- and D+/R+ serostatus have a slightly negative impact on 
graft survival. These findings can be informative and used for patient counseling before 
undergoing living donor kidney transplantation.
FR-PO868 Poster Friday
Transplantation: Translational and Transplant Pathology
The Outcomes of Kidney Retransplantation After Graft Loss Due to BK 
Virus Nephropathy
Napat Leeaphorn,1 Woojin James Chon,1 Lee S. Cummings,1 
Wisit Cheungpasitporn.2 1Renal Transplant Program, University of Missouri-
Kansas City School of Medicine/Saint Luke’s Health System, Kansas City, MO; 
2Division of Nephrology, Department of Medicine, University of Mississippi 
Medical Center, Jackson, MS.
Background: Existing literature on outcomes of kidney retransplantation in patients 
with previous graft failure due to BK virus nephropathy (BKVN) is scarce.
Methods: Using UNOS/OPTN data, we analyzed adult patients who received their 
second kidney transplant between 2005 and 2015.
Results: 321 out of 15,724 patients lost their first graft to BKVN (BK-group) with 
a median follow-up time of 4.2 years. Of these 321 patients in BK-group, 54 patients 
underwent preemptive second kidney transplantation. Retransplant occurred at a median 
of 2.2 years after graft failure. Patients in BK-group were twice more likely to receive 
basiliximab when compared to patients who lost their first graft due to other causes. One-
year acute rejection rate in BK-group was 15%. As of March 3, 2017, 264/321 grafts were 
still functioning with 6 grafts that failed due to BKVN. Kaplan- Meier death-censored graft 
survival rates at 1, 3, and 5-year after retransplantation in BK-group were 96.9%, 95.4%, 
and 90.5%, respectively, which were comparable to other causes of graft loss (and perhaps 
superior to patients who lost their first graft due to acute rejection) [Figure 1]. Patient 
survival in BK-group was similar to other causes of graft loss. The log-rank test was not 
performed due to unbalanced sample sizes across the groups.
Conclusions: Retransplantation after graft loss due to BKVN appears to be associated 
with good outcomes. However, the clinical interpretation of this study is limited by the lack 
of information on viral clearance and transplant nephrectomy prior to retransplantation.
FR-PO869 Poster Friday
Transplantation: Translational and Transplant Pathology
Impact of Antiviral Dose Adjustments on Risk for Breakthrough CMV 
Viremia After Kidney Transplantation
Suphamai Bunnapradist, Korntip Phonphok, Ittikorn Spanuchart, Tin N. Duong, 
Erik L. Lum, Elaine F. Reed, Joanna Schaenman. David Geffen School of 
Medicine at UCLA, Los Angeles, CA.
Background: CMV infection continues to cause significant morbidity in kidney 
transplant recipients in the modern era of transplantation. CMV seronegative patients with 
CMV seropositive donors are at highest risk for complications, including invasive disease 
and loss of allograft function. Inadequate drug dosing is associated with breakthrough 
viremia and drug resistance. We sought to evaluate whether drug dosing was associated 
with CMV viremia.
Methods: We reviewed CMV PCR testing results from 1297 adult kidney transplant 
recipients (excluding multiorgan transplants) between the years 2013-2017. We performed 
chart review to obtain antiviral prophylaxis regimens prior to viremia, and assessed sCr and 
calculated GFR at regimen start. Adequacy of dose adjustment for renal insufficiency was 
determined based on the package insert for valganciclovir to determine whether there was 
an association between antiviral dosing and breakthrough CMV viremia.
Results: We identified 14 seronegative kidney transplant recipients who developed 
CMV viremia during the first year after transplantation. 9 had received basiliximab (64%) 
and 5 (36%) antithymocyte globulin. 3 patients experienced biopsy-proven rejection (2 
ACR and 1 AMR) prior to CMV viremia. The median time to viremia was 75 days (range 
62-178). 5 patients (36%) were not taking valganciclovir at the time of viremia detection,
while 9 patients (64%) were on valganciclovir. 8 of the 9 (89%) patients on valganciclovir 
were on dose-adjusted regimens at the time of viremia, correct according to the Valcyte
package insert, at doses ranging from 450 mg once daily to 450 mg 3x/week.
Conclusions: Despite appropriate valganciclovir dose-adjustment, breakthrough CMV 
viremia occurred. This suggests that renal impairment is associated with CMV infection 
either because standard dose adjustments are inadequate, impaired drug absorption, or 
exacerbation of impaired CMV immune response. This suggests a role for therapeutic drug 
monitoring, and for the need for more effective antiviral prophylaxis medications. Future 
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studies will evaluate patterns of drug dosing associated with CMV viremia in seropositive 
transplant recipients. Immunologic analysis will be performed to identify patients lacking 
effective CMV-specific immune response in need of prolonged antiviral prophaylaxis.
FR-PO870 Poster Friday
Transplantation: Translational and Transplant Pathology
The Molecular Profile in Kidney Allograft Highlighting Subclinical Acute 
Rejection (SAR): Towards a Targeted Treatment
Sharon N. Cox,1,2 Samantha Chiurlia,2 Francesco P. Schena.1,2 The Italian 
Transplantomics Group 1University of Bari, Bari, Italy; 2Schena Foundation, 
Valenzano, Bari, Italy.
Background: SAR diagnosed by protocol biopsy is an independent risk factor for 
chronic allograft injury. We organized a molecular study on 24 AB0 compatible cadaveric 
kidney transplant recipients with standard immunological risk who received protocol biopsy 
in the first post-transplant year. Aim of our study was to identify specific gene expression 
changes that characterize SAR and to highlight specific therapeutic interventions based on 
the molecular fingerprints.
Methods: Total RNA was extracted from archival FFPE renal tissue samples of 12 
patients with SAR scored by 2 pathologists according to the updated Banff criteria and 
a control group of 12 patients with normal histological findings in protocol biopsies 
performed at 3- and 12-months post-transplant. All patients had a stable renal function 
(mean serum creat < 1.65 mg/dL). The cRNA fragments were hybridized on GeneChips 
Agilent. Genome-wide gene expression profiles were generated and bioinformatic analysis 
was done with Genespring. A false discovery rate (FDR) <0.02 and fold change > 2 were 
applied. Canonical pathways and biological functions were explored using Ingenuity 
pathway analysis (IPA) software. Real Time PCR was used for validation of the identified 
transcripts.
Results: We identified 1849 genes aberrantly modulated in SAR biopsies, 184 were 
down-regulated and 1257 up-regulated. Three-dimensional Principal Component Analysis 
showed a different spatial distribution between the SAR patients and control Patients. 
The most significant canonical pathways were Natural killer cell signalling (p=0.00413), 
Wnt/β-catenin pathway (p=0.03) Role of cytokines in mediating communication between 
immune cells (p=0.04). The top selected networks highlighted several modulated genes 
involved in Acute Kidney Injury and candidate transcripts were validated by qRT-PCR.
Conclusions: Our data demonstrates a specific fingerprint associated with SAR 
characterized by various genes involved in molecular inflammatory processes and crosstalk 
between immune cells. These results suggest the possibility of early recognition and 
targeted treatment before chronic allograft disease.
Funding: Government Support - Non-U.S.
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Transplantation: Translational and Transplant Pathology
Urinary Exosomal MicroRNA as a Non-Invasive Biomarker for the 
Diagnosis of Acute Rejection in Kidney Transplant Recipients
Yu ho Lee,1 Seo Jung-Woo,1 Su Woong Jung,1 Yang gyun Kim,1 Ju young Moon,1 
Jin sug Kim,1 Kyung-hwan Jeong,1 Byung ha Chung,2 Sangho Lee.1 1Department 
of Nephrology, Kyung Hee University, Seoul, Republic of Korea; 2Seoul St. 
Mary’s Hospital, Seoul, Republic of Korea.
Background: Acute rejection (AR) is the main obstacle to the graft survival after 
kidney transplantation. Urinary exosome is a promising source of biomarker for various 
kidney diseases, but few studies determined the clinical relevance of urinary exosomal 
microRNA in kidney transplant recipients. The purpose of this study was to investigate the 
profiles of urinary exosomal microRNAs to discover novel biomarkers of AR in patients 
who underwent kidney transplantation.
Methods: urinary exosomal microRNAs from 108 kidney transplant recipients were 
extracted. The candidate microRNAs for the diagnosis of AR were selected based on 
Nanostring analysis of urinary exosomal microRNAs, meta-analysis and the review of 
literature. The levels of candidate microRNAs were further confirmed by quantitative real-
time polymerase chain reaction. The diagnostic value of final candidate microRNAs was 
determined in independent validation group.
Results: Nanostring analysis found that the expressions of 14 microRNAs were 
significantly altered in patients with AR compared to those with stable graft function. Meta-
analysis and the review of literature revealed 10 and 7 additional candidate microRNAs of 
AR, respectively. Quantitative real-time polymerase chain reaction confirmed that a total 
of 7 microRNAs maintained their differential expressions, and 4 microRNAs (hsa-miR-
21-5p, hsa-miR-30a-3p, hsa-miR-4488, and hsa-miR-4532) were chosen as final candidate 
microRNAs of AR by forward stepwise logistic regression model. The combinations of the 
levels of these 4 microRNAs effectively discriminated patients with AR from other patients 
in validation group, with an AUC value of 0.790.
Conclusions: This study demonstrated that the profiles of urinary exosomal 
microRNAs are altered in kidney transplant recipients having AR, and these differences 
could be potential non-invasive biomarkers for the diagnosis of AR.
Funding: Government Support - Non-U.S.
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Transplantation: Translational and Transplant Pathology
Involvement of Genetic Variation and Related Gene Expression Changes 
on Acute Rejection in Renal Transplant Recipients
Hyeon Seok Hwang,1 Yang gyun Kim,1 Ju young Moon,1 Tae won Lee,1 Chan-
Duck Kim,2 Byung ha Chung,3 Sangho Lee.1 1Division of Nephrology, 
Department of Internal Medicine, College of Medicine, Kyung Hee University, 
Seoul, Republic of Korea; 2Kyungpook University Hospital, Daegu, Republic of 
Korea; 3Seoul St. Mary’s Hospital, Seoul, Republic of Korea.
Background: Acute rejection (AR) is one of the major risk factors for renal allograft 
loss. The effect of genetic factors on the transplant outcomes has been clear. However, the 
correlation between genetic variation and acute rejection remains undetermined.
Methods: We collected blood samples from recipients with biopsy-proven AR 
(n = 81) and with stable graft function (n = 48). Gene expression data was pooled from RNA 
microarray and RNA sequencing. Integrative analysis combining genome-wide association 
studies (GWAS) and expression quantitative trait loci (eQTL) was used to identify single 
nucleotide polymorphisms (SNPs) for acute rejection.
Results: In eQTL analysis, we detected potential 35,465 SNPs, which correlated with 
RNA expression. We analyzed AR-related SNPs in GWAS with covariate adjustment, 
and detected 140 overlapped SNPs in integrative analyses of eQTL and GWAS. The 
corresponding genes of these SNPs were matched with genes whose expression level 
differs between patients with AR and stable graft, and three loci were finally mated. One 
locus encompasses PFDN6, which involves the activation and development of lymphocyte. 
Two other loci encompasses ZSCAN10 and HEBP2, which involves the DNA binding 
transcription factor activity and microtubule dynamics, respectively.
Conclusions: Our integrated analysis of GWAS and eQTL helps to find relevant genes, 
which had both biological and clinical significance, and identify three novel acute rejection 
susceptibility loci in renal transplant recipients.
FR-PO873 Poster Friday
Transplantation: Translational and Transplant Pathology
Differential Expression of Plasma miRNA in Acute Transplant Rejection
Amaryllis H. Van Craenenbroeck,2,1 Steven J. Van laere,1 Els M. Gielis,1 
Annemieke Smet,1 Amélie Dendooven,2,1 Rachel Hellemans,2 
Marie M. Couttenye,2 Benedicte De winter,1 Emeline M. Van craenenbroeck,2,1 
Kristien J. Ledeganck,1 Daniel Abramowicz.2,1 1University of Antwerp, Antwerp, 
Belgium; 2University Hospital of Antwerp (UZA), Edegem, Belgium.
Background: Transplant rejection remains a major clinical problem in nephrology. 
miRNAs, negative epigenetic regulators of gene expression at the posttranscriptional level, 
are involved in various conditions including kidney disease. We performed next-generation 
sequencing (NGS-)based miRNA profiling of plasma to discover a miRNA signature of 
acute graft rejection in kidney transplant recipients.
Methods: 6 stable (STA, 4 male, 46 ± 8 years) and 4 patients with biopsy-proven 
acute rejection (AR, 1 male, 44 ± 10 yrs) within the first 3 months after transplantation 
were studied. AR was defined as a rise in creatinine ≥ 0.3 mg/dl and a score ≥ Banff 2 on 
biopsy. STA patients had normal biopsies and stable creatinine levels. NGS was performed 
on isolated miRNA from EDTA plasma. Obtained read counts were normalized for library 
size, log2 transformed and subjected to differential miRNA expression analysis (limma-
package BioConductor). Support Vector Machine (SVM) classification was applied to build 
and cross-validate (i.e. leave-one-out method) a predictive model for graft rejection.
Results: 68 miRNA (26 novel) were differentially expressed in AR vs STA (p<0.05) 
with 16 miRNA being downregulated and 52 miRNA upregulated (Fig1). The SVM 
classification model revealed a signature of 4 miRNAs (miR-16-2, miR-361, miR-629 and 
miR-199a) that could predict AR with 90% accuracy, and a positive and negative predictive 
value of 100% and 86%, respectively.
Conclusions: We found a novel and unique plasma signature of 4 miRNA in AR 
patients. Prior to clinical implementation, prospective validation in an independent cohort 
with sensitivity and specificity analysis is mandatory. In addition, study of the involved 
miRNA and their mRNA targets can offer more insights into underlying disease mechanisms.
Funding: Government Support - Non-U.S.
Volcano plot: plasma miRNA expression profiles AR vs STA
Transplantation: Translational and Transplant Pathology
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
650
J Am Soc Nephrol 29: 2018 Poster/Friday
FR-PO874 Poster Friday
Transplantation: Translational and Transplant Pathology
Reduced Early Acute Rejection with Depleting Induction and Steroid 
Minimization Maintenance in Pediatric Kidney Transplant Recipients
Megan V. Yanik, Lucinda Weaver, Michael E. Seifert. University of Alabama at 
Birmingham, Birmingham, AL.
Background: Prolonged steroid exposure in pediatric kidney transplant recipients 
(PKTRs) can result in adverse effects. Recent studies indicate steroid minimization (SM) 
is effective compared to steroid based (SB) regimens, but outcomes data in PKTRs are 
limited. Subclinical rejection is prevalent in PKTRs, and is associated with poor outcomes.
Methods: We hypothesized that SM with depleting induction would decrease 
risk of acute rejection (AR) during the first post-transplant year in PKTRs compared 
to a SB regimen with non-depleting induction. A single-center, retrospective cohort 
study was performed on PKTRs from 8/2011 to 8/2017. The primary exposure was the 
immunosuppression regimen. Biopsies were performed for surveillance at 3- and 6-months 
post-transplant, and as indicated for allograft dysfunction. The primary outcome was AR 
by 1 year, including borderline, cellular, and antibody mediated. Secondary outcomes 
included allograft function, calcineurin inhibitor nephrotoxicity (CNIT), viral infections, 
and neutropenia.
Results: The cohort included 63 PKTRs; 21 and 42 patients on the SM and SB 
regimens. The median age at transplant was 12.9 years. The cohort included 37% black and 
71% deceased donor PKTRs. Overall, 32% of PKTRs had AR by 1 year post-transplant, 
with 80% of those detected on surveillance biopsy. By Kaplan-Meier analysis, PKTRs 
on SM had significantly less AR than those on the SB regimen (Figure 1, log rank p = 
0.02). There was no significant difference in mean eGFR at 1 year in the SM vs SB groups. 
There were also no differences in the rate of CNIT, BK nephropathy, CMV viremia, or 
neutropenia. PKTRs in the SM group had a lower incidence of EBV viremia (33% vs 69%, 
p = 0.01).
Conclusions: The incidence of AR in the first year post-transplant was significantly 
reduced in PKTRs undergoing a SM regimen. Further study is needed to determine the 
effect of SM on long term outcomes in PKTRs.
Figure 1
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Molecular Assessment of Pre-Implantation Transplant Kidney Biopsies
Enver Akalin,1 Mariel Barbachan e Silva,2 Maria Ajaimy,1 Valeria Mas,3 Pilib Ó 
Broin.4 1Montefiore Medical Center, Bronx, NY; 2National University of Ireland, 
Galway, Galway, Ireland; 3University of Virginia, Charlottesville, VA; 4NUI 
Galway, Galway, Ireland.
Background: Deceased-donor (DD) kidneys are at higher risk for ischemia/reperfusion 
injury leading to increased inflammatory mediators compared to living donors (LD). We 
investigated the association between intragraft molecular gene expression profiles and 
clinical outcomes including delayed graft function (DGF) and allograft function.
Methods: The study included 48 pre-implantation kidney biopsy samples (29 LD and 
19 DD). Patients were grouped on the basis of cold ischemia time (CIT) < 16 or > 16 hrs 
and presence of poor clinical/histological markers (final donor serum creatinine > 1.9 mg/dl, 
donor age > 60 yo, glomerulosclerosis/interstitial fibrosis/vascular sclerosis > 10%). The 
gene expression profiles were assayed using Affymetrix HuGene 1.0 ST arrays.
Results: DD pre-implantation biopsies showed increased expression of injury 
and repair (IRIT), gamma interferon and rejection (GRIT), cytotoxic T cell (CAT) and 
constitutive macrophage (CMAT) associated pathogenesis based transcripts (PBTs) 
compared to LD biopsies. CIT did not affect intragraft gene expression profiles. Biopsies 
with poor clinical/histological markers had increased expression of NKAT and endothelial 
cell associated transcripts (ENDAT). DGF occurred in 47% of DD patients but intragraft 
gene expression profiles were similar to patients who did not develop DGF. Patients with 
lower eGFR (<50 ml/min) at 1 year had increased expression of CAT, NKAT, CMAT and 
B cell associated transcripts at their pre-implantation biopsies compared to patients with 
higher eGFR (> 50 ml/min).
Conclusions: Pre-implantation DD biopsies showed increased expression of 
transcripts associated with increased immune activity. This is exacerbated if the donor had 
any poor clinical/histological markers, but not with increased CIT. Molecular analysis of 
pre-implantation biopsies did not differentiate patients based on DGF status but did show 
association of specific PBTs with better allograft function at 1 year
Figure
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CYP4F11 - A Potential Marker of Accommodation in ABO-Incompatible 
Renal Transplant Biopsies
Candice A. Roufosse,1 H. Terence Cook,3 Michelle Willicombe,1 Tom Cairns,2 
Jack W. Galliford,2 Frederic J. Toulza,1 Kathy M. Dominy.1 1Imperial College 
London, London, United Kingdom; 2IMPERIAL COLLEGE HEALTHCARE, 
LONDON, United Kingdom; 3Imperial College of London, London, United 
Kingdom.
Background: Recipients of an ABO incompatible transplant have circulating anti-AB 
antibodies, A and/or B antigens expressed on endothelium and usually C4d deposition on the 
endothelium, yet this seldom leads to antibody-mediated rejection. It has been hypothesised 
that this is related to upregulation of complement regulator and/or anti-apoptotic transcripts. 
We sought to identify differentially expressed genes between ABO-incompatible (ABOi) 
and ABO-compatible (ABOc) surveillance biopsies with normal histology.
Methods: RNA sequencing was performed to identify differentially expressed genes 
between 4 ABOi and 4 ABOc surveillance biopsies with normal histology. Differential 
expression was validated using RNA from formalin-fixed paraffin-embedded tissue from 
14 ABOi and 80 ABOc renal transplant patients, using a Nanostring nCounter custom panel.
Results: RNA sequencing identified a number of differentially expressed genes. 
None of the complement regulator and/or anti-apoptotic genes were upregulated in ABOi 
samples. Eighteen genes considered the top hits in sequencing analysis were validated 
using a Nanostring nCounter custom panel. The only differentially expressed gene that was 
confirmed was CYP4F11, which was reduced in ABOi biopsies (p=0.001, Mann-Whitney 
test) (See figure 1).
Conclusions: Genes classically hypothesised to be up-regulated in ABOi transplants 
were not found to have differential expression. Expression of cytochrome p450 4F11 isoform 
(CYP4F11) is reduced in ABOi patients. Most of the substrates of cytochrome p450 4F 
isoforms are eicosanoids, which play important roles in the inflammatory response. Down-
regulation of CYP4F11 in ABOi transplants may be be playing a role in accommodation to 
the anti-A or B antibodies and the presence of complement on the endothelial cell surface..
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C4d Positive Renal Transplant Biopsies with No Other Evidence of 
Rejection: A Transcript Expression Investigation Using NanoString 
nCounter Technology
Candice A. Roufosse,2 Michelle Willicombe,3 Hannah K. Beckwith,3 
Tom Cairns,1 Dawn Goodall,1 Paul Brookes,1 H. Terence Cook,3 
Kathy M. Dominy.4 1Imperial College Healthcare NHS Trust, London, United 
Kingdom; 2Centre for Inflammatory Diseases, Imperial College, London, United 
Kingdom; 3Imperial College of London, London, United Kingdom; 4Imperial 
College London, London, United Kingdom.
Background: Immunohistochemical staining for C4d in peritubular capillaries has 
been part of antibody-mediated rejection (AbMR) definition in the Banff Classification 
for Allograft Pathology since 2003. However, with limited sensitivity and specificity, the 
clinical significance of C4d-positive biopsies without evidence of rejection (C4d+ WER) 
is unknown. We investigated the molecular significance of C4d positivity in such biopsies 
from both ABO-compatible and incompatible renal transplant patients.
Methods: RNA was extracted from formalin-fixed paraffin-embedded renal transplant 
biopsies (n=125) and gene expression analysis of 35 AbMR-associated transcripts carried 
out using the NanoString nCounter system.
Results: AbMR-associated transcripts were significantly increased in samples with 
AbMR or suspicious for AbMR. A subgroup of 17/35 transcripts that best distinguished 
AbMR from C4d-negative biopsies without evidence of rejection was used to study C4d+ 
WER samples. There was no differential expression between C4d negative and C4d 
positive biopsies WER from both ABO incompatible and compatible transplants. The 
geometric mean of 17 differentially expressed genes was used to assign the C4d+WER 
biopsies a high- or low-risk score for AbMR. Follow-up biopsies showed AbMR within 1 
year of initial biopsy in 5/7 high-risk patients but only 2/46 low-risk patients. In multivariate 
logistic regression analysis, elevated transcript levels in a C4d+ WER biopsy were 
associated with increased odds for biopsy-proven AbMR on follow-up (p=0.032, odds ratio 
16.318), whereas factors including DSA status and time from transplant to biopsy were not.
Conclusions: Gene expression analysis in C4d+WER samples has the potential to 
identify patients at risk of imminent AbMR.
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C3 Deposition on Biopsy Is an Independent Risk Factor for Allograft 
Failure in Transplant Glomerulopathy
Emily Joachim, Daniel C. Felix, Christi A. Albert, Brad C. Astor, 
Weixiong Zhong, Arjang Djamali, Sarah E. Panzer. University of Wisconsin, 
Madison, WI.
Background: Transplant glomerulopathy (TG) is a well-established cause of renal 
allograft loss, but the prognostic significance of complement activity in TG remains unclear. 
We hypothesized patients with evidence of complement-mediated allograft injury are at 
higher risk of graft failure.
Methods: Kidney transplant recipients who received a biopsy diagnosis of TG (cg 
score≥1a) between 2011-2014 and had immunofluorescence (IF) performed were eligible 
for the study. Primary outcome was allograft failure (re-transplant, return to dialysis or 
death).
Results: Of the 111 patients included in the study, 72 (65%) had allograft failure, 
with a median follow-up of 3 years. Patients with C3 deposition vs. no C3 deposition 
had a higher rate of allograft failure (78 vs. 55%, respectively). Adjusted multivariate 
analysis demonstrated an increased risk of graft failure in patients with C3 deposition vs. 
no C3 (HR 1.37, 95% CI 1.12-1.69, P=0.002); this was not observed for C4d and C1q 
(Fig 1). Chronicity score was also associated with allograft loss (HR 1.26, 95% CI 1.13-
1.42, P=0.0001). C3 positive vs. negative patients did not differ with respect to cause of 
ESRD, induction or maintenance immunosuppression, donor type, PRA or presence of 
Class I or II donor-specific antibodies.
Conclusions: In this cohort of patients with TG, C3 deposition was independently 
associated with increased risk of allograft failure. Other complement products were not 
found to be significant in predicting allograft loss. Future studies are needed to validate 
these findings, but our results suggest that IF should routinely be performed on transplant 
biopsies, as C3 deposition may indicate TG patients who are at higher risk for allograft loss.
Funding: Other NIH Support - KL2TR002374 and UL1TR000427
Fig 1: C3 is associated with decreased allograft survival
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C4d Staining Following Thymoglobulin Treatment for Acute Cellular 
Rejection
Veronica A. Taylor,1 Aesha Maniar,3 David P. Witte,1 Bradley P. Dixon,2 
David K. Hooper.1 1Cincinnati Children’s Hospital Medical Center, Cincinnati, 
OH; 2Children’s Hospital of Colorado, Aurora, CO; 3University of Cincinnati 
College of Medicine, Cincinnati, OH.
Background: Rejection is an important cause of allograft failure in kidney transplant 
recipients (KTRs). Treatment is guided by histologic and biochemical findings indicating 
cellular and/or humoral origin. C4d staining is one of the diagnostic criteria for antibody 
mediated rejection (ABMR). At our center we observed an increase in C4d staining on some 
biopsies following thymoglobulin treatment for acute T-cell mediated rejection (TCMR).
Methods: We performed retrospective review of all KTRs at our pediatric center from 
January 2013 to April 2018 who received thymoglobulin treatment for acute TCMR and 
who had a follow-up biopsy within 45 days of diagnosis. Patients who had C4d staining 
or other histologic evidence of ABMR on initial biopsy were excluded. We evaluated C4d 
staining on repeat biopsy and compared patients who did not have existing or de novo donor 
specific antibodies (DSAs) within 12 months of diagnosis to those who did.
Results: 14 KTRs received an average of 12.7mg/kg of thymoglobulin over 4-14 
days. Mean time between TCMR diagnosis and follow-up biopsy was 14.9 days. 8 patients 
remained negative for DSAs during the defined peri-rejection period. Of the 6 patients 
found to have positive DSAs, 1 showed persistence of known chronic class II DSAs and 5 
developed de novo DSAs (4 within 6 weeks of TCMR diagnosis and 1 at 7 months). Post-
thymoglobulin C4d staining increased in all 6 DSA-positive patients but only 3/8 (37.5%) 
of DSA-negative patients (p=0.03). Histologic evidence of ABMR (capillaritis) on follow-
up biopsy was seen in two patients with de novo DSAs.
Conclusions: Positive C4d staining can be seen following thymoglobulin treatment 
of rejection even in the absence of DSAs. C4d staining increased following thymoglobulin 
therapy in all patients with DSAs, sometimes before the DSA was detectable. These findings 
may indicate thymoglobulin enhancement of complement activation by DSAs, non-
DSA ABMR, or independent in situ complement activation facilitated by the polyclonal 
xenoantibody preparation.
C4d staining following thymoglobulin treatment of TCMR
PTC, peritubular capillaries
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Causes of Living Donor Rejection: A Single Center Experience
Erik L. Lum,1 Jenny I. Shen,2 Jennifer L. Beaumont,6 Satoru Kawakita,6 
Amy D. Waterman,3 Anjay Rastogi,5 Hans A. Gritsch.4 1Nephrology, David 
Geffen School of Medicine, Los Angeles, CA; 2LaBiomed at Harbor-UCLA, 
Torrance, CA; 3Transplant Research and Education Center/ Terasaki Research 
Institute, Los Angeles, CA; 4UCLA, Los Angeles, CA; 5Division of Nephrology, 
Los Angeles, CA; 6Terasaki Research Institute, Los Angeles, CA.
Background: Living donor kidney transplantation (LDKT) is the preferred treatment 
for end stage kidney disease because it leads to better survival than either dialysis or 
deceased donor transplantation. Yet, the rate of LDKT has not grown despite high numbers 
of potential donors. Understanding the reasons that potential donors are rejected is key to 
developing effective interventions to increase LDKT.
Methods: In this single center retrospective observational study from UCLA Medical 
Center, both a transplant nephrologist and a transplant surgeon reviewed the medical 
records of all potential living donors presented to the living donor selection committee from 
2009 to 2014 and coded the reasons they were rejected as donors. Reasons were categorized 
as medical, surgical, social, or “other”.
Results: Out of 1370 patients, 55% (760) were accepted as potential donors, 16% (225) 
required further workup, and 29% (385) were denied as donors. 84% (323) of those rejected 
were rejected for multiple reasons (Figure). The top 3 most common reasons for rejection 
were medical: young age, family history of diabetes, and obesity. The top social reason was 
a prior history of psychiatric illness other than depression, and the top surgical reason for 
rejection was evidence of a renal lesion.
Conclusions: Most potential donors were denied for multiple reasons. Effective 
interventions to increase the rate of acceptance of potential donors will need to be multi-
faceted since addressing just a single cause for rejection is unlikely to clear a potential 
donor for donation.
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Does Non-Adherence Predict the Futile Treatment of Severe Acute Kidney 
Transplant Rejection?
Ahmed Al-Sheyyab,1 Laura Binari,1 Meghan E. Kapp,1 Stefanie Bala,2 
Nikita Wilson,1 Beatrice P. Concepcion.1 1Vanderbilt University Medical Center, 
Nashville, TN; 2Vanderbilt.University Medical Center, Nashville, TN.
Background: To treat or not to treat-- that is the question a clinician faces when a 
patient presents with renal failure in the setting of non-adherence and is found to have acute 
rejection. Potent rejection therapy, with its associated risks and cost, should arguably be 
withheld if treatment is to be futile. In this study we aimed to identify clinico-pathologic 
characteristics, with particular interest on non-adherence, that are associated with futile 
treatment. We defined futile treatment as graft loss occurring within 6 mos of acute rejection 
treatment.
Methods: The study included patients >=18y with biopsy-proven acute rejection 
and received maximal rejection therapy with a lymphocyte-depleting agent, with/without 
AMR treatment. Patient/transplant characteristics, adherence status and outcomes were 
collected via chart review. Descriptive statistics were utilized to compare groups. The 
outcome was all-cause graft loss within 6 mos of acute rejection treatment. Multivariable 
poisson regression with robust variance analysis was utilized to quantify the association of 
predictors with the outcome.
Results: 115 patients were included in the study, 46% of which were non-adherent. 
Non-adherent patients were younger (36 vs 46 y), more likely to be on steroid withdrawal 
(32 vs 16%), attained a lower nadir SCr (1.2 vs 1.8 mg/dL) and rejected later (65 vs 19 
mos from transplant). There was no difference in eGFR at presentation or Banff grade on 
biopsy. Overall, 31% of patients lost their grafts within 6 mos of acute rejection, with a 
higher percentage in the non-adherent group (42% vs 23%, p=0.03). In adjusted analysis, 
non-adherent patients had an increased RR of graft loss within 6 mos of acute rejection 
(RR 1.9, p<0.01). Other predictors of futile treatment included eGFR <=10 at presentation 
and >5% interstitial fibrosis on biopsy. Age, race, Banff grade, presence of concomitant 
AMR and type of lymphocyte depleting agent used were not significantly associated with 
the outcome.
Conclusions: Patients who are non-adherent are at 2-fold higher risk for futile 
treatment of acute rejection despite lymphocyte depletion. Other risk factors include severe 
renal dysfunction on presentation and the presence of interstitial fibrosis. In such patients, 
withholding potent rejection therapy should be considered, and ESRD planning should be 
initiated.
FR-PO882 Poster Friday
Transplantation: Translational and Transplant Pathology
Treatment of Biopsy-Proven Borderline Rejection in Kidney Transplant 
Recipients
Leigh-Anne Dale,1 Demetra Tsapepas,3 Syed A. Husain,1 Sumit Mohan.2 
Columbia University Renal Epidemiology [CURE] 1Columbia University 
Medical Center, New York, NY; 2Columbia University, New York, NY; 3NewYork-
Presbyterian Hospital, Columbia University Medical Center, New York, NY.
Background: Borderline cellular rejections are now the most common type of 
rejection found after kidney transplantation. Most centers either treat borderline rejection 
episodes with a pulse of high dose corticosteroids or do not provide any additional 
immunosuppression.
Methods: We identified 161 consecutive patients (50.6 ± 14.8 yrs, 62% male) who had 
a borderline rejection on allograft biopsy with no prior evidence of biopsy proven acute 
rejection between 2008 – 2015 at our center. While the majority of patients received our 
protocol of high dose corticosteroids, we identified 29 patients who did not receive any 
additional immunosuppression. We compared improvement in renal function over 4 weeks 
after the rejection episode for those who were treated versus those who were not.
Results: Recipients who were treated were significantly younger (55.7±12.7 vs 
49.4±15.1 years p=0.03) than recipients who were not treated but were similar with 
respect to gender distribution, time from transplant to biopsy (347.7±486 vs 264.1±481.9 
days, p=ns), and the creatinine at the time of biopsy (2.29±0.95 vs 2.57±1.48 mg/dL, 
p=ns). There was no difference in the decrease in serum creatinine at 4 weeks (0.31±0.55 
not treated vs 0.59±1.28 mg/dL treated, p=ns) and 90 days (0.48±0.2 not treated vs 
0.64±1.1 mg/dL not treated) following the biopsy between the two groups. While there were 
a higher number of graft failures among patients who were not treated (28.1% vs 18.2%, 
p=ns), this difference was not significant. [figure1]
Conclusions: The treatment of isolated borderline rejections with high dose pulse 
steroids did not improve short term outcomes in this single-center retrospective study. The 
higher rate of graft failure in the nontreated arm is however concerning and more studies 
are needed to understand the optimal management strategy for biopsy proven borderline 
rejections.
Time from biopsy to graft failure
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Adenovirus Allograft Nephropathy Mimicking Acute T Cell Rejection
Kawther F. Alquadan, Xu Zeng, Abhilash Koratala. University of Florida, 
Gainesville, FL.
Introduction: Adenovirus is associated with significant morbidity and mortality 
in renal transplant recipients and may even lead to the loss of allograft. Adenovirus 
nephropathy can be confused with acute cellular rejection as illustrated in our case. As the 
management of these two entities is completely different, clinical correlation is crucial.
Case Description: A 33-year-old African American woman with a history of ESRD 
status post deceased donor kidney transplantation was admitted for acute kidney injury 
(AKI) with a Scr of 8mg/dL (baseline 1.3). Her pre-transplant CPRA was 29%, received 
Alemtuzumab for induction immunosuppression (IS) followed by mycophenolate 
mofetil, tacrolimus and prednisone for maintenance. Her post-transplant course was 
complicated by BK viremia that resolved with reduction in IS. This time, BK virus 
serology was negative and she was given methylprednisolone 1 gram/day for 3 days for 
suspected rejection. She later developed fever and hematuria and clinically deteriorated 
despite receiving broad-spectrum antibiotics. Blood cultures remained negative. Allograft 
biopsy demonstrated severe interstitial inflammation with T cells, mononuclear cells and 
plasma cells with severe tubulitis [Figure]. Immunohistochemistry staining was negative 
for adenovirus but serum adenovirus PCR was positive with 10 million copies/ml. 
Her respiratory status worsened and CT scan of the chest showed tree-in-bud nodular 
opacities. Adenovirus PCR was positive in BAL and in the urine suggestive of adenovirus 
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pulmonary and renal allograft involvement. Mycophenolate was held and she received 
treatment with intravenous immunoglobulin and cidofovir. Patient clinically improved and 
Scr was 1.5mg/dl at discharge. A repeat biopsy at follow-up visit was negative for rejection, 
showed mild interstitial fibrosis and tubular atrophy with no glomerulosclerosis [Figure].
Discussion: High index of suspicion for adenovirus infection is required in renal graft 
dysfunction, especially in the setting of hematuria. Histology can mimic acute rejection, 
which creates a diagnostic dilemma. Tissue adenovirus immunostains, though usually 
reliable, may not be always positive like in our case.
FR-PO884 Poster Friday
Transplantation: Translational and Transplant Pathology
The Role of Plasma Donor-Derived Cell-Free DNA in Minimal Invasive 
Graft Monitoring
Els M. Gielis,1 Kristien J. Ledeganck,1 Amélie Dendooven,2 Pieter Meysman,3 
Charlie Beirnaert,3 Kris Laukens,3 Joachim De schrijver,4 Steven Van Laecke,5 
Marie-Paule Emonds,6 Benedicte De winter,1 Jean-Louis Bosmans,7,1 Jurgen Del 
favero,4 Daniel Abramowicz.7,1 1Laboratory of Experimental Medicine and 
Pediatrics, University of Antwerp, Antwerp, Belgium; 2Dept. of Pathology, 
University Hospital of Antwerp (UZA), Edegem, Belgium; 3Biomedical informatics 
research center Antwerpen (Biomina), University of Antwerp, Antwerp, Belgium; 
4Agilent Technologies, Niel, Belgium; 5Renal Division, Ghent University Hospital, 
Ghent, Belgium; 6Histocompatibility and Immunogenetic Laboratory, Belgian Red 
Cross Flanders, Mechelen, Belgium; 7Dept. of Nephrology and Hypertension, 
Antwerp University Hospital, Edegem, Belgium.
Background: After transplantation, cell-free DNA derived from the donor organ 
(ddcfDNA) can be detected in the recipient’s circulation. We aimed to investigate plasma 
ddcfDNA kinetics in renal transplant recipients thereby evaluating the role of this biomarker 
in graft monitoring.
Methods: From 107 renal transplant recipients, plasma samples were collected 
longitudinally from day 1 until 3 months after transplantation within a multicenter set-
up. Cell-free DNA from the donor was quantified in plasma as a fraction of total cell-free 
DNA by next generation sequencing using a targeted, multiplex PCR based method for the 
analysis of single nucleotide polymorphisms.
Results: Slope normalization analysis was performed in 42 patients that met predefined 
criteria for stable graft recipients. After an exponential decrease in ddcfDNA, a mean stable 
baseline level of 0.455% + 0.427 (2 SD) was reached on average 9.85 (± 5.6 days) after 
transplantation. In the entire cohort, patients that were not stabilized by day 10 (n = 37) 
had higher individual baseline ddcfDNA values (p = 0.007) and higher ddcfDNA fractions 
on day 1 (p = 0.0002). Sixteen recipients exhibited abnormal non-exponential ddcfDNA 
kinetics in the early post-engraftment phase; and this was associated with the occurrence 
of an early adverse event including a urinary tract infection, a surgical adverse event or 
episode of hydronephrosis that required treatment, a BKV or CMV infection episode or 
prerenal acute kidney injury (p=0.0012). From day 10 onwards, increases of ddcfDNA% 
above the baseline value of 0.882% (mean+2 SD) were significantly associated with the 
occurrence of episodes of acute rejection (p = 0.017), acute tubular necrosis (p = 0.011) and 
pyelonephritis (p = 0.032).
Conclusions: Within 10 days after transplantation, plasma ddcfDNA fractions decrease 
to a stable baseline level. From day 10 onwards, increases of ddcfDNA% are associated 
with graft injury related to acute rejection, acute tubular necrosis or pyelonephritis.
Funding: Government Support - Non-U.S.
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Donor-Derived Cell-Free DNA in Renal Transplant Recipients with 
Delayed Graft Function
Thin Thin Maw,4 Jonathan Bromberg,2 Jim Yee,1 Matthew Gillespie,1 
Daniel C. Brennan.3 1CareDx, Pasadena, CA; 2University of Maryland, 
Baltimore, MD; 3Johns Hopkins, Baltimore, MD; 4Keck School of Medicine 
USC, Los Angeles, CA.
Background: Delayed graft function (DGF) is a major barrier to improved outcomes 
after kidney transplantation (KTx) with no definitive tool available to assess severity or 
chances for recovery. Donor-derived cell-free DNA (dd-cfDNA) was previously validated 
to discriminate active rejection in KTx pts but its characteristics have not been defined in 
those with/at risk for DGF. This report describes dd-cfDNA levels in a cohort of KTx pts 
with suspected DGF.
Methods: dd-cfDNA samples of KTX pts with suspected DGF at three centers were 
obtained between Days 1-16 post-tx as part of the Donor-derived Cell-free DNA in Blood 
for Diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study. Similar 
clinical data were collected at each sample visit during this early post-tx period as was 
collected during later visits per DART protocol.
Results: dd-cfDNA samples were obtained from 17 KTx pts with suspected DGF. All 
received a deceased donor KTx (mean CIT 23 ±9 hours; mean KDPI 64 ±17). Mean dd-
cfDNA level was 1.47% (SD 2.25%) in samples collected Days 1-16 post-tx and 0.60% 
(SD 0.99%) in samples collected at Months 1-24 post-tx. By comparison, the mean level in 
a reference cohort without DGF from DART was 0.34% (SD 0.58%) in samples collected 
30 or more days post-tx. No obvious correlation was seen between Scr and dd-cfDNA in 
samples from Days 1-16 (Fig. 1) or in Months 1-24 (Fig. 2).
Conclusions: dd-cfDNA levels are higher early post-tx in suspected DGF samples vs. 
later time points and in those without DGF. Larger studies with long-term follow-up are 
needed comparing dd-cfDNA levels directly in pts with vs. without DGF after KTx. This 
may allow for more accurate assessment of dd-cfDNA patterns related to DGF severity/
recovery.
Funding: Commercial Support - CareDx
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Transplantation: Translational and Transplant Pathology
The Association Between Location of Eplet Mismatches, De Novo Donor 
Specific Antibodies, and Acute Rejection in Simultaneous Pancreas-Kid-
ney Transplant Recipients Using Novel Machine Learning Methods
Ankit Sharma,1,2 Craig Coorey,1 Anne T. Taverniti,1 Brian J. Nankivell,3 
Jeremy R. Chapman,3 Jonathan C. Craig,1 Wai H. Lim,5 Jean Yang,4 
Germaine Wong.1,2 1Centre for Kidney Research, Westmead, NSW, Australia; 
2School of Public Health, University of Sydney, Sydney, NSW, Australia; 
3Westmead Hospital, WESTMEAD, NSW, Australia; 4University of Sydney, 
Sydney, NSW, Australia; 5Sir Charles Gairdner Hospital, Nedlands, WA, 
Australia.
Background: To determine the association between HLA class and location of 
eplet mismatches with de novo donor specific antibodies (dnDSA) and acute rejection in 
simultaneous pancreas-kidney (SPK) transplant recipients.
Methods: The cohort consisted of SPK recipients (n=170) transplanted in New South 
Wales, Australia between 2005 and 2017. Using machine learning models (random forest), 
we determined the association between the number and location of class specific eplet 
mismatches, and adverse allograft outcomes (dnDSA formation and acute rejection (acute 
cellular (ACR) and (antibody-mediated (AMR)). One hundred times 5-fold cross validation 
was conducted using R.
Results: The cohort included 93 (55%) males, with mean age at transplant of 38.7 years 
(SD 7.0) and median follow up time of 5.0 years (IQR: 2.1, 7.1). The median total number 
of class I and II eplet mismatches were 17 (IQR: 13-22) and 34 (IQR: 22-47), respectively. 
The most important (highest Mean Decrease Accuracy) class I eplet mismatches for 
predicting dnDSA and any acute rejection corresponded to locations 102HV, 149TAH, 
152RE, 163RW, 21H, 44RM, 44RMA and 82LR; and for class II mismatches at 76L. For 
the prediction of class I and II dnDSA, the median AUC and balanced error rate from the 
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location of class I eplet mismatches were 57.8% (SD: 3.5%) and 47.0% (SD: 1.6%); and 
for class II were 53.5% (SD: 2.6%) and 50.9% (SD: 2.5%), respectively. The median AUC 
and balanced error rate for predicting any acute rejection from class I eplet locations were 
54.3% (SD: 2.7%) and 50.2% (SD: 2.7%); and for class II were 56.7% (SD: 3.3%) and 
43.9% (SD: 2.7%), respectively.
Conclusions: In this cohort of SPK recipients, the location of class I mismatches best 
classify recipients with dnDSA and any acute rejection.
FR-PO887 Poster Friday
Transplantation: Translational and Transplant Pathology
Comparison of Banff Allograft Injury Scores of Patients with De Novo 
Donor-Specific Antibodies (DSAs) to Patients with Preformed DSAs
Maria Ajaimy, Adriana Colovai, Nicole A. Hayde, Enver Akalin. Montefiore 
Medical Center, Bronx, NY.
Background: We aimed to compare histological features of rejection in patients with 
preformed and de novo DSAs and its association with clinical outcomes
Methods: This is a prospective study including 681 non-HLA-identical patients who 
received a kidney tx between 1/2009 and 12/ 2014 at our center. Protocol testing for DSA 
via LABScreen single antigen beads was done before and at 1, 3, 12 months, and then 
annually after kidney tx or when clinically indicated. Tx kidney biopsies are performed as 
clinically indicated
Results: 114 (17%) patients had preformed DSA. During a median 3.8 (2.4-5.3) years 
of follow-up, de novo DSA developed in 92 patients (13%) at a median of 1.24(0.71-2.35) 
years after kidney tx. While there was no difference in patient survival, de novo DSA 
group had significantly lower graft survival (63.8% vs. 88.6%, P<0.001), higher antibody-
mediated rejection (ABMR) (13.04% vs. 6.14%, p=0.001), transplant glomerulopathy 
(16.6% vs. 9% vs. 4.7%, P=0.004) and T cell mediated rejection (14.13%vs. 2.63%, 
p=0.001) compared to patients with preformed DSA. ABMR developed at a median 0.39 
years (0.13-1.4) in pre-transplant DSA patients and at 1.25 years (0.25-3.31) in de novo 
DSA ones. When comparing the Banff allograft injury scores in 16 pre DSA and 34 de novo 
DSA biopsies, mean total acute Banff allograft injury score (g+ i+t+ptc+v, 6.29±3.57 vs. 
4.19±3.39, p=0.046) was statistically significantly higher in the de novo DSA. The rest of 
acute and chronic allograft injury scores were not significantly different
Conclusions: Development of de novo DSA after kidney tx is associated with higher 
total acute allograft injury score, rejection episodes, and lower allograft survival compared 
to preformed DSA.
Banff Scores
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Long Term Follow Up for Antibody Mediated Rejection of Kidney 
Transplant Due to Angiotensin II Type 1 Receptor Antibodies
Sami Alasfar,1 Nada Alachkar,3 Edward S. Kraus,4 Mary Carmelle Philogene.2 
1Medicine, Johns Hopkins University, Baltimore, MD; 2Johns Hopkins 
University, Baltimore, MD; 3Johns Hopkins University, Baltimore, MD; 4Johns 
Hopkins University, Baltimore, MD.
Background: A new appreciation for the contribution of non-HLA antibodies (Abs) 
in kidney transplantation (K-TXP) has arisen as a result of reports of antibody mediated 
rejection (ABMR) without HLA Abs. Abs directed against the angiotensin II type 1 receptor 
(AT1R-Ab) have received greater scrutiny because of the existence of a commercially 
available assay. Studies on the treatment and long term follow up of AT1R-Ab mediated 
ABMR are lacking
Methods: Among K-TXP patients with positive (≥17 Units/ml) or borderline (10-17 
Units/ml) AT1R-Ab, we retrospectively identified those with biopsy proven ABMR by 
Banff 2017 and had negative or low level HLA Abs at the time of rejection
Results: 14 patients were identified. Patients’ characteristics are shown in table 1. 
Median time of follow up from ABMR is 24 months. Median time from transplant to 
ABMR is10 months. With regards to treatment, 9 received plasmapheresis and intravenous 
immunoglobulins +/- high dose corticosteroids (HDCS), 1 received HDCS, and 1 received 
HDCS and thymoglobulin. Of treated patients, 6 responded. One lost allograft due 
to recurrence of ABMR. Of all patients, 10 had follow up biopsy. 5 had improvment in 
histological findings, and the other 5 developed transplant glomuerlopathy. Of the 3 who 
did not receive any treatment, 1 progressed to allograft loss, 1 had resolution on follow up 
biopsy, and 1 remained with elevated but stable serum Creatinine. Of the 11 who received 
treatment, 9 had evidence of reduction in AT1R-Ab titer. Of the three who did not receive 
treatment, 1 had improvement in AT1R-Ab titer
Conclusions: AT1R-Ab mediated ABMR is seen in HLA sensitized and non sensitized 
patients. Conventional ABMR treatment reduces AT1R-Ab titer in most patients but not 
all achieve clinical response. As with HLA antibodies, AT1R-Ab may lead to transplant 
glomerulopathy
Table 1
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ABO Incompatible Kidney Transplantation Without Use of Anti-CD20 
Antibody or Splenectomy: Experience from Northern India
Amit Sharma, Harinder J. Gill. FORTIS HOSPITAL MOHALI, MOHALI, 
PUNJAB, India.
Background: ABO-incompatible (ABOi) renal transplants help in crossing an 
important immunological barrier against kidney transplantation, thereby meeting the unmet 
demands of renal transplants. The study was conducted to assess ABOi transplant without 
the use of Anti CD20 antibody or splenectomy and compare their outcomes with ABO 
compatible (ABOc) transplants.
Methods: The study period was from January 2014 to February 2018. 290 patients 
were divided into two groups: ABOi (n=33) or ABOc (n=257) living renal donors. In 
ABOi cases, plasmapheresis and low dose intravenous immunoglobulin (100 mg/kg) was 
given till isoagglutinin titer were <1:8. All patients received induction immunosuppression: 
Thymoglobulin (1 mg/kg/day for 3 days) for all ABOi and ABOc with HLA mismatch > 
3/6 and Basiliximab in ABOc with HLA mismatch < 3/6. In ABOi, titers were monitored 
post-operatively and plasmapheresis was done if they increased to >1:8 in first week and 
>1:16 in second and third week post transplant. Patient and allograft survival; 1, 3, 6, 12,
24, and 36-month renal function; infectious complications; and incidence of rejection were 
measured.
Results: 30.3% of the ABOi recipients and 22.17% of ABOc recipients were females. 
Median isoagglutinin titer at start was 1:32 (1:1 to 1:256). Mean number of plasmapheresis 
required were 3. In ABOi group, Mean±SD creatinine levels were 1.37±0.41 mg/dL at 
1 month, 1.29±0.31 mg/dL at 12 months, and 1.36±0.39 mg/dL at 36 months. In ABOc 
group, Mean±SD creatinine levels were 1.26±0.41 mg/dL at 1 month, 1.26±0.44 mg/dL at 
12 months, and 1.28±0.45 mg/dL at 36 months. In the ABOi group, there were 6 episodes of 
acute antibody mediated rejection (AMR) and 1 patient had acute cellular rejection (ACR), 
which were successfully treated (3 AMR and 4 ACR were observed in the ABOc group). 
Two patients succumbed to fungal sepsis in the ABOi group.
Conclusions: Successful ABOi renal transplantation is possible without the use 
of splenectomy or Anti-CD20 treatment but AMR episodes as well as fungal sepsis are 
significantly high.
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CD19+ Cell Behavior in the 12 Months Following a Single Dose of 
Rituximab in Patients with Humoral Rejection: Clinical and Histological 
Outcomes
Itzel A. Martinez, José roberto Marino sanchez, Mariedel Trujeque, 
Jesus I. Santander, Flor M. Zamora-Mejia, Hilda Juárez-Contreras, 
Raquel A. Vazquez, Luis Llorente Peters, Guadalupe Lima gonzalez, Abraham 
Cohen-Bucay, Josefina Alberú, Lluvia A. Marino-Vazquez, Luis E. Morales-
Buenrostro. Instituto Nacional de Ciencias Medicas y Nutricion Salvador 
Zubiran, Mexico, Mexico.
Background: Treatment of antibody mediated rejection (AMR) commonly includes 
rituximab (RTX). It has been suggested that a single dose of RTX is enough to deplete 
CD19+ cells. Aim: to analyze CD19+ cell behavior during the 12 months following a 500 
mg dose of RTX and its correlation with clinical and histological outcomes.
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Methods: Prospective cohort study of 122 kidney transplant recipients with biopsy 
proven AMR who received a single dose of RTX 500 mg as part of standard AMR treatment 
between 2012 and 2018. Peripheral CD19+ cells were measured at baseline, 15, 30, 90, 180, 
270, and 360 days after RTX infusion, and correlated this data with clinical and histological 
outcomes.
Results: 122 patients were included. Mean age was 35±13 y, 56.6% female, median 
time to rejection was 6y post-transplant. Treatment included PE and IVIG in 75%, 21% 
also received Bortezomib. All patients received 500 mg of RTX and were followed for 
a median of 21mo (0.1-83). Median allograft survival after AMR was 5.5y. CD19+ cell 
depletion (<10 cells) at 1mo was associated with less IFTA at follow-up biopsy (p=0.01) 
and improvement of proteinuria at last follow-up (p=0.05). Early CD19+ cell repopulation 
was associated with higher graft loss and dead (p=0.03). Persistent CD19+ cell depletion 
(<10 cells) at 12mo was associated with better graft and patient survival (0.04).
Conclusions: A single dose of RTX achieved CD19+ cell depletion in more than 80% 
of patients, which lasted at least 6 mo. CD19+ cell depletion is associated with improvement 
of proteinuria and less IFTA; and the persistence of CD19+ cell depletion at 12mo improves 
graft and patient survival.
CD19+ cell depletion patterns.
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High Level of HLA-DP Expression in Kidney Donors Is Associated with a 
Reduced Graft Survival
Andreas Heinzel,1 Roman Reindl-Schwaighofer,1 Alexander Kainz,1 
Kira Jelencsics,1 Karin Hu,1 Petra Hruba,2 Ondrej Viklicky,2 Georg Bohmig,1 
Brendan Keating,3 Rainer Oberbauer.1 1Department of Nephrology, Medical 
University of Vienna, Vienna, Vienna, Austria; 2Institute for Clinical and 
Experimental Medicine, Department of Nephrology, Prague, Czechia; 
3University of Pennsylvania, Philadelphia, PA.
Background: HLA-DP mismatch between kidney allograft donors and recipients 
has increasingly been recognized as risk factor for adverse long-term outcome following 
transplantation. Current matching algorithms do not account for HLA-DP mismatch. The 
single nucleotide variant rs9277534 in the 3′ UTR of DPB1 is associated with HLA-DPB1 
expression levels.
Methods: We made use of the iGeneTrain consortium and genotyped 477 first kidney 
transplant recipients and respective deceased donors from two centers in Vienna and Prague. 
HLA eplet mismatch was calculated for the HLA-A, -B, -C, -DP, -DQ, and -DR loci. The 
median follow-up time of the cohort was 6.5 years. Kaplan-Meier analysis and a Cox PH 
model were used to assess the association of rs9277534 with death censored graft loss.
Results: The rs9277534 variant influencing HLA-DPB1 expression levels is associated 
with graft loss after kidney transplantation. Kaplan-Meier analysis (figure 1) showed that 
presence of one or two copies of a ‘G’ allele at rs9277534 in the donor was associated with 
an elevated risk for graft loss. This association remained significant in a multivariable Cox 
model after adjustment for donor age and full HLA eplet mismatch (HR of rs9277534: 2.05 
CI: 1.15 – 3.67).
Conclusions: Presence of the high expression variant in kidney allograft donors is 
associated with a reduced graft survival.
Figure 1: KM plot relating kidney allograft donor status of the rs9277534 variant influencing 
HLA-DPB1 expression with death censored graft loss after transplantation.
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Biopsy Guided Evaluation in Patients with Renal Impairment Awaiting 
Liver Transplantation - How Kidney Biopsies Save Organs
Bojana Simunov,1 Mladen Knotek.2 1University Hospital Merkur, Zagreb, 
Croatia; 2University of Zagreb Medical School, Clinical Hospital Merkur, 
Zagreb, Croatia.
Background: After the introduction of MELD score in liver allocation, the number 
of simultaneous liver-kidney transplantations (SLKT) significantly increased therefore 
contributing to the shortage of allografts for patients waitlisted for kidney transplantation. 
We analyzed the data in our high-volume transplant center with a stable number of SLKT 
and reviewed our biopsy-guided kidney allocation policy in pts with renal dysfunction 
undergoing liver transplantation (LT).
Methods: We analyzed LT and SLKT performed in UH Merkur, Croatia from April 
2007 to April 2018. As significant renal impairment at time of enlisting we defined serum 
creatinine higher or equal to 2 mg/dL, renal replacement therapy (RRT) or pathologic 
proteinuria higher than p/c 1 g/g.
Results: In total 1056 LT and 19 SLKT were identified. 129 pts fulfilled the criteria 
for renal impairment given above. There were 95 male pts (73,6%). 13 patients had ESRD 
receiving RRT prior to referral for LT and were automatically enlisted for SLKT. From 
those 13, in 2 pts SLKT was performed because of primary hyperoxaluria. In evaluation 
of other pts with renal dysfunction 22 renal biopsies were performed under US guidance 
after correction of coagulation parameters. There were no major complications of biopsies. 
Other 94 pts were diagnosed with acute kidney injury/hepatorenal syndrome (AKI/HRS). 
The most common pathohistological diagnosis was IgA nephropathy (63,6%), followed 
by ATN (18,2%) and diabetic nephropathy (9,1%). The cut-off for SLKT was more than 
40% interstitial fibrosis and tubule atrophy (IFTA), or more than 30% of globally sclerosed 
glomeruli (GS) on biopsy. Based on biopsy results additional 6 pts were enlisted for SLKT. 
None of the patients with presumed AKI/HRS who received only LT and survived for more 
than one-month post-LT required RRT at one-month post-LT.
Conclusions: We believe that kidney biopsy is a useful and safe tool to avoid kidney 
graft wasting when evaluating enlistment for SLKT. We enlist a patient for SLKT if IFTA 
is higher than 40% or GS more than 30%. A separate indication for SLKT are metabolic 
diseases. In decompensated liver cirrhosis HRS develops and makes evaluation of kidney 
recovery potential speculative. In our experience, percutaneous kidney biopsy in pts 
with advanced liver disease was not linked to adverse events and is a safe procedure in 
experienced centers.
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Proteomic Analysis of Perfusate from Machine Cold Perfusion of 
Transplant Kidneys: Comparison Between Circulatory and Neurological 
Death
Andrea Angeletti,2 Chiara Donadei,1 Matteo Ravaioli,1 Vanessa De pace,2 
Valeria Corradetti,1 Giorgia Comai,1 Gaetano La Manna.1 1University Hospital 
of Bologna, Bologna, Italy; 2University Hospital of Bologna, Bologna, Italy.
Background: Renal donation after circulatory death (DCD) is associated with increased 
of delayed graft function (DGF) events shortly after transplant and with a decrease in renal 
function at 1 year compared to donation after neurological death (DND). Machine cold 
perfusion has been suggested to reduce incidence of DGF and improved long and short-term 
function in marginal kidneys and those obtained from DCD donors. We compared several 
early biomarkers of renal injury in perfusate of kidneys from DCD and DND.
Methods: Perfusates from DCD and DND were collected (n=25) at the beginning 
(T0) and at the end (T1) of perfusion and analyzed by Luminex technology for neutrophil 
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gelatinase-associated lipocalin (NGAL), Cystatin C, Kidney Injury Molecule-1 (KIM-1), 
Monocyte chemoattractant protein-1 (MCP-1), and trefoil factor 3 (TFF3).
Results: Donor kidneys characteristics are resumed in Table. The highest levels of 
early biomarkers of renal tubular injury were seen for the DCD compared to DND kidneys 
for all markers except for MCP-1, the key chemokine that regulate migration and infiltration 
of monocytes/macrophages (Figure). No differences are reports for DGF of recipients.
Conclusions: Comparison of the perfusates from the different types of kidneys has 
allowed us to identify increased levels of biomarkers, representatives of increased acute 
tubular damage, that will be useful in future research into improving DCD kidneys outcome.
Funding: Clinical Revenue Support
Table
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Urinary RANTES, IL-4, and IL-6 as Potential Prognostic Markers of 
Early Renal Outcome in Living Donor Kidney Transplantation
Minjung Kim, Hyo jin Boo, Song in Baeg, Eun jeong Lee, Hye Ryoun Jang, 
Jung eun Lee, Dae Joong Kim, Ha Young Oh, Wooseong Huh, Yoon-Goo Kim. 
Samsung medical center, Seoul, Republic of Korea.
Background: Changes in intrarenal immunologic micromilieu has been shown to 
affect the renal outcome in kidney transplantation. Recent studies have shown that some 
cytokines and chemokines may have potential as non-invasive diagnostic markers that 
detect early injury after kidney transplantation. This prospective study aimed to investigate 
the diagnostic value of urinary cytokines and chemokines after living donor kidney 
transplantation as prognostic markers of early renal outcome.
Methods: Serum and urine samples were serially collected from kidney transplant 
patients at the following time points; during transplantation, 8 hours, 24 hours, 72 hours, 
1 week, 3 months, and 1 year after transplantation. Cytokines and chemokines including 
regulated on activation, normal T cell expressed and secreted (RANTES), fractalkine, 
interleukin (IL)-10, IL-4, IL-6, monocyte chemoattractant protein (MCP)-1, tumor 
necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF) were measured 
in 64 patients. Patients were divided into either the good prognosis group (eGFR at post-
transplant 3 months ≥ 60ml/min/1.73m2 or eGFR change ≥ -5 between post-transplant 3 
and 12 months) or the poor prognosis group (eGFR at post-transplant 3 months < 60ml/
min/1.73m2 or eGFR change < -5 between post-transplant 3 and 12 months). T-test and one-
way or two-way ANOVA tests were used for statistical analysis.
Results: The median age of patients was 42.3 years and 70.3% were male. Urinary 
RANTES (P < 0.001) and urinary IL-4 (P < 0.05) at 24 hours after transplantation were 
higher in the good prognosis group. When patients were divided by eGFR change between 
3 months and 1 year after transplantation, urinary IL-6 at 3 months after transplantation (P < 
0.05) was higher in the good prognosis group. There were no differences in serum cytokines 
or chemokines between groups.
Conclusions: Our study showed the potential clinical value of urinary RANTES and 
IL-4 measured at 24 hours after transplantation as well as urinary IL-6 at 3 months after 
transplantation as non-invasive predictors of early renal outcome after living donor kidney 
transplantation.
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Plasma Fibroblast Growth Factor 21 Plasma Concentration in Patients 
After Kidney Transplantation
Marcin Adamczak, Magdalena Bartmanska, Andrzej Wiecek. Department of 
Nephrology, Transplantation and Internal Medicine, Medical University of 
Silesia, Katowice, Poland, Katowice, Poland.
Background: Fibroblast growth factor 21 (FGF21) is a protein hormone involved in 
the regulation of energy expenditure. The results of clinical studies suggest that plasma 
FGF21 concentration increases with the progression of chronic kidney disease. The aim of 
the present study was to analyze the effect of successful kidney transplantation on plasma 
FGF21 concentration and to study the factors related to plasma FGF21 concentration in 
patients long-term after kidney transplantation.
Methods: Forty patients with chronic kidney disease (CKD) 5 or 5D before kidney 
transplantation [27 women and 13 men aged 47.0 (39.3 - 54.0)], 180 patients long-term 
after kidney transplantation [70 women and 110 men aged 52 (47,4 – 54)] and 50 healthy 
subjects [28 women and 22 men aged 50.0 (47.6 - 58.0)] were enrolled into this study. 
In CKD patients, plasma FGF21 concentrations were measured four times (immediately 
before and 14 and 30 days, and 6 months after kidney transplantation). In patients long-
term after kidney transplantation and in healthy subjects, this measurement was made once.
Results: In patients before kidney transplantation plasma FGF21 concentration 
were significantly higher than in healthy subjects [1013.0 pg/ml (744.4-1635.7 pg/ml) vs 
256.0 pg/ml (219.0 – 332.0 pg/ml); p <0.001]. At 14, 30 days and 6 months after kidney 
transplantation, a significant decrease of plasma FGF21 was observed [1013.0 pg / ml 
(744.4 - 1635.7 pg / ml); 322.5 pg/ml (199.0 - 546.8 pg/ml); 367.5 pg/ml (289.3 - 483.5 
pg/ml); 363.5 pg/ml (293.5 - 508.2 pg/ml) (p <0.001), respectively]. In patients long-
term after kidney transplantation, a negative correlation was found between plasma FGF 
21 concentration and estimated glomerular filtration (eGFR) (R = -0.165, p <0.05) and 
a positive correlations between plasma FGF21 concentration and HOMA (R = 0.185, p 
<0.02), BMI (R = 0.148, p <0.05) and serum triglycerides concentration (R = 0.362, p 
<0.001).
Conclusions: 1. In patients after kidney transplantation a decrease of plasma FGF 21 
concentration was found. 2. Plasma FGF21 concentration in patients long-term after kidney 
transplantation is related to the degree of impairment renal function and metabolic status.
Funding: Government Support - Non-U.S.
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Oxalate Nephropathy Due to Enteric Hyperoxaluria in the Renal 
Allograft: A Case Series
Christine Firth, Margaret Ryan, Mira T. Keddis. The Mayo Clinic Arizona, 
Scottsdale, AZ.
Background: Secondary hyperoxaluria due to enteric causes is an underrecognized 
cause of renal allograft injury and loss. We present a single center case series of oxalate 
nephropathy in kidney transplant (KTx) patients due to enteric hyperoxaluria (EH).
Methods: Cases of oxalate nephropathy based on pathological description from 2008 
to 2018 were ascertained. Cases of primary hyperoxaluria were excluded. Clinical risk 
factors for EH, serum and urine oxalate levels around the time of the biopsy, treatment, and 
allograft outcomes were analyzed.
Results: Fifteen cases of oxalate nephropathy were identified. Median follow-up was 
3.0 years (range 0.4 to 8.6 years). Median time from transplant to allograft biopsy showing 
oxalate nephropathy was 104 days (range 14 days to 8.6 years). The most common pre-
Tx risk factors for EH included short bowel syndrome (27%) and gastric bypass (13%). 
Post-Tx risk factors included chronic diarrhea (33%) and frequent antibiotic use (27%) 
with presumed altered gut flora. Median serum oxalate was 13.4 umol/L (range 2.7 to 37.5 
[normal 0.4 to 3]) and median 24-hour urine oxalate was 97.7 mg/24 hours (range 40.5 to 
121.2 [normal 9.7 to 40.5]). The predominant treatment was a low oxalate diet, increased 
oral fluids (93%), coupled by dietician counseling (87%) and calcium supplementation 
(93%). At last follow-up, 6 patients had GFR<45ml/min, 4 had GFR<30ml/min and 4 were 
on dialysis. [Table1]
Conclusions: Enteric causes of hyperoxaluria in KTx patients can be attributed to 
pre and post-transplant risk factors. Oxalate nephropathy due to EH in KTx patients is an 
important cause of allograft failure and warrants a standardized approach for early detection 
and treatment approach tailored for patients’ unique risk factors.
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Glomerular Neovascularization in Renal Allograft: Clinical and Patholog-
ical Significance
Anri Sawada,1,2 Masayoshi Okumi,3 Kohei Unagami,3 Shohei Fuchinoue,3 
Sekiko Taneda,4 Hideki Ishida,6 Motoshi Hattori,3 Kazunari Tanabe,3 
Akira Shimizu,2 Junki Koike,5 Yoji Nagashima,7 Kosaku Nitta.3 1Tokyo women’s 
medical university, Tokyo----, Japan; 2Nippion Medical School, Tokyo, Japan; 
3Tokyo Women’s Medical University, Shinjuku-ku, Japan; 4Tokyo womens’ 
medical university, Tokyo, Japan; 5St.Marianna University, Kawasaki, Japan; 
6Tokyo Women’s Medical University, Tokyo, Japan; 7TTokyo Women’s Medical 
University, Tokyo, Japan.
Background: An extra efferent arteriole is often observed in the glomerular vascular 
pole. This morphological change is referred to as polar vasculosis (PV). PV has been 
associated with glomerular hypertrophy and is considered as a sign for detecting early 
recurrent diabetic nephropathy after renal allograft. We have often noted PV even in 
cases without diabetic nephropathy after renal allograft; however, its significance remains 
uncertain. In the present study, we examined the clinical and pathological significance of 
PV in renal allograft.
Methods: This study included 9,004 renal biopsy specimens obtained from January 
2007 to December 2017 at the Tokyo Women’s Medical University.
Results: PV was identified in 186 biopsies obtained from 165 patients. We excluded 
44 biopsies from 36 patients because of transmitted PV, which was detected in pre-
transplantation biopsy. We identified 142 biopsies from 129 patients as the PV group. In 
addition, we identified 130 control renal allograft recipients who were matched according 
to their age and post-transplantation period. We obtained the clinical information of 48 and 
116 patients in the PV and control groups, respectively. In the PV group, the mean age was 
49.0 ± 14.0 years, and the mean post-transplantation period was 1850.1 ± 2235.7 days. In 
the pathological findings, a significant correlation was observed among glomerulomegaly, 
focal segmental glomerulosclerosis lesion, mm score, ah score, and aah score in Banff score 
(P < 0.05). The clinical findings revealed a significant correlation between the tacrolimus 
trough level at two weeks post-transplantation and the systolic blood pressure (P < 0.05).
Conclusions: This findings of this study indicated that polar vasculosis is associated 
with calcineurin inhibitor toxicity along with glomerular hypertrophy.
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Validation of a Cellular Assay for Detection of Over-Immunosuppression 
in Kidney Recipients: An Interim Report
François Bouchard-Boivin, Olivier Desy, Stephanie Beland, Sacha A. De Serres. 
CHU de Québec - Laval University, Quebec, QC, Canada.
Background: The transplantation community lacks a clinical tool to diagnose over-
immunosuppression, resulting in major clinical side effects. Recently, our laboratory has 
unveiled an association between the cytokine secretion of intermediate CD14+CD16+ 
monocytes stimulated in vitro with Epstein-Barr Virus (EBV) peptides and the status of 
over-immunosuppression in a prospective, longitudinal cohort of kidney recipients. We are 
now validating the test in a large cross-sectional cohort.
Methods: We recruited 120 unsensitized kidney recipients, isolated their peripheral 
blood mononuclear cells at 2 timepoints (3mo interval) and stimulated the cells with EBV 
peptides overnight. Staining for viability, CD14 and CD16 and tumor necrosis factor 
(TNF-α) was performed to quantify cytokine secretion of intermediate monocytes by flow 
cytometry.
Results: We report interim results of the first 24 patients. Mean±SD age was 56±13 
years and mean glomerular filtration rate was 46±15 mL/min/1.73m2. Median time 
(25-75th percentiles) post-transplant was 2 (1 – 8) years. Patients were treated with 
prednisone, mycophenolate and tacrolimus. Eleven patients received induction therapy. 
There were 15 controls and 9 cases, including 7 opportunistic infections, 1 recurring 
bacterial infections and 1 de novo neoplasia, events which happened on mean of 1.4±2.0 
months after blood was withdrawn for the assay. Mean TNF-α-positive cells on the first 
sample was 70±20% for the controls and 53±15% for the cases. All but one patient who 
scored below the previously established threshold (<73% TNF-α) were confirmed on the 
second sample. AUC of the ROC curve was 0.83±0.09 (p<0.01). Preliminary values of 
sensibility, specificity, positive and negative predictive values were 89% (8/9), 60% (9/15), 
57% (8/14) and 90% (9/10) respectively.
Conclusions: These interim results seem to confirm that over-immunosuppressed 
patients have lower intermediate monocyte response to EBV peptides. Furthermore, they 
show high sensibility and negative predictive value, similar to the derivation cohort. This 
assay could allow ruling out over-immunosuppressive state in the clinical setting.
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Mammalian Target of Rapamycin (mTOR) Inhibitor Might Augment 
Klotho Levels of Kidney Transplant Recipients
Yukiko Hasuike,1 Kosuke Mizusaki,1 Tomoko Kimura,1 Yasuyuki Nagasawa,1 
Takahiro Kuragano,1 Yusuke Yamada,2 Michio Nojima,2 Shingo Yamamoto,2 
Masaharu Ishihara.1 1Div Kidney and Dialysis, Dep Internal Medicine, Hyogo 
College of Medicine, Nishinomiya City, Japan; 2Dep. Urology, Hyogo College 
of Medicine, Nishinomiya, Japan.
Background: α-Klotho, an anti-aging kidney-secreted hormone, exists in several 
forms including the membrane and a soluble form (sKlotho). sKlotho level of chronic 
kidney disease (CKD) patients is reduced. sKlotho administration attenuated renal fibrosis 
and dysfunction. It was reported that mTOR inhibitor reduce interstitial fibrosis and 
glomerular sclerosis of kidney transplantation (TPL) recipients, however, the mechanism 
is unclear. We investigated the influence of mTOR inhibitor on sKlotho of CKD patients 
before and after TPL.
Methods: This was a retrospective, observational study of kidney TPL recipients who 
were treated in Kidney Transplant Center of Hyogo College of Medicine (from 2001 July to 
2016 October). Blood samples were collected before and 1-year after TPL and stored until 
assay. Serum sKlotho and fibroblast growth factor (FGF)-23 concentrations were measured 
using human ELISA, respectively. Several factors related to CKD (Ca, iP, intact parathyroid 
hormone, and 1,25(OH)2vitamin D) were examined.
Results: The CKD patients (n=36) were participated. Median age and vintage of 
participants was 37.0 (IQR, 27.5-50.5) y.o. and 4.6 (1.0-8.8) years. In this study, 75.0% 
(n=27) of kidney TPL were living donor, 8.3% (n=3) were received preemptive TPL, 
and 36.1% (n=13) were administrated mTOR inhibitor (everolimus). Comparing before 
and after TPL, sKlotho level was significantly increased (p<0.001) and FGF23 level was 
decreased (p<0.001). After TPL, sKlotho level of participants with mTOR inhibitor was 
significantly higher than that without mTOR inhibitor, 537 (367-659) pg/ml vs 332.4 (250-
550) pg/ml (p=0.026, Figure 1). There was no significant difference of the other parameters
between before and after TPL.
Conclusions: Administration of mTOR inhibitor might augment Klotho level of CKD 
patients after TPL.
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Clinicopathologic Characteristics of Kidney Allografts with Donor- 
Derived Diabetic Nephropathy
Kuang-Yu Jen,1 Hannah Lee,2 Ling-Xin Chen,1 Guofeng Gao,1 
Junichiro Sageshima.1 1University of California, Davis, Sacramento, CA; 
2UCSF, Cupertino, CA.
Background: The general consensus is that donor kidneys with biopsy proven diabetic 
nephropathy (DN) should be discarded, although data regarding outcomes of these cases 
is lacking. In this study, the clincopathologic characteristics of allografts with moderate to 
advanced donor-derived DN was examined.
Methods: Retrospective analysis (between 06/2011 to 01/2017) of all kidney 
transplant recipients with biopsy proven class II or III DN within the first six months 
post-transplantation was performed. For each patient, all biopsies were reviewed to assess 
progression/regression in disease. Glomerular changes were classified based on Tervaert 
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pathologic classification. Associated clinical data were extracted from electronic medical 
records, including donor information.
Results: Fifteen recipients received donor kidneys with DN from 11 donors. All but 
one donor had confirmed history of long-standing diabetes, while 47% of recipients had 
history of diabetes. Nine grafts had class III, two had class IIb, and four had class IIa donor-
derived DN. Mean clinical follow up time was 13.2 months (range 3-30 months). Four grafts 
(27%) failed within the first year, three of which were due to primary non-function and one 
showed slow graft function without need for dialysis but had subsequent rapid deterioration 
within 9 months. Two failed grafts had class IIb and two had class III DN, while none 
of the class IIa grafts failed. Two of the failed grafts had contralateral sister kidneys that 
demonstrated good renal function. Of the functional grafts, four (36%) experienced delayed 
graft function. Average creatinine at latest follow up for functional grafts was 1.4 mg/dL, 
and none experienced rejection episodes. No significant histologic progression/regression 
in DN class was observed, and no histologic findings on initial biopsy were significant for 
predicting graft failure.
Conclusions: Despite the high incidence of failed grafts, 73% of recipients in this 
cohort experienced successful transplantation using kidneys with moderate to advanced 
donor-derived DN. Although no histologic findings were statistically significant for 
predicting graft failure, the grafts that failed showed either class IIb or III DN and not class 
IIa DN, suggesting that kidenys with class IIa DN may be safe to use.
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Plasma Cell Infiltrate in Allograft Rejection in Kidney Transplant 
Recipients
Shuo-ming Ou,1 Der-Cherng Tarng.2 1Division of Nephrology, Taipei Veteren 
General Hospital, Taipei, Taiwan; 2Taipei Veteran’s General Hospital, Taipei, 
Taiwan.
Background: Allograft rejection has always been the chief obstacle to renal outcomes 
in kidney transplant recipients. We aimed to evaluate the different kidney allograft rejection 
phenotypes between acute cellular rejection with and without plasma cell infiltrate.
Methods: We conducted a hospital-based study including 1237 kidney transplant 
recipients between Jan 1, 2002 to Dec 31, 2017 in a tertiary medical center. Of them, we 
assessed patients who received renal biopsy and biopsy samples showed allograft rejection, 
which was defined by the renal function deterioration and histopathological lesions. The 
primary outcome of interest included kidney allograft loss and reinitiation of dialysis, graft 
histology, the severity of microvascular invasion and tubulitis.
Results: In our study, 1237 patients were included in the main analyses, of whom 
293 (23.7%) had acute biopsy-proven rejection. We evaluated distinct patterns of kidney 
allograft rejection: T cell rejection and antibody mediated rejection with and without plasma 
infiltrates. Risk of failure to achieve graft function returning to to baseline after 6 month 
rescue therapy was highest in rejection with plasma cell infiltrate (hazard ratio [HR], 2.00; 
95% confidence interval [CI], 1.142–3.307; P = 0.0105), followed by antibody rejection 
without plasma cell infiltrates (HR 1.25), compared with T cell mediated rejection without 
plasma cell infiltrate.
Conclusions: In our study, we found that allograft rejection with plasma cell infiltrates 
were associated with poor renal outcomes compared to those without plasma cell infiltrates. 
Therefore, nephrologists and renal pathologists need to be aware of this entity and arrange 
more aggressive management to salvage kidney allografts.
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Safety and Efficacy of Management of Refractory Cytomegalovirus 
Infection in Kidney Transplant Recipients Treated with Foscarnet and 
Conversion from Antimetabolite to mTOR Inhibitor
Renato D. Foresto,1,2 Maria A. Hazin,3 Alejandro Zapata,3 Daniel 
wagner C. Santos.4 1Federal University of São Paulo, São Paulo, Brazil; 
2Tranplantation, Hospital do Rim, São Paulo, Brazil; 3UNIFESP, São Paulo, 
Brazil; 4Federal University of Sao Paulo, Sao Paulo, Brazil.
Background: Cytomegalovirus (CMV) infection is a frequent complication after 
kidney transplantation and it is associated with graft dysfunction and increased mortality. 
Foscarnet may be an alternative to ganciclovir-resistant or CMV refractory infections. As 
additional therapies, there are limited published studies assessing the conversion from 
antimetabolite (mycophenolate or azathioprine) to mTOR inhibitor (mTORi) to avoid 
recurrence.
Methods: We retrospectively evaluated the adverse events and outcomes of the 
treatment of refractory CMV with foscarnet from January 1, 2010 to April 30, 2018 and 
we analyze the outcomes of the group of patients who were submitted to conversion from 
antimetabolite to mTORi.
Results: We evaluated 28 patients with refractory CMV treated with foscarnet; 89.3% 
received thymoglobulin as induction therapy and, as a maintenance therapy, 46.4% started 
with azathioprine and 53.6% with mycophenolate. The first episode of CMV occurred, on 
average, 40 days after transplantation. The average duration of therapy with ganciclovir was 
98 days and 34.9 days with foscarnet. The UL97 mutation was present in all cases and the 
UL54 mutation was in 28.7%. After treatment with foscarnet, 17.8% had CMV recurrence. 
During treatment, 92.8% had antimetabolite discontinued, 64.3% were converted to mTORi. 
There were 19 recurring cases of CMV, 7 of them (36.8%) after conversion to mTORi 
against 12 cases (63.2%) in patients that not received mTORi. About the adverse effects to 
foscarnet, hypomagnesemia is the most common (82.1%), followed by hypophosphatemia 
(57.1%) and leucopenia (46.4%). There were 4 graft rejections and 3 deaths.
Conclusions: Prolonged use of ganciclovir with doses not adjusted for renal function 
as well as the immunological status of the transplanted patient are considered the main risk 
factors for resistance to ganciclovir therapy. Foscarnet seems to be an effective alternative 
in the control of viremia and treatment of CMV invasive disease. However, adverse events 
should be monitored cautiously, avoiding unfavorable outcomes for the graft. Preliminary 
data show that the conversion from antimetabolite to mTOR inhibitor is effective to avoid 
recurrence of CMV episodes.
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The Rate of Cytomegalovirus Infection and Disease in Renal Transplant 
Patients
Mark allen T. Bibera, Muna Alnimri, Diana Hao, Kathie Le, Elizabeth Zhu, 
Andrea Rieland, Denise M. Roach, Jennifer Brown. UC Davis Medical Center, 
Sacramento, CA.
Background: Cytomegalovirus (CMV) is a common opportunistic pathogen in renal 
transplant recipients (RTR) and is known to cause significant morbidity and mortality. To 
prevent CMV infection and disease, this single center academic institution utilizes both 
valganciclovir prophylaxis and continued monitoring through the outpatient transplant refill 
and mailing program (RAMP). The purpose of this study is to determine the incidence 
of CMV infection and disease in RTR who received valganciclovir and were enrolled in 
RAMP.
Methods: This is a retrospective, single center, cohort study of adult RTR between 
2014-2016. Patients were eligible if enrolled in RAMP, >18 years old, and able to take oral 
valganciclovir. The primary endpoint was the incidence of CMV infection or disease in the 
first year post-transplant. The secondary endpoint was the dose of valganciclovir at various 
time intervals post-transplant for a subgroup of 100 patients (including all patients with 
infection and disease).
Results: A total of 418 RTR of CMV high risk (Donor+/Recipient-) and intermediate 
risk (D+/R+, D-/R+) were included. Most were male (59%) and of Hispanic (38%) or 
Caucasian (26%) descent. Their mean age was 51 years old (range 18 to 81). Of the 418 
patients, CMV infection occurred in 15 (3.6%) and disease occurred in 2 (0.48%), with 
the majority of these cases occurring in the D+/R- group (11/17). For the subgroup of 100 
patients evaluated for valganciclovir dosing, 50% of patients were dosed higher and 20% 
were dosed lower than recommended at hospital discharge. At weeks 4, 8, and 12 post-
transplant 54-58% received lower and 12-20% received higher dosing than recommended.
Conclusions: The incidence of CMV infection and disease was lower than what is 
reported in the literature, with the highest prevalence in the D+/R- group. A combination 
of outpatient monitoring through RAMP and aggressive upfront dosing, followed by 
subsequent dose reductions in the outpatient setting likely contributed to the low rate of 
CMV infection and disease.
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Clinical Significance of Using the Banff 2017 Polyomavirus Nephropathy 
Classification in Kidney Transplantation: A Single Center Experience
Amita Maibam,1 Virgilius Cornea,1 Ana L. Castellanos,1 Amr E. Mohamed,1 
Waleed Hassan,1 Xiaonan Mei,1 Maria Yaseen,1 Roberto Gedaly,1 
Thomas H. Waid.2 1University of Kentucky, Lexington, KY; 2University of 
Kentucky Medical Center, Lexington, KY.
Background: BK virus is a known cause of BK polyomavirus nephropathy (PVN) and 
renal allograft failure. The 2017 Banff PVN classification is based on intrarenal polyoma 
viral load and Banff interstitial fibrosis score. The aim of this study is to examine the clinical 
significance of using PVN classes and its correlation with allograft survival.
Methods: This is a single-center retrospective analysis of all patients with BK viremia 
(BKV) > 10,000 copies/ml from 2009 to 2017 who underwent for-cause renal allograft 
biopsy. Patients were histologically classified into Banff Class 1, 2 or 3. Kidney function 
was compared between groups. A Kaplan-Meier analysis was performed to compare renal 
allograft survival differences among the groups using log rank test.
Results: BKV was identified in 122 patients (88 male and 34 female). Renal allograft 
biopsy was performed in 61 patients (50%). Seventeen patients (27.9%) had only PVN, and 
another 17 patients (27.9%) had only acute cellular rejection (ACR), whereas concomitant 
PVN and ACR were found in 4 patients (6.6%). The remaining 23 patients (37.7%) 
had neither PVN nor ACR. There was no statistically significant difference in clinical, 
demographic and laboratory parameters between the PVN groups. Out of 17 patients with 
PVN, one patient had class 1 (5.8%), 9 had class 2 (52.9%) and 7 had class 3 (41.2%). The 
single patient with class 1 PVN was excluded from the analysis. There was a trend toward 
better graft survival in PVN class 2 compared to class 3 (figure 1), but it failed to reach 
statistical significance.
Conclusions: Allograft survival was not statistically different between PVN class 2 and 
3 although a non-significant trend towards worse graft survival was seen in PVN class 3.
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BKV Clearance Time Correlates with the Exhaustion State and T-Cell 
Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant 
Patients with Severe BKV Infection
Ulrik Stervbo,1 Mikalai Nienen,1 Petra Reinke,2 Timm H. Westhoff,1 Nina Babel.1 
1University Hospital Marien Hospital Herne, Herne, Germany; 2Charité, 
Campus Virchow Klinikum, Berlin, Germany.
Background: Reactivation of the BK polyomavirus is known to lead to severe 
complications in kidney transplant patients. The current treatment strategy relies on 
decreasing the immunosuppression to allow the immune system to clear the virus. Recently 
we demonstrated a clear association between the resolution of BKV reactivation and 
reconstitution of BKV-specific CD4+ T-cells. However, the factors determining the duration 
of the clearance of the viral infection remain unknown.
Methods: Here we apply a combination of in-depth multiparametric flow cytometry 
and CDR3 beta chain receptor repertoire analysis of BKV specific T-cells to a cohort of 5 
kidney transplant patients with BKV reactivation. In this manner we were able to track the 
TCR repertoires at single clone levels during the clinical course of BKV infection.
Results: The number of BKV-specific T-cells in peripheral blood did not affect the 
duration of BKV infection. In contrast, the diversity of the T-cell receptor repertoire as well 
as exhaustion status of BKV-specific T-cells correlated with the duration of viral clearance. 
This duration was further found to be independent of hyperexpanded, immunodominant 
BKV-specific T-cell clones and of the overall magnitude of cellular immunity. Rather, 
the diversity of BKV-specific TCR repertoire in peripheral blood: high diversity of the 
repertoire and lack of PD1 and TIM-3 exhaustion markers on BKV-specific T-cells is 
associated with short remission time.
Conclusions: Our data demonstrate that the quality (exhaustion status and shape of the 
repertoire) rather than quantity of BKV-specific T-cells determines the remission time after 
BKV reactivation.
Funding: NIDDK Support, Government Support - Non-U.S.
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BK Virus Seroprevalence in Donors and Kidney Transplant Recipients 
and Their Correlation with Development of BK Virus Infection in the 
Post-Transplant Period
Andrea Portilla,1 Idalia Parra,6 Rodrigo Rosado canto,1 José roberto Marino 
sanchez,4 Cristinoc Cruz,5 Abraham Cohen-Bucay,2 Norma O. Uribe-uribe,3 
Josefina Alberú,5 Luis E. Morales-Buenrostro.1 1Instituto Nacional de Ciencias 
Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico; 2Boston 
University Medical Center, Boston, MA; 3Instituto Nacional de Ciencias 
Medicas y Nutricion, “Salvador Zubiran”, Mexico City, Mexico; 4Instituto 
Nacional de ciencias médicas Salvador Zubirán, Ciudad de mexico, Mexico; 
5INCMNSZ, Mexico, Mexico; 6Instituto Mexicano del Seguro Social, 
Guadalajara, Mexico.
Background: BK virus (BKV) nephritis is a common cause of allograft dysfunction, 
which is related to the level of immunosuppression. Since no specific antiviral treatment 
is available, predictive markers that could help clinicians personalize the level of 
immunosuppression given to a specific patient are needed. Aims: to evaluate BKV 
seroprevalence in kidney donors and recipients as a predictive factor of BKV viruria, 
viremia and BKV nephritis in the post-transplant period.
Methods: BK-IgG ELISA qualitative test (MyBioSource Inc, San Diego, CA), was 
measured in 169 pts (81 donors and 88 recipients) before kidney transplantation. 76 
recipients were followed post-transplant with BKV-PCR in blood and urine at 1, 3, 6, 9, 
and 12 months after transplantation. In addition, protocol biopsies at 3 and 12 months, and 
for-cause biopsies due to allograft dysfunction were performed.
Results: 58% of donors and 62.5% of recipients were seropositive prior to 
transplantation. Mean follow-up of transplant recipients was 198 days. They were divided 
into high risk (D+/R-, n=25) and moderate/low risk (D-/R+, D+/R+ and D-/R-, n=51). 
Viruria, viremia and BK nephritis developed in 16%, 12%, and 4% in the high risk, 
and 15.7%, 11.7%, 5.8% in the moderate/low risk group, respectively (p=0.9). Time to 
development of viruria, viremia, and BKV nephropathy was evaluated with the Kaplan-
Meier in both groups and no statistically significance was observed [Figure 1].
Conclusions: BKV seroprevalence in Mexican population was 58.0% in donors and 
62.5% in kidney transplant recipients. No correlation was observed between pretransplant 
serological status of donor and/or recipient and the post-transplant development of BKV 
viruria, viremia, and nephritis.
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Plasma Cell Neoplasms After Renal Allograft: A Single-Center Experience
Chitra Bhosekar, Tepsiri Chongkrairatanakul, Anita D’Souza, Bhavna Bhasin. 
Medical College of Wisconsin, Menomonee Falls, WI.
Background: Plasma cell disorders (PCD) are B-cell neoplasms that develop as a 
consequence of dysregulated B-cell clonal proliferation. The various types of PCD include 
monoclonal gammopathy of unknown significance (MGUS), multiple myeloma (MM) 
and monoclonal gammopathy of renal significance (MGRS). PCD and their complications 
can impact graft survival and other outcomes following kidney transplantation (KT). This 
underscores the need to investigate the natural history of PCD after KT.
Methods: Retrospective chart review was done at our institution in patients >18 years 
who had KT between 2008 and 2017 to identify those developing PCD after KT. Patients 
with a PCD before KT were excluded from the study.
Results: Of the 711 patients who received KT, 12 (1.68%) developed PCD. Three 
patients developed MM, 2 developed MGRS and 7 had MGUS in the post-transplant 
course. The study population was predominantly male (75%). Patients in the MM group 
were younger (mean age 54 years, range 47-67) than those in the MGUS (mean age 57, 
range 39-69) and MGRS groups (mean age 80 years, range 74-86) at the time of transplant. 
The mean time from transplant to PCD was 2.9, 3.2 and 4.6 years respectively in the MGRS, 
MGUS and MM groups. Mean follow up of survivors in the study was 5.9 years. Epstein 
Barr virus (EBV) positivity was noted in all 3 MM patients but in 50% of MGRS and 
28% of MGUS groups. The mean creatinine at last follow up was higher (2 mg/dL) in 
MM subjects and was similar (1.7 mg/dL) in the MGRS and MGUS groups. Induction and 
maintenance immunosuppressive regimens used were similar in three groups. One MM 
patient died 3 years after diagnosis but all other patients were alive with a functioning graft 
at last follow up.
Conclusions: We found an incidence of new PCD after KT of 1.68% over a 10-year 
period after KT, which is similar to the incidence of post-transplant lymphoproliferative 
disorder (1.5%-2%). The risk of developing MM may be higher in patients who are 
transplanted at a younger age though the time from transplant to diagnosis may be 
longer than other types of PCD. EBV status at KT may influence development of MM 
post-transplant suggesting a role of immunosuppression. These findings merit further 
examination in a larger study.
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Mutational Signature of Urothelial Carcinoma After Kidney  
Transplantation as Revealed by Whole-Exome Sequencing (WES)
Lee-Moay Lim, Daw-yang Hwang, Hung-Tien Kuo. Kaohsiung Medical 
University Hospital Division of Nephrology, Kaohsiung City, Taiwan.
Background: Urothelial carcinoma (UC) has the characteristic of high degree molecular 
heterogeneity. In Taiwan, UC is the most common cancer after kidney transplantation(KT). 
Mutational profiles by WES could help in identifying not only UC-specific genes but also 
novel genes for disease specific therapeutic target and outcomes. We perform WES of UC 
developed after KT in an effort to discover the molecular genetics of UC.
Methods: Formalin-fixed paraffin-embedded archival samples of UC from 6 kidney 
transplant patients in our center were obtained. Patients with UC diagnosed before the 
transplant surgery were excluded. All patients were sporadic, without any family history 
of UC. For control group, we selected 5 hemodialysis patients with UC diagnosed after the 
commencement of dialysis treatment. DNA was extracted for WES analysis.
Results: Missense mutations were the most common type of somatic mutation (Figure 
1a, 2). The A:T→T:A transition was the most significant nucleotide changes (Figure 1b). 
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Our WES data was matched with the Cosmic, Intogen, and TCGA database for onco-driver 
genes. We newly identified five genes, including GNAQ, MLLT10, SEPT6, SLC34A2, 
NTRK3, which comprised of 25% of mutations specifically in our patients (Figure 2).
Conclusions: The finding of A:T→T:A transition as the most significant nucleotide 
changes was different from TCGA cohort, as about 51% of their mutation resulted in 
TpC>T or G. Our results suggest that the genetic mutation in our cohort might be associated 
with aristolochic acid (AA) exposure, which is the one of the risk factor for renal failure and 
UC development. This preliminary data provides clues for understanding the mutational 
landscape of UC developed after KT.
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Predictive Role of Histological and Immunological Parameters in ABMR 
in a Cohort of Renal Transplanted Patients
Anna Regalia,1 Mariarosaria Campise,1 Carlo M. Alfieri,1 Donata Cresseri,1 
Gabriella Moroni,1 Maria Teresa Gandolfo,1 Valentina Binda,1 
Piergiorgio Messa.1,2 1Fondazione IRCCS Ca’ Granda Ospedale Policlinico 
Milan, Milan, Italy; 2Università degli Studi di Milano, Milan, Italy.
Background: In clinical practice, the diagnosis of antibody-mediated rejection 
(ABMR) is based on three main components: specific histological lesions, presence of peri-
tubular capillaries C4d and of circulating anti-HLA donor specific antibodies (cDSA). Our 
study aims to evaluate the concordance between histological and immunological diagnostic 
elements of ABMR and their predictive role on renal transplant (RTx) prognosis.
Methods: Among the 486 RTx patients transplanted from deceased donors in our Unit 
(2004-2015), 115 patients were submitted to renal biopsy (RBx) on clinical indications and 
evaluated for tissue C4d and cDSA (Luminex). Follow-up time was 3.7±2.7 yrs. According 
to histological lesions, RBx were categorized in: ABMR (hABMR), T-cell mediated 
rejection (hTCMR) or other lesions (hO). In addition, a categorization according to C4d 
positivity (C4d+/C4d-) and presence of cDSA at RBx (cDSA+/cDSA-) was made. In the 
relationship between histological and immunological elements, we considered 4 groups: 
cDSA-/C4d- (gr-A); cDSA-/C4d+ (gr-B); cDSA+/C4d- (gr-C); cDSA+/C4d+ (gr-D).
Results: Among the 115 RBx, 20%, 21% and 59% were respectively hABMR, 
hTCMR and hO. Compared to others, hABMR had higher PRA at RTx (p=0.03), higher 
Prot-U at RBx (p=0.01), more prevalence of C4d+ and cDSA+ (both p <0.0001) and shorter 
follow-up after RBx (p=0.03). In hABMR, 17.4% and 8.7% were in gr-A and gr-B, 30.4% 
and 43.5% in gr-C and gr-D (p<0.0001); in hTCMR, 95.8% and 0% were in gr-A and gr-B, 
4.2% and 0% in gr-C and gr-D (p<0.0001); in hO, 80.9% and 2.9% were in gr-A and gr-B, 
14.7% and 1.5% in gr-C and gr-D (p<0.0001); hABMR, C4d+ and DSA+ were singularly 
associated with graft loss, but among them h-ABMR was the only independent predictive 
factor for graft loss (HR 2.64 - p=0.01). Kaplan Meier analysis showed a worse graft 
outcome in hABMR compared to other histological diagnoses (p<0.001). h-ABMR had 
also higher graft loss discriminative power than C4d+ and cDSA+ (AUC 0.70, p<0.001). 
No discriminative informative advantages were found considering together h-ABMR and/
or C4d+ and/or cDSA+.
Conclusions: Our data suggest that the histological evaluation of RTx is an unavoidable 
test for the diagnosis of graft dysfunction and represents the best prognostic parameter.
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Outcomes of Two Diarrhea-Causing Infections in Kidney Transplant 
Recipients
Stacey Rolak,1 Sarah E. Di Bartolomeo,1 Brad C. Astor,3 Sandesh Parajuli.2 
1University of Wisconsin School of Medicine and Public Health, Madison, WI; 
2UW Health, Madison, WI; 3University of Wisconsin, Madison, WI.
Background: Diarrhea caused by infection from Clostridium difficile (CD) or 
Norovirus (NV) is a common complication in immunosuppressed kidney transplant 
recipients (KTRs). There is limited data comparing the outcomes of these infections in 
KTRs. Comparing the outcomes of these two prevalent infections may inform preventive 
and therapeutic strategies in patient management.
Methods: We examined KTRs transplanted at our center between 01/01/1994 to 
12/31/2014 who suffered from CD or NV infection-related diarrhea. Those who suffered CD 
or NV infection were matched with controls randomly selected from surviving recipients 
without these infections to that point in time with a 5:1 ratio. Outcomes examined include 
number of CD or NV infections, interval from transplant to infection, and graft failure.
Results: Of 4941 kidney transplants performed during the study period, 294 developed 
primary CD and 64 developed NV. Mean interval from transplant to infection was 
1401±1621 days for CD infection and 1355±1357 days for NV infection. Polycystic kidney 
disease, diabetes, and glomerulonephritis were more common in the CD group compared 
to NV (p<0.05). Median uncensored graft survival following infection was 456 days for 
CD, 541 days for NV, and 1276 days for controls. Cox proportional hazard regression 
demonstrated that those with CD had higher risk of graft failure than controls (HR 2.43, 
95% CI 2.07 to 2.87, p<0.01). Graft failure in the CD group and NV group were higher than 
for the control group at different times (Table 1).
Conclusions: Both CD and NV infection are associated with deleterious effects on 
kidney graft survival. Prevention and early management of these infections may prolong 
graft survival.
Funding: Private Foundation Support
Table 1. Graft failure in CD, NV, and control study groups.
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Presence of Anti-HBs Confers Protection Against Hepatitis B Virus 
Infection in HBsAg-Negative and Anti-HBc-Positive Patients Undergoing 
Kidney Transplantation
Jae wan Jeon,1 Kang Wook Lee,1 Ki Ryang Na,1 Youngrok Ham,1 Dae Eun Choi,2 
Haeri Kim.1 1Chungnam National University Hospital, Daejeon, Republic of 
Korea; 2Chungnam National University, Daejeon, Republic of Korea.
Background: The American Gastroenterological Association (AGA) and European 
Association for the Study of the Liver (EASL) recommend that hepatitis B surface antigen 
(HBsAg)-negative and hepatitis B core antibody (anti-HBc)-positive patients who receive 
immunosuppression should be monitored for hepatitis B virus (HBV) infection regardless of 
hepatitis B surface antibody (anti-HBs) status. However, anti-HBs may provide protection 
against HBV infection. To investigate whether the presence of anti-HBs in addition to anti-
HBc confers protection, we classified HBsAg-negative kidney transplantation (KT) patients 
into 4 groups according to anti-HBc and anti-HBs status, and compared the HBV infection 
rate between the anti-HBc(+)/anti-HBs(+) group and the other 3 groups.
Methods: In this single-center retrospective study, we classified 1,959 patients into 
4 groups: anti-HBc(-)/anti-HBs(-) (n=356), anti-HBc(-)/antiHBs(+) (n=652), anti-HBc(+)/
anti-HBs(-) (n=142), and anti-HBc(+)/anti-HBs(+) (n=809).
Results: HBV infection was noted in 31 patients (1.6%) after KT. There was a 
significant difference in HBV infection rate between anti-HBc(+)/anti-HBs(+) (1.2%) and 
anti-HBc(+)/anti-HBs(-) (5.6%) (p<0.001), but not between anti-HBc(+)/anti-HBs(+) and 
anti-HBc(-)/anti-HBs(-) (1.1%) or anti-HBc(-)/anti-HBs(+) (1.4%). There was a significant 
difference in HBV infection rate according to anti-HBs titer, but no difference according to 
the donor viral profile. Hepatic failure occurred in 1 anti-HBc(+)/anti-HBs(-) patient and 1 
anti-HBc(+)/anti-HBs(+) patient, both of whom died. Hepatocellular carcinoma was noted 
in 4 anti-HBc(-) patients, but not in anti-HBc(+) patients.
Conclusions: The presence of anti-HBs confers protection against HBV infection. The 
EASL or AGA guidelines may be modified to indicate that monitoring should be performed 
for HBV infection after KT in HBsAg(-)/anti-HBc(+)/anti-HBs(-) patients, but not in 
HBsAg(-)/anti-HBc(+)/anti-HBs(+) patients.
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Transplantation: Translational and Transplant Pathology
The Risk of Hepatitis B Virus Reactivation with Rituximab  
Desensitization in HBsAg-Positive Kidney Transplant Recipients
Yuri Seo,1 Chung Hee Baek,2 Su-Kil Park.2 1Asan medical center, Seoul, 
Republic of Korea; 2Asan Medical Center, Songpa-gu, SEOUL, Republic of 
Korea.
Background: Rituximab, as a powerful immunosuppressive agent, is used for ABO 
mismatched Kidney transplantation (KT) or flow cytometry positive patients. Because 
rituximab has elevated risk for hepatitis B virus (HBV) reactivation, antiviral prophylaxis is 
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recommended for positive hepatitis B surface antigen (HBsAg(+)) recipients. The purpose of 
this study was to evaluate whether treatment with an antiviral agent is enough for preventing 
HBV reactivation in HBsAg(+) patients who had KT with rituximab desensitization.
Methods: The 128 patients who underwent KT from 2009 to 2016 identified as 
HBsAg(+) before KT in a single center were retrospectively analyzed. They were divided 
into two groups according to whether rituximab was used or not (29 patients in Rituximab(+) 
group, 99 patients in Rituximab(-) group). HBV reactivation was diagnosed by an increase 
in HBV DNA more than 2 log10 international units/mL or a detectable HBV DNA level 
when previously undetectable HBV DNA. In addition, HBV reactivation was compared 
between 500 mg and 200 mg in rituximab(+) group.
Results: Reactivation of HBV DNA was detected in 4 among 29 (13.79%) HBsAg(+) 
patients in rituximab(+) group and 20 among 99 (20.20%) HBsAg(+) patients in 
rituximab(-) groups (P=0.592). The 4 patients with HBV reactivation in rituximab(+) group 
had already taken antiviral agents since KT (Table1). LFT elevation was detected in 2 of 
the 4 patients that HBV DNA was reactivated. The elevated LFT or reactivated HBV DNA 
was spontaneously resolved without change of antiviral agents. The Number of HBV DNA 
reactivation was not lowered according to changing rituximab dose from 500 mg (1/8, 
12.50%) to 200 mg (3/21, 14.29%) in rituximab(+) group.
Conclusions: When HBsAg(+) patients received KT, the use of Rituximab may not 
increase HBV reactivation. It is suggested that the usage of antiviral agents is efficient 
prophylaxis for HBV reactivation of HBsAg(+) recipients who had KT with rituximab 
desensitization.
Table 1. Time of DNA reactivation after KT in the 4 patients with HBV reactivation in 
rituximab(+) group (by year)
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HIV-Infected Kidney Allograft Recipients Managed with  
Anti- 
Thymocyte Globulin Induction
Ayman Al Jurdi,1 Esther C. Liu,3 Meredith J. Aull,4 Michelle L. Lubetzky,2,1 
David Serur,5 Sandip Kapur,4 Thangamani Muthukumar.1 1New York 
Presbyterian Hospital / Weill Cornell Medicine, New York, NY; 2Division of 
Nephrology and Hypertension, New York, NY; 3New York Presbyterian, New 
York, NY; 4Weill Cornell Medical College, New York, NY; 5The Rogosin Institute, 
New York, NY.
Background: Reconsiderations of the risks involved in using immunosuppressive 
therapy in patients with HIV have resulted in a welcome foray into providing kidney 
allografts to HIV-infected patients. Anti-thymocyte globulin (ATG) induction reduces acute 
rejection but its use in HIV-infected kidney transplant recipients is limited. We assessed the 
long-term outcomes of HIV-infected kidney transplant recipients at our center managed 
with ATG induction.
Methods: Single center chart review of HIV-infected kidney allograft recipients 
between 2006 and 2016 who received induction immunosuppression with ATG. 
Maintenance immunosuppression included tacrolimus and mycophenolate with or without 
corticosteroids. Infection prophylaxis included clotrimazole, valganciclovir and co-
trimoxazole. Primary outcome measures were patient and graft survival. Patients who did 
not meet their primary outcomes were censored at their last follow up.
Results: Twenty-nine HIV-infected patients (34% female, 66% black, 83% early 
corticosteroid withdrawal) underwent deceased (n=24) or living donor (n=5) kidney 
transplantation. Median (IQR) age was 54 years (50-59). CD4+ T-lymphocyte count was 
455 (392-508). Graft and patient survival were 96.6% and 96.6% at 12 months respectively 
(Fig. 1). At 12 months post-transplantation, acute rejection-free survival was 96.4% and 
infection-free survival was 55.2%. Sustained HIV viral suppression was observed in 69% of 
patients. Ten patients (34%) developed 11 malignancies during their follow up.
Conclusions: Induction immunosuppression with anti-thymocyte globulin is associated 
with excellent clinical outcomes in HIV-infected kidney allograft recipients.
Figure 1. Kaplan-Meier graft (Left) and patient survival (Right) estimates of 29 HIV-
infected kidney recipients at our center managed with Thymoglobulin induction 
immunosuppression.
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Clinical Experience of Prevalence and Prophylaxis for Latent  
Tuberculosis Infection in Living Donor Kidney Transplant Recipients
Tae Hyun Ban,1 Byung ha Chung,2 Bumsoon Choi,4 Cheol Whee Park,3 Yong-
Soo Kim,5 Chul Woo Yang.2 1Seoul St. Mary’s hospital, Seoul, SEOUL, Republic 
of Korea; 2Seoul St. Mary’s Hospital, Seoul, Republic of Korea; 3The Catholic 
University of Korea, Seoul, Republic of Korea; 4Division of Nephrology, 
Department of Internal Medicine, Seoul, Republic of Korea; 5The Catholic 
University of Korea College of Medicine, Seoul, Republic of Korea.
Background: Latent tuberculosis infection (LTBI) is a risk factor of active tuberculosis 
(TB) in kidney transplant recipients (KTRs). Transplant-associated TB poses a significant 
risk for both graft loss and patient death. Current guideline recommends LTBI prophylaxis 
in KTRs. The aim of this study was to assess the property of current LTBI prophylaxis.
Methods: We investigated 404 living donor KTRs between November 2013 and 
December 2017. We analyzed Data including QFT, TST, chest radiography, past TB 
history, post-transplant TB incidence, and current practice of LTBI prophylaxis. LTBI was 
diagnosed to one of following criteria: (1) positive result in tuberculin skin test (TST) or 
interferon-gamma release assays (IGRA) by QuantiFERON-TB Gold In-Tube test (QFT); 
(2) the old healed TB sequelae in chest radiography without TB treatment history; (3)
previously insufficient TB treatment history; (4) contact history with active pulmonary TB 
patient within a year. Initial prophylactic agent for LTBI was isoniazid 300mg per day.
Results: The mean follow-up period of the patients 25.6 ± 14.2 months. QFT was 
positive in 37.6% (n=152), while TST was only positive in 13.1% (n=30). Additionally, 
only seven patients (1.7%) among patients with negative QFT were positive TST. On the 
other hand, there was no tuberculosis outbreak in living donor kidney transplant recipients 
during followed-up period. A total of 137 subjects were prescribed INH. Of them, 37 
patients (27%) underwent adverse events, with the most common adverse event being 
hepatotoxicity, most occurring within three months.
Conclusions: Careful surveillance in KTRs needs at early period of INH prophylaxis. 
High incidence of adverse events of INH prophylaxis including hepatotoxicity suggests to 
need additional strategies to reduce that in LTBI prophylaxis.
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High Plasma Cadmium and Late Graft Failure in Renal Transplant 
Recipients
Joppe J. Vodegel,1 Michele F. Eisenga,1 Tim J. Knobbe,1 Rosa G. Lammerts,1 
Martin H. De Borst,3 Stefan P. Berger,1 Ilja M. Nolte,2 Daniel J. Touw,3 
Stephan J. Bakker.1 1Nephrology, University Medical Center Groningen, 
Groningen, Netherlands; 2Epidemiology, University Medical Center Groningen, 
Groningen, Netherlands; 3Clinical Pharmacy and Pharmacology, University 
Medical Center Groningen, Groningen, Netherlands.
Background: Although short-term outcome after kidney transplantation has strongly 
improved, late graft failure remains a major distress for both patient and physician, and its 
etiology is poorly understood. This urges the identification of new treatable risk factors 
for late graft failure. In the general population, substantially increased plasma cadmium 
levels contribute to progressive renal function loss. Since renal transplant recipients 
(RTRs) only have one functioning kidney which is also exposed to noxious factors during 
transplantation, we assumed that RTRs are more susceptible to cadmium nephrotoxicity. 
Therefore, we hypothesized that higher plasma cadmium levels, even below the normal 
range, are associated with an increased risk of graft failure in RTRs.
Methods: The study was conducted in the TransplantLines Food and Nutrition 
Biobank cohort study. Plasma cadmium was measured using inductive coupled plasma 
mass spectrometry (ICP-MS). All RTRs (age>18 years) had a functioning graft for more 
than one year. Cox regression analyses were used to investigate prospective associations of 
cadmium with graft failure.
Results: We included 706 RTRs (age 53±13 years; 56.8% males at mean 5.4 
(1.9-12.0) years after transplantation). Mean plasma cadmium levels were 0.70 ± 0.13 μg/L 
(normal range <5 μg/L) and eGFR was 45.0 ± 18.7 ml/min/1.73m2 (normal range 
90 – 120 ml/min/1.73m2). During follow-up for 4.9 (3.3-5.5) years, 80 (11.3%) RTRs 
developed graft failure. In univariable analysis, increased plasma cadmium levels were 
associated with increased risk of graft failure (hazard ratio (HR) 2.49 [95%CI 1.73-3.58], 
P < 0.001). In multivariate analysis, after adjustment for age, sex, proteinuria, primary renal 
disease, time since transplantation, acute rejection, cold ischemia time, HLA mismatches, 
deceased donor status, BMI, systolic blood pressure, plasma glucose, diabetes, smoking, 
and alcohol use, the association of cadmium with graft failure remained (HR 2.23 [1.39-
3.57], P = 0.001).
Conclusions: We conclude that cadmium levels are associated with an increased risk 
of graft failure in RTRs. Interventions aiming at reducing bodily cadmium concentrations, 
e.g. chelation therapy, seem warranted to improve long-term graft survival after renal
transplantation.
Funding: Government Support - Non-U.S.
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Evaluating the Functional Response of a Barrier-Free Glomerulus-on-a-
Chip System to Injury: A Novel Tool for Renal Personalized Medicine
Julia Marcheque,2 Paolo Cravedi,4 Roger E. De Filippo,3 Laura Perin,3 
Stefano Da Sacco.1 1Children’s Hospital Los Angeles, Los Angeles, CA; 
2Children’s Hospital Los Angeles, Los Angeles, CA; 3Childrens Hospital Los 
Angeles, Los Angeles, CA; 4Mount Sinai, New York, NY.
Background: With increasing rates of renal failure, there is an urgent need of 
implementing new strategies for understanding glomerular pathophysiology and for 
developing efficient patient-specific drug screening tools. To this regard, we recreated an in 
vitro 3D multicellular platform that allows fluid perfusion and proper interactions between 
podocytes and glomerular endothelial cells (hGEC). This glomerulus-on-a-chip system can 
be used to study the complex architecture and function of the glomerular filtration barrier 
(GFB).
Methods: Human amniotic fluid derived podocytes (hAKPC-P), human immortalized 
podocytes (iPod), primary human podocytes (pPod) and human fibroblasts (negative control) 
were seeded on microfluidic chips (OrganoplatesTM) with hGEC. Immunofluorescence was 
performed for podocyte, endothelial and GBM markers. Barrier selective-permeability was 
investigated. Feasibility of the system for high throughput screening and disease modeling 
was evaluated by measuring permselectivity following Puromycin Aminonucleoside 
(PAN) injury or culture with serum from FSGS (focal segmental glomerular sclerosis) and 
membranous nephropathy (MN) patients.
Results: We have developed an innovative, barrier-free, glomerulus-on-a-chip system. 
hAKPC-P, iPOD and pPOD formed a slit diaphragm-like structure expressing nephrin and 
podocin. CD31-expressing hGEC formed capillary-like structures. De-novo deposition of 
GBM components such as collagen IValpha3,4,5 and laminin alpha5 was confirmed for 
hAKPC-P and pPOD but not iPOD. Albumin permselectivity was confirmed on chips 
with hAKPC-P, pPOD and less efficiently for iPOD while use of fibroblast lead to marked 
albumin leakage. Permselectivity was impaired following PAN administration as confirmed 
by our experiments. In the presence of MN serum (but not from healthy controls or FSGS) 
IgG-mediated injury to the barrier caused albumin leakage, suggesting an MN specific 
mediated damage.
Conclusions: We have successfully developed a glomerulus-on-a-chip system that 
closely mimics the GFB and provides a powerful tool for studying renal regenerative, 
disease mechanisms and toxicity effects. In conclusion, this system will increase our ability 
to individualize treatments and drug susceptibility, thus ultimately benefiting patients 
affected by renal failure.
Funding: Private Foundation Support
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Dynamic Chromatin Accessibility at Poised Developmental Enhancers of 
Nephron Progenitors
Renfang Song, Melody C. Baddoo, Hongbing Liu, Zubaida R. Saifudeen, 
Samir S. El-Dahr. Tulane University School of Medicine, New Orleans, LA.
Background: Remodeling of chromatin accessibility at dynamic lineage-specific 
enhancers has emerged as a key mechanism in the control of cell fate in health and disease. 
Recent studies defining the gene regulatory network of nephron progenitor cells (NPC) have 
identified cis-acting modules bound to the master transcription factors (mTF) Six2, Osr1, 
and Wt1. However, it is unclear how these combinatorial factors gain access to chromatin 
to define enhancer function. In this study, we mapped the chromatin landscape of NPC 
to determine accessibility of developmental enhancers to mTFs during the NPC lifespan.
Methods: Self-renewing young (E13.5, E16.5), and differentiating old (P0 and P2) 
Six2+/GFP+ NPCs were subjected to genome-wide ATAC-seq to map open chromatin 
regions, i.e., accessible enhancers. Chromatin states (poised, active, repressed) of enhancers 
were determined by ChIP-seq of H3K4me1, H3K27ac, and H3K27me3, respectively. 
Enhancer access and chromatin states were integrated with genome-wide mTF binding 
(ChIP-seq) and gene expression (RNA-seq).
Results: We examined 80 poised NPC genes that bind the three mTFs and show >4-
fold increase in mRNA expression during NPC lifespan. mTFs occupancy corresponded to 
K4me1-marked (poised) chromatin regions in young NPC and to K4me1/K27ac-marked 
active enhancers in old NPC. Surprisingly, activation of differentiation poised enhancers 
(and gene transcription) correlated with progressive reduction in the size of open chromatin 
regions and thus to accessible cis-acting elements. In comparison, NPC lacking the 
H3K27 methyltransferases, Ezh1 and Ezh2, displayed persistent open chromatin at poised 
enhancers.
Conclusions: Progressive restriction of access to dynamic developmental enhancers 
may act as a gateway to fine-tune the timing of differentiation gene expression and cessation 
of nephrogenesis. Targeted epigenome editing of developmental enhancers may be a useful 
strategy to manipulate NPC fate and lifespan.
Funding: NIDDK Support
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Comprehensive Analysis of Chromatin Signature and Transcriptome 
Uncovers Functional lncRNAs Expressed in Nephron Progenitor Cells
Masaki Nishikawa,1,2 Shunsuke Yuri,3 Hiroshi Kimura,4 Naomi Yanagawa,1,2 
Morgan Hamon,1,2 Peter V. Hauser,1,2 Lifu Zhao,1,2 Oak D. Jo,1,2 
Norimoto Yanagawa.1,2 Renal Regeneration Laboratory 1David Geffen School of 
Medicine, University of California, Los Angeles, CA; 2Medical and Research 
Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, 
North Hills, CA; 3Nara Institute of Science & Technology, Nara, Japan; 4Tokai 
University, Hiratsuka, Japan.
Background: Emerging evidence from recent studies has unraveled the roles of long 
noncoding RNAs (lncRNAs) in the function of various tissues. However, little is known 
about the roles of lncRNAs in kidney development. In our present study, we aimed to 
identify functional lncRNAs in one of the three lineages of kidney progenitor cells, i.e., 
metanephric mesenchymal (MM) cells.
Methods: MM cells were purified by FACS from Cited1nuc-TagRFP-T mouse embryonic 
kidneys, and comprehensive analyses of the chromatin signature and transcriptome were 
conducted by RNA-seq and ChIP-seq.
Results: We found seventeen lncRNAs that were expressed specifically in MM cells 
with an active chromatin signature, while remaining silenced in a bivalent chromatin state 
in non-MM cells. Out of these MM specific lncRNAs, we identified a lncRNA, Gm29418, 
in a distal enhancer region of Six2, a key regulatory gene of MM cells. We further identified 
three transcript variants of Gm29418 by Rapid Amplification of cDNA Ends (RACE), and 
confirmed that the transcription-start-sites (TSSs) of these variants were consistent with the 
result of Cap Analysis Gene Expression (CAGE). In support of the enhancer-like function of 
Gm29418 on Six2 expression, we found that knock-down of Gm29418 by two independent 
anti-sense locked nucleic acid (LNA) phosphorothioate gapmers suppressed Six2 mRNA 
expression levels in MM cells. We also found that over-expression of Gm29418 led to an 
increase in Six2 mRNA expression levels in a mouse MM cell line.
Conclusions: In conclusion, we demonstrated in our present study that a 
comprehensive analysis of chromatin signature and transcriptome can be a powerful tool 
in screening lncRNAs in various tissues, which led us to identify a lncRNA, Gm29418, 
in renal progenitor cells that has an enhancer-like function on a key regulatory gene, Six2.
Funding: Private Foundation Support
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Netrin-1 Directs Neurovascular Patterning Required for Proper Kidney 
Development
Lori L. O’Brien,1 Deanna M. Hardesty,2 Shamus L. Cooper.2 1University of 
North Carolina at Chapel Hill, Chapel Hill, NC; 2University of North Carolina 
at Chapel Hill, Chapel Hill, NC.
Background: Proper kidney development requires the coordinated growth and 
differentiation of multiple cell types. Alterations to nephron number and function can 
have significant health consequences. While advances have been made in elucidating 
how nephron progenitors form, differentiate, and interact with the adjacent stroma and 
collecting duct system, almost nothing is known about how the neural and vascular systems 
influence these processes or even how they become established in the fetal kidney. This is 
a significant void in our understanding, given the critical importance of vascular perfusion 
and innervation for mature organ formation and function.
Methods: To this end, we have interrogated the function of netrin-1 in the developing 
kidney. Netrin-1 is an axon guidance cue which also regulates vessel pathfinding. Netrin-1 
(Ntn1) is highly expressed by the stromal progenitors. We conditionally deleted Ntn1 in 
these cells and examined the resulting phenotypes with light-sheet and confocal microscopy 
in addition to standard histological techniques.
Results: Ntn1 loss results in abbarent neural and vascular networks. Normal patterning 
is disrupted, leading to localized networks which are in excess or deficient. Additionally, 
ectopic neurovascular tracts are found on the outside surface of the kidney which can 
infiltrate and severely disrupt local tissue morphology. Mutant kidneys are hypoplastic 
with an extension of nephron progenitor lifespan by ~2 days. Deletion of Unc5c, a known 
receptor for netrin-1 which is expressed by the nephron progenitors, does not result in 
any obvious developmental defects. Therefore, we predict the hypoplastic and progenitor 
phenotypes we observe are due to a disruption in signals that the nerves/vessels supply to 
nephron progenitors and the branching collecting duct system, rather than a direct action of 
netrin-1. Consistent with congenital renal defects having ongoing effects into adulthood, 
we find that mutant adult kidneys show focally dilated and vacuolated tubules indicative of 
tubular injury, as well as abnormal glomerular histology.
Conclusions: These studies have provided novel insights into the establishment of 
neurovascular networks in the developing kidney and the implications for adult function. 
Such findings will help inform efforts to engineer kidneys de novo, where establishing 
proper kidney filtration will be essential.
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Stromal Prorenin Receptor (PRR) Is Critical for Normal Kidney 
Development
Ihor V. Yosypiv,1 Maria Luisa S. Sequeira Lopez,2 Renfang Song.3 1Pediatrics, 
Tulane University, New Orleans, LA; 2University of Virginia, Charlottesville, 
VA; 3Tulane University, New Orleans, LA.
Background: The transcription factor Foxd1, a specific marker of kidney stromal cells, 
is critical for normal kidney development. Global loss of the PRR, a receptor for renin and 
prorenin, is lethal in mice, indicating its essential role in embryonic development. Here, we 
investigated the role of the PRR in Foxd1+ stromal progenitors in mice.
Methods: Foxd1-eGFP-Cre+ mice were crossed with PRRflox/flox mice. The resulting 
Foxd1Cre+/PRRflox/flox mice represent deletion of the PRR in Foxd1+ stromal progenitors 
(cKO). Control mice consisted of Foxd1Cre-/PRRflox/flox littermates (Con). Molecular marker 
analysis was performed by immunohistochemistry in kidneys on E17.5. Glomerular 
number was counted at P0 from 3 consecutive H&E-stained sections/kidney adjacent to 
the longitudinal midplane. Conscious systolic, diastolic and mean tail-cuff arterterial blood 
pressure (BP) was measured in heterozygous (Foxd1PRR+/-) (Het, n=3) and Con (n=3) mice at 
2 months of age using a Visitech BP2000 system (Visitech Systems, Apex, NC).
Results: cKO mice showed neonatal mortality. Although kidney weight did not differ 
in surviving cKO mice on P0, the number of glomeruli per kidney section was reduced 
in cKO compared with Con (39±3.7 vs. 68±2.3, p<0.001). Immunofluorescence showed 
reduced expression of stromal markers Foxd1 and Meis1, expansion of Six2+ nephron 
progenitors, reduced expression of Jag1, lack of WT1+ glomeruli in more differentiated 
nephrons, decrease in the expression of renin and of α-SMA in the developing interstitium 
in cKO kidneys. cKO mice had fewer and thinner intrarenal arteries and arterioles. Systolic, 
diastolic and mean BP did not differ in Het and Con mice (124±3.5 vs. 133±11, p=0.4; 69±3 
vs. 68±5, p=0.9; 88±3 vs. 92±7, p=0.6).
Conclusions: We conclude that stromal PRR restricts excessive expansion of nephron 
progenitors, thereby promoting nephron differentiation. In addition, stromal PRR is crucial 
for the differentiation of renin-positive cells as well as smooth muscle and the proper 
formation of the renal arterial tree.
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DNMT1 in Six2 Progenitor Cells Is Essential for Transposable Element 
Silencing and Kidney Development
Jihwan Park,1 Szu-Yuan Li,2 Kiwung Chung,1 Rojesh Shrestha,1 Matthew Palmer,1 
Katalin Susztak.1 1University of Pennsylvania, Philadelphia, PA; 2Taipei 
Veterans General Hospital, Taipei City, Taiwan.
Background: In mammalians cytosine methylation (5mC) is erased in the embryo and 
reestablished during development and differentiation. De novo DNA methyltransferases 
such as Dnmt3a and 4b plays key role in establishing methylation, while Dnmt1, a 
hemimethylase copies methylation during cell division. Much attention has been placed 
on promoters and enhancer methylation as they play role in gene expression regulation.
Methods: We performed genome methylation analysis by reduced representation 
of bisulfate sequencing (RRBS) during kidney development. We examined the renal 
phenotype of mice with genetic deletion of Dnmts and Tets in the Six2+ population which 
can differentiate nephrons in mice.
Results: Differential methylation of enhancer regions was the most prominent when 
kidneys of newborn and adult mice were compared. Mice with conditional deletion of 
Dnmt3a, 3b, Tet1 and Tet2 showed no significant renal abnormalities. In contrast, Six2Cre/
Dnmt1fl/fl mice died within 24hrs of birth and had small kidneys. Surprisingly, the greatest 
methylation difference in Dnmt1 knock-out mice was observed on transposable elements 
(TE). RNA sequencing also detected the expression endogenous retroviruses indicating the 
release of silencing of TE. In addition, Dnmt1 KO kidneys expressed high levels of genes 
that exclusively expressed in early embryos. The re-expression of ERV was not tolerated by 
the cells and induced the expression of endogenous RNA sensing pathways and interferon 
response and ultimately resulting in cell death.
Conclusions: Our results showed that Dnmt1-mediated DNA methylation is essential 
for kidney development by preventing the demethylation of TEs and dedifferentiation of 
progenitor cells.
Funding: NIDDK Support
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Modulation of Lef/Tcf Activity in Response to Differential β-Catenin 
Levels Underlies Nephron Progenitor Differentiation
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Aaron C. Brown,2 Leif Oxburgh,2 Andrew P. McMahon.3 The McMahon 
Laboratory 1University of Southern California, Los Angeles, CA; 2Maine 
Medical Center Research Institute, Scarborough, ME; 3Keck School of Medicine 
of the University of Southern California, Los Angeles, CA; 4University of 
Southern California, Los Angeles, CA; 5The University of Southern California, 
Los Angeles, CA.
Background: The Wnt9b ligand and β-catenin are required for both nephron progenitor 
cell (NPC) self-renewal and differentiation (Carrol et al., 2005; Park et al., 2007; Karner et 
al., 2011). Though high Wnt pathway activity stimulates NPC commitment, stabilized β-
catenin binds to enhancers regulating both self-renewal and NPC differentiation targets, 
with opposing transcriptional outcomes (Park et al., 2012). How different levels of 
β-catenin result in distinct outcomes for NPCs remains to be determined.
Methods: To investigate the molecular mechanism behind Wnt/β-catenin-driven NPC 
self-renewal and differentiation, we modeled the two processes in vitro in NPEM culture 
medium (Brown et al., 2015) which enables NPC expansion when supplemented with low 
levels of CHIR99021 (CHIR), a β-catenin agonist, and NPC differentiation with elevated 
CHIR levels. Gene expression and epigenetic profiles were determined by bulk RNA-Seq 
and ATAC-Seq, followed up with immunohistochemistry on key targets-of-interest. To 
directly map genomic targets of Lef/Tcf factors and β-catenin, we performed ChIP-Seq on 
NPCs under expansion and differentiation conditions.
Results: RNA-Seq and immunohistochemistry data suggests differential expression 
levels of Lef/Tcf factors between NPC cultured in low and high levels of CHIR. In the high 
CHIR condition, the transcriptional repressor Tcf7l1 is down-regulated, while the activators 
Tcf7 and Lef1 are up-regulated. ATAC-Seq analysis showed strong enrichment of Tcf/Lef 
footprint in open chromatin regions specific to high CHIR condition, suggesting a role of 
β-catenin in activating relevant enhancers. Direct ChIP-Seq for Lef/Tcf factors showed 
a rapid replacement of Tcf7l1/Tcf7l2 repressors by Tcf7/Lef1 activators at enhancers for 
differentiation target genes on stabilization of β-catenin.
Conclusions: We propose a model wherein Tcf7l1/Tcf7l2 repressors maintain 
NPC self-renewal state by silencing enhancers involved in differentiation and β-catenin 
stabilization triggers a switch promoting the engagement of Tcf7/Lef1 activators. This 
state is reinforced by a positive feedback loop where Lef1 is a target of itself. Given the 
widespread role of Wnt signaling in stem/progenitor cell programs, these findings are likely 
to have broader significance beyond the mammalian kidney.
Funding: NIDDK Support
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SIX2+CITED1+ Human Nephron Progenitors: Novel Insights of Wilms 
Tumor Biology
Astgik Petrosyan,2 Matthew E. Thornton,1 Julia Marcheque,2 Brendan Grubbs,1 
Stefano Da Sacco,2 Laura Perin.2 1University of Southern California, Los 
Angeles, CA; 2Children’s Hospital Los Angeles, Los Angeles, CA.
Background: Wilms tumor (WT) accounts for 95% of renal malignancies in children 
and is characterized by uncontrolled proliferation of nephron progenitors (NP) without 
generation of functional nephrons. Due to inability of isolating these human NP, little is 
known about WT formation and specifically the involvement of NP in tumor progression. 
Using our validated Smartflares technique we isolated NP expressing SIX2 and CITED1 (the 
master genes regulating nephrogenesis) from WT samples and from human fetal kidneys 
(hFK) and compared them in terms of gene expression by RNA-seq. We also performed in 
vivo and in vitro experiments to study regulation of self-renewal vs differentiation of NP.
Methods: WT (#3) and hFK (#3) samples were digested to single cell suspension, 
incubated with Smartflare-probe and SIX2+CITED1+ cells were immediately sorted and 
processed for RNA-seq. Using a nephrogenic specific media, we established conditions for 
long-term culture of NP cells and study in vitro mechanism of self-renewal vs differentiation 
of NP from both WT and hFK. We also transplanted NP in vivo to study tumorogenesis.
Results: We confirmed expression of SIX2+CITED1+ cells in WT samples within the 
blastema and ~ 9% of the total population was expressing these markers (while ~0.2% 
was present in hFK). WT-NP present a similar pattern of expression of developmental 
genes as hFK-NP but increased expression of EYA1, SALL4 and decreased expression 
of LEF1 and FOXD1 suggesting their self-renewal state. WT-NP showed, as expected, 
upregulation of pluripotency genes (OCT-4, NANOG) and modulation of cell cycle 
regulators indicating their shorter G1 phase (typical of pluripotent/cancer stem cells). WT-
NP presented modulation of integrin signaling, which plays an important role in exit to 
differentiation during nephrogenesis. WT-NP and hFK-NP were cultured in vitro for more 
than 28d maintaining expression of SIX2 and CITED1. Modulation of integrin outside-in 
signaling reduced SIX2 and CITED1 long-term in vitro and reduced tumor growth in vivo.
Conclusions: This work represents the first characterization of SIX2+CITED1+ cells 
from WT and suggests the importance of matrix-cell interaction in development and tumor 
formation. These studies can help to increase our knowledge on human nephrogenesis and 
the development of new strategies aimed at halting tumor progression.
Funding: Private Foundation Support
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TAZ Plays an Important Role in Maintenance of Podocyte Viability
Jianchun Chen,1,2 Raymond C. Harris.1,2 1Nephrology/Medicine, Vanderbilt 
University Medical Center, Nashville, TN; 2Nephrology, Department of Veterans 
Affairs, Nashville, TN.
Background: TAZ (also known as WWTR1), a paralogue of YAP, is an important 
nuclear effector of the Hippo signaling pathway. TAZ shares 45% amino acid identity with 
YAP and they share some redundant roles in some organ development, but they also differ in 
some functions. TAZ is highly expressed in kidney, especially in renal proximal tubule cells. 
TAZ global knockout causes early mortality in a subset of homozygous mice, while bilateral 
kidney cysts and a pulmonary emphysema-like phenotype presented in the surviving 
adult mice. YAP is highly expressed in the nucleus of podocytes, and podocyte-specific 
deletion of YAP causes FSGS and progressive renal failure. The goal of these studies was to 
determine whether TAZ also plays a physiologic role in podocytes.
Methods: Mice with podocyte-TAZ deletion (TAZpodKO) were generated by crossing 
TAZflox/flox mice with podocin-Cre recombinase transgenic mice. Urinary albumin excretion 
and kidney histology and podocyte number per glomerulus were evaluated in TAZpodKO and 
WT mice. Immunoblotting analysis of isolated glomerulus lysates of TAZpodKO or TAZpodWT 
mice were performed. In cultured mouse podocytes, cell morphology and cell lysates were 
evaluated after silencing TAZ with specific siRNAs.
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Results: 41.7% of TAZpodKO mice develop mild proteinuria at age of 3-4 weeks (n=36), 
with a urine albumin/creatinine ratio of 89.57 ± 12.67 vs 27.86 ± 1.55 (μg/mg, n=7). At 9 
weeks of age, compared to TAZpodWT mice, the glomeruli of TAZpodKO mouse kidney had 
focal sclerosis and significant podocyte loss (WT1+ cells: 13.23 ± 0.699 vs. 17.85 ± 0.608 
(n=13). There was increased YAP expression and nuclear localization in the TAZpodKO mice 
compared with TAZpodWT mice. Glomeruli of TAZpodKO mice had increased cleaved-caspase 
3 and decreased Bcl2 expression. In cultured podocytes, silencing TAZ by siRNA altered 
cell morphology and F-actin distribution, up-regulated of cleaved-caspase 3 and inhibited 
Bcl2 expression.
Conclusions: This study demonstrates that TAZ expression plays an important role in 
maintenance of podocytes, which cannot be compensated by its paralogue YAP.
Funding: NIDDK Support, Veterans Affairs Support, Other U.S. Government Support
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Clathrin-Dependent Nephrin Endocytosis Mediated by Y1139RSL Motif 
Is Essential for Glomerular Slit Diaphragm Formation
Eugenel B. Espiritu,1 Matt G. Sampson,4 Kunimasa Yan,2 Neil A. Hukriede,1 
Agnieszka Swiatecka-Urban.3 1University of Pittsburgh, Pittsburgh, PA; 2Kyorin 
University School of Medicine, Mitaka, Japan; 3Children’s Hospital of 
Pittsburgh of UMPC, Pittsburgh, PA; 4University of Michigan, Ann Arbor, MI.
Background: Nephrin is critical to the glomerular slit diaphragm. The cytoplasmic tail 
of human nephrin contains a YxxØ-type motif Y1139RSL & genetic variation of this motif in 
human cases supports its potential importance. A c.C3418T nucleotide change, resulting in 
p.R1140C, has been implicated as causal for congenital nephrotic syndrome (CNS) in one of
the first reported patients, & was found as a single allele in siblings with CNS.
Methods: We generated expression plasmids for human (hs) nephrin (hs-Nephrin-
WT), hs-Nephrin-Y1139F mimicking non-phosphorylated tyrosine, or hs-Nephrin-Y1139A 
disrupting YxxØ endocytic motif. We transfected these into a human podocyte line, which 
were used for coimmuprecipitations (CoIP), clathrin-coated vesicle & endocytic assays. In 
zebrafish, we depleted endogenous nephrin by morpholino (dr-Nephrin-MO) injections & 
performed rescues with RNA derived from the aforementioned hs-Nephrin plasmids. We 
assayed for edema, a phenotype previously shown in nephrin morphants, & for glomerular 
organization imaged by single plane illumination microscopy & electron microscopy.
Results: In podocytes, Hs-Nephrin CoIP with clathrin & the adaptor complex AP-2; 
residue Y1139 was phosphorylated. The Y1139F substitution increased clathrin-dependent 
nephrin endocytosis & reduced the steady-state abundance & stability of nephrin at the 
podocyte plasma membrane. By contrast, the Y1139A substitution had the opposite effects. 
Zebrafish embryos depleted of nephrin exhibited pericardial & yolk edema, curvature of the 
body axis, & amorphous glomerular & podocyte foot process organization. Co-injecting 
the hs-Nephrin-Y1139F transcript with dr-Nephrin-MO partially rescued the phenotype & 
improved defects in glomerular & foot process organization, similar or superior to hs-
Nephrin-WT. By contrast, morphants injected with hs-Nephrin-Y1139A failed to rescue, 
having phenotypes similar to dr-Nephrin-MO alone.
Conclusions: The Y1139RSL motif is a structural element for clathrin-dependent 
nephrin endocytosis & functions as a phosphorylation-sensitive signal essential for the 
slit diaphragm formation. We propose that the Y1139RSL-mediated endocytosis helps to 
maintain asymmetric distribution of nephrin in specialized membrane domains leading to 
podocyte differentiation & formation of the slit diaphragm.
Funding: NIDDK Support
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Role of the Circadian Clock in the Timing of Branching Morphogenesis 
and Kidney Development
Rosemary V. Sampogna,1 Hanbin Dan,2 Thomas L. Ruan.3 1Medicine, Columbia 
University, New York, NY; 2Columbia University, New York, NY; 3Columbia 
University Medical Center, New York, NY.
Background: Kidney development is guided by a complex array of molecular signals 
that guide precise arrangement of ~1 million nephrons. Developmental errors such as 
renal hypodysplasia are a leading cause of pediatric kidney failure. Extremely rapid and 
stereotypic branching of the ureteric tree during early kidney development gives rise to a 
stochastic branching pattern but with a much slower, controlled and constant tip doubling 
rate during the second half of development (JASN 2015;26(10):2414). We also found that 
iron deficiency has a profound effect on nephron number and branching morphogenesis. 
Because core circadian clock transcription factors bind heme, we hypothesized that this 
timer plays a role in the timing of kidney development.
Methods: We studied the roles of circadian clock regulators Clock and Bmal1 during 
kidney development by quantitating branching parameters in global knockout and in 
conditional mutants. We also measured continuous circadian clock gene expression in 
developing kidneys using luminescence microscopy. Mice also were mated for a 1-hour 
time period at “lights on” and subsequently RNASeq was performed from embryonic days 
18.0 to 20.0 (E18.0 to E20.0) at exact 4-hour intervals to measure gene expression patterns. 
Relevant genes were mapped to specific nephron structures and compared to adult kidneys.
Results: Luminescence studies confirmed the activity of an autonomous peripheral 
clock in the developing kidney. Oscillatory expression of core clock genes became 
measurable by E18.5. Quantification of branching parameters showed decreased nephron 
number in Bmal1-/- kidneys at E14.5 and at E19.5 (mean glomerular number [SD] 664±103 
vs. 956±84, p> 0.05). Moreover, when pregnancies were timed strictly, RNASeq analysis 
identified 6,949 transcripts with significant rhythmicity between days E18.0 and E20.0 
(p<0.05). Many genes were kidney-specific and known to regulate cell cycle and core 
developmental processes.
Conclusions: While known to regulate renal processes in the adult, we found that 
circadian regulators also provide a critical timing mechanism during kidney development by 
controlling gene expression. These regulators are required during a critical developmental 
window. Investigation of circadian-regulated pathways may uncover new targets that can be 
exploited to prevent disease or aid kidney development.
Funding: NIDDK Support, Private Foundation Support
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Genetic Regulation of Intermediate Mesoderm Specification
Elliot Perens,1 Jasmine Hernandez,2 Andrew Houk,2 Kristina M. Garske,3 
Camilla Teng,5 Gage Crump,5 Deborah Yelon.2 1Pediatrics & Biological 
Sciences, University of California, San Diego, La Jolla, CA; 2University of 
California, San Diego, La Jolla, CA; 3University of California, Los Angeles, Los 
Angeles, CA; 5University of Southern California, Los Angeles, CA.
Background: The kidneys are derived from the intermediate mesoderm (IM), yet the 
pathways that determine the precise dimensions of the IM in the early embryo are poorly 
understood. We have found that the bHLH transcription factor Hand2 limits the size of 
the pronephron by refining IM dimensions. In hand2 mutants, the IM is expanded, and 
the IM is diminished when hand2 is overexpressed. The hand2-expressing portion of the 
posterior mesoderm lies laterally adjacent to the IM, and a set of venous precursors arises at 
the interface between these two territories. hand2 promotes venous precursor development 
while suppressing IM formation in this region. Furthermore, Hand2 and the similarly 
localized zinc-finger transcription factor Osr1 have functionally antagonistic influences on 
both kidney and vein development.
Methods: Our studies of hand2 and osr1 provide valuable entry points for the 
identification of additional factors that regulate IM specification. How do hand2 and osr1 
coordinate the development of the IM and venous progenitor populations? Do hand2 and 
osr1 impact the same genes as they execute these functions? To address these questions, we 
aim to identify additional genes in the hand2 and osr1 pathways.
Results: Preliminary analysis has revealed a potent role for bHLH transcription factor 
Twist1a in modulating IM and vessel precursor formation. Furthermore, to identify genes 
regulated by hand2, we have evaluated expression profiles from wild-type, hand2 loss-
of-function, and hand2 gain-of-function embryos. Additionally, to increase the sensitivity 
of our investigation, we have compiled expression profiles from sorted hand2-expressing 
cells in wild-type and hand2 loss-of-function embryos. We are currently analyzing our most 
intriguing candidate genes, including twist1a, through loss-of-function, gain-of-function, 
and genetic epistasis experiments to determine their roles in IM formation and their genetic 
interaction with hand2 and osr1; updated findings will be presented.
Conclusions: Together, our studies will elucidate the roles of hand2 and osr1 in 
defining the boundaries of the IM by balancing formation of the kidney and vein lineages.
Funding: NIDDK Support
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Transcription Factor 21 Is Required for Branching Morphogenesis and 
Regulates the GDNF-Axis in Kidney Development
Gal Finer,2,4 Shintaro Ide,1 Tomokazu Souma,3 Tuncer Onay,2 Jing Jin,2 
Minghao Ye,2 Xiangmin Zhao,2 Yoshiro Maezawa,1 Susan E. Quaggin.2 1Chiba 
University Graduate School of Medicine, Chiba, Japan; 2Northwestern 
University, Chicago, IL; 3Duke University, Durham, NC; 4Ann & Robert H. 
Lurie Children’s Hospital of Chicago, Chicago, IL.
Background: The definitive mammalian kidney develops through reciprocal inductive 
signals between the metanephric mesenchyme (MM) and ureteric bud (UB). Transcription 
factor 21 (Tcf21) is highly expressed in cells of the MM including Six2+ condensing 
mesenchyme (CM) and Foxd1+ stromal mesenchyme (SM). Tcf21 knockout (KO) mice 
die in the perinatal period with severe renal hypodysplasia. In humans, Tcf21 levels are 
reduced in renal tissue from stillborn infants with renal dysplasia. However, molecular 
mechanism(s) to explain these renal defects are not yet known.
Methods: We utilized systemic and conditional Tcf21 knockout mouse models and 
employed immunohistochemistry, in-situ hybridization, RT qPCR and kidney explant 
studies.
Results: Tcf21 null kidneys show very abnormal UB branching and arrested 
mesenchymal-to-epithelial transition, reminiscent of human CAKUT. These changes are 
accompanied by decrease in Gdnf mRNA levels and protein and by low Ret and Wnt11 
mRNA levels starting at embryonic day (E)12.5. In contrast, global deletion of Tcf21 does 
not attenuate the expression of members of the retioic acid and fibroblast growth factor 
signaling pathways, nor does it reduce expression of inducers of Gdnf (e.g. Osr1, Eya1, 
and Pax2). The stromal factor Bmp4, a potent inhibitor of Gdnf, is increased in kidneys 
from Tcf21 KO mice, offering a potential mechanism. Under the hypothesis of pleiotropism, 
we dissociated Tcf21’s effects in distinct cell lineages of the MM by studying the kidney 
phenotype of selective removal of Tcf21 from the renal stroma (Tcf21fl/fl;FoxD1-Cre strain) 
and from the CM (Tcf21fl/fl;Six2-Cre strain). Absence of Tcf21 from the stroma leads to low 
Gdnf and abnormal UB branching at E14.5 and results in paucity of collecting ducts and 
severe urinary concentrating defect at 4 wks of life. In contrast, deletion of Tcf21 from the 
CM leads to abnormal glomerulogenesis and proteinuria but has no obvious effects on Gdnf 
expression or the development of the collecting ducts.
Conclusions: Taken together, our data illustrate distinct roles of Tcf21 in the stromal 
mesenchyme and cap mesenchyme in kidney development and support a model whereby 
Tcf21 regulates key molecular pathways required for branching morphogenesis. Direct 
genetic targets for Tcf21 in the kidney have not yet identified.
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Developmental Loss of Intercalated Cells increases but Pharmacological 
Carbonic Anhydrase Suppression Decreases Pyelonephritis Susceptibility
Andrew L. Schwaderer,1 Vijay Saxena,1 John Ketz,2 George J. Schwartz,3 
David S. Hains,1 Robert L. Fairchild.4 1Indiana University, Zionsville, IN; 
2Nationwide Children’s Hospital, Columbus, OH; 3University of Rochester, 
Rochester, NY; 4Lerner Research Institute, Cleveland Clinic Foundation, 
Cleveland, OH.
Background: We had previously shown that carbonic anhydrase (CA) 2 knockout 
mice (Car2-/-) have an intercalated cell deficiency and are susceptible to pyelonephritis. 
However it was not known whether this pyelonephritis risk is due to systemic absense CA, 
renal absence of CA, decreased CA activity or developmental depletement of intercalated 
cells. We hypothesized that the pyelonephritis susceptibility in Car2-/- mice is secondary to 
intercalated cell deficiency
Methods: We compared pyelonephritis susceptiblity following transplantation of 
Car2-/- kidneys into wild type mice (isolated renal Car2 absence), transplantation of 
wild type (WT) kidneys into Car2-/-mice (nonrenal Car2 absence) and transpantation of 
control WT kidneys into WT mice. To determine whether pharmacological suppression of 
CA results in a similar pyelonephritis risk to developmental intercalated cell absence, we 
identified the dose of acetazolamide that suppressed renal carbonic anhydrase activity then 
compared pyelonephritis risk in treated versus untreated C57Bl/6J WT mice. Experimental 
pyelonephritis was induced by transurethral inoculation of uropathogenic E.coli (UPEC).
Results: Results are presented in Figure 1: Compared WT donor/WT recipient, the 
Car2-/-donor/WT recipient, but not the WT donor/Car2-/-recipient group had higher kidney 
(A) but not bladder (B) bacterial burdens at 24-hours post UPEC inoculation. Both 50 mg 
and 100 mg of acetazolamide given intraperitoneally suppressed CA (C) and increased urine 
pH (D). There was no difference between kidney (E-F) or bladder (G) bacterial burdens at 
24 hours between acetazolamide treated and control mice. Mice treated with acetazolamide 
had lower kidney (H-I), but not bladder (K) bacterial burdens at 6-hours.
Conclusions: Developmental absence of intercalated cells is responsible for the 
pyelonephritis risk in Car2-/-mice. Surprisingly acetazolamide appears to be protective 
against pyelonephritis, at least at an early time point.
Funding: NIDDK Support
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Homeogene Emx1 Is a Required Downstream Component of the Mecom-
Tbx2 Genetic Pathway That Regulates Pronephros Distal Segment 
Formation
Elvin e Morales, Rebecca A. Wingert. University of Notre Dame, Notre Dame, IN.
Background: Vertebrate kidneys contain nephron functional units where 
specialized cell types are organized into segments with discrete physiological roles. Many 
gaps remain in our understanding of how segment regions develop. To date, several 
studies have identified key signaling molecules and transcription factors that are essential 
for segment patterning in the pronephros, which has been speculated to offer a primitive 
blueprint for nephron segmentation in other kidney forms. empty spiracles homeobox 
gene 1 (emx1) encodes a homeodomain transcription factor that is expressed in renal 
progenitors during early stages of pronephros development, and numbers among those 
genes that have been implicated to act downstream of retinoic acid (RA) signaling during 
segmentation.
Methods: Here, we used reverse genetics approaches to study the role of emx1 during 
nephron formation. We discovered that emx1 is required to regulate the balance of distal 
segment domains within the distal pronephros, and then performed a suite of genetic 
epistasis and expression studies to elucidate its relationship with other essential segment 
patterning components.
Results: emx1 deficiency altered distal segment domains without changes in cell 
turnover or physical traits like cell size and morphology. In exploring further how 
Emx1 influences nephron pattern, we found that RA, which induces proximal and 
represses distal fates during early intermediate mesoderm development, negatively 
regulates emx1 expression. Next, through a series of epistasis studies, we found that Emx1 
acts downstream of a genetic cascade involving the essential distal segment genes Mecom 
and Tbx2. Finally, we determined that Emx1 restricts the expression boundary of 
irx3b to control distal segment territories.
Conclusions: Taken together, our work reveals how emx1 is a necessary 
component of the pronephros genetic segmentation network, which has broad 
implications for understanding the regulatory cascades that orchestrate vertebrate 
nephron patterning.
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Morphogenesis and Function of the Nephron-Collecting Duct Connection
Ping Zhang,1,2 Ling Gu,1 Jing Cong,1,3 Jie Zhang,1 Jesper S. Thomsen,4 
Arne A. Andreasen,4 Hui Wang,1 Si-Qi Deng,1 Erik I. Christensen,4 Xiao-
Yue Zhai.1 1China Medical University, Shenyang, China; 2Jin Zhou Medical 
University, Jinzhou, China; 3Shenyang Medical College, Shenyang, China; 
4Aarhus University, Aarhus, Denmark.
Background: A correct morphogenesis of the connection between nephrons and 
collecting ducts (CD) profoundly impacts the ability of the renal system to regulate the 
water-salt and acid-base balances in adults. However, the origin of the nephron-CD 
connection has yet to be established.
Methods: These observations were based on the morphology and computer-assisted 
tubular tracing on LM and EM serial sections.
Results: The present study showed that the nephron-CD connection was initiated by 
fusion of cells arising from the renal vesicle (RV) and the terminal tip of the ureteric bud 
(UB). One terminal tip often connected with two nephrons at different developing stages. 
A lumen in the nephron-CD connection was observed early at the S-shaped body stage, 
where the opening to the tip consisted mainly of distal tubule cells mixed with a few tip 
cells. With nephron development, the nephron-CD connection elongates with tip and RV 
cells, and the connection is then composed of cells expressing Na+-Cl- co-transporters, 
H+-ATPase, and AQP2, with a similar distribution as in the adult kidney. AQP2 and 
H+-ATPase, was constantly expressed at the UB trunk, increasingly expressed at the UB 
neck, while the expression was undetectable at the UB tip.
Conclusions: The study suggests that the nephron-CD connection is initiated by cell-
cell fusion between RV and UB tip cells, then it elongates with participation of UB tip and 
neck cells, and finally it matures into the connecting tubule as the glomerulus develops.
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Loss of Dicer Activity in the Peri-Wolffian Duct Stroma Leads to 
Increased Rates of Vesicoureteral Reflux
Melissa J. Anslow,1 Sunder Sims-Lucas,1 Carlton M. Bates,1 Jacqueline Ho.2 
1Children’s Hospital of Pittsburgh, Pittsburgh, PA; 2Children’s Hosp of 
Pittsburgh of UPMC, Pittsburgh, PA.
Background: Vesicoureteral reflux (VUR) is associated with urinary tract infections, 
hypertension, and reflux nephropathy, a leading cause of pediatric end-stage renal disease. 
Formation and location of the vesicoureteral junction is determined largely by the induction 
site of the ureteric bud from the Wolffian duct, which depends mostly on signals from the 
surrounding stroma. VUR appears heritable, but no single genetic mutation causes most 
known cases of VUR. miRNAs are small, noncoding RNAs, processed by Dicer, that 
regulate gene expression post-transcriptionally. We hypothesize that miRNAs are necessary 
for vesicoureteral junction development and prevention of VUR.
Methods: We generated a transgenic mouse model with loss of Dicer in the peri-
Wolffian duct stroma (Tbx18cre; DicerFl/Fl). We performed euthanized cystograms and 3D 
reconstructions of the ureters and bladder on mutants and controls (Tbx18Cre negative 
littermates). We performed whole mount Calbindin immunostaining at E11.5 to assess the 
ureteric bud induction site.
Results: Euthanized cystograms demonstrated significantly higher rates of VUR in 
the mutant mice compared to control [40% (6/15) of Dicer mutants as opposed to 3.8% 
(2/52) of controls (p < 0.01)]. 3D reconstructions showed lower ureteral insertions into the 
bladder and shorter intravesicular tunnel lengths on the side of VUR in mutants compared 
to control mice and non-refluxing mutant ureters (p < 0.05). Calbindin immunostaining 
reveals a cranially shifted ureteric bud induction site in E11.5 mutants compared to controls 
(p < 0.05).
Conclusions: These data suggest for the first time that miRNAs have a role in 
preventing VUR. This appears due to a requirement for miRNAs in peri-Wolffian duct 
stroma for normal ureteric bud induction and subsequent ureter insertion into the bladder. 
Future work will assess molecular mechanisms by which deletion of miRNAs in the peri-
Wolffian duct stroma leads to VUR and elucidate which miRNAs in the peri-Wolffian duct 
stroma are critical for normal ureteric bud induction.
Funding: NIDDK Support, Other NIH Support - NICHD K12 HD052892 (expected 
7/1/18)
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Role of Fgfr2 in DNA Damage in Bladder Urothelium After  
Cyclophosphamide Injury
Sridhar T. Narla,2 Caitlin M. Schaefer,2 Daniel S. Bushnell,2 Carlton M. Bates.1,2 
1Children’s Hospital of Pittsburgh, Pittsburgh, PA; 2University of Pittsburgh, 
Pittsburgh, PA.
Background: Stimulation of fibroblast growth factor 2 (Fgfr2) (IIb isoform) by 
keratinocyte growth factor (KGF), reduces injury in many epithelial cells. Deletion of 
Fgfr2IIIb prolongs cyclophosphamide (CPP)-induced bladder urothelial injury. Our 
purpose was to identify roles for Fgfr2 in bladder urothelial repair after CPP- injury.
Methods: We first subjected wildtype mice to a 150 mg/kg intraperitoneal (IP) dose of 
CPP to characterize the injury/ repair and to determine expression of Fgfr2 after injury. To 
determine roles of Fgfr2 in CPP-induced injury, we used a Tamoxifen inducible ShhCre line 
to knockout Fgfr2 in all urothelial layers (ShhcreFgfr2KO), and subjected Cre-negative and 
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knockout mice to IP CPP. We performed general histological staining, in situ hybridization, 
and immunostaining.
Results: In controls, we observed major loss of urothelium, hemorrhage, and 
inflammation 1-day post CPP. We noted urothelial hyperplasia from 3-10 days post injury. In 
situ hybridization showed increased Fgfr2 expression at 1 and 3 days post injury in control 
urothelium. We also observed evidence of DNA damage by γH2AX immunostaining in 
control urothelium at 3-7 days, which was reduced by 10 days. In the knockout studies, 
we observed significant decreases in weight at 1 and 3 days post-CPP in ShhcreFgfr2KO 
vs. Cre-negative mice. We noted similar urothelial loss, hemorrhage and inflammation 
1-day post CPP in Cre-negative and mutant bladders. At 3 days post injury, ShhcreFgfr2KO
bladders had ongoing marked hemorrhage and inflammation with reduced uroplakin 
staining vs. Cre-negative mice. While mutants and Cre-negative mice had expansion of 
Keratin 14 (Krt14)-positive presumptive progenitor cells across basal layers 3 days-post
CPP, Cre negative mice had 6-7 urothelial cell layers while ShhcreFgfr2KO had only 3-4
cell layers. Also, mutants had many (mostly Krt14+) cells that were hypertrophic with
enlarged nuclei (suggesting a cell cycle block). Furthermore, mutants had 2-fold increases 
in γH2AX+ nuclei vs. Cre negative mice.
Conclusions: Together, Fgfr2 appears dispensable for Krt14+ progenitor cell 
expansion after CPP-injury, but appears required for DNA repair and proliferation/cell 
cycle progression/differentiation of Krt14+ progenitors. Administration of KGF to wildtype 
bladders injured by CPP may enhance DNA repair.
Funding: NIDDK Support
FR-PO934 Poster Friday
Development, Stem Cells, Regenerative Medicine - II
Comprehensive Gene Expression Analysis for Pax2 Related Genes with 
Existing FANTOM Database
Yuta Yamamura, Kengo Furuichi, Akinori Hara, Yasunori Iwata, Norihiko Sakai, 
Miho Shimizu, Takashi Wada. Kanazawa University, Kanazawa, Japan.
Background: Pax2 is essential transcriptional factor for kidney development. Pax2 
homo knockout mouse shows kidney agenesis and neonatal lethal. In human, PAX2 mutation 
is major causative genes for Renal coloboma syndrome (RCS), which is characterized 
by kidney hypoplasia or dysplasia and abnormality of the optic nerve. It is reported that 
Pax2 involved in ureteric bud branching via the regulation of Gdnf expression. Pax2 is 
known to involve both gene expression and suppression through epigenetic mechanism, 
apart from the role of transcriptional factor. In this study, using gene expression of mouse 
embryonic kidney from FANTOM database, comprehensive analysis for the genes which 
involved to Pax2 were evaluated. Furthermore, the role of PAX2 gene during human kidney 
development is not clear. Gene expression analysis in the kidney lineage cells differentiated 
from human induced pluripotent stem cells(iPSC)was performed.
Methods: To evaluate Pax2 related genes in mouse, we extracted gene expression 
data during kidney development (from embryonic day 14.5 to neonatal day 30). In the 
view of embryonic time course and organs, the correlation to Pax2 gene expression was 
evaluated. To evaluate PAX2 related gene in human, human iPSCwas differentiated into 
kidney lineage cells with reported methods (Taguchi, et al. Cell Stem Cells 2014). Some 
markers for kidney lineage cells were checked by immunocytochemistry and qPCR. Gene 
expressions of extracted candidate genes from mouse database were confirmed using the 
kidney lineage cells differentiated from human iPSC.
Results: About 180000 promoter expression data during mouse kidney development 
were extracted. The correlation to Pax2 promoter for time course and organswas 
evaluated. 3646 genes and 135 genes were extracted respectively. 18 genes, including 
some known essential genes for kidney development were overlapping. Human iPSC was 
differentiated to kidney lineage cells and checked PAX2 and other kidney lineage markers 
by immunocytochemistry and qPCR.A part of 18 genes were confirmed by qPCRin human 
differentiated kidney lineage cells.
Conclusions: Comprehensive analysis using FANTOM databaseis useful for 
identification of Pax2 related genes during kidney development.
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Effect of Hypoxia on Subpopulations of Cells During Kidney Development
Peter V. Hauser,1,2 Morgan Hamon,1,3 Lifu Zhao,4 Masaki Nishikawa,1,3 
Naomi Yanagawa,4 Norimoto Yanagawa.1,3 1Greater Los Angeles Veterans 
Administration, Los Angeles, CA; 2Department of Integrative Biology and 
Physiology, University of California at Los Angeles, Los Angeles, CA; 
3Department of Medicine, University of California at Los Angeles, Los Angeles, 
CA; 4Sepulveda Research Corporation, North Hills, CA.
Background: During early developmental stages, embryonic kidneys are not 
fully vascularized and exposed to hypoxic condition (HC). HC is known to influence 
cell proliferation and survival, ureteric bud (UB) branching and vascularization of the 
developing kidney. We aimed in our present study to gain further insight into the effect 
of HC on different subpopulations of cells in embryonic kidneys at early developmental 
stages.
Methods: E11.5-13.5 embryonic kidneys were obtained from Hoxb7Venus, Foxd1GFP, 
Six2EGFP,Cited1RFPmice and cultured under either HC or normal condition (NC) for up to 
120h. Cell viability and gene expression pattern of Hoxb7+, FoxD1+, Six2+and Cited1+cells 
were analyzed by flow cytometry and q-RT-PCR, respectively. UB branching morphogenesis 
was analyzed under confocal microscopy to generate 3D images for measurements of organ 
volume, branching generations, branching length and diameter by using a gradient vector 
based software (TreeSurveyor).
Results: We found that HC reduced overall cell viability after 24, 48, 72, 96 and 120h. 
However, as compared to Foxd1+stromal cells and Six2+metanephric mesenchymal (MM) 
cells, Hoxb7+UB cells and Cited1+MM cells were less susceptible to HC and showed 
reduced cell death after 48, 72, and 96h. HC increased the number of branching generations 
in E12.5 and E13.5 kidneys after 24h and decreased at 48 and 72h, while E11.5 kidneys were 
not affected. HC further increased the length and diameter of UB branches in E13.5 kidneys 
at 24h but not at 48 and 72h. HC increased HIF1a mRNA levels in E12.5 kidneys at 48h 
and 72h, but normalized at 96h. HC also upregulated the mRNA levels of angiotensinogen 
at 24h, 48h and 72h, renin and angiotensin receptor 2 at 72h, while angiotensin receptor 1 
was unchanged.
Conclusions: We conclude that HC imposes different effects on different 
subpopulations of cells in embryonic kidneys at different developmental stages. Studies are 
ongoing to further characterize the effects of HC on different subpopulations of cells during 
kidney development.
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Transcription Factor HNF-1β Regulates Axonal Guidance Genes During 
Kidney Development
Annie Shao, Karam S. Aboudehen, Siu Chiu Chan, Peter Igarashi. University of 
Minnesota, Minneapolis, MN.
Background: Mutations of the transcription factor hepatocyte nuclear factor 1β (HNF-
1β) represent the most common genetic cause of congenital anomalies of the kidney and 
urinary tract (CAKUT). HNF-1β plays essential roles in kidney development through 
the regulation of branching morphogenesis, nephrogenesis, and nephron patterning. 
However, the molecular mechanisms whereby mutations of HNF-1β cause CAKUT 
remain incompletely understood. Here, we used chromatin immunoprecipitation and deep 
sequencing (ChIP-seq) to identify novel transcriptional targets of HNF-1β in the developing 
mouse kidney.
Methods: Chromatin was extracted from wild-type E14.5 mouse metanephroi, 
immunoprecipitated with an anti-HNF-1β antibody, and sequenced using next-generation 
sequencing. HNF-1β binding sites were mapped to the mouse genome, and nearby genes 
were identified. The functions of HNF-1β target genes were determined using Ingenuity 
Pathway Analysis (IPA). The expression of HNF-1β target genes in wild-type and HNF-1β-
deficient mIMCD3 cells was measured using RNA-seq.
Results: ChIP-seq identified 8,490 HNF-1β binding sites in chromatin from E14.5 
mouse kidneys, including peaks at known HNF-1β developmental genes, such as Wnt9 
and Pax8. 6,104 binding sites were novel and were not previously detected by ChIP-seq in 
mIMCD3 cells. IPA analysis of HNF-1β target genes revealed that axonal guidance was the 
highest scoring canonical pathway. HNF-1β binding sites were identified near 63 axonal 
guidance genes, including netrins (Ntn4), netrin receptor (Unc5c), semaphorins (Sema4a, 
Sema3g, Sema3d, Sema6a), and ephrins (Eph4b). RNA-seq analysis showed altered 
expression of core axonal guidance genes in HNF-1β-deficient cells compared to wild-type 
cells, suggesting that they were directly regulated by HNF-1β.
Conclusions: HNF-1β regulates the transcription of axonal guidance genes in the 
developing mouse kidney. In addition to their roles in axonal guidance, netrins, semaphorins, 
and ephrins are essential for branching morphogenesis in epithelial organs such as the lung. 
Dysregulation of axonal guidance genes may underlie branching defects in HNF-1β mutant 
kidneys.
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ZEB2 in Renal Stromal Progenitors Regulates Nephrogenesis and 
Nephron Endowment in Mice
Sudhir Kumar, Weining Lu. Boston University Medical Center, Boston, MA.
Background: ZEB2 is a SMAD-interacting transcription factor that is mutated in 
Mowat-Wilson syndrome, a congenital disorder with renal anomalies. ZEB2 is highly 
expressed in developing kidney stromal progenitors and is a target gene for FOXD1, a 
transcription factor and an early marker for renal stromal progenitors. FOXD1 regulates 
nephrogenesis and nephron endowment during kidney development while Foxd1 knockout 
mice have aberrant ZEB2 expression. However, the role of ZEB2 in nephrogenesis and 
nephron endowment is not known.
Methods: We analyzed the nephrogenesis and nephron endowment in Zeb2 stroma-
specific conditional knockout mice Zeb2flox/flox;Foxd1Cre+ (Zeb2 cKO) and their wild-type 
littermate controls. Glomerular numbers were quantified by direct counting using kidney 
histology and nephrin immunostaining. Nephron progenitors were analyzed using SIX2, 
WT1 and PAX2 markers. Nephrogenesis was analyzed by immunostaining using nephron 
morphogenesis markers Jagged1, megalin, uromodulin, pan-cytokeratin and Dolichos 
Biflorus Agglutinin (DBA). Cell proliferation in developing kidney was analyzed by 
phospho-Histone H3.
Results: We found that Zeb2 cKO had significantly less glomerular numbers at newborn 
and 3 weeks old compared to wild type littermate controls (p<0.01). Immunohistochemical 
analysis showed that newborn Zeb2 cKO kidneys have fewer SIX2+ nephron progenitors 
compared to wild type littermate controls. This result was also confirmed by WT1 and 
PAX2 immunostaining. Jagged1, megalin, and uromodulin staining demonstrated abnormal 
nephron structure in Zeb2 cKO kidneys. Pan-cytokeratin and DBA staining showed 
defective ureteric branching morphogenesis. Newborn Zeb2 cKO mice also have reduced 
cell proliferation in the nephrogenic zone as compared to wild type littermate controls.
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Conclusions: ZEB2 in renal stromal progenitors regulates SIX2+ nephron progenitor 
self-renewal and differentiation. Loss of Zeb2 in renal stromal progenitors leads to abnormal 
nephrogenesis, low nephron endowment and congenital renal anomalies.
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Abcg2-Expressing Endothelial Cells Contribute to Kidney Postnatal 
Vascular Growth and Maintenance
Ellen Go,1 Yang Lin,2 Mervin C. Yoder,2 David P. Basile.2 1Indiana University, 
Indianapolis, IN; 2Indiana University School of Medicine, Indianapolis, IN.
Background: Tissue blood vessels are lined by endothelial cells (EC) with 
heterogeneous states of proliferative potential. Several groups have recently identified 
resident vascular endothelial stem cells (VESC) and confirmed their critical role in vascular 
growth as they are highly proliferative, give rise to clonal endothelial colonies and are able 
to form vessels upon in vivo transplantation into sites of ischemia and hypoxia. Many other 
tissue resident stem cells express the ATP-binding cassette family drug transporter, Abcg2. 
We examined if Abcg2-expressing EC contribute to development of the kidney vasculature.
Methods: We crossed Abcg2CreERT2 knock-in mice, which faithfully express Cre in 
Abcg2-expressing cells, with ROSATdTomato transgenic reporter mice to make Abcg2TT 
mice. TdTomato labels Abcg2-expressing cells and their progenies upon tamoxifen 
injection. We performed lineage tracing studies by injecting Abcg2TT mice at postnatal 
day 0 (neonate) or 42 (adult). Flow cytometry analysis of TdTomato+ EC was performed 
at days 1, 7, 21 and 56 post-tamoxifen in neonates, and days 1, 42 and 84 post-tamoxifen 
in adults. MACS-sorted EC from transgenic mice one day after tamoxifen injection were 
plated on OP-9 cultures and examined for the presence of endothelial colonies after 14 days.
Results: In neonates, 8.3±1.7% of total EC expressed TdTomato one day after 
tamoxifen injection. After 7 days, this population contributed to 36.0±11.1% of all kidney 
EC. In adult mice, 2.9±1.3% of total EC was labeled one day after a single tamoxifen 
injection. This population contributed to 15.4±2.9% of total kidney EC after 84 days. BrdU 
labeling studies are currently examining whether the turnover of kidney EC during these 
stages of development are derived from this population. The frequency of colony formation 
of TdTomato labeled EC is significantly higher than non-labeled EC.
Conclusions: Neonate and adult murine kidney blood vessels contain Abcg2-expressing 
EC that contribute to kidney vessel growth during development and maintenance of kidney 
vessel homeostasis in vivo. Thus, Abcg2-expressing EC may represent kidney VESC.
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The Role of Mir218 in the Function of the Renal Vasculature
Wenqing Yin,1 Andrew M. Siedlecki.2 1Brigham and Women’s Hospital, Boston, 
MA; 2Brigham and Women’s Hospital, Boston, MA.
Background: Vascular density is critical to normal kidney function. Reduced renal 
capillary number is associated with hypertension, chronic kidney disease, and kidney 
failure. Endothelial progenitor cells play a pivotal role in the construction of endocapillaries 
as well as their repair following ischemic injury. The function of endothelial progenitor-
derived cells is dependent on cellular programs regulated by select microRNA. Mir218 
directs retinal endothelial cell migration and motor neuron development. The role of mir218 
in the function of the renal vasculature is widely unknown.
Methods: With CRISPR/Cas9 gene editing, we created an animal model, with germ-
line miR-218-2 deletion (miR218-/-). These miR218-/- mice were subjected to bilateral 
renal ischemia-reperfusion injury (IRI) for 26 minutes, or sham surgery at 3 months of age 
and then evaluation the kidney function at 48 and 96 hours. Immunofluorescence staining 
of CD31 was assessed for the vascular density in this context.
Results: Following renal-specific ischemia/reperfusion injury, miR218-/- mice (n=6) 
were slow to recover renal function after 48 and 96 hours. There was a 20% of miR218-
/- mice suffered fulminant renal failure and died within 96 hours. In miR218-/- mice, a 
lower vascular density in kidney with reduced renal capillary number were identified by 
CD31 staining.
Conclusions: With CRISPR/Cas9 gene editing approach to knock out miR-218-2 in 
the regulation of endothelial cell migration, we demonstrate for the first time the critical role 
of mir218 in the function of the renal vasculature.
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Single Nucleus RNA-Seq from Fresh and Frozen Adult Mouse Kidney 
Offers Major Advantages over Single Cell RNA-Seq
Haojia Wu, Yuhei Kirita, Erinn L. Donnelly, Benjamin D. Humphreys. The 
Humphreys Lab Renal Division Washington University School of Medicine, 
Saint Louis, MO.
Background: Single-cell sequencing methods (scRNA-seq) have emerged as powerful 
tools for identification of cell types and states in kidney. However, generating a healthy 
single cell suspension is one of the biggest challenges to the field, limited by stress artifacts, 
RNA degradation and dissociation bias. We tested the hypothesis that single nucleus RNA-
seq (snRNA-seq) is a superior approach.
Methods: We created 3,796 single cell transcriptomes from mouse kidney using 
the Dropseq platform, and single nucleus transcriptomes using the protocols from sNuc-
Dropseq (2,951 nuclei), DroNc-seq (2,739 nuclei) and 10x Chromium (2,027 nuclei). 
We applied unbiased computational approaches to compare the gene expression and cell 
composition for each kidney cell type across different platforms. Finally, we aligned the cell 
types from snRNA-seq techniques to uncover the variations in gene expression within the 
shared subpopulations across techniques.
Results: 12 clusters were identified in the scRNA-seq dataset with most clusters from 
tubule and no cells at all from glomerulus. One cluster specifically expressed genes that were 
previously defined as artifactual dissociation-induced stress response genes induced by the 
cell dissociation protocol. By contrast, snRNA-seq from all platforms captured a diversity 
of kidney cell types including glomerular podocytes, mesangial cells and endothelial cells. 
The artifact cell cluster was not observed in the snRNA-seq datasets since the procedure is 
carried out on ice. Integrated analysis revealed that all snRNA-seq techniques can detect the 
same kidney cell types but DroNc-seq can capture more transcripts at the same sequencing 
depth over other snRNA-seq techniques. We also demonstrate that snRNA-seq is feasible 
on snap frozen tissue.
Conclusions: snRNA-seq provides substantial advantages over scRNA-seq in kidney, 
including the absence of dissociation-induced transcriptional artifacts, better representation 
of glomerular cell types (reduced dissociation bias) and the ability to perform snRNA-seq 
on archival, frozen samples.
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Single-Nucleus Transcriptome Sequencing of Fetal Kidney Cells Identifies 
a Transient Pro-Angiogenic Signature in Developing Podocytes
Albert D. Kim,2,1 Andrew P. McMahon,2 Kun Zhang.3 McMahon Laboratory 
1University of Southern California, Los Angeles, CA; 2Keck School of Medicine 
of the University of Southern California, Los Angeles, CA; 3University of 
California at San Diego, San Diego, CA.
Background: The renal corpuscle is composed of cell types including parietal 
epithelium, podocytes, mesangium, and endothelium. How this critical structure is 
generated from its constituent precursor cells during development is not well understood. 
Transcriptional profiling of the developing human kidney can provide novel insights into 
developmental processes.
Methods: Nephrogenic zone and renal corpuscles from 13 to 16 week human fetal 
kidneys were profiled by single nuclear Drop-seq and cell clusters were resolved using 
Pagoda2. To better understand nephron development, we performed trajectory analysis using 
Monocle. Specific predictions of genes identifying specific cell types and developmental 
transition were validated by in situ hybridization and immunohistochemistry. A specific 
hypothesis formulated on the transient production of secreted factors by podocytes co-
regulating vascular and mesangial cell types was explored in vitro.
Results: SnDrop-seq identified 12 different nephrogenic clusters that were identified 
by known markers. Novel gene expression was discovered and validated in our analysis. 
Computational ordering of transcriptomes along a developmental trajectory revealed 
that a novel transient expression signature was present within precursors progressing 
to the podocyte lineage prior to expression of mature markers. Anatomical and in vitro 
characterization of these genes support an angiogenesis-promoting function within this 
transient population.
Conclusions: Previous studies have established that cell signaling including VEGF 
signaling is required for glomerular vascularization in vivo, however attempts to recapitulate 
this process in vitro have failed. Our findings provide insight into a critical spatiotemporal 
program that aids in the formation of the primary filtration unit in the kidney. Our findings 
provide new insight into human glomerular developmental programs and highlight novel 
targets-of-interest to explore in human kidney disease.
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Single Cell RNA-Seq Identifies Molecular Fingerprints of Endothelial Cell 
Subpopulations in Kidney
Alex X. Zhou,1,2 Liqun He,3 Christer Betsholtz,3,2 Pernille B. Laerkegaard 
Hansen.4 1IMED CVRM, AstraZeneca Gothenburg, Mölndal, Sweden; 2ICMC, 
Karolinska Institute, Stockholm, Sweden; 3Uppsala University, Uppsala, 
Sweden; 4IMED CVRM, AstraZeneca Gothenburg, Mölndal, Sweden.
Background: The kidney consists of functionally and anatomically discrete vascular 
plexus, and correspondingly distinct endothelial cell (EC) subpopulations. The precise 
targeting of renal vascular plexus in treatment requires a comprehensive understanding of 
the molecular characteristics of EC subpopulations. This study aims to distinguish renal EC 
subpopulations through dissection of their molecular fingerprints using single cell RNA-
Seq (scRNA-Seq) analysis.
Methods: The BTBR mouse was perfused with magnetic Dynabeads that were 
subsequently trapped in glomeruli. The kidneys were enzymatically digested and glomeruli 
containing Dynabeads were removed. The cell suspension was further incubated with 
Pecam1 antibody and Pecam1+ single cells were FACS sorted onto a 384-well plate. Single 
EC cDNA library was generated and RNA-Seq was performed on Illumina HiSeq 2500. 
Unsupervised clustering of EC subpopulations was performed with BackSPIN analysis.
Results: Pecam1 antibody selection of renal cell suspension produced a rather purified 
EC population, with ~80% successfully sequenced single cells being ECs. The ECs were 
clustered into 3 major subpopulations: the big vessel ECs (~30% of total ECs), peritubular 
capillary ECs (~36%), and glomerular ECs (~34%). These subpopulations displayed 
distinct molecular fingerprints. In particular, the glomerular and peritubular ECs showed 
differential gene expression patterns in vascular endothelial growth factor receptors, 
angiopoietin receptors, adrenomedullin system, caveolae-associated proteins, endocytic 
transport proteins, etc. The recent whole kidney scRNA-Seq analysis (Park et al, Science 
2018) provided us an overall picture of the renal single cell population but limited resolution 
in ECs (Pecam1+ ~1% of total cell population, peritubular ECs ~10% of EC population). In 
contrast, a dedicated EC scRNA-Seq may facilitate balancing various EC subpopulations in 
a single study and revealing in-depth definition of EC subpopulations in kidney.
Conclusions: The renal EC subpopulations display certain distinct gene expression 
patterns as revealed by scRNA-seq, which underscores the potential of selecting specific 
mechanisms for targeted vascular therapies in renal diseases.
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Single Cell Transcriptional Profiling of Kidney Organoids Identifies a 
Novel Gene Activation Signal in Human Glomerular Disease
Jennifer L. Harder,1 Rajasree Menon,1 Edgar A. Otto,1 Jian Zhou,5 Sean Eddy,1 
Viji Nair,1 Jeffrey B. Hodgin,4 Roger C. Wiggins,6 Olga Troyanskaya,5 
Benjamin S. Freedman,3 Matthias Kretzler.2 1University of Michigan, Ann Arbor, 
MI; 2U.Michigan, Ann Arbor, MI; 3University of Washington, Seattle, WA; 4The 
University of Michigan, Ann Arbor, MI; 5Princeton University, Princeton, NJ; 
6University of Michigan Health System, Ann Arbor, MI.
Background: Proposed mechanisms for podocyte (PC) compensation in kidney disease 
include dedifferentiation and non-PC transdifferentiation. Identifying genes expressed 
during PC development may reveal novel aspects of pathogenesis and progression of 
glomerular disease. Analysis of developing human kidneys is limited by availability and 
relative rarity of PCs in tissue. Kidney organoids generated from human stem cells offer a 
novel ex vivo system to explore gene expression during PC development.
Methods: We generated kidney organoids from human stem cells and performed single 
cell RNA sequencing. Over 10,000 transcriptomes were combined and clustered using an 
unsupervised algorithm. Single cell transcriptomes from organoids and developing human 
kidneys were combined to create developmental trajectories for multiple cell lineages 
originating from central progenitors. Genes expressed uniquely in cell clusters were 
identified and expression was quantified in bulk transcriptomic data from microdissected 
glomeruli isolated from humans with kidney disease (ERCB) and analyzed relative to eGFR 
and proteinuria.
Results: Cell clustering revealed two putative groups of PCs. Trajectory analysis 
confirmed both groups mapped to the same cell lineage expressing NPHS2 but separated 
along the spectrum into early and mature. Early and mature clusters uniquely expressed 69 
and 169 genes respectively. The cumulative expression score for the early (but not mature) 
PC gene set was significantly upregulated (p<0.01) in diseased glomerular tissue relative 
to living donors. Intriguingly, the early PC set contained genes previously unrecognized as 
being involved in kidney disease including LYPD1 and PRSS23, each of which correlated 
with proteinuria and inversely correlated with eGFR.
Conclusions: Developing PCs in kidney organoids express a group of genes that are 
not expressed in later stage PCs. Expression of these genes in the human adult glomerulus is 
associated with the presence of kidney disease, suggesting reactivation of a developmental 
transcriptional program in cells in the glomerulus. This approach identifies the beneficial 
role of single cell transcriptional profiling of kidney organoids in identification of novel 
biomarkers of kidney disease.
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High-Throughput Analysis of Single Cells in Immunofluorescent Kidney 
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Background: Immunofluorescence staining is a standard method for analyzing 
histological, physiological and pathophysiological markers in a variety of cell types and 
compartments of kidney tissue. However the final quantification of image data is still often 
performed by manual counting, a time consuming and potentially biased process.
Methods: With the open source software Fiji and R we are able to automatically 
analyze a variety of markers in complete kidney sections. Following the automatic 
acquisition of high-resolution sections our batch-processing is able to classify and detect up 
to 100.000 nuclei per kidney section by marker-controlled watershed with a systematic error 
rate below 5%. This approach largely eliminates personal bias, reduces analysis time and 
enables semiautomatic tissue compartmentation for stereometric analysis. By thresholding 
and segmentation of additional channels cells can be classified as marker-positive. Parallel 
documentation and a database creation with nuclear characteristics, spatial parameters 
and marker-positivity enable complete reproducibility and verification of the results in the 
original image.
Results: We used our approach to quantify renin-abundancy in a previously described 
triple-transgenic mouse with an inducible Gs alpha knockout (Lachman et al., 2017, 
JASN). This evaluation correlated to the counting of renin-producing cells by kidney FACS 
(p<0.001, Pearson). Furthermore we successfully quantified proliferation (PCNA) and 
apoptosis (TUNEL)-staining in a mouse model of serum induced kidney damage with our 
analysis algorithms. We could also asses the differential activation of TGF-beta signaling 
pathway in kidney compartments in an animal model of STZ-induced diabetic nephropathy 
by quantifying nuclear pSMAD.
Conclusions: Our novel quantification approach is easily implementable, versatile and 
generates high amounts of data. The systematic nature of methodic errors combined with 
high cell count in complete sections and the absence of personal bias results in advantages 
towards manual quantification. While the high number of nuclei assessed per sample is 
comparable to FACS, our approach requires less tissue, avoids artifacts related to organ 
disintegration and provides a spatial resolution of the data sets.
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Spatial and Sex-Related Cell Diversity in the Adult Mouse Kidney 
Through scRNA-Seq Profiling
Andrew Ransick,1 Albert D. Kim,2 Andrew P. McMahon.3 1Broad-CIRM Center 
for Regenerative Med.& Stem Cell Research, Keck School of Med. of USC, Los 
Angeles, CA; 2University of Southern California, Los Angeles, CA; 3Keck School 
of Medicine of the University of Southern California, Los Angeles, CA.
Background: Applying single cell RNA Sequencing (scRNA-seq) methodology to 
adult mouse kidneys facilitates examination of the gene expression profiles of individual 
kidney cell-types in high resolution. Recent studies have shown the power of this approach 
for adult mouse whole kidney (Han et al., Cell; Park et al, Science). By incorporating zonal 
dissection of tissue samples and both sexes, we are generating a high resolution map of 
kidney cell types that integrates spatial organization and sex-related differences.
Methods: We profiled adult kidneys from two male and female wildtype C57B6/J 
strain mice. Prior to tissue dissociation, kidneys were dissected along the corticomedullary 
axis (CMA) to isolate pieces containing exclusively cortex, outer medulla or inner medulla/
papilla. Tissue dissociation at 12 C utilized cold active proteases to reduce stress responses. 
scRNA-seq profiling used 10XGenomics Chromium platform. PCA and identification of 
variably expressed genes executed with Seurat v2.3 package in RStudio.
Results: We obtained 38,039 transcriptional profiles from four mice representing all 
expected cell types of the adult kidney, though podocytes were underrepresented. Initial 
analysis has focused on identifying lineage, zonal and sex differences. We observe expected 
zonal clustering for known cell types. Although within specific lineages distributed along 
the CMA, we find regional diversity in profiles and can identify cell types excluded 
from published scRNA-seq studies. A marked sex diversity was observed in specific cell 
populations, confirming and extending known sex-related differences in kidney gene 
expression. Our zonal analysis also facilitates mapping regional diversity amongst the 
associated cell populations (eg. vascular, mesenchyme, immune-related).
Conclusions: These data generate a solid foundation for building a high resolution map 
of cell diversity in the adult male and female mouse kidney. We will discuss our progress 
towards this goal and review new insights that have come from scRNA-seq analysis of 
specific kidney lineages.
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Transcriptome Analyses of Altered Mouse Kidney Development Following 
Maternal Interleukin-6 Exposure During Gestation
Tarak Srivastava,1 Daniel P. Heruth,1 Robert E. Garola,1 Mukut Sharma.2 
1Childrens’s Mercy Hospital, Kansas City, MO; 2KCVA Medical Center, Kansas 
City, MO.
Background: Children born to obese mothers have higher incidence of renal anomalies. 
Obesity is characterized by systemic inflammation. IL-6, an inflammatory cytokine, can 
cross the placental barrier, and is elevated in the amniotic fluid of obese women. Increasing 
evidence suggest that epigenetic mechanisms and microRNA (miRNA) interact in a 
bidirectional manner, a potential key mechanism for environmental effects on development. 
We hypothesized that renal development would be affected by elevated levels of maternal 
IL-6 brought about by epigenetic changes that alter both miRNA and RNA expression.
Methods: Pregnant C57BL/6 mice received either normal saline or IL-6 (10 pg/g BW) 
intraperitoneally on alternate days from E12.5. Fetal kidneys (E20.5) were removed from 
uterine horns by dissection and fixed in 10% formalin or used to isolate DNA and total 
RNA. LC-MS analysis of hydrolyzed DNA was performed to evaluate for methylation 
changes. TruSeq RNA Libraries (saline n=5, IL-6 n=5) were subjected to miRNA- and 
RNA-seq on an Illumina platform. Reads were mapped to the mouse reference genome and 
analyzed by miRDeep2.pl and Tuxedo Suite for miRNA-seq and RNA-seq, respectively.
Results: Maternal IL-6 administration resulted in decreased renal cortical parenchyma 
(358.4±74.3μm) compared with control (453.9±80.5μm, n=5, p=0.04). LC-MS analysis 
found a 10% increase in methylated cytosine in the IL-6 group suggesting epigenetic 
modifications in fetal kidney DNA. These modifications correlated (q<0.05) with 58 and 
2087 differentially expressed (DE) miRNAs and RNAs, respectively. Stringent target 
prediction (score>90) identified 1350 mRNA regulated by the 58 miRNA of which 196 
(9.4%) were present in the list of 2087 DE genes. Nephrotoxicity, as predicted by Ingenuity 
Pathway Analysis, associated with Renal Necrosis/Cell Death (p=1.5E-11, 104 genes) and 
Renal Damage (p=1.2E-8, 52 genes). We have identified the STAT3 (p=3.2E-06, 20 genes), 
NRF2-Mediated Oxidative Stress Response (p=3.5E-06, 37 genes) and Glucocorticoid 
Receptor Signaling (1.9E-05, 53 genes) pathways for further analysis and confirmation.
Conclusions: Our model of maternal IL-6 administration has allowed us to better 
understand the role of environment mediated changes on epigenetics and global gene 
expression in kidney development.
Funding: Private Foundation Support
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Amphiregulin Mediated Cellular Reprogramming Modulates  
Inflammation and Tissue Remodeling Following Kidney Injury
Vikram Sabapathy,1 Nardos T. Cheru,2 Saleh Mohammad,1 Rajkumar 
Venkatadri,1 Rahul Sharma.1 1Center for Immunity, Inflammation and 
Regenerative Medicine (CIIR), University of Virginia, Charlottesville, VA; 
2Department of Chemistry, University of Virginia, Charlottesville, VA.
Background: Acute Kidney injury (AKI) is a major cause of mortality and morbidity. 
There is a growing evidence of interaction between tissue-resident immune cells and 
epithelial progenitor cells that participate in the process of regeneration. Recent studies 
indicate that Amphiregulin (AREG), a member of epidermal growth factor (EGF) family, 
also secreted by immune cells and has been shown to modulate both host immunity and 
tolerance mechanism. We hypothesize that AREG, produced by Regulatory T Cells (Tregs) 
promotes tissue repair and regeneration. In this study, we investigated differential effects 
of AREG towards promoting tissue homeostasis and regeneration using both in vivo and 
in vitro models.
Methods: Murine ischemia-reperfusion injury (IRI) and Endotoxemic renal injury 
models were developed to investigate a therapeutic effect of AREG. The protective effect 
of cytokine treatment both before and after the injury was examined. The structure and 
function of the kidney were probed using flow cytometry, intravital microscopy, histology, 
immunohistochemistry, quantitative gene expression and biochemical analysis. Kidney 
organoids and tubular epithelial cell line were used to probe the efficacy of AREG under 
in vitro conditions.
Results: Our findings showed that treatment with AREG immediately after injury 
not only enhanced the expansion of Tregs but also accentuates the suppressive function 
of Tregs, thus preventing kidney damage and preserving renal function in murine models. 
On the other hand, impediment of EGFR signaling resulted in increased fibrosis and 
deterioration of kidney function. Experiments using kidney organoids showed that addition 
of exogenous AREG attenuated cell death in an in vitro model of injury. Interestingly, direct 
addition of AREG to proximal tubular epithelial cell culture resulted in the development of 
cellular plasticity. Furthermore, AREG knockout mouse model was used to elucidate the 
role of AREG mediated regeneration in AKI.
Conclusions: This study addresses the application of AREG in immunomodulation 
and renal regeneration as a therapeutic approach for renal injury and sheds light on the 
mechanisms enforced by immune cells in the switch of maladaptive repair to successful 
regeneration.
Funding: NIDDK Support, Other NIH Support - 1R01 DK105833, 1R01 AI116725, 
Commercial Support - AstraZeneca-UVA Alliance for Diabetic Nephropathy (RS), Private 
Foundation Support
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c-Myc Is a Modulator of Pkd1 Gene and Polycystic Kidney Disease 
Progression
Camila Parrot, Almira Kurbegovic, Guanhan Yao, Marie Trudel. Institut de
Recherches Cliniques de Montreal, Montreal, QC, Canada.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is one of 
the most common disorders associated mainly with Pkd1/Pc1 mutations. Orthologous 
Pc1 dosage-reduced and -increased mouse models develop renal tubular cysts. A causal 
connection between c-Myc-targeted overexpression and PKD was determined from 
transgenic SBM mice that closely resemble ADPKD and orthologous mouse models. Using 
these mouse models, we investigated for a clear regulatory interplay and signaling crosstalk 
between c-Myc and Pkd1 or Pc1.
Methods: Kidney tissues of SBM and four Pc1-dosage models were analyzed for 
molecular expression at mRNA levels by qPCR, at protein levels by WB and for cellular 
expression by IHC. Pkd1 gene regulation was assessed in vivo using genome ChIP analysis. 
Direct causal connection was interrogated by in vivo genetic interactions.
Results: We showed that renal regulation in four Pc1 dosage-reduced and -increased 
mouse models converge toward stimulation of c-Myc expression along with β-catenin (~5-
10-fold) in tubular epithelial cells as in ADPKD renal tissues. This systematic increase
defined c-Myc as a key Pkd1 node in cystogenesis and confered the high relevance of
the SBM transgenic mice for further analysis. Enhanced c-Myc in SBM transgenic mice
led conversely to striking upregulation of Pkd1/Pc1 expression (~10-fold) and β-catenin
activation, uncovering reciprocal crosstalk between c-Myc and Pc1. In adult SBM kidneys, 
c-Myc ChIP analysis showed strongly enriched binding on Pkd1 promoter associated
with RNA pol II, consistent with Pkd1 upregulation during cystogenesis. Similar c-Myc
direct binding also at birth uncovered an equivalent role on Pkd1 regulation during renal
developmental program, suggesting a role in condensing metanephric mesenchymal stem
cells as for c-Myc. These data revealed an inter-regulatory network of c-Myc and Pc1 in
normal physiologic and PKD conditions and shed light on PKD1 upregulation in the face of 
human ADPKD mutation. Genetic ablation of c-Myc in Pc1-reduced and -increased mouse 
models significantly attenuates cyst growth, proliferation and PKD progression, providing 
evidence that c-Myc is a Pkd1 causal cystogenic factor.
Conclusions: Together our data determined a dual role for c-Myc, as a major 
contributor in a feed-forward regulatory Pkd1–c-Myc loop mechanism and in Pc1-induced 
cystogenesis that may also prevail in human ADPKD.
Funding: Government Support - Non-U.S.
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A RhoA-YAP-c-Myc Signaling Axis Promotes the Development of 
Polycystic Kidney Disease
Jing Cai. University of Texas Southwestern Medical Center, Dallas, TX.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited 
disorder caused by mutations in PKD1 or PKD2 and affects 1 in 500-1000 humans. Limited 
treatment is currently available for ADPKD and there is great interest in identifying 
molecular targets and/or pathways for the development of mechanism-based therapeutics. 
In mammals, the Hippo signaling pathway comprises several tumor suppressors (NF2, 
Sav1, Mst1/2, Lats1/2, etc.) acting through a kinase cascade to affect the phosphorylation 
and cytoplasmic retention of the oncoproteins YAP/TAZ, transcriptional coactivators of 
the TEF/TEAD family transcription factors to transactivate growth-promoting genes. In 
this study, we investigated the function and regulation of the Hippo signaling pathway in 
ADPKD.
Methods: We performed gene set enrichment analysis of YAP/TAZ/TEAD target genes 
after global gene profiling on human PKD1 polycystic kidney cysts compared to minimally 
cystic tissues using Affymetrix cDNA arrays, analyzed various genetically engineered 
mouse models with kidney cystogenesis, and searched for kinase inhibitors that promoted 
tubulogenesis in 3D-cultured Pkd1 mutant mouse kidney inner medullary collecting duct 
(mIMCD3) cells through an unbiased kinase inhibitor screen.
Results: Our results showed that YAP/TAZ were activated in human ADPKD kidney 
cysts compared to minimally cystic tissues. While transgenic overexpression of YAP 
promoted proliferation and tubule dilation in mouse kidneys, loss of YAP/TAZ or their 
transcription target c-Myc suppressed cystogenesis in a mouse ADPKD model resulting 
from Pkd1 deficiency. Through the comprehensive kinase inhibitor screen, we identified a 
signaling pathway involving the RhoGEF LARG, the small GTPase RhoA and the RhoA 
effector Rho-associated kinase (ROCK) as a critical signaling module between PKD1 and 
YAP. Further corroborating its physiological importance, inhibition of RhoA signaling 
suppressed cystogenesis in 3D culture of Pkd1 mutant kidney cells as well as Pkd1 mutant 
mouse kidneys in vivo.
Conclusions: Taken together, our findings shed light on the mechanisms underlying 
ADPKD pathogenesis and implicate the RhoA-YAP-c-Myc signaling axis as a critical 
mediator and potential drug target in ADPKD.
Funding: NIDDK Support, Other U.S. Government Support, Private Foundation 
Support
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Reconstitution of ADPKD Cyst Formation in 3D Culture Reveals a Role 
for YAP 1 in Cyst Lumen Size
Robert L. Bacallao,1,2 Sherry G. Clendenon,4 Clark D. Wells.3 1Indiana 
University School of Medicine, Indianapolis, IN; 2Medicine, Richard Roudebush 
VAMC, Indianapolis, IN; 3Indiana University School Medicine, Indianapolis, 
IN; 4Indiana University, Bloomington, IN.
Background: Proximal tubule cells grown in 3D culture, initiate cyst emergence 
with uniformly small lumens upon expression of CDH8. Prior studies indicate that cyst 
expansion in ADPKD results from increased proliferation from increased YAP1 signaling. 
We tested the hypothesis that YAP1 action is sufficient to cause enlarged cyst lumens in 3D 
culture and YAP1 interference by AMOTL1 decreases lumen size.
Methods: Immune-blots were carried out on lysates of confluent PKD Q4004X and 
HmPKT cells using antibodies for SAV1, MST1/2, MOB1, p-MOB1 (thr 35), LATS1, YAP/
TAZ, p-YAP (ser 127) and p-YAP (ser 397). HK2 cells were transduced with lentivirus 
bearing constitutively active YAP1-5SA and grown in 3D culture. Cyst emergence was 
activated by cell transduction with adenovirus bearing CDH8. Separately, PKD Q4004X 
cells were transduced with lentivirus expressing YAP1-5SA or AMOTL1 (S262E) and grown 
in Matrigel for 14 days. Cysts were imaged and analyzed with Image J.
Results: Cyst epithelia had lower expression of SAV1, MST2, LATS1, YAP1 and 
TAZ and reduced ratio of p-YAP (ser 127) over YAP1. These cells also showed increased 
levels of p-MOB1 and p-YAP (Ser 397). HK-2 cells transduced with lentivirus expressing 
YAP1-5SA formed normal tubule arrays in 3D culture. However, when cyst emergence is 
activated by microinjected CDH8 expressing adenovirus, large lumen cysts are formed. In 
separate experiments, PKD Q4004X cells were grown in Matrigel for 14 days to allow for 
cyst formation. PKD Q4004X cells transduced with YAP1-5AS or AMOTL1 (S262E) were 
compared to control PKD Q4004X cells. After 14 days, samples were fixed, stained and 
imaged to determine cyst size using ImageJ. PKD Q4004X cells had an average maximum 
area of 177.89 ± 7.16 μm2 . PKDQ 4004X cells transduced with AMOTL1 (S262E) had an 
average area of 122.77± 6.03 μm2 (p<0.01). PKDQ4004X cells transduced with YAP1-5SA 
had an average area of 6619.66 ± 773.78 μm2 (p<0.01).
Conclusions: 1) Cystogenesis can be reproduced by the combined activation of CDH8 
and YAP1. 2) CDH8 expression initiates decreased cell-cell adhesion that is sufficient for 
cyst emergence. 3) YAP1 expression in the absence of CDH8 activation does not promote 
cyst formation. 3) Cyst size in ADPKD cells can be inhibited by AMOTL1 and increased 
by YAP1. 4) Overall, YAP1 activation following cyst emergence is necessary for increased 
lumen size in ADPKD.
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Bile Acid Receptor Agonists and Metformin Slow Cyst Growth and 
Correct Perturbed Energy Metabolism in PKD1-Null Kidney Cells
Hui Li,1 Polly Huang,1 Aurash Naser-Tavakolian,1 Daniel Rivera,1 Moshe Levi,2 
Kenneth R. Hallows.1 1USC Keck School of Medicine, Los Angeles, CA; 
2Georgetown University, Washington, DC.
Background: Autosomal dominant polycystic kidney disease (ADPKD), caused 
by mutations in polycystin-1 (PKD1) or polycystin-2 (PKD2), presents with progressive 
development of renal cysts and eventual end-stage kidney disease. PKD1-null cells have 
increased proliferation and decreased AMP-activated kinase (AMPK) activity, along with 
dysregulated cellular metabolism. Bile acid receptor agonists, INT-777 and INT-767, 
promote a shift from glycolytic to fatty acid oxidative metabolism and regulate several 
key signaling pathways, including inflammation, fibrosis and the AMPK and extracellular 
signal-regulated kinases (ERK) pathways. Here we sought to determine whether these 
agonists alone or in combination with the AMPK activator metformin, may be effective 
as novel therapeutics for ADPKD by correcting dysregulated metabolism and slowing cyst 
growth in PKD1-null cells in vitro.
Methods: Using PKD1-null kidney epithelial cells, we examined AMPK and ERK 
pathway markers and levels of key glycolytic enzymes by immunoblotting, which were 
correlated with effects of various treatments. 3-D cultures were used to assess cyst growth 
after treatment with INT-767 or INT-777 alone or in combination with metformin. Seahorse 
assays were performed to evaluate cellular metabolic phenotypes under different conditions.
Results: INT-767 treatment of PKD1-null cells activated the AMPK and inhibited 
the ERK pathways and expression of the key glycolytic enzyme PDK1. INT-767 also 
reduced glycolytic fluxes while significantly increasing mitochondrial oxidative respiration 
as compared with control cells. INT-777 treatment also increased fatty acid oxidation in 
PKD1-null cells. Both INT-767 and INT-777 inhibited cystogenesis of PKD1-null cells 
in 3D cultures. Moreover, combination INT-767 or INT-777 treatment with metformin, 
another potential therapeutic for ADPKD, achieved much better control of cyst growth than 
either drug alone.
Conclusions: The bile acid receptor agonists INT-767 or INT-777 in combination with 
the AMPK activator metformin appear to have a synergistic effect on slowing cyst growth 
and correcting perturbed energy metabolism in PKD-deficient ADPKD kidney epithelial 
cells. These beneficial effects may potentially occur via activation of the AMPK pathway 
and will be explored further using in vivo ADPKD mouse models.
Funding: NIDDK Support, Other U.S. Government Support
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New Organoid Model for ADPKD Reveals Pkd2 Loss Disrupts Apical 
Junctional Complex and Master Scaffold Ezrin
Eryn E. Dixon, Owen M. Woodward. University of Maryland School of 
Medicine, Baltimore, MD.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is 
characterized by progressive cystogenesis, resulting in end stage renal disease. This 
common monogenetic disorder is attributed to loss of function mutations in the genes, 
PKD1 and PKD2, that encode for transmembrane proteins, polycystin 1 and 2. Hallmark 
components of cystogenesis, including increased proliferation, changes in apicobasolateral 
compartmentalization, and a secretory phenotype, suggest a defect in the organization of 
renal epithelial cells following PKD1/2 loss.
Methods: Immunofluorescent morphometric analysis of nephrectomized kidney tissue 
from ADPKD patients recently revealed significant changes in the morphology of the 
apical compartment, demarcated by zonula occludens 1 (ZO-1), in small, emerging cysts, 
when compared to normal tubules. Additionally, transepithelial electrical resistance assays 
using inducible Pkd2 Cre (Pkd2 Pax8 rtTA TetOCre +mTmG) primary cells suggest that 
inactivation of Pkd2 results in a decrease in resistance, indicating disruption of junctional 
integrity.
Results: While many pathways have been implicated in the complex progression of 
cystogenesis, these results suggest disruption of the apical junctional complex (AJC), may 
be responsible for changes in the organization and compartmentalization of apical proteins 
and signaling. Using a new in vitro tubule model system designed to investigate the initiation 
of cyst formation directly following the loss of functional polycystin 2 (PC2), we have 
demonstrated that loss of PC2 results in a decrease in master scaffold of apical compartment 
organization, ezrin. Furthermore, an inducible Pkd2 Cre mouse model demonstrates that 
ezrin loss can be recapitulated in vivo following inactivation of Pkd2 with doxycycline. 
Human ADPKD cystic tissue exhibits a decrease in ezrin protein abundance relative to 
normal kidneys and aberrant localization in cyst walls.
Conclusions: Therefore, the initiation of cystogenesis in ADPKD may be dependent 
on PC2’s regulation of the AJC and master scaffold, ezrin, highlighting a novel function of 
PC2 in renal epithelial cells.
Funding: NIDDK Support, Other NIH Support - NIGMS, T32 Training Program in 
Integrative Membrane Biology, Private Foundation Support
FR-PO953 Poster Friday
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Mitochondrial Morphological Abnormality in Cyst Epithelial Cells of 
Autosomal Dominant Polycystic Kidney Disease Patients
Yu Ishimoto,6 Masaomi Nangaku,6 Saori Nishio,1 Haruna Kawano,9 
Shigeo Horie,5 Tomoko Kasahara,7 Kenji Osafune,8 Junichi Hoshino,2 
Yoshifumi Ubara,2 Akira Shimizu,4 Masanori Kugita,3 Shizuko Nagao,3 
Kenjiro Honda,6 Reiko Inagi.6 1Hokkaido University, Sapporo, Japan; 
2Toranomon Hospital, Tokyo, Japan; 3Fujita Health University, Toyoake, Japan; 
4Nippion Medical School, Tokyo, Japan; 5Juntendo University, Tokyo, Japan; 
6University of Tokyo School of Medicine, Tokyo, Japan; 7Kyoto University, 
Kyoto, Japan; 8Center for iPS Cell Research and Application, Kyoto University, 
Kyoto City, Kyoto, Japan; 9Juntendo university, Tokyo, Japan.
Background: Recent studies reported that polycystin-1 affects mitochondrial function 
directly or indirectly and facilitates pathogenesis of autosomal dominant polycystic kidney 
disease (ADPKD). However, it is not confirmed in the kidney of ADPKD patients.
Methods: We conducted multi-center study, collected the kidney tissues from 
20 ADPKD patients (this study was approved by the research ethics committees of the 
Graduate School of Medicine and Faculty of Medicine, The University of Tokyo. No.11560-
(2)). By transmission electron microscopy, mitochondrial morphology was assessed in the 
kidney from ADPKD patients or ADPKD model animals. Quantification of mitochondrial 
morphology was done using ImageJ software.
Results: In cyst epithelial cells with cuboidal shape, mitochondria are abundant. In 
contrast, in the cyst epithelial cells, which reduce their height, the number of mitochondria 
was decreased, and subsequently, mitochondria are almost gone in the cyst epithelial 
cells with flat shape. The mean volume of the cyst epithelial cells of ADPKD patients 
(mtADPKD) were about 1.2 times larger than in the tubules of normal human control 
(mtCON). Mitochondria of mtCON exhibited a wide variety of morphologies (elongated 
and fragmented), however that of mtADPKD showed almost uniform with round shape. 
In addition, mtADPKD showed indistinct cristae formation. These characteristics of 
abnormal mitochondrial shape are the same with that observed in the cyst epithelial cells of 
Pkd1flox/flox:Ksp-Cre mice and Pax8rtTA;TetO-Cre;Pkd2lox/flox mice but different from that of 
Cy/+ rat.
Conclusions: Our results indicate that mitochondria in the cyst epithelial cells 
of ADPKD patients swollen with indistinct cristae formation and this might be the 
characteristics of polycystin-1 or polycystin-2 dysfunction in the kidney of ADPKD 
patients. Mitochondrial dynamics serves a variety of different functions, including cell 
proliferation. Similar mitochondrial morphological change was observed in cancer cells 
and which might reflect pathological derangements characteristic of ADPKD has marked 
similarities to those of solid tumors.
Funding: Government Support - Non-U.S.
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CaSR Activation Corrects the Impaired Mitochondrial Energy Status in 
Human Cell Models of ADPKD
Annarita Di Mise,1 Marianna Ranieri,1 Mariangela Centrone,1 Maria Venneri,1 
Grazia Tamma,1 Daniela Valenti,2 Giovanna Valenti.1 1University of Bari, Bari, 
Italy; 2Institute of Biomembranes, Bioenergetics and Molecular 
Biotechonologies, Bari, Italy.
Background: Clinical and fundamental research data suggest that reduced resting 
cytosolic calcium (Ca2+) concentration and increased level of cAMP are two of the most 
proximal events in the pathogenesis of Autosomal Dominant Polycystic Kidney Disease 
(ADPKD). Reduced cellular free Ca2+ found in ADPKD, can on the other hand affect 
mitochondrial function and ATP production and, interestingly, a relationship between 
mitochondria and renal polycystic diseases have been suggested. CaSR is a G protein 
coupled receptor, which plays an essential role in regulating Ca2+ homeostasis whose 
activation is associated with an increase in intracellular Ca2+ and decrease in cAMP. We 
have recently reported (Di Mise et al, Sci Rep, 2018) that selective CaSR activation reduces 
intracellular cAMP and mTOR, and increases intracellular Ca2+, reversing the principal 
ADPKD dysregulations. Here, the effect of CaSR activation on mitochondrial energy status 
is investigated.
Methods: Control human conditionally immortalized Proximal Tubular Epithelial cells 
with stably down-regulated PKD1 (ciPTEC-PC1KD) were used as experimental tools.
Results: The investigation of the bioenergetics status in ciPTEC-PC1KD revealed a 
multilevel inhibition of the mitochondrial ATP production by oxidative phosphorylation 
(OXPHOS) in ciPTEC-PC1KD compared with wt cells, specifically at complex I, 
complex II and complex IV levels. Interestingly, ciPTEC-PC1KD have significantly lower 
mitochondrial Ca2+ levels (88.05 2.6%), associated with a severe deficit in mitochondrial 
ATP production (38 ± 4%), with respect to wt cells, secondary to the OXPHOS 
impairment. Notably, selective CaSR activation with the calcimimetic NPS-R568 increases 
mitochondrial Ca2+ content close to the levels found in resting wt cells, and fully recovers 
the cell energy deficit associated to the PC1 silencing.
Conclusions: Together these data indicate that, besides reversing altered intracellular 
Ca2+, cAMP and mTOR, selective CaSR activation in PKD1 deficient cells corrects 
mitochondrial energy status that, in ADPKD, is known to facilitate cyst formation. These 
findings identify CaSR as a potential therapeutic target.
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Connective Tissue Growth Factor Is Regulated by TGF-β2 and ERK via 
Smad2/3 in Autosomal Dominant Polycystic Kidney Disease
Hyunho Kim,1 Ji-Hye Kim,1 Jinmo Sung,1 Hyunsuk Kim,4 Jeong ok So,1 
Jiseon Kim,1 Hyunjin Ryu,1 Hayne C. Park,2 Yun Kyu Oh,3 Curie Ahn.1 1Seoul 
National University Hospital, JongNo-Gu, SEOUL, Republic of Korea; 2Kangnam 
Sacred Heart Hospital, SEOUL, Republic of Korea; 3Department of Internal 
Medicine, Boramae Medical Center, Seoul, Republic of Korea; 4Chuncheon Sacred 
Heart Hospital, Chuncheon, GangWon-Do, Republic of Korea.
Background: In autosomal dominant polycystic kidney disease (ADPKD), the 
mechanism of pericystic fibrosis is not elucidated. Connective tissue growth factor (CTGF) 
plays an important role in the renal fibrosis. Also, It is known that ERK phosphorylates 
the linker region of Smad3 to enhance and activity of ERK is increased in ADPKD. Here, 
we study whether CTGF is regulated by TGF-β and ERK via Smad2/3 signal pathway in 
ADPKD.
Methods: To examine the expression of CTGF and phosphorylation of Smad2/3, we 
performed immunohistochemistry(IHC) and Western blot of ADPKD kidney tissues and 
isolated cyst cells. To investigate whether Smad2/3 signal pathway was involved in the 
upregulation of CTGF and the role of ERK in Smad2/3 pathway, we treated A83-01, which 
blocked phosphorylation of Smad2/3, and ERK inhibitor, PD98059, into cyst cells. Next, 
we performed ELISA and RT-PCR to examine which TGF-β induced Smad2/3 pathway in 
ADPKD.
Results: In kidney tissues and isolated cyst cells of ADPKD patients, we found that 
expression of CTGF and phosphorylation of Smad2/3 were increased. The expression of 
CTGF and nuclear localization of phospho-Smad3 were reduced on treatment of A83-01. 
Thus, Smad2/3 pathway induced the expression of CTGF. We found that TGF-β2 was 
secreted and mRNA of TGF-β2 was increased in cyst cells. On the treatment of TGF-β2, 
phosphorylation of Smad2/3 and expression of CTGF were increased. When we treated 
ERK inhibitor, PD98059, it was found that nuclear phospho-Smad2/3 was reduced in 
nuclear/cytosol fractionation and immunofluorescence. Next, we study whether PC1 
repressed TGF-β2 via AKT. IMCD cells expressing PC1 showed that secretion and mRNA 
of TGF-β2 were reduced. After treatment AKT inhibitor, the secretion and mRNA of 
TGF-β2 were increased indicating PC1 downregulated TGF-β2 via AKT.
Conclusions: Taken together, our results suggested that CTGF was regulated by 
TGF-β2 and ERK via Smad2/3 signal pathway in pericystic fibrosis of ADPKD.
Funding: Government Support - Non-U.S.
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Dysregulated 4E-BP1 Pathway in Polycystic Kidney Disease
Sara Holditch,1 Daniel Atwood,2,1 Carolyn N. Brown,1 Charles L. Edelstein.1 
1UC Denver Anschutz Medical Campus, Aurora, CO; 2University of Colorado 
Anschutz, Aurora, CO.
Background: Unchecked proliferation of cystic epithelial cells is a major contributor 
to cyst growth in PKD. The 4E-BP1 pathway is a crucial checkpoint in translation and 
cellular proliferation, regulated by multiple stimulatory factors like PKCα, ERK, and AKT. 
The aim of this study was to 1) determine whether the 4E-BP1 pathway is dysregulated 
in human PKD1-/- cells, 2) examine the effects of an AKT and mTOR insensitive 4E-BP1 
(F113A) on protein translation, proliferation, and 3) assess the feasibility of in vivo gene 
therapy of F113A 4E-BP1 adeno-associated virus (AAV9) in neonatal and adult mice.
Methods: Immunoblot, proliferation, and luciferase assays were performed on human 
epithelial cells from normal renal cortical tubular epithelium (PKD1+/+) and ADPKD cyst-
lining epithelium (PKD1-/-) transfected with pCAG-TdTomato or pCAG-F113A. AAV9 
F113A, and AAV9-TdTomato vectors were prepared and administered from D3 and to D17, 
or D120 to D180.
Results: There was increased phospho (p4E-BP1) species and increased pPKCa(3.6±0.2 
vs 0.6±0.0DU***), pERK(3.6±0.2 vs 0.5±0.2DU***), and pAKT(0.6±0.1 vs 0.2±0.1DU*), 
in PKD1-/- vs. PKD1+/+ cells respectively. In vitro, F113A expression reduced p4E-BP1 
S65 (1.4±0.2 vs 0.02±0.01DU***), reduced cyclin D1 (0.65±0.04 vs 0.51±0.10DU*) and 
increased autophagosome marker, LC3-II, (0.02±0.00 vs 0.31±0.13DU*) expression in 
PKD1-/- cells. Stimulation with insulin resulted in maintained p4E-BP1 suppression with 
F113A in PKD1-/- (2.1±0.3 vs 0.2±0.1DU***). F113A also reduced cap-dependent protein 
translation (by 37%**), and 72hr proliferation (250±4 vs 180±5 480/528nm O.D***). 
In neonatal and adult mice, administration of AAV9 resulted in detectable F113A RNA in 
the heart, kidney, and liver, and reduced p4E-BP1 S65 expression in the heart (2.0±1.3 vs 
0.6±0.4DU*). *p<0.05, **p<0.01, *** p<0.001 vs to control.
Conclusions: In PKD, a setting of cystic tubular epithelial hyperproliferation, the 4E-
BP1 pathway is dysregulated with increased phosphoregulation of 4E-BP1 by multiple 
overactive kinases such as; PKCa, ERK, AKT. In vitro, F113A expression in PKD1-/- cells, 
results in hypophosphorylated 4E-BP1 species, reduced cap dependent protein translation, 
reduced proliferation, and increased autophagosomes. F113A gene therapy to counter the 
dysregulated 4E-BP1 pathway in in vivo models of PKD is feasible to inhibit a pathway 
seemingly integral to the pathobiology of PKD.
Funding: Other U.S. Government Support, Private Foundation Support
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Polycystin-1 Signaling Is Regulated by a Stachel-Like Sequence
Brenda S. Magenheimer, Robin L. Maser. University of Kansas Medical Center, 
Kansas City, KS.
Background: Polycystin-1 (PC1) is involved in modulation of G protein signaling, 
but the regulatory mechanism is unknown. Similar to the Adhesion class of GPCRs, PC1 
undergoes auto-catalyzed cleavage at a GPS motif present within its conserved GAIN 
domain that generates noncovalently-associated extracellular N-terminal (NTF) and 
membrane-embedded C-terminal (CTF) fragments. Adhesion GPCR signaling can be 
regulated by residues in the extracellular stalk (the so-called ‘Stachel sequence’) of the CTF 
that are exposed upon removal of the NTF. We hypothesized that PC1-mediated signaling is 
regulated by a Stachel-like sequence within the N-terminus of its CTF.
Methods: Full-length (FL) or CTF forms of PC1 with wild type or mutant stalk 
sequences (i.e., deletion, ADPKD-associated missense, or alanine substitution) were 
transiently expressed in HEK293T cells. Activation of a co-transfected NFAT promoter-
luciferase reporter and levels of total and surface-expressed protein were compared between 
mutant and wild type PC1.
Results: FL PC1 activated the NFAT reporter in a dose-dependent fashion, while the CTF 
demonstrated an inverse dose relationship possibly dependent on its % surface expression. 
Deletion of the entire stalk region from CTF eliminated NFAT reporter activation, which 
was not solely due to reduced total protein or surface expression levels. Alanine-scanning 
of the CTF stalk sequence resulted in a range of effects on NFAT activity, from abolishment 
to augmentation, which were not entirely consistent with changes in mutant CTF expression 
characteristics. ADPKD missense mutations in the CTF stalk abolished NFAT activation 
with varying effects on total or surface protein expression. The same ADPKD mutations 
when engineered into FL PC1 also inhibited NFAT reporter activation, but had differing 
effects on GPS cleavage and cell surface expression.
Conclusions: The CTF may be the ‘native form’ of PC1 responsible for signaling to 
the NFAT reporter, whose signaling ability is dependent on the presence of the extracellular 
stalk. Mutation analyses implicate specific residues within the stalk that are critical for 
NFAT activation, which are likely involved in intramolecular interactions with membrane-
embedded portions of the CTF. These observations are consistent with an adhesion GPCR-
like and a stalk/Stachel sequence-dependent mechanism for PC1-mediated signaling.
Funding: Other U.S. Government Support, Private Foundation Support
FR-PO958 Poster Friday
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Protection Effect of Klotho on Cyst Growth in Autosomal Dominant 
Polycystic Kidney Disease
Xiaoyan Li, Lei Bu, Jiayi Lyu, Xia Zhou, Ewud Agborbesong, Xiaogang Li. 
University of Kansas Medical Center, Kansas City, KS.
Background: ADPKD is the most common hereditary renal disorder. Klotho is a 
protein with a single transmembrane domain, which is mainly expressed in the kidney 
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and acts as a co-receptor for fibroblast growth factor 23 (FGF23). The membrane bound 
extracellular domain of Klotho (soluble α-Klotho) can be cleaved and released into the 
blood stream. The soluble a-Klotho levels in ADPKD patients was decreased. However, the 
mechanisms for the downregulation of Klothos and its roles in regulating cyst development 
remain unknown.
Methods: To evaluate a potential role of Klotho in cyst pathophysiology, we 
investigated the expression of Klotho in cystic kidneys from ADPKD patients and 
Pkd1flox/flox conditional knockout mice by using immunohistochemistry staining, western 
blot and qRT-PCR. A recombinant mouse Klotho was used to evaluate its effects on cyst 
growth in vivo.
Results: We found that the expression of Klotho in the kidneys from ADPKD patients 
and Pkd1 knockout mice was decreased in addition to the decrease of the soluble a-Klotho 
levels in the serum of ADPKD patients. We further found that the methylation on the 
promoter of Klotho was increased in the genome of ADPKD patients and Pkd1 mutant 
mice, which provided a mechanism for the downregulation of Klothos in ADPKD by the 
upregulated DNA methyltransferases (DNMTs). Treatment with the recombinant mouse 
Klotho delayed cyst growth as seen by decreased cystic index, kidney weight (KW)/
body weight (BW) ratios, blood urea nitrogen (BUN) levels, cyst lining epithelial cell 
proliferation, and increased cyst lining epithelial cell apoptosis in Pkd1 mutant mice (all 
p < 0.01). Klotho treatment decreased the activation and phosphorylation of Akt, ERK, Rb, 
S6, and STAT3, whereas it increased the expression of p21. Since Klotho overexpression 
mice is normal and the average lifespan is about 20-30% longer that the wild type mice, 
overexpression or treatment with Klotho should not only protect renal function but also has 
less side effect.
Conclusions: The expression of Klotho was not only deceased in the serum of ADPKD 
patients but also in the kidneys from ADPKD patient and Pkd1 knockout mice, which was 
regulated by the DNMTs mediated methylation on the promoter of Klotho. Treatment with 
the recombinant Klotho may be a viable new therapy for ADPKD.
Funding: NIDDK Support
FR-PO959 Poster Friday
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Homeostasis of Phosphate Kinase PIPKIγ and Phosphatase INPP5E 
Modulates the Ciliary Accumulation of Polycystin2 in ADPKD
Chuan Chen. Mayo Clinic, Rochester, MN.
Background: Primary cilia defects lead to a panel of genetic human disorders, 
collectively termed as ciliopathies. Polycystin2 as a transmembrane protein functions to 
interact with PKD1 and maintains normal orientationof tubular architecture. Mutations 
in either PKD1 or PKD2 causes autosomal dominant polycystic kidney disease 
(ADPKD), which is also considered to be among the ciliopathy diseases. The function 
of phosphoinositides in mediating acute response, and acting as constitutive signals to 
help define organelle identity, are also emphasized by various human diseases. Recently, 
several studies implicated the involvement of PI species in ciliopathies. Also, Homeostasis 
of Phosphoinositide PI(4)P and PI(4,5)P2 functions significantly in cilia, and mutations in 
the phosphatases INPP5E can significantly increase ciliary PI(4,5)P2. But the relationship 
between regulated homoeostasis of PIs and ciliopathy proteins still remain to explore in 
the future.
Methods: Cell culture and transfection of DNA constructs and siRNA 
Immunofluorescence microscopy Immunoprecipitation and pull-down assay
Results: Phosphatidylinositol phosphate kinase PIPKIγ and phosphatase INPP5E 
cordinate to regulate homeostasis of PI(4)P and PI(4,5)P2 in cilia. Recently, we discovered 
In INPP5E knock-out MEF cells, endogenous ciliary pool of polycystin2 is significantly 
increased, while PIPKIγ depletion can partially reduce the accumulation of polycystin2. 
Also, in GANAB cell which always exhibits the absent ciliary localization of polycystin2, 
after knocking down INPP5E, we also observed increased PC2 accumulation. To verify 
this observation, we treated GANAB cell with the INPP5E inhibitor and found similar 
ciliary accumulation of PC2 after 24h treatment. As mutations in INPP5E increased ciliary 
PI(4,5)P2, we hypothesized that the enriched PI(4,5)P2 promoted PC2 accumulation. By 
overexpressing PIPKIγ kinase domain or its activator protein HYLS1 in GANAB cells, the 
increased PC2 signal in cilia also convinced our hypothesis.
Conclusions: By activating PIPKIr or inhibiting INPP5E, we found enriched PI(4.5)
P2 is associated with ciliary PC2 accumulation. As reduced level of PC2 can always lead to 
kidney disease ADPKD, increased dosage of ciliary PC2 by PI(4,5)P2 may provide some 
new targets to understand the relationship between PIs and kidney diseases and also new 
methods for studying ADPKD.
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Polycystin 1 (PC1) and NPHP1 Interact with Ciliary LKB1 to Regulate 
Inflammation, Providing New Insights into the Pathophysiology of 
Ciliopathy Phenotypes
E. Wolfgang Kuehn,4 Amandine Viau,2 Frank Bienaime,3 Kamile Lukas,4 
Abhijeet Todkar,4 Toma A. Yakulov,4 Alexis Hofherr,4 Florian Grahammer,1 
Oliver Kretz,1 Roland Nitschke,7 Tobias B. Huber,1 Fabiola Terzi,6 
Michael Kottgen,4 Melanie Boerries,8 Hauke Busch,5 Gerd Walz.4 1University 
Hospital Hamburg-Eppendorf, Hamburg, Germany; 2INSERM U1151 / INEM,
Paris, France; 3INSERM U845 - Universite Paris Descartes - APHP, Paris,
France; 4University Freiburg Medical Center, Freiburg, Germany; 5University 
of Lübeck, Lübeck, Germany; 6INSERM, Paris, France; 7University Freiburg,
Freiburg, Germany; 8DKFZ/DKTK, Freiburg, Germany.
Background: Peritubular inflammation and fibrosis are key aspects of the renal 
ciliopathies nephronophthisis (NPH) and autosomal dominant polycystic kidney disease 
(ADPKD). In addition, macrophages drive cyst growth in the latter. Yet, the mechanism, 
how mutations in NPHP or PKD genes cause inflammation, is unknown.
Methods: Biochemistry, expression screens, molecular biology, imaging, transgenic 
animal models, immune phenotyping.
Results: We find that loss of Lkb1 in the kidney results in an NPH phenotype. LKB1 
interacts with NPHP1 and PC1 to regulate CCL2 expression through an intra-ciliary 
mechanism. Loss of Lkb1 or Pkd1 in the kidney leads to increased numbers of CCR2 
positive mononuclear phagocytes. Simultaneous targeting of Ccl2 or the essential cilia 
protein Kif3a in Pkd1 mutant mice prevents CCL2 expression, macrophage expansion and 
leads to an ameliorated phenotype.
Conclusions: Our findings describe a novel physiological role for PC1 and NPHP1 
as gatekeepers of peritubular immune cell numbers and explain how disturbance of this 
function results in an essential pathological process driving these entities.
Funding: Government Support - Non-U.S.
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Deletion of Ift-A Gene, Thm1, Differentially Affects Cystic Kidney Disease 
in Pkd1 and Jck Mouse Models
Wei Wang, Luciane M. Silva, Bailey A. Allard, Robin L. Maser, Pamela V. Tran. 
University of Kansas Medical Center, Kansas City, KS.
Background: Primary cilia are signaling organelles that are built and maintained by 
intraflagellar transport (IFT) complexes B and A. The role of primary cilia in renal cystic 
disease is poorly understood. Ciliary dysfunction causes renal cystic disease, yet ablation of 
cilia via Ift-B gene deletion and pharmacological shortening of cilia attenuated renal cystic 
disease in Pkd1 conditional knock-out (cko) and jck mutant mice, respectively. Such results 
suggest that cilia-mediated signaling within a renal cystic disease background may be pro-
cystogenic. In contrast to deletion of an Ift-B gene, which often results in cilia loss, deletion 
of an Ift-A gene causes shortened cilia with protein accumulation in bulbous distal tips and 
can have opposing effects on signaling. Thus we examined the effect of Ift-A deficiency on 
a renal cystic disease background.
Methods: Using the ROSA-CreERT recombinase, Thm1 was deleted together 
with Pkd1 in mice at 5 weeks of age, and in jck mutant mice at perinatal and postnatal 
(4 weeks) ages.
Results: Thm1 deletion attenuated Pkd1 cko renal cystic disease, decreasing BUN, 
cell proliferation, and P-STAT3 and P-ERK levels in Thm1;Pkd1 dko kidneys relative to 
Pkd1 cko kidneys. In contrast, Thm1 deletion caused a combinatorial effect in jck mice. 
While jck mice showed renal cysts of collecting duct and Loop of Henle tubular origins, 
perinatal deletion of Thm1 in jck mutants caused additional cysts of proximal tubular origin, 
and increased BUN. Deletion of Thm1 at 4 weeks of age in jck mutants did not affect 
proximal tubules, but did increase cell proliferation and BUN in Thm1; jck double mutant 
females. Renal P-STAT3 and P-ERK levels correlated with disease severity in all mutants. 
Additionally, primary cilia were elongated in jck mice, and Thm1 deletion in jck mice 
caused elongated cilia with IFT81 accumulation at the distal tips.
Conclusions: Attenuated renal cystic disease in Thm1;Pkd1 dko mice suggests 
that Pkd1 renal cystogenesis requires Ift-A, while the combinatorial effect in Thm1;jck 
double mutant kidneys suggests independent cyst-promoting roles for Thm1 and jck. 
The contrasting effects of Thm1 deletion in Pkd1 and jck mutants may reveal divergent 
mechanisms underlying Pkd1 and jck renal cystogenesis.
Funding: NIDDK Support
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Targeting Axoneme Polyglutamylation as a Potential Therapeutic 
Approach for ADPKD Treatment
Kai He. Mayo Clinic, Rochester, MN.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the 
most common inherited renal disorders, causing uncontrolled growth of cysts in kidney 
eventually leading to kidney failure. Primary cilia, the non-motile sensory devices on most 
cell surfaces, have been suggested as the key organelles in the pathogenesis of ADPKD. 
Proper targeting/maintenance of Polycystin 1(PC1)/ Polycystin 2(PC2) heterodimer on 
cilia surface are critical for cilia as mechano-sensor. Dysfunctional polycystins would 
compromise cilia-dependent signaling in maintaining normal nephron structure and lead 
to cystogenesis. Recently, accumulating evidence suggest a link between the level of 
functional Polycystins and disease severity, indicative of a dosage model of cystogenesis 
in ADPKD. Theoretically, restoring the functional level of cilia polycystins is a promising 
therapeutic strategy to delay or even prevent the cystogenesis. However, perusing this 
strategy is impeded by the lack of understanding of how the ciliary targeting/maintenance 
of polycystins is controlled.
Methods: 1. Immunoprecipitation and GST pull-down. 2. MDCK cyst formation in 
3D culture. 3. Immunofluorescence microscopy. 4. Live-cell imaging. 5. Western blotting. 
6. Bio-ID.
Results: Axoneme polyglutamylation is specifically regulated by a Joubert syndrome 
protein ARL13B and tuned by the balance of glutamylases TTLL5/6 and deglutamylase 
CCP5. ARL13B interacts with RAB11 effector FIP5 to promote the ciliary import of 
glutamylases. Hypoglutamylation caused by a deficient FIP5-regulated trafficking impairs 
the proper anchoring of PC2 in cilia. Remarkably, depletion of CCP5 effectively promotes 
hyperglutamylation and restores the ciliary PC2 in GANAB-/- cells. By implementing 
axoneme polyglutamylation as readout, we initiated a preliminary imaging-based drug 
screen. We identified several hits which could induce axoneme hyperglutamylation and 
increase PC2 dosage and, importantly, suppress MDCK cyst formation in 3D culture, 
implicating the therapeutic potential of targeting axoneme polyglutamylation for ADPKD.
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Conclusions: 1. ARL13B-FIP5-regulated ciliary import of glutamylases is essential 
for axoneme polyglutamylation. 2. Axoneme polyglutamylation anchors ciliary PC2. 3. 
Restoring ciliary polycystins by increasing axoneme polyglutamylation could be a potential 
therapeutic approach for ADPKD treatment.
Funding: NIDDK Support, Private Foundation Support
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Genomic Background of Adults with Suspected Ciliopathy on Renal 
Biopsy
Takuya Fujimaru,1 Takayasu Mori,1 Shintaro Mandai,1 Motoko Chiga,1 
Hiroaki Kikuchi,1 Fumiaki Ando,1 Yutaro Mori,1 Koichiro Susa,1 Kiyoshi Isobe,1 
Soichiro Iimori,1 Naohiro Nomura,1 Shotaro Naito,1 Tomokazu Okado,1 
Tatemitsu Rai,1 Katsushi Nagatsuji,2 Kiyotaka Nagahama,3 Eikan Mishima,4 
Toshio Mochizuki,5 Akinari Sekine,6 Junichi Hoshino,6 Yoshifumi Ubara,6 
Shinichi Uchida,1 Eisei Sohara.1 1Tokyo Medical and Dental University, Tokyo, 
Japan; 2Osaka City General Hospital, Osaka, Japan; 3Kyorin University, Tokyo, 
Japan; 4Tohoku University, Miyagi, Japan; 5Tokyo Woman’s Medical University, 
Tokyo, Japan; 6Toranomon Hospital, Tokyo, Japan.
Background: In adult patients, ciliopathy is often difficult to make a precise 
diagnosis based on clinical features, because they usually have no specific findings such as 
retinitis pigmentosa or liver dysfunction. Furthermore, it is impossible to make a definitive 
genetic diagnosis by renal biopsy. Therefore, genetic testing is crucial for precise 
diagnosis and clinical management of the patients and their families.
Methods: We investigated 17 adult patients who were suspected ciliopathy by renal 
biopsy. Their pathological findings were tubular dilatation or thickening and lamellation 
of tubular basement membranes. All patients had no extrarenal findings (retinitis 
pigmentosa and liver function disorder) and no family history of ciliopathy. 
Comprehensive genetic testing was performed using capture-based next-generation 
sequencing for 69 genes that cause nine types of hereditary cystic kidney diseases 
(autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney 
disease, nephronophthisis, Joubert syndrome, Meckel syndrome, Senior-Loken syndrome, 
Bardet-Biedl syndrome, autosomal dominant tubulointerstitial kidney disease, etc.).
Results: Median age at renal biopsy was 55 (17–84) years old and seven patients 
(41%) were male. Through our analysis, two patients had homozygous full gene deletions 
of NPHP1. Additionally, compound heterozygous mutations in NPHP3, NPHP4 and 
CEP164 were found in each one patient. The patients who had pathogenic mutations were 
significantly younger than those without mutations (median, 26 years old vs 68 years old, 
P = 0.045, Mann-Whitney U test), and no mutations in the known genes were detected in 
those aged ≥50 years (n = 9).
Conclusions: In the adult patients suspected of ciliopathy by renal biopsy, 
29% were genetically diagnosed as nephronophthisis by our comprehensive genetic 
testing. Additionally, older patients tend not to have any pathogenic mutations in the 
known genes.
Funding: Government Support - Non-U.S.
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Deletion of Cep164 in the Collecting Duct Causes Polycystic Kidney 
Disease-Like Phenotype
Rannar Airik,4 Merlin Airik,4 Markus Schueler,3 Carlton M. 
Bates,1 Friedhelm Hildebrandt.2 1Children’s Hospital of Pittsburgh, 
Pittsburgh, PA; 2Boston Children’s Hospital, Boston, MA; 3University of 
Erlangen, Erlangen, Germany; 4University of Pittsburgh, Pittsburgh, PA.
Background: Nephronophthisis is an inherited cause of polycystic kidney disease 
that represents the most common cause of end-stage renal failure in the first three decades of 
life. Although all known genes associated with the disease phenotype localize to the cilia, 
the underpinning pathomechanisms remain largely unknown. We recently reported that 
mutations in centrosomal protein 164(CEP164) gene, cause nephronophthisis with 
extrarenal manifestations in humans. In order to study the function of Cep164 in mouse we 
generated a Cep164 transgenic mouse model.
Methods: Targeted Cep164 ES cells were obtained from KOMP and injected into 
blastocysts to generate the Cep164-/- mice. Collecting duct-specific deletion of Cep164 was 
achieved by crossing Hoxb7-Cre mice with Cep164loxP/loxP mice. Immunofluorescence staining 
was used to study the expression of ciliary proteins both in celture and in the kidney. 
Gross morphological characterization and tissue histological analysis of mutant mice was 
performed on E9.5 embryos, P7, P14 and P21 animals.
Results: Whole body deletion of Cep164 resulted in mid-gestational lethality in mice. 
Molecular analysis revealed that the mutant animals lacked primary cilia and had impaired 
hedgehog signaling. To circumvent embryonic lethality, Cep164 was deleted from the kidney 
collecting duct using Hoxb7-Cre mice. Deletion of Cep164 abolished cilia in the collecting 
duct cells of Hoxb7-Cre;Cep164loxP/loxP mice. The mutant kidneys developed normally until P7, 
after which they underwent a rapid cyst formation in the collecting ducts, which led to 
widespread structural damage, kidney failure and mortality by P21. Morphological and 
molecular analysis demonstrated that the rapid cyst growth was caused by uncontrolled cell 
proliferation in the collecting duct epithelium. Treatment with cyclin-dependent kinase 
inhibitors mitigated the rapid cyst growth in Hoxb7-Cre;Cep164loxP/loxP mice.
Conclusions: Our data demonstrate that abrogation of Cep164 leads to severe 
developmental abnormalities in early mouse embryogensis due to defective ciliary 
signaling. Conditional ablation of Cep164 in the collecting duct results in massive cyst 
growth in postnatal kidneys, resembling the pathogenesis of autosomal polycystic kidney 
disease. Together, Cep164 mouse represents a novel genetic model of autosomal recessive 
polycystic kidney disease.
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Consequences of Centrosome Numerical Aberrations in Cystic Kidney 
Disease
Moe Mahjoub,1 Tao Cheng,1 Lai Kuan Dionne,2 Kyuhwan Shim.1 1Washington 
University School of Medicine/Nephrology, ST LOUIS, MO; 2Washington 
University St. Louis, St. Louis, MO.
Background: The centrosome and primary cilium act together as a cellular “hub” 
to regulate several important developmental signaling pathways. Defects in centrosome 
biogenesis can result in numerical aberrations in centrosome-cilium number, resulting 
in cells that either lose these structures or assemble too many. Importantly, numerical 
aberrations in centrosomes have been reported in various types of cystic kidney disease 
including ADPKD, nephronophthisis, and cystic kidneys of ciliopathy patients. What 
remains unknown are the consequences of centrosome numerical aberrations during 
embryonic kidney development, adult kidney homeostasis, and after renal injury.
Methods: To ablate centrosomes we utilized mice harboring a conditional allele of 
Cep120 (Cep120f/f), which we previously showed is essential for centrosome formation. To 
increase centrosome number, we used a transgenic mouse with a conditional overexpression 
allele of the kinase Plk4 (Tg::mChPlk4), known as the master regulator of centrosome 
duplication. Cep120f/for Tg::mChPlk4 mice were crossed with Six2-Cre or Hoxb7-Cre 
animals to cause ablation/amplification of centrosomes in the metanephric mesenchyme or 
ureteric bud epithelium, respectively. Finally, these mice were mated with Slc34a1-CreERTor 
Ksp-CreERTto induce overexpression/loss of centrosomes in fully developed kidneys.
Results: Increasing centrosome number perturbed mitotic spindle morphology, 
ciliary assembly, and signaling pathways essential for growth of renal progenitors. This 
resulted in defective branching morphogenesis, renal hypoplasia, and rapid cystogenesis 
after birth. Moreover, centrosome amplification sensitized kidneys in adult mice, causing 
cystogenesis following ischemic renal injury. In contrast, loss of centrosomes did not have 
an adverse effect on progenitor cell proliferation, nor caused renal hypoplasia. In fact, loss 
of centrosomes resulted in enlarged kidneys that became rapidly cystic. Remarkably, loss 
of centrosomes during kidney homeostasis did not affect overall kidney function, nor cause 
cyst formation.
Conclusions: Our results highlight the heterogeneity of response to centrosomal 
numerical aberrations in different renal cells types and developmental stages. These results 
indicate that the underlying signaling changes are likely to be different, and suggest that 
therapeutic strategies will have to be developed separately for each case.
Funding: NIDDK Support
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Structure-Function Analysis of Inversin in Proximal Ciliary Patterning 
and Ciliary Transport
Lillian Xu,1 Giada G. Bianchi,2 Peter G. Czarnecki,3 Jagesh V. Shah.4 1Princeton 
University, Crozet, VA; 2Dana Farber Cancer Institute, Boston, MA; 3Brigham 
and Women’s Hospital, Boston, MA; 4Harvard Medical School, Boston, MA.
Background: The proximal end of the primary cilium contains the inversin compartment 
(IC), comprised of four interacting ciliopathy proteins, inversin (INVS), NEK8, ANKS6 
and NPHP3. Mutations in these proteins give rise to a multiorgan malformation syndrome, 
with L-/R-asymmetry perturbations, congenital heart defects and polycystic kidney disease. 
The most upstream factor in the IC is inversin, which is necessary for IC localization of 
the other proteins. The goal of this study is (1) to identify the structural determinants of 
inversin, necessary and/or sufficient for IC reconstitution and (2) to analyze ciliary length 
and intraflagellar transport (IFT) phenotypes in presence or absence of IC proteins.
Methods: CRISPR/Cas9-mediated gene knockout Lentiviral and retroviral transduction 
Immunofluorescence microscopy Immunoprecipitation Western-blot Live fluorescence cell 
imaging Kymograph analysis
Results: Immunofluorescence for FLAG-antigen revealed proximal ciliary localization 
only of FLAG-tagged full-length inversin and C-terminal truncations (INVS[745-1065] 
and INVS[554-1065]), but not N-terminal truncations INVS[1-553] and INVS[1-744]. 
Furthermore, only full-length inversin, and none of the partial add-backs were capable to 
localize NEK8 and ANKS6 to the IC. These results suggest that the ciliary signal sequence 
of inversin lies in its C-terminal domain, but the full-length protein, including the N-terminal 
ANK-repeat domain is required to assemble the other proteins in the IC. Moreover, we 
analyzed ciliary length and IFT-B particle velocities in CRISPR/Cas9-knockouts and full-
length add-backs of IC proteins. Loss of inversin led to a >30% decrease in ciliary length 
and of IFT-B particle velocity, while a lentiviral full-length INVS add-back completely 
rescued both knockout phenotypes. An identical phenotype was observed with NPHP3, 
while NEK8 knockout revealed ~30% ciliary length increase and acceleration in IFT-B 
transport velocity.
Conclusions: As ciliary lengthening control and IFT particle velocity are physiological 
readouts for ciliary function, our results indicate that inversin is necessary and sufficient 
for ciliary homeostasis. The similar behavior of inversin and NPHP3 knockout phenotypes 
suggests that inversin may function through NPHP3, while NEK8 may play an independent 
role as a kinase.
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Stat3 Activation Is Elevated in Pre-Cystic Kidneys of Thm1 Conditional 
Knock-out Mice
Luciane M. Silva, Sumedha S. Gunewardena, Pamela V. Tran. University of 
Kansas Medical Center, Kansas City, KS.
Background: Primary cilia are sensory organelles that mediate signaling pathways. 
Dysfunction of cilia leads to renal cystic disease. Multiple cellular and signaling aberrations 
contribute to renal cystogenesis, while the initiating molecular mechanisms remain 
unknown. In mice, perinatal global deletion of the ciliary gene, Thm1, causes renal cysts 
beginning at postnatal day (P) 15.
Methods: To identify molecular events that initiate renal cystogenesis in Thm1 
conditional knockout (cko) mice, we performed RNA sequencing on kidney RNA lysates 
of pre-cystic P9 and cystic P42, Thm1 cko mice and control littermates. We reasoned 
that genes with significantly altered expression at both P9 and P42 would represent early 
initiation events leading to cystogenesis.
Results: Endothelin 1, Egr2, Fos, Jun, Stat3, endothelial Vcam1, immune genes, 
Complement C3 and Adcy7, were upregulated at P9 and further upregulated at P42. Western 
blot analysis showed increased P-STAT3 at P10, and upregulation of multiple components 
of STAT and EDN1-MAPK signaling pathways at P42. Immunohistochemistry revealed 
more intense nuclear localization of P-STAT3 in epithelial cells of non-dilated and dilated 
tubules at P20, and in cyst-lining epithelial cells and interstitial cells at P42. To study the 
connection between primary ciliary dysfunction and upregulated STAT3 signaling, we have 
generated Thm1 knock-down human renal 293T clonal cell lines. These cell lines show 
shortened primary cilia with IFT81 accumulation in a bulb-like structure at the distal tip, 
indicative of a retrograde ciliary protein trafficking defect.
Conclusions: Our data reveal upregulated Stat3 activation in pre-cystic Thm1 cko 
kidneys and suggest that simultaneous alteration of gene expression and signaling in 
renal epithelial, vascular and immune cells may potentiate renal cyst initiation. We are 
examining mechanisms by which Thm1-deficient cilia cause increased Stat3 activation 
and are inhibiting Stat3 pharmacologically in Thm1 cko mice. This may reveal initiating 
mechanisms underlying Thm1-deficient renal cystogenesis.
Funding: NIDDK Support
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Collecting Duct-Specific Deletion of the Transcription Factor  
Grainyhead-Like 2 (Grhl2) Aggravates Cyst Growth in Polycystic Kidney 
Disease
Zeliha Y. Yurtdas,1,5 Ergin Kilic,4 Emanuel Wyler,5 Peter Boor,3 Kai M. Schmidt-
Ott.2,5 1Berlin Institute for Urologic Research, Berlin, Germany; 2Charite - 
Universitaetsmedizin Berlin, Berlin, Germany; 3RWTH University Aachen, 
Aachen, Germany; 4Institut für Pathologie am Klinikum Leverkusen, Leverkusen, 
Germany; 5Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Background: Polycystic kidney disease (PKD) is a genetic disorder characterized 
by the development of cysts as a result of abnormalities in proliferation, apoptosis and 
dedifferentiation of the renal epithelium. The transcription factor Grhl2 is highly expressed 
in the collecting duct cells of the kidney and controls epithelial barrier function in the mouse 
kidney. The collecting duct is known to be an important source of cysts in PKD, but whether 
Grhl2 is involved in cyst formation and growth is not known.
Methods: To investigate the role of Grhl2 in PKD pathogenesis, we first examined 
GRHL2 protein expression in kidney samples from patients with autosomal dominant 
PKD (ADPKD). We then studied the effects of a collecting duct-specific Grhl2 deletion 
on a mouse model with slowly progressive PKD caused by overexpression of the human 
MYC proto-oncogene. We compared renal phenotypes of HoxB7-Cre; R26StopFLMYC; 
Grhl2flox/flox mice and HoxB7Cre; R26StopFLMYC mice using functional, histological 
assays and gene expression profiling.
Results: Analyses of patient samples with ADPKD (n=6) revealed that GRHL2 protein 
was downregulated by 65% in collecting duct-derived cyst-lining epithelia when compared 
with its expression in healthy collecting ducts (n=4). HoxB7Cre; R26StopFLMYC mice 
developed slowly progressive bilateral polycystic kidneys that mimicked human ADPKD. 
Collecting duct-specific deletion of Grhl2 in the kidneys of HoxB7Cre, R26StopFLMYC 
mice (HoxB7-Cre; R26StopFLMYC; Grhl2flox/flox) markedly accelerated PKD progression, 
led to a more aggressive bilateral cystic kidney disease, and caused early lethality. 
Proliferation and apoptosis rates of cyst-lining epithelia were found to be significantly 
higher in HoxB7Cre; R26StopFLMYC; Grhl2 flox/flox mice compared with HoxB7Cre; 
R26StopFLMYC mice. Furthermore, a genome-wide analysis of differentially regulated 
genes in HoxB7Cre; R26StopFLMYC; Grhl2 flox/flox mice compared with HoxB7-Cre; 
R26StopFLMYC mice identified deregulation of genes involved in cell-cycle regulation 
and epithelial cell polarity.
Conclusions: Our data indicate a role for Grhl2 and its target gene program in the 
progression of collecting duct-derived cyst formation in PKD. Targeting Grhl2 activity may 
constitute a novel strategy to limit cyst progression.
Funding: Private Foundation Support
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Cyst Growth in the Anks6pR823W Model of ADPKD Is Reduced by the 
Anks3I454E Mutation
Euan Clark,1 Christian Gosmann,1 Hermann-Josef Groene,2 Dominique 
Gauguier,3 James Bowie,4 Sigrid C. Hoffmann.1 1Medical Faculty Mannheim, 
University of Heidelberg, Mannheim, Germany; 2German Cancer Research 
Center, University of Heidelberg, Heidelberg, Germany; 3INSERM, Paris, 
France; 4University of California, Los Angeles, Los Angeles, CA.
Background: The Anks6R823W mutation in rats causes an ADPKD-like phenotype with 
massive renal cyst growth leading to kidney failure and death. Previously we demonstrated 
that this mutation prevents the Anks6-SAM domain from binding to the Anks3-SAM 
domain and disrupts the spatial expression of both proteins. Since Anks6-Anks3 binding 
prevents Anks3-Anks3 SAM domain interactions it is possible that increased formation of 
Anks3 homopolymers is part of the pathological process. Thus, we created a rat with an 
Anks3I454E mutation in the SAM domain where Anks3 can no longer bind to itself but can 
interact with Anks6.
Methods: The Anks3I454E mutation was generated using CRISPR-Cas9 in Sprague 
Dawley rats. Clinical parameters in 24-h urine and blood plasma were determined to 
evaluate renal function. Histological analysis and western blots were performed by standard 
techniques. These rats were crossed into the TGR-CMV-Anks6pR823W line and the kidneys 
of the offspring investigated at 2 and 4 weeks. Cysts were counted and scored using a 4 
point scale.
Results: No histological abnormalities were observed in the kidneys of Anks3I454E/
I454E rats up to 1 year of age. There was an increase in urine osmolarity and a decrease 
in the concentration of plasma parameters in these rats, probably due to increased water 
reabsorption in the kidney, supported by an increase in aquaporin 2 expression. In 
TGR-CMV-Anks6pR823WAnks3WT rats, cyst growth started within the first 10 days after 
birth leading to massive kidney hypertrophy. In both the 2 and 4 week old TGR-CMV-
Anks6pR823W carrying the Anks3I454E mutation there was a significant reduction in the kidney 
to body weight ratio and cyst score with the largest reduction in Anks3I454E/I454E rats versus 
TGR-CMV-Anks6pR823WAnks3WT rats (2 weeks: kw/bw p=0.0003, cyst score p=0.0001; 4 
weeks: kw/bw p=0.0086, cyst score p=0.0001).
Conclusions: 1) The disruption of Anks3-Anks3 binding via the SAM domain is not 
pathological in rats and causes increased water reuptake in the kidney. 2) The disruption of 
Anks3-Anks3 binding in the Anks6pR823W rat model of ADPKD significantly reduces the rate 
of cyst growth and this effect is increased in Anks3I454E homozygous versus heterozygous 
rats. This study was supported by the grant of the NIH (5RO1DK100482) to JB and SH.
Funding: NIDDK Support
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Biallelic ANKS6 Variants Causing Late Onset Ciliopathy with CKD in 
Adulthood
Markus Schueler,3 Bernt Popp,1 Karl Knaup,2 Michael S. Wiesener.3 1Friedrich-
Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; 
2University of Erlangen-Nuremberg, Erlangen, Germany; 3University Hospital 
Erlangen, Erlangen, Germany.
Background: The progressive and irreversible conditions summarized under the term 
“Chronic kidney diseases” (CKD) are a heterogeneous group of disorders with significant 
health and economic effects. Affected individuals and their nephrologists are often unaware 
of underlying causes. Diagnostic tools used in clinical practice, such as kidney biopsy 
do not always yield to a definitive diagnosis. High-throughput sequencing methods have 
advanced our ability to identify the underlying molecular etiology in families with unknown 
origin of CKD.
Methods: Whole exome sequencing (WES) was performed in two sisters from a non- 
consanguineous family of German descent who presented with CKD onset in mid-adulthood 
(>30 years of age). DNA was extracted from whole blood, enriched, and sequenced on a 
HiSeq2500. In addition patient-derived fibroblasts from skin biopsies were cultured for 
performing functional studies via immunoblotting.
Results: WES detected two disease associated variants c.[934G>C;938A>C], 
p.[(A312P);(D313A)]) and c.1973-3C>G in the ANKS6 gene in both affected siblings. 
Segregation testing by Sanger sequencing confirmed compound heterozygosity. The ciliary 
protein ANKS6 localizes to the proximal compartment of the cilium, where it regulates 
ciliary signaling. Mutations in ANKS6 are known to cause Nephronophthisis-related 
ciliopathies in humans, including laterality defects and congenital hepatic fibrosis. Renal 
biopsy of both patients showed tubulointerstitial fibrosis and glomerulosclerosis. Careful 
clinical examination does not reveal any extra-renal findings in both affected individuals. 
Interestingly, immunoblotting studies from patient-derived fibroblasts show a nearly 
complete loss of the ANKS6 protein and suggest an effect on gene dosage for both the 
missense and the splicing variant.
Conclusions: In summary, we confirmed the diagnosis of an ANKS6-associated 
Nephronophthisis which is typically syndromic and juvenile-onset in two adults with CKD 
onset in mid-adulthood, highlighting the extreme heterogeneity of CKD. Offering genetic 
testing to families with renal disease of unknown origin can improve our knowledge of 
the clinical course in CKD entities, leads to a better understanding of pathophysiological 
mechanism and may help to develop novel therapeutic strategies, possibly also of relevance 
to the broader field of kidney diseases.
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The Exhaustive Screening Tool Is Superior to the Simplified Version to 
Identify Pediatric Patients with a Pathogenic HNF1β Genotype
Mallory L. Downie,1 Rebekah Jobling,1 Natasha Jawa,1 Damien G. Noone,1 
Mathieu Lemaire.2 1The Hospital for Sick Children, Toronto, ON, Canada; 
2Hospital for Sick Children, Toronto, ON, Canada.
Background: Pathogenic genotypes involving hepatocyte nuclear factor-1 beta 
(HNF1β) are now recognized as the most frequent cause of monogenic congenital anomalies 
of the kidney and urinary tract (CAKUT), a leading cause of paediatric-onset chronic kidney 
disease (CKD). Identifying these patients is challenging due to the substantial phenotypic 
heterogeneity across age groups. We sought to characterize the paediatric phenotype of 
HNF1β disease and to assess the utility of established screening tools (exhaustive or 
simplified) for pediatric patients with renal cysts.
Methods: Between 2011 and 2018, 45 patients with renal cysts from our institution 
were tested for mutations in the gene HNF1β.
Results: Testing was positive in 17/39 (44%) unrelated kindreds (total, 21/45 patients) 
with median age at diagnosis of 6.1 years (range 0.1-17.3). A heterozygous deletion 
encompassing the entire HNF1β gene was detected in all but 2/17 kindreds that had 
either a gene duplication or a point mutation, respectively. Analysis of the three multiplex 
kindreds revealed significant intrafamilial phenotypic heterogeneity. The most common 
clinical features included hypomagnesemia (53%, 9/17), neurodevelopmental problems 
(43%, 9/21), hyperuricemia (50%, 4/8), hyperparathyroidism (33%, 3/9), and pancreatic 
hypoplasia (14%, 3/21). Clinical features commonly reported in adults were rare: no 
patients with hypokalemia or early-onset gout, and two patients with either maturity-onset 
diabetes of the young (MODY) or unexplained elevated liver enzymes. The exhaustive 
screening tool identified all affected patients but required testing 80% of the patients who 
tested negative (19/24). In contrast, the simplified screening tool called for genetic testing 
for only 4/45 patients, all of whom ultimately tested positive.
Conclusions: We observed that patients harboring a HNF1β mutation display variable 
phenotypic penetrance and expressivity. This heterogeneity was even noted among 
members of multiplex kindreds. A comparison of the simplified and exhaustive screening 
tools applied to pediatric patients with renal cysts reveals that the latter is more sensitive to 
identify patients with pathogenic HNF1β genotypes.
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ADTKD-HNF1B Has a Slow-Progressive Phenotype in Childhood—with 
the Exception of Very Early Onset Cases: Results of the German 
Multicenter HNF1B Childhood Registry
Stefanie Weber,1 Christine Okorn,2 Martin Kömhoff,1 Peter F. Hoyer.2 HNF1B 
Registry Study Group 1University Children’s Hospital Marburg, Marburg, 
Germany; 2University Hospital Essen, Essen, Germany.
Background: HNF1B nephropathy is part of the autosomal dominant tubulointerstitial 
kidney disease spectrum (ADTKD) and affects pediatric patients with bilateral (cystic) 
dysplasia. The clinical variability, the absence of genotype-phenotype correlations, and 
limited long-term data render counseling of affected families difficult.
Methods: Longitudinal data of 62 children with ADTKD-HNF1B was obtained in a 
multicenter approach. Genetic family analysis was performed in 30/62 cases.
Results: 87% of ADTKD-HNF1B patients had bilateral dysplasia, 74% visible 
bilateral and 16% unilateral renal cysts at the end of observation. Cyst development 
was non-progressive in 72% with a mean GFR loss of -0.33 ml/min/1.73qm per year 
(±8.9). In patients with an increase in cyst number, the annual GFR reduction was 
-2.8 ml/min/1.73qm (±13.2), in the total cohort -1.0 ml/min/1.73qm (±10.3). A subset of
ADTKD-HNF1B patients differs from this group and develops ESRD at very early ages < 2
years. Hyperuricaemia (37%) was a frequent finding at young age (median 1 year), whereas 
hypomagnesemia (24%), elevated liver enzymes (21%) and hyperglycaemia (8%) showed 
an increased incidence in the teenaged child. Genetic analysis revealed no genotype-
phenotype correlations but a significant parent-of-origin effect with a preponderance of 
78% of maternal inheritance in dominant cases.
Conclusions: In most children, ADTKD-HNF1B has a non-progressive course of cyst 
development and a slow-progressive course of kidney function. A subgroup of patients 
develops ESRD at very young age < 2years requiring special medical attention. Patients 
will be annually followed in the registry and new patients can be included at any time.
Funding: Government Support - Non-U.S.
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Clinical Characteristics of HNF1B Related Disorders in Japanese 
Population
China Nagano,1 Naoya Morisada,3 Nana Sakakibara,1 Tomohiko Yamamura,1 
Kandai Nozu,1 Kazumoto Iijima,1 Shogo Minamikawa.2 1Department of 
Pediatrics, Kobe University Graduate School of Medicine, Hyogo, Japan; 
2Kobe University Graduate School of Medicine, Kobe, Japan; 3Department of 
Clinical Genetics, Hyogo Prefectural Kobe Children’s Hospital, Hyogo, Japan.
Background: Hepatocyte nuclear factor 1β (HNF1B) gene is located at chromosome 
17q12 and is known as the causative gene for the renal cysts and diabetes syndrome 
(RCAD). It is also well known that various phenotypes of congenital anomalies of the 
kidney and urinary tract (CAKUT) or Bartter-like electrolyte abnormalities can be caused 
by HNF1B variants. In addition, 17q12 deletion syndrome shows multi-system disorders 
as well as RCAD.
Methods: We conducted gene screening for cases with RCAD, CAKUT and Bartter-
like syndrome cases. As a result, 31 cases were detected heterozygous variants or whole 
gene deletions in HNF1B (heterozygous variant: 18 cases and deletion: 13 cases). All cases 
with deletion were diagnosed with 17q12 deletion syndrome confirmed by MLPA or array 
CGH. A retrospective review of clinical data was conducted for these cases.
Results: Most cases had morphological abnormalities in the renal urinary tract 
system. Diabetes developed in 11 cases (38%). Hyperuricemia and hypomagnesemia were 
associated with 5 cases (17%) and 12 cases (41%), respectively. Pancreatic malformations 
were detected in 6 cases (21%). Nine patients (31%) had liver abnormalities. When data 
were classified by mutation types, the eGFR (estimated glomerular filtration rate) levels 
were significantly lower in the patients who carried heterozygous variants compared 
with those in the patients who carried deletions (median: 37.9 ml/min/1.73 m2 vs 
55.9 ml/min/1.73 m2, p=0.0264). Patients who carried deletions had higher frequencies of 
hypomagnesemia (p=0.0005) and neurological complications (p=0.0064) than those who 
carried variants.
Conclusions: We presented the clinical characteristics of HNF1B related disorders. To 
predict the renal prognosis or onset of extra renal complications, accurate genetic diagnosis 
at an early age is important. HNF1B related disorders show various clinical symptoms and 
should be noted for accurate diagnosis.
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Extracellular Vesicle Induction of Cortical Collecting Duct Cell Growth
John J. Bissler,1 Sharon L. Barone,2 Kamyar A. Zahedi,2 Manoocher Soleimani.2 
1Le Bonheur Children’s Hospital and St. Jude Children’s Research Hospital, 
Memphis, TN; 2University of Cincinnati, Cincinnati, OH.
Background: Tuberous sclerosis complex (TSC), a genetic tumor suppressor 
syndrome, is caused by inactivation of either TSC1 or TSC2 genes. Renal manifestations 
include early onset chronic kidney disease, angiomyolipomata and multiple patterns of 
renal cystic disease. The mechanism of cystogenesis has been assumed to be somehow 
linked to the PKD1 gene that is adjacent to the TSC2 gene, though the precise mechanism 
remains unclear.
Methods: We used transgenic animals with aquaporin-2 promoter driven Cre 
recombinase and renin-1c promoter regulated Cre recombinase to specifically inactivate the 
Tsc2 and Tsc1 genes in principal cells (Aqp2CreTsc2) and renal pericytes (Ren1cCreTsc1), 
respectively. We also used CRISPR/CAS9 technology to disrupt the Tsc1 or Tsc2 gene in a 
principal cell line and used ultracentrifugation to isolate extracellular vesicles. Conditioned 
media or isolated extracellular vesicles were used in cell culture studies with M1 intercalated 
cell line as a target. We measured the phosphorylation of S6 expression as a read out.
Results: Both animals develop renal cystic disease, by far more prominently in the 
renal cortex, and the cysts highly expressed pS6. Cystic epithelium was predominantly type 
A intercalated cells, and principal cells seemed to drop out with time in the Aqp2CreTsc2 
renal cysts. The cysts in both animals continued to express tuberin and hamartin, and 
we noted extracellular vesicles in some of the smaller cyst lumens of perfused animals. 
Using a tissue culture model we found that principal cell extracellular vesicles activated 
intercalated cell mTORC1 activity, and this was exaggerated if either the Tsc1 or Tsc2 gene 
was disrupted.
Conclusions: We demonstrate that mice with principal cell specific Tsc2 inactivation 
and mice with renal pericyte Tsc1 inactivation develop cortical cystic disease comprised 
of type A intercalated cells. The cystic epithelium appears to have an activated mTORC1 
axis, though still express hamartin and tuberin. Cell culture experiments suggest a role for 
extracellular vesicles in this growth activation signal.
Funding: Other U.S. Government Support
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Manifestations of Renal Disease in Adult Patients with Tuberous Sclerosis 
Complex–Reference Center Experience
Agnieszka Tarasewicz,1 Alicja Debska-Slizien,1 Beata Rutkowska,2 
Edyta Szurowska,2 Anna B. Marcinkowska,2 Marcin Matuszewski.3 1Department 
of Nephrology, Transplantology and Internal Medicine, Medical University of 
Gdansk, Gdansk, Poland; 2Department of Radiology, Medical University of 
Gdansk, Gdansk, Poland; 3Department of Urology, Medical University of 
Gdansk, Gdansk, Poland.
Background: Renal involvement is a considerable cause of mortality and morbidity 
in tuberous sclerosis complex (TSC) patients and include angiomyolipomas (AMLs), 
cysts and malignant tumors. Surgical treatment of life-threatening bleeding from AMLs 
additionally impairs kidney function, while treatment with mammalian target of rapamycin 
inhibitor (mTORI) is effective in preventing bleeding complications and preserving renal 
function. However, data concerning proteinuria, albuminuria and hypertension in TSC 
patients, as possibly modifiable risk factors of chronic kidney failure (CKF) is limited.
Methods: The initial assessment was performed in 32 TSC patients admitted to 
reference academic TSC center from 03/2016 to 01/2018. Study group consisted of 15 
men and 17 women in the mean age of 32±11.6 yrs. Prevalence of renal manifestations, 
CKF, hypertension, proteinuria (urinary protein-to-creatinine ratio;uPCR) and albuminuria 
(urinary albumin-to-creatinine ratio;uACR) were studied.
Results: TSC renal manifestations were: AMLs (29/32; 91%), cysts (17/32; 53%) 
and renal cell carcinoma (1/32; 3%). 25% patients were previously nephrectomised due 
to complications related to AMLs. eGFR<60 mL/min was found in 19% individuals. The 
incidence of proteinuria (uPCR>150mg/g), albuminuria (uACR>30mg/g) and hypertension 
were 41%, 44% and 34%, respectively. TSC patients after nephrectomy in comparison with 
non-nephrectomised patients had statistically significant decline of kidney function-higher 
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creatinine level (1.48±0.52mg/dL vs 0.97±0.63mg/dL) and lower eGFR (52.5±21.4mL/
min vs 93.67±30.91mL/min) and also higher albuminuria (uACR 346.7±677.6mg/g vs 
49.41±90.27mg/g);(p<0.05). The differences in prevalence of hypertension (50% in patients 
after nephrectomy vs 29% in non-nephrectomised;p=0.397) and quantity of proteinuria 
(uPCR 579.3±1003.2mg/g vs 263.8±516.7mg/g;p=0.25) were insignificant.
Conclusions: The incidence of renal manifestations was consistent with previous 
reports. Adult TSC patients have relatively high prevalence of CKF as well as its potentially 
modifiable risk factors, hypertension, proteinuria, albuminuria. The previous nephrectomy 
seems to have a significant impact on kidney function, that supports the invaluable role of 
pre-emptive treatment of AMLs with mTORI to prevent need of surgery.
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Renal Involvement in Tuberous Sclerosis Complex
Agne Cerkauskaite,1 Marius Miglinas,1 Dovile Jonuskaite,1 Ausvydas Patasius,2 
Augustina Jankauskiene,1 Rimante Cerkauskiene.1 1Institute of Clinical 
Medicine, Faculty of Medicine, Vilnius University, Lithuania, Vilnius, Lithuania; 
2National Cancer Institute, Faculty of Medicine, Vilnius University, Lithuania, 
Vilnius, Lithuania.
Background: Tuberous sclerosis complex (TSC) is a rare, genetic disorder caused by 
alterations in tumor suppresor proteins such as hamartin or tuberin leading to uncontrolled 
activity of the mTOR pathway and, consequently, to the development of the tumors, known 
as hemartomas. TSC manifestation is multisystemic including renal, cardiac, pulmonologic, 
neurological, cutaneous lesions and can differ depending on disease related genetic variants. 
Mutations of at least two different genes, the TSC1 gene or the TSC2 gene, are known 
to cause TSC. We analyzed clinically or genetically diagnosed TSC with different TSC 
gene mutations and disease manifestations, focusing on renal findings: renal cysts (RC), 
angiomyolipomas (AML) or renocellular carcinoma (RCC).
Methods: A retrospective data analysis of the clinical and radiographic (CT or MRI) 
records of the patients with TSC was made.
Results: 25 patients (14 children and 11 adults), 13 females and 12 males were 
included. Diagnosis was genetically confirmed in 56% patients, with TSC2 and TSC1 
genes 64,3%, 35,7% respectively. All patients had more than one organ involvement. Renal 
lesions were seen in 72 % of patients with an average age at diagnosis 25,3 years (2 – 60 y). 
AML occurred in 72,2%, bilateral RC - in 44,44%, while no RCC was observed. Both cysts 
and AML were significantly more frequent and more numerous in TSC2 comparing with 
TSC1. Bilateral renal cysts were presented in 50% of all AML cases. TSC2 gene mutation 
was not more common in patients with combination of AML and renal cysts than in those 
with AML as would be expected. Two patients with bilateral AML underwent nephrectomy 
before systemic disease was suspected. Disease progression correlated with the age 
(p<0.05). Everolimus was introduced in 4 patients, 1 of them had TSC, 2 patients had TSC2 
mutations and 1 was not genetically confirmed. Response to the treatment was successful 
in 89% at 6 months period and did not differ between different mutation types (p<0.01).
Conclusions: Renal involvement is high and significantly associated with genotype, 
TSC2 mutation has more severe manifestation. Everolimus showed effectiveness in 
reducing angiomyolipoma in all types of mutations.
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Metformin Ameliorates Kidney Injury of Tsc1ptKO Mice Through 
AMPK/AKT Pathway
Yili Fang, Zhigang Zhang, Huijuan Wu. Department of Pathology, School of 
Basic Medical Sciences, Fudan University, Shanghai, China.
Background: As an intractable branch among chronic kidney diseases, tuberous 
sclerosis complex (TSC) in kidney usually expresses kidney enlargement, increasing cysts, 
interstitial fibrosis and serious damage on renal function. One of the critical mechanism 
underlies TSC is aberrant down-regulation of 5’AMP-activated protein kinase (AMPK) 
phosphorylation. Indicated by several researches, metformin showed excellent functions in 
reducing inflammation and inhibiting proliferation through AMPK phosphorylation, as well 
as decreasing the level of interstitial fibrosis. Therefore, we investigated whether metformin 
could induce the amelioration of kidney injury in TSC.
Methods: Firstly, we established the Tsc1 knockout in proximal tubule (Tsc1ptKO) 
mice model, which caused striking kidney growth. Then we performed metformin by 
intraperitoneal injection in Tsc1ptKO mice by 1 week of age for 1-3 weeks every day.
Results: We observed that metformin significantly reduced kidney growth in Tsc1ptKO 
mice by 4 weeks of age, with obvious shrunken kidneys size, decreased amount and size 
in cysts as well as obvious decline in proteinuria and serum creatinine level. Besides, 
immunochemistry showed metformin inhibited proliferation and induced apoptosis of 
proximal tubular epithelial cells in Tsc1ptKO mice, meanwhile reduced inflammation and 
interstitial fibrosis. The above alterations were induced by apparent AMPK phosphorylation 
under the influence of metformin, which was confirmed by immunoblotting and 
immunochemistry.
Conclusions: Altogether, these results proved the amelioration effect of metformin on 
the kidney injury of Tsc1ptKO, which provides an innovative idea for clinical treatment on 
TSC and related kidney diseases.
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Proliferation of Intercalated Cells in Cystic Epithelium of Principal 
Cell-Specific Tsc1-KO Mice
Sharon L. Barone,1,2 Kamyar A. Zahedi,1,2 Marybeth Brooks,1,2 Stefan Somlo,3 
Jie Xu,1 John J. Bissler,4 Manoocher Soleimani.1,2 1University of Cincinnati, 
Cincinnati, OH; 2Research Services, Veterans Affairs Medical Center, 
Cincinnati, OH; 3Yale University, New Haven, CT; 4Le Bonheur Children’s 
Hospital and St. Jude Children’s Research Hospital, Memphis, TN.
Background: Tuberous sclerosis complex (TSC) is a genetic disorder caused by 
inactivation of either TSC1 or TSC2 genes and affects multiple organs. In the kidney, TSC 
presents with development of angiomyolipomas and renal cysts, which lead to renal failure. 
Despite our knowledge regarding its genetics, little is known about the promotion of cyst 
growth and enlargement in TSC.
Methods: Mice with principal cell specific inactivation of Tsc1 (Tsc1 floxed mice 
crossed with Aqp-2-promoter driven cre mice) develop an increasing number of cortical 
cysts as they age.
Results: Single and double immunofluorescence labeling studies demonstrated that 
cyst epithelium is predominantly comprised of A-intercalated (IC) cells, as shown by 
strong expression of apical H+-ATPase and pro-renin receptor (PRR). Cyst formation in 
Tsc1-KO mice is preceded by extensive areas of proliferation in the cortical collecting 
ducts (CCD), which are exclusively comprised of mitotically active (PCNA-positive) 
A-intercalated cells. This is distinct from a mouse model of ADPKD (Pkd1-KO mice),
in which CCD-derived cystic epithelium contains numerous principal cells. Expression
of Foxi1 transcription factor, a master regulator of intercalated cells and their acid base
transport machinery, robustly increased in kidneys of young Tsc1-KO mice. Kidney cysts
show mTORC1 activation in intercalated cells as determined by phosphorylation of p70-S6 
kinase 1 (S6K1). Kidney cysts from humans with TSC display a similar preponderance of 
intercalated cells in their epithelium.
Conclusions: We propose that the robust proliferation and propagation of A-intercalated 
cells is crucial to kidney cystogenesis in Tsc1-KO mice. We further propose that unlike cysts 
in PKD, which respond to AVP antagonism by reduction in their fluid secretion and size, 
TSC1 cysts, which hardly contain any principal cells will be resistant to AVP antagonists. 
We suggest that the pathogenesis of kidney cyst formation and fluid secretion into the cyst in 
TSC is distinct from PKD, is associated with proliferation of intercalated cells and gradual 
disappearance of principal cells in cyst epithelium, is independent of AVP-receptor/ADH 
axis and is energized by H+-ATPase and Pro-renin Receptor.
Funding: NIDDK Support, Veterans Affairs Support, Other U.S. Government Support
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The C-Term of Human Fibrocystin Regulates STAT3-Dependent 
Transcription
Amrei Maxi Mandel,1 Claudia Dafinger,1,2 Thomas Benzing,3,4 Thomas Weimbs,5 
Bernhard Schermer,3,4 Max Liebau.3,6 1Cologne Excellence Cluster on Cellular 
Stress Responses in Ageing-Associated Diseases (CECAD), University of 
Cologne, Cologne, Germany; 2Department of Pediatrics and Department II of 
Internal Medicine, University Hospital of Cologne, Cologne, Germany; 3Cologne 
Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases 
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Background: Autosomal recessive polycystic kidney disease (ARPKD) is the rare 
but severe form of PKD characterized by early fibrocystic renal alterations and congenital 
hepatic fibrosis. The disease is mainly caused by mutations in PKHD1, encoding the 
4,074aa transmembrane protein Fibrocystin (FC). The molecular mechanisms leading 
to ARPKD and Fibrocystin’s cellular function are poorly understood. Experimental and 
clinical data suggest that there may be partial overlap with pathomechanisms of autosomal 
dominant PKD.
Methods: We evaluated effects of the C-term of human FC on STAT3-dependent 
transcription and the SRC-STAT3 axis by applying standard techniques such as 
immunoprecipitation, immunochemistry and luciferase reporter assays.
Results: We identify a link of human FC to the regulation of STAT3-dependent 
transcription with activation of factor STAT3 in cyst-lining epithelial cells of ARPKD 
patient kidneys. Strikingly, a C-terminal truncation of FC negatively regulates SRC- and 
JAK2-dependent STAT3 activity and can be found in a common protein complex with SRC 
and JAK2. C-terminal FC also modulates SRC-dependent STAT3-activation after SRC-
activation by forskolin-induced increased intracellular levels of cAMP. Mutation analyses 
point to a role of C-term FC in the activation of SRC.
Conclusions: This data is in accordance with recent observations that showed a 
beneficial effect of both SRC and STAT3 inhibitors in orthologous and non-orthologous 
rodent models of PKD. We present insights into potential molecular mechanisms by 
providing evidence for a regulation of the SRC-STAT3-axis by human C-terminal FC.
Funding: Government Support - Non-U.S.
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
677
J Am Soc Nephrol 29: 2018 Poster/Friday
FR-PO980 Poster Friday
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Human Urine Derived Renal Epithelial Cells Provide Insights into Kidney 
Specific Alternate Splicing Variants in NPHP3
Holly R. Mabillard,2 Elisa Molinari,3 Friedhelm Hildebrandt,4 
Carsten Bergmann,5 John A. Sayer.1,2 1Newcastle University, Newcastle, United 
Kingdom; 2Renal Services, Newcastle Hospitals NHS Trust, Newcastle, United 
Kingdom; 3University of Newcastle, Newcastle upon Tyne, United Kingdom; 
4Boston Children’s Hospital, Boston, MA; 5Center for Human Genetics, 
Bioscientia, Ingelheim, Germany.
Background: The majority of multi-exon genes undergo alternative splicing to produce 
different mRNA transcripts and this may occur in a tissue-specific manner. Assessment of 
mRNA transcripts isolated from blood samples may sometimes be unhelpful in determining 
the pathogenicity of putative splice-site variants affecting kidney specific mRNA transcripts.
Methods: Here we present data demonstrating the power of using human urine derived 
renal epithelial cells (hUREC) as a source of kidney RNA. We report clinical and molecular 
genetic data from 3 affected cases from two families all with end stage renal disease by 15 
years of age.
Results: In both families, heterozygous variants which are predicted to affect function 
in NPHP3 were found on one allele, in combination with a synonymous SNV (c.2154C>T; 
p.Phe718=, 18 base pairs from the exon-intron boundary within exon 15 of NPHP3. The
only mRNA transcript amplified from wild type whole blood showed complete splicing out 
of exon 15. Urine samples obtained from control subjects and the father of family 2, who
carried the synonymous SNV variant, were therefore used to culture hUREC and allowed us 
to obtain kidney specific mRNA. Control kidney mRNA showed normal splicing of exon 15 
whilst the mRNA from the patient’s father confirmed evidence of a heterozygous alternate 
splicing of exon 15 of NPHP3.
Conclusions: Analysis of RNA derived from hUREC allows for a comparison of 
kidney specific and whole blood RNA transcripts and for assessment of the pathogenicity of 
putative splice variants leading to end stage kidney disease.
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CD206 Positive Renal Resident Macrophages Are Associated with Cyst 
Progression in a Juvenile-Induced Cilia Mutant Mouse Model
Zhang Li, Kurt Zimmerman, Michal Mrug, Bradley K. Yoder. University of 
Alabama at Birmingham, Birmingham, AL.
Background: Polycystic kidney disease (PKD) is one of the most common inherited 
genetic renal diseases. Abnormalities in the structure or function of primary cilia are 
one cause of kidney cyst growth in animal models of PKD and human patients, but the 
mechanism of how primary cilia regulate cystogenesis is largely undefined. Recent data 
suggests that macrophages are associated with cyst formation in PKD; however, the 
contribution of specific macrophage subsets in promoting renal cyst formation and how this 
is related to ciliary dysfunction and cyst progression is unknown.
Methods: To address the involvement of cilia and macrophage subtypes in cyst 
formation, our lab utilized an inducible cilia deletion mouse model by conditionally 
disrupting the Ift88 gene. Macrophage populations were analyzed in both wild type and 
cilia mutant backgrounds as well as in human autosomal dominant PKD (ADPKD) patients 
with end-stage renal disease via immunofluorescence microscopy and flow cytometry at 
different time points following cilia loss.
Results: Our mouse data indicate that there is a predominant subset of renal resident 
macrophages expressing CD206 in juvenile WT mice and that the number of CD206+ 
macrophages decreases rapidly as the mice mature into adulthood. However, in conditional 
cilia deficient mice, induction of cilia loss in juvenile stages leads to persistently elevated 
numbers of CD206+ macrophages compared to control mice. Moreover, our data show 
that in the juvenile period the severity of cyst formation is associated with the time of 
cilia deletion. Early induction of cilia loss (e.g. P3), coincides with greater number of 
CD206+ macrophages and increased cyst severity compared to induction at later ages (e.g. 
P7). Preliminary analysis of kidneys from ADPKD patients shows increased numbers of 
CD206+ macrophages compared to normal human kidneys.
Conclusions: These data suggest that CD206+ macrophages are involved in renal 
cystogenesis in human patients and mouse models of renal cyst formation.
Funding: NIDDK Support, Veterans Affairs Support
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Clinical and Radiologic Features of Older-Age ARPKD Patients
André L. Moraes, Elieser H. Watanabe, Precil D. Neves, Andreia Watanabe, 
Luiz F. Onuchic. University of Sao Paulo, S?o Paulo, Brazil.
Background: Autosomal recessive polycystic kidney disease (ARPKD) presents 
classically in pediatric age, affecting primarily kidney and liver and constituting a frequent 
cause of ESKD in children. While its manifestations are well characterized and quantified 
in pediatric population, they are not so well established in adults.
Methods: To assess the disease burden in older patients (pts), we retrospectively 
analyzed the biometric, clinical, laboratorial and radiologic features in a case series of 12 
ARPKD individuals with ≥16 years of age.
Results: This study included 7 male and 5 female pts, with median age of 22 years 
(19.0-34.5). Mean height and body mass index were 172.0±10.5 cm and 21.3±2.8 kg/m2 in 
males and 160.2±6.4 cm and 20.9±3.9 kg/m2 in females. Half of the pts were hypertensive, 
evenly distributed among the 6 cases in renal replacement therapy (RRT) and the 6 pts not 
in this therapy. RRT was initiated at 17.5±8.1 years, including 5 kidney transplants and 
1 hemodialysis. Two pts (16.7%) developed nephrocalcinosis, 1 of them with associated 
nephrolithiasis. One pt underwent unilateral nephrectomy prior to kidney transplantation. 
Total kidney volume (TKV) was calculated in 8 pts for whom computed tomography or 
magnetic resonance imaging was available, showing a mean value of 575.6±540.4 mL. 
TKV did not correlate with RRT requirement (p=0.49). The 2 pts with shrunken kidneys 
were in RRT. Post-transplant native TKV (3-9 years of follow-up) displayed a trend of lower 
values compared to kidneys of nontransplanted pts [115.1 mL (50.5-337.8) vs 535.4 mL 
(396.2-1387.0); p=0.07]. Most of the 12 cases developed liver and/or portal hypertension-
related manifestations, including hypersplenism (66.7%), esophageal varices (50%), Caroli 
syndrome (25%), and need of liver transplantation (8.3%). One pt died due to rupture of a 
basilar artery dolichoectasia, however no episodes of cholangitis were observed.
Conclusions: In addition to findings expected in older ARPKD pts, our analyses 
revealed relevant complementary information and brought interesting insights into 
ARPKD clinical reality. Our data suggest absence of growth deficit and lower frequencies 
of hypertension and cholangitis in older pts than reported for younger or broad-age pt 
populations. Moreover, kidney size tends to decrease after transplantation, reproducing 
findings obtained in autosomal dominant PKD.
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A Cross-Sectional Characterization of Young Adult ARPKD Patients 
– Data from the ARegPKD Cohort Study
Kathrin Burgmaier,1 Thomas Benzing,2 Djalila Mekahli,3 Bruno Ranchin,6 
Franz S. Schaefer,4 Max Liebau.5 1University Hospital Cologne, Cologne,
Germany; 2University of Cologne, Köln, Germany; 3KULeuven, Leuven,
Belgium; 4University of Heidelberg, Heidelberg, Germany; 5University Hospital 
Of Cologne; Children’s Hospital, Koeln, Germany; 6Pediatrics, Lyon, France.
Background: Autosomal recessive polycystic kidney disease (ARPKD) shows 
pronounced phenotypic variability. Although the classic phenotype is a severe disease of 
early childhood, a substantial number of ARPKD patients nowadays reaches adulthood and 
a minor proportion of patients is diagnosed with ARPKD in adulthood. Knowledge about 
clinical courses of adult patients suffering from ARPKD is scarce.
Methods: A cross-sectional analysis was performed on data sets of 45 adult patients 
with documented visits after their 18th birthday deriving from the international ARPKD 
cohort study ARegPKD.
Results: Median age at analysis was 21.4 (18.0-29.0) years, age at diagnosis 0.5 (-0.2-
25.0) years. 53.3 % of patients are male. PKHD1 was sequenced in 22/45 patients with a 
variant detection rate of 78%. One quarter of patients showed prenatal abnormalities. Most 
frequent symptoms at primary manifestation were extended abdomen with palpable tumor, 
arterial hypertension and urinary tract infection. One patient suffered from gastrointestinal 
bleeding at primary manifestation. 22 patients received 34 transplanted organs (median 
age at first transplantation 14.7 (2.4-42.8) years), with 7 patients receiving at least two 
transplantations. More than half of the young adults showed hepatomegaly, one third 
showed splenomegaly. Complications due to portal hypertension in form of varices were 
observed in one quarter of patients. 84.4% of patients received antihypertensive medication. 
At the timepoint of analysis renal function of native kidneys lies within CKD stages 1 to 
3 in more than 50% of patients, 40.5% of patients received renal replacement therapy in 
their history.
Conclusions: Although ARPKD is classically a severe pediatric hepatorenal disorder, 
more and more patients reach adulthood. We describe a well-phenotyped cohort of young 
adult ARPKD patients setting a basis for the identification of clinical complications 
evolving in adulthood.
Funding: Private Foundation Support, Government Support - Non-U.S.
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CRISPR-Mutant Organoids Identify Cystogenic Signal Pathways in the 
Early and Late Stages of Polycystic Kidney Disease
Tomoya Miyoshi,1 Navin R. Gupta,1,2 M. Todd Valerius,1,2 Ryuji Morizane.1,2 
1Brigham & Women’s Hospital/Harvard Medical School, Boston, MA; 2Harvard 
Stem Cell Institute, Cambridge, MA.
Background: Human pluripotent stem cell (hPSC)-derived nephron organoids have 
significant potential for the development of targeted therapies for polycystic kidney disease 
(PKD). Previously, we generated heterozygous and homozygous PKHD1 mutant hPSCs by 
CRISPR/Cas9 genome editing to establish autosomal recessive PKD (ARPKD) models in 
human cells. Following standardization to isogenic controls, here we identify cystogenic 
signal pathways of ARPKD for the potential development of novel therapeutics.
Methods: Following an identical differentiation protocol, nephron organoids were 
generated from heterozygous (PKHD1+/-, isogenic control) and homozygous (PKHD1-/-) 
mutants in 3D culture. Organoids were treated with and without forskolin, a cAMP 
inducer, and cyst formation was evaluated by bright field and fluorescent microscopy. Cell 
proliferation was assessed by Ki67 positivity in proximal (LTL+) and distal (CDH1+) tubule 
cells. RNA was isolated from organoids on differentiation day 35. RNA was amplified, 
fluorescently labeled, hybridized to a microarray (Toray, 3D-Gene® Human mRNA Oligo 
chip 25k), and signal pathway analysis was conducted using Metacore™.
Results: Gene expression analysis identified 1056 genes that differed by > 2-fold 
between heterozygous and homozygous mutants cultured without forskolin, the latter 
manifesting tubular dilatation (early cystic phase). Pathway analysis identified 50 signal 
pathways specific to the homozygous mutant in this early cystic phase (p<0.01), including 
the Rho kinase pathway known to induce loss of cellular polarity in PKD. Treatment with 
forskolin induced large cysts (late cystic phase) limited to homozygous mutants, which 
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display 1876 genes differing by > 2-fold compared to similarly treated isogenic controls. 
96 signal pathways were identified as specific in the late cystic phase of the disease and 
included proliferative transcriptional phenotypes.
Conclusions: The CRISPR approach enabled generation of isogenic controls which 
differentiated into nephron organoids following an identical protocol. Global gene 
expression analyses identified 50 and 96 specific signal pathways in the early and late 
cystic phases of PKD, respectively, in comparison to an isogenic control. These signals may 
identify novel therapeutic targets for PKD at different stages of the disease.
Funding: NIDDK Support, Private Foundation Support
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Post-developmental Inactivation of Pkhd1 Results in Liver Cysts in Mice
Whitney E. Besse,1 Charlotte E. Roosendaal,1 Xin Tian,1 Rachel Gallagher,1 
Stefan Somlo.1,2 1Dept. of Internal Medicine, Yale School of Medicine, New 
Haven, CT; 2Dept. of Genetics, Yale School of Medicine, New Haven, CT.
Background: Autosomal recessive polycystic kidney disease (ARPKD), caused 
by recessive mutations in the PKHD1 gene, is a rare congenital disease characterized by 
diffusely cystic kidneys and hepatic fibrosis. We recently found genome-wide significant 
enrichment of adult heterozygous PKHD1 carriers in our cohort of genetically unresolved 
autosomal dominant polycystic kidney and liver disease (ADPKD/ADPLD). ADPKD/
ADPLD cysts originate when over time somatic second hit mutations in scattered cells 
result in the cellular recessive genotype. In order to explore the hypothesis that, like ADPLD 
cysts, cysts in PKHD1 carriers could result from post-developmental biallelic loss, we used 
the Cre;Lox system to inactivate Pkhd1 post-developmentally in mouse liver.
Methods: Using a Pkhd1flox allele, originally used to generate the Pkhd1del3-4/del3-4 mouse 
model, we generated the following mice; Pkhd1fl/fl;UBC-Cre (experimental, n=13) and 
Pkhd1fl/+;UBC-Cre (littermate controls, n=12). All mice were induced with Tamoxifen at 
postnatal day 28 for 5 days and aged to 17 weeks. Liver and kidney histology was examined 
for cystic disease.
Results: Histological analysis performed on experimental (n=8) livers demonstrated 
polycystic livers with minimal pericystic inflammatory infiltrate, while “control” livers 
were normal. Anti-cytokeratin 19 (CK19) staining demonstrated the cysts were of biliary 
origin, consistent with both ARPKD and ADPKD mouse models, with significant increase 
in the CK19+ cell area percentage [6.1% (n=8) vs. 0.5% (n=8)] and cystic index [15.6% 
(n=8) vs. 3.0% (n=8)]. The mean liver weight to body weight ratio (LW/BW) for the Pkhd1fl/
fl;UBC-Cre animals was 5.8 ± 0.8% (n=13) versus 4.3± 0.6% (n=12) (P<0.0001). These data 
are comparable to Pkhd1del4/del4, and within range of the ADPKD mouse model Pkd1fl/fl;UBC-
Cre with the same age and induction regime. Female mice had the most profound effect 
(LW/BW, 6.2± 0.4% vs. 3.8± 0.2%, n=5 females each). The Pkhd1fl/fl;UBC-Cre kidneys 
appeared histologically normal.
Conclusions: Post-developmental inactivation of Pkhd1 results in cystic liver disease 
indicative that Pkhd1 after development is required for biliary epithelial homeostasis. 
This finding supports investigation of whether the human polycystic liver disease seen in 
PKHD1 carriers may indeed fit the ADPKD/ADPLD mechanistic paradigm.
Funding: Other NIH Support - NIH T32 DK007276 Methods in Nephrologic Research
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Pkd1-Pkhd1 Interaction During Embryonic Development via a  
Mitochondria-Dependent Mechanism
Rebecca V. Walker,1 Qin N. Yao,1 Hangxue Xu,1 Kristen F. Swaney,2 Rong Li,3 
Patricia Outeda,4 Terry J. Watnick,5 Gregory G. Germino,6 Feng Qian.5 Qian 
1umaryland, Baltimore, MD; 2Johns Hopkins University, Baltimore, MD; 3Johns 
Hopkins University SOM, Baltimore, MD; 4University of Maryland, Baltimore, 
MD; 5University of Maryland School of Medicine, Baltimore, MD; 6Deputy 
Director, NIDDK/NIH, Bethesda, MD.
Background: PKD occurs in autosomal dominant or recessive forms, caused by 
mutations mainly in PKD1 (PC1) or PKHD1 (FC) respectively. PC1 cleavage at the GPS 
motif is required for efficient ciliary trafficking and is frequently disrupted by PKD1 
mutations. Non-cleavable PC1 in Pkd1V/V knockin mice sufficiently maintains kidney 
structure during embryonic development, yet rapid cystogenesis in distal tubules (DTs), but 
not proximal tubules (PTs), ensues postnatally. The pancreas remains intact throughout the 
lifespan. Pkhd1 mutants display negligible renal and pancreatic disease but show increased 
dilation in the renal DTs and pancreas in adult stages with heterozygous Pkd1 deletion; yet 
early-onset cystogenesis was not detected.
Methods: We performed genetic studies using Pkd1V and Pkhd1 mutant alleles to test 
for their interaction during development and the role of PC1 cleavage. To examine the 
role of Pkhd1 in the interaction, we analyzed biochemical, morphological and subcellular 
characteristics of mutant kidneys by western blot, scanning electron and immunofluorescent 
microscopy.
Results: When combined with Pkhd1 hypomorphic or null mutation, Pkd1V/V mice 
developed rapid renal cystic dilation, progressing from PTs to DTs, during embryonic 
development and die perinatally. Pancreas is also severely dilated with a single central 
lumen. Mitochondrial structural defects were observed in Pkhd1 mutant kidneys. A FC 
C-terminal fragment translocated into mitochondria in cultured renal epithelial cells.
Deleting this FC region caused PT cystic dilation and enhanced DT dilation in early
postnatal Pkd1V/V mice.
Conclusions: Pkhd1 inactivation triggers severe early-onset renal and pancreatic 
cystogenesis in the absence of PC1 cleavage. Pkd1 and Pkhd1 interact for regulating 
proper tubular structure of the two major organs during embryonic development. This 
interaction operates for uncleaved PC1 at a non-ciliary site and involves FC’s C-terminus. 
Pkhd1 mutation may confer a strong procystic state that significantly contributes to early-
onset kidney and pancreas disease through its C-terminus by a mitochondria-dependent 
mechanism.
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Mice Lacking Pkhd1 Exons 3-67 Develop Biliary but Not Renal 
Abnormalities
Luis F. Menezes,1 Fang Zhou,1 Mahiro Kurashige,1 Patricia Outeda,2 
Terry J. Watnick,2 Gregory G. Germino.1 1NIDDK, National Institute of Health, 
Bethesda, MD; 2University of Maryland School of Medicine, Baltimore, MD.
Background: Autosomal recessive polycystic kidney disease (ARPKD; OMIM 
263200) is caused by mutations in PKHD1 and is characterized by cysts/dilations in kidney 
collecting ducts, liver biliary cysts and portal fibrosis. While orthologous mouse models of 
ARPKD reproduce the liver phenotype, the kidney disease is mild, of low penetrance and 
strain-dependent. It was suggested that Pkhd1 alternative splicing could compensate for the 
lack of full-length Pkhd1. Here we tested if genomic deletion of most of the Pkhd1 locus 
could exacerbate the renal pathology.
Methods: We had previously generated two Pkhd1 mouse models: Pkhd1flox3-4, with 
loxP sites flanking exons 3-4; and Pkhd1flox67HA, with loxP sites flanking the last exon (67). 
We bred mice carrying Pkhd1del3-4/del67 alleles to Ddx4-Cre mice, a transgenic line with 
cre activity in embryonic germ cells of males and females. Starting with 6 independent 
Pkhd1del3-4/del67 vs. Ddx4-Cre crosses, we obtained 9 heterozygous Pkhd1del3-67 mutants, and 
started 4 independent founder lines, which were bred separately to homozygosis, generating 
a total of 28 Pkhd1del3-67/del3-67 (4 to 12 per founder) with overlapping phenotypes. Subsequent 
generations were allowed to interbreed across founder-lines. A total of 84 Pkhd1del3-67/del3-
67 were harvested between 30 and 440 days at approximately 10-day intervals, and two 
animals were allowed to age to 620 days. Animal body, liver and kidney weights were 
measured; kidneys and livers were visually inspected. In a subset of samples we measured 
eye weight and embedded kidney, liver and eyes for histological analysis.
Results: None of the animals had abnormal kidney size or macroscopic appearance, and 
histologic analysis confirmed absence of dilated tubules. In contrast, all analyzed animals 
had some degree of liver pathology, characterized by biliary cysts, duct proliferation and 
variable degrees of periportal fibrosis and cholangitis. Large coledochal and pancreatic 
cysts, and ascitis were occasionally observed. Additional phenotypes included ophthalmic 
pathology.
Conclusions: Compensation by alternative splice variants cannot explain the mild 
kidney phenotype in orthologous ARPKD mouse models. Further studies are required to 
determine if Pkhd1 or other sequences in the deleted genomic region are responsible for the 
additional unexpected phenotypes.
Funding: NIDDK Support
FR-PO988 Poster Friday
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Adult Inactivation of Pkhd1 Results in Liver Cysts in an ARPKD Mouse 
Model
Luis F. Menezes, Fang Zhou, Gregory G. Germino. NIDDK/NIH, Bethesda, MD.
Background: Autosomal recessive polycystic kidney disease (ARPKD; OMIM 
263200) is a severe disease of infancy and childhood caused by mutations in PKHD1. A 
common feature of both human disease and orthologous mouse models is biliary duct cysts 
with portal tract fibrosis, usually attributed to ductal plate malformation, a developmental 
disorder. According to this model, immature biliary ducts fail to remodel/involute during 
embryogenesis, leading to congenital fibrosis and biliary cysts. In this study we tested if 
adult loss of Pkhd1 could result in biliary cysts and portal fibrosis in mature livers.
Methods: The Pkhd1Tm1Ggg (Pkhd1flox3–4) mouse line was crossed to FLPeR mice 
expressing the FLP1 recombinase (stock 003946, Jackson Laboratories) to remove the 
neomycin cassette, since previous studies determined that uninduced mice developed liver 
lesions over time. The resulting Pkhd1delneo.flox3–4 was bred to C57/BL6 tamoxifen-Cre (stock 
004682, Jackson Laboratories). A set of 53 Pkhd1delneo.flox3–4 mice with or without transgene 
cre expression (cre negative: 8 females and 8 males; cre positive: 15 females and 22 males) 
was induced at 40 days of age by one intraperitoneal injection of 0.2 mg/g tamoxifen and 
harvested between ages 100 and 328. An additional set of 29 mice was aged without being 
induced with tamoxifen (cre negative: 4 females and 7 males; cre positive: 9 females and 
9 males). Animal body, liver and kidney weights were measured, and the kidney and livers 
were visually inspected. A subset of samples was embedded for histological analysis.
Results: Uninduced animals and induced cre negative mice had normal kidney and 
macroscopically normal liver morphology up to 300 days of age. Cre positive animals had 
enlarged livers with visible cysts starting on day 200 (n=7), progressively more affected 
with age. Expression of cre recombinase was a statistically significant determinant of liver 
cystic phenotype (p<0.001) in induced mice. No obvious kidney cysts were detected in 
any mice, and there was no statistical significance in kidney/body weight between induced 
animal with or without cre expression.
Conclusions: Adult inactivation of Pkhd1 mimics germline inactivation in causing 
an ARPKD liver phenotype in a mouse model. This suggests that additional mechanisms, 
independent of ductal plate remodeling and involution, may play a role in the ARPKD 
polycystic liver.
Funding: NIDDK Support
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Fibrocystin-Deficient MDCKII Cells: Defective Control of Cell Adhesion 
and Polarity Blocks Epithelial Morphogenesis
Wolfgang H. Ziegler, Birga Soetje, Lisa P. Marten, Ljupcho Fenov, 
Dieter Haffner. Hannover Medical School, Hannover, Germany.
Background: Mutations of the Pkhd1 genecause autosomal recessive polycystic 
kidney disease (ARPKD). Pkhd1 encodes fibrocystin/polyductin (FPC), a very large, ciliary 
type I membraneproteinof mostly uncharacterized function, which is suggested to affect 
adhesion signaling of cells. Contributions of altered epithelial cell interaction to the disease 
process of ARPKD are not understood. Here, we propose a model wherein inadequate 
control of cell adhesion and centrosome positioning prevent formation (and homeostasis) 
of correctly polarized epithelia.
Methods: Based on Pkhd1 silencing, we analyze FPC function in cells with renal 
collecting duct characteristics, Madin-Darby canine kidney cells (MDCKII). Cells are 
studied on micro-pattered chips in 3D cell culture conditions allowing analysis of polarity, 
lumen formation and ciliogenesis in epithelial spheroids. Quantitative automated image 
processing is applied to analyze z-stacks of 5-color fluorescence images. To determine 
critical differences in cell adhesion parameters, MDCK cells are studied also on chips in their 
1-/2-cell stages. Activation of adhesion signaling is addressed based on phosphorylation of 
the FAK/Src axis.
Results: Using defined adhesion conditions, we quantified the impact of FPC deficiency 
on size / density of adhesion sites, cell shape characteristics and initiation of an apical 
surface. Effects on apicobasal polarity and lumen formation correlate significantly with 
positioning of centrosomes in 1-/2-cell stages, and activation of adhesion signaling. FPC-
deficient cells reveal defects in the formation of correctly polarized epithelial spheroids, 
which are restored upon transient reduction of actomyosin contractility during the critical 
early phase of the morphogenesis assay.
Conclusions: Altered adhesion sensing and interaction of FPC-deficient epithelial 
cells lead to impaired epithelial morphogenesis and by implication homeostasis, which 
are suggested to lie at the heart of progressive epithelial defects in ARPKD. Closely 
controlled cell-based models with selective genetic alterations provide the means for a 
better molecular understanding and furthermore options to test pharmacological correction 
of epithelial defects.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO990 Poster Friday
PKD Cellular Pathogenesis, ARPKD, ADTKD, Ciliopathies
Nuclear Complexes Containing FPC-CTD/Mcm3/Mcm5/STAT1 Define a 
Myc-Regulatory Pathway in Mouse with Implications for Renal 
Cystogenesis
Santiago Cuevas,1 Chaozhe Yang,6 Naoe Harafuji,2 Maryanne Odinakachukwu,6 
Gregory G. Germino,5 Patricia Outeda,4 Terry J. Watnick,3 Lisa M. Guay-
Woodford.2 1Center for Transitional Science, Children’s National Health System, 
Washington, DC; 2Children’s National Health System, Washington, DC; 
3University of Maryland School of Medicine, Baltimore, MD; 4University of 
Maryland, Baltimore, MD; 5Deputy Director, NIDDK/NIH, Bethesda, MD; 
6Children’s National Medical Center, Bowie, MD.
Background: ARPKD (MIM 263200) typically results from mutations in PKHD1. 
The intracellular C-terminal domain (FPC-CTD), encoded by exon 67, undergoes regulated 
membrane-release (Kaimori, 2007). Using single particle EM, we have shown that affinity-
captured, natively-formed FPC-CTD nuclear assemblies integrate into DNA networks 
in ring-shaped structures reminiscent of known DNA-binding proteins (Harafuji, 2016). 
The current study was designed to examine FPC-CTD binding partners and their nuclear 
function.
Methods: Stable cell lines expressing V5-tagged FPC-CTD were generated; cell 
lysates fractionated on glycerol gradients; and immunoprecipitation (IP) were performed. 
Proteins were identified by mass spectrometry (IP-MS) and interactions confirmed by co-
IP. Kidneys from ARPKD patients as well as the Pkhd1cyli, Pkhd1del67, Pkhd1del3-67, Cys1cpk 
mouse models were examined by RT-PCR, immunohistochemistry, and IB. Chromatin 
immunoprecipitation (ChIP) and luciferase reporter assays were conducted using the Myc 
P1 promoter.
Results: IP-MS identified 34 proteins, including four members of the minichromosome 
maintenance protein complex (Mcm3, Mcm5, Mcm6, Mcm7). IP confirmed FPC-CTD-
Mcm3, FPC-CTD-Mcm5, and Mcm5-STAT1 interactions. In FPC-CTD stable cell lines, 
Myc is upregulated. FPC-CTD binds to the P1 promoter (ChIP) and enhances Myc P1 
promoter activity (luciferase assay). When compared to controls, we observed Myc 
overexpression in human ARPKD and Cys1cpk cystic kidneys, but not in Pkhd1cyli, Pkhd1del67, 
or Pkhd1del3-67 kidneys, none of which express cystic disease.
Conclusions: Trudel (2015) has proposed that Myc overexpression defines a causative 
pathway in renal cystic disease. In this study, we show that: 1) in vitro, FPC-CTD 
upregulates Myc expression; and 2) FPC-CTD nuclear complexes contain Mcm3/Mcm5. 
Mcm5 interacts with STAT1, which transcriptionally represses Myc expression (Ramana, 
2000). Our data suggest a reciprocal mechanism in which FPC-CTD activates, while STAT1 
represses Myc expression. This model may explain the lack of Myc upregulation in mouse 
kidneys with reduced or absent FPC-CTD. Given that the mouse and human FPC-CTD 
share only 41% identity, we speculate that there are species-specific differences in Myc 
translational regulation.
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Urinary Metabolic Profiling by NMR Spectrometry Associates with eGFR 
in a Cohort of Patients with ADPKD
Shosha E. Dekker,1 Aswin Verhoeven,2 Darius Soonawala,1 Oleg Mayboroda,2 
Johan W. De Fijter.1 1Nephrology, Leiden University Medical Center, Leiden, 
Netherlands; 2Center for Proteomics and Metabolomics, Leiden University 
Medical Center, Leiden, Netherlands.
Background: With the advent of therapeutic options to slow the rate of disease 
progression in patients with autosomal dominant polycystic kidney disease (ADPKD), 
there is an unmet need for biomarkers to select those at high-risk of rapid progression in 
the early stages of their disease. This study explored changes in the urinary metabolome 
associated with different chronic kidney disease (CKD) stages or estimated glomerular 
filtration rate (eGFR) in ADPKD, which is a first step towards identifying markers for early 
risk stratification.
Methods: Quantitative metabolic profiling (1H NMR-spectrometry) was performed 
on spot urine samples obtained from 338 ADPKD patients with various CKD-stages, 
84 healthy controls and 42 chronic, non-ADPKD, renal disease patients. Uni- and 
multivariate analyses were used to detect differences between the groups and associations 
between metabolic profiles and eGFR (CKD-EPI equation). Findings were validated in an 
independent cohort of 163 ADPKD patients.
Results: Twenty-nine urinary metabolites were quantified from the spectra. Logistic 
regression reliably distinguished ADPKD patients from healthy controls (AIC(DF 
30,392)=185.7, p=6×10-46, pR2=0.70; cross-validated AUC of 0.947 for CKD stage 1 in 
ADPKD). In patients with ADPKD, six metabolites were significantly decreased and 
seven significantly increased as compared to healthy controls, while metabolic profiling 
did not discriminate ADPKD from other renal diseases with comparable eGFRs. Sixteen 
metabolites correlated with eGFR in ADPKD patients, with the metabolite with the highest 
negative correlation having a pearson correlation coefficient of -0.72 (p=5×10-55) and the 
highest positive correlation of r=0.66 (p<2×10-16). A multiple linear regression model 
for eGFR was constructed based on all metabolite levels (F(30,308)=39.95; p=5×10-87, 
R2=0.79). A much simpler model, however, based on the ratio of the two metabolites with 
the highest correlation only also served as a good predictor for eGFR (F(2,336)=536.2; 
p=1×10-71, R2=0.615). Using the later model, the results were validated in a separate cohort 
(F(30,133)=6.293; p=6×10-14, R2=0.578).
Conclusions: Quantitative NMR profiling enabled identification of urinary metabolic 
markers that distinguished ADPKD patients from healthy controls and markers that were 
also significantly associated with eGFR.
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Kidney-Targeting Nanoparticles for Drug Delivery in Polycystic Kidney 
Disease
Eun ji Chung,1 Jonathan Wang,1 Hui Li,1 Kenneth R. Hallows.2 1University of 
Southern California, Los Angeles, CA; 2Keck School of Medicine of USC, Los 
Angeles, CA.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is 
characterized by progressive kidney cyst growth and leads to ESRD. Currently, one drug, 
tolvaptan has been recently FDA-approved to decrease cyst expansion, although repurposed 
drugs such as metformin and rapamycin used for diabetes and immunosuppression, have also 
been proposed. Unfortunately, these drugs suffer from short half-life, poor bioavailability, 
and adverse side effects. To mitigate these limitations, we describe the development of 
kidney-targeting multimodal micelles (KMs) that accumulate in the kidneys and can deliver 
therapy for ADPKD via oral administration.
Methods: KKEEE3K is synthesized on an automated peptide synthesizer, and 
conjugated to DSPE-PEG2000. Metformin, cy7, and peptide amphiphiles are purified by 
HPLC and mass spectrometry. Upon micelle construction, nanoparticles were characterized 
by dynamic light scattering, transmission electron microscopy (TEM), and zeta potential. 
To assess therapeutic efficacy in vitro, mouse cortical collecting duct cells were treated 
with metformin-KMs and AMPK activation measured by immunoblotting against phospho-
AMPK and ENaC current. Towards oral delivery of nanoparticles, KMs were encapsulated 
into chitosan nanocapsules to enhance mucoadhesion and passage through the GI tract.
Results: KMs and non-targeting (NT) micelles were found to have an average diameter 
of 15.0 and 12 nm, and zeta potential -7.8 and -1.4 mV, respectively. To test therapeutic 
effciacy, mouse cortical collecting duct cells incubated with 300 uM metformin-KMs 
showed enhanced activation of phospho-AMPK and decreased ENaC current compared 
to metformin-NT micelles or free metformin. Chitosan nanocapsules were developed by 
ionic gelation using sodium tripolyphosphate. TEM images showed chitosan particles 
were between 20-150 nm in diameter, which is large enough to encapsulate KMs. Current 
work includes investigating additional factors affecting chitosan particle size, stability, and 
mucoadhesive strength, such as deacetylation, molecular weight, and tri-methylation of 
chitosan, and assessing metformin-KM release kinetics, adhesion to CaCo-2 cells, and in 
vivo therapeutic studies in ADPKD mouse models.
Conclusions: Our approach is the first nanomedicine effort for ADPKD and will 
provide many new insights as well as potentially establish a novel therapeutic for ADPKD.
Funding: Other NIH Support - NHLBI, R00HL124279-01A1
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Kidney-Specific Targeting Using PLGA Nanoparticles in Polycystic 
Kidney Disease Mice
Yasin Oduk,1 Jifeng Huang,2 Lan He,2 Takamitsu Saigusa.2 1Biomedical 
Engineering, University of Alabama at Birmingham, Birmingham, AL; 2Medicine/
Nephrology, University of Alabama at Birmingham, Birmingham, AL.
Background: Drugs that slow cystogenesis in murine models may not show similar 
results in clinical trials, possibly due to the smaller dose used in humans to avoid systemic 
side effects. One way to improve the efficiency of the drugs in the kidney, without 
increasing the drug dose/risk for adverse effects, is kidney-specific drug delivery. Polymeric 
nanoparticles (NP) can encapsulate drugs and they are small enough in size which can freely 
filter through the glomerulus and be reabsorbed in the tubules, without potentially being 
taken up by extra-renal organs. The purpose of this study is to determine the bio distribution 
of NP in polycystic kidney disease (PKD) mouse.
Methods: Fluorescent coumarin-6 encapsulated poly(lactic-co-glycolic acid) (PLGA) 
biodegradable polymer nanoparticles were prepared by a double emulsion method with an 
average size of 124 ± 26nm, confirmed by scanning electron microscopy (SEM). PLGA-
NP was administered via tail vein injection at the concentration of 50mg/kg to adult Pkd1 
mice with moderate kidney cyst formation and control mice with no kidney cyst. Mice were 
sacrificed at 1, 4, 24, 48 and 72 hours after injection. Kidney, liver, heart, lung, and spleen 
were harvested and fixed for immunofluorescence and transmission electron microscopy 
(EM).
Results: Kidneys from both PKD and control mice revealed strong green fluorescent 
staining in the proximal tubules and in the arterial endothelium at 1 to 4 hour after injection, 
retaining its fluorescence at 24 hours and fading at 72 hours. There was PLGA-NP uptake in 
kidney cystic structures for both proximal and distal tubular cysts. PLGA NPs were present 
in the liver, heart, lung, and spleen early after the NP injections (1 to 4 hours) but diminished 
over time. The overall intensity of NP’s in the extrarenal organs were significantly lower 
compared to the kidney. EM of kidney harvested at 24 hours revealed an intact NP structure 
in the cytosolic compartment of the tubular epithelium.
Conclusions: PLGA-NP in PKD mice were predominantly reabsorbed in the kidney 
tubules and cystic epithelia compared to extra-renal organs including the liver. PLGA-NP 
may have a role in kidney-specific drug delivery in PKD.
Funding: NIDDK Support
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A Bioinformatics Analysis of Gene Expression in Experimental Alport 
Syndrome Reveals an Fstl1 Signature in the Kidney
Nicholas Maksimowski,1 Xuewen Song,1 Eun Hui Bae,2 York P. Pei,3 
James W. Scholey.1 1University of Toronto, Toronto, ON, Canada; 2Chonnam 
National University Hospital, Gwangju, Republic of Korea; 3University Health 
Network and University of Toronto, Toronto, ON, Canada.
Background: Alport syndrome (AS) is a rare inherited form of chronic kidney disease 
characterized by progressive nephropathy and the development of end stage renal disease. 
It is caused by mutations in the Col4a3, Col4a4, and Col4a5 genes. The goal of my studies 
is to better understand the pathogenesis of AS in the kidney.
Methods: We performed studies using a well-characterized experimental murine model 
of AS. Global gene expression profiling of renal cortical mRNA samples was performed 
in male Col4a3-/- mice and Col4a3+/+ control mice at 4 and 7 weeks of age to identify 
early differentially expressed genes. We performed a cluster analysis and constructed a heat 
map on the microarray studies at 4 and 7 weeks of age. Studies using HK2 cells were 
conducted to analyze inflammation and apoptosis related to a protein of interest and its 
cognate receptor. Finally, using a transgenic mouse model with a reduction in our protein of 
interest we performed UUO at 7 weeks of age.
Results: The microarray analysis revealed that only 5 genes were differentially 
expressed in the kidneys of male Col4a3-/- mice at 4 weeks of age compared to Col4a3+/+. 
Amongst these genes was Follistatin-related protein 1 (FSTL1). We used search tool for the 
retrieval of interacting genes/proteins to predict protein-protein interactions (PPIs) thereby 
identifying a functional protein association network for FSTL1. The network included 39 
proteins. Cluster analysis of the cognate genes from the FSTL1 protein network showed 
marked upregulation of gene expression at 7 weeks of age. FSTL1 increased NFκB 
mediated luciferase activity, caspase 3 activation and PARP cleavage in HK2 cells. These 
effects were due, at least in part to TLR4 receptor activation. The RT-qPCR analysis of 
mice that were subjected to UUO surgery showed an increase in FSTL1 expression as well 
as an increase in the expression of FSTL1’s cognate receptors compared to sham controls.
Conclusions: Our microarray and bioinformatics analyses identified early upregulation 
of FSTL1 in the kidneys of Col4a3-/- mice. A FSTL1 gene signature, based on predicted 
PPIs, emerged in the kidneys by 7 weeks of age. FSTL1 elicited an inflammatory response 
and activated apoptosis in HK2 cells. These findings support the hypothesis that FSTL1 
may be a novel determinant of kidney injury in mice with experimental AS.
FR-PO995 Poster Friday
Genetic Diseases of the Kidneys: Non-Cystic - II
Sparsentan, a Dual Angiotensin II Type 1 (AT1) and Endothelin Type A 
(ETA) Receptor Antagonist, Prevents Renal Disease in COL4A3 
-/- Autosomal Alport Mice
Dominic E. Cosgrove,1 Brianna M. Dufek,1 Duane C. Delimont,1 
Daniel T. Meehan,2 Gina C. Samuelson,1 Kai Liu,3 Celia P. Jenkinson,3 
Bob Armstrong,3 Radko Komers.3 1Boys Town National Research Hospital, 
Omaha, NE; 2Boys Town National Research Hospital, Omaha, NE; 3Retrophin, 
Inc., Portland, OR.
Background: Strain-mediated induction of endothelin (ET-1) in glomerular endothelial 
cells activates ETA receptors on mesangial cells, initiating invasion of glomerular capillaries 
by mesangial filopodia. The filopodia deposit matrix in the glomerular basement membrane 
resulting in stimulation of NFκB activity in podocytes and expression of pro-inflammatory 
cytokines, culminating in glomerulosclerosis and interstitial fibrosis. Both ETA receptor 
blockade and angiotensin-converting enzyme (ACE) inhibition have been shown to 
ameliorate these events in Alport mice. Therefore, we explored the ability of sparsentan to 
improve nephropathy in this model.
Methods: Alport mice were treated once daily with sparsentan (60 or 200 mg/kg given 
orally; n=3–4/group) or vehicle (n=4) from 3–7 weeks of age. Blood pressure (BP) and 
urinary protein/creatinine ratio (UP/C) were determined at the end of the study, together 
with determination of fibronectin and collagen 1 protein (COL1) immunohistochemistry 
(IHC) in kidney sections as an assessment of glomerulosclerosis and tubulointerstitial 
fibrosis.
Results: BP was not significantly different in Alport mice treated with sparsentan 
compared to vehicle at 7 weeks of age. Sparsentan led to significantly lower UP/C (60 mg: 
5.6±3.0 mg/mg, n=4, P<0.05; 200 mg: 0.8±1.4 mg/mg, n=3, P<0.01) compared to vehicle-
treated Alport mice (34.1±17.4 mg/mg, n=4). The percentage of sclerotic glomeruli, 
determined from fibronectin IHC was lower (P<0.01) in Alport mice that received 
sparsentan at 60 mg/kg (3.5±1.6%) or 200 mg/kg (1.4±1.3%) compared to vehicle-treated 
mice (39.0±19.5%). COL1 immunoreactivity was absent in sparsentan-treated Alport mice, 
similar to wild-type mice. In contrast, vehicle-treated Alport mice had a COL1 score of 
2.5±0.6 (arbitrary units).
Conclusions: This preclinical study demonstrates that sparsentan, a dual ETA and 
AT1 receptor antagonist provides nephroprotection in Alport mice, in both glomerular and 
tubulointerstitial compartments. A further preclinical study is under way to explore the 
activity of sparsentan compared with ACE inhibition, the current standard of care in Alport 
renal disease.
Funding: Commercial Support - Retrophin, Inc., San Diego, CA
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Transcriptome-Based Discovery of Lysine Deacetylase Inhibition as a 
Novel Treatment Approach to Alport Syndrome
Vanessa R. Williams,1 Ana Konvalinka,2,1 Xuewen Song,2 Rohan John,2,1 
York P. Pei,2,1 James W. Scholey.2,1 1University of Toronto, Toronto, ON, Canada; 
2University Health Network, Toronto, ON, Canada.
Background: Alport syndrome (AS) is a hereditary progressive disorder caused by 
mutations in type IV collagen genes. It is characterized by early proteinuria and activation 
of the renin-angiotensin system (RAS). Few effective treatment approaches to AS are 
currently available. Therefore, we applied a drug repurposing strategy to examine a novel 
therapy.
Methods: RNA expression profiling of kidney cortices from Col4a3–/– (KO) and wild-
type (WT) mice on a 129/SvJ background was performed at 4 and 7 weeks of age. A disease 
progression signature composed of differentially expressed genes was used to query the 
Connectivity Map (CMAP). CMAP identified vorinostat, a lysine deacetylase inhibitor, as 
a potential therapy. KO mice were treated with vorinostat (50 mg/kg/day in DMSO by oral 
gavage) from 4 to 7 weeks of age. Mice were euthanized at 7 weeks of age for kidney function, 
structure, inflammation, and fibrosis analyses. Separate groups were followed for assessment 
of lifespan. Finally, angiotensin II-stimulated human proximal tubule epithelial (HK-2) cells 
were treated with vorinostat (5 μM) and used to assess mechanisms of drug action.
Results: Vorinostat increased the acetylation of lysine in the kidney. This was associated 
with a significant increase in survival (n = 19/group) and a trend toward decreased serum 
creatinine and proteinuria (n = 6-10/group). Vorinostat had no effect on glomerulosclerosis, 
but significantly reduced urinary excretion of NGAL, a marker of tubular injury. mRNA 
for cytokines and kidney injury markers including Fn1, Havcr1, and Tnf were reduced in 
the kidneys of treated mice (n = 6/group). Kidney tissue protein analysis showed lowered 
αSMA and proinflammatory cytokine expression. Pilot mechanistic studies revealed that 
vorinostat exerts its beneficial effects, at least in part by, dampening mitogen-activated 
protein kinase (MAPK) signaling and subsequent activator protein 1 (AP-1) transcription 
factor activation.
Conclusions: CMAP analysis identified vorinostat as a novel therapy for AS. Testing 
of the putative therapy showed that it exerts renoprotective effects and extends the lifespan 
of KO mice. Future studies will provide more insight into the molecular mechanisms 
of vorinostat through assessment of lysine acetylation, and MAPK and AP-1 signaling 
pathways in the progression of AS nephropathy.
Funding: Government Support - Non-U.S.
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Urine and Blood Biomarkers Correlate with Rate of eGFR Decline in 
Alport Syndrome
Michelle N. Rheault,1 Oliver Gross,2 Bertrand Knebelmann,4 James F. Simon,3 
Jale Guner,5 Mark Deeg,5 Clifford E. Kashtan.1 1University of Minnesota, 
Minneapolis, MN; 2University Medicine Goettingen, Goettingen, Germany; 
3Cleveland Clinic, Cleveland, OH; 4Necker Hopsital, Paris, France; 5Regulus 
Therapeutics, San Diego, CA.
Background: Alport syndrome (AS) is a genetic condition leading to progressive 
glomerular disease and hearing loss in many affected individuals. This natural history study 
was performed to identify novel predictors of kidney function decline in patients with AS 
in order to populate future clinical trials with individuals at greatest risk of progressive 
kidney disease.
Methods: ATHENA (NCT02136862) was a non-interventional, global, multicenter 
study enrolling patients with CKD due to AS. Urine and plasma renal biomarkers and 
estimated GFR (eGFR) were assessed at baseline and every 12 weeks thereafter for up 
to 2 years. Pearson correlations of the GFR slope (provided at least 3 time points) with 
each baseline biomarker were derived. Statistical significance was based on FDR adjusted 
p-value <0.02.
Results: 165 individuals were enrolled (33.9% male, 64.8% X-linked, age mean 44.8
years, 83% white). Baseline mean eGFR was 63.9 (SD 21.6) ml/min/1.73m2 and 24 urine 
protein was 1844mg (SD 2608). The median slope of eGFR was -2.35 ml/min/year. Higher 
serum albumin, protein, and CO2 correlated with a less negative slope of decline in eGFR. 
Higher urine albumin/cr ratio, urine protein/cr ratio, chloride, cholesterol, LDL cholesterol, 
and NGAL correlated with a more negative slope of decline in eGFR.
Conclusions: A number of urine and blood biomarkers correlate with short term rate of 
decline in eGFR in patients with AS. Multivariable models to predict slope of GFR decline 
using demographic and baseline biomarker data are in progress.
Funding: Commercial Support - Regulus Therapeutics
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Glomerular Endothelial Cell Identity and Contribution to CKD in Alport 
Syndrome
Sargis Sedrakyan,1,2 Hasmik Soloyan,1 Valentina Villani,1 Matthew E. Thornton,2 
Laura Perin.3 GOFARR laboratory for organ regenerative research and cell 
therapeutics 1Children’s Hospital Los Angeles, Los Angeles, CA; 2University of 
Southern California, Los Angeles, CA; 3Childrens Hospital Los Angeles, Los 
Angeles, CA.
Background: Many studies suggest that glomerular endothelial cell (GEC) injury 
plays a key role in the development of chronic kidney disease, but whether they contribute 
to pathogenesis and progression of Alport syndrome (AS) is not clearly established. In AS, 
a hereditary CKD characterized by the mutations in the collagen IVα3α4α5 protein, the 
major constituent of the glomerular basement membrane (GBM), we found morphological 
and biological alterations in GEC very early during disease progression and before the onset 
of heavy proteinuria. Thus, we hypothesized that in our model of CKD, GEC damage plays 
a key role.
Methods: To investigate our hypothesis we generated GEC specific (Tek-Cre driven) 
tdTomato reporter AS mice, harvested their glomeruli by the sieving method and isolated 
GEC by FACS. GEC were characterized and studied by flow cytometry analysis, PCR and 
WB at different time points along disease progression. GEC transcriptome profiling was 
performed by NGS on Illumina HiSeq 4000 and further analyzed by alignment of reads to 
Genecode M16 mouse genome. Differential gene expression analysis was performed post 
RUV normalization by BIOBASE and Ingenuity Pathway Analysis tools.
Results: We identified two unique subsets of endothelial cells within the glomerulus of 
WT mice, and for the first time also in AS mice, which might present different functional 
roles during AS progression. We showed a significant increase in endothelial fenestration 
size, loss of glycocalyx integrity and alteration of VEGF signaling in GEC, early during 
progression and before the onset of proteinuria in AS mice. In addition, we identified 
differentially expressed genes involved in the angiogenic, stress response and metabolic 
regulatory pathways such as VEGF, PPAR, and FATp4.
Conclusions: In sum, our data indicate that GEC injury is an important early event that 
sets the stage for further progression and onset of proteinuria in Alport mice. Characterization 
of the transcriptional profile of GEC in AS mice could lead to the development of targeted 
new therapies for the treatment of CKD.
Funding: Private Foundation Support
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Factors Regulating the Severity in Male X-Linked Alport Syndrome: 
Study of 367 Cases
Tomohiko Yamamura,1 Kandai Nozu,1 China Nagano,1 Tomoko Horinouchi,1 
Keita Nakanishi,1 Shogo Minamikawa,1 Hiroshi Kaito,1 Yuko Shima,2 
Koichi Nakanishi,3 Kazumoto Iijima.1 1Kobe University Graduate School of 
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Background: X-linked Alport syndrome (XLAS) is a hereditary disease caused by 
mutations of COL4A5 gene. Affected males generally develop end-stage renal disease 
(ESRD) in early or middle adulthood. It has been reported some factors such as genotype or 
ACEI treatment affect renal prognosis. However, comprehensive analysis for the influence 
of factors regulating the severity using large-scale data has not been reported.
Methods: We conducted a retrospective study of 367 male patients in 231 families 
who were genetically diagnosed with XLAS at our institute. We collected clinical data 
from medical records and constructed renal survival curve. These curves were compared 
depending on the following differences in clinicopathological or genetic features; presence 
of hearing loss, findings of α5 staining positivity on glomerular basement membrane, 
treatment with ACEI/ARB and genotype. Regarding genotype, renal survival curve was 
constructed on not only each mutation type but also dividing all genotypes into two groups 
of truncating and non-truncating variants.
Results: The median age of our cohort was 12yrs. 149 cases reached ESRD and the 
median renal survival period was 33yrs. Ocular changes were detected in 6.1% and hearing 
loss was 34%. There was a significant difference in the median renal survival period 
between cases with (27yrs, n=94) and without hearing loss (55yrs, n=134) (P=0.0116), 
α5 staining positive (>60yrs, n=54) and negative (28yrs, n=75) (P=0.0052), treated by 
ACEI/ARB (43yrs, n=112) and not treated (28yrs, n=72) (P=0.0079). The median renal 
survival period of each mutation type was 18yrs (nonsense mutation, n=29), 21yrs (large 
rearrangement, n=14), 25yrs (splicing variant, n=57), 26yrs (small rearrangement, n=62) 
and 40yrs (missense mutation, n=196). In addition, there was a significant difference 
between cases with truncating (20yrs, n=102) and non-truncating variants (39yrs, n=241) 
(p<0.0001).
Conclusions: It was shown that the renal prognosis of male XLAS was regulated 
by various factors. In particular, treatment with ACEI/ARB dramatically improved renal 
prognosis. In addition, we also showed that the strong genotype-phenotype correlation was 
observed not only among mutation types but also, and for the first time, between cases with 
truncating and non-truncating variants.
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Angiotensin-(1-7) Attenuates Renal Injury in Experimental Alport 
Syndrome
Hong sang Choi,1 Chang Seong Kim,1 Seong Kwon Ma,1 Soo Wan Kim,1 
James W. Scholey,2 Eun Hui Bae.1 1Chonnam National University Medical 
School, Gwangju, Republic of Korea; 2University of Toronto, Toronto, ON, 
Canada.
Background: Angiotensin-(1–7) [Ang-(1–7)] antagonize the actions of the renin-
angiotensin-aldosterone system via the Mas receptor and thereby has a renoprotective 
effects. Previously, murine recombinant angiotensin-converting enzyme (ACE) 2 has been 
reported to have renoprotective effects in experimental Alport syndrome but the effect of 
direct administration of Ang-(1-7) has not been studied.
Methods: To examine the effects of Ang-(1-7) on Alport syndrome, Col4a3 knockout 
mice, a model of Alport syndrome were used. Mice were divided into three groups: saline-
treated wild type mice group, saline-treated Col4a3 knockout mice group, and Ang-(1-7) 
treated Col4a3 knockout mice group. Ang-(1–7) was continuously infused (25 μg/[kg×h]) 
using osmotic mini-pumps.
Results: Col4a3 knockout mice revealed increased α-smooth muscle actin (SMA) 
and fibronectin expression which attenuated by Ang-(1-7) treatment. Messenger RNA 
(mRNA) expression of α-SMA, fibronectin and Collagen I were suppressed by Ang-(1-7) 
treatment. Ang-(1-7) treatment alleviated the transforming growth factor (TGF)-β/Smad 
signaling. Ang-(1-7) attenuated protein expression of ED-1 and heme oxygenase-1, 
indicating the attenuation of renal inflammation. mRNA expression of inflammatory 
cytokine, TNF-α, MCP-1 and adhesion molecule ICAM-1, VCAM-1 were also decreased 
by Ang-(1-7) treatment. The ratio of cleaved caspase 3 to caspase 3 was increased in 
Col4A3 knockout mice kidney which was decreased by ang-(1-7) treatment, indicating 
attenuation of apoptosis by ang-(1-7). Lastly, ang-(1-7) influenced the alter the ACE2-Ang-
(1-7)-Mas receptor axis, as it downregulated angiotensin-1 receptor and upregulated ACE2 
and Mas receptor.
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Conclusions: Thus, treatment with ang-(1-7) alter the ACE2-Ang-(1-7)-Mas receptor 
axis in the kidneys of Col4a3 knockout mice and attenuates the progression of Alport 
syndrome nephropathy.
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Quality of Life Changes as Measured with SF-36 in Patients with Alport 
Syndrome: Results from the ATHENA Natural History Study in Alport 
Syndrome Patients
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San Diego, CA.
Background: Alport Syndrome (AS) is a rare genetic disorder caused by mutations in 
genes coding for type IV collagen (COL4) α3, α4 and α5 proteins leading to hematuria, 
renal failure, hearing loss and eye involvement. CKD is associated with progressively worse 
quality of life (QOL) scores. The presence of a progressive genetic disease can also impact 
QOL. QOL in patients with AS has not previously been reported.
Methods: ATHENA (NCT02136862) was an international multi-center observational 
cohort study designed to characterize the progression of renal dysfunction in subjects 
with AS. Patients were followed for up to 24 months with serial evaluations. An SF-36 
questionnaire was completed at baseline and every 24 weeks. The change in SF-36 score 
over time was modeled using mixed model repeated measures. The models incorporated 
baseline score, time in weeks, and subgroup indicators.
Results: 165 patients were enrolled. The study population is described elsewhere. For 
the entire cohort, the baseline score for physical component summary was 52.5; mental 
component summary was 49.7. Five domains decreased (p<0.05) during the study: general 
health, role limitations due to physical health, mental health, role limitations due to 
emotional problems and social functioning. The mental component summary was lower in 
females, those with X-linked mutations, and eGFR>60ml/min/1.73m2. These three groups 
were more likely to have domain scores decrease with time. The only significant domain 
difference between subgroups was general health which was lower in females and those 
with eGFR>60 ml/min/1.73m2.
Conclusions: In patients with AS, QOL scores using the SF-36 are low and decrease 
with time. Lower baseline eGFR is associated with lower QOL. Women, those with 
X-linked mutations and with eGFR>60 ml/min/1.73m2 showed significantly greater 
decreases in QOL scores over time.
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Identification of Novel Secretion-Defective Mutations of Type IV Collagen 
α5 Genes by Split NanoLuc-Based α345(IV) Trimer Formation Assay
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Kandai Nozu,2 Kazumoto Iijima,2 Hirofumi Kai.1,4 1Kumamoto University 
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Background: Alport syndrome (AS) is a hereditary glomerular disease caused by a 
mutation in type IV collagen α3, α4, or α5 (α3/α4/α5(IV)), components of the glomerular 
basement membrane (GBM). Several hundred different mutations have been found in AS 
patients and the phenotype differs depending on the mutation. Generally, immunostaining 
of renal biopsy specimens for type IV collagen is useful for predicting prognosis; however, 
its invasiveness and incompleteness on the prediction accuracy are clinically problematic. 
Here, by utilizing the cell-based system to assess α345(IV) trimer formation (Omachi K., 
et al., Cell Chemical Biology 2018), we evaluate the capability of α345(IV) trimer 
formation of several α5 missense mutants that are clinically relevant but poorly understood.
Methods: Split nanoLuc-fusion α3/ α5 and α4 were transfected into HEK293T cells, 
and luminescence was assessed in the cell lysate for intracellular trimer and in culture media 
for secreted trimer. Scatterplot analysis of the intracellular/secreted RLU ratio from cells 
expressing the WT or several α5 missense mutants classifies the character of mutants.
Results: Trimer formation assay revealed that G509R, G805R, G953V, G1000V, 
G1030S, G1140V, G1143S α5 mutants have normal properties of intracellular trimerization 
(>98%) and extracellular secretion (>65%). Scatterplot analysis showed that most of the 
mutants (G509R, G805R, G953V, G1143S) with mild phenotype (no obvious proteinuria) 
showed the similar pattern as the WT, while some mutants (G1000V, G1030S, G1140V) 
exhibited secretion-dependent defect. Particularly, G1140V with severe phenotype (obvious 
proteinuria) showed significantly increased intracellular accumulation of trimer (>130%).
Conclusions: Trimer formation assay reveals that three α5 mutants (G1000V, G1030S, 
G1140V) had defect in secretion. Because patient with G1140V mutation had relatively 
severe clinical phenotype, our system may, at least in part, reflect genotype-phenotype 
correlation. Further phenotypic characterization would also be needed for G1000V and 
G1030S mutations. Moreover, because adjacent mutations G1140V and G1143S had severe 
and mild phenotypes, respectively, structure and molecular bases on differential phenotypes 
is now under investigation.
Funding: Government Support - Non-U.S.
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Human NOS1AP Recessive Mutations Impair Podocyte Filopodia 
Formation and Cell Migration and Cause Steroid-Resistant Nephrotic 
Syndrome Through CDC42 Dysregulation
Amar J. Majmundar,1 Verena Klambt,1 Ronen Schneider,1 Thomas Kitzler,1 
Eugen Widmeier,1 Daniela A. Braun,1 Shirlee Shril,1 Neveen Soliman,2 
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Background: Steroid resistant nephrotic syndrome (SRNS) is the second leading cause 
of chronic kidney disease in the first three decades of life. Mutations in >39 genes provide a 
monogenic cause in up to 29.5% of SRNS cases (JASN 26:1279, 2015) with defined patho-
mechanisms (NDT 31:1802, 2016) including dysregulation of the small GTPase CDC42 
(Ashraf Nat Commun 2018, in press).
Methods: Whole exome sequencing (WES) was performed in ~500 SRNS subjects 
to discover a novel genetic cause. IF was performed on rat kidney sections. In a human 
podocyte cell line, we performed active-CDC42 ELISA, live cell imaging as well as 
shRNA-mediated downregulation and cDNA over-expression of NOS1AP.
Results: We identified homozygous recessive mutations in 2 unrelated children with 
SRNS in NOS1AP (c.428G>A; p.C143Y and c.345-3T>G; p.I116Afs*4). NOS1AP encodes 
an adaptor protein that interacts with nitric oxide synthase (NOS) and with NOS effectors 
through its phospho-tyrosine binding domain (PTB) (Neuron 28:183, 2000). The C143 
residue within the PTB is conserved to C. elegans and in 85/101 human PTB sequences and 
registered strong in silico conservation scores. The c.345-3T>G coding change is predicted 
to reduce splicing, cause skipping of exon 5, and result in the truncation p.I116Afs*4. Both 
mutations are not observed, even heterozygously, in the gnomAD Genome Aggregation 
Database. NOS1AP is expressed selectively in podocytes, not endothelial or mesangial 
cells, of rat kidney glomeruli. Transfection of wild-type NOS1AP induced filopodia in 58% 
of immortalized human podocytes, while NOS1AP constructs containing SRNS subject 
mutations failed to generate filopodia. NOS1AP shRNA-mediated knockdown reduced 
podocyte migration. This was rescued by wild-type NOS1AP over-expression but not by 
NOS1AP mutants. Active CDC42 levels, which promote filopodia and migration (Curr 
Opin Cell Biol 36:103, 2015), were induced by wild-type NOS1AP but not by patients’ 
mutants. Induction of filopodia by NOS1AP over-expression was inhibited by CDC42 
chemical inhibitor CASIN.
Conclusions: We discovered recessive NOS1AP mutations as a novel monogenic cause 
of SRNS, leading to podocyte dysfunction through CDC42 dysregulation.
Funding: NIDDK Support, Private Foundation Support
FR-PO1004 Poster Friday
Genetic Diseases of the Kidneys: Non-Cystic - II
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Renoprotective Effect in a Podocyte-Specific Coq8b-Knockout Mouse 
Model of Nephrotic Syndrome
Eugen Widmeier,1,2 Makiko Nakayama,1 Hannah Hugo,1 Seyoung Yu,5 Heon 
Yung Gee,4 Friedhelm Hildebrandt.3 1Boston Children’s Hospital, Harvard 
Medical School, Boston, MA; 2Department of Nephrology, University of 
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Brookline, MA; 4Yonsei University College of Medicine, Boston, Republic of 
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Background: Steroid resistant nephrotic syndrome (SRNS) inevitably progresses to 
end-stage renal disease (ESRD) within the first three decades of life, requiring dialysis or 
transplantation for survival. Human mutations in the COQ8B gene (known also as ADCK4 
- aarF domain containing kinase 4) cause SRNS (Ashraf JCI 123:5179, 2013). To study
the function of COQ8B in podocytes we generated a podocyte specific Coq8b-knockout 
mouse model
Methods: Nphs2.Cre mice were crossed with Coq8blox/lox mice, to generate podocyte 
specific Coq8b knockout mice (Coq8bΔPodocyte) on a C57BL/6 background. Treatment with 
2,4-dihydroxybenzoic acid (2,4-diHB) at 25 mM in the drinking water was started at 3 
months of age. Kidneys were harvested for histological and ultrastructural analysis at 9 
months in the untreated cohort and at 13 month in the cohort under treatment. Blood and 
urine were collected monthly for metabolic studies
Results: Coq8bΔPodocyte mice displayed onset of proteinuria at 4 months. Non-treated 
Coq8bΔPodocyte mice displayed a significant reduction in survival (40% alive) being moribund 
at 12 months of age progressing to ESRD (n=15). In contrast, Coq8bΔPodocyte mice treated 
with 2,4-diHB (n=12) showed significantly improved survival (100% alive), comparable to 
their untreated Coq8bΔPodocyte and wild type littermates. Histological analysis of Coq8bΔPodocyte 
kidneys at 9 months demonstrated severe global and focal segmental glomerular sclerosis 
(FSGS) with extensive interstitial fibrosis and tubular atrophy. Electron microscopy studies 
revealed severe foot process effacement and disturbed podocyte cell morphology. In 
contrast, treatment of Coq8bΔPodocyte mice with 2,4-diHB significantly reduced the levels of 
proteinuria and prevented the development of FSGS as well as foot process effacement 
maintaining normal renal function in treated mice at 13 months (n=12)
Conclusions: Our data demonstrate that 2,4-diHB, metabolite that functions to bypass 
the hydroxylation step mediated by Coq7 of the CoQ10 biosynthesis pathway efficiently 
ameliorates proteinuria and prevents FSGS in Coq8bΔPodocyte mice. Further, our study reveals 
a potential novel treatment option in 2,4-diHB for human SRNS caused by dysfunction in 
the CoQ10 biosynthesis pathway
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GAS2L2 as a Candidate Gene for Nephrotic Syndrome
Eugen Widmeier,1 Hannah Hugo,2 Shirlee Shril,3 Friedhelm Hildebrandt.2 
1Boston Children’s Hospital, Harvard Medical School, Boston, MA; 2Boston 
Children’s Hospital, Boston, MA; 3Boston Childrens Hospital, Boston, MA.
Background: Steroid resistant nephrotic syndrome (SRNS) inevitably progresses to 
end-stage renal disease (ESRD) within the first three decades of life requiring dialysis or 
transplantation for survival. To date discovery of more than 50 different monogenic causes 
of SRNS has helped to elucidate the pathogenesis of SRNS.
Methods: To identify novel mongenic causes of NS, we performed whole exome 
sequencing, homozygosity mapping, and targeted exon sequencing. To investigate 
molecular mechanisms of a newly identified monogenic cause of NS in vitro, we generated 
immortalized human podocyte cell lines with stable knockdown of the GAS2L2 gene.
Results: By next-generation sequencing, we identified a homozygous recessive 
missense mutation in a region of high evolutionary conservation (Drosophila melanogaster) 
within the GAS2 domain of GAS2L2 gene (c.817C>T, p.Arg273Cys) in a patient with early 
onset NS. GAS2L2 is a known linker between actin filaments and microtubules. We show 
that GFP-GAS2L2 localizes to the cytoskeleton filaments and that knockdown of GAS2L2 
results in severe defect of podocytes migration rate.
Conclusions: We discovered a recessive mutation of GAS2L2 as a likely novel 
monogenic cause of early-onset SRNS. We propose that the disease phenotype is caused by 
defect of crosstalk between actin filaments and microtubules.
Funding: Other NIH Support - DK076683
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Recessive Mutations in the Kirrel Gene in Human Nephrotic Syndrome 
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Martin Helmstädter,4 Pankaj Srivastava,1 Kenneth Kwon,1 Shirlee Shril,2 
Carsten Bergmann,3 Tobias B. Huber,3 Friedhelm Hildebrandt,2 Deepak Nihalani.1 
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Freiburg, Germany.
Background: Steroid-resistant nephrotic syndrome inevitably progresses to end-stage 
renal disease within the first three decades of life requiring dialysis or transplantation for 
survival. Podocyte proteins Neph1 and Nephrin form a critical structural framework of a 
functional glomerular filtration barrier. While many mutations in the Nephrin gene have 
been described, there are no reports of human mutations in the Neph1/Kirrel gene associated 
with the NS.
Methods: To identify novel monogenic causes of NS, we performed whole exome 
sequencing. To investigate the molecular mechanisms of a newly identified monogenic 
cause of NS in vitro we generated stable podocyte cell lines expressing human wild-type 
and mutant Neph1. IF studies were performed for localization defects for Neph1 mutants. 
Neph1 knockdown in podocytes using specific shRNA was performed to evaluate the effect 
of Neph1 depletion on cell proliferation and migration.
Results: Using next-generation sequencing, we identified two homozygous recessive 
missense mutations in two unrelated families with NS, which were in a region of high 
evolutionary conservation (Danio rerio). Immunofluorescence studies revealed that unlike 
WT Neph1, both Neph1 mutants failed to localize at the podocyte cell membrane (Fig 1). 
Additionally, we find an increased accumulation of these proteins in endosomes suggesting 
defective localization, which may contribute to the disease phenotype. Further, these mutant 
cell lines formed impaired tight junctions as evaluated by the permeability assay using 
labeled BSA.
Conclusions: This is the first report showing mutations in the Kirrel gene in FSGS 
patients.
Funding: NIDDK Support
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Mutations of NEK3, PREX1, or TIAM1 Are Novel Causes of Nephrotic 
Syndrome
Shazia Ashraf,1 Heon Yung Gee,2 Youying Mao,1 Tilman Jobst-Schwan,1 
Shirlee Shril,1 Friedhelm Hildebrandt.1 1Div of Nephrology, Boston Children’s 
Hospital, Harvard Medical School, Boston, MA; 2Dept of Pharmacology, Yonsei 
University College of Medicine, Seoul, Republic of Korea.
Background: Nephrotic syndrome (NS) is a heterogeneous group of disorders 
characterized by gross proteinuria with hypoalbuminemia and edema. The identification of 
>55 single-gene causes provided new insights into the pathogenesis of NS, linking Rho-like 
small GTPases to podocyte function.
Methods: We performed whole exome sequencing (WES) to identify novel monogenic 
causes of NS in >1,000 individuals with NS.
Results: We identified 4 different recessive mutations in 3 different genes NEK3, PREX1 
and TIAM1 in 4 unrelated families with NS. Specifically, in a family of two siblings (F754) 
with steroid-sensitive NS, we identified a homozygous truncating mutation, N209Kfs*21 in 
NEK3 (NIMA Related Kinase 3), which is known to be activated by prolactin stimulation, 
leading to phosphorylation of the GEF-VAV2 and thereby activation of the Rac1-GTPase. 
Accordingly, by coimmunoprecipitation, we demonstrated that NEK3 interacts with VAV1, 
VAV2 and EDH2 proteins. The mutated NEK3 protein showed stronger binding affinity 
with VAV1 but abrogated the interaction with EHD2. Coimmunofluorescence staining of 
NEK3 in developing rat kidney sections (P1) showed that NEK3 localizes to the cytoplasm 
of podocytes. Additionally, we discovered mutations in PREX1 (family F1070, M1546T 
[Hom], conserved to D. rerio) and TIAM1 (family F1287, R23C [het] and A163V [het], both 
conserved to D. rerio; family F1, p.R23C [Hom]). We thereby identified PREX1 and TIAM1 
as two novel GEFs for Rac1 that are relevant for podocyte function.
Conclusions: We have identified mutations of NEK3, PREX1 and TIAM1 as novel 
causes of NS. Our findings confirm that Rho-like small GTPase signaling in podocytes 
can cause NS.
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Mutations in 4 Diaphanous Related Formins as Novel Causes of Nephrotic 
Syndrome
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Friedhelm Hildebrandt.3 1Nephrology, Boston Children’s Hospital, Boston, MA; 
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Children’s Hospital, Boston, MA; 4Boston Childrens Hospital, Boston, MA; 
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Background: Nephrotic Syndrome (NS) is the second most frequent cause of end-
stage renal disease in the first 3 decades of life. Identification of >55 monogenic genes 
that cause NS if mutated (Vivante et al, Nat Rev Nephrol, 12:133, 2016), has rendered 
first insights into disease mechanisms of NS. Diaphanous Related Formins (DRF) regulate 
actin polymerization and bundling, and have a role in directing microtubules, filopodia and 
lamelipodia formation. Mutations in the DID domain of the Formin gene, INF2, have been 
shown to cause NS (Brown, Nat Gen, 42:72, 2010).
Methods: To identify novel monogenic causes of NS we performed whole exome 
sequencing (WES) in a worldwide cohort of ~600 individuals with NS.
Results: In 5 unrelated patients with early onset NS, we discovered recessive mutations 
in the following 4 DRF encoding genes: A homozygous mutation in DIAPH1 (individual 
B1678, p.Gln1098Leu). Gln1098 is part of the DIAPH1 actin nucleating domain, FH2. A 
hemizygous mutation In DIAPH2 (B2506, p.Arg1075Trp). Arg1075 is part of the basic 
region (‘RRKR’ sequence) of the DAD domain and is critical for auto-inhibition by binding 
to the DID domain. From the crystal structure of mDia1 we predict that the mutation would 
interrupt the DID-DAD interaction. In DIAPH3 we found mutations in two individuals with 
NS (A1938 p.Thr431Ala, homozygous, and F983 p.Asn346Ser; p.Arg28His compound 
het.). Thr431 is located in a loop between alpha helix 1 and alpha helix 2 of the predicted 
dimerization domain. In the crystal structure, Asn346 is in the DID domain and within 
the DAD-binding site, thus the Asn346Ser substitution is predicted to alter DID-DAD 
binding. Furthermore, we found a mutation in DAAM2 (individual B1068, Ala335Gln, 
homozygous). Ala335 is located in the DID domain of DAAM2. All mutations are deemed 
disease causing by SIFT, MutTaster and PolyPhen2 prediction programs. All variants are 
absent hemizygously or homozygously from the gnomAD database.
Conclusions: We here discovered mutations in the DRF encoding genesDIAPH1,2,3 
and DAAM2 as 4 potential novel monogenic causes of NS. Crystal structure analysis 
predicts disruption of the interacting domains DIA- DAD and of the interaction of FH2 
with actin as the underlying mechanisms.
Funding: Other NIH Support - National Institutes of Health to F.H. (DK076683)
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Recessive Mutations of LAMA3 Cause Nephrotic Syndrome
Youying Mao, Shazia Ashraf, Nina Mann, Makiko Nakayama, 
Caroline M. Kolvenbach, Ronen Schneider, Amar J. Majmundar, Shirlee Shril, 
Friedhelm Hildebrandt. Boston Childrens Hospital, Harvard Medical School, 
Boston, MA.
Background: Integrin α3β1 represents the major podocyte integrin heterodimer. 
Itga3 knock out mice have severe defects in podocyte growth and differentiation, and in 
glomerular basement membrane organization (Kreidberg Development 122:3537, 1996), 
and ITGB4 mutation causes nephrotic syndrome (NS) in humans. In the glomerular 
basement membrane, integrin α3β1 is the main receptor for laminins, which are 
heterotrimers composed of laminin subunits α5 (LAMA5) or subunits α3 (LAMA3), β2 
(LAMB2) and g1 (LAMC1). Monogenic mutations in two laminin genes have been identified 
to cause NS in humans, including LAMA5 (Braun NDT, in press 2018) and LAMB2 (Zenker 
Hum Mol Genet 13: 2625, 2004). In additional LAMA3 knock out mice have abnormal 
glomerulogenesis (Abrass KI 70:1062, 2006).
Methods: To identify additional monogenic causes of NS, we performed whole exome 
sequencing in a cohort of 600 families with pediatric NS under a recessive model.
Results: In 3 families, in whom mutation in the 55 known monogenic genes of NS were 
excluded, we identified 3 different homozygous mutations in the gene LAMA3 as likely 
causative for NS. In family B149 with congenital NS, we detected the mutation p.S1359A 
(homozygous, conserved to X.tropicalis). In A2069 2 siblings with steroid dependent NS, 
we detected the mutation p.T2527I (homozygous, conserved to G.gallus). In A2563 with 
steroid sensitive NS, we detected homozygous truncation mutation p.E1354*.
Conclusions: We here identified LAMA3 as a new candidate gene for pediatric NS.
Funding: Other NIH Support - National Institutes of Health to F.H. (DK076683)
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Background: We have previously shown that variants in PLCG2 are associated with the 
development of SSNS in a cohort of South Asian children. PLCγ2 is an essential signaling 
component of leukocyte driven adaptive immunity and inflammation. Therefore, we 
hypothesized that PLCG2 variants are associated with pattern of response to corticosteroid 
therapy in NS and variability in prevalence of NS across ancestries/ethnicities.
Methods: We performed high throughput next generation targeted sequencing of 
PLCG2 in a multi-ethnic cohort of 583 children with the nephrotic syndrome. Identified 
variants that are likely to have effects on gene function (missense, stop codon, frameshift, 
and obligatory splice site variants) were compared with presumed controls in the gnomAD 
database. Additionally, we analyzed specific PLCG2 variants and their association with 
steroid therapy response (SSNS vs SRNS) and ancestry (European, African, Asian) in our 
cohort.
Results: We identified 10 distinct variants that are associated with NS in our multi 
ethnic cohort, most of which were associated with SSNS (majority with p<0.001). One of 
the variants (N174H) is novel, i.e. absent from all public databases. Seven of the variants 
are predicted to be pathogenic by in silico analysis and one occurs at an obligatory splice 
site (Q838). The variants associated with SSNS are grouped tightly in the EF-hand domain 
that is predicted to affect calcium binding and in the autoregulatory region, a region that is 
linked to increased PLCγ2 activity and inflammation. Variant burden was associated with 
disease in patients with European or Asian ancestry but not in those of African ancestry.
Conclusions: Rare variants in PLCG2 are associated with NS and may predict the 
pattern of response to therapy. The clustering of variants in specific PLCγ2 regulatory 
domains suggests that these variants are important in the pathogenesis of NS and pattern 
of response to therapy. Furthermore, this data indicates that SSNS-associated variants in 
PLCG2 may alter calcium-dependent inflammation signaling.
Funding: NIDDK Support, Private Foundation Support
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Background: We previously reported that mutations in ANLN cause familial forms 
of focal segmental glomerulosclerosis (FSGS). Anillin is a F-actin binding protein that 
modulates podocyte cell motility and interacts with the phosphoinositide 3-kinase (PI-3K) 
pathway through the slit diaphragm adaptor protein CD2A-associated Protein (CD2AP). 
However, it is unclear how ANLNR431C causes the FSGS phenotype. We hypothesized that 
the R431C mutation exerts its pathogenic effects by uncoupling ANLN from CD2AP and 
inducing aberrant PI3K/AKT signaling.
Methods: To understand the cellular effects of ANLNR431C, we performed in vitro 
functional assays using human podocyte cell lines stably expressing ANLNWT or ANLNR431C.
Results: We found that ANLNR431C increased cell migration (p=0.001), enhanced 
cellular proliferation (p=0.001), and apoptosis (p=0.029) relative to ANLNWT cells. 
Biochemical characterization of these dysregulated phenotypes revealed hyperactivation 
of the PI-3K/AKT/mTOR/Rac1 signaling axis and activation of mTOR-driven ER stress in 
ANLNR431C podocytes. Podocyte hypermotility, hyperproliferation, and ER stress-induced 
apoptosis were ameliorated by inhibition of mTOR, GSK-3b, Rac1, or calcineurin (Cn). 
Additionally, we found that endogenous ANLN and mTOR expression are regulated by the 
Cn/NFAT pathway suggesting that the benefits derived from calcineurin inhibition in FSGS 
may be due, in part, to the suppression of endogenous anillin and mTOR protein levels.
Conclusions: The ANLNR431C mutation causes multiple derangements in podocyte 
function through hyperactivation of PI-3K/AKT/mTOR/p70S6K/Rac1 signaling. These 
studies illustrate that rational therapeutic targets for familial FSGS can be identified through 
biochemical characterization of dysregulated podocyte phenotypes.
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Splicing Assay with Hybrid Minigene: Assessing Pathogenicities in 
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Background: X-linked Alport syndrome is a congenital renal disease caused by 
mutations in COL4A5. In recent years, splicing is focused on as the origin of pathogenicity 
and the target of treatment. But the effect and mechanism of aberrant splicing caused by 
intronic mutations of COL4A5 are not fully established. To assess the splicing abnormalities 
arising from intronic mutations of COL4A5, we conducted this research.
Methods: We conducted functional splicing assay with hybrid minigene for 7 intronic 
mutations in COL4A5 (1 was found in our case and 6 were in reported cases shown on the 
Human Gene Mutation Database). In addition, we conducted in silico analysis using HSF 
(http://www.umd.be/HSF3/HSF.shtml) and SVM-BP finder (http://regulatorygenomics.upf.
edu/Software/SVM_BP/) to predict and assess the mechanisms for aberrant splicing.
Results: The minigene assay showed exon skipping by 4 variants, exon skipping+10bp 
insertion by 1 variant and no change by 1 variant. For 1 variant, it was difficult to assess the 
splicing pattern by some reason and our assay did not work. Among 3 of them, the patients’ 
transcript analyses were conducted and the results were completely consistent with our in 
vitro assay results. In silico analysis revealed that in 3 variants, polypyrimidine tracts were 
weakened and in 2 variants, dramatic change in splicing regulation elements binding sites 
were observed.
Conclusions: Our splicing assay with hybrid minigene make it possible to assess 
whether the mutation cause aberrant splicing. In addition, in silico tools can assess the 
mechanisms for causing aberrant splicing. Our findings may help the discovery of treatment 
strategy.
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Genomic Analysis of Focal Segmental Glomerulosclerosis in Thailand
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Vorasuk Shotelersuk. Chulalongkorn University, Bangkok, Thailand.
Background: Focal segmental glomerulosclerosis (FSGS) has currently been found 
to be caused by mutations in at least 62 genes. Recently, next generation sequencing 
has provided a robust tool to identify its causative genes. Mutational spectra of various 
populations are usually different. We sought to identify causative variants in Thai patients 
with FSGS.
Methods: Patients aged one year or older with biopsy-proven FSGS without clinical 
and laboratory evidence of secondary causes were included in this study. DNA samples, 
pedigree and clinical information were obtained. Mutation analysis was performed by 
whole exome sequencing (WES) method. Patients were screened in 62 known genes 
formerly reported to cause FSGS. Exome data were interpreted using Variant Interpreter 
and the American College of Medical Genetics and Genomics (ACMG) criteria. Patients 
without causative mutations identified by WES will be analyzed by trio study to determine 
pathogenicity in variant of uncertain significance. New gene may also be discovered by 
trio study.
Results: WES identified the pathogenic variants in two out of 24 unrelated patients 
(8.3%) with biopsy-proven FSGS. A novel c.905del (p.G302Vfs*23) in exon 15 of the 
COL4A4 gene resulting in frameshift was detected in one patient. Mutations in COL4A4, 
encoded collagen type 4 alpha 4, are responsible for autosomal dominant Alport’s syndrome, 
revealing the fact that this patient was previously misdiagnosed as idiopathic FSGS. 
Another patient harbored a novel c.357+1G>A mutation in exon 3 in the ZMPSTE24 gene, 
which encoded zinc metallopeptidase. ZMPSTE24 mutations are found to be associated 
with mandibuloacral dysplasia, an autosomal recessive musculoskeletal disorder in which 
some patients developed FSGS. In addition to FSGS, our patient also had jaw malocclusion. 
Although we could identify only one mutant allele in ZMPSTE24 in the patient, it remains 
possible that the other mutant allele could not be detected by WES.
Conclusions: Using WES, we successfully identified disease-causing variants in only 
4.2% of patients with FSGS. To date, this is the first study in Thailand for genetic approach 
toward diagnosis of FSGS which could provide more accurate disease management and 
counseling. An appropriate testing algorithm is needed for developing future Thai guideline.
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Genetic Alterations in Familial Focal Segmental Glomerulosclerosis
Yasar Caliskan,1,2 Whitney E. Besse,1 Ashima Gulati,1 Erol Demir,2 
Mehmet S. Sever,2 Shuta Ishibe,1 Stefan Somlo.1 1Division of Nephrology, Yale 
School of Medicine, Yale University, New Haven, CT; 2Division of Nephrology, 
Department of Internal Medicine, Istanbul School of Medicine, Istanbul 
University, Istanbul, Turkey.
Background: The phenotypic variability observed in focal segmental 
glomerulosclerosis (FSGS) patients bearing mutations in the same gene suggests that 
modifier genes may impact renal presentation and outcomes. We investigated genetic 
alterations observed in inherited adult FSGS patients.
Methods: We analyzed 172 unrelated patients with biopsy proven idiopathic FSGS 
including familial (n=46) and non-familial (n=126) cases. Genetic sequencing, either whole 
exome sequencing (n=32) or a targeted gene panel (n=14), was performed on these 46 
index patients with family history of kidney disease. Variants were included if: minor allele 
frequency <0.01 (recessive) or <0.001 (dominant); loss of function mutation or missense 
with CADD score ≥15; not seen as homozygotes in any control databases; amino acid 
residue conserved through evolution in multicellular organisms. Variant interpretation was 
done using the ACMG guideline.
Results: The median age of onset [29 (12-48) vs 35.5 (3-73) years] was significantly 
earlier in patients with familial FSGS compared to non-familial cases (p=0.004). The median 
follow up in months after diagnoses was similar between familial [38 (2-276)] and non-
familial [42 (1-235)] cases (p=0.86). During follow-up, ESRD progression was higher in 
familial cases (21/46, 45.7%) compared with non-familial cases (22/126, 17.5%) (p<0.001). 
We identified a pathogenic genotype in 26 out of 46 familial cases. Thirteen individuals 
were explained by heterozygous (7/46, 15%) or homozygous/hemizygous/compound 
heterozygous (6/46, 13%) collagen IV gene (COL4) mutations. Thirteen individuals (13/46, 
28%) were explained by mutations in the documented or recently proposed FSGS genes 
with or without a concurrent COL4 mutation [NPHS2 hom (n=2), NPHS2 hom/COL4A5 
hem (n=1), ADCK4 hom (n=2), NUP107 hom (n=1), SCARB2 hom (n=1), TRPC6 het 
(n=1), LMX1B het (n=1), ARHGAP24 het/COL4A3 het (n=1), ABCA6 hom/COL4A4 het 
(n=1), LAMA5 hom/COL4A4 het (n=1), PALLD hom/COL4A5 het (n=1)].
Conclusions: Collagen IV gene mutations explain a significant fraction of familial 
FSGS in our population. In a limited number of patients with parental consanguinity 
carrying pathogenic genotype in podocyte-related genes, COL4 mutations were also found. 
Further analysis of the phenotype in patients with this co-inheritance could shed light on 
variations in phenotype in familial FSGS.
Funding: Other NIH Support - Yale Center for Mendelian Genomics (NIH 
M#UM1HG006504-05)
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Loss of Podocyte-Specific SGPL1 Results in Albuminuria and Focal 
Segmental Glomerulosclerosis in Hypertensive Mice
Jeffrey B. Hodgin,1 Piming Zhao,2 Jinghui Luo,4 Yingbao Yang,4 Julie D. Saba.3 
1The University of Michigan, Ann Arbor, MI; 2Children’s Hospital Oakland 
Research Institute, Oakland, CA; 3Children’s Hospital Oakland Research 
Institute, Oakland, CA; 4University of Michigan, Ann Arbor, MI.
Background: Steroid-resistant nephrotic syndrome (SRNS) often manifests as focal 
segmental glomerulosclerosis (FSGS), has no efficient treatment, and carries a high risk 
of relapse after transplant. Inactivating SGPL1 mutations cause a familial form of SRNS, 
but the cellular and molecular mechanisms are unknown. SGPL1 encodes sphingosine 
phosphate lyase (SPL), an enzyme responsible for the irreversible degradation of 
sphingosine-1-phosphate (S1P). S1P is a bioactive lipid that ligates to a family of G protein-
coupled receptors (S1PRs) whose signaling regulates cell survival, migration and immune 
cell trafficking. Because whole body SGPL1 knockout mice die in the perinatal period, and 
most monogenic causes of SRNS result from recessive or dominant mutations in genes 
localized to the podocyte, we focused on podocyte-specific SGPL1.
Methods: We generated conditional knockout mice lacking SGPL1 expression in 
podocytes (SPLPodo_KO). Hypertension was induced in wild-type (WT) and SPLPodo_KO 
mice by nephrectomy, implanted osmotic minipumps releasing angiotensin II (AngII, 
1.2 μg/kg/min), and 1% NaCl in the drinking water. Blood pressure was measured by 
tail-cuff, 24-hr-urine was collected, and kidneys harvested at 4 weeks for histology. SPL-
deficient cultured human podocytes were generated by CRISPR/Cas9, assayed for S1P 
levels, and treated with AngII. Autophagy was assayed by Western blotting of LC3A-I and 
-II.
Results: SPLPodo_KO mice had no spontaneous phenotype. Compared to WT mice (n=6), 
hypertensive SPLPodo_KO mice (n=8) had elevated albumin-to-creatinine ratio (ACR g/g) 
(2.7+/-1.8 vs 0.5+/-.1 at 2 wks and 8.1+/-5.7 vs 1.93+/-3.7 at 4 wks; both P<0.05). In 
addition, the % glomerulosclerosis in hypertensive SPLPodo_KO was more than double than 
WT mice (1.51+/-0.71% vs 0.70+/-0.21%; P<0.05). In vitro studies revealed undetectable 
SPL expression and activity and sphingolipid accumulation in SGPL1-KO vs WT human 
podocytes. In addition, SGPL1-KO human podocytes showed increased autophagy with 
AngII exposure, indicating increased sensitivity to injury.
Conclusions: We found that SPLPodo_KO mice are profoundly sensitive to glomerular 
stress, indicating a prominent role for this signaling pathway in FSGS. Therapeutic 
targeting of S1P signaling, such as with the S1PR antagonist FTY720, which is already 
FDA approved for use, may be beneficial.
Funding: NIDDK Support
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Modeling of FSGS in Podocin R138Q Knock-in iPSC-Derived Human 
Organoids
Amy D. Westerling-Bui, Christina N. Cheng, Alyssa Fanelli, Grinal M. Corriea, 
Hien G. Hoang, Thomas Soare, Thomas T. Tibbitts, Jean-Christophe 
P. Harmange, Peter H. Mundel. Goldfinch Bio, Cambridge, MA.
Background: The recent development of iPSC derived human kidney organoids
has opened the possibility to study human kidney physiology and pathophysiology in a 
differentiated, three-dimensional human experimental system in vitro. Organoids are an 
attractive approach to study genetic causes of human kidney diseases, such as FSGS. 
However, due to the fact that organoids are thought to represent second trimester human 
kidneys and due to lack of vascularization and urine flow, whether they can be used as a 
model system of human kidney diseases remains uncertain.
Methods: To explore whether FSGS can be reproducibly modeled in human iPSC-
derived organoids, we generated CRISPR/Cas9-engineered podocin R138Q knock-in 
iPSCs and developed a protocol for their successful differentiation into human kidney 
organoids. The human podocin R138Q mutation was chosen in this proof-of-concept study 
because this variant causes FSGS with early disease onset and rapid progression to end-
stage renal disease in patients and homologous R140Q causes FSGS in knock-in mice.
Results: Here we present a thorough characterization of R138Q organoids at the 
structural, molecular, cellular and pathophysiological level. We also present data on the 
phenotypic changes resulting from the treatment of organoids with pharmacologic agents.
Conclusions: We conclude that using iPSC-derived organoid technology is a 
promising tool for modeling human kidney disease, as it empowers ongoing drug discovery 
for genetically defined FSGS.
Funding: Commercial Support - Goldfinch Bio, Inc.
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A Novel Heterozygous Missense Mutation of Wilms’ Tumor 1 May Cause 
FSGS Through Dysregulated Expression of ARHGAP24
Gentzon Hall,1 Matt G. Sampson,2 Brandon M. Lane,3 Olivia G. Gregory,4 
Maria E. Kovalik,3 Guanghong Wu,5 Megan Chryst-Stangl,6 Liming Wang,1 
Robert F. Spurney,1 Rasheed A. Gbadegesin.1 1Duke University Medical Center, 
Durham, NC; 2University of Michigan, Ann Arbor, MI; 3Duke University, 
Durham, NC; 4Duke University Medical Center, Durham, NC; 5Duke university, 
Durham, NC; 6Duke Molecular Physiology Institute, Durham, NC.
Background: Mutations of the transcriptional regulator Wilms’ Tumor 1 are most 
commonly associated with syndromic disease but some mutations have been shown 
to cause renal-limited disease. We previously reported a novel heterozygous missense 
mutation (Exon 9; p.R458Q) of Wilms’ Tumor 1 that caused non-syndromic autosomal 
dominant FSGS in two Northern European kindreds. We now report a second novel WT1 
mutation (Exon 8; p.R443G) as a cause of non-syndromic autosomal dominant FSGS in a 
3-generation kindred from North-Central India.
Methods: Direct sequencing, lentivirus-mediated WT1 expression, immunoblot, 
immunofluorescence imaging, electrophoretic mobility shift assay (EMSA) and apoptosis 
assays.
Results: A novel heterozygous missense mutation of WT1 (Exon 8; p.R443G) was 
identified by direct sequencing of the proband and an affected cousin in a North-Central 
Indian kindred with non-syndromic FSGS. An autosomal dominant pattern of inheritance 
was suggested by male-to-male transmission across three generations of the family. 
Substitution of the highly conserved arginine residue at position 443 was considered 
damaging by in-silico prediction. The R443G mutation impaired DNA-binding by EMSA 
and distorted the secondary structure of the transcription factor DNA-binding domain by 
in-silico modeling. WT1 was previously identified as a potential regulator of ARHGAP24; 
a known FSGS gene that regulates podocyte cytoskeletal dynamics and survival through 
modulation of Rac1 activity. ARHGAP24 protein expression was significantly upregulated 
in WT1R443G podocytes (p=0.003; n=3) relative to WT1WT podocytes. Consistent with the 
increase in ARHGAP24 expression, WT1R443G podocytes exhibited decreased motility 
(p=0.01; n=3) and increased apoptosis (p=0.04; n=5) accompanied by a significant decrease 
in STAT3 phosphorylation at Ser727 (p=0.02; n=3); a Rac1-mediated prosurvival post-
translational modification. These findings suggest that WT1 functions as an inhibitor of 
ARHGAP24 expression and the R443G mutation impairs this inhibitory effect.
Conclusions: The novel WT1R443G mutation causes non-syndromic FSGS. The 
mutation induces an upregulation of ARHGAP24 expression and increases podocyte 
apoptosis probably through decreased Rac1-mediated prosurvival signaling.
Funding: NIDDK Support, Private Foundation Support
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The LMX1βR246Q Mutation Induces Podocyte Injury Through 
Dysregulation of Cholesterol Transport Gene Expression
Gentzon Hall,1 Gloria Michelle Ducasa,2 Brandon M. Lane,3 Maxwell S. Lagas,4 
Maria E. Kovalik,3 Olivia G. Gregory,5 Guanghong Wu,1 Megan Chryst-Stangl,1 
Liming Wang,1 Robert F. Spurney,1 Alessia Fornoni,6 Rasheed A. Gbadegesin.1 
1Duke University Medical Center, Durham, NC; 2University of Miami School of 
Medicine, Miami, FL; 3Duke University, Durham, NC; 4University of Arizona, 
Phoenix, AZ; 5Duke University, Durham, NC; 6University of Miami, Miami, FL.
Background: We previously reported a heterozygous missense mutation of the LIM 
Homeobox Transcription Factor 1 Beta (LMX1β) as a cause of nail-platella-like renal 
disease (NPLRD) in two families with hereditary FSGS. Currently, there are no targeted 
therapies for LMX1βR246Q-induced glomerulopathy. We hypothesized that LMX1βR246Q 
disrupts the expression of disease-relevant molecular targets within key signaling pathways 
that may be amenable to pharmacotherapy. To test this hypothesis, we performed an 
unbiased, whole-transcriptomic analysis in our established LMX1β
WT
 and LMX1βR246Q-
overexpressing podocyte lines to uncover potential therapeutic targets.
Methods: We conducted RNA-seq, qPCR, immunoblot, cholesterol efflux assays and 
apoptosis assays in our established LMX1β
WT
, LMX1βR246Q- and VIVIT overexpressing 
podocytes to evaluate the effect of the LMX1βR246Q mutation on cholesterol transport gene 
expression, cholesterol efflux and viability.
Results: Using RNA-seq, we determined that LMX1βR246Q-overexpressing podocytes 
express significantly reduced levels of ATP-binding Cassette Transporter Family A1 
(ABCA1) and ABCG1 relative to LMX1β
WT
-overexpressing podocytes. These results 
were confirmed by qRCR. Protein expression of ABCA1 and ABCG1 was similarly 
reduced. Consistent with these findings, LMX1βR246Q-overexpressing podocytes displayed 
significantly increased lipid droplet accumulation, decreased basal and Apo-AI-stimulated 
cholesterol efflux and increased apoptosis relative to LMX1β
WT
-overexpressing podocytes. 
Evaluation of the putative promoter regions for ABCA1 and ABCG1 revealed no LMX1β 
binding sequences (i.e. FLAT-E or FLAT-F) but did reveal multiple candidate NFAT binding 
sequences. LMX1βR246Q-overexpressing podocytes displayed decreased NFAT4 expression 
and ABCA transporter expression was decreased in VIVIT-overexpressing podocytes.
Conclusions: The LMX1βR246Q mutation may cause FSGS, in part, through the 
dysregulation of NFAT-dependent lipid trafficking gene expression. This study provides the 
first demonstration of a potential role for impaired lipid trafficking in the pathobiology of 
familial FSGS and suggests that lipid depleting therapies may have a role in the treatment 
of some forms of familial FSGS.
Funding: NIDDK Support, Private Foundation Support
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Interstrain Variation in Severity of Nephropathy and Immunoglobulin 
Levels in HIV-1 Transgenic Mice
Nicholas J. Steers,1 Young-Ji Na,1 Natalia D. Demaria,1 Wan yee Lam,1 
Vivette D. D’Agati,2 Ali G. Gharavi.1 1Columbia University, New York, NY; 
2Columbia University College of Physicians and Surgeons, New York, NY.
Background: We studied the genetic and immunological determinants of nephropathy 
in HIV-1 transgenic (Tg) mice, a model that displays the clinical and molecular signatures 
of collapsing FSGS. On the FVB/NJ background over 80% of the Tg-FVB mice develop 
significant glomerulosclerosis; however F1 hybrids with other inbred strains of mice 
demonstrate variable penetrance from completely resistant to highly sensitive.
Methods: Tg-FVB mice were crossed with 12 different inbred strains of mice to 
generate F1 hybrids. At 8 weeks of age, we evaluated the severity of nephropathy by 
histology, analysis BUN, and serum IgA and IgG. Urine was analyzed for proteinuria, 
hematuria and NGAL.
Results: Three stains (A/J, C3H/HeJ, and DBA/1J) were highly sensitive to the Tg 
resulting in severe glomerulosclerosis, 4 strains (129S1/SvImJ, C57BL6/J, C57BL6/NJ, 
and CAST/EiJ) were resistant to the Tg resulting in limited to no glomerulosclerosis, and 
5 strains (CBA/J, DBA/2J, NOD/ShiLtJ, NZO/HlLtJ and WSB/EiJ) had intermediate 
glomerulosclerosis. Preliminary analysis of the laboratory strains of mice indicated 
that the MHC haplotype b was associated with limited to no glomerulosclerosis. The 
glomerulosclerosis score correlated with the presence of casts, interstitial fibrosis and 
tubular atrophy, interstitial inflammation, proteinuria, elevated plasma BUN, and decreased 
plasma IgG concentrations. To determine if there were baseline differences between the 
12 wildtype F1 hybrid mice, IgA, IgG and BUN plasma concentrations were determined. 
Significant differences were observed in the BUN (ANOVA p-value = 0.014), IgG (ANOVA 
p-value = 0.016), and highly significant differences were observed in plasma IgA (ANOVA 
p-value = 0.0022), between the groups of mice. No kidney pathologywas observed in the
wildtype F1 hybrid mice.
Conclusions: Our data demonstrates differences in the immunoglobulin levels and 
BUN in the steady state of 12 different F1 wildtype strains of mice. The MHC b haplotype 
was associated with reduced penetrance of nephropathy. Future studies will include 
additional inbred stains of mice and GWAS analysis, to confirm findings and identify 
additional immunological and genetic influences.
Funding: Other U.S. Government Support
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Precise Modeling of NUP93 Highlights Downstream Pathways
Katherine R. Bull,1 Moin Saleem,2 Richard J. Cornall.1 1University of Oxford, 
Oxford, United Kingdom; 2University of Bristol, Bristol, United Kingdom.
Background: Variants in nuclear pore complex components, including NUP93, 
cause steroid resistant nephrotic syndrome (SRNS), but underlying mechanisms are 
not understood. NUP93 null mutations are likely to be lethal. Genetic validation and 
investigation requires tools to link genetics to cellular function. Conventional methods in 
immortalized podocytes fail to model non-null variants under physiological promotors, and 
are limited by transfection resistance. To better mimic human disease we applied CRISPR/
Cas9 to model a NUP93 variant.
Methods: Lentivirus was used to generate human podocytes constitutively expressing 
Cas9 and introduce guide sequences. Motility was assessed by scratch assay. 150 bp PE 
polyA RNA-Seq (HiSeq4000) was analysed in R, fitting a quasi likelihood generalised 
linear model with edgeR.
Results: Lentiviral podocyte CRISPR is efficient, disrupting 43% of alleles, 98% after 
single cell selection. We modeled a homozygous mutation in exon 13 of NUP93, identified 
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in a child with SRNS. Edited podocytes had NUP93 protein but reduced motility. We 
performed RNA-Seq on NUP93, wildtype and two Wilms Tumor 1 (WT1) podocyte lines. 
WT1 requires cofactor translocation; the WT1 transcriptomes clustered, but were distant 
from NUP93, suggesting NUP93 is not essential for WT1 function. Comparing NUP93 to 
wildtype, 3011 genes were significantly differentially expressed. Gene ontology analysis 
highlighted cell cycle, proliferation and interferon signalling. Highly overexpressed genes 
included ID2, which regulates proliferation and is repressed by SMAD4. Since NUP93 
facilitates SMAD4 nuclear transport, this suggests a pathway.
Conclusions: Lentiviral CRISPR efficiently induces mutation in immortalized 
podocytes, providing a new technique for genetic manipulation of this cell line. Using this 
approach we modeled human SRNS disease due to aberrant NUP93 and highlight potential 
downstream targets.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Ablation of PFN1 Expression Causes Proteinuric Disease
Christopher E. Pedigo,1 Kazunori Inoue,2 Xuefei Tian,2 Elizabeth Cross,2 
Ying Wang,1 Shuta Ishibe,1 Wei Li.1 1Yale University, New Haven, CT; 2Yale 
University, New Haven, CT.
Background: Understanding the pathobiology of glomerular diseases is paramount as 
it accounts 80% of end stage kidney disease cases in the US. Recent reports have identified 
human mutations in INF2 to cause proteinuric disease leading to loss of F-actin stress 
fiber formation in podocytes. Our study focused on an INF2 interactor Profilin 1(PFN1), 
a protein involved in the elongation of F-actin fibers. Despite the discovery of reduced 
PFN1 expression in microdissected Diabetic Kidney Disease(DKD) patient glomeruli, the 
function of PFN1 in podocytes is unknown. To investigate the role of Pfn1 in podocytes we 
studied diabetic mice, generated podocyte specific Pfn1 knockout mice and used CRISPR-
Cas9 to knockout PFN1 in cultured human podocytes.
Methods: Glomeruli from the DKD model, db/db, were isolated using dynabeads. 
Analysis for RNA and protein were performed. Podocyte specific Pfn1 knockout mice were 
generated and phenotyped. Purified primary podocytes were isolated from Pfn1KO mice 
by breeding to the Terminator mouse. CRISPR-Cas9 mediated PFN1 knockout (PFN1KO) 
cultured human podocytes were generated and analyzed.
Results: Pfn1 expression is reduced in glomeruli from db/db mice compared to controls. 
To understand the role PFN1 in podocytes, podocyte specific Pfn1 knockout(Pfn1KO) 
mice were generated. Pfn1KO mice demonstrated progressive albuminuria starting at 3 
weeks(p<0.05) and severe kidney failure (p<0.05) leading to morbidity and mortality by 
(p<0.05) by 9 weeks of age. Histological analysis revealed increased mesangial expansion 
(PAS staining, p<0.05) and progressive interstitial fibrosis/proteinaceous casts (Trichrome 
Staining, p<0.05) by 6 weeks of age. Ultrastructural analysis revealed podocyte foot process 
effacement and vacuole-like structures which was recapitulated by similar structures in 
PFN1KO cultured human podocytes. Primary mouse Pfn1KO podocytes and PFN1KO 
cultured human podocytes revealed a significant reduction in ability to spread and migrate 
(p<0.05).
Conclusions: Our data suggest that loss of podocyte Pfn1 expression is sufficient to 
cause podocyte injury, identifying PFN1 as an essential regulator of podocyte function 
and maintenance. These data support further identification of PFN1 regulatory targets in 
podocytopathies.
Funding: NIDDK Support, Other NIH Support - DOD, Other U.S. Government 
Support
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Elucidating Transport Kinetics of Risk-Variant APOL1 Through the 
Secretory Pathway Helps to Understand Molecular Mechanism of Kidney 
Cell Toxicity
Zayd Daruwala,1,3 Jayne Raper,2 Joseph A. Giovinazzo,4 Alejandro J. Friedman.4 
1CUNY Hunter College, New York City, NY; 2City University of New york, New 
York, NY; 3The Graduate Center of the City of New York, New York City, NY; 
4Hunter College, New York, NY.
Background: APOL1 is an innate immunity factor circulating on HDL particles, 
forming cation specific channels in African trypanosomes that lead to ionic imbalance 
and osmotic lysis. When endocytosed by the parasite, APOL1 undergoes a necessary 
acidification followed by neutralization upon recycling to the plasma membrane. G1 and 
G2 variants of APOL1 protect against human-infective trypanosomes but increase the risk 
of kidney disease. Within a human cell, APOL1 traffics along the secretory pathway, which 
is acidified at the golgi followed by neutralization at the plasma membrane. We show that 
the trafficking kinetics of G2 and non-risk G0 are similar as they travel along the secretory 
pathway. We also find that APOL1 is membrane-bound within the cell and is not secreted 
out.
Methods: Stably transfected FlpIn Trex HEK 293 cells were generated expressing the 
cDNA of APOL1 variants under a tet-inducible promoter. Soluble proteins were separated 
from membrane-bound proteins through subcellular fractionation. Cells were collected at 
different time points to analyze intracellular APOL1 localization. Organelles were separated 
using mechanical lysis and sucrose gradient ultracentrifugation. Protein co-localization 
with organelles was analyzed via Western blot. Toxicity was measured by quantifying LDH 
release. Culture media was immunoprecipitated to pull down APOL1.
Results: Subcellular fractionation showed APOL1 co-localizing in membrane-bound 
fractions. Sucrose gradient separation of organelles revealed that the majority of G0 and 
G2 APOL1 localized to the plasma membrane within 10 hours of induction of expression. 
Unlike G0, the G2 variant leads to cell swelling followed by cell lysis. No APOL1 secretion 
was detected in the media of cells expressing any of the variants.
Conclusions: We report that there is no secretion of G0 or G2 APOL1 into the media, 
indicating that the toxicity is related to intracellular localization of G2. There appears 
to be no distinction between G0 and G2 APOL1 in relation to their trafficking through 
the secretory pathway to the plasma membrane. However while both associate with the 
membrane fraction, G2 is toxic to cells but G0 is not, hinting to a hypothetical chaperone or 
regulatory mechanism that G2 evades, allowing for ion channel formation.
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A Modifier Genetic Screen for APOL1 in Drosophila Nephrocytes 
Identified Potential Therapeutic Targets That Rescue the Renal Toxicity of 
APOL1
Zhe Han.1,2 1Genetic Medicine, Children’s National Health System, Washington, 
DC; 2Precision Medicine and Genomics, George Washington University, 
Washington, DC.
Background: African Americans are at higher risk for developing chronic kidney 
diseases due to APOL1 risk alleles (RA), but the treatment is lacking. We generated a 
Drosophila model of APOL1 nephropathy by expressing APOL1-G1 in nephrocytes, which 
share striking similarities with podocytes. APOL1-G1 expression in nephrocytes led to loss 
of renal function and cell death, providing a platform to identify genes that modifies APOL1 
renal toxicity.
Methods: We designed and performed a modifier genetic screen for APOL1 in 
Drosophila, by crossing thousands of transgenic RNAi lines to a master line that carries four 
transgenes: a nephrocyte-specific driver (Dot-Gal4), a nephrocyte function readout (MHC-
ANF-RFP), a marker (Hand-GFP) and the UAS-APOL1-G1 over a balancer chromosome. 
We examined and compared the effects of silencing each individual gene in nephrocytes, 
with or without APOL1-G1. We also used a human kidney cell line to validate our findings.
Results: We identified ~20 genes (out of ~1000) that could modify the APOL1-G1 
toxicity in nephrocytes. Silencing of these genes alone in nephrocytes did not generate a 
phenotype, but the toxicity was increased in a synergistic manner together with APOL1-G1, 
suggesting that these genes could antagonize APOL1-G1 toxicity when over-expressed. 
We therefore generated transgenic lines to over-express these genes in nephrocytes. We 
discovered that two of these genes, when over-expressed with APOL1-G1, could rescue the 
functional defects of nephrocytes caused by APOL1-G1 expression. We further tested these 
two genes in a human kidney cell line, and found that they encode proteins that co-localize 
and directly bind to APOL1. Furthermore, expression of these two genes in human kidney 
cells significantly rescued the cell death caused by APOL1-G1 expression.
Conclusions: Our findings suggest that the Drosophila genetic screen can be used to 
identify modifier genes for APOL1 renal toxicity. Our data suggest that an evolutionarily 
conserved genetic network mediates the renal toxicity of APOL1-RA. Using Drosophila 
genetic screen and cultured human kidney cells, we discovered two genes that antagonize 
the renal toxicity of APOL1-G1 in both fly nephrocytes and human kidney cells, as potential 
therapeutic targets for APOL1 nephropathy.
Funding: NIDDK Support
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pH-Dependent Channel Formation by APOL1: Gateway to Toxicity?
Russell P. Thomson,1 Joseph A. Giovinazzo,1 Charles M. Schaub,2 Alan 
Finkelstein,3 Jayne Raper.1 1Department of Biological Sciences, Hunter College, 
City University of New York, New York, NY; 2The Graduate Center of the City 
University of New York and Hunter College CUNY, New York, NY; 3Department 
of Physiology and Biophysics, Albert Einstein College of Medicine, New York, NY.
Background: African variants of apolipoprotein L-I (APOL1) are strongly associated 
with kidney disease among African Americans. APOL1 variants are cytotoxic when 
expressed in human cells, a property which is associated with the formation of pH-
dependent cation fluxes across the plasma membrane. This cation flux is likely mediated by 
APOL1 itself as recombinant APOL1 forms pH-gated cation-selective channels in planar 
lipid bilayers that are similarly affected by pH. Here we show that APOL1 of baboons also 
forms a cation-selective conductance in planar lipid bilayers, but that this conductance is 
largely unaffected by pH. We identify two human APOL1-specific residues - tyrosine-351 
and glutamate-355 - that combine to produce channel closure at acidic pH and opening at 
neutral pH.
Methods: We utilized human-baboon APOL1 chimeras and site-directed mutagenesis 
to identify residues involved in pH gating. Recombinant proteins were produced in E. coli 
and incorporated into planar lipid bilayers using established techniques.
Results: Similar to baboon APOL1, a human-baboon APOL1 chimera containing the 
C-terminal 46 residues of baboon APOL1 produced channels that remained open at acidic, 
as well as neutral pH. This effect could be entirely replicated with the single change of
tyrosine-351 for its baboon-specific counterpart glycine, but was only partially recapitulated 
by the more conservative tyrosine-351 for phenylalanine substitution. A single substitution 
of human APOL1 glutamate-355 for the uncharged glutamine also abrogated pH gating.
Conclusions: We propose that under acidic conditions the bulky side-chain of Tyr-
351 is positioned to effect channel closure. Upon pH neutralization Glu-355 becomes 
negatively charged, allowing for displacement of Tyr-351 and for channel opening to occur. 
Investigations are currently underway to determine if mutation of channel gating behavior 
affects the toxicity of APOL1 when expressed in human cells.
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Genetic Diseases of the Kidneys: Non-Cystic - II
Changing the Channel: Mutational Analysis of APOL1 Reveals Structural 
Insights Impacting G1 and G2 Associated Kidney Disease
Charles M. Schaub,1,2 Russell P. Thomson,3 Joseph A. Giovinazzo,3 
Alan Finkelstein,4 Jayne Raper.5 1Biochemistry, The Graduate Center of the City 
of New York, New York, NY; 2Biology, Hunter College CUNY, New York, NY; 
3Hunter College, New York, NY; 4Albert Einstein College of Medicine, New 
York, NY; 5City University of New york, New York, NY.
Background: The human innate immunity factor Apolipoprotein L-1 (APOL1), is 
a cation selective channel that protects against African Trypanosomes. The channel has 
two putative transmembrane domains, requires acidification for activation, and opens upon 
subsequent neutralization. Natural variants of APOL1, G1 and G2, have been recognized 
as risk factors for kidney disease. Investigating the structure of APOL1 would assist in 
identifying mechanisms of channel formation responsible for kidney cell toxicity caused 
by the G1 and G2 variants.
Methods: Recombinant APOL1 (rAPOL1) was purified from E. coli BL21-DE3-
RIPL cells expressing the pNIC-28 vector. The effects of single and multiple amino acid 
substitutions were first tested for trypanolytic activity, followed by channel formation and 
ion selectivity in planar lipid bilayers. Blue Native PAGE of APOL1 expressing FlpIn 
TREX 293 cells along with SDS-PAGE of rAPOL1 was performed to visualize oligomers 
of the APOL1 channel. Protease protection assays of rAPOL1 channels in LUVs were 
used to ascertain orientation and channel transmembrane domains via silver stain and mass 
spectrometry.
Results: At acidic pH, rAPOL1 G0 is a non-ideal cation channel. Substituting amino 
acids in the second predicted transmembrane domain not only inhibited in vitro trypanolytic 
activity, but also altered channel conductance and cation selectivity. Changes in the leucine 
zipper motif at the C-terminus abolished rAPOL1 activity in vitro and in planar lipid 
bilayers. Mutations within the C-terminus, that retain trypanolytic activity, indicate that 
rAPOL1 is an oligomer as a functional channel. Furthermore, oligomers of APOL1 have 
been visualized by Blue Native PAGE from the TREX 293 cells upon release from the ER. 
Fragments of the digested rAPOL1 channel protected by LUVs designate orientation and 
transmembrane regions.
Conclusions: These findings reveal that APOL1 requires oligomerization to form a 
functional channel, which is driven by residues in the C-terminus. In addition, we identified 
specific amino acids in the second transmembrane domain that govern cation selectivity.
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Genetic Diseases of the Kidneys: Non-Cystic - II
APOL1 (G0) Confers Protection from HIVAN by Facilitating Parietal 
Epithelial Cell (PEC) Transition to Podocytes (PD)
Vinod Kumar,1 Nitpriya Paliwal,2 Xiqian Lan,2 Kamesh R. Ayasolla,2 Seyedeh 
Shadafarin Marashi Shoshtari,8 Sheetal Chowdhary,7 Ashwani Malhotra,3 
Catherine Meyer-Schwesinger,5 Karl Skorecki,4 Pravin C. Singhal.6 1Fienstine 
Institute for Medical Research, NEW YORK, NY; 2Feinstein Institute for Medical 
Research, Jersey city, NJ; 3Feinstein Institute Medical Research and NSLIJ, 
MANHASSET, NY; 4Rambam Health Care Campus, Haifa, Israel; 5University of 
Hamburg, Hamburg, Germany; 6North Shore LIJ Health System, Great Neck, 
NY; 7Feinstein Institute of Medical Research, New Hyde Park, NY; 8The 
Feinstein Institute for Medical Research, Manhasset, NY.
Background: The majority of HIV infected Africans carrying APOL1 risk alleles 
develop HIVAN if not treated with antiviral therapy. On the contrary, HIV infected Africans 
as well as Caucasians carrying APOL1 wild-type (G0), rarely develop HIVAN. We 
hypothesize that APOL1G0 facilitates PDs renewal by PECs, thus allowing replenishment 
of HIV-induced podocyte loss, whereas, PECs expressing APOL1G1 or APOL1G2 are not 
able to complete the transition and accumulate into Bowman’s space.
Methods: To aim transition (differentiation) to PDs, immortalized human PECs were 
incubated in special media for 14 days. PEC- transduced with either Vector or HIV (NL4-3) 
were assayed for APOL1 expression. To determine the role of APOL1, differentiated PECs 
were transduced with Vector, APOL1G0, APOL1G1, or APOL1G2 lentivirus. After 48 
hours, cellular lysates were probed PEC (PAX2 and Claudin 1) and PD (CD2AP, WT1, 
α-actinin, and podocalyxin) markers. To determine the role of APOL1-miR193a axis, 
cellular lysates of above-mentioned transduced cells were assayed for miR193a expression 
and PEC/PD markers. To confirm the disruption of APOL1-miR193a axis, HEKs (human 
embryonic kidney cells with undetectable APOL1 expression) were transfected with 
Vector, APOL1G0, APOL1G1, or APOL1G2 plasmids followed by evaluation of miR193a 
expression and PEC/PD markers. Human renal biopsy specimens and renal cortical sections 
of 4-week and 8-week old HIV transgenic mice (Tg26) expressing APOL1G0, APOL1G1, 
and APOL1G2 were graded for the severity of renal lesions.
Results: HIV induced the expression of APOL1 in PECs. The induction of APOL1 
in undifferentiated PECs and HEKs down-regulated miR193a expression but stimulated 
the expression of PD markers. APOL1G1 and APOL1G2 in differentiated PDs as well 
as in differentiated PECs down-regulated PD markers but upregulated the expression of 
miR193a. Renal biopsy specimens of HIVAN patients displayed accumulation of PECs 
in Bowman’s space with the expression of occasional PD markers. Tg26: APOL1G0 mice 
displayed minimal accumulation of PECs in Bowman’s space as well as minimal renal 
lesions vs. TG26: APOL1 G1/G2 mice.
Conclusions: APOL1G0 prevents the development of HIVAN through facilitating 
PECs transition to PDs.
Funding: NIDDK Support
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Role of Epigenetics in Parietal Epithelial Cell Transition
Vinod Kumar,1 Kamesh R. Ayasolla,2 Xiqian Lan,2 Nitpriya Paliwal,2 
Sheetal Chowdhary,8 Seyedeh Shadafarin Marashi Shoshtari,3 Ashwani 
Malhotra,4 Catherine Meyer-Schwesinger,5 Karl Skorecki,6 Pravin C. Singhal.7 
1Fienstine Institute for Medical Research, NEW YORK, NY; 2Feinstein Institute 
for Medical Research, Manhasset, NY; 3The Feinstein Institute for Medical 
Research, Manhasset, NY; 4Feinstein Institute Medical Research and NSLIJ, 
MANHASSET, NY; 5University of Hamburg, Hamburg, Germany; 6Rambam 
Health Care Campus, Haifa, Israel; 7North Shore LIJ Health System, Great 
Neck, NY; 8Feinstein Institute of Medical Research, New Hyde Park, NY.
Background: APOL1 is a minor component of circulating lipid-rich multiprotein 
complexes in certain primate species including humans. It is expressed in liver, pancreas, 
kidney, brain, macrophages, and endothelial cells. In kidneys, APOL1 protein is expressed 
in podocytes, tubular, and vascular smooth muscle cells. Parietal epithelial cells (PECs) 
do not express APOL1 under a normal physiologic state. We hypothesize that epigenetic 
factors have a potential to induce APOL1 expression in PECs for their participation in PDs 
renewal in adverse milieus
Methods: Immortalized human PECs (at 33°C) were transduced with either vector (V) 
or HIV (NL4-3) (n=4); PECs were incubated in media containing variable concentration 
of IFN-γ (0, 5, 10, and 20 nM) for 48 hours (n=4); PECs were treated with either buffer, 
azacytidine (5 μM, a demethylating agent), or SAHA (10μM, a histone deacetylation 
inhibitor) for 48 Hours (n=4). Protein blots were probed for APOL1, DNMT 1-3, HDAC 
1-4, H3K27me3, H3K4me3, H3K8/9ac, and reprobed for β-actin. cDNAs were amplified for 
DNMT1-4, HDAC1-4, and APOL1 with specific primers. RNAs were assayed for miR193a.
To confirm histone acetylation at miR193a gene promoter, ChiP assay was carried out. To 
confirm binding of miR193a to APOL1 gene promoter, RIP-ChIP assay was performed. To 
measure methylation of CpG islands at miR193a gene, Bisulphite sequencing was carried
out in PECVs and PECHIVs.
Results: Both HIV and IFN-γ induced APOL1 expression in PECs. PECHIV and IFN-
γ-treated PECs showed 2- to 2.5-fold decrease in miR193a expressions, respectively; as 
expected, inhibition of miR193a in PECs also resulted in the induction of APOL1expression. 
The treatment of PECs with either azacytidine or SAHA induced the expression of APOL1 
as well as decreased (3-fold) miR193a levels. HIV and IFN-γ enhanced the expression 
of DNMT3b, HDAC4, HK4me3, and H3K27me3, but down-regulated the expression of 
H3K8/9ac. ChIP assay revealed histone methylation at 27 lysine residues. RIP-ChIP assay 
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confirmed binding of miR193a on APOL1 gene promoter. Bisulphite-sequencing displayed 
enhanced methylation of CpG islands at miR193a gene in PECHIVs.
Conclusions: Epigenetic factors play a role in the induction of PECs expression of 
APOL1 through modulation of miR193a expression in adverse milieus.
Funding: NIDDK Support
FR-PO1028 Poster Friday
Genetic Diseases of the Kidneys: Non-Cystic - II
Community-Based Evaluation of APOL1 Genetic Testing in African 
Americans: National Stakeholder Meeting and Return of Results 
Recommendations
Bessie A. Young,1,2 Kerri L. Cavanaugh,3 James G. Wilson,4 Erika Blacksher,5 
Stephanie M. Fullerton,5 Ebele Umeukeje,3 Jonathan Himmelfarb,2 Wylie Burke.5 
1Hospital and Specialty Medicine and Seattle COIN, Veterans Affairs Puget 
Sound Health Care System, Seattle, WA; 2Kidney Research Institute, Department 
of Medicine, Division of Nephrology, University of Washington, Seattle, WA; 
3Vanderbilt University Medical Center, Nashville, TN; 4University of Mississippi 
Medical Center, Jackson, MS; 5University of Washington, Seattle, WA.
Background: African Americans (AA) are 2-4 times more likely to develop ESRD, 
compared to whites. Apolipoprotein L1 (APOL1) high-risk variants have been associated 
with greater risk of developing non-diabetic ESRD among African Americans (AAs), 
incident CKD, proteinuria, and transplant failure compared to those with wild type 
APOL1. Currently there is a lack of national guidelines for genetic testing for APOL1 in 
transplantation and general clinical care.
Methods: We convened a national meeting of stakeholders (researchers, clinicians, 
patients, family members, community members, national advocacy and professional 
organizations, and NIH representatives) to develop guidance for policy-makers and 
clinicians regarding APOL1 genetic testing in transplantation and general clinical care. 
We identified areas of consensus, disagreement, and needed research. Participants received 
educational information, APOL1 research updates, results of stakeholder interviews and 
of community deliberative groups. Participants discussed APOL1 relevant policy concerns 
regarding genetic testing.
Results: After 2 days of discussion, draft conclusions regarding APOL1 were 
developed, including: 1) AA should be informed about APOL1 risk; 2) APOL1 testing 
should be integrated into renal transplant programs; 3) routine use of APOL1 testing 
in general clinical care is not recommended, because it is not actionable; 4) research is 
crucial to ensure better understanding of APOL1 risk; and 5) AA community involvement 
in the development of policies and educational materials about APOL1 risk and testing is 
recommended to ensure testing policies address community preferences. Areas with lack of 
consensus included: 1) whether transplant programs should require APOL1 testing of living 
donors; 2) whether transplant recipients should be told the APOL1 status of transplanted 
kidneys; and 3) access to APOL1 testing in general clinical care.
Conclusions: Draft conclusions from a national stakeholder meeting regarding 
APOL1 risk indicate consensus regarding informing the AA community regarding APOL1 
genetic testing in transplantation, but lack of consensus regarding using APOL1 testing 
to determine eligibility for transplant donation or in general clinical care, given current 
research knowledge.
Funding: NIDDK Support, Other NIH Support - NHGRI, Veterans Affairs Support
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Loss of Function of EMP2 Does Not Cause Glomerular Disease in Mice
Michael D. Donnan, Rizaldy P. Scott, Tuncer Onay, Ummiye venus Onay, 
Antoine Tarjus, Susan E. Quaggin. Northwestern University, Feinberg School of 
Medicine, Chicago, IL.
Background: Mutations in the human gene Epithelial Membrane Protein 2 (EMP2) 
have been linked to childhood-onset nephrotic syndrome (OMIM#615861) with expression 
reported within podocytes. In mice, the Emp2 gene is necessary for embryo implantation 
and placental angiogenesis. Its gene product, a tetraspan integral membrane protein, affects 
various cell behaviors including cell adhesion and migration. To further understand its 
role in glomerular disease, we studied Emp2 expression and generated cell-specific Emp2 
knockout (KO) mice.
Methods: Emp2 mRNA was profiled in various tissues using qRT-PCR analysis. We 
created a conditional floxed Emp2 allele carrying a lacZ cassette that allows whole-mount 
β-galactosidase (β-gal) histochemical analysis of Emp2 expression. We created podocyte-
specific knockout and null Emp2 mutant mice by breeding floxed Emp2 animals with 
Nphs1-Cre and EIIa-Cre driver strains, respectively. Emp2 mutant mice were assessed for 
proteinuria and renal histology.
Results: Based on qRT-PCR analysis, Emp2 expression was highest in lungs, but is 
expressed in multiple other organs including the kidney. β-gal staining reveals that Emp2 is 
present in the vasculature. In the kidney, β-gal staining is found in large caliber vessels but is 
surprisingly absent in glomeruli. By 3 months of age, mice lacking Emp2 within podocytes 
or globally do not exhibit proteinuria or renal abnormalities.
Conclusions: In contrast to previous reports, we did not observe significant Emp2 
expression in podocytes or within the glomerulus. Emp2 deficiency in mice did not cause 
overt kidney disease. Our data demonstrate a vascular pattern of expression throughout 
multiple tissues. These findings suggest that Emp2 may have a key endothelial function, 
which would explain reports implicating Emp2 in placental vascular development and 
tumor angiogenesis. Our findings do not support a causative role for EMP2 mutations in 
patients with childhood-onset nephrotic syndrome.
FR-PO1030 Poster Friday
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Exome-Wide Association Study for C3 Glomerulopathies
Young-Ji Na,2 Yifu Li,2 Maddalena Marasa,2 Priya Krithivasan,2 
Nicholas J. Steers,2 Elena Sanchez,2 Elena Goicoechea de jorge,6 Manuel Praga,3 
Andrew S. Bomback,2 Krzysztof Kiryluk,2 Santiago Rodriguez de Cordoba,4 
Gerald B. Appel,5 Ali G. Gharavi.2 2Columbia University, New York, NY; 
3Hospital 12 de Octubre, Pozuelo De Alarcon, Spain; 4Consejo Superior de 
Investigaciones Cientificas, Madrid, Spain; 5Columbia University College of 
Physicians and Surgeons, Scarsdale, NY; 6Complutense University Madrid, 
Madrid, Spain.
Background: C3 glomerulopathies (C3Gs) include a spectrum of rare diseases 
such as C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), which share 
phenotypic similarities and underlying genetic commonalities. Mutations in components 
of the complement pathway have been implicated, but the genetic underpinnings are 
largely unknown. The aim of this study is to use whole-exome sequencing to improve 
understanding of the genetic architecture of C3G.
Methods: We performed a case-control exome-wide collapsing analysis using 282 
case subjects with C3Gs [C3GN, DDD, and immune complex-mediated MPGN] and 
9,825 control subjects with no known kidney diseases. To identify risk signals, we tested 
all protein-coding genes for an excess of ultra-rare genetic variation among the cases, 
compared with control samples. We tested multiple models, including loss-of-function 
variants and non-benign nonsynonymous variants. We also applied regional intolerance 
model based on missense tolerance ratio (MTR).
Results: In multiple model, patients with C3G had a higher frequency of loss-of-
function variants and non-benign nonsynonymous variants in Complement Factor H  
(P = 6.51 X 10-07), C3 (P = 1.04 X 10-04) in the dominant models and C5 (P = 0.0279) 
and CFB (P = 0.0279) in the recessive models. Rare putatively pathogenic variants were 
detected mainly among C3GN cases. In addition, we identified many signals that did not 
reach exome-wide significance but represent interesting candidate genes for C3Gs.
Conclusions: We identified excess ultra-rare variation in several known C3G genes 
under both dominant and recessive models. These data suggest that exome sequencing can 
discover rare risk alleles for C3Gs enhancing the established gene-mapping paradigms.
Funding: NIDDK Support
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Kank1 Knockout Fish Causes Proteinuria
Keiko Oda,1 Kan Katayama,1 Akiko Tanoue,1,2 Eiji Ishikawa,1 Masaaki Ito.1 1Mie 
University Graduate School of Medicine, Tsu, Japan; 2Murase Hospital, Suzuka, 
Japan.
Background: Kank family consists of Kank1-4 and contains KN motif, coiled-coil 
domains, and ankyrin-repeats. Kank1 protein is mostly located in the cytoplasm and is 
thought to play a role in organizing actin cytoskeleton. Recently, Kank1 is reported to be 
associated with nephrotic syndrome.
Methods: The expression pattern of Kank1 protein was examined in human frozen 
kidney sections. Since Kank1 is a conserved gene between human and zebrafish, kank1 
knockout zebrafish has been used in this study. The mutant kank1 zebrafish line has a C to T 
point mutation in exon 3 of kank1 gene, which results in a premature stop codon from CAA 
(Q) to TAA. By utilizing kank1 knockout zebrafish embryos, we examined its phenotype 
and performed a functional assay by injecting fluorescent-conjugated dextrans.
Results: Kank1 protein was localized in the podocytes and the proximal tubules. 
Genotyping of zebrafish embryos from kank1 heterozygous parents was performed by 
polymerase chain reaction method. The phenotype of kank1 knockout embryos at 4 days 
per fertilization (dpf) was comparable with that of wild-type embryos. The morphology 
of pronephros in kank1 knockout embryos was also comparable with that in wild-type 
embryos under Periodic acid–Schiff stain. However, there was an uptake of both 500-kDa 
fluorescein isothiocyanate and 10-kDa rhodamine dextrans in the proximal tubules of kank1 
knockout embryos at 3.5 dpf while there was only an uptake of 10-kDa rhodamine dextran 
in the those of wild-type embryos.
Conclusions: Knockout of kank1 in zebrafish might be related to the disturbed filtration 
barrier in the pronephros and support the human data in nephrotic syndrome.
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TRPC6 Overexpression Mice Produced Proteinuria with Downregulated 
Podocyte Genes
Zi Jin Sun,1 Yaochun Zhang,1 Jun li Ng,1 Ping Liao,3 Tuck wah Soong,4 Siong-
Chuan Chong,5 Yiong Huak Chan,6 Hui Kim Yap,2,7 Kar Hui Ng.1,7 1Paediatrics, 
National University of Singapore, Singapore, Singapore; 2National University 
Hospital, Singapore, Singapore; 3Research, National Neuroscience Institute, 
Singapore, Singapore; 4Physiology, National University of Singapore, Singapore, 
Singapore; 5Paediatrics, National University of Singapore, Singapore, Singapore; 
6Biostatistics Unit, National University of Singapore, Singapore, Singapore; 
7Khoo Teck Puat – National University Children’s Medical Institute, National 
University Health System, Singapore, Singapore.
Background: Mutations in transient receptor potential channel-6 (TRPC6) can cause 
autosomal dominant FSGS. We have previously identified novel p.R68W TRPC6 gain-of-
function mutation. We aim to study the disease-causing mechanism of p.R68W mutation.
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Methods: Wild type (OEwt) and p.R68W (OEmut) TRPC6 were overexpressed in FVB/N 
mice by pronuclear microinjection. The albumin:creatinine ratios were obtained. Podocyte 
gene expressions were measured by reverse-transcription PCR and western blot analysis. 
Podocyte ultrastructural changes were assesssed by transmission electron microscopy and 
transgene localization was performed by immunogold staining. Statistical analysis was 
performed using Mann-Whitney U test.
Results: Over one third of both groups of overexpression mice had albuminuria, and 
lower body weights compared with control mice from 6 month. Interestingly, OEwt were 
significantly lighter compared with OEmut since 6.5 month. Kidney electron microscopy 
slices demonstrated extensive podocyte foot process effacement in both OE mice. 
Immunogold staining revealed TRPC6 in OEwt mice localized predominantly in the central 
cytoplasmic areas, whereas in OEmut, TRPC6 occurred predominantly at the peripheral and 
central parts of the foot processes. Quantitative PCR data showed that nephrin and podocin 
expressions were decreased in OE mice compared to wild-type, and to a greater degree in 
the OEwt compared to OEmut.
Conclusions: Our work suggests p.R68W mutation may affect TRPC6 intracellular 
trafficking and its interactions with the slit diaphragm proteins in the podocytes.
Funding: Government Support - Non-U.S.
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Targeting MTAP-Deficient Cells in Advanced Renal Cell Carcinoma
Jihao Xu, David Yang, Robert Weiss, Ching-Hsien Chen. UC Davis, Davis, CA.
Background: The metabolic enzyme methylthioadenosine phosphorylase (MTAP) has 
been reported to function as a tumor suppressor and the lack of this gene was found in 
approximately 58% of kidney cancer (or renal cell carcinoma, RCC) cases. However, the 
mechanisms of how MTAP regulates RCC progression still remain unknown.
Methods: Tissue microarray and immunohistochemistry (IHC) were performed to 
analyze the correlation between MTAP expression and IGF-1R phosphorylation in RCC. A 
phospho-receptor tyrosine kinase array screen was utilized to assess RCC signaling pathway 
activity. Genetic manipulations were achieved by siRNA knockdown, CRISPR/Cas9 
and ectopic expression approaches. In addition, we used an IGF-1R inhibitor, linsitinib, 
to suppress type 1 Insulin Growth Factor 1 Receptor (IGF-1R) signaling. In vitro and in 
vivo tumor suppressive activities of MTAP were confirmed by MTT, colony formation, 
migration assays and in vivo subcutaneous implantation. MTAP-regulated gene expression 
and signaling were determined by qRT-PCR and Western blots.
Results: We found a decrease of protein-methylation level concomitant with an 
increase in tyrosine phosphorylation in MTAP-knockout cells. We next performed a receptor 
tyrosine kinase array screen and identified IGF1R as the top-one candidate with upregulated 
tyrosine phosphorylation in response to MTAP loss. Western blots showed an elevation of 
IGF1R phosphorylation and its signaling after MTAP knockout. IHC staining on a tissue 
microarray has also confirmed an inversely association between IGF-1R phosphorylation 
and MTAP expression. We noticed a decrease of cell viability, migration, invasion and 
colony-forming capabilities in MTAP-knockout RCC cells after linsitinib treatment. 
Surprisingly, RCC cells were more sensitive to this inhibitor in response to MTAP loss, 
suggesting that MTAP-deficient become addicted to IGF1R activity.
Conclusions: IGF-1R signaling is a driver pathway conferring aggressive nature to 
MTAP-deleted renal cell carcinomas.
Funding: Commercial Support - Dialysis Clinic, Inc. (DCI#C-3917)
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Stromal Signaling Promotes ccRCC Tumor Growth Through FOXD1 
Overexpression
Kyle H. Bond, Ashwani K. Gupta, Leif Oxburgh. Oxburgh Lab Maine Medical 
Center Research Institute, Scarborough, ME.
Background: Clear cell renal cell carcinoma (ccRCC) is the 8th most common 
cancer in the U.S.. Although tyrosine kinase inhibitors (TKIs) have improved survival 
in patients, many patients are not responsive to TKI are in need of more options. The 
tumor microenvironment (TME) in ccRCC is not well understood and may be a potential 
target. The transcription factor FOXD1 has been shown to be upregulated in lung, breast, 
and kidney cancer. Functionally, FOXD1 regulates epithelial-stromal signaling in the 
developing kidney. We hypothesize that FOXD1 overexpression in ccRCC would promote 
tumor growth through stromal signaling.
Methods: The relevancy FOXD1 was first determined through RNA-seq and 
staining analyses. ccRCC tumor microarrays (TMAs) were stained for FOXD1, PECAM, 
aSMA, PDGFRb, and NG2. A Kaplain-Meier survival analysis for FOXD1 expression 
was performed using data from The Cancer Genome Atlas (TCGA). A potential FOXD1 
binding site analyses using the TRANSFAC FOXD1 binding site matrix was performed. 
Binding site were compared to previously reported FOXD1-/- RNA-microarray data 
to determine direct binding targets. Results were confirmed by qPCR in renal proximal 
tubule cells (RPTECs) after transfection with a FOXD1 adenovirus. SLIT2 was found to 
be a functionally relevant target in kidney cancer and was assessed for its role in fibroblast 
signaling through scratch assays, 3D migration assays, and multiplex proximity ligation 
assays. Knockdown of FOXD1 in the 786-O cell line followed by qPCR, western blot, and 
migration analyses.
Results: 65% of TMA samples stained positively for FOXD1. FOXD1 expression 
within the cancer cells correlated with stromal PDGFRβ expression (p<4.5x10-6). FOXD1-
high ccRCC patients had a worse survival outcome (FOXD1 low= 2830 days; FOXD1 
high= 1913 days). FOXD1 binding site analysis, RNA-microarray, and qPCR found FGF1, 
SLIT2, and Decorin to be potential secreted signaling molecules repressed by FOXD1. 
Scratch assays on fibroblasts showed that SLIT2 reduced PDGFBB-induced cell migration 
(p<0.27). Additionally, 3D migration co-culture with 786-O cancer cells determined a 
repulsive effect of SLIT2 in 3D culture as well (5μm p=1.34x10-4; 50μm p=1.64x10-2).
Conclusions: FOXD1 is an important prognostic marker for aggressiveness in ccRCC. 
The importance of fibroblast recruitment by cancer cells in ccRCC is still not known.
Funding: NIDDK Support, Other U.S. Government Support
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Birt Hogg Dubé Syndrome (BHD) and Hereditary Leiomyomatosis and 
Renal Cell Carcinoma Syndrome (HRLCC): An Effective Multidisci-
plinary Approach to Hereditary Renal Cancer Predisposing Syndromes
Andrew J. Mallett,1,2 Helen Mar fan,3 Rachel Susman,3 Janette L. Wakeling,3 
Simon T. Wood,4 Mohammad Al-shinnag.1,3 1Kidney Health Service, Royal 
Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 2Faculty of 
Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Genetic 
Health Queensland, Royal Brisbane and Women’s Hospital, Brisbane, QLD, 
Australia; 4Department of Urology, Princess Alexandra Hospital, Brisbane, 
QLD, Australia.
Background: BHD and HLRCC are rare hereditary disorders caused by germline 
FLCNand FHmutations respectively. BHD is characterized by skin fibrofolliculomas, 
lung cysts, spontaneous pneumothorax and Renal Cell Carcinoma (RCC). HLRCCis 
characterized by skin piloleiomyomas, uterine leiomyomas and RCC. BHD and HLRCC 
are autosomal dominant disorders and have estimated cumulative risk of RCC 16% with 
life-long screening recommended. We aimed to assess adherence to surveillance guidelines 
in an Australian BHD and HLRCC cohort and to describe disease characteristics.
Methods: All patients with a diagnosis of BHD or HLRCC at RBWH 01/01/2014-
31/12/2017 were included (HREC/17/QRBW/276). All patients were initially assessed and 
counselled by a Clinical Geneticist and then referred to an Adult Nephrologist. Baseline and 
incidental clinical variables were extracted and analysed.
Results: 40 patients were identified (18 BHD, 22 HLRCC) with a median age of 
49.5years. The median and cumulative follow up were 1year and 76years respectively. 
Surveillance renal MRI occurred in 32/40 patients on annual basis. Of 8/40 without 
surveillance imaging 4 were yet to have imaging, 3 were lost follow up and 1 patient 
had logistic difficulties. RCC was diagnosed in 8/40 patients: 2/18 with BHD were 
diagnosed with RCC aged 73 and 77 both prior to commencement of surveillance. 6/22 
patients with HLRCC were diagnosed with RCC (2/22 during surveillance) and 4/22 
prior to commencement of surveillance (11-43 years). Amongst BHD patients, cutaneous 
fibrofolliculoma was noted in 8/18 patients, lung cysts in 3/18 patients, spontaneous 
pneumothorax in 3/18 patients, and past parotid oncocytoma in 2/18. Amongst those with 
HLRCC, cutaneous leiomyoma were noted in 15/22, cutaneous leiomyosarcoma in 1/22 
and uterine fibroids in 10/16 female patients.
Conclusions: Evidence-based RCC screening in BHD and HLRCC cohort is feasible 
and able to identify incident renal lesions. Multidisciplinary patient management enables 
expedited genetic counselling, diagnosis, longitudinal screening and RCC management. 
The success of this clinical model warrants consideration of undertaking longitudinal 
screening of BHD and HLRCC patients by nephrologists.
FR-PO1036 Poster Friday
Genetic Diseases of the Kidneys: Non-Cystic - II
Efficiency and Safety of mTOR Inhibitors for Tuberous Sclerosis 
Complex-Associated Renal Angiomyolipoma
Andreea Andronesi,1,2 Bogdan Obrisca,1 Bogdan M. Sorohan,1 Danut Andronesi,3 
Cristina Cristache,1 Gener Ismail.1,2 1Nephrology Department, Fundeni Clinical 
Institute, Bucharest, Romania; 2Nephrology Department, University of Medicine 
and Pharmacy Carol Davila, Bucharest, Romania; 3General Surgery and Liver 
Transplant Department, Fundeni Clinical Institute, Bucharest, Romania.
Background: Kidney involvement is the most important cause of morbidity and 
mortality in adult patients with tuberous sclerosis complex (TSC). mTOR inhibitor 
Everolimus (EVE) is the only pathogenic treatment approved. Since TSC is a rare genetic 
disease, long-term experience with EVE is still limited.
Methods: TSC patients treated with EVE for renal angiomyolipoma (AML) at 
increased bleeding risk without immediate surgery indication were followed prospectively. 
Kidney CT or MRI (same modality throughout the study for each patient) was done at 
baseline and annually thereafter. Treatment response was evaluated as percentage of 
reduction of sum of volumes of all target AML identified at baseline. Adverse events (AE) 
were graded according to the CTCAE v3.0.
Results: Between January 2015-May 2018 17 patients (12F, 5M), mean age 34.8±7.5 
years (17-61), started treatment with EVE. Baseline diameter of the biggest AML was 
7.7±2.8 cm (3.8-12), 7 patients had a history of spontaneous AML bleeding with 4 of them 
suffering total one-sided nephrectomy. Baseline eGFR was 78.8±36.1 ml/min/1.73 m2  
CKD-EPI (9-126): 5 patients had stage 2 CKD, 1 patient stage 3, 2 patients stage 4 and 
1 patient stage 5. Initial EVE dose was 10 mg/day, with dose adjustments according to 
target trough level (5-15 mcg/l) and tolerance. Total treatment period was 23.4±11.4 months 
(5-45). 69.2% of patients had a more than 30% response after 12 months and the proportion 
of patients with response ≥50% increased over time. No patient had new bleeding episodes, 
neither increase in AML volume or new AML (Table 1). All patients experienced AE, the 
most frequent one being dyslipidemia in 16 patients. The severity of AE was grade 1 or 2, 
with maximum incidence during the first 12 months, with no need for permanent treatment 
withdrawal.
Conclusions: Treatment of TSC-associated renal AML with EVE is efficient and 
well tolerated. mTOR pathway regulates many major cellular processes, so AE to EVE 
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are frequent. Since this is a life-time treatment, careful surveillance is essential to rapidly 
identify and treat these AE.
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Outcomes of Arterial Embolization in Treating Renal Angiomyolipomas: 
A Single Center Experience
Saad Mohammed Shariff, Alian Albalas, Ammar Almehmi, Ahmed K. Abdel 
Aal. University of Alabama at Birmingham, Birmingham, AL.
Background: Selective arterial embolization (SAE) of renal angiomyolipoma (AML) 
is associated with parenchymal loss and contrast exposure. The aim of this study was to 
evaluate the baseline characteristics and the change in glomerular filtration rate (GFR) in 
patients with AML following SAE.
Methods: This study included all AML cases that were treated with SAE procedure 
at our center from 2004 to 2017. Data on demographics, tumor size, and other laboratory 
values were collected. Serum creatinine and calculated GFR were assessed immediately 
prior and 3 months after SAE procedure. GFR was calculated using CKD-EPI formula.
Results: Our cohort included 44 patients who underwent SAE. The indications 
for SAE included back pain, hematuria and retroperitoneal hemorrhage. Baseline 
characteristics were: age (mean ± SD) 47± 16.5 years; 77% females; 68% whites; 
and 36% were hypertensive. Acute kidney injury (AKI) was encountered in 4 patients 
(9%) following the SAE procedure. The (mean ± SD) serum creatinine increase from 
0.97 ± 0.48 to 1.17 ± 0.88 mg/dl (p=0.008) after SAE procedure. The GFR dropped from 
86.7 ± 25.8 to 79.7 ± 28.8 ml/min after procedure (p= 0.001). Post SAE GFR correlated 
with the tumor size (p= 0.047). Further, patients who developed AKI was found to have 
larger AML as compared to those with no AKI (16.8 vs 7 cm; p<0.0001).
Conclusions: Following the embolization of renal AML, there was a statistically 
significant decrease in GFR. Further, tumor size was associated with post procedure GFR 
and AKI incidence. Although the decrease in GFR could be in part attributed to the partial 
parenchymal loss and contrast exposure, its clinical significance is yet to be elucidated.
Baseline Characteristics and changes in GFR & Creatinine after AML Embolization
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Trans-Ethnic Genome-Wide Association Study of Kidney Function 
Identifies Novel Loci Influencing the Risk for Kidney Stone
Nora Franceschini,1 Thu H. Le,2 Artur Akbarov,3 Maciej Tomaszewski,3 
Andrew P. Morris.4 COGENT-Kidney Consortium 1Epidemiology, University of 
North Carolina Chapel Hill, Chapel Hill, NC; 2University of Virginia, 
Charlottesville, VA; 3University of Manchester, Manchester, United Kingdom; 
4University of Liverpool, Liverpool, United Kingdom.
Background: Genetic variants in the UMOD and RGS14 genes are associated with 
kidney function and the risk of kidney stone. We hypothesized that additional kidney 
function loci influence the risk of kidney stone.
Methods: We performed trans-ethnic meta-analysis of genome-wide association 
studies of estimated glomerular filtration rate (eGFR) in 312,468 individuals of diverse 
ancestry, followed by fine-mapping of regions informed by functional and regulatory 
annotations. Variants driving eGFR association signals were queried in 452,264 UK 
Biobank participants of European descent for association with ICD clinical code of calculus 
of kidney or ureter. Associations were validated in an independent sample of 20,339 
individuals of diverse ancestry (44% European ancestry) with self-reported diagnosis and 
history of kidney stones.
Results: We identified 93 loci attaining genome-wide significant evidence of association 
with eGFR (p<5x10-8), of which 20 were novel. After adjusting for multiple testing, five 
eGFR loci were associated with an ICD-code diagnosis of kidney stone in the UK Biobank. 
These included the two loci previously associated with kidney stones (UMOD, rs77924615, 
p=1.6 x 10-16 and RGS14, p=2.0 x10-8), a novel eGFR locus CERS2 (rs267738, p=1.6 x 10-5), 
and two known eGFR loci: CYP24A1 (rs17216707, p=9.0x10-10), and PRKAG2 (p=2.4 x10-5). 
The association of the CERS2 variant with kidney stone replicated in the independent multi-
ethnic study (p=0.008).
Conclusions: Several genetic variants associated with eGFR also confer risk for kidney 
stone, supporting shared genetic factors for kidney function and stone formation.
Funding: NIDDK Support, Other NIH Support - NIMHD, NHLBI
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Autosomal Dominant Tubulointerstitial Kidney Diseases: A Single Center 
Five-Year Cohort
Joana Gameiro,1 Jose A. Lopes,1 Sofia C. Jorge.2 1Service of Nephrology and 
Renal Transplantation, Centro Hospitalar Lisboa Norte, Lisbon, Portugal; 
2Portuguese Society of Nepghrology, Lisbon, Portugal.
Background: In patients with chronic kidney disease of unknown cause, certain 
aspects of clinical history, urinalysis and renal ultrasound might point to hereditary chronic 
interstitial nephritis (CIN). Recent sequencing technologies, such as Next-Generation 
Sequencing (NGS), have been used to identify and characterize different genetic kidney 
diseases, difficult to diagnose up until recently. The authors present this single center 
cohort of patients with identified mutations in genes responsible for autosomal dominant 
tubulointerstitial kidney diseases (ADTKD) in the last 5 years.
Methods: Over the last five years, when patients with CKD of unknown cause 
presented with a phenotype suggestive of CIN, NGS study of the UMOD, REN and HNF1B 
genes was performed, if negative, variable number tandem repeat (VNTR) mutations of the 
MUC1 gene were researched, if negative, multiplex ligation-dependent probe amplification 
(MLPA) was performed to find further mutations of the HNF1B gene.
Results: In the past five years, our department has identified ADTKD in 22 patients. 
Mutations identified included UMOD gene in 2 families (c.1463G>A (p.Gly488Asp); 
c.628G>A (p.Gly210Ser)) and 1 patient (c.859T>C (p.Cys287Arg)), MUC1 gene in 4
families, REN gene in 1 patient with two variants one of them not described yet (c.29G>A 
e c.338C>T), and HNF1β gene in 2 patients.
Conclusions: A suggestive phenotype includes bland urinalysis, hyperuricemia without 
proportion to the CKD stage, anemia not proportional to the CKD stage, hypercalemia, 
acidemia, urinary concentration defects, normal to low blood pressure and medullary renal 
cysts. Although some clinical manifestations might suggest a specific gene, many clinical 
aspects of different gene mutations might have a similar phenotype. NGS technology is 
promising in improving the approach to patients with hereditary CKD, and has allowed 
us to diagnose several patients with CKD of unknown cause. The availability, celerity 
and cost-effectiveness of this approach make it advantageous over the sequential study of 
each gene with Sanger sequencing technique. The generalization of these technologies to 
identify genetic diseases requires consistent identification of phenotypes and integration of 
data obtained. Therefore, the creation of diagnostic panels is crucial to increase diagnostic 
accuracy.
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BM-Transplant Mouse Model of MPO-ANCA-GPA
Marco A. Alba,2 Peiqi Hu,2 Hong Xiao,2 Ronald J. Falk,1 J. Charles Jennette.2 
1UNC Kidney Center, Chapel Hill, NC; 2UNC-Chapel Hill, Chapel Hill, NC.
Background: Granulomatosis with polyangiitis is an ANCA-vasculitis characterized 
by necrotizing granulomatous inflammation and small vessel vasculitis. Pathogenic 
mechanisms involved in the development of GPA remain poorly understood. Therefore, we 
sought to develop a reliable murine GPA model.
Methods: MPO-knockout mice (n=8) previously immunized with mouse MPO were 
exposed to lethal irradiation, followed by transplantation of MPO-expressing bone marrow 
(1.5x107 BM cells); resulting in circulating anti-MPO antibodies and MPO+ neutrophils. 
Lipopolysaccharide (LPS, 5μg) was administered by intratracheal instillation 3 weeks after 
BM transplant; mice were euthanized one week after.
Results: Engraftment of MPO-positive BM in combination of IT LPS resulted in the 
development of typical pulmonary and kidney ANCA-associated lesions in various phases 
of evolution, i.e., lung granulomatous lesions and vasculitis in addition to necrotizing 
crescentic glomerulonephritis (Figure 1).
Conclusions: A reproducible mouse model of MPO-ANCA-GPA is reported. Our 
results demonstrate that: 1) LPS functions as synergistic pro-inflammatory factor for 
facilitating anti-MPO induced pulmonary granulomatosis and 2) The effect of long-term 
exposure to anti-MPO-ANCA resulted in lung and kidney inflammatory lesions of different 
ages of evolution, closely mimicking human disease.
Funding: Other NIH Support - *
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The Investigation on the Production of Anti-Neutrophil Cytoplasmic 
Antibodies in Chronic Bronchitis Rat
Guangqun Xing. Department of Nephrology The Affiliated Hospital of Qingdao 
University, Qingdao, China.
Background: The purpose of this study was to investigate the possibility of the 
production of Anti-Neutrophil Cytoplasmic Antibodies(ANCA) in the rat model of chronic 
bronchitis with a long-term and recurrent infection.
Methods: The chronic bronchitis model was designed by double stimulation with 
smoke and lipopolysaccharide(LPS). Rats were divided into four groups, including healthy 
control rats (group N), group with chronic bronchitis(group CB), group with healthy rats 
stimulated with PBS and Phorbol-12-mytistate-13-Beetate(PMA)(group N/PBS+PMA), 
group with chronic bronchitis stimulated with LPS and PMA(group CB/LPS+PMA). 
Immunological markers, which include Citrullinated Histone H3(CitH3), myeloperoxidase 
anti-neutrophil cytoplasmic antibodies(MPO-ANCA) and proteinase 3 anti-neutrophil 
cytoplasmic antibodies(PR3-ANCA) were measured by enzyme-linked immune sorbent 
assay(ELISA) at different timepoint after each stimulation. The pulmonary and kidney 
tissue samples were taken for histopathology. All of related parameters indicators were 
measured and compared by optimal statistical methods.
Results: (1) The rat models of chronic bronchitis were established and verified by 
histopathology. (2)With multiple and recurrent stimulation with LPS and/or PMA, the 
serum levels of CitH3 and MPO-ANCA were found increased gradually. (3)Compared to 
those in group N, group CB and group N/PBS+PMA, the serum levels of CitH3 in group 
CB/LPS+PMA were found increased significantly. (4)The serum levels of MPO-ANCA in 
group N/PBS+PMA and group CB/LPS+PMA were higher than those in group N and group 
CB. (5)The serum levels of CitH3 in rats were positively correlated with the serum levels 
of MPO-ANCA(r=0.490, p=0.024). (6)In group with CB/LPS+PMA, mild renal pathology 
changes could be observed with inflammatory cells infiltration, while no significant 
functional changes were detected.
Conclusions: With a rat model of chronic bronchitis, recurrent infections combined 
with multiple stimulation with PMA, MPO-ANCA could be produced.
Funding: Government Support - Non-U.S.
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Urinary CD163 Levels Reflect Crescentic Glomerulonephritis in 
ANCA-Associated Vasculitis
Joop Aendekerk,1 Sjoerd Timmermans,1 Peter Heeringa,2 Pieter V. Paassen.1 
1Maastricht University Medical Center, Maastricht, Netherlands; 2University 
Medical Center Groningen, Groningen, Netherlands.
Background: Early recognition of renal flares in ANCA-associated vasculitis (AAV) 
can be challenging, particularly among patients with persistent or recurrent urinary 
abnormalities. Kidney biopsies are therefore often needed to detect active vasculitis. 
Urinary soluble CD163 (usCD163) has been shown to reflect early renal disease. Animal 
studies demonstrated that increased usCD163 reflects early stage necrotizing and crescentic 
glomerulonephritis (GN). However, this needs confirmation in humans to establish its 
role as a marker of active renal AAV. Also, it is unknown whether tubulointerstitial and/or 
vascular damage can affect usCD163 levels. Therefore, we analyzed usCD163 in relation to 
histologic data on kidney biopsy.
Methods: Thirty-two patients with AAV underwent a kidney biopsy because of 
suspected renal vasculitis (de novo, n=13; renal flare, n=19); concurrently, urine samples 
were collected. None of the patients were receiving immunosuppressive treatment before 
biopsy. usCD163 was analyzed by ELISA and corrected for creatinine excretion. Kidney 
tissue samples were classified according to the ANCA GN classification and scored for 
tubulointerstitial and vascular damage.
Results: Increased usCD163 levels were found in 27 (90%) out of 30 patients with 
crescentic GN but not those with normal kidney tissue (n=2) or controls (n=6), underlining 
usCD163’s specificity; median usCD136 levels did not differ between de novo and relapsing 
patients (302 versus 521 ng/mmol, P=0.1). In patients with crescentic GN, usCD163 
correlated with the number of affected glomeruli (R2=0.61, P<0.001), but no differences 
were found according to ANCA GN class. Neither tubulointerstitial nor vascular damage 
affected usCD163 levels. Patients classified as sclerotic class however, progressed more 
often to the composite endpoint of CKD5, ESRD, and death as compared to those classified 
as focal, crescentic, and mixed class (n/N= 6/11 and n/N=3/18; P<0.05). No association 
between usCD163 and the composite endpoint were found.
Conclusions: usCD163 is linked to crescentic GN in de novo patients with AAV, as 
well as during relapses. Both tubulointerstitial and vascular damage do not affect usCD163 
levels, suggesting that usCD163 specifically reflects crescentic GN and should be used as a 
marker of active renal disease in AAV.
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Familial Goodpasture’s Disease Associated with a Deletion in COL4A3: A 
Potential Clue to Etiology
Harald Seeger,1 Vadim Pedchenko,2 Sergey Budko,7 Ariana Gaspert,3 
Carsten Bergmann,4,6 Johan Lorenzen,1 Rudolf P. Wuthrich,1 Billy G. Hudson,2 
Andreas D. Kistler.5 1Department of Nephrology, University Hospital Zurich, 
Zurich, Switzerland; 2Vanderbilt University Medical Center, Nashville, TN; 
3Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; 
4Center for Human Genetics, Ingelheim, Germany; 5Nephrology, Kantonsspital 
Frauenfeld, Frauenfeld, Switzerland; 6Department of Medicine, University 
Hospital Freiburg, Freiburg, Germany; 7Vanderbilt Univ Medical Center, 
Nashville, TN.
Introduction: Goodpasture’s (GP) or anti-glomerular basement membrane (GBM) 
disease is characterized by glomerulonephritis (GN) and/or alveolar hemorrhage. It is 
caused by antibodies that bind the non-collagenous domain (NC1) of the collagen IV α345 
network in the GBM and alveolar basement membranes. Antibodies bind to α3 and α5 
NC1 monomers but not native α345NC1 hexamers, indicating that a perturbation of the 
quaternary structure of the hexamer is required for eliciting an autoimmune response. We 
describe a case of familial GP disease associated with a structural alteration in the α345NC1 
domain.
Case Description: The index patient was affected at the age of 45 years by alveolar 
hemorrhage and renal failure due to GN with linear IgG deposits in the GBM and circulating 
anti-GBM antibodies. Her son developed the same clinical phenotype at the age of 24 years. 
Genetic analysis revealed a heterozygous 18 base pair deletion in both subjects in the region 
of the COL4A3 gene coding for the NC1 domain. The deletion contains the stop codon and 
leads to an elongated collagen α3NC1 domain, which substitutes 8 additional amino acid 
(AA) residues for the very last C-terminal AA.
Discussion: COL4A3 mutations typically cause autosomal Alport’s or thin basement 
membrane disease, yet there was no evidence for this in our patients. Anti-GBM 
antibodies behaved like in classical GP cases. They reacted with dissociated, but not 
native α345NC1hexamers, and bound to the wild type α3NC1 monomer at both EA and 
EB epitopes. Analysis of the 3D model of the α345 hexamer revealed that the mutant 
extension of 8 polar and hydrophobic residues is located proximal to the EA and EB 
epitopes. Potentially, the extension can fold into the crevice between both epitopes and 
lead to conformational changes that impact epitope presentation. The epitope structure may 
be altered to include residues of the extension or rendered accessible by the antibody. In 
conclusion, this is the first report of a COL4A3 mutation associated with GP disease. The 
occurrence of this mutation in two family members, with autoantibodies against the α3NC1 
autoantigen, indicates that it plays a key role in disease etiology. The association of this 
mutation with disease may be a clue to the etiology of both familial and sporadic cases of 
GP disease.
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Significance of Glomerular Fibrinoid Necrosis in ANCA-Associated 
Vasculitis
Marco Delsante,1 Francesca Costigliolo,2 S.M. Bagnasco,1 Avi Z. Rosenberg.1 
1Renal Pathology, Johns Hopkins Hospital, Baltimore, MD; 2Nephrology, 
University of Genoa, Genova, Italy.
Background: ANCA-associated vasculitis (AAV) represent a group of severe diseases 
with frequent kidney involvement and poor renal prognosis. Risk factor for progression 
to ESRD include creatinine at presentation, presence of globally sclerosed glomeruli 
and arteriosclerosis. The 2010 histologic classification of AAV includes 4 classes (focal, 
crescentic, mixed and sclerotic), based on the rate of globally sclerosed glomeruli, cellular 
crescents and normal glomeruli. To our knowledge, the prognostic value of glomerular 
fibrinoid necrosis (FN) quantification in AAV has not been evaluated.
Methods: We retrospectively studied 45 consecutive renal biopsies with diagnosis 
of AAV (01/2010-5/2015). Conventional stains were used to assess the percentage of 
glomeruli showing FN, cellular crescents, global sclerosis and presence of vascular FN. For 
31 patients, follow-up data were available for clinicopathological correlations
Results: Fibrinoid necrosis was observed frequently in our cohort (91%), involving 
an average of 22% (SD±20.5) of the glomeruli. When different histological classes were 
analyzed, percentage of FN was higher in crescentic (biopsies with >50% of the glomeruli 
showing cellular crescents) compared to other categories (Figure 1). The presence of 
>20% of the glomeruli showing FN was not correlated with a worse renal survival at
any time of the follow up. No significant correlation was found between percentage of 
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glomerular FN and gender, ethnicity, age, ANCA levels (ELISA), eGFR at diagnosis and 
presence of vascular FN. The distribution of glomerular FN was the same in different 
vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic 
granulomatosis with polyangiitis).
Conclusions: FN is seen in the presence of active crescentic lesions and is less likely 
observed in biopsies with advanced chronicity. Higher percentage of FN is not associated 
with worse renal prognosis, suggesting an active inflammatory process, potentially 
reversible after adequate therapy.
Figure 1. Distribution of percentage FN in different classes of AAV.
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Transcriptional Dysregulation in Low Density Granulocytes from Patients 
with ANCA Vasculitis
Dominic J. Ciavatta,1,2 Britta E. Jones,1 William Bass,1 Carolina A. Herrera,1,3 
Christian Agosto-Burgos,1,3 Caroline J. Poulton,1 Joshua Starmer,2 
Meghan E. Free,1,3 J. Charles Jennette,3,1 Ronald J. Falk.1,4 1UNC Kidney Center, 
University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Genetics, 
Univesity of North Carolina at Chapel Hill, Chapel Hill, NC; 3Pathology and 
Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, 
NC; 4Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Background: ANCA vasculitis is characterized by elevated expression of autoantigen 
genes, MPO and PRTN3; however, the source and implications of the elevated expression 
are unresolved.
Methods: We isolated monocytes, neutrophils, and an enriched fraction of PBMC from 
30 healthy controls (HC) and 75 patients. PBMC from 8 HC and 18 patients were sorted 
for CD15+ and CD15+/CD10+ cells. Low density granulocytes (LDG) were enriched from 
PBMC of 28 HC and 67 patients. Gene expression was measured by quantitative RT-PCR. 
LDG were immunophenotyped by flow cytometry for cell surface markers.
Results: Expression of MPO and PRTN3 was significantly elevated in active patients 
compared to controls in neutrophils (2.6 and 3.6-fold) and in an enriched PBMC fraction 
(7 and 15.8-fold). Based on the greater fold-change expression in the PBMC fraction we 
sorted PBMC into CD15+ and CD15+/CD10+ cells. The nuclear morphology of the CD15+ 
cells is consistent with immature progenitor granulocytes, while the CD15+/CD10+ cells 
had segmented nuclei of mature neutrophils. We purified LDGs containing both CD15+ and 
CD15+/CD10+ cells. MPO and PRTN3 expression in LDGs were elevated in active patients 
compared to controls (9.3 and 16.5-fold), and correlated with expression in total leukocytes 
(WBC). LDG heterogeneity was analyzed by flow cytometry and the percentages of cell 
populations were compared to autoantigen gene expression. The percent of LDGs in PBMC 
and the percent of CD15+ cells in the LDG population showed weak correlations with MPO 
and PRTN3 expression (r2<0.09) (Figure).
Conclusions: The frequency of LDGs or CD15+ cells explains less than 10% of the 
variation in MPO and PRTN3 expression suggesting transcriptional dysregulation, not an 
increase in neutrophil progenitors, drives increased expression.
Funding: NIDDK Support
Heatmap represents the correlation coefficients (color scale shown at right) for pairwise 
comparisons.
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Immunoproteasome-Deficiency Attenuates Antibody-Mediated Podocyte 
Injury
Wiebke Sachs,1 Marlies Sachs,2 Catherine Meyer-Schwesinger.3 AG Meyer-
Schwesinger 1University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 2UKE, Hamburg, Germany; 3University of Hamburg, Hamburg, 
Germany.
Background: Membranous nephropathy (MN) is an autoimmune disease characterized 
by subepithelial immune complex deposition and podocyte injury. Persistent podocyte 
injury during MN is associated with the upregulation of the ubiquitin-proteasome system 
(UPS), wherein the immunoproteasome is responsible for enhanced protein degradation 
and for generating peptides for MHC class I presentation. Here we address the impact of 
immunoproteasome-deficiency on the development of antibody-mediated podocyte injury.
Methods: Anti-podocyte nephritis (APN), a model for MN, was induced in global-
β5i and podocyte-specific β5i deficient mice as well as littermate controls. As clinical 
parameters urine albumin/creatinine and BUN were measured. Morphological analysis of 
the kidney was obtained via PAS staining. Proteasomal function and activity of isolated 
glomeruli were analyzed via Western Blot and proteasomal activity assays.
Results: The development of proteinuria during APN was attenuated in global- and 
podocyte-specific β5i deficient mice compared to wildtype littermates. Western blot 
analysis revealed the upregulation of the standard proteasome in β5i deficient mice during 
APN. This was also shown in the upregulation of the chymotrypsin-like activity (the major 
proteasomal activity) in the β5i deficient mice.
Conclusions: Immunoproteasome-deficiency protects against antibody-mediated 
podocyte injury in mice. This can be explained by the upregulation of the standard 
proteasome, which leads to a different quantity and quality of peptide generation.
Funding: Government Support - Non-U.S.
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The Effect of B Cell Targeted Therapies on Autoantibodies and  
Excessive Neutrophil Extracellular Trap Formation in Systemic  
Lupus Erythematosus Patients
Laura S. van Dam,1 Zgjim Osmani,1 Tineke Kraaij,1 Sylvia Kamerling,1 
Jaap A. Bakker,1 Hans Ulrich Scherer,1 Ton J. Rabelink,1 Reinhard E. Voll,2 
David Isenberg,3 Cees van Kooten,1 Yoe Kie Onno Teng.1 1LUMC, Leiden, 
Netherlands; 2University Medical Center Freiburg, Freiburg, Germany; 
3University College London, London, United Kingdom.
Background: Systemic lupus erythematosus (SLE) is a severe systemic autoimmune 
disease characterized by immune-complexes (ICx) which cause inflammation and damage. 
Effective targeting of autoantibody secreting cells could be key to reset autoimmunity. 
Functionally, SLE-specific ICx are important triggers of neutrophil extracellular trap (NET) 
formation. A consortium was formed to study B-cell targeted therapies, including RTX, 
Bortezomib (BTZ) or combination of RTX + Belimumab (BLM). The present study aimed 
to investigate the effects of these therapies on relevant autoantibody levels and excessive 
NET formation.
Methods: This study involved three cohorts of severe SLE patients that were eligible 
to experimental treatment with RTX (n=16), BTZ (n=12) or RTX+BLM (n=16). A cross-
sectional cohort of 35 SLE patients served as a control cohort. A panel of SLE relevant 
autoantibodies against dsDNA, histones, nucleosomes and C1q were measured by ELISA. 
NET formation was quantified by a novel highly-sensitive assay using 3D confocal 
microscopy (Kraaij et al. 2016).
Results: Comparing three regimens, RTX+BLM resulted in the strongest significant 
reduction on anti-dsDNA, anti-Histone and anti-Nucleosomes antibodies compared to a 
smaller decrease by RTX and BTZ. Interestingly, RTX+BLM specifically decreased anti-
C1q antibodies, which were not targeted by RTX or BTZ. ICx-mediated NET formation 
was only significantly decreased with a median of 75% [53 – 85%] after RTX+BLM 
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(p=0.0002). Successful seroconversion of autoantibodies associated with decreased NET 
formation (p=0.02). The latter phenomenon was further corroborated in an independent 
cohort of SLE patients, where excessive NET formation associated with the presence of 
three or more autoantibody specificities (p=0.02), and specifically with the presence of anti-
C1q antibodies (p=0.03).
Conclusions: In this reverse, translational study of B-cell targeted therapies, we 
demonstrate that anti-C1q autoantibodies were derived from Blys-dependent proliferating 
plasmablasts because they were only susceptible to RTX+BLM therapy. Moreover, 
therapeutically narrowing of the autoantibody repertoire decreased immune-complex 
mediated NET formation.
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Efficiency and Safety of Thalidomide Combined with Dexamethasone in 
Patients with Proliferative Glomerulonephritis with Monoclonal IgG 
Deposit
Zhen Cheng, Zhihong Liu, Zhou Wei, Juan Li. National Clinical Research 
Center of Kidney Diseases, Jinling Hospital, Nanjing University School of 
Medicine, Nanjing, China.
Background: To evaluate the efficacy and safety of thalidomide combined with 
dexamethasone (TD) in patients with proliferative glomerulonephritis with monoclonal 
IgG deposits(PGNMID).
Methods: We retrospectively analyzed the clinical data of 12 patients diagnosed with 
PGNMID from December 2015 to November 2017 in Jinling Hospital, who received TD 
regimen, and 32 PGNMID patients treated with non-TD regimen from 2011 to 2016.
Results: There are 4 males and 8 females with a median age of 48.5(27,63) yr taking 
the regimen of TD. With a mean follow-up of 7.5 mo, 6(50%) patients achieve renal 
response, including 2(16.7%) patients achieving complete response and 4(33.3%) patients 
achieving partial response, median time of response was 5.5 mo. 5(83.3%) patients got 
hematological response, in which 1(16.7%) patients obtain complete response, 2(33.3%) 
patients obtain very good partial response and 2(33.3%) patients obtain partial response. 
After treatment, serum albumin improved(P=0.002), serum creatinine kept stable(P=0.79), 
urine protein decreased(P=0.099), and no patient progressed to ESRD. One patient got 
histopathological recovery. During the secondary renal biopsy, the monoclonal IgG3 and 
κ light chain deposited in kidney disappeared completely, and glomerular nodular changes 
also improved. There was no statistical difference in clinical data between the two groups
except for gender. With a mean follow-up of 19.2 mo in non-TD group, 5(15.6%) patients 
achieve renal response, including 3(9.4%) patients achieving complete responseand 2(6.3%) 
patients achieving partial response. The renal response rate was lower than those in TD
group (P=0.045). 3 (33.3%) patients got hematological response. Serum creatinine in the
last follow-up were worse than the baseline(P=0.046), albumin (P=0.005) and proteinuria
(P=0.044) were improved, and 8(25%) patients progressed to ESRD with an average time 
of 25.2 mo. The common side effects of TD group were numbness (50%), edema (50%) and 
sleepiness (50%), but most of the patients were tolerable through symptomatic treatment
and drug reduction.
Conclusions: The TD regimen is effective for PGNMID patients. Side effects are 
common but most of the patients can tolerate it.
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Suboptimal Dosing of Initial Eculizumab Therapy in aHUS?
Caroline Duineveld,1 Kioa L. Wijnsma,2 Elena Volokhina,3 Nicole Van De Kar,2 
Jack F. Wetzels.1 1Department of Nephrology, Radboudumc, Nijmegen, 
Netherlands; 2Department of Pediatric Nephrology, Amalia Children’s Hospital, 
Nijmegen, Netherlands; 3Department of Laboratory Medicine, Radboudumc, 
Nijmegen, Netherlands.
Background: Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation 
of the alternative complement pathway. With the introduction of the complement inhibitor 
eculizumab the prognosis of aHUS patients has significantly improved. Initiation of 
eculizumab immediately at disease onset is advised to prevent persistent kidney injury. 
For complete blockade of the terminal complement pathway eculizumab trough levels of 
50-100 μg/ml are recommended. However, recent data suggested that the advised treatment 
protocol may be insufficient: low eculizumab levels in the induction phase were followed 
by eculizumab levels exceeding the recommended trough levels in the maintenance phase. 
(Volokhina, 2017).
Methods: We have extended previous observations and evaluated all adult aHUS 
patients who were treated with eculizumab in our center from 2013 to 2018.
Results: Eculizumab was used as induction therapy 23 times in 19 adult aHUS patients. 
Eculizumab trough levels after the first dose were measured in 12 patients. Five patients 
did not maintain eculizumab levels of >50 μg/ml after the first dose. This was paralleled 
by incomplete complement blockade. After the second infusion target levels were attained 
in all patients. No differences in gender, body-weight, CRP, creatinine-protein ratio and the 
presence of edema at presentation were found between the patients who did and did not 
reach target level. Eculizumab levels after the second dose increased far above target range 
and resulted in near complete blockade of the classical complement pathway (measured 
with Wieslab® Euro Diagnostica complement system screen) in all patients (reference 
value 69-129%, complete deficiency <1%) (Figure).
Conclusions: After the first dose of eculizumab trough levels were not reached in 41% 
of the patients. Subsequent eculizumab levels exceed the recommendation. Our results 
suggest that the current induction protocol is insufficient: the first dose should be increased 
or the interval shortened, later doses may be reduced.
Funding: Commercial Support - Health insurance association, The Netherlands, 
Government Support - Non-U.S.
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The Study on the Mechanism of SOCS1/STAT1 Regulate Renal Inflam-
mation in Mesangial Proliferative Glomerulonephritis Models
Jiuxu Bai, Xiangmei Chen. Chinese PLA General Hospital, Beijing, China.
Background: Glomerulonephritis (GN) is characterized by intraglomerular 
inflammation and is a major cause of end-stage renal disease. Inflammation plays a crucial 
role in the progress of mesangial proliferative glomerulonephritis (MsGN). The suppressor 
of cytokine signaling (SOCS) proteins which are inhibitors of cytokine signaling pathways 
unveiled an important mechanism for the negative regulation of the cytokine-induced JAK/
STAT pathway. This study examined whether SOCS1 can regulate renal inflammation in 
MsGN models.
Methods: In Vivo: Rat (Thy 1.1 GN) and mouse (Habu GN) mesangial proliferative 
nephritis models were established. The expression of SOCS1, MHC class II, STAT1, 
inflammatory cells and cytokines were analyzed in MsGN modes. In Vitro: IFN-γ-stimulated 
mouse mesangial cells(MMCs)were transfected with SOCS1 plasmids. Meanwhile, we 
used STAT1 inhibitor fludarabine in IFN-γtreated MMCs. The expression of MHC class II, 
STAT1 and cytokines were analyzed.
Results: Thy1.1 GN recapitulates the main features of human mesangial proliferative 
glomerular diseases, was generated. In addition, mouse GN was induced with Habu snake 
venom (HV). The number of macrophages and CD4 T cells increased significantly in 
glomeruli of MsGN models. Expression of IFN-γ, TNF-α, IL-12A and IL-12B increased 
significantly in the course of Thy 1.1 and Habu nephritis. MHC class II is expressed in 
mesangial cells of MsGN models. SOCS1 protein also showed a significant decrease 
and P-STAT1 increased significantly at early stage in MsGN models. It suggested that 
SOCS1/STAT1 participate in MsGN model progression. STAT1 inhibitor decreases renal 
inflammation and ameliorates glomerular lesions in Habu GN. The overexpression of 
SOCS1 repress MHC class II and STAT1 phosphorylation which is induced by IFN-γ in 
mesangial cells. STAT-1 inhibitor could inhibit IFN-γ-induced CIITA promoter activity and 
MHC class II significantly.
Conclusions: This study emphasizes the pivotal role of the SOCS1/STAT1 axis in 
regulating inflammation in mesangial proliferative glomerulonephritis. In addition, it 
demonstrates that SOCS1 is a critical regulator of cellular sensitivity to IFN-γ-induced 
CIITA and MHC class II expression in mesangial cells. The negative feedback between 
the expression of SOCS1 and inflammation may play an important role in the mesangial 
proliferative glomerulonephritis.
Funding: Government Support - Non-U.S.
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Evolution of Autoantibody Function in C3 Glomerulopathy
Alexandria Leonhardt,2 Dingwu Shao,2 Yuzhou Zhang,2 Richard J. Smith,1,2 
Carla M. Nester.1,2 1Medicine and Pediatrics, University of Iowa Hospitals and 
Clinics, Iowa City, IA; 2Molecular Otolaryngology and Renal Research 
Laboratory, University of Iowa, IOWA CITY, IA.
Background: Autoantibodies play an important role in the pathogenesis of C3 
Glomerulopathy (C3G). Binding of either C3 nephritic factors (C3Nef) or Factor B 
autoantibodies (FBAA) to the alternate complement (AP) pathway’s C3 convertase (C3C) 
stabilizes this critical enzyme, prolonging its half-life and preventing normal regulation of 
the AP. The stabilizing characteristic of these antibodies are well described. Little is known 
about their correlation with disease natural history. Further characterization of C3G disease 
related autoantibodies has the potential to influence patient management algorithms.
Methods: Our study cohort included 8 C3G patients (drawn from the University of 
Iowa’s C3G Natural History Study) in whom at least 3 squential draws were available (4 
FBAA and 4 C3Nef). Comprehensive biomarker studies and autoantibody kinetic studies 
(SPR) were performed across multiple times points of disease course. Comparisons were 
made between C3C t ½, comprehensive biomarker assays and measures of clinical activity.
Results: FBAA kinetics were independent of FBAA titer or complement biomarker, 
and tended to be static over time. In contrast, the C3C stabilizing kinetic of C3Nef were 
more variable over disease course - tending to trend downward. In one patient, the C3Nef 
stabilization of C3C dropped by factor of 4 (211 minutes to 49.5 minutes over a 6 yr period 
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- with 5min being normal). This change was associated with a normalization of a previously 
undetectable C3.
Conclusions: Point assessments of C3Nef are insufficient to fully characterize the 
function of this autoantibody. C3Nef kinetics evolve over disease course and are associated 
with changes in both biomarkers of complement dysregulation and clinical activity. This 
preliminary data prompts a number of interesting hypotheses, not the least of which is the 
concept that C3Nef functional testing may be a way to detect “windows” of relative disease 
quiescence in given patients.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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Complement and Cytokine Characterization of C3GN
Nicholas J. Steers,1 Debanjana Chatterjee,1 Wan yee Lam,1 Natalia D. Demaria,1 
Andrew S. Bomback,1 Gerald B. Appel,2 Ali G. Gharavi.1 1Columbia University, 
New York, NY; 2Columbia University College of Physicians and Surgeons, 
Scarsdale, NY.
Background: The complement pathway is an innate immune defense mechanism, 
when uncontrolled can cause damage to host tissues including the kidney upon uncontrolled 
activation of the alternative complement pathway (ACP). C3GN is characterized by 
deposits in the glomerulus made up entirely of complement C3 protein without the presence 
of immunoglobulins.
Methods: We determined the cytokine and complement profiles derived from the 
plasma of 40 C3GN cases, and 15 healthy controls (HC), utilizing the Luminex assay.
Results: Analysis of the plasma from 40 C3GN patients compared to HC revealed 
significant decreases in the complement pathway proteins C3 (424±336 vs 673±118 μg/ml), 
C4 (233±71 vs 392±115 μg/ml), C4b (10.9±4.3 vs 15.9±3.1 μg/ml), C5 (15.8±8.3 
vs 24.3±6.4 μg/ml), CFH (247±60 vs 285±44 μg/ml), and Properdin (19.2±5.3 vs 
25.2+5.6 μg/ml). In-depth analysis of the plasma derived from C3GN patients identified 
significantly low C3 levels (2*SD below Average HC) in 21 patients, in which 72% of 
these had significantly low levels of plasma C5. Key components of the ACP are CFH 
and properdin, and we only identified 10 patients with significantly low levels CFH 
(7 associated with low plasma C3), and 11 with significantly low levels properdin 
(8 associated with low plasma C3). Global cytokine analysis in C3GN plasma determined 
significant increases in proinflammatory cytokines TNFα detected in 100% of C3GN 
patients (17.9+8.9 pg/ml) and IL-1α detected in 82% of C3GN patients (80.3±80.1 pg/
ml) compared to HC ((100%) 7.2+3.6 and (40%) 29.7+29.9 pg/ml, respectively). Cytokine 
analysis demonstrated bi-modal patterns with increased percentage of C3GN patients
having elevated levels of pro-inflammatory cytokines, IL-6 and IL-12p40 was more 
prevalent in the plasma of C3GN patients (45% and 50% respectively), compared to HC
(26% and 26% respectively)
Conclusions: The plasma of C3GN patients demonstrates activation of the ACP and 
elevated levels of proinflammatory cytokines that are associated with stimuli know to 
activate the ACP. Our data set is being expanded to include additional samples and will be 
correlated with the clinical status of patients. In-depth profiling of immunological markers 
and the specific relationships will able to design a panel specific to individual complement 
associated glomerular pathology.
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C3 Glomerulopathy: Pattern of Injury and Response to Treatment
Luis A. Castillo. Nephrology, Clínica de la Costa, Barranquilla, Colombia.
Background: C3 glomerulopathy refers to those renal lesions characterized 
histologically by predominant C3 accumulation within the glomerulus with absent or scanty 
immunoglobulin deposition, and pathogenetically by aberrant regulation of the alternative 
pathway of complement. Objectives:To describe the evolution of renal involvement and the 
response to treatment with 1year follow- up.
Methods: Observational study case series type. The data were extracted from 
NefroRed©, a platform that contains the socio-demographic, anthropometric, clinical and 
laboratory data of 1340 patients with kidney biopsies from 2007-2015. It was selected for 
the study those patients that showed the pattern of glomerulonephathy and C3 deposits only 
or predominant. The primary endpoint for subjects enrolled was change in proteinuria and 
serum creatinine over treatment period. Patients will be subclassified into three groups, 
those who had been treated with mycophenolate mofetil (MMF), Cyclophosphamide (CP) 
and those who had anti-complement therapy with eculizumab (ECZ). Statistical analysis 
descriptive.
Results: 34 patients with C3 glomerulopathy were identified. Pathological lesion: 
80% membranoproliferative glomerulonphritis, 6.7% GSFS, 6.7% mesangial proliferative, 
6.7% membranous. Clinical preentation: 86.67% Nephrotic Syndrome, 26.67% nephrytic 
syndrome, 13% renal insuficiency, 53.33% Hypertension. 15 patients received active 
treatment with CP, 12 with MMF and 3 with eculizumab.
Conclusions: The scope of the study is limited largely because of the rarity of these 
disorders. There was not a response to ECZ. The treatment with MMF improved proteinuria 
but not renal function. The CP improved proteinuria and creatinine. Reports suggest that a in 
our population the cyclophosphamide is more effective. Formal trial of comprising a greater 
number of well-characterized patients is warranted.
Comparison of the CrSr and Proteinuria between MMF, ECZ and CP
MMF: Mofetil Mycophenolate; CP: Cyclophosphamide; ECZ: Eculizumab; SrCr: Serum 
Creatinine; NS: Not Significant.
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Comparison Among Dominant C1q Positive Cases Including C1q 
Nephropathy Classified by Immunofluorescence
Erina Ono, Shuichiro Endo, Takeshi Matsubara, Hideki Yokoi, Eri Muso, 
Motoko Yanagita. Department of Nephrology, Kyoto university Hospital, Kyoto, 
Japan.
Background: Although the disease entity of C1q nephropathy was first described 
by Jennette and Hipp in 1985, the characteristics of the heterogeneous phenotypes and 
the pathogenic role of C1q for the disease progression has not been elucidated yet. We 
analyzed dominant C1q positive renal biopsy specimens to speculate the significance of 
C1q localization.
Methods: A total of 1763 consecutive patients performed renal biopsy at Kyoto 
University Hospital from 1982 through 2001 were investigated. We analyzed 34 cases 
(1.9%) with dominantly C1q-positive staining excluding lupus nephritis, IgA nephropathy, 
and membranous nephropathy. Next, we classified these patients into three groups; C1q 
mono-dominant (mC1q) group (n=3) with no immunoglobulin deposition and C1q co-
dominant group (total n=31) with IgG (cC1q-IgG) (n=19) or IgM (cC1q-IgM) (n=12).
Results: Precise pathological analysis showed in mC1q group, minor glomerular 
abnormality in light microscopy (LM), with mesangium localization of C1q with C3d 
positivity in immunofluorescence microscopy (IF). Apparent electron dense deposit (EDD) 
and foot process effacement were observed in electron microscopy (EM). CC1q-IgG group 
revealed variety of glomerulonephritis pattern frequently showing capillary wall involved 
glomerular lesion such as double contour, subendothelial deposit and crescent formation 
with high frequency of global sclerosis. C1q localized in capillary wall and mesangium 
accompanying IgG, and IgM in all cases and additional IgA in 15 cases with strongly 
positive C3c and C3d in IF. CC1q-IgM group exhibited focal segmental sclerosis and 
double contour in LM. C1q was positive in mesangium colocalized with IgM and C3d 
in all but C3c in some in IF. EDD was negative in all 6 cases in EM. Laboratory data 
revealed cC1q-IgG group included relatively severe cases in creatinine level and hematuria 
compared with the other two groups.
Conclusions: The hypothesis of glomerular injury through activation of complement 
system might be applicable via immune complex formation in cC1q-IgG group, directly in 
mC1q group and not applicable in cC1q-IgM group. The analysis of dominant C1q-positve 
renal biopsy specimens include several diseases in these case series raises the possibility 
that current category of C1q nephropathy indicates some specific condition of existing 
diseases.
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Fibrillary Glomerulonephritis: Clinical Features and Outcomes in an 
Ethnically Diverse Urban European Population
Sandhi W. Nyunt, Kassiani Skordilis, Peter Hewins, Miriam Berry. University 
Hospitals Birmingham, Birmingham, United Kingdom.
Background: Fibrillary glomerulonephritis (FGN) is a rare glomerular lesion 
characterised by the presence of 20nm fibrillary deposits on electron microscopy (EM). It is 
usually associated with poor renal outcomes. The largest case series to date describe North 
American populations.
Methods: We performed a retrospective case note review of patients with FGN, 
identified through the renal histology database at our tertiary referral hospital in the UK 
from 2001-17. EM has been performed routinely on all native biopsies since 2014.
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Results: We identified 19 patients with FGN. 7 had a second histological lesion 
present including: IgA disease (2), vasculitis (4) nodular glomerulosclerosis (1). The 
median age at presentation was 58 (47-72) years, with a female preponderance (1.7:1 
F:M). 83% were Caucasian. There were no strong associations with systemic disease. At 
presentation, median eGFR was 44 (20-68) ml/min and urine albumin:creatinine ratio 
264 (80-351) mg/mmol. Hypertension (35%), proteinuria (88%), haematuria (71%) and 
hypercholesterolaemia (71%) were common while nephrotic syndrome was rare (11%). 
38% patients received immunomodulatory therapy: corticosteroids (n=6), mycophenolate 
mofetil (n=2), azathioprine (n=1), cyclophosphamide (n=1). After median 44 (22-49) 
months follow-up, 47% patients were clinically stable, 6% had progressive CKD, 35% had 
progressed to end stage renal disease (ESRD) and 12% had died. Of those patients receiving 
immunomodulatory therapy, n=3 were stable, n=2 progressed to ESRD and n=1 had died. 
Renal insufficiency and significant proteinuria at diagnosis were risk factors for poor renal 
outcomes. Patients with FGN alone had significantly better renal outcomes than those with 
a second histological lesion; 75% of patients with vasculitic lesions progressed to ESRD.
Conclusions: Diagnosis of FGN has become more common with routine use of EM. 
FGN was more common in Caucasian patients, even in an ethnically diverse population. 
In contrast to previous studies, there were no strong associations with systemic disease. 
The efficacy of immunomodulatory therapy is difficult to evaluate in a small sample 
size. Significant proteinuria and renal insufficiency were poor prognostic indicators. 
Renal outcomes were better than in published case series; longer follow-up is required to 
determine the significance of this observation.
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ABIN1 Contributes to Glomerulonephritis via Induction of IP-10 
Expression and Activity
David W. Powell,1 Mark B. Vieyra,1 Shweta Tandon,1 Erik Korte,2 
Michelle T. Barati,1 Kenneth Gagnon,1 Kenneth R. McLeish,1 Dawn J. Caster.1 
Immune-Mediated Kidney Disease Laboratory 1Medicine/Nephrology and 
Hypertension, University of Louisville, Louisville, KY; 2University of Louiville, 
Louisville, KY.
Background: Our research to define genetic risks of glomerular inflammation identified 
variants in TNIP1 as risks for development of lupus nephritis. TINIP1 encodes ABIN1, 
a physiological inhibitor of NF-κB and MAPK-mediated inflammation. We reported that 
loss of ABIN1 function in podocytes (ABIN1[D485N]) exacerbates immune-mediated 
podocyte injury and enhances podocyte cytokine and chemokine production in vivo and 
in vitro, leading to enhanced neutrophil recruitment and activation. The NF-κB-mediated 
chemokine IFN-γ-inducible protein 10 (IP-10) had a > 20-fold increase in gene expression 
in podocytes with loss of ABIN1 activity. The current study tested the hypothesis that IP-10 
contributes to ABIN1-mediated podocyte injury and glomerular inflammation.
Methods: In vitro exocytosis (flow cytometry for granule markers CD66b and CD35) 
and chemotaxis (transwell migration assay) of primary human neutrophils was measured 
following incubation with recombinant IP-10 w/wo a known activator FMLF. Urinary 
IP-10 levels were measured by ELISA 24 h following administration of nephrotoxic anti-
GBM antibody in WT and ABIN1[D485N] mice. Proteinuria was measured 24 h following 
administration of anti-GBM in WT and ABIN1[D485N] mice w/wo pre-treatment with 
neutralizing IP-10 antibody.
Results: Recombinant IP-10 did not activate neutrophil chemotaxis alone, but 
significantly primed the response to FMLF. IP-10 activated neutrophil exocytosis alone 
and also primed the FMLF response. Urinary IP-10 levels were significantly higher in 
ABIN1[D485N] mice than WT mice 24 h-post anti-GBM administration. Anti-GBM-
induced proteinuria was inhibited by pre-treatment with IP-10 antibody in WT and 
ABIN1[D485N] mice.
Conclusions: Our data suggest that genetic disruption of ABIN1 in podocytes results 
in enhance production of IP-10 during experimental glomerulonephritis and that IP-10 
production regulates neutrophil activation and contributes to glomerular damage leading 
to proteinuria. Our data provide clinical relevance for the finding that IP-10 is a urinary 
biomarker for lupus nephritis (LN). The use of IP-10 neutralizing antibody for treatment of 
ulcerative colitis and rheumatoid arthritis, suggests a new therapeutic approach for patients 
with LN associated with variants for TNIP1 or other NF-κB or MAPK regulatory genes.
Funding: Other NIH Support - NIAMS, Clinical Revenue Support
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Elevated Levels of Urinary Extracellular Vesicle Fibroblast-Specific 
Protein 1 in Patients with Active Crescentic Glomerulonephritis
Yukie Morikawa,1 Naoki Takahashi,1 Kazuko Kamiyama,1 Kazuhisa Nishimori,1 
Yudai Nishikawa,1 Mamiko Kobayashi,1 Sachiko Fukushima,1 Seiji Yokoi,1 
Daisuke Mikami,1 Hideki Kimura,1 Kenji Kasuno,1 Masanori Hara,2 
Masayuki Iwano.1 1University of Fukui, Yoshida-gun, Japan; 2Niigata Wellness 
(Iwamuro Health Promotion Center), Niigata, Japan.
Background: Extracellular vesicles (EVs), including exosomes, are present in a 
variety of bodily fluids, including urine. We previously reported that large numbers of 
fibroblast-specific protein 1 (FSP1)-expressing cells accumulate within damaged glomeruli 
and that urinary FSP1 could potentially serve as a biomarker of ongoing glomerular injury. 
However, the precise mechanism by which urinary FSP1 is secreted is unknown.
Methods: To address that issue, we collected urine samples from 37 patients with 
various types of glomerular disease (6 with ANCA-associated nephritis, 11 with IgA 
nephropathy, 11 with membranous nephropathy, 6 with minimal-change disease and 
3 with lupus nephritis), purified the urinary EVs using total exosome isolation regent, 
and characterized the vesicles using Nanosight, western blotting and immunoelectron 
microscopy. We measured FSP1 levels in total urine and EVs fraction with sandwich 
ELISA. FSP1 level associated with crescentic formation were evaluated by receiver 
operating characteristic (ROC) curve analysis.
Results: Deemed to be mainly exosomes, based on their size distribution, the vesicles 
contained FSP1. Moreover, a portion of these FSP1-positive EVs were also positive for 
podocalyxin. ELISAs showed that FSP1 levels in urinary EVs correlated positively with 
rates of biopsy-proven cellular crescent formation (r = 0.562, P < 0.001) and total crescent 
formation (r = 0.448, P = 0.005) among total glomeruli. FSP1 levels in urinary EVs were 
significantly higher in patients with cellular crescents affecting 20% or more of their 
glomeruli than in those with fewer affected glomeruli (P = 0.003). FSP1 level in EVs for 
predicting cellular crescent formation affecting more 20% was 2.4 ng/mL, with an area 
under the ROC curve were 0.88 (95%CI, 0.693 to 1.070). FSP1 levels in urinary EVs also 
correlated positively with total urinary FSP1 levels (r = 0.834, P < 0.001) in patients with 
at least one cellular crescent.
Conclusions: These data suggest that a portion of urinary FSP1 is secreted as 
microvesicles originating from podocytes, and that FSP1 levels in urinary EVs reflect active 
and ongoing glomerular injury, such as cellular crescent formation.
FR-PO1058 Poster Friday
Glomerular Diseases: Immunology and Inflammation - II
Deficiency for the Chemokine Receptor CCR2 Protects from Glomerular 
Injury and Interstitial Fibrosis in Adriamycin-Induced Glomerulosclerosis
Anja Wilkening, Nuru Eltrich, Bruno Luckow, Volker Vielhauer. Nephrologisches 
Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität 
München, Ludwig-Maximilians-University Munich, Munich, Germany.
Background: Glomerulosclerosis and tubulointerstitial fibrosis are hallmarks of 
chronic kidney injury leading to end-stage renal disease. Inflammatory mechanisms 
contribute to glomerular and interstitial scaring including chemokine-mediated 
recruitment of leukocytes. In particular, accumulation of chemokine receptor CCR2 
expressing macrophages promotes renal injury and fibrotic remodeling in diseases like 
glomerulonephritis and diabetic nephropathy. However, whether CCR2 plays a functional 
role in the initiation and progression of primary glomerulosclerosis induced by podocyte 
injury remains unclear.
Methods: To explore potential pro-inflammatory and pro-fibrotic functions of CCR2 in 
focal segmental glomerulosclerosis (FSGS) we analyzed adriamycin-induced nephropathy, 
a murine model of FSGS, in BALB/c wild-type and Ccr2-deficient mice.
Results: In adriamycin-induced FSGS progressive glomerular scaring and reduced 
glomerular nephrin expression was paralleled by induced glomerular expression of the CCR2 
chemokine ligand CCL2. In comparison to wild-type, Ccr2-deficient mice with adriamycin 
nephropathy showed reduced albuminuria and preserved renal function. Whereas the extent 
of glomerular podocyte and endothelial cell injury was similar, glomerular sclerosis and 
glomerular macrophage infiltration were reduced in Ccr2-deficient mice. Moreover, Ccr2 
deficiency decreased tubular damage, interstitial leukocyte infiltration, renal inflammation 
and renal expression of extracellular matrix molecules. Consistently, tubulointerstitial 
fibrosis, accumulation of αSMA-positive myofibroblasts and renal fibroctyes were reduced 
in Ccr2-deficient kidneys.
Conclusions: Our data indicate that the chemokine receptor CCR2 contributes 
to glomerular scaring and interstitial fibrosis in FSGS by facilitating glomerular and 
tubulointerstitial infiltration of macrophages, renal inflammation, and renal accumulation 
of fibrocytes. Thus, CCR2 is an important mediator of glomerular injury and progression of 
FSGS. CCR2 targeting therapies may represent a novel approach for its treatment.
Funding: Government Support - Non-U.S.
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The Acute-Phase Protein α1-Acid Glycoprotein Ameliorates Proteinuria 
Through Maintaining Renal Endothelial Barrier Function and  
Modulating Macrophages Polarization in Proteinuric Kidney Disease
Rui Fujimura,1,2 Kento Nishida,1 Jing Bi,1,2 Hiroshi Watanabe,1 Toru Maruyama.1 
1Department of Biopharmaceutics, Graduate School of Pharmaceutical 
Sciences, Kumamoto University, Kumamoto-shi, Japan; 2Program for Leading 
Graduate Schools “HIGO (Health life science: Interdisciplinary and Glocal 
Oriented) Program”, Kumamoto University, Kumamoto, Japan.
Background: Proteinuria is the hallmark of progressive chronic kidney disease (CKD). 
It is highly desired to develop an effective strategy that prevents glomerular filtration 
barrier injury and renal inflammation which can cause proteinuria. The acute phase plasma 
protein, α1-acid glycoprotein (AGP) is a component of glomerular endothelial barrier and 
contributes to maintaining an intact barrier. In addition, we have previously showed that 
AGP has anti-inflammatory action via up-regulating CD163 in macrophage. The purpose of 
this study is to evaluate the renoprotective effect of exogenously administered-AGP against 
adriamycin-induced nephropathy (AN), a model of chronic proteinuric renal disease.
Methods: AN-mice were created by the administration of 15mg/kg of adriamycin. 
AGP was administered to AN mice (iv) from day 1 to day 5. Mice were sacrificed on day 
7 or 21. Renal function, structural injury and inflammation were evaluated. The renal 
glomerular distribution of exogenous administered AGP was examined by immunostaining 
using anti-AGP antibody. To investigate the effect of AGP on macrophage polarization, in 
vitroexperiments were performed using PMA-differentiated THP-1 cells.
Results: AGP administration ameliorated AN-induced proteinuria, histological changes 
and macrophage infiltration in renal tissue. We also found the decreased distribution of 
endogenous AGP on the glomerulus in AN-mice, but this decrease was recovered by 
the administration of exogenous AGP. In kidney of AGP-treated mice, increased mRNA 
expression of CD163, M2 macrophage marker, and decreased mRNA expression of iNOS, 
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M1 macrophage marker, were observed. To confirm this finding in vitro, we investigated 
the effect of AGP on THP-1-derived macrophage polarization. The data showed that 
AGP treatment significantly increased CD163 mRNA expressions, while it decreased 
iNOS mRNA expression, suggesting that AGP could be able to modulate the macrophage 
phenotype to anti-inflammatory potential.
Conclusions: AGP ameliorates proteinuria through maintaining renal endothelial 
barrier function and modulating macrophages polarization.
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Classic IL-6R Signaling in CD4+ T Cells Directs Nephritogenic Th17 
Responses and Enhances Treg Function
Julia Hagenstein, Simon Melderis, Anna Nosko, Matthias Warkotsch, 
Johannes V. Richter, Malte A. Kluger, Oliver M. Steinmetz. Steinmetz Lab 
University Hospital Hamburg Eppendorf, Hamburg, Germany.
Background: Th17 cells are central pathogenic mediators of glomerulonephritis (GN), 
while regulatory T cells (Tregs) mediate protection. The pleiotropic cytokine IL-6 was 
shown to modulate the function of both cell populations, but many aspects in this process 
remain unclear. These include the mode of IL-6 signaling responsible (classic, alternative or 
cluster), whether IL-6 effects are mediated in a cell intrinsic fashion or indirectly and finally 
the functional importance of T cell subtype specific IL-6R signaling for GN.
Methods: Selective abrogation of classic IL-6 signalling on T cells was achieved by 
generating quadruple transgenic CD4CrexIL-6Rafl/fl mice, harbouring flourochromes under 
control of the Foxp3 (FIR) and IL-10 promoters (Tiger). The NTN model of crescentic 
GN was studied in these mice and in Rag1-/- recipients after transfer of different CD4+ T 
cell populations.
Results: Rag1-/- recipients of IL-6R deficient CD4+ T cells showed significantly and 
selectively reduced splenic and renal Th17 responses. In line, renal neutrophil recruitment 
was substantially diminished. Surprisingly, however, the course of NTN was not 
ameliorated. As one possible explanation, we found reduced Treg infiltration into recipient 
kidneys of IL-6R deficient CD4+ T cells. Additional studies in CD4CrexIL-6Rfl/flxFIRxTiger 
mice revealed, that production of anti-inflammatory IL-10 by Foxp3+ Tregs and Foxp3- Tr1 
cells, was not affected by absence of IL-6R signaling. In a next step, we transferred Treg 
depleted CD4+ T cells into Rag1-/- mice and again studied NTN. Also in this setting, Th17 
responses were strikingly reduced by lack of IL-6R signaling in CD4+ T cells. Importantly, 
however, in the absence of Tregs in both groups, NTN was significantly ameliorated in 
recipients of IL-6R deficient CD4+ Teff.
Conclusions: Our data indicate, that classic IL-6R signaling on T cells, induces 
nephritogenic Th17 reponses and aggravates crescentic GN. Surprisingly, however, classic 
IL-6R signaling also enhances Treg function via currently undefined pathways. Given the 
impact on potential IL-6R directed therapies, the underlying molecular mechanisms clearly 
need to be defined by further studies.
Funding: Government Support - Non-U.S.
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Kidney-Targeted Autoimmunity Exposed in Human Immune System Mice
Jeffrey R. Ord, Amy G. Clark, Anastasiya Birukova, Lanette Fee, 
Yohannes G. Asfaw, Robert M. Tighe, Mary H. Foster. Duke University Medical 
Center, Durham, NC.
Background: Lupus and anti-GBM nephritis are paradigmatic systemic and organ-
specific autoimmune diseases, respectively, in which kidney and other organ injury is 
induced by pathogenic autoantibodies. Gene-environment interactions are implicated in 
disease induction, yet mechanisms by which this occurs in man are poorly understood. 
We explored the utility of an in vivo human immune system model (HuHSC-NSG) to 
study autoimmune regulation by inhaled crystalline silica, an environmental exposure 
compellingly linked to multiple human autoimmune diseases with a prominent humoral 
component.
Methods: Conditioned immunodeficient NOD-scid-gamma (NSG) mice were 
intravenously injected with CD34+ human hematopoietic stem cells (HSC) from two 
different donors and monitored for reconstitution with a human immune system. Three 
months after engraftment, mice were exposed to crystalline silica (Si) or vehicle (V, saline) 
by oropharyngeal aspiration. Tissue was collected 1-3 months post-aspiration. Chimerism 
was determined by flow cytometry, and lung pathology and lymphocytic infiltrates were 
scored by investigators blinded to experimental conditions. Serum autoantibodies that 
bound DNA or the NC1 domain of the alpha3 chain of collagen IV were measured using 
enzyme linked immunosorbent assay. Data are reported as mean±SD.
Results: HuHSC-NSG mice (n=29) demonstrated mean spleen chimerism of 
57.6±28.4%, with the human CD45+ subset composed of 70.7±18.6% B cells and 
19.4±20.1% T cells. Si-exposed subjects developed significantly greater lung injury and 
inflammation than did their V-exposed counterparts, with composite lung pathology score 
2.8±2.2 vs 0.7±1.7, Si vs V, p<0.05. Focal infiltrates of human CD45+ leukocytes were 
observed in Si-exposed lungs. All mice developed circulating human IgM and IgG, and 
a subset had detectable circulating human anti-DNA or anti-alpha3(IV)NC1 collagen 
autoantibodies.
Conclusions: NSG mice reconstituted with a human immune system develop Si-
induced lung injury and circulating autoantibodies with specificities relevant to human 
antibody-mediated nephritis. This model should be useful in studying gene-environment 
interactions that promote pathogenic autoimmunity in humans, without putting volunteers 
or patients at risk.
Funding: Other NIH Support - NIEHS (National Institute of Environmental Health 
Sciences)
FR-PO1062 Poster Friday
Glomerular Diseases: Immunology and Inflammation - II
Treatment of Glomerulonephritis Using Drugs Targeting Folate Receptor 
Expressing Activated Macrophages
Gabriela E. Garcia,1 Yingjuan J. Lu,4 Luan D. Truong,2 Richard J. Johnson,1 
Christopher P. Leamon.3 1University of Colorado Denver, Greenwood Village, 
CO; 2The Methodist Hospital, Houston, TX; 3Endocyte Inc, West Lafayette, IN; 
4Endocyte, West Lafayette, IN.
Background: Macrophages are linked with the irreversible scarring that leads to end-
stage renal disease. Since activated macrophages highly express a functional folate receptor 
β (FRβ), targeting this population of macrophages with folate-linked drugs could increase 
selectivity in the treatment of inflammatory diseases.
Methods: Accordingly, we synthesized and investigated the biologic activity of a 
novel folic acid-aminopterin conjugate (FA-AMT) designed to intracellularly deliver AMT 
specifically via the FR. The anti-inflammatory activity of FA-AMT was evaluated in a model 
of severe, macrophage-mediated anti-glomerular basement membrane glomerulonephritis 
in WKY rats.
Results: Toxicity assessment demonstrated that FA-AMT is not toxic (its maximum 
tolerated dose was 40-fold higher compared to unmodified AMT). We found that treatment 
with FA-AMT significantly attenuated kidney injury and preserved normal renal function. 
Glomerular proliferation, necrotizing lesion, crescent formation, tubulointersititial injury 
(TIN), and the number of tubular casts, a good indicator of chronic TIN injury, were 
markedly reduced in the FA-AMT-treatment group compared with the control group. FA-
AMT reduced glomerular macrophage infiltration (52%) and decreased M1 macrophage 
phenotype without affecting M2 macrophages. Notably, interstitial macrophage 
accumulation that predicts progression of kidney injury was decreased in rats treated with 
FA-AMT. The expression of CCL2 and the pro-fibrotic cytokine TGF-β were reduced in 
nephritic glomeruli with FA-AMT treatment. Importantly, in rats treated with FA-AMT 
there was a significant reduction in the deposition of type I, III, and IV, collagens. Staining 
with specific anti-FRβ antibody showed no expression of this receptor in normal kidneys, 
however, in nephritic kidneys FRβ was mainly expressed on macrophages present in the 
crescents and also on macrophages within the glomerular capillaries. Notably, in rats treated 
with FA-AMT, the expression of FRβ was decreased and correlated with less macrophage 
infiltration and reduced crescent formation.
Conclusions: These findings suggest that targeting kidney activated macrophages 
attenuates inflammation and prevents progression of kidney injury and that because this is a 
FR-restricted specific treatment systemic immunosuppression can be prevented.
Funding: NIDDK Support
FR-PO1063 Poster Friday
Glomerular Diseases: Immunology and Inflammation - II
KLF4 on Macrophages Attenuates TNF-α Mediated Kidney  
Inflammation and Fibrosis in Autoimmune Nephritis
Yi Wen,1 Jamie Privratsky,1 Xiaohan Lu,1 Jiafa Ren,1 Bi-Cheng Liu,2 
Steven D. Crowley.1,3 1Duke University Medical Center, Durham, NC; 2Zhong 
Da Hospital, Southeast University Medical School, Nanjing, China; 3Division of 
Nephrology, Department of Medicine, Duke University and Durham VA Medical 
Centers, Durham, NC.
Background: The Kruppel-like factor (KLF) family of transcriptional regulators play 
complex roles in the pathogenesis of kidney disease. We recently found that activating type 
1 angiotensin receptors in macrophages upregulates KLF4 and paradoxically limits renal 
fibrosis. As KLF4 attenuates NF-kB-dependent vascular injury, we directly investigated the 
role of macrophage KLF4 in renal inflammation and fibrosis using the murine nephrotoxic 
serum nephritis (NTS) model. As KLF4 suppressed TNF-α in intra-renal macrophages 
in our studies, we additionally probed the contribution of macrophage TNF-α to NTS 
progression.
Methods: Mice with floxed alleles for the genes encoding KLF4 or TNF-α were 
bred with LysM-Cre mice to yield KLF4 or TNF “MKO” mice with macrophage-specific 
deletion of KLF4 or TNF-α, respectively. NTS was induced in KLF4 MKO, TNF MKO, 
and wild-type (WT) littermate control mice by IV injections of sheep IgG followed 5 days 
later by sheep anti-mouse GBM serum.
Results: At day 14 NTS, KLF4 MKO mice compared to WTs had augmented 
glomerular matrix deposition (44.4 ± 3.3 vs 33.7 ± 2.5%; P = 0.04), urinary albumin/Cr 
ratios (7.7 ± 0.8 vs 5.3 ± 0.6 mg/mg; P = 0.05), and renal NGAL mRNA (1.3 ± 0.1 vs 
1.0 ± 0.2 au; P = 0.03). KLF4 MKO kidneys also showed increased mRNA levels for 
collagen 1 (1.9 ± 0.2 vs 1.0 ± 0.3 au; P = 0.01), fibronectin (1.7 ± 0.2 vs 1.0 ± 0.2 au; 
P = 0.03), and the fibrosis mediators TGF-β (1.4 ± 0.1 vs 1.0 ± 0.2 au; P = 0.03) and PAI-1 
(1.4 ± 0.1 vs 1.0 ± 0.2 au; P = 0.03). CD11b+ Ly6Chi inflammatory macrophages isolated 
directly from NTS kidneys of KLF4 MKO animals had 50% higher TNF-α expression than 
WTs (1.5 ± 0.1 vs 1.0 ± 0.1 au; P = 0.04). To explore whether macrophage KLF4 protects 
the kidney by suppressing TNF-α, we repeated our NTS studies in TNF MKO mice and WT 
controls. At day 14 of NTS, TNF MKOs compared to WTs had reduced glomerular matrix 
deposition (33.2 ± 0.6% vs 43.8 ± 1.6%; P < 0.01), urine albumin/Cr ratios (3.6 ± 0.4 vs 4.7 
± 0.3 mg/mg; P = 0.04), and mRNA levels for NGAL (0.5 ± 0.1 vs 1.0 ± 0.2 au; P = 0.02),
collagen 1(0.5 ± 0.2 vs 1.0 ± 0.2 au; P = 0.04), aSMA (0.3 ± 0.1 vs 1.0 ± 0.2 au; P < 0.01), 
and PAI-1 (0.6 ± 0.1 vs 1.0 ± 0.1 au; P < 0.01).
Conclusions: KLF4 activation on macrophages mitigates renal injury and fibrosis 
during NTS by inhibiting production of macrophage-derived TNF-α.
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Characterisation of a Novel P2X7 Deficient Rat and Differential 
Requirement for P2X7 for Release of IL-1β from Bone Marrow Derived 
Cells In Vitro
Maria Prendecki,1 Ana Isabel Garcia Diaz,1 Stephen P. McAdoo,1 
Jacques Behmoaras,1 H. Terence Cook,1 Robert J. Unwin,2 Charles D. Pusey,1 
Frederick W. Tam,1 Tim Aitman.3 1Imperial College London, London, United 
Kingdom; 2University College London Medical School, London, United 
Kingdom; 3University of Edinburgh, Edinburgh, United Kingdom.
Background: P2X7 is an ionotropic receptor activated by extracellular ATP and 
expressed on immune cells including macrophages and dendritic cells. P2X7 may have an 
important role in kidney disease. However, the specific role of P2X7 in different cell types 
is controversial. We characterise a novel P2X7 knockout (KO) rat and define the role of 
P2X7 in IL-1β production in bone marrow derived macrophages (BMDM) and dendritic 
cells (BMDC).
Methods: A P2X7 KO rat was created using zinc finger nucleases. Cells and tissues 
were used for extraction of protein and mRNA for Western blot and PCR. P2X7 function 
was assessed using uptake of Yo-pro1 dye in response to ATP and by stimulating cells 
with LPS 1μg/ml followed by ATP 5mM, and measuring IL-1β production. When P2X7 
antagonist or caspase-1 inhibitor was used this was added 30 mins prior to LPS.
Results: No P2X7 protein was detected in P2X7 KO rat cells or tissue. BMDM 
and BMDC from WKY WT but not P2X7 KO rats formed pores and took up Yo-pro1 
following ATP stimulation. As expected, WKY WT BMDM produced significant IL-1β 
when stimulated with LPS plus ATP compared to LPS alone. In contrast, BMDM from 
P2X7 KO rats did not produce IL-1β (Figure 1A). However, both WKY WT and P2X7 KO 
BMDC were able to cleave IL-1β following stimulation with LPS alone, Use of a P2X7 
antagonist (A438079) confirmed this was P2X7 independent (Figure 1B). IL-1β release was 
independent of K+ efflux from cells, but was inhibited by a caspase-1 inhibitor.
Conclusions: This is the first description of a novel P2X7 KO rat showing it is a 
true knockout. BMDC (but not BMDM) do not require a second signal via P2X7/ATP to 
produce active IL-1β. IL-1β is a powerful pro-inflammatory cytokine and is thought to 
play a role in human and experimental glomerulonephritis; understanding how different 
cell types use different pathways to produce IL-1β will improve our understanding of the 
pathogenesis of kidney diseases.
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Neuraminidase Activity Mediates IL-6 Secretion from Activated Lupus 
Mesangial Cells Through TLR4 and MAPK p38
Tamara Nowling,1 Kamala Sundararaj,2 Jessalyn I. Rodgers.2 1Medicine, 
Medical University of South Carolina, Charleston, SC; 2Medical University of 
South Carolina, Charleston, SC.
Background: Glycosphingolipid (GSL) levels and the activity/levels of the enzyme 
neuraminidase (NEU), which mediates GSL catabolism, are elevated in the kidneys and/
or urine of lupus mice and human patients with nephritis compared to their non-nephritic 
counterparts and healthy controls. We recently demonstrated that NEU activity mediates 
IL-6 secretion from mesangial cells (MCs) in response to activation by heat aggregated 
IgG (HA-IgG) and lupus serum. Our previous results demonstrated that NEU1 and NEU3 
staining partially overlapped with IgG deposits in cell cultures of primary MCs stimulated 
with HA-IgG and in renal sections of kidneys from nephritic lupus mice. Both Fcγ receptors 
(FcγRs) and TLRs can mediate immune complex activation of cells, are expressed by MCs, 
and were shown to be involved in progression of lupus nephritis. In this study, we examined 
the role of FcγRs and toll like receptors (TLRs), and downstream signaling pathways in 
NEU-mediated secretion of IL-6 by activated lupus prone MCs.
Methods: Cell surface receptors and MAPK pathways were identified by treating 
MC cultures with antibodies and inhibitors, respectively, prior to activation with HA-IgG 
or lupus serum. Phosphorylation of p38 was analyzed by western immunoblot. Cellular 
localization of NEUs and TLR4 was performed by immunofluorescence. Screening of 
cytokines secreted by MCs was performed using a 20-plex Luminex cytokine array. Levels 
of individual cytokines were quantified by ELISA.
Results: Blocking TLR4 significantly inhibited, while blocking FcγRs had no effect on, 
NEU-mediated IL-6 secretion by activated MCs. Preliminary results show overlap between 
TLR4 and NEU1 at the plasma membrane of MCs. An inhibitor of the p38 MAPK pathway 
significantly blocked NEU mediated IL-6 secretion. Phosphorylation of p38 was increased 
following activation of MCs with HA-IgG or lupus serum and was blocked when NEU 
activity was inhibited or NEU1 expression was reduced. Although several cytokines were 
secreted in response to activation by both HA-IgG and lupus serum, only IL-6 and IP-10 
(CXCL10) were blocked when NEU activity was inhibited.
Conclusions: Together our results suggest that NEU specifically mediates secretion of 
IL-6 and IP-10, two cytokines important during early development of lupus nephritis, from 
activated lupus prone MCs through a TLR4-p38 MAPK pathway.
Funding: Other U.S. Government Support
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Patient Derived Endothelial Cells as Tool to Study the Effects of Shiga 
Toxin on the Vascular Endothelium: The BO(ST)EC-Study
Wouter J. Feitz,1 Nicole Van De Kar,2 Christoph Licht.1 1The Hospital for Sick 
Children, Toronto, ON, Canada; 2UMC St. Radboud Nymegen, Nijmegen, 
Netherlands.
Background: Hemolytic Uremic Syndrome (HUS) is a form of thrombotic 
microangiopathy (TMA), which is characterized by hemolytic anemia, thrombocytopenia 
and acute renal failure. HUS is caused by infections with Shiga toxin (Stx) producing 
Escherichia coli with subsequent damage of the vascular endothelium (STEC-HUS or 
eHUS). We have established an in vitrosystem to screen for endothelial susceptibility 
factors: using Blood Outgrowth Endothelial Cells (BOECs) we can study the function of the 
endothelium of individual eHUS patients. We hypothesize that endothelial characteristics 
determine the response to Stx and thus the manifestation of eHUS.
Methods: BOECs from a healthy donor were used (male, 50 years old). Experiments 
were done in threefold (N=3) or as indicated in the figure. Previous literature has shown that 
Stx preferentially binds to the endothelial Gb3 receptor. In our study, Vero cells (positive 
control) and BOECs were cultured. Immunofluorescence imaging of live cells was used 
to confirm presence or absence of the Gb3 receptor on the cell surface. Using confocal 
immunofluorescence microscopy, binding of Stx to the cell surface was determined. A 
lactate dehydrogenase (LDH) cytotoxicity assay was used to assess for cytotoxicity of 
Stx and to standardize Stx concentrations for future experiments aiming at a level of cell 
damage of 50%. With flow cytometry, using antibodies for Annexin V and PI, necrotic vs. 
apoptotic cell death in response to Stx incubation was quantified. Finally, the effect of Stx 
on endothelial cell motility was determined in a scratch wound assay.
Results: We found that: 1) the Gb3 receptor is present on the cell surface of BOECs; 
2) there is an expected positive dose-response relationship, wherein a higher concentration
of Stx resulted in increased cell damage. Pre-treatment with TNF-alpha 10 ng/ml for 24
hours and treatment with Stx type 2 10-5 ug/ml resulted in 50% cell death; 3) incubation
of BOECs with Stx resulted in more apoptotic than necrotic cell death; and 4) endothelial 
wound healing was impaired when cells were incubated with Stx.
Conclusions: BOECs are a promising tool with high translational potential to study 
effects of Stx on the vascular endothelium.
Funding: Government Support - Non-U.S.
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Glomerular Endothelial Cells Lacking Neonatal Fc Receptor Have 
Decreased Major Histocompatibility Complex Type II Expression Due to 
Decreased Transcriptional Signaling
James F. Dylewski,2,1 Evgenia Dobrinskikh,2 Sizhao Lu,2 Linda Lewis,2 
Judith Blaine.3 1Denver Health Medical Center, Denver, CO; 2University of 
Colorado, Denver, Aurora, CO; 3University of Colorado Denver, Aurora, CO.
Background: Glomerulonephritis (GN) requires intrinsic renal cells that express 
Major Histocompatibility complex type II (MHCII) to propagate the disease. Glomerular 
endothelial cells (GEnC) can express MHCII but it is unclear if they can present antigen. 
Neonatal Fc receptor (FcRn) is a trafficking protein that is required for antigen processing 
and presentation and is also expressed in GEnC. It has been demonstrated that when FcRn is 
globally knocked out, GN is prevented. The exact mechanism by which knock out of FcRn 
offers protection from GN is incompletely understood. An understanding of how FcRn is 
involved in MHCII expression by GEnC could lead to novel therapeutic options.
Methods: We isolated and purified GEnC from wild type (WT) & FcRn knockout 
(KO) mice by isolating glomeruli. We then used von Willebrand factor (vWF) coated 
dynabeads to isolate the endothelial cells. The cells were characterized using IF for 
vWF and a podocyte specific marker (WT1). Once characterized & purified, we used a 
temperature sensitive SV40 virus to conditionally immortalize both the cell lines. The cells 
were grown under permissive conditions at 33oC and differentiated at 37oC. Quantitative 
PCR (qPCR) was used to demonstrate appropriate expression of endothelial cell markers 
and verify the expression of FcRn in WT and absence in KO. We then treated our GEnCs 
with INFγ and TNFα and used flow cytometry to evaluate for the expression of CD146 (an 
endothelial cell marker) and MHCII. We also used qPCR to evaluate mRNA expression of 
MHCII, MHCII chaperone protein (CD74 also known as invariant chain), and transcript 
regulator protein (CIITA) to evaluate for differences in level of expression of MHCII and 
its key transcriptional components.
Results: We demonstrated by flow cytometry that while IFNγ significantly upregulated 
expression of MHCII in both WT and KO, KO GEnC had significantly less expression 
of MHCII compared to WT. We also found significantly less MHCII, CD74, and CIITA 
mRNA in KO compared to WT GEnC.
Conclusions: These findings suggest that the absence of FcRn alters the signaling 
needed for MHCII transcription. This finding may provide new insight and offer potential 
new targets for therapies GN.
Funding: NIDDK Support
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Concerted Role of Kruppel-Like Factor 4 and Endothelial Nitric Oxide 
Synthase in the Renal Endothelium
Chelsea C. Estrada,2 Stephanie Cardona,1 Sandeep K. Mallipattu,1 
Vivette D. D’Agati.3 1Stony Brook Medicine, Lynbrook, NY; 2Stony Brook 
University Medical Center, Stony Brook, NY; 3Columbia University College of 
Physicians and Surgeons, New York, NY.
Background: Both the transcription factor, Kruppel-like Factor 4 (KLF4), and 
endothelial nitric oxide synthase (NOS3), play critical roles in the maintenance of a healthy 
endothelium. A cooperative relationship between the two genes is likely, as endothelial 
KLF4 positively regulates NOS3 expression-. In the kidney, at baseline, endothelial deletion 
of either Klf4 or Nos3 does not result in overt changes. Upon stress however, endothelial 
Klf4 knockout mice had exacerbated renal failure after ischemic reperfusion injury. 
Similarly, Nos3 deletion resulted in increased glomerular injury and albuminuria in models 
of chronic kidney disease. Based on these data, we hypothesize that endothelial-specific 
double-knockout of Klf4 and Nos3 will disrupt maintenance of the renal endothelium in 
the healthy kidney.
Methods: Endothelial-specific Klf4 knockdown mice (Klf4ΔEC) were generated 
(C57BL/6) by crossing Klf4fl/fl with Cdh5-Cre mice. Klf4ΔEC and Nos3-/- mice were crossed 
to generate double knockout mice (DKO), and Klf4fl/fl mice used as control. Periodic acid-
Schiff (PAS), electron microscopy (EM), immunofluorescence (IF), ELISA and RT-PCR 
were performed to investigate the effects of DKO on the renal endothelium. 12 week male 
mice we used in all studies.
Results: In the renal cortex, Klf4ΔEC mice had decreased Nos3 expression as compared 
with control, while Nos-/- mice exhibited increased Klf4 expression. DKO mice had 
decreased expression of both Klf4 and Nos3. DKO mice had increased albuminuria and 
serum creatinine as compared with Klf4fl/fl, Klf4ΔEC, and Nos-/- mice. PAS of DKO mice 
revealed glomeruli with capillary congestion and endothelial cell (EC) swelling, and some 
glomeruli with widespread loss of ECs and tuft collapse, as well as increased glomerular 
volume, as compared to all other groups. On EM, DKO mice exhibited ECs with loss 
of fenestrae and focal areas of subendothelial widening, mesangiolysis and glomerular 
basement membrane duplication. IF revealed increased glomerular Isolectin B4 and 
complement membrane attack complex (C5b-9) in DKO mice as compared with all other 
groups, suggesting disruption of the endothelium and complement activation.
Conclusions: Our results suggest a synergistic interaction between endothelial Klf4 
and Nos3 signaling in the maintenance of glomerular endothelial function and structure.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
FR-PO1069 Poster Friday
Glomerular Diseases: Immunology and Inflammation - II
Anti-Angiogenic Factors Increase Thrombomodulin Expression in the 
Kidney in Pre-eclampsia: A Role for Endothelin?
Manon Bos,1 Katrina M. Mirabito Colafella,2 Marie-Louise Van der hoorn,1 
Rosanne J. Turner,6 Jan A. Bruijn,3 Kitty Bloemenkamp,5 Alexander H. Danser,4 
Anton H. Van den meiracker,7 Hans J. Baelde.1 1Leiden University Medical 
Center, Leiden, Netherlands; 2Monash University, Clayton, NSW, Australia; 
3Leiden University Medical Center, Dept.Pathology, Leiden, Netherlands; 
4Erasmus Medical Center, Rotterdam, Netherlands; 5Birth Centre Wilhelmina 
Children’s Hospital,University Medical Cetre Utrecht, the Netehrlands, Leiden, 
Netherlands; 6Leiden University Medical Centre, Leiden, Netherlands; 
7Erasmus MC, Rotterdam, Netherlands.
Background: Pre-eclampsia (PE) is a pregnancy related syndrome characterized by 
angiogenic imbalance, which results in symptoms such as hypertension. Furthermore, 
the kidney is frequently affected in PE. Similar symptoms are observed during treatment 
of patients with angiogenesis inhibitors like Sunitinib. Thrombomodulin is an essential 
endothelial regulator of inflammation and coagulation. Serum levels of the breakdown 
product of thrombomodulin are increased in PE. Here, we investigated thrombomodulin 
expression in kidneys of women with PE and hypertensive rats exposed to Sunitinib.
Methods: Renal tissue was collected from 34 pregnant women (23 controls, 11 PE) 
and 14 hypertensive non-pregnant women. Furthermore, kidneys were collected from 
male WKY rats treated with vehicle, Sunitinib (14 mg/kg/day) alone or in combination 
with endothelin receptor type A (ETA) antagonist Sitaxentan (30 or 100 mg/kg/day) or 
non-selective ETA/B antagonist Macitentan (30 mg/kg/day) for 8 days. Blood pressure 
in rats was measured by telemetry. Thrombomodulin expression was investigated with 
immunohistochemistry and qPCR.
Results: Glomerular thrombomodulin protein expression is increased in kidneys of 
women with PE compared to pregnant women and hypertensive non-pregnant women 
(P<0.01). Renal thrombomodulin expression originated from the glomerular vascular pole, 
and is not associated with other histopathologic lesions. Exposure to Sunitinib results in 
1.5-times higher renal thrombomodulin mRNA expression in WKY rats (P<0.05), and 
Sitaxentan at both doses (P<0.001), but not macitentan, normalized this increase. Both 
antagonists fully prevent the Sunitinib-induced rise in blood pressure.
Conclusions: Renal thrombomodulin expression is increased both in PE and during 
Sunitinib mediated angiogenic inhibition. Thrombomodulin upregulation appears to be 
ETA receptor-mediated, and ETB receptors counterbalance this effect in a blood pressure-
independent manner. Our data suggest that selective ETA receptor blockade may have long-
term renoprotective effects. This may also be true in patients treated with angiogenesis 
inhibitors.
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Functional Consequences of Complement Activation on Vascular 
Endothelial Cells - Results of a Pilot RNA Seq Study
Erin N. Jacobs,1,2 Magdalena Riedl Khursigara,3 Carolina Ortiz,4 Christoph Licht.3 
1University of Toronto, Toronto, ON, Canada; 2Cell Biology, SickKids Research 
Institute, Toronto, ON, Canada; 3The Hospital for Sick Children, Toronto, ON, 
Canada; 4Hospital for Sick Children, Toronto, ON, Canada.
Background: Complement dysregulation on vascular endothelial cells (ECs) causes 
EC injury and leads to thrombotic microangiopathy (TMA), such as atypical hemolytic 
uremic syndrome (aHUS). As 50% of aHUS causing mutations are unknown, there is 
clinical need to find additional pathways and genes involved in the TMA phenotype. Here, 
we report the results of an unbiased RNA seq approach to investigate complement-induced 
responses of ECs on a molecular level.
Methods: Complement activation on ECs was induced via sensitization, activating the 
classical complement pathway, on blood outgrowth endothelial cells (BOECs) from healthy 
controls. RNA was isolated 1 hour after treatment. A stranded paired end RNA seq library 
was used, quality assessed with FASTQC software, and adapters trimmed using Trim 
Galore. Manual analysis of regulated genes was carried out with a cutoff of fold change 
> |1.5|. Gene function was determined based on literature analysis (pubmed; genecards).
Functional assays included neutrophil adhesion in a microfluidic chamber (Bioflux), wound 
closure assay, measurement of transendothelial resistance with a voltohmmeter and IF
staining for VE-Cadherin.
Results: RNA seq revealed three major findings, (i) upregulation of genes involved 
in leukocyte adhesion (e.g. ICAM, E-selectin); (ii) regulation of genes collectively 
resulting in loss of cytoskeletal re-arrangement (e.g. downregulation of RhoA activators 
and upregulation of ROCK 1 inhibitors); and (iii) downregulation of genes involved in 
cell adhesion (e.g. VE-Cadherin). Functional relevance of these findings was confirmed 
by complement-induced (i) EC neutrophil adhesion (Bioflux); (ii) defective EC migration 
(wound closure assay); and (iii) decreased transendothelial resistance and VE-Cadherin 
staining (voltohmmeter and IF). Importantly, all these effects were reversible when 
complement activation was blocked, using complement inactivated serum.
Conclusions: Complement activation on ECs results in an array of molecular responses 
functionally resulting in (i) neutrophil adhesion, (ii) defective cell migration, and (iii) loss 
of cell-cell adhesion. Detailed mechanism and their link to the clinical phenotype of TMA 
remains to be elucidated in future research.
Funding: Government Support - Non-U.S.
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Erythropoietin Prevents TH17 Induction and Sodium Chloride-Driven 
Kidney Inflammation by Inhibiting SGK1-Dependent IL-17 Production
Chiara Cantarelli,3 Andrea Angeletti,1 Chiara Donadei,2 Clara Fischman,1 
Julian Horwitz,1 Gaetano La Manna,2 Peter S. Heeger,1 Paolo Cravedi.1 1Icahn School 
of Medicine at Mount Sinai, New York, NY; 2Nephrology, Dialysis and Kidney 
Transplantation, Bologna, Italy; 3University Hospital, Parma, Parma, Italy.
Background: High sodium chloride (NaCl) intake worsens kidney pathology by 
promoting TH17 differentiation. Since erythropoietin (EPO) is predominantly produced in 
the kidney where NaCl concentrations are high, and because EPO has newly recognized 
immunoregulatory functions, we tested the hypothesis that kidney-derived EPO prevents 
TH17 differentiation and thereby modulates TH17-dependent kidney pathology.
Methods: To study the role of endogenous and recombinant EPO on TH17 cells in vivo, we 
used murine models of kidney disease associated with TH17 induction, including aristolochic 
acid (ArA) nephropathy (+/- high NaCl diet), MRL-lpr and pristane lupus nephritis models. 
In vitro studies supplemented by adoptive transfer of naïve or TH17 cells into rag1
-/- mice were 
used to determine the direct role of EPO on TH17 induction (Figure 1A).
Results: Recombinant EPO and transgenic EPO overexpression limited pathology, 
while in vivo shRNA-induced EPO downregulation augmented ArA-induced TH17 
formation and the clinical expression of disease. Recombinant EPO administration also 
prevented development of glomerular disease in lupus models, clinical results that were 
associated with reduced frequencies of TH17 cells. In rag1
-/- adoptive transfer experiments, 
EPO directly inhibited in vivo TH17 development (Figure 1B-C) and promoted trans-
differentiation of TH17 into regulatory T cells. Using murine and human T cells, we 
then showed that EPO ligation of its T cell-expressed receptor abrogated NaCl-induced 
upregulation of Sgk1 gene expression and blocked p38 activity to prevent SGK1 
phosphorylation, thereby limiting RORC induction and TH17 differentiation.
Conclusions: EPO physiologically and therapeutically inhibits TH17 cell differentiation 
and TH17-associated autoimmune kidney pathology by antagonizing intracellular signaling 
pathways required for NaCl-driven TH17 differentiation.
Funding: NIDDK Support
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Glomerular Diseases: Immunology and Inflammation - II
Role of the ICOS/ICOS-L Costimulatory Pathway and of Circulating 
Extracellular Vesicles as Potential Biomarkers and New Therapeutic 
Targets in Lupus Nephritis
Vincenzo Cantaluppi,1 Martina Mazzariol,2 Guido Merlotti,3 Marco Quaglia.4 
1University of Piemonte Orientale (UPO), Novara, Italy; 2University of 
Piemonte Orientale, Novara, Novara, Italy; 3University of Piemonte Orientale, 
Novara, Italy; 4Università del Piemonte Orientale, Torino, Italy.
Background: The costimulatory pathway ICOS/ICOS-L and extracellular vesicles 
(EV), microparticles known to have a role in cell-to-cell communication, both appear to 
be involved in tissue injury associated with SLE. The aim of this study was to evaluate the 
association between ICOS, ICOS-L or EV plasma levels and clinical expression of lupus 
nephritis (LN).
Methods: Main clinical and laboratory parameters were compared among 67 SLE 
patients (52 with LN and 15 with only rheumatological SLE) and 50 healthy controls. 
Plasma levels of ICOS/ICOS-L were assessed by ELISA and EV were evaluated by 
Nanotrack and FACS analysis.
Results: Serum levels of ICOS and ICOS-L were significantly increased in SLE as 
compared with healthy controls (p<0.001) and associated with disease duration (p=0.036 
for ICOS and p<0.001 for ICOS-L), presence and severity of LN at diagnosis (p=0.017 
and p=0.001), proteinuria (p=0.014 and p<0.001) and nephritic sediment (p=0.005 and 
p=0.010). ICOS levels also correlated with established scores such as SLICC (p=0.027) 
and SLEDAI-2K (p=0.001) at diagnosis. At univariate logistic regression analysis, disease 
onset at younger age (p=0.007), ICOS (p=0.044) and ICOS-L levels (p=0.009) were 
associated with LN; however, at multivariate analysis only disease onset at younger age 
(p=0.018) and ICOS-L (p=0,047) were indipendently associated with renal involvement. 
Plasma EV levels were higher in SLE patients with LN (p<0.001) without discrimination 
between prolipherative and non-prolipherative classes: however, EV levels correlated with 
proteinuria (p=0.032) and ICOS levels (p=0.026). Of interest, FACS analysis revealed the 
presence of both ICOS and ICOS-L on EV surface.
Conclusions: ICOS and ICOS-L plasma levels are increased in SLE and appear to 
identify a subset of SLE patients with long-lasting disease and severe LN at presentation. 
In addition, plasma EV levels were also higher in SLE patients with LN and correlated 
with ICOS: circulating EV carried ICOS and ICOS-L proteins. ICOS/ICOS-L pathway and 
circulating EV may be potential biomarkers and new therapeutic targets in LN.
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Targeting TH17 Plasticity in Immune Mediated Inflammatory Diseases
Shiwa Soukou. Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.
Background: During T cell development, naive T cells can differentiate into effector T 
cells (e.g TH1 and TH17) or into regulatory T cells (e.g. Foxp3
NegTR1 and Foxp3
Pos Treg cells). 
Originally every single CD4 T cell lineage was thought to be stable after differentiation and 
to represent a functional homogenous population of cells. Recent data suggest that CD4 
T cells and TH17 cells in particular, have higher plasticity in the brain and in the intestine, 
where TH17 cells are able to convert into TH1 cells and into TR1 cells respectively.
Methods: To prove the conversion from TH17 cells towards TR1exTH17 and the role 
of TR1exTH17 cells in the kidneys of nephritic, we used Fate+ (Foxp3RFP IL-10eGFP 
IL-17AKata IL-17ACRE R26YFP mice) and IL17ACre IL10fl/fl mice. Mice were 
immunized with nephrotoxic sheep serum. Additionally we treated them with PBS or 15 μg 
of αCD3 monoclonal antibody (mAB) intraperitoneally (i.p.). Injections were done at day 
8 and day 10 post immunization. The mice were analyzed 4 hours after the last injection. 
Multiparametric flow cytometric analysis was performed and clinical parameters were 
measured in urine and plasma. Moreover histological analysis was done using Periodic 
acid–Schiff (PAS) staining that detects polysaccharides and mucosubstances.
Results: We could show that spontaneous and induced conversion of TH17 cells into 
TR1exTH17 over the course of NTN induction take place. Furthermore induction of NTN 
in IL17ACre IL10fl/fl mice showed aggravated glomerulonephritis.
Conclusions: Our first aim was to demonstrate the existence of TR1exTH17 in the 
kidneys of nephritic mice. Moreover we showed that the regulatory fate of TH17 cells 
(IL-10 producing TH17 and TR1exTH17 cells) can play an important role. Furthermore 
preliminary data show that deletion of IL-10 production by TH17 and exTH17cells can 
result in aggravated outcome of GN. However whether kidney IL-10 producing Foxp3Neg 
CD4 T cells are a functional homogenous population of regulatory cells remains unknown 
and the molecular mechanism underlying the conversion of TH17 into TR1 cells remain to 
be discovered
Funding: Government Support - Non-U.S.
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Elucidating the Role of Neutrophil Extracellular Traps in Atypical 
Hemolytic Uremic Syndrome
Samuel E. Suntharalingham,1 Carolina Ortiz,2 Christoph Licht.3 1University of 
Toronto, Toronto, ON, Canada; 2Hospital for Sick Children, Toronto, ON, 
Canada; 3The Hospital for Sick Children, Toronto, ON, Canada.
Background: About 10% of patients manifest hemolytic uremic syndrome (HUS) 
without toxins or diarrhea. These cases are referred to as atypical HUS (aHUS) and occur 
due to a dysregulated complement system leading to unchecked complement activation on 
the vascular endothelium. Genetic mutations account for only 50-60% of aHUS cases only 
with a large variation in the age and severity of the disease phenotype. For the past decade, 
neutrophils have been shown to produce neutrophil extracellular traps (NETs), which are 
associated with proinflammatory and prothrombotic properties. We propose that NETs are 
involved in aHUS pathogenesis.
Methods: Resting neutrophils freshly isolated from healthy donors were used (male, 
ages 18-24 years old). Experiments were done at least threefold (N=3). We have previously 
shown that neutrophils contain complement components, which they deposit on NETs, 
and that NETs contribute to complement activation. In this study, we aim to determine 
if NETosis can be induced by complement activation. In order to activate complement, 
neutrophils were sensitized via a monoclonal anti-human CD59 (x30 min) followed by 
incubation with 50% human serum as source of complement (x4 h). Immunofluorescence 
(IF) imaging was performed to visualize NETosis and complement activation. A SYTOX 
Green assay was used to quantify the kinetics of NETs formation.
Results: We found that: 1) the use of our complement sensitization protocol resulted 
in C3b deposition and C5b-9 complex formation on neutrophils; 2) NETosis could be 
induced in a complement-dependent manner; 3) both citrullinated Histone 3 (cit-H3) 
and myeloperoxidase (MPO) are both present in the NETs of complement-stimulated 
neutrophils.
Conclusions: Complement activation taking place on the surface of neutrophils induces 
NETosis, a new finding pointing towards a crucial role for neutrophils in the pathogenesis 
of complement-mediated TMA.
Funding: Government Support - Non-U.S.
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Rituximab Associated Hypogammaglobulinaemia in Autoimmune 
Disease: Long Term Outcomes
Joanna Tieu,2 Rona M. Smith,1 Seerapani Gopaluni,3 David R. Jayne.3 
1Cambridge University Hospitals, UK, Cambridge, United Kingdom; 2University 
of Cambridge, University of Adelaide, Cambridge, United Kingdom; 3University 
of Cambridge, Cambridge, United Kingdom.
Background: Despite a low incidence of hypogammaglobulinemia (HG) in clinical 
trials using rituximab (RTX), HG occurs in follow-up of patients with autoimmune disease. 
Immunoglobulin replacement therapy (IRT) has been used to reduce infection rates but 
there is a paucity of data on its efficacy and impact on longer-term outcomes. We examined 
the characteristics of patients with RTX associated HG in autoimmune disease, and their 
long-term outcomes with and without IRT.
Methods: Patients attending a Vasculitis and Lupus clinic, who received RTX for 
autoimmune disease between 2004 and 2012, with an immunoglobulin G (IgG) <7 g/L 
on at least 2 occasions were included in this retrospective case note review. Patients were 
categorized into nadir IgG subgroups of <3 g/L, 3 to <5 g/L and 5 to <7 g/L. Categorical 
variables are summarised as proportions, and continuous variables as mean ± standard 
deviation or median [interquartile range (IQR)]. Differences between nadir IgG subgroups 
were assessed by Chi squared tests and trends across subgroups confirmed by Somer’s D 
tests. Continuous variables were compared using analysis of variance (ANOVA), Kruskall-
Wallis and Wilcoxon sign ranked tests as appropriate. Analyses were performed in SPSS.
Results: Of 142 patients, 101 (71.1%) had ANCA associated vasculitis, 18 (12.7%) 
systemic lupus erythematosus and 23 (16.2%) other diagnoses. Most received RTX for 
relapsing (69.3%) or refractory (25.0%) disease. Mean follow-up was 97.2 months. 
Progressive HG was observed. Median time to IgG <5 g/L was 22.5 months [IQR 3.0 to 
61.5] and to IgG <3 g/L was 24.5 months [IQR 4.0 to 80.75]. Mycophenolate use prior to 
RTX (p=0.05) and prednisolone use following RTX (p=0.04) were associated with a lower 
nadir of IgG. IRT was commenced in 29 patients, the majority (65.5%) with IgG <3 g/L. 
It was well tolerated, with 2 discontinuing due to adverse effects. IRT was withdrawn 
without excess recurrent infections in 5 patients. IRT was associated with a reduction in 
annual infection rates (p<0.001). Severe infections (requiring intravenous antibiotics or 
hospital admission) were uncommon, with no change with the use of IRT.
Conclusions: RTX associated HG is progressively identified with longer term follow-
up. Although annual infection rates were low, in patients with recurrent infection, IRT was 
associated with a reduction in infection burden.
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Persistent B-Cell Depletion After Rituximab
Debbie Chen,1 Zachary S. Wallace,2 Jillian Rosenthal,2 Alexander T. Sipilief,2 
Karen A. Laliberte,2 John Niles,2 Frank B. Cortazar.2 1MGH, Boston, MA; 
2Massachusetts General Hospital, Boston, MA.
Background: Rituximab (RTX), an anti-CD20 monoclonal antibody, is an effective 
therapy for many glomerular diseases. Following RTX, B cell reconstitution occurs at a 
median of 8 months, and the vast majority of patients have B cell return by 18 months. We 
report 7 patients with autoimmune kidney disease who developed persistent B cell depletion 
following RTX.
Methods: We performed a retrospective analysis of patients with glomerular disease 
treated with rituximab between 2006-2017. Patients who had persistent B cell depletion, 
defined as undetectable CD20+ B cells determined by flow cytometry for > 2 years after 
their last rituximab dose, were included in the study. Patient characteristics, serological 
markers of disease, adverse events, and survival were examined.
Results: We identified 7 patients with persistent B cell depletion. Six patients were 
treated for ANCA vasculitis and one for lupus nephritis. Patients received a median of 
13 RTX doses (range, 5 to 22). Following the final RTX, B cells in these patients have 
remained undetectable for a median of 5.2 years (range, 3.9 to 6.9). Four patients developed 
significant hypogammaglobulinemia (IgG < 400 mg/dL) and two received IVIG. RTX-
induced late-onset neutropenia occurred in 3 patients. Five patients developed serious 
infections and one patient died in the setting of infection associated with recurrent late onset 
neutropenia. No patient had recurrence of their underlying autoimmune disease.
Conclusions: Persistent B cell depletion after rituximab is a rare but important 
complication of therapy that appears to be associated with late-onset neutropenia and 
serious infections. The mechanism of this phenomenon is unclear. Additional investigation 
into the risk factors and pathogenesis of this complication are needed.
Patient and Outcome Characteristics
LON: late onset neutropenia
Major infections: infection leading to hospitalization or requiring intravenous antibiotics
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The Oxidized Linoleic Acid Metabolite 12,13-Dihydroxy-9Z- 
Octadecanoid Acid (12,13-DiHOME) Mediates Recovery from  
Nephrotoxic Nephritis
Nino Kvirkvelia,1 Malgorzata McMenamin,1 Ahmed Ibrahim,1,2 Mohamed 
Al-Shabrawey,1 Michael P. Madaio.1 1Augusta University, Augusta, GA; 
2Mansoura University, Masoura, Egypt.
Background: The number of anti-inflammatory lipid molecules is increasing and their 
role in nephritis is not well investigated. In particular, the enzymatic activity of soluble 
Epoxide Hydrolyze (sHE) and its products such as 9,10-DiHOME and 12,13-DiHOME 
were shown to be critical for resolution of inflammation. Biosynthesis of these products 
starts from linoleic acid by cytochrome P450 (CYP) oxidases, followed by hydrolysis 
catalyzed by soluble epoxide hydrolases. We hypothesized that synthesis, metabolism or 
signaling of oxidized linoleic acid metabolites may be affected at the site of inflammation 
and that 12,13-DiHOME has an important role in resolution of nephritis.
Methods: To investigate changes in lipid profiles in differentially treated mice, 
lipidomic analysis was carried out by LC/MC in Lipidomics Core Facility (Wayne State 
University, Detroit, MI). Panel of 144 lipid molecules were measured in plasma of mice at 
day 7 after induction of nephrotoxic nephritis (NTN), induced by injection of nephrotoxic 
serum (13,5μl/g bw). Kidney endothelial cells were treated with 12,13-DiHOME (250nM) 
and TNF-α (10ng/ml) was added after 1h. TNF-α induced upregulation of VCAM-1 was 
investigated by flow cytometry after 24 h.
Results: Lipidomic plasma profiles of polyunsaturated fatty acid metabolites in nephrotic 
mice showed marked decrease of two molecules: 9,10-DiHOME and 12,13-DiHOME. The 
role of 12,13-DiHOME was further evaluated in NTN: after induction of nephritis mice 
were treated with 12,13-DiHOME (20ng/g bw) or vehicle, starting on day 2, than every 48h, 
and mice were sacrificed on day 7. 12,13-DiHOME treatment completely normalized both 
BUN levels and histology (NTN mice: BUN = 117.72 ± 3.2, NTN 12,13-DiHOME injected 
mice BUN = 15.50 ± 0.43, p<0.0002). In glomerular endothelial cells, 12,13-DiHOME 
treatment reduced TNF-α induced upregulation of VCAM-1 by 49%.
Conclusions: The results of the study suggest that administration of 12,13-DiHOME 
during NTN protects kidneys from severe inflammation, in part, by limiting upregulation 
of adhesion molecules on kidney endothelial cells and therefore, may have therapeutic 
potential for the treatment of nephritis.
FR-PO1078 Poster Friday
Glomerular Diseases: Immunology and Inflammation - II
Urine Podocin to Nephrin mRNA Ratio Is Associated with Activity of 
Crescentic Necrotizing Glomerulonephritis
Akihiro Minakawa,1 Akihiro Fukuda,2 Masao Kikuchi,1 Yuji Sato,1 
Shouichi Fujimoto.1 1University of Miyazaki, Miyazaki, Japan; 2Oita University, 
Yufu, Japan.
Background: Crescentic necrotizing glomerulonephritis (CNGN) rapidly leads to 
progressive glomerulonephritis syndrome, which then leads to irreversible renal failure 
without appropriate therapy. To estimate the severity of CNGN, renal biopsy is required. 
However, renal biopsy is sometimes not applied because of a severe general condition. 
If urine podocyte-specific mRNA predicts the severity of CNGN, it may be a useful tool.
Methods: A total of 28 patients with biopsy-proven CNGN (males: 16, mean age: 
64.6±12.8 years) were enrolled during the past 7 years, with pathological data available for 
27 patients. Kidney biopsy samples were used for immunostaining of podocytes and urine 
samples for podocyte mRNA with the patient’s consent by document.
Results: A blood test showed an estimated glomerular filtration rate of 24.9±18.7 
mL/min and C-reactive protein level of 3.33±3.68 mg/dL. Histological analysis showed 
3 patients with crescent class, 3 with sclerotic class, 9 with focal class and 12 with mixed 
class according to EUVAS classification. Immunostaining showed a podocyte number of 
297.2±133/glom and podocyte density of 75.8±32/106μm3. A urinary mRNA study showed 
a urine podocin:nephrin mRNA ratio (PNR) of 1.46±0.80 and urine podocin mRNA:urine 
creatinine ratio (U-pod/CR) of 476.8±525.3. The podocyte number and density were lower, 
and the PNR and U-pod/CR were higher compared with those of healthy controls in our 
previous report (419±81/glom, 129±49/106μm3, 0.36±0.29, 4.3±4.6, respectively). Using 
EUVAS criteria, the podocyte number in the sclerotic class and podocyte density in the 
crescent and sclerotic classes tended to be lower compared with the other classes. The 
PNR and U-pod/CR in these classes, except for the sclerotic class, tended to be increased, 
which suggested a “podocyte-depleted” stage of sclerotic class. Remarkably, the PNR 
was significantly correlated with the percentage of glomeruli with acute crescents per 
unsolidified glomeruli (p<0.01, R2=0.28). Log10 of the U-pod/CR was also correlated with 
it, except for 6 severe crescentic cases (p<0.01, R2=0.40).
Conclusions: Urine podocyte mRNA, especially the PNR, might be a useful tool for 
evaluating activity of CNGN.
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miR-150 Inhibitor Ameliorates Three Immune-Involved Kidney Diseases 
by Reducing Inflammation and Fibrosis
Junjun Luan,1 Huimeng Qi,1 Jingqi Fu,2 Congcong Jiao,1 Weiwei Kong,1 
Chengjie Chen,2 Xiangfei Cui,1 Jingbo Pi,2 Yanqiu Wang,1 Detian Li,1 Hua Zhou.1 
1Department of Nephrology, The Affiliated Shengjing Hospital of China Medical 
University, Shenyang, China; 2Program of Environmental Toxicology, School of 
Public Health, China Medical University, Shenyang, China.
Background: Renal fibrosis from immune-involved kidney diseases remains 
refractory. We previously reported that miR-150 increased in the repeated renal biopsies 
from patients with lupus nephritis (LN) and found that miR-150 mimic promoted fibrosis in 
three human kidney resident cells in vitro. We aimed to clarify whether miR-150 inhibitor 
can ameliorate renal fibrosis in three kidney disease mouse models and to identify the 
corresponding mechanisms.
Methods: We first examined miR-150 in renal biopsies from patients with new 
onset LN or focal segmental glomerulosclerosis (FSGS). Then we observed the time 
course of renal miR-150 in mouse models including spontaneously developed Fcgr2b−/− 
LN, adriamycin-induced FSGS, and folic acid-induced tubulointerstitial fibrosis (TIF). 
Lastly, the efficacy and safety of locked nucleic acid (LNA)-anti-miR-150 (2mg/kg, twice 
a week) were studied when it was subcutaneously injected to LN mice for 8 weeks, to 
FSGS mice for 6 weeks, and to TIF mice for 4 weeks. The kidney injury (proteinuria, 
serological indices, and histology damage on PAS and Masson staining), renal levels of 
pro-inflammatory cytokines (IFN-γ, IL-6, and TNF-α), profibrotic genes (TGF-β, α-SMA, 
fibronectin, and collagen1), antifibrotic gene suppressor of cytokine signaling 1 (SOCS1), 
and the infiltration of lymphocytes and macrophages were investigated in mice with LNA-
anti-miR-150 treatment comparisons to the scrambled LNA.
Results: miR-150 was increased in renal biopsies of LN and FSGS patients compared 
to normal kidneys. miR-150 showed higher expression in the kidneys of mice than in other 
studied organs. LNA-anti-miR-150 downregulated renal miR-150 levels and ameliorated 
kidney injury in LN, FSGS, and TIF mice without any organ toxicity. The above observed 
pro-inflammatory cytokines, profibrotic genes, and the infiltration of lymphocytes and 
macrophages increased while antifibrotic gene SOCS1 decreased in the kidneys of disease 
mice. LNA-anti-miR-150 decreased the inflammation, fibrosis, and inflammatory cells 
while increased SOCS1 compared to the scrambled LNA.
Conclusions: miR-150 inhibitor played important renal protective roles in three 
immune-involved kidney diseases with final renal fibrosis. This suggests that miR-150 
inhibitor might be a promising therapeutic agent for renal fibrosis.
Funding: Government Support - Non-U.S.
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The Histopathological Spectrum of Monoclonal Gammopathies of Renal 
Significance: A Single Centre Experience
Andreas Kousios,1 Tara K. Brah,1 Ethan Troy-Barnes,1 Neill D. Duncan,1 Rawya 
Charif,1 H. Terence Cook,3 Candice A. Roufosse.2 1West London Renal and 
Transplant Centre, Imperial College Healthcare NHS Trust, London, United 
Kingdom; 2Renal Pathology, Imperial College Healthcare NHS Trust, London, 
United Kingdom; 3Imperial College of London, London, United Kingdom.
Background: Monoclonal Gammopathy of Renal Significance (MGRS) encompasses 
renal histopathological entities caused by Monoclonal Immunoglobulins (MIg) in patients 
who do not meet criteria of symptomatic lymphoma or myeloma (MM). We describe 
the spectrum of MGRS histopathological diagnoses in the context of the underlying 
haematological disease in our centre.
Methods: Native renal biopsies performed during 2006-2017 were reviewed. Those 
with evidence of MIg or light chain in glomeruli, tubules, vessels and/or interstitium were 
included. C3GN and TMA were excluded.
Results: Out of 4,374 kidney biopsies, MIg-associated lesions were identified in 163 
cases (3.7%). After exclusion of symptomatic MM and lymphomas 68 biopsies (1.5%) 
were consistent with MGRS. Renal histological diagnoses included: AIg amyloidosis 
(n=28, 41%), Proliferative GN with MIg Deposits(PGNMID) (n=13, 19%), MIg 
Deposition Disease(MIDD) (n=12, 18%), Light Chain Tubulopathy (n=5, 7%), Type-1 
Cryoglobulinaemic GN (n=6, 9%), Intracapillary Monoclonocal IgM without Cryoglobulin 
(n=2, 3%), Crystal Cryoglobulinaemia (n=1, 1.5%) and Fibrillary Light Chain restricted 
GN (n=1, 1.5%). Only 24 out of 42 patients in whom Serum Free Light Chain assay was 
performed had an abnormal ratio. Overall, haematological diagnosis was possible in bone 
marrow histology (BMAT) or lymph node biopsy in 53 patients. These included: MGRS 
with less than 10% plasma cells in BMAT (n=30, 56.6%), Smouldering Myeloma (n=17, 
32%), lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinaemia (n=2, 3.7%), 
chronic lymphocytic leukaemia (n=3, 5.6%) and marginal zone lymphoma (n=1, 1.8%). In 
8/13 PGNMID and 3/12 MIDD cases a clonal B cell or plasma cell clone was undetectable 
in BMAT.
Conclusions: MGRS are increasingly recognised since the term introduction in 2012 
and this type of renal histopathology is also frequent in Smouldering Myeloma. Renal 
histopathology must be interpreted in conjunction with the haematological diagnosis 
to guide treatment decisions. However, current diagnostic methods underperform and 
consensus diagnostic approaches incorporating renal and haematological histopathology 
are lacking.
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Diagnosis and Outcomes of Monoclonal Gammopathy of Renal  
Significance: A Single Centre Study
Andreas Kousios,2 Neill D. Duncan,2 Candice A. Roufosse,1 H. Terence Cook,3 
Rawya Charif.2 1Imperial College Healthcare NHS Trust, London, United 
Kingdom; 2West London Renal and Transplant Centre, Imperial College 
Healthcare NHS Trust, London, United Kingdom; 3Imperial College of London, 
London, United Kingdom.
Background: Monoclonal Gammopathies of Renal Significance (MGRS) are caused 
by monoclonal immunoglobulins (MIg) produced by B cell or plasma cell clonal disorders, 
which do not meet criteria of symptomatic lymphoma or myeloma (MM). Treatment 
objective in MGRS is the preservation of kidney function.
Methods: Records of patients with native kidney biopsy during 2006 – 2017 were 
reviewed. Amyloidosis, C3GN and TMA were excluded.
Results: 41 biopsies out of 4.374 (1%) were consistent with MGRS. Mean age 
at diagnosis was 63±12 years. Renal histological diagnoses included: proliferative 
glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) (n=16, 
39%), monoclonal immunoglobulin deposition disease (MIDD) (n=13, 32%), light 
chain tubulopathy (LCT) (n=5, 12%), type-1 cryoglobulinaemic glomerulonephritis 
(n=6, 15%), fibrillary glomerulopathy (FibGN) (n=1, 2%). 22/41 patients had abnormal 
protein electrophoresis and/or free light chain ratio. 32/41 had bone marrow biopsy 
and haematological diagnoses included: MGRS with <10% plasma cells (n=22, 69%), 
smouldering myeloma (n=5, 15%), Waldenstrom’s Macroglobulinaemia (n=1, 3%), 
chronic lymphocytic leukaemia (n=3, 10%) and marginal zone lymphoma (n=1, 3%). 16 
patients were treated with myeloma-based protocols (bortezomib ± autologous stem cell 
transplantation). In cases with very low or unidentifiable clone, treatment was heterogenous, 
including glomerulonephritis protocols (cyclophosphamide, steroids ±Rituximab) (n=16) 
or conservative management (n=9). During median follow-up of 26 months (4-123) in 38 
patients, 26 had stable/improved renal function, 1 worsening renal function (>30% eGFR 
decrease) and 11 progressed to ESRD. 9 patients died (table 1).
Conclusions: Haematological assessment of MGRS must exclude symptomatic 
myeloma or lymphoma and identify the pathogenic clone to direct specific therapy. Case 
studies in our series indicate that early detection and treatment improves renal outcomes, 
however consensus diagnostic and treatment approaches are missing.
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Multiple Deposition Phenotypes of Monoclonal Immunoglobulin 
Deposition Disease on Renal Biopsy: Significance of Treatment
Sreedhar R. Adapa,2 Cynthia C. Nast,1 Hemant Dhingra.2 1Cedars-Sinai Medical 
Center, Los Angeles, CA; 2The Nephrology Group, Inc, Fresno, CA.
Introduction: Plasma cell dyscrasias frequently involve the kidney causing 
renal dysfunction. Various morphologies occur in kidneys, infrequently with several 
manifestations in one biopsy. We present a case, which revealed multiple pathological 
features on same biopsy, which responded to treatment.
Case Description: A 61 year old female presented with fatigue and dyspnea for 3 
months. She had new onset renal failure with creatinine 3.0 mg/dL and proteinuria. 
Serological work up revealed monoclonal gammopathy with elevated K:L ratio of 1394. 
Renal biopsy revealed several paraprotein manifestations including kappa light chain 
deposition disease, monoclonal fibrillary glomerulonephritis, cryocrystalglobulenemia and 
fibrillary/tubular cast nephropathy. There was also incidental LECT 2 amyloidosis, negative 
for kappa light chain and confirmed by mass spectrometry. Bone marrow biopsy revealed 10-
20% kappa restricted plasma cells. She received 8 cycles of CyBorD (Cyclophosphamide, 
Bortizomib and Dexamethasone) chemotherapy. Renal function improved with the recent 
creatinine 1.1 mg/dL and decreased proteinuria. K:L ratio improved to 1.7. Repeat bone 
marrow biopsy showed no evidence of abnormal plasma cells by immunohistochemistry. 
The patient is currently being evaluated for an autologous stem cell transplant.
Discussion: The finding of several concurrent morphologic manifestations of light 
chain deposition in one biopsy suggests local microenvironment effects in addition to 
structural properties of the light chain. The renal recovery demonstrates responsiveness to 
chemotherapy irrespective of the form of light chain deposition noted on biopsy. In this 
setting, amyloid may not always be light chain related, and other amyloid types should be 
considered when light chain staining is discrepant.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
A Clone-Directed Treatment Approach for the Monoclonal  
Gammopathies of Renal Significance
Alex Dinh,1 Jordana B. Cohen,2 Matthew Palmer,3 Alfred Garfall,4 Laura 
M. Dember,2 Dan T. Vogl,4 Brendan M. Weiss,4 Jonathan J. Hogan.2 1Division of 
Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, 
PA; 2Division of Nephrology, University of Pennsylvania School of Medicine,
Philadelphia, PA; 3Pathology, University of Pennsylvania, Philadelphia, PA; 
4Division of Hematology-Oncology, University of Pennsylvania School of
Medicine, Philadelphia, PA.
Background: Monoclonal gammopathy of renal significance (MGRS) is a non-
malignant hematologic condition causing paraprotein-mediated kidney disease. We recently 
published our experience using a clone-directed approach to patients with PGNMID. Here, 
we present our experience using the same approach to 22 patients with non-PGNMID 
paraprotein-mediated nephropathies.
Methods: We retrospectively reviewed 22 patients with MGRS to describe their renal 
and hematologic presentations and outcomes. For patients with initial proteinuria <0.5 g, 
complete renal response (CR) was defined as proteinuria <0.01 g (24h urine) or g/g (Uprot/Cr 
ratio) and partial renal response (PR) as proteinuria reduction by 50%. For patients starting 
with nephrotic range proteinuria, CR and PR were defined as proteinuria <0.5 g and <3.5 
g, respectively. For patients with initial proteinuria between 0.5 and 3.5 g, CR and PR 
were defined as proteinuria <0.49 g and 50% reduction of proteinuria, respectively. Renal 
response required stable/improved eGFR. Hematologic studies and responses are presented 
descriptively.
Results: Histologic diagnoses included LCDD (n= 9), immunotactoid glomerulopathy 
(n= 3), paraprotein-associated C3 GN (n= 2), monoclonal membranous nephropathy 
(n= 3), and 1 case each of monoclonal fibrillary GN, heavy chain deposition disease, light 
and heavy chain deposition disease, type 1 cryoglobulinemic GN, and light chain proximal 
tubulopathy. Median eGFR (interquartile range) was 30 mL/min (18 to 48 mL/min). 
Median baseline proteinuria (IQR) was 2.11 g (1.1 to 3.9 g). 4 patients presented on RRT. 
An underlying clone was detected in 18 patients (82%), of whom 13 had plasma cell clones 
and 5 had B cell clones. 17 (77%) patients had detectable paraprotein on serum or urine 
immunofixation. 4 patients were not treated due to stable renal disease. Of 18 patients who 
underwent treatment, 3 achieved renal CR and 6 achieved renal PR (50% overall response 
rate). No patient on HD came off RRT, and 1 patient progressed to ESRD during follow-
up. Of patients who received clone-directed therapy and were not on RRT at diagnosis, the 
overall renal response rate was 64%. 71% of patients had an improvement in paraprotein 
levels.
Conclusions: Clone-directed therapy led to a high overall response rate in patients 
with MGRS.
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Chemotherapy Response and 2 Years Follow-Up of Proliferative 
Glomerulonephritis with Monoclonal Immunoglobulin Deposits 
(PGNMID)
Ricardo Valjalo,1 Camila Pena,1 Gonzalo P. Mendez.2 1Hospital del Salvador, 
Santiago, Chile; 2Pontificia Universidad Catolica de Chile., Vitacura, Chile.
Background: The term monoclonal gammopathy of renal significance (MGRS) 
represents all monoclonal gammopathies that are associated with the development of a 
kidney disease but do not meet the definition of hematological malignancies. PGNMID 
is an uncommon MGRS–related glomerular disorder characterized by monoclonal Ig 
deposits resulting in an endocapillary proliferative or membranoproliferative histological 
pattern of injury. It usually manifests with proteinuria, microscopic hematuria and renal 
impairment. Treatment for PGNMID has included RAS blockage, rituximab, chemotherapy 
and immunosuppressive therapy with variable results. Nonetheless, reports with treatment 
outcomes are scarce, heterogeneous and retrospective, so the benefits of specific treatment 
remain unclear. Here we report for first time, the prospective results of 3 cases of PGNMID 
treated with a cyclophosphamide, thalidomide and dexamethasone (CTD regimen) based 
oral chemotherapy.
Methods: Prospective analysis. Three cases of PGNMID were identified during 2015 
at Hospital del Salvador (Santiago, Chile). The biopsies were analyzed using standard 
techniques for light microscopy, IF, and EM. The presence of plasma cell dyscrasia and 
other conditions were evaluated. All patients received CTD regimen and RAS blockage.
Results: Two patients made their debut with impure nephrotic syndrome and rapidly 
progressive renal failure. Patient 2 had subnephrotic proteinuria and hematuria. In all 
cases M-protein could not be detected by serum or urine PEP/IF and only κ/λ relation 
was elevated. All patients had no bone marrow involvement, and autoimmunity study was 
negative. The IF revealed mesangial deposits restricted to IgG3-kappa in patients 1 and 3, 
and IgA kappa in patient 2. After CTD regimen, two patients achieved complete remission 
with no adverse effects and no relapses after 2 years of follow-up. The third patient had a 
serious pneumonia with severe AKI and dialysis requirement after 8 months of initiating 
chemotherapy. Thereafter had a serious Clostridium difficile infection, chemotherapy was 
stopped and the patient continued on dialysis.
Conclusions: The CTD chemotherapy regimen was successful in the treatment of 
PGNMID attaining long-term complete remission. CTD regimen seems to be an effective 
treatment, but we must put attention on chemotherapy related adverse effects
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Comparison of Two Renal Staging Systems and Response Criteria of AL 
Amyloidosis
Maria E. Drosou, Eli Muchtar, Nelson Leung. Mayo Clinic, Rochester, MN.
Background: Light chain (AL) amyloidosis affects the kidney in 70% of the patients. 
Renal survival and response are critical for the treatment decision. We carried out this study 
to evaluate the two sets of baseline staging system and renal response and progression 
criteria (Palladini et al. and Kastritis et al.) recently proposed in our own population.
Methods: AL cases with renal involvement at Mayo Clinic between 01/2003 and 
01/2015 were screened. Patients were excluded if: dialysis dependence at the time of 
diagnosis or <3 months of treatment initiation, incomplete data set and treatment initiation 
more than 1 month before AL diagnosis. Our cohort was evaluated at baseline and at 3, 6 
and 12 months. The study’s endpoint was renal survival, defined as the time from treatment 
initiation to dialysis initiation or of last follow up. We used competing risks statistical 
analysis and the C (Concordance) index to compare the two models.
Results: Out of 836 patients with AL and renal involvement, 495 were selected. 
The median age was 61(54-68) years and 62% were male. Median serum creatinine was 
1.1(0.9-1.4) mg/dl, median eGFR was 66(47-82) ml/min/1.73 m2 and median proteinuria 
was 5.1(2.5-8.2) g/d. Table 1 shows the distribution of our cohort in stages. For ESRD 
onset, hazard ratio (HR) for stage II vs I was 21[NL1] (p= 0.003) and for stage III vs II 
was 3.02(p<0.001) for the Palladini staging system (C= 0.74). HR for stage II vs I was 4.3 
(p=0.161) and for stage III vs II was 4.76 (p< 0.001) for the Kastritis staging (C =0.73). 
At 3 months, neither criteria met statistically significant predictive value. The Palladini 
progression criteria were superior both at 6 months [HR: 9.68 (p<0.001, C =0.79) vs 
HR: 3.03 (p=0.002, C= 0.65)] and at 12months [HR: 7.24 (p<0.001, C =0.75) vs HR: 
5.47(p<0.001, C=0.72)]. Both response criteria showed comparable results at 6 and 12 
months after treatment initiation.
Conclusions: Both Palladini and Kastritis renal staging systems predict renal survival 
well. Renal progression and response assessed using serum creatinine and 24 hour urine 
protein appear to have little prognostic value earlier than 6 months.
Distribution of Patients by Different Staging Systems
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Renal Outcome and Prognosis Analysis of Light Chain Amyloidosis and 
Renal Involvement
Zixuan Zhu,1 Xuemei Li,1 Ming-Xi Li.2 1Peking Union Medical College 
Hospital, Beijing, China; 2Peking Union Medical College Hospital (PUMCH), 
BEIJING, China.
Background: Light-chain (AL) amyloidosis is the most common and serious type of 
systemic amyloidosis. Most studies only focused on the overall survival of AL amyloidosis. 
Renal involvement is one of the most common complications of the disease which can lead 
to end-stage renal disease (ESRD). Our study compared clinical features of the amyloidosis 
cohort in multiple aspects, and emphasized on renal outcomes. And we also aimed to 
validate two staging system for renal involvement in Asian populations firstly.
Methods: Patients with newly diagnosed AL amyloidosis and kidney involvement 
which was proved by renal biopsy in Beijing Union Medical College Hospital from January 
1, 2002 to December 31, 2017 were included. Demographic characteristics and clinical 
features were summarized. Cases diagnosed after 2011 were followed up. A comparative 
analysis of the baseline condition and prognosis was made between primary and secondary 
amyloidosis, κ and λtype. Two renal staging system were proposed in 2014 and 2017, based 
on proteinuria (24hUP>5g/d) and eGFR (<50ml/min/1.73m2) or 24hUP/eGFR at diagnosis. 
Patients were divided into renal stage I-III and renal stage 1-3 respectively by two criteria. 
The baseline conditions and renal outcomes were analyzed and compared to evaluate the 
prognostic value of the two systems.
Results: A total of 76 cases were included. All cases had renal involvement. 44 cases 
were followed up. 49 cases (64.5%) showed nephrotic syndrome, and 28 cases (36.8%) 
showed renal insufficiency at the time of diagnosis. There was no significant difference 
in clinical features, organ involvement renal outcome and survival between κ and λ cases, 
primary AL amyloidosis and AL amyloidosis secondary to multiple myeloma(MM). The 
renal staging system based on 24hUP and eGFR were validated. There was a significant 
difference in renal outcome among renal stage I-III (p=0.003). Based on the 24hUP/eGFR 
system, there was no ESRD in both stage 1 and stage 2. A significant difference was seen 
between phase 3 and two other stages (p=0.008).
Conclusions: The clinical manifestations, renal outcome, and survival of AL 
amyloidosis are not affected by primary or secondary to MM, and different type of light 
chain. For the first time, the prognostic value of renal staging system based on 24hUP and 
eGFR was validated in Asian populations, which is of great significance in guiding clinical 
treatment.
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Significant Reduction in Proteinuria After Treatment with Tafamidis
Asuncion Ferrer-Nadal,1 Tomas Ripoll,2 Mercedes Uson,3 Antoni Figuerola,4 
Juan Buades.5 TTRhA Spanish Group 1Nephrology, Hospital Son Llàtzer, Palma 
de Mallorca, Spain; 2Cardiology, Hospital Son Llatzer, Palma de Mallorca, 
Spain; 3Neurology, Hospital Son Llatzer, Palma de Mallorca, Spain; 4Neurology, 
Hospital Son Llatzer, Palma de Mallorca, Spain; 5Internal Medicine, Hospital 
Son Llatzer, Palma de Mallorca, Spain.
Introduction: Hereditary Transthyretin Amyloidosis (hATTR) in Mallorca represents 
the fifth world focus. Tafamidis (Vyndaqel, Pfizer) has been used since 2011 with promising 
expectations. It promotes stabilization of the TTR tetramer and slow tissue deposition. 
Consequently, it contributes to change the course of disease, slowing the presentation of 
clinical manifestations. The Portuguese group presented few cases with small reduction in 
proteinuria last year. We present now an interesting case of a significant decrease in heavy 
proteinuria.
Case Description: We display the first case presented (to our knowledge) with great 
proteinuria reduction from nephrotic range to mild range. This is a well documented 
female case of late onset Val30Met. Amyloid deposits were confirmed by positive congo 
red stain in a skin biopsy. Patient came into the outpatient consultation due to cardiology 
manifestations. Patient was studied in depth, and then neurologic, intestinal and nephrologic 
impairment was also found. Nephrotic range proteinuria of 4,2 g in 24h with kidney 
dysfunction were present. We also found an unusual dissociation among glomerular 
filtration rate formulas (urine and blood results). Therefore, we performed a 51Cr-EDTA 
renal function, and also conducted a dynamic study with 99mTc-MAG3 scintigraphy. 6 
months after taking tafamidis, proteinuria was reduced to 1,6 g in 24h.
Discussion: This finding may be very promising for the future to slow the natural 
course of proteinuric kidney TTR amyloidosis disease. It will permit to avoid or slow 
progression to end-stage renal disease and renal replacement therapy.
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Masked Hypertensive Disorders Are Prevalent in Active Lupus Nephritis 
Patients
Mariedel Trujeque, Yesser J. López hernández, Jesus I. Santander, 
Luis E. Morales-Buenrostro, Juan M. Mejia-Vilet. Instituto Nacional de 
Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico.
Background: SLE patients have an increased cardiovascular mortality. In CKD, 
24h-ABPM studies demonstrate a high-prevalence of masked hypertensive disorders.
Methods: From March 2016 to April 2018, 58 active lupus nephritis patients were 
evaluated by 24h-BP monitoring the day of the renal biopsy procedure. Two validated 
oscillometric-based devices were used (Spacelabs 91207 and Welch Allyn 6100). A registry 
was considered appropriate if >20 daytime and >7 nighttime measurements were available. 
For analysis, patients were divided into those with or without previous hypertension.
Results: Out of 58 LN patients, 17 (29%) had a previous hypertension dx. These 
patients were older, had higher in-clinic BP and their renal biopsy showed higher interstitial 
fibrosis/tubular atrophy. In the 24h-BPM, patients with previous HT had higher overall, 
daytime and nocturnal BP. However, the nocturnal decrease of BP was diminished and 
not different between groups. Only 11 (19%) patients had normal dipping, in 30 (52%) it 
was decreased, and in 17 (29%) was absent. White-coat hypertension (WCH) was found 
in 3/11 (27%) in-clinic HT and masked uncontrolled hypertension in 3/6 (50%) of in-
clinic controlled patients. In the non-previous HT group, WCH was found in 4/11 (36%) 
of in-office HT patients and masked hypertension in 12/30 (40%) of in-office controlled 
patients. The nighttime systolic and diastolic BP were more frequently abnormal compared 
to daytime measurements.
Conclusions: Masked hypertensive disorders are frequent in lupus nephritis patients. 
As BP thresholds are part of an appropriate management of proteinuric diseases, 24h blood 
pressure measurements should be considered in clinical practice. These studies were made 
as inpatients and should be corroborated with ambulatory measurements.
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Urinary Soluble CD163 as a Biomarker for Lupus Nephritis
Junya Suwa,1 Hidekazu Ikeuchi,1 Hiroshi Kajiyama,3 Hiroko Hamatani,1 
Masao Nakasatomi,1 Yoriaki Kaneko,1 Toru Sakairi,1 Yoshihisa Nojima,2 
Keiju Hiromura,1 Toshihide Mimura.3 1Gunma University Graduate School of 
Medicine, Maebashi, Japan; 2Japan Red Cross Maebashi Hospital, Maebashi, 
Japan; 3Saitama Medical University, Saitama, Japan.
Background: Recently, it has been reported that urinary soluble CD163 (UsCD163) 
reflects glomerular inflammation of ANCA-associated nephritis and lupus nephritis (LN). 
We examined the significance of UsCD163 as a biomarker for histological activity and 
treatment response of LN.
Methods: We investigated the levels of UsCD163 before and after treatment in 52 LN 
patients (49 females, median age 37 years old) who were diagnosed as ISN/RPS Class III, 
IV or V and treated for LN since 2010 to 2015 in Gunma University and Saitama Medical 
University hospitals by ELISA. We also examined whether UsCD163 could be a predictor 
of remission of LN.
Results: RESULTS: Levels of UsCD163/creatine (Cr) were higher in Cass IV 
and Class V compared to Class III: III, 2.55 (1.40-5.55); IV, 8.84 (3.05-19.1); V, 8.10 
(7.14-10.3) ng/mgCr;, median, (IQR). Significant correlations were observed between 
levels of UsCD163/Cr and urinary protein/Cr or systemic lupus erythematosus disease 
activity index (SLEDAI) score, but not eGFR (r=0.421, p=0.0026; r=0.465, p<0.001; 
r=-0.212, p=0.143). Associations between UsCD163/Cr and histological parameters were 
shown in Table 1. Significant positive correlations were found between levels of UsCD163/Cr 
and activity index, leukocyte infiltration or cellular crescents. UsCD163/Cr levels rapidly 
decreased after treatments. Receiver operating characteristic analysis showed UsCD 
163/Cr >17.3 ng/mgCr before treatment was predictor of the presence of cellular crescent 
(sensitivity 85%, specificity 44%). UsCD163/Cr <3.0 ng/mgCr before treatment was a 
predictive marker for early proteinuria remission defined as urine protein/Cr <0.3 g/gCr at 
3 months after treatment (sensitivity 42%, specificity 92%, positive predictive value 92%, 
negative predictive value 69%).
Conclusions: UsCD163 could be a potential biomarker for histological activity and 
treatment response of LN.
Funding: Government Support - Non-U.S.
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Table 1. Correlation between UsCD163/Cr and histological parameters
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A Composite Urinary Biomarkers to Predict Pathological  
Tubulointerstitial Lesions in Lupus Nephritis
Ying Tan,1 Ying Ding,2 Minghui Zhao.3 1Peking University first hospital, Beijing, 
China; 2Pekin university international hospital, Beijing, China; 3Reanl division, 
Peking University First Hospital, Beijing, China.
Background: This study aims to evaluate the clinical value of urinary biomarkers 
including kidney injury molecule-1 (KIM-1), neutrophil gelatinase–associated lipocalin 
(NGAL) and monocyte chemoattractant protein 1 (MCP-1) in lupus nephritis.
Methods: A total of 109 biopsy-proven lupus nephritis patients were included, and 50 
healthy individuals were collected as the normal controls. The urinary KIM-1, NGAL and 
MCP-1 levels were measured by ELISA, and the correlations of clinical and histological 
features with them were further assessed. Receiver operating characteristic curves were 
performed and cox regression model was applied to identify prognostic factors associated 
with renal outcomes.
Results: Active lupus nephritis patients exhibited elevated urinary levels of KIM-1, 
NGAL and MCP-1 in comparison with lupus nephritis patients in remission (P<0.001) 
and healthy controls (P<0.001). The urinary KIM-1 level was correlated with pathological 
tubular atrophy (r=0.208, P<0.05) and increased significantly in the presence of interstitial 
inflammatory lesions (P=0.031). The urinary KIM-1, NGAL and MCP-1 levels were 
higher in patients with active tubulo-interstitial lesions than those with only chronic lesions 
(P=0.015, P=0.230 and P=0.086, respectively). A combination of KIM-1, NGAL and MCP-
1 was a good indicator for diagnosing active tubulo-interstitial lesions (AUC: 0.796). The 
combination of KIM-1 and NGAL was identified as an independent risk factor for renal 
outcomes (HR 7.572, P<0.05).
Conclusions: The urinary KIM-1, NGAL, MCP-1 levels were associated with kidney 
injury indices in lupus nephritis. The combination of the three biomarkers increased its 
power in predicting tubulo-interstitial lesions and renal outcomes.
Funding: Government Support - Non-U.S.
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Urine Epidermal Growth Factor Is a Biomarker of Tubulointerstitial 
Damage in Lupus Nephritis (LN)
John P. Shapiro,1 Juan M. Mejia-Vilet,2 Huijuan Song,1 Daniel J. Birmingham,1 
Samir V. Parikh,1 Brad H. Rovin.1 for the CKD Biomarker Consortium 1Ohio 
State University Wexner Medical Center, Columbus, OH; 2Instituto Nacional de 
Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico.
Background: An agnostic proteomic survey of urine from patients with LN showed 
significantly decreased levels of pro-epidermal growth factor (EGF) in patients who had 
developed chronic kidney disease (CKD). Urine (u)EGF has previously been shown 
to predict progressive CKD in several glomerular diseases. Therefore, we examined the 
association of uEGF with kidney biopsy findings and kidney function in patients with LN.
Methods: EGF was measured by specific ELISA in urine collected at the time of 
kidney biopsy in 23 Mexican and 29 Midwestern (45% African American, 45% Caucasian) 
LN patients, and was characterized by immunoblotting. uEGF was also measured in serial 
urine samples from patients with 1-5 years of longitudinal follow-up.
Results: Results: uEGF in 29 Midwestern LN patients at kidney biopsy was 11.7±10.1 
ng/mg Cr compared to 26.5±13.7 ng/mg Cr in 8 lupus patients with no history of LN 
(p<0.05). Immunoblotting demonstrated uEGF was mainly high molecular weight (pro-
EGF forms). uEGF correlated inversely with serum creatinine (SCr), biopsy chronicity 
index (CI), tubular atrophy and interstitial fibrosis (Table). There was no correlation with 
proteinuria, biopsy activity index (AI) or the histologic components of the AI (Table). 
Patients (n=7) with stable CKD showed low but steady levels of uEGF over 1-4 years of 
follow-up. Patients with progressive CKD (n=6) showed a decline in uEGF over 1-5 years. 
uEGF fell in patients with acute kidney injury (AKI, n=7), rebounded in 4 (57%) patients 
when AKI resolved but remained below baseline in 3 (43%) patients, who either did not 
recover AKI or recovered but later developed CKD.
Conclusions: uEGF is a biomarker of chronic tubulointerstitial damage in LN. Low 
and falling uEGF suggests progressive CKD. uEGF also decreases in AKI and may signal 
future CKD if levels do not improve.
Funding: NIDDK Support, Private Foundation Support
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Polyomavirus BK, BKV MicroRNA, and Urinary Neutrophil  
Gelatinase-Associated Lipocalin Can Be Used as Potential Biomarkers  
of Lupus Nephritis
Yi-Jung Li. Linkou Kidney Research Center Nephrology, Kidney Research 
Center, Department of Nephrology, Linkou Chang-Gung Memorial Hospital, 
Taiwan, Tauyuan, Taiwan.
Background: Lupus nephritis (LN) frequently progresses to end-stage renal disease. 
Finding a biomarker for LN and a predictor for the development of chronic kidney disease 
(CKD) is important for patients with systemic lupus erythematosus (SLE).
Methods: Ninety patients with SLE were divided into biopsy-proven LN (n = 54) and 
no kidney involvement (non-LN) (n = 36) groups and followed up for 54 months.
Results: Of 36 patients with LN, 3 (5.6%) had class II disease, 3 (5.6%) had class III, 
35 (64.8%) had class IV, 10 (18.5%) had class V, and 3 (5.6 %) had class VI (advanced 
sclerosis). Compared to the non-LN group, patients in the LN group had higher autoimmunity 
evidenced by a higher proportion of low C3 and C4 levels, positive anti-double-stranded 
DNA antibody levels, and lower estimated glomerular filtration rates (eGFR). Urinary 
neutrophil gelatinase-associated lipocalin (uNGAL) levels were significantly higher 
in the LN group (LN vs non-LN, 670 vs 33 ng/mL, respectively). The patients with 
LN had a higher urinary polyomavirus BK (BKV) load (3.6 vs 3.0 log copies/mL) 
and a lower urinary BKV miRNA (miR-B1) 5p level (0.29 vs 0.55 log copies/mL, 
p = 0.025), while there was no significant difference in the level of miR-B1-3p. Urinary 
miR-B1-5p level but not urinary BKV load was negatively correlated with uNGAL level (r 
= -0.22, p = 0.004). At the cutoff value of 80 ng/mL, the receiver operating characteristic 
curve analysis showed that uNGAL level as a predictor of the presence of LN had a high 
sensitivity (98%) and specificity (100%) (area under the curve [AUC], 0.997; p < 0.001). 
During the 54-month follow-up period, 14 (7%) patients with LN and none of the non-
LN patients developed CKD. Multivariate Cox regression analysis revealed that baseline 
uNGAL level was the only predictive factor for CKD development, while baseline serum 
creatinine level and eGFR were not.
Conclusions: An elevated urinary BKV viral load with a decreased level of miR-B1 
implies the presence of LN. In addition, an increased uNGAL level is a good biomarker 
not only in predicting the presence of LN but also for prediction of CKD development in 
patients with SLE.
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Glomerular Phospholipase A2 Receptor Antigen in Lupus Membranous 
Nephritis
Mayumi Nakata,1 Tomo Suzuki,1 Shiika Watanabe,1 Daisuke Ichikawa,1 
Junki Koike,2 Yugo Shibagaki.1 1St. Marianna University Hospital, Kawasaki, 
Japan; 2Kawasaki Municipal Tama Hospital, Kawasaki, Japan.
Background: Phospholipase A2 receptor (PLA2R) is the major pathogenetic antigen 
in idiopathic membranous nephropathy (iMN). Anti-PLA2R antibody is detected in 
approximately 70% with iMN and glomerular PLA2R expression by immunofluorescence 
and serum PLA2R antibody are often observed. Its prevalence and characteristics in lupus 
membranous nephritis remains to be undetermined.
Methods: We conducted a cross-sectional study at two-centers in Japan, including 
patients whose renal biopsies show ISN/RPS Class V lupus nephritis, between May 25, 
2012 to March 31, 2018. We performed immunofluorescence analysis of frozen section for 
PLA2R expression using anti-PLA2R antibody. We evaluated the clinical and pathological 
features between positive-PLA2R group (PLA2R-P) and negative group (PLA2R-N) and 
checked the serum anti-PLA2R antibody only in PLA2R-P.
Results: We analyzed the glomerular expression of PLA2R Ag in 23 patients, as 
many as 5 patients had positive glomerular PLA2R antigen expression. As shown in the 
Table, we compared the characteristics between PLA2R-P and PLA2R-N. The age and the 
duration from the diagnosis of SLE to biopsy were higher in PLA2R-P, but not significantly. 
Although the difference in the levels of proteinuria was not significant, the level of serum 
total protein was significantly lower in PLA2R-P. The levels of C3 and C4, and the intensity 
of glomerular IgG1 deposition were significantly higher in PLA2R-P. On the other hand, 
serum anti-PLA2R antibody level are all normal in the PLA2R-P.
Conclusions: Significant proportion of class V lupus nephritis showed positive PLA2R 
in kidney specimen in spite of absence of circulating anti-PLA2R antibody. Cases with 
positive PLA2R had significantly lower serum total protein and higher complement levels. 
Higher complement and proteinuria level may indicate poor activity of lupus nephritis and 
more phenotypical similarity to iMN.
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Characteristics of lupus nephritis ClassV.
FR-PO1094 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
APOL1 Risk Variants in Brazilians with Lupus Nephritis
Gisele Vajgel,2,1 Suelen C. Lima,1 Pamela J. Hicks,6 Denise M. Costa,2,3 
Camila B. Oliveira,2,3 Lucila Maria Valente,2 Gianna Mastroianni-kirsztajn,4 
Barry I. Freedman,6 Paula S. Sandrin-Garcia.1 1Biomol Lab, LIKA/UFPE, 
Recife, Brazil; 2Hospital Das Clinicas, Recife, Brazil; 3IMIP, Recife, Brazil; 
4Nephrology, UNIFESP, Sao Paulo, Brazil; 6Wake Forest Baptist Health, 
Winston Salem, NC.
Background: APOL1 2 risk variants have been associated to collapsing glomerulopathy 
and end stage renal disease (ESRD) in lupus nephritis (LN) patients. The prevalence of 
APOL1 G1 and G2 variants in Brazilians is unknown. The present study aimed to analyze 
the frequency of APOL1 risk variants in a cohort of LN patients in 3 GN clinics in Brazil.
Methods: APOL1 G1 and G2 variants were genotyped in 173 patients who fulfilled 
SLEDAI criteria for lupus and LN class III, IV or V, randomly chosen in three outpatient 
clinics. DNA extraction from whole blood was performed using the PureGene system. 
Two single- nucleotide polymorphisms (SNPs) in the APOL1 G1 nephropathy risk 
variant (rs73885319; rs60910145) and an indel for the G2 risk variant (rs71785313) were 
genotyped using Taqman assays on the ViiA 7 platfom (Applied Biosystems for Life Tech). 
Clinical and lab data were analyzed using R studio.
Results: Patients data are summarized in table1. G1/G1 genotype was found in 3 
non-white women (1.7%). They were 21, 29 and 51 years and had LN for 12, 120 and 47 
months, respectively. All of them had LN class IV and received treatment with CF, MMF 
and steroids. Their outcomes in the last follow-up were ESRD in the youngest and CKD 
stage 4 in the others.
Conclusions: APOL1 risk variants are rare in Brazilians LN patients, however all 
patients who expressed 2 risk variants had worse outcomes (ESRD or CKD stage 4).
Table 1: Clinical characteristics and outcomes of 173 patients.
CF: Cyclophosphamide; MMF: Micophenolate Mophetil; F/U: follow-up.
FR-PO1095 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
What Is the Value of a Repeat Kidney Biopsy in Children and Young 
Adults with Lupus Nephritis?
Suhas M. Radhakrishna, Johanna Chang, Robert Sheets, Peter D. Yorgin. UC 
San Diego/Rady Children’s Hospital, San Diego, CA.
Background: Adult lupus nephritis (LN) studies have shown a lack of correlation 
between follow-up kidney biopsy results and clinical parameters. This study investigated 
whether kidney biopsy findings in children and young adults with LN performed after 
induction and maintenance therapy would better determine the response to medical therapy 
than clinical parameters.
Methods: 64 subjects, 11-18 yrs of age, met 1997 revised ACR classification criteria 
for systemic lupus erythematosus (SLE) with biopsy proven LN at Rady Children’s Hospital 
in San Diego between 1/1/2005 - 1/1/15. 12 subjects had a repeat biopsy 1 yr after diagnosis 
and 14 additional subjects had a repeat biopsy within 5 yrs of diagnosis. ACR criteria for 
complete remission (CR), partial remission (PR) and no remission (NR) were assessed at 
the time of repeat biopsy. Correlation between clinical remission status and biopsy findings 
was investigated. The study had IRB approval (#161748X, 6/30/17).
Results: At the time of repeat biopsy, 6 of 26 subjects achieved CR, 3 subjects 
achieved PR and 17 subjects had NR. Changes in IgG deposition, activity, and chronicity 
were statistically significant between the CR and NR groups. However, within CR and NR 
groups there were unexpected results: Among the 6 subjects achieving CR, 4 had the same 
or worse WHO class, 1 had higher activity and 3 had higher chronicity scores at the time 
of repeat biopsy. Among the 17 NR subjects, 5 had better or stable WHO classification. 
Furthermore, repeat kidney biopsies led to significant changes in therapy in both CR and 
NR groups.
Conclusions: In general, there was poor concordance between ACR remission criteria 
and repeat biopsy findings in children who achieved CR and NR, with notable exceptions. 
The discrepancy between clinical findings and kidney biopsy results in such cases should 
be further investigated. The large number of NR patients likely reflects bias toward repeat 
biopsy in clinical non-responders.
Comparison of Complete and No ACR Remission Groups
All columns show results at the time of the initial and repeat kidney biopsy. * statistical 
difference (p<0.05) between CR and NR groups.
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Lupus Nephritis IV-S versus IV-G: Different Characteristics and Renal 
Outcomes
Camila B. Oliveira, Gisele Vajgel, Denise M. Costa, Maria Alina G. Cavalcante, 
Lucila Maria Valente. Hospital das Clinicas - UFPE, Recife(PE) BRAZIL, 
Brazil.
Background: The ISN/RPS classification of lupus nephritis (LN) divided class 
IV into segmental and global (IV-S and IV-G), based on evidence suggesting different 
characteristics and renal outcomes. However, others subsequent studies failed to detect 
these differences. The aim of this study was to compare characteristics and renal outcomes 
of classes IV-S and IV-G.
Methods: Retrospective cohort of adult patients with lupus and biopsy proven class 
IV according to ISN/RPS classification. Clinicopathological characteristics and long-term 
follow-up were analyzed. Primary end point was ESRD.
Results: Clinicopathological data and renal outcomes of 89 patients with LN class IV 
are shown in Table 1. There was no difference in tubular atrophy and interstitial fibrosis 
between classes. Compared to patients with class IV-S, patients with class IV-G had a risk 
2.8 times greater of doubling sCr (95%CI 1.4-6.7; p=0.001) and 3.9 times greater of ESRD 
(95%CI 1.4-5.6; p=0.006).
Conclusions: Patients with class IV-G had more severe clinicopathological presentation 
and worse renal outcomes compared to patients with class IV-S.
Glomerular Diseases: Clinical, Outcomes, Trials - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
707
J Am Soc Nephrol 29: 2018 Poster/Friday
Baseline clinicopathological characteristics and renal outcomes of 89 patients with lupus 
nephritis class IV
Values expressed as median with range (25th – 75th percentile); Creatinine Clearance was 
calculated by CKD-EPI equation; * T-test; ¥ Fisher’s exact test; ‡ Chi-squared test; § Mann-
Whitney test.
FR-PO1097 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
Activation of the Alternative Complement Pathway Predicts Renal 
Outcome in Patients with Lupus Nephritis
Hyunwoo Kim, Jinseok Kim. Jeju National University Hospital, Jeju City, 
Republic of Korea.
Background: The aim of this study was to clarify the glomerular activation of 
complement pathways in patients with lupus nephritis, and to elucidate the association 
between these complement activation types and clinical outcomes.
Methods: We enrolled 100 patients with biopsy-proven lupus nephritis from 2003 to 
2016 from the lupus cohort at the Busan Paik Hospital and the Jeju National University 
Hospital in Korea. The patients were divided into two groups based on the patterns of 
glomerular complements deposits: The presence of C4 and C1q deposits with C3 deposits in 
the glomerulus was considered to be the evidence for the activation of the classical pathway 
(group I, n=83) and glomerular C3 deposition without C4 and C1q deposits was considered 
as a marker for the activation of the alternative pathway (group II, n=17). The study 
endpoint was progression of kidney dysfunction defined as the decline rate of estimated 
glomerular filtration rate (GFR) of more than 1 ml/min/1.73 m2 per year.
Results: The mean age of the patients was 32.9 ± 10.7 years. Ten patients were male, 
34 patients were hypertensive, 24 patients had a GFR < 60 ml/min/1.73 m2, and 38 patients 
had nephrotic range of proteinuria at the time of kidney biopsy. Compared to the group I 
patients, those in group II were older (31.1 ± 10.1 vs. 41.5 ± 9.5 years, p <0.001), more 
hypertensive (29% vs. 59%, p=0.020), and more male dominant (6% vs. 29%, p=0.003). 
Considering histopathologic features, group I patients had higher glomerular deposition of 
IgG and IgA than those in group II. Endocapillary hypercellularity and fibrinoid necrosis 
were also more frequently found in group I patients compared with those in group II. 
The median follow-up time was 4.3 years (interquartile range: 2.6–7.6 years). The rate 
of decline in estimated GFR was greater in group II patients than in group I patients 
(-5.7 ml/min/1.73 m2 per year vs. 1.4 ml/min/1.73 m2 per year; p=0.034).
Conclusions: This study showed that the patients with the alternative complement 
activation had poor renal outcome compared to the patients with the classical complement 
pathway, suggesting that the alternative complement activation may play a pathogenic role 
in the progression of lupus nephritis.
FR-PO1098 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
The Clinical Indicators to Predict Active Lesion in Kidney Biopsy 
Specimen in Patients with Lupus Nephritis
Daisuke Ichikawa,1 Eri Okada,3 Tomo Suzuki,1 Shiika Watanabe,1 Junki Koike,4 
Yugo Shibagaki.2 1St Marianna University of Medical School, Yokohama City, 
Japan; 2St Marianna University Hospital, Kawasaki, Japan; 3St. Marianna 
University School of Medicine, Kawasaki, Japan; 4the Kawasaki Municipal 
Tama Hospital, Kawasaki Citiy Tama Ward, Japan.
Background: The histological activity of International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) class IIIa or IVa lupus nephritis affect physician’s decision 
making in treatment. Because renal biopsy has inevitable risk for bleeding, it is preferable 
that we can make decision only with clinical parameters. However, few studies have 
addressed this important issue so far.
Methods: We reviewed the renal biopsy specimen of 120 patients with SLE 
retrospectively. We analyzed whether and which laboratory findings are correlated with 
histological activity.
Results: The histologically active lesion of lupus nephritis was found in 73.3% of all 
the patients, in 50% of the patients with the group of no hematuria, and in 70.8% of the 
patients with intermittent hematuria. Hematuria significantly correlated with histological 
activity with a sensitivity of 86.4% and a specificity of 37.5%, and significant proteinuria 
[0.5 g/gram creatinine (gCr)] significantly correlated with histological activity with a 
sensitivity of 84.1% and a specificity of 34.4%. If combining hematuria and proteinuria, the 
sensitivity for histological active lesion increased to 96.6%. Low serum C3 (< 65 mg/dl) 
significantly correlated with renal disease activity with a sensitivity of 79.1%, and high 
serum anti-DNA antibody (10 IU/ml) significantly correlated with histological activity 
with a sensitivity of 91.4%. Existence of at least one of these clinical indicators (hematuria, 
proteinuria, high anti-DNA antibody and low C3) showed 100% sensitivity for histological 
activity. Those with high specificity were persistent hematuria (specificity 71.5%), anti-
DNA antibody40 IU / ml (specificity 73.1%), and existence of all 4 of the clinical 
indicators (specificity 81.3%).
Conclusions: Isolated or intermittent hematuria did not predict histological activity 
so well. In order to avoid overlooking active lupus nephritis without kidney biopsy, we 
should count not only hematuria but also significant proteinuria, low C3 and high anti-DNA 
antibody. If the renal biopsy is not possible, but we still suspect activity such as in cases with 
progressive decline in kidney function, persistent hematuria, anti-DNA antibody40 IU/ml 
and presence of all 4 of clinical indicators strongly suggest disease activity and may help us 
make decision for active treatment.
FR-PO1099 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
Lupus Nephritis (LN) Patients with Crescentic Proliferative Lesions Show 
Lower IgG Glomerular Staining
André L. Moraes,1 Marcela T. Aguirre,3 Lectícia Jorge,2 Cristiane B. Dias,4 
Viktoria Woronik.1 Nephrology Division 1Hospital das Clínicas da Faculdade 
de Medicina da Universidade de São Paulo, São Paulo, Brazil; 2University of 
São Paulo, São Paulo, Brazil; 3Hospital das Clinicas FM USP Sao Paulo, 
CUENCA, Ecuador; 4University of Sao Paulo, Brazil, São Paulo, Brazil.
Background: Literature is scarce in describing outcomes and histological associations 
of LN patients with crescents. The immunofluorescence findings may suggest the 
pathophysiology of lesions and therefore have implications in the clinical behavior of LN. 
Our objective was to evaluate renal outcome and histological associations of patients with 
proliferative LN with and without crescents.
Methods: In this single-center, retrospective cohort study, 138 eligible LN patients 
were evaluated. The clinical features at baseline and at the end of follow-up were evaluated. 
eGFR was calculated using CKD-EPI equation. Kidney biopsies were classified according 
to the ISN/RPS Classification and immunofluorescence patterns. We performed comparative 
analyses between groups with different proportions and without crescentic lesions in kidney 
biopsy. Univariate analysis utilized Chi Squared test (n,%) for count and one-way analysis 
of variance, followed by Student- Newman Keuls tests for continuous variables.
Results: As shown in the image below.
Conclusions: Patients with crescentic (≥50% crescents) form showed at baseline, 
lower CKD-EPI (p<0.05), higher activity index (p<0.05) and lower intensity of IgG 
staining (p<0.05) than patients with no crescents on biopsy. The groups presented no 
difference in clinical outcomes, however, at the end of follow-up, the crescentic group 
presented a trend towards a higher proportion of individuals with CKD-EPI under 
60ml/min/1.73m2.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Evaluation of the Full-House Immunofluorescence Pattern (FH) in 
Patients Without Systemic Lupus Erythematosus (SLE): A Single Centre 
Observation Study
Pinelopi Kouki,1 Aikaterini A. Damianaki,1 Aglaia Chalkia,1 
Panagiota E. Giannou,1 Harikleia Gakiopoulou,2 Dimitrios Vassilopoulos,3 
Dimitrios I. Petras.1 1Nephrology Department, Hippokration Hospital of Arhens, 
Athens, Greece; 2University of Athens, Athens, Greece; 3National and 
Kapodistrian University of Athens School of Medicine, ATHENS, Greece.
Background: Strong interest is shown recently for FH pattern in patients without SLE 
nephritis. The purpose of the study is to identify patients with the above-mentioned entity 
and to evaluate clinical-laboratory findings and outcomes.
Methods: It consists of 8 patients with a FH pattern, defined as concomitant deposition 
of immunoglobulins (IgA, IgM, IgG) and two complement factors (C3, C1), non-diagnosed 
SLE who have undergone kidney biopsy over 4 years. Existing biopsies were reassessed by 
a nephropathologist and categorized according to the international histological classification 
of SLE. Anthropometry, eGFR, proteinuria, clinical course and histological findings were 
recorded.
Results: Two groups, idiopathic FH-non-lupus-nephropathy (iFHN) (n = 4) 
were identified based on the absence of histological findings defining specific 
glomerulonephritis(GN) (e.g. absence of PLA2R-antigen expression etc.) and secondary 
FH-non-lupus-nephropathy (sFHN) (n = 4) (e.g., expression of PLA2R-antigen, IgA +++, 
etc.). Patients with iFHN exhibit higher proteinuria (mean 9.45g / 24h), low eGFR (mean 
28.8 ml / min / 1.73m2), significant consumption of C1q, C3, significant glomerulosclerosis 
and interstitial inflammation. The most common light microscopy pattern was 
membranoproliferative GN and response to personalized treatment was unsatisfactory. 
Patients with sFHN exhibit lower proteinuria (mean 7.32 g / 24 h), high eGFR (mean 
81.1 ml / min / 1.73 m 2), mild deposition of C1q, C3, mild glomerulosclerosis and interstitial 
inflammation. The prominent light microscopy pattern was membranous nephropathy and 
response to treatment was satisfactory.
Conclusions: IFHN may reflect a clinicopathological entity with aggravating features 
and an unfavorable prognosis. Further studies are needed in order to corroborate that 
conclusion and to establish better approach to the treatment.
FR-PO1101 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
Chronic Changes in Lupus Nephritis Biopsies – When to Treat? Could 
Complement C3c Be an Indicator for Missed Activity?
Hannah R. Wilson, Tabitha Turner-Stokes, Iara Dasilva Santos, Megan Griffith, 
Jeremy B. Levy, Tom Cairns, H. Terence Cook, Liz Lightstone. Imperial College 
London, Hammersmith Hospital, London, United Kingdom.
Background: Management of biopsies showing chronic disease only is a common 
clinical conundrum in lupus nephritis (LN), especially when the biopsy is performed due to 
clinical features indicating activity. We have recently demonstrated that complement C3c 
staining is an indicator of current activity of the complement pathway in LN. We analysed 
characteristics that prompted treatment of patients with biopsies showing LN class III/
IV(C) only from our LN cohort & reviewed whether positive C3c staining is a surrogate 
for disease activity.
Methods: Demographic, clinical, histopathological & outcome data were reviewed 
for renal biopsies showing III/IV(C) LN between 1/1/1996 & 1/1/2016. Treated patients 
were compared with untreated patients. C3c positive & C3c negative biopsies were then 
compared.
Results: 129 biopsies were performed over the 20 years which showed III/IV(C) 
disease only. 53% of these patients had escalation of their treatment post biopsy. 31 of the 
patients with a “chronic” biopsy had a subsequent biopsy available for review.
Conclusions: Deciding to treat patients with only chronic changes on biopsy was 
significantly associated with indication for biopsy, positive C3c staining, presence of 
subendothelial deposits & eGFR at the time of biopsy. However, our analysis thus far does 
not show a benefit of treating these patients as uPCR is actually higher in treated patients 
at 1 year although improved from baseline & eGFR, better at baseline in the treated group, 
actually falls. The repeat biopsies may suggest that not treating those with C3 positivity may 
lead to progressive scarring.
FR-PO1102 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
Comparison of Treatment Eras in a Large Cohort of Lupus Nephritis: 
Maintenance of Long Term Outcomes with Significantly Lower Burden of 
Immunosuppression and Corticosteroid Use
Hannah R. Wilson,2 Tabitha Turner-Stokes,2 Iara Dasilva Santos,1,2 
Megan Griffith,2 Jeremy B. Levy,2 Tom Cairns,2 H. Terence Cook,2 
Liz Lightstone.2 1Fundacio Puigvert, BARCELONA, Spain; 2Imperial College 
London, Hammersmith Hospital, London, United Kingdom.
Background: Lupus Nephritis (LN) is a common & severe manifestation of systemic 
lupus erythematosus (SLE) requiring long courses of immunosuppression. Our lupus centre 
was established when 2 renal units merged in late 2005 & new protocols were developed 
focused on reducing the use of corticosteroids & increasing the use CD20+ B cell depletion 
therapy. We reviewed our large multi-ethnic cohort to assess the impact of these changes.
Methods: Demographic, clinical, histopathological & outcome data were reviewed for 
all patients with renal biopsies showing LN from 1/1/1996 to 1/1/2016. Patients treated 
1996-2005 & 2006 onwards were compared. Data analysed per patient or per biopsy as 
appropriate.
Results: 819 biopsies (151 pre 2006, 668 post 2006) were performed on 476 patients 
over the 20 years. 172 patients were diagnosed with LN pre 2006 & 302 post. Whilst 
there was no significant difference in patient gender or ethnicity between the eras, age at 
diagnosis was significantly different with a mean of 32 pre 2006 & 37 post 2006 (p<0.001). 
The baseline eGFR, urine protein creatinine ratio & dsDNA titres were not significantly 
different between the eras.
Conclusions: Treatment regimens have altered significantly post 2006 with a 
much greater use of anti CD20 therapy & a significant reduction in (high dose) CyP & 
prednisolone exposure for patients. Despite the significant reduction in the burden of 
immunosuppression, rates of response to treatment, flare & 10 year survival with preserved 
renal function have been maintained.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Characteristics Associated with Repeat Native Renal Biopsy in Lupus 
Nephritis
Harpreet K. Singh,1 Susan L. Hogan,3 Caroline J. Poulton,4 Yichun Hu,5 
Patrick H. Nachman.2 1University of North Carolina, Chapel Hill, NC; 
2University of Minnesota, Minneapolis, MN; 3University of North Carolina, 
Chapel Hill, Chapel Hill, NC; 4UNC Kidney Center, Chapel Hill, NC; 5UNC 
Kidney Center & Dividdions of Nephrology & Hypertension, Chapel Hill, NC.
Background: There is great interest in using repeat kidney biopsies to determine 
the response to treatment and outcomes of patients with lupus nephritis (LN). Although 
some patients with lupus nephritis undergo a repeat kidney biopsy, the factors that lead 
to the decision to repeat a biopsy and how the repeat biopsy alters treatment are not well 
understood. We evaluated the timing and explored factors associated with repeat kidney 
biopsy.
Methods: We identified 42 patients ≥ 18 years old with biopsy proven LN who 
underwent a repeat native renal biopsy from 2010 to 2018. A retrospective review was 
performed focusing on the clinical and histopathologic characteristics associated with a 
repeat biopsy. Both the reference and repeat biopsies were evaluated via the ISN/RPS 
classification.
Results: Of the patients included, 37 (88%) were women, 30 (71%) were black. The 
median age at reference biopsy was 28.74 years (IQR: 22.41, 37.77) and 34.33 years (26.70, 
43.58) at repeat biopsy. The median interval time to repeat biopsy 2.96 (2.21, 7.83). The 
interval time between biopsies increased over the selected time period. The serum creatinine 
increased between reference and repeat biopsies (median 1.12 (0.1, 1.70) vs. median 1.38 
(0.90, 2.54)). The results of the clinical and histological factors are addressed in the figure 
below.
Conclusions: Several factors were associated with the decision to repeat a native 
kidney biopsy in patients with lupus nephritis including time from reference biopsy, elevated 
serum creatinine, active urine sediment, hypoalbuminemia, and anti dsDNA positivity. The 
decision to repeat a biopsy was associated with a change in immunosuppression for the 
majority of our cohort. Looking ahead, we hope to use these clinical and histopathologic 
factors to establish and clarify how a repeat biopsy can lead to changes in management in 
our patients with lupus nephritis.
FR-PO1104 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
A Nationwide Analysis of Outcomes of Adult Lupus Nephritis in Japan
Keiju Hiromura,1 Hidekazu Ikeuchi,1 Hitoshi Sugiyama,2 Hiroshi Sato,3 
Hitoshi Yokoyama,4 Yoshihisa Nojima.5 JSN Lupus Nephritis Study Group 
1Gunma University Graduate School of Medicine, Maebashi, Japan; 2Okayama 
University Graduate School Medicine, Okayama, Japan; 3Tohoku University 
Graduate School of Pharmaceutical Sciences, Sendai, Japan; 4Kanazawa 
Medical University, Ishikawa, Japan; 5Japan Red Cross Maebashi Hospital, 
Maebashi, Japan.
Background: Although the prognosis of lupus nephritis (LN) has been improved, some 
patients reached end-stage renal disease (ESRD). We aimed to examine recent prognosis of 
LN in Japan using nation-wide registry.
Methods: This study is a retrospective cohort study. Adult patients (18 years old or 
older) who were registered as LN in Japan Renal Biopsy Registry (J-RBR) between 2007 
and 2012 were examined. Primary endpoint was defined as doubling serum creatinine 
(S-Cr) or ESRD requiring renal replacement therapy. Data were expressed as median (IQR).
Results: 498 patients (88 male), age 39 (30-52) years-old, from 27 institutions 
were evaluated. New-onset of LN, 348 patients; relapse, 106 patients; refractory, 35 
patients; others, 9 patients. Clinical data at the renal biopsy were as follows: eGFR 78.3 
(56.3-100.8) ml/min/1.73m2, urinary protein 2.04 (0.87-4.30) g/gCr. 40.0% of patients had 
nephrotic syndrome and 12.2% of patients showed rapidly progressive glomerulonephritis 
clinically. The frequency of each ISN/RPS Class was as follows: I, 1.6%; II, 5.8%; III, 
26.9%; IV, 46.6%; V, 18.5%; VI, 0.6%. During the observation period of 63 (49-82) 
months, 36 patients (7.2%) reached primary endpoints, 75 patients (15.1%) reached 1.5 
times increase in S-Cr or ESRD, and 27 patients (5.4%) died. Renal survival (not doubling 
S-Cr or ESRD) curve in each Class was calculated by Kaplan-Meier analysis and shown
in Figure 1. The 5-year renal survival and 5-year patient survival was 94.0% and 94.8% in
total patients, and 92.1% and 93.1% even in Class IV, respectively. Among patients with
new-onset LN (n=348), the 5-year renal survival and 5-year patient survival was 94.8% and 
94.2% in total patients, and 93.1% and 92.4% in Class IV, respectively.
Conclusions: Recent prognosis of LN are relatively good at least 5 years after renal 
biopsy in real-world clinical practice in Japan.
Funding: Government Support - Non-U.S.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
A Proposal for Outcome Prediction in Lupus Nephritis Based on Bayesian 
Statistics
Juan M. Mejia-Vilet, Luis Tamez Pedroza, Sonia Rodriguez, Ricardo Correa-
Rotter, Luis E. Morales-Buenrostro. Instituto Nacional de Ciencias Medicas y 
Nutricion Salvador Zubiran, Mexico, Mexico.
Background: A focus in lupus nephritis (LN) is to define the best criteria for response 
to therapy based on hard renal outcomes. The definition of resistant disease remains 
heterogeneous.
Methods: The aim of the study was to determine the prognostic value of clinical 
parameters to predict renal survival and progression to ESRD. Clinical predictors were 
evaluated at 6/12 months after treatment as absolute values, absolute or percentage changes 
and predictor’s value normalization. The best cutoff was defined as the value where positive 
likelihood ratios (+LR) were persistently >3.0 for renal survival (response) or ESRD 
development (resistance).
Results: Of 248 patients with proteinuria >2.0g/g and complete induction treatment, 
we included 133 patients with >5 years follow-up. 36 (27.1%) progressed to ESRD. The 
best predictors for response were creatinine or eGFR at 6/12 months (AUC 0.798/0.856), 
proteinuria at 6/12 months (0.735/0.832) and hemoglobin at 6/12 months (AUC 0.689/ 
AUC 0.786). Predictors for resistance after 6 months of treatment included creatinine or 
eGFR (AUC 0.815), proteinuria percentage change (0.735), and albumin percentage change 
(AUC 0.599). Hematuria and serological parameters (dsDNA-antibodies, C3, C4) were not 
appropriate prognostic predictors. After censoring at different times of follow-up, it was 
observed that the longer the follow-up, the cutoff for each parameter had a lower valule. The 
best prognosis for renal survival was given by 12-month proteinuria <0.75g/g (+LR=3.08), 
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eGFR>82ml/min (+LR=3.00) and hemoglobin>12g/dl (+LR=3.04). The best predictors 
for resistance were 6-month eGFR<61ml/min (+LR=3.13), proteinuria decrease <10% 
(+LR=3.29) and increase of serum albumin <0.3g/dl (+LR=3.39).
Conclusions: Likelihood ratios may be used to define the best values for response 
and resistance to therapy in LN. Proteinuria, renal function and hemoglobin at 12-months 
predict renal survival while proteinuria, eGFR and change in serum albumin may define 
resistant disease.
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The Risk of ESRD in Systemic Lupus Erythematosus: A Nationwide 
Population-Based Study in Korea
Hong sang Choi, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Soo 
Wan Kim. Chonnam National University Medical School, Gwangju, Republic of 
Korea.
Background: SLE is known to be one of the leading cause of end-stage renal disease 
(ESRD). The aim of this study was to estimate the incidence rate of ESRD and the risk 
factors for progression to ESRD in SLE patients compared to general population.
Methods: 21,253 SLE patients (mean age, 41.91±13.22 years; female, 90.4%) were 
extracted from the Korean National Health Insurance Service database between 2008 and 
2014. Age-and sex-matched controls (n=106,265) were randomly sampled in a 5:1 ratio 
from non-SLE individuals. Both cohorts were followed up for incident ESRD until 2015.
Results: During the total 8 years of follow-up, 145 (0.14%) cases of ESRD was newly 
developed in SLE patients and 533 (2.51%) cases in matched controls (incidence: 4.075 
and 0.219 per 1000 person-year, respectively). SLE patients were at higher risk for ESRD 
development compared to matched controls (odd ratio (OR), 10.134; 95% confidence 
interval (CI) 8.368-12.343) after multivariate adjustment. In subgroup analysis, the risk 
for ESRD was higher in male with SLE (OR, 7.952; 95% CI 5.26-12.272), in female with 
SLE (OR, 10.82; 95% CI 8.719-13.526), in 20-39 year-old patients with SLE (OR, 22.57; 
95% CI 14.588-36.449), in 40-64 year-old patients with SLE (OR, 22.57; 95% CI 14.588-
36.449), in elder than 65 year-old patients with SLE (OR, 5.122; 95% CI 3.431-7.649) than 
matched control, respectively.
Conclusions: SLE was associated with an increasing incidence of ESRD
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Outcomes of Pure Membranous Lupus Nephritis in an Urban  
Predominantly African-American Patient Population
Jeffy Kenny Thomas,1 Muhannad Alqudsi,1 Furheen Baig,1 Courtney E. Hoge,1 
Sung S. Lim,1 Jason Cobb.2 Emory Nephrology 1Emory University, Atlanta, GA; 
2Emory University School of Medicine, Atlanta, GA.
Background: Treatment options for pure membranous (class V) lupus nephritis 
(LN) include prednisone, cyclophosphamide (CYC), calcineurin inhibitors (CNI), and 
mycophenolate mofetil (MMF). There is a paucity of data on the use of MMF; a pooled 
analysis from studies for the treatment of proliferative LN have compared MMF to CYC 
for the treatment of pure membranous LN. We are comparing the outcomes of pure 
membranous LN patients treated with MMF in comparison to other therapies in our urban 
predominantly African-American patient population.
Methods: Kidney biopsy log from 2010 – 2017, and a retrospective chart review 
was completed. We excluded any patients with proliferative disease (active or chronic). 
We analyzed data (t-test comparison) comparing LN class V patients treated with MMF in 
comparison to other therapies.
Results: There was 101 patients with pure membranous LN and 54 patients with 
sufficient follow-up data were included. Induction regimens: MMF (n=29) and (n=25) other 
therapies (6=CYC, 3=CNI, 12=prednisone alone, 3=azathioprine, 1=ARB alone). Racial 
demographics: 51=black race (94%), 1=Hispanic, 1=white, 1=native Hawaiian. 52 female 
patients. Average follow-up 3.5 years. MMF treated group: initial serum creatinine (Scr) - 
0.85 mg/dL, initial serum albumin (Salb) 2.67 g/dL, and initial urine protein/creatinine ratio 
(UPC) of 4.14 mg/g. Other therapies group: initial Scr – 1.58 g/dL, initial Salb 2.53 g/dL, 
and initial UPC of 4.32 mg/g. MMF treated: final Scr – 0.89 mg/dL, final Salb 3.30 g/dL, and 
final UPC 1.39 mg/g. Other therapies: final Scr – 1.53 mg/dL, final Salb 3.55 g/dL, and final 
UPC of 0.70 mg/g. There was no difference in percent with abnormal C3, C4, or dsDNA. At 
baseline Scr was 1.58 mg/dL (other group) vs. 0.85 mg/dL (MMF group) p <.05, and at final 
Scr 1.53 mg/dL (other group) vs. 0.89 mg/dL (MMF) p =.08.
Conclusions: In our predominantly African-American patient population MMF is 
effective as other therapies for Class V LN. There was a significant difference in initial 
Scr between the MMF and other therapies group, and the difference remained throughout. 
There was a greater than 50% reduction in UPC in both groups. The study displayed a good 
prognosis in both groups at the end of treatment.
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Progressive Improvement of Renal Survival over the Last Five Decades in 
499 Italian Patients with Lupus Nephritis
Gabriella Moroni,1 Francesca Raffiotta,1 Augusto Vaglio,4 Piergiorgio Messa,1,2 
Renato A. Sinico.3 1IRCCS Fondazione Ca Granda Ospedale Policlinico 
Milano, Milan, Italy; 2Università degli Studi di Milano, Milan, Italy; 3AO San 
Carlo Borromeo, Milano, Italy; 4Parma University Hospital, Parma, Italy.
Background: To examine the changes in lupus nephritis (LN) prognosis during the 
course of the last fifty years and to search for the prognostic factors associated with patient 
and renal outcomes.
Methods: Four hundred and ninety-nine patients (pts) (85.6% women) were included 
in the study; they were followed for a median period of 10.6 years (IQR 4-18). They were 
diagnosed from 1970 to 2016 and were subdivided into three periods (P) based on the year 
of LN diagnosis: P1 1970-1985: 106 pts; P2 1986-2001: 158 pts; P3 2002-2016: 235 pts.
Results: As Induction therapy, in each period, more than 2/3 of pts received 
methylprednisolone pulses, and more than 50% received cyclophosphamide. Azathioprine 
was given to 16% of pts in P1, 12% in P2, and 4% in P3, mycophenolate mofetil (MMF) in 
3% of pts in P2 and in 34% in P3. For maintenance therapy, azathioprine and MMF were 
used respectively in P1 in 28% and in 1% of patients, in P2 in 39% and in 15%, and in P3 in 
30 and in 54%. The CKD free survival at 10 and at 20 years was 75% and 66% in P1, 85.5% 
and 80.2% in P2 and 91.5% in P3 (p=0.0069). The ESRD free survival at 10 and at 20 years 
were respectively 87% and 80% in P1, 94% and 90% in P2 and 99% in P3 (p=0.0019). 
Patient survival at 10 and at 20 years were respectively: in P1 94% and 87%, in P2 98% and 
94% and in P3 95%. At multivariate analysis, carried out in the entire cohort, among the 
characteristics at presentation, Log serum creatinine (RR 2.39 for any increase in Log serum 
creatinine), high activity (RR 1.06 for any unit increase in activity index) and chronicity 
index (RR 1.13 for any unit increase in chronicity index), arterial hypertension (RR4.16) 
and the absence of maintenance immunosuppressive therapy (RR 2.08) predicted CKD. The 
same features predicted ESRD with the addition of male gender (RR 3.34). Male gender 
(RR 2.88), older age (1.07 for any increase in one year of age) and Log serum creatinine 
(RR1.8) were independent predictors of death.
Conclusions: The progressive improvement in renal survival in our cohort is the result 
of a comprehensive approach, which includes a prompt diagnosis of renal involvement, 
treatment based on renal biopsy, and increased clinical experience in the management of 
LN complications.
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The Short and Long Term Effect of Methylprednisolone Pulse Therapy 
for Lupus Nephritis Treated with Multi-target Therapy
Lan Lan, Xiabing Lang. Zhejiang University, Hangzhou, China.
Background: Muti-target therapy was applied to the severe lupus nephritis, especially 
the patients with severe proteinuria. Methylprednisolon pulse therapy was used in the initial 
phase of induction therapy in some patients. We conducted this study to assess the short and 
long term effect of methylprednisolon pulse therapy on the lupus nephritis patients treated 
with muti-target therapy.
Methods: It’s a retrospective study from 2007-2016, 43 patients diagnosed as lupus 
nephritis received muti-target therapy in our center, including prednisone combined with 
MMF and tacrolimus. 19 patients received methylprednisolon pulse therapy in the initial 
phase of induction therapy, 24 patients only received prednisone combined with MMF 
and tacrolimus. The dose of methylprednisolon pulse therapy was intravenous injection 
500mg*3 days, following prednisone dose was 0.8-1.0mg/kg. The dose of MMF was 
1.0-1.5g/d, the initial dose of tacrolimus was 0.05 mg/kg/d, the target trough levels was 3 
to 8 ng/mL for 24 weeks, and then reduced to 3 to 6 ng/mL. In the patients combined with 
acute renal injury (AKI), we accessed the short term outcome by the decrease of serum 
creatinine in 1 and 3 month. Long term outcome variables included mean remission rate, 
average remission time.
Results: There was a significant difference in the decrease of creatinine between the 
two groups in 1 month (P=0.04). However, there was no significant difference in 3 month. 
In the 12 months follow up, 16 of 19 patients in the methylprednisolon pulse therapy 
group (84.2%) experienced remission (either complete or partial), and 12 of 19 patients 
(63.1%) experienced complete remission. In the group only receive muti-target therapy, 20 
of 24 (83.3%) patients experienced remission, and 13 of 24 patients (54.2%) experienced 
complete remission. There were no significant difference in remission rate and remission 
time between the two groups (p=0.93 p=0.87). We also did not found significant difference 
in the serum creatinine and UP/Cr in 3, 6, 12month.
Conclusions: Methylprednisolon pulse therapy seemed had no significant effect on the 
long-term prognosis of lupus nephritis treated with muti-target therapy, but maybe it had 
better effect on the recovery of AKI patients.
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Mycophenolate Mofetil in Lupus Nephritis: Long Term Efficacy and 
Safety Outcomes
Hannah K. Beckwith,1,2 Beatriz R. Cubillo,1 Camilla Pillay,1 Megan Griffith,1 
Jeremy B. Levy,1 Tom Cairns,1 Liz Lightstone.1,2 1Imperial College Lupus 
Centre, London, United Kingdom; 2Imperial College London, Hammersmith 
Hospital, London, United Kingdom.
Background: There is a lack of long-term (LT) efficacy and safety data for 
Mycophenolate mofetil (MMF) in the treatment of lupus nephritis (LN) [1]. We have used 
MMF since 1999 and undertook a retrospective case-note review of all patients whose 
treatment included MMF and at least 10 years follow-up (FU).
Methods: 96 patients with biopsy-proven LN who started MMF ≥10 years ago were 
identified for the study.
Results: 75 (78%) were female; 20 (21%) Black and 8 (8%) Asian. At diagnostic 
renal biopsy, median age was 35 years (IQR 26-45), serum creatinine (SCr) 90umol/l (IQR 
73-140) and UPCR 318 mg/mmol (IQR 153-569). The median length of FU was 11.6
years (IQR 10.7-13.6). Median cumulative MMF exposure was 8.4 years (IQR 5.5-11.5).
17/96 (18%) reached ESRD (median 67 months, range 3-188) and 5/96 (5%) died during
FU (median 124 months, IQR 86-129). The rates at 7 years FU (12/96 and 1/96) were
not statistically different to those reported in the LT FU of the MAINTAIN trial (p= 0.55,
p=0.08) [2]. Median duration of MMF was 5.4 years (IQR 2.0-7.2) in the patients who 
died. At our unit, treatment regimens changed during the time period reviewed, moving to 
induction with MMF +/- Rituximab, mostly without oral steroids. We found no difference 
in adverse events between the Cyclophosphamide and MMF regimens, and patients did
equally well on either regimen (Table 1). Importantly, no significant difference in adverse 
events was seen with MMF exposure ≥10 years vs <10 years (p=0.91) (IQR 11.2-13.6 vs
3.8-7.6).
Conclusions: This is the largest study to report LT outcomes in patients receiving 
MMF and the first to report data over ten years. LT treatment with MMF appears to be 
safe and our data supports the use of non-CyP based regimens. The increase in number of 
patients with ESRD or who died after 7 years FU emphasises the importance of LT follow 
up data in these cohorts. References [1] Bertsias GK et al. Ann Rheum Dis 2012;71:1771-
1782 [2] Tamirou F et al. Ann Rheum Dis 2016;75:526–531
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Mycophenolate Mofetil in the Treatment of Chinese Patients with Active 
Lupus Nephritis: A Systematic Review and Meta-Analysis
Minlin Zhou,1 Hongxin Zhao,2 Yuxian Zhu,2 Xin Wang,2 Haitao Zhang.1 
1National Clinical Research Center of Kidney Diseases, Jinling Hospital, 
Nanjing University School of Medicine, Nanjing, China; 2Shanghai Roche 
Pharmaceuticals Ltd., Shanghai, China.
Background: Mycophenolate mofetil (MMF) has been recommended as induction 
and maintenance therapy for lupus nephritis (LN). MMF has shown superiority over 
cyclophosphamide (CYC) in LN patients of Hispanic or mixed race. So far, there has been 
no comprehensive review of the efficacy and safety of MMF in the treatment of LN that 
focused on Chinese patients. Thus, the present study aims to investigate the efficacy and 
safety of MMF in the treatment of Chinese patients with LN.
Methods: The following databases were searched: PubMed and EMBASE (from 
January 1979–January 2018); and the Cochrane Collaboration, China National Knowledge 
Infrastructure, Wanfang, and SinoMed (in January 2018). The search strategies comprised: 
(mycophenolate mofetil AND (cyclophosphamide OR azathioprine)) AND (lupus nephritis 
OR lupus glomerulonephritis OR proliferative glomerulonephritis OR membranous 
glomerulonephritis OR systemic lupus erythematosus) in English and in Chinese. Two 
reviewers independently assessed each identified clinical trial. Meta-analysis was conducted 
by using RevMan5.3 software.
Results: A total of 12 eligible randomized controlled trials (RCTs; 5 English and 7 
Chinese articles; total 557 patients) were included. Nine RCTs reported complete remission 
(CR). The complete remission rate was significantly higher in the MMF group (48.9%) than 
in the CYC group (37.4%) (relative risk [RR] 1.28; 95% confidence interval [CI]: 1.05, 
1.55; p=0.01). There was no significant difference in the total remission rate between the 
two groups of induction therapy (TR [CR + partial remission]; RR 1.11; 95% CI: 0.97, 1.26; 
p=0.12). MMF versus CYC during induction therapy was associated with significantly 
lower risks of infection (RR 0.58; 95% CI: 0.41, 0.84; p=0.004), leukopenia (RR 0.26; 95% 
CI: 0.11, 0.66; p=0.004), alopecia (RR 0.12; 95% CI: 0.03, 0.43; p=0.001), and amenorrhea 
(RR 0.15; 95% CI: 0.04, 0.56; p=0.004). No significant difference in relapse rate was 
evident between the MMF and AZA groups (RR 1.15; 95% CI: 0.59, 2.26; p=0.68).
Conclusions: MMF for induction treatment of lupus nephritis in China is superior to 
CYC in complete remission and is safer.
Funding: Commercial Support - This study was sponsored and funded by Shanghai 
Roche Pharmaceuticals Ltd. We thank Xiaoyan Han and Yang Yang, employees from 
Shanghai Roche Pharmaceuticals Ltd. for assistance with data analysis.We thank David 
Murdoch, of Edanz Medical Writing, for providing medical writing support, which was 
funded by Shanghai Roche Pharmaceuticals Ltd.
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Insights from Machine Learning Analysis of Collated Lupus Nephritis 
Trials
Liliana M. Gomez Mendez,2,1 Jian Dai,1 Jason Kutarnia,3 Scott Howser,7 
Jay Schuren,7 Dana Mcclintock,5 Matthew Cascino,6 Marco Prunotto.4 
1Genentech, South San Francisco, CA; 2University of California San Francisco, 
San Francisco, United States Minor Outlying Islands; 3Mitre, Bedford, MA; 4F. 
Hoffmann-La Roche Ltd., Basel, Switzerland; 5Genentech, Inc, South San 
Francisco, CA; 6Genentech, Inc., South San Francisco, CA; 7DataRobot, 
Boston, MA.
Background: Machine learning (ML) analyses are being increasingly used in diverse 
fields of medical research to identify parameters associated with disease progression and/
or outcome. We tested this method for identifying variables associated with complete renal 
response (CRR) in lupus nephritis (LN).
Methods: Data collated from two clinical trials, LUNAR (NCT00282347)1 and 
BELONG (NCT00626197)2, compared the addition of rituximab1 or ocrelizumab2 vs. 
placebo in addition to background therapy for the treatment of LN. We deployed supervised 
ML method of symbolic regression using Eureqa® software to analyze variables for 
CRR in these studies. For patients with baseline creatinine >1, CRR was defined as urine 
protein/creatinine ratio (UPCR) <0.5 and creatinine <1 at 1 year. CRR for patients with 
baseline creatinine <1 was UPCR <0.5 and creatinine <125% of baseline at 1 year. Logistic 
regression was used to validate the association between identified variables and CRR found 
via ML analyses.
Results: We found that unbiased ML analysis identified variables known to be 
associated with CRR, such as baseline UPCR and eGFR. Furthermore, ML analysis 
identified other variables to be associated with CRR, including systolic blood pressure (BP) 
at baseline and Week 16, and positive anti-RNP antibody at baseline. Logistic regression 
determined that every 10 mmHg increment in systolic BP had an odds ratio (OR) of 0.84 
(95% CI: 0.73, 0.96) for CRR at 1 year. At Week 16, every 10 mmHg increment in systolic 
BP had an OR of 0.82 (95% CI: 0.7, 0.95) for CRR at 1 year. Logistic regression showed an 
OR of 2.1 (95% CI: 1.3, 3.5) for CRR at 1 year with anti-RNP antibody positivity at baseline 
(n=182), adjusting for treatment received, baseline proteinuria, and eGFR.
Conclusions: In conclusion, ML algorithms can be successfully used in identifying 
variables associated with clinical response, especially in a complex and heterogeneous 
disease such as LN. These analyses highlighted systolic BP at baseline and Week 16, as 
well as baseline anti-RNP antibody positivity, to be associated with CRR. The association 
between anti-RNP antibody at baseline and CRR at 1 year warrants further investigation. 
1. Rovin et al., Arthritis Rheum 2012; 64, 1215-26. 2. Mysler et al., Arthritis Rheum 2013; 
65, 2368-79.
Funding: Commercial Support - Genentech, Inc., South San Francisco, CA, USA
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Clinical Outcomes and Response to Anti-Thrombotic Treatment  
Among Patients with Concomitant Lupus Nephritis and Thrombotic 
Microangiopathy: A Multicentre Cohort Study
Savino Sciascia,2 Roberta Fenoglio,1 Dario Roccatello.3 1Hospital Hub San 
Giovanni, Turin, Italy; 2Nephrology and Dialysis Unit and Center of Research of 
Immunopathology and Rare Diseases (CMID), Giovanni Bosco Hospital and 
University of Turin, Italy, Center of Research of Immunopathology and Rare 
Diseases (CMID), Division of Clinical Immunology, Giovanni Bosco Hospital 
and University of Turin, Ita, Turin, Italy; 3Ospedale San GIovanni Bosco, 
Torino, Italy.
Background: The renal vascular involvement is an important prognostic marker of 
lupus nephritis (LN). The thrombotic microangiopathy (TMA) presents with severe clinical 
manifestations and have a high mortality. However, the management of patients (pts) with 
TMA and LN needs further investigation. AIM: We sought to assess renal outcomes to 
anti-thrombotic treatments in addition to conventional immunosuppression (IS) in pts with 
biopsy proven LN and TMA
Methods: 97 pts with biopsy-proven LN and TMA were retrospectively analysed. A 
complete response (CR) was defined as proteinuria <0.5 g/24h and normal or near-normal 
(within 10% of normal GFR if previously abnormal) GFR. Partial Response (PR) was 
defined as a ≥50% reduction in proteinuria to subnephrotic levels and normal or near-
normal GFR. Renal outcomes were assessed at 1 year post biopsy.
Results: The mean age of the pts was 38.9±15.2 years. The clinical presentations were 
nephrotic syndrome, nephritic syndrome, and asymptomatic urinary abnormalities. 9 pts 
were classified Class III (including 2 as ClassIII + V), 82 as Class IV (10 as Class IV-
segmental(IV-S) and 72 as Class IV-global (IV-G), including 4 as Class IV-G +V) and 6 as 
Class V. 42 (43%) pts presented with acute and 55 (57%) with features of chronic TMA. All 
pts had received treatment with standard IS and steroids. At 12 months, CR was observed in 
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37 pts (38.1%), PR in 22 (22.6%) and no response in 38 (39.1%). 61 patients (62.9%) were 
antiphospholipid positive (aPL) and 37 (38.1%) received anticoagulation with vitamin-K 
antagonist (VKA) and/or heparins. Presence of aPLs (OR, 2.4; p=0.03), anti-DNA positivity 
(OR, 12.8; p=0.002), and chronic features of TMA (OR, 3.0; p=0.04) were all found to be 
associated with no response. In aPL positive pts, variables that were significantly associated 
with CR+PR were features of acute TMA rather than chronic (OR, 8.62; 95% CI 1.4–97.1; 
p=0.03) and the use of VKA/heparins (OR, 2.1; 95% CI 1.02–16.2; P=0.046).
Conclusions: In pts with concomitant LN and TMA, the presence of aPL and chronic 
features of TMA were associated with poorer renal outcomes. In pts with aPL, the use of 
anticoagulation appeared protective and warrants further investigation as a therapeutic tool, 
especially in the setting of acute TMA.
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Herpes Zoster and Disseminated Zoster in Lupus Nephritis: Incidence 
Rates in Real-World Claims Data
Katherine Belendiuk,1 Yingjie Ding,2 Devika Chawla,1 Matthew Cascino.1 
1Genentech, South San Francisco, CA; 2Genesis Research, Hoboken, NJ.
Background: Herpes zoster is a highly morbid condition. Overall rates of herpes 
zoster in immunocompetent individuals in a claims database were 0.45 per 100 PY, 
with risk increasing with age [1]. Rates of herpes zoster and disseminated herpes zoster 
among patients with lupus nephritis (LN) have not previously been described. This study 
characterized rates of herpes zoster and disseminated zoster infections in patients with LN 
using population-based claims data.
Methods: We conducted a retrospective cohort study using the Truven Healthcare 
MarketScan® Commercial Claims and Encounters and Medicare Supplemental and 
Coordination of Benefits database between 2000 and 2014. Patients with LN were identified 
using modifications to a validated claims data algorithm [2]. Herpes zoster cases were 
identified using ICD9 codes 053.xx. All patients received medical care in the U.S. and had 
6 months of continuous medical and drug coverage ± first LN diagnosis (i.e. index). End of 
study was the first of end of enrollment or end of database.
Results: 11,068 patients with LN were identified and followed for a mean of 6.8 years 
(Table). Among patients with LN there were 955 incident cases of herpes zoster events 
reported, of which 157 (16%) were considered disseminated. Incidence rates of herpes 
zoster and disseminated zoster were 2.6 (95% CI 2.4 to 2.7) and 0.4 (95% CI 0.3 to 0.5) per 
100 PY, respectively.
Conclusions: Patients with LN appear to be at increased risk for herpes zoster 
relative to the general population. A substantial minority of LN patients with herpes 
zoster develop dissemination. Further characterization of the relative contributions of age, 
immunosuppressive therapies, and disease factors is warranted. 1. Johnson BH et al. BMC 
Infectious Diseases, 2015;15:502. 2. Chibnik LB et al. Lupus, 2010;19:741-3.
Funding: Commercial Support - Genentech, Inc.
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Clinical Implications on Simple Attachment and Endothelial Damage in 
the Glomeruli of Adult Nephrotic Focal Segmental Glomerulosclerosis 
(FSGS): A Retrospective Cohort Study
Takaya Ozeki,1 Michio Nagata,2 Takayuki Katsuno,1,3 Sawako Kato,1 
Yoshinari Yasuda,1 Naotake Tsuboi,1,4 Shoichi Maruyama.1 1Nagoya University 
Graduate School of Medicine, Nagoya, Japan; 2Kidney and Vascular Pathology, 
University of Tsukuba, Tsukuba, Japan; 3Department of Nephrology and 
Rheumatology, Aichi Medical University, Nagakute, Japan; 4Department of 
Nephrology, Fujita Medical University, Toyoake, Japan.
Background: Although Columbia classification are widely used, clinical importance 
of specific pathological findings in FSGS is unclear. We focused on simple attachment 
and findings of endothelial damage in the glomeruli on light microscopy and evaluated 
the association between these findings and therapeutic reactivity of adult nephrotic FSGS.
Methods: Forty-eight out of 183 biopsy-proven FSGS during 2005-2015 were 
included: ≥20 years old, nephrotic syndrome, received immunosuppressive therapy and 
whose pathological slides or paraffin blocks were available. Pathological review was 
done by 3 nephrologists and 1 renal pathologist. Among 11 patients who did not fit the 
definition of any variants in Columbia classification, cases who only have small synechia 
to Bowman capsule were categorized to “simple attachment” and who only have findings 
indicating endothelial damage i.e., mesangiolysis and/or double contour of GBM without 
matrix accumulation were categorized into “endothelial damage only”. Response to 
immunosuppressive treatment of these patients were compared with that of typical FSGS 
variants.
Results: There were 16 TIP (33.3%), 17 CEL (35.4%) and 4 NOS (8.3%). None showed 
collapsing or perihilar variant. There were 5 “simple attachment” cases and 6 “endothelial 
damage only” cases. No difference was observed in the details of immunosuppressive 
treatment among the subgroups. Kaplan-Meier method revealed that “simple attachment” 
cases showed the best therapeutic response and NOS showed the worst response. And 
“endothelial damage only” cases showed similar response to CEL or TIP.
Conclusions: Synechia or findings of endothelial damage are commonly observed in 
FSGS on light microscopy, although they do not play key roles in diagnosis and classification 
of FSGS. In adult nephrotic FSGS, simple attachment indicated good therapeutic response. 
On the other hand, even if patients only have the findings of endothelial damage, it might be 
clinically equivalent to other variants of FSGS.
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Renal Disease in Pregnancy - Doing Biopsy Matters to Lives
Asif A. Ansari,1 Anand C. Reddy,1 Narothama Reddy Aeddula,2 
Rajnarsing Chennamaneni,3 Uzair Waheed,4 Srikala Meda,3 Leela 
sharath Pillarisetty,5 Rami Batarseh.6 1Permian Basin Kidney Center, Midland, 
TX; 2Deaconess Health System, Evansville, IL; 3Medical Center Hospital, 
Odessa, TX; 4Texas A&M, College Station, TX; 5MCHS, Midland, TX; 6Texas 
Tech University health and science center - Permian Basin, Odessa, TX.
Background: Renal disease is extemely rare in pregnancy but presents a therapeutic 
dilemma when diagnosed. It is a poor prognostic marker for fetal and maternal health. 
There is limited data and recommendations to guide therapy in this subset of population 
are lacking. We report our experience with 19 pregnant patients undergoing renal biopsies 
over a period of 5 years.
Methods: All pregnant patients undergoing renal biopsy at our facility were included 
in this retrospective analysis. Electronic medical records of nephrology, obsterician services 
and histo-pathological reports were accessed. Patient confidentiality was preserved. Data 
was collected from january 1, 2013 to april 30, 2018.
Results: Nephrotic syndrome was the most common indication for a renal biopsy 
during pregnancy accounting for 16/19 patients (84%). Lupus nephritis was diagnosed 
in 4/18 patients necessitating an immunosuppressive regimen. The median gestation was 
32 weeks (range 20–40) with loss of two fetuses. Non diabetic patients with nephrotic 
syndrome were at a higher risk for pre ecclampsia than diabetic patients with nephrotic 
syndrome (p<0.05). Three patients progressed to end stage renal failure needing dialysis, 
there were no maternal deaths during the follow up period. Table 1 shows characteristic 
features of this group.
Conclusions: Our series of selected pregnant patients undergoing renal biopsy 
demonstrates the variety of pathology in this group. Ante partum renal biopsy is safe in early 
pregnancy but should be considered only if there is a high likelihood to alter conventional 
therapy, and aid progression of pregnancy to fetal viability. Close monitoring and early 
intervention is key to improving feto-maternal outcomes particularly in non diabetic 
patients with neprhotic syndrome.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Histopathological Findings in Mixed Connective Tissue Disease with 
Renal Involvement
Silvia Ramirez,1 Luis E. Morales-Buenrostro,1 Ricardo Correa-Rotter,2 
Eduardo Martin,1 Norma O. Uribe-uribe,3 Laura Cardenas,1 Montserrat Reyes,1 
Tatiana S. Rodriguez.1 1Instituto Nacional de Ciencias Medicas y Nutricion 
Salvador Zubiran, Mexico City, Mexico; 2Institutor Nacional de la Nutricion, 
Mexico City, Mexico; 3Instituto Nacional de Ciencias Medicas y Nutricion, 
“Salvador Zubiran”, Mexico City, Mexico.
Background: Renal involvement in mixed connective tissue disease (MCTD) is 
uncommon and present in up to 20% of patients, most commonly, an immune-complex 
nephropathy. The aim of the study was to identify the prevalence of renal involvement and 
describe renal histophatological findings in MCTD.
Methods: Single center retrospective cohort of MCTD (2003-2017) according to the 
Alarcón-Segovia criteria, assessed to identify cases with renal involvement. Histological 
findings of biopsied patients are described.
Results: 131 MCTD patients were identified, of which 14 (10.7%) had renal 
involvement, 7 underwent a renal biopsy, 6/7 were women; mean age at onset of renal 
involvement 47.1 ± 7.5 years. Most frequent extra-renal clinical manifestations were: 
Raynaud’s phenomenon and arthritis, both in 7 (100%), puffy hands in 6 (85.7%), 
sclerodactily in 5 (71.4%), myositis in 5 (71.4%), and interstitial lung disease in 3 
(42.8%). Median time elapsed from MCTD diagnosis to renal involvement was 82 (2-208) 
months. Four (57.1%) presented with sub-nephrotic proteinuria, 3 (42.8%) with nephrotic 
range proteinuria and 3 (42.8%) with CKD-EPI eGFR <60ml/min/1.73m2. Histological 
diagnoses: pauci-immune focal necrotizing and crescentic glomerulonephritis (GN) (2 pts; 
one developed positive ANCA antibodies), lupus nephritis (LN) class III + V ISN/RPS 2003 
(1), LN class IV ISN/RPS 2003 with thrombotic microangiopathy (1), non-LN membranous 
GN (2) and minimal mesangioproliferative GN (1). Six (85.7%) achieved either total or 
partial remission at a median follow up of 61 (1-363) months with combination of steroids 
and other immunosuppressant. No patient required renal replacement treatment.
Conclusions: In our cohort of MCTD, prevalence of renal involvement was low. Renal 
biopsy demonstrated a diversity of histological patterns: glomerulonephritis, vasculopathy, 
and overlap with ANCA associated vasculitis; these options should be considered in the 
differential diagnoses of MCTD patients with renal involvement.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Clinical Outcomes of Renal Biopsy-Proven Thrombotic Microangiopathy
Eunjeong Kang,1 Dong Ki Kim,1 Kook-Hwan Oh,1 Kwon Wook Joo,1 Yon 
Su Kim,2 Ho Jun Chin,3 Hajeong Lee.2 1Seoul National University Hospital, 
Seoul, Republic of Korea; 2Seoul National University College of Medicine, 
Seoul, Republic of Korea; 3Seoul National University Bundang Hospital, Seong 
nam, Republic of Korea.
Background: The kidney is the most commonly affected organ by thrombotic 
microangiopathy (TMA)-associated pathologic changes, however, there is lack of studies 
regarding the clinical outcomes of renal-biopsy proven TMA.
Methods: The patients diagnosed as TMA from 2005 to 2018 in 2 tertiary hospitals 
were enrolled. Of these 186 patients, children and those who not diagnosed with renal biopsy 
were excluded. These patients divided into 3 groups according to causes of TMA; typical 
hemolytic uremic syndrome (HUS), atypical HUS, and secondary TMA. Only 1 patient 
who classified typical HUS was excluded in the statistical analysis. Renal outcome was 
defined in 2 ways; renal function deterioration to end-stage renal disease (ESRD) who were 
depended on dialysis or kidney transplantation (KTPL) and the last measured estimated 
glomerular filtration rate (eGFR) <45mL/min/1.73m2. Age, sex, eGFR rate at diagnosis, 
systolic blood pressure (SBP), hemoglobin, platelet, albumin, diabetes, hypertension, and 
classification of TMA were included as covariates in the multivariable analysis.
Results: Among 67 patients, patients who diagnosed with TMA after KTPL were 
15(22.3%). Mean age was 54.0±15.5 years and 44(62.0%) were male. During 48.6 months 
of follow-up, 12 (17.9%) patients died, and 18(26.9%) patients (11 [26.8%] of secondary 
TMA vs. 7 [26.9%] in aHUS) had maintenance dialysis or KTPL. The patients who had 
last eGFR <45mL/min/1.73m2 was 35(49.3%). There was no significant difference in all-
cause mortality (log-rank P=0.293) and ESRD (log rank P=0.378) between atypical HUS 
and secondary TMA. SBP (hazard ratio [HR] 1.030, 95% confidential interval [CI] 1.006-
1.055, P=0.015) and eGFR at diagnosis (HR 0.966, 95% CI 0.939-0.993, P=0.014) were 
associated with ESRD progression in univariate analysis, however, these associations did 
not observed in multivariable analysis. eGFR at diagnosis was the only risk factor for the 
final measured eGFR <45mL/min/1.73m2 in multivariate logistic regression (OR 0.952, 
95% CI 0.920-0.985, P=0.004). Only age was associated with all-cause mortality (HR 
1.079, 95% CI 1.010-1.152, P=0.024) in multivariable analysis.
Conclusions: SBP and eGFR at diagnosis were significantly associated with ESRD 
progression in renal biopsy-proven TMA. There was no significant difference in all-cause 
mortality and ESRD progression between atypical HUS and secondary TMA.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
A Combined Unenhanced Computed Tomography and Biopsy-Based 
Method for Estimating the Total Nephron Number in Humans
Takaya Sasaki, Nobuo Tsuboi, Yusuke Okabayashi, Kotaro Haruhara, 
Go Kanzaki, Kentaro Koike, Akimitsu Kobayashi, Izumi Yamamoto, 
Takashi Yokoo. Division of Nephrology and Hypertension, Department of 
Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Background: Methods for estimating the individual total nephron number in the 
clinical setting may be useful for predicting the progression of renal diseases. Rcently, 
simple methods have been proposed for estimating the total nephron number by the 
combined use of enhanced computed tomography (CT) and a renal biopsy in living kidney 
donors. However, renal disease patients are often not suitable candidates for intravenous 
contrast media administration. Thus, these methods are limited in daily clinical use for 
such patients, with further improvements in the methodology required. This study aimed 
to establish a method of estimating the total nephron number by the combined use of 
unenhanced CT and biopsy-based stereology.
Methods: We made a model for estimating the renal cortex volume measured by 
enhanced CT imaging as a true renal cortex volume. Using pre-donation contrast CT 
angiograms, transplantation donor kidneys were three-dimensionally reconstructed, and the 
total renal cortical volume was measured. The cortical volume estimates in unenhanced CT 
were determined by multiplying the semi-automatically measured parenchymal volume and 
the cortex coefficient. The total nephron number was determined by the combined use of the 
CT-based cortical volume and the glomerular density per volume in an implantation biopsy. 
The relative errors were calculated to assess the agreement between the methods.
Results: The values for the parenchymal volume and those for the cortical volume 
measured in enhanced CT showed a tight correlation (r = 0.949). The cortical to parenchymal 
volume ratio (0.715) was unaffected by any clinical factors, including age, body size and 
hypertension, and was defined as the cortex coefficient. The cortical volume and total 
nephron number estimated by unenhanced CT were consistent with those estimated by 
enhanced CT, with minimal relative errors (Table).
Conclusions: These results support the feasibility of estimating the total number of 
nephrons by the combined use of unenhanced CT and biopsy-based stereology, with a 
possible application for renal disease patients.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
The Total Nephron Number and Responses to Corticosteroid Therapy in 
Patients with Minimal Change Nephrotic Syndrome
Takaya Sasaki, Nobuo Tsuboi, Yusuke Okabayashi, Kotaro Haruhara, 
Go Kanzaki, Kentaro Koike, Takashi Yokoo. The Jikei University School of 
Medicine, Minato-ku, Japan.
Background: The etiologies of minimal change nephrotic syndrome (MCNS) remain 
largely unknown; however, indirect evidence suggests that the weight at birth, which is 
related to the total nephron number, may affect the response to corticosteroid therapy. This 
study investigated the involvement of the total nephron number in the clinical course of 
MCNS.
Methods: Patients who exhibited acute-onset nephrotic syndrome, with a histological 
diagnosis of MCNS, were retrospectively analyzed. The total nephron number was 
estimated using a simplified method based on the combined use of unenhanced computed 
tomography and the non-sclerotic glomerular density of renal biopsy specimens. The single 
nephron glomerular filtration rate (snGFR) and single nephron urinary protein excretion 
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(snUPE) values were calculated by dividing the eGFR or UPE by the total nephron number. 
The glomerular volume (GV) was estimated by the measured mean glomerular area.
Results: A total of 38 MCNS patients were analyzed. The estimated total nephron 
number ranged from 140,000 to 1,800,000 per kidney among the patients and was inversely 
correlated with GV (r=-0.433, p=0.007). At the time of the diagnosis, the snGFR and snUPE 
values of the low-nephron group were significantly higher than those of the high-nephron 
group (139 vs 58 nl/min/1.73m2 and 15.3 vs 7.1 μg/day, respectively). There was no 
significant difference in the total amount of UPE (7.4 vs 8.7 g/day) or the selectivity index 
(0.05 vs 0.05) of the groups. The reduction in snUPE (Figure A) and the time to complete 
remission (Figure B) during corticosteroid therapy were significantly slower in the low-
nephron group, with no difference in the dose of corticosteroids. The total nephron number 
was found to be associated with the UPE at four weeks after the initiation of corticosteroid 
therapy, independent of age and the renal function.
Conclusions: Individual differences in the total nephron number in MCNS patients 
may influence the responses to corticosteroid therapy, possibly through the alteration of the 
single nephron dynamics.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
The Impact of Birth Weight in Children with Biopsy Confirmed Nephrotic 
Syndrome
Candace D. Henderson,1 Yichun Hu,2 Susan L. Hogan,2 Caroline J. Poulton,1 
Keia Sanderson,3 Carmen E. Mendoza,4 Kristin B. Kennedy,1 Keisha L. Gibson.3 
1UNC Kidney Center, Chapel Hill, NC; 2University of North Carolina, Chapel 
Hill, Chapel Hill, NC; 3University of North Carolina Kidney Center, Chapel 
Hill, NC; 4University of North Carolina, Chapel Hill, NC.
Background: Nephrotic syndrome is a growing cause of chronic kidney disease 
(CKD) in children and can lead to end-stage kidney disease (ESKD). This study evaluates 
the impact of low birth weight (LBW) in children with nephrotic syndrome. Additional risk 
factors such as gestational age and kidney size were also assessed.
Methods: This retrospective cohort study reviewed the medical records of 75 children 
included in the UNC Glomerular Disease Collaborative Network ages 0-18 years with 
biopsy proven minimal change disease (MCD), focal segmental glomerulosclerosis 
(FSGS), and membranous nephropathy (MN) for both modifiable and non-modifiable risk 
factors to determine potential associations between birth history and disease and its impact 
on disease progression to ESKD.
Results: Thirteen (17%) were born with LBW. FSGS was more frequent in LBW 
children (92%) compared to normal birth weight (NBW) (55%), while NBW children were 
more likely to develop MCD (37%) compared to LBW children (8%). LBW children had 
higher body mass index (BMI) compared to NBW children. The proportion of LBW and 
NBW children progressing to ESKD was similar (23% vs 27% respectively).
Conclusions: Our findings suggest that LBW is associated with disease type, specifically 
FSGS, and higher weight. Although numbers are small, progression to eGFR≤30 appeared 
similar by birth weight. A larger sample size and longer follow-up is needed to further 
investigate the potential impact of low nephron number from LBW, especially in the setting 
of these glomerular diseases, and the relationship with overweight/obesity status.
FR-PO1122 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
Variability in Treatment of Childhood Nephrotic Syndrome in Africa
Chris Esezobor,1 Damien G. Noone,2 Rasheed A. Gbadegesin,3 Rulan S. Parekh.4 
H3 Africa Kidney Disease Research Network 1Department of Paediatrics, 
College of Medicine University of Lagos, Lagos, Nigeria; 2The Hospital for Sick 
Children, Toronto, ON, Canada; 3Duke University Medical Center, Durham, 
NC; 4The Hospital For Sick Children, Toronto, ON, Canada.
Background: Idiopathic nephrotic syndrome (NS) is the most common glomerular 
disease in African children. Clinical practice is guided based on limited resources for 
diagnosis and management of NS in most of the African continent. We aimed to determine 
variability in treatment of NS in Africa to develop a consensus guideline for the treatment 
of NS in middle and low-income countries.
Methods: Using the KDIGO guidelines as the basis for the management of NS, 
we developed a survey to assess current practices in 6 Sub-Saharan African countries. 
Approximately 50 adult and pediatric nephrologists from West, East and South Africa, in 
the H3 Africa Kidney Disease Research Network, were invited to complete the survey. 
Responses on treatment choices, duration of therapy, management of relapses and 
management of steroid resistant NS (SRNS) were collected.
Results: 30 nephrologists (20 pediatric, 4 adult and 6 both) from 19 hospital centers 
located in Nigeria, Ghana, Cameroon, Uganda, Tanzania and South Africa, completed the 
survey. Variability in treatment choices and practice were observed when compared with 
international guidelines. The definition of child varies by country, ranging from ages 12-18 
(median 17), thus adult nephrologists also manage idiopathic NS. The initial treatment of 
steroid sensitive NS, and the definition and management of relapses varied widely across 
the respondents (Figure). Remission was defined by negative urinary protein ranging from 
3-7 days (median 3). Only about 50% prescribed calcineurin inhibitors for children with
SRNS.
Conclusions: Management of NS varied widely across and within countries in 
Africa, thus the importance of a consensus guideline tailored to an African context. Adult 
nephrologists often manage adolescents and youth, thus need to be aware of the pediatric 
management. Standardizing practice across the continent will provide an opportunity to 
understand the burden and long-term outcomes of NS.
Funding: NIDDK Support, Government Support - Non-U.S.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Effects of LDL-Apheresis in Adult Refractory Nephrotic Syndrome and 
Its Reproducibility
Hideki Takizawa,1 Yoshinosuke Shimamura,1 Yayoi Ogawa.2 1Teine Keijinkai 
Hospital, Sapporo, Japan; 2Hokkaido Renal Pathology Center, Sapporo, Japan.
Background: In 2018, Humanitarian device exemption allowed to utilize LDL-
apheresis (LDL-A) for the treatment in adult patients with nephrotic-range focal segmental 
glomerulosclerosis (FSGS), but the efficacy is still uncertain. We performed case series of 
LDL-A in patients with refractory nephrotic syndrome, including FSGS, in a tertiary care 
center in Japan.
Methods: The efficacy of LDL-A was evaluated in 15 cases of refractory nephrotic 
syndrome (FSGS, n=4; minimal change disease (MCD), n=7; membranous nephropathy 
(MN), n=4) enrolled from April 2008 to April 2018. Demographic and clinical parameters 
were compared before and after performing LDL-A. Additionally, the efficacy of the second 
trial of LDL-A was evaluated in relapsed cases after the first trial of LDL-A.
Results: In 15 patients, all patients, except one, received immunosuppressive agents 
(prednisolone, 14; cyclosporine, 6; cyclophosphamide, 2), and there was no statistically 
significant reduction in proteinuria before initiating LDL-A (p=0.051; t-test). However, 
there were statistically significant reduction in proteinuria after performing the first trial 
of LDL-A in all groups (FSGS, 9.1 ± 1.9 g/day to 2.6 ± 1.0; MCD, 5.4 ± 1.4 to 0.4 ± 
0.1; MN, 6.4 ± 0.5 to 2.3 ± 0.5; p <0.005; MANOVA). Multivariate analysis revealed the 
rate of remission was higher in MCD compared to other groups (R2=0.49, p<0.005). In 
relapsed cases after the first trial of LDL-A (n=7), the second trial of LDL-A was effective 
to reduce proteinuria, and there was no statistically difference in between the first trial and 
the second trial of LDL-A (First trial, 5.6 ± 1.1 to 0.7 ± 0.3; Second trial, 7.2 ± 1.5 to 
0.8 ± 0.5, p=0.382; MANOVA).
Conclusions: This study suggested that LDL-A was effective for reducing proteinuria 
in patients with refractory nephrotic syndrome, and its effectiveness was reproducible. This 
may contributed to planning treatment strategies in these patients.
FR-PO1124 Poster Friday
Glomerular Diseases: Clinical, Outcomes, Trials - II
Lower Doses of Prednisolone Are Sufficient for Initial Treatment in 
Adult-Onset Minimal Change Nephrotic Syndrome
Maiko Kimura,1 Takayuki Fujii,2 Tanaka Hiroaki,2 Noriko Terasaki,2 Kaiji Saito,2 
Satoshi Suzuki.2 Seirei Sakura Citizen Hospital 1Graduate School of Medicine 
and School of Medicine, Chiba University, Chiba, Japan; 2Seirei Sakura Citizen 
Hospital, Sakura city, Japan.
Background: KDIGO Guideline suggests that prednisolone (PSL) should be given at 
a single daily dose of 1 mg/kg, as initial treatment in adult-onset minimal change nephrotic 
syndrome (MCNS). However, there is no convincing evidence to support the guideline’s 
suggestion. It remains unclear how much the initial dose of PSL for MCNS should be 
given. On the other hand, from the viewpoint of side effects, the lower dose of PSL is fairly 
advantageous.
Methods: This retrospective cohort trial was performed in a single center between 
1987 and 2017. Inclusion criteria were adult-onset MCNS diagnosed by kidney biopsy. 
These participants were classified into Low PSL group (L group, < 0.6 mg/kg), Moderate 
PSL group (M group,  0.6 mg/kg and < 0.8 mg/kg) and High PSL group (H group, 
 0.8mg/kg). The primary outcomes of interest were time to first remission and first relapse 
of proteinuria. They were analyzed with ANOVA, log-rank test, and multivariate Cox 
proportional hazards models.
Results: A total of 58 patients were enrolled in this clinical trial. All of these patients 
at any dose of prednisolone achieved remission within a median of 16 (8-45) days in L 
group, 14 (6-166) days in M group, and 20 (8-37) days in H group. Long-rank test showed 
that there were no significant differences in the primary outcomes among three groups. 
Multivariate Cox proportional hazards revealed that although age (per 10 yr) and serum 
creatinine (per log 1mg/dl) were prognosis factors for the time to the first remission, PSL 
dose was not a significant factor (HR, 1.07; 95%CI, 0.43 to 2.79 (L group vs H group), 0.99 ; 
95%CI, 0.41 to 2.44 (M group vs H group)). Additionally, multivariate Cox regression 
analysis for the incidence of relapse did not significantly indicate any prognostic factor.
Conclusions: Low or moderate doses of PSL are sufficient for initial treatment in adult-
onset MCNS regarding the time to remission and incidence of relapse.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Adult Outcome of Childhood-Onset Steroid-Dependent Idiopathic 
Nephrotic Syndrome in the Rituximab Era
Emmanuelle M. Plaisier,1 Claire Dossier,2 Karine Dahan,1 Pierre M. Ronco,1 
Veronique Baudouin,4 Tim Ulinski,3 Georges Deschênes.2 1Nephrology and 
Dialysis, APHP Tenon, Paris, France; 2Pediatric nephrology, APHP Robert 
Debré, Paris, France; 3Pediatric Nephrology, APHP - Trousseau and UPMC, 
Paris, France; 4APHP-Robert Debré Hospital, Paris, France.
Background: Idiopathic nephrotic syndrome (INS) represents the most frequent 
glomerular disease in childhood, with up to 60% of patients experiencing frequent relapses 
and steroid dependency requiring long-lasting steroid therapy and immunosuppressive (IS) 
drugs. Outcome and optimal therapy at adulthood, as well as long-term complications of 
childhood IS exposure is poorly documented.
Methods: We retrospectively analyzed a monocentric cohort of 43 patients with 
childhood-onset steroid-dependent INS. Relapses in adulthood were treated with steroids or 
a combinaison of steroids and rituximab (RTX), with the exclusion of all other IS.
Results: Median age at the INS diagnosis and at the last follow-up was 4 years (1-17) 
and 24 (19-40) years, respectively, with a median duration of follow-up at adulthood of 7 
(1-21) years. At pediatric age, 42 (98%) patients received at least one nonsteroidal IS drug, 
including calcineurin inhibitors in 29 (67%), mycophenolate mofetil in 26 (60%), RTX in 
17 (39%), an alkylating agent in 15 (35%), and levamisole in 13 (30%). At entry in the adult 
care, 16 (37%) of the patients still received an IS drug other than RTX. Relapse occurred 
in 32 (74%) of patients at adult age with 5 patients presenting at least 2 episodes. In 9 
patients, relapse occurred more than 3 years after steroids and IS discontinuation. Relapses 
were treated with steroids alone in two patients, while the other 29 received a combination 
of steroids and RTX, followed, for 20/29 patients, by a reinfusion of RTX either at B-cell 
recovery or at fixed intervals (6 to 12 months), up to 24 months. At last follow-up, 36 (84%) 
patients were in complete remission, with a treatment-free duration of more than 24 months 
in 12 (28%), of 12 to 24 months in 8 (19%) and of less than 12 months in 16 (37%). All 
but one patients were free of steroids and IS drugs. No patient experienced infection or 
cytopenia and one patient developed neoplasia most likely unrelated to IS.
Conclusions: Childhood-onset steroid-dependent INS remains a concern at adulthood 
with a high rate of relapse occurring after a variable delay. RTX is a safe and efficient 
steroid-sparing agent allowing maintenance of remission and discontinuation other IS. No 
late-onset severe complication related to childhood therapies was recorded.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Identifying Functional Subclasses of Nephrotic Syndrome by Consensus 
Non-Negative Matrix Factorization Clustering of Glomerular 
Transcriptome
Habib Hamidi,1 Sean Eddy,1 Matthias Kretzler,1 John R. Sedor,3 
Lawrence B. Holzman,2 John F. O’Toole,3 Laura H. Mariani.1 1University of 
Michigan, Ann Arbor, MI; 2University of Pennsylvania, Philadelphia, PA; 
3Cleveland Clinic, Cleveland, OH.
Background: Defining nephrotic syndrome in mechanistic terms is a prerequisite 
to develop targeted therapies. Consensus non-negative matrix factorization (NMF) is a 
clustering approach used with tumor specimen transcriptomics to identify functionally 
relevant subtypes.
Methods: NMF clustering was applied to glomerular mRNA expression from 
nephrotic syndrome patient biopsies (NEPTUNE cohort). Individual gene expression 
levels from the glomerular compartment were normalized to mean expression to maximize 
individual patient differences over shared disease & tissue expression. Cox proportional 
hazards models were fit for complete proteinuria remission (CR, UPCR <0.3 mg/mg) and 
ESRD/40% eGFR decline. Significance analysis of microarray identified cluster specific 
differentially expressed genes that were used in pathway enrichment analysis to determine 
functional relevance.
Results: NMF separated 138 patients into 4 clusters which did not differ by diagnosis 
(MCD, FSGS, MN and IgAN, p 0.25), age (p 0.72), sex (p 0.25) or UPCR (p 0.28). Cluster 1 
had lower mean eGFR (63 mL/min vs 81, 77 and 85; p 0.04) and greater black race (54% vs 
10%, 24%, 19%, p <0.01). In unadjusted models, cluster 1 had least CR (HR 0.51, 95%CI 
0.3–1.0, p-value 0.06) and greatest loss of eGFR (HR 5.4 95%CI 2.5–12.0, p-value <0.01). 
The eGFR association persisted after adjustment for baseline eGFR and race. Pathway 
enrichment of cluster-specific genes demonstrated unique processes: cluster 1-targetable 
signaling pathways (e.g. integrin, EGF-R, TLR), cluster 2-pentose phosphate metabolism, 
cluster 3-metabolic pathways (e.g.Vit D, pyruvate, galactose), cluster 4-cadherin signaling.
Conclusions: NMF clustering of glomerular kidney tissue mRNA expression 
levels revealed 4 clusters which were distinct from conventional classification. Pathway 
enrichment of gene signatures for each cluster revealed distinct molecular processes which 
may help to inform future treatment strategies.
Funding: NIDDK Support, Other NIH Support - NCATS, Private Foundation Support
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Glomerular Diseases: Clinical, Outcomes, Trials - II
APOL1 Risk Alleles Are Critical for the Development of Collapsing 
Glomerulopathy in Brazilian Children
Andreia Watanabe,3 Precil D. Neves,3 Elieser H. Watanabe,3 Antonio M. Lerario,2 
Fabiola L. Padovan,3 Amanda M. Narcizo,3 Friedhelm Hildebrandt,1 Matt 
G. Sampson,2 Luiz F. Onuchic.3 1Boston Children’s Hospital, Boston, MA; 
2University of Michigan, Ann Arbor, MI; 3University of Sao Paulo, Sao Paulo,
Brazil.
Background: Collapsing glomerulopathy (CG) is associated with worse renal outcome 
than any FSGS histologic variant, while APOL1 risk alleles are associated with FSGS and 
increased susceptibility to CG. In pediatric population, such alleles are related to later FSGS 
presentation, worse eGFR and faster progression to ESKD.
Methods: A retrospective analysis of 41 children with steroid-resistant nephrotic 
syndrome (SRNS) or congenital NS (CNS) with onset at 2 months-16 years was performed. 
All had biopsies analyzed by renal pathologists. Mutational analysis in 42 genes related to 
glomerular diseases was performed using a capture-based, customized panel followed by 
NGS using an Illumina MiSeq V2.
Results: CG was diagnosed in 10/41 patients, all negative for HIV, hepatitis B and C 
and CMV. Of these 10, 5 were Caucasian (C) and 5 mixed race (MR); all self-reported. 
Five CG children were treated with prednisone plus FK506/CyA/MMF and 2 with 
methylprednisolone boluses (renal failure at presentation). Two with CNS were given no 
immunosuppression. 8/10 CG patients reached ESKD within 0.0-3.8 years after initial 
manifestation. The other 2 have eGFR of 88 and 60 mL/min/1.73m2, after 4 and 5 years 
of follow-up, respectively. A high-risk (HR) APOL1 genotype was detected in 5/10 CG 
patients, 2 C and 3 MR. 2/5 were extreme preterm; the other 3 had birth weight <3 kg. Of 
the remaining 5 with CG, 2/5 had 1 APOL1 risk allele (1 C and 1 MR), 1 was homozygous 
for a novel likely pathogenic variant in PLCE1 (p.L1233P), and 1 was heterozygous for a 
rare, frameshift variant in LAMB2. Of the 31 without CG, 4 had a single APOL1 risk allele 
and 27 none. Overall, Brazilian children with CG had significantly higher odds of harboring 
a HR APOL1 genotype (OR=∞, CI:6.6,∞: p=0.0003).
Conclusions: For Brazilian children with SRNS/CNS, as compared to other histologic 
diagnoses, those with CG have greatly increased odds of having a HR APOL1 genotype. 
Furthermore, the burden of APOL1-associated SRNS/CNS spanned self-described races. 
Finally, all with CG and HR APOL1 genotype had an abnormal birth history. The discovered 
racial, histologic, and birth history correlates of a HR APOL1 genotype have important 
implications for future APOL1 genotyping efforts in research and clinical settings in Brazil.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Predictors of Remission in Collapsing Glomerulopathy
Mateus J. Luvizotto, Gerard F. Sales, Precil D. Neves, Luis Yu, Cristiane B. Dias, 
Viktoria Woronik, Lectícia Jorge. University of Sao Paulo, Brazil, São Paulo, 
Brazil.
Background: Collapsing Glomerulopathy (CG) has usually been associated with poor 
renal outcomes. The goal of this study was to identify predictors of remission in the CG.
Methods: A retrospective analysis was performed on all CG diagnosed by kidney 
biopsy between 1996 and 2016. Clinical and laboratory data were collected at baseline and 
at the end of follow up. Remission has been defined as 50% reduction in baseline proteinuria 
and <3.5 g/day. Outcome was defined as ESRD or doubling of baseline creatinine.
Results: Logistic regression analysis showed that remission was significantly 
associated with a better renal outcome (OR 0.08, 95%CI 0.02-0.3, p<0.001), even after 
adjustments for baseline CKD-EPI and proteinuria. Clinical features of the groups with 
and without remission are summarized in Figure 1. A second logistic regression analysis 
showed that female and interstitial fibrosis are the only independent predictors associated 
with remission in CG (OR 0.28, 95%CI 0.09-0.84, p 0.02 and OR 10.9,95%CI 1.2-98 
p 0.034)
Conclusions: Predicting remission with baseline features is difficult, but female and 
patients without interstitial fibrosis are more likely to achieve remission. Moreover, patients 
with CG who showed remission had a better outcome and this should be (a goal of therapy)
attempted.
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Collapsing Glomerulopathy in Hepatitis C Virus Positive Patients: A 
Retrospective Autopsy Study of 95 Cases
Yasir Lal, Hania Kassem, Aijan T. Ukudeyeva, Derald D. Charles, Samantha 
V. Etienne, Wayne G. Fischer, Marjan Afrouzian. UTMB, Galveston, TX.
Background: Patients (pts) with hepatitis C virus (HCV) infection may present with a 
variety of glomerular diseases, however Collapsing glomerulopathy (CG) is an uncommon 
presentation. In most pts, this lesion is associated with human immunodeficiency virus 
(HIV) infection while in a small number of cases, CG is considered to be idiopathic. The 
aim of this study was to determine the prevalence of CG in HCV-positive, HIV-negative 
(HCV+ HIV-) pts, using autopsy material to explore the significance of this association 
through clinical, pathological and laboratory correlation.
Methods: We performed a retrospective autopsy study, examining the renal 
parenchyma of 95 HCV+ pts. Pts with positive or unknown HIV status or those who 
had exposure to interferon (IFN) therapy were excluded. Thereafter, the presence of 
CG (test group) or absence of CG (control group) was recorded using hematoxylin and 
eosin, periodic acid-Schiff and Jones stains. Clinical and laboratory correlation included 
evaluation of demographics, terminal serum creatinine, HCV serology, viral load (VL), 
dipstick proteinuria, serum albumin (Alb), and cause of death. A t-test (pooled variances) 
was used for comparison of continuous variables such as age, BMI, HCV VL and Alb. 
Comparison of categorical variables such as gender, race, and HCV genotype was based 
on contingency analysis.
Results: Forty cases were excluded based on HIV status and IFN exposure. CG was 
identified in 19/55 pts (34.5 %). There was no significant difference in age, race, BMI, Alb, 
creatinine, proteinuria or cause of death among the two groups. HCV VL was higher in the 
test group but the difference was not statistically significant.
Conclusions: To our knowledge, this is the largest autopsy study describing the 
occurrence of CG in HCV+ HIV- pts. Our results demonstrate an association and prevalence 
of CG in HCV infection that have not been previously established. Therefore, CG should 
be considered in HCV+ HIV- pts who present with renal failure and proteinuria. Further 
studies are needed to elucidate prevalence and pathogenesis of CG in these pts.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Quantitative Mass Spectrometry Aided Urine Biomarker Analysis in 
Nephrotic Syndrome
Timothy Cummins,1,2 Daniel W. Wilkey,1,2 Michelle T. Barati,1,2 Dawn J. Caster,1,2 
Frederick W. Benz,3 Michael Merchant,1,2 Jon B. Klein.1,2 1University of Louisville 
Kidney Disease Program, Louisville, KY; 2University of Louisville Medicine, 
Louisville, KY; 3Pharmacology, University of Louisville, Louisville, KY.
Background: Accurate and precise diagnosis of chronic renal diseases can be aided 
using biomarkers. Methodological advancements in mass spectrometry and bioinformatics 
have improved the ability to identify and quantitate protein biomarkers induced in 
disease. Proteins and peptides that are present in patient urine are indicative of changes 
in homeostasis of the kidney and other organs. Identification and quantitation of these 
components of the urine proteome will be useful in determining effective new biomarkers 
of kidney disease. Loss of kidney function corresponds with increased leakage of protein 
and peptide components into the urine. Profiling and quantitation of urinary markers of 
renal disease progression is important towards a better understanding and characterization 
of distinct glomerular diseases.
Methods: In this work we present a mass spectrometry workflow utilizing multiplex 
tandem mass tag (TMT) quantitation of whole urine proteins from patients with nephrotic 
syndrome and in remission.
Results: Combined 2D-LC-MS/MS-TMT analysis yielded ~800 protein identifications, 
~480 were quantitated. Over 200 proteins were upregulated in disease and 50 were 
downregulated.
Conclusions: Our current study includes urine TMT analysis from 3 patients with 
nephrotic syndrome and post-treatment follow-up upon remission. The sample set, though 
small, is ideal for looking at effects of normalization on intra and inter-patient protein 
quantitation as we were also able to see a difference in the effects of race and sex in one 
sample that clearly clusters differently from the other two patients. Clinical data, specifically 
urinary creatinine, was used to normalize TMT values. Employing these methods on larger 
patient cohorts will help in uncovering novel biomarkers of nephrotic syndrom.
Funding: NIDDK Support, Private Foundation Support
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Clinical and Histological Risk Factors Predicting Progression to ESRD in 
Patients with Secondary FSGS
Aditya S. Pawar, Andrew D. Rule, Kriselle maris Lao, Mariam P. Alexander, 
Lisa E. Vaughan, Fernando C. Fervenza, Ladan Zand. Mayo Clinic, Rochester, MN.
Background: Secondary FSGS is a proteinuric renal disease that develops as a result 
of increased hemodynamic stress on the glomeruli. The aim of study was to identify clinical 
characteristics and histological factors in patients with secondary FSGS that predicted 
progression to ESRD.
Methods: Adult patients (>18 y) with a native kidney biopsy and diagnosis of FSGS 
between 1993-2015 were identified. Those with additional glomerular lesions (e.g. diabetes 
or vasculitis) or missing clinical or biopsy data were excluded. Comprehensive chart 
review was performed on the remaining FSGS patients to identify candidate clinical and 
histological predictors (n=149). Cox proportional hazards regression models were used to 
identify predictors for incident ESRD (eGFR <15 or need for transplantation or dialysis).
Results: Out of 149 patients, 60 had primary FSGS (S. albumin <3.5 g/dL & urinary 
protein (UP) ≥ 3.5g/24h), 89 had secondary FSGS (S. albumin ≥3.5 g/dL & any degree 
of proteinuria). In patients with secondary FSGS mean (SD) age was 52 (17) years, 41% 
female, & 73% white. Median [IQR] BMI was 30 [26-34] kg/m2, S. creatinine was 1.7 [1.3-
2.4] mg/dL, eGFRcreatinine was 40 [28-57] ml/min, 24h UP was 2.6[1.3-4.4] g, and median 
follow-up was 34 [12-60] months. ESRD occurred in 33% of these patients. Clinical 
predictors of ESRD were older age, lower eGFR, use of immunosuppression, and absence 
of renin-angiotensin blockade (Table 1). The only renal biopsy histological predictor of 
ESRD was severe arteriosclerosis, though IFTA was borderline significant. The degree of 
global sclerosis, foot process effacement and glomerulomegaly was not predictive. Severe 
arteriosclerosis was predictive after adjusting for age (p=0.04).
Conclusions: Arteriosclerosis appears to be an important and under-recognized 
predictor of progression to ESRD in patients with secondary FSGS independent of age.
Univariate analysis
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Clinicopathological Discrimination of Primary and Genetic Focal 
Segmental Glomerulosclerosis in Children
Kiyonobu Ishizuka,1 Yutaka Harita,2 Takaya Iida,1 Takeshi Nagasawa,1 Hideki 
Ban,1 Yoko Shirai,1 Tomoo Yabuuchi,1 Naoto Kaneko,1 Kenichiro Miura,1 
Taeko Hashimoto,3 Motoshi Hattori.1 1Tokyo Women’s Medical University, 
Shinjuku-ku, Japan; 2Dept. of Pediatrics, Tokyo University, Tokyo, Japan; 
3Yamagata University, Yamagata-city, Japan.
Background: (Background) FSGS is classified as primary FSGS caused by 
unidentified humoral factor(s) and secondary FSGS including genetic abnormalities, and 
the cause of the disease of each patient has crucial implication on treatment strategies 
and renal transplant success. Sethi S, et al. described that >80% foot process effacement 
covering glomerular surface area is suggestive of primary form in adult FSGS by comparing 
nephrotic patients with non-nephrotic ones (Nephrol Dial Transplant, 2015). However, it is 
known that nephrotic syndrome can be observed not only in primary form but genetic one in 
children. Therefore, we conducted a clinicopathological study comparing clinically proven 
primary FSGS with genetic FSGS.
Methods: Pediatric FSGS patients (10 primary and 8 genetic) who progressed to 
ESRD and underwent renal transplantation were included in this study. All the primary 
FSGS patients had posttransplant recurrence, and all the patients with genetic FSGS carried 
pathogenic mutations and did not have posttransplant recurrence. We retrospectively 
analyzed their clinical course and histology of the native kidneys before transplantation. 
The degree of foot process effacement (FE) of podocytes was calculated as the ratio of the 
FE area on capillary loops to glomerular surface area.
Results: There were no differences between primary and genetic FSGS on age at 
onset (5.5 ± 3.0 years, 4.6 ± 3.0 years) and the period from onset to ESRD (5.5 ± 4 years, 
4.5 ± 3.5 years). The period from onset to kidney biopsy was significantly shorter in genetic 
than primary FSGS (0.7 ± 1.4 years vs 3.4 ± 3.4 years) (p = 0.02). The rate of nephrosis at 
onset, and of edema observed during the course, and of the initial responsiveness to steroid 
treatment were all significantly higher in primary FSGS (p <0.01). Serum total protein (TP) 
at the time of kidney biopsy was significantly lower in primary FSGS (3.7 ± 0.6 g / dl vs 
5.3 ± 1.1 g / dl) (p <0.01) with TP above 3.9 g/dl predicting genetic (sensitivity 100%; 
specificity 75%; AUC 0.927). The percentage of FE at 80% completely discriminated 
primary from genetic cases (98 ± 6% vs 61 ± 12%).
Conclusions: Discrimination between primary and genetic FSGS could be possible by 
integrating the pathological findings with clinical information.
FR-PO1133 Poster Friday
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Idiopathic FSGS: Outcome in Adult Patients with Initial 
Steroid-Resistance
Ilse M. Rood, Aernoud Bavinck, Marieke van Rijn, Jeroen Deegens, 
Jack F. Wetzels. Radboud University Medical Center, Nijmegen, Netherlands.
Background: Idiopathic focal segmental glomerulosclerosis (iFSGS) is a common 
cause of nephrotic syndrome (NS) in adults. Guidelines advise initial therapy with 
corticosteroids (CS). The clinical outcome of patients with initial steroid-resistance is ill-
defined.
Methods: Retrospective cohort study of adult patients with biopsy-proven FSGS, 
nephrotic syndrome, and steroid-resistance (no complete remission (CR) after 8 weeks of 
treatment with high dose CS). We evaluated late response (CR or partial remission (PR); use 
of second line immunosuppressive treatment; predictors for kidney function deterioration; 
and long-term outcome.
Results: We included 51 patients (31 males), mean age 46 years, referred to our 
academic clinic between 1995 and 2014. Only 6 patients were in PR at 8 weeks. High dose 
CS monotherapy was continued for a median of 17 weeks (IQR 11-21), with a total duration 
of 56 weeks (IQR 28-83). The cumulative incidence of CR and PR were 0 and 16 patients 
at 16 weeks and 1 and 23 patients at 24 weeks of treatment. In total, 9 patients (18%) 
attained a CR and 16 patients (31%) attained a PR during initial (continued) treatment with 
CS. Seven patients in PR were subsequently treated with other immunosuppressive therapy 
(IS), resulting in CR in three. 22 patients received additional immunosuppressive therapy 
because of persistent nephrotic range proteinuria, seven attained a CR and 10 attained a 
PR. Additionally, one patient attained a spontaneous CR 2.5 years after IS therapy was 
discontinued. At end of FU 12 patients were in CR, 22 in PR, 17 had a (persistent or 
relapsed) NS. 6 patients had developed ESRD. In 29 patients eGFR was below p5 of age-
matched controls.19 patients had kidney function deterioration ≥ 3ml/min/1.73m2 per year. 
Older age, FSGS-tip, and CR were associated with stable kidney function. Remarkably, PR 
was not a predictor for a stable kidney function. The definition of PR as recently proposed 
by Troost et al. (a 40% reduction in proteinuria (<1.5 g/g)) was also not associated with a 
stable kidney function.
Conclusions: Long-term outcome in patients with steroid resistance is not uniformly 
dismal. Still, kidney function deterioration ≥ 3ml/min/1.73m2 per year occurs in 37%. Better 
biomarkers are needed to predict long term outcome in patients with iFSGS.
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Glomerular Diseases: Clinical, Outcomes, Trials - II
Kidney Outcome with Primary Focal Segmental Glomerulosclerosis 
(FSGS) by Using a Predictive Model
Shahrzad Ossareh,1 Mansoureh Yahyaei,1 Mojgan Asgari,3 Hanri Afghahi.2 
1Medicine, Iran University of Medical Sciences, Hasheminejad Kidney Center, 
Tehran, Tehran, Islamic Republic of Iran; 2Nephrology, Skaraborg Hospital, 
Skövde, Sweden; 3Pathology, Iran University of Medical Sciences- Hasheminejad 
Kidney center, Tehran, Islamic Republic of Iran.
Background: To develop a model of prediction of chronic kidney disease (CKD)/ end- 
stage kidney disease (ESKD) (dialysis or kidney transplantation) in patients with primary 
FSGS by baseline clinical, laboratory and pathological findings as predictors.
Methods: 201 patients with primary FSGS (59% male, mean age: 38±15 years, 
baseline serum creatinine (bSCr): 1.89±1.64 mg/dl, eGFR 65±38 ml/min/1.73 m2 (MDRD) 
and mean proteinuria: 4.6±3.6 g/24 hours were followed. Time-dependent Cox model and 
C statistics for discrimination were used to develop a predictive model. The patients were 
classified into 3 risk groups of low (bSCr<1.5 mg/dl and interstitial fibrosis/ tubular atrophy 
(IF/TA) and segmental glomerulosclerosis (SGS)< 25%, medium (bSCr: 1.5- 2 mg/dl, and 
IF/TA and SGS: 25-50%) and high (bSCr>2 mg/dl and IF/TA and SGS> 50%). Kaplan–
Meier and the log-rank tests were used to estimate kidney survival in each group. Interaction 
between independent variables was estimated.
Results: During the mean follow-up of 55±27 months, 46 patients (23%) developed 
CKD and 36 (18%) ESKD. Ninety patients (44%) did not respond to treatment and among 
them, 76 patients (84%) developed CKD/ESKD. In multivariate model 1 mg/dl higher bSCr 
(HR: 1.63, 95% CI: 1.12-2.37), 1% increase in SGS (HR: 1.04, 95% CI: 1.01-1.08) and 1% 
increase in IF/TA (HR: 1.06, 95% CI: 1.03-1.09)in kidney biopsy, were associated with 
increased risk. In adjusted model, higher baseline proteinuria and collapsing variant (NOS 
variant as reference) were not significantly associated with risk of CKD/ESKD (P=0.671 
and P=0.136, respectively). The median kidney survival was 8.1 years (95% CI, 7.7-8.6 
years) in low risk and 3.1 years (95%, 2.2- 4.1 years) in high-risk patients. In prediction 
model the accuracy of the applied score for prediction of CKD with discrimination by C 
statistics was C= 0.84 (95% CI: 0.78-0.91) for 5 years.
Conclusions: In patients with primary FSGS, higher bSCr, SGS and IF/TA scores were 
the strongest predictors for CKD/ESKD. In adjusted model higher proteinuria at baseline 
was not associated with increased risk of CKD/ESKD. Interestingly collapsing variant 
did not increase the risk of CKD/ESKD after adjustment for IF/TA score. These findings 
indicated the importance of baseline GFR and the degree of chronicity at biopsy rather than 
histologic variants as predictors of kidney outcome.
FR-PO1135 Poster Friday
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Utility of Columbia Classification in Focal Segmental Glomerulosclerosis: 
Renal Prognosis and Treatment-Response Among the Pathological 
Variants
Akihiro Tsuchimoto,1 Yuta Matsukuma,1 Kenji Ueki,1 Kaneyasu Nakagawa,1 
Shigeru Tanaka,2 Kosuke Masutani,3 Koji Mitsuiki,4 Ritsuko Katafuchi,5 
Kazuhiko Tsuruya,6 Toshiaki Nakano,1 Takanari Kitazono.1 1Kyushu University, 
Fukuoka, Japan; 2Fukuoka Dental College, Fukuoka, Japan; 3Fukuoka 
University, Fukuoka, Japan; 4Fukuoka Red Cross Hospital, Fukuoka, Japan; 
5National Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan; 6Nara 
Medical University, Kashihara, Japan.
Background: The utility of the Columbia classification (Col-class) for focal segmental 
glomerulosclerosis (FSGS) has not yet been fully proven.
Methods: We extracted 201 FSGS patients from 10 nephrology centers in Japan 
and investigated the differences of a composite renal endpoint, defined as doubling of 
serum creatinine and/or development of end-stage renal disease, in pathological variants. 
Sensitivity analysis was used to prove the utility of the Col-class to predict renal outcomes. 
Additionally, the renal protective effects of steroids and/or immunosuppression (steroid/IS) 
were investigated in patients stratified according to Col-class.
Results: The patients were classified into the variants as follows: not otherwise 
specified (NOS) (n=120, 60%), perihilar (n=31, 15%), cellular (n=24, 12%), tip (n=15, 
7%), and collapsing variant (n=11, 5%). No tip variant patients reached the renal endpoint. 
The renal outcome in the collapsing variant was significantly poorer than those in the NOS 
(hazard ratio [HR] 3.65, P=0.010), while the outcome in perihilar and cellular variant were 
similar to those in NOS. In the sensitivity analysis, the area under the receiver operating 
characteristics curve for the renal endpoint was increased by adding Col-class to a model 
including common risk factors (P=0.041). Steroid/IS use was associated with good renal 
outcome in the cellular variant (HR 0.03, P=0.017).
Conclusions: The Col-class is useful to predict renal prognosis in Japanese patients 
with FSGS. In addition to good prognosis in the tip and poor in the collapsing variant, renal 
protective effect of steroid/IS in the cellular variant was newly revealed.
Effect of steroid/immunosuppressant use on composite renal survival in each pathological 
variant of focal segmental glomerulosclerosis.
FR-PO1136 Poster Friday
Pediatric Nephrology - I
Systolic Blood Pressure Z-Score Accurately Predicts Development of 
Posterior Reversible Encephalopathy Syndrome in Children
Emily K. Gall, Andrew M. South. Wake Forest School of Medicine, Winston-
Salem, NC.
Background: While posterior reversible encephalopathy syndrome (PRES) is often 
reversible, it increases morbidity and mortality in children and adults. High blood pressure 
(BP) is a major risk factor for PRES and is thought to alter cerebral vascular autoregulation 
leading to vasogenic edema. However, little is known about what severity of high BP 
predicts PRES, especially in children, as most patients with high BP do not develop PRES. 
The purpose of this study is to determine a clinically meaningful BP threshold above which 
the risk of developing PRES is increased.
Methods: We recorded the maximum systolic BP and diastolic BP and BP z-scores 
in the 14 days preceding development of PRES in a case-control study of 35 children with 
PRES compared to 14 controls matched on similar risk factors (underlying disease, renal 
function, and medications) and who had clinical concern for PRES but had normal brain 
magnetic resonance imaging. We used logistic regression models to determine the effect 
of maximum BP on the risk of developing PRES, reported as odds ratios with 95% CI. We 
then constructed receiver operator characteristic (ROC) curves for different maximum-BP 
cut points to determine their prognostic ability to predict PRES and calculated sensitivity, 
specificity, and positive and negative predictive values.
Results: Cases had a higher rate of baseline hypertension (97.1% vs 64.3%, p=0.005) 
but were otherwise well matched. 14-day maximum SBP z-score was strongly associated 
with PRES (OR 4.0, 95% CI 1.6 to 9.6). ROC analysis revealed that 14-day maximum 
SBP z-score ≥3.0 accurately predicted PRES (AUC 0.95, 95% CI 0.88 to 1.0) with 91.2% 
sensitivity (95% CI 81.4 to 100%) and 84.6% specificity (65.2 to 100%), indicating a 
positive predictive value of 93.9% (84.3 to 100%) and a negative predictive value of 78.6% 
(56.9 to 100%).
Conclusions: Our study demonstrated that a maximum SBP z-score of 3.0 or higher 
in the preceding 14 days accurately predicted PRES development in pediatric cases as 
compared to controls with similar risk factors. This indicates that the SBP 99th percentile for 
age, sex, and height (equivalent to a z-score of 3.0) may be a clinically relevant threshold 
indicating that aggressive BP reduction is warranted in children at high risk for PRES in 
order to prevent target organ damage in the brain.
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Standardizing and Optimizing Blood Pressure Measurement Across 16 
Pediatric Transplant Centers: The Improving Renal Outcomes 
Collaborative
Michael E. Seifert,1 Rouba Garro,2 Roshan P. George,2 Gina-Marie Barletta,13 
Craig W. Belsha,6 Abanti Chaudhuri,16 Jens W. Goebel,7 David B. Kershaw,5 
Debora Matossian,15 Jason Misurac,4 Corina Nailescu,8 Christina R. Nguyen,17 
Meghan Pearl,9 Ari Pollack,14 Cozumel S. Pruette,10 Pamela Singer,11 
Bradley A. Warady,12 Devesh S. Dahale,3 David K. Hooper.3 Improving Renal 
Outcomes Collaborative 1University of Alabama at Birmingham, Birmingham, 
AL; 2Emory Children’s Center, Atlanta, GA; 3Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH; 4University of Iowa, Iowa City, IA; 5University 
of Michigan, Ann Arbor, MI; 6Saint Louis University, Saint Louis, MO; 
7Children’s Hospital Colorado, Aurora, CO; 8James Whitcomb Riley Hospital 
For Children, Indianapolis, IN; 9Mattel Children’s Hospital at UCLA, Los 
Angeles, CA; 10Johns Hopkins University, Baltimore, MD; 11Cohen Children’s 
Medical Center, New Hyde Park, NY; 12Children’s Mercy Kansas City, Kansas 
City, MO; 13Pediatric Kidney Disease & Hypertension Centers, Phoenix, AZ; 
14Seattle Children’s Hospital, Seattle, WA; 15Lurie Children’s Hospital, Chicago, 
IL; 16Stanford University, Stanford, CA; 17Children’s Hospital of Pittsburgh of 
UPMC, Pittsburgh, PA.
Background: Hypertension is prevalent in 60-90% of pediatric renal transplant 
recipients. Uncontrolled hypertension contributes to cardiovascular (CV) death and graft 
loss. Non-standardized blood measure (BP) measurement limits the ability to control 
hypertension in this population. Here, we report efforts from the Improving Renal 
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Outcomes Collaborative (IROC) to standardize appropriate BP measurement across 16 
pediatric kidney transplant centers.
Methods: In total, 16 centers participated in structured quality improvement (QI) 
activities as facilitated by the IROC QI fundamentals course. We prospectively collected 
clinic BP data from August 2016 to May 2018 and calculated the proportion of visits with 
appropriate BP measurement according to 5 criteria from published guidelines. For each 
center, data were analyzed over 2 time periods: a 12-week baseline pre-intervention period 
and a 20-week post-intervention period. We used run charts to quantify improvements in 
BP measurement.
Results: We analyzed BP measurement data from 5,242 transplant clinic visits. Prior 
to IROC interventions, BP was measured appropriately at 10% of visits. Less than 15% 
of centers were measuring arm circumference, allowing 5 minutes of rest, or averaging 2 
manual readings if the initial BP was elevated. Within 10 weeks post-intervention, BP was 
measured appropriately at 85% of visits. This improvement was sustained for at least 10 
weeks (Figure).
Conclusions: Using the infrastructure of the IROC learning health system, we 
standardized BP measurement across 16 pediatric transplant centers, allowing for more 
accurate assessment of BP and further interventions to reduce CV risk in pediatric kidney 
transplant recipients.
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Effect of Elevated Systolic Blood Pressure and Pulse Pressure on the 
Progression of CKD in Children
Rupesh Raina,1,2 Vinod Krishnappa,3 Shyam sunder R. Polaconda,4 
Gaurav Kapur,5 Kirsten Kusumi,6 Maroun Mhanna.7 1Cleveland Clinic Akron 
General, Broadview Heights, OH; 2Pediatric Neprhology, Akron Children’s 
Hospital, Akron, OH; 3Akron Nephrology Associates/Cleveland Clinic Akron 
General, Akron, OH; 4Akron Nephrology Associates, Akron, OH; 5Children’s 
Hospital of Michigan, Detroit, MI; 6Akron Children’s Hospital, Akron, OH; 
7Metrohealth Medical Center, Cleveland, OH.
Background: Increased systolic blood pressure (SBP) and pulse pressure (PP) are 
associated with the progression of chronic kidney disease (CKD) and there is a good 
correlation between increased left ventricular mass index (LVMI) and decline in glomerular 
filtration rate (GFR). However, the exact nature of the relationship between PP, SBP, and 
LVMI has not been established in children with CKD, which this study aims to investigate.
Methods: This is a retrospective study of pediatric patients with CKD utilizing Chronic 
Kidney Disease in Children (CKiD) database from the National Institute of Diabetes and 
Digestive Kidney Disease (NIDDK) registry. Only children with iohexol-based GFR 
(iGFR) < 60 ml/min/1.73 m2(n=620) were included for analysis. Analysis of relationships 
between SBP vs iGFR, diastolic blood pressure (DBP) vs iGFR, PP vs iGFR and LVMI vs 
iGFR were done using a two-tailed significance test and Pearson’s correlation coefficient. 
Statistical analysis was done using SPSS software.
Results: The clinical characteristics at baseline were age 9.8 ± 4.4 years (mean 
± SD), iGFR 37.9 ± 12.1 ml/min/1.73 m2, SBP 107.9 ± 13.5 mm Hg, DBP 66.3 ± 11.4
mm Hg, PP 41.7 ± 10.8 mm Hg, and LVMI 30.9 ± 9.3. Increasing SBP and PP strongly
correlated with decreasing iGFR (r=-0.16, p<0.001 and r=-0.08, p<0.003) (Figures 1 & 2). 
Increasing DBP also correlated well with decreasing iGFR (r=-0.11, p<0.01). This inverse 
relationship was also maintained between LVMI and iGFR (r=-0.09, p<0.05). No significant 
association found between PP and LVMI (r = 0.037; p = 0.334).
Conclusions: A strong inverse relationship exists between iGFR and LVMI, SBP, DBP, 
PP. These findings suggest that effective blood pressure control is of paramount importance 
in CKD children to decrease the rate of decline in renal function.
Figure 1 & 2. Relationship between iohexol-based GFR (iGFR)with systolic blood pressure 
and pulse pressure in children with chronic kidney disease
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Hypertension in Children with Acute Lymphoblastic Leukemia in the 
Modern Era
Reeti Kumar,1 Suzanne Reed,1 John D. Mahan.2 1Nationwide Children’s 
Hospital, Columbus, OH; 2Nationwide Children’s Hospital, Columbus, OH.
Background: In recent decades, the prognosis of acute lymphoblastic leukemia (ALL) 
has improved with innovations in chemotherapy, bone marrow transplantation (BMT), 
& better supportive therapy. Given these better outcomes, understanding & managing 
complications associated with ALL have become more important. Hypertension (HTN) is 
a known complication of ALL & has been attributed to multiple factors, including renal 
leukemic infiltration, AKI, & high dose steroids. There is a paucity of data on the incidence 
of HTN in children diagnosed with ALL in the recent decades. Prior studies have shown 
wide variation in incidence of HTN ranging from 6.3-52.9% in children with ALL. The 
aim of this study is to define the incidence of acute & chronic HTN in pediatric patients 
diagnosed with ALL in more recent years.
Methods: This study is a retrospective chart review of pediatric patients diagnosed 
with ALL at Nationwide Children’s Hospital between 1/1/2008 & 12/31/2016. BP data 
was collected from diagnosis to 9 yrs post-diagnosis or until a following end point: lost to 
follow-up, received BMT, or deceased. BP values obtained in the lower extremity or while 
the patient was agitated were excluded. Acute HTN was defined as systolic blood pressure 
(SBP) %/or diastolic blood pressure (DBP) ≥ 95th %tile for age/height at diagnosis & 1 
month post diagnosis. Chronic HTN was defined as 2 consecutive SBP %/or DBP readings 
≥ 95th %tile for age/height 6 months or more after ALL diagnosis.
Results: 222 patients were reviewed. The incidence of acute HTN was 35% & chronic 
HTN 34%. 52% of pts who had acute HTN developed chronic HTN, whereas 24% of pts 
who were normotensive in 1st month of diagnosis developed chronic HTN. There was 
an overall trend in increased HTN indices (subject’s BP/subject-specific 95th %tile) from 
diagnosis to 1 month post diagnosis. Median HTN indices for SBP increased from 0.98 to 
1.04 & for DBP increased from 0.91 to 1.00. A large percentage of hypertensive patients 
did not receive anti-HTN therapy - 55% with acute HTN & 76% with chronic HTN were 
untreated.
Conclusions: Among children with ALL, there is a high incidence of HTN at time of 
diagnosis & in long-term follow-up. There is an overall trend for higher blood pressures after 
initiation of induction chemotherapy. In children with ALL, HTN often goes undiagnosed & 
untreated & yet is likely to convey long term sequelae.
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Left Ventricular Mass Index (LVMI) Improves with Resolution of 
Hypertension in Incident Pediatric Hemodialysis Patients
Shweta S. Shah,1,2 Alisa A. Acosta,1,2 Sarah J. Swartz,1,2 Jessica Geer,1 
Marisa D. Juarez,1 Poyyapakkam Srivaths.1,2 1Texas Children’s Hospital, 
Houston, TX; 2Baylor College of Medicine, Houston, TX.
Background: Left ventricular hypertrophy (LVH), determined by increased left 
ventricular mass indexed for allometric height^ 2.7 (LVMI), is highly prevalent in children 
receiving chronic dialysis (CD). Natural history of LVH in pediatric (ped) CD patients (pts) 
is not well known; one study showed no change in LVMI after 6 months of starting CD. We 
have shown LVMI improves with control of HTN in CD patients. For this study, the aim 
was to investigate the relationship of fluid overload (FO) and HTN with LVMI in incident 
HD patients.
Methods: Retrospective chart review from a single center to identify pts starting HD 
from 2012-2017. Pts with echocardiogram (ECHO) within 3 months of starting HD and 
repeat ECHO in 6-12 months while continuing HD were included. Pts were excluded if 
follow up ECHO was not available or pts initiated CD at another center and initial ECHO 
not available. Charts reviewed for demographics, relevant labs, hypertension (HTN) defined 
by treatment with antihypertensive meds; FO as identified by % above dry wt; LVMI was 
converted to percentiles based on published normative values for age and gender.
Results: 43 pts (22 male), mean age 13.1 (range 3-17.41 years); 38/43 pts who had 
HTN at HD initiation also had increased LVMI (96.6 ± 8.09%tile vs. 81.25 ± 12.5%tile). 
Mean LVMI from initiation decreased significantly on follow up ECHO (initiation 94.7 ± 
9.94 %tile vs. 81.13 ± 24.8%tile, p= 0.0006), independent of age or gender. Those who had 
resolution of HTN had improved LVMI, while those with continued HTN did not improve 
LVMI (Table). Pts in our study had only minimal FO over the 6-12 month period: (3.6 ± 1.2 
%, range 1.25% -6.54%). FO was not associated with LVMI change (mixed effects model 
p=0.2). Hgb, phosphorus, calcium or PTH were also not associated with LVMI change.
Conclusions: Ped HD pts with HTN at initiation had elevated LVMI. LVMI improved 
significantly within 6-12 months of HD initiation. Hypertension resolution was associated 
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with improvement of LVMI. In our population of pts with tight fluid control, FO was not 
associated with change in LVMI.
*p=0.003, ** NS; paired t test
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Left-Ventricular Hypertrophy and Diastolic Dysfunction in Korean 
Children with CKD: Data from the KNOW-Ped CKD Study
Yeonhee Lee,1 Heeyeon Cho,1 Hyun Jin Choi,2 Hee Gyung Kang,2 IL-Soo Ha,2 
Hae Il Cheong,2 Kyoung Hee Han,3 Seong heon Kim,4 Min Hyun Cho,5 Jae 
Il Shin,6 Hyesun Hyun,7 Joo Hoon Lee,8 Young seo Park.8 1Pediatrics, Samsung 
Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic 
of Korea; 2Pediatrics, Seoul National University Children’s Hospital, Seoul, 
Republic of Korea; 3Pediatrics, Jeju National University School of Medicine, 
Jeju, Republic of Korea; 4Pediatrics, Pusan National University Children’s 
Hospital, Yangsan, Republic of Korea; 5Pediatrics, Kyungpook National 
University Hospital, Daegu, Republic of Korea; 6Pediatrics, Yonsei University 
College of Medicine, Seoul, Republic of Korea; 7Pediatrics, St. Vincent’s 
Hospital, The Catholic University College of Medicine, Suwon, Republic of 
Korea; 8Pediatrics, Asan Medical Center, Seoul, Republic of Korea.
Background: Left-ventricular (LV) hypertrophy (LVH) and LV diastolic dysfunction 
are early marker of cardiovascular disease in pediatric chronic kidney disease (CKD), and 
the early detection of LVH is important to prevent morbidity and mortality in children with 
CKD. However, there is no consensus on the ideal method of defining LVH in pediatric 
CKD patients. The aim of this study was to evaluate the LVH measurement methods and 
the association the presence of LVH and LV diastolic dysfunction in Korean children with 
CKD.
Methods: We used the baseline data of the KoreaN cohort study for Outcome in 
patients With Pediatric Chronic Kidney Disease (KNOW-Ped CKD), a nationwide, 10-
year, prospective, observational cohort study of pediatric CKD. A total 310 patients were 
included in the final analysis.
Results: The mean age of the patients was 10.3±5.2 years, and male to female ratio was 
2.2:1. The mean value of LV mass index (LVMI) was 38.3g/m2.7. The mean ejection fraction 
and fractional shortening was 66.8 and 36.6%, respectively. According to an LVH diagnosis 
by LVMI ≥ 38.6 g/m2.7, 128 patients (41.3 %) were diagnosed with LVH. Using the z-score 
> 1.64 reference values, 19 patients (6.1 %) were diagnosed with LVH. According to the
ratio of early/late diastolic myocardial velocity (E/A ratio < 0.9 or > 2.0), 101 patients (32.5 
%) had diastolic dysfunction. Sixteen patients (6.4 %) were diagnosed as having diastolic
dysfunction by mitral peak velocity of early filling to early diastolic mitral annular velocity 
(E/E’ ratio > 15). Kappa coefficient showed a significant value of 0.076 between LVH 
by LVMI >38.6g/m2.7 and diastolic dysfunction by E/E’ ratio > 15. LVMI calculation for
predicting E / E ‘> 15 by Youden’s index method is 32.1g/m2.7
Conclusions: The study suggests that the definition of LVH by LVMI ≥ 38.6 g/m2.7 
could be more associated with diastolic dysfunction according to E/E’ > 15. Further 
investigation to find a better method of defining LVH to predict cardiac dysfunction in the 
children with CKD is necessary.
Funding: Government Support - Non-U.S.
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Secular Trends in Prevalence of Hypertension and Elevated Blood 
Pressure Among Korean Children and Adolescents: The Korea National 
Health and Nutrition Examination Survey 2007-2015
Yeonhee Lee,1 Hyesun Hyun,2 Heeyeon Cho.1 1Pediatrics, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, Republic of 
Korea; 2Pediatrics, St. Vincent’s Hospital, The Catholic University College of 
Medicine, Suwon, Republic of Korea.
Background: Hypertension is an important health problem and the prevalence of 
hypertension in children and adolescents has been gradually increasing. We aimed to 
analysis the recent trends in blood pressure (BP) levels and the prevalence of hypertension 
among Korean children and adolescents. We also analyzed the potential contributing factors.
Methods: This study examines data obtained from the Korea National Health and 
Nutrition Examination Survey (KNHANES) 2007-2015 which were combined into 3 
time periods (2007-2009, 2010-2012, and 2013-2015). The KNHANES is a nationally 
representative surveillance system, which has been conducted cross-sectionally since 1998 
by the Korea Centers for Disease Control and Prevention and the Ministry of Health and 
Welfare. In the present study, a total of 7,889 Korean children and adolescents aged 10-18 
years were included.
Results: The distributions of sex and age were not significantly different across 3 periods 
(2007-2009, 2010-2012, and 2013-2015). There were no significant changes in proportion 
of obesity and overweight from 2007-2009 to 2013-2015, while body mass index z-score 
significantly increased in total population from 2007-2009 to 2013-2015. Additionally, 
weight circumference and abdominal obesity were significantly increased from 2007-2009 
to 2013-2015. For dietary factors, daily intake of calories, total fat, carbohydrate, protein 
and fiber increased, while daily intake of sodium decreased significantly. Mean systolic 
BP levels significantly increased from 2007-2009 to 2013-2015 in total population, while 
diastolic BP values did not increase in total population. In 2013-2015, the prevalence of 
elevated BP and hypertension were 8.8% and 9.0%, respectively. Compared to those in 
2007-2009, the prevalence of elevated BP in 2013-2015 increased in total population, 
especially, boys, and obese subgroup. The prevalence of hypertension in obese group in 
2013-2015 was 27.7%, which was significantly increased from 2007-2009 to 2013-2015. 
Regression analysis revealed the association between central obesity and diastolic BP. Girls 
were less likely to have hypertension than boys.
Conclusions: Mean systolic BP and the prevalence of elevated BP increased from 
2007-2009 to 2013-2015. The possible influencing factor is obesity, and further analysis 
is necessary.
Funding: Government Support - Non-U.S.
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Association of Body Mass Index with CKD and Hypertension 4 Years 
After Pediatric Cardiac Surgery
Michael Zappitelli,1 Chirag R. Parikh,2 Jason H. Greenberg,3 Paul L. Kimmel,4 
James S. Kaufman,5 Prasad Devarajan.6 ASSESS-AKI investigators 1Toronto 
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 2Yale 
University and VAMC, New Haven, CT; 3Yale University, New Haven, CT; 
4National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), 
Bethesda, MD; 5VA New York Harbor Healthcare System, New York, NY; 
6Cincinnati Children’s Hospital, Cincinnati, OH.
Background: We previously found that children undergoing cardiac surgery (CS) are 
at high risk of developing chronic kidney disease (CKD) and hypertension (HTN); however, 
CKD was not associated with post-operative (postop) acute kidney injury. Hypothesis: 
Body mass index (BMI) and peri-operative factors are associated with long-term CKD and 
HTN development after pediatric CS (PedCS).
Methods: Prospective cohort study (Montreal, Canada; Cincinnati, USA). Subjects: 
<18 years(y) old having CS, recruited pre-operatively (preop) followed postop and serially 
for 4y. At 4y, clinical data, height/weight, blood pressure (BP), blood and urine were 
collected. 4y outcomes: CKD (eGFR<90ml/min/1.73m2) or albumin-to-creatinine ratio≥3 
mg/mmol; HTN: BP≥95th percentile. Age at surgery <1y, RACHS-1 (surgical complexity 
score)≥3, preop eGFR, and 4y BMI z-score and overweight (OW, BMI≥85th percentile), 
were compared between outcome groups. 4y BMI association with CKD (adjusted for 
perioperative factors) was evaluated using multiple logistic regression (LR).
Results: 96/124 children had 4y data available: 24% had CKD; 13% had HTN; 22% 
were OW. Age<1y at surgery, RACHS-1≥3, smoking and OW were more common in 
CKD vs. no CKD patients(Table). No study variables were significantly associated with 4y 
HTN(Table). In multiple LR including age, RACHS-1 and preop eGFR, age<1y at surgery 
and each 10-unit decrease in preop eGFR were associated with a 5.9 (95% CI 1.8-18.6)-fold 
and 1.2 (95% CI 1.0-1.4)-fold adjusted risk for 4y CKD, respectively. When adjusted for 
age, RACHS-1 and preop eGFR, each 1 unit BMI z-score increase (at 4y) was associated 
with 1.5 (95% CI 1.0-2.2)-fold adjusted risk for 4y CKD. Sample size did not allow for LR 
analysis on HTN risk.
Conclusions: Young age at surgery and OW at follow-up are associated with CKD 4y 
after PedCS. Research is needed to understand the relation between young age and other 
risk factors for CKD development after PedCS. Post-PedCS interventions should aim to 
reduce long-term cardiovascular risk.
Funding: NIDDK Support
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Diacylglycerol Kinase Epsilon (DGKE) Deficiency in Endothelial Cell 
Results in Marked Abnormalities in Phosphoinositides
Vincent So,2 Christopher H. Choy,3 Joanne Grimmer,4 Roberto Botelho,3 
Alexis Traynor-Kaplan,5 Mathieu Lemaire.1 1Nephrology/Cell Biology, Hospital 
for Sick Children, Toronto, ON, Canada; 2University of Toronto, Hospital for 
Sick Children, Markham, ON, Canada; 3Ryerson University, Toronto, ON, 
Canada; 4Children’s Hospital of Western Ontario, London, ON, Canada; 
5University of Washington, North Bend, WA.
Background: Loss-of-function mutations in DGKE cause a rare form of atypical 
hemolytic-uremic syndrome (aHUS) that does not implicate complement hyperactivation. 
Patients are typically diagnosed before age 1, have disease relapses until age 5 and develop 
end-stage kidney disease before adulthood. There is currently no treatment, but renal 
transplantation is safe. Diacylglycerol (DAG) is produced when phosphatidylinositol 
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4,5-bisphosphate (PIP2) is cleaved by phospholipase C. DGKE is a lipid kinase that 
phosphorylates DAG to phosphatidic acid (PA). When produced, PA is shuttled to the 
endoplasmic reticulum where it is used to reconstitute the pool of PIP2 (as part of the PI 
cycle). The consequences of DGKE deficiency in human endothelial cells are unknown. 
A better understanding of DGKE disease pathophysiology is critical to developing new 
therapies for these patients. Our objective is to quantify the impact of DGKE deficiency 
in endothelia on membrane lipids that play key roles in DGKE biology, including 
diacylglycerol, phosphatidic acid and phosphoinositides.
Methods: We used orthogonal methods to compare the lipid levels in wild-type and 
DGKE-deficient endothelial cells derived from human vein endothelial cells (HUVEC) 
with a CRISPR/Cas9-engineered deletion in the DGKE gene. These methods included mass 
spectrometry lipidomics, cellular labelling with 3H-inositol followed by high-performance 
liquid chromatography (HPLC), and live-tracking of transfected fluorescent-labelled PIP2 
biosensor. The novel mass spectrometry lipidomics approach that we developed was also 
applied to an endothelial cell line derived from a patient with novel pathogenic DGKE 
mutations (c.A494G; p.D165G) and glomeruli extracted from the kidneys of a new Dgke-
null mouse model (generated with CRISPR/Cas9).
Results: Mass spectrometry lipidomics revealed significant PIP2 reduction in DGKE-
null HUVEC. These results were corroborated using the same protocol applied to a patient-
derived endothelial cell line and glomeruli from Dgke-null mice. 3H-inositol labelling and 
fluorescent lipid biosensor experiments confirmed a significant reduction in PIP2 in DGKE-
deficient HUVEC.
Conclusions: Low endothelial PIP2 levels is likely to play a central role in the triggering 
the pro-thrombotic phenotype observed in patients with DGKE aHUS.
Funding: Other NIH Support - Kidney Foundation of Canada
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Child and Parental Perspectives on Communication and Decision-Making 
in Pediatric CKD: A Focus Group Study
Talia M. Gutman,2,1 Camilla S. Hanson,2,1 Sarah Bernays,2 Jonathan C. Craig,1,3 
Allison Tong.2,1 SONG-Kids Investigators and SONG-Kids Steering Group 
1Centre for Kidney Research, The Children’s Hospital at Westmead, Bondi 
Junction, NSW, Australia; 2School of Public Health, The University of Sydney, 
Sydney, NSW, Australia; 3College of Medicine and Public Health, Flinders 
University, Adelaide, SA, Australia.
Background: Effective communication and shared decision-making improves quality 
of care and patient outcomes, but can be particularly challenging in pediatric chronic 
disease as children depend on their parents and clinicians to manage complex healthcare 
and developmental needs. This study aims to describe the perspectives of children with 
chronic kidney disease (CKD) and their parents with regard to communication and 
decision-making.
Methods: Children with CKD (n=34) and parents (n=62) from six centers across six 
cities in Australia, Canada and the United States participated in 16 focus groups. Transcripts 
were analyzed thematically.
Results: We identified four themes: (1) disempowered by knowledge imbalance 
(unprepared and ill-informed, suspicion of censorship, inadequacy as technicians); (2) 
recognizing own expertise (intuition and instinct unique to parental bond, emerging 
wisdom and confidence, identifying opportunities for control and inclusion, empowering 
participation in children); (3) striving to assert own priorities (negotiating broader life 
impacts, choosing to defer decisional burden, overprotected and overruled, struggling to 
voice own preferences); and (4) managing child’s involvement (respecting child’s expertise, 
attributing ‘risky’ behaviors to rebellion, protecting children from illness burden).
Conclusions: Parents value partnership with clinicians and consider long-term 
and quality of life implications of their child’s illness. Children with CKD want more 
involvement in treatment decision-making but are limited by vulnerability, fear, and 
uncertainty. There is a need to support the child to better enable them to become partners 
in decision-making and prepare them for adulthood. Collaborative and informed decision-
making that addresses the priorities and concerns of both children and parents is needed.
Funding: Government Support - Non-U.S.
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Timing of Dialysis Education and Patients’ and Families’ Preferences in 
Children with CKD
Julien Hogan,1 Runze Li,1 Michael Arenson,1 Rachel E. Patzer,2 
Larry A. Greenbaum.1 1Emory University, Atlanta, GA; 2Emory Transplant 
Center, Atlanta, GA.
Background: There is no strong evidence favoring PD or HD in children; it is 
recommended that patients actively participate in the choice of dialysis modality. The 
first step for including patients in the decision-making process is to provide them with 
information on dialysis modalities. However, there is currently limited data on the timing of 
RRT education in children with CKD and on families’ and patients’ preferences.
Methods: The CKiD study is a prospective cohort study that enrolled patients 1–16 yrs 
with an eGFR of 30–90 mL/minute/1.73 m2. Clinical data and laboratory data are collected 
annually. Patients and families are asked at baseline and annually about the information 
received on dialysis modalities and their preferred dialysis modality. Logistic regression 
was used to study factors associated with education status.
Results: 240/370 patients reported not having received any information on RRT prior 
to inclusion in the cohort. Patients informed at baseline were more likely to have advanced 
CKD; there was a trend toward a lower probability of information in African American 
patients or if no family history of CKD. There was no association between CKD duration 
and the probability of information on RRT. Among the 94 patients who discussed dialysis 
with their provider during follow-up, 69 (73%) had no preference between PD and HD. 
Among them, 22 had repeated assessment of their preference; 5 decided on HD, 3 on PD. 
CKD progression was the only factor associated with change in modality preference. 118 
patients discussed transplantation with their provider during follow-up; 23 discussed only 
deceased donor transplantation, 3 only living donor, 22 both options and 70 reported not 
being informed of donor sources.
Conclusions: Patient and family self-reported prevalence of education on RRT is low. 
Starting education on RRT at earlier CKD stages and focusing on populations reporting a 
low level of information such as African American patients and patients with no familial 
history of kidney disease may improve education rates. Moreover, the extremely low rate of 
selecting a dialysis modality is very concerning and could lead to less thoughtful decision-
making when patients approach ESRD. Further studies are needed to develop educational 
interventions and assess their ability to help the patients and families choose their dialysis 
modality.
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Sex and Glomerular Filtration Rate Trajectories: Insights from the CKiD 
Cohort Study
Julien Hogan,1 Geeta Karadkhele,1 Stéphanie Bonneric,2 Rachel E. Patzer,1 
Larry A. Greenbaum.1 1Emory University, Atlanta, GA; 2Hôpital Robert Debré, 
Paris, France.
Background: The effect of gender on CKD progression has not been specifically 
studied in children. Moreover, differences in CKD progression have been hypothesized to 
partially explain gender disparities in access to transplantation. This study aims to identify 
distinct trajectories of GFR decline and to investigate the effect of gender on GFR decline.
Methods: The CKiD study is a prospective cohort study that enrolled patients 1–16 yrs 
with an eGFR of 30–90 mL/minute/1.73 m2. Clinical and laboratory data, including GFR, 
are collected annually. Latent class mixed model was used to identify GFR trajectories. 
Multinomial logistic regression was used to study patient characteristics associated with 
each trajectory.
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Results: 888 patients were included. Among nonglomerular patients (613), we 
observed 4 GFR trajectories: 35 with median baseline GFR/no decline; 327 with high 
baseline GFR/slow decline; 231 with low baseline GFR/slow decline and 20 with high 
baseline GFR/rapid decline (Figure 1, class 1 to 4 respectively). Known risk factors of 
progression differed between trajectories. The proportion of girls was higher in the group 
with stable GFR (57%) than in other groups (32-35%). Patients with stable GFR had lower 
prevalence of acidosis, anemia and proteinuria. Female gender remained associated with 
the absence of progression (OR 2.7 [1.3-5.5]) after adjusting for other risk factors. This 
effect remained after stratification on pubertal status. Among glomerular patients (275), 
progression was mostly related to the underlying glomerulopathy.
Conclusions: The slower progression in girls is driven by a subgroup with 
nonglomerular diseases and stable GFR. The effect of gender seems independent of pubertal 
status, arguing against a direct effect of sex hormone to explain gender disparity in CKD 
progression.
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Impact of Chronic Illness in Children on Families: Kidney Disease (KD) 
versus Diabetes Mellitus (DM)
Howard Trachtman,1 Laura Malaga-Dieguez,1 Suzanne M. Vento,2 Laura 
Jane Pehrson,1 Sandra L. Rodgin,1 Hayley Y. Adkisson,1 Lara Brodzinsky,1 
Rebecca Lois,1 Jeniece Ilkowitz,1 Mary P. Gallagher.1 1NYU Langone Health, 
New York, NY; 2NYU Langone Health, New York, NY.
Background: Chronic illness in children has adverse effects on family members 
besides the patient and can impact the integrity and function of the family unit. Most 
previous studies have examined a single disease entity. However, there has been limited 
assessment comparing the effect of different illnesses on family function.
Methods: Established patients treated in the pediatric ambulatory Nephrology or 
DM clinics were included in the study. Their parents were asked to complete the 2-page 
Pediatric Quality-of-Life Family Impact Module (PedsQL-FIM), version 2.0, a validated 
survey instrument. Clinical and laboratory data were retrieved from the electronic health 
record. Data were summarized as mean±SD. Disease group and child age were entered 
as predictors in linear regression analyses with FIM total and subscale scores as outcome 
variables. Comparisons between groups were assessed using paired t-tests.
Results: 96 patients (43 F: 53 M) were evaluated in the Nephrology Clinic and 55 
(30 F: 25 M) in the DM Clinic. The mean age of the patients was 13.0±3.9 and 10.4± 6.3 
yr, respectively. Within the KD sample, older age was significantly associated with lower 
scores on all FIM subscale scores. Gender was not a significant predicator for FIM scores in 
either disease group. Controlling for age, chronic illness group was a significant predictor 
of the FIM total and subscale scores. Parents of D patients endorsed significantly lower 
total FIM scores compared to the KD patients (D 58±16; KD 79±17 p <0.001) as well as on 
subscales of physical, emotional, social, and cognitive functioning, communication, worry, 
daily activities, family relationships, and reports of health-related quality of life (P<0.01).
Conclusions: Our findings confirm that chronic illness in childhood adversely affects 
a wide range of aspects of family function. The impact is greater in older children with 
KD and varies depending on the disease context. Families with children who have DM 
manifested greater disturbances than those with children who have isolated KD. Further 
study is warranted to assess the effects of the underlying renal disease and intensity of 
medical care and whether there are specific features can be used to identify vulnerable 
families.
Funding: NIDDK Support, Clinical Revenue Support
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Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) 
Levels During Pregnancy
Howard Trachtman,1 Suzanne M. Vento,1 Joseph F. Gilbert,1 Tony T. Koshy,1 
Yelena Afanasyeva,1 David C. Wei,3 Jochen Reiser,2 Leonardo Trasande.1 1NYU 
Langone Health, New York, NY; 2Rush University Medical Center, Chicago, IL; 
3Rush University, Chicago, IL.
Background: suPAR is an inflammatory mediator that has been linked to the 
pathogenesis of FSGS and progression of chronic kidney disease in children and adults. 
Overexpression of suPAR leads to reduced nephron development in preclinical models. 
This study was designed to measure suPAR in pregnant women to determine the range 
of fetal exposure to this molecule and its potential influence on antenatal human kidney 
growth.
Methods: Pregnant women enrolled in the Children’s Health and Environment Study 
(CHES) provided serum samples obtaining during 1-3 trimesters. Clinical information 
was obtained from the electronic health record. suPAR levels were determined by ELISA 
(Virogates, Copenhagen, Denmark). Data are presented as mean±SD. Results were analyzed 
by Pearson correlation and ANOVA.
Results: 515 mothers were studied, age 31±6 yr, and racial distribution 44% Caucasian, 
7% African American, 9 % Asian, and 41% other/unspecified. 46% of the women were 
Hispanic. 29% had completed a high school education or less and 28% had an annual 
income <$50,000. There were 464 livebirths, 50.4% girls. The serum suPAR levels (mean, 
SD, minimum, maximum) are summarized in the Table. The suPAR levels in the subgroup 
of women who provided more than one sample during pregnancy were closely correlated 
(r=0.79-0.94, P<0.0001)). The decline in serum suPAR levels from trimester 1 to 3 was 
highly significant (P<0.001).
Conclusions: Maternal suPAR levels are detectable throughout pregnancy but decline 
from trimester 1 to 3. The levels are highly correlated and steady during the course of 
pregnancy in an individual woman. There is more than a 10-fold range in suPAR 
concentration which may contribute to the biological variation in nephron number at birth. 
Follow-up assessment in the infants will be performed in the prospective Environmental 
Influences on Child Health Outcomes (ECHO) cohort study.
Funding: NIDDK Support
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Establishing an Organisational Entity to Support Development of 
Therapeutics in Children with CKD: A KHI Initiative
Michelle N. Rheault,1 H. William Schnaper,8 Pam Duquette,7 Debbie S. Gipson,2 
Teresa Lewis,9 Alicia Neu,10 Franz S. Schaefer,3 Melissa West,4 Johan Vande 
walle,5 Stuart Goldstein,6 Katrin Uhlig.11 1University of Minnesota, Minneapolis, 
MN; 2University of Michigan Mott Children’s Hospital, Ann Arbor, MI; 3University 
of Heidelberg, Heidelberg, Germany; 4American Society of Nephrology, 
Washington, DC; 5UZGent, Gent, Belgium; 6Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH; 7Nephcure Kidney International, Baltimore, MD; 
8Feinberg School of Medicine, Chicago, IL; 9The University of Oklahoma Health 
Sciences, Oklahoma City, OK; 10Johns Hopkins University School of Medicine, 
Baltimore, MD; 11Keryx Biopharmaceuticals, Brookline, MA.
Background: A Kidney Health Initiative (KHI) workgroup on ‘Overcoming Barriers 
to Drug Development in Children with CKD’ identified the need for more concerted and 
rational planning and conduct of clinical trials in children with CKD to address EMA and 
FDA regulatory requirement.
Methods: An Implementation Committee was charged to establish an organizational 
entity that will help optimize planning of therapeutic trials in children with CKD. Its charter 
addresses aims, guiding principles, composition of a standing Leadership Committee, 
committee operations, and funding.
Results: The aims of the new entity are to a) Enable feasibility assessment of available 
patient populations through data sharing and access to CKD pediatric registries b) Facilitate 
assessment of the capacity of various pediatric kidney clinical trial organizations c) Assist 
with identification of expertise that can provide consultation on study planning. To manage 
potential conflicts of interest, this entity needs to adhere to guiding principles regarding 
transparency, information sharing, international participation and collaboration, and 
financial independence, while respecting the rights and intellectual property of principal 
investigators, sponsors, and trial networks, and ensuring the confidentiality of proprietary 
information and protected patient information. The Leadership Committee will be comprised 
of representatives from pediatric collaborative trial networks, patient/family support groups 
and subject matter experts without industry sponsors. Operationally, industry sponsors will 
be able to submit queries and requests that will be reviewed, triaged, and addressed by 
the Leadership Committee. The Implementation Committee will draft a finance model, 
sustainability plan, and identify a permanent administrative home with a commitment to 
transparency, equity, and economy. In the interim, KHI will continue to support this entity.
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Conclusions: This new entity will seek collaboration with other stakeholders to better 
support therapeutic development in children with CKD.
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Risk Factors for Progression of CKD in Children: Results from the 
Korean Cohort Study for Outcome in Patients with Pediatric CKD 
(KNOW-Ped CKD)
Yo Han Ahn,1 Hyun Jin Choi,2 Kyoung Hee Han,3 Seong heon Kim,4 
Heeyeon Cho,5 Min Hyun Cho,6 Jae Il Shin,7 Joo Hoon Lee,8 Hee Gyung Kang,2 
Young seo Park,8 Hae Il Cheong,2 IL-Soo Ha.2 1Department of Pediatrics, Seoul 
National University Bundang Hospital, Seongnam, Republic of Korea; 
2Department of Pediatrics, Seoul National University Children’s Hospital, 
Seoul, Republic of Korea; 3Department of Pediatrics, Jeju National University 
School of Medicine, Jeju, Republic of Korea; 4Department of Pediatrics, Pusan 
National University Children’s Hospital, Yangsan, Republic of Korea; 
5Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul, Republic of Korea; 6Department of Pediatrics, 
Kyungpook National University, School of Medicine, Daegu, Republic of Korea; 
7Department of Pediatrics, Yonsei University College of Medicine, Severance 
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Medical Center Children’s Hospital, University of Ulsan College of Medicine, 
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Background: The prevalence of chronic kidney disease (CKD) has increased over the 
last decades. Several large studies of Western countries have reported risk factors of CKD 
progression in pediatric patients, while comprehensive studies on pediatric CKD are rare 
in Asian countries. We aimed to evaluate risk factors for the progression of CKD of Korea 
using KNOW-Ped CKD data.
Methods: In KNOW-PedCKD, 437 children with stage 1 to 5 of CKD were enrolled 
and 432 patients were followed more than 6 months between July 2011 and May 2017. The 
progression of CKD was defined as a composite renal event of renal replacement therapy or 
a ≥50% decline in estimated glomerular filtration rate. The baseline clinical and laboratory 
variables were analyzed.
Results: The progression of CKD occurred in 136 (31.4%) patients after median 
follow ups of 1.9 (IQR 0.7-3.2) years. In Kaplan-Meier analysis, the median renal survival 
of all analyzed CKD patients was estimated as 5.2 years. In multivariate analysis, after 
adjustment with Cox regression model, 6 variables remained as independent risk factors 
of CKD progression: male sex, CKD stage 4 and 5, hypertension, urine protein/creatinine 
ratio ≥0.5 mg/mg, serum albumin <3.8 mg/dL, and anemia. Among them, proteinuria, 
hypoalbuminemia, hypertension and anemia could be modifiable and treatable, in 
accordance to previous findings in the Western studies.
Conclusions: In KNOW-pedCKD cohort, risk factors for CKD progression in Korean 
pediatric patients were found, including modifiable factors. Applying these findings to the 
clinic might improve the outcome of pediatric CKD.
Funding: Government Support - Non-U.S.
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Observational Descriptive Analysis from the Korean Pediatric CKD 
Registry
Yo Han Ahn,1 Hyun Jin Choi,2 KyungMi Jang,3 Eun mi Yang,4 Kyoung 
Hee Han,5 Seong heon Kim,6 Jin-Soon Suh,7 Heeyeon Cho,8 Min Hyun Cho,9 
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2Department of Pediatrics, Seoul National University Children’s Hospital, 
Seoul, Republic of Korea; 3Department of Pediatrics, Yeungnam University 
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Korea; 4Department of Pediatrics, Chonnam National University Medical 
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Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic 
of Korea; 9Department of Pediatrics, Kyungpook National University, School of 
Medicine, Daegu, Republic of Korea; 10Department of Pediatrics, Yonsei 
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of Korea; 11Department of Pediatrics, Asan Medical Center Children’s Hospital, 
University of Ulsan College of Medicine, Seoul, Republic of Korea; 12Department 
of Pediatrics, Wonju Severance Christian Hospital, Wonju, Republic of Korea.
Background: The prevalence of chronic kidney disease (CKD) has increased over the 
last decades. Nevertheless, there still are limited data on epidemiology of childhood CKD 
in Korea. To improve the understanding and management of Korean pediatric patients with 
CKD, we established the Korean Pediatric CKD Registry in 2004. We aimed to assess the 
incidence and prevalence of end stage renal disease (ESRD), etiology, renal replacement 
therapy (RRT) modalities in children with CKD.
Methods: From January 2004 to December 2016, 713 patients <20 years of age with 
CKD have been registered in the Korean Pediatric CKD Registry. Demographic and clinical 
data were collected from 16 centers. Updating of the data was done at least once a year. We 
analyzed patients who started RRT before the age of 20 years.
Results: Among 713 enrolled patients, 442 patents developed end stage renal disease at 
mean age of 9.8±5.4 years. The age distribution was as follows: <5 years 21.0%, 5-9 years 
27.1%, 10-14 years 33.0%, and 18.8% were >15 years. The main causes of ESRD were 
glomerulopathy (40.7%) and congenital anomalies of kidney and urinary tract (CAKUT, 
24.8%). Glomerulopathy predominated in females, while CAKUT was the majority among 
males. The annual incidence of ESRD had increased from 1.75 per million age-related 
populations (pmarp) in 2004 to 2.58 pmarp in 2016. The point prevalence of ESRD was 2.38 
pmarp in 2004, and 4.67 pmarp in 2016. The first modality of RRT was peritoneal dialysis 
in 240 (54.3%), hemodialysis in 118 (26.7%), and preemptive kidney transplantation in 84 
(19.0%) patients. Pre-emptive kidney transplantation was more common in older age group 
(5.1% in age of 0 to <5 years and 28.9% in age of 15 to <20 years).
Conclusions: This study provided the epidemiologic profile of Korean pediatric 
patients with ESRD. The number of pediatric patients with ESRD had steadily increased. 
Peritoneal dialysis was the preferred method of RRT for children in Korea.
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Longitudinal Measures of Serum Bicarbonate and Kidney Disease 
Progression: Results from the CKiD Cohort
Denver D. Brown,1 Kimberly J. Reidy,2 Jennifer Roem,3 Derek Ng,3 Juhi Kumar,4 
Matthew K. Abramowitz,9 Susan L. Furth,5 George J. Schwartz,6 
Bradley A. Warady,7 Frederick J. Kaskel,8 Michal L. Melamed.9 1The Childrens 
Hospital at Montefiore, Bronx, NY; 2Children’s Hospital at Montefiore/ Albert 
Einstein College of Medicine, Bronxville, NY; 3Johns Hopkins Bloomberg 
School of Public Health, Baltimore, MD; 4Weill Cornell Medical College, New 
York, NY; 5The Children’s Hospital of Philadelphia, Philadelphia, PA; 
6University of Rochester, Rochester, NY; 7Children’s Mercy Kansas City, Kansas 
City, MO; 8Children’s Hospital at Montefiore, Bronx, NY; 9Albert Einstein 
College of Medicine, Bronx, NY.
Background: Acidosis is a frequent complication of pediatric CKD; however, the 
longitudinal changes of serum bicarbonate over time in glomerular and non-glomerular 
kidney disease has not been examined.
Methods: This study consisted of 787 children with at least two serum bicarbonate 
measurements in the CKiD cohort. To describe baseline bicarbonate levels and changes 
over time, linear mixed models with random intercepts were fit with bicarbonate in the 
log scale. The relationship between bicarbonate and eGFR was described using a repeated 
measures linear regression with generalized estimating equations. All analyses were 
stratified by underlying non-glomerular and glomerular diagnoses.
Results: 558 children with non-glomerular CKD contributed 3325 visits, and 229 
with a glomerular diagnosis contributed 1050 visits. The prevalence of acidosis (serum 
bicarbonate <22 mmol/L) at baseline was 38% and 28% for those with a non-glomerular 
and glomerular diagnosis, respectively (p= 0.01). The prevalence of alkali therapy at 
baseline was 30% and 8%, respectively. For those with non-glomerular disease, the mean 
baseline bicarbonate level was 23.1 mmol/L (95%CI: 22.9, 23.3) and the mean change per 
year was +0.1% (95%CI: -0.1%, +0.3%). Among those with glomerular disease, the mean 
baseline bicarbonate level was 24.0 mmol/L (95%CI: 23.6, 24.4) and the mean change per 
year was -0.4% (95%CI: -0.7%, -0.003%), indicating a significant reduction over time. 
Per 20% decrease in eGFR, those with non-glomerular CKD had a decrease of -2.39% 
(-2.79% to -1.99%) while children with glomerular disease had a -3.23% decrease (-3.72% 
to -2.74%) in their bicarbonate levels (p=0.01 for the comparison). Baseline acidosis was 
associated with a faster decline in eGFR (-6.0% [-12.8% to -1.0%] vs. -2.9% [-6.8% to 
-0.4%], p<0.001) in non-glomerular CKD but not in glomerular CKD (-4.8% [-14.9% to 
0.3%] vs. -6.0% [-14.0% to -1.4%]).
Conclusions: In non-glomerular CKD, bicarbonate levels start lower but do not 
decrease as rapidly as in children with glomerular CKD. However, low baseline bicarbonate 
levels are associated with a faster decline in eGFR only in those children with non-
glomerular CKD. Future data will assess whether these relationships may be attenuated by 
effective alkali therapy.
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Primary Care Prescriptions of Nephrotoxic Medications to Children with 
CKD
Claire Lefebvre,1 Kristian B. Filion,4 Pauline Reynier,3 Robert Platt,1 
Michael Zappitelli.2 1McGill University, Montreal, QC, Canada; 2Toronto 
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 3Lady 
davis institute, Montreal, QC, Canada; 4McGill University, Montreal, QC, 
Canada.
Background: Nephrotoxic medication (NTM) prescription practices for children with 
chronic kidney disease (CKD) are unknown. Our objective was to determine if primary care 
prescriptions of NTMs differ for children with and without CKD.
Methods: We conducted a retrospective, population-based, matched cohort study of 
patients aged <18 years registered at a general practice participating in the UK Clinical 
Practice Research Datalink (CPRD) from 1997 to 2017, with linkage to Hospital Episode 
Statistics data. Patients with incident CKD were matched 4:1 to non-CKD patients on CKD 
diagnosis date, sex, age, CPRD practice, and number of pre-cohort entry physician visits. 
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Prevalence of prescription of NTM was compared between CKD and non-CKD patients, 
with adjusted prescription rates calculated using multivariable binomial regression.
Results: From our base cohort of 1,535,816 patients, we identified 1018 with incident 
CKD and 4072 non-CKD matches; mean age: 9.8 years [range: 1.1-17.9]; 52% male; 
mean follow-up time 3.2 vs. 3.3 years in CKD vs. non-CKD patients. CKD patients had 
higher prevalences of diabetes, hypertension, heart failure/surgery, and past hospitalizations 
(p<0.01 for all). A total of 32% CKD patients and 14.6% non-CKD patients were prescribed 
≥1 NTM during follow-up (p<0.01). Excluding ACE-inhibitors and salicylates, 25.8% and 
14.5% were prescribed ≥1 NTM, respectively. From cohort entry to end of follow-up, the
proportion of CKD patients receiving ≥1 NTM remained similar (17.6%-19.5%/year).
Adjusted NTM prescription rates in CKD vs. non-CKD patients were 37.0 (95% CI 19.4-
70.6) vs. 3.7 (95% CI 2.1-6.6) prescriptions/100 person-years, respectively (rate ratio [RR]:
9.9 (95% CI 7.3-13.4). Excluding ACE inhibitors and salicylates, the adjusted RR was 4.1 
(95% CI 2.1-6.6).
Conclusions: NTMs are prescribed at elevated rates to children with CKD. There may 
be a need for awareness/education interventions aimed at primary care practitioners on 
potential harm from NTMs on pediatric CKD progression.
Funding: Government Support - Non-U.S.
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Long-Term Safety of Cinacalcet in Pediatric CKD Subjects on Dialysis
Bradley A. Warady,2 Sunfa Cheng,1 Fei Wang,1 William W. Stark,1 
Karel Vondrak.3 1Amgen INC, Newbury Park, CA; 2Children’s Mercy Kansas 
City, Kansas City, MO; 3University Hospital Prague-Motol, Prague 5, Czechia.
Background: The calcimimetic cinacalcet is indicated for treatment (tx) of secondary 
hyperparathyroidism in adults with CKD on dialysis. Its use was evaluated in pediatric 
CKD subjects (subj) on dialysis in 2 parent trials: NCT01439867 (single arm; age 28d-<6y) 
and NCT02138838 (open-label; cinacalcet vs standard of care [SOC]; age 6-<18y). This 
phase 3, single-arm, open-label extension evaluated cinacalcet use in subj who completed 
the parent trials or were still on study at early parent trial termination.
Methods: This 32-week (W) (28 tx+4 follow-up) study assessed the safety of 
cinacalcet based on incidence of tx-emergent adverse events (TEAE) of interest (primary 
endpoint [EP]). Secondary EP included ≥30% mean iPTH reduction during W11+15 
and 23+28, % mean iPTH change during W23+28 (each assessed only in SOC subj in 
NCT02138838), and ≥30% mean iPTH reduction and change in serum Ca and P during 
W23+28 (all subj). Cinacalcet subj in the parent study continued the same dose; SOC 
subj had iPTH ≥300pg/mL and Ca ≥8.8mg/dL, and received initial doses of 0.2mg/kg/d. 
Cinacalcet was titrated (up to 2.5mg/kg/d; ≤60mg/d [age <6y] or ≤180mg/d [age ≥6y]) to 
PTH ≥150-<300pg/mL and to maintain corrected Ca ≥8.4mg/dL or ionized Ca ≥1.05mmol/L 
for subj 6-<18y, and ≥9.0mg/dL or ionized Ca ≥1.13mmol/L for subj <2y.
Results: Of 28 enrolled subj, 5 discontinued tx due to renal transplant (n=2), 
parathyroidectomy, death unrelated to tx, and subj request (n=1 each). Mean (SD) age and 
cinacalcet exposure were 12.6 (3.9) y and 170 (52) d. 10 (40%) (W11-15) and 4 (18%) 
(W23-28) subj had ≥20% of doses withheld. 20 (71.4%) subj had ≥1 TEAE, most commonly 
hypocalcemia and pyrexia (n=3 each). Incidence of TEAE of interest were: hypocalcemia 
(n=5,17.9%), nervous system disorders excluding seizures (n=4,14.3%), hypersensitivity 
(n=2,7.1%), drug-related hepatic disorders, and fracture (n=1,3.6% each); none deemed 
serious. The proportion achieving ≥30% iPTH decrease is below. Median (Q1,Q3) iPTH 
change (prior SOC only) at W23+28 was 11.4% (-20.6, 27.3). Overall W23+28 median 
(Q1,Q3) serum Ca and P (mg/dL) change was -0.25 (-0.66, 0.10) and 0.06 (-0.94, 0.69).
Conclusions: There were no new/unexpected safety concerns in these pediatric CKD 
subj on dialysis.
Funding: Commercial Support - This study was funded by Amgen, Inc.
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Response to Erythropoietin in Pediatric Patients with CKD: Insights from 
an In Vitro Bioassay
Rachel Gavish,1 Salmas Watad,1 Nathalie Bencalifa,2 Ori J. Goldberg,1 
Orly Haskin,3 Miriam Davidovits,3 Gili Koren,3 Yafa Falush,3 Drorit Neumann,2 
Irit Krause.1 1Pediatrics C, Schneider Children’s Medical Center of Israel, Petah 
Tikva, Israel; 2Cell and Developmental Biology, Tel-Aviv University, Tel - Aviv, 
Israel; 3Institute of Pediatric Nephrology, Schneider Children’s Medical Center 
of Israel, Petah Tikva, Israel.
Background: Decreased production of erythropoietin (EPO) is a major cause of 
anemia associated with chronic kidney disease (CKD). Treatment with recombinant human 
EPO (rHuEPO) improves patients’ quality of life and survival, yet, there is a marked 
variability in response to rHuEPO. At present, there is no available laboratory test which 
can evaluate responsiveness to EPO treatment. The aim of the present study was to exploit 
an in vitro bioassay for estimating the inhibitory effect of uremic environment on EPO-
dependent erythroid cell proliferation
Methods: EPO-dependent human erythroleukemia cells (UT-7) were incubated with 
exogenous EPO (2u/ml) and sera obtained from 60 pediatric patients (age 1-23 years). 
Three groups were studied: 1) 12 children on dialysis (4 peritoneal, 8 hemodialysis), 2) 28 
patients with CKD1-5 (not on dialysis) and 3) 20 healthy children.
Results: Sera from dialysis patients inhibited UT-7 cell growth in comparison to the 
CKD group and healthy controls at 48 hours (p=0.003 and p=0.04, respectively) and at 
72h (p=0.02 and p=0.07, respectively). In 18 patients treated with rHuEPO, a significant 
inverse correlation was found between the EPO resistance index and cell proliferation at 48 
(p=0.007, r=-0.63) and 72 hours (p=0.03, r=-0.52).
Conclusions: Our findings support the presence of erythropoiesis inhibitory 
substances in uremic sera. EPO/EPO-R dependent mechanisms may play a role in 
inhibiting erythropoiesis. The in vitro bioassay described herein may serve as an indicator 
of rHuEPO responsiveness and enable further investigation of underlying mechanisms of 
EPO resistance
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Ultrafiltration Rates Observed in a Large Pediatric Hemodialysis Cohort 
Routinely Exceed Weight Based Adult Limit: Call for Action
Verena Gotta,1,2 Olivera Marsenic Couloures,3 Marc Pfister.4 1Pediatric 
Pharmacology and Pharmacometrics, University of Basel Children’s Hospital, 
Basel, Switzerland; 2Hosptital Pharmacy, University Hospital Basel, Basel, 
Switzerland; 3Pediatric Nephrology, Yale University School of Medicine, New 
Haven, CT; 4Pediatric Pharmacology and Pharmacometrics, University of 
Basel Children’s Hospital, Basel, Switzerland, Hilterfingen, Switzerland.
Background: Ultrafiltration rates (UFR) in adult hemodialysis (HD) patients of >10 
and especially >13 ml/kg/hr were found to be associated with greater risk of cardiovascular 
(CV) morbidity and mortality, leading to limiting UFR in adults to 13 ml/kg/hr. CV disease 
is the main cause of death in children on HD. Children have higher need for UF than adults 
to allow adequate nutrition and growth, but there is no data of UFR routinely provided to
children. This is the first study to report UFR from a large pediatric HD cohort.
Methods: We retrospectively analyzed data from 17844 HD sessions in 1592 children 
and adolescents 1-18 years and weight (wt) 8.3-163 kg, receiving standard outpatient 
HD in DaVita centers between 2004 and 2016. There were total of 2535 patient-years 
with median 16 (interquartile range (IQR): 5-42) HD sessions per patient. Median UFR 
[ml/kg/hr; (preWt-postWt)/postWt/hr)] was calculated for each patient and year of age. HD 
was provided 3x/week for a duration of 1.75-5 (median 3.25, IQR: 3.0-3.6) hrs. UFR of >10 
and >13 were analyzed in relation to age, weight and HD duration (Chi-squared/Fisher-
exact test).
Results: UFR was significantly different between patients of different age and wt, and 
among patients receiving different HD duration (Table). UFR >10 and >13 ranged between 
35-57% and 17-46% respectively based on age (P<0.05) while it was 14-62% and 1-43%
respectively based on wt (P<0.001). Patients with highest UFR were 6-11 years old and
weighed 25-50 kg. UFR >13 mL/kg/min remained similar (30-34%) for HD durations 93-
210 min, but decreased to 27% and 18% for longer sessions of 211-240 and >240 min,
respectively.
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Conclusions: Pediatric UFR frequently exceed upper limit recommended for adults if 
HD lasts <4 hrs especially in children weighing 25-50 kg. Additional studies are needed to 
define pediatric-specific upper UFR limits that could decrease CV mortality. If lower UFR 
is found to be beneficial in children, a global change in chronic pediatric HD prescription 
will be required allowing longer and/or more frequent HD treatments.
Funding: Private Foundation Support
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Acquired Cystic Kidney Disease in Children and Young Adults  
Undergoing Dialysis
Myung hyun Cho,1 Ji hyun Kim,1 Hee Gyung Kang,2 Hae Il Cheong,2 IL-Soo Ha.2 
1Seoul National university Children’s hospital, Seoul, Republic of Korea; 2Seoul 
National University Children’s Hospital, Seoul, Republic of Korea.
Background: Acquired cystic kidney disease (ACKD) describes bilateral cystic 
degeneration of the kidneys in patients who do not have cystic diseases. It is known as 
a common complication of end-stage renal disease (ESRD) in adults, however pediatric 
studies were scarce. We aimed to determine the prevalence, time of occurrence, and 
complications of ACKD in children and young adults undergoing dialysis.
Methods: We retrospectively reviewed the medical records of ESRD patients who 
were followed at Seoul National University Children’s Hospital between January 2015 and 
April 2018. We enrolled a patient if he/she had taken kidney imaging of ultrasonography or 
computer tomography after initiating maintenance dialysis. Patients with hereditary cystic 
disease were excluded.
Results: A total of 64 patients (male : female = 40 : 24) were enrolled. Maintenance 
renal replacement therapy was required at their mean age of 9.3 ± 6.0 years old. Causes of 
ESRD were non-cystic congenital anomalies of the kidney and the urinary tract (CAKUT) 
in 14 (21.9%), non CAKUT (glomerulonephritis in 34, nephrotoxin induced nephropathy 
in 4, hyperoxaluria in 2, and so on) in 44 (68.8%), and unknown in 6 (9.4%). Forty seven 
(73.4%) patients were on peritoneal dialysis, 12 (18.8%) on hemodialysis, and 5 (7.8%) on 
both. ACKD was found in 32 (50.0%). ACKD was detected 3.0 ± 2.5 years after the start 
of dialysis. In non CAKUT, the prevalence of ACKD increased with duration of dialysis, 
however it was not significant in non-cystic CAKUT (Fig. 1). Four (non CAKUT in 3 and 
unknown etiology in 1) had serious complications of ACKD; two had renal cell carcinomas, 
and 2 experienced massive hemorrhage. Complications occurred 3.9 to 12.2 years after the 
start of dialysis.
Conclusions: ACKD complicates ESRD of children and young adults as well. Since 
ACKD may accompany serious complications such as malignancy and hemorrhage, routine 
surveillance is necessary in high risk patients on maintenance dialysis.
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Distribution of the Pediatric Refugee Population with Renal Replacement 
Therapy in Germany
Johanna Lemke,2 Raphael Schild,2 Lars Pape,1 Jun Oh.2 and Members of the 
German Society for Pediatric Nephrology (GPN) 1Hannover Medical School, 
Hannover, Germany; 2Universtiy Childrens Hospital Hamburg Eppendorf, 
Hamburg, Germany.
Background: In 2016, about 2 million people immigrated to the EU. With 1 million 
people Germany reported the largest number of immigrants, of which an estimated 300,000 
were children. Data on prevalence and management of refugee patients with end-stage renal 
disease are rare. Numbers focusing on the pediatric cohort are not available. Our goal was 
to obtain information on the size and distribution of the pediatric refugee population with 
renal replacement therapy (RRT). In addition, we wanted to gain insights into the problems 
and challenges in the care of these patients.
Methods: We interviewed all pediatric dialysis centers in Germany about the number 
of pediatric refugee patients on RRT at the time of the survey. We also asked the number of 
patients from the most common countries of origin (Syria, Afghanistan and Iraq). Subjective 
problems and challenges in the care of this cohort should be listed.
Results: 86% of the centers indicated that they provide care to refugee children on 
RRT. A total of 69 refugee children were treated with RRT in the centers surveyed. 52/69 
(75%) received dialysis therapy, 43 of which were on HD and 9 on PD. 17/69 children 
(25%) underwent RTx. 34/69 (46%) came from either Syria, Afghanistan or Iraq. In 2017 
a total of 232 children were on dialysis in Germany, which makes the group of dialyzed 
refugee children account for approximately 22% of the total German pediatric dialysis 
population. With regard to the challenges in the care of these patients, difficulties in 
communication, non-compliance, administrative as well as psychosocial problems were 
most frequently mentioned. In summary, most centers indicated that the care of this group 
of patients presents their institution with great financial and logistical challenges.
Conclusions: Our survey shows that the majority of pediatric dialysis centers care for 
refugee children. The refugee population represents a large proportion of the total pediatric 
dialysis population in Germany. The challenges in treating these patients are complex 
and consume many personnel and logistical resources. To ensure holistic care for these 
children close cooperation between medical staff, dieticians, social workers, interpreters 
and psychologists is required. Interdisciplinary training should be established in the 
treating centers. The additional burden should be registered and compensated for by public 
authorities.
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Tentori,4 Martin J. Schreiber,4 Steven M. Brunelli,4 Kamyar Kalantar-Zadeh.1 
1Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Division of Nephrology and Hypertension, University of California, Irvine, 
Orange, CA; 2University of California Los Angeles, Los Angeles, CA; 3Feinberg 
School of Medicine, Northwestern University, Chicago, IL; 4DaVita Clinical 
Research, Denver, CO; 5Emory University School of Medicine, Atlanta, GA.
Background: Hypoalbuminemia is a strong predictor of hospitalization in adult 
dialysis patients. However, there are scarce data on the association between serum albumin 
levels and hospitalization among pediatric patients new to dialysis therapy.
Methods: In a cohort of children (1–17 years) who received dialysis therapy at a large 
US dialysis organization during 2007–2011 and who had available data on serum albumin 
within 1 year following initiation of dialysis, we examined the association of serum albumin 
levels with hospitalization frequency and total hospitalization days using negative binomial 
regression models. Hospitalizations for transplantation were excluded.
Results: Among eligible patients, median (IQR) age was 14 (10–16) years and 
mean±SD baseline serum albumin level was 3.7±0.8 g/dL. There appeared to be a U-shaped 
association between serum albumin and hospitalization frequency; hospitalization rates 
(95% CI) were 2.7 (2.2–3.2), 1.9 (1.5–2.4), 1.6 (1.3–1.9), 2.7 (1.7–3.6) per patient-year 
among patients with serum albumin levels <3.5, 3.5 to <4.0, 4.0 to <4.5 and ≥4.5 g/dL, 
respectively. The case mix-adjusted incidence rate ratios (IRRs) (95% CI) were 1.63 (1.24–
2.13), 1.32 (1.10–1.58), and 1.25 (1.06–1.49) at serum albumin level of 3.0, 3.5, and 4.5 
g/dL, respectively (ref: 4.0 g/dL). Consistent trends were observed in hospitalization days 
[Figure].
Conclusions: Both high and low serum albumin levels were associated with 
hospitalization in children with ESRD on dialysis. Hospitalization for high serum albumin 
may be due to favorable or unfavorable status, such as access placement or dehydration, 
respectively.
Funding: NIDDK Support
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Analysis of Survival of Low Weight Children (<15 kg) Undergoing 
Chronic Hemodialysis: Mortality and Risk Factors
Cristina Henriques,1 Simone Vieira,1 Shirlei Komi,1 Maria fernanda C. Carvalho,1 
Paulo C. Koch nogueira.2 1Hospital Samaritano, Sao Paulo, Brazil; 2UNIFESP, 
Sao Paulo, Brazil.
Background: With the technological advances in hemodialysis, it is currently possible 
to offer this type of therapy to young and low weight children. Our objective is to analyze 
the survival of children undergoing hemodialysis and risk factors impacting mortality
Methods: Retrospective analysis of patients undergoing chronic hemodialysis between 
January 2015 and January 2018 was performed. The sample included 65 patients (14F and 
51M) with median age at start of hemodialysis of 1.3 years (13 days - 9.6 years) and median 
follow-up of 536 days (54 days - 5.2 years). The most frequent etiology was CAKUT (63%) 
followed by Renal Dysplasia (8%). At study baseline, median weight was 8.1Kg (2.3kg-
13.7kg), median Z-score for weight/age -3.94 and median Z-score for height/age -3.16. 
Enteral feeding was required in 32 patients via gastrostomy. In this sample, 30 patients had 
anuria and 43 patients had undergone peritoneal dialysis prior to hemodialysis. 61 patients 
were on daily hemodialysis (8 patients had 7 sessions/week) with 90-180 minute sessions 
according to individual needs. Vasoactive drugs to maintain adequate blood pressure for the 
procedure were required in 26 patients.
Results: Of the 65 patients, 30 (46%) were transplanted, 27 (42%) remained on HD 
and 8 (12%) died. The cumulative survival rate was 96% for 1-year, 86% for 2-year, 80% 
for 3-year and 70% for 5-year survival. Considering transplant as a concurrent event, the 
following factors had the greatest impact: a) Cardiopathy – presence associated with a 
23 times greater probability of death (95%CI= 5 - 103; p<0.001) b) Anuria – presence 
associated with an 8 times greater probability of death (95%CI = 1 - 67; p=0.050) c) Z-score 
for height/age - every 1 SD increase in Z-score reduced chance of death by 46% (95%CI = 
16% - 66%; p=0.006) d) Z-score for weight/age - every 1 SD increase in Z-score reduced 
chance of death by 56% (95%CI = 33% - 71%; p<0.001)
Conclusions: Hemodialysis is a viable therapy in low weight children awaiting kidney 
transplant. Survival rates found were similar to those reported in the literature. The presence 
of cardiopathy risk factor had the greatest impact on probability of death in the sample. The 
patients with highest survival rates were those with better nutritional status and residual 
renal function.
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End-of-Life Care in Young Dialysis Patients
Robert N. Foley,1 Donal J. Sexton,2 Scott Reule.3 1University of Minnesota, 
Minneapolis, MN; 2The Irish Longitudinal Study on Ageing (TILDA), Trinity 
College Dublin., Dublin, Ireland; 3VA, Minneapolis, MN.
Background: Although end-stage kidney disease in the young is often a progressive 
disorder with high mortality, end-of-life care in this population has not been well 
characterized. In particular, it is unknown whether end-of-life care has changed over time 
and whether racial and ethnic disparities are present.
Methods: We used United States Renal Data System files to examine these issues 
among patients dying on maintenance dialysis in the US at age 0-20 years, between 2000 
and 2014 (N=1647).
Results: While the proportions that discontinued dialysis were similar in 2000-2006 
and 2007-2014 (14.8% Vs. 17.9, P-Value 0.09), the proportions receiving hospice care 
(3.6% Vs. 12.8%, P-Value <0.001) and dying outside of hospital (25.1% Vs. 33.8%, 
P-Value <0.001) both rose. Dialysis discontinuation (20.6% in white Vs. 10.4% in African 
American, P-Value <0.001), hospice care (11.1% in white Vs. 3.9% in African American,
P-Value <0.001) and non-hospital death (35.6% in white Vs. 23.7% in African American,
P-Value <0.001) were less likely in decadents from minority populations than in those of
non-Hispanic white race-ethnicity. Findings regarding temporal trends and racial disparities
were similar when adjustment was made for age, sex, and race/ethnicity.
Conclusions: While end of life care has changed substantially over time, 
discontinuation of dialysis, hospice care and death outside of hospital remain exceptional 
in young patients dying on maintenance dialysis. In addition, substantial racial and ethnic 
disparities are present.
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A Nephrology Transition Clinic in the Adult Care Setting: A Pilot Program
Laura Nishi,1 Cybele Ghossein.2 1Nephrology/HTN, Northwestern Medicine, 
Chicago, IL; 2Northwestern University- Feinberg School of Medicine, Chicago, IL.
Background: Young adults (YA) with chronic illnesses transitioning care from 
pediatric to adult medical facilities face many obstacles. Pediatric care providers are 
mindful of barriers to a smooth transition and the importance of a formal transition process, 
while adult care providers are often unaware, leading to an inconsistent transition process 
in the adult care setting. Three years ago, Northwestern Medicine (NM) Nephrology 
implemented a pilot transition of care program for YA with renal disease transitioning from 
Lurie Children’s Hospital to NM. We report here on our experiences.
Methods: Pediatric nephrology providers identified patients who they deemed ready 
to transition to adult providers. Prior to transition clinic, the adult multidisciplinary team, 
consisting of the nephrologist, physician assistant (PA), and social worker, reviewed patients 
with the pediatric team. The first appointment occurred at Lurie Children’s Hospital, which 
is located across the street from NM. Subsequent visits were then held at NM. At the initial 
visit, the patient was seen by the PA, nephrologist and if deemed appropriate, the social 
worker. The transition team reviewed each patient bimonthly to determine if proper follow 
up including testing and appointments had occurred, and if not, the patient was contacted 
to arrange for these.
Results: A total of 69 patients were seen in a three year period. Of these, 6 patients 
have been lost to follow up. 5 patients were no longer able to be followed due to insurance 
changes. 2 patients were deemed not to require further nephrology follow up. 42 patients 
have followed up as instructed at NM. There are 9 patients who have pending follow ups. 
4 patients started peritoneal dialysis and are thus are no longer cared for in the transition 
clinic. Finally, 1 patient started hemodialysis right away, was subsequently transplanted, 
and is now seen back in the transition clinic.
Conclusions: Based on our three year pilot experience, transition of care from pediatric 
to adult nephrology providers can be successfully facilitated with engagement of an adult 
nephrology team, close communication with a pediatric team, and a formal transition clinic 
protocol. In the future, we plan to continue this as a formal program in nephrology as well 
as extending it to other medical specialties within the NM system.
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Evaluating Renal Outcomes in Adolescents Born Extremely Premature of 
the ELGAN (Extremely Low Gestational Age Newborn) Cohort
Keia Sanderson,1 Emily H. Chang,2 William A. Primack,3 Michael O’Shea.3 
1University of North Carolina Kidney Center, Chapel Hill, NC; 2UNC Kidney 
Center, Chapel Hill, NC; 3University of North Carolina, Chapel Hill, NC.
Background: Premature birth is associated with decreased nephron number 
and an increased lifetime risk for chronic kidney disease (CKD). Yet there is lack of 
recommendation for renal follow up of children born prematurely. The aim of the study is to 
characterize the prevalence of macroalbuminuria, elevated blood pressure, and/or abnormal 
renal mass (predictors of CKD) in adolescents with a history of extremely premature birth.
Methods: We obtained 2 manual blood pressures, a random urinalysis, and 
sonographic measurements of kidney length and volume on 17 consecutively enrolled 15-
year old children born at <28 weeks gestation of the UNC Extremely Low Gestational Age 
Newborns (ELGAN) cohort.
Results: Of the 17 currently enrolled participants, 65% were male, 53% were Caucasian 
(33%identified as Hispanic) and 47% were African-American. Their mean age was 15 years. 
Median blood pressure was 115/69 mmHg with 35% of the cohort demonstrating elevated 
mean blood pressures. Median urine albumin/creatinine ratio was 7.75μg/mg with 24% of 
the cohort demonstrating significant random macroalbuminuria (>30μg/mg). Sonographic 
measurements are listed in Table 1. Twenty-nine percent of participants demonstrated 
abnormal renal mass (18% right renal hypoplasia, 6% right renal hypertrophy, 6% left renal 
hypoplasia, 6% left renal hypertrophy). No gross renal anatomical abnormalities were seen 
via ultrasound.
Conclusions: Nearly half (47%) of adolescents in this extremely low gestational age 
cohort were found to have abnormal renal mass, macroalbuminuria, or elevated blood 
pressures. Enrollment is ongoing. This data suggests that renal follow up of children with a 
history of extremely premature birth should be considered.
Funding: Other NIH Support - KL2TR001109, National Institutes of Health, John 
Buse, MD, PhD (PI), North Carolina Translational & Clinical Sciences Institute, Scholar 
Project: Renal outcomes in children with a history of extreme prematurity. Role of first 
author: Post-Doctoral KL2 Scholar
Table 1: Sonographic Renal Measurements of Adolescents of the ELGAN cohort
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Incidence and Long-Term Outcomes of Neonatal Renal Vein Thrombosis 
in Ontario: A Population-Based Cohort Study
Allison C. Ouellette,1 Liz Darling,1 Glenda Babe,2 Richard Perez,3 
Anthony K. Chan,1 Rahul Chanchlani.1 1McMaster University, Hamilton, ON, 
Canada; 2Institute for Clinical and Evaluative Sciences, Hamilton, ON, Canada; 
3ICES, Hamilton, Cabo Verde.
Background: There is limited data at a population level on the burden and long-term 
outcomes of neonatal renal vein thrombosis (nRVT). We conducted a cohort study to 
determine the incidence and long-term outcomes including hypertension (HTN), chronic 
kidney disease (CKD), end-stage renal disease (ESRD) and mortality associated with nRVT 
during a period of 24 years.
Methods: Health administrative databases, housed at the Institute for Clinical 
Evaluative Sciences, were used to identify all neonates ≤28 days of age born in Ontario, 
Canada from 1992-2016 and compared all neonates with nRVT vs. the total neonatal 
population without nRVT. The primary outcome was the composite risk of long-term 
outcomes including CKD, ESRD (chronic dialysis or kidney transplant) and all-cause 
mortality. The secondary outcome was the long-term risk of HTN. Incidence rates (IR) were 
calculated and Cox proportional hazard models were fitted for all outcomes.
Results: The annual IR of nRVT in Ontario from 1992-2016 was 2.6 per 100,000 live 
births (total 85 cases from 3,001,637 live births). The median follow-up was 11 years in both 
cohorts. There was a male preponderance (64%) of nRVT. A greater proportion of nRVT 
vs. comparator cohort was premature (45% vs. 8%, Standardized Difference 0.92). After 
adjusting for confounders, patients with nRVT were at a 17-fold increased risk of CKD 
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or death (Hazard Ratio (HR) 16.9, 95% CI 12.3-23.2, p<.0001) and an 18-fold increased 
risk of HTN (HR 17.7, 95% CI 12.6-25.0, p<.0001) vs. the comparator cohort. None of the 
nRVT cohort developed ESRD.
Conclusions: Patients with nRVT remain at higher risk than the general neonatal 
population of long-tern morbidity and mortality, indicating the need for long-term 
follow-up.
Table 1: Incident rates and hazard ratios of adverse outcomes among patients with nRVT in 
Ontario from 1992-2016
† All outcomes were significant with p<0.0001
*Adjusted for sex, congenital heart disease, respiratory distress syndrome, sepsis, maternal 
preeclampsia or eclampsia, and maternal diabetes.
CKD, chronic kidney disease; HTN, hypertension; HR, hazard ratio; CI, confidence interval.
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Common Clinical Markers Predict ESRD in Children with Obstructive 
Uropathy
Daryl J. Mcleod, Christina B. Ching, Yuri V. Sebastião, Kirk M. McHugh, 
Brian Becknell. Nationwide Children’s Hospital, Columbus, OH.
Background: Obstructive uropathy (OU) is the leading cause of pediatric chronic 
kidney disease (CKD) and end stage renal disease (ESRD). Children who escape the 
newborn period with mild to moderate CKD continue to be at increased risk for progression, 
especially as they undergo pubertal changes. The predictive ability of clinical markers 
throughout childhood is poorly defined in OU.
Methods: Patients with OU were identified in the Chronic Kidney Disease in Children 
Study (CKiD), a prospective observational cohort of children with mild to moderate CKD. 
The primary outcome of interest was ESRD (Cases). OU patients who did not progress to 
ESRD during follow-up (Controls) were age matched to Cases. Glomerular Filtration Rate 
(GFR), urine (protein/Cr and microalbumin/Cr), and serum (CO2, phosphate, albumin, and 
hemoglobin), were evaluated as predictor variables both at baseline and over time.
Results: Median age at baseline and outcome was 10 vs.16 years(y) respectively. Cases 
(n=27) and Controls (n=41) had significant differences in baseline GFR (36.9 vs. 53.5 ml/
min/1.73m2), urine protein/Cr (0.40 vs. 0.22) and microalbumin/Cr (0.58 vs. 0.03), and 
serum C02 (20 vs. 22 mmol/L) and hemoglobin (12.4 vs. 13.2 g/dL) respectively. GFR 
declined 3.07 ml/min/1.73m2/y faster in Cases (p<.0001) (Figure). Urine protein/Cr and 
microalbumin/Cr declined 0.16/y and 0.11/y faster in Cases respectively (p≤0.001 for both). 
Serum phosphate increased 0.11 mg/dL/y and albumin and hemoglobin decreased 0.04 g/
dL/y and 0.14 g/dL/y faster for Cases respectively (p<0.05 for all).
Conclusions: Baseline and longitudinal evaluation of clinical measures predicts ESRD 
in children with mild to moderate CKD from OU. Optimal cutoff values require further 
evaluation so that children identified at high risk can undergo closer surveillance that may 
allow changes in management to slow or halt progression.
Figure. Estimated change in GFR over time in the CKiD OU cohort
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Antibiotic Prophylaxis for Prevention of Urinary Tract Infections in the 
First Year of Life in Children with Vesicoureteral Reflux Diagnosed 
Following Antenatal Hydronephrosis: A Systematic Review
Jennifer Leigh,1 Stephanie Sanger,1 Jo-Anne Petropoulos,1 Luis H. Braga,2 
Rahul Chanchlani.1 1McMaster University, Hamilton, ON, Canada; 2Hamilton 
Health Science, Hamilton, ON, Canada.
Background: Children with antenatal hydronephrosis (ANH) and vesicoureteral reflux 
(VUR) are presumed to be at higher risk of urinary tract infection (UTI) after birth. As such, 
continuous antibiotic prophylaxis (CAP) has been empirically recommended for newborns 
who have ANH and VUR to reduce the rate of UTI during the first year of life, however, 
there is limited data to support this practice. The objective of this systematic review was 
to determine whether CAP prevents UTI within the 1st year of life in children with VUR 
diagnosed in the workup of ANH.
Methods: A systematic search of all relevant studies was conducted using 4 electronic 
(Medline, Embase, CINAHL, and CENTRAL) databases using appropriate key words 
without language restriction by an expert librarian. A time limit of January 1985 to May 
2017 was applied. Eligible studies included children with VUR diagnosed in the workup 
of ANH with or without antibiotic prophylaxis, and reported development of UTI. Two 
independent reviewers performed title and abstract screening and full-text review. Primary 
outcome was to compare rate of UTI among those on CAP to those not on CAP.
Results: Of 6903 citations screened, 17 were selected, giving a total population of 845 
(69.1 % male, median age 6 days (IQR= 29) who met the inclusion criteria. Most studies 
were retrospective, and of low quality evidence. Overall, 14.7% of patients developed at 
least one breakthrough UTI despite being on CAP. A common theme throughout studies was 
that higher grade VUR (IV-V) was associated with higher incidence of breakthrough UTI. 
Only two studies included in our review compared UTI rates in children on CAP (combined 
UTI risk 13.2%) compared to those not on CAP (UTI risk 42.7%), and thus meta-analysis 
could not be performed.
Conclusions: Despite the use of CAP, 14.7% of children with VUR diagnosed in the 
setting of ANH continue to develop UTI. However, there is limited published literature 
comparing UTI rates in this patient population to those not on CAP, thereby making any 
meaningful inference impossible. The effect of CAP on UTI rates in patients with ANH and 
postnatal VUR thus remains unclear and requires further investigation.
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Congenital Nephrogenic Diabetes Insipidus: A Review of 50 Pediatric 
Patients from MWPNC Centers
Cynthia J. D’Alessandri-Silva,1 Melinda Carpenter,2 Rose M. Ayoob,12 
Aftab S. Chishti,3 John P. Barcia,4 Alexandru R. Constantinescu,5 Julie 
Goodwin,6 Shireen Hashmat,13 Larry A. Greenbaum,7 Sherene Mason,1 Jason 
Misurac,8 Melissa A. Muff-Luett,9 Shweta S. Shah,10 Patricia L. Weng,11 
John D. Mahan.12 1Connecticut Children’s Medical Center, Hartford, CT; 
2Connecticut Children’s Medical Center, Hartford, CT; 3University of Kentucky, 
Lexington, KY; 4UVA Pediatric Nephrology, Charlottesville, VA; 5Joe DiMaggio 
Children’s Hospital, Hollywood, FL; 6Yale University School of Medicine, New 
Haven, CT; 7Emory University, Atlanta, GA; 8University of Iowa, Iowa City, IA; 
9University of Nebraska Medical Center/ Children’s Hospital of Omaha, Omaha, 
NE; 10Texas Children’s Hospital, Houston, TX; 11UCLA, Los Angeles, CA; 
12Nationwide Children’s Hospital, Columbus, OH; 13University of Chicago, 
Chicago, IL.
Background: Congenital Nephrogenic Diabetes Insipidus (NDI) is a rare genetic 
disorder that causes massive polyuria. To better understand NDI in children, we present, 
to our knowledge, the largest retrospective case series to date. Our objective for this study 
was to describe clinical presentation, genetic etiology, treatment and outcomes in patients 
< 21 years with NDI.
Methods: Midwest Pediatric Nephrology Consortium centers (MWPNC) conducted a 
retrospective chart review.
Results: We report 50 subjects from 12 centers. Median age at diagnosis was 125 days 
(interquartile range (IQR), 37, 296) with 86% male. 66% were white, 14% black, 8% Asian 
and 12% other race. 18% had a water deprivation test and 50% had a DDAVP loading test 
(median age at DDAVP 155 days (IQR, 101, 392)). At diagnosis, 74% had an elevated 
serum osmolality (> 300 MOsm/L). 54% had genetic testing with mutations in AVPR2 
(65%), AQP2 (14%), and unavailable (21%). 28% had a diagnosis of CKD; 55% Stage 1, 
36% Stage 2 and 9% Stage 5. Median age at time of CKD diagnosis was 4.1 years (IQR, 
3.1, 9.4). 18% had abnormal renal ultrasound findings; the majority were hydronephrosis 
and pelvicaliectasis. Table 1 lists pharmacologic interventions. Other medications included 
chlorothiazide (2%), chlorthiadone (4%), other NSAIDS (8%) and spironolactone (6%). 
Figure 1 lists nutritional management. At last follow-up, 52% reported to have enuresis.
Conclusions: Our results suggest a multi-centered approach to this rare disease yields 
robust information that can inform future novel treatment studies and creation of a clinical 
consensus for management of children with NDI.
Pharmacologic Interventions
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Albuminuria Sparing Effects of Hydroxyurea in Children with Sickle Cell 
Anemia
Rima S. Zahr,1 Jane S. Hankins,2 Winfred C. Wang,2 Guolian Kang,2 Chen Li,2 
Jeremie H. Estepp,2 Jeffrey Lebensburger.3 1University of Tennessee, Memphis, 
TN; 2St. Jude Children’s Research Hospital, Memphis, TN; 3UAB, Mountain 
Brook, AL.
Background: Renal complications in sickle cell anemia (SCA) begin early in childhood 
as hyposthenuria, glomerular hyperfiltration and albuminuria. Hydroxyurea (HU) use in 
SCA improves anemia, induces fetal hemoglobin and reduces sickle cell complications. We 
evaluated the long term effects of initiating hydroxyurea in patients with albuminuria and 
without albuminuria. We tested the hypothesis that initiation of HU in SCD children and 
young adults with albuminuria would improve urine measurements.
Methods: Participants were children < 18 yrs of age with SCA who were enrolled in 
two prospective cohorts and had longitudinal assessment of urine albumin to creatinine 
ratios (ACR) available. ACR values were captured at baseline, during the first 12 months of 
HU therapy and every year thereafter. The main outcome of the analysis, the development 
of albuminuria, was evaluated by two methodologies: a comparison of proportion between 
baseline and on hydroxyurea therapy and a time-to-development of albuminuria during 
hydroxyurea therapy.
Results: Albuminuria was present at baseline in 49% of our cohort. At one year of HU 
treatment, 38% with albuminuria normalized. Participants older than 10 at HU initiation 
had a 1.35x increase in the hazard ratio for developing ACR compared to younger than 10 
years. We found that an ACR level of ≥ 100 mg/g to be a significant cut-point for recurrence.
Conclusions: The impact of HU on normalizing albuminuria may be dependent on 
baseline age at initiation of treatment and level of albuminuria. Our study provides the 
novel finding that hydroxyurea, initiated in younger age with lower levels of albuminuria 
can strongly benefit from the addition of HU therapy and titration to the maximal tolerated 
dose. Clinicians should not defer initiating HU for renoprotection until patients are older 
and experiencing moderate to severe albuminuria.
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Morbidity of Childhood Nephrotic Syndrome: The Childhood Nephrotic 
Syndrome Observational Study, a Midwest Pediatric Nephrology 
Consortium Study
Chia- Shi Wang,2 Oleh M. Akchurin,3 Larry A. Greenbaum,4 John D. Mahan,5 
William E. Smoyer,5 Michelle N. Rheault.1 CNOS investigators 1University of 
Minnesota, Minneapolis, MN; 2Emory University, Atlanta, GA; 3Weill Cornell 
College of Medicine, New York, NY; 4Emory University, Atlanta, GA; 
5Nationwide Children’s Hospital, Columbus, OH.
Background: Childhood nephrotic syndrome (NS) is one of the most common 
pediatric chronic kidney diseases. Systematic studies of the complexity of treatment and 
disease complications are rare.
Methods: The Childhood Nephrotic Syndrome Study (CNOS) is an international, 
prospective, observational study of children 1-18 yrs with idiopathic NS enrolled within 
2 mos of NS diagnosis. Demographic and clinical data are collected at presentation, 3 
mos, and yearly. We describe healthcare utilization, treatment, treatment response, and 
disease complications among CNOS participants followed for at least 1 yr. Changes in 
corticosteroid (CST) treatment response from initial episode were noted.
Results: As of April 1, 2018, 127 had completed 12 mos follow-up. All patients were 
hospitalized at least once, with a total of 265 hospitalizations (2.1 hospitalizations/patient-
year). The most common primary reason for hospitalization (82/265, 31% hospitalizations) 
was edema. Hospitalizations were complicated by blood clots in 3 patients (2.4%) and 
infections in 13 (10.2%). The majority of patients (77.2%) responded to the initial course 
of CST; however, an additional 5/98 (5.1%) were CST-resistant at 1 yr (i.e., late steroid-
resistance). Frequently relapsing or CST-dependent NS was seen in 38/127 (29.9%). 
Second-line therapies were used in 69/127 (54.3%, Table). One patient (0.8%) reached end-
stage renal disease.
Conclusions: Healthcare utilization and disease morbidity are high in childhood NS. 
Treatment is complex, with a large proportion of patients exposed to immunosuppressive 
agents in addition to CST, even among those initially responsive to CST. Further research 
and quality improvement efforts are needed to decrease hospitalizations and morbidity in 
children with NS.
Funding: Private Foundation Support
Immunosuppressive therapies in first year of NS diagnosis
*Disease classification based on response to initial course of CST
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Risk Stratification for Disease Recurrence in Children with Steroid 
Resistant Nephrotic Syndrome (SRNS) Following Kidney Transplantation 
(Midwest Pediatric Nephrology Consortium [MWPNC] Study)
Rasheed A. Gbadegesin,1 Jonathan H. Pelletier,9 Karan Kumar,10 
Rachel M. Engen,15 Adam R. Bensimhon,11 Jennifer D. Varner,2 Michelle 
N. Rheault,3 Tarak Srivastava,4 Cynthia J. D’Alessandri-Silva,16 T. Keefe Davis,1 
Scott E. Wenderfer,12 Keisha L. Gibson,5 David T. Selewski,1 John P. Barcia,6 
Patricia L. Weng,7 Christoph Licht,13 John W. Foreman,14 Delbert R. Wigfall,1 
Annabelle N. Chua,10 Eileen W. Tsai,7 Christoph Hornik,10 Shashi K. Nagaraj,1 
Larry A. Greenbaum.8 1Duke University Medical Center, Durham, NC; 2Duke 
University School of Medicine, Durham, NC; 3University of Minnesota,
Minneapolis, MN; 4Childrens’s Mercy Hospital, Kansas City, MO; 5University 
of North Carolina Kidney Center, Chapel Hill, NC; 6UVA Pediatric Nephrology, 
Charlottesville, VA; 7UCLA, Los Angeles, CA; 8Emory University, Atlanta, GA; 
9Duke University Hospital, Durham, NC; 10Duke University, Durham, NC; 
11Duke, Chapel Hill, NC; 12Baylor College of Medicine, Houston, TX; 13The 
Hospital for Sick Children, Toronto, ON, Canada; 14Duke University Health
System, Durham, NC; 15Seattle Children’s Hospital, Seattle, WA; 16Connecticut 
Children’s Medical Center, Hartford, CT.
Background: Steroid resistant nephrotic syndrome (SRNS) due to FSGS and MCD 
is a leading cause of end stage kidney disease (ESKD) in children. Recurrence of primary 
disease following transplantation is a major cause of allograft loss. The clinical determinants 
of disease recurrence are not completely known. Our objective was to determine risk factors 
for recurrence of FSGS/MCD following kidney transplantation.
Methods: Multicenter study of pediatric patients with kidney transplants performed for 
ESKD due to SRNS between 1/2006-12/2015. Patients with primary-SRNS (PSRNS) were 
defined as those initially resistant to corticosteroid therapy at diagnosis, and patients with 
late-SRNS (LSRNS) as those initially responsive to steroids who subsequently developed 
steroid resistance. We performed logistic regression to determine risk factors associated 
with nephrotic syndrome (NS) recurrence.
Results: We included 158 eligible participants in our analysis; 64 (41%) had recurrence 
of NS in their renal allograft. Disease recurrence occurred in 78% of patients with LSRNS 
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compared to 39% of those with PSRNS. Patients with MCD on initial native kidney biopsy 
had a 76% recurrence rate compared with a 40% recurrence rate in those with FSGS. The 
recurrence rate in patients with monogenic SRNS was 0%. Multivariable analysis showed 
that MCD histology (OR; 95% CI: 5.6; 1.3-23.7) compared to FSGS predicted disease 
recurrence.
Conclusions: Pediatric patients with MCD and LSRNS are at higher risk of disease 
recurrence following kidney transplantation. Based on our findings, it is possible to use 
genetic findings, native kidney biopsy findings and pattern of therapy response prior to 
kidney transplant to stratify patients with SRNS undergoing renal transplant into a low-risk 
group (monogenic NS), a medium-risk group (FSGS on native kidney biopsy and PSRNS), 
and a high-risk group (MCD on native kidney biopsy and/or LSRNS).
Funding: NIDDK Support
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Renal Recovery and Prognostic Factors in Children Following Liver 
Transplantation: A Single Center Experience
Rainer Büscher,1 Nicholas Gantenberg,1 Tobias Storbeck,2 Anja K. Büscher,1 
Henrike Stopfkuchen,1 Peter F. Hoyer.1 1Paediatric Nephrology, University 
Hospital Essen, Essen, Germany; 2Paediatric Gastroenterology and Liver 
Transplantation, University Hospital Essen, Essen, Germany.
Background: Progression to chronic renal disease (CKD) is highly prevalent in adults 
following liver transplantation (LT) with a profound impact on patient survival, assuming 
that the prevalence of renal dysfunction is also considerably high in children. We report our 
experiences in a large paediatric transplant center and try to identify risk factors leading to 
a decline of renal function.
Methods: We retrospectively analyzed all 161 LT patients at our hospital from 2010 to 
2017 (84 female). Medical records were reviewed for demographic, laboratory and clinical 
data. Patients were stratified into groups < 5 kg, 5-10 kg and > 10 kg. Change of renal 
function (slopes) was defined as loss/increase of GFR using the Schwartz formula and 
progress to renal failure within the first 4 weeks after LT was stratified according to the 
pRIFLE criteria. Mean observation time was 31 months (6 to 93 months).
Results: Out of 161 patients, 134 were younger than 6 years at time of LT (74%). 
Average survival time in 5 years was 86%. CKD preexisted in 16 children (10%), nine 
undergoing dialysis before LT (5.5%). 7/145 proceeded to ESRD over 5 years (4.8%). 
Other patients developed pRIFLE I (21%), II (23%), III (11%) within the first 4 weeks after 
LT. Average GFR within 4 weeks after LT was lower in group <5kg (66 ml/min/1.73m2) 
compared to 81 (5-10 kg) and 114 (>10kg) ml/min/1.73m2. All GFR-slopes remained stable 
and were not significantly different from each other (<5kg: 0.01 vs. >5-10kg: 0,01 vs. 
>10kg: -0,35 ml/min/1,73m2/28 days). Within the entire observation time, all GFR-slopes
showed a significant increase (<5kg: 14 vs. 5-10kg: 4 vs. >10kg: 3 ml/min/1.73m2/year).
Regarding potential risk factors, 16 patients (10%) exceeded ABPM mean blood pressure
values higher the 95th percentile, and 8 patients (5%) higher the 75th percentile. All other 
patients remained lower the 50th percentile. Albuminuria was rare (4%) and did not occur 
significantly more often in any subgroup. No independent risk factors for a decline of GFR 
to ESRD could be detected in all patients.
Conclusions: In contrast to adults, progress to ESRD in children following LT was 
rare (<5%) and most patients developed a normal GFR. Independent risk factors could 
not be defined. However, renal function, hypertension and proteinuria should be monitored 
regularly.
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Trends in Living Donation by Race/Ethnicity in Pediatric ESRD
Sandra Amaral,1 Charles E. McCulloch,2 Celina Brunson,1 Erica Winnicki,2 
Garrett R. Roll,2 Brian K. Lee,2 Elaine Ku.2 1The Children’s Hospital of 
Philadelphia, Philadelphia, PA; 2University of California San Francisco, San 
Francisco, CA.
Background: Living donation is the best treatment option for children with ESRD, 
yet living donation rates have declined. With increased knowledge about living donor (LD) 
risk, racial/ethnic disparities in LD rates for children may have increased.
Methods: We performed a retrospective cohort study of children <18 yrs with 
incident ESRD 1995-2015 in the US Renal Data System. Using Cox models, we examined 
associations between race/ethnicity, LD transplant rates and changes over time, adjusting 
for recipient and donor factors. We also examined donor-recipient relationships by race/
ethnicity.
Results: Among 14,926 children, 46.8% received LD transplants. Overall, LD rates 
declined by 3%/yr since 1995, however the LD rates for Asian children remained stable. 
Notably, differences in LD rates by race/ethnicity persisted (Fig. 1). Compared with non-
Hispanic whites (NHW), Hispanic children were 50% less likely (HR 0.50 (0.45-0.55)), 
Asians 57% less likely (HR 0.43(0.35-0.52)) and Blacks 70% less likely (HR 0.30 (0.27-
0.34)) to receive LD transplant within 2 yrs. of ESRD onset. While 96% of NHW recipients 
had white donors, only 59% of Asian recipients had Asian donors (p<0.001). Asian 
recipients were more likely to have non-related donors and Black recipients were less likely 
to have parents as donors (p< 0.001, Table 1).
Conclusions: Stark racial/ethnic disparities in pediatric access to LD transplant persist. 
Differences in donor-recipient relationships as contributors to these disparities should be 
further explored.
Fig.1. Time trends in LD transplant by race/ethnicity, 1995-2015.
Table 1. Donor-recipient characteristics by race/ethncity.
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Risk Factors for Early Readmission Post Pediatric Kidney 
Transplantation
Shanthi S. Balani,1 Stephanie T. Nguyen,2 Jessica L. Brennan,3 Paul R. Brakeman.1 
1UCSF, San Francisco, CA; 2Pediatric Nephrology, University of California, 
Davis, Sacramento, CA; 3UCSF Medical Center, San Francisco, CA.
Background: Early hospital readmissions are associated with morbidity, mortality and 
significant health care costs. To date, no published studies have evaluated risk factors for 
early readmission following pediatric kidney transplantation.
Methods: Retrospective chart review was performed for all pediatric kidney transplant 
recipients from 2012 – 2017 at the University of California, San Francisco. Early hospital 
readmissions were defined as any unplanned admission within 30 days of being discharged 
from the hospital following a kidney transplant; admissions for elective procedures were 
excluded. Baseline characteristics evaluated included age, insurance, race, education, 
prior dialysis, donor type, cold ischemia time, prior transplantation, peritoneal placement 
of transplant, immunosuppressive regimen, length of hospital stay, weekend/holiday 
discharge, discharge medications, tacrolimus level, hemoglobin, albumin, and creatinine at 
discharge. Analysis was done using Student t-test and Pearson chi square test.
Results: There were 90 pediatric kidney transplant recipients. The rate of early 
readmission was 25%. Causes for readmission were: elevated creatinine (26%), vomiting/
diarrhea with dehydration (26%) and hypertension associated complications (9%). Pre-
transplant dialysis significantly predicted readmission (Hemodialysis 43.7%, peritoneal 
dialysis 21.4% and pre-emptive transplants 10.3%, p<0.05). Racial distribution among 
readmissions was also found to be statistically significant (Blacks 62%, Whites 21%, 
Hispanic 23%, Asian 0%, other 42%, p=0.05). Other non-significant predictors for 
readmission included: public versus private insurance (30% vs 16%, p=0.8) and number 
of anti-hypertensives at time of discharge (36% on 2 or more medications vs 18% on none, 
p=0.3). No difference was seen in readmission rates based on age, education, donor type or 
immunosuppressive regimen.
Conclusions: The rate of early readmissions for our pediatric population was less 
than for adult patients (25% vs 30-36%). The most common causes for readmission were 
elevated creatinine and vomiting/diarrhea. Prior dialysis and race significantly predicted 
readmission. Targeted interventions for patients identified as being at risk based on 
these results may help reduce the rate of readmissions for pediatric patients after kidney 
transplantation.
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Change in Kidney Function for Three Years in Pediatric Kidney 
Transplant Recipients
Junya Hashimoto,1,2 Yuko Hamasaki,1,2 Yusuke Takahashi,1,2 Masaki Muramatsu,2 
Takeshi Kawamura,2 Ken Sakai,2 Seiichiro Shishido.1,2 1Pediatric Nephrology, 
Toho University Faculty of Medicine, Ota-ku, Japan; 2Nephrology, Toho 
University Faculty of Medicine, Ohta-ku, Japan.
Background: Few data show the changes in graft function after kidney transplantation 
(KTx) in children. We retrospectively investigated the change in kidney function for three 
years in pediatric kidney transplant recipients based on estimated glomerular filtration rate 
(eGFR).
Methods: We enrolled the recipients aged 2−15 years who underwent living-donor 
KTx at our institution between 2009 and 2017. We excluded the recipients with primary 
non-function (n=2), low muscle bulk due to being bedridden (n=2). In 56 recipients, 
changes in eGFR were evaluated for three years after KTx. eGFR was calculated by the 
creatinine-based equation for Japanese children and adolescents aged 2−18 years.
Results: During follow-up, patient and graft survival rates were 100%. Twenty-five 
recipients (44.6%) experienced acute rejection with treatment. The mean age of recipients 
and donors were 8.1±4.0, and 41.1±7.8 years old. Congenital anomalies of the kidney and 
urinary tract (n=34) was the most common disease for end stage kidney disease. The mean 
eGFR (ml/min./1.73m2) at 1, 4, 12, 24, and 36 months (M) after KTx were 85.1±18.6, 
73.4±16.6, 67.0±15.7, 65.3±15.0, 66.4±18.9, respectively. eGFR at 1 and 12 M post-
transplant showed significant difference (p<0.0001, paired t-test). eGFR became stable at 
12 M post-transplant and thereafter. In 17 recipients (30.4%), eGFR at 36 M was below 60. 
On multivariable logistic regression analyses, eGFR <60 at 1 M after KTx was the impact 
factor related to eGFR <60 at 36 M.
Conclusions: Approximately 70% of the recipients showed kidney function equivalent 
to over CKD stage 3 at three years after KTx, though eGFR declined within the first year 
post-transplant. To preserve long-term kidney graft function, the recipients with low eGFR 
at one month post-transplant need careful management.
Fig. Change of the mean eGFR of 56 pediatric recipients after living-donor KTx.
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Co-Produced Videos to Improve Knowledge Among Patients and 
Caregivers with a Kidney Transplant
Devesh S. Dahale,1 Margret Kamel,2 Ansara Piebenga,3 David K. Hooper,1 
Pamela D. Winterberg.2,4 Improving Renal Outcomes Collaborative (IROC) 
1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 2Pediatrics, 
Emory University School of Medicine, Atlanta, GA; 3Improving Renal Outcomes 
Collaborative, Cincinnati, OH; 4Children’s Healthcare of Atlanta, Atlanta, GA.
Background: The Improving Renal Outcomes Collaborative (IROC) is a networked 
learning health system of 23 pediatric centers committed to improving the health, longevity, 
and quality of life of children with kidney disease. IROC’s Community Engagement 
Workgroup (CEW) was established to engage patients and caregivers in co-production to 
achieve health care goals. In line with IROC’s first aim to improve blood pressure (BP) 
control in children with kidney transplants, the CEW implemented a project to raise 
awareness of BP management amongst its members using video content.
Methods: CEW members created a list of questions regarding the relevance of BP 
control to health, accurate BP measurement, and treatment of high BP. They then co-
produced 10 short videos of pediatric nephrologists teaching these topics on camera. Videos 
were distributed to patients and caregivers and multiple-choice questions were used to 
assess knowledge of topic areas before and after viewing the content. Open-ended questions 
prompted viewers to describe future behaviors influenced by watching each video. Paired 
responses were analyzed to determine knowledge of topic areas most improved by the video 
content. Thematic analysis of free-text responses was used to identify future behaviors.
Results: A total of 23 participants (3 patients, 14 caregivers, 4 healthcare professionals 
and 2 caregiver/healthcare), viewed a median of 5 (IQR 3-9) videos. Videos had on average 
11.4 ± 1.1 viewers who submitted paired pre- and post-video responses. Participants 
demonstrated the largest improvements in knowledge about the prevalence of high BP 
after kidney transplant (correct response 7% pre- vs 92% post-video), ideal BP levels 
(45% vs 100%), and the nutrient focus of the DASH diet (25% vs 100%). Future behaviors 
stimulated by the content viewing included BP self-monitoring, implementation of lifestyle 
modification, and desire to have more in-depth conversation with healthcare providers 
about BP management.
Conclusions: Co-produced videos improved BP knowledge among participants who 
also appear motivated to engage in self-care and conversations with healthcare providers 
about lifestyle modifications for BP control. We intend to use the feedback from this pilot 
to create a patient education program at IROC centers using the Knowledge-Attitude-
Behavior (KAB) model.
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Ethnography: A Novel Approach to Improving Care for Pediatric Kidney 
Transplant Recipients
O. N. Ray Bignall,1 Veronica A. Taylor,1 Ahna L. Pai,1 Jens W. Goebel,2 Justin 
Masterson,3 Cassie L. Kirby,1 David K. Hooper.1 Improving Renal Outcomes 
Collaborative 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 
2Children’s Hospital Colorado, Aurora, CO; 3SEEK Company, Cincinnati, OH.
Background: Current models of care for pediatric kidney transplant recipients 
(pKTRs) may be ill-suited to meet their needs, leading to suboptimal utilization, barriers 
to adherence, and psychosocial stressors that adversely affect both patients and families. 
Optimizing care delivery for these complex patients requires insight into their social and 
emotional needs, perceptions of care, and future goals. Aiming to inform design of an 
improved system of care, we assessed convergent and divergent perceptions of pKTRs and 
their families.
Methods: We conducted a qualitative analysis of semi-structured interviews and 
ethnographies with pKTRs (n=12; ages 11-22) and caregivers (n=15) identified in the 
Improving Renal Outcomes Collaborative (IROC). Participants were selected and stratified 
according to medical and psychosocial complexity, and level of engagement with their 
transplant team. Audio recorded interviews were transcribed and assessed for themes using 
a grounded theory approach.
Results: Considerations around Kidney Care was the major theme that emerged 
from both pKTRs and caregivers, particularly experience on dialysis and learning about 
kidney disease care. Other cross-cutting themes included maintaining a sense of normalcy; 
inability to recognize signs of kidney disease prior to transplant; and reluctance to meet 
other pKTRs. Major themes more common among caregivers were Family Dynamics (e.g. 
caregiver stress/strain and consideration of family members as organ donors; p<0.001) 
and Life Stressors (e.g. moving or traveling for a child’s transplant care; p<0.001). More 
common among patients were Education/Social Development (e.g. impact of disease on 
school and extracurricular activities; p<0.001), and Transition of Care (e.g. transition to 
an adult provider; p<0.001). Co-produced with patients and families, ethnographies were 
used to generate thematic personas to aid in the development of IROC, our learning health 
system designed to improve health and quality of life for pKTRs.
Conclusions: Understanding patient and family motivations and needs are 
fundamental to designing new, more effective systems of care. Such systems should address 
both common motifs as well as those specific to patients and caregivers in order to foster 
engagement and shared decision making between patients and the medical team.
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Proteinuria in Children and Adolescents Following Renal  
Transplantation: Results from the Cooperative European  
Pediatric Renal Transplant Initiative (CERTAIN)
Anja K. Büscher,1 Daniel Bernard,1 Henrike Stopfkuchen,1 Rainer Büscher,1 
Peter F. Hoyer,1 Tomas Seeman,3 Kai Krupka,2 Burkhard Toenshoff.2 Members 
of the CERTAIN registry study group 1Pediatric Nephrology, University 
Children’s Hospital, Essen, Germany; 2University Children’s Hospital, 
Heidelberg, Germany; 3University Children’s Hospital Motol, Prague, Czechia.
Background: Proteinuria is a major risk factor for the progression of chronic kidney 
disease and - in patients after renal transplantation (RTx) - associated with higher mortality 
and an increased risk of graft failure. Pediatric studies are rare, often limited due to small 
patient numbers and present heterogenous results regarding prevalence and outcome.
Methods: Data of 195 children (mean age at RTx 10.6±5.2 years, 60% male) from 
the CERTAIN registry was analyzed 3 months, 1 and 3 ys post RTx. Prevalence, quantity 
and quality of proteinuria was correlated with GFR and potential influencing factors 
were evaluated (underlying disease, BMI, dialysis, HLA-mismatch, cold ischemia time, 
immunosuppression (IS), BKV infection).
Results: 77% of patients developed proteinuria >200mg/g creatinine (crea) within 3 
months post RTx, 9% of these > 1000mg/g crea; Proteinuria was of glomerular origin in 
71% and decreased by 40% within 3 ys. Increasing proteinuria was negatively correlated 
with GFR especially in the long-term follow-up (p=0.004, 3ys post RTx). Patients with 
glomerulopathies had significantly higher proteinuria (p<0.001) after 3ys post RTx. BMI 
SDS was positively correlated with proteinuria (p<0.03) at time of RTx, but this effect 
did not persist over time. Cold ischemia time was correlated with the extent of proteinuria 
(p=0.01) as well as the number of HLA mismatches. Patients with BKV infection developed 
proteinuria in 52% (with higher urinary protein excretion compared to BKV negative 
patients (p<0.001). The mode of dialysis and the type of IS did not influence proteinuria 
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significantly, but we detected slightly higher levels of urinary protein in patients with a 
history of peritoneal dialysis and in mTOR inhibitor-based IS, respectively. Proteinuria did 
not correlate with hypertension, duration of dialysis, CMV/EBV or urinary tract infections.
Conclusions: The majority of pediatric patients developed proteinuria following RTx, 
Although proteinuria was of only mild to moderate extent in most patients and decreased 
over time, it was significantly correlated with a reduction of GFR. Proteinuria was 
associated with several risk factors with the highest impact for a prolonged cold ischemia 
time, high number of HLA mismatches and BKV infection.
Funding: Clinical Revenue Support
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Differential Cytokine Profiles for Non-Human Leukocyte Antigen 
(Non-HLA) and HLA Antibodies in Pediatric Kidney Transplantation
Meghan Pearl,1 Jonathan Grotts,1 Maura Rossetti,1 Qiuheng J. Zhang,1 
Patricia L. Weng,1 David Elashoff,1 Elaine F. Reed,1 Eileen W. Tsai.2 1UCLA, Los 
Angeles, CA; 2Duke University, Durham, NC.
Background: The inflammatory profiles associated with human leukocyte antigen 
(HLA) and non-HLA antibodies to G-protein coupled receptors in kidney transplant 
recipients (KTRs) are unknown. We have recently shown that angiotensin II type 1 receptor 
antibody (AT1R-Ab) and Endothelin-1 Type A receptor antibody (ETAR-Ab) are prevalent 
and associated with poor outcomes in pediatric KTRs. We aimed to compare inflammatory 
profiles of AT1R-Ab, ETAR-Ab, and HLA donor specific antibodies (DSA) in pediatric 
KTRs.
Methods: 233 blood samples from 65 pediatric KTRs were analyzed. ETAR-Ab 
(ELISA), AT1R-Ab (ELISA), HLA DSA (Luminex), and TNF-α, IL-1β, IL-8, IFN-γ, IL-
17, IL-6 (Luminex) were measured in blood samples taken at 6 months (m), 12m, and 
24m post-transplant and during episodes of rejection. Based on a receiver operating curve 
analysis, > 10 and >17 units/ml was considered positive for ETAR-Ab and AT1R-Ab and 
≥1000 MFI was considered positive for HLA DSA.
Results: HLA DSA, AT1R-Ab, and ETAR-Ab were positive in 25 (11%), 92 (40%), 
and 50 (22%) of samples respectively. 96% of samples positive for ETAR-Ab also had 
AT1R-Ab. All three antibodies were associated with elevations in IL-8 while AT1R-Ab was 
associated with elevations in all 6 cytokines (Table 1).
Conclusions: AT1R-Ab is associated with a distinct inflammatory profile compared 
to HLA DSA or ETAR-Ab in the first 2 years post-transplant. Further studies are needed 
to understand the distinct mechanisms of HLA vs. non-HLA antibody mediated allograft 
injury.
Funding: Private Foundation Support
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Weight Changes on Dialysis and During Transplant Associate with 
Mortality Risk in Children
Matthew Roberts,1 Mark Mitsnefes,2 Charles E. McCulloch,1 Larry 
A. Greenbaum,3 Barbara A. Grimes,4 Elaine Ku.1 1University of California San
Francisco, San Francisco, CA; 2Cincinnati Children’s Hospital, Cincinnati,
OH; 3Emory University, Atlanta, GA; 4UCSF, San Francisco, CA.
Background: Few studies have explored how weight change during ESRD may 
associate with survival in children. Our objective was to examine the association between 
weight changes during RRT and risk of death in a prevalent cohort of children with ESRD. 
Secondarily, we sought to determine whether the association between weight changes and 
mortality would differ based on ESRD treatment modality (dialysis vs. transplant).
Methods: We performed a retrospective cohort study using data from the Pediatric 
Growth and Development Special Study, a longitudinal study within the United States 
Renal Data System that followed children with ESRD over a 3-year period. The primary 
predictor was annualized BMI z-score changes divided into quintiles. Cutoff values for 
these BMI z-score changes were -0.50, -0.13, 0.09, and 0.57, and the middle quintile served 
as the reference category. Outcome was all-cause mortality. We used Cox models (adjusted 
for age, sex, race, cause of ESRD and median neighborhood income) to examine the 
association between the predictor and outcome and to test for an interaction with treatment 
modality.
Results: We included 1,182 children followed for a median duration of 19 years, of 
whom 35% died during follow-up. Mean age was 15 years, 40% were female, and 21% 
had CAKUT as the cause of their ESRD. We found a U-shaped association between weight 
change and mortality (Figure 1): both large declines in BMI z-score (>-0.50 per year) and 
large gains in BMI z-score (>0.57 per year) were associated with an increased risk of death. 
No interaction was noted between annualized BMI z-score change and treatment modality 
(p=0.15). Results were similar when follow-up was limited to 5 and 10 years after the last 
weight and height measurements were obtained.
Conclusions: Weight gain and weight loss after dialysis initiation or during transplant 
are strong predictors of long-term survival for children with ESRD. Maintenance of a stable 
weight may be associated with better survival in children receiving RRT, regardless of RRT 
modality.
Funding: Private Foundation Support
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Executive and Intellectual Functions of Young Hungarian Kidney 
Transplant Recipients
Marta M. Varga,1 Miklos Gyori,1 Anett Nagy,2 Aniko Varga,3 Gyorgy S. Reusz,4 
Attila J. Szabo.4,5 1Institute for the Psychology of Special Needs, Faculty of 
Special Education, ELTE University, Budapest, Hungary, Budapest, Hungary; 
2Institute of Special Needs Education for People with Atypical Behaviour and 
Cognition, Faculty of Special Education, ELTE University, Budapest, Hungary, 
Budapest, Hungary; 3ELTE University, Budapest, Hungary, Budapest, Hungary; 
41st. Department of Pediatrics, Semmelweis University, Budapest, Hungary, 
Budapest, Hungary; 5MTA-SE Pediatrics and Nephrology Research Group, 
Budapest, Hungary, Budapest, Hungary.
Background: CKD is frequently associated with impaired executive functions, 
intellectual problems and atypical development in children and adolescent. Results of 
the last decade indicate that neuropsychological outcomes with kidney transplant (Tx) 
recipients are more favorable than was detected in earlier reports. However, data on factors 
associated with neurocognitive dysfunctions in Tx recipients are limited.
Methods: We conducted a cross-sectional analysis comparing digital measuring 
of executive functions (using Wisconsin Card Sorting Test /WCST/, Corsi Test /Corsi/, 
Stroop Effect Test /STROOP/) of 26 kidney transplant recipients by matching them in 
pairs on gender, age, maternal education and IQ with healthy controls. Socio-demographic 
characteristics, laboratory data and comorbidities have been collected.
Results: The average age was 17±2 years, 73% was male, the average estimated GFR 
was 60±14 ml/min. Kidney transplant adolescent had a below average overall IQ (WISC-
IV/WAIS-IV IQ=85±17). The first preliminary data on executive functions suggest no 
significant differences between the achievement of transplant and IQ matched healthy pairs 
in visuo-spacial short term memory (Corsi) (F=2.37, p=0.41), cognitive flexibility (WCST) 
(F=0.31, p=0.95) and selective attention and inhibition (STROOP) (F=2.97, p=0.32). All 
IQ domain of Tx recipients had significant negative correlation with transplant vintage 
(Full IQ scores: R=-0.52, p<0.01). The intellectual function had also inverse correlation 
with cumulative lifetime length of hospitalization (R=-0.47, p=0.01). Hospitalization time 
and maternal education had strong negative correlation (R=-0.57, p<0.01) while IQ and 
maternal education had no relation in our sample of Tx group (R=0.31, p=0.13). Cognitive 
flexibility (perseverative (R=-0.42 p=0.03) and conceptual level responses (R=-0.59 
p=0.001) indicated a strong inverse correlation with lifetime cumulative dialysis vintage 
in Tx recipients.
Conclusions: Young kidney transplant recipients have impairments of intellectual 
function that are associated with transplant vintage and lifetime hospitalization. IQ matched 
transplant and healthy groups had no differences in executive functions. Higher dialysis 
vintage of Tx adolescents indicated lower cognitive flexibility.
Funding: Government Support - Non-U.S.
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Outcomes of Belatacept Regimen with the Use of Precision Medicine in 
Kidney Transplantation
Jun Shoji,1 Qizhi Tang,2 Flavio Vincenti.3 1Transplant Nephrology, University of 
California San Francisco, San Francisco, CA; 2University of California San 
Francisco School of Medicine, San Francisco, CA; 3University of California 
San Francisco, San Francisco, CA.
Background: Belatacept is a costimulation blocker that has been increasingly used 
as maintenance immunosuppression to improve long term outcomes in kidney transplant 
recipients. Since acute rejection in patients on belatacept have been noted to be more 
frequent and histologically more severe, identifying the select population of patients 
with Precision Medicine who will benefit from belatacept is important. We investigated 
pretransplant recipient immune profiles to determine which lymphocyte populations would 
be the best predictor in identifying patients who will be at lowest risk for costimulation 
blockade-resistant rejection.
Transplantation: Clinical Outcomes
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
732
J Am Soc Nephrol 29: 2018 Poster/Saturday
Methods: We prospectively enrolled 64 kidney transplant recipients (44 deceased; 
20 living donors) at our center to receive denovo belatacept from August 2012 to March 
2017. PMBCs were collected prior to transplantation and at the time of cause and protocol 
biopsies. All patients received thymoglobulin for induction with belatacept 10mg/kg 
administered on POD 1, 4, 14, 28, 56, and 84. Monthly maintenance dose of 5mg/kg was 
given starting week 16. Patients were initially on MMF but were converted to everolimus 
after 1 month. Prednisone was maintained on 56 patients and withdrawn on 8 patients. 
Protocol biopsies were performed at 6 months.
Results: On cause biopsies, 3 patients were noted to have ACR 1a (at 4 weeks, 6 weeks, 
4 months), 1 with ACR 1b (at 2 months), 3 with ACR 2b (at 2 months, 3 months, 9 months), 
1 with AMR (at 4 months), and 1 with simultaneous ACR 1a and AMR (at 7 months). 
In addition, 16 patients were found to have borderline rejection on protocol biopsies. 28 
patients did not have any inflammation on biopsies. 56 patients remained on belatacept and 
8 patients were converted to tacrolimus (1 patient was switched to tacrolimus due to poor 
intravenous access and not due to rejection). 6 of the 9 rejections occurred in those who 
were on MMF and not on mTORi. 2 of 9 patients who were noted to have rejection were 
patients on steroid withdraw.
Conclusions: CD28-CD8 T cells are associated with belatacept-resistant rejection since 
these are memory cells unaffected by CD28 blockade. Pretransplant immunotyping and 
functional assessment of circulating lymphocytes may provide a useful tool for selection of 
patients suitable for belatacept therapy.
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One Year Kidney Transplant Outcomes Using Belatacept and Sirolimus 
Maintenance Immunosuppression
Carol A. Traynor,2 Allan D. Kirk.1 1Duke University School of Medicine, 
Durham, NC; 2Division of Nephrology, Duke University, Durham, NC.
Background: Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression 
fafter kidney transplantation, but are associated with adverse events when used long 
term. Belatacept, a CTLA4-Ig fusion protein, is a costimulation blocker that prevents 
T-lymphocyte activation. It provides effective immunosuppression post kidney transplant
and allows CNI free immunosuppression. Typical regimens include belatacept with
mycophenolate mofetil and steroids, and have been associated with higher acute rejection
rates than CNI based regimens. We describe our experience using a belatacept and sirolimus 
based maintenance immunosuppression regimen.
Methods: This is a retrospective analysis of patients treated with belatacept maintenance 
therapy at a single center. Patients were eligible for belatacept if: age<70, BMI<35, EBV 
IgG positive, no donor specific antibody. They received alemtuzumab induction (30 mg, 
intravenously), infusion of belatacept (10mg/Kg Day 0,4 and end of week 2,4,8, and 12; 
then 5 mg/kg every month, and oral sirolimus 2mg daily, dose adjusted for 24-hour trough 
8-10ng/ml.
Results: Baseline demographics are outlined in table 1. There was 100% patient and
graft survival at one year. There was no delayed graft function. Acute rejection occurred 
in 13.6%. Median GFR at one year was 55ml/minute. Median protein/creatinine ratio was 
262 mg/g Creatinine. There were 25 infections in 13 patients. There were 9 viral infections. 
CMV and BK virus occurred at a rate of 13.6% and 13.6%, respectively. There were 10 
bacterial infections-the majority (80%) were urinary tract infections. There were 6 fungal 
infections-all were mucocutaneous infections. There were no cases of post transplant 
lymphoproliferative disease.
Conclusions: A combination of costimulation blockade with belatacept, alemtuzumab 
induction and daily sirolimus enables use of a CNI and steroid free maintenance 
immunosuppression regimen in select patients. There were excellent one-year graft 
outcomes, and it was well tolerated with an acceptable side effect profile. Longer follow 
up is needed.
Baseline Demographics
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The Epidemiologic Burden of Tacrolimus Variability Among US Kidney 
Transplant Recipients
Pratik B. Shah,1 Jennifer L. Ennis,2 Patrick Cunningham,1 Michelle A. Josephson,1 
Rita L. McGill.1 1University of Chicago, Chicago, IL; 2Litholink Corporation, 
Chicago, IL.
Background: Within-patient tacrolimus level variability has been shown to be 
a risk factor for de novo donor specific antibody (DSA) formation and increased death 
censored graft failure (DCGF) among kidney transplant recipients in single-center reports. 
We evaluated the correlation between subtherapeutic tacrolimus levels and tacrolimus 
variability in a large national data set.
Methods: We evaluated all tacrolimus levels drawn at any LabCorp® facility in the 
United States, between November 2011 and September 2017, with a diagnosis code for 
kidney transplant. Levels drawn within the six months after the earliest value were excluded, 
to exclude patients with new allografts. Patients were included if there were at least three 
tacrolimus levels thereafter. Tacrolimus variability was calculated as the coefficient of 
variability of the tacrolimus levels as: 100 x (standard deviation/mean) and compared to a 
risk threshold of 30% (Rodrigo et al., 2016). The percentage of subtherapeutic (< 4.0 ng/dL) 
tacrolimus levels (%subT) was calculated for each subject. The associations of tacrolimus 
variability with %subT were assessed with correlation analysis and linear regression.
Results: There were 410,257 tacrolimus levels among 27,375 patients, of whom 43.1% 
were women. Mean age was 52.5±14.4 years. Median follow-up was 26.5 (IQR=12.8-46.1) 
months. The median number of tacrolimus levels per patient was 11 (IQR=6-20). Median 
tacrolimus variability was 30.6%, with 51.6% of patients exceeding 30% variability. Median 
%subT was 11.1% (IQR=0-30.8%), and 34.3% of patients had no subtherapeutic levels. The 
correlation coefficient between tacrolimus variability and %subT was 0.253 (P<0.001). In 
linear regression, tacrolimus variability increased 1.86% for each 10% increase in %subT 
(P<0.001), but R-squared for this model was only 0.06.
Conclusions: More than half of established kidney transplant patients from a large 
national sample exhibited a level of tacrolimus variability that has been previously 
associated with 2 to 3- fold increased hazards of DSA and DCGF. Tacrolimus variability 
has an association with subtherapeutic levels, but likely reflects a complicated constellation 
of clinical factors and scenarios that merit further study.
SA-PO004 Poster Saturday
Transplantation: Clinical Outcomes
Calcineurin Inhibitors, Macrolides, and the Risk of Adverse Drug Events 
in Kidney Transplant Recipients
Rachel H. Jeong,1 Robert R. Quinn,2 Krista L. Lentine,3 Anita Lloyd,1 
Pietro Ravani,2 Brenda Hemmelgarn,2 Branko Braam,1 Amit X. Garg,4 
Kevin C. Wen,1 Anita Wong,5 Sita Gourishankar,1 Ngan Lam.1 1University of 
Alberta, Edmonton, AB, Canada; 2University of Calgary, Calgary, AB, Canada; 
3Saint Louis University, St. Louis, MO; 4London Health Sciences Centre, 
London, ON, Canada; 5Alberta Health Services, Edmonton, AB, Canada.
Background: Calcineurin inhibitors (CNI; cyclosporine, tacrolimus) are critical for 
kidney transplant immunosuppression, but have multiple potential drug interactions, such 
as with macrolide antibiotics. Clarithromycin and erythromycin inhibit CNI metabolism 
and increase the risk of CNI nephrotoxicity, while azithromycin does not.
Methods: We conducted a retrospective cohort study using linked healthcare 
databases in Alberta, Canada to study kidney transplant recipients from 2008-2015. We 
identified CNI-macrolide co-prescriptions and compared outcomes in those who received 
clarithromycin/erythromycin vs. azithromycin. The primary outcome was a composite of 
all-cause hospitalization, acute kidney injury (creatinine increase ≥0.3 mg/dL or 1.5-times 
baseline), or death within 30 days of the macrolide prescription.
Results: Of the 293 recipients who were co-prescribed a CNI and a macrolide, 38% 
(n=112) were prescribed clarithromycin/erythromycin while 62% (n=181) were prescribed 
azithromycin. Over half of the clarithromycin/erythromycin prescriptions were from 
general practitioners. There was no significant difference in the primary outcome between 
the two groups (17% vs. 11%, p=0.11); however, the risk of all-cause hospitalization was 
3-times higher in the clarithromycin/erythromycin group than in the azithromycin group
(10% vs. 3%; odds ratio [OR] 3.18, 95% CI 1.14 to 8.84, p=0.02). The odds of having an 
outpatient serum creatinine measurement within 30-days of the macrolide prescription were 
41% less likely for clarithromycin/erythromycin users compared to azithromycin users
(56% vs. 69%; OR 0.59, 95% CI 0.36 to 0.96, p=0.03). Although there was no difference
in acute kidney injury between the two groups, there was a significantly greater decrease in 
eGFR in the clarithromycin/erythromycin group compared to the azithromycin group (-5.4
vs. -1.9 mL/min/1.73 m2, p<0.05).
Conclusions: In conclusion, clarithromycin and erythromycin were frequently co-
prescribed in kidney transplant recipients on CNIs despite known drug interactions. 
Clarithromycin/erythromycin users were at higher risk of hospitalization compared to 
azithromycin users. Safer prescribing practices in kidney transplant recipients are warranted.
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Transplantation: Clinical Outcomes
Trough Tacrolimus Levels in Kidney Transplant Recipients and  
Non-Melanoma Skin Cancer Risk over Follow Up
Donal J. Sexton,1 Susan L. Murray,1 Peter J. Conlon.2 1Nephrology and Kidney 
Transplantation, Beaumont Hospital and The Royal College of Surgeons in 
Ireland, Dublin, Ireland; 2Beaumont Hospital, Dublin 9, Co Dublin, Ireland.
Background: Whether Tacrolimus exposure is independently associated with non 
melanoma skin cancer (NMSC) incidence has not been fully characterised.
Methods: Retrospective analysis of the Irish National Kidney Transplant database 
linked with laboratory data from clinical practice. Generalised estimating equations with 
random effects were used to investigate repeated measures of trough Tacrolimus levels tested 
in clinical practice in recipients (as a time-varying covariate) and NMSC development. 
Exposure to Tacrolimus was also calcuated using the trapezoid rule to calcuate area under 
the curve (AUC), and time-averaged trough values. SAS v9.4 was used for data analysis.
Results: N=1540 kidney transplant recpieints were included, 95% of whom 
were deceased donor transplants and 41% female. 38% of donors were female. NMSC 
development (N=188), was independently associated with serum trough Tacrolimus levels 
over follow up (see table 1). However this association was not significant after adjusting 
for era of transplantation. This was true both of serum tacrolimus as a time-varying 
parameter and AUC Tacrolimus. Factors such as mean, median, min, max, and variability 
in Tacrolimus were not associated with NMSC overall. Limiations include possible 
confounding by overall imunnosupressive burden, survivor bias as well as the fact that 
follow up length and frequency of testing varied for each participant.
Conclusions: From repeated measures analysis of clinical practice laboratory data, 
while Tacrolimus exposure as measured by trough values and AUC associate with NMSC 
development over follow up, this association is attenuated after accounting for transplant 
vintage.
Results of generalized estimating equation analysis with trough Tacrolimus levels as a time-
varying covariate
SA-PO006 Poster Saturday
Transplantation: Clinical Outcomes
Outcomes in Simultaneous Pancreas Kidney Transplant in the US 
Stratified by Induction and Use of Corticosteroids
Daniel Keys, Samy M. Riad, Robert N. Foley. University of Minnesota, 
Minneapolis, MN.
Background: Simultaneous Pancreas Kidney (SPK) transplantation is an excellent 
option for patients with significant renal impairment and diabetes. Outcomes for SPK have 
improved over the past decade. However, the ideal immunosuppression and induction 
remains unclear. We sought to analyze outcomes of graft loss and death as stratified by 
induction and use of low dose corticosteroid.
Methods: Between 2000-2016, 14676 SPK transplants were analyzed in the Scientific 
Registry of Transplant Recipients (SRTR) database. Groups were made by no induction, 
IL-2 antagonism, anti-thymocyte globulin (ATG), and alemtuzumab induction with (CCS) 
and without steroids (CSW). We adjusted for multiple variables including donor age, 
recipient age, PRA, length of time on dialysis, sex, race, history of heart disease, and HLA 
mismatches. We analyzed HR for death, kidney and pancreas allograft loss. Adjustment 
factors included: era; donor and recipient age, sex, race, weight and number of HLA 
mismatches; recipient time on dialysis, comorbidity, and panel reactive antibodies.
Results: Mean follow up for the cohort was 7.4 years. Regarding induction and steroid 
strategies, the likelihood of kidney allograft loss was lowest with CCS/ATG (13.2%, 
adjusted hazards ratio [AHR] 0.63 [0.53-0.76], P-Value <0.01, Table 1); pancreas allograft 
loss was least likely with CSW/ATG (15.9%, AHR 0.61 [0.51-0.73], P-Value <0.01, Table 
2); death likelihood was lowest with CCS/ATG (12.7%, 0.8 [0.66-0.96], P-Value 0.02, Table 
3).
Conclusions: In 14676 SPK transplants from the US, different induction and 
maintenance steroid strategies were associated with substantial variationin allograft 
survival and death. Kidney and pancreas allograft survival were longer with corticosteroids 
and overall survival was longer with CCS/ATG.
SA-PO007 Poster Saturday
Transplantation: Clinical Outcomes
Utility of Induction Agents in Simultaneous Liver-Kidney Transplantation
Nashila AbdulRahim, Suman Krishna Kotla, Lee E. Anderson, Hao Liu, 
Bekir Tanriover, Venkatesh Kumar Ariyamuthu. Internal Medicine/Nephrology, 
UT Southwestern Medical Center, Dallas, TX.
Background: The number of simultaneous liver-kidney transplants (SLKT) and 
utilization of induction therapy in SLKT is on the rise. There is little published evidence of 
utility of induction agents when contemporary maintenance immunosuppression regimen 
with tacrolimus, mycophenolic acid, and prednisone (TAC/MPA/PRED) is used.
Methods: We queried the OPTN registry for adult SLKT recipients in the US between 
2002-2016. We divided the cohort into three groups based on induction agent: rabbit anti-
thymocyte globulin (r-ATG, N=436), interleukin 2 receptor antagonists (IL2-RA, N=1,189) 
and no-induction (N=1,763) being the reference group. All patients were maintained on 
TAC/MPA/PRED at the time of discharge. The primary outcomes were post-transplant 
all-cause mortality and acute rejection rates at 6 months. Survival rates were analyzed 
using Kaplan-Meier (KM) method and compared between groups using the log rank test. 
We estimated hazard and odd ratios for our primary outcomes using a propensity score 
analysis (inverse probability weighting -IPW) adjusted Cox proportional hazard and logistic 
regression models.
Results: Compared with no-induction, the multivariable IPW adjusted Cox proportional 
hazard analyses showed an increased mortality with r-ATG (HR=1.31, 95% CI 1.04-1.65, 
p-value=0.02). At six-months post-transplant, acute rejection rates (both liver and kidney)
were less than 10% and were not statistically significant between three induction categories 
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based on multivariable IPW adjusted logistic regression analysis. Mortality secondary to 
infection was statistically higher in r-ATG group.
Conclusions: In SLKT recipients maintained on TAC/MPA/PRED, induction 
categories were associated with similar rejection rates at six-months. Compared to no 
induction, r-ATG appears to increase mortality risk, probably secondary to infections. 
Benefit of IL2-RA induction in SLKT remains controversial.
SA-PO008 Poster Saturday
Transplantation: Clinical Outcomes
Steroid Maintenance and Outcomes in Kidney Transplant Recipients with 
Native Kidney Glomerulonephritis: An Analysis of OPTN/UNOS 
Database
Swati Arora, Kalathil K. Sureshkumar, Bhavna Chopra. Division of Nephrology, 
Allegheny General Hospital, Pittsburgh, PA.
Background: Kidney transplant recipients with history of native kidney 
glomerulonephritis (GN) are at increased risk of graft loss from recurrent GN. It is unclear 
if steroid maintenance could help in preventing recurrent disease and improve outcomes in 
these patients.
Methods: Using the United Network for Organ Sharing database, we identified adult 
kidney-only transplant recipients from 2001-2015, who had GN as cause of ESRD, who 
received induction therapy and were discharged on calcineurin inhibitor/mycophenolic acid 
with steroid maintenance (SM), n=14,610 or steroid withdrawal(SW), n=6, 406. Using a 
multivariate Cox-model adjusting for donor, transplant and recipient related factors, overall 
and death censored graft failure rates and patient death rates were compared between the 
SM and SW groups in patients with GN.
Results: There was significant difference between SM and SW groups in overall graft 
failure and patient death with a Hazard ratio (95% CI) of 1.10 (1.03-1.19) p-value of 0.009 
and 1.21 (1.09-1.34) p-<0.001, respectively. However, there was no significant difference 
between the groups for death censored graft failure, hazard ratio 1.04 (0.95-1.14).
Conclusions: Despite a presumed potential benefit of steroid maintenance in reducing 
the risk for recurrent post-transplant GN, our study found increased risk for death with 
functioning graft associated with steroid use in KTRs with history of native kidney GN 
who received peri-operative induction followed by CNI/MMF maintenance. This could 
be a consequence of enhanced cumulative immunosuppression since these patients were 
likely exposed to prior immunosuppressive therapy for native kidney GN. Limitations are 
retrospective study design and possibility of residual confounding.
Figure: Patient Survival comparing Steroid Maintenance(SM) vs Steroid Withdrawl(SW) in 
Transplant Recipients with Glomerulonephritis
SA-PO009 Poster Saturday
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Corticosteroid Avoidance Among Low Immunologic Risk Adult Renal 
Transplant Recipients of a Living Donor: A Meta-Analysis
Amor Patrice Socorro E. Estabillo,1 Luis V. Limchiu,1 Anthony 
Russell Villanueva,1 Marichel P. Coronel.2 1National Kidney and Transplant 
Institute, East Avenue, Quezon City, QUEZON CITY, Philippines; 2Adult 
Nephrology, National Kidney and Transplant Institute, Quezon CIty, Philippines.
Background: Chronic kidney disease is a devastating condition causing global public 
health burden with high economic cost to health care systems. Renal Transplantation is the 
standard of care among other forms of renal replacement therapy. Corticosteroids have a 
critical role, yet its long-term use is associated with a multitude of adverse effects leading 
to a greater deal of morbidity and mortality post-transplantation. Most researches include 
heterogenous group of populations: adult and pediatric, low and high immunologic risk 
recipient of a living or deceased donor. Studies including deceased organ donor population 
may not be applicable in our local setting since deceased organ donation in some countries 
are low, mainly due to scarcity of potential donor. Outcome studies on rejection rates may be 
varied by the immunological-risk status of the donor-recipient pair. Despite the increasing 
research, corticosteroid sparing following renal transplantation remains a controversial 
issue, hence the first meta-analysis to focus on a corticosteroid avoidace among low 
immunologic risk adult renal transplant recipients of a living donor.
Methods: Systematic literature review of the electronic database Cochrane Library, 
MEDLINE Ovid SP and Clinical Trials.gov were searched for randomized-controlled trials 
from September-November 2017. Statistical analyses used was random-effects model.
Results: Included 5 studies met the eligibility criteria (N=788). There is no 
increased risk in the steroid avoidance group having biopsy proven acute rejection at 12 
months (RR:0.72[0.51,1.01]) I2 10% p=0.05). A significant reduction towards the risk 
of New Onset of Diabetes Mellitus After Transplantation (RR:0.41[0.25,0.67]; I2=0% 
p=0.0003). Likewise, hypertension (RR:0.35[0.12,1.02] I2=82%p=.05) and Infection 
(RR:0.69[0.46,1.04]; I2=71%p=0.07) was reduced post-transplantation.
Conclusions: Steroid avoidance is non-inferior to maintenance group in terms of 
biopsy proven acute rejection at 12-months. Metabolic complications and risk of infection 
were reduced post-transplantation as well.
SA-PO010 Poster Saturday
Transplantation: Clinical Outcomes
Clinical Outcomes and Factors Related with Mycophenolate Mofetil 
Withdrawal in Kidney Transplant Recipients
Woo Yeong Park,1,2 Hayeon Park,1 Jin hyuk Paek,1,2 Kyubok Jin,1,2 
Seungyeup Han.1,2 1Department of Internal Medicine, Keimyung University 
School of Medicine, Daegu, Republic of Korea; 2Keimyung University Kidney 
Institute, Daegu, Republic of Korea.
Background: Although the most effective initial maintenance immunosuppressants in 
kidney transplantation (KT) have been known as a combination of calcineurin inhibitor 
(CNI), steroid, and mycophenolate mofetil (MMF), immunosuppressive regimen has been 
changed due to several reasons within 1-year after KT. The most common changing pattern 
was MMF withdrawal, but the clinical course of the kidney transplant recipients (KTRs) 
after MMF withdrawal was not known clearly. The purpose of this study is to investigate 
the causes of MMF withdrawal, and the clinical outcomes and factors related with MMF 
withdrawal in KTRs.
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Methods: We retrospectively analyzed the medical records of 626 KTRs performed KT 
at Dongsan Medical Center between 2000 and 2016. We evaluated the incidence of acute 
rejection, allograft and patient survival rates, and factors related with MMF withdrawal.
Results: Mean age of KTRs was 44.1 ± 11.6 years. Median time between KT and 
MMF withdrawal was 6.4 (range, 3.2 – 32.1) months. The most common cause of MMF 
withdrawal was infection (70.7%), followed by hematologic abnormalities (9.1%), and 
gastrointestinal trouble (7.7%). The proportion of cytomegalovirus infection was the highest 
(60.5%) among all infections, followed by BK virus infection (18.4%). The proportion of 
female KTRs and the incidence of BPAR were significantly higher in the MMF withdrawal 
arm compared with the non-MMF withdrawal arm (57.7% vs. 34.4%, P < 0.001; 27.4% vs. 
8.9%, P < 0.001). Death-censored graft survival and patient survival rates were significantly 
lower in the MMF withdrawal arm compared with the non-MMF withdrawal arm (P < 
0.001; P < 0.001). In multivariate analysis, MMF withdrawal was an independent risk factor 
for graft failure after adjustment for recipient age, gender, infection, and deceased donor KT 
(HR 6.058, 95% C.I., 3.172-11.569, P < 0.001).
Conclusions: The incidence of acute rejection, graft failure, and patient mortality rates 
in KT were high after MMF withdrawal. Therefore, MMF withdrawal should be considered 
carefully and resumed as soon as possible.
SA-PO011 Poster Saturday
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A Promising Novel Approach with Everolimus-Based Quadruple 
Maintenance Therapy in Kidney Transplant Recipients with  
Difficult-to-Treat Rejections
Pierre Larsson,1 Bodil Englund,1 Jana Ekberg,1 Marie Felldin,1 Verena Broecker,3 
Lars Mjörnstedt,1 Seema Baid-Agrawal.2 1Transplant Institute, Sahlgrenska 
University Hospital, Gothenburg, Sweden; 2Department of Nephrology and 
Transplant Institute, Sahlgrenska University Hospital, University of Gothenburg, 
Gothenburrg, Sweden; 3Department of Pathology, Sahlgrenska University 
Hospital, Gothenburg, Sweden.
Background: Chronic rejections and treatment-resistant acute rejections are difficult 
to treat and lead to progressive loss of graft function in kidney transplant recipients (KTR). 
Here we review our experience with a novel approach to treat such rejections by adding 
everolimus, an inhibitor of mammalian target of rapamycin (mTOR) as a “rescue therapy” 
to the conventional triple maintenance therapy (prednisolone + mycophenolate mofetil + 
calcineurin inhibitor).
Methods: We analysed in detail electronic medical charts of 34 KTR who received 
everolimus-based quadruple therapy for biopsy-proven chronic rejections or treatment-
resistant acute rejections between 2011-2017. A response to treatment was defined as an 
improvement/stabilization in the graft function (eGFR slope/year ≥1 ml/min/1.73m2/year).
Results: The results are summarized in the table below. Stabilization in graft function 
(eGFR) was seen at 48 months after treatment (table + figure), more so in acute as compared 
to chronic rejection subgroup. Treatment was stopped in 10 patients due to adverse events.
Conclusions: Everolimus-based maintenance quadruple therapy appears to be 
apromising novel approach for chronic rejections and treatment-resistant acute rejections, 
both of which are difficult to treat. Further randomized controlled studies are needed to 
confirm our findings.
Patients receiving quadruple therapy (N=34)
SA-PO012 Poster Saturday
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Immunosuppression in the Failing Allograft: To Wean or Not to Wean?
Michelle L. Lubetzky,1 Rex Friedlander,3 Darshana Dadhania.2 1Division of 
Nephrology and Hypertension, New York, NY; 2Weill Cornell Medical College, 
New York, NY; 3The Rogosin Institute, New York, NY.
Background: Sensitization is frequent after failed allograft yet there are no clear 
management strategies for tapering of immunosuppression.
Methods: We performed cross-sectional chart review of patients who were re-listed for 
repeat kidney transplant after either failed/failing allograft and subdivided them based upon 
their most recent calculated panel reactive antibody (cPRA) into two groups, LOW PRA, 
cPRA of <10% (n=18) or HIGH PRA, cPRA 100% (n=20).
Results: Table 1 describes the baseline characteristics. More patients in the 100% 
cPRA group had >1 prior transplant (35% versus 5.5%, p=0.05), but there was no difference 
in other sensitizing events or acute rejection episodes between the groups. All patients in 
the HIGH cPRA had failed allografts, while 8 patients in the LOW PRA group were pre-
emptive and had functioning grafts (p<0.001). In the HIGH CPRA group, 30% had 0 CPRA 
at time of graft failure and the CPRA significantly increased in this cohort at follow up 
(Figure1; p<0.001), most of which (75%) were taken off immunosuppression during that 
time.
Conclusions: Graft failure leading to subsequent tapering of immunosuppression may 
be a risk factor for increase in CPRA while awaiting re-transplant. There is a need for a more 
standardized approach to weaning immunosuppression to avoid sensitization.
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Trends in Transplant Nephrectomy After Kidney Allograft Failure in the 
United States
Medha Airy, Jingbo Niu, Wolfgang C. Winkelmayer. Baylor College of 
Medicine, Houston, TX.
Background: Patients with end-stage kidney disease whose transplants have failed 
experience worse outcomes compared to those on dialysis not previously transplanted. 
Following allograft failure, transplant nephrectomy is commonly considered in patients with 
symptomatic rejection, infections, malignancy, or resistant anemia. Over the years, early 
allograft nephrectomies have declined due to improved short-term transplant outcomes, but 
information on the trends regarding nephrectomy among patients with later allograft failure 
is lacking. This study examined the trends over two decades in transplant nephrectomy 
following kidney allograft failure.
Methods: We used the US Renal Data System to identify all patients whose first 
kidney allograft failed >90 days after transplant and who had Medicare fee-for-service 
at the time. Patients were followed for any allograft nephrectomy within 1-year post-
allograft failure. We used Cox proportional hazards models with year of allograft failure 
as the exposure of interest while adjusting for sociodemographic and health-related 
patient characteristics. Follow-up was censored at 1 year, loss of Medicare fee-for-service, 
re-transplantation, or death
Results: We included 29,496 patients whose first kidney transplant failed between 
1996 and 2013. Multivariable-adjusted Cox models indicated non-significant hazard ratios 
(HR) for transplant nephrectomy between 1996 (referent) and 2006; thereafter, the rates of 
transplant nephrectomy declined considerably with HR of 0.85 (0.73, 1.00) for 2007 and 
0.58 (0.49-0.69) for 2013
Conclusions: While adjusted rates of transplant nephrectomy were essentially static 
between 1996 and 2006, they have decreased considerably thereafter. The reasons for this 
trend are unclear but may reflect greater recognition of transplant nephrectomy-associated 
allosensitization.
SA-PO014 Poster Saturday
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Successful Kidney Transplantation in Adults with Antibody Deficiencies
Melanie Schoutteten, Maarten H. Christiaans. Maastricht University Medical 
Centre, Eersel, Netherlands.
Introduction: Antibody deficiencies (common variable immunodeficiency (CVID) 
and hypogammaglobulinemia (HGG)) associate with a high prevalence of infections, 
autoimmunity, granulomas and malignancies. Immune suppression in transplantation may 
amplify this risk. Therefore, in many centers these patients are not considered as suitable 
candidates for renal transplantation. In literature, only 2 cases of kidney transplantation in 
CVID patients are reported, both with bad short-term outcome. Because our center has a 
long track record in kidney transplantation with reduced immune suppression we decided 
to develop a set of preconditioning criteria and pioneered a transplantation program. We 
present 1 patient with CVID and 1 with HGG, both transplanted with good clinical and 
renal outcome.
Case Description: A 43-year old female known with ESRD due to reflux nephropathy 
and CVID, received a 43-year old DBD-renal transplant. Immunosuppression consisted 
of tacrolimus and low dose steroids. IVIG was continued. Protocol biopsy at month 3 
was normal and steroids were withdrawn. Posttransplant, she had a few recurrent urinary 
and respiratory infections for which prophylactic azithromycin was given. 3 years 
posttransplantation patient is still in good clinical condition without malignancies and with 
a persistent good renal function (eGFR 40ml/min). A 61-year old male with ESRD due to 
polycystic kidney disease, known with HGG, was transplanted with a 64-year old DCD 
donor kidney with IGF. Immunosuppression consisted of tacrolimus, low dose steroids for 
10 days and mycophenolate mofetil for 3 months. IVIG was continued. He had no acute 
rejection nor infection besides twice an asymptomatic cystitis. Until now, 2 years after 
transplantation, he has a persistent renal function of 28.3ml/min.
Discussion: Uniqueness of the cases We present 2 pioneer cases of successful renal 
transplantation in patients with antibody deficiency. Take away lesson Our data provide a 
framework for a pre-transplant risk reduction strategy combined with a specific immune 
suppressive regimen under an umbrella of IVIG supplementation allowing safe kidney 
transplantation of immune deficient patients.
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Induction Therapy in Elderly Kidney Transplant Recipients with Low 
Immunological Risk
Christophe Masset,1,7 Julie Boucquemont,2 Fanny Buron,3 Valerie Garrigue,4 
Elisabeth Cassuto,5 Marc Ladrière,6 Yohann Foucher,2 Jacques Dantal.1,7 1Nantes 
University Hospital, Nantes, France., Nantes, France; 2Université de Nantes; 
UMR INSERM 1246 - SPHERE, Nantes, France; 3Hospices Civils de Lyon, 
Lyon, France; 4University Hospital Montpellier, Montpellier, France; 5chu Nice, 
NICE Cedex 3, France; 6CHRU NANCY, Vandoeuvre les Nancy, France; 
7Institut de Transplantation Urologie Néphrologie, Nantes, France.
Background: Thymoglobulin (ATG) and Basiliximab (BSX) lead to similar rejection 
rates in low immunological risk patients. ATG could be benefit on Delayed Graft Function 
(DGF) and allow corticosteroid avoidance, supporting its use in elderly recipients. In 
contrast, it seems to be associated with infectious and malignancy risk, supporting the use 
of BSX, especially in recipients with low immunological risk. The benefit-risk balance 
remains unclear. We thus compared post-transplantation outcomes in elderly recipients with 
low immunological risk according to their induction therapy.
Methods: We conducted a French multicentric study on non-immunized ≥ 65 years 
patients receiving a first kidney transplant between 2010 and 2017 and an induction therapy 
by ATG or BSX. The principal outcome was patient and graft survival. We also studied 
the cumulative probabilities of infection, first acute rejection episode, malignancy; de 
novo DSA and eGFR at 1-year post transplantation; and occurrence of DGF. Cox, logistic 
or linear models were used depending on the studied outcome. To consider possible 
confounding variables, we weighted the models on the propensity scores.
Results: 204 (53.3%) patients were included in the BSX group, 179 (46.7%) in the 
ATG group. Average age was respectively 71.0 and 70.5 years. Patient and graft survival at 
3 years post-transplantation were 74% (95%CI from 65% to 84%) in the ATG group, and 
68% (95%CI from 60% to 78%) in the BSX group. The corresponding HR (Hazard Ratio) 
equalled 0.96 between the BSX group compared to the ATG group (95%CI from 0.58 to 
1.60). The probability of infection at 1-year post-transplantation were 52% (95%CI from 
59% to 44%) in the BSX group versus 51% (95%CI from 59% to 42%) in the ATG group, 
without significant difference. There was no difference in all the others evaluated outcomes 
as indicated in Figure 1.
Conclusions: In elderly recipients, induction therapy by ATG does not seem to lead to 
poorer outcomes compared to BSX.
SA-PO016 Poster Saturday
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Is More Intensive Induction Immunosuppression Therapy for Highly 
Sensitized Kidney Transplant Recipients Better?
Inna Mohamadou,1 Marie Matignon,4 Stephanie Malard,2 David Buob,3 
Philippe Grimbert,4 Anissa Moktefi,5 Eric Rondeau,1 Yosu Luque.1 1Urgences 
Néphrologiques et Transplantation rénale. Hôpital Tenon. Assistance Publique 
Hopitaux de Paris, Paris, France; 2Saint Louis Hospital APHP, Paris, France; 
3Tenon Hospital, Paris, France; 4Nephrology and transplantation department, 
Mondor Hospital, Creteil, France; 5AP- HP, Hopital Henri Mondor, Creteil, 
France.
Background: Induction immunosuppression for highly sensitized kidney recipients 
varies, in particular the use of plasma exchanges (PE) and rituximab following 
transplantation to prevent antibody-mediated rejection (ABMR) and increase graft survival. 
We compared two induction strategies for patients undergoing kidney transplantation with a 
high level (MFI>3000) of pre-formed donor-specific antibody (DSA).
Methods: Our retrospective study included 45 kidney transplant recipients in two 
French centers, transplanted between 2012 and 2017. All patients had at least one pre-
formed DSA (MFI > 3000) within 6 months before transplantation. All patients received 
anti-thymocyte globulin, a calcineurin inhibitor, mycophenolate mofetil and steroids on the 
day of transplantation. 22 of these 45 patients also received 5 PE and one rituximab dose 
(group A), whereas the remaining 23 patients did not (group B). Patients were followed for 
1 to 6 years after transplantation.
Results: Comparing group A to group B, recipients’ age (48±14 vs. 47±12 years), 
donors’ age (54±16 vs. 57±12 years), cold ischemia time (16±6 vs. 19±7 hours) and MFI 
of the immunodominant DSA (8735±4192 vs. 10106± 6015) were similar (p=ns for all). 
There was no overall difference in the rate of biopsy-proven acute rejection at 1 year 
post-transplantation (n=9, 41% in group A vs. n=7, 30% in group B). ABMR occurred in 
n=6 vs. n=7 patients, and T-cell mediated rejection was observed in n=3 vs. n=0 patients, 
respectively in groups A and B. There was no difference in graft survival rate at 1 year post-
transplant (91% in group A vs. 83% in group B, p=ns). Finally, the incidence of infectious, 
anaphylactic, thrombotic or hemorrhagic events was similar between the two groups.
Conclusions: Our study suggests that an intensive induction immunosuppressive 
therapy using PE and rituximab during early post-transplantation period does not decrease 
ABMR incidence or improve 1-year graft survival in highly sensitized recipients. An effect 
of PE on anti-thymocyte globulin pharmacokinetics could not be excluded.
SA-PO017 Poster Saturday
Transplantation: Clinical Outcomes
Risk Factors for Delayed Graft Function in Deceased Donor Kidney 
Transplantation: Is Intra-Operative Thymoglobulin Preventive?
Neda Naderi,1,2 Mohammad reza Khatami,1 Mahboob Lessan-Pezeshki,1 
Simin Dashti-Khavidaki,1 Azam Alamdari,1 Armin Safdarpour,1 Hamid Moradi.2 
1Nephrology Research Center, Tehran University of Medical Sciences, Tehran, 
Islamic Republic of Iran; 2Harold Simmons Center for Kidney Disease Research 
and Epidemiology, Division of Nephrology and Hypertension, University of 
California, Irvine, CA.
Background: Delayed graft function (DGF) is associated with significant adverse 
outcomes in deceased donor kidney transplantation including lower graft survival. 
However, risk factors and potential preventive strategies like intraoperative thymoglobulin 
(ATG) have not yet been fully evaluated.
Methods: We retrospectively examined medical records of 182 first time cadaveric 
kidney transplant recipients from two major kidney transplant centers from 2014-2016. 
Risk factors for DGF in recipients were evaluated using multivariate logistic regression 
analysis.
Results: The mean age was 43±13 years and the majority of participants were 
male (64%). The rate of intra-operative blood transfusion was 16%. The overall rate of 
DGF was 24.2%. Mean serum creatinine at discharge and length of hospital stay were 
significantly higher in patients with DGF compared with those without DGF (2.5 vs. 
1.4 mg/dl and 25 vs. 14 days, respectively). Intra-operative ATG was significantly associated 
with a lower rate of DGF (adjusted odds ratio [AOR], 0.33, 95% CI, 0.11-0.95). Intra-
operative transfusion (AOR, 3.7, 95% CI, 1.4-9.9) and diabetes mellitus (AOR, 3.7, 95% 
CI, 1.5-8.9) were significantly associated with higher risk of DGF. There was no statistically 
significant association between DGF and recipients’ age, sex, body mass index or duration 
of pre-transplant dialysis.
Conclusions: This study showed that intra-operative blood transfusion and diabetes 
mellitus were independent risk factors for the development of DGF. Meanwhile, 
administration of intra-operative ATG was associated with a reduced odds ratio of DGF. 
Future studies are needed to evaluate the potential role of ATG in DGF-related renal 
outcomes.
SA-PO018 Poster Saturday
Transplantation: Clinical Outcomes
Role of Liver Transplantation in the Treatment of Fibrinogen Aa-Chain 
Amyloidosis
Arie Stangou,2 Steven R. Zeldenrust,1 Nelson Leung,1 Jennifer H. Pinney,7 
Maria E. Drosou,1 Thomas R. Schwab,4 Oren Fix,5 Russell H. Wiesner,3 
Merrill D. Benson.6 1Mayo Clinic, Rochester, MN; 2Queen Elizabeth Hospital, 
Birmingham, United Kingdom; 3Mayo clinic, Rochester, MN; 4Mayo Clinic 
Rochester, Rochester, MN; 5Swedish Medical Center, Seattle, WA; 6Indiana 
University School of Medicine, Indianapolis, IN; 7Department of Renal 
Medicine, University Hospital Birmingham, Worcestershire, United Kingdom.
Background: Variants of fibrinogen Aα-chain (AFib) cause the commonest type of 
hereditary amyloid nephropathy in Europe and probably the US. Fibrinogen production 
is exclusively hepatic and kidney transplants often fail within 1-5 years with recurrent 
amyloidosis. The addition of liver transplantation (LT) offers curative potential. We present 
the long-term experience of the first 15 AFib patients who received liver grafts in our 
Institutions in the UK and US, and discuss the merits and scope for optimal utilisation of 
this valuable resource.
Methods: Ten British and 5 US patients with AFib E526V and amyloid nephropathy 
were listed for transplantation between 1995-2017. Dominant features were proteinuria 
(66%) median 7.37 (2.5-9.8) g/D and kidney impairment, median GFR 25 (0-104) ml/min. 
Extra-renal amyloid manifestations included cardiac (40%) and gastrointestinal (66.6%) 
autonomic neuropathy and clinically significant splenic amyloidosis (27%). Thirteen 
patients, median age 59 (49-63), 9 male, received liver-kidney transplant (LKT); two 
females aged 54 and 58, kidney disease stage 1 and 3 respectively, received isolated liver 
grafts (LT).
Results: At median posttransplant fol-up 133 months (12-277), there is no amyloid 
progression and cumulative patient survival in the entire cohort is 80%. LKT patient 
survival is 76.9%, kidney/ liver graft 92.3%, posttransplant GFR 46 (41-78) ml/min. Three 
adverse outcomes due to biliary or vascular complications occurred early postoperatively in 
the subgroup of 9 patients who received LKT after long-term haemodialysis (survival only 
66.7%). In contrast, in those receiving pre-emptive LKT or LT alone patient survival was 
100%. Both recipients of isolated LT maintain normal liver and stable renal function with 
diminishing proteinuria at 12 and 95 months.
Conclusions: The therapeutic potential of liver transplantation in fibrinogen 
amyloidosis is truly curative. Best transplant benefit from the addition of liver to kidney 
grafts was achieved in low risk pre-dialysis patients. Timely intervention in the pre-dialysis 
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setting utilising liver transplantation alone is rational, feasible and effective. We support 
consideration of this approach to halt disease progression and prevent haemodialysis.
SA-PO019 Poster Saturday
Transplantation: Clinical Outcomes
Impact of CYP3A5 Polymorphism on Clinical Outcome After Renal 
Transplantation
Remi Lenain,2,1 Aghiles Hamroun,2,1 Mehdi Maanaoui,2,1 Cynthia Van der 
hauwaert,6 Franck Broly,5 Myriam Labalette,7 Nicolas Pottier,4 
Christelle Cauffiez,3,1 Francois Glowacki.2,1 1Lille University Hospital Center, 
Lille, France; 2CHRU Lille, Lille, France; 3EA4483, Lille, France; 4University 
of lille, Lille, France; 5Centre de Biologie Pathologie Génétique, Lille, France; 
6EA 4483 Faculté de Médecine de Lille, Lille, France; 7CHRU Lille, Lille, 
France.
Background: Tacrolimus exhibits pharmacokinetics variability partly explained by 
CYP3A5 activity. In contrast to *3/*3 genotype, those carrying at least one CYP3A5*1 
allele exhibit higher enzyme activity leading to lower Tac through blood level despite higher 
daily dose. In this study, we aimed to evaluate the impact of CYP3A5 polymorphism on 
renal graft outcome
Methods: This monocentric cohort includes 1252 renal transplant recipients with a 
mean follow up (FU) of 4 years (up to 12.1y). Genotyping of the 6986A>G allelic variant 
corresponding to CYP3A5*3 was systematically performed. After 3-months post-transplant, 
Tac through blood level target range was 5-7ng/ml. However in order to avoid Tac-induced 
nephrotoxicity, Tac daily dose was limited to a maximum of 0.1 mg/kg/day irrespective of 
CYP3A5 genotype
Results: Our sample includes 224 CYP3A5*1/- patients (13.9%) including 35 *1/*1 
genotype recipients. During the FU, we observed 221 graft losses or deaths (17.65%). 
At baseline, there was no significant difference in characteristics between *3/*3 and *1/- 
groups. Despite higher daily dose, *1/- recipients exhibit systematically significant lower 
Tac through blood level during the FU (p<0.01). Multivariate analysis doesn’t show any 
significant influence of *1/- genotype (HR=0.73, CI95% 0.48–1.09, p=0.12) on patient-
graft survival. However, GFR decline was significantly lower for the *1/- group (p=0.004). 
At five years, eGFR was significantly better for *1/- recipients (47 vs 42 mL/min/1.73m2, 
p<0.001). CYP3A5 genotype doesn’t impact the risk of rejection (HR for *1/- group=0.96, 
CI95% 0.66-1.42, p=0.87)
Conclusions: In this long-term study, CYP3A5*1/- recipients exhibited lower Tac 
through blood level with no impact on the rejection rate. Renal survival was independent 
of CYP3A5 genotype. However, the kidney graft function was significantly better in this 
subgroup showing a lower Tac-induced nephrotoxicity
SA-PO020 Poster Saturday
Transplantation: Clinical Outcomes
HLA Desensitization Using Rituximab/Immunoadsorption Before Kidney 
Transplantation
Lionel Rostaing.1,2 1Pôle DIGIDUNE, La Tronche, France; 2Faculté de 
médecine, université Joseph Fourié, GRENOBLE, France.
Background: Many kidney-transplant (KT) candidates are sensitized against HLA-
antigens, making it difficult to find a suitable HLA-compatible donor. Pretransplant HLA-
desensitization strategies have shown improved patient survival after transplantation. This 
single-centre study included 14 KT candidates (of which seven had a potential living-donor) 
that underwent kidney transplantation after desensitization comprising two rituximab 
injections (375 mg/m2) with concomitant immunosuppression [tacrolimus + mycophenolic 
acid + steroids, and semi-specific immunoadsorption (IA) (GlobaffinÒ columns)].
Methods: IA sessions were performed until anti-HLA alloantibodies become ≤3,000 
mean fluorescent intensity (MFI). At transplantation, all patients were induced with ATG. 
On average, recipients of a living-kidney had 12 (12-15) pretransplant IA sessions; at 
transplant their donor-specific alloantibodies (DSA) had MFI of ≤3,000 except for 2 with 
no rebound at posttransplant. Recipients of deceased donors had 15 (8-83) pretransplant IA 
sessions; all of them had a DSA at transplantation; however, MFI was ≤4,000 in all cases 
but one (anti-DPA1 at 7,000). After transplantation, there was no prophylactic IA therapy 
in both groups.
Results: No living-kidney recipients and one deceased-donor recipient had antibody-
mediated rejections (ABMR), which was successfully treated with eculizumab. Follow-up 
kidney biopsies (at a median of 12 months posttransplantation) were normal except for two 
cases in which there were signs of subclinical ABMR. There was no significant infectious 
complications.
Conclusions: Semi-specific immunoadsorption was very effective at achieving HLA 
desensitization.
SA-PO021 Poster Saturday
Transplantation: Clinical Outcomes
De Novo Complement-Activating Donor Specific Antibodies Are Highly 
Responsive to Therapy
Vaka K. Sigurjonsdottir, Paul C. Grimm. Stanford University Medical Center, 
Stanford, CA.
Background: After recognizing that graft failure was more common in our patients 
with positive de Novo DSAs (dnDSAs) by C1q we started using the C1q assay as a guide to 
therapy of rejection. The aim of this study was to investigate response to treatment as well 
as characteristics and allograft function of pediatric renal transplant patients with positive 
dnDSA by C1q.
Methods: Retrospective cohort of 35 pediatric renal transplant patients, age 1-20 years, 
who formed C1q dnDSAs identified by screening or investigation of allograft dysfunction 
with at least 6 month follow up. C1q dnDSAs were identified by single-antigen flow bead 
assay. Outcomes were evolution of C1q dnDSAs and graft function in patients with C1q. 
GFR was estimated using Schwartz method. The same pathologists reviewed all biopsies.
Results: Followup was 36 months (11-96) (Median (range).) Figure 1 shows 
evolution of C1q. Therapy consisted of Solumedrol (n=19), Thymoglobulin (n=15), 
IVIG (n=23), Rituximab (n=20) and 1 received Bortezomib / plasmapheresis. Steroid 
free immunosuppression was converted to steroid based in 9 patients. Maintenance 
immunosuppression was adjusted/increased when appropriate, adherence anticipatory 
guidance was provided as needed. During the follow up period, 5 patients, had allograft 
failure. Figure 2 shows Kaplan–Meier curves for renal survival.
Conclusions: Interventions directed against complement-binding DSA at our center, 
reduced or eliminated the C1q biomarker significantly. Persistence of C1q antibodies was 
associated with worse allograft outcome
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Transplantation: Clinical Outcomes
Predictors of Graft Survival at Diagnosis of Antibody-Mediated Renal 
Allograft Rejection
Michael Duerr,1 Friederike Bachmann,1 Nils Lachmann,1 Jens Klotsche,2 
Fabian Halleck,1 Kaiyin Wu,3 Lutz Liefeldt,1 Klemens Budde,1 Johannes Waiser.1 
AG Duerr & Waiser 1Charité Universitaetsmedizin Berlin, Berlin, Germany; 
2German Rheumatism Research Center Berlin, a Leibniz Institute, Berlin, 
Germany; 3Institut für Pathologie, Charite Campus Mitte, Berlin, Berlin, 
Germany.
Background: Treatment of antibody-mediated rejection (ABMR) after renal 
transplantation is unsatisfactory. In order to improve treatment efficacy, it is necessary to 
identify parameters, which independently predict graft survival at diagnosis.
Methods: We investigated 54 consecutive renal allograft recipients with a diagnosis 
of ABMR between 2005 and 2015. Patients were treated with five different consecutive 
treatment groups of 10-12 patients. Patient characteristics, renal function and HLA antibody 
status at diagnosis, baseline renal biopsy results and immunosuppressive treatment were 
thoroughly recorded. The identification of diverse risk factors of graft loss at 24 months 
after diagnosis was investigated uni- and multivariate by a Cox proportional hazard model.
Results: Concerning the underlying patient characteristics including baseline 
parameters at diagnosis, we found no major differences between treatment groups. 
Multivariable analysis showed that transplant glomerulopathy, microvascular inflammation, 
and eGFR were predictive for graft loss at 24 months after diagnosis (table 1). 
In our analysis proteinuria (per 500mg/day) was statistically not a risk factor in the 
univariate analysis (HR 1.12; 95% CI 0.99-1.27; p=0.072). Notably, a significant (>10%) 
decrease of DSAmax (HR 0.62; 95% CI 0.25-1.52; p=0.294) following treatment was not 
associated with an improved graft survival compared to patients with no significant DSA 
decrease. Treatment with cyclophosphamide (6x15mg/m2) plus high-dose intravenous 
immunoglobulins (IVIG) (1.5g/kg) was superior compared to treatment with rituximab 
(1x500mg) (HR 0.10; 95% CI 0.02-0.54; p=0.008) or bortezomib (4x1.3mg/m2) plus low-
dose IVIG (30g) (HR 0.16; 95% CI 0.02-0.99; p=0.049).
Conclusions: Histopathological signs of acute and chronic ABMR as well as renal 
function at diagnosis are independent risk factors for graft survival. Treatment with 
cyclophosphamide plus high-dose IVIG seems to be advantageous. Prospective studies 
including patients with defined risk factors are needed in order to further improve treatment 
efficacy.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
SA-PO023 Poster Saturday
Transplantation: Clinical Outcomes
Outcomes Following Living Donor Kidney Transplantation in Patients 
with Donor-Specific HLA Antibodies After Desensitization with 
Immunoadsorption
Florian Kälble,2,1 Luiza Pego silva,2,1 Claudius Speer,2,1 Christian Nusshag,2,1 
Matthias Schaier,2,1 Martin G. Zeier,2,1 Arianeb Mehrabi,2 Caner Süsal,2 
Christian Morath.2,1 1Nierenzentrum Heidelberg, Heidelberg, Germany; 
2University Hospital Heidelberg, Heidelberg, Germany.
Background: Due to the current organ shortage, living donor kidney transplantation 
is increasingly performed over human leukocyte antigen (HLA) or ABO antibody barriers. 
Uncertainty still exists concerning the risk for antibody-mediated rejection episodes, 
possibly limiting long-term graft survival. The present study aimed to evaluate the outcomes 
of kidney transplantations performed after desensitization in patients with donor-specific 
HLA antibodies compared to standard risk recipients.
Methods: Thirty-eight sensitized patients were included in the study. Sixteen patients 
had a positive CDC and/or ELISA crossmatch result with their prospective living donor 
and 32 patients had Luminex-detected donor-specific HLA antibodies (DSA). Patients were 
successfully desensitized by immunoadsorption treatment (median of 8 treatments) and 
anti-CD20 antibody rituximab (N=36) combined with antithymocyte globulin (N=20) or 
anti-IL2 receptor antibody therapy (N=18). Twelve patients were additionally treated by 
plasmapheresis. All patients received a kidney transplant from a living donor. Postoperative 
apheresis was performed in 28 patients. The outcomes of the 38 patients were retrospectively 
compared to outcomes of 76 standard risk recipients (2:1 matching).
Results: During a median of 8 pretransplant immunoadsorption treatments, IgG was 
reduced by 98% and IgM by 78% in sensitized patients. After transplantation, sensitized 
patients showed comparable death-censored graft survival and patient survival compared 
to standard risk recipients. Infectious complications, surgical complications and rejection 
rates (18% in both groups) were not significantly different between groups. Median 1-year 
serum creatinine was with 1.31 mg/dL in sensitized recipients not significantly different to 
the 1.38 mg/dL in standard risk recipients. One-year urinary protein excretion was also not 
significantly different with a low 10.8 and 10.5 g/mol creatinine, respectively.
Conclusions: Our desensitization protocol for sensitized living donor kidney transplant 
recipients results in good graft outcomes with comparable side effects and rejections rates 
to standard risk recipients.
SA-PO024 Poster Saturday
Transplantation: Clinical Outcomes
Outcomes in Sensitized Kidney Transplant Recipients Treated with 
Rituximab
Perola Lamba,1 Isha Lamba,2 Rex Friedlander,3 Michelle L. Lubetzky,4 
John R. Lee,4 Jun B. Lee,3 Choli Hartono,3 David Serur,3 Thangamani 
Muthukumar,4 Vijay K. Sharma,3 Darshana Dadhania.4 Weill Cornell Medicine 
1Department of Medicine, New York Presbyterian/Weill Cornell Medicine, New 
York, NY; 2Weill Cornell Medicine-Qatar, Doha, Qatar; 3The Rogosin Institute, 
New York, NY; 4Division of Nephrology and Hypertension, Weill Cornell 
Medicine, New York, NY.
Background: Donor specific antibodies (DSAs) are associated with increased risk of 
rejection & graft loss following kidney transplantation (KT). Patients with DSA & positive 
flow cytometry crossmatch (XM) were treated with rituximab at transplant while those with 
negative XM and DSA were not. We evaluated clinical outcomes of patients with DSA at 
time of transplant stratified by rituximab therapy.
Methods: Retrospective review of sensitized KT recipients with DSA were studied 
excluding ABO-incompatible transplants. Graft survival was compared using log-rank test 
& multivariable analysis was performed using logistic regression.
Results: Individuals treated with rituximab were more likely to receive steroid 
maintenance & had higher DSA MFI-Sum (Table 1). One-year acute rejection rates were 
not different between those treated with & without rituximab. The survival of rituximab 
treated group was significantly lower (Fig. 1, P=0.02). In a logistic regression model, none 
of the variables were independent predictors of graft survival, rituximab therapy (P=0.24), 
steroid therapy (P=0.83), MFI-Sum category (P=0.44).
Conclusions: Among sensitized patients, those treated with rituximab had higher 
levels of DSA and had decreased overall graft survival. Treatment with rituximab was 
not independently associated with increased risk of graft loss. Additional studies are need 
to truly evaluate the risks & benefits of rituximab therapy in the highly sensitized patient 
population.
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Transplantation: Clinical Outcomes
The Risk of Renal Re-Transplantation
Anke Schwarz, Theodor Framke, Hermann G. Haller. Hannover Medical 
School, Hannover, Germany.
Background: Renal transplant programs comprise around 15% of re-transplantations. 
We aimed to know if renal re-transplantation (Tx2) has a higher risk than first transplantation 
(Tx1), and if so, to analyze the reasons for it.
Methods: This is a retrospective monocenter study by comparing graft and patient 
survival of all 162 Tx2 patients transplanted 2000 to 2009 (study group) with 162 Tx1 
patients matched for age (± 10 years), gender, date of transplantation (± 18 months), and the 
kind of kidney donation (control group). We looked for differences in clinical parameters 
with a possible influence on graft and patient survival (observation time 8 to 17 years).
Results: Graft and patient survival of TX2 was inferior to that of TX1 patients 
(p=0.0011 resp p=0.0477, test for paired data). Group TX2 had a longer dialysis treatment 
than TX1 (113.0±52.5 vs 65.6±33.9 months; p<0.0001); more often HLA mismatches (MM) 
(2.54±1.75 vs 2.08±1.65, p=0.0129) and preformed panel reactive HLA-antibodies (PRA) 
>30% (15.4% vs 1.9%, p=0.0001); and more often induction therapy by thymoglobulin
instead of IL-2R antibody (59.9% vs 1.9%, p<0.0001). The number of patients with
rejection (39.57% vs 36.4%) and of rejections per patient (0.58±0.92 vs 0.56±0.87) were
not different; however, graft failure by acute and chronic rejection was more frequent in the 
Tx2 group (32.22% vs 21.21%, p=0.0137). The number of patients with severe infections
threatening life and/or graft function was not different (41.36% vs 39.5%); however, death 
by severe infection was more frequent in group Tx2 (0.0411). Testing several variables by 
Kaplan-Meier curves, Tx2 show an inferior graft survival than Tx1 patients with a higher
number of HLA-MM (logrank p=0.0137), with humoral rejection (logrank p=0.0037), and 
have a higher mortality with several concomitant diseases, (logrank p<0.0001), especially
cardiovascular disease (logrank p<0.0001), and severe infection (logrank p=0.0001).
Conclusions: Tx2 patients have several reasons for an inferior graft and patient 
survival compared to Tx1 patients: a) Immunologic reasons (more often HLA MM and high 
PRA, more often graft failure by rejection); b) higher mortality by concomitant diseases, 
especially cardiovascular disease and infection; c) less capacity to adapt to immunologic 
and infectious problems and failure to cope with them.
SA-PO026 Poster Saturday
Transplantation: Clinical Outcomes
Kidney Transplantation Outcomes in Patients with Idiopathic Membranous  
Nephropathy as Primary Disease
Sophia Lionaki,1 Sophia Akritidou,1 Alexandra Mavroudi,1 Georgios Liapis,1 
Aliki Iniotaki,2 Georgios Zavos,3 John Boletis.1,4 1Nephrology, Laiko Hospital, 
Athens, Greece; 2Histocompatibility, Gennimatas Hospital, Athens, Greece; 
3Transplantation Unit, Laiko, Athens, Greece; 4Medicine, National & 
Kapodistrian University of Athens, Athens, Greece.
Background: Kidney transplantation (KTx) is the treatment of choice for patients 
with glomerular diseases. However, in some occasions relapse of the primary disease in the 
graft may impact graft survival. We aimed to explore the outcome of KTx in patients who 
ended in ESRD due to idiopathic membranous nephropathy (IMN), the frequency of disease 
relapse in the graft along with the response to the current treatment options.
Methods: We retrospectively studied all patients with IMN as primary disease, 
transplanted in our hospital between 1990-2016. All patients had biopsy proven IMN 
in their native kidneys. Demographics and characteristics related to the donors and the 
recipients at KTx were recorded, including, dialysis time, immunosuppressive schemes, 
histocompatibility data, acute rejection episodes, patient and graft survival, and eGFR at the 
end of the follow up time. Relapses of IMN were recorded in conjunction with the given 
treatment and the related response. All patients with IMN relapse were initially treated with 
an ACE inhibitor (fosinopril) and depending on the response or not, received either the 
Ponticelli protocol, as 2ndline therapy, or more recently rituximab.
Results: We identified 18 patients with ESRD due to IMN who received a graft 
between 1990-2016 in our hospital. The mean age at the time of KTx was 47±11.5 years and 
13(72.2%) of them were males. The mean time in dialysis was 63.2(±51.5) months, the graft 
was from deceased donors in 13 cases (72.2%), with a mean donor age of 46(±15.46) years. 
During a follow up time of 84.97(±57.6) months after KTx, 7 patients (38.8%) experienced 
at least one episode of IMN relapse. Time to relapse was 45.6(±42.7) months from KTx 
and 24-hour proteinuria was 4.12(±2.88) gr. Two patients experienced acute rejection, one 
of them during the relapse of IMN. At the end of the follow up time, patients’ survival was 
100%, graft survival was 88.9%, with a mean serum creatinine of 1.8(±0.23) mg/dl, eGFR 
of 60.84 (±27.3) ml/min/1.73m2 and mean 24-hour proteinuria of 0.75(±0.58) gr.
Conclusions: Relapse of IMN in the graft is not rare, but in most occasions is responsive 
to therapy, either with inhibition of the renin angiotensin system, either with enhancement 
of immunosuppressive treatment, and generally it does not affect long term graft survival.
SA-PO027 Poster Saturday
Transplantation: Clinical Outcomes
Outcomes of Kidney Transplant Recipients with Pre-Transplant, 
Recurrence, and Post-Transplant Malignant Melanoma
Sarah E. Di Bartolomeo, Stacey Rolak, Brad C. Astor, Sandesh Parajuli. 
University of Wisconsin School of Medicine and Public Health, Madison, WI.
Background: Kidney transplant recipients (KTRs) have an increased risk of 
malignancy, especially skin cancer. Patients with pre-transplant melanoma usually wait 
a longer period before transplantation than their counterparts with non-melanoma skin 
cancers as there is limited data on risk of recurrence and outcomes of pre, recurrent and 
post-transplant melanoma.
Methods: We analyzed the outcomes of KTRs transplanted at our center between 
01/01/1994 and 12/31/2014 who reported pre-transplant melanoma, recurrence of 
melanoma after transplant and post-transplant melanoma.
Results: Of 4941 KTRs within the abovementioned time-period, thirty-four had a 
history of melanoma prior to renal transplant, of which 6 (18%) had recurrence of melanoma 
post-transplant. Mean wait time from melanoma diagnosis to transplant was 389 ± 311 days 
for non-recurrent patients and 422 ± 411 days (p=0.32). The mean interval to recurrence 
of melanoma was 6.2 ± 3.7 years after transplant. Five of the 6 patients with recurrence 
had end stage renal disease due to diabetes. All KTRs with or without recurrence were 
Caucasian. The cumulative incidence of biopsy-confirmed rejection was 50% (n=3) in those 
with recurrence, compared to 4% (n=1) in those without recurrence (p=<0.001). The mean 
interval from transplant to rejection was 2.9 ± 1.6 and 1.4 years respectively. The cumulative 
incidence of death censored graft loss was 17% (n=1) among recurrent melanoma patients 
with an interval from transplant to graft loss of 6.0 years while the incidence among only 
pre-transplant melanoma was 14% (n=4) with an interval of 5.0 ± 3.1 years. Similarly, 
there were a total of forty-five Caucasian KTRs with post-transplant melanoma. The mean 
interval from transplant to melanoma was 4.4 ± 3.1 years. The incidence of death censored 
graft loss was 11% (n=5) at last follow-up.
Conclusions: Recurrence of melanoma is common among KTRs with pre-transplant 
melanoma, especially among KTRs with diabetes. Incidence of biopsy proven rejection 
and graft failure among recurrent melanoma is high. Proper risk stratification and early 
diagnosis may improve patient and graft survival.
SA-PO028 Poster Saturday
Transplantation: Clinical Outcomes
History of Posttraumatic Stress Disorder, and Mortality After Kidney 
Transplantation
Miklos Z. Molnar,1,3 Ashmita Siwakoti,1 Praveen Kumar Potukuchi,1 
Abduzhappar Gaipov,1 Manish Talwar,1,3 Vasanthi Balaraman,1,3 Arijit 
Chakravarty,1,3 Elani Streja,2 James D. Eason,1,3 Kamyar Kalantar-Zadeh,2 
Csaba P. Kovesdy.1 1University of Tennessee Health Science Center, Memphis, 
TN; 2University of California Irvine, School of Medicine, Orange, CA; 
3University of TN/Methodist Transplant Institute, Memphis, TN.
Background: History of posttraumatic stress disorder (PTSD), if uncontrolled, 
represents a relative contraindication for kidney transplantation. However, no previous 
large study assessed the association between pre-transplant history of PTSD and post-
transplantation outcomes.
Methods: We examined 4,479 US veterans who underwent kidney transplantation. The 
diagnosis of history of PTSD was based on a validated algorithm. Associations between pre-
transplantation PTSD and all-cause mortality was examined in unadjusted and multivariable 
adjusted Cox proportional regression models.
Results: From among 4,479 veterans, 282 (6.3%) had a history of PTSD. The 
mean±SD age of the cohort at baseline was 61±11 years, 91% were male, 66% and 28% 
of patients were white and African-American, respectively and 31% received living 
transplantation. Compared to patients without history of PTSD, patients with a history of 
PTSD had similar risk of all-cause death [Hazard Ratio (HR) (95% Confidence Interval 
(CI)): 1.12 (0.82-1.51)] in our unadjusted model as shown in Figure 1. After adjustment 
for socio-demographic, comorbidity, medication, dialysis and transplant related variables 
there was no association between history of PTSD and all-cause mortality [HR (95%CI): 
1.17 (0.83-1.65)].
Conclusions: After careful selection, pre-transplantation PTSD does not appear to be 
associated with higher mortality in kidney transplant recipients.
Funding: NIDDK Support
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Figure 1: Probability of Death in Recipients with and without PTSD
SA-PO029 Poster Saturday
Transplantation: Clinical Outcomes
Establishing a Core Outcome Measure for Life Participation: A Standard-
ized Outcomes in Nephrology – Kidney Transplantation (SONG-Tx) 
Consensus Workshop Report
Angela Ju,1,2 Michelle A. Josephson,3 Kevin J. Fowler,4 Jonathan C. Craig,5 
Martin Howell,6 Allison Tong.7 1The University of Sydneyd, Sydney, NSW, 
Australia; 2Center for Kidney Research, Westmead, NSW, Australia; 3University 
of Chicago, Chicago, IL; 4Kidney Health Initiative, Elmhurst, IL; 5University of 
Sydney/Children’s Hospital, Sydney, NSW, Australia; 6University of Sydney, 
School of Public Health, Sydney, NSW, Australia; 7The University of Sydney, 
Seven Hills, NSW, Australia.
Background: Kidney transplantation confers substantial survival and quality of 
life benefits for many patients with end-stage kidney disease compared with dialysis but 
complications and side effects of immunosuppression can impair participation in daily life 
activities. Life participation is a critically important patient-reported outcome for kidney 
transplant recipients but it is inconsistently and infrequently measured in trials. We convened 
a consensus workshop on establishing a core outcome measure for life participation for use 
in all trials in kidney transplantation.
Methods: Twenty-five (43%) kidney transplant recipients/caregivers and 33 (57%) 
health professionals from eight countries participated in six facilitated breakout group 
discussions. Transcripts were analyzed thematically
Results: Four themes were identified. Returning to normality conveyed the patients’ 
goals to fulfil their given roles (i.e. in their family, work, and community) and re-establish 
a normal lifestyle. Recognizing the diverse meaning and activities of ‘life’ explicitly 
acknowledged life participation as a subjective concept that could refer to different 
activities (e.g. employment, recreation, family duties) for each individual patient. Capturing 
vulnerability and fluctuations post-transplant (e.g. due to complications and side-effects) 
distinguished between experiences in the first year post-transplant and the long-term impact 
of transplantation. Having a scientifically rigorous, feasible and meaningful measure was 
expected to enable consistent and frequent assessment of life participation in trials in kidney 
transplantation.
Conclusions: A feasible and validated core outcome measure for life participation is 
needed so this high-priority patient-reported outcome can be consistently and meaningfully 
assessed in trials in kidney transplantation to inform decision-making and care of patients.
SA-PO030 Poster Saturday
Transplantation: Clinical Outcomes
Fatigue Predicts Graft and Patient Survival After Kidney Transplant
John D. Peipert, Juan C. Caicedo, Kelsey L. Ensor, David Cella, John 
J. Friedewald, Michael Abecassis, Daniela Ladner, Zeeshan Butt. Northwestern 
University Transplant Outcomes Research Collaborative-NUTORC
Northwestern University, Chicago, IL.
Background: Fatigue is a prevalent post- kidney transplant (KT) symptom, and it is 
associated with reduced overall health-related quality of life and decreased kidney function. 
Yet, its association with graft and patient survival is unclear.
Methods: Using the SF-36 Vitality (Vit) scale and a single question from the Functional 
Assessment of Cancer Therapy – Kidney Symptom Index, “I have a lack of energy” (GP1), 
we examined change in fatigue from pre- and post-KT (3 months and 1 year) among 528 
KT patients between 10/29/2007 and 08/18/2016 at a large academic transplant center. The 
Vit scale ranges from 0-100, and GP1 ranges from 0-4. On both measures, higher scores 
indicate less fatigue. We examined whether pre-KT fatigue and slope of change in fatigue 
from pre- to post-KT were associated with 1- and 3-year death censored graft survival 
(DCGS) and patient survival.
Results: Respectively, mean Vit and GP5 scores increased from pre-KT to 3 mo and 1 
year post-KT: Vit - 45.4, 63.5, 67.3 (p<0.001); GP1 – 1.8, 2.7, 2.9 (p<0.001). There was a 
significant association with change in creatinine from pre- to post-KT with fatigue measured 
by both the Vit and GP1 (p<0.001 for each). Patients with median or below Vit scores pre-
KT had significantly lower 1 year DCGS rates (93.2% vs. 96.9%, p=0.045) and patient 
survival rates (96.2% vs. 99.6%, p=0.006). Patients with median or below slope in Vit score 
change from pre- to post-KT had lower 3 year DCGS rates (88.5% vs. 96.2%, p=0.002) 
(Figure). Similar to these results, patients with median or below slope in GP1 score change 
from pre- to post-KT had lower 3 year DCGS rates (88.8% vs. 94.6%, p=0.04).
Conclusions: Fatigue is associated with reduced kidney function, graft failure, and 
mortality after KT. Patients with high risk for graft loss and mortality also suffer from higher 
fatigue after KT than those with well working kidneys. Future research should explore how 
monitoring fatigue might improve post-KT follow-up.
SA-PO031 Poster Saturday
Transplantation: Clinical Outcomes
Long-Term Outcome of Kidney Transplant Recipients Admitted to the 
Intensive Care Unit
Amgad E. El Agroudy.1,2 1Medicine, College of Medicine and Medical Sciences, 
Arabian Gulf University, Manama, Bahrain; 2Nephrology and Transplantation 
Unit, Salmaniya Medical Complex, Manama, Bahrain.
Background: The goal of this study was to evaluate the course and outcome of kidney 
transplant (KT) recipients admitted to ICU.
Methods: We reviewed the data of all adult renal transplant recipients who are admitted 
to the ICU at our center, between 1997 and 2017 that included the demographic features, 
causes of end-stage renal disease (ESRD), causes of admission, time between transplantation 
and admission and ICU courses and outcome. Among 379 KT followed up in our center, 60 
patients were admitted to ICU and were categorized to early (during first 3 months; n=28); 
intermediate (3–12 months; n=7); and late (12 months and afterwards, n=25).
Results: The rate of ICU admission was 15.9% and the mean age was 48.3 ± 12.6 
years. The main cause of admissions was surgical complication (71%) in early group 
and infection (57% and 80%) in later groups, respectively. Mortality on discharge was 
significantly higher in late admission (52%) (p=0.0001) and the leading cause of death in 
all groups was sepsis (89%). Twenty patients required ventilator that was an independent 
risk factor for mortality (P < 0.05). There was statistically significant decrease in the overall 
5-year and 10-year patient survival (P = 0.031) in KT patients admitted to the ICU.
Conclusions: Our study shows that the main reason for ICU admissions was infections
especially in late admission. Mortality rate were relatively high and was linked to need 
for ventilators. Admission to the ICU is usually associated with decrease in the graft and 
patient survival.
SA-PO032 Poster Saturday
Transplantation: Clinical Outcomes
Anemia at One Year After Kidney Transplantation Is a Risk Factor of 
Graft and Patient Survival
Amgad E. El Agroudy.1,2 1Medicine, College of Medicine and Medical Sciences, 
Arabian Gulf University, Manama, Bahrain; 2Nephrology and Transplantation 
Unit, Salmaniya Medical Complex, Manama, Bahrain.
Background: Post-transplant anemia is multifactorial and highly prevalent. The 
purpose of this study was to assess whether the presence of anemia at 12 months year is an 
independent risk factor of mortality and graft survival.
Methods: All patients followed-up at a single center who survived at least 1 year 
after transplantation and with serum creatinine ≤140 μmol/l (n = 297) were included. 
Demographic and clinical data were collected at baseline and at 1 year. Patients were divided 
into two groups (anemic and nonanemic) based on the presence of anemia (hemoglobin; 13 
g/dl in men and 12 g/dl in women) at 12 months.
Results: Baseline characteristics such as age, gender, type of donor, etiology of end-
stage kidney disease, pre-emptive transplant, duration of pre-transplant dialysis, type of 
primary immunosuppression and mismatches were similar in both groups. There was 
statistically higher use of induction therapy (p=0.021), rate of acute rejection after the first 
year (p=0.020), CMV infection (p=0.015) and chronic allograft damage (p=0.004) in anemic 
group compared to nonanemic group. Creatinine clearance at last follow-up was significantly 
lower in anemic (59.3 ± 10.8 ml/min) and nonanemic groups (45.3 ± 12.5 ml/mim) 
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(P = 0.039). A Kaplan–Meier survival analysis at 10-year post-transplant showed 
significantly poorer death-censored graft survival in the anemic group, P = 0.04 and patient 
survival (p=0.03). There was more statistically rate of death with function graft in anemic 
group (p=0.043).
Conclusions: In this study, anemia at 1 year was independently associated with death-
censored graft and patient survival. Anemic patients have higher rate of acute rejection, and 
chronic allograft damage.
SA-PO033 Poster Saturday
Transplantation: Clinical Outcomes
The Combination of Area Under Curve of Estimated Glomerular 
Filtration Rate for 2 Years and Annual Rate Change of Estimated 
Glomerular Filtration Rate Predicts Long-Term Outcome in Kidney 
Transplants
Eun jeong Lee, Song in Baeg, Hyo jin Boo, Minjung Kim, Hye Ryoun Jang, 
Jung eun Lee, Dae Joong Kim, Yoon-Goo Kim, Ha Young Oh, Wooseong Huh. 
Samsung Medical Center, Seoul, Republic of Korea.
Background: Improvement of short-term outcomes in kidney transplant (KT) has 
required clinical trials to evaluate long-term hard outcomes for validation of new therapies. 
However, because of time and cost, it is very difficult to conduct a clinical trial using hard 
outcomes in KT. To solve the problem, the use of surrogate marker should be considered. 
We examined the possibility of the combination of area under curve of estimated glomerular 
filtration rate for 2 years (AUCeGFR2yrs) and % change in estimated glomerular filtration 
rate (eGFR) between years 1 and 2 after KT as a surrogate marker for long-term graft 
failure.
Methods: We studied 1423 kidney transplants performed from 1996 to 2013 at 
Samsung Medical Center, Seoul, Korea, including 202 graft losses (time to graft failure, 
median 8.4 years [5.4 - 12.4]) and 54 deaths (time to death, median 9.1 years [5.7 - 13.2]). 
Combination of AUCeGFR2yrs (>1300 ml/min
.month vs ≤ 1300 ml/min.month) and % 
change in eGFR (> 2% vs ≤ 2%) was assessed to determine risk of graft failure using Cox 
proportional hazard analysis.
Results: The combination was significantly associated with graft failure (p < 0.0001). 
Patients with AUCeGFR2yrs ≤ 1300 ml/min
.month and % change in eGFR ≤ 2% formed 
16.7% of all patients and showed higher graft failure risk (hazard ratio [HR], 3.36; 95% 
confidence interval [95% CI], 2.52 to 4.48). The Harrell C-index of the combination 
was 0.65 (95% CI, 0.60 to 0.69), and was internally validated via 5-fold cross-validation 
(average Harrell C-index, 0.64; 95% CI, 0.60 to 0.68). We also evaluated a known surrogate 
marker, ≥ 30% decline in eGFR between years 1 and 3 after KT. The incidence of ≥ 30% 
decline in eGFR was 6.9% of patients. HR of graft failure was 7.18 (95% CI, 5.22 to 9.89) 
and Harrell C-index was 0.65 (95% CI, 0.63 to 0.66).
Conclusions: We conclude the proposed combination might be useful as a surrogate 
outcome in KT trials in that it requires shorter surveillance period (2 years) than the known 
surrogate marker (3 years) while having comparable predictability. External validations 
should be conducted.
SA-PO034 Poster Saturday
Transplantation: Clinical Outcomes
Impact of Donor Age on Outcome of Kidney Transplantation from 
Deceased Donor with Histologic AKI
Myung-Gyu Kim, Junyong Lee, Jihyun Yang, Sewon Oh, Sang-Kyung Jo. 
Korea University Anam Hospital, Korea University College of Medicine, Seoul, 
Republic of Korea.
Background: The shortage of donors has expanded donor criteria and kidneys from 
elderly donors with AKI have been used for transplant recently, but safety and prognosis 
are not well known. Here, we examined the effect of donor age on outcomes of kidney 
transplant (KT) from donor with histologic AKI.
Methods: We analyzed retrospectively the medical records of 59 deceased-donor KT 
with acute tubular necrosis (ATN) on pre-implantation donor kidney biopsy between March 
2012 and October 2017. Histologic quantifications of ATN and inflammation, glomerular 
sclerosis (GS), interstitial fibrosis, tubular atrophy, and arterial sclerosis were performed.
Results: Twenty and thirty nine recipients were received kidney from old 
(>60, 68.9±5.0) and young donors (≤60, 45.9±9.6) with ATN, respectively. In the old 
donors, a significant increase in donor Cr was observed only in 44%, diabetic patients were 
higher, women were dominant, and the percent of GS(%) was significantly higher than 
in young donors. After KT, six months eGFR was significantly lower in recipients who 
received kidney from old donors than form young donors. Donor creatinine level and AKI 
severity according to AKIN criteria did not significantly affect the recipient outcome in both 
groups during 6mo post-transplant. However, only in KT from old donors, the presence 
of ATN and GS(%) were found to be significant factors exacerbating renal outcome at 
6mo, but not in KT from young donor. In particular, in multivariate analysis, the sum of 
ATN scoring and GS percent was the strongest independent factor for predicting elderly 
recipient renal function, suggesting that aged kidney is an important factor in modifying 
the outcomes of AKI.
Conclusions: Taken together, the assessment of AKI based on creatinine is not useful 
for predicting prognosis, but in KT from old donors, acute tissue injury as well as GS could 
predict renal outcome. Therefore, a donor allocation protocol with evaluating histologic 
acute and chronic lesions through pre-implantation donor kidney biopsy need to be 
developed when KT from old donors.
SA-PO035 Poster Saturday
Transplantation: Clinical Outcomes
Incidence, Outcomes, and Predictors of Pregnancy in Kidney Transplant 
Recipients
Silvi Shah, Annette Christianson, Karthikeyan Meganathan, Anthony 
C. Leonard, Charuhas V. Thakar. University of Cincinnati, Cincinnati, OH.
Background: Although kidney transplant improves reproductive function in women
with end stage renal disease (ESRD), pregnancy in kidney transplant recipients remains 
challenging due to risk of adverse outcomes. Temporal trends in pregnancy rate, fetal 
outcomes and its predictors in women with kidney transplants are not well studied.
Methods: We evaluated women aged 15-49 years who received a kidney transplant 
between 1/1/2005 and 12/31/2011 from the United States Renal Data System and who had 
Medicare as the primary payer for the entire 3 years after the date of transplantation or 
until graft failure or death. Temporal trends in pregnancy rates and fetal outcomes were 
studied. Case mix adjusted multivariate Poisson regression analysis was used to determine 
predictors of pregnancy.
Results: Overall, 308 pregnancies were identified in 9939 women. Mean maternal 
age was 30±7 year. Pregnancy rate was 11.4 per 1000 person-year (95% CI, 10.1-12.7). 
Pregnancy rates were roughly constant in the years 2005-2011. Of the known pregnancy 
outcomes, rate of live-birth was 42.6%, and stillbirth was 3.7%. Another 14.4% were 
reported as either live birth or stillbirth. Rate of spontaneous abortion was 32.4%, 
therapeutic abortion was 6.5% and ectopic pregnancy was 1.4%. Compared to women 
aged 25–29 years at time of conception, the pregnancy rate was lower in women aged 
30–34 years (Incidence risk ratio [IRR], 0.56; CI, 0.41-0.77), 35-39 years (IRR, 0.16; CI 
0.10-0.25), 40-44 years (IRR, 0.08; CI, 0.04-0.13), and 45-49 years (IRR, 0.06; CI, 0.03-
0.10). Hispanic women had higher rates of pregnancy as compared to White women (IRR, 
1.6; CI, 1.2-2.1). In transplant recipients, as compared to women with ESRD due to diabetes, 
pregnancy rate was higher in women with ESRD due to hypertension (IRR, 1.3; CI, 1.0-
1.7), glomerulonephritis (IRR, 2.4; CI, 1.1-5.3), and cystic/hereditary diseases (IRR, 3.3; 
CI, 1.4-7.8). Women had higher rate of pregnancy in the second (IRR, 1.7; CI, 1.3-2.3) and 
third post transplant year (IRR, 1.7; CI, 1.3-2.3) as compared to first post transplant year.
Conclusions: Pregnancy in kidney transplant recipients is not uncommon and rates 
were relatively constant in in the last decade. Younger and Hispanic patients; and those 
with conception after the first post transplant had the highest rates of becoming pregnant.
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Pregnancy Outcomes in Women with Kidney Transplant: Meta-Analysis 
and Systematic Review
Silvi Shah,1 Renganathan Lalgudi venkatesan,1 Ayank Gupta,3 Emily B. Kean,1 
Maitrik K. Sanghavi,1 Tiffany J. Grant,1 Anu Gupta.2 1University of Cincinnati, 
Cincinnati, OH; 2Buffalo Medical Group, Buffalo, NY; 3The University of 
Cincinnati, Cincinnati, OH.
Background: Reproductive function in women with end stage renal disease generally 
improves after kidney transplant. However, pregnancy remains challenging due to the risk 
of adverse clinical outcomes. This systematic review aimed to determine the pregnancy 
outcomes in patients with kidney transplant, including live birth rate, nature and rates of 
maternal and fetal adverse events, and risk of graft failure.
Methods: We searched PubMed/MEDLINE, Elsevier EMBASE, Scopus, BIOSIS 
Previews, ISI Science Citation Index Expanded, and the Cochrane Central Register of 
Controlled Trials from their date of inception through August 2017 according to PRISMA 
guidelines for studies reporting incidence and outcomes of pregnancy in women with 
kidney transplant.
Results: Of 1343 unique studies, 87 met inclusion criteria, representing 6712 
pregnancies in 4174 kidney transplant recipients. Mean maternal age was 29±2 years. The 
live-birth rate was 72.9% (95% CI 70.0-75.6). Other pregnancy outcomes included induced 
abortions (12.4%; 95% CI, 10.4-14.7), miscarriages (15.4%; 95% CI, 13.8-17.2), stillbirths 
(5.1%; 95% CI, 4.0-6.5), and ectopic pregnancies (2.4%; 95% CI, 1.5-3.7). Maternal 
complications that were determined included preeclampsia (21.5%; 95% CI, 18.5-24.9), 
gestational diabetes (5.7%, 95% CI 3.7-8.9), pregnancy induced hypertension (24.1%; 95% 
CI, 18.1-31.5), and cesarean section (62.6%, 95% CI 57.6-67.3). Fetal complications of 
preterm delivery was 43.1% (95% CI 38.7-47.6). Mean gestational age was 34.9 weeks, and 
mean birth weight was 2470 grams. With regards to graft outcomes, rate of acute rejection 
during pregnancy was 9.4% (95% CI, 6.4%-13.7%). Adverse pregnancy outcomes of 
cesarean section and neonatal deaths were highest, and live birth rate were less favorable 
in the 2-3 year interval as compared to 1-2 year and > 3 year interval following kidney 
transplant. Rates of spontaneous abortion were highest in women with mean maternal age < 
25 years and > 35 years as compared to women aged 25-35 years.
Conclusions: Majority of pregnancies following kidney transplant are successful and 
do not have an adverse impact on fetal survival. However the risks of maternal and fetal 
complications are high in women with kidney transplant and should be considered in patient 
counseling and clinical decision making.
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Timing of Native Nephrectomy and Kidney Transplant Outcomes in 
Children
Sarah J. Kizilbash,1 Priyamvadha Balaji,1 Resha Tejpaul,2 Jane M. Lewis,1 
Priya Verghese.3 1University of Minnesota, Minneapolis, MN; 2Univ of MN Dept 
of Urology, Minneapolis, MN; 3University of Minnesota Masonic Children’s 
Hospital, Minneapolis, MN.
Background: Native nephrectomies are indicated for various reasons in pediatric 
kidney transplant (pKtx) candidates. Nephrectomies may be performed prior to (2-stage) 
or at the time of transplant (1-stage). The optimal timing of nephrectomies remains 
controversial and there are no data comparing the outcomes associated with two approaches.
Methods: We retrospectively examined 32 consecutive pKtx recipients who underwent 
native nephrectomies at the University of Minnesota between 01/01/2011 and 12/31/2016. 
We investigated the effect of the timing of nephrectomy on patient and graft survival using 
Kaplan-Meir and log-rank test. We compared categorical variables using Fisher exact and 
continuous variables using Wilcoxon rank sum tests.
Results: Our cohort included 21 patients with 1-stage and 11 patients with 2-stage 
nephrectomies. Clinical characteristics are presented in table 1. Although statistically 
insignificant, patients with 2-stage tended to be older. Indications for nephrectomy included 
vesicoureteral reflux/urinary infections (40.6%), nephrotic syndrome (31.3%) and cystic 
kidney diseases (15.6%). There were no differences in the indications for nephrectomy 
between 1-stage versus (vs.) 2-stage patients. There was no difference in the rate of peri-
operative complications between two groups. For 2-stage, median length of hospital stay 
(LOS) after nephrectomy was 7.5 days (range: 6-10), and median time to transplant was 
4.3 months (range: 3-73) for living and 15 months (range: 3 -180) for deceased donor 
recipients. Posttransplant LOS was significantly shorter for 2-stage patients (median days: 
12 vs. 8, p 0.03). There were no differences in 1-year patient (100% vs. 100%, p 1.0) or graft 
survival (95% vs. 90.9%, p 0.68) between 1-stage vs. 2-stage patients.
Conclusions: There were no differences in 1-year patient and graft survival between 
pKtx recipients with 1-stage vs. 2-stage native nephrectomies. Posttransplant LOS was 
shorter for patients undergoing 2-stage nephrectomies; however, they required two 
hospitalizations.
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Solid Organ Transplantation and Mortality Following Diffuse Large B 
Cell Lymphoma
Sarah J. Kizilbash,1 Michaela R. Richardson,1 Jon J. Snyder,3 Bertram 
L. Kasiske,2 Eric A. Engels,4 Ajay K. Israni.2 1University of Minnesota,
Minneapolis, MN; 2Hennepin County Medical Center, Minneapolis, MN; 
3Minneapolis Medical Research Foundation, Minneapolis, MN; 4National 
Cancer Institute, Bethesda, MD.
Background: Diffuse large B cell lymphoma (DLBCL) is a common malignancy 
in all age groups after solid organ transplant. The effects of prior transplant on mortality 
following DLBCL and the effect modification by age at diagnosis have not been described.
Methods: We used 11 state cancer registries to identify all DLBCL cases in those states 
and ascertained history of organ transplant through a linkage to the Scientific Registry of 
Transplant Recipients. We used a Cox proportional hazard model to examine the effect 
of transplant on mortality after adjusting for age at DLBCL diagnosis, sex, race, year of 
diagnosis, site of DLBCL, stage of cancer at diagnosis and treatment. We also investigated 
an interaction between age at diagnosis and transplant status.
Results: Our cohort included 1,338 DLBCL cases with prior organ transplant and 
132,713 without. Compared with non-transplant patients, transplant recipients had lower 
mean age at diagnosis (48.5 vs. 62.4 years, p <0.0001), male preponderance (67.5 vs. 
53.3%, p <0.0001), higher incidence of extranodal disease (49.7 vs. 37.5%, p <0.0001), and 
higher prevalence of distant stage at diagnosis (47.5 vs. 43%, p <0.0001). After multivariate 
adjustment, overall (adjusted hazard ratio (aHR): 1.83, 95% CI: 1.71-1.96) and cancer-
specific mortality (aHR: 1.21, 95% CI: 1.1-1.33) were higher in transplant recipients than in 
non-transplant patients. The effect of transplant on mortality following DLBCL was highest 
in patients aged younger than 20 years at diagnosis (Figure).
Conclusions: Prior organ transplant is associated with an increased risk of overall and 
cancer-specific mortality following DLBCL. The effect of transplant on mortality is highest 
in DLBCL patients aged younger than 20 years at diagnosis.
Overall mortality of patients with DLBCL with prior organ transplant compared to those 
without
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Adult Educational and Vocational Outcomes of Pediatric Solid Organ 
Transplant Recipients in Canada
Mina Matsuda-Abedini,1,2 Jeffrey Schiff,3 Jennifer Harrison,3 Bethany J. Foster.4 
1The Hospital for Sick Children, Toronto, Toronto, ON, Canada; 2University of 
Toronto, Toronto, ON, Canada; 3Toronto General Hospital, Toronto, ON, 
Canada; 4McGill University Health Center, Montreal, QC, Canada.
Background: There are a paucity of data on educational attainment and vocational 
outcomes in young adults who received solid organ transplants in childhood.
Methods: Young adults (18-25 years) who had received a solid organ transplant at 
<18y old completed questionnaires in outpatient transplant clinics at seven centres across 
Canada. The transplant cohort was compared with the age-matched general Canadian 
population over the same time period (2016-2017) using Statistics Canada survey data (over 
3.5 million people 18-25 years).
Results: There were 161 transplant recipient participants with a mean age of 22 ±2.3 
years; 55% were male. The median age at diagnosis of organ failure was 9.5 years [IQR 
2, 15]. There were 112 (70%) who had received a kidney, 37 (23%) a liver, and 12 (7%) a 
heart. Compared with the age-matched general population, transplant recipients were less 
likely to have a university degree (9.3% vs. 14.9%; risk difference -5.5% [95%CI -10.0% 
to -1.1%]; P=0.048) or to be employed (68.4% vs. 83.0%; risk difference -14.6% [95%CI 
–22.0% to -7.2%]; P<0.0001). Among those employed, a higher percentage of transplant 
recipients (81.6%) earned less than the Low Income Cut-Offs (LICO) compared to the
general population (64.6%); risk difference 17.1%[95%CI 8.9% to 25.2%]; p<0.001). LICO 
is defined as an income threshold below which a family will likely devote a larger share of 
its income on the necessities of food, shelter, and clothing than the average family.
Conclusions: Young adult survivors of pediatric solid organ transplantation in Canada 
have lower educational achievement and are less likely to be employed than the age-
matched general population. Similar findings were recently reported in Europe. In order to 
improve the educational and vocational outcomes, greater advocacy and support are needed 
for pediatric recipients of solid organ transplant as they transition to adulthood.
Funding: Government Support - Non-U.S.
SA-PO040 Poster Saturday
Transplantation: Clinical Outcomes
MR Urogram Without Contrast in Transplant Obstructive Uropathy
Juan C. Infante,1,2 Jayanthi Chandar,2,4 Gaetano Ciancio,1,2 Marissa J. Defreitas,2,4 
Alireza Alam,3,4 Chryso P. Katsoufis,2,4 Mohammed Farhan Ali,2 Carolyn 
L. Abitbol.2,4 1University of Miami, Miami, FL; 2University of Miami/Jackson
Health Systems, Miami, FL; 3Jackson Memorial Hospital, Miami, FL; 
4University of Miami/ Pediatric Nephrology, Miami, FL.
Introduction: After kidney transplantation, hydronephrosis is a common problem 
that may result from obstruction or reflux. A voiding cystourethrogram entails urethral 
catheterization, radiation exposure, and patient discomfort. Alternatively, an MR urogram 
(MRU) can be performed without any potentially toxic intravenous (IV) contrast agent. We 
present a case that shows the feasibility MRU with an IV saline bolus and furosemide only.
Case Description: A 17 year-old boy with a kidney transplant presented with rising 
creatinine and recurrent hydronephrosis 9 months after the transplant. The immediate post-
transplant course was notable for hydronephrosis and stricture in the ureterovesical junction 
(UVJ) treated with balloon ureteroplasty one month after surgery. The hydronephrosis 
improved after balloon ureteroplasty, but over the next 5 months there was a gradual decline 
in kidney function and the patient experienced recurrent episodes of acute kidney injury 
(AKI). Renal ultrasound showed recurrence of the hydronephrosis; the differential included 
recurrence of the UVJ stricture versus reflux. An MRU without contrast revealed “moderate 
hydroureteronephrosis with tight narrowing at the UVJ.” Intraoperatively, stone fragments 
were discovered along the wall of the distal ureter causing obstruction of the UVJ, but no 
stricture was present. The ureteral re-implantation was revised to allow passage of possible 
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future stones. There were no further episodes of AKI or hydronephrosis up to 4 months 
after the revision.
Discussion: MRU using IV saline and furosemide can yield high-quality 3D images 
that identify targets for intervention in the setting of renal dysfunction while also avoiding 
nephrogenic systemic fibrosis.
3D MR urogram without contrast showing (A) moderate hydroureteronephrosis and tight 
narrowing near the UVJ. (B) Hollow view shows the narrowing near the UVJ followed by 
the urine jets in the bladder, consistent with partial obstruction.
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Outcomes of Dialysis and Transplantation in Cystinosis from NAPRTCS 
Database
Ewa Elenberg. Texas Children’s Hospital, Baylor College of Medicine, Houston, TX.
Background: Cystinosis (Cys) is a rare genetic disease. There are no sufficient 
published data on outcomes of dialysis and kidney transplantation in Cys patients (pts). 
North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) was 
established in 1987 with the goal to study transplant pts. The database was expanded in 
1992 to include dialysis pts. As of 2015, the NAPRTCS has data on over 7039 dialysis and 
18225 transplant pts.
Methods: Retrospective analysis of NAPRTCS database of registered dialysis and 
renal transplant cystinosis pts. Data on Cys pts are compared to other registry pts with non-
recurrent, i.e. non-immunologic causes (NIC) of potential graft loss. Specific aims were to 
investigate potential differences among studied dialysis and transplant pts.
Results: Dialysis data from 95 Cys pts were compared to 1472 NIC dialysis pts. There 
was statistical significance in blood pressure (BP), height and weight Z-Score, growth 
deficit, the use of rGH, calcium and PTH levels. Dialysis survival was better in Cys pts 
(p-value 0.046). There is no statistical difference in gender, dialysis modality, anemia, 
erythropoietin use, albumin, phosphorus level and time to transplant while on dialysis. 
Transplant data from 231 transplant Cys pts were compared to 2844 transplant NIC pts. 
Data was collected in 6 months (mo) interval from baseline at 30 days post transplant 
(p/Tx) to 60 mo p/Tx. Baseline height Z-Score was low in both groups: with mean Z-Score 
in NIC -2 and in Cys – 3.39 (p-value<0.005). Though improved height Z-Score at 60 mo 
p/TX to mean -1.84 in NIC, vs.-2.92 in Cys, the difference remains statistically significant. 
Weight Z-Score between 2 groups remains statistically significant with baseline mean at 
-1.22 for NCI vs. -2.59 for Cys. Although weight Z-score is gradually improving over time 
in both groups, at 60mo p/Tx mean Z-Score for NIC is -0.33 vs Cys -1.68 (p-value <0.005). 
There was no statistical difference in gender, creatinine levels, systolic and diastolic blood 
pressure Z-Scores, graft survival, donor source (LRD vs. DD), preemptive transplant, time 
to first rejection, number of transplants.
Conclusions: Height and weight Z-Scores in Cys dialysis and transplant pts were 
poorer when compared NIC pts. Cys pts have improved dialysis survival. Cys transplant 
pts did not differ from NIC pts in BP Z-Scores, donor source, preemptive transplant, graft 
survival, time to first rejection.
Funding: NIDDK Support, Commercial Support - This is investigator initiated study, 
supported by Horizon
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Transplantation: Clinical Outcomes
Mortality and Morbidity in Kidney Transplant Recipients with a Failing 
Graft
Ngan Lam,1 Robert R. Quinn,2 Devon J. Boyne,2 Peter Austin,3 Patricia 
Campbell,1 Brenda Hemmelgarn,2 Greg A. Knoll,4 Serdar Yilmaz,2 
Pietro Ravani.2 1University of Alberta, Edmonton, AB, Canada; 2University of 
Calgary, Calgary, AB, Canada; 3Institute for Clinical Evaluative Sciences, 
Toronto, AB, Canada; 4Ottawa Hospital, Ottawa, ON, Canada.
Background: There is little information on mortality and morbidity in kidney 
transplant recipients with a failing graft. Due to their history of renal disease and exposure 
to immunosuppression, recipients may be at higher risk of adverse outcomes compared to 
non-transplant controls with similar degree of chronic kidney disease.
Methods: We performed a retrospective study of kidney transplant recipients with a 
failing graft in Alberta, Canada (2002-2013), defined as ≥2 eGFR measurements between 
15-30 mL/min/1.73 m2 that were 90-365 days apart. We propensity-score matched
(1:1) recipients with a failing graft to non-transplant patients on several demographic
characteristics, clinical, and laboratory data. We used Cox regression to compare the hazard 
for death between the two groups and negative binomial regression to compare hospital
admission rates.
Results: We identified 521 kidney transplant recipients with a failing graft and matched 
487 (93%) of them to a non-transplant control. The median age of the cohort was 56 years 
(IQR 45-65) and 41% were women. Compared to matched non-transplant controls, kidney 
transplant recipients with a failing graft had a higher rate of death (hazard ratio 1.25, 95% 
CI 1.01-1.55; p=0.039) and hospitalization (rate ratio 1.72, 95% CI 1.44-2.06; p<0.001). 
Kidney transplant recipients also had significantly higher rates of hospitalization for 
cardiovascular events and infections, but not cancer.
Conclusions: A failing kidney transplant adds further mortality and morbidity burden 
to chronic kidney disease. This information may assist the discussion of prognosis in kidney 
transplant recipients with a failing graft and the design of strategies to minimize risks.
Figure. Kaplan-Meier estimated survival probabilities stratified by transplant status
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Benzodiazepines and Opioid Co-Prescriptions: Outcome Implications in 
Kidney Transplant Recipients
Ngan Lam,2 Mark Schnitzler,11 David A. Axelrod,3 Vikas R. Dharnidharka,6 
Dorry L. Segev,4 Abhijit S. Naik,10 Huiling Xiao,5 Gregory P. Hess,7 Bertram 
L. Kasiske,8 Tarek Alhamad,9 Krista L. Lentine.1 1Saint Louis University, St. 
Louis, MO; 2University of Alberta, Edmonton, AB, Canada; 3Lahey Hospital
and Clinic, Burlington, MA; 4Johns Hopkins University, Baltimore, MD; 5St. 
Louis University, St. Louis, MO; 6Washington University School of Medicine, St 
Louis, MO; 7LDI University of Pennsylvania/Symphony Health, Conshohocken, 
PA; 8Hennepin County Medical Center, Minneapolis, MN; 9Washington 
University in St. Louis, St. Louis, MO; 10University of Michigan, St. Louis, MI; 
11Saint Louis Univ, St Louis, MO.
Background: Recent studies identify coprescription of benzodiazepines and opioids 
as a risk factor for adverse outcomes in the general population. We previously described 
associations of opioid use before kidney transplantation (KTx) with mortality after KTx, 
but the implications of benzodiazepine use in the KTx population have not been described.
Methods: We examined a novel linkages of SRTR registry data with records from a 
pharmaceutical claims warehouse (2008-2015) to characterize benzodiazepine and opioid 
use in the year before KTx and associations (adjusted hazard ratio, 95% LCLaHR95% UCL) with 
death over 1yr post-KTx.
Results: Among 75,430 KTx recipients with available medication data in the year 
prior to KTx, 7.3% & 43.1% filled a prescription for a benzodiazepine or opioid in the pre-
KTx year. Use of both medications was more common among recipients who were white, 
unemployed, and received prior KTx. Benzodiazepine use rose with higher opioid use, from 
3.2% among opioid non-uses to 10.2% among those with highest level opioid use (Fig 1). 
Compared to non-users, high-level pre-KTx benzodiazepine use was associated with a 
51% (aHR 1.141.511.99) increased risk of death in the year after transplant. Opioid use bore 
a strong graded relationship with post-KTx survival, and prognostic impact high pre-KTx 
benzodiazepines was preserved after adjustment for opioids, although an interaction was 
not present (aHR 1.041.371.83) (Fig 2).
Conclusions: Benzodiazepines use is correlated with opioid fills before KTx, and 
these agents have additive associations with post-KTx mortality. Future research is needed 
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to examine mechanisms of these associations and impact of reducing coprescription on 
improving outcomes after KTx.
SA-PO044 Poster Saturday
Transplantation: Clinical Outcomes
Transplantation for Veterans Receiving Dialysis in VA and Non-VA 
Settings
Virginia Wang,1,2 Cynthia Coffman,1,2 Karen M. Stechuchak,1 Paul Hebert,3 
Ann M. O’Hare,3 David Edelman,1,2 Matthew L. Maciejewski.1,2 1Durham VA HCS, 
Durham, NC; 2Duke Univ, Durham, NC; 3VA Puget Sound HCS, Seattle, WA.
Background: Veterans with end-stage renal disease can receive dialysis under a range 
of different settings and payment structures including Medicare community dialysis, VA, 
and VA-purchased community-based dialysis (VA-PC). An earlier study reported similar 
rates of renal transplant among VA and Medicare users but little is known about rates of 
transplantation among Veterans receiving dialysis in different settings. This study compares 
receipt of renal transplantation among Veterans across dialysis settings.
Methods: We merged VA and Medicare data to construct a national cohort of VA-
enrolled Veterans who initiated chronic dialysis in 2008-2011. Cohort members were 
classified based on dialysis setting during the 2-year period immediately following dialysis 
initiation: VA, VA-PC in community, Medicare-financed dialysis in community, or more 
than one of these arrangements (“Dual settings”). We used a Cox proportional hazards 
model (censoring at death) to examine associations between 2-year dialysis setting and 
transplantation, adjusting for patient characteristics.
Results: Of the 27,301 cohort members, 67% received dialysis under Medicare only, 
11% received dialysis through VA-PC only, 4% were treated in VA only, and 18% were 
treated in Dual settings. Roughly 2.5% of Veterans received a kidney transplant within 
2 years, in an average 375 days after dialysis start (median=366, IQR=358). In adjusted 
analyses, Veterans receiving dialysis in VA, VA-PC, and Dual settings had similar 
transplantation rates that were lower than those under Medicare (HR=0.45, 95% CI= 0.29, 
0.72; HR=0.49, 95% CI=0.35, 0.68; and HR=0.57, 95% CI=0.43, 0.76, respectively). 
Estimated 2-year transplant rates are shown in Fig 1.
Conclusions: Rates of renal transplant are lower among Veterans who receive any VA-
financed dialysis than for those receiving Medicare-financed dialysis. More work is needed 
to identify barriers to kidney transplant among Veterans whose dialysis is financed by the 
VA.
Funding: Veterans Affairs Support
Fig 1. Estimated 2-year transplantation rates, by dialysis setting
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Is It Time to Switch? Comparing Transplant Outcomes Among Dialysis 
Modalities: Analysis from the United States Renal Data System (USRDS)
Brittany L. Schreiber, Omar A. Aleter, Vishy Chaudhary, Wayne G. Fischer, 
Yasir Lal, Hania Kassem. University of Texas Medical Branch, Galveston, TX.
Background: The effect of pre-transplant dialysis modality (DM) on transplant (Tx) 
outcomes has been a topic of study for many years. However, studies have largely compared 
patients (pts) on a single modality, either hemodialysis (HD) or peritoneal dialysis (PD). 
Though still controversial, pts on PD have been shown to have a higher likelihood of Tx, 
shorter time to Tx, and higher recipient survival rates than pts on HD. It is unknown whether 
pts who switch from HD to PD benefit similarly. This question has become particularly 
important given the incentive provided by the prospective payment system dialysis bundle 
for transitioning pts to PD. The aim of our study was to compare the effect of DM, including 
pts who switch from HD to PD, on the likelihood of Tx, time to Tx and recipient survival.
Methods: Our study is a retrospective analysis of data obtained from the USRDS 
from May 2012 to December 2015. Pts were divided into 3 groups: HD only (n=637778), 
PD only (n=43733) and pts who switched from HD to PD (n=23816); pts who switched 
from PD to HD were excluded. Groups were then compared to determine the likelihood 
of Tx among each group. Groups were further divided into pts who had received a single 
kidney Tx to determine the effect of DM on time to Tx and recipient survival rate. Statistical 
analysis included Contingency Analysis for likelihood of Tx, Oneway ANOVA for time to 
Tx, Kaplan-Meier survival curves, and Cox Proportional Hazards for the effects of predictor 
variables on pts survival.
Results: Pts in the HD to PD group had a higher likelihood of Tx (5% absolute, 
p<0.01), shorter time to Tx (1.54 years, p<0.01), and higher recipient survival compared to 
the HD only group (p<0.01). Besides higher age upon dialysis initiation, the only baseline 
characteristic negatively affecting survival in the HD to PD group was the presence 
of diabetes. This group also had similar advantages over the PD only group except for 
likelihood of Tx.
Conclusions: Our study showed that pts who switched from HD to PD had a higher 
likelihood of Tx, shorter time to Tx and improved recipient survival compared to other 
DM. Given the potential benefit gained by pts on PD, switching to PD regardless of initial 
modality may lead to improved Tx outcomes.
SA-PO046 Poster Saturday
Transplantation: Clinical Outcomes
Cost of Follow-Up Care within the First Year of Kidney Transplantation 
at the National Kidney and Transplant Institute
Irina M. Rey-Roxas,1 Benita S. Padilla,1 Concesa Casasola,1 Carlo irwin 
A. Panelo.2 1National Kidney and Transplant Institute, Quezon City, Philippines; 
2University of the Philippines Manila, Manila, Philippines.
Background: The high cost of kidney transplantation (KT) and follow-up care 
contribute to the low rate of transplantation among Filipino End Stage Renal Disease 
(ESRD) patients. The cost of transplant procedures is better understood and provided basis 
for a transplant benefit package in the National Health Insurance Program. However, no 
studies on the cost of follow-up care, particularly on which subgroups of patients incur 
higher costs have been done in the Philippines. Objectives. This study aims to estimate the 
direct medical cost of follow-up care within the first year of kidney transplantation.
Methods: We analyzed records of 129 adult Filipino patients who underwent primary 
kidney transplant from June 2014 to May 2016 at the National Kidney and Transplant 
Institute (NKTI). A subgroup analysis based on immunologic risks as well as comorbidities 
using the Charlson comorbidity index (CCI) was also done. Direct costs of medical care 
were estimated by computing for the average cost of medical care consisting of professional 
fees, medicines and supplies, and diagnostics for both outpatient consults and hospital 
admissions.
Results: The estimated average direct cost of medical care within the first year of 
transplantation was PHP 655,616 (USD 13,312 based on USD1=PhP50) per patient. Those 
with high CCI incurred 46% higher average direct cost than those with low CCI (USD 
17,899 vs USD 11259). Diabetics incurred 56% higher costs compared to non-diabetics 
(USD 20,237 vs USD 11,399). The difference in average cost between those with high 
immunologic risk and low immunologic risk was negligible. The cost of care showed a 
downward trend in the first year post KT, regardless of immunologic risk or CCI score. For 
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outpatient care, medications (85%) was the main cost driver while for admitted cases it was 
diagnostic work-up (37%).
Conclusions: The high cost of outpatient medications, especially for immunosuppressive 
drugs and insulin therapy, indicate the need for financing of follow-up care after kidney 
transplantation. A prospective study with a span of more than a year is needed to better 
understand the cost of follow up care after transplantation.
SA-PO047 Poster Saturday
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Economic Impacts of Alternative Kidney Transplant Immunosuppression: 
A National Cohort Study
Krista L. Lentine,1 David A. Axelrod,2 Vikas R. Dharnidharka,3 Huiling Xiao,4 
Daniel C. Brennan,5 Dorry L. Segev,6 Rosemary Ouseph,7 Henry B. Randall,13 
Abhijit S. Naik,12 Ngan Lam,8 Tarek Alhamad,9 Bertram L. Kasiske,10 Gregory 
P. Hess,11 Mark Schnitzler.14 1Saint Louis University, St. Louis, MO; 2Lahey 
Hospital and Clinic, Burlington, MA; 3Washington University School of
Medicine, St Louis, MO; 4St. Louis University, St. Louis, MO; 5Johns Hopkins,
Baltimore, MD; 6Johns Hopkins University, Baltimore, MD; 7St Louis University, 
St Louis, MO; 8University of Alberta, Edmonton, AB, Canada; 9Washington 
University in St. Louis, St. Louis, MO; 10Hennepin County Medical Center,
Minneapolis, MN; 11LDI University of Pennsylvania/Symphony Health,
Conshohocken, PA; 12Unviersity of Michign, Ann Arbor, MI; 13SSM Health/
SLUH, St. Louis, MO; 14Saint Louis Univ, St Louis, MO.
Background: Economic outcomes are increasingly considered along with clinical 
efficacy to guide choice of alternative therapies. We examined the cost impact of kidney 
transplant (KTx) induction and maintenance suppression (ISx) in a large national US cohort.
Methods: Cost data for the transplant hospitalization were drawn from linkage of the 
SRTR registry with financial records from the University HealthSystem Consortium of 
US academic hospitals (2002 –2013, N= 62,002 KTx). Cost of post-transplant care were 
estimated from Medicare Part A %B payments (N= 62,698). Marginal costs of induction 
(all periods) and maintenance (Yr 1, Yr 2, Yr 3) ISx were estimated from multivariate 
regression, including adjustment for baseline recipient, donor, and transplant factors.
Results: Compared to IL2rAb, Thymoglobulin (TMG, $10,066) and other induction 
($21,627) was associated with increased costs of the transplant hospitalization, while 
Campath was initially cost saving ($4,208. Subsequently, patients induced with TMG 
had significantly lower costs in Yr1 ($2,108) and Yr 2 ($1,834) post-KTx. Compared to 
triple maintenance ISx, steroid-free recipients incurred lower costs in Yr 1 ($4,011), while 
all other maintenance regimens were associated with higher costs in Yr 1. Patients who 
received mTORi-based and CsA-based ISx continued to incur higher costs in Yrs 2 and 3 
post-KTx. (Figure)
Conclusions: Induction and maintenance ISx are associated with differential costs 
of care during the transplant hospitalization and post-transplant periods, which may be 
mediated by different complication rates. Initial higher costs of TMG induction appear to 
be followed by later cost savings
Funding: NIDDK Support
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RISE to Transition: A Structured Transition Protocol for Renal  
Transplant Recipient Children
Rupesh Raina,1,2 Vinod Krishnappa.3 1Cleveland Clinic Akron General, 
Broadview Heights, OH; 2Akron Children’s Hospital, Akron, OH; 3Akron 
Nephrology Associates/Cleveland Clinic Akron General, Akron, OH.
Background: The transition from pediatric to adult medical services is an important 
time in the life of an adolescent or young adult with a renal transplant. Failure to properly 
transition can lead to medical non-adherence and subsequent loss of graft and/or return to 
dialysis.
Methods: To establish a locally-adapted, patient-focused, kidney transplant transition 
program, we implemented the RISE protocol. This was defined by four competency 
areas: Rise, Insight, Self-Reliance, and Establish; identified through literature review and 
experience. Seventeen patients (6 female and 11 males, mean age 14.5 yrs), who received 
a renal transplant in the preceding 2-9 years (mean 5.6 years, median 7), went through 
transition protocols. The transition process spanned two years to overlap medical care 
between pediatric nephrologists and key adult physicians and related services. The final 
transition was completed at 21 years of age.
Results: Adolescents and parents did not differ significantly in their general views 
and stated that they would appreciate the support provided by a transition program. 
However, the parents appreciated the support during transfer significantly more than did the 
adolescents. Eighty five percent of patients and family felt generally well informed of the 
RISE transition. However, 70% preferred to receive more information about their disease 
and overall health during their transfer period. When asked for the key person during the 
transfer, 62% of respondents mentioned the pediatrician, 6% said “others,” and 30% stated 
that it was the nurses. The relevant issues during transfer were cited as medication (35%), 
education and employment (27%), disease knowledge (13%), and environment in the adult 
service (25%).
Conclusions: RISE protocol and its four competency areas are the key to an effective 
transition to the adult services. Self-reliance and the establishment of healthy choices aim 
to improve patient autonomy and emotional burden, and to minimize disruptions in their 
daily lives. Recognition and insight aim to educate the patient in all aspects of their disease. 
Education about medical, social, vocational/educational, and interpersonal effects of their 
disease and treatment will help to improve adherence as well as alter patient perspectives 
of their disease.
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Kidney Cancer After Renal Transplant: 14 Year Review
Dennis Hu,1 Suresh K. Rijhwani,2 Harlan C. Rust,2 Usama T. Hussein,2 
Sandeep Magoon,2 Thomas R. McCune.2 1Eastern Virginia Medical School, 
Norfolk, VA; 2Nephrology Associates of Tidewater, Norfolk, VA.
Background: Renal transplant patients are 7 times more likely than the general 
population to have renal cell carcinoma (RCC). Possible explanations include 
immunosuppression leading to increased oncogenic viral infections and acquired cystic 
kidney disease from hemodialysis. Due to the rapid growth and metastasis of RCC, renal 
ultrasounds (US) have been used as a screening tool; however, there is no uniform guideline 
on US frequency after renal transplantation.
Methods: Retrospective chart review of 962 renal transplant recipients at Sentara 
Norfolk General Hospital from 7/1/04-9/30/17 was performed. All patients received similar 
immunosuppression regimens and serial US by protocol at year 1,3,5,7,9,11 and 13 after 
transplant. Data involving gender, race, age at transplant, underlying cause of ESRD, and 
US results were collected. Tumor characteristics including timing of development, mass 
location, pathology, staging, and outcome were assessed.
Results: 27 RCC cases were diagnosed in 19 patients. RCC incidence was 2.8%. 
Multifocal RCC was seen in 4 patients (3 at the same interval, 1 four years after previous 
nephrectomy) and all had bilateral nephrectomies. RCC was significantly higher in males 
than females (89% males, 11% females, p<0.05). Median time of RCC diagnosis was 3.55 
years. Tumor staging was 78% T1aNxMx, 18% T1bNxMx, 4% T3aNxMx. All patients had 
nephrectomies.
Conclusions: Renal US at 2 year intervals after transplant captured all RCC cases. 5 
patients were diagnosed in between the standard interval due to symptoms (e.g. hematuria). 
Men are at increased risk of RCC. Polycystic kidney disease is not associated with 
developing RCC. All RCC involved native kidneys and were cured with nephrectomy. 
Biannual US should be continued indefinitely after transplant and on any remaining kidneys 
after nephrectomy due to multi-centric occurrence.
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Exposure to a Functioning Kidney Transplant and Cancer Risks
Eric H. Au,1,2 Jeremy R. Chapman,3 Armando Teixeira-Pinto,1,2 
Jonathan C. Craig,1,2 Germaine Wong.1,2 1School of Public Health, Faculty of 
Medicine and Health, The University of Sydney, Sydney, NSW, Australia; 2Centre 
for Kidney Research, Children’s Hospital at Westmead, Sydney, NSW, Australia; 
3Centre for Transplant and Renal Research, Westmead Hospital, Sydney, NSW, 
Australia.
Background: Kidney transplant recipients experience higher cancer incidence and 
mortality compared to the general population. It is uncertain whether this increased risk 
varies with graft function. This study aims to compare the cancer incidence and mortality 
rates in transplant recipients during periods of graft function and graft failure with the age- 
and gender-matched general population.
Methods: All Australian patients who commenced renal replacement therapy between 
1982 and 2014 were included from the Australia and New Zealand Dialysis and Transplant 
Registry. Cancer incidence and mortality for dialysis patients and transplant recipients 
during periods of graft function and graft failure were compared with the Australian general 
population using standardized incidence (SIR) and mortality (SMR) ratios.
Results: A total of 47,127 dialysis patients without transplants, 15,413 with 1st 
transplants, 3873 after 1st graft failure, 1596 and 545 with 2nd transplants and 2nd graft failure 
were identified and followed for 297,626 patient-years. The standardized incidence and 
mortality rates (per 100,000 patient-years) were 727 and 336 in dialysis patients; 1322 and 
675 in recipients with 1st transplants; 1017 and 367 after 1st graft failure; 1531 and 870 for 2nd 
transplants and 1434 and 880 after 2nd graft failure. Cancer SIRs (95% CI) and SMRs (95% 
CI) were 1.2 (1.1-1.2) and 1.3 (1.2-1.4) for dialysis patients; 2.1 (2.0-2.2) and 2.6 (2.4-2.8) 
for recipients with 1st transplant; 1.6 (1.4-1.9) and 1.4 (1.0-1.9) after 1st graft failure;
2.4 (2.1-2.9) and 3.4 (2.6-4.2) for 2nd transplants; 2.3 (1.5-3.4) and 3.4 (1.8-5.9) after 2nd
graft failure.
Conclusions: An increased cancer incidence and mortality risk is observed during 
periods with a functioning kidney transplant. Among patients with failed allografts, cancer 
incidence and mortality remained higher than the general population, but the increased risk 
appears lower than recipients with functioning grafts.
Funding: Government Support - Non-U.S.
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Post-Transplant Survival Among Patients with Pretransplant Treatment 
for Prostate Cancer
Nagaraju Sarabu,1 Nicholas K. Schiltz.2 1University Hospitals Cleveland Medical 
Center, Cleveland, OH; 2Case Western Reserve University, Cleveland, OH.
Background: Optimal pre-kidney transplant treatment and waiting time for transplant 
among patients with prostate cancer is unclear.
Methods: We studied male patients, 40 years or older, with ESRD who had Medicare 
claims for prostate cancer and two main types of treatment (radiation and prostatectomy) 
utilizing USRDS (United States Renal Data System). We stratified patients into three 
categories based on waiting time to transplant from the time the prostate cancer was treated 
(0-2, 2-5, >5 years). We used Kaplan-Meier method to compare post-transplant survival 
among the strata. We used Cox proportional hazards model to assess relative risks of death 
between the groups.
Results: There were a total of 920 patients who had kidney transplants with prior 
history of treatment for prostate cancer. Figure 1a shows KM curves, stratified by waiting 
time (p-values = <0.01). Compared to 0-2 years of waiting time, 2-5 years had 13% higher 
likelihood of death (HR: 1.13, 95% CI:0.88-1.44) and >5 years had 73% higher likelihood 
of death (HR: 1.73, 95% CI:1.30-2.3). Prostatectomy was associated with a better post-
transplant survival than radiation (Figure 1b).
Conclusions: Prostatectomy and kidney transplant without significant delay may be 
optimal choices for patients with prostate cancer and eligible for kidney transplant.
Kaplan Meier survival curves for patients, stratified by waiting time (1a) and type of 
treatment (1b)
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Long-Term Outcomes of Sequential Hematopoietic Stem Cell  
Transplantation and Kidney Transplantation
Carla L. Moreira,1 M Hasib Sidiqi,2 Fernando G. Cosio,3 Nelson Leung.3 
1Nephrology Department, Centro Hospitalar do Porto, Porto, Portugal; 
2Division of Hematology, Mayo Clinic, Rochester, MN; 3Division of Nephrology 
and Hypertension, Mayo Clinic, Rochester, MN.
Background: Hematopoietic stem cell transplantation (HSCT) patients are known to 
be at risk for both acute and chronic kidney disease. Experience on sequential HSCT and 
kidney transplant (KT) is limited.
Methods: We conducted a retrospective cohort study of adult patients who underwent 
both HSCT and KT at Mayo Clinic, Rochester, between 1988 and 2018.
Results: In our cohort of 54 patients, male represented 57% (n=31) and the median age 
was 64.2 (56.8, 70.1) years-old. Thirty-six patients (66.7%) received HSCT first followed 
by KT, while 18 (33.3%) received KT prior to HSCT. In both groups, immunoglobulin 
related amyloidosis represented 50% of hematologic diagnosis. Living kidney donor was 
equally distributed in both groups, representing 83% (n=45) of the donors, with 60% 
(n=27) from a relative. T-cell depleting induction was significantly more frequent in 
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the KT first group (94% vs 19%, p<0.001). Primary kidney disease recurrence was not 
significantly different in HSCT first vs KT first (19% vs 39%, p=0.19), and both groups 
displayed excellent kidney allograft survival at 1y (94% vs 89%) and 5y (94% vs 89%), 
p=0.51. KT first did not affect allograft outcome (HR 1.7, 95% CI 0.4-7.9, p=0.51) nor did 
maintenance immunosuppression (HR 2.8, 95% CI 0.6-11.9, p=0.16). Acute cell mediated 
rejection (ACMR) seemed to worsen KT prognosis (HR 10.7, 95% CI 1.6-71.7, p=0.01). 
However, in multivariate analysis, ACMR revealed only a trend towards significant worse 
allograft prognosis (HR 22.8, 95% CI 1.0-520.8, p=0.05). Overall patient survival was 
better in patients submitted to HSCT first, both at 5y (97% vs 76%) and 10y (90% vs 63%), 
p=0.0001. EBV seronegative status at KT (HR 2.9, 95% CI 1.1-7.8, p=0.039), KT first (HR 
6.0, 95% CI 2.2-16.5, p=0.0001), use of T-cell depleting agent (HR 3.2, 95% CI 1.2-8.7, 
p=0.02), severe infection (HR 19.6, 95% CI 2.6-148.1, p=0.004) and renal allograft failure 
(HR 3.2, 95% CI 1.2-8.8, p=0.02) were significantly associated with poor patient outcome. 
In multivariate analysis, only history of severe infection was significantly associated with 
poor survival (HR 14.0, 95% CI 1.6-125.8, p=0.02).
Conclusions: Our study supports KT safety in patients with history of HSCT, with 
better allograft function and overall patient survival observed when HSCT is performed 
first.
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Post Transplantation Anemia: Causes, Severity and Their Association with 
Graft and Patient Survival
Amir Schechter, Ruth Rahamimov, Anat Gafter-Gvili, Benaya Rozen-zvi. Rabin 
Medical Center, Petah Tikva, Israel.
Background: Post transplantation anemia (PTA) is common among kidney transplant 
patients. PTA is associated with increased graft loss and in most studies with increased 
mortality. We aimed to evaluate association of PTA its severity and specific causes with 
late outcomes.
Methods: Patients who underwent kidney transplantation in Rabin Medical Center 
(RMC). Data were collected from the kidney transplant registry during the years 2002-2016. 
Anemia was defined in accordance with World Health Organization (WHO) criteria, severe 
anemia was defined as hemoglobin lower than 11 g/dL. We evaluated all separate anemia 
events during the follow-up period, for each event a full laboratory workup was collected. 
Specific causes for each anemia episode were documented (acute rejection, acute kidney 
injury [AKI], infection and nutritional deficiencies). Primary outcome was a composite of 
patient and graft survival. We used univariate and multivariate time varying Cox models 
to evaluate association between severity and specific causes of anemia to the outcomes.
Results: Our cohort included 1139 patients, out of which 412 (36.2%) had PTA during 
the follow-up period. Distribution of causes of anemia were acute rejection and/or AKI 
(11.9%), infections (16.7%), hematological disorders, bleeding or hemolysis (9%) and 
nutritional deficiencies (29.1%). No obvious reason was found in 137 patients (33.3%). On 
multivariable analyses, the anemia group was significantly associated with a composite of 
graft loss and mortality, (HR 2.063, 95% CI 1.542-2.761, p<0.001), and with each outcome 
separately. Severe anemia was significantly associated with graft loss and mortality 
combined (HR 4.362, 95% CI 3.035-6.270, p<0.001) and separately. A weaker association 
was found between mild anemia and graft loss, but not with mortality. Causes of anemia: 
AKI & acute rejection (HR 5.570, 95% CI 3.784-8.198, p<0.001), infectious (HR 2.483, 
95% CI 1.536-4.016, p<0.001) and nutritional deficiencies (HR 1.882, 95% CI 1.203-2.942, 
p=0.006) were all associated with graft loss or mortality.
Conclusions: PTA is associated with graft loss and mortality. Anemia severity and 
etiology affects this association. An anemia workup is recommended for PTA.
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Predicting CKD in Lung Transplant Recipients
Salman Ahmed,1 Leonardo V. Riella,2 Gary C. Curhan.3 1Brigham and Women’s 
Hospital, Boston, MA; 2Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA; 3Channing Division of Network Medicine, Brigham and 
Women’s Hospital, Boston, MA.
Background: There is a high incidence of chronic kidney disease (CKD) following 
lung transplantation. We examined baseline risk factors for CKD in a cohort of patients who 
had undergone lung transplantation.
Methods: Retrospective cohort study of 333 patients who underwent lung 
transplantation between January 2005 and September 2016. The follow-up period ended 
April 2018. Of 333 patients, we excluded: 22 underwent transplantation elsewhere; 26 
had prior CKD; 8 had fewer than two outpatient serum creatinine values available; 10 
died within 6 months; 2 were excluded for missing BMI data; and 17 lacked data on pre-
transplant pulmonary arterial systolic pressure. The primary outcome was CKD III at up to 
2 years following lung transplantation, defined by two eGFR values < 60 ml/min/1.73 m2 at 
least three months apart on outpatient labs.
Results: Of the 248 eligible patients, 185 developed CKD III or worse. In a multivariate 
logistic regression model, age (OR 1.06, per year, 95% CI 1.02-1.11) and female sex (OR 
4.42, 95% CI 1.92-10.18) were associated with a higher risk of CKD III. The following 
pre-transplant variables were not significantly associated with increased risk of CKD: body 
mass index (BMI), pulmonary arterial systolic pressure (PASP), diabetes, hypertension, or 
etiology of lung disease. Higher pre-transplant eGFR showed a trend towards a lower risk. 
New onset hypertension post-transplant was not associated with CKD III.
Conclusions: Older and female patients are at higher risk for developing CKD III 
after lung transplantation. Future research should evaluate risk factors for additional renal 
outcomes, including acute kidney injury, dialysis and renal transplantation.
Funding: NIDDK Support
Multivariate adjusted odds ratios for CKD III in lung transplant patients
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Transplantation: Clinical Outcomes
Outcomes of CRRT in Patients with End Stage Liver Disease (ESLD)
Margaret Spolnik, Maryn Gardner, Marwan Ghabril, Eric S. Orman, 
Sharon M. Moe, Melissa D. Anderson. Indiana University School of Medicine, 
Indianapolis, IN.
Background: Patients with ESLD have high mortality when dialysis is required. In 
2015, a hepato-renal service was started in order to improve outcomes of patients with 
combined kidney-liver failure. We compared outcomes of all ESLD patients that underwent 
CRRT (venous-venous hemofiltration) before and after the implementation of the novel 
inpatient rounding service.
Methods: Patients undergoing CRRT with a concomitant diagnosis of ESLD (based on 
ICD-9/10 codes) were identified in the pre year (all of 2013 n = 46) and the post hepatorenal 
service year (all of 2016, n = 39). Charts were then manually reviewed to confirm diagnoses, 
and compare the cohorts by t-test/Mann/Whitney for continuous variables, and chi-square/
Fisher’s exact for categorical variables.
Results: There were no differences in the two cohorts (2013 and 2016) for age, 
gender, BMI, cause of ESLD, ascites, etoh intake, smoking and baseline co-morbidities on 
admission. More patients had a history of CKD in 2013 than in 2016 (p<0.002). CRRT was 
started after 4 and 7 days from admission (median, 2013 and 2016 respectively). At the time 
of initiation of CRRT, there was no difference between the two cohorts in laboratory data 
(albumin, sodium, INR, creatinine, bilirubin), or MELD score. The outcomes of patients in 
both cohorts are shown in Table 1.
Conclusions: Patients with ESLD requiring CRRT have very high mortality within 
90 days unless transplanted, higher than predicted by MELD scores. The implemtation 
of a hepato-renal inpatient rouding service staffed by both Nephrology and Hepatology 
facilitated collaborative and consistent decisions about goals of care in these critically ill 
patients, increasing the proportion of patients transplanted.
Outcomes of ESLD patients receiving CRRT
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Transplantation: Clinical Outcomes
Systematic Review of Risk Indices Used in Pancreas Transplantation
Jonathan E. Ling,2 Timothy E. Coughlan,3 Kevan Polkinghorne,2 John Kanellis.1 
1Monash Medical Centre, Clayton, VIC, Australia; 2Monash Medical Centre 
and Monash University, Melbourne, VIC, Australia; 3Monash Health, Hawthorn, 
NSW, Australia.
Background: Risk indices (RI) using donor and recipient characteristics assist in organ 
allocation and acceptance decisions by predicting post-transplant outcomes such as graft 
and patient survival. While RI have been derived for use in pancreas transplantation (PTx), 
they are not widely utilised. We intend to review the ability of available RI to predict PTx 
outcomes.
Methods: Medline Plus, Embase via OVID and the Cochrane Library were searched 
for studies describing derivation or use of RI in PTx up to 1st November 2017. Primary 
outcomes of interest were pancreas graft and patient survival, with secondary outcomes of 
organ acceptance. Data extraction was performed using the Checklist for Critical Appraisal 
and data extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) 
and risk of bias assessment was done via the Quality in Prognostic Studies (QUIPS) tool.
Results: 2418 abstracts were screened with 32 studies entering full-text analysis. Of 
these 32 studies, 8 were abstracts with no full-text retrievable despite contacting authors. 
10/32 studies derived 23 models predicting outcomes of interest. 2/23 models were RI that 
were externally validated in 24/32 studies. 21/23 models were derived without external 
validation. RI were the pancreas donor risk index (PDRI) and the pancreas pre-procurement 
score (P-PASS). Apart from their covariates, common covariates in other models included 
recipient age and body mass index (BMI), dialysis duration pre-transplant, history of 
diabetes, transplant type, and immunosuppression regimen. Risk of bias was generally 
low in the studies with model derivation. Conversely, abstracts tended to have high risk of 
bias. Deficiencies in reporting included handling of missing data, covariates and follow-up 
duration. Discrimination and calibration was only described in 10 and 2 studies respectively. 
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Heterogeneity was present in model derivation method, outcome definitions and study 
results. PDRI was significantly associated with pancreas graft survival in 9 studies and 
P-PASS was significantly associated with pancreas donor acceptance in 3 studies.
Conclusions: RI in PTx have not been widely validated apart from P-PASS and PDRI. 
Within a validated cohort, PDRI (as a categorical variable) and P-PASS have value in 
predicting pancreas graft survival and in predicting donor pancreas acceptance respectively.
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One-Year Outcome Experience of Deceased Donor Kidney Transplanta-
tion Post-KAS Implementation
Priyamvada Singh,1 Bhavnish Bucktowarsing,1 Jon R. Von Visger,1 Uday 
S. Nori,1 Hemant K. Parekh,2 Todd E. Pesavento,1 Alejandro Diez.1 1The Ohio
State University Wexner Medical Center, Columbus, OH; 2Ohio State University 
Wexner Medical Center, Columbus, OH.
Background: The new kidney allocation system (KAS) implemented on December 4, 
2014, has a goal to improve access to transplant for under represented groups, such as the 
highly sensitized patients (calculated panel reactive antibodies, cPRA ≥90%).
Methods: We performed a single-center retrospective review of transplants performed 
on highly sensitized recipients and compared outcomes, in relation to the implementation 
of KAS.
Results: 164 DDKT were performed in 22 months prior to KAS implementation 
whereas 187 were performed 22 months post-KAS implementation. Out of 351 transplants 
during this period, 33 had a PRA of ≥ 90% (11 pre-KAS, 22 Post) and 14 had a PRA of 
100% (2 Pre, 12 Post) consistent with the bolus effects seen in the previous reports. We 
also compared the one-year outcomes of patients with ‘0’ cPRA with ≥ 90% CPRA. Out of 
148 patients selected between periods of December 2014 to October 2016, 126 had cPRA 
of 0% and 22 had a cPRA of ≥ 90. All patients had at least one-year post-transplant follow 
up. We didn’t find any significant differences in primary outcomes of graft survival, all-
cause mortality, delayed graft function and return to dialysis (table 1). Cold ischemia time 
was significantly higher post KAS possibly owing to a greater regional sharing (table 2). 
Although biopsy-proven rejection was more prevalent in highly sensitized patients 
compared to non-sensitized it was not statistically significant. Unlike previously published 
reports, we didn’t find any difference in outcomes among the two groups based on waitlist 
time and time on dialysis. Additionally, duration of hospital stay, readmissions and serum 
creatinine was similar in both groups.
Conclusions: Results are reassuring as we found no differences in outcomes between 
both groups but it still warrants long-term follow up.
SA-PO058 Poster Saturday
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The Impact of New Kidney Allocation System on Health Care Utilization
Randeep Kashyap, M Katherine Dokus, Sheel Clerk, Jeremy G. Taylor, 
Mark S. Orloff, Todd Jusko, Scott Mcintosh. University of Rochester Medical 
Center, Rochester, NY.
Background: The kidney allocation system (KAS) in the United States was 
dramatically changed in December 2014 with the goal of increasing access, decreasing 
inequities and improving longevity matching. Studies have shown that duration of pre-
transplant dialysis, cold ischemia times and delayed graft function rates significantly 
increased as a result. We hypothesize that these downstream effects of KAS would impact 
health care resource utilization- namely readmission rates and length of hospital stay.
Methods: The Organ Procurement and Transplantation Network’s Standard Transplant 
Analysis and Research (STAR) file containing only adult deceased-donor kidney only 
transplants from 6/3/14- 6/5/2015 was analyzed. The cohort of recipients transplanted in 
the 6 months prior to KAS was compared to a cohort of those transplanted during the first 6 
months after the allocation change.
Results: A total of 11,964 kidney-only transplants with six months of post-transplant 
follow-up data were included in the analysis. Demographics were comparable between the 
two groups. Median length of hospital stay post-transplant was not different between groups 
(median 5 days, IQR 4-8 for both). Hospital readmissions within 6 months of transplant 
discharge, however, were significantly higher post-KAS (37.4% vs. 40.1%, p=0.004). 
Reasons for readmission were not included as part of the dataset, but due to increased rates 
of delayed graft function and its consequences in the post-KAS cohort 23.7% pre vs. 29.9% 
(p<0.001), it is hypothesized that known related complications such as hyperkalemia, acid-
base disturbances and fluid imbalance may have contributed to readmissions.
Conclusions: Although the new kidney allocation system seems to be achieving 
many of the goals it set out to accomplish, it appears that more health care resources are 
being utilized post-transplant as measured by readmission and delayed graft function 
rates. Insurers and hospital administrators should be aware of the potential constraints and 
make accommodations in contract language and reimbursement rates as a result of the 
observations from this study. A formal cost-effectiveness analysis should be the subject of 
future investigations.
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Use of Virtual Crossmatch Exclusively to Allocate Deceased Donor Kidney 
Transplant
Essa Abuhelaiqa,1 Shaefiq B. Thappy,1 Mohamad M. Alkadi,1 Jehan Mahmoud,2 
Mona Jarman,2 Awais Nauman,1 Muhammad Asim,1 Omar Fituri,1 Hassan 
A. Al-Malki.1 1Nephrology, Hamad Medical Corporation, Doha, Qatar; 2Hamad
Medical Corporation, DOHA, Qatar.
Background: Virtual crossmatch (VXM) using Luminex single antigen bead has 
significantly improved prediction of a negative crossmatch due to its high sensitivity. An 
actual pretransplant lymphocyte crossmatch such as complement dependent cytotoxicity 
crossmatch (CDCXM) or flow cytometry crossmatch (FCXM) is typically required; 
however, it may delay deceased donor renal transplantation (DDRT) and possibly affect 
allograft outcomes. We evaluated the safety of only using VXM pretransplant without 
waiting for actual crossmatch to allocate DDRT.
Methods: In our center, we have initiated a protocol to allocate kidneys from brain-
dead deceased donors based on VXM since 2015. 46 DDRT were performed at our center 
between 2010 to 2017. 21 (45%) recipients only underwent pretransplant VXM, and all 
were found to have a negative FCXM retrospectively. We evaluated the effect of this 
protocol on cold ischemia time (CIT), delayed graft function (DGF), acute rejection (AR) 
within first year post transplant, and graft survival.
Results: There was a significant reduction of CIT by more than 6 hours (P=0.001) 
when FCXM was not done prospectively prior to transplant. 3 out of 25 (12%) patients with 
prospective FCXM had DGF, while no DGF was observed in retrospective FCXM (P=0.2). 
AR within first year occurred in 4% of prospective vs. 5% retrospective FCXM. 1-year 
and 3-year graft survival rates were 96% vs. 100% and 92% vs. 88%, in prospective vs. 
retrospective FCXM, respectively.
Conclusions: Use of pretransplant VXM exclusively for final DDRT allocation 
decision reduces duration of CIT and may reduce incidence of DGF without increasing risk 
of AR or affecting graft survival
SA-PO060 Poster Saturday
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Disproportionate Allocation of High Quality Kidneys to Highly Sensitized 
Recipients in the New Kidney Allocation System Despite a Limited “Bolus 
Effect”
Syed shahyan Bakhtiyar, Abbas Rana, Natasha N. Dave, Michael Kueht, 
John A. Goss, Bhamidipati V. Murthy. Baylor College of Medicine, Houston, TX.
Background: The 2014 Kidney Allocation System (KAS) aims to minimize death 
with functioning grafts, and increase transplantation rates among highly sensitized 
patients (PRA≥98%). We examined if preferential allocation to high PRA patients results 
in disproportionate allocation of high quality kidneys (Kidney Donor Performance Index 
< 0.2) to these patients, and if a “bolus effect” dissipates the allocation over time.
Methods: Using the UNOS data, kidney transplantations from the start of the new 
system 12/4/2014-12/31/17 (study group) were compared with those for two preceding 
years - 12/4/2012-12/3/2014 (control group) for pre- and post-transplant characteristics, 
and overall graft and patient survival.
Results: Excluding living donors (n=28,785) and multi-organ transplants (n=8,896), 
there were 37,933 recipients in study group, and 21,412 in control group. One year patient 
and graft survival in the study versus the control group were 96.8% vs 96.9% (p<0.0001) 
and 94.4% vs 94.2% (p<0.0001) respectively. In the study group, 4,564(12%) high PRA 
patients were transplanted, compared to 704(3.3%) in the control group. 1,384/8,180 
(16.9%) of high quality kidneys in the study group were received by high PRA patients, 
compared to 181/4,542 (4%) in the control; four-monthly analysis of the study group shows 
that high PRA recipients of these kidneys decreased from 116/532 (21.8%) in December 
2014–March 2015 to 122/936 (13.03%) in September–December 2017. Among these high 
PRA recipients of high quality kidneys, there was no difference in one year patient (98% vs 
96.1%, p=0.8) and graft survival (96.6% vs 92.2%, p=0.5) between the study and control 
group respectively.
Conclusions: Despite a decreased trend in high quality kidney allocation to high PRA 
patients in the new system over time, it is still significantly higher than in the old system. 
Thus, any bolus effect is only partial. While there is no difference in patient and graft 
survival in this cohort, follow-up may be too short to show a difference. As such, a national 
policy may be needed to optimize this allocation in the new KAS.
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Association Between Kidney Donor Risk of ESRD (KDRE) and Donor 
Selection/Deferral
Divya Seth,1 Jennifer R. Milan,1 Se ri Bae,1 Kirsten L. Johansen,2 Brian K. Lee,4 
Deborah B. Adey,3 Elaine Ku.1 1UCSF, Berkeley, CA; 2University of California, 
San Franicsco, San Francisco, CA; 3University of California, San Francisco, San 
Francisco, CA; 4University of California San Francisco, San Francisco, CA.
Background: The Kidney Donor Risk of ESRD equation (KDRE) provides transplant 
centers a tool to assess the patient-specific risk of developing ESRD in living kidney 
donors based on age, sex, race, body mass index (BMI), and relationship to the recipient 
(http://www.transplantmodels.com/donesrd/). The goal of this study was to determine 
whether medical decisions surrounding donor eligibility align with the empirical KDRE 
predicted risk. We hypothesized that higher KDRE scores would be associated with a higher 
likelihood of donor deferral due to medical unsuitability.
Methods: The KDRE was determined by chart review of donor evaluations performed 
at a single center from 2009 - 2017 for a convenience sample of potential donors. The 
association between the 5-year predicted risk of ESRD and odds of deferral/acceptance was 
examined using unadjusted logistic models. Due to a lack of association between the KDRE 
score and donor deferral, we adjusted for factors within and outside of the KDRE (systolic 
BP, smoking) to determine which factors were most strongly associated with deferral from 
donation.
Results: 313 donors had sufficient data to calculate the KDRE score. Mean age was 
31±10 years and median BMI was 33. Evaluated donors were 49% White, 31% Hispanic, 
6% Black; 44% male, and 52% of donors were related to the recipient. 34% of evaluated 
donors were deferred. There was no association between the KDRE predicted ESRD risk 
and donor deferral (Table), even after accounting for factors not in the KDRE score (systolic 
BP and smoking). When we adjusted for factors already in the KDRE score, older age was 
the only factor that was strongly associated with odds of deferral (OR 2.14 per 10-year 
increase in age [95% CI 1.48-3.10]).
Conclusions: We did not find the KDRE predicted ESRD risk to be associated with 
donor deferral or acceptance. Of the factors considered, older age was the strongest factor 
that was associated with donor deferral.
Funding: NIDDK Support
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State-Wide Coordination of the Follow-Up of Living Kidney Donors Only 
Marginally Improves the Follow-Up Rate
Matthew D. Jose,1,2 Ellie Cash,2 Gabrielle E. Brailsford,2 Geoff Kirkland.1 
1Renal Unit, Royal Hobart Hospital, Hobart, TAS, Australia; 2School of 
Medicine, University of Tasmania, Hobart, TAS, Australia.
Background: Post-donation follow-up care is recommended by KDIGO for Living 
kidney donors (LKD). There is little long-term data on living kidney donors in Australia 
due to incomplete follow-up. In 2012 we centralised the follow-up of all LKD within the 
state. Our aim was to audit the effectiveness of this intervention and the effect on the rate 
of LKD follow-up.
Methods: In 2012 we reported follow-up of LKD at 1 year of 70%, but less than 10% 
at 5 years. Statewide follow-up was changed to be coordinated out of a single follow-up 
centre, with tests and appointments organized by standard mail and follow-up phone calls. 
We reviewed the effectiveness of this intervention.
Results: We identified 183 LKD, of which 126 (63% female, mean age 62 years, mean 
time since donation 9 years) were recorded in the both the statewide database and the Living 
Kidney Donor Registry (LKDR) at ANZDATA. Changing to a single, statewide follow-up 
centre achieved 50-70% of follow-up every year from 2014-17. This ranged from 75% 
at one year post-donation, 61% at 5 and 48% > 5 years post-donation as recorded locally 
in 2017. Reporting to the LKDR was lower at 25%, 33% & 22% respectively. From the 
ANZDATA follow up, 63 patients had a recorded systolic blood pressure measurement at 
their last follow up. 31% of these patients had hypertension requiring anti-hypertensive 
medication with 1.3 the average number of agents required.
Conclusions: The results show that clinical follow up decreases as time post donation 
increases. Statewide coordination of donor follow-up improved baseline results but there 
is still further improvement to be made. There is discrepancy between local data collection 
and submission to the Living Kidney Donor Registry at ANZDATA. Improved coordination 
and data submission would allow for more accurate follow up data of LKD.
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Differences in Transplant Rates Across Race/Ethnicities Post-KAS 
Implementation
Andric C. Perez-Ortiz,1,2 Nahel Elias.1 1Massachusetts General Hospital, 
Boston, MA; 2School of Public Health, Yale University, New Haven, CT.
Background: The Kidney Allocation System (KAS) aimed to decrease racial 
allocation disparity, indirectly improving transplant rates (TR) for non-Whites. 3 years 
after implementation, we lack evidence of this specific efficacy. We here assess whether 
the waitlisting and transplant rates across races/ethnicities have improved after KAS 
implementation.
Methods: To assess any systematic difference in US TR (1989-2017) and the effect pre- 
(1989-2014) and post-KAS (2015-2017), we calculated the slope per year basis. We then, 
using linear regression, estimated the effect of race/ethnicity on kidney waitlist addition 
and TR across periods, also addressing donor type for TR. To eliminate improved deceased 
donation effect, we compared kidney and liver TR. A difference indicates a positive impact 
of KAS. Finally, we similarly evaluated the rate of change for kidney waitlist additions. We 
used data from OPTN database and for linear models R.
Results: We show three distinct periods wherein the kidney TR varied. Between 1989–
2006 and 2015–2017, there was a significant positive slope, higher in the later. However, 
between 2006–2014 there was no change in TR. Furthermore, compared to deceased liver 
TR after KAS implementation (2015-2017), kidney TR increased up to 76% (p=0.02). 
Before 2015, there were no differences between the two groups (p>0.2). Moreover, kidney 
TR has steadily risen for non-Whites compared to Whites (p=0.03). KAS implementation 
increased the rate for non-Whites 13-fold compared to Whites (p=0.04). Lastly, this 
improvement was not mirrored in the waitlist additions, and KAS did not change the slope.
Conclusions: We have preliminary evidence that KAS allocation has improved TR 
especially benefiting non-Whites (Blacks, Hispanics, Asians). Waitlist addition did not 
equally change, arguing for the need to alter referral and listing practice.
Figure
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Should Kidneys at High Risk for Discard Be Allocated to Preemptive 
Deceased Donor Kidney Transplant Candidates?
Justin Gill,1 Matthew J. Kadatz,1 John S. Gill,3 Jagbir Gill.2 1University of British 
Columbia, Vancouver, BC, Canada; 2St. Paul’s Hospital, West Vancouver, BC, 
Canada; 3(St. Paul’s Hospital/University of British Columbia), Vancouver, BC, 
Canada.
Background: Over 19% of recovered kidneys are discarded annually in the US. 
Identifying patients with favourable outcomes after transplantation with kidneys at high 
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risk of discard may inform strategies to increase organ utilization. Preemptive deceased 
donor kidney transplant recipients have superior post-transplant outcomes compared to 
recipients on dialysis, partly due to the presence of native kidney function. We hypothesize 
that allocation of kidneys at high risk of discard to selected preemptive candidates could 
offer acceptable outcomes.
Methods: We ranked and grouped into quartiles all deceased donors in SRTR between 
2000-15 based on their probability of kidney discard using a validated score that predicts 
discard based on donor characteristics. We conducted a paired kidney analysis, where 1 
kidney was transplanted in a preemptive recipient and the mate kidney from the same donor 
was transplanted into a nonpreemptive recipient, to compare the risk of DGF and all cause 
graft loss (ACGL) in non-preemptive and preemptive recipients, stratified by donors’ risk 
of kidney discard using Cox and logistic regression models.
Results: The figure shows unadjusted graft survival in preemptive and non-preemptive 
recipients, stratified by donors’ probability of kidney discard. The risk of discard was 
associated with inferior graft survival, as recipients of kidneys at the greatest risk of 
discard (Q4) demonstrated the worst graft survival. However, outcomes among preemptive 
recipients were significantly better. After adjusting for recipient and transplant factors, 
preemptive recipients who received kidneys at the greatest risk of discard (Q4) had a 
significantly lower risk of DGF (OR; 95%CI 0.22; 0.18-0.26) and of ACGL (HR; 95%CI 
0.81; 0.72-0.90).
Conclusions: Allocation of kidneys at high risk of discard to selected preemptive 
candidates (eg. patients with prolonged wait-times) may increase organ utilization while 
optimizing outcomes.
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APOL1 Genotyping in Potential Kidney Donors of African Descent
Vasishta S. Tatapudi, Bonnie E. Lonze, Nicole M. Ali, Bruce Gelb, 
Robert A. Montgomery. NYU Langone Health, New York, NY.
Background: Inheritance of two APOL1 risk variants accounts for the excess risk 
of non-diabetic ESRD in African Americans when compared to Caucasian, Hispanic and 
Asian Americans. African American living donors have a higher risk of ESRD than matched 
non-black donors. APOL1 genotyping in potential kidney donors of African descent may 
identify individuals at risk for progressive CKD following donation.
Methods: We report the retrospective analysis of APOL1 genotyping in a cohort of 
African American potential kidney donors. In July 2016, we initiated targeted genotyping 
of all African American kidney donor candidates. African American candidates with two 
APOL1 risk variants were excluded from kidney donation.
Results: A total of 28 African American kidney donor candidates were evaluated 
between July 2016 and April 2018. 2 (7%) were found to have two APOL1 risk variants 
(high risk genotype). Low risk genotype was identified in 10 (36%) candidates who had one 
risk variant and 16 (57%) candidates who had none. To date, 15 candidates have completed 
their donor work-up. Of these, 7 (47%) have already undergone donor nephrectomy, and 
4 (27%) were cleared for surgery and are awaiting operation. 4 (27%) of the candidates 
did not meet our center specific criteria for donation. 2 out these 4 candidates who were 
excluded from donation were ruled out expressly for having been found to have two APOL1 
risk variants.
Conclusions: APOL1 genotyping led to the exclusion of two donors who might have 
previously been allowed to donate, possibly mitigating their risk of CKD/ESRD and 
suboptimal graft outcomes in recipients.
Baseline characteristics of potential kidney donors
SA-PO066 Poster Saturday
Transplantation: Recipient and Donor Assessment
Community Deliberations on APOL1 Testing in African Americans
Ebele Umeukeje,1,2 Wylie Burke,3 Kerri L. Cavanaugh,1,2 Stephanie M. Fullerton,3 
James G. Wilson,4 Bessie A. Young,3,5 Erika Blacksher.3 1Vanderbilt University 
Medical Center, Nashville, TN; 2Vanderbilt Center for Kidney Disease, Nashville, 
TN; 3University of Washington, Seattle, WA; 4University of Mississippi Medical 
Center, Jackson, MS; 5VA Puget Sound Health Care System, Seattle, WA.
Background: African Americans (AA) are 2-4 times more likely to develop ESRD, 
compared to whites. Apolipoprotein L1 (APOL1) variants have been associated with greater 
risk of developing non-diabetic ESRD among African Americans (AAs), and greater risk 
of developing incident CKD, proteinuria, and transplant failure. Mechanisms of risk and 
penetrance, and effective preventive measures for kidney disease remain unclear. We 
engaged AAs to discuss potential pros and cons of APOL1 risk testing in routine patient 
and kidney transplant care.
Methods: As part of a larger assessment of stakeholder views, we conducted 
community deliberations with self-identified AAs in Seattle WA (n=14), Nashville TN 
(n=14), and Jackson MS (n=11). Information on APOL1 genetic risk was provided prior 
to, and during each meeting. Plenary and small group discussions were held followed by 
2 rounds of polling on APOL1 testing options. Deliberations occurred over 2 days for 10 
hours per site. Participants at each site reviewed results and provided feedback.
Results: Participants were diverse in gender, age, education, and kidney disease 
experience. With regard to routine patient care, responses varied on who should be tested: 
all AAs(64%); AAs with CKD risk factors(21%); AAs with signs of CKD(10%); no 
AAs(5%). Increased knowledge, improved self-care, and aid to clinical management and 
research were reasons to support testing. Lack of clinical utility and increased psychological 
burdens, potential discrimination and cost, were reasons to oppose testing. Participants 
agreed unanimously that deceased donor kidneys be tested. Views on APOL1 testing in 
other kidney transplant scenarios varied: offer testing to potential living donors(95%); 
require testing in potential living donors(73%), and prevent living donors with APOL1 risk 
from donating(10%). Participants felt that APOL1 testing was ‘actionable’ in the transplant 
setting, but expressed concern that it might reduce kidney supply.
Conclusions: Well-informed AAs have valuable input on best practices in APOL1 
testing in routine patient and kidney transplant care. There was consensus that deceased 
donor kidneys should be tested for APOL1 risk; however, views on APOL1 risk testing 
in other scenarios were divergent. Continued stakeholder deliberation is imperative as the 
science evolves to inform best practices.
Funding: Other NIH Support - NIH / National Human Genome Research Institute 
(NHGRI)
SA-PO067 Poster Saturday
Transplantation: Recipient and Donor Assessment
Prevalence of G1 and G2 APOL1 Gene Variants in Afrodescendant 
Patients from the Unit of Kidney Transplant in a High Complexity 
Medical Center in Cali, Colombia
Carlos D. Rebolledo. Fundacion Valle del Lili, Cali, Valle, Colombia.
Background: In recent years, the presence of APOL1 genetic variants has been 
recognized as a risk factor of chronic kidney disease in afrodescendant patients, especially 
variants related to the risk alleles G1 and G2 (1)(2). Patients with two allelic variants are 
at higher risk, and tend to require dialysis up to 9 years earlier than patients with no risk 
alleles (2). In addition, receptors of kidney transplant from donors with APOL1 variants 
seem to have a worse posttransplant prognosis and higher risk of graft dysfunction (3)(4)
(5). The aim of this study is to determine the prevalence of these allelic variants among the 
afrodescendant patients from the kidney transplant unit at Fundacion Valle del Lili (FVL).
Methods: Observational, cross-sectional study including afrodescendant patients with 
chronic kidney disease from the kidney transplant unit at FVL, who were on the waitlist or 
were already recipients of kidney transplant. The study period was defined from January to 
November 2017
Results: A total of 103 patients were included, 56% (n=57) were female. The mean age 
was 48 years old (SD 13 years), the mean time of dialysis before kidney transplant was 4 
years, 89% had clinical history of arterial hypertension. APOL1 gene variants were found 
in 62% (n=64) of patients, of them 32.8% (n=21) were G1 heterozygotes, 39% (n=25) were 
G1 homozygotes, 4.6% (n=3) were G2 homozygotes, and 23.4% (n=15) were mixed G1/
G2. There were none G2 heterozygotes.
Conclusions: This study describes that in the afrodescendant population with chronic 
kidney disease at FVL the frequency of APOL1 variants is high, nevertheless these results 
cannot be extrapolated to the general population, and larger population studies are required 
to accurately assess the frequency of APOL1 variants in our country. This study represents 
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a cornerstone for new lines of research on this field in our institution, a national referral 
center for kidney transplants.
SA-PO068 Poster Saturday
Transplantation: Recipient and Donor Assessment
Racial Disparities in Long-Term Outcomes in Kidney Transplantation 
from Elderly Donors in United States
Silvi Shah, Masaaki Yamada, Rohit P. Jain. University of Cincinnati, Cincinnati, OH.
Background: Kidney transplantation offers survival benefit and improved quality of 
life in end stage renal disease (ESRD) patients. Because the waiting list continues to grow, 
there has been an increase in the utilization of kidneys from older donors. We examined 
the racial disparities in graft and patient outcomes of patients after transplantation with old 
kidneys.
Methods: We identified 19,820 kidney transplant recipients based on donor age 
≥ 60 year between January 2000 and December 2016 from the United Network for Organ 
Sharing (UNOS) Standard Transplant Analysis and Research data. Using case-mix adjusted 
logistic regression models; we examined the effects of race on 3-year death censored graft 
loss (DCGL) and 3-year recipient survival in kidney transplant recipients (KTR) of elderly 
donors.
Results: Elderly donors accounted for 7.9% of all donors. Of the 19,820 recipients 
of old kidneys, 57.9% were Whites, 22.8% were Blacks, 6.4% were Asians, 11.1% were 
Hispanics and 1.9% were others. 45.6% were males. Mean donor age was 64±3 years and 
mean recipient age was 59±11 years. Overall, 3-year DCGL was 12% and 3-year recipient 
survival was 86.2%. In adjusted analyses, Blacks were more likely than Whites (odds ratio 
[OR], 1.21; 95% confidence interval [CI], 1.08-1.36, p<0.001) to experience DCGL at 3 
years. Additionally, both Hispanics (OR, 0.77; CI, 0.66-0.91, p=0.002) and Asians (OR, 
0.72; CI, 0.58-0.90, p=0.003) were less likely than Whites to experience DCGL at 3 years. 
In adjusted analyses, Blacks (OR, 0.83; CI, 0.74-0.92, p<0.001), Hispanics (OR, 0.71; CI, 
0.61-0.82, p<0.001) and Asians (OR, 0.75; CI, 0.62-0.90, p<0.001) were less likely than 
Whites to die at 3 years after receiving a kidney from an elderly donor.
Conclusions: Among KTR of elderly donors, Blacks are at 21% higher risk of graft 
failure than Whites at 3 years but survive longer after transplantation. As compared to 
Whites, both Hispanics and Asians are less likely to experience DCGR at 3 years and are 
less likely to die within 3 years of getting a kidney transplant from older donor. Further 
studies are needed to assess additional factors contributing to disparities in graft and 
recipient survival in KTR of old kidneys.
SA-PO069 Poster Saturday
Transplantation: Recipient and Donor Assessment
Genetic Ancestry as a Predictor of Kidney Transplant Outcomes
Y. Dana Neugut, Lili Liu, Junying Zhang, David Fasel, Karla Mehl,
Jaclyn L. Wold, Fatih Ozay, Olivia Balderes, Sumit Mohan, Jai Radhakrishnan, 
Lloyd E. Ratner, David J. Cohen, Ali G. Gharavi, Krzysztof Kiryluk. Columbia 
University Medical Center, New York, NY.
Background: African-American (AA) kidney recipients have higher rates of allograft 
rejection and failure. However, it is unknown to what extent the inferior outcomes in self-
reported AA’s are due to genetic effects or confounding by socioeconomic status (SES). 
In this study, we test the effects of recipient African admixture, a quantitative measure of 
genetic ancestry derived from genome-wide SNP data, in multivariable models adjusted 
for SES factors.
Methods: Our study used a multiethnic retrospective single center cohort of 1,083 
kidney allograft recipients, including 206 self-reported AA’s. Subjects were genotyped 
with high resolution SNP arrays (MEGA chip, Illumina); African admixture proportions 
were derived using ADMIXTURE software. All subjects were geo-coded and U.S. census 
tract variables were used as proxies of SES. Multivariable Cox models were constructed 
to predict time to biopsy-proven rejection and time to death-censored allograft failure, and 
race-related variables of interest were tested in each model.
Results: The cohort median follow-up time was 78.3 months, and included 432 
patients with rejection (median 5.9 months) and 193 with failure (median 72.3 months). We 
confirmed significant impact of recipient’s self-reported AA race (HR 1.47 (95% CI: 1.18-
1.83)) and African admixture proportion (HR 1.64 (95% CI: 1.22-2.19)) on acute rejection. 
Both race-related metrics also had similar effects in the adjusted models of allograft failure 
(self-report: HR 1.42 (95% CI: 1.02-1.97); admixture: HR 1.48 (95% CI: 0.96-2.29)). 
Recipient APOL1 risk genotype status, associated with African ancestry and several kidney 
diseases, did not explain these associations. U.S. census-derived median income and 
education level did not confound the association between race and either rejection or failure.
Conclusions: Our study is the first to test a genetic measure of recipient African 
ancestry for inclusion in clinical models of kidney transplant outcomes. Based on our 
results, self-reported AA race and a genetically-derived continuous measure of African 
ancestry performed similarly in predicting the risk of allograft rejection and failure, and 
both predictors were independent after multivariable adjustment for U.S. census-based 
metrics of SES.
Funding: NIDDK Support
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The Multiple Faces of a Hepatitis C Donor
Cagla Keceli,2 Nashila AbdulRahim,1 Burhaneddin Sandikci,2 Yuan Zhong,2 
Ricardo M. La Hoz,1 Bekir Tanriover,1 Venkatesh Kumar Ariyamuthu.1 1UT 
Southwestern Medical Center, Dallas, TX; 2The University of Chicago Booth 
School of Business, Chicago, IL.
Background: Public Health Service (PHS) increased risk donors are on the rise in the 
US and provide an underutilized pool of organs. With the advent of a myriad of Hepatitis C 
treatment options, use of these organs has become an attractive option for select recipients. 
An updated list of characteristics of all PHS increased risk donors is presented here.
Methods: UNOS database was queried for all deceased donor kidneys retrieved 
between 4/1/2015 and 9/30/17. The study population was divided into four categories based 
on their hepatitis C antibody (Ab) and nucleic acid testing (NAT): Ab-/NAT-, Ab-/NAT+, 
Ab+/NAT-; Ab+/NAT+. Characteristics of age, gender, race, donation after cardiac death 
(DCD), PHS increased risk, BMI, diabetes, macrovesicular fat, and KDPI are investigated 
across the four donor categories.
Results: Mean age of Ab-/NAT- donors is slightly higher than Ab-/NAT+, Ab+/NAT+, 
and Ab+/NAT- donors; Ab-/NAT-, Ab+/NAT-, and Ab+/NAT+ donors are predominantly 
male. Region 2 has the highest number of donors with NAT and/or Ab + carrier status. Ab+/
NAT- donors have the highest, mean KDPI of 54.1. Less than 10% of all deceased donors 
are diabetics. While 21% of Ab-NAT- donors were characterized as PHS increased risk, 
nearly 15% of NAT and/or Ab + carrier donors did not meet PHS criteria by definition.
Conclusions: Our data sheds light into characteristics of all deceased donors over a 2.5 
year period. It questions the accuracy of screening criteria for PHS increased risk donors. 
Delineation of these features allows for identification of an underutilized organ pool for an 
appropriate kidney transplant recipient group.
Donor Characteristics
SA-PO071 Poster Saturday
Transplantation: Recipient and Donor Assessment
Ten-Year Analysis of Transplant Recipients of High KDPI Kidneys
Giorgia Comai,1 Maria Cappuccilli,1 Andrea Angeletti,1 Valeria Corradetti,1 
Vania Cuna,1 Olga Baraldi,1 Diletta Conte,1 Chiara Donadei,1 Matteo Ravaioli,2 
Gaetano La Manna.1 1Department of Experimental Diagnostic and Specialty 
Medicine, University of Bologna, Bologna, Italy; 2Department of Medical and 
Surgical Sciences, University of Bologna, Bologna, Italy.
Background: The growing shortage of transplantable kidneys have pointed a great 
attention on the use of expanded criteria donors (ECDs). About 15% of deceased donor 
kidneys come from marginal donors, but there is some evidence to indicate that ECD 
recipients have poorer prognosis, higher incidence of DGF (31% vs 23%) and elevated risk 
of graft loss, up to 70%. However, the use of ECDs is an effort to increase the pool of organs 
available for transplant, reduce waiting times on transplant list and ensure optimal allocation 
of marginal kidneys in the elderly. Kidney Donor Profile Index (KDPI) is a score, ranging 
from 0% to 100%, based on the quality of all kidneys recovered in the previous year, and 
estimates the potential function of a donated kidney. A donor KDPI>85% is assumed to 
be equivalent to an ECD kidney. UNOS data show that only 11% of kidneys from donors 
with KDPI>85% are used for transplant, and their 5-year survival approximates only 50%.
Methods: This is a retrospective analysis of KDPI in 246 adult kidney transplants (192 
single, 54 double) from ECD donors between 2007 and 2016. The mean recipient age was 
60.2 years, donor age 67.4 years, KDPI 90.5%, cold ischemia time 14 h, total Karpinski 
score 3.9, glomerulosclerosis 0.4, interstitial fibrosis 0.9. tubular atrophy 0.6, IFTA 1.5, 
vascular score 1.1.
Results: Ten-year graft and patient survival were 76% and 80%, respectively 
(Fig. 1). The incidence of DGF was 44.7%, that of acute rejection 14.6%. GFR at discharge, 
at 1 year, at 5 years, and at 10 years were 41.5±21.8, 44.9±18.4, 49.5±20, and 53.4±27 
mL/min, respectively. Considering total Karpinski score or single histological lesions, no 
correlation was found with graft and patient survival, DGF and rejection rates. KDPI, donor 
age and recipient age were predictive of 1-year eGFR decline.
Conclusions: The high survival rates and the satisfying functional performance suggest 
a good medium-long term prognosis for renal transplant recipients of high KDPI kidneys 
considered as marginal according to the ECD classification.
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Transplantation: Recipient and Donor Assessment
Usefulness of the Assessment of CT-Based Donor Kidney Function 
Compared with Radionuclide Scintigraphy
Sun-myoung Kang,1 Soomin Jeung,1 Yuri Seo,2 Chung Hee Baek,1 Su-Kil Park,1 
Hyosang Kim.3 1Asan Medical Center, Seoul, Republic of Korea; 2Asan medical 
center, Seoul, Republic of Korea; 3Asan Medical Center, University of Ulsan 
College of Medicine, SEOUL, Republic of Korea.
Background: Pretransplant graft volume and function has been demonstrated to be an 
important factor in subsequent allograft outcomes. Most transplant centers underwent renal 
split function test to assess functional asymmetry with technetium dimercaptosuccinic acid 
(99mTc-DMSA) renography and/or computed tomography (CT). We evaluated which of the 
two methods better reflected posttransplant renal function.
Methods: We analyzed 159 living donors who underwent pretransplant kidney 
evaluation with both 99mTc-DMSA renography and CT, and their matching recipients. 
We measured glomerular filtration rate (GFR) in donor with 51Chromium (Cr) plasma 
clearance and in recipients using the chronic kidney disease epidemiology collaboration 
formula (CKD-EPI) equation at 1, 6, and 12 months after transplantation. Kidney volumes 
were calculated using semi-automatic, three-dimensional (3D) CT volumetry methods. 
Absolute transplanted graft GFR was calculated by donor GFR (ml/min) x the proportion of 
donated kidney to total kidney (transplanted kidney volume/total kidney volume in CT, and 
transplanted kidney isotope uptake/total uptake in renography).
Results: The mean absolute transplanted graft GFR were 53.3±10.6 ml/min by 
renography and 53.5±10.7 ml/min by CT (p=0.872). Posttransplant graft functions 
were 84.5±18.6, 72.3±14.1, and 74.9±16.7 ml/min/1.73m2, at 1, 6, and 12 months 
after transplantation, respectively. Pearson correlation coefficients between absolute 
transplanted graft GFR and posttransplant GFR were 0.289, 0.362, and 0.256 in renography 
(all p<0.001), and 0.318, 0.378, and 0.269 (all p<0.001) in CT at 1, 6, and 12 months, 
respectively. Multiple linear regression analysis adjusted by age and gender demonstrated 
that a 1 ml/min increase in absolute transplanted graft GFR calculated by 3D CT volume 
was associated with 0.56±0.13 ml/min/1.73m2 increase in posttransplant GFR, and one year 
increase in recipient age was associated with a 0.46±0.12 ml/min/1.73m2 reduction of GFR.
Conclusions: 3D CT volumetry method is more useful to predict renal graft outcome 
than isotope renography before transplantation.
SA-PO073 Poster Saturday
Transplantation: Recipient and Donor Assessment
Patients with a Failed Transplant Derive a Greater Survival Benefit from 
Transplantation Than Primary Transplant Recipients
Stephanie Clark,1 Ahad Abdalla,1 Jagbir Gill,2 John S. Gill.3 1Providence Health 
Care, Vancouver, BC, Canada; 2St. Paul’s Hospital, West Vancouver, BC, 
Canada; 3(St. Paul’s Hospital/University of British Columbia), Vancouver, BC, 
Canada.
Background: The organ shortage demands evidence to support the use of deceased 
donor kidneys in higher risk groups. Repeat transplant recipients have a higher risk of 
allograft failure than first transplant recipients.
Methods: Using data from the United States Renal Data System between 2000-2016 
we determined the relative risk of death in adult patients wait-listed for a first (n=334,162) 
or repeat (n= 26,815) deceased donor kidney transplant using multivariate non-proportional 
hazards analyses in which transplantation was treated as a time dependent co-variate. 
The models adjusted for differences in patient age, sex, race, cause of ESRD, comorbid 
conditions and year of wait-listing.
Results: The figure shows the relative risk of death in patients who received a first 
or repeat transplant at different time points after transplantation compared to similar 
patients (i.e. either first or repeat wait-list candidates) who remained on dialysis. Early 
after transplantation, first transplant recipients had a higher risk of death compared to 
first transplant candidates who remained on dialysis; this risk declined with time after 
transplantation. In contrast repeat transplant recipients had an immediate decreased risk 
of death compared to failed transplant recipients who remained on dialysis and this risk 
continued to decrease over time. Accordingly the time to equal risk of death compared to 
continued treatment with dialysis was 105 days in first transplant recipients versus 0 days 
in repeat transplant recipients; and the time to equal survival compared to treatment with 
dialysis was greater in first transplant recipients than in repeat transplant recipients.
Conclusions: Transplantation is associated with a greater survival benefit in repeat 
transplant candidates. Further studies are needed to determine whether current wait-listing 
practices of patients with a failed transplant are overly restrictive.
Funding: Government Support - Non-U.S.
SA-PO074 Poster Saturday
Transplantation: Recipient and Donor Assessment
Applying Computer Vision to Evaluate Percent Global Glomerulosclerosis 
in Donor Kidney Biopsies
Satoru Kudose, Matthew S. Hunt, Jon N. Marsh, S. joshua J. Swamidass, 
Joseph Gaut. Washington University School of Medicine, St. Louis, MO.
Background: Determining percent global glomerulosclerosis (GS) in donor 
kidney frozen wedge biopsies is used to determine organ viability. However, pathologic 
examination is labor-intensive and error prone. Previously, we developed a convolutional 
neural network (CNN) to quantify percent GS in scanned kidney biopsy whole slide images 
(WSI). The aim of this study is to compare CNN with pathologist evaluation of percent GS 
in scanned WSI.
Methods: Twenty consecutive donor kidney frozen wedge biopsies taken from April 
to August 2016 were scanned at 20x using an Aperio Scanscope CS scanner as part of 
routine clinical workflow. Four pathologists and one trainee manually enumerated globally 
sclerosed and non-sclerosed glomeruli using Aperio ImageScope, blinded to clinical data, in 
a setting mimicking routine clinical practice. The CNN evaluated the same WSI. Pathologist 
agreement was assessed using intraclass correlation coefficient (ICC).
Results: ICCs for pathologist evaluation of percent GS showed excellent agreement 
(0.8). Variability increased among cases with >10% GS. Percent GS determined by the 
CNN was within the pathologist range in 15/20 (75%) cases (Figure 1). CNN determined 
mean absolute difference of percent GS from pathologist median was 2% (range 0 – 6.1%).
Conclusions: The CNN quantifies percent GS in frozen section donor kidney wedge 
biopsies with performance comparable to pathologists and has potential to be incorporated 
in clinical practice.
Funding: Private Foundation Support
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Transplantation: Recipient and Donor Assessment
Estimation of the Total Nephron Number in Japanese Living Kidney 
Donors Using Combined CT Angiography and Biopsy Approach
Takaya Sasaki, Nobuo Tsuboi, Yusuke Okabayashi, Go Kanzaki, 
Kotaro Haruhara, Kentaro Koike, Akimitsu Kobayashi, Izumi Yamamoto, 
Makoto Ogura, Takashi Yokoo. Division of Nephrology and Hypertension, 
Department of Internal Medicine, The Jikei University School of Medicine, 
Tokyo, Japan.
Background: Increasing evidence suggests that individuals with low nephron number 
have an increased lifetime risk of renal insufficiency, thereby emphasizing the importance 
of evaluating total nephron number in each individual. In recent years, new methods have 
been described for estimating human total nephron number using a combination of image 
analysis and renal biopsy, though the reproducibility and accuracy of these methods remain 
uncertain. This study estimated total nephron number in healthy Japanese subjects using 
such a method.
Methods: Implantation biopsies from forty-four living kidney donors were analyzed. 
Using pre-donation contrast CT angiograms, transplantation donor kidneys were three-
dimensionally reconstructed, and total renal cortical volume was estimated. Total nephron 
number was estimated based on glomerular density in biopsy specimens and total renal 
cortical volume. The obtained results were analyzed in relation to clinical variables and 
compared with those of a previously reported Japanese autopsy study.
Results: The estimated total nephron number in this cohort was 650,000±220,000 
(mean±SD) per kidney. Total nephron number ranged from 280,000 to 1,220,000 per kidney 
(4.4-fold) and correlated directly with eGFR (r=0.328, p=0.030) and inversely with age 
(r=-0.355, p=0.018). The estimated total nephron number obtained in the present study was 
25% less than that reported in American living kidney donors using the same procedure, and 
similar to that obtained in a previous Japanese autopsy study using the dissector/fractionator 
method (Table).
Conclusions: These results confirm the feasibility of a combined CT angiography and 
biopsy-based method to estimate total nephron number in humans.
Comparison of estimated total nephron number by different methods
SA-PO076 Poster Saturday
Transplantation: Recipient and Donor Assessment
Outcomes of Declined Kidneys Subsequently Transplanted Elsewhere: A 
National Registry Analysis
Maria Ibrahim,1 Jennifer D. Mehew,1 Chris Callaghan.2 1NHS Blood and 
Transplant, Bristol, United Kingdom; 2Guy’s Hospital, London, United 
Kingdom.
Background: A recent trend in donor demographics has led to transplantation of organs 
from donors with increasing age and comorbidities in the UK. In view of this changing 
climate, individual assessment of kidneys offers is increasingly important.
Methods: Data from the UK Transplant Registry held by National Health Service 
Blood and Transplant (NHSBT) were analysed. Offers made to adult patients through the 
National Kidney Allocation Scheme (NKAS) from donation after brain-death (DBD) donors 
between 1 January 2010 and 31 December 2014 were included. A cohort of 5,973 offers was 
identified, excluding offers made via the UK fast track scheme and those leading to dual 
or en bloc transplants. Only kidneys declined for donor-specific reasons were examined.
Results: There was a large variation in offer decline rates between centres across the 
UK, ranging from 17% to 54%. ‘Donor unsuitable - past medical history’ was the most 
common reason for decline. Comparisons were made for kidneys that were declined, 
subsequently transplanted elsewhere, and remained ‘functioning ’ (as defined as patients 
with an eGFR > 20 at 12months) and stratified by centre (Figure 1). There was some 
disparity between centres however no significant outliers were identified. Centre specific 
outcomes of patients on the waiting list for whom kidney offers were declined, where the 
kidney was subsequently transplanted (n=976) in another patient and remained functioning, 
were also analysed. In this cohort, up to 9% of patients were removed from the transplant 
waiting list due to clinical deterioration and mortality was up to 15% for each centre.
Conclusions: There is variation in donor-specific decline rates across centres in the UK 
which could reflect a disparity in ‘risk-appetite’ amongst clinicians. Approximately 75% 
of declined DBD kidney offers that are transplanted elsewhere have >20 at 12 months. 
Mortality and morbidity of patients who remain on the waiting list is high. Better means of 
assessing donor risk are needed due to a high decline rate of these organs.
SA-PO077 Poster Saturday
Transplantation: Recipient and Donor Assessment
Appropriateness and Outcomes of Premature Pre-emptive Renal 
Transplants (PPRT), i.e. Renal Transplants at GFR>/= 19mL/min
Snehal Shrivastava,1 Naoru Koizumi,3 Deepak K. Malhotra,2 Jorge Ortiz.1 
1University Of Toledo Medical Center, Toledo, OH; 2The University of Toledo, 
Toledo, OH; 3George Mason University, Arlington, VA.
Background: A pre-emptive kidney transplant is the best renal replacement therapy for 
ESRD patients. There are no guidelines for the GFR at which pre-emptive transplantation 
should occur. Pre-emptive renal transplants at GFR >15 ml/min represent about nine percent 
of total recipient population per year. The goal of this study is to evaluate the outcomes of 
PPRTs. Another objective of this study is to outline the donor, recipient, and transplant 
characteristics of pre-emptive renal transplants.
Methods: Retrospective analysis of the UNOS database was performed on19,207 
preemptive renal transplants, including deceased donors (n=12,951) and living donors 
(n=6,256), between years 2010-2016. Patient survival or death-censored graft survival were 
compared across predetermined eGFR groups at the time of transplantation, using Kaplan-
Meier curves. Relevant donor, transplant & recipient characteristics were compared using 
t-/Wilcoxon-Mann-Whitney & Chi-sq/Fishers exact tests. Logistic regression was used to 
identify factors associated with pre-emptive renal transplants. Cox regression analysis was 
used to identify risk factors for adverse outcomes.
Results: In PPRT with all types of donors, the rate of graft survival is lower at higher 
GFRs (>/=19). History of diabetes in the recipient (OR=1.176, p=0.000), high number 
of previous transplants (OR=1.332, p=0.000) & older age (OR=1.004, p=0.012) increase 
the odds of receiving pre-emptive renal transplants. High BMI (OR=0.988, p=0.000) and 
high levels of HLA mismatch (OR=0.965, p=0.001) are less likely to receive a preemptive 
transplant. Increased risk of graft failure is seen in recipients with an increased number 
of previous transplants (HR=1.155, p=0.029), higher KDRI (HR=1.567, p=0.009) and 
diabetes (HR=1.218, p=0.021).
Conclusions: PPRT is associated with worse graft outcomes across all donor and 
recipient characteristics studied. Installation of guidelines for GFR at which pre-emptive 
renal transplants should occur is warranted through further research. This is especially 
important as PPRTs, (transplants occurring at GFR >/=19) may represent wastage of 
existing renal function in recipients, earlier exposure to surgical risks for live donors and 
recipients, and potential early requirement of next renal transplant.
SA-PO078 Poster Saturday
Transplantation: Recipient and Donor Assessment
Clinical Significance of Kidney Donor Profile Index on the Post- 
Transplant Clinical Outcomes Between Elderly and Young Kidney 
Transplant Recipients: A Multicenter Cohort Study
Woo Yeong Park,1,2 Jong hoon Lee,3 Jeong Ho Kim,4 Kyubok Jin,1,2 
Seungyeup Han,1,2 Bumsoon Choi,3 Chul Woo Yang,3 Byung ha Chung.3 
1Department of Internal Medicine, Keimyung University School of Medicine, 
Daegu, Republic of Korea; 2Keimyung University Kidney Institute, Daegu, 
Republic of Korea; 3Seoul St. Mary’s Hospital, Seoul, Republic of Korea; 
4Daejeon St. Mary’s Hospital, Daejeon, Republic of Korea.
Background: We investigated the clinical significance of Kidney Donor Profile Index 
(KDPI) system for the prediction of the clinical outcomes of elderly- or young kidney 
transplant recipients (KTRs) in deceased donor kidney transplantation (DDKT).
Methods: Six hundred fifty-seven KTRs receiving kidneys from 526 deceased donors 
(DDs) were included from four transplant centers. We divided high KDPI and low KDPI 
by 65%, the median value of KDPI score, and divided elderly KTRs and young KTRs at 
55 years old. We investigated the incidence of delayed graft function (DGF), biopsy-proven 
acute rejection (BPAR), allograft and patient survival rates between elderly and young 
KTRs donated from DDs with high KDPI- or low KDPI score.
Results: We analyzed 224 (34.1%) elderly KTRs and 433 (65.9%) young KTRs. There 
were no significant differences in the incidence of DGF and BPAR between elderly KTRs 
and young KTRs donated from DDs with high KDPI- or low KDPI score. In elderly KTRs, 
there was no significant difference of death-censored graft survival and patient survival 
rates between high KDPI-KT and low KDPI-KT groups. However, in young KTRs, high 
KDPI-KT group was significantly lower in death-censored graft survival rate compared 
with low KDPI-KT group (P=0.006), and there was no significant difference of patient 
survival rate between the two groups. In multivariate analysis, high KDPI score was an 
independent risk factor for allograft failure in young KTRs after adjustment for recipient 
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and donor age, gender, acute rejection, and induction immunosuppresant (HR 2.376, 95% 
C.I., 1.251-4.511, P = 0.008), but not in the elderly KTRs. Among 4 groups, high KDPI-
young KT group showed the highest risk for allograft failure compared with other three
groups and a significant interaction between high KDPI donors and young KTRs on the 
allograft outcome (P=0.002).
Conclusions: High KDPI in DDs showed significant adverse impact on the allograft 
survival in young KTRs, but it was not prognostic factor in elderly KTRs.
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Follow-Up Care of Living Kidney Donors
Ngan Lam,1 Krista L. Lentine,2 Brenda Hemmelgarn,3 Scott Klarenbach,1 
Robert R. Quinn,3 Anita Lloyd,1 Sita Gourishankar,1 Amit X. Garg.4 1University 
of Alberta, Edmonton, AB, Canada; 2Saint Louis University, St. Louis, MO; 
3University of Calgary, Calgary, AB, Canada; 4London Health Sciences Centre, 
London, ON, Canada.
Background: Previous guidelines recommend that living kidney donors receive 
lifelong annual follow-up care to assess renal health. Whether these best practice 
recommendations are currently being followed is unclear.
Methods: We conducted a retrospective study using linked databases in Alberta, 
Canada to follow living kidney donors from 2002 to 2014. We determined the proportion of 
donors who had an annual outpatient physician visit and laboratory measurements for serum 
creatinine and albuminuria.
Results: There were 534 living kidney donors with a median follow-up of 7 years 
(maximum 13 years). The median age at the time of donation was 41 years and 62% 
were female. Overall, 25% of donors had all three markers of care (physician visit, serum 
creatinine, albuminuria measurement) in each year of follow-up. Adherence to physician 
visits was higher than serum creatinine or albuminuria measurements (67% vs. 31% vs. 
28% of donors, respectively). Donors with guideline-concordant care were more likely to 
be older, reside closer to the transplant center, and receive their nephrectomy in more recent 
years.
Conclusions: These findings suggest significant evidence-practice gaps, in that the 
majority of donors saw a physician, but the minority had measurements of kidney function 
or albuminuria. Future interventions should target improving follow-up care for all donors.
Proportion of donors who have evidence of follow-up care during each post-donation year.
SA-PO080 Poster Saturday
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Trends in the Timing of Preemptive Kidney Transplantation in Children
Erica Winnicki, Kirsten L. Johansen, Charles E. McCulloch, Jason T. Lee, 
Elaine Ku. UC San Francisco, San Francisco, CA.
Background: There has been a recent trend toward starting dialysis at higher levels of 
kidney function in children. Whether there has been a similar trend for preemptive kidney 
transplantation (PKT) in children is unknown.
Methods: We identified 3,278 children (age 1-17 years) in the US Renal Data System 
who underwent PKT between 1995 and 2015 and had data available to estimate glomerular 
filtration rate (eGFR) using the bedside Schwartz equation. We evaluated the trend in eGFR 
at time of PKT over time and differences in recipient characteristics between those who 
received PKT early (eGFR >10 ml/min/1.73m2) vs. late (eGFR ≤10 ml/min/1.73m2).
Results: Mean eGFR at the time of PKT increased significantly over time (Figure), 
from 9.1 ml/min/1.73m2 in 1995 to 13.5 ml/min/1.73m2 in 2015 (p<0.001). The trend 
toward earlier transplantation was similar among recipients of living and deceased donor 
organs (p for interaction=0.67). The proportion of children undergoing PKT early increased 
from 31% in 1995 to 71% in 2015. Overall, 57% of children underwent PKT early (mean 
eGFR 15.5 ml/min/1.73 m2). Compared to children who underwent PKT late (mean eGFR 
7.5 ml/min/1.73 m2), those who were transplanted early were older, more often of white 
race, and less likely to have a living donor (Table).
Conclusions: PKT is occurring at higher levels of eGFR over time in children. Further 
studies should examine possible reasons for this trend and whether timing of PKT is 
associated with allograft survival or mortality.
Funding: NIDDK Support
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Mapping Compensatory Renal Hypertrophy and Hyperfiltration in Living 
Kidney Donors Using Multiparametric Magnetic Resonance Imaging
Anna S. Li,1,2 Josephine H. Naish,1 Matthew J. Gough,1 Patrick Hamilton,1,2 
Paul E. Brenchley,1,2 Rachel Lennon,1,2 Alastair J. Hutchison.1,2 1University of 
Manchester, Manchester, United Kingdom; 2Manchester University NHS 
Foundation Trust, Manchester, United Kingdom.
Background: Despite sustained glomerular hypertrophy and hyperfiltration, the vast 
majority of living donors do not develop hyperfiltration injury with fibrosis and progressive 
GFR decline. Our study uses serial multiparametric MRI to assess volume and blood flow 
of the remaining kidney in the first month post-donor nephrectomy. Relationships between 
changes in kidney volume, renal blood flow (RBF) and single kidney GFR (SKGFR) may 
reflect functional reserve of the remaining kidney and provide insight into the early stages 
of nephron loss in the development of CKD.
Methods: 6 living kidney donors underwent 3 sessions of MRI and creatinine-based 
eGFR measurements prior to, 4 days after, and 4 weeks after nephrectomy. The non-
contrast multiparametric MR protocol includes: whole kidney volumetric assessment 
by manual delineation using a multi-slice T1-weighted (inversion-recovery) turbo-spin 
echo; assessment of RBF using a FAIR arterial spin labelling (FAIR-ASL) technique; and 
quantitative T1-mapping using a MOLLI technique.
Results: Median age of the donors was 57 (35 to 67); baseline kidney volume was 
141±21mL, increasing to 183±38mL at day 4 and 179±32mL at week 4. SKGFR was 
46±5mL/min at baseline, increasing to 61±12mL/min at day 4 and 60±9mL/min at week 
4. RBF per unit weight did not change significantly at either day 4 (5.7±0.8 mL/g/min) or 
week 4 (6.4±0.4mL/g/min) from baseline (5.8±1.6mL/g/min). T1 value of the renal cortex 
saw a small increase at day 4 (1.64s) compared to baseline (1.53s), which is maintained at 
week 4 (1.62s).
Conclusions: The results show that compensatory hypertrophy and hyperfiltration 
started rapidly following renal tissue loss, became established within a few days, and 
sustained over the next 3-4 weeks. Given adult glomerular number does not increase 
in compensatory hypertrophy, our preliminary findings indicate that average single 
glomerular volume and GFR rose post-donation. As RBF per unit weight did not change 
post-nephrectomy in our cohort, with glomerular hypertrophy, this suggests that overall 
single glomerular blood flow would also increase. Further study into this growth of normal 
tissue is required to identify imaging biomarkers for nephron reserve and capacity for 
compensation before the onset of hyperfiltration injury.
Funding: Commercial Support - Shire Pharmaceuticals
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Clinical Significance of the Kidney Donor Profile Index in Deceased 
Donors for Prediction of Post-Transplant Clinical Outcomes: A  
Multicenter Cohort Study
Jong hoon Lee,1 Woo Yeong Park,2 Bumsoon Choi,3 Cheol Whee Park,4 Chul 
Woo Yang,5 Yong-Soo Kim,7 Kyubok Jin,6 Seungyeup Han,6 Byung ha Chung.8 
1Seoul St. Mary’s hospital, Seoul, Republic of Korea; 2Dongsan Medical Center, 
Daegu, Republic of Korea; 3Division of Nephrology, Department of Internal 
Medicine, Seoul, Republic of Korea; 4The Catholic University of Korea, Seoul, 
Republic of Korea; 5Seoul St. Mary’s Hospital, Seoul, Republic of Korea; 
6Keimyung University School of Medicine, Daegu, BUSAN, Republic of Korea; 
7The Catholic University of Korea College of Medicine, Seoul, Republic of 
Korea; 8Seoul St. Mary’s Hospital, Seoul, Republic of Korea.
Background: We investigated whether the Kidney Donor Profile Index (KDPI) system 
is useful in predicting clinical outcomes in deceased donor kidney transplantation (DDKT).
Methods: Four hundred sixty-nine kidney transplant recipients (KTRs) receiving 
kidneys from 359 deceased donors were included in this study, which involved three 
transplant centers. KTRs were divided into high and low KDPI KTR groups based on the 
median KDPI score of 67%. We compared clinical outcomes between the high KDPI and 
low KDPI groups.
Results: There were no significant differences in the incidence of delayed graft 
function and acute rejection between high and low KDPI KTR groups. In comparison with 
histologic findings in allograft tissues obtained within three months from KT, the proportion 
of glomerulosclerosis was significantly higher in the high KDPI KTR group than in the low 
KDPI KTR group. With Kaplan-Meier analysis, the graft survival rate was significantly 
lower in the high KDPI KTR group than in the low KDPI KTR group (Log rank, P=0.017), 
and multivariate analysis also demonstrated that a high KDPI score was a significant risk 
factor for death censored allograft failure (HR 2.62, 95% CI, 1.29–5.33, P=0.008).
Conclusions: The KDPI scoring system is useful in predicting allograft outcomes in a 
Korean DDKT cohort.
Analysis of long-term outcome. (A) Comparison of death-censored graft survival rates 
between high and low KDPI KTR groups (P<0.001, Log-rank test) (B) Comparison of 
patient survival rates between high and low KDPI KTR groups (P=0.132, Log-rank test)
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Interdisciplinary Care Improves Transplant Evaluation Rates Prior to 
ESRD Among High-Risk Patients with Advanced CKD
Tanya S. Johns,1 Michelle M. Estrella,2 L. Ebony Boulware,3 Michal 
L. Melamed.4 1Montefiore Medical Center, Bronx, NY; 2University of California, 
San Francisco and San Francisco VA Medical Center, San Francisco, CA; 
3Duke University School of Medicine, Durham, NC; 4Albert Einstein College of 
Medicine, Bronx, NY.
Background: Despite the established benefits of kidney transplantation for patients 
with advanced CKD, data suggest that referral to transplant nephrology is often delayed, 
even among patients with established nephrology care. Healthcare delivery interventions to 
foster transplant evaluation prior to developing ESRD are greatly needed. Interdisciplinary 
care (IDC), which includes nurse practitioner care coordination, is a promising intervention 
that may increase transplantation evaluation among patients with CKD.
Methods: We compared incident ESRD patients who received nurse practitioner care 
coordination as part of our IDC clinic (n= 100) to a contemporaneous cohort of incident 
ESRD (n= 1872) patients who received usual nephrology care alone at Montefiore Medical 
Center from 10/1/2013 - 10/31/2017. Montefiore Medical Center is a large tertiary institution 
that serves a predominately urban and poor African American and Hispanic population. All 
patients studied had established care with a general nephrologist and were eligible for IDC 
but receipt of IDC was limited by resource availability.
Results: Of the 1,972 patients included in our study, the mean age was 58 (SD 14.8), 
43% were female, and 69% self-identified as African American or Hispanic. The baseline 
characteristics were similar between the two groups. Patients who received IDC were more 
likely to be evaluated by transplant nephrology prior to developing ESRD, 44% versus 24% 
(p < 0.001). The odds of transplant evaluation prior to developing ESRD was 3 times higher 
(OR 3.0 [CI 1.9- 4.6) for patients who received IDC versus usual care alone after adjusting 
for age, race, ethnicity, sex, and baseline comorbidities including diabetes, hypertension 
and cardiovascular disease. African Americans or Hispanics were less likely and younger 
patients were more likely to be evaluated by transplant nephrology prior to ESRD.
Conclusions: Interdisciplinary care (also known as multidisciplinary care) is 
associated with greater likelihood of transplant evaluation prior to ESRD compared to usual 
nephrology care alone in a racially and ethnically diverse population of lower SES. Larger 
multicenter studies are needed to determine the impact of IDC on transplant evaluation rates 
among patients with advanced CKD.
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Use and Outcomes of Kidneys from Donors with Angiomyolipoma: A 
Systematic Review
Desiree Garcia Anton, Franco H. Cabeza Rivera, Wisit Cheungpasitporn. 
University of Mississippi Medical Center, Ridgeland, MS.
Background: Renal angiomyolipoma (AML) is the most frequent mesenchymal tumor 
of the kidney. Although there is a rare possibility of malignant transformation of AML, this 
risk has not been studied in immunosuppressed patients. The safety of donors with AML 
and their kidney transplant recipients has not been well established.
Methods: A literature search was conducted utilizing MEDLINE, EMBASE and 
Cochrane Database from inception through May 15th, 2018. We included studies that 
reported outcomes of kidney donors with AML or recipients of donor with AML. The 
protocol for this meta-analysis is registered with PROSPERO (International Prospective 
Register of Systematic Reviews; no. CRD42018095157).
Results: 15 studies with a total of 17 donors with AML were identified. None of the 
donors had a diagnosis of tuberous sclerosis (TSC), pulmonary lymphangioleiomyomatosis 
(LAM), or epithelioid variant of AML. Donor age ranged from 35 to 77 years, and recipient 
age ranged from 27 to 62 years. 92% of the donors were female. Only 8% were deceased 
donor renal transplant. The majority of donors underwent ex-vivo resection (65%) prior to 
transplantation, followed by no resection (18%), and the remaining had in-vivo resection. 
Tumor size varied from 0.4 cm to 7 cm, and the majority (87%) were localized in the right 
kidney. Follow up time ranged from 1 to 107 months. Donor creatinine pre-nephrectomy 
ranged 0.89-1.1 mg/dL and post-nephrectomy creatinine 1.0 to 1.17 mg/dL. In those who 
did not have resection of the AML, tumor size remained stable. None of the donors with 
AML had end-stage renal disease or died at last follow-up. None of the recipients had 
malignant transformation of AML.
Conclusions: These findings are reassuring for the safety of donors with AML (without 
TSC or LAM) as well as their recipients without evidence of malignant transformation of 
AML. As such, this can also positively impact the donor pool by increasing the number of 
available kidneys.
SA-PO085 Poster Saturday
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Racial Disparities in Access to Kidney Transplant: Medically (In)
Appropriate?
Elaine Ku,1 Brian K. Lee,1 Charles E. McCulloch,1 Garrett R. Roll,1 
Deborah B. Adey,3 Kirsten L. Johansen.2 1University of California San 
Francisco, San Francisco, CA; 2University of California, San Franicsco, San 
Francisco, CA; 3University of California, San Francisco, San Francisco, CA.
Background: Racial and ethnic disparities are known to be present in kidney transplant 
access. Our objective was to understand whether differences in recipient medical eligibility 
contribute to these known disparities.
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Methods: We included 1,573,786 adults who started dialysis between 1995-2015 
according to the US Renal Data System. The exposure was race/ethnicity (non-Hispanic 
white [NHW], non-Hispanic black [NHB], or Hispanic). Outcomes were differences 
in medical eligibility for and time to kidney transplant after dialysis initiation. We used 
multivariable Cox models to examine the association between predictor and outcome. We 
then repeated our Cox models, excluding individuals who may be medically ineligible for 
transplant (e.g. age>70, malignancy, heart disease, and body mass index>35 kg/m2).
Results: During 4.1 years of mean follow-up, 129,820 patients received a transplant. 
NHBs and Hispanics had a lower prevalence of potential medical barriers [Figure 1] to 
transplant at time of dialysis initiation than NHWs. Overall, access to transplant was 56% 
lower in NHBs and 43% lower in Hispanics compared to NHWs [Figure 2A]. When we 
repeated our Cox models after excluding patients who may be medically ineligible for 
transplantation (70% of the population), these disparities widened in the remaining “very 
healthy” subcohort [Figure 2B].
Conclusions: NHBs and Hispanics had fewer medical contraindications but lower 
access to transplantation than NHWs. Differences in medical eligibility do not appear to 
explain racial/ethnic disparities in access to transplant, and in fact, may mask the magnitude 
of the inequities that are present. These findings are concerning, as the healthiest candidates 
appear to have the lowest access to transplant.
Funding: NIDDK Support
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Effects of Age and Body Mass Index on Enlargement of the Remaining 
Kidney in Living Kidney Transplant Donors
Makoto Tsujita. Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Background: In living kidney transplant donors, recent studies have reported some 
problems related to long term safety of living kidney donations. After nephrectomy, 
compensatory hypertrophy of the remaining kidney occurs to recover kidney function. To 
know how large it would be is very informative. However, factors that affect compensatory 
hypertrophy remain unknown.
Methods: Kidney volumes were measured using computed tomography volumetry 
before donation and one year after kidney donation in continuous 83 living kidney 
transplant donors from 2014 to 2015 at Nagoya Daini Red Cross Hospital, Japan. Ratio of 
kidney volume before donation and one year after donation was measured. Factors such as 
age, body mass index (BMI), estimated glomerular filtration rate (eGFR), blood pressure 
(BP) and so on which could affect the ratio were evaluated. Selection of kidney transplant 
donors was done according to the guideline set by the Japanese Society of Transplantation.
Results: Thirty-seven donors among all kidney donors evaluated in the study were 
men. Mean age before donation was 57.0 ± 10.7 years. eGFR before donation was 
associated with kidney volume (r=0.24 p=0.04). Age had a negative correlation with the 
ratio (r=0.40, p<0.001), but BMI and eGFR had a positive correlation respectively (r=0.21 
p=0.05, r=0.24 p=0.04, respectively). However, the difference in eGFR before donation and 
one year after donation was not associate with the ratio. Multivariate analysis showed that 
age and BMI had strong association with the ratio.
Conclusions: Age and BMI were associated with compensatory renal hypertrophy. 
These factors would be taken more into consideration in the selection of living kidney 
transplant donors.
SA-PO087 Poster Saturday
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Renal Transplantation: Does Race Play a Role?
Sarah T. Suliman, Jeremy Carlson, Carmen Smotherman, Shiva Gautam, 
Ljubomir M. Ilic. University of Florida College of Medicine Jacksonville, 
Jacksonville, FL.
Background: Multiple studies have revealed discrepancy in healthcare access and 
outcomes in certain racial populations. We present a retrospective cohort study of end stage 
renal disease (ESRD) patients from our institution scrutinizing whether or not race is a 
factor in the referral process for renal transplantation.
Methods: The study population included all of the adult 200 ESRD patients who 
are currently receiving hemodialysis at the outpatient dialysis unit at the University of 
Florida (UF) Health in Jacksonville from January 2016 to February 2018. We divided 
race into 3 categories: Blacks, Whites, and Others, which consisted mostly of Hispanic 
patients together with other races/ethnicities. Outcomes were categorized as the patients 
who refused referral, who were not referred for transplant, and who were referred for 
transplant. We also collected established factors in the transplant evaluation process such 
as age, Hemoglobin A1c ≥ 7, Body mass index ≥ 40, left ventricular ejection fraction 
≤ 40, presence of coronary or peripheral arterial disease (PAD/CAD), albumin level 
< 3.5, and cancer, cirrhosis and smoking history. All data were collected using chart review 
and analyzed using univariate analyses and multinomial logistic regression. Associations
between the race and outcome categories are presented as adjusted Odds Ratios (OR) with 
95% confidence interval (CI) using the not-referred group as the reference category. The 
study was approved by the UF IRB committee.
Results: In the univariate analysis, age, PAD/CAD, and albumin level were found to 
be potential confounders and were included in the final model. Blacks (OR=16.0, 95%CI 
3.3-77.2, p=0.018) and Whites (OR=22.5, 95%CI 3.4-149.8, p=0.013) were more likely to 
be referred for transplant than not compared to Others. The odds of transplant refusal versus 
a non-referral in Blacks and Whites were not different from Others (p=0.270, and p=0.171, 
respectively).
Conclusions: In our nephrology practice, Blacks and Whites were more frequently 
referred for renal transplant than other ethnicities/races. There was no difference between the 
races in transplant refusal, which might point to satisfactory education and communication 
across the race groups. At this point we speculate the lack of funding and immigration 
status might play a role in the observed differences. Future studies are needed to address 
these possibilities.
SA-PO088 Poster Saturday
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Does Financial Assistance for Travel and Subsistence Costs Alleviate 
Racial/Ethnic Disparities in Living Kidney Donation? An Analysis of 
NLDAC and SRTR Data
Amit K. Mathur,1 Jiawei Xing,2 Patricia H. Warren,5 Kimberly A. Gifford,4 
Barry A. Hong,6 Akinlolu O. Ojo,3 Robert Merion.2 National Living Donor 
Assistance Center 1Mayo Clinic, Phoenix, AZ; 2Arbor Research Collaborative 
for Health, Ann Arbor, MI; 3University of Arizona Health Sciences, Tucson, AZ; 
4American Society of Transplant Surgeons (ASTS), Arlington, VA; 5American 
Society of Transplant Surgeons, Arlington, VA; 6Washington University School 
of Medicine, St Louis, MO.
Background: The National Living Donor Assistance Center (NLDAC) enables living 
donor kidney transplants (LKDT) through means-tested financial assistance of living 
kidney donors (LKD). Since LKDT occurs at lower rates in minority populations, we aimed 
to determine whether NLDAC utilization is associated with minority donor and recipient 
characteristics.
Methods: We retrospectively matched LKD data from NLDAC to Scientific Registry 
of Transplant Recipients (SRTR) data (2012-2015). We compared sociodemographic 
factors between NLDAC-using and non-NLDAC-using donors. Generalized linear mixed 
models with center-level random effects were used to estimate the impact of demographics 
on donor NLDAC use.
Results: There were 16,822 LKDT from 2012-2015. Matching to SRTR was successful 
for 86% of 1,419 NLDAC LKDT. Compared to non-NLDAC LKD, NLDAC LKD had a 
higher proportion of females (67% vs 62%), black race (15% vs 11%), Latino ethnicity 
(20% vs 14%), and were less educated (less than bachelors vs bachelors or more, 48% vs 
45%).. NLDAC LKDT recipients were more often black (17% vs 13%), Latino (20% vs 
14%), and less educated (all p<0.05). On multivariable analysis, NLDAC utilization was 
associated with LKD characteristics included LKD black race (OR 1.46, p=0.008), Latino 
ethnicity (OR 1.32, p=0.029), and female sex (OR 1.23, p=0.001); and LKDT recipient 
characteristics of black race (OR 1.38, p=0.017), Latino ethnicity (OR 1.29, p=0.047), and 
lower education (OR 1.17, p=0.012).
Conclusions: Living donor and recipient racial and ethnic minority status, as well as 
recipient educational status, were associated with higher NLDAC utilization among LKDT 
in the US. These data suggest that financial assistance programs for living donors alleviate 
disparities in access to LKDT.
Funding: Other U.S. Government Support
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Impact of Machine Perfusion on Delayed Graft Function and Graft 
Survival from High-Risk Donors
Larissa G. Andrade, Frederico C. Cavalcanti, Lucila Maria Valente. Universidade 
Federal de Pernambuco, Recife, Brazil.
Background: After kidney transplantation(KT), graft may not function immediately 
and patient needs to undergo dialysis, characterizing delayed graft function (DGF). DGF 
increases length of hospital stay (LHS), costs and reduces graft survival (GS). DGF 
incidence is higher in expanded criteria donor (ECD), prolonged cold ischemia time (CIT) 
and donors with renal dysfunction. Machine perfusion (MP) is a method of preservation 
that can reduce DGF incidence. We analyzed DGF incidence, its duration, CIT, LHS, 
1-year graft and patient survival and renal function estimated by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) at 1, 3, 6, 9 and 12 months in KT with CS 
compared to MP after CS.
Methods: Retrospective cohort, in a single center. We included KT from DCE or 
standard deceased donors if CIT ≥ 24 hours, cardiorespiratory arrest before donation or 
creatinine ≥1.8mg/dL prior to retrieval from January 2015 to December 2016, 1-year follow 
up.
Results: Sample was 92 patients, 52 in MP group. Differences between groups were: 
age of recipient higher in MP group and donor creatinine prior to retrieval 0.7mg/dL higher 
in CS group. DGF incidence was 86.5% in MP group and 95% in CS group, p=0.29. There 
were no differences in DGF duration or LHS. CIT was 8.19 hours higher in the MP group, 
p<0.01. GS was 90.4% in the MP group and 87.5% in CS group. Patient survival was 
94.2% in MP group and 95% in CS group. There were no differences in CKD-EPI at 1, 
3, 6, 9 and 12 months. After 1-year KT, 89.6% of MP group and 66.7% of CS group had 
CKD-EPI higher than 30mL/min/1.73m2, p=0.01. In multivariate analysis, risk factors for 
worse 1-year graft function were: donor age (OR 1.11 CI95% 1.01-1.22; p=0,03) and CS 
preservation (OR 6.52 CI 95% 1.46-29.08; p=0.01).
Conclusions: The higher CIT in MP group did not increase incidence of DGF. 1-year 
graft function were better in MP preservation.
SA-PO090 Poster Saturday
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Selecting and Educating Hepatitis C Virus (HCV) Un-infected Kidney 
Transplant (KT) Waiting List Recipients for a Clinical Trial to Receive an 
HCV-Infected KT
Meghan E. Sise,1 Donald F. Chute,1 Jenna L. Gustafson,1 Sakuni Silva,1 David 
Wojciechowski,1 Nahel Elias,1 Raymond T. Chung,2 Winfred W. Williams.1 
1Massachusetts General Hospital, Boston, MA; 2MGH, Boston, MA.
Background: Using HCV-infected (HCV+) donors for KT into HCV-uninfected 
(HCV-) recipients is a novel strategy to increase access to KT and decrease high rates of 
organ discard. Patient (pt) selection and education is key to ensure ability to comply with 
protocol requirements and fully understand risks/benefits.
Methods: NCT02945150 is an investigator-initiated clinical trial to transplant 11 
HCV- KT pts with a HCV+ KT. Pre-emptive use of elbasvir/grazoprevir to cure HCV in the 
recipient. We describe the criteria used to select pts, education process, characteristics of the 
consented pts, and study outcomes of HCV+ KT.
Results: We present enrollment criteria and rationale, which focus on ensuring that 
high quality HCV+ kidneys are accepted for transplantation and recipients have been 
selected to maximize safety and benefit. The process of enrolling pts is shown in Figure 1. 
Pt education focuses on 5 themes: 1) HCV in general 2) Effect of HCV on kidney availability 
3) Genotypes of HCV and treatment 4) Logistics of study visits 5) Side effects of elbasvir/
grazoprevir. The full “education session” is provided. 23 pts have provided consent, mean 
age 57 (SD 8), 61% Male, 78% White, 13% Black, 9% Hispanic. Two were excluded due 
to psychosocial or medical comorbidities. Twelve are undergoing medical clearance for KT. 
Nine were approved and their UNOS status changed to “willing to accept HCV+ organ.”
Five underwent KT and four are waiting. All donors had genotype 1A infection. None had 
resistance-associated variants. (Numbers, transplant, and viral outcomes to be updated at 
time of presentation).
Conclusions: It is important to have a multidisciplinary team to identify the appropriate 
pts for HCV+ to HCV- KT and a thorough process of education, consent, and evaluation so 
that pts understand the risks of the protocol and the KT itself.
Funding: Commercial Support - Merck
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Access to the Kidney Transplant Waitlist for Patients with HIV and ESRD
Ashton A. Shaffer,1 Hao Ying,1 Nadia M. Chu,1 Alvin G. Thomas,2 Christine 
E. Haugen,1 Dorry L. Segev,1 Mara McAdams-DeMarco.1 1Johns Hopkins
University, Baltimore, MD; 2UNC Chapel HIll, Chapel Hill, NC.
Background: Patients with HIV and end-stage renal disease (ESRD) experience 
higher mortality on dialysis than those without HIV. These HIV+ dialysis patients may face 
barriers to kidney transplantation (KT) that result from delayed referrals or factors identified 
at the time of evaluation.
Methods: We used a prospective, longitudinal multi-center cohort to study 98 HIV+ 
and 3,105 HIV- patients with ESRD who were evaluated for KT between 2008 and 2017. 
We compared patient characteristics and estimated the likelihood of listing by HIV-status 
using adjusted Cox regression. The presence of comorbidities was defined as a Charlson 
comorbidity index (CCI) score ≥1; cognitive impairment was defined as a mini-mental state 
exam score ≤80.
Results: Patients with HIV were more often young (median 54 vs. 56 years old), 
African American (91 vs. 43%), men (72 vs. 59%), with cognitive impairment (15 vs. 
6%), and longer time on dialysis prior to KT evaluation (median 2.4 vs. 1.3 years) than 
those without HIV. Within 1 year of KT evaluation, 52 HIV+ and 2,010 HIV- patients 
were listed for KT; median time from evaluation to listing was 133 days for HIV- patients 
and 315 days for HIV+ patients (Figure 1). Adjusting for age, gender, African American 
race, comorbidities, and cognitive impairment, patients with HIV were less likely to be 
listed (aHR: 0.70, 95%CI: 0.52-0.93; p<0.05). However, additionally adjusting for time on 
dialysis attenuated this difference (aHR: 0.90, 95%CI: 0.67-1.20; p=0.5).
Conclusions: HIV+ patients have a lower likelihood of KT listing that is not explained 
by differences in patients’ characteristics other than time on dialysis prior to evaluation. 
Decreasing time from dialysis initiation to referral for evaluation may improve access to 
KT for HIV+ patients with ESRD.
Funding: NIDDK Support, Other NIH Support - F30DK116658 (Shaffer), 
T32AG000247 (Chu), F32AG053025 (Haugen), K24DK101828 (Segev), K01AG043501 
& R01AG055781 (McAdams-DeMarco)
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Transplantation: Recipient and Donor Assessment
Kidney Transplant Evaluation with Blood Oxygen Level Dependent 
(BOLD) and Diffusion-Weighted MRI: A Pilot Study
Meyeon Park,1 Ying Gao,3 Zoltan G. Laszik,2 Zhen J. Wang.4 1UCSF, San 
Francisco, CA; 2University of California San Francisco, San Francisco, CA; 
3University of California, San Francisco, San Francisco, CA; 4UCSF Medical 
Center, San Francisco, CA.
Background: Methods to identify etiologies of kidney allograft dysfunction in kidney 
transplant recipients (KTR) are generally limited to biopsy (bx). Blood oxygen level-
dependent (BOLD) MRI can provide surrogate markers of tissue oxygen bioavailability. 
Diffusion-weighted (DW) intravoxel incoherent motion (IVIM) method can assess capillary 
perfusion and molecular diffusion, which may indicate tissue fibrosis. We explored these 
MRI methods as a non-invasive strategy to evaluate KTR undergoing bx.
Methods: We enrolled 14 KTR who underwent bx (12 protocol, 2 cause) at our center. 
Participants underwent research MRI scanning using BOLD and IVIM-DW protocols. 
Allograft bx were scored using Banff criteria by a single trained renal pathologist per clinical 
protocol. Individual Banff criteria were categorized as ordinal variables and corresponding 
MRI values were compared by the Kruskal-Wallis test. The mean difference estimate of the 
standardized MRI values between dichotomized abnormal and normal categories of Banff 
scores was calculated. Receiver operating characteristics (ROC) analysis was performed.
Results: Mean age was 50 (+/- 16); 9 (64%) were women. More severe grades of total 
inflammation (ti) were associated with lower BOLD R2* values (12.6 v. 13.8 v. 15, p=0.05); 
this may reflect lower oxygen consumption. Higher Banff scores for t, ptc, and i were 
associated with reduced capillary perfusion measured by IVIM-DW MRI (Fig). Area under 
curve (std error) for cortical interstitial fibrosis 0.8 (0.15) by BOLD and 0.95 (0.07) by DW.
Conclusions: BOLD and IVIM-DW MRI measures correlate with tissue pathology. 
IVIM-DW MRI may have more precision than BOLD to distinguish certain pathologic 
features on allograft bx. Functional MRI measures may be a useful screening tool to 
minimize kidney allograft bx.
Funding: NIDDK Support, Private Foundation Support
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Transplantation: Recipient and Donor Assessment
Ferumoxytol-Enhanced MR Angiography (FeMRA) vs CT Angiography 
(CTA) for the Assessment of Potential Kidney Transplant Recipients
Sokratis Stoumpos,1,2 Pauline Hall barrientos,5 Aleksandra Radjenovic,3 
Giles Roditi,6 David Kingsmore,4 Patrick B. Mark.2,1 1Renal & Transplant Unit, 
Queen Elizabeth University Hospital, Glasgow, United Kingdom; 
2Cardiovascular Research Centre, University of Glasgow, Glasgow, United 
Kingdom; 3University of Glasgow, Glasgow, United Kingdom; 4NHS, Glascow, 
United Kingdom; 5NHS, Glasgow, United Kingdom; 6NHS GG & C, Glasgow, 
United Kingdom.
Background: Conventional vascular imaging techniques are problematic in chronic 
kidney disease (CKD) patients due to associated risks, invasiveness and imprecision. CT 
angiography (CTA) is routinely used to assess the vasculature of CKD patients before 
transplant listing. Ferumoxytol, licensed for iron-deficiency anaemia, was originally 
developed as an MRI contrast agent and reduces T1 properties of tissue on MRI.
Methods: Prospective comparative study of ferumoxytol-enhanced MRA (FeMRA) vs 
CTA for aortoiliac imaging in kidney transplant (KT) candidates. MRA using ferumoxytol 
3mg/kg as intravenous contrast agent was performed in addition to CTA. We also used 
a specific MRI sequence called StarVIBE to detect vascular calcifications in similar way 
to CT using contrast-free techniques. Two independent readers assessed the FeMRA/
StarVIBE and a third reader the CTA (gold standard). Interclass correlation coefficient 
(ICC) was performed to assess interobserver agreement. Comparisons of lumen diameter, 
calcification, and signal intensity at predefined vascular sections were performed. For 
continuous variables, mean differences (and CI) were estimated and Bland-Altman plots of 
interobserver variability were created. Steady-state images were analyzed using the Horos 
image viewer (vs3, LGPL-3.0).
Results: 28 patients (mean age 68 [SD 15] yr; 58% men; 42% diabetics) undergoing 
CTA for pre-operative KT candidacy assessment were enrolled. There was excellent 
intraobserver agreement in assessment of the arterial diameter, vein diameter and 
calcification (ICC 0.91 [95% CI 079-0.96], 0.89 [0.79-0.94] and 0.95 [0.89-0.98], 
respectively). There were no significant differences in assessment of the arterial diameter 
and calcification between FeMRA/StarVIBE and CTA (arterial diameter 1.34 [0.42] vs 1.30 
[0.44]cm; p=0.63, area of calcification 0.43 [0.35] vs 0.39 [0.29]mm2; p=0.53, respectively). 
However, signal intensity and qualitative lumen depiction in the venous vasculature was 
superior with FeMRA (p<0.001).
Conclusions: FeMRA combined with StarVIBE is comparable to CTA for assessment 
of lumen diameter, calcification and signal intensity in the abdominopelvic arterial 
vasculature of CKD patients due for KT listing with the significant advantage of improved 
venous depiction with no nephrotoxicity.
Funding: Commercial Support - AMAG Pharmaceuticals
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Transplantation: Recipient and Donor Assessment
Contrasting Relationships Between Deprivation, Kidney Transplantation, 
and Live Donation
Keith Gillis,1 Julie Glen,2 Jennifer S. Lees,1 Maximilian R. Ralston,2 Colin 
C. Geddes,2 Karen S. Stevenson,2 Jamie P. Traynor,2 Patrick B. Mark.1 Glasgow 
Renal Research Group 1University of Glasgow, Glasgow, United Kingdom; 
2NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.
Background: Socioeconomic deprivation (SED) is associated with reduced access to 
pre-emptive and live kidney donation for end stage kidney disease (ESKD). We investigated 
the association between SED and access to, and progression through, potential live donor 
(PLD) assessment.
Methods: Retrospective analyses of routinely collected healthcare data were 
performed. A postcode of residence-based tool, the Scottish Index of Multiple Deprivation 
(SIMD), was used as a marker of SED; the cohort was grouped numerically into those with 
greater deprivation (SIMD≤3) and those without. A survival analysis was performed to test 
for interaction between SIMD and time to either drop-out or live donor nephrectomy.
Results: Of 7765 patients attending clinic, 1298 reached ESKD; 113 received a 
pre-emptive transplant. Patients receiving pre-emptive transplant had higher SIMD 
(5±7 vs 4±5; p=0.003); SIMD, cardiovascular disease, referral age and proteinuria were 
independently associated with pre-emptive transplant on logistic regression. 1208 PLDs 
were evaluated between 2009 and 2018 with an age of 45.8±21.4 years, follow-up 3.4±8.5 
months and SIMD of 4±5. The PLDs from deprived areas were assessed at younger age 
(42.9±21.6 vs 48.4±21.1 years; p<0.001). SED was not asssociated with likelihood of 
successful donation (8 vs 11%; p=0.13) but was associated with more frequent referral 
for psychological assessment (13 vs 9%; p=0.03); there was no difference in discussion 
of the National Kidney Sharing Scheme (7 vs 9%; p=0.22). The cumulative incidence of 
successful donation was no different between groups (log rank p=0.27). In an analysis of 
the recipients of the PLDs, there was no association between SED and renal replacement 
therapy status (pre-emptive recipients 55 vs 62%; p=0.21), nor recipient eGFR (13.0±8.4 vs 
13.1±7.6 ml/min/1.73m2, p=0.56) at time of PLD approach. In an evaluation by postal code 
sector, there was no association between lower SIMD and the number of PLDs per 100,000 
population (r = -0.024, p=0.75).
Conclusions: Although SED is associated with reduced incidence of live and pre-
emptive transplantation, in recipients in whom PLDs are assessed, deprivation does not 
affect outcome of the evaluation process. Resources should be focused on encouraging an 
approach of PLDs for all suitable patients nearing ESKD.
SA-PO095 Poster Saturday
Transplantation: Recipient and Donor Assessment
Multiparametric MRI Characteristics of the Renal Allograft in the Early 
Post-Transplant Period
Keith Gillis,1 Sarah Allwood-Spiers,2 Alastair J. Rankin,1 Giles Roditi,2 
Aleksandra Radjenovic,1 Rajan Patel,1 Patrick B. Mark.1 Glasgow Renal 
Research Group 1University of Glasgow, Glasgow, United Kingdom; 2NHS 
Greater Glasgow and Clyde, Glasgow, United Kingdom.
Background: Renal allograft function is currently measured using estimated glomerular 
filtration rate (eGFR) and proteinuria, however these do not provide comprehensive 
information regarding prognosis or presence of important pathological features such as 
fibrosis. Use of multi-parametric magnetic resonance imaging (MRI) may yield novel 
biomarkers for prediction of outcome and response to therapy in renal transplantation.
Methods: Patients undergoing renal transplantation underwent multi-parametric MRI 
at 6 weeks post operatively. Routine clinical and biochemical measures were made. MRI 
protocol entailed arterial spin labelling (ASL) perfusion, T1 relaxation time and R2*. 
Apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were measured, and 
tractography maps produced, by diffusion weighted imaging.
Results: 20 patients were recruited with median age 55.5±12.8 years, eGFR of 51.8±27.4 
ml/min/1.73m2, and trough tacrolimus of 8.7±2.5 ng/mL. Cortical ASL was 283.0±116.2 
ml/min/100g, ADC 1.69±0.11 x10-3 mm2/s, FA 0.22±0.04, T1 was 1715±114 ms. 
ADC had a significant correlation with eGFR (r=0.48, p=0.03), and a negative 
association with cold ischaemia time (r=-0.55, p=0.01) and recipient age (r=-0.45, 
p=0.04). There was also a negative correlation between recipient age and cortical ASL 
(r=-0.60, p=0.04), Differences in transplant function were visible on diffusion tensor 
imaging (figure 1).
Conclusions: Diffusion weighted imaging may provide a novel method of evaluating 
renal transplant structure and function. Further research is required to determine if this 
provides increased prognostic information additional to existing biochemical measures.
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Transplantation: Recipient and Donor Assessment
Social Determinants of Quality of Life in Patients Evaluated for Kidney 
Transplant
Hannah Wesselman,2 Shu Wang,2 Chung-Chou H. Chang,2 John R. Pleis,5 
Kellee Kendall,2 Emilee J. Croswell,2 Mary amanda Dew,2 Mark L. Unruh,3 
Ron Shapiro,4 Larissa Myaskovsky.1 1University of New Mexico, Albuquerque, 
NM; 2University of Pittsburgh, Pittsburgh, PA; 3University of New Mexico, Los 
Ranchos, NM; 4Recanati/Miller Transplantation Institute, New York, NY; 5VA 
Pittsburgh, Pittsburgh, PA.
Background: Non-Hispanic African Americans (AA) have a higher incidence of 
ESRD but lower rates of kidney transplant (KT), and poorer quality of life (QOL) compared 
to non-Hispanic whites (WH). Disparities persist after adjusting for medical factors (e.g., 
comorbidity, dialysis). We assessed whether race disparities in QOL would persist in 
patients evaluated for KT after adjusting for medical and social determinants, including 
demographic (e.g., age, income), cultural (e.g., perceived discrimination, medical mistrust), 
psychosocial (e.g., social support, emotional distress), and knowledge (e.g., knowledge, 
learning activities) factors.
Methods: We conducted a longitudinal cohort study with 1035 (AA=260; WH=775) 
patients undergoing KT evaluation at the UPMC Starzl Transplant Institute. Patients 
completed an interview after initiating KT evaluation to assess social determinants; and 
another interview after being accepted, rejected, or withdrawing from evaluation, to assess 
kidney-specific (symptoms/problems, sleep, lifestyle effects, burden, cognitive function, 
work, sexual function) and general QOL (mental and physical composite scores) using 
the Kidney Disease QOL scale. We built multivariable regression models to test the 
hypothesized relationships.
Results: Our sample was 38% female, mean age=57, 73% had family income < 
$50,000, 52% married, 35% public insurance, 27% private, and 38% public/private. Race 
differences in kidney-specific QOL outcomes were no longer significant when social 
determinants were included in the model. Instead, psychosocial (e.g., mastery, social 
support, emotional distress), transplant knowledge (e.g., concerns, learning activities, 
knowledge), and demographic (e.g., age, sex, income, insurance) factors were significant 
predictors. For general QOL outcomes, race continued to be a significant predictor even 
after we identified several significant psychosocial, transplant knowledge, and demographic 
predictors (all predictors significant at p<.05).
Conclusions: A combination of social determinants predicted QOL outcomes for KT 
patients, which mediated race differences, especially for kidney-specific QOL. Transplant 
centers may help ensure better QOL in their patients as they await KT by promoting 
psychosocial support, and ensuring candidates’ understanding of KT.
Funding: NIDDK Support, Private Foundation Support
SA-PO097 Poster Saturday
Transplantation: Recipient and Donor Assessment
The Impact of Systematic Review of Status 7 Patients on the Kidney 
Transplant Waitlist
Ashish Kataria,2,1 Rocco C. Venuto,2,1 Jon R. Von Visger,2,1 Shirley S. Chang,2,1 
Bryan Lamphron,2 Vaqar H. Shah,1 Aijaz A. Gundroo.2,1 1Medicine/Nephrology, 
University at Buffalo, Buffalo, NY; 2Erie County Medical Center, Buffalo, NY.
Background: Patients (pts) listed status 7 on the kidney transplant (Tx) waitlist are 
more likely to die rather than be transplanted. They need to overcome one or more barriers 
in order to move to status 1. These barriers could either be medical or psycho-social (PS) 
but are significant enough to exclude them from recieving organ offers. We speculated that 
by systematically re-evaluating status 7 pts, we might overcome the barriers and expedite 
their Tx.
Methods: Biweekly status 7 re-evaluation meetings were started in April 2016 and 
continued through April 2018. The attendees were a transplant physician champion and 
members of all components of the transplant team. These were held in parallel to the 
recipient selection meetings. For each status 7 patient, the attendees performed an intense 
scrutiny of the individual barriers against activation and developed a specific action plan. 
A descriptive analysis of the status 7 pts at the start and end of study was performed and 
patient demographic and listing outcomes were studied.
Results: A total of 266 status 7 pts were evaluated(Table1). 18.4% of them overcame 
remaining barriers preventing activation and majority (85.7%) in this group recieved a Tx 
after being inactive on the waitlist for average 805 days. 39% of inactive patients were 
deemed ineligible and were removed from the waitlist. These pts were older than those 
who recieved a Tx (mean age 60.6 versus 52.7 years) and were inactive for average 1593 
days. 17.6% status 7 pts died while only 73 (27.4%) pts still remain inactive on the waitlist. 
Common barriers against activation were CP and PS issues in all categories.
Conclusions: Re-evaluation of status 7 pts has the potential to expedite their 
transplantation or removal of those pts from the waitlist who are unlikely to get activated 
for a kidney Tx. We have incorporated this process on a continuing basis.
CP-Cardio-pulmonary, PS-Psycho-social, Onc-Oncologic, I-Infection
SA-PO098 Poster Saturday
Transplantation: Recipient and Donor Assessment
Aged Kidney Grafts: Another Potential Long-Term Risk in Living Kidney 
Transplantation
Sayoko Yonemoto,1 Takayuki Hamano,2 Naohiko Fujii,1 Yoshitaka Isaka.2 
1Hyogo Prefectural Nishinomiya Hospital, Nishinomiya-city, Japan; 2Osaka 
University Graduate School of Medicine, Suita, Japan.
Background: As marital kidney transplantaion increases, the living kidney donor’s 
age, or the age of the kidney graft at transplantaion, becomes older in Japan; however, 
its effect on graft survival has not been well-studied. We evaluated the long-term kidney 
function of both donors and recipients in transplantaion with aged or non-aged kidney 
grafts.
Methods: In this prospective observational study, we enrolled 130 consecutive living 
kidney donors and recipients (65 pairs) in a single transplant unit in Japan from November 
1, 2008 to May 31, 2013. We divided them into two groups by donor’s age (D-Age<65 and 
D-Age≥65), and longitudinally followed estimated glomerular filtration rate (eGFR) every 
year until May 31, 2018. The temporal changes in eGFR of donors and recipients were
analyzed by mixed effects models with random intercepts and random slopes, allowing a
quadratic term for time-interaction and a 2-by-2 factorial interaction (D-Age and donor-
recipient).
Results: The median donors’ and recipients’ ages were 60 and 46 years old, respectively. 
We had 19 donors (29.2%) who were over 65 years old. We had 39 females (60%) in donors 
and 25 females (38.5%) in recipients. There was no significant difference in eGFR before 
donation between D-Age<65 and D-Age≥65 group. In the D-Age≥65 group, eGFR declines 
started in donors and recipients four years and two years after transplantation, respectively, 
while in the D-Age<65 group eGFR was sustained in donors and slightly decline in 
recipients (p for interaction<0.01). No significant difference in trajectory of eGFR was 
observed between recipients and their donors in D-Age≥65 group (p=0.50).
Conclusions: In this study, eGFRs in both donors and recipients were declined after 
living kidney transplantation with aged grafts. We should be careful when we use aging 
kidney in transplantaion.
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Transplantation: Recipient and Donor Assessment
Postdonation Renal Function Predicts New Onset Antihypertensive 
Medication Use After Living Kidney Donation
Krista L. Lentine,1 Abhijit S. Naik,9 Ngan Lam,2 Amit X. Garg,3 Dorry L. Segev,4 
David A. Axelrod,10 Huiling Xiao,5 Macey L. Henderson,11 Allan Massie,12 Chi-
yuan Hsu,8 Bertram L. Kasiske,6 Gregory P. Hess,7 Mark Schnitzler.13 1Saint 
Louis University, St. Louis, MO; 2University of Alberta, Edmonton, AB, Canada; 
3London Health Sciences Centre, London, ON, Canada; 4Johns Hopkins 
University, Baltimore, MD; 5St. Louis University, St. Louis, MO; 6Hennepin 
County Medical Center, Minneapolis, MN; 7LDI University of Pennsylvania/
Symphony Health, Conshohocken, PA; 8University of California San Francisco, 
San Francisco, CA; 9University Michigan, Ann Arbor, MI; 10Lahey Hospital and 
Clinic, Burlington, MA; 11Johns Hopkins, Baltimore, MD; 12Johns Hopkins 
School of Medicine, Baltimore, MD; 13Saint Louis Univ, St Louis, MO.
Background: Limited data are available on the outcome implications of renal function 
after living kidney donation.
Methods: We constructed a novel database linking SRTR registry identifiers, serum 
creatinine (SCr) values from an electronic medical records warehouse, and pharmacy fill 
records for 3,593 living kidney donors (1989–2016) without predonation hypertension per 
the registry. Estimated glomerular filtration rate (eGFR, ml/min/1.73 m2) was computed 
from SCr by the CKD-EPI equation. Pharmacy enrollment was assessed within ±90 days of 
each postdonation SCr, followed by identification of antihypertensive medication (AHM) 
fills in those with pharmacy records eligibility. A mixed effects model was constructed to 
assess associations of postdonation eGFR (adjusted odds ratio, 95%LCL aOR 95% UCL) and other 
baseline factors with AHM treatment requirements after donation.
Results: The linked database captured an average of 3 post-donation SCr values per 
donor (range: 1 to 38). Lower postdonation eGFR bore a graded association with increased 
AHM use (eGFR 30–44: aOR 0.951.472.26; <30: aOR 1.08 5.902.52). Other significant (P<0.05) 
correlates of postdonation AHM fills included black race (aOR 2.22), BMI >30 kg/m2 
(aOR 2.09), first-degree donor-recipient relationship (aOR 1.79), “pre-hypertension” at 
donation (SBP 120-139: aOR 1.94; DBP 80-89: aOR 1.99), and longer time since donation. 
Predonation eGFR was not significantly associated with AHM use in the multi-level model. 
[Fig.]
Conclusions: Lower eGFR levels after living kidney donation are associated with need 
for AHM treatment. Further work should define relationships of postdonation renal function 
with renal and cardiovascular morbidity.
Funding: NIDDK Support
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Transplantation: Recipient and Donor Assessment
Which US-Listed Candidates Travel Abroad for Kidney Transplant?
Alvin G. Thomas,1,2 Brittany Koons,4 Ashton A. Shaffer,2 Fawaz Al Ammary,2 
Krista L. Lentine,3 Mara McAdams-DeMarco,2 Tamara M. Kear,4 
Dorry L. Segev,2 Helene Moriarty,4 Macey L. Henderson.2 1UNC Chapel HIll, 
Chapel Hill, NC; 2Johns Hopkins University, Baltimore, MD; 3Saint Louis 
University, St. Louis, MO; 4Villanova University, Villanova, PA.
Background: Kidney transplant (KT) candidates listed in the United States (US) wait 
several years to receive a transplant. Some candidates opt to withdraw from the US waitlist 
and receive a KT abroad.
Methods: Using the SRTR 2010-2016, we compared 364 adult KT candidates who 
received KT abroad to 76,133 candidates removed for deceased donor KT. We assessed 
factors associated with receiving KT abroad using adjusted logistic regression accounting 
for possible race/citizenship interactions.
Results: KT candidates who received a KT abroad were more often male (p<0.001), 
younger (p<0.01), college educated (p<0.001), and had private insurance (p<0.001). These 
candidates spent less time on dialysis (1.6 vs. 3.8 years, p<0.001), and were often first-time 
KT candidates (p<0.001). The likelihood of KT abroad differed by race and citizenship 
(interaction p<0.001). White US citizens/residents (C/R) were the reference group. White 
non-US citizens/non-US residents (NC/NR) had the highest odds of KT abroad (aOR: 
63.27113.59203.92, p<0.001). Hispanic C/R residents had a 2.6-fold (aOR: 1.752.603.84, p<0.001) 
higher odds and Hispanic NC/NR had a 13.9 fold (aOR: 6.0413.8731.87, p<0.001) higher odds 
of KT abroad. Asian C/R had a 15.7-fold (aOR: 11.6915.6720.99, p<0.001) higher odds and 
Asian NC/NR had a 34.2-fold (aOR: 14.1134.1682.70, p<0.001) higher odds of KT abroad. 
The countries most frequently traveled to were the Philippines (n=93) and India (n=52) 
(Figure 1).
Conclusions: Although travel for transplant remains a rare practice for US-listed 
candidates, those with the means to travel, lower access to transplant, and possible 
connections outside the US might opt to travel abroad for transplant. Since follow-up care 
will primarily take place in the US, the nephrology community needs better data on these 
candidates and their post-transplant outcomes.
Funding: NIDDK Support, Other NIH Support - T32 HL007055 (Thomas), 
K01AG043501 (McAdams-DeMarco), R01AG055781 (McAdams-DeMarco), K24 
DK101828 (Segev), K01 DK114388 (Henderson), Private Foundation Support
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Transplantation: Recipient and Donor Assessment
Nephron Dose Does Not Predict Renal Function After Live Donor Renal 
Transplantation
Steven Goorachan,1 Rachel J. Youngs,2 Richard J. Baker.2 1St. James Hospital, 
Leeds, United Kingdom; 2SJUH, Leeds, United Kingdom.
Background: In our live donor transplant programme we consider isotopic 
determinations of donor glomerular filtration rate (GFR) as an indicator of the donor kidney 
quality. We also measure isotopic split renal function and thus by multiplying the two 
together we can calculate the potential “nephron dose” of the transplant. This has been used 
anecdotally as a guide to the quality of the graft and to inform the likely outcome in terms 
of function. This consideration has recently become more pertinent with the expansion of 
the national live donor sharing scheme since multiple potential donors may be considered 
for any particular recipient.
Methods: We recorded 147 patients from August 2008 to August 2017 excluding: those 
without follow up data; paediatric patients; and those with early graft loss (< year). Data set 
included estimated and measured GFR, split function of kidneys, Recipient body surface 
area (BSA), and recipient eGFR (MDRD equation) at 3, 6 and 12 months post transplant. 
We determined Nephron Dose using the formula: Measured isotopic GFR x percentage 
function of donated kidney = Nephron dose. We also measured the recipient’s eGFR post 
transplant at t=3, 6 and 12 months, and corrected these measurements to recipients BSA. We 
measured the strength of the association using correlation coefficients.
Results: We report that the was no clear correlation with nephron dose to renal function 
at 3, 6 or 12 months whether eGFR was corrected for recipient body surface area or not, 
(table).
Conclusions: Nephron dose was not found to be strongly correlated with recipient 
transplant function at 3, 6 or 12 months following live donor renal transplants. This may 
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represent inaccuracy of either isotopic studies in donors to determine renal function or 
the MDRD formula to estimate true GFR post renal transplant. However we propose that 
postoperative transplant function is determined by a complex interplay between several 
factors, many of which are either recipient derived or external (e.g. viral infections and drug 
toxicity). The weak correlation demonstrated does not support overzealous interpretation of 
donor functional data even when derived from isotopic studies.
Correlation Coefficients for Nephron Dose and eGFR
SA-PO102 Poster Saturday
Diabetic Kidney Disease: Basic - III
Characterization and Establishment of Non-Human Primate Models of 
Diabetic CKD
Rosario M. Perez, Flordeliza P. De Villa, Dawei Wang, Joseph A. Gabriel, 
Luping Zhu, Yong Yang, Lichuan Yang, Tony Wang, Zhiming Ding, Bob Zhang. 
Kunming Biomed International, Kunming City, China.
Background: The lack of translatable diabetic nephropathy animal models has greatly 
dampened the development of novel CKD therapies. This study aims to characterize a large 
cohort of high-fat diet (HFD)-induced type 2 diabetic nephropathy (T2DN) NHPs with 
substantial translational value to CKD drug development.
Methods: Animals with FBG ≥150 mg/dL and HbA1c ≥6% were screened from 
>1,500 male cynomolgus monkeys on HFD for ≥1.5 years. The following parameters 
were monitored: 24-h albumin-creatinine ratio (ACR); BP measurements; and, GFR by
FITC-inulin. Animals were classified based on GFR severity grades and renal histology 
was scored based on the International Pathologic Classification of Glomerular Changes in 
Diabetic Kidney Disease.
Results: A 25% prevalence of T2DN-CKD was observed. Similar to human DN, 
albuminuria was confirmed as the earliest marker of glomerular disease. Serum creatinine 
was normal except in animals with kidney failure. DN-CKD monkeys had significantly 
elevated ACR levels compared to age-matched lean and obese monkeys, and to insulin-
treated T2D monkeys. Systolic, diastolic and mean arterial pressure levels were significantly 
higher in DN-CKD. Over 75% had overt albuminuria with moderate to severe GFR 
reduction (GFR Stages 3-4) while 2% had kidney failure (GFR Stage 5). GFR reduction 
occurred even without substantive shifts from normo- or micro- to macroalbuminuria. No 
marked correlation between GFR and ACR was observed. These findings suggested that, as 
seen in human patients, macroalbuminuria did not represent an obligatory phase for renal 
function reduction in T2DN-CKD. Albuminuria with GFR Stages 3-4 were associated with 
mesangial expansion and thickening and/or fibrosis of the basement membranes (Class 1 to 
2a/b). Kimmelstiel–Wilson lesions (Class 3) were seen with kidney failure.
Conclusions: A large cohort of DN-CKD monkeys was characterized using quantitative 
clinical laboratory and histopathologic indicators of DKD development and progression. 
The cynomolgus monkey CKD model resembles the disease characteristics in man and can 
be regarded as one of the most clinically relevant models for the efficacy evaluation of new 
therapeutic modalities for DN-CKD.
SA-PO103 Poster Saturday
Diabetic Kidney Disease: Basic - III
A Novel Surgery-Induced Rat Model of Diabetic Nephropathy Displaying 
Progressive Albuminuria, Glomerular Hypertrophy, and 
Glomerulosclerosis
Mette V. Østergaard,2 Thea T. Johansen,2 Thomas Secher,2 Frederikke 
E. Sembach,2 Kristoffer Rigbolt,2 Torben Skarsfeldt,1 Niels Vrang,2 Keld
Fosgerau,2 Lisbeth N. Fink.2 1Serodus, Oslo, Norway; 2Gubra ApS, Hørsholm,
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Background: Diabetic nephropathy (DN) is a long-term complication of diabetes 
characterized by albuminuria and loss of kidney function. No new therapies targeting 
DN have been introduced for decades, partly due to the lack of preclinical animal models 
recapitulating key features of human DN. Here, we characterized a novel preclinical model 
of DN in pancreatectomized (Px) uni-nephrectomized (UNx) rats.
Methods: Px-UNx (n=11) and sham (n=12) operations were performed at 8 wks of age 
in male SPD rats. Blood glucose was >18 mmol/L in Px-UNx rats from 2 wks post-surgery. 
Urinary renal injury markers were measured 2, 6 and 9 wks after surgery and glomerular 
filtration rate (GFR) 9 wks after surgery. At termination 11 wks post-surgery, kidneys were 
processed for histology, stereology and next generation sequencing (NGS).
Results: Urinary albumin and NGAL excretion was increased from 2 wks post-surgery in 
Px-UNx vs Sham and highest after 9 wks for both albumin (13473±7619 vs 370±170 μg/mg 
creatinine, p<0.001) and NGAL (13.28±1.76 vs 2.68±0.43 μg/mg creatinine, p<0.001). 
Urinary podocalyxin excretion was increased from 6 wks and peaked 9 wks post-surgery 
in Px-UNx (195.2±41.9 vs 11.8±2.0 ng/mg creatinine, p<0.001). GFR was higher in Px-
UNx vs Sham (8.2±0.3 vs 6.6±0.3 mL/min/kg, p<0.01). At termination, plasma urea was 
increased in Px-UNx (9.4±0.7 vs 5.5±0.2 mmol/L, p<0.001). Right kidney weight and 
volume was nearly doubled in Px-UNx vs Sham (both p<0.001), as were renal cortex 
(69.1% increase, p<0.001) and glomerulus volumes (57.7% increase, p<0.001). Kidney 
fibrosis (398±24 vs 210±9.8 mg collagen III, p<0.001) and glomerulosclerosis (11.1±0.8 
vs 6.3±0.3 mm3 collagen IV, p<0.001) was increased in Px-UNx vs Sham rats. Px-UNx 
increased gene expression of tubular injury markers (KIM-1, NGAL), collagens and 
fibronectin in renal cortex and reduced nephrin expression.
Conclusions: The Px-UNx model of DN develops extensive renal hypertrophy, 
hyperfiltration and fibrosis concomitant with early excretion of both glomerular and 
tubular injury markers. In rats, Px in combination with UNx represents a novel time-saving 
and robust alternative to STZ-induced diabetes and genetic models for preclinical drug 
development targeting DN.
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Dysregulation of the Ubiquitin Ligase Component Kelch-Like 3 Causes 
Na-Cl Cotransporter Activation and Salt Retention in Type 2 Diabetes 
Mellitus
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Chikayuki Morimoto,1 Toshiro Fujita,3 Shunya Uchida,1 Shigeru Shibata.1 
1Teikyo University School of Medicine, Tokyo, Japan; 2Shinsen Ikebukuro Clinic, 
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Background: Salt-sensitive hypertension is frequently associated with type 2 DM. 
However, the pathogenesis remains unclear. Kelch-like 3 (KLHL3) is a component of an 
E3 ubiquitin ligase complex that targets With-No-Lysine kinases for degradation, thereby 
regulating downstream Na-Cl cotransporter (NCC). Mutations and inactivation of KLHL3 
increase NCC activity, resulting in hypertension and hyperkalemia. Previously, we have 
reported that angiotensin II (Shibata et al. PNAS 2014) and K+ depletion (Ishizawa et al. 
BBRC 2016) inactivate KLHL3 by protein kinase C (PKC)-mediated phosphorylation at 
S433 in the Kelch-domain. In this study, we examined the possible involvement of KLHL3 
in the diabetic kidney, using a model of type 2 diabetes.
Methods: KLHL3 phosphorylated at S433 (KLHL3S433-P), total KLHL3, and NCC 
levels were evaluated in the kidney of db/db mice by Western blotting. In some experiments, 
db/db mice received a PKC inhibitor bisindolylmaleimide I (BIMI), SGLT2 inhibitor 
ipragliflozin, and a thiazolidinedione pioglitazone.
Results: KLHL3S433-P, NCC and active PKC levels were all increased in the kidney 
of db/db mice. Administration of BIM to db/db mice significantly reduced KLHL3S433-P 
and NCC levels (P < 0.05). Consistently, urinary Na+ levels were increased in db/db mice 
receiving BIM (76 ± 8.7 μEq/6h in db/db mice receiving BIM vs. 48 ± 4.5 μEq/6h in db/db 
mice receiving vehicle; P < 0.05). To evaluate the effects of SGLT2 inhibition on this 
pathway, db/db mice received ipragliflozin or pioglitazone (as a control). Of note, KLHL3 
phosphorylation and NCC induction were reduced by ipragliflozin but not by pioglitazone, 
although blood glucose levels were similarly reduced by the two hypoglycemic agents. 
PKC activity was reduced by ipragliflozin but not by pioglitazone, explaining the distinct 
effects of the two hypoglycemic agents on KLHL3 and NCC.
Conclusions: These data demonstrate the involvement of KLHL3 in the increased salt 
reabsorption in obese diabetes mellitus, and provide insights into the mechanisms for the 
protective effect of SGLT2 inhibitors.
Funding: Government Support - Non-U.S.
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A Mouse Model of Moderate Diabetic Nephropathy on a Metabolic 
Syndrome Background
Arianne van Koppen,1,2 Christa De Ruiter,1 Joline Attema,1 Geurt Stokman,1 
Reinout Stoop.1 1Metabolic Health Research, TNO, Leiden, Netherlands; 
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Background: Mouse models of diabetic nephropathy (DN) which not only 
recapitulate the early phases of the disease but also progress to a more advanced phase 
are urgently needed. We aim to develop a translational DN mouse model on metabolic 
syndrome background by incorporating the three main features of DN viz hyperglycemia, 
hyperlipidemia and hypertension.
Methods: Male KKAy mice were uninefrectomized and received high fat (45%) diet 
alone (HFD) or with prohypertensive (HFD+hyp) for 14 wk. At regular intervals, systolic 
blood pressure (SBP), 24h diuresis and plasma was collected. At sacrifice, GFR (inulin 
clearance) was determined, and renal injury was scored using histology. Age-matched 
chow-fed animals were controls.
Results: Mice fed with HFD developed hyperglycemia and hyperlipidemia. The 
prohypertensive group developed hypertension. GFR was significantly reduced in the 
HFD+hyp group compared to controls (2.5μl/min/g BW vs 4.6μl/min/g BW). Renal 
injury score showed glomerular hypertrophy, mesangium expansion, glomerulosclerosis, 
hyalinosis, micro-aneurisms and tubulo-interstitial fibrosis.
Conclusions: Combining three key features of DN in one mouse model induces 
moderate DN with a decline in GFR and morphological features resembling the human 
situation. We are currently forming a consortium to identify the temporal dynamics of key 
processes involved in disease development and progression.
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Glomerular Injury and Progressive Cardiac Dysfunction in the Obese 
ZSF1 Rat, a New Model of Diabetic Nephropathy and Heart Failure with 
Preserved Ejection Fraction
Elyse Di marco,1 Erik Michaëlsson,1 Charlotte Ericson,1 Margareta Behrendt,2 
Maria Stromstedt,1 Magnus Soderberg,1 Johannes Wikstrom,1 Anna Granqvist.1 
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Background: Efforts to develop effective therapies against interlinked cardiac and 
renal diseases are hampered by the lack of preclinical models. We have investigated whether 
the hypertensive, diabetic, obese ZSF1 rat represents a valid experimental disease model 
for diabetic nephropathy (DN) and heart failure with preserved ejection fraction (HFpEF).
Methods: The renal (glomerular filtration rate- GFR, albuminuria, histology) and the 
cardiac (functional non-invasive imaging/invasive haemodynamics, histology) phenotypes 
were investigated in obese and lean male ZSF1 rats. Uninephrectomy (UNX) was performed 
in obese rats at 12-weeks of age followed by administration of high-salt diet (HSD) and 
treatment with ACE inhibitor Lisinopril for 10 weeks.
Results: Obese UNX ZSF1 rats displayed progressive albuminuria, reduced GFR 
and glomerular injury evidenced by increased desmin and reduced WT1 immunostaining, 
reduced podocyte-specific gene expression (podocin, nephrin, WT1) compared to lean 
ZSF1 rats. The renal histological phenotype was severely aggravated by HSD, consistent 
with marked increases in urinary biomarkers KIM-1, NGAL and Cystatin C. UNX rats 
fed HSD showed an increase in NTproBNP, a marker of cardiac stress, in line with 
progressive cardiac hypertrophy and impaired ventricular relaxation. Lisinopril treatment 
of UNX+HSD-rats had no effect on the renal phenotype or cardiac relaxation, but markedly 
improved systolic function.
Conclusions: The obese ZSF1 rat with UNX is a suitable model of renal dysfunction 
with progressive glomerular injury and the addition of HSD elicits a HFpEF phenotype. 
This model now allows us to investigate potential therapies targeting these interlinked 
diseases.
Funding: Commercial Support - AstraZeneca
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Loss of Podocyte Glucocorticoid Receptor Worsens Fibrosis in a Mouse 
Model of Diabetes
Swayam P. Srivastava, Julie Goodwin. Pediatrics, Yale University School of 
Medicine, New Haven, CT.
Background: Glomerular fibrosis, which is a key component of diabetic nephropathy, 
is characterized by deposition of extracellular matrix, alteration of the glomerular structure 
and dysfunction of the glomerular filtration barrier. The role of the podocyte glucocorticoid 
receptor (pGR) in the pathogenesis of diabetic nephropathy has not been explored yet. 
Based on previous studies which showed that pGR was critical in the response to renal 
injury, we hypothesized that loss of pGR would result in worsened fibrosis.
Methods: Streptozotocin (STZ) 200 mg/kg was used to induce diabetes in 10-week old 
pGR KO mice ((GRfl/fl; podocin Cre+) and control litter mates (GRfl/fl; podocin Cre-). After 
STZ injection, mice were maintained for 4 months prior to sacrifice. Body weight, kidney 
weight, blood glucose and urine microalbumin/creatinine ratio were assessed in normal 
and diabetic mice of both genotypes. Glomerular fibrosis and segmental glomerulosclerosis 
were analyzed by staining kidney sections in diabetic mice of both genotypes. Western blot 
and immunofluorescent staining were also used to examine key pro-fibrotic targets. One 
way ANOVA with Tukey’s post-test was used to determine statistical significance.
Results: Non-diabetic control and pGR KO mice did not have any differences in body 
weight, kidney weight, blood glucose, urinary microalbumin excretion, or kidney histology. 
Diabetic control and pGR KO mice showed similar body weight, and blood glucose levels, 
but kidney weight was significantly higher in diabetic pGR KO mice (15.8 vs. 14.7 mg/g 
body weight, n= 5/group, p=0.04). Glomerular collagen deposition, glomerular surface 
area and mesangial expansion were all significantly increased in pGR KO mice. We did 
not observe any significant differences in the level of interstitial fibrosis. Western blotting 
and immunofluorescent staining of kidney sections revealed induction of mesenchymal 
activation which was associated with glomerular deposition of fibronectin and collagen I 
in diabetic pGR KO mice.
Conclusions: From these results we conclude that: 1. loss of pGR worsens the severity 
of fibrosis in our mouse model of diabetes 2. pGR is tonically suppressing mesenchymal 
activation pathways 3. modulation of pGR may represent a novel therapeutic pathway for 
diabetic nephropathy
Funding: NIDDK Support
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Regulation of Renal Gluconeogenesis in Acidotic Proximal Tubule-(PT) 
Targeted Dual Insulin/Insulin-Like-Growth Factor (IGF) Receptor 
Knockout Mice
Maurice B. Fluitt,1 Abdullah Aljaylani,1 Swasti Tiwari,2 Carolyn M. Ecelbarger.1 
1Georgetown University, Washington, DC; 2Sanjay Gandhi PGI, Lucknow, 
India.
Background: Acidosis is associated with an increase in renal gluconeogenesis 
due to upregulation of ammoniagenesis, which liberates α-ketoglutarate, a substrate 
for gluconeogenesis. Insulin and IGF1 have been postulated to upregulate transport of 
glutamine into PT (precursor of ammoniagenesis), but may also be associated with decreased 
gluconeogenic capacity by phosphorylating forkhead box protein 01 (FOX01). Thus, net 
regulation of renal gluconeogenesis by insulin in the context of acidosis is uncertain.
Methods: We bred PT-select dual Insr/Igf1r knockout mice with Cre-recombinase 
driven by the γ-glutamyltransferase promoter. Male and female KO and WT littermates 
were made acidotic by consuming 280 mM NH4Cl in the drinking water for 7 days.
Results: Male KO mice demonstrated a 23% increase in fasting glucose (18-hr) with 
acid loading, while this increase was 2% in the WT males. In contrast, female WT mice 
had a mean 8% decrease and KO a 5% increase, indicating less sensitivity of females. 
Acid-treated male KO mice had lower blood pH and bicarbonate as compared to same sex 
WT (significant interaction). Female mice did not show this genotype dichotomy. Ex vivo 
capacity to synthesize glucose (with unlimited substrate) was measured in proximal tubule 
suspensions harvested from acid- and control- treated WT and KO mice. PT harvested from 
control KO males produced 56% more glucose then WT males. In agreement, the ratio of 
phosphorylated (Serine 256) FOX01 to total FOX01 was 37% lower in PT from the KO 
versus WT male mice. Acid loading increased glucose producing capacity of PT only in the 
WT males, while reducing the pFOX01/FOX01 ratio in all groups. In agreement, in males, 
acidosis significantly increased renal protein abundances of two rate-limiting enzymes 
in gluconeogenesis, i.e., fructose bisphosphatase-1 (FBP1) and phosphoenolpyruvate 
carboxykinase (PEPCK). The increase in FBP1 was 2-fold higher in the KO mice; however, 
KO mice also had significantly lower cortical expression of glucose-6-phosphatase 
(terminal gluconeogenic enzyme).
Conclusions: Chronic acidosis increases the capacity of the PT to produce glucose. 
Insulin and/or IGF1 appear to be involved in homeostatic regulation of this production via 
FOX01.
Funding: Clinical Revenue Support
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Anti-Proteinuric Actions of Angiotensin II Receptor Blockade in a Mouse 
Model of Diabetic Nephropathy
Kengo Azushima,2,1 Susan B. Gurley,3 Thomas M. Coffman.2,4 1Department of 
Medical Science and Cardiorenal Medicine, Yokohama City University 
Graduate School of Mediceine, Yokohama, Japan; 2Cardivascular and 
Metabolic Disorders Program, Duke-NUS Medical School, Singapore, 
Singapore; 3Oregon Health and Science University, Portland, OR; 4Division of 
Nephrology, Department of Medicine, Duke University, and Durham VA Health 
Care System, Durham, NC.
Background: The progress in the research field of Diabetic nephropathy (DN) 
has been disturbed by the lack of reliable animal models. We have developed a mouse 
model exhibiting cardinal characteristics of human DN including high-grade albuminuria, 
glomerulosclerosis and genetic susceptibility to kidney damage. Because responsiveness 
to blockade of the renin-angiotensin system (RAS) is a key feature of human DN, we 
examined the impact of an angiotensin II receptor blocker (ARB) in our mouse model.
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Methods: We generated mice with heterozygous for the Ins2C96Y (Akita) allele combined 
with a single-copy renin transgene (ReninTg), with renin expression under control of the 
albumin promoter. Akita-ReninTg mice on a 129/SvEv inbred background, which tends to 
exhibit exaggerated susceptibility to kidney disease, were generated through back-crossing. 
In the Acute protocol, losartan (10mg/kg/day) was given to 16-week old 129 Akita-ReninTg 
for 10 days, whereas in the Chronic protocol, losartan was administered daily from 12-24 
weeks of age. Urine samples were collected over a 24-hour period using metabolic cages 
and albumin levels were measured with immunoassay.
Results: By 24 weeks of age, 129 Akita-ReninTg mice develop substantial albuminuria 
with severe renal pathological changes including mesangial expansion, nodular 
glomerulosclerosis and renal interstitial inflammatory cells accumulation. In 16-week 
old 129 Akita-ReninTg mice, Acute ARB administration caused an abrupt and significant 
reduction of albuminuria from 1049±325 to 308±156 μg/day (p=0.004). In the Chronic 
protocol, baseline levels of albumin excretion were similar between treated and untreated 
groups (767±154 vs 905±169 μg/day). ARB treatment prevented the progressive increase 
of albuminuria compared to untreated controls at 18 (721±136 vs 142±27 μg/day; p=0.001) 
and 24 (1480±562 vs 193±42 μg/day; p=0.045) weeks of age.
Conclusions: 129 Akita-ReninTg mice replicate key features of human DN, including 
responsiveness to RAS blockade. As in humans, the anti-proteinuric actions of ARB can 
be seen early after initiating treatment, likely representing acute reversal of abnormal 
glomerular hemodynamics and/or permeability. Chronic ARB administration causes a 
significant reduction in albuminuria that is sustained during the entire treatment period, 
likely due to protection against Ang II-dependent kidney injury.
Funding: Government Support - Non-U.S.
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Protein O-GlcNAcylation Regulates Renal Lipolysis During Fasting and 
Diabetes
Sho Sugahara,1 Shinji Kume,1 Kosuke Yamahara,1 Mako Yamahara,1 
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Japan; 2Department of Nephrology, Kyoto University Graduate School of 
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Background: Energy metabolism in kidney proximal tubular cells (PTCs) is unique 
because their ATP production largely depends on lipolysis rather than glycolysis, regardless 
of feeding or fasting. Furthermore, disrupted renal lipolysis is involved in the pathogenesis 
of tubular damage in various kidney diseases including diabetic kidney disease. Thus, 
elucidating detailed mechanisms of renal fatty acid metabolism should contribute to a 
novel therapy for kidney diseases. O-GlcNAcylation is a post-translational modification 
and acts an intracellular nutrient sensor. This study was designed to examine the role of 
O-GlcNAcylation in renal fatty acid metabolism under fasting and diabetes.
Methods: O-GlcNAc transferase (Ogt) is the sole enzyme for O-GlcNAcylation. We 
generated inducible PTC-specific Ogt-knockout mice (PTC-Ogty/-mice) by crossbreeding 
female Ogtf/fmice with male tamoxifen-inducible PTC-specific Cre transgenic mice 
(NDRG1-CreERT2mice), and analyzed their renal phenotype under fasting and high fat diet 
(HFD)-induced obese diabetes.
Results: PTC-Ogty/-mice showed no significant renal phenotype under ad-libitum 
feeding condition, but showed significant increases in urinary excretions of albumin, 
glucose and various ions after 48 hours fasting. Cellular apoptosis, significant intracellular 
lipid droplet accumulation, mitochondrial fragmentation and decreased ATP contents 
in renal cortex were observed in PTCs of fasted PTC-Ogty/-mice. Furthermore, PTC-
Ogty/-mice developed severe tubular cell damage under HFD-induced obesity diabetic 
condition. Proteomic analysis revealed that PTC-Ogty/-mice showed significant change in 
lipid metabolism pathway and dramatic decrease in protein expression level of a neutral 
lipid esterase, Carboxilesterase-1 (CES-1), which was associated with decreased activity in 
Farnesoid X receptor (FXR).
Conclusions: Protein O-GlcNAcylation is essential for maintaining renal lipolysis 
under fasting and obesity diabetic condition through regulating FXR-CES1 axis.
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Elevation of NMN in the TG Mice Overexpressing Nampt in the Proximal 
Tubules Suppresses Albuminuria and Diabetic Tubulopathy by Maintain-
ing Megalin Expression
Kazuhiro Hasegawa, Shu Wakino, Hiroshi Itoh. Keio University, Tokyo, Japan.
Background: Nicotinamide phosphoribosyltransferase (Nampt) synthesizes 
nicotinamide mononculeotide (NMN), which is the precursor of nicotinamide adenosine 
diphosphate (NAD). Nampt is expressed more abundantly in proximal tubules (PTs) than 
in other tissues. NMN injections have been shown to suppress acute kidney injury; however, 
the effects of renal NMN or Nampt in diabetic nephropathy remain unclear. We created 
kidney-specific Nampt-overexpressing transgenic (TG) mice using the promoter sodium-
phosphate cotransporter IIa (Npt2) driven specifically in PTs for investigating them.
Methods: Wild-type littermate (WT) or TG 8-week old male mice were subjected to 
intraperitoneal injections of 50 mg/kg/day streptozotocin (STZ) or saline (Sal) for 5 days 
(WT+Sal, WT+STZ, TG+Sal, TG+STZ).
Results: After 16 weeks, Nampt, NMN, and NAD levels in WT+STZ were decreased, 
but were rescued in TG+STZ. Tubular Basement membrane (TBM) thickening, type 
IV collagen deposition, and PT apoptosis were significantly higher in WT+STZ, and 
were attenuated in TG+STZ. Our DNA microarray analyses showed the profibrotic and 
proapoptotic gene, tissue inhibitor of metalloproteinases 1 (TIMP-1), was highly 
increased in WT+STZ, but suppressed in TG+STZ. Glomerular changes such as glomerular 
basement membrane (GBM) thickening and podocyte foot-process effacement occurred 
in both WT+STZ and TG+STZ. However, the albuinuria present in WT+STZ was 
significantly suppressed in TG+STZ. Thus, we hypothesized that TG elevates albumin 
reabsorption despite not affecting podocytes. Consistent with this, albumin endocytosis 
and megalin expression were reduced in WT+STZ, but retained in TG+STZ, whereas 
cubilin was not altered. In promoter assays, the decrease in Nampt/NMN/NAD repressed 
Sirt6 activity, which acetylated and activated RelA binding to TIMP-1 promoter regions. 
The transfection of TIMP-1 vector in cultured PTs causes excessive collagen IV production 
and Erk phosphorylation, which reportedly reduces megalin expression and elevates PT 
apoptosis. These changes were totally blocked in TG mice.
Conclusions: Nampt TG/NMN/NAD potentiates Sirt6 activity, deacetylating RelA 
and silencing TIMP-1 transcription. This protects against TBM thickening, type IV collagen 
deposition, and Erk activation. Thus, Nampt appears to maintain megalin and albumin 
reabsorption.
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Dapagliflozin Reduces Glomerular Hyperfiltration and Improves Urine 
Parameters in db/db Mice on High Protein Diet: A 4-week Model of 
Diabetic Nephropathy
Francois Briand,1 Sisse A. Nørgaard,2 Noémie Burr,1 Clément Costard,1 
Emmanuel Brousseau,3 Nourdine Faresse,1 Fredrik Wolfhagen Sand,2 
Thierry Sulpice.1 1Physiogenex SAS, Labege, France; 2Novo Nordisk A/S, 
Maaloev, Denmark; 3Physiogenex, Labege, France.
Background: Preclinical animal models of glomerular hyperfiltration and diabetic 
nephropathy (DN) are needed for rapidly evaluating novel drugs targeting these 
complications. In this goal, obese and diabetic db/db mice are routinely used, but require 
several weeks to only show mild-albuminuria and early kidney disorders seen in human DN. 
Since high protein diet (HPD) are known to accelerate DN in human and animal models, we 
therefore developed a 4-week HPD fed db/db mouse model, in which the sodium glucose 
cotransporter 2 inhibitor dapagliflozin (DAPA) was evaluated.
Methods: 12-week old db/db male mice were placed on a HPD (60%kcal from protein) 
and treated with vehicle or DAPA 10mg/kg orally once daily for 4 weeks. Non-diabetic 
db/+ males on HPD treated with vehicle were included as negative control. Oral glucose 
tolerance test (OGTT), biochemical assays and glomerular filtration rate (GFR), assessed 
with FITC-sinistrin i.v. injection and transdermal monitors, were performed.
Results: Compared to db/+, db/db mice on HPD were strongly hyperglycemic, 
showed increased urine glucose excretion (UGE), higher albuminuria (+127%), and 
evident hyperfiltration, with a 40% higher GFR vs. db/+ (p<0.05 for all parameters). 
Compared to db/db treated with vehicle, DAPA blunted hyperglycemia in fasting state and 
during the OGTT (73% reduction in glucose area under the curve) and strongly increased 
fasting plasma ketone levels by 300% (all p<0.001). As expected, DAPA increased UGE 
by 116% (p<0.01 vs. vehicle) and reduced albumin/creatinine ratio by 40%, although not 
significantly. Compared with vehicle, DAPA reduced proteinuria and creatinine clearance by 
36% (p<0.001) and 45% (p<0.05). Additionally, DAPA significantly reduced hyperfiltration 
with a 12% and 21% reduction in GFR at 2 and 4 weeks of treatment, respectively.
Conclusions: The present data indicate that DAPA shows significant benefits on kidney 
dysfunction in the 4-week HPD fed db/db mouse model. This fast model should be useful to 
rapidly evaluate drugs targeting diabetic nephropathy and glomerular hyperfiltration.
Funding: Commercial Support - PHYSIOGENEX SAS
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Unilateral Nephrectomy and Salt Loading Differentially Alter  
Glomerular Filtration Rate in the Hypertensive, Obese, Type 2  
Diabetic SDT Fatty Rat Model of Diabetic Nephropathy
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Background: Evaluation of drugs targeting diabetic nephropathy (DN) requires 
diabetic animal models developing renal complications and alteration of glomerular 
filtration rate (GFR) in a short period of time. These models should exhibit hyperfiltration 
followed by a >50% GFR decline. The hypertensive, obese, Spontaneously Diabetic Torii 
(SDT) fatty rat develops kidney lesions and may serve as a relevant model for DN. To 
promote alteration of GFR, we here evaluated the effects of unilateral nephrectomy (Unx) 
and salt loading in SDT fatty rats.
Methods: 10-week old, male SDT fatty rats were included into 4 treatment groups 
(n=7/group): 1) normal water without Unx, 2) 0.3% salt water with Unx, 3) 0.6% salt water 
without Unx or 4) 0.8% salt water without Unx. Biochemical parameters and GFR were 
then followed for 13 weeks.
Results: Compared to SDT fatty rats under normal water without Unx, salt 
supplementation and Unx slightly attenuated the diabetic phenotype, with lower 
hyperglycemia (~400mg/dL vs. ~600mg/dL). However, it also resulted in a progressive 
induction of dyslipidemia, leading to a strong hypertriglyceridemia (~2000mg/dL vs. 
~500mg/dL in rats under normal water without Unx) and hypercholesterolemia (~450mg/
dL vs. ~150mg/dL) at 13 weeks. Under normal water without Unx, SDT fatty rats showed a 
gradual increase in hyperfiltration over 13 weeks with GFR raising from 13 +/- 2 to 22 +/- 5 
mL/min/kg. This gradual increase was abolished by 0.6% salt without Unx, with stable GFR 
values over 13 weeks. However, 0.8% salt without Unx induced a progressive decline in 
GFR (36% lower at 13 weeks vs. baseline). In sharp contrast, 0.3% salt with Unx resulted in 
a rapid GFR decline from 2 weeks to 13 weeks (63% lower than baseline).
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Conclusions: In the SDT fatty rat, Unx and salt loading have limited effect on diabetic 
state while they favor induction of dyslipidemia and differentially alter GFR. Depending on 
the experimental setting, this rat model should be helpful to evaluate the effects of drugs on 
hyperfiltration and GFR decline for the treatment of DN.
Funding: Commercial Support - SCOHIA PHARMA Inc.
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Effect of Dual Inhibition of Dipeptidyl Peptidase IV (DPP4) and Sodium/
Glucose Cotransporter (SGLT2) on Tacrolimus-Induced Diabetic Rats
Do-hyun Na. The Catholic University of Korea, Seoul, Korea, Seoul, Republic of 
Korea.
Background: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) and depeptidyl 
peptidase IV inhibitor (DPP4i) are promising antidiabetic drug but their combined use in 
tacrolimus (TAC)-induced diabetes mellitus (DM) is still undetermined. We evaluated the 
effect of dual inhibition of dipeptidyl deptidase IV (DPP4) and sodium/glucose cotransporter 
(SGLT2) on TAC-induced diabetes mellitus (DM) and renal injury in an experimental rat 
model. DM.
Methods: DM was induced by injection of injection of TAC (1.5mg/kg, 
subcutaneously) for 3 weeks, then DPP4i gemigliptin (20mg/kg/day, oral gavage) and/or 
SGLT2i empagliflozin (10mg/kg/day, oral gavage) were given for 4 more weeks. The effect 
of gemigliptin and/or empagliflozin was evaluated by assessing intraperitoneal glucose 
tolerance test (IPGTT) and by measuring markers of oxidative stress, apoptosis. Also, 
Morphologic change of kidney was observed.
Results: IPGTT showed that dual inhibition of DPP4 and SGLT2 showed synergistic 
effect on glucose lowering compared to DPP4i alone or SGLT2i alone group. In Kidney, 
combination treatment group of gemigliptin and empagliflozin alleviated TAC-induced 
renal dysfunction and decreased albumin excretion and histopathogic injury compared with 
TAC group or gemigliptin or empagliflozin alone group. Increased oxidative stress and 
apoptotic cell death by TAC was remarkably decreased with gemigliptin or empagliflozin 
treatment in serum and renal tissues, and this improvement was significantly prominent 
in combination group compared to gemigliptin or empagliflozin alone group. TAC 
induced a two-fold increase in SGLT-2 expression, while combination of gemigliptin and 
empagliflozin decreased SGLT-2 expression and further increased urinary glucose excretion 
compared to the TAC group.
Conclusions: In conclusion, dual inhibition of DPP4 and SGLT2 is effective in 
controlling TAC-induced hyperglycemia and has protective effect on TAC-induced renal 
injury, this finding provides basis clinical use of dual inhibition of DPP4 and SGLT2 in renal 
transplant patients with TAC-induced DM.
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NADPH-Oxidase NOX5 Aggravates Renal Injury in Akita Mouse Model 
of Diabetic Nephropathy
Jay C. Jha,1 Mark E. Cooper,1 Chris R. Kennedy,2 Rhian Touyz,3 Karin Jandeleit-
Dahm.1 1Monash University, Melbourne, VIC, Australia; 2Kidney Research 
Centre, Ottawa, ON, Canada; 3Glasgow University, Glasgow, United Kingdom.
Background: Renal reactive oxygen species (ROS) play an important role in mediating 
kidney injury in diabetes. Increasing evidence suggests that the pro-oxidant enzyme, Nox5 
plays a significant role in human diabetic nephropathy (DN). Nox5 is present in humans 
and rabbits but not in mice or rats. Thus, there is a paucity of information about Nox5 in 
conventional animal models of DN. We examined the role of Nox5 in the insulin deficient 
diabetic Akita mice model using human inducible transgenic mice that express Nox5 
selectively in endothelial cells (VEcad+Nox5+) or in mesangial cells (SM22+Nox5+). We 
also examined the endogenous expression of Nox5 in a high fat fed rabbit model of kidney 
disease.
Methods: At week 10 mice were culled and kidneys were removed for the assessment 
of structural damage as well as gene and protein expression of markers of inflammation, 
fibrosis and oxidative stress. Protein expression of Nox5 and its localization in glomerular 
cells (endothelial and mesangial cells) were examined in transgenic mice by immunostaining. 
We also examined expression of pro-fibrotic gene in high fat fed rabbits by next generation 
sequencing (NGS) and RT-PCR and renal injury by histochemistry
Results: Expression of Nox5 was confirmed in glomerular endothelial and mesangial 
cells of transgenic mice. Diabetes induced increase in glomerulosclerosis, gene and protein 
expression of fibronectin and MCP-1 as well as nitrotyrosine were further increase in 
both diabetic Nox5 transgenic mice. Moreover, increased expression of Nox5 in high fat 
fed rabbits versus normal diet fed rabbits was associated with increased expression of 
fibronectin, CTGF, collagen IV and VCAM-1 as well as increased mesangial expansion 
in the kidney.
Conclusions: These findings in both transgenic mice model (endothelial and mesangial 
cells) suggest that Nox5 plays a significant role in mediating renal injury in diabetes.
SA-PO116 Poster Saturday
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Suramin Inhibits Activation of Inflammasome and Protects Against 
Progression of Diabetic Kidney Disease in KK-Ay Mice
Kaori Oda,1 Satoshi Miyamoto,2 Ryo Kodera,2,3 Jun Wada,1 Kenichi Shikata.2 
1Graduate School of Medicine Dentistry and Pharmaceutical Sciences, 
Okayama University, Okayama, Japan; 2Center for Innovative Clinical 
Medicine, Okayama University Hospital, Okayama, Japan; 3Osafune Clinic, 
Setouchi, Japan.
Background: Inflammasome is a protein complex that leads to production of IL-1β and 
IL-18 through activation of caspase-1, and danger-associated molecular patterns (DAMPs) 
trigger inflammasome activation via P2 receptors (P2Rs). We have shown that both serum 
and urinary IL-18 levels are elevated in patients with diabetic kidney disease (DKD). Mass 
spectrometry imaging has revealed that ATP, one of the major DAMPs, is increased in 
the glomeruli of diabetic mice. The aim of this study was to determine if suramin, a non-
selective P2Rs antagonist, protects against DKD in KK-Ay mice.
Methods: Four weeks-aged male C57BL/6 (B) mice and diabetic KK-Ay (K) mice 
(KK-Ay/TaJcl strain) were randomly assigned to four groups: B+vehicle (BV), B+suramin, 
K+vehicle (KV) and K+suramin (KS), n=6-12/group. Vehicle or suramin (1 mg/kgBW) 
were injected intraperitoneally once every two weeks over an 8-week period. Glomerular 
size and mesangial matrix area were assessed by morphometric analysis. Expression of 
inflammasome-related genes and proteins were quantified by quantitative PCR and western 
blot. The localization of P2Rs were examined by double staining.
Results: Urinary albumin/creatinine ratio was elevated in KV (280.0 ± 29.3 mg/gCr, 
p<0.001) vs. BV (1.7 ± 0.3 mg/gCr), and significantly reduced in KS (160.6 ± 27.3 mg/gCr, 
p<0.01), whereas there were no significant differences in body weight or HbA1c between 
both diabetic groups. Glomerular size and glomerular mesangial matrix area were 
significantly increased in KV and reduced to 78% (p<0.001) and 66% (p<0.001) of KV 
levels by suramin treatment, respectively. Importantly, mRNA expression of P2X4R and 
P2X7R in both renal cortex and isolated glomeruli were significantly suppressed in KS 
compared with KV (p<0.05). P2X4R and P2X7R were mainly distributed in mesangial 
cells in the glomerulus of KK-Ay mice. Protein expression of NLRP3, a key component of 
inflammasome, was increased in KV vs. BV, and significantly suppressed in KS (p<0.05). 
The increase in IL-18 mRNA expression in KV was significantly suppressed in KS (p<0.01), 
and a similar trend was observed in IL-18 protein level in renal cortex.
Conclusions: We found that suramin can improve features of DKD with type 2 diabetes 
and may be renoprotective via suppression of inflammasome activation. Suramin may be 
beneficial for the treatment of DKD.
Funding: Commercial Support - Eli Lilly Japan K.K.
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Marked Improvement of Renal Lesions by Treatment with Mimetic 
Peptide of SOCS1 in the Diabetic Model BTBR ob/ob
Lucas Opazo-Ríos,1 Yenniffer Sanchez,1 Raúl R. Rodrigues díez,2 Daniel Carpio,1 
Carolina Lavoz,1 Paola Krall,1 Jesus Egido,2 Carmen Gomez-Guerrero,2 
Maria A. Droguett,1 Sergio A. Mezzano.1 Unidad de Nefrología, Facultad de 
Medicina, UACH. 1Unidad de Nefrología, Universidad Austral de Chile, 
Valdivia, Chile; 2Renal and Vascular Research Lab, IIS-Fundación Jiménez 
Díaz-Autónoma University of Madrid, CIBERDEM, Madrid, Spain.
Background: Type 2 Diabetes (T2D) is a global public health problem, with Diabetic 
Nephropathy (DN) being the main cause of chronic renal disease worldwide. Although 
current treatments delay the evolution of the disease, it is necessary to establish new 
therapeutic strategies in early stages of DN, in order to promote renoprotection. The JAK/
STAT signaling pathway participates in the diabetic renal disease, through the induction 
of genes involved in inflammation and oxidative stress. Among the different mechanisms 
for JAK/STAT control, the family of SOCS proteins has been proposed as new molecular 
targets for the treatment of DN. Our aim was to evaluate the effect of SOCS1 mimetic 
peptide (MiS1) on the development of early renal damage associated with T2D.
Methods: Four groups of BTBR ob/ob mice (6 weeks old) were treated 3 days/week 
for 7 weeks with active peptide (2 and 4 μg), mutant peptide (4 μg) or vehicle. At the end 
of the study, animals were sacrificed to obtain blood, urine and kidney tissue samples for 
further analysis.
Results: The treatment of diabetic mice with active MiS1 significantly reduced the 
ACR ratio and renal weight, improves the glomerular and tubulointerstitial damage and 
increased podocyte numbers. Treated mice exhibited a decrease in the renal inflammatory 
infiltrate (F4/80 and CD3), lower gene expression of proinflammatory cytokines (Tnfα 
and Il-12) and chemokines (Ccl2 and Ccl5) and reduced phosphorylation of STAT1 
and STAT3. No changes were observed in glycemia and body weight. Concomitantly, 
peptide administration diminished the renal levels of superoxide anion and 8-hydroxy-
2'-deoxyguanosine (marker of DNA oxidative damage) and altered the expression of the 
Nrf2/-heme oxygenase-1 pathway and redox balance enzymes (Nox4, Sod1 and Catalase). 
Finally, we observed a reduction of lipid peroxidation (4-hydroxy-2-hexenal) and gene 
expression of scavenger receptors (SR-B/CD36 and SR-A/CD204).
Conclusions: In conclusion, the MiS1 peptide improves the renal damage and is efective 
in modulating the inflammatory milieu and oxidative stress in an early renal damage in the 
BTBR ob/ob model. Fondecyt Project N° 1160465. PhD. Grant N° 21150768, CONICYT, 
CHILE. MINECO Project SAF2015-63696R and FIS Proyect PI17/01495, SPAIN.
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Overexpression of Sirtuin 3 in Obesity-Induced CKD Mice Model
Florian Juszczak,2,1 Inès Jadot,1 Julie Storder,3 Olivia Botton,1 Anne-
Emilie Decleves,2 Thierry Arnould,1 Nathalie Caron.1 1University of Namur, 
Namur, Belgium; 2Laboratory of Molecular Biology, University of Mons, 
Belgium, NIMY (MONS), Belgium; 3University of Namur, Namur Research 
Institute for Life Sciences, Namur, Belgium.
Background: Obesity and metabolic syndrome are independent risk factors for 
chronic kidney disease (CKD). Obesity-induced CKD is characterized by a progressive 
decline of the renal function and the development of tubulointerstitial fibrosis. Recently, 
studies showing ectopic lipid depositions in proximal tubular cells have emerged along 
with mitochondria dysfunction, suggesting a lipotoxicity in these cells. However, molecular 
mechanisms underlying these processes are still unclear. Our study will focus on the 
involvement of sirtuin 3 (SIRT3), a NAD+-dependent deacetylase, in the ectopic lipid 
accumulation in kidney cells leading to CKD. SIRT3, mainly expressed in mitochondria, is 
known to play a critical role in metabolic responses and mitochondria functions.
Methods: Male C57BL/6 WT and SIRT3 transgenic mice were assigned either to a low 
fat diet (LFD) or a high fat diet (HFD) for 20 weeks. At the end of the protocol, urine, blood 
and kidney samples were collected. Kidney function was investigated and morphological 
analyses were performed.
Results: Wild-Type HFD mice presented renal hypertrophy and impaired renal 
function as attested by an increased albuminuria and proteinuria. Evidence of proximal 
tubule injury was observed in these mice with the presence of enlarged lipid vacuoles. 
In addition, these alterations were associated with the reduction of AMPK activity and 
the decrease in the relative mRNA and protein expression of SIRT3. Interestingly, renal 
hypertrophy and impaired renal function were significantly improved in SIRT3 transgenic 
mice fed a HFD. This was also associated with a reduced number and size of ectopic lipid 
vacuoles in proximal tubular cells.
Conclusions: These findings reveal that SIRT3 plays a critical role in ectopic lipid 
accumulation in proximal tubular cells and impairment of renal function. Systemic 
overexpression of SIRT3 normalizes the renal alterations observed in HFD WT mice and 
may thus be a potential strategy to improve altered lipid metabolism in HFD-induced CKD.
Funding: Government Support - Non-U.S.
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VHL Deletion in Renal Proximal Tubules of Mice Ameliorates Hallmarks 
of Diabetic Nephropathy
Martina Bötttner,1 Eileen Dahlke,3 Franziska Theilig.2 1University of Kiel, Kiel, 
Germany; 2Christian-Albrechts University zu Kiel, Kiel, Germany; 3CAU Kiel, 
Kiel, Germany.
Background: Diabetic nephropathy is the leading cause of end-stage renal disease 
and frequently affects patients with type 2 diabetes mellitus. Glomerular hyperfiltration 
and phenotypic changes in proximal tubule epithelial cells (PTECs) are the initial signs of 
diabetic nephropathy. Systemic activation of hypoxia-inducible factors (HIFs) was shown 
to prevent diabetes-induced alterations in kidney oxygen metabolism.
Methods: To analyze in detail whether renal tubular HIF activation is sufficient to 
prevent functional and morphological alteration of diabetic nephropathy, SGLT2Cre/VHLflox 
mice were generated and diabetes mellitus was induced by streptozotocin application.
Results: FITC-inulin clearance analysis revealed a strong increase in diabetic VHLflox 
control mice which was abrogated in diabetic SGLT2Cre/VHLflox mice showing similar 
values as the non-diabetic control mice. Blood glucose concentration and urinary volume 
excretion were significantly increased in diabetic mice without significant differences 
between genotypes. However, osmotically-induced hyponatremia was only observed in 
diabetic VHLflox mice whereas diabetic SGLT2Cre/VHLflox had values similar to non-diabetic 
controls. Urinary electrolyte, glucose and phosphate excretion was increased in diabetic 
mice and more pronounced in diabetic SGLT2Cre/VHLflox compared to diabetic VHLflox mice.
Conclusions: In summary, our study reveals that induction of proximal tubular HIF 
are able to prevent diabetes induced glomerular hyperfiltration. Additionally, osmotically-
induced hyponatremia was also prevented upon HIF activation most probably through 
reduced proximal tubular glucose reabsorption and thereby leading to its increased urinary 
excretion.
Funding: Private Foundation Support
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The Iron-Klotho-VDR Axis Is a Major Determinant of Proximal 
Convoluted Tubule Injury in Haptoglobin 2-2 Genotype Diabetic 
Nephropathy Patients and mice
Farid M. Nakhoul,1,2 Evgeny Farber,5 Nakhoul Nakhoul,6 Inbal Dahan.3,4 
1Nephrology %Hypertension, Baruch padeh Poriya Medical center, Tiberias, 
Israel; 2Azrieli faculty of Medicine Bar Ilan University, Ramat gan, Israel; 3Baruch 
Padeh Poriya Med Ctr, Tiberias, Israel; 4Diabetes & Metabolism lab, Baruch 
padeh Poriya Medical center, Tiberias, Israel; 5Nephrology & Hypertension, 
Baruch Padeh Poriya Medical Center, Tiberias, Israel; 6Diabetic and metabolism 
Lab, Baruch Padeh Poriya Medical center, Lower Galille, Israel.
Background: The haptoglobin (Hp) genotype (1-1, 2-2) is a major determinant of DN 
progression in DM patients. Hp 2-2 DM patients & mice have increased iron deposits in 
the PCT, leading to renal injury. The mechanism of the PCT injury in DN remains elusive. 
In the kidney, 1,25(OH)2D3 suppresses the inflammatory response to renal tubular injury 
and requires normal renal expression of the α-klotho protein. Increased renal iron deposits 
in the PCT of Hp 2-2 DN may affects α-klotho-Vitamin D receptor axis and exacerbates 
PCT injury
Methods: Seven-week-old male mice were made diabetic by IP injection of 50 mg/kg of 
STZ per day for 5 consecutive days. Mice were sacrificed after a DM duration of 2 months. 
DM mice with Hp 2-2 and Hp1-1, DM and non-DM CKD patients were included. 
Kidney biopsies from mice and patients were subject to immunohistochemistry (IHC) 
and PAS staining. Mice kidney lysates were subjected to western blot analysis.
Results: A marked accumulation of iron deposits in the renal PCT of Hp 2-2 DM mice 
compared to Hp 1-1 DM or with Hp 2-2 non-DM mice. The expression of renal α-klotho 
was reduced significantly in the PCT of DN mice and patients with the Hp 2-2 genotype in 
mice and humans compared to DM Hp 1-1 genotype in mice and CKD humans Western 
blot analysis of the mice renal lysates show that VDR renal expression was decreased 
significantly in the PCT of DN Hp 2-2 sections compared to DM Hp 1-1 genotype. The 
renal expression of 1-α-hydroxylase was increased significantly in DN mice with Hp 2-2 
genotype compared with DM Hp 1-1 genotype
Conclusions: The Iron-Klotho-VDR axis is a key player in themechanism of iron-
mediated PCT injury in DN mice and patients with Hp 2-2 genotype Increased iron deposits 
in the PCT of Hp 2-2 genotype can lead to reduced renal expression of α-klotho and VDR 
protein level and PCT injury. Targeting the iron-klotho-Vit. D axis in DM Hp 2-2 patients 
may explore new ideas on pathog. and TX of early DN
SA-PO121 Poster Saturday
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Overexpression of Hedgehog Interacting Protein in Renal Proximal 
Tubule Promotes Renal Tubulointerstitial Fibrosis in a Type I Diabetes 
Model
Shiao-Ying Chang,1 Min-Chun Liao,1 Xin-Ping Zhao,1 Chao-Sheng Lo,1 
Isabelle Chenier,1 Julie R. Ingelfinger,2 John S. Chan,1 Shao-Ling Zhang.1 
1CRCHUM, Universite de Montreal, Montreal, QC, Canada; 2The New England 
Journal of Medicine, Boston, MA.
Background: We previously reported (Sci. Report 2018) that renal hedgehog 
interacting protein (Hhip) gene expression is highly elevated in the kidneys of diabetic 
animal models and promotes the development of diabetic nephropathy. Since the molecular 
mechanism(s) of action in renal proximal tubular cells (RPTCs) is incompletely known, 
we examined the action of Hhip and its underlying mechanisms under diabetic conditions 
in RPTCs.
Methods: At 11 weeks of age male wild type (WT, C57BL6) and Hhip-transgenic 
(Tg) mice that specifically overexpressed Hhip in their RPTCs had diabetes induced with 
streptozotocin (STZ) (i.p., 50 mg/kg/day) for five consecutive days. Mice were euthanized 
4 weeks after the STZ injection. Physiological parameters, kidney function (urinary 
albumin/creatinine ratio (ACR) and glomerular filtration rate (GFR)), renal morphology 
and molecular analysis of genes expression in renal proximal tubules were carried out. For 
in vitro studies, a rat immortalized RPTCs cell line (IRPTCs) was used.
Results: Non-diabetic Hhip-Tg mice were phenotypically indistinguishable from WT 
animals but had higher mRNA levels of fibrotic genes (TGFβ1, α-SMA) in their RPTCs. 
As compared to diabetic WT animals, diabetic Hhip-Tg mice exhibited pronounced 
tubulointerstitial fibrosis -- ‘tubulopathy’ features-- and increased renal heparanase 
(HPSE) [HPSE is a key player in renal fibrosis by mediating TGFβ1- related epithelial-
mesenchymal transition (EMT) in tubular epithelial cells]. In vitro, recombinant Hhip 
(rHhip) dose-dependently stimulated HPSE expression and increased rat TGFβ1 promoter 
activity (pGL4.20/TGFβ1 (N-1016/+143)) in IRPTCs. Transient transfection of Hhip 
cDNA enhanced the expression of HPSE vs. control plasmid in IRPTCs. Finally, Hhip 
siRNA attenuated high glucose-stimulation of HPSE expression and/or TGFβ1- EMT 
signaling and ameliorated tubular fibrosis and apoptosis.
Conclusions: Overexpression of Hhip in RPTCs, which aggravates diabetes-related 
renal tubulointerstitial fibrosis, is mediated, at least in part, via elevated HPSE-TGFβ1-
EMT signaling.
Funding: Government Support - Non-U.S.
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Angiotensin-Neprilysin Inhibition Protects Glomerular Function and 
Structure and Lowers TRPC6 in Diabetic Hypertensive Rats
Estrellita Uijl,1 Daan C. ’t Hart,2 Lodi C. Roksnoer,3 Marian Clahsen - van 
Groningen,1 Robert Zietse,4 Johan Van der vlag,5 Tom Nijenhuis,2 Jaap A. Joles,6 
Ewout J. Hoorn,4 Alexander H. Danser.4 1Erasmus MC, Rotterdam, Netherlands; 
2Radboud university medical center, Nijmegen, Netherlands; 3Maasstad ziekenhuis, 
Rotterdam, Netherlands; 4Erasmus Medical Center, Rotterdam, Netherlands; 
5Radboud University Nijmegen Medical Centre; Dept of Nephrology, Nijmegen, 
Netherlands; 6University Medical Center Utrecht, Utrecht, Netherlands.
Background: Dual blockade with Angiotensin Receptor/Neprilysin Inhibition (ARNI) 
reduces glomerulosclerosis better than single AR blockade (ARB) in diabetic, hypertensive 
rats, but the renoprotective mechanisms remain unknown. Here, we hypothesized that this is 
mediated by superior blood pressure regulation, improved renal hemodynamics, protection 
of podocyte integrity and/or suppression of renal inflammation.
Methods: To address this, TGR(mREN2)27 rats (a model of angiotensin II-dependent 
hypertension) were made diabetic for 12 weeks and treated with vehicle (n=10), valsartan 
(n=7) or sacubitril/valsartan (ARNI; n=8) for the final 3 weeks. Mean arterial pressure 
(MAP) was measured via radiotelemetry.
Results: Sacubitril/valsartan lowered MAP by 50±4 mmHg and valsartan by 43±4 
mmHg (P=0.3). Sacubitril/valsartan resulted in better glycemic control and lower heart 
weight compared to vehicle and higher urinary atrial natriuretic peptide vs. valsartan (P<0.05 
for all). Histologically, sacubitril/valsartan resulted in markedly lower glomerulosclerosis 
scores than both valsartan and vehicle (P<0.05). Despite higher effective renal plasma 
flow and glomerular filtration rates, sacubitril/valsartan did not improve filtration fraction. 
Analysis of the renal cortex for protein abundance of the transient receptor potential cation 
channel C6 (TRPC6) showed ~50% reduction after sacubitril/valsartan (P=0.06 vs. vehicle). 
Kidney immune cell infiltration did not differ between groups.
Conclusions: In conclusion, ARNI offers drug-class specific renoprotection in a 
pre-clinical model of diabetes and hypertension. Renoprotection is unrelated to renal 
hemodynamics or inflammation but may be related to the protective effects of natriuretic 
peptides and/or improved glycaemia on podocyte integrity, possibly via attenuation of Ca2+ 
influx through TRPC6 channels.
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Angiopoietin-Like Protein 2 Promotes the Progression of Diabetic Kidney 
Disease
Toshihisa Ishii, Fumihiko Furuya, Kenichiro Kitamura. Third Department of 
Internal Medicine, University of Yamanashi, JAPAN University of Yamanashi, 
1110 Shimokato, Chuo,Yamanashi, Japan.
Background: Angiopoietin-like protein 2 (ANGPTL2) is a circulating, pro-
inflammatory protein. To examine the role of ANGPTL2 in the pathogenesis of diabetic 
kidney disease (DKD), we studied the epigenetic regulation of angptl2 expression in 
diabetes patients.
Methods: We determined the relationship between serum ANGPTL2 levels and the 
progression of DKD in cross-sectional (220 patients) and cohort (145 patients, 7-year 
follow-up) studies. In addition, we investigated the effect of DNA methylation on angptl2 
expression and also studied the direct effect of ANGPTL2 on the podocyte function.The 
main outcome is the progression of DKD.
Results: Multivariate logistic regression analyses revealed that the baseline level 
of serum ANGPTL2 was an independent risk factor for the progression of DKD during 
follow-up periods. We found that DNA methylation levels of ANGPTL2 promoter in 
circulating monocytes were correlated with the serum ANGPTL2 levels in diabetes patients. 
Furthermore, in vitro, ANGPTL2 directly increased albumin permeability of the cultured 
podocyte through the translocation of zona occludens-1 from the membrane to the cytosol 
via the activation of focal adhesion kinase.
Conclusions: ANGPTL2 could be a strong mediator of DKD and serves as a good 
predictive biomarker for its progression.
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A1AR Alleviates Tubulo-Interstitial Fibrosis by Inhibiting Peritubular 
Capillary Loss in Diabetic Nephropathy
Dongli Tian, Xiaoxiao Shi, Xiaoyan Peng, Ying Ma, Peng Xia, Yubing Wen, 
Limeng Chen. Department of Nephrology, Peking Union Medical College 
Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Background: We previously observed A1 adenosine receptor (A1AR) had a protective 
role in the progression of diabetic nephropathy. But the mechanism was not clear. The 
disintegration of interstitial pericytes may cause peritubular capillary(PTC) loss and 
interstitial fibrosis. In this study, we used A1AR deficient diabetic mice to prove whether 
A1AR plays a role in the pericyte detachment mediated PTC loss and in the progress of 
renal interstitial fibrosis.
Methods: Eight week-old male C57BL/6J A1AR-/- and WT mice were given two 
consecutive days’ intraperitoneal injection streptozotocin to establish type 1 diabetic 
nephropathy mice. At 4w and 16w for modeling, mice were sacrificed to collect blood, 
urine and kidney samples for intensive detection.
Results: We successfully established streptozotocin induced type 1 diabetic 
nephropathy model in WT and A1AR deficient mice. At 4 weeks, albuminuria and mild 
renal pathological leisure were observed in WT diabetic mice, with up-regulation of A1AR 
protein expression (1.3times, P=0.042). At 16weeks, more serious albuminuria and renal 
pathological leisure were observed in WT diabetic mice than at 4weeks, along with pericyte 
detachment induced platelet-derived growth factor receptor (PDGFR) activation(1.3times, 
P=0.023) and peritubular capillary injury(CD34 staining). While in A1AR-/- diabetic mice, 
severer renal tubular interstitial fibrosis and increased pre-clollagen I expression(1.8times, 
P<0.001) were observed than in WT diabetic mice, along with activation of inflammation, 
including increased inflammasome nod -like receptor protein 3 (NLRP3, 2.0 times, 
P=0.006), and it’s downstream proinflammatory cytokine IL-1β. Meanwhile more increased 
protein expression of PDGFR (1.4times, P=0.008) and PTC lost (1.3times, P=0.016) were 
detected by immunohistochemistry and western-blot.
Conclusions: A1AR plays a protective role in the PDGFR-mediated peritubular 
capillary loss to alleviate renal tubular interstitial fibrosis in type 1 diabetic nephropathy.
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High Protein Diet and Potassium Depletion Exacerbate Ammonia 
Synthesis and Renal Hypertrophy in Rats with Type I Diabetes
Hassane Amlal, Sihame Amlal, Perwez Alam. University of Cincinnati, 
Cincinnati, OH.
Background: We have previously reported that the early onset of hyperglycemia 
stimulates ammoniagenesis, which contributes to the development of early renal 
hypertrophy in both type 1 (T1) and type 2 diabetes mellitus (DM) (ASN abstarct, 2017). In 
these studies, we examined whether other ammoniagenic conditions such as K+ depletion 
and high protein (HP) diet worsen renal hypertrophy in rat with T1 DM.
Methods: Male rats were housed in metabolic cages with free access to paired control 
diet and water and subjected to vehicle or streptozotocin (STZ)-induced DM. After 1 week, 
diabetic rats were divided into 3 groups: one group was switched to a K+-free (KD) diet 
(DM+KD), another group was switched to a HP diet (DM+HP) and the 3rd group remained 
on normal diet for another week (DM). Vehicle-treated rats were fed control diet (control), 
K+-free or HP diets for 1 week. On the last day, 24 hour urine was collected and assayed 
for NH4
+ excretion. The animals were sacrificed, kidneys were removed, weighed and 
cortex was isolated. The protein abundance of ammoniagenic enzymes (glutaminase or GA 
and glutamate dehydrogenase or GDH) and glutamine transporter SN1 in the cortex was 
examined by immunoblotting.
Results: The results showed that NH4+ excretion and kidney mass (kidney weight/BW) 
were significantly increased in DM, KD and HP diet vs. control with a further increase in 
DM+KD and DM+HP diet vs. DM alone. Immunoblotting studies showed a significant 
increase in the protein abundance of GA, GDH and SN1 in KD and in HP diet, respectively, 
vs. control. Interestingly, the protein abundance of GA, GDH and SN1 was unchanged in 
DM vs. control. The results further showed a significant upregulation of GA (4-fold), GDH 
(2.5-fold) and SN1 (8-fold) in DM+KD vs. DM alone. In DM+HP group, GA (138%) and 
GDH (158%) were upregulated, but SN1 remained unchanged vs. DM alone.
Conclusions: 1- In all three conditions (DM, KD and HP diet), the stimulation of 
ammoniagenesis correlates with the development of renal hypertrophy. 2- Diabetic animals 
exhibited a further increase (additive effect) in ammonia production and renal mass when 
subjected to potassium depletion or high protein diet, indicating that these conditions 
activate different and synergistic signaling mechanism(s). 3- KD and HP diet are risk factors 
for rapid progression of kidney disease in diabetes mellitus.
Funding: NIDDK Support, Clinical Revenue Support
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The β2-Adrenergic Receptor Agonist Formoterol Improves Renal 
Function and Decreases Fibrotic and Mitochondrial Fusion/Fission 
Proteins in a Mouse Model of Diabetic Nephropathy
Kristan H. Cleveland, Robert B. Cameron, Frank C. Brosius, Rick 
G. Schnellmann. University of Arizona, Tucson, AZ.
Background: Diabetic nephropathy (DN) is a significant cause of chronic kidney 
disease and accounts for 50% of all end-stage renal disease. Current therapies for DN, such 
as glycemic and blood pressure control and renin-angiotensin system blockade, only slow 
the progression of DN. Therefore, we examined the effect of formoterol, a β2-adrenergic 
receptor agonist previously shown to induce mitochondrial biogenesis and promote 
recovery from acute kidney injury, on renal function and fibrotic and mitochondrial proteins 
in db/db mice, a validated mouse model of DN.
Methods: Female diabetic db/db and non-diabetic db/m (control) mice 9 weeks of age 
were treated with formoterol (0.3 mg/kg, i.p.) or saline daily for three weeks. Mice were 
placed in metabolic cages weekly for 18 hr and urine collected. Body weight and serum 
glucose were measured weekly and renal function was measured by serum creatinine levels. 
Kidneys were harvested after three weeks and changes in expression of mitochondrial and 
fibrotic proteins were measured using immunoblot analysis.
Results: At 12 weeks of age, formoterol decreased serum glucose and creatinine in 
diabetic mice compared to vehicle treated mice without altering body weight. Mitochondrial 
fission protein phospho-Drp1, and fibrotic proteins TGF-β1, phospho-SMAD3 and α-SMA 
were increased in diabetic mouse kidneys and were restored to control levels with formoterol 
treatment. Additionally, mitochondrial fusion proteins Mfn1 and Mfn2 were decreased in 
diabetic mouse kidneys and increased to control levels with formoterol treatment. Complete 
DN phenotyping is ongoing.
Conclusions: Formoterol treatment in a DN model resulted in improved serum 
creatinine, decreased kidney profibrotic protein levels and restored mitochondrial fusion/
fission protein levels in a DN model. These results suggest that formoterol could be a 
potential therapy for DN.
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RIP1 and RIP3 Inhibition Ameliorate Albuminuria and Renal Tubular 
Injury in Diabetic Nephropathy
Xi Tang,1 Lingzhi Li,1 Liang Ma,1 Ping Fu.2 1West China Hospital, Sichuan 
University, Chengdu, China; 2West China Hospital of Sichuan University, 
Chengdu, China.
Background: Hyperglycemia is a key factor in the development of diabetic 
nephropathy, which is characterized by renal tubular inflammation, apoptosis and 
interstitial fibrosis. Receptor interaction protein 1 (RIP1) and 3 (RIP3) plays important role 
in necroptosis, apoptosis, autophage and inflammation. The present study was aimed to 
confirm the hypothesis that RIP3 mediated high glucose-mediated renal tubular cells and 
that inhibition of RIP3 confer protection against this injury in type 2 diabetes.
Methods: 10-week diabetic db/db mice were administrated with selective RIP1 
inhibitor, necrostatin-1 (1.65 mg/kg.d, ip), or RIP3 inhibitor, GSK2399872A (1.9mmol/kg.d, 
ip), or an equal volume of PBS, or ramipril (3 mg/kg.d, po) for a total of 8 weeks. Non-
diabetic db/m mice were used as control.
Results: In db/db mice, renal tubular RIP1 and RIP3 expression was significantly stonger 
than db/m mice. Treatment of necrostatin-1 or GSK2399872A ameliorate albuminuria, 
reducing the expression of TGF-β, collagen I, fibronectin, α-SMA, and caspase 3 in diabetic 
kidney. The albuminuria lowering effects of GSK2399872A (820.08±98.52 mg/g) is better 
than that of necrostatin-1 (1058.7704±102.35 mg/g) and ramipril (1800.66±15.68 mg/g).
Conclusions: Our findings suggest a pathogenic role of overexpressed RIP1 and RIP3 
in diabetic nephropathy. Inhibition of Rip1 and Rip3 ameliorates albuminuria, renal tubular 
apoptosis and fibrosis in type 2 diabetes.
SA-PO128 Poster Saturday
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Empagliflozin Ameliorates Diabetic Nephropathy in BTBR ob/ob Mice
Kelly L. Hudkins,2 Xianwu Li,2 Charles E. Alpers.2,1 Alpers Lab 1University of 
Washington Medical Center, Seattle, WA; 2University of Washington, Seattle, WA.
Background: The SGLT2 inhibitor empagliflozin has demonstrated success in 
regulating elevated blood sugars in diabetic patients via enhanced glucose excretion 
in the urine, and has been successful in ameliorating complications of type II diabetes 
including cardiovascular disease and nephropathy. We sought to test whether treatment 
with empagliflozin (EMPA) with and without concurrent losartan (LOS) treatment would 
ameliorate pathology, proteinuria and restore podocyte number in the BTBR ob/ob model 
of diabetic nephropathy. The latter may be a relevant mechanism that contributes to the 
observed benefits seen in type II diabetic patients treated with this drug.
Methods: At 18 weeks of age BTBR ob/ob and BTBR WT female mice (n=12 each 
group), proven to be diabetic by elevated blood glucose levels, were fed chow formulated 
with 300 mg/kg EMPA with and without concurrent LOS treatment (EMPA/LOS), normal 
chow or were given leptin (LEP) vis osmotic minipump. They were treated for 6 weeks. 
At the end of the experiment, at 24 weeks of age, the mice were placed into a metabolic 
chamber for 6 hours to obtain a timed urine and a fasting blood glucose level was recorded. 
The mice were then euthanized, blood collected via cardiac puncture and organs harvested 
for study.
Results: Treatment with LEP, EMPA and EMPA/LOS all resulted in a significant 
reduction of blood glucose. Only treatment with LEP resulted in weight loss. EMPA and 
EMPA/LOS treatment did not affect proteinuria in individual BTBR ob/ob mice while LEP 
replacement resulted in a significant drop in proteinuria in individual BTBR ob/ob mice. 
Group averages of albumin creatinine ratios (ACR) and albumin excretion extrapolated 
to 24 hour urines did drop significantly in all treatment groups. Additionally, all treatment 
arms resulted in a significant reduction of mesangial matrix accumulation and prevented 
glomerular hypertrophy. Analysis of podocyte number is pending.
Conclusions: From these studies, we conclude that EMPA and EMPA/LOS is nearly 
as effective as LEP replacement in ameliorating some of the pathology and clinical 
manifestations of diabetic nephropathy in the leptin deficient BTBR ob/ob mouse. Further 
analysis will be done to determine whether podocyte number is restored by these treatments, 
which may be a contributing factor to the improvement seen in human diabetic patients 
being treated with SGLT2 inhibitors.
Funding: Commercial Support - Boehringer Ingelheim and Lilly IIS Grant Program 
for Diabetes
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Low Doses of GDT-01 Improve Diabetic Nephropathy and Preserve GFR 
in ZSF1 Rats over 7 Months by Improving In Vivo Sialylation
Sumant S. Chugh,1 Joubert B. Kharlyngdoh,1 Maria Del Nogal Avila,1 
Ranjan Das,1 Hector Donoro blazquez,1 Eduardo Molina-Jijon,1 
Lionel C. Clement,1 Camille E. Mace,1 Carmen Avila-Casado.2 Glomerular 
Disease Therapeutics Laboratory 1Rush University Medical Center, Chicago, IL; 
2University Health Network, University of Toronto, Toronto, ON, Canada.
Background: Studies on rat diabetic nephropathy using the previously published 
sialic acid precursor ManNAc (Clement LC et al Nature Medicine Jan 2011) worsen 
hyperglycaemia in ZDF rats, which is harmful in the long term. We conducted a 7 month 
study to improve in vivo sialylation in the glomerulus using the compound GDT-01 with 
the goal of studying its effect on CKD and hyperglycaemia in rat diabetic nephropathy.
Methods: We treated 5 month old male ZSF1 rats (n = 6 rats / group) with taps water or 
GDT-01 in tap water over a period of 7 months, and measured proteinuria, BUN, creatinine, 
blood glucose, other blood parameters, and assessed renal histological changes on the 
termination of the study.
Results: A declining dose regimen for GDT-01 was used, and the actual dose delivered 
(mg / Kg; mean ± SE) over 3 separate periods was as follows: Period A, Days 0 to 95, 
136.8 ± 11.8; Period B, Days 96 to 122, 21.5 ± 5; Period 3, Days 123 to 222, 3.7 ± 0.2. 
Proteinuria was consistently lower in the treated group in Period C (10/14 readings, 
P<0.05), occasionally in Period B (1/4 readings) and rarely lower in Period A (2/14 
readings). Blood glucose levels were similar between the GDT-01 and water groups. BUN 
and creatinine were consistently lower in the treatment group in Period C (BUN, 7/14, 
P < 0.05 to 0.01; creatinine, 5/14, P<0.05), and only occasionally in Periods A and B. 
Detailed renal histology and sialylation analysis are ongoing.
Conclusions: Low oral doses of the sialylation inducing compound GDT-01 improve 
GFR and proteinuria over prolonged periods of time without worsening hyperglycaemia in 
ZSF1 diabetic rats.
Funding: NIDDK Support
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H+-ATPase Blockade Reduced Renal Gluconeogenesis and Mitochondria 
Metabolism and Lowered Plasma Glucose in a Type 2 Diabetic Rat Model
Mayu Uchida, Akihiro Tojo, Yoshiki Murayama, Masahito Furuichi, 
Hiroshi Satonaka, Toshihiko Ishimitsu. Department of Cardiology & 
Nephrology, Dokkyo Medical University, Mibu, Japan.
Background: Vacuolar H+-adenosine triphosphatase (ATPase) plays important roles 
in urinary acid excretion, vesicular acidification to activate enzymes, endocytosis, and the 
membrane recycling of transporters in the kidney. We have recently reported blockade of 
H+-ATPase reduced plasma glucose in type 1 diabetic rat by reducing renal gluconeogenesis. 
Using proteome analysis of the kidney of type 2 diabetic rats, we investigated effect of 
bafilomycin B1, a specific blocker of H+-ATPase, on renal glucose metabolism.
Methods: Male Spontaneously Diabetic Torii (SDT) rats were treated with Bafilomycin 
B1(BFM)100nmol/kg BW for 7 days. After 24-hour starvation in the metabolic cage, the 
kidneys were analyzed using iTRAQ protein expression and relative quantification analysis.
Results: Renal expression and activity of H+-ATPase were increased with elevated 
urinary ammonium excretion. In the diabetic kidney, the enzymes in gluconeogenesis, 
TCA cycle, mitochondria respiratory chain, and ammoniagenesis were relatively increased 
compared with those in the kidney of control rat. The BFM reduced urinary ammonium 
excretion and decreased the plasma glucose level in diabetic rats (298±38 vs. 171±27 mg/dL, 
p<0.02, n=6). The protein expression of enzymes in mitochondria respiratory chain, TCA 
cycle, and gluconeogenesis were decreased by BFM treatment.
Conclusions: H+-ATPase inhibitor, bafilomycin, lowered plasma glucose after 
24-hour starvation by suppression of renal gluconeogenesis and mitochondria metabolism. 
H+-ATPase could be a new therapeutic target for diabetes mellitus.
Funding: Government Support - Non-U.S.
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Renal Phospholipid Accumulation in High-Fat Diet Fed Streptozotocin 
Induced Diabetic Mice Depends on Ketohexokinase
Tomohito Doke,1 Takuji Ishimoto,1 Takahiro Hayasaki,1 Richard J. Johnson,2 
Shoichi Maruyama.1 1Nagoya University Graduate School of Medicine, Nagoya, 
Japan; 2University of Colorado Denver, Aurora, CO.
Background: Excessive fat intake contributes to the development of obesity and 
metabolic syndrome, which is associated with renal dysfunction in CKD patients including 
diabetic kidney disease (DKD). It has been reported that renal lipid metabolism may play 
a direct role in DKD progression. However, the detailed mechanisms of lipid metabolism 
in renal tubular cells of DKD remain unclear. Recently, we have reported that western diet 
induced steatohepatitis was dependent on ketohexokinase, a primary enzyme of fructose. 
Fructose is produced endogenously in DKD through the activation of polyol pathway. In 
this study, we investigated that the effects of fructose metabolism on lipid accumulation 
in DKD.
Methods: In male, C57BL6/J background wild type (WT) mice and ketohexokinase-
knockout (KHK-KO) mice, which lack both KHK isoforms; KHK-A and C, diabetes was 
induced by streptozotocin (50mg/kg 5 consecutive days, intraperitoneal injection). They 
were fed 45% high fat diet (HFD) for 24 weeks, and then analyzed for renal lipid and 
fructose metabolism, and renal injury.
Results: Biochemical analysis demonstrated lipid parameters and blood glucose 
was not different between HFD fed diabetic WT and KHK-KO mice. We found 
remarkable vacuolization in renal proximal tubule in diabetic WT fed HFD. However, 
this vacuolization was prevented in diabetic KHK-KO fed HFD. This vacuolization was 
considered as phospholipid droplets by results of oil red o staining, toluidine blue staining 
and electron microscope images. The lipidomics showed renal phosphatidylglycerol (PG) 
was significantly increased in diabetic WT fed HFD compared to diabetic KHK-KO fed 
HFD. These increased renal PG was significantly correlated with phospholipid droplets, 
however renal triglyceride was not correlated significantly. The renal gene expressions 
of fatty oxidation (ACOX1, CPT1a) and cholesterol efflux (ABCA1, ABCG1, ApoE) 
were significantly decreased in diabetic WT fed HFD compared to diabetic KHK-KO fed 
HFD. These decreased gene expressions were significantly correlated with the number of 
phospholipid droplets.
Conclusions: These findings suggested that the inhibition of fructose metabolism in 
high fat fed diabetic mice ameliorated the renal phospholipid accumulation by improving 
the impaired fat oxidation and cholesterol efflux in kidney.
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The Role of PCSK9 on the Glomerular Lipid Accumulation and Renal 
Injury in the Diabetic Kidney Disease
Jimin Park,1 Boyoung Nam,1 Sukyung Kang,1 Arum Choi,1 Meiyan Wu,2 Seung 
Hyeok Han,1 Tae-Hyun Yoo.1 1Yonsei University College of Medicine, Seoul, 
Republic of Korea; 2The First Hospital of Jilin University, Changchun, China.
Background: Glomerular lipid accumulation is one of the pathologic characteristics 
of diabetic kidney disease (DKD). Recent evidences suggested that proprotein convertase 
subtilisin kexin type 9 (PCSK9) has a particular effect on the cellular lipid homeostasis. We 
aimed to evaluate the role of PCSK9 on the lipid accumulation in glomeruli and podocyte 
under the diabetic conditions.
Methods: C57BL/6 and PCSK9 knockout (KO) mice were maintained with high fat 
diet for 12 weeks with low dose streptozocin intraperitoneal injection. Urinary albumin-to-
creatinine ratio (ACR), total cholesterol and triglyceride in kidney tissues were measured. 
BODIPY 493/503 staining was performed for evaluating lipid accumulation in the kidney. 
Foot process effacement in glomeruli was evaluated by standard transmission electron 
microscopy. In vitro study, mouse podocytes were stimulated with TNF-α and palmitic 
acid, and PCSK9 was up- or down-regulated by overexpressing lenti virus or siRNA. 
Apoptosis, mitochondrial morphology and energy metabolic key enzymes were evaluated 
both in vivo and vitro.
Results: Blood glucose and serum cholesterol were significantly increased, and urinary 
ACR and foot process effacement were increased in diabetic mice and these changes were 
exaggerated in the PCSK9 KO mouse with diabetes. Cholesterol and triglyceride levels in 
the kidney tissues were higher in PCSK KO mice with diabetes than those in control and 
diabetic mice. Mitochondrial morphology and the expression of energy metabolic enzymes 
were disturbed in the kidneys of diabetic PCSK KO mice. In vitro, the intracellular lipid 
contents was increased and apoptosis combined with mitochondrial swelling and crista 
disruption were also increased in podotyes with TNF-α and palmitic acid stimuli. All 
of these changes were ameliorated through mPCSK9 overexpression and aggravated by 
PCSK9 siRNA treatment.
Conclusions: These findings suggest that PCSK9 down-regulation in the podocytes 
is involved in lipid accumulation and consequent mitochondrial dysfunction and apoptosis 
in the DKD.
SA-PO133 Poster Saturday
Diabetic Kidney Disease: Basic - III
Whole-Kidney 3D Imaging for Assessment of Glomerular Number and 
Size in a Mouse Model of Diabetic Nephropathy
Jacob Hecksher-Sørensen, Urmas Roostalu, Katrine Fabricius, Niels Vrang, 
Jacob Jelsing, Thomas Secher, Lisbeth N. Fink. Gubra, Hørsholm, Denmark.
Background: Diabetic nephropathy (DN) is a major long-term complication of 
diabetes characterized by kidney hypertrophy and hyperfunction. To facilitate a rapid and 
unbiased evaluation of drug efficacy on glomerular size and number in preclinical studies, 
we investigated the use of light sheet microscopy as a new high-end 3D methodology to 
study whole-kidney glomerular changes in a mouse model of DN.
Methods: Unilateral nephrectomy (UNx) was performed in diabetic db/db mice to 
accelerate the development of nephropathy. UNx was performed in 18 weeks-old male db/
db mice and terminated 6 weeks later. Mice were stratified and randomly assigned into 
UNx (n=8) or sham (n=8) based on baseline blood glucose levels. To determine the effect 
of UNx on whole-kidney glomerular morphology, mice were injected with lectin-594 prior 
to termination. Intact kidneys were scanned using light sheet microscopy (LSM). Using 3D 
image analysis, the total number of glomeruli were quantified and segmented according to 
individual size.
Results: Progression of diabetes remained similar in db/db control and db/db UNx 
mice. In contrast, terminal kidney weight was increased in db/db UNx mice, indicative 
of renal insufficiency leading to kidney hypertrophy. In agreement with stereology-
based quantitative analyses on tissue sections, 3D-LSM confirmed an increase in kidney 
glomerular size in db/db UNx mice compared to db/db sham controls, while glomerular 
numbers were similar in both groups (≈14.000 glomeruli/kidney). Lectin-594 labelled 
kidneys were subsequently processed for Wilms’ tumor-1 (Wt1), collagen IV and podocin 
expression using conventional immunohistochemistry. All antigens were readily detected, 
confirming that whole-kidney imaging was compatible for subsequent conventional 
immunohistochemistry.
Conclusions: In conclusion, LSM was successfully applied to evaluate renal and 
glomerular hypertrophy at the whole-organ level in a db/db UNx mice model of DN. Whole-
kidney 3D imaging offers a novel approach for evaluating changes in key glomerular markers 
of DN, while maintaining the ability to perform conventional immunohistochemistry on the 
same tissue. The detailed analysis of all glomeruli enables for high-resolution evaluation of 
glomerular effects of novel treatment modalities in DN.
SA-PO134 Poster Saturday
Diabetic Kidney Disease: Basic - III
Morphological Changes in the Kidney, Liver, and Pancreas of Type 2 
Diabetic Rats Treated with H+-ATPase Inhibitor
Yoshiki Murayama, Akihiro Tojo, Mayu Uchida, Makoto Abe, Akiko Kaiga, 
Jun Hirao, Masahito Furuichi, Akihiko Nagase, Sho Onoda, Takehiro Ohira, 
Hiroshi Satonaka, Toshihiko Ishimitsu. Department of Cardiology & 
Nephrology, Dokkyo Medical University, Tochigi, Japan.
Background: We reported that H+-ATPase specific inhibitor, bafilomycin (BFM), 
lowered fasting plasma glucose via suppression of renal gluconeogenesis in type 1 diabetic 
rat. To elucidate the plasma glucose lowering effect of BFM, we investigated morphological 
changes in the kidney, liver, and pancreas in the type 2 diabetic rats.
Methods: Male Spontaneously Diabetic Torii (SDT) rats were treated with BFM B1 
100 nmol/kg for 7 days., After collecting urine, insulin glucose test was performed and then, 
the organs were fixed and observed with light microscope and electron microscope.
Results: H+-ATPase was expressed in the proximal tubule, collecting duct, 
hepatocytes, and pancreatic islet cells. The endocytosis vesicles on the luminal side of the 
proximal tubules were increased in diabetics. BFM treatment decreased apical endocytotic 
vesicles, whereas vesicles were accumulated in the basal area of proximal tubule. Enlarged 
mitochondria in diabetic rats became smaller by BFM treatment. The liver of diabetic rat 
showed fatty changes, which was suppressed by BFM treatment. The islets of pancreas and 
insulin vesicles were decreased in diabetic rat. BFM treatment restored islet atrophy and 
increased insulin vesicles. Insulin sensitivity evaluated by KITT values was significantly 
decreased in diabetic rat compared with that in control (1.4±0.8 in diabetes vs. 8.8±1.1 
in control, p<0.001), which was ameliorated by BFM treatment (3.4±0.1, P<0.05). BFM 
significantly reduced fasting blood glucose in diabetes.
Conclusions: In type 2 diabetes, H +-ATPase inhibitor bafilomycin suppressed 
proximal tubular endocytic vesicles and mitochondrial enlargement, reduced hepatic fat 
accumulation, and restored pancreatic insulin vesicles in diabetic rat. Thus, bafilomycin 
lowered fasting plasma glucose and ameliorated insulin sensitivity.
Funding: Government Support - Non-U.S.
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Diabetic Kidney Disease: Basic - III
Urinary Serum Amyloid A and Clinical Outcomes in Advanced Diabetic 
Kidney Disease
Brad Dieter,1 Sterling McPherson,2 Maryam Afkarian,3 Rick L. Meek,7 Ian H. de 
Boer,4 Rajnish Mehrotra,5 Katherine R. Tuttle.6 1Providence Health Care, 
Spokane, WA; 2Washington State University College of Medicine, Spokane, WA; 
3University of California, Davis, Sacramento, CA; 4Division of Nephrology and 
Kidney Research Institute, University of Washington, Seattle, WA; 5University of 
Washington, Seattle, WA; 6University of Washington School of Medicine, 
Spokane, WA; 7Providence Sacred Heart Medical Center, Spokane, WA.
Background: Serum amyloid A (SAA) is elevated in the kidneys from humans and 
mice with diabetic kidney disease (DKD). SAA promotes a broad inflammatory response 
and overexpression of SAA exacerbates albuminuria and glomerulosclerosis in diabetic 
mice. The study aim was to determine the relationship of urinary SAA to clinical outcomes 
in patients with advanced DKD.
Methods: Urinary SAA was measured (enzyme-linked immunosorbent assay) in a 
cohort with type 2 diabetes and advanced DKD defined by urine protein-to-creatinine ratio 
>500 mg/g. Associations of urinary SAA with ESRD and death were tested using Cox-
proportional hazard models. The models were adjusted for DKD risk factors: age, sex, race, 
hemoglobin A1c, and systolic blood pressure.
Results: Baseline characteristics included: age 57±8 (mean±SD) years, women (65/115; 
57%), Mexican-American (82/115; 71%), hemoglobin A1c 8.6±2.3%, systolic blood 
pressure 153±28 mm Hg, urine albumin-to-creatinine ratio 1874, 756-3950 mg/g (median, 
interquartile range), estimated glomerular filtration rate (eGFR; CKD-EPI-creatinine) 
56±22 mL/min/1.73m2, diabetes duration 15±6 years, body mass index 32±9 kg/m2, 
renin angiotensin system inhibitor use (92/115; 80%). Participants with SAA-positive 
urine (58/115; 50%) had lower eGFR (SAA-positive 51±19 mL/min/1.73m2 versus SAA-
negative 60±24 mL/min/1.73m2, p=0.025), and higher albuminuria (SAA-positive 3094 
[1180–4677] versus SAA-negative 1089 [55 –1955], p=0.030). SAA positivity in urine was 
associated with ESRD (hazards ratio [HR] 2.50, 95% confidence interval [CI] 1.23–5.08, 
p=0.011), but not death (HR 0.92, 95% CI 0.44–1.94, p=0.83) over a median of 3.5 years. 
After DKD risk factor adjustment, risk of ESRD imparted by SAA positivity in urine 
remained similar (HR 2.42, 95% CI 1.15 – 5.12, p=0.020).
Conclusions: In patients with advanced DKD, those with SAA-positive urine had 
lower eGFR and higher albuminuria compared to those with SAA-negative urine. Urinary 
SAA forecasted ESRD after adjustment for DKD risk factors. These relationships point to 
SAA as a candidate mechanism for DKD progression in diabetic patients with advanced 
DKD.
SA-PO136 Poster Saturday
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Urine Metabolites Report on Dysregulated Kidney Metabolism in 
Diabetes and Hypertension
Julia J. Scialla,1 James R. Bain,1,2 Michael Muehlbauer,1,2 Olga Ilkayeva,2 Jean-
Paul Kovalik,3 Christopher B. Newgard,1,2 Thomas M. Coffman,1,3 
Susan B. Gurley.4 1Duke University Medical Center, Durham, NC; 2Duke 
Molecular Physiology Institute, Durham, NC; 3Duke-NUS Medical School, 
Singapore, Singapore; 4Oregon Health and Science University, Durham, NC.
Background: Interrogating the molecular pathophysiology of kidney disease is 
challenged by limited clinical biopsy specimens. We evaluated concordance of kidney and 
urine metabolites in mouse models of diabetes mellitus (DM) and hypertension (HTN) to 
explore urine metabolomics as a tool to investigate kidney diseases in patients.
Methods: We profiled kidney and urine metabolites in the Akita model of type 1 DM 
(Akita+/-), the Akita Renin transgene model of DKD (Akita+/-Rtg+/-), the Rtg+/- model of HTN, 
and wild type mice (WT; n=14 each). 24h urines were collected by metabolic cage and 
organs harvested at 12 wks. Kidneys were frozen and homogenized in acetonitrile:formic 
acid and urines concentrations were standardized. Nontargeted GC/MS was performed and 
annotated with spectral libraries. Unidentifiable metabolites or those missing >50% were 
removed, with other values imputed. Comparisons utilized principal components (PC), 
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partial least squares discriminant analysis (PLS-DA), and sparse generalized canonical 
correlation.
Results: Using PLS-DA, higher levels of multiple metabolites discriminated DM 
(Akita+/- and Akita+/-Rtg+/-) from non-DM (Rtg+/- or WT) including: branched chain amino 
acids, simple sugars, and ketones (β-hydroxybutyrate; BHB) in kidneys; and lactate, 
pyruvate, and ketones (BHB and acetoacetate) and related compounds (2-hydroxybutyrate) 
in urine. After data reduction by PC, similar kidney and urine PCs were correlated within 
phenotypes. In DM, kidney PC1 contained valine, pyruvate and simple sugars. This 
correlated with urine PC1 (r=0.65) characterized by branched fatty acids, keto acids and 
acyl glycines. Within non-DM, urine PC1 composed primarily of tricarboxylic acid (TCA) 
cycle-related organic anions (OAs) correlated directly with a similar TCA-cycle related PC 
in kidney lysates (r=0.71) with levels higher in Rtg+/-.
Conclusions: Similar kidney and urine metabolite PCs correlate in models with and 
without DM. The predominance of sugars and ketones in profiles from uncontrolled DM 
models may obscure discovery relevant to treated DM in patients. Studies in non-DM 
highlight urine TCA cycle-related OAs as potential biomarkers of kidney metabolism. 
Whether TCA cycle-related OAs may be useful in human studies involving treated DM 
requires confirmation.
Funding: NIDDK Support
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Effects of the SGLT-2 Inhibitor Dapagliflozin on Volume Status in Patients 
with Type 2 Diabetes and Elevated Albuminuria
Claire Dekkers,1 Ron T. Gansevoort,1 Bart J. Kramers,2 Hiddo J. Lambers 
Heerspink.1 1University Medical Center Groningen, Groningen, Netherlands; 
2Harvard, Groningen, Netherlands.
Background: SGLT-2 inhibitors reduce the risk for heart failure events in patients 
with type 2 diabetes at high cardiovascular risk. These beneficial effects are thought to 
be attributed to diuretic effects. The aim of this study was to assess whether these diuretic 
effects can be attributed to osmotic or natriuretic diuresis in patients with type 2 diabetes 
and elevated albuminuria.
Methods: A post-hoc analysis was performed of a randomized placebo controlled 
cross-over trial that assessed the effects of dapagliflozin (DAPA) 10 mg/day therapy in 
31 patients with type 2 diabetes and elevated albuminuria (median UAE 521 mg/24h). 
Blood samples and 24-hour urine were collected at start and end of each 6-weeks treatment 
period. Markers of volume status including sodium, urea, copeptin, renin, NT-proBNP and 
osmolality were measured. Free water clearance (FWC) was calculated as urine flow minus 
osmolar clearance.
Results: Compared to placebo, DAPA therapy increased fractional lithium excretion 
(reflecting reduced sodium reabsorption), urinary glucose excretion, urine osmolality, 
copeptin and renin, and it decreased FWC (table). DAPA therapy did not change plasma 
osmolality, sodium, and NT-proBNP.
Conclusions: The observed increases in fractional lithium excretion, glucose excretion 
and urine osmolality, and the combined increase in copeptin and renin during DAPA therapy 
suggests that both osmotic and natriuretic diuresis are involved. These findings are based 
on 6-weeks changes in fluid markers, when patients already have reached a new steady 
state. Further research is needed to characterize acute volume and diuretic effects of DAPA.
SA-PO138 Poster Saturday
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Effects of Dapagliflozin on Albuminuria, Renal Function, and Renin- 
Angiotensin-Aldosterone Hormones in Type 2 Diabetes
Mie K. Eickhoff,2 Marie Frimodt-Moller,2 Niklas R. Jørgensen,3,4 Peter Rossing,2 
Frederik Persson.1 1Steno Diabetes Center, Gentofte, Denmark; 2Steno Diabetes 
Center Copenhagen, Gentofte, Denmark; 3Department of Clinical Biochemistry, 
Rigshospitalet, Glostrup, Denmark; 4OPEN, Odense Patient data Explorative 
Network, Odense University Hospital, Odense, Denmark.
Background: Sodium glucose cotransporter 2 inhibitors (SGLT2i) have shown a 
cardio- and renoprotective effect. The mechanism for this effect and the interaction with 
the renin-angiotensin-aldosterone system (RAAS) is only partially understood. Therefore, 
we aim to evaluate the effect of dapagliflozin treatment on albuminuria, measured GFR, 
24h blood pressure (BP) and hormone levels of the RAAS when added to standard care 
including RAAS blocking treatment in patients with type 2 diabetes (T2D).
Methods: Double-masked randomized placebo-controlled crossover trial of 12 weeks 
treatment with dapagliflozin 10 mg or matching placebo. All patients were treated with 
RAAS blocking treatment. Included patients (n=40) had T2D and albuminuria at baseline. 
At the end of the treatment periods 3 consecutive morning spot urines were collected as well 
as 24h BP measurement and 51Cr-EDTA clearance performed. Values at the end of treatment 
periods (placebo vs. dapagliflozin) were compared using mixed model analysis.
Results: Baseline age was 65 (SD±8), 90% were male, HbA1c was 73 mmol/mol 
(SD±15), 24h BP 148/82 mmHg (SD±12.5/7.7), geometric mean urinary albumin creatinine 
ratio (UACR) 147 (IQR 75-289) mg/g and mean eGFR 85 ml/min/1.72 m2 (SD±19.7). 
After 12 weeks treatment UACR was reduced 36% (95% CI 16-56%) during treatment 
with dapagliflozin vs. placebo (p<0.01), GFR decreased 10.9 (5-16) ml/min/1.72 m2  
(p<0.01), HbA1c was reduced 7.4 (5-10) mmol/mol (p<0.01) and 24h BP 4.8/2.7 mmHg 
(p=0.023/0.031). Plasma renin concentration increased 37% (9-66%, p = 0.012), plasma 
renin activity increased 41% (7—74%, p = 0.019), angiotensin II increased 37% (1-73%, p 
= 0.046) whereas plasma aldosterone was unchanged.
Conclusions: When added to standard RAAS blocking treatment dapagliflozin 10 mg 
vs. placebo once daily was associated with a significant reduction in albuminuria, 24h BP 
and GFR in patients with T2D and albuminuria. A concomitant increase in RAAS hormones 
was observed, possibly caused by increased diuresis as an effect of natriuresis.
Funding: Commercial Support - AstraZeneca
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Effect of Dapagliflozin on Cardiac Function and Biomarkers in Patients 
with Type 2 Diabetes and Albuminuria – A Randomized Study
Mie K. Eickhoff,1 Flemming J. Olsen,3 Marie Frimodt-Moller,1 Lars J. Díaz,1 
Jens Faber,2 Magnus T. Jensen,3 Peter Rossing,1 Frederik Persson.1 1Steno 
Diabetes Center Copenhagen, Gentofte, Denmark; 2Herlev University Hospital, 
Herlev, Denmark; 3Department of Cardiology, Herlev-Gentofte Hospital, 
Copenhagen, Denmark.
Background: Sodium glucose cotransporter 2 inhibitors (SGLT2i) have shown cardio- 
and reno-protective properties. The aim here is to evaluate the effect of dapagliflozin (dapa) 
treatment on myocardial function assessed with advanced echocardiography (TTE), and 
cardiac biomarkers when added to standard care in patients with type 2 diabetes (T2D).
Methods: This is a sub-study of a double-masked randomized placebo-controlled 
crossover trial of 12 weeks treatment with dapa 10 mg once daily or placebo. All patients 
(n=40) were on RAS blocking treatment, had T2D and albuminuria at baseline. At the end of 
the treatment period TTE was performed, 51Cr-EDTA, albuminuria and 24h blood pressure 
were measured, as well as cardiac markers in plasma; NTproBNP, troponin I, MRproANP, 
MRproADM, TNF-α, IL-6 and copeptin. Global longitudinal strain (GLS) was the primary 
systolic echocardiographic endpoint. To assess diastolic function a combined diastolic 
endpoint was used including mean early diastolic myocardial velocity (e’), ratio between 
early transmitral inflow velocity (E) and e’ (E/e’), atrial volume and pulmonary pressure 
(TRmaxPG).
Results: Baseline geometric mean urinary albumin creatinine ratio (UACR) was 147 
(IQR 75-289) mg/g, mean eGFR 85 (SD±19.7) ml/min/1.72 m2. Baseline HbA1c was 73 
(SD±15) mmol/mol, 24h blood pressure 148/82 (SD±12.5/7.7) mmHg, diabetes duration 
16.5 (SD±4,8) years, age 65 (SD±8) years and 90% were male. After 12 weeks treatment 
with dapa vs. placebo, HbA1c was reduced by 7.4 (5-10) mmol/mol (p<0.01) and 24h blood 
pressure decreased 4.8/2.7 mmHg (p=0.023/0.031). Left ventricular ejection fraction after 
placebo was 55.5 (SD±6.7) % and 53.7 (SD±6.7) % after active treatment – a non-significant 
change. GLS did not change whereas diastolic function improved significantly with 19.8% 
(3.3-36.3%, p = 0.021). Plasma concentration of NTproBNP, troponin I, MRproANP, 
MRproADM, TNF-α and IL-6 did not change. Plasma concentration of copeptin increased 
with 32.3% (p<0.0001).
Conclusions: Treatment of dapa 10 mg vs. placebo in patients with albuminuria was 
associated with an improvement in diastolic function but not in GLS in people with T2D 
and albuminuria. Also an increase in copeptin was observed possibly reflecting increased 
diuresis due to natriuresis.
Funding: Commercial Support - AstraZeneca
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Dapagliflozin Added to Verinurad plus Febuxostat Reduces Serum Uric 
Acid Without Increasing Urinary Uric Acid Excretion in Subjects with 
Hyperuricemia
Austin G. Stack,1 Fredrik Erlandsson,2 David S. Han,3 Jan Oscarsson,2 
Ronald Goldwater,4 Nalina Dronamraju,5 Susanne Johansson,2 Eva K. Johnsson.2 
1Graduate Entry Medical School, University of Limerick, Limerick, Ireland; 
2AstraZeneca, Mölndal, Sweden; 3PAREXEL International, California, CA; 
4PAREXEL International, Baltimore, MD; 5AstraZeneca, Mölndal, Sweden.
Background: Hyperuricemia is associated with gout, kidney stones and CV events. An 
intensive urate lowering strategy combines a xanthine oxidase inhibitor (febuxostat [FEB]) 
and a URAT-1 inhibitor (verinurad [VER]) to maximize serum uric acid (sUA) reduction. 
Dapagliflozin (DAPA, SGLT2 inhibitor) reduces sUA by an unknown mechanism(s). 
Excessive UA excretion may damage renal tubules due to crystallization at high levels, so 
any DAPA-mediated effect on urinary UA (uUA) should be explored. We examined effects 
of DAPA on sUA and uUA excretion on top of VER+FEB in hyperuricemia.
Methods: A randomized, placebo-controlled, 2-way crossover study was conducted 
in adults with asymptomatic hyperuricemia over 7-d periods after washout. Groups (1:1) 
received oral VER 9mg+FEB 80mg+DAPA 10mg (Gp1), or VER+FEB+placebo (Gp2). 
Urine was collected hourly and for 24h on D–1 (baseline [BL]) and D7 of each period. 
Primary endpoint was difference from D7 to D–1 in peak uUA excretion between groups 
(ΔGp1–ΔGp2). Secondary measures were change in serum levels and 24-h urinary excretion 
of UA, Cr, and Na. AEs were monitored. Data are shown as mean (SD) and LSM (95% CI).
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Results: Enrolled subjects (n=24) were male, mean age 43y. At BL (D–2), median 
BMI and eGFR were 29 kg/m2 and 85 mL/min/1.73m2 with mean (SD) sUA 445.3 (60.8) 
μmol/L. BL levels of sCr and sNa were (Gp1/Gp2) 93.8/95.8 μmol/L and 138/139 mmol/L, 
respectively. Peak uUA was available for 13 subjects and 24h urine for all. After DAPA,
subjects showed no increase in peak UA excretion on D7 (mg/h); Grp1 –5.33 (–15.04, 4.37), 
Gp2 –7.20 (–16.91, 2.51); mean difference 1.87 (–7.63, 11.36). No difference was seen in 
total 24h UA excretion. After DAPA, subjects showed significantly reduced sUA levels; 
mean difference (Gp1 vs Gp2) on D7 was –76.35 (–104.02, –48.68) μmol/L (p<0.01). No 
between-group differences were seen in sCr or sNa. 8 subjects had 9 AE (Gp1 n=5; Gp2,
n=4), all mild, no inter-group differences. DAPA did not affect VER or FEB PK.
Conclusions: Addition of DAPA to an intensive UA lowering strategy with VER+FEB 
provides additional sUA lowering without increase in urinary UA excretion, or changes in 
sCr; suggesting a DAPA+VER+FEB combination will not adversely affect kidney function 
(NCT03316131).
Funding: Commercial Support - AstraZeneca
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Can Improvements in Cardiac and Vascular Hemodynamic Markers 
Explain the Kidney Benefit with Empagliflozin in the EMPA-REG 
OUTCOME® Trial?
Bernhard K. Krämer,1 Johannes F. Mann,2 Stefan Hantel,3 Odd Erik Johansen,4 
Maximilian von Eynatten,3 Christoph Wanner,5 Sibylle J. Hauske.1,3 1University 
Medical Center Mannheim, University of Heidelberg, Mannheim, Germany; 
2KfH Nierenzentrum, München, Germany; 3Boehringer Ingelheim International 
GmbH, Ingelheim, Germany; 4Boehringer Ingelheim Norway, Asker, Norway; 
5Würzburg University Clinic, Würzburg, Germany.
Background: In the EMPA-REG OUTCOME trial (NCT01131676) empagliflozin 
(EMPA) added to standard of care significantly reduced clinically relevant kidney outcomes 
by 39% in patients with type 2 diabetes (T2D) and established cardiovascular disease 
(CVD). As EMPA can reduce arterial stiffness and improve vascular compliance, these 
effects could be potential mediators of the kidney protective effects observed. We assessed 
whether the effect of EMPA on indices of arterial stiffness and vascular compliance could 
be related to kidney outcomes.
Methods: Patients were randomized (1:1:1) to EMPA 10 mg, EMPA 25 mg, or placebo 
(PBO); this post-hoc analysis compared the pooled EMPA group vs PBO. We calculated 
change from baseline to week 12 in indices of arterial stiffness (pulse pressure), vascular 
resistance (mean arterial pressure), and cardiac workload (double product). Subgroups 
for these indices (depicted as changes above or below the median) were used to assess 
potential effects on incident or worsening nephropathy (composite of progression to 
macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy, or 
renal death) and all outcome events occurring after week 12 were included in this analysis.
Results: A total of 7020 patients were randomized and treated with ≥1 study drug dose. 
As previously reported, EMPA significantly reduced cardiac and vascular hemodynamic 
markers vs PBO at week 12. However, the reduction in risk of incident or worsening 
nephropathy with EMPA was consistent between the three subgroups for indices, regardless 
of magnitude of their respective changes (Figure).
Conclusions: In patients with T2D and established CVD, empagliflozin produced a 
consistent benefit on kidney outcomes between subgroups for indices of arterial stiffness, 
vascular resistance, and cardiac workload.
Funding: Commercial Support - Boehringer Ingelheim & Eli Lilly and Company 
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Reduction in Weight and Adiposity Indices and Kidney Outcomes with 
Empagliflozin in Patients with Type 2 Diabetes (T2D): Results from the 
EMPA-REG OUTCOME® Trial
Talat Alp Ikizler,1 Peter Stenvinkel,2 Ian J. Neeland,3 Stefan Hantel,4 Odd 
Erik Johansen,5 Maximilian von Eynatten,6 Christoph Wanner,7 Audrey Koitka-
Weber.6,8 1Vanderbilt University Medical Center, Nashville, TN; 2Karolinska 
University Hospital Huddinge, Stockholm, Sweden; 3UT Southwestern Medical 
Center, Dallas, TX; 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach 
an der Riss, Germany; 5Boehringer-Ingelheim, Asker, Norway; 6Boehringer 
Ingelheim, Ingelheim, Germany; 7University Hospital, Wuerzburg, Germany; 
8Würzburg University Clinic, Würzburg, Germany.
Background: Empagliflozin (EMPA), a sodium-glucose co-transporter-2 inhibitor, 
significantly reduced the risk of prespecified kidney outcomes by 39% when added to 
standard of care in patients with T2D and established cardiovascular disease (CVD) in the 
EMPA-REG OUTCOME® trial. As obesity increases the risk for chronic kidney disease 
(CKD) and its progression to end-stage kidney disease, we explored the potential interaction 
between changes in weight/adiposity and the kidney-protective effects of EMPA.
Methods: In EMPA-REG OUTCOME®, 7020 patients were randomized (1:1:1) to 
daily EMPA 10 or 25 mg or placebo (PBO). Background glucose-lowering therapy was 
unchanged for the first 12 weeks. We analyzed kidney outcomes in subgroups based on 
change in weight and adiposity markers from baseline to week 12. Differences in risk for 
pooled EMPA vs PBO were assessed using a Cox proportional hazards model adjusting for 
clinical covariates.
Results: Median observation time was 3.1 years. At baseline, the EMPA and PBO 
groups had similar mean weight (86.6 vs 86.2 kg, respectively), body mass index (30.7 vs 
30.6 kg/m2), waist circumference (105.0 vs 104.7 cm), and estimated total body fat (33.4% 
vs 33.5%). Changes in these parameters from baseline to week 12 did not significantly 
affect the reduced risk of incident or worsening nephropathy observed after week 12 with 
EMPA vs PBO (Figure; treatment by subgroup interaction p-value >0.05 for all).
Conclusions: The beneficial effect of EMPA on kidney outcomes was consistent 
irrespective of changes in weight or body fat in T2D patients with established CVD. The 
EMPA-KIDNEY trial will provide further insight into the effects of EMPA on adiposity and 
kidney outcomes in CKD patients with or without diabetes.
Funding: Commercial Support - Boehringer Ingelheim & Eli Lilly and Company 
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Effects of Canagliflozin on Serum Potassium in the CANVAS Program
Matthew R. Weir,1 Dainius Balis,2 Dick de Zeeuw,3 Vlado Perkovic.4 1University 
of Maryland School of Medicine, Baltimore, MD; 2Janssen Research & 
Development, LLC, Raritan, NJ; 3University of Groningen, University Medical 
Center Groningen, Groningen, Netherlands; 4The George Institute for Global 
Health, Sydney, NSW, Australia.
Background: Canagliflozin (CANA) is a sodium glucose co-transporter 2 (SGLT2) 
inhibitor used for the treatment of type 2 diabetes mellitus (T2DM). The US label Warnings 
and Precautions section notes a risk of hyperkalemia with CANA in patients with moderate 
renal impairment who are taking medications that interfere with potassium excretion. 
Serum potassium levels were assessed in patients at high cardiovascular (CV) risk in the 
CANagliflozin cardioVascular Assessment Study (CANVAS) Program, comprised of the 
CANVAS and CANVAS-R trials.
Methods: The CANVAS Program randomized 10,142 participants with T2DM and 
high CV risk to CANA or placebo (PBO); 80% were on renin-angiotensin aldosterone 
system (RAAS) inhibitors at baseline. Serum potassium measurements were performed 
in a central laboratory; values meeting predefined limit of change criteria (PDLC) were 
prespecified and assessed using results obtained up to 2 days after the last dose of study 
drug.
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Results: In the CANVAS Program, the risk of decreased serum potassium (PDLC 
<3.4 mEq/L and >15% decrease from baseline) was similar between the CANA and PBO 
arms (Table; hazard ratio [HR] 0.96 [95% confidence interval (CI) 0.72, 1.28]). The HR 
(95% CI) for increased serum potassium (PDLC >5.4 mEq/L and >15% increase from 
baseline) was 1.03 (0.89, 1.20) and for serum potassium ≥6.5 mEq/L was 0.84 (0.50, 1.41). 
Generally similar results were seen in subgroups by baseline eGFR (<45, 45-<60, & 
≥60 mL/min/1.73 m2; Table).
Conclusions: In the CANVAS Program, no significant differences in the risk of hypo- 
or hyperkalemia were observed with CANA versus PBO overall or in participants with
renal impairment.
Funding: Commercial Support - Janssen Research & Development, LLC
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Comparison Between Clinical Trial and Real-World Use of Sodium- 
Glucose Co-Transporter-2 Inhibitors According to CKD Status
Jung-Im Shin,1 Josef Coresh,1 Elizabeth Selvin,1 Lesley Inker,3 Alex R. Chang,2 
Morgan Grams.1 1Johns Hopkins University, Baltimore, MD; 2Geisinger Medical 
Center, Danville, PA; 3Tufts Medical Center, Boston, MA.
Background: Clinical trials typically enroll highly selective patient populations 
and often include few participants with chronic kidney disease (CKD). Our objective 
was to compare participants characteristics and outcomes in trials of sodium-glucose co-
transporter-2 inhibitors (SGLT-2i) with SGLT-2i users in real-world settings according to 
CKD status.
Methods: We compared characteristics, mortality, and HbA1c change at 12 weeks 
among SGLT-2i users in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular 
Outcome Event Trial in Type 2 Diabetes Mellitus Patients) with patients in the Geisinger 
Health System from June 2013 to January 2017 according to CKD status. CKD was 
defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 according to 
Modification of Diet in Renal Disease equation or macroalbuminuria.
Results: From 2013 to 2016, prescription of SGLT-2i increased in each category of 
eGFR (G1-2 [0.3% to 5.3%] and G3-5 [0.2% to 2%], all P<0.001). Compared to trial 
participants, real-world users of SGLT-2i were younger, more obese, with a much lower 
prevalence of coronary artery disease (Table). Real-world users had lower mortality than 
their counterparts in the trial, and these differences were present in patients with and without 
CKD. The magnitude of HbA1c reduction from baseline to 12 weeks was similar between 
trial participants and real-world users.
Conclusions: Despite the difference in baseline characteristics between trial and real-
world users, SGLT-2i appeared to have similar glucose-lowering effect in individuals with 
diabetes regardless of CKD status. Further research is warranted to investigate the effects of 
SGLT-2i on cardiovascular and kidney outcomes in patients with CKD.
Funding: Other NIH Support - T32HL007024
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Intensive Insulin Therapy Reduces Urinary Angiotensinogen in Type 1 
Diabetes: A Possible Mechanism of Renoprotection via Renin Angiotensin 
System (RAS) Downregulation
Sheeba H. Ba aqeel,1 Alejandro Sanchez,1 Minghao Ye,1 Jan Wysocki,1 
Mark E. Molitch,3 Daniel Batlle.2 1Northwestern University Feinberg School of 
Medicine, Chicago, IL; 2Northwestern University Feinberg School of Medicine, 
Chicago, IL; 3Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: Optimal glycemic control is well known to protect people with diabetes 
from developing kidney disease but the mechanism is unknown. Kidney angiotensinogen 
(AOG) gene expression has been shown to be regulated by glucose that stimulates AOG 
mRNA and also by insulin that inhibits glucose induced stimulation of AOG transcription 
in proximal tubule cells via an insulin responsive element that binds two transcription 
factors, hnRNP F & hnRNP K. We examined if in patients with type1 diabetes and 
microalbuminuria, urinary angiotensinogen (uAOG) is reduced by intensive insulin therapy. 
For this, we evaluated uAOG in biosamples from the Diabetes Control and Complications 
Trial (DCCT) participants with type1 diabetes and microalbuminuria allocated to either 
intensive or standard insulin therapy
Methods: Urine samples from DCCT participants provided by the NIDDK repository 
consisted of participants who had been allocated to intensive (n=58) or standard insulin 
(n=41) and had microalbuminuria at study entry. uAOG was measured after a median of 
5years of therapy (range 3-6) in both groups. Patients were not taking any medications such 
as RAS blockers that could have influenced uAOG results. Mann-Whitney test was used to 
measure the differences in levels of uAOG between the two groups
Results: At the study entry, there were no significant differences in age, gender, 
disease duration, blood pressure, GFR, albumin excretion rate and HbA1C between the 
two groups. At the study visit there were again no significant differences in age, gender, 
disease duration, blood pressure or GFR. Albumin excretion rate was also not significantly 
different. HbA1c was higher in the group on standard when compared to intensive therapy 
(median 8.9, range 5.7-9.2 vs 7.0, 6.8-12% P<0.001). uAOG was significantly decreased in 
participants on intensive compared to standard therapy (median 3.98, range 0.4-96 vs 7.4, 
range 1.3-295ng/mg, P=0.005)
Conclusions: In type1 diabetes with microalbuminuria, intensive insulin decreases 
uAOG when compared to standard insulin. This suggests that optimization of glycemic 
control with intensive insulin, by suppressing uAOG downregulates kidney RAS 
overactivity and unravels an important mechanism for the well-known renoprotective effect 
of insulin in humans.
Funding: NIDDK Support
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Primary Efficacy Analyses from a Phase 2 Trial of the Safety and Efficacy 
of Bardoxolone Methyl in Patients with Type 1 Diabetes
Arnold L. Silva,1 Ahmed M. Awad,5 Geoffrey A. Block,2 Melanie Chin,3 
Colin J. Meyer,3 Kevin Schroeder,6 Pablo E. Pergola.4 1Boise Kidney & 
Hypertension Institute, Meridian, ID; 2Colorado Kidney Care, Denver, CO; 
3Reata Pharmaceuticals, Irving, TX; 4Renal Associates, PA, San Antonio, TX; 
5Clinical Research Consultants, LLC, Kansas City, MO; 6Ohio Kidney 
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Background: Bardoxolone methyl (BARD) has been shown to significantly increase 
eGFR in patients with CKD and type 2 diabetes or Alport syndrome suggesting that the 
anti-inflammatory and anti-fibrotic effects of BARD may target the common pathways 
contributing to GFR loss in multiple forms of CKD. As a result, a Phase 2 trial (PHOENIX, 
NCT03366337) was initiated to test the hypothesis that BARD will improve kidney 
function in patients with CKD due to type 1 diabetes mellitus (T1DM) as well as other 
forms of CKD.
Methods: The Phase 2 open-label, multicenter study enrolled a cohort of patients 
T1DM confirmed by fasting C-peptide levels. Eligible patients were 18 to 65 years of age 
with eGFR values between 30 to 90 mL/min/1.73 m2 and urine albumin to creatinine ratio 
(UACR) ≤ 2500 mg/g. Patients received BARD at an initial dose of 5 mg, dose-escalated to 
20 mg (for patients with baseline UACR ≤ 300 mg/g) or to 30 mg (for patients with baseline 
UACR > 300 mg/g) and were treated for 12 weeks. The primary efficacy endpoint was 
the change from baseline eGFR after 12 weeks of treatment. Interim results for the cohort 
enrolling patients with T1DM are described herein.
Results: At data cutoff on May 15th, 2018, 3/19 (16%) of the enrolled patients with 
T1DM had completed the study. From a mean (± SE) baseline eGFR of 68.2 ± 3.8 mL/
min/1.73 m2, BARD treatment resulted in a significant increase from baseline in eGFR of 
7.9 ± 2.9 mL/min/1.73 m2 (p=0.008) at Week 12. No patients have discontinued from the 
study and no serious AEs considered related to BARD have been reported in this ongoing 
trial.
Conclusions: BARD was generally well tolerated and significantly increased eGFR in 
patients with T1DM. In patients with other forms of CKD, short term eGFR increases with 
BARD are predictive of durable eGFR improvements and additional studies are needed to 
study the longer-term effects of BARD on eGFR in T1DM.
Funding: Commercial Support - Reata Pharmaceuticals
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Disease Characteristics and Outcomes in Patients with CKD and Type 2 
Diabetes: A Matched Cohort Study of Spironolactone Users and 
Non-Users
Michael Blankenburg,1 Csaba P. Kovesdy,2 Anne-Kathrin Fett,3 Emile Schokker,4 
Alain Gay.5 1Bayer Pharma AG, Berlin, Germany; 2University of Tennessee 
Health Science Center, Memphis, TN; 3QuintilesIMS, Frankfurt, Germany; 
4IQVIA, Frankfurt, Germany; 5Bayer, BERLIN, Germany.
Background: This study aimed to assess disease characteristics and outcomes in 
cohorts of spironolactone users and non-users with chronic kidney disease (CKD) and type 
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2 diabetes (T2D) who were matched on demographic and clinical characteristics, including 
CKD stage.
Methods: Patients with CKD and T2D were identified in the US claims database 
PharMetrics Plus using ICD-9 and ICD-10 codes. Outcomes of interest including CKD 
progression, clinical events, healthcare use and costs were described in the matched cohorts 
using summary statistics; mortality analyses were conducted in a sub-cohort with linkable 
data in Experian. The impact of persistent or non-persistent spironolactone use (≥6 vs. <6 
months treatment duration) was also evaluated.
Results: The matched cohorts (n=5,465 each) both had a median age of 62 years and 
61% of patients were male. Despite matching, spironolactone users had more comorbidities 
at baseline than non-users (Charlson comorbidity index score 4+, 89% vs. 78%). During 
one-year of follow-up, progression to a more severe CKD stage occurred in 30% of 
spironolactone users and 18% of non-users. Annual median healthcare costs per person 
were $33,013 for spironolactone users and $22,598 for non-users; 62% and 50% of patients 
had at least one inpatient visit, respectively. The mortality rate per person-year was 4% 
for spironolactone users and 7% for non-users; however, the mortality rate assessment 
was conducted in a younger sub-cohort with lower rates of heart failure (n=1,431 each). 
Persistent spironolactone users had fewer clinical events, lower healthcare use and costs and 
a reduced likelihood of CKD progression than non-persistent users.
Conclusions: In this study, spironolactone users were more severely ill, had worse 
clinical outcomes and higher healthcare use and costs than non-users. These findings 
highlight the unmet medical need in this patient population and the need for better treatment 
options.
Funding: Commercial Support - Bayer AG
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Low Dose Anti-Thromboxane Reduces Urinary Albumin in Patients with 
Diabetic Kidney Disease
Eva Steiness,1 Nikolai Brun,1 Torben Skarsfeldt,1 Karl M. Derwahl.2 1Serodus, 
Oslo, Norway; 2Ikfe Berlin, Berlin, Germany.
Background: Thromboxane facilitates coagulation but is also a pro-inflammatory 
endogenous agent. SER150 is an oral, small molecule with a novel dual mode of action 
that inhibits thromboxane synthase and simultaneously blocks the thromboxane receptor. 
SER150 inhibited thrombocytes agglutination both in healthy and diabetic patients. Studies 
in healthy volunteers and in patients with Type 2 diabetes doses from 0,375 to 2,5 mg/kg 
body weight, SER150 dose-dependently increased bleeding time from insignificant values 
and up to 294 seconds after the highest dose investigated. However, a dose of 0,16 mg/kg 
insignificantly attenuated bleeding time compared to placebo and insignificantly reduced 
agglutination of ex-vivo stimulated (U16466) thrombocytes for few minutes.
Methods: A double-blind, placebo-controlled, clinical study included 49 diabetic 
patients with HbA1c of 7,08 mmol/mol, blood pressure of 132/75 mmHg and urine albumin 
> 30 mg/g creatinine (ACR). The patients were treated with SER150 at doses of either 15 
mg BID or 30 mg BID (0,16mg/kg or 0,32mg/kg BID) for 4 weeks.
Results: SER150 treatment caused ACR gradually to decrease during the 4 weeks and 
was statistically significant reduced from baseline (p<0,02 and p<0.04 respectively). 25% of 
patients with micro-albuminuria at baseline (ACR >30 £300) became normo-albuminuric 
during the 4 weeks on SER150 treatment. All patients with macro-albuminuria (ACR >300) 
experienced a decrease in urinary albumin and 45% shifted from macro-albuminuria to 
micro-albuminuria.
Conclusions: These findings suggest two different sites of action with different dose-
efficacy relation of the anti-thromboxane agent SER150. One at the thrombocytes and one 
at different, still unknown, site of action in the kidney at sites essential for the damage of 
renal filtration barrier in patients with diabetic kidney disease. The aim of the next clinical 
study is to confirm SER150 induced decrease in ACR in patients with diabetes and macro-
albuminuria (ACR >500). Furthermore, to demonstrate that decrease in ACR is maintained 
over time (6 month) with a dose of 15 mg BID. The primary endpoint will be a composite 
of ACR and a group of relevant renal surrogate markers.
Funding: Commercial Support - Serodus ASA, Norway
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Randomized Placebo-Controlled Trials of Tangshen Formula in Diabetic 
Kidney Disease
Meihua Yan, Ping Li. China-Japan Friendship Hospital, Beijing, China.
Background: Patients with diabetic mellitus are at high risk of progressing into diabetic 
kidney disease (DKD), which is associated with high morbidity and mortality. Current drug 
therapies for DKD are not entirely satisfactory. Tangshen Formula (TSF) is a Chinese herbal 
medicine remedy for DKD based on empirical evidence gleaned from Chinese medicine 
practitioners.The multinational, randomized, double-blind, placebo controlled trials of TSF 
Treatment on DKD (TTD)-1 and TTD-2 evaluated the effects of TSF on DKD when added 
to standard therapy.
Methods: In TTD-1 trial, we randomly assigned 180 DKD patients with mild to 
moderate disease (urinary albumin excretion rate (UAER) >20 μg/min, and/or 24-hour 
urinary protein (24h UP) between 0.5 and 2.0 g/d, and estimated glomerular filtration 
rate(eGFR) between 60 ml/min and 130 ml/min) to receive either placebo or TSF. In 
TTD-2 trial, 146 DKD patients with moderate to severe disease (24h UP between 0.5 and 
3.5 g/d, and serum creatinine < 265 μmol/L (3 mg/dl)) to receive either placebo or TSF. 
Each trial continued intervention for 24 weeks. Primary outcome was urinary protein level, 
measured by UAER for participants with microalbuminuria, 24h UP for participants with 
macroalbuminuria. Secondary outcomes included renal function, serum lipids, quality of 
life, symptoms, and adverse events.
Results: For participants with macroalbuminuria, TSF displayed a statistically 
significant decrease in 24h UP in TTD-1(TSF −0.21 compared with placebo 0.36g, with 
a mean difference of −0.57g; 95% CI, −1.05 to −0.09, P=0.024), while no statistically 
significant difference was found in TTD-2(TSF 0.74 compared with placebo 0.21 g, with 
a mean difference of 0.55g; 95% CI, -0.03 to 1.13, P=0.111). The eGFR was improved in 
both trials (TTD-1: TSF 1.96 compared with placebo −7.05 ml/min/1.73m2, with a mean 
difference of 9.01 ml/min/1.73m2, 95% CI, −0.10 to 18.13, P=0.031) (TTD2: TSF 4.22 
compared with placebo -4.8 ml/min/1.73m2, with a mean difference of 7.8 ml/min/1.73m2, 
95% CI, 2.10 to 12.68, P=0.016). Other secondary outcomes showed no statistically 
significant difference between groups or in the incidence of adverse events in both trials.
Conclusions: TSF appears to provide additional benefits in improving eGFR in DKD 
patients, based on conventional treatments. Trial Registration TTD-1:Chinese Clinical Trial 
Registry ChiCTR-TRC-10000843 TTD-2: ChiCTR-TRC-13003566
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Tie2 Activation via VE-PTP Inhibition for Treatment of Diabetic Kidney 
Disease
Kevin G. Peters, Mitchell Brigell, Steve Pakola. Aerpio Pharmaceuticals, 
Cincinnati, OH.
Background: Considering the current epidemic of diabetes, new treatments for 
diabetic vascular complications, including diabetic kidney disease (DKD) are urgently 
needed. VE-PTP is a vascular endothelial receptor tyrosine phosphatase that negatively 
regulates Tie2 activation, a critical axis for maintaining endothelial function and vascular 
stability. Importantly, VE-PTP is upregulated by hyperglycemia and hypoxia, conditions 
associated with decreased Tie2 activation and progression of diabetic complications. Thus, 
targeting VE-PTP inhibition to restore Tie2 activation is a promising approach to treat 
diabetic vascular complications, including DKD. Here we report results from a post-hoc 
analysis demonstrating improvement in UACR in patients with diabetic eye disease treated 
for three months with AKB-9778, a potent and selective small molecule VE-PTP inhibitor.
Methods: The TIME-2 study was a Phase 2a, double-masked, parallel-group trial in 
which 144 patients with diabetic retinopathy complicated by diabetic macular edema were 
randomized to one of three treatment groups: AKB-9778 (15 mg) subcutaneous (SC) BID 
monotherapy plus sham intravitreal injection; AKB-9778 SC BID plus monthly Lucentis 
(0.3mg) intravitreal injection; and placebo SC BID plus monthly Lucentis intravitreal 
injection monotherapy. Although the study was designed to assess the effect of AKB-
9778 on diabetic eye disease, UACR was measured at baseline and at end of the 3-month 
treatment period. Patients with increased UACR at baseline (UACR ≥30 mg/g) were 
included in the analysis.
Results: About 50% of patients in the study had UACR ≥30 mg/g at baseline, 
approximately equally distributed among the three treatment groups. There was an ~ 20% 
reduction in geometric mean UACR from baseline in both AKB-9778 active treatment 
arms, while there was an increase in UACR in the placebo arm (Figure 1).
Conclusions: These findings represent the first clinical evidence of potential beneficial 
effects of a VE-PTP inhibitor in patients with DKD and underscore the therapeutic potential 
of Tie2 activation in DKD and other diabetic vascular complications.
Funding: Commercial Support - Aerpio Pharmaceuticals, Inc.
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Effects of Senolytic Agents on Blood- and Urine-Borne Extracellular 
Vesicles from Senescent Cells in Diabetic Kidney Disease: A Pilot Study
LaTonya J. Hickson,1 James L. Kirkland,2 Kumar Sanjay,3 Tamara Tchkonia,2 
Stephen C. Textor,2 Lilach O. Lerman,4 Muthuvel Jayachandran.2 1Division of 
Nephrology and Hypertension, Mayo Clinic, Rochester, MN; 2Mayo Clinic, 
Rochester, MN; 3Mayo Clinic, Rochester, MN, Rochester, MN; 4Mayo Clinic 
College of Medicine, Rochester, MN.
Background: Cellular senescence, from DNA damages leading to cell cycle arrest 
and increased expression of p16, contributes to the pathogenesis of diabetic kidney disease 
(DKD). Affected blood and kidney cells generate pro-inflammatory cytokines causing 
kidney injury. Extracellular vesicles (EV) shed by cells represent novel biomarkers of 
disease and disease activity. We tested the hypothesis that clearance of senescent cell 
abundance via senolytic agents would decrease markers of senescence, inflammation and 
kidney injury which could be identified through EV examination.
Methods: DKD subjects were randomized to senolytic drugs (n=5; a single 3-days 
oral regimen) vs “no treatment” (n=2). EVs were characterized and quantified in platelet-
free plasma and cell-free urine sampled at Days 0, 14, and 120 by standardized digital 
flow cytometer methods using fluorophore conjugated preselected markers specific 
antibodies: senescence (p16), inflammation (CD45), kidney injury (KIM-1, NGAL). A 
non-EV (soluble) plasma biomarker of DKD progression, tumor necrosis factor receptor-1 
(TNFR-1), was also measured.
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Results: Of 7 male subjects, mean age was 71±6 years and eGFR 29±10 mL/
min/1.73m2. Over 120 days, treated subjects had decreased levels of inflammatory and 
senescent cell-derived EVs in plasma while untreated subjects showed progressive increases 
(Figure). Plasma TNFR1 biomarker levels did not differ. Similarly, senescent cell-derived 
urinary EVs and kidney injury marker (KIM-1 and NGAL) positive urine EVs tended to fall 
over time in treated while EVs rose in untreated subjects.
Conclusions: These early pilot study findings suggest that senolytic agents may 
attenuate progression of senescent cell abundance, inflammation, and kidney injury in 
patients with DKD.
Funding: NIDDK Support, Private Foundation Support
Inflammatory and senescent-cell derived EVs in DKD subjects by senolytic-treated 
and untreated groups
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Patient Motivation Scoring and Outcomes in the Diabetes CKD Clinic
LaTonya J. Hickson,1 Bjoerg Thorsteinsdottir,2 Kristin C. Mara,3 
Sudhi Upadhyaya,4 Minji Lee,4 Ladan Zand,1 Felicity T. Enders,3,4 
Vincent J. Canzanello.1 1Nephrology and Hypertension, Mayo Clinic, Rochester, 
MN; 2Primary Care Internal Medicine, Mayo Clinic, Rochester, MN; 3Health 
Sciences Research, Mayo Clinic, Rochester, MN; 4Center for the Science of 
Health Care Delivery, Mayo Clinic, Rochester, MN.
Background: Given the global CKD burden, innovative methods to improve patient’s 
perception of autonomy and self-care are needed. We examined the association of variables 
in a patient motivation “Kidney and Heart Health” (KHH) Scoring system on CKD 
progression.
Methods: Diabetic-CKD (DM-CKD) patients were treated in a single-center, 
specialized clinic combining consultation from 1) hypertension-trained nurses and 2) 
physician/advanced practitioners. At each visit, patients were assigned points for meeting 
lifestyle (tobacco use, weight loss, alcohol use, exercise, and healthy diet) and objective 
(blood pressure, hemoglobin, LDL cholesterol, bone mineral metabolism, proteinuria, 
hemoglobin A1c, aspirin use) goals. CKD progression composite endpoint was defined as 
eGFR<10, dialysis, kidney transplant, or 40% reduction baseline eGFR. Time dependent 
cox hazards regression models examined the association between each KHH goal and CKD 
progression.
Results: From 2010-2016, 422 DM-CKD (eGFR 10-60mL/min/1.73m2 inclusion) 
patients were treated; 61% male, 91% white, mean Charlson index 8.7±3.5, mean eGFR 
31.8 ±12.1. Mean KHH score was 8.8±3.5 (out of 12). KHH categories with <75% patients 
reaching goal were: LDL (68%), weight (68%), bone metabolism (63%), exercise (51%), 
hemoglobin A1c (47%), and proteinuria (43%). Over 2.6 years (median), 177 met CKD 
progression composite endpoint (86 dialysis, 26 transplant, 53 eGFR <10, and 127 had 
40% reduction eGFR). 82 died. Univariate hazard ratios for each category are shown, 
Figure. Multivariable models revealed older age, achieving BP, LDL, hemoglobin, bone 
metabolism, and exercise goals significantly associated with lower risk of CKD progression 
while weight and lower eGFR associated with higher risk compared to those not meeting 
lifestyle or objective goals.
Conclusions: Patient motivation scores used in a specialty CKD clinic relate to 
observed DM-CKD progression outcomes.
Funding: NIDDK Support, Private Foundation Support
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Effect of Oral Sodium Bicarbonate on Urine TGF-β1 in Non-Acidotic 
Diabetic Kidney Disease (DKD)
Kalani L. Raphael,1,2 Tom Greene,2 Guo Wei,2 Alfred K. Cheung,1,2 
Srinivasan Beddhu.1,2 1VA Salt Lake City Health Care System, Salt Lake City, 
UT; 2University of Utah, Salt Lake City, UT.
Background: Oral NaHCO3 may preserve GFR in CKD patients with normal serum 
(s) HCO3
- by attenuating physiological responses that enhance H+ excretion to maintain
normal s-HCO3
-, but cause kidney fibrosis. Along these lines, urine (u) NH4
+ is directly
associated with uTGF-β1 in CKD. NaHCO3 reduces uNH4
+ and, in hypertensive CKD,
uTGF-β1. Whether NaHCO3 reduces uTGF-β1 in DKD is unknown.
Methods: We conducted a single-center, randomized, double-blinded, placebo-
controlled study in 74 US veterans with stage 2-4 DKD, ACR ≥30 mg/g, and s-HCO3
- 22-
28 meq/L. Participants received NaHCO3 (0.5 meq/kg-LBW/d, n=35) or placebo (n=39) 
for 6 months. The primary analysis applied a mixed effect model to compare mean Δ from 
baseline in uTGF-β1/Cr over 3- and 6-months after controlling for baseline uTGF-β1/Cr.
Results: Mean baseline values were age 71 years, eGFR 51 ml/min/1.73m2, SBP 
127 mm Hg, ACR (median) 121 mg/g, s-HCO3
- 24 meq/L, u-pH 5.5, uNH4
+ 1.4 meq/hr, and 
u-titratable acids (uTA) 1.3 meq/hr. Baseline characteristics were similar between groups.
NaHCO3 had expected effects on u-pH, u-TA, and s-HCO3
- but did not lower uNH4
+ (Table)
or uTGF-β1/Cr (Figure). NaHCO3 had no effect on ACR, however eGFR was higher with 
NaHCO3 (5.7 ml/min/1.73m
2, 95% CI 1.2-10.2). There were no significant differences in 
BP, weight, or s-K+ between groups during follow-up.
Conclusions: Oral NaHCO3 did not reduce uTGF-β1 or uNH4+ in persons with non-
acidotic DKD. The effect of NaHCO3 on kidney NH3 production may be attenuated in 
DKD, perhaps because kidney gluconeogenesis also produces NH3. NaHCO3 increased 
eGFR, however long-term effects of NaHCO3 on eGFR in DKD should be determined.
Funding: Veterans Affairs Support
Mean values of acid-base indices over 3- and 6-months by treatment group.
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Design of Pentoxifylline in Diabetic Kidney Disease (VA PTXRx)
David J. Leehey,1,2 Ian Craig,3 Domenic Reda,4 Kim Carlson,4 Todd A. Conner,5 
Rajiv Agarwal,6 James S. Kaufman,7 Robert Anderson,8 Grant D. Huang,9 
Nicholas Emanuele.1 1Hines VA Hospital, Hines, IL; 2Loyola University Medical 
Center, Maywood, IL; 3Perry Point Cooperative Studies Program Coordinating 
Center, Perryville, MD; 4Hines VA Cooperative Studies Program Coordinating 
Center, Hines, IL; 5VA CSP CRPCC, Albuquerque, NM; 6Roudebush VA 
Hospital, Indianapolis, IN; 7VA New York Harbor Healthcare System, New York, 
NY; 8Omaha VA Hospital, Omaha, NE; 9Director, Cooperative Studies Program 
(CSP), Washington, DC.
Background: Diabetic kidney disease (DKD) is the most frequent cause of chronic 
kidney disease (CKD) and end-stage renal disease (ESRD) in the U.S. Despite control of 
blood pressure and blockade of the renin-angiotensin-aldosterone system (RAAS), many 
patients continue to progress to ESRD, requiring costly dialysis or transplantation and 
resulting in high mortality. The non-specific phosphodiesterase inhibitor pentoxifylline 
(PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease. 
Recent experimental and clinical data suggest that PTX, when added to usual care, leads 
to a reduction in albuminuria and inflammation and may decrease progression of DKD. 
However, a large scale multicenter randomized clinical trial is needed to determine whether 
this agent can reduce hard endpoints such as ESRD and death in patients with DKD.
Methods: VA PTXRx is a randomized, controlled multicenter Veterans Affairs (VA) 
Cooperative Study to test the hypothesis that PTX, when added to usual care, leads to a 
reduction in the incidence of ESRD and death in type 2 diabetic patients with DKD when 
compared to usual care plus placebo. Secondary endpoints will be: (1) quality of life (2) 
time until doubling of serum creatinine, (3) hospitalization for congestive heart failure 
(CHF), (4) a three-point MACE (cardiovascular death, non-fatal myocardial infarction, 
non-fatal stroke), (5) peripheral vascular disease (PVD), (6) percentage of participants with 
≥ 50% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline, (7) Rate
of change in estimated glomerular filtration rate (eGFR) per year during the study period. 
Drug safety will also be analyzed as a secondary outcome. The key statistical assumption is 
that the primary endpoint will occur in 26.6% of the placebo group at six years with a risk 
reduction of 19% for PTX compared with the placebo group. The study aims to randomize 
2510 participants to either PTX or placebo. The expected event rates were estimated using 
retrospective data from a cohort of veterans meeting study inclusion criteria obtained from 
a nationwide VA database.
Results: N/A
Conclusions: If PTX is found to reduce the incidence of ESRD and/or death with 
an acceptable safety profile, this will reduce the personal and financial burden of renal 
replacement therapy for patients with DKD.
Funding: Veterans Affairs Support
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Pharmacokinetic-Pharmacodynamic Relationships for the Effect of 
Selonsertib on eGFR in a Phase 2 Study in Subjects with Diabetic Kidney 
Disease
Brian J. Kirby, Cara H. Nelson, Andrew Billin, Fang Chen, Uptal D. Patel, 
Anita Mathias. Gilead Sciences, Inc., Foster City, CA.
Background: Selonsertib (SEL) is a first-in-class, small molecule apoptosis signal-
regulating kinase 1 (ASK1) inhibitor in clinical development for the treatment of diabetic 
kidney disease (DKD) and nonalcoholic steatohepatitis. In a Phase 2 dose ranging study 
in subjects with Stage 3a to 4 DKD, SEL was safe and well tolerated, showed a dose- 
dependent acute reduction in eGFR (baseline to WK4, as a result of inhibition of renal 
creatinine secretion), and at the 18 mg dose resulted in 75% reduction in the slope of 
chronic eGFR decline (WK4 to WK48) compared to placebo. This analysis characterizes 
the pharmacokinetic-pharmacodynamic (PK/PD) relationships observed in this study.
Methods: Subjects were administered 2, 6, or 18 mg SEL, or placebo once daily for 
48 WKs. Serum creatinine based eGFR was assessed at baseline and throughout treatment. 
Samples were collected for plasma exposure of SEL (AUCtau by population PK) and 
phosphorylation status of p38 (%P-p38: downstream marker of ASK1 inhibition) in blood. 
PK/PD relationships for SEL exposure, %P-p38 and eGFR were characterized.
Results: 260 subjects with measureable SEL AUCtau,%P-p38, and eGFR estimates 
were included in this analysis. SEL PK/PD relationships (figure) depict the acute and 
chronic changes in eGFR versus SEL exposure or dose (A) and %P-p38 (B), respectively. 
Mean exposure from SEL 18 mg provided near maximal %P-p38 inhibition (74% of Emax), 
and resided on the flat portion of the exposure-response curve for effect on chronic eGFR 
slope.
Conclusions: These PK/PD analyses provide further understanding of the relationships 
between SEL, ASK1 pathway inhibition, acute change and chronic slope of eGFR, 
supporting further clinical evaluation of the safety and efficacy of SEL 18 mg in subjects 
with DKD.
Funding: Commercial Support - Gilead Sciences Inc.
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Toxic Renal Effects from Intravitreal Bevacizumab for Proliferative 
Diabetic Retinopathy in the Patients with Chronic Diabetic Kidney 
Disease
Anita Kamarzarian,1 Adrian Au,3 Madeline Yung,4 Kirollos E. Zaki,5 
Cameron Pole,4 Golriz Jafari,2 Phuong-Chi T. Pham.2 1UCLA -Olive View 
Medical Center, La Canada, CA; 2UCLA-Olive View Medical Center, Los 
Angeles, CA; 3University of California, Los Angeles, Los Angeles, CA; 4UCLA, 
Los Angeles, CA; 5Olive View - UCLA Medical Center, Sylmar, CA.
Background: Intravitreal injection of Bevacizumab, a monoclonal antibody directed 
against the vascular endothelial growth factor (VEGF), has revolutionized the management 
of proliferative diabetic retinopathy and diabetic macular edema. Here we evaluate the 
effects of intravitreal bevacizumab on renal parameters.
Methods: This study is a consecutive case-control retrospective study performed from 
January 01, 2016 to January 01, 2017 at the Olive View-UCLA Medical Center. An initial 
screening of all 2763 encounters in the outpatient adult renal clinic during the study period 
was performed to identify patients with proliferative Diabetic retinopathy (PDR) recieving 
bevacizumab intravitreal injections and were age matched controls with dilated fundoscopic 
exams demonstrating sin diabetic retinopathy (sDR), non-proliferative diabetic retinopathy 
(NPDR), or PDR without bevacizumab. T0 is defined as the first injection of bevacizumab. 
The average follow-up prior to T0 was empirically determined to be 13.15 months. Data 
collected from EMR and statistical tests were performed on Microsoft Excel.
Results: Patients treated with bevacizumab had significantly higher incidence of 
dialysis with 50% requiring dialysis as compared to 7.1% in NPDR and PDR groups. After 
injection the eGFR decline over 12 months in the bevacizumab group was twice as rapid 
as PDR without bevacizumab (p=0.02) and four times as rapid as NPDR (p = 2.67E-0.5). 
There was an increase in the amount of anti-hypertensive medications used to manage HTN 
from 1.9 ± 1.2 to 3.2 ± 1.3 (p=0.01)
Conclusions: Diabetic patients with diabetic CKD receiving intraocular anti-VEGF 
therapy have more rapid rate of progression of their CKD, have higher incidence of dialysis 
initiation and require more antihypertensive medications. We also noted both progression 
and higher level of proteinuria but could not capture this effect statistically based on our 
study scale.
Figure 1. Rate comparison for e-GFR change between groups
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Effect of Bariatric Surgery on Renal Function in Morbidly Obese Patients
Anil Bhalla, Ashwani Gupta, Aakash Shingada, Anurag Gupta, Vinant Bhargava, 
Lovy Gaur, Anant Joshi, Devinder S. Rana. Nephrology, Sir Ganga Ram 
Hospital, New Delhi, India.
Background: Morbid obesity is associated with glomerular hyperfiltration, which 
favours the occurrence of proteinuria. We studied the effect of bariatric surgery on renal 
function in morbidly obese patients at 6 months post surgery.
Methods: This was a prospective observational study of 75 patients who underwent 
laparoscopic sleeve gastrectomy for weight reduction. Baseline pre-surgery BMI was 
calculated and serum creatinine, HbA1C level, 24 hour urinary protein excretion and 
creatinine clearance(CrCl) was estimated. Investigations were repeated 6 months post 
surgery to assess change in the renal parameters.
Results: Mean age was 38.8 years (60% females, 40% males). 51.5% patients were 
hypertensive & 17.6% had diabetes mellitus. Mean weight before bariatric surgery was 
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119.93kg with a reduction of 25.60kg (21.34%) at 6 months post surgery (p<0.0001). 
Mean BMI before surgery was 45.13 kg/m2 with a reduction of 9.79 kg/m2 (21.69%) at 6 
months post surgery(p<0.001). Mean serum creatinine before surgery was 0.82 mg/dl with a 
reduction of 0.08 mg/dl (9.75%) 6 month post surgery (p<0.001). Mean pre-op HbA1c was 
6.3% with a reduction of 0.74% (11.7%) at 6 months post surgery (p<0.001). Mean CrCl 
before surgery was 140.69 ml/min with a reduction of 22.89 ml/min (16.2%) 6 month post 
surgery (p<0.0001). Mean proteinuria before surgery was 224.82 mg/d with a reduction 
of 57.98 mg/dl (25.77%) 6 month post surgery (p<0.0001). Mean albuminuria before 
bariatric surgery was 62.53 mg/day with a reduction of 17.35 mg/day (27.74%) 6 months 
post surgery (p<0.0001). Sub-group analysis showed that pre-operative CrCl was higher in 
diabetics (144.50 ml/min vs 139.88 ml/min), but the reduction in creatinine clearance was 
similar between the two groups (p-0.092). Mean baseline proteinuria was higher in diabetics 
(331.25 mg/day vs 202.02 mg/day) and reduction in proteinuria at 6 month post op was 
more in diabetics (128.92 mg/day (38.91%) vs 42.79 mg/day (21.18%), p-0.001).
Conclusions: This study shows that obesity related glomerular hyperfiltration improves 
significantly after bariatric surgery with significant decline in proteinuria. The improvement 
in hyperfiltration may prevent the development of overt obesity related glomerulopathy.
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Acute Hyperoxia and Slow Deep Breathing Improve Baroreflex Sensitivity 
in Long-Duration Type 1 Diabetes Irrespective of Macroalbuminuria
Jens christian Laursen,1 Christian S. Hansen,2 Marco Bordino,3 Emilie Hein 
Zobel,2 Signe Abitz Winther,1 Per-Henrik Groop,3 Marie Frimodt-Moller,1 
Peter Rossing.1 1Steno Diabetes Center Copenhagen, Gentofte, Denmark; 2Steno 
Diabetes Center, Gentofte, Denmark; 3University of Helsinki and Helsinki 
University Hospital, Helsinki, Finland.
Background: In previous studies, hyperoxia and slow deep breathing (SDB) acutely 
improved measures of autonomic dysfunction in young patients with type 1 diabetes (T1D) 
and in patients with type 2 diabetes (T2D). Such effects have not been addressed in patients 
with T1D and concomitant macroalbuminuria and/or existing autonomic dysfunction. The 
aim of this study is to examine the effect of acute oxygen inhalation and SDB on measures 
of autonomic dysfunction and whether these could be modified by albuminuria or existing 
autonomic dysfunction.
Methods: Fifty-four patients with T1D (57% male) were enrolled in a cross-sectional 
study where 29 patients had normoalbuminuria and 25 had presence of/or historical 
macroalbuminuria. Mean age (SD) and diabetes duration were 59.8 years (9.5) and 37.5 
years (14.4) respectively. Patients were exposed to acute oxygen inhalation and SDB, 
while obtaining measures of autonomic function and blood oxygen saturation. Autonomic 
function was assessed by baroreflex sensitivity (BRS) and the standard deviation of the 
normal-normal intervals (SDNN).
Results: Acute oxygen inhalation was associated with an increase of 21.3% (95%CI 
9.8;34) and 8.3% (95%CI 0.1;17) in BRS (ms/mmHg) and SDNN (ms) respectively. SDB 
was associated with an increase of 31.6% (95%CI 13.2;5) and 32.8% (95%CI 18.2;49.1) in 
BRS (ms/mmHg) and SDNN (ms) respectively. Combined oxygen inhalation and SDB was 
associated with an increase of 29.8% (9.8;53.4) and 44.2% (95%CI 27.1;63.5 in BRS (ms/
mmHg) and SDNN (ms) respectively. Patients with existing autonomic dysfunction had 
an improved effect of combined interventions on BRS. Albuminuria or existing autonomic 
dysfunction did not modify any other associations.
Conclusions: Hyperoxia and SDB improve BRS and SDNN in T1D even in the 
presence of macroalbuminuria and existing autonomic dysfunction. This suggests that 
hypoxia might be involved in the pathogenic mechanisms of autonomic dysfunction in 
T1D. Further studies exploring the pathological pathways causing tissue hypoxia may 
improve the understanding of diabetic neuropathy.
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Both High Levels of Hb1Ac and HbA1c Variability Are Associated with 
Increased Risk of All-Cause Mortality in Patients with Diabetes and 
Maintenance Dialysis
Hanri Afghahi,1 Salmir Nasic,2 Helena Rydell,5 Bogdan S. Matei,4 
Johan Svensson.3 1Nephrology, Skaraborgs hospital, Skövde, Sweden; 
2Skaraborg hospital, Skövde, Sweden; 3Skaraborg Central Hospital, Skövde, 
Sweden; 4Skaraborgs Hospital, Skövde, Sweden; 5Karolinska University 
Hospital, Stockholm, Sweden.
Background: Little is known of the association between variability of glycemic control 
and the risk of all-cause mortality in patients with diabetes and maintenance dialysis. Aim: 
We assessed the relationship between long-term glycemic control, as estimated using 
mean values and variability of blood HbA1c, and the risk of all-cause mortality in diabetic 
patients on chronic dialysis.
Methods: We included 3930 patients (age 65±14 years, 63% men) with diabetes (type 
1 or 2) and regular dialysis treatment [hemodialysis (HD), n = 2487 (63%); peritoneal 
dialysis (PD), n = 796 (20%); and both HD and PD, n = 647 (17%)]. Data were available 
from the Swedish Renal Register (SNR); the follow-up period was 2008 - 2017 (mean 
follow-up: 2.3± 2.2 years). HbA1c was defined as the mean of the reported values. HbA1c 
variability was determined by the coefficient of variation (CV), calculated as the ratio 
between the standard deviation (SD) and the mean HbA1c, HbA1c(SD)/HbA1c(mean). 
Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using time-
dependent Cox models, which included adjustments for demographics, laboratory findings 
and comorbidity.
Results: During follow-up, 2027 (52%) deaths occurred. We used HbA1c 31-42 mmol/
mol (5- 6%) as reference group. The multivariate Cox analyses showed increased mortality 
risk for HbA1c 62-72 mmol/mol (7.8-8.7%; HR 1.40, 95% CI 1.17 - 1.65) and HbA1c 73-
82 mmol/mol (8.8-9.7%; HR 1.70, 95% CI 1.34 - 2.13) (both P<0.001). In a subanalysis of 
2061 patients, we estimated the association between HbA1c variability and the risk of death. 
HbA1c CV< 0.5 was used as reference group. In the multivariate Cox analyses, HbA1c CVs 
of 2.84-4.60 and > 4.6 were associated with increased risk of mortality (HR 1.98, 95% CI 
1.54- 2.47 and HR 1.99, 95% CI 1.54- 2.57, respectively) (both P<0.001).
Conclusions: We did not find a J-shaped relation between HbA1c level and risk of 
mortality in dialysis patients with diabetes. Instead, low mean HbA1c was associated with 
improved survival, and HbA1c variability was strongly associated with increased risk of 
all-cause mortality. These findings suggest that glycemic control as well as the stability of 
glycaemia level are important in patients with diabetes and maintenance dialysis treatment.
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Glycated Hemoglobin and Serum Fructosamine as Indicators of Glycemic 
Status in Patients with Type 2 Diabetes and CKD
Lubaina Presswala, Yael T. Harris, Susana Hong, Kenar D. Jhaveri, 
Vipulbhai Sakhiya, Meng Zhang, Steven Fishbane. CGM Study Department of 
Medicine, Zucker School of Medicine at Hofstra / Northwell, Great Neck, NY.
Background: Among patients with type 2 diabetes mellitus (T2DM) and nondialysis 
chronic kidney disease (n-CKD) it is unclear whether measures of chronic glycemia, 
HbA1C and serum fructosamine (SF), are accurate. Previous studies have been of very 
small sample size or failed to use continuous glucose monitoring (CGM), relying instead 
on a few random glucose levels. The purpose of this study was to determine the accuracy of 
HbA1C and SF in T2DM and n-CKD by relating to CGM data.
Methods: We studied 60 patients with T2Dm and n-CKD defined as eGFR 0-45 
ml/min. Patients wore the CGM (Abbott FreeStyle Libre Pro) for 14 days, with glucose 
recorded every 15 minutes (maximum of 1,344 glucose measurements). Blood tests were 
drawn in the fasting state after the 14 day CGM. HbA1C and SF were compared by linear 
regression to patients’ average glucose concentration (AGC) calculated as all of a patient’s 
CGM glucose results divided by the total number of measurements.
Results: 60 patients wore the CGM for a mean of 12.7±2.9 days. Mean age was 
72.4±10.4 years, 75% of patients were men, 15% were black, and mean eGFR 25.6±10.5. 
The mean glucose concentration was 152.2±56.6 mg/dL, mean HbA1C 7.1±1.5% and SF 
301.9±57.7 μmol/L. HbA1C was significantly correlated with AGC, r=0.83, p<0.0001. The 
relationship was characterized by the formula, AGC=31.8 x HbA1C - 73.3. A sensitivity 
analysis among the 39 patients with eGFR < 30 ml/min. HbA1C remained significantly 
correlated with AGC, r=0.80, p=0.01 in these patients. There was no significant correlation 
between serum fructosamine and AGC, r=0.54, p=0.8.
Conclusions: HbA1C, but not serum fructosamine, was an excellent measure of 
chronic glycemic control among patients with type 2 diabetes and CKD. Further studies 
with larger sample sizes would be helpful to confirm these findings.
Funding: Clinical Revenue Support
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BP and Hemoglobin A1c Threshold Associated with Higher Prevalence of 
CKD in Elderly People with Diabetes
Jee eun Park,2 Eun jeong Lee,1 Wooseong Huh,3 Dae Joong Kim,3 Jung eun Lee.3 
1Samsung Medical Center, Seoul, Seoul, Republic of Korea; 2Kangwon National 
University Hospital, Chuncheon, Republic of Korea; 3Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background: Chronic kidney disease (CKD) is a major health problem in elderly 
with diabetes. The study examined the clinical parameters associated with CKD in elderly 
diabetes, stratified by age groups.
Methods: Total 3068 patients with diabetes ≥ 65 years old (YO) were identified. CKD 
was defined as albuminuria or eGFR < 60mL/min/1.73m2. CKD prevalence was analyzed 
according to age (65-69, 70-74, ≥75 YO), HbA1c (<6.5%, intermediate, ≥7.5%) and blood 
pressure (BP) (<130/80, intermediate, ≥140/90mmHg).
Results: CKD prevalence increased with age (65-69 YO group: 40%, 70-74 YO 
group: 51%, ≥75 YO group: 67%, P < 0.001). CKD prevalence increased with HbA1c in 
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65-69, 70-74 YO group, but not in ≥75 YO group (P<0.001, P<0.001 and P=0.081 for 
trend, respectively). With higher BP levels, CKD prevalence also increased in 65-69, 
70-74 YO group, but not in ≥75 YO group (P=0.002, P<0.001 and P=0.281 for trend, 
respectively). Multivariate analysis showed that age, sex, body mass index, HbA1c ≥7.5%, 
BP ≥140/90mmHg, diabetes duration were associated with CKD. However, when stratified 
by age, higher HbA1c and BP were not associated with risk of CKD in subjects ≥75 YO 
(Table 1).
Conclusions: Overall, the thresholds associated with increased prevalence of CKD 
were 7.5% for HbA1c level and 140/90 mmHg for BP in elderly diabetes. However, the 
association of CKD with BP and HbA1c levels were not evident in subjects ≥75 YO.
Table 1. Multivariate logistic regression analysis to examine the associations between 
covariates and chronic kidney disease
OR, Odds ratio; CI, Confidential interval; BP, Blood pressure; ref., reference
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Anemia Modifies the Associations Between Hemoglobin A1c and 
Outcomes in CKD
Molly Jung,1 Elizabeth Selvin,10 Casey Rebholz,2 Clare Lee,13 Jing Chen,3 
Jiang He,4 Chi-yuan Hsu,5 James P. Lash,6 Madhumita J. Mohanty,14 
Sankar D. Navaneethan,7 Sylvia E. Rosas,11 Elias Spanakis,12 Matthew R. Weir,8 
Tariq Shafi.9 1Johns Hopkins University, Baltimore, CA; 2Johns Hopkins 
University, Baltimore, MD; 3Tulane School of Medicine, New Orleans, LA; 
4Tulane School of Public Health and Tropical Medicine, New Orleans, LA; 
5University of California San Francisco, San Francisco, CA; 6University of 
Illinois at Chicago, Chicago, IL; 7Baylor College of Medicine, Sugar Land, TX; 
8University of Maryland School of Medicine, Baltimore, MD; 9Johns Hopkins 
University, Baltimore, MD; 10Johns Hopkins University, Baltimore, MD; 11Joslin 
Diabetes Center, Boston, MA; 12University of Maryland, Baltimore, MD; 13Johns 
Hopkins University, Baltimore, MD; 14Wayne State University, Detroit, MI.
Background: CKD and diabetes commonly co-occur. However, glycemic control and 
glycemic targets in these patients remain undefined.
Methods: In 1,833 participants of the Chronic Renal Insufficiency Cohort with 
diabetes, we assessed the association between baseline hemoglobin A1c (A1c) and death, 
first cardiovascular disease (CVD) event, and CKD progression using multivariable-
adjusted Cox models. We also investigated: a) effect modification by anemia, eGFR, or 
albuminuria; and b) linearity of the association using spline models.
Results: At baseline, mean age was 59 years, mean eGFR was 41 mL/min/1.73 m2, 
mean A1c was 7.6%, and mean hemoglobin was 12 g/dL. During a median 6 years of 
follow-up, higher A1c was associated with worse outcomes (Figure 1); risk per 1% higher 
A1c was 10% for death, 10% for CVD events, and 5% for CKD progression. Anemia 
(hemoglobin<11 g/dL) was associated with non-linear associations for all three outcomes 
(Figure 2). A1c was associated with CKD progression in patients with eGFR≥30 ml/
min/1.73m2 but not below that level. There was no effect modification by albuminuria.
Conclusions: In patients with CKD and diabetes, poor glycemic control contributes 
to a higher risk of death and CVD events. Individualized A1c targets and/or alternative 
markers of glycemia may be useful in diabetic CKD patients with anemia.
Funding: Other NIH Support - U01DK060990, U01DK060984, U01DK061022, 
U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, 
UL1TR000003, UL1TR000439 , UL1RR029879, P20 GM109036, UL1 RR-024131, T32 
HL007024
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Poor Glycemic Control Increases Mortality in Elderly Dialysis Patients 
with Diabetes - A Nationwide Prospective Cohort in Korea
Jung Nam An,1 Yong Chul Kim,2 Yun Kyu Oh,4 Yong-Lim Kim,3 Chun Soo Lim,1 
Jung Pyo Lee.1 1Seoul National University Boramae Medical Center, Seoul, 
SEOUL, Republic of Korea; 2SNUH, Seoul, Republic of Korea; 3Kyungpook 
National University Hospital, Daegu, Republic of Korea; 4Department of Internal 
Medicine, Boramae Medical Center, Seoul, Republic of Korea.
Background: Glycemic control, defined as glycated hemoglobin (HbA1c), was known 
to be an important factor for mortality in diabetic end-stage renal disease (ESRD) patients. 
However, the clinical impacts of glycemic control had not been fully elucidated in the 
elderly diabetic ESRD patients. We investigated whether glycemic control had clinical 
impact on all-cause mortality of elderly dialysis patients with diabetes.
Methods: A total of 755 diabetic patients (≥ 65 years) who had a value of HbA1c at 
the time of cohort enrollment were extracted from a nationwide prospective ESRD cohort 
in Korea between August 2008 and February 2015. The patients were divided into three 
groups according to the degree of glycemic control (< 6.5%, 6.5-7.9%, and ≥ 8.0%).
Results: The patients in the highest group of HbA1c (≥ 8.0%) were 132 (17.5%), 
which were younger, had higher vintages of dialysis, and higher percentage of peritoneal 
dialysis than the other two groups. Mortality rate was 57.2% during the median follow-up 
of 56.3 months. Patients with poor glycemic control (≥ 8.0%) had a higher risk of mortality 
compared with those in the HbA1c < 6.5% (hazard ratio [HR] 1.37; 95% confidence interval 
[CI] 1.06-1.77; P = 0.016). In subgroup analysis by dialysis modality, HbA1c ≥ 8.0% was 
a risk factor for mortality in the patients on peritoneal dialysis (HR 1.66; 95% CI 1.02-
2.70; P = 0.041). Multivariate analysis adjusting for age, sex, comorbidity, dialysis vintage, 
and dialysis modality verified a significant association between poor glycemic control (≥ 
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8.0%) and mortality rate in the elderly diabetic ESRD patients (HR 1.53; 95% CI 1.17-2.00; 
P = 0.002).
Conclusions: Poor glycemic control was significantly associated with mortality in the 
elderly dialysis patients, which suggests that lowering HbA1c to at least less than 8.0% 
might decrease mortality rate.
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Diabetic Kidney Disease: Clinical - II
Nutritional Status Is the Strongest Factor for Hemodialysis (HD)-Medi-
ated Improvements in Insulin Resistance in Patients with Type 2 Diabetes
Satoshi Funakoshi,1 Jyunichiro Hashiguchi,2 Kenji Sawase,1 Tayo Kawazu,1 
Yuko Maruyama,3 Takashi Harada,3 Yoko Obata,4 Tomoya Nishino.5 1Nagasaki 
Kidney Center, Nagasaki, Japan; 2Nagasaki Kidney Center, Nagasaki, Japan; 
3Nagasaki Kidney Center, Nagasaki, Japan; 4Nagasaki University Hospital, 
Nagasaki, Japan; 5Nagasaki University School of Medicine, Nagasaki, Japan.
Background: Changes in C-peptide index (CPI) and HOMA-R before and after 
hemodialysis (HD) were compared to explore factors associated with insulin resistance in 
diabetic patients receiving HD.
Methods: Fasting blood samples were drawn from type 2 diabetic patients receiving 
maintenance HD but not insulin therapy at our clinic before HD on the first day of the week 
they went on HD (pre-HD) as well as on the next day (post-HD). Then CPI and HOMA-R 
were calculated from serum glucose, C-peptide and Immunoreactive Insulin (IRI) values 
to examine correlations between changes in CPI, HOMA-R, serum parameters and patient 
characteristics.
Results: The mean post-HD CPI and HOMA-R were significantly lower than 
the mean pre-HD values (CPI; 6.7 ± 2.7 vs. 8.1 ± 3.3 ng/mL, HOMA-R; 0.7 ± 0.3 vs. 
1.1 ± 0.3 μU/mL, respectively) in the 19 type 2 diabetic patients (men/women, 12/7) 
included in the study. The rate of decrease in CPI and HOMA-R was strongly positively 
correlated with geriatric nutritional risk index (GNRI) (R2 = 0.6423) in these patients, while 
it was not correlated with their glycoalbumin (GA) or fasting glucose values.
Conclusions: Despite reports that HD leads to resolution of uremia and excessive fluid 
overload resulting in improvements in insulin resistance, to date, very few reports compared 
insulin resistance before and after HD. This study showed that the rate of decrease in CPI 
was not increased in patients with favorable glycemic control but significantly increased in 
those with favorable nutritional status, suggesting that the patient’s overall status may have 
a role to play in HD-mediated improvements in insulin resistance in the short term.
Funding: Private Foundation Support
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Free Vitamin D Is Independently Associated with Mean Arterial Blood 
Pressure in Diabetic Patients with Impaired Kidney Function
Daniela S. Bachert,6 Mira Pavkovic,3 Peter Sandner,3 Shufei Zeng,1 Carl-
Friedrich Hocher,5,3 Oleg Tsuprykov,2,7 Saban Elitok,4 Berthold Hocher.2 Charité 
University Berlin 1Charité University Berlin, Berlin, Germany; 2University of 
Potsdam, Potsdam, Germany; 3Bayer AG, Pharmaceuticals, Wuppertal, 
Germany; 4Department of Nepherology and Endocrinology/Diabetology, 
Klinikum Ernst von Bergmann, Potsdam, Germany; 5Charles University, 
Prague, Prague, Czechia; 6Dialysiscenter Potsdam /Institute for Nutritional 
Science, University of Potsdam, Potsdam, Germany, Potsdam, Germany; 7IFLB, 
Institute for Laboratory Medicine Berlin, Berlin, Germany.
Background: Blood pressure control is key for the prevention of complications of 
diabetes such as CKD progression. Vitamin D is thought to play a role in blood pressure 
regulation in diabetic patients. Total 25-hydroxyvitamin D are currently routinely used in 
clinical practice to assess vitamin D status. In the circulation, vitamin D – like other steroid 
hormones – is bound to a special carrier – vitamin D-binding protein (DBP). Only very tiny 
amounts of the total vitamin D are free and potentially biologically active, because only 
free vitamin D interact with the vitamin D receptor. The aim of the study was to compare 
the association of free and total vitamin D with blood pressure in diabetic patients with 
impaired kidney function.
Methods: Free and total vitamin D concentration were measured in 225 diabetic 
patients with impaired kidney function. Mean arterial blood pressure (MAP) was calculated 
based on 3 independent ambulatory blood pressure measurements and was 93.1 +/- 11.0 
mmHg. Patients received cholecalciferol if needed. The cholecalciferol dose was adjusted 
after total vitamin D measurements every 3 months to meet vitamin D serum targets as 
defined by the German Society of Nutritional Medicine. Multiple linear regression 
analysis considering age, sex, BMI, eGFR, family history of hypertension, treatment with 
antihypertensive drugs and diuretics as confounding factors.
Results: This study revealed that free vitamin D was independently associated with 
MAP (p=0.026, CI: -1.285 – -0.049) whereas total vitamin D was not associated with MAP 
(p=0.308; CI: - 0.285 – 0.091).
Conclusions: Free – but not total - vitamin D serum concentrations in patients 
with diabetes and impaired kidney function are interdependently invers correlated with 
blood pressure, a key disease progression factor. This study suggests that free vitamin 
D measurements might be a better clinical tool – as compared to measurements of total 
vitamin D - to adjust vitamin D therapy in diabetic patients with impaired kidney function. 
However, reference values and treatment targets for free vitamin D in diabetic patients with 
impaired kidney disease have to be established.
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Trends of Non-Traumatic Lower Extremity Amputation in People with 
ESRD, by Diabetes Status, United States, 2000-2015
Jessica L. Harding, Meda E. Pavkov, Nilka Rios Burrows, Edward Gregg. 
Centers for Disease Control and Prevention, Atlanta, GA.
Background: Non-traumatic lower extremity amputation (NLEA) is a complication of 
end-stage renal disease (ESRD) and diabetes mellitus (DM). Contemporary trend data on 
NLEA among people with ESRD are lacking.
Methods: We estimated incident NLEA hospitalizations during 2000-2015 in adults 
with ESRD from the U.S. Renal Data System. Rates of first NLEA were estimated for 
any NLEA, minor NLEA (below ankle) and major NLEA (through or above ankle) using 
ICD-9 procedure codes from January 2000 to September 2015 and ICD-10 from October 
to December 2015. Hospitalization rates were stratified by primary cause of ESRD (DM or 
no-DM). Time trends were assessed using Joinpoint regression and annual percent changes 
(APC) reported.
Results: Among ESRD-DM, age-standardised rates for any NLEA declined 32% (from 
36.4 to 24.9 per 1,000 persons) from 2000-2010 (APC= -3.87, p<0.05), and then did not 
change from 2010-2015 (APC=0.21, p=0.8) (Figure). Major NLEA rates declined 49% 
throughout the period (APC=-4.98, p<0.05), and minor NLEA rates declined 22% from 
2000-2009 (APC=-2.63, p<0.05) and then did not change from 2009-2015 (APC=1.42, 
p=0.08). Among ESRD-noDM, rates for any NLEA declined 25% (from 5.3 to 4.0 per 
1,000 persons) from 2000-2008 (APC=-3.66, p<0.05), and then did not change from 2008-
2015 (APC=0.52, p=0.4). Major NLEA rates declined 39% from 2000-2011 (APC=-4.95, 
p<0.05) and then did not change from 2000-2015 (APC=1.02, p=0.6), and minor NLEA 
rates did not change from 2000-2008 (APC=-1.31, p=0.08) and then increased 19% from 
2008-2015 (APC=2.47, p<0.05).
Conclusions: Despite an initial period of decline, the later stagnation in rates of any 
NLEA in adults with ESRD seem to be driven by a lack of further declines in minor NLEAs. 
Increased attention to preventive foot care in the ESRD population might be considered, 
particularly for those with ESRD-DM where NLEA rates remain almost six times higher 
than ESRD-noDM.
Figure Age-standardized hospitalization rates for non-traumatic lower extremity 
amputations (NLEA) among people with ESRD with diabetes (DM) (A) and without 
diabetes (noDM) (B), United States, 2000-2015
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A European Hemodialysis Multicenter Implementation of a Standardized 
Diabetic Foot Examination Protocol
Werner Kleophas,1 Maciej B. Drozdz,2 Szymon Brzosko,3,4 Joao M. Frazao,5 
Fatima F. Silva,6 Abdulkareem Alsuwaida,7,8 Mahesh Krishnan,9 
Stefan H. Jacobson.10 1DaVita Germany, Dusseldorf, Germany; 2DaVita Poland, 
Krakow, Poland; 3DaVita Poland, Bialystok, Poland; 4Department of 
Nephrology, Medical University of Bialystok, Bialystok, Poland; 5Nephrology 
and Infectiology Research and Development Group, INEB, and School of 
Medicine, Porto University, Portugal, Porto, Portugal; 6DaVita Portugal, 
Alfragide, Portugal; 7King Saud University, Riyadh, Saudi Arabia; 8DaVita 
Saudi Arabia, Riyadh, Saudi Arabia; 9DaVita, Inc, Denver, CO; 10Danderyd 
Hospital, Stockholm, Sweden.
Background: Diabetics on hemodialysis (HD) have an increased risk for foot ulcers 
(FU), infections, and limb amputation. Pain and other symptoms are often reduced due to 
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neuropathy resulting in late diagnosis. We assessed the frequency of foot complications 
following implementation of a standardized foot examination in a cohort of prevalent 
diabetic HD patients in 26 DaVita centers in Germany, Poland and Portugal. We analyzed 
differences and associations with demographic data, practices and laboratory data.
Methods: A standardized foot examination was performed in 1025 diabetic HD 
patients in Germany (n=674), Poland (n=179) and Portugal (n=172). The examination 
includes: previous FU, amputation etc; inspection of feet (skin, nails); examination of pedal 
pulses (a dorsalis pedis and tibialis posterior) and foot sensory level. Foot complications 
were classified according to Wagner (grade 0-5); PAD was classified by clinical pulse 
measurement (normal=0, weak=1, missing=2).
Results: Mean (SD) patient age was 70.4 (14) years (NS between countries). 8.7% 
had a prior amputation; this was less common in Germany (p<0.001). A normal pulse in 
left and right a dorsalis pedis was present in 45% and 44% of patients, respectively, pulses 
were absent in 33% and 34% (p<0.001 between countries). For left and right a tibialis 
posterior, normal pulse was present in 37% and 37% of patients, respectively, pulses were 
absent in in 43% and 42% (p<0.001 between countries). Wagner classification score was 
0 or 1 in 95.5% of patients and 4-5 in 1.8% (NS between countries). In a subgroup of 351 
patients from Poland and Portugal there were no significant correlations between Wagner 
score and age, sex, BMI, Kt/V, vascular access, Charlson comorbidity index, Hb, albumin, 
phosphorus, and PTH. Patients with skin edema were older (p<0.05), had higher Charlson 
comorbidity index (p<0.05), lower Hb (p<0.05), lower albumin (p=0.01) and higher 
phosphorus (p=0.004).
Conclusions: Implementation of a standardized foot examination protocol in a large 
cohort of European diabetic patients on HD revealed a high prevalence of clinically 
significant complications that warrant close attention. This simple clinical tool is suitable 
to identify patients at high risk and could be the basis of a program to improve health 
outcomes.
Funding: Commercial Support - DaVita, Inc
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Prevalence of Increased Rate of Reduced Estimated Glomerular Filtration 
despite Advances in Diabetes Mellitus Treatment
Makoto Araki. Suwa Central Hospital, Chino, Japan.
Background: Unlike in other countries, diabetes treatment in Japan follows a unique 
approach, such as the rare use of metformin before 2010 and the frequent use of dipeptidyl 
peptidase-4 inhibitor (DPP4i) after 2009. We investigated the pharmacological effects of 
antidiabetic drugs on glycemic control and renal function in Japan.
Methods: We conducted a retrospective, serial, cross-sectional analysis of individuals 
aged ≥18 years who used more than one antidiabetic drug at a single center in Japan between 
2008 and 2017. The exclusion criteria were individuals who had continuously sustained an 
estimated glomerular filtration rate (eGFR) of <10 ml/min/1.73 m2 (including those who 
received chronic dialysis). All data were extracted from patient’s medical records.
Results: Between 2008 and 2017, the number of patients with diabetes mellitus has 
increased from 805 to 1190, and the average age of diabetic patients has increased from 
65.6 to 68.8 years. Meanwhile, the number of prescription drugs has increased by 2.3 times. 
The use of antidiabetic drugs has remarkably increased the DPP4I and metformin levels 
(0% to 34% and 24%, respectively), whereas the insulin (46% to 15%) and sulfonylurea 
(42% to 11%) levels have decreased. The hemoglobin A1c levels have improved 
(7.8% to 7.3%); however, eGFR has decreased (from 73 to 65 ml/min/1.73 m2), and the 
ratio of eGFR <60 ml/min/1.73 m2 group has increased (from 25% to 39%). This tendency 
remained unchanged even when analyzed for background-matched cases between 2008 and 
2017.
Conclusions: Pharmacological advances in the treatment of diabetes mellitus can 
improve glycemic control but not renal function.
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Declining CKD Prevalence Among Patients with Diabetes in the United 
States
Jennifer L. Bragg-Gresham, Xiaosong Zhang, William H. Herman, Rajiv Saran. 
University of Michigan, Ann Arbor, MI.
Background: Diabetes mellitus (DM) is a major risk factor for the development of 
chronic kidney disease (CKD) and is the assigned primary cause for almost half of all new 
end stage renal disease cases in the US. Diabetics with high blood pressure, poor glucose 
control, inherited tendency, and poor diet are at an increased risk of developing CKD. In this 
work, we sought to examine the prevalence of CKD among diabetics over time in the US.
Methods: Data from 5,278 patients with DM (diagnosed, taking medication, or HbA1c 
> 7%) from the National Health and Nutrition Examination Survey (NHANES, 2001-2016) 
was examined to estimate prevalence of CKD in 4-year cohorts, using population survey
weights. CKD was defined either as an estimated glomerular filtration rate (eGFR) < 60 
ml/min/1.73m2 or urine albumin-to-creatinine ratio (UACR) > 30 mg/g. Weighted logistic 
regression was used to assess significance of this decline.
Results: The prevalence of CKD among patients with DM declined steadily from 
2001 to 2016. In contrast, the prevalence of CKD among patients with hypertension (HTN; 
diagnosed, receiving antihypertensive medication, or blood pressure >140/90) did not show 
a similar trend. The decline in CKD prevalence for DM is primarily driven by a lower 
prevalence of albuminuria (UACR > 30 mg/g) rather than low eGFR, which appeared 
stable over these years. This trend was significant with an OR=0.90 (95% CI: 0.85-0.96) per 
each 4-year more recent time period and increased in magnitude when adjusted for patient 
demographics (OR=0.88, 95% CI: 0.82-0.94).
Conclusions: The prevalence of CKD, in particular albuminuria, among patients with 
DM has decreased steadily in the US over the past 16 years, while its prevalence among 
patients with HTN has been stable. Future work will investigate potential reasons for this 
steady decline, such as greater awareness of diabetes and its complications, improvements 
in blood pressure control, glycemic control, adherence to healthier diet, weight control, and 
physical exercise.
Funding: NIDDK Support
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Younger Age, Afro-Caribbean Ethnicity, and Residual Albuminuria 
Predict Renal Function Decline in Patients with Diabetic Kidney Disease 
on Renin Angiotensin System Blockade
Nikolaos Fountoulakis,2 Luigi Gnudi,3 Janaka J. Karalliedde.1 1King’s College 
London, Kent, United Kingdom; 2King’s College London, London, United 
Kingdom; 3King’s College London, London, United Kingdom.
Background: There is heterogeneity in the progression of renal function decline in 
diabetic kidney disease (DKD). The clinical markers and patient features that predict loss 
of renal function in DKD despite renin angiotensin system (RAS) treament remain unclear.
Methods: In a single centre study we studied 266 (n=50 Type 1 and n=216 Type 2) 
patients with DKD on RAS blockade. All patients had baseline estimated glomerular 
filtration rate (eGFR) by Modification of Diet in Renal Disease Study equation >45 ml/min. 
Patients were followed up for a median 10 years with standardised clinical care measures. 
Primary endpoint was progression of DKD defined as eGFR fall >5ml/min/year or end 
stage renal disease (ESRD-dialysis or transplantation). In a cause specific Cox proportional 
hazards model predictors of ESRD were also evaluated with death from any cause as 
competing event.
Results: In the T1DM cohort patients with progression (n=13) as compared to 
those without (n=37), In multivariate analyses [odds ratio (OR) and 95% confidence 
intervals (CI)] duration of diabetes OR 0.74 (0.56 - 0.99), baseline eGFR 1.09 (1.01 to 
1.17) and ACR 9.5 (1.35- 66.7) were independent predictors of progression, p<0.05 for 
all. Similarly for T2DM cohort (n=216, 62% male, 40% Afro-Caribbean), 20% (n=50) 
had progression. Baseline eGFR, OR (95%CI), 1.04 (1.02 to 1.06) and ACR 1.4 (1.05- 
1.9) were independent predictors of progression, p<0.05 for all. In T2DM 44 patients 
developed ESRD, these patients as compared to those without ESRD (n=172) were younger 
(57.3 ± 10.5 vs. 62 ± 10.4 years), more likely to be Afro-Caribbean (87% vs. 34%) with 
higher ACR [30.0 (12.7 - 30.0) vs. 9.1 (2.0 - 30.0) mg/mmol], p<0.05 for all. In cause 
specific competing risk analyses, hazard ratio (95% CI), age 0.94 (0.91 - 0.98), Afro-
Caribbean ethnicity 2.30 (1.07 - 4.90), and ACR 1.53 (1.08 - 2.16) were independent 
predictors of ESRD, p<0.05 for all.
Conclusions: In DKD residual albuminuria despite RAS blockade increased risk of 
significant renal function decline. In T2DM younger age, residual albuminuria and Afro-
Caribbean ethnicity increase risk of ESRD. Treatments that reduce residual albuminuria 
despite RAS may help reduce progression of DKD.
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Comparison of Risk Prediction Using the CKD-EPI Equations or the 
MDRD Study Equation for Estimated Glomerular Filtration Rate in 
Chinese Patients with Diabetic Nephropathy
Yiting Wang. Division of Nephrology, West China Hospital of Sichuan 
University, Division of Nephrology, West China Hospital of Sichuan University, 
Chengdu, China.
Background: To evaluate risk implications of estimated glomerular filtration 
calculated by CKD-EPI equations (eGFRCKD-EPI-CysC, eGFRCKD-EPI-Cr-CysC) compared to eGFR 
by eGFRCKD-EPI-Cr and eGFRMDRD in Chinese patients with diabetic nephropathy (DN).
Methods: A retrospective study was conducted 363 patients with renal-biopsy DN, 
227 patients of them were followed up at least one year. The stages of chronic kidney 
disease (CKD) were classified by different equations. The eGFR concordance between each 
two equations was assessed by Bland–Altman plots. The correlation between eGFR and 
pathological findings was using Spearman analysis. The end point was defined by receiving 
renal replacement therapy (RRT). Log Rank and Cox regression were employed to evaluate 
risk implications of eGFRCKD-EPI and eGFRMDRD.
Results: Overall, the proportion of CKD 3-5 stages (eGFR, 60mL/min/1.73 m2) was 
57.2%, 56.1%, 72.1%, and 64.1% by the eGFRMDRD, eGFRCKD-EPI-Cr, eGFRCKD-EPI-CysC and 
eGFRCKD-EPI-Cr-CysC respectively. The concordance between eGFRCKD-EPI-CysC and eGFRCKD-
EPI-Cr-CysC (mean bias: 1.20), and between eGFRMDRD and eGFRCKD-EPI-Cr (mean bias: 4.21) 
were superior to others. However, the bias of eGFRMDRD and eGFRCKD-EPI-Cr enlarged when 
eGFR was great than 60mL/min/1.73 m2. Compared to eGFRCKD-EPI-Cr, 40% and 18% 
of patients were reclassified from CKD 1-2 stages to CKD 3-5 by CKD-EPI-CysC and 
CKD-EPI-Cr-CysC, respectively, and reached the end point quicker than not reclassified 
patients (P<0.01); 67.6% and 55.3% of patients with eGFRCKD-EPI-Cr 45-60 were reclassified 
to CKD 3b-5 stages by CKD-EPI-CysC and CKD-EPI-Cr-CysC, respectively, however, 
no significant difference of renal survival time was observed compared to not reclassified 
patients. The results were similar when compared to eGFRMDRD. The hazard ratio was 0.960 
(95% CI 0.949-0.971), 0.961 (95% CI 0.950-0.971), 0.940 (95% CI 0.925-0.955) and 0.947 
(95% CI 0.934-0.960) for eGFRMDRD, eGFRCKD-EPI-Cr, eGFRCKD-EPI-CysC and eGFRCKD-EPI-Cr-CysC 
respectively, when eGFR was regarded as continuous variables.
Conclusions: eGFRCKD-EPI-CysC and eGFRCKD-EPI-Cr-CysC classified more patients to CKD 
3-5 stages and more accurately categorized the risk of RRT than did eGFRCKD-EPI-Cr in
Chinese DN patients.
Funding: Government Support - Non-U.S.
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Socioeconomic, Demographic, and Clinical Associations of CKD in 
Diabetes in a Population-Based Australian Cohort: Results from the 
EXTEND45 Study
Louisa Sukkar,1,2 Amy Kang,1 Min Jun,3 Celine Foote,1 Roberto Pecoits-Filho,4 
Brendon L. Neuen,1 Kris Rogers,1 Alan Cass,7 Carol A. Pollock,5 Germaine 
Wong,5 John Knight,1 David Peiris,1 Martin P. Gallagher,1 Meg J. Jardine.6 
EXTEND45 Steering Committee 1The George Institute for Global Health, 
Sydney, NSW, Australia; 2School of Public Health, The University of Sydney, 
Sydney, NSW, Australia; 3The George Institute for Global Health, UNSW 
Sydney, Newtown, NSW, Australia; 4Pontificia Universidade Catolica do 
Parana, Curitiba, Brazil; 5The University of Sydney, St. Leonards, NSW, 
Australia; 6The George Institute for Global Health, UNSW, Newtown, NSW, 
Australia; 7Menzies School of Health Research, Darwin, NT, Australia.
Background: Type 2 diabetes is the leading cause of Chronic Kidney Disease (CKD) 
in the developed world. Identifying people with diabetes at increased risk of developing 
CKD is the first step to developing preventative strategies to reduce this burden. We aimed 
to estimate the incidence rate and associations of CKD in people with diabetes.
Methods: Based on data from the EXTEND45 study (the 45 and Up Study linked to 
[1] hospital and community pathology datasets by the Centre for Health Record Linkage 
[CHeReL] and [2] the Medicare Benefits Schedule [MBS] and Pharmaceutical Benefits 
Scheme [PBS] datasets provided by the Department of Human Services), we identified 
a population-based Australian cohort (2006-2014) of 24,400 people aged ≥45 years
with diabetes. We used Poisson regression to estimate CKD (eGFR<60 ml/min/1.73m2) 
incidence and prevalence. Multivariable Cox regression was used to examine associations 
between baseline sociodemographic factors, comorbidities and incident CKD
Results: Of 24,400 participants with diabetes, 2,789 (11.4%) had prevalent CKD and 
1,771 (7.2%) developed incident CKD over a mean follow-up of 4.3 years. CKD incidence 
rate was 4.93 (95% confidence interval [CI]: 4.70-5.16) per 100 person-years. Compared 
to those who had no CKD, those with CKD were older (mean age: 64.7, 75.2, 70.2 years, 
for no CKD, prevalent CKD, incident CKD respectively), had a lower proportion of current 
smokers (7.9%, 3.1% 4.7% respectively) and a lower proportion with an annual household 
income of >$70,000 (17.1%, 6.2%, 10.5%). Incident CKD was predicted by age (hazard 
ratio [HR]: 1.07 [1.07-1.08] per year increase), geography (Outer regional vs major city: 
1.41 [1.17-1.69]), BMI (obese vs normal: 1.43 [1.23-1.68]), presence of hypertension (1.48 
[1.27-1.73]), coronary heart disease (1.24 [1.11-1.40]) and depression (1.26 [1.09-1.45]).
Conclusions: In a contemporary cohort of Australians with diabetes, the incidence of 
CKD is high and independently predicted by age as well as geography, obesity, a baseline 
history of cardiovascular disease and depression. These associations provide potential 
targets for early intervention in these at risk groups.
Funding: Commercial Support - The EXTEND45 Study is funded through peer-
reviewed (NSW Cardiovascular Research Network Collaborative Project Grant), and 
unrestricted industry (from MSD, Amgen and Eli Lilly) research grants.
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Large Cross-Sectional Study Revealed the Conditions, Pathogenesis, and 
Progression of Diabetic Kidney Disease and Early Decliner in Japan
Yui Yoshida, Yosuke Hirakawa, Tetsuhiro Tanaka, Masaomi Nangaku. Division 
of Nephrology and Endocrinology, the University of Tokyo the University of 
Tokyo, Tokyo, Japan.
Background: Estimated glomerular filtration rate (eGFR) decline precedes albuminuria 
in a certain portion of diabetic patients. Thus, albuminuria and/or low eGFR in diabetic 
patients were defined as ‘Diabetic Kidney Disease (DKD)’. In addition, the existence of 
‘early decliner’ attracts a lot of attention, whose eGFR declines rapidly from early stage in 
DKD patients. To understand the prevalence of DKD and the risk factor of early decliner, 
we integrated several cohorts and cross-sectional data.
Methods: We continue adding up the 14,000 patients data with 9 hospitals, who were 
diagnosed as diabetes mellitus and did not receive dialysis. Prevalence was calculated 
based on cross-sectional data in the baseline of each cohort. We defined DKD as 
albuminuria ≥ 30 mg/gCr and/or eGFR < 60 ml/min/1.73m2. We did 2 types of analysis to 
look for the risk factors of early decliner, firstly by defined eGFR declined by more than 
5 ml/min/1.73m2/year with normal eGFR in the baseline and secondly by trajectory analysis 
to compare with the provisional standard.
Results: The proportion of DKD was 52% in total with available data. 8.3% patients 
were categorized as early decliner with the definition of eGFR decline by more than 
5 ml/min/1.73m2/year. By trajectory analysis, 21% patients were classified as early 
decliner whose eGFR decline rate was 4.84 ml/min/1.73m2/year (Image). Two kinds of 
analyses revealed that the common risk factors with early decliner group were high level of 
albuminuria and eGFR in the baseline.
Conclusions: The proportion of DKD were over 50% in all diabetic patients in 
Japan. The mean eGFR decline rate of early decliner by trajectory analysis was 4.84 ml/
min/1.73m2/year, similar to provisional standard. The common risk factors of early decliner 
were high level of albuminuria and eGFR in the baseline status by two types of analyses.
Classification of eGFR trajectories.
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Diabetic Kidney Disease: Clinical - II
Inflammation and Kidney Injury in Diabetic African American Men
Elimelda M. Ongeri,1 Lei Cao,1 Olugbemiga E. Jegede,2 Scott H. Harrison,1 
Robert H. Newman.1 1Biology, North Carolina A&T State University, 
Greensboro, NC; 2Cone Health, Greensboro, NC.
Background: African Americans (AA) are disproportionately burdened by diabetes and 
diabetic kidney disease (DKD). However, little is known about the cellular and molecular 
mechanisms underlying the onset and progression of DKD in this population. AA men are 
especially underrepresented in biomedical research. We recently reported undiagnosed 
kidney injury in a significant proportion of diabetic AA men served by a community clinic 
in Greensboro, NC. The goal of the current study was to determine the association between 
specific inflammation markers and kidney injury in diabetic AA men.
Methods: We recruited three groups of AA men aged 18-65 years: 1) diabetics without 
diagnosed kidney disease (n=87); 2) diabetics with diagnosed DKD (n=20); and 3) age-
matched non-diabetic controls (n=81). Assays for urinary albumin and creatinine as well 
as plasma kidney injury molecule 1 (KIM-1) and urinary neutrophil gelatinase associated 
lipocalin (NGAL) were used for biochemical assessment of kidney function. Enzyme-
linked immunosorbent assays were used to measure the plasma and urinary levels of seven 
inflammatory markers: adiponectin, C-reactive protein (CRP), tumor necrosis factor-
α (TNF-α), TNF receptor 1 (TNFR1), TNF receptor 2 (TNFR2), interleukin-6 (IL-6), 
and intercellular cell adhesion molecule-1 (ICAM-1). A heat map was generated for the
“inflammation profile” for each individual in the study.
Results: Plasma levels of TNF-α, TNFR1 and TNFR2 increased with severity of DKD 
and were significantly higher in diabetic patients with macroalbuminuria compared to non-
diabetic controls and diabetics with normoalbuminuria or microalbuminuria. Likewise, 
urinary levels of ICAM-1 were higher in diabetic patients with macroalbuminuria compared 
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to the other groups. Indeed urinary ICAM-1, plasma TNF-α, and plasma adiponectin had 
moderate positive correlations with UACR while the levels of TNFR1 and TNFR2 in the 
plasma were strongly correlated with kidney injury. In contrast, though plasma CRP was 
elevated in diabetics relative to non-diabetic controls, its levels did not correlate with kidney 
injury. The number of individuals with elevated levels of multiple inflammation markers 
increased with the severity of kidney injury.
Conclusions: These data suggest that inflammation, particularly that mediated by the 
TNF-α/NF-κB signaling axis, may play a role in the pathogenesis of DKD in AA men.
Funding: Other NIH Support - (1) NIMHD - Minority Men's Health Initiative 
(MMHI), and (2) NIGMS
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Sex Disparity to Kidney Transplant Varies by Cause of ESRD
Patrick Ahearn, Kirsten L. Johansen, Charles E. McCulloch, Barbara A. Grimes, 
Elaine Ku. UCSF, San Francisco, CA.
Background: Women are significantly less likely to undergo transplantation than men. 
The possibility that transplant access differs by underlying cause of ESRD among men and 
women has not been thoroughly evaluated.
Methods: Using data from the US Renal Data System (USRDS), we performed 
a retrospective cohort study of adults who required their first renal replacement therapy 
between January 1, 1995 and June 30, 2016. In two approaches, considering either 
all patients with ESRD or only those with a waitlist date, we examined the association 
between sex and likelihood of transplant by cause of ESRD (including diabetes mellitus 
type 2 (DM2), hypertension, cystic/obstructive disease, and diabetes mellitus type 1) using 
adjusted Cox models.
Results: There were 266,616 kidney transplants among 2,228,769 adults with ESRD. 
In fully adjusted analyses, the likelihood of transplant for women was 0.82 (95% CI 0.82-
0.83) times that of men in the full cohort and 0.91 (95% CI 0.90-0.92) times that of men 
considering only those registered on the waitlist. In both analyses, cause of ESRD modified 
the association between sex and access to transplantation (p<0.001), such that likelihood of 
transplant was markedly lower in women (vs. men) with ESRD due to DM2. In contrast, 
the sex disparity in transplant access was less profound in women with other causes of 
ESRD (figure).
Conclusions: Sex disparity in kidney transplant access varies substantially by cause 
of ESRD. Regardless of whether analyses included all patients with ESRD or only those 
registered on the waitlist, women (vs. men) with DM2 had the lowest access to kidney 
transplant compared to women (vs. men) with other attributed causes of kidney disease. 
This disparity is concerning, given that DM2 is the leading cause of ESRD in the US, and 
these patterns were observed even among those waitlisted for transplant.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Establishing a Hazard Predictive Model of Renal Outcomes for Diabetic 
Nephropathy
Qiqi Feng,1 Tan-qi Lou.2 1The Third Affiliated Hospital of Sun Yat-sen University, 
Guangzhou, China; 2The Third Affiliated Hospital of Sun Yat-Sen University, 
Guangzhou, China.
Background: The present study aims to find out the independent risk factors associated 
with loss of renal functions in diabetic nephropathy (DN) and to further establish a hazard 
predictive model to evaluate prognosis of DN patients.
Methods: We enrolled patients with biopsy-proven DN in our hospital between January 
2004 to June 2014. They were followed up until reaching the renal end-points including 
renal replacement therapy and doubling of serum creatinine before 31 December 2014. 
Univariate and multivariate Cox regression models were used to determine the independent 
variables associated with prognosis. A hazard predictive model was established based on 
the prognostic index (PI) determined by the regression coefficients in the multivariate Cox 
model.
Results: The mean follow-up duration was 25.9 months. Of the 57 people enrolled 
in this study, 25 reached the renal outcomes. The clinical and pathological parameters 
associated with renal outcomes in the univariate Cox regression models were introduced 
into the multivariate Cox models which showed that estimated glomerular filtration rate 
(eGFR), blood urea nitrogen (BUN), hemoglobin and scoring of interstitial fibrosis and 
tubular atrophy (IFTA) were independent risk factors for reaching renal end-points. 
The independent risk factors were included in the PI calculations to establish the hazard 
predictive model of renal outcomes. Participants were randomly divided into the training 
set (n = 38) and the validation set (n = 19). Patients with PI≤0.807 were assigned to the low-
risk group while patients with PI>0.807 were assigned to the high-risk group based on the 
cut-off point of the ROC curve (AUC 0.901, 95%CI 0.800-1.000, P = 0.000) with the renal 
endpoints as the state variable and PIs as the test variable in the training set. The survival 
analysis showed that there was significant difference in the renal survival curves between 
the low-risk group and the high-risk group in both sets. The AUCs of ROCs in both sets 
were greater than the AUCs of ROCs of any single risk factors.
Conclusions: The hazard predictive model combining clinical and pathologic 
independent variables were able to predict prognosis of DN with more accuracy so as to 
help clinicians act early to patients with high risk of developing ESRD.
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The Relationship of Pathologic Classification and Prognosis in Diabetic 
Nephropathy
Qiqi Feng,1 Meijun Si,2 Yuanqing Li.1 1The Third Affiliated Hospital of Sun 
Yat-sen University, Guangzhou, China; 2The third affiliated hospital, Sun 
Yat-sen University, Guangzhou, China.
Background: The present study is aimed to explore the relationship between clinical 
manifestations and pathological changes in diabetic nephropathy (DN) and to assess the 
predictive power of the pathologic classification for DN established by the Renal Pathology 
Society in 2010.
Methods: Patients with type 1 or type 2 diabetes and biopsy-proven DN in the Third 
Affiliated Hospital of Sun Yat-sen University between January 2004 to June 2014 were 
enrolled in the present study and were followed up until 31 December 2014. The outcome 
was defined as renal end-points including renal replacement therapy and doubling of serum 
creatinine as well as all-cause mortality. The laboratory and histologic data were analyzed 
and outcomes were assessed using survival analysis.
Results: The Fifty-seven people enrolled in this study were categorized into Class IIa 
(n = 9), Class IIb (n = 9), Class III (n = 25) and Class IV (n = 14) while no participants 
belonged to Class I. The changes of Class IIa were slight and those of Class IV were 
severe both in the clinical data (diabetic duration, blood pressure, eGFR, urine protein 
excretion rate, albumin and hemoglobin) and the pathological data (percentage of global 
glomerulosclerosis, percentage and scoring of interstitial fibrosis and tubular atrophy, 
scoring of interstitial inflammation and incidence of large vessel lesions). There were 
no significant differences between Class IIb and III in the above variables except for the 
scoring of arteriosclerosis. The mean follow-up duration was 25.9 months. Twenty-five 
patients reached the renal outcomes and six people reached all-cause mortality. The survival 
analysis showed that there were significant differences among the renal survival curves of 
different glomerular classes and of different interstitial and vascular scorings, but not in the 
survival curves related to all-cause mortality.
Conclusions: The glomerular classes were not completely associated with renal 
prognosis in that the clinical manifestations and renal outcomes were benign in Class IIa, 
moderate but similar in Class IIb and III and severe in Class IV. The glomerular classification 
and interstitial and vascular scorings were associated to renal prognosis but not to mortality.
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Diabetic Kidney Disease: Clinical - II
Similarity and Difference of Clinicopathological Features Between 
Diabetic Nephropathy and Hypertensive Nephrosclerosis: A Nationwide 
Kidney Biopsy Study in Japan
Kengo Furuichi,1 Miho Shimizu,2 Tadashi Toyama,3 Yasunori Iwata,1 
Norihiko Sakai,1 Takashi Wada.1 1Kanazawa University, Kanazawa, Japan; 
2Division of Nephrology, Kanazawa University Hospital, Kanazawa, Japan; 
3Kanazawa University Hospital, Kanazawa, Japan.
Background: Diabetic kidney disease is the major cause of end-stage kidney disease 
in developed countries. Moreover, hypertensive nephrosclerosis is increasing cause of 
end-stage kidney disease in Japan. In this study, we evaluated clinicopathological features 
between diabetic nephropathy and hypertensive nephrosclerosis using nationwide biopsy 
samples in Japan.
Methods: The clinical data of 600 biopsy-confirmed diabetic nephropathy patients and 
184 biopsy-confirmed hypertensive nephrosclerosispatients were collected retrospectively 
from 13 centres throughout Japan under the support from the Japan Agency for Medical 
Research and Development. Pathological features and decreasing rate ofestimated 
GFR (eGFR) were evaluated between the two biopsy cohorts under the CKD heat map 
classification.
Results: The median observation period was 70.4 (IQR; 20.9-101.0) months in 
diabetic nephropathy and 73.2 (IQR; 31.2-116.4) months in hypertensive nephrosclerosis. 
In the CKD heat map categories, Green and Yellow (G&Y), Orange and Red category 
contained 103, 149, and 348 cases in diabetic nephropathy and 36, 57, and 91 cases in 
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hypertensive nephrosclerosis, respectively. In clinical factors, body mass index, systolic 
and diastolic blood pressure were higher in patients with hypertensive nephrosclerosis 
than diabetic nephropathy in G&Y category. Declining speed of eGFR was no 
difference between two cohorts (diabetic nephropathy, hypertensive nephrosclerosis; 1.7, 
2.4 mL/min/1.73 m2/year, respectively). However, there was no difference in pathological 
findings between two groups in the category. In contrast to G&Y category, declining speed 
of eGFR was higher in patients with diabetic nephropathy than hypertensive nephrosclerosis 
in Red category (diabetic nephropathy, hypertensive nephrosclerosis; 5.8, 1.3 mL/min/1.73 
m2/year, respectively). In accordance with the clinical findings, pathological findings of 
interstitial fibrosis and cell infiltration and arteriolar hyalinosis were progressed in diabetic 
nephropathy in Red category.
Conclusions: Although, it is so difficult to clearly distinguish pure kidney lesions 
caused by diabetes and hypertension, it would be important that these overlapped 
pathological findings be confirmed on kidney biopsy in diabetic cases with hypertension.
Funding: Government Support - Non-U.S.
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The Safety and Feasibility of Obtaining Research Kidney Tissue from 
Patients with Diabetes: Transformative Research in Diabetic Nephropathy 
(TRIDENT Study)
Amy K. Mottl,2 Katalin Susztak,1 Jonathan J. Hogan,3 Pietro A. Canetta,14 
Kirk N. Campbell,4 Matthias Kretzler,5 Tamara Isakova,6 Christos Argyropoulos,7 
Richard A. Lafayette,8 Shweta Bansal,9 Harold M. Szerlip,10 Salem Almaani,11 
Randy L. Luciano,12 Raymond R. Townsend,13 Kishor B. Devalaraja-
Narashimha,15 Nick Cammack,16 Shira Blady,1 Matthew Palmer,1 Paolo Guarnieri.17 
TRIDENT Consortium 1University of Pennsylvania, Philadelphia, PA; 
2University of North Carolina at Chapel Hill, Chapel Hill, NC; 3Hospital of the 
University of Pennsylvania, Haddonfield, NJ; 4Icahn School of Medicine at 
Mount Sinai, New York, NY; 5U.Michigan, Ann Arbor, MI; 6Feinberg School of 
Medicine, Northwestern University, Chicago, IL; 7University of New Mexico, 
Albuquerque, NM; 8Stanford University, Stanford, CA; 9University of Texas 
Health Science Center at San Antonio, San Antonio, TX; 10Baylor University 
Medical Center, Dallas, TX; 11The Ohio State University, Columbus, OH; 12Yale 
University School of Medicine, New Haven, CT; 13University of Pennsylvania 
School of Medicine, Villanova, PA; 14Medicine, Columbia, New York, NY; 
15Regeneron Pharmaceuticals, Tarrytown, NY; 16GSK, Stevenage, United 
Kingdom; 17Boehringer Ingelheim, Ridgefield, CT.
Background: There is a paucity of novel or specific therapeutics for diabetic kidney 
disease (DKD) due, in part, to its pathogenetic heterogeneity and lack of human kidney 
tissue for direct interrogation. TRIDENT (NCT02986984) is a multicenter consortium 
aimed at generating a longitudinal observational cohort study of 300 adults with diabetes 
and kidney tissue available for multi omics characterization of DKD. As part of the study 
initiation, we determined the safety and feasibility of obtaining research kidney tissue from 
patients undergoing clinical biopsy.
Methods: Individuals with diabetes, scheduled for clinical kidney biopsy, provided 
written consent to allow for an extra core of kidney tissue for research purposes. Inclusion 
criteria included confirmation of diabetic glomerulosclerosis, including superimposed non-
DKD. A clinically significant complication was defined as a perinephric hematoma >5cm, 
drop in hemoglobin >2g/dl, need for transfusion or procedure to halt bleeding or anesthesia 
related complications leading to prolonged hospital stay.
Results: Recruitment began in JAN 2017. To date, 69 individuals (>70% of those 
approached) have provided written consent, 56 biopsies performed, 49 research cores 
obtained; 6 patients excluded due to a lack of diabetic glomerulosclerosis on biopsy. 40 
participants met inclusion criteria with 18 instances of superimposed nondiabetic pathology: 
12 diagnoses of GN, 2 of AIN, 2 of acute tubular injury, 1 CTIN, and 1 pyelonephritis. The 
mean age was 54 years (±13) and 15 (38%) were female and 13 (33%) African American. 
Of the 49 biopsies in which an extra core was obtained, there were 2 clinically significant 
complications; 1 was a hematoma >5cm and the other was respiratory distress from 
anesthesia-related aspiration.
Conclusions: These preliminary results indicate that it is safe and feasible to obtain 
research kidney tissue from patients with diabetes undergoing clinical kidney biopsy. The 
TRIDENT Study is positioned to generate the molecular profiles necessary to unravel the 
heterogenous pathways involved in DKD.
Funding: Commercial Support - Boehringer-Ingelheim, GSK, Regeneron
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Hyperkalemia in CKD: Can Virtual Patient Simulation Improve 
Management?
Amy Larkin,1 Susan Gitzinger,2 Donald Blatherwick,2 Martin Warters,2 
Gwen S. Littman.3 1Medscape Education, Nicholasville, KY; 2Medscape, 
Medford, NJ; 3WedMD, Durham, NC.
Background: We sought to determine if an online, virtual patient simulation (VPS)-
based continuing medical education (CME) intervention could improve performance of 
nephrologists and primary care physicians (PCPs) in the evidence-based management of 
chronic kidney disease (CKD)-associated hyperkalemia.
Methods: The intervention comprised two patients presenting in a VPS platform that 
allows learners to order lab tests, make diagnoses, and prescribe treatments mirroring the 
scope and depth of actual practice. Eevidence-based clinical guidance (CG) was provided 
following each decision, followed by the opportunity to modify their clinical decisions. 
Each user’s baseline (pre-CG) decisions were compared to their post-CG decisions using a 
2-tailed paired t-test to determine P values. The CME launched online February 13, 2018, 
and data were collected through May 7, 2018.
Results: Case 1 (n=51 Nephrologists; n=367 PCPs): Diagnose hyperkalemia: 
16% improvement among nephrologists (51% pre-CG vs 67% post-CG; P=.051), 51% 
improvement among PCPs (50% pre-CG vs 71% post-CG; P<.001) Continue/modify 
spironolactone therapy: 12% improvement among nephrologists (14% pre-CG vs 26% 
post-CG; P=.085), 15% improvement among PCPs (11% pre-CG vs 26% post-CG; 
P<.001) Order follow-up potassium test: 12% improvement among nephrologists (59% 
pre-CG vs 71% post-CG; P=.105), 17% improvement among PCPs (50% pre-CG vs 67% 
post-CG; P<.001) Prescribe a potassium binder: 22% improvement among nephrologists 
(16% pre-CG vs 18% post-CG; P=.395), 0% improvement among PCPs (4% pre-CG vs 
4% post-CG; P=.5) Case 2 (n=34 Nephrologists; n=307 PCPs): Diagnose CKD Stage 
3b: 41% improvement among nephrologists (9% pre-CG vs 50% post-CG; P<.001), 26% 
improvement among PCPs (17% pre-CG vs 43% post-CG; P<.001) Appropriately initiate 
hyperkalemia therapy: 47% improvement among nephrologists (18% pre-CG vs 67% 
post-CG; P<.001), 48% improvement among PCPs (7% pre-CG vs 54% post-CG; P<.001) 
Appropriately discontinue spironolactone: 29% improvement among nephrologists (9% 
pre-CG vs 38% post-CG; P=.001), 24% improvement among PCPs (30% pre-CG vs 54% 
post-CG; P<.001)
Conclusions: VPS that immerses and engages physicians in an authentic and practical 
learning experience improved evidence-based clinical decisions of both nephrologists and 
PCPs related to hyperkalemia management.
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The Electrolyte Club: A Flipped Hyponatremia Curriculum for Internal 
Medicine Residents to Promote Integration of Sodium and Water 
Physiology into Clinical Care
Helbert Rondon Berrios. University of Pittsburgh School of Medicine, 
Pittsburgh, PA.
Background: Decreased interest in nephrology has been linked to perceptions that 
nephrology encompasses complicated and poorly taught subjects. The flipped classroom 
has emerged as an innovative teaching approach by encouraging higher-order thinking 
and active participation. We examined the effectiveness and acceptability of a flipped 
hyponatremia curriculum for Internal Medicine Residents with the goals of improving 
hyponatremia knowledge and confidence in applying basic sodium and water physiology 
into clinical care.
Methods: Residents rotating in the renal service at UPMC Presbyterian hospital 
from June 2017 to May 2018 were eligible to participate. Residents were excluded if they 
declined to participate or were unable to either attend all sessions or undergo assessment. 
Residents rotated in 4-wk blocks. Residents in a given block were assigned to either a 
standard curriculum (SC) or a flipped curriculum (FC). Each curriculum was applied 6 
times during the year. Residents in FC were required to watch 2-3 video lectures before 
each session. For this purpose, 10 video lectures on hyponatremia were developed using 
Camtasia software. FC in-class activities consisted of four 45-min sessions with a facilitator 
that included a clicker quiz, time for questions, and case discussions. SC consisted of two 
1-h chalk talks. Residents completed a pretest, a posttest, and a 5-point Likert scale survey 
at the end of each curriculum. Paired sample t-test was used to compare pretest and posttest 
scores within each curriculum and two-sample t-test was used to compare knowledge
improvement (posttest-pretest) between the two curricula.
Results: Twenty-nine residents were included in the study. There was a significant 
knowledge improvement after both curricula. There was no difference in knowledge 
improvement between FC and SC (33±15.6% vs. 31.7±14.9% respectively, P=0.79). 
Residents in FC rated 4.5±0.6 their confidence in applying basic sodium and water 
physiology into patient care, 3.9±1.1 their preference for the flipped classroom model over 
the traditional lecture, and 4.4±0.6 their overall satisfaction with FC.
Conclusions: FC improved residents’ hyponatremia knowledge but was not superior to 
SC. FC improved resident confidence in applying basic sodium and water physiology into 
patient care. FC had a great acceptability among residents.
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Self-Guided Video-Based Modules to Teach Hyponatremia to Trainees: A 
Pilot Study
Lowell J. Lo, Thuy M. Nguyen. Medicine, UCSF, San Francisco, CA.
Background: Hyponatremia is the most commonly encountered electrolyte disturbance 
in the hospital with an estimated prevalence up to 42%. Despite its prevalence, medical 
students and residents do not feel comfortable managing this condition. Hyponatremia 
encompasses many complex concepts in renal physiology making it a difficult topic to learn 
and teach. We conducted a pilot study to evaluate the impact of an online video module on 
learners’ ability to diagnosis and manage hyponatremia.
Methods: UCSF nephrologists created a module consisting of short online videos 
reviewing the pathophysiology of hyponatremia coupled with self-directed high-yield 
cases. This module is available on the UCSF collaborative learning environment website. 
We asked medical students and residents rotating through the nephrology elective to 
complete the module over the course of an assigned two-week block. We used ten board-
style multiple-choice questions as a surrogate marker of comprehension. Learners were 
instructed to complete the same questions before and after completion of the module. 
Participants also completed a short Likert-scale survey to evaluate their experience with 
the module.
Results: Over nine months, six medical students and one resident completed the 
module. Paired sample T-test was conducted to compare mean scores pre and post module. 
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There was a statistically significant difference between scores before (mean = 4.38, 
SD 1.30) and after the module (mean = 5.25, SD 1.58, t(7) = -2.81, p = 0.026). Learners 
reported spending between 2-8 hours on the material. Of the seven learners who completed 
the survey, all felt more comfortable diagnosing and proposing a treatment plan for 
hyponatremia after completion of the module.
Conclusions: The results suggest learners’ comprehension and comfort with 
hyponatremia concepts and treatment plans improves after completing our online module. 
Survey feedback regarding the mixed video and case format was positive. Our module 
is an effective method to teach hyponatremia and can serve as a guide for future online 
educational curricula on complex renal topics.
SA-PO183 Poster Saturday
Educational Research
On-line vs Face-to-Face Education to Improve Dietitians’ Clinical 
Competence in Early CKD
Roxana Marquez-Herrera, Laura Cortes-Sanabria, Hector Martinez Ramirez, 
Alfonso M. Cueto-Manzano. Unidad de Investigación en Enfermedades 
Renales, Guadalajara, Mexico.
Background: Adequate clinical competence (CC) of dietitians for prevention and 
management of early chronic kidney disease (CKD) would have an important impact to 
reduce the burden of ESRD. Unfortunately, this is not frequently observed, particularly in 
primary health-care. Online education offers advantages for continuing education; however, 
its effect on CC remains unclear. Aim: To compare the impact of an online vs face-to-face 
education program on dietitians’ CC regarding nutritional care of early CKD
Methods: Eighty-one dietitians were included; renal dietitians or those who were 
currently taking any CKD training were excluded. Dietitians were included in an online 
group (N 56) or face-to-face group (N 25). Educative interventions were developed by a 
multidisciplinary team (clinical and education experts), based on constructivism paradigm 
and focused on nutritional aspects of prevention and management of early CKD. Education 
content and duration (8 weeks) of both interventions were similar; online education was 
asynchronic, face-to-face was performed 1 session (4h)/week. To evaluate CC, a validated 
questionnaire (0-120 points) measuring dietitians’ capability to identify risk factors, 
integrate diagnosis, correctly use of nutritional therapeutic resources and identify iatrogenic 
behaviors, was applied at the beginning and the end of study
Results: Age, gender, work experience (yrs), and previous attendance to online courses 
were similar between groups. Baseline CC score was low in both groups: face-to-face 47 
(41-56) vs online 48 (39-58), p=0.60, but increased in both of them at the end of study: 
face-to-face 74% (29-97, p<0.0001) and online 63% (26-91,p<0.0001); no difference in 
intergroup comparison was observed (p=0.57). In general, 58% of dietitians increased from 
low to high CC (p<0.0001). Terminal efficiency was >90% in both groups, and >90% of 
participants rated the interventions as good or very good
Conclusions: Online and face-to-face educative interventions were successfully 
developed. CC of dietitians increased similarly after both educative interventions. Online 
education could be useful and effective to train dietitians in prevention and management of 
early CKD, overcoming limitations of time, distance and costs of face-to-face education
SA-PO184 Poster Saturday
Educational Research
WhatsApp in Nephrology Training
Kenar D. Jhaveri, Alia Hasan, Steven Fishbane. Nephrology, Zucker School of 
Medicine at Hofstra/Northwell, Great Neck, NY.
Background: We are living in an era of technology where smart phones and hence 
social media have entered into many aspects of our life. Novel educational means are 
necessary to transfer knowledge in the current era of digital learners. WhatsApp is one such 
application that is used by several individuals to communicate internationally. The role of 
this app is unknown in medical education and specifically in nephrology education.
Methods: To explore the potential of WhatsApp as an instructional strategy for 
nephrology fellows via asynchronous question/answer methodology. To evaluate the 
WhatsApp fellows educational venture, focus groups are planned with experienced 
qualitative researchers.
Results: All fellows in our training program-8, participated for a 6 month pilot period. 
5 faculty were assigned to run the app. The faculty would ask 1-2 questions per week that 
were board style multiple style questions and responses were received from all 8 fellows 
for 90% of the questions, with explanations provided. The faculty would then provide the 
correct answer along with the detailed discussion and references. Dialogues and discussions 
would be sparked as a result of questions. There was 100% satisfaction of fellows 
participating in the project. The questions ranged from various topics from ESRD, acid 
base, AKI, glomerular diseases and transplantation. Two focus groups are being planned to 
better evaluate the use of the app as a pedagogical tool integrated into fellowship training. 
First focus group will involve the fellows and a second one will involve the faculty. Results 
are pending for the focus group component of the project.
Conclusions: WhatsApp is an effective social media tool to motivate, augment and 
perhaps improve the learning of nephrology fellows in training. Similar strategies should be 
evaluated in resident and medical student education of nephrology.
SA-PO185 Poster Saturday
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Handheld Ultrasound Devices May Lead to a Transformation of Physical 
Diagnosis Practices in Much the Same Way as Laënnec’s 1816 Invention 
of the Stethoscope
Laith Al-Rabadi,1 Patrick Ockerse,2 Jennifer Cotton,2 Megan Fix,2 James Fair,2 
Qussay Marashly,1 Ragheed Aldulaimi,1 Josephine Abraham,1 Boyd Richards,3 
Isaac E. Hall.1 1Internal Medicine Department-Renal Division, University of 
Utah Hospital, Salt Lake, UT; 2Emergency Department, University of Utah 
Hospital, Salt Lake, UT; 3Division of Pediatric Administration, University Of 
Utah, Salt Lake, UT.
Background: Ultrasonography is a fundamental tool for assessing kidney dysfunction 
and volume status in multiple settings. As new handheld devices connected to small US 
probes have become available, it is now more practical for students to accurately and rapidly 
perform kidney and volume assessments themselves at the bedside. The lack of formal 
kidney US training during medical school and frequent clinical difficulties in determining 
volume status in settings of acute kidney injury (AKI) lead to trainee incompetence with 
regard to kidney imaging and AKI evaluation and management. Thus, our aim was to 
determine whether handheld US technology helps trainees learn significant and practical 
nephrology content.
Methods: For this IRB-approved project, we measured the usefulness of handheld US 
among medical students. We taught basic skills for focused US examination in hospitalized 
settings of AKI to exclude hydronephrosis, determine kidney size and echogenicity, and 
assess volume status by visualizing the inferior vena cava. These interactive, educational 
sessions were incorporated into the University of Utah “Transition to Internship” clerkship 
for 4th-year medical students. Introductory and interactive modules described basic US 
physics and additional concepts to acquire and interpret kidney sonograms. Teaching 
sessions were then followed by an 8-hour hands-on workshop. After participating, students 
were given surveys consisting of questions with five-point Likert scales.
Results: Out of the 64 students that filled out survey responses, 98% indicated that 
the curriculum enhanced their medical education, made them feel competent to perform 
handheld US, and that the handheld US technique was helpful for volume assessment. All 
responding students indicated that handheld US improved their understanding of 3D renal 
anatomy. Ninety-six percent of students wanted more US incorporated into the medical 
curriculum.
Conclusions: Handheld US was very well-received as a valuable teaching tool among 
4th-year medical students. Students were able to demonstrate proper US technique and 
focused interpretation with regard to kidney and volume status assessment, and nearly all 
indicated that the experience enhanced their education.
SA-PO186 Poster Saturday
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Hemodialysis Central Venous Catheter Placement by Nephrology Fellows
Denisse Arellano-Mendez, Javier Soto-Vargas, Julio A. Gutierrez-Prieto, 
Godhy E. Hernandez Gonzalez, Omar I. Delgado-Ayon, Carlos Daniel Jiménez 
Mejía, Leonardo Pazarin-Villaseñor, Ma Anabel Salazar Lopez, Mario A. García 
Cárdenas, Renato Parra Michel. Universidad de Guadalajara, Centro 
Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital 
General Regional No 46 del IMSS, Guadalajara, Mexico.
Background: There is no evidence about the number of central venous catheter 
(CVC) procedures required for a nephrology fellow to acquire competency, besides, these 
procedures are now being perform by other specialties, moving those away from the basic 
training of a nephrology program. Nevertheless, in low and middle-income countries, 
the nephrologist has a key role in CVC placement. Our main objective is to present the 
experience in CVC placement in a nephrology fellowship program.
Methods: During March 2017 to February 2018, six first-year nephrology fellows 
performed 362 procedures. We collected information about number of catheter placed 
by every fellow, technique (anatomic landmarks or ultrasound guidance [USG]), if it was 
urgent, vascular region, number, and type of complications. Then we analyzed factors 
related to occurrence of complications in a multivariate model adjusted for vascular region, 
urgency of the procedure, use of USG and the time since the beginning of the study year.
Results: The median number of procedures was 60 (range 31-90) per fellow. The 
overall success rate was 95.3%, with 98 (27.1%) minor and no major complications. The 
more prevalent complications were bleeding (40, 11%), hematoma formation (15, 4.1%), 
>3 punctures (25, 6.9%), and arterial punctures (17, 4.7%). In the logistic regression
model, the use of USG had a trend toward to a significant association for complications 
(OR 0.62, CI 95% 0.38-1.00, P =0.05), while in a Cox regression the use of USG reached
significance with a 48% risk reduction for complications (HR 0.52 CI 95% 0.33-0.80, 
P <0.01). USG use increased after 90 days of training; therefore, we analyzed the association
of USG to complications considering time as a covariate. Before 90 days the presence of
complications was independent to USG usage (HR 0.81 CI 95% 0.47-1.41, P=0.47), and after
90 days there were a higher risk reduction (HR 0.23 CI 95% 0.11-0.5, P <0.01).
Conclusions: The CVC placement by nephrology fellows is safe and successful; it 
should be part of nephrologist formation and include training on USG to reduce the risk 
for complications.
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Dialysis Catheter Placement Experience of US Adult Nephrology Fellows: 
A National Survey
Hitesh H. Shah, Fatima Sheikh, Kenar D. Jhaveri. Zucker School of Medicine at 
Hofstra/Northwell, Great Neck, NY.
Background: Nephrology fellows in the United States (US) are required to 
acquire skills and demonstrate competency in the placement of temporary/non-tunneled 
hemodialysis catheter (NT-HDC) during fellowship. To gain a greater insight in the dialysis 
catheter placement experience of US adult nephrology fellows, we carried out a national 
survey of nephrology fellows.
Methods: An anonymous on-line survey was created and sent to US adult nephrology 
fellows via fellowship program coordinators in May 2018.
Results: So far, 113 fellows have responded to our survey. 48% were graduating in 
2018. Most NT-HDCs were placed in the hospital. While 26% had not placed any femoral 
NT-HDC during fellowship, 28% had placed >10. 36% had placed >10 internal jugular 
NT-HDC during fellowship, while 28% had placed none. 34% received simulation based 
training, 12% received bedside training, 23% received both simulation and bedside training, 
while 31% did not receive any formal training in NT-HDC placement. 53% had most of 
their NT-HDC placements supervised by a nephrology attending. However, 49% had no 
nephrology attending placing NT-HDC in their institutions. 43% needed to place at least 5 
NT-HDCs before independently performing this procedure during fellowship, while 16% 
required ≥10. While 70% reported having received adequate training in NT-HDC placement 
during their fellowship, only 32% planned to place NT-HDC after graduation. While 67% 
felt that fellowship programs should be required to train fellows in NT-HDC placement, 
majority (57%) felt that nephrologist should not place NT-HDC in clinical practice. Reasons 
cited for those who had inadequate or no training in NT-HDC included: lack of formal 
training (23%), lack of opportunities to place NT-HDC (23%), lack of nephrology faculty 
interest (20%) and lack of faculty expertise (16%). 16% had placed at least 1 tunneled HD 
catheter and only 1 fellow had placed 1 PD catheter during fellowship.
Conclusions: While majority of fellows report adequate training in NT-HDC 
placement, a significant percentage of fellow had not placed a femoral or internal jugular 
NT-HDC during fellowship. Majority received simulation based training, however a 
significant percentage did not receive any formal training in NT-HDC placement during 
fellowship. Fellowship programs should take measures to ensure that all fellows receive 
adequate training in NT-HDC placement.
SA-PO188 Poster Saturday
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Journal Publications of U.S. Adult Nephrology Fellowship Training 
Program Directors
Hitesh H. Shah,1 Vipulbhai Sakhiya.2 1Zucker School of Medicine at Hofstra/
Northwell, Great Neck, NY; 2Northwell Health, Great Neck, NY.
Background: Publication in peer-reviewed journals can be considered as one measure 
of scholarly activity among academicians. Peer-reviewed journal publications (PR-JPs) 
of current US adult nephrology fellowship training program directors (N-TPDs) are not 
known.
Methods: A PubMed search for PR-JPs was conducted for a period of 3 years (2015-
2018) for N-TPDs serving in academic year 2017-18. Data was abstracted in May 2018. 
Publications were categorized as follows: basic science research (BSR), prospective 
clinical study (PCS), retrospective clinical study (RCS), clinical outcomes research (COR), 
randomized clinical trial (RCT), meta-analysis (MA), educational research (ER), quality 
improvement study (QIS), case report/series (CR/S), review article (RA), editorial (E) and 
letter to editor (LT-E). Data was analyzed for 150 N-TPDs.
Results: 35 (23%) N-TPDs had no PR-JP in the last 3 academic years. While 33% had 
≤3 publications, 31% had 4-9 publications and 12% had ≥10 publications. We identified 
656 PR-JPs by N-TPDs over the past 3years, out of which 125 (19%) publications had an 
N-TPD as the primary author (PA), 176 (27%) had an N-TPD as a corresponding author
(CA) and 96 (15%) had an N-TPD as both the primary and CA. 37% were clinical research
(PCS, RCS, COR, RCT, MA) related publications. The remaining publications were as
follows: RA-22%, CR/S-16%, BSR-7%, ER-6%, E-6%, LT-E-3%, and QIS-2%. While 
35% of N-TPDs had at least one PR-JP as a PA over the past 3 years, 41% had at least one 
publication as CA and 31% had at least one as primary and CA. In the last 3 years, 83 (55%) 
N-TPDs had authored at least one clinical research related publication, 25 (17%) had an
ER related publication, while 18 (12%) had a BSR publication. When analyzed by gender, 
51 female N-TPDs had total of 247 PR-JPs with a mean of 4.8 ±5.09 in past 3 years as
compared to 99 male N-TPDs who had total of 409 PR-JPs with a mean of 4.1 ±5.05. There 
was no statistically significant difference between both groups (p = 0.42).
Conclusions: Nearly one in 4 N-TPDs had no PR-JP over the last 3 years. Nearly one-
third N-TPDs were primary and CA on at least one PR-JP over the last 3 years. While half 
of the PR-JPs were either clinical research, BSR or ER related publications, the remaining 
were CR/S, RA, E, LT-E, or QIS. The top 2 categories with the most publications were RA 
and CR/S. Female N-TPDs had more PR-JPs than male N-TPDs.
SA-PO189 Poster Saturday
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Enhancing Interest and Learning in Nephrology Among US Medical 
Students
Hitesh H. Shah, Nupur N. Uppal, Kenar D. Jhaveri. Zucker School of Medicine 
at Hofstra/Northwell, Great Neck, NY.
Background: Interest in nephrology careers remains low among United States (US) 
medical graduates. The type of nephrology elective that US medical students experience 
may play an important role in creating and enhancing interest in nephrology career.
Methods: A redesigned 4-week nephrology elective was created at our institution 
for US medical students. Our redesigned elective included both 2-week inpatient (IP) and 
2-week outpatient (OP) nephrology experiences. The OP rotation included 10 half-days
of various nephrology clinic experiences, 2 half-days of immediate post-transplant clinic,
1 half-day of kidney donor evaluation clinic, 2 half-days of PD clinic and 3 half-days of
outpatient HD rounding. Our redesigned elective also included educational conferences.
To evaluate the elective experience, all medical students were asked to complete an on-line 
survey following the completion of their rotation.
Results: From July 2012 to February 2018, twenty-five 4th year medical students 
(from 15 different US medical schools) completed our redesigned elective. All students 
responded to our survey. All reported adequate OP nephrology experience during their 
elective. 80% of the students had worked with 1 or 2 faculty members during the IP setting. 
In comparison, 88% were exposed to at least 4 different faculty members during the OP 
experiences. 92% had interacted with at least 4 different fellows during the elective. All 
reported that the elective experience enhanced their exposure and knowledge in nephrology. 
They also thought that this elective structure provided them with a better insight into what 
nephrologists do in practice. 88% of the students reported that this elective experience 
created an interest in nephrology career. Majority (64%) of the students responded that they 
would consider nephrology as one of their 3 top career choices as a result of this elective 
experience.
Conclusions: Measures to enhance interest and learning in nephrology among medical 
students are needed. We believe that the restructured elective provides the medical student 
with a much needed and realistic exposure to nephrology careers. Based on our experience, 
we recommend all nephrology training programs to consider this elective structure for 
medical students.
SA-PO190 Poster Saturday
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Development and Preliminary Validation of a Formative Peritoneal 
Dialysis Objective Structured Clinical Examination
Brian C. Y’Barbo,1 Christina M. Yuan,1 Sam W. Gao,4 Christopher J. LeBrun,2 
Robert Nee,1 David K. Oliver,1 Mark C. Saddler,3 Maura A. Watson,1 
Lisa K. Prince.1 Nephrology Education Research & Development Consortium 
1Walter Reed National Military Medical Center, Bethesda, MD; 2Nephrology 
Associates PC, Columbus, MS; 3Durango Nephrology Associates, Durango, 
CO; 4Naval Medical Center Portsmouth, Virginia Beach, VA.
Background: Only about 10% of incident end-stage renal disease patients beginning 
renal replacement therapy select peritoneal dialysis (PD) in the US. One reason may be 
limited PD experience during Nephrology fellowship training. Training programs often 
use simulation to boost experience in the absence of clinical opportunities. Structured test 
questions can provide this simulation, help to assess fellow knowledge in this area, and aid 
in determining program level practice patterns.
Methods: We devised a formative objective structured clinical examination (OSCE) 
focusing on the management of a PD patient with peritonitis and ultrafiltration dysfunction. 
After blueprint development and identification of key objectives (based on the International 
Society for Peritoneal Dialysis Peritonitis practice guideline), the case and the scoring 
rubric were constructed based on a real-life example. After review by 2 subject experts, it 
was evaluated by a 9-member test committee consisting of 8 board-certified nephrologists 
(4 academic, 4 clinical) and one experienced PD nurse. The final case consisted of 10 free 
response questions (total 22 points) and required written orders for PD exchanges and 
antibiotic management.
Results: The final OSCE was sent to two groups (test and validation committees) to 
determine the passing threshold. The test committee set the passing threshold using Ebel’s 
method. The passing score was set at 16 of 22. Median relevance was essential or important 
for all questions with a content validity index of 91%. The validation committee (16 board-
certified practicing nephrologist a median of 5 years (IQR 9) post-graduation) took the 
test. Mean score was 19 (SD 2). 94% of the validators passed the test and scored 85% on 
evidence based questions. Median time to take the test was 33 minutes (IQR 19).
Conclusions: Preliminary validation is now complete, and the next phase will involve 
testing of nephrology fellows who have just completed their first year of fellowship training. 
Disclaimer: The views expressed are those of the authors and do not reflect the official 
policy of the Department of the Army/Navy/Air Force, the Department of Defense, National 
Institutes of Health, or the United States Government.
Funding: Other U.S. Government Support
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Safety of Kidney Biopsy Performed by Nephrology Trainees vs Interven-
tional Radiology
Manasi Bapat,1 Timothy C. Martin,6 Siddhartha Kattamanchi,2 Joji E. Tokita,3 
Shuchita Sharma,1 Girish N. Nadkarni,4 Steven G. Coca,5 Swati Mehta,6 
Lili Chan.1 1Icahn School of Medicine, Mount Sinai Hospital, NY, New York, NY; 
2Mount Sinai Medical Center, New Rochelle, NY; 3Mount Sinai School of 
Medicine, New York, NY; 4Ichan School of Medicine, New York, NY; 5Icahn 
School of Medicine at Mount Sinai, New York, NY; 6Albany Medical Center, 
Rensselaer, NY.
Background: Kidney biopsy is the gold standard in the diagnosis and management of 
kidney diseases, yet most nephrology fellows are not getting adequate training in kidney 
biopsies. Our aim was to review kidney biopsies performed by nephrology trainees under 
the supervision of nephrologist with outcomes compared to interventional radiology (IR).
Methods: This is a retrospective cohort study of 251 patients who underwent a 
native kidney biopsy at Mount Sinai Hospital (MSH) and Albany Medical Center (AMC) 
from 2016 - 2017. Biopsies done at MSH were performed by nephrology fellows under 
nephrology supervision while those done at AMC were done by IR.
Results: There were 251 patients who underwent kidney biopsy; mean age was 
51 ± 16 years, 52% were male, and 60% were done by nephrology fellows. The most 
frequent indication for biopsy was non-nephrotic range proteinuria, 83 (33.2%). ddAVP 
was given in15 of biopsies performed by nephrology trainees and 1 of biopsies performed 
by IR; there was no difference in BUN between the MSH or AMC cohorts (40±24 mg/dL 
vs 37±27 mg/dL respectively, P=0.24). Diagnostic yield (≥11 glomeruli) did not differ by 
operator, trainee 89% vs. IR 94%, p=0.14. There was no difference in hematoma or track 
formation by proceduralist (IR 6% vs. trainee 10%, p=0.1) or for ED visits for outpatient 
biopsies (IR 4% vs trainee 4%). Transfusions were higher in those performed by IR 
(11% vs. 1%, P<0.001). Mean change in hemoglobin while not statistically different was 
clinically meaningful (trainee 0.2±0.7 g/dL vs. IR 1.6±10.7, P=0.1) After adjustment for 
patient and biopsy characteristics, prebiopsy hemoglobin but not proceduralist type was a 
significantly associated with higher odds of 1gm drop in hemoglobin, (adjusted odds ratio 
1.4, 95% CI 1.1 – 1.7).
Conclusions: Nephrology trainees can safely perform kidney biopsies with similar 
diagnostic yield and complication rates.
Funding: NIDDK Support
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Viability and Fidelity of Low-Cost Gelatin Percutaneous Renal Biopsy 
Phantom in Simulation Training
Elena Qirjazi,1 Ian Y. Chan,2 Juliya Hemmett,1 Faisal Rehman,1 Roya Etemad-
Rezai.2,3 1Nephrology, Western University, London, ON, Canada; 2Radiology, 
Western University, London, ON, Canada; 3London Health Scinces Center, 
Western University, London, ON, Canada.
Background: Percutaneous renal biopsies are crucial for the accurate diagnosis and 
prognosis of many renal diseases. Most trainees learn this procedure directly on patients, 
despite its risks. Commercially available phantoms are available for simulation training, 
but they are expensive and have a limited number of needling attempts. We developed 
and evaluated an inexpensive kidney biopsy phantom created using ingredients available 
in most grocery stores.
Methods: The renal biopsy phantom was constructed by inserting a weighted porcine 
kidney into a gelatinous solution consisting of a mixture of unflavored gelatin, sugar-free 
psyllium hydrophilic mucilloid fiber (Metamucil), and boiling water. The phantom was 
refrigerated to allow the gelatin to solidify before use. We evaluated this phantom during 
three separate 1-hour workshops attended by a combination of nephrologists, nephrology 
fellows, and radiology and internal medicine residents. Each workshop consisted of a 
10-minute didactic demonstration on how to perform ultrasound-guided renal biopsies. The 
participants then had the opportunity to perform simulated ultrasound-guided biopsies on
1) the gelatin-phantom, and 2) a commercially available phantom (cost ~ $4000 USD). 
Participants evaluated the workshop and the phantoms using anonymous surveys. Data 
were analyzed using descriptive statistics and two sample t-tests.
Results: A reproducible gelatin phantom was engineered with a material cost under 
$20 USD. 39 individuals participated in the 3 workshops and completed the surveys. Most 
participants agreed that kidney biopsy simulations are helpful in training residents, and 
found the workshop effective. The gelatin and commercial phantoms were rated similarly 
over a number of characteristics, including size, consistency and sonographic changes 
with multiple needling. Overall, the gelatin phantom was considered superior by 80% of 
participants. Participants commented: “Great session!”, and “Gelatin phantom is a brilliant 
simulation tool. It is cheap and you can make new models as needed for tracks”.
Conclusions: We were able to construct an inexpensive and easily reproducible 
gelatin-based renal biopsy phantom. Our phantom was non-inferior to a more expensive 
commercial counterpart.
SA-PO193 Poster Saturday
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Identifying and Integrating Patient and Caregiver Perspectives in Clinical 
Practice Guidelines for Percutaneous Renal Biopsy
Talia M. Gutman,2,1 Pamela A. Lopez-Vargas,1 Karine E. Manera,2,1 
Jonathan C. Craig,1,4 Laura J. James,2,1 Allison Tong,2,1 Paul J. Champion de 
Crespigny.3 KHA-CARI Renal Biopsy Guideline Writing Group and KHA-
CARI Office Team 1Centre for Kidney Research, The Children’s Hospital at 
Westmead, Sydney, NSW, Australia; 2School of Public Health, The University of 
Sydney, Sydney, NSW, Australia; 3Nephrology, The Royal Melbourne Hospital, 
Parkville, VIC, Australia; 4College of Medicine and Public Health, Flinders 
University, Adelaide, SA, Australia.
Background: Percutaneous renal biopsy is often essential for providing reliable 
diagnostic and prognostic information for people with suspected kidney disease, however 
the procedure can lead to complications and concerns among patients. This study 
aims to identify and integrate patient priorities and perspectives into the Kidney Health 
Australia – Caring for Australasians with Renal Impairment clinical practice guidelines for 
renal biopsy, to ensure patient-relevance.
Methods: We convened a workshop, consisting of three simultaneous focus groups and 
a plenary session, with ten patients who had undergone a renal biopsy and seven caregivers. 
Topics and outcomes prioritized by patients and their caregivers were compared to those 
identified by the guideline working group, which was comprised of seven nephrologists. 
Transcripts and flipcharts were analyzed thematically to identify the reasons for participants’ 
choices.
Results: In total, 34 topics/outcomes were identified, 14 of which were common to 
the list of 28 previously identified by the guideline working group. Most of the new topics 
identified by patients/caregivers were related to communication and education, psychosocial 
support, and self-management. We identified five themes underpinning the reasons for topic 
and outcome selection: alleviating anxiety and unnecessary distress, minimizing discomfort 
and disruption, supporting family and caregivers, enabling self-management, and protecting 
their kidney. A new topic on patient care and education was added to the guideline as a 
result.
Conclusions: Patient and caregiver involvement in developing guidelines on renal 
biopsy ensured that their concerns and needs for education, psychosocial support, and 
self-management were explicitly addressed; enabling a patient-centred approach to renal 
biopsies.
Funding: Government Support - Non-U.S.
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Breaking Bad News: A 2 Year, Multi-Center Simulation Exercise Assessing 
Renal Replacement Therapy and Kidney Biopsy Communication Skills
Lisa K. Prince,1 Brian C. Y’Barbo,1 Jeffrey A. Mikita,1 Anna M. Howle,1 
Scott D. Cohen,7 Oliver Lenz,2 Laura J. Maursetter,3 Sharon E. Maynard,4 
Stephen M. Sozio,5 Amy N. Sussman,6 Christina M. Yuan.1 Nephrology 
Education Research & Development Consortium 1Walter Reed National Military 
Medical Center, Silver Spring, MD; 2University of Miami, Miami, FL; 3University 
of Wisconsin School of Medicine & Public Health, Madison, WI; 4Lehigh Valley 
Health Network, Emmaus, PA; 5Johns Hopkins University School of Medicine, 
Baltimore, MD; 6University of Arizona, Tucson, AZ; 7The George Washington 
University School of Medicine and Health Sciences, Washington, DC.
Background: There are few quantitative, simulation-based assessments for nephrology-
specific interpersonal communication skills (ICS) and professionalism (PROF) milestones. 
We developed a “Breaking Bad News” simulation to assess fellow counseling competence 
in 3 scenarios: a surrogate decision maker for acute renal replacement therapy (RRT), a 
patient with end stage kidney disease for RRT, and a patient with glomerulonephritis for 
kidney biopsy.
Methods: After reviewing a clinical summary, fellows counsel each of the 3 simulated 
patients (SPs) who have received a summary of their character’s medical and social 
situation. Faculty were instructed on the scenarios, use of the Mini-CEx, and the information 
provided to fellows and SPs. Fellow performance was assessed using 2 previously validated 
tools: the Mini-Clinical Examination Exercise (Mini-CEx) and the Essential Elements of 
Communication-Global Rating Scale 2005 (EEC-GRS). Both have a 1-5 rating scale with 
scores of 3 or greater being satisfactory. SPs rate fellow ICS and PROF using the EEC-GRS, 
and nephrology faculty, observing from outside of the room, use the Mini-CEx to evaluate 
medical knowledge and ICS. Fellows receive 5 minutes on-the-spot performance feedback 
at the end of each 15 minute scenario from both SP and faculty.
Results: 56 fellows completed the OSCE. The 2017 administration included 26 
fellows (5 training programs), and the ongoing 2018 administration included 30 fellows 
(6 of a total 8 programs). EEC-GRS scores were not significantly different between first 
and second year fellows (p=0.27). No significant difference was found between training 
years when comparing any EEC-GRS score <3 or any Mini-CEx score <3. Only 13% of 
fellows scored <3 on any item in the chronic dialysis counseling Mini-CEx, while 45% and 
43% respectively scored <3 on at least one item on the acute RRT counseling and kidney 
biopsy scenarios.
Conclusions: Overall, fellows communicate well and professionally with high ratings 
on EEC-GRS. Fellows counsel patients well on chronic RRT but had deficiencies in 
counseling on risks of acute RRT and kidney biopsy. The results allow program directors 
to adjust curriculum and provide quantitative assessment of ACGME milestones progress.
Funding: Other U.S. Government Support
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Differing Expectations of Transitions of Care Within a Nephrology 
Practice: Should We Transition to Train More?
Sayee Sundar Alagusundaramoorthy,1 Samantha J. Strennen,3 
Laura J. Maursetter,2 Gauri Bhutani.1 1University of Wisconsin, Madison, WI; 
2University of Wisconsin School of Medicine & Public Health, Madison, WI; 
3University of Wisconsin-Madison, Madison, WI.
Background: Ineffective transitions of care (TOC) communication is a major 
contributing factor to medical errors.
Methods: As part of an endeavor to standardize TOC practice in our division, we 
conducted a two-step survey-based study of TOC perceptions among faculty and fellows 
over the last one year. Data was collected anonymously via two different electronic surveys. 
The first (Survey1) focused on providers’ perceptions of the TOC practice in the division. 
The second (Survey2) asked for a self-assessment about providers’ own TOC procedure. 
Fisher’s exact test was used for statistical analysis of the survey results.
Results: Attendings were significantly less satisfied with the current division TOC 
practice as compared to fellows (table). Both attendings and fellows appeared equally 
satisfied with their own TOC methods. APP response fell between physician and fellow 
responses for most questions. Most faculty (71%) and fellow (66.7%) responses indicated 
they would prefer changes in current TOC practice.
Conclusions: Our results reveal a gap between TOC expectations and self-reflection 
amongst faculty and fellows in one division. This may reflect a lack of formal training 
to align expectations in TOC practice. The general acceptance of the division TOC 
environment by fellows likely stems from the fact that the majority of TOC documentation 
is done by this group. Overall, most providers were interested in changes to improve TOC 
practices. We plan on step-wise changes including instituting a standardized division TOC 
policy, EMR support, formal training in TOC, and continuing assessment of TOC practice 
and environment in the division.
SA-PO196 Poster Saturday
Educational Research
Leveraging the Internet to Showcase Abstracts and ePosters: Online 
Engagement at a National Meeting
Vijay Lapsia, Joseph A. Vassalotti. Icahn School of Medicine at Mount Sinai, 
New York, NY.
Background: Scientific posters are traditionally printed and presented on site to 
interactively share research findings. However, this format is limiting, particularly with 
digital media and archival that allows for review of posters by attendees virtually after the 
meeting is over. It is unknown if hosting abstracts and posters online can improve access 
and enhance engagement.
Methods: Authors of accepted abstracts for National Kidney Foundation’s 2018 Spring 
Clinical Meetings were invited to upload posters in an online gallery displaying abstracts, 
posters and supplementary media. As a part of the submission, authors completed a brief 
survey. Web analytics software tools were embedded to measure audience engagement and 
usage during and after the meeting. Categorical data from the survey and audience data 
from web analytics were analyzed for frequency & descriptive statistics and usage trends.
Results: A total of 458 abstracts with 254 supplementary media files were submitted 
for consideration, 365 of which were accepted for publication and currently displayed at 
https://nkf2018scm.site online. Almost all authors gave permission to publish the poster 
online (96.7%) and a little over half (58.6%) uploaded posters to the online gallery. The 
survey response rate was 35.2%. Top features that users recommended included the ability 
to connect with other authors (73.2%), comment and save gallery items (68%), ability to 
view the gallery as well as media files including video and images on smartphones (64.6%) 
and integration with social media to share submissions (52.7%). Audience analytics 
revealed 2,114 users from 59 countries accessed the gallery within 30 days of the meeting, 
1,190 of which came online during the 4 day meeting. Users were predmoninatly from 
the USA (78.04%), more than half (55.95%) used a mobile device, with 78.5% on iOS 
devices and 30.2% using the chrome browser. Peak gallery usage coincided with the first 
two days of the meeting with late morning and early evening being the busiest hours. 
Notable referral sources included stocktwits.com a social media platform for investors 
(98 referrals), medical news sites and pharma company intranets.
Conclusions: Hosting abstracts, posters and supplementary media in an online gallery 
can extend and enhance engagement during and after the meeting. Access to the gallery on 
mobile devices may be key to improving usage.
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Use of a Standardized Curriculum to Increase Resident Interest in 
Nephrology
Srikar Kumar. University of North Carolina, Chapel Hill, NC.
Background: Interest in nephrology fellowship continues to be low among current 
internal medicine residents. While there are many reasons for this decline, several studies 
have suggested that residents develop negative perceptions of the field during their training. 
Given that most residents only spend a little time during their training working with the 
nephrology service, it is possible that they have minimal exposure to areas such as transplant, 
nephropathology, critical care nephrology, and interventional nephrology. This quality 
improvement project aims to increase resident interest in nephrology by implementing a 
curriculum for residents rotating on the nephrology consult service, increasing exposure 
to different aspects of the field, and facilitating mentorship. At our institution, residents 
have an opportunity to rotate through with the nephrology inpatient consult service during 
elective time. Currently, there are no guidelines for the residents while on the nephrology 
elective; they generally see 1-2 consults per day with guidance from a fellow or attending. 
Without any recommended guidelines, many residents finish their elective with no exposure 
to the breadth of the field.
Methods: A preliminary ten question survey was sent to the internal medicine residents. 
This survey was simple, with yes or no questions, determining what residents had exposure 
to during their elective. The final question assessed their interest in nephrology. Based on 
these findings, a curriculum was given to residents at the beginning of their rotation. Every 
six months, the survey will be resent and the curriculum revised based on the findings.
Results: A majority of residents received basic didactic lectures for topics such as acute 
kidney injury and fluids/electrolytes. But, most did not have exposure to dialysis catheter 
placement or renal biopsies, had no bedside teaching regarding how dialysis or CRRT 
machines work, and did not review renal pathology with the in-house renal pathologists. 
These are among the regular activities performed at our institution.
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Conclusions: Without any guidelines, the survey confirmed that many residents were 
missing out on unique opportunities in nephrology. While the project is ongoing with 
changes to come, the preliminary findings suggest that a standardized curriculum with focus 
on mentorship can potentially improve resident experiences in our field.
SA-PO198 Poster Saturday
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Keeping It Renal: Grassroots Effort to Increase Local Interest in 
Nephrology
Sana Waheed,1 Stephen M. Sozio,2 Tripti Singh,1 Laura J. Maursetter.3 
1University Of Wisconsin School Of Medicine and Public Health, Madison, WI; 
2Johns Hopkins University School of Medicine, Baltimore, MD; 3University of 
Wisconsin School of Medicine & Public Health, Madison, WI.
Background: National efforts have been made to increase medical student interest in 
nephrology through ASN sponsored programs like TREKS and STARS. Our goal was to 
create a local effort at University of Wisconsin (UW) to publicize nephrology as a career 
option for medical students to improve recruitment to nephrology.
Methods: As a result of curricular tranformation at UW in 2016, renal pathophysiology 
was taught during the first months of medical school with students learning about complex 
renal diseases early in their career with a more hands-on, case-based approach. This early 
exposure provided the opportunity to create a forum where students with an interest in 
nephrology could come together with nephrology faculty and explore the options of the 
field. As a result, the students created the nephrology interest group (N-IG). We describe the 
early experience of this, and analyze trends in involvement in nephrology-related activities.
Results: The N-IG hosts three events during the year: 1. Discussing different career 
trajectories in nephrology by faculty in various roles, 2. “Night with Nephrology”, which 
was a jeopardy style game with a combination of trivia and nephrology questions and 3. 
Discussing interesting cases in nephrology with faculty to apply pathophysiology to patient 
care. By highlighting the cognitively stimulating and diverse nature of nephrology, we 
were able to increase the number of students spending dedicated time in nephrology related 
activities, most of them showing a statistically signifcant trend by year (Figure 1)
Conclusions: At our institution, a student led nephrology interest group was effective 
in increasing recruitment to nephrology related experiences. Similar interest groups can 
be created at other institutions by early nephrology involvement in the medical school 
curriculum, harnessing the energy of enthusiastic students, and utilizing support of 
nephrology faculty. Long-term follow up will determine if this involvement is fruitful for 
recruitment into the field.
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Targeted Primary Prevention Pilot for High School Students Living in 
High-Risk Areas for ESRD
Julie A. Wright Nunes,1 Panduranga S. Rao,1 Ben Ransier,2 Jean DuRussel-
Weston,2 Brad Newman,2 Kim Eagle.1 1University of Michigan Health System, Ann 
Arbor, MI; 2University of Michigan, Project Healthy Schools, Ann Arbor, MI.
Background: Development of chronic kidney disease (CKD) risk factors depends 
heavily on behaviors learned early in life. There is a paucity of research examining ways to 
improve youth health behavior and education to prevent later development of CKD.
Methods: A Health and Wellness community-based program partnered with clinicians 
and educators at one academic medical center to develop a kidney education module. 
This module was delivered by two kidney doctors to 11th grade students at an urban high 
school in Detroit, Michigan. The 1.5 hour kidney education module included didactic and 
hands-on exercises that were literacy-sensitive and introduced students to kidney anatomy, 
physiology, and function as well as risk factors for CKD and health behaviors needed to 
prevent it. Pilot aims were to; 1. Examine feasibility of delivering the kidney education 
module to high-school science classes, and 2. Determine student perceptions about the 
usefulness of the kidney education module.
Results: Thirty-seven students and one science teacher received the kidney education 
module in March 2016. Thirty-six students filled out voluntary surveys consisting of six 
questions asking about their perceptions of the kidney education module. All students 
(n=36, 100%) were of African American race and in the 11th grade. One-hundred percent 
(n=36) said the kidney education was personally helpful and that they learned “a good 
amount / a lot”. Forty-four percent (16 students) reported knowing someone afflicted by 
kidney disease. The majority said the kidney education module would be helpful for future 
students (n=34, 94%), and that they would share what they learned with family (n=24, 
67%) and friends (n=22, 61%). The program was repeated in Spring of 2017, and is now 
incorporated into the standard curriculum -- taught annually by the high school science 
teacher.
Conclusions: This pilot offers a promising model for educating and empowering youth 
to learn about chronic kidney disease and its prevention. Feasibility was supported in rapid 
uptake and adoption at the school. Student perceptions were overwhelmingly positive. 
There may be secondary gains when students share what they learned with family / friends. 
Next steps include adapting the program for other schools and examining its impact on 
behaviors, knowledge and clinical indices over time.
Funding: NIDDK Support
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Improving Health Behavior and Supporting Kidney Health Literacy in 
Kids to Prevent Kidney Disease
Julie A. Wright Nunes,2 Kim Eagle,2 Ben Ransier,1 Jean DuRussel-Weston,1 
Brad Newman,1 Panduranga S. Rao.2 1University of Michigan, Project Healthy 
Schools, Ann Arbor, MI; 2University of Michigan Health System, Ann Arbor, MI.
Background: The majority of chronic kidney disease (CKD) is preventable and largely 
depends on health knowledge and behaviors acquired early in life. There is a paucity of 
research examining ways to improve youth health behavior and education to prevent CKD.
Methods: The objective of this study was to pilot test a literacy-sensitive kidney 
education module to support healthy behavior and reduce long-term modifiable risk factors 
for kidney disease in youth located in two middle schools; one within the city of Detroit, 
Michigan. The other, in a suburb outside of Detroit. The kidney education module included 
3 kidney health lesson plans delivered to 6th and 7th-grade students by their science teachers 
during science class. Content was didactic and hands-on, and included education on kidney 
structure, function and behaviors needed to reduce risk for CKD. We assessed feasibility of 
and fidelity to the kidney education module by direct observation, and elicited student and 
teacher perspectives about the program using standardized surveys.
Results: One-hundred and ninety-one (n=191) students received the kidney education 
module; 53% were located in the Detroit-based middle school and 47% in the outlying 
suburb. Collective demographics were: 28% African American, 50% female, 33% Hispanic 
or Latino, 12% Asian, and < 10% other / combined races. Science teachers (n=3) exhibited 
high fidelity with 100% completion of all 3 lesson plans at both middle schools. Eighty-
five percent of students said they learned “a good amount / a lot”; 76% thought the kidney 
education would be helpful for other students; 51% shared what they learned with family 
or friends; and 65% said they were interested in receiving more science lessons about other 
body systems. Teachers and students reported an increase in knowledge about the kidneys 
and kidney disease. Next steps will include assessment of long-term knowledge gains and 
intent for behavior change in students over time.
Conclusions: Our kidney education module was feasible to implement seamlessly 
into two diverse middle school science curriculums. Both teachers and students reported 
immediate knowledge gains. Students rated the program very favorably. Future work will 
examine associations between the kidney education module and additional psychosocial, 
behavioral and clinical indices in students over time.
Funding: NIDDK Support
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Raising Awareness on AKI: A Latin American Experience
Raul Lombardi,1 Alejandro Ferreiro,8 Guillermo J. Rosa diez,2 Alvaro Margolis,3 
Luis Yu,4 Mauricio Younes-Ibrahim,9 Emmanuel A. Burdmann,7 Fátima Oeyen,5 
Walter Douthat.6 1Servicio Medico Integral, Montevideo, Uruguay; 2Hospital 
Italiano de Buenos Aires, Buenos Aires, Argentina; 3EviMed, Montevideo, 
Uruguay; 4University of Sao Paulo School of Medicine, Sao Paulo, Brazil; 
5AFEd Learning, Montevideo, Uruguay; 6Hospital Privado-Universitario de 
Cordoba, Cordoba, Argentina; 7University of Sao Paulo Medical School, Sao 
Paulo, Brazil; 8School of Medicine, MONTEVIDEO, Uruguay; 9Internal 
Medicine, University of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Raising awareness on acute kidney injury (AKI) is an essential strategy 
for minimizing the burden of this lethal syndrome, and so the AKI Commission of the Latin 
American Society of Nephrology and Hypertension carried out an educational program 
based on network learning.
Methods: Two online courses with similar methodology were done, one for 
nephrologists and the other for primary care physicians (PCP). The courses were developed 
as a distance education, asynchronous online modality with multiple educational strategies: 
readings, videos, e-rounds and clinical simulation. Knowledge gain was explored through a 
10-question test before and after completing the course.
Results: Course for Nephrologist: 779 participants from 21 countries; 52% male; 46%
under 35 yrs. Mean qualification increased from 5.87 to 8.01 (36% gain of knowledge). 
Course for PCP: 2011 participants, 81% of whom physicians. Time from graduation <5 
years in 52%. In both courses, clinical simulation was considered the best part and lack 
of time the main limitation for learning. Because 48% of attendees of the nephrologists’ 
course stated their will to participate in AKI activities, a Latin American AKI Network 
site (RedIRA) composed by a brief review, a clinical forum, a self-assessment and a 
Educational Research
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bibliography on AKI was launched on a monthly basis on November 2016. To date there 
are 335 users from 18 countries.
Conclusions: Distance education techniques were effective for learning about AKI, 
and are a potential tool for the development of a sustainable structure for communication, 
exchange and integration of physicians involved in the care of patients with AKI.
Funding: Private Foundation Support
Comparative table of course’s feaures
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Will the Nephrologist See You Now? Results from the ASN/ERA-EDTA/
ISN Global Nephrology Workforce Survey
Kurtis Pivert,1 Stephen M. Sozio,2 Fergus J. Caskey,3 Adeera Levin.4 1Workforce 
and Career Advancement, American Society of Nephrology, Washington, DC; 
2Johns Hopkins University School of Medicine, Baltimore, MD; 3University of 
Bristol, Bristol, United Kingdom; 4St. Paul’s Hospital and University of British 
Columbia, Vancouver, BC, Canada.
Background: In low- and middle-income countries, concerns exist about nephrology 
workforce adequacy to meet population needs; and in high-income regions, concerns exist 
about declining interest in nephrology among trainees. ASN, ERA-EDTA, and ISN initiated 
a joint project to determine how kidney care delivery trends may affect future workforce 
demands by quantifying variation in nephrology scope of practice at the country- and 
region-specific level.
Methods: A survey was designed to capture national kidney health delivery measures, 
including nephrology training/certification and scope of practice; number of nephrologists/
country; and range of kidney care provided by nephrologists, other physicians, and 
extenders. Given the global audience, the tool was translated and adapted to several formats 
before being distributed to leaders of national nephrology or medical societies in 167 
countries.
Results: Sixty-eight countries (41%) have responded. There was little variation between 
regions in the scope of nephrology practice, with nephrologists the primary physicians for 
most key kidney health services/therapeutic areas (Fig 1 left). Yet ~50% noted nephrologists 
were not the primary physician for CKD stages 1–3 and hypertension. Nephrologists 
commonly prescribe biopsies (98%) yet are less likely to perform them (71%) (Fig 1 right). 
Stratified by region, Europe demonstrated the most intra- and interregional variability in 
scope of practice (e.g., 42% of European respondents reported nephrologists were primarily 
responsible for CRRT vs. 64% globally). A majority (60%) required nephrologists to be 
present in the dialysis facility, and many nephrologists rounded each dialysis session 
(hospitals, 50%; other facilities, 41%).
Conclusions: The Global Nephrology Workforce Survey found less interregional, 
but substantial intraregional, variation in the scope of kidney health services provided by 
nephrologists. A complete analysis of kidney health delivery trends will be translated to help 
assess nephrology workforce demands and inform regional efforts to ensure patients receive 
consistent, high-quality care.
Fig 1
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The 2018 NKF Survey of Nephrology Advanced Practitioners
Kim Zuber,1 Kevin F. Erickson,2 Jane S. Davis.3 1American Academy of 
Nephrology PAs, Oceanside, CA; 2Baylor College of Medicine, Bellaire, TX; 
3University of Alabama at Birmingham, Birmingham, AL.
Background: For the last 10 years, NKF has administered a biannual online survey 
open to all nephrology APs asking about demographics, scope of practice, working 
experience and benefits. We describe the survey process and key findings from the most 
recent survey administered in early 2018.
Methods: A Survey Monkey link was sent to all nephrology APs (PAs, NPs, CNS) 
belonging to NKF’s Council of APs. Respondents were encouraged to share the survey 
link with any nephrology AP, NKF member or not. The survey was open from 1/18-4/18 
with monthly reminders & a push for responses at Spring Clinical Meetings. Response rate 
was 64%.
Results: Survey responses included 47 states and DC, with the most results from 
TX, OH, NC, GA and IL (18,16,14,13,13 respectively). The 2018 survey indicated an 
increase in minority representation among APs & a shift towards a younger workforce. HD 
management has been, and continues to be, a major activity of nephrology APs with 86% 
involved. Among APs reporting HD management, 82% conducted MCP visits. The average 
number of HD patients/wk is 50-100, a decrease from previous surveys. The average 
number of HD units/wk is 2-3 & 1-2 hours/wk driving. Office/Clinic duties were reported 
by 71% of the respondents with CKD clinic & emergent appointments (hospital discharge/
ESRD/AKI work-ins) common. Teaching (patients, APs, RNs, staff) was reported by 54% 
of respondents, while 23% of respondents saw PD patients; mainly in PD clinic. 47% of 
respondents see patients in the hospital, with the majority seeing consults and inpatient 
rounds. More APs report taking call (HD/PD, hospital and office) although the majority 
report no after-hours call. Average salaries increased to $106,000/yr with PAs earning more 
than NPs. This was the 10th year in a row of salary increases, although the rate of increase 
has decreased. Most common benefits include CME, malpractice, retirement and health 
insurance.
Conclusions: The NKF survey includes a detailed overview of the nephrology AP 
workforce in the United States. While the nephrology AP job description has changed 
slightly over time, with more time spent on call, outpatient dialysis remains an important 
area of AP involvement and APs continue to work in hospitals, office/clinic and are involved 
in education. It will be important to continue monitoring the evolution of the role of APs 
in nephrology, as they continue to complement the needs of the nephrologist and increase 
income to the practice.
Funding: Private Foundation Support
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A Biopsy of the Nephrology Workforce in a Low-Middle Income Country: 
The Guatemalan Example
Pablo Garcia,1 Ever O. Cipriano,2 Vicente Sanchez Polo.2 1Saint Peter’s 
University Hospital, New Brunswick, NJ; 2Nephrology, Instituto Guatemalteco 
de Seguridad Social, Guatemala, Guatemala.
Background: Chronic kidney disease (CKD) is an increasing global health concern, 
with increasing prevalence in low to middle income countries. The availability of 
nephrologists is integral to providing care to a large population of CKD patients. In this 
study, we describe and characterize the nephrology workforce in Guatemala.
Methods: Using the National Registry of Nephrologists, we divided practices by 
private settings, academic settings, or those in both settings. We reported the number of 
nephrologists per million inhabitants using data from the Guatemalan Institute of Statistics. 
We also determined the area of practice (urban or rural), and characterized practitioners 
based on the country of training. Lastly, we determined the number of fellowship positions 
available in Guatemala.
Results: We note a total of 72 nephrologists in Guatemala, of which 64 were adult 
nephrologists and 8 were pediatric nephrologists. This represents 4.9 nephrologists per 
million inhabitants. 68% of nephrologists practice in Guatemala City (urban area), while 
32% practice in rural areas. Overall, 64% work in private settings, 6.25% in academics, and 
30% in both settings. 74% trained in Guatemala, while 26% trained abroad. The workforce 
is 73% male. There are two adult and one pediatric nephrology fellowship training programs 
in Guatemala and all are located in Guatemala City (urban area). Currently, there are a 
total of 14 fellows in training of which 13 are adult nephrology fellows and 1 is pediatric 
nephrology fellow.
Conclusions: In Guatemala, there are only 4.9 nephrologists per million people. The 
majority of nephrologists are male and were trained in Guatemala. Most nephrologists work 
in private settings, and only one-third practice in a rural area. There are three nephrology 
programs in Guatemala. We still have room for improvement. Based on these results, 
we should focus in increasing educational opportunities, create incentives to increase 
the number of nephrologist practicing in rural areas, open more opportunities for female 
physicians, increase the number of nephrology fellowship training programs in rural areas 
and create incentives for physicians interested in academic medicine to increase the number 
of nephrologist practicing in academic settings.
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Teaching Communications Skills in Nephrology Utilizing Sociodrama
Maulin Shah,1 Robert Lorch,1 Walter F. Baile,2 Biruh Workeneh,2 
Rajeev Raghavan.1 1Baylor College of Medicine, Houston, TX; 2MD Anderson 
Cancer Center, Houston, TX.
Background: Although conversations between patients and nephrologists regarding 
chronic kidney disease (CKD) prognosis are associated with improved patient care and 
decreased surrogate burden, they reportedly occur infrequently. Most Nephrology training 
programs lack dedicated communication skills training (CST), and graduating fellows feel 
unprepared for these difficult conversations. Simulated conversations using standardized 
patients are effective in CST but are costly, and it is difficult to find and train committed 
actors. Alternatively, incorporating sociodrama techniques have been successful in 
Oncology CST. Sociodrama involves group members enacting social situations guided by 
a facilitator using techniques (primarily role-play, role reversal, and doubling--revealing 
unspoken thoughts and feelings) to enhance learning.
Educational Research
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Methods: We developed a one-day, sociodramatic, facilitator-led nephrology CST 
workshop. Workshops began with warm-up exercises to reduce anxiety and promote 
participation. Learners are then guided in enacting the clinical scenarios they find most 
challenging. Key communication skills are taught during these role-plays. Topics included 
giving bad news, discussing prognosis, eliciting goals of care, and addressing family 
concerns. Strategies included were giving information and assessing understanding as 
well as responding to emotion with empathic statements (e.g. ‘tell me more”, and ‘I wish’ 
statements). Participants were asked to complete surveys anonymously after the workshop.
Results: 24 surveys (18 trainees and 6 faculty) were collected in 2017 and 2018. 
Although 42% of participants were apprehensive of sociodramatic enactments, only 17% 
had some difficulty. 100% of responses indicated that sociodrama enhanced learning and 
92% indicated plans to incorporate learned skills into practice with 75% interested in further 
CST. Participants also indicated the day-long session to be lengthy.
Conclusions: Teaching communication skills in nephrology utilizing sociodrama 
is feasible, effective, and economical. Most participants found the workshop effective 
and intended to incorporate learned skills into practice. Follow-up surveys are needed to 
determine whether participants have used learned skills. Incorporating CST in an abridged 
format intermittently in the context of fellowship training may further increase the impact 
of this training.
SA-PO206 Poster Saturday
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Using Social Media to Augment Traditional Medical Education Delivery 
During Inpatient Rotations
Sayna Norouzi,4 Matthew A. Sparks,1 Swapnil Hiremath,6 Pablo Garcia,2 
Joel M. Topf,5 Silvi Shah.3 1Duke University and Durham VA Medical Centers, 
Durham, NC; 2Saint Peter’s University Hospital, New Brunswick, NJ; 
3University of Cincinnati, Cincinnati, OH; 4Saint Louis University, Saint Louis, 
MO; 5St. Clair, Detroit, MI; 6University of Ottawa, Ottawa, ON, Canada.
Background: Social media in medicine has the potential to encourage lifelong learning. 
Medical students and residents frequently use social media for a variety of purposes. We 
devised a pilot project to assess to utility of using social media to deliver medical education 
to trainees during inpatient rotations.
Methods: Two online tools (Twitter question polls and YouTube videos) created by 
an internal medicine resident were utilized to deliver educational content during a month-
long inpatient rotation, including nephrology ward rotation. Medical students and internal 
medicine residents were notified about these teaching tools via website and by direct email. 
Twitter was used to post a one question poll for 5 days on important topics in nephrology 
relevant to inpatient nephrology. Trainees answered questions online and received a 
5-10 minutes lecture about the topic on the following day. Short animation videos (2-3
minutes) were made on clinical trials about contrast induced acute kidney injury by the
internal medicine resident, and posted on YouTube (https://youtu.be/DoOQ5-xFcvc). An 
anonymous electronic survey was conducted regarding trainees’ educational experience
after two months.
Results: From the total of 73 responses, 81% completed the survey: 26% interns, 55% 
residents and 19% medical students. 37% were women. Over a month, two videos received 
290 combined views. Overall, 90% reported watching the online videos less than 3 times, 
7% 3-5 times and the remaining more than 5 times. On their educational experience; 73% 
rated it as “very educational”, 23%“somewhat educational” and only 4% as “minimal 
educational value”. In addition, 63% of respondents believed the videos were extremely 
helpful to remember the clinical trial results and 97% of respondents said they would watch 
any upcoming videos, and would be keen to participate again in the online questions on 
Twitter.
Conclusions: Social media tools such as Twitter and YouTube can augment traditional 
content delivery to enhance the learners experience. These tools can be effectively deployed 
on inpatient rotations. Implementing innovative tools such as social media, can improve the 
educational experience for trainees.
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Landmark Nephrology: A Multi-faceted Interactive Tool Showcasing the 
Classic Trials in Nephrology
Nikhil Agrawal,1 Diana Mina,2 Neil Roy,4 Danwen Yang,3 Stewart H. Lecker.1 
1Beth Israel Deaconess Medical Center, Brookline, MA; 2UCSF Division of 
Nephrology, San Francisco, CA; 3Bidmc, Boston, MA; 4BIDMC, Boston, MA.
Background: Nephrology has a long history of truly landmark clinical studies that 
have helped guide our clinical practice and make it evidence-based. To recognize the 
genesis of our current guidelines, it is critical to be familiar with the clinical studies that 
inform our current practice. Highlighting these studies also demonstrate the advances this 
field has made and motivates developing nephrologists to participate in clinical research. 
We took on the challenge of showcasing these landmark studies in nephrology in a way that 
is interactive, fun and useful.
Methods: We formed a committee of nephrology fellows and faculty from multiple 
major academic centers across US. A list of topics in clinical nephrology was developed and 
landmark clinical studies within each topic were selected, based on the relevance of these 
studies to current nephrology practice. Using these topic areas and leveraging concepts in 
adult learning, we created narrated short videos, visual abstracts, question banks, quizzes 
and games.
Results: We have developed a portal landmarknephrology.com which has free and 
easily accessible content on landmark clinical trials. Eight content areas are currently 
represented, ranging from peritoneal dialysis adequacy to steroids in IgA nephropathy. 
Another 12 topics are in production. The distribution of this content is via the website, 
and social media including YouTube and Twitter. The website also provides options for 
nephrology educators to easily identify the landmark studies and download material to 
create stimulating classroom lectures.
Conclusions: Landmark Nephrology provides a portal for trainees and practicing 
nephrologists to learn about evidence based practice in nephrology and challenge their 
knowledge about clinical trials in the field. It is a passionate effort to find new, exciting 
ways to showcase nephrology’s track record of producing truly landmark clinical studies 
and motivate the next generation of renal clinicians and scientists.
Website Homepage
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Renal-Limited TMA (Thrombotic Microangiopathy) in Patients with 
HSCT (Hematopoietic Stem Cell Transplant): An Endothelial Variant of 
Graft vs Host Disease (GVHD)
Alia Hasan,2 Rimda Wanchoo,4 James M. Pullman,5 Kenar D. Jhaveri,3 
Nupur N. Uppal.1 1Hofstra Northwell School of Medicine, Great Neck, NY; 
2Northwell Health, Briarwood, NY; 3Northwell Health Sys, Great Neck, NY; 
4Zucker School of Medicine at Hofstra Northwell, GREAT NECK, NY; 
5Montefiore Medical Center, Bronx, NY.
Introduction: Thrombotic microangiopathy (TMA) and graft versus host disease 
(GVHD) are well-recognized complications of hematopoietic stem cell transplantation 
(HSCT). TMA in HSCT (TA-TMA) is characterized by endothelial injury triggered by 
chemo-radiotherapy, infections or immunosuppressive drugs. Recent data suggests that 
GVHD itself may be a trigger of TA-TMA. We report 2 cases where GVHD in HSCT was 
associated with renal-limited TMA.
Case Description: A 58-year-old female with history of HSCT one year ago, was 
admitted with sub-acute acute kidney injury (AKI), worsening hypertension (HTN), 
nephrotic range proteinuria and anemia. Patient was on cyclosporine treatment for 
gastrointestinal GVHD at the time of admission. During the hospitalization, cyclosporine 
was discontinued. However, kidney function continued to worsen and she eventually 
required dialysis. A kidney biopsy confirmed acute on chronic TMA with minimal fibrosis. 
She received 2 doses of rituximab which led to the resolution of her AKI over 6 weeks. The 
patient eventually died due to sepsis. Our other patient, a 58-year-old-female with a second 
HSCT on tacrolimus therapy for skin GVHD, developed AKI 1 year after transplant along 
with worsening HTN, new onset proteinuria, and anemia. Her SCr worsened from 1.1mg/dl 
to 3.8mg/dl despite discontinuation of tacrolimus. A kidney biopsy revealed chronic TMA, 
with tubular reticular inclusion bodies (TRIs) without any viral etiology demonstrable by 
serology or immunohistochemistry.
Discussion: A relationship between GVHD and TA-TMA has been previously 
described but was confounded by calcineurin inhibitor use, infections, heterogeneous study 
populations, and retrospective study designs. Our findings suggest a possible link between 
GVHD and TA-TMA since both our patients presented with active GVHD in another organ 
concomitant with renal HSCT-TMA. Our first patient’s gastrointestinal GVHD and TA-
TMA improved following anti-B cell therapy (rituximab). Our second patient showed 
evidence of a high interferon state (TRIs) in the kidney which is also seen in GVHD. Our 
findings suggest that TA-TMA represents a form of “renal GVHD” or “endothelial GVHD”. 
However, more research is needed to understand the exact mechanism of development of 
GVHD associated TA-TMA.
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Influenza Triggered Thrombotic Microangiopathy
Eric Pitts,3 Amanda Tchakarov,1 Jaya Kala.2,4 1Department of Pathology, 
University of Texas Medical School at Houston, Houston, TX; 2Division of Renal 
disease and Hypertension, UT Health Science Center, Houston, Houston, TX; 
3Division of Renal disease and Hypertension, UT Health Science Center, 
Houston, Houston, TX; 4Section of Nephrology, UT- MD Anderson Cancer 
Center, Houston, TX.
Introduction: Thrombotic microangiopathy(TMA) is a clinical entity characterized 
by intravascular microangiopathic hemolytic anemia, thrombocytopenia and acute kidney 
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injury. Influenza virus triggered TMA(iTMA) has been rarely reported. Paucity in literature 
of this clinical entity prompted this report of iTMA. With this report we would like to 
highlight the importance of understanding other potential causes of TMA in a patient on 
proteasome inhibitor, also known to cause TMA.
Case Description: A 69 year old lady with diabetes mellitus, hypertension, chronic 
kidney disease and multiple myeloma on chemotherapy, presented with fever, weakness, 
shortness of breath and cough for past one day. She received her 14th cycle of carfilzomib 
and dexamethasone, two days prior to presentation. Her blood pressure was 188/98 mm Hg. 
Laboratory testing showed creatinine at baseline of 2.2 mg/dl but revealed positive Influenza 
A. She was admitted for hypertensive urgency and sepsis due to influenza. She was started 
on Osteltamivir and cancer chemotherapy was held. On day 4 of admission, nephrology was 
consulted for elevated creatinine of 3.18 mg/dl. Despite volume resuscitation her creatinine 
continued to rise to 6.88 mg/dl. Further evaluation showed that her hemoglobin drop to
7.7gm/dl, platelets 34,000/uL, lactate dehydrogenase elevated at 849U/l, undetectable
haptoglobin. This in addition to hypertensive urgency prompted the diagnosis of TMA.
ADAMSTS 13 activity was normal. Hemodialysis was started for worsening renal function 
and oliguria. Renal biopsy suggested presence of TMA. She received a course of ostelamivir 
and needed dialysis for a week. After the therapy she stayed off dialysis and returned to
baseline creatinine in 2 weeks. Our patient was on carfilzomib for the last 11 months, known 
to cause TMA, however she developed it only after the influenza infection. She couldn’t 
restart carfilzomib due to financial issues.
Discussion: Influenza associated TMA is a rare entity. It has been reported to occur 
around 4 days after the onset of infection, like in our patient. The outcome of iTMA is 
generally favorable with supportive care.. Our patient was on carfilzomib for 11months 
and the only apparent trigger for the TMA was influenza. Identification of the etiology and 
differentiation between drug induced complement dysregulation and influenza associated 
HUS without identifiable complement abnormalities are crucial for treatment.
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Renal Thrombotic Microangiopathy with Multiple Myeloma: Resolution 
with Chemotherapy
Lindsey Ehren,2 Dae Hyun Lee,2 Kayla Shirley,2 Abu-Sayeef Mirza,2 
Onyekachi C. Obi,3 Claude Bassil,3 Rachid Baz,4 Donald E. Wheeler.1 1Pathology 
and Cell Biology, University of South Florida, Tampa, FL; 2Internal Medicine, 
University of South Florida, Tampa, FL; 3Nephrology and Hypertension, 
University of South Florida, Tampa, FL, FL; 4H. Lee Moffitt Cancer Center & 
Research Institute, Tampa, FL.
Introduction: Thrombotic microangiopathy (TMA) is a clinical entity described 
by systemic microvascular occlusion, causing hemolytic anemia and thrombocytopenia 
resulting in end-organ ischemia. Numerous mechanisms may cause the condition including 
direct immunoglobulin deposition or chemotherapy. TMA is a pathological diagnosis 
characterized by fibrin thrombi within arterial vessels including the capillaries. Recent 
literature shows up to 13.7% of patients with thrombotic microangiopathy have monoclonal 
immunoglobulin. We present a case in which renal TMA-associated acute kidney injury 
responded to multiple myeloma treatment.
Case Description: A 43-year-old male with history of recent Bell’s palsy and 
peripheral neuropathy presented with abdominal distension, dyspnea and unintended weight 
loss. Initial evaluation was significant for anemia (Hgb 8.9g/dL), normal platelet count 
(265,000/mm3), normal LDH (139 U/L) and acute kidney injury (Creatinine 2.2mg/dL). 
CT of abdomen and pelvis demonstrated large-volume ascites and nonspecific sclerotic 
density in left iliac bone. Subsequent workup included a bone marrow biopsy significant 
for 30% plasma cells with 90% cellularity, and serum protein electrophoresis of positive 
IgA lambda monoclonal gammopathy (IgA 928mg/dL, M spike 0.5g/dL). Diagnosis of 
plasma cell myeloma was made. Renal biopsy was consistent with chronic thrombotic 
microangiopathy without immunoglobulin deposits by IFM or EM. The patient was treated 
with cyclophosphamide and prednisone (50mg). Renal function improved within the first 
three weeks of treatment to 1.3mg/dL.
Discussion: Very few cases have reported renal TMA with multiple myeloma to date. 
Distinct from the typical light-chain associated renal tubular injury of multiple myeloma, 
AKI due to TMA is also described. Our patient is one of few reported cases in which 
myeloma treatment resulted in improvement in renal TMA-induced renal insufficiency. 
Further investigation is needed to establish management guidelines for renal failure in this 
setting.
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A Case of Diffuse and Nodular Glomerulosclerosis in Waldenstrom’s 
Macroglobulinemia
Lindsey Ehren,2 Dae Hyun Lee,2 Nicoleta Radoianu,3 Abhishek M. Kumar,1 
Claude Bassil,3 Liying Fu.4 1University of South Florida College of Medicine, 
New Port Richey, FL; 2Internal Medicine, University of South Florida, Tampa, 
FL; 3Nephrology and Hypertension, University of South Florida, Tampa, FL; 
4Tampa General Hospital, Tampa, FL.
Introduction: Diffuse and nodular glomerulosclerosis (DNGS) is commonly 
associated with diabetic nephropathy and occasionally with tobacco users. However, it 
has also been associated with amyloidosis, cryoglobulinemia, and light-chain deposition 
disease. To the best of our knowledge, there is no published data on DNGS without light 
chain deposition in Waldenstrom’s Macroglobulinemia (WM). We present a case of DNGS 
in a non-diabetic, non-smoker with WM.
Case Description: A 72-year-old male with past medical history of Waldenstrom’s 
Macroglobulinemia develops worsening renal function after CP-R (cyclophosphamide/ 
prednisone plus rituximab) treatment with partial remission. He does not have diabetes, 
hypertension or other comorbidities; he is a non-smoker. He uses minimal NSAIDs and 
denies recent or prior intravenous contrast use. Two months after completion of CP-R 
regimen, creatinine started rising from baseline 1.0mg/dL to 2.2mg/dL over two years. 
Serum IgM decreased from 3414 to 2360 after treatment. Blood glucose, liver function panel, 
and albumin levels were normal. Renal ultrasound showed normal echogenicity without 
hydronephrosis. Kidney biopsy showed moderate diffuse and nodular glomerulosclerosis 
with focal cortical atrophy, hypoperfusion and focal global and segmental glomerulosclerosis 
and moderate vascular sclerosis. Biopsy showed stronger background staining for kappa 
light chains compared to lambda light chains, without Randall-type electron dense deposits. 
There was no evidence of monoclonal immunoglobulin deposition, amyloidosis, light chain 
tubulopathy or light chain cast nephropathy.
Discussion: Waldenstrom’s Macroglobulinemia is a hematologic malignancy 
characterized by clonal proliferation of B-lymphocytes producing IgM monoclonal 
gammopathy secretion. It could involve the kidney through large intracapillary IgM 
deposition, cryoglobulin or amyloidosis related injury. Per literature review, there are no 
documented cases of DNGS in a patient with WM without history of diabetes or tobacco 
use. Further research is required to evaluate the prevalence and mechanism behind the 
association of DNGS and WM.
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Anti-C5 Antibody for Thrombotic Microangiopathy in Scleroderma Renal 
Crisis
Shana M. Machado,2 Jaya Kala.1 1Division of Renal disease and Hypertension, 
UT Health Science Center, Houston, Houston, TX; 2Division of Renal disease 
and Hypertension, UT Health Science Center, Houston, Houston, TX.
Introduction: Scleroderma renal crisis(SRC), presenting as malignant hypertension, 
acute kidney injury(AKI), thrombocytopenia and microangiopathic hemolytic anemia, is 
a major complication of systemic sclerosis. Seen more common in patients treated with 
glucocorticoids. Prognosis remains severe despite treatment with angiotensin converting 
enzyme inhibitor(ACEI). Studies suggest that complement activation trigger thrombotic 
microangiopathy(TMA) in SRC. We report a case of SRC with TMA treated with anti-C5 
antibody
Case Description: 51 yr-old female with hypertension, hypothyroidism, dyspnea due 
to interstitial lung disease(ILD), without kidney disease, presented with worsening vision 
and severe headache. She was on myfortic and prednisone for the past 8 months for ILD. Her 
computed tomography scan revealed frontal cortical subarachnoid hemorrhage and bilateral 
posterior parietal subcortical hypo densities. For her high blood pressures she was started on 
Cardene drip. Hemodialysis was started for uremic symptoms with creatinine of 4.06 mg/dl 
and blood urea nitrogen 92 mg/dl. Laboratory evaluation with platelets 161,000/cmm, 
LDH 800U/L, hemoglobin10.5g/dl and haptoglobin undetectable, few schistiocytes, normal 
ADAMTS13activity, AKI and hypertensive emergency indicated possibility of TMA, 
likely atypical hemolytic uremic syndrome. Rheumatological evaluation of ILD revealed 
nucleolar pattern ANA and high PMSL antibody indicating NSIP with PM-Scl overlap 
without skin involvement. There was high suspicion of SRC, possibly precipitated with the 
use of glucocorticoids. Despite captopril she did not show any signs of renal recovery. Renal 
biopsy done revealed presence of acute TMA with arterial, arteriolar and glomerular C5b-9 
staining. These findings were suggestive of the presence of complement dyregulation and 
therefore decision to start anti-C5 antibody(ecluzimab) was made. The patient’s platelets 
count recovered with 3 doses of ecluzimab. The patient is currently on the maintenance 
dose of ecluzimab. She has improved renal functions, requiring dialysis once a week. Her 
genetic testing is awaited
Discussion: Scleroderma renal crisis have high incidence of end stage renal disease 
despite use of ACEI. Since, complement activation has been described in autoimmune 
disorders including SRC, we considered the use of anti-C5 antibody in the treatment of 
TMA in our patient to achieve decreased dialysis dependence.
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Eculizumab Responsive Atypical Hemolytic Uremic Syndrome Triggered 
by a Multisystem Lupus Flare
Bushra Syed,2,1 Hernan Rincon-Choles,2,1 Juan C. Calle.2,1 1Nephrology, Cleveland 
clinic Foundation, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH.
Introduction: Uninhibited alternative complement pathway activation leads to 
complement mediated hemolytic uremic syndrome. Infections, pregnancy, drugs or ongoing 
lupus activity can trigger this cascade. Concurrent occurrence of aHUS with lupus is rare. 
We present a case of aHUS with hematological and renal responsiveness to eculizumab
Case Description: A 25-year-old Caucasian female with HTN, IgA deficiency 
and class III A + V lupus nephritis on maintenance prednisone, mycophenolate and 
hydroxychloroquine, presented with abdominal pain and encephalopathy. Workup showed 
Hb of 7.9g/dl, thrombocytopenia, schistocytes, low haptoglobin and elevated LDH. 
TTP and autoimmune hemolysis were ruled out. Hypocomplementemia and positive 
dsDNA and ANA were noted. Soluble membrane attack complex level was elevated and 
membrane cofactor protein was low. Factors H, I, B were within normal limits. Factor 
H autoantibody, antiphospholipid antibody panel and scleroderma antibodies were 
negative. Creatinine peaked at 5 mg/dl (baseline1.2mg/dl)and she had nephrotic range 
proteinuria -6g. Hemorrhagic pancreatitis and cerebritis seen on imaging. Infectious 
etiologies were ruled out. Renal biopsy showed Class III and V Lupus with moderate 
activity, thrombotic microangiopathy and diffuse ATN. Despite initiation of pulse dose 
steroids, cyclophosphamide she developed multisystem organ failure requiring mechanical 
ventilation, renal replacement therapy and multiple transfusions. Plasma exchange was 
deferred due to IgA deficiency. Subsequently initiated on eculizumab with improvement 
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in hematological parameters after 2 doses. Renal recovery with discontniuation of dialysis 
occurred after 4 doses. She remains in remission on prednisone, MMF, hydroxychloroquine 
and eculizumab at 9 month follow up with a Cr of 0.7 and proteinuria of 0.5g.
Discussion: Active Lupus serves as a driver for aHUS. Thrombotic microangiopathy is 
an independent risk factor for poor outcome in lupus nephritis with mortality rates of over 
30% despite the use of multimodal treatment strategies. Terminal complement inhibitors 
can effectively induce hematological and renal response and there should be a low clinical 
threshold to initiate eculizumab in the setting of refractory disease. Data regarding the 
optimal dosing schedule, monitoring and treatment end points is lacking and needs 
additional studies.
SA-PO214 Poster Saturday
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Eculizumab Treatment in Recurrent Dense Deposit Disease
Duy T. Vu,1 Joe Ghata.2 1University of Oklahoma Heath sciences center, Yukon, 
OK; 2OUHSC, Oklahoma City, OK.
Introduction: Dense deposit disease (DDD) is a rare complement-mediated glomerular 
disease typically affecting children and young adults. About 50% of affected patients 
develop end stage renal disease by 10 years. Treatment decisions are primarily based on 
case reports, expert opinion, etc. Terminal complement proteins are thought to be involved 
in the pathogenesis of DDD. Eculizumab, an anti-C5 antibody, prevents the formation of 
the terminal complement complex, however the efficacy with this drug has been mixed.
Case Description: We present a 23 years old female with DDD diagnosed at age 10. 
She underwent cadaveric renal transplant at age 19. A year later, she developed biopsy 
proven recurrent DDD in her renal allograft. She also had elevation in the C5-9 complex 
(328 ng/mL), creatinine (1.65 mg/dL), and protein/creatinine ratio (6.1 grams). She was 
started on Eculizumab 900 mg weekly injection for 4 weeks and then 1200 mg every two 
weeks for 16 months. Biochemical markers normalized after 1 dose without adverse events. 
She was in clinical remission from DDD for 18 months when her creatinine (baseline 1-1.2 
mg/dL) rose and peaked at 2.59 mg/dL with nephrotic range proteinuria (pro/cr ratio was 
12 grams). Biopsy of her renal allograft again revealed recurrent DDD. She had elevated 
plasma Ba fragment and soluble C5b-9 and low C3, C4, and C5 which are consistent 
with abnormal activation of the alternative pathway. The alternative pathway functional 
assay was low and is consistent with the consumption of the above complements. The 
complement Bb level was borderline elevated. The C3Nef, C4Nef, C5Nef, and Nef activity 
assay were all negative. Complement factor I, factor H, and properdin levels were normal. 
In summary, these results support the recurrence of DDD. Subsequently, the patient was 
given Eculizumab 1200 mg every two weeks with rapid improvement in peripheral edema, 
creatinine, and proteinuria.
Discussion: Our patient suffered from DDD, a rare and incurable kidney disease, but 
demonstrated quick and effective response to eculizumab. Eculizumab induced remission in 
our patient. The natural history of this disease has a high recurrence rate which was evident 
in our patient. However, it is promising that she demonstrated clinical response despite 
relapse. This case suggests eculizumab may be effective in treating recurrent DDD and 
preserving the renal allograft.
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Eculizumab for the Treatment of Recurrent C3 Glomerulonephritis 
Caused by a C3 Gain of Function Mutation
Joon S. Kim,1 Ryan Mullane,2 Scott G. Westphal,3 Eric D. Langewisch,2 
Clifford D. Miles.2 1University of Nebraska Medical Center, Omaha, NE; 
2University of Nebraska Medical Center, Omaha, NE; 3University of Nebraska 
Medical Center-Nebraska Medicine, Omaha, NE.
Introduction: C3 glomerulonephritis (C3GN) is a glomerular disease caused by 
excessive activation of the alternative complement pathway and often leads to end-stage 
renal disease. Following kidney transplantation, the recurrence risk is high and may cause 
premature allograft failure. Eculizumab prevents the membrane attack complex (MAC) 
formation and provides terminal complement inhibition. Here we present a case of early 
recurrent post-transplant C3GN in a patient with a C3 gene mutation that was successfully 
treated with eculizumab.
Case Description: A 38 year old female with a history of chronic kidney disease 
received a living unrelated kidney transplant. Prior to her transplant, she was diagnosed with 
C3GN which was refractory to corticosteroids, mycophenolate, and rituximab. Evaluation 
revealed a C3 gain of function mutation. Complement inhibitory factors were normal and 
she did not have a C3 nephritic factor. An elevated level of soluble MAC (sMAC) was noted 
prior to transplantation. She had immediate graft function following her transplant and she 
was maintained on tacrolimus, mycophenolate, and prednisone following basiliximab 
induction. Her creatinine reached a nadir of 1.1 mg/dl, but she developed early acute 
allograft dysfunction and proteinuria within the first few weeks of transplant and biopsy 
revealed early recurrence of C3GN. She was treated with high dose corticosteroids and 
plasmapheresis, but continued progression of renal dysfunction with rising sMAC levels, 
proteinuria, and activity of C3GN on a repeat biopsy. After initiation of eculizumab, her 
sMAC levels normalized, proteinuria resolved, and the allograft function improved. She 
is now >1 year out from transplantation with stable allograft function and no evidence of 
complications related to the eculizumab.
Discussion: Eculizumab appears to have a role in select patients with recurrent C3GN. 
Since not all patients with C3GN improve with eculizumab, more research is needed to 
define patients expected to benefit from this therapy. Patients with recurrent C3GN due to a 
gain of function mutation in the C3 gene should be considered for early eculizumab therapy 
to preserve allograft function and decrease excessive complement activity.
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C3 Glomerulonephritis, a Rare Etiology of the Pulmonary Renal 
Syndrome
Shane A. Bobart, Sanjeev Sethi, Fernando C. Fervenza. Mayo Clinic, Rochester, MN.
Introduction: C3 Glomerulopathy (C3GN) is a rare disease due to complement factor 
deposition in the glomerulus as a result of dysregulation of the alternative complement 
pathway. We present a rare case of C3GN presenting with diffuse alveolar hemorrhage 
(DAH) as a pulmonary-renal syndrome.
Case Description: A 20 year old female presented to the emergency department with 
flank pain and hematuria. Approximately 8 weeks prior, she had polyarthralgia, purpuric 
rash over the abdomen, buttocks and lower extremities with associated edema. She was 
treated for post-streptoccocal infection in the setting of high ASO titer (1490 IU/mL). On 
examination, she demonstrated persistent petechial rash and new right sided CVA tenderness. 
Blood pressure was 126/70 mmHg. On investigation, she was anemic with hemoglobin 8.1, 
had an acute kidney injury with creatinine 1.6 mg/dL and urinalysis showed 3.5 grams 
predicted 24 hour proteinuria, dysmorphic hematuria, >100 RBCs per high power field. 
Serology tests were notable for negative ANA, PR3-ANCA, MPO-ANCA, anti-GBM, 
Cryoglobulin, Hepatitis, HIV serology and paraproteinemia studies. Kidney biopsy showed 
focal endocapillary proliferative, crescentic, and necrotizing glomerulonephritis with bright 
glomerular C3 staining. On electron microscopy there was mesangial, intramembranous 
and sub-endothelial deposits with absence of sub-epithelial humps. She was initiated 
on pulse dose steroids and subsequently developed spontaneous hemoptysis requiring 
emergent intubation. Bronchoscopy confirmed DAH with cytopathology showing 0% 
hemosiderin-laden macrophages. Further work up revealed low complement (C3 40, C4 
6 mg/dL) with decreased function of the alternate complement pathway at 55% (75-170% 
normal range). A diagnosis of C3GN with associated pulmonary hemorrhage was made. 
She required plasmapheresis and transitioned to prednisone and mycophenolate mofetil. 
As an outpatient, genetic testing showed 3 copies of C3GN risk alleles, but with negative 
mutations for complement factor H and factor I, negative factor H autoantibody or C3 
nephritic factor. Renal function deteriorated despite aggressive immunosuppression and 
eculizumab therapy and she required hemodialysis.
Discussion: C3GN should also be considered part of the differential diagnosis in the 
setting of ANCA negative pulmonary renal syndrome.
SA-PO217 Poster Saturday
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C3 Glomerulonephritis in Children
Ji hyun Kim, Hee Gyung Kang, IL-Soo Ha, Hae Il Cheong. Seoul National 
University Children’s Hospital, Seoul, Republic of Korea.
Introduction: C3 glomerulonephritis (C3GN) is marked by subendothelial and/
or mesangial electron dense deposits, which displays isolated glomerular C3 deposition 
without concomitant staining for Ig. Since clinical manifestations and long-term outcome 
of C3GN have not been clarified yet, especially those in children, we reviewed our cases 
of pediatric C3GN. Among more than two thousand biopsy cases performed in our center 
since Jan 2004 (for 15 years), ten cases (M:F 5:5) were compatible to C3GN. Their medical 
records were retrospectively reviewed.
Case Description: Pediatric C3GN patients at our center presented at their median 
age of 9.2 years with asymptomatic urinary abnormality (n=6), acute glomerulonephritis 
(n=3) or nephrotic syndrome (n=1). Hematuria was noted in nine (6 microscopic and 3 
gross hematuria). Initial renal function was normal range in all. Initial serum C3 levels 
were low in all the cases but one. Pathologic diagnoses were C3GN for three, but those who 
were presented before 2015 had been initially diagnosed as PIGN (n=3) or MPGN (n=4); 
One patient with pathologic diagnosis of PIGN had follow-up biopsy in 20.2 months and 
finally diagnosed C3GN. All the patients were managed with ACE inhibitor or ARB, and 
eight were treated with additional steroid and other immunosuppressants of CNI or MMF. 
One patient with poor compliance progressed to ESRD in 5 years, despite therapeutic trial 
of eculizumab. The other 9 patients had normal renal function at last visit; Last serum C3 
levels were normal in 4 and persistently low in the rest.
Discussion: Pediatric cases of C3GN showed diverse presentation, and some of the 
were initially mis-diagnosed as PIGN. Interestingly their outcome was fair, although our 
number of subjects was too small to draw any conclusion. For better understanding of this 
entity, further study on regulatory system of ACP is required, as well as other markers which 
can predict clinical course of C3GN.
Patient characteristics
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LCAT Deficiency with C3 Glomerulopathy: Case Report
Gerard F. Sales,1 Jordan D. Vasconcellos,3 Gabriela C. Segura,1 Tomas 
D. Ferreira,4 Lectícia Jorge,2 Viktoria Woronik.2 1Hospital das Clínicas
University of São Paulo (USP), SÃO PAULO, Brazil; 2University of São Paulo,
São Paulo, Brazil; 3Faculdade de Medicida da Universidade de Sao Paulo, São 
Paulo, Brazil; 4Universidade de São Paulo, São Paulo, Brazil.
Introduction: Lecithin cholesterol acyltransferase (LCAT) deficiency is an autosomal 
recessive disorder of lipoprotein metabolism that produces deposit of unesterified 
cholesterol in the cornea, kidneys, and erythrocytes. Kidney biopsy typically shows 
vacuolation of glomerular capillary walls, foam cells and spiculation as well as duplication 
of the glomerular basal membrane (GBM). The immunofluorescense (IF) studies are 
typically negative although C3 non specific depositions are described. Here we present a 
case of LCAT deficiency that showed some C3 glomerulopathy aspects.
Case Description: We report a case of a 19-year-old woman with a brother diagnosed 
with LCAT deficiency who presented with low limb edema, foamy urine and corneal 
fish-eye-like alterations. Laboratory tests showed extremely low HDL levels (3 mg/dl), 
normal renal function (CKD-EPI 137 ml/min/1,73m2), subnefrotic proteinuria 
(1,8 gr/24 hours), anemia (hemoglobin 10,0g/dl) and normal complement (C3 108 mg/dL; 
C4 27,4 mg/dL). Kidney biopsy evidenced podocyte and mesangium vacuolation, double-
contour basal membrane and subendothelial as well as intramembranous hyaline deposits. 
On IF we found only C3 granular depositions with medium intensity (2+) on the glomerular 
capillary wall and tubular basal membrane with diffuse distribution.
Discussion: In literature, we found two cases reported of LCAT deficiency associated 
with dense deposit disease (DDD). Our patient had mixed lesions of LCAT deficiency 
and medium (2+) intensity C3 deposition pointing more to a C3 glomerulopathy than to 
a non specific deposition. Electronic microscopy in process should define the diagnosis. 
It has been affirmed that structural changes in renal GBM could occur due to alterations 
in galactosyl fraction provoked by extraneous material deposition. Therefore, we can 
speculate that deposition of abnormal non esterified cholesterol in LCAT deficiency could 
be related to activation of complement cascade.
SA-PO219 Poster Saturday
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What Lies in-Between: A Case of C3 Glomerulopathy with Non-Hemolytic 
Renal Microangiopathy and a Unique C3 Variant
Ali D. Jandal, Weixiong Zhong, Sana Waheed, Gauri Bhutani. University of 
Wisconsin School of Medicine and Public Health, Madison, WI.
Introduction: A difference in location of alternate pathway dysregulation is thought 
to be the cause of the distinct clinical disorders of C3 glomerulopathy (C3G) and atypical 
hemolytic uremic syndrome (aHUS).
Case Description: A 36 year-old female with history of prior alcohol abuse 
presented with abdomen pain, nausea, and vomiting for one day prior to admission. 
Serum creatinine (S.Cr) was 2.6 mg/dL (unclear baseline) and serum lipase was 445 U/L. 
Urinalysis showed hematuria and urine protein-creatinine ratio (UPC) was 6.35 g/g. Her 
pancreatitis was managed conservatively. Pain improved but S.Cr reached 7.5 mg/dL 
by hospital day (HD) #5 - a kidney biopsy was performed and pulse dose steroids were 
initiated. [Fig1] A membranoproliferative glomerulonephritis with focal crescents and 
positive C3 was found. Severe diffuse endothelial swelling and small amounts of electron 
dense deposits were seen on electron microscopy. No hemolysis was detected but 
plasmapheresis (PP) was started due to worsening S.Cr. Renal function improved; patient 
was discharged on steroids and cyclophosphamide as eculizumab was not approved by 
insurance. Complement genetic testing revealed a unique variant in 1 allele of C3 gene and 
a heterozygous deletion of CFHR3-CFHR1. Now, two months later, patient is readmitted 
with recurrence of her renal syndrome and pancreatitis.
Discussion: Endothelial damage, recurrent pancreatitis and response to PP are features 
of aHUS. These, together with a C3 positive crescentic glomerulonephritis, sparse deposits 
and a unique C3 genetic variant strongly suggest the possibility of a syndrome with overlap 
between C3G and aHUS.
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Postpartum Associated Atypical Hemolytic Uremic Syndrome
Hristo Shivarov,1 Maria V. DeVita.2 1Lenox Hill Hospital - Northwell Health 
System, Secaucus, NJ; 2Lenox Hill Hospital- Northwell Health System, New 
York, NY.
Introduction: Pregnancy associated atypical hemolytic uremic syndrome is a rare, 
life threatening, progressive systemic disease of uncontrolled activity of the alternate 
complement pathway resulting in systemic thrombotic microangiopathy during pregnancy 
or postpartum period. The diagnosis of this condition is challenging and can mimic various 
diseases found during pregnancy and the postpartum.
Case Description: 35 year old woman without significant past medical history 
who presented to our hospital for elective delivery at 37th weeks gestation. During the 
induction period the labor arrested, the patient became hypertensive to 170/100 mmHg with 
subsequent fetal bradycardia necessitating a C-section. Immediately postpartum uterine 
atony with severe hemorrhage was observed. The patient was intubated and was placed 
on pressor support. Severe anemia was registered with hemoglobin drop to 6.8 from 12.0 
g/dl. The hemoglobin level was 6.9 g/dl after transfusion 4 units of PRBC. There were 
no overt signs of bleeding. Additional studies showed: LDH 1324 u/l, haptolgobin <10 
mg/dl, and platelets – 62 from 212 K/uL; schistocytes were noticed on peripheral smear. 
Deterioration of the renal function was observed over the next 48 hours with anuria, 
creatinine peaked to 7.02 mg/dl. Hemodialysis was initiated for oliguria, hyperkalemia 
and fluid overload. Subsequent studies showed decreased level of C3 at 73 mg/dl with 
normal C4. Differential diagnosis included TTP, severe pre-eclampsia, aHUS, malignant 
hypertension and ischemic ATN. Plasma exchange was started with iv prednisone 
100 mg/daily, ADAMTS13 was 42% excluding TTP. Eculizumab 900 mg/weekly was 
started 5 days POD. Gradually the hemoglobin level and platelets stabilized. The patient 
was extubated and the hemolysis resolved. HD treatment was discontinued on POD 19 after 
significant improvement of the renal function and good control of blood pressure. During 
the hospital stay she received total of three doses of eculizumab. The patient was discharged 
with continuation with eculizumab biweekly
Discussion: Diagnosis of pregnancy associated aHUS must be considered early in 
postpartum period in patient with hemolysis, rapid deterioration of renal function despite 
the possibility of superimposed acute tubular injury, abnormal complement function and 
normal ADAMTS13 activity. Early initiation of treatment with plasma exchange and 
eculizumab has proven its efficacy in postpartum aHUS.
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A Rare Case of Clostridium Difficile Causing Atypical Hemolytic Uremic 
Syndrome
Jessamyn Carter, Narottam Regmi. University of Oklahoma School of 
Community Medicine, Tulsa, OK.
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare form of 
thrombotic microangiopathy mediated by excess activation or dysregulation of the alternate 
complement pathway. The incidence is 2 per 1 million people in the United States. We 
present a case of aHUS caused by C. difficile with persistent renal failure.
Case Description: 52-year-old morbidly obese man with hypertension, sleep apnea, 
and recurrent deep vein thrombosis admitted for worsening fatigue and bloody diarrhea since 
treatment with clindamycin then trimethoprim-sulfamethoxazole 2 weeks prior. He had 
acute renal failure with creatinine 4.9 and oliguria, hemolytic anemia, thrombocytopenia, 
leukocytosis, and active urine sediment with RBCs, WBCs and protein. CT abdomen and 
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renal ultrasound were unremarkable. Left renal biopsy showed severe acute glomerular 
microangiopathic injury. He began intermittent hemodialysis (HD) and plasma exchange. 
ADAMTS13, total complement, C3/C4, ANA and ANCA and tests for E.coli 0157:H7, 
Shiga toxin, HIV, and hepatitis were normal. aHUS genotype panel was equivocal. Stool 
was positive for C. difficile. After plasma exchange and steroids, he remained oliguric 
on HD. Eculizumab was started for aHUS. Despite treatment, he remains HD dependent 
awaiting transplant.
Discussion: 90% of HUS is secondary, usually to E.coli 0157:H7 or Shiga toxin 
(typical diarrhea+ HUS), S. pneumoniae infection, pregnancy, or drugs. There is no known 
causation by clindamycin or trimethoprim-sulfamethoxazole. Normal complement and 
equivocal aHUS genotype results do not rule out aHUS. A few case reports suggest C. 
difficile infection may cause HUS, though prior cases had full renal recovery. Our patient’s 
clinical, lab, and histopathologic findings support diagnosis of aHUS from C. difficile 
infection. Though rare, C. difficile must be considered as a cause of aHUS. Our patient 
presents further difficulty as renal function remains poor despite antibiotic therapy and 
eculizumab.
Biopsy with cortical necrosis, severe acute glomerular microangiopathy
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Myeloma Kidney with C3 Deposition
Asif Khan, Elie El-Charabaty, Suzanne E. El Sayegh. Staten Island University 
Hospital, Brooklyn, NY.
Introduction: Renal complications of multiple myeloma (MM) include monoclonal 
immunoglobulin deposition disease and myeloma cast nephropathy. Up to 50% of MM 
patients present with renal impairment at diagnosis, 20% may present with acute kidney 
injury (AKI) and 10% require dialysis. In C3 glomerulopathy, which is one of the 
complement-mediated types of Membranoproliferative Glomerulonephritis (MPGN), 
defects in complement regulatory proteins promotes the excessive activation of the 
alternative pathway.
Case Description: A 59-year-old man with a two-year history of hypertension 
presented with generalized weakness for the past 3 months. Physical examination reveals a 
well-appearing male with a bp 137/77 mmHg, pulse 103 bpm, with fairly normal physical 
findings. On admission: Hb 9.1 g/dl; RBC 1.45 mil/mm3; WBC 3.2 th/mm3; plt 94 th/mm3; 
BUN 94 mg/dl; Cr 10.47 mg/dL (baseline Cr 1.5 mg/dL); BUN/Cr 8.77; FeNa 8.7%; Na 130 
mEq/L; K 6.2 mEq/L; HCO3 14 mEq/L; Urine analysis showed 2+ protein with bland urine 
sediment and microscopic hematuria. 24-hour urine protein was 2g/day. Renal ultrasound 
showed 0.6 cm right renal cyst. The patient was admitted to ICU for hyperkalemia with 
AKI and was consequently hemodialyzed. Serologies were notable for low levels of C3 
(46 mg/dL) with normal C4 were observed. Immunofixation by Electrophoresis of both 
serum and urine showed free Lambda band present. Serum plasma electrophoresis showed 
two M-spikes: Lambda light chains and IgG Lambda. Free kappa/lambda ratio <0.01. Urine 
electrophoresis showed three monoclonal bands. Serum levels of IgG 2500 mg/dl. A renal 
biopsy was performed and cast nephropathy was identified with mesangial staining for C3. 
Bone marrow biopsy showed CD 56 positive Plasma Cell Myeloma. MM was diagnosed 
with IgG lambda cast nephropathy and ESRD on dialysis with pancytopenia. He was treated 
with Velcade, Cytoxan, and dexamethasone. SPEP status post chemotherapy showed two 
M-spikes with improvement of renal function and normal C3 levels. At 4 months post-
biopsy, the patient remained dependent on hemodialysis therapy and required multiple
blood transfusions.
Discussion: We hypothesize in monoclonal gammopathy induced C3 glomerulopathy, 
paraprotein itself is acting as a trigger that activates and dysregulates the AC pathway 
systemically. Thus, it is highly feasible to tailor the treatment to reduce the amount of 
paraproteins in C3 glomerulopathy associated with Myeloma kidney.
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Myeloma-Like Cast Nephropathy in a Patient with Pancreatic Mixed 
Acinar-Neuroendocrine Cancer
Haiyan Zhang,1 Omar Mamlouk,2 Manoj Bhattarai,6 Amit Lahoti,4 
Biruh Workeneh,5 William F. Glass.3 1Pathology, The University of Texas Health 
Science Center, Houston, TX; 2Nephrology, University of Texas Health Science 
Center at Houston, Houston, TX; 3Pathology, University of Texas – Houston 
Medical School, Houston, TX; 4M D Anderson Cancer Center, Houston, TX; 
5MD Anderson Cancer Center, Houston, TX; 6Nephrology, The University of 
Texas Health at San Antonio, San Antonio, TX.
Introduction: Myeloma cast nephropathy is a very serious diagnosis, which triggers 
immediate work-up for multiple myeloma and aggressive chemotherapy. However, there 
are rare renal conditions with morphological features similar to myeloma cast nephropathy 
but without evidence of plasma cell dyscrasia or monoclonal gammopathy. “Myeloma”-like 
casts result from precipitation of abnormal proteins along with Tamm Horsfall glycoprotein 
in distal tubules and collecting ducts leading to an inflammatory response with giant cells 
and acute kidney injury. Myeloma-like casts have been reported occasionally in patients 
with pancreatic adenocarcinoma, thyroid cancer, HIV, antibiotic and cisplatin use. We 
present here a case of myeloma-like cast nephropathy in a patient with pancreatic mixed 
acinar-neuroendocrine cancer (MANEC).
Case Description: The patient was a 60-year old male undergoing chemotherapy for 
biopsy-confirmed pancreatic MANEC with metastasis to liver. He presented with acute 
kidney injury (AKI) and mild proteinuria without hematuria or pyuria. Ultrasound showed 
normal renal size and echogenicity with no signs of obstruction. The kidney biopsy was 
obtained due to AKI with no clear etiology. The biopsy showed diffuse acute tubular 
epithelial injury with focal tubular obstruction by casts that varied in size. Some casts appear 
crumbled or moth-eaten. Focal casts were also associated with an inflammatory reaction that 
included neutrophils and/or syncytial multinucleated giant cells. No monoconal paraprotein 
detected in the biopsy, serum or urine. HIV screening test was negative and patient had no 
history of cisplatin use.
Discussion: Pancreatic MANEC is very rare. Myeloma-like cast nephropathy associated 
with pancreatic neoplasia is even rarer and has been seen only with adenocarcinomas. Thus, 
in this case, the myeloma-like cast are more likely associated with the exocrine component 
(acinar carcinoma), which produces excessive proteins obstructing the distal tubules, 
and cause tubular epithelial injury and inflammation with multinucleated giant cells. To 
our knowledge, this is the first report of myeloma-like cast nephropathy associated with 
neuroendocrine neoplasms. Because of the significant clinical associations and treatment 
differences, it is critical not to misdiagnosis this entity as myeloma cast nephropathy.
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A Case of Monoclonal Gammopathy Presenting with an Unexpectedly 
High Level of Serum Creatinine Due to Positive Interference in an 
Enzymatic Assay
Ryoko Mizuhara, Naoto Hamano, Masahiro Koizumi. Tokai University School 
of Medicine Division of Nephrology, Endocrinology, and Metabolism Tokai 
University School of Medicine, Isehara, Japan.
Introduction: In Japan, serum creatinine level is routinely measured by enzymatic 
method and a variety of enzyme assay kits are available. Monoclonal gammopathy can 
interfere with enzymatic assay for creatinine.
Case Description: A 78-year-old man was referred to the department of thoracic 
surgery in our hospital for the evaluation of lung tumor. At the initial visit to our hospital, 
the level of serum creatinine increased sharply from 1.03 mg/dl to 4.68 mg/dl during 5 
days before the referral. He was generally well, and did not complain of anorexia, fever 
or oliguria. (No causative drug or infection was detected.) Other laboratory tests revealed 
a BUN level of 21 mg/dL, almost normal urinalysis (with microscopic hematuria), and an 
IgM level of 1366 mg/dL. We performed kidney biopsy, but could not identify the cause 
of AKI. In the meantime, we diagnosed lymphoplasmacytic lymphoma based on bone 
marrow biopsy. Despite high creatinine level measured in our hospital, that measured in 
the other hospital soon after the biopsy was nearly normal. To elucidate the cause of the 
discrepancy in the measured values, we analyzed the measurement methods. We observed 
the formation of white precipitation after addition of the reagent of the creatinine assay 
kit using in our hospital to the serum of this patient. This turbidity was not found when 
measuring by Jaffe method or by enzymatic method after protein removal from his sera, 
leading to the diagnosis of pseudohypercreatininemia secondary to paraproteinemia. GFR 
estimated from serum cystatin C was 33.3 ml/min/1.73m2, consistent with that from ”true” 
serum creatinine.
Discussion: Pseudohypercreatininemia should be considered in the search for the 
cause of isolated creatinine elevation in patients with paraproteinemia. In such patients, we 
should measure serum creatinine by multiple methods to evaluate renal function accurately. 
Comprehensive evaluation of creatinine measured by multiple methods and cystatin C may 
provide accurate renal function of patients with monoclonal gammopathy.
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Where’s the Clone? Successful Treatment of Monoclonal Gammopathy of 
Renal Significance with Type 1 Cryoglobulinemia with Plasma-Cell 
Directed Therapy
Ana C. Onuchic-Whitford,1 Veronica E. Klepeis,2 Andrew S. Allegretti.2 
1Brigham and Women’s Hospital / Massachusetts General Hospital, Boston, 
MA; 2Massachusetts General Hospital, Boston, MA.
Introduction: Type 1 cryoglobulins are monoclonal immunoglobulins produced 
by clonal expansion of B cells. They are often associated with an overt hematologic 
malignancy, but sometimes occur without identification of a monoclonal cell population. 
We describe a case of type 1 cryoglobulinemia with a rare crystalline morphology on renal 
pathology and without an evident monoclonal population, that had excellent response to 
plasmapheresis and plasma-cell directed therapy.
Case Description: A healthy 61 year old woman initially presented with one 
year of intermittent knuckle swelling in cold weather and bilateral calf pain. She later 
developed generalized weakness and was admitted with hypertensive emergency, AKI 
[serum creatinine (SCr) 2.0 mg/dL], edema, livedo reticularis, and blurry vision. Workup 
was notable for dysmorphic red cells on urine sediment, 2 grams of proteinuria, low 
complements, normal serum calcium, serum Kappa/Lambda ratio 5.73, IgG kappa M 
spike, and 2% type I cryoprecipitate. Renal biopsy showed crescentic and necrotizing 
cryoglobulinemic glomerulonephritis with crystalline morphology of monoclonal IgG1 
kappa (see Figure). Bone marrow biopsy showed no clonal cell population. The patient 
was treated with pulse steroids, plasmapheresis, and maintained on cyclophosphamide, 
bortezomib and dexamethasone, resulting in rapid improvement of symptoms and SCr to 
0.96 mg/dL after 7 weeks.
Discussion: This case illustrates a classical presentation of monoclonal gammopathy 
of renal significance, where renal damage ensues from cryoglobulin deposition, likely 
produced by a monoclonal population not detectable by standard testing. Treatment 
of this hidden population by clonal cell-directed therapy resulted in excellent renal and 
symptomatic recovery. Additionally, pathology images reveal the assembly of monoclonal 
immunoglobulins into crystals, a rare variant of cryoglobulinemia.
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The Clone Wars: Evolving Treatment of Proliferative Glomerulonephritis 
with Monoclonal Immunoglobulin G Deposits
Sandhya Manohar, Nelson Leung. Mayo Clinic, Rochester, MN.
Introduction: Proliferative glomerulonephritis with monoclonal immunoglobulin G 
deposits (PGNMID) is a recently described entity and as we become more aware of this 
in our patients, its treatment poses the next challenge. Here we present a patient we cared 
for and the dynamic changes in his response to therapy that helped us guide his treatment 
regimen.
Case Description: A 63 year old male was found to have 8 g/d proteinuria and chronic 
kidney disease at the time of a cardiac evaluation 14 years ago. Kidney biopsy was reported 
elsewhere as membranous nephropathy and was treated initially with cyclophosphamide 
(C) and prednisone(P) with improvement in his proteinuria down to 3 g/d. Rituximab (R)
was added with improvement in proteinuria to 1 g/d but was not continued due to coverage 
issues, and was eventually maintained on cyclosporine. He came to us for a second opinion 
and the diagnosis of PGNMID was made with no evidence of systemic disease. His kidneys 
eventually failed and he underwent a deceased donor kidney transplant. After 4 years he
developed proteinuria of 800mg/d. Kidney allograft biopsy showed recurrence of PGNMID 
with same IgG kappa. Serology and bone marrow was negative but flow cytometry showed 
rare polyclonal plasma cells. He was treated with Rituximab initially with improvement in 
proteinuria down to 267mg/d but slowly increased to 1.1g/d after 3 months despite negative 
CD20. RCP was given with a more sustained response and his treatment was changed to
be directed at CD38 cells with Rituximab and bortezomib (V) for a likely LPL clone with 
continued improvement in proteinuria.
Discussion: PGNMID in native kidney can be indolent but post-transplant it is usually 
aggressive and hence need prompt clone-directed therapy. The clones capable of producing 
PGNMID are plasma cell, lymphoplasmacytic (LPL) clone, and CLL clone. Our patient had 
no confirmed clone. Initial response to Rituximab suggests that it was a CD20 clone but he 
progressed and the regimen of RCP was given to knock out cells affecting both CD20 and 
CD38. His initial response to rituximab and quick recurrence is suggestive that he may have 
an LPL clone with CD38 cells that are more difficult to eradicate and considering his prior 
cytoxan exposure was switched to a bortezomib based regimen. The choice of therapy can 
be difficult, requiring a deeper understanding of PGNMID disease process.
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Plasmablastic Lymphoma Associated with IgD Lambda Light Chain 
Monoclonal Gammopathy and Severe AKI
Matthew Abramson,1,2 Ilya Glezerman.3 1New York Presbyterian, New York, NY; 
2Nephrology, Memorial Sloan Kettering Cancer Center, New York, NY; 
3Memorial Sloan Kettering Cancer Center, New York, NY.
Introduction: Light chain cast nephropathy is the most common pattern of acute 
kidney injury in patients with multiple myeloma, seen in up to 47.5% of cases. Free light 
chains (FLC) are freely filtered and undergo endocytosis by proximal tubular cells via apical 
receptors. When these receptors become saturated, the resultant load of urinary free FLC 
co-aggregate with uromodulin causing precipitation and obstruction of the distal tubules, 
and inducing an inflammatory response. Most cases result from a single plasma clone of 
multiple myeloma. 2% of myeloma cases are of the IgD variant; only 5 cases have been 
reported to cause light chain cast nephropathy, and none as a result of lymphoma. This 
report describes the first case of presumed IgD lambda light chain cast nephropathy due to 
plasmablastic lymphoma.
Case Description: 74 year-old man status-post nephrectomy at age 2, history of diffuse 
large B cell lymphoma status post R-CHOP in 2016 attaining complete remission, recent 
biopsy of new perisplenic lymph node revealing plasmablastic lymphoma, who presented 
with anorexia and decreased urine output. Nephrology was consulted for acute kidney injury 
(AKI) with creatinine of 9.7mg/dL (baseline of 1.2mg/dL). He was found to have an IgD 
monoclonal gammopathy (1.4 g/dL), increasing serum lambda light chains (from 91mg/dL 
3 weeks prior to 624mg/dL), and a kappa:lambda ratio of <0.01. 24-hour urine protein was 
2.39g with M-spike of 1.65g and urinary immune-fixation positive for IgD lambda light 
chains. There was no obstruction on renal ultrasound. Bone marrow biopsy showed 0.2% 
lambda restricted clone, but no plasmacytosis. Although kidney biopsy was not obtained, 
the presumed diagnosis was IgD lambda light chain cast nephropathy. He was given 
intravenous hydration followed by cyclophosphamide, bortezomib, and dexamethasone. 
Serum creatinine improved rapidly to 3.1 mg/dL, serum lambda FLC improved to 40 mg/dL 
over the following week and patient was discharged home.
Discussion: Our patient developed severe AKI in the setting of IgD lambda FLC 
gammopathy likely leading to the development of cast nephropathy. Multiple myeloma 
literature reports up to 80% chance of renal recovery in patients with 60% reduction of 
serum FLC by 21 days. This patient had a similar remarkable response to standard myeloma 
therapy although his underlying pathology was plasmablastic lymphoma.
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Proliferative Glomerulonephritis with Monoclonal Immunoglobulin M 
Deposits
Sneha Shrestha,1 Surya V. Seshan,2 James M. Chevalier.1 1Nyph/Weil Cornell 
Medical Center, New York, NY; 2Weill Cornell Medical Center, New York, NY.
Introduction: Proliferative glomerulonephritis with monoclonal immunoglobulin G 
deposits (PGNMID) was first described as a distinct entity in 2004. Only few case reports 
of PGNMID with IgM or IgA dominant deposition have been described. Here we report our 
case with clinical and histopathological features of PGNMID with Ig M dominant deposit.
Case Description: A 37 year old gentleman with diabetes mellitus-type 2, 
hypertension and obesity, presented with leg swelling and foamy urine for two weeks. 
Clinical exam was significant for BP 155/97mmHg and 2+ pedal edema. Labs revealed 
elevated serum creatinine(1.28mg/dl, baseline 0.9mg/dl, peak over the course of follow 
up 6.26mg/dl) and albumin of 2.5gm/dl. Urinalysis showed specific gravity of 1.015, pH 
of 6.4, 4+ protein and 2+ blood, 11-30 RBCs per hpf. Urine microalbumin to creatinine 
ratio was 5680 and urine protein creatinine ratio was 8gm per gm. Hemoglobin A1c was 
6.8. There was no M spike. Serum free light chains were mildly elevated with normal ratio. 
Bone marrow biopsy did not show monoclonal plasmacytosis. Cryoglobulin levels were 
repeatedly normal. Kidney biopsy showed moderately advanced diabetic nephropathy and 
nodular diabetic glomerulosclerosis, class III superimposed by IgM kappa proliferative 
glomerulonephritis. There was significant endocapillary and mesangial cellularity on light 
microscopy. Immunofluoroscence revealed granular 3+ IgM,3+ kappa light chain, 1-2+ 
C3 and 1-2+ C1q along the glomerular capillary walls and focally in the mesangium; and 
nonspecific 1+IgG, 1+ lambda and kappa light chains along the glomerular capillary walls, 
mesangial areas and tubular basement membrane. Electron microscopy showed scattered 
finely granular subendothelial electron dense deposits. He was treated with statin, diuretics 
and ARB was added when creatinine stabilized. He was given pulse dose of iv steroids, 
plasmapheresis (to remove IgM) and iv rituximab. Since he did not respond, he was further 
treated with cyclophosphamide and mycophenolate mofetil with regression of proteinuria 
and creatinine improvement.
Discussion: PGNMID is characterized by immunofluorescence findings of monoclonal 
IgG deposits and electron-dense deposits (EDDs) localized to glomeruli. Our case with 
histopathological features of PGNMID but with Ig M deposits adds to handful of similar 
case reports. We propose expansion of Nasr et al’s classification to include IgM and IgA 
dominant variant.
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Proliferative Glomerulonephritis with Monoclonal IgG Deposits
Divya Shankaranarayanan,1 Choli Hartono,1 Jun B. Lee,1 Steven Salvatore.2 
1Department of Nephrology, Weill Cornell Medicine, New York City, NY; 
2Department of Pathology, Weill Cornell Medical College, New York, NY.
Introduction: Proliferative glomerulonephritis with monoclonal IgG deposits 
(PGNMID) is a form of monoclonal gammopathy of renal significance (MGRS). We 
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present a case of rapidly progressive glomerulonephritis in a patient with smoldering 
multiple myeloma (SMM) who responded to steroid pulse in addition to bortezomib and 
cyclophosphamide.
Case Description: This was a 74-year-old female with SMM who presented 
with serum creatinine of 3.06mg/dl from 0.9mg/dL one week prior, normal C3/C4, 
negative cryoglobulin, κ/ λ ratio of 82.6/11.3 (7.29), serum albumin of 2.4g/dl, and no 
monoclonal spike on serum or urine protein electrophoresis. However, free κ light chains 
were present on urine immunofixation. The urinalysis revealed 5RBC/HPF and 24-hour 
urine protein was 3.93g. Bone marrow biopsy done at an outside facility showed κ light 
chain myeloma with 10-15% marrow involvement. Kidney biopsy (Figure 1.) showed a 
membranoproliferative pattern of glomerulonephritis with monoclonal IgG-kappa deposits 
by immunofluorescence and there were 8 glomeruli (of 31) with cellular crescents. No 
other monoclonal paraprotein related diseases were present. Electron microscopy showed 
occasional electron dense deposits in the subendothelial space and fine focal mesangial 
electron dense deposits. The patient was treated with methylprednisolone 500mg daily 
followed by a prednisone taper and bortezomib twice weekly 1.3mg/m2alternating with 
cyclophosphamide along with dexamethasone. The serum creatinine had peaked at 6.8mg/dl 
and improved with treatment to 1.8mg/dl by day 25 of initial presentation
Discussion: First described in 2004, PGNMID is a renal-limited glomerular disease, 
characterized by paucity of circulating paraproteins with presence of monoclonal IgG 
(usually IgG3-kappa) deposits in the glomeruli. The optimal treatment for this disease is not 
known. This case is unique due to rapid renal progression and prompt response to treatment. 
Considering PGNMID as a differential diagnosis of AKI in a patient with SMM and RPGN 
“picture” is important since early treatment may alter the renal prognosis in such patients.
Figure-1
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Proliferative Glomerulonephritis with Monoclonal IgG Deposits Leading 
to the Diagnosis of B Cell Lymphoma
Wael A. Hanna,1 Vivette D. D’Agati,2 James P. Reichart.3 1Lehigh Valley 
Hospital, Breinigsville, PA; 2Columbia University College of Physicians and 
Surgeons, New York, NY; 3Valley Kidney Specialists, Macungie, PA.
Introduction: Proliferative glomerulonephritis with monoclonal immunoglobulin 
deposits (PGNMID) is a rare glomerular disease within the MGRS spectrum, first described 
in 2004. Membranoproliferative GN is the most common histologic pattern.
Case Description: A 70-year-old female with a history of mild hypertension (HTN) 
was referred for renal insufficiency and uncontrolled HTN. On examination, BP was 
180/84 with otherwise normal cardiopulmonary exam and no edema. Lab data showed 
elevated S Cr of 1.9 mg/dL. Urinalysis displayed proteinuria and microhematuria with 
dysmorphic RBCs. The urine protein:Cr ratio was 1.9 g/g with serum albumin of 3.8 g/dL. 
CBC showed Hb of 11.6 g/dL with normal WBC count and differential. Serology for 
hepatitis, cryoglobulin, C3, C4, ANCA and anti-GBM antibody were negative. Serum 
immunofixation revealed IgM- kappa and IgM-lambda M-spikes with FLC kappa/
lambda ratio of 2.2. Renal biopsy showed diffuse endocapillary proliferative GN with 
membranoproliferative features. Immunofluorescence revealed mesangial and glomerular 
capillary wall staining for IgG, C3, C1q and kappa light chain, with restricted positivity 
for IgG subtype 3. EM displayed granular mesangial and subendothelial electron dense 
deposits. The findings were diagnostic of PGNMID with monoclonal IgG3-kappa deposits. 
Bone marrow biopsy showed (1%) kappa-restricted B cell lymphoma. She received four 
weekly doses of rituximab infusion after which she achieved clinical renal remission. 
Ten weeks after initiating rituximab, S Cr and UPCR had fallen to 1.3 mg/dL and 0.2 g/g 
respectively.
Discussion: PGNMID presents typically with nephrotic range proteinuria, renal 
insufficiency, hematuria and HTN and 20% of patients progress to ESRD. Only 20-30% of 
patients have a detectable M-protein in the serum or urine. The MIg detected in the serum 
may not be identical to the MIg in the kidney deposits, as shown in this case. Our case 
illustrates that an onconephrologic approach to detect and target the underlying B-cell clone 
can lead to clinical remission of PGNMID.
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Outcome of Patients with Multiple Myeloma Who Undergo Autologous 
Stem Cell Transplantation Followed by Renal Transplantation: A Case 
Series Report
Maria Ibrahim,1,2 Sapna Shah,2 Reuben Benjamin,4 Michael Delaney,1 
Steve Schey.3 1National Health Service, Watford, United Kingdom; 2Renal, 
Kings College Hospital NHS Foundation Trust, London, United Kingdom; 
3King?s College London, London, United Kingdom; 4King’s College Hospital, 
London, London, United Kingdom.
Introduction: Autologous stem cell transplantation (ASCT) and novel therapies have 
improved the prognosis of patients with multiple myeloma (MM). For those who undergo 
ASCT whilst on dialysis, a similar survival compared with the overall MM population has 
been reported. For patients achieving remission following ASCT, kidney transplantation 
is an attractive option, offering an improved quality of life and significant economic 
advantage.
Case Description: This case series investigates the outcome of 5 subjects who 
underwent an ASCT for MM with subsequent kidney transplantation. Subjects were 
identified from our regional hospitals between 2006 and 2012. 2 females and 3 males were 
identified. All patients were Caucasian with a median age of 54years (range 37- 64). 4 
patients presented with end stage renal disease (ESRD) and 1 progressed to ESRD shortly 
after diagnosis. Induction chemotherapy regimens with novel agents including thalidomide 
and bortezomib were utilised. Following attainment of very good partial remission (VGPR) 
or complete remission (CR), high dose melphalan ASCTs were performed after a median of 
11 months (range 8-22months). Kidney transplantation (living donor, n=3, deceased donor, 
n=2) with tacrolimus based immunosuppression regimens were completed at a median of 27 
months after ASCT (range 16-43months). Patients 1 and 3 experienced relapse of myeloma 
at 40 months and 13 months after kidney transplantation. Patient 1 received bortezomib 
based treatment to achieve CR, but later relapsed again. He developed sepsis related AKI 
and commenced dialysis. He died 1 month later. Patient 3 was treated with thalidomide and 
achieved VGPR. He developed a second relapse 5 months later and died with a functioning 
allograft (eGFR 21). Patients 2, 4 and 5 remained alive at the end of the follow up period 
(median time 67months) with eGFRs of 62, 11 and 50 respectively. Median kidney graft 
survival time was 66 months (range 47–95months).
Discussion: 5 patients with MM undergoing ASCT followed by renal transplantation 
achieved dialysis independence for a median of 66 months. Our study adds to the literature 
supporting kidney transplantation as the preferred treatment for ESRD following successful 
ASCT for MM and is useful when counselling patients reagrding renal and haematological 
outcomes.
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IgA Heavy Chain Monoclonal Immunoglobulin Deposition Disease in a 
Kidney Transplant Recipient
Rana El Sabbagh, Meghan E. Kapp, Kelly A. Birdwell, Beatrice P. Concepcion. 
Vanderbilt University Medical Center, Nashville, TN.
Introduction: IgA heavy chain deposition disease should be differentiated from disease 
with polytypic IgA deposits given distinct clinical, histological and pathophysiologic 
features. Here, we present a case of IgA heavy chain monoclonal immunoglobulin deposition 
disease in a transplant recipient with a reported primary disease of IgA nephropathy.
Case Description: A 49-year-old man with a reported history of IgA nephropathy 
who failed medical therapy including cyclophosphamide, prednisone and mycophenolate 
resulting in ESRD. He received a renal allograft 3 years prior which was reportedly lost due 
to recurrent disease. He underwent a second living unrelated transplant with alemtuzumab/
steroid induction and tacrolimus/mycophenolate/steroid maintenance immunosuppression. 
Two years posttransplant, he developed worsening kidney function with a SCr of 2 mg/dL 
(baseline 1.6 mg/dL) and new proteinuria of 3.7g/g. Kidney biopsy was performed and light 
microscopy revealed mild to moderate mesangial expansion with apparent eosinophilic 
deposits and segmental double contours of the glomerular basement membrane (GBM). 
Immunofluorescence, showed 3+ pseudolinear staining along GBM and tubular basement 
membranes (TBM), smudgy mesangial staining and vascular staining for IgA without 
corresponding light chain staining. By electron microscopy, punctate amorphous deposits 
were present along the inner aspect of GBM and outer aspect of TBM and around vascular 
smooth muscle cells with mesangial deposits showing focal short fibrillary substructure. 
He was referred to hematology and a bone marrow biopsy which showed a plasma cell 
neoplasm. He was started on bortezomib and dexamethasone but after 1 cycle developed 
severe AKI requiring HD. He did not recover function and was ultimately declared ESRD.
Discussion: IgA heavy chain monoclonal immunoglobulin deposition disease is a 
distinct clinico-pathologic entity which if left unrecognized or untreated can cause kidney 
allograft loss. This disease warrants a careful hematologic work-up to evaluate for a plasma 
cell dyscrasia and progression towards symptomatic IgA multiple myeloma. Although 
unsuccessful in this case, anti-myeloma agents appear to favorably influence renal prognosis. 
A hematological response may ultimately permit successful kidney transplantation with 
improved graft viability and decreased risk of recurrence.
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A Rare Case of Crystalglobulin-Induced Nephropathy
Jon W. Mares,2 Jason R. Pettus,1 Elizabeth J. Brant.1 1Dartmouth-Hitchcock 
Medical Center, Lebanon, NH; 2Dartmouth Hitchcock Nephrology Fellowship, 
Hanover, NH.
Introduction: The term monoclonal gammopathy of renal significance (MGRS) 
describes paraprotein-dependent kidney diseases that do not meet criteria for overt 
multiple myeloma, including cast nephropathy, Ig deposition disease and amyloidosis. 
Crystalglobulin-induced nephropathy (CGN), a rare paraprotein-related disease, is most 
commonly associated with multiple myeloma. We herein report an extremely rare case of 
CGN associated with MGRS.
Case Description: A 75 year-old man with metastatic prostate cancer and normal 
renal function presented with anuric AKI requiring dialysis. Serum protein electrophoresis 
showed 0.3 g/dl IgG kappa monoclonal protein. Serum free κ/λ ratio was 2.3 (ref. 0.5-2.43). 
ANCA, anti-GBM, hepatitis serologies, rheumatoid factor, C3, C4, and cryoglobulins were 
normal. Hydronephrosis was not seen on renal ultrasound. Renal biopsy revealed overt 
coagulative necrosis (infarction) of 40% of sampled cortical tissue on light microscopy. 
Abundant PAS-positive crystalline thrombi were present in interlobular arteries, glomerular 
arterioles and capillaries, and focally extending into proximal tubules. (Fig. 1) Congo red 
staining was negative. Immunofluorescence showed dim IgG kappa staining in crystalline 
thrombi. By electron microscopy, crystalline thrombi displayed polygonal and angulated 
forms with distinctive fine parallel linear organization. Findings confirmed crystalglobulin-
induced nephropathy. Bone marrow biopsy was then performed, revealing metastatic 
prostate cancer without demonstrable multiple myeloma. His hospital course was 
complicated by GI bleed and thromboembolic cerebral infarcts. He died 6 weeks after initial 
presentation upon discontinuing dialysis.
Discussion: CGN is a rare entity usually associated with multiple myeloma, whereas 
our patient had MGRS. Given a potentially devastating outcome, CGN should be considered 
in patients presenting with AKI and monoclonal gammopathy.
Fig. 1
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Crystalglobulinemia: A Rare and Complex Clinical Entity
Zi R. Zhang, Sara Ruddock-Walker, Pravir V. Baxi, Casey N. Gashti, 
Roger A. Rodby. Rush University Medical Center, Chicago, IL.
Introduction: Crystalglobulinemia (CryG) is a rare Monoclonal Gammopathy of Renal 
Significance (MGRS) that results in a crystalline appearing precipitation of paraproteins 
in the glomeruli. These paraproteins are unique in that they are not cryoprecipitable, but 
form immune aggregates that appear crystalline on Electron Microscopy (EM). Clinical 
manifestations include purpura, arthropathy and AKI. We present a case of crystalglobulin-
induced AKI in a pt with a monoclonal IgA lambda paraproteinemia. Early recognition and 
treatment led to resolution of her AKI.
Case Description: A 44-y/o F p/w arthralgias, HTN and edema. Labs: Cr of 1.4 mg/dL 
and Alb 3.7 g/dL. UA: +RBCs with a urine alb/Cr ratio of 6.3 g/g. Workup: ANA, ANCA, 
C3, C4, and hepatitis all neg or nml. Monoclonal IgA lambda was seen on serum and 
urine immunofixation. Serum k/l ratio was 0.76. A renal biopsy demonstrated on Light 
Microscopy: Lobular glomeruli with the majority showing intracapillary eosinophilic 
thrombi that stained 3+ for IgA and lambda (kappa-). EM: the thrombi were composed 
of crystalline structures with an organized substructure of parallel linear arrays (Fig 1). 
No evidence of cast nephropathy. Serum cryoglobulins were repeatedly negative. She 
developed AKI (Cr of 4.2) and was started on plasmapheresis (TPE) and steroids. A bone 
marrow biopsy showed a plasma cell neoplasm in 7% of cells with lambda predominance 
by flow cytometry. Therapy with bortezomib and cyclophosphamide was administered. A 
bone survey showed no lytic lesions. Three weeks following initiation of therapy, her Cr 
improved to 1.0.
Discussion: CryG is rare and illustrates the complexity of the MGRS spectrum. 
Diagnosis requires histologic evidence of characteristic crystalglobulin deposition within 
the vasculature in the absence of circulating cryoglobulins. This case emphasizes the 
importance of specific histologic diagnosis to guide treatment for pts with MGRS. In this 
case, TPE and steroids served as a bridge until directed chemotherapy was started.
Renal Biopsy
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A Case of Waldenström Macroglobulinemia Recovering from Dialysis-Re-
quiring AKI by Steroid Monotherapy
Naokata Kutsuzawa, Yosuke Nakagawa, Naoto Hamano, Masahiro Koizumi, 
Takehiko Wada, Masafumi Fukagawa. Tokai University School of Medicine, 
Isehara, Japan.
Introduction: Lymphoplasmacytic lymphoma (LPL) is an uncommon mature B cell 
lymphoma, whereas Waldenström macroglobulinemia (WM) is a subset of LPL involving 
the bone marrow with an IgM monoclonal gammopathy in blood. WM mainly presents 
with symptoms associated with anemia and hyperviscosity syndrome. WM-associated 
nephropathy is rare and its prognosis is unknown. Here, we report a case of LPL/WM 
recovering from dialysis-requiring acute kidney injury by steroid monotherapy.
Case Description: A 76-year-old Japanese woman who had been previously healthy 
admitted to the hospital with complaint of abdominal pain. She became anuric soon after 
admission, followed by progressive dyspnea due to pulmonary edema. She was referred 
to our hospital and hemodialysis was started for volume control. She presented with no 
neurological symptoms but funduscopy showed dilated and tortuous retinal veins with 
hemorrhagic exudates, which suggested hyperviscosity syndrome. She had severe anemia 
with rouleaux formation, high level of serum IgM (3776 mg/dl) and monoclonal IgM with 
lambda light chain on serum immunoelectrophoresis. Bone marrow biopsy demonstrated 
infiltration by small lymphocytes that exhibit plasma cell differentiation and she was given 
a diagnosis of LPL/WM. Renal biopsy demonstrated acute tubular necrosis with cast 
nephropathy and neoplastic lymphocytic infiltration in the interstitium. There were IgM 
deposits in the glomerular basement membrane and widespread thrombi in the capillaries. 
She underwent the treatment with high-dose dexamethasone, which steadily made her 
renal insufficiency ameliorated. Finally, hemodialysis therapy was discontinued at the 31st 
hospital day.
Discussion: Prognosis of WM-associated nephropathy depends on the type of renal 
pathology. This case suggested that acute kidney injury mainly caused by neoplastic 
lymphocytic infiltration might be reversible by chemotherapy.
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IgA Nephropathy Associated with Cystic Fibrosis: Role of Recurrent 
Infections as Etiology
Priyanka Wani,1 Burl R. Don,2 Andrew I. Chin.3 1University of California Davis 
Medical Center, Sacramento, CA; 2University of California Medical Center, 
Sacramento, CA; 3University of California Davis, Sacramento, CA.
Introduction: Cystic fibrosis (CF), is the most common autosomal recessive condition 
in the caucasian population, and is due to mutations in cystic fibrosis transmembrane 
regulator (CFTR) gene that codes for a regulated chloride channel. CF is multisystem 
disorder primarily affecting the lungs, digestive system, sweat glands and reproductive 
tract; renal involvement is relatively uncommon in CF despite the high expression of CFTR 
in the kidney. Reported glomerular diseases associated with CF include AA amyloidosis, 
membranoproliferative and post-infectious glomerulonephritis. We present a 28 year old 
Caucasian male with CF who presented with worsening renal function, and nephrotic range 
proteinuria diagnosed with IgA Nephropathy
Case Description: A 28 year old Caucasian male with CF for over 10 years presented 
progressive worsening proteinuria from 700 mg/day two years ago to more recently 8 
grams/day. His prior renal history included recurrent episodes of respiratory infections and 
acute kidney injury and the progressive loss of renal function. Evaluation of proteinuria 
noted negative ANA, ANCA, anti-dsDNA, but a low serum C3. Serum creatinine levels 
ranged from 2-3 mg/dL. Urine microscopy revealed many dysmorphic RBC’s. A renal 
biopsy was performed and light microscopy revealed mild to moderate mesangial widening 
with mesangial hypercellularity but no endocapillary hypercellularity. IF staining was 
positive for IgA and C3. The tubulointerstitium demonstrated widespread interstitial fibrosis 
and tubular atrophy. Congo red stain was negative for amyloid. The MEST indices were 
noted as M1, E0, S0, and T2. The patient was treated conservatively with losartan and 
without immunosuppression. Renal function remained stable and proteinuria decreased 
from 8 grams to 5 grams/day over a four month period.
Discussion: Frequent mucosal infections and inflammation, as seen in CF, may be 
associated with a chronic production of IgA. This patient had an extensive 10 year history of 
recurrent mucosal infections which were poorly treated. This may have led to aberrant IgA 
production due to abnormal glycoforms leading to mesangial immune complex deposition 
and complement activation (low C3) as observed in our case. Therefore recurrent infections 
associated with CF may have an important role in the pathogenesis of IgA nephropathy.
SA-PO237 Poster Saturday
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IgA Dominant Membranoproliferative Glomerulonephritis
Lance Bechtold,1 Jennifer Aranas,2 Mhd kussay Alsamkari,3 
Erika R. Bracamonte,2 Sireesha Koppula.2 1Banner University Med Center 
Tucson, Tucson, AZ; 2University of Arizona, Tucson, AZ; 3Banner, Tempe, AZ.
Introduction: IgA Nephropathy is widely accepted as the most common cause of 
glomerulonephritis worldwide. Far less common and somewhat controversial is IgA 
Dominant Membranoproliferative Glomerulonephritis. Most mentions of this unique 
pathology are described in case studies with suggested etiologies including: cirrhosis, burn 
victims, and children.
Case Description: We present a case of a 74 year old woman who presented with 
acute encephalopathy after one month of cough and URI like symptoms. She had recently 
returned from a family gathering where she was exposed to several sick contacts. The 
patient had prior history of CKD-3b, hypertension, and carcinoid tumor, for which she was 
on active treatment with octreotide for several years. Initial labs were significant for acute 
kidney injury with serum creatinine of 2.67mg/dL and urine protein to creatinine ratio of 
18,134mg/g. She was initially treated with IV fluids and antibiotics with no improvement 
to her renal function. She underwent renal biopsy which demonstrated the characteristic 
features of MPGN on light and electron microscopy along with a notable predominance of 
IgA on immunofluorescence microscopy. She eventually required hemodialysis and pulse 
dose IV steroids followed by tapering course of oral steroids. Given the paucity of reported 
cases, along with the lack of proven treatment strategies and the issue of her active carcinoid 
tumor, our treatment options were limited to steroids. She was referred for re-evaluation and 
was cleared of carcinoid. She then began a trial of oral cyclophosphamide (CPA). After two 
weeks of treatment, she developed issues of recurrent E.coli UTI and later development of 
community acquired pneumonia, forcing us to stop CPA. She continued on hemodialysis for 
a total of three months before renal recovery allowed her to stop dialysis. At last follow up, 
the patient had returned to her baseline serum creatinine of 1.2 mg/dL and had improvement 
of her proteinuria with urine protein/creatinine ratio of 5121mg/g. She continued to have 
intermittent episodes of frank hematuria. The patient had not undergone repeat biopsy. She 
was pending infectious clearance to resume her course of CPA.
Discussion: Given the lack of proven treatment modalities, we felt that this case 
presented an opportunity to share a reasonable and effective treatment option for future 
patients.
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Membranoproliferative Glomerulonephritis Due to Monoclonal 
Gammopathy of Renal Significance: The Value of Pronase-Digestion
Win Win Moe,2 Dominick Santoriello,1 James Drakakis,2 Naveed N. Masani.2 
1Columbia University Medical Center, New York, NY; 2NYU Winthrop Hospital, 
Mineola, NY.
Introduction: Membranoproliferative glomerulonephritis (MPGN), a characteristic 
light microscopic (LM) finding seen on renal biopsy, is further classified based on 
immunofluorescence (IF) findings. Immune-complex deposition is one cause of MPGN and 
may be secondary to monoclonal immunoglobulin deposits. IF on pronase digested tissue 
can aid in revealing masked monoclonal deposits. A wide spectrum of hematologic diseases 
are associated with kidney deposition of monoclonal immunoglobulin deposits; however 
in many patients, there is no identifiable hematologic condition and the term monoclonal 
gammopathy of renal significance (MGRS) has been applied.
Case Description: A 65-year-old male presents with hypertension, weight gain 
with bilateral lower extremity edema, and subacute kidney injury with creatinine of 
1.81 mg/dl (baseline: 0.9 mg/dl). Urinalysis demonstrated 3+ protein, 2+ blood, with 
protein creatinine ratio of 10.3 g/g and a serum albumin of 2.8 g/dL. Serum immunofixation 
was positive for IgG-kappa; remainder of paraprotein workup and glomerular serologies, 
including complement levels, were either normal or negative. Renal biopsy findings on 
light microscopy were consistent with an MPGN pattern of injury, subacute, with nodular 
mesangial sclerosing features; initial IF demonstrated trace to 1+ granular to semi-linear 
glomerular capillary wall staining for C3 only; repeat IF performed on pronase-digested 
tissue revealed trace to 1+ granular to semi-linear glomerular capillary wall staining for IgG 
with trace C3 and trace kappa, and no significant staining for lambda. Electron microscopy 
did not reveal any evidence of dense deposit disease. These findings support the diagnosis 
of MPGN with IgG-kappa monoclonal deposits. Subsequently patient underwent bone 
marrow biopsy and full body PET scan, neither of which demonstrated any evidence of 
B-cell clonal expansion/population. Given these findings, the patient’s MPGN appears to 
be secondary to MGRS. Therapy was initiated with oral corticosteroids and Rituxamab.
Discussion: An MPGN pattern of injury represents a diagnostic and therapeutic 
challenge. Findings on IF are critical to help determine the underlying cause. This case 
demonstrates MGRS as underlying etiology of MPGN, and the value of IF analysis via 
pronase-digestion to aid in “unmasking” hidden monoclonal deposits.
SA-PO239 Poster Saturday
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Idiopathic Membranoproliferative Glomerulonephritis: A Grey Zone
Justin Lee Loy, Freddy R. Malpartida, Xu Zeng, Abhilash Koratala. University 
of Florida Gainesville, Gainesville, FL.
Introduction: ‘Idiopathic’ membranoproliferative glomerulonephritis (MPGN) is rare 
compared to secondary forms and usually a progressive disease. Studies evaluating the role 
of steroids were primarily done in children and the data is sparse in adults. Mycophenolate 
mofetil is effective and can be used as a steroid-sparing agent in the treatment of idiopathic-
MPGN.
Case Description: A 22-year-old White man a recent diagnosis of hypertension was 
referred to Nephrology department for elevated serum creatinine and proteinuria. He was 
asymptomatic at presentation except for swelling in the legs for few months. Laboratory data 
was significant for a creatinine of 2mg/dL, serum albumin 2.5g/dL, low serum complements 
and urine protein-creatinine ratio ~17g/g (Ref: <150 mg/g). Renal biopsy demonstrated 
MPGN [Figure] with moderate interstitial fibrosis. Secondary causes of MPGN including 
hepatitis C, lupus, and monoclonal gammopathies were excluded by appropriate tests. 
He was started on prednisone 80mg/day and proteinuria reduced to ~3.7g/g in 8 weeks. 
However, he did not tolerate steroid taper and proteinuria worsened. He was then started 
on Mycophenolate mofetil (MMF) 1000mg twice-a-day with reduction in proteinuria to 
1.8g/g in ~6 weeks and serum albumin improved to 3.3g/dL. We plan to continue MMF 
monotherapy for 2-3 years similar to lupus nephritis treatment.
Discussion: Idiopathic MPGN is very uncommon in developed countries and the 
evidence base underlying the treatment recommendations is weak. MMF is a potent 
immunosuppressive agent which is being increasingly used in primary glomerulonephritides, 
along with lupus nephritis. Current data from small studies including our case supports the 
use of this agent in idiopathic MPGN.
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MPGN and Sarcoidosis: A Rare Presentation
Alamgir Mirza,2 Sandeep Magoon.1 1eastern virginia medical school, Norfolk, 
VA; 2eastern virginia medical school, Norfolk, VA.
Introduction: Sarcoidosis is a chronic multi-system disease characterized by non-
caseating granulomas. It can affect kidneys, but glomerular involvement is rare. There are 
few case reports of sarcoidosis with membranoproliferative glomerulonephritis (MPGN) 
where the causality was not proven clearly. Last case described in literature was in 1986. To 
best of our knowledge, our case is the first in which MPGN is causally related to Sarcoidosis, 
presented with rapidly progressive glomerulonephritis and severe AKI and first one to be 
reported since the new classification for MPGN has been proposed.
Case Description: A 32 years old African American male with past medical history 
of bilateral knee arthritis presented to the hospital with bilateral ankle edema and rash 
in lower extremities. He was in acute kidney injury (AKI) with creatinine of 3.5 mg/dL. 
Creatinine 2 years ago was 1.3 mg/dL. Urinalysis showed proteinuria, hematuria, no 
red blood cell cast. Proteinuia was 6.2 gm/day. Hepatitis B and C, and HIV tests were 
negative. Cryoglobulin and paraprotein studies were negative. ANA was positive at 1:40, 
other autoimmune serologies and complements were negative. Angiotensin converting 
enzyme was elevated at 92 U/L. Renal ultrasound was unremarkable. CT chest showed 
bilateral hilar lymphadenopathy. Renal biopsy showed MPGN of uncertain etiology. 
Immunofluorescence (IF) was positive for IgG, IgA, IgM, C3, C1q deposits. Creatinine 
improved from a peak of 7.4 mg/dL to 3.4 mg/dL with pulse steroids and was discharged on 
prednisone. A week later he presented back with worsening renal function and was started 
on dialysis. Lymph node biopsy revealed non caseating granulomas and no infection. Bone 
marrow biopsy was negative. Cellcept was added to his regimen. His interdylactic rise of 
creatinine is decreasing. Renal recovery is anticipated.
Discussion: Patient’s presentation with arthritis and rash raised suspicion of sarcoidosis 
related vasculitis supported by a “full house” on IF in renal biopsy and non caseating 
granulomas on lymph node biopsy. Work up for lymphoma, paraproteinemia, infection and 
other autoimmune diseases were negative. In Summary, MPGN with Sarcoidosis is very 
rare. However when no other etiology is identified, Sarcoidosis should be considered in the 
differential. There is no consensus on treatment. Steroid is treatment of choice. Aggressive 
therapy, namely Rituximab, cellcept, plasmapheresis should be considered in severe AKI.
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Type 1 Cryoglobulinemia with Skin, Nerve, Pulmonary, and Renal 
Involvement Preceding a Diagnosis of Multiple Myeloma
Akshita Narra,1 Nicole K. Andeen,1,2 Rupali S. Avasare.1 1Division of Nephrology, 
Oregon Health and Science University, Portland, OR; 2Renal Pathology, 
Oregon Health Science University, Portland, OR.
Introduction: Type 1 cryoglobulinemia is a rare cause of glomerulonephritis(GN). 
Here we present a case of a patient with type 1 cryoglobulinemic vasculitis with multiorgan 
involvement who met criteria for multiple myeloma 1.5 years after initial presentation.
Case Description: A 56-year-old Caucasian male presented with progressively 
worsening bilateral lower extremity pain and numbness followed by a lacey purple rash and 
small volume hemoptysis. Serologic workup was negative for ANA, anti-cardiolipin-ab, 
ANCA, anti-GBM ab, hepatitis B/C, RF, CCP, and cryoglobulin. He had low C3(73mg/
dL), normal C4, elevated M protein(0.3gm/dL), elevated serum kappa(175mg/dL) and 
normal lambda light chains. Bone marrow (BM) biopsy showed 5% monoclonal plasma 
cells. BM and fat pad biopsies were negative for amyloid. Bronchoscopy was unrevealing. 
Skin biopsy was inconclusive, but was notable for leucocytoclastic vasculitis vs thrombotic 
process. He was initiated on high dose prednisone and rituximab therapy. His symptoms 
waxed and waned and ultimately he developed hematuria, nephrotic-range proteinuria, and 
acute kidney injury (creatinine 2.3mg/dL) a year later. Kidney biopsy revealed segmental 
endocapillary hypercellularity, sub endothelial and mesangial eosinophilic immune deposits 
with 20% crescents. IF was positive for IgG(3+), kappa light chain(2-3+), and C3(1+). 
EM showed organized immune deposits with straight to slightly curved rods 10-17 nm 
in diameter very characteristic of cryoglobulinemic GN. A repeat BM biopsy showed 
expansion of the monoclonal plasma clone to 20%.He was initiated on plasmapheresis, 
steroids, cyclophosphamide, and carfilzomib with improvement in his symptoms and renal 
function. Repeat serum cryoglobulin and cryofibrinogen remained undetectable.
Discussion: This case highlights the challenges with diagnosing cryoglobulinemia based 
on serologic tests alone, and the differential diagnosis and treatment of cryoglobulinemia 
due to multiple myeloma. We emphasize therapy should be directed toward the causative 
plasma cell clone, which in this case was rituximab resistant. We present good outcomes 
after an induction therapy with steroids and plasmapheresis for a rapidly progressive GN 
due to cryoglobulinemia. Finally, we present a regimen of steroids, cyclophosphamide and 
carfilzomib in place of bortezomib for patients with significant nerve involvement.
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Persistent HCV-Related Cryoglobulinemic Glomerulonephritis Following 
Sustained Virologic Remission and Rituximab Monotherapy
Tyler Woodell, Divine Ribakare, Rupali S. Avasare, Nicole K. Andeen. Oregon 
Health & Science University, Portland, OR.
Introduction: Hepatitis C virus (HCV)-related cryoglobulinemia is treated with direct-
acting antiviral therapy and immunosuppression if severe end-organ damage is present. 
We present a patient with persistent HCV-related cryoglobulinemic glomerulonephritis 
(GN) years after sustained virologic remission (SVR) refractory to rituximab monotherapy. 
With the help of our oncology colleagues we are targeting therapy to a low grade 
lymphoproliferative disorder producing cryoglobulins.
Case Description: A 62 year-old Caucasian man presented with palpable purpura 
on his lower extremities, nephrotic syndrome, and acute kidney injury in 2010. Serologic 
workup was notable for HCV (peak viral load 1.3 million iU/mL), depressed C4 level, 
markedly elevated rheumatoid factor (>650 iU/mL, nl 0 – 14) and type II cryoglobulinemia 
(monoclonal IgM kappa and polyclonal IgG); SPEP, UPEP, and serum free light chains 
were unremarkable. Kidney biopsy showed membranoproliferative GN with IgM kappa 
deposits, suggestive of cryoglobulinemic GN. A bone marrow biopsy did not show a clonal 
cell population. He achieved SVR at three months following treatment with simeprevir 
and sofosbuvir, but his nephrotic range proteinuria and purpura persisted. In 2015, the 
patient was treated with two courses of rituximab, however he continued to have nephrotic 
range proteinuria and cryoglobulinemia. A kidney biopsy was repeated and showed 
membranoproliferative GN with hyaline thrombi as well as subendothelial and mesangial 
deposits without a clear substructure, and a low-grade CD-20+ B cell lymphoma. He is 
currently being treated with rituximab and bendamustine for low grade B cell lymphoma. 
At last follow-up proteinuria improved from 8.1 to 4.2 grams/day; eGFR declined from 30 
to 18ml/min/1.73m2.
Discussion: HCV-related cryoglobulinemic GN following SVR is increasingly 
recognized. This case of cryoglobulinemia highlights the intersection between HCV 
(typically types II-III) and lymphoproliferative disorders (typically type I), and draws 
attention to the need for appropriately targeted therapies. Given the growing use of direct-
acting antiviral agents for HCV, novel therapeutic strategies are needed to effectively treat 
refractory cases of HCV-related cryoglobulinemic GN.
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Cry, Cry Again: A Case of Idiopathic Cryoglobulinemia
Nupur Kikani,1 Sehrish Ali,2 Rajeev Raghavan.1 1Baylor College of Medicine, 
Houston, TX; 2BCM Nephrology, Sugar Land, TX.
Introduction: Cryoglobulinemia is characterized by the presence of cryoglobulins 
in the serum, and it is commonly associated with persistent viral infections, autoimmune 
diseases, and lymphoproliferative disorders. Although there are standardized treatments 
for viral or malignancy associated cryoglobulinemia, a protocol for idiopathic non-viral 
cryoglobulinemia has yet to be described. Literature supports using a combination of high 
dose glucocorticoid therapy and plasmapheresis. In true idiopathic cryoglobulinemia, 
Rituximab has improved outcomes in published cases. Here, we present a patient with 
newly diagnosed idiopathic cryoglobulinemia in whom Rituximab was added to high dose 
steroids resulting in improvement of renal function
Case Description: A 66-year old male with a history of leukocytoclastic vasculitis 
diagnosed by biopsy of a right leg rash 7 years prior, presented with 2.5 weeks of new 
onset lower extremity edema and scrotal swelling. He had new onset hypertension, acute 
kidney injury, hyperkalemia, and non-anion gap metabolic acidosis. A 24-hour urine 
collection was consistent with nephrotic range proteinuria. A laboratory work-up showed 
an undetectable C4, low-normal C3, positive rheumatoid factor, and positive ANA with 
titer >640. Kidney biopsy revealed immune deposits consistent with cryoglobulinemia and 
immunofluorescence was negative for other pathology (Figure 1). The remaining viral and 
autoimmune laboratory work up was negative, including both Hepatitis panel and HCV 
RNA. The patient received three days of pulse dose steroids followed by a single dose of 
rituximab at 375 mg/m2. His creatinine, proteinuria, and overall clinical picture improved 
and has persisted.
Discussion: Guidelines to treat idiopathic non-viral cryoglobulinemia do not exist. 
Rituximab may be an effective and intuitive adjunct treatment, per literature review and 
in our patient.
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Novel Approach to Treatment of Mixed Cryoglobulinemia with Kidney 
Involvement: Case Report
Marianne Camargo,1 Tara I. Chang,2 Robert T. Isom,3 David J. Iberri,4 
Michelle M. O’Shaughnessy.5 1Nephrology, Icahn School of Medicine at Mount 
Sinai, New York, NY; 2Stanford University School of Medicine, Palo Alto, CA; 
3Stanford University School of Medicine, Palo Alto, CA; 4Stanford Cancer 
Center, Stanford, CA; 5Stanford University, Palo Alto, CA.
Introduction: Mixed cryoglobulinemia (CG) is rarely associated with hepatitis B 
virus (HBV) infection. Monoclonal CG can result from an underlying lymphoproliferative 
disorder. We report a case of mixed CG with treated HBV and a low-grade 
lymphoproliferative disorder. Adverse reactions to standard therapies motivated a novel 
proteasome-inhibitor based approach
Case Description: A 67-year-old woman with a 5-year history of mixed CG 
and membranoproliferative glomerulonephritis experienced cerebrovascular and 
gastrointestinal ischemia with deteriorating kidney function, persistent hematuria, and 
proteinuria, while receiving maintenance tacrolimus and prednisone. Prior therapies 
included mycophenolate (persistent disease activity), rituximab (serum sickness), 
cyclophosphamide (leukopenia), and azathioprine (persistent disease activity). Labs 
included: +RhF, +HBV sAg with negative sAb (treated with entecavir with undetectable 
viral load), negative HCV, +IgM monoclonal gammopathy, and hypogammaglobulinemia. 
Before further immunosuppressive therapy, she received subcutaneous immunoglobulin 
for hypogammaglobulinemia. She developed palpable purpura, increasing creatinine (2.1 
to 4.3 mg/dL), and increasing cryocrit, consistent with an immunoglobulin-triggered CG 
vasculitis flare. Given underlying monoclonal gammopathy, we initiated bortezomib and 
dexamethasone. Her creatinine initially declined to 2.8 mg/dL; however, she then developed 
severe diarrhea (attributed to bortezomib toxicity). Repeat kidney biopsy revealed 5 of 
19 glomeruli with global sclerosis, 6 of 19 with cellular crescents, and large IgM Kappa 
positive subendothelial cryoglobulin deposits. She received 5 days of plasma exchange and 
intravenous corticosteroids followed by carfilzomib as an alternate proteasome inhibitor: 
response pending at time of abstract submission.
Discussion: Unlike prior cases of HBV-associated CG, our patient had persistent 
disease activity despite viremia clearance. Cryoglobulinemic vasculitis flares following 
intravenous or subcutaneous immunoglobulin have not been widely reported. A proteasome 
inhibitor-based approach might represent a novel treatment option when standard therapies 
fail.
SA-PO245 Poster Saturday
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Gall Bladder Arteritis in a 35-Year-Old Lady with Mixed Cryoglobulin-
emia Syndrome
Maria I. Kiliaris,2 Husham R. Abuleis,1 Packiam Shenbagaraman.1 1Oxford 
University Hospitals NHS Foundation Trust, Oxford, United Kingdom; 2Milton 
Keynes University Hospital NHS Foundation Trust, Milton Keynes, United 
Kingdom.
Introduction: Mixed Cryoglobulinemia Syndrome is a systemic disease caused by the 
deposition of circulating immune complexes (cryoglobulins) in small and medium –sized 
arteries. Type II cryoglobulinemia is most often due to Chronic Hepatitis C infection and it 
is also seen in autoimmune disorders such as SLE and Sjogren’s syndrome. Whilst skin and 
renal involvement are common clinical features, gall bladder involvement is very rare and 
we report a case of cholecystitis due to cryoglobulinemic vasculitis.
Case Description: A 35-year-old lady with Sjogren’s syndrome presented in 
August 2016 with systemic symptoms, acute kidney injury(AKI), hypertension, 
significant hemoproteinuria, low C3 and C4 and positive cryoglobulins (type II). ANCA 
and anti GBM antibodies were negative. PET CT scan and a bone marrow trephine 
were done to exclude lymphoma. She underwent a kidney biopsy which confirmed 
cryoglobulinaemic glomerulonephritis and was managed with plasmapheresis, Rituximab 
and Methylprednisolone followed by oral prednisolone. Her systemic symptoms, kidney 
function and proteinuria improved. In December 2016 her condition relapsed with systemic 
symptoms, skin rash, worsening renal function and positive cryoglobulins (cryocrit 8%). 
She responded to another course of plasmapheresis, Rituximab and prednisolone. In May 
2017 she was admitted under Gastroenterology for right upper quadrant pain, raised CRP 
and deranged liver function tests. She was diagnosed with acute cholecystitis. At this time 
she developed another cryoglobulinemic relapse with oliguric AKI. She was managed again 
with plasmapheresis, Rituximab and prednisolone. She also needed hemodialysis briefly. 
She had an interval cholecystectomy. The gall bladder histology was reported to show florid 
arteritis in the medium sized arteries related to cryoglobulinemia (images will be provided 
in the poster). Her kidney biopsy was repeated and it also showed arteritis with severe 
chronic damage. Cyclophosphamide was added to the treatment regimen to prevent further 
relapses and because of the extra-renal disease.
Discussion: To our knowledge this is the first case report of cryoglobulinemic vasculitis 
that manifested in the gall bladder and mimicked acute cholecystitis during a relapse. The 
diagnosis can be missed or delayed and therefore careful examination and correlation with 
the clinical picture is essential.
SA-PO246 Poster Saturday
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Fungal Endocarditis and ANCA-Vasculitis: More Than a Mere 
Coincidence?
Hussain Aboud, William L. Clapp, Abhilash Koratala. University of Florida, 
Gainesville, FL.
Introduction: Glomerulonephritis (GN) due to infective (bacterial) endocarditis is well 
documented, with the most common lesions being necrotizing and crescentic GN, followed 
by endocapillary proliferative GN. Prominent C3 staining and subepithelial immune 
deposits on EM are commonly associated with infection-related GN than Pauci-immune 
picture of ANCA vasculitis. Herein, we present a case of Pauci-immune proliferative GN in 
a patient with fungal endocarditis.
Case Description: A 52-year-old White man with a history of intravenous drug abuse, 
chronic hepatitis C and diabetes mellitus initially presented to our institution with fever 
and bilateral lower extremity rash/palpable purpura. Biopsy of the rash demonstrated small 
and medium vessel vasculitis. He was also found to have native aortic valve endocarditis 
with ~1.5 cm vegetation and Candida parapsilosis fungemia which failed treatment with 
Micafungin and therefore switched to amphotericin B and flucytosine. Later, he developed 
worsening renal function with sub-nephrotic proteinuria and work up revealed dysmorphic 
RBCs in the urine, hypocomplementemia, positive C-ANCA, PR3 and cryoglobulins. In the 
presence of multiple confounding factors and varied differentials (e.g. hepatitis C-MPGN, 
post-infectious GN, ANCA vasculitis), a renal biopsy was obtained which showed 
proliferative Pauci-immune glomerulonephritis with ATN [Figure]. His renal function 
worsened requiring dialysis. Immunosuppressive therapy was not attempted because of 
active fungemia.
Discussion: Interestingly, ANCA antibody is found in up to 28% of the tested patients 
with infective endocarditis. However, Post-infectious Pauci-immune GN in association with 
Candida parapsilosis has never been reported in the literature to the best of our knowledge. 
It is likely that the fungal capsular polysaccharide activates complement cascade and 
triggers inflammation. Whether ANCA-antibody was a coexistent distinct entity or induced 
by fungal infection or underlying hepatitis C in our patient remains elusive.
SA-PO247 Poster Saturday
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Relapsing Hepatitis B (HBV)-Associated Vasculitis with Features of 
Polyarteritis Nodosa (PAN) and cANCA-Associated Vasculitis
Usman A. Khan,2 Sardar H. Ijaz,1 Aemen S. Khakwani,2 Joe Ghata.2 1internal 
medicine, University of Oklahoma Health Sciences Center, Oklahoma city, OK; 
2OUHSC, Oklahoma City, OK.
Introduction: HBV-associated vasculitis typically manifests as the medium 
vessel vasculitis, PAN. HBV-associated PAN (HBV-PAN) is ANCA(-), without 
glomerulonephritis (GN) or pulmonary involvement; relapse does not occur after successful 
HBV seroconversion. We describe a unique case of HBV-associated vasculitis with features 
of a small and medium sized overlap vasculitis and atypical long term course.
Case Description: The patient is a 60-year-old male with hypertension and HBV 
who initially presented with abdominal pain and scrotal swelling. Abdominal angiogram 
revealed beaded morphology and aneurysms involving mesenteric, hepatic, and 
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intraparenchymal renal arteries. Hepatitis B core antibody, cANCA, PR3, and rheumatoid 
factor were (+). He received pulse steroids and Cytoxan for treatment of PAN and Entecavir 
for HBV, resulting in resolution of symptoms. Serum Cr rose from 0.8 mg/dL to 2.0 mg/dL 
during the first 2 months of treatment, and then remained stable. Multiple urinalysis (UA) 
measurements were negative. Two years later, the patient developed abdominal pain, 
orchitis, hemoptysis, and acute kidney injury (serum Cr of 11 mg/dL). HBV viral load 
was negative. UA showed 3+ blood and 3+ protein. Renal biopsy displayed pauci-immune 
crescentic GN with active crescents involving ~ 50% of the glomeruli (Figure A, Jones 
stain). Two arteries had evidence of past arteritis with elastic lamina disruption (Figure B, 
EVG stain); acute necrotizing arteritis was not present. The patient recovered renal function 
(most recent serum Cr=3.2 mg/dL) after therapy with pulse steroids, plasma exchange, 
Rituxan, and Cytoxan.
Discussion: Our patient with HBV-associated vasculitis initially presented with 
manifestations of medium vessel involvement, but with an unusual feature of cANCA/
PR3 seropositivity. Relapse occurred 2 years later with PAN symptoms (orchitis, 
severe abdominal pain) and evidence of ANCA-associated small vessel vasculitis (GN, 
hemoptysis). While the initial trigger may have been HBV, the vasculitis later became self-
perpetuating as it recurred during a time when there was no HBV viremia. Patients with 
HBV-PAN who are ANCA+, should be closely followed because they could be at higher 
risk of vasculitis relapse.
SA-PO248 Poster Saturday
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ANCA Negative Pauci-Immune Crescentic Glomerulonephritis Associated 
with Cervical Carcinoma
Ujjala Kumar,1 Kioumars Bolourian kashi,1 Cynthia Miracle,1 Dinna Cruz,2 
Aleksandra Novikov,1 Bethany E. Karl.1 1UCSD, San Diego, CA; 2University of 
California San Diego, San Diego, CA.
Introduction: Glomerulonephritis (GN) associated with solid tumors is a rare but well-
known entity. Various forms of paraneoplastic GN have been described in the literature, 
most common being membranous and minimal change disease. Here we present a case of 
cervical cancer and rapidly progressive crescentic GN involving near 100% of the glomeruli 
sampled.
Case Description: A 58-year-old woman admitted for rising creatinine found on 
routine labs prior to initiation of chemotherapy. Medical history was significant for 
recently diagnosed poorly differentiated cervical carcinoma, AJCC stage IIB., for which 
she had been actively receiving radiation therapy. She denied prior kidney disease, 
use of non-steroidals nor recent antibiotics. On presentation, Cr was 2.4 mg/dL from 
baseline of 0.9 mg/dL a month prior to presentation. Urinalysis revealed active sediments. 
24-hour urine quantified proteinuria in nephrotic range (8 gms/24-hr). Extensive GN 
work-up was negative. Serum protein electrophoresis and urine immunofixation showed 
no monoclonal gammopathy. A renal ultrasound showed normal size kidneys. A kidney
biopsy divulged severe, active necrotizing and crescentic glomerulonephritis involving
nearly 100% of 22 sampled glomeruli. There were cellular crescents and amyloidosis, type 
AA, with extensive glomerular and focal vascular involvement. Acute tubular injury and
extensive tubulointerstitial inflammation were also noted. Patient’s renal function continued 
to deteriorate in parallel to progression of her malignancy and was eventually started on
hemodialysis five months after her initial diagnosis of GN. Unfortunately, patient was never 
deemed a candidate for chemotherapy due to poor performance status. She continued to
decline and transitioned to comfort care passing less than 7 months from her initial renal
diagnosis.
Discussion: We present a unique case of rapidly progressive crescentic GN associated 
with cervical cancer. There have been cases of membranous glomerulonephritis associated 
with cervical cancer but crescentic GN has not been reported in the literature to the best 
of our knowledge. As in other cases of paraneoplastic GN, treatment targeted towards the 
cancer results in resolution of the GN in most cases but our patient was not a chemotherapy 
candidate and her disease ultimately progressed to end stage renal disease.
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Necrotizing ANCA Positive Glomerulonephritis Associated in Culture 
Negative Endocarditis
Lumen A. Mendez Castaner,1 Antonio A. Armstrong,1 Aza Abdalla,2 
Lorena Cuebas-Rosado,4 David B. Thomas,3 Zain Mithani.5 Jackson Memorial 
Hospital 1Jackson Memorial Hospital, Miami, FL; 2Jackson health Miami, 
Coral Springs, FL; 3University of Miami, Miller School of Medicine, Miami, FL; 
4Miami VA Hospital, Miami, FL; 5University of Miami, Miami, FL.
Introduction: Renal involvement is a common extra cardiac manifestation of infective 
endocarditis (IE) affecting up to 50% of all patient. Kidney manifestations in IE are 
variable, including direct consequence of infection such septic emboli, immune complex 
glomerulonephritis and more interestingly ANCA associated glomerulonephritis have 
been described. Making challenging the differentiation between infectious endocarditis 
related glomerulonephritis and small vessel vasculitis. Even more a subgroup of patient 
with culture negative infectious endocarditis has been associated with glomerular disease 
and seropositive ANCA titers caused by Bartonella species, been the most common cause 
of culture negative endocarditi. Diagnosis relies on clinical suspicion and serologic titers 
diagnostic tools.
Case Description: Case of a 73 year old with no past medical history who presented with 
progressive shortness of breath for 3 weeks associated with fever and chills. Complaining of 
bloodey sputum for the past 3 days. Physical Exam showed bilateral ronchies and crackles. 
Pitting edema +2. Labs serum cr 5.90mg/dL, eGFR 9mL/min/1.73m2. WBC 7.7, Hgb 
6.5g/dl. UA RBC > 182, WBC 27, Upr > 100mg/dL. UPCR 4.4, C3 73, C4 14.8, ANCA 
PR3 positive. CT chest showing bilateral calcified granulomas. Echocardiogram showed 
1.5 x 1.4cm calcified irregular mass noted in the tricuspid valve. Received broad spectrum 
antibiotics. Blood cultures negative. Renal biopsy showed crescetic focal necrotizing 
glomerulonephritis, with moderate fibrosis. Immunofluorescence(IF) showed mensagial 
IgG(1+), IgA(1+), IgM(2+), C3(2+),C1q(2+), kappa(2+) and lambda(2+). Ultrastructurally 
showed mesangial matrix immune complex type dense deposits. Bartonella henselae titers 
IgG 1:1024. Treated antimicrobial and pulse steroid followed by tapered.
Discussion: This case highlights the unique complexity in differentiating between 
primary small vessel vasculitis vs infectious endocarditis related glomerulonephritis, where 
initial serology can be misinterpreted. Ultimately with the clinical and renal biopsy findings 
along with bartonella titers lead to the diagnosis of culture negative endocarditis related 
glomerulonephritis
SA-PO250 Poster Saturday
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Eosinophilic Granulomatosis with Polyangiitis - Renal Biopsy Can Aid in 
Guiding Therapy
Mayanka Kamboj, Gajapathiraju Chamarthi, Rupam Ruchi. University of 
florida, Gainesville, FL.
Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA), a rare systemic 
vasculitis; can cause end organ damage with eosinophilic infiltration of the extravascular 
tissue and necrotizing vasculitis. Patients with renal involvement usually develop rapidly 
progressive glomerulonephritis (GN).
Case Description: 61-year-old female with 1.5-year history of asthma, recurrent 
sinusitis with nasal polyposis presented with fever. Lab work showed leukocytosis (WBC 
23,400/mm3 with 29% eosinophils), serum creatinine (SCr) 0.7 mg/dL, microscopic 
hematuria, proteinuria and positive antineutrophil cytoplasmic antibody (ANCA) 1:320 
with myeloperoxidase specificity. Therapy with glucocorticoids was initiated. She 
developed acute kidney injury, initially atrribited to volume depletion; when SCr worsened 
to 1.9 mg/dL and improved to 1.3 mg/dL with IV fluids. Renal biopsy showed segmental 
necrotizing pauci-immune GN with crescent formation. Treatment with cyclophosphamide 
(CYC) (10mg/kg) was initiated. On 3 week follow up, SCr worsened to 2.7 mg/dL when 
CYC was escalated to 15mg/kg/dose for the next 3 doses. Her SCr improved and stabilized 
at 2 mg/dL over the next 2 months.
Discussion: Renal function as measured by SCr can be relatively preserved in 
crescentic ANCA vasculitis. Biopsy showing renal involvement affected the decision to 
initiate therapy with CYC in this patient. The rapidity of decline in renal function despite 
treatment foretells that the patient could have had a worse renal outcome with delay in 
appropriate immunosuppressive (IS) therapy. Our case emphasizes the importance of 
doing a renal biopsy in patients with systemic features of EGPA and active urine sediment 
even with normal relatively preserved SCr, not only for definitive diagnosis but also guide 
clinicians to pursue aggressive early IS therapy and improve renal prognosis.
Glomerulus showing a cellular crescent (methanamine silver staining)
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PSGN – When Kidneys Take a Hit
Muhammad Deen,2 Omomengbe Oni,1 Rahmat Na’Allah.1 1University of Illinois 
College of Medicine at Peoria, Peoria, IL; 2University of Illinois College of 
Mediicine at Peoria, Peoria, IL.
Introduction: Complication of Streptococcal pharyngitis leading to post-streptococcal 
glomerulonephritis.
Case Description: 12 year old boy presented with hematuria, oliguria, arthralgia, 
periorbital and peripheral edema in the setting of acute kidney injury. 10 days prior 
to admission, patient was diagnosed with recurrent strep throat infection which was 
treated with Amoxicillin-Clavulanic acid. Examination findings were positive for diffuse 
maculopapular rash and presence of cola colored urine. On admission, lab work was 
significant for Cr 1.10 (baseline Cr 0.50), elevated ASO titer 983, DNase B Ab 1390 and UA 
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positive for blood and protein. What was surprising, that the patient had normal complement 
(C3 and C4) levels at presentation. Appropriate fluid resuscitation was initiated, resulting 
in an improvement in urine output and renal function, but a fall in C3 and total complement 
levels was noted. Given this atypical presentation, along with possible concerns for other 
forms of vasculitis especially Henoch Schonlein Purpura, a short burst of steroid treatment 
was initiated. Patient showed significant clinical improvement with complete resolution of 
hematuria, oliguria, proteinuria, edema and rash. Follow up with PCP and nephrology in 
6 weeks revealed a normal complement level and given this scenario, a diagnosis of post-
streptococcal glomerulonephritis (PSGN) was made.
Discussion: The hallmark of GN is inflammation within the glomeruli that typically 
manifests as hematuria and proteinuria. Renal function may be reduced, depending on 
the severity of the acute condition or the presence of chronic glomerular injury. Post-
streptococcal glomerulonephritis is the leading cause of acute nephritic syndrome. Most 
cases are sporadic, although the disease has been known to occur in epidemic form. The 
overall incidence of PSGN in the United States has significantly decreased with good long 
term prognosis. More than 95% of patients recover spontaneously and return to baseline 
renal function within three to four weeks with no long term sequelae. Acute PSGN usually 
is diagnosed on clinical and serologic grounds without the need for biopsy, especially in 
children with a typical history.
SA-PO252 Poster Saturday
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A Challenging Diagnosis and a Missed Treatment Opportunity: A Case of 
Bartonella Endocarditis Complicated with Rapidly Progressive 
Glomerulonephritis
Mohamed Mortagy,1 Lauren Lamie.2 1Western Michigan University School of 
Medicine, Kalamazoo, MI; 2WMU Homer Stryker MD School of Medicine, 
Kalamazoo, MI.
Introduction: Bartonella is the most common cause of culture negative endocarditis 
in the USA which is complicated by kidney failure in 45% of patients. Diagnosing 
Bartonella endocarditis is very challenging but crucial. Treating bartonella associated 
glomerulonephritis (GN) with immunosuppressants is fatal.
Case Description: This is a 52-year-old male with a history of bioprosthetic aortic 
valve replacement (AVR) who presents to the ED with 6 days of bilateral flank pain and 
hematuria. Physical exam was largely unremarkable including no rashes. Creatinine was 
7 mg/dl. Urinalysis was remarkable for gross blood, 100 RBCs, proteinuria and RBCs 
casts. Imaging of abdomen and pelvis were unremarkable. Autoimmune workup was 
negative. Urgent hemodialysis (HD) and corticosteroids were started. Kidney biopsy was 
inconclusive due to inadequate tissue. He was discharged on outpatient HD and a steroid 
taper. One month later, repeat kidney biopsy showed crescentic segmental necrotizing 
GN and focal deposits of IgM, C19 and C3. He was readmitted for plasmapheresis and 
a steroid course and then discharged with maintenance HD. Over the next 2 months, the 
patient had multiple episodes of fever, but blood cultures were persistently negative. After 
four months from initial presentation, he presented to the ED with chest pain and fever. 
He was diagnosed with NSTEMI. Trans-esophageal echocardiogram showed a small 
mildly calcified echodensity on the bioprosthetic AVR indicating endocarditis and a small 
echolucent area in the perivalvular region suggestive of an aortic root abscess. The patient 
subsequently underwent a sternotomy and aortic valve replacement. PCR performed on the 
vegetation was positive for Bartonella, as well as Bartonella henselae serology was positive 
for IgG (1/1024) and IgM (> 1/20).
Discussion: The interval development of endocarditis on echocardiogram, positive 
Bartonella antibodies and PCR suggest the patient developed GN associated with 
Bartonella endocarditis. Bartonella is a frequent cause of culture negative endocarditis. 
Immune deposits showing C3 dominance with IgM staining are consistent with chronic 
infection related GN. This case highlights the importance of ruling out infectious 
etiologies of GN before starting immunosuppressants. As treating an active infection with 
immunosuppressive agents can be life threatening.
SA-PO253 Poster Saturday
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Bartonella Endocarditis Causing Immune Complex Mediated 
Glomerulonephritis
Hamid Mukhtar,1 Anubha Mutneja.2 1Iowa Methodist Medical Center, Des 
Moines, IA; 2Iowa Kidney Physicians, PC, Des Moines, IA.
Introduction: Bartonella is associated with subacute bacterial endocarditis. While 
vegetations are commonly seen, rarely there are cases of subacute endocarditis showing 
only valvular thickening. We describe one such case of bartonella endocarditis with immune 
complex mediated glomerulonephritis.
Case Description: A 63-year-old male with history of aortic bioprosthetic valve 
presented with fevers, chills and myalgias. On presentation, labs showed pancyctopenia- Hb 
6.6 g/dL, ANC 1500 per mm3 and platelet 39 k/mm3. Creatinine was 3.8 mg/dL, urinalysis 
showed proteinuria 2+ along with hematuria. LDH was 293 U/L, haptoglobin 25 mg/dL, 
peripheral smear did not show any schistocytes. Serological work-up showed low C3 at 
71 mg/dL, normal C4, negative ANA, positive c-ANCA (1:256) and positive PR-3 Ab. Bone 
marrow biopsy showed myeloid hyperplasia, reactive-appearing along with polyclonal 
expansion of plasma cells 10-20%. Renal biopsy showed endocapillary proliferation with 
no fibrinoid necrosis or cellular crescents. IF showed near full house immune complex 
deposition with granular, mesangial staining for IgG (2+), IgM (1+), C3 (2+), C1q (trace), 
kappa (2-3+) and lambda (1+). Infectious work-up showed positive titers for Bartonella 
Henselae, both IgG (>1:1024) and IgM (1:512), serum PCR was negative. TEE showed 
severe stenosis of the prosthetic aortic valve and patient was started on doxycycline for 
Bartonella endocarditis. Four weeks later, he was noted to have partial recovery in renal 
function but continued to be dialysis dependent given high fluid gains.
Discussion: Bartonella endocarditis can lead to immune complex mediated 
glomerulonephritis. Even with absence of characteristic vegetations, presence of positive 
antibody titers along with hypocomplementemia and immune -complex mediated GN, 
support the diagnosis of endocarditis. Bartonella PCR even though has high specificity, its 
sensitivity is only about 40-70%. Timely initiation of appropriate antibiotic therapy may 
improve renal outcome.
SA-PO254 Poster Saturday
Trainee Case Reports - V
Triple Hit – Case of IgA nephropathy with Thin Glomerular Basement 
Disease and Nutcracker Syndrome
Solomiia Savedchuk,1 Saima Mansuri.2 1Beaumont Health, Royal Oak, MI; 
2Beaumont Hospital, Royal oak, MI.
Introduction: Included in the differential of hematuria are IgA nephropathy (IgAN) 
and thin glomerular basement membrane disease (TGBM). IgAN is the most common cause 
of idiopathic glomerulonephritis with slow progression to End Stage Renal Disease in up 
to 50% of patients. IgAN has been reported to be associated with TGBM. Recurrent gross 
hematuria could also be seen in nutcracker syndrome, the incidence of which is increasing 
with the use of CT/MR-angiography. We report a patient diagnosed concomitantly with 
nutcracker syndrome, IgAN, and TGBM
Case Description: We present a case of 33-year-old Caucasian female with hematuria. 
She reported microscopic hematuria since the age of 7 and strong family history of 
microscopic hematuria. Five years prior to presentation she started developing intermittent 
gross hematuria with periods of stress and URTIs. Her past medical history is significant 
for long-standing abdominal and pelvic pain. She also reported episodes of orthostatic 
hypotension. She was diagnosed with median arcuate ligament syndrome and underwent 
MAL release in 2015 without resolution of symptoms. Physical exam was unremarkable. 
Laboratory and other work up was unremarkable except for 3+ blood with numerous 
RBC/hpf without evidence of infection on urinalysis. Urine protein:creatinine ratio ranged 
from 0.62-2.04. She had orthostatic proteinuria. Her renal function was stable. Her prior 
MRA from 2015 revealed a focal narrowing of left renal vein (LRV) between aorta and 
SMA. Given this constellation of symptoms, not completely explained by one pathology, 
possibility of nutcracker syndrome was entertained and CTA was repeated which confirmed 
the LRV narrowing. However, due to her family history of hematuria, intermittent episodes 
of gross hematuria and proteinuria, a renal biopsy was performed with findings suggestive 
of IgAN and TGBM.
Discussion: There are published case reports about the association between IgAN 
and TGBM as well as IgAN and nutcracker syndrome. However, coexistence of all three 
diseases has not been reported. There are no distinguishing clinical or laboratory features. 
The causal relationship and prognosis remains unclear. The presence of multiple glomerular 
pathology poses a unique diagnostic and management challenge. This, combined with 
anatomic vascular abnormality, further complicates management.
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A Terrible Triad: A Case of Anti-GBM, Membranous, and Waldenstrom’s
Niranjan Gunasekaran,2 Yashpal S. Kanwar,1 Eudora Eng.2 1Northwestern 
University Medical School, Chicago, IL; 2Northwestern University Feinberg 
School of Medicine, Chicago, IL.
Introduction: Anti-GBM disease is a rare disease with a very rapid and destructive 
course. Much of the knowledge gained has been through case reports and case series. Here, 
we describe a case of anti-GBM complicated by many factors and the treatment regimen 
used.
Case Description: A 52y/o man with cryoglobulinemia manifested only by 
pruritus presented with 12 days of fever, malaise, night sweats and anorexia. Admission 
creatinine was 1.7, from a baseline 3 days prior of 0.9. Creatinine rapidly worsened and 
he became oliguric by the 3rd hospital day. Renal biopsy was done on day 4. A dialysis 
catheter was placed on day 5, anti-GBM resulted at 7.6 and light and IF of renal biopsy 
showed membranous nephropathy, anti-GBM with necrotizing crescentic GN and 
severe tubulointerstitial disease. He was pulsed with steroids, started on plasmapheresis, 
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dialysis, and IV cyclophosphamide. Because of the membranous nephropathy, history of 
paraproteinemia, increased IgM lambda and lymphadenopathy, bone marrow biopsy was 
done, showing Waldenstrom’s macroglobulinemia. However, due to prior reports that 
Waldenstrom’s is linked to a number of autoimmune diseases including cases of RPGN, 
he was switched to rituximab, with increasing urine volume up to 2L/day, and decreasing 
pre-dialysis BUN and creatinine. However, after 6 of 8 cycles of ritumab, anti-GBM 
titer rebounded to 144. He was re-pulsed with steroids, restarted on cyclophosphamide 
and underwent daily plasmapheresis for 3 weeks until the GBM titer was zero. Despite 
preserved urine volume, he remains on hemodialysis.
Discussion: Although there are reports of simultaneous membranous and anti-GBM, 
or Waldenstrom’s and membranous, we could find only one case report of anti-GBM 
disese and Waldenstrom’s, and none with all three. Rituximab, an accepted treatment for 
Waldenstrom’s and membranous nephropathy has been used in a few patients with anti-
GBM, mostly those who failed cyclophosphamide. Despite an initial response to therapy, 
he relapsed after completion of plasmapheresis, while still receiving rituximab. We suspect 
membranous nephropathy secondary to Waldenstrom’s. PLA2R was negative but obtained 
after plasmapheresis/dialysis. We speculate uncovering of the Goodpasture’s epitope, 
secondary to another underlying process.
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A Case of Concurrent IgA Nephropathy and Microscopic Polyangiitis
Kristine Soltanpour,1 Tiffany N. Caza,2 Apurv Khanna.1 1Nephrology, Upstate 
University Hospital, Syracuse, NY; 2SUNY Upstate Medical University, Clay, NY.
Introduction: IgA nephropathy is the most common cause of glomerulonephritis 
worldwide. It is rarely seen to concur with anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis. This is a case of a elderly female patient with an overlap of microscopic 
polyangiitis and IgA nephropathy responsible for acute kidney injury which responded to 
immunotherapy.
Case Description: An 82 year old lady with a history of hypertension and diabetes 
mellitus presented to the hospital for evaluation of AKI detected on routine blood work. 
Her creatinine was 5.3 mg/dL from a baseline of 1.2 mg/dL and she had hematuria for 
over 1 year. She has a past medical history of multiple autoimmune diseases, including 
thyroid disease, vitiligo, keratoconjunctivitis sicca, arthritis, and myopathy, and remote 
pancreatic adenocarcinoma status-post Whipple procedure. Review of systems was 
positive for fatigue, chills, arthralgias, myalgias, back pain, and dysuria. Physical exam 
was unremarkable. UA was significant for glycosuria (50 mg/dL), hemoglobinuria (3+), 
hematuria (34 RBC/hpf), and proteinuria (3.0 grams). Serology shown a positive ANA, 
positive ANCA with anti-MPO specificity, and hypocomplementemia (C3 48 mg/dL, C4 9 
mg/dL). A renal biopsy revealed crescentic glomerulonephritis, glomerular IgA-dominant 
immune complex deposition, and peritubular capillaritis in the setting of advanced arterio-
nephrosclerosis. A severe, active glomerulonephritis with fibrous and fibrocellular crescents 
was present, concurrent with low grade immune complex deposition, which was IgA-
dominant and was restricted to the mesangium. This suggested that the ANCA-associated 
process was predominant, with concurrent IgA nephropathy. The patient was treated with 
Cytoxan and pulse steroid therapy. The patient had an acute drop in hemoglobin to 6.5 
mg/dL with respiratory distress with increased oxygen requirements, and was found to 
have an alveolar hemorrhage. The patient was given oxygen, red cell transfusions, and 
plasmapheresis. There were no additional complications and the patient had improved 
respiratory and renal function at follow up.
Discussion: Although IgA nephropathy and ANCA-associated vasculitis do not 
frequently overlap clinically, recognition of concurrence is critical, as these cases are 
associated with aggressive disease with rapidly progressive glomerulonephritis, yet have 
good outcomes with immunosuppressive therapy.
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Concomitant Atypical Hemolytic Uremic Syndrome and Lupus Nephritis 
in a Pregnant Woman
Mohan krishna Bangaru,1,3 Sulaiman J. Barkho,1,2 Noreen F. Rossi,4 
Yeohan Song.5,2 1Nephrology, Wayne State University School of Medicine, 
Detroit, MI; 2Detroit Medical Center, St Clair Shores, MI; 3Detroit Medical 
Center, Detroit, MI; 4Wayne State University School of Medicine, Detroit, MI; 
5Wayne State University/Detroit Medical Center, Detroit, MI.
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare but devastating 
condition. It involves uncontrolled activation of alternative complement pathway either due 
to genetic mutation or autoantibodies leading to dysfunction of regulatory proteins. Various 
triggering factors have been associated with aHUS including infections, pregnancy, drugs, 
and systemic lupus erythematosus (SLE). In pregnancy with known SLE, diagnosing aHUS 
can be delayed as the presentation may mimic a flare of lupus nephritis.
Case Description: A 20-year female diagnosed with lupus nephritis (Class 
III) diagnosed at the age of 13 was on maintenance therapy with prednisone and
mycophenolate mofetil with preserved renal function for 6 years, creatinine 0.6 mg/ml. 
She stopped taking immunosuppressive medications on her own initiative. Two months
later she became pregnant. At 10 weeks gestation, creatinine had increased to 3.3 mg/dl 
accompanied by severe anemia, thrombocytopenia, high anti-ds DNA titers, and severe
hypocomplementemia. Her pregnancy was terminated, and she was placed on hemodialysis 
and was discharged after being treated as a lupus nephritis flare with prednisone and 
cyclophosphamide. She was readmitted 2 weeks later with shortness of breath worsening
anemia and thrombocytopenia with numerous schistocytes. ADAMTS13 activity level
was 100% prompting initiation of plasmapheresis, but without improvement. aHUS panel 
showed low complement factor H levels with normal complement factors I and B. Renal
biopsy showed class V lupus nephritis and thrombotic microangiopathy with focal interstitial 
fibrosis consistent with aHUS. She was initiated on eculizumab as well as prednisone and 
mycophenolate mofetil and continues on hemodialysis and this pharmacologic regimen.
Discussion: Diagnosis of aHUS can be difficult and is often delayed in patients as the 
clinical presentation may mimic lupus nephritis particularly in pregnancy or may be present 
together with lupus nephritis. Assessment of the alternative complement pathway, early 
diagnosis and treatment with eculizumab is important in these setting.
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Vancomycin Associated AKI: Think of Thrombotic Microangiopathy
Anshul Bhalla, Matthias Wacker, Nitender Goyal. Tufts Medical Center, 
BOSTON, MA.
Introduction: Vancomycin-induced renal toxicity is common and thought to be 
due to interstitial nephritis or direct tubular toxicity. Vancomycin can also induce an 
immunological response, leading to production of drug-dependent anti-platelet antibodies 
and cause immune-mediated thrombocytopenia. A similar antibody mediated process can 
be associated with drug-induced thrombotic microangiopathy (TMA) and AKI.
Case Description: A 51 year old woman, who recently completed a 2 week course 
of Levofloxacin for pneumonia, was diagnosed with a lung abscess and empyema and 
initiated on Vancomycin, Cefepime and Metronidazole along with a chest tube placement. 
She remained hemodynamically stable with kidney function at baseline. On hospital day 5, 
she developed oliguric AKI with supratherapeutic vancomycin levels. She was also noted 
to be thrombocytopenic. Hemolysis labs were abnormal with LDH 730 and haptoglobin 
<10. Peripheral smear showed 10-12 schistocytes/hpf. Liver function tests, disseminated 
intravascular coagulation workup, complement levels, auto-immune and vasculitis 
serologies were within normal limits. ADAMTS13 activity was markedly low (<5%) 
and ADAMTS13 inhibitor presence was confirmed with Bethesda assay. Vancomycin-
dependent anti-platelet antibody (tested at Blood Center of Wisconsin) was positive. 
Diagnosis of acquired TTP was made and managed with discontinuation of vancomycin and 
initiation of plasma exchange for a total of 4 exchanges and prednisone with improvement 
in platelet count, hemolysis parameters and kidney function. (Table 1).
Discussion: We report a case of acquired TTP with ADAMTS13 inhibitor and 
vancomycin-dependent antiplatelet antibody. A previous study reported one patient 
with suspected vancomycin-induced TMA with presence of anti-platelet antibodies but 
ADAMTS13 activity was not tested. In our case, timing of TMA and AKI after 5 days of 
vancomycin exposure along with presence of the antibody point towards a vancomycin 
associated immune mediated process. It is difficult to ascertain if the antiplatelet antibody 
was detected as the ADAMTS13 inhibitor or if both antibodies co-existed. TMA should be 
identified as a cause of vancomycin associated AKI.
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Eculizumab in the Setting of Gemcitabine Induced Thrombotic 
Microangiopathy
Adam Klein, Renuka Chowdhury. Methodist Health Systems of Dallas, 
Dallas, TX.
Introduction: Thrombotic Microangiopathy (TMA) is a rarely encountered side effect 
in gemcitabine use. Previous studies have suggested that eculizumab might be an effective 
treatment in gemcitabine induced TMA. We present a case of gemcitabine induced TMA in 
a patient who did not improve with supportive care and withdrawal of the offending agent, 
who was successfully treated with eculizumab.
Case Description: A 68-year-old female with history of hypertension and metastatic 
breast cancer, previously treated with carboplatin and gemcitabine presented with anemia 
and fever. The patient was noted to have hemoglobin 4.6g/dL, reticulocyte percentage 
4.79, elevated total bilirubin 2.5 mg/dL, evidence of hemolysis (haptoglobin < 20 mg/dL, 
elevated LDH 2810.0 U/L, and schistocytes on the peripheral smear), and thrombocytopenia 
(platelet count 83 x 103/uL). The patient had initiated treatment with gemcitabine two days 
before presenting to the Emergency Department. The patient’s creatinine on admission was 
2.7 mg/dL, previously 0.80 mg/dL. Despite discontinuation of gemcitabine and institution of 
supportive care, the patient’s creatinine continued to rise throughout her hospitalization and 
she became anuric requiring dialysis. Needle core kidney biopsy demonstrated thrombotic 
microangiopathy. The patient underwent treatment with eculizumab and had recovery of her 
kidney function with improvement in her creatinine and urine output.
Discussion: Treatment with eculizumab in gemcitabine induced TMA has shown good 
results in previous case studies as well as an observational, retrospective, multicentric study 
previously performed in four French centers. In this report, the use of eculizumab supports 
the benefit of C5 inhibition for the treatment of gemcitabine induced TMA refractory to 
supportive care.
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Successful Treatment of Refractory Gemcitabine-Associated Thrombotic 
Microangiopathy with Eculizumab
Daniil Shimonov,1 Naomi Friedman,3 Minesh Khatri.2 1Internal Medicine, NYU-
Winthrop Hospital, Mineola, NY; 2Nephrology, NYU-Winthrop Hospital, 
Mineola, NY; 3Stony Brook School of Medicine, Bronx, NY.
Introduction: Gemcitabine can lead to thrombotic microangiopathy (TMA) which 
is characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia and 
AKI. We report a novel treatment approach for a man with pancreatic carcinoma with 
refractory gemcitabine associated TMA successfully treated with eculizumab, a monoclonal 
antibody against C5 complement.
Case Description: A 69-year-old man with a history of pancreatic adenocarcinoma 
treated with gemcitabine and normal baseline renal function (Cr 1.0mg/dl) presented with 
thrombocytopenia (platelets 31 K/uL), MAHA (schistocytes and LDH 582 IU/L), and 
AKI (Cr 2.1mg/dl) concerning for Gemcitabine-associated Thrombotic Microangiopathy 
(GA-TMA), subsequently diagnosed by renal biopsy. Initially, chemotherapy was held and 
patient was started on high dose glucocorticoids and 20 PLEX treatments, with rituximab 
added the next month due to ongoing TMA. There was mild improvement in renal function, 
but hemolysis and thrombocytopenia persisted, prompting implementation of eculizumab 
a month later. Patient’s hematologic parameters improved and kidney function stabilized. 
In the meantime, chemotherapy was delayed for 5 months, his cancer progressed, and he 
passed away 7 months after presentation.
Discussion: This case report demonstrated that eculizumab could successfully treat 
refractory GA-TMA. GA-TMA is a rare condition that carries mortality rates from 50-70%. 
Discontinuing gemcitabine, initiating steroids, PLEX, dialysis, and rituximab have been 
standard therapy. Eculizumab has been shown in a few case reports to normalize some or 
all the parameters of the disorder, indicating that dysregulation of the complement pathway 
may play a significant role. Our patient did not respond well to steroids, PLEX and rituximab 
prompting a novel approach with eculizumab, with subsequent significant improvement 
in the hemolytic parameters and stabilization of renal function. Further research should 
focus on randomized controlled trials comparing eculizumab with standard therapy for 
GA-TMA, and potentially as first line therapy to possibly allow for earlier initiation of 
non-Gemcitabine chemotherapeutic agents. We need an improved understanding of the 
mechanisms by which certain chemotherapeutic agents induce TMA, and be able to better 
identify patients that would be most likely to benefit from eculizumab.
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Ideal Clinical Outcome and Potential Cost Savings with Individualized 
Eculizumab Dosing using Bayesian Modeling in Atypical Hemolytic 
Uremic Syndrome
Stefanie W. Benoit,1 Keri A. Drake,2 Tsuyoshi Fukuda,3 Bradley P. Dixon.4 
1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 2UT 
Southwestern Medical Center, Dallas, TX; 3Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH; 4Children’s Hospital of Colorado, Aurora, CO.
Introduction: Ecullizumab (Ecu) acquisition cost is approximately $7,000 per 300mg 
vial. There is limited literature regarding individualized Ecu dosing in atypical hemolytic 
uremic syndrome (aHUS), particularly in pediatric patients and as disease activity varies.
Case Description: A previously healthy 4 year old male presented with acute onset 
muscle weakness, elevated creatine kinase, and elevated liver enzymes. He subsequently 
developed anemia, thrombocytopenia, hypertension, and anuric acute kidney injury 
requiring dialysis. A muscle biopsy revealed microthrombi in skeletal muscle vessels, and 
a renal biopsy confirmed thrombotic microangiopathy. He showed clinical improvement 
with Ecu, although he required an increase in dose amount and frequency to maintain 
clinical stability and Ecu level >100mcg/mL. With increased dosing, he achieved remission 
with eventually normalized kidney function. Dosing was adjusted based on Ecu levels 
to maintenance on standard Ecu dosing. Pharmacokinetic (PK) analysis using Bayesian 
fitting with population PK parameters (Fig.1) now indicates a sufficient Ecu level could be 
maintained with every 3 week dosing. The cost of the Ecu doses required to suppress his 
early, severe disease was $84,000. Standard dosing costs $14,000 every 2 weeks; $364,000 
per year. Spacing to every 3 weeks would cost $242,200, a savings of $121,800 per year.
Discussion: This report describes an unusual presentation of aHUS with severe 
multisystem involvement and highlights the potential for improved clinical outcomes and 
cost savings by individualizing Ecu dosing in aHUS patients.
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Therapeutic Plasma Exchange in Carfilzomib Associated Thrombotic 
Microangiopathy
Jonida Krate, Ibrahim Qaqish. Internal Medicine, St. Joseph’s Hospital and 
Medical Center Phoenix, Arizona, Phoenix, AZ.
Introduction: Thrombotic microangiopathy (TMA) was reported to be associated with 
second generation proteasome inhibitors. The role of therapeutic plasma exchange(TPE) in 
management of carfilzomib induced TMA is not clear. Here we present our experience on 
TPE use in management of carfilzomib induced TMA.
Case Description: 61 year old man with past medical history of congestive heart 
failure, type 2 diabetes mellitus, hypertension, chronic kidney disease, diagnosed with 
kappa light chain multiple myeloma in February 2016. He was started on Cybor-D 
chemotherapy in March 2016. His chemotherapy was interrupted several times due to acute 
kidney injury (AKI). Subsequently, he progressed and he was transitioned to carfilzomib, 
revlimid, and dexamethasone combination of chemotherapy in May 2017. Two months 
after initiation of carfilzomib therapy patient developed markedly elevated BUN and serum 
creatinine. Patient underwent kidney biopsy, which revealed abundant glomerulosclerosis 
(8/10 globally sclerotic) and ~ 70% of interstitial fibrosis and tubular atrophy. Some non-
sclerotic glomeruli showed global capillary thrombosis and necrosis. Patient underwent 
eight sessions of TPE. Lactate dehydrogenase improved after termination of carfilzomib 
and continued to improve after TPE. Haptoglobin improved after TPE. Platelet count did 
improve despite termination of chemotherapy and TPE. Unfortunately, because of severity 
of AKI patient never regained kidney function and required chronic hemodialysis.
Discussion: We presented case of TMA after initiation of carfilzomib for the treatment 
of multiple myeloma. Patient did not have ADAMTS 31 deficiency. TPE was held to 
assess for platelet response, which remained stable then increased and therefore TPE was 
not resumed. In our patient platelete transfusion given prior to renal biopsy confounded 
interpretation of total TPE. Given the pattern of minimal hematological and clinical 
response in our patient to TPE compared to the response in patients with idiopathic TTP, we 
speculate the optimum role of TPE is minimal or not established in Carfilzomib associated 
TMA. Discontinuation of the drug remains an important management strategy and the role 
of TPE is still not categorized by ASFA. Clinicians should be aware of rare association 
between carfilzomib underlying TMA. Discontinuation of the drug, future drug avoidance 
and supportive care is the corner stone of management.
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Reversible Dialysis Dependent AKI Due to Carfilzomib Induced 
Thrombotic Microangiopathy (TMA)
Abhishek J. Patel,2 Aravind Dasari,2 Hieu Q. Vo,2 Barry M. Wall.1,2 University of 
Tennessee Health Science Center, Memphis, TN, United States 1Veterans Affairs 
Medical Center, Memphis, TN; 2Nephrology, University of Tennessee Health 
Science Center, Memphis, TN.
Introduction: Renal complications of carfilzomib, a second-generation proteasome 
inhibitor used in treatment of relapsed or refractory multiple myeloma, are typically mild 
and reversible. However, severe acute kidney injury (AKI) related to TMA and tumor lysis 
have also been reported. We report an additional patient with kidney biopsy confirmed TMA 
leading to dialysis dependent AKI that fully resolved after discontinuing caflizomib without 
the use of immunosuppressive medications or plasmapheresis.
Case Description: 56 year old male with stage 1 IgG kappa light chain restricted 
multiple myeloma with 50-60% of bone marrow replacement with CD138+ plasma cells 
with t(11;14) translocation received intial treatment with bortezomib, lenalidomide and 
dexamethasone with minimal response. He was then treated with one cycle of carfilzomib 
(20 mg/m2 on 2 consecutive days), lenalidomide, and dexamethasone. He subsequently 
presented two weeks later with non-oliguric AKI with a serum creatinine of 10.3 mg/dL 
(pre-treatment creatinine, 0.9 mg/dl). He was euvolemic by clinical examination and no 
kidney abnormalities were noted on kidney ultrasound. Additional laboratory included: 
uric acid 11.7mg/dL, serum calcium 7.5mg/dL, phosphorus 4.8mg/dL and potassium 
3.6mg/dL. Hemoglobin had decreased from 13.8 to 9.8 g/dl, platelet count decreased 
from 384 to 72 K/ul, and schistocytes were noted on the peripheral blood smear. AKI 
worsened despite discontinuing carfilzomib and the administration of intravenous fluids 
and rasburicase. Temporary hemodialysis support was required for one week. Renal biopsy 
revealed thrombotic microangiopathy, acute tubular injury, moderate arteriosclerosis and 
arteriolar hyalinosis. AKI rapidly resolved with follow up serum creatinine of 1.1 mg/dL. 
Similarly, hemoglobin and plateltet count gradually returned to pre- treatment values. 
He is currently being evaluated for autologous stem cell transplantation and has not been 
rechallenged with carfilzomib..
Discussion: Our patient had renal biopsy proven TMA following a single cycle of 
carfilzomib treatment that resulted in dialysis dependent non-oliguric AKI with associated 
microangiopathic anemia and thrombocytopenia. AKI was reversible after discontinuing 
carflizomab without concomitant use of plasmapheresis or immunosuppressive medications, 
consistent with direct drug induced toxicity.
SA-PO264 Poster Saturday
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A Rare Case of Methamphetamine Induced Thrombotic Microangiopathy 
and End Stage Renal Failure
Kothai divya Guruswamy sangameswaran, Krishna M. Baradhi. OU Tulsa OU 
-Tulsa School of Community Medicine, Tulsa, OK.
Introduction: Recreational drug abuse is not only a major public health problem
with significant morbidity and mortality, but also one of the frequently neglected risk 
factors for End Stage Renal Disease (ESRD). Amongst these inconsiderate risk factors,
methamphetamine induced Thrombotic Microangiopathy (TMA) and ESRD is indeed a
rare entity. We report a rare case of ESRD from methamphetamine induced TMA and stress 
the importance of recognizing methamphetamine as a cause of ESRD.
Case Description: A 26 year-old-man with history of drug abuse presented with
fatigue, dyspnea and epistaxis for two weeks. Exam revealed a pale young man with
tachycardia, pedal edema and a BP of 210/124 mm of Hg. Labs showed hemoglobin of
5gm/dl with mild thrombocytopenia and renal failure with BUN of 171mg/dl and creatinine 
of 20mg/dl. Peripheral smear revealed schistocytes, consistent with microangiopathic
hemolysis, yet did not favor hemolytic uremic syndrome-thrombotic thrombocytopenic
purpura due to minimally elevated LDH, normal haptoglobin, bilirubin and ADAMTS13
activity. Serological work up for vasculitis was unrevealing and a renal biopsy was done
which showed thrombotic microangiopathic injury and advanced glomerulosclerosis. He
was declared ESRD based on biopsy and remained dialysis-dependent. TMA induced
ESRD is doubtlessly from methamphetamine abuse, as the patient admitted to using crystal 
methamphetamine on a weekly basis for many years with several episodes of hypertensive 
surges as evident by severe left ventricular hypertrophy on echocardiogram.
Discussion: Methamphetamine is a psycho-stimulant, sympathomimetic drug, well
known to cause systemic hypertension and cardiomyopathy. A recent study from South
Africa showed malignant hypertension in 44.7% and chronic kidney disease in 95.7%
of methamphetamine users. Our case report illustrates the need for detailed drug history
and considering methamphetamine as a potential cause of TMA and ESRD, as early
identification and cessation of drug abuse could prevent irreversible renal damage.
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A Curious Case of Methamphetamine Induced Renal Pseudo-Vasculitis
Gajapathiraju Chamarthi, Justin Lee Loy, Abhilash Koratala. University of
Flroida, Gainesville, FL.
Introduction: Methamphetamine is a synthetic-drug that is widely abused by young 
adults and can have deleterious effects on many organ systems including the kidney. 
Hyponatremia and AKI from non-traumatic rhabdomyolysis are the most common 
manifestations pertinent to renal system. Herein, we present a case of methamphetamine 
ingestion mimicking systemic vasculitis in a patient with multiorgan failure.
Case Description: A 38-year-old man who was otherwise healthy except for chronic 
back pain presented to the local hospital with weakness and epigastric pain. Examination 
revealed several skin pustules on his legs, which he attributed to insect bites. His urine 
toxicology screen was positive for amphetamines and serum creatinine (Scr) was 1.4mg/dL. 
He soon developed sepsis with respiratory failure requiring mechanical ventilation and AKI 
requiring dialysis and transferred to our facility for further management. On exam, petechial 
and purpuric lesions were noted on legs and laboratory data including serum CPK, liver 
enzymes, IgG4 were within normal limits. Viral Hepatitis and HIV testing, vasculitic work 
up including ANA, ANCA, cryoglobulin was negative. Skin biopsy was not suggestive of 
vasculitis but could not yield specific etiology. Renal biopsy was consistent with ATN but 
also showed medium vessel vasculitis (Figure) which can be associated with illicit drug 
use such as cocaine and methamphetamine. Patient had renal recovery and was dialysis 
independent at discharge.
Discussion: Amphetamine derivatives are widely abused drugs for their euphoric, 
stimulant and hallucinogen properties. Hyponatremia and AKI are frequent complications 
of their use. AKI typically results from rhabdomyolysis. Other rare manifestations such 
as isolated proximal tubular dysfunction, obstructive nephropathy from bladder neck 
dysfunction and seronegative necrotizing vasculitis as in our patient have been reported and 
Nephrologists have to be familiar with these for appropriate management.
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Resistant Hypertension in Dialysis Patients: Pitfalls of Biochemical Testing
Gajapathiraju Chamarthi,1 Justin Lee Loy,2 A. A. Ejaz,2 Rajesh Mohandas.2 
1University of Flroida, Gainesville, FL; 2University of Florida Gainesville, 
Gainesville, FL.
Introduction: Hypertension is common in patents with End Stage Renal Disease 
(ESRD). Fluid retention and excess sympathetic activity are thought to be responsible for 
high blood pressures in majority of these patients. Rarely, pheochromocytomas have been 
reported in patients with ESRD. Non-specific elevation of catecholamine levels in renal 
failure, inability to check urinary catecholamine levels and interference from medications 
can make diagnosis challenging. We present a patient with ESRD with severely elevated 
catecholamine levels.
Case Description: 68-year-old female with ESRD on hemodialysis presented with a 
BP of 260/80 mm Hg and pulmonary edema. She was started on a Nicardipine infusion 
and underwent dialysis with aggressive ultrafiltration. She was restarted on her usual 
antihypertensive medications (Amlodipine 10 mg daily, Clonidine 0.3mg TID, Hydralazine 
100mg TID, Labetalol 300mg TID, Losartan 100 mg daily and Prazosin 2mg bid). A work 
up for secondary causes of hypertension revealed markedly elevated norepinephrine levels 
of 7332 pg/ml (ref range 80- 520) and plasma normetanephrine at 3.26 nmol/L (ref range 
0-0.89). Epinephrine and metanephrine levels were within normal limits. Patient underwent 
an extensive imaging for occult pheochromocytoma including CT scan of abdomen and
pelvis, 123 MIBG scan, Octreotide scan and whole body PET scan, all of which failed to
reveal any evidence of a catecholamine secreting tumor.
Discussion: Catecholamine levels are often elevated in patients with ESRD and normal 
levels in chronic kidney disease or ESRD have not been established. Our patient had levels of 
norepinephrine that were 14 fold higher than upper limit of the reference range. She was on 
Mirtazapine, Prazosin and Labetalol, all of which can specifically increase norepinephrine 
levels. Normal metanephrine levels, absence of tumors on imaging, improvement in blood 
pressures with ultrafiltration and a downward trend in norepinephrine levels suggested the 
elevated norepinephrine levels were due to a combination of medications and ESRD. We 
conclude that one should be cautious in interpreting biochemical tests for pheochromocytoma 
in patients with kidney disease, particularly those on dialysis. Elevations in metanephrines 
might be more specific for pheochromocytoma. More studies are necessary to establish cut 
offs for catecholamine levels in dialysis patients.
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Holy “Molly!” An Intriguing Case of AKI
Gajapathiraju Chamarthi, Justin Lee Loy, Abhilash Koratala. University of 
Flroida, Gainesville, FL.
Introduction: Molly is the slang for ‘molecular’, which refers to the powder or crystal 
form of the synthetic psychoactive drug MDMA (3,4-methylenedioxymethamphetamine). 
Molly is often mixed with other drugs and substances such as bath salts (e.g. 4-methyl-
apyrrolidinohexanophenone) and is not safe. While urine toxicology can detect 
amphetamines, current drug screens do not typically detect bath salts and other contaminants. 
MDMA can lead to severe hyperthermia, hyponatremia, liver, kidney and cardiovascular 
failure. Herein, we present a case of severe AKI in a Molly abuser.
Case Description: A 41-year-old man with a history of polysubstance abuse 
including alcohol, cocaine and molly presented to our institution with abdominal pain 
and vomiting. He has been taking molly prior to presentation and urine drug screen was 
positive for amphetamine. Labs showed AKI with a serum creatinine of 9 mg/dL (baseline 
0.9), hyperkalemia (K 7 mmol/L) and hyperphosphatemia (P 18 mg/dL). Serum sodium 
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was relatively normal (134 mmol/L). Serum creatine kinase (CPK) was elevated at 
6814 U/L (Ref: 5-180). UA showed large blood on dipstick with 5 RBC/hpf consistent 
with myoglobinuria. Imaging excluded obstructive nephropathy and he was treated with 
intravenous hydration and supportive care. His renal function improved gradually over next 
several days.
Discussion: AKI associated with MDMA is primarily attributable to rhabdomyolysis, 
which could result from direct myocyte toxicity or seizures from symptomatic hyponatremia. 
Excessive physical exertion in the setting of inadequate water intake and impaired 
thermoregulation often complicates the picture. Direct tubulotoxicity, necrotizing vasculitis 
and malignant hypertension are other mechanisms of AKI. Rarely, it can cause bladder neck 
dysfunction leading to obstructive nephropathy. In addition, bath salts that contaminate 
molly can cause ATN and rhabdomyolysis. In addition to tubular toxicity, our patient could 
have had more severe rhabdomyolysis prior to presentation leading to pigment-induced 
AKI though the presentation CPK was not very high. It is also not certain whether his 
kidney injury is a result of MDMA alone or related to bath salts/other contaminants as well. 
Clinicians need to consider all these possibilities while evaluating patients with AKI and 
suspected drug abuse. History may not be always clear, especially in obtunded patients.
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Spontaneous Renal Artery Dissection: A Diagnostic and Therapeutic 
Challenge
Gajapathiraju Chamarthi, Abhilash Koratala, Justin Lee Loy, Rupam Ruchi. 
University of Florida Gainesville, Gainesville, FL.
Introduction: Spontaneous renal artery dissection (SRD) is a rare and under-recognized 
entity and is distinct from traumatic or iatrogenic causes of renal artery dissection. Herein, 
we present a case of SRD that mimicked a urinary tract infection (UTI).
Case Description: A 44-year-old woman presented to our institution for worsening 
right flank pain associated with fever and chills. 5 days prior to presentation, she was 
empirically treated at a local facility for UTI with an oral antibiotic, which failed to relieve 
her symptoms. Laboratory data was significant for neutrophil-predominant leukocytosis 
and elevated lactate dehydrogenase. Because of the persistent flank pain, a CTA of the 
abdomen was obtained which showed right renal infarct and irregularity of the lumen of the 
renal artery, concerning for focal dissection. Vasculitis work up was negative. Angiogram 
demonstrated proximal dissection with distal aneurysmal dilatation affecting the superior 
segmental branch of the right renal artery. Several branches arising from the abnormal 
vessel appeared to perfuse viable renal parenchyma, mostly within the superior pole and 
embolization was not performed due to the risk of infarcting such a large volume of tissue, 
possibly leading to abscess formation. The patient was treated conservatively with medical 
management for pain and hypertension and was discharged in a stable condition.
Discussion: SRD is most commonly encountered in middle aged men and has been 
associated with malignant hypertension, fibromuscular dysplasia, collagen vascular diseases, 
cocaine use and extracorporeal shock wave lithotripsy in the literature. The symptoms can 
be nonspecific and often mimic other conditions such as pyelonephritis and nephrolithiasis. 
Conservative management includes hypertension and pain control with or without systemic 
anticoagulation. Endovascular interventions and surgical revascularization are reserved 
for patients with hemodynamically significant occlusions of the arteries, uncontrolled 
renovascular hypertension and worsening renal function or progression of dissection.
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Methimazole-Induced Severe Anti-Neutrophil Cytoplasmic Antibody 
Associated Vasculitis with Rapidly Progressing Glomerulonephritis
Neelofar R. Khan,4 Rimda Wanchoo,4 Vanesa Bijol,1 Kenar D. Jhaveri,2 
Nupur N. Uppal.3 1Northwell Health Hofstra University, Lake Success, NY; 
2Northwell Health Sys, Great Neck, NY; 3Hofstra Northwell School of Medicine, 
Great Neck, NY; 4Zucker School of Medicine at Hofstra Northwell, GREAT 
NECK, NY.
Introduction: Vasculitis associated with anti-neutrophil cytoplasmic antibodies 
(ANCA) is a rare complication of treatment with antithyroid medications. It has been 
mainly described in patients treated with Propylthiouracil(PTU), and rarely with use of 
Methimazole(MMI). While most reported cases of MMI induced ANCA associated 
vasculitis(AAV) were diagnosed on skin or lung pathology, we report a unique case of 
severe, systemic, kidney biopsy proven drug induced AAV with MMI.
Case Description: A 64-year-old Guyanese woman with primary hyperthyroidism 
presented with abdominal pain and diarrhea. On admission, herserum creatinine(Scr) was 
2.8mg/dl (baseline 1.2mg/dl). She denied use of NSAIDs, PPIs or herbal medications 
however reported to have completed course of clarithromycin for a respiratory infection 2 
weeks ago. Her only home medication at the time of presentation was methimazole. During 
the course of her hospitalization, she developed gross hematuria with worsening AKI. UA 
showed 173 RBCs, 13 WBCs and spot urine protein to creatinine ratio of 1.2. Serological 
work up was positive for Anti-Nuclear Antibody (ANA 1;640), p(perinuclar)-ANCA 
(1:320) and Myeloperoxidase antibody (MPO 109.4). C(cytoplasmic)-ANCA, proteinase 
3(PR3) and double stranded DNA antibodies were negative. She was initiated on pulse 
dose corticosteroids and underwent kidney biopsy which showed 25 glomeruli, of which 
2 were globally sclerosed, 4 had cellular crescents with all arteries revealing extensive 
necrosis and signs of small vessel vasculitis with minimal chronic changes and no tubular 
changes; Pathology findings were consistent with pauci immune vasculitis/ AAV, thought to 
be drug induced. Methimazole was held. Few days later, she developed hemoptysis and was 
initiated on plasmapheresis for concern of pulmonary alveolar hemorrhage. She eventually 
became oliguric requiring hemodialysis. Worsening of her vasculitis lead to her demise 
despite aggressive medical management.
Discussion: The reported incidence of MPO ANCA Vasculitis for PTU is 39.2 
times higher compared to that with MMI. Although uncommon, MMI can lead to AAV. 
Nephrologists, rheumatologists and endocrinologists should all be aware of this rare, life 
threatening complication of MMI.
SA-PO270 Poster Saturday
Trainee Case Reports - VI
A Case of Golimumab-Associated Pauci-Immune Glomerulonephritis
Sandhira Wijayaratne,2 Nikhil Agrawal,1 Philip S. Kemp,1 Joseph Kupferman.1 
1Beth Israel Deaconess Medical Center, Brookline, MA; 2Harvard Medical 
School, Boston, MA.
Introduction: Golimumab is a monoclonal TNF-alpha inhibitor approved for 
rheumatoid arthritis (RA), ulcerative colitis (UC), psoriatic arthritis, and ankylosing 
spondylitis. It may be preferred in some patients due to easier dosing (monthly subQ 
injections) and ability to control symptoms in UC. Clinical trials studying golimumab have 
not reported glomerulonephritis as an adverse event, though there is at least one report of 
golimumab accelerating preexisting lupus nephritis. To our knowledge, there have been no 
reports of golimumab-associated, new-onset glomerulonephritis. Here, we present a patient 
with RA on golimumab who developed a pauci-immune crescentic glomerulonephritis with 
no signs of systemic vascultitis.
Case Description: 87-year-old male with hypertension and rheumatoid arthritis 
referred by his rheumatologist with a creatinine of 2.6 mg/dL. He had a baseline creatinine 
of 1.29 mg/dL and 0.9 mg/dL, four months and nine months prior to his presentation, 
respectively. His RA was previously managed by steroids but was switched four years ago 
to monthly golimumab, last dose was 2 months ago. Urinalysis showed 3+ protein, negative 
leukocytes, 80-100 RBC/hpf, and 5-7 acanthocytes/hpf. Labs including C3, C4, ANA, 
ANCA, dsDNA, anti-histone antibody, cryoglobulin, Hepatitis B and C serologies, SPEP, 
UPEP were ordered; all eventually came back negative. Renal biopsy showed 18 of the 36 
glomeruli had extracapillary proliferation, 14 of which had evidence of fibrinoid necrosis 
or cellular crescents. Findings were consistent with a diagnosis of pauci-immune crescentic 
glomerulonephritis. Over the course of the patient’s 5-day hospital stay, his creatinine 
was stable with a range of 2.5-2.8 mg/dL. He was discharged on 60 mg prednisone daily, 
golimumab was not restarted.
Discussion: This case represents the first report of crescentic pauci-immune 
glomerulonephritis associated with golimumab. With increasing use of TNF-alpha 
inhibitors, there lies a risk of increased episodes of glomerulonephritis associated with these 
medications. As with this patient, renal limited vasculitis may not appear until years into 
treatment, and could present with aggressive features. Patients should be monitored for 
glomerulonephritis and screening protocols with serial urinalysis and serum creatinine may 
be necessary. Long term data may help define relative risk with individual medications.
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PR3 Positive Crescentic Glomerulonephritis in Pembrolizumab Treated 
Metastatic Melanoma
Maria Joana A. Thomas,1 Andrew I. Chin.2 1University of California Davis Medical 
Center, Sacramento, CA; 2University of California Davis, Sacramento, CA.
Introduction: Immune checkpoint blockade has demonstrated to be effective for 
treating various cancers including melanomas. Pembrolizumab, a monoclonal antibody that 
targets the programmed cell death (PD-1) receptor of lymphocytes, enhances immunologic 
destruction of cancer cells. The PD-1 pathway plays an important role in immunologic 
homeostasis, enabling the body to defend against pathogens while protecting against self-
reactivity. Use of these medications may lead to dysregulation of T cell activation, causing 
a pathologic immune response, including inciting autoimmunity.
Case Description: A 73 year old woman with metastatic melanoma with normal renal 
function was treated with 4 doses of Pembrolizumab. Creatinine rose to 1.7 mg/dL. Biopsy 
revealed acute and chronic interstitial nephritis. After the drug was held, Prednisone 60 mg 
daily was started. Creatinine remained at 1.6 - 1.9 mg/dL. Twelve months later, she 
developed arthralgias and targetoid lesions on her fingers. A skin punch biopsy showed 
vasculitis. Creatinine was 5.2 mg/dL. UPC was 2.9 g/g. Complements were normal. 
Cryoglobulin, MPO, HIV, hepatitis panel and renal ultrasound were negative. She tested 
positive for PR3-ANCA at 1675 U/mL (normal 0-19 U/mL). Biopsy revealed pauci-
immune crescentic glomerulonephritis (GN). She received 6 sessions of plasmapheresis, 
weekly Rituximab with Methylprednisolone, and later switched to Prednisone 60 mg daily. 
Creatinine improved with a decrease in PR3 titers. Rituximab maintenance infusions were 
terminated due to progression of melanoma.
Discussion: There are a few cases of Minimal Change Disease and IgA Nephropathy 
reported with PD-1 inhibitor, and a case of Granulomatous Polyangiitis after a single dose 
of Pembrolizumab. Immune-related adverse events have been cited to start within a few 
weeks to months after treatment, but can occur anytime after treatment discontinuation, 
with skin events usually the first to appear. Our patient presented with skin findings and 
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had severe renal injury from PR3-positive GN. T-cell activation has been implicated in 
the development of crescentic GN. We postulate that Pembrolizumab set the scene for 
a dysregulation of T cell function, with development of a pathogenic autoantibody such 
as PR3-ANCA, as well as possibly unmasking an underlying autoimmunity. This report 
highlights an important potential renal effect from this drug.
SA-PO272 Poster Saturday
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Immune Checkpoint Inhibitor (ICI) Induced Necrotizing Granulomatous 
Arteritis, Interstitial Nephritis, and Dermatitis
Sneha Mohan,1 Gunjan Garg,2 Evan A. Farkash,2 Rachel Perlman.2 1All India 
Institute of Medical Sciences (AIIMS), New Delhi, India; 2University of 
Michigan, Ann Arbor, MI.
Introduction: With emergence of ICIs as potent agents against melanoma, there has 
been a rapid surge in use of drugs like ipilimumab, targeted against cytotoxic T lymphocyte 
associated antigen 4(CTLA-4), and nivolumab, targeted against programmed death 1(PD-1) 
protein. Immune related adverse events (IRAE), including skin lesions and AKI, have 
been reported with use of ICIs. Nivolumab has been associated with sarcoidal pattern of 
granulomatous dermatitis while both drugs have been associated with acute interstitial 
nephritis (AIN). We present a case of skin and renal complications following concomitant 
nivolumab and ipilimumab therapy.
Case Description: A 67 yo man diagnosed with melanoma 9mos ago, on 3rd cycle of 
ipilimumab and nivolumab presented with fever, skin rash and AKI. Serum creatinine (Cr) 
was 2.65 mg/dL (baseline 0.8 mg/dL). Skin biopsy (Bx) showed granulomatous dermatitis 
compatible with granuloma annulare. Renal Bx showed necrotizing granulomatous 
arteritis with interstitial fibrosis and tubular atrophy (Fig). ANA and ANCA were negative. 
Mycobacterial and fungal causes were excluded. Given the suspicion of ICIs related 
cutaneous and renal side effects, both drugs were stopped and 80mg daily oral prednisone 
was initiated for 1mo followed by slow taper. Rash improved rapidly and Cr returned to 
baseline.
Discussion: These findings describe another pathological manifestation of ICIs. 
We suspect that synergistic effects of anti-CTLA-4 and anti-PD1 therapy triggered the 
granulomatous arteritis. With increasing use of ICIs for melanoma and other cancers, it is 
important to be vigilant of their side effects. Steroid therapy, initiated early, appears to have 
utility in reversing IRAEs.
Renal Bx showing obliteration of an intralobular artery by granulomatous inflammation with 
multinucleated giant cells, accompanied by interstitial hemorrhage and AIN. H&E, 200x
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Lupus Nephritis Due to Anti-TNF Alpha Therapy
Kamal Nayyar,1 Dominick Santoriello,2 James Drakakis,1 Naveed N. Masani.1 
1NYU Winthrop Hospital, Mineola, NY; 2Columbia University Medical Center, 
New York, NY.
Introduction: Drug induced lupus erythematosus is a lupus-like syndrome temporally 
related to continuous drug exposure which resolves upon drug discontinuation. Findings 
include skin manifestations, arthritis, serositis, and ANA/anti-DS DNA seropositivity. It 
can be divided into systemic, subacute cutaneous, and chronic cutaneous forms. Drugs most 
frequently associated are hydralazine, procainamide, and quinidine. In rare cases, anti-TNF 
alpha therapies have also been implicated. It is estimated that up to 10% of SLE cases are 
drug-induced. Such autoimmunity is idiosyncratic and unpredictable.
Case Description: An 80 year old male with a past medical history significant for DM 
II, hypertension, resolved hepatitis B infection, seropositive Rheumatoid Arthritis (RA), 
and CKD stage III with a baseline creatinine of 1.5 mg/dl was started on Etanercept (anti-
TNF alpha therapy) due to severe erosive RA. After 6 months of treatment he presented 
with joint pains and swelling of the extremities, was noted to have acute renal failure 
with a creatinine of 2.0 mg/dl, proteinuria of 1.2 gm, new onset microscopic hematuria, 
hypocomplementemia, and anti -DsDNA/ANA seropositivity. Renal biopsy revealed diffuse 
endocapillary glomerulonephritis with immunofluorescence staining for IgG, IgA, C3, c1q, 
kappa and lambda; electron microscopy was devoid of tubuloreticular inclusion bodies. 
Given the lack of extra-renal SLE findings and the timing of etanercept, the biopsy findings 
were attributed to TNF-alpha inhibitor therapy, which was subsequently discontinued. 
The patient was treated with corticosteroids, with stabilization of renal parameters and 
resolution of anti-DsDNA and ANA positivity. Of note, the patient exhibited no other SLE 
type symptoms prior to or since TNF-alpha inhibitor therapy. Therapy for RA was switched 
to Rituximab.
Discussion: Anti-TNF alpha induced lupus represents a major therapeutic challenge. 
Most cases are caused by infliximab, followed by etanercept and adalimumab. Symptoms 
range from mild cutaneous lesions, to more systemic involvement including pericardial 
effusions, deep venous thrombosis, pneumonitis, and lupus nephritis. Most of the reported 
clinical features of anti-TNF-alpha -induced SLE present as cutaneous lesions, which 
are similar to those present in idiopathic SLE. This case exhibits the silent menace of the 
exceedingly rare anti-TNF-alpha induced lupus nephritis.
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An Unusual Case of Hydronephrosis Caused by Iliac Artery Aneurysm
Kamal Nayyar, James Drakakis, Louis J. Imbriano. NYU Winthrop Hospital, 
Mineola, NY.
Introduction: Isolated internal iliac artery aneurysm is a rare but serious condition 
of which nephrologist should be aware. The natural history is one of continued expansion 
and rupture with high mortality rate. These can result in hydronephrosis and hydroureter 
with displacement of the ureter by a mass lesion. With proper treatment survival can be 
improved. Here we discuss a case of patient with acute renal failure in the setting of a pelvic 
kidney and symptomatic iliac artery aneurysm.
Case Description: A 66 year old male with a history of hypertension, hyperlipidemia, 
and smoking was admitted with angina. Serum creatinine was 1.7 mg/dl, and urinalysis 
showed trace proteinuria with no blood. Cardiac catheterization revealed 2 vessel disease. 
Within 12 hours of admission the patient developed vomiting, diarrhea, hypotension and new 
onset paresis of the left upper extremity. Creatinine rose in a saw-tooth pattern to 4.0 mg/dl 
over 5 days. MRI of the brain without contrast revealed a small right posterior frontal 
cortical infarct as well as multiple lacunes in the right basal ganglia, and 60% stenosis 
of the origin of the right internal carotid with an ulcerated plaque. During the angiogram, 
films of the aorta revealed mild right renal artery stenosis and an ectopic left pelvic kidney 
with hydronephrosis due to a 3.3 cm left common iliac artery aneurysm impinging on the 
ureter. Surgery was performed to repair the common iliac artery aneurysm and relieve the 
obstructed ureter of the pelvic kidney. Hydronephrosis of the left pelvic kidney was partially 
relieved, and subsequent renal scans showed no significant hydronephrosis.
Discussion: This patient demonstrates an obstructed pelvic kidney by an asymptomatic 
common iliac artery aneurysm. Isolated iliac artery aneurysms are exceedingly rare, account 
for <7% of all intra-abdominal aneurysms and are found in only 0.03% of the population 
in autopsy studies. They are most often due to atherosclerotic vascular disease occurring in 
males in the 7th or 8th decade. Symptoms vary and are related to pressure by the aneurysm 
on the ureter, the internal iliac vein, the lumbosacral nerve trunk, the external iliac vein, 
obturator nerve, and the colon. The risk of hydronephrosis may be increased in the pelvic 
kidney due to malrotation of the kidney and an anteriorly placed renal pelvis. This case 
exhibits the silent menace of an iliac artery aneurysm.
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Drug Induced Lupus Nephritis in Psoriasis Secondary to Adalimumab 
Use
Gurleen Kaur,1 James L. Bailey.2 1Emory, Decatur, GA; 2Emory University 
School of Medicine, Atlanta, GA.
Introduction: Adalimumab, an anti-Tumor necrotic factor α agent (anti-TNF α), is 
approved by the FDA for treatment of moderate to severe chronic plaque psoriasis. The drug 
is generally well-tolerated, however auto immunity with the development of systemic lupus 
erythematosus (SLE) is a rarely reported. We describe a case of Adalimumab being used for 
chronic plaque psoriasis in which the patient developed lupus nephritis.
Case Description: A 32 year-old-lady with refractory chronic plaque psoriasis had 
been on Adalimumab for 3 months and presented with a 3-day history of bilateral lower 
extremity swelling. On evaluation, she was found to have a malar rash and alopecia, 
hemoglobin 6.7g/dL, creatinine 0.6 mg/dL, albumin 1.5g/dL, UA 3+ protein and 50 
RBCs. A spot urinary protein: creatinine ratio was 4.8g/g with microalbumin of >1g. 
Further work up for proteinuria revealed a positive ANA, SSA, Anti Ro, Anti La, RNP, 
Anti Smith (519 AU/mL), ds DNA (1257 IU/mL), anti-histone (>999 AU/mL) while 
other serological work up was negative. A renal biopsy was performed on day 3: focal 
proliferative glomerulonephritis with 1 focally sclerosed glomerulus and full house 
staining on immunofluorescence consistent with class III lupus nephritis was found. The 
adalimumab was stopped and she was started on Prednisone and Hydroxychloroquine. On 
follow up, she was started on cyclophosphamide. Subsequently, her proteinuria and other 
symptoms improved.
Discussion: “Anti-TNF α-induced lupus (ATIL)” is characterized by high prevalence of 
anti-dsDNA antibodies (>90%) and low prevalence of ant histone (57%) with respect to the 
classic form of SLE. The presence of SLE meeting the American college of rheumatology 
guidelines and concomitant exposure to lupus-inducing drug are widely accepted criteria 
for ATIL. There have been no cases reported in the literature of adalimumab induced 
lupus nephritis. In our case, the lupus nephritis improved after discontinuation of the drug, 
supporting the diagnosis of ATIL. Symptoms resolve within 3 weeks to 6 months after 
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stopping the drug. Additional immunosuppressant medications may be required to achieve 
full remission.
SA-PO276 Poster Saturday
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Glomerular Injury Related to Immune Related Adverse Events: IgA 
Nephropathy After Nivolumab Therapy for Postoperative Recurrence of 
Lung Cancer
Maho Iwaki, Seiji Kishi, Masanori Minato, Masanori Tamaki, Fumi Kishi, 
Taichi Murakami, Hideharu Abe, Kojiro Nagai. Department of Nephrology, 
Tokushima University, Tokushima, Japan.
Introduction: Immune checkpoint inhibitors (ICIs; anti-PD-1 or anti-CTLA-4) are 
becoming a common and an important therapeutic option for cancer patients. ICIs are 
associated with a unique category of side effects calld immune-related adverse events (irAE) 
and physicians should be aware of its clinical importance. According to previous reports, 
renal irAEs are less frequent than other organ involvement and glomerulonephritis is not 
typical. In this report, we present a case of nivolumab associated mesangial proliferative 
glomerulonephritis (IgA nephropathy), previously not reported.
Case Description: A 72-year-old man with postoperative recurrence of lung squamous 
cell carcinoma treated with nivolumab (anti-PD-1 antibody) who developed proteinuria and 
worsening kidney function was referred to our department. Ten months previously, he had 
been started on intravenous nivolumab therapy because of the postoperative recurrence of 
lung squamous cell carcinoma (cT3N2M0 stage IIIA). Six months after the first nivolumab 
treatment, the patient’s creatinine began to increase and proteinuria was noted. Kidney 
biopsy showed mesangial proliferative glomerulonephritis with C3 and IgA deposition. 
Electron-microscopy demonstrated a small amount of high electron-dense deposits in the 
subepithelial and mesangial regions. After drug withdrawal, the proteinuria improved and 
the deterioration of the renal function was halted.
Discussion: To our knowledge, this is the very rare case of biopsy-proven immune 
complex glomerulonephritis following treatment with ICI. Although it may be difficult to 
prove a causal relationship of ICI and IgA nephropathy, we suspect nivolumab played a role 
in the pathogenetis of IgA nephropathy. The patient did not have disease-precipitating events 
such as upper respiratoty infection prior to the disease onset and we observed the decrease 
in proteinuria and improvement in serum creatinine after drug withdrawal. The previous 
study showed PD-1 knockout mice develop immune complex glomerulonephritis. These 
findings suggested that PD-1 signaling pathway is important to minimize T-cell-mediated 
renal inflammation. Glomerular lesions have been exacerbated from subacute to chronic 
course in our case, which suggests the possibility of another type of disease progression.
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IgM Nephropathy, M-Spike, and Chronic EBV Infection with  
Certolizumab Use
Arun Rajasekaran,1 Mario A. Mendoza.2 1University of Central Florida College 
of Medicine, Kissimmee, FL; 2Orlando VA Medical Center, Orlando, FL.
Introduction: IgM Nephropathy is a rare cause of nephrotic syndrome seen in children 
and young adults. We describe IgM nephropathy causing nephrotic syndrome in an elderly 
male with normal serum IgM levels and having Rheumatoid Arthritis (RA); who also had 
tubuloreticular inclusions in his kidney likely caused by chronic EBV infection.
Case Description: A 60 year old male with known RA and ulcerative colitis, on 
Certolizumab and prednisone therapy, presented with nephrotic range proteinuria. Erosive 
hand joints and pedal edema were seen. He has known high-titer Rheumatoid factor 
positive RA with negative anti-CCP antibodies. Labs revealed a normal electrolyte panel, 
total protein, albumin and renal function. UA showed 3(+) protein. 24-hour-urine specimen 
revealed 3360 mg of protein. ANA titers were 1:160 (homogenous pattern). Anti-dsDNA, 
anti-MPO and Proteinase-3 antibodies; and ANCA panel were negative. Complements were 
low (C3 – 67, C4 – 14). Hepatitis B, C, HIV and CMV serologies were negative. EBV IgM 
titers were negative, but EBV IgG (728 U/ml) titers were markedly elevated. Serum IgM was 
normal (178 mg/dl), with a mild increase in IgA (657 mg/dl) and IgG (1858 mg/dl) levels. 
No monoclonal proteins were seen on UPEP. SPEP revealed an IgG Kappa monoclonal 
band. Renal biopsy was performed and LM showed mild mesangial hypercellularity, mild 
to moderate interstitial fibrosis with tubular atrophy. IF showed mesangial regions staining 
for IgM (3+), IgG (1+), IgA (1+), C3 (1+), and trace kappa and lambda light chains. EM 
demonstrated patchy podocyte foot processes effacement, several electron dense deposits 
in an expanded mesangial matrix. Few subepithelial and subendothelial deposits were 
noted, and many tubuloreticular inclusions were seen. Oncology opined that the IgG 
Kappa monoclonal band in the SPEP was likely secondary to Certolizumab use, and his 
Certolizumab was held and a repeat SPEP is pending. Oral diuretics and Lisinopril were 
started given his edema and proteinuria.
Discussion: Renal IgM deposits can be seen in RA. RA patients’ have impaired control 
of EBV infection and have high antibody titers against EBV antigens. Our patient had IgM 
nephropathy with a normal serum IgM level, and our case highlights the need to test for 
EBV in the setting of RA and IgM nephropathy.
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Membranoproliferative Glomerulonephritis (MPGN) Associated with 
Nivolumab Therapy
Jessica Cruz Whitley, Priyanka Wani, Brian Y. Young. University of California 
Davis Medical Center, Sacramento, CA.
Introduction: Nivolumab is a chemotherapeutic checkpoint inhibitor targeting PD-1 
receptors on T cells. Nivolumab has classically been associated with acute interstitial 
nephritis (AIN). We present a case of Nivolumab associated nephrotic syndrome due to 
MPGN.
Case Description: 75-year-old female with a history of non-Hodgkin’s lymphoma 
s/p allogenic bone marrow transplant 10 years prior was diagnosed with metastatic anal 
cancer. She was unresponsive to surgery and chemoradiation, and thus Nivolumab was 
initiated. Two months into Nivolumab therapy, her creatinine rose from 1.07 to 1.63mg/dl. 
Nivolumab was held and she was started on prednisone for presumed AIN. Atypically, 
she had edema and new onset proteinuria with 12.5 g/g on spot UPCR. Urinalysis was 
otherwise negative. Workup showed C3 and C4 were low at 76 and 10. Paraproteins, 
ANA, ASO, HBsAg, HCV ab, ANCA, and cryoglobulin were negative. After four weeks 
of prednisone, her proteinuria persisted. Kidney biopsy showed subendothelial deposits 
of C3 and IgM consistent with MPGN and mild interstitial inflammation. No features of 
TMA were found. Findings were felt due to persistent Nivolumab injury. Nivolumab was 
held for 3 months while prednisone continued. Her creatinine and proteinuria improved but 
unfortunately her cancer progressed, and she chose to pass away on hospice. Spot UPCR 
at that time was 1.1 g/g.
Discussion: This case demonstrates an atypical association of Nivolumab with MPGN. 
Nephrotic syndrome has been rarely reported with checkpoint inhibitors, though prior cases 
were minimal change disease and membranous nephropathy. We believe this to be the first 
case of checkpoint inhibitor associated MPGN, suggesting these agents can lead to a broad 
spectrum of immune-related kidney disorders
PAS / EM with MPGN and subendothelial deposits of C3 and IgM
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Secondary (AA) Amyloidosis Associated with Checkpoint Inhibition
Anne D. Sebastian,1 William L. Whittier,2 David J. Cimbaluk.2 1Rush University 
Medical Center, Chicago, IL; 2Rush University Medical Center, Chicago, IL.
Introduction: Nivolumab (Nb) is an immune checkpoint inhibitor (CPI) which targets 
solid tumors but can cause nephrotoxicity by accelerating systemic inflammation. We report 
a case of a patient who achieved partial remission of squamous cell lung cancer (SCLC) 
with Nb but later developed nephrotic syndrome from secondary (AA) amyloidosis.
Case Description: A 75 y.o. white man presented with anasarca. He was diagnosed 
with metastatic SCLC 2 years ago and received 4 cycles of Nb. His last dose was 10 months 
ago. It was stopped due to failure to thrive as he had acheived partial remission. Exam 
notable for diffuse anasarca. Alb 1.1 g/dL, Cr 0.76 mg/dL. ANA (-). C3 77, C4 25 mg/dL, 
RF 67 IU, CRP 86.8 mg/L, ESR >140 mm/hr. SIEP and UIEP (-) for monoclonal protein. 
A year ago, Alb 2.6 g/dL, UA trace protein. Renal biopsy demonstrated apple green 
birefringent deposits in the glomeruli and arterioles on Congo red (Figure 1). Amyloid A 
immunostain was (+). IF was (+) for full house mesangial staining of IgG (3+), IgA (3+), 
IgM (2+), C3 (3+), C1q (3+) and C4 (1+) and equal for κ & λ stain (3+). EM with randomly 
arranged fibrils 8-12 nm in the GBM & mesangium. He was started on prednisone, bactrim, 
and colchicine and his U P/C improved to 5.1 g/g in 3 months. His inflammatory markers 
improved and his SCLC remained in partial remission.
Discussion: We present a patient with secondary (AA) amyloidosis with diffusely 
positive mesangial IF 10 months after receiving Nb. Although progressive cancers can 
be associated with AA amyloidosis, his SCLC was in partial remission, making it an 
unlikely etiology. In addition, his elevated ESR, CRP, RF, and full house IF are signs of 
active inflammation. CPIs exert their antineoplastic action by accelerating inflammation, 
causing interstitial nephritis. In contrast, our case illustrates the possibility that the immune 
checkpoint inhibitor created an uncontrolled inflammatory response leading to secondary 
(AA) amyloidosis.
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Dasatinib-Associated FSGS: A Case Report
Valentina Loi,1 Nicola Lepori,1 Matteo Floris,1 Anna Maria Asunis,2 
Andrea Angioi,1 Riccardo Cao,1 Alice Atzeni,1 Doloretta Piras,1 
Gianfranca Cabiddu,1 Antonello Pani.1 1Nephrology, Ospedale Brotzu, Cagliari, 
Italy; 2Anatomic Pathology, Ospedale Brotzu, Cagliari, Italy.
Introduction: Renal adverse effects associated with the use of TKI include arterial 
hypertension, proteinuria, acute kidney injury (AKI), and thrombotic microangiopathy 
(TMA); however there are only a few reports of TKI-associated nephrotic syndrome
Case Description: A 69 y/o woman was diagnosed in June 2016 with Philadelphia 
chromosome-positive chronic myeloid leukaemia for which she was initially treated 
with hydroxyurea 1.5 g/day for 2 weeks and then with Dasatinib100 mg/day achieving 
complete remission. Her past medical history included arterial hypertension, type 2 diabetes 
mellitus and dyslipidaemia. Her previous kidney function was normal and she had no 
proteinuria. After 8 months on Dasatinib, the patient developed a progressive and rapid 
worsening of her kidney function (sCr from 0.76 to 2.2mg/dL) associated with the onset 
of a nephrotic syndrome with proteinuria up to 6g/24h, hypoalbuminemia (serum albumin 
2.4g/dL), lower extremity pitting oedema and mild pleural and pericardial effusion. Blood 
cell count showed a mild anaemia; ANA, ANCA, HBV and HCV markers, complement 
were normal. In consideration of this clinical picture, the drug dose was reduced to 100mg 
every other day. Over the next few months her kidney function remained stable with sCr 
of 1.7mg/dL, proteinuria of 3.5g/24h, serum albumin of 2.9g/dL, total cholesterol level 
of 297mg/dL. In October 2017 the patient underwent a kidney biopsy. Light microscopy 
showed glomeruli with segmental collapse of the tuft with concomitant pseudo-crescents. 
A mild mesangial expansion with a limited cellular proliferation was diffusely observed. 
Of interest, endothelial cells showed swollen cytoplasm with evident nuclei, suggestive 
of a diffuse endothelial injury. Tubuli, interstitium and vessels were unremarkable. IF 
was unremarkable. The patient was started on prednisone (0,5 mg/Kg/die) and Dasatinib 
was discontinued. After 6 months of treatment, proteinuria improved to 2,2g/24 hours, 
albuminemia raised to 3.5 g/dl and sCr improved to 1.5 mg/dl
Discussion: The improvement in proteinuria and albuminemia after cessation of 
Dasatinib and steroid treatment strongly imply this association between the nephritic 
syndrome and the treatment. This is, to our knowledge, the first case of focal segmental 
glomerulosclerosis secondary to Dasatinib treatment in an adult patient
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A Case of Lenalidomide-Induced Tubulointerstitial Nephritis
Alex Dinh,1 Matthew Palmer,2 Jonathan J. Hogan.3 1Internal Medicine, 
University of Pennsylvania, Philadelphia, PA; 2Pathology, University of 
Pennsylvania, Philadelphia, PA; 3Nephrology, University of Pennsylvania, 
Philadelphia, PA.
Introduction: Lenalidomide is a thalidomide-derivate immunomodulatory drug that 
has shown efficacy in multiple myeloma and relapsed Hodgkin Lymphoma (HL). Renal 
insufficiency with lenalinomide is commonly-observed but poorly characterized. We 
describe a patient with relapsed HL who developed AKI and lower extremity rash while 
taking lenalidomide, with kidney biopsy showing tubulointerstitial nephritis.
Case Description: A 24-year-old male had refractory HL previously treated 
with autologous stem cell transplant four years prior to presentation, and nivolumab, 
pembrolizumab, and chimeric antigen receptor T cell therapy two years prior to presentation. 
During this time his SCr increased from 0.5-0.8 mg/dL to 1.1-1.6 mg/dL. Lenalidomide 
was started and over four months his SCr elevated to 2.3 mg/dL. Urinalysis was negative 
for protein, blood and leukocyte esterase, and microscopy showed no red blood cells or 
white blood cells. Peripheral blood eosinophils were elevated with a peak of 14%. Imaging 
revealed no evidence of obstruction. Lenalidomide was discontinued without improvement 
of his SCr. During the same month of discontinuing lenalidomide, he developed a rash 
on his lower extremity, and skin biopsy showed psoriasiform epidermal hyperplasia and 
chronic inflammation. A kidney biopsy showed patchy tubulointerstitial inflammation 
accompanied by tubulitis with mild chronicity, and approximately 10% interstitial fibrosis 
consistent with a diagnosis of tubulointerstitial nephritis. Mononuclear infiltrative cells 
were negative for lymphoma. He received three days of intravenous methylprednisolone 
125 mg and oral prednisone with a subsequent steroid taper. His SCr returned to his prior 
baseline of 1.1 to 1.6 mg/dL at one month follow-up and his lower extremity rash resolved. 
Peripheral blood eosinophils returned to normal.
Discussion: Renal insufficiency associated with lenalidomide is commonly reported 
in plasma cell dyscrasias, but very few patients undergo kidney biopsies to establish 
the mechanism of kidney injury. The patient’s treatment exposures prior to receiving 
lenalidomide included multiple T cell modulating therapies. Three case reports to date 
have been published describing lenalidominde-associated interstitial nephritis in patients 
with multiple myeloma. This is the first case to describe lenalidomide-induced interstitial 
nephritis in a patient undergoing treatment for HL.
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Varenicline Associated Acute Interstitial Nephritis
Hamza Salam, Areeba Jawed. Wayne State University, Detroit, MI.
Introduction: Varenicline is a nicotinic receptor partial agonist with proven benefits 
in smoking cessation. It is not known to cause renal toxicity. 2 case reports describe acute 
insterstitial nephritis (AIN) due to varenciline with pre-existing renal impairment. We 
describe a case with normal renal function who presented with acute renal failure soon after 
starting varenicline.
Case Description: 59-year-old male with history of HIV, hepatitis C, hyperthyroidism, 
hypertension and diabetes mellitus. Patient presented with worsening lower extremity 
edema. He was on HAART therapy with darunavir, etravirine and raltegravir. Other 
medications included amlodipine, lisinopril, metformin, glipizide, terazosin and 
varenicline. Varenicline was started 1 month prior to presentation and was the only new 
medication. Patient had normal kidney function at baseline serum creatinine (sCr) 1.1 as per 
labs drawn 2 months prior. Physical exam showed a middle-aged man with normal vitals, 
bilateral pitting edema up to the ankles, mild abdominal distension. Initial labs showed sCr 
6.5, BUN 60, albumin 3, normal CBC, LFTs, lipase and CPK. On Urinalysis, blood 2+, 
protein 300, WBC 20-50, WBC esterase 1+,. Spot urine protein to creatinine ratio was 6.5. 
Ultrasound showed subtle hypoechoic bilateral renal pyramids with increased echogenicity 
in the renal parenchyma possibly related to underlying renal disease or inflammation. 
Patient was started on intermittent hemodialysis due to declining urine output and uremia. 
A renal biopsy was performed during admission that confirmed acute interstitial nephritis. 
Varenciline was held, patient was started on steroids. Renal function began improving and 
dialysis was stopped. sCr returned to baseline at clinic follow up.
Discussion: This is only the third case describing Varenciline associated AIN. A careful 
medication history with biopsy was essential in diagnosing cause for kidney injury in this 
patient with multiple comorbidities.
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Novel Oral Anticoagulant and AKI: Apixaban Induced Acute Interstitial 
Nephritis
Christina Dimaria,1 Wael A. Hanna,2 Damon J. Mcenroe,4 James P. Reichart.3 
1Einstein Medical Center, Cherry Hill, NJ; 2Lehigh Valley Hospital, Breinigsville, 
PA; 3Valley Kidney Specialists, Macungie, PA; 4Lehigh Valley Health Network, 
Allentown, PA.
Introduction: Novel Oral AntiCoagulants (NOACs) are changing the landscape 
of clinical practice for patients requiring short and long term anticoagulation. This case 
presentation of Apixaban-induced acute interstitial nephritis (AIN) shows a side effect of an 
increasingly common medication.
Case Description: A 70 year-old male with PMH of HTN, CHF, Atrial Fibrillation 
presented with a 2-month history of fatigue and intermittent hematuria. Home medications 
were Apixaban, Amlodipine, Epleronone, Cholecaliferol, Dofetilide, Metoprolol, and 
Rosuvastatin. He denied NSAID or PPI use. Physical exam showed normal vitals 
with trace edema and no rash. Laboratory studies showed S Cr of 2.6 mg/dL (baseline 
0.90 mg/dL). Renal US showed no hydronephrosis or stones. Urinalysis showed 11-20 
WBC, 100 RBC/hpf with urine protein:creatinine ratio of 0.57 g/g. ANA, ANCA, C3, C4 
and SPEP were negative. While holding Apixaban for a renal biopsy, S Cr trended down 
to 2.2 mg/dL. Renal biopsy showed acute tubulointerstitial nephritis with eosinophilic 
component. The immunofluorescence microscopy displayed weak mesangial granular 
staining with IgA and glomerular tuft staining with C3 suggestive of IgA nephropathy. He 
received Prednisone 60 mg daily for two weeks with a taper. Apixaban was restarted and the 
patient’s S Cr increased to 3.8 mg/dL. Apixaban was discontinued and Warfarin was started. 
S Cr improved slowly to 1.3 mg/dL and his hematuria improved to microscopic hematuria 
over a 4-month period.
Discussion: Oral anticoagulant can cause AKI by inducing glomerular hematuria 
or rarely AIN. Our patient had IgA nephropathy which can explain his persistent 
microhematuria while on the anticoagulants. The biopsy results and the patient’s clinical 
improvement substantiate the diagnosis. Given the increasing use of Apixaban, it is worth 
recognizing that it can cause AIN at any time. To the best of our knowledge, there are only 
two reported biopsy proven cases of Apixaban induced AIN.
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A Case of Rivaroxaban Associated Nephropathy
Adrian Krukowski,1 Sai prasad Gadapa,2 Alexander J. Gallan,3 Anthony Chang,4 
Patrick Cunningham.2 1Weiss Hospital, Chicago, IL; 2University of Chicago, 
Chicago, IL; 3The University of Chicago, Chicago, IL; 4UChicago Medicine, 
Chicago, IL.
Introduction: The adverse effects of oral anticoagulants (ACs) are commonly 
related to bleeding, however, a less common complication described with warfarin is the 
development of AC nephropathy. Novel ACs are quickly replacing warfarin, as they do not 
require monitoring of INR. Because they have not been used as long, the scope of their 
adverse effects are still coming to light.
Case Description: A 55-year-old Caucasian man was referred to the Nephrology clinic 
for worsening renal function. His PMHx includes a nerve sheath sarcoma in his right arm 
treated with surgery, radiation, and ifosfamide 15 years prior, stable CKD-II, and a large 
unprovoked pulmonary embolism 3 years prior. There was no history of hypertension or 
diabetes. He was placed on rivaroxaban with the intention of lifelong anticoagulation. 
He had otherwise been active and well. He denied hematuria, cloudy/frothy urine, 
nephrolithiasis, dysuria, edema, or dyspnea. Medications were rivaroxaban 20 mg daily, 
famotidine, and tramadol PRN. Social and family history was unremarkable. Physical exam 
revealed clear breath sounds and absent lower extremity edema. On presentation, creatinine 
(Cr) was 1.6 mg/dL and GFR was 45 mL/min. Other lab testing was unremarkable. His 
previous baseline serum Cr was stable at 1.2-1.4 mg/dL until two months before referral. 
UA revealed 1+ blood, 1+ protein, 3-5 RBCs/HPF, and no casts. Spot protein/Cr ratio 
revealed a value of 0.18, compared to a single measurement of 1.2 a year prior. Renal 
US was normal. Renal biopsy revealed eosinophilic granular intratubular casts with 
occasional RBCs, and mild acute tubular injury. Glomeruli showed congestion with RBCs 
and focal duplication of the glomerular basement membrane. Electron microscopy revealed 
multilayering of the peritubular capillary basement membranes but no other abnormalities. 
No immune complex-mediated disease was identified. Two months after biopsy serum 
creatinine is unchanged.
Discussion: There have been few published reports of nephropathy associated with 
novel ACs. As these drugs become more popular, it is possible that the incidence of 
associated nephropathy will increase. Extrapolating his decline in GFR suggests the patient 
could need renal replacement therapy in the next 10 years. Therefore, it is important to raise 
awareness that novel oral ACs such as rivaroxaban may be a cause of worsening kidney 
function.
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Aminocaproic Acid Induced Anuria
Salah-ud-din Amjad,1 Jason M. Kidd.2 1Virginia Commonwealth University, 
Richmond, VA; 2VCU Medical Center, Richmond, VA.
Introduction: 59 year old woman with leukemia and severe thrombocytopenia 
developed acute kidney injury following treatment with Aminocaproic acid.
Case Description: A 59 year old female with leukemia and severe thrombocytopenia 
developed the acute onset of bilateral lower back pain. Prior to this, she had been 
receiving Aminocaproic acid (Amicar) for epistaxis and easy bruising related to her 
thrombocytopenia (platelets < 2000 repeatedly). Subsequently, she became anuric and 
serum creatinine increased from 0.55 mg/dl to 1.98 mg/dl. Potassium was 6 mEq/L. A 
renal sonogram showed bilateral hydronephrosis. A foley catheter was placed with minimal 
output. Contrast tomography was performed with IV contrast and showed no masses or 
hematoma. Urology was consulted and was initially hesitant to perform invasive testing 
due to her thrombocytopenia and immune suppressed state. She was started on dialysis for 
management of hyperkalemia. She ultimately underwent cystourethroscopy and was found 
to have clots bilaterally obstructing the ureteral openings in the bladder without any other 
filling defects. In the following 2-3 days, urine output began to increase with improved 
clearance and intermittent dialysis was stopped. Patient had full renal recovery.
Discussion: We believe this case has important clinical relevance due to the use of 
aminocaproic acid leading to obstruction and need for short term dialysis. Recognizing the 
clinical presentation of Amicar related renal failure can help direct the care and provide 
resolution such as in our case. It is known that in patients with upper urinary tract bleeding, 
the use of Amicar has resulted in intrarenal obstruction in the form of glomerular capillary 
thrombosis or clots within the renal pelvis and ureters. Keeping this in mind, benefits should 
outweigh the risks if Amicar is to be used. A question to be asked is the adverse effect of 
renal failure dose related or is it merely due to exposure of the drug. An important point to 
remember is that Amicar is renally excreted which would change dosing in a patient with 
pre-existing renal dysfunction or would need dynamic dose regulation in someone who 
suffers new kidney injury while on the drug. Contrast Induced injury was less likely in 
our patient due to acute kidney injury occurring earlier than expected in CIN. Also, renal 
recovery occurring after obstruction was corrected is more of a reason that renal injury was 
due to Amicar related obstructive uropathy.
Trainee Case Reports - VI
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
810
J Am Soc Nephrol 29: 2018 Poster/Saturday
SA-PO286 Poster Saturday
Trainee Case Reports - VI
Osmotic Nephrosis: SGLT2 Inhibitor (SGLT2-i) Leaves a Footprint 
Behind
Amit Kaushal,1 Gautam M. Phadke,1,4 Richard J. Johnson,2 Aleksandra Kukla,3 
Mariam P. Alexander,3 Weimin Hao,1,4 Miguel A. Lanaspa,2 Adit S. Mahale.1,4 
1University of North Dakota School of Medicine, Fargo, ND; 2University of 
Colorado Denver, Aurora, CO; 3Mayo Clinic, Rochester, MN; 4Sanford Heath, 
Fargo, ND.
Introduction: SGLT2-i causing acute kidney injury has been reported. Our case, 
defines the pathogenesis of severe AKI due to SGLT2-i. This class of medications cause 
functional reduction in GFR by activating tubuloglomerular feedback from enhanced distal 
sodium delivery. Osmotic nephropathy due to use of Canagliflozin has not been reported.
Case Description: A sixty eight year old diabetic, hypertensive Caucasian male, 
recovering from left septic knee due to group B streptococcus infection at a swing bed, got 
admitted with oliguric renal failure. His baseline creatinine was 1.2 mg/dL, with eGFR 62 
ml.min and no baseline proteinuria, last A1c of 7.2% one month prior. One week prior to
admission, he was started on Canagliflozin 300 mg daily. No history of volume depletion, 
and no evidence of hypotension, contrast exposure, or NSAID use noted. He was on
furosemide 80 mg daily, Enalapril 5 mg daily. Complements were normal, urine revealed
active sediment and 2.3 grams proteinuria. Hemodialysis was initiated due to oliguric AKI. 
Canagliflozin was stopped. Week after admission, creatinine improved to 1.7 mg/dL and the 
patient is off dialysis. Biopsy revealed features of osmotic nephrosis (Fig. 1).
Discussion: Enhanced glucose delivery to S3 segment of proximal tubule (PT) due 
to it’s blocked uptake at S1 segment of PT by SGLT2-i, activates osmosensitive aldose 
reductase. Glucose is converted to sorbitol and to fructose. Fructose-uric acid axis is 
postulated in pathogenesis of chronic kidney injury related to diabetic nephropathy. In our 
case, although the exact etiology of osmotic nephrosis is not known, we hypothesize that 
higher concentrations of intracellular fructose may have caused local toxicity leading to the 
described pathological changes and severe acute renal failure.
Osmotic Nephrosis : Proximal tubule cell with severe vacuolization, loss of brush 
border, and cell death
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Euglycemic Diabetic Ketoacidosis Caused by a Sodium Glucose Cotrans-
porter-2 Inhibitor
Jacob A. Hettenbaugh,1 Faizan Syed,1 Scott G. Westphal.2 1University of 
Nebraska Medical Center, Omaha, NE; 2University of Nebraska Medical 
Center-Nebraska Medicine, Omaha, NE.
Introduction: The use of Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors in the 
treatment of diabetes mellitus has continued to grow in the last several years, owing to their 
ability to reduce cardiovascular morbidity and mortality, and prevent incident or progressive 
diabetic nephropathy. With their increasing use, providers must understand the side effect 
profile of this new drug class. Here, we present a case of euglycemic diabetic ketoacidosis 
secondary to empaglliflozin, which is a rare, but potentially life threatening complication 
of SGLT-2 inhibitors.
Case Description: A 53-year-old man with type 2 diabetes mellitus managed with 
metformin and empagliflozin, presented with progressive nausea and vomiting, and was 
found to have a severe anion gap metabolic acidosis. On presentation, his pH was 7.11, 
serum bicarbonate 5 mmol/L, and anion gap was severely elevated. His blood glucose was 
184 mg/dl. Beta-hydroxybutryate was markedly elevated, serum lactate was normal at 
0.8 mmol/L, and serum creatinine was 1.0 mg/dl. He was diagnosed with non-hyperglycemic 
diabetic ketoacidosis based on strong clinical suspicion. Although glucose was < 200 mg/dl, 
he was treated with IV insulin and withdrawal of his empagliflozin. Within two days his 
acidemia had resolved with serum pH improving to 7.37, serum bicarbonate increasing to 
24 mmol/L, and resolution of his anion gap.
Discussion: Ketoacidosis is a rare complication of SGLT-2 inhibitors. Unlike diabetic 
ketoacidosis in patients with type 1 diabetes mellitus, patients taking SGLT-2 inhibitors 
do not present with overt hyperglycemia. Due to this, ketoacidosis may go unrecognized 
leading to a delay in diagnosis and therapy. The cause of this complication is assumed to be 
due to decreased insulin production and loss of regulation of glucagon leading to increased 
glucagon secretion. As many nephrologists are now using SGLT-2 inhibitors regularly in 
patients with type 2 diabetes mellitus, providers need to be aware of this rare, but potentially 
serious complication in order to make a prompt diagnosis and institute timely treatment.
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ARF Caused by Tacrolimus Nephrotoxicity Due to Enhanced Absorption 
Mediated by Ledipasvir Inhibition of Gut Permeability-Glycoprotein
Usman A. Khan,1 Kai Lau,2 Taseen A. Syed,2 Aemen S. Khakwani.3 1University 
of Oklahoma Health Science Center, Oklahoma City, OK; 2University of 
Oklahoma Health Sciences Center, Oklahoma cty, OK; 3University of Oklahoma 
Health Sciences Center, Oklahoma city, OK.
Introduction: Recently discovered Novel Direct-acting antivirals (DAA’s) have 
completely changed the spectrum of Hep.C treatment with multiple studies showing 
sustained virological response of over 90% in many genotypes. Treatment of hepatitis C with 
DAA’s in renal transplant has been associated with nephrotoxicity at the pharmacodynamic 
level due to indirect interaction with immunosuppressive medications especially tacrolimus. 
We report a case of acute renal failure from increased tacrolimus plasma levels secondary to 
Harvoni mediated inhibition of gut permeability- glycoprotein.
Case Description: 65-yo M with a h/o renal transplant for ESRD due to DM and 
HTN and hep.C being treated with Harvoni (ledipasvir/sofosbuvir) was admitted for 
incidental ARF when presented initially for lesions on his AVF.His immunosuppression 
was tacrolimus 5 mg q 12 h and MMF 1 g bid. Physical exam was within normal limits. 
Lab was remarkable for an acute bump in Cr from his baseline of 1.5 to 2.1 mg%, along 
with blood tacrolimus level of 14 ng/ml. There were no identifiable nephrotoxic insults 
or medications. The clinical diagnosis of tacrolimus nephrotoxicty was made and was 
attributed to excessive gut tacrolimus absorption because ledipasvir is known to inhibit 
the gut p-Glycoprotein which normally limits the absorption of tacrolimus. His dose was 
gradually reduced from the home regimen of 5 mg bid to 2 mg bid, with a subsequent 
drop in his tacrolimus levels and recovery of serum creatinine to baseline of 1.5 mg% at 
a tacrolimus level of 7.8 ng/ml. After resolution of his ARF, he was discharged on 2 mg 
bid with the target tacrolimus level 6-8 ng/ml while he was still getting Harvoni. After 
the completion of his 12-week course of Harvoni, he was put back on a higher dose of 
tacrolimus, to avoid allograft rejection due to inadequate tacrolimus level secondary to the 
sudden drop in gut absorption without ledipasvir.
Discussion: Emerging DAAs seem to have a reduced potential for drug interactions, 
which will facilitate their use in the treatment of HCV in renal transplant patient. Close 
monitoring and dose titration of immunosuppressive medication especially Tacrolimus in 
renal transplant HCV infected patients being treated with DAA’s is important to prevent 
Nephrotoxicity from higher plasma levels and renal rejection from lower plasma levels of 
tacrolimus.
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Severe Drug-Induced Bilateral Obstructive Nephropathy in a Lung 
Transplant Recipient: A Case Report and Literature Review
Vidhit Puri,1 Pridvi Kandagatla,1 Nishant K. Puri,1 Gunjan Garg,1 Tina Nigam,2 
Sowmya Goranta,3 Raviprasenna K. Parasuraman.1 1University of Michigan, 
Ann Arbor, MI; 2Michigan State University, Lansing, MI; 3Hurley Medical 
Center, Flint, MI.
Introduction: Drug induced nephrolithiasis is rare and accounts for 1-2 % of all 
renal stone disease. Sulfamethoxazole mediated renal injury is mostly from interstitial 
nephritis and crystalluria with occasional renal stone formation. We present a rare case of 
Sulfamethoxazole induced acute bilateral ureteral stones causing hydronephrosis and severe 
AKI in a lung transplant recipient.
Case Description: A 59-year-old lung transplant recipient presented with a 3-day 
history of bilateral flank pain, weakness, anorexia, and decreased urine output after 4 weeks 
of high dose sulfamethoxazole-trimethoprim (Bactrim DS 2 TID) for cavitating Nocardia 
pneumonia. Examination was significant for moderate volume depletion, bilateral flank 
tenderness and oligo-anuria. Serum chemistry was significant for creatinine of 5.08 mg/
dL (baseline 0.9), hyponatremia (130meq/L), and hyperkalemia (5.2meq/L) with a normal 
uric acid level. UA showed aciduria (pH=5.0). US and CT showed bilateral ureteral 
stones, hydronephrosis and bladder sediment layering (Fig.1a). Patient underwent bilateral 
ureteral stent placement and the urine (frank hematuria, unable to appreciate crystals) was 
strained and subjected for stone analysis. The infrared spectroscopy (IS) showed > 95% of 
absorbance pattern consistent with N4-acetylsulfamethoxazole, confirming the diagnosis 
of sulfamethoxazole stone (Fig.1b). Cessation of Bactrim therapy, urine alkalization, and 
volume replacement resulted in resolution of hydronephrosis and complete recovery of 
renal function.
Discussion: Bactrim induced interstitial nephritis, hyperkalemia and crystalluria is 
frequently seen. However, acute bilateral ureteral stone causing obstructive nephropathy 
is rare and to our knowledge not reported. The major risk factors include higher dose of 
medication, low urinary pH (poor solubility), and volume depletion. Our case exemplifies 
the importance of monitoring patient’s urine pH, crystalluria, renal function, and volume 
status when using high doses of Bactrim.
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A. CT showing Distal Rt & Proximal Lt ureteral calculus with stone layering in bladder. B. 
IS showing stone composition matching metabolite of sulfamethoxazole.
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Stones and Woes: A Case of Tiopronin Associated Proteinuria
Sehrish Ali, Ahmed A. Awan, Prejith P. Rajendran, Natasha N. Dave, 
Jingyin Yan. Nephrology, Baylor College of Medicine, Houston, TX.
Introduction: Cystinuria is a rare genetic disorder characterized by impaired renal 
cystine transport causing increased cystine excretion and cystine nephrolithiasis. Treatment 
aims at maintaining urine cystine concentration below solubility level by hydration and 
alkalization. Patients resistant to conservative measures or who have a high cystine 
excretion rates are treated with Tiopronin or D-penicillamine. Tiopronin is usually well 
tolerated. Here we report a rare side effect of Tiopronin induced nephrotic range proteinuria.
Case Description: A 41 year-old woman with kidney stones for six years, presented 
to our stone clinic with complaints of recurrent stone passage. Her past medical history 
is significant for multiple urological procedures for stone removal. Her stone analysis 
showed 100% cystine calculi. She was managed with increased hydration and potassium 
citrate (60meq/daily) for stone prevention and she reported good compliance to treatment. 
However, CT of abdomen showed recurrent bilateral staghorn renal calculi. She underwent 
bilateral complicated procedures, and eventually the stone burden was cleared. Given 
the resistance to conservative treatment, she was started on Tiopronin at 800mg per day, 
which was gradually increased to 1000mg per day. At six months followup, 24 hour urine 
test showed decreased supersaturation and increased capacity of cystine. Repeat imaging 
of kidneys showed no new stone formation. However, she developed proteinuria from a 
baseline of 0.11mg/dL to 3.8mg/dL. Initially, a lower dose of Tiopronin was attempted 
with no improvement in the proteinuria. Subsequently, Tiopronin was withdrawn, and a 
resolution of the proteinuria was noted after that.
Discussion: Tiopronin is effective in reducing cystine stones in up to 70% of patients. 
With a better side effect profile compared to D-penicillamine, Tiopronin is first line for 
patients resistant to conservative therapy. Proteinuria due to Tiopronin is a rare, dose 
dependent side effect that resolves with cessation of therapy. Optimal monitoring for adverse 
effects is still not well defined; nonetheless, clinicians remain vigilant by monitoring urine 
protein to creatinine ratios every three to six months while patients are on Tiopronin.
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Sulfadiazine Induced Crystalluria
Alice Chedid, Mohamad A. Hanouneh, Keiko I. Greenberg. Johns Hopkins 
University School of Medicine, Division of Nephrology, Baltimore, MD.
Introduction: Crystal-induced acute kidney injury (AKI) is caused by the intratubular 
precipitation of crystals, which results in obstruction. Crystal-induced AKI mostly occurs as 
a result of acute uric acid nephropathy and following the administration of drugs or toxins 
that are poorly soluble.
Case Description: A 23 year-old man with history of untreated HIV presented with 1 
week history of right sided weakness. HIV viral load was 274,000 copies/mL and absolute 
CD4 count was 2 /cu mm. Brain MRI showed bilateral ring enhancing lesions. Patient 
was started empirically on pyrimethamine 75 mg daily, sulfadiazine 1.5 g q6 hours and 
leucovorin 25 mg daily. Brain biopsy confirmed the diagnosis of toxoplasmosis. Hospital 
course was complicated by AKI 8 days after starting this regimen. Labs revealed BUN 
12 mg/dL and serum creatinine 2.0 mg/dL (baseline 0.8 mg/dL). Urinalysis showed no 
hematuria or pyuria; pH was 6. Urine protein/creatinine ratio was 0.42 g/g. Kidney 
ultrasound showed non-obstructing bilateral ureteral stones. Examination of urine sediment 
under polarized light revealed multiple yellow brown asymmetric rosette shaped crystals 
(sulfonamide crystals) (figure 1). Sulfadiazine was discontinued and patient was switched to 
clindamycin. Patient was treated with IV fluids (sodium bicarbonate) to alkalinize the urine 
(urine pH goal was > 7 with urine output goal was 2 L/day). The patient’s serum creatinine 
returned to baseline within 8 days.
Discussion: Sulfadiazine induced crystalluria is a serious complication in patients 
with AIDS who are treated for toxoplasmosis. Predisposing factors include high dose of 
sulfadiazine and volume depletion. It usually presents with AKI within 3 weeks of starting 
the medication. Treatment requires stopping the offending agent, aggressive IV hydration 
(UOP at least 1.5 L/day) and bicarbonate infusion to alkaline the urine (goal pH > 7).
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Two Cases of Lurasidone-Associated AKI
Nimesh K. Shah,1 Valerie S. Barta,2 Fatima Sheikh,3 Hitesh H. Shah.4 
1Nephrology and Hypertension Division, Lenox Hill Hospital, New York, NY; 
2Hofstra Northwell School of Medicine Lenox Hill Hospital, New York, NY; 
3Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY; 4Zucker 
School of Medicine at Hofstra/Northwell, Great Neck, NY.
Introduction: Lurasidone (Latuda) is a novel atypical antipsychotic used for 
schizophrenia and bipolar disorder. AKI has rarely been reported with lurasidone in trials. 
We report the first two clinical cases of AKI with lurasidone, including the first case of 
biopsy proven chronic interstitial nephritis (CIN).
Case Description: Case 1: 70-year old bipolar female was sent to ER for serum 
creatinine (Scr) of 8.4mg/dL. Scr was 1mg/dL six months prior. Medications included 
lurasidone, escitalopram, lamotrigine, lithium (Li), alprazolam, amphetamine, anastrazole, 
propranolol, and metformin. Lurasidone was the only new medication, started 6 months 
prior. Vitals and physical exam were unremarkable. Serum potassium was 6mmol/L, 
CO2 13mmol/L and Li 0.6mmol/L. 24-hr urine protein was 0.7g. Serologic work-up was 
negative. Metformin and Li stopped and patient discharged with Scr of 6.2mg/dL. Patient 
re-hospitalized one month later for Scr 9.8mg/dL requiring 3 sessions of hemodialysis for 
uremia. Kidney biopsy showed ATN and severe chronic interstitial nephritis (CIN). The 
lack of micro-cysts or granulomatous CIN was inconsistent with Li or lamotrigine induced 
AKI respectively. Oral corticosteroids initiated and lurasidone was held. Scr decreased to 
2.6mg/dL four weeks later. Case 2: 50-year old male with schizophrenia was seen in clinic 
for elevated Scr of 1.6mg/dL. Scr was 1.3, 6 months prior to presentation. Medications 
included lurasidone, clozapine, clozaril, klonopin, lamictal, tamsulosin and metoprolol. 
Physical exam was unremarkable. Spot urine total protein-to-creatinine was 0.1. Serological 
work-up was negative. Lurasidone dose was reduced from 160mg to 80mg daily and Scr 
subsequently decreased to 1.3mg/dL.
Discussion: A review of FDA Adverse Event Reporting System (FAERS) revealed 
AKI in 18/3076 users of lurasidone. All cases were female ≥60years with AKI seen within 
1yr of drug initiation. CrCl <50mL/min raises serum levels of lurasidone thereby increasing 
risk of AKI, as does adjunctive therapy with Lithium. AKI improved in our cases after 
discontinuation and steroids, or reduction of lurasidone therapy alone. It is important for 
clinicians to be aware of the potential AKI and CIN risk associated with lurasidone so renal 
function can be closely monitored in these patients.
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Rapid Loss of Kidney Function Associated with the Use of Capreomycin
Rafaela M. Gouveia,1 Moacir C. Netto,1 Ana Paula Gueiros,1 Mirna D. Meira,1 
Cidcley N. Cabral,1 Heliana M. Mello.2 1Instituto de Medicina Integral Professor 
Fernando Figueira, Recife, Brazil; 2IMIP, Recife, Brazil.
Introduction: Capreomycin (CPM) is used in the treatment of resistant forms of 
tuberculosis (TB), resulting in the adverse effect of nephrotoxicity. In the acute forms, 
tubular necrosis or glomerular alteration occurs, which is reversible if the use of the drug 
is suspended. Chronic impairment is characterized by interstitial nephritis. We report the 
case of a patient who developed severe renal dysfunction associated with the use of CPM.
Case Description: Male (aged 65), diabetes mellitus (DM) for 4 years, diagnosed 
with pulmonary TB (positive smear microscopy), initiated treatment with Rifampicin 
(RFP), Isoniazid, Pyrazinamide (PZA) and Etambutol (ETB). After 9 months, he remained 
symptomatic and GeneXpert detected resistance to RFP. In June 2017, he initiated 
treatment with CPM, ETB, Levofloxacin, Terizidone and PZA. At this time, he presented 
with creatinine (Cr mg/dL) 0.58 and hemoglobin (Hb g/dL) 13. After 6 months on the new 
treatment, he presented with Cr 2.5. In the ninth month, with negative sputum culture and 
undetectable GeneXpert, CPM and PZA were suspended, as recommended by the Brazilian 
Ministry of Health. In the tenth month, Cr was 2.64 and Hb 8.2, and the dosage of the other 
medications was adjusted according to the glomerular filtration rate (GFR). Although CPM 
was suspended, the patient evolved with no improvement in the GFR, with Cr 2.46, an 
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absence of proteinuria, hematuria or leukocyturia and proteinuria/24h 162mg. He presented 
a normal kidney ultrasound and a fundoscopy with non-proliferative diabetic retinopathy. 
Renal biopsy: normal glomeruli, no mesangial, endo or extracapillary proliferation, 
necrosis, sclerosis or thickening of the basement membrane; mild atrophy and interstitial 
fibrosis, with interstitial mononuclear infiltrate and arterial segment with mild fibro-intimal 
hyperplasia. Immunofluorescence did not demonstrate immunocomplexes.
Discussion: This case demonstrates a rapid, severe alteration of the GFR in a diabetic, 
normotensive patient with no evident proteinuria. The biopsy did not reveal kidney 
impairment from the DM. The literature reports few cases on nephrotoxicity from CPM. 
This study emphasizes the importance of strict controlling the GFR in patients on CPM, 
especially the elderly and those with comorbidities.
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Effectiveness of Hemodialysis and L-Carnitine in Severe Valproate 
Overdose
Mubasshar Rehman,1 Ambreen Azhar,2 Martine Pollack-Zollman.3 1Mount Sinai 
Saint Luke’s and mount Sinai West, Bronx, NY; 2mount sinai st lukes, New York, 
NY; 3Mount Sinai Hospital, NY, NY.
Introduction: Valproic acid (VPA) is used to treat seizure disorders and psychiatric 
illnesses. Acute VPA intoxication usually results in mild, self-limited CNS depression. VPA 
and its metabolites are low molecular weight, osmotically active acids and anions that may 
cause elevated osmolar and anion gap metabolic acidosis, hypocalcemia, hypernatremia, 
hyperammonemia with or without hepatic failure, cerebral edema leading to death if 
ingested in large doses. Prospective studies are lacking with regard to the management of 
VPA overdose, and the available data is mainly from case reports or retrospective studies. 
We present a case of sodium valproate overdose where hemodialysis was used due to rapid 
clinical deterioration
Case Description: A 24 year old female with seizure disorder on VPA and prior suicide 
attempts was brought to the ED with incoherent speech and encephalopathy after ingesting 
100 tabs (100mg each) of VPA Shortly after arrival, she became agitated and required 
mechanical ventilation and pressor support. VPA level was >1200μg/ml along with AGMA, 
osmolar gap, hypernatremia, hypocalcemia and hyperammonemia (see table). CT head was 
negative for cerebral edema. She was admitted for acute VPA Toxicity. Charcoal suspension 
via NGT and L-carnitine infusion were initiated. Due to rapid clinical deterioration, she 
required a single 6 hour session of emergent hemodialysis with an Optiflux F160 dialyzer, 
Qb 400cc/min. Following dialysis, she clinically improved and VPA level was 439μg/ml 
at 24hrs
Discussion: Our patient presented with classic symptoms and lab abnormalities 
seen in acute VPA toxicity. Due to its low molecular weight and high free serum levels 
at supratherapeutic doses, hemodialysis seems an effective treatment. Mitochondial 
dysfunction and carnitine depletion occurs with VPA toxicity which leads to 
hyperammonemia. Retrospective studies suggest the use of L-carnitine to reverse these 
defects and hemodialysis can also be used for further ammonia clearance
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A Case of Phenobarbital Overdose - Managed by High Flux Hemodialysis
Huiwen Chen. University of Pittsburgh Medical Center, Pittsburgh, PA.
Introduction: Intentional and accidental drug overdose result in approximately 
10, 000 death per year. While some overdose can be managed with antidote, others might 
require more invasive care. Although techniques such as charcoal hemoperfusion have 
gone obsolete, hemodialysis (HD) has become the new standard to remove drugs that 
are moderately protein bound but small in size. We present a case of phenobarbital (PB) 
overdose corrected by HD.
Case Description: A 52 year old female with a history of seizure on PB who was 
brought to the hospital because of unresponsiveness secondary to an apparent suicide 
attempt via medication overdose. Ingestions occurred more than 24 hours prior to arrival. 
Vitals:T 36.8C, BP 106/82, HR 113, RR 40, Sat: 96% on non-rebreather. GCS< 8 She was 
breathing spontaneously and pupils were small but reactive to light. She was intubated 
for airway protection. Serum chemistry was within normal limits. Urine drug screening 
was positive for PB, benzodiazepine, and opioids. The rest of the toxicology workup was 
negative. Urine PB level was 147.9 ug/ml and therapeutic range is between 30 to 40 ug/ml. 
CT brain did not show cerebral pathology. EEG was consistent with cortical irritability and 
potential for seizure. Given that there was a national shortage of bicarbonate solution, serum 
and urine alkalization were not performed. One session of four-hour hemodialysis (HD) was 
initiated. Initial post-HD PB level was 54.2 ug/ml. Two hour post-HD PB level was 35.6 
ug/ml. Patient was able to open her eyes the following day with drug level 43 ug/ml. No 
further dialysis was required.
Discussion: The therapeutic level of PB for seizure disorder is 30-40 ug/ml. A 
concentration above 60 ug/ml is considered toxic. The half life of PB in adults is between 
50 to 140 hours depends on patients’ age. Although PB is 20-45 percent protein bound, its 
plasma volume of distribution is large, between 0.6-1.0 L/kg, and the molecular size is only 
232 daltons, making elimination of the drug easily with HD. The calculated time for this 
patient to reach non-toxic level of drug concentration with native renal clearance would be 
at least 100 hours. However, it took less than 24 hours to reach similar level with the help 
of HD. Take home message: While PB overdose can be treated with supportive care, in 
patients who are intubated, implementation of HD can effectively reduce the serum drug 
level and potentially reduce ventilator time.
SA-PO296 Poster Saturday
Trainee Case Reports - VI
Outpatient Drug Dosing for Patients with CKD: Is It Time to Include 
Pharmacists?
Talar Kharadjian, Marie Pietruszka, Tripti Singh. University of Wisconsin 
Health & Clinics, Madison, WI.
Introduction: Neurotoxicity due to inappropriate valacyclovir dosing in patients 
with chronic kidney disease (CKD) is a recognized adverse effect. Electronic databases 
such as Lexicomp provide pharmacists and physicians with standard dose reductions for 
renal clearance. Our cases demonstrate the inadequacy of our current systems, which 
unfortunately failed to avert these preventable outcomes.
Case Description: Case 1 51-year-old male with end-stage renal disease (ESRD) 
on hemodialysis (HD) was seen in primary care clinic for shingles. Due to ongoing renal 
transplant workup, he was given valacyclovir 1g three times daily (immunocompromised 
dosing). Two days later, he presented to the emergency department (ED) with confusion 
and visual hallucinations. A pharmacist reviewed the dose and recommended switching 
to acyclovir 800mg five times daily based on clinical indication rather than renal dosing. 
He later returned to the ED with worsening symptoms. His pre-dialysis acyclovir level 
was 12mg/L, improved to 3.5mg/L after 3 hours of HD. He had daily HD for 3 days and 
discharged on valacyclovir 500mg daily for 7 days. Case 2 53-year-old male with HIV 
and ESRD on HD developed shingles treated with valacyclovir 1g three times daily (HIV 
dosing). He became somnolent, agitated and confused. He was admitted for neurotoxicity 
due to inappropriate valacyclovir dosing, treated with urgent HD for 3 hours. Symptoms 
improved over 24 hours and he discharged on valacyclovir 500mg daily for 7 days.
Discussion: Our cases demonstrate the limitations of our current electronic medical 
record, which does not alert prescribers to data present in the chart at the time of medication 
order entry, namely glomerular filtration rate (GFR) and diagnosis of CKD. Such alerts can 
reduce the risk of inappropriate renal dosing. We also propose that community pharmacists 
be granted access to the medical record to properly verify dosing in the outpatient context 
as it occurs on inpatient wards. This would provide added safety to a currently disjointed 
prescriber-pharmacist interface in the outpatient setting. Another solution would be an 
identifying bracelet for patients with GFR<30 mL/min per 1.73m2, similar to community 
Do Not Resuscitate (DNR) bracelets, which would also foster greater public and provider 
awareness regarding the vulnerability of this patient population to such medical errors.
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Fibromuscular Dysplasia in a Patient with Vascular Type Ehlers-Danlos 
Syndrome Who Presented with Spontaneous Renal Artery Perforation
Junaid Nasir, Anum Bilal, Rafia I. Chaudhry, Loay H. Salman. Nephrology, 
Albany Medical Center, Albany, NY.
Introduction: Fibromuscular Dysplasia (FMD) is a rare segmental disease of small and 
medium sized arterial wall musculature. FMD is noninflammtory and nonatherosclerotic 
in nature and affects renal and internal carotid arteries in 75% of cases. Renovascular 
hypertension in young females is the most common presentation, while spontaneous 
dissection, bleeding and renal infarction is rare; however these are seen more often in males 
affected by FMD. We present a rare case of coexistent FMD and Ehers-Danlos Syndrome 
presenting as spontaneous renal artery dissection.
Case Description: A 44-year-old male presented to the ED with severe left flank pain. 
Patient was hypotensive (S.B.P 80 mmHg), in hemorrhagic shock and had AKI, Hb 9.8 
gm/dL, Cr 1.69 mg/dL). CT angiogram abdomen revealed massive retroperitoneal bleed 
from left renal artery. Emergent laparotomy confirmed pseudoaneurysm from dissected left 
renal artery extending to sub-segmental arteries. Revascularization attempt was futile due 
to friability of the vessels and left nephrectomy was performed. Histologic evaluation of 
the kidney demonstrated marked fibrointimal thickening with hypocellular intimal sclerosis 
and focal cellular fibroplasia, medial hypertrophy, and abrupt broad regions deficient in 
internal elastic lamina. The severe fibro-obliterative renovascular disease findings were 
consistent with fibromuscular dysplasia, with features of both the medial fibroplasia and 
intimal type. Genetic testing was performed confirming pathogenic mutation in COL3A1 
gene (c.1106G>T) diagnostic of Vascular Ehlers-Danlos Syndrome (vEDS).
Discussion: Spontaneous renal artery dissection is rare, and has been associated 
with FMD (especially in males), malignant hypertension, severe atherosclerosis, severe 
trauma, Marfan syndrome, or Ehlers-Danlos syndrome. vEDS has an Autosomal Dominant 
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inheritance, and is the most severe form of EDS, increasing the risk of arterial aneurysm 
rupture. Co-existing FMD and vEDS of renal artery has not been described before. This 
case highlights the need for genetic testing of patients diagnosed with FMD, to rule out 
additional connective tissue disorders, as co-existence of both conditions can potentially 
increase the risk of life threatening complications.
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Takayasu’s Arteritis Induced Bilateral Renal Artery Stenosis Refractory 
to Medical Therapy
Rahul Kumar, Georges Nakhoul, Jonathan J. Taliercio. Cleveland Clinic 
Foundation Glickman Urological and Kidney Institute, Cleveland, OH.
Introduction: Takayasu’s arteritis (TAK) is a granulomatous large-vessel vasculitis. 
It primarily affects women of age 10 to 40 years. In patients with TAK, the prevalence 
of hypertension varies from 23% to 76% across the world and about half of the case are 
secondary to renal artery involvement. In this study, we present a patient with difficult to 
control hypertension and worsening renal function secondary to TAK induced renal artery 
stenosis in spite of adequate medical management.
Case Description: A 39-year-old Caucasian female presented with sudden onset chest 
pain, left arm pain, muscle ache, and 50-pound weight loss over the past one year. Patient 
has a past medical history of multiple sclerosis, ulcerative colitis, and cigarette smoking. 
On exam, blood pressure was 110/72 mmHg in the right arm and 88/70 mmHg in the left 
arm. A left subclavian bruit was present with a feeble left radial pulse. EKG showed an 
anterior STEMI. A coronary angiogram revealed 99% LAD ostial stenosis and incidentally 
showed high-grade stenosis of the proximal left subclavian and bilateral renal arteries. 
The patient underwent an urgent coronary artery bypass graft. On further workup, a CT 
angiogram showed severe stenosis of the proximal left subclavian artery, superior and 
inferior mesenteric artery, celiac artery and bilateral renal artery (80% RRA and 90% LRA 
stenosis). A clinical diagnosis of Takayasu’s arteritis was made and the patient was started 
on prednisone and methotrexate. At a six-month follow-up, the patient was found to have 
BP of 160/90 mmHg in spite of being on four antihypertensives including an ACE-I and 
a decreased eGFR of 40 ml/min/1.73m2. MRA abdomen showed a completely occluded 
right renal artery with an atrophied right kidney. Renal Duplex US showed LRA proximal 
stenosis with a significantly increased PSV of 760 cm/sec and RRI of 60%. An aortogram 
confirmed the RRA occlusion. The patient underwent left aorto-renal bypass grafting of her 
solitary kidney. A six-month follow-up showed improved eGFR to 76 ml/min/1.73m2 and a 
decrease in antihypertensive medicines to carvedilol and enalapril.
Discussion: In TAK with advanced renal artery stenosis refractory to medical therapy, 
endovascular or surgical revascularization is the treatment of choice. The patient was 
prevented from becoming dialysis dependent by the timely recognition, close monitoring, 
and intervention.
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Baroreceptor Failure – A Rare Form of Secondary Hypertension
Kai Chin,2,1 Jesse M. Wickham.2,1 1UT Health San Antonio, San Antonio, TX; 
2Nephrology, San Antonio Military Medical Center, San Antonio, TX.
Introduction: Baroreceptors in the neck play a large role in blood pressure (BP) 
regulation. They sense distension of the vessel wall and help stabilize blood pressures 
during changes in volume and/or posture. Injury to the baroreceptors can cause extremely 
labile blood pressure with BP surges. We present a case of baroreceptor failure, a rare form 
of secondary hypertension.
Case Description: A 65-year-old male with hypertension (HTN), anxiety and soft 
palate cancer s/p radiation therapy was admitted for planned carotid endarterectomy. 
Patient’s BP rose to 290/102mmHg when he was placed supine in the operating room. 
Surgery was aborted and nephrology was consulted to assist with BP therapy and secondary 
workup. Patient stated these BP surges had been occurring for years. However, they only 
began after he received radiation therapy to his neck at age 55. His current medications 
were Felodipine 10mg daily and Carvedilol 12.5mg twice daily. Patient kept detailed BP 
logs 6 times a day with average BP 210s/100s mmHg, with surges to 260 mmHg systolic. 
Patient stated he used to be on many BP medications to treat his surges, but it would cause 
severe hypotension if he didn’t have surges. Patient had a secondary HTN workup which 
was negative for pheochromocytoma, hyperaldosteronism, and renal artery stenosis. He 
also had Positron Emission Tomography and Computerized Tomography scans done for 
surveillance of his cancer, which were negative for new masses. As a result, we concluded 
the patient likely had baroreceptor failure caused by radiation therapy to his neck. Review 
of the literature showed that Clonidine and benzodiazepines are beneficial in limiting BP 
surges. He was started on Clonidine 0.1mg/24hr patch and discharged with follow-up to 
titrate his Clonidine and wean his other BP medications. His Alprazolam for anxiety was 
switched to Diazepam as well. After 3 months, patient was on Clonidine 0.4mg/24hr patch, 
Valium 10mg BID and no longer on Felodipine or Carvedilol. His peak surge BPs are now 
180 mmHg systolic, and average BP is now 160-180/70-90 mmHg.
Discussion: Baroreceptor failure is a rare form of secondary hypertension, but it can 
be suspected if a patient presents with very labile blood pressure and high BP surges. Very 
commonly, there is a history of neck trauma (i.e. radiation therapy, neck surgery). Clonidine 
(central alpha-2 agonists) and benzodiazepines are effective in reducing blood pressure 
surges.
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Hypertension Associated with Herbal Supplements: “Diosmin Complex,” 
“Raphacholin C,” and “Herbatka Fix Na Cholesterol”: A Case Report
Jaibir Bhullar,1 Ravleen K. Saini,1 Shaheen Jadidi,2 Rayaan A. Rauf,3 
Suneel M. Udani.4 1Avalon University School of Medicine, Youngstown, OH; 
2Midwestern University, Downers Grove, IL; 3Advocate Good Samaritan 
Hospital, Downers Grove, IL; 4Nephrology Associates of Northern Illinois and 
Indiana, Oakbrook, IL.
Introduction: We report a case of hypertension associated with the ingestion of several 
Herbal Supplements (Diosmin Complex, Raphacholin C, and Herbatka Fix Na Cholestrol).
Case Description: A 60-year-old female patient, who had been ingesting these 
supplements sporadically for years, had increased her intake to twice a day for a month. 
Over the course of that month the patient developed palpitations, weight gain, trace edema, 
and mild jugular venous distention. Laboratory findings were notable for hypokalemia, 
hypocalcemia and hypomagnesemia with normal renal function. Urine chemistries 
confirmed mineralocorticoid excess with the presence of renal potassium wasting. The 
nutritional substance was subsequently ceased and supportive treatment was begun 
with low-dose carvedilol 6.25mg BID, and oral and IV potassium supplement. Further 
investigation was done of the renin aldosterone axis which confirmed the absence of 
primary hyperaldosteronism or high plasma renin activity. The patient’s condition improved 
rapidly with supportive treatment and ceasing of the supplements.
Discussion: Current information regarding the adverse effects of these herbal 
supplements is very scarce, therefore potential damage should be kept in mind before 
ingesting these nutritional supplements or anything similar. This report serves as an 
important reminder to the public, as well as healthcare providers, of the potential of 
hypertensive urgency related to such nutritional supplements.
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Application of a Central Iliac Arteriovenous Coupler Device in Severe 
Resistant Hypertension: A 3.5-Year Follow-Up
Susanne Jung,1 Christian Ott,2 Marina V. Karg,3 Agnes Bosch,3 Michael Schmid,4 
Stephan Achenbach,5 Roland E. Schmieder.4 1Departments of Cardiology, 
Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-
Nuremberg, Erlangen, Germany; 2Friedrich-Alexander University Erlangen-
Nürnberg, Erlangen, Germany; 3University Hospital of Erlangen, Erlangen, 
Germany; 4University Hospital Erlangen, Erlangen, Germany; 5Friedrich-
Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Introduction: In patients with resistant hypertension (RH), iliac arteriovenous (AV) 
coupler implantation leads to blood pressure (BP) reduction via decreased total vascular 
resistance and improved arterial compliance. However, long-term efficacy and safety need 
to be further explored. We report on the first case of 3.5-year follow-up (FU) in a patient 
treated by coupler implantation, who underwent repeated right heart catheterization (RHC).
Case Description: A patient with RH was admitted to hospital. Despite treatment 
with 6 anti-hypertensives his BP was poorly controlled. Previously, he had undergone 
renal denervation, not leading to significant BP decrease. Therefore an AV coupler was 
implanted in our catheterization laboratory, causing a periinterventional BP decrease from 
198/90 to 163/69mmHg. The patient was discharged with a BP of 122/71mmHg. After 
3 months there was a sustained BP decrease, whereas later it was fluctuant (office BP: 
147-173/85-95mmHg, ABPM: 153-166/81-94mmHg) probably due to medication non-
adherence, confirmed by a urinary screening test. One year later the patient was hospitalized 
with iliac venous stenosis, which was treated by venoplasty and stenting. After 3.5 years
he complained about progressive dyspnea and weight gain. FU RHC showed an increased 
pulmonary artery-, right atrial- and wedge-pressure as well as cardiac index and a decreased 
pulmonary vascular resistance. Central aortic pressure had decreased indicating device
effectiveness. An invasive closure maneuver led to an immediate BP increase (+30mmHg) 
and a similar decrease after re-opening of the coupler, verifying its functionality. To
unload the right ventricle, an intensive diuretic therapy was introduced leading to clinical
improvement.
Discussion: This is the first case of 3.5-year FU after arteriovenous coupler 
implantation, leading to significant BP decrease. We verified a proper long-term function 
of the device and demonstrated changes in hemodynamic parameters related to volume 
congestion, which were resolved by an intensified diuretic therapy.
Hemodynamic changes obtained by RHC
S-systolic/d-diastolic/m-mean
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Post-Implantation Syndrome Following Abdominal Aortic Aneurysm 
Repair Causing Podocytopathy
Corey J. Cavanaugh, Randy L. Luciano. Yale University School of Medicine, 
New Haven, CT.
Introduction: A systemic inflammatory response of fever, leukocytosis, and pleural 
effusion following various vascular interventions including endovascular aortic repair 
(EVAR) is well recognized phenomena known as post-implantation syndrome. We describe 
a case of podocytopathy following EVAR.
Case Description: A 69-year-old man with no significant previous medical history 
presented with fevers progressive generalized edema and shortness of air after undergoing 
EVAR for ruptured abdominal aortic aneurysm (AAA) one month prior. He underwent 
repeat CT of the chest abdomen and pelvis, revealing bilateral pleural effusions that were 
proven exudative, with intact endovascular repair. His serum albumin fell to 2.0g/dl from 
a previous baseline of 3.8g/dl, with 2+ proteinuria on urinalysis. Urine microscopy was 
notable for Maltese crosses reflecting lipid droplets. The serum creatinine (SCr) remained 
at baseline of 1.4 mg/dl. A renal biopsy showed 4 glomeruli, 1 with global sclerosis, focal 
interstitial infiltrate of lymphocytes and plasma cells, global foot process effacement 
on electron microscopy without immune complex deposition. Immunofluorescence 
was not completed. A final diagnosis of MCD or unsampled primary focal segmental 
glomerulosclerosis (FSGS) was given by the renal pathologist and given scarring with 
interstitial infiltrate a clinical diagnosis of FSGS was more likely. A unifying diagnosis 
of post-implantation syndrome was made after an extensive infectious, vasculitis, and 
rheumatologic work up were negative. Prednisone 60mg daily with loop diuretics was 
started. Upon follow up his serum albumin rose to 3.6g/dl, his edema and pleural effusions 
had resolved.
Discussion: Post-implantation syndrome describes the clinical entity of systemic 
inflammatory response after repair of AAA. The incidence of the syndrome has been 
reported to vary widely between 3% and 60% for AAAs. We describe the first case of 
podocytopathy following EVAR in a patient with post-implantation syndrome, that 
responded to corticosteroids.
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A Tough Nut to Crack
Danielle Janosevic,1 Michael T. Eadon.2 1Indiana University School of Medicine, 
Indianapolis, IN; 2Indiana University Division of Nephrology, Indianapolis, IN.
Introduction: “Nutcracker Kidney” is a puzzling diagnosis which conventional 
imaging can miss. We present a case with a high degree of clinical suspicion wherein 
positional Doppler imaging was required to confirm the diagnosis.
Case Description: A 37 year old African American male with no past medical history 
presented with several months of intermittent gross hematuria associated with left sided 
flank pain radiating to his bladder, which was exacerbated with vigorous physical activity 
and would resolve completely with rest. He had been self-medicating for the pain with 
NSAIDs on a daily basis (200-400 mg/d). Physical exam revealed a male of thin, tall 
stature, with a mild tenderness over the suprapubic region and left CVA. Labs: serum 
creatinine of 1.21 mg/dl (GFR MDRD 82 ml/min/1.73 m2), and urine microscopy with non-
dysmorphic red blood cells (>250 on UA, no WBC), 24 hour urine protein of 338 mg/day. 
Negative urine culture and urine fungal culture. C3 was 91 mg/dl, C4 was 10 mg/dl and 
ANA was negative. He had a normal hemoglobin electrophoresis, 24 h urine calcium 128 
mg/d. CT scan of abdomen/pelvis was significant for absence of renal calculi, cysts, or 
hydroureteronephrosis. CT also noted an unremarkable bladder, no papillary necrosis, no 
AVM, and widely patent bilateral renal veins. A cystoscopy revealed negative cytology 
without bladder masses. A renal doppler study in the supine and standing position was 
obtained due to a high suspicion for dynamic renal vein compression. The study revealed 
a normal right renal vein in the supine, seated, and standing positions. Two left renal veins 
were noted. While one left renal vein was non-pathologic, the second left renal vein doppler 
showed intact flow in the supine and seated positions, but continuous flow suggestive of 
compression in the standing position. The patient was offered intravascular intervention, but 
elected conservative therapy by limiting provocative physical activity.
Discussion: “Nutcracker kidney” is a challenging clinical diagnosis. The mechanism 
of “nutcracker kidney” is venous hypertension from compression of the left renal vein 
between the aorta and superior mesenteric artery. Clinicians must maintain a high index of 
suspicion to diagnose it with targeted dynamic imaging. In this case, all standard imaging 
failed to reveal the etiology and only the use of positional (standing) Doppler interrogation 
confirmed the diagnosis.
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A Diagnostic Challenge: Acute Nutcracker Abdomen
Sandheep Venkataraman,1 John S. Kang,2 Lin N. Lwin.1 1Montefiore Medical 
Center, Bronx, NY; 2Metropolitan Hospital Center, New York, NY.
Introduction: Nutcracker syndrome or left renal vein entrapment syndrome is a rare 
condition caused by the compression of left renal vein between the abdominal aorta and 
superior mesenteric artery (SMA). We describe the case of a young female presenting with 
intractable pain.
Case Description: 26-year old woman with history of recently diagnosed untreated H. 
pylori gastritis presented with sudden onset severe abdominal pain which lasted three weeks. 
The pain was sharp and worsened with food intake. She denied fever, nausea, vomiting, 
blood in urine, or recent NSAID use. She was tender to palpation over right and left upper 
quadrants of abdomen. Labs were normal. CT scan with IV contrast revealed left renal vein 
compressed between the aorta and the SMA, congested left kidney, medullary edema, and 
numerous retroperitoneal venous collaterals. This was thought to be incidental. She was 
diagnosed as gastritis and discharged on H. pylori treatment. However, she returned one 
month later with persistent abdominal pain. Renal doppler ultrasound showed significant 
narrowing of left renal vein with significant velocity gradient, consistent with Nutcracker 
syndrome. Contrast venography revealed proximal left renal vein narrowing, with elevated 
distal left renal vein pressure, which resolved with stent placement. She became pain-free 
after the procedure.
Discussion: Nutcracker syndrome was first described in 1937. It occurs due to an 
idiopathic decrease in the angle between the aorta and the SMA (to less than 35 degrees), 
with consequent compression of the left renal vein. It is most often asymptomatic, painless, 
and requires a high index of suspicion to diagnose. Serum biochemistry and urinalysis 
are often unremarkable. Our patient presented atypically with only acute abdominal pain, 
which can have a broad differential, making this diagnosis easy to miss. In some cases 
of nutcracker syndrome, severely increased pressure can lead to abnormal thin-walled 
collaterals which rupture leading to gross or microscopic hematuria, which was not seen 
in our patient. The diagnosis is usually made based on degree of stenosis and increased 
flow velocity as seen on doppler ultrasound. Venography is confirmatory. Treatment can be 
conservative or surgical. Given the rarity of the condition and limited evidence, the long-
term prognosis remains to be elucidated.
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Deletion of Matrix Metalloproteinase-10 Ameliorates Aldosterone-Induced 
Glomerular Injury in Guanylyl Cyclase-A Knockout Mice
Keisuke Osaki,1 Yukiko Kato,1 Naohiro Toda,2 Akira Ishii,1 Keita P. Mori,1 
Shoko Ohno,1 Kiyoshi Mori,5 Masato Kasahara,3 Masashi Mukoyama,6 
Motoko Yanagita,4 Hideki Yokoi.1 1Kyoto University Graduate School of 
Medicine, Kyoto, Japan; 2Kansai Electric Power Hospital, Osaka, Japan; 
3Institute for Clinical and Translational Science Nara Medical University 
Hospital, Kashihara, Japan; 4Department of Nephrology, Kyoto University 
Graduate School of Medicine, Kyoto, Japan; 5School of Pharmaceut Sci, 
University of Shizuoka, Shizuoka, Japan; 6Kumamoto University Graduate 
School of Medical Sciences, Kumamoto, Japan.
Background: Recently, we and others have unveiled the novel renal function 
of natriuretic peptide receptor/guanylyl cyclase-A (GC-A) system on antagonizing 
aldosterone-induced podocyte injury as well as the conventional effects on natriuresis 
and reducing blood pressure. We previously investigated uninephrectomized, aldosterone-
infused, and high salt diet-fed (ALDO) systemic GC-A knockout (KO) mice, resulting in 
hypertension, massive albuminuria, mesangial expansion and podocyte injury. However, 
genes involved in glomerular injury are elusive.
Methods: To identify responsible genes for podocyte injury, we compared glomerular 
mRNAs from ALDO control mice with ALDO systemic GC-A KO mice using microarray. 
Furthermore, we examined the role of the identified gene using its KO mice. We performed 
immunofluorescence study for an identified protein.
Results: Microarray analysis revealed that matrix metalloproteinase-10 (MMP-10) 
was upregulated more than 40 times in glomeruli of ALDO GC-A KO mice. To investigate 
the role of MMP-10, we generated double KO (DKO) mice for systemic GC-A and 
systemic MMP-10. ALDO systemic GC-A and MMP-10 DKO mice showed 80% reduction 
of albuminuria (4657μg/mgCr vs 24516μg/mgCr, p<0.05), and amelioration of podocyte 
injury demonstrated by improvement of foot process effacement and preservation of 
podocyte number, compared with ALDO systemic GC-A KO mice. Glomerular mRNA 
expression of extracellular matrix-related genes such as Tgfb1, Ctgf, and Col4a3 was 
upregulated in ALDO GC-A KO mice, and the upregulation was canceled by deletion of 
MMP-10. Immunofluorescence study revealed that MMP-10 expression was pronounced 
mainly in glomerular cells in ALDO GC-A KO mice. MMP-10 expression was also 
increased in proliferative lesions of human glomerular diseases such as Lupus nephritis, 
ANCA related nephritis, and IgA nephritis. In vitro, mRNA expression of MMP-10 was 
increased in human podocytes with TNF-α or TGF-β stimulation.
Conclusions: These results suggest that MMP-10 plays a crucial role in aldosterone- 
induced podocyte injury in GC-A KO mice, and can be a potential new target for treating 
kidney diseases.
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Par3A and Par3B Orchestrate Podocyte Polarity
Sybille Köhler,1 Sandra Iden,2 Carien M. Niessen,4 Bernhard Schermer,1 
Thomas Benzing,2 Barry Denholm,3 Paul T. Brinkkoetter.1 1University Hospital 
Cologne, Cologne, Germany; 2University of Cologne, Cologne, Germany; 
3Edinburgh University, Edinburgh, United Kingdom; 4CECAD University clinic 
of Cologne, Cologne, Germany.
Background: Polarity signaling through the aPKC-Par polarity complex is essential 
for the development and maintenance of the podocyte architecture and the function of 
the glomerular filtration barrier of the kidney. Despite its well-established role in aPKC-
mediated signaling, Par3A appears to be dispensable for the function of the glomerular 
filtration barrier. Interestingly, loss of Par3B also did not result in albuminuria and 
glomerulosclerosis.
Methods: To study potential compensatory mechanisms between Par3A and Par3B, we 
employed conditional in vivo targeting strategies specifically in podocytes and generated 
podocyte-specific Par3A/B double knockout mice.
Results: Within 8 weeks Par3A/B DKO mice developed severe proteinuria and renal 
failure. We utilized Drosophila nephrocytes to further study the interplay between the 
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different Par3 proteins. Here, we show co-localization of the Par3A/B homolog bazooka 
and the nephrocyte diaphragm proteins Sns (nephrin) and Duf (NEPH1) at different 
developmental stages. Silencing bazooka expression resulted in disturbed nephrocyte 
diaphragm morphology, severe filtration defects and delayed larval development. To 
investigate the functional role of Par3A and Par3B, we re-expressed different murine Par3 
variants in a bazooka knockdown background using the UAS-GAL4 system. Here, we 
performed several morphological and functional studies and observed different degrees 
of rescue potential. We utilized high resolution microscopy to resolve the nephrocyte 
diaphragm pattern and observed a decreased coverage and severely changed localization 
of Duf (dNeph) and Pyd (dZO-1) after nephrocyte-specific depletion of bazooka. This 
phenotype can be partially rescued by re-expression of aPKCiota-binding Par3 variants, 
while the 100kDa Par3A variant and Par3B present with almost no rescue. As none of 
the Par3 variants is able to provide a full rescue and to study the potential compensatory 
phenotype between Par3A and Par3B we generated Par3A/B double rescue flies and could 
show an almost complete rescue in Duf (dNeph) and Pyd (dZO-1) localization, confirming 
the compensatory potential of the two Par3 variants.
Conclusions: Taken together, these findings support the hypothesis of a potential 
compensatory mechanism between Par3A and Par3B to maintain polarity signaling at the 
slit diaphragm which are - at least partially – independent of aPKC.
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Complete Lack of Synaptopodin Causes No Overt Podocyte Defects
Liang Ning,2 Hani Suleiman,2 Jeffrey H. Miner.1 1Washington University School 
of Medicine, St. Louis, MO; 2Washington University, St. Louis, MO.
Background: Synaptopodin (Synpo) is an actin-associated protein found in podocyte 
foot processes and in dendritic spines. Many functions in regulating the actin cytoskeleton 
via RhoA and other pathways have been ascribed to Synpo, yet no pathogenic mutations in 
SYNPO have been discovered in patients. Several naturally occurring Synpo isoforms have 
been described (e.g., Synpo-short and -long), and a novel truncated protein (Synpo-T) was 
detected in the podocytes of Synpomutant mice. Synpo-T was reported to maintain some 
Synpo functions, thus preventing a major podocyte phenotype from emerging. To further 
investigate the functions of Synpo in podocytes, we attempted to knockout the majority of 
the Synpogene and prevent production of a protein.
Methods: We used CRISPR/Cas9 in embryos with two guide RNAs targeting near the 
5’ and 3’ ends of the Synpo gene to attempt to either delete most of the gene or mutate each 
end to prevent protein production. DNA sequencing was used to identify specific mutations. 
Immunofluorescence and western blotting using antibodies to amino-terminal, internal, 
and carboxyl-terminal epitopes were used to assay for Synpo protein. Mutant mice were 
observed for up to 12 months. Urine, blood, and tissue were taken at select time points to 
evaluate albuminuria, BUN, histopathology, and glomerular capillary wall ultrastructure. 
Super-resolution imaging was used to characterize the cytoskeleton. Adriamycin injections 
were performed.
Results: Many mutations were discovered in 80 founder mice: small deletions and 
insertions that shifted the reading frame; two deletions of 8 kb between the gRNA target 
sites; a 6 kb inversion; and a 3’ deletion of 7 bp that produced a truncated protein. Several 
of these were made homozygous or compound heterozygous. There were no significant 
differences in body weight between the mutants and controls. Urinary protein levels were 
normal up to 12 months regardless of the Synpo mutation(s) present. There were no obvious 
histological or ultrastructural abnormalities in 36-week-old mutant mice, and the actin 
cytoskeleton showed no obvious defects other than the absence of Synpo. However, Synpo 
mutant podocytes had worse injury from ADR.
Conclusions: Synaptopodin is dispensable for the development and maintenance of 
podocytes and for function of the glomerular filtration barrier. This is consistent with the 
lack of SYNPO mutations found in proteinuric patients.
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Protecting Glomerular Disease Progression in Mice Lacking Podocyte 
Associated Talin1 by Tangshen Formula
Tingting Zhao,3,1 Xuefei Tian,2 Ping Li,3 Shuta Ishibe.4 1Yale School of Medicine, 
New Haven, CT; 2Yale University, New Haven, CT; 3China-Japan Friendship 
Hospital, Beijing, China; 4Yale University School of Medicine, New Haven, CT.
Background: Loss of podocyte associated talin1 in mice results in severe proteinuria 
and kidney failure. Tangshen Formula (TSF), a traditional Chinese Medicine, has been 
confirmed to play a renal protective effect in rats with diabetic kidney disease and in patients 
with type 2 diabetic kidney disease. In this study, we further investigate the effect of TSF in 
genetic mouse model of disease where robust proteinuria is evident.
Methods: Twelve 8 weeks old Tln1fl/fl Pod-rtTA TetO-Cre mice (iTln1 KO) were 
induced with doxycycline for three weeks to specifically delete talin1 expression in the 
podocytes. After 2 weeks of doxycycline induction, the mice were separated into two 
groups +/- TSF treatment (6 vs 6). TSF were delivered by oral gavage at a dosage of 2.4g/Kg 
body weight/day for total of 5 weeks.
Results: Two weeks of doxycycline induction in the iTln1 KO mice, resulted in robust 
albuminuria prior to treatment (TSF treatment group: 817.35 ± 69.99 vs 53.02 ±10.34 μg/mg 
creatinine; Placebo treatment group: 781.97 ±72.70 vs 63.49 ±15.52 μg/mg creatinine) 
measured by ELISA. Following TSF or Placebo treatment for 5 weeks, TSF treatment 
in the iTln1 KO mice significantly reduced albuminuria compared to the placebo group 
(2136.88 ±270.32 vs 4028.4±516.67 μg/mg creatinine, P<0.05). TSF treatment in the 
iTln1 KO mice improved renal function measured by plasma creatinine (0.46±004 mg/dl 
to 0.33±0.03 mg/dl. P<0.05). TSF treatment in iTln1 KO mice ameliorated glomerulosclerosis 
and inhibited tubulointerstitial injury including interstitial fibrosis, tubular dilatation, and 
proteinaceous casts. Ultrastructural examination by transmission electron micrographs also 
showed improvement in foot process effacement and thickness of the basement membrane 
in iTln1 KO mice treated with TSF.
Conclusions: These results suggest a potential therapeutic role of TSF mice with 
proteinuric kidney disease and may have a protective role in human glomerulonephropathies.
Funding: Government Support - Non-U.S.
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Deletion of NuRD Component MTA2 in Nephron Progenitors Results in 
Renal Hypoplasia and Focal Segmental Glomerulosclerosis
Jeannine M. Basta,1,2 Lynn Robbins,1,2 Lisa Stout,1 Darcy R. Denner,3 
Michael I. Rauchman.1,2 1Internal Medicine- Nephrology, Washington University 
in St. Louis, St. Louis, MO; 2VA St. Louis Healthcare System, St. Louis, MO; 
3Washington University in St. Louis, St. Louis, MO.
Background: The Nucleosome Remodeling and Deacetylase Complex (NuRD) is a 
large multi-protein, evolutionarily conserved chromatin remodeling complex that harnesses 
the power of ATP via the ATPase Chd4 (Mi2β) to mediate nucleosome sliding and 
remodeling. It also has histone deacetylase activity via Hdac 1/2. We showed that the NuRD 
component Mi2β and the association between Sall1-NuRD is required for the regulation of 
nephron progenitor cells (NPCs).
Methods: In this study we deleted the NuRD specific component Mta2 in Six2+ NPCs.
Results: Mutant mice were viable, although mild renal hypoplasia was evident 
at embryonic day (E)14-16 (kidney area/body weight 41.2±2.6 vs 53.6±1.7 mm2/gm). 
Immunostaining for nephron segment specific markers showed that the nephrogenic zone 
was not reduced and all differentiating nephron structures appeared normal in the mutant. 
RNA-seq analysis at E17 showed a number of downregulated genes important for metabolic 
pathways (23 genes, p=9.78X10-4), indicating reduced metabolic fitness of NPCs may 
account for renal hypoplasia. By 2 months of age Mta2 mutant mice developed proteinuria 
(1614±469 vs 53±15 ug albumin/mg creatinine, n= 20 mut, 13 control). Analysis of mutant 
kidneys revealed findings consistent with focal segmental glomerulosclerosis (FSGS), 
including mesangial hypercellularity, segmental glomerular scarring, and tip lesions. At 
6 months of age albuminuria progressed in the mutant (7110±3739 vs 25±4, n=8 mut 8 
control); histopathology showed an increase in globally sclerotic glomeruli, proliferation of 
parietal epithelial cells with formation of pseudo-crescents, and trichrome staining revealed 
tubulo-interstitial fibrosis. Mitochondrial dysfunction in podocytes has been shown to 
contribute to development of FSGS. Transcriptional profiling at 2 months of age revealed 
significant enrichment in the oxidative phosphorylation pathway for downregulated genes 
in the mutant (35 genes, p=1.18 X 10-18). Mutant mice frequently die after 6 months of 
age, however survivors at 1 year of age have significantly elevated sCr (0.16±0.013 vs 
0.122±0.009 mg/dL, p=0.035, n= 5 mut, 10 control).
Conclusions: Our results suggest that regulation of metabolic homeostasis by NuRD is 
required for proper kidney development and for maintenance of normal glomerular function 
after birth.
Funding: NIDDK Support
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Intervention with the Novel Fibrokinase Inhibitor ANG3070 Mitigates 
Glomerular Scarring and Attenuates Proteinuria in a Model of Focal 
Segmental Glomerulosclerosis
Prakash Narayan,1 Quaisar Ali,2 Latha Paka,1 Jingsong Li,2 Dibyendu Dana,2 
Satishkumar V. Gadhiya,2 An-Hu Li,2 Michael A. Yamin,2 Itzhak D. Goldberg.2 
1Angion Biomedica Corp, Uniondale, NY; 2Angion Biomedica Corp., Uniondale, NY.
Background: Steroid-resistant (SR) primary Focal Segmental Glomerulosclerosis 
(FSGS) is accompanied by nephrotic-range proteinuria and necessitates renal replacement 
therapy. We investigated the effects of a novel small molecule platelet-derived growth 
factor (PDGF) receptor + vascular endothelial growth factor (VEGF) receptor inhibitor, 
ANG3070, in a clinically relevant model of FSGS.
Methods: Adult male rats were administered puromycin ((puro), 100 mg/kg, 
intraperitoneal) or saline (sham). On day 3, after onset of proteinuria, the puro cohort was 
randomized to vehicle or ANG3070. Twenty-four hour urine was collected on days 7 and 
14 at which kidneys were retrieved for analysis.
Results: Puro administration was associated with accumulation of PDGF in the 
glomerulus, increased glomerular dimension and scarring, and proteinuria. Intervention with 
ANG3070 attenuated proteinuria on days 7 and 14. Puro-induced glomerular hypertrophy 
and scarring were both reduced with ANG3070 intervention. Proteinuria-induced tubular 
toxicity was also reduced with drug.
Conclusions: In a clinically relevant model of FSGS, intervention with ANG3070 is 
beneficial. These data, form, in part, the basis for using a Precision Medicine approach to 
evaluate safety and efficacy of this drug in SR primary FSGS.
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Differences in Podocyte Regeneration Between Cortical and Juxtamedul-
lary Nephrons Defined by 3D Analysis and STED Imaging
Maria Lucia Angelotti,1 Giulia Antonelli,2 Carolina Conte,2 Maria elena Melica,3 
Hans J. Anders,4 Paola Romagnani.2 1Excellence Center for Research, Transfer 
and High Education Denothe, University of Florence, Florence, Italy; 
2University of Florence, Florence, Italy; 3Università di Firenze, Florence, Italy; 
4Klinikum der Universitat Munchen, Munchen, Germany.
Background: Podocyte injury is a central pathomechanism of glomerulosclerosis. 
Regeneration of lost podocytes from podocyte progenitors along Bowman’s capsule can 
occur but the number of new podocytes seemed to be rather low. We hypothesized that 
traditional 2D tissue analysis underestimates podocyte regeneration and that injury and 
regeneration are not equally distributed between cortical and juxtamedullary nephrons.
Methods: To test this concept we employed Nphs2.rtTA;TetO.Cre;mT/mG and Pax2.
rtTA;TetO.Cre;mT/mG mice to quantify adriamycin (ADR)-related podocyte loss and 
de novo podocyte formation from Pax2+ podocyte progenitors by lineage tracing, using 
Z-stack confocal microscopy for 3D quantitative analysis and STED microscopy to assure 
integration of new podocytes into the glomerular filtration barrier. CXCL12 inhibition was
used to assess drug-related enhancement of podocyte regeneration.
Results: 2D analysis underestimated the percentage of glomeruli showing podocyte 
regeneration in comparison to 3D (8.05% vs 25.23% p<0.05). Doxycyclin-induced 
podocyte labeling in Nphs2.iCreER;mT/mG mice revealed a higher number of podocytes 
in juxtamedullary glomeruli vs. cortical glomeruli (52.56±1.5 vs 81.96±2.85, p<0.001). In 
contrast, doxycyclin-induced Pax2+ progenitor labeling in Pax2.rtTA;TetO.Cre;mT/mG  
mice revealed that less juxtamedullary glomeruli had progenitors along Bowman’s capsule 
vs. cortical glomeruli (79.03±0.15% vs 46.15±2.2%, p<0.05). Upon ADR exposure, Nphs2.
iCreER;mT/mG mice juxtamedullary glomeruli lost a higher percentage of podocytes as 
compared to cortical glomeruli (13.79±3.18% vs 34.11±1.65%, p<0.05). Pax2.rtTA;TetO.
Cre;mT/mG mice revealed that podocyte regeneration was limited in juxtamedullary 
glomeruli, while cortical glomeruli revealed new progenitor-derived podocytes, a 
difference that increased with CXCL12 inhibition (24.03±4.8 vs 75.96±4.8, p<0.05). STED 
microscopy revealed the ultrastructure of new podocytes, including secondary and tertiary 
foot processes. CXCL12 blockade also resulted in proteinuria improvement (p<0.05 at 28 
days).
Conclusions: These results show that juxtamedullary and cortical nephrons differ in 
their capacity to regenerate podocytes upon injury and explain the clinical observation that 
FSGS starts and is more severe in juxtamedullary nephrons.
Funding: Government Support - Non-U.S.
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Mechano-Growth Factor (MGF) Mediation of Glomerulosclerosis (GS) 
Involves Activation of PKC
Yongxin Gao,2 Emma P. Bueno,1 Nanjoo Shin,2 Leighton R. James,1 
Charles W. Heilig.1 1UF COM- Jacksonville, Jacksonville, FL; 2University of 
Florida, Jacksonville, FL.
Background: We previously reported PKC ß1 and PKC a activation in our non-diabetic 
GS mouse model Fvb Os/+, with reduced glomerular numbers, glomerular hypertension, 
and increased SNGFR. GS develops rapidly after birth leading to renal failure and 
premature demise. MGF is expressed in the glomeruli and is responsive to stretch in other 
tissues. Here we investigate MGF expression in Fvb Os/+ glomeruli, in cultured Fvb Os/+ 
mesangial cells(MC), and potential MGF-regulation of PKC activation. We hypothesize 
that MGF activation of PKC may explain the GS in Fvb Os/+ mice and excess extracellular 
matrix (ECM) in cultured Fvb Os/+ mesangial cells (MC).
Methods: 1. Fvb Os/+ and Fvb +/+ mouse kidneys were harvested and fixed at age 4 
weeks for PAS staining and immunolabelling (0 - 4+) for MGF, active PKC ß1 and active 
PKC a; Total glomerular or MC proteins were also isolated for Western analyses of selected 
proteins then semiquantitated. 2. Primary culture MC’s from mice of both genotypes were 
grown to 80-100 % confluence in DMEM medium 8mM glucose,10% FBS at 37 C and 
5% CO2. 3. Normal mouse MC’s transduced (pWZLneo MoMuLV expression vector) to 
overexpress (MGF-S), or suppress (MGF-AS) MGF were examined with Western analyses 
to investigate potential PKC regulation by MGF. 4. Mean ± SEM was determined and 
statistical analyses performed with one way ANOVA, & Students T-test where indicated.
Results: 1. Fvb Os/+ glomeruli exhibited > 2-fold (P < .005) increase in glomerular 
MGF vs. control. 2. Fvb Os/+ MC’s had 1.6-fold elevated MGF (P < 0.05), with increased 
active PKC ß1 (3.5-fold, P < 0.005) and active PKC a (2.9-fold, P < 0.005). This correlated 
with increased fibronectin (FN) and Type IV collagen (Col-IV) in the cells. 3. MGF-S had 
4.5-fold overexpression of MGF protein, (P < 0.02), with increased active PKC ß1 (4-fold, 
P < 0.05) and PKC a (4-fold P < 0.05). MGF-AS had 50% suppression of basal PKCß1.
Conclusions: 1. Increased MGF was observed in FvbOs/+ glomeruli and cultured Fvb 
Os/+ MC, correlating with PKC B1 and PKC a activation in both. High MGF and PKC 
activation were maintained with passage of Fvb Os/+ MC in vitro, associated with high FN 
and Col-IV. 2. MGF-S also exhibited activation of PKC ß1 and PKC a, which may mediate 
the increased ECM in these cells as well.
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The Molecular Mechanism of Action of AT2R Agonist Compound 21 
(C21) on Ameliorating Murine FSGS
Min-Chun Liao,1 Shiao-Ying Chang,1 Chao-Sheng Lo,1 Isabelle Chenier,1 
Julie R. Ingelfinger,2 John S. Chan,1 Shao-Ling Zhang.1 1CRCHUM, Universite 
de Montreal, Montreal, QC, Canada; 2The New England Journal of Medicine, 
Boston, MA.
Background: We previously reported (J Pathology 2017) that angiotensin II type 2 
receptor (AT2R) deficiency is associated with podocyte loss and podocyte transition from 
normal morphology to apoptotic and/or fibrotic-like phenotype via hedgehog interacting 
protein (Hhip) gene expression. Here, we examined whether the administration of 
AT2R agonist Compound 21 (C21) would ameliorate murine FSGS and investigated the 
underlying mechanisms both in vivo and in vitro.
Methods: FSGS was induced by a single intravenous injection of doxorubicin 
(18 mg/kg, body weight, in saline) in both male wild type (WT) and AT2R knockout (KO) 
mice at 8 weeks of age. Mice were euthanized 4 weeks after doxorubicin injection. Five 
subgroups of mice including WT [Control (WT-Con), WT-FSGS, FSGS treated with C21 
(0.3 mg/kg/day, intraperitoneal (i.p.) (WT-FSGS-C21] and AT2R KO mice [Control (KO-
Con) and KO-FSGS] were studied. Physiological parameters, renal morphology/function 
analysis and molecular analysis in glomeruli were carried out; in vitro studies were done in 
a mouse podocyte cell line (mPODs).
Results: FSGS was far more severe in AT2RKO mice as compared to WT-FSGS mice, 
evidences by profound glomerulosclerosis on Periodic Acid Schiff and Masson trichrome 
staining, increased podocyte loss (synaptopodin- and p57-immunofluorescence (IF) 
staining) and more proteinuria (urinary albumin/creatinine ratio measurement and urinary 
Coomassie blue staining), together underscoring the key role of AT2R in FSGS-related 
podocyte-glomerulopathy. As compared with WT-Con, WT animals with FSGS had high 
numbers of parietal epithelial cells (PECs), which are paired homeobox 2 (Pax2) positive 
cells, but fewer podocytes (IF-p57 positive and IF-Pax2 negative cells). Intriguingly, C21 
administration (WT-FSGS-C21) ameliorated the features of FSGS (proteinuria, renal 
morphology/function) via inhibition of glomerular Hhip expression. In vitro, increased 
Hhip and Pax2 gene expression with transient transfection of respective cDNAs promoted 
apoptotic and/or fibrotic-like phenotype shift in podocytes.
Conclusions: The glomerular AT2R-Pax2-Hhip axis appears to be involved in the 
transition of podocytes to PECs; we speculate such transition occurs through AT2R-Pax2-
Hhip modulation of PEC-related profibrotic effects and subsequent podocyte loss/sclerosis 
in FSGS
Funding: Government Support - Non-U.S.
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Klotho Ameliorates Diabetic Glomerulonephritis by Suppressing TRPC6 
in Podocytes
Jinho Lee, Tsogbadrakh B. Bodokhsuren, Sohyun Yun, Hyunjin Ryu, 
Eunjeong Kang, Minjung Kang, Curie Ahn, Kook-Hwan Oh. Seoul National 
University Hospital, Seoul, Republic of Korea.
Background: Glomerular podocyte injury is the hallmark of diabetic nephropathy 
(DN). This damage is related with increase of transient receptor potential channel 6 
(TRPC6) calcium channel in podocytes, mediating calcium influx, thus causing foot process 
effacement. Since klotho is reported as a TRPC6-suppressing factor in nephrectomized 
mice, we hypothesized that klotho may also inhibit diabetes-induced TRPC6 up-regulation 
in podocytes, thereby reduce albuminuria.
Methods: We injected recombinant klotho protein (rKL) into db/db and db/m mice for 
8 weeks, and collected the urine and the kidney. We treated rKL to cultured podocytes, with 
or without high glucose (HG, 30mM) exposed.
Results: rKL treated db/db mice showed dramatic glomerular recovery, including 
amelioration of basement membrane thickening and foot process effacement, as well as 
remarkably reduced albuminuria. We also confirmed increased renal expression of TRPC6 
and its downstream molecules, PI3K and calcineurin in diabetic mice, were normalized by 
rKL. Next, we analyzed TRPC6, PI3K and calcineurin in podocytes. HG-mediated increase 
of TRPC6 in podocytes is normalized by rKL treatment, showing improved cell survival 
and reduced intracellular calcium in HG environment.
Conclusions: Our data reveals that klotho protects the podocytes in diabetic condition 
by suppression of TRPC6.
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rKL treat to db/db mice induced: a) reduced albuminuria, and b) glomerular recovery.
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A TRPC5 Inhibitor Protects Podocytes from Injury in a Minimal Change 
Disease Rat Model
Yiming Zhou,1,2 Fan Zhang,1,2 Andrew J. Watts,1,2 Katherine A. Vernon,1,2 
Anna Greka.1,2 1Brigham and Women’s Hospital/Harvard Medical School, 
Boston, MA; 2Broad Institute of MIT and Harvard, Cambridge, MA.
Background: Inhibition of the Rac1-TRPC5 disease pathway in podocytes using 
specific TRPC5 ion channel inhibitors has been shown to protect from podocyte injury and 
loss in two pre-clinical animal models: a transgenic rat model of FSGS and a spontaneous 
hypertensive rat model of FSGS. Since the Rac1-TRPC5 disease pathway has been 
implicated in the earliest cytoskeletal podocyte changes leading to the development of 
nephrotic range proteinuria, we asked whether TRPC5 inhibition can confer benefit in a rat 
model of minimal change disease (MCD).
Methods: We investigated the effect of the specific TRPC5 inhibitor AC1903 in a 
puromycin aminonucleoside (PAN)-induced rat model. PAN treatment has been shown 
to induced podocyte injury, foot process effacement and proteinuria with no glomerular 
histological changes in rats, which most closely resembles human MCD.
Results: We found that a single injection of 50 mg/kg PAN caused podocyte injury and 
led to a significant increase in proteinuria 7 days after a single injection of PAN. Treatment 
with AC1903 administered intraperitoneally (i.p.) twice daily significantly reduced the 
amount of proteinuria induced by PAN injection as measured in 24 hour urine collected 
in metabolic cages on day 7 post-PAN injection. In histologic analysis of rat kidney tissue, 
no glomuerular lesions or other obvious changes were found, whereas electron microscopy 
revealed severe foot process effacement (FPE) induced by single PAN injection. This 
was significantly ameliorated after treatment with AC1903. Western blotting from rat 
kidney lysates showed that treatment with AC1903 preserved synaptopodin and podocin 
abundance in PAN rats.
Conclusions: Taken together, these results show that inhibition of TRPC5 ion channels 
by AC1903 protects podocytes from injury in a rat model of MCD. Our data thus highlight 
the potential of this therapeutic strategy for the full spectrum of nephrotic syndrome from 
MCD to FSGS.
Funding: NIDDK Support
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Differential Effects of TRPC5 and TRPC6 Channels in Angiotensin II 
Induced Glomerular Hyperpermeability
Carl M. Öberg,1,2 Julia Dolinina,1,2 Anna Rippe.1 Renal Physiology & Peritoneal 
Dialysis Group 1Department of Clinical Sciences Lund, Lund University, Lund, 
Sweden; 2Department of Nephrology, Skane University Hospital, Lund, Sweden.
Background: Angiotensin II (Ang II) rapidly induces marked, dynamic increases 
in the permeability of the glomerular filtration barrier (GFB) in rats. After binding to its 
receptor(s), Ang II elicits Ca2+ influx into cells mediated by TRPC5 and TRPC6 (transient 
receptor potential canonical type 5 and 6). We here identifed TRPC5 and TRPC6 as 
regulators of Ang II induced glomerular hyperpermeability while the latter also appears to 
be involved in the hemodynamic effects induced by Ang II.
Methods: In anesthetized Sprague-Dawley rats, the left ureter was cannulated for urine 
collection and blood access was achieved. Rats were infused with Ang II (80 ng kg–1 min–1) 
alone, or together with the TRPC5 blocker clemizole or low dose La3+ (activates TRPC5, 
blocks TRPC6) or high dose La3+ (blocks both TRPC5 and TRPC6). Plasma and urine 
samples were taken during baseline and at 5 min after the start of the infusions and analyzed 
by high-performance size-exclusion chromatography for determination of glomerular 
sieving coefficients (θ) for Ficoll 10-80Å (1-8 nm).
Results: Ang II infusion into rats caused marked increases in glomerular permeability 
to large Ficoll molecules (Ficoll 50–80Å), which were abrogated by the TRPC5 blocker 
clemizole, having no effect on glomerular filtration rate (GFR) or Ang II mediated increase 
in MAP (ΔMAP). In contrast, agents blocking TRPC6 (high and low dose La3+) significantly 
lowered ΔMAP and nearly completely abrogated Ang II induced hyperpermeability effects. 
The higher dose of La3+, blocking both TRPC5 and TRPC6, significantly lowered left-
kidney GFR.
Conclusions: Our data unveil differential effects of Ca2+ signaling via TRPC5 and 
TRPC6 following Ang II stimulation. Especially, it appears that inhibition of TRPC5 in rats 
can abrogate AngII-induced glomerular hyperpermeability without affecting GFR or Ang II 
induced increases in MAP. Inhibition of TRPC5 may thus be a potential target for a novel 
antiproteinuric agent.
Funding: Government Support - Non-U.S.
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Small Molecule Inhibition of TRPC5 Protects Against Podocyte Injury 
and Proteinuria in FSGS
Amy D. Westerling-Bui,1 Maria Beconi,1 Hien G. Hoang,1 Maolin Yu,2 
Matthew Daniels,1 Goran Malojcic,1 Mark Ledeboer,1 Liron Walsh,1 
Thomas T. Tibbitts,1 Jean-Christophe P. Harmange,1 Peter H. Mundel.1 
1Goldfinch Bio, Cambridge, MA; 2Goldfinch Bio, Cambridge, MA.
Background: FSGS is a rare kidney disorder of the podocyte with a high likelihood 
of progression to kidney failure. The activation of the TRPC5-RAC1 pathway in podocytes 
is a critical driver of proteinuria in many forms of familial and sporadic FSGS. The 
Ca2+permeable TRPC5 channel is a critical mediator of proteinuria in FSGS. Inhibition of 
TRPC5 channel activity protects against proteinuria and podocyte loss in AT1R transgenic 
and Dahl salt sensitive rats (Zhou et al. Science, 2017).
Methods: We performed high throughput screening of a structurally diverse compound 
collection followed by lead optimization for the development of several potent TRPC5 
inhibitors. We then analyzed the TRPC5 inhibitors in several in vitro models of podocyte 
injury (protamine sulfate induced cytoskeletal disruption, restoration of stress fibers in 
synaptopodin-depleted podocytes, inhibition of pathogenic podocyte migration) and in the 
DOCA-salt rat model of FSGS in vivo.
Results: Here we report the identification of potent and selective small molecule 
inhibitors of TRPC5. activity against TRPC5 and selectivity across other TRP channels 
were determined using FLIPR based assays and electrophysiology. We show that TRPC5 
inhibition protects against protamine sulfate induced loss of stress fibers. TRPC5 inhibition 
also restores stress fibers in podocytes after knockdown of synaptopodin. We further show 
that inhibition of TRPC5 suppresses pathogenic podocyte motility in a scratch assay. 
Finally, we demonstrate that inhibition of TRPC5 suppresses proteinuria in hypertension-
induced FSGS in uninephrectomized DOCA salt rats without altering blood pressure.
Conclusions: In summary, we have identified new selective small molecule inhibitors 
of TRPC5 for the treatment of proteinuria in FSGS.
Funding: Commercial Support - Goldfinch Bio, Inc.
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Aldosterone Causes Albuminuria by Inducing MMP-Mediated  
Glomerular Endothelial Glycocalyx Dysfunction
Matthew J. Butler,1 Raina D. Ramnath,1 Hiroyuki Kadoya,2 Rebecca R. Foster,1 
Janos Peti-Peterdi,2 Simon C. Satchell.1 1University of Bristol, Bristol, United 
Kingdom; 2University of Southern California, Los Angeles, CA.
Background: Aldosterone contributes to renal disease. Mineralocorticoid receptor 
(MR) inhibitors slow disease progression but side effects limit their use. Damage to 
the endothelial glycocalyx (glx), a luminal biopolymer layer, has been implicated in 
pathogenesis of endothelial dysfunction and albuminuria. We investigated if glx damage 
contributes to aldosterone-induced renal disease.
Methods: In vitro human glomerular endothelial cells (GEnC) were exposed to 
0.1nM aldosterone for 5 days +/- 1μm spironolactone. In vivo mice received aldosterone 
(0.6μg/g/day via osmotic minipump) and 1.0% NaCl drinking water +/- 5mg/kg MMP2/9 
inhibitor I.P. daily. Tail cuff blood pressure (BP) measurements were conducted after 
5 days training. MMP2 activity was studied using a specific activity assay. Multiphoton 
microscopy was used to measure the glomerular sieving coefficient for albumin (GSCalb) 
and a novel peak-to-peak method was developed to assess changes in GEnC glx thickness 
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over time. ELISAs were used to measure syndecan-4 ectodomain concentrations and urine 
albumin levels.
Results: In vitro aldosterone reduced GEnC syndecan-4 ectodomain expression 0.76 
fold (p=0.02) and increased MMP2 mRNA 4.5 fold (p=0.0003). Spironolactone blocked 
these effects. In vivo aldosterone resulted in significant albuminuria by day 10. Aldosterone 
increased glomerular MMP2 mRNA expression 5.3 fold (p=0.003) and plasma active 
MMP2 (22 vs 27ng/ml, p=0.045) without altering the systolic BP. The GSCalb increased 
7.6 fold by day 10 (p=0.0079) and the GEnC glx thickness fell from 1.1μm to 0.59μm 
(p=0.0013). No significant changes were detected in controls. Daily IP MMP2/9 inhibitor 
prevented glx loss, maintained the GSCalb and prevented albuminuria without affecting the 
BP. Changes in glx depth predicted changes GSCalb within the same glomeruli (R
2=0.8185, 
p=0.0028), highlighting the importance of the glx in limiting albumin filtration.
Conclusions: Syndecan-4 (a key glx component and known substrate for MMP2) is 
shed in response to aldosterone via an MR-MMP dependent pathway. In vivo aldosterone 
results in significant thinning of the GEnC glx and albuminuria. MMP inhibition preserved 
the glx and prevented albuminuria and could represent a novel potential therapeutic strategy.
Funding: Government Support - Non-U.S.
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Ezetimibe Protects from Renal Dysfunction in a Mouse Model of Alport 
Syndrome
Judith T. Molina David,1,2 Jin Ju Kim,1,2 Javier T. Varona Santos,1,2 
Sandra M. Merscher,1,2 Alessia Fornoni.1,2 11Katz Family Division of Nephrology 
and Hypertension, Department of Medicine, University of Miami Miller School of 
Medicine, Miami, Florida., Miami, FL; 22Peggy and Harold Katz Family Drug 
Discovery Center, University of Miami Miller School of Medicine, Miami, FL.
Background: Alport Syndrome (AS) is characterized by renal disease inevitably 
progressing to end-stage kidney disease (ESKD), and no treatment strategies are currently 
available. We have recently discovered an important contribution of renal parenchyma lipid 
accumulation to ESKD in mice affected by AS. We hypothesized that treatment with the 
lipid-lowering compound ezetimibe (EZ), which targets the cholesterol transport protein 
Nieman Pick C1-like 1 protein and has been shown to modulate fatty acid uptake in other 
organs, can prevent renal lipid accumulation and podocyte injury in an experimental mouse 
model of AS thus improving renal function.
Methods: EZ was administered for 4 weeks by oral gavage at 5 mg/kg to 4-week-old 
knockout (KO) and wildtype (WT) mice. All mice were sacrificed at 8 weeks of age. The 
following four groups of mice were analyzed: WT, WT + EZ, KO and KO + EZ.
Results: We detected a significant decrease in the albumin-to-creatinine ratio (ACR) in 
KO mice treated with EZ when compared to untreated KO mice (p<0.01). Additionally, a 
decrease of BUN and serum creatinine levels was observed (p<0.05). EZ treatment of KO 
mice also resulted in a significant reduction in the body weight loss observed during disease 
progression (p<0.05). Furthermore, EZ normalized renal lipid metabolism as indicated 
by decreased total kidney cortex triglyceride content in EZ treated KO mice compared to 
untreated mice (p<0.05).
Conclusions: Based on these results, we conclude that EZ improves renal function 
in experimental AS and could represent a new repurposing strategy for the treatment of 
affected patients.
Funding: Private Foundation Support
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Differential Pathogenic Roles of Notch4 and Notch3 in the Progression of 
HIV Associated Nephropathy
Jessica Y. Idowu,2 Trisha Home,1 Pravin C. Singhal,3 Timothy A. Fields,2 
Madhulika Sharma.2 1University of Kansas Medical Centre, Kansas City, KS; 
2University of Kansas Medical Center, Kansas, KS; 3North Shore LIJ Health 
System, Great Neck, NY.
Background: Notch pathway activation plays a central role in pathogenesis of many 
glomerular diseases. We have previously shown that Notch 4 and Notch 3 were up-regulated 
in various renal cells in HIV associated Nephropathy (HIVAN) patients and rodent models 
of HIVAN. Notch inhibition by gamma secretase inhibitors ameliorated disease progression 
in the Tg26 mouse model of HIVAN. Since gamma secretase inhibitors are associated with 
toxicity in clinics, here we explore individual effects of genetic inhibition of Notch4 and 
Notch3 on HIVAN pathogenesis.
Methods: Tg26 mice were bred with mice deleted for the intracellular domain of 
Notch 4 and Notch 3 separately to generate Tg26 mice with homozygous Notch4 deletion 
and homozygous Notch3 deletion, respectively. The effect of Notch4 and Notch3 deletion 
in Tg26 mice was determined by analyzing renal function, histology, cell proliferation/ 
podocyte differentiation and inflammatory markers.
Results: Deletion of either Notch 4 or Notch 3 in Tg26 mice significantly decreased 
the mortality rate and reduced kidney injury in Tg26 mice. While, Notch 4 deletion in male 
Tg26 mice reduced kidney injury, controlled cell proliferation, cell differentiation and 
inflammatory response of NF kappa B positive cells in Tg26 mice, it was not enough to 
significantly reduce proteinuria and blood urea nitrogen (BUN) levels. In contrast, genetic 
depletion of Notch3 appeared to be effective in a broader way, controlling proteinuria and 
BUN in Tg26 mice. In addition, histological studies indicated a significant improvement in 
kidney injury as evident by the reduction in glomerulosclerosis, tubule-interstitial fibrosis 
and interstitial inflammation in Notch3 deleted Tg26 mice. More studies are underway to 
reveal subtle roles of Notch4 and Notch3 activation in HIVAN.
Conclusions: Our study supports a non-redundant role of Notch 4 and Notch 3 
in HIVAN pathogenesis and suggests therapeutic implications of Notch3 and Notch 4 
inhibition in HIV associated nephropathy.
Funding: NIDDK Support
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Targeted Inhibition of Calpain-1 and -2 Activities Improves the  
Progression of Proteinuric Kidney Disease in Mice Following Podocyte 
Injury
Xuefei Tian, Kazunori Inoue, Christopher E. Pedigo, Shuta Ishibe. Yale 
University School of Medicine, New Haven, CT.
Background: We have previously shown that calpain activation occurs in mice 
glomerular injury models and in urine samples of proteinuric patients with FSGS. However, 
calpain’s function in podocyte biology has not been fully elucidated. This study examines 
whether the decrease in calpain-1/-2 activities, by calpain inhibitor or deletion of podocyte-
associated CAPN4 improves the progression of mice podocyte injury.
Methods: Using the proteinuric models Tln1fl/fl Podcin-Cre mice (Germline Talin1 
podocyte knockout mice, Tln1 KO) and Doxycycline inducible Tln1fl/fl Pod-rtTA TetO-
Cre mice (iTln1 KO), inhibiting calpain-1/-2 activities with calpain inhibitor III (CI) was 
examined for albuminuria, histological changes, and kidney function. Furthermore, a 
mouse model with podocyte-specific deletion of CAPN4 was generated abrogating both 
calpain-1/-2 activities. We investigated the above changes on the Tln1fl/fl CAPN4fl/fl Podcin-
Cre mice (Tln1+CAPN4 DKO) and Tln1fl/fl Pod-rtTA TetO-Cre mice (iTln1+CAPN4 DKO).
Results: Treatment of Tln1 KO mice with CI (30mg/kg B.W/day, i.p) was started at 
2 weeks of age when robust albuminuria was already present. At 8 weeks, significantly 
reduced albuminuria was observed in the CI treated mice (18229.61±1537.80 vs 12963.55 
±1182.49 μg/mg creatinine). Furthermore, treatment with CI prolonged the survival of the
Tln1 KO mice (median survival: 9 weeks vs 4 weeks). Treatment with CI for 4 weeks in
the iTln1 KO mice also reduced the degree of albuminuria (4949.55±320.46 vs 3327.87
±217.28 μg/mg creatinine), improved renal histological lesions, and kidney function. Mice
with genetic ablation of CAPN4 in podocytes on the background of Tln1 KO or iTln1 
KO reduced the degree of albuminuria (18574.82±1703.31 vs 13398.37 ±1457.07 μg/mg 
creatinine in Tln1 KO vs Tln1+ CAPN4 DKO at 8 weeks of age; 4335.27±438.42 vs
2445.92 ±367.28 μg/mg creatinine in iTln1 KO vs iTln1+CAPN4 DKO), while also
improving the renal histological lesions and kidney function, and leading to the prolonged 
survival (median survival: 9 weeks vs 4.5 weeks in Tln1+CAPN4 DKO vs Tln1 KO).
Conclusions: Proteinuric kidney disease in both germline Tln1 KO or iTln1 KO mice 
are attenuated by reduction of calpain-1/-2 activities, thus representing a potential novel 
therapeutic strategy for the progression of proteinuric kidney disease.
Funding: NIDDK Support
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Elucidating the Pathogenesis of Focal Segmental Glomerulosclerosis Using 
CRISPR/Cas9 Mediated Genome Engineering
Linus Butt,2 David Unnersjö-Jess,1 Markus M. Rinschen,2 Dervla Reilly,2 
Lioba Ester,2 Hjalmar Brismar,1 Paul T. Brinkkoetter,2 Bernhard Schermer,2 
Thomas Benzing.3 1Royal Institute of Technology, Solna, Sweden; 2University 
Hospital Cologne, Cologne, Germany; 3University of Cologne, Köln, Germany.
Background: NPHS2 encodes for the PHB-domain protein podocin and is one of 
the most frequently mutated genes in patients with Focal Segmental Glomerulosclerosis 
(FSGS). Currently, loss of podocytes is regarded as the hallmark of the pathogenesis of 
FSGS. Investigating the initial molecular events causing podocyte injury and depletion is of 
utmost importance for future preventive and therapeutic strategies.
Methods: Here, we present a mouse model for a late-onset FSGS phenotype. Using 
CRISPR/Cas9 mediated genome engineering, we separately integrated two point mutations 
in the Nphs2 gene which, in compound-heterozygosity, represent a commonly found 
genotype in patients with a late-onset.
Results: In vivo data of compound-heterozygous animals reveal an early onset of 
mild proteinuria long before the manifestation of FSGS lesions. The proteinuria increases 
gradually and reaches nephrotic range in young adult mice (> 8 weeks). Histologically, 
FSGS lesions are found between 8 and 20 weeks. By using STED microscopy at different 
time points (P0, 2, 4, 8, 20 weeks) we show a shortening and widening of the foot processes 
and a decreasing containment of the capillary surface by the secondary processes in 
compound-heterozygous in comparison to control mice. Quantification of podocyte 
numbers in kidney sections revealed a progressive decline in mutant mice. The glomerular 
proteome at 3 weeks shows a general decrease in podocyte specific proteins, in particular 
of polarity related proteins.
Conclusions: In this study, we have generated a late-onset FSGS disease model 
resembling human genetic disease by using CRISPR/Cas9 mediated genome engineering. 
Mutant mice develop progressive proteinuria accompanied by a full blown morphological 
manifestation of FSGS. Delineation of the foot process microarchitecture by STED 
microscopy shows a loss of the distinct microarchitecture of the podocyte and a decreased 
containment of the capillary surface as an early pathological sign that precedes the onset of 
massive proteinuria. Interestingly, the containment is relatively steady throughout the first 
phase of podocyte depletion, possibly by expansion of individual foot processes. The shift 
in the glomerular proteome is consistent with a podocyte dedifferentitation and/or loss of 
polarity.
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Podocyte-Specific Deletion of Hypoxia-Inducible Factor 1α (Hif-1α) 
Identifies Downstream Mediators That Are Targets to Prevent  
Proteinuria and Subsequent Glomerulosclerosis
Xiaoyan Liang, H. William Schnaper, Tomoko Hayashida. Northwestern 
University, Chicago, IL.
Background: While augmentation of signals mediated by HIFs preserves organs in 
ischemia, the role of HIFs in more chronic glomerulopathies following podocyte injury is 
rather controversial. We recently reported that mice in which systemic knockout of HIF-
1α is induced at the age of 6 weeks demonstrate significantly less fibrosis in Adriamycin 
(ADR)-induced glomerulopathy. Others previously reported that podocyte-specific deletion 
of von Hippel Lindau protein, that targets HIFs for degradation, resulted in increased 
expression of HIFs and severe glomerulopathy in mice. These results suggest that HIFs 
aggravate glomerular injury. Here, we further evaluated the roles of HIF specifically in 
podocytes, using mice that lack podocyte HIF-1α.
Methods: HIF-1αf/f mice were crossed with NPHS2-Cre mice. Adriamycin (ADR, 
10mg/kgBW) was administered intravenously to the HIF-1α -/-Podo or their wild-type (WT) 
littermates to induce glomerulopathy, and urine and kidneys were obtained on day14. RNA 
was isolated from cryosectioned glomerular samples using laser-capture microdissection, 
and HIF-1α-target gene were evaluated by qPCR. HIF-1α knockdown podocytes were 
generated using lenti-viral shRNAs.
Results: HIF-1α-/-Podo mice were viable and no proteinuria was detected basally. ADR 
caused severe proteinuria, glomerular fibrosis and podocyte effacement in WT mice, 
whereas in HIF-1α-/-Podo mice, proteinuria and glomerular sclerosis were minimally observed 
and podocyte structures were preserved. Among known HIF-1α-target genes tested, Irg2 
and Mif were increased in glomeruli of WT mice treated with ADR but not in HIF-1α-/-Podo 
mice, whereas ApoE expression was elevated in both WT and HIF-1α-/-Podo glomeruli. PGK 
expression was not changed in either group of mice. In cultured mouse podocytes, Mix1, 
Eef1a1 and ApoE were differentially expressed in the presence or absence of HIF-1α after 
TGF-β1 treatment, whereas Irf7, Mt2 and Plod2 were regulated independent of HIF-1α.
Conclusions: We have identified several HIF-1α target genes that could play a role 
in in proteinuria and glomerulosclerosis. These could be novel therapeutic targets for 
glomerulopathy.
Funding: NIDDK Support
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Inhibiting Podocyte Endoplasmic Reticulum Stress-Mediated Apoptosis to 
Treat Genetic Nephrotic Syndrome
Sun-Ji Park, Ying M. Chen. Division of Nephrology, Washington university in St. 
Louis, St. Louis, MO.
Background: Pierson syndrome (OMIM 609049) characterized by congenital 
nephrotic syndrome (NS) and diffuse mesangial sclerosis, is caused by mutations in LAMB2 
encoding laminin β2. The major laminin heterotrimer in the mature glomerular basement 
membrane is laminin α5β2γ1, and laminin trimerization occurs in the endoplasmic 
reticulum (ER). There is no effective treatment for Pierson syndrome and most cases of 
genetic forms of NS. Here for the first time, we have shown that targeting podocyte ER 
stress-specific apoptosis may provide a new therapeutic approach to treat Pierson syndrome 
and other genetic nephrotic syndromes.
Methods: To recapitulate human Pierson syndrome, Lamb2 null mice were generated. 
We isolated mouse glomeruli and cultured primary podocytes before the onset of significant 
proteinuria to investigate ER stress signaling cascades. Western blot was utilized to 
determine ER stress-induced pro-apoptotic pathway. Furthermore, Lamb2-/- mice were 
crossed with Chop-/- mice to investigate the functional consequence of CHOP (C/EBP 
homologous protein) deletion in the disease development.
Results: At the early stage of NS, LAMB2 deficiency induced podocyte ER stress and 
selectively activated ATF6 (activating transcription factor 6) pathway without involvement 
of IRE1α and PERK pathways. Moreover, LAMB2 depletion differentially triggered 
ER stress-specific CHOP pro-apoptotic pathway, but not caspase 12 and JNK pathways, 
in mutant podocytes. Most importantly, CHOP ablation in Lamb2-/- mice significantly 
prolonged the lifespan of Lamb2 null mice.
Conclusions: Despite the importance of podocyte ER dysfunction in the pathogenesis 
of NS, there is no treatment that targets the podocyte ER. Our promising results indicate 
that antagonizing the pro-apoptotic CHOP pathway in ER-stressed podocytes may lead to 
paradigm-shifting innovative therapeutic strategies to combat genetic or acquired NS.
Funding: Other NIH Support - NIH grants R01 DK105056A1, R03DK106451, 
K08DK089015, Other U.S. Government Support
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GLEPP1 Deficiency Alters GBM Composition and Extracellular Matrix 
(ECM) Deposition in Aging Mice
Eva Koenigshausen,1 Ernest Kaufmann,1 Christian Weigel,1 Philip Schüppler,1 
Catherine Meyer-Schwesinger,2 Magdalena Woznowski,1 Lars C. Rump,1 
Lorenz Sellin.1 1Medical Faculty Heinrich-Heine-University Düsseldorf, 
Düsseldorf, Germany; 2University of Hamburg, Hamburg, Germany.
Background: Proteinuria results from a defect in the glomerular filter which is 
composed of the fenestrated endothelium, the glomerular basement membrane (GBM) and 
the podocytes. Major components of the GBM are collagen IV (col IV), agrin, nidogen and 
laminin. Col IV of the mature GBM is composed of alpha 3, 4, 5 chains while the immature 
GBM is built of col IV alpha 1, 2, 1 chains. Mutations in the GLEPP1 gene lead to nephrotic 
syndrome in humans. GLEPP1 is a receptor tyrosine phosphatase within podocytes and 
its deficiency leads to morphologic GBM alterations and proteinuria in aging mice. Its 
molecular function is still unknown.
Methods: GLEPP1 WT and KO mice were analyzed at 4, 6 and 10 months of age. 
Glomeruli were isolated. For col IV analysis, glomeruli were digested with collagenase 
to release col IV NC1 domains. Immunofluorescence of mouse kidneys was performed 
for col IV chains. Primary podocytes were isolated and analyzed for purity by WT1 
immunofluorescence staining. Podocytes were lysed, ECM digested with collagenase and 
subjected to western blot analysis. Col IV chain specific antibodies against NC1 domains of 
col IV alpha 1, 2, 3 and 5 were used. In addition, antibodies against laminin alpha 1, agrin 
and nidogen 1 were used.
Results: Glomerular col IV alpha 1 and 2 protein chain expression is significantly 
enhanced in 6 and 10 month old GLEPP1 KO mice, while col IV alpha 1 and 2 protein 
expression levels are reduced in GLEPP1 KO mice at 4 months of age. Glomerular laminin 
alpha 1 protein expression is significantly elevated in GLEPP1 KO mice compared to 
controls at 10 months of age. Immunofluorescence of col IV chains in kidney sections 
of GLEPP1 WT and KO mice localized enhanced expression of immature col IV chains 
within the GBM. Purity of primary podocytes of GLEPP1 WT and KO mice was confirmed 
by WT1 staining. Col IV deposition by GLEPP1 KO primary podocytes in cell culture 
resembles the col IV expression pattern with increased expression of col IV alpha 1 and 2 
and decreased expression of col IV alpha 5 in GLEPP1 KO mice. These data confirm our 
previous results from rt-PCR and immunofluorescence.
Conclusions: GLEPP1 deficiency leads to an immature GBM composition which is 
responsible for less mechanical stability of the GBM and proteinuria in aging mice and 
humans.
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Development of a Glomerular Specific Targeting System with  
Perfluorocarbon Nanoparticles
Jin Wei,1 Ryan Grabau,1 Jie Zhang,1 Lei Wang,1 Samuel Wickline,1 Hua Pan,1 
Ruisheng Liu.2 1USF, Tampa, FL; 2University of South Florida College of 
Medicine, Tampa, FL.
Background: Perfluorocarbon (PFC) nanoparticles (NPs) are primarily limited to 
intravascular space. Glomerular basement membrane (GBM) is the only site where collagen 
IV (Col4) has direct contact with blood via fenestrated capillary endothelium. Our goal is to 
develop a novel Col4-targeted PFC NP that selectively targets kidney glomeruli as a local 
therapeutic vehicle.
Methods: Col4 -targeted PFC NPs were formulated by coupling PFC NPs to a Col4-
targeting ligand. The binding specificity and efficiency of the Col4 -targeted NPs were 
evaluated on Col4 coated plate surfaces, in vitro with primary glomerular endothelial cells 
and mesangial cells, and in vivo in C57BL/6 mice.
Results: Rhodamine labeled Col4 targeted or non-targeted PFC NPs were applied in 
Col4 pre-coated 96 wells plate at stepwise doses (1, 2, 5, 10 and 20 ul/ml). The binding 
affinity was determined by fluorescence intensity with IVIS. The wells incubated with Col4 
targeted PFC NPs showed a dose dependent increase in fluorescence as radiant efficiency 
e10 (0.37 ± 0.03, 0.51 ± 0.05, 1.33 ± 0.07, 2.38 ± 0.19, 2.71 ± 0.28). Minimal non-specific 
binding appeared. To evaluate the targeting properties in vitro, 1ul/ml rhodamine labeled 
Col4 targeted or non-targeted PFC NPs were applied on glomerular endothelial cells and 
mesangial cells. Significant cellular uptake of the Col4 targeted PFC NPs was observed, 
while it was not detectable in the cells incubated with non-targeted NPs. To evaluate the 
targeting properties in vivo, C57BL/6 mice were treated i.v. with 100ul rhodamine labeled 
Col4 targeted or non-targeted PFC NPs. Col4 targeted PFC NPs localized to glomeruli in 
the kidney sections, whereas non-targeted PFC NPs were undetectable, as shown in Figure.
Conclusions: We have designed PFC nanoparticles that selectively target glomeruli by 
binding to Col4 of GBM.
Funding: NIDDK Support
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The Hippo Effector Tead1 Interacts with Wt1 on a Gene-Regulatory Level 
by Co-Binding at Podocyte Enhancers
Mahdieh Rahmatollahi,1 Tsimafei Padvitski,2 Bernhard Schermer,1 
Thomas Benzing,1 Andreas Beyer,2 Martin Kann.1 1Department II of Internal 
Medicine, University of Cologne, Cologne, Germany; 2University of Cologne, 
Köln, Germany.
Background: In a genome-wide analysis of gene-regulatory functions of the 
transcription factor (TF) Wt1 in podocytes we identified an interaction of Wt1 with hippo 
signaling, which has since emerged as a key pathway relevant to podocyte health and 
disease. However, gene regulatory effects of hippo signaling in podocytes have not been 
examined in detail. Here we investigate Wt1 and Tead1 co-regulation in wildtype podocytes 
in vivo by ChIPseq.
Methods: ChIP-seq for Tead1 and Wt1 was carried out on wildtype mouse glomeruli. 
Bioinformatic analyses were conducted using standard software and algorithms.
Results: ChIP-seq for Tead1 on mouse glomeruli identified more than 19,000 high 
confidence and reproducible Tead1 peaks. Tead1 binding occurred at both, promoters and 
enhancers as indicated by histone modification signatures obtained from ENCODE ChIPseq 
data. Functional analysis of Tead1 binding events by GO enrichment algorithms revealed 
differential functions of enhancer vs promoter binding. Promoter binding sites were 
predominantly located at genes involved in pathways canonically linked to hippo signaling 
such as regulation of apoptosis and cell cycle. In contrast, enhancer binding occurred at 
genes of signaling pathways highly relevant to podocytes, such as integrin signaling, the 
actin cytoskeleton, and Tgf-beta/Smad signaling. Tead1 also bound enhancers relevant 
to Vegf-, and PDGF-signaling genes suggesting novel links between hippo signaling and 
further signaling pathways in podocytes as well as novel contexts of hippo signaling in 
general. Integrative analysis of Wt1 and Tead1 ChIPseq data showed co-binding of the 
two TFs in ~7,000 instances with predominance of enhancer binding events. Enhancer 
co-binding of Wt1 and Tead1 showed speicifc overrepresentation of genes relevant to 
adherens junctions and focal adhesions when compared to datasets obtained from one TF 
only. Furthermore, many of the cis-regulatory regions co-bound by Wt1 and Tead1 were 
associated with genes relevant to glomerular disease and FSGS in particular.
Conclusions: In summary, integrative analysis of Tead1 and Wt1 ChIPseq data in 
podocytes in vivo reveals novel candidate pathways interacting with hippo signaling. We 
identify a functional interaction of the TFs to control cell-adhesion signaling bearing high 
relevance to glomerular disease.
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APOL1 G1 Risk Variant Contributes to Podocyte Injury in a Mouse 
Model of FSGS
Mengyuan Ge,1 Gloria Michelle Ducasa,1 Maarten Hoek,2 Jeffrey B. Kopp,3 
Sandra M. Merscher,1 Alessia Fornoni.1 1University of Miami School of 
Medicine, Miami, FL; 2Merck & Co., Inc, Kenilworth, NJ; 3NIDDK, NIH, 
Bethesda, MD.
Background: Focal segmental glomerulosclerosis (FSGS) is the most common 
primary glomerular disorder causing chronic kidney disease. Susceptibility to FSGS in 
African Americans is associated with the presence of genetic variants of the Apolipoprotein 
L 1 gene (APOL1) named G1 and G2. We recently published that mice with podocyte-
specific, doxycycline (Dox)-inducible expression of constitutively active NFATc1nuc 
(NFAT) represent a valuable new model for FSGS.
Methods: Human BAC transgenic mice that express the different APOL1 genetic 
variants (G0, G1, G2) under the endogenous promoter were used in this study. Podocyte 
specific Dox-inducible constitutively active NFATc1 mice (NFAT;Podocin-rtTA, DT) were 
expanded for consecutive breeding to G0, G1 or G2 BAC transgenic mice to generate triple 
transgenic mice (APOL1;NFAT;Podocin-rtTA, TT). NFATc1nuc transgene expression was 
induced by feeding of doxycycline chow (200 ppm) for 4 months. Urinary albumin-to-
creatinine ratios were determined using mouse specific albumin ELISA and creatinine 
companion kits. Blood samples collected from mice at sacrifice were analyzed for BUN. 
Perfused kidneys were fixed and paraffin embedded for H&E, PAS staining.
Results: We tested the relative contribution of APOL1 risk variant expression to 
podocyte injury in mice expressing each of the APOL1 genetic variants under the control 
of the endogenous promoter region at baseline as well as in a mouse model of FSGS-like 
injury. Glomerular expression of APOL1 mRNA was similar among BAC transgenic mice 
carrying APOL1 G0 and G1, but significantly lower in G2 carrying mice (p<0.01) and 
these mice did not develop proteinuria for at least up to 7 months of age. Histological 
analysis among APOL1 transgenic mice carrying each of the APOL1 genetic variants and 
wildtype mice revealed no differences. However, Dox-induced TT mice carrying the G1 
allele showed increased proteinuria, higher serum BUN levels and a more severe form of 
glomerulosclerosis when compared with induced TT mice carrying G0 or G2. Induced G1 
TT mice were also characterized by an earlier onset of proteinuria which remained sustained 
over time.
Conclusions: Our data reveal that transgenic APOL1 risk variant expression in mice 
does not impair kidney function at baseline whereas APOL1 G1 expression may contribute 
to APOL1 mediated susceptibility in NFAT-mediated FSGS.
Funding: NIDDK Support
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ApoL1 G0, G1, and G2 Are Expressed on the Podocyte Cell Membrane 
with Similar Overall Topologies
Nidhi Gupta, Suzie J. Scales. Genentech, South San Francisco, CA.
Background: Human Apolipoprotein L1 (ApoL1) is responsible for innate immunity 
against trypanosome infections. Two variants of ApoL1, G1 and G2, are responsible for 
the high rate of kidney disease in African diaspora and cause kidney podocyte damage 
by unclear mechanisms. ApoL1 can form pH-gated cation (K+ and Na+) channels in lipid 
bilayers, as well as pH-independent chloride channels in liposomes. Two papers showed 
overexpressed ApoL1 in HEK-293 cells forms potassium efflux channels at the cell 
surface, which leads to stress-activated protein kinase stimulation and cell death. However, 
contradictory results were obtained regarding ApoL1 G0 toxicity thereby questioning if G1 
and G2 toxicity is variant specific or expression level dependent. Total expression levels (by 
Western Blot) may not be indicative of cell surface ApoL1 levels. It is actually unclear if 
endogenous ApoL1 and its variants are found at the cell surface and whether differences in 
trafficking, expression level or topology could account for the differential toxicity. Also, not 
much is known regarding toxicity in podocytes.
Methods: Using a panel of in house generated ApoL1-specific monoclonal antibodies 
to various domains, we performed flow cytometry on wild type podocytes. We also 
generated several clones of ApoL1 knockout podocytes stably re-expressing doxycycline-
inducible ApoL1 G0, G1 or G2 to avoid any interactions (potential heterozygosity) with 
endogenous ApoL1. Cells were also tested for variant specific cell toxicity at comparable 
surface expression levels.
Results: By flow cytometry, endogenous ApoL1 was found at the cell surface of wild 
type podocytes, with most of the pore forming domain and end of the SRA-interacting 
domain exposed, but not the membrane-addressing domain. Surface ApoL1 was 
increased up to 500x in the inducible podocytes in a dose-dependent manner, but G0/G1/
G2 maintained similar topology to endogenous ApoL1. We aim to clarify if cytotoxicity 
correlates with cell surface expression or variant genotype.
Conclusions: Endogenous ApoL1 and stably transfected G0/G1/G2 are all expressed 
on the podocyte plasma membrane with similar gross topology and are therefore correctly 
located to form potential surface ion channels. Thus, any differential ionic conductance is 
likely not due to gross topology differences at the plasma membrane.
Funding: Commercial Support - Genentech
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ApoL1 Is Not Normally Internalized by Podocytes
Suzie J. Scales, Nidhi Gupta, Andrew S. Peterson. Genentech, South San 
Francisco, CA.
Background: Human Apolipoprotein L1 (ApoL1) is secreted by the liver and 
circulates on HDL particles, where it protects from human African trypanosomiasis 
(sleeping sickness). This innate immunity is achieved by internalization of HDL particles to 
the trypanosome lysosomes, where ApoL1 forms pores leading to trypanolysis. ApoL1 G1 
and G2 variants evolved in Africans to kill additional species of trypanosome, but greatly 
increase the risk of chronic kidney disease (ApoL1-nephropathies) by unclear mechanisms 
involving loss of kidney podocytes. The “internalization model” posits that circulating 
ApoL1 is internalized into podocytes to cause damage akin to trypanolysis, while the 
“intrinsic model” supposes that endogenous ApoL1 variants in podocytes are cytotoxic. 
Recombinant ApoL1 was reportedly internalized into podocytes, potentially supporting 
the internalization model, but the destination compartment was unclear. Most other studies 
support the intrinsic model, but have yet to agree on a cellular mechanism, ranging from ER 
stress, mitochondrial or lysosomal permeability, endocytic or autophagy disruption to cell 
surface cation channel activity. Clarification on whether intrinsic ApoL1 or ApoL1 in HDL 
particles is really internalized in podocytes might help to pinpoint the correct mechanism.
Methods: We evaluated internalization of recombinant ApoL1, ApoL1 in HDL 
particles, endogenous ApoL1 and stably expressed ApoL1 variants in cultured podocytes 
by immunofluorescence microscopy with ApoL1-specific monoclonal antibodies.
Results: Recombinant ApoL1 was internalized by podocytes, but only by virtue 
of being sticky, as it bound to other proteins in the media. Non-sticky ApoL1 in native 
HDL particles up to 1mg/ml or in amphipol was not visibly internalized by podocytes. 
Monoclonal antibodies detected endogenous ApoL1 in podocytes at the cell surface, but 
were not endocytosed. Overexpressed ApoL1 in podocytes likewise remained at the cell 
surface, unless the antibodies were aggregated.
Conclusions: Neither intrinsic ApoL1 nor HDL-bound ApoL1 is detectably 
internalized by podocytes in vitro, suggesting ApoL1 is not actively trafficked to endosomes 
or lysosomes. These data do not support the circulating model of ApoL1 activity and further 
suggest that intrinsic secreted ApoL1 might exert its effect at the plasma membrane rather 
than in the endolysosomal system.
Funding: Commercial Support - Genentech
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Semaphorin3A-Inhibitor Ameliorates Podocytopathy and Tubular 
Fibrosis in Adriamycin-Induced Renal Injury
Yizhen Sang,2 Kenji Tsuji,2 Akiko Inoue-Torii,1 Kazuhiko Fukushima,2 
Shinji Kitamura,2 Jun Wada.2 1Eiju General Hospital, Tokyo, Japan; 2Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical 
Scineces, Okayama, Japan.
Background: Semaphorin3A (SEMA3A) is a guidance protein that regulates 
angiogenesis, cell motility, immune cell regulation and cancer progression. In the 
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mammalian adult kidneys, SEMA3A and its receptor, neuropilin-1 (NRP1) are expressed 
in podocytes, tubular cells and collecting ducts. However, the pathophysiological roles of 
the SEMA3A in renal diseases are still unclear. Here we analyzed the role of the SEMA3A-
NRP1 signaling using the adriamycin (ADR)-induced podocytopathy mouse model and 
examined the therapeutic effect of SEMA3A-inhibitor.
Methods: Wild-type male Balb/c mice (10-week old) were assigned into three groups 
(n=5): ADR group (single injection of 10 mg/kg ADR by tail vein), ADR+SEMA3A-I 
group (ADR injection + daily intraperitoneal injection of 20 μg SEMA3A-inhibitor) and 
control group (saline injection by tail vein). All the mice were sacrificed 2 weeks after the 
ADR injection, and the expression of SEMA3A and NRP1, proteinuria, tubular injury and 
renal fibrosis were analyzed. We also examined the effect of recombinant SEMA3A and 
SEMA3A-inhibitor on immortalized mouse podocytes and proximal tubular cells (mProx24 
cells) in vitro.
Results: The expression of SEMA3A in podocyte and NRP1 in proximal tubular cells 
were dramatically increased in ADR group compared to control group. SEMA3A-inhibitor 
significantly attenuated ADR-induced albuminuria (urinary albumin / creatinine ratio (mg/
gCr): ADR group vs. ADR+SEMA3A-I group; 626.5±102.9 vs. 66.0±7.4, p<0.05), tubular 
injury and tubular fibrosis as well as the cell apoptosis in both podocytes and tubular cells. 
In vitro, SEMA3A caused the cell apoptosis in cultured podocytes and proximal tubular 
cells as well as the increase of TGF-β1 expression. In addition, the treatment with TGF-β1 
increased NRP1 mRNA expression in the podocytes (5.2-fold) and proximal tubular cells 
(1.7-fold) compared to the control, implying SEMA3A-NRP1 signaling is associated with 
tubular fibrosis. Taken together, increased SEMA3A expression in podocytes induced by 
ADR might cause podocytopathy and proximal tubular injury by accelerating cell apoptosis 
and renal fibrosis.
Conclusions: SEMA3A-inhibitor ameliorates podocytopathy and tubular fibrosis in 
ADR-induced renal injury. It would be the therapeutic target for preventing the progression 
of the renal injury.
Funding: Government Support - Non-U.S.
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ARHGEF7 Promotes Stress Fiber Loss in Podocytes by Activation of Rac1
Lovisa Bergwall,2 Hanna I. Wallentin,1 Roberto Boi,2 Anna Granqvist,1 
Jenny C. Nystrom,2 Lisa Buvall.1,2 1CVRM, IMED Biotech Unit, AstraZeneca, 
Gothenburg, Sweden; 2University of Gothenburg, Goteborg, Sweden.
Background: Today it’s known that most kidney diseases are caused by damages 
to the glomerular filtration barrier, partially by disruption of the actin cytoskeleton in the 
podocyte. Mutations in several actin regulatory proteins have been identified in patients 
with renal disease with several of them found to be present in proteins regulating actin 
cytoskeleton formation. The small RhoGTPase proteins are central in actin cytoskeleton 
regulation and lately several studies support the detrimental role of activation of the small 
RhoGTPase Rac1 and its role in stress fiber loss in podocytes.
Methods: In this study we aimed at identifying RhoGTPase regulatory proteins 
important in actin cytoskeleton loss in podocytes by using phosphoproteomics, lentiviral 
shRNA knockdown and stressfiber analysis on cultured podocytes, in combination with 
RNA sequencing of glomeruli from diabetic nephropathy animal models.
Results: By using protamine sulfate, known to cause actin cytoskeleton injury, on 
cultured podocytes followed by phosphoproteomics and pathway analysis we identified 
actin cytoskeleton to be the top ranked activated pathway. The guanine nucleotide 
exchange factor ARHGEF7 was identified to be phosphorylated at Ser 340, a site when 
phosphorylated known to cause Rac1 activation. Podocytes depleted of ARHGEF7 was 
protected from stress fiber loss when exposed to protamine sulfate, further confirming the 
involvement of ARHGEF7 in actin cytoskeleton rearrangement. In combination, RNA 
sequencing data from two diabetic nephropathy models, BTBR ob/ob and eNOS db/db 
mice, showed increased levels of ARHGEF7 in isolated glomeruli, indicating increased 
ARHGEF7 activity in nephrotic syndrome.
Conclusions: These data reviles upregulation of ARHGEF7 in diabetic nephropathy 
mice models and that ARHGEF7 plays a central role in podocyte actin cytoskeleton 
regulation, promoting loss of actin cytoskeleton in podocytes by the activation of Rac1.
Funding: Commercial Support - AstraZeneca, Private Foundation Support, 
Government Support - Non-U.S.
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Extracellular Vesicles as Local Messengers in Glomerular Cross-Talk
Sargis Sedrakyan,1 Hasmik Soloyan,3 Paola Aguiari,2 Laura Perin.1 GOFARR 
laboratory for organ regenerative research and cell therapeutics 1Childrens 
Hospital Los Angeles, Los Angeles, CA; 2Children’s Hospital, Los Angeles, Los 
Angeles, CA; 3Children’s Hospital Los Angeles, Los Angeles, CA.
Background: The crosstalk between the podocyte and glomerular endothelial cells 
(GEC) is vital for the maintenance of glomerular function. Any slight alteration of their 
communication propagates injury and disruption of glomerular function, commonly 
observed during CKD. Extracellular vesicles (EV) have key paracrine functions in 
physiological and pathological processes. Thus, we hypothesize that EVs play important 
role in glomerular crosstalk through horizontal transfer of their cargo to the target cells, 
especially during CKD when the glomerular filtration barrier is damaged. In particular, this 
study focuses on the transfer and paracrine signaling of GEC-EV to podocytes.
Methods: We isolated EV from GEC and characterized them by Nanosight analyzer, 
PCR, WB and flow cytometry for size distribution, RNA and protein content, and for surface 
marker expression. We used a no-cell-contact co-culture model to establish the transfer and 
intake of GEC-EV by podocytes, which was further confirmed in isolated glomeruli by 
the Cre-lox method. Podocytes exposed to GEC-EV were analyzed by PCR. To study EV 
transfer in vivo we used a transgenic model of CKD, Alport syndrome - characterized by 
a deficiency in the type IVα5 collagen and expression of tdTomato in endothelial cells, 
including GEC. TEM studies using immunogold co-labeling for tdTomato and CD63 were 
used to identify EV origin and uptake.
Results: GEC-EVs expressed exosomal CD9, C63, cell-adhesion and angiogenic 
markers, especially the VEGF receptors type I and II. In vitro, transfer of normal GEC-
EV to podocytes was confirmed by the Cre-lox activation of the tdTomato in podocytes 
by the Cre protein delivered via the GEC-EV. Transfer of GEC-EVs maintained podocyte 
morphology, WT1, podocin, nephrin and VEGF expression, while podocytes exposed to 
EVs isolated from Alport GEC showed alteration of these markers, thus possibly indicating 
that Alport GEC-EVs present a different cargo than normal GEC-EVs. In vivo, TEM data 
showed a presence of GEC-EV in podocytes, confirming EV transfer across the glomerular 
filtration barrier.
Conclusions: Our data suggest that EV transfer across the glomerular filtration barrier is 
an essential physiological event that regulates cellular function in podocytes. Identification 
of novel mediators of endothelial-podocyte crosstalk may lead to the development of more 
effective treatments for glomerular kidney disease.
Funding: Private Foundation Support
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Association of uTWEAK Levels with Histological Findings, Endothelial 
and Tubulointerstitial Markers (VEGF/VCAM-1, TGFβ) in Patients with 
Lupus Nephritis (LN)
Fabiola Reyes,4 Germain Toledo,4 Virgilia Soto,3 L. M. Perez-Navarro,2 
Rafael Valdez-Ortiz.1 1Hospital General de Mexico, Mexico City, Mexico; 
2Hospital General de México Dr. Eduardo Liceaga, México, Mexico; 3INC 
Ignacio Chavez, Mexico City, Mexico; 4IMSS, México, Mexico.
Background: Urinary TWEAK levels (uTWEAK) are a sensitive and specific 
biomarker in the evaluation of LN in patients with SLE, however, its association with 
histological findings and expression of endothelial and tubulointerstitial lesion marker is 
unknown.
Methods: Cross-sectional study. We determinate the degree of association between 
uTWEAK with histological findings and markers of endothelial lesion (VEFG and 
VCAM-1) and tubulointerstitial (TFGβ) in patients with LN that have not been received 
immunosuppressive treatment. Non parametric statistics, logistic regression model, 95%CI, 
and p <0.05 were performed as statistically significant.
Results: Thirty-six patients were evaluated, 83.3% (30) were female. With predominance 
of histological class IV+V (41.6%). In the histological findings, 63.8% had a low chronicity 
index (<6 points), the activity index (AI) was 50% >12 points. The uTWEAK according 
to the histological class did not show statistically significant differences. In 72.2% of the 
patients, VEGF at glomerular was ≥50% and at the arteriolar level, 77.8% of the patients 
presented deposits of ≥50%. In Figure 1, the correlation between the histological findings 
and the endothelial and tubolointerstitial biomarkers is observed. Although, uTWEAK was 
not associated significantly with AI and arteriolar VEGF deposits (OR 4.18, p= 0.223 and 
11.298, p= 0.120), effect size (d-Cohen) was of 0.78 and 1.33 respectively.
Conclusions: The uTWEAK represents a sensitive and specific biomarker in the 
evaluation of LN in patients with SLE, however, his expression does not seem to distinguish 
between the different classes of LN; an association was found with AI and VEGF. It is 
relevant to evaluate the outcome of the patients and to establish if the markers evaluated 
have an impact on the prognosis of the patients.
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Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated 
Membranous Nephropathy
Franziska Von haxthausen, Linda Reinhard, Elion Hoxha, Rolf A. Stahl. III. 
Department of Internal Medicine, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany.
Background: The immunologic mechanisms leading to initiation of primary MN 
are assumed to be different from those in cancer-associated MN, however, the evidence 
for this proposal has not been systematically evaluated. For decades primary MN was 
considered to have an IgG4-driven autoimmune genesis, while secondary MN associated 
with other diseases, most notably cancer, was not linked to IgG4. The identification of the 
phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type-1 domain-containing 
7A (THSD7A) as target antigens of autoimmunity in MN now allows a pathogenesis-
driven differential diagnosis and may help to better understand the differences between 
the pathomechanisms of primary and secondary MN. Recent data showing a molecular 
link between THSD7A expression in tumors and THSD7A-antibody positive MN suggest a 
similar pathogenesis of malignancy-associated and primary MN.
Methods: In this study we systematically analyzed circulating antigen-specific IgG 
subclasses in the serum of 76 patients with PLA2R1-associated MN and 41 patients with 
THSD7A-associated MN in relationship to concurrent malignancy and disease outcome. 
All IgG subclasses were analyzed by Western blot. Twenty-three patients in the study had 
a malignancy-associated MN. Human lung and glomerular protein extracts were analyzed 
under non-reducing conditions for expression of both PLA2R1 and THSD7A.
Results: At baseline all 117 patients were positive for IgG4-antibodies against either 
PLA2R1 or THSD7A, while IgG3, IgG1 and IgG2-antibodies were found in 87%, 72% and 
26% of patients, respectively. There were no differences in the IgG subclass distribution 
between patients with primary versus cancer-associated MN and no association with disease 
outcome. Both podocytes and lung bronchioles showed expression of both PLA2R1 and 
THSD7A when analyzed by immunofluorescence and Western blot. Every antigen-specific 
IgG subclass showed identical antigen-binding in both organs and autoantibodies bound the 
respective antigen only under non-reducing conditions.
Conclusions: We conclude that antigen-specific IgG subclasses do not differentiate 
between primary and malignancy-associated MN or predict disease prognosis. The data 
support the view that one common pathway may lead to primary and cancer-associated MN 
induced by PLA2R1- or THSD7A-antibodies.
Funding: Government Support - Non-U.S.
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The Conformational Anti-Phospholipase A2 Receptor Autoantibodies in 
Primary Membranous Nephropathy
Quansheng Zhu,1 Meryl A. Waldman,3 Liyo Kao,2 Hong Tang.1 1ImmunoWork, 
Monrovia, CA; 2Division of Nephrology, UCLA, Los Angeles, CA; 3NIDDK, 
NIH, Bethesda, MD.
Background: Primary membranous nephropathy (PMN) is a leading cause of 
nephrotic syndrome in adults. The dominant antigen, phospholipase A2 receptor (PLA2R) 
is detected in the subepithelial immune deposits in over 80% of the PMN patients. Anti-
PLA2R autoantibodies (PLA2R-Ab) bind to PLA2Rs on the basal surface of the podocytes 
triggering immune complex formation in situ that impairs the glomerular filtration barrier 
function causing massive leakage of the plasma proteins into the urine. We and others 
determined that the dominant epitope for autoantibody binding is located at the N-terminus 
of PLA2R. Additional studies also reported that 3 independent epitopes are present in 
PLA2R and that epitope spreading occurs in the patients and is associated with disease 
progression. Here we further characterized the autoantibody-PLA2R epitope interaction 
using 48 patient samples.
Methods: 48 PLA2R-Ab positive sera from patients with biopsy-proven MN 
were collected and assessed for their reactivities to PLA2R using Western-blot, 
immunoprecipitation under the native condition and immunodiffusion assays.
Results: 6 serum samples were identified to react strongly to the region of CysR-
FnII-CTLD1-3, but weakly to the region of CysR-FnII-CTLD1 when diluted at 1:5000 
on the Western-blot. 42 samples collected from patients who had relapsed disease all 
reacted strongly to the CysR-FnII-CTLD1 region at the same dilution. Follow-up studies 
in 3 patients who did not receive immunosuppressive treatment demonstrated that the 
autoantibodies initially reacted to the large CysR-FnII-CTLD1-3 region but later switched 
to the small CysR-FnII-CTLD1 region, coinciding with the worsening of proteinuria. 
Further analysis of autoantibody interaction with the purified PLA2R extracellular region 
in the immunodiffusion assay indicated that no insoluble lattice could be formed with any 
of the collected sera, suggesting that PLA2R is unlikely to have independent, separated 
epitopes in the extracellular region.
Conclusions: Our results indicated that two overlapping PLA2R epitope regions 
are present in the PMN patients with the autoantibody reaction to CysR-FnII-CTLD1-3 
is likely to occur before the reaction to CysR-FnII-CTLD1. This data suggest that the 
overall conformation of PLA2R plays an important role in autoantibody formation and that 
autoantibody maturation is associated with PMN progression.
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Proteomic Analysis of Complement Factors in PLA2R-Positive  
Membranous Nephropathy
Sanjeev Sethi,1 Benjamin J. Madden,1 Cristine Charlesworth,1 Daniel C. Cattran,2 
Fernando C. Fervenza.1 1Mayo Clinic, Rochester, MN; 2Toronto General 
Hospital, Toronto, ON, Canada.
Background: Membranous nephropathy (MN) is characterized by deposition of 
immune-complexes and complement factors along the glomerular basement membrane. 
Phospholipase A2 receptor (PLA2R) is the target antigen in approximately 70% of MN. 
Although complement deposition is seen PLA2R-associated MN, a comprehensive and 
detailed analysis of complement factors in PLA2R-associated MN has not been done.
Methods: We used laser microdissection and mass spectrometry (MS) to dissect 
glomeruli and identify the glomerular and complement proteins in 7 cases of PLA2R-
associated MN. For control cases, we used 6 cases of time 0 transplant protocol biopsies.
Results: MS identified very high total spectral counts (TSC) for PLA2R in all cases of 
PLA2R-associated MN with average TSC of 87 (range 45-135). In comparison, the avarage 
TSC in control cases was only 5 (range 0-7) which is similar to many house-keeping 
proteins. With regards to complement factors, C3 was the most abundant complement 
protein with average TSC of 413 (range 324-708), followed by C4 (C4-B avg 176, C4-A 
avg 174). Moderately high TSC of C9 (avg 79,) and C5 (avg 54) were also detected. Lesser 
amounts of C6 (avg 31), C7 (avg 20) and C8 (avg 21) were also present. C1 was absent or 
present in very low spectral counts. In addition, complement regulating facors- complement 
factor H (avg 57), complement factor H-related protein 5 (avg 65.5) and complement 
factor H-related protein 1 (avg 30) were also detected. The average TSC of complement 
factors in control cases for C3, C4-B, C4-A and C5 was 107, 40, 39, and 5, respectively. 
With regards to immunoglobulins (Ig) in PLA2R-associated MN, IgG4 was the most 
abundant Ig (avg 91), followed by IgG1 (avg 68), IgG3 (avg 64) and IgG2 (avg 49). 
The avgerage Ig total TSC in control cases for IgG4, IgG1, IgG3 and IgG2 was 22, 56, 45 
and 45, respectively.
Conclusions: Using MS analysis, we show accumulation of large amounts of C3 and 
C4, followed by C9 and C5, and lesser amounts of C6, C7 and C8 indicating a role of 
complement in the pathogenesis of PLA2R-associated MN. The TSC of C3 and C4 was 
much higher than the TSC of PLA2R or Ig indicating amplification and accumulation of 
complement factors in greater amounts than the PLA2R antigen or Ig. The large amounts of 
C3 and C4 and absence of C1 suggests involvement of the lectin pathway.
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Exostosin 1/Exostosin 2-Associated Membranous Nephropathy
Sanjeev Sethi, Benjamin J. Madden, Cristine Charlesworth, Fernando 
C. Fervenza. Mayo Clinic, Rochester, MN.
Background: Membranous nephropathy (MN) is is characterized by deposition of
immune-complexes and complement along the glomerular basement membrane (GBM). 
Phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain containing 7A 
are target antigens in ~70% and 5% cases, respectively. In the remaining cases, the target 
antigen is unknown.
Methods: We studied 22 cases of MN: 7 PLA2R-positive and 15 PLA2R-negative; 
and 6 control time 0 transplant protocol biopsies. Glomeruli were laser microdissected and 
mass spectrometry (MS) was performed to detect the proteomic profile. This was followed 
by immunohistochemical studies (IHC) to identify and localize the overexpressed proteins.
Results: MS identified high total spectral counts (TSC) for PLA2R in cases of PLA2R-
positive MN. In 5 of the 15 PLA2R-negative MN, high TSC for both exostosin 1 (EXT1) 
and exostosin 2 (EXT2) were present. The TSC of EXT1 and EXT2 were comparable to the 
TSC of PLA2R in PLA2R-positive cases. EXT I and II are glycosyltransferases that exist 
as heterodimers and are responsible for the synthesis of the heparin sulfate backbone in the 
GBM. Of the remaining 10 PLA2R-negative cases, 2 cases of negative PLA2R by IF were 
positive for PLA2R, 3 cases had suboptimal tissue, and in 5 cases comparable high TSC of a 
single protein was not present. EXT1 and EXT2 were absent in PLA2R-positive and control 
cases. None of the PLA2R negative cases showed THS7DA. In all MN cases, high TSC for 
complement factors and Ig were also present. To confirm the findings we performed IHC 
that showed bright granular EXT1 and EXT2 GBM staining in EXT1/EXT2-positive MN 
cases, in a distribution similar to Ig (Figure 1). Furthermore, EXT1/EXT2 staining was 
specfic as staining for Exostosin-like 2 (EXTL2) was negative in the EXT1/EXT2-positive 
cases. All control and PLA2R-positive cases were negative for EXT1/EXT2/EXTL2.
Conclusions: A subset of PLA2R-negative MN is associated with accumulation of 
EXT1 and EXT2 in GBM, representing a distinct subtype of MN.
EXT1 and EXT2 staining in 3 cases of PLA2R-negative MN. Each column is 1 case.
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Generating a Mouse Model of Membranous Nephropathy (MN)
Samuel J. Rhoden,1 Franziska Lausecker,1 Maryline Fresquet,1 Antony Adamson,1 
Thomas A. Jowitt,1 Paul E. Brenchley,2 Rachel Lennon.1 1University of 
Manchester, Manchester, United Kingdom; 2Manchester Royal Infirmary, 
Manchester, United Kingdom.
Background: 75% of patients with MN develop autoantibodies against PLA2R, which 
is expressed on podocytes. Autoantibody binding causes immune complex deposition 
in the glomerular basement membrane (GBM), podocyte effacement and the clinical 
phenotypes of proteinuria and nephrotic syndrome. The lack of an in vivo model for MN, 
due to rodents expressing minimal PLA2R on podocytes, has impeded the investigation 
of disease mechanisms and novel therapeutics. The aims of this study were to 1) 
develop a podocyte-specific PLA2R knock-in mouse and 2) induce MN through passive 
transfer of anti-PLA2R antibodies.
Methods: A transgene was created for insertion of a flag-tagged PLA2R fragment 
(NC3) containing the transmembrane and the first 5 extracellular domains, including the 
immunodominant epitope of PLA2R. Podocyte restricted expression of NC3 is driven 
by the NPHS2 promoter. Transgene positive pups were bred with BL6/J mice to spawn 
heterozygous knock-in mice. Kidneys, glomeruli and podocytes were isolated from 
subsequent offspring for analysis by reverse transcription PCR (RT-PCR), targeted locus 
amplification (TLA) sequencing, western blotting (WB), and immunohistochemistry (IHC). 
Induction of MN in PLA2R knock-in mice will be achieved by intravenous injection of 
human anti-PLA2R and analysed for glomerular deposition, proteinuria and complement 
activation.
Results: TLA sequencing confirmed successful in-frame insertion of the transgene in 
PLA2R knock-in mice. RT-PCR and WB analysis of kidneys and glomeruli demonstrated 
the expression of NC3 mRNA and protein in PLA2R knock-in mice. IHC of kidney sections 
using human anti-PLA2R antibodies indicated strong podocyte staining of NC3 in the 
glomerulus of PLA2R knock-in mice. PLA2R knock-in mice demonstrated no differences 
to wild type mice in regards to proteinuria, weight and histology under basal conditions. 
We anticipate that injection of MN patient IgG will induce the MN phenotype in PLA2R 
knock-in mice.
Conclusions: We have successfully developed a PLA2R knock-in mouse. Expression 
of NC3 did not induce a phenotype under basal conditions. Current work focusses on 
the induction of MN using patient IgG. This mouse model gives exciting prospects for 
validating the pathogenicity of anti-PLA2R antibodies and the role of immune complex 
formation, complement activation and GBM thickening in causing proteinuria.
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T-Regulatory and B-Regulatory Cells in Primary Membranous 
Nephropathy
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Vivekanand Jha.3 1Postgraduate Institute of Medical Education & Research, 
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Background: Primary membranous nephropathy (PMN) is an antibody-mediated 
disease. Both T-regulatory (TREGs) and B-regulatory (BREGs) cells are decreased in 
patients with autoimmune disease. The data on TREGs and BREGs in PMN is very scanty. 
We evaluated the TREG and BREG population in patients of PMN treated with cyclical 
cyclophosphamide and steroid therapy (cCTX/GC).
Methods: Twenty-four patients of PMN and 10 healthy controls were enrolled in the 
study at Nehru Hospital, PGIMER, Chandigarh. All the patients were resistant to restrictive 
strategy and were treated with cCTX/GC therapy. The proteinuria, serum creatinine and 
serum albumin were tested at monthly intervals and blood samples were collected prior to 
starting cCTX/GC and at 6 and 8 (2 months wash out) months of therapy. The peripheral 
blood mononuclear cells (PBMCs) were isolated from the collected blood samples using 
density gradient centrifugation. PBMCs after staining with fluorochrome-conjugated 
antibodies were then subjected to flow cytometric analysis for detection of TREGs 
(CD3+CD4+CD25hiCD127loFoxP3+) and BREGs (CD19+CD5+CD1dhiIL10+) at all time-
points. TREGs and BREGs are presented as the percentage of CD3+CD4+ and CD19+ 
cells, respectively.
Results: The mean proteinuria, serum albumin and creatinine at baseline was 
8.74±4.85 g, 2.33±0.80 g/dL and 1.06± 0.53 mg/dL, respectively. Patients with PMN had 
a lower percentage of TREGs and BREGs compared to healthy controls (p<0.05). There 
was a significant increase in both BREGs and TREGs with the treatment at 6 and 8 months 
(Table). The rise in both BREGs and TREGs were apparent after stopping (8 months) 
immunosuppressive therapy (Table).
Conclusions: As compared to the healthy controls, patients with PMN displayed a 
lower percentage of TREGs and BREGs. Both TREGs and BREGs significantly improved 
with disease-specific therapy. The increase in both the regulatory cells is apparent after two 
months of stopping cCTX/GC.
Funding: Government Support - Non-U.S.
BREGs and TREGs in Primary Membranous Nephropathy
Values are expressed as frequencies. TREGs- Regulatory T cells, BREGs- Regulatory B 
cells
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Pre-Diagnostic Evaluation of Anti-Phospholipase A2 Receptor Antibodies 
in Primary Membranous Nephropathy
Megha R. Joshi,1 Peter D. Burbelo,3 Meryl A. Waldman,4 Sarah M. Gordon,2 
John S. Thurlow,1 Stephen W. Olson.1 1Nephrology, Walter Reed National 
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Background: M-type phospholipase A2 receptor antibodies (PLA2R –Ab) are present 
in 60-80% of primary membranous nephropathy (pMN) cases at diagnosis. PLA2R-Ab is 
assumed to directly contribute to pMN pathophysiology, but there has not been confirmatory 
animal models or evaluation of PLA2R –Ab before pMN diagnosis. We sought to describe 
PLA2R-Ab levels before both biopsy diagnosis and documented proteinuria before biopsy 
diagnosis to better understand pMN pathophysiology.
Methods: We performed a retrospective case-control Department of Defense Serum 
Repository (DoDSR) study comparing PLA2R-Ab in patients with pMN, presumed 
secondary MN, and healthy controls. MN cases were first identified and confirmed by 
review of the military electronic medical record. Background data was collected to include 
the earliest date of abnormal proteinuria and the most recent date of negative proteinuria 
before biopsy diagnosis. Based on background and biopsy data, MN patients were divided 
into pMN and secondary MN cases. The DoDSR then provided up to 4 prediagnostic 
specimens for each MN case and age, race, sex and age of serum matched healthy controls. 
PLA2R-Ab was measured at the NIH using a luciferase assay.
Results: More pMN cases had elevated PLA2R-Ab than secondary membranous 
disease controls before biopsy diagnosis [44% (59/134) vs. 2.8% (1/35), p<0.001]. No 
matching healthy controls had detectable PLA2R-Ab at any time point. PLA2R-Ab became 
elevated a median of 274 days prior to biopsy diagnosis (IQR: 63days, 811 days). 15 cases 
demonstrated significantly elevated prediagnostic PLA2R-Ab at or up to 5 years prior to the 
earliest documentation of non-nephrotic range proteinuria before biopsy diagnosis. Two 
unique cases demonstrated elevated PLA2R-Ab with confirmed negative proteinuria over a 
year before biopsy diagnosis.
Conclusions: PLA2R-Ab is detectable not only before biopsy proven pMN, but also 
prior to the earliest subclinical presence of non-nephrotic range proteinuria which supports 
a direct contribution to the pathogenesis of pMN. Early serum testing of PLA2R-Ab in 
patients with unexplained non-nephrotic range proteinuria may allow for early diagnosis 
and monitoring of pMN.
Funding: Other NIH Support - Dr. Peter Burbelo ran the samples at the NIH, Other 
U.S. Government Support
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PLA2R1 Epitope Recognition Patterns and Clinical Outcome in Patients 
with Membranous Nephropathy
Elion Hoxha,1 Gunther Zahner,3 Linda Reinhard,1 Rolf A. Stahl.2 1III. Department 
of Internal Medicine, University Medical Center Hamburg-Eppendorf, 
Hamburg, Germany; 2University of Hamburg, Hamburg, Germany; 3University 
hospital hamburg, Hamburg, Germany.
Background: Phospholipase A2 receptor 1 antibodies (PLA2R1-ab) are found in 80% 
of patients with membranous nephropathy (MN). While PLA2R1-ab levels are closely 
associated with treatment response and disease prognosis, the clinical role of epitope 
regions targeted by autoantibodies is less clear.
Methods: The epitope recognition patterns of PLA2R1-ab from 150 patients with 
newly diagnosed PLA2R1-associated MN were analyzed by Western blot and correlated 
with disease activity, clinical characteristics and outcome.
Results: In addition to the three known epitope regions in the CysR, CTLD1 and 
CTLD7 domains, we identified a fourth epitope region in the CTLD8 domain of PLA2R1. 
While PLA2R1-ab from all patients recognized an epitope in the N-terminal region (defined 
as CysR – CTLD1 domains), 82.7% of patients also recognized a C-terminal epitope in 
PLA2R1, namely in the CTLD7 and/or CTLD8 domain. Patients with C-terminal epitope 
recognition had almost 10-fold higher PLA2R1-ab levels, higher proteinuria and needed 
immunosuppressive treatment twice as often as patients with epitope recognition confined at 
the N-terminal region of PLA2R1. After adjusting for these factors in multivariate analyses, 
C-terminal epitope recognition was not predictive for any of the clinical study endpoints,
defined as depletion of PLA2R1-ab, remission of proteinuria, and doubling of serum
creatinine during follow-up. Additional dilution of sera recognizing C-terminal epitopes of 
PLA2R1 led to abolishment of C-terminal epitope recognition, while N-terminal epitopes
remained detectable. Therefore, one can speculate, that some of the 17.3% of patients in our 
cohort, who only showed reactivity to the N-terminal region of PLA2R1, may also have had
autoantibodies targeting the C-terminal region, however, the sensitivity of the method was 
not sufficient to detect them.
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Conclusions: There are at least four target epitope regions in the PLA2R1 and a clear 
association between epitope recognition patterns and PLA2R1-ab levels. C-terminal epitope 
recognition is not associated with disease outcome if all other clinical variables are adjusted 
for, therefore considering PLA2R1-ab levels is fundamental for the interpretation of the 
clinical relevance of PLA2R1 epitope recognition patterns.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Relation Between Anti-PLA2R Titer and the Likelihood of Spontaneous 
Remission in Membranous Nephropathy
Elias A. Jatem,1 Luisa Martin-conde,2 Maria Molina,1 María P. Marco,1 
Alfonso Segarra.1 1Hospital Universitari Arnau de Vilanova, Lleida, Spain; 
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Background: In idiopathic membranous nephropathy (iMN), the antibody titer of 
anti-PLA2R correlates with the activity of the disease and the likelihood of spontaneous 
remission (SR). Based on measurements of the basal anti-PLA2R titer, some authors have 
proposed algorithms, for guiding the decision making process regarding the timing for 
initiation of immunosuppresive treatment in patients with iMN. Objectives: 1.- To analyze 
the probability of SR based on the initial titer of anti-PLA2R antibodies. 2.- Analyze if the 
dynamic of the antibody titer during the observation period, allows for a better estimation 
of the likelihood of SR.
Methods: 94 patients with iMN with anti-PLA2R antibody titers> 20 U / mL at 
the time of diagnosis. The patients were followed for at least 6 months before initiation 
immunosuppressive therapy. Blood samples were obtained prospectively at the time of 
diagnosis, at 8 weeks, at 12, and at 24 weeks after diagnosis. The measurement of the anti-
PLA2R titer, and the predictive capacity of these titers on the likelihood of SR was analyzed 
with ROC curves, univariate and multivariate analysis.
Results: 28 of 94 patients (29.8%) entered immunological remission followed by 
clinical remission, which was total in 5 patients (5.31%) and partial in 23 (24.4%). The 
mean interval between diagnosis and immunological and clinical remission was 5.9 ± 1.6 
months and 6.5 ± 2.3 months, respectively. Patients with SR presented lower proteinuria, 
lower anti-PLA2R titers at diagnosis, and a significant decrease thereof over time. The 
probability of SR was associated linearly with ranges of values, but not with a single value. 
The logistic model with greater predictive capacity included the basal titers and the change 
at 12 weeks.
Conclusions: In patients with iMN, the probability of SR can be estimated with 
adequate predictive power from the baseline anti-PLA2R antibodies, but a best estimation 
model is obtained when adding the antibody titer at 12 weeks.
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PLA2R Expression in Pediatric Membranous Nephropathy: A Multi- 
Institution Retrospective Study
Marco Delsante,1 Marco Allinovi,2 Donghyang Kwon,5 Miriam Conces,4 
Benedetta Mazzinghi,2 Bakri Alzarka,3 Bhaskar Kallakury,5 Avi Z. Rosenberg.1 
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Background: Membranous nephropathy (MN) is a rare cause of nephrotic syndrome 
in children and can be idiopathic (IMN) or secondary to systemic diseases (i.e. SLE, chronic 
infections and malignancy). In adults with IMN, antibodies against phospholipase A2 
receptor (PLA2R) are present in 57-82% of patients and expression of PLA2R is increased 
in glomeruli by histochemical staining. The latter is a useful diagnostic tool allowing the 
pathologist to suggest an idiopathic versus secondary process. However, PLA2R expression 
in children with MN has not been studied in large cohorts, and small case series have shown 
lower sensitivity (6-45%) compared to adults.
Methods: We retrospectively collected 82 cases of IMN and secondary MN (lupus-
related (SLEMN) and non-SLEMN) from 4 Institutions. Formalin fixed paraffin embedded 
sections were stained for PLA2R and scored blindly as positive or negative and results 
were correlated with clinical, histomorphologic, IF and electron microscopy (EM) findings.
Results: Of 37 IMN, PLA2R-positivity was observed in 62% of cases, was variable 
in non-SLEMN (54%) and mostly negative in SLEMN (91%). Thus, PLA2R staining 
alone was not sufficient to parse IMN from non-SLEMN (p=0.61). SLEMN were more 
likely to show mesangial expansion compared to IMN and non-SLEMN (p<0.0001 and 
p=0.0016 respectively), subendothelial deposits (p<0.0001) and more mesangial deposits 
compared to IMN (p=0.0004) but not non-SLEMN (p=0.1228). Tubuloreticular inclusions 
were more frequent in SLEMN and non-SLEMN compared to IMN (p<0.0001 and 
0.0004 respectively) with no difference between SLEMN and non-SLEMN. IF patterns 
were similar in IMN and non-SLEMN with more “full-house” patterns in SLEMN. 
PLA2R-negative cases were more likely to have mesangial expansion, full house staining, 
subendothelial and mesangial deposits (p=0.0381, 0.0341, 0.0008 and 0.0351 respectively). 
Glomerular basement membrane alterations, global/segmental glomerulosclerosis (%) and 
tubulointerstitial scarring (%) did not differ significantly between groups.
Conclusions: We show a higher prevalence (62%) of PLA2R positive IMN compared 
to previous reports. However, PLA2R positivity was observed in a 54% of secondary 
MN (non-SLEMN). PLA2R-positivity did not correlate with any specific histological 
characteristics but was uncommon in SLEMN.
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Patients with Anti-U1 Ribonucleoprotein (RNP) Antibody
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Background: The significance of anti-ribonucleoprotein (RNP) antibody and anti-Sm 
antibody remains still unclear on patients with systemic lupus erythematosus (SLE) or mix 
connective tissue disease (MCTD).
Methods: Thirty patients showing the positivity for antinuclear antibodies (ANA) and 
anti-RNP antibody, who were diagnosed with SLE or MCTD and received renal biopsy 
in our hospital between January 1980 and December 2014, were retrospectively enrolled 
into this study. These 30 patients were classified into 4 groups based upon anti-dsDNA 
(+)/(-) and anti-Sm (+)/(-); group A (n = 10): anti-dsDNA(-) plus anti-Sm(-), group B 
(n = 7): anti-dsDNA(-) plus anti-Sm (+), group C (n = 6): anti-dsDNA(+) plus anti-Sm(-), 
and group D (n = 7): anti-dsDNA(+) plus anti-Sm(+). Among these 4 groups, clinical 
marker and renal histology were compared. Renal histology showed 3 types including pure 
subepithelial membranous nephropathy(MN), mesangial proliferative nephropathy(MES), 
and MN plus MES.
Results: Thirty patients with anti-RNP antibody included SLE (n = 25) and MCTD 
(n = 5). The mean age (SE) was 38.6 (2.5) years, and 26 out of 30 patients (87%) were 
women. Fourteen patients (47%) showed the positivity for anti-Sm antibody and thirteen 
patients (43%) showed the positivity for anti-dsDNA antibody. Anti-Sm (-) groups showed 
normocomplementemia, and anti-Sm (+) groups showed hypocomplementemia. Pure MN 
was noted in anti-dsDNA (-) group or anti-Sm (-) group. The comparison between group A 
and group B showed that anti-Sm (-) has a close relation with normo-complementemia and 
MN lesion, and anti-Sm (+) has close relation with hypo-complementemia and MES lesion 
on patients with RNP(+) and ds-DNA(-). The comparison between group C and group D 
showed that anti-Sm (+) has close relation with hypo-complementemia, but does not have 
any relation with renal histology on patients with RNP(+) and ds-DNA(+).
Conclusions: Our study indicates that the single positivity of anti-RNP antibody 
contributes to MN formation with normocomplementemia, while additional positivity of 
anti-Sm antibody results in hypocomplementemia-related MES formation.
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Background: Primary membranous nephropathy (PMN) is characterized by the 
presence of antibodies to the podocyte, but little is known on circulating T and B cell 
populations, especially the percentages of TFH and Breg.
Methods: We performed a comprehensive follow-cytometric analysis of 38 T and 
B lymphocyte subpopulations, including intracellular staining for IFN-g, IL-4, and IL-
17 production in 16 patients with severe PMN and compared them with 12 age-matched 
healthy individuals.
Results: Within the T cell compartment, we found that patients with PMN had 
significantly fewer CD4+CD25+CD127lo Tregs (Treg; p=0.04), IL-17+CD4+ TH17 cells 
(p=0.01), and CD4+CXCR5+PD1+ TFH cells (p=0.02) than healthy controls (Figure 1A). 
While CD4+CD45RO+CD27- effector T cells were not differentially increased in PMN 
patients compared to healthy controls, they positively correlated with proteinuria in 
the PMN patients at baseline (r2=0.33; p=0.02). Within the B cell compartment, PMN 
patients had significantly fewer CD19+CD27+IgD+ unswitched B cells (p=0.01) and 
CD19+IgD+CD27-CD24loCD38lo naïve transitional B cells (p<0.0001) and significantly 
more CD19+CD25+CD71+ Bregs (p=0.046) than healthy controls (Figure 1B). Within PMN 
patients, we did not find a relationship between anti-PLA2R antibodies and any of the T or 
B cell subsets investigated.
Conclusions: Consistent with previous reports, patients with PMN display a 
unique immune phenotype characterized by reduced Treg and naïve B cell percentages. 
Unexpectedly, we newly found that PMN patients also display increased Breg, fewer TFH, 
and a positive correlation between CD4+ effector T cells and proteinuria, suggesting a 
pathogenic link.
Funding: NIDDK Support
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Clinical Characteristics and Renal Outcomes in Patients Developing 
Membranous Nephropathy After Allogeneic Stem Cell Transplantation
Roman A. Shingarev,2 Ann A. Jakubowski,2 Surya V. Seshan,1 Insara Jaffer 
Sathick,2 Edgar A. Jaimes,2 Ilya Glezerman.2 1Weill Cornell Medical Center, 
New York, NY; 2Memorial Sloan Kettering Cancer Center, New York, NY.
Introduction: The overall probability of developing nephrotic syndrome (NS) in 
allogeneic stem cell transplant (allo-SCT) patients with graft-versus-host disease (GVHD) 
is estimated to be 8%. Membranous nephropathy (MN) accounts for the majority of 
these cases and has been ascribed to renal-specific manifestation of GVHD based on MN 
association with GVHD in other organs, immunosuppression (IS) reduction at the time 
of MN diagnosis and negative tissue PLA2R staining. Treatment regimens range from 
corticosteroids (CS) to rituximab with variable clinical response.
Case Description: Chart review identified 8 cases of clinically diagnosed NS at our 
institution that developed after allo-SCT from 2010 through 2017 and was evaluated with 
kidney biopsy. No transplants had antigen mismatch. All had a history of, but no concurrent 
GVHD in the settings of IS reduction. Minimal change disease was responsible for 3 and 
MN for 5 cases. Stain for PLA2R was present in the glomerular capillary loops in 4 of 5 MN 
cases. Plasma PLA2R titers were negative when checked. Partial or complete remission 
of proteinuria (PTN) was achieved in 4 MN cases with the utilization of single agent 
Tacrolimus or its combination with CS, without complications arising from the treatment 
(Table).
Discussion: We report a series of MN cases diagnosed after allo-SCT and characterized 
by PLA2R-positive tissue staining. Although the presence of PLA2R in the glomerular 
tissue is thought to be specific for idiopathic MN, our findings raise the possibility of 
PLA2R being an epi-phenomenon occurring in both idiopathic and GVHD-related MN. 
Tacrolimus alone appears to be effective in inducing at least partial remission of PTN. 
Additional CS may confer a faster and more durable response; however, this benefit must 
be weighed against the side effects associated with their long-term use.
AML, acute myeloid leukemia; CS, corticosteroids; GVHD, graft-versus-host disease; 
MDS, myelodysplastic syndrome; TCL, T-Cell lymphoma
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Complement Activation Products in the Circulation and Urine of Primary 
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Background: Complement activation plays a substantial role in the pathogenesis of 
primary membranous nephropathy (pMN). C5b-9, C3c, MBL, and factor B have been 
documented in the subepithelial immune deposits. However, the changing of complement 
activation products in circulation and urine is not clear.
Methods: We measured the circulating and urinary levels of C1q, MBL, C4d, Bb, 
properdin, C3a, C5a, and sC5b-9, in 134 patients with biopsy-proven pMN, by enzyme-
linked immunosorbent assay. All the plasma values were corrected by eGFR and all the 
urinary values were corrected by urinary creatinine and urinary protein excretion. Anti-
PLA2R antibodies were measured in all patients.
Results: The plasma complement activation products were elevated both in the 
patients with and without anti-PLA2R antibodies. C3a levels were remarkably increased 
in the circulation and urine, much higher than the elevated levels of C5a. C5b-9 was in 
normal range in plasma, but significantly higher in urine. The urinary C5a had a positive 
correlation with anti-PLA2R antibody levels and urinary protein. The plasma level of C4d 
was elevated, but C1q and MBL were comparable to healthy controls. Positive correlations 
were observed between plasma C4d/MBL and urinary protein, only in the patients with 
positive anti-PLA2R antibodies but not in those without. The plasma level of Bb was 
elevated and had positive correlation with urinary protein only in the patients without anti-
PLA2R antibodies.
Conclusions: Complement activation products were remarkable increased in pMN and 
may serve as sensitive biomarkers of disease activity. The complement may be activated 
through lectin pathway with the existence of anti-PLA2R antibodies, while through 
alternative pathway in the absence of antibody.
Funding: Government Support - Non-U.S.
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Background: Membranous nephropathy (MN) autoantigens have been discovered 
using the established laboratory technique of Western blotting, in which human sera from 
patients with MN were utilized to screen for specific reactivity with proteins extracted from 
human glomerular fractions. The objective of the present study was to investigate a highly 
characterized group of patients using a technology routinely adopted in antibody epitope 
mapping.
Methods: Sera from patients with membranous nephropathy, selected to have good 
(n=5) or bad prognosis (n=5) at hospitalization (T0) or twelve months after (T12) were 
hybridized with a whole proteome peptide array chip. The intensity of the signal retrieved 
by whole proteome peptide array chip was used to feed a weight gene co-expression 
network analysis (WGCNA) algorithm to identify a network of relationships between the 
signals and renal outcome in search of established and novel antigens of MN.
Results: Whole proteome peptide array technology allowed retrieving known antigens 
(e.g., PLA2R1 or THSPD7A) and identified specific peptide sequences on those proteins 
recognized by autoantibodies predictive of renal outcome. Peptides belonging to previously 
unknown target antigens in MN were also retrieved.
Conclusions: Whole proteome peptide array and extracellular protein microarray 
technologies can be profitably applied to the study of autoimmune diseases. The 
technologies identify known antigens of MN and novel unknown ones. Those preliminary 
findings need extensive validation in a large patient set.
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Deletion of the Mitochondrial Complex-IV Co-Factor Heme A: 
Farnesyltransferase Causes FSGS and Interferon Response
Jea-Hyun Baek,1 Ivan G. Gomez,1 Yukihiro Wada,3 Allie M. Roach,1 
Don J. Mahad,4 Jeremy S. Duffield.1,2 1Biogen Inc., Cambridge, MA; 2University 
of Washington, Seattle, WA; 3Division of Nephrology, Department of Medicine, 
Showa University School of Medicine, Tokyo, Japan; 4University of Edinburgh, 
Edinburgh, United Kingdom.
Background: Mutations in mitochondrial DNA as well as in nuclear-encoded 
mitochondrial proteins have been reported to cause tubulointerstitial kidney diseases and 
focal segmental glomerulosclerosis (FSGS). More recently, genes and pathways affecting 
mitochondrial turnover and permeability have been implicated in adult onset FSGS. 
Furthermore, dysfunctioning mitochondria may be capable of engaging intracellular innate 
immune sensing pathways.
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Methods: To determine the impact of mitochondrial dysfunction in FSGS and secondary 
innate immune responses, we generated Cre/loxP transgenic mice to create loss-of-function 
deletion mutation of the Complex IV assembly co-factor heme A:farnesyltransferase 
(COX10) restricted to cells of the developing nephrons.
Results: These mice develop severe, early onset FSGS with innate immune activation, 
and die prematurely with kidney failure. Mutant kidneys showed loss of glomerular and 
tubular epithelial function, epithelial apoptosis and in addition a marked interferon response. 
In vitro modeling of Cox10 deletion in primary kidney epithelium compromises oxygen 
consumption, ATP generation, and induces oxidative stress. In addition, loss of Cox10 
triggers a selective interferon response, which may be caused by the leak of mitochondrial 
DNA into the cytosol activating the intracellular DNA sensor, STING.
Conclusions: This new animal model provides a mechanism to study mitochondrial 
dysfunction in vivo and demonstrates a direct link between mitochondrial dysfunction and 
intracellular innate immune response.
Funding: Other NIH Support - DK093493 and DK094768, Commercial Support - 
Biogen
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Chang-Yien Chan,1,2 Isaac Liu,1,2 Kong Peng Lam,3 Kar Hui Ng,1,2 Hui
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Teck Puat-National University Children’s Medical Institute, National University 
Health System, Singapore, Singapore; 3Bioprocessing Technology Institute,
A*STAR, SINGAPORE, Singapore.
Background: We recently reported a subgroup of focal segmental glomerulosclerosis 
(FSGS) patients bearing an immunological signature of T-cell hyporesponsiveness who 
responded to rituximab treatment, suggesting a possible role of B-T cell interactions in 
modulating podocyte injury. This study aimed to investigate the B-cell profiles in this 
subgroup of immune-mediated FSGS.
Methods: At baseline before rituximab treatment, FSGS patients were stratified into the 
hyporesponsive T-cell activation (HT) and non-HT groups. HT group is defined by activated 
IFN-γ+CD3+ expression <2.5% following PMA and ionomycin stimulation. Blood samples 
were washed thrice before staining of B-cell subsets using lysed whole blood method. 
B-cells were isolated using CD19 microbeads and stimulated with lipopolysaccharide
(LPS) for 4 hours. Cytokine levels in culture supernatants were quantified using multiplex 
suspension bead array system.
Results: 19 FSGS patients receiving rituximab were recruited of which 11 patients were 
in the HT group. At baseline, the FSGS HT group showed significantly higher percentage of 
double negative (DN) memory B cells (CD19+CD27-IgD-) (7.8±1.1%) compared to FSGS 
non-HT patients (3.8±0.6%) (P=0.009), although this did not reach statistical significance 
compared to 14 controls (4.8±0.6%) (P=0.08) and 12 patients with minimal change disease 
(MCD) (5.8±0.9%) (P=0.2). Following stimulation, of the 27 cytokines analysed, B-cell
production of IL-4, IL-9 and IL-10 levels were also significantly higher in FSGS HT group 
compared to non-HT group (Table 1). Among these cytokines, only IL-4 and IL-10 levels in 
FSGS HT group were significantly higher than MCD.
Conclusions: FSGS rituximab responders with HT phenotype demonstrated elevated 
DN memory B cells, IL-4 producing Be-2 cells and IL-10 producing regulatory B-cells, 
possibly explaining the T-cell hyporesponsiveness.
Funding: Government Support - Non-U.S.
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Complement Components Activation in Subjects with Primary FSGS 
Associates with Reduced Glomerular Expression of Decay Accelerating 
Factor (DAF)
Clara Fischman,1 Andrea Angeletti,2 Chiara Donadei,3 Deborah Malvi,4 
Chiara Cantarelli,5 Gaetano La Manna,4 Paolo Cravedi.1 1Icahn School of 
Medicine at Mount Sinai, New York, NY; 2Mount Sinai Nephrology, Pianoro, 
Italy; 3Nephrology, Dialysis and Kidney Transplantation, Bologna, Italy; 
4DIMES - University of Bologna, Bologna, Italy; 5University Hospital, Parma, 
Parma, Italy.
Background: Split products of complement system activation (Ba, Bb, C4a and C5b9) 
have been identified in plasma and urine of subjects with primary FSGS at the time of 
diagnosis. We hypothesized that complement system activation in FSGS results from a 
downregulation of DAF (CD55), a cell surface expressed complement regulator.
Methods: We measured urine C3a and C5a in 23 subjects with primary FSGS at the 
time of diagnosis and serially thereafter and in 10 healthy controls by ELISA. We stained for 
C3d and DAF in renal sections of 10 subjects with primary FSGS and of 10 healthy controls 
(healthy sections obtained from nephrectomies for neoplasm).
Results: At the time of diagnosis, patients with primary FSGS have detectable urinary 
C3a and C5a, whose values are positively correlated with proteinuria (Figure 1A-B). 
Urine of healthy subjects was undetectable for both C3a and C5a. After therapy, proteinuria 
decline was paralleled by a reduction in both C3a and C5a in the urine (Figure 1C). 
In patients with primary FSGS, glomerular C3 deposits were associated with reduced 
expression of CD55 (Figure 1D).
Conclusions: Reduced glomerular expression of DAF is associated with glomerular 
C3 deposits and higher levels of complement components in the urine, suggesting a possible 
effect of DAF in complement activation during FSGS, and, possibly, in mediating renal 
injury.
Funding: NIDDK Support
Figure 1. C3a (A) and C5a (B) in the urine from FSGS patients at the time of biopsy. 
Levels of proteinuria, urinary C3a, and C5a at the time of biopsy and serially thereafter (C). 
Representative C3d deposit (IF) and DAF expression (IHC) in the glomeruli from FSGS 
patients and control kidneys (D).
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Complement Activation Mediates Accelerated Tubular and Glomerular 
Inflammaging in Adriamycin (Adr)-Induced FSGS
Giuseppe Castellano,1 Alessandra Stasi,1 Chiara Divella,1 Rossana Franzin,1 
Fabio Sallustio,1,3 Claudia Curci,1 Paola Pontrelli,4 Loreto Gesualdo,1 
Paolo Cravedi.2 1University of Bari, BARI, Italy; 2Icahn School of Medicine at 
Mount Sinai, New York, NY; 3Department of Basic Medical Sciences, 
Neuroscience and Sense Organs, University of Bari, Bari, Italy; 4University of 
Bari-Dept. of Emergency and Organ Transplantation, Bari, Italy.
Background: Complement activation and chronic low-grade inflammation 
(inflammaging) have been implicated in renal disease progression. Whether complement 
activation on podocytes promotes inflammaging and mediates progression of FSGS is 
unknown.
Methods: We stimulated human primary podocytes with C5a (10-7M) and H2O2 
(300μM; positive control) for 24h and then we measured p21 gene expression by qPCR to 
assess senescence. Then, we injected newly developed DAFfl/fl podocin-CrePOS and DAFfl/
fl podocin-CreNEG controls (on a B6 background) with Adr (20mg/kg, i.v.). We serially 
measured urine albumin/creatinine (A/C) and at 6 weeks we quantified histological injury 
and stained sections for complement activation products and for senescence markers 
(WNT4, β-catenin, and p16INK4a).
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Results: C5a stimulation induced cellular senescence in podocytes as demonstrated 
by an increase in p21 marker in vitro (p<0.05). While podocin-CRENEG mice were resistant 
to Adr, DAFfl/fl-podocin-CrePOS had glomerular deposition of C3b and severe proteinuria 
(albumin/creatinine: 788.9±342.7 vs. 52.8±59.1mg/g; P<0.05). Immunohistochemistry 
analyses showed that DAFfl/fl-podocin-CrePOS had a significant increase in tubular WNT4, 
β-catenin and p16INK4a expression in the nuclei compared to podocin-CRENEG mice (p<0.05). 
Podocytes and epithelial cells of Bowman’s capsule also showed significantly increased 
WNT4 and β-catenin expression in DAFfl/fl-podocin-CrePOS compared to podocin-CRENEG 
animals (p<0.05) (Figure).
Conclusions: We demonstrated that DAF deficiency and complement activation 
induce accelerated senescence in podocytes and tubular epithelium. These data provide a 
rationale for testing inhibition of cell senesce as a strategy to retard complement-mediated 
renal disease progression.
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A Composite Diagnostic Assay for FSGS
Kamalika Mukherjee,1 Nada Alachkar,2 Changkyu Gu,4 Garrett Garborcauskas,5 
Monica H. Stevens,4 Jochen Reiser,3 Sanja Sever.4 1Massachusetts General 
Hospital/Harvard Medical School, Charlestown, MA; 2Johns Hopkins Hospital, 
Baltimore, MD; 3Rush University Medical Center, Chicago, IL; 4Massachusetts 
General Hospital, Charlestown, MA; 5The Massachusetts General Hospital, 
Charlestown, MA.
Background: Proteolytic cleavage of the membrane bound urokinase-type 
plasminogen activator receptor (uPAR) leads to the release of its soluble form suPAR, which 
has been identified in body fluids. The full-length suPAR undergoes further cleavage and 
exists in two additional forms: suPARII−III (fragment consists of domain 2 and 3) and suPARI 
(fragment consists of domain 1). Elevated levels of plasma suPAR and suPAR mediated 
β3 integrin activation on podocytes have been associated with renal dysfunction and the 
onset of chronic kidney disease (CKD). However, an increase in suPAR level has also been 
reported in other disease conditions such as cancer. Therefore, only suPAR level may not 
be sufficient as a diagnostic parameter for CKD. Here, we sought to develop a composite 
scoring system, which considers multiple biomarkers, to generate an efficient diagnostic 
platform for focal segmental glomerulosclerosis (FSGS), a type of CKD.
Methods: Serum samples obtained from healthy individuals and patients with FSGS 
were analyzed. The levels of full-length suPAR, αvβ3 integrin activation and the presence 
of suPARII−III fragment were determined. The data were statistically analyzed to develop a 
biomarker based predictive assay for FSGS.
Results: The majority of FSGS patients exhibited high levels of suPAR and αvβ3 
integrin activation on human podocytes in culture. A subset of patients’ serum was positive 
for the presence of suPARII-III fragment.
Conclusions: The composite diagnostic assay suggests suPAR fragment driven αvβ3 
integrin activation in FSGS.
Funding: NIDDK Support
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Complement Deposits Are Not Just Non-Specifically Entrapped in FSGS: 
C4d Can Precede the Development of Recurrent FSGS in Allograft 
Biopsies
Nina A. Van de Lest, Malu Zandbergen, Ron Wolterbeek, Jan A. Bruijn, 
Ingeborg M. Bajema, Marion Scharpfenecker, Jamie S. Chua. Leiden University 
Medical Center, Leiden, Netherlands.
Background: Complement deposition in focal segmental glomerulosclerosis (FSGS) is 
often considered aspecific entrapment in sclerotic lesions. However, recent studies showed 
that complement activation may be involved in the development of FSGS. We previously 
found that C4d deposition precedes the development of segmental glomerulosclerosis in 
an animal model of FSGS, and that C4d is present in non-sclerotic glomeruli of patients 
with FSGS. Here, we investigated if complement activation can precede the development 
of recurrent FSGS after transplantation. To this end, we studied C4d deposition in 
transplantation biopsies prior to the development of recurrent FSGS lesions.
Methods: We stained allograft biopsies without FSGS lesions from 34 patients with 
native primary FSGS for C4d: 18 patients developed recurrent proteinuria or recurrent 
FSGS in follow-up biopsies and 16 patients did not. As controls, we included allograft 
biopsies from 34 patients with a native kidney disease other than FSGS. Patients with 
confounding factors for C4d deposition were excluded.
Results: In allograft biopsies of patients with recurrent proteinuria or recurrent FSGS, 
glomerular C4d preceded the recurrence of FSGS lesions in 72% of patients (n=18). This 
was significantly more prevalent than in transplantation controls (27%; p=0.001). In 16 
patients who did not develop recurrent proteinuria or FSGS, the prevalence of glomerular 
C4d was similar compared to transplantation controls (50% and 27%, respectively; p<0.10).
Conclusions: Our data show that C4d deposition precedes the recurrence of segmental 
lesions in patients with native FSGS, specifically at the onset of proteinuria. As the FSGS 
lesions had not yet developed, our data refute the hypothesis of non-specific entrapment 
as sole etiology for observed complement deposition. As C4d is a stable biomarker of 
complement activation, our data provide further evidence for complement activation in 
the development of FSGS. We suggest that a subgroup of patients with FSGS may have 
increased susceptibility to complement-mediated injury. Complement-inhibiting therapies 
could be promising in these cases.
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Apolipoprotein L1 Dynamics in Human Parietal Epithelial Cell (PEC) 
Molecular Phenotype Kinetics
Vinod Kumar,1 Nitpriya Paliwal,5 Xiqian Lan,5 Kamesh R. Ayasolla,5 Seyedeh 
Shadafarin Marashi Shoshtari,2 Sheetal Chowdhary,3 Ashwani Malhotra,8 
Catherine Meyer-Schwesinger,4 Karl Skorecki,6 Pravin C. Singhal.7 1Fienstine 
Institute for Medical Research, New York, NY; 2The Feinstein Institute for 
Medical Research, Manhasset, NY; 3Feinstein Institute of Medical Research, 
New Hyde Park, NY; 4University of Hamburg, Hamburg, Germany; 5Feinstein 
Institute for Medical Research, Manhasset, NY; 6Rambam Health Care Campus, 
Haifa, Israel; 7North Shore LIJ Health System, Great Neck, NY; 8Feinstein 
Institute Medical Research and NSLIJ, MANHASSET, NY.
Background: PECs do not express APOL1. We hypothesize that APOL1 expression 
emerges in PECs for podocytes’ (PDs) renewal (PECs’ transition) in adverse milieus. We 
further hypothesize that the absence of APOL1 favors the PEC phenotype and that the 
induction of APOL1 transitions to PD renewal.
Methods: Immortalized human PECs, which proliferate at 33οC and differentiate 
(transition) after 14 days after incubation in special media were characterized and used. 
PECs’ expression of APOL1 was evaluated at different time intervals (0, 4, 8, 14 days) 
during their transition (Tr). Effects of a miR193a inhibitor/ overexpression of miR193a 
as well as APOL1-silencing/APOL1-overexpression was evaluated on PECs’ expression 
APOL1 and miR193a. Effects of vitamin D receptor agonist (VDA), IFN-y, and HIV were 
examined on the induction of APOL1 and associated expression of PD markers in HEKs 
and PECs. Luciferase assay was used to establish a putative interaction between miR193a 
and APOL1 in PECs. To confirm the PEC induction of APOL1 in vivo, renal biopsy 
specimens of HIVAN patients were co-labeled for APOL1 and synaptopodin.
Results: PECs at 33οC did not exhibit APOL1 expression. During PECs’ transition, 
APOL1 expression coincided with the expression of PD markers (PEC transition) along 
with down-regulation of miR193a. The induction of APOL1 down-regulated miR193a and 
induced PD markers in PECs; whereas, the APOL1-silencing in Tr-PECs up- regulated 
miR193a expression suggesting a reciprocally linked feedback loop relationship between 
APOL1 and miR193a. HIV, IFN-γ, and VDA down-regulated miR193a expression as well 
as induced the expression of APOL1 and PD markers both in PECs. Since silencing of 
APOL1 attenuated HIV-, VDA-, and IFN-y-induced expression of PD makers, it appears 
that APOL1 is an important functional constituent of miR193a-APOL1 axis. This notion 
was further confirmed by enhanced expression of PEC markers in APOL1 silenced Tr-PECs 
despite down-regulation of miR193a. Luciferase assay suggested a putative interaction 
between miR-193a and APOL1. Renal biopsy specimens from HIVAN patients revealed 
PECs’ expression of APOL1 and synaptopodin.
Conclusions: APOL1 absence favors PECs’ phenotype but its expression facilitates 
PECs transition
Funding: NIDDK Support
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Modulation of APOL1-miR193a Axis Protects Against Apoptosis in 
Adverse Milieus
Vinod Kumar,4 Nitpriya Paliwal,2 Xiqian Lan,2 Kamesh R. Ayasolla,2 
Sheetal Chowdhary,6 Seyedeh Shadafarin Marashi Shoshtari,7 
Ashwani Malhotra,5 Karl Skorecki,1 Pravin C. Singhal.3 1Rambam Health Care 
Campus, Haifa, Israel; 2Feinstein Institute for Medical Research, Manhasset, 
NY; 3Medicine, Feinstein Institute for Medical Research, Manhasset, NY; 
4Fienstine Institute for Medical Research, NEW YORK, NY; 5Feinstein Institute 
Medical Research and NSLIJ, MANHASSET, NY; 6Feinstein Institute of Medical 
Research, New Hyde Park, NY; 7The Feinstein Institute for Medical Research, 
Manhasset, NY.
Background: Both Puromycin aminonucleoside (PAN) and adriamycin are known to 
promote podocyte (PD) apoptosis in both in vitro and in vivo studies. We have recently 
reported that APOL1 wild-type (G0) has a potential to preserve podocyte molecular 
Glomerular Diseases: Immunology and Inflammation - III
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
828
J Am Soc Nephrol 29: 2018 Poster/Saturday
phenotype in high glucose milieu. APOL1 inversely regulates PD expression of miR193a 
and forms reciprocally linked feedback relationship. We now hypothesize that upregulation 
of APOL1-miR193a axis has a potential to prevent PD apoptosis in PAN and adriamycin 
milieus.
Methods: To aim differentiation, immortalized human podocytes (PDs) stably 
expressing vector (PDV) or APOL1G0 (wild- type, PDG0) were incubated in media for 
10 days. Differentiated (D) PDVs and PDG0 were treated with different concentrations 
of Adriamycin (0,5, 15, 30, 50, and 100 nM) or PAN (0, 5, 10, 25, 50, and 100 nM) for 
48 hours (n=4); in other sets, DPDVs were incubated in media containing Adriamycin 
(30 mM), PAN (50 nM), with/without miR193a inhibitor (25 nM) for 48 hours (n=4). 
Cells were evaluated for reactive oxygen species (ROS) generation (DCF detection assay), 
caspase-3 cleavage, and apoptosis (TUNEL assay). Proteins and RNAs were extracted 
from cells treated under similar conditions (n=4). Protein blots were probed for APOL1 
and caspase-3; RNAs were assayed for miR193a. DPDs were transduced with either empty 
vector and miR193a plasmid and evaluated for APOL1 and caspase-3 expressions.
Results: PDVs displayed higher (P<0.01 vs. respective controls) generation of ROS 
and a greater (P<0.01 vs. respective controls) percentage of apoptosis when compared 
to PDG0, both in adriamycin and PAN milieus. PDG0 displayed enhanced (two-fold) 
expression of APOL1, but decreased (2.8-fold) miR193a levels when compared to PDVs. 
Both Adriamycin and PAN exhibited enhanced PD expression of miR193a and caspase-3. 
MicroRNA193a inhibitor decreased (3-fold) miR193a levels, increased APOL1 (1.8-fold) 
expression, and attenuated (P<0.5 vs. adriamycin and PAN) apoptosis in both adriamycin 
and PAN milieus. DPDs overexpressing miR193a displayed decreased expression of 
APOL1 and enhanced cleavage of caspase-3.
Conclusions: APOL1Go provides protection against apoptosis in adverse milieus 
through down-regulation of miR193a and attenuated generation of ROS.
Funding: NIDDK Support
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A Cross-Talk Between HIV-Injured Podocytes and Parietal Epithelial 
Cells (PECs) Results in Proliferation of PECs
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Seyedeh Shadafarin Marashi Shoshtari,7 Ashwani Malhotra,3 Catherine Meyer-
Schwesinger,4 Karl Skorecki,5 Pravin C. Singhal.6 1Feinstein Institute for 
Medical Research, Manhasset, NY; 2Fienstine Institute for Medical Research, 
NEW YORK, NY; 3Feinstein Institute Medical Research and NSLIJ, 
MANHASSET, NY; 4University of Hamburg, Hamburg, Germany; 5Rambam 
Health Care Campus, Haifa, Israel; 6North Shore LIJ Health System, Great 
Neck, NY; 7The Feinstein Institute for Medical Research, Manhasset, NY; 
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Background: HIV-associated nephropathy is characterized by an abundance of 
proliferating PECs in Bowman’s space. The involved mechanism of PECs proliferation 
in HIV milieu is not clear. Interleukin (IL)-1 β has been reported to stimulate PECs 
proliferation. We have recently reported that HIV infection stimulates generation of IL-1β 
by PDs. We now hypothesize that a cross-talk between HIV-infected PDs and PECs would 
promote PECs proliferation.
Methods: Immortalized differentiated human PDs (DPDs) were transduced with either 
vector (DPDV) or HIV (NL4-3, DPDHIV) and assayed for pyroptosis (morphologic assay). 
Control DPDs and DPDHIV were incubated in serum-free media for 24 hours. Incubation 
(conditioned, C) media was collected and stored at -80°C. PECs were incubated in serum-
free media containing 10% of control (DPDV) and experimental (DPDHIV) conditioned 
media for 48 hours. In another set of experiments, PECs were incubated in serum-free 
media containing 10% control and experimental media with or without IL-1β (neutralizing) 
antibodies for 48 hours. Cells were evaluated for proliferation by MTT cellular growth 
assay. To confirm the role of cross-talk, PECs were grown in outer wells and DPDV/
DPDHIVs were seeded into inner wells (Trans-well plates). After 48 hours, cells in outer 
wells were assayed for proliferation. Cellular lysates/incubation media of DPDVs and 
DPDHIVs were assayed for IL-1β by ELISA. Additionally, PECs grown on coverslips were 
treated with 10% control and experimental media for 48 hours followed by immunolabeling 
for either PCNA or Ki67.
Results: DPDHIV displayed a higher percentage of cells with pyroptosis (P<0.01 vs 
respective controls). Cellular lysates and incubation media of DPDHIV showed increased 
(P<0.05 vs. DPDV) content of IL-1β. Conditioned media of DPDHIV promoted PECs 
proliferation; however, anti-IL-1β antibody partially inhibited DPDHIV-conditioned 
media-mediated proliferation. PECs growing in outer wells of trans-well plates containing 
DPDHIV also displayed enhanced proliferation. PECs treated with DPDHIV conditioned 
media exhibited a higher percentage (P<0.01 vs. DPDV) of PCNA/Ki67 +ve cells.
Conclusions: A cross-talk between PDs to PECs promotes PECs proliferation in HIV 
milieu.
Funding: NIDDK Support
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HIV-Induced Parietal Epithelial Cell Proliferation: Role of miR193a
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Pravin C. Singhal.7 1Fienstine Institute for Medical Research, NEW YORK, NY; 
2Feinstein Institute for Medical Research, Manhasset, NY; 3The Feinstein 
Institute for Medical Research, Manhasset, NY; 4Feinstein Institute Medical 
Research and NSLIJ, MANHASSET, NY; 5University of Hamburg, Hamburg, 
Germany; 6Rambam Health Care Campus, Haifa, Israel; 7North Shore LIJ 
Health System, Great Neck, NY; 8Feinstein Institute of Medical Research, New 
Hyde Park, NY.
Background: miR193a has been reported to play an important role in the determination 
of glomerular epithelial cells’ phenotype. miR193a is a tumor suppressor gene and its 
downregulation has been associated with enhanced cellular proliferation. HIV-associated 
nephropathy (HIVAN) is characterized by an accumulation of proliferating parietal 
epithelial cells (PECs) in the Bowman’s space; however, the involved mechanism is not 
clear. Since HIV down-regulates the expression of miR193a, we asked whether HIV is 
stimulating PECs proliferation through down-regulation of miR193a.
Methods: Immortalized PECs were transduced with vector (PECV) or different 
concentrations of HIV (104, 103, 102, and 101 GEU/ml; PECHIV) followed by growth 
arrest (24 hours), followed by incubation in media containing 1% serum for 48 hours 
(n=4). Cell growth was assayed by cell count and MTT assay. To determine the role of 
miR193a, PECVs and PECHIV were transduced with empty vector (25 nM), miR193a 
(25 nM), an inhibitor of miR193a (25 nM) plasmids (n=4). After 48 hours, proteins and 
RNAs were extracted. Protein blots were probed for molecular markers of mTOR (p-mTOR, 
p-70S6K, p-4EBP, and p-eEF) and epithelial-mesenchymal transition (α-SMA, SNAIL, and 
fibronectin; EMT) pathways and reprobed for β-actin. RNAs were assayed for miR193a. In 
vivo studies, renal tissues of 4-week old control and HIV transgenic (Tg26) mice (n=6) were
evaluated for the activation of mTOR and EMT pathways (Western blotting analysis and 
immuno-labeling of renal cortical sections). Renal tissues from control and Tg26 mice were 
also examined for miR193a expression (Fluorescent in situ hybridization, FISH).
Results: PECHIV stimulated PEC proliferation at lower concentrations (103 and 
102 GEU/ml). PECHIVs-overexpressing miR193a exhibited a decrease in proliferation 
when compared to PECHIVs. PECHIVs and renal tissues from Tg26 mice showed the 
activation of the mTOR as well as EMT pathways. Renal cortical sections of Tg26 mice 
showed a decrease in miR193a expression when compared to control mice; additionally, 
renal cortical sections of Tg26 mice displayed enhanced proliferation of PECs as indicated 
by an increased number PCNA +ve cells in Bowman’s space.
Conclusions: HIV induces PEC proliferation through down-regulation of miR193a.
Funding: NIDDK Support
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Disrupted APOL1-miRNA Axis Induces an Imbalance Between Autophagic 
Load and Handling in Podocytes Expressing APOL1 Risk Alleles
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Background: MicroRNA193a has been reported to enhance autophagy in several cell 
types. A recent report suggests that human podocytes (PDs) expressing APOL1 risk alleles 
(G1 and G2) have an altered autophagic reflux. We hypothesize that disruption of APOL1-
miR193a axis would contribute to an imbalance between autophagic load and handling in 
PDs expressing APOL1 risk alleles.
Methods: Immortalized human podocytes (PDs) stably expressing vector, APOL1G0/
G1/G2 were differentiated and evaluated for APOL1 (protein and mRNA) and miR193a 
expressions. To determine the effect of miR193a on autophagy, PDs were transfected 
with empty vector or different concentrations of miR193a plasmid (0, 50, 100 nM), or an 
inhibitor of miR193a (0, 25, 50, and 100 nM), followed by an evaluation for autophagy 
markers (P62, LC3II, and beclin 1). To determine the role of the mTOR pathway, PDs 
were transfected with either empty vector, miR193a, or a miR193a inhibitor (plasmids) 
followed by analysis for phos-mTOR and GAPDH by Western blotting. To examine the role 
of miR193a-APOL1 axis, PDs were transfected with either scrambled or APOL1 siRNA 
and then evaluated for miR193a expression and autophagy markers. To examine autophagic 
flux, PDs expressing vector (PDV), APOL1G0/G1/G2 were transfected with GFP-tagged 
LC3II plasmid and treated with Bafilomycin (100 nm) and examined at 0, 2, and 4 hours 
under a confocal microscope.
Results: APOL1G0 down-regulated but APOL1G1 and APOL1G2 upregulated 
miR193a expression in PDs. Overexpression of miR193a down-regulated but a miR193a 
inhibitor enhanced the expression of phos-mTOR. APOL1-silenced PDs showed enhanced 
expression of miR193a as well as of autophagy markers. PDs expressing APOL1G1 and G2 
displayed a higher expression of LC3II in a time course manner in Bafilomycin blockade 
experiments, suggesting an increased load or sluggish autophagic flux. Since APOL1 risk 
alleles displayed 2.5- fold higher expression of miR193a when compared to PDs expressing 
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APOL1G0, it appears that they carried an enhanced autophagic load, in addition to sluggish 
autophagic flux.
Conclusions: Disrupted APOL1-miR193a axis induces an imbalance between 
autophagic load and handing in podocytes expressing APOL1 risk alleles.
Funding: NIDDK Support
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What’s the RUSH? The Role of Calcium in APOL1 Toxicity
Joseph A. Giovinazzo,1 Russell P. Thomson,1 Nailya Khalizova,1 Nirav Malani,3 
Ryan Schreiner,2 Jayne Raper.1 1CUNY Hunter College, Brooklyn, NY; 2Weill 
CornellMedical College, New York, NY; 3Independent, Flemington, NJ.
Background: APOL1 is an innate immunity protein that forms toxic ion channels in 
trypanosomes. Variants of APOL1, G1 and G2 but not G0, are linked to kidney disease, 
however the mechanism responsible remains controversial. Here we propose that the key 
upstream event is APOL1 localization to the plasma membrane (PM), where it forms 
channels that lead to the passage of ions across the membrane, with Ca2+ influx being a 
driver of cell death.
Methods: APOL1 was expressed in FlpIn TREX 293 cells or HEK and CHO cells 
via the Retention Using Selective Hooks (RUSH) system. RUSH is a streptavidin-binding 
method that retains tagged APOL1 in the ER until biotin addition. Toxicity was measured 
via LDH release. rAPOL1 was purified from E. coli and reconstituted in planar lipid bilayers 
to measure channel selectivity. High throughput widefield microscopy was performed to 
quantify cytosolic and ER Ca2+ in cells expressing indicators GCaMP6f and ER-LAR-
GECO, along with viability dye DRAQ7. IF with confocal microscopy was performed to 
quantify APOL1 localization.
Results: When retained in the ER, G1 and G2 are not toxic, and only release from the 
ER leads to cell death. The toxicity of G1 is delayed relative to G2, and G0 is not toxic. 
A previous study in Xenopus oocytes reported that APOL1 leads to Ca2+ influx. We tested 
rAPOL1 selectivity and found that all variants form channels that are permeable to Ca2+. 
Furthermore, G1 and G2 toxicity is dependent on extracellular Ca2+, as increasing [Ca2+] 
led to more cell death, while chelation with EGTA rescued. Measurement of cytosolic Ca2+ 
revealed that G1 and G2, only after ER release, led to a significant Ca2+ influx over 2-4h that 
preceded cell swelling and death. IF indicated that APOL1 localizes to the PM prior to Ca2+ 
influx, and that G1 traffics slower than G2. Simultaneous measurement of cytosolic and ER 
Ca2+ demonstrated that there is no ER Ca2+ release.
Conclusions: These data demonstrate that the toxicity of G1 and G2 requires PM 
localization and an influx of Ca2+. We also report a novel difference between the trafficking 
and toxicity kinetics of G1 and G2. The ion channel at the plasma membrane is likely the 
key event that leads to cell death, and the sustained influx of Ca2+ may unify the disparate 
theories of APOL1 toxicity, from mitochondrial damage to inflammatory pathways, which 
can all be triggered by Ca2+.
Funding: Other NIH Support - BREAD: Basic Mechanisms Underlying Species-
Specific Trypanosome Resistance #0965413, Private Foundation Support
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Characterization of Novel APOL1 G0, G1S342G and APOL1-/- Podocyte 
Cell Lines and Their Response to HIV Infection
Heidi Karttunen,2 Alan Rosales,2 Xiaobo Gao,2 Michael J. Ross.1 1Albert 
Einstein College of Medicine/ Montefiore Medical Center, Bronx, NY; 2Albert 
Einstein College of Medicine, Bronx, NY.
Background: Persons with APOL1 high risk genotypes are at increased risk of several 
forms of progressive CKD and remarkably, have a 29 to 89-fold increased risk of HIV-
associated nephropathy (HIVAN). HIV gene expression in renal epithelial cells, including 
podocytes, is a critical mediator of HIVAN pathogenesis but previous studies have failed 
to detect an increase in APOL1 expression in HIVAN biopsy specimens, suggesting that 
changes in APOL1 function, and not expression levels, may drive pathogenesis. The 
APOL1 G1 risk allele consists of 2 nonsynonymous SNPs (S342G and I384M) and S342G 
is likely sufficient to drive the risk attributed to G1. Since overexpression models may not 
accurately model APOL1 function, we used CRISPR-Cas9 to generate isogenic human 
podocyte lines with APOL1 G0, G1S342G, and APOL1-/- and determine the effects of APOL1 
genotype upon response to HIV infection.
Methods: We used CRISPR-Cas9 to modify conditionally immortalized APOL1G0/G0 
podocytes. Guide RNAs and single stranded oligonucleotides were designed to target the 
APOL1 locus to generate the G1S342G allele or delete exons 4 and 5 (APOL1-/-). In lentiviral 
transduction studies, podocytes were transduced with VSV-pseudotyped NL4-3DG/P-
EGFP (HIV), or HR-IRES-EGFP (control). Endogenous APOL1 was immunprecipitated 
after HIV or control infection and APOL1-binding proteins were identified by mass 
spectrometry.
Results: Clonal homozygous G1S342G and APOL1-/- podocytes lines were generated. All 
podocyte lines expressed normal podocyte markers, including podocin. APOL1 expression 
was lower in G1S342G than G0 podocytes and APOL1 expression increased as podocytes 
were differentiated at 37C. Proteasome inhibition increased APOL1 protein abundance, 
suggesting that it is degraded by the ubiquitin-proteasome system. HIV infection did not 
increase APOL1 expression in any podocyte cell lines. Immunoprecipitation of endogenous 
APOL1 after HIV or control infection and identification of APOL1 binding proteins by 
mass spectrometry identified numerous cellular proteins that differentially bind G1S342G in 
the presence of HIV infection with known roles in kidney injury.
Conclusions: We developed novel podocyte cell lines with alterations in the APOL1 
coding sequence that will allow for studies to determine changes in function of the APOL1 
alleles when expressed at physiologic levels.
Funding: NIDDK Support
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APOL1 RNA Is Differentially Spliced in Nephrotic Syndrome and in 
Response to Therapy
Jiro Kino,1 Amy Webb,2 Melinda A. Chanley,3 William E. Smoyer,3,2 
Shipra Agrawal.1,2 1The Research Institute at Nationwide Children’s Hospital, 
Columbus, OH; 2Ohio State University, Dublin, OH; 3Nationwide Children’s 
Hospital, Columbus, OH.
Background: APOL1 has been a subject of intense research since the discovery of the 
association of its risk alleles with heightened risk for end stage kidney disease in African 
Americans. However, the potential role of alternate splicing of APOL1 in podocyte biology 
and in the regulation of kidney disease is unknown. Recent evidence suggests that the 
presence and/or absence of exons 2 and 4 distinguish known splice variants of APOL1, and 
that exon 4 contributes to cytotoxicity. We hypothesized that APOL1 RNA is differentially 
spliced in nephrotic syndrome (NS) and in response to glucocorticoid (GC) therapy, thus 
playing a potential pathophysiological role in both disease and health, regardless of APOL1 
haplotype.
Methods: APOL1 RNA and splice variant expression was analyzed in podocytes 
injured with puromycin aminonucleoside (PAN), and treated with dexamethasone (Dex) by 
RT-PCR using splice variant specific primers. Splice variant analyses were also performed 
in circulating leukocytes of children with steroid sensitive (SSNS) and steroid resistant NS 
(SRNS), before and following initial GC therapy (N =8 SSNS and 8 SRNS paired samples). 
T-test and 2 way ANOVA statistical analyses were performed to measure relative variant
expression.
Results: Podocytes expressed all 5 known splice variants of APOL1 [v.A, variant3 
v.A, v.B1,v.B3 and v.C]. Higher relative expressions of exon 4 (+) [v.A, v.B1] and exon 2 
(-) [v.A, v.C] forms were observed, with variant 1 [v.A] the most predominantly expressed 
form. Dex increased the relative expression of splice variants exon 4 (+) and exon2 (-),
which in contrast was decreased with PAN-induced injury. Although RNASeq data analysis 
was unable to detect these variants, in-depth RT-PCR analyses revealed that both exon 4 (+) 
and (-) variants were expressed in the circulating leukocytes of SSNS and SRNS patients, 
while exon 2 (+) forms were only minimally expressed. SRNS patients had increased
levels of almost all APOL1 variants [except exon 2 (+)] compared to SSNS patient prior to 
GC treatment. GC treatment induced expression of most of the recognized splice variants
increased in SSNS, but decreased them to varying degrees in SRNS.
Conclusions: Cultured podocytes and circulating human leukocytes express distinct 
APOL1 splice variant patterns and differential splicing of APOL1 is associated with NS and 
in response to GC therapy.
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CD80 and CD163 as Biomarkers of Nephrotic Syndrome
Marie C. Hogan,1 Anatilde M. Gonzalez guerrico,1 Jonathan P. Troost,2,3 
Adam M. Wright,1 Fernando C. Fervenza,1 George G. Klee,1 John C. Lieske.1 
NEPTUNE Consortium 1Mayo Clinic, Rochester, MN; 2University of Michigan, 
Ann Arbor, MI; 3NEPTUNE Consortium, Ann Arbor, MI.
Background: Cellular expression of CD80 and CD163 may play a role in the 
pathogenesis of certain glomerulopathies. Urinary or blood concentrations may predict and/
or track response to specific immunosuppressive therapies and long term renal function.
Methods: Urine was obtained from Mayo Clinic patients (286) and NEPTUNE 
cohort participants (104) with biopsy-proven minimal change disease (MCD, 103), focal 
segmental glomerulosclerosis (FSGS, 97), lupus nephritis (LN, 31), IgA nephropathy 
(IgAN, 28), and membranous nephropathy (MN, 54), as well as non glomerular disease 
patients with autosomal dominant polycystic kidney disease (ADPKD, 9), pyuria (19), and 
controls (34). Data expressed as (mean, median (IQR)) was analyzed by Kruskal-Wallis 
test, generalized estimating equation models (GEE) or receiver operating characteristic 
(AUC) curve analysis.
Results: CD80/Creatinine and CD163/Creatinine were higher in relapse vs remission 
in paired urine samples of MCD and FSGS cases (GEE: Active vs. remission p<0.0001); 
MCD vs. FSGS p<0.0001). Urinary CD80/Creatinine ratios were higher in active MCD, 
LN, DN and CD163/Creatinine was higher in active LN compared to active cases of other 
glomerular diseases or controls (Table 1). Differences remained significant after adjusting 
for proteinuria (p≤0.01; GEE).
Conclusions: Urinary CD80 and CD163 excretions varied between disease groups and 
by disease activity. These results suggest a pathogenic role for these molecules in certain 
glomerular diseases, including diabetic nephropathy.
Funding: Commercial Support - Bristol-Myers Squibb, Private Foundation Support
Urinary CD80/creat and CD163/Creat discriminate by proteinuric kidney disease type.
GEE analysis of Log-CD80/Creat and CD163/Creat across controls, pyuria, ADPKD and 
samples with proteinuria ≥2 for DN, FSGS, IgAN, Lupus, MCD, and MN.
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Identifying the Role of Soluble Circulating Permeability Factors in 
Proteinuria in a Zebrafish Parabiosis Model
Heiko J. Schenk,2 Janina Müller-Deile,2 Patricia A. Schroder,1 Mario Schiffer.2,1 
1Mount Desert Island Biological Laboratory, Salisbury Cove, ME; 2Hannover 
Medical School, Hannover, Germany.
Background: Proteinuria may be induced by an impairment in any component of the 
glomerular filtration barrier. To determine the role of circulating permeability factors to 
cause proteinuria through glomerular damage as a result from reduced specific podocyte 
protein expression, we developed a parabiosis-based zebrafish model to generate a common 
circulation between two zebrafish larvae.
Methods: Zebrafish eggs were dechorionated at the 128-cell blastula stage and moved 
to the desired orientation for fusion that was achieved by a micro cell transfer from one 
embryo to the other with a glass micropipette. We injected npnt-morpholino (MO) into the 
yolk of a 1-4 cell embryo of Tg(flk1-mCherry) zebrafish and performed the fusion at a 256-
cell stage with control Tg(l-fabp:eGFP-DBP) zebrafish embryos. By using a FITC-labelled 
MO, we ruled out a MO-transfer between both parabionts. Common circulation and loss of 
plasma proteins were investigated and the glomeruli of both zebrafish pairs were analyzed 
using electron microscopy.
Results: We fused blastulae from Tg(l-fabp:eGFP-DBP) zebrafish that express a green 
fluorescent vitamin D binding protein in their blood plasma with blastulae of Tg(flk1-
mCherry) zebrafish that express a red fluorescent endothelium. Confocal imaging of 
parabiotic zebrafish with these backgrounds showed a detectable green fluorescent plasma 
protein from the Tg(l-fabp:eGFP-DBP) zebrafish in the red fluorescent blood vessels of the 
Tg(flk1-mCherry) parabiotic partner at 72 hpf, indicative of a common circulation system. 
Fluorescence analysis of the parabiotic zebrafish larvae after npnt knockdown revealed a 
reduction of the eGFP-labelled protein from the common circulatory system suggestive 
of proteinuria. Knockdown of npnt in the injected parabiont showed podocyte effacement 
and altered glomerular basement membrane. Remarkably, also the control parabiotic 
partner developed podocyte effacement and glomerular endothelial swelling as well but 
had a regular glomerular basement membrane. We could not only detect proteinuria and 
glomerular damage caused by the knockdown of the podocyte gene npnt in injected fish, 
but also in the fused partner.
Conclusions: These data suggest that circulating permeability factors may be induced 
by proteinuria even when an induced dysregulation of a podocyte gene is the initiating 
cause.
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Podocyte-Specific Crb2 Knockout Mice Cause Proteinuria
Kan Katayama,1,2 Yugo Ito,3 Masaaki Ito.1 1Department of Cardiology and 
Nephrology, Mie university graduate school of medicine, Tsu, Japan; 
2Department of Medical Biochemistry and Biophysics, Karolinska Institute, 
Stockholm, Sweden; 3Department of Medical Biochemistry and Biophysics, 
Karolinska Institute, Stockholm, Sweden.
Background: Crumbs 2, Crb2 is known to be expressed in the podocytes. Knockdown 
of crb2 caused cardiac edema in zebrafish and full knockout of Crb2 resulted in embryonic 
lethality. Moreover, there have been reports of steroid-resistant nephrotic syndrome by 
CRB2 mutations. However, its precise mechanism is still elusive.
Methods: We generated conditional Crb2 floxed mice that possessed loxP sites 
flanking exon 7 and 8. Podocyte-specific Crb2 knockout mice were generated by breeding 
Crb2 conditional knockout mice with NPHS2-Cre mice. Urine, blood, and renal histology 
were examined in NPHS2-Cre or Crb2 flox/flox or NPHS2-Cre & Crb2 flox/flox mice.
Results: NPHS2-Cre & Crb2 flox/flox mice showed massive proteinuria at two or six 
months of age compared to NPHS2-Cre mice or Crb2 flox/flox mice. Blood urea nitrogen 
or serum creatinine at two months of age was comparable among the three groups. Although 
renal histology at two months of age was also comparable among the three groups, 
glomerular sclerotic indices of NPHS2-Cre & Crb2 flox/flox mice at six months of age 
were significantly higher than those of NPHS2-Cre mice or Crb2 flox/flox mice.
Conclusions: Knockout of Crb2 in the podocytes might play an important role in 
developing proteinuria.
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Podocyte-Expressed STAT5 Confers Protection During Experimental 
Glomerulonephritis and Adriamycin Nephropathy in Mice
Kevin Louis,2 Aïssata Niasse,2 Anthony Corchia,2 Hélène Dobosziewicz,2 
Placier Sandrine,2 Yi-chun Xu-dubois,2 Sophie Vandermeersch,2 Eric Rondeau,3 
Laurent Mesnard,3 Yosu Luque.1 1Assistance Publique Hopitaux de Paris, Paris, 
France; 2Inserm U1155, Hôpital Tenon, Paris, France; 3APHP; University 
Paris 6, PARIS, France.
Background: Glomerular diseases are a leading cause of chronic kidney failure and the 
podocyte is one of the main target of these diseases. We previously evidenced a protective 
role for a podocyte-expressed immune receptor such as the common gamma chain (γC) 
during glomerulonephritis. We also found that STAT5, a transcriptional factor classically 
described and activated downstream γC in T cells is upregulated in podocytes during 
glomerulonephritis. Hitherto, STAT5 role in podocyte remains to be determined.
Methods: Using mice with a podocyte-specific deletion of Stat5, we analyzed the role 
of STAT5 in two experimental models of glomerular diseases.
Results: First, during crescentic glomerulonephritis, podocytic-STAT5 deficient 
mice developed increased proteinuria compared to their wild-type littermates. Second, 
during adriamycin induced-nephropathy, the absence of podocyte STAT5 led to increased 
albuminuria and severe podocytic injuries in comparison to controls (Figure 1). Moreover 
podocytic lesions were associated with loss of podocyte differentiation markers such as 
WT1 especially in podocytic-STAT5 deficient animals. Renal T-cells and macrophages 
infiltration were not affected by the deletion of podocytic Stat5.
Conclusions: Taken together, our results suggest an yet unsuspected protective role of 
podocytic γC /STAT5 signaling during glomerular diseases.
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Expression of Chemokine Receptor 2 (CCR2) on Renal Podocyte 
Progenitor Stem Cells
Bin N. Zhao,1 Zhenhua Miao,2 Linda Ertl,2 Xiaoping Zang,3 Israel Charo,2 
Thomas J. Schall,2 Rajinder Singh.2 1Chemocentryx Inc., Mountain View, CA; 
2ChemoCentryx, Mt View, CA; 3ChemoCentryx, Inc., Mountain View, CA.
Background: Several lines of evidence support a role for chemokine receptor 2 (CCR2) 
through interaction with its ligand CCL2 in the pathogenesis of kidney diseases. We have 
shown recently that inhibition of CCR2 by small molecule inhibitors markedly reduce 
proteinuria, improve renal function and preserve or restore podocyte density in murine 
models of Focal Segmental Glomerulosclerosis (FSGS). To understand the mechanism of 
this protection, we have examined the expression of CCR2 on human and murine kidneys.
Methods: CCR2 expression on the kidneys was assessed by immunohitochemistry 
(IHC) on formalin fixed, paraffin-embedded human and mouse kidney sections, and by 
flow cytometry with freshly isolated murine renal cells.
Results: IHC with a human CCR2 antibody revealed CCR2 expression on glomerular 
cells in human CCR2 knock-in, but not CCR2 knockout mouse kidneys. Flow cytometry 
of freshly isolated murine kidney cells confirmed CCR2 expression on CD45 negative-
cells, indicating that the positive IHC signal was not due to mature blood cells. CD133 
and CD24 are cell surface markers of a heterogeneous population of renal progenitor 
cells, and approximately 5% of these cells also express the podocyte marker podocalyxin 
(PDX), marking them as podocyte precursors. By flow cytometry we found that ~8% of 
the murine renal CD133+CD24+ PDX+ cells, were also positive for CCR2, indicating that 
CCR2 was present on a subset of cells destined to become mature podocytes. Finally we 
used IHC to examine CCR2 expression on human renal biopsies of FSGS patients and non 
FSGS patients and found out that increased staining for CCR2 in the FSGS kidneys in the 
glomerulus and Bowman’s capsule areas. These data provide clear evidence that CCR2, the 
target of the small molecule that we have shown reduces proteinuria and improves renal 
function in murine models of FSGS is present on non-hematopoietic cells in the kidney.
Conclusions: This is the first demonstration of the presence of CCR2 on renal 
progenitor cells that are destined to become podocytes, and reveals a potential new role for 
this chemokine receptor whose function as been heretofore mainly connected to monocyte/
macrophage biology. Taken together, these data provide the foundation for a mechanistic 
understanding of the therapeutic benefit of CCR2 antagonists in FSGS, and possibly other 
renal diseases.
Funding: Clinical Revenue Support
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Anti-Proteinuria Effect of Antibody Against ANGPTL3 Coiled-Coil 
Domain on Adriamycin-Induced Nephropathy in Mice
Hong Xu,1,2 Jia Rao,1,2 Qian Shen.1,2 1Children’s Hospital of Fudan university, 
Shanghai, China; 2Shanghai Kidney Development & Pediatric Kidney Disease 
Research Center, Shanghai, China.
Background: We firstly found that Angiopoietin-like-3 (Angptl3) expression is 
increased in glomerular podocytes of nephrotic syndrome. Our previous research showed 
Angptl3 plays an important role in podocyte injury and proteinuria. This study aims to 
confirm whether proteinuria in Adriamycin-induced nephropathy mice can be alleviated 
though neutralizing Angptl3 by antibody.
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Methods: The polyantibody against Angptl3-CCD was prepared (namely Anti-
angptl3-antibody). Nephropathy was established by Adriamycin injection in 8-12 wk-old 
female mice. The blockade of Angptl3 by Anti-angptl3-antibody (20mg/kg) was performed 
every three days for nine times after Adriamycin injection. All mice were sacrificed on day 
28. Proteinuria was measured weekly. Albumin, TG and T-CHO in serum were measured on 
day 28, Histological changes were observed by light microscopy and transmission electron 
microscope. The distribution of antibody was confirmed by IF analysis.
Results: The Anti-angptl3-antibody can recognize angptl3 specifically. On the 14th 
day after modeling, proteinuria in the ADR group was significantly increased, but not in 
ADR plus Anti-angptl3-antibody group until 28th day. The proteinuria of the ADR plus 
Anti-angptl3-antibody group was significantly lower than that of the ADR group both 
on the 21th day and 28th(4.46±0.88 vs 11.36±1.00,P=0.010, 21th day; 6.11±1.33 vs 
18.97±4.33,P=0.008, 28th day). Compared to the ADR group, serum ALB was higher 
(p=0.05, n=5), serum CHO (p<0.01, n=5) and TG (p=0.026, n=5) were lower in the ADR 
plus Anti-angptl3-antibody group. The levels of serum creatinine did not show significantly 
difference in each group. Focal sclerotic glomeruli were found in the renal tissue of the 
ADR group, but not found in the ADR plus Anti-angptl3-antibody group. Podocyte injury in 
the ADR plus Anti-angptl3-antibody group was markedly relieved compared with the ADR 
group, in which Podocyte foot processes were widely fused. The Anti-angptl3-antibody was 
detected in the liver and kidney where Angptl3 is expressed in higher amount.
Conclusions: This study demonstrated that Anti-angptl3-antibody can delayed the 
appearance of proteinuria and decreased the level of proteinuria in Adriamycin-induced 
nephropathy in mice.
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A Novel Mouse Model Embodying Minimal-Change Nephrotic Syndrome 
Through Crumbs 2-Mediated Signaling to the Cytoskeleton in Podocytes
Ichiro Hada,1 Naoaki Mikami,1 Satoka Mori,5 Yoshiaki Hirayama,4 
Akira Shimizu,2 Kunimasa Yan.3 1Kyorin University, Mitaka, Japan; 2Nippion 
Medical School, Tokyo, Japan; 3Kyorin University School of Medicine, Mitaka, 
Japan; 4Denka-seiken co., ltd., Gosen-shi, Japan; 5Denka Co., Ltd., Tokyo, 
Japan.
Background: The cellular events in podocyte injury causing minimal-change 
nephrotic syndrome (MCNS) remain largely obscure. Recent reports implicated genetic 
mutation of crumbs homolog 2 (CRB2), a type-1 transmembrane protein, as a cause of 
congenital nephrotic syndrome. However, an involvement of CRB2 dysfunction in the 
selective permeability barrier of mature glomerulus has not been demonstrated. The aim of 
the present study is to determine whether MCNS is caused by alteration of CRB2-mediated 
signaling in podocytes.
Methods: A partial recombinant protein including the extracellular part of mouse 
CRB2 was produced in an Escherichia coli system. An Enzyme-Linked Immunosorbent 
Assay was established to measure anti-CRB2 antibody in the serum. C3H/HeNmice and 
A/Jmice (complement C5 deficient mice) were injected with CRB2 recombinant protein. 
Urinary protein was analyzed, and kidney tissue was subjected to immunofluorescence 
microscopy, light microscopy, electron microscopy and immuno-electron microscopy of 
actin. Isolated glomeruli were subjected to Western blot analysis of phosphorylated moesin.
Results: Both C3H/HeNmice and A/J mice developed massive proteinuria at 4-6 
weeks after immunization with CRB recombinant protein, which was associated with 
elevation of anti-CRB2 antibody. Light microscopy revealed minimal glomerular lesions 
even at a heavily proteinuric stage. Electron microscopy revealed prominent foot process 
effacement where broad dense areas were seen. Immuno-electron microscopy showed that 
these areas were positively immunostained for actin. Immunofluorescence microscopy 
revealed positive IgG staining in podocyte foot processes, but not complement C3. Finally, 
Western blot analysis showed phosphorylation of moesin in glomerular samples at the 
proteinuric stage.
Conclusions: The present study reveals a novel pathway involved in the 
pathophysiology of MCNS through an interaction between CRB2-mediated signaling and 
the actin cytoskeleton network. CRB2 may be an important scaffold molecule that mediates 
outside-in signaling in podocytes, thereby leading to actin cytoskeleton reorganization and 
resulting in MCNS.
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Knockout of the Neonatal Fc Receptor (FcRn) Abrogates IL6 Mediated 
Signaling in Podocytes
Pantipa Tonsawan,2 James F. Dylewski,3 Judith Blaine.1 1University of Colorado 
Denver, AURORA, CO; 2Khon Kaen University, Khon Kaen, Thailand; 
3University of Colorado Hospital, Aurora, CO.
Background: FcRn has been shown to be required for antigen presentation in dendritic 
cells and global knockout of FcRn attenuates immune mediated kidney disease. FcRn is 
expressed in podocytes but the role of podocyte FcRn in immune mediated renal disease is 
unknown. Previous work has shown that podocytes express the IL6 receptor and produce 
IL6 under proinflammatory conditions. Here we examine the role of FcRn in the IL6-
mediated inflammatory response in podocytes.
Methods: We examined IL6 production by ELISA and expression by qPCR in WT 
and FcRn knockout (KO) podocytes after treatment with proinflammatory stimuli including 
albumin, IgG, interferon gamma (IFNγ) and immune complexes. We performed western 
blot analysis of the IL6-mediated Jak/STAT signaling pathway after treatment of WT and 
FcRn KO podocytes with IFNγ and immune complexes. We also examined podocyte 
motility in WT and FcRn KO podocytes in vitro after a proinflammatory challenge. In vivo, 
we examined synaptopodin expression in WT and podocyte-specific FcRn KO mice as 
inhibition of IL6 has been shown to decrease synaptopodin expression.
Results: We found that FcRn KO podocytes produced minimal amounts of IL6 
after treatment with albumin, IgG or immune complexes whereas WT podocytes had a 
robust response. FcRn KO podocytes also had minimal expression of IL6 as measured by 
qPCR compared to WT after an immune challenge. By western blot analysis, FcRn KO 
podocytes expressed significantly less phosphorylated STAT3, a key component in the IL6 
signaling pathway, than WT after treatment with IFNγ or immune complexes. In a scratch 
assay to assess mobility, FcRn KO podocytes showed increased mobility compared to WT, 
suggesting defects in actin dynamics. Expression of synaptopodin in the glomerulus was 
also significantly reduced in podocyte-specific FcRn KO mice compared to controls at 6 and 
12 months of age, suggesting FcRn mediated defects in synaptopodin regulation.
Conclusions: This study shows that in podocytes, FcRn modulates the IL6-mediated 
response to proinflammatory stimuli and regulates podocyte motility and synaptopodin 
expression.
Funding: NIDDK Support
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Impact of Toxic Loss of Function of Ubiquitin C-Terminal Hydrolase L1 
(UCH-L1) on Podocyte Integrity
Julia Reichelt,1 Gunther Zahner,1 Elion Hoxha,2 Rolf A. Stahl,3 Catherine Meyer-
Schwesinger.3 1University hospital hamburg, Hamburg, Germany; 2III. 
Department of Internal Medicine, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany; 3University of Hamburg, Hamburg, Germany.
Background: The deubiquitinating enzyme ubiquitin C-terminal hydrolase L1 
(UCH-L1) is highly de novo expressed in affected podocytes in human membranous 
nephropathy (MN), its role in podocyte injury remains elusive. We could previously 
demonstrate that UCH-L1 induces podocyte hypertrophy in MN. Furthermore, chemical 
inhibition of UCH-L1 hydrolysis function was shown to ameliorate experimental MN, 
suggesting a disease-perpetuating effect of UCH-L1 activity in podocytes. It is known that 
oxidative modification of UCH-L1 in the brain secondary to oxidative stress could lead 
to a dysfunctional mutant protein, which could affect neuronal proteostasis by aberrant 
protein interactions. We therefore investigated the differential contribution of intact and 
oxidative modified UCH-L1 for the development of podocyte injury in MN. Furthermore, 
we searched for the existence and binding affinity of reported UCH-L1 autoantibodies to 
intact and modified UCH-L1 in sera of patients with MN.
Methods: To assess the effects of altered enzymatic and biochemical properties of 
UCH-L1, mice with a podocyte-specific overexpression of UCH-L1 wildtype or with an 
enzymatic-deficient UCH-L1 I93M protein were generated and investigated by Western 
blot, enzyme activity assays and immunohistochemistry. Sera from patients with MN were 
investigated for the occurrence of UCH-L1 autoantibodies by Western blot. For this purpose 
flag-tagged human wildtype UCH-L1 or human mutant I93M protein were cloned and 
transiently overexpressed in HEK-293T cells.
Results: UCH-L1 I93M induced a significant accumulation of polyubiquitinated 
proteins in isolated glomeruli of transgenic mice resulting from proteasomal impairment. 
Expression of intact UCH-L1 on the other hand eventuated in increased proteasomal 
capacity accompanied by a dedifferentiated podocyte phenotype and mild proteinuria. 
A subset of sera (30 %) from MN patients contained anti-UCH-L1 autoantibodies. The 
quantification of UCH-L1 autoantibody reactivity showed a higher binding capacity to the 
defect I93M UCH-L1 protein than to the wildtype UCH-L1 protein.
Conclusions: Expression of UCH-L1 I93M results in a protein accumulative phenotype 
in podocytes similar to the one observed in human MN. Anti-UCH-L1 antibodies with an 
enhanced binding capacity to the defect I93M UCH-L1 protein are present in a subset of 
MN patients.
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Malignant Hypertension Induced Vicious Circle Culminating in Podocyte 
Detachment
Ramzia Abu hamad,3 Ilia Beberashvili,2 Shai Efrati.1 1Nephrology and Reseach 
Unit, Assaf Harofeh Medical Center, Zerifin, Israel; 2Nephrology Division, Assaf 
Harofeh Medical Center, Zerifin, Israel; 3Nephrology Division, Assaf Harofeh 
Medical Center, Zerifin, Israel.
Background: . Renal injuries induced by increased intra-glomerular pressure coincide 
with podocyte damage and proteinuria. In a previous study we have demonstrated that in a 
direct response to pressure, podocytes increase Angiotensin-II levels and via AT1 receptors 
to structural changes in adhesion proteins, culminating in viable podocyte detachment. 
The aim of this study was to further investigate the pathophysiologic effect of malignant 
hypertension on podocyte mitochondrial functions, NOX4, SOD2 and inflammatory 
mediators.
Methods: Human Podocyte cells were exposed to high hydrostatic pressure for 1h, 
to mimic the incidence of malignant hypertension. Podocytes were placed in mesangial 
cell media pre-exposed to pressure to simulate the paracrine effect. Mitochondrial function, 
NOX4, SOD2, Angiotensin-II, inflammatory mediators, integrinβ1 expression and 
Podocyte detachment were evaluated.
Results: Pressure enforcement decreased mitochondrial membrane potential 
accompanied by a reduction of SOD2. Moreover, augmented detachment of viable/
apoptotic podocytes with decrease expression of integrins β1, mediated via AT1/AT2, 
was induced by the high pressure. Mesangial pre-exposed to pressure release exaggerated 
amounts of Angiotensin-II and TGFβ1. Podocytes placed in this mesangial media induced 
an inflammatory flare-up increase via TGFβ1 and Il-6. In addition, an increase of NOX4 
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and decline of SOD2 resulted in mitochondrial membrane potential decrease mediated via 
AT1/AT2 leading to apoptosis.
Conclusions: Malignant hypertension, induced mitochondrial dysfunction combined 
with structural changes and detachment of Podocyte mediated by increase Angiotensin-II. 
The paracrine effect, mediated by increasing production of Angiotensin-II by the mesangial 
cells, increase apoptosis and enhance mitochondrial dysfunction via decrease SOD2, 
activation of NOX4 and flare-up of inflammatory mediators.
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Sorting Nexin 9 Facilitates Podocin Endocytosis in the Injured Podocyte
Yu Sasaki. Juntendo University, Tokyo, Japan.
Background: The irreversibility of glomerulosclerotic changes depends on the degree 
of podocyte injury. We have previously demonstrated the endocytic translocation of 
podocin to the subcellular area in severely injured podocytes and found that this process 
is the primary disease trigger. We identified the protein sorting nexin 9 (SNX9) as a novel 
facilitator of podocin endocytosis in a yeast two-hybrid analysis. SNX9 is involved in 
clathrin-mediated endocytosis, actin rearrangement and vesicle transport regulation.
Methods: We conducted co-immunoprecipitation assays to confirm the interaction 
between podocin and SNX9 using lysates of FLAG-podocinand GFP-SNX9-overexpressing 
cells. To map the podocin binding site(s) in SNX9, we tested the abilities of various truncated 
GFP-SNX9 constructs to co-precipitate with FLAG-podocin. To further demonstrate that 
podocin can directly bind to SNX9, we performed GST pull-down assays with purified 
recombinant proteins. To detect SNX9 expression in kidney samples, we subjected normal 
and adriamycin (ADR)-injected mice to immunofluorescence staining. To evaluate SNX9 
expression in vitro, we performed immunofluorescence staining on non-treated and ADR-
treated cultured human podocytes. To assess SNX9 expression in human kidney glomeruli, 
we subjected human kidney biopsy specimens to immunofluorescence staining.
Results: Our results revealed and confirmed that SNX9 interacts with podocin exclusively 
through the Bin–Amphiphysin–Rvs (BAR) domain of SNX9. Immunofluorescence 
staining revealed the expression of SNX9 in response to podocyte adriamycin-induced 
injury both in vitro and in vivo. Finally, an analysis of human glomerular disease biopsy 
samples demonstrated strong SNX9 expression and co-localization with podocin in samples 
representative of severe podocyte injury, such as IgA nephropathy with poor prognosis, 
membranous nephropathy and focal segmental glomerulosclerosis.
Conclusions: We identified SNX9 as a facilitator of podocin endocytosis in severe 
podocyte injury and demonstrated the expression of SNX9 in the podocytes of both 
nephropathy model mice and human patients with irreversible glomerular disease.
Funding: Government Support - Non-U.S.
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Novel Role for Albumin and Its Modifications in Podocyte and  
Glomerular Injury
Shipra Agrawal,1 Jiro Kino,1 Tetsuya Kitao,2 Melinda A. Chanley,2 
William E. Smoyer.2 1The Research Institute at Nationwide Children’s Hospital, 
Columbus, OH; 2Nationwide Children’s Hospital, Columbus, OH.
Background: Albuminuria is both a characteristic hallmark and a known risk factor 
for progressive glomerular disease. We previously identified that both albumin deficiency 
and albumin overload resulted in enhanced glomerular injury. We thus hypothesized that 
glomerular and podocyte injury can be regulated by modifications of albumin levels, 
binding to free fatty acid (FFA) and associated factors, and molecular charge.
Methods: In vitro podocyte injury was studied following exposure to native albumin 
(anionic), delipidated albumin, FFA, and cationic albumin. The ability of plasmapheresis 
effluents (PE) from nephrotic patients to induce podocyte injury in vivo and in vitro was also 
analyzed. Additional analyses included testing the ability of various clinically applicable 
matrices to ameliorate albumin- and PE-induced podocyte injury.
Results: While exposure of podocytes to albumin or FFA (lauric acid, oleic acid 
and arachidonic acid) alone reduced podocyte viability, supplementation of FFA with 
delipidated albumin restored podocyte viability. Albumin exposure also activated the 
kinases p38 MAPK, JNK/SAPK and AKT. While arachidonic acid and delipidated 
albumin alone did not activate these kinases, activation was moderately increased when 
podocytes were exposed to their combination. Additionally, cationic albumin induced 
greater podocyte toxicity vs. albumin, even at 1000x lower concentration. Translational 
studies in nephrotic PE revealed diverse signs of direct podocyte injury, including reduced 
viability, actin cytoskeletal disruption, lipid accumulation, activation of Erk1/2 and JNK/
SAPK, and induction of COX-2. Importantly, some of these responses were attenuated by 
pretreatment of PE with selected matrices (charcoal, blue sepharose, liposorber gel and 
dextran sulfate). Finally, compared to the albumin alone-treated rats, we found significantly 
greater albuminuria at 48 hr in rats also injected with nephrotic PE.
Conclusions: Albumin modifications, including altered levels, binding to FFA and 
associated factors, and altered ionic charge can regulate albumin-induced podocyte and 
glomerular injury. Moreover, treatment with clinically applicable matrices appears to be 
able reduce this injury, thus representing a potential novel mechanistic approach to reduce 
glomerular injury and disease progression.
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Predicting and Defining Steroid Resistance in Pediatric Nephrotic 
Syndrome by Cytokine Profiling
Shipra Agrawal,1 Manuela Colucci,2 Jyotsna Nateri,3 Mark W. Hall,4 
Marina Vivarelli,5 William E. Smoyer.6 1The Research Institute at Nationwide 
Children’s Hospital, Columbus, OH; 2Bambino Gesù Children’s Hospital - 
IRCCS, Rome, Italy; 3Nationwide Childrens Hospital, Columbus, OH; 
4Nationwide Children’s Hospital, Columbus, OH; 5Bambino Gesu Children 
Hospital and Research Center IRCCS, Rome, Italy; 6Nationwide Children’s 
Hospital, Columbus, OH.
Background: Steroids (glucocorticoids, GC) are the cornerstone of therapy for 
nephrotic syndrome (NS). However, they only induce remission of NS in ~50% of adults 
and ~80% of children. Unfortunately, there are no validated biomarkers able to predict 
steroid response in NS. Several clinical and experimental observations suggest that 
reversible immune dysregulation is a key feature of idiopathic NS. This study aims to 
identify early prognostic immunological biomarkers and molecular pathways associated 
with steroid resistance in NS pediatric patients.
Methods: Paired plasma samples were collected from 26 steroid-sensitive NS (SSNS) 
and 13 steroid-resistant NS (SRNS) patients, obtained both at initial disease presentation 
and after ~7 weeks of GC therapy, when SSNS vs SRNS was clinically determined. 
The cytokine profiling was performed using a 27 cytokine panel on a Luminex® 
Technology platform using a bead-based fluorescence assay. Data were compared using 
the nonparametric Wilcoxon signed-rank test and the Mann Whitney U test (statistically 
significant differences at p<0.05).
Results: In comparison to SSNS, SRNS patients at presentation showed higher plasma 
levels of IL-1β, IL-6, IL-8, TNF-α, IFN-γ, IL-7, and MIP-1α, and reduced levels of IL-
1Ra, IL-2, IL-9, MIP-1β. GC treatment of SSNS patients induced significant reductions in 
all of the elevated cytokine levels above (IL-6 undetectable at presentation in most SSNS 
patients). Of note, circulating cytokine levels appear not be influenced by differences in 
proteinuria, as we found reduced levels in SSNS patients in remission. In contrast, GC 
therapy in SRNS patients failed to induce remission or to significantly reduce the above 
plasma cytokine levels (except for TNF-α).
Conclusions: These studies suggest that an increase in a panel of plasma pro-
inflammatory cytokines, produced primarily by monocytes/macrophages and Th1 cells, 
may be able to predict steroid resistance in NS prior to GC treatment. In addition, steroid-
resistance is also associated with persistence elevated levels of pro-inflammatory cytokines, 
suggesting a potential pathogenic role for these circulating factors in SRNS.
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The Proteasomal Degradation System Plays a Prominent Role in Podocyte 
Protein Homeostasis
Wiebke Sachs,1 Marlies Sachs,3 Catherine Meyer-Schwesinger.2 AG Meyer-
Schwesinger 1University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 2University of Hamburg, Hamburg, Germany; 3UKE, Hamburg, 
Germany.
Background: Protein degradation plays a major role in protein quality control and 
therefore in cell homeostasis. Two different degradation systems are responsible for 
clearance of disused or defective proteins, the ubiquitin-proteasome system (UPS) and 
the autophagy-lysosome system (ALS). During membranous nephropathy the UPS is 
upregulated. The aim of the project is to understand the significance and interplay of the 
proteasomal and lysosomal degradation system for podocyte proteostasis under naïve 
conditions and during THSD7A-associated membranous nephropathy.
Methods: For proteasomal inhibition, Balb/C mice were treated with epoxomicin 
over 4 days. As models of lysosomal impairment Balb/C mice were treated with the 
lysosomal inhibitor leupeptin A over 4 days or mice with general lysosomal dysfunction 
(Mucolipidosis (ML) type II) were analyzed. To investigate the effect of the degradation 
systems on disease progression, THSD7A-associated MN was induced and mice were 
treated in a preventive and a therapeutic regimen with proteasomal inhibitors and leupeptin 
A. Renal function was assessed by BUN and creatinine measurements, podocyte injury by 
proteinuria. The glomerular and tubulointerstitial integrity was assessed by PAS, confocal
and electron microscopy. The effects of proteasomal or lysosomal inhibition on glomerular 
cell proteostasis were analyzed by Western blotting and enzyme activity assays.
Results: Mice treated with epoxomicin developed proteinuria with abnormal 
glomerular protein accumulations in the subepithelial space and in podocytes. Leupeptin 
A treatment did not affect proteasomal activity in glomeruli and the tubulointerstitium. 
Morphological analyses were significant for abnormal accumulations in tubular cells and the 
glomerular mesangium. MLII mice showed severe lysosomal dysfunction in glomeruli and 
tubulointerstitial cells without the development of proteinuria. Morphologically, MLII mice 
exhibited accumulations of large lysosomes in all resident glomerular cells. Therapeutic and 
preventive inhibition of both degradation systems during THSD7A-associated MN led to 
increased proteinuria compared to the controls.
Conclusions: Failure of the proteasomal degradation system has a great impact on 
podocyte cell proteostasis. Inhibition of either the proteasomal or the lysosomal degradation 
system enhances the progression of THSD7A-associated MN.
Funding: Government Support - Non-U.S.
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P2X7-ATP May Mediate Propagation of Podocyte Damage
Kazuyoshi Yamamoto,2 Masahiro Okabe,2 Taiji Matsusaka,1 Takashi Yokoo.2 
1Tokai University School of Medicine, Isehara, Japan; 2The Jikei University 
School of Medicine, Tokyo, Japan.
Background: We previously generated a mosaic mouse model in which a fraction of 
podocytes express hCD25 and can be injured by hCD25-directed immunotoxin, LMB2. 
After injection with LMB2, not only hCD25(+) podocytes but also hCD25(-) podocytes 
were injured. A possible mechanism is that damage-associated molecular patterns 
(DAMPs) released from the damaged podocytes may secondarily injure the hCD25(-) 
podocytes. In the present study, we aim to find a candidate molecule that mediates spreading 
of podocyte damage.
Methods: Mosaic mice (n=4, each time point) were injected with 25 ng/g BW of 
LMB2, hCD25(+) and (-) podocytes were harvested by FACS sorting, and RNAs were 
analyzed with Agilent’s 8X66K microarray. Functional assay was performed in primary 
cultured mouse podocytes by transiently transfecting expression plasmid.
Results: Among DAMPs and their receptors, we found that P2X7 mRNA was 
markedly increased both in hCD25(+) podocytes (>3000 folds) and in hCD25(-) cells 
(59 folds) 4 days after LMB2, which were confirmed by qRT-PCR analysis (>40,000 folds, 
53 folds). P2X7 is a receptor for extracellular ATP and triggers signaling pathways leading 
to inflammation and cell death in immune cells. To test the role of P2X7-ATP in podocytes, 
we transfected primary cultured podocytes with P2X7 expressing plasmid. By 2 hours 
after administration of ATP (1 mM), cell number decreased by 53.4%, with 18.6% of cells 
incorporating propidium iodide. This is contrasting to P2X7 expressing cells without ATP, 
or mock-transfected cells with or without ATP, in which cell number decrease was <5% and 
propidium iodide incorporation was <2%. 6.7% of P2X7 expressing podocytes were stained 
with Annexin V one hour after ATP, whereas 2.6% of mock + ATP cells and 0% of P2X7 
without ATP were Annexin V +.
Conclusions: These suggest that podocytes in damaged glomeruli express P2X7, 
respond to ATP released from adjacent dying podocytes, and are secondarily damaged. 
Thus, P2X7-ATP may mediate propagation of podocyte damage.
Funding: Government Support - Non-U.S.
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Angiotensin II-Induced Podocyte Apoptosis Is Ameliorated by AMPK 
Activation and the Improvement of CD2AP
Tae-Sun Ha. Chungbuk National University College of Medicine, Cheongju-si, 
Republic of Korea.
Background: Angiotensin II (Ang II) promotes the development and progression of 
proteinuria and renal diseases and induces podocyte apoptosis. CD2-associated protein 
(CD2AP) in podocytes, anchoring slit diaphragm proteins to actin filaments of podocyte 
cytoskeleton, facilitates the nephrin-induced PI3-K/AKT signaling, which protects 
podocytes from apoptosis. AMP-activated protein kinase (AMPK), as a sensor of cellular 
energy status, has been known to play an important role in the pathophysiology of metabolic 
diseases, including diabetes, and its renal complications. We investigated the role of AMPK 
on the changes of CD2AP and podocyte apoptosis induced by Ang II.
Methods: Mouse podocytes were incubated in media containing various concentrations 
of Ang II and AMPK-related agents. The changes of CD2AP and podocyte apoptosis were 
observed by confocal imaging, western blotting, TUNEL assay and FACS assay according 
to the presence of Ang II.
Results: CD2AP and AMPKα were located diffusely but predominantly in peripheral 
cytoplasm and co-localized with nephrin. Ang II reduced AMPKa in time and dose-
sensitive manners and also decreased CD2AP stainings diffusely and induced spatial 
separation from concentrated nephrin, similar to those of compound C-treated condition. 
AICAR and metformin, AMPK activators, ameliorated the abnormal distributional changes 
of AMPKα and CD2AP. Ang II also reduced (Thr172) phosphorylation of AMPKα and 
CD2AP in time- and concentration-dependent manners, which were significantly recovered 
by metformin and AICAR. Ang II type 1 receptor antagonist, losartan also recovered 
CD2AP suppressed by Ang II. LY294002, a PI3-K inhibitor, reduced CD2AP suppressed 
by Ang II. Ang II increased apoptosis in time- and concentration-dependent manners, which 
were ameliorated by AMPK activators, however, aggravated by siCD2AP.
Conclusions: Our findings suggest that Ang II induces the relocation and suppression 
of podocyte CD2AP and AMPKα via Ang II type 1 receptor and through the inhibition of 
PI3-K signaling, which trigger podocyte apoptosis induced by Ang II.
Funding: Government Support - Non-U.S.
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IL-9 Ameliorates Progressive Glomerulosclerosis
Tingting Xiong,2 Madena Attar,3 Martina Becker,4 Jan-Eric Turner.1 Turner Lab 
1University Medical Center Hamburg, Hamburg, Germany; 2University Medical 
Center Hamburg, Hamburg, Germany; 3University Medical Center Hamburg, 
Hamburg, Germany; 4University Medical Center Hamburg, Hamburg, Germany.
Background: It has been established that IL-9 expression enhances tissue regeneration 
after lung injury, but data about the involvement of IL-9 in renal tissue protection are still 
very limited. Especially, the potential role of IL-9 in immune-mediated kidney disease 
is largely unknown. In this study, we focus on the role of IL-9 in Adriamycin-induced 
nephropathy (AN), a mouse model of focal and segmental glomerulosclerosis.
Methods: Progressive glomerulosclerosis in wild-type and Il9-/- mice was induced 
by injection of Adriamycin and analyses of histopathology, renal function parameters, 
albuminuria and renal immune cell infiltration were performed. The role of selective IL-9 
deficiency of either the innate or the adaptive immune system for the outcome of AN was 
examined in Il9-/-Rag2-/- mice and IL-9deltaT,B mixed bone marrow chimeras, respectively. 
Il9Cre x R26reYFP fate reporter mice were used to assess the cellular source of IL-9 in AN.
Results: Il9-/- mice with AN displayed accelerated development of proteinuria, 
aggravated glomerulosclerosis and deterioration of kidney function, as compared to wild 
type (WT) mice. In line, electron microscopy revealed early aggravation of podocyte damage 
in Il9-/- mice. First experiments with IL-9 fate reporter mice suggested that T cells might be 
a major source of IL-9 in the injured kidney. Accordingly, innate IL-9 deficiency in Il9-/-
Rag2-/- mice did not alter the outcome of AN, whereas selective deficiency of adaptive IL-9 
in IL-9deltaT,B mixed bone marrow chimeras resulted in aggravation of glomerulosclerosis 
and kidney impairment, comparable to the phenotype observed in the completely IL-9-
deficient mice. Possible mechanisms of the protective IL-9 effect, such as a direct pro-
survival effect on glomerular epithelial or endothelial cells, are under active investigation.
Conclusions: In summary, we demonstrate here that IL-9 deficiency aggravates kidney 
failure in Adriamycin-induced nephropathy. As a cellular source of IL-9, T cells seem to 
play an important role in this model. The tissue-protective mechanisms of IL-9 need to 
be further elucidated and may offer a therapeutic approach in immune-mediated kidney 
diseases in the future.
Funding: Government Support - Non-U.S.
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Beneficial Effect of Low-Density Lipoprotein Apheresis via Modifying 
Immune System in Patients with Refractory Nephrotic Syndrome
Hiroko Kakita,1 Hiroyuki Suzuki,1 Tatsuo Tsukamoto,1 Eri Muso.1,2 1Nephrology 
& Dialysis, Tazuke Kofukai Foundation, Medical Research Institute, Kitano 
Hospital, Osaka, Japan; 2Food and Nutrition, Faculty of Contemporary home 
Economics, Kyoto Kacho University, Kyoto, Japan.
Background: In refractory nephrotic syndrome (rNS), in addition to direct injury 
of heavy proteinuria, longstanding hypercholesterolemia is known to provide poor renal 
outcome. The amelioration of dyslipidemia by low-density lipoprotein apheresis (LDL-A) 
in combination with conventional therapy was reported to induce rapid remission of NS 
primarily in focal segmental glomerulosclerosis (FSGS) and evidence of these beneficial 
effect has additionally accumulated in minimal change nephrotic syndrome (MCNS) and 
membranous nephropathy (MN). As the mechanism of action, in addition to the renal 
protection by rapid removal of low-density lipoprotein cholesterol (LDL-C), LDL-A 
has been proved to provide amelioration of macrophage dysfunction, restore steroid and 
cyclosporine susceptibility and adsorption of circulating permeability factors. To investigate 
immune-modulatory effect, we measured serum cytokines and chemokines level before 
and after LDL-A in a patient of FSGS and compared with familial hypercholesterolemia 
(FH) and reported significant and specific increase of Interleukin-10 (IL-10) after LDL-A 
in rNS, but not in FH. In the present study, in order to obtain more precise elucidation of 
immunological effect and disease specificity of LDL-A, the changes of not only serum but 
peripheral blood mononuclear cell (PBMC) cytoplasmic cytokines in patients with FSGS, 
MCNS and MN were evaluated.
Methods: Serum cytokines level before and after LDL-A sessions was assessed in 
three cases of rNS due to FSGS (6 sessions), MCNS (12) and MN (4), and compared with 
a non-NS, arteriosclerosis obliterans (ASO) patient treated by LDL-A (5 sessions). 27 types 
of cytokines were measured by Bio-Plex Pro human 27-plex kit (Bio-Rad). Cytoplasmic 
cytokines among PBMC were evaluated by flow cytometry.
Results: IL-10 was significantly elevated after LDL-A in all NS patients (p=7.2x10-5). 
In ASO, IL-10 was not detected in sera before nor after LDL-A. Cytoplasmic IL-10 was 
positive in CD19+CD5+ cells, CD19-CD5-cells and CD19-CD5+cells. In addition, another 
anti-inflammatory cytokine, IL-1 receptor antagonist (IL-1Ra) was significantly elevated 
after LDL-A (p<0.002) in both NS and ASO.
Conclusions: LDL-A may induce rapid remission in rNS patients, via 
immunomodulation by session synchronized elevation of IL-1Ra and IL-10 regardless of 
causative disease.
Funding: Commercial Support - Kaneka Medical Product.,Co.Ltd.
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Proteasome Inhibitors (PIs) Reduce PAN Induced Proteinuria by 
Enhancing FOXO3a/β-Catenin Complex in Minimal Change Disease 
(MCD)
Himanshu Vashistha,1 Frank C. Abbruscato,1 Radhakrishna Baliga.2 1Ochsner 
Health System, New Orleans, LA; 2LSU Health Sciences Center, Shreveport, LA.
Background: Proteasomes play a major role in the pathophysiology of several disease 
processes in part through its action on a crucial transcription factor, nuclear factor-kappa B 
(NF-κB). NF-κB regulates the expression of a variety of inflammatory genes and plays a 
major role in MCD. The role of PIs in ongoing glomerular injury and the potential beneficial 
effects of PIs have not been previously examined. We show here that administration of 
PIs resulted in marked protection against puromycin aminonucleoside (PAN) -induced 
proteinuria by enhancing nuclear FOXO3a/β-Catenin complex, increasing expression of 
antioxidant enzymes and attenuates reactive oxygen species (ROS).
Methods: MCD was induced in rats by injecting PAN IV as a single dose and 
proteinuria measured as albumin to creatinine ratio (ACR) (μg/mg) until day 10. MG-132 
was administered by osmotic pumps and Carfilzomib (CAR) was administered IV. Proteins 
were analyzed by Western Blot and immunocytochemistry. Immunohistochemical analysis 
was also performed on the kidney cortical sections.
Results: Administration of MG-132 and CAR prevented PAN induced proteinuria 
(PAN 147±29, MG132+PAN 98±32*, CAR+PAN 75+18*; P<0.05* compared to PAN 
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alone). This was accompanied by marked decrease in lipid peroxidation in PIs-treated rats 
compared to PAN alone. MG-132 significantly decreased the nuclear translocation of NF-KB, 
activation of IL-6, up regulation of CYP, significantly reduced H2O2 release and 8-Oxo-dG 
expression in cultured human podocytes. Electron Microscopy data showed that MG-132 
and CAR treatment prevented foot process effacement of podocytes. Immunohistochemical 
analysis of cortical sections of PIs treated rats and immunocytochemical analysis of 
cultured human podocytes treated with PIs revealed increased β-Catenin and FOXO3a 
colocalization. Human podocytes treated with PIs showed upregulated PAN induced HO-1 
and SOD with significant decrease in cell death.
Conclusions: These in vitro and in vivo data imply the crucial role of proteasome 
in progressive glomerular injury. CAR, which is currently used in humans should be 
considered as a potential therapeutic alternative in MCD.
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Nephrotic Range of Proteinuria with Cholesterol Crystal Embolization
Eri Ataka,1 Kenji Harada,2 Akihiro Tsuchimoto,3 Hidetoshi Kanai.4 1Kokura 
memorial Hospital, Kitakyushu, Japan; 2Kokura memorial hospital, Kitakyusyu 
city, Japan; 3Kyushu University, Fukuoka, Japan; 4Kokura Memorial Hospital, 
Kita Kyushu, Japan.
Introduction: Cholesterol crystal embolism(CCE) is often caused by transcatheter 
therapy, vascular surgery or anticoagulant therapy, clinically characterized by vessel 
obstruction from cholesterol crystals and the subsequently provoked immune response. 
Once it developed in kidney, renal function may gradually decline. Moreover, renal 
prognosis is poor with the majority of patients having progressive kidney failure. Generally, 
proteinuria is rare with CCE patients.
Case Description: Here, we report a case of nephrotic range of proteinuria caused by 
CCE. A 72-years-old man with atherosclerotic disease such as hypertension, diabetes mellitus 
and an abdominal aortic aneurysm, underwent percutaneous coronary intervention(PCI) on 
February 1, 2017. Acute kidney injury and nephrotic range of proteinuria occurred after 
four months of PCI. Kidney biopsy was performed to determine the etiology of renal 
dysfunction and massive proteinuria. Renal pathological diagnosis revealed CCE and focal 
segmental glomerulosclerosis(FSGS), severe endocapillary proliferation with foam cells. 
Steroid pulse therapy and oral prednisolone at a dose of 30 mg/day were administered. After 
those therapy serum-creatinine level and protein to creatinine ratio improved from 2.5 mg/
dL to 1.3 mg/dL and 8 g/gCr to 0.5 g/gCr, respectively.
Discussion: Renal cholesterol crystal embolization with massive proteinuria is rare. In 
this case, endocapillary proliferation with foam cells thought to be caused by CCE. These 
suggests that steroid therapy might be effective treatment for CCE with FSGS lesions 
accompanied by proteinuria.
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(STEC-HUS) in Adults: An Underrecognized Cause of Thrombotic 
Microangiopathy
Caroline Duineveld,1 Kioa L. Wijnsma,2 Jack F. Wetzels,1 Nicole Van De Kar.2 
the Dutch aHUS working group 1Department of Nephrology, Radboudumc, 
Nijmegen, Netherlands; 2Department of Pediatric Nephrology, Amalia 
Children’s Hospital, Nijmegen, Netherlands.
Background: In children, most cases of hemolytic uremic syndrome (HUS) are caused 
by an infection with a Shiga toxin-producing Escherichia coli (STEC). In contrast, in adults 
most cases of HUS are considered to be atypical HUS (aHUS), attributed to dysregulation 
of the alternative complement system. However, during major outbreaks of STEC infection, 
hemolytic uremic syndrome in adults is not uncommon and morbidity and mortality, 
especially in elderly patients, may be considerable. Only few sporadic cases of STEC-HUS 
in adults have been described. Typically, STEC HUS is preceded by diarrhea, which is 
reported to be bloody in 60% of the patients. In the Netherlands routine screening for STEC 
is not recommended in adults with TMA, unless diarrhea is present.
Methods: Since 2015/2016, patients presenting with TMA in the Netherlands, in which 
aHUS is suspected, are discussed by the Dutch aHUS working group. Diagnostic options 
are carefully evaluated. This has increased awareness for STEC-HUS testing.
Results: Of 44 TMA patients who were discussed in the Dutch aHUS Working Group 
in the time period 2015/2016-2018, aHUS was diagnosed in 24 patients. STEC-HUS was 
found as the cause of TMA in 10 adult patients. Detailed clinical information could be 
obtained from seven STEC-HUS patients. The age of the patients ranged between 17 and 74 
years. Of note, in three patients no diarrhea was reported. All presented with TMA (median 
thrombocytes 30 x 109/L (range 8-33), LDH 1409 g/L (range 946-3265) and an undetectable 
haptoglobin (<0.10 g/L)). Fecal or rectal swab PCR for Shiga toxin (Stx) was positive in all 
patients. In five patients PCR Stx2 was positive; two of them also had a positive PCR for 
STx1. Serotype could be identified in four patients: O157, O27:H6, O-:H34 and O183:H18. 
Acute renal injury was seen in six patients, and four were treated with hemodialysis. Renal 
function recovered in five patients, however one patient remaining dependent on dialysis. 
Median eGFR was 83 ml/min/1.73 m2 (range <5-133) after a follow-up of 1 to 15 months 
after presentation.
Conclusions: STEC HUS among adults is not uncommon and may not be preceded by 
diarrhea. We advocate routine screening for STEC infection in adults patients presenting 
with TMA.
Funding: Commercial Support - National Health Care Institute, The Netherlands, 
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Systemic Sclerosis Medications and the Prevention of Scleroderma Renal 
Crisis
Sarah M. Gordon,3 Robert Nee,2 Stephen W. Olson.1 1Nephrology, Walter Reed 
National Military Medical Center, Bethesda, MD; 2Walter Reed National 
Military Medical Center, Vienna, VA; 3TAMC, Kaneohe, HI.
Background: Scleroderma Renal Crisis (SRC) develops abruptly in systemic sclerosis 
(SSc) and is associated with significant morbidity and mortality. High risk SSc subjects may 
benefit from treatment to prevent SRC. Though angiotensin converting enzyme inhibitors 
(ACEi) are the standard of care for SRC at diagnosis, previous case series found no benefit 
for initiation at SSc diagnosis to prevent SRC and a potential paradoxical association with 
development of SRC. There are no previous cohort studies of the potential prophylactic 
benefit for calcium channel blockers (CCB), angiotensin receptor blockers (ARB), 
endothelin receptor blockers (ERB), non-steroidal anti-inflammatory drugs (NSAID), or 
mycophenolate mofetil (MMF) to prevent SRC.
Methods: : In this retrospective cohort study of the entire military electronic medical 
record between 2005 and 2016, we compared the use of ACEi, ARB, CCB, NSAID, ERB 
and MMF after SSc diagnosis for 31 cases who subsequently developed SRC to 322 SSc 
without SRC disease controls. We conducted logistic regression analyses to evaluate for 
medications independently associated with SRC.
Results: Baseline ACEi use was more common in SSc patients that subsequently 
developed SRC [77% (24/31) vs. 33% (108/322), p<0.001]. ACEi was associated with an 
increased risk for SRC adjusted for age, race, gender, and prednisone use [odds ratio (OR) 
4.0, 95% confidence interval (CI) 1.6-10.3, P=0.003]. On stratified analyses, there was no 
association between ACEi and SRC in the absence of proteinuria, while in the presence 
of proteinuria, ACEi was significantly associated with SRC [OR 5.28, 95% CI 1.1-29.2, 
p=0.03]. In addition, a doubling of ACEi dose [61% (19/31) vs. 12% (38/322), p<0.001) 
and achieving maximum ACEi dose [45% (14/31) vs. 4% (14/322), p<0.001] after SSc 
diagnosis was associated with future SRC. CCB, ARB, NSAIDs, ERB, and MMF use were 
not significantly associated with SRC.
Conclusions: Medications commonly used in SSC were not associated with a reduced 
risk of SRC. Paradoxically, ACEi use at SSC diagnosis was associated with an increased 
risk of SRC. This relationship was observed only in those with a heightened risk for SRC 
from proteinuria, suggesting that it may be a passive marker of evolving subclinical disease. 
SSC patients that require ACEi should be more closely monitored for SRC.
Funding: Other U.S. Government Support
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N-Acetylmannosamine (ManNAc) Therapy Mitigates Glomerular 
Hyposialylation and Proteinuria
Marjan Huizing,2 Jonathan P. Troost,1 Petcharat Leoyklang,2 Steven P. Bodine,2 
Matthias Kretzler,1 William Gahl,2 Jeffrey B. Kopp,3 May christine Malicdan.2 
1University of Michigan, Ann Arbor, MI; 2Medical Genetics Branch, NHGRI,
NIH, Bethesda, MD; 3Kidney Disease Branch, NIDDK, NIH, Bethesda, MD.
Background: Glomerular hyposialylation of glycoproteins and glycolipids has been 
implicated in human and experimental nephrotic syndromes. In this study we assessed the 
prevalence of glomerular hyposialylation in human nephrotic syndromes and explored 
therapeutic potential of the sialic acid precursor N-acetylmannosamine (ManNAc) in three 
different nephrotic mouse models.
Methods: We created neuraminidase-induced and adriamycin-induced nephrotic mice 
and a nephrotic knock-in mouse model deficient in Gne, a central enzyme in sialic acid 
biosynthesis. ManNAc was administered in drinking water (~1 g/kg/d) to all three mouse 
models and clinical/biochemical parameters were assessed at different timepoints. Human 
glomerular sialylation was assessed by lectin histochemistry and confocal imaging in kidney 
biopsies of 91 well-phenotyped subjects with minimal change disease (MCD; 29 subjects), 
focal segmental glomerulosclerosis (FSGS; 37 subjects) or membranous nephropathy (MN; 
25 subjects) supplied by the Nephrotic Syndrome Study Network (NEPTUNE).
Results: In all three mouse models, ManNAc administration increased glomerular 
sialylation and markedly reduced proteinuria and podocyte injury within a week of treatment. 
Hyposialylation was detected in an unexpectedly high percentage (~72%) of human kidney 
biopsies across all three disease entities, indicating that this condition may occur frequently, 
remains greatly unexplored and, importantly, may be treatable. Correlating sialylation status 
to clinical, pathological or other documented subject data, showed a trend of correlation of 
severe glomerular hyposialylation with decreased eGFR, increased interstitial fibrosis and 
increased tubular atrophy, in particular in FSGS subjects.
Conclusions: These encouraging preclinical data, together with minimal toxicity 
of oral ManNAc therapy in humans (demonstrated in Phase 1 and 2 clinical trials for 
the rare hyposialylation disorder GNE myopathy) led to obtaining an Investigational 
New Drug approval to start a Phase 1 clinical trial to evaluate the safety, tolerability and 
pharmacokinetics of ManNAc in subects with primary podocyte diseases (ClinicalTrials.
gov NCT02639260). Preliminary results of this ongoing study are promising regarding 
safety and tolerability in subjects with glomerular disease.
Funding: NIDDK Support, Other NIH Support - NHGRI support, Commercial 
Support - Escala Therapeutics, Leadiant Biosciences
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Two Cases of Multicentric Castleman Disease with Nephrotic Syndrome 
Treated with Tocilizumab
Naoya Fukunaga,1 Kohei Aoki,1 Akihiro Fukuda,1 Takeshi Nakata,1 
Noriko Uesugi,3 Satoshi Hisano,4 Hirotaka Shibata.2 1Oita University, Yuhu, 
Japan; 2Oita University Faculty of Medicine, Yufu city, Japan; 3Fukuoka 
university, Fukuoka-city, Japan; 4University of Occupational and Environment 
Health, Kitakyushu, Japan.
Introduction: Multicentric Castleman disease (CD) is a systemic lymphoproliferative 
disease with an incompletely understood etiology. Renal complications of this disease have 
been reported in a few cases. We herein report two cases of multicentric CD with nephrotic 
syndrome treated with tocilizumab.
Case Description: Case 1 A 58-year-old man was diagnosed with multicentric CD 
by lymph node biopsy 7 years previously. He was followed closely without therapy 
because of his asymptomatic condition. He was admitted to our hospital with acute 
onset of nephrotic syndrome [albumin, 2.0 g/dl; urine protein:creatinine ratio (UP/UCr), 
4 g/g creatinine). Light microscopic examination of kidney biopsy specimens revealed 
membranous nephropathy with cellular and fibrocellular crescents. Based on these findings, 
we diagnosed the patient with secondary membranous nephropathy due to CD. Steroid and 
tocilizumab therapy was started. After 3 months, the proteinuria had improved (UP/UCr 
< 1 g/g creatinine). Case 2 A 49-year-old woman was diagnosed with multicentric CD by 
lymph node biopsy 9 years previously. She was followed closely without therapy because of 
her asymptomatic condition. She was admitted to our hospital with acute onset of nephrotic 
syndrome (albumin, 2.0 g/dl; UP/UCr, 5 g/g creatinine). Light microscopic examination of 
kidney biopsy specimens revealed Congo red stain-positive amyloid deposition. Based on 
these findings, we diagnosed the patient with secondary amyloidosis due to CD. Steroid and 
tocilizumab therapy was started.
Discussion: Few reports have described the various renal complications of CD, such 
as minimal change disease, mesangial proliferative glomerulonephritis, membranous 
glomerulonephritis, and amyloidosis. We have herein described two rare cases of multicentric 
CD with nephrotic syndrome and effective treatment with tocilizumab. Tocilizumab may be 
another therapeutic choice for multicentric CD with nephrotic syndrome.
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Serum Cystatin C Is a Significant Marker of Early Glomerular and 
Tubular Interstitial Lesions in Patients with Primary Glomerulonephritis: 
Results from Single Center Cross-Sectional Single-Blind Study
Elena Saganova, Olga Galkina, Vasiliy Sipovskii, Alexey Smirnov. Pavlov First 
Saint-Petersburg State Medical University, Saint-Petersburg, Russian 
Federation.
Background: Serum Cystatin C (sCysC) is well known endogenous alternative marker 
of GFR in research and clinical practice. sCysC can be used as a predictor of adverse 
outcomes in patients with CKD. However, the role of sCysC is not still obvious in patients 
with glomerulonephritis (GN) especially as a predictor of morphological lesions. Our aim 
was to assess sCysC as a predictor of various morphological lesions in patients with GN
Methods: 91 patients [50 male,41 female; age Me(min 18;max 83) – 42(28; 55) 
years] with biopsy proven GN and without AKI, infectious diseases, severe heart failure, 
respiratory insufficiency, cancer, abnormal thyroid status and treatment with prednisolone 
more than 10 mg/per day were enrolled in the study. Based on the results of kidney biopsy in 
31% of cases a focal segmental glomerulosclerosis was diagnosed, in 28,5% – membranous 
nephropathy, in 40,5% – IgA-nephropathy. sCysC was measured in the morning on the 
day of biopsy by immunoturbidimetric method. The extent of glomerulosclerosis (GS) 
was assessed quantitatively. Tubulo-interstitial fibrosis (TIF) and tubular atrophy (TA) – 
semi-quantitatively. According to the degree of each morphological lesions all patients 
consistently were separated into 2 groups: “light” (GS less than 25% or TIF/TA grade 0 or 
1) and “severe” (GS ≥ than 25% or TIF/TA grade 2-3). We evaluated specificity, sensitivity, 
diagnostic accuracy of sCysC regarding to the extent of each morphological lesion (GS/
TIF/TA) by ROC-analysis
Results: sCysC was positively associated with GS (p<0,001;r=0,53), TIF 
(p<0,001;r=0,68) and TA (p<0,001;r=0,68). sCysC was significantly higher in patients with 
“light” GS (p<0,001), TIF (p<0,001) and TA (p<0,001). All patients were separated in 2 
groups using sCysC according to the degree of morphological lesions (“light” or “severe”)
(Figure 1)
Conclusions: sCysC is a significant marker of various morphological lesions in patient 
with GN. sCysC can be used as a predictor of mild degree of glomerular and interstitial 
sclerosis, tubular atrophy with high diagnostic value
Funding: Government Support - Non-U.S.
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First-in-Man Cross-Sectional Single Center Study of Multimarker Panel 
Validation for Early Prediction of Morphological Lesions in Patients with 
Primary Glomerulonephritis
Elena Saganova, Olga Galkina, Vasiliy Sipovskii, Alexey Smirnov. Pavlov First 
Saint-Petersburg State Medical University, Saint-Petersburg, Russian 
Federation.
Background: Measurement of various biomarkers (BM) as a predictors of 
morphological lesions can improve detection and risk stratification for CKD progression. 
Our aim was to evaluate combination of serum und urinary BM as a predictor of various 
morphological lesions in patients with glomerulonephritis (GN)
Methods: 100 patients[52 male; age Me(min 18;max 83) – 39(27; 54) years] with 
biopsy proven GN, without AKI, infectious diseases, severe heart failure, respiratory 
insufficiency, cancer, abnormal thyroid status, prednisolone treatment more than 10 mg/per 
day were included in the study. Based on the results of kidney biopsy in 9% of cases 
minimal change disease was diagnosed, in 28% – focal segmental glomerulosclerosis, in 
26% – membranous nephropathy and in 37% – IgA-nephropathy. Serum/urine (24-hour 
collection) creatinine (sCr/uCr), cystatin C (sCysC/uCysC), EFMg, urinary transferrin 
(uTr), IgG (uIgG), α1-microglobulin, β2-microglobulin were measured in the morning 
on the day of biopsy. The extent of glomerulosclerosis (GS) was assessed quantitatively, 
tubulo-interstitial fibrosis(TIF), tubular atrophy(TA) - semi-quantitatively. According to the 
degree of each morphological lesions (GS/TIF/TA) all patients consistently were separated 
into 2 groups: “light”(GS less than 25% or TIF/TA grade 0 or 1) and “severe”(GS ≥ than 
25% or TIF/TA grade 2-3). We evaluated specificity, sensitivity diagnostic accuracy of BM 
panel regarding to the extent of GS/TIF/TA by multivariate and ROC-analysis
Results: Discriminant linear function analysis followed by ROC analysis showed that 
from included to the panel BM (Figure 1): GS (Biomarker Panel 1 (BP1); p<0.001; Fig1A), 
TIF (BP2; p<0.001; Fig1B), TA (BP3; p<0.001; Fig1C) were associated with sCr, sCysC, 
uTr, uIgG
Conclusions: Combination of sCr, sCysC, uTr, uIgG is a significant biomarker panel 
of various morphological lesions in patient with GN and can be used as a strong predictor of 
mild degree of GS, TIF and TA with high sensitivity, specificity and accuracy.
Funding: Government Support - Non-U.S.
Figure 1. ROC curves with 95% CI of Biomarkers Panels for A – GS; B – TIF; C – TA
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Geospatial Clustering of Incident Glomerulonephritis Suggests Dis-
ease-Specific Risk Factors
Mark Canney,1,2 Dilshani Induruwage,2 Heather N. Reich,3 Sean Barbour.1,2 
1University of British Columbia, Vancouver, BC, Canada; 2BC Provincial Renal 
Agency, Vancouver, BC, Canada; 3Toronto General Hospital, Toronto, ON, 
Canada.
Background: Few studies have rigorously evaluated regional differences in the 
incidence of glomerulonephritis (GN) subtypes, thus limiting our understanding of potential 
sociodemographic or environmental risk factors. As such, we used population-level data 
from British Columbia (BC), Canada, to investigate geospatial differences in the incidence 
of biopsy-proven membranous nephropathy (MN), IgA nephropathy (IgAN) and ANCA-
associated vasculitis (AAV).
Methods: All native kidney biopsies in BC from 1/1/2000 to 12/31/2012 were analyzed 
from a central registry to identify all cases of GN. Patient-level data were captured via 
linkage with provincial administrative databases. We used local health authorities (n=75) 
to define discrete geographical regions in BC (population 4.6 million) with region-level 
age, sex and race distributions from census data. For each GN we employed a hierarchial 
Bayesian model to estimate the incidence rate ratio (IRR) for each region accounting for 
adjacent spatial correlation. Contiguous regions with high probability of IRR>1.0 were 
combined into super-regions to estimate the IRR adjusted for age, sex and race.
Results: A total of 1624 patients were included: 401 MN (mean age 56, 57% male); 
824 IgAN (mean age 44, 61% male); 399 AAV (mean age 61, 45% male). For each 
GN we identified several regions with high probability of being a cluster (Figure). The 
number of clusters and magnitude of increased risk were greatest for AAV (IRR 1.1-3.5), 
intermediate for IgAN (IRR 1.2-2.2) and lowest for MN (IRR 1.1-1.9). Results were similar 
for aggregated super-regions after multivariable adjustment.
Conclusions: Using a novel and robust approach, we describe geospatial clustering of 
biopsy-proven GN which varied by GN subtype and was not explained by inter-regional 
differences in age, sex and race. Our findings suggest that health services delivery for each 
type of GN needs to be tailored to individual regions at higher risk, and that there are likely 
disease-specific environmental and/or genetic risk factors that require further study.
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Areas with high probability of being a cluster for MN (a), IgAN (b) and AAV (c). The color 
gradient represents the magnitude of IRR.
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The Impact of a Diagnostic Support System on Rare Disease Cases
Simon Ronicke,1,2 Dr. martin C. Hirsch,2 Ewelina Türk,2 Annette D. Wagner.1 
1Medizinische Hochschule Hannover, Hannover, Germany; 2Ada Health GmbH, 
Berlin, Germany.
Background: Diagnostic support systems (DSS) can be used to enhance clinical 
diagnosis. We report about the use of Ada/DX, a DSS in development, in an outpatient clinic 
for rare inflammatory systemic diseases with kidney involvement. Presenting preliminary 
results, we evaluate the system’s diagnostic accuracy and potential impact on the time to 
diagnosis.
Methods: This retrospective study is being conducted at the outpatient clinic for 
rare inflammatory systemic diseases with kidney involvement at the Hannover Medical 
School, Germany. To date, 67 (of a total 120) patient cases with confirmed diagnosis were 
included. The time of the visit of first documented symptoms and the time of diagnosis was 
identified. Time to diagnosis (TD) was calculated. Information from the medical record 
was transferred to the DSS and the disease suggestions in the DSS were evaluated. Primary 
endpoint was the correctness of top disease suggestions for the visit of diagnosis. In these 
cases, secondary endpoints were the time to first correct top rare disease suggestion (TR) 
and the time to first correct top 5 rare disease suggestion (T5R). The difference between 
TD and TR and the difference between TD and T5R was calculated. Wilcoxon signed-rank 
test was conducted.
Results: On preliminary evaluation, primary accuracy of top suggestions of the DSS at 
the time of diagnosis was 80.6% (71.1% to 90,3%, 95% CI). The table shows a comparison 
of time to diagnosis with and without the aid of the DSS. The Wilcoxon signed-rank test 
shows a significant difference for TD - TR (z-score -4.78, α=0.05, p<0.001) and TD - T5R 
(z-score -5.44, α=0.05, p<0.001).
Conclusions: The DSS suggested the correct diseases based on information from the 
medical record in most of the analysed rare disease cases. The DSS often suggested the 
correct diseases at times prior to the visit of diagnosis. DSS might help to reduce time 
to diagnosis and improve patient outcomes. Prospective research is needed to verify the 
results.
Comparison of the original time to diagnosis and the time to correct DDS disease suggestions
Times expressed in months
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Studying Rare Disease Using an Electronic Health Record (EHR) and 
Machine Learning Based Approach: The Kaiser Permanente Southern 
California (KPSC) Membranous Nephropathy (MN) Cohort
Amy Z. Sun,1 Yu-Hsiang Shu,4 Teresa N. Harrison,4 Michelle M. O’Shaughnessy,2 
John J. Sim.3 1Department of Internal Medicine, Kaiser Permanente Los Angeles 
Medical Center, Los Angeles, CA; 2Division of Nephrology, Stanford University, 
Palo Alto, CA; 3Division of Nephrology and Hypertension, Kaiser Permanente Los 
Angeles Medical Center, Los Angeles, CA; 4Kaiser Permanente, Pasadena, CA.
Background: Large scale epidemiology studies on glomerular disease such as 
MN are needed. Identifying MN patients using EHR is limited by the need to manually 
review kidney biopsy pathology reports (gold standard diagnostic test) to confirm cases. 
An ability to accurately identify patients with MN using only structured EHR data (e.g. 
diagnosis codes) would enhance the efficiency and scale of observational and comparative 
effectiveness studies within this population.
Methods: A retrospective cohort study was performed among KPSC patients who 
underwent a kidney biopsy 6/28/1999-6/25/2015 (n=5542). Biopsies were manually 
reviewed and designated as MN or non-MN. The sensitivity (SN), specificity (SP), and 
positive predictive value (PPV) of ICD9 diagnosis codes appearing w/in 1 yr after biopsy 
were determined using 2 approaches: 1) Clinical (581.1, 582.1, or 583.1, MN specific 
codes) AND 2) Machine learning (ICD9 codes, kidney-related or not, with highest 
predictive performance).
Results: Among biopsy proven MN cases, 59% and 86% received a MN diagnosis w/
in 30 days and 1 yr after biopsy, respectively. The SN and SP of this clinical approach were 
86% and 76% respectively, but the PPV was 26%. If >2 codes were required, SP increased 
and PPV improved, but SN declined. Machine learning approach detected that using just 2 
ICD9 codes (581.1 or 583.1) improved SP to 94% and PPV to 58% with a decrease in SN to 
83%. SP was 98%, PPV 78%, and SN 64% if ≥3 codes was required.
Conclusions: Our study is the one of the first to leverage the EHR (ICD codes) to 
identify patients with biopsy-proven MN. Data-driven approaches showed better overall 
performance than a solely clinical-based approach. Expanding machine learning approaches 
to include demographics, additional clinical data, or free text from pathology reports might 
further increase diagnostic performance.
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Conceptualizing the Future of Personalized Precision Medicine for 
Glomerular Disease
Debbie S. Gipson,1 Howard Trachtman,2 L. Barisoni,3 Jeffrey B. Hodgin,4 
Habib Hamidi,5 Sean Eddy,5 Laura H. Mariani,5 Matt G. Sampson,5 
Lawrence B. Holzman,6 Jonathan P. Troost,5 John R. Sedor,7 Matthias Kretzler.8 
Nephrotic Syndrome Study Network 1University of Michigan Mott Children’s 
Hospital, Ann Arbor, MI; 2NYU Langone Health, New York, NY; 3U. Miami, Miller 
School of Medicine, Miami Beach, FL; 4The University of Michigan, Ann Arbor, 
MI; 5University of Michigan, Ann Arbor, MI; 6University of Pennsylvania, 
Philadelphia, PA; 7Cleveland Clinic, Cleveland, OH; 8U.Michigan, Ann Arbor, MI.
Background: Glomerular disease therapy selection and outcomes have been hampered 
by imprecise disease characterization. Scientific advances have been generated in research 
contexts but few have crossed the research - patient care divide.
Methods: We hypothesized that comprehensive clinical, demographic and molecular 
phenotypes could be integrated into a personalized, comprehensive disease profile that could 
be used to understand the disease within nephrotic syndrome subjects. Physician- scientists 
and project managers from NEPTUNE were invited to participate in the model development. 
A multicenter, interdisciplinary NEPTUNE Kidney Review Board (KRB) model was created. 
Testing of this model used archived cases from the NEPTUNE study cohort. Return of results 
to caregivers or subjects was prohibited during this model testing phase.
Results: Data domains including, clinical phenotype, pathology, genetics, renal gene 
expression, and proteomics, were evaluated for each case. KRB participants were educated 
about data domain content, analytic methods, results display and supporting evidence 
from published literature. Multicenter web-enabled conferences were used to a) present 
case-specific information, b) review subject-specific data for each domain and c) integrate 
the multi-scalar data to develop theoretical management and treatment strategies for the 
subject. The multicenter, NEPTUNE KRB pilot was launched in February 2018. This pilot 
phase allowed the team to practice baseline evaluation of each case using a systems biology 
approach in a blinded manner, assemble the information into a case specific knowledge 
environment. Following discussion, the outcome of the case based on longitudinal 
observation was disclosed.
Conclusions: Integration of clinical, pathologic and molecular data will enable 
personalized disease profiling and will be essential in matching the right therapies for 
the right patients. In order to accomplish this, a prepared community of clinicians and 
scientists are needed to effectively interpret the strengths and limitations of the evidence. 
Furthermore, addition of patient advisors and ethicists will strengthen this initiative. KRBs 
provide a rational and effective strategy to bring precision health to the glomerular disease 
community.
Funding: NIDDK Support, Other NIH Support - NIDDK, NCATS, RDCRN
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Changes of Epidemiology, Renal and Patient Outcomes over Time in 
Glomerular Disease of Korea
Minjung Kang,1 Sehoon Park,2 Dong Ki Kim,2 Kook-Hwan Oh,2 Kwon 
Wook Joo,2 Yon Su Kim,3 Ho Jun Chin,4 Hajeong Lee.3 1Seoul National 
University Hospital, Seoul, Republic of Korea; 2Seoul National University 
Hospital, Jongno-gu, SEOUL, Republic of Korea; 3Seoul National University 
College of Medicine, Seoul, Republic of Korea; 4Seoul National University 
Bundang Hospital, Seong nam, Republic of Korea.
Background: Epidemiology of glomerular disease has been revealed temporal changes 
according to the population sanitation standard, socioeconomic status, and improvement 
of medical care. We aimed to explore changes of epidemiology, renal and patient outcome 
over time in glomerular disease (GD) in Korea, which is one of countries experienced rapid 
socioeconomic changes during short time.
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Methods: After excluding 98 with more than the second times biopsy, 7,402 biopsy-
proven primary and secondary GD patients from 1979 to 2018 are included from 2 tertiary 
hospitals. The outcome is CKD progression and all-cause mortality. CKD progression is 
defined as either incident ESRD or halving eGFR.
Results: During median 59 (18 - 138) months of follow-up period, patients who 
were taken kidney biopsy tended to be significantly older and more women over time. 
In overall, the most common primary GD was IgA nephropathy (IgAN), followed by 
membranous nephropathy (MN), minimal change disease (MCD), and focal segmental 
glomerulosclerosis (FSGS) with similar proportions. The most common secondary GD was 
lupus nephritis (LN), diabetic nephropathy (DN), and hepatitis-B-associated GN (HBGN). 
Proportion of IgAN had continuously increased over time, however it showed plateau since 
2009, then it decreased to a certain degree. Proportion of MCD had decreased, whereas 
that of crescentic GD had increased as times go by. Diagnosis of MN or FSGS was not 
affected by the time change. Among secondary GDs, LN remained most common, however, 
it has decreased recently. DN has increased dramatically, whereas HBGN has decreased 
continuously. Patients presenting nephrotic syndrome has been decreased recently. 10-year 
renal survival was the lowest in DN (45.0%), followed by crescentic GD (62.0%), FSGS 
(78.4%), and IgAN (83.7%). Patient survival was the lowest in crescentic GD (76.6%), 
followed by DN (88.6%). Other GN showed similar patient survival with more than 90% 
of rate.
Conclusions: From our large cohort with long term follow-up, we identified significant 
changes in demographic or epidemiologic characteristics as well as outcomes of overall 
GDs. Improvement of socioeconomic and medical care may contribute to these changes.
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A Review of Therapies over 17 Years for Glomerular Disease in a Single 
Center
Sara Syeda, Sairah Sharif. Brown University, Cranston, RI.
Background: Glomerular disease is the third leading cause of end stage renal disease 
in adults in the United States. There is lack of consensus on treating glomerular disease 
due to general lack of randomized control trials in this field. There is a lot of variability in 
therapy both due to physician and patient factors.
Methods: We undertook this study to evaluate the trends in therapies of the most 
common glomerular diagnosis over the years in our center. This is a retrospective chart 
review of medical therapies of 322 patients who underwent a kidney biopsy between year 
august 2000 to october 2017. We also reviewed pregnancy outcomes of patients who were 
diagnosed with glomerular disease. Patients who did not have a renal biopsy at our center 
were excluded.
Results: Results: Our study population is ethnically diverse with 68% white, 16% 
black, 3% asian and 2% hispanic patients. The 3 most common clinical presentation that 
lead to renal biopsy were acute kidney injury, nephrotic syndrome and a combination of 
both. Amongst nephrotic syndrome FSGS was treated with steroids 80%, cyclosporine 
20%, tacrolimus 14%, MCD was treated with steroids 99%, and membranous nephropathy 
was treated with steroids 90%, cyclophosphamide 30% of the cases. Patients with IgANP 
got renin angiotensin inhibitors 72%, steroids 22% of the time. Patients with ANCA 
vasculitis got steroids 95% of the time, cyclophosphamide 64% and rituximab 30% of the 
time. The therapy changed over time and rituximab use was more after 2012. Out of females 
between ages 18 to 50 years, 20 got pregnant any time after renal biopsy. Out of these 
pregnancies the live birth was 30%. The most common immunosuppressive drug to be used 
during pregnancy was mycophenolate and most common anti-hypertensive methyldopa. 
Pregnancy induced hypertension and preeclampsia was frequent 72%.
Conclusions: In our ethnically diverse population we found that LN, FSGS, MGN and 
IgANP were the most common glomerular disease. We found a great variability in treatment 
of glomerular disease including more rituximab after 2012.
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Changes in Patient-Reported Outcomes and Glomerular Disease Activity: 
CureGN
Shannon L. Murphy,1 John D. Mahan,2 Jonathan P. Troost,3 Tarak Srivastava,4 
Amy Kogon,5 Yi Cai,6 T. Keefe Davis,15 Hilda E. Fernandez,7 Alessia Fornoni,8 
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8University of Miami, Miami, FL; 9Duke University Medical Center, Durham,
NC; 10University of Minnesota, Minneapolis, MN; 11Cohen Children’s Medical
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Hospital, Ann Arbor, MI; 13University of Washington School of Medicine,
Spokane, WA; 14Emory University, Atlanta, GA; 15Washington University, St. 
Louis, MO; 16University of Wisconsin Children’s Hospital, Madison, WI.
Background: Prior cross sectional studies suggest that health-related quality of life 
(HRQOL) is worse in patients with active glomerular disease compared with inactive 
patients. This analysis was conducted to assess changes in longitudinal HRQOL with 
changing disease status.
Methods: Longitudinal data were collected in CureGN, a cohort of patients with 
minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, 
IgA vasculitis or IgA nephropathy. HRQOL was assessed at enrollment and at visits 
ranging from 1 - 3 times annually for up to 5 years with the Patient Reported Outcomes 
Measurement Information System (PROMIS). Global Health, Anxiety, and Fatigue 
domains were measured in all; Mobility was measured in children; and Sleep was measured 
in adults. Linear mixed effects models were used to evaluate HRQOL responsiveness to 
changes in disease activity.
Results: 416 Children and 1,011 Adults with PROMIS scores were included in the 
analysis. Edema was associated with all PROMIS domains other than Adult Mental Health 
(Figure). For example, children with edema resolution had improved Mobility (change 
+4.1; 95% CI +1.9 to +6.3), while those with edema onset had worse Mobility (change=
-2.8 CI=-5.2 to -0.4). Serum albumin also associated with HRQOL for Child Global
Health, Child Mobility, and all Adult Domains (effect sizes of +0.8 to +2.1 points per g/dL, 
p<0.05).
Conclusions: HRQOL, as measured by PROMIS, was responsive to changes in 
glomerular disease patient edema and serum albumin levels with score changes ranging 
from 0.3 - 1.3 times the PROMIS minimally important difference of 3. Future studies may 
reveal a glomerular disease specific PRO instrument to be more sensitive to within patient 
changes in disease status.
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Glomerular Diseases: Clinical, Outcomes, Trials - III
Disease Activity in Longstanding Glomerular Diseases: The Columbia 
University-CureGN Experience
Elisa Delbarba,1 Maddalena Marasa,3 Stacy E. Piva,2 Debanjana Chatterjee,3 
Byum hee Kil,3 Xueru Mu,3 Ali G. Gharavi,3 Andrew S. Bomback.3 On Behalf 
of the CureGN Consortium 1Spedali Civili di Brescia, Cologne, Italy; 2Columbia 
University Medical Center, New York, NY; 3Columbia University, New York, NY.
Background: Glomerular diseases are characterized by variable disease activity 
over many years. The CureGN study enrolls patients (pts) with minimal change disease 
(MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and 
IgA nephropathy (IgAN) whose 1st biopsy falls within 5 years of enrollment. We aimed to 
determine whether pts with more longstanding disease would show similar disease activity 
as CureGN pts.
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Methods: Using CureGN’s definitions of disease activity, we compared activity in pts 
followed at Columbia & excluded from CureGN due to their 1st biopsy done prior than 
5 years from screening (Out of Window, OW) to both enrolled Columbia pts (CUMC) & 
to the entire CureGN cohort. For the OW, we assessed disease activity at the 1st clinical 
encounter from Nov 2014 (when CureGN enrollment opened). For the CureGN pts, we 
used disease activity at enrollment.
Results: OW and CUMC pts were similar in age, sex, and race; the CureGN cohort 
had a greater representation of African-Americans compared to the CUMC and OW. OW 
pts had, on average, lower eGFR than both CUMC and CureGN ones. For each disease 
subtype, disease activity in the OW cohort was equal or higher than disease activity in both 
the entire CureGN and the CUMC cohort (Fig1). When limiting our comparisons to disease 
activity in “incident” CUMC pts (1st diagnostic biopsy within 6 months of enrollment), 
OW pts demonstrated similar activity rates as incident pts (91% MCD, 60% FSGS, 73% 
MN, 80% IgA). Disease activity also did not differ by comparison for treatment thresholds.
Conclusions: Disease activity did not differ among pts with shorter vs longer duration 
of disease. Our OW cohort may include pts with more severe disease variants who still 
require a careful follow-up >5 years after initial diagnosis. Such pts are potentially highly 
informative for understanding the clinical course and pathogenesis of glomerulopathies and 
can help identify risk factors mediating more chronic subtypes of disease.
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Glomerular Diseases: Clinical, Outcomes, Trials - III
Factors Associated with Incident Diabetes in Patients with Glomerular 
Disease: The CureGN Study
Amy K. Mottl,1 Sarah Mansfield,11 Matthew Palmer,2 Andrew S. Bomback,3 
Carla M. Nester,4 Virginie Royal,5 L. Barisoni,6 Michael B. Stokes,7 J. 
Charles Jennette,1 Matthias Kretzler,8 Katherine R. Tuttle,9 Cynthia C. Nast.10 
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2University of 
Pennsylvania, Philadelphia, PA; 3Columbia University, New York, NY; 
4University of Iowa Hospitals and Clinics, Iowa City, IA; 5Hopital Maisonneuve-
Rosemont, Montreal, QC, Canada; 6U. Miami, Miller School of Medicine, 
Miami Beach, FL; 7Columbia University Medical Center, New York, NY; 8U.
Michigan, Ann Arbor, MI; 9University of Washington School of Medicine, 
Spokane, WA; 10Cedars-Sinai Medical Center, Los Angeles, CA; 11Arbor 
Research, Ann Arbor, MI.
Background: Glomerular disease is often complicated by incident diabetes which may 
raise the long-term risk:benefit ratio of immunosuppressive treatment. There is a paucity 
of information regarding descriptive characteristics of individuals with glomerular disease 
and incident diabetes.
Methods: We studied 2009 individuals from the CureGN Cohort Study, an 
observational cohort study of people with IgA Nephropathy/Vasculitis (IgAN/IgAV), 
Membranous Nephropathy (MN), Focal Segmental Glomerulosclerosis (FSGS) and 
Minimal Change Disease (MCD), followed prospectively starting less than 5 years after 
kidney biopsy. We compared sociodemographic and clinical characteristics of individuals 
with versus without incident diabetes diagnosed after kidney biopsy. Statistical significance 
was calculated using Chi-square or Fisher’s exact test for categorical or Kruskal-Wallis test 
for continuous variables.
Results: There were 71 individuals with incident diabetes diagnosed a median of 4 
(IQR 0-22) months after kidney biopsy. Diabetes was considered medication induced in 44 
(62%) and 75% were treated with insulin. Characteristics of individuals with and without 
incident diabetes are shown in the table. Incident diabetes was more frequent in MN than 
in other glomerular diseases. Patients with versus without incident diabetes were older, 
more likely to have a family history of diabetes, and had a greater prevalence of obesity, 
smoking, hypertension and cardiovascular disease at enrollment. There was no difference 
in cumulative exposure to steroids between those with versus without incident diabetes.
Conclusions: Incident diabetes was more common in MN than other glomerular 
diseases, possibly due to older age at presentation of this disease. The absence of a 
difference in steroid exposure between those with versus without incident diabetes was 
unexpected and will be the focus of future analyses.
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Predictors of Non-Linearity in eGFR Trajectories in the Nephrotic 
Syndrome Study Network (NEPTUNE)
Abigail R. Smith,1 Nan Ji,1 Jarcy Zee,1 Viji Nair,2 Laura H. Mariani.1,2 1Arbor 
Research Collaborative for Health, Ann Arbor, MI; 2University of Michigan, 
Ann Arbor, MI.
Background: Surrogate outcomes for end-stage kidney disease (e.g. eGFR slope 
or 40% decline) often assume linear changes, which may not always reflect true eGFR 
trajectories. The objective of this study was to identify patient characteristics associated 
with non-linear eGFR trajectories in a cohort of patients with nephrotic syndrome.
Methods: Data were obtained from the NEPTUNE study, a multicenter observational 
cohort study of adult and pediatric patients with >500mg/day of proteinuria enrolled at 
the time of clinically indicated biopsy or initial presentation of disease without biopsy 
(pediatric patients). eGFR was calculated using the CKD-Epi formula for patients ≥18 years 
old and modified CKiD-Schwartz formula for patients <18. Probability of non-linearity 
(PNL) was calculated using Bayesian smoothing of individual eGFR trajectories, and 
patient demographic and clinical variables and follow-up time were used to predict PNL in 
multivariable linear regression.
Results: 385 patients with ≥3 eGFR measurements and ≥1 year of follow-up were 
included (median follow up time 39 months). Median PNL was 0.047, with 15.6% and 
6.5% having a PNL >50% and >75%, respectively. Higher baseline eGFR and UPCR, black 
race and steroid use at baseline were associated with higher PNL (9% increase per 10 unit 
increase in eGFR, p=0.001; 4% increase per unit increase in UPCR, p=0.011; 40% higher 
in black patients, p=0.038; 56% higher with steroid use at baseline, p=0.008, Table). Age 
and maximum follow-up time were associated with lower PNL (16% decrease per 10 year 
increase in age, p<0.001; 34% decrease per year increase in follow-up time, p<0.001).
Conclusions: While non-linear eGFR trajectories were common in this cohort, 
increasing follow-up time resulted in more linear trajectories. Higher baseline eGFR, 
younger age, black race, and steroid use were associated with higher probability of non-
linear eGFR trajectories. Surrogate outcomes that assume linearity may be valid with 
sufficient follow-up.
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Glomerular Diseases: Clinical, Outcomes, Trials - III
Infectious Complications in Patients with Glomerular Disease: An 
Analysis of the Cure Glomerulonephropathy (CureGN) Study
Dorey A. Glenn,1 Candace D. Henderson,1 Yichun Hu,1 Dawn Zinsser,6 
Michelle M. O’Shaughnessy,2 Larry A. Greenbaum,3 Jarcy Zee,6 
Andrew S. Bomback,4 Keisha L. Gibson,1 Amy K. Mottl,1 Susan L. Hogan,1 
Patrick H. Nachman,5 Ronald J. Falk.1 CureGN Consortium 1University of North 
Carolina at Chapel Hill, Chapel Hill, NC; 2Stanford University, Palo Alto, CA; 
3Emory University, Atlanta, GA; 4Columbia University, New York, NY; 
5University of Minnesota, Minneapolis, MN; 6Arbor Research Collaborative for 
Health, Ann Arbor, MI.
Background: Infections are an important contributor to patient morbidity and mortality 
in glomerular disease (GD). We sought to understand the epidemiology of infections and 
infection-related healthcare utilization among patients with GD.
Methods: CureGN is a prospective multi-center cohort study of patients with minimal 
change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous 
nephropathy (MN), or IgA Nephropathy/Vasculitis (IgAN/IgAV). We describe the rate of 
infections requiring hospitalization or emergency department (ED) visit, primary infection 
sites, hospital lengths of stay, and ICU use within this cohort, stratified by age and GD type.
Results: Overall, 202 confirmed infections occurred in 158 (8%) of 1965 participants 
over a mean follow up time of 1.3 years (SD 0.9), a rate of 0.08 infections per person year. 
Ten percent of all hospitalizations or ED visits were due to infection. The rate of infection-
related hospitalizations or ED visits was significantly higher in children (p<0.001), and 
in patients with MCD relative to MN (p=0.02) or IgAN/IgAV (p=0.004). Admission to 
the ICU was required in 9% of infection-related hospitalizations. The most frequent sites 
of infection were the lower (23%) and upper (23%) respiratory tract, and gastrointestinal 
system (13%).
Conclusions: Infection-related ED visits and hospitalizations are an important 
contributor to healthcare utilization among patients with GD. Further study is needed to 
analyze risk factors for infection and develop strategies to mitigate these events. Attention 
should focus on children and those with MCD, who have the highest rates of infection-
related healthcare utilization.
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Patient Experience in ANCA-Associated Vasculitis - Challenges from 
Diagnosis and Need for New Approaches
Peter A. Rutherford,1 Dieter K. Goette,1 James E. O’Donoghue,2 Xierong Liu.2 
1Vifor Pharma, Zurich, Switzerland; 2Elma Research, London, United Kingdom.
Background: ANCA-associated vasculitis (AAV) brings challenges to patients in terms 
of acute illness and then a long term remitting relapsing condition. Therapy is complex and 
associated with significant acute toxicity as well as cumulative damage. Relatively little is 
known about the patient experience and how it evolves over time.
Methods: Qualitative research was performed using 1 on 1 interviews with 33 AAV 
patients (11 male) from 4 EU countries. 20 patients had granulomatosis with polyangiitis, 
12 microscopic polyangiitis, and 1 had eosinophilic granulomatosis with polyangiitis. AAV 
duration (median 3.5 years, range 1-32) and patient age (3 < 40 years, 25 aged 40-80 years 
and 25 > 70 years) allowed rich insight from diagnosis through follow up.
Results: Thematic analysis of the interviews identified issues along the patient journey. 
Key findings were: (1) Suboptimal referral – long delays in diagnosis lead to long lasting 
psychological damage, worsened with treatment; (2) Recognition - sudden onset and 
misdiagnosis impairs patient experience. Patients are concerned over low empathy and 
understanding of their needs by healthcare professionals; (3) Knowledge gaps – patients 
want to know when they will return to normal and the duration of therapy and its impact; 
(4) Measuring response – patients have a low awareness of how their response is assessed 
clinically with scales/scores; instead they refer to the importance of “feeling better” and
going home; (5) Decision making – patients report a low involvement in treatment decisions 
particularly over glucocorticoids (GCs) and immunosuppression; and (6) Unmet needs –
patients have high regard for the efficiency of GCs in the acute phase but report major side 
effects which impair quality of life and functional status as GC dose changes. Findings were 
consistent across the 4 countries; differences reflected variations in healthcare system and 
organization.
Conclusions: Patients are challenged before and after diagnosis and once treatment 
begins with evolving experience over time. Physicians need to be aware of AAV patients 
concerns and needs from first interaction, when assessing response, and if treatment changes 
are needed. GCs pose a particular problem for patients and new therapies which reduce the 
significant treatment burden of AAV would be beneficial.
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Patients with Relapsing ANCA-Associated Vasculitis (AAV) Experience 
Unmet Needs around Remission Induction and Therapy Related Adverse 
Events
Peter A. Rutherford,1 Dieter K. Goette,1 Melinda Stamm,2 Xierong Liu.2 1Vifor 
Pharma, Glattbrugg, Switzerland; 2Elma Research, London, United Kingdom.
Background: Relapse in AAV remains a clinical challenge, with 5-10% of patients 
experiencing relapses of varying severity each year. Such patients are at risk from both acute 
vasculitis damage but also drug toxicity and cumulative organ damage related to AAV and 
glucocorticoid (GC) adverse events. This study aimed to measure outcomes and adverse 
events in relapsing AAV patients in real clinical practice.
Methods: 268 relapsing AAV patients from 4 European countries received remission 
induction therapy between 2014-17 and data collected at baseline, 1, 3, 6 and 12 months 
following commencement of induction therapy was reviewed retrospectively.
Results: Patient mean age was 58.3 years with 60% male; 54% of patients had 
granulomatosis with polyangiitis, and 46% had microscopic polyangiitis. At the time of 
relapse, 7.1% of patients had experienced a past GC adverse event and only 16.0% were 
free from comorbidity. Birmingham vasculitis activity score (BVAS) was used in 17% at 
relapse diagnosis and 21% at time of relapse. Vasculitis was reported as mild/localized 
in 9.7 % of patients 64.6% as moderate systemic, and 25.7% as severe, life threatening. 
44.0% of patients received rituximab and 35.1% received cyclophosphamide, whilst 76.5% 
received GCs. As BVAS was not used routinely, clinical response was assessed as full (no 
vasculitis activity and GC taper on track), partial (reduction in vasculitis activity), or no 
response (no improvement in vasculitis). Response to therapy varied, and adverse events 
and infections were common. Full response at 1 month was associated with good 12-month 
outcomes (81% full response), whereas a partial response at 1 month (53%) was associated 
with less favourable 12-month outcomes (49% full response).
Conclusions: Relapsing AAV patients frequently have comorbidities and their response 
to remission induction therapy is variable. An early positive response associates with a good 
response rate at 12 months. Many patients experience adverse events, and infections are 
common especially early in treatment. Relapsing patients still face unmet medical needs.
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Real World Experience in ANCA-Associated Vasculitis (AAV) – A 
Complex Pathway of Patient Referral, Diagnosis, and Management
Peter A. Rutherford,1 Dieter K. Goette,1 Melinda Stamm,2 Xierong Liu.2 1Vifor 
Pharma, Glattbrugg, Switzerland; 2Elma Research, London, United Kingdom.
Background: AAV is a severe systemic small vessel vasculitis with frequent renal 
involvement. Diagnosis can be difficult and referral pathways complicated with potentially 
several different specialists involved. Patient comorbidity is important but poorly reported. 
This retrospective study aimed to examine referral, diagnosis, and therapy outcomes in 
AAV patients managed in routine clinical practice.
Methods: A retrospective study was performed on 1197 patients receiving care from 
399 physicians in 4 EU countries and 929 incident AAV patients are reported here. Patients 
were referred between 2014-17 and data collected at baseline and 1, 3, 6 and 12 months 
following commencement of therapy.
Results: Mean patient age was 56.8 years and 54% were male. 75% of patients were 
referred by other physicians, 25% direct acute presentations with only 16% referred with 
ANCA diagnosis. Referral symptoms were general in most cases – fatigue (58%), fever 
(54%), weight loss (53%), joint pain (47%) – 64% had renal disease. Physicians reported 
that 16% of patients had had symptoms for over 3 months. Comorbidities were common 
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(hypertension 45%, diabetes 18%, COPD/asthma 15%, coronary arterial disease 10%, 
arthritis 9%, osteoporosis 7% and cardiac failure 6%) with only 32% having none. At 
diagnosis, the median eGFR 35 ml/min, protein excretion median 595 mg/24 hours and 
62% had microscopic haematuria; a renal biopsy was performed in 64%. Granulomatosis 
with polyangiitis was diagnosed in 54% of patients. In only 12% of patients was a formal 
scale (Birmingham Vasculitis Activity Scale, BVAS) used to assess activity. Clinically, 
12% had mild disease, 54% had moderate/systemic disease and 34% had severe/rapidly 
progressive disease. Resource use at diagnosis and treatment was significant with a mean 
length of stay of 17 days including 3 intensive care unit days. 83% of patients were managed 
in collaboration with other specialties (Nephrologist 51%, Rheumatologist 27%, Internal 
Medicine 18%, Respiratory 16%, ENT 11%).
Conclusions: AAV patients have complex pathways to diagnosis and many have 
features of renal disease at presentation. Most patients have comorbidities which need to 
be considered during AAV therapy. BVAS is used rarely in clinical practice and resource 
utilization at presentation is significant.
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Response to Induction Therapy and Treatment Adverse Events in Incident 
ANCA-Associated Vasculitis (AAV) Patients
Peter A. Rutherford,1 Dieter K. Goette,1 Melinda Stamm,2 Xierong Liu.2 1Vifor 
Pharma, Glattbrugg, Switzerland; 2Elma Research, London, United Kingdom.
Background: AAV is a severe systemic vasculitis with a variable clinical presentation 
and frequent renal involvement. Rapid induction of remission is desirable and therapy 
is typically a combination of high dose glucocorticoids (GC) with rituximab (RTX) or 
cyclophosphamide (CYC). Treatment-related adverse events (AEs) are common and 
contribute to long term organ damage as well as acute morbidity. This retrospective study 
aimed to document clinical outcomes and AEs in incident AAV patients managed in routine 
clinical practice.
Methods: 929 incident AAV patients from 4 European countries (399 physicians) were 
diagnosed between 2014-17 and data collected at baseline, 1, 3, 6 and 12 months following 
commencement of induction therapy was reviewed.
Results: 54% of patients had granulomatosis with polyangiitis, and 46% had 
microscopic polyangiitis; mean age was 56.82 years (SD 14.2) with 53.7% male. 
Birmingham vasculitis activity score (BVAS) was used in only 12% of cases. Physicians 
reported 12% patients as mild/localized, 54% as moderate systemic and 34% as severe 
life threatening AAV. Induction therapy varied with 59% receiving CYC, 24% RTX and 
3% a combination of CYC+RTX+GC, whilst 83% received GCs. As BVAS was not 
used routinely, clinical response was assessed as full (no vasculitis activity and GC taper 
on track), partial (reduction in vasculitis activity), or no response (no improvement in 
vasculitis). Response rate varied and AEs were common. Full response at 1 month was 
associated with good 12-month outcomes (81% full response) whereas partial response 
at 1 month (56%) was associated with less favorable outcomes (58% full response at 12 
months). 6% of incident patients relapsed within the first 12 months.
Conclusions: Response rate to remission induction therapy in AAV is still variable. 
Early response is associated with a better response rate at 12 months. Infections and 
treatment-related AEs are common, especially in the first 3 months. New targeted therapy 
options are needed to improve response rates and reduce burden of therapy.
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Adverse Events Due to Glucocorticoids in ANCA-Associated Vasculitis 
Are Frequent but Reporting Should Improve
Peter A. Rutherford,1 Dieter K. Goette,1 Tanvi Patil,2 Priyanga N. Aerian,2 
Kumari Priyanka.2 1Vifor Pharma, Glattbrugg, Switzerland; 2Indegene, 
Bengaluru, India.
Background: High dose glucocorticoids (GCs) are an integral part of therapy in 
ANCA-associated vasculitis (AAV). The adverse event (AE) profile of GC is well known 
and can lead to acute and chronic toxicity, resulting in an unmet need in clinical practice 
to reduce GC exposure in AAV. This systematic literature review aimed to examine AEs 
related to GC use in AAV clinical studies.
Methods: A systematic literature review was performed of studies published between 1 
Jan 2007 and 30 January 2018. Data on GC-related AEs (any untoward medical occurrence) 
and serious AEs (defined in European Medicines Agency CPMP/ICH/377/95) which 
threaten life or function were extracted from studies.
Results: Thirty-three studies were identified in which GC-related AEs were published. 
Of the 25,745 patients enrolled in the 33 studies, 24,566 were exposed to GCs. Seventeen 
studies reported AEs only, with 23 reporting serious AEs. Overall AE rate in AAV studies 
appears low possibly due to under-reporting, as GC effects are so well known. The most 
common serious AEs were infection and mortality. Infection was the leading cause of 
mortality, occurring more frequently in the first 6 months of treatment. Generally, infections 
are commonly reported but site and microbiological cause of infection were presented 
rarely. Metabolic and infection are the most common AEs, and 83% of metabolic events are 
due to diabetes mellitus. Musculoskeletal AEs and serious AEs are also relatively common.
Conclusions: GC related AE reporting in AAV studies can be improved and follow 
published guidelines (EULAR Ann Rheum Dis 2010; 69: 1913-19). Serious AEs such as 
mortality and infection remain a major clinical problem. Metabolic and musculoskeletal 
events are also a patient burden. New therapeutic options for AAV should aim to reduce 
this AE profile.
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Glomerular Diseases: Clinical, Outcomes, Trials - III
Clinical and Therapy Related Risk Factors for Survival in ANCA-Associ-
ated Glomerulonephritis
Silke R. Brix,1 Verena Wunsch,2 Silay Arici,2 Martin Busch,3 Martin Nitschke,4 
Wolfram J. Jabs,5 Tobias B. Huber,1 Ulf Panzer,1 Rolf A. Stahl.1 1University 
Hospital Hamburg-Eppendorf, Hamburg, Germany; 2University of Hamburg, 
Hamburg, Germany; 3University Hospital Jena, Jena, Germany; 4University of 
Lübeck, Lübeck, Germany; 5Vivantes, Berlin, Germany.
Background: Renal involvement and infectious complications have great impact 
on mortality in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis.
Methods: We retrospectively investigated a multicenter ANCA-associated 
glomerulonephritis (GN) cohort for clinical and therapy related factors associated with 
relapse, end stage renal disease (ESRD) and survival in these patients.
Results: In 270 patients with a newly diagnosed, biopsy proven ANCA-associated 
necrotizing crescentic GN, the most sensitive markers for mortality were age and 
development of ESRD (p<0.0001, respectively). Gender, antibody and disease subtype 
did not influence patient survival. Patients with renal limited disease had the same renal 
and overall survival compared to patients with multi-organ involvement, e.g. patients 
with pulmorenal syndrome. Patients who were dialysis dependent at the time of diagnosis 
had a higher mortality during follow up (p<0.05). There was no difference in mortality 
between cyclophosphamide and rituximab treated patients. In the elderly population 
(age ≥ 70 years; n=84), a sub-cohort was given a reduced induction immunosuppression (4-6 
cycles of 500mg; n=29). These patients had a higher rate of survival (p<0.05) compared to 
elderly patients with a regular cyclophosphamide induction while no differences in dialysis 
dependence or relapses were detected.
Conclusions: Our data suggest that a reduced induction immunosuppression in 
elderly patients may be appropriate, as this population seems not to benefit from a higher 
cyclophosphamide induction dosage.
Funding: Government Support - Non-U.S.
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The Cyclophosphamide-Sparing Role of an Intensified B-Cells Depletion 
Protocol in ANCA-Associated Vasculitis: A Case-Control Study
Roberta Fenoglio,1 Savino Sciascia,2 Dario Roccatello.3 1Nephrology and 
Dialysis Unit and Center of Research of Immunopathology and Rare Diseases, 
Hospital Hub San Giovanni, Turin, Italy; 2Nephrology and Dialysis Unit and 
Center of Research of Immunopathology and Rare Diseases (CMID), Giovanni 
Bosco Hospital and University of Turin, Italy, Center of Research of 
Immunopathology and Rare Diseases (CMID), Division of Clinical Immunology, 
Giovanni Bosco Hospital and University of Turin, Ita, Turin, Italy; 3Ospedale 
San GIovanni Bosco, Torino, Italy.
Background: ANCA-associated vasculitis (AAV) are systemic diseases with relapsing 
chronic course. The management of AAV requires the use of immunosuppressive drugs 
whose use is associated with potential toxicity. This case-control study aims to evaluate 
the immunosuppressive-sparing effect of rituximab (RTX) used with cyclophosphamide 
(CYC), compared to a traditional regimen based on high-dose CYC.
Methods: 26 patients (pts) with AAV with a necrotising extracapillary 
glomerulonephritis were prospectively enrolled. 13 pts received the intensified protocol of 
B-lymphocyte depletion therapy (IBCDT) “4+2” with RTX and CYC (4 weekly infusions 
of RTX followed by 2 monthly followed by prednisone tapered to 5 mg/day in 3 months). 
13 pts treated with the high-dose CYC treatment protocol followed by azathioprine as 
maintenance therapy were enrolled as controls.
Results: In the 13 cases treated with the IBCDT we observed a significant reduction 
in mean values of parameter of disease activity. After administration of RTX, a significant 
reduction of the mean s-creatinine values and BVAS was observed. All pts had full B-cell 
depletion on peripheral blood after the first IBCDT protocol after 1 year. No further 
maintenance therapy was given. In the cases, a response was observed in 8/13 cases. 4 
pts did not respond and a death was observed for cardiovascular causes. No significant 
difference was observed in terms of response to therapy between the two groups. The 
IBCDT allows a significant reduction in the cumulative dose of CYC to which each 
patient was exposed during follow-up, reaching statistical significance levels (p <0.001). 
Calculated on a monthly basis, the “4+2” protocol allowed an average reduction in the CYC 
cumulative dose equivalent to 827 mg/month.
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Conclusions: in a selected sample of patients with AAV with renal involvement, the 
IBCT regimen appeared to be non inferior in terms of the efficacy when compared to CYC-
based standard regimens. Moreover, the IBCDT regimen allowed a net reduction in the 
cumulative average dose of CYC to which pts are exposed, quantifiable in approximately 
1g/month.
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B Cell Suppression and Relapse of Vasculitis in Maintenance Therapy of 
Rituximab for Granulomatosis with Polyangiitis
Miho Karube, Soko Kawashima, Shinya Kaname. Kyorin University School of 
Medicine, Tokyo, Japan.
Background: The protocol of rituximab (RTX) use during the maintenance treatment 
for ANCA-associated vasculitis has not been established. Thus, we retrospectively 
investigated the efficacy of RTX between the regular and “on-demand” use in patients with 
granulomatosis with polyangiitis (GPA).
Methods: The subjects were 8 GPA patients in our hospital, and RTX was introduced 
by refractory active vasculitis with cyclophosphamide (CY) treatment difficulties or CY 
contraindications. The Japanese 8 patients with GPA refractory to or contraindicated for 
cyclophosphamide (CY) were investigated. The patients were 6 males and 2 females, with 
the median ages of 68 years old, and we compared B cell counts, relapse rates between 
6 regular-use cases with every 6 months and 2 on-demand-use cases when RTX were 
administered after the reconstitution of B cells. We also examined glucocorticoid doses 
and safety profiles.
Results: The RTX were used as a single dose of 375 mg/m2 in all patients. The periods 
from remission to the initial maintenance therapy were 7 to 12 months. The two “on-
demand” patients showed eGFR less than 45 ml/min /1.73 m 2. In the regular-use group, no 
relapses of vasculitis or reappearance of B cells were observed. In the on-demand-use cases, 
the reappearance of B cells was seen after 8.5 months on average, and one of the two cases 
showed relapse of vasculitis with worsening renal function, proteinuria and CRP positivity 
after an interval of 20 months. Both groups showed comparable glucocorticoid doses and 
no serious infection was observed in both groups.
Conclusions: It is suggested that the regular use of RTX was well tolerated and 
may show persistent remission induction, rather than on-demand use, in the maintenance 
treatment for patients with GPA, although further study in the large cohort is required.
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10 Year, Age-Stratified Outcomes of ANCA Associated Vasculitis Treated 
with IV Cyclophosphamide
Hugh Leonard,1,2 Bhrigu Raj Sood,4 Marie B. Condon,3 David Makanjuola,3 
Fiona E. Harris.5 1St Helier Hospital, London, United Kingdom; 2Department of 
Transplantation, Immunology and Mucosal Biology, King’s College London, 
London, United Kingdom; 3St. Helier Hospital, Surrey, United Kingdom; 4South 
West Thames Renal Unit, Carshalton, United Kingdom; 5Epsom and St Helier 
NHS Trust, Surrey, United Kingdom.
Background: ANCA associated vasculitis (AAV) is a multisystem disease with 
morbidity and mortality associated with disease and treatment. The aim is to induce and 
maintain remission, and minimise side effects. Studies suggest high mortality among treated 
elderly patients and concerns have been raised about under-treatment in younger patients. 
We use IV cyclophosphamide (CyP) for induction (dose adjusted for age, weight and 
eGFR). We present mortality and renal outcomes in patients treated with IV CyP for AAV 
followed by maintenance therapy with Azathioprine or Mycophenolate.
Methods: Data was collected from medical records of patients treated with IV CyP 
from Jan 2007 to Jan 2017 with follow up until May 2018.
Results: 197 patients met the inclusion criteria: 54% men, 89% Caucasian, median 
age of 70(18-89) and 45% had PR3 antibodies. 41% were dialysis-dependent at diagnosis. 
IV steroids were used in 58% and Plasma Exchange in 32%. Induction with CyP was not 
completed in 4 patients due to intolerance/infection. Rituximab was given to 3 who failed 
to achieve remission. Median follow up was 60 months(10-133). 44(22%) patients died 
due to: infection(9), vasculitis(3), malignancy(6) and other(26). 5 died during induction: 
2 of vasculitis and 3 of unknown causes. 42 had at least one relapse. Of the 80 who were 
dialysis-dependent at diagnosis, 52 recovered renal function. Age(p<0.01) and end-stage 
renal failure(adjusted OR 8.1, p<0.01) were associated with mortality. 27 new cancers were 
detected during follow up.
Conclusions: We report on a single-centre cohort followed up for up to 10 years with 
a large number of elderly patients. The oldest age group had longest time to relapse, but 
also the highest unadjusted mortality and highest frequency of advanced CKD. There was a 
trend towards more relapses among younger patients. Although the dose of CyP is stratified 
according to age and renal function, this study highlights the possibility of under-treatment 
in younger patients.
Table 1 (Outcomes according to age)
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Pregnancy Outcomes in ANCA-Associated Vasculitis: A Retrospective 
Review
Melissa L. Swee,1 Jennifer Strouse,1 Mandeep S. Gill,1 Manish Suneja,2 
Bharat Kumar.3 1University of Iowa, North Liberty, IA; 2The University of Iowa, 
Iowa City, IA; 3University of Iowa Hospitals and Clinics, Iowa City, IA.
Background: ANCA-Associated Vasculitis (AAV) is a small-vessel vasculitis that 
predominantly affects the kidneys and respiratory tract, among other organ systems. It has 
been traditionally associated with elderly males, but its occurrence in young, potentially 
childbearing, females is increasingly being recognized. In this study, we characterize the 
outcomes of pregnancy in ANCA-associated vasculitis.
Methods: We performed a retrospective chart review of all patients at the University 
of Iowa Hospitals and Clinics with a positive PR3 or MPO and a documented diagnosis 
of vasculitis between 2000 and 2017. Inclusion criteria included female sex and age 
younger than 45. Charts were reviewed to identify disease activity, clinical manifestations, 
medication regimens, and pregnancy outcomes.
Results: 24 patients met the inclusion criteria, of which 11 were pregnant at some 
point, accounting for 29 total pregnancies. Among these, 8 had at least one pregnancy after 
the diagnosis of AAV and 5 before the diagnosis. Those who were pregnant after diagnosis 
all had single pregnancies and accounted for 16 pregnancies in total. Seven pregnancies 
were viable, 2 are currently gravid, and 7 resulted in spontaneous abortions. Six (75%) were 
MPO positive while 2 (25%) were PR3 positive. Two patients were on moderate doses of 
prednisone (15mg – 20mg daily); the others were not on any immunosuppressive therapy. 
For induction therapy, 5 had cyclophosphamide, 1 had rituximab, and 2 had limited disease 
not requiring induction therapy. In vitro fertilization was documented in only 1 patient. Four 
were delivered by Caesarean section. All 6 who have completed pregnancy experienced 
complications, including premature birth (4), preeclampsia (2), preterm premature rupture 
of membranes (1), and cholestasis of pregnancy (1). One required tracheostomy for 
subglottic stenosis at 11 weeks.
Conclusions: Women with AAV should be considered at high risk for pregnancy 
complications due to the underlying disease and chronic immunosuppressive treatment 
regimens. With very close clinical monitoring, women with AAV may be able to conceive 
and give birth.
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The Endothelial Glycocalyx Is Damaged in Acute ANCA-Associated 
Vasculitis and Is Improved After Treatment
Hui Liew,1,2 Matthew A. Roberts,1,2 Lawrence P. McMahon.1,2 1Renal Medicine, 
Eastern Health, Melbourne, VIC, Australia; 2Monash University, Melbourne, 
VIC, Australia.
Background: The endothelial glycocalyx (EG) lines and protects the luminal surface 
of the endothelium. Damage to this layer can be detected by increased serum levels of EG 
constituents as well as an increase in the perfused boundary region (PBR) of sublingual 
capillaries using the novel Glycocheck™ device. ANCA-associated vasculitis (AAV) is a 
widespread inflammatory process affecting blood vessels, causing endothelial dysfunction 
(ED). The effects of AAV on the EG are unknown.
Methods: We aimed to examine the effects of acute AAV and its treatment on the 
EG compared to healthy controls by collecting blood for EG markers (syndecan-1 and 
hyaluronan), markers of ED (vascular cell adhesion molecule: VCAM-1), urine for 
albumin:creatinine ratio (uACR), and performing a PBR measurement. Investigations 
for controls were performed once, whereas vasculitis patients were studied at the time of 
admission, after 2 weeks of plasma exchange (PEX) if indicated, and after 3 months of 
immunosuppressive therapy.
Results: Patients with acute AAV (n=8) and healthy controls (n=28) were recruited. 
Mean ages were 63 ± 13 years and 40 ± 13 years (p<0.001), respectively. AAV patients 
demonstrated EG damage at baseline compared to controls, with higher syndecan-1 and 
hyaluronan levels and a greater PBR. Three patients required dialysis, and one remained 
on dialysis at 3 months. After treatment, the median eGFR of AAV patients increased from 
12 (3-40) mL/min at baseline to 19 (6-60) after plasma exchange (p=0.031, n=5), but not 
at 3 months. Median syndecan-1 levels decreased significantly from baseline to 3 months 
with a corresponding decrease in PBR values. However, no differences were detected in 
hyaluronan, VCAM-1 or uACR at any point.
Conclusions: Markers of EG damage were higher in the AAV patients at baseline 
compared to controls. The PBR and syndecan-1 levels of these patients improved at 
3 months, reflecting an improvement in the EG layer due either to treatment or better 
renal function. The lack of change in hyaluronan and VCAM-1 levels warrants further 
investigation.
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Glomerular Diseases: Clinical, Outcomes, Trials - III
Urinary Cell mRNA Profiling Distinguishes Disease Activity in ANCA GN
Sam Kant,1,4 Carol Y. Li,3 Thangamani Muthukumar,3 Duvuru Geetha.2 
1University of Maryland Medical Center, Baltimore, MD; 2John Hopkins 
Bayview Medical Center, Baltimore, MD; 3Weill Cornell Medical College, New 
York, NY; 4Johns Hopkins Hospital, Baltimore, MD.
Background: Hematuria, proteinuria and increase in serum creatinine are noninvasive 
but inaccurate indicators of active GN. Renal biopsy is the gold standard for diagnosis of 
active GN but recurrent biopsies can be laden with risk. We aimed to ascertain if urinary cell 
mRNA profiling could be used to differentiate active versus remission phase in ANCA GN
Methods: Patients with biopsy proven ANCA GN were enrolled and activity was 
scored using BVAS. Patients in active phase had urine sample collected at the time of 
diagnostic biopsy and remission samples were collected during remission phase with a 
BVAS of zero. Total RNA was isolated from the urinary cells and mRNA expression of 
specific genes was examined by reverse transcription and PCR. We measured urinary cell 
levels of 19 mRNA’s encoding proteins implicated in innate and adaptive autoimmunity. 
The levels of mRNA in the urinary cells for each sample were normalized by the levels of 
18S rRNA in the same sample. Mann-Whitney U test and AUC were used to evaluate the 
ability of mRNA’s to discriminate between groups
Results: Eleven patients with active disease and 17 in remission were enrolled. There 
were no significant differences between the groups with respect to age and ANCA subtype. 
Urinary expression of mRNA’s for the cytotoxic attack molecules Perforin (p=0.001) and 
Granzyme B (p=0.02), B cell CD20 (p=0.012), Vimentin (p=0.0068), and RANTES (p=0.5) 
was significantly higher in active disease group compared to remission group. There were 
no significant differences between the groups for mRNA’s encoding TGFβ1, FOX-3,CD25
,Tbet,CD3GB,MCP1,MIG,C3,CXCR3,E-cad,NKCC2,VEGF,CD46 and IP10. ROC curve 
analysis demonstrates these markers can discriminate vasculitic activity (Image1)
Conclusions: This study demonstrates that urine mRNA profiling may be a non-
invasive method of monitoring disease activity in ANCA GN. Elevated levels of perforin, 
granzyme B and CD20 are consistent with the role of cytotoxic T cells and B cells in ANCA 
GN
SA-PO413 Poster Saturday
Glomerular Diseases: Clinical, Outcomes, Trials - III
Characterization of Lymphocytic Interstitial Infiltrate in ANCA GN
Sam Kant,1,3 Lois J. Arend,3 Eric J. Gapud,4 Duvuru Geetha.2 1University of 
Maryland, Baltimore, MD; 2John Hopkins Bayview Medical Center, Baltimore, 
MD; 3Johns Hopkins Hospital, Baltimore, MD; 4Johns Hopkins School of 
Medicine, Baltimore, MD.
Background: B %T cells have a pathogenic role in ANCA associated vasculitis. There 
are differences in renal outcome based on ANCA type, therefore, we sought to characterize 
the interstitial lymphocytic infiltrate in ANCA GN to determine differences in relation to 
ANCA type and entry GFR.
Methods: Renal biopsies of patients with ANCA GN were stained for CD3, CD4, 
CD20, C4d and FOXP3. The percentage of cortical interstitium containing positive cells 
was determined by light microscopy. Demographics, ANCA type and entry eGFR were 
recorded. The level of staining was compared between ANCA type and entry eGFR using 
Wilcoxon rank sum test.
Results: Renal biopsies of 16 patients with MPO and 14 with PR3 ANCA GN were 
studied. CD3 cells were the predominant cells, with CD4 and FOXP3 staining positive in 
all biopsies. C4d staining was negative in all biopsies. There was no significant difference 
in staining between MPO and PR3 groups. However, regardless of ANCA type, FOXP3 
staining was significantly higher in patients with baseline GFR<10 compared with GFR>10 
(mean 7.54, SD 6.6 versus mean 2.67, SD 3.6; p=0.04). Image 1 demonstrates scatter plots 
of mean percentage of interstitial staining for markers and entry GFR(blgfr) in MPO and 
PR3 subsets.
Conclusions: These data confirm the role of CD4 cells in ANCA GN and demonstrate 
no differences in interstitial T and B cell infiltrates between PR3 and MPO ANCA GN. A 
higher FOXP3 signal suggests a role for regulatory T cells and merits further characterization 
of CD4 T cell subset.
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Urinary CD11b and CD163 Reflect Clinical and Histological Disease 
Activity in Renal Involvement of Anti-Neutrophil Cytoplasmic Anti-
body-Associated Vasculitides
Yuki Yokoe, Naotake Tsuboi, Shoichi Maruyama. Nagoya University Graduate 
School of Medicine, Nagoya, Japan.
Background: Glomerular leukocyte infiltration on histology reflects the renal 
inflammation in various forms of glomerulonephritis. Especially glomerular crescent 
formation, evidenced with robust extracapillary leukocyte and epithelial cell proliferation 
at the active stage, often present on glomerulonephritis complicated with anti-neutrophil 
cytoplasmic antibody (ANCA)-associated vasculitides (AAV), has been proposed as a 
significant indicator of the disease activity and prognosis. Both cell surface molecules of 
CD11b, an α subunit of leukocyte integrin Mac-1 expressed on neutrophils and monocytes/
macrophages, and of CD163, a scavenger receptor expressed on macrophages, have been 
demonstrated their cleavage from leukocyte upon inflammation-related cell activation. In 
the present study, we investigated the clinical significance of urinary CD11b (U-CD11b) 
and CD163 (U-CD163) as potential biomarkers for AAV.
Methods: We measured U-CD11b and U-CD163 by ELISA in AAV patient samples 
from the institutional (N-KDR; 61 patients at the diagnosis) and Japanese nation-wide 
(RemIT-JAV-RPGN; 138 at the diagnosis and 56 patients after 6 months treatment) cohorts, 
and evaluated those associations with clinical and histological parameters.
Results: Both U-CD11b and U-CD163 significantly correlated with renal score of 
Birmingham Vasculitis Activity Score (BVAS), and were particularly elevated in AAV 
patients classified in crescentic category by European Vasculitis Study Group (EUVAS) 
evaluation. Histological analysis for leukocyte profiles demonstrated significant association 
of U-CD11b levels with glomerular CD11b+ cell numbers both in endo- and extra-capillary. 
On the other hand, U-CD163 reflected glomerular CD163+ cells in extra-capillary. 
Significant reduction of U-CD163 (U-CD163; p<0.001, U-CD11b; p=0.26) was observed 
in identical AAV patients at 6 months following by the remission induction therapy.
Conclusions: U-CD11b and U-CD163 reflect clinical and histological disease activity 
of AAV renal manifestations, in particular glomerular crescentic formation. Moreover, 
these two biomarkers can respectively associate with the glomerular infiltrates of different 
leukocyte subsets in endo- and extra- capillary. U-CD163 may superior to U-CD11b for the 
evaluation of therapeutic efficacy in clinical settings.
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Molecular Risk Prediction in ANCA-Associated Crescentic Glomerulone-
phritis: Added Value over Clinical and Histologic Parameters
Benjamin A. Adam, Kristalee Watson, Peter Dromparis, Ainslie M. Hildebrand, 
Michael Mengel. University of Alberta, Edmonton, AB, Canada.
Background: Novel molecular tools have the potential to improve current clinical 
and histology-based risk classification systems for ANCA-associated crescentic 
glomerulonephritis (GN). We aimed to assess the utility of gene expression for improving 
biopsy-based risk prediction in these patients.
Methods: NanoString was used to measure the expression of 54 previously-described 
inflammation, nephron injury and crescent-related genes in 74 archival, formalin-fixed 
paraffin-embedded (FFPE) native kidney biopsies with ANCA-associated crescentic GN. 
Corresponding clinical and histologic data were retrieved. Multivariate Cox proportional 
hazards regression was used to identify the clinical, histologic and gene expression 
variables independently predictive of end-stage renal disease (ESRD). Receiver operating 
characteristic (ROC) curve, net reclassification index (NRI) and integrated discrimination 
improvement (IDI) analyses were used to compare full and reduced logistic regression 
models composed of the independently predictive variables. Kaplan-Meier renal survival 
curves were used to further assess differences in model performance. Data analysis was 
performed using nSolver and R.
Results: Multivariate Cox analysis demonstrated lower patient age (p=0.002), higher 
percentage global glomerulosclerosis (p=0.003) and higher expression of crescent-
related genes (p<0.001) to be independently predictive of ESRD. Comparison of logistic 
regression models demonstrated that adding crescentic gene expression to age and 
global glomerulosclerosis significantly improved the prediction of ESRD versus age and 
global glomerulosclerosis alone (AUC 85.1 vs. 71.9, respectively, p=0.023; continuous 
NRI 94.1%, p<0.001; IDI 17.3%, p=0.001). Kaplan-Meier renal survival curves further 
demonstrated improved model performance with the addition of crescentic gene expression 
(Figure 1).
Conclusions: Adding FFPE-derived gene expression to existing clinical and histologic 
parameters improves the prediction of ESRD in ANCA-associated crescentic GN.
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Soluble CD163 Differentiates Active Vasculitis and Lupus Nephritis from 
Inactive Disease
Daniel A. Amador, Juan M. Mejia-Vilet, Cristinoc Cruz, Ricardo Correa-Rotter, 
Jose A. Nino-Cruz. Instituto Nacional de Ciencias Medicas y Nutricion Salvador 
Zubiran, Mexico, Mexico.
Background: Urine soluble CD163 (sCD163) is an enzymatically cleaved form of 
CD163 that has been described to discriminate active from inactive renal ANCA-associated 
vasculitis (rAAV) with 71-87% sensitivity and >97% specificity. sCD163 has also been 
reported to be elevated in active lupus nephritis (aLN).
Methods: The aim of the study was to evaluate urine sCD163 in patients with rAAV 
(n=20), systemically-active AAV without renal vasculitis (sAAV, n=5), inactive AAV (iAAV, 
n=4), aLN (n=10), clinically-inactive LN (iLN,n=5), and living-kidney donors (KD,n=5). 
To explore other diseases that may increase urine sCD163 we also evaluated patients with 
tubulointerstitial nephritis including tuberculous TIN (n=3) and IgG4 TIN (n=2).
Results: Median BVAS score was 19 (14-23), 7 (5-18) and 0(0-0) in rAAV, sAAV and 
iAAV respectively. Renal BVAS was 12 (10-12) in rAAV and 0 in both sAAV and iAAV. aLN 
patients had a median NIH activity score of 11 (10-12) and chronicity score of 4 (3-5). M 
edian urine sCD163 titers were 3.5ng/mg (1.8-20.0) in rAAV, 0.4ng/mg (0.03-1.1) in sAAV, 
and 0.2ng/mg (0.1-0.3) in iAAV (Figure 1A). The AUC was 0.919 to differentiate rAAV 
from non-renal AAV (p<0.001). With a cutoff>1.75ng/mg the sensitivity was 80% and 
specificity 100%. Median urine sCD163 was 66.3ng/mg (52.0-182.0) in aLN compared to 
1.0ng/mg (0.3-3.8) in iLN with 100% sensitivity and specificity to differentiate between both 
groups (Figure 1B). Tuberculous TIN and IgG4 TIN had urine sCD163 values >3.0ng/mg.
Conclusions: Urine sCD163 is a good biomarker to differentiate both active renal AAV 
and active LN from inactive disease. Nevertheless, urine sCD163 titers were highest in 
aLN. This molecule can be also elevated in other diseases such as granulomatous and IgG4 
TIN. Its use as biomarker should be further explored in longitudinal cohorts.
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The Association Between Lymphocyte Counts and Risk of Relapse and 
Risk of Serious Infection in Patients with ANCA-Associated Vasculitis
Lonnie Pyne,1 Michael Walsh,1 Kathleen Quinn,2 Nader A. Khalidi,1 Laila 
Alharbi.3 1McMaster University, Hamilton, ON, Canada; 2Western University, 
London, ON, Canada; 3macmaster university, Hamilton, ON, Canada.
Background: Patients with anti-neutrophil cytoplasm antibody (ANCA) associated 
vasculitis (AAV) commonly have relapses of their disease and/or infections. Lymphocyte 
counts may represent both a biomarker of adequate immunosuppressive treatment and an 
increased risk of infection. We assessed the association between lymphocytes counts and 
both infection and relapse in patients with AAV.
Methods: We conducted a single centre, retrospective review of patients with 
known AAV and abstracted patient characteristics at the time of relapse requiring 
immunosuppressive treatment up to 24 months after relapse. We assessed the relationship 
between lymphocyte counts and the outcomes of relapse and infection using multi-level 
logistic regression in which laboratory data including lymphocyte counts were treated as 
time-varying. All models were adjusted for age, neutropenia, need for dialysis and type of 
ANCA.
Results: We identified 158 patients of which 149 had useable data. During the follow-
up period there were 87 relapses in 59 patients and 39 infections requiring antibiotics in 
26 patients. Lymphocyte counts <0.05 x 109 were not significantly associated with relapse 
(odds ratio 1.02, 95% confidence interval 0.26 to 3.98). Lymphocyte counts <0.5 x 109 were 
independently associated with infection (odds ratio 7.00, 95% confidence interval 2.77 to 
17.7).
Conclusions: Lymphopenia appeared more strongly associated with infection than it 
was protective of relapse. These data suggest inducing lymphopenia may cause more harm 
than benefit in patients with AAV.
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ANCA-Associated Vasculitis Through the Continuum of Age: A Retro-
spective Chart Review
Mandeep S. Gill,1 Bharat Kumar,2 Jennifer Strouse,1 Melissa L. Swee,1 
Manish Suneja.3 1University of Iowa, Iowa City, IA; 2University of Iowa 
Hospitals and Clinics, Iowa City, IA; 3The University of Iowa, Iowa City, IA.
Background: ANCA-associated vasculitis (AAV) is a heterogenous group of small-
vessel vasculitides that typically affects the kidneys, respiratory tract, and other organ 
systems. The onset of AAV may occur at any age, although literature suggests that this 
is more common in the elderly. We aim to characterize the clinical and laboratory 
manifestations of AAV based on age of onset in pediatric and adult patients younger than 35 
years, compared to other age groups.
Methods: We performed a retrospective chart review of all patients with positive MPO 
or PR3 lab results by ELISA and a diagnosis of vasculitis from 2000 to 2017. Patients were 
classified into four groups according to age and divided into two groups each depending on 
MPO or PR3 serotypes. These features were compared to one another through descriptive 
statistics, as noted in table 1.
Results: 141 patients were identified based on the inclusion criteria, of which 31 were 
below the age of 35. The majority of patients were white females. Upper respiratory tract 
involvement and arthritis were much more common in the pediatric and adults younger 
than 35. PR3 was also more frequent in this group as well. Renal and lower respiratory 
involvement were comparable between the age groups.
Conclusions: Onset of AAV in young adulthood has distinct characteristics that more 
closely resemble pediatric AAV than compared to their older counterparts. Prior literature 
demonstrates a much higher percentage of extra-renal, extra-respiratory involvement in the 
pediatric population, which is consistent in our sample as well. Further analysis on clinical 
presentation, prognosis and treatment outcomes are forthcoming.
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ANCA-Associated Vasculitis in a Predominantly Hispanic Population in 
the Western United States
Yan Zhong,1 Nina Petrosyan,2 Philip M. Carpenter,3 Li Ding,3 Becky M. O’Neal, 
C-TAGME,4 Hui Yi Shan.4 1LAC USC Medical Center, Los Angeles, CA; 2Keck 
School of Medicine, Los Angeles, CA; 3University of Southern California, Los
Angeles, CA; 4University of Southern California/LAC+USC Medical Center,
Los Angeles, CA.
Background: ANCA-associated vasculitis (AAV) is a group of rare systemic 
autoimmune diseases with significant geographic and ethnic differences in disease 
prevalence and severity. Both environmental factors and genetic susceptibility are thought 
to contribute to such differences. Most published data thus far have been collected from 
Caucasian and Asian patients. The aim of this study is to characterize the features of AAV in 
a specific cohort of patients, predominately of Mexican descent, who reside in the Western 
United States.
Methods: A retrospective review of all native kidney biopsies for patients above age 
of 18 years old that were performed at the Los Angeles County University of Southern 
California Hospital from 2008-2018 was done. 43 patients with AAV were identified. Based 
on pathology results, we classified these patients into focal, crescentic, mixed and sclerotic 
subtypes.
Results: Among the 43 patients, 38 were Hispanic and 20 of which were from 
Mexico. The mean age at diagnosis was 49.8 years old. Patients’ median serum creatinine 
on presentation was 2.4 mg/dl. 17 patients (39.5%) had kidney involvement alone, 5 
patients (11.6%) with kidney and nasopharyngeal, 13 (30.2%) with kidney and lung, and 
8 (18.6%) with kidney, lung and nasopharyngeal involvement. 30 patients (73.2%) were 
myeloperoxidase (MPO) positive and 10 (24.4%) were proteinase (PR3) positive. One 
patient was both MPO and PR3 positive. Pathological classification revealed 15 focal, 11 
crescentic, 8 mixed, and 9 sclerotic subtypes. The majority (83%) of the patients received 
steroids with rituximab or steroids with cyclophosphamide. At 1 year of follow up, 7 
(16.3%) patients relapsed, 12 (27.9%) patients had ESRD, and 4 (9.3%) patients died.
Conclusions: Our study showed that this predominately Mexican-American cohort 
residing in the Western United States from 2008-2018 presented with AAV at younger age 
and had worse 1-year renal survival as compared to data published on Asian and Caucasian 
populations. In addition, kidney involvement and MPO positivity dominated this cohort.
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Risk Factors for Progression to ESRD in Patients with ANCA Associated 
Vasculitis - Experiences from a Chinese Single Center
Ying Xu,1 Fei Han,2 Jianghua Chen.3 1The kidney disease center, The first 
affiliated hospital, College of Medicine, Zhejiang University, Hangzhou, China; 
2First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 
China; 3The Kidney Disease Center, The First Affiliated Hospital, College of 
Medicine, Zhejiang University, Hangzhou, China.
Background: Although ANCA associated vasculitis (AAV) is not a common disease, 
AAV renal damage is the leading rapidly progressive glomerulonephritis leading to end-
stage renal disease (ESRD). If we can screen out the risk factors for progression to ESRD, 
it will be valuable for the treatment.
Methods: 498 AAV patients diagnosed from October 23, 1999 to February 15, 2017 
were enrolled, the latest follow up date was February 21, 2018. The general conditions, 
clinical manifestations, laboratory investigations, renal biopsy results, treatment regimens 
and prognosis (renal/patient survival) were analyzed.
Results: Among the 498 cases, there were 283 females and 215 males. The average 
onset age was 60.9±14.5 years old (10-90). MPO-AAV was more than PR3-AAV (91% 
vs 9%). 486 patients (97.6%) had renal impairment. 216 patients (44.4%) received renal 
biopsy. 54 patients (11.1%) received dialysis at the onset and 11 of them get rid of dialysis. 
Apart from 56 patients (11.2%) lost to follow up and 53 patients (10.6%) died, we divided 
patients to ESRD group (n=145) and Stable group (n=302). We compared the baseline data 
of the two groups (age, sex, onset to diagnosis time, clinical presentation, BVAS score 
and lab investigation) and treatment regimen (whether plasma replacement, whether or 
not glucocorticoid pulse therapy). The results showed that the parameters associated with 
the progression of the patients to ESRD included the type of vasculitis (P=0.016), the 
combination of hypertension (P<0.001), the combination of fever (P=0.048), hemoglobin 
level, platelet level, 24-hour proteinuria, serum creatinine level, eGFR level and the need 
for dialysis (P<0.001). Multiple factor Cox regression analysis showed that daily urine 
protein (3.21±2.46 vs 1.71±1.61g, 95% CI 0.67-0.99, P=0.041) and eGFR level (9.25±6.10 
vs 44.37±40.76ml/min, 95% CI 1.018-1.159, P=0.013) were independent risk factors for 
the patient’s progression to ESRD.
Conclusions: The prognosis of renal function was poor in patients with heavier 
proteinuria or lower eGFR level. Due to the low rate of renal biopsy, we found that the 
segmental crescentic ratio and fibrinous necrosis were associated with deterioration of renal 
function, but not independent risk factors.
SA-PO421 Poster Saturday
Glomerular Diseases: Clinical, Outcomes, Trials - III
The Antineutrophil Cytoplasmic Antibody–Associated Vasculitides 
Concomitant with IgG4-Related Disease: A Case Series
Fei Han. First Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou, China.
Background: Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides 
(AAV) and IgG4-related disease (IgG4-RD) have similarities in clinical characteristics 
and histopathological features. Concomitance of these two diseases have been reported 
previously.
Methods: We compared the characteristics of AAV patients, IgG4-RD patients and 
concomitant AAV and IgG4-RD patients in our center. One hundred and sixty-nine AAV 
patients, 58 IgG4-related disease patients and 8 concomitant patients were included. The 
serum IgG subclasses of MPO-ANCA were measured.
Results: The patients in concomitant group had both elevated serum IgG4 level and 
positive ANCA. They had lower levels of hemoglobin, serum albumin, glomerular filtration 
rate and higher levels of platelet, serum creatinine, erythrocyte sedimentation rate and 
C-reactive protein compared with IgG4-RD group. Their involved organs were mainly
kidney (100%), lung (62.5%) and lacrimal glands (62.5%). They had higher serum globulin 
level and even lower serum albumin level than patients with AAV. Six renal biopsies were 
performed in concomitant group. They achieved remission with improved renal function,
one patient was on maintained dialysis and one patient died of acute gastric perforation.
The IgG4 subclass of MPO-ANCA was higher in concomitant group than in AAV group
(OD450 value 12.42±6.63 vs 3.03±3.67, P=0.017), whereas the other three subclasses
(IgG1, IgG2 and IgG3) of MPO-ANCA were parallel between these groups.
Conclusions: We showed a new overlap syndrome of AAV and IgG4-RD, and the 
IgG4 subclass of ANCA may be a pathogenic factor in this concomitant disease. Besides, 
we suggested the concomitant patients be treated as AAV, as they were more likely to show 
the clinical features of AAV.
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A Cohort Study to Assess the Role of Sensitivity C-Reactive Protein Level 
in the Evaluation of Activity and Prognosis of Microscopic Polyangiitis
Bin Zhu. Hangzhou Hospital of Chinese Medicine, Hangzhou, China.
Background: To investigate the role of high-sensitive C-reactive protein(hs-CRP) 
level for the evaluation of activity and prognosis of microscopic polyangiitis(MPA).
Methods: A total of 149 patients with MPA were enrolled from June 23rd, 2008 to 
January 20th, 2017. We collected demographic characteristics, biochemical parameters and 
pathological changes. These patients were divided into high hs-CRP group and low hs-CRP 
group at the cutpoint of 7.05 of the median of hs-CRP of these patients to compare the 
clinical features and prognosis between these two groups. A Kaplan–Meier survival analysis 
was performed to compare the survival rate using a log-rank test. Cox proportional hazards 
models were used to evaluate the association between hs-CRP levels and outcomes.
Results: The patients with crescentic type in the high hs-CRP group was significantly 
higher than that in the low hs-CRP group. The patients with sclerotic type was lower 
than that in the low hs-CRP group. The cases to reach the primary outcome (death, renal 
replacement therapy) in the hs-CRP group were significantly higher than that in the low 
hs-CRP group(Figure 1). A high level of hs-CRP(HR: 3.11, 95% CI: 1.10 to 8.80) and renal 
interstitial infiltrates(HR: 2.94, 95% CI: 1.14 to 7.58) were independent risk factors for the 
progression of microscopic polyangiitis by a multivariable COX regression analysis.
Conclusions: Baseline serum hs-CRP level was a risk factor for the progression of 
microscopic polyangiitis, indicating that serum hs-CRP could be adopted as a clinical 
parameter for the evaluation of microscopic polyangiitis.
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Figure 1. The patients survival rate in the high hs-CRP group was worse than that in the 
low hs-CRP group.
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Biomarkers of Complement Activity in C3 Glomerulopathy Patients
Andrew S. Bomback,1 Byum hee Kil,1 Amanda Luu,3 Yongsen Zhao,4 
Manuel D. Galvan,3 Jane A. Thanassi,3 Hetal S. Kocinsky,3 Steven D. Podos,5 
Wengang Yang,3 Mingjun Huang,6 Gerald B. Appel.2 1Columbia University, New 
York, NY; 2Columbia University College of Physicians and Surgeons, Scarsdale, 
NY; 3Achillion Pharmaceuticals, New Haven, CT; 4Achillion Pharmaceuticals, 
Inc., New Haven, CT; 5Achillion Pharmaceutical, Inc., New Haven, CT; 
6Achillion Pharmacueticals, New Haven, CT.
Background: C3 glomerulopathies (C3G) are characterized by isolated or dominant 
glomerular C3 staining on immunofluorescence that implies an etiology rooted in 
dysregulation of the alternative complement pathway. To date, no biomarkers for disease 
activity have reliably predicted outcomes in C3G.
Methods: We measured circulating factor D, factor B, Ba, Bb, plasma and serum 
C3, and C3a as potential biomarkers of complement activity in a group of C3G patients 
with longitudinal outcome data. The primary outcome combined doubling of creatinine, 
progression to CKD stage 5, ESRD, transplantation, or death. The secondary outcome was 
remission, defined as stable creatinine with >50% reduction in proteinuria to subnephrotic 
range.
Results: We compiled a biomarker profile on 38 C3G patients (25 with C3 
glomerulonephritis and 13 with dense deposit disease) with a mean follow-up of 62 months 
from diagnosis to last encounter. Factor D levels were low in 50% of patients, factor B levels 
were low in 21% of patients, plasma C3 levels were low in 53% of patients, and serum C3 
levels were low in 42%. Factor B split products, Ba and Bb, were elevated in 66% and 55% 
of patients, respectively, while C3a was elevated in 61% of patients. Seven patients reached 
late or end stage kidney disease. In univariate analyses, Ba (p=0.002) and Bb (p=0.03) 
levels, but not C3a levels (p=0.2), emerged as predictors for the primary outcome. Plasma 
(p=0.04) but not serum (p=0.2) levels of C3 were also predictive of progression. Seventeen 
patients achieved disease remission, but no biomarker was predictive of this outcome.
Conclusions: Elevated levels of the factor B split products (Ba and Bb), which denote 
newly formed C3 convertase of the alternative pathway, are associated with progression of 
C3G to advanced and end stage kidney disease. These biomarkers may help risk-stratify 
newly diagnosed C3G patients and present a treatment target for disease.
Funding: Commercial Support - Achillion Pharmaceuticals
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Evaluation of Urine Complement Biomarker in C3G Following  
∆∆Complement Alternative Pathway Inhibition with ACH-4471
Manuel D. Galvan,1 Jane A. Thanassi,1 Dharaben Patel,1 Steven D. Podos,1 
Amanda Luu,1 Guangwei Yang,1 Yongsen Zhao,1 Hetal S. Kocinsky,2 
Catherine L. Kelleher,2 Michael Geffner,2 Thomas D. Barbour,3 Wengang Yang,1 
Mingjun Huang.1 1Complement Biology, Achillion Pharmaceuticals, Inc., New 
Haven, CT; 2Clinical Development, Achillion Pharmaceuticals, Inc., New 
Haven, CT; 3Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia.
Background: C3 glomerulopathy (C3G) is a rare disease of complement alternative 
pathway (AP) dysregulation that is characterized by glomerular C3 fragment accumulation, 
progressive kidney damage, and proteinuria. Preliminary data from an ongoing 14-day 
proof-of mechanism clinical trial provided evidence that ACH-4471, an oral AP-specific 
inhibitor that blocks complement factor D (CFD) function, can reverse the systemic 
AP hyperactivation and reduce the proteinuria in C3G patients. Although complement 
biomarkers in blood are valuable for assessing systemic AP activation, their levels in urine 
may provide additional information about AP activation in the kidney. Here, we report a 
comparative evaluation of systemic and urinary AP biomarkers in C3G patients enrolled in 
the aforementioned clinical study of ACH-4471.
Methods: Urine and blood samples were collected from patients at protocol-specified 
timepoints prior to, during, and after dosing with ACH-4471. Complement biomarkers 
including the proximal and terminal complement activation products, Ba and sC5b-9, were 
measured in serum or plasma and in urine samples. Serum, plasma, and urine from non-
study healthy volunteers served as control samples. Urinary levels of complement products 
were normalized to urinary creatinine levels and are denoted as “/Cr”.
Results: Urinary Ba/Cr and/or sC5b-9/Cr levels at baseline were significantly higher 
in patients than in healthy controls, even though plasma Ba and sC5b-9 levels were not 
always above normal. Following dosing with ACH-4471, urinary Ba/Cr and/or sC5b-9/Cr 
levels were significantly decreased, often to a greater extent than the levels of plasma Ba 
and sC5b-9. Lastly, the reductions in urinary Ba/Cr and sC5b-9/Cr levels during treatment 
were independent of the accompanying reduction in proteinuria, as indicated by the 
comparable reductions observed when urinary Ba and sC5b-9 levels were normalized to 
urinary albumin.
Conclusions: Our findings suggest that complement proteins in urine may serve as 
additional biomarkers for understanding C3G pathology and predicting responsiveness to 
ACH-4471.
Funding: Commercial Support - Achillion Pharmaceuticals
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C3 Glomerulopathy: Clinical Determinants of Prognosis and Response to 
Immunosuppression
Fernando Caravaca-Fontan,1 Teresa Cavero escribano,2 Elena Goicoechea de 
jorge,3 Manuel Praga.2 on behalf of GLOSEN group 1Nephrology, Hospital 
Universitario 12 de Octubre, Madrid, Spain; 2Nephrology, Hospital 
Universitario 12 de Octubre, Madrid, Spain; 3Complutense University Madrid, 
Madrid, Spain.
Background: C3 glomerulopathy (C3G) is a clinicopathological entity secondary to a 
dysregulation of the alternative complement pathway. Despite significant advances in our 
understanding of the pathophysiology of this disease, less is known about its prognostic 
determinants.
Methods: Retrospective, observational study in 28 hospitals belonging to GLOSEN 
group. All patients fulfilling diagnostic criteria of C3G were included. Clinical, biochemical 
and histologic parameters of prognostic interest were recorded to analyze the main 
determinants of disease progression and response to different therapeutic regimens.
Results: The study group consisted of 104 patients: 90 C3 glomerulonephritis 
(C3GN) and 14 dense deposit disease (DDD). 17% were diagnosed during pediatric 
age, 49% between 18-50 years, and 34% above 50 years. A monoclonal gammopathy of 
unknown significance was observed in 16% of patients. The most common presentation 
in pediatric age was nephrotic syndrome, whereas acute kidney injury and isolated urinary 
abnormalities were the most frequent clinical findings in adults. Membranoproliferative 
glomerulonephritis was the most predominant pattern of injury, with C3 only deposition in 
49% of cases. In a median follow-up of 48 months [IQR:18–100], 45 patients (43%) achieved 
remission (partial or complete). Treatment with steroids and mycophenolate mofetil was 
associated with significant improvement in renal survival compared to other treatments or 
conservative management. During the follow-up period, 45 patients (43%) developed end-
stage renal disease (ESRD). By Cox regression analysis, the main determinants of ESRD 
were: age (HR: 1.026;C.I.95%: 1.008–1.044; p=0.004), serum creatinine at diagnosis 
(HR: 1.213;C.I.95%: 1.115–1.318;p<0.0001), and degree of interstitial fibrosis and tubular 
atrophy (HR: 1.891;C.I.95%: 1.384–2.582;p<0.0001). No differences were found between 
C3GN and DDD. Twenty-five patients (24%) underwent kidney transplantation, 14 of 
which (56%) had disease recurrence after a median follow-up of 12 months [3–107].
Conclusions: C3G is associated with poor renal outcome in a substantial percentage 
of patients. Steroids and mycophenolate were shown to be the most effective regimen to 
achieve remission. Older age, elevated serum creatinine and tubular atrophy/interstitial 
fibrosis were the main determinants of renal survival.
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Expression and Role of TET Proteins in Fetal Kidneys of Control and 
Nutrient-Restricted Rat Dams
Mariko Hida, Midori Awazu. Keio University School of Medicine, Tokyo, Japan.
Background: The ten-eleven translocation (TET) proteins are enzymes that oxidize 
5-methylcytosine to 5-hydroxymethylcytosine and regulate DNA methylation and
hydroxymethylation, which are important epigenetic modifications in fetal programming. 
We previously reported that inhibition of DNA methylation reduces ureteric branching and 
kidney growth in organ culture (ASN 2015). We also showed that kidneys of offspring of 
nutrient-restricted rat dams were characterized by reduction in global DNA methylation,
ureteric branching, and kidney size. In the present study, we examined global DNA
hydroxymethylation and the expression of TET proteins in fetal kidneys of control (CON) 
and nutrient-restricted (NR) rat dams. The role of TET proteins was further examined in
organ culture.
Methods: NR rats were subjected to 50% food restriction throughout pregnancy. 
Expression of TET1, 2, and 3 was analyzed by immunoblot in the kidney of embryonic day 
18 (E18). Global DNA hydroxymethylation was quantified by ELISA. In organ culture, E13 
to E14 metanephroi were cultured for 2 to 3 days in the presence or absence of ascorbic acid 
that facilitates TET enzyme activity, or dimethyloxallyl glycine (DMOG), a small-molecule 
inhibitor of TET.
Results: TET1, 2, and 3 were expressed in the E18 kidney and their expression was 
increased in NR compared with CON. Global DNA hydroxymethylation was also increased 
in NR compared with CON by 1.5-fold. Metanephroi cultured with ascorbic acid 0.1 
mg/mL had significantly fewer ureteric bud tips (6.5±0.3 vs 9.0±0.3 per kidney) with no 
difference in kidney size (6.1±0.4 vs 6.1±0.5 arbitrary units) compared with those cultured 
with vehicle. DMOG 1 mM, on the other hand, significantly decreased both ureteric bud 
tip number (3.0±0.6 vs 9.7±1.7 per kidney) and kidney size (1.1±0.1 vs 1.9±0.2 arbitrary 
units). The effect of DMOG was similar in metanephroi cultured from nutrient-restricted 
dams. Thus ureteric tip number (2.7±0.3 vs 8.0±1.2 per kidney) and kidney size (1.2±0.1 vs 
1.9±0.2 arbitrary units) were significantly decreased by DMOG.
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Conclusions: TET proteins are expressed in fetal kidney with increased levels in NR, 
which is characterized by higher global DNA hydroxymethylation. Both stimulation and 
inhibition of TET disturb normal kidney development. Whether TET proteins regulate 
kidney development through DNA methylation and or hydroxymethylation needs to be 
investigated.
Funding: Government Support - Non-U.S.
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Spatiotemporal Patterning of Intrarenal Urothelium During 
Embryogenesis
Monica L. Hoff,1,2 Claudia F. Mosley,2 Kirk M. McHugh,1,2 Brian Becknell,1 
Ashley R. Jackson.1 1Nationwide Children’s Hospital, Columbus, OH; 2The 
Ohio State University, Columbus, OH.
Background: Congenital urinary tract obstruction (UTO) is a leading cause of 
chronic kidney disease in children. Intrarenal urothelial remodeling occurs prior to 
parenchymal injury, and formation of a protective uroplakin (Upk) plaque is a key feature 
of UTO remodeling. Little is known about progenitor-progeny relationships within the 
renal urothelium during development, precluding efforts to promote adaptive urothelial 
remodeling during UTO.
Methods: Krt5+, Krt7+, Krt14+, p63+, and Upk+ renal urothelial cells (RUCs) were 
localized at embryonic days (E)15-E18. EdU (thymidine analogue) was used to identify 
stage-specific proliferation indices. Krt7+ was used to establish total RUC counts. Renal 
urothelial thickness was measured at each stage. Krt5CreERT2 and Upk2CreERT2 lines were used 
to indelibly label Krt5+ or Upk2+ cells and their daughters at E16.
Results: Renal urothelial thickness decreased from E15-E18, and demonstrated 
heterogeneous expression patterns in renal papilla, fornix and pelvis. Rare, discrete Upk+ 
RUCs were first observed at E16 and formed a nearly contiguous apical lining by E18. 
Basal Krt5+ RUCs were first identified at E17. Krt14+ RUCs were robustly expressed at 
E17-E18. p63+ RUCs were observed in basal renal urothelium beginning at E16, commonly 
localized to Krt5+ RUCs at E17. Proliferation peaked at E15 and EdU co-localized more 
commonly to Krt5+ rather than Upk+ RUCs.
Conclusions: Renal urothelium thinned as RUC specification occurred. The 
identification of Upk+ RUCs at E16 coincides with the initiation of urine production. 
The appearance of Upk+ prior to Krt5+ RUCs indicates an earlier need for terminally 
differentiated characteristics, while co-localization of EdU to Krt5+ RUCs suggests 
a developmental progenitor role. Lineage assays will determine progenitor-progeny 
relationships and establish model systems to evaluate candidate pathways utilized during 
UTO remodeling.
Funding: NIDDK Support
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Transient Hydronephrosis in the Developing Kidney Leads to Long-Term 
Epigenetic Changes and Increased Susceptibility to Acute Renal Failure in 
Adulthood
Scott R. Manson,1,2 Carlos AF Molina,1,2 Paul Austin.1,2 1Pediatric Urology, 
Texas Children’s Hospital, Houston, TX; 2Urology, Baylor College of Medicine, 
Houston, TX.
Background: The criteria for surgical intervention in patients with congenital 
urinary obstruction are poorly defined and little is known about the long-term effects 
of hydronephrosis in the developing kidney. In this study, we evaluated the impact of 
developmental context on disease progression, the need for intervention, and long-term 
susceptibility to kidney disease.
Methods: Disease progression was compared in murine models of unilateral ureteral 
obstruction (UUO) at P1 during nephrogenesis, P14 during the proliferative growth phase, 
and P60 at maturity. A reversible UUO model (rUUO) was used in neonates to assess the 
impact of intervention and its timing on long-term outcomes at maturity including growth 
and maturation, kidney function, and susceptibility to acute renal failure after unilateral 
ischemic injury (IR/Nx). Disease progression was evaluated by histological methods, 
functional assessment (serum BUN/Cre), and whole transcriptome analysis (RNA-seq).
Results: While UUO at P60 leads to inflammation and fibrosis, disease progression in 
neonates is instead characterized by profound developmental deficits. UUO at P1 triggers a 
43.8% decrease in nephrogenesis and 35.2% decrease in kidney growth. UUO at P14 results 
in a 61.6% decrease in proliferation and 26.3% decrease in kidney growth. Impaired renal 
maturation is prevented by early intervention following rUUO at P14 but not P1 (Recovery/
P1 – 27.1%, P14 – 67.1%). Although mice subjected to rUUO at P14 had only minimal 
differences in kidney weight and function after 12 weeks of recovery, whole transcriptome 
analysis showed significant changes in the expression of 30.4% of all genes. Furthermore, 
when these mice were challenged with an IR/Nx protocol that typically has only moderate 
effects, they strikingly exhibited acute renal failure (SrCre: CON – 1.8, rUUO – 3.1) and 
low rates of survival (CON – 100.0%, rUUO – 12.5%). [All results are p<0.05]
Conclusions: This study reveals that developmental context has a significant impact 
on disease mechanisms, long-term outcomes, and treatment strategies. While deficits in 
nephrogenesis are irreversible, early intervention restores proliferative growth and kidney 
function. Continued monitoring is required even after recovery as the epigenetic signature 
remains altered and there is an elevated risk for kidney disease.
Funding: NIDDK Support, Private Foundation Support
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Terminal Differentiation of the Intrarenal Urothelium Attenuates Kidney 
Injury During Congenital and Acquired Urinary Tract Obstruction
Ashley R. Jackson,1 Birong Li,1 Shira H. Cohen,2 Sudipti Gupta,4 
Christina B. Ching,3 Kirk M. McHugh,1 Brian Becknell.1 1Nationwide Children’s 
Hospital, Columbus, OH; 2The Research Institute at Nationwide Children’s 
Hospital, Columbus, OH; 3Nationwide Children’s Hospital, Columbus, OH; 
4Nationwide Childrens Hospital, Columbus, OH.
Background: Congenital urinary tract obstruction (UTO) is the leading cause of 
chronic kidney disease and end stage renal disease in children. Despite timely detection and 
surgical correction of the primary obstructive lesion, outcomes vary widely with regard to 
CKD progression. We hypothesized that remodeling of the intrarenal urothelium confers a 
protective adaptation during congenital and acquired UTO, by terminal differentiation and 
elaboration of a highly compliant uroplakin (Upk) plaque.
Methods: The Upk plaque was destabilized in a congenital model of functional lower 
UTO by generating Mgb-/-;Upk1b-/- mice. As an acute UTO model, unilateral ureteral 
obstruction (UUO) was induced in young adult Upk1b-/- and wild type (WT) mice. 
Alternatively, diphtheria toxin (DT)-mediated depletion of Upk(+) cells was induced 
following UUO. Urine UPK2 and UPK3A levels were measured by ELISA in children 
undergoing pyeloplasty for ureteropelvic junction obstruction (UPJO) versus nonobstructed 
controls.
Results: During congenital and acquired UTO, progressive hydronephrosis triggers 
reorganization of the intrarenal urothelium, which elaborates a continuous Upk plaque. 
Upk1b-/-;Mgb-/- mice experience accelerated onset of bilateral hydronephrosis with severe 
(>67%) parenchymal loss, leading to renal failure and mortality in adolescence. Upk1b 
deletion or depletion of Upk+ cells accelerate renal parenchymal loss following ureteral 
ligation, attesting to a conserved, stabilizing role for Upk plaque deposition in the acutely 
obstructed kidney. Lineage analysis demonstrates that UUO triggers a sequence of Upk 
plaque loss, proliferation, and reacquisition of the Upk plaque by Upk+ cells. Children with 
UPJO manifest higher urinary UPK protein levels than unobstructed controls.
Conclusions: These complementary experiments provide the first evidence that the 
Upk plaque confers an essential, protective adaptation to preserve renal parenchymal 
integrity during congenital and acquired urinary tract obstruction.
Funding: NIDDK Support
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Urinary NGAL as a Risk Factor for Recurrence of Febrile Urinary Tract 
Infection in Children
Sohsaku Yamanouchi, Takahisa Kimata, Yuko Akagawa, Shohei Akagawa, 
Shoji Tsuji, Kazunari Kaneko. Department of Pediatrics, Kansai Medical 
University Kansai Medical University, Hirakata-shi, Japan.
Background: Urinary neutrophil gelatinase-associated lipocalin (NGAL) has received 
attention recently as a sensitive biomarker of acute kidney injury. However, its ability to 
protect endogenously against urinary tract infection (UTI) is lesser known. That is, NGAL, 
which is expressed and secreted from activated neutrophils, acts as an iron chelator and 
antibacterial peptide that suppresses the growth of Escherichia coli and other bacteria. 
Purpose: To prove the hypothesis that reduced NGAL expression causes recurrence of 
febrile UTI (fUTI) in children.
Methods: The subjects were 45 children who were diagnosed as having fUTI and 
treated at our institution from 2012 to 2016 (median age, 1.5 years; 34 boys). We measured 
their urinary NGAL levels in the non-infected stage (at least 4 months since fUTI recovery). 
To examine risk factors for recurrence of fUTI, the subjects were divided into a non-recurrent 
group (24 cases) and a recurrent group (21 cases) according to the presence or absence of 
fUTI over 1 year. The following items were examined as risk factors: age, sex, presence 
or absence of grade III or higher vesicoureteral reflux (VUR; all cases received preventive 
antibiotics), presence or absence of renal scarring, and urinary biomarkers (NGAL and β2-
microglobulin). The urinary biomarkers were corrected for creatinine (Cr) level.
Results: In a multiple logistic regression analysis, significant differences between 
the groups were not observed for age, sex, renal scarring, or β2-microglobulin/Cr level, 
while the recurrent group had significantly more cases with grade III or higher VUR 
(p < 0.01). Furthermore, the urinary NGAL/Cr in the recurrent group (median, 3.2 μg/gCr; 
interquartile range, 2.0–4.0 μg/gCr) was significantly lower than that in the non-recurrent 
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group (median, 16 μg/gCr; interquartile range, 11–20 μg/gCr; p = 0.016). We then created 
the ROC curve to examine the cut off value of NGAL for predicting recurrence of fUTI. In 
the area under the ROC curve, which was calculated for NAGL/Cr, was 0.86. Cut off value 
of 7.6 μg/gCr appeared to have the best predicting accuracy yielding a specificity of 81% 
and a sensitivity of 88%.
Conclusions: Reduced level of urinary NGAL, which functions to protect endogenously 
against UTI, is a risk factor of recurrence of fUTI and thus could serve as a biomarker.
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The Ribonuclease Inhibitor Regulates the Host Immune Response to 
Uropathogenic Escherichia coli
Hanna H. Cortado,1 Sudipti Gupta,2 Birong Li,1 Ashley R. Jackson,1 
Christina B. Ching,3 Brian Becknell.1 1Nationwide Children’s Hospital, 
Columbus, OH; 2Nationwide Childrens Hospital, Columbus, OH; 3Nationwide 
Children’s Hospital, Columbus, OH.
Background: The Ribonuclease (RNase) A Superfamily encodes cationic antimicrobial 
peptides with bactericidal activity toward uropathogens. The endogenous RNase Inhibitor 
(RI) binds to RNases with femtomolar affinity and inhibits their antimicrobial activity. 
Here, we tested the hypothesis that RI serves a critical role in regulating the host innate 
immune response during experimental urinary tract infection (UTI).
Methods: We investigated RI expression in the urinary tract by immunofluorescence 
microscopy and evaluation of beta-galactosidase activity in RILacZ reporter mice. Using Cre/
LoxP recombination, we deleted RI ubiquitously (RIΔUBI) or selectively in urothelial cells 
(RIΔURO) or leukocytes (RIΔWBC) of adult mice. We transurethrally inoculated control and RI 
conditional knockout mice with uropathogenic Escherichia coli (UPEC) and enumerated 
bacterial burden in urinary tract tissues by homogenization and serial plating.
Results: We identified RI expression by bladder umbrella cells, renal collecting 
ducts, and phagocytes, all distinct sources of antimicrobial RNase secretion during UTI. 
Ubiquitous RI deletion led to rapid onset of erosive esophagitis and gastritis, resulting in 
profound weight loss and failure to thrive, precluding investigation of UTI susceptibility. 
RIΔURO mice were healthy and deletion of RI within umbrella cells did not lead to alterations 
in UPEC burden during experimental UTI. In contrast, RIΔWBC animals were protected from 
experimental UTI, with significantly reduced bladder UPEC burden, compared to controls.
Conclusions: RI is a negative regulator of the host leukocyte response to UPEC. 
Interfering with RI-RNase interactions represents a novel, rational approach to augment 
innate immunity during UTI.
Funding: NIDDK Support
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Ribonuclease 6 Protects the Kidney from Ascending Infection by 
Uropathogenic Escherichia coli
Hanna H. Cortado,1 Sudipti Gupta,2 Birong Li,1 Ashley R. Jackson,1 
Christina B. Ching,3 Brian Becknell.1 1Nationwide Children’s Hospital, 
Columbus, OH; 2Nationwide Childrens Hospital, Columbus, OH; 3Nationwide 
Children’s Hospital, Columbus, OH.
Background: Ribonuclease 6 (RNase 6) is an evolutionarily-conserved antimicrobial 
peptide with potent bactericidal activity that is induced during urinary tract infection 
(UTI). Previously, we demonstrated that human and mouse RNase 6 kills uropathogenic 
Escherichia coli (UPEC) in vitro at low micromolar concentrations. Here, we investigated 
the hypothesis that RNase 6 serves an essential protective role in limiting ascending 
infection by UPEC in vivo.
Methods: We generated a Rnase6EGFP knock-in allele to (1) identify the cellular sources 
of RNase 6 in Rnase6EGFP/+ mice; and (2) to determine the consequence of biallelic Rnase6 
deletion (Rnase6EGFP/EGFP) on host susceptibility to experimental UTI. We evaluated EGFP 
fluorescence by flow cytometry and epifluorescence microscopy. We evaluated bactericidal 
activity and nitric oxide production by bone marrow-derived macrophages using gentamicin 
protection and fluorometric assays, respectively. We transurethrally inoculated Rnase6EGFP/
EGFP, Rnase6EGFP/+, and control female mice with UPEC. We enumerated bacterial burden in 
urinary tract tissues by homogenization and serial plating.
Results: Flow cytometry in Rnase6EGFP/+ mice reveals EGFP expression by circulating 
Ly6Chi monocytes which undergo maximal recruitment to the infected bladder by 6 hours 
post infection. In addition, we identified EGFP expression within resident macrophages of 
the bladder and kidney. In contrast, the Rnase6 promoter is not active in renal or bladder 
epithelial cells. We confirmed Rnase6 deletion in Rnase6EGFP/EGFP mice, which displayed 
normal urinary tract development, fertility, and hematopoiesis. Rnase6 deficiency did not 
inhibit nitric oxide production or UPEC killing by bone marrow-derived macrophages. In 
contrast, Rnase6 deficiency resulted in increased susceptibility to experimental UTI, with 
significantly higher UPEC burden throughout the urinary tract, compared to control mice.
Conclusions: Use of Rnase6EGFP/+ mice offers a powerful approach to track cellular 
sources of RNase 6, as well as a means to screen compounds that regulate Rnase6 promoter 
activity in the future. Use of Rnase6EGFP/EGFP mice confirms a critical role for RNase 6 in 
UPEC clearance in vivo.
Funding: NIDDK Support
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Dual Role for the Uroplakin Plaque in Establishment and Maintenance 
Phases of Urinary Tract Infection
Birong Li, Ashley R. Jackson, Brian Becknell. Nationwide Children’s Hospital, 
Columbus, OH.
Background: Uropathogenic Escherichia coli (UPEC) account for up to 90% of 
human urinary tract infections (UTI). Specialized epithelial cells of the bladder produce 
glycosylated uroplakin (Upk) plaques, which bind to type I fimbriae of UPEC in a mannose-
dependent manner. Here we evaluated the role and regulation of the Upk plaque during 
experimental UTI.
Methods: We established acute experimental UTI in 6-8 week old female Upk1b-/- and 
FVB/N mice by transurethral inoculation of UPEC or Enterococcus faecalis. Intracellular 
bacterial communities were detected based on β-galactosidase activity. Upk proteins 
were localized by immunohistochemistry, and plaque ultrastructure was visualized by 
transmission electron microscopy. Urothelial barrier function was evaluated on the basis of 
permeability to FITC-Dextran. We modeled chronic UTI by UPEC inoculation of 6-8 week 
old female C3H/HeOuJ mice.
Results: Upk1b deletion results in absent uroplakin plaque on the apical surface of 
bladder epithelial cells and increased permeability to FITC-Dextran. While intracellular 
bacterial communities were easily detectable in control urothelium, Upk1b-/- bladders 
lacked these intracellular reservoirs of UPEC entirely. Moreover, Upk1b loss led to reduced 
neutrophil infiltration of the bladder urothelium. Consistent with the failure of UPEC to 
invade the epithelium in the absence of the Upk plaque, Upk1b-/- mice exhibited reduced 
UPEC urinary tract colonization compared to controls (p < 0.05, Mann-Whitney U test). In 
contrast, Upk plaque loss did not impact the ability of Enterococcus faecalis to establish 
experimental UTI. When UTI were established in the chronic C3H/HeOuJ model, Upk 
mRNA and Upk protein levels decreased rapidly and remained suppressed for up to 4 weeks 
following infection.
Conclusions: Upk1b is critically required for Upk plaque assembly in superficial 
bladder epithelial cells. The Upk plaque initially facilitates UPEC invasion of the bladder, 
but this structure is dispensable for maintenance of infection, as chronic UTI results in 
downregulation of Upk plaque assembly at the mRNA and protein levels.
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RNase 7 Shields the Kidney and Bladder from Uropathogens
Kristin Bender,5 Tad Eichler,2 Matthew J. Murtha,3 Birong Li,4 Brian Becknell,4 
John D. Spencer.1 1The Research Institute at Nationwide Children’s, Columbus, 
OH; 2The Research Institute at Nationwide Childrens Hospital, COLUMBUS, 
OH; 3Ohio State University Hospital, Columbus, OH; 4Nationwide Children’s 
Hospital, Columbus, OH; 5The Research Institute at Nationwide Children’s 
Hospital, Columbus, OH.
Background: In an era of multi-drug resistant pathogens, new therapies are needed 
to prevent urinary tract infections (UTI). Our laboratory identified Ribonuclease 7 (R7) 
as a human antimicrobial peptide that is secreted by the bladder urothelium and kidney’s 
intercalated cells into the urine. Neutralization of R7’s urinary antibacterial activity 
facilitates uropathogenic Escherichia coli (UPEC) replication. While R7 has potent 
bactericidal activity against UPEC, our understanding of its contributions to urothelial 
defenses is limited in vivo because its expression is absent in the laboratory mouse and 
restricted to humans/upper primates. Thus, we generated humanized transgenic R7 mice 
and assess R7’s in vivo antimicrobial activity.
Methods: Using BAC-based recombineering, we integrated the human RNASE7 gene 
into the mouse genome. BAC-R7 transcript and peptide expression was characterized in 
kidneys and bladders from R7 transgenic mice and littermate controls in states of health 
and after mice were transurethrally infected with UPEC. R7 cytotoxicity and its impact 
on murine immunity was evaluated with cytokine arrays, complete blood counts, serum 
chemistry, and histology. R7’s antibacterial activity was evaluated by subjecting mice to 
experimental UTI. After infection, kidneys, bladders, and urine were collected and UPEC 
burden was quantitated.
Results: R7 transgenic mice had normal development, phenotypes, and urinary tract 
histology. R7 mRNA and peptide expression were detected in bladder and kidneys of 
transgenic mice. Immunostaining localized R7 production to the kidney’s intercalated cells 
and the bladder urothelium, which mirrors human expression. R7 mice had normal renal 
function, cytokine profiles, and complete blood counts. After UTI, R7 transgenic mice had 
2-3 fold lower urine, bladder, and kidney UPEC burden compared to littermate controls.
Following UPEC inoculation, R7 mRNA and peptide expression increased in bladders and 
kidneys.
Conclusions: R7 expression in our transgenic humanized mice is similar to humans. R7 
has limited cellular toxicity and does not impact basal murine immune function. Following 
experimental UTI, R7-expressing mice are significantly protected from UPEC. These 
studies provide the needed evidence that R7 has a key role in urothelial defense against 
UPEC and suggest that R7 may be an ideal candidate to develop as a new UTI therapy.
Funding: NIDDK Support
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Fibroblast Growth Factor 23 Is Associated with Impaired Cognition in 
Children with CKD
Jennifer S. Yokoyama,7 Mina Matsuda-Abedini,2 Bradley A. Warady,3 
Susan L. Furth,4 Stephen R. Hooper,5 Anthony A. Portale,6 Farzana Perwad.1 
1Pediatrics, University of California San Francisco, San Francisco, CA; 2The 
Hospital for Sick Children, Toronto, Toronto, ON, Canada; 3Children’s Mercy 
Kansas City, Kansas City, MO; 4The Children’s Hospital of Philadelphia, 
Philadelphia, PA; 5University of North Carolina School of Medicine, Chapel 
Hill, NC; 6University of California San Francisco, San Francisco, CA; 
7University of California, San Francisco, San Francisco, CA.
Background: Plasma FGF23 concentrations increase early in the course of chronic 
kidney disease (CKD) in children and are a strong predictor of disease progression and 
left ventricular hypertrophy. High plasma FGF23 has been linked to cognitive dysfunction 
and cerebrovascular disease in adults with CKD. Whether FGF23 associates with impaired 
cognition in children is unknown.
Methods: In 538 children with CKD stages 2-4 enrolled in the Chronic Kidney Disease 
in Children (CKiD) study, we measured plasma C-terminal FGF23 and phosphorus and 
performed cognitive function tests of intelligence, academic achievement, and targeted 
executive functions. We used multivariate linear regression to analyze cross-sectional 
associations of baseline FGF23 and phosphorus concentrations with standardized cognitive 
test scores and cognitive risk (defined as a score ≥1 standard deviation (SD) below mean 
performance for age in healthy children), adjusting for age, sex, race, estimated GFR, 
proteinuria, blood pressure, and anemia.
Results: At baseline, median age was 12 [95% CI: 8.3, 15.2] years, eGFR was 54 
[40.5, 67.8] ml/min/1.73 m2, plasma FGF23 and phosphorus were 168 [78, 175] RU/ml 
and 4.2 [4, 4.9] mg/dl, respectively. In univariate analyses, higher tertiles of FGF23 
were associated significantly with impaired test scores for errors of omission, a measure 
of attention regulation (p=0.002, 2-tailed Kruskal-Wallis rank test), and academic 
achievement (p=0.06). In fully adjusted analyses, we observed that each 50% increase in 
plasma FGF23 was associated with a 1 SD worsening of omission scores (β=2.07 [0.7-3.4], 
p=0.003). The percentage of children at risk for one or more cognitive deficits ranged 
from 18 to 32%. Furthermore, the cognitive risk for errors of omission was 14% higher in 
children in the highest compared to the lowest FGF23 tertile (p=0.01, 2-tailed chi-squared 
test). Plasma phosphorus, normalized for age, did not associate with cognitive test scores 
or cognitive risk.
Conclusions: In children with pre-dialysis CKD, higher baseline plasma FGF23 
is associated with lower performance in targeted tests of executive function, specifically 
attention regulation, independent of GFR. These data suggest that high plasma FGF23 
contributes to a greater risk for disorders of attention regulation as GFR declines.
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FGF23, Blood Pressure, and Urinary Sodium Handling in Young CKD 
Patients
Michael Freundlich,1 Carlos Cuervo,2,1 Carolyn L. Abitbol.3 1Pediatric 
Nephrology, University of Miami, Miami, FL; 2university of miami/jackson 
memorial hospital, Miami, FL; 3University of Miami/ Pediatric Nephrology, 
Miami, FL.
Background: FGF23 has been associated with hypertension, partly attributed, 
to experimental observations describing FGF23-mediated enhanced Na reabsorption 
in the distal tubule, ↓natriuresis, volume expansion and hypertension. We examined 
whether FGF23 levels and urinary Na excretion are associated with blood pressure (BP) 
measurements in patients with incipient chronic kidney disease (CKD).
Methods: Systolic (S) and Diastolic (D) Blood pressure (BP) height- and age-adjusted 
percentiles (%ti), and C-terminal FGF23, 24-hour natriuresis (UNa), and fractional excetion 
of Na (FENa) were analyzed in young patients with CKD stages 1,2 and 3. Estimated GFR 
(eGFR) were calculated by cystatin (cys) and creatinine (cr) equations.
Results: 57 patients (age± SD, 14.5 ±2.1 years; 41 males), 17 African Americans, 
26 Whites and 14 of other ethnicities, were defined CKD stages 1,2 and 3 by eGFRcys 
(94±29; 37-188) and eGFRcr (97±33; 34-71) ml/min/1.73 m2. Serum Na, P, 1,25(OH)2D 
and plasma renin were normal. UNa (162±73 mEq/24 hours), FENa (0.6±0.46; 0.03-1.8 %) 
or FGF23 levels (113±83; 13-606 RU/ml, normal< 200 RU/ml) did not correlate with SBP 
%ti (69±32; >95 in 30%) or DBP %ti (66±24; >95 in 10%). Although FGF23 levels were 
higher in CKD stages 2 and 3 vs Stage1, natriuresis and FENa values did not differ among 
groups (Table). Patients with FENa < 1st quartile (0.24%) had FGF23 levels (103 ± 55 RU/ml) 
comparable to those in higher quartiles (119±94 RU/ml), and SBP %ti were similar in both 
groups (57±32 vs 71±31, respectively).
Conclusions: Despite higher levels of FGF23 in CKD stages 2-3 vs. Stage 1, 
FENa values were comparable, and neither FGF23 nor FENa correlated with BP. These 
observations do not support a role of FGF23-mediated increased tubular reabsorption of Na 
as a mediator of elevated BP in the earlier stages of CKD.
Funding: Clinical Revenue Support
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Persistent Asymptomatic Isolated Hematuria in Children in IgA 
Nephropathy: Histopathological Features and Prognosis
Cambier Alexandra,1 Marion Rabant,2 Michel Peuchmaur,3 Alexandre Hertig,4 
Georges Deschênes,5 Remi Salomon,6 Julien Hogan,7 Thomas Robert.8 1Robert 
Debré hospital, PARIS, France; 2NECKER Hospital, PARIS, France; 3APHP 
Université Diderot Paris7, Paris, France; 4Sorbonne University, Paris, France; 
5Hospital Robert Debre/Pediatric Nephrology, Paris, France; 6hopital Necker, 
PARIS, France; 7Emory University, Atlanta, GA; 8Assistance Publique des 
Hôpitaux de Marseille, Marseille, France.
Background: Patients with recurrent episodes of macroscopic hematuria and persistent 
isolated microscopic hematuria (proteinuria<0.03g/mmol creatinuria and EGFR> 90ml/
min/1.73m2) in IgA nephropathy (IgAN) does not correlate with prognosis. Early studies 
suggest that gross hematuria was associated with better outcome and with normal or minor 
abnormalities tissue on biopsy. We studied clincial and histological findings and prognosis 
in children with biopsy-proven with persistent isolated microscopic hematuria.
Methods: Data on 82 consecutive children were reviewed. 14 children with persistent 
isolated microscopic hematuria (median 11.7 years old; median of clinical follow-up 4.3 
years) were reviewed. Renal biopsies were scored for Oxford classification.
Results: 13 out 14 patients were male. Analysis of renal biopsies finds: Mesangial 
proliferation in 9 patients (64,3%), endocapillary proliferation in 7 (50%) patients and 
no patient have extracapillary proliferation. Focal glomerulosclerosis/adhesion was 
found in 8 (57.1%) patients, podocytopathic features in 1 (8.3%) patient and no patient 
have tubular atrophy/interstitial fibrosis. 2 (14.3%) patients received steroid therapy and 
5 (35.7%) patients were treated with supportive care treatment alone (renin angiotensin 
system blockade (RASb)). At the last clinical follow up, no patients reach end-stage of renal 
disease, median eGFR was 100.9 ml/min/1.73m2 and median proteinuria 0.15 g/g.
Conclusions: In western countries, recurrent isolated microscopic hematuria is not a 
common indication for kidney biopsy. In our study, we show that children with recurrent 
episodes of macroscopic hematuria and persistent isolated microscopic hematuria does not 
preclude normal or minor abnormalities tissue. Renal biopsy should be proposed in children 
with recurrent episodes of macroscopic hematuria and persistent isolated microscopic 
hematuria. Mesangial and endocapillary proliferation is significantly associated with a poor 
long-term renal outcome and should open discussion about treatment (steroid therapy and/
or RASb) even in absence of proteinuria and renal dysfunction.
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Immunosuppressive Treatment in Children with IgA Nephropathy and 
Evidence to Support the Clinical Value of Podocytopathic Features
Cambier Alexandra,1 Marion Rabant,2 Michel Peuchmaur,3 Alexandre Hertig,4 
Georges Deschênes,5 Remi Salomon,6 Julien Hogan,7 Thomas Robert.8 1Robert 
Debré hospital, Paris, France; 2NECKER Hospital, PARIS, France; 3APHP 
Université Diderot Paris7, Paris, France; 4Sorbonne University, Paris, France; 
5Hospital Robert Debre/Pediatric Nephrology, Paris, France; 6hopital Necker, 
PARIS, France; 7Emory University, Atlanta, GA; 8Assistance Publique des 
Hôpitaux de Marseille, Marseille, France.
Background: There is a need for treatment guidelines and prognostic factor 
identification in children with primary IgA nephropathy (IgAN). We analyzed the causative 
effect of steroids and the applicability of the Oxford classification
Methods: Data on 82 consecutive children (mean 10.6 years; median follow-up 
3.3 years) were reviewed. 21 patients (25.6%) presented with acute kidney injury, and 6 
(7.3%) with nephrotic syndrome. Renal biopsies were scored for Oxford classification, 
podocytopathic features, and extracapillary proliferation in two groups: a groupG1, treated 
with steroid therapy (later in association with cyclophosphamide) and supportive care (renin 
angiotensin system blockade) and a group treated by supportive care alone.
Results: The two groups were not comparable, since baseline clinical data were 
different. eGFR in immunosupressive group significantly improved between M0 and 
M6 from 89.9 (61.2–114.5) to 111.7 (101.7–120)ml/min/1.73m2, p=0.001). Proteinuria 
also significantly decreased from (1.6 (1–4.3) to 0.3 (0.2–0.7)g/g creat, p<0.001). In the 
supportive care group group, eGFR and proteinuria remained stable. Podocytopathic 
features were predictive of renal function decline by univariable (-4.9±14.9ml/min/1.73m2, 
p=0.0079) and multivariable analysis and of poor renal prognosis to a combined event 
(renal function impairment more than 10% of the eGFR baseline or chronic kidney disease 
stage 3 at 6 months) in univariable and multivariable analysis. MEST-C score failed to 
prove its prognostic value.
Conclusions: Immunosuppressive treatment, especially steroid therapy, seems 
beneficial in children with glomerular inflammation and proliferation. The Oxford 
classification does not appear to be entirely appropriate in predicting long-term renal 
prognosis for children, whereas the characteristics of podocytopathy are strongly predictive 
of renal prognosis.
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Clinical and Histological Differences Between Adults and Children in New 
Onset IgA Nephropathy
Cambier Alexandra,1 Marion Rabant,2 Michel Peuchmaur,3 Alexandre Hertig,4 
Georges Deschênes,5 Remi Salomon,2 Julien Hogan,6 Thomas Robert.7 1Robert 
Debré hospital, Paris, France; 2NECKER Hospital, PARIS, France; 3APHP 
Université Diderot Paris7, Paris, France; 4Sorbonne University, Paris, France; 
5Hospital Robert Debre/Pediatric Nephrology, Paris, France; 6Emory 
University, Atlanta, GA; 7Assistance Publique des Hôpitaux de Marseille, 
Marseille, France.
Background: Recent studies showed that prognosis of children IgAN could be as 
severe as adults but would manifest differently. We addressed this question comparing 
clinical and histological characteristics at diagnostic of IgAN between children and adult.
Methods: Data on 211 consecutive patients, including 82 children and 129 adults were 
reviewed. Renal biopsies were scored for Oxford classification and podocytopathic features.
Results: Estimated glomerular filtration (eGFR) and serum albumin at diagnostic was 
lower in adults compared to children (64 vs 89.5 ml/min/1,73m2; p=0.0001) and (3.4 vs 
3.8g/dl, p=0.0001). Serum albumin was lower in children compared to adults (3.4 vs 3.8g/dl, 
p=0.0001) while proteinuria was not different. Histological analysis of kidney biopsy 
finds higher proportion of mesangial (M1) and endocapillary (E1) proliferation in children 
compared to adult (M1 (80.7% vs 27.9% p=0.0001); E1 (71.3% vs 30% p=0.0001). Focal 
glomerulosclerosis (S1), tubular atrophy/interstitial fibrosis ≥ 25% (T1) and podocytopathic 
features (P1) were higher in adult, (S1 (81.5% vs 61.3% p=0.0012), T1 (49.5% vs 1.35% 
p=0.0001), P1 (33.8% vs 16.4% p=0.007)). Proteinuria was associated with M1, E1 and C1 
in children (M1, p=0.001; E1, p=0.0005; C1, p=0.0014) whereas proteinuria was associated 
with S1, P1 and T1 in adult (S1, p=0.0001; P1, p=0.0001; T1, p=0.001). After steroid 
treatment, proteinuria decreased in children (1.54 (0.9–3.6) to 0.03 (0.2–0.7)g/g, p<0.001) 
and in adult group (1.31 (0.77–2.2) to 0.4 (0.2–1)g/g, p<0.001). eGFR remain stable in 
adult (41.4 to 36.9 ml/min/1.73m2) and increase significantly in children (98.6 to 109,3 ml/
min/1.73m2) between M0 and last follow-up.
Conclusions: In children IgAN, proteinuria is related to glomerular proliferative 
lesions whereas in adult proteinuria is related to chronic lesions. Steroid would be 
more effectiveness on eGFR and proteinuria in children due to the steroid sensitivity of 
glomerular lesion.
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Does MEST-C Score Predict Outcomes in Pediatric Henoch Schönlein 
Purpura Nephritis?
Adam Jimenez,1 Ashton Chen,2 Jen-Jar Lin,2 Andrew M. South.2 1Wake Forest 
School of Medicine, Winston-Salem, NC; 2Wake Forest Baptist Health, Winston 
Salem, NC.
Background: Children with Henoch-Schönlein purpura nephritis (HSPN) are at risk 
for long-term negative renal outcomes. HSPN renal biopsies have been graded using the 
International Study of Kidney Disease in Children criteria, which is limited by a lack of 
correlation with outcomes. The MEST-C scoring system by 2016 Oxford Classification 
has been shown to predict poor outcomes in IgA nephropathy (IgAN) but its utility in 
predicting outcomes in HSPN is incompletely described. Our hypothesis is that MEST-C 
score predicts outcomes in US children with HSPN.
Methods: Data of 32 children with HSPN referred to pediatric nephrology who 
underwent renal biopsy between April 1, 2004 and March 1, 2018 were reviewed. Logistic 
regression analysis was used to compare MEST-C scores to a composite outcome at the last 
known follow-up visit: hypertension (systolic or diastolic blood pressure ≥95% for age/
sex/height), chronic kidney disease (glomerular filtration rate <90 mL/min/1.73 m2), or 
proteinuria (urine protein-to-creatinine ratio >0.2 mg/mg).
Results: Their median baseline age was 7.9 years (IQR 5.9); 56% were male, 16% 
were Hispanic, 12.5% African-Americans, and 71.5% Caucasians. 31% of patients had a S1 
score. After a median follow up of 2.7 years (IQR 4.3), 34% of patients reached the outcome. 
Of the MEST-C components, only S1 was significantly associated with the outcome (OR 
10.5, 95% CI 1.9 to 59.4). ROC analysis revealed that an S1 score predicted the outcome 
(AUC 0.75, 95% CI 0.58 to 0.91) with 63.6% sensitivity (95% CI 30.8 to 89.1%) and 85.7% 
specificity (63.7 to 97.0%), indicating a positive predictive value of 70.0% (34.8 to 93.3%) 
and a negative predictive value of 81.8% (59.7 to 94.8%).
Conclusions: Our study demonstrated that MEST-C score, specifically S1, strongly 
predicted the development of hypertension, proteinuria, and chronic kidney disease in 
HSPN children in the US. Further investigation in larger, multi-center studies are warranted 
to validate our findings.
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Clinical Relevance of C4d Deposition in Pediatric IgA Nephropathy
Min Hyun Cho,2 Jaehun Jung,2 Yong-Jin Kim,1 Man-hoon Han,1 Hee Sun Baek.2 
1Pathology, Kyungpook National University Hospital, Daegu, Republic of 
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Background: Immunoglobulin A nephropathy (IgAN) is one of the most common 
causes of primary glomerulonephritis and is characterized by predominant IgA deposition 
in the glomerulus mesangium. Recently, it has been well-known that the activation of 
complement system plays an important role in the development and progression of IgAN. 
The aim of this study is to investigate the association between the evidence of C4d staining 
and clinical or histopathologic features of pediatric IgAN patients.
Methods: Fifty-six pediatric patients diagnosed with IgA nephropathy through renal 
biopsy from 2006 to 2017 were reviewed retrospectively. Immunohistochemical C4d 
staining was performed in all biopsy tissues. Clinical/histopathological features were 
statistically analyzed according to C4d staining positivity.
Results: A total of 56 patients (male 58.9%, female 41.1%) were included in the study 
and the mean age at diagnosis was 12.1 ± 4.7 years. Among the 56 patients, 31 (55.4%) 
showed positive glomerular C4d staining; a mesangial (n=16), a peripheral capillary (n=11), 
or a mixed (n=4) distribution pattern. Urine protein-to-creatinine ratio was significantly 
higher in C4d-positive patients (p = 0.001). The severity of mesangial proliferation 
according to the Haas and Oxford classification were significantly associated with positive 
C4d staining (p < 0.001). In the Haas classification, the positive rate of C4d in patients with 
subclass I was 12.9% (n=4), but in them with subclass III and IV were 45.2% (n=14) and 
38.7% (n=12), respectively. In addition, as for the Oxford classification of IgAN, positive 
C4d staining turned out to be significantly associated with the evidence of mesangial 
proliferation (M1) (p<0.001). The positive rate of C4d in patients with M1 was 67.7% 
(n=21), but in them with M0, 32.3% (n=10). However, there was no significant association 
of the evidence of endocapillary hypercellularity, segmental sclerosis, and tubulointerstitial 
fibrosis/atrophy between the patients with positive C4d and them with negative C4d. 
Additionally, as for C4d staining patterns such as mesangial, peripheral capillary or mixed 
patterns, there was no significant correlation between these patterns and histologic severity 
of the Haas or Oxford classification.
Conclusions: Positive C4d staining was found to be significantly associated with 
clinical/histopathological progression of pediatric IgAN.
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Renal Involvement of Inflammatory Bowel Diseases in Children and 
Adolescents: From Korean Pediatric IBD Cohort
Min Hyun Cho,1 Jaehun Jung,1 Hee Sun Baek,1 Heeyeon Cho,2 Yeonhee Lee.2 
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Korea; 2Samsung Medical Center, Seoul, Republic of Korea.
Background: Recently, the incidence of inflammatory bowel disease (IBD) has been 
rising rapidly, and several reports have described renal complications of IBD. We evaluated 
the clinical manifestations of renal complications in children with IBD to enable early 
detection and prompt treatment of renal complications.
Methods: We retrospectively reviewed the medical records of 456 children and 
adolescents aged <20 years who had been diagnosed with IBD since 2000. We analyzed age, 
sex, medication use, IBD disease activity, and clinical manifestations of renal symptoms.
Results: Our study comprised 456 children with IBD including 299 boys (65.6%) and 
157 girls (34.4%) with a mean age±SD of 14±3 years. The mean follow-up period was 
4.61±2.93 years. The study included 346 children with Crohn’s disease (CD, 75.9%) and 
110 with ulcerative colitis (UC, 24.1%), and the incidence of CD was >UC. Among the 456 
children studied, 67 (14.7%) showed confirmed renal manifestations, and 59 were identified 
as children with CD and 8 as children with UC. We observed 26 children (38.8%) with 
isolated hematuria, 30 (44.8%) with isolated proteinuria, and 11 (16.4%) with hematuria 
and concomitant proteinuria. A renal biopsy was performed in 7 children with CD. Of them, 
5 children showed both microscopic hematuria and proteinuria. Persistent microscopic 
hematuria and recurrent gross hematuria was observed in 2 children. Histopathological 
examination revealed IgA nephropathy in 5 children (71.4%) and Henoch-Schönlein purpura 
(HSP) nephritis in 1 child (14.2%), whereas 1 child (14.2%) showed no histopathological 
abnormalities. IBD disease activity was evaluated in 102 children, of which 81 showed 
CD and 21 showed UC. No significant correlation was observed between the IBD disease 
activity and the presence of renal manifestations in 102 children in whom we were able to 
assess disease activity. In all 102 children, disease activity was mild, and the disease was 
well controlled.
Conclusions: Children with IBD are more likely to show kidney-related symptoms 
than healthy children and adolescents. Therefore, regular screening of urine and evaluation 
of renal function are necessary for early detection of renal complications.
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Long-Term Outcome of 62 Pediatric Henoch-Schönlein Nephritis Patients 
Treated with Methylprednisolone Pulses or Cyclosporine A
Antti Koskela,1 Timo Jahnukainen,5 Kira Endén,7 Pekka M. Arikoski,3 
Janne T. Kataja,2 Matti Nuutinen,4 Elisa Ylinen.6 1University of Helsinki and 
Helsinki University Hospital, Finland, Helsinki, Finland; 2Turku University 
Hospital, Turku, Finland; 3Kuopio University Hospital, Kuopio, Finland; 4Oulu 
University Hospital, Oulu, Finland; 5Children?s Hospital, Helsinki University 
Hospital, Helsinki, Finland; 6Children’s Hospital, University of Helsinki, 
Helsinki University Hospital, Helsinki, Finland; 7Tampere University hospital, 
Tampere, Finland.
Background: The optimal treatment of Henoch-Schönlein purpura nephritis (HSN) 
has remained unclear. We evaluated the outcome of pediatric HSN patients treated initially 
with methylprednisolone (MP) or cyclosporine A (CyA) in the five university hospitals in 
Finland between 1996 and 2011.
Methods: The medical charts were reviewed until the last follow-up visit and 47 (76 %) 
patients attended also additional urine and blood sample screening. MP-treated patients 
(n=42) received three 30 mg/kg pulses followed by oral prednisone for a median of 4.3 
(IQR 3.8 – 5.9) months. Median treatment time for CyA-treated patients (n=20) was 1.2 
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(IQR 1.0 – 1.7) years with an initial target blood concentration of 150-200 μmol/l. Fifty-
nine (95 %) patients had received ACE-Is and/or ARBs.
Results: Baseline characteristics at the time of renal biopsy and outcome after a mean 
follow-up of 10.8 years are shown in Table 1. Eighteen (90 %) CyA-treated and 26 (62 
%) MP-treated patients achieved favorable treatment response with initial treatment and 
needed no additional immunosuppressive therapy (RR 1.45, 95 % CI 1.07 – 1.96, p=0.035; 
for favorable treatment response). One patient developed ESRD and another patient had 
decreased renal function (eGFR <60 ml/min/1.73m2), both initially treated with MP. Six 
patients (5 MP, 1 CyA) had mildly decreased renal function (eGFR 60 – 89 ml/min/1.73m2), 
one of them having non-nephrotic proteinuria.
Conclusions: Renal outcome was good in both treatment groups. However, CyA-
treated patients needed less additional immunosuppressive treatment and none of the 
initially CyA-treated patients had decreased renal function (eGFR <60 ml/min/1.73m2) after 
10.8 years of follow-up. Urinary abnormalities may persist or develop and therefore long-
term follow-up of HSN patients is mandatory.
Funding: Private Foundation Support
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Clinicopathological Significance in Juvenile-Onset Silent Lupus Nephritis
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1Wakayama Medical University, Wakayama City, Japan; 2Graduate School of 
Medicine, University of the Ryukyus, Nishihara-cho, Japan; 3Hyogo Prefectural 
Kobe Children’s Hospital, Kobe, Japan; 4Dept. of Pediatrics, Kobe Univ. 
Graduate School of Medicine, Kobe, Japan.
Background: In patients with juvenile-onset systemic lupus erythematosus (SLE), 
there have been reports of silent lupus nephritis (SLN) patients without abnormal urinalysis 
and renal impairment. Currently, renal biopsies are the gold standard for diagnosis and 
monitoring of LN. The purpose of this study is to clarify the clinicopathological significance 
of juvenile-onset SLN.
Methods: Retrospective analysis of 57 patients who underwent renal biopsy among 59 
patients diagnosed as juvenile-onset SLE who met the American College of Rheumatology 
criteria for the classification of SLE between December 2000 and March 2017 to compare 
clinical and pathological findings between SLN and others.
Results: There were 27 patients (47.4%) with SLN. Clinical findings showed significant 
differences (SLN vs. non-SLN) in eGFR (174.9 vs 147.5 ml/min/1.73m2, p=.02) and serum 
C3 level (76.0 vs 46.5 mg/dl, p=.04). The distribution of ISN/RPS classes of LN was as 
follows: class I: II: III: IV: V (12: 11: 3: 1: 0 vs 2: 7: 6: 14: 1; p=.003). Though SLN group 
showed milder pathological presentation, 4 cases with SLN showed severe pathological 
findings such as class III or IV. The 4 patients with class III and IV had significantly higher 
dsDNA antibody titer (159.2 vs 42.1 IU/ml, p =.02) and lower serum C3 level (37 vs 77 
mg/dl, p =.03) than the other SLN cases. As to immunofluorescence, all patients showed 
the deposition of immunoglobulins and the degree of deposition of IgG and C3 in SLN was 
significantly weaker than in non-SLN. In electron microscopy, the degree of subendothelial 
and subepithelial EDD was significantly weaker in SLN.
Conclusions: Most of the patients with SLN showed milder pathological presentation, 
but some cases showed severe pathological presentation regardless of minor clinical 
presentations. We confirmed an importance of renal biopsies for juvenile-onset SLE. Serum 
C3 level might be an important marker of the severity of SLN.
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Altered Expression of CD46 Mediated Tr1 Cytoplasmic Isoforms 
Associated with IL-10 Secretion Can Induce Remission of Active Lupus 
Nephritis
Ching-Yuang Lin. Children’s Hospital, China Medical University, Taichung, 
Taiwan.
Background: CD46-costimulated T cells in the presence of IL-2 acquire a Tr1 type 
Treg phenotype, secreting high amount IL-10 and granzyme B. There was two forms of 
CD46 cytoplasmic isoforms. Cyt1 inhibits and Cyt2 augments inflammation. To elucidate 
whether CD46 mediated Cr1 cells can induce remission in active lupus nephritis (LN) by 
intravenous methylprednisolone (IVMP) therapy, we evaluate IL-10 secreting Tr1 cells in 
peripheral blood mononuclear cells (PBMCs) and renal biopsy specimens, the capacity 
of CD46+ Tr1 cells to induce IL-10 production, altered expression of CD46 cytoplasmic 
ioforms before and after IVMP therapy.
Methods: PBMCs were isolated from fourty pediatric class III or IV LN active LN 
patients and from ten healthy controls before and after three days of IVMP. Purified CD4+ T 
cells from patients before and after IVMP as well as healthy controls were stimulated with 
anti-CD3 and CD46 mAbs in the presence of IL-2 to generated Tr1 cells.
Results: Decreased CD46 expression on CD4+ T cell in PBMCs and renal biopsy 
specimens from active LN patients versus controls, correlating with higher anti-dsDNA 
Ab level and lower serum C3, C4 levels. IL-10, granzyme B, CCR4, CCR7 expression and 
CD4+ T cell proliferation were diminished by CD3/CD46-activated Tr1 cells in active LN. 
CD4+ T cell from active LN patients showed a statistically increase in IFN-r+ T cells when 
compared to healthy control T cells following CD3 activation but failed to switch efficiently 
from IFN-r to IL-10 production following CD3+/CD46 stimulation. After IVMP altered 
expression of CD46+ Tr1 cell cytoplasmic isoform with increasing CD46-Cyt1/ -Cyt2 ratio. 
IVMP also increased AKT phosphorylation and enhanced adhesion, migration of CD3/
CD46 activated Tr1 cells and IFN-r switch to IL-10 production in active LN patients.
Conclusions: Switching efficiency from IFN-r to IL-10 production of CD3+/CD46 
stimulated Tr1 cells was failed in active LN patients. IVMP rescue INF-r switching IL-10 
production associated with induction of remission in active LN also increasing adhesion 
and migratory capacity to suppress inflammation by CD46-mediated Tr1 cells. Thus, 
pharmacologic intervention to alter pattern of CD46-Cyt1, -Cyt2 expression with inducing 
IL-10 secretion by CD46 medicated Tr1 cells are viable approach in active LN patients.
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Association of APOL1 Risk Variants with Subclinical Renal Disease in 
HIV Infected Children and Apparently Healthy Children from Central 
Africa (Democratic Republic of Congo)
Pepe M. Ekulu,1,2 Michel N. Aloni,2 François Lepira,3 Elena N. Levtchenko.1 
1Department of Paediatric Nephrology & Growth and Regeneration, KU 
Leuven, Leuven, Belgium; 2Division of Nephrology, Department of Pediatrics, 
University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the); 
3Division of Nephrology, Department of Internal Medicine, University of 
Kinshasa, Kinshasa, Congo.
Background: Apolipoprotein-L1 (APOL1) risk variants G1 and G2 increase the risk 
of progressive chronic kidney disease (CKD), including HIV-related CKD, among sub-
Saharan African descents. HIV infection, a substantial healthcare problem in sub-Saharan 
Africa, is an extremely potent trigger factor for APOL1 kidney disease. However, data 
on APOL1 risk genotypes from Central Africa still remain limited and the association 
with HIV-related CKD is not yet well documented. We aimed to describe the prevalence 
of APOL1 risk variants in the Democratic Republic of Congo (DRC) and to assess the 
association between these variants and the subclinical renal disease in both HIV infected 
children and apparently healthy children.
Methods: A total of 813 participants, of whom 401 HIV infected children treated 
with antiretroviral therapy (ART) and 412 apparently healthy children, were enrolled from 
four large districts in Kinshasa, the capital of the DRC. APOL1 high-risk genotype (HRG) 
was defined by the presence of 2 risk variants (G1/G1, G2/G2, and G1/G2) and low risk 
genotype (LRG) if 0 or 1 risk variants were present. As the main outcomes, reduced kidney 
function was defined as eGFR <60 ml/min per 1.73 m2 and elevated urine albumin-to-
creatinine ratio (ACR) ≥ 30mg/g.
Results: From 813 participants, APOL1 sequence analysis revealed 52 (6.4%) carrying 
HRG. Regarding LRG, 168 (20.6%) participants carried G1/G0 while 116 (14%) carried 
G2/G0. Of 401 HIV infected children, 72 (18%) had elevated albuminuria versus 40 (9.7%) 
out of 412 apparently healthy children (p<0.001) and reduced kidney function was detected 
in 26 (6.5%) against 13 (3.1%) (p=0.019). Considering the association between APOL1 
HRG and renal disease, 18/23 (78.3%) HIV infected children carrying HRG had elevated 
albuminuria (0R 21.6, 95%CI 7.3-76.6; p<0.001) against 5/29 (17.2%) apparently healthy 
children (0R 2.1, 95%CI 0.6-6.0; p=0.137). No significant difference was found concerning 
the reduced renal function.
Conclusions: The APOL1 risk variants are highly prevalent in the DRC. The HIV 
infection is strongly associated with the presence of subclinical renal disease, especially in 
those carrying the APOL1 HRG.
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Novel Truncating Mutations in Autosomal Dominant FSGS Genes Cause 
Childhood Onset Steroid-Resistant Nephrotic Syndrome
Jennifer D. Varner,1,2 Megan Chryst-Stangl,2 Tracy E. Hunley,3 Brandon 
M. Lane,2 Guanghong Wu,2 Gentzon Hall,4 Rasheed A. Gbadegesin.5 1Duke 
University School of Medicine, Durham, NC; 2Duke Molecular Physiology
Institute, Durham, NC; 3Vanderbilt University Medical Center, Nashville, TN; 
4Division of Nephrology, Duke University Medical Center, Durham, NC; 
5Department of Pediatrics, Duke University Medical Center, Durham, NC.
Background: Steroid-resistant nephrotic syndrome (SRNS) is a leading cause of 
end stage kidney disease in children. Most autosomal dominant genes are presumed to 
be due to gain-of-function mutations. Mutations in transient receptor potential canonical 
6 (TRPC6) and inverted formin 2 (INF2) have been described in familial focal segmental 
glomerulosclerosis (FSGS). Most of the mutations described are missense mutations. 
Truncating (loss of function) mutations in these genes have not been well described.
Methods: We identified 181 families with SRNS in our worldwide cohort. Families 
were screened for variants in ten known autosomal dominant FSGS genes (INF2, TRPC6, 
COL4A3, COL4A4, WT1, ACTN4, ANLN, CD2AP, ARHGAP24, and LMX1B) using 
targeted sequencing of custom amplicons (TSCA). Causative mutations were defined as 
non-synonymous variants, obligatory splice site variants, or truncating variants that had 
a minor allele frequency <1% in the normal population. Non-synonymous variants were 
considered pathogenic if they were also reported to be deleterious by at least 2 in silico 
software models. Variants were confirmed using Sanger sequencing.
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Results: We identified two novel truncating mutations in TRPC6 and INF2, respectively, 
in two families with onset of disease at age <10 years. Family DUK34462 consists of three 
affected members with an autosomal dominant pattern of inheritance. We identified a novel 
stop codon change in INF2 (p.E249X) in a child who presented with disease at the age of 
eight years. The second family is DUK40015 with one affected individual with onset of 
disease at the age of ten years. We identified a frameshift mutation in TRPC6 (p.G39fsX41) 
in this child. Apart from early onset of disease, the phenotype in these two families was not 
different from individuals with missense mutations in the two genes, in that they both have 
therapy resistant disease.
Conclusions: In conclusion, truncating mutations in autosomal dominant SRNS/
FSGS genes may cause early onset childhood SRNS, likely by haploinsufficiency effect 
on pathways that are critical for normal development of the glomerular filtration barrier.
Funding: NIDDK Support, Private Foundation Support
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Evidence Against Routine Genetic Testing for SRNS in an Outbred 
Population
Jennifer D. Varner,1,2 Megan Chryst-Stangl,3 Chris Esezobor,4 Brandon M. Lane,3 
Guanghong Wu,2 Gentzon Hall,5 Rasheed A. Gbadegesin.6 1Duke University 
School of Medicine, Durham, NC; 2Duke Molecular Physiology Institute, 
Durham, NC; 3Duke Molecular Physiology Institute, Durham, NC; 4College of 
Medicine, University of Lagos, Akoka, Nigeria; 5Division of Nephrology, Duke 
University Medical Center, Durham, NC; 6Department of Pediatrics, Duke 
University Medical Center, Durham, NC.
Background: Steroid-resistant nephrotic syndrome (SRNS) is a leading cause of end 
stage kidney disease in children. Recent advances in genomic technology have led to the 
identification of more than 50 genetic causes of SRNS, most of which code for proteins 
located within the glomerular filtration barrier. Despite these advances, there are no clear 
clinical guidelines for genetic screening in patients with SRNS.
Methods: Our worldwide multi-ethnic cohort consisted of 492 individuals from 181 
families with SRNS, of whom 86 families had familial disease and 95 individuals had 
sporadic disease. Initial genetic screening was performed by direct sequencing of candidate 
genes and whole exome sequencing. Analysis in recent years was performed using targeted 
high-throughput sequencing of 42 known SRNS genes and risk loci. Causative mutations 
were defined as missense variants, truncating variants, and obligatory splice site variants 
with a minor allele frequency <1% in the normal population. Non-synonymous variants 
were considered pathogenic if determined to be deleterious by at least two in silico software 
models. In order to provide clinical guidelines, we evaluated for differences in age at disease 
onset, sex, race, family history of SRNS or chronic kidney disease (CKD), extra-renal 
manifestations, and renal biopsy findings.
Results: We identified disease causing variants in 34/81 (39.5%) families with familial 
SRNS and 6/95 (6.3%) individuals with sporadic disease. Amongst families with hereditary 
disease, causative variants were identified in 44.6% of families with presumed autosomal 
dominant inheritance and 23.8% of families with presumed autosomal recessive inheritance. 
Variants in INF2, COL4A3, and WT1 accounted for over half of all causative mutations. 
Family history of SRNS or CKD was the only significant clinical factor predictive of 
identifying a causative mutation (χ2 p<0.00001).
Conclusions: In this worldwide cohort, we identified causative mutations in almost 
40% of all families with hereditary SRNS, compared to only 6% of individuals with 
sporadic disease, making family history the single most important clinical predictor of 
monogenic causes of disease. These data support the use of genetic testing in patients with 
a positive family history of SRNS, and selective testing in those with sporadic disease.
Funding: NIDDK Support, Private Foundation Support
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Adrenal Suppression After Prednisolone Treatment in Children with 
Idiopathic Nephrotic Syndrome: A Multicenter Prospective Study
Ryoko Harada,1 Kaori Kikunaga,1 Koichi Kamei,2 Riku Hamada,1 
Hiroko Nagata,3 Takashi Ando,4 Kenji Ishikura.2 1Tokyo Metropolitan Children’s 
Medical Center, Tokyo, Japan; 2National Center for Child Health and 
Development, Tokyo, Japan; 3Kumamoto University, Kumamoto, Japan; 
4Tsukuba Gakuen hospital, Tsukuba, Japan.
Background: Severe iatrogenic adrenal insufficiency can occur after steroid treatment. 
However, there have been a limited number of studies in adrenal insufficiency after 
prednisolone (PSL) treatment in children with idiopathic nephrotic syndrome (NS), despite 
much repeated use of PSL.
Methods: We prospectively obtained data of patients with NS aged 2 to 19 years 
who underwent PSL treatment using International Study of Kidney Disease in Children 
(ISKDC) regimen from September 2016 to August 2017 at two children’s hospitals in 
Tokyo. In the present study, adrenal insufficiency was defined as cortisol values less than 
5 mcg/dL at 9 AM, based on our previous study in Kawasaki disease showing that single 
serum cortisol values less than 5 mcg/dL obtained at 9 AM from children treated with PSL 
were significantly correlated with peak serum cortisol value less than 15 mcg/dL in the 
corticotropin-releasing hormone stimulation test. Patients were divided into two groups and 
compared: an adrenal insufficient group (I) and a sufficient group (S) based on the serum 
cortisol values.
Results: Ninety-eight children (70 boys) were enrolled and analyzed in this study: 12 
(12.2%, 10 boys) were in the I group and 86 children (87.8%, 60 boys) were in the S 
group. The median serum cortisol value was 7.7 mcg/dL [IQR 6.9-15.1]. There was no 
statistically significant difference in age, period from final PSL administration to the cortisol 
measurement, or number of relapses between the two groups. The median dosage of PSL 
over one year up to the cortisol measurement day in the I group was significantly higher than 
that in the S group (3000 mg [778-5359] vs 0 mg [0-1395], p=0.004), and the number of 
children who experienced relapses during PSL treatment in the I group was also more than 
those of the S group (4/12 (33.3%) vs 8/86 (9.3%), p=0.038).
Conclusions: Adrenal suppression can occur in a significant proportion of children with 
NS treated with PSL. Care must be taken to avoid adrenal insufficiency in these children. A 
measurement of serum cortisol values after PSL treatment is necessary, particularly in those 
receiving high-dose steroid within a year.
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Vitamin D Receptor Gene Polymorphisms in Childhood Idiopathic 
Nephrotic Syndrome
Yee-Hsuan Chiou,1,2 Shiao-Ping Huang,3 Nai-Wen Fang.1 1Kaohsiung Veterans 
General Hospital, Kaohsiung, Taiwan; 2School of Medicine, National Yang-
Ming University, Taipei, Taiwan; 3Fooyin University, Kaohsiung, Taiwan.
Background: Idiopathic nephrotic syndrome (INS) is the most frequent type of 
nephrotic syndrome in children. The pathogenesis of remains controversial and may be 
mediated by the immune system and the imbalance between T-helper cell subtype 1 (Th1) 
and subtype 2 (Th2) cytokines, which are regulated by the vitamin D. Vitamin D exerts its 
effects through its receptor (VDR). Its response to steroids treatment are also varied. The 
aim of this study was to analyze the correlation between the VDR gene polymorphisms and 
the response to steroids treatment in INS children.
Methods: Thirty four patients with INS were enrolled and divided into 2 groups: 
18 steroid-sensitive (SS) and 16 steroid-resistance (SR). To analyze the VDR gene 
polymorphisms, the SNP genotyping for Fok1, Apa1, Cdx2, Taq1, Bsm1 were performed 
using TaqMan Genotyping Assays. The genotypic and allele frequency were analyzed.
Results: The Apa1 C allele was associated with steroid resistance then A allele [OR 8.75, 
p=0.009]. The frequency of the C allele was significantly higher in SR than in SS subjects 
(0.84 vs. 0.47, respectively). The Bsm1 G allele was associated with steroid resistance then 
A allele [OR 7.00, p=0.017]. The frequency of the G allele was significantly higher in SR 
than in SS subjects (0.88 vs. 0.50, respectively). The Fok1 C allele was associated with 
steroid resistance then T allele [odds ratio (OR) 6.00, p=0.015]. The frequency of the C 
allele was significantly higher in SR than in SS subjects (0.66 vs. 0.33, respectively). There 
was no significant correlation in Cdx2 and Taq1 polymorphisms in VDR gene between 
treatment response.
Conclusions: Our results indicate that among our pediatric patients with INS, the VDR 
gene polymorphism: Fok1, Apa1, and Bsm1 were associated with steroid resistance; while 
the Cdx2 and Taq1 gene polymorphisms showed no statistical significance between these 
2 groups.
Funding: Government Support - Non-U.S.
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Urine Biomarker Potential for Assessment of Disease Activity in Pediatric 
Nephrotic Syndrome
Taketsugu Hama,1 Yu Tanaka,1 Masashi Sato,1 Hironobu Mukaiyama,1 
Yuko Shima,1 Koichi Nakanishi,3 Norishige Yoshikawa,2 Hiroyuki Suzuki.1 
1Pediatrics, Wakayama Medical University, Wakayama, Japan; 2Clinical Study 
Support Center, Wakayama Medical University, Wakayama, Japan; 3Department 
of Child Health and Welfare (Pediatrics), Graduate School of Medicine, 
University of the Ryukyus, Okinawa, Japan.
Background: Biomarkers are considered to be a powerful tool of diagnosis and 
assessment of disease activity. Currently, proteinuria is the standard means of diagnosis of 
nephrotic syndrome (NS). Other non-invasive biomarkers are desired, especially those that 
may provide better understanding of NS activity than proteinuria.
Methods: We extracted urine RNA and using real-time PCR, examined the expression 
levels of various biomarkers. Expression levels were then compared between NS and other 
diseases. We also investigated the correlation between biomarkers and the conditions of 
disease across four stages; pre-treatment proteinuria (stage 1), proteinuria during treatment 
(stage 2), remission during treatment (stage 3) and post-treatment remission (stage 4). At our 
hospital, 117 RNA samples were taken from 104 consecutive patients with various kidney 
diseases (30 nephrotic syndrome, 27 IgAN, 15 isolated hematuria, 7 isolated proteinuria, 25 
others). Across the four stages, the 30 NS patients provided 46 RNA samples (stage 1 = 7, 
stage 2 = 8, stage 3 = 12, stage 4 = 19).
Results: Using biomarkers, we could diagnose NS and observe its activity across the 
four stages. Pediatric NS samples showed significantly higher levels of liver fatty acid-
binding protein (FABP-1) (p<0.01), megalin (p<0.01), cubilin (p<0.01) and lower level of 
podocin (p<0.01) compared to the other diseases. In NS samples only, FABP-1, cubilin and 
kidney injury molecule-1 (KIM-1) expression levels correlated positively with urine protein 
volume, whereas podocin correlated negatively. FABP-1 expression was around double and 
podocin expression was approximately 75% lower in relapse than in remission (Table 1). In 
stage 2, cubilin expression doubled. In stage 3, KIM-1 expression increased 170%.
Conclusions: Urine RNA expressions reveal clues to the pathophysiology of NS. 
Urine biomarkers other than proteinuria can be considered an effective non-invasive tool to 
understand disease activity in pediatric NS.
Funding: Government Support - Non-U.S.
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Table 1. Urine RNA relative expression
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Urinary CD80 as a Novel Biomarker of Podocyte Injury
Shoji Tsuji, Yuko Akagawa, Takahisa Kimata, Sohsaku Yamanouchi, 
Shohei Akagawa, Kazunari Kaneko. Kansai Medical University, Hirakata-shi, 
Japan.
Background: CD80, which is expressed by antigen-presenting cells, was recently 
reported to also be expressed in podocytes in pathological conditions such as idiopathic 
nephrotic syndrome (INS); moreover, CD80 over-expression could be detected in urine 
(Reiser J, et al. 2004; Garin, EH, et al. 2009). However, as there are many skeptical reports, 
a conclusion has yet to be drawn. The purpose of this study was to clarify whether podocyte-
derived CD80 appears in urine, where it may serve as a biomarker for podocyte disorder.
Methods: Patients with INS (median age 7.9 years, n=10) were grouped into initial 
attack and relapse (group A), and remission (group B), and compared with patients with 
other renal diseases (e.g., IgA vasculitis nephritis; median age 8.2 years, n=7; group C). 
Single voided urine and serum samples were collected at the same time. Urine and serum 
CD80 levels were measured by ELISA and compared among the three groups to examine 
potential correlations. The correlation between urine CD80 and urinary protein excretion 
was also investigated. In addition, puromycin was added to a human podocyte cell line to 
prepare an in vitro INS model, and expression of CD80 after 72 hours was confirmed using 
western blotting.
Results: (1) Urinary CD80 was significantly increased in group A compared with group 
B (group A:group B=465.94:0.00; ng/gCre, numerical value is median, p=0.0072). Group A 
was also higher than group C, however there was no significant difference (group A:group 
C=465.94:422.04, p=0.65). (2) Although there was no significant correlation between 
urinary CD80 and serum CD80 values, there was a correlation between urinary CD80 and 
urinary protein excretion (r=0.24, p=0.17; r=0.35, p=0.0031, respectively). (3) As a result 
of administration of puromycin to the human podocyte cell line, CD80 expression was 
increased almost two-fold compared with control (untreated podocytes: puromycin-treated 
poocytes=8201.26:16309.43, p=0.015).
Conclusions: A significant amount of CD80 was excreted in the urine of INS and other 
renal disease patients, and its concentration did not correlate with serum concentration. 
In addition, CD80 expression was also confirmed in an INS human cell line model. 
Furthermore, urinary CD80 was significantly correlated with amount of urinary protein 
reflecting podocyte injury, suggesting that it could be a biomarker of podocyte disorder.
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All-Trans Retinoic Acid Directly Acts on Podocytes by Regulating CD80 
Expression
Yuko Akagawa, Shoji Tsuji, Shohei Akagawa, Sohsaku Yamanouchi, 
Takahisa Kimata, Kazunari Kaneko. Kansai Medical University, Osaka, Japan.
Background: Pathogenesis of minimal change nephrotic syndrome (MCNS) remains 
unclear, though recent studies suggest a role for malfunction of regulatory T cells (Tregs) 
and abnormal expression of several podocyte-related molecules, such as CD80 (Garin E, et 
al. Pediatric Nephrology, 2016). All-trans retinoic acid (ATRA) has the potential to regulate 
the immune system, including induction and differentiation of Tregs, in addition to its 
vitamin function. Therefore, we aimed to investigate the potential of ATRA as a protective 
therapy for MCNS through suppression of CD80 in vitro.
Methods: Human-derived immortalized podocytes were treated with puromycin 
aminonucleoside (PAN) as an in vitro model of MCNS. Cells were treated with ATRA 
(10 μM) or DMSO in starvation medium on day 1 followed by PAN (50 μg/ml), or PBS on 
day 0. Samples were collected after 72 h for analysis. Protein expression levels of CD80 and 
retinoic acid receptor (RAR) were measured by western blotting.
Results: PAN induced increased protein expression of CD80 and RAR both of which 
were restored by ATRA treatment (Figure1). These results suggested that the overexpression 
of CD80 after PAN stimulation can be restored by ATRA through RAR.
Conclusions: ATRA suppresses CD80 overexpression caused by PAN stimulation 
through RAR in podocytes. ATRA might have an antiproteinuric effect on MCNS through 
its direct effect on podocytes.
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Expression and Functional Activity of Multidrug Resistance-Associated 
Protein-1 and P-Glycoprotein on T-Cells Is Associated with Steroid 
Resistance Nephrotic Syndrome in Children
Narayan Prasad,1 Harshit Singh,2 Saurabh Chaturvedi,2 Akhilesh Jaiswal,3 
Vikas Agarwal.2 1SGPGIMS CAMPUS, Lucknow, India; 2SGPGIMS, Lucknow, 
India; 3Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 
India.
Background: Steroid remains as mainstay of therapy for Idiopathic Nephrotic 
Syndrome (NS). Other than histological factors like changes from minimal change to 
FSGS, pharmacogenomic factors may affect steroid response, however not well studied. 
Overexpression of P-glycoprotein (P-gp) and Multidrug resistance associated protein 1 
(MRP-1) modulate pharmacokinetics of steroid and contribute in steroid resistance.
Methods: P-gp, MRP-1 expression were evaluated on whole blood and functional 
activity on peripheral blood mononuclear cells (PBMCs) by Flow Cytometry in steroid 
sensitive NS (SSNS) (n=80,male 43, age=8.54±4.3 yrs);and steroid resistant NS (SRNS) 
(n=50, male 29, age=7.72±3.6yrs). Multi resistance activity factor (MAF) was calculated 
using formula (MAFMDR1=100× (FMDR1-F0)/FMDR1).
Results: Percentage of P-gp (10.35±2.15 vs 4.19±1.07, p<0.001);and MRP-
1(17.03±3.45 vs 8.71±2.97, p<0.001) were significantly higher in SRNS than SSNS. 
Absolute P-gp (64.96±12.78 vs 32.63±12.07, p<0.001) and MRP-1 (64.72±10.27 vs 
40.28±11.24, p<0.001) expression were also significantly high in SRNS. P-gp expression 
on CD4+ (6.08±1.06 vs 4.34±1.47, p<0.001); and CD8+cells (8.65±2.19 vs 3.99±1.72, 
p<0.001) was significantly higher in SRNS than SSNS. MRP-1 expression on CD4+ cells 
(12.06±2.91 vs 3.35±0.83, p=0.001); and CD8+cells (5.11±0.68 vs 1.59±0.39, p<0.001) 
was significantly high in SRNS.Functional activity of P-gp (66.12±12.71 v/s 28.22±7.35, 
p<0.001);and MRP-1 (72.30±8.38 v/s 32.38±8.89,p<0.001) was significantly increased in 
SRNS.
Conclusions: Overexpression of P-gp and MRP-1 on T cells contribute in steroid 
resistance and may be biomarker of steroid resistance. Use of P-gp and MRP-1 inhibitors 
may prevent SRNS status.
Funding: Government Support - Non-U.S.
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Metabolite Predictors of CKD Progression in Children
Michelle Denburg,1 Alison G. Abraham,5 Josef Coresh,3 Jingsha Chen,5 
Morgan Grams,10 Harold I. Feldman,7 Paul L. Kimmel,6 Casey Rebholz,5 
Eugene P. Rhee,8 Vasan S. Ramachandran,9 Bradley A. Warady,4 Susan L. Furth.2 
for the CKD Biomarkers Consortium 1The Children’s Hospital of Philadelphia, 
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 
PA; 2The Children’s Hospital of Philadelphia, Philadelphia, PA; 3Welch Center 
for Prevention, Epidemiology & Clinical Research, Baltimore, MD; 4Children’s 
Mercy Kansas City, Kansas City, MO; 5Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD; 6National Institute of Diabetes and Digestive 
Kidney Diseases (NIDDK), Bethesda, MD; 7University of Pennsylvania, 
Philadelphia, PA; 8Massachusetts General Hospital, Newton, MA; 9Boston 
University School of Medicine, Framingham, MA; 10Johns Hopkins University, 
Baltimore, MD.
Background: We sought to perform the first large-scale discovery of novel metabolite 
biomarkers of CKD progression in children.
Methods: We evaluated an untargeted GC/MS2 and LC/MS2-based metabolomics 
quantification (Metabolon) of baseline plasma samples from 587 Chronic Kidney Disease 
in Children (CKiD) participants. Cox proportional hazards and lognormal regression were 
used to examine the association between standardized, log transformed metabolites and 
progression to end stage kidney disease (ESKD: dialysis/transplant), adjusting for age, sex, 
race, body mass index, hypertension, anemia, glomerular (G) vs. non-glomerular (NG) 
diagnosis, serum albumin, proteinuria, and estimated glomerular filtration rate (eGFR). 
Stratified analyses were performed within G and NG subgroups.
Results: Cohort characteristics were: 354 male (60%); median age 12.3 years; median 
eGFR 53.2 mL/min/1.73m2; 409 (70%) NG diagnosis. 171 (29%) developed ESKD over 
a median observation time of 5.0 years (inter-quartile range 3.1-7.5). Of 949 known 
non-drug metabolites identified, 16 were associated with time to ESKD in both the fully 
adjusted Cox and lognormal models by the pathway specific false discovery rate threshold 
<0.05 (Figure). 13 were lipids and 6 were in the hexosylceramide pathway. 10 of the 16 
metabolites remained associated in stratified analyses, mostly within the G subgroup, and 
the magnitude of the HR was generally greater than that for the full cohort. An additional 
9 metabolites (4 in the lysoplasmalogen pathway) were identified in stratified analyses, 
predominantly within the G group.
Conclusions: Untargeted metabolomic profiling identified several novel metabolite 
biomarkers associated with CKD progression in children independent of established 
predictors, including hypertension, proteinuria and eGFR, and distinct from metabolites 
identified in adult studies. Further studies are needed to replicate these findings and 
delineate mechanism.
Funding: NIDDK Support
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Evaluation of Urinary C5b-9 as a Biomarker of Hematopoietic Stem Cell 
Transplant-Associated Thrombotic Microangiopathy
Stefanie W. Benoit,1 Stella M. Davies,1 Thelma Kathman,1 Jay Patel,1 
Melinda Tepe,1 Adam Lane,1 Bradley P. Dixon.2 1Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH; 2Children’s Hospital of Colorado, Aurora, CO.
Background: Thrombotic microangiopathy (TMA) affects 39% of pediatric 
hematopoietic stem cell transplant (HSCT) patients. Renal involvement, characterized 
by hypertension, proteinuria, and kidney injury, may be confounded by the side effects 
of corticosteroids and calcineurin inhibitors, and highly sensitive and specific biomarkers 
for HSCT TMA are currently lacking. Urinary C5b-9 (uMAC) is associated with disease 
activity in other forms of TMA such as preeclampsia. However, complement activation has 
been demonstrated in vitro when plasma is acidified by mixing with urine. We hypothesized 
that uMAC would be associated with the diagnosis of HSCT TMA, but potentially 
confounded by BK cystitis.
Methods: uMAC was measured prospectively in 80 consecutive pediatric allogeneic 
HSCT patients weekly from Days 0 – 35, and Days 48, 60, and 100 using a commercial 
ELISA clinically validated for use with urine. Association of uMAC with patient, primary 
disease, and HSCT characteristics was assessed. We then analyzed the association between 
the clinical outcomes of measurable uMAC, hematuria, BK viremia, and BK cystitis with 
the diagnosis of TMA.
Results: 48 patients had at least one uMAC >0ng/mL. There were no patient, 
primary disease, and HSCT characteristics associated with having measurable uMAC. In 
univariate analysis, TMA was associated with uMAC (p=0.04), hematuria (p<0.001), BK 
viremia (p<0.01), and BK cystitis (p<0.01). In multivariate analysis, uMAC was no longer 
associated with TMA (p=0.94), whereas BK viremia (p<0.01) and hematuria (p<0.05) 
maintained their association with TMA.
Conclusions: uMAC is not associated with HSCT TMA. uMAC is confounded by 
hematuria, which may have implications for its use and interpretation in other disease 
processes. Unexpectedly, hematuria demonstrated a strong association with TMA diagnosis 
in HSCT patients, perhaps suggesting its utility as an additional diagnostic criterion in 
establishing the diagnosis of TMA.
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Coexisting Variations in Complement Regulatory Genes Increase Risk of 
Relapse in Anti-Factor H (FH) Antibodies Associated Atypical Hemolytic 
Uremic Syndrome (aHUS)
Priyanka Khandelwal,1 Mohammed Faruq,2 Mamta Puraswani,1 Aditi Sinha,1 
Arvind Bagga.1 Indian HUS database 1All India Institute of Medical Sciences, 
New Delhi, India; 2Institute of Genomics and Integrative Biology, New Delhi, 
India.
Background: Patients with anti-FH antibodies, comprising one-half of children with 
aHUS in India, are managed by PEX and immunosuppression (IS). While deficiency of FH 
related protein-1 (CFHR1) is strongly associated, prevalence of additional variations and 
their impact on outcomes is unclear.
Methods: Of 435 children with anti-FH aHUS in the nationwide database, 93 (21%) 
were screened by targeted sequencing of 27 genes, comprising full length CFH, CFI, CFB, 
C3, CD46, THBD, DGKE, coding regions of CFHR1-5, PLG, ADAMTS13 and lectin & 
terminal pathway. Genotype-phenotype correlation and risk-factors for relapse & adverse 
outcomes (eGFR <30 mL/min/1.73 m2 or death) were evaluated.
Results: Patients aged 9±3 yr had high anti-FH titers (median 4684 AU/ml) that 
persisted >1000 AU/ml during remission in one-third. At 44-mo follow up, adverse 
outcome was seen in 20% and relapses in 30% (17% and 30% in database, respectively; 
P=0.02 and <0.001). Sequencing at mean depth of 123X (96% coverage) showed variants 
of unknown significance (VUS) in 6.5% (Table). MLPA showed homozygous deletion 
(90%) or duplication (N=1) of CFHR1. Severity of renal and extrarenal manifestations 
were independent of genetic variations. Prompt PEX (Hazard ratio, HR=1.03; P=0.009), 
lower anti-FH titers (HR=1.00; P=0.06) and lower peak creatinine (HR=1.2; P=0.008) were 
associated with improved outcomes. MASP1 (c.*822C>T) polymorphism protected against 
relapses (allele frequency relapsers 0.015; non- relapsers 0.11; P=0.02). Maintenance IS 
(odds ratio, OR=10; P=0.02), no coexisting variations (OR=13; P=0.03); low C3 at onset 
(OR=5; P=0.03) and MASP1 polymorphism (OR=8; P=0.06) independently reduced the 
risk of relapses.
Conclusions: Prompt PEX & IS improves long-term outcomes and prevents relapses 
in patients with anti-FH aHUS. Coexisting variations in regulatory genes might predispose 
to relapses.
Funding: Government Support - Non-U.S.
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CH50 Result Variability by Methodology in Eculizumab-Treated Patients 
with Atypical Hemolytic Uremic Syndrome
Ellen Cody,1 Ashley Frazer-Abel,2,3 Bradley P. Dixon.1,2 1Department of 
Pediatrics, University of Colorado School of Medicine, Aurora, CO; 
2Department of Medicine, University of Colorado School of Medicine, Aurora, 
CO; 3Exsera BioLab, University of Colorado School of Medicine, Aurora, CO.
Background: The advent of complement-targeted therapy for the treatment of atypical 
hemolytic uremic syndrome (aHUS) has led to an increasing use of pharmacodynamic 
monitoring in patients to ensure adequate complement blockade to suppress disease 
activity. Measurement of terminal pathway activity and functionality with plasma sC5b-9 
and CH50, respectively, have gained wide acceptance as means to assess the adequacy of 
complement blockade in such patients. However, methodologies for the CH50 assay may 
vary widely among institutions, and some methodologies may be insufficiently sensitive to 
determine such adequacy of blockade.
Methods: In patients treated with eculizumab for aHUS and other forms of thrombotic 
microangiopathy, CH50 was clinically measured at regular intervals during the induction 
phase of treatment by a laboratory-developed standard hemolytic assay. We compared 
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these results to results obtained by two additional methods, the Wieslab CP assay and an 
instrument-based liposomal assay for CH50. Adequate complement blockade was defined 
as a CH50 value less than 10% of the lower limit of normal for each assay.
Results: We identified that in a number of patients treated with eculizumab, breakthrough 
of complement blockade prior to the next scheduled dose of eculizumab was noted by an 
upward trend of CH50 results obtained by hemolytic methodology, whereas values obtained 
by both Wieslab CP and instrument-based methodologies suggested ongoing suppression 
and did not detect this breakthrough in blockade. Breakthrough of complement blockade 
in several instances influenced therapeutic decision making, in which supplemental doses 
were administered to ensure sufficiency of suppression of disease activity.
Conclusions: These findings suggest that the sensitivity of CH50 to detect small 
but clinically meaningful changes in complement suppression may differ by assay 
methodology, and that care must be taken in the interpretation of the results of these assays 
for pharmacodynamic monitoring of patients on eculizumab.
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Pediatric CKD Is Associated with Lower Cortical and Cerebellar Brain 
Volumes
Lyndsay Harshman,1 Marci Novak,2 Vincent Magnotta,3 Susan L. Furth,4 
Patrick D. Brophy,6 Peggy C. Nopoulos.5 1Pediatric Nephrology, University of 
Iowa Stead Family Children’s Hospital, Iowa City, IA; 2University of Iowa Stead 
Family Children’s Hospital, Iowa City, IA; 3University of Iowa, Iowa City, IA; 
4The Children’s Hospital of Philadelphia, Philadelphia, PA; 5University of iowa, 
Iowa City, IA; 6University of Rochester, Rochester, NY.
Background: Children with chronic kidney disease (CKD) are at risk for neurocognitive 
deficit. Neuroimaging studies provide the opportunity to accurately assess the brain and 
provide clues to the underlying mechanisms of observed neurocognitive abnormalities. 
To date, only a few published studies exist evaluating brain structure in pediatric CKD 
and often involve heterogenous samples with late CKD/end-stage populations of varying 
etiologies.
Methods: The purpose of this study is to quantitatively characterize brain structure in 
relationship to neurocognitive function in pediatric CKD patients with mild to moderate, 
non-glomerular CKD compared to age- and gender-matched, healthy controls using 
magnetic resonance imaging (MRI). Patients age 6-16 with congenital, non-glomerular 
causes of CKD (eGFR 30-90 ml/min/1.73m2) were invited to participate. Participants 
completed a neurocognitive evaluation, laboratory evaluation and MRI scan. The MRI scan 
included structural and functional sequences.
Results: Neurocognitive and structural MRI data were available for 26 participants 
(11 cases, 15 controls). Cases showed significantly lower cortical brain volume 
(p = 0.046) and notable volumetric decreases within the cerebellum (p= 0.016). There is 
specifically lower cerebellar gray matter in cases compared to controls (p =0.009). Data 
suggest potential for a direct relationship between structural abnormality of the cerebellum 
and lower eGFR (R2= 0.267, see Figure 1).
Conclusions: Our data link volumetric differences noted most prominently in the 
cerebellums of CKD participants with lower eGFR. It is possible that the decline in renal 
function associated with CKD may perpetuate these findings. Understanding the influence 
of pediatric CKD progression and severity on the developing brain may allow enhanced 
awareness of the role of disease progression on neurodevelopmental outcomes in childhood 
and inform new approaches to treatment and patient education across the CKD lifespan.
Funding: NIDDK Support
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Genomic Disorders, CKD, and Neurocognitive Status in Youth
Hilda E. Fernandez,1 Emma Kirschner,1 Emily Groopman,1 Rachel E. Reingold,1 
Pooja Vekaria,1 Susan L. Furth,2 Ali G. Gharavi.1 1Columbia University, New 
York, NY; 2The Children’s Hospital of Philadelphia, Philadelphia, PA.
Background: A subset of youth w/ chronic kidney disease (CKD) harbor genomic 
disorders that impair both kidney and neurobehavioral function. The resultant neurocognitive 
(NC) deficits may impact patient outcomes, e.g. suboptimal medication adherence or poor 
school/work performance.
Methods: We are conducting genomic and NC testing in youth aged 8-25y w/ 
CKD (CKD Stage 2-5, on dialysis, or transplanted). Analyses integrate assessment of 
microarray and exome sequence to identify pathogenic variants associated w/ CKD and 
neurodevelopmental disorders. Enrollment goal is 200 subjects.
Results: Thus far, 30 subjects have completed NC testing (Table) and 24 underwent 
genomic analysis. On NC testing (Figure), we noted impaired NC outcomes, including 
lower IQ, weaknesses in global executive functioning, worse attention, and higher anxiety. 
In 3 of 24 cases who completed exome sequencing, we detected putatively pathogenic 
variants for monogenic forms of CKD: 2 w/ COL4A5 variants, associated w/ X-linked 
Alport syndrome; 1 w/ a ROBO2 variant, associated w/ Vesicoureteral Reflux 2. None had 
known pathogenic variants associated w/ neurodevelopmental disorders.
Conclusions: Our preliminary results support the need for genomic and NC assessment 
in youth w/ CKD to enable specific diagnosis and support early interventions. Further study 
incorporating genomic and NC performance data will help to elucidate genetic factors 
underlying CKD and NC deficits.
Funding: NIDDK Support
Participant Characteristics, N = 30
Data as N (%)
Frequency tables of neurocognitive testing outcomes.
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Renal Complications in Congenital Anomaly Syndrome Patients with 
Genetic Variants
Tomoko Uehara,1 Hisato Suzuki,1 Toshiki Takenouchi,2 Kenjiro Kosaki.2 1Keio 
University School of Medicine, Shinjuku-ku, Japan; 2Keio University, Tokyo, 
Japan.
Background: Early detection and early treatment of renal complications of patients 
with intellectual disabilities are critical for predicting their prognosis. However, phenotypes 
of kidney diseases are usually silent and, therefore, it is difficult to make early diagnosis. We 
assessed the renal complications among patients with intellectual disabilities.
Methods: 1211 patients who showed intellectual disabilities and congenital anomalies 
and their parents were recruited through the Japanese nation-wide undiagnosed disease 
program, Initiative on Rare and Undiagnosed Diseases (IRUD). Whole blood was collected 
from them after informed consent. Comprehensive genetic diagnosis was performed by 
medical exome sequencing (MES; Illumina TruSightOne, Illumina MiSeq) or whole exome 
sequencing (WES; Agilent SureSelect, Illumina HiSeq2000). Variants detected by the 
sequencer were filtered on quality, frequency, segregation pattern, previous reports, and 
genetic function and were confirmed by Sanger sequencing.
Results: Diagnoses were made in 417 patients (34.4 %) and renal complications 
were presented in 41(9.8 %) of these 417 patients. Among these 41 patients, kidney 
hypoplasia was present in seven patients, vesicoureteral reflux was present in one patients, 
hydronephrosis was present in seven patients, and multiple cystic kidney disease was 
present in one patient. Sequence analyses identified constitutional variants including 
AUTS2, CHD7, CREBBP, EFTUD2, GNB1, KAT6A, KAT6B, KMT2A, KMT2D, MAGEL2, 
PBX1, PURA, and UBE3B.
Conclusions: Renal phenotypes were not rare but critical complications of patients 
with congenital anomaly syndromes. Various types of kidney diseases were present in them 
and most of these diseases were able to be detected by urinary test or kidney echogram. 
However, it is difficult to make early diagnosis and early treatment of kidney complications 
if they were not taken into doctor’s considerations. Furthermore, there were not only 
disease with high incidence of kidney phenotypes like CHARGE syndrome, or Rubinstein-
Taybe syndrome, but also diseases with low incidence of kidney diseases, such as Kabuki 
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syndrome or Cornelia de Lange syndrome. Taken together, to perform both urinary test and 
kidney echogram at least once may be need for patients with congenital anomaly syndromes 
to be made early detection and treatment of kidney diseases.
Funding: Government Support - Non-U.S.
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Primary Cause of Kidney Disease and Mortality in Children on Dialysis
Yusuke Okuda, Melissa Soohoo, Yoshitsugu Obi, Elani Streja, Ying Tang, 
Connie Rhee, Kamyar Kalantar-Zadeh. Harold Simmons Center for Kidney 
Disease Research and Epidemiology, Division of Nephrology and Hypertension, 
University of California, Irvine, Orange, CA.
Background: Congenital anomalies of the kidney and urinary tract (CAKUT) has been 
associated with slower progression of chronic kidney disease in children. However, little is 
known about the association of CAKUT vs. other primary causes of kidney disease with 
mortality risk after dialysis initiation.
Methods: We used the United States Renal Data System to identify 25,761 incident 
dialysis patients who were ≤21 years old between 1995–2016. We examined the risk of 
the primary cause of kidney disease with mortality using adjusted Cox models. Sensitivity 
analyses included stratification on age and individual non-CAKUT causes, and propensity 
score (PS)-matched analyses. The PS was calculated based on case mix variables.
Results: The median (IQR) age was 17 (11–19) years and 4,780 (19%) had CAKUT. 
The case mix-adjusted hazard ratio (HR) for CAKUT patients was 0.72 (95%CI, 
0.64–0.81) (ref: non-CAKUT). In age stratified analysis, the case mix-adjusted HRs 
(95%CIs) for CAKUT patients were 0.66 (0.54–0.80), 0.56 (0.39–0.80), 0.66 (0.50–0.86), 
0.97 (0.80–1.18) in <6 years, 6–<13 years, 13–<18 years, and ≥18 years, respectively (ref: 
non-CAKUT) [Figure]. Among the non-CAKUT causes, mortality associated with primary 
glomerulonephritis (HR, 0.93; 95%CI, 0.80–1.10) and focal segmental glomerulosclerosis 
(HR, 0.89; 95%CI, 0.75–1.04) was comparable or slightly lower compared to CAKUT, 
whereas most other causes were associated with higher mortality risk. The lower mortality 
risk in CAKUT patients was consistent in the PS-matched cohort.
Conclusions: CAKUT was associated with lower mortality in children on dialysis, 
especially in those younger than 18 years old. Additional studies are needed to investigate 
the mortality risk for rare non-CAKUT causes.
Funding: NIDDK Support
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Estimated Glomerular Filtration Rate at Dialysis Initiation and Mortality 
in Children
Yusuke Okuda, Melissa Soohoo, Yoshitsugu Obi, Elani Streja, Ying Tang, 
Connie Rhee, Kamyar Kalantar-Zadeh. Harold Simmons Center for Kidney 
Disease Research and Epidemiology, Division of Nephrology and Hypertension, 
University of California, Irvine, Orange, CA.
Background: The timing of dialysis initiation and estimated glomerular filtration rate 
(eGFR) has been hotly debated for adult dialysis patients. However, there are scarce data on 
the association between eGFR at dialysis initiation and mortality in children.
Methods: In a cohort of incident dialysis patients from 1995-2016 identified from the 
United States Renal Data System and aged 1–17 years old, we examined the association of 
eGFR at dialysis initiation with mortality. Mortality risk was estimated using Cox model 
with three levels of adjustment, i.e., unadjusted, case mix-adjusted, and fully adjusted 
model including height, body mass index, hemoglobin, and albumin. eGFR was calculated 
using the pediatric specific bedside Schwartz equation.
Results: Among 10,251 included patients, median age was 13 (IQR: 10–16) years and 
median eGFR was 7.8 (IQR: 5.7–10.5) mL/min/1.73 m2. There appeared a trend toward 
higher mortality risk across higher eGFR. In particular, eGFR <5 mL/min/1.73 m2 was 
associated with low mortality (fully adjusted hazard ratio [HR], 0.64; 95%CI, 0.50–0.84) 
(reference: eGFR 5 to <7 mL/min/1.73 m2). This association was consistent in children ≥6 
years old, whereas HR was 1.25 (95%CI: 0.67–2.31) for eGFR<5 mL/min/1.73 m2 among 
those <6 years old (reference: eGFR 5 to <7 mL/min/1.73 m2) [Figure].
Conclusions: Low eGFR at dialysis initiation was associated with lower mortality, 
especially for eGFR levels less than 5 mL/min/1.73 m2 in incident dialysis children. The 
result does not suggest an independent indication of dialysis initiation based on eGFR. 
If the clinical status allows it, eGFR at dialysis initiation should be considered. Further 
considerations are needed in children younger than 6 years old.
Funding: NIDDK Support
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Cause of Death in Children and Young Adults Treated with Dialysis: 
1990-2015
Elaine Ku,1 Patrick Ahearn,3 Charles E. McCulloch,1 Barbara A. Grimes,3 
Mark Mitsnefes.2 1University of California San Francisco, San Francisco, CA; 
2Cincinnati Children’s Hospital, Cincinnati, OH; 3UCSF, San Francisco, CA.
Background: Survival of children on dialysis has improved over the last two decades. 
However, few studies have examined whether there have been differences in attributed 
causes of death (cardiovascular, infectious, or malignancy-related) over time in children or 
young adults treated with dialysis.
Methods: We included patients ages 0-25 years who started dialysis between 1990-
2010 followed through December 31, 2015 in the United States Renal Data System. We 
examined overall mortality and cause-specific mortality (categorized as cardiovascular 
(CV), infectious, or malignancy-related) by calendar year. We used Cox models to examine 
differences in the risk of all-cause and cause-specific mortality over time (using 1995 as a 
reference), accounting for age at dialysis initiation, sex, race, median neighborhood income, 
cause of ESRD, and insurance type. Follow-up was censored at receipt of a first kidney 
transplant.
Results: We included a total of 41,339 individuals who started dialysis between 1990-
2010, of whom 6344 died during 3.5 years of follow-up. Mean age was 16 yrs, 56% were 
male. 54% of deaths were secondary to CV causes, 14% infectious causes, and 2% were 
secondary to malignancy. In adjusted analysis, risk of overall death appeared to increase 
initially up to 2006, then decreased thereafter (Figure, p<0.001 for non-linearity). Risk of 
CV-related death also increased initially, but then declined after 2006 (p<0.001 for non-
linearity). Risk of infectious-related death steadily decreased over time by 4%/yr (p<0.001, 
Figure). In contrast, risk of malignancy-related death increased over time by 4%/yr,
although this trend did not achieve statistical significance (p=0.08).
Conclusions: Survival in a prevalent cohort of children and young adults receiving 
dialysis appears to be relatively stable over the last two decades, but differed by cause of 
death. Risk of infectious-related death has steadily improved, whereas risk of malignancy-
related death has steadily increased over time. Further studies are needed to understand the 
reasons for these findings.
Funding: Other NIH Support - NHLBI
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Impact of Fluid Overload on Growth of Low-Weight Children (<15 kg) 
Undergoing Chronic Hemodialysis
Cristina Henriques,1 Simone Vieira,1 Shirlei Komi,1 Maria fernanda C. Carvalho,1 
Paulo C. Koch nogueira.2 1Hospital Samaritano, Sao Paulo, Brazil; 2UNIFESP, 
Sao Paulo, Brazil.
Background: To assess whether fluid overload estimated by interdialytic weight gain 
(IWG) in low-weight children on hemodialysis (HD) impacts patient growth.
Methods: Prospective cohort study of 43 patients (11F and 32M) with weight <15 
kg. 91% of patients underwent daily HD. IWG was defined as the difference between pre-
HD weight and estimated dry weight of the patient, expressed as percentage of weight. 
IWG was estimated at each HD session and the median of all values during follow-up was 
then calculated for each individual. The following procedures were adopted to estimate 
possible effect of IWG on patient growth: a) Growth during the 6-month follow-up period 
was calculated, defined as the delta between the repeated measures of the Z-score of height 
for age parameter (first measure minus second measure).
Results: Median follow-up time was 151 days (IQR = 141 to 153 days). At study 
baseline, median patient age was 2.0 years (IQR = 0.8 to 2.9) and median Z-score for 
weight/age was -3.0 (IQR= -4.5 to -2.4). Median Z-score for height/age was -3.8 (IQR = -5.2 
to -2.6) at study baseline and -3.5 (IQR=-4.8 to -2.8) at end of follow-up, a difference that 
was not statistically significant for the overall sample (p=0.365). The assessment of IWG 
of all patients at 6 months revealed a median of 2.8% (IQR 0.0% – 6.2%). Patients were 
classified according to IWG into: a) High IWG, where 20 patients had IWG exceeding the 
median (>2.8%); and b) Low IWG, where 23 patients had IWG lower than the median 
(<2.8%). Comparison of height delta revealed 0.22 (-0.02 to 0.53) in the Low IWG group 
versus -0.12 (-0.31 to 0.24) in the High IWG group, a statistically significant difference 
(p=0.030) indicating impaired growth in the children with High IWG. On the repeated 
measures model using the GEE, a significant difference (p=0.026) in slope of Z-score of 
height for age curves was evident between groups with Low IWG=0.3 (SE=0.1) and High 
IWG=-0.1 (SE=0.1).
Conclusions: Besides the specific factors of CKD that lead to growth deficit, High 
IWG can negatively impact growth, representing a further factor impairing height in these 
patients. Hypervolemia promotes greater energy expenditure and contributes to systemic 
inflammation, leading directly or indirectly to greater protein-calorie depletion.
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AKI Biomarkers Associate with Risk for Diabetic Nephropathy
Robin A. Kremsdorf,2,1 Lisa S. Topor.2,1 1Pediatrics, Hasbro Children’s 
Hospsital, Providence, RI; 2Brown University, Providence, RI.
Background: Children with diabetes mellitus (DM) are at significant risk to 
develop diabetic nephropathy. While conventional therapies (glycemic control, treating 
microalbuminuria with ACE inhibition) can reduce this risk, other determinants of renal 
outcomes in children with DM are poorly understood. We measured urine biomarkers 
of acute renal tubular injury in children and young adults with DM to identify if these 
biomarkers correlate with traditional renal risk factors.
Methods: Subjects between the ages of 10-21 years were recruited from DM clinics. 
Inclusion criteria included Type 1 DM for 3 years or longer or Type 2 DM for any duration. 
Clinical data, blood samples, and urine samples were obtained. The urine biomarkers 
neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM1), and 
liver fatty-acid binding protein (L-FABP) were measured. Linear regression was used to 
analyze the relationship between each biomarker and clinical parameters (age, duration of 
diabetes, gender, hemoglobin A1c, presence of microalbuminuria > 30 mg/g).
Results: Of 155 subjects, 64 (41%) were female, 109 (70%) where white, and 129 
(83%) had Type 1 DM. Mean (standard deviation, SD) age was 15.5 (2.7) years. Mean 
(SD) hemoglobin A1c was 9.1% (1.7) in those with Type 1 DM and 7.9% (2.6) among 
those with Type 2 DM. NGAL was associated with female gender (43 ng/mL higher 
in females), higher KIM-1 associated with microalbuminuria (6047 pg/mL higher 
in the presence of microalbuminuria), and L-FABP associated with hemoglobin A1c 
(0.23 pg/mL lower for each 1% increase of HgbA1c). These associations persisted when the 
analysis was restricted to subjects with Type 1 DM.
Conclusions: Amongst children and young adults with DM, acute kidney injury 
biomarkers have baseline associations with known risk factors for diabetic nephropathy. 
It will be important to determine if these biomarkers are associated with clinically relevant 
endpoints in the future.
Funding: Private Foundation Support
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Predictors of AKI in Pediatric Rhabdomyolysis
Rebecca Levy,1 Frederick J. Kaskel,2 Michal L. Melamed,3 Kimberly J. Reidy.1 
1Children’s Hospital at Montefiore/ Albert Einstein College of Medicine, 
Bronxville, NY; 2Children’s Hospital at Montefiore, Bronx, NY; 3Albert Einstein 
College of Medicine, Bronx, NY.
Background: Rhabdomyolysis is an uncommon but serious disease in children. The 
most serious complication of rhabdomyolysis is acute kidney injury (AKI). Risk factors for 
AKI include greater hematuria, faster fluid administration, and higher initial creatine kinase 
(CK). Here, we describe the baseline characteristics of children with rhabdomyolysis and 
identify predictors of AKI in a large, urban tertiary care children’s hospital.
Methods: This study was a retrospective cohort. Participants included children (aged 
less than 18 years) evaluated in the Children’s Hospital at Montefiore (CHAM) 1/1/2006-
12/31/2015 with CK >1000. The outcome is AKI defined as increase in sCr ≥0.3mg/dL. 
Potential covariates were identified from biologically plausible variables and include age, 
sex, race, and biochemical markers at presentation. Bivariate associations were explored 
using Χ2 tests, t test or Mann-Whitney U test fas appropriate. All analysis was conducted 
using STATA v15.0. Protocols were approved by the AECOM IRB.
Results: A total of 447 participants were identified, of whom 124 had AKI. Participants 
with rhabdomyolysis and AKI were younger and more often female than those without; 
they did not differ by race. Participants with AKI had higher initial CK, were more acidotic, 
and had higher baseline phosphorus levels than participants without AKI but did not differ 
in baseline potassium or calcium (Table 1).
Conclusions: Demographic characteristics and baseline biochemistry are associated 
with increased risk of AKI in pediatric rhabdomyolysis. Strengths of this study include large 
sample size. Limitations include missing data and inability to confirm etiology; detailed 
chart review is ongoing. Next steps include regression analysis and validation of adult risk 
prediction equations.
Funding: Other NIH Support - 2 T32 DK 7110-43
Baseline Characteristics of Participants
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Novel Cardiac Biomarkers for AKI Risk Stratification After Pediatric 
Cardiac Surgery
Jason H. Greenberg,1 Michael R. Parsons,6 Michael Zappitelli,2 Yaqi Jia,3 
Heather Thiessen Philbrook,3 Prasad Devarajan,4 Allen D. Everett,7 
Chirag R. Parikh.5 TRIBE-AKI 1Yale University, New Haven, CT; 2Toronto 
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 3Yale 
University, New Haven, CT; 4Cincinnati Children’s Hospital, Cincinnati, OH; 
5Yale University and VAMC, New Haven, CT; 6Johns Hopkins, Baltimore, MD; 
7Johns Hopkins School of Medicine, Baltimore, MD.
Background: Children undergoing cardiac surgery are at high risk for postoperative 
AKI. Novel biomarkers are needed to improve risk stratification of AKI with consideration 
given to changes in physiology and biomarker distribution throughout childhood.
Methods: We enrolled children from 1 month to 18 years old, undergoing 
cardiopulmonary bypass. Plasma ST2, galectin-3, and NTproBNP, three FDA approved 
biomarkers of cardiac stretch or fibrosis, were measured preoperatively and postoperatively 
on day 1, within 6 hours of cardiac surgery.
Results: Postoperatively, AKI, defined by a doubling of baseline serum creatinine or 
dialysis, was diagnosed in 79/395 (29%) children. NTproBNP was the only biomarker in 
the preoperative period that was significantly different between patients with vs without 
AKI (median 0.7 [0.3, 2.9] vs. median 0.4 [0.2, 1.1]). First post-operative ST2, galectin-3, 
and NTproBNP were significantly higher in patients with vs. without AKI (ST2: median 
21.2 [9.7, 74.0] vs 7.7 [3.8, 24.2] (p<0.001), galectin-3: median 16.4 [10.6, 21.0] vs 13.3 
[9.4, 17.9], NTproBNP: median 1.3 [0.7, 6.5] vs. 0.6 [0.2, 2.2). A significant interaction 
between biomarker and age was present for both galectin-3 and NTproBNP (p<0.05). In 
children ≥2 years old, after multivariable adjustment, the highest tertile of preoperative 
galectin-3 and NTproBNP as well as day 1 ST2, galectin-3, and NTproBNP were associated 
with AKI (Table 1).
Conclusions: Novel cardiac biomarkers, particularly ST2 measured within 6 hours of 
cardiac surgery, can be used for risk stratification of AKI. The performance of biomarkers 
after cardiac surgery is affected by age and additional research is required to develop novel 
cardiac biomarkers for children less than 2 years old.
Funding: NIDDK Support
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Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics, and Pharmacodynamics of Etelcalcetide in Subjects 
Aged 2-<18 Years with sHPT Receiving Maintenance Dialysis
Lucy Yan,1 Ogo I. Egbuna,4 Claus Peter Schmitt,6 Christina Taylan,3 Johan Vande 
walle,5 Jude Ngang,4 Bradley A. Warady.2 1Amgen, San Mateo, CA; 2Children’s 
Mercy Kansas City, Kansas City, MO; 3University Hospital of Cologne, Cologne, 
Germany; 4Amgen Inc, Thousand Oaks, CA; 5UZGent, Gent, Belgium; 6Center 
for Pediatric and Adolescent Medicine, Heidelberg, Germany.
Background: Approximately 60% to 80% of the paediatric dialysis population receives 
treatment for secondary HPT with vitamin D. The burden of complications of secondary 
HPT in the paediatric dialysis population and limitations of current therapy underscore the 
need for better treatments for secondary HPT in these patients. Etelcalcetide is the only 
calcimimetic formulated for IV administration and is administered TIW (three times a 
week) as a bolus dose at the end of the haemodialysis treatment.
Methods: This phase 1 study was conducted to investigate the safety, tolerability, PK 
and PD characteristics of etelcalcetide after the administration of a single dose that may 
represent a safe starting dose for this titratable drug to paediatric hemodialysis patients. 
Subjects (2 to < 18 yrs old) received a single IV dose of 0.035 mg/kg etelcalcetide at the 
end of a hemodialysis session. Intensive PK and PD samples were collected on Day 1 at 10 
min and 4 hours after etelcalcetide administration and for 10 days post dose with a safety 
follow-up period of up to 30 days post dose.
Results: Six subjects (3M, 3F, 6-15 yrs old) have completed the study. In general, the 
single dose of etelcalcetide was well tolerated. Adverse events reported during this study 
were consistent with the known safety profile of etelcalcetide. All corrected calcium levels 
reported were above 2.25 mmol/L. No clinical symptoms possibly related to hypocalcemia 
were observed. PK exposure was within the predicted range at this dose level (see Figure 
below- the dipping point on Day 3 was related to hemodialysis).
Conclusions: Single dose of 0.035 mg/kg etelcalcetide is well tolerated in paediatric 
patients on hemodialysis. The preliminary PK and safety data collected so far are within the 
predicted range at this dose level.
Funding: Commercial Support - This study was funded by Amgen, Inc.
See Figure - Plasma Etelcalcetide Concentration (Log) -Time
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Burosumab Improved Rickets and Clinical Outcomes Compared to 
Conventional Therapy in Children with XLH
Anthony A. Portale,1 Erik Imel,2 Craig Munns,4 Leanne M. Ward,3 
Michael Whyte,5 Jill Simmons,6 Raja Padidela,7 Meng Mao,8 Alison Skrinar,8 
Javier San martin,8 Francis H. Glorieux.9 1University of California San 
Francisco, San Francisco, CA; 2Indiana University School of Medicine, 
Indianapolis, IN; 3Children’s Hospital of Eastern Ontario, University of Ottawa, 
Ottawa, ON, Canada; 4The Children’s Hospital at Westmead, Westmead, NSW, 
Australia; 5Washington University School of Medicine, St. Louis, MO; 
6Vanderbilt University Medical Center, Nashville, TN; 7Manchester University 
NHS Foundation Trust, Manchester, United Kingdom; 8Ultragenyx 
Pharmaceutical Inc., Novato, CA; 9Shriners Hospital for Children-Canada, 
Montreal, QC, Canada.
Background: In children with X-linked hypophosphatemia (XLH), high circulating 
levels of FGF23 cause hypophosphatemia with consequent rickets, skeletal deformities, 
and growth impairment. Burosumab is an FDA-approved fully human monoclonal antibody 
against FGF23 for patients ≥1 year of age with XLH. Conventional therapy consists of 
multiple daily doses of oral phosphate and active vitamin D (Pi/D).
Methods: In the study CL301 (NCT02915705), 61 children with XLH (1-12 years 
old) were randomized (1:1) to receive subcutaneous burosumab starting at 0.8 mg/kg every 
2 weeks (wk) or Pi/D as prescribed by the investigator. Eligibility criteria included a Total 
Rickets Severity Score (RSS) ≥2.0.
Results: Burosumab showed significantly greater improvement than Pi/D in rickets as 
assessed by radiologists blinded to treatment using the radiographic global impression of 
change (RGI-C) at Wk 40 (primary endpoint). More subjects in the burosumab group had 
substantial healing (RGI-C ≥+2.0) at Wk 40, compared with the Pi/D group (21/29, 72% 
vs 2/32, 6%; odds ratio of healing 39.1, p<0.0001). Decreases in rickets severity assessed 
by RSS and alkaline phosphatase also were greater with burosumab. Increases in serum 
phosphorus were greater with burosumab than with Pi/D. Standing height Z-score increased 
from a baseline mean (SD) of -2.32 (1.17) to -2.12 (1.22) at Wk 40 for burosumab; and 
from -2.05 (0.87) to -1.97 (0.87) for Pi/D. Percent predicted distance walked increased with 
burosumab (Baseline to Wk 40: 62% to 72%) and was unchanged with Pi/D (76% to 75%). 
Adverse events of interest were higher in the burosumab group, but were mild to moderate 
in severity overall, with no discontinuations.
Conclusions: Burosumab resulted in significantly greater improvement in rickets and 
serum phosphorus than conventional therapy in 1-12 year-old children with XLH.
Funding: Commercial Support - Ultragenyx Pharmaceutical Inc.
Summary of Efficacy in UX023-CL301
Higher RGI-C and lower RSS = improvement; p-values from ANCOVA (Rickets) & GEE 
(ALP, TmP/GFR, and Pi).
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Bone and Circulating Sclerostin and Histomorphometry in Pediatric 
Patients with CKD
Marciana Laster,1 Renata C. Pereira,2 Barbara Gales,1 Isidro B. Salusky.3 
1University of California Los Angeles, Los Angeles, CA; 2University of 
California, Los Angeles, CA; 3Mattel Children’s Hospital, Los Angeles, CA.
Background: Serum sclerostin, a bone formation inhibitor, increases in CKD but 
little is known of its role in predicting turnover and mineralization states in pediatric renal 
osteodystrophy.
Methods: Serum sclerostin was measured in a group of 58 dialysis and 35 pre-dialysis 
CKD patients at the time of iliac crest bone biopsy. Sclerostin expression in bone biopsy 
specimens was quantified using immunohistochemistry (IHC). Spearman correlations and 
multivariable linear regression analyses were performed to determine the relationship 
between serum and bone sclerostin levels and parameters of the TMV bone classification 
system. Models were controlled for gender and PTH-two well-known confounders of serum 
sclerostin.
Results: Cohort characteristics are presented in Table 1. Median serum sclerostin levels 
were higher in the dialysis vs. CKD patients; although IHC expression was no different 
(Table 2). In dialysis patients, significant correlations (p<0.05) included sclerostin with 
osteoid thickness (OTH, r=-0.27), osteoid volume (OV/BV, r=-0.26) and osteoid surface 
(OS/BS, r=-0.26). These relationships were lost after adjustment for gender and PTH. In 
CKD patients, significant correlations included serum sclerostin with bone formation rate 
(BFR/BS, r=-0.37) and eroded surface (ES/BS, r=-0.48). Both relationships persisted after 
adjustment resulting in sclerostin predicting 3% lower BFR/BS and 2% lower ES/BS for 
every unit increase in sclerostin (p=0.03 and p=0.01, respectively). Bone expression of 
sclerostin predominated in cortical areas and likely for this reason failed to correlate with 
trabecular TMV parameters.
Conclusions: The association of serum sclerostin with bone histomorphometry varies 
across the spectrum of GFR. The association of sclerostin with bone turnover in CKD 
patients is consistent with descriptions of Wnt antagonism as an early determinant of bone 
turnover in CKD. Such findings may have potential therapeutic implications in CKD-MBD.
Funding: NIDDK Support
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Real-World Utilization of Prescription Medications to Manage Pain in 
Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Myrlene Sanon,1 Efstathios N. Michalopoulos,2 Robert A. Stellhorn,1 
Dorothee Oberdhan,2 Christina Pao,1 Linda Mccormick.1 1Otsuka Pharmaceutical 
Development & Commercialization, Inc., Princeton, NJ; 2Otsuka Pharmaceutical 
Development & Commercialization, Inc., Rockville, MD.
Background: ADPKD is a rare inherited disease characterized by progressive kidney 
enlargement and leads to end stage renal disease. Symptoms of ADPKD include chronic 
and transient types of pain in more than 80% of patients which can range in severity from 
mild to disabling. Understanding utilization of pain medications is important given pain has 
been linked to lower quality of life. Study aims to characterize management of pain through 
use of prescription medications.
Methods: Patients diagnosed with ADPKD (ICD-9/10 codes 753.12, 753.13, Q61.2, 
or Q61.3) were selected from Optum Clinformatics 2007-2017 US research database which 
is comprised of 7 million commercial and Medicare Advantage beneficiaries. Patients were 
aged 18 years or older, with continuous medical and pharmacy benefits for 6 months pre-
index date (baseline period) and at least 6 months post-index date. The index date was the 
date of ADPKD diagnosis. Descriptive analyses described baseline patient characteristics, 
comorbidities, and utilization of pain medications by drug class during one-year post 
index-date. Included pain medications were selected per literature assessment of common 
pharmacologic treatments for the management of non-neuropathic and neuropathic pain 
syndromes.
Results: 8,984 ADPKD patients met study inclusion criteria. Mean age was 57 years 
(SD=17) and 50% male. Mean follow-up time was 36 months (SD=27). At baseline, the 
mean Charlson comorbidity score was 1.86 and common medical comorbidities included 
hypertension (65%), diabetes (25%), chronic pulmonary disorder (14%), depression (9%), 
and anxiety (8%). Seventy percent (N=6,285) received at least one prescription for a 
medication commonly used to treat pain during one-year post index. Opioids were used by 
50% of patients, followed by corticosteroids (31%), hypnotics including benzodiazepines 
(28%), antidepressants (20%), NSAIDS (18%), and anticonvulsants (11%).
Conclusions: Results show pharmacologic treatment of pain is common in patients 
with ADPKD with high use of opioids, corticosteroids, hypnotics, antidepressants, and 
NSAIDS. Use of NSAIDs in this population is relatively contraindicated suggesting higher 
severity of pain in this population and warrants further investigation.
Funding: Commercial Support - Otsuka Pharmaceutical Development & 
Commercialization, Inc.
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AD(H)PKD – A Prospective Cohort Study on the Use of Tolvaptan in 
ADPKD
Roman-Ulrich Mueller, Polina Todorova, Victor Suárez, Bernhard Schermer, 
Thomas Benzing, Volker R. Burst, Franziska Grundmann. Dept. 2 of Internal 
Medicine, University of Cologne, Koeln, Germany.
Background: The approval of tolvaptan as the first targeted therapy of autosomal-
dominant polycystic kidney disease is a significant progress in the treatment of this disease. 
But how is this therapy managed in the real-life setting? How is it accepted by patients 
taking into account the consecutive polyuria?
Methods: To answer these questions, we initiated the AD(H)PKD registry which 
enrolls ADPKD patients that have not reached ESRD yet and present with the question 
whether tolvaptan would be a treatment option. We collect data on a yearly basis including 
lab values, kidney volume, quality of life, adherence, genotype, extrarenal manifestations, 
comorbidity, side effects and complications.
Results: Since the start of the study at the end of 2015 until May 2018 more than 450 
patients could be enrolled. Here, we present - apart from the general characterization of the 
cohort – first data regarding the use of tolvaptan in the real-life setting. The urine volume 
increases to 5-7.5 liters in the majority of patients on tolvaptan. The largest increase occurs 
when starting the first dose step (45/15 mg), whilst the further uptitration (60/30 and 90/30 
mg) only shows a minor additional effect on urine output. The same holds true for urine 
osmolality. Adherence to the therapy is currently about 80%; most patients that discontinue 
tolvaptan do so early after initation with polyuria-related events being the most common 
reason. More than 75% of patients report little to no problems with the therapy in everyday 
life. Patients skip a dose 1-2x per month on average and do so mainly due to professional 
and leisure-time activities.
Conclusions: The AD(H)PKD study continues successful enrolment and allows for a 
first insight into patient-reported outcomes like quality of life and feasibility of the therapy. 
The adherence of about 80% confirms the data obtained in TEMPO 3:4. Furthermore, 
AD(H)PKD provides the first systematic data on urine volume and osmolality in the real-
life setting. These results will be very helpful for guiding management of ADPKD patients 
and patient counselling in the future.
Funding: Commercial Support - Otsuka Germany, Private Foundation Support, 
Government Support - Non-U.S.
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An Analysis of Novel Quantitative MRI Parameters to Evaluate Cystic 
Burden in Autosomal-Dominant Polycystic Kidney Disease
Roman-Ulrich Mueller,1 Florian Siedek,2 Daniel Pinto dos santos,2 
Stefan Haneder,2 Thomas Benzing,1 Thorsten Persigehl,2 Bettina Baessler,2 
Franziska Grundmann.1 1Dept. 2 of Internal Medicine, University of Cologne, 
Koeln, Germany; 2Institute of Diagnostic and Interventional Radiology, 
University of Cologne, Cologne, Germany.
Background: In ADPKD, parameters that correlate with severity of disease are of 
crucial importance in guiding the management. To date, these rely primarily on genetics, 
clinical evaluation and kidney volumetry (TKV). Whilst TKV has been shown to be a 
very useful tool to predict future outcome, measuring the cyst fraction would be favorable. 
However, this is currently not feasible in the everyday clinical setting. Here, we present a 
novel approach employing MRI T2 mapping.
Methods: 141 ADPKD patients from the AD(H)PKD-cohort and 10 healthy controls 
underwent MRI (1.5T system). HtTKV was calculated on coronary T2-weighted images 
using semi-automatic segmentation. Renal T2 relaxation times [ms] were generated using a 
Gradient-Spin-Echo (GraSE) T2 mapping sequence. Cyst fractions and mean T2 relaxation 
times (kidney-T2) were calculated using a plugin in Osirix. For analysis of T2-times of 
the remaining renal parenchyma (parenchyma-T2) a single ROI was chosen manually in 3 
slices of each kidney and the results were averaged. Based on the cyst fraction patients were 
separated into three groups (<35%, 36-70%,> 70%).
Results: Obtaining parenchyma-T2 required 6-10fold less time than kidney-T2 or 
htTKV by semiautomatic segmentation (0,78±0,14 vs. 4,78±1,17 min, p<0,001, 0,78 ±0,14 
vs. 7,59±1,57 min, p<.001). Importantly, parenchyma-T2 showed a similarly strong 
correlation to the cyst fraction (r=0,77, p<0,001) as kidney-T2 (r=0,77, p<0,001) and 
resulted in the clearest separation of patient groups. HtTKV showed only a moderate 
correlation to cyst fraction (r= 0,48, p<0,001) and did not allow for a clear group separation. 
Limiting the analysis to CKD stage 1 (n = 47) increased this discriminatory power whilst 
maintaining a similar correlation to the cyst fraction (parenchyma-T2: r=0,81; kidney-T2: 
r=0,79; htTKV: r = 0,48, p<0,001 for all).
ADPKD: Clinical Studies
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
859
J Am Soc Nephrol 29: 2018 Poster/Saturday
Conclusions: Renal T2-mapping allows the determination of novel imaging parameters 
which show a high correlation to the cyst fraction. Whilst currently used methods for 
measuring TKV and cyst fraction are time-consuming, parenchyma-T2 can be measured 
within one minute. The high correlation with cyst fraction makes this parameter a promising 
biomarker, the power of which regarding disease progression will now be examined.
Funding: Commercial Support - Otsuka Germany, Private Foundation Support, 
Government Support - Non-U.S.
SA-PO475 Poster Saturday
ADPKD: Clinical Studies
Acute Tolvaptan Treatment Has No Immediate Effect on Renal Plasma 
Flow or Glomerular Filtration Rate in Polycystic Kidney Disease
My E. Malmberg,1,4 Rikke L. Sønderbæk,1,4 Frank H. Mose,1 Jens jorgen Jensen,2 
June A. Ejlersen,2 Erling B. Pedersen,3 Jesper N. Bech.1 1University Clinic in 
Nephrology and Hypertension, Regional Hospital Unit West Jutland, Holstebro, 
Denmark; 2Department of Nuclear Medicine, Regional Hospital Unit West 
Jutland, Herning, Denmark; 3University Clinic in Nephrology and Hypertension, 
Hospital Jutland West, Risskov, Denmark; 4University of Aarhus, Aarhus, 
Denmark.
Background: Autosomal dominant polycystic kidney disease ADPKD is a common 
genetic disorder, characterized by formation of cysts in the kidneys, causing gradual 
renal failure. Tolvaptan is a vasopressin 2 antagonist that seems to reduce the decline in 
glomerular filtration rate (GFR) in ADPKD. The mechanisms are not fully understood and 
could, at least partly, be related to changes in renal plasma flow (RPF). The purpose of this 
randomized, cross-over, double-blind, placebo-controlled study was to investigate if acute 
tolvaptan treatment increases RPF and/or GFR in patients with ADPKD.
Methods: We studied 18 ADPKD patients (chronic kidney disease stages 1-3) on 
two separate occasions after a single dose of tolvaptan 60 mg or placebo. Two hours after 
treatment, RPF and GFR were measured by 99-mTc-DTPA renography. Blood pressure was 
measured every fifteen minutes throughout the day by Mobil-O-Graph®. Renal vascular 
resistance (RVR) was estimated by the equation mean arterial pressure/RPF.
Results: 99-mTc-DTPA renography showed a similar RPF after tolvaptan treatment 
and placebo treatment (673 ±262 ml/min vs. 650 ±209 ml/min p = 0.571). GFR estimated 
by 99-mTc-DTPA renography was also unchanged after tolvaptan (78 ±26 ml/min after 
tolvaptan vs. 79 ±21 ml/min after placebo p = 0.774). During renography, after tolvaptan 
intake, the brachial systolic blood pressures dropped significantly (135 ±13 mmHg after 
tolvaptan vs. 141 ±19 mmHg after placebo p = 0.043). We found no significant change 
in brachial diastolic, central systolic or central diastolic blood pressure. Estimated RVR 
during renography was unchanged after tolvaptan treatment (0.20 ±0.12 mmHg/ml/min 
after tolvaptan vs. 0.20 ±0.08 mmHg/ml/min after placebo p = 0.908).
Conclusions: Our results suggest that acute tolvaptan treatment has no immediate 
effect on RPF and GFR. Our results do not support the hypothesis that the effect of tolvaptan 
on ADPKD progression is mediated by changes in renal hemodynamics.
Funding: Commercial Support - Otsuka Pharmaceutical, Government Support - Non-
U.S.
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The Impact of Tolvaptan on Glomerular Filtration Rate in Patients with 
Autosomal Dominant Polycystic Kidney Disease
Gabrielle Côté, Lori Asselin-Thompstone, Paul Rene De Cotret, Fabrice Mac-
Way, Mohsen Agharazii. CHU de Quebec, Hotel-Dieu de Quebec Hospital, 
Quebec, QC, Canada.
Background: Tolvaptan, a V2 receptor antagonist that induces aquaresis, has been 
shown through placebo-controlled studies to slow the decline in kidney function of patients 
with autosomal dominant polycystic kidney disease (ADPKD). Polyuria is a significant 
side-effect that can be attenuated by reducing daily sodium intake. In a cohort of ADPKD 
on tolvaptan, we aimed to identify the determinants of polyuria, to evaluate the impact of 
dietary counselling on the natriuresis and to compare the decline of estimated glomerular 
filtration rate (eGFR) before and after tolvaptan.
Methods: Retrospective study of 29 patients with ADPKD on tolvaptan. Serum 
creatinine level and 24-hour urine collection with volume and natriuresis were obtained 
before tolvaptan initiation. Patients had individual nutrition counselling to reduce their 
sodium intake. Tolvaptan was introduced after the nutrition counselling with serum 
creatinine level and 24-hour urine collection obtained on treatment. Polyuria was arbitrary 
defined as a urine volume of >5L/d. We used linear regression model and generalized 
estimation equations to analyse the data.
Results: The average of age and eGFR were respectively 44±11 years and 
60±25 mL/min/1.73m2. The urinary volume increased from 2.5 to 5.2L/d (95%CI: 4.6 to 
5.8) on tolvaptan. Dietetic counselling resulted in a reduction of natriuresis (147 mmol/d 
(95%CI: 129 to165) to 131mmol/d (95%CI: 114 to 184)) (p=0.028). For each baseline 
increment of 10 mmol of daily sodium intake the odds ratio of polyuria was 3.4 (95%CI: 
2.7-4.5). After adjusting for tolvaptan dose, an increase in 100 mmol of sodium intake was 
associated with an additional urinary volume of 1.1 L/d (95%CI: 0.6 to 1.6). The annual 
rate of eGFR loss was -5.5 ml/min/1.73m2/year (95%CI: -8.2 to -2.7) before tolvaptan and 
-1.6 ml/min/1.73m2/year (95%CI: -3.5 to 0.2) on tolvaptan. This slower rate of decline was 
statistically significant (p=0.033).
Conclusions: Natriuresis before tolvaptan is the major determinant of the polyuria on 
tolvaptan, but natriuresis can be significantly reduced by dietetic counselling. In this small 
cohort, we observed a slower decline in renal function after tolvaptan, as compared to the 
annual rate of decline before treatment with tolvaptan.
SA-PO477 Poster Saturday
ADPKD: Clinical Studies
Association Between Initial Dose of Tolvaptan and Reduction of Total 
Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
Kenjiro Honda,1 Ryo Matsuura,4 Yu Ishimoto,2 Masaomi Nangaku.3 1The 
University of Tokyo, Tokyo, Japan; 2Tokyo University, Hongo, Japan; 3the 
University of Tokyo School of Medicine, Tokyo, Japan; 4The University of Tokyo 
Hospital, Tokyo, Japan.
Background: It is occasionally difficult to increase dosage of tolvaptan in autosomal 
dominant polycystic kidney disease (ADPKD) treatment. The reason of difficulty in increase 
of tolvaptan dosage is mainly limitation of water intake. Therefore, the effect of lower 
tolvaptan dose is one of major concerns in ADPKD treatment. Despite that TEMPO3:4 trial 
and REPRISE trial revealed efficacy of high dose tolvaptan among ADPKD patients, dose-
dependent efficacy of tolvaptan remains unclear.
Methods: We selected ADPKD patients who underwent tolvaptan treatment from 2014 
to 2017 in our department. The association between averaged dose of tolvaptan during the 
first six months after the initiation of tolvaptan treatment and change rate of total kidney 
volume after the treatment. Total kidney volume was estimated by abdominal MRI.
Results: The median age of 10 male and 14 female patients was 50 years (IQR, 
45 to 65 years). The total kidney volume, height-adjusted total kidney volume, and annual 
change rate were 1024mL (918 to 1819mL), 673mL/m (606 to 1137mL/m), +10.7% (+7.7 
to +26.6%), respectively. Serum creatinine level was 0.9mg/dL (0.74 to1.42mg/dL), and 
eGFR was 52mL/min/1.73m2 (37.7 to 71.8 mL/min/1.73m2). CKD G2, G3a, G3b and G4 
were 11 (44%), 4 (16%), 6 (24%), and 4 (16%) while Mayo classification 1A, 1B, 1C, 1D, 
and 1E were 0 (0%), 14 (58%), 3 (13%), 4 (17%), and 3 (13%). The annual rate of total 
kidney volume after tolvaptan treatment for six months was significantly lower than that 
of pretreatment level by -9.6% (-29.1 to +3.2%) (P<1x10-5). When all the patients were 
divided into two groups according to median of difference between annual total kidney 
volume change before and six months after tolvaptan treatment, averaged tolvaptan dose 
during the first six months of tolvaptan treatment was higher in a group with stronger 
inhibition of kidney enlargement than a group with weaker inhibition of kidney enlargement 
(P=0.05). Mayo classification and CKD GFR stage were similar between the stronger and 
weaker inhibition groups.
Conclusions: Early effect on inhibition of total kidney volume growth may be 
associated with initial tolvaptan dose during the first six months after the initiation of 
tolvaptan treatment.
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Clinical Features Expecting High Efficacy of Tolvaptan in ADPKD 
Patients
Yuta Kogure,1 Kaori Takayanagi,1 Mariko Sato,1 Yu Shimozato,1 Kento Hirose,1 
Kunihiko Yasuda,2 Yuya Shioda,2 Minoru Hatano,1 Tomonari Ogawa,1 
Koichi Kanozawa,1 Hajime Hasegawa.1 1Saitama Medical Center, Saitama 
Medical University, Saitama, Japan; 2Saitama Medical center, Saitama Medical 
University, Kawagoe, Japan.
Background: Clinical efficacy of tolvaptan is variable in individual ADPKD patient. 
In our facility, we manage 120 ADPKD patients at present, and adapt 49 patients to the 
tolvaptan therapy. Among the cases, 40 patients have been proceeded more than one year 
after induction to the therapy, they are enabled to be examined the efficacy of tolvaptan. 
When the effectiveness would be defined as the reduction of total kidney volume (TKV) 
or the annual expansion rate of kidney volume (kidney growth rate: KGR) being less than 
5%, tolvaptan showed approximately 70% of effectiveness in our facility. In this study, we 
retrospectively studied common clinical features in ADPKD patients who showed higher 
efficacy to tolvaptan by primarily focusing on KGR.
Methods: Forty ADPKD patients who had been treated with tolvaptan for at least one 
year were included in this study. KGR was calculated by CT-based total kidney volume 
(TKV) at one-year prior, just before, and one-year passed to the therapy. Response to 
tolvaptan was determined by ΔKGR (subtraction of pre-KGR from post-KGR), and 
negative value of ΔKGR indicates that the increase in TKV was inhibited by tolvaptan. 
Enrolled patients were stratified into 3 groups by ΔKGR value, and multiple clinical 
parameters were compared between 1st tertile group (1TG, lowest ΔKGR indicating highly 
effective) and 3rd tertile group (3TG, highest ΔKGR indicating poorly effective).
Results: ΔKGR values in 1TG and 3TG were -16.9% and 13.3%, respectively. Baseline 
values of TKV, KGR, systolic blood pressure (SBP), body mass index (BMI) and eGFR 
were significantly different between 1TG and 3TG (median TKV: 2005 mL vs 2534 mL, 
median KGR: 18.4% vs 3.0%, SBP: 123.1±16.5 mmHg vs 133.9±17.7 mmHg, BMI: 
22.5±4.0 vs 26.3±7.4, eGFR: 57.1±23.7 mL/min vs 40.5±14.1 mL/min).
Conclusions: Present study may indicate that ADPKD patients who show less TKV, 
higher KGR, lower blood pressure, not-obese and renal function is not severely damaged 
would be expected higher efficacy of tolvaptan.
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Tolvaptan (TLV) in Children and Adolescents with Autosomal Dominant 
Polycystic Kidney Disease (ADPKD): Design of a Two-Part, Randomized, 
Double-Blind, Placebo (PBO)-Controlled Trial
Franz S. Schaefer,1 Djalila Mekahli,2 Francesco Emma,3 Rodney D. Gilbert,4 
Detlef Bockenhauer,5 Melissa A. Cadnapaphornchai,6 Lily Shi,7 Ann 
Dandurand,7 Suzanne Watkin,7 Susan E. Shoaf.7 1University of Heidelberg, 
Heidelberg, Germany; 2KULeuven, Leuven, Belgium; 3Bambino Gesu Children’s 
Hospital, Rome, Italy; 4Southampton Children’s Hospital, Southampton, United 
Kingdom; 5University College London, London, United Kingdom; 6Rocky 
Mountain Pediatric Kidney Center, Rocky Mountain Hospital for Children at 
Presbyterian St. Luke’s Medical Center, Denver, CO; 7Otsuka Pharmaceutical 
Development & Commercialization, Rockville, MD.
Background: TLV slows ADPKD progression in adults; its value in affected children 
and adolescents remains unknown. The first trial to assess TLV in pediatric ADPKD is 
currently ongoing (NCT02964273). We present the unique features of the trial population 
and its design.
Methods: This multicenter trial comprises two phases: Phase A is one year, 
randomized, double-blind, and PBO-controlled, Phase B is a two year open-label extension 
for subjects who completed Phase A. As formal diagnostic criteria for pediatric ADPKD 
are not developed, an advisory panel agreed eligibility would be based on family history/
genetic criteria and would require ≥ 10 renal cysts measuring ≥ 0.5 cm on MRI to warrant 
treatment. Subjects (n=60) are allocated into 4 groups by gender and age (12–14y;15–17y). 
Subjects aged 4–11y may enroll. TLV is initiated at a weight-adjusted split dose ≤ 67% of 
the adult starting dose to allow for acclimation to excess diuresis; TLV is up-titrated after 1 
wk to approximate the weight-adjusted starting dose for adults. Down-titration is permitted 
per tolerance. Assessments include spot urine osmolality and specific gravity (co-primary 
endpoints), total kidney volume, eGFR, PD parameters (urine volume, fluid intake and fluid 
balance, serum sodium, serum creatinine, and free water clearance), PK parameters, and 
generic pediatric QoL assessments. Safety parameters include AEs, changes in creatinine, 
vital signs, and lab values. Subjects are tested for ALT/AST, alkaline phosphatase and total 
bilirubin during screening and for ALT/AST monthly during treatment. Liver function tests 
are reviewed by investigators, and by independent hepatic adjudication and independent 
data monitoring committees. Stringent monitoring and intervention rules ensure rapid 
response to any potential hepatic signals.
Results: Pending
Conclusions: Kidney enlargement is continuous in ADPKD; cysts expand years before 
a reduction in GFR is apparent. This trial assesses the tolerability of TLV and begins to 
test the hypothesis that early treatment with a disease-modifying agent might be beneficial. 
Available interim data will be presented.
Funding: Commercial Support - Otsuka Pharmaceutical Development & 
Commercialization, Rockville, MD, USA
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Canadian Real-Life Assessment of Tolvaptan in Autosomal Dominant 
Polycystic Kidney Disease (ADPKD): C-MAJOR Study and Hepatic 
Safety Monitoring Program
Philip McFarlane,1 Daniel G. Bichet,4 Luc Bergeron,2 Annick Laplante.3 1St. 
Michael’s Hospital, Toronto, ON, Canada; 2Otsuka Canada Pharmaceutical 
Inc., Saint-Laurent, QC, Canada; 3Otsuka Canada, Saint-Sauveur, QC, Canada; 
4University of Montreal, Montreal, QC, Canada.
Background: Tolvaptan is the only treatment slowing renal function decline, kidney 
enlargement and progression to end-stage renal disease in ADPKD. Health Canada mandated 
a patient registry of long-term clinical outcomes and a hepatic safety monitoring and 
distribution program (HSMDP) to mitigate the risk of liver injury. The objectives were to 
describe the baseline characteristics, quality of life (QoL), adherence, liver profile elevation 
rates and overall safety profile of patients enrolled in the real life setting of these two programs.
Methods: This is the 3rd interim analysis of C-MAJOR, the Canadian, non-
interventional registry of ADPKD patients treated with tolvaptan and the 1st analysis of the 
HSMDP documenting the appropriate laboratory monitoring of hepatic function.
Results: 1143 and 250 patients were included in the HSMDP and C-MAJOR, 
respectively. At tolvaptan initiation, hypertension (77%), hepatic cysts (63%), and renal 
pain (21%) were the most common ADPKD manifestations. Patients presented with chronic 
kidney disease (CKD) Stage 1 (16%), 2 (28%), 3a (24%), 3b (20%) and 4 (8%) and with 
family history of ADPKD (77%) and family history of early ESRD (36%). At treatment 
initiation, 87 % of patients were considered at high risk of disease progression as per the 
Mayo classification (1C, D or E). QoL was assessed in newly initiated tolvaptan patients. 
Although not significantly different, progressively severe ADPKD-Pain and Discomfort 
Scale and Impact Scale scores in all domains were observed for increasing CKD stage. 
Over a mean (SD) follow-up of 64.1 (43.0) weeks, 3.1% of the 941 patients on tolvaptan 
experienced an elevation of LFT >3 X ULN. No cases of drug-induced liver injury were 
reported. The 6, 12 and 24-month treatment persistence rates on tolvaptan were 89.2%, 
83.9% and 77.9% respectively. 47% of patients experienced an adverse event, most 
commonly nocturia (12%), polydipsia (9%), hypertension (8%), dizziness (7%), polyuria 
(6%) and fatigue (5%).
Conclusions: This interim report on real-life utilization of tolvaptan in Canada provides 
evidence of advanced disease at treatment initiation. The safety profile and persistence rate 
are similar to that reported in clinical trials. The liver safety evidence demonstrates that the 
HSMDP is effective in mitigating the risks to the patients.
Funding: Commercial Support - Otsuka Canada Pharmaceutical Inc.
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Gender-Specific Differences in Baseline Fluid and Solute Intake in the 
PREVENT-ADPKD Study
Carly Mannix,1,2 Annette Wong,1,2 Jennifer Zhang,1,2 Sunil V. Badve,4 
Neil Boudville,3 David C. Harris,1,2 Vincent W. Lee,1,2 Kamal Sud,1,5 Bradley 
J. Erickson,7 Vicente E. Torres,7 Anna M. Rangan,6 Margaret Allman-Farinelli,6 
Gopi Rangan.1,2 PREVENT-ADPKD 1Centre for Transplant and Renal
Research, The Westmead Institute for Medical Research, The University of
Sydney, Sydney, NSW, Australia; 2Department of Renal Medicine, Westmead
Hospital, Sydney, NSW, Australia; 3Sir Charles Gairdner Hospital, Nedlands,
WA, Australia; 4Department of Nephrology, St George Hospital, Kogarah, NSW, 
Australia; 5Department of Renal Medicine, Nepean Hospital, Sydney, NSW,
Australia; 6School of Life and Environmental Sciences, The University of
Sydney, Sydney, NSW, Australia; 7Translational Polycystic Kidney Disease
Center, Mayo Clinic, Rochester, MN.
Background: Adequate hydration may slow the postnatal growth of renal cysts in 
autosomal dominant polycystic kidney disease (ADPKD) by attenuating the release of 
arginine vasopressin (AVP). However, the efficacy, safety and feasibility of this approach, 
and whether baseline fluid and dietary solute intakes vary by gender are not known.
Methods: PREVENT-ADPKD is a 3-yr multi-centre randomized controlled trial 
determining the effect of Prescribed Fluid Intake (sufficient to reduce urine osmolality to 
≤270 mOsmol coupled with reduced dietary solute intake) on the progression of height-
corrected total kidney volume (Ht-TKV) compared to Usual Fluid Intake in ADPKD
patients (eGFR≥30ml/min/1.73m2; Mayo Class 1B-1E). Recruitment was completed in
May 2018.
Results: Of 1571 patients assessed for eligibility at 13 sites in Australia, 1295 were 
excluded due to ineligibility (n=1144) or declined to participate (n=151). The remaining 
276 patients consented to the study, of whom 89 failed run-in (Mayo Subclass 1A, 
n=37; atypical kidneys, n=3; cannot do MRI, n=5; eGFR<30, n=7; pregnancy, n=2; 
non-compliance, n=31; and other exclusion criteria met, n=4) and 187 were randomised 
into Usual Fluid Intake (n=93) or Prescribed Fluid Intake (n=94). The median age of the 
randomised cohort was 43 yrs (range: 19-67; 94 women; 72% caucasian). At baseline, men 
had worse clinical characteristics of ADPKD (higher blood pressure, Ht-TKV and serum 
creatinine; P<0.001) but reported less kidney pain (P=0.03). Baseline 24hr urine volume did 
not differ by gender (P=0.85), whereas men had higher 24hr urine osmolality (26.6%), 24hr 
urine sodium excretion (31.0%), serum osmolality (1.7%) and serum copeptin (biomarker 
of AVP release) (116.1%) compared to women (P<0.001). Ninety percent of the cohort 
consumed caffeinated drinks but this did not differ by gender.
Conclusions: Baseline fluid intake is not affected by gender, but dietary sodium intake 
and AVP release are higher in men compared to women with ADPKD. These data support 
the importance of targeting both fluid and dietary solute intake to synergise the possible 
benefits of the intervention in PREVENT-ADPKD.
Funding: Commercial Support - Danone Nutricia Research, Private Foundation 
Support, Government Support - Non-U.S.
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Random Daytime Spot Urine Correlates with Twenty-Four Hour Urine 
Osmolality in Patients with Autosomal Dominant Polycystic Kidney 
Disease
Carly Mannix,1,2 Annette Wong,1,2 Jennifer Zhang,1,2 Vincent W. Lee,1,2 
David C. Harris,1,2 Kamal Sud,1,3 Gopi Rangan.1,2 PREVENT-ADPKD 1Centre 
for Transplant and Renal Research, The Westmead Institute for Medical 
Research, The University of Sydney, Sydney, NSW, Australia; 2Department of 
Renal Medicine, Westmead Hospital, Western Sydney Local Health District, 
Sydney, NSW, Australia; 3Department of Renal Medicine, Nepean Hospital, 
Nepean Blue Mountains Local Health District, Sydney, NSW, Australia.
Background: Urine osmolality (UOsm) is a surrogate measure of hydration and 
dietary solute intake, regulated by levels of circulating arginine vasopressin (AVP). 
Monitoring UOsm may be useful to gauge adherence to fluid and diet prescriptions in 
autosomal dominant polycystic kidney disease (ADPKD). Traditionally, UOsm has been 
determined by 24hr urine collection but patients find this method cumbersome, and hence 
we investigated if spot urine could serve as an alternative method. The aim of this study 
was to determine the relationship between random daytime spot UOsm and 24hr UOsm in 
patients with ADPKD.
Methods: Random spot urine was collected prospectively from ADPKD patients (18-
65 years, eGFR≥30 mL/min/1.73m2) during the Screening Visit of the PREVENT-ADPKD 
study (a randomised controlled trial investigating the efficacy of prescribed fluid intake on 
kidney cyst growth). Urine specific gravity (USG) and serum copeptin (a biomarker of AVP 
release) were also analysed at the study visit, and patients then performed two 24hr urine 
collections over the subsequent 12 weeks.
Results: Seventy-nine participants were included (age:43±11 ys; 54% male). The mean 
spot UOsm was 491±196 mOsmol/L and correlated moderately with the mean 24hr UOsm 
(424±173 mOsmol/L; r=0.56; P<0.001). In contrast, the association between spot UOsm to 
urine creatinine ratio and the mean 24hr UOsm was weak (r=0.16, P=0.03). As expected, 
spot UOsm predicted the USG (P<0.001), and the latter was also positively correlated with 
the mean 24hr UOsm (r=049, P<0.001). Spot UOsm had a weak association with serum 
copeptin (median 4.2, range 0.9-28.1 pmol/L; r=0.26; P<0.001).
Conclusions: These data suggest that spot urine collected randomly during the day 
(either at a clinic visit for measurement of UOsm or by patient self-monitoring for USG) 
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may be an alternative method to estimate 24hr UOsm in patients with ADPKD. Further 
prospective studies and the outcome of the PREVENT-ADPKD trial are required to validate 
these findings.
Funding: Commercial Support - Danone Nutricia Research, Private Foundation 
Support, Government Support - Non-U.S.
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A Randomised Feasibility Trial of High vs Ad Libitum Water Intake in 
Autosomal Polycystic Kidney Disease
Ragada El- Damanawi,1,2 Michael C. Lee,3 Tess M. Harris,4 Laura B. Mader,5 
Holly Pavey,2 Ian Wilkinson,1,2 Alison Burrows,6 Przemyslaw R. Woznowski,6 
Yoav Ben-shlomo,6 Fiona E. Karet,7 Thomas F. Hiemstra.1,2 1Department of 
Medicine, Division of Experimental Medicine and Immunotherapeutics, 
Cambridge, United Kingdom; 2Cambridge Clinical Trials Unit, Cambridge, 
United Kingdom; 3Division of Anaesthesia, University of Cambridge, 
Cambridge, United Kingdom; 4Polycystic Kidney Disease Charity, London, 
United Kingdom; 5Patient Led Research Hub, Cambridge, United Kingdom; 
6University of Bristol, Bristol, United Kingdom; 7Department of Medical 
Genetics, University of Cambridge, Cambridge, United Kingdom.
Background: High water intake is a rational therapeutic approach in Autosomal 
Dominant Polycystic Kidney Disease (ADPKD) and may have similar benefits to tolvaptan, 
but the efficacy of high water intake in slowing ADPKD progression has not been assessed. 
It is not known whether a randomised trial of high water intake in ADPKD would be 
feasible.
Methods: In a single-centre, open label randomised controlled feasibility trial, we 
assigned adult ADPKD patients with an eGFR≥20ml/min/1.73m2 to either 1) individualised 
daily fluid prescription with target urine osmolality ≤270mOsm/kg (HW), or 2) drinking to 
thirst (AW), over 8 weeks. Co-primary feasibility endpoints were the recruitment rate and 
separation between treatment arms in urine osmolality.
Results: 42 participants (57% female, age 46±13 years) were randomised (1:1) 
to HW (n=21) and AW (n=21) at a recruitment rate of 1 patient every 10 days. Baseline 
characteristics did not differ between trial arms (eGFR 68.4 (35.9-107.2) vs 75.8 (35.9-
107.2) ml/min respectively). Significantly more HW patients achieved the target uOsm 
(14/21, 67%) compared to the AW group (5/21, 24%) during the 8 week treatment period 
(p<0.001), with uOsm significantly lower throughout follow-up in the in the HW group 
(Figure, p=0.02). There were no significant differences in CKD-EPI eGFR between arms, 
and no acute effects on 51Cr-EDTA GFR.
Conclusions: Rapid recruitment to the trial, compliance with prescribed fluid intake, 
and separation between trial arms in uOsm suggest that a large-scale trial of high water 
intake in ADPKD is feasible.
Change in urine osmolality over time by treatment group
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Smart Water Bottle Technology and Adherence to Fluid Prescription in 
ADPKD Patients
Kendall I. Elue,1 Michael Gwede,1 Amina Madhwala,2 Diboro L. Kanabolo,1 
Rita L. McGill,1 Anna L. Zisman,1 Arlene B. Chapman.1 1University of Chicago, 
Chicago, IL; 2Touro College Of Osteopathic Medicine, Naperville, IL.
Background: The Vasopressin (V) V2 receptor antagonist, Tolvaptan, slows cyst 
growth and loss of kidney function in autosomal dominant polycystic kidney disease 
(ADPKD). Water intake inhibits V secretion and may have similar benefits. Using 
smartphone technology, the water bottle (HidrateSpark© (SB)) reminds individuals to drink 
at specific times and documents volume and time of fluid intake. We sought to determine if 
SB and dietary recommendations (DR) improved fluid prescription adherence versus DR 
alone.
Methods: SB was tested to known volumes for accuracy and 24-hour urine volume 
(24UV) (mean % error= -3.69%, p=NS), precision (relative uncertainty=0.0035), limit of 
detection (15 mL), between bottle reproducibility (p=0.94), and inter and intra-operator 
reliability (0.005% variability, p=0.97; p=0.216) were calculated. Subjects were randomized 
to receive DR or DR/SB and prescribed a 20% increase in fluid intake from their most 
recent 24UV or 3 liters/day, whichever was greater. All subjects received DR at 6 weeks and 
completed 24UV at 6 and 12 weeks. DR and DR/SB groups were analyzed for significance 
utilizing chi-square analysis methods comparing the proportion that met fluid goals and a 
t-test comparing mean fluid intake.
Results: With 36 subjects enrolled, 15 DR and 15 DR/SB completed the study. Target 
fluid intake in DR and DR/SB were 3460.88±416.3 and 3661.5±752.5 mL (p=NS). At 6
weeks, 40 and 67% of DR and DR/SB subjects met fluid goals (p=0.143). At week 12, 40 
and 80% of DR and DR/SB subjects met fluid goals (p<0.03). At 6 and 12 weeks, DR/SB 
fluid intake was greater than DR (p=0.026; p=0.006). DR/SB subjects used SB 88.25% 
and 80.5% of days between 0-6 and 6-12 wks. DR/SB patients met or exceeded their fluid 
prescription on 41% of days.
Conclusions: DR/SB subjects attained their fluid prescriptions more often than DR
subjects. Additionally, DR/SB patients displayed greater adherence and fluid intake with 
longer use of the bottle. However, day-to-day adherence was less than ideal. This indicates 
that use of a smart water bottle increases hydration, provides the potential for ongoing
feedback, and can potentially lead to sustained behavioral change in ADPKD patients.
SA-PO485 Poster Saturday
ADPKD: Clinical Studies
Effect of Somatostatin Analogues on the Vasopressin Pathway in Patients 
with ADPKD
A. L. Messchendorp,1 Bart J. Kramers,1 Katrin Stade,2 Esther Meijer,1 
Ron T. Gansevoort.1 DIPAK consortium 1UMCG, Groningen, Netherlands; 
2Brahms GmbH, Hennigsdorf, Germany.
Background: The vasopressin V2 receptor antagonist tolvaptan slows the rates of 
total kidney volume growth and GFR decline in ADPKD, but its effect is limited and 
aquaretic side effects hamper wide spread clinical use. Therefore somatostatin analogues 
are of interest, which also interfere with cyst formation. Interestingly, several studies 
have suggested that somatostatin is involved in renal water handling, indicating that there 
may be an interaction between the somatostatin and vasopressin pathways. We therefore 
investigated if the somatostatin analogue lanreotide has an effect on vasopressin levels and 
aquaresis in patients with ADPKD.
Methods: Patients were included who participated in the DIPAK-1 study, a randomized, 
open-label controlled clinical trial to test the efficacy and safety of the somatostatin analogue 
lanreotide in later stage ADPKD. Patients were invited for a baseline visit, and randomized 
to receive either lanreotide or standard care in a 1:1 ratio. Blood and 24 hour urine samples 
were collected at baseline and after 12 weeks. Free water clearance (FWC) was calculated 
as 24 hour urine volume-((Urine osmolality*24 hour urine volume)/plasma osmolality) and 
fractional free water clearance (FFWC) as (FWC/eGFR)*100%.
Results: Overall, 305 ADPKD patients were included, 53% female, 48±7 years of age, 
with an eGFR of 50±11 ml/min/1.73m2. At baseline, there were no differences in plasma 
copeptin levels (a surrogate for vasopressin), 24 hour urine volume, FWC and FFWC 
between patients randomized to lanreotide (n=153) or standard care (n=152). From baseline 
to week 12, we observed no differences in change in plasma copeptin, 24 hour volume, 
FWC and FFWC between patients receiving lanreotide or standard care (-0.93±13.5 vs. 
-0.07±5.58 pmol/L, p=0.48; -0.02±0.6 vs. 0.07±0.7 L/24hr, p=0.25; 0.09±0.6 vs. 0.2±0.8 
L/24hr, p=0.39 and 0.2±1.3 vs. 0.3±1.7 %, p=0.79 respectively).
Conclusions: The somatostatin analogue lanreotide does not affect vasopressin 
levels or aquaresis in patients with ADPKD. Our data therefore do not support an effect of 
somatostatin on the vasopressin pathway. An effect of lanreotide on vasopressin V2 receptor 
antagonist induced renoprotection and polyuria is therefore not to be expected.
Funding: Commercial Support - IPSEN pharmaceuticals, Thermo Fisher Scientific
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Two Year Open Label Extension Study of Pasireotide LAR in Polycystic 
Liver and Kidney Disease
Marie C. Hogan,1 Lisa E. Vaughan,2 Walter K. Kremers,2 Kathleen Leistikow,2 
Andrew J. Metzger,1 Marie E. Edwards,2 Vicente E. Torres,1 Tetyana V. Masyuk.1 
1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN.
Background: Mass symptoms from liver (LV) & kidney (KV) volumes negatively 
impact quality of life in ADPKD & ADPLD patients. The SST analog Pasireotide LAR 
(Pas LAR) has a broader binding profile & higher affinity to SST receptors with potential 
for greater efficacy than octreotide or lanreotide. In our one year randomized controlled trial 
Pas LAR signifiantly reduced LVs and KVs but not GFR decline.
Methods: Pas LAR was offered to all participants every 28d for an additional 2 yrs. 
Changes beyond yr 1 in all subjects on continued or beginning (placebo in year 1) PasLAR 
for another 2 yrs were assessed. Using MRI, % changes in LV in placebo group before (yr 1) 
& after (yrs 2-3) cross-over to active treatment were assessed and effects of Pas LAR for 3 
years. Annualized % changes in LV in treatment arm at yr 3 compared to the placebo arm 
during yr 1 & changes in KV from baseline at 12 & 36 mo in ADPKD cases were also 
assessed.
Results: Of 41 participants who completed LV measurements at 12 mo, 24 had LV and 
15 had KV data at end of yr 3. Among 6 given placebo at baseline, the difference in the rate 
of change in LV baseline to yr 1 (5.4%) vs in the OLEon period from yr 1 to OLEend (-2.4%) 
was significantly decreased (P=0.037). Among the 4 patients given placebo at baseline with 
KV available, the difference in the rate of change in KV baseline to yr 1 (6.0%) vs. in the 
OLEon period from yr 1 to OLEend (-1.2%) decreased (P=0.043). Similarly, differences in 
the rate of change in LV of patients on placebo baseline to yr 1 (n=6, 5.4%) vs those from 
the Pas LAR group baseline to OLEend (n=18, -0.3%) were lower (P=0.046). Differences 
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in the rate of change in KV of patients on placebo baseline to yr 1 (n=4, 6.0%) vs those 
from the treatment group baseline to OLEend (n=11, 0.2%), (P=0.068). Of 17 who 
discontinued the study during OLEon reasons included 6 hepatectomies (2 later returned to 
OLEon), 2 had liver transplants, 7 with hyperglycemia.
Conclusions: Over three years Pas LAR continued to significantly slow the progressive 
increase in LV & TKV growth rates to a lesser extent, but participants experienced a higher 
frequency of AEs (hyperglycemia and diabetes).
Funding: NIDDK Support, Commercial Support - Novartis, Private Foundation 
Support
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Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in 
Autosomal Dominant Polycystic Kidney Disease
Bairbre A. McNicholas,2 William P. Martin,3 Marie E. Edwards,1 
Patrick S. Kamath,4 Vicente E. Torres,1 Peter C. Harris,1 Marie C. Hogan.1 
1Mayo Clinic, Rochester, MN; 2Division of Intensive Care, Galway University 
Hospitals, Galway, Ireland; 3Galway University Hospital, Health Service 
Executive West, Galway, Ireland; 4Mayo Clinic, Rochester, MN.
Background: Pancreatic Cyst lesions in ADPKD are primarily cysts. They are 
recognized increasingly, with isolated reports of intraductal papillary mucinous neoplasia 
(IPMN).
Methods: Tertiary care center retrospective study to determine prevalence, number, 
size, and location of pancreatic abnormalities (pancreatic cyst lesions [PCLs], IPMN, and 
not-otherwise-specified abnormalities) with abdominal magnetic resonance imaging (MRI) 
of genotyped ADPKD patients (1998 - 2013) and compared with age- and sex-matched 
non-ADPKD controls. We evaluated presentation, investigation, and management of all 
IPMNs among individuals with ADPKD (1997- 2016), for natural history and management 
of pancreatic abnormalities.
Results: Abdominal MRIs (104 with and 167 without gadolinium) were examined for 
271 genotyped ADPKD patients. At least 1 PCL was noted in 19% of ADPKD patients 
(n=52) compared with 10.2% of controls (n=28) (P=.03). Mean (SD) age at diagnosis was 
42(12) years for ADPKD vs 50(9) years (controls) (P<.001). Thirty-seven (71%) had a 
solitary PCL; 15 (28%) had multiple. PCL prevalence did not differ by genotype. IPMNs 
were detected in 1% of ADPKD cases. Among 12 IPMN patients (7 branch duct; 5 main 
duct or mixed type) monitored for ~140 months, 2 with main duct IPMN required Whipple 
resection, and 1 patient died of complications from small-bowel obstruction after declining 
surgical intervention.
Conclusions: With MRI, PCLs were detected in 19% and IPMNs in 1% of 271 
ADPKD patients with proven mutations, without difference across genotypes. PCLs were 
asymptomatic and remained stable in size. No malignant transformation occurred among 
12 IPMN patients.
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Epidemiology of Autosomal Dominant Polycystic Kidney Disease 
(ADPKD) in Olmsted County
Tatsuya Suwabe,1 Alanna Chamberlain,1 Emilie Cornec-Le Gall,2,1 
Jill M. Killian,1 Peter C. Harris,1 Vicente E. Torres.1 1Mayo Clinic, Rochester, 
MN; 2Centre Hospitalier Universitaire de Brest, BREST, France.
Background: ADPKD is the most common inherited kidney disease. A prior study in 
Olmsted County estimated an incidence of ADPKD of 1.38 per 100,000 during 1935–1980; 
however, contemporary data on the incidence of ADPKD are scarce. We aimed to determine 
the incidence of ADPKD in Olmsted County, MN during 1980-2016.
Methods: Mayo Clinic and Olmsted Medical Center (OMC) deliver most health care 
to Olmsted County residents. We searched diagnostic codes and the Mayo Clinic and OMC 
radiology databases to identify subjects and all medical records were reviewed to validate 
ADPKD diagnoses using the following criteria. Diagnosis of definite ADPKD was based on 
radiographic findings plus family history of ADPKD or genetic testing; likely ADPKD, on 
>10 cysts in each kidney without advanced CKD or different renal cystic diseases; possible 
ADPKD, on cyst number exceeding the 97.5 percentile in kidney donors of the same sex
and age. Incidence of ADPKD during 1980-2016 and point prevalences for the year 2010
were calculated.
Results: We reviewed medical charts and abdominal images and/or radiology reports 
of 1,231 subjects with diagnostic codes of cystic disease during 1980-2016, and the medical 
charts and abdominal CT or MR scans of 2,765 subjects with multiple cysts from radiology 
databases during 1997-2016. 364 patients with incident ADPKD (85 definite, 45 likely, 234 
possible) were identified. Overall age and sex adjusted annual incidence rates of definite 
ADPKD were 1.79 (95% CI: 1.40, 2.17) and those of definite or likely ADPKD 3.06 (2.52, 
3.60) per 100,000 person-years. The peak incidence rate of definite and likely cases was 
5.27 (3.07, 8.44) in the 60-69 year age group. Incidence rates of possible ADPKD increased 
markedly after 1997 when CT and MRI became available electronically. On January 1, 
2010, the overall age and sex adjusted prevalence of definite ADPKD was 47.0 (35.4, 58.5), 
definite or likely ADPKD was 68.0 (53.9, 82.1) and definite, likely or possible ADPKD was 
123.9 (104.6, 143.2) per 100,000 population.
Conclusions: The incidence of definite or likely ADPKD was 2.22 times higher than 
in the 1935-1980 study likely due to more comprehensive ascertainment of the population. 
Genetic testing will be necessary to determine how many of the patients classified as 
possible cases have ADPKD or another genetic renal cystic disease.
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ADPKD: Clinical Studies
Prediction of Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
Outcomes at Birth
Michal Mrug,1 Tiange Shi,2 Vicente E. Torres,3 Frederic F. Rahbari-Oskoui,4 
Kyongtae T. Bae,2 Peter C. Harris,3 Lisa M. Guay-Woodford,5 William 
M. Bennett,6 Alan S. Yu,7 Arlene B. Chapman.8 1University of Alabama at
Birmingham, Birmingham, AL; 2University of Pittsburgh, Pittsburgh, PA; 3Mayo
Clinic, Rochester, MN; 4Emory University School of Medicine, Atlanta, GA; 
5Children’s National Health System, Washington, DC; 6Legacy Good Samaritan 
Medical Center, Portland, OR; 7University of Kansas Medical Center, Kansas
City, KS; 8University of Chicago, Chicago, IL.
Background: The identification of high-risk ADPKD patients at birth may help them 
to receive appropriate medical attention.
Methods: We developed logistic, tree and random forests models for reaching CKD 
stage 3b progression endpoint (GFR<45 ml/min/1.73m2) based on data collected by the 
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease study (CRISP; 
241 ADPKD adults). We validated these models using data collected by the HALT-A study 
(558 ADPKD adults). In addition to the GFR endpoint and age, analyzed variables included 
race, gender, birth weight, gene type and mutation strength-based indices (data available 
at birth).
Results: The logistic regression model yielded area under an ROC curve (AUC) 0.786 
(95% CI: 0.7231, 0.8491; p<0.001). The tree model pruned to the optimal complexity 
parameter of 0.038 had a similar prognostic ability as the logistic model (their 95% CI of 
AUC overlapped). Random forests grown by 1000 bootstrap replicate samples of a size of 
196 samples with replacement improved the prognostic ability of the factors available at 
birth and reached AUC 0.91 (95% CI:0.8689, 0.9467; p<0.001). Validation of these models 
in HALT-A cohort revealed much lower AUC for the logistic regression model (AUC 
0.537), the tree model (AUC 0.552), as well as random forests (AUC 0.612). This likely 
occurred in part due to overfitting during analyses of CRISP data.
Conclusions: The data available at birth have modest value in prediction of advanced 
CKD outcomes based on information collected in the CRISP and HALT-A studies. Our 
analyses also demonstrate an essential role of predictive model validation using independent 
cohort datasets.
Funding: NIDDK Support
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Defining the Prevalence and Clinical Characteristics of Atypical Polycystic 
Kidney Disease (PKD)
Ioan-Andrei Iliuta,1 Aung Z. Win,2 Beili Shi,1 Marina Pourafkari,2 Elsa Guiard,1 
Korosh Khalili,2 York P. Pei.1 1Nephrology, University Health Network, Toronto, 
Toronto, ON, Canada; 2Medical Imaging, University Health Network, Toronto, 
Toronto, ON, Canada.
Background: The Mayo Clinic Imaging Classification is now widely used for risk 
assessment of autosomal dominant polycystic kidney disease, but requires exclusion of 
cases with atypical kidney imaging. Here, we report the first systematic study to define the 
prevalence and clinical correlates of atypical PKD.
Methods: We reviewed all patients seen at the Toronto General Hospital PKD Clinic 
between 5/2007 to 10/2017 for their clinical, genetic, and MRI/CT results. Atypical PKD 
was classified as: (i) unilateral, (ii) segmental, (iii) asymmetric, (iv) lopsided, (v) mild 
lopsided, (vi) unilateral or bilateral atrophy, or (vii) segmental sparing.
Results: 7.6% (n=36) of 472 patients reviewed displayed imaging patterns consistent 
with atypical PKD. Compared to patients with a typical imaging pattern, they were older 
with normal renal function and displayed a high rate of no mutation detected (see Table).
Conclusions: Atypical PKD is generally associated with mild kidney disease and needs 
to be vigorously excluded from kidney volume-based risk assessment. The etiologies of 
these cases are likely heterogeneous, but many may be underpinned by somatic mosaicism 
which can be unravelled by Next Generation Sequencing.
Characteristics of cohort
*one patient had bilineal (PKD1 NT/PKD2) inheritance;
PT: protein-truncating; NT: non-truncating; NMD: no mutation detected; IQR: interquartile 
range
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PROPKD Score Predicts Kidney Decline in Australian Patients with 
Autosomal Dominant Polycystic Kidney Disease in Clinical Practice
Andrew J. Mallett,1,2 Samuel S. Chan,1,2 Chirag Patel.3 1Kidney Health Service, 
Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 2Faculty of 
Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Genetic 
Health Queensland, Royal Brisbane and Women’s Hospital, Brisbane, QLD, 
Australia.
Background: The PROPKD score was recently developed from a single-country 
cohort study to enable risk stratification of progression to end-stage kidney disease in 
patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The aim of 
this study was to validate whether the PROPKD score predicts kidney function decline in 
clinical practice amongst Australian ADPKD patients.
Methods: A cross-sectional study was conducted of 39 unrelated individuals with 
genetically confirmed ADPKD encountered by the Queensland Conjoint Renal Genetics 
Clinic Service between 1stJanuary 1994 to 31stMay, 2018. Clinical and genetic factors were 
examined using the PROPKD score, to assess its relationship with kidney function decline 
prediction over a three year period.
Results: Of the 39 individuals in this study, 15 patients were low risk, 17 were 
intermediate risk and 7 were high risk. The median age for the low risk group commencing 
renal replacement therapy (RRT) was 60 years, 54.5 years for the intermediate risk group, 
and 55.3 years for the high risk group. Of those who commenced RRT, 1 was high risk, 6 
were intermediate risk and 1 was low risk. One high risk patient underwent pre-empt live 
transplant at 48 years. The median change in estimated glomerular filtration rate (CKD-EPI) 
in the low risk group was 1.5ml/min/1.73m2/yr, 12.5 ml/min/1.73m2/yr in the intermediate 
risk group and 15 ml/min/1.73m2/yr in the high risk group (p<0.001). There were no deaths 
from this cohort.
Conclusions: The PROPKD score accurately predicts kidney function decline in 
patients with ADPKD in this Australian cohort in clinical practice. This prediction tool 
may enable future personalised clinical prognostication and therapeutic management of 
ADPKD, as well as for potential participants to be identified for clinical trials.
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Disease Symptoms and Poor Quality of Life (QoL) in Patients with 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Preserved 
Kidney Function
Aaron Yarlas,2 Dorothee Oberdhan,1 Holly Krasa,1 Stephen M. Maher,2 
Jakob B. Bjorner.2 1Otsuka, Rockville, MD; 2Optum Patient Insights, Johnston, RI.
Background: ADPKD is a hereditary progressive disease in which enlarging kidney 
cysts impair function and lead to kidney failure. In general, patients in early-stage chronic 
kidney disease [CKD] (eg, stages 1 and 2) tend to have normal QoL, but there is variability 
in disease burden with early-stage ADPKD. A subgroup of patients within an observational 
study had significant disease burden prior to renal function decline. We examine the 
characteristics of this subgroup.
Methods: Data were from a multi-center, longitudinal, observational study of 3,409 
adult ADPKD patients (NCT01430494) with 990 and 956 patients in CKD stages 1 and 
2, respectively. A subgroup of patients in stages 1 or 2 (n=42) was identified based on 
poor scores (≥3 points) on 2 of 3 ADPKD-Impact scale (ADPKD-IS) subscales (physical, 
emotional, fatigue). We examined associations of poor ADPKD-IS scores with clinical 
outcomes (eg, albuminuria, kidney stones, urinary tract infection [UTI]), biomarkers 
(eg, height-adjusted total kidney volume, estimated glomerular filtration rate, abdominal 
girth), and patient-reported outcome (PRO) measures (ADPKD-Urinary Impact Scale, SF-
12v2® Health Survey, Brief Pain Inventory). Analyses used χ2 tests, receiver operating 
characteristic (ROC) curves, and Cohen’s d effect sizes for mean differences.
Results: Patients in the poor ADPKD-IS subsample were more likely than other early-
stage CKD patients to have albuminuria, hematuria, kidney pain, kidney stones, and UTI 
(all p <.05). ROC analyses found that biomarkers did not distinguish between the poor 
ADPKD-IS subgroup and other early-stage patients: all areas under the curve (AUC) ≤.60, 
all p >.05. All PRO scores accurately differentiated the poor ADPKD-IS subgroup from the 
remaining early stage sample: AUCs from .83 to .95 (all p <.0001), with large mean sample 
differences (all d ≥ 1.6).
Conclusions: A subgroup of ADPKD patients in early-stage CKD experience poor 
symptomatology and QOL. These patients are more likely to have albuminuria, hematuria, 
kidney pain, kidney stones, or UTI.
Funding: Commercial Support - Otsuka Pharmaceutical Development & 
Commercialization, Inc.
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Patient-Reported Outcomes (PROs) as Predictors of Healthcare 
Utilization (HCU) and Work Outcomes in Patients with Autosomal 
Dominant Polycystic Kidney Disease (ADPKD)
Aaron Yarlas,2 Dorothee Oberdhan,1 Holly Krasa,1 Asia Sikora Kessler,2 
Stephen M. Maher,2 Jakob B. Bjorner.2 1Otsuka, Rockville, MD; 2Optum Patient 
Insights, Johnston, RI.
Background: ADPKD is a rare progressive hereditary disease where cysts in the 
kidneys reduce renal function, often leading to kidney failure. ADPKD is associated with 
deficits in patients’ quality of life (QoL) and functioning. We examine if PROs predict HCU 
and work outcomes in ADPKD patients.
Methods: In a global, multi-center, longitudinal, observational study of 3,409 
ADPKD patients (NCT01430494) data collection at baseline and every 6 months (up to 
30 months) included measures of ADPKD-associated symptoms and health burden 
(ADPKD-Impact Scale [ADPKD-IS], ADPKD-Urinary Impact Scale [ADPKD-UIS]), 
generic QoL (SF-12v2® Health Survey [SF-12v2]), and pain (Brief Pain Inventory-Short 
Form [BPI-SF]) as well as HCU and work outcomes. Separate logistic regression models 
examined each PRO as a predictor of dichotomous HCU (0, ≥1 hospitalization) and work 
outcomes (0, ≥1 sick days). Ordinary least squares regression examined each PRO as a 
predictor of continuous work outcomes (sick days, work effectiveness). Baseline to month 
18 data were used for this analysis.
Results: The likelihood of ≥1 hospitalization in the previous 6 months was significantly 
predicted by worse baseline scores on ADPKD-IS fatigue, emotional, and physical scales 
(Odds ratios [ORs] from 1.55 to 1.77), ADPKD-UIS frequency, nocturia, and urgency 
scales (ORs from 1.32 to 1.43), SF-12v2 physical and mental component summaries (ORs: 
0.97, 0.96), and BPI-SF pain severity and pain interference scales (ORs: 1.11, 1.16), all 
P <.05. The likelihood of ≥1 sick day in the previous 6 months was significantly predicted 
by worse scores on ADPKD-IS and ADPKD-UIS scales (ORs from 1.24 to 1.76), SF-12v2 
summaries (ORs: 0.95, 0.96), and BPI-SF scales (ORs: 1.25, 1.26), all P <.001. Worse 
scores on PROs predicted a higher number of work days missed (all P <.001), while worse 
scores on ADPKD-IS and ADPKD-UIS scales, SF-12v2 summaries, and the BPI-SF pain 
interference scale predicted lower work effectiveness (all P <.05).
Conclusions: ADPKD-associated symptoms, QoL, and pain PROs were predictive of 
ADPKD patients’ HCU and work outcomes. These findings support the inclusion of PROs 
in clinical studies and practice with ADPKD patients.
Funding: Commercial Support - Otsuka Pharmaceutical Development & 
Commercialization, Inc.
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ADPKD: Clinical Studies
Patient and Caregiver Beliefs, Attitudes, and Perspectives on Genetic 
Screening and Testing for Autosomal Polycystic Kidney Disease
Charlotte Logeman,1,2 Yeoung Jee Cho,16 Gopi Rangan,6 Talia M. Gutman,1,2 
Jonathan C. Craig,3 Albert C. Ong,7 Arlene B. Chapman,8 Curie Ahn,9 
Ron T. Gansevoort,11 Ronald D. Perrone,12 Tess M. Harris,13 Vicente E. Torres,14 
York P. Pei,15 Jessica Ryan,10 Andrea K. Viecelli,16 Claire Geneste,17 Yaerim Kim,9 
Martin Howell,18 Karine E. Manera,4 Armando Teixeira-Pinto,5 Allison Tong.4 
SONG-PKD Steering Group 1Centre for Kidney Research, Camperdown, NSW, 
Australia; 2School of Public Health, University of Sydney, Sydney, NSW, 
Australia; 3University of Sydney/Children’s Hospital, Sydney, NSW, Australia; 
4The University of Sydney, Westmead, NSW, Australia; 5University of Sydney, 
Camperdown, NSW, Australia; 6Westmead Institute for Medical Research, The 
University of Sydney, Sydney, NSW, Australia; 7University of Sheffield, Sheffield, 
United Kingdom; 8University of Chicago, Chicago, IL; 9Seoul National 
University Hospital, Seoul, Republic of Korea; 10Monash Health, Clayton, NSW, 
Australia; 11University Medical Center Groningen, Groningen, Netherlands; 
12Tufts Medical Center, Boston, MA; 13Polycystic Kidney Disease Charity, 
London, United Kingdom; 14Mayo Clinic, Rochester, MN; 15University Health 
Network and University of Toronto, Toronto, ON, Canada; 16Princess Alexandra 
Hospital, Brisbane, QLD, Australia; 17University Francois Rabelais, Tours, 
France; 18University of Sydney, School of Public Health, Sydney, NSW, Australia.
Background: Predictive genetic screening and testing is available for accurate and 
early diagnosis of hereditary autosomal polycystic kidney disease. However, the complex 
ethical and psychosocial implications can make decision-making challenging and data on 
patients’ perspectives are limited. We aimed to describe patient and caregiver perspectives 
on the value and risks of genetic screening and testing for autosomal polycystic kidney 
disease (ADPKD).
Methods: 154 participants (120 patients and 34 caregivers) from 8 centres in Australia, 
France and Korea participated in 17 focus groups. Transcripts were analysed thematically.
Results: We identified five themes: financial constraints (insecurity in the inability 
to obtain life insurance, self-doubt in limited work opportunities, financial barrier of test); 
futility in unpredictability (accepting erratic and diverse manifestation of disease, inevitable 
disease progression, daunted by perplexity of results); lacking autonomy and support 
in decisions (overwhelmed by ambiguous information, medicalising family planning, 
appeasing the family, financial barrier); seizing control of wellbeing (gaining confidence 
through disease management, reassurance in family resilience, hope for health innovations 
to benefit the next generation, minimalising regret with preparation); and anticipating 
impact on quality of life (comforted by lack of symptoms, decisional uncertainty in risk 
of inheriting PKD, judging the value of life with PKD in family planning, guilt in foetal 
testing or abortion).
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Conclusions: For patients with ADPKD, genetic screening or testing provides an 
opportunity for them to take ownership of their health through family planning and 
preventive measures. However, they are also concerned and uncertain about the accessibility 
of these services, psychological sequelae of testing, and potential financial consequences. 
Patient-centred genetic counselling and education that addresses patients’ concerns may 
support informed decision-making about genetic testing and screening in ADPKD.
SA-PO495 Poster Saturday
ADPKD: Clinical Studies
Patient-Reported Disease Burden and Urinary Impact in Autosomal 
Dominant Polycystic Kidney Disease (ADPKD)
Dorothee Oberdhan,1 Myrlene Sanon,1 Indra Agarwal,1 Frank S. Czerwiec,1 
Ronald D. Perrone.2 1Otsuka, Rockville, MD; 2Tufts Medical Center, Boston, MA.
Background: ADPKD is an inherited disease leading to kidney enlargement, 
worsening of kidney function, and quality of life impacts. ADPKD patients experience 
symptoms consistent with urine concentration deficits, such as polyuria, nocturia, urinary 
frequency and urgency. Combined with tolvaptan (TLV) therapy those symptoms may be 
accentuated.
Methods: In a randomized, placebo-controlled, double-blind clinical trial 
(NCT01451827) urinary burden, and health-related quality of life (HRQoL) were assessed 
over 8 weeks. Urinary burden was measured by number of voids and 24h urine volume. 
HRQoL measures included the ADPKD Impact Scale (ADPKD-IS), ADPKD Urinary 
Impact Scale (ADPKD-UIS), and SF-12v2 Physical and Mental Component Summary 
(PCS and MCS).
Results: A total of 177 subjects enrolled in the clinical trial. 134 subjects were 
randomized to various doses of TLV in several formulations (50-120mg/day, pooled) and 42 
subjects to placebo (PLC). Mean number of voids were similar for TLV and PLC subjects 
at baseline (daytime: 6.4 vs 6.2; nighttime: 1.5 vs 1.6) but increased in the TLV group by 
Week 8 (daytime: 10.1 vs 6.9, p=0.0002; nighttime: 2.4 vs 1.5, p≤0.00001). Mean 24h urine 
volume at baseline was similar between TLV and PLC subjects (2.3L vs 2.4L) but increased 
in the TLV group through Week 8 (6.1L vs 2.9L, p<0.0001). Compliance was 98% for TLV 
vs 97% for PLC.
Conclusions: Baseline urinary burden is low with subjects reporting only minimal 
bother/impact during daytime and slightly higher burden associated with nocturia. With 
tolvaptan treatment, the urine volume doubled and number of voids increased by over 
50% with intermediate increases in patient-reported urinary burden during daytime and 
nighttime. Overall HRQoL showed no noticeable change during the study duration even 
with increased urinary burden.
Funding: Commercial Support - Otsuka Pharmaceutical Development & 
Commercialization, Inc.
Mean HRQoL
SA-PO496 Poster Saturday
ADPKD: Clinical Studies
Patients Values and Preferences About Renal Cysts: A Survey
Reem Mustafa. University of Kansas, Kansas City, KS.
Background: Renal cysts are a common incidental finding on radiographic imaging. 
While most cysts are indolent, individuals with such cysts are frequently monitored for 
interval growth and potential malignant transformation, which is ultimately rare.
Methods: We are deploying a cross-sectional survey to patients who have billing 
code for renal cysts and those who do not in the Greater Plain Collaborative (GPC) de-
identified dataset. We developed and prepiloted a survey that assesses patients values and 
preferences about renal cysts. Here we present preliminary results from the University of 
Kansas Medical Center.
Results: To date, there have been 71 respondents. The mean age was 61 (range 30-82) 
years. 4% were Asian, 3% were black, 91% were white and 56% were female. The majority 
of respondents were college graduates (33%) or possessed post graduate degrees (37%). 
72% of people reported no family history of kidney disease, and 66% of respondents (47 
people) reported being told by a doctor that they have a kidney cyst. Of those with a renal 
cyst, 24 reported having one cyst. 39 people reported having no treatment plan for their 
cyst(s), and of those who reported having a treatment plan (n=15), all reported follow-
up visits providing a sense of security and reassurance. 12 of these 15 reported that they 
would worry more about the cyst(s) if there were no follow-up. 15 people with renal cyst(s) 
reported seeing their primary care physician for their cyst, and 30 people reported seeing 
a nephrologist for their cyst(s). Of those with a renal cyst, 34 felt their doctor considered 
their values and opinions regarding follow-up imaging for renal cyst(s). 29/71 respondents 
wanted to know more about their cyst(s), and 23/29 specified wanting to know more about 
how often it should be imaged, if there are treatments, and the risk of progression to cancer. 
20/71 people reported feeling anxious or would feel anxious about their renal cyst(s)
Conclusions: There is wide variability in patient values and preferences regarding renal 
cysts and their follow-up. While some expressed concerns about the risk of progression to 
cancer, others were not worried at all. It is unclear if this correlates to knowledge about 
prognosis of renal cysts or perceived risk. Guidance on this topic is needed and could help 
physicians and patients with shared decision making regarding renal cyst management.
Funding: Other U.S. Government Support
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Composite End Points in ADPKD Studies: A Guide for Best Practices
Reem Mustafa,1 David Baron,4 Frank S. Czerwiec,5 Alan S. Yu,2 
Ronald D. Perrone.3 for the Polycystic Kidney Disease Outcome Consortium 
(PKDOC) composite outcomes subcommittee 1University of Kansas, Kansas 
City, KS; 2University of Kansas Medical Center, Kansas City, KS; 3Tufts Medical 
Center, Boston, MA; 4PKD Foundation, Kansas City, MO; 5Otsuka Pharma. 
Devel. & Comm., Inc., Rockville, MD.
Background: There is considerable inconsistency in the outcomes reported in 
Autosomal Dominate Polycystic Kidney Disease (ADPKD) and how they are measured. In 
this article, we aim to highlight the appropriateness of different outcomes to be included as 
a component in composite outcomes
Methods: We developed guidance including a summary table for components of 
the composite end points in ADPKD. We utilized the results of a systematic review and 
discussions among the Polycystic Kidney Disease Outcome Consortium (PKDOC) 
composite endpoint subcommittee. The subcommittee consists of Scientists, clinicians, 
methodologists, manufacturers, patients, advocacy groups representatives, and critical path 
institute representatives, all with experience in ADPKD. The investigators assessed the face 
validity of the suggested guidance and used an iterative approach of feedback, revision, 
and testing.
Results: Table 1 summarizes outcomes that are reported in ADPKD studies and the 
different ways they can be measured. It also explores pros and cons for including them as 
part of a composite outcome for ADPKD studies.
Conclusions: Composite end points will continue to be used in ADPKD studies and 
may be more utilized in-light of new approved treatments. Understanding the unique 
considerations about the different components and their use in ADPKD studies is essential 
in developing high quality evidence that will appropriately assess the short and long term 
effects of different interventions.
Table 1
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Identifying Patient-Important Outcomes in Polycystic Kidney Disease: An 
International Nominal Group Technique Study
Yeoung Jee Cho,1 Talia M. Gutman,2 Gopi Rangan,3 Jonathan C. Craig,4 
Andrea K. Viecelli,5 Claire Geneste,8 Yaerim Kim,6 Curie Ahn,6 Hyunsuk Kim,9 
David W. Johnson,5 Allison Tong.7 on behalf of SONG-PKD Steering Committee 
1Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia; 2Centre 
for Kidney Research, Bondi Junction, NSW, Australia; 3Westmead Institute for 
Medical Research, The University of Sydney, Sydney, NSW, Australia; 
4University of Sydney/Children’s Hospital, Sydney, NSW, Australia; 5Princess 
Alexandra Hospital, Brisbane, QLD, Australia; 6Seoul National University 
Hospital, Seoul, Republic of Korea; 7The University of Sydney, Seven Hills, 
NSW, Australia; 8University Francois Rabelais, Tours, France; 9Chuncheon 
Sacred Heart Hospital, Chuncheon, Gangwon-Do, Republic of Korea.
Background: Patients with autosomal dominant polycystic kidney disease (ADPKD) 
are at increased risk of premature mortality, morbidities, and complications, which severely 
impair quality of life. However, patient-centered outcomes are not consistently reported 
intrials in ADPKD, which can limit shared decision-making. We aimed to identify outcomes 
important to patients and caregivers and the reasons for their priorities.
Methods: Patients with ADPKD and their caregivers were purposively selected from 
eight centers across Australia, France and Republic of Korea. Participants identified ranked 
and discussed outcomes for trials in ADPKD. We calculated an importance score (0-1) for 
each outcome and conducted thematic analyses.
Results: Across 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 
78 (mean 54.5 years) identified 55 oucomes. The 10 highest ranked outcomes were: kidney 
function (mean importance score 0.36), end stage kidney disease (0.32), survival (0.21), 
cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work 
(0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue 
(0.12). Three themes were identified: threatening sembalance of normality, inability to 
control, and making sense of the diverse risks.
Conclusions: For patients with ADPKD and their caregivers, kidney function, delayed 
progression to end stage kidney disease and survival were the highest priorities, and 
were focused on achieving normality, and maintaining control over health and lifestyle. 
Implementing these patient-important outcomes may improve the meaning and relevance 
of trials to inform clinical care in ADPKD.
Funding: Private Foundation Support
Mean importance score by patient status
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Description and Variability of Dietary Intake of Patients with Autosomal 
Dominant Polycystic Kidney Disease
Melanie Betz,1 Arlene B. Chapman.2 1University of Chicago Medicine, Chicago, 
IL; 2University of Chicago, Chicago, IL.
Background: Nutrition counseling is imperative for Autosomal Dominant Polycystic 
Kidney Disease (ADPKD) patients; proper intake of protein and sodium can delay cyst 
growth and reducing diet acid load may delay progression of disease. Little has been 
published describing the diet of ADPKD patients. Food records collected over 3 days are 
standard practice to account for daily variations in intake. However, it is unknown how 
much nutrient intakes vary and if three days of food records are necessary. The objective 
of this project was to describe the diet of ADPKD patients and to understand how much 
nutrient intake varies daily.
Methods: Three-day food records were collected in a genetic disorder nephrology 
clinic at University of Chicago Medicine. A Registered Dietitian provided food record 
instructions and analyzed the record with National Data Research System, 2017. Potential 
Renal Acid Load (PRAL) and the variability of nutrient intake between three days of food 
record for a single patient were calculated.
Results: A total of 22 patients were included in analysis with a mean age of 48.18years, 
BMI of 26.6kg/m2 and GFR of 58.29ml/min (n=15); 91% were Caucasian. See table for 
dietary analysis results and day-to-day variability.
Conclusions: ADPKD patients are consuming excess protein, sodium, saturated fat 
and cholesterol; whereas potassium, calcium and fiber intake is inadequate. These results 
showcase the importance of nutrition counseling for ADPKD patients. Nutrient intake 
varies greatly from day to day, highlighting the importance of capturing more than a single 
day when assessing diet.
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Survey of Contemporary Management of ADPKD Highlights Need for 
Improved Knowledge Translation
Tae won Yi,1 Mark Canney,1 Adeera Levin,2 Micheli U. Bevilacqua.1 
1Department of Nephrology, University of British Columbia, Vancouver, BC, 
Canada; 2St. Paul’s Hospital and University of British Columbia, Vancouver, 
BC, Canada.
Background: Recent years have witnessed a paradigm shift in the management of 
ADPKD, including novel biomarkers of disease progression such as total kidney volume 
(TKV), refined blood pressure (BP) targets, and repurposed drugs such as Tolvaptan. We 
sought to identify clinician’s familiarity with and usage of these new management tools in 
contemporary-real world practice.
Methods: An online survey of 20 questions was disseminated to 71 nephrologists across 
British Columbia. The survey consisted of multiple choice questions regarding: clinician 
demographics, sources of information regarding ADPKD care, self-identified needs for 
optimal management of ADPKD, types of renal prognostication tools used, imaging tests 
and frequency of follow up imaging, blood pressure targets, and understanding of Tolvaptan 
utility.
Results: A total of 22 nephrologists (28%) completed the questionnaire. 89% of 
respondents are assessing risk of renal progression before GFR decline in their ADPKD 
patients, with a variety of tools being used. 90% of respondents obtain additional imaging 
after diagnosis in some or all of their ADPKD patients, but only 40% report use of imaging 
to assess risk of renal progression. 1 in 5 respondents are confident in their ability to interpret 
metrics of kidney size in ADPKD. 60% of nephrologists have been approached by patients 
about Tolvaptan, but 55% of respondents were not confident or only somewhat confident in 
their ability to identify which patients would benefit from treatment with Tolvaptan. Only 
30% of respondents use the HALT-PKD BP target of <110/75 with the remainder using 
higher BP targets. The necessity for clear treatment guidelines and algorithms was identified 
by 25% of clinicians as the greatest unmet need.
Conclusions: The results of this survey indicate that there is variability in practice 
patterns, usage and familiarity with evidence-based ADPKD management tools among 
clinical nephrologists. Although only a minority of clinicians are confident in their ability to 
use these new tools and treatments appropriately, the vast majority show interest in further 
education. This emphasizes a need for ongoing efforts to translate these developments in 
ADPKD care into routine clinical practice.
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Standardized Image Acquisition and Measurement Methods Yield 
Accurate Total Kidney Volume Assessment in Polycystic Kidneys via CT 
or MRI
Micheli U. Bevilacqua,1,2 Cameron Hague,1 Alexandra Romann,2 Hana Sheitt,1 
Dragos M. Vasilescu,1 Tae won Yi,1 Adeera Levin.1,2 1University of British 
Columbia, Vancouver, BC, Canada; 2BC Provincial Renal Agency, Vancouver, 
BC, Canada.
Background: Total Kidney Volume (TKV) assessment is a robust tool for predicting 
renal prognosis in autosomal dominant polycystic kidney disease (ADPKD) but is difficult 
to obtain outside of research settings or large academic centers. Bringing TKV measurement 
into routine clinical practice requires imaging protocols that are widely available and 
interpretation methods that are feasible for clinical radiologists.
Methods: 30 participants >18 years of age with a diagnosis of ADPKD were recruited. 
Participants underwent 3 scans; an MRI, a low-dose CT (LD) scan and an ultra-low dose 
CT scan (ULD). The ULD was also reconstructed via model based iterative reconstruction 
(MBIR) yielding a 4th image set. The images from the 4 modalities were analyzed with 
three standardized TKV measurement equations and compared to the gold standard 
method of MRI manual planimetry. Images were interpreted by radiologists using detailed 
measurement instructions, but without any formal training in TKV. Accuracy, variation 
and reproducibility of the different imaging modalities and measurement techniques was 
assessed.
Results: All imaging modalities (LD, ULD and MBIR) as well as all measurement 
equations (‘Traditional ellipsoid’, ‘Mayo ellipsoid’ and the ‘mid-slice method’) had 
excellent correlation with the gold standard with r2 values for all being over 0.97. 
Variation was within ranges reported in previous analyses of TKV measurement, although 
un-reconstructed ULD and the mid-slice method showed higher variability. Intraclass 
Correlation Coefficients were >0.98 for all methods, demonstrating high reproducibility. 
The standardized measurement methods had interpretation times of 5 minutes compared to 
45 minutes for the gold standard. The ULD CT scan had a mean effective radiation dose of 
0.88 mSv, a value approaching average exposure for an abdominal x-ray series.
Conclusions: Accurate and reproducible TKV measurements can be obtained using 
time saving interpretation methods and readily available image acquisition methods 
including abbreviated CT protocols with minimal radiation exposure. These results confirm 
the accuracy of a variety of standardized TKV measurement methods which may facilitate 
the implementation of TKV assessment in routine clinical use across diverse practice 
settings.
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Using Segmental Bioelectrical Impedance Analysis to Predict Abdominal 
Cystic Organ Volumes in Autosomal Dominant Polycystic Kidney Disease
Hyunjin Ryu,1 Hyunsuk Kim,3 Hayne C. Park,4 Kook-Hwan Oh,1 Curie Ahn,1 
Yun Kyu Oh.2 1Seoul National University Hospital, JongNo-Gu, SEOUL, 
Republic of Korea; 2Department of Internal Medicine, Boramae Medical Center, 
Seoul, Republic of Korea; 3Chuncheon Sacred Heart Hospital, Chuncheon, 
Gangwon-Do, Republic of Korea; 4Kangnam Sacred Heart Hospital, Seoul, 
Republic of Korea.
Background: Increased abdominal cystic organ volume are risk factor for pressure-
related complications and malnutrition in autosomal dominant polycystic kidney disease 
(ADPKD). However measuring actual abdominal cystic organ volume can be difficult in 
routine practice. Bioelectrical impedance analysis (BIA) are non-invasive, easy-to-use tool 
which can be applied in outpatient clinic. In this study, we evaluated the association of 
segmental BIA parameters with abdominal cystic organ volume in ADPKD patients.
Methods: In this single center, cross-sectional study, segmental BIA (Inbody S10) were 
measured and height-adjusted total kidney and liver volume (htTKLV) were calculated 
using recent CT scan in all patients.
Results: A total of 288 patients were included in the study and 47.9% were female. The 
mean age was 48.3±12.2 years and the mean estimated glomerular filtration rate (eGFR) 
was 65.3±25.3 mL/min/1.73m2. The median values of htTKLV were 1,776 mL/m (IQR 
1,361–2,381 mL/m). The highest correlation between BIA parameters and nature log value 
of htTKLV (ln htTKLV) was observed for the ratio of extracellular water to total body 
water (ECW/TBW) of trunk (ECW/TBWTR) (r=0.466), followed by whole-body (ECW/
TBW
WB
) (r=0.407), lower extremity (ECW/TBWLE) (r=0.385), and phase angle of trunk 
(PhATR) (r=0.215). The phase angle of lower extremity (PhALE) correlated negatively with 
ln htTKLV (r=-0.279). To exclude the effect of renal function on BIA, the subgroup analysis 
of patients with eGFR ≥45 mL/min/1.73 m2 were conducted and correlations were similar. 
In the Receiver-operating characteristics analysis to predict the significant htTKLV (defined 
as ≥2,400 mL/m, the value known to increase 8.7 fold of malnutrition risk from previous 
study), ECW/TBWTR showed the largest area under curve (0.726) with the following order; 
ECW/TBW
WB
 (0.697), ECW/TBWLE (0.683), PhALE (0.637) and PhATR (0.601). The cut off 
value of ECW/TBWTR to predict significant htTKLV was ≥0.387 with sensitivity of 57.7% 
and specificity of 76%.
Conclusions: Among segmental BIA parameters, ECW/TBWTR showed highest 
correlation with htTKLV. Using the cut off value of ECW/TBWTR ≥0.387, significant 
htTKLV values of ≥ 2,400 mL/m can be detected with sensitivity of 57.7% and specificity 
of 76%.
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Alteration of Tubular Secretion in Polycystic Kidney Disease
Ke Wang,1 Leila R. Zelnick,2 Yan Chen,1 Andrew N. Hoofnagle,1 
Terry J. Watnick,3 Stephen L. Seliger,3 Bryan R. Kestenbaum.1 1University of 
Washington, Seattle, WA; 2Kidney Research Institute, Seattle, WA; 3University of 
Maryland School of Medicine, Baltimore, MD.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common genetic cause of kidney disease. Glomerular filtration rate (GFR) typically remains 
normal during early stages of disease; however the impact of ADPKD on other kidney 
functions is less certain. We compared proximal tubular solute clearance in 124 ADPKD 
patients from the Baltimore PKD Center to that of healthy controls and individuals with 
non-ADPKD chronic kidney disease (CKD).
Methods: We used liquid chromatography-mass spectrometry to quantify serum and 
urine concentrations of ten secretory solutes and calculated solute fractional excretions 
relative to creatinine. For 31 ADPKD patients with normal estimated GFR (eGFR), we 
compared fractional excretions with 25 healthy individuals. For 93 ADPKD patients with 
impaired eGFR, we compared fractional excretions with 91 general CKD patients from 
the Seattle Kidney Study matched by age, race, gender, and eGFR stage. We used linear 
regression to compare relative differences in fractional excretions adjusted for eGFR, age, 
gender, and body mass index. Among ADPKD patients we used linear regression to assess 
associations of fractional excretion with height adjusted kidney volume, determined by 
magnetic resonance imaging.
Results: The fractional excretions of most secretory solutes were lower in PKD patients 
compared with healthy controls and general CKD patients. Associations for six solutes were 
significant after accounting for multiple comparisons (Table). None of the secretory solutes 
were associated with kidney volume.
Conclusions: Secretory solute excretion is lower in ADPKD patients compared with 
healthy controls and general CKD patients independent of eGFR.
Funding: NIDDK Support
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*denotes statistical significance at Bonferroni p-value threshold <0.005
**Adjusted for age, gender, body mass index, eGFR
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Arterial stiffness Is Independently Associated with Total Kidney Volume 
in Children and Young Adults with ADPKD
Kristen L. Nowak, Mikaela R. Malaczewski, Berenice Y. Gitomer, Diana George, 
Michel Chonchol. University of Colorado Denver: Anschutz Medical Campus, 
Aurora, CO.
Background: Large-elastic artery stiffness is independently associated with both 
impaired kidney function and future decline in estimated glomerular filtration rate (eGFR) 
in chronic kidney disease. In patients with autosomal dominant polycystic kidney disease 
(ADPKD), an increase in total kidney volume (TKV) precedes the decline in kidney 
function and is a prognostic marker of future kidney function decline. We hypothesized that 
large-elastic artery stiffness, measured as carotid-femoral pulse-wave velocity (CFPWV), 
would be independently associated with height-adjusted TKV (htTKV) in children and 
young adults with ADPKD and preserved kidney function.
Methods: 51 non-diabetic children and young adults (6-25 years) with ADPKD and 
eGFR >90 ml/min/1.73m2 with baseline data from an ongoing clinical trial underwent 
measurement of CFPWV and htTKV (by magnetic resonance imaging). The cross-sectional 
association of CFPWV with htTKV was evaluated using multiple linear regression models.
Results: Mean±s.d. age was 19±5 years, median htTKV was 371 (274, 509) ml/mm, 
and median CFPWV was 515 (455, 569) cm/sec. htTKV was greater in participants with 
CFPWV above the median (455 [308, 969] ml/m) compared to below the median (309 
[267, 397] ml/m; p<0.0001). After adjustment for age, sex, race/ethnicity, systolic blood 
pressure, eGFR, and overweight/obesity, greater CFPWV was associated with larger htTKV 
(β-estimate: 11.27; 95% Confidence Interval: 1.0, 21.6, per 10 unit increase in CFPWV; 
p<0.05).
Conclusions: In children and young adults with ADPKD, CFPWV is independently 
associated with increased htTKV, an important predictor of progression in early-stage 
disease. Targeting arterial stiffness may be a novel strategy to slow kidney growth in 
children and young adults with ADPKD.
Funding: NIDDK Support
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Overweight and Obesity Are Independently Associated with Total Kidney 
Volume in Children and Young Adults with ADPKD
Kristen L. Nowak, Mikaela R. Malaczewski, Berenice Y. Gitomer, Diana George, 
Michel Chonchol. University of Colorado Anschutz Medical Campus, Aurora, CO.
Background: Similar to the general population, body-mass index (BMI) in individuals 
with autosomal dominant polycystic kidney disease (ADPKD) has been increasing 
over recent decades. We recently reported that overweight and obesity are predictors of 
progression in adults with early-stage ADPKD who participated in the HALT-PKD study. 
We hypothesized that overweight and obesity would be also be independently associated 
with height-adjusted total kidney volume (htTKV) even earlier in the course of the disease 
(children and young adults).
Methods: 51 non-diabetic children and young adults (6-25 years) with ADPKD and 
estimated glomerular filtration rate (eGFR) >90 ml/min/1.73m2 with baseline data from an 
ongoing clinical trial were classified as normal weight (<85th BMI percentile for age, sex, 
and height in children; BMI of 18.5-24.9 kg/m2 in adults; ref; n=37), or overweight/obese 
(≥85th BMI percentile in children; BMI ≥25.0 in adults; n=14), using body weights adjusted 
to remove the contribution of kidneys. The cross-sectional association of overweight/
obesity with htTKV by magnetic resonance imaging was evaluated using multiple logistic 
regression models.
Results: Mean±s.d. age was 19±5 years and median htTKV was 371 (274, 509) ml/m. 
htTKV was greater in the overweight/obese group (532 [421, 969] ml/m) compared to the 
normal weight group (316 [258, 428] ml/m; p=0.01). After adjustment for age, sex, race/
ethnicity, systolic blood pressure, eGFR, and glucose, overweight/obesity was associated 
with increased odds of htTKV above the median compared to normal weight (Odds Ratio: 
25.6; 95% Confidence Interval: 2.1, 333.3).
Conclusions: In children and young adults with ADPKD, overweight and obesity are 
independently associated with increased height-adjusted total kidney volume, an important 
predictor of progression in early-stage disease. Maintaining ideal body weight may be an 
important strategy to slow kidney growth in children and young adults with ADPKD.
Funding: NIDDK Support
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Nephrolithiasis as a Risk Factor for Kidney Disease Progression in 
ADPKD
Berenice Y. Gitomer,1 Zhiying You,2 Wei Wang,3 Godela M. Brosnahan,4 
Kristen L. Nowak,5 Katharina Hopp,13 Peter C. Harris,6 Vicente E. Torres,6 
Arlene B. Chapman,7 Ronald D. Perrone,8 Theodore I. Steinman,9 Alan S. Yu,10 
Kyongtae T. Bae,11 Kaleab Abebe,11 Michel Chonchol.12 1Div. Renal Diseases 
and Hypertension, Aurora, CO; 2UC Denver, Aurora, CO; 3University of 
Colorado Anschutz Medical Campus, Aurora, CO; 4University of Colorado 
Denver, Aurora, CO; 5University of Colorado Denver: Anschutz Medical 
Campus, Aurora, CO; 6Mayo Clinic, Rochester, MN; 7University of Chicago, 
Chicago, IL; 8Tufts Medical Center, Boston, MA; 9Beth Israel Deaconess 
Medical Center, Boston, MA; 10University of Kansas Medical Center, Kansas 
City, KS; 11University of Pittsburgh, Pittsburgh, PA; 12University of Colorado, 
Aurora, CO; 13University of Colorado Denver, AMC, Aurora, CO.
Background: Kidney stones are a frequent complication among patients with 
autosomal dominant polycystic kidney disease (ADPKD). Previous studies have shown a 
higher risk of incident chronic kidney disease in persons with a history of kidney stones, but 
these studies did not examine patients with ADPKD. Thus, we hypothesized that a history of 
kidney stones may affect the rate of kidney function decline or increase in height corrected 
total kidney volume (HtTKV) in patients with ADPKD.
Methods: We assessed the association between a history of nephrolithiasis and annual 
rate of eGFR decline or % increase HtTKV using linear regression in 898 HALT-PKD study 
participants. To better ensure the temporal relation between nephrolithiasis and kidney 
function decline, we required that eGFR measurements were at least 180 days after the 
date of the kidney stone ascertainment. Analyses were adjusted for age, sex, body mass 
index, randomization group, baseline eGFR, systolic blood pressure, albumin excretion and 
genotype.
Results: A total of 898 subjects (mean age 43±10 years), comprising 789 non-
stone forming (NKS) subjects and 109 subjects (46 with eGFR > 60 and 63 with eGFR 
25-60 ml/min/1.73m2 at baseline) with kidney stones (KS) and complete data were included
in the analysis of eGFR decline. Baseline eGFR was 70±26 ml/min/1.73m2 in the NKS
group and 70±28 ml/min/1.73m2 in the KS group (p= 0.9). Stone forming patients had a
significantly faster yearly rate of kidney function decline of -5.3 ±8.3 ml/min/1.73m2 vs.
NKS -3.6±4.1 ml/min/1.73m2 after adjustment for all variables (p<0.001). A total of 435
subjects (mean age 37±8.3 years), comprising 389 NKS (HtTKV 710±413 ml) and 46 KS 
(HtTKV 727±449ml) were included in the analysis of kidney volume progression. There
was no significant difference in the rate of increase in HtTKV between the NKS and KS 
groups.
Conclusions: The presence of kidney stones was associated with more rapid loss of 
kidney function, thus may be a risk factor for more rapid kidney disease progression in 
ADPKD. As there were fewer subjects and imaging measures over the course of the HALT-
PKD study this may confound ability to detect an effect of kidney stones on the rate of 
increase in HtTKV.
Funding: NIDDK Support
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ADPKD: Clinical Studies
Serum Micro RNA Levels and Disease Progression in ADPKD
Berenice Y. Gitomer,1 Wei Wang,2 Aik choon Tan,2 Zhiying You,4 
Kristen L. Nowak,5 Katharina Hopp,13 Godela M. Brosnahan,6 Peter C. Harris,7 
Vicente E. Torres,7 Arlene B. Chapman,8 Ronald D. Perrone,9 Theodore 
I. Steinman,10 Alan S. Yu,11 Kyongtae T. Bae,12 Kaleab Abebe,12 Michel Chonchol.3
1Div. Renal Diseases and Hypertension, Aurora, CO; 2University of Colorado
Anschutz Medical Campus, Aurora, CO; 3University of Colorado, Aurora, CO; 
4UC Denver, Aurora, CO; 5University of Colorado Denver: Anschutz Medical
Campus, Aurora, CO; 6University of Colorado Denver, Aurora, CO; 7Mayo
Clinic, Rochester, MN; 8University of Chicago, Chicago, IL; 9Tufts Medical
Center, Boston, MA; 10Beth Israel Deaconess Medical Center, Boston, MA; 
11University of Kansas Medical Center, Kansas City, KS; 12University of
Pittsburgh, Pittsburgh, PA; 13University of Colorado Denver, AMC, Aurora, CO.
Background: The rate of kidney disease progression is highly variable among patients 
with autosomal dominant polycystic kidney disease (ADPKD). Unfortunately, there is 
currently no biomarker that accurately predicts disease progression especially in the early 
stages of disease while kidney function is normal. Changes in circulating micro RNA (miR) 
levels occur in patients with chronic kidney disease and also in patients with acute kidney 
injury. We hypothesized that a signature of miRs may distinguish ADPKD patients at 
increased risk for faster kidney disease progression.
Methods: Forty-six serum samples from HALT ADPKD study participants were 
analyzed, 23 from fast progressors (eGFR decline > 3.4 ml/min/1.73m2/year) and 23 from 
slow/normal progressors (eGFR decline ≤ 3.4 ml/min/1.73m2/year). Subjects were matched 
by sex, gene mutation, mutation type and age (± 5 years). Serum miRs were analyzed by 
RNASeq and human mature miRNA sequences were mapped to miRBase 21.
Results: The baseline characteristics and eGFR decline rate for both groups are shown 
in Table 1. The differentially expressed miRs in the fast compared to slow progressors 
included miR 1246, miR 6785-5p and miR 323a-3p which were significantly up-regulated 
in the fast progressors while miR 93, miR 451a and miR 106-5p were down regulated. 
Pathways associated with up-regulated miRs included adherens junction, renal cell 
carcinoma and AMP kinase signaling and those associated with down-regulated miRs 
included TGF-β and mTOR signaling, focal adhesion and extracellular matrix interaction.
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Conclusions: The results indicate that aberrant expression of serum miRs occurs in 
ADPKD patients with fast disease progression. These may indicate further disruption of 
key pathways in patients with faster kidney disease progression. Future validation in a large 
cohort will be necessary to fully chracterize the key signature of discriminatory miRs.
Funding: NIDDK Support, Private Foundation Support
Table 1 Characteristics of ADPKD Population for RNAseq
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Urinary Epidermal Growth Factor/Monocyte Chemotactic Peptide 1 
Ratio Predicts Outcome in Patients with Autosomal Dominant Polycystic 
Kidney Disease
Silvia Matino,1 Maria T. Rocchetti,6 Francesco Pesce,1 Giovanni Piscopo,2 
Maddalena Gigante,5 Francesco Trepiccione,3 Giovanna Capolongo,4 
Marco A. Moschetta,8 Giovambattista Capasso,7 Loreto Gesualdo.1 1University 
of Bari, Porto Cesareo, Italy; 2Ospedale della Murgia, Altamura, Italy; 
3University of Campania “Luigi Vanvitelli”, Napoli, Italy; 4Second University of 
Naples, Naples, Italy; 5University of Foggia, Foggia, Italy; 6University of 
Foggia-Faculty of Medicine-Biomedical Sciences Department, Fogga, Italy; 
7University of Campania Luigi Vanvitelli, Napoli, Italy; 8University of Bari 
Medical School, BARI, Italy.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a common 
inherited condition leading to end stage renal disease, but it is difficult to predict the rate 
of disease progression. Total kidney volume (TKV) is an independent prognostic marker 
of renal function decline and is used to define the Mayo classification. Urinary Epidermal 
Growth Factor/Monocyte Chemotactic Peptide 1 ratio (uEGF/MCP1) has been shown to be 
a prognostic biomarker in IgA nephropathy. In this study, we tested the role of uEGF/MCP1 
in predicting outcome of ADPKD patients according to the Mayo classification.
Methods: A cohort of 46 (32 F, 14 M) patients with ADPKD consecutively enrolled 
was evaluated. Urinary EGF and MCP1 levels were measured by ELISA. TKV calculation 
and Mayo classification were based on MRI measurements. The Mayo classification was 
used for the prediction of the eGFR at 10 years to calculate the ΔT0-T10. The outcome 
was defined as follows: Mayo Classes 1A-1B patients were classified as “non-progressors”, 
whereas 1C-1E patients were classified as rapid disease “progressors” (corresponding to a 
predicted eGFR decrease ≥2.5 mL/min/1.73 m2 per year).
Results: Clinical data at baseline (T0) were the following: age 44±13 years, eGFR 
71±32 ml/min/1.73 m2, TKV 1239 (731–2287) ml, uEGF/MCP1 58.5 (16.8–127.1), Mayo 
Class (no.) 1A (3), 1B (10), 1C (13), 1D (16), 1E (4), progressors/non-progressors (no.) 
33/13. uEGF/MCP1 at T0 was significantly different across Mayo Classes (p=2.14e-05) 
showing a trend towards a reduction in Class 1E and correlated with the predicted 
variation of eGFR at 10 years (ΔT0-T10, r =-0.405, p=0.004). In addition, both urinary 
EGF (r=-0.313, p=0.027) and MCP1 (r=0.404, p=0.004) correlated with the ΔT0-T10. In 
a multivariate analysis including adjustment for age and sex we found that uEGF/MCP1 
at T0 is an independent predictor of outcome (OR 0.98; 95% CI: 0.97-0.99, p=0.005) and 
this model showed an area under the ROC curve of 0.90 (95% CI: 0.81-0.98), achieving a 
specificity of 0.92 and a sensitivity of 0.82.
Conclusions: These findings show that uEGF/MCP1 can be used as a reliable and 
non-invasive biomarker for the estimation of disease progression in patients with ADPKD.
Funding: Government Support - Non-U.S.
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Identifying Urine Biomarkers of Disease Progression in Pediatric 
Autosomal Dominant Polycystic Kidney Disease Patients
Madhurima Baliga,1 Jost Klawitter,2 Uwe Christians,6 Michel Chonchol,2 
Berenice Y. Gitomer,4 Melissa A. Cadnapaphornchai,3 Jelena Klawitter.5 
1University of Colorado School of Medicine, Aurora, CO; 2University of 
Colorado, Aurora, CO; 3Rocky Mountain Pediatric Kidney Center, Rocky 
Mountain Hospital for Children at Presbyterian St. Luke’s Medical Center, 
Denver, CO; 4Div. Renal Diseases and Hypertension, Aurora, CO; 5University 
of Colorado Denver, Aurora, CO; 6Department of Anesthesiology, University of 
Colorado Denver, Aurora, CO.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
commonly inherited kidney disease. Though children with ADPKD show normal renal 
function, rapid cyst development is already occurring. In this study, we aimed to identify 
urine biomarkers of disease progression in the pediatric ADPKD population.
Methods: Urine samples from 70 ADPKD patients aged 8-26 years were collected at 
baseline. Following collection at baseline, 37 patients were randomized to a pravastatin 
treatment group and 33 to a placebo group. Metabolomic analysis of urine was performed 
using targeted liquid chromatography-mass spectrometry. Within the treatment and placebo 
groups, differences between biomarkers at baseline and 36 months were evaluated. 
Metabolites with a P value < 0.05 were identified as significant. Pathway analysis was 
conducted on significant metabolites.
Results: Within the pravastatin treatment group, 27 metabolites were uniquely and 
significantly changed. Metabolites involved in glutamine metabolism (glutamic acid, α-
ketoglutarate) and pyruvate metabolism (dihydroxyacetone phosphate, acetylphosphate) 
were all decreased at 36 months. Interestingly, ascorbic acid, a metabolite with antioxidant 
properties, was increased by 59% at 36 months in the treatment group. Within the placebo 
group, 37 metabolites were uniquely and significantly changed. Metabolites of the citric 
acid cycle (oxaloacetic acid, malic acid, cis-aconitic acid, citric acid, pyruvic acid) were 
decreased, and literature confirms that citric acid cycle activity is decreased in patients with 
CKD. Trimethylamine N-oxide (TMAO) is a marker of atherosclerotic risk and it has been 
shown to be elevated in the plasma of patients with CKD, in part due to decreased renal 
clearance. Our results were consistent with this finding as we found metabolites involved 
in the TMAO pathway (betaine, choline, and TMAO) to be decreased in the placebo group 
at 36 months.
Conclusions: Progression of ADPKD was associated with a decline in the renal 
clearance of citric acid cycle and betaine metabolism intermediates, preceding any loss of 
renal function. Future work involves correlating urine metabolites to plasma metabolites 
in order to identify biomarkers that may be able to risk stratify patients over the course of 
the disease.
Funding: NIDDK Support
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Plasma Metabolomics to Identify Biomarkers and Altered Pathways in 
ADPKD
Madhurima Baliga,1 Jost Klawitter,3 Uwe Christians,6 Michel Chonchol,3 
Berenice Y. Gitomer,2 Melissa A. Cadnapaphornchai,4 Jelena Klawitter.5 
1University of Colorado School of Medicine, Aurora, CO; 2Div. Renal Diseases 
and Hypertension, Aurora, CO; 3University of Colorado, Aurora, CO; 4Rocky 
Mountain Pediatric Kidney Center, Rocky Mountain Hospital for Children at 
Presbyterian St. Luke’s Medical Center, Denver, CO; 5University of Colorado 
Denver, Aurora, CO; 6Department of Anesthesiology, University of Colorado 
Denver, Aurora, CO.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
commonly inherited kidney disease. Though children with ADPKD show normal renal 
function prior to adulthood, rapid cyst development is already occurring. In this study, 
we aimed to identify plasma biomarkers of disease progression in the pediatric ADPKD 
population.
Methods: Plasma samples from 81 ADPKD patients aged 8-22 years were collected. 
Samples from healthy children (60 subjects, aged 1-3 years) served as a control. 
Metabolomic analysis was performed using liquid chromatography-mass spectrometry and 
differences in biomarkers between healthy subjects and ADPKD patients were evaluated. 
Additionally, longitudinal analysis of the ADPKD patients was completed over 36 months. 
Metabolites with a P value < 0.05 and a fold change of 50% or greater were identified as 
significant. Pathway analysis was conducted on significant metabolites.
Results: Cardiovascular risk markers and intermediates of the methionine cycle (uric 
acid, allantoin, cysteine, S-adenosyl-homocysteine, methionine sulfoxide), intermediates of 
the Krebs cycle and glycolysis (pyruvate, α-ketoglutarate, D-glyceraldehyde-3-phosphate), 
and bile acids (deoxycholic and cholic acids) were increased in plasma in ADPKD patients. 
An increase in intermediates of tryptophan metabolism (kynurenine, 3-hydroxykunurenine, 
xanthurenic acid and anthranilic acid) was accompanied by a decrease in nicotinamide 
in patients with ADPKD. The concentration of pipecolic acid, a diagnostic marker for 
peroxisome biogenesis disorders such as the renal cystic disorder Zellweger syndrome, 
was also significantly higher in ADPKD patients. Longitudinal analysis of ADPKD patients 
showed the above metabolites remained changed at 36 months. For the tryptophan pathway, 
changes became more pronounced.
Conclusions: Kynurenine metabolism is elevated in children with ADPKD suggesting 
that its direct targeting via, for example inhibition of the pathway’s regulating enzyme 
indolamine-2,3-dioxygenase (IDO1), could prevent progression of the disease. Markers 
of cardiovascular risk were increased in pediatric ADPKD patients compared to healthy 
subjects. Qualification of these as markers for disease progression could help to risk stratify 
patients and help identify molecular targets for further therapeutic developments.
Funding: NIDDK Support
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Proteomic Differential Study Associated to Autosomal Dominant 
Polycystic Kidney Disease in Mouse Embryonic Models
Vanesa Calviño,2 Adrian Cordido,3 Marta Vizoso,2 Susana Bravo,4 Candido Diaz-
Rodriguez,5 Miguel A. Garcia-Gonzalez.1 1Health Research Institute of Santiago 
de Compostela (IDIS)., Santiago de Compostela, Spain; 2Health Research 
Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; 
3Instituto de Investigacion Sanitaria (IDIS) de Santiago de Compostela, 
Santiago de Compostela, Spain; 4Instituto de Investigación Sanitaria (IDIS) de 
Santiago de Compostela, Santiago de Compostela, Spain; 5University Clinical 
Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain.
Background: The autosomal dominant polycystic kidney disease (ADPKD) is a 
genetic disease characterized by the formation of cysts along the nephrons that can lead to 
renal failure. It is associated with other extrarenal manifestations such as the formation of 
hepatic or pancreatic cysts, aneurysms, etc. ADPKD is caused by mutations in the PKD1, 
PKD2 and GANAβ genes. Mouse models of ADPKD with homozygous variants in PKD1 
or PKD2 genes present cystogenesis from day 15.5 of gestation and die during embryonic 
development typically around day 17. The study of these models at embryonic ages could 
be useful to investigate the molecular mechanisms involved in the onset of cyst formation.
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Methods: In order to identify proteins and pathways involved in cystogenesis, we 
compared the proteome of double mutants vs. healthy mouse embryos kidney. Embryo 
kidneys were removed at day 15.5 and 16.5 from two animal models of ADPKD with 
germline mutations in the PKD1 (PKD1del2-4) and PKD2 (PKD2Δ11-13) genes as well as wild 
type animals. A combined study of two mass spectrometry technologies was carried out: 
LC-MALDI using a MALDI TOF-TOF 4800 and LC-MS / MS using a MALDI-TripleTOF 
6600. The differential proteome of double mutants and healthy mice was identified and their 
involved pathways were analyzed with Reactome.
Results: We identified 1 protein in E15.5 PKD1 double mutant model not detected 
in healthy embryo, 6 in E16.5 PKD1, 2 in E15.5 PKD2 and 19 in E16.5 PKD2. We also 
identified 37 proteins in E15.5 PKD1 models only detected in healthy individuals; 20 in 
E16.5 PKD1; 20 in E15.5 PKD2 and 5 in E16.5 PKD2. These proteins are involved in 
different pathways such as metabolism, signal transduction, transcription and immune 
system as well as development biology, vesicle-mediated transport, hemostasis or cell cycle 
among others.
Conclusions: Our results would contribute to improve the knowledge on the molecular 
mechanisms underlying the processes of cystogenesis, as well as to identify possible 
therapeutic targets.
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Proteomic Analysis for the Identification of the PKD1 Related Signaling 
Pathways and Direct Targeting of Polycystic Kidney and Liver Disease: 
Few Cysts Remain Uncontrolled
Adrian Cordido,1 Miguel A. Garcia-Gonzalez,1 Marta Vizoso,1 Vanesa Calviño,2 
Candido Diaz-Rodriguez,3 Susana Bravo.1 1Health Research Institute of 
Santiago de Compostela (IDIS)., Santiago de Compostela, Spain; 2Health 
Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 
Spain; 3University Clinical Hospital of Santiago de Compostela (CHUS), 
Santiago de Compostela, Spain.
Background: Different mechanisms have been related to the pathogenesis of renal and 
hepatic cystogenesis but the identification of the proteome signature for the identification 
of the cystogenic fingerprint and consequent treatment approaches has never been 
develop up to date.
Methods: We inactivated Pkd1 (Pkd1cond/condTamCre) gene at postnatal day 10/11 
(cystic window) and postnatal day 15/16 (non-cystic window) and recollected organs at 
day 30 for kidney (cystic kidney proteome or CKP) and liver (cystic liver proteome or 
CLP) proteome analysis by mass spectrometry MALDI-TOF. We refined the renal and 
hepatic cystogenic proteome (Reactome, KEGG, FunRich, String) by the identification of 
34 specific proteins related to the liver phenotype (26 up and 8 down) and 22 to the kidney 
phenotype (16 up and 6 down).
Results: As expected, the major pathways related to CKP and CLP are signal 
transduction, immune system, metabolism and metabolism of proteins. Interestingly, 
vesicle-mediated transport and cell cycle pathways are specifically related to CLP and, in 
contrast, extracellular matrix organization and developmental biology pathways are specific 
of CKP. Based on this and previous results, approach treatment of PKD animals allowing 
us to inhibition of liver cystogenesis and significantly reduction of kidney cystic index and 
volume, recovering physiological parameters of kidney and liver function. In addition, we 
combined our molecules with known therapies for ADPKD (Tolvaptan) showing recovery 
of kidney and liver physiological parameters, although THP-positive nephron segment and 
a low portion of DBA positive remain cystic. This indicates the need of continuing puzzling 
out the remaining cysts for further treatments.
Conclusions: We described a list of new signaling pathways and possible targets 
for the development of specific therapeutic approaches for renal and hepatic phenotypes 
related to ADPKD. This data opens a new understanding of the molecular basis of the 
disease based on an organ specific protein profile of cystogenesis.
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Exploring KIM-1 as a Marker for Kidney Disease in ADPKD: Analysis 
from the HALT-PKD Studies
Lama A. Noureddine,1 Berenice Y. Gitomer,2 Zhiying You,3 Wei Wang,4 
Michel Chonchol,5 Diana I. Jalal.6 HALT Investigators 1Universty of Iowa 
Carver College of Medicine, Iowa City, IA; 2Div. Renal Diseases and 
Hypertension, Aurora, CO; 3UC Denver, Aurora, CO; 4University of Colorado 
Anschutz Medical Campus, Aurora, CO; 5University of Colorado, Aurora, CO; 
6University of Iowa, Iowa City, IA.
Background: Cyst compression of renal tubules and intrarenal microvasculature play 
a vital role in progression of autosomal dominant polycystic kidney disease (ADPKD) and 
may induce kidney injury molecule-1 (KIM-1). We hypothesized that urinary KIM-1 is a 
marker of disease progression in ADPKD.
Methods: We measured baseline and 48-month urinary KIM-1/urinary creatinine 
(UKIM-1/Cr) of participants in the HALT-PKD studies. We evaluated whether UKIM-1/Cr 
predicted decline in eGFR in studies A and B (n=738) or increase in height-adjusted TKV 
(TKV) in study A (n=283) and whether intensive, compared to standard, blood pressure 
(BP) control lowered UKIM-1/Cr over 48 months in study A (n=101).
Results: Higher baseline UKIM-1/Cr was associated with decline in eGFR in 
unadjusted analysis (β-estimate for eGFR slope=-0.04, 95% C.I. -0.06- -0.01, P=0.0006). 
After adjusting for demographics, PKD1 genotype, SBP, DBP, BMI, baseline eGFR, 
urinary albumin/Cr ratio (UACR), and TKV, baseline UKIM-1/Cr was associated with 
slightly greater kidney function decline (β-estimate = -0.03, 95% C.I. -0.05- -0.003, 
P= 0.03). In linear mixed model regression analysis, baseline UKIM-1/Cr was associated 
with increased TKV over time in the multivariate model (β-estimate= 0.10, 95% C.I. 
0.002-0.20, P=0.05). Intensive, compared to standard, BP control was not associated 
with lower UKIM-1/Cr levels. However, after adjusting for interaction with baseline 
UACR, intensive BP control was associated with lower KIM-1 in the multivariate model 
(β-estimate= -0.27, 95% C.I. -0.52- -0.011, P= 0.04). This persisted after adjustment for 
renal blood flow and inflammatory markers (Table).
Conclusions: UKIM-1/Cr was associated with slightly greater decline in kidney 
function in ADPKD and intensive BP control was associated with lower UKIM-1/Cr over 
48 months. Further studies are needed to determine what role KIM-1 plays in ADPKD 
progression.
Effect of intensive vs standard BP control on UKIM-1/Cr in study A:
*adjusted for demographics age, male gender, PKD1 genotype, SBP, DBP, BMI, baseline
eGFR, baseline UACR, baseline TKV, and baseline renal blood flow
#: Variables in * + high sensitivity CRP (hs-CRP), interleukin-6 (IL-6)
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Assessment of Endocannabinoid System as a Biomarker for Progression of 
ADPKD
Cristina Sempio,1 Jost Klawitter,1 Uwe Christians,2 Michel Chonchol,1 
Melissa A. Cadnapaphornchai,3 Berenice Y. Gitomer,4 Jelena Klawitter.5 
1Department of Anesthesiology, University of Colorado Denver, Aurora, CO; 
2Department of Anesthesiology, University of Colorado Denver, Aurora, CO; 
3Rocky Mountain Pediatric Kidney Center, Rocky Mountain Hospital for 
Children at Presbyterian St. Luke’s Medical Center, Denver, CO; 4Div. Renal 
Diseases and Hypertension, Aurora, CO; 5Department of Anesthesiology, 
University of Colorado Denver, Aurora, CO.
Background: Endocannabinoids (eCBs) are endogenous lipid ligands of the 
cannabinoid-1 receptor (CB1). In the renal vasculature, CB1 is involved in the regulation 
of renal blood flow and hemodynamics via NO release. Expression of CB1 and main eCBs 
are significantly increased in the fibrotic kidney where they modulate inflammation and 
fibrosis, another pathophysiological mechanism of autosomal dominant polycystic kidney 
disease (ADPKD).
Methods: Plasma from children and young adults with ADPKD and normal renal 
function were collected during an interventional trial at 0, 18 and 36 months. A single 
serum sample from adult ADPKD patients was collected at baseline of a cross-sectional 
trial (n=71, eGFR >60 mL/min per 1.73m2). All patients had available measures of total 
kidney volume (normalized to height (HtTKV) in pediatric patients or to body surface area 
(TKV/BSA) in adult patients) and left ventricular mass index (LVMI). Analysis of fourteen 
eCBs was performed using a liquid chromatography tandem mass spectrometry with online 
extraction. Statistical analysis was performed using SPSS v. 24.
Results: In children and young adults, plasma AEA (n=118, cross-sectional) correlated 
with HtTKV. The association was independent of the treatment group but highly dependent 
on child’s age. After control for age and sex, linoeyl ethanolamide was positively correlated 
with HtTKV and cardiovascular LVMI. In 11 placebo treated pediatric patients with 
available samples at 0 and 36 months, the change in concentration of O-arachidonoyl 
ethanolamide positively correlated with ΔHtTKV (r=0.659) adjusted for age and sex. In 
adult ADPKD patients, plasma palmitoyl- (r=0.379) and stearoyl-ethanolamide (r=0.426) 
positively correlated with TKV/BSA, after control for age and sex. AEA also increased with 
disease progression; significant negative correlation between the renal function as measured 
by eGFR and AEA (r=-0.395) was observed.
Conclusions: Our results showed that an overall increase of the circulating 
endocannabinoids is present in patients with ADPKD, with manifestations already present 
early in the disease, in children with ADPKD and normal kidney function. Thus, eCBs 
should be evaluated for their potential as biomarkers of ADPKD severity and progression 
and in mechanistic studies evaluating CB1’s role in mediating renal fibrosis.
Funding: NIDDK Support
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NADPH Oxidase (NOX4) and Mitochondrial Injury Contribute to 
Oxidative Stress and Endothelial Dysfunction in Young Normotensive 
Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Suleyman Y. Goksu, Gizem Yilmaz, Fouad T. Chebib, Alfonso Eirin, 
Amir Lerman, Lilach O. Lerman, Peter C. Harris, Vicente E. Torres, 
Maria V. Irazabal. Mayo Clinic, Rochester, MN.
Background: Endothelial dysfunction (ED) is an independent predictor of 
cardiovascular (CV) events. In ADPKD, ED and oxidative stress (OS) develop early on, 
preceding hypertension (HTN) and renal function decline. However, the mechanisms 
responsible remain unknown. We hypothesized that NOX4 and mitochondrial injury 
contribute to OS and ED preceding HTN in young normotensive ADPKD patients.
Methods: We prospectively measured plasma levels of homocysteine (Hcy), 
8-isoprostane, NOX4 and the mtDNA genes cytochrome-c oxidase-3 (COX3) and
nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit-1 (ND1), in young,
normotensive (without BP medication) ADPKD patients, and age/gender-matched healthy 
volunteers (HV) (n=10, each). Total kidney volume (TKV) and Renal Blood Flow (RBF)
were evaluated by MRI.
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Results: BP levels were higher in ADPKD, and HtTKV was twofold higher in ADPKD 
vs. controls. Yet, eGFR and RBF were similar between the groups (Table). Plasma Hcy, 
8-isoprostanes and NOX4 were higher in ADPKD (Figure), and correlated directly with
HtTKV (p<0.05, figure), but the correlation with RBF was not significant. Plasma mtDNA 
levels were lower in ADPKD vs controls, and correlated inversely with HtTKV (R2 0.397
and 0.392 respectively).
Conclusions: Early ADPKD is associated with elevated Hcy, 8-isoprostane, and NOX4, 
and decreased mtDNA levels, which precede the reduction in RBF and the development 
of HTN, and are associated with disease severity. These findings suggest that NOX4 and 
mitochondrial abnormalities contribute to oxidative stress, endothelial dysfunction, and 
possibly the development of HTN and disease progression in ADPKD
Funding: Private Foundation Support
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ELiSA, a Phase 2 Clinical Study with the Novel Vasopressin V2 Receptor 
Antagonist Lixivaptan in Patients with Autosomal Dominant Polycystic 
Kidney Disease
Lorenzo Pellegrini,1 Linda C. Hogan,1 Ruth Ann Subach.2 1Palladio Biosciences, 
Newtown, PA; 2DS InPharmatics, LLC, Harleysville, PA.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of 
the most prevalent inherited genetic diseases of the kidney in humans. Recent advances 
established vasopressin V2 receptor inhibition as a clinically validated mechanism of action 
for the treatment of ADPKD; however, safe and effective disease-modifying therapies for 
ADPKD are still lacking. Here we describe a first-in-patients clinical study with lixivaptan, 
a potent, selective vasopressin V2 antagonist, in patients with ADPKD.
Methods: ELiSA (Evaluation of Lixivaptan in Subjects with ADPKD) is a phase 2, 
open-label, multicenter clinical study of lixivaptan in patients with ADPKD to be conducted 
at up to 15 clinical sites in the United States. Eligible patients will include adults aged 18–60 
years with relatively preserved kidney function (chronic kidney disease CKD1 and CKD2; 
n = 16) or moderately impaired renal function (CKD3; n = 16). Two doses of lixivaptan, 
administered for 7 days, will be tested in eight patients within each patient group.
Results: The primary objectives of the ELiSA study are to characterize the safety, 
tolerability and pharmacokinetic profile of lixivaptan and its major metabolites following 
multiple doses in ADPKD patients with various degrees of kidney function impairment. 
The secondary objectives are to characterize the effect of lixivaptan on pharmacodynamic 
markers that have been shown to correlate with the clinical activity of vasopressin 
antagonists in the treatment of ADPKD, including urine osmolality, urine output, serum 
creatinine, plasma copeptin and total kidney volume.
Conclusions: The ELiSA clinical study is an important milestone toward the potential 
approval of lixivaptan as a safe and effective therapy for the treatment of ADPKD in a 
broad patient population. Study results will inform the design and execution of an upcoming 
pivotal registration study with lixivaptan for the treatment of ADPKD.
Funding: Commercial Support - Palladio Biosciences, Inc.
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Soluble Urokinase Plasminogen Activator Receptor Levels Predict Renal 
Function Decline in Autosomal Dominant Polycystic Kidney Disease
Salim Hayek,2 Sharin Roth,3 Christina Pao,3 Martin G. Zeier,4 David C. Wei,1 
Jochen Reiser.1 1Rush University Medical Center, Chicago, IL; 2Emory 
University School of Medicine, Atlanta, GA; 3Otsuka Pharmaceutical 
Development and Commercialization, Princeton, NJ; 4Heidelberg University, 
Heidelberg, Germany.
Background: Levels of soluble urokinase-type plasminogen activator receptor 
(suPAR), a signaling molecule and marker of immune activation, have been shown to 
predict incident kidney disease. Patients with autosomal dominant polycystic kidney disease 
(ADPKD) experience progressive but highly variables rates of decline in renal function, 
with highly heterogenous outcomes. Whether suPAR levels are predictive of decreasing 
kidney function in patients with ADPKD independently of known prognostic factors such 
as proteinuria and kidney volume, is unknown.
Methods: SuPAR levels were measured in a subset of 479 patients with ADPKD (mean 
age 39, 52% male, 80% Caucasians) enrolled in the TEMPO 3:4 trial and randomized to the 
placebo arm. All subjects randomized into the placebo arm with plasma samples that were 
available were included. Patients underwent scheduled follow-up for 3 years, with repeated 
measurements of height-adjusted kidney volume (htTKV), urine albumin-creatinine ratio 
(UACR), and Cockcroft-Gault calculated estimated glomerular filtration rate (eGFR). 
Linear mixed models for repeated measures were used adjusting for age, gender, baseline 
eGFR, UACR and htTKV to examine the association between baseline suPAR levels 
stratified by tertiles and follow-up eGFR measures.
Results: At baseline, the median suPAR level was 2544 pg/mL [IQR 2125-3221], 
with 32% of subjects having suPAR levels≥3000 pg/mL, while median eGFR was 78 
[IQR 62;96] and htTKV 853 mL/m [IQR 623-1151]. Baseline suPAR levels were weakly 
associated with htTKV (β 0.15 95%CI[0.00;0.29] independently of eGFR, UACR, gender, 
age and hypertension. Patients in the first, second and third tertiles of suPAR had a 10%, 
15% and 23% decrease in eGFR (P<0.001), and a 18%, 18% and 17% increase in htTKV 
at 3-years follow-up (P=0.6). The associations did not differ according to gender and was 
independent of age, baseline UACR and eGFR.
Conclusions: SuPAR levels were associated with decline in renal function in patients 
with ADPKD. Whether suPAR can be used as a prognostic marker to identify patients at 
high risk of decline in renal function that would benefit from early therapeutic intervention 
remains to be determined.
Funding: NIDDK Support
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Preeclampsia an Under Recognised Cause of AKI in Pregnancy
Raja Ramachandran,1 Krishan Lal L. Gupta,3 Vivekanand Jha.2 1Nehru Hospital, 
Chandigarh, India; 2George Institute for Global Health, New Delhi, India; 
3Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Background: Obstetric acute kidney injury (AKI) constitutes about 8-12% of all AKI 
in developing countries, with blood loss and sepsis as the main causes. Reliance on clinical 
parameters alone may lead to underestimation of the prevalence of preeclampsia (PE) in 
those with AKI, and use of biomarkers may help identify more cases.
Methods: All patients with obstetric AKI referred to the nephrology unit from 
September 2015 to August 2017 were evaluated. PE was diagnosed as clinical (cPE) in the 
presence of new onset of hypertension and proteinuria (≥ 1+ on dipstick) or hypertension 
and end-organ dysfunction with or without proteinuria after 20 weeks of gestation in a 
previously normotensive woman; and serological (sPE) on the basis of soluble fms-like 
tyrosine kinase(FLT1)/placental growth factor (PIGF) ratio of > 85 (<34 weeks of gestation) 
and > 110 (≥34 weeks of gestation) when clinical findings were indeterminate. Patients 
with pre-existing CKD or known systemic illnesses were excluded. We evaluated 6-month 
maternal and fetal outcomes in all patients.
Results: Out of a total of 73 patients seen during the study, 64 (87.7%) were seen 
in third trimester/postpartum period. The mean age was 26.38±3.92 (range 19-38) years. 
Thirty-six (49%), 34 (47%), and 57 (78%) patients had evidence of blood loss, sepsis 
and HUS respectively. cPE was diagnosed in 19 (30%) cases, and an additional 11 (17%) 
showed evidence of sPE. Fourteen (47%), 11 (37%) and 27 (90%) patients with PE had 
haemorrhage, sepsis and of HUS respectively. A total of 5 (17%) patients died, and 10 
(33%) failed to recover from AKI. Only 6 (20%) had a successful fetal outcome.
Conclusions: Use of clinical criteria alone leads to under-diagnosis of PE in patients 
with obstetric AKI in developing countries. Sepsis, blood loss and AKI mask the clinical 
manifestations.
Funding: Private Foundation Support
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Effect of Spironolactone in Ischemic AKI in Critically Ill Cancer Patients: 
A Pilot Study
Bertha M. Cordova-Sanchez,1 Silvio A. Ñamendys- Silva,1 Rosalba Pérez-
villalva,2 Juan A. Ortega-Trejo,2 Luis E. Morales-Buenrostro,2 Norma Bobadilla.2,3 
1Instituto Nacional de Cancerologia, Mexico City, Mexico; 2Instituto Nacional 
de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; 
3Instituto de Investigaciones Biomedicas, Mexico City, Mexico.
Background: Acute kidney injury (AKI) is a common complication in critically ill 
patients, about 30% of cases occur after major surgery caused by hypoperfusion. Cancer 
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patients who undergo major surgery have a greater AKI risk, due to factors associated 
with cancer or its treatment. Previous animal studies from our laboratory showed that 
mineralocorticoid receptor blockade with spironolactone, after renal ischemia/reperfusion 
prevents AKI. In this pilot study, we explored the tolerance and effectiveness of 
spironolactone for AKI prevention in critically ill cancer patients after major surgery.
Methods: We included 24 patients in a randomized, double-blinded, placebo-control 
trial. Patients received either spironolactone 25 mg or placebo, at 0, 24, and 48 h after surgery 
and were followed for five days. Our outcomes were AKI defined by KDIGO criteria, urinary 
biomarkers, hyperkalemia, lactate clearance, and days with vasopressor use.
Results: There were no differences between groups at inclusion. In spironolactone 
group, 6/12 patients developed AKI compared to 7/12 patients in placebo group (p=0.682). 
Spironolactone did not alter potassium, lactate clearance, or days with vasopressor. We 
analyzed the percentage change in biomarkers obtained at 48 h compared to the baseline 
level. We found that NGAL decrease and KIM1 increase significantly in spironolactone 
group.
Conclusions: In this exploratory study, we observed that spironolactone was well 
tolerated, although it did not reduce the incidence of clinical AKI in relation with the sample 
size, the significant decrease in urinary NGAL in the group treated with spironolactone 
suggests a decrease in tubular damage. These data can be useful in the design of larger 
controlled studies.
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Rate of AKI with Epithelial Growth Factor Tyrosine Kinase Inhibitors
Sheron Latcha,1 Michaela Scott.2 1Medicine, Memorial Sloan Kettering Cancer 
Center, New York, NY; 2Medicine, New York Medical College, New York, NY.
Background: Epithelial growth factor receptor (EGFR) mutations are found in several 
tumors, especially non-small cell lung cancer (NSCLC), occurring in 10-15% of NSCLC in 
Europe and 30-40% in Asia. Renal dysfunction is rare with EGFR TKIs. In phase III clinical 
trials, one patient on erlotinib had any grade renal failure and 1.5% of patients treated with 
gefitinib had an elevated creatinine (Cr). EGFR is expressed throughout the mammalian 
kidney and EGF and EGFR ligands are involved in renal development. In animal models, 
EGFR activation, and reductions in EGFR or EGFR TKI activity are associated with both 
benefit and harm to renal function, depending on the model of renal injury. The purpose of 
this this study is to determine the rate of acute kidney injury (AKI) with the use of EGFR 
TKIs at a single center.
Methods: Retrospective data was collected on all adult patients at our institution who 
received any EGFR TKI from 1/1/2014-12/31/2016. Demographic data, baseline Cr (Cr 
within 30 days prior to treatment) and peak Cr after each treatment cycle were collected. 
AKI was defined as an increase in Cr ≥1.5x baseline. Incomplete recovery of renal function 
was defined as a last Cr ≥25% of baseline. All statistical analyses was conducted using R 
version 3.4.4. A p-value of <0.05 was considered statistically significant.
Results: Analyses was performed on 1831 observations in 503 patients. Of 503 
patients, AKI occurred in 121 (24%). Of these, 103(85%) had incomplete recovery of renal 
function. The average time from baseline to last Cr was 314.8 days. Overall, 85% of patients 
were treated for lung cancer. AKI occured in 26% of lung cancer patients and 92% of all 
patients with AKI had underlying lung cancer (p=0.001). Overall, 385 (77%) patients were 
treated with erlotinib. AKI occured in 28% of patients treated with erlotinib and 89% of all 
patients with AKI had received erlotinib (p=0.002). Overall, the group was largely white 
(67%), non-Hispanic (91%) and female (70%), with no significant differences between 
those with and without AKI.
Conclusions: The rate of AKI with any EGFR TKI was 24%. On follow up, 85% of 
patients never returned to within 25% of their baseline Cr. AKI rates were significantly 
higher in lung cancer patients and with erlotinib use. Retrospective data with it attendant 
limitations cannot assign causality or define mechanisms. This relationship needs further 
examination.
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Immune Interstitial Nephritis Complicating Treatment of Lung Cancer
Krishna M. Baradhi,1 Kothai divya Guruswamy sangameswaran.2 1Nephrology, 
University of Oklahoma, Tulsa, OK; 2OU -Tulsa School of Community Medicine, 
Tulsa, OK.
Introduction: Immune check point inhibitors (ICPIs) have revolutionized the treatment 
of cancer therapy in the modern era. Amongst these, Nivolumab targeting programmed-
death-1 (PD-1) and its ligand (PD-L1) is increasingly being used for treatment of metastatic 
melanoma, non-small cell lung cancer, and renal carcinomas. The advent of these novel 
biologics, also brought with them the unique spectrum of immune mediated adverse effects. 
We describe a case of nivolumab induced immune nephritis and stress the importance of 
renal surveillance, as early recognition and treatment can prevent irreversible renal damage.
Case Description: An 82-yr-old female with metastatic squamous cell carcinoma of 
lung was admitted to the hospital due to Acute kidney injury (AKI) (creatinine 3.3 mg/dl), 
found on routine labs. Her chemotherapy was recently changed from paclitaxel to nivolumab 
due to non-response to paclitaxel as well as positive PD-1 mutation. Urinalysis showed 
persistent pyuria with 1% eosinophils and renal ultrasound was unremarkable. Renal biopsy 
done to further evaluate, revealed diffuse mononuclear infiltrate, predominantly plasma 
cells in the tubulointerstitial compartment with severe tubulitis. Patient was diagnosed 
with nivolumab induced immune tubulointerstitial nephritis. Her kidney function gradually 
improved to creatinine of 1 mg/dl, with withdrawal of nivolumab and short course of 
steroids. Our case spotlights the immune mediated injury and warrants renal monitoring 
while on ICPIs.
Discussion: Nivolumab is an IgG4 fully humanized monoclonal antibody, precisely 
a PD-1 inhibitor. Nivolumab is highly effective in treating melanoma, lung and renal 
cancers. As the use of these ICPIs is widening, prevalence of immune adverse effects is 
also spiraling. The incidence of AKI associated with these ICPIs was found to be 2.2 % 
per Cortazar et al, however recent studies showed higher incidence of 9.9 – 29 %. Clinical 
awareness regarding these unfamiliar immune side effects of ICPIs should be raised, as 
timely diagnosis and early intervention plays a crucial role in the management of these 
complications. Renal surveillance every two weeks is recommended while on ICPIs and 
withdrawal of offending agent is based on the severity of AKI and cancer prognostic risk. 
Multidisciplinary approach and close alliance between oncologists and nephrologists is 
advocated for optimal clinical outcomes.
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Outcome and Possible Mechanism of Acute Tubulointerstitial Nephritis
Dong hwan Yun,1 Min woo Kang,1 Minjung Kang,1 Soie Kwon,1 Jung Nam An,3 
Dong Ki Kim,2 Yon Su Kim,1 Jung Pyo Lee,3 Ho Jun Chin,4 Seung Seok Han.1 
1Seoul National University College of Medicine, Seoul, Republic of Korea; 
2Seoul National University Hospital, Seoul, Republic of Korea; 3Seoul National 
University Boramae Medical Center, Seoul, SEOUL, Republic of Korea; 4Seoul 
National University Bundang Hospital, Seong nam, Republic of Korea.
Background: Acute tubulointerstitial nephritis (ATIN) is an important cause of acute 
kidney injury (AKI) and often described as a potentially reversible disease. Some previous 
guidelines or studies recommended corticosteroid usage, but the role of steroids remains 
controversial and underlying mechanisms remain unresolved. The study purpose was to 
evaluate the steroid effect and the possible mechanism of ATIN.
Methods: A total of 82 adult patients with biopsy-proven ATIN except combined 
glomerulonephritis, pyelonephritis, and vasculopathy from three tertiary referral centers 
were recruited between 2001 and 2017. Renal recovery was defined as improvement 
in Cr level to 1.3 mg/dL or ≥ 50% decrease of the peak Cr. The effect of corticosteroid 
therapy was determined using multivariate logistic model.. Plasma and urine inflammatory 
cytokines at the time of biopsy were analyzed using a multi-analyte flow assay kit (n=33).
Results: Causes of ATIN included unknown (74.4%), drugs (17.1%), autoimmune 
(6.1%), and obstructive disease (2.4%). In drug-induced ATIN, herbal medication was 
the most common cause (35.7%), and followed by NSAID (28.6%), antibiotics (28.6%). 
Overall, 76.8% of ATIN patients experienced renal recovery once or more. 59.8% of 
patients encountered renal recovery status at 6 months post-biopsy. 23.2% of the patients 
were dependent on dialysis at final follow-up. Among a total of 82 patients with unknown 
and drug-induced ATIN, 24 patients (82.9%) were treated with corticosteroid. There were no 
significant difference in renal recovery, ESRD progression, and mortality between steroid-
treated and non-treated groups. In both Cox regression for renal recovery and logistic 
regression for renal recovery at 6 months post-biopsy, steroid use was not significant factor. 
Among several inflammatory cytokines, monocyte chemotactic protein 1 and interleukin-8 
levels were markedly elevated in both plasma and urine; and interleukin-18 levels were 
high in plasma alone
Conclusions: Steroid use may not determine the overall outcome of ATIN. Therefore, 
targeting therapy based on the pathophysiology of ATIN should be investigated to improve 
overall outcomes. The present cytokine results will be helpful to develop a novel targeting 
therapy for ATIN.
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AKI Due to Methotrexate-Induced Crystal Nephropathy with Electron 
Microscopy
Gabriel Contreras,2 Aza Abdalla,1 Pooja D. Amarapurkar,1 David B. Thomas.3 
1Jackson Memorial Hospital/University of Miami, Miami, FL; 2University of 
Miami, Miami, FL; 3University of Miami, Miller School of Medicine, Miami, FL.
Introduction: High dose methotrexate (MTX) (infusion of 1.5 to 8.0 gm/m2) is a 
key component of regimens for treatment of primary central nervous system lymphoma 
(PCNSL). 90% of MTX and its metabolites are excreted via the kidney. They are poorly 
soluble in acid pH and need intense hydration and alkalization of the urine (pH > 7) to 
reduce the risk of acute kidney injury (AKI) to less than 5%. Here, we present a case of AKI 
due to MTX-induced crystal nephropathy with by electron microscopy.
Case Description: A 53 years old male presented with frontal headaches. Imaging 
study followed by brain biopsy confirmed the diagnosis of PCNSL. Patient had normal 
baseline serum creatinine of 0.91 mg/dL prior to two infusions of high dose MTX 3.5 
gm/m2 on 3/7/18 and 3/21/18. MTX and serum creatinine levels peaked at 12.3 mmol/L 
on 3/24/18 and 5.82 mg/dl on 3/28/18 respectively. Patient developed AKI in spite of 
maintaining intensive hydration, urine pH between 8 and 9 with the use of crystalloid 
solution of sodium bicarbonate and an adequate urine output of approximately 100 mL/hour. 
The urine sediment showed brownish crystals. Kidney biopsy done on 4/3/18, revealed light 
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microscopy diffuse severe acute tubular epithelial cell injury (acute tubular necrosis, ATN) 
with tubular lumen MTX crystals also present by electron microscopy (image 1). After 
discontinuing MTX, the serum creatinine gradually improved to a level of 2.1 mg/dL on the 
day of discharge on 4/21/18.
Discussion: supersaturation is the initial step in crystallization of MTX in the renal 
tubular lumens, may occur despite maintaining adequate urine output and urine alkalization 
and leads to MTX-induced crystal nephropathy. We report a case of MTX-induced crystal 
nephropat, renal biopsy morphologic features of nephrotoxic ATN and MTX crystals both 
by light microscopy and electron microscopy.
IMAGE 1
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Severe AKI Due to Minocycline-Associated Heme Pigment Nephropathy
Abdallah Sassine Geara,1 Matthew Palmer,3 Afshin K. Hannani,4 
Jonathan J. Hogan.2 1Nephrology, University of Pennsylvania, Philadelphia, PA; 
2Hospital of the University of Pennsylvania, Haddonfield, NJ; 3University of 
Pennsylvania, Philadelphia, PA; 4Mercer Renal Associates, PA, Hamilton, NJ.
Introduction: Minocycline-associated acute kidney injury (AKI) is rarely reported 
in the literature. We present a patient with two separate episodes of minocycline-induced 
hemolytic anemia with severe AKI due to heme pigment nephropathy.
Case Description: A 45-year-old woman with a history of recurrent acne resumed 
minocycline after a six-month hiatus from taking the drug. She developed acute nausea, 
vomiting and dark urine within hours of drug administration, and presented to the hospital. 
She was noted to have AKI (SCr peaked at 5.8 mg/dL) and acute hemolytic anemia 
(Hemoglobin decreased from 14 to 10 g/dL; LDH 2335 U/L; haptoglobin < 15 mg/dL). 
A UA was positive for 1+ protein and gross blood with RBC 2-5/HPF. A kidney biopsy 
showed acute tubular injury with multifocal pigmented casts with negative immunostaining 
for myoglobin. There was no evidence of thrombotic microangiopathy. Her minocycline 
was held and her AKI and anemia resolved without additional therapy. One year after this 
episode, she was restarted on minocycline for recurrent acne, and again experienced nausea, 
vomiting, diarrhea and back pain within few hours of the first minocycline dose. She 
presented to the hospital where she developed anuric AKI (peak SCr 8.0 mg/dL), hemolytic 
anemia (Hgb of 11.0 g/dL; LDH 3000 U/L; haptoglobin < 15 mg/dL) and thrombocytopenia 
(Plts 40,000/μL). She was started on plasma exchange therapy due to an initial concern for 
TTP. A repeat kidney biopsy was not performed. She again had rapid and full recovery of 
AKI, hemolytic anemia and thrombocytopenia with holding minocycline. .
Discussion: Minocycline-induced hemolytic anemia is rare, with only 1 published 
case of hemolytic anemia and hemoglobulinuria. An FDA Adverse Events reporting system 
search revealed 5 cases of anemia and 1 case of anuria attributed to minocycline. AKI was 
more frequently recorded (48 cases). This is the first report of biopsy-proven heme pigment 
nephropathy associated with minocycline.
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Effectiveness of Inactivated Hantavirus Vaccine on the Disease Severity of 
Hemorrhagic Fever with Renal Syndrome
Yongjin Yi,1 Hayne C. Park.2 1Armed Forces Capital Hospital, Seongnam-si, 
GYEONGGI-DO, Republic of Korea; 2Kangnam Sacred Heart Hospital, Seoul, 
Republic of Korea.
Background: An inactive Hantaan virus vaccine (iHV) has been broadly used as a 
preventive strategy in the South Korean army. After the vaccination program, the overall 
incidence of Hantavirus cases was reduced. However, hundreds of new HFRS cases occur 
annually. Furthermore, few studies have demonstrated the efficacy of the iHV’s in field 
settings. This study aimed to evaluate the vaccine efficacy on HFRS severity.
Methods: From 2009 to 2017, we registered all reported Hantavirus cases in the South 
Korean army hospitals along with the patients’ vaccination history. We retrospectively 
classified HFRS patients into both groups according to their vaccination records: no history 
of iHV vaccination and valid vaccination. To evaluate the vaccine efficacy on the severity 
of renal injury, acute kidney injury (AKI)  stage 3 and event of dialysis were investigated.
Results: We assessed the effect of the vaccine on severity in 18 and 110 HFRS patients 
with and without valid vaccination history, respectively. In the valid-vaccination group, 
six of 18 patients (33.3%) had stage 3 AKI, compared to 60 of 110 (54.5%) HFRS patients 
in the non-vaccination group. The vaccine efficacy against HFRS progression (VEp) was 
58.1% (95% confidence interval [CI]: -31.3–88.0%).
Conclusions: The vaccine efficacy against the progression of HFRS in this case-
control study failed to show a statistically significant result. However, different severity 
profiles were observed between the vaccinated and none-vaccinated groups. More studies 
with large vaccinated populations are needed to demonstrate the effectiveness of the vaccine 
in patients with HFRS.
Funding: Government Support - Non-U.S.
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Eculizumab Safety: 5-Year Experience from the Global aHUS Registry
Eric Rondeau,1 Daniel Landau,2 Spero R. Cataland,3 Christoph Gasteyger,5 
Nicholas J. Webb.4 1Urgences Néphrologiques et Transplantation Rénale, 
Hôpital Tenon and Université Paris VI, Paris, France; 2Schneider Children’s 
Medical Center, Sackler School of Medicine, Petach Tikva, Israel; 3Division of 
Hematology, The Ohio State University, Wexner Medical Center, Columbus, 
OH; 4Department of Paediatric Nephrology, University of Manchester, Royal 
Manchester Children’s Hospital, Manchester, United Kingdom; 5Alexion 
Pharma GmbH, Zürich, Switzerland.
Background: Eculizumab (ECU) is approved for treatment of atypical hemolytic 
uremic syndrome (aHUS), a rare and life-threatening disease. The Global aHUS Registry 
was initiated in 2012 and has recruited both ECU- and non-ECU-treated adult and pediatric 
patients (pts).
Methods: This observational, multinational Registry (NCT01522183) evaluates safety 
and effectiveness of ECU in pts with aHUS, while also assessing clinical characteristics 
at enrollment and follow-up visits every 6 months thereafter, irrespective of disease 
management. Herein, we report baseline characteristics and targeted safety events from 
adult and pediatric pts who were “ever treated” (ET) vs “never treated” (NT) with ECU in 
the first 5 years of the Registry through the study cut-off date of January 26, 2017.
Results: Overall, N=1321 pts (ET, n=865; NT, n=456) have been enrolled. In ET 
patients, mean (SD) ECU exposure was 2.17 (1.56) years in adults and 2.72 (1.74) years 
in children. At baseline, ET pts had greater rates of organ involvement (renal: 79.2% vs 
23.7%; gastrointestinal: 35.0% vs 9.9%; cardiovascular: 28.3% vs 8.6%; CNS: 25.9% vs 
7.9%; and pulmonary: 15.0% vs 6.4%), and poorer quality of life (lower median Functional 
Assessment of Chronic Illness Therapy–Fatigue scores: 30 vs 41), compared with NT pts, 
respectively. Prespecified targeted safety events reported for 801 adult and 464 pediatric 
pts are presented in the Table. No differences in event rates between ET and NT pts were 
observed, except for serious infections in pediatric pts, which were more common in ET 
vs NT.
Conclusions: Five-year data from the Global aHUS Registry reveal no new safety 
signals with ECU treatment in either adult or pediatric ET pts, confirming ECU’s safety 
profile and, therefore, its positive benefit:risk ratio in a real-world setting.
Funding: Commercial Support - Alexion Pharmaceuticals, Inc.
AKI: Clinical, Outcomes, Trials - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
873
J Am Soc Nephrol 29: 2018 Poster/Saturday
SA-PO527 Poster Saturday
AKI: Clinical, Outcomes, Trials - II
Differences in Cardiovascular and Renal Complication Rates in Throm-
botic Microangiopathies with and Without Hemolytic Uremic Syndromes
Sanjeev Gupta,1 Srikanth Yandrapalli,2 Savneek S. Chugh.3 1Westchester county 
medical center, White Plains, NY; 2Westchester Medical Center, Valhala, NY; 
3New York Medical College, Hartsdale, NY.
Background: Pathophysiologic differences between different thrombotic 
microangiopathies (TMAs) might predispose to varying complications. We sought to study 
if there is a difference in the incidence of cardiovascular and renal complications between 
hemolytic uremic syndrome (HUS)-TMA and non-HUS TMAs.
Methods: We queried the United States National Inpatient Sample years 2005 to 2014 
to identify hospitalizations in adult patients (age≥18 years) complicated by either HUS-
TMA or non-HUS TMA using ICD-9 codes 283.11 (HUS) and 446.6 (TMA). In this cohort, 
we analyzed differences in the rates of acute myocardial infarction (AMI), heart failure 
(HF), stroke or transient ischemic attack (TIA), acute kidney injury (AKI), plasmapheresis 
and hemodialysis requirement, and in-hospital mortality.
Results: Out the weighted 59,166 cases in our study (mean patient age 50 years, 64% 
women), HUS-TMA was present in 24.5% (N=14,508) and non-HUS TMA in 75.5% 
(N=44,658). Patients with non-HUS TMA were older than those with HUS-TMA (mean 
age 50 years vs 48 years, p<0.001) but had similar gender distribution (women: 64.5% vs 
62.9%, p=0.171). Compared to HUS-TMA, non-HUS TMA had higher rates of AMI (5.3% 
vs 4.2%, p=0.017), stroke/TIA (8.2% vs 3.0%, p<0.001), and plasmapheresis use (39.2% 
vs 30.9%, p<0.001). Compared to non-HUS TMA, HUS-TMA had higher rates of AKI 
(58.2% vs 36.4%, p<0.001), CHF (15.7% vs 12.5%, p<0.001), and HD requirement (41.6% 
vs 16.7%, p<0.001). In-hospital mortality was higher with non-HUS TMA (10.2%) than 
with HUS-TMA (8.5%, p=0.011).
Conclusions: In this large study of TMAs, HUS-TMAs were associated with more 
renal complications and non-HUS TMAs with more cardiovascular complications. The 
microvascular derangements in non-HUS TMA might be responsible for the higher 
incidence of AMI and stroke/TIA, whereas fluid balance disturbances from renal failure 
might contribute to increased heart failure with HUS-TMA. The high complication rates 
and mortality associated with these conditions necessitate further research into identifying 
underlying mechanisms and developing appropriate therapeutic strategies.
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The Risk Factors Analysis of Idiopathic Membranous Nephropathy 
Complicated with AKI
Yi-yi Xie,2 Li-jun Xie,1 Yunhua Liao.1 1Renal Division, Department of Medicine, 
First Affiliated Hospital of Guangxi Medical University, Nanning, China; 2The 
second people’s hospital of nanning, Nanning, China.
Background: Idiopathic membranous nephropathy (IMN) is the most conmon 
pathological types for nephrotic syndrome. In Chinese population, the proportion of IMN in 
primary glomerular disease increased obviously in recent years. Acute kidney injury(AKI) 
is a common complication of IMN. The risk factors of IMN complicate with AKI were 
unknown.
Methods: We collected the clinical data of 129 IMN patients diagnosed by renal 
biopsy from March 2011 to October 2015 in the First Affiliated Hospital of Guangxi 
Medical University, including 35 IMN patients complicated with AKI (AKI group) and 
94 IMN patients without AKI (Non-AKI group). The age, blood pressure, BMI, blood 
homocysteine, blood 25(OH) vit-D3, 24h urinary protein, many other laboratory parameters 
and pathological parameters were compared between these two group. Single factor analysis 
and multivariate analysis were conducted to explore the independent risk factors of AKI.
Results: The age, systolic blood pressure(SBP), blood homocysteine, blood 25(OH) 
vit-D3, 24h urinary protein, blood IgG and blood IgG/C3 showed significant statistically 
differences between these two group (P <0.05). In AKI group, age, SBP, 24h urinary 
protein, blood homocysteine was higher than those in non-AKI group, but blood 25(OH) 
vit-D3, blood IgG, blood IgG/C3 was lower than those in non-AKI group. The SBP, level of 
blood homocyhsteine, level of low-density lipoprotein cholesterol, and level of 24 urinary 
protein was positively correlated with the occurrence of AKI (P<0.05). However, the 
level of 25(OH) vit-D3, blood IgG and blood IgG/C3 was negatively correlated with the 
occurrence of AKI (P <0.05). In multivariate analysis, high blood homocysteine, high 24h 
urinary protein, hypertension, high pathological stage was the risk factors of AKI.
Conclusions: The IMN patients, with advancing age, higher SBP, higher serum 
homocysteine, lower serum 25(OH) vit-D3, lower IgG/C3 and higher pathological stage 
were more prone to complicate with AKI.
Funding: Government Support - Non-U.S.
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Randomized Controlled Trial of Omega 3 Fatty Acids to Reduce 
Contrast-Induced Nephropathy in CKD Patients Undergoing Coronary 
Angiography
Fadel A. Al-Rowaie, Khalid I. Almatham. King Fahad Medical City, Riyadh, 
Saudi Arabia.
Background: Contrast-induced nephropathy (CIN) is a leading cause of acquired acute 
kidney injury and has been associated with prolonged hospitalization and adverse clinical 
outcomes. The results of studies investigating the effects of antioxidants on the prevention 
of CIN remain inconsistent. Omega 3 fatty acids have been shown to reduce inflammatory 
markers and oxidative stress, improve endothelial function, and reduce kidney dysfunction 
following reperfusion injury and chronic renal insufficiency in animal models. This pilot 
study aimed to determine the effects of omega 3 fatty acids on CIN prevention in patients 
with chronic kidney disease (CKD) undergoing coronary angiography
Methods: 67 patients were assigned to the N-acetylcysteine (NAC) and 63 patients 
were assigned to the omega 3 fatty acids (omacor ®). Both drugs were administered orally 
twice per day on the day prior to and on the day of contrast administration, for a total of 2 
days. The primary endpoint was the occurrence of CIN, defined as an increase in baseline 
serum creatinine levels of > 0.5 mg/dl (44 μmol/l) or > 25% increase in serum creatinine 
levels from baseline levels 48–72 h following contrast administration. The secondary 
endpoints were: the need for renal replacement therapy, death, and length of hospitalization 
after contrast administration
Results: Of the 130 CKD patients enrolled in this study, 10 (7.7%) experienced an 
increase of at least 0.5 mg/dl (44 μmol/l) in serum creatinine levels 48 h after administration 
of the contrast agent, including 5 of the 67 patients in the NAC group (7.5%) and 5 of the 
63 patients in the omega 3 fatty acids group (7.9%; P = 0.919). There were no significant 
differences in the need for renal replacement therapy or in the mortality rate between both 
groups
Conclusions: Short-term prophylactic omega 3 fatty acid treatment with hydration 
does not reduce CIN in CKD patients undergoing coronary angiography
Funding: Government Support - Non-U.S.
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Are the Iodinated Contrast Media Dangerous? Influence of Iodinated 
Contrast Media on Renal and Thyroid Gland in Patients with CKD
Dorota Brodowska-Kania,1 Stanislaw Niemczyk.2 1MIlitary Intitiute of 
Medicine, Warsaw, Poland; 2Military Medical Institute of Warsaw, Warsaw, 
Poland.
Background: The aim of our study was to assess the risk and incidence of CIN in 
patients with CKD, the impact of iodine CM on the endocrine function of the thyroid gland 
and the impact of renal impairment on the risk of contrast-induced hypothyroidism or 
hyperthyroidism.
Methods: We included 75 patients(pts). The first CKD-Group: 36pts with eGFR<60ml/
min. (mean age 69.4±11, male-72.2%). The second RRT-Group: 20pts chronically dialysed 
(mean age 63.7±12.2, male-50%). The control group: 19pts with eGFR>60 ml/min, 
(mean age 48.2±18.0, male-57.9%). CIN prevention were conducted among all patients: 
hydration and N-acetylocysteine. All patients received iomeprol or iohexol. Patients were 
monitored for 6 months after the administration of CM (48 hours, 14 days and 6 months 
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after contrast administration). Creatinine, urea, eGFR, cystatin C, TSH, free-T3(fT3), free-
T4(fT4), reverse-T3(rT3), were monitored. The results were statistically analyzed. Study 
was approved by the Ethics Committee.
Results: AKI was found in 2.7% in test group (3 pts). In the CKD group, the mean 
creatinine was 1.65mg / dl (1.33-2.28), eGFR 39.91 ± 12.89, cystatin C 2.17mg / dl ± 
0.83, urea 67.7mg / dl ± 27.55. Increase in creatinine value was not statistically significant 
(ΔCREA 0.2 p = 0.8, Δcystatin C-0.04, p = 0.891, and ΔeGFR = 0.62, p = 0.912 within 
48 hours after administration of CM. In the CKD group two weeks after administration 
of CM a decrease fT3, ΔfT31CKD -0.39 ± 0.77 p1CKD = 0.004. changes fT3 persisted 
during the 6 months follow-up (ΔfT32CKD = -0.36 ± 0.91 p2CKD = 0.023). The changes 
of ΔfT3 were no correlation with dose of CM and eGFR. In the group of RRT a change of 
ΔfT41RRT 1.58 ± 2.56 p1RRT = 0.013 was observed after 2 weeks, which maintained for 
6 months (ΔfT42RRT 2.0 ± 3.38 p2RRT = 0.016). In the control group the changes were 
minimal and not statistically significant. No thyroid dysfunction was observed.
Conclusions: Adverse effects of intravenous administration of iodine contrast are rare. 
CIN in the group with CKD is 2.7%. CM have no adverse effect on kidney and thyroid 
function among patients with good function of these organs. CKD is not a risk factor for 
contrast-induced hyperthyroidism or hypothyroidism. Changes in thyroid hormones were 
statistically significant but asymptomatic. CM are not so dangerous. Further research is 
needed.
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New Perspectives on Bothrops-Induced AKI: Novel Biomarkers and 
Coagulation Disturbances
Polianna Lemos m.m. albuquerque,2 Geraldo B. Silva Junior,1 
Gdayllon Cavalcante meneses,2 Alice maria Costa martins,2 
Jacques Raubenheimer,3 Fathima Shihana,3 Nicholas Buckley,4 Elizabeth De 
francesco daher.2 1University of Fortaleza, Fortaleza, Brazil; 2Federal University 
of Ceara, Fortaleza, Brazil; 3University of Sydney, Sydney, NSW, Australia; 4The 
University of Sydney, Sydney, NSW, Australia.
Background: Bothrops sp is the most common snake genus associated with acute 
kidney injury (AKI) in Latin America. We evaluated novel biomarkers and coagulation 
disturbances among patients with Bothrops venom-induced AKI.
Methods: This is a prospective study of patients with snakebite (Bothrops)-induced 
AKI admitted to a referral emergency hospital in Fortaleza city, Brazil, from December 
2015 to December 2016. Biomarkers were measured in blood (sNGAL) and urine (uNGAL, 
uMCP-1, uKIM-1, VCAM-1 and IL-6) using ELISA.
Results: 63 patients were included, and 22 (34.9%) developed AKI. The age, time 
elapsed between snakebite and administration of antivenom, number of administered 
antivenom vials, gender distribution and severity of the envenomation were similar in 
the groups. The biomarkers uMCP-1 and uNGAL were significantly higher in the AKI 
group: uMCP-1 (471.2 ± 60.40 vs. 288.8 ± 41.42pg/ml; p=0.014) and uNGAL (15.27 ± 
1.28 vs. 10.29 ± 1.06ng/ml; p=0.006). The activated partial thromboplastin time (APTT) 
on admission, was significantly longer in the AKI group (p=0.011). Urinary proteinuria 
correlated highly with two specific urine biomarkers: uMCP-1 (r=0.5242, p=0.0003) and 
uNGAL (r=0.4938, p=0.0008). The fractional excretion of sodium (FENa) also strongly 
correlated with uMCP-1 (r=0.8696, p<0.0001) and uNGAL (r=0.6833, p<0.0001). 
The correlation between FENa and uMCP-1was largely confined to the AKI-group (Figure 
1). The FEK also positively correlated with uMCP-1 (r=0.5775, p<0.0001) and uNGAL 
(r=0.5647, p=0.0001).
Conclusions: Coagulation abnormalities seem to be a pivotal factor in AKI 
development in Bothrops-induced AKI. The higher levels of uMCP-1 and uNGAL could 
represent early tubular and glomerular dysfunction caused by snakebite venom, and the 
abnormalities in fractional excretion of electrolytes point to tubular transport dysfunction.
Funding: Government Support - Non-U.S.
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Ex Vivo MSC Therapy for Subjects with AKI
Rita N. Barcia. Sentien Biotechnologies, Lexington, MA.
Background: Mesenchymal stromal cells (MSCs) are known to secrete potent 
molecules and extracellular vesicles contributing to immunomodulation and wound 
healing. There is a good deal of interest in MSC based approaches for the treatment of 
human kidney injury driven by evidence that MSCs repair the kidney by paracrine and 
endocrine mechanisms (Humphreys & Bonventre, 2008). Though clinical trials using 
MSCs as infusion therapeutics have been successful in demonstrating safety, clear 
clinical benefit has not consistently been realized. Lack of clinical effectiveness may be 
due to ineffective dosing of MSCs and short exposure times of the infused cells. Sentien 
Biotechnologies has pioneered a new way to control the delivery of MSC secreted factors 
by using an ex vivo cell therapy approach as a novel route of extracorporeal administration. 
Sentien’s lead product consists of a continuous flow bioreactor with MSCs immobilized on 
the extraluminal side of a hollow fiber membrane. Patient’s blood flows through the lumen 
of the hollow fibers and are conditioned by MSC secreted factors, allowing for the blood 
cells and MSCs to sense their environment and react to it.
Methods: In vitro studies were performed to assess MSC function within Sentien’s 
reactors. The technology was also tested as a continuous ex vivo therapy in an ischemia/
reperfusion dog model of Acute Kidney Injury (AKI). Toxicological studies were performed 
in healthy dogs. A multi-center, randomized, placebo-controlled double-blind study of 
extracorporeal MSC therapy has begun in human subjects with AKI receiving continuous 
renal replacement therapy.
Results: In vitro studies showed that MSCs are viabile and responsive in the biorector. 
In a dog model of AKI, an increase in survival was observed in the treated animals. 
Additionally, toxicological studies verified a pharmacokinetic and pharmacodynamic 
response to MSCs that was consistent with a potent immunomodulatory mechanism of 
action. Preliminary results from the ongoing clinical trial will be presented.
Conclusions: Ex vivo MSC therapy using this reactor technology has promise for other 
clinical applications requiring systemic immunotherapy for tissue repair and regeneration.
Funding: NIDDK Support
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The Effect of Fluid Resuscitation with Normal Saline versus Ringer’s 
Acetate on Renal Function and Host Defense in Severe Sepsis/Septic 
Shock Patients: A Randomized Controlled Trial
Sasithorn Kunupakan,1 Sadudee Peerapornratana,2 Nuttha Lumlertgul,3 
Nicha Thamrongsat,4 Kearkiat Praditpornsilpa,2 Kriang Tungsanga,5 
Somchai Eiam-Ong,2 Nattachai Srisawat.1 1Chulalongkorn university, Bangkok, 
Thailand; 2Chulalongkorn University, Bangkok, Thailand; 3Renal Division, 
Chulalongkorn University, Bangkok, Thailand; 4Chulalongkorn university, 
Bangkok, Thailand; 5King Chulalong Memorial lHospital, Bangkok, Thailand.
Background: Recent large observational studies in severe sepsis showed that Normal 
Saline (NSS) might worsen acute kidney injury (AKI) determined by serum creatinine. 
In animal model with sepsis, NSS could impair monocyte/neutrophil functions, the main 
host defense mechanism during sepsis, and this impairment might cause renal dysfunction.
Methods: NSS or RA was utilized for volume expansion during fluid resuscitation 
phase for 72 hours. The treatment followed the recommendations for fluid therapy provided 
by the Surviving Sepsis Campaign. Blood and urine samples were collected at 72 hrs. 
Primary outcome was median difference of uNGAL levels on day 3. Secondary outcomes 
were difference of monocyte HLA-DR (mHLA-DR)expression, neutrophil chemotaxis 
activity, and CD11b expression on day 3, and maximum AKI state on day 7.
Results: Fifty-nine patients were recruited, 29 and 30 for NSS and RA, respectively. 
The volume of resuscitation during the first 6 hours were comparable (NSS=1000 
(1000,2000) mL, RA=1000 (700,1500) mL, p=0.38). Patients receiving NSS became more 
acidic than RA. There was no significant difference in renal function between both groups 
at baseline. The median uNGAL levels were not different between groups (NSS=111 (36.4, 
262.2) ng/mL, RA= 32.7 (8.85, 178.1) ng/mL, p=0.59), mHLA-DR expression, neutrophil 
chemotaxis, and CD11b expression on day 3 were no improvement in NSS groups. But 
there were significant improvement in chemotaxis (p=0.024) and mHLA-DR expression 
(p=0.036) in RA group. The maximal AKI state determined by serum creatinine on day 7 
were not different (NSS=24.1%, RA=26.7%, p=0.82).
Conclusions: Our study showed that there was significant improvement of 
immunoparalysis status (increased HLA-DR and chemotaxis activity) in RA group. No 
significant difference in tubular dysfunction between groups. (But lower trends of uNGAL 
and L-FABP in RA group.)
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Balanced Crystalloids vs Normal Saline and Risk of AKI in Critically Ill 
Patients: A Systematic Review and Meta-Analysis
Mengyao Tang,1 Jerald Cherian,1 Sahir Kalim.2 1Vanderbilt University Medical 
Center, Nashville, TN; 2Massachusetts General Hospital/ Harvard Medical 
School, Cambridge, MA.
Background: In both animals and in vitro human studies, the high chloride content 
of normal saline (NS) has been linked with adverse pathophysiological effects. Emerging 
evidence, including a recent large clinical trial, suggests that balanced fluids (e.g. lactated 
Ringer or Plasma-Lyte A) may result in fewer adverse renal outcomes. However, whether 
NS is associated with a higher incidence of AKI when compared to balanced crystalloids in 
critically ill adults remains controversial.
Methods: A meta-analysis of RCTs and observational studies that enrolled critically ill 
patients receiving balanced crystalloids or NS in an ICU setting was conducted. Electronic 
databases (PubMed, EMBASE, Cochrane) were searched from inception until April 2018. 
Relative risks (RR) and 95% CIs were pooled using the random effects model in STATA. 
The primary outcome was AKI, as defined by the individual study. The secondary outcome 
was the requirement for renal replacement therapy (RRT).
Results: Five studies with a total of 24,429 patients met the eligibility criteria and 
were included. The definition of AKI was based on KIDGO criteria, RIFLE criteria or ICD-
9 code. The risk of AKI with balanced crystalloids was not significantly different when 
compared to NS (RR 0.94; 95% CI, 0.87, 1.01, p=0.08) (Figure 1), but there was a trend 
toward a more favorable outcome. There was also no difference between the two groups in 
new RRT requirements (RR 0.98; 95% CI, 0.87, 1.09, p=0.65).
Conclusions: Although there is a trend toward less detriment to renal function with 
balanced crystalloids, the current evidence insufficiently supports their use over NS for 
fluid resuscitation to decrease the risk of AKI or RRT requirement in critically ill patients 
in the ICUs. Current studies are limited by the inconsistent definition of AKI. Therefore, 
additional clinical trials adopting a standardized AKI definition are needed to further clarify 
the ideal resuscitation fluid for critically ill patients.
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AKI Evaluation and Mortality Risk on Mexican Patients
Priscila B. Villalvazo,2 Milagros M. Flores Fonseca,1 Viridiana Rodriguez,3 
Benjamin Gomez-Navarro,4 Jorge Andrade-Sierra.5 1Centro Medico Nacional 
de Occidente, Guadalajara, Mexico; 2IMSS, Zapopan, Jaliscco, Mexico; 
3Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; 4IMSS, HECMNO, 
Zapopan, Jalisco, Mexico; 5Universidad de Guadalajara, Cucs, Guadalajara, 
Jalisco Mexico, Mexico.
Background: AKI prevalence in Mexico is unknown and mortality rates are estimated 
16 – 18%, its presence increases the risk of death in critically ill patients and is associated 
with high morbidity and mortality. In Mexico, limited data including early RRT, AKI 
biomarkers, furosemide response and risks factors of AKI progression, remains AKI 
treatment controversial. This study aimed to evaluate characteristics and risk factors of AKI 
and predict RRT and renal function recovery.
Methods: We analyze a single center AKI cohort of 112 Mexican patients. Serum 
creatinine assay was done to diagnose AKI. Demographics, clinical and biochemical 
profiles, risk factors for AKI and RRT prescription was assessed and reported during 
diagnosis and discharge. Outcome measures were renal recovery, mortality and causes of 
death.
Results: Mean age was 56.81 ± 18.38 years, 73% on AKI stage 3, mixed causes 
(60%) and pre-renal AKI (26%) were the most frequent forms. Main etiologies were 
cardiovascular disease (30%) and sepsis (24%). Of 112 patients, 49% initiate RRT and 55% 
had renal recovery. Global mortality rate was 48% mainly due to cardiovascular disease. We 
observed significant differences between (p=0.05) in serum creatinine admission OR=01.65 
(1.47-1.83) and fluid balance OR=1.56 (1.45-1.69) as risk factors for RRT and furosemide 
response OR 9.16 (4.03-39.96) as renal recovery factor.
Conclusions: This was the first study that evaluate AKI risk factors, allowing RRT 
therapy and enhance renal recovery. Our findings support the furosemide stress test 
response strongly allows the adequate risk stratification, and can be used for early RRT 
initiation and might prolong time to renal recovery. Further studies are needed to determine 
if at the time of admission measurement of AKI biomarkers, may significantly improve the 
ability to predict hard outcomes (RRT, renal recovery and death).
Funding: Government Support - Non-U.S.
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AKI in a Developing Country: Clinical Course, Renal Recovery and 
Patient Outcome
Arunkumar Subbiah, Sanjay K. Agarwal, Dipankar M. Bhowmik, 
Sandeep Mahajan, Soumita Bagchi, Raj K. Yadav. All India Institute of Medical 
Sciences, New Delhi, India.
Background: Acute Kidney Injury (AKI) is an important determinant of outcome in 
hospitalized patients. Moreover, there is a risk for future development of Chronic Kidney 
Disease (CKD). Though the long-term impact of AKI has been studied in developed 
countries, there is a paucity of data in this area from the Indian subcontinent. This single-
centre study aimed to assess the pattern, clinical spectrum and long-term outcome of AKI.
Methods: In this prospective observational cohort study, detailed demographic and 
clinical data at presentation, during hospital stay and follow-up at 1, 3, 6 and 12 months after 
discharge were obtained prospectively for a cohort of patients with AKI. Both community 
(CAAKI) and hospital acquired AKI (HAAKI) were included. Patient with preexisting 
CKD were excluded. Outcome variables were in-hospital mortality, renal function at 
discharge and on long-term follow-up.
Results: Of the 476 patients, majority of the cases, 395 (83%) were CAAKI. The mean 
age was 44.8 ± 18.7 years. Etiology groups included medical (84%), surgical (10%) and 
obstetric (6%) with sepsis (176/476; 36.9%) being the most common cause of AKI. The 
in-hospital mortality rate was 38%. Age >60 yrs (HR = 1.51; 95% CI, 1.11 – 2.07), oliguria 
(HR = 1.48; 95% CI, 1.05 – 2.10) and need for ventilator (HR = 2.45; 95% CI, 1.36 – 
4.41) and/or inotropes (HR = 14.4; 95% CI, 6.28 – 33.05) were predictors of mortality. At 
discharge, 146 (30.7%) patients had complete renal recovery, while 149 (31.3%) had partial 
renal recovery. Oliguria (p < 0.001), hypoalbuminaemia (p = 0.001) and need for renal 
replacement therapy (RRT) (p = 0.01) were significantly associated with partial recovery. 
Of the 295 patients on follow-up, 211 (71.5%) patients had normal renal function, 4 (1.4%) 
died and 33 (11.2%) lost to follow up; 41(14%) patients developed CKD while 6 (2%) were 
dialysis dependent. The need for RRT during hospital stay was the single most important 
factor predicting the risk of CKD (OR 1.77, 95% CI, 1.12-2.78).
Conclusions: In conclusion, our data shows that AKI in hospitalized patients still has 
high mortality. Though a fairly good percentage of cases recovered, there is a definite risk of 
CKD development, especially in patients who required RRT during hospitalization.
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Recovery from AKI-Requiring Dialysis in Hospital Survivors Discharged 
to a Rehabilitation Facility
Meredith McAdams,1 Melissa R. Jordan,3 Victor M. Ortiz-Soriano,3 
George Vasquez-Rios,4 Brian S. Armentrout, MS, PA-C,1 Florence Lima,3 
Javier A. Neyra.2 1University of Kentucky, Lexington, KY; 2University of 
Kentucky Medical Center, Lexington, KY; 3University of Kentucky, Lexington, 
KY; 4Saint Louis University School of Medicine, Saint Louis, MO.
Background: Acute kidney injury-requiring dialysis (AKI-D) occurs in about 5% 
of hospitalized patients and is associated with poor outcome. Little is known about the 
incidence of AKI-D recovery following hospital discharge. We aim to examine AKI-D 
recovery in hospital survivors transferred to an affiliated rehabilitation facility (Select) with 
need of hemodialysis (HD) for AKI.
Methods: Single-center, retrospective cohort study of 42 patients who were admitted 
to the University of Kentucky Hospital (8/2015 to 3/2018), suffered from AKI-D and were 
transferred to Select with ongoing need for HD. Kidney recovery was defined as the patient 
being alive and no longer requiring HD support. Kidney recovery was assessed at the 
time of discharge from Select and from Select discharge until the end of the observation 
period (5/2018). Multivariable logistic regression models were performed to assess clinical 
characteristics associated with kidney recovery.
Results: Mean (SD) age was 61.4 (9.6) years; 61.9% were males and 90.5% whites. 
A total of 29 out of 42 patients (69%) recovered kidney function by the time of discharge 
from Select. Of these, 5 (17%) died after Select discharge (median follow-up 9.1 months). 
A total of 5 (12%) patients died during their stay at Select. Of the 8 (19%) patients that 
were discharged from Select with HD-dependent status, 3 (38%) died and only 1 recovered 
kidney function (median follow-up 16.5 months). The total number of hospital dialysis days 
was independently associated with kidney recovery at Select discharge (OR 0.81, 95% CI 
0.68–0.98, p=0.027) and the number of intradialytic hypotension events during the stay at 
Select was associated with death or HD-dependent status at follow-up (OR 1.24, 95% CI 
1.02–1.51, p=0.034).
Conclusions: At least 2 out of 3 patients transferred to a rehabilitation facility with 
AKI-D diagnosis recovered kidney function no longer requiring HD by the time of 
discharge. Dialysis-specific characteristics such as total days and intradialytic hypotension 
events may play a key role in the development of risk prediction models and ‘best clinical 
practices’ to promote kidney recovery in this susceptible population.
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Long Term Outcomes of Acute Tubular Necrosis and Acute Tubulointer-
stitial Nephritis
Sewon Oh,1 Junyong Lee,2 Jihyun Yang,3 Myung-Gyu Kim,4 Sang-Kyung Jo.5 
1Korea University Anam Hospital, Korea University College of Medicine, Seoul, 
Republic of Korea; 2Korea University Anam Hospital, Seongbuk-Gu, Seoul, 
Republic of Korea; 3Korea universtiy Anam hospital, Seoul, Republic of Korea; 
4National Institutes of Health, Bethesda, MD; 5Korea University Hospital, 
Seoul, Republic of Korea.
Background: Renal damage of acute tubular necrosis (ATN) and acute tubulointerstitial 
nephritis (ATIN) are considered reversible. However, the prevalence and long-term outcome 
of ATN and ATIN were unknown.
Methods: We included 4690 adult patients who had underwent kidney biopsy in two 
tertiary hospital in Korea during 1979-2017. We excluded patients with biopsy confirmed 
end stage renal disease (ESRD), previous kidney transplantation, malignancy, and 
inadequate biopsy specimen.
Results: Mean age was 39.0±15.5 years and 55% was male. Primary glomerulonephritis 
(PGN) was 3466 (65.4%), secondary glomerulonephritis (SGN) was 1088 (20.5%), and 
ATN or ATIN was 136 (2.6%). Patients with ATN or ATIN were significantly older compared 
than PGN or SGN (P<0.001) and had lower eGFR (P<0.001; 31.9±28.0, 74.5±36.6, and 
70.9±38.5ml/min/1.73m2, respectively). Mortality was the highest in patients with SGN 
(18.0%). Mortality in patients with PGN was 8.7%, and ATN or ATIN was 7.4% (P<0.001). 
The incidence of ESRD was much lower in patients with ATN or ATIN (2.9%) compared 
than PGN (14.4%) or SGN (15.0%) (P=0.001). During 156.8 ± 101.8 months follow up 
period, the adjusted risk of mortality was higher in patients with SGN compared than PGN 
(RR 2.156; 95% CI, 1.795-2.590). However, risk of mortality was not significantly different 
between PGN and ATN or ATIN. The adjusted risk of ESRD was significantly lower in 
patients with ATN or ATIN (RR 0.100; 95% CI, 0.037-0.268) compared than PGN, and 
the risks of ESRD was not different between PGN and SGN during 155.3±105.8 months.
Conclusions: The risk of long-term mortality was not different between PGN and ATN 
or ATIN. Although the risk of ESRD was significantly lower in patients with ATN or ATIN 
compared than GN, 2.9% of ATN or ATIN patients progressed to ESRD.
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AKI in Patients with Hip Fracture: A Single Centre Experience
Anna K. Forbes, Nivi Singh, Bhrigu Raj Sood. Epsom and St Helier NHS Trust, 
Carshalton, United Kingdom.
Background: Hip fracture is the most common serious injury in the elderly associated 
with high morbidity and mortality. These patients are high risk of developing acute kidney 
injury (AKI). We evaluated the incidence of AKI occurring anytime during admission and 
impact on length of stay (LoS) and mortality in patients admitted with hip fracture. St Helier 
Hospital Hip Fracture Unit is the best performing and second busiest in London according 
to the Department of Health’s Best Practice Tariff. We sought to establish if this good 
practice translated to reduced AKI incidence and improved outcomes.
Methods: This is a retrospective observational study of patients presenting to St Helier 
Hospital Hip Fracture Unit between January 2015 and December 2016. Patients were 
identified from the National Hip Fracture Database. AKI was identified from electronic 
pathology alerts and defined according to Kidney Disease Improving Global Outcomes 
criteria.
Results: 861 patients presented with hip fracture; 246 males (28.6%) and 615 females 
(71.4%). Mean age was 83.4 years (60-104 years) and median LoS was 23 days (IQR 11-27 
days). 16.4% (141) patients developed AKI; 11.1% (96) with AKI stage 1, 3% (26) with 
AK1 stage 2 and 2.6% (19) with AKI stage 3. AKI was associated with increased LoS. 
Death was adjusted for by assigning median LoS to those who died. Median LoS was 31 
days (IQR 16-36 days) in patients with AKI compared to 22 days (IQR 11-25 days) without 
AKI. Patients who developed AKI were less likely to be discharged home. 31.9% patients 
with AKI were discharged to their own home compared with 41.7% of patients without 
AKI. AKI was associated with increased unadjusted mortality. Patients with AKI had a 30 
day mortality of 16.3% compared with 4.4% in patients without AKI. 30 day mortality was 
15.6%, 19.2% and 15.8% in patients with AKI stage 1, 2 and 3, respectively. Patients with 
AKI had an inpatient mortality of 16.3% compared with 3.75% in patients without AKI. 
Inpatient mortality was 13.5%, 19.2% and 26.3% in patients with AKI stage 1, 2 and 3, 
respectively.
Conclusions: The incidence of AKI at our unit (16.4%) is significantly lower than 
previously published data (24%) but despite this, it is associated with increased LoS and 
mortality. This suggests early and intensive ortho-geriatrician and multi-disciplinary team 
input can improve AKI incidence and also outcomes in these patients.
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Temporal Trend of Utilization of Palliative Care Encounters in Hospital-
ized Patients with Dialysis Requiring AKI - A Nationwide Analysis
Yumeng Wen,1,2 Marcelo X. Hernandez Cuchillas,1,2 Changchuan Jiang,1,2 
David Mariuma,1,2 Di Pan.1,2 1Mount Sinai St Luke’s and Mount Sinai West, New 
York, NY; 2Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Dialysis requiring AKI (AKID) is major cause of in-hospital morbidity 
and carries high rate of mortality. We sought to investigate the temporal trend of the 
utilization of palliative care (PC) in hospitalized patients with AKID in United States.
Methods: We conducted a retrospective study using the national inpatient sample from 
2005 to 2014, to identify hospitalized patients complicated by AKID. The outcomes were 
the temporal trend and factors associated with utilization of PC in hospital. Multivariate 
logistic analysis was conducted to calculate odds ratios, adjusting for demographics, 
hospital characteristics, comorbidities and code status. Analysis was performed using Stata 
14.0.
Results: A cohort of 808,159 patients was identified from 2005 to 2014, of whom 
5.88% had palliative care consult referral. The incidence of palliative care contact increased 
from 0.41% in 2005 to 12.38% in 2014 (aOR 1.18, p<0.01). Patients who received palliative 
care contact, compared to who did not, were older (65.37 vs 62.50, p<0.01) and more likely 
to die in hospital (75.00% vs. 25.62%, p<0.01). Factors associated with more frequent 
PC referral included more cormobidities, Caucasian race (compared to other minorities), 
teaching hospitals, larger hospitals, hospitals region other than Northeastern area, Medicaid 
insurance and do not resuscitate status (shown in Table 1).
Conclusions: The use of palliative care consultation for patients with AKID who are 
admitted to hospitals, based on the NIS, is approximately 5.88%. Race, insurance status, 
hospital size, location and teaching status all were associated with differential rates of 
referral. There was a significant increase in palliative care use observed from 2005 to 2014.
SA-PO541 Poster Saturday
AKI: Clinical, Outcomes, Trials - II
Prognostic Tool in Dialysis Treated AKI
Tatiana Tanasiychuk, Alon Antebi, Daniel Kushnir, Jerom Marcuson, 
Amnon Gil, Tatyana Gorlachev, Victoria Svistunov, Muhammad Abd Elhalim, 
Oleg Sura, Victor Frajewicki. Department of Nephrology and Hypertension, 
Carmel Medical Center, Haifa, Israel.
Background: AKI is a common condition in hospitalized patients, having a mortality 
which may exceed 50%. Although dialysis may extend life in some subjects with AKI, 
elderly patients, with multiple comorbidities have a significantly shortened life expectancy. 
Attempts to identify prognostic models for a more accurate estimation of survival for AKI 
which was treated by dialysis were not successful. Utility of the “surprise” question to 
identify chronic dialysis patients with high mortality was reported, but studies on general 
population of seriously ill patients this question performs poor to modest predictive tool. 
The aim of our study was to identify the sensitivity of the “surprise” question in patients 
with unscheduled in-hospital started dialysis.
Methods: Prospective cohort study of all AKI patients who were treated by 
hemodialysis between January 1st, 2013 and December 31, 2017 in our center. During this 
period nephrologists had to answer the “surprise” question (Would I be surprised if this 
patient died in the next 6 months?) regarding every patient with AKI at the day of the first 
dialysis.
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Results: The cohort included 475 patients, 60% males, 60% diabetics, aged 72.8 ± 
12.2 (Range 20.6-98.7). In 31% of cases patients suffered from AKI and in 69% from Acute 
on Chronic Kidney Disease. In 41%, patients started dialysis in an ICU. The 30- days- 
all- cause mortality was 37% and the 6-months mortality rate 53%. The 7-days mortality 
was 20%. The Positive Predictive Value of the “surprise” question was 65%, the Negative 
Predictive Value 58% with a Sensitivity 58% and Specificity 65%.
Conclusions: The “surprise” question showed a weak predictive value for death in AKI 
patients treated by dialysis. Since patients requiring dialysis have a poor general prognosis, 
we need more sensitive instruments to choose the right patient for the right treatment 
avoiding unnecessary and futile treatments.
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AKI Outcomes as a Quality Paradigm: A Health Systems Approach
Prakash S. Gudsoorkar,1 Jwalant R. Modi,1 Karthikeyan Meganathan,1 
Anthony C. Leonard,1 Charuhas V. Thakar.1,2 1University of Cincinnati, 
Cincinnati, OH; 2Renal Section, Cincinnati VAMC, Cincinnati, OH.
Background: Acute kidney injury (AKI) affects 1-in-3 hospitalized patients; survivors 
face long-term consequences including high risk of re-admissions, end-stage renal disease 
(ESRD), or mortality. Retrospective studies estimate that only 15-20% of patients receive 
follow-up renal care within one year of discharge. At a large tertiary care health system, we 
operationalized and implemented a quality improvement program (QIP) to track discharge 
disposition and post-discharge follow-up renal care of all AKI consults.
Methods: By combining billing data and health-system wide informatics, we considered 
all non-ESRD, non-transplant hospitalizations receiving renal consults for each calendar 
quarter. The first hospitalization with an AKI renal consult in each quarter was considered 
as the index event. Discharge dispositions included expired/hospice, inter-facility transfers 
(long-term acute care/acute care), home with self-care or home-health, nursing home, and 
others. All survivors except inter-facility transfers were considered eligible for renal follow-
up metric defined as any renal contact within 90-days of discharge (office visits, chronic 
dialysis visits, or renal follow-up during readmission). We also tracked all-cause 90-day 
re-admissions. Chi-square and Kruskal-Wallis test was used for comparison across quarters.
Results: Between 10/2015 and 12/2017 (9 quarters) we identified 2,383 AKI consults 
(60% male, 64% White). Overall, 22% expired/discharged to hospice (18% to 25% across 
quarters; p = 0.70); 12% inter-facility transfers; and 66% were eligible for renal follow-up 
metric (23% home with self-care; 18% home with home-care; 23% rehab-nursing home; 
2% others). Of the eligible patients, 42% met the metric (range from 39% to 49% across 
quarters p=0.09); renal office visits occurred in 29% (range across quarters 22% to 37%), 
with a median time to renal visit of 31 days (q1, q3, 18, 49). Overall 90-day re-admission 
rate was 40% (range 35 to 46% across quarters; p=0.29), with median time to re-admission 
of 17 days (q1, q3, 7, 42).
Conclusions: This is the first report of operationalizing system-wide AKI metrics in 
real-time and can inform optimal strategies to improve post-discharge care in AKI. Such 
informatics-based QIP have the potential to plan and implement targeted resource allocation 
and improve patient and process outcomes.
Funding: Clinical Revenue Support
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Integrating Electronic Alerts and Clinical Decision Support Systems to 
Improve Diagnosis and Management of AKI
Shina Menon,1,2 Hong Wu,1 Rod Tarrago,1,2 Karyn Yonekawa.1,2 1Seattle 
Children’s Hospital, Seattle, WA; 2Pediatrics, University of Washington, Seattle, 
WA.
Background: Acute kidney injury(AKI) is a common clinical event with severe 
consequences. It is associated with prolonged hospital stay, increased risk of mortality and 
progression to chronic kidney disease. It is often underrecognized and underdiagnosed as 
seen in studies with significant discrepancy in incidence based on methods (administrative 
data vs chart review). Early, accurate diagnosis and correct management can improve the 
standard of care and patient outcomes
Methods: This is preliminary data from an ongoing prospective intervention study 
across all non-nephrology, non-intensive care patients (6 mo-18yrs) at Seattle Children’s 
Hospital. Our aim was to see if an electronic-alert (e-alert) combined with a clinical decision 
support system (CDSS) can improve detection and outcome of AKI. We developed an 
automated real-time e-alert using Kidney Disease Improving Global Outcomes (KDIGO) 
criteria. E-Alert with stage of AKI was sent as a text page to the contact provider in a 
patient’s electronic health record. It was linked to a CDSS providing basic guidelines on 
AKI management. The CDSS did not place orders or consults automatically.
Results: 83 AKI alerts were recorded across both phases(Table). Both groups had 
similar baseline characteristics including age, admitting service, history of transplant or past 
AKI. There was significant difference in the recognition and documentation of AKI (41%, 
pre-alert phase vs 80%, alert phase, p<0.005). More renal consults were obtained for severe 
AKI (≥KDIGO Stage 2) in the alert phase (86.6% vs 36.3%, p<0.005). A higher proportion 
of patients in alert phase showed return to a baseline kidney function by discharge. Data on 
follow up and long term outcome is awaited.
Conclusions: Our study shows that AKI remains under diagnosed. E-alerts improve 
the recognition of AKI, enabling providers to intervene early. They encourage nephrology 
consultation for severe AKI. This may improve outcomes of children with AKI
Key differences between the study phases
* p<0.005
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Real Time Utilization of TIMP2*IGFBP7 in ICU Patients: A Quality 
Initiative
Jay L. Koyner,1 Samantha Gunning,1 Alissa Kunczt,1 Sharon A. Trevino,1 Siaw 
li Chan,2 Sarah E. Groboske,1 Edward K. Leung,3 Kiang-Teck J. Yeo.1 1University 
of Chicago, Chicago, IL; 2Rochester Regional Health, Rochester, NY; 3The 
University of Chicago, Chicago, IL.
Background: Little is known about the real-time clinical use of urinary [tissue inhibitor 
of metalloproteinase-2]*[insulin-like growth factor binding protein 7] (Nephrocheck, 
Astute Medical) (NC) in mixed ICU patients at risk for acute kidney injury (AKI).
Methods: We conducted a single center before and after quality initiative assessing 
outcomes in ICU patients at risk for severe AKI (defined as elevated cardiovascular or 
pulmonary SOFA score or having KDIGO Stage 1 AKI). We compared 70 retrospective 
patients who had NC measured but never clinically reported with 60 prospective patients 
who had NC reported with clinical guidance about their severe AKI risk. We assessed 
patient outcomes including maximal AKI stage, need for RRT, nephrotoxin exposure and 
need for nephrology consult.
Results: There was no difference in age, race, gender, baseline hypertension, 
diabetes, CKD, baseline serum creatinine (SCr) between the retrospective and prospective 
cohorts. Compared to prospective patients, retrospective patients had higher APACHE II 
scores(p<0.001), but there was no difference in the need for vasoactive medications(p=0.87). 
On the day the biomarker was measured both SCr and NC were higher in the prospective 
cohort.(Table) Despite higher NC values in the prospective cohort there was no difference 
in the development of Stage 2/3 AKI (p=0.72) or the need for RRT (p=0.68). There was a 
trend toward decreased mortality in the prospective group (p=0.08). The prospective cohort 
was more likely to have a nephrology consult in the 24 hours following NC measurement. 
Prospective patients with a NC>2.0 (n=19) were less likely to be exposed to a nephrotoxins 
(NSAIDs, Aminoglycosides, amphotericin, r adiocontrast and diuretics) over the first 48 
hours compared to retrospective patients with NC>2.0 (n=12)(p<0.01).
Conclusions: Real-time NC measurement decreases nephrotoxin exposure in at risk 
patients, increases nephrology-based care and improves ICU patient outcomes.
TIMP2*IGFBP7 Outcomes
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AKI Awareness Among Hospitalized Survivors of AKI
Joseph Lunyera, Aviel N. Alkon, Jennie Riley, Cassandra Bowman, 
Dinushika Mohottige, Jennifer St. Clair Russell, Clarissa J. Diamantidis. Duke 
University School of Medicine, Durham, NC.
Background: Low health literacy (HL) has been linked to poor patient awareness 
of health conditions, particularly chronic kidney disease (CKD). Little is known about 
patients’ awareness of AKI, and the role of HL. Using data from the Change AKI study, 
we examined the association of patient and clinical factors with AKI awareness among 
hospitalized survivors.
Methods: The Change AKI Study is an ongoing pilot study of an AKI educational 
intervention for hospitalized survivors of AKI at Duke University Hospital, seen in 
consultation by an inpatient nephrology service, and enrolled beginning in 2017. All 
participants completed baseline and 1-month surveys of AKI-related risk factors and 
awareness. We defined adequate HL at baseline as a Rapid Estimation of Health Literacy 
Measure (REALM-SF) score ≥7. The primary outcome was baseline AKI awareness, 
defined as a “yes” response to the question “Before right now, did anyone in the hospital tell 
you that you had acute kidney injury?” We used multivariate logistic regression to examine 
the association of HL with baseline AKI awareness, adjusted for patient demographic 
(age, sex, race, education) and clinical (severity of AKI, need for dialysis, baseline CKD) 
factors. In a post hoc analysis, we examined the association of discharge-related factors 
(AKI in discharge summary, instructions, or schedule follow-up care) with AKI awareness 
at follow-up among those previously unaware at baseline.
Results: Among 61 AKI survivors, 46% were aware of their AKI diagnosis at baseline 
and 78% had adequate HL. HL was not associated with AKI awareness (odds ratio 2.25, 
95% confidence interval 0.61-8.31), even after accounting for demographic or clinical 
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factors. Of 45 participants at follow-up, 20% and 68% had AKI mentioned in their discharge 
instructions and summaries, respectively. Only 37% had scheduled follow-up care for AKI. 
Of 30 participants who were unaware at baseline, 43% were aware at follow-up; discharge-
related factors were not associated with new AKI awareness.
Conclusions: AKI awareness in hospitalized patients seems unrelated to HL, 
demographic or clinical factors. Discharge-related educational and follow-up processes are 
suboptimal and need improvement. Multifactorial interventions targeting AKI awareness 
need further investigation.
Funding: NIDDK Support
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Nephrology Consultation After AKI Can Improve Patients’ In-Hospital 
Survival
Jeonghwan Lee,1 Ji Young Ryu,2 Hyung Eun Son,2 Ho Jun Chin,3 Ki Young Na,3 
Sejoong Kim.3 1Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, 
Republic of Korea; 2Internal Medicine, Seoul National University Bundang 
Hospital, Seongnam, Republic of Korea; 3Seoul National University Bundang 
Hospital, Seong nam, Republic of Korea.
Background: The significance of nephrology consultation in patients with acute 
kidney injury (AKI) is not well established.
Methods: We enrolled a total of 20,914 patients who were admitted to the Seoul 
National University Bundang Hospital from January 1, 2013 to December 31, 2013. All 
clinical and laboratory data were retrieved retrospectively from the electronic medical 
record database.
Results: In total, 2,603 (12.4%) patients had AKI during admission (8.7% AKI stage 
1, 2.1% AKI stage 2, 1.6% AKI stage 3). Among the 2603 patients with AKI, 446 (17.1%) 
patients were referred to nephrologists for consultation. Patients who were referred to 
nephrologists showed characteristics of older age (68.7 ± 14.6 vs. 66.3 ± 15.7 years old, 
P = 0.0002), male preponderance (60.8% vs. 55.6 %, P = 0.045), more surgical operation 
(39.7% vs. 29.6%, P < 0.001), more ICU care (51.8% vs 24.1%, P < 0.001), increased 
baseline creatinine level (1.51 ± 1.58 vs. 1.05 ± 1.28, P < 0.001), high comorbidity score 
(0.89 ± 1.00 vs. 0.67 ± 0.75), and more advanced AKI stage (eg. AKI stage 3, 33.6% vs. 
9.0%, P < 0.001). Overall, patients who were referred to nephrologists for consultation 
showed similar survival rate compared with patients who were not consulted to nephrologist 
(log-rank P = 0.223, HR 1.190 (0.899-1.575). After propensity score matching (1:1, n= 
359 in both group), both group showed comparable clinical characteristics, and nephrology 
consulted patients showed better survival outcomes (log-rank P = 0.07, HR 0.614 (0.428-
0.881). The time from AKI to nephrology consultation and time to answer after consultation 
did not significantly affect patient survival.
Conclusions: Patients with AKI who were consulted to nephrologists have a better 
survival prognosis than those who were not. AKI patients should be encouraged to be 
consulted to nephrologists for appropriate management and improvement of clinical 
outcomes.
Propensity Score Matched Patients Survival after AKI according to the Nephrology 
Consultation.
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Provider-Level Exposure to AKI Alerts in an Ongoing Randomized Trial
Francis P. Wilson,1 Melissa Martin,1 Yu Yamamoto,6 Erica Moreira,6 
Chirag R. Parikh,2 Harold I. Feldman,3 Amit X. Garg,4 Paul M. Palevsky,5 
Ugochukwu C. Ugwuowo,6 Aditya Biswas.6 1Yale School of Medicine, New 
Haven, CT; 2Yale University and VAMC, New Haven, CT; 3University of 
Pennsylvania, Philadelphia, PA; 4London Health Sciences Centre, London, ON, 
Canada; 5University of Pittsburgh/VA Pittsburgh Healthcare System, Pittsburgh, 
PA; 6Yale University, New Haven, CT.
Background: Electronic alerts for acute kidney injury (AKI) are increasingly 
considered in clinical care because of the potential harms that may come from missed 
diagnoses of AKI. Alert fatigue, however, may reduce the effectiveness of AKI alerts.
Methods: The Electronic Alerts for AKI Amelioration (ELAIA-1) trial began in March 
2018 and will randomize 6,030 patients to real-time, electronic health record-based AKI 
alerts or usual care across 6 hospitals. Alerts fire when the electronic health record is opened 
by an MD, NP, or PA while AKI diagnostic criteria are met. In this preliminary analysis, we 
describe the differential exposure to AKI alerts at the provider level.
Results: Two months into the study, 10,665 alerts had fired for 217 patients with AKI 
over a six-week period, at a median of 30 (IQR 13-72) alerts per patient. At the patient 
level, the median alert duration was 1.1 (0.5-2.9) days. A total of 996 unique providers 
were exposed to alerts with a median of 0.09 (.05-0.31) alerts per day per provider. Fellows 
received the most alerts per day while attending physicians and PAs received the fewest. 
Alert burden was highest in the ICU (Figure) and substantially lower in the hospital wards 
and emergency department.
Conclusions: Despite the large total number of alerts, provider alert burden was 
generally low. Fellows experienced the highest median number of alerts per day, a potential 
signal for higher risk of alert fatigue. Providers caring for patients in the ICU may also be 
at higher risk of alert fatigue.
Funding: NIDDK Support
Exposure to AKI Alerts by Provider Type
SA-PO548 Poster Saturday
AKI: Clinical, Outcomes, Trials - II
Focused Ultrasound in Nephrology: A Nephrology Fellow’s Perspective
Muhammad O. Saleem,1 Colleen S. Boyle,1 Azeem Mohammed,1 
John J. White,1,2 Laura L. Mulloy,1,2 N. Stanley Nahman.1,2 Nephrons@AU 
1Medical College of Georgia, Augusta University, Augusta, GA; 2Norwood 
VAMC, Augusta, GA.
Background: The portable bedside ultrasound has recently been widely used in 
clinical practice. The time efficient bedside evaluation is invaluable in managing a patient. 
Focused Assessment with Sonography for Trauma (FAST) exam is a standard now in 
Emergency Medicine. Renal fellows are also being encouraged by training programs to 
use this evolving tool to improve patient care. So we performed a series of case studies to 
assess usefulness of portable bedside sonography on acute renal consults, termed Focused 
Ultrasound in Nephrology (FUN)
Methods: 14 patients were studied by a renal fellow and subjected to FUN. All patients 
had Acute Kidney Injury with an initial impression of pre, post or intra-renal etiology. 
Volume status was defined by physical exam. Bedside FUN was performed on the same 
day to see if it changed management. FUN is a quick 4 point bedside ultrasound on initial 
assessment of patients using a Philips Lumify portable ultrasound. 4 points chosen were 
bilateral lung scans at mid-axillary lines to look for lung B-lines, IVC for >50% collapsibility 
on inspiration and bladder scan for distension. Extra 2 point kidney ultrasound to look for 
kidney size and hydronephrosis was excluded because of lack of training.
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Results: 5 out of 14 patients’ management was changed on the basis of FUN: 6 scan 
findings validated the physical exam and 3 did not benefit from the study. 3 patients who 
were initially rendered euvolemic on physical exam, received IV diuretics when found to 
have significant lung B-lines (>3) with non-collapsing IVC by FUN. 2 patients who were 
initially rendered euvolemic had a change in diagnosis to pre-renal and received volume 
expansion when found more than 50% IVC collapsibility without significant lung B lines. 
In 3 cases bladder distension was picked up earlier at bedside and later confirmed by a 
sonogram performed by radiology.
Conclusions: We propose a 4-6 point FUN exam by fellows on acute renal consults. It 
is a real time assessment of intravascular volume status (pre-renal), pulmonary congestion, 
bladder obstruction (post-renal) and renal anatomy. Minor training is needed but potential 
benefits far outweigh the limitations of bedside FUN.
SA-PO549 Poster Saturday
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Comparison of Effectiveness of Renal Ultrasonography in the Work-up of 
AKI Before and After the Introduction of a Risk Stratification Model
Anna S. Gutman,1,2 Shimshon Wiesel,3 Naureen Narula,3 Nicholas Fuca,3 
Lazer Leifer,4 Suzanne E. El Sayegh.3 1Northwell Health, Brooklyn, NY; 
2Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY; 3Staten 
Island University Hospital, Staten Island, NY; 4SIUH, Brooklyn, NY.
Background: In 2010, Licurse et al, created the Licurse Model for risk stratification of 
patients according to the probability of having an obstructive cause of acute kidney injury 
(AKI). The researchers suggested that renal ultrasonography (RUS) findings do not change 
the management of patients with AKI in most cases. They found that performing RUS 
only in patients with a higher pre-test probability of urinary tract obstruction conserves 
resources. They constructed a model consisting of seven variables, which stratified patients 
with AKI into low, medium, and high risk of obstructive cause of AKI.
Methods: We conducted a retrospective chart review project looking at a total of 482 
patient charts, who had RUS performed in the work up of AKI from Jan. 2012 to Mar. 
2018 at Staten Island University Hospital. In the months of Oct. 2017 through Dec. 2017 
we performed an intervention, which consisted of educating the house staff regarding the 
appropriate use of a RUS in the work up of AKI. We compared the percentage of patients 
who met the criteria of the Licurse Model for ordering RUS, had positive findings on RUS, 
and had a change in clinical management based on the RUS findings before and after our 
intervention.
Results: We found that the percentage of patients who had RUS in the work up of 
AKI was 49.9% before the intervention, compared to 49.3% after the intervention, P-value 
0.936. The percentage of patients who had a change in clinical management based on RUS 
findings was 7.23% before the intervention, and 6.17% after the intervention, P-value 0.734.
Conclusions: Our results show that there was no improvement in the effectiveness of 
RUS for the work up of AKI after the intervention at our facility. Our intervention consisted 
of educating the resident physicians, and a small number of the attending physicians about 
the proper use of RUS for the work up of AKI.
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Absence of Hydronephrosis Does Not Exclude Obstructive Nephropathy
Abhilash Koratala,1 Olanrewaju A. Olaoye.2 1University of Florida, Gainesville, 
FL; 2University of Florida, Division of Nephrology, Gainesville, FL.
Introduction: Clinicians should be aware of the pitfalls associated with diagnostic 
renal imaging.
Case Description: A 63-year-old man with a history of nephrolithiasis and neurogenic 
bladder requiring chronic indwelling urinary catheter was admitted for urinary tract 
infection and acute kidney injury (AKI) with a serum creatinine of 3.6 mg/dL (baseline 
~1.9-2.2). Bedside renal sonogram did not demonstrate hydronephrosis or nephrolithiasis 
[Figure-1A,B]. Non-contrast CT scan of the abdomen also was negative for hydronephrosis 
but showed a 2.6 cm staghorn-appearing calculus in the right kidney [Figure-1C]. As 
the patient appeared dehydrated, he was treated with intravenous hydration along with 
antibiotics. However, renal function continued to worsen. Because of high index of 
suspicion for obstructive nephropathy, a radioisotope-lasix renogram was performed, which 
demonstrated complete obstruction on the right [Figure-2A]. Moreover, right kidney had a 
differential function of ~70%, which explains AKI with unilateral obstruction. Interestingly, 
a repeat renal sonogram demonstrated mild hydronephrosis and calculus in the right kidney 
[Figure-2B,C]. Serum creatinine improved significantly after nephrostomy tube placement, 
reaching baseline in a few days.
Discussion: Renal imaging can be negative for hydronephrosis in the setting of 
volume depletion. It should be repeated after volume repletion if the index of suspicion for 
obstructive nephropathy is high. Radioisotope renography is beneficial in selected cases. 
Early diagnosis is crucial for timely intervention and prevention of irreversible renal injury.
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Association of Body Mass Index with Outcomes in a Critically Ill 
Population on Renal Replacement Therapy
Sophia L. Ambruso,1 Sarah Faubel,1 Benjamin Griffin,2 Anna J. Jovanovich,3 
Jessica B. Kendrick,4 Zhiying You,5 Paul M. Palevsky.6 1University of Colorado 
Denver, Denver, CO; 2University of Colorado, Aurora, CO; 3Denver VA / 
University of Colorado, Denver, CO; 4University of Colorado School of 
Medicine, Aurora, CO; 5UC Denver, Aurora, CO; 6University of Pittsburgh/VA 
Pittsburgh Healthcare System, Pittsburgh, PA.
Background: The prevalence of obesity is rising in the critically ill population. Acute 
kidney injury (AKI) is a common complication seen in the intensive care unit (ICU) with 
5% requiring renal replacement therapy (RRT). Limited data exists on the association of 
body mass index (BMI) and outcomes in patients on RRT in the ICU. In our study, we 
investigated the impact of very high and very low BMI on mortality rates.
Methods: We conducted a secondary analysis of the Acute Renal Failure Trial Network 
(ATN) database, which compared less-intensive to more-intensive RRT dosing in the ICU 
population with AKI. Weights >128.5kg, which exceeded the max dosing capabilities of 
the Prisma machine at the time, were excluded. In this analysis, patients were categorized 
into BMI quintiles; Q1 (<23.5kg/m2, n=173), Q2 (23.5-26.2kg/m2, n=174), Q3 (26.21-
28.39kg/m2, n=173), Q4 (28.4-32.77kg/m2, n=174) and Q5 (≥32.78kg/m2, n=174). Q3 was 
the comparison value. Our primary endpoint was 60-day mortality. Logistic regression was 
used to adjust for demographics, SOFA score, Charlson score and treatment strategy.
Results: Participants were mainly white (79%) males (70%) with a mean age of 
60 ± 15.3 and overall mortality rate of 52%. Those in the highest quintile of BMI had a 
lower mortality rate (mortality rate 44% vs. 53%, 59%, 51% and 56% in quintiles 1,2,3 
and 4, respectively). However, compared to quintile 3, those in the highest quintile did not 
have significantly lower odds of mortality in unadjusted or adjusted models. Compared 
to quintile 3, lower quintiles of BMI did not have a significant association with mortality.
Conclusions: Very high and very low BMI was not associated with an increased risk of 
mortality in critically ill patients requiring RRT. The small number of patients per quintile 
limited the power of this study. Larger studies analyzing the impact of BMI on mortality in 
critically ill patients with AKI is needed.
Multivariate analysis for 60-day ICU mortality
Model 1: Age, race, gender
Model 2: SOFA score, Charlson score, Treatment strategy + Model 1
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Analysis of Survival After Initiation of Continuous Renal Replacement 
Therapy in Patients with Extracorporeal Membrane Oxygenation
George Kuo. Nephrology, Chang Gung Memorial Hospital, Linkou, Taoyuan, 
Taiwan.
Background: No study has specifically investigated the duration of continuous 
renal replacement therapy (CRRT) in patients who suffered acute kidney injury during 
extracorporeal membrane oxygenation (ECMO) support. However, there are concerns that 
prolonged CRRT may be futile.
Methods: A retrospective population-based cohort study using Taiwan National Health 
Insurance Research Database data collected between January 1, 2007 and December 31, 
2013. Patients who received ECMO and CRRT during the study period were included. We 
divided the patients into three groups based on the duration of CRRT received: ≤ 3 days, 
4–6 days, and ≥ 7 days.
Results: The overall survival after discharge did differ significantly among the three 
CRRT groups. The patients who received CRRT ≥ 7 days had a higher risk of ESRD than 
did those who received CRRT ≤ 3 days (adjusted hazard ratio [aHR] 3.46, 95% confidence 
interval [CI] 1.47–8.14) and between 4 and 6 days (aHR 3.10, 95% CI 1.03–9.29). The 
incidence of ventilator dependent was higher in the patients with CRRT ≥ 7 days than 
in those with ≤ 3 days (aHR 2.45, 95% CI 1.32–4.54). The CRRT ≥ 7 days group also 
exhibited a higher readmission rate than did the 4–6 days and ≤ 3 days groups (aHR 1.43, 
95% CI 1.04–1.96 and aHR 1.67, 95% CI 1.13–2.47, respectively).
Conclusions: Our study found similar long-term survival but increased long-term 
ESRD and ventilator dependency among the ECMO patients who underwent CRRT for 7 
days or more. These results offer reason to be concerned that this aggressive form of life 
support may maintain patient survival but do so at the cost of long-term disabilities and, 
consequently, a lower quality of life
Funding: Private Foundation Support
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Platelet Decrease Following Continuous Renal Replacement Therapy 
(CRRT) Initiation Predicts Mortality in Patients with Severe AKI
Benjamin Griffin,1 Nigel Arruda,1 Anna J. Jovanovich,2 Katja M. Gist,3 
Muhammad Aftab,4 Diana I. Jalal,5 Sarah Faubel.6 1University of Colorado, 
Aurora, CO; 2Denver VA / University of Colorado, Denver, CO; 3University of 
Colorado, Children’s Hospital Colorado, Aurora, CO; 4University of Colorado, 
Anschutz Medical Center, Aurora, CO; 5University of Iowa, Iowa City, IA; 
6University of Colorado Denver, Denver, CO.
Background: Thrombocytopenia is common in critically ill patients and is associated 
with increased mortality. Recent data suggest that CRRT is associated with decreased 
circulating platelet levels, possibly due to consumptive platelet-filter interactions. The 
impact of this platelet decrease on mortality is unclear. The purpose of this study was to 
examine the impact of platelet decrease following CRRT initiation on in-hospital mortality.
Methods: We conducted a retrospective analysis of adult patients initiated on CRRT 
at the University of Colorado Hospital between July 2015 and September 2016. Patients 
who died < 24 hours after CRRT initiation were excluded. Patients were categorized based 
on the percentage decrease from pre-CRRT levels to nadir following CRRT initiation: (1) 
no decrease (platelet increase from baseline), (2) mild decrease (0-50% decrease), and (3) 
severe decrease (>50% decrease). The primary outcome was in-hospital mortality. Logistic 
regression was used to adjust for SOFA score (excluding platelet component), body mass 
index (BMI), gender, and baseline platelets.
Results: A total of 154 cases met inclusion criteria. Platelet counts decreased in 101 
(65.6%) patients and 38 (24.7%) had a decrease of >50%. In-hospital mortality occurred 
in 72 (46.7%) patients. Patients with a severe decrease in platelets were 3.16 times more 
likely to die in the hospital compared to patients with an increase in platelets after adjusting 
for confounders (Table 1). In this study, <50% platelet decrease was not associated with 
mortality.
Conclusions: Platelet consumption following CRRT initiation is common, and a severe 
decrease is independently associated with mortality after adjusting for confounders. The 
mechanism of platelet decrease and its impact on mortality in patients requiring CRRT 
merits further study.
Funding: Other NIH Support - T32 DK 007135
Table 1. Effect of platelet decrease in final multivariate model for in-hospital mortality
*Platelet decreases are in comparison to patients with an increase in platelets following
CRRT initiation. The model was also adjusted for SOFA score (minus platelet component), 
Gender, BMI, and baseline platelets.
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Continuous Renal Replacement Therapy Is Associated with Acute 
Myocardial Injury in Critically Ill Patients
Marat Slessarev,1 Fabio R. Salerno,2 Christopher W. McIntyre.3 1University of 
Western Ontario, London, ON, Canada; 2Clinica Nefrologica H San Gerardo, 
Monza, Italy; 3London Health Sciences Centre, London, ON, Canada.
Background: Intermittent renal replacement therapy induces cardiac stunning in 
chronic hemodialysis (HD) and acute kidney injury (AKI) patients. In chronic HD, recurrent 
stunning contributes to heart failure and cardiac death, with ultrafiltration and intra-dialytic 
hypotension being the principal determinants of this injury. Continuous renal replacement 
therapy (CRRT), with its lower ultrafiltration rates and improved hemodynamic profile, 
should protect against cardiac stunning in AKI. We assessed whether CRRT is associated 
with cardiac stunning in critically ill patients with AKI.
Methods: We prospectively measured cardiac function using global and segmental 
longitudinal left ventricular (LV) strain derived from transthoracic echocardiography in 11 
critically ill patients who were started on CRRT for AKI. We compared measurements at 
4, 8 and 24 hours to baseline immediately prior to initiation of CRRT, with each patient 
serving as their own control. We also recorded blood pressure, heart rate, dose of vasoactive 
medications and ICU mortality.
Results: 10/11 patients developed new regional cardiac stunning, with 8/11 within 4 
hours of starting CRRT, despite stable hemodynamics. The number of affected LV segments 
varied from 1 to 11 (out of 12). The stunning occurred both in patients with preserved and 
impaired baseline cardiac function, and 7/11 patients died in the ICU.
Conclusions: Initiation of CRRT in critically ill patients with AKI is associated with 
cardiac stunning despite stable hemodynamics. This mechanism may explain lack of 
clinical benefit of CRRT over intermittent modalities and warrants further investigation to 
improve cardiovascular outcomes in critically ill patients with AKI.
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The Impact of Early Initiation of Continuous Renal Replacement Therapy 
in Critically Ill Patients with AKI
Junyong Lee, Jihyun Yang, Sang-Kyung Jo, Sewon Oh, Myung-Gyu Kim. 
Korea University Anam Hospital, Seongbuk-Gu, SEOUL, Republic of Korea.
Background: The acute kidney injury (AKI) in ICU patients is one of a risk factor 
for mortality ICU patients. Continuous renal replacement therapy (CRRT) widely used 
in various situation, but the optimal timing for initiation of CRRT in critically ill patients 
with AKI remains controversial. The purpose of this study is to investigate the impact of 
early, preemptive initiation on outcomes of AKI patients in ICU compare to classic, delayed 
initiation.
Methods: This is two center retrospective review from 2014 to 2017. Any type of 
stage IV cancer patients, CRRT duration less than 24 hours, end-stage renal disease with 
hemodialysis or peritoneal dialysis or kidney transplanted patients were excluded. The 
primary clinical outcome variables were 90-day Mortality and Renal recovery. Renal 
recovery was defined by creatinine clearance (≥15 mL/minute) with no need for renal 
replacement therapy at 90 days.
Results: Total 1152 patients are included, 583 patients were analyzed. Compare to 
delayed initiation group, early initiation group had lower eGFR(80 vs 52 mL/min/1.73m2, 
p<0.001), more chronic kidney disease patients which is defined eGFR lower than 
60 mL/min/1.73m2 (59 vs 19%, p<0.001), more extra-corporeal membrane oxygenation 
application (1 vs 8%, p=0.005), longer survival period (42.2 vs 58.01 days, p=0.03), severe 
inflammatory/infectious condition (leukocytosis and higher C-reactive protein level). 
Ventilator care and higher APACHE-II score, classic initiation of CRRT were risk factors 
for non-real recovery at 90day. Elderly, CKD, underlying liver disease, higher APACHE-II 
score, ECMO, and delayed initiation were risk factors for 90-day mortality.
Conclusions: Delayed initiation of CRRT was independently associated with 90-day 
mortality. They showed lower renal recovery than the non-classic group. Delayed initiation 
of CRRT was independently associated with greater odds of non-renal recovery. Initiating 
CRRT in critically ill patients with AKI should not be delayed until fulfillment of classic 
indications.
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Modified APACHE II and SOFA Scores in Patients Requiring Continuous 
Renal Replacement Therapy
Yaerim Kim,1 Dong Ki Kim,1 Ho Jun Chin,2 Ki Young Na,2 Kwon Wook Joo,1 
Yon Su Kim,1 Sejoong Kim,2 Seung Seok Han.1 1Seoul National University 
Hospital, Seoul, Republic of Korea; 2Seoul National University Bundang 
Hospital, Seong nam, Republic of Korea.
Background: Based on the worse outcomes of intensive care unit patients, acute 
physiology and chronic health evaluation II (APACHE II) and sepsis-related organ failure 
assessment (SOFA) scores have been frequently used to predict mortality. Nevertheless, 
these prediction models have not been optimized to the patients receiving continuous renal 
replacement therapy (CRRT) because of acute kidney injury.
Methods: A total of 828 patients who underwent CRRT from June 2010 to December 
2015 were retrospectively reviewed. All the components of APACHE II and SOFA were 
collected at the time of starting CRRT. End-points were 7-day and 30-day mortality. Based 
on the restricted cubic spline results, modified scores were assigned to each variable. 
Additionally, abbreviated model including the best predictable variables alone was 
developed after stepwise selection analysis.
Results: The prediction powers indicated by c-statistics were 0.683 and 0.668 for 7- 
and 30-day mortality by APACHE II; and 0.683 and 0.660 for 7- and 30-day mortality by 
SOFA. After modification of these models, the prediction powers increased up to 0.765 for 
APACHE II and 0.775 for SOFA. Using multivariate stepwise analysis, the respiratory rate, 
FiO2, bilirubin, pH, and inotropics used were selected in the abbreviated 7-day mortality 
model (c-statistics = 0.765). For a 30-day mortality model, AaDO2, respiratory rate, 
Glasgow coma scale, hematocrit, whole blood cells, bilirubin, potassium, and inotropics 
used were selected (c-statistics = 0.771).
Conclusions: Modified APACHE II and SOFA models are better than the originals 
in predicting mortality of patients receiving CRRT, which may ultimately be helpful in 
clinical practice.
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Hypotension within One-Hour from Starting CRRT Is an Independent 
Predictor for In-Hospital Mortality
Khaled Shawwa,1 Panagiotis Kompotiatis,1 Brandon M. Wiley,2 Jacob Jentzer,1 
Kianoush Kashani.2 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN.
Background: In-hospital mortality in critically ill patients who require renal 
replacement therapy is high. Patients who receive CRRT may be at higher risk for 
hemodynamic instability that can have implications in terms of renal recovery and mortality.
Methods: This is a retrospective analysis of a cohort of patients admitted to the ICUs 
at a tertiary care hospital from December 2006 through November 2015 who underwent 
CRRT. The primary outcome was in-hospital mortality. Multivariate logistic regression was 
performed to identify independent predictors of in-hospital mortality. Hypotension within 
the first hour of CRRT initiation was defined as: MAP <60 mm Hg, SBP <90 mm Hg or 
a decline in SBP >40 mm Hg from baseline, a positive fluid balance more than 500 ml or 
increased vasopressor requirement.
Results: The analysis included 1,743 patients, 345 (19.8%) with ESRD and 1,398 
(80.2%) with AKI. The median age was 63 (IQR 53-73) years with 699 (40%) female, 
median Charlson comorbidity index 5 (IQR 3-7) and median SOFA on the day of CRRT 
initiation was 12 (IQR 9-14). Overall in-hospital mortality occurred was 50%. Hypotension 
within one hour of CRRT initiation occurred in 64% of the patients. Predictors of in-hospital 
mortality in univariate analysis included: SOFA score (OR 1.13 per 1 unit increase, 95% 
CI:1.10-1.16), mechanical ventilation (OR 1.6, 95% CI:1.2-2.1), hypotension within 1 hour 
(OR 1.6, 95% CI:1.3-1.9), AKI compared to ESRD (OR 1.9, 95% CI:1.5-2.5) and modified 
shock index (OR 2.1 per 1 unit increase, 95% CI:1.7-2.7). Hypotension within one hour 
of CRRT initiation remained an independent predictor of in-hospital mortality (OR 1.45, 
95% CI:1.15- 1.82, p=0.001), after adjusting for age, gender, SOFA score, mechanical 
ventilation, fluid balance between ICU admission and CRRT initiation, modified shock 
index, Charlson comorbidity index, AKI vs ESRD, ICU type, creatinine closest to CRRT 
initiation and ICU day number when CRRT was initiated.
Conclusions: Hypotension occurs frequently in patients receiving CRRT despite being 
chosen as a modality with better hemodynamic tolerance. Hypotension during the first 
hour after initiating CRRT is a significant independent risk factor for in-hospital mortality. 
Further studies are required to help understand this phenomenon given its implications for 
in-hospital mortality.
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Predictive Factors for Successful Discontinuation of Continuous Renal 
Replacement Therapy in AKI
Song in Baeg, Hyo jin Boo, Minjung Kim, Eun jeong Lee, Jung eun Lee, 
Wooseong Huh, Dae Joong Kim, Yoon-Goo Kim, Ha Young Oh, Hye 
Ryoun Jang. Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Republic of Korea.
Background: Although continuous renal replacement therapy (CRRT) is the standard 
treatment for severe acute kidney injury (AKI) in critically ill patients, there is no practical 
consensus for discontinuing CRRT. In this retrospective study, predictive factors for 
successful discontinuation of CRRT was investigated.
Methods: Adult patients (≥18 years) who received CRRT at Samsung Medical Center 
from June 2007 to June 2017 were included (n=4166). Patients with preexisting end 
stage renal disease (ESRD), patients who progressed to ESRD within 1 year after CRRT 
discontinuation or died within 7 days were excluded. Successful discontinuation of CRRT 
was defined as no requirement of RRT for 7 days after discontinuing CRRT. Patients were 
divided into the failure group and the success group. Clinical information and laboratory 
results were collected via electronic medical records.
Results: A total of 1158 patients were analyzed. There were no differences in 
comorbidities. The duration of CRRT was longer in the failure group. Mean arterial 
pressure (MAP) on discontinuation day (D0) was lower in the success group (failure vs. 
success, 80.86±12.56 vs. 78.95±12.51 mmHg, p=0.010). Urine output on the day before 
discontinuation (D-1) (140 vs. 648 mL/day, p<0.001) and D0 (253 vs. 1298 mL/day, 
p<0.001) and the proportion of patients who received vasopressors on D-1 (26.6% vs. 
43.1%, p<0.001) and D0 (19.1% vs. 34.8%, p<0.001) were higher in the success group. 
Serum potassium on D0 was lower in the success group (4.02±0.45 vs. 3.88±0.46 mmol/L, 
p<0.001). Multivariable analysis showed that urine output on D0 (odds ratio [OR], 1.621; 
95% confidence interval [CI], 1.468 to 1.789; p<0.0001), difference in HCO3 between 
D0 and D-1 (OR, 1.070; CI, 1.009 to 1.135; p=0.0231) and vasopressor use on D0 (OR, 
2.306; CI, 1.348 to 3.946; P=0.0023) were significant predictive factors for successful 
discontinuation of CRRT. MAP on D0 (OR, 0.980; CI, 0.969 to 0.992; p=0.0007) and serum 
potassium on D0 (OR, 0.592; CI, 0.732 to 0.809; p=0.001) were also significant predictive 
factors.
Conclusions: Our study showed that greater urine output, maintenance of adequate 
blood pressure with vasopressors, and lower normal range of serum potassium on 
discontinuation day were associated with successful discontinuation of CRRT.
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CVVH Yields Better Renal Outcomes Than Intermittent Hemodialysis 
Among Traumatic Intracranial Hemorrhage Patients with AKI: A 
Nationwide Population-Based Retrospective Study in Taiwan
Min-Feng Tseng,2 Chia-chao Wu.1 1Tri-Service General Hospital, Taipei, 
Taiwan; 21. Division of Nephrology, Department of Internal Medicine, Zuoying 
Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, 
Taipei City, Taiwan.
Background: Traumatic intracranial hemorrhage (TICH) patients with acute kidney 
injury (AKI) were reported to have a high mortality rate. Renal replacement therapy (RRT) 
is indicated for patients with severe kidney injury. This study aimed to compare the effects 
of different RRT modalities in terms of chronic dialysis rate among adult TICH patients 
with AKI.
Methods: A retrospective search of computerized hospital records from 2000 to 2010 for 
patients with a discharge diagnosis of TICH was conducted to identify the index cases. We 
collected the data of TICH patients with increased intracranial pressure combined with severe 
AKI who received intermittent hemodialysis (IHD) or continuous veno-venous hemofiltration 
(CVVH) as RRT. The outcome was dialysis dependence between 2000 and 2010.
Results: From a total of 310 patients who were enrolled in the study, 134 (43%) 
received CVVH and 176 (57%) received IHD. The risk of dialysis dependency was 
significantly lower in the CVVH group than in the IHD group (adjusted hazard ratio: 0.368, 
95% CI, 0.158–0.858, P = 0.034). Diabetes mellitus and coronary artery disease were risk 
factors for dialysis dependency. CVVH compared with IHD modality was associated with 
lower dialysis dependency rate in TICH patients combined with AKI and diabetes mellitus 
and those with an injury severity score (ISS) ≥16.
Conclusions: CVVH may yield better renal outcomes than IHD among TICH patients 
with AKI, especially those with diabetes mellitus and an ISS ≥16. Therefore, the beneficial 
impact of CVVH on TICH patients needs to be clarified in a large cohort study in future.
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AKI in Patients Requiring Extracorporeal Membrane Oxygenation
Fouad Kutuby,1 Jay L. Koyner,1 Rebecca Rose,2 Tae H. Song.1 1University of 
Chicago, Chicago, IL; 2University of Chicago Medicine, Chicago, IL.
Background: There is limited published data on the outcomes in those with AKI after 
extracorporeal membrane oxygenation (ECMO) cannulation.
Methods: We performed a single center retrospective study of patients who underwent 
ECMO cannulation between 1/2015 and 7/2017. We excluded patients with pre-existing 
End Stage Renal Disease (ESRD) and those who died within 24 hours of ECMO initiation. 
AKI was defined by the KDIGO criteria within 7 days of ECMO cannulation. Survival 
analyses were performed using the log-rank test.
Results: We found 117 patients but excluded 23(18 of whom died within 24 hours of 
ECMO). Of the remaining 94 patients 76(81%) received veno-arterial (VA-ECMO) and 
18 received Veno-venous (VV-ECMO). Of the 94 patients, 13(13.8%) did not experience 
AKI during their entire hospital stay. AKI prior to ECMO cannulation occurred in 42(44%) 
patients and 39(41%) patients only developed AKI after ECMO. Of those with AKI(n=81), 
16 developed Stage 2 AKI, 51 developed Stage 3 AKI of which 47(50%) received renal 
replacement therapy (RRT). AKI rates were not different across VA and VV ECMO(p=0.15). 
Patients with any AKI were more likely to die at 30 and 90 days compared to those without 
any AKI(p<0.01 for both). Figure A demonstrates no difference in 90 day mortality between 
those with pre-ECMO AKI compared to those with post-ECMO AKI (p=0.64). Those who 
did receive RRT(n=47) did not have significantly different pHs, hemoglobin or other pre-
ECMO co-morbidities (CKD, CHF, Diabetes) compared to those without RRT(n=47). In a 
multivariate model the presence of pre-ECMO vasopressors was an independent predictor 
for the need for RRT(OR(95%CI) 4.59(1.10-19.2)p=0.037). Patients requiring RRT had 
increased 90-day mortality compared to those without RRT(p<0.003) Figure B.
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Conclusions: AKI is common in the setting of ECMO. While there was no difference 
in mortality in those with pre versus post ECMO AKI, AKI requiring RRT significantly 
decreases patient survival at 90 days.
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Inhibition of PARP1 Attenuates Rat Renal Ischemia Reperfusion Injury
Christina Bracken,1 Katelyn Pulito,1 Jeff H. Stanwix,1 Robert W. Shine,1 
Mahati Krishna,2 Nan Ji,1 Effie Tozzo,1 Dominique Stickens.1 1Mitobridge, an 
Astellas company, Cambridge, MA; 2Syngene International Pvt. Ltd., Bangalore, 
India.
Background: Renal ischemia reperfusion injury (IRI) generates superoxide and other 
reactive species and induces PARP1 activation to repair ROS-mediated DNA strand breaks. 
However, PARP1 activation depletes NAD+ and ATP, and promotes pro-inflammatory 
signal transduction, all of which can exacerbate IRI. We hypothesized that inhibiting PARP1 
would decrease/prevent NAD+ depletion and reduce IR-induced acute kidney injury (AKI).
Methods: We evaluated the ability of a novel and selective PARP1 inhibitor, Cmpd 
A to boost NAD+ and mitochondrial respiration in control and cisplatin challenged human 
proximal tubule cells (PTC). Sprague-Dawley rats underwent a 50 minute bilateral IR 
and were administered Cmpd A (or vehicle), twice daily at 0.1, 0.3, 1, 5, or 15 mg/kg by 
intravenous injection for 2 days, beginning at 4 hours post reperfusion. Cmpd A activity was 
assessed by measuring renal PAR levels, NAD+ and its breakdown products, by ELISA or 
mass spectrometry. Renal injury biomarkers were measured in plasma at 24 and 48 hr post 
reperfusion and tubular injury was evaluated by histopathology. Gene expression analysis 
for inflammatory mediators and Vegfa were assessed using Nanostring technology.
Results: Cmpd A treatment increases NAD+ levels by 35% and enhances mitochondrial 
respiration under normal PTC culture conditions while preventing nephrotoxin-induced 
NAD+ depletion when PTC are treated with cisplatin. In the rat model of IR-AKI, Cmpd 
A lowers plasma creatinine and BUN dose dependently at 24 and 48 hr post injury. This 
translates to improved renal function via increased creatinine clearance and normalization 
of fractional excretion of Na+ (FENa). Assessment of kidney histopathology at 48 hr post 
reperfusion revealed that Cmpd A normalizes renal tubular architecture. In addition, Cmpd 
A treatment reduces IR-induced upregulation of inflammatory mediators and restores the 
downregulation of Vegfa gene expression.
Conclusions: Dosing of a selective PARP1 inhibitor after an ischemic AKI event in 
rats recovers renal and tubular function. Mechanistically, our data suggest that this effect is 
mediated by a reduction of pro-inflammatory signaling, preservation of Vegfa and increase 
of NAD+ levels.
Funding: Commercial Support - Astellas
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The Protective Effect of Klotho Against Contrast-Associated AKI via the 
Anti-Oxidative Effect
Kyoung Hye Kong, Hyung Jung Oh, Dong-Ryeol Ryu. Ewha Womans 
University, Seoul, Republic of Korea.
Background: Contrast-associated acute kidney injury (CA-AKI) is defined as AKI 
caused by the supplementation of iodinated contrast agents, and oxidative stress is one of 
its main factors. Klotho, an anti-aging gene, shows anti-oxidative activity and is expressed 
in renal tubular cells. We investigated the protective effect of klotho against CA-AKI via 
the anti-oxidative effect.
Methods: We used NRK-52E cell lines and iopamidol as the contrast agent. 
Experiments were performed after cell cultures were divided into one of three groups: 
the control, iopamidol, and iopamidol+recombinant klotho (rKL) groups. Moreover, the 
siRNA-mediated knockdown of klotho (siklotho) was also done to reveal the endogenous 
klotho effect. Cell viability and oxidative stress were measured, and real-time PCR and 
western blotting were performed. We also designed a CA-AKI mouse model with ketorolac, 
L-NAME and iopamidol, and performed experiments similar to our in vitro experiments.
Results: The viability of the NRK-52E cells significantly decreased, but oxidative 
stress significantly increased after 200 mgI iopamidol was supplemented for 1h compared 
to the controls. Protein and mRNA expressions of klotho also significantly decreased, while 
apoptotic markers (Bax/Bcl2, cleaved caspase3) increased significantly after iopamidol 
injection. However, the decrease in cell viability after iopamidol supplementation 
was significantly attenuated after the cells were exposed to rKL, and rKL mitigated the 
elevated apoptotic markers and oxidative stress under iopamidol injection. Additionally, 
the apoptotic markers and oxidative stress were significantly upregulated in the group of 
iopamidol-treated siklotho compared to the iopamidol-treated NTC group. Our in vivo study 
results showed similar trends to our in vitro experiments.
Conclusions: This study showed that klotho can protect against CA-AKI via the 
anti-oxidative effect. These findings provide new insight into the mechanisms behind the 
protective effect of klotho in CA-AKI.
Funding: Government Support - Non-U.S.
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Increased Soluble Guanylyl Cyclase Activity in Ischemia/Reperfusion 
Induced AKI Suppresses PGC-1a and Mitochondrial Biogenesis
Pallavi Bhargava,1,2 Rick G. Schnellmann.1 1Pharmacology and Toxicology, 
University of Arizona, Tucson, AZ; 2Drug Discovery and Biomedical Sciences, 
Medical University of South Carolina, Charleston, SC.
Background: Acute Kidney Injury (AKI) can result from numerous causes such as 
ischemia/reperfusion (I/R) injury. We have shown that mitochondrial biogenesis (MB) is 
persistently suppressed following diverse injuries and that stimulation of MB, by targeting 
PGC-1a, the master regulator of MB, promotes recovery of renal function. Soluble guanylyl 
cyclase (sGC) is a heterodimer that catalyzes the production of cGMP from guanosine 
triphosphate (GTP). cGMP can be increased by sGC activity or by pharmacological 
inhibition of phosphodiesterases (PDE) 3 and 5, enzymes that degrade cGMP. Although 
inhibition of PDE3 and 5 induces MB and promotes renal recovery in AKI models, the role 
of sGC in AKI has received minimal attention.
Methods: Mice underwent bilateral I/R and were euthanized 24 h later. Kidney 
function was determined by serum creatinine (SCr). Cell signaling was measured using RT-
qPCR and immunoblot analysis. sGC enzyme activity was determined by measuring cGMP 
in renal cortical homogenates.
Results: SCr increased 10-fold to 1.8 mg/dL 24 h after I/R injury. While renal cortical 
protein expression of the sGC subunits was not altered, sGC activity increased 1.6-fold in 
I/R mice compared to sham mice. Increased cGMP activated protein kinase G (PKG). In 
turn, phosphorylated p38, a target of PKG, increased in I/R mice. Phosphorylated FOXO1, 
a target of activated p38, also increased, inhibiting FOXO1 translocation into the nucleus. 
PGC-1a mRNA, a transcriptional target of FOXO1, decreased 24 h after I/R.
Conclusions: I/R injury initiates a signaling pathway comprised of sGC-cGMP-PKG-
p38-FOXO1-PGC-1a and resulted in decreased PGC-1a transcription. These results are 
consistent with previous findings demonstrating decreased PGC-1a in various forms of AKI 
and the suppression of MB.
Funding: Other NIH Support - National Institutes of Health National Institute of 
General Medical Sciences, Veterans Affairs Support
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Adipose Stem Cell-Derived Exosomes Afford Effective Survival Benefits 
and Functional Rescue from Severe, Progressive IRI-Induced AKI in Rats
Anna Gooch,2 Ping Zhang,2 Zhuma Hu,2 Christof Westenfelder.1 1University of 
Utah and VA Medical Centers, Salt Lake City, UT; 2SCT, Salt Lake City, UT.
Background: Bone marrow and Adipose-derived Mesenchymal Stem Cells (M/ASCs) 
are effective for prevention of Acute Kidney Injury (AKI). Yet when MSCs are given 48 hrs 
post-insult, a time at which severe clinical AKI is diagnosed and when no rescue therapy 
is currently available, they are ineffective or potentially damaging because the introduction 
of large cells (~50μm) into the compromised microvasculature may impair renal function. 
M/ASCs’ renoprotection is mediated by their paracrine release of anti-inflammatory and 
trophic cytokines and their exosomes. Exosomes signal, post uptake by target cells, through 
the lateral transfer of mRNAs, miRNAs, DNA, proteins, and lipids. Since ASC-derived 
exosomes can prevent AKI we tested whether their small size and ability to move through 
the compromised renal microvasculature might allow them to provide effective rescue 
therapy for late stage AKI.
Methods: Exosomes from Sprague Dawley (SD) rat ASCs were isolated post 24 hr 
culture in SFM, purified using the ExoQuick-TC kit, and characterized for size, protein and 
gene expression of relevant markers. I/R AKI (52 min bilateral renal pedicle clamp) was 
induced in female SD rats. If the SCr value on D2 was greater than that on D1, then rats were 
administered via left carotid artery either 1 ml of Vehicle (PBS; n=8), Exosomes (200 μg 
protein-equivalent; ~4x10e10 exosomes; n=6), or ASCs (2x10e6 ASCs; n=6) on D3.
Results: 1e6 ASCs secrete ~ 4.9x10e10 exosomes and other microvesicles (mode 136.7 
nm) and >95% express CD44 and CD29, and carry mRNAs of renoprotective genes expressed 
in ASCs. While both ASC and exosome administration improved survival over PBS, renal 
function only showed significant and sustained improvement in exosome-treated rats.
Conclusions: ASC-derived exosome therapy 3 days post progressive AKI, when renal 
blood flow is significantly impaired and when most clinical AKI is diagnosed, is superior 
to ASC therapy, likely due to their ability to deliver their renoproetective cargo into the 
compromised renal microcirculation. These data have, we posit, significant translational 
promise for the development of an effective rescue therapy for advanced AKI.
Funding: Commercial Support - SCT
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Transfer of Healthy Isolated Mitochondria in Established Injury Reduces 
Progression to Fibrosis
Kyle J. Alexander, Kailo H. Schlegel, Amandeep Bajwa. University of Virginia, 
Charlottesville, VA.
Background: Ischemia induces altered bioenergetics with increased mitochondrial 
swelling and reactive oxygen species (ROS) and ultimately degradation of cellular function. 
Therapeutic interventions that target to improve mitochondrial health to repair, reprogram 
or replace mitochondria to restore respiratory functions are beneficial for prevention and/or 
treatment of established disease.
Methods: Renal injury was assessed by plasma creatinine (PCr; mg/dl). 8-wk old 
C57BL/6 mice were i.v. injected with isolated mitochondria (50mcg, from healthy non-
ischemic mouse liver). 1d, 3d or 5d after unilateral IRI. Nephrectomy of contra-lateral 
control kidney was done on day 13. Change in fibrosis genes were measured by RTPCR 
and histology changes with Masson trichrome and picrosirius red were done on day 14. For 
in vitro studies, PT cells (TKPTS) were treated with 10 or 20 mcg of isolated mitochondria 
1d prior to analysis that included measurement of ATP levels, mitochondrial functions 
(Seahorse analyzer), cytokines (RTPCR), immunofluorescence microscopy (uptake 
efficiency) and flow cytometry (mitotracker dyes).
Results: In vivo studies demonstrated treatment of mice with 50 mcg of mitochondria at 
1d, 3d or 5d after IRI significantly protected compared to vehicle treated mice after IRI [Day 
14 PCr (0.6±0.04 (+1d) vs 0.68±0.18 (+3d) vs 0.57±0.18 (+5d) vs 1.54±0.16), p<0.05]. 
Transfer of labeled isolated mitochondria (mitotracker dye) signal was found in spleen (in 
macrophages) and kidney (in PT, identified with anti-CD13 antibody [labels brush border]). 
The +3d mitochondria treated kidneys had significantly lower levels of Acta and Col3a1 and 
significantly higher PGC1α gene expression compared to vehicle treated mice at day 14. 
In vitro studies demonstrate that treatment of TKPTS with mitochondria had significantly 
higher levels of ATP, higher basal oxygen consumption rate and spare respiratory capacity 
measured by Seahorse analyzer.
Conclusions: Our current study demonstrates that up take of healthy mitochondria by 
PT helps maintain bioenergetics through upregulation of mitochondria biogenesis gene, 
PGC1α. Treatment to mice with established AKI with mitochondria attenuates progression 
to fibrosis compared to vehicle treated mice. Mitochondria could be used as a therapeutic 
modality to lessen progression of AKI to CKD.
Funding: Other NIH Support - ASN Foundation Grant
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Kidney Injury Under Oxidative Stress Release CD36 and CD47 
Microparticles
Begoña Campos,1 Samuel P. Bockhorst,1 Keith L. Saum,1 Charuhas V. Thakar.1,2 
Kidney Injury Translational Research Group 1University of Cincinnati, 
Cincinnati, OH; 2Renal Section, Cincinnatin VAMC, Cincinnati, OH.
Background: Kidney epithelial cell damage is the major cause of acute kidney injury 
(AKI). Thrombospondin 1 (TSP-1) is released by renal epithelial cells and mediates 
kidney damage in murine ischemia reperfusion injury (IRI). TSP-1 exerts its inflammatory 
modulating effects through signaling of CD36 (pro-inflammatory) and CD47 (anti-
inflammatory) ligands. Given that CD36 reduces angiogenesis, and stimulates VEGF 
induced migration and apoptosis, whereas CD47 stimulate angiogenesis, these ligands 
may play a role in epithelial to endothelial cross-talk. We hypothesized that in both in vivo 
murine models of IRI and in vitro models of oxidative stress to human renal epithelial cells 
(h-RPTEC), CD36 and CD47 proteins will be released as MP significantly when compared 
to control.
Methods: h-RPTEC line was used and oxidative stress (induced by adding 0.03 mM 
of H2O2 for 1hr) was evaluated for MP release and apoptosis compared to controls. IRI was 
performed in C57BL/6 mice by renal pedicle clamp for 30 minutes followed by reperfusion 
compared to sham. Animals were euthanized at 48 hrs. Histology was performed by 
standard techniques to evaluate kidney damage. Citrate poor plasma was collected at 0, 12, 
48 hrs to measure urea (BUN). MP were measured with flow cytometry and were reported 
at 105 /ml and analyzed by flow jo software. Unpaired t test Welch’s correction were used 
for comparisons.
Results: h-RPTEC contained CD36 and CD47 receptors in the cellular membrane, 
confirmed by immunohistochemistry. Upon exposure to H2O2, cell viability study showed 
25% apoptotic, 15% in necrotic and 60% viable. A a significant increase of release of MP 
was observed for CD36 vs control (2.7 X105 MP/ml vs. 0.73 X105 MP/ml; p=0.001); and 
for CD47 vs control (31.84 105 MP/ml vs 2.51 105 MP/ml; p=0.001). For in vivo studies, 
compared to sham, IRI mice showed that MP containing CD36 were released at 12 hr and 
remained elevated at 48 hr. In contrast, CD47 showed an increase at 12 hrs and returned 
towards baseline by 48 hr. Analysis of percent expression showed that CD36 expression 
increased with time compared with CD47.
Conclusions: In murine and in vitro models of oxidative stress CD36 and CD47 are 
released as MP. Given the role of TSP-1 and other thrombomodulins in AKI, MP may serve 
as ligands to both potentiate epithelial cell injury as well as mediate cross-talk between 
epithelium and endothelium.
Funding: Clinical Revenue Support
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Microparticles Can Phenotype Ischemic and Nephrotoxic AKI
Begoña Campos,1 Samuel P. Bockhorst,1 Keith L. Saum,1 Charuhas V. Thakar.1,2 
Kidney Injury Translational Research Group 1University of Cincinnati, 
Cincinnati, OH; 2Renal Section, Cincinnati VAMC, Cincinnati, OH.
Background: Acute tubular necrosis is the major cause of acute kidney injury (AKI), 
occuring due to ischemia reperfusion injury (IRI) or nephrotoxicity (NT); however, it 
cannot be differentiated by biochemical or histological parameters. Although biomarkers 
allow earlier identification of AKI, they cannot discriminate cause-specificity, leading to 
impediment in translating novel therapies. Our prior work confirmed that CD10, CD13 and 
CD146 proteins on renal epithelial cells are released as microparticles (MP) upon exposure 
to oxidative or inflammatory stress. We evaluated whether these MP can discriminate IRI 
or NT in murine models.
Methods: In C57BL/6 mice, IRI was performed by clamping both renal pedicles for 
30 minutes followed by reperfusion and NT was induced by injecting intraperitoneal (IP) 
Cisplatin at 20 mg/kg. Sham mice underwent surgery without clamp in IRI and IP normal 
saline in NT. Mice were euthanized at 48 hrs and examined by standard techniques for renal 
histology. Citrate poor plasma was collected at 0, 12, 48 hrs. Blood urea nitrogen (BUN), 
neutrophil gelatinase associated lipocalin (NGAL); and MP containing CD10, CD13 and 
CD146 were measured using flow cytometry and analyzed by flow jo software. MP were 
expressed as 105/ml, and compared within each model over time, and across models by 
Chi-square tests.
Results: AKI was confirmed in IRI and NT samples by histology, BUN and NGAL 
levels at 48 hrs. In IRI (48 hrs), CD10 and CD13 MP increased by 1.77 and 1.5 fold 
respectively, but CD146 declined by 1.7 fold from baseline. In contrast, NT model showed 
decline of MP quantity at 48 hrs relative to baseline in CD10, CD13 and CD146 by 1.5, 
1.5 and 3.6 fold respectively. When examined across the models, then proportion of MP 
released at 48 hrs in IRI were 64% CD10, 6% CD13 and 30% CD146. Interestingly NT 
model showed distinctly different proportions: 6% CD10, 18% CD13 and 76% CD146 
quantitatively. (p<0.0001 for comparison across models)
Conclusions: Despite similar biochemical, histological and biomarker parameters, MP 
quantity changed over time differently in each model. More importantly, the pattern of MP 
proportions almost switched across IRI and NT models, allowing discrimnation of ischemic 
and toxic cell injury. MP measured in plasma can phenotype AKI based on cause-specificity 
and can lead to development of novel diagnostic or therapeutic strategies.
Funding: Other NIH Support - Intramural funds, Clinical Revenue Support
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β-Hydroxybutyrate Attenuates Renal Ischemia-Reperfusion Injury 
Through Its Anti-Pyroptotic Effects via Epigenetic Mechanism
Takaya Tajima,1 Ayumi Matsui,1 Tomoaki Ito,1 Kiyotaka Uchiyama,3 
Shu Wakino,2 Hiroshi Itoh.4 1Keio medical university, TOKYO, Japan; 2Keio 
University, Tokyo-to, Japan; 3Keio University, School of Medicine, Tokyo, 
Japan; 4Keio University School of Medicine, Tokyo, Japan.
Background: An endogenous ketone, β-hydroxybutyrate(β-OHB) is used as an 
energy source in various organs including kidney and has therapeutic benefits against stress 
conditions. In this study, we evaluated its protective effects and potential mechanisms in 
renal ischemia/reperfusion injury(IR).
Methods: Male C57BL/6J mice undetook heminephrectomy and separated into 
4 groups: saline-treated sham-operated mice (Sham: n=6), β-OHB-treated sham mice 
(Sham+β-OHB ; n=6), saline-treated mice with IR (IR; n=8), β-OHB-treated mice with 
IR (IR+β-OHB; n=8). In IR injury mice were subject to clamping of both renal arteries 
and veins for 45 min and to reperfusion. β-OHB was administered continuously by 
osmotic mini-pump at the dose of 8 mg/h. Kidneys were harvested 24 h after IR injury, 
and functional and molecular parameters were evaluated. In vitro studies, HK-2 cells were 
incubated for 1 h with mineral oil to induce hypoxic injury, and incubated for 24 h after 
medium replacement. These HK-2 cells were treated with various doses of β-OHB and 
molecular parameters were evaluated.
Results: In IR mice, blood urea nitrogen, serum creatinine levels, and renal tissue 
injury scores were significantly higher than those in control mice. These values were 
significantly lowered in IR+β-OHB group. β-OHB treatment significantly reduced the 
TUNEL-positive cell number and increased FOXO3 and its downstream target molecule, 
apoptosis repressor with caspase recruitment domain (ARC) expressions. Although β-
OHB unchanged the apoptotic markers, it decreased the expressions of caspase-1, the 
proinflammatory cytokines interleukin (IL)-1β and IL-18 in IR-injured kidneys, indicating 
that β-OHB blocked pyroptotic cell death rather than apoptotic cell death. In HK-2 cell 
subject to hypoxic insult, β-OHB reduced the number of cell death through the inhibition of 
pyroptosis pathway in FOXO3-dependent fashion. Histone acetylation deceased in IR mice 
and in hypoxic HK-2 cells through the inactivation of histone acetyltransferase activity. 
This reduction was ameliorated by β-OHB through the inactivation of histone deacetylase.
Conclusions: β-OHB attenuates renal IR injury by its anti-pyroptotic effect through its 
epigenetic effects on FOXO3 expression.
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Regulation of Fibronectin Splicing with Antisense Oligonucleotides in an 
Aristolochic Acid Model of AKI to CKD
Pritpal S. Virdee,1 Mark E. Dockrell,3 Mysore K. Phanish.2 1South West Thames 
Institute For Renal Research, London, United Kingdom; 2Epsom and St helier 
University Hospitals NHS Trust, Carshalton, London, United Kingdom; 3South 
West Thames Institute for Renal Research, Surrey, United Kingdom.
Background: Extra Domain A Fibronectin (EDA+FN) is an active glycoprotein 
present at sites of fibrosis and is produced through post transcriptional alternative splicing of 
mRNA. Bonventre et al have previously described an early peak at 3 hours with significant 
fall in EDA+FN at 6 weeks post ischaemia reperfusion injury. We developed a murine 
model of aristolochic acid nephropathy (AAN) exhibiting acute to chronic progression 
and investigated the effects of RNAse H-Independent ASO on EDA+FN expression and 
subsequent impact on markers and mediators of tubulointerstitial fibrosis.
Methods: In a short model of AAN, CD1 mice aged 10 weeks received subcutaneous 
(SC) PBS (n=6), RNAse H-independent negative control (NC-ASO, n=6) or target antisense 
(T-ASO, n=6) at 50mg/kg at day -1 followed by one dose of intraperitoneal (IP) AA 3.5mg/kg 
on day 1 for each arm, mice culled at day 3. In the long model they were injected with IP 
AA 3.5mg/kg on days 1 and 5 followed by SC PBS (n=6) or 50mg/kg NC-ASO (n=12) or 
T-ASO (n=12) at day -1 and 3 and then weekly injections until day 96. Whole kidney tissue 
was extracted and RNA analysis undertaken using RT PCR.
Results: In the short model KIM1, CD68 and EDA + FN mRNA expression was 
significantly increased at 48 hr post AA compared to Day 0 (p<0.05). T-ASO reduced 
EDA+FN mRNA significantly compared to NC-ASO (p<0.0001) with no effect on CD68 or 
KIM1. TGFβ1 expression was downregulated by T-ASO (p<0.05). In PBS arm of the long 
model at day 96, compared to day 0 there was statistically significant increase in mRNA 
expression of EDA+FN, EDA-FN, TGFβ1, LTBP1, MMP2, MMP9, αSMA, KIM1 and 
Coll1a1. At day 96, T-ASO resulted in significant knock down of mRNA expression of 
EDA+FN, TGFβ1and LTBP1 compared against NC-ASO with no effect on expression of 
αSMA, Coll1a1, MMP2 or KIM1.
Conclusions: In this model of AAN we have demonstrated increased mRNA expression 
of EDA+FN in the early phase but also sustained at day 96. We have demonstrated the 
ability to knockdown EDA+FN mRNA at both time points and also noted knockdown of 
TGFβ1 and LTBP1 mRNA with our target antisense suggesting a functional interaction. 
Antisense did not have an effect on markers of AKI or other mediators of fibrosis. Further 
analysis of samples with immunohistochemistry will help determine whether T-ASO has an 
impact on attenuation of fibrosis in this model.
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Inhibition of CXCR3 Expression Through Blockade of STAT3 Alpha 
Signaling Down-Regulates Inflammation of Renal Ischemia-Reperfusion 
Injury
Jae Yoon Park,1 Kyung Don Yoo,4 Sung joon Shin,1 Kyung Soo Kim,1 Yon 
Su Kim,3 Seung Hee Yang.2,3 1Dongguk University Ilsan Hospital, Gyeonggido, 
Republic of Korea; 2Kidney Research Institute, Seoul National University, Seoul, 
Republic of Korea; 3Seoul National University College of Medicine, Seoul, 
Republic of Korea; 4Dongguk University Gyeongju Hospital, Gyeongju-si, 
SEOUL, Republic of Korea.
Background: Signal transducer and activator of transcription 3 (STAT3) is the main 
mediator of interleukin 6 (IL-6)–type cytokine signaling. Although it exists in two isoforms: 
the full-length STAT3α and the truncated STAT3β, their role in acute kidney injury is not 
clarified. We investigated their relative function through inhibiting STAT3α in ischemia-
reperfusion (IR)-induced renal inflammation.
Methods: IR injury was induced in B6 wild type mice. Stattic (a nonpeptide small 
molecular inhibitor of STAT3 activation and dimerization) was treated 3 hours prior to IR 
injury. We quantified intrarenal cytokine expression using real-time PCR and performed 
FACS analysis. We cultured human tubular epithelial cells (TECs) in hypoxic condition and 
evaluated the effect of Stattic treatment. We detected the isoforms of phosphorylated STAT3 
using western blot analaysis.
Results: IR injury produced more severe tubular damage in control group than in 
Stattic-treated mice (serum creatinine, 2.2±0.1 versus 1.6±0.1 mg/dL, p<0.05). Although 
inflammatory cytokines/chemokines, such as IL-6, total STAT3, STAT3α, CXCR3, IL-10 
and TGF-β were increased by IR injury in control group, they were attenuated in Stattic-
treated mice. Apoptosis of TECs and infiltration of mononuclear cells and macrophages 
were decreased and the expression of STAT3α as well as total STAT3 was reduced in 
Stattic-treated mice. These findings were supported by in-vitro study with human TECs. 
Whereas the level of pSTAT3α was elevated in the hypoxia-conditioned TECs and it was 
decreased in Stattic-treated cells, the level of pSTAT3β was not changed in both cell groups. 
The expression of CXCR3 was decreased in accordance to the STAT3α decrease and the 
supernatant levels of IL-6 and IL-8 were decreased in Stattic-treated cells.
Conclusions: We demonstrated that the activation of STAT3 is associated with 
progression of IR injury and the α-isoform may contribute as major player. These 
mechanisms of STAT3/CXCR3 signaling according to each isoforms suggest a novel 
strategy for management of AKI with STAT3 inhibitor.
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PHD Inhibition Reduces Reactive Oxidative Stress in In Vitro Ischemia 
Model
Marie Ito,1 Tetsuhiro Tanaka,2 Takeshi Wakashima,3,1 Masaomi Nangaku,2 
Kenji Fukui.3 1the University of Tokyo graduate school of medicine, Tokyo, 
Japan; 2the University of Tokyo School of Medicine, Tokyo, Japan; 3Biological 
and Pharmacological Research Laboratories, Central Pharmaceutical Research 
Institute, Japan Tobacco Inc., Osaka, Japan.
Background: Hypoxia-inducible factor (HIF) is widely accepted to mediate the 
protection by hypoxic preconditioning in both in vitro and in vivo ischemia models but 
the underlying mechanism remains unknown. Prolyl hydroxylase domain proteins (PHDs) 
serve as main HIF regulator via hydroxylation of HIF-α leading to its degradation. Several 
PHD inhibitors, including enarodustat are now under clinical trials as treatment for renal 
anemia and the beneficial effect might go far beyond.
Methods: We investigated the role of PHD inhibition in oxygen-glucose deprived 
(OGD) model of human renal tubular cells (HK2) as an in vitro model of renal ischemia. 
Enarodustat or siRNA knockdown of PHD isoforms was used to study the impact of 
PHD inhibition on cytoprotection and ROS. Cell viability and ROS were measured 
using the Muse™ Count & Viability Assay Kit and Oxidative Stress Kit according to the 
manufacturer’s instructions. mRNAs for antioxidative genes (GPX1, catalase, SOD1, 
SOD2, HO-1 and NQO1) were quantified by real-time PCR. Specific effects of HIF 
isoforms and respective antioxidative genes were studied using siRNA knockdown series. 
The role of autophagy was evaluated with Atg7-KO cells.
Results: Enarodustat treatment and siRNA knockdown of PHD2, but not of PHD1 or 
PHD3, significantly increased cell viability and reduced reactive oxygen species (ROS) 
levels by HIF stabilization. These effects were offset by simultaneous knockdown of 
HIF-α isoforms. HIF-1α alone could confer protection in both viability and ROS levels, 
while the contribution of HIF2 was only evident in combination with HIF1, with a larger 
role in viability. As candidate mechanisms for ROS elimination, we examined the role of 
autophagy and antioxidants. Autophagy reduces ROS by degrading damaged mitochondria 
in several models. However, in our OGD model cell death and ROS were not increased 
in Atg7-KO cells. Next we measured the mRNA levels of antioxidants and among them 
superoxide dismutase 2 (SOD2) and heme oxygenase-1 (HO-1) are significantly increased 
in enarodustat-treated cells. While SOD2 knockdown had little effect, HO-1 knockdown 
partially abrogated the cytoprotection and ROS reduction by PHD inhibition.
Conclusions: HIF stabilization by PHD inhibition increased cell viability and 
decreased ROS levels, and HO-1 partially mediated the effect.
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Hypoproteic Diet During Pregnancy and/or Lactation Differentially 
Affects the Response of the Offspring to an Episode of AKI
Luis E. García-Ortuño,1,2 Jonatan Barrera-Chimal,1 Rosalba Pérez-villalva,1,2 
Juan A. Ortega-Trejo,1,2 Ixchel Q. Lima Posada,1,2 Luis A. Reyes castro,3 
Norma Bobadilla.1,2 1Molecular Physology Unit, Mexico City, Mexico; 
2INCMNZS-UNAM, Mexico City, Mexico; 3INCMNSZ, MEXICO, Mexico.
Background: Protein restriction during pregnancy induces morpho-functional 
alterations related to deficient nephrogenesis. We studied the renal functional and 
morphological significance of protein restriction during pregnancy (Preg), lactation (Lact) 
or both, in the adult stage of the offspring and their repercussion on the AKI severity.
Methods: Female rats were randomly assigned to the following groups: C = standard 
diet, (SD) during Preg and Lact; CR = SD during Preg and protein restriction diet (PR) 
during Lact; RC = PR during Preg and SD during Lact and RR = PR during Preg and Lact. 
Three months after birth, at least twelve male offspring of each group underwent randomly 
to bilateral renal ischemia for 45 min (IR) or sham surgery. Thus, eight groups were studied 
24 h after reperfusion: C, C+IR, CR, CR+IR, RC, RC+IR, RR and RR+IR.
Results: The CR, RC, and RR groups exhibited a significant reduction by ≈ 15% in 
the nephron number that was associated with a reduction in renal blood flow (RBF). In 
spite of this, glomerular hypertrophy was observed together with a significant reduction in 
endothelin, angiotensinogen and their receptors, as well as catalase and GPx mRNA levels. 
In the next table appears the % change in renal function and vasoactive factors mRNA levels 
after the IR injury compared to their respective control group.
Conclusions: During basal conditions, the lesser nephrons observed in the offspring 
of protein-restricted mothers was associated with glomerular hypertrophy and reduced 
expression in vasoconstrictor factors. The ischemic insult in these groups induced a 
differential vasoconstrictor response that allowed a faster recovery in RBF, as compared 
to control group. These results suggest that CR, RC and RR groups respond better to an 
ischemic insult and most likely to the long-term consequences of AKI.
Funding: Government Support - Non-U.S.
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Hypoxia Induces Ligand-Receptor Interactions to Mediate Exosome 
Targeting to Endothelial Cells in AKI
Jose L. Vinas,2 Matthew Spence,2 Alex Gutsol,5 Dylan Burger,2 
Joe A. Zimpelmann,4 David Allan,3 Kevin D. Burns.1 1Medicine, Kidney 
Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 
Ottawa, ON, Canada; 2Medicine, Kidney Research Centre, Ottawa Hospital 
Research Institute, University of Ottawa, Ottawa, ON, Canada; 3Ottawa 
Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada; 
4Kidney Research Centre, Ottawa Hospital Research Institute, University of 
Ottawa, Ottawa, ON, Canada; 5Kidney Research Centre, Ottawa Hospital 
Research Institute, University of Ottawa, Ottawa, ON, Canada.
Background: Intravenous (i.v.) injection of exosomes derived from human endothelial 
colony forming cells (ECFCs) leads to selective targeting of the kidneys after ischemic 
injury in mice, along with increased miR-486-5p levels. Mechanisms mediating recruitment 
of exosomes are unclear. We previously showed that exosomes express CXC chemokine 
receptor type 4 (CXCR4), and a neutralizing antibody to stromal cell-derived factor (SDF)-
1α prevented exosome uptake into normoxic endothelial cells. Here, we determined if 
exosomes transfer miR-486-5p to endothelial cells and nephron segments after kidney 
ischemic injury, and further explored the role of the CXCR4/SDF-1α interaction.
Methods: Ischemia-reperfusion kidney injury was induced in mice by renal vascular 
clamp, with or without i.v. infusion of ECFC exosomes. Kidneys were removed 30 min 
after reperfusion, and endothelial cells were isolated by enzymatic digestion and sorting 
using CD31-labeled magnetic beads, followed by PCR for miR-486-5p. Proximal tubules 
and glomeruli were microdissected. Human umbilical vein endothelial cells (HUVECs) 
were exposed to hypoxia to study the role of CXCR4/SDF-1α interaction.
Results: Infusion of ECFC exosomes increased kidney cortical levels of miR-486-5p 
at 30 min after reperfusion (P<0.05; n=4). Exosomes significantly increased miR-486-5p 
levels in endothelial cells, proximal tubules, and glomeruli (P<0.05 vs ischemia-reperfusion 
alone; n=4). PKH26-labeled exosomes were detected mainly in the tubulointerstitial 
compartment of the kidney 30 min after infusion. In HUVECs, hypoxia increased secreted 
levels of SDF-1α and enhanced exosome uptake. Incubation with neutralizing antibody to 
SDF-1α or the CXCR4 inhibitor Plerixafor blocked exosome uptake into hypoxic HUVECs 
(n=4). Hypoxia also increased uptake of exosomal-derived Cy3-labeled miR-486-5p, which 
was inhibited by either neutralizing antibody to SDF-1α or Plerixafor (n=4).
Conclusions: ECFC exosomes target endothelial cells, proximal tubules, and glomeruli 
in ischemic kidneys, with transfer of miR-486-5p. Selective targeting of ischemic kidneys 
by exosomes may involve an interaction of exosomal CXCR4 with hypoxia-induced SDF-
1α in endothelial cells. These data provide further support for the promising therapeutic 
potential of ECFC exosomes in human acute kidney injury.
Funding: Government Support - Non-U.S.
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Fibroblast mTORC2/PPARγ-Dependent HGF Production Protects Against 
Tubular Cell Death and AKI
Gui Yuan, Chunsun Dai. Nanjing medical university, Nanjing, China.
Background: Kidney interstitial fibroblasts play a crucial role in dictating tubular cell 
fate and the outcome of acute kidney injury (AKI). However, the underlying mechanisms 
remain to be further determined.
Methods: Mouse model with inducible Rictor gene deletion in fibroblast was generated. 
Kidney ischemia/reperfusion injury was employed to induce acute kidney injury in mice.
Results: Here, we found that Rictor/mTORC2 signaling was activated in mouse 
kidney interstitial fibroblasts after ischemia/reperfusion injury (IRI). Ablation of Rictor in 
fibroblasts led to more severe kidney dysfunction and morphological damage in mice after 
IRI compared to their littermate controls. More tubular cell apoptosis and inflammatory 
cell accumulation were detected in the knockout kidneys after IRI. In in vitro, a co-culture 
system between fibroblasts and tubular cells was generated. Blockade of Rictor/mTORC2 
signaling in fibroblasts with Rictor gene ablation or pharmacological inhibition facilitated 
staurosporine-induced tubular cell death. In addition, blocking fibroblast mTORC2 signaling 
could downregulate its peroxisome proliferator-activated receptor gamma (PPARγ) and 
hepatocyte growth factor (HGF) expression, as well as attenuate c-met signaling activation 
in tubular cells. Moreover, activation of fibroblast PPARγ could augment HGF expression 
and attenuate tubular cell death. Notably, in mouse kidneys, ablation of fibroblast Rictor 
reduced the PPARg and HGF expression. The tyrosine phosphorylation of HGF receptor 
c-met was also diminished in the knockout kidneys after IRI.
Conclusions: Together, these data suggests that Rictor/mTORC2 signaling activation
in kidney interstitial fibroblasts may protect against tubular cell death and dictate the 
outcome of acute kidney injury through PPARγ-stimulated HGF production.
Funding: Government Support - Non-U.S.
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Cultured Renal Tubular Epithelia in Migration Develop 3 Forms of 
Filopodia Having an Inherent Short Diameter: A Scanning Electron 
Microscope (SEM) Study
Kiyoko Inui,1 Hiroyuki Morita,2 Yoshihiko Inoue,1 Yoshinori Sato,1 
Eri Kawashima,1 Ashio Yoshimura,3 Fumihiko Koiwa.1 1Showa University 
Fujigaoka Hospital, Yokohama, kanagawa, Japan; 2Aichi Medical University 
School of Medicine, Nagakute, Japan; 3Shinyokohama Daiichi Clinic, 
Yokohama, Japan.
Background: Renal tubular epithelial regenerate themselves after severe injuries as 
exemplified in acute kidney injury (AKI), when cell migration plays a crucial role. Studies 
have demonstrated that formations of filopodia are pivotal in cell migration. However, 
ultrastructure of cells with filopodia in migration largely remains to be seen. In this study, 
we use scanning electron microscope (SEM), and report fine ultrastructural images of 
filopodia that tubular epithelia form in cell migration.
Methods: Rat renal epthelialia, NRK-52E, were grown to confluence, and then, 
scratched or subcultured. At various time points until the next 100% confluence, they were 
fixed and subjected to SEM analysis. Filopodia were found in the specimens almost without 
exceptions. 20 different areas were randomly picked up to measure the short and long 
diameters of filopodia.
Results: Major findings of this study were 1) Filopodia were classified into 3 groups: 
having A(32±9)nm, B(108±16) nm, and C(155±21) nm short diameters. 2) Typically, the 
ratio of the short diameter to the long diameter in A, B, and C were 1:70, 1:150, and 1:400, 
respectively. 3) Group C filopodia were the major one when the cells were directionally 
migrating at >70% confluence. Interestingly, Group C filopodia was seen after the cells 
were grown to confluence (Figure). Appearances of Group A filopodia were rare.
Conclusions: Our ultrastructural study identified 3 forms of filopodia, although 
reciprocal relationship among them remained to be elucidated. Each one was associated 
with cell migration. We propose a hypothesis that group C filopodia play a role in learning 
the position of a cell in relation to adjacent ones.
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3D Organellar Morphological Dynamics in Kidney Tissue Using SIM 
Super-Resolution Microscopy
Kensei Taguchi,1 Craig R. Brooks.2 1Vanderbilt University Medical Center/
Division of Nephrology & Hpertension, Nashville, TN; 2Vanderbilt University 
Medical Center/Division of Nephrology & Hpertension, Nashville, TN.
Background: Organellar dynamics, mitochondrial morphology, endoplasmic reticulum 
(ER) morphology and autophagosome formation, are key components in the pathology of 
kidney disease. Imaging organellar dynamics in isolated cells has been a cornerstone to 
our understanding of cellular biology. Visualizing changes in these organelles in kidney 
tissue, however, remains difficult and largely limited to electron microscopy (EM), which 
provides a very narrow two dimensional image of the cellular/organellar structure. Thus, 
our understanding of organelle structure in vivo, and how this structure changes with 
disease, remains limited. Here, we investigate whether structured illumination microscopy 
(SIM) could be used to visualize three dimensional organellar dynamics in kidney tissue.
Methods: Human biopsies or kidneys from sham, aristolochic acid- or ischemic 
reperfusion-injured C57BL/6 mice were fixed and paraffin embedded following standard 
protocols. Sections of the kidneys were mounted on silane-treated coverslips and stained 
for intracellular organelles markers, and then imaged by Nikon N-SIM microscope. Kidney 
tissue was co-stained for markers of kidney injury, such as kidney injury molecule 1 (KIM-1) 
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and markers of the cell cycle. Changes in organelle structure were quantified with Imaris 
software.
Results: SIM reveals a dramatic increase in the number and size of autophagosomes 
in injured tubular cells marked with KIM-1. Likewise, the ER morphology is significantly 
altered in injured kidneys. Mitochondrial morphology was found to be far more complex 
than suggested by EM. 3D rendering of the mitochondria demonstrates that within one 
cell in uninjured kidneys the mitochondrial network is nearly continuous. After injury, this 
network breaks down into many smaller mitochondria. Importantly, SIM analysis of human 
kidney tissue exhibits dramatic changes in mitochondrial and other organelle structures.
Conclusions: SIM imaging provides a novel approach to analyze organellar dynamics 
and interfaces of organelles in kidney tissue and enables a 3D morphological analysis. 
KIM-1 staining is associated with increased autophagy and mitochondrial fragmentation. 
When combined with Injury or other markers SIM imaging can help delineate the pathways 
involved in organelle dynamics in vivo in human disease or animal models.
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A Novel 3D Cell Model That Mimics Renal Tubular Injury and Repair
Shuan Zhao,1 Jiachang Hu,2 Xialian Xu.3 1Zhongshan hospital, Fudan University, 
Shanghai, China; 2Zhongshan hospital of Fudan University, Shanghai, China; 
3Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Acute kidney injury (AKI) is a major health problem with high 
morbidity and mortality. Despite decades of research, there is still no specific therapy for 
AKI. To develop targeted therapies to prevent or treat AKI, a basic prerequisite is a clear 
understanding of how cells repair injured kidney. When epithelial cells in the proximal 
portion of the nephron are damaged they rapidly proliferate to repair the damage to the 
kidney. Here, we developed a novel 3D culture model of AKI and, in a key insight, looked 
for genes that were involved in injury and repair.
Methods: A mosaic MDCK cysts were cultured in Matrigel and damaged at Day 7. 
During cysts repairing, total RNA of MDCK cells at indicated stages were extracted, 
purified and concentrated. After microarray analysis, genes that significantly expressed 
were selected, and verified in mouse ischemic reperfusion injury model at multiple time 
points by qRT-PCR.
Results: In our 3D culture system, cysts with monolayer of highly polarized cells were 
formed at Day6. Sectional cells in mosaic cyst could be induce apoptosis by oligomerization 
of a membrane localized, truncated form of caspase 8 and thereby cause damage to the cysts. 
Intriguingly, the remaining cells in the damaged cysts were able to re-enter the cell cycle, 
and restore the cysts to their pre-apoptotic state. Microarray analysis highlights a cascade 
of temporal-specific gene expression patterns related to tubular injury/repair. Seven genes 
that involved in cell junction and adhesion were selected and verified in animal AKI model. 
Three of those genes were significantly upregulated at 24h after IRI, two of those genes were 
dramatically reduced after IRI, and one gene’s expression has no change before 48h.
Conclusions: Using this 3D cell model of AKI, we have generated a list of gene 
candidates. Seven genes that related to cell junction and adhesion were identified, and 
expression patterns were similar between cell and mouse AKI model at multiple time points.
Funding: Government Support - Non-U.S.
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Mitigation of AKI in Mice Using DNase I Inhibitor
Todd Fite,1 Alena Savenka,1 Alexei G. Basnakian.1,2 1University of Arkansas for 
Medical Sciences, Little Rock, AR; 2Central Arkansas Veterans Healthcare 
System, Little Rock, AR.
Background: Our previous studies showed that genetic inactivation of the most active 
kidney apoptotic endonuclease, DNase I, was partially protective against tubular epithelial 
cell death induced by hypoxia-reoxygenation or cisplatin. Our recent discovery of the first 
pharmaceutically meaningful DNase I inhibitor, IG-17, provides an opportunity for the 
development of first anti-DNase drug mitigating acute kidney injury (AKI).
Methods: In vitro experiments using kidney tubular epithelial NRK-52E cells showed 
that IG-17 was able to suppress DNase activity inside the cells, and provided partial 
protection against hypoxia-reoxygenation, cisplatin or hemin toxicity measured using LDH 
release assay and TUNEL.
Results: The absence of IG-17 toxicity in mice at 1, 5 or 25 mg/kg was shown by 14 
blood plasma assays for organ function. AKI experiments were done in male and female 
mice subjected to bilateral kidney 50-min ischemia followed by 24-h reoxygenation, or 
injected with cisplatin (20 mg/kg, IP), or glycerol (50% solution, 8 ml/kg, IM). Kidney 
failure was measured by serum creatinine and BUN. Structural kidney damage was assessed 
by acute tubular necrosis and TUNEL. In all three in vivo models, SC or IP injections of 
IG-17 (5 mg/kg) were either partially (ischemia-reperfusion, cisplatin) or fully protective 
(glycerol).
Conclusions: The results of this study suggest that IG-17 has a promise as the first non-
toxic anti-DNase agent for mitigation of AKI.
Funding: NIDDK Support, Veterans Affairs Support, Other U.S. Government Support
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Inhibition of BRD4 with MS417 Lessens the Inflammatory Response 
Following Ischemia Reperfusion Injury
Shelby Reid,1 Xiaohua Zhou,2 Rohan John,3 James W. Scholey.2 1Institute of 
Medical Science, University of Toronto, Toronto, ON, Canada; 2University of 
Toronto, Toronto, ON, Canada; 3University Health Network, Toronto, ON, 
Canada.
Background: A key regulator of the immune and inflammatory response is the NFκB//
Rel protein family. A variety of stimuli, including ischemia reperfusion injury (IRI), 
activate the NFκB signalling cascade which stimulates the transcription of genes primarily 
involved in immune and inflammatory response. A key regulator of NFκB transcription is 
BRD4 which binds to acetylated RelA leading to the recruitment and activation of CDK9, 
subsequently resulting in the phosphorylation of RNA polymerase II and the transcriptional 
activation of NFκB target genes. The key role of BRD4 in transcription has led to the 
development of small molecule inhibitors that competitively bind to the acetylated RelA. 
One inhibitor, MS417, has shown promise in attenuating injury in different models of 
kidney injury, but has yet to be analyzed in a model of ischemia reperfusion injury.
Methods: Male C57BL/6 mice were treated with 1 μM of MS417 or vehicle via oral 
gavage daily for 7 days before unilateral IR was performed by clamping off the renal artery 
for 45 minutes followed by reperfusion. Daily treatment was continued until the time of 
sacrifice when tissue was collected for immunohistochemistry (IHC) and PCR analysis. 
Fixed kidney tissue was paraffin-embedded, sectioned, stained with periodic acid–Schiff 
(PAS) and scored for glomerular injury as well as for infiltrating neutrophils in a blinded 
manner. RNA was extracted from snap-frozen kidney tissue and was reverse transcribed 
into cDNA which was subsequently used in quantitative polymerase chain reaction.
Results: IHC staining for tubular injury and neutrophil infiltration showed a marked 
increase in the control group (treatment with saline) when compared to shams (no IRI). 
Treatment with MS417 prior to IR resulted in a lower trend in both injury and neutrophil 
infiltration. Administration of MS417 further suppressed the increase of the transcript levels 
of the proinflammatory markers C-C Motif Chemokine Ligand 2, Interleukin-1β, and 
Interleukin-6 by approximately 50%.
Conclusions: Treatment with the BRD4 inhibitor, MS414, prior to IR resulted 
in reduced tubular injury and neutrophil recruitment as well as reduced expression of 
proinflammatory genes. Further analysis of MS417’s specificity and role in lessening the 
inflammatory response following IR is required.
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PMMA-Based Continuous-Adsorbitive-Hemofiltration Abrogated 
Complement Activation and Tubular Senescence-Associated Secretory 
Phenotype (SASP) in LPS-Induced AKI
Giuseppe Castellano,1 Alessandra Stasi,1 Chiara Divella,1 Rossana Franzin,1 
Fabio Sallustio,1 Claudia Curci,1 Angela Picerno,2 Claudio Ronco,3 
Vincenzo Cantaluppi,6 Massimo de Cal,4 Mauro Neri,4 Anna Lorenzin,5 
Giovanni B. Pertosa,1 Loreto Gesualdo.1 1University of Bari, BARI, Italy; 
2University of Bari “Aldo Moro”, Bari, Italy; 3Ospedale “S. Bortolo” AZ. ULSS 
6, Vicenza, Italy; 4San Bortolo Hospital, Vicenza, Italy; 5IRRIV, Vicenza, Italy; 
6University of Piemonte Orientale (UPO), Novara, Italy.
Background: During sepsis-induced AKI, inflammatory mediators could induce a 
maladaptive response in tubular epithelial cells (TEC). Hemofeel (TORAY, Japan) is a 
PMMA membrane based hemofilter indicated for blood purification therapies in continuous 
modality (CRRT), combining filtration and adsorption.
Methods: After 3h from LPS infusion, 8 pigs (female, 40-50 Kg) were treated with 
PMMA-CVVH (CH-1.8 W series), working in post-dilution modality (time =7 hours; 
Qb= 150 ml/min; Effluent rate =2000 ml/h; Substitution Rate = 2000 ml/h; UF 
rate = 0 ml/h). 8 control pigs received no treatment and developed endotoxemia-induced 
oliguric AKI. Renal biopsies were collected at 24h and analyzed by IHC and IF. Systemic 
Complement activation was evaluated by Wieslab kit. In vitro, tubular epithelial cells (TEC) 
were stimulated with LPS (4μg/ml) for 24h and then analyzed for SASP markers (p53, p21, 
cyp1b1, Klotho) by qPCR.
Results: A significant activation of Complement classical and alternative pathways was 
observed at 3h and 24h after LPS infusion. Histological and Confocal analysis revealed 
extensive Pentraxin-3 and collagen deposits at the interstitial level, along capillaries with 
diffuse glomerular thrombi compared to healthy pigs (T24LPS vs T24CTR, p <0.05). 
Interestingly, we found significant TEC senescence with increased p16INK4a expression 
(IHC T24LPS vs T24CTR p <0.05). PMMA-CVVH treatment significantly reduced 
Complement activation and antagonized SASP by restoring p16INK4a basal expression 
(T24LPS vs T24PMMA p <0.05). In accordance, LPS stimulation of TEC (24h) in vitro 
induced accelerated senescence by up-regulating p53, p21, cyp1b1 (2-DDCT: LPS: 
4.3 ± 0.63 vs Basal: 1 ± 0.00, p <0.05) and reducing Klotho expression (p <0.05).
Conclusions: Endotoxemia can induce AKI with systemic Complement activation 
leading to the development of SASP phenotype in TEC. PMMA treatment might be a new 
therapeutic approach to prevent Complement activation in LPS-induced AKI.
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The Stabilizing Effect of Dipeptidyl Peptidase-4 Inhibitors on the 
Epithelial Barrier in the Colistin-Induced Tubular Injury
Ji Young Ryu,1 Kipyo Kim,1 Hyung Eun Son,1 Ho Jun Chin,1,2 Sejoong Kim.1,2 
1Seoul National University Bundang Hospital, Seongnam, Republic of Korea; 
2Department of Internal Medicine, Seoul National University College of 
Medicine, Seoul, Republic of Korea.
Background: Recently, dipeptidyl peptidase-4 inhibitors (DPP4i) have been identified 
to have some pleiotropic effects in different kidney diseases including diabetic kidney 
disease, ischemic acute kidney injury. In terms of pathophysiology, few studies have 
examined the effects of DPP4i on the epithelial barrier in drug-induced acute kidney injury. 
The increased tubular epithelial cell permeability and barrier dysfunction have been shown 
in previous studies regarding colistin-induced nephrotoxicity. This study was performed to 
evaluate the renoprotective effect of DDP4i in colistin-induced tubular injury using a two-
layered kidney-on-a-chip device.
Methods: The kidney-on-a-chip device consists of upper and lower channels 
mimicking intraluminal space and interstitial space. Kidney tubular epithelial cells were 
seeded into upper channel and exposed to colistin at a concentration of 400 μg/ml for 
48 hours under physiological shear stress condition (1 dyn/cm2). Evogliptin (Suganon®, 
Dong Ah Pharm., Korea) was administered to the lower channel at a concentration of 50 nM 
for 48 hours. Transmembrane permeability, tight junction protein expression, cell viability, 
and tubular injury marker, kidney injury molecule-1 (KIM-1), in outlet-collected media 
were evaluated in evogliptin-treated and control groups.
Results: After colistin treatment, transmembrane permeability increased from 6.75% 
to 51.5%, but evogliptin decreased transmembrane permeability to 34.6%. In addition, the 
fluorescence intensity of tight junction proteins, occludin and ZO-1, which were reduced 
by 56.2% and 44.5% after colistin exposure, were maintained during the treatment with 
evogliptin. The dead cell percentage and KIM-1 level were slightly decreased in evogliptin-
treated groups.
Conclusions: We identified some renoprotective effects of the DPP4i on the epithelial 
barriers in short-term colistin-induced tubular injury. Further studies are required for the 
cytoprotective effect in long-term colistin injury models.
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Exercise Attenuates Ischemia–Reperfusion-Induced AKI
Joao Paulo M. Telles, Isabella P. Zanfra, Leticia U. De Castro, Amaro N. Duarte-
Neto, Jose Manuel Condor Capcha, Mirela Santinho, Lucia Andrade. University 
of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Background: Aerobic (endurance) and strength (resistance) exercise have both been 
proven to be beneficial for patients with chronic kidney disease. Acute kidney injury 
continues to be the leading cause of death among critical care patients. We hypothesized 
that there is cross-talk between muscles and the kidneys and that exercise could attenuate 
the renal damage caused by ischemia–reperfusion. In this study, we assess the impact of 
exercise in rats submitted to renal ischemia–reperfusion injury (IRI).
Methods: Wistar rats were divided into two groups: Exer+IRI (n = 7), in which rats 
were submitted to a standardized protocol consisting in a treadmill run at up to 60% of the 
maximum calculated speed and climbing of a standardized ladder (30 min of running+10 
climbs with tail weights, 5 times a week for 8 weeks), followed by bilateral clamping of 
the kidney hila (30 min) and subsequent reperfusion; and control+IRI (n = 6) in which 
the protocol consisted in a treadmill run at the lowest speed (30 min, 5 times a week for 8 
weeks: control condition), bilateral clamping of the kidney hila (30 min), and subsequent 
reperfusion. All studies were performed 48 h after reperfusion. Data are mean ± SEM.
Results: Serum levels of urea were higher in control+IRI rats than in Exer+IRI rats 
(143 ± 43 vs. 92 ± 12 mg/dl), as were urinary levels of NGAL (46 ± 10.6 vs. 24 ± 5.6 μg/mg 
urinary creatinine, p < 0.05). In kidney tissue, protein expression of Toll-like receptor 4 
(TLR4) was higher in control+IRI rats than in Exer+IRI rats (105 ± 2.4 vs. 67 ± 1.9%; 
p < 0.01). Renal protein expression of Klotho was lower in control+IRI rats than in 
Exer+IRI rats (99.5 ± 1.6 vs. 134 ± 6.7%; p < 0.01) as was protein expression of manganese 
superoxide dismutase (98.8 ± 2.2 vs. 122 ± 5.7%, p <0.01). Renal apoptosis (determined by 
TUNEL) was lower in Exer+IRI rats than in control+IRI rats (3.7 ± 0.8 vs. 11.5 ± 5.0 positive 
cells/0.087 mm2; p < 0.05). Acute tubular necrosis was more extensive in control+IRI rats 
than in Exer+IRI rats (5.3 ± 0.6 vs. 3.8 ± 0.4, p < 0.05), most control+IRI rats presenting 
damage in >50% of the tubular area, compared with <50% for the Exer+IRI rats.
Conclusions: Exercise attenuates renal IRI by decreasing TLR4 expression and is 
renoprotective in a Klotho-dependent manner. (FAPESP)
Funding: Government Support - Non-U.S.
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Renal Hypercoagulability Is Front and Center in Ischemic Injury
Jesus H. Dominguez,1 James M. Dominguez,2 Danhui Xie,3 Katherine J. Kelly.2 
1VAMC, Indianapolis, IN; 2Indiana University, Indianapolis, IN; 3IUPUI, 
Indianapolis, IN.
Background: The transition of acute kidney injury (AKI) to chronic kidney disease 
(CKD) is common and misunderstood. We hypothesize that widespread renal clotting 
impairs reperfusion following renal ischemia in rats. This renal response is manifested as 
no-reflow in the microcirculation, causing swaths of renal micro ischemia, inflammation, 
apoptosis and fibrosis.
Methods: SD rats (n = 5/group) were subjected to 50 minutes of renal ischemia and 
then to 6 days of reperfusion. We used RNAseq comprehensive transcriptome analysis and 
measured 12,159 renal transcripts in sham and ischemic rats. The data were analyzed with 
established informatics tools.
Results: Renal ischemia activated the intrinsic renal clotting system and clotted renal 
microvessels. This response to injury included prothrombotic stimulation manifested by 
renal tubular activation of tissue factor (up 1.9 fold; p<0.002), and inhibition of tissue factor 
pathway inhibitor (down 1.44 fold, p = 0.008). Moreover, all three chains of renal fibrinogen 
were upregulated (up to 33 fold; 2.2E-10) and circulating fibrinogen also surged: 140±30 
to 719±29 mg/dl, p<0.0024. Renal plasminogen was not expressed. There was major 
inhibition of fibrinolysis represented by activation of plasminogen activator inhibitor (up 
5.6 fold; p = 1.7E-7), lack of response in renal urokinase and tisue plasminogen activator, 
and inhibition of plasminogen activator kallikrein (down 10 fold, p = 1.85E-6). In addition 
the thrombin receptor F2rl1 was activated 2 fold (p<0.0001). Complement component 
C1qa,b,c increased 3 fold (p <0.0001), C3 (up 5 fold p= 1.2E-5), and C4 a,b (up 12.56 and 
20 fold respectively, p = 1.9E-13). These renal mRNA changes were associated with similar 
responses in renal cognate proteins and fibrin deposition. Kegg pathway analysis confirmed 
differential expression in ischemia of coagulation and complement pathways P=2.68 x 10-3.
Conclusions: We suggest the renal pro-thrombotic and fibrinolytic balance is essential 
to protect and assure competent blood flow. In renal injury, this balance is disrupted in 
favor of hypercoagulability. The risk to renal microthrombosis is further enhanced by 
complement activation and inhibition of a robust renal fibrinolytic system. We propose that 
in ischemic AKI the most optimal option is to re-activate fibrinolysis, anticipating that anti-
coagulant agents are unlikely to be effective.
Funding: Veterans Affairs Support
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High Throughput Metabolic Flux Analysis of Intact Kidney Tissue 
Reveals Abnormal Mitochondrial Respiration During AKI to CKD 
Transition
Aqeela Afzal, Andres A. Urrutia, Volker H. Haase. Vanderbilt University 
Medical Center, Nashville, TN.
Background: Mitochondrial dysfunction has been implicated in the pathogenesis of 
multiple renal diseases, including acute kidney injury (AKI) and chronic kidney disease 
(CKD). However, knowledge about mitochondrial function during AKI to CKD transition 
is limited. The assessment of basal oxygen consumption rates (OCR) and the responses 
to electron transport chain inhibitors and uncoupling agents represent the first steps in 
evaluating cellular mitochondrial function. In order to avoid artifacts associated with 
tissue disruption or primary cell culture, we developed a novel method that permits the 
measurement of OCR in intact kidney tissue slices and investigated mitochondrial function 
during AKI to CKD transition.
Methods: 9-12 week-old C57/BL6 male mice were subjected to unilateral ischemia 
reperfusion injury (IRI) induced by 30 minutes of renal pedicle clamping. Kidneys were 
analyzed immediately after clamp removal (no-reperfusion) and at 24 hours, day 3, day 7 
and day 21 post IRI. After removal of the kidney capsule, a portion of the kidney was used 
for DNA, RNA and histologic analysis. The remainder of the kidney was submerged in 
oxygenated modified Ringers solution. 1mm punch-biοpsies were obtained from 100 μm 
vibratome sections of kidney pole tissue and loaded into an islet capture plate. OCR and 
extracellular acidification rates (ECAR) were analyzed with a Seahorse XFe24 metabolic 
flux analyzer.
Results: Basal OCR and ECAR rates were significantly reduced immediately following 
IRI and recovered incompletely by day 3 post IRI. Day 7 and day 21 were characterized by 
a further reduction in OCR and ECAR below day 3 levels. The reduction in OCR correlated 
with significantly diminished mitochondrial DNA and gene expression levels and the 
development of fibrosis at day 7 an day 21. Similarly reduced ECAR values were associated 
with reduced glycolytic gene expression.
Conclusions: Here we present a novel approach for high throughput monitoring and 
analysis of mitochondrial respiration in intact kidney tissue sections. Our data indicate that 
AKI to CKD transition is associated with reduced mitochondrial respiration and glycolysis 
rates. A detailed protocol of this method will be presented at the meeting.
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Lipopolysaccharide Causes Renal Biotin Uptake Inhibition via a 
Transcriptional Mechanism
Ashwinkumar subramenium S. Ganapathy,3 Hamid Moradi,1,4 
Veedamali Subramanian,1 Hamid M. Said.2 1University of California, Irvine, 
Orange, CA; 2UCI/VA, Long Beach, CA; 3Penn State Hershey Medical Center, 
Hershey, PA; 4Long Beach VA Healthcare System, Long Beach, CA.
Background: Biotin (vitamin B7), a water-soluble vitamin, is indispensable for normal 
human health and its deficiency is associated with various severe clinical conditions. Renal 
proximal tubule epithelial cells are critical to maintaining normal body biotin homeostasis 
by mediating its reabsorption via a specific carrier mediated process (sodium-dependent 
multivitamin transporter [SMVT]). Although it has also been shown that lipopolysaccharides 
(LPS) can cause intestinal biotin deficiency by inhibiting its absorption, very little is known 
about the effect of inflammation and LPS on the kidney biotin uptake process.
Methods: Given the major role of inflammation in kidney disease and injury we sought 
to assess the effect of LPS exposure on renal biotin transport. We evaluated the impact of 
LPS on renal biotin uptake, expression, promoter activity and transcriptional regulation 
using in vitro (human proximal tubule kidney epithelial HK2 cells) and in vivo (mice) 
models subjected to LPS for 72 hours.
Results: The HK2 cells treated with LPS from gram negative E. coli (10 μg/ml) 
exhibited a significant inhibition in carrier-mediated biotin uptake, compared to controls. 
This inhibition was associated with a significant reduction in SMVT protein, mRNA 
and hnRNA expression levels. Similar inhibition of SMVT protein, mRNA and hnRNA 
expression levels were also observed in mice injected with LPS (2 mg/kg body weight). 
Additionally, we found that SLC5A6 (biotin) promoter activity was attenuated following 
LPS treatment of HK2 cells. This was associated with a significant reduction in the mRNA 
expression levels of activator protein-2 (AP-2), a transcription factor which drives the 
SLC5A6 promoter activity, in both of our in vitro and in vivo models.
Conclusions: This study shows for the first time that LPS inhibits renal biotin uptake 
via a transcriptionally-mediated mechanism. The potential clinical impact of these findings 
and possible role of biotin therapy in kidney injury caused by LPS remains to be determined.
Funding: NIDDK Support, Veterans Affairs Support
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Lack of DJ-1 Amplifies Sepsis-Associated AKI and Increases Daxx-Medi-
ated Parenchymal Apoptosis
Joseph T. Leeds,1 Yogesh M. Scindia,2 Valentina Loi,3 Ewa U. Mandziak,1 
Saleh Mohammad,1 Sundararaman Swaminathan.1 1University of Virginia, 
Charlottesville, VA; 2Univerisity of Virginia, Charlottesville, VA; 3AO Brotzu 
Cagliari, Cagliari, Italy.
Background: Sepsis is frequently complicated by acute kidney injury (AKI). AKI in 
sepsis is associated with increased morbidity and mortality. Studies of sepsis-induced AKI 
suggest that uncontrolled inflammatory responses to tubular injury can further worsen renal 
damage. DJ-1 is a known anti-oxidant protein that is expressed in the brain, kidney, and 
immune cells. The role of DJ-1 in sepsis is not clear. AKI is one of the common sepsis-
associated pathologies, and there is no data on the role of DJ-1 in sepsis-associated AKI.
Methods: Wildtype and DJ-1 knockout mice both on B6 background were administered 
6.5 mg/kg LPS (i.p.) and tissues were harvested 24 hours later. Renal function and injury, as 
well as markers for inflammation were studied. Inner Medullary Collecting Duct cells 
(iMCD3) were used to study activation as well as cytotoxic serum responses.
Results: Compared to WT mice, DJ-1(-/-) mice were more susceptible to LPS-induced 
AKI as indicated by higher plasma creatinine (WT LPS 0.61 ± 0.11 Vs DJ-1(-/-) LPS  
0.87 ± 0.23; p= 0.0006) and Kidney Injury Marker-1 (KIM-1). Markers of renal 
inflammation (s100A8 and s100A9) and Reactive Oxidant/Nitrogen Stress (ROS/RNS) 
were increased in renal tissue of DJ-1 deficient mice. The increased oxidative stress was 
associated with induction of Daxx-mediated apoptosis in the kidney. We demonstrate a 
protective effect of DJ-1 against LPS serum toxicity with in vitro studies on IMCD3 cells.
Conclusions: Our data suggests DJ-1 plays an important protective role in against 
sepsis-associated renal inflammation and injury, through ROS/RNS control, and by 
preventing Daxx-dependent apoptosis.
SA-PO587 Poster Saturday
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Severity and Frequency of Tubule Injury Induced by Ischemia-Reperfu-
sion Determines Prognosis of AKI
Yang Dong, Ying Fan, Qunzi Zhang, Jiejun Wen, Yiyun Wang, Niansong Wang. 
Shanghai 6th People’s Hospital affiliated to Shanghai Jiaotong University, 
Shanghai, China.
Background: Ischemia is a common etiology in human acute kidney injury (AKI), 
which is an underestimated, yet significant predisposing factor for development of chronic 
kidney disease (CKD). However, a systematic and explicit reference standard is lacking for 
researchers when IRI models with divergent outcomes are to establish. Also, the biomarkers 
reflecting AKI to CKD progression are particularly lacking. The purpose of the current 
study was to establish suitable mice models simulating different clinical situations of renal 
ischemia patients, investigating the time and frequency effect of ischemia on AKI and 
subsequent AKI to CKD progression and exploring the potential function of noninvasive 
biomarkers KIM-1 and NGAL in predicting the renal outcome and prognosis.
Methods: Male C57BL/6J mice were subjected to different durations and episodes 
of ischemia attack for the UIRI (Unilateral Ischemia-Reperfusion Injury). We collected 
and analyzed the kidney samples at different time point post-ischemia. The concomitant 
changes of tubular injury biomarkers KIM-1 and NGAL in blood and urine along with 
different disease progression pattern were also investigated.
Results: We found that short-term duration of ischemia induced mild and reversible 
AKI in mice, while long-term duration of ischemia led to severe and progressive AKI. 
Repeated attack of moderate ischemia reperfusion injury could be applied to establish 
a model of AKI on CKD in mice. Furthermore, levels of KIM-1 and NGAL restored 
completely in reversible AKI, while they remained increased in progressive AKI. To be 
specific, levels of NGAL presented an increasing tendency till the chronic phase of the 
disease, while levels of KIM-1 merely peaked at the acute phase then suffered a subsequent 
decrease although still significantly higher than basal values.
Conclusions: In conclusion, different severity and frequency of ischemia injury 
dictate the divergent outcomes of ischemia-induced AKI. Both KIM-1 and NGAL enable 
noninvasive and early detection of AKI, also NGAL may better reflecting and predicting the 
process of AKI to CKD progression.
Funding: Government Support - Non-U.S.
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PBI-4050 Reduces Systemic Inflammation, Electrolyte Disturbances, and 
Renal Injury in Mice with Sepsis-Induced AKI: Role of GPR84
Jean-Francois Thibodeau,1,3 Chet E. Holterman,3 Marie-Pier Cloutier,1 Jean-
Christophe Simard,1 Lyne Gagnon,1 Pierre Laurin,1 Richard L. Hébert,2,3 
Francois A. Leblond,1 Chris R. Kennedy.2,3 1Prometic Biosciences Inc., Laval, 
QC, Canada; 2Department of Cellular and Molecular Medicine, Faculty of 
Medicine, University of Ottawa, Ottawa, ON, Canada; 3Kidney Research 
Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Background: PBI-4050, Prometic Biosciences Inc.’s lead drug candidate, exerts 
anti-inflammatory and anti-fibrotic effects in several diabetic and non-diabetic models of 
kidney injury through modulation of GPR40 and GPR84 fatty acid receptors. Primarily in 
macrophages and fibroblasts, we have shown that the pro-inflammatory GPR84 receptor is 
induced in cultured human renal cells including proximal tubule epithelial cells (hPTEC) 
and podocytes (hPod) stimulated with bacterial lipopolysaccharides (LPS). We therefore 
queried the impact of PBI-4050 in a model of endotoxemia-induced AKI and evaluated the 
role of GPR84 in this regard.
Methods: Eight-week old male C57BL/6 mice were treated with PBI-4050 (200 mg/kg 
BW, p.o.) for 14 days followed by LPS (10 mg/kg, i.p.)-challenge and sacrificed 24 hours 
later.
Results: AKI was confirmed as LPS led to a rapid rise in plasma creatinine and urea, which 
were significantly decreased in PBI-4050-treated mice. LPS-induced hyperphosphatemia, 
hyperkalemia, hypocalcaemia and hypoglycemia, were also significantly improved by PBI-
4050. Circulating levels of several major pro-inflammatory cytokines, including IL-1β, 
IL-6, MCP-1, TNFα, CXCL-1 and Rantes (CCL5) correlated with creatinine levels, and 
were significantly decreased by PBI-4050 in LPS mice. Moreover, PBI-4050 reduced LPS-
induced albuminuria and albuminemia. Histological assessment revealed tubular cell injury 
was reduced and PT-megalin expression improved with PBI-4050, as was peri-glomerular 
and tubulointerstitial α-SMA expression. In a pilot study, GPR84-/- mice challenged with 
24 hours LPS showed modest yet significant improvements in renal function. LPS caused 
GPR84 induction in cultured hPTECs and hPODs. PBI-4050 treatment in LPS-stimulated 
hPTEC and hPods decreased pro-inflammatory gene expression including MCP-1, IL-6 
and IL-8.
Conclusions: Taken together, PBI-4050 improves systemic inflammation and 
indicators of glomerular and tubular injury in a model of LPS-induced AKI partly through 
GPR84 and may directly target specific renal cell types including PTEC’s and podocytes.
Funding: Commercial Support - Prometic Life Sciences Inc.
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Ceria-Zirconia Nanoparticles as an Enhanced Multi-Antioxidant 
Attenuates Apoptosis of Human Kidney Proximal Tubular Epithelial Cells 
in Hypoxia
Se-Hee Yoon,1 Jang-Hee Cho,2 Won Min Hwang,1 Sung-Ro Yun,1 Kuk-Ro Yoon.3 
1Konyang University Hospital, Daejeon, Republic of Korea; 2Kyungpook 
National University Hospital, Daegu, Republic of Korea; 3Hannam University, 
Daejeon, Republic of Korea.
Background: Hypoxia is an important cause of acute kidney injury (AKI) in various 
conditions because kidneys are one of the most susceptible organ to hypoxia. Various 
mechanisms have been introduced as mediators of the AKI caused by hypoxia, including 
calcium overload, endoplasmic reticulum stress, complement system activation, and 
reactive oxygen species (ROS). ROS play an important role in hypoxia induced AKI by 
affecting the function of cellular DNA, proteins, and lipids. The use of antioxidants can 
benefit the control and prevention of hypoxia induced AKI. Ceria-Zirconia nanoparticles 
(CZ NPs) exhibit superoxide dismutase and catalase mimetic activities. We investigated the 
effect of CZ NPs in cultures of hypoxia exposed human proximal tubular epithelial cells.
Methods: CZ NPs with size 2-3nm were synthesized using non-hydrolytic sol-gel 
reaction. To investigate the catalytic effect of CZ NPs, reactive oxygen species (ROS) 
production was measured using DHE, DCF-DA and amplex red assay. Cellular survival rate 
and cytotoxicity were measured with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay. Cellular signaling pathway were studied by real time polymerase 
chain reaction and Western blot analysis.
Results: Cell survival was reduced in a dose-dependent manner for 24h after hypoxia 
exposure. Hypoxia caused a significant increase in ROS production 24 h after hypoxia. 
The extent of the effect of hypoxia on ROS levels was significantly reduced by CZ 
NPs treatment. CZ NPs downregulated proinflammatory markers and reduced caspase 
3/7 activity in hypoxic HK-2 cells. CZ NPs also improved the survival of HK-2 cells in 
response to hypoxia.
Conclusions: CZ NPs have the potential as a therapeutic medicine for preventing ROS-
related hypoxia induced AKI
SA-PO590 Poster Saturday
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NADPH Oxidase 4 Mediates TGF-β1/Smad Signaling Pathway Induced 
AKI in Hypoxia
Se-Hee Yoon,1 Jang-Hee Cho,2 Won Min Hwang,1 Sung-Ro Yun.1 1Konyang 
University Hospital, Daejeon, Republic of Korea; 2Kyungpook National 
University Hospital, Daegu, Republic of Korea.
Background: Hypoxia is an important cause of acute kidney injury (AKI) in various 
conditions because kidneys are one of the most susceptible organ to hypoxia. Reactive 
oxygen species (ROS) plays an important role in hypoxia induced AKI. Among various 
sources of ROS, nicotinamide adenine dinucleotide 3-phosphate (NADPH) oxidase (Nox) 
is the major intracellular non- mitochondrial ROS source. Because among seven Nox 
families, Nox4 is the most abundant in the human kidney, changes of Nox4 expression 
in hypoxia are predicted to affect the progression of AKI by altering the intracellular ROS 
level in the kidney. Based on these observations, we investigated the role of Nox4 and the 
benefits of Nox4 inhibition in hypoxia induced AKI.
Methods: The hypoxic injury induced in HK-2 cells by hypoxia chamber and CoCl2. 
Reverse transcription polymerase chain reaction for Nox4 and TGF-β1 was performed. 
Western blotting for Nox4 and Smad pathway were done. ROS production was detected 
using a DHE stain and Amplex red assay. HK-2 cells were transfected with siNox4 and 
pretreated with GKT137831(most specific Nox1/4 inhibitor). ELISA has been used 
to measure TGF-β1 levels. The effect of treatment with TGF-β1 type 1 tyrosine kinase 
inhibitor SB431542 on Nox4 expression was observed.
Results: Expression of Nox4 in cultured human renal proximal tubular epithelial cells 
(HK-2) was significantly increased by hypoxic stimulation. TGF-β1 was endogenously 
secreted by hypoxic HK-2 cells. SB4315432 (a TGF-β1 receptor I inhibitor) significantly 
inhibited Nox4 expression in HK-2 cells through the Smad-dependent cell signaling 
pathway. Silencing of Nox4 using Nox4 siRNA and pharmacologic inhibition with 
GKT137831 reduced the production of ROS and attenuated the apoptotic pathway. 
In addition, knockdown of Nox4 increased cell survival in hypoxic HK-2 cells and 
pretreatment with GKT137831 reproduce these results.
Conclusions: This study demonstrates that hypoxia induces HK-2 cell apoptosis 
through a signaling pathway involving TGF-β1 via Smad pathway induction of Nox4-
dependent ROS generation. Therapies targeting Nox4 may be effective against hypoxia-
induced AKI.
SA-PO591 Poster Saturday
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Ischemia Time Effects Long-Term Kidney Function in a Murine Model of 
Unilateral Ischemic AKI
Danielle Soranno,1 Lara A. Kirkbride-Romeo,2 Sarah Faubel.1 1University of 
Colorado Denver, Denver, CO; 2University of Colorado, School of Medicine, 
Aurora, CO.
Background: The duration of ischemia that allows for complete recovery remains 
undetermined. Parekh performed a prospective study in patients undergoing unilateral 
ischemia-reperfusion acute kidney injury (UiAKI) for partial nephrectomy, and evaluated 
histological, serum and urine biomarker changes. Their findings suggested that while there 
was evidence of acute biomarker and histological injury, the injury was short-lived and did 
not correlate with ischemia times. This study has been utilized clinically to reassure against 
long-term renal damage following prolonged ischemia, but did not include outcomes 
beyond the immediate post-operative period.
Methods: Adult male C57BL/6 mice underwent UiAKI or sham procedure on the left 
kidney for 32 or 60 minutes. Serum and urine biomarkers were evaluated at 2, 6, and 24 
hours, and 14 and 28 days. Transcutaneous glomerular filtration rate (tGFR) was measured 
serially. Additional 14 and 28 day groups underwent healthy unilateral nephrectomy 3 days 
prior to sacrifice in order to unmask any compensatory hyperfiltration.
Results: tGFR and histological outcomes demonstrated significant functional 
impairment and fibrosis despite reassuring serum biomarkers at the 14 and 28 day time-
points.
Conclusions: Ischemia time correlates with functional impairment and fibrosis despite 
reassuring urine and serum biomarkers. Efforts to limit ischemia time in renal-sparing 
surgery remain warranted.
(A) Serum creatinine and (B) Urine KIM-1 were reassuring at the day 14 and 28 time-
points (without nephrectomy), while functional assessment of glomerular filtration rate and 
histological outcomes demonstrated higher degrees of injury proportional to the ischedmia 
time. Specifically, 32 minutes of ischemia did not impair GFR 28 days later (C) and (E) 
while 60 minutes of ischemia resulted in nil function of the injured kidney (D) and (E).
Picrosirius Red staining demonstrated increased fibrosis in the left injured kidney for both 
the 32 and 60 minute ischemia times (F). n = 5-7, p < 0.05.
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Metabolomic Alterations in a Mouse Model of Cisplatin-Induced AKI
Yong Jin (James) Lim,1 Emily D. Hartjes,1 Brad Urquhart.1,2 1Physiology and 
Pharmacology, Western University, London, ON, Canada; 2Medicine, Division 
of Nephrology, Western University, London, ON, Canada.
Background: Cisplatin-induced acute kidney injury (AKI) occurs in approximately 
1/3 of patients receiving cisplatin therapy, but the reason why only certain patients develop 
AKI is unknown. AKI is currently diagnosed by increases in serum creatinine (SCr), but 
nephrotoxicity develops prior to detectable rises in SCr. Discovery of novel predictive/
diagnostic markers of AKI is necessary and may help explain the differential susceptibility 
of cisplatin patients to AKI. FVB mice have shown greater susceptibility to cisplatin AKI 
than C57BL/6 mice. These two strains were used to model the variability of cisplatin 
nephrotoxicity observed in humans. We aim to: 1) Determine the differences in expression 
of renal transporters and enzymes involved in cisplatin disposition these mouse strains; 2) 
Investigate metabolic differences between FVB and C57BL/6 mice using metabolomics, 
with the aim of biomarker discovery.
Methods: FVB and C57BL/6 strains were treated with 15 mg/kg cisplatin or saline by 
intraperitoneal injection. Mice were sacrificed 1 and 3 days following treatment, and blood, 
urine, and kidneys were collected. Gene expression was assessed using RT-PCR. Liquid 
chromatography-mass spectrometry was used for untargeted metabolomics.
Results: Renal expression of transporters Oct2 and Oat1, and metabolizing enzyme 
Ggt1 were higher (+20%, p<0.05; +38%, p<0.01; +45%, p<0.05) in untreated FVB mice 
compared to C57BL/6. Principle component analysis (PCA) of plasma and kidney samples 
from untreated FVB and C57BL/6 showed visual separation based on mouse strain. PCA 
of day 3 plasma and kidney samples separated cisplatin and saline groups for both strains. 
Multivariate analysis revealed uremic toxins indoxyl sulfate, phenyl sulfate and p-cresyl 
sulfate to be altered in cisplatin AKI.
Conclusions: FVB mice exhibited increased expression of various renal transporters 
and enzymes involved in cisplatin disposition, as compared to C57BL/6. PCA clustering of 
plasma and kidney samples from untreated mice indicates baseline metabolic differences 
between the strains, while separation by treatment (saline vs. cisplatin) suggests that 
cisplatin administration alters the metabolic profile of the mice. Future work will further 
characterize metabolic changes associated with cisplatin AKI. Our data suggests possible 
mechanisms why FVB mice are more susceptible to cisplatin AKI compared to C57BL/6 
mice.
Funding: Government Support - Non-U.S.
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Coenzyme Q-10 Protects Against Radiocontrast-Induced AKI by 
Regulating Heme Oxygenase-1 (HO-1) and Inducible Nitric Oxide 
Synthase (iNOS)
Sheila M. Fernandes,2,1 Maria De Fatima Vattimo,2,1 Cassiane D. da Fonseca,2,1 
Mirian Watanabe,2,1 Karina B. Peres,2,1 Carolina F. Vasco.3 1EEUSP, São Paulo, 
Brazil; 2Universidade de São Paulo (USP), São Paulo, Brazil; 3Universidade de 
São Paulo, São Paulo, Brazil.
Background: Radiocontrast agents are thought to induce acute kidney injury in part 
through increased production of reactive oxygen species. Recently, we reported that IC 
reduced inulin clearance and increased urinary peroxides, nitric oxide and TBARS with 
consumption of antioxidant reserve, that were significantly attenuated by COQ-10 (Vattimo 
MFF, JASN 2016). The aim of this study is to examine if the renoprotective effect of COQ-
10 is mediated by heme oxygenase-1 (HO-1) and inducible nitric oxide synthase (iNOS) 
in diabetic rats.
Methods: Adult male Wistar rats, randomized into 4 groups: Citrate - citrate buffer 
(streptozotocin vehicle); DM (streptozotocin, 65 mg/kg, iv).; DM+IC - DM animals 
that after 4 weeks received iodinated contrast (IC, 6 ml/kg, ip); DM+IC+CO-Q10 - DM 
preconditioned animals (COQ-10, (10 mg/kg, ip). Were evaluated gene expression and 
protein syntesis of heme oxygenase-1 (HO-1) and inducible nitric oxide synthase (iNOS) in 
CI-AKI in diabetic rats treated with COQ-10.
Results: Treatment with IC significantly incresed gene expression and reduced protein 
syntesis of HO-1 in diabetic rats compared the DM group. COQ-10 induced an elevation in 
gene expression and in the protein syntesis of HO-1. IC led to a increasing the levels of gene 
expression and protein syntesis of iNOS in the kidney rats diabetic. Treatment with COQ-10 
was able to attenuate the increase in iNOS protein levels observed in DM+CI group.
Conclusions: The data highlighted that the regulation of HO-1 and iNOS can be point 
out as the mechanism involved in the renal protective effect of the COQ10 in the CI-AKI in 
diabetic rats, probably due to its anti-oxidative and anti-nitrosative effective.
Funding: Government Support - Non-U.S.
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Heme Oxigenase-1 (HO-1) and Inducible Nitric Oxide Synthase (iNOS) 
Modulate by Resveratrol in Contrast-Induced AKI in CKD Rats
Sheila M. Fernandes,5,4 Maria De Fatima Vattimo,5,4 Mirian Watanabe,2,4 
Karina B. Peres,3,4 Daniel M. Martins,1 Carolina F. Vasco.6 Experimental lab on 
animal models 1University of São Paulo, Carapicuíba, Brazil; 2University of 
Sao Paulo, Sao Paulo, Brazil; 3EEUSP, São Paulo, Brazil; 4Escola de 
Enfermagem da USP (EEUSP), Universidade de São Paulo (USP), São Paulo, 
Brazil; 5Universidade de São Paulo (USP), São Paulo, Brazil; 6Universidade de 
São Paulo, São Paulo, Brazil.
Background: Iodinated contrast (IC)-induced acute kidney injury (AKI) is an important 
complication in patients with chronic kidney disease (CKD). In previous studies, we 
demonstrated a protective effect of Resveratrol (R) treatment demonstrated improvement of 
renal function in IC-AKI by renal hemodynamic modulation in CKD rats (VATTIMO MFF, 
JASN 2016). The aim of this study was to evaluate the potential renoprotective effect of 
resveratrol as anti-oxidate and anti-nitrosative by modulation of heme oxygenase-1 (HO-1) 
and nitric oxide induced synostosis (iNOS) in rats with CKD treated with IC.
Methods: Wistar, adult, male rats were randomized in four groups. Sham (control 
group), 5/6 (CKD model: 5/6 nefrectomy), 5/6+IC (CKD model + IC, 6ml/Kg, 
intraperitoneal- i.p., single dose), 5/6+IC+R (CKD model + R, 25 mg/Kg, intraperitoneal, 
single dose + IC, i.p, single dose, 30 minutes after R). Gene expression and protein syntesis 
of HO-1 and iNOS in renal tissue were evaluated.
Results: Treatment with IC significantly incresed gene expression and protein 
synthesis of HO-1 in 5/6 + IC rats compared to the 5/6 (DRC model) group and treatment 
with Resveratrol induced an additional elevation in gene expression and in the protein 
synthesis of HO-1 in 5/6 + IC + R rats. The levels of gene expression and protein synthesis 
of iNOS also to increase in the kidney of 5/6+IC group. 5/6 + IC + R reduced iNOS protein 
levels compared to 5/6 + IC rats.
Conclusions: These results demonstrate that Resveratrol influence renal HO-1 and 
iNOS expression after IC-induced AKI in CKD rats and may contribute to better outcomes 
in this setting by involvement in the modulation of oxidative and nitrosative stress.
Funding: Government Support - Non-U.S.
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Renal Epithelial Cells Reprogram Metabolism to Adapt to Sepsis
Carlos L. Manrique-Caballero, David R. Emlet, Alicia Frank, Abigail E. Marrow, 
John A. Kellum, Hernando Gomez Danies. Center for Critical Care Nephrology, 
University of Pittsburgh, Pittsburgh, PA.
Background: Adaptive metabolic reprogramming may play a key role in the 
development of sepsis induced acute kidney injury (AKI). Like monocytes, renal tissue 
shifts metabolism toward glycolysis early after cecal ligation and puncture. In monocytes, 
this shift is driven by the hypoxia inducible factor (HIF-1a) though expression of pyruvate 
kinase M2 (PKM2) and pyruvate dehydrogenase kinase (PDHK), whereas return to 
oxidative phosphorylation (OXPHOS) is driven by the activation of Sirtuin 1 (Sirt1). We 
hypothesized that human kidney 2 cells (HK2) follow the same biphasic reprogramming as 
an adaptive mechanism to sepsis.
Methods: HK2 were cultured in serum containing media and plated in XF24 
microplates and 6-well plates for Seahorse and immunoblotting (WB) respectively at 
21% O2. Cells were treated with vehicle or sepsis mix (SM=LPS+HMGB1). We measured 
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) as surrogates 
of glycolysis and OXPHOS, respectively at 3 and 24 hours after treatment. HIF-1a, PDHK, 
Sirt1 and b-Actin were identified by WB at 3, 6, and 24h.
Results: SM induced a decline in ECAR and an increase in OCR at 24h (Fig 1), 
suggesting that utilization of glycolysis decreases, and utilization of OXPHOS increases 
by 24h of SM. SM induced an increase in HIF-1α levels at 3h, with a late decrease by 
24h. Protein levels of the downstream HIF-1α target, PDHK also increased from 3 to 6h, 
followed by a similar decline by 24h. SM induced a delayed increase in Sirt1 by 24h, with 
an early suppression at 3h (Fig 2).
Conclusions: Our study shows that in response to SM, HK2 cells shift metabolism 
by decreasing the use of glycolysis and increasing the use of OXPHOS by 24h. Increased 
expression of drivers and mediators of glycolysis early (3h) after SM, followed by a late 
(24h) decline in glycolysis concomitant with increased expression of drivers of OXPHOS, 
suggests a biphasic HK2 response to inflammation, reminiscent of that of monocytes.
Funding: Other NIH Support - 1K08GM117310-01A1
Fig 1. Change in glycolysis and OXPHOS from 3 to 24h after exposure to SM Fig 2. Protein 
expression of drivers of glycolysis and OXPHOS in HK2 cells after SM
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Cyclophilin A Promotes AKI and Inflammation Following Renal 
Ischaemia/Reperfusion Injury
Khai Gene Leong,1,2 Elyce Ozols,1,2 John Kanellis,1,2 David J. Nikolic-
Paterson,1,2 Frank Y. Ma.1,2 1Department of Nephrology, Monash Health, Clayton, 
VIC, Australia; 2Centre for Inflammatory Diseases, Monash University, Clayton, 
VIC, Australia.
Background: Cyclophilins are enzymes that regulate protein folding. During various 
pathological conditions, cyclophilin A (CypA) has been shown to promote leukocyte 
recruitment and inflammation. However, the contribution of CypA in acute kidney injury 
(AKI) and renal fibrosis is poorly understood. The aim of this study was to determine 
the role of CypA in renal tubular damage, inflammation, and fibrosis using the: (1) renal 
ischaemia/reperfusion injury (IRI), and (2) unilateral ureteric obstruction (UUO) models.
Methods: Groups (n=10) of wild type (WT) and CypA-/- mice on the 129 background 
were subjected to either: (1) bilateral renal IRI (19min at 37°C) and killed 24 hours post 
reperfusion, or (2) UUO surgery and killed on day 7. Controls were sham operated.
Results: Renal IRI induced AKI with a >6-fold rise in serum creatinine (sCr) in WT 
mice (41±13.8 vs 6.3±1.7umol/L in sham; P<0.0001) and marked tubular damage based on 
the tubular injury score, increased KIM-1 mRNA levels, and tubular cell death (TUNEL+ 
cells; all P<0.0001 vs sham). CypA-/- mice were protected from renal dysfunction with 
a 50% improvement of sCr (20.7±3.5umol/L; P<0.0001), less histologic tubular damage 
(P<0.01), lower KIM-1 mRNA levels (P<0.01), and less tubular cell death (P<0.001). 
Renal IRI caused upregulated mRNA levels of inflammatory molecules (TNF-α and IL-
36-α; P<0.05), and neutrophil infiltration (Ly6G+ cells; P<0.0001). CypA-/- mice had 
a clear reduction in inflammatory molecules (P<0.05) and less infiltrating neutrophils 
(P<0.001). UUO in WT mice resulted in significant renal fibrosis (3-fold increase in 
collagen IV deposition by immunostaining; P<0.001 vs sham), with significant infiltrates 
of macrophages (F4/80+ cells), T cells (CD3+ cells) and neutrophils (Ly6G+ cells) (all
P<0.0001 vs sham). CypA-/- mice were not protected from renal fibrosis or leukocyte 
infiltration in the UUO model.
Conclusions: CypA contributes to leukocyte infiltration and inflammation leading 
to AKI following IRI. In comparison, the leukocyte infiltration and renal fibrosis seen 
following the less severe tubular injury in UUO does not require CypA. This contrast may 
relate to differences in CypA release/secretion by tubular cells in the two models.
SA-PO597 Poster Saturday
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Preexisting CKD Impairs Recovery from AKI in Female Rats
Jacqui Potter, Aaron J. Polichnowski. East Tennessee State University, Johnson 
City, TN.
Background: We previously demonstrated that male rats with preexisting CKD exhibit 
impaired recovery from AKI and the subsequent development of de novo mechanisms of 
CKD progression. The goal of this study was to determine if impaired recovery from AKI is 
also observed in female rats with preexisting CKD.
Methods: We induced two levels of CKD in 10-12 week old male and female Sprague-
Dawley rats by performing either 50% renal mass reduction via a right uninephrectomy 
(UNX, n=14, 6 females) or 75% renal mass reduction via a right UNX + surgical excision 
of 1/2 of the left kidney (3/4 NX, n=12, 6 females). Two weeks later, rats were subjected 
to 35 minute ischemia-reperfusion (IR)-induced AKI. Blood samples were obtained prior 
to IR and at 48 hours and 7, 14 and 28 days post IR to assess plasma creatinine (PCr). A 24-
hour urine collection was performed in a subset of rats prior to IR and at 28 days post IR to 
assess proteinuria. At the end of the study, renal pathology and tubular vimentin expression 
were assessed.
Results: The severity of AKI, based on PCr levels 48 hours post AKI, was similar 
between UNX vs. 3/4 NX groups. The severity of AKI was lower (P<0.05) in females 
vs. males with 3/4 NX (1.9±0.3 vs. 3.3±0.3 mg/dl) but not significantly different between 
females vs. males with UNX (1.7±0.6 vs. 2.7±0.4 mg/dl). While minimal injury and 
vimentin expression (0.7±0.2) was observed in females with UNX, females with 3/4 
NX exhibited greater (P<0.05) tubular vimentin staining (1.3±0.3), tubular injury and 
fibrosis 28 days post IR. Moreover, recovery of PCr over 28 days post IR was delayed in 
females with 3/4 NX vs. UNX. Finally, female rats with 3/4 NX developed substantial 
(P<0.05) increases in proteinuria 28 days post IR as compared to pre-IR levels (195±57 vs. 
62±20 mg/day) while proteinuria was similar at 28 days post IR vs. pre-IR in female rats 
with UNX (21±4 vs. 23±5 mg/day). Males with 3/4 NX exhibited impaired recovery from 
AKI and the development of proteinuria 28 days post AKI as compared to males with UNX.
Conclusions: These data support previous studies documenting resistance to IR-
induced AKI in female vs. male rats. However, our data indicate that preexisting CKD of 
greater than 50% renal mass reduction predisposes female rats to impaired recovery from 
AKI and the subsequent development of mechanisms of CKD progression, similar to male 
rats.
Funding: Private Foundation Support
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Double-Negative T-Cells That Express PD-1 Are Early Responders During 
Ischemic AKI
Mohanraj Sadasivam,1 Sanjeev Noel,1 Sul A Lee,2 Abdel Hamad,1 Hamid Rabb.2 
1Johns Hopkins University, Baltimore, MD; 2Johns Hopkins University School 
of Medicine, Baltimore, MD.
Background: Unconventional T cells (e.g. Tregs and γδT cells) are increasingly 
recognized for their roles in maintaining homeostasis and protecting non-lymphoid tissues 
against injury/stress. CD4-CD8- double negative (DN) αβT cells are abundant in mouse 
and human kidneys, actively dividing in steady state and involved in protecting against 
ischemic AKI. However, there is less knowledge about DN T cells residing in kidney are 
known.
Methods: C57BL/6J (WT), B6.129P2-B2mtm1Unc/J (β2m KO), B6.129S2-H2dlAb1-
Ea/J (MHC II KO), B6.129P2-H2-K1tm1Bpe H2-D1tm1Bpe/DcrJ (KD KO) and Nu/J mice 
were used for this study, n=3-7/group. Human kidney samples were from nephrectomies for 
renal cancers. Kidney lymphocytes were isolated and analyzed by flow cytometry.
Results: Our data demonstrates that kidney DN T cells are thymus-derived as lack of 
thymus significantly reduced the absolute count of DN T cells in kidney (WT, 2.2x104 vs. 
Nu/J, 0.24x104, P<0.05) and also comprised of two (PD-1+ and NK1.1+) subsets whose 
development and homeostasis are dependent on non-classical MHC class I molecules. 
Development of the NK1.1+ subset is restricted by β2m-dependent non-classical MHC 
molecules as the frequency of NK1.1+ DN T cells was significantly reduced in β2m KO 
(10.3±2) but not in KD-deficient mice (21.5±2) then WT mice (23.1±3, P<0.001). In contrast, 
homeostasis but not development of the PD-1 subset is regulated by β2m-dependent non-
classical MHC molecules as the frequency of PD-1+ DN T cells was significantly higher 
in β2m KO (70.2±5) then WT mice (44.2±3 P<0.001). DN T-cells are present in kidney of 
β2m KO mice, but lose their phenotypic activation (>60%, P<0.001), spontaneous steady 
proliferation (>40%, P<0.05) and undergo apoptosis. DN T cells retained in kidneys of 
β2m KO mice are mostly PD-1+ and remain functionally responsive to external stimuli 
as indicated by their rapid activation and expansion in response to ischemic AKI. Both 
normal human kidney and cancer samples express the PD-1+ (% normal, 39.5±8 vs. tumor, 
47.9±7.8) and NK1.1+ subsets (% normal, 26.2±8.4 vs. tumor, 23.0±8.3).
Conclusions: These findings demonstrate that kidney DN T cells, particularly PD-
1+ DN T cells, are early responders of the renal immune surveillance system utilizing 
recognition/activation/regulation mechanisms that differ from conventional T cells.
Funding: NIDDK Support
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Targeting Enhancer of Zeste Homolog 2 Protects Against AKI
Xiaoxu Zhou,2 Shougang Zhuang.1 1Rhode Island Hospital, Alpert Medical 
School of Brown University, Providence, RI; 2Rhode Island Hospital, Brown 
University, Providence, RI.
Background: Despite the established oncogenic and profibrotic functions of enhancer 
of zeste homolog 2 (EZH2), a methyltransferase that induces histone H3 lysine 27 
trimethylation (H3K27me3), its role in acute kidney injury (AKI) remains unclear.
Methods: In this study, we examined the effect of EZH2 inhibition on acute kidney 
injury in murine models induced by induced by either ischemia-reperfusion (IR) or folic 
acid (FA).
Results: We demonstrated that EZH2 and H3K27me3 were upregulated in the murine 
kidney with AKI in both models. Pharmacologic inhibition of EZH2 with 3-deazaneplanocin 
A (3-DZNeP) inhibited tubular injury in both models as demonstrated by a decrease in 
renal dysfunction, reduced neutrophil gelatinase-associated lipocalin expression and a 
lower rate of renal tubule cell death. Injury to the kidney resulted in reduced expression 
of E-cadherin and ZO-1, whereas EZH2 inhibition largely preserved their expression. 
Moreover, 3-DZNep was effective in counteracting the increased expression of matrix 
metalloproteinase (MMP) -2 and -9 as well as the phosphorylation of Raf-1 and ERK1/2 in 
the injured kidney. Conversely, blocking EZH2 reversed the decrease of tissue inhibitor of 
metalloproteinase (TIMP)-2 and -3 and Raf kinase inhibitor protein (RKIP) in the kidney 
after acute injury. Similarly, oxidant injury to cultured kidney proximal tubular epithelial 
cells caused a decrease in the expression of E-cadherin, ZO-1, TIMP-2/-3, and RKIP as 
well as an increase in the expression of MMP-2/9 and phosphorylation of Raf-1 ERK1/2. 
Blocking EZH2 with 3-DZNep or SiRNA hindered these responses.
Conclusions: These results suggest that targeting EZH2 protects against AKI through 
a mechanism associated with the preservation of adhesion/junctions, reduction of matrix 
metalloproteinases and attenuation of the Raf-1/ERK1/2 pathway.
Funding: NIDDK Support
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Deciphering the Role of Angpt4-Tie2 Signaling in the Kidney
Antoine Tarjus,1,2 Rizaldy P. Scott,1,2 Tuncer Onay,1,2 Susan E. Quaggin.1,2 
Quaggin lab 1Northwestern University, Feinberg School of Medicine, Chicago, 
IL; 2Department of Medecine, Division of Nephrology and Hypertension, 
Northwestern Medecine, Chicago, IL.
Background: The angiopoietin-Tie2 signaling pathway is fundamental for vascular 
development and has been linked to numerous kidney diseases including diabetic nephropathy 
and sepsis-related AKI. The pathway is composed of two receptors, Tie1 and Tie2, and 
three ligands, Angiopoiein-1, Angiopoietin-2 and Angiopoietin-4 (Angpt-4). Among the 
ligands, Angpt-4 has been poorly characterized. While Angpt4 has been suggested to act as 
a Tie2 agonist and seems to be highly regulated by hypoxia, its physiological role remains 
elusive. Moreover, the study of Angpt-4 function is currently challenging due to the lack of 
knockout transgenic model. In order to decipher its physiological role, we have developed 
a new Angpt4 mouse model.
Methods: We generated a new reporter and conditional allele for Angpt4 in mice. Using 
the X-gal chromogenic substrate of the β-galactosidase, this model allows us to characterize 
high-resolution expression pattern of Angpt-4. To identify the cell type expressing Angpt-4, 
we performed immunohistochemical staining on tissue sections using antibody coupled with 
the alkaline phosphatase enzyme. Global and timed deletion of Angpt4 was accomplished 
using ubiquitous and tetON inducible Cre-deletor lines.
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Results: X-gal staining reveals strong expression restricted to the vasculature of organs 
including the kidney, adrenal glands, gonads, and mesentery. In the kidney, X-gal staining is 
found in the renal and interlobular arteries. Using an antibody against Transgelin (SM22), a 
marker of smooth muscle cells, we show Angpt-4 co-localizes with vascular smooth muscle 
cells in the kidney. Global KO mice survive to birth and renal function testing is underway.
Conclusions: Our data demonstrate a highly specific vascular pattern of expression 
for Angpt-4 in smooth muscle cells of the vascular wall. These observations suggest that 
Angpt-4 may have a role in arterial function with potential impact in the pathology of renal 
ischemia as Angpt-4 has been shown to be regulated by hypoxia.
SA-PO601 Poster Saturday
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Targeting IL-17 Activity Protects from Salt Sensitive Progression of CKD 
Following AKI
Purvi Mehrotra,1 Riley P. O’Shaughnessy,2 David P. Basile.3 1Indiana School of 
Medicine, Indianapolis, IN; 2IUSM, Indianapolis, IN; 3Indiana University 
School of Medicine, Indianapolis, IN.
Background: Patients surviving AKI have a higher risk for chronic kidney disease 
(CKD). Previous studies in rats demonstrate that inhibition of T-cell activity (e.g., using 
mycophenolate or losartan) following recovery from AKI attenuates the subsequent 
development ofproteinuria, inflammation and fibrosis. Th17 cells, characterized by IL-17 
secretion, are the predominant T helper subset associated with the AKI-to-CKD transition. 
Blockade of IL-17 activity using IL-17Rc receptor antagonist significantly decreased 
fibrosis and neutrophil recruitment in post ischemic rats compared to vehicle treated 
controls but other parameters of AKI-CKD transition have not been evaluated.
Methods: Male Sprague Dawley rats were subjected to unilateral I/R (40min) and 
allowed to recover for 5 weeks on low salt diet (0.4%). Rats were subjected contralateral 
nephrectomy UNx and elevated dietary NaCl (4%) for 4 additional weeks to hasten CKD. 
The rats were injected anti-IL-17 (5 mg/kg) or IgG control during the exposure to high salt 
diet and blood pressure measured by telemetry.
Results: Renal hypertrophy was evident in post-AKI IgG-treated rats relative to sham 
(~14%), which was significantly attenuated by IL-17 neutralizing antibody (p<0.05). 
There was a significant increase in the levels CD4+IL17+ cells and CD4+IFNγ+ cells in 
kidney of post AKI rats which was significantly reduced by IL-17 neutralizing antibody 
(IL17: IgG 17847±3787 and IL-17 7360±1680; p£0.05; IFNγ+: IgG 2703±495 and IL-
17 1083±314; cells/g tissue p£0.05). Histological examination demonstrated that anti-
IL17 antibody treatment reduced the level of renal fibrosis as indicated by picrosirius red 
staining. In addition, m-RNA expression of Kim-1 and Tgf-bwas reduced by 25% and 42% 
respectively. Mean arterial blood pressure was significantly attenuated by ~ 12 mm Hg in 
post-ischemic rats treated with anti-IL17 relative to vehicle treated post-AKI rats.
Conclusions: These data suggest that enhanced expression of CD4+IL-17 cells 
contribute to renal inflammation, fibrosis and hypertension in CKD following AKI.
Funding: NIDDK Support
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Hypoxic Preconditioning Suppresses Renal Inflammation in Ischemic and 
Septic AKI
Rafael Torosyan, Ganeshkumar Rajendran, Michael P. Schonfeld, 
Pinelopi P. Kapitsinou. University of Kansas Medical Center, Kansas City, KS.
Background: Prolyl-hydroxylases (PHDs) have emerged as safeguards of cellular 
metabolism through their oxygen sensing function, which enables them to regulate the 
activity of hypoxia-inducible factors (HIF). We previously reported that activation of HIF 
signaling via pharmacologic inhibition of PHDs (PHI) protects against kidney ischemia 
reperfusion injury (IRI). Here, we investigated whether HIF activation through exposure 
to normobaric hypoxia mimics the renoprotection induced by PHI. Using an unbiased 
metabolomic approach, we identified conserved metabolic responses between these 
interventions.
Methods: C57BL/6 male mice aged 8-10 weeks were subjected to normobaric hypoxia 
(8% O2) for 48 hours prior to induction of AKI via unilateral renal artery clamping (IRI) 
or LPS administration. Untargeted metabolomic screening by a GC/MS and LC/MS based 
platform was performed in sera from mice treated with PHI or exposed to acute hypoxia.
Results: Pre-ischemic exposure to normobaric hypoxia attenuated kidney injury at 
day 3 post IRI as indicated by improved kidney histogical scores and a 2.3-fold reduction 
of Kim1 mRNA levels in kidney homogenates compared to normoxic controls (n=7-8, 
P=0.0002). Furthermore, hypoxic preconditioning suppressed the expression of pro-
inflammatory genes Vcam1 and Tnfα by 2.6-fold (n=7-8, P<0.0001) and diminished the 
infiltration of Ly6B.2+ve cells in injured kidneys by 85% (P<0.0001) compared to controls. 
In a septic model of AKI induced by LPS, hypoxic preconditioning suppressed the 
transcripts of Tnfα and Il-6 by 2.3- and 5-fold respectively (Day 1 post LPS, n= 11-14; p 
< 0.009). Comparative untargeted metabolomic analysis revealed that exposure to hypoxia 
and pharmacologic PHD inhibition led to significantly overlapping alterations in serum 
metabolome. For instance, serum levels of α-ketoglutarate, a TCA cycle metabolite, were 
reduced by 60% in the setting of hypoxic preconditioning (n=8, P <0.0001) and by 36% 
with PHD inhibition (n=8, P = 0.004) compared to their corresponding controls.
Conclusions: Our data demonstrate that exposure to normobaric hypoxia attenuates 
kidney inflammation in both IRI-and sepsis-induced AKI. Furthermore, PHD inhibition 
induced by exposure to hypoxia or pharmacologic means lead to metabolic reprogramming, 
which may play a critical role in regulating inflammatory responses in the context of AKI.
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Conditional Histone Deacetylase-2 Knockout Within Renal Tubular Cells 
Is Protective in Renal Ischemia-Reperfusion Injury
David D. Aufhauser,1 Seth Concors,1 Zhonglin Wang,1 Douglas R. Murken,1 
Paul T. Hernandez,1 Guanghui Ge,1 Wayne W. Hancock,2 Matthew H. Levine.2 
1University of Pennsylvania, Philadelphia, PA; 2Children’s Hospital of 
Philadelphia and University of Pennsylvania, Philadelphia, PA.
Background: Ischemia/reperfusion injury (IRI) is a major source of morbidity in renal 
transplantation and other surgical scenarios. In renal transplantation, IRI contributes to poor 
outcomes and early graft loss. Histone deacetylases (HDACs) regulate diverse cellular 
processes. We have previously shown that the class I HDACs 1 and 2 have reciprocal effects 
on renal ischemia-reperfusion injury (IRI) with HDAC1 deletion increasing vulnerability 
and HDAC2 protection providing profound protection. A more thorough understanding of 
the mechanism of this protection, including the site of action, is critical to develop specific 
targeting in IRI.
Methods: Renal tubule-specific tamoxifen-inducible HDAC-2 knockout (HDAC2-
pax8), and tamoxifen-treated WT female (WT) control mice were used. Mice were subjected 
to warm renal IRI through unilateral clamping of the renal pedicle and contralateral 
nephrectomy under strict temperature control. Creatinine and BUN were examined at 24-, 
48-, 72-, and 96-hours post-IRI.
Results: HDAC2-pax8 mice had significant protection from renal injury after renal 
IRI versus WT mice, as shown by decreased elevations in BUN and Cr post-injury (Figure 
1, p<0.005).
Conclusions: Renal tubule-specific HDAC2 deletion is protective in a standardized 
model of renal warm IRI. We have now moved from showing efficacy with pan-HDAC 
inhibition to kidney-specific inhibition and now to proximal tubule-specific inhibition. This 
finding has important translational potential and provides guidance for identifying renal-
specific targets for clinical use.
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Renal Tubular Epithelial Cell Proliferation Inhibition by C-Reactive 
Protein and Myeloid Derived Suppressor Cells
Rachel Jimenez,1 Alexander J. Szalai.2 1University of Alabama at Birmingham, 
Birmingham, AL; 2The University of Alabama at Birmingham, Birmingham, AL.
Background: Re-establishment of renal function after acute kidney injury (AKI) 
largely depends on the recovery of injured renal tubular epithelial cells (RTEC). However, 
the inflammatory response that accompanies AKI complicates RTEC recuperation. In a 
series of studies, we showed that C-reactive protein (CRP), a well-known biomarker of 
inflammation, plays a causal role in AKI i.e. human CRP transgenic mice (CRPtg) subjected 
to renal ischemia-reperfusion have more severe AKI compared to CRP knockout mice. 
Notably, for CRPtg the exacerbation of AKI is accompanied by increased renal infiltration 
by myeloid derived suppressor cells (MDSC), and depletion of human CRP blunts both 
MDSC infiltration and renal injury. In the present study we explored the CRP → MDSC 
→ RTEC axis.
Methods: To determine the direct impact of human CRP on MDSC functions and
RTEC health, and to establish whether MDSCs can suppress RTEC proliferation, primary 
mouse RTECs were isolated and mouse MDSCs were generated from bone marrow (BM-
MDSC) and studied in vitro using microscopy, flow cytometry, and co-culture assays.
Results: We first confirmed that BM-MDSCs (CD11b+CD11c-F4/80-Ly6C+Ly6G+ cells 
with an immature nuclear morphology) effectively suppressed the proliferation of CD3ε/
CD28-stimulated CD4+ T cells and that this BM-MDSC suppressive action is enhanced 
by human CRP. When human CRP was added to freshly isolated bone marrow, human 
CRP increased the proportion of BM-MDSCs ultimately generated and also increased the 
proportion of BM-MDSCs entering S phase. Co-cultures with BM-MDSCs in transwells 
inhibited the cell cycling of primary RTEC monolayers.
Conclusions: Our results show that human CRP promotes the generation of MDSCs 
from bone marrow precursors and enhances their ability to suppress target-cells. Our 
initial evidence suggests BM-MDSCs suppress primary RTEC cell cycling in a contact-
independent manner. These new in vitro data align with our earlier observation that AKI 
is worsened in CRPtg. We hypothesize that in CRPtg with AKI, human CRP enhances 
the noxious effects of renal infiltrating MDSCs, thereby promoting inhibition of RTEC 
and delaying their recovery. Ongoing work investigates whether human CRP enhances the 
MDSC-mediated suppression of RTEC proliferation and whether this effect requires MDSC 
expression of CRP receptor(s).
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Impact of Ciprofloxacin on Renal Tubular Epithelial Injury Through the 
Interaction of Autophagy and Apoptosis
Woo Yeong Park,1,2 Hayeon Park,1 Kyubok Jin,1,2 Sung Bae Park,1,2 
Seungyeup Han.1,2 1Internal Medicine, Keimyung University School of Medicine, 
Daegu, Republic of Korea; 2Keimyung University Kidney Institute, Daegu, 
Republic of Korea.
Background: Autophagy and apoptosis play an important role in renal tubular epithelial 
injury by hypoxia, nutrient deprivation, and oxidative stress. Recent research reported that 
antibiotics might contribute to ischemic renal injury characterized by both apoptosis and 
inflammation, but the mechanism remains unclear. Therefore, we investigated the impact 
of ciprofloxacin on renal tubular epithelial injury through the interaction of autophagy and 
apoptosis.
Methods: We used MDCK cells, a model for renal distal tubular epithelial cells. We 
performed TUNEL assay to identify the effect of ciprofloxacin for cell viability under 
nutrient deprivation for 48 hours (hrs). We assessed apoptosis and autophagy markers 
to investigate the effect of ciprofloxacin through the interaction between apoptosis and 
autophagy.
Results: In the TUNEL assay, the ratio of apoptotic cells/total cells was significantly 
lower in the ciprofloxacin group (100 ug/mL) than in the control group (0 ug/mL) 
(7.17 ± 1.25 vs. 20.41 ± 1.04, P < 0.001). Among apoptosis markers, the ratio of pBax/Bax 
was reduced at 6 hr, and pBcl-2/Bcl-2 was increased at 12 hr in the ciprofloxacin group 
compared with the control group. In the MAPK pathway, located further upstream of Bax 
and Bcl-2, the ratio of pJNK/JNK, pp38/p38, and pERK/ERK was decreased at 12 hr in the 
ciprofloxacin group compared to the control group. The ratio of cleaved caspase 3/caspase 
3, the final effector caspase, was decreased at 36 hr in the ciprofloxacin group compared 
with the control group. Among autophagy markers, the level of Beclin-1 was increased at 
6 hr in the ciprofloxacin group compared with control group, and the level of LC3B was 
increased after 12 hr. Finally, activation of autophagy by ciprofloxacin during apoptosis by 
nutrient deprivation might cause recovery of renal tubular epithelial injury.
Conclusions: Ciprofloxacin can help to restore cell viability against renal tubular 
epithelial injury under nutrient deprivation condition, and the cell viability by ciprofloxacin 
might be associated with the crosstalk of autophagy and apoptosis. Therefore, ciprofloxacin 
is helpful to increase cell viability through activation of autophagy under ischemic renal 
injury.
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5-HT1F Receptor Mediates Renal Vascular Homeostasis and Mitochon-
drial Biogenesis
Tess Dupre, Rick G. Schnellmann. Pharmacology/Toxicology, University of
Arizona, Tucson, AZ.
Background: Acute kidney injury (AKI) is a devastating disease with no treatment 
options. After AKI, there is a marked reduction in renal vasculature. Thus, promoting 
vascular recovery following AKI could facilitate renal repair as the vasculature is responsible 
for carrying oxygen and nutrients to extravascular tissues. Our laboratory has shown that 
stimulating mitochondrial biogenesis (MB) through the 5-HT1F receptor stimulates recovery 
from AKI. In contrast, 5HT1F receptor knockout mice have decreased MB and poor renal 
recovery. Importantly, induction of MB has been linked to increased angiogenesis. Thus, 
we hypothesized that the 5HT1F receptor plays a role in vascular homeostasis and mediates 
MB in renal endothelial cells.
Methods: Primary human glomerular endothelial cells (HEC) and mouse glomerular 
endothelial cells (MEC) were treated with the 5-HT1F receptor agonists LY344864 or 
lasmiditan (0-500 nM) for 24 or 72h. Mitochondrial respiration using Seahorse analysis, 
mitochondrial proteins using immunoblot analysis and mitochondrial copy number using 
qPCR analysis was determined. Immunohistochemical analysis for CD31 was performed 
on paraffin embedded kidney sections.
Results: We determined that HEC and MEC express the 5-HT1F receptor. Treatment 
of HEC and MEC with LY344864 or lasmiditan induced MB, as evidenced by maximal 
mitochondrial respiration, a marker of MB. HEC that were treated with lasmiditan or 
LY344864 had increased expression of nuclear- and mitochondrial-encoded proteins 
(PGC1α, TFAM, NDUFS1, COX-1, and VDAC) and mitochondrial DNA copy number, 
confirming MB and increased mitochondrial content. Lastly, 5-HT1F receptor knockout 
mice had decreased renal vascular content, as immunohistochemical analysis revealed 
decreased CD31+ renal endothelial cells.
Conclusions: Stimulation of 5-HT1F receptor with LY344864 and lasmiditan induces 
MB in HEC and MEC, in vitro, and 5-HT1F receptor mediates vascular homeostasis, in vivo. 
We propose that inducing MB in endothelial cells after AKI could restore vascular function 
and stimulate renal repair and recovery.
Funding: Other NIH Support - 7R01GM084147-09, T32HL007249-40, Veterans 
Affairs Support
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Abnormal Uromodulin Glycosylation in AKI and Its Interaction with 
Protein in Lectin Pathway of Complement
Kunjing Gong,1 Min Xia,2 Yaqin Wang,3 Nan Hu,1 Yuqing Chen.1 1Peking 
University First Hospital, Beijing, China; 2Renal Division, Peking University 
First Hospital, Beijing, China; 3Renal division, Peking University First Hospital, 
Beijing, China.
Background: Uromodulin (UMOD) is a glycoprotein with a carbohydrate content, 
nearly 30%. It might protect against urinary tract infection and kidney stones, have roles 
in kidney injury and innate immunity. Many functions were glycosylation dependent. 
Mannose binding lectin (MBL) and collectin 11 (CL-11) were the initiated protein of lectin 
pathway (LP) with a carbohydrate-recognition domain (CRD). In the present study, we 
measured the glycosylation of acute kidney injury (AKI) patients and the binding affinity of 
UMOD to lectin pathway protein in modified glycosylation of uromodulin
Methods: 10 AKI patients and 10 healthy control recruited for this study after matched 
their age and gender. After purified the UMOD with diatomaceous earth, structure of the 
protein glycosylation chains was analyzed using matrix assisted laser desorption/ionization-
time of flight mass spectrometry (MALDI-TOF MS). Different kinds of glycosidase 
digested UMOD to make glycan-deficient protein. Binding affinity of uromodulin to MBL 
and CL-11 were probed by ELISA
Results: The profile of MALDI-TOF-MS N-glycans released from uromodulin healthy 
control showed more complex N-glycan structures. The amount of high mannose and core 
fucosylation were increase in the AKI patients compare with those healthy control (P<0.05). 
Native uromodulin could bind to CL-11 (Ca2+ independent) and MBL(Ca2+ dependent). The 
binding activity of UMOD to CL-11 was significantly decreased by digesting the protein 
with fucosidase and neuraminidase. Digested by EndoH could decrease the binding activity 
as well, while the decrease was slightly.
Conclusions: Abnormal glycosylation of UMOD could be observed in AKI patients. 
UMOD bind to lectin pathway protein, and this interaction was dependent on glycan 
structure of UMOD.
Funding: Government Support - Non-U.S.
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Hes1, a Newly Identified Downstream Mediator of α7nAChR on 
Macrophages in the Cholinergic Anti-Inflammatory Pathway, Plays a 
Protective Role in AKI
Tsuyoshi Inoue,1,2 Chikara Abe,3 Shinji Tanaka,1 Diane L. Rosin,1 
Masaomi Nangaku,2 Youichiro Wada,2 Mark D. Okusa.1 1University of Virginia, 
Charlottesville, VA; 2The University of Tokyo, Tokyo, Japan; 3Gifu University, 
Gifu, Japan.
Background: The cholinergic anti-inflammatory pathway (CAP) links the nervous 
and immune systems and modulates innate and adaptive immunity. Activation of the CAP 
by vagus nerve stimulation (VNS) exerts protective effects in a wide variety of clinical 
disorders including rheumatoid arthritis and Crohn’s disease. The CAP involves splenic 
alpha7-nicotinic acetylcholine receptor (α7nAChR)-positive macrophages although their 
detailed role in vivo has yet to be established.
Methods: RNA-seq using peritoneal macrphages from WT and α7nAChRKO mice 
was performed after nicotine and/or LPS treatment. Kidney IRI (bilateral, 26 mins) was 
used as an acute kidney injury model and was performed 24 hr after VNS (left side, 5 Hz, 
50 μA for 10 min) treatment or adoptive transfer of treated-macrophages. Kidney injury 
was evaluated 24 hr later using plasma creatinine, kidney Kim-1 mRNA expression and 
histology (H&E). TNF level in the media was measured by ELISA and RAW 264.7 cells 
were used as macrophages for the experiments requiring modifications of gene expression.
Results: Adoptive transfer of 1x105 nicotine-treated peritoneal macrophages from 
α7nAChR+/+ (α7WT; progeny control) but not from α7nAChR-/- (α7KO) mice protected 
kidneys of recipient mice from IRI, showing the importance of α7nAChR on macrophages. 
Nicotine-induced genes whose expressions were lower (<1/2 compared to α7nAChR+/+-
derived cells) in α7nAChR-/--derived peritoneal macrophages were extracted by RNA-
seq. We focused on hairy and enhancer of split-1 (Hes1), a basic helix-loop-helix (bHLH) 
transcription factor that acts as a transcriptional repressor of genes that require a bHLH 
protein for their transcription. VNS induced Hes1 expression in peritoneal macrophags. 
siRNA against Hes1 inhibited nicotine-induced TNF suppression, and Hes1 overexpression 
suppressed LPS-stimulated TNF induction in RAW 264.7 cells. Hes1 overexpression in 
RAW 264.7 cells mainly induced macrophage M2 markers (anti-inflammatory). Lastly we 
found that adoptive transfer of Hes1-overexpressing RAW 264.7 cells protected the kidney 
from IRI.
Conclusions: These data demonstrate that Hes1 is a new downstream signaling 
molecule of α7nAChR in the CAP.
Funding: NIDDK Support
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Influence of Renal Ischemia-Reperfusion Injury on Renal Neutrophil 
Gelatinase-Associated Lipocalin Receptor (24p3R) in Rats
Yusuke Arakawa,1,2 Kentarou Ushijima,3 Akiko Mii,4 Shuichi Tsuruoka,4 
Akio Fujimura.5 1Nephrology, Nippon Medical School, Tokyo, Japan; 
2Pharmacology, Jichi Medical University, Tochigi, Japan; 3Jichi Medical 
University, Shimotsuke, Japan; 4Nippon Medical School, Tokyo, Japan; 5Jichi 
Medical Univ., Simotsuke, Japan.
Background: The neutrophil gelatinase-associated lipocalin (NGAL) receptor 
(24p3R) is expressed in distal nephron, and contributes to the endocytosis of NGAL in 
urine. This study was undertaken to evaluate an influence of renal ischemia-reperfusion 
injury on 24p3R.
Methods: Unilateral renal pedicle was clamped for 0, 10, 20, 30, or 45 min in male 
Wistar rats. Urine was collected for 24hours after reperfusion, and ischemic kidney was 
obtained.
Results: Renal NGAL mRNA expression and urinary NGAL excretion elevated in rats 
with renal ischemia for more than 20min. On the other hand, renal mRNA expressions 
of 24p3R, and megalin and cubilin which are expressed in proximal nephron and uptake 
NGAL in urine, decreased in animals with renal ischemia for more than 20min. Renal 
protein expressions of 24p3R and megalin decreased in rats with renal ischemia for 30 
and 45min.
Conclusions: This study showed for the first time that renal 24p3R decreased in 
response to renal ischemia. As NGAL in urine is reabsorbed by the megalin-cubilin complex 
at the proximal nephron and by the 24p3R at the distal nephron, the down-regulations of 
these proteins might contribute to the elevated urinary NGAL excretion in rats with renal 
ischemia-reperfusion injury.
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Lipopolysaccharide Induces Filtrate Leakage from Tubular Lumen to 
Interstitial Space via Proximal Tubular TLR4-Dependent Pathway in 
Mice
Daisuke Nakano,1 Helge Wiig,4 Motoko Yanagita,5 Jens Titze,2 Akira Nishiyama.3 
1Kagawa University, Kagawa, Japan; 2Duke - National University of Singapore, 
Singapore, Singapore; 3Kagawa University Medical School, Kita-Gun, Japan; 
4University of Bergen, Bergen, Norway; 5Department of Nephrology, Kyoto 
University Graduate School of Medicine, Kyoto, Japan.
Background: We previously reported by using intravital imaging technique 
that lipopolysaccharide (LPS) slowed proximal tubular flow rate in an early phase of 
endotoxemia. However, the mechanism by which LPS reduced tubular flow rate was 
unclear. Hereby, we hypothesized that LPS might disrupt tight junction in proximal tubular 
cells and induce leakage of filtrate through a Toll-like receptor 4 (TLR4)-dependent 
mechanism.
Methods: Tubular flow rate was determined by the timing of the appearance and 
disappearance of intravenously injected dyes in the early segments of proximal tubules in 
mice under 2-photon laser microscopy observation.
Results: LPS at 5 mg/kg did not change the inflow rate of filtrate into the proximal 
tubules, which reflect unchanged GFR, and significantly reduced the outflow rate from the 
proximal tubules at 6h. LPS at 15 mg/kg reduced both inflow and outflow rate. Both dosages 
of LPS induced oliguria. LPS (5 mg/kg) induced paracellular leakage of FITC-inulin and 
reduced tight junction mRNA expression (occludin and cldn2). LPS also increased water 
content, interstitial hydrostatic pressure and Na+/K+ ratio in the kidney, indicating the 
accumulation of extracellular fluid in the interstitium. These changes were diminished 
by the conditional knock out of TLR4 in proximal tubules. Furthermore, denuding renal 
capsule further slowed tubular flow down, suggesting that increasing interstitial pressure 
might counteract the leakage.
Conclusions: Our results suggest that LPS disrupted tight junction of proximal tubular 
cells via a TLR4-dependent mechanism, resulting in paracellular leakage of filtrate to 
interstitium in an early phase of endotoxemia in mice.
Funding: Government Support - Non-U.S.
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Clinician Attitudes Toward Implementation of Precision Medicine
Purnima R. Tripathy,2 Karthik Kannegolla,1 Ranjani N. Moorthi,3 
Michael T. Eadon.4 1Indiana University, Bloomington, IN; 2Nephrology, indiana 
university, Indianapolis, IN; 3Indiana University School of Medicine, 
Indianapolis, IN; 4Indiana University Division of Nephrology, Indianapolis, IN.
Background: Advancements in understanding the genetic basis of CKD & 
pharmacogenomic drug dosing are facilitated by the discovery of genetic predictors. We 
implemented precision medicine testing in our renal clinics to assess CKD progression risk 
and hypertension drug dosing.
Methods: Physicians on nephrology services (N=42) were surveyed about their 
knowledge, attitude & willingness to act on genetic testing results. A 26 question survey 
was graded on a LIKERT scale from “strongly agree” to “strongly disagree.” Respondents 
were stratified according to knowledge & attitude. Statistics were calculated with a Fisher’s 
exact test. We hypothesized clinicians who agreed sufficient evidence was available to 
support implementation would have more positive attitudes & greater willingness to act 
on genetic data.
Results: Respondents were grouped as those who agreed there is sufficient evidence 
to implement genetic testing (supporters N=14) & those who disagreed (nonsupporters 
N=28). Compared to nonsupporters, supporters agreed that: 1) genetic testing helps them 
better identify etiology of CKD (p=0.05), 2) the presence of 2 APOL1 risk alleles impacts 
their management of focal segmental glomerulosclerosis (p=0.05), 3) testing could change 
their choice of antihypertensives (p=0.01) and 4) testing will help to delay the progression 
of CKD (p=0.006). Most respondents agreed (98%) that a patient’s genetic profile can 
influence their response to antihypertensives. We assessed the attitude of clinicians toward 
genetic testing by asking “whether a discussion of genetic test results is too time-consuming 
for an encounter”. Clinicians who agreed (negative attitude N=19) & those who disagreed 
(positive attitude N=23) showed differences in their willingness to act on genetic data. Those 
who felt there is sufficient time to discuss results also agreed that genetic testing of CKD 
patients provides information that changes their dialysis preparation strategies (p=0.02).
Conclusions: Physicians with greater awareness of the evidence supporting 
implementation of genomic testing appear to be more likely to act on the genomic results.
Funding: Clinical Revenue Support
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A Novel Nomogram to Predict the Reliability of Estimated Glomerular 
Filtration Rate Formula in Oncology Patients
Yichun Cheng,1 Liu Huang,2 Yunfeng Han,3 Gang Xu,5 Shuwang Ge.4 
1Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong 
University of Science and Technology, Wuhan, China; 2Oncology, Tongji 
Hospital, Tongji Medical College, Huazhong University of Science and 
Technology, Wuhan, China; 3Nuclear Medicine, Tongji Hospital, Tongji Medical 
College, Huazhong University of Science and Technology, Wuhan, China; 
4Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of 
Science and Technology, Wuhan, China; 5Nephrology, Tongji hospital affiliated 
to Tongji medical college, Huazhong University of Science and Technology, 
Wuhan, China.
Background: Formulae of estimated glomerular filtration rate (eGFR) based on serum 
creatinine (Scr) are routinely used for drug dosage in oncology patients, however, they are 
inaccurate in some populations. Our aim was to identify population characteristics where 
eGFR formulae performed poorly and thereby build a nomogram to predict the reliability 
of estimates.
Methods: Measured GFR (mGFR) using isotope from 444 oncology patients were 
compared with eGFR from four formulae (Cockcroft-Gault, de-indexed MDRD, de-
indexed CKD-EPI and Wright). Multivariate logistic regression was applied to identify 
characteristics associated with inaccurate eGFR and construct a predictive nomogram.
Results: The Cockcroft–Gault formula exhibited estimates with lowest bias and 
highest precision. Nonetheless, it was still unreliable in a relevant proportion of patients. 
The percentage of patients within 30%, 20%, and 10% of the accurate percentage error 
(APE) was seen in only 62.8%, 47.7% and 24.8% of patients respectively. Inaccuracy was 
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found in overweight patients or in patients with BUN/Scr ratio greater than 20 or with eGFR 
greater than 60 ml/min/1.73m2. A novel nomogram was constructed to help oncologists to 
predict the risk of inaccuracy of eGFR. The calibration curve showed good agreement.
Conclusions: Our results suggest that all eGFR formulae tend to overestimate the 
eGFR in oncology patients. Our nomogram may assist oncologists in decision-making 
when mGFR is needed.
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Mechanism of Difference in Plasma and Urinary Clearance Glomerular 
Filtration Rate (GFR) Determinations
Ruben M. Sandoval,1 Silvia B. Campos-bilderback,2 Mark C. Wagner,3 
Jered Myslinski,1 Bruce A. Molitoris.1 1Indiana University School of Medicine, 
Indianapolis, IN; 2Indiana University, Indianapolis, IN; 3Indiana University 
Medical Center, Indianapolis, IN.
Background: It is well established, but not understood, that plasma clearance GFRs 
exceed urinary clearance GFRs for the same filtered marker, often by 5-10%. Therefore, 
the present studies were undertaken to determine the role of proximal tubule endocytosis in 
reducing urinary excretion of filtration markers.
Methods: To visualize and quantify the effect of PTC uptake on reducing urinary GFR 
determinations freely filterable fluorescently labeled dextrans, inulin and small molecular 
weight proteins were investigated. All had a glomerular sieving coefficient of 1.0, and given 
by bolus intravenous administration. Ratiometric analysis of 2-photon images and urinary 
quantification of neutral (TRITC) and negatively charged (FITC) markers was used to 
quantify PTC uptake and the effect of charge on PTC uptake.
Results: Intravital 2-photon imaging revealed PTC endocytic uptake of freely 
filtered GFR markers was rapid, dose and time dependent. pH mediated quenching 
of FITC fluorescence resulted in a pseudo-reduction in apparent PTC uptake of FITC 
labeled markers. Neutrally charged fluorescent markers were internalized by PTC S2 > S1. 
Negatively charged FITC dextrans and inulins were preferentially taken up versus a neutral 
TRITC inulin, particularly in S1 PTC. Two-photon imaging demonstrated that a negative 
charge increased PTC uptake, as the injected ratio of FITC /TRITC inulin was increased 
from 0.504 to 0.729 +/- 0.056 for a 45% increase in negatively charge inulin uptake. On 
the other hand, the urine FITC/TIRTC ratio decreased 38.7% +/-0.1%, consistent with 
increased PTC endocytosis of negatively charged inulin.
Conclusions: PTC reabsorbed filtration markers, including inulin, in a dose and time 
dependent fashion via endocytosis. PTC uptake explains in part the reduction in urinary 
compared to plasma GFR clearance. Finally, a negative charge on these molecules increases 
uptake by PTC, especially in the S1 segment.
Funding: Other NIH Support - NIH O’Brien Center grant P30-DK079312
SA-PO614 Poster Saturday
Pharmacology
Renal and Dialytic Clearances of Uremic Solutes
Jerome Lowenstein,1 Aleksey Etinger,1 James Slater,2 Bjorn Meijers,3 
Robert Holzman.4 1New York University Medical Center, New York, NY; 2NYU 
Langone Health, New York, NY; 3University Hospitals Leuven, Leuven, Belgium; 
4NYU School of Medicine, New York, NY.
Background: Many uremic solutes are protein bound and removed by proximal 
tubular organic anion transporters (OATs) rather than filtration.
Methods: In 4 subjects undergoing right heart catheterization, samples were obtained 
from the right renal vein and the inferior vena cava below the renal veins.Total and 
ultrafiltrate concentrations of uremic solutes were measured utilizing MS-HPLC.
Results: Renal extraction ratio (removal across the renal vascular bed) and renal 
excretion fraction (renal clearance of solute relative to creatinine) varied greatly. HA and 
PAG exhibited the highest renal extraction ratios and excretion fractions approximating 
values reported for para-amino-hippurate (PAH). The dialytic clearance of these solutes 
exhibited the same pattern but never exceeded estimated creatinine clearance. Highly 
bound solutes (IS, PCS) exhibited low renal extraction and low renal excretion fractions. 
KA was an anomaly. Though highly bound, renal extraction and excretion were higher than 
expected, possibly related to pKa or other unique properties of this solute.
Conclusions: The findings suggest that endogenous hippurate clearance might provide 
a measure of effective renal plasma flow. The finding that uremic retention solutes such as 
IS, PCS, and KA, known to bind to OAT receptors on vascular endothelium where they 
act as transcription factors, are also tightly bound to albumin suggests that protein binding 
serves to deliver solutes to receptors in a manner analogous to the delivery of hormones, 
bound to carrier proteins, from an endocrine source to distant receptors.
Funding: Private Foundation Support
Protein binding, extraction, and excretion of Uremic Retention Solutes
*In ESRD patients(PLoS ONE 13(2): e0192770) **Mean +/- SD *** Minimum estimate
based on levels below the limit of detection, 0.002
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The Pathophysiology of Augmented Renal Clearance Similarly Affects 
Hepatic Clearance in Critically Ill Trauma Patients
George N. Coritsidis, Sean Yaphe, Jayaramakrishna Depa, Scott Lee. Elmhurst 
Hospital Center, Forest Hills, NY.
Background: In trauma, the systemic inflammatory response and intensive care therapy 
leads to a hypermetabolic state described as Augmented Renal Clearance (ARC). Literature 
has shown an association between ARC and sub-therapeutic antibiotic concentrations and 
suggests worst clinical outcomes. We examined whether hepatic clearance is also augmented 
in trauma by measuring Dilantin levels (DL), a drug primarily metabolized by the liver.
Methods: A retrospective review of the trauma registry at our level 1 trauma center 
was conducted from 2009 to 2014 for adults admitted for traumatic brain injury receiving 
Dilantin. Patients with acute kidney injury were excluded. GFR was estimated using CKD-
Epi formula. DL were corrected for hypoalbuminemia (<3 g/dL) and compared between 
ARC patients (eGFR ≥ 130) and those without (nARC) at 24, 48 hours, and 72 hours.
Results: There were a total of 98 nARC (eGFR= 97.4) and 20 ARC patients 
(eGFR=133.3) all of which dosed similarly. ARC patients were younger, had lower 
creatinine and DL at 72 hours. At 48 and 72 hours the correlation comparing eGFR to DL is 
negative (p<.05). At 48 hours ALT levels were significantly higher (p<0.05).
Conclusions: ARC patients had lower DL at 24 and 48 hours, and DL correlated 
negatively with GFR augmentation. ALT and AST levels were higher in the ARC patients 
possibly due to increased hepatic function. In ARC, hepatic clearance may also be 
augmented raising issues of drug dosing regardless of renal or hepatic metabolism.
Descriptive statistics comparing ARC vs non-ARC patients
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Probability of Target Attainment Estimated by Residual Blood Sampling 
Agrees with Intensive Sampling Predictions
Christin M. Giordano McAuliffe,2 Katherine Akers,3 Megha Salani,4 
Sylvia M. Verhoven,2 Pratish C. Patel,2 Jennifer M. Colby,2 Matthew S. Shotwell,1 
William H. Fissell.2 1Vanderbilt University, Nashville, TN; 2Vanderbilt University 
Medical Center, Nashville, TN; 3Western Nephrology, Denver, CO; 4Nephrology 
Associates of Mobile, PA, Mobile, AL.
Background: Patients with critical illness and multiple organ failure have altered 
pharmacokinetics and are at risk of over- or under- dosing. Patient-specific estimates of 
target attainment require timed and repeated phlebotomy. This additional loss of blood is 
undesirable and, in a research setting, requires individual informed consent. Blood tests 
ordered for clinical purposes rarely consume the entire sample volume. We hypothesized 
that residual blood samples could be used to estimate target attainment in critically ill 
patients.
Methods: We adapted Bayesian population-pharmacokinetic statistical tools to 
accommodate the sparse sampling and irregular timing of clinical samples. This method 
incorporates dosing history, a priori estimates of population heterogeneity, other available 
clinical information, and patient-specific measurements of piperacillin concentration in 
residual blood samples to estimate patient-specific probability of target attainment. We 
compared these estimates to a gold-standard estimate of target attainment using intensive 
repeated sampling in ten patients.
Results: There was excellent agreement between the two methods. Just one of ten 
subjects was misclassified as having failed to meet target exposure, and that was in a 
subject whose residual sample was obtained 72 hours prior to intensive sampling for the 
gold-standard estimate. Excluding this subject, the correlation between the residual and 
gold-standard estimate of drug exposure was 0.91 (95% CI: 0.62, 0.98). No subjects were 
misclassified as having attained target exposures when they had not.
Conclusions: Although this was a small sample, consistent results in this subtype 
of patient demonstrates that residual blood sampling may be useful for the estimation of 
antibiotic target attainment. As a result, residual blood sampling may be an efficient use 
of patient blood, a scarce resource, for pharmacokinetic measurements and therapeutic 
drug monitoring. Overall, residual blood sampling would reduce blood loss and potentially 
lower requirements for blood transfusion during a prolonged hospital stay. In addition, use 
of residual blood sampling may increase research participation, as it would allow for the 
avoidance of additional venipuncture which is often a common barrier to consent.
Funding: Commercial Support - Baxter Healthcare
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Prevalence and Adverse Outcomes Associated with Opioid Prescriptions 
Across the Range of eGFR
Tessa K. Novick,1 Aditya L. Surapaneni,1 Jung-Im Shin,1 G caleb Alexander,1 
Lesley Inker,3 Alex R. Chang,2 Morgan Grams.1 1Johns Hopkins University, 
Baltimore, MD; 2Geisinger Medical Center, Danville, PA; 3Tufts Medical Center, 
Boston, MA.
Background: Kidney disease limits therapeutic options for pain control given the 
relative contraindication to non-steroidal antiflammatory drugs. The goal of this study was 
to assess the prevalence and safety of prescription opioid use across the range of eGFR in 
a U.S. outpatient population.
Methods: Using electronic medical records from the Geisinger Health System, 
we described trends in opioid prescriptions by CKD stage between 2011 and 2016. In a 
cohort matched on propensity for ≥2 opioid prescriptions during a 2-year baseline period 
(2011-2013) we used Cox proportional hazards regression to evaluate the association 
between opiate prescription compared to no opiate prescription and death, total 
hospitalizations, non-pathologic fracture, and presentations for altered mental status, as well 
as whether associations differed by eGFR level.
Results: Opioid prescriptions increased over time, particularly among patients with 
eGFR < 30 ml/min/1.73m2. For example, 43.5% patients with eGFR < 30 ml/min were 
prescribed opioids in 2011 compared to 46.4% in 2016 (p for trend < 0.001). Among 22,261 
patients receiving at least two opiate prescriptions during the baseline period, a suitable 
match was found for 5,337 based on 23 clinical and demographic covariates. Patients with 
opioid prescriptions had significantly increased risk for death (HR 1.39, 95% CI 1.16-1.67), 
hospitalization (HR 1.51, 95% CI 1.39-1.63), and non-pathologic fracture (HR 1.51, 
95% CI 1.33-1.72) compared to their counterparts for all levels of eGFR (p >0.05), but 
differences in altered mental status were not statistically significant (HR 1.22, 95% CI 0.79-
1.88) (Figure).
Conclusions: Opioid prescriptions are common in patients with CKD and are 
associated with higher risk for death, hospital admissions and non-pathologic fracture.
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G-Protein Signaling and Kappa Opioid Mediated Aquaresis
Kevin Ebert, Daniel R. Kapusta. Louisiana State University Health Sciences
Center, New Orleans, LA.
Background: Kappa opioid agonists act centrally to inhibit antidiuretic hormone 
(ADH) secretion and increase renal sympathetic nerve activity. Together, these effects lead 
to a water diuresis. However, the signaling pathway by which kappa opioid receptor (KOR) 
activation produces these effects remains unknown. In prior studies, we have shown that 
activation of opioid receptor like one (ORL1) by the ligand nociceptin produces a marked 
diuresis in rats by a downstream G-alpha z protein pathway that inhibits ADH secretion. 
These studies investigated whether central G-alpha protein signaling pathways also 
contribute in producing the diuretic and/or antinatriuretic response to central administration 
of the kappa opioid agonist, U-50488H.
Methods: Sprague Dawley rats were implanted with an intracerebroventricular (i.c.v.) 
cannulae and pretreated with vehicle or pertussis toxin (PT), which inhibits the Gi/o family 
of proteins except for Gz. After 48-hrs pretreatment, rats were instrumented with cannula in 
the femoral artery, vein, and bladder and infused i.v. with isotonic saline (55 μl/min). After 
stabilization, blood pressure (BP), heart rate (HR), and urine output (V) was collected in 
conscious rats before (control) and for 90-min after (10-min collections) i.c.v. U-50488H 
(n=6).
Results: In vehicle pretreated rats, i.c.v. U-50488H produced a marked increase in V 
(max Δ, 101±8 ul/min) and decrease in urinary sodium excretion (UNaV; max Δ, 5±0.5 
ueq/min). The diuretic response produced by U-50488H was significantly (p<0.05) blunted 
by pretreatment with PT (max Δ, 57±3 ul/min). In contrast, PT did not alter the decrease in 
UNaV. U-50488H did not alter BP or HR in either group. To explore which G-alpha proteins 
may participate in mediating the kappa diuresis, separate rats were pretreated i.c.v. (24-hrs) 
with an oligodeoxynucleotide (ODN), which selectively targeted a specific G-alpha protein. 
In these studies, pretreatment of groups of rats (n=6/group) with a single ODN for either 
Gi1, Gi2, Gi3, Go, or Gz, failed to blunt the maximal diuresis as compared to the increase 
in V produced by i.c.v. U-50488H in scrambled ODN treated rats.
Conclusions: These results demonstrate that central kappa opioids produce a pertussis 
toxin sensitive diuresis, but not antinatriuresis. This suggests that a combination of Gi/o 
proteins may be required to produce the aquaretic effects of kappa opioid agonists.
Funding: Other NIH Support - NIH NIGMS COBRE 5P30GM106392
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Ouabain Regulated Phosphoproteome Reveals Molecular Mechanisms 
Behind Na,K-ATPase Control of Cell Adhesion, Proliferation, and 
Survival of Renal Cells
Lena Scott,1 Liang Zhang,1 Jacopo M. Fontana,1 Daniel Svensson,1 
Hjalmar Brismar,2,1 Anita Aperia.1 1Department of Women’s and Children’s 
Health, Karolinska Institutet, Stockholm, Sweden; 2Royal Institute of Technology, 
Stockholm, Sweden.
Background: Ouabain, a Na,K-ATPase ligand, triggers calcium release and Erk 
phosphorylation. Ouabain protects from apoptosis and stimulates proliferation and cell 
contact in primary and immortalized kidney epithelial cells. However, the mechanisms that 
connect the calcium and Erk signaling with the downstream effects are unknown.
Methods: We have performed a proteomic and phosphoproteomic study on COS cells, 
derived from embryonic monkey kidney. Cells were treated with ouabain for 10 and 20 
min in concentrations that do not increase [Na+]i. Hierarchical clustering was applied to 
describe the temporal pattern of phosphorylation events. Gene ontology analysis was then 
used to examine whether phosphorylation events with different temporal patterns regulate 
distinct cellular processes. To verify the significance of identified proteins, siRNA studies 
were performed on primary rat proximal tubule cells.
Results: We identified 1941 ouabain-regulated sites that were either phosphorylated 
or dephosphorylated in a transient or sustained manner. The state of phosphorylation 
for proteins associated with cell adhesion and proliferation was prominently altered by 
ouabain. Analysis of protein-protein interaction networks showed a high connectivity 
of phosphoproteins that regulate cell adhesion and cell proliferation. Protein kinases 
and calcium dependent protein kinases were enriched among the proteins where the 
phosphorylation state is regulated by ouabain. Downregulation of protein expression by 
siRNA showed that CaMKK1 and CaMK2γ are essential for ouabain protection from 
apoptosis caused by serum deprivation or exposure to high glucose
Conclusions: This study represents a major advancement in the understanding of the 
dual function of Na,K-ATPase as an ion pump and as a signal transducer. It offers an insight 
into the role of ouabain for kidney growth and development and for protection against 
apoptosis.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to 
Warfarin in Atrial Fibrillation Patients on Chronic Hemodialysis
Estella Davis,1,3 Dallin Darais,3 Khalid Bashir,2,4 Kevin T. Fuji.1 1Pharmacy 
Practice, Creighton University School of Pharmacy, Omaha, NE; 2CHI Clinic, 
Nephrology, Omaha, NE; 3Pharmacy, CHI Health-Creighton University 
Medical Center- Bergan Mercy, Omaha, NE; 4Medicine, Creighton University 
School of Medicine, Omaha, NE.
Background: ESRD patients on hemodialysis (HD) were excluded from safety and 
efficacy studies of direct-acting oral anticoagulants (DOACs) in atrial fibrillation (AF). The 
objective of this study was to evaluate prescribing, dose selection, and safety outcomes of 
DOACs compared to warfarin in AF patients on chronic HD. Secondary objectives were 
to evaluate major ISTH bleeding and clinically relevant non-major bleeding (CRNMB).
Methods: This was a retrospective study of AF patients on outpatient HD and oral 
anticoagulation (OAC) with warfarin or DOAC from April 2010-April 2016. Records were 
obtained from metro area CHI Health System and Dialysis Clinics Inc. Data was analyzed 
using descriptive statistics, ANOVA and chi-square.
Results: 91 patients were included (52% male, 79% white, mean age 69). Average 
CHA2DS2Vasc was 4.6 and HASBLED was 3.8. Warfarin was the initial OAC in most 
patients (n=76), mean dose 29mg/week. 15 patients were initially on DOACs: apixaban 
2.5mg (n=7), apixaban 5mg (n=5), dabigatran 75mg (n=2), and dabigatran 150mg (n=1). 
Of 14 patients whose initial OAC was switched, 12 switched to apixaban 5mg or 2.5mg. 
Initial apixaban was dosed appropriately in most patients (83%) compared to apixaban 
switches (42%) where 9 on low dose did not meet dose reduction criteria. HASBLED scores 
were higher in switched patients not dosed appropriately (4 vs. 3.2, p=0.156). 26 patients 
experienced a bleed, with significantly more bleeding in warfarin compared to DOAC (31% 
vs 28%, p=0.022) patients. Most major bleeds (n=7), CRNMB (n=12), and major plus 
CRNMB (n=1) occurred with warfarin alone. Bleeding in DOAC patients: 1 on warfarin to 
dabigatran 75mg (major), 1 on warfarin to apixaban 2.5mg (major), 2 on apixaban 2.5mg 
(CRNMB), 1 on warfarin to dabigatran 150mg (major and CRNMB), and 1 on dabigatran 
150mg to apixaban 5mg (major and CRNMB).
Conclusions: More HD patients were prescribed warfarin initially and more of these 
patients experienced a bleed. More prescribers selected appropriate dose apixaban as the 
initial DOAC or switched to it as low dose when dose reduction criteria were not met. 
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Bleeding occurred in DOAC patients with prior warfarin therapy, switching between 
DOACs, and maintained on the initial DOAC. Larger studies evaluating DOAC prescribing 
and impact on safety in AF patients on chronic HD are warranted.
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Increasing Use of Direct Oral Anticoagulants Among Hemodialysis 
Patients with Medicare Prescription Drug Coverage
Eric D. Weinhandl,1,2 Debabrata Ray,1 Kristine Kubisiak,1 Allan J. Collins.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: For decades, warfarin was the only agent to be used for long-term 
anticoagulation. Since 2010, a series of direct oral anticoagulants (DOACs) have been 
approved by the United States Food and Drug Administration, including dabigatran, 
rivaroxaban, apixaban, edoxaban, and betrixaban. The efficacy and safety of DOACs 
in hemodialysis (HD) patients is poorly understood. We assessed trends in utilization of 
warfarin and DOACs among HD patients in 2011-2015.
Methods: We analyzed data from the United States Renal Data System. For each 
calendar month from January 2011 to December 2015, we identified patients who 
underwent HD and were enrolled in Medicare Part C or D; we also assessed whether HD 
was delivered in a facility or at home. From pharmacy claims, we identified whether each 
patient possessed a supply of warfarin, rivaroxaban, apixaban, or edoxaban. We estimated 
percentages of patients with a supply of any anticoagulant, any DOAC, and individual 
DOACs. We fit logistic generalized estimating equations of DOAC use, with adjustment 
for age, race, sex, primary cause of end-stage renal disease (ESRD), and dialytic setting.
Results: Monthly sample sizes increased from roughly 249,000 in January 2011 
to 311,000 in December 2015. During this era, the percentage of patients using any 
anticoagulant steadily increased from 9.2% to 10.2%. However, the percentage of patients 
using warfarin reached an apex of 9.4% in December 2013 and subsequently fell to less 
than 9.0% in late 2015. Concurrently, the percentage of patients using any DOAC increased 
from 0.1% to 1.3%. By December 2015, 11.6% of patients using an anticoagulant were 
DOAC users and 93.0% of patients using a DOAC were apixaban users. Among patient-
months with anticoagulant use in 2015, positive predictors of DOAC use were older age 
and Asian (versus white) race; negative predictors were black (versus white) race and 
glomerulonephritis and polycystic kidney disease (versus diabetes) as the primary cause 
of ESRD. Relative to in-center hemodialysis, home hemodialysis was associated with 18% 
lower odds of DOAC use, but the association was not statistically significant (P = 0.09).
Conclusions: Among hemodialysis patients, warfarin use is decreasing, DOAC use is 
increasing, and apixaban dominates DOAC utilization. Direct comparisons of warfarin and 
apixaban are urgently needed.
Funding: Commercial Support - NxStage Medical, Inc.
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Prevalence and Outcomes Associated with NSAID Use in Patients with 
CKD
Samantha L. Chan,2 Etienne Macedo,2 Danuta Trzebinska,2 Linda Awdishu.1 
1UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, 
CA; 2University of California San Diego, San Diego, CA.
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated 
with an increased risk of incident acute kidney injury and chronic kidney disease (CKD). 
The effect of NSAIDs on the rate of CKD progression is still uncertain. The purpose of 
this study is to measure the prevalence of NSAID use in CKD patients under the care of a 
nephrologist compared to a primary care physican (PCP) and evaluate the impact of NSAID 
use on CKD progression.
Methods: This is a single center, retrospective study of patients with CKD stage 3 to 
5 over a 1 year period. Patients 18 years or older with GFR < 60 mL/min (2 occasions), an 
office visit with nephrologist or PCP and an active NSAID prescription were included. We 
excluded hospitalized patients, transplant recipients, AKI episodes or dialysis dependency. 
We evaluated the change in GFR pre and post NSAID prescription over 1 year compared to 
non-NSAID users and compared nephrology to PCP care. Multivariate logistic regression 
identified potential co-variates of GFR change.
Results: Of the 2,157 patients included in the study, 12.2% had an NSAID prescription; 
9.6% vs. 15% for patients receiving care from a nephrologist or PCP (p<0.001). Table 1 
describes baseline demographics. GFR change was -3.9 vs. -3.7 mL/min/1.73 m2 (p=NS) 
for NSAID users and non-users, respectively. In patients managed by a nephrologist, GFR 
change was -4.94 vs. -4.21 mL/min/1.73m2 (p=NS) in users and non-users, while GFR 
change for patients managed by a PCP was -3.18 vs. -3.05 mL/min/1.73m2 (p=NS) in users 
and non-users, respectively. Age (p<0.001), diabetes (p=0.02) and hepatitis C (p=0.001) 
were significantly associated with GFR change.
Conclusions: NSAIDs are prescribed to more than one out of every ten patients with 
CKD; more often by PCPs than nephrologists. Over 1 year, there was no statistically 
significant GFR change for NSAID users compared to non-users. Further long term studies 
are warranted to confirm safety of this medication class.
Baseline Demographics
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Cause Specific Mortality Attributable to Proton Pump Inhibitor
Yan Xie,1 Benjamin C. Bowe,2 Tingting Li,3 Yan Yan,4 Hong Xian,5 
Ziyad Al-Aly.1 1VA Saint Louis Health Care System, Saint Louis, MO; 2Research 
and Development Service, Veterans Affairs St Louis Health Care System, St. 
Louis, MO; 3Washington University in St. Louis, Saint Louis, MO; 4Washington 
University Medical School, Saint Louis, MO; 5Saint Louis University College 
for Public Health & Social Justice, St. Louis, MO.
Background: Proton pump inhibitors (PPI) are widely used; and their use is associated 
with increased risk of adverse events and death. However, a detailed analysis of the cause 
of the death distribution among users of PPI is not available. In this work, we aimed to 
characterize the cause of death among users of PPI.
Methods: A cohort of 325,307 new users of PPI or H2 blockers was built. Cause 
of death data from National Death Index was used to examine the association between 
PPI and cause specific morality. Multiple survival models including proportional hazards 
models, accelerated failure time models, and additive hazard models were used. we used 
an instrumental variable approach based on clinicians’ prescribing behavior and high-
dimensional propensity score in domains including diagnoses, procedures, medications and 
laboratory results to account for measured and unmeasured confounders, respectively. For 
each outcome, model-covariate combination with smallest Brier score was selected and the 
survival possibility for the cohort was calculated.
Results: During 10 years of follow up, PPI use was significantly associated with all-
cause mortality, and mortality from circulatory, and genitourinary causes. Compared to 
users of H2 blockers, event rate per 1000 persons attributable to PPI use was 5.44 (17.57, 
33.43), 9.91 (3.94, 15.79) and 5.17 (2.83, 7.51) for all-cause, circulatory and genitourinary 
mortality, respectively. The excess death accounted for 6.94% (4.85, 9.03), 7.15% (2.90, 
11.17) and 32.58% (19.34, 43.56) of all the all-cause, circulatory, and genitourinary 
mortality in PPI users. Further analyses within the circulatory and genitourinary causes 
showed PPI use was associated with 8.07 (3.29, 12.77) and 3.66 (1.95, 5.46) excess death 
per 1000 persons from coronary artery disease and chronic kidney disease, which accounted 
for 10.22% (4.27, 15.72) and 35.97% (21.07, 48.23) of the related deaths. Death from 
acute kidney injury was not associated with PPI use (excess death 0.61 (-0.27, 1.51) and 
population attributable fraction 29.32% (-15.42, 56.11)).
Conclusions: In this work, we used advanced statistical methodologies to map the 
cause of death distribution among users of PPI. Our findings suggest that PPI use is 
associated with increased mortality from circulatory and genitourinary causes, but not other 
causes of death. PPI should only be used when medically indicated.
Funding: Veterans Affairs Support
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Retrospective Population Scale Analysis Reveals Associations of Pro-
ton-Pump Inhibitor Use with Kidney Related Disorders
Tigran Makunts, Isaac V. Cohen, Ruben Abagyan, Linda Awdishu. UCSD 
Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA.
Background: Proton pump inhibitors (PPIs) are one of the most widely prescribed and 
sold drugs globally. Recent studies have revealed associations between PPI use and acute 
kidney injury (AKI), chronic kidney disease (CKD), and end stage renal disease (ESRD). 
The growing concern over potentially serious adverse events (AE) associated with their use 
warrants an evaluation of post marketing surveillance.
Methods: This is a retrospective study of 9.5 million voluntary adverse event (AE) 
reports to the FDA Adverse Event Reporting System (FAERS) from January 2004 to 
August 2017. Two cohorts were constructed from these reports: (1) PPI (n=665,735) and (2) 
histamine receptor antagonists (H2RA) (n=124,251) cohorts. Any report of patients taking 
concurrent nephrotoxins or where age was not reported was excluded resulting in 150,361 
PPI and 29,115 H2RA AE reports. Outcomes were CKD, AKI, ESRD, nephrolithiasis and 
electrolyte disorders (hypomagnesemia, hypocalcemia and hypokalemia) defined by coding 
data. Frequencies of all reported AEs and corresponding odds ratios (OR) were calculated 
in each cohort.
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Results: Patients who received PPIs had a significant increase in the number of reports 
for CKD OR 1.87 95% CI [1.3, 2.7], AKI 1.23 [1.1, 1.4], nephrolithiasis 2.16 [1.6, 2.9], 
hypomagnesemia 2.62 [2, 3.4], and hypocalcemia 1.95 [1.5, 2.5]. There was no significant 
difference in the frequency of hypokalemia 1.15 [0.91, 1.5] and ESRD 7.17 [0.99, 52]. 
Significant increases in CKD reports were identified for omeprazole 1.89 [1.3, 2.8], 
esomeprazole 1.95 [1.3, 2.9], dexlansoprazole 10.65 [3.3, 35]. Omeprazole and pantoprazole 
were significantly associated with increased AKI reports, 1.54 [1.4, 1.7] and 1.64 [1.4, 1.9], 
respectively whereas esomeprazole had a decrease in AKI reports 0.85 [0.75, 0.96].
Conclusions: In this study, we replicated the association between PPI exposure and 
the increased risk of AKI, CKD and electrolyte abnormalities from the AE reports in the 
FAERS database. To our knowledge this is the first large scale study showing a significant 
association of PPI use with nephrolithiasis. We found differences in AE reporting risk for 
individual PPIs. Further studies evaluating individual drug effects are warranted to confirm 
these findings.
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Does Desmopressin Decrease Kidney Biopsy Bleeding Risk in Patients 
with CKD?
Cagil D. Arslan, Ambarish Athavale, Edwin Okyne, Peter D. Hart. John H 
Stroger Hospital of Cook county, Chicago, IL.
Background: Kidney biopsy, the gold standard for diagnosing kidney disease, is 
associated with bleeding risk. Desmopressin is routinely prescribed to improve platelet 
function and decrease bleeding risk of kidney biopsy. It is not known if desmopressin 
decreases the risk of clinically significant bleeding (defined as post-biopsy hematoma, 
decrease in hemoglobin or need for RBC transfusion) in patients with CKD.
Methods: Retrospective review of consecutive percutaneous kidney biopsies 
performed at Stroger hospital between January 2014 and March 2018. CKD was defined 
as eGFR < 60ml/min/1.73 m2. All biopsies were performed under real-time ultrasound 
guidance. Patients with bleeding time > 10 minutes were excluded from the study.
Results: 323 kidney biopsies were performed during the study period of which 217 
had CKD. As compared to patients who did not receive desmopressin, administration of 
desmopressin did not decrease the risk of post-biopsy hematoma (18.94% in desmopressin 
group vs 19.44% in non-desmopressin group; p = 0.90) or need for blood transfusion 
(p=0.08). The mean decrease in hemoglobin was statistically significant in the desmopressin 
group than the non-desmopressin group (0.79 g/dl vs 0.46 g/dl; p = 0.0001) but not clinically 
significant. Both groups had adequate number of glomeruli on biopsy.
Conclusions: Routine administration of desmopressin in patients with CKD did not 
reduce the risk of clinically significant post-biopsy bleeding.
Clinical features and outcomes of kidney biopsy in patients with CKD
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Use of Urinary Exosomes to Confirm Pharmacological Activity of CXA-10 
on Nrf2 and Heat Shock Response Gene Expression in the Kidney of 
Patients with CKD
Rachel Garner,1 Anna-Liisa Levonen,5 Carla Chieffo,2 Christine M. Debouck,3 
Francisco J. Schopfer,4 Diane K. Jorkasky.1 1Complexa, Inc., Berwyn, PA; 
2Complexa, Inc. Consultant, Berwyn, PA; 3Ardennes Biosciences LLC, Wayne, 
PA; 4University of Pittsburgh, Pittsburgh, PA; 5University of Eastern Finland, 
Kuopio, Finland.
Background: CXA-10 is an electrophilic nitrated fatty acid being developed for focal 
segmental glomerular sclerosis. In animal studies, CXA-10 modulated several pathways 
including activation of nuclear factor E2-related factor 2 (Nrf2) and heat shock response 
(HSR). Urinary exosomes are small cell-derived vesicles shed from kidney cells that carry 
mRNA and proteins. Genetic material in urinary exosomes reflects gene activation in the 
kidney. The purpose of this study was to examine the ability of CXA-10 to induce Nrf2- 
and HSR-dependent gene expression in blood and kidney of subjects with chronic kidney 
disease (CKD).
Methods: This was a multicenter, open-label, single-dose study of CXA-10 in subjects 
with moderate and severe CKD. Four subjects received a 1-hour infusion of 0.34 mg/kg and 
8 subjects received a 1-hour infusion of 0.68 mg/kg CXA-10. Gene expression assessments 
were conducted from predose to 96 hours postdose as the time course of responses was 
unknown. Whole blood and urine samples were collected for analysis of target genes by 
qRT-PCR in isolated PBMCs and exosomes, respectively. Target genes were from the Nrf2 
pathway, NAD(P)H quinone dehydrogenase 1 (NQO1) and Heme Oxygenase 1 (HMOX-1) 
and the heat shock pathway, Heat Shock Protein Family A and 1B (HSPA1A/B).
Results: Gene expression increased after CXA-10 dosing for all target genes. 
Maximum gene expression per subject showed a dose-response relationship for NQO1 and 
HSP1A/B in both PBMCs and urinary exosomes. Gene expression response, defined as 
≥3-fold increase from baseline, was exhibited in 10 subjects (83.3%) for ≥1 target gene.
PBMC gene expression response was observed in 8 subjects (66.7%) and urinary exosome 
gene expression in 6 subjects (50%). HSPA1A/B showed the highest level of induction in 
both PBMCs and urinary exosomes.
Conclusions: A single IV dose of CXA-10 increases cellular protective Nrf2- and HSR-
related genes in subjects with CKD. This study demonstrates the first human translation of 
the pharmacological actions of CXA-10 that have been previously characterized in vitro and 
in animal models. To our knowledge, this is the first use of urinary exosomes to demonstrate 
the pharmacological action in the target organ of a novel drug in clinical development.
Funding: Commercial Support - Complexa, Inc.
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Tumor Lysis Syndrome Linked to Anticancer Agents: An Analysis Using 
the FDA Adverse Event Reporting System
Akimasa Sanagawa,1,2 Yuji Hotta,2 Masahiro Kondo,1,3 Nishikawa Ryohei,4 
Masahiro Tohkin,4 Kazunori Kimura.2,3 1Department of Pharmacy, Nagoya City 
University Hospital, Nagoya, Japan; 2Department of Hospital Pharmacy, 
Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, 
Japan; 3Department of Clinical Pharmacy, Graduate School of Medical 
Sciences, Nagoya City University, Nagoya, Japan; 4Department of Regulatory 
Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 
Nagoya, Japan.
Background: Tumor lysis syndrome (TLS) is an oncologic emergency that can lead 
to severe renal impairment, cardiac arrhythmias, seizures, and death. We used the Food and 
Drug Administration Adverse Reporting System (FAERS) database to identify associations 
between anticancer agents and TLS.
Methods: Reports of TLS were retrieved from the FAERS database. Reporting odds 
ratios (RORs) were used to estimate associations between TLS and old and new anticancer 
agents or their combinations.
Results: We identified 1,615 TLS cases from among 4,330,807 case reports from the 
first quarter of 2004 through the first quarter of 2014. Statistically significant risk signals 
were detected for 56 of 64 anticancer agents. Bortezomib (BOR), a drug used for multiple 
myeloma (MM), had a high ROR and large number of TLS events relative to that of 
molecular-targeted drugs (161 TLS events, ROR = 28.89, 95% CI: 24.53−34.02). However, 
MM is a disease considered low-risk for TLS. We analyzed regimens containing novel 
MM drugs (e.g., BOR, lenalidomide, and thalidomide). Of those drugs, TLS was more 
frequently reported for BOR-containing treatments than for other MM treatments (Fig. 1).
Conclusions: Although the risk of TLS is generally considered low for MM patients, 
careful evaluation of TLS risk is recommended for those receiving BOR-containing therapy.
Funding: Government Support - Non-U.S.
Fig. 1 Estimates of TLS risk in MM chemotherapy regimens. Chemotherapy drug 
combinations are in blue cells. Values listed are for the TLS risk of column-defined 
combinations relative to that of row-defined combinations. For RORs in the opposing 
direction, reciprocals of the listed values must be used. ROR values > 1 favor the column-
defined combinations. Light blue and gray cells indicate statistical significance. Ranges 
represent 95% confidence intervals.
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The Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in 
Haemodiafiltration
Sine Donnellan,2 Dan Wright,1 Stephen Duffull,1 Tracey L. Putt,2 
John B. Schollum,2 Robert J. Walker.1 1University of Otago, Dunedin, New 
Zealand; 2Dunedin Hospital, Dunedin, New Zealand.
Background: Meropenem and piperacillin/tazoobactam (PIPC/TAZ) are commonly 
used in the treatment of sepsis. Their effectiveness is dependent upon time above minimium 
inhibitory concentration (MIC). Dosing practices in haemodiafiltration (HDF) rely on 
extrapolation from intermittent haemodialysis (IHD) or continuous renal replacement 
therapies and may lead to subtherapeutic concentration due to fundamental differences in 
membrane characteristics, duration of therapy and blood flow rates.
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Methods: We performed an open label pilot study on 6 stable haemodialysis patients. 
HDF prescription was based upon our local intensive care practice. Patient characteristics, 
bioimpendance and any deviation from prescription were documented. Meropenem (1g) 
was administered 1 hour prior to commencement of HDF. 12 blood samples were taken 
(baseline, pre, post membrane during HDF and 1 hour post cessation). This was repeated 
with PIPC/TAZ (4.5g) 1 week later. Samples were analysed by validated chromatography. 
Pharmacokinetic modelling analysis was performed on each of the samples using 
non-compartmental methods. Extrapolation of plasma concentrations to 12 hrs was 
approximated assuming an exponential decline, given by; Cp(t) =Cp0 x e
-kt were Cp(t) is the 
plasma concentration at time (12 hrs post=dose in this case),Cp0 is the plasma concentration 
at time 0, and k is the terminal phase rate constant.
Results: Participants were mostly male with a mean age of 63.8±14 yrs. 
Haemodiafiltration clearance (HDCL) ranged from 8.9-10.8 L/h for meropenem and 
9.6-19.1 L/h for PIPC/TAZ with an area under the plasma concentration-time curve during 
HDF (AUCHDF) of 83-99 and 195-351 mg/L*h respectively. Fig 1 shows approximation 
of the PIPC/TAZ and meropenem data assuming the HDF continued for 12 hours without 
repeated dosing.
Conclusions: Meropenem and PIPC/TAZ removal during HDF is substantial with 
potential subtherapeutic concentration after a relatively short period.
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Meropenem Renal Kinetics in Human Kidney Biopsies
Rodrigo Sepúlveda, Patricio Downey, Juan P. Huidobro, Dagoberto Soto, 
Max Andresen. Pontificia Universidad Católica de Chile, Santiago, Chile.
Background: Urinary tract infection is the most common bacterial infection. Usually 
it has good prognosis even though some cases can have serious complications. Last decades 
multi-resistant bacterial strains are arising but development of antibiotics has declined. 
Meropenem is a broad-spectrum antibiotic with activity against many bacteria including 
multi-resistant strains; however, its renal tissue kinetics is unknown.
Methods: We conducted a descriptive study in humans with indication of kidney 
biopsy. Meropenem was infused over 30 minutes one hour before biopsy performed and 
was evaluated the plasmatic concentration after meropenem infusion (T1), 60 minutes 
(T2) and 120 minutes (T3). Also meropenem concentration in the kidney sample was 
measured. It was used a fluorescent biosensor for B-Lactams antibiotics to measure levels 
of meropenem.
Results: In 14 patients, 64% women, body mass index was 26.3 ±2.9, eGFR was 
57.5 ±44.1 ml/min/1.73m2 and plasma albumin 3.8 ±0.9 g/dL. Kidney biopsy was 
done at 68.9 ±20.3 minutes after meropenem infusion; the second plasma sample was 
obtained at 82.1 ±21.2 minutes and the third at 149.6 ±31.5 minutes. Meropenem 
concentrations at T1, T2 and T3 were 45.9 ±10, 20.7 ±13, 16.6 ±13 μg/mL respectively. Mean 
kidney sample weight was 5.9 ±3.0 mg and meropenem concentration was 3.1 ±1.9 μg/mL. 
For each patient a decay curve was constructed and meropenem plasma concentration was 
estimated at the biopsy time. The ratio of meropenem concentration between plasma and 
renal tissue (mP/mK) was 14 ±10% with a range of 3.8% – 34.8%. Meropenem excretion 
occurs predominantly by glomerular filtration, thus plasma concentration and glomerular 
filtration rate determine the filtered load, modifying the urinary concentration and keeping 
the (mP/mK) ratio constant over time. The absence of linear correlation between (mP/mK) 
ratio and eGFR supports this idea. With the standard meropenem doses and normal renal 
function, we estimate that is possible treating with bactericide effect to bacteria with MIC90 
<0.76 μg/mL.
Conclusions: With standard meropenem doses is possible achieve adequate 
concentration in renal parenchyma to treat, with bactericide effect, most frequent 
uropathogens. Nevertheless, for resistant bacteria is necessary increase the dose or consider 
another antibiotic. Renal failure does not avoid achieving adequate meropenem renal tissue 
concentrations.
Funding: Private Foundation Support
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Pharmacokinetics of Intraperitoneal Cefazolin and Ceftazidime in 
Automated Peritoneal Dialysis Patients with Peritonitis
Pinpongsarn Triyawatanyu,1 Pisut Katavetin,3 Pajaree Chariyavilaskul,2 
Weeraya Phaisal,4 Sadudee Peerapornratana,2 Talerngsak Kanjanabuch,2 
Kearkiat Praditpornsilpa,2 Somchai Eiam-Ong.2 1Chulalongkorn university, 
Nongkhai, Thailand; 2Chulalongkorn University, Bangkok, Thailand; 3King 
Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of 
Medicine, Chulalongkorn University, Bangkok, Thailand; 4chulalongkorn 
university, Bangkok, Thailand.
Background: The current peritoneal dialysis (PD) guideline suggested that 
intraperitoneal (IP) antibiotics should be administered only in a long dwell (≥6 hours). 
We previously showed that IP cefazolin and ceftazidime during short-dwell cycling PD 
(<2-hour) could provide adequate plasma concentration for up to 24 hours in non-peritonitis 
patients. This study was aimed to evaluate bioavailability, as well as plasma and dialysate 
concentration of IP cefazolin and ceftazidime during short-dwell cycling PD in patients 
with peritonitis.
Methods: PD patients with peritonitis were enrolled. Cefazolin and ceftazidime (2,500 
mg each) were added in a 5-liter bag containing 2.5% dextrose PD fluid, placed on the 
warmer of PD cycling machine. Another 5-liter bag of PD fluid was connected to the 
machine, off the warmer. Patients underwent 5 exchanges of 2-liter PD fluid over 10 hours 
by the PD cycling machine without last fill or additional dwell. Antibiotics concentrations 
were determined by high-performance liquid chromatography.
Results: Six PD patients with peritonitis participated in this study. The IP bioavailability 
of cefazolin and ceftazidime were 50.3±16.4% and 56.6±18.4%, respectively. Plasma 
cefazolin and ceftazidime levels exceeded the minimum inhibitory concentration (MIC) of 
8 mg/L within the first hour (cefazolin 37.0±6.5 and ceftazidime 21.4±5.7 mg/L), peak at 10 
hours (100.1±4.0 and 54.0±14.5 mg/L) and then sustained well above the MIC at 24 hours 
after the infusion (82.3±3.2 and 40.2±10.5 mg/L). Dialysate cefazolin and ceftazidime 
levels were also sustained above the MIC throughout the PD session in all patients.
Conclusions: The IP cefazolin and ceftazidime during short dwells in peritonitis 
patients provided sufficient bioavailability as well as adequate plasma and dialysate 
concentrations. This regimen should be one of the standard regimens for treatment of 
peritonitis in PD patients.
Funding: Government Support - Non-U.S.
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The Distribution Profile of Anti-Sense Oligonucleotides Indicates That 
Proximal Tubular Targets Should Be Prioritized in Renal Disease
Anna Granqvist,1 Lena William-Olsson,1 Barbro Basta,2 Charlotte Ericson,1 
Pernilla Tonelius,1 Åsa Wåhlander,1 Thomas Bell,4 Patrik Andersson,1 
Magnus Soderberg,1 Robert J. Unwin,3 Mark J. Anderton,1 Christine Ahlström.1 
1AstraZeneca, Molndal, Sweden; 2Astrazeneca, Mondal, Sweden; 3University 
College London Medical School, London, United Kingdom; 4Ionis 
Pharmaceuticals, Carlsbad, CA.
Background: Antisense oligonucleotides (ASOs) are predominantly taken up by the 
liver and kidneys, which makes them a potentially attractive modality for the treatment of 
renal disease. However, it is not clear to what extent ASOs reach the different compartments 
of the kidney. The biodistribution of ASOs is dependent on plasma protein binding, which 
delays urinary excretion, but may also facilitate uptake into proximal tubular cells (PTCs).
Methods: We investigated the tissue exposure and distribution of a phosphorothioate 
cEt gapmer ASO in three different renal disease models: the diabetic BTBRob/ob, the 5/6 
nephrectomy and the adenine diet mouse models. Mice were subcutaneously administered 
weekly doses of 3, 10 or 30 mg/kg ASO and followed for between 2 and 12 weeks.
Results: In all treated animals, renal tissue ASO exposure and significant knockdown 
of the target gene were achieved. Detailed analysis of the ASO distribution and knockdown 
revealed that the primary site of action is the PTCs, whereas knockdown in the glomerular 
compartment required higher doses. Uptake of ASOs in distal tubules was only detected in 
the adenine model in which PTCs were severely injured.
Conclusions: These results indicate that ASOs can primarily be used for treatment 
targets in PTCs, while targets in the distal tubule will require facilitated delivery for efficient 
knockdown.
Funding: Commercial Support - AstraZeneca
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Identification of Patients with High Probability of Not or Poorly 
Responding to Mycophenolic Acid Prodrugs
Wolfgang Winnicki, Gurkan Sengoelge. Medical University of Vienna, Vienna, 
Austria.
Background: The antiproliferative agent mycophenolic acid (MPA) exerts its 
immunosuppressive effect by a selective inhibition of inosine 5’-monophosphate 
dehydrogenase (IMPDH), the rate-limiting enzyme of purine metabolism. The isoenzyme 
IMPDH2 predominates in activated lymphocytes, and its inhibition by MPA is part of 
standard immunosuppressive therapy in transplant medicine. Previously, factors which 
might explain differences in MPA efficacy and tolerability among patients have been 
studied: polymorphism rs11706052 in the IMPDH2 gene has been identified to reduce the 
antiproliferative effect of MPA on lymphocytes; data on therapeutic drug monitoring using 
MPA trough levels and IMPDH activity were not conclusive. Yet, whether a combination of 
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pharmacogenomic, pharmacokinetic and pharmacodynamic factors explain the differences 
in response to MPA therapy and drug tolerance remains to be elucidated.
Methods: This was designed as a prospective study of kidney transplant patients with 
and without biopsy-proven rejection (BPR). Both groups were tested for the presence 
of SNP rs11706052. In addition, MPA trough levels in plasma were measured by high 
performance liquid chromatography and IMPDH enzyme activity in peripheral blood 
mononuclear cells was tested by liquid chromatography–mass spectrometry. Correlations 
between BPR and the presence of rs11706052, MPA trough levels, IMPDH activity as well 
as the IMPDH/MPA ratio (assuming that a higher IMPDH activity requires higher MPA 
trough levels for an adequate immunosuppressive effect) were examined.
Results: Preliminary results from 50 kidney transplant recipients with biopsy-proven 
rejection and 100 controls without rejection suggest 1.) IMPDH activity was significantly 
higher in patients with BPR compared to patients with a stable graft function over 12 
months with no immunological complications, 2.) no correlation between IMPDH activity 
and MPA levels, BPR and the IMPDH/MPA ratio, 3.) no influence of rs11706052.
Conclusions: This is the clinical extension of our previous in vitro study, which has 
shown that the polymorphism rs11706052 reduces the immunosuppressive effect of MPA. 
This prospective study investigates the susceptibility to reject kidney allografts using a 
combined pharmacogenomic, pharmacokinetic and pharmacodynamic approach.
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Tacrolimus Troughs and Doses in African American, Asian, Caucasian, 
and Hispanic/Native American Kidney Transplant (tx) Recipients
Pamala A. Jacobson,1 David P. Schladt,2 William S. Oetting,1 Baolin Wu,1 
Weihua Guan,1 Casey R. Dorr,2 Rory P. Remmel,1 Roslyn B. Mannon,3 
David N. Ikle,4 Arthur J. Matas,1 Ajay K. Israni.5,1 DeKAF Genomics 1University 
of Minnesota, Minneapolis, MN; 2Minneapolis Medical Research Foundation, 
Minneapolis, MN; 3University of Alabama at Birmingham, Birmingham, AL; 
4Rho Federal Systems Division, Chapel Hill, NC; 5Hennepin County Medical 
Center, Minneapolis, MN.
Background: TAC is an immune suppressant with a narrow therapeutic index and 
high inter-individual pharmacokinetic (PK) variability. African Americans (AA) have lower 
troughs and higher dose requirements primarily due to the CYP3A5*1 allele that results 
in CYP3A expression. Caucasians have higher troughs and lower dose requirements due 
to the loss of function variants CYP3A5*3 and CYP3A4*22. TAC trough and genotype 
relationships for Asian and Hispanic/Native Americans are not well described.
Methods: 2739 adult kidney tx recipients enrolled in the multicenter DeKAF 
Genomics and the GEN03 genome wide association studies (GWAS) who received TAC 
maintenance and had TAC troughs available in the first 6 mo posttx were studied. Race was 
identified and confirmed through principal component analysis using the GWAS. We tested 
the association between genetic variants (CYP3A5*3, *6 and *7, CYP3A4*22) and dose-
normalized TAC troughs in each population adjusting for center, age and gender
Results: The allele frequency of CYP3A5*3 differed between the groups; 0.30, 0.72, 
0.92, 0.84 in AA, Asian, Caucasian and Hispanic/Native Americans, respectively. The 
median (IQR) TAC dose-normalized trough, dose and trough by population are in the table. 
CYP3A5*3 was highly significant in all groups (p = 3.3E-09 to 4.9E-127). CYP3A5*6 and 
*7 were associated with troughs in the AA group (p=2.0E-12 and 1.3E-24) and CYP3A4*22 
in the Caucasian group (2.2xE-22).
Conclusions: The Hispanic/Native American group had the highest dose-normalized 
TAC trough and the AA the lowest. The most rapid TAC metabolism occurs in AA followed 
by Asians, Caucasians and Hispanic/Native Americans. Genetic variants that influence 
TAC metabolism are highly significant and vary by race. This data suggest that additional 
variants may be present in the Asian and Hispanic/Native American groups which impact 
CYP3A4 and 5 substrate metabolism.
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Safety and Single Ascending Dose Pharmacokinetic Study of DUR-928 in 
Patients with CKD versus Matched Control Subjects
Jaymin C. Shah, David J. Ellis, Andrew R. Miksztal, Wei Qi Lin. DURECT 
Corporation, Cupertino, CA.
Background: DUR-928 ((5-cholesten-3β,25-diol 3-sulfate (25HC3S)) is an 
endogenous intracellular sulfated oxysterol that has been shown to regulate lipid 
metabolism, inflammatory response, and cell survival. This first-in-class investigational 
product is being developed for the treatment of various liver and kidney diseases. Animal 
ADME studies have shown that ≈ 17% of DUR-928 is eliminated through the urine. This 
study was to evaluate the impact of renal impairment in chronic kidney disease (CKD), on 
the safety and pharmacokinetics (PK) of DUR-928.
Methods: The study was a Phase 1b, open label, single ascending dose study to 
evaluate the safety and PK of IM injected DUR-928 in patients with moderate and severe 
kidney function impairment (Stage 3 and Stage 4 CKD) and matched control subjects 
(MCS), matched by age, BMI, and gender, with normal kidney function. The two doses of 
DUR-928 in the study were 30 mg and 120 mg. Biomarkers were also examined. All study 
subjects were followed through 7 days post dosing.
Results: Eleven CKD patients (Stage 3 (N=8), Stage 4 (N=3)) and six MCS completed 
the study. A total of 13 TEAEs were reported by 8 participants, mostly mild and none were 
severe. A clinically non-significant decrease (≈ 10%) in exposure was observed in CKD 
patients as compared to MCS at both dose levels of DUR-928. The AUC values for 30 and 
120 mg doses in CKD patients were 1061 and 4304 ng*hr/mL vs. 1138 and 4766 ng*hr/mL 
in MCS. Similarly, the Cmax values for 30 and 120 mg doses in CKD patients were 281 and 
890 ng/mL vs. 345 and 997 ng/mL in MCS. The plasma half-life (T½) was in the range of 
1.5 to 2 hours. Participants with elevated levels of CK-18 (markers of cell death) or bilirubin 
at baseline showed considerable reduction of these markers at 12 or 24 - 48 hours after a 
single IM injection of DUR-928.
Conclusions: Single IM doses of DUR-928 in CKD patients were found to be well 
tolerated. Kidney function impairment did not impact the PK of DUR-928. These data 
support further evaluation of DUR-928 in patients with kidney disease.
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Evaluation of the Antioxidant Effects of Benzbromarone in Angiotensin II 
Induced Hypertension Model
Daisuke Kadowaki,1 Yuki Narita,2 Shigeyuki Miyamura,1 Kohei Uchimura,3,4 
Kenichiro Kitamura,4 Toru Maruyama,2 Sumio Hirata,2 Hakaru Seo.1 1School of 
Pharmacy, Sojo University, Kumamoto, Japan; 2School of Pharmacy, Kumamoto 
University, Kumamoto, Japan; 3Washington University in St. Louis, Saint Louis, 
MO; 4University of Yamanashi School of Medicine, Chuo, Japan.
Background: Uric acid exerts an important antioxidant effect against external oxidative 
stress under physiological conditions. However, oxidative stress induced by hyperuricemia 
is closely associated with the renin-angiotensin system, as well as the onset and progression 
of cardiovascular disease (CVD) and chronic kidney disease (CKD). Furthermore, uric 
acid locally activates the renin-angiotensin system, thus producing angiotensin II and 
subsequently increasing intracellular oxidative stress. Benzbromarone has been reported to 
suppress uric acid reabsorption via uric acid transporter 1 inhibition in renal tubular cells. In 
this study, we evaluated the antioxidant effect of benzbromarone from several perspectives 
in vitro and in vivo.
Methods: First, the direct radical-trapping capacity of benzbromarone was measured 
by chemiluminescence assay and electron paramagnetic resonance spectroscopy in vitro. 
Second, the intracellular antioxidant activity of benzbromarone was evaluated using 
endothelial cells. Finally, the antioxidant effects of benzbromarone were evaluated in vivo 
via oral administration of benzbromarone for 4 weeks to model rats with angiotensin II– and 
salt-induced hypertension.
Results: benzbromarone showed direct radical scavenging capacity against the 
superoxide anion radical in vitro. In addition, benzbromarone inhibited reactive oxygen 
species production that was induced by angiotensin II or uric acid in endothelial cells. In 
in vivo study, benzbromarone did not alter plasma uric acid levels or blood pressure, but 
significantly reduced the levels of advanced oxidation protein products, which are oxidative 
stress markers. Furthermore, dihydroethidium staining of the kidney revealed a reduction in 
oxidative stress after benzbromarone administration.
Conclusions: These findings suggest that benzbromarone possesses the ability directly 
to scavenge radicals and may act as an antioxidant against uric acid and angiotensin II-
induced oxidative stresses in endothelial cells or angiotensin II induced hypertension.
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C-PAM, a Novel Iron Oxide-based Oral Drug, Efficiently Lowers Serum 
PI
Susanne E. Wagner,2 Jörg Schnorr,1 Monika Ebert,1 Nicola Stolzenburg,1
Matthias Taupitz.1 1Charité - Universitätsmedizin Berlin, Berlin, Germany; 
2Wagner MSL Management, Mahlow, Germany.
Background: C-PAM is a novel compound designed for use as a serum Pi-lowering oral 
drug. It is composed of iron (Fe) oxide nanoparticles with a maghemite structure, mannitol, 
inulin, and Arabic gum. In previous analytical tests, C-PAM had a superior Pi-binding 
capacity compared to major approved Pi-binders. The hypothesis of this experimental in 
vivo study is that C-PAM more efficiently lowers serum Pi compared to those Pi-binders.
Methods: Healthy male Sprague-Dawley rats with a starting weight of 250 g were 
treated with drug co-feeding for 4 weeks (n=8 rats per group). C-PAM was added to 
Altromin standard 1320 diet (containing 0.6 wt% free adsorbable Pi) at 0.125, 0.25, and 
0.5 wt% Fe. For comparison, three groups received Fosrenol® at 0.25 wt% La, Renvela® 
at 0.5 wt% sevelamer carbonate, and Velphoro® at 0.25 wt% Fe. As controls, one group 
received standard diet only and one group the carbohydrate components of C-PAM 
(mannitol, inulin, Arabic gum) at 2.0 wt%. Blood was sampled at the end of the 4-week 
study period and analyzed for serum Pi and standard parameters of hematology and clinical 
chemistry. For histopathology, HE and iron stains of liver, spleen, heart, lung, kidney, 
stomach, duodenum, jejunum, ileum, colon, and intestinal lymph nodes were assessed. 
Student’s t-test was used for statistical analysis.
Results: At all doses investigated, C-PAM reduced serum Pi significantly (0.125 wt%: 
p <.05, 0.25 and 0.5 wt%: p <.01). None of the other products tested or the carbohydrate 
components of C-PAM had a significant serum Pi lowering effect (figure). For C-PAM, 
except serum Pi, there was no effect on hematology and clinical chemistry parameters. No 
histopathologic changes were observed.
Conclusions: Even at a low dose, C-PAM effectively reduces serum Pi in healthy rats 
and thus is superior to three major approved products.
Funding: Government Support - Non-U.S.
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In vivo efficacy of C-PAM in lowering serum Pi at three different doses compared with 
three approved products, the carbohydrate components of C-PAM only, and with a control 
group (*p<.05; **p<.01).
SA-PO637 Poster Saturday
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C-PAM, a Novel Serum Phosphate-Lowering Oral Drug with Dual Mode 
of Action, Prevents Serum Phosphate Rise After Drug Skip
Matthias Taupitz,1 Jörg Schnorr,1 Nicola Stolzenburg,1 Franziska Rausch,1 
Monika Ebert,1 Susanne E. Wagner.3 1Charité - Universitätsmedizin Berlin,
Berlin, Germany; 3Wagner MSL Management, Mahlow, Germany.
Background: In ESRD patients, medications based on Pi-binders to control serum 
Pi require regular oral drug intake with each meal. Such a regimen is not conducive to 
adequate compliance, and occasional drug skipping is one reason why <20% of patients 
have serum Pi levels within the KDOQI® recommended target range. C-PAM is a novel 
compound consisting of iron oxide nanoparticles with a maghemite structure, mannitol, 
inulin, and Arabic gum. C-PAM showed superior Pi-binding in earlier analytical tests and 
better serum Pi-lowering in experimental in vivo studies, both compared to major approved 
drugs. The hypothesis for this experimental study was that, for C-PAM, a 1-day drug skip 
does not significantly increase serum Pi.
Methods: Healthy male Sprague-Dawley rats (CD Charles River) with an initial 
weight > 320 g were treated with drug co-feeding for 4 weeks (n=8 rats per group). Group 
A: C-PAM added to Altromin standard 1320 diet (0.47% digestable Pi) at 0.75 wt% total 
drug substance. Group B: Renvela® at 1.5 wt% total drug substance. Blood was sampled 
at the end of each week (W1 to W4) for analysis of serum Pi. During one day before W3 
blood sampling, rats received the standard diet only. After W4 sampling, rats were sacrificed 
and the intestine was analyzed for NaPi2b expression using PCR. For statistical analysis 
student’s t-test was used.
Results: Serum Pi was as follows [mmol/l]: C-PAM: BL 2.31±.21; W1 2.13±.21; 
W2 2.15±.27; W3 (after drug skip) 2.29±.20; W4 1.92±.20. Renvela®: BL 2.60±.25; W1 
1.89±.24; W2 1.93±.44; W3 (after drug skip) 2.56±.27; W4 1.87±.13. After drug skip the 
rise was 7% (n.s.) and 33% (p<.01) resp. After drug skip the values were -10% and +1% 
resp. compared to age matched controls (n.s.). PCR analysis showed less expression of 
NaPi2b (ΔΔCt) in the proximal jejunum in the C-PAM group (3.08±.05) compared to the 
Renvela group (5.30±2.56, p<.05).
Conclusions: C-PAM effectively reduces serum Pi at a low dose and is robust against 
a 1-d drug skip, which is because of its dual mode of action combining highly effective Pi 
binding with an effect on NaPi2b transporters. If C-PAM is equally effective in the clinical 
setting, treatment of ESRD patients may be impoved by a significantly lower pill burden 
with better maintainance of serum Pi within the KDOQI® recommended target range.
Funding: Government Support - Non-U.S.
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Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney 
Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage 
Schedule
Rui Fujimura,1,2 Hiroshi Watanabe,3 Kenshiro Hirata,4 Toru Maruyama.3 
1Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto 
University, Kumamoto, Japan; 2Program for Leading Graduate Schools “HIGO 
(Health life science: Interdisciplinary and Glocal Oriented) Program, 
Kumamoto University, Kumamoto, Japan; 3Biopharmaceutics, School of 
Pharmacy, Kumamoto University, Kumamoto, Japan; 4Pharmacy, Japanese 
Red Cross Kumamoto Hospital, Kumamoto, Japan, Kumamoto, Japan.
Background: The mechanism responsible for the decreased extra-renal CYP3A activity 
in chronic kidney disease (CKD) patients remains unknown. Using an animal model, we 
previously found that elevated levels of serum intact parathyroid hormone (iPTH) caused 
a reduced CYP3A activity. The purpose of this study is to investigate whether serum iPTH 
levels affects the pharmacokinetics of tacrolimus, a CYP3A substrate, and its dosage 
schedule in kidney transplant recipients.
Methods: Thirty-four patients who were recipients of kidney transplantation between 
April 2014 and March 2016 and were administrated prolonged-release tacrolimus 
(Graceptor®, Astellas Pharm Inc.) once daily were the subjects of this study. Among the 34 
patients, 22 patients had received the concomitant CYP3A substrate drug. To clarify the role 
of iPTH on the pharmacokinetics of tacrolimus, we performed the analysis using 12 patients 
who had not been administered concomitant CYP3A substrate drug.
Results: To investigate the relationship between serum iPTH levels and tacrolimus 
trough levels, we monitored the serum iPTH levels in patients before kidney transplantation. 
At this time point, serum iPTH levels in these subjects were increased, but with large 
deviations due to the difference in the patients’ background such as the causes of and the 
progression of renal failure and complications. Therefore, we examined the correlation 
between serum iPTH levels and trough levels after the first oral administration of tacrolimus 
at 4 days before kidney transplantation. A significant positive correlation between serum 
iPTH level and the initial trough level for tacrolimus was found. This indicates that the 
tacrolimus trough level before transplantation was higher in patients with high serum iPTH 
levels as compared to patients with low iPTH values. These data suggest that CYP3A 
activity might be lower in patients with high serum iPTH levels, as was observed in the 
previous animal study, and that the initial trough level of tacrolimus could be predicted from 
serum iPTH levels before kidney transplantation.
Conclusions: Monitoring serum iPTH levels could predict the trough level for the 
initial administration of tacrolimus, and may serve as an index for the initial dose of 
tacrolimus in kidney transplantation patients.
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Rhein Attenuates D-Galactose Induced Renal Aging via Regulation of 
mTOR-Mediated Autophagy
Yue Tu, Diping Chen, Yihuang Gu. Department of TCM Health Preservation, 
Nanjing University of Chinese Medicine, Nanjing, China.
Background: In recent years, traditional Chinese herbal medications (TCHMs) are 
found to possess potent anti-aging activities. Rhubarb, derived from the root of Rheum 
palmatum, has been found to have anti-aging pharmacological effect. Rhein, a bioactive 
constituent of rhubarb, plays a vital role in its pharmacological effect. However, the 
potential mechanism of rhein in anti-aging remains unclear. Autophagy and its related 
signaling pathway mTOR play the important roles in aging.
Methods: In vitro, D-galactose (D-gal) was used to induce renal cellular aging in NRK-
52E cells, following treating with or without rhein or vitamin E (VE). To measure renal 
cellular aging, the klotho protein expression was detected, and the senescence-associated-
β-galactosidase (SA-β-gal) staining were observed. To study the changes of autophagy in 
the aging effects, several key autophagic markers protein expressions, including LC3 I/II, 
beclin1, SQSTM1/p62 and phospho-p62 (p-p62), were detected. Further, the changes 
of key protein expressions in mTOR signaling, including mTOR, and phospho-mTOR 
(Ser2448 and Ser2481), were detected in the same condition. The changes of the key protein 
expressions in mTOR-mediated autophagy were detected in NRK-52E cells exposed to 
D-gal and rhein or VE with or without mTOR inhibitor rapamycin (RAP) and mTOR
activator MHY1485. In vivo, SD rats were divided into Normal, D-gal, Rhein-low dose,
Rhein-high dose, VE, RAP and MHY1485 groups. The renal aging and mTOR-mediated 
autophagy related protein expressions and SA-β-gal staining were detected.
Results: Results showed that, renal tubular cellular aging in vitro and renal aging in vivo 
both induced by D-gal could be ameliorated by rhein and VE by inducing klotho protein 
expression, and attenuating the positive area of SA-β-gal staining. Rhein and VE could 
regulate mTOR-mediated autophagy by reducing autophagic related protein expressions 
and increasing mTOR signaling related protein expressions both in vitro and in vivo.
Conclusions: In this study, we demonstrated that rhein, similar to VE, could alleviate 
renal aging via regulating mTOR-mediated autophagy. These findings suggest that targeting 
autophagy and related signaling pathways may provide new strategies in the age-associated 
renal damage of the elderly patients.
Funding: Government Support - Non-U.S.
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Effect of CKD on Fexofenadine Disposition in Humanized OATP1B1/1B3 
Mice
Nicholas Tonial,1 Yong Jin (James) Lim,1 Brad Urquhart.1,2 1Physiology and 
Pharmacology, Western University, London, ON, Canada; 2Medicine, Division 
of Nephrology, Western University, London, ON, Canada.
Background: Patients with chronic kidney disease (CKD) often experience variable 
responses to drug therapies evidenced by their elevated incidence of adverse drug reactions. 
Cytochrome P450s (CYPs) and drug transporters are major contributors to drug disposition, 
as they mediate drug metabolism and removal from blood, respectively, to facilitate non-
renal excretion. Rodent models of CKD exhibit reduced CYP expression and activity. 
However, the impact of CKD on drug transporters, namely organic anion transporting 
polypeptides (OATPs), is not well elucidated. Fexofenadine is a commonly used transporter 
probe ideal to study non-renal clearance since it is not metabolized and not eliminated in 
the urine. Multiple studies have documented significantly increased fexofenadine exposure 
in CKD patients, although the mechanism is unclear. This study investigated the effects 
of CKD on hepatic drug transporter activity in a humanized hepatic OATP1B1/1B3 
mouse model by evaluating the liver distribution fexofenadine. It was hypothesized that 
CKD would decrease the activity of these transporters, as shown by a reduction in hepatic 
fexofenadine distribution.
Methods: CKD was induced in humanized OATP1B1 and OATP1B3 FVB/N mice by 
feeding chow supplemented with 0.2% adenine (n=6) for a total of 28 days while controls 
(n=6) received standard chow. Blood and organs were collected at sacrifice and plasma 
creatinine concentrations and the liver to plasma ratio of fexofenadine (L:PFEX) were 
measured using ultra performance liquid chromatography coupled to mass spectrometry.
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Results: Plasma creatinine was two-fold higher in adenine-fed mice compared to 
controls (p=0.0011). L:PFEXwas reduced by 15%, indicating a modest decrease in hepatic 
fexofenadine liver distribution (p=0.1870).
Conclusions: Induction of CKD did not significantly alter the liver distribution of 
fexofenadine in the humanized hepatic OATP1B1/1B3 mouse model. Further analysis into 
expression levels of these transporters, and other hepatic transporters such as P-glycoprotein, 
will provide further insight into the impact of CKD on drug transporters and distribution of 
fexofenadine in the liver.
Funding: Government Support - Non-U.S.
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Activity of Brincidofovir (BCV) Against Murine Polyoma Virus (MuPyV) 
in a Mouse Infection Model
Odin Naderer,1 Heidi Colton,1 Ge Jin,2 Matthew D. Lauver,2 Aron Lukacher.2 
1Chimerix, Durham, NC; 2Pennsylvania State University, Hershey, PA.
Background: BK virus (BKV) is a ubiquitous polyomavirus which can result in 
up to 10% of kidney transplant recipients to develop BKV-associated nephropathy and 
organ loss. As no antivirals are available, the current treatment paradigm is reduction of 
immunosuppression which can risk organ rejection. An active antiviral capable of reducing 
BK viral burden while maintaining optimal immunosuppression could have a substantial 
impact on the survival of existing kidney grafts and avoid re-transplantation. BCV is a lipid 
conjugated nucleotide analog of cidofovir (CDV) with potent antiviral activity against BKV 
in vitro (EC50= 0.02 uM) without CDV-associated nephrotoxicity. In this study, we assessed 
the in vivo antiviral activity of BCV against a murine polyomavirus (MuPyV) which infects 
the kidney in a mouse model.
Methods: Fifteen C57BL/6 mice (8–12 weeks old) were randomized 1:1:1 to placebo, 
BCV 20mg/kg or BCV 40mg/kg IP twice weekly. Treatment was given on Day -7, Day -3, 
Day 1, and Day 4. Mice were inoculated in hind footpads with 1.0 × 106 PFU of MuPyV on 
Day 1. qPCR of kidney and spleen were performed at Day 5 (Termination).
Results: All mice tolerated all BCV IP doses to termination. BCV 20 mg/kg or higher 
delivered IP decreased viral load in the kidney by ~1 log.
Conclusions: BCV demonstrated antiviral activity in mice infected with MuPyV in 
this prophylaxis model. Evaluation of BCV activity in a post -infection treatment model of 
MuPyV is warranted to support BCV as a potential treatment for BKV.
Funding: Commercial Support - Chimerix
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Brincidofovir (BCV) Demonstrates Antiviral Activity Against Murine 
Polyoma Virus (MuPyV) in a Mouse Model of Acute Infection
Odin Naderer,1 Heidi Colton,1 Ge Jin,2 Matthew D. Lauver,2 Aron Lukacher.2 
1Chimerix, Durham, NC; 2Pennsylvania State University, Hershey, PA.
Background: BK virus (BKV) is a ubiquitous polyomavirus which can result in up 
to 10% of kidney transplant recipients to develop BKV-associated nephropathy and organ 
loss. As no antivirals are available, the current treatment is reduction of immunosuppression 
which can risk organ rejection. An active antiviral capable of reducing viral burden while 
maintaining immunosuppression could have a substantial impact on the survival of existing 
kidney grafts and avoid re-transplantation. BCV is a lipid conjugated nucleotide analog 
of cidofovir (CDV) with potent antiviral activity against BKV in vitro (EC50= 0.02 uM) 
without CDV-associated nephrotoxicity. In this acute infection-treatment model study, we 
assessed the antiviral activity of BCV against MuPyV which infects the kidney.
Methods: Twenty-seven C57BL/6 mice (8–12 weeks old) were assigned to one of 
three treatment groups (n=6/group) or three corresponding placebo groups (n=3/group). For 
the treatment groups, BCV 80 mg/kg was delivered over a one-week period as a single dose 
or through divided doses: BCV 80mg/kg IP on Day 1; BCV 40mg/kg IP on Days 1 and 4; 
or BCV ~13 mg/kg IP on Days 1-6. Mice were inoculated in hind footpads with 1.0 × 106 
PFU of MuPyV on Day 1. qPCR of kidney and spleen were performed at Day 7. Placebo 
groups were pooled for analysis.
Results: All mice tolerated all BCV IP doses to termination. All animals that received 
BCV had kidney viral loads 2-logs lower than animals that received placebo.
Conclusions: BCV reduced the viral load in the kidneys of mice acutely infected with 
MuPyV in this model. Further evaluation of BCV activity in immunocompromised mice 
with chronic MuPyV is planned to further explore BCV as a potential treatment for BKV.
Funding: Commercial Support - Chimerix
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Characterization of GFB-8438, a Potent and Selective TRPC5 Inhibitor 
Under Evaluation for the Treatment of FSGS
Maria Beconi, Mark Ledeboer, Maolin Yu, Matthew Daniels, Goran Malojcic, 
Marie F. Coeffet-LeGal, Xin-Ru Pan-Zhou, Peter H. Mundel, Jean-
Christophe P. Harmange. Goldfinch Bio, Cambridge, MA.
Background: The predominant role of podocyte in the development of FSGS is 
well established. One of the central mechanisms leading to FSGS is the disruption of 
the podocyte actin cytoskeleton via Rac1 activation. TRPC5 has been identified as a key 
regulator of Rac1 activation in podocytes and its role was reinforced by the antiproteinuric 
effect of two TRPC5 small molecule inhibitors in two models of FSGS (Zhou et al, 2017). 
Here we present the preclinical characterization of GFB-8438, a potent and selective 
inhibitor of TRPC5. Metabolism, pharmacokinetic and the pharmacology of GFB-8438 
will be discussed.
Methods: High throughput screening of a structurally diverse compound collection 
followed by lead optimization yielded several potent TRPC5 inhibitors. GFB-8438 
inhibitory activity against TRPC5 and selectivity across other TRP channels were 
determined using FLIPR based assays and electrophysiology. Additional profiling 
was conducted using standard receptor and kinase panels. In vitro routes and clearance 
mechanisms across species and drug-drug interaction (DDI) potential were evaluated 
using standard ADME assays. The pharmacokinetic profile was characterized in rats and 
dogs at 1 mg/kg iv (solution) and at 3, 10, 30 and 100 mg/kg po (suspension). The in vivo 
efficacy was evaluated in a uni-nephrectomized DOCA-salt rat model of FSGS. PK/PD 
relationships were derived.
Results: GFB-8438 is a potent TRPC5 inhibitor with high selectivity against TRPC6. 
Further profiling in standard receptor and kinase panels did not reveal any off-target 
activities. GFB-8438 is metabolized primarily by oxidation and renal clearance is predicted 
to be low. Oral bioavailability in rats and dogs is acceptable, with favorable human PK 
projections given the low rate of hepatic metabolism. When dosed to DOCA-salt rats (single 
daily dose for 21 consecutive days), GFB-8438 reduced the rate of albuminuria progression 
without affecting the blood pressure. Rate of albuminuria reduction correlated well with 
exposure.
Conclusions: GFB-8438 is a potent and selective TPRC5 inhibitor with favorable 
DMPK and pharmacology characteristics under evaluation for the treatment of FSGS. 
Characterization in toxicology models is ongoing.
Funding: Commercial Support - Goldfinch Bio
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Preclinical Safety and Scalability of VIS649 Production for Clinical Trials 
for the Treatment of IgA Nephropathy
Veronica M. Miller, Susan E. Sloan, Emily A. Helger, James R. Myette, 
Pat Vollmer, Kristy J. Szretter, Ketan Deotale, Brian J. Pereira. Visterra, Inc., 
Waltham, MA.
Background: IgA Nephropathy (IgAN) is the most common cause of glomerulonephritis 
worldwide, with no disease-specific therapies currently available. VIS649 is a humanized 
IgG2 monoclonal antibody targeting the cytokine named A Proliferation Inducing Ligand 
(APRIL) that is implicated in the pathophysiology of IgAN. To demonstrate the feasibility 
of generating a commercially available VIS649 treatment, the preclinical effects, potency 
and safety attributes of VIS649 materials that were produced using a range of scaled down 
bench-top and scaled up manufacturing processes were compared.
Methods: VIS649 was first produced in-house using a CHO cell line – Batch 1, 
followed by small scale production at a CRO using a pool of CHO clones (Batch 2) and 
finally at a larger-scale manufacturing plant using CHO cells from a research cell bank 
(Batch 3). Each batch of VIS649 was then assessed for preclinical safety and efficacy in 
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non-human primates (NHPs). In addition, in vitro analytical assays were used to compare 
the batches including APRIL binding (ELISA), and engagement with immune factors and 
receptors (complement, FcRI, FcRII and FcRIII binding by Octet). Finally, because glycans 
can influence the half-life and metabolism of immunoglobulins the glycan profile of each 
batch was assessed using MS, HPLC and CE methods.
Results: VIS649 synthesized at each scale was found to produce equivalent maximal 
reductions in circulating IgA levels (~70%) in the NHP studies. Furthermore, in vitro 
assessments confirmed that the three batches of VIS649 had similar binding to APRIL, as 
well as minimal FcRI, II, III and complement binding. Observed minor changes in glycans 
were not found to impact in vivo or in vitro VIS649 activity.
Conclusions: These data confirm that VIS649 production can be consistently scaled 
from small to larger scale manufacturing, while retaining important potency, purity and 
safety characteristics. These results support that large-scale production of VIS649 will be 
suitable for use in clinical trials to assess both safety and efficacy in IgAN patients.
Funding: Commercial Support - Visterra Inc.
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Crotamine, a Cell Penetrating Peptide, Targeting Renal Proximal Tubular 
Epithelial Cells: A Potential Future for Kidney Gene Therapy
Joana D. Campeiro,1,2 Wendy Dam,1 Sunamita C. Lima,2 Gabriela G. Monte,2 
Lilian Caroline G. Oliveira,2 Marcela B. Nering,2 Gustavo M. Viana,2 
Eduardo B. Oliveira,3 Jacob van den Born,1 Mirian A. Hayashi.2 1University 
Medical Center Groningen, São Paulo, Brazil; 2Federal University of São 
Paulo, São Paulo, Brazil; 3University of São Paulo, Ribeirão Preto, Brazil.
Background: Activated proximal tubular epithelial cells (PTECs) play a crucial role in 
progressive tubulointerstitial fibrosis in native and transplanted kidneys. Active targeting of 
PTECs by non-viral gene delivery vectors such as cell penetrating peptides (CPPs) might 
be useful to influence the expression of genes in these cells, however most CPPs are not 
very cell type specific. Crotamine, isolated from the venom of rattlesnake, is characterized 
as CPP due to its ability to cross lipid cell membranes. Crotamine is also able to form 
complexes with DNA molecules and contains a nuclear retention motif, which helps to 
deliver DNA cargo into the nucleus enabling its use as a cell transfection agent. The ability 
of crotamine to internalize and carry molecules into cells is dependent on proteoglycans 
present on the cell membrane.
Methods: Crotamine was administered intraperitoneally to 14 week-old mice for 21 
consecutive days. Main organs and body weight, food and water intake and renal function 
biomarkers were assessed. Fluorescently-labeled Cy3-crotamine was injected to track its 
localization throughout the kidney. Kidney was collected for immunohistochemistry assays. 
Crotamine binding, uptake and reporter gene expression was assessed in PTEC cell line.
Results: We demonstrated the safety of long-term crotamine administration and after 
injection into mice, crotamine passes the glomerular filter, is selectively taken up by PTECs, 
and subsequently localized into the nuclei of these cells. In vitro we could show that the 
binding and uptake of crotamine into PTEC cell line is mediated via the heparan sulfate side 
chains of syndecan-1, a major proteoglycan on these cells. In vitro we also showed efficient 
gene-delivery and reporter gene expression in this cell line.
Conclusions: This study shows the in vivo applicability of using crotamine as PTEC 
specific gene delivery nanocarrier and might be a prototypic example of the next generation 
kidney specific non-viral gene delivery vectors to modulate aberrant gene expression in 
PTECs in kidneys in order to slow down progressive tubulointerstitial fibrosis. Support: 
FAPESP/Capes.
Funding: Government Support - Non-U.S.
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Unbiased Interrogation of Clinically-Indicated Biopsies Identifies 
Discoidin Domain Receptor Inhibition as Target for Anti-Fibrotic 
Therapy: Cell, Animal, and Pharmacological Intervention Studies
Richard E. Gilbert,1,2 Kerri Thai,1 Yanling Zhang,3 Lauren V. Caldwell,4 
Darren A. Yuen.1,2 1St. Michael’s Hospital, Toronto, ON, Canada; 2Fibrocor 
Therapeutics, Toronto, ON, Canada; 3St. Michael Hospital, University of 
Toronto, Toronto, ON, Canada; 4Lunenfeld Tanenbaum Research Institute, Ajax, 
ON, Canada.
Background: Regardless of etiology, most forms of kidney disease are characterized 
by advancing fibrosis, the extent of which correlates closely with declining kidney function. 
As such, fibrogenesis may be a final common pathway in kidney disease progression so 
that strategies to temper it may attenuate the loss of function in a broad range of kidney 
diseases. While most efforts at developing anti-fibrotic drugs have focused on inhibiting 
transforming growth factor-beta (TGF-beta) or connective tissue growth factor (CTGF), 
other yet unidentified mediators may also be importamt targets for therapeutic development.
Methods: RNA was extracted from 14, -80C degrees frozen, clinically-indicated 
kidney transplant biopsies and subjected to RNASeq analysis. Clinical data including 
sequential eGFR values were also collected.
Results: In addition to TGF-ß and CTGF we also found that the abundance of discoidin 
domain receptor (DDR) mRNA correlated closely with both the extent of fibrosis (rho=0.6, 
p=0.01) and rate of eGFR decline (rho=0.6, p=0.01). Since DDR is a receptor tyrosine kinase 
that is activated by binding to fibrillary collagen, we exposed NRK-49F renal fibroblasts 
(p<0.05) to type I collagen and noted that this not only led to DDR phosphorylation 
but also induced the de novo synthesis of collagen, identified by the incorporation of 
3H-proline. We next synthesized a DDR inhibitor, 6j (Wang et al., J. Med. Chem. 2016, 
59, 5911−5916), showing that it dose-dependently reduced DDR phosphorylation and 
3H-proline incorporation in renal fibroblasts (p<0.05) in response to collagen I. We then 
conducted in vivo proof-of-concept studies in the unilateral ureteric obstruction (UUO) 
model of kidney fibrosis showing robust reduction in collagen III deposition at 50 mg/kg/
day (p<0.05) at 7 days.
Conclusions: Merging unbiased transcriptomic analysis of clinically-indicated 
kidney biopsies with histopathological and clinical data can identify novel mediators of 
fibrogenesis. The pathophysiological relevance of the so-derived targets can then be 
assessed by in vitro and in vivo models as a prelude to the development of new therapies 
for human use that aim to slow, arrest or potentially even reverse the progression of CKD.
Funding: Commercial Support - Fibrocor Therapeutics, Private Foundation Support
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Dexamethasone-Loaded Macrophage-Derived Microvesicles: A Novel 
Approach for Enhanced Anti-Inflammatory Efficacy for Renal Disease
Tao-Tao Tang, Linli Lv, Cao Jingyuan, Ye Feng, Zuolin Li, Bi-Cheng Liu. 
Zhong Da Hospital, Southeast University, Nanjing, China.
Background: Although glucocorticoids are the mainstays in the treatment of 
renal disease, the dose dependent side effects have largely restricted their clinical use. 
Microvesicles (MVs) are nano-sized extracellular vesicles with a membrane lipid bilayer 
that are shed by cells and efficiently entering other cells. Here, we investigated whether 
macrophage-derived MVs can function as efficient carriers of dexamethasone (DEX), and 
the anti-inflammatory efficacy of the novel DEX delivery system was assessed in both in 
vitro and in vivo models of renal disease.
Methods: MVs were prepared from the supernatants of RAW 264.7 cells treated with 
DEX by centrifugation. In vivo, the therapeutic potential of DEX-packaging MVs (MV-
DEX) was assessed in LPS and Adriamycin (ADR) induced nephropathy model. In vitro, 
the therapeutic efficacy was assessed in glomerular endothelial cells (GECs).
Results: The mean diameter of MV-DEX was 140.7±4.8 nm and the average drug 
content was 6.2μg/1×1010 MVs. Compared with GECs without LPS stimulation, more MVs 
were accumulated in the inflamed GECs. Consistently, the higher renal radiance signal of 
DID-labelled MVs was observed in LPS and ADR model. The extent of average radiance 
was positively correlated with renal TNF-α or IL-6 protein levels. In vitro, we found that the 
mRNA levels of proinflammatory cytokines, protein expression of NF-κB p65 and p-p65, 
and levels of TNF-α and IL-6 in the supernatants were significantly inhibited by MV-DEX 
treatment. Inflammation was blunted with free DEX, however, to a much lesser extent 
than with MV-DEX therapy. In LPS model, treatment with MV-DEX increased the animal 
survival rate. In ADR model, albuminuria, glomerulosclerosis and foot process effacement 
were remarkedly ameliorated with MV-DEX threatment. In both models, the mRNA 
levels of proinflammatory cytokines, protein expression of p65 and p-p65, and infiltration 
of inflammatory cells were inhibited after MV-DEX treatment. Interestingly, MV-DEX 
treatment showed better therapeutic efficacy than free DEX both in vivo and in vitro.
Conclusions: Our studies firstly demonstrated that macrophage-derived MVs could 
efficiently deliver DEX into inflamed kidney and exhibit a superior ability to suppress renal 
inflammation compared to routine DEX therapy.
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Safety and Efficacy of a New Biomimetic Sorbent Hemoperfusion Device 
in Removing Bacteria from Hemodialysis Patients with Blood Stream 
Infections - Results of a Multicenter First-in-Human Study
Gabriele C. Eden,1 Julius Schmidt,2 Stefan Büttner,5 Alexandros Rovas,4 
Philipp Kümpers,3 Bernhard M. Schmidt,2 Jan T. Kielstein.1 1Academic Teaching 
Hospital Braunschweig, Braunschweig, Germany; 2Hannover Medical School, 
Hannover, Germany; 3University Clinics Münster, Münster, Germany; 
4University Hospital Münster, Münster, Germany; 5University hospital 
Frankfurt, Frankfurt am Main, Germany.
Background: Prompt reduction of bacterial load improves survial of bacteremic 
patients, so strategies above and beyound antibiotics are invesitagted. Binding of bacteria 
to heparan sulfate can be used to remove bacteria from the circulating blood by mimicking 
heparan sulfate grafting heparin to beads packed in a column. This device, the Seraph® 100 
Blood Filter (Seraph), also removes toxins, and cytokines. Aim of this multicenter first in 
human study was to asses safety and efficacy of the Seraph in hemodialysis patients with 
bacteremia.
Methods: Fifteen (3F/12M, median age 75 [66-79] years) patients were included 
(www.clinicaltrials.gov. NCT02914132). The Seraph was placed in series, upstream from 
a dialyzer during a single four hour dialysis session. Vital signs as well as coordinates of 
the hemodialysis and a detailed laboratory analysis were performed. Efficacy was evaluated 
by measuring time to positivity in the blood cultures taken before and after the Seraph at 
several time points. Patient follow up was 14 days.
Results: As the last patient was enrolled before the abstract deadline complete data are 
only available in 14 patients. Vital signs remained stable and peripheral oxygen saturation 
improved during treatment unrelated to fluid removal. In patients with bacteremia at the 
time of treatment despite an adequate dose on antibiotics (4 out of 15), Seraph lead to a 
decrease in bacterial count.
Conclusions: Seraph treatment is well tolerated by hemodialysis patients, and can 
quickly remove bacteria from blood. It’s rapid, broad-spectrum binding and inherent 
blood compatibility suggest future use as a prophylactic, or at the first sign of bloodstream 
infection, even before pathogen identification. Improvement of oxygen saturation during 
treatment deserves further investigation.
Funding: Commercial Support - ExThera Medical
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Urinary Exosomes Identify Inflammatory Pathways in Vancomycin 
Induced AKI
Amy Le,1 Jordan Amato,1 Vidhyut G. Jani,1 Robert Mills,1 David J. Gonzalez,1 
Ashita J. Tolwani,3 Anjali Acharya,2 Jorge Cerda,4 Melanie S. Joy,5 
Sucheta M. Vaingankar,6 Satish P. Ramachandrarao,6 Ravindra L. Mehta,6 
Linda Awdishu.1,6 1UCSD Skaggs School of Pharmacy and Pharmaceutical 
Sciences, La Jolla, CA; 2Jacobi Medical Center, Albert Einstein College of 
Medicine, Bronx, NY; 3University of Alabama at Birmingham, Birmingham, AL; 
4Capital District Renal Physicians, Albany, NY; 5University of Colorado 
Anschutz Medical Campus, Aurora, CO; 6University of California San Diego 
School of Medicine, San Diego, CA.
Background: Vancomycin is used as a first line empiric therapy for gram positive 
organisms such as resistant Staphylococcus species. Vancomycin-induced acute kidney 
injury (VAN-AKI) has been reported in up to 43% of patients, especially in those targeting 
higher trough concentrations. The mechanism of injury in humans remains not well 
understood with recent evidence pointing to cast nephropathy. In this study, we investigate 
the protein contents of urinary exosomes in patients with VAN-AKI to further elucidate 
mechanisms of injury.
Methods: Urine samples from 10 patients with VAN-AKI who were enrolled in 
the DIRECT study and 12 healthy control urine samples from the UAB-UCSD O’Brien 
Center Biorepository were included in the analysis. Exosomes were extracted using solvent 
exclusion principle and polyethylene glycol induced precipitation. Protein quantification 
was analyzed by high throughput liquid chromatography/mass spectrometry. Significant 
proteins were determined by Pi score >1, which accounts for both fold change and t-test 
significance. Western blotting is currently being conducted as validation of proteomic 
findings.
Results: Subjects were male with a mean age of 40.8±18.3 years, BMI of 26.6±7.0, 
and a distribution of comorbidities. The mean peak serum creatinine was 3.7±1.4 mg/dL 
and time to kidney injury was 4.0±3.0 days. At discharge, 90% of patients demonstrated 
none or partial recovery; 33% experienced full recovery by day 28. Twelve samples were 
included in the final proteomic analysis and revealed 2009 proteins in all samples and 251 
proteins significantly associated with VAN-AKI (Pi score >1). The top discriminatory 
proteins were fibrinogen, complement C3, complement C4, galectin-3-binding protein, 
alpha-2 macroglobulin, immunoglobulin heavy constant mu and serotransferrin. Galectin-3 
binding protein binds glycoproteins such as serotransferrin and alpha 2 macroglobulin 
and up-regulation has been previously correlated with inflammation, fibrosis and rapid 
kidney function decline. Fibrinogen upregulation and complement activation have been 
demonstrated after ischemia reperfusion injury.
Conclusions: Urinary exosomes reveal up-regulation of inflammatory proteins after 
nephrotoxic injury in VAN-AKI.
Funding: NIDDK Support, Private Foundation Support
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Attenuation of Renal Ischemic Reperfusion Injury in Rats with DUR-928, 
a Novel, First-in-Class Therapeutic in Development for Renal Disease
Mee J. Kim, Hongwei Wu, Wei Qi Lin. DURECT Corporation, Cupertino, CA.
Background: DUR-928 (5-cholesten-3β,25-diol 3-sulfate) is a first-in-class, 
endogenous sulfated oxysterol that regulates lipid metabolism, inflammatory response, and 
cell survival. It has been reported that this molecule protects against acute organ injury, 
including the kidney, and improved survival, from LPS-induced endotoxin shock and 
acetaminophen overdose/toxicity mouse models when administered at doses of 25-50 mg/kg 
by intraperitoneal (IP) injection.
Methods: In this study, the potential therapeutic effect of DUR-928 was investigated 
in a rodent model of acute kidney injury (AKI) induced by renal ischemia/reperfusion (I/R) 
injury. Renal ischemia was achieved by transient occlusion of the left kidney in adult male 
Lewis rats (9-11 weeks of age) for 50 minutes. At reperfusion, the right kidney was removed. 
Rats were randomized into three treatment groups (N=6 rats/vehicle control; N=11-12 rats/
DUR-928) for IP administration of DUR-928 (25 mg/kg/day) or vehicle control. Three or 
four daily IP injections of DUR-928 or vehicle control were administered and rats were 
followed through 7 days of observation after I/R injury.
Results: On Days -2 (Baseline), 3 and 7 after surgery, serum creatinine (sCr) and blood 
urea nitrogen (BUN) were measured to evaluate renal function. Induction of I/R injury in rats 
was successfully achieved. sCr and BUN levels peaked significantly on Day 3 compared to 
Baseline. Improvement of these measures was observed on Day 7 due to spontaneous self-
recovery that is characteristic of this I/R injury model. IP administration of 4 daily doses of 
25 mg/kg DUR-928 resulted in significant reductions in sCr and BUN compared to vehicle-
treated rats on Day 3, suggesting improved renal function. DUR-928 treatment resulted 
in a 63% reduction in sCr (118.4±85.9 mg/dL versus 317.3±296.6 mg/dL; p<0.05) and a 
57% reduction in BUN (23.4±14.8 mg/dL versus 54.0±27.7 mg/dL; p<0.05) compared to 
vehicle. Similar results were found with 3 daily doses of DUR-928, with a 43% reduction in 
sCr (p=0.05) and 45% reduction in BUN (p<0.05), compared to vehicle.
Conclusions: The current study highlights the potential of DUR-928 to attenuate 
kidney injury in an acute setting and supports the continued evaluation of DUR-928 in 
renal disease.
Funding: Commercial Support - DURECT Corporation
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Multipronged Systems Approach to Enhance Medication Safety in 
Patients with CKD
Sijie Zheng,1 Dennis Y. Wu,2 Lin Duong,3 Tracy Y. Jonelis.4 KPNC Renal 
Pharmacy Group 1The Permanente Medical Group, Oakland, CA; 2Kaiser 
Permanente, Modesto, CA; 3HMO, Vacaville, CA; 4The Permanente Medical 
Group, Inc, San Francisco, CA.
Background: In the United States, 1 in 7 people have chronic kidney disease (CKD), 
over 650,000 people have end stage renal disease (ESRD). Patients with CKD experience 
polypharmacy with ESRD patients taking average 10-12 prescriptions. Pharmacokinetic 
differences in CKD/ESRD patients require increased awareness and dose adjustment to 
minimize adverse events from prescription and OTC medications or herbal supplements. Kaiser 
Permanente Northern California (KPNC) is an integrated health care system that provides care 
to 4.3 million members with over 300,000 CKD patients through 21 medical centers.
Methods: In 2016, a workgroup was formed to improve medication safety for 
patients with CKD. The workgroup comprises of nephrologists, pharmacists and pharmacy 
informatics across the region. The work group met monthly via web conferencing. The 
workgroup outreached to relevant stakeholders and decision-makers between meetings. 
Leveraging Electronic Medical Record (EMR) and the expertise of the members, the 
workgroup used a multipronged systems approach to identify gaps and developed 
standardized protocols. The work group also optimized processes to enhance medication 
safety in CKD and to reduce acute kidney injury (AKI).
Results: In the inpatient setting, the work group standardized protocols for antibiotic 
dosing, created order sets to minimize use of nephrotoxic agents including elimination of 
sodium phosphate enema use, and implemented calcineurin inhibitor drug interaction alerts. 
Additionally, EMR alerts are being placed for outpatient prescriptions that require dose 
adjustment or are contraindicated in CKD. In the home setting, herbal supplements and 
OTC medications tip sheet was produced for patient education and kidney protection.
Conclusions: In an integrated healthcare system such as KPNC, creation of an 
integrated nephrology pharmacy workgroup may help develop objectives and provide 
implementation strategies to reduce potential adverse medication events in patients with 
CKD.
Funding: Private Foundation Support
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Efficacy of Teriparatide and Denosumab on Bone Mineral Density in 
Dialysis Patients: A Meta-Analysis
Anawin Sanguankeo,1,3 Sikarin Upala.2,3 1Johns Hopkins University, Baltimore, 
MD; 2University of Chicago, Cooperstown, NY; 3Preventive and Social 
Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 
Thailand.
Background: Teriparatide and denosumab are therapeutic agents proven to increase 
bone density and prevent fracture in patients with osteoporosis. Evidence of efficacy of 
these agents in end-stage renal disease (ESRD) is still lacking. This meta-analysis evaluated 
the effect of Teriparatide and denosumab on bone mineral density (BMD) and biochemical 
testing in ESRD patients on dialysis.
Methods: We comprehensively searched the databases of MEDLINE, EMBASE, and 
Cochrane Databases. The inclusion criteria were published studies using denosumab or 
teriparatide in dialysis patients with low bone mass for at least six months. The primary 
outcome was BMD at the femoral neck, lumbar spine, and radius. The secondary outcome 
was parathyroid hormone (PTH), calcium, phosphorus, and bone-specific alkaline 
phosphatase (BSAP). A random-effects meta-analysis was performed to compare the 
change in outcome at baseline and after denosumab or teriparatide was given.
Results: Four studies using teriparatide were included in the meta-analysis of BMD. 
Overall, there was no significant change in BMD at the femoral neck (p=0.59), lumbar 
spine (p=0.05), or radius (p=0.23). There was also no significant change in calcium 
(p=0.33), phosphorus (p=0.23), PTH (p=0.46), and BSAP (p=0.86). Four studies using 
denosumab were included in the meta-analysis. There was a significant decrease in PTH 
with a standardized mean difference of 2.22 (95% CI: 0.13 to 4.31). No significant change 
in calcium (p=0.37), phosphorus (p=0.43), and BSAP (p=0.15) was found. There was not 
enough study to assess the effect on BMD.
Conclusions: Current evidence does not support the use of denosumab or teriparatide 
in dialysis patients with low bone mass. More studies are needed to evaluate efficacy and 
safety of these therapeutic agents for osteoporosis in this population.
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Forest plot of comparison for Teriparatide and BMD at A) Femoral neck and B) Lumbar 
spine
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Bone Mineral Density and Handgrip Strength in Early CKD: Cross-Sec-
tional Analysis of CARTaGENE
Louis-Charles Desbiens,1 Remi Goupil,2 Francois Madore,2 Fabrice Mac-Way.1 
1CHU de Québec - Université Laval, Québec, QC, Canada; 2Hopital du Sacre-
Coeur de Montreal, Montreal, QC, Canada.
Background: Bone mineral density (BMD) and handgrip strength (HGS) are 
associated with adverse outcomes in general and advanced CKD populations. However, 
how early CKD impacts these two parameters has not been well studied.
Methods: Cross-sectional analysis of CARTaGENE, a population-based health 
survey of 40 to 69 years old individuals from Quebec. Individuals with data on estimated 
glomerular filtration rate (eGFR) over 30 ml/min/1,73m2, BMD and HGS were included. 
BMD was measured by quantitative ultrasound at the calcaneus and HGS by a hand 
dynamometer. Early CKD was expressed continuously (eGFR) and categorically (KDIGO 
stages). Association between CKD, BMD and HGS was assessed with linear regression 
in univariate and multivariate models adjusted for demographics, comorbidities and 
medication. BMD results were stratified for sex because of an interaction between CKD 
and sex.
Results: We included 15,721 individuals (51% male with a mean age of 54 years and 
a mean eGFR of 88 ml/min/1.73m2). 47% of individuals had G2 CKD and 4% G3 CKD. 
Mean BMD t-score was 0.19 in non-CKD individuals, 0.22 in G2 CKD and 0.08 in G3 
CKD (G3 vs G1-G2 p=0.01). Mean HGS was 68kg in non-CKD individuals, 69kg in G2 
CKD and 64kg in G3 CKD (G3 vs G1-G2 p<0.001). In univariate analysis, eGFR was not 
associated with HGS, but was positively associated with BMD in men and negatively in 
women. In adjusted models, eGFR was negatively associated with both HGS and BMD 
(Table). G2 and G3 CKD were associated with higher HGS compared to non-CKD. G2 
CKD was associated with increased BMD in both men and women while G3 CKD was 
associated with increased BMD in men only.
Conclusions: In a large population of 40 to 69 years old individuals and in contrast to 
advanced CKD, early CKD is not associated with a decrease in BMD and HGS.
Funding: Government Support - Non-U.S.
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Effect of Denosumab on Trabecular Bone Score (TBS) in De Novo Kidney 
Transplant Recipients (KTR)
Rudolf P. Wuthrich,1 Nicole Graf,2 Marco Bonani.3 1University Hospital, Zurich, 
Switzerland; 2graf biostatistics, Winterthur, Switzerland; 3University Hospital 
Zurich, Zurich, Switzerland.
Background: Kidney transplant recipients (KTR) are at high risk to lose bone mass 
in the first year after transplantation. The trabecular bone score (TBS) represents a recently 
developed parameter of lumbar spine bone texture that correlates with the occurrence 
of fractures. The utility of the TBS and its response to anti-resorptive treatment with 
denosumab in the first year after kidney transplantation is not known.
Methods: Post-hoc analysis of 1-year changes in TBS in 44 de novo KTR (mean age 
50.6±12.6 years; 28 [64%] were male; mean baseline eGFR 54.1±16.5 ml/min/1.73 m2) 
which were randomized 1:1 to denosumab or no treatment, and correlation with 1-year areal 
bone mineral density (aBMD) changes at the lumbar spine and total hip as assessed by dual 
energy X-ray absorptiometry (DXA), and peripheral bone microarchitecture as assessed by 
high-resolution peripheral quantitative computed tomography (HRpQCT).
Results: The baseline TBS in KTR amounted to 1.312±0.101 which was reduced 
compared to an age-matched normal control population (1.464±0.071). There was a 
significant correlation between TBS and aBMD at the lumbar spine (Spearman’s ρ=0.56; 
p<0.001) and total hip (ρ=0.33; p<0.05). The TBS also correlated with HRpQCT-derived 
total (ρ=0.49; p<0.05) and trabecular volumetric BMD at the tibia (ρ=0.57; p<0.01), 
whereas no such correlation was found at the radius. Denosumab treatment led to an 
increase in TBS, paralleling the BMD changes at the lumbar spine. More denosumab-
treated than control KTR showed an increase in TBS at 6 months (91% vs. 55%; p<0.01) 
and 12 months (87% vs 71%; p=ns). TBS increased more in denosumab-treated than control 
KTR (+4.0% vs +1.5%) in the first 6 months, but changed little (-0.4% vs +0.6%) in the 
subsequent 6 months.
Conclusions: The TBS represents a valuable parameter which provides additional data 
on bone health in KTR. The increase in TBS in denosumab-treated de novo KTR suggests 
that denosumab may improve bone microarchitecture in KTR.
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AKI Followed by Complete Recovery Is Associated with Increased Bone 
Fracture Risk
Sophia L. Ambruso,2 Zhiying You,3 Benjamin Griffin,2 John R. Holmen,4 
Titte Srinivas,5 Michel Chonchol,2 Sarah Faubel,6 Anna J. Jovanovich.1,7 1Denver 
VA, Denver, CO; 2University of Colorado, Denver, CO; 3UC Denver, Aurora, 
CO; 4Intermountain Healthcare, Murray, UT; 5Intermountain Medical Center, 
Murray, UT; 6University of Colorado Denver, Denver, CO; 7University of 
Colorado, Aurora, CO.
Background: Acute kidney injury (AKI) affects multiple organ systems, including 
bone mineral metabolism. Fracture risk is increased among dialysis-requiring AKI patients. 
The relationship between fracture risk and AKI with complete recovery has not been 
characterized. We investigated fracture risk following an admission complicated by non-
dialysis requiring AKI with complete recovery in a propensity score-matched cohort of 
cases and controls.
Methods: We identified 1139 AKI cases (AKI Network definition) with complete 
recovery at discharge, defined by creatinine <1.10 times the pre-admit baseline value, during 
a hospitalization between January 1, 1999 and December 31, 2009 from an integrated health 
care delivery system. We matched 1139 controls (no AKI during index admission) based 
on a propensity score including age, sex, race, prior inpatient visits, baseline creatinine, all 
comorbidities in the Charlson index, and season of admission. The primary outcome was 
incident bone fracture following discharge. Cox proportional hazards models were adjusted 
for prior fracture and body mass index (BMI) and censored for death.
Results: Baseline characteristics among cases and controls were similar: age 62 ± 17 
years, 45% female, 92% white, creatinine 0.9 ± 0.2 mg/dL. During a median [IQR] follow-
up of 63 [10-87] months, 294 (26%) AKI cases and 169 (15%) controls had a bone fracture. 
Those with AKI followed by complete recovery had a two-fold increased hazard of bone 
fracture (HR 2.13 [95% CI, 1.76-2.58]; p=<0.0001). After adjusting for prior fracture and 
BMI the association persisted but was somewhat attenuated (HR 1.49 [95% CI, 1.23-1.80]; 
p<0.0001).
Conclusions: Hospitalized patients whose course was complicated by non-dialysis 
requiring AKI with complete kidney function recovery had an increased risk of fracture 
following discharge compared to propensity score-matched controls. These data suggest 
alterations in bone mineral metabolism during AKI may be associated with long-term risk 
of fracture even if serum creatinine returns to baseline. Further studies investigating bone 
and mineral metabolism pathophysiology and AKI are warranted.
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The Relationship Between Density Measurements and Histomorphometric 
Parameters of Cortical Bone of Patients in the Early Stages of CKD
Amandha Bittencourt,1 Maria Eugenia F. Canziani,1 Larissa Rodrigues,1 
Carlos E. Rochitte,2 Aluizio B. Carvalho.1 1Federal University of Sao Paulo, Sao 
Paulo, Brazil; 2Heart Institute (InCor) University of São Paulo Medical School, 
São Paulo, Brazil.
Background: Cortical bone comprises a compact tissue, which is denser, less porous 
and metabolically active than trabecular bone. These differences give to the cortical bone 
a mechanical function while the mineral homeostasis is the main role of the trabecular 
bone. In order to evaluate these tissues, bone biopsy is the gold standard tool, but it is 
an invasive and expensive method. In this context, the possibility of using a non-invasive 
technique is clinically relevant. Quantitative computed tomography of the vertebrae (QCT) 
is effective for evaluating trabecular bone when compared to structural histomorphometric 
parameters of patients with chronic kidney disease (CKD). This relationship has not yet 
been fully evaluated in cortical bone. We investigated the relationship between vertebrae 
density measured by QCT and structural histomorphometric parameters of cortical bone of 
patients in the early stages of chronic kidney disease.
Methods: A post-hoc analysis of a cross-sectional study with 50 CKD stage 2-5ND 
patients undergone QCT and bone biopsy. Undecalcified bone samples from iliac crest was 
submitted to histomorphometric analysis using the Osteomeasure software (Osteometrics 
Inc., Atlanta, GA, USA). The histomorphometric parameters analyzed were: Ct.Po (cortical 
porosity) and Ct.Th (cortical thickness). The cortical bone density, expressed in Hounsfield 
Units (HU), was obtained by QCT from the thoracic vertebrae at the aorta root.
Results: Patients were 52±10years, 68%male and 30%diabetes mellitus. Laboratorial 
data included eGFR34±16 mL/min/1.73m2, ionized calcium 1.30±0.06mmol/L, phosphorus 
3.8±0.7mg/dL, alkaline phosphatase 116(71.5;160.5)U/L; iPTH 83(53.5;167.5)pg/
mL, 25OHD30.8±10.1ng/dL and 1,25OH2D 35.8(30;47.5)pg/mL. Regarding cortical 
histomorphometric parameters, cortical porosity was 4.6%(2.6;6.6) and cortical thickness 
was 578.4±151.8μm. The cortical bone density was 379.0 HU(344.7;411.4). There was no 
correlation between cortical porosity and cortical density(p=0.67) or cortical thickness and 
cortical density(p=0.41).
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Conclusions: Cortical bone density measured by quantitative computed tomography is 
not associated to structural histomorphometric parameters of cortical bone of patients in the 
early stages of chronic kidney disease.
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Etelcalcetide in the Treatment of Secondary Hyperparathyroidism in 
Patients Uncontrolled with Cinacalcet – Results from a Prospective Study
Andre L. Weigert,1,3 Manuel A. Amoedo,1,4 Teresa Mendes,5 Marco A. Marques,6 
Catarina Meng,2 Luciano Pereira,1,2 Joao M. Frazao.1,2 1DaVita, Portugal, 
Portugal; 2Nephrology, São João Hospital Center and School of Medicine, 
Porto, Portugal; 3Hospital Santa Cruz, School of Medicine, Lisbon, Portugal; 
4Nephrology, Hospital Divino Espírito Santo, Évora, Portugal; 5Nephrology, 
CHUC, Coimbra, Portugal; 6Affidea Laboratories, Lisbon, Portugal.
Background: Secondary hyperparathyroidism (sHPT) is associated with increased 
risk of fractures, vascular calcifications and all-cause mortality. Etelcalcetide is a new 
calcimimetic with a pharmacokinetic profile that allows thrice weekly intravenous(IV) 
dosing after hemodialysis(HD), recently approved for sHPT treatment. There is scarce 
clinical experience with this agent with respect to its efficacy in patients with sHPT that is 
uncontrolled with cinacalcet.
Methods: We conducted a prospective cohort study in prevalent HD patients in DaVita 
clinics in Portugal who had uncontrolled sHPT under cinacalcet treatment for at least 3 
months. Inclusion criteria included mean intact PTH(iPTH) levels above 800 pg/mL and 
total calcium(Ca) above 8.3 mg/dL in the previous 3 months. After 1 week of cinacalcet 
washout, etelcalcetide 5mg IV/HD was initiated. iPTH, Ca and phosphorus were followed; 
FGF-23 and sclerostin levels were analyzed before the start of etelcalcetide and after 6 
months.
Results: Thirty-four patients participated in the study; mean age was 60.7(SD ± 12.3) 
years; median time on HD was 82.5(7-296) months and median cinacalcet dose was 
180(90-840) mg/week. Median etelcalcetide dose remained at 5mg/HD at 3 and 6 months. 
Evolution of biochemical parameters is represented in the figure. Over 6 months of 
etelcalcetide treatment, serum FGF-23 decreased from 39.3(23.0-43.3) pmol/L to 29.1(11.5 
-115.6) pmol/L and sclerostin increased from 37.2(5.8 – 200.7) pmol/L to 71.7(28.2- 185.5) 
pmolL (p<0.0001).
Conclusions: Etelcalcetide was efficacious in improving sHPT control in this group of 
patients and significantly increased plasma sclerostin concentration. This is the first study 
describing the impact of etelcalcetide treatment on plasma sclerostin levels.
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Superior Effects of Etelcalcetide Compared to Cinacalcet on Increasing 
Bone Mineral Density in Patients Receiving Hemodialysis with Secondary 
Hyperparathyroidism
Satoshi Funakoshi,3 Jyunichiro Hashiguchi,3 Tayo Kawazu,3 Kenji Sawase,3 
Yuko Maruyama,3 Yoko Obata,1 Tomoya Nishino,2 Takashi Harada.3 1Nagasaki 
University Hospital, Nagasaki, Japan; 2Nagasaki University School of Medicine, 
Nagasaki, Japan; 3Nagasaki Kidney Hospital, Nagasaki, Japan.
Background: Etelcalcetide hydrochloride (ET) is a novel peptide calcimimetic agent 
that has a similar mechanism of action as cinacalcet hydrochloride (CT). Clinical trials have 
demonstrated the safety and efficacy of ET in hemodialysis (HD) patients. In this study we 
evaluated the efficacy of ET on increasing bone mineral density (BMD) in HD patients with 
secondary hyperparathyroidism (SHPT).
Methods: Ten HD patients with SHPT (M/F: 6/4, mean age: 61.9 years, mean HD 
duration: 10.3 months) who received oral CT were enrolled in this study after their informed 
consent was obtained. Various doses of oral CT were converted to 5mg of intravenous 
ET, and bone resorption markers; TRCP-5b, NTx and bone formation marker; BAP were 
compared in each patient. BMD was assessed 6 months after conversion to ET treatment by 
digital image processing (DIP).
Results: As shown in figure, significant declines (p<0.05) were observed in serum 
levels of TRCP-5b and NTx (from 710.0 ± 289.0 to 420.9 ± 221.1 mU/dL, from 179.6 ± 
35.5 to 112.1 ± 26.1 nmol BCE/L, respectively). On the other hand, there was no significant 
change in serum BAP level. Notably, BMD was significantly increased 6 months after ET 
treatment was started (p<0.05).
Conclusions: In our study, significant decrease of bone resorption markers, TRCP-5b 
and NTx, along with no alteration of BAP as a bone formation marker may explain the 
significant increase in BMD in HD patients with SHPT.
Funding: Private Foundation Support
SA-PO659 Poster Saturday
Bone and Mineral Metabolism: Clinical - II
Denosumab: Is It Safe to Use in CKD?
Eimear Mckenna. Altnagelvin Area Hospital, Derry, United Kingdom.
Background: Denosumab is a monoclonal antibody directed against receptor 
activator of RANK ligand used to treat osteoporosis. It has been promoted as safe to use 
in Chronic Kidney Disease (CKD) as it does not appear to accumulate in kidney failure 
and because of the experience in a small number of patients with CKD 3-4 enrolled in 
RCTs. There is no evidence for use in CKD 5. Case reports show patients with severe CKD 
are at higher risk of developing hypocalcemia following Denosumab. This may be due to 
hyperparathyroidism and vitamin D deficiency. In this case series we have examined the 
incidence of hypocalcemia following Denosumab treatment and tried to identify any risk 
factors.
Methods: Patients with CKD stages 3-5 attending our service treated with Denosumab 
in the last 5 years were included. Retrospective data was collected using an electronic 
patient database. Data collected included Corrected calcium levels prior to and after dosing, 
vitamin D and Parathormone (PTH) levels prior to dosing.
Results: 14 patients were identified; 9 had a functioning renal transplant and 1 patient 
was on hemodialysis. 4 patients were male and 10 female. Mean duration of treatment was 
2.2 years. Average eGFR was 27 ml/min/1.73m2. Mean patient age was 60 years (range 
44-84). Mean BMI was 25 (range 19-36). 11 patients were on oral steroids. The average
calcium prior to dosing was 2.35 mmol/l (2.12 to 2.54) falling to 1.98mmol/l (1.58-2.22)
after dosing. 9 patients achieved their lowest calcium at 1 week, 2 at 4 weeks and 3 at 8
weeks. Average PTH level prior to dosing was 153ng/l (42-371) and after was 888ng/l (155-
1990). 5 patients developed severe hypocalcemia (corrected calcium less than1.9mmol/l),
average prior calcium in this group was 2.39mmol/l (2.22 – 2.54) falling to 1.77mmol/l
(range 1.58 – 1.86). The average prior PTH was 206ng/l, rising to 1171ng/l after denosumab. 
Four patients did not have Vitamin D checked before dosing.
Conclusions: Denosumab will cause a small but not clinically significant reduction 
in serum Calcium in most patients with CKD. Severe hypocalcaemia can result if Vitamin 
D levels are unknown or in higher PTH levels. eGFR does not seem to correlate with the 
risk of hypocalcaemia. The biochemical abnormalities associated with CKD should be 
corrected, specifically, calcium, phosphate, PTH and vitamin D. Densoumab is the preferred 
treatment in CKD 4/5 however its use should be avoided in severe hyperparathyroidism and 
vitamin D deficiency.
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Proton Pump Inhibitors, But Not Histamine-2 Receptor Antagonists, 
Associate with Hip Fracture Risk Among Patients on Hemodialysis
Chandan Vangala,1,2 Jingbo Niu,1 William E. Mitch,1 Sankar D. Navaneethan,1 
Wolfgang C. Winkelmayer.1 1Baylor College of Medicine, Houston, TX; 
2Division of Nephrology, Michael E. DeBakey VA Medical Center, Houston, TX.
Background: An association between proton pump inhibitor (PPI) use and hip fracture 
risk has been described in the general population, where the primary causative hypothesis 
focuses on impaired gastrointestinal calcium absorption. The impact of acid suppressor use 
on hip fracture risk in a high-risk subset, patients with end-stage kidney disease requiring 
hemodialysis, is unknown and could help further distinguish the reason for increased 
susceptibility among PPI users.
Methods: Using the U.S. Renal Data System (USRDS), we identified all hip fracture 
events recorded between 2009 and 2014 among hemodialysis-dependent patients. Eligible 
cases were matched on index date with 10 controls. We identified PPI and histamine-2 
receptor antagonist use from Medicare Part D claims covering 3 years prior to index 
date and stratified according to proportion of days covered by filled prescriptions. Using 
logistic regression with multiple imputation for missing data, we estimated unadjusted and 
multivariable-adjusted odds ratios (OR) and 95% confidence intervals (CI).
Results: We studied 4,551 cases and 45,510 controls. Cases were older, more likely 
to be female and Caucasian, and had shorter dialysis vintage; fewer were obese. A larger 
proportion of cases had any prior PPI (70% vs. 63%) or histamine-2 receptor antagonist 
(25% vs. 23%) use. Use of PPI was associated with higher risk of hip fracture (adjusted OR 
1.19, 95% CI 1.11-1.28). This association remained within subgroups of low, moderate, 
and high PPI use, yielding adjusted ORs of 1.16 (1.06-1.27), 1.21 (1.11-1.31), and 1.20 
(1.09-1.32), respectively.
Conclusions: Conclusion: Among patients with end-stage kidney disease on 
hemodialysis, PPIs, and not histamine-2 receptor antagonists, were associated with hip 
fracture events.
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Selective Serotonin Reuptake Inhibitors Associate with Hip Fracture Risk 
Among Patients on Hemodialysis
Chandan Vangala,1,2 Jingbo Niu,1 Sankar D. Navaneethan,1 
Wolfgang C. Winkelmayer.1 1Baylor College of Medicine, Houston, TX; 
2Division of Nephrology, Michael E. DeBakey VA Medical Center, Houston, TX.
Background: Selective serotonin reuptake inhibitor (SSRI) use has been associated 
with hip fracture risk in the general population. Patients with end-stage renal disease 
on hemodialysis (HD) are a unique, high-risk subset with distinct metabolism and bone 
pathology, and the impact of SSRI use on hip fracture risk in this subset remains unexplored.
Methods: Using the U.S. Renal Data System, we identified all hip fracture events 
recorded between 2006 and 2014 among HD-dependent patients. Eligible cases were 
matched on index date with 10 controls; all were required to have >1 year of Medicare 
Parts A & B coverage. To study cumulative long-term exposure, we further required >3 
years of part D coverage. We defined and stratified SSRI use by the proportion of days 
covered by filled prescriptions in the 3 years prior to index. In a separate study of short-term 
exposure, we selected subjects with >18 months of Part D coverage and required no prior 
antidepressant use for 1 year (months 7-18). We defined SSRI use by filled claims in the 6 
months prior to index. Using conditional logistic regression, we estimated unadjusted and 
multivariable-adjusted odds ratios (OR) and 95% confidence intervals (CI).
Results: In the long-term study, we identified 4,551 cases and 45,510 controls. 
Compared to controls, a larger proportion of cases had any prior SSRI (37.2% vs. 27.6%) 
use. Use of SSRIs was associated with increased hip fracture risk (adjusted OR 1.30, 95% 
CI 1.20-1.40). The subgroups of low, moderate, and high SSRI use yielded adjusted ORs 
of 1.27 (1.15-1.41), 1.32 (1.19-1.45), and 1.31 (1.16-1.47), respectively. In the short-term 
study, we examined 4,354 cases and 43,540 controls. Increased hip fracture risk was also 
associated with short-term use of SSRIs (adjusted OR 1.51, 95% CI 1.29-1.76).
Conclusions: Compared to long-term SSRI use, the stronger association of short-
term use with increased hip fracture risk in HD-dependent patients may suggest an acute 
mechanism potentially related to falls.
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Association Between Malnutrition-Inflammation Complex Syndrome 
(MICS) and the Risk for Bone-Vascular Events in Patients Receiving 
Maintenance Hemodialysis: The Q-Cohort Study
Shunsuke Yamada,1 Hokuto Arase,1 Masanori Tokumoto,5 Masatomo Taniguchi,4 
Hisako Yoshida,3 Kazuhiko Tsuruya,2 Toshiaki Nakano,1 Takanari Kitazono.1 
1Department of Medicine and Clinical Science, Kyushu University, Fukuoka, Japan; 
2Nara Medical University, Kashihara, Japan; 3Osaka City University Graduate 
School of Medicine, Osaka, Japan; 4Fukuoka Renal Clinic, Fukuoka, Japan; 
5Department of Internal Medicine, Fukuoka Dental College, Sawara-ku, Japan.
Background: Malnutrition-inflammation complex syndrome (MICS) is highly 
prevalent in hemodialysis patients and increases the risk for morbidity and mortality. 
MICS is supposed to affect bone-vascular system. However, it is unknown whether 
MICS increases the risk for both bone fracture and cardiovascular events in maintenance 
hemodialysis patients. To determine the association between MICS and those risks, we 
analyzed the data of the Q-Cohort Study, a multicenter, prospective, observational study.
Methods: A total of 2887 hemodialysis patients were included in the analysis. As a 
simple indicator for MICS, we newly developed a score (0-12) reflecting MICS by semi-
quantitatively scaling the following five baseline parameters and adding up the scores of 
each parameters; age (0-3), serum levels of albumin (0-3), creatinine (0-3), and C-reactive 
protein (0-2), and body mass index (0-1). The main outcomes were the incidence of bone 
fracture, cardiovascular events, and all-cause death. The main exposure was MICS score. 
Patients were divided into four groups based on the MICS score; 0-3, 4-5, 6-8, and 9-12). 
Risk estimates for each outcome were calculated by Cox proportional hazards model with 
multivariable adjustments.
Results: During the median follow-up period of four years, 134 patients developed 
bone fracture, 519 patients developed cardiovascular events, and 482 patients died of any 
cause. The average MICS score was 5.16. Patients in the highest MICS score group (9-12) 
showed an increased risk for bone fracture, cardiovascular events, and all-cause mortality 
(HR [95%CI]; 2.14 [1.08–4.02], 2.17 [1.52–2.96], and 5.07 [3.37–7.63], respectively) 
compared with the lowest MICS score group (0-3). We also confirmed the internal validity 
of our MICS score by applying bootstrap resampling. A principal analysis also confirmed 
that the five parameters of the MICS score increased the risk for the three outcomes 
examined in our patients.
Conclusions: A higher MICS score was associated with the increased risk for bone 
fracture and cardiovascular events in patients receiving hemodialysis.
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Effectiveness of Elcatonin in Osteoporosis Patients Undergoing 
Hemodialysis
Jin ho Lee,1 Seon Deok Hwang,2 Seoung Woo Lee,3 Woo Yeong Park,7 Jeong 
Ho Kim,8 Hee yeoun Kim,4 Seong min Kim,5 Joon Seok Oh,6 Dongyeol Lee,1 
Yong hun Sin,9 Joong Kyung Kim.1 1Bong Seng Memorial Hospital, Busan, 
Republic of Korea; 2Inha University College of Medicine, Incheon, Republic of 
Korea; 3Inha University Hospital, Inchon City, Republic of Korea; 4Bongseng 
hospital, Busan, Republic of Korea; 5Dongrae Bongseng Hospital, Busan, 
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Republic of Korea.
Background: Osteoporosis is a very serious risk factor for fractures that are related 
to patient mortality, Quality of Life worsening, and hospitalization in hemodialysis(HD) 
patients. In particular, treatment methods are very limited in HD patients compared with 
normal population. Therefore, most dialysis patients will not be able to treat osteoporosis, 
which can lead to bone fractures. On the other hand, elcatonin inhibits bone resorption and 
causes bone bone mineral density(BMD) elevation, but it is difficult to maintain bone mass 
and strengh. Although this medication reduces osteoporosis-induced pain, it is known to 
increase bone mass in some studies, and it can also be used in dialysis patients
Methods: We retrospectively studied 32 elecatonin-treated HD patients and 178 
untreated HD patients. The follow up period was from 2005 to 2017, and the study was 
conducted at a single center. Osteoporosis was defined by WHO criteria (T score <-2.5). 
Elcatonin treatment group was diagnosed with osteoporosis, and 20 units were injected 
intramuscularly once a week after the patient ’s consent was obtained. The primary outcome 
were Incidence of bone fracture, changes in BMD. Secondary outcomes was reduction of 
bone pain
Results: Fractures were observed in 7 patients (21%) in the Elcatonin group and 9 (11%) 
in the control group, but there was no statistical significance(p-value = 0.088). In 2013, the 
BMD in the Elcatonin group was 0.689 ± 0.039 which was statistically significantly lower 
than that of the control group of 0.937 ± 0.181(p-value <0.001). Also, in 2018, the BMD of 
the elcitonin group was 0.724 ± 0.08, which was statistically significantly lower than that of 
the control group of 0.9672 ± 0.186(p-value <0.001). There was no significant difference in 
reduction of bone pain between the two groups
Conclusions: Elcatonin was not effective in reducing the frequency of fractures or 
reducing bone pain in hemodialysis patients. Rather, the Elcatonin group had a further 
decrease in BMD compared with the control group. It is possible that the results have been 
observed to be worse because the Elcatonin group has been used on existing osteoporosis 
patients. However, Elcatonin seems to be ineffective in HD patients because it causes pain, 
increases drug costs and is not effective in treating osteoporosis.
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Bone Mineral Density in Patients with CKD: Hip Is More Affected Than 
Spine
Kalyanna S. Bezerra de carvalho,1 Melani Custodio,4 Rosa M. Moyses,3 
Raquel F. Vasco,1 Vanda Jorgetti,2 Rosilene M. Elias.2 1Hospital das Clinicas 
HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil;, São Paulo, Brazil; 
2Universidade de Sao Paulo, Sao Paulo, Brazil; 3Universidade Nove de Julho, 
São Paulo, Brazil; 4Universidade de São Paulo, São Paulo, Brazil.
Background: Patients with chronic kidney disease (CKD) have a higher risk of fracture 
than the general population. Osteoporosis is a co-prevalent disease, twice as common in this 
population, and dual-energy X-ray absorptiometry (DXA) has been recognized to predict 
fracture in CKD. We hypothesized that low bone mineral density (BMD) will be more 
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prevalent as kidney function decreases and will be associated with biomarkers of mineral 
and bone disease.
Methods: We investigated the features of BMD in patients with CKD stages 1-5, 
in a decade observation. DXA obtained from January 1st 2007 to Dec 31st 2017, clinical, 
demographic and biochemical data at the time of image acquisition were recorded. A total 
of 1,172 patients were enrolled into this study (81.3% women, 79.9 % white, and 8.6% 
diabetic).
Results: Osteopenia and osteoporosis in at least one site (total hip or spine) were 
found in 32.7% and 20.0% of patients, respectively. As CKD progresses, the percentage 
of patients with normal BMD decreases whereas the percentage of osteopenia and 
osteoporosis increases, which was mostly due to the total hip involvement. Older age 
and hyperparathyroidism (PTH>65pg/ml) were independently risk factors for osteopenia/
osteoporosis at total hip. Regarding spine, female gender, older age and higher iCa were 
independently associated with the risk of osteopenia/osteoporosis in the entire population. 
The odds ratios for osteoporosis/osteopenia at the hip were 1.14 (95% CI: 2.10-3.85) 
and 1.05 (95% CI: 1.87-3.35) for patients with eGFR <15 and 15-30 ml/min/1.73m2, 
respectively. None eGFR category was significantly associated with the risk of osteoporosis/
osteopenia at the spine.
Conclusions: We confirmed the risk factors for low BMD already described for the 
general population, and demonstrated the association with impaired renal function and the 
more expressive hip involvement than spine. In addition, hyperparathyroidism seems to be 
an additional, and sizable risk factor in this population.
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Bone Loss in Kidney Transplant Recipients and Patients on Dialysis 
Treated with Nocturnal Hemodialysis, Conventional Hemodialysis, and 
Peritoneal Dialysis
Thijs T. Jansz,1 Hanna C. Willems,5 Pim A. De jong,2 Marianne C. Verhaar,1 
Brigit C. van Jaarsveld.3,4 1Nephrology and Hypertension, University Medical 
Center Utrecht, Utrecht, Netherlands; 2Radiology, University Medical Center 
Utrecht, Utrecht, Netherlands; 3Nephrology, VU University Medical Center, 
Amsterdam, Netherlands; 4Dianet Dialysis Centers, Utrecht, Netherlands; 
5Internal Medicine and Geriatrics, Academic Medical Center Amsterdam, 
Amsterdam, Netherlands.
Background: Patients on dialysis have an increased risk of fractures due to mineral 
bone disorder. This disturbed mineral metabolism is improved by nocturnal hemodialysis, 
an intensified hemodialysis regimen, and completely normalized by kidney transplantation. 
This study therefore had two aims: to compare bone loss and its determinants in kidney 
transplant recipients and patients on dialysis, and to compare bone loss between patients on 
nocturnal hemodialysis, conventional hemodialysis, and peritoneal dialysis.
Methods: In this prospective observational study, we measured trabecular bone 
mineral density at the thoracic spine with computed tomography annually for up to 3 years 
in 45 incident kidney transplant recipients and 78 patients on dialysis (30 on nocturnal 
hemodialysis, 28 on conventional hemodialysis, and 20 on peritoneal dialysis), who were 
all transplantation candidates. We used mixed models to compare bone loss between 
treatment groups and used logistic regression to assess determinants of significant bone loss.
Results: Overall, mean age was 51 ±13 years, and 80 (65%) were male. Bone mineral 
density remained stable in kidney transplant recipients (change 1.9, 95% confidence 
interval -1.4; 5.2 mg/cm3 per year), while it decreased in patients on dialysis at a rate of 
-6.4, 95% confidence interval -9.2; -3.7 mg/cm3 per year (P<0.001 for difference). In
kidney transplant recipients, determinants of significant bone loss were female sex and 
over 50 years old (P=0.01), higher baseline bone mineral density (P=0.01), and no calcium 
supplementation (P=0.03). In patients on dialysis, determinants were female sex (P=0.01)
and low parathyroid hormone levels (P=0.03). In patients on dialysis, bone loss was similar 
in patients on nocturnal hemodialysis, conventional hemodialysis, and peritoneal dialysis
(P=0.92 for differences).
Conclusions: After kidney transplantation patients have stable trabecular bone mineral 
density, while patients who remain on dialysis lose substantial amounts of trabecular bone. 
This loss is similar in treatment with nocturnal hemodialysis, conventional hemodialysis, 
and peritoneal dialysis. Whether this is due to oversuppression of parathyroid hormone 
needs further study.
Funding: Commercial Support - Amgen, Baxter, Fresenius Medical Care, Novartis, 
Roche, Shire., Private Foundation Support
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Variability and Facility Predictors of Cinacalcet Prescription Among US 
Hemodialysis Facilities
Douglas S. Fuller,1 Shan Xing,2 Vasily Belozeroff,2 Alon Yehoshua,2 
Hal Morgenstern,3 Bruce M. Robinson,1 Robert J. Rubin,4 Nisha Bhatt,2 
Ronald L. Pisoni.1 1Arbor Research Collaborative for Health, Ann Arbor, MI; 
2Amgen Inc, Thousand Oaks, CA; 3University of Michigan, Ann Arbor, MI; 
4Georgetown University, Bethesda, MD.
Background: Calcimimetic drugs used to treat secondary hyperparathyroidism (SHPT) 
are being considered for inclusion in the ESRD bundled payment system. Understanding 
of utilization patterns of calcimimetics across dialysis facilities may help align financial 
incentives with clinical goals. The objective of our study was to describe the distribution 
of cinacalcet prescription across dialysis facilities and to explore factors that may influence 
utilization of cinacalcet.
Methods: We used monthly cross-sectional data from the Dialysis Outcomes and 
Practice Patterns Study in 2014 to characterize the distribution of cinacalcet prescription 
across 203 US hemodialysis facilities (10,521 patients). Based on associations with PTH 
levels from patient-level analyses, we used linear mixed-effects regression to estimate the 
association between three facility-level exposures – % black, % <65 years old, % having 
a dialysis vintage ≥3 years – and the prevalence of cinacalcet prescription, adjusting for 
facility- and patient-level potential confounders.
Results: The average unadjusted mean percentage of patients in each facility prescribed 
cinacalcet was 23.0% in June 2014 (median, 21.9%; IQR, 12.8-30.5%). The percentage 
of patients in each facility prescribed cinacalcet in June 2014 was strongly and positively 
associated with the percentage of patients in the facility who were black, <65 years old, and 
had a dialysis vintage ≥3 years, adjusting for patient case-mix and dialysis chain affiliation 
(Figure).
Conclusions: Given these systematic differences of cinacalcet use across dialysis 
facilities, facilities treating proportionally more patients who are black, under age 65, and 
having ≥3 years on dialysis may bear disproportionally greater financial burden for treating 
patients with SHPT after calcimimetics are added to the ESRD bundle. Additional studies 
evaluating the differential financial impact on facilities of adding calcimimetics to the 
bundle are warranted.
Funding: Commercial Support - All support is provided without restrictions on 
publications. All funds are made to Arbor Research Collaborative for Health and not 
directly to Mr. Fuller. The full DOPPS Program support and additional support for specific 
projects and countries can be found here: https://www.dopps.org/AboutUs/Support.aspx
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The Effects of Lanthanum Carbonate on Bone Metabolic Markers and 
Bone Mineral Density in Incident Hemodialysis Patients
Kimihiko Goto, Shunsuke Goto, Hideki Fujii, Keiji Kono, Shinichi Nishi. Kobe 
University Graduate School of Medicine, Kobe, Japan.
Background: Abnormal bone turnover is a risk factor for cardiovascular disease 
in hemodialysis (HD) patients. Lanthanum carbonate (LC) is widely used as one of 
calcium-free phosphate binders and some clinical trials reported the effect of LC on 
vascular calcification in HD patients. We previously conducted a randomized controlled 
trial which focused on the effect of LC on coronary artery calcification compared with 
calcium carbonate (CC) in patients after initiating HD. The aim of the present study was to 
investigate the effect of LC on bone metabolic markers and bone mineral density (BMD) 
compared with CC in subjects new to HD.
Methods: We conducted a post hoc analysis from our previous randomized controlled 
trial. We measured osteocalcin (OC), bone alkaline phosphatase (BAP), tartrate-resistant 
acid phosphatase 5b (TRACP-5b), and sclerostin in serum at baseline, 12, and 18 months. 
The measurement of BMD at lumbar spine and femoral neck was performed at the same 
time. The patients who did not have the data of bone metabolic markers were excluded from 
this study. Finally, 65 subjects were included in the present study.
Results: Serum OC, BAP, TRACP-5b, and sclerostin levels were comparable between 
the two groups at baseline. Serum OC levels in the LC group were significantly higher 
than those in the CC group at 18 months [LC vs CC, 30.0 (18.9-53.2) pg/mL vs 21.7 
(15.3-28.3) pg/mL, p = 0.015]. Serum BAP and TRACP-5b levels tended to be higher in 
the LC group than in the CC group at 18 months [LC vs CC; BAP, 11.9 (8.1-18.5) vs 
9.5 (8-12.9) μg/L, P = 0.174; TRACP-5b, 456.0 (228.0-644.0) vs 326.5 (183.3-487.5) mU/dL, 
P = 0.158, respectively]. Serum sclerostin levels were not different between the two groups. 
Although serum phosphate levels were comparable between the two groups, serum calcium 
levels tended to be lower and intact parathyroid hormone levels tended to be higher in the 
LC group than those in the CC group at 18 months. BMD at both lumbar spine and femoral 
neck were comparable between the two groups.
Conclusions: In the present study, bone formation and resorption markers were higher 
in the LC group than in the CC group. Our findings suggested that the treatment of LC was 
able to maintain proper bone turnover compared with calcium-containing phosphate binders 
in incident HD patients.
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Etelcalcetide Utilization Pattern in a Mid-Size Dialysis Organization
Virginia (Ginger) S. Arnott,2 Tzu-Chieh Lin,1 David C. Hallett,3 Nisha Bhatt,1 
Ayodele Erinle.4,2 1Amgen, THOUSAND OAKS, CA; 2U.S. Renal Care, 
Midlothian, TX; 3Amgen Inc., Glendale, CA; 4High Desert Nephrology 
Associates, Gallup, NM.
Background: Etelcalcetide is a new calcimimetic agent just entered into clinical 
practice. The aims of this study are to describe the initial etelcalcetide doses, titration 
and changes of three key laboratory indices for secondary hyperparathyroidism (SHPT) 
management.
Methods: This retrospective cohort study included all US ESRD patients ≥18 years, 
who had received in-center hemodialysis at US Renal Care centers and initiated etelcalcetide 
between 2/2017 and 2/2018. Every patient was followed from etelcalcetide initiation date 
until the earliest date of 6 months, death, transplantation, parathyroidectomy, termination 
of follow-up. Descriptive analyses (mean, median and %) for etelcalcetide dosage, 3 key 
laboratory indices for SHPT management (parathyroid hormone (PTH), corrected calcium 
(cCa) and phosphorus (P)) were presented at baseline period and during follow-up.
Results: A total of 1,100 patients initiated etelcalcetide, and the mean (SD) age was 
58.7±13.8 years. A total of 86.4% of patients initiated etelcalcetide at 5mg, and 11.4% at 
2.5mg three times a week (TIW). The mean (SD) monthly dosage increased from 5.0±1.3 mg 
at the first month to 6.9±3.6 mg at the 6th month (Figure 1A). After etelcalcetide initiation, 
the proportion of patients achieved a PTH goal of <600 increased from 19% to 51%. During 
follow-up, 19-24% of patients had at least one cCa level <8.4mg/dL, with <2% (of 1,100) 
had cCa <7.5 mg/dL (Figure 1B). The median P level remained between 5.5-5.7 mg/dL 
during follow-up.
Conclusions: We found the vast majority of patients were initiated on etelcalcetide at 
a dose of 5 mg TIW consistent with approved prescribing information. The prevalence of 
serious hypocalcemia was low, with less than 2% of patients ever having cCa levels <7.5 
mg/dL.
Funding: Commercial Support - Amgen, Thousand Oaks
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Etelcalcetide from Controlled Trial to Bedside
Domenico Russo,1 Daniela Di giuseppe,3 Salvatore Coppola,7 Biagio Di iorio,2 
Pasquale Guastaferro,4 Yuri Battaglia,5 Luca Di Lullo,6 Bernadette Scognamiglio,1 
Vincenzo Panuccio.8 1Public Health, University Federico Ii, Naples, Italy; 
2Landolfi Hospital Solofra, Avellino, Italy, Solofra, Italy; 3VENODIAL, Cava dei 
tirreni, Italy; 4Sant’Angelo dei lombardi hospital, Avellino, Italy; 5Hospital-
University St. Anna, Ferrara, Italy; 6U.O.C. Nefrologia e Dialisi, Grottaferrata, 
Italy; 7P.O. Piedimonte matese, Caserta, Italy; 8UO Nefrologia, Dialisi, 
Trapianto, Reggio Calabria, Italy.
Background: Cinacalcet reduces high PTH levels (SHPT) in dialysis patients. 
Relevant complaints associate cinacalcet: nausea, vomiting, hypocalcemia. Therefore, 
clinicians are forced to reduce dose or discontinue cinacalcet with consequent poor PTH 
control. Etelcalcetide in randomized trials resulted non inferior to cinacalcet at lowering 
PTH. Common adverse events are hypocalcemia and gastrointestinal symptoms. This pilot 
observational multicenter study was conducted to evaluate efficacy and occurrence of side 
effects of etelcalcetide in a “real world” setting that is different from randomized controlled 
trials.
Methods: Patients on thrice weekly maintenance hemodialysis, stable doses of 
phosphate binders, calcitriol or active vitamin D were evaluated. Investigator were free in 
prescriving starting dose and etelcalcetide increments. Biochemistry and side effects were 
recorded after etelcalcetide. Clinician’s satisfaction was evaluated by questionnaire.
Results: n.73 patients (mean age:61±13 years; males:62 %; diabetics:25 %;dialysis 
vintage:78±52months) received etelcalcetide. Many patients (83%) were treated with 
cinacalcet (median daily dose:30 mg). Cinacalcet-dependent gastrointestinal side effect 
were 49%; episodes of hypocalcemia were 4. No changes were observed in phosphate 
binder, vitamin D sterols and ESA doses, and serum hemoglobin concentration. Further 
results are reported in table.
Conclusions: The study shows that in high-risk dialysis patients, lower doses of 
etelcalcetide than that reported before reduce PTH with minimal gastrointestinal discomfort 
and low occurrence of hypocalcemia requiring drug discontinuation. The effect on PTH 
seems dose dependent. Almost all participating clinicians regarded etelcalcetide as very 
handy medication. Larger study and longer follow-up in “real world” setting are mandatory.
*p<0.01 Vs baseline; **p<0.02 Vs baseline
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Daily versus Post-Dialysis Administration of Calcimimetics for the 
Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: 
An Interventional, Multi-center Study
Tarek M. Demerdash,1,2 Mostafa A. Abdelkhalek,1,3 Mohammed M. Assem,1,2 
Mahmoud M. Shaheen,1,2 Farida Elsafty,1 Ibrahim A. Jubran,1 Saad S. Alobaili,1 
Abdullah Kashgary,1,4 Wisam H. Al-Badr,1 Abdulkareem Alsuwaida.1 1DaVita-
Saudi Arabia, Riyadh, Saudi Arabia; 2Cairo University, Cairo, Egypt; 
3Mansoura Faculty of Medicine - Mansoura University, Mansoura, Egypt; 
4King Abdulaziz University, Jeddah, Saudi Arabia.
Background: Treatment of secondary hyperparathyroidism (SHPT) in patients on 
hemodialysis (HD) may be hampered by poor medication adherence. The aim of this study 
was to assess the effectiveness of supervised, post-HD administration of calcimimetics in 
controlling mineral bone disorder (MBD) in patients on maintenance HD.
Methods: This was a multi-center prospective study that included adults treated 
at DaVita HD facilities in Saudi Arabia with HD vintage ≥6 months and proven SHPT. 
Patients with previous parathyroidectomy, baseline corrected calcium <8.4 mg/dL, tertiary 
HPT, and patients having other causes of hyper- or hypo-calcemia were excluded. As of 
Nov 1, 2017, study patients were shifted from daily dosing of calcimimetics to three weekly 
doses taken at the end of each HD session. Intact parathyroid hormone (iPTH), serum 
calcium, phosphorus, alkaline phosphatase levels, dosage of phosphate binders (calcium 
carbonate/sevelamer), and vitamin D analog were compared at baseline and 6 months after 
initiation of thrice-weekly calcimimetic dosing.
Results: A total of 73 HD patients switched to receive calcimimetics after dialysis. After 
6 months, there was a significant reduction in both calcimimetic dose (p=0.005) and iPTH 
(p=0.013). Despite the absence of any significant change in serum calcium, phosphorus, 
or alkaline phosphatase, there was an increase in calcium carbonate dose (p<0.009) and a 
reduction in sevelamer dose (p<0.011)
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Conclusions: Compared to daily dosing, supervised calcimimetic dosing after HD was 
more effective in controlling SHPT. Evaluation in large-scale randomized controlled studies 
is recommended.
Funding: Commercial Support - DaVita
Effects of alternate dose of cinacalcet on laboratory values and dosage of medications
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Conversion from Cinacalcet to Etelcalcetide in a Mid-Size Dialysis 
Organization: Real-World Therapeutic Conversion
Dongyang Shang,1 Shaun S. Collard,1 Graham E. Abra,1,2 Brigitte Schiller.1,2 
1Satellite Healthcare, San Jose, CA; 2Stanford University, Palo Alto, CA.
Background: There are two FDA approved calcimimetics available in the United 
States, intravenous etelcalcetide and oral cinacalcet. There is limited data to guide 
therapeutic conversion from cinacalcet to etelcalcetide in a real-world hemodialysis (HD) 
setting. Here we describe our experience with conversion from cinacalcet to etelcalcetide 
HD patients in a mid-size dialysis provider organization.
Methods: Data from 1264 in-center hemodialysis patients treated with cinacalcet 
from 60 dialysis centers from December 2017 to April 2018 are reported. Conversion from 
cinacalcet to etelcalcetide occurred in February 2018. All patients started etelcalcetide at 
2.5 mg IV three times a week regardless of previous cinacalcet dose after a 7 day wash out 
period. Etelcalcetide doses were subsequently adjusted monthly to achieve a target iPTH of 
150-700 pg/mL and an adjusted calcium of 8.0-10.2 mg/dL.
Results: The percentage of patients with an adjusted calcium reaching the target iPTH 
declined temporarily, but increased in month 1 and 2 after conversion. Monitoring in all 
patients treated with etelcalcetide, recorded the following adverse events (AEs) profiles: 
4% of patients experienced nausea/vomiting and 24% hypotension. No severe AEs were 
reported.
Conclusions: In this real-world dosing conversion from cinacalcet to etelcalcetide 
aggregated biochemical targets after converting all patients to etelcalcetide 2.5 mg IV three 
times a week regardless of previous cinacalcet dose showed a decrease in percentage of 
patients reaching iPTH targets during conversion month with improving iPTH results in 
the subsequent two months post conversion. Side effect profile was unchanged compared 
to commonly reported AEs.
Figure: Proportion of Converted Patients by iPTH Ranges
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Uremic Periodontitis: Bacterial Dysbiosis and Immune Dysfunction
David Randall,1 Asil Alsam,2 Julius E. Kieswich,1 Susan Joseph,2 
Kieran Mccafferty,1 Michael A. Curtis,2 Muhammad M. Yaqoob.1 1William 
Harvey Research Institute, Queen Mary University of London, London, United 
Kingdom; 2Dental Institute, Kings College London, London, United Kingdom.
Background: Patients with CKD have a high incidence of periodontitis, which acts as 
a marker for increased mortality in these individuals. We sought to establish whether this 
represents a causal association, and to understand the mechanisms responsible.
Methods: Two models of CKD were used in wild-type Wistar rats: feeding with 
0.75% adenine and subtotal nephrectomy. Of the uremic animals, half were housed with 
other uremics whilst half were housed with controls. The oral microbiome was assessed 
using next-generation sequencing and culture-based methods. Periodontal bone loss was 
measured as the distance between the cemento-enamel junction and the alveolar bone 
ridge, supplemented by immunohistochemistry, micro-CT imaging and scanning electron 
microscopy.
Results: In both models of CKD, uremic rats displayed significantly more periodontal 
bone loss than controls (alveolar bone level > 0.1mm lower in uremics, p<0.0001). These 
animals displayed substantial oral dysbiosis compared to controls, including a reduction 
in cultured bacterial counts (log 5.95 vs log 6.21, p=0.05), increased alpha diversity (Inv 
Simpson index 10.3 vs 6.46, p=0.03), a decline in health-associated phylum Firmicutes 
(55.2% vs 66%, p=0.05) and genus Streptococcus (29.8% vs 45.8%, p=0.004), and 
an increase in disease-associated Gammaproteobacteria (29.6% vs 19.4%, p=0.038). 
Histology and imaging confirmed bone disease associated with IL-17 driven inflammation. 
Significantly, uremic rats housed with healthy controls demonstrated milder bone loss than 
those housed with other uremics (p=0.037).
Conclusions: This work proves for the first time that periodontitis can be caused 
by uremia. A key role for bacterial dysbiosis is suggested from the fact that periodontal 
disease was partially reversed in uremic animals housed with controls. We propose that oral 
bacterial dysbiosis induces Th17-driven inflammatory periodontal bone loss.
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The Ability of Intact Parathyroid Hormone and Total Alkaline Phospha-
tase to Predict Bone Turnover in Patients with Renal Osteodystrophy
Jose E. Gueiros, Ana Paula Gueiros, Luiz A. Coutinho, Julia B. Vaz. UFPE, 
Recife, Brazil.
Background: Bone turnover (BT) markers reflect bone cell activity and are useful in 
the diagnosis and management of chronic kidney disease-mineral and bone disorders. Bone 
biopsy (BB) is considered gold standard for diagnosing renal osteodystrophy, although it 
should be reserved just for certain patients. The objective of this study was to evaluate 
the predictive value of intact parathyroid hormone (iPTH) and total alkaline phosphatase 
(tALP) as BT markers.
Methods: This was a cross-sectional retrospective diagnostic test study. Two hundred and 
eleven patients were assessed through BB and serum levels of iPTH and tALP. iPTH assays 
were performed using the same methodology (chemiluminescence: NR: 15-65 pg/mL). 
For the tALP analysis, an index representing the ratio between tALP and the maximum 
reference value for the method was used, since there are tests with different methodologies. 
According to histological diagnosis, the patients were divided into high turnover (HT), 
those with fibrous osteitis and mixed disease, and low turnover (LT), those with adynamic 
bone disease and osteomalacia. An analysis was conducted in order to derive the area under 
the receiver operating characteristic (ROC) curve (AUROC) to determine the diagnostic 
ability of BT as a biomarker.
Results: Patients (48.9 years) had been on hemodialysis for 9.5 years, of whom 84% 
and 16% were classified as HT and LT, respectively. The median serum level of iPTH was 
1296 in the HT patients, and 116 in LT patients. The median tALP index was 1.82 for the 
HT and 0.9 for the LT patients. To predict HT, the iPTH presented an AUROC of 0.908, with 
a cutoff value of 363 with a sensitivity of 82.5% and a specificity of 88%; while the tALP 
index demonstrated an AUROC of 0.747, with a cutoff value of 1.01, with a sensitivity of 
72.3% and a specificity of 65%. To predict LT, the iPTH and tALP index were not good 
markers, with an AUROC of 0.092 and 0.253, respectively. Limitations: Histomorphometry 
and bone alkaline phosphatase were not performed; Predominance of severe secondary 
hyperparathyroidism.
Conclusions: Our results have demonstrated that the iPTH and tALP were excellent 
predictors for HT, but it was evident that iPTH was far superior.
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Twenty-Four Hour Urine Testing in Kidney Stone Formers: A Veterans 
Health Administration Study
Calyani Ganesan,1 I-Chun Thomas,5 Andrew J. Sun,2 Simon Conti,4 
Christopher S. Elliott,4 Joseph C. Liao,2 Manjula Kurella Tamura,2 Glenn 
M. Chertow,3 John Leppert,2 Alan C. Pao.2 1Stanford Nephrology, Redwood City, 
CA; 2Stanford University, Palo Alto, CA; 3Stanford University School of
Medicine, Palo Alto, CA; 4Stanford, San Jose, CA; 5VA Palo Alto, PALO ALTO, 
CA.
Background: The American Urological Association recommends 24-hour urine 
testing in stone formers to prevent recurrent stones. However national practice patterns of 
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metabolic evaluation which utilize urine testing remain uncharacterized. To address this, 
we identified stone formers in the national Veterans Health Administration (VHA) database 
and assessed the characteristics of those who received 24-hour urine testing and the timing 
and frequency of testing.
Methods: We defined stone formers as those with one or more inpatient ICD-9 codes 
for stones, two or more outpatient ICD-9 codes for stones, or one or more CPT codes 
for stone procedures in 2007-13 using the national VHA database. We defined a 24-hour 
urine test as having a 24-hour urine calcium, oxalate, citrate or sulfate measurement. We 
compared demographics and clinical characteristics among Veterans who received testing 
and those who did not. We determined the timing and frequency of 24-hour urine testing and 
evaluated whether urine testing varied geographically. We assessed factors associated with 
24-hour testing using multivariable regression.
Results: We identified 130,489 individuals with a stone encounter between 2007-2013. 
Within this stone cohort, 13.3% (19,288 individuals) underwent 24-hour urine testing. 
These individuals were younger, had fewer comorbidities, and were more likely to be 
seen on an outpatient basis. In addition, those with 24-hour urine testing had more stone 
procedures than those who did not (3.0 ± 2.8 vs. 2.3 ± 2.1, p <.001). The majority of testing 
occurred within 1 year of a stone encounter. There was considerable geographic variation 
in the utilization of 24-hour urine tests, ranging between 1% and 40% across VA facilities, 
with the most frequent testing in the western United States.
Conclusions: We found high facility level variation in 24-hour urine testing among 
stone formers. Our results suggest that in addition to patient risk, physician practice patterns 
influence the use of 24-hour testing in urinary stone disease. Comparative effectiveness 
research could help to define the role of 24-hour urine testing in the evaluation and 
management of kidney stones.
Funding: Private Foundation Support
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Prevalence of Kidney Stones in Cystic Fibrosis
Jeremy F. Wright,1,2 David S. Goldfarb,3,4 Eric N. Taylor,1,2 Jonathan Zuckerman.1,2 
1Maine Medical Center, Portland, ME; 2Tufts University School of Medicine, 
Boston, MA; 3NYU Medical School, New York, NY; 4New York Harbor VAMC, 
New York, NY.
Background: Cystic fibrosis (CF) may predispose patients to urinary stone disease 
(USD) via several proposed mechanisms including antibiotic exposure and intestinal 
malabsorption. Prevalence of USD in patients with CF was estimated at 2-6% in studies 
with mean age 16-27 years. These data are limited by small sample sizes and single-center 
settings. The CF Foundation Patient Registry (CFFPR) began collecting prevalence data 
on USD in 2006.
Methods: We studied 29,396 patients in the CFFPR living in 2016 to calculate 
age-stratified prevalence of USD.USD was assessed by trained CF clinic staff at each 
encounter. For 15,531 patients age 18 or older we examined associations between age, BMI, 
demographics, CFTR mutation class, other clinical parameters, and prevalent USD using 
multivariate logistic regression.
Results: Overall prevalence of USD was 3.1% (95% CI 2.9-3.3%). Prevalence under 
age 18 years was 0.4% (0.3-0.5%), 18 to 24 years, 3.1% (2.7-3.6%), 25 to 34 years, 6.4% 
(5.8 -7.1%), 35 to 44 years, 7.5% (6.5-8.5%), and 45 years and older, 6.7% (5.8-7.8%). 
Mean age of all patients was 21.3 years. We also calculated prevalence for age ranges 20-
29, and 30-39 years to compare with published NHANES data for the general population. 
Stone prevalence was 4.8% and 7.1% in in CF patients within these two age cohorts, 
respectively, compared to 3.4 and 6.4% in NHANES. Multivariate adjusted odds ratios for 
stone prevalence were significant for female sex, OR 1.4 (95% CI 1.2-1.7), severe CFTR 
mutations, OR 1.8 (1.2-2.5), diabetes, OR 1.2 (1.0-1.5), hypertension, OR 1.4 (1.0 -1.9), and 
chronic macrolide therapy, OR 1.3 (1.1-1.6). BMI was not associated with USD.
Conclusions: USD prevalence in CFFPR may be higher than in the general population 
and increased with age. Some risk factors for stone disease in the general population appear 
significant for adult patients with CF, including hypertension and diabetes. However, BMI 
did not show the same relationship. Several novel associations with USD in CF patients 
also were identified, including a greater prevalence in women. This study is limited by the 
method of USD assessment; it is possible patients with more severe CF had higher rates of 
reported asymptomatic stones incidentally diagnosed due to more frequent imaging. As life 
expectancy of people with CF increases, the prevalence of USD may also increase.
Funding: Private Foundation Support
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Correlation of Papillary Grading and Metabolic Parameters in Calcium 
Stone Formers
Anna L. Zisman, Fredric L. Coe, Elaine M. Worcester. University of Chicago, 
Chicago, IL.
Background: Papillary grading has emerged as a novel technique to standardize 
ureteroscopic findings, but its relationship to stone pathogenesis is poorly understood. As 
24-hour urine metabolic risk parameters predict stone type and likelihood of recurrence, we 
sought to determine whether papillary grading correlates with these parameters.
Methods: Patients’ endoscopic findings during stone procedures were graded by two 
urologists at a single academic institution using a previously described renal papillary 
grading system. This system quantifies the degree of Randall’s plaque (RP), pitting, 
plugging, and loss of contour, yielding a summary score for each papillum. Composite 
scores were generated by averaging all papillary scores from a single kidney. Patients were 
included if they had calcium based stones and completed two 24-hour urine collections 
with paired serum studies prior to treatment. Pearson correlations were used to determine 
relationships between individual components of the score, total score, and average across 
the categories as related to urinary metabolic risk factors.
Results: 41 patients (43% Male, 63% Caucasian) were included. The mean age was 
52.1 yrs (±7.5) and mean BMI was 30.8 (±4.0) kg/m2. Contour was inversely related to 24 
hr urine calcium (P<0.05) and calcium phosphate supersaturation (SSCaP) (p<0.05). Pitting 
is directly related to 24-hr urine oxalate (p<0.05) and inversely related to urine volume 
(p<0.05) (Figure). No significant correlations were found for urine pH or 24 hr urine citrate. 
Significant differences in RP scores (AA 0.53, C 1.35, p<0.003), but not the other grading 
components, were noted across racial groups.
Conclusions: Papillary grading correlates with 24 hr urine volume, calcium, oxalate, 
and SSCaP. Racial differences in RP burden suggest differing mechanisms of calcium 
lithogenesis by race which warrants further study.
Funding: NIDDK Support
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Prevention of Recurrent Stones and CKD in Kidney Stone Formers: What 
Are the Goals for Biochemical Parameters in Urine Collections?
Juan Carlos Ramirez-Sandoval,1 Cynthia Garcia-Sanchez,3 Ricardo Correa-
Rotter.2 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, 
México city, Mexico; 2Institutor Nacional de la Nutricion, Mexico City, Mexico; 
3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, 
Mexico.
Background: The evidence of effective prevention of recurrent stone formation and 
CKD in kidney stone formers (KSF) through the treatment of biochemical abnormalities 
present in repeated 24h urine collections (24UC) is scarce. Our aim was to analyze the 
association between metabolic control (assessed by yearly 24UC) and kidney stone 
recurrence rates and decline in eGFR in KSF attending a nephrolithiasis clinic.
Methods: Single-center cohort study of KSF with at least three 24UC and ≥2 years of 
follow-up. Exclusions: primary hyperparathyroidism, eGFR >30 mL/min/1.73m2. Medical 
data, including chemistry of 24UC, were compared using analysis of variance and general 
linear modelling.
Results: Of 220 KSF, 63% had absorptive hypercalciuria and 64% hipocitraturia 
(median follow-up of 4 yrs [IQR 4-5.2 yrs]). All KSF with hypercalciuria received 
chlortalidone. 24UC abnormalities display a trend to improve along time in all the cohort. 
Stone recurrence (≥2 episodes, 35% of KSF) was associated with higher urinary Ca/Cr index 
compared with KSF free of stone recurrence at follow up with treatment (yearly mean 24UC 
Ca/Cr 0.15±0.08 Vs. 0.12±0.05 respectively, p=0.02). Inappropriate eGFR decline (>2 mL/
min/year) not related to obstruction or AKI episodes was observe in 13% of KSF and was 
associated with lower citraturia (yearly median citrate 192 mg/24UC [IQR 153-290] Vs 354 
mg/24UC [IQR 237-541], p=0.003). Other parameters of the 24UC (volume recollected, Na, 
oxaluria, or uricosuria) were not associated with recurrence or eGFR decline.
Conclusions: Among 24UC yearly measurement; a very low Ca/Cr index was effective 
preventing stone recurrence in KSF. Low citrate excretion predicted an inappropriate eGFR 
decline, even before treatment.
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Figure. Association between repeated urinary chemistry of yearly 24-hour collections and 
renal outcomes. A) Calciuria/creatinuria index and stone recurrence. B) Citrate excretion 
and eGFR Slope Decline.
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Manifestations of Kidney Stone Recurrence and Their Prediction by Risk 
Factors
Matthew R. D’Costa, Kristin C. Mara, William E. Haley, Felicity T. Enders, 
Terri J. Vrtiska, Cynthia H. Mccollough, John C. Lieske, Andrew D. Rule. Mayo 
Clinic, Rochester, MN.
Background: The relationship between symptomatic and radiographic kidney stone 
recurrence is unclear. Risk factors may also differ in their association with symptomatic and 
radiographic recurrence.
Methods: First-time symptomatic stone formers were recruited from 2009 to 2013 
in MN and FL. Baseline and 5-year follow-up visits included CT scans, surveys, and 
medical record review. At 5 years, symptomatic recurrence was identified by clinical care 
(medical record) and self-report (survey); radiographic recurrence was identified by new 
stone, stone growth, or stone disappearance between CT’s. A Recurrence of Kidney Stone 
(ROKS) score summed risk factors for recurrence (young age, male gender, high BMI, 
family history of stones, pregnancy, asymptomatic or suspected stone prior to first episode, 
history of a brushite/struvite/uric acid stone, no history of COM stone, pelvic/lower pole 
stone, no uterovesical junction stone, number of stones in kidney, and diameter of largest 
kidney stone). The 5-year incidence of recurrence and its association with ROKS score 
was compared.
Results: There were 175 stone formers studied (55% had an asymptomatic kidney 
stone at baseline). By year 5, 19% had symptomatic recurrence (clinical care), 25% had 
symptomatic recurrence (self-report), 35% had a new stone, 24% had stone growth, and 
26% had stone disappearance. Of those with an asymptomatic stone, 47% had stone 
disappearance, and 50% of those had a concurrent symptomatic recurrence. Symptomatic 
recurrence by clinical care versus self-report was more strongly associated with new 
stone (OR=4.8 95% CI [2.2-10.6] versus 1.9 [1.0-3.9]) or stone disappearance (OR=3.9 
[1.8-8.5] versus 2.0 [1.0-4.2]). The ROKS score associated more strongly with radiographic 
recurrence than only symptomatic recurrence (Table).
Conclusions: Clinical care is more strongly associated with recurrence than self-report. 
Half of first-time stone formers have an asymptomatic stone. By 5 years, half of these 
stones will have passed with symptoms occurring half the time (Rule of Halves). While 
symptomatic recurrence is more clinically relevant, asymptomatic radiographic recurrence 
is better predicted by risk factors.
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Rotating Shift Work and Kidney Stones
Megan Prochaska,1 Eric N. Taylor,3 Gary C. Curhan.2 1Renal, Brigham and 
Women’s Hospital, Boston, MA; 2Channing Division of Network Medicine, 
Brigham and Women’s Hospital, Boston, MA; 3Maine Medical Center and Tufts 
University School of Medicine, Portland, ME.
Background: Related to circadian rhythm, which is the 24-hour periodicity of 
physiologic processes, there is diurnal variation in excretion of urinary factors, including 
factors associated with kidney stone risk. Rotating shift work disrupts circadian rhythm but 
has not been evaluated as a risk factor for kidney stones. We examined rotating shift work 
with risk of incident kidney stones and 24-hour urine composition in the Nurses’ Health 
Study II.
Methods: We conducted a prospective analysis of 101,983 Nurses’ Health Study II 
participants who provided information on rotating shift work and kidney stones. We used 
multivariate adjusted Cox proportional hazards models to compare current (1 to 9 months, 
or 10 or greater months) and past rotating shift work to no rotating shift work. In a separate 
analysis, we used multivariate adjusted Cox proportional hazards models to compare 
cumulative shift work exposure to no shift work. We also analyzed rotating shift work in 
24-hour urine collections from 3811 participants. We used ANOVA to compare urinary 
factors by rotating shift work duration.
Results: In 22 years of follow-up, there were 3,281 incident kidney stones. Compared 
with no rotating shift work, the multivariate adjusted relative risks for incident kidney stone 
were 1.16 (95% CI 0.92 to 1.46) for 1 to 9 months current rotating shift work, 1.12 (95% CI 
0.92 to 1.34) for 10 months or greater current rotating shift work, and 1.12 (95% CI 1.04 to 
1.20) for past rotating shift work. Compared with no rotating shift work, participants with 
the highest exposure of cumulative rotating shift work, 10 years or greater, the multivariate 
adjusted risk for incident kidney stone was 1.19 (95% CI 1.06 to 1.34). There were no 
substantial differences or trends in the urine composition profiles when comparing 24-hour 
urine collections for participants who had no rotating shift work, 1 to 4 months, 5 to 14 
months, and 15 months or greater of rotating shift work during the collection period.
Conclusions: Rotating shift work was associated with a slightly higher risk of incident 
kidney stone compared with no rotating shift work. There were no differences in urine 
composition based on rotating shift work.
Funding: NIDDK Support
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Stone Frequency Determines Health-Related Quality of Life (HRQoL) in 
Cystine Stone Formers (CSF)
Frank Modersitzki,1,2 David S. Goldfarb.1,2 Rare Kidney Stone Consortium 1New 
York University School of Medicine, New York, NY; 2New York Harbor VAMC, 
New York, NY.
Background: CSF have lower HRQoL compared to US Standard Population. We have 
shown previously that HRQoL results need to be controlled for the last stone event and 
comorbidities. We now show the first longitudinal HRQoL domain profiles for baseline and 
two yearly follow-ups.
Methods: CSF were enrolled from the RKSC registry. HRQoL was measured with 
the generic non-disease specific SF-36v2. Results were calculated as norm-based scores 
(NBS) based on US Standard Population (Domain score mean = 50). We selected 3 stone 
frequency groups (SFG): low (stone-free during observation period), medium (minimum 
of one stone event between 31 - 365 days) and high (stone event always present within 
30 days of the survey), and compared the groups’ HRQoL at baseline and second follow-up.
Results: We scored 386 surveys. 78 participants (32 males and 46 females) were 
compared at baseline and 2 follow-up assessments. Mean age was 45 years (male 
44/ female 46). Repeated measure ANOVA showed no difference within each SFG over 
time (Fig 1). However, domain scores were significantly different between SFG’s (p<0.05) 
at each time point, with low>medium>high stone frequency. Whether surgical intervention 
was required, and type, were not predictors of HRQoL outcomes. Better HRQoL tracked 
with lower cystine excretion per liter on 24h urine collections; lower cystine capacity and 
higher citrate doses were underpowered (NS).
Conclusions: CSF with high stone event rates experience worse HRQoL over time, 
while CSF with no stone events achieved better HRQoL than US standard. Clinnical data 
suggest that the high SFG is undertreated.
Funding: NIDDK Support
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Vascular Calcifications in Patients with Calcium and Uric Acid Kidney 
Stone Composition
Pietro Manuel Ferraro,1 Riccardo Marano,2 Aniello Primiano,3 Jacopo Gervasoni,4 
Giovanni Gambaro.1 1Fondazione Policlinico Universitario A. Gemelli, Rome, 
Italy; 2Polyclinic Foundation A. Gemelli IRCCS - Catholic University, Rome, 
Italy; 3Istituto di Biochimica e Biochimica Clinica Università Cattolica del 
Sacro Cuore, Rome, Italy; 4Area Diagnostica di Laboratorio IRCCS Fondazione 
Policlinico Universitario A. Gemelli, Rome, Italy.
Background: Kidney stone disease has been associated with incident cardiovascular 
events, as well as with vascular calcifications. It is not known whether the likelihood and 
extent of vascular calcifications differ in patients with different types of stone composition.
Methods: We retrospectively evaluated CT scan images of patients who underwent at 
least one kidney stone composition analysis during the 2015-2018 period. Kidney stones 
were analyzed by Fourier-transform infrared spectroscopy and categorized as follows: 
calcium stones (≥50% calcium oxalate or calcium phosphate), uric acid stones (any uric 
acid). A calcification score was calculated from the CT scan images at the abdominal aorta 
and expressed as calcium volume. The radiologist who performed the calcification score 
evaluation was not aware of the stone composition group of the patients. For patients who 
underwent multiple kidney stone composition analyses and/or CT scans, information on 
vascular calcification was obtained from the CT scan closest in time to a kidney stone 
composition analysis.
Results: We enrolled 30 patients with at least one kidney stone composition analysis 
in the observation period who had undergone at least one CT scan examination at our 
Institution. Average age was 56±16 years, 16 (53%) were males. Patients with uric acid 
stones had significantly higher values of calcification at abdominal aorta (975 mm3, 95% 
CI −3, 1,953 mm3; p=0.05). However, such differences attenuated after adjustment for age 
(370 mm3, 95% CI −598, 1,337 mm3; p=0.44).
Conclusions: Patients who form uric acid stones seem to have worse calcifications at 
abdominal aorta compared with those who form calcium stones; however, this association 
could be at least in part mediated by differences in age between groups.
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Nephrolithiasis in HIV+ Patients with CKD: A Case Series
Ryan Spiardi, Maliha Ahmed, Robert Fleyshman, Abbas Raza, Suzanne Boyle. 
Drexel University College of Medicine, Philadelphia, PA.
Background: Nephrolithiasis and CKD are highly prevalent in the HIV+ population, 
independent of each other. The association between some anti-retroviral therapy (ART) and 
both nephrolithiasis and CKD, respectively, has been demonstrated. However, amongst 
HIV+ patients, there are limited data on the relationship between nephrolithiasis and CKD 
progression. It is unknown if HIV+ patients have risk factors for nephrolithiasis beyond 
ART. We describe a series of HIV+ patients with a history of nephrolithiasis in a CKD 
clinic.
Methods: In a CKD clinic of HIV+ patients (n = 55), we identified those with history 
of nephrolithiasis by radiology or self-report. Data was collected on demographics; co-
morbidities; HIV control; age at first stone; urologic interventions; ART; creatinine trends; 
urine chemistries; and stone composition.
Results: The prevalence of nephrolithiasis was 21.8% (n = 12). Sixty-seven percent 
were black; 92% male; 75% had HTN; 8%, DM. At the initial CKD appointment, median 
age was 53; baseline creatinine, 1.5 mg/dl (IQR, 1.2-1.8); eGFR, 49 ml/min/1.73m2; 
UPCR, 1.02 (IQR, 0.37-1.89). Ninety-two percent had an undetectable viral load (VL). 
Eighty-three percent had taken tenofovir disoproxil fumarate (TDF); 50%, atazanavir; 17%, 
indinavir. The majority had their first stone after HIV diagnosis (58%) and 42% of first 
episodes were between ages 51-60. After the first stone, there was a generalized upward 
creatinine slope in 75% of patients (n = 9). Only one patient had data on stone composition, 
and two, urine chemistry.
Conclusions: There was a high prevalence of nephrolithiasis among HIV+ patients 
in a CKD clinic. Most patients had their first stone after HIV diagnosis and experienced 
an upward slope in creatinine after this. Nearly all had early CKD with sub-nephrotic 
proteinuria and undetectable VL. While most patients had exposure to ART that might 
increase stone risk, we cannot infer that this entirely accounts for the high prevalence. 
Studies show that proximal tubule cells are a reservoir for HIV. This could be a potential 
risk factor for stones by altering urine chemistry. Controlled studies are needed to describe 
urine chemistries in HIV+ patients with nephrolithiasis as well as the association between 
nephrolithiasis and CKD progression.
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Independent Effects of Age and Kidney Function on Urine pH in Stone 
Forming Patients
Cameron J. Menezes,1 John R. Asplin,2 Elaine M. Worcester,1 Fredric L. Coe.1 
1University of Chicago, Chicago, IL; 2Litholink Corp, Chicago, IL.
Background: We have found that normal women (W) have higher urine pH (UpH) 
than men (M) fed identical diets in a clinical research center. Prevalence of high UpH-
dependent phosphate stones decreases with age while that of uric acid stones – signifying 
low UpH - increases. We sought to determine if UpH falls with age in a large population 
of stone formers (SF), and if so to quantify the independent effects of sex, falling renal 
function, and age itself.
Methods: From a large dataset of 12839 SF patients with pretreatment 24 hour urine 
collections and matching serum collections (Litholink) we selected 7891 (3605 F) SF 
without markers of systemic disease, infections, or missing lab values. The final dataset was 
used to model UpH using continuous generalized linear models with urine potential renal 
acid load (uPRAL) calculated from urine charge balance, age, creatinine clearance (CCr) 
and their appropriate cross products. To directly compare the effect sizes of CCr and age, 
we treated both as categorical variables in a separate analysis.
Results: UpH in W was higher than M at all ages and UpH declines with age and CCr 
via separable effects. uPRAL, age, and CCr are all significant (p<.01) predictors of UpH 
(Table), and the effect of uPRAL is conditioned by both CCr and age. The observed sex 
difference is fully accounted for after adjustment in both the continuous and categorical 
models of UpH.
Conclusions: Age and CCr exert separate effects on UpH in SF patients. Of the two, 
age is the more important predictor with an effect size approximately twice that of CCr. 
UpH is most strongly conditioned by uPRAL with effects that are mediated by age and 
kidney function.
Funding: NIDDK Support
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Correlation of Vitamin D and Insulin Resistance Among Calcium Kidney 
Stone Formers
Pulkit Gandhi,1 Roopali G. Gandhi,2 Jie Tang.3 1Brown University, Providence, 
RI; 2Rhode island hospital, Providence, RI; 3University Medicine; Brown 
University, West Roxbury, MA.
Background: Existing evidence suggest that vitamin D could play a role in the 
pathogenesis of type 2 diabetes, by affecting insulin sensitivity. However, the interaction of 
25(OH)-vitamin D (25D) with insulin sensitivity has not been examined in calcium kidney 
stone formers, a unique population whose 1,25(OH) vitamin D (1,25-D) action seems to 
be hyperactive.
Methods: Prevalent non-diabetic calcium kidney stone formers from 2015 to 2018 
were enrolled in this study. We assessed the association between serum 25D and insulin 
resistance measured by Homeostatic model assessment insulin resistance {HOMA IR = 
(fasting glucose (mg/dl) × fasting insulin (mU/L)/(405)} using univariate analysis and 
multivariate regression model adjusting for demographics and important clinical covariates. 
P values less than 0.05 were considered significant.
Results: A total of 94 non-diabetic calcium kidney stone formers were enrolled in this 
study. Among them, 51% were male, 86% were Caucasian, 38% had history of hypertension, 
and 29% had history of dyslipidemia. Mean age was 54 years, mean creatinine clearance 
(CrCl) was 131 ml/min, mean body mass index was 31.3 kg/m2, mean serum 25D was 
28 ng/ml, mean serum 1,25D was 52 pg/ml and mean serum parathyroid hormone level 
was 66 pg/ml. The mean HOMA IR was calculated at 8.1. In univariate analysis, 25D had 
no significant association with HOMA-IR (p=0.68), however, hypertension, dyslipidemia, 
CrCl and BMI associated significantly with HOMA-IR (p<0.05). After adjusting for 
demographics, 25D again did not associate significantly with HOMA-IR (p=0.33), but the 
associations between HOMA-IR and hypertension, dyslipidemia, CrCl and BMI remained 
significant (p<0.05). Finally, after adjusting for demographics, hypertension, dyslipidemia, 
CrCl, BMI and serum uric acid, the association between 25D and HOMA-IR remained 
insignificant (p=0.14). Like 25D, serum 1,25D levels had no association with HOMA-IR in 
univariate and multivariate analyses.
Conclusions: Unlike the general population, low serum 25D levels, had no significant 
association with insulin-resistance measured by HOMA IR in calcium kidney stone formers.
Funding: Private Foundation Support, Clinical Revenue Support
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Unmet Need in Enteric Hyperoxaluria: Clinical Characteristics and Stone 
Burden in Patients from ALLN-177 Studies
Sagar U. Nigwekar,1 James E. Lingeman,2 Linda H. Easter,3 Danica Grujic,4 
Zhiqun Zhang,4 Annamaria T. Kausz.4 1Massachusetts General Hospital, 
Cambridge, MA; 2IU Health Physicians Urology, Indianapolis, IN; 3Wake 
Forest School of Medicine, Kernersville, NC; 4Allena Pharmaceuticals, Inc, 
Newton, MA.
Background: Hyperoxaluria (HOx) is a serious metabolic disorder and a key risk factor 
for progression of kidney stone (KS) disease and other renal complications. Patients with 
malabsorptive gastrointestinal (GI) conditions (e.g., bariatric surgery, Crohn’s disease) can 
develop what is called enteric HOx (EH) due to over-absorption of oxalate (Ox). Standard 
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of care interventions are non-specific, and many have persistently high urine Ox (UOx) 
levels. The existing KS burden in patients with EH has not been described.
Methods: Baseline data on33 patients with EH enrolled in 3 Phase II studies of ALLN-
177 (an oral, non-absorbed, Ox-specific enzyme therapy) were analyzed. Medications, 
24-hr urine parameters, KS history, and dietary Ox were assessed in all 3 studies; computed 
tomograms (CT) were obtained in 2 studies to define silent KS burden (active renal colic 
was exclusionary).
Results: Mean age was 64 (range 41-82) and 57.6% were female. The enteric condition 
was bariatric surgery in 24 (73%), Crohn’s in 5 (15%), pancreatic insufficiency in 2 (6%) 
and ‘other’ disease in 2 (6%). Mean (SD) dietary Ox was 185±138 mg/d, urine volume 
1.9± 0.8 L/d and UOx 102±55 mg/d. Twenty-one (64%) subjects overall were on 
calcium and/or citrate supplements, thiazides, allopurinol and/or pyridoxine. Among the 
28 participants who provided KS medical history, 93% had at least one KS episode in past 
5 years. Among the 20 participants who had a CT scan, 16 (80%) had at least one KS and 
8 (40%) had KS in both kidneys; on average participants had 3 KS. Notably, 4 (20%) had 
KS >10 mm and 8 (40%) had KS 5-10 mm in size.
Conclusions: Despite standard interventions, patients with EH had persistently high 
UOx. In addition, a substantial KS burden was found on CT; many patients had multiple 
KS, including some with larger KS that could require urological intervention. Both HOx and 
KS burden are risk factors for progressive loss of kidney function. Our analysis highlights 
a significant unmet need in the EH population, and the current ALLN-177 development 
program is focused on addressing this.
Funding: Commercial Support - Allena Pharmaceuticals
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Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients
Lama Nazzal,1 Menghan Liu,1 Barbara M. Seide,3 Mary Mcintosh,5 
Ignacio Granja,4 John R. Asplin,4 Melody Ho,1 Dawn S. Milliner,3 
David S. Goldfarb,1,2 Martin J. Blaser.1 The Rare Kidney Stone Consortium 
1New York University School of Medicine, New York, NY; 2New York Harbor 
VAMC, Hastings on Hudson, NY; 3Mayo Clinic, Rochester, MN; 4Litholink 
Corp, Chicago, IL; 5University of Arizona College of Medicine, Tucson, AZ.
Background: About 60–80% of kidney stones are composed of calcium oxalate 
(CaOx); idiopathic CaOx kidney stones (CaOPx), primary hyperoxaluria (PH) and enteric 
hyperoxaluria (EH) are diseases predisposing to stones. Oxalobacter formigenes (Oxf) is 
a human gut commensal that depends on oxalate for its carbon and energy, and may be 
protective against CaOx stones. We hypothesize that the microbiome community structure 
differs between patients with CaOx, PH, EH and normal subjects (NS). We also expect 
that Oxf isolates from PH patients will result in further reduction in urinary oxalate when 
compared to Oxf reference strain CC13, in a germ-free (GF) mouse model.
Methods: We collected fecal specimens from 34 subjects (mean age: 39.1 ± 11.9 years) 
with PH (n=6), CaOPx (n=10), EH (n= 5) and NS (n=13) in a cross-sectional observational 
study, and tested fecal samples from the groups by: 1)16S rRNA sequencing to determine 
the microbiome community structure, 2)PCR and qPCR for Oxf colonization and, 3)
culturing in high oxalate selective media for indication of Oxf presence and subsequent 
isolation. We isolated Oxf from 4 PH (Oxf PH) subjects. We gavaged a growing culture 
of PH Oxf (n=6), Oxf reference strain CC13 (Oxf CC13) (n=5), and sham (n=6) into adult 
C5B6 GF mice, observing them for 4 weeks. We collected urine from mice for 48 hours 
before sacrifice to be tested for oxalate and creatinine (Uox/cr).
Results: Oxf was detected in 6 (46%) of 13 NS, 1 (10%) of 10 CaOPx, 0 (0%)of 4 
EH, and 5 (83%) of 6 PH. Microbiome analysis revealed that the 4 groups differed in beta 
diversity, based on Bray-Curtis dissimilarity (p=0.08). Alpha diversity analysis trended 
toward lower Shannon and phylogenetic diversity index in the CaOPx and EH subjects 
compared to PH and NS. Introducing the PH Oxf to GF mice led to lower Uox/cr than in 
uninoculated controls (0.68 ± 0.14, and 2.26 ±0.49, respectively, p=0.04 by Mann-Whitney 
U test), but not significantly different from the Oxf CC13-innoculated mice (0.68 ± 0.14, 
and 0.91 ±0.24, respectively, p=0.26 by Mann-Whitney U test).
Conclusions: These studies provide evidence of differences in Oxf colonization rates 
and in microbiome composition in patients with CaOx stones and show the functional 
capacity of a PH Oxf strain to ameliorate hyperoxaluria. Studies to expand these patient 
groups are on-going.
Funding: NIDDK Support, Private Foundation Support
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Pharmacokinetics and Pharmacodynamics of SNF472 in Calciphylaxis 
Patients: Results from a Phase 2 Clinical Trial (SNFCT2015_04)
Carolina Salcedo,2 Miquel D. Ferrer,2,1 Maria del mar Perez,2 Ana-
Zeralda Canals,2 Joan Perelló.2,1 1University of the Balearic Islands, Palma, 
Spain; 2Laboratoris Sanifit, Palma de Mallorca, Illes Balears, Spain.
Background: SNF472 is a selective calcification inhibitor that interferes in the 
formation and growth of hydroxyapatite crystals. It is being developed for the treatment of 
calciphylaxis (CUA), a severe form of vascular calcification that affects the small vessels 
under the skin in patients with end-stage renal disease on hemodialysis (HD).
Methods: This was an open label, single arm trial investigating the effect of SNF472 
on top of standard of care in the treatment of CUA in HD patients. Patients were treated for 
12 weeks with intravenous 6-9 mg/kg of SNF472 three times per week during each dialysis 
session. The dose (400, 450, 700 or 900 mg) was adjusted by body weight categories. 
SNF472 levels were measured in plasma samples obtained pre-HD (baseline) and at the end 
of SNF472 infusion on the first and the last treatment sessions. Another aliquot of plasma 
was used to measure ex-vivo the propensity of plasma to induce calcium phosphate (CaP) 
crystallization as a pharmacodynamic (PD) measurement.
Results: The study enrolled 14 patients with 11 completing the treatment. The 
maximum SNF472 concentration in plasma was 29.1 ± 19.1 μM in week 1 and 
26.3 ± 21.3 μM in week 12. There was no accumulation of SNF472 or any effect of repeated 
administration for up to 12 weeks in the exposure to the compound, confirming the results 
of a previous phase 1b trial in HD patients. The ex-vivo induction of CaP crystallization 
was inhibited up to 65 ± 14% after treatment with SNF472 (week 1) and up to 60 ± 29% at 
week 12. No differences attributable to the doses tested were observed concerning the PD 
effect, as all doses were on the plateau of the effect. These results were in accordance with 
the previous data seen in the Phase 1b trial. No inhibition of crystallization was evidenced 
in one patient that did not present detectable SNF472 levels (<0.76 μM) after treatment at 
week 12, showing a relationship between SNF472 circulating levels and PD.
Conclusions: These results suggest that the administration of SNF472 to CUA patients 
on HD allows to attain potentially therapeutic levels, as evidenced by both its circulating 
levels and the inhibition of ex-vivo calcification induction.
Funding: Commercial Support - Laboratoris Sanifit
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The Novel Bone Alkaline Phosphatase Isoform B1x in Serum Identifies 
Patients with Calciphylaxis on Vitamin K Antagonist Treatment
Mathias Haarhaus,1,2 Vincent Brandenburg,3 Markus Ketteler,4 Rafael Kramann,5 
Per Magnusson.2 1Dep. of Renal Medicine, CLINTEC, Karolinska University 
Hospital, Karolinska Institutet, Stockholm, Sweden; 2Department of Clinical 
Chemistry, Linköping University, Linköping, Sweden; 3Department of 
Cardiology, Nephrology and Intensive Care Medicine, Rhein-Maas Klinikum, 
Würselen, Germany; 4Klinikum Coburg GmbH, Coburg, Germany; 5RWTH 
Aachen University, Aachen, Germany.
Background: The novel bone alkaline phosphatase (BALP) isoform B1x is only 
detectable in serum from patients with advanced chronic kidney disease (CKD) or end-
stage renal disease. B1x has been proposed as a marker for low bone turnover, furthermore, 
B1x activity increases in calcifying vascular smooth muscle cells. Vitamin K antagonists 
(VKA) prevent activation of the potent vascular calcification inhibitor matrix Gla protein. 
VKA is associated with an increased risk for calciphylaxis (calcific uremic arteriolopathy, 
CUA), a rare and often fatal complication associated with severe calcification of arterioles. 
The objective was to study the appearance of B1x in serum from CKD patients with CUA.
Methods: Seventeen CKD patients with CUA (15 on hemodialysis, 1 transplanted, 1 
pre-dialysis) were recruited from the European Calciphylaxis Network. Serum total ALP 
was determined by a kinetic assay and the BALP isoforms (B/I, B1, B1x and B2) by high-
performance liquid chromatography. Fetuin A, intact parathyroid hormone (iPTH), total 
BALP (ELISA), C-reactive protein, sclerostin, C-terminal fibroblast growth factor 23, 
tartrate-resistant acid phosphatase type 5b (TRAP5b), osteoprotegerin, 25-OH vitamin D, 
total calcium (Ca) and phosphate were also assessed.
Results: B1x was detected in 10 patients (56%). These patients were more often 
treated with VKA (7 VKA patients B1x positive, vs 1 VKA patient B1x negative), had a 
more frequent history of myocardial infarction, lower total ALP (P=0.025), lower BALP 
(P=0.025), lower BALP isoform B1 (P<0.001) and lower total Ca (P=0.014) in serum. 
There was a tendency towards lower iPTH and lower TRAP5b (P=0.055 for both).
Conclusions: Patients with B1x were more often treated with VKA. Circulating bone 
markers indicate an association of B1x with low bone turnover. We hypothesize that VKA 
induce a specific subtype of vascular calcification, which is different from non-VKA-users. 
Based on the BALP isoform analysis, subgroups of CUA could be identified, which might 
also reveal differences in terms of bone metabolism.
Funding: Commercial Support - Amgen, Government Support - Non-U.S.
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Improvements in Calcific Uremic Arteriolopathy Wound Healing During 
SNF472 Treatment Assessed with the BWAT-CUA
Smeeta Sinha,1 Lisa Gould,2,3 Vincent Brandenburg,4 Glenn M. Chertow,5 
Stephan Miller,6 Rekha Garg,6 Alex Gold,6 Joan Perelló.7 1Salford Royal NHS 
Foundation Trust, Salford, United Kingdom; 2South Shore Hospital Center for 
Wound Healing, Weymouth, MA; 3Department of Medicine, Brown University, 
Providence, RI; 4University Hospital, Aachen, Germany; 5Nephrology Division, 
Stanford University School of Medicine, Palo Alto, CA; 6Sanifit, San Diego, CA; 
7Laboratoris Sanifit, Palma de Mallorca, Spain.
Background: Calcific uremic arteriolopathy (CUA/calciphylaxis) in patients with 
end-stage renal disease is a severe form of vascular calcification characterized by painful 
necrotic skin ulcers and very high mortality. No approved therapies are available. The 
investigational drug SNF472 is an intravenous formulation of myo-inositol hexaphosphate 
that inhibits formation and growth of hydroxyapatite crystals, the final common step in the 
pathophysiology of vascular calcification. A recent open-label, single-arm, 12-week Phase 2 
trial of SNF472 in patients with CUA receiving hemodialysis demonstrated statistically and 
clinically significant improvements from baseline to end-of-study in wound healing, pain, 
and wound-related quality of life (NCT02790073).
Methods: 14 patients with CUA were treated with SNF472 thrice weekly during each 
hemodialysis session for up to 12 weeks. We assessed effect on wound healing with the 
Bates-Jensen Wound Assessment Tool (BWAT), a 13-item, objective, quantitative tool 
originally developed and validated for the assessment of pressure ulcers. Based on the 
expert opinion of specialists in plastic surgery, wound care, and nephrology (all experienced 
in the care of patients with CUA) we derived a targeted modification of the BWAT using 8 
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items focused on prototypical features of CUA lesions: necrotic tissue type, necrotic tissue 
amount, exudate type, exudate amount, skin color surrounding wound, peripheral tissue 
edema, peripheral tissue induration, and granulation tissue.
Results: Mean (SE) BWAT-CUA improved from 21.2 ± 2.0 at baseline to 14.9 ± 1.4 
at Week 12 (p<0.002). Among the individual BWAT items, the largest improvements were 
observed for peripheral tissue induration, skin color surrounding wound, and granulation 
tissue.
Conclusions: BWAT-CUA is an objective and quantitative tool targeted for evaluation 
of CUA lesions and will be used in the upcoming Phase 3 randomized controlled trial of 
SNF472 for CUA.
Funding: Commercial Support - Sanifit
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National Trends in Hospitalization in the US Calciphylaxis Population 
from 2007 to 2014
Pablo Garcia,2,1 Paris Charilaou,1 Xavier F. Parada,3 Mario R. Funes-Hernandez,4 
Sagar U. Nigwekar.3 1Saint Peter’s University Hospital, New Brunswick, NJ; 
2Nephrology, Stanford University, Palo Alto, CA; 3Massachusetts General 
Hospital, Boston, MA; 4Saint Peter’s University Hospital, Somerset, NJ.
Background: Calciphylaxis is a rare syndrome of vascular calcification characterized 
by occlusion of microvessels in the subcutaneous adipose tissue and dermis, resulting in 
painful, ischemic skin lesions. The definitive diagnosis is made by confirming the presence 
of calcified dermal arterioles on a skin biopsy in a patient with clinical suspicion for 
calciphylaxis. In this study we describe the trends and patient distribution and characteristics 
of calciphylaxis in the US inpatient population from 2007-2014.
Methods: We included all adult discharges from the National Inpatient Sample (NIS) 
from 2007-2014, from large (>=325 beds) teaching hospitals, excluding cases with missing 
data on age, gender, or inpatient mortality. We used a previously published algorithm to 
identify patients with calciphylaxis from the NIS. This algorithm applies the ICD-9-CM 
diagnosis code 275.49 “Other Disorders of Calcium Metabolism” in combination with the 
ICD-9 code 86.1.
Results: We identified 1576 probable calciphylaxis discharges from 2007 to 2014, with 
69% patients on dialysis of which 90% where patients on HD, 54.8% were white and 70.5% 
were females. Mean age was 59 years (95% CI: 57 to 61 years). 35% belonged in the lowest 
income quartile and 17% belonged to the upper quartile in the US. Most patients were 
located in the Southern (39.8%) and Midwest (29%) Region of the US. 49% of the patients 
had DM, 19% were obese, 78% had HTN and 26% had A-Fib. Overall inpatient mortality 
was 7.9%. The median length of stay was 11 days (range 0-98) and mean hospitalization 
cost was $31467 ±$2127. We found that 63% patients were discharged to rehab, skilled 
nursing facility or home with nurse care and 37% went home.
Conclusions: Calciphylaxis was more prevalent in females. One third of the patients 
belonged to the lowest income quartile. Most of the patients with calciphylaxis were located 
in the Southern and Midwest Region. Most of the patients were discharged to rehab, skilled 
nursing facility or home with nurse.
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Modeling Decision Making for IV Vitamin D Titration in Patients on 
Hemodialysis (HD)
Rasheeda K. Hall,1 Jonathan A. Wilson,1 Alyssa C. Platt,1 Patti Ephraim,3 
Daniel E. Weiner,2 L. Ebony Boulware,1 Jane F. Pendergast,1 Julia J. Scialla.1 
1Duke University, Durham, NC; 2Tufts Medical Center, Boston, MA; 3Johns 
Hopkins University, Baltimore, MD.
Background: Studies in HD often focus exclusively on parathyroid hormone (PTH) 
as the driver of intravenous (IV) vitamin D titration. We hypothesized that a constellation 
of mineral metabolism (MM) laboratories (labs), including calcium (Ca), phosphorus (Pi) 
and PTH, influence titration.
Methods: We retrospectively studied 62,284 decisions in 5442 patients initiating in-
center HD between 2006-2008 in Dialysis Clinic, Inc. facilities with non-missing data. We 
used multinomial transition mixed models to predict increase, decrease or no change in IV 
vitamin D based on monthly albumin-corrected Ca, Pi, and PTH using piecewise linear 
functions with knots at 8.0 and 10.2 mg/dl for Ca, 3.5 and 5.5 mg/dl for Pi, and 150 and 300 
pg/ml for PTH, 3 sets of lagged monthly lab values, and interactions between current labs 
to capture a fully integrated lab phenotype. Adding piecewise functions and lab interactions 
improved fit as reflected in AIC (66,282 vs. 80,084).
Results: Participants contributed a mean ± SD of 9.3 ± 8.5 treatment months. The 
PTH threshold at which IV vitamin D is more likely to be increased than decreased is the 
intersection of solid (probability of increase) and dashed (probability of decrease) lines 
(Figure). This threshold PTH is higher when Ca and Pi were higher, demonstrating that Ca 
and Pi influence providers’ effective PTH titration goal. Titration or addition of alternative 
therapies, such as cinacalcet, are not depicted here, but are also impacted by integrated lab 
phenotypes (data not shown).
Conclusions: Prescribers consider multiple lab dimensions when titrating IV vitamin 
D. Comparative effectiveness studies and trials in MM may be improved by appropriately 
capturing complex lab phenotypes that contribute to decision-making.
Funding: NIDDK Support
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Free 25(OH) Vitamin D and Mortality Among Hemodialysis Patients
Etienne Novel-Catin,1 Laetitia Koppe,1,4 Anaïs Bouchara,1 Marie-
christine Carlier,1 Myriam Pastural,3 Granjon Samuel,2 Jean-christophe Szelag,3 
Maurice Laville,1 Denis Fouque,1,4 Solenne Pelletier.1 1University Center 
Hospital - Lyon Sud, Saint Priest, France; 2Cerballiance laboratory, Lyon, 
France; 3AURAL, LYON, France; 4CarMeN laboratory INSERM U1060, 
F-69621 Villeurbane, France.
Background: Most of the circulating 25-(OH) vitamin D (abbreviated 25(OH)D) is
bound to proteins. Free vitamin D represents only 1% of the circulating vitamin D. There 
is abundant evidence that this free faction is the bioactive form of vitamin D. Total 25(OH)
D deficiency has been associated with early mortality and cardiovascular events (CV) in 
chronic kidney disease (CKD) patients. The aim of the present study was to investigate 
a potential association between serum free 25(OH)D levels and i) other biochemical 
parameters of mineral metabolism, (ii) CV events and (iii) mortality.
Methods: 253 patients undergoing maintenance hemodialysis (HD) were included. 
Serum free 25(OH)D measurement by ELISA (Diasource® Leuven, Belgium) as well as 
routine biochemistry tests were performed. Enrolled patients were prospectively monitored 
for cardiovascular (CV) events and mortality.
Results: During a mean study period of 2.5 years, 48 patients died and 60 suffered 
from a CV event. Median serum free 25(OH)D was 6.01 pg/ml [4.67 – 7.39] and median 
total 25(OH)D was 32.2μg/l [24.8-39.9]. Free 25(OH)D was strongly associated with total 
25(OH)D (r= 0.77, p < 0.01). Free 25(OH)D was positively associated with serum calcium 
levels (r= 0.29, p<0.01) and negatively with serum PTH (r= - 0.19, p<0.01). Kaplan-Meier 
analysis showed no significant association between below median free 25(OH) and all-
cause mortality (log rank, p=0.25, see figure 1) nor CV events (log rank, p=0.91).
Conclusions: This is the first study reporting survival depending on free 25(OH)D 
status in maintenance dialysis patients. It shows that free 25(OH)D levels are not associated 
with mortality nor cardiovascular events among maintenance HD patients. Our data concur 
with precedent results showing that bioavailable vitamin D is positively associated with 
calcium levels and negatively associated with serum PTH.
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Relationship Between Bioelectrical Impedance Body Composition and 
CKD-MBD in Dialysis Patients
Eduardo J. de Sa Carneiro Filho,2 Shirley F. Crispilho,1 Lilian Cordeiro,2 
Maria Dalboni,1 Rosilene M. Elias,2,1 Rosa M. Moyses.2,1 1Universidade Nove de 
Julho, São Paulo, Brazil; 2Universidade de Sao Paulo, Sao Paulo, Brazil.
Background: Recent studies have assessed body composition through multifrequency 
bioelectrical impedance analysis (MF-BIA). However, none has employed this technique to 
test the associations of CKD-MBD with body composition. As recent experimental studies 
have linked hyperparathyroidism with an increase in energy expenditure, it is important to 
validate this hypothesis in a clinical scenario.
Methods: In a transversal study, we evaluated 160 prevalent dialysis patients 
(hemodialysis, HD = 99; peritoneal dialysis, PD = 61) through whole-body and segmental 
composition and correlated MF-BIA with CKD-MBD parameters.
Results: Patients were 49 years old (range 18-90), with BMI = 24.6 kg/m2 (13.3-
49.3), fat mass (FAT) = 17.8 kg (1.1-61.5), muscular mass (MUSC) = 25.6 kg (10.1-45.4), 
bone mineral content (BMC) = 2.78 kg (2.43-3.30). In PD patients, serum 25 vitamin 
D correlated with MUSC (r= 0.41 p = 0.002) and BMC (r = 0.42 p =0.002). Alkaline 
phosphatase correlated negatively with FAT (r = - 0.30. p 0.02). No significant correlations 
were found for parathormone, calcium, phosphate or albumin. In HD patients, we did not 
find any significant correlation between MF-BIA and CKD-MBD parameters.
Conclusions: Assuming the accuracy of MF-BIA, in PD patients, higher serum vitamin 
D levels were associated with lower risk of sarcopenia and low bone mineral density, 
whereas higher alkaline phosphatase was linked with lower fat mass. Future prospective 
studies should evaluate whether cholecalciferol supplementation and hyperparathyroidism 
control could improve muscle, bone and fat masses in these patients.
Funding: Government Support - Non-U.S.
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Efficacy of High versus Conventional Dose of Ergocalciferol Supplementation 
on Serum 25-Hydroxyvitamin D and Interleukin-6 Levels in Hemodialysis 
Patients with Vitamin D Deficiency
Wittaya Siricheepchaiyan, Pamila Tasanavipas, Theerasak Tangwonglert, 
Naowanit Nata, Amnart Chaiprasert, Ouppatham Supasyndh, Bancha Satirapoj. 
Phramongkutklao Hospital, Bangkok, Thailand.
Background: Vitamin D deficiency alters innate and adaptive immune function, 
which will increase inflammatory cytokines production. Long-term dialysis is chronic 
inflammatory state and it has high prevalence of vitamin D deficiency. Trials examining the 
efficacy, and dosage of ergocalciferol supplementation in end stage renal disease (ESRD) 
on hemodialysis have been limited.
Methods: A multicenter, randomized, controlled trial was conducted in ESRD 
on hemodialysis with serum 25-hydroxyvitamin D (25[OH]D) level < 30 ng/mL. 
The conventional-group (N=35) and the high-dose group (N=35) were treated with 
ergocalciferol according to the K/DOQI guidelines and double dosage of ergocalciferol 
from the recommendation for 8 weeks, respectively. The main outcomes were measured by 
serum 25[OH]D, IL-6, calcium, and phosphorus levels.
Results: At the end of 8-week, there was a statistically significantly greater increase of 
mean serum 25[OH]D levels in the high-dose group compared with the conventional-dose 
group (17.8 ng/mL [95%CI 15.8 to 19.7] vs. 9.2 ng/mL [95%CI 7.4 to 11.1], P<0.001) 
and the high-dose group had also higher achievement of vitamin D sufficiency (25[OH]D 
level >30 ng/mL) than the conventional-dose group (97.4% vs. 76.4%, P=0.012). A trend 
toward lower serum IL-6 levels in the high-dose group (-0.45 pg/mL [95%CI -3.57 to 2.68], 
P=0.772) and there was a statistically significance lower serum IL-6 levels in the subgroup 
who had baseline serum 25[OH]D levels < 20 ng/mL (-2.67 pg/mL [IQR -6.56 to -0.17], 
P=0.039). There were no differences between the two groups in changes in serum calcium, 
phosphorus levels, and adverse events.
Conclusions: Oral high-dose ergocalciferol supplementation has achieved higher 
vitamin D sufficiency than standard recommendation dose in ESRD patients on dialysis 
with vitamin D deficiency. It might also be benefit on reduction of the inflammatory 
cytokine in group of patients with baseline serum 25[OH]D levels < 20 ng/mL.
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Evaluation of Long Term Supplementation with Cholecalciferol on the 
Levels of 25-Hydroxyvitamin D (25[OH]D) and on Bone Turnover 
Biomarkers of Chronic Hemodialysis Patients
Andreas Bozikas,1 Iliana Kiriakoutzik,1 Eleni Kitoukidi,1 Pinelopi Pisanidou,1 
Styliani Vakiani,1 Antigoni Martika,1 Nikolaos Georgilas,1 Panagiotis Pangidis,1 
Konstantinos Tsitouridis,3 Asimoula Koteli,2 Sofia Spaia.1 1Nephrology, General 
Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece; 2Microbiology, 
General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece; 3Radiology, 
General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece.
Background: We addressed the safety of long term supplementation with 
cholecalciferol in maintenance hemodialysis patients along with its effect on markers of 
bone and mineral metabolism.
Methods: Sixty stable hemodialysis patients, initially, received a dose of 1200 
IU of cholecalciferol orally, once daily, every 48 hours, for 18 months. This dose was, 
subsequently, increased to 1200 IU, once daily for another 6 months. 25[OH]D levels 
were measured at 0, 4, 12, 18, and 24 months along with Ca, P, ALP, iPTH, HbA1c levels 
and BMI. Additionally, all patients had a T – score evaluation by dual – energy x – ray 
absorptiometry (DXA) at the beginning of the study and after 12 and 24 months.
Results: All patients proved to be 25[OH]D deficient, regardless that measurements 
were done during the summer period (increasd sunlight). There was no correlation of 
the low 25[OH]D levels with age, sex, time on hemodialysis and HbA1c levels, but they 
did correlate to BMI, implicating diet as a source of 25[OH]D. Likewise, we observed 
no correlation with the administration of phosphate binders, statins or vitamin D receptor 
activators. Alternate day supplementation improved 25[OH]D levels, which evolved from 
the deficient level to stage of insufficiency (p<0.01). Daily administration – after 18 months 
– was achieved by 46 patients (76%). Annual screening of bone density revealed gradual
amelioration of T – score (p<0.01). No significant changes of the other markers were 
observed.
Conclusions: In conclusion, the very low levels of calcidiol in dialysis patients should 
draw considerable attention. A “safe” threshold of 20 ng/ml was achieved by choosing the 
alternate day supplementation of 1200 IU of cholecalciferol, with no particular financial 
burden and succeeding compliance. The positive effect on bone density which was shown 
in this long term study regards more extended research. Although supplementation with 
calcidiol is not considered to be an essential treatment, yet, we consider that there are 
sufficient data to support long term supplementation of 25[OH]D for maintenance dialysis 
patients.
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Paricalcitol and Renal Anemia: A Novel Association Beyond Inflammation
Miguel Uriol Rivera,1 Angel Garcia-Alvarez,2 Manuel Luque-Ramírez.3 
1Hospital Universitario Son Espases, Palma de Mallorca, Spain; 2Hospital 
Comarcal de Inca, Inca, Spain; 3Hospital Universitario Ramón y Cajal, Madrid, 
Spain.
Background: The utilization of the paricalcitol (a selective vitamin d receptor activator) 
for the control of the secondary hyperthyroidisms (SHPT) and its antinflammatory properties 
have been associated with a better response to the erythropoietic stimulating agents(ESA). 
Whether the effect of the paricalcitol is directly associated with the erythropoiteic process 
and its influence on endogenous erythropoietin production is unknow. Objective: To 
evaluate the influence of the paricalcitol on the novel parameters associated with the 
erythropoiesis in anemic hemodialysis patients.
Methods: These are the results of the secondary objective of the MIR-EPO trial 
(EudraCT: 2009-015511-40). Study subjects were allocated to those treated with 
paricalcitol (group A: N=23) and those without it (group B, N=8). Plasma factors associated 
with inflammatory anemia (interleuquin-6 and hepcidin) and accelerated red blood cells 
death (eryptosis: soluble alpha-Klotho levels) were evaluated. Plasma erythropoietin and its 
main transcriptional factor: hypoxia inducible factor 2-alpha (HIF-2a)) were also evaluated 
during the evaluation period (from month 3 to 6).
Results: Five patients (22%) under paricalcitol stopped ESA by protocol (P=0.06). 
Lower IL-6 and higher s-klotho levels were observed in those under paricalcitol. 
Erythropoietin levels (median) increased significantly from 10 to 20 mUI/ml in patients 
under paricalcitol. The percentage of patients who increased HIF-2a at M6 with respect 
to M3 (35%) was also significantly only in the group A (P=0.01). After adjusting by IL-6 
levels, HIF-2a increased in the group A (0.40 pg/ml,log P=0.030), but did not change in the 
group B (-0.31 pg/ml,log P=0.340). Free serum iron and transferrin saturation index changes 
correlate negatively with changes on IL-6 and positively with s-Klotho changes.
Conclusions: The use of the paricalcitol may improves the erythropoiesis process 
through direct effect on erythropoietin/HIF-2a axes stimulation. Our results suggest an 
important influence of the vitamin D selective activation on iron metabolism, erythropoietin 
synthesis and could be on eryptosis process. Larger controlled studies are needed to confirm 
these findings for potential benefit of the paricalcitol for renal anemia control.
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Renal Complication and Mineral Ion Abnormalities in Patients with 
Jansen Metaphyseal Chondrodysplasia
Hiroshi Saito,1,2 Harald Jüppner.1,2 1Massachusetts General Hospital, Boston, 
MA; 2Pediatric Nephrology Unit, Harvard Medical School, Boston, MA.
Background: Jansen metaphyseal chondrodysplasia (JMC) is a rare disease that 
is caused by heterozygous, activating mutations in the PTH/PTHrP receptor (PTHR1). 
Expression of PTHR1 mutants in growth plate chondrocyte impairs their maturation 
leading to marked skeletal abnormalities. Because the PTHR1 is also expressed in kidney 
and bone, JMC patients can develop PTH-independent hypercalcemia, hypophosphatemia, 
and high bone turnover, and thus nephrocalcinosis and impaired renal function. Long-term 
outcome of multiple JMC patients was recently reported (Saito et al., JCEM, 2018). We now 
emphasize the renal abnormalities associated with JMC.
Methods: Clinical and laboratory findings in 24 patients with JMC due to five different 
PTHR1 mutations (H223R, T410P, T410R, I458R, and I458K).
Results: During the first 2 weeks of life, calcium levels were normal in most patients. 
During childhood hypercalcemia was severe (11.8±1.4 mg/dL), but improved by adulthood 
(10.0±1.0 mg/dl). Phosphate and PTH levels were at the lower end of normal ranges. 
Urinary Ca/Cr (mg/mg) were consistently elevated (children, 0.8±0.4; adults, 0.3±0.2; 
normal:<0.2). Growth was severely impaired resulting in adult heights well below the 3rd 
percentile; furthermore, scoliosis and other skeletal deformities were noted. Most young 
JMC patients had nephrocalcinosis, but normal renal function. Two middle-aged patients 
revealed continuously worsening renal function, probably secondary to stag horn renal 
calculi, recurrent UTIs, and urinary tract obstructions.
Conclusions: Activating PTHR1 mutations are associated with persistently increased 
urinary calcium excretion, which is caused by the PTH-independent hypercalcemia. 
Hypercalciuria contributes early in life to nephrocalcinosis, which leads in adults to a 
decline in renal function. Treatment with bisphosphonates to reduce bone resorption may 
limit calcium excretion to slow the progression of chronic kidney disease. Although an 
inverse PTH agonist, namely [L11,dW12,W23,Y36]PTHrP(7–36), reduced basal cAMP 
signaling of the mutant PTHR1s in vitro, it remains to be determined whether such peptides 
have therapeutic potential.
Funding: Other NIH Support - National Institutes of Health; DK11794 (PO1); 
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Risk Factors Associated with Hyperparathyroidism in Maintenance 
Hemodialysis Patients
Sinee Disthabanchong. Division of Nephrology, Faculty of Medicine, 
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Background: The severity and progression of hyperparathyroidism (HPT) are different 
among individuals with end-stage-renal disease. Factors other than decreased 1,25-OH-D 
level and phosphate retention likely participate in the severity and progression of HPT. The 
present study identified risk factors associated with the progression of HPT as well as factors 
associated with parathyroid hormone (PTH) levels above the KDIGO’s recommended 
range in maintenance hemodialysis patients.
Methods: Five hundred and one patients were included. Exclusion criteria were 
previous parathyroidectomy or taking calcimimetic. Changes in PTH levels over 24 months 
were categorized into 4 patterns as follows, “progression” (increase in PTH levels >= 50%), 
“reduction” (decrease in PTH levels > 50%), “fluctuation” (changes in PTH levels >= 50% 
in BOTH directions) and “stable” (changes in PTH levels < 50% in either directions).
Results: 29% of PTH values were > 9 times, 22% were < 2 times and 49% were between 
2-9 times of the upper normal limit (UNL). Progression of HPT occurs in 32%, reduction
in 19%, fluctuation in 21% and stable in 28% of the patients. The progression group was 
more likely to have PTH levels > 300 pg/mL, whereas the fluctuation and reduction groups 
were more likely to have PTH levels <= 300 pg/mL. Factors associated with the progression 
of HPT were younger age, non-diabetics, suboptimal insurance program (limited access to 
non-calcium binders and newer drugs), higher PTH levels and higher serum phosphate.
Factors associated with PTH levels > 9 times the UNL were younger age, not having DM, 
CVD and DLP, prolonged dialysis vintage, suboptimal insurance program, higher active
vitamin D dose, higher serum phosphate, albumin and creatinine.
Conclusions: Young healthy patients (not having CVD risks including DM and DLP) 
with better overall health status (higher serum albumin, phosphate and creatinine) are likely 
to experience the progression of HPT overtime. Prolonged dialysis vintage and suboptimal 
insurance program also play substantial roles in the increase in PTH level above the 
KDIGO’s recommended range.
Funding: Government Support - Non-U.S.
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Association of Secondary Hyperparathyroidism with Thymic Atrophy in 
Patients with CKD
Kenichiro Iio,1 Rei Iio,3 Takayuki Hamano,2 Yoshitaka Isaka,2 Yutaka Ando.1 
1National Hospital Organization, Osaka Minami Medical Center, 
Kawachinagano, Japan; 2Osaka University Graduate School of Medicine, 
Suita, Japan; 3Osaka General Medical Center, Osaka, Japan.
Background: Immune aging, including thymic atrophy, is accelerated in patients 
with chronic kidney disease (CKD) and can lead to cardiovascular and infectious 
diseases. However, the mechanism of thymic atrophy is not well understood. Mineral 
and bone disorders (MBD) affect mortality through bone-related factors and blood vessel 
calcification; parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) also 
affect immune cells and possibly thymic atrophy.
Methods: We examined the cross-sectional association between thymic atrophy, 
evaluated as the number of CD3+CD4+CD45RA+CD31+ cells [recent thymic emigrants 
(RTE)/μL], and MBD-related factors (PTH, FGF23, and alkaline phosphatase) in patients 
with non-dialysis-dependent CKD.
Results: This study enrolled 125 patients with CKD (median eGFR, 17 mL/min/1.73 m2). 
Age (r = −0.46) and male sex (r = −0.34) correlated negatively and eGFR (r = 0.27) 
correlated positively with RTE. In terms of MBD-related factors, corrected calcium 
(r = 0.27) correlated positively whereas PTH (r = −0.36) and alkaline phosphatase 
(r = −0.20) correlated negatively with RTE. In contrast, FGF23 and phosphorus were not 
correlated with RTE. Multivariate non-linear regression analysis adjusted for age, sex, 
eGFR, diabetes, corrected calcium, phosphorus, vitamin D supplementation, and use of 
phosphate binder indicated a negative association between PTH and log-transformed RTE 
(P = 0.030, P for non-linearity = 0.124). However, FGF23 and alkaline phosphatase were 
not associated with RTE.
Conclusions: Secondary hyperparathyroidism appears to be related to thymic atrophy, 
contributing to immune abnormalities in patients with CKD. Our findings may partially 
explain the mechanism through which PTH is associated with mortality.
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Serum 1,25-Dihydroxyvitamin D Concentrations in Maintenance 
Hemodialysis Patients: In the Era of CKD-MBD Guideline
Eiji Ishimura,1,2 Shinya Nakatani,3 Senji Okuno,4 Shuko Ueda,1 
Nobuyuki Kuwamura,1 Yukihiro Nin,1 Tetsuya Makino,1 Ryusuke Kakiya,1 
Masaaki Inaba.3 1Meijibashi Hospital, Matsubara, Osaka 580-0045, Japan; 
2Osaka City University Graduate school of Medicine, Abeno-ku, Japan; 3Osaka 
City University Graduate School of Medicine, Osaka, Japan; 4Shirasagi 
Hospital, Osaka, Japan.
Background: In hemodialysis (HD) patients, serum levels of 1,25-dihydroxyvitamin D 
(1,25D), an active form of vitamin D, are low; however, 1,25D, even in low, was reported to 
play an important role in HD patients (Ando R et al, J Jap Soc Dial Ther 1996). Currently, 
little is known about serum 1,25D concentrations in HD patients, particularly in the era of 
CKD-MBD guideline. We measured serum 1,25D concentrations in stable HD patients, and 
examined their association with clinical factors.
Methods: A total of 89 HD patients (71±11 year-old, 48 males, HD duration 9.4±7.4 
years, 36 with type 2 diabetes) were examined. Serum 1,25D was measured by a 1,25D 
RIA kit (Ishimura E et al. Kidney Int 1999), and intact PTH by a Elecsys PTH IRMA assay 
(Kurajoh M et al. Osteoporos Int 2008).
Results: Serum 1,25D concentrations were 14.4±8.0 pg/ml, being lower compared 
to those of healthy subjects. Serum 1,25D concentrations were significantly higher in 
males than in females (p=0.045). They were tended to be negatively correlated with age 
(r=-0.034, p=0.083) and HD duration (r=-0.042, p=0.055). Serum 1,25D concentrations 
were significantly, negatively associated with intact PTH (r=-0.085,p〈0.001), although 
they were not with serum calcium or phosphate. There were no significant differences in 
serum 1,25D between patients with (n=65) and without vitamin D treatment, and between 
those with (n=12) and without calcimimetics. However, serum 1,25D concentrations 
in patients with intravenous treatment of maxiacalcitol, an active form of vitamin D, 
(n=12) were significantly higher than those without (p=0.045). In a multiple regression 
analysis after adjustment of age, gender, HD duration, and vitamin D treatment, serum 
1,25D concentrations were significantly, independently associated with serum intact PTH 
(β=-0.310, p=0.003) (R2=0.200, p=0.002).
Conclusions: These results indicate that serum 1,25D, even in low, is significantly 
associated with intact PHT. The results also suggest that, even in the era of CKD-MBD 
guidelines, a clinical importance of serum 1,25D concentrations may be re-considered 
for the assessment of CKD-MBD, particularly in regards to prevention of secondary 
hyperparathyroidism. Intravenous, rather than oral, vitamin D treatment may be useful for 
treatment of secondary hyperparathyroidism.
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Secondary Hyperparathyroidism: Are KDIGO Guidelines for PTH 
Testing Being Followed?
Nicholas S. Roetker,1 James B. Wetmore,2 Yi Peng,1 Akhtar Ashfaq,3 
David T. Gilbertson.1 1Chronic Disease Research Group, Minneapolis, MN; 
2Hennepin County Medical Center, Minneapolis, MN; 3OPKO Health, Miami, FL.
Background: KDIGO recommends that patients with chronic kidney disease (CKD) 
undergo parathyroid hormone (PTH) testing beginning in CKD stage 3 followed by testing 
in stage 4 (every 6-12 months) and in stage 5 (every 3-6 months). KDIGO also suggests 
a role for 25-hydroxyvitamin D [25(OH)D] testing, although frequency is not specified. 
Adherence to these guidelines is unknown.
Methods: Using the 2007-2015 20% Medicare sample, we identified a cohort of 
patients with stage 3, 4, or 5 CKD. CKD stage was determined by presence of two or more 
claims with ICD-9-CM codes for CKD. Only patients with 30 or more days of follow-up 
were included. Frequency of 25(OH)D and PTH testing was identified using laboratory 
procedure codes. Factors associated with PTH testing by each CKD stage were then 
determined using separate logistic regression models.
Results: A total of 381,332 (stage 3), 86,875 (stage 4), and 14,401 (stage 5) CKD 
patients were identified. Over mean follow-up of 2.3 ± 1.8 (stage 3), 1.3 ± 1.3 (stage 4), and 
0.7 ± 0.9 (stage 5) years, 54% of stage 3, 61% of stage 4, and 70% of stage 5 patients were 
not tested for 25(OH)D deficiency; corresponding percentages for PTH were 66%, 56%, 
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and 52%, respectively (Table). Factors inversely associated with PTH testing were older 
age and presence of most comorbid conditions.
Conclusions: Testing for 25(OH)D deficiency was relatively infrequent. PTH testing 
was undertaken less than half as often as is recommend by KDIGO guidelines. This is 
potentially concerning, especially since recent data indicate it can be challenging to achieve 
PTH targets even with routine testing. How the uncertainty over optimal PTH targets in 
CKD, as discussed in the current KDIGO guidelines, will affect future testing patterns, 
should be studied.
Funding: Commercial Support - OPKO Pharmaceuticals, LLC
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Diagnosis of Renal Osteodystrophy by Bone Histomorphometry in 
Chronic Hemodialysis (HD) Patients
Suthanit Laowalert,1 Tanatorn Khotavivattana,1 Lalita Wattanachanya,2 
Pobe Luangjarmekorn,3 Suwasin Udomkarnjananun,4 Pisut Katavetin,5 
Paweena Susantitaphong,4 Somchai Eiam-Ong,4 Kearkiat Praditpornsilpa.4 
1Division of Nephrology, Bangkok, Thailand; 2endocrinology, King 
Chulalongkorn Memorial Hospital, Bangkok, Thailand; 3orthopedics, 
Chulalongkorn university, Bangkok, Thailand; 4Chulalongkorn University, 
Bangkok, Thailand; 5King Chulalongkorn Memorial Hospital, Thai Red Cross 
Society and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Management of secondary hyperparathyroidism has been evolving 
and requires more investigations. Currently, the relatively “wide” recommended target 
for intact parathyroid hormone (iPTH) level has proved to be reasonable only in limited 
circumstances. This study was conducted to determine the prevalence of various types of 
renal osteodystrophy in Thailand and to investigate the correlation between bone markers 
and bone histomorphometry to suggest an optimal iPTH level.
Methods: 22 chronic HD patients participated in this cross-sectional study. iPTH, serum 
calcium, phosphate and 25-hydroxyvitamin D and bone turnover markers including tartrate-
resistant acid phosphatase-5b (TRAP-5b) and bone specific alkaline phosphatase (B-ALP) 
were measured. Double tetracycline-labeled iliac crest bone specimens were evaluated for 
static and dynamic parameters by using specialized program (Osteomeasure®). The types 
of bone histomorphometry were classified based on turnover (T), mineralization (M), and 
volume (V) classification.
Results: Mean age and iPTH were 48±10 years and 523±238 pg/mL, respectively. 
Median dialysis vintage was 64 months. Adynamic bone disease was the most common 
bone abnormalities (50%), followed by osteitis fibrosa (40.9%) and mixed uremic 
osteodystrophy (9.1%). No evidences of osteomalacia and aluminum bone disease were 
detected. iPTH at the cutoff of 484.5 pg/mL predicted high bone turnover with an area under 
the receiver operating characteristic curve (AUROC) of 0.86 (95 % CI 0.70-1.0) with the 
sensitivity and specificity of 0.82 and 0.82 respectively.
Conclusions: Adynamic bone disease remains the most common bone disease among 
chronic HD patients in Thai population, albeit iPTH levels were close to the upper limit 
target of KDIGO guideline. Our study suggested that bone biopsy is required as an accurate 
diagnostic tool and providing guide for the treatment of chronic HD patients with renal 
osteodystrophy.
Funding: Government Support - Non-U.S.
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Parathyroidectomy (PTX) and Anemia in a Cohort of Italian Dialysis 
Patients
Sandro Mazzaferro.1,2 1Dept. Cardiovascular, Respiratory, Nephrology, 
Anesthetic and Geriatric Sciences, Sapienza University of Rome, Roma, Italy; 
2On behalf of the Italian Study Group of Mineral Metabolism, IT, Italy.
Background: Secondary hyperparathyroidism (SHP) negatively affects endogenous 
erythropoietin (EPO) synthesis, bone marrow erythroid progenitors, and red cell survival, 
thus contributing to anemia. PTX is generally thought to be followed by improved anemia 
control. However, low turnover bone disease (LTBD), a common finding after PTX, could 
negatively affect anemia. We compared anemic status and EPO therapy in two prevalent 
populations of dialysis patientswho received or not PTX
Methods: We enrolled both hemo- and peritoneal dialysis patients, aged ≥18 y, from 
149 Italian dialysis units. The control group (C) was selected to be comparable to the 
prevalent population of PTX patients for age, sex and dialysis duration. Local EC approved 
the protocol (N° 888/09).
Results: We obtained data of 527 PTX patients (age: 57.90±12.52 yo; M/F = 44/56%; 
D time: 14.5±8.4 y) and 432 C patients (age 58.9±16.5 y.o.; M/F = 45/55 %; D time 
11.7±2.6 y). PTH levels were lower in PTX (181.9±292.5 vs 333.7±293.7 pg/ml; p<.01), 
with 17 % and 35% respectively at KDOQI target (p<.001). In particular, cases with 
values <150pg/ml were 60% and 20% in the PTX and C groups respectively (p<.001). 
PTX patients were similarly less at target for Ca (50.9 vs 57.6, p<.001) and P (55.3 vs 
58.8%; p<.05). Hemoglobin levels (PTX=11.3±1.1vs C=11.3±1.1 mg/dl), hsCRP (PTX 
2.82±4.93 vs C=2.59±5.39 mg/dl) and ESR (PTX=32.29±23.98 vs C=36.46±24.49 mm/hr) 
were similar in the two groups. Ferritin values were higher in the C group (443.1±363.39 
vs 339.84±336.9mg/dl; p<.0001). Patients receiving ESA (either epoietin or darbepoietin) 
were significantly higher in the PTX group (80.9% vs 70%, X2=15.2; p<.001) while average 
doses of EPO (expressed as mean darbepoietin considering 1 mcg darbepoietin = 200 IU 
epoietin), were not different (PTX 0.34±0.25 vs C 0.33±0.25mcg/Kg/weekly).
Conclusions: Our data suggest that, in the long term, PTX does not associate with 
improved anemia. This is possibly due, in our population, to worse biochemical control of 
SHP, most frequently showing low PTH (indicative of LTBD). In conclusion, it seems thatit 
is more important the biochemical control of SHP than neck surgery to improve anemia in 
dialysis.
Funding: Commercial Support - Unrestricted grant by Amgen
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Clinical Outcomes and Costs of Parathyroidectomy in CKD Patients
Andrew J. Mallett,1,2 Scott Jones,1 Katharine Hegerty,1 Carla E. Scuderi,1 
Jesseca Eglington,1 Huan Zhang,1 Toni Broadbent,1 Ben Green.1 1Kidney Health 
Service, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 
2Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Background: Cinacalcet (CT) for treatment of secondary hyperparathyroidism (SHPT) 
in chronic kidney disease (CKD) was withdrawn in August 2016 from the Australian 
Pharmaceutical Benefits Scheme. We aimed to audit parathyroidectomy (PT) for SHPT in 
CKD, and, to compare PT costs to those of CT therapyin one tertiary Australian centre.
Methods: A retrospective audit of CKD patients with SHPT at a tertiary Australian 
centre who underwent PT between 1/1/11 and 31/6/17 (n=44) (HREC/17/QRBW/231). 
Median wait time to renal transplant in Australia is 2.4yrs (range 1.3-4.1yrs) thus centre-
specific total cost of 2.4yrs of CT therapy 60mg/day was calculated and compared to 
the total cost of PT based on hospital records, length of stay (LOS) and peri-operative 
complications (Cx).
Results: 34 and 11 PT were performed respectively in the 67months pre & 11months 
post August 2016. Median age and body mass index of patients undergoing PT were 51.5yrs 
(range 24-79yrs) and 29 (range 22-55). 30/34 patients were on dialysis. 5/34 patients were 
treated according to centre-specific pre-operative protocol. 18/34 patients were treated 
as per protocol post-operatively. 23/34 patients experienced post-operative Cx/s; ≥2 Cx 
in 52%. The median LOS post-PT was 6.5days (range 2-35days) with 32% of patients 
admitted to the intensive care unit. There was a 23.5% re-admission rate within 28 days 
of PT. All-cause mortality was 5% at 12months post-PT. A median of 5 outpatient reviews 
(range 0-37) were required before patients had two consecutive post-operative serum 
calcium results in normal range whilst on oral therapy. The median follow-up of patients 
post-PT was 25.5 months. The mean cost of CT ($13,149/patient) was less than the mean 
total cost of PT ($23,062/patient; range $11,375-53,279/patient). The median postoperative 
LOS was 7.51days (range 3.47-35.74days).
Conclusions: PT for SHPT in CKD patients is associated with a significant Cx, 
protocol non-adherence, re-admission rate and cost. There has been an overall increased 
annual rate of PT for SHPT in CKD patients. Further, we identified CT to be more cost-
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effective than PT as a treatment approach in CKD patients with SHPT. Optimised patient 
selection, protocol review and clinician engagement is indicated to guide best treatment 
for patients.
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An Examination of Multiple Explanations for Secondary 
Hyperparathyroidism
Kenneth R. Phelps,1,2 Darius Mason.3 1Research, Stratton VAMC, Albany, NY; 
2Medicine, Albany Medical College, Albany, NY; 3Pharmacy, Methodist South 
Hospital, Memphis, TN.
Background: We have advanced the tradeoff-in-the-nephron hypothesis to explain the 
evolution of secondary hyperparathyroidism (SHPT) in CKD (Nutrients 2017;9:pii:E427). 
The hypothesis states that a high phosphate (P) concentration in the cortical distal nephron 
([P]CDN) limits availability of calcium (Ca) for reabsorption and necessitates high [PTH] 
for maintenance of normocalcemia. With assumptions, P excreted per volume of filtrate 
(EP/Ccr) is a surrogate for [P]CDN to which [PTH] can be compared. In the present study, we 
used contemporaneous data to assess our hypothesis and others.
Methods: Fasting specimens of serum (s), plasma, and urine (u) were obtained from 
30 patients with stages 3 or 4 CKD (mean eGFR 29.5 mL/min/1.73m2). Concentrations 
of creatinine ([cr]), P, Ca, and ionized calcium ([Ca]i) were measured with standard 
methods. [PTH]1-84 and intact [FGF23] were measured with ELISAs (Scantibodies and 
Immutopics), [25OHD] with an enzyme immunoassay (immunodiagnosticsystems), and 
[1,25(OH)2D] with a radioimmunoassay (Labcorp). EP/Ccr and ECa/Ccr were calculated as 
[P]u[cr]s/[cr]u and [Ca]u[cr]s/[cr]u. Simple linear regressions were performed to examine 
theories of SHPT (see table).
Results: [PTH] varied directly with 100/eGFR, ECa/Ccr, [FGF23], and EP/Ccr. Other 
regressions were not significant.
Conclusions: The direct relationship of [PTH] to ECa/Ccr undermines the theory of 
skeletal resistance to PTH. The relationship to [FGF23] probably reflects dependence of 
FGF23 synthesis on PTH (Kidney Int 2017;92:165). The regression of [PTH] on EP/Ccr 
supports the tradeoff-in-the-nephron hypothesis. The regression also explains the inverse 
relationship of [PTH] to eGFR and the historic observation that influx of P determines 
[PTH] in CKD. Our data do not support other explanations for SHPT.
Funding: Veterans Affairs Support, Commercial Support - Sanofi-Genzyme
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Cost Effective Model for Bone Mineral Disease Management in Hemodial-
ysis Population in Qatar
Mohamed Y. Mohamed, Fadwa S. Al-Ali, Abdullah Hamad. Hamad Medical 
Corporation, Doha, Qatar.
Background: Hemodialysis population have multiple comorbidities with high 
morbidity and mortality. High calcium level contributes to vascular calcification 
and increased cardiovascular mortality in the dialysis population. Hypercalcemia, 
hyperphosphataemia and high parathyroid hormone level are related to vascular calcification 
and increased cardiovascular mortality. On our annual report we found suboptimal MBD 
results in 2015. That is why a change was needed.
Methods: BMD team consisted of 2 part-time nurses and a nephrologist who provided 
extensive training for 2 months to work almost independently. We started April 2016 
and followed theses target for calcium. We followed this available target for calcium 
(<2.37 mmol/L), phosphorus (<1.75 mmol.) And PTH (150-600 pg/mL) or >800 pg/mL 
(negative outcome). Nurse review the results within 4 days after blood extraction with 
the nephrologist and prescription were written simultaneously (physician prescription is 
mandatory), Data collection was done under IRB approval.
Results: all first-floor patient’s (176/380) were included. Over a short period, we were 
able to achieve our targets. There was statistically significant difference in the number of 
patients in target range for PTH in interventional group compared with standard care group 
in the ground floor (43% versus 17%), (P value <0.005), and PTH less than 800(15% versus 
83%),(P Value 0.0006). Through proper accounting for medicine dispensing, we were able 
to reduce number of prescription and pill burden. Reduced number of sevelamer tablets 
estimated at 4.5 tablets/Week/Patient (average of 30 tablets/week/patient in the new model 
versus 34.5 in the standard of care) with annual course surfing estimated at 60,000 $. 
Cinacalcet consumption dropped from 430 mg/week/patient to 370mg/week/patient with 
an annual cost saving of 125000 US dollars.
Conclusions: MBD nurse manager model in dialysis was successful to achieve, exceed 
and maintain patients within benchmark for calcium, phosphorus, and PTH.
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Determinants of Secondary Hyperparathyroidism Progression in CKD 
Patients
Raquel F. Vasco,1 Flávia L. Carvalho Goncalves,1 Rosilene M. Elias,1,2 
Rosa M. Moyses.1,2 1Universidade de Sao Paulo, Sao Paulo, Brazil; 
2Universidade Nove de Julho, São Paulo, Brazil.
Background: Secondary hyperparathyroidism (SHPT) is a common complication in 
patients with CKD and should be early identified and managed. However, it is still unknown 
which factors are associated with SHPT progression.
Methods: Electronic charts of all nephrology outpatients clinic (n=1,170) in the period 
between Jan-2017 and Dec-2017 with CKD stages 3 and 4 were included. Estimated 
glomerular filtration rate (eGFR) based on CKD-EPI equation and biochemical parameters 
were assessed. Patients were divided in two groups: those who exhibited SHPT (final PTH 
> 150 pg/ml; n= 279) and those who did not (n = 891).
Results: Patients who developed SHPT had lower basal calcium (9.45 ± 0.6 vs. 
9.57 ± 0.5 mg/dl), eGFR (24±7 vs. 34±11 ml/min, p=0.002) and 25 vitD (25±10 vs. 27±10 
ng/dl, p=0.002), despite a trend for a higher prevalence of cholecalciferol supplementation 
(77 vs. 72%, p=0.07). They also had higher phosphate (3.68 ± 0.7 vs. 3.52 ± 0.7 mg/dl, 
p=0.001) and eGFR loss (3.3±6 vs. 1.0±7.6 ml/mi, p=0.0001). No association was found for 
age or gender. Multivariate analysis disclosed that SHPT progression was associated with 
more rapid progression of CKD, as well as lower vit D and higher phosphate at baseline.
Conclusions: Our data suggest that patients with faster progression of SHPT 
present lower eGFR and 25 vitD and higher phosphate, even within the reference range. 
These patients should be closely monitored and future prospective studies might show 
whether interventions such as phosphate restriction and more vigorous cholecalciferol 
supplementation could change the SHPT natural history.
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A Qualitative Analysis of the Medical Record of a National Cohort of 
Patients with Advanced Kidney Disease Not Treated with Maintenance 
Dialysis in the US Department of Veterans Affairs
Susan P. Wong,1,2 Lynne V. Mcfarland,3,1 Chuan-fen Liu,5 Ann M. O’Hare.4,2 1VA 
Health Services Research and Development Center, Seattle, WA; 2University of 
Washington, Seattle, WA; 3Puget Sound VA, Seattle, WA; 4VA Puget Sound 
Health Care System, Seattle, WA; 5VA Puget Sound Health Care System, 
HSR&D, Seattle, WA.
Background: Although it is widely recognized that not all patients with advanced 
chronic kidney disease (CKD) will choose to receive maintenance dialysis, little is known 
about the clinical context in which these decisions occur.
Methods: We performed an in-depth qualitative analysis of the electronic medical 
records of a national cohort of 851 patients with advanced CKD and in whom there had 
been a decision not to initiate maintenance dialysis in the Veterans Affairs (VA) healthcare 
system between 2000-2011. We used inductive content analysis to identify clinical events, 
care processes, healthcare interactions and documented concerns of patients and providers 
relevant to the decision not to pursue dialysis
Results: Overall, 66.6% of cohort members were white and 61.3% were aged ≥75 
years. We identified three major dynamics relevant to understanding the context in which 
decisions not to pursue dialysis unfolded: 1) Perseveration about dialysis, which reflected 
circumstances in which some patients had refused dialysis but providers did not readily 
accept this decision and seemed rooted to the possibility of starting dialysis. Providers 
repeatedly questioned patients’ preferences, questioned patients’ competency to make this 
decision, increased opportunities for patients to initiate dialysis, and proceeded as if patients 
would change their minds about dialysis; 2) Not candidates for dialysis, which reflected 
circumstances in which providers deemed some patients not to be candidates or appropriate 
for dialysis on the basis of patients’ characteristics and expected prognosis rather than on 
patients’ values and preferences; and, 3) Nothing left to offer, which reflected providers’ 
tendency to view that they had little else to offer when patients did not receive dialysis and 
pressed patients to enter hospice care, often before patients were ready.
Conclusions: Our findings reveal the all-or-nothing approach to caring for patients 
with advanced CKD who did not pursue maintenance dialysis. Greater efforts are needed 
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to develop patient-centered models of care for advanced CKD capable of supporting those 
who do not to start dialysis.
Funding: NIDDK Support, Veterans Affairs Support
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Association Between eGFR and Cognitive Performance
Suzanne Dominique Genest,1 Remi Goupil,2 Josee Bouchard,2 
Stephan Troyanov,2 Francois Madore.2 1Université de Montréal, Montreal, QC, 
Canada; 2Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada.
Background: Moderate to severe chronic renal failure is known to be associated 
with cognitive impairment; however, few studies have looked at the impact of subclinical 
kidney dysfunction on cognition. This study aimed at investigating the association between 
cognition and eGFR in a population-based cohort.
Methods: We evaluated cardiovascular, renal and cognitive profiles in randomly 
selected individuals from the general population between the ages of 40 and 69 years. 
Cognitive function was quantified by computer-based testing of reaction time, paired 
associates learning (memory), and verbal-numerical reasoning. eGFR was estimated using 
the CKD-EPI equation. We used multivariate analysis to study the association between 
eGFR and cognition, while adjusting for confounders, including age, gender, income, 
education, smoking, hypertension, dyslipidemia, diabetes, body mass index, cardiovascular 
diseases, alcohol intake and psychoactive medication use.
Results: A total of 15 897 patients had cognitive testing and eGFR measurements 
performed during the same clinic visit. Mean eGFR was 88.0± 14.6 ml/min/1.73m2. After 
adjusting for age, gender, income, education, alcohol intake and known cardiovascular 
risk factors, lower eGFR was significantly associated with poorer performance on reaction 
time testing, paired associates learning (memory), and verbal-numerical reasoning. 
These associations remained significant after further adjustment for use of psychoactive 
medications (cf. table).
Conclusions: Subclinical renal dysfunction may be associated with impaired cognitive 
performance, independently of known risk factors for cognitive decline.
Funding: Government Support - Non-U.S.
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Trajectories of Distress in Older Patients at Initiation of Haemodialysis
Helen Alston,1 Aine Burns.2 1Royal Free Hospital, London, United Kingdom; 
2Centre for Nephrology Royal Free NHS Trust, London, United Kingdom.
Background: Previous studies examined trajectories of functional status (Kurella 
Tamura et al, 2010; Murtagh et al, 2011) and trajectories of quality of life (da Silva Gane et 
al, 2012) at dialysis initiation. We compared trajectories of functional status and distress in 
older patients before and after dialysis initiation.
Methods: We obtained records for 316 CKD4/5 patients aged <70 with ≥3 DTs and 
KPSs in their patient record. 23 started haemodialysis during the study period. Linear 
regression analysed distress, KPS and other factors of interest at baseline. Multi-level 
regression analysed changes in DT and KPS score over time. Visual Graphical Analysis 
(VGA) assessed the trajectories of patients who started dialysis in the study period.
Results: For each 10% loss of functional performance on the KPS, DT score fell by 
0.47 (p<0.001). The relationship between DT scores and factors such as gender, eGFR and 
age, was not statistically significant. We identified 5 categories of DT trajectory: 1: increase 
in distress around the time of starting dialysis, returning to baseline levels of distress 
(psychological adaptation) after a couple of months 2: increase in distress around the time 
of starting dialysis, but with no return to baseline 3: unaffected by the start of dialysis – 
reported no distress at all 4: unaffected by start of dialysis because they were so distressed 
all the time that dialysis made no difference to their DT scores 5: unaffected by start of 
dialysis but experienced a rise in distress at other times.
Conclusions: A majority of participants experienced a rise in DT score around start 
of dialysis, and for some this did not return to baseline even after six months. However 
low eGFR was not associated with higher levels of distress. How do we reconcile this? We 
found an association between functional status and distress, suggesting that the distressing 
aspects of dialysis initiation may be unrelated to declining kidney function, instead due to 
the impact of haemodialysis on their previous life.
Funding: Private Foundation Support
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Impact of Effective Treatment of Hyponatremia in Geriatric Patients
Volker R. Burst,2 Franziska Grundmann,3 Victor Suárez,4 Polina Todorova,1 
Paul T. Brinkkoetter.1 1University Hospital Cologne, Cologne, Germany; 
2Department 2 of Internal Medicine, Renal Division; University of Cologne, 
Cologne, Germany; 3University of Cologne, Cologne, Germany; 4University 
Hospital of Cologne, Koeln, Germany.
Background: Hyponatremia is highly prevalent in old age and associated with 
increased morbidity and mortality. Until now it is not known whether effective treatment of 
frequently perceived asymptomatic hyponatremia in the geriatric population has an impact 
on patient outcome. Here, we investigate the effect of inpatient treatment of patients with 
hypotonic hyponatremia on neurocognitive and motor performance using a comprehensive 
geriatric assessment (CGA).
Methods: 150 geriatric patients with serum [Na+] <130 mEq/L on admission and 
complete diagnostic datasets were enrolled. The results of the CGA on admission as well as 
the change of individual CGA tests until discharge were compared to a matched (sex, age, 
Barthel index of activities of daily living [ADL]) control group.
Results: Both groups were similar with respect to comorbidities and clinical 
characteristics. There were no differences in the individual assessments (ADL, Tinetti’s 
Mobility Assessment, Timed Up and Go-Test, Mini-Mental State Examination [MMSE], 
handgrip strength, Geriatric Depression Scale, Clock-drawing Test, and Esslinger Transfer 
Scale) at baseline (i.e. upon admission). A small but highly significant improvement as 
compared to the control group between baseline and time of discharge was observed with 
regard to ADL (mean(SD): 14.3(17.12)] vs. 9.84(14.67); P=0.002) and MMSE (mean(SD): 
1.43(3.71) vs. 0.72(2.17); P=0.002) in the primary analysis group and this improvement was 
attributable to those patients in which serum [Na+] was increased by >5 mEq/L whereas no 
improvement was seen in those in which serum [Na+] was increased by only ≤5 mEq/L. 
However, regression analyses were not able to confirm a statistically significant association 
between effective [Na+] increase and CGA outcome within the primary analysis group. 
With respect to the subgroup of euvolemic hyponatremia, only changes of MMSE results 
were significantly different.
Conclusions: With the most robust changes observed with ADL and MMSE, the results 
of this prospective observational study suggest a true impact of treating hyponatremia on 
quality of life and neurocognitive function. However, the detected differences are small and 
further investigations are needed to prove their clinical relevance.
Funding: Commercial Support - Otsuka
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Patiromer and Maintenance of RAASI Therapy in Hyperkalemic 
Medicare Patients
Nihar Desai,1 Christopher G. Rowan,2 Paula J. Alvarez,3 Jeanene Fogli,3 
Robert D. Toto.4 1Yale School of Medicine, New Haven, CT; 2COHRDATA, LLC, 
Santa Monica, CA; 3Relypsa, Inc., a Vifor Pharma Group Company, Redwood 
City, CA; 4University of Texas Southwestern Medical Center, Dallas, TX.
Background: Continuing RAASI is critical for patients (pts) with high cardiovascular 
risk. Patiromer (PAT) is a Na-free non-absorbed K+-binder approved for hyperkalemia 
(HK) treatment in Oct 2015. PAT has been shown to reduce recurrent HK and allow pts 
to maintain RAASI. This retrospective cohort study evaluated RAASI utilization among 
Medicare Advantage pts with HK.
Methods: RAASI utilization was evaluated from a large, de-identified national health 
insurance claims database from 1/1/16 to 3/31/17. Three HK cohorts were identified based 
on: dispensed a K+-binder, either 1) patiromer [PAT cohort] or 2) SPS [SPS cohort], or 3) 
HK diagnosis code without a K+-binder dispensed (HK cohort). Pts were included who had 
a pre-index serum K+ ≥5.0 mEq/L and were continuously exposed to RAASI for ≥6 months 
pre-index (ie, date of first K+-binder dispensing or HK diagnosis). We evaluated RAASI 
continuation and down-titration (the latter assessed for lisinopril, losartan, and valsartan) 
within 1, 3, and 6 months post-index.
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Results: Pre-index pt characteristics and sample sizes are listed in the Table. At 
6 months post-index RAASI continuation rates were 87%, 72%, and 57% (Figure) and 
down-titration rates were 11%, 11%, and 9% in the PAT, SPS, and HK cohorts, respectively.
Conclusions: The highest RAASI continuation rate was observed in the PAT cohort 
across all time intervals, and down-titration rates in all 3 cohorts were low (~10%). Further 
study is warranted to fully elucidate these findings in early patiromer users.
Funding: Commercial Support - Supported by Relypsa, Inc., a Vifor Pharma Group 
Company
Table: Pre-Index Patient Characteristics and Sample Sizes by Cohort.
Figure: RAASI Continuation Rates at 1, 3, and 6 Months Post-Index by Cohort.
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Discharge Destination and Disparities in Dialysis Patients’ Post-Acute 
Care
Nancy G. Kutner,1 Rebecca H. Zhang,2 C. Barrett Bowling.3 1Emory University 
School of Medicine, Atlanta, GA; 2Emory University, Atlanta, GA; 3Durham VA 
Medical Center, Durham, NC.
Background: Post-acute care (PAC) goals emphasize functional recovery and reduced 
re-hospitalization, and PAC use has increased markedly since 2000. However, a recent concern 
is that lack of evidence-based guidelines for PAC decision-making creates opportunities 
for disparities in care, as in black/white disparities in PAC post-arthroplasty (JAMA 2018) 
and in PAC services among older community residents (JAGS 2017). Home health (HH) 
and skilled nursing facility (SNF) are most used but include substantially different levels of 
patient support (HH higher) and cost (HH lower). The inpatient rehabilitation facility (IRF) 
emphasizes physician involvement and care coordination, and IRF cost is higher. Outcomes 
following IRF may be superior to those following SNF for comparable patients with hip 
fracture and stroke diagnoses. Using Medicare claims data in USRDS files, we examined 
dialysis patient PAC patterns after lower-extremity amputation (LEA), fracture, and stroke, 
conditions for which kidney patients and blacks are at increased risk.
Methods: Prevalent dialysis patients with Medical Evidence data and Medicare Part 
A/B coverage, who were hospitalized at least once 11/2011-12/2012 followed by one or 
more PAC provider claims in 2012, were the study cohort (n=85,242). We identified IRF 
providers by matching CMS Certification Numbers with USRDS facility IDs in a provider 
crosswalk file. USRDS maintains HH and SNF analysis files. Dialysis patients’ receipt of 
HH, SNF and IRF following LEA (n=10,290), fracture (n=10,119), and stroke (n=5,537) 
was observed in claims data.
Results: Median (IQR) age was 66 (58, 75) for HH users, 72 (63, 80) for SNF users, 
and 69 (60, 77) for IRF users. Women were 50% of HH and SNF users and 45% of IRF 
users; blacks were 32% (HH), 29% (SNF), and 30% (IRF). The percentage of dialysis 
patients with LEA, fracture and stroke was larger among IRF users than among SNF 
users, but SNF use far exceeded IRF use. Among those who received IRF services, blacks 
accounted for 39% of those with LEA and 31% of those with stroke, but only 17% of all 
IRF patients with fracture.
Conclusions: Equity is needed in PAC choices, and the challenge of “who belongs 
where” when multiple PAC options are available calls for well-designed studies of patients’ 
rehabilitation needs and outcomes during an extended window of patient experience.
Funding: NIDDK Support, Veterans Affairs Support
SA-PO714 Poster Saturday
Geriatric Nephrology
Health Outcome Priorities of Older Adults with Advanced CKD and 
Concordance with Their Nephrology Providers’ Perceptions
Sarah Ramer,3 Cassianne Robinson-Cohen,1 Aihua Bian,2 Thomas G. Stewart,1 
Loren Lipworth,1 Khaled Abdel-Kader.1 1Vanderbilt University Medical Center, 
Nashville, TN; 2Vanderbilt University, Nashville, TN; 3Icahn School of Medicine 
at Mount Sinai, New York, NY.
Background: Nephrology providers must understand their patients’ priorities before 
recommending treatments, especially in older adults, for whom the tradeoffs in risks and 
benefits become more salient. We therefore elicited the health outcome priorities (HOPs) 
of older adults with advanced non-dialysis-dependent CKD; examined the association 
between priorities, self-reported health, and acceptance of common end-of-life scenarios; 
and measured concordance between patients’ priorities and providers’ perceptions of these 
priorities.
Methods: Patients ≥ 60 years old with non-dialysis-dependent CKD stages 4-5 
recruited from a US nephrology clinic completed a validated HOP tool, self-rated health 
question, and end-of-life scenarios tool. For each enrolled patient, the nephrology provider 
completed the same HOP tool.
Results: Among 271 patients, 46% women, with median age 71, 49% chose 
maintaining independence as their top HOP, followed by staying alive (35%), reducing pain 
(9%), and reducing other symptoms (6%) (Figure). 49% ranked staying alive as their 3rd 
or 4th priority. There was no association between patients’ self-rated health and top priority 
ranking (P=0.33), but for 6 of 13 common end-of-life scenarios (e.g., “are an emotional or 
financial burden to family”), reported acceptance significantly differed by top HOP. Patient-
provider concordance on HOPs was overall poor (weighted kappa <0.1 for all 4 choices at 
any rank).
Conclusions: Nearly half of a group of older adults with advanced CKD ranked 
maintaining independence as their top HOP. Almost as many ranked staying alive as their 
last or second-to-last HOP. Nephrology providers demonstrated limited knowledge of their 
patients’ priorities.
Funding: Private Foundation Support
Patients’ 1st (main bars) and 2nd (sub-bars) HOP choices
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Factors Associated with Fractures in Octogenarian Patients with CKD
Flávia L. Carvalho Goncalves,1 Venceslau A. Coelho,1 Mariana P. Veloso,1 
Raquel F. Vasco,1 Rosa M. Moyses,1,2 Rosilene M. Elias.1 1HCFMUSP - SP - 
BRASIL, BRASILIA, Brazil; 2Universidade Nove de Julho, São Paulo, Brazil.
Background: Fracture risk is increased in chronic kidney disease (CKD), and is 
associated with a higher mortality rate, mainly in the elderly patients. However, little is 
known regarding the factors associated with fracture risk in octogenarian patients with CKD
Methods: This study investigates the associations among bone turnover markers, 
cognition, comorbidities and prevalent fractures in a cohort of octogenarian CKD patients. 
The comprehensive geriatric assessment was applied by a geriatric and nephrologist 
team, and data obtained in two occasions were extracted from electronic charts including 
estimated glomerular filtration rate (eGFR) based on CKD-EPI equation, biochemical 
and demographic data, modified mini-mental state examination (MMSE), and Charlson 
Comorbidity Index (CCI). The median time between assessments was 174 days.
Results: The fracture prevalence was 26.5% in a sample of 49 patients (67% men, age 
83±7 years). We did not find differences regarding age, gender, eGFR, proteinuria, calcium, 
phosphate PTH, serum vitamin D, supplementation of cholecalciferol, use of omeprazole, 
diuretic and calcitriol between those with and without fractures (p>0.05). However, patients 
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who had fracture had higher comorbidity - CCI >7 (92% vs. 8%; p=0.031) and lower 
MMSE scores (15±9 vs. 23±5; p=0.018). During the follow-up, we observed that patients 
with fracture had a rapid loss of renal function (eGFR -0.016 ± 0.040 vs. 0.019 ± 0.052 ml/
min/1.73m2/month, p=0.017).
Conclusions: Elderly patients with CKD who experience fractures are usually marked 
by more comorbidities, more cognitive deficits, and greater loss of renal function. A closing 
monitoring of falls and a multidisciplinary care is warranted to minimize fractures and 
understand the mechanisms of deteriorating renal function.
SA-PO716 Poster Saturday
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Quantitative Gait Abnormalities and Risk of Falls in CKD
Jeannie Tran,3 Emmeline Ayers,1 Joe Verghese,2 Matthew K. Abramowitz.1 
1Albert Einstein College of Medicine, New York, NY; 2AECOM, Bronx, NY; 
3UCLA, Culver City, CA.
Background: Physical function is impaired in people with chronic kidney disease 
(CKD), leading to a high risk of falls and the development of disability. It is not known 
whether gait abnormalities are present which may explain their risk of falling.
Methods: Quantitative and clinical gait assessments and kidney function measurement 
were performed in 330 community dwelling adults aged 65 years and older. Fall history 
was obtained every two months by standardized telephone questionnaire. CKD was defined 
as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2. Cox proportional 
hazards models adjusted for demographics, comorbidities, and history of falls were created 
to examine the risk of falls.
Results: Participants with CKD had slower gait speed, as well as gait cycle 
abnormalities including shorter stride length and greater time in the stance and double-
support phases. Cadence and stride length variability did not differ between CKD and 
non-CKD. Among people with CKD, lower eGFR was significantly associated with the 
severity of gait cycle abnormalities (per 10 mL/min/1.73m2 lower eGFR: 3.6 cm (95% CI 
1.4-5.8) shorter stride length; 0.7% (95% CI 0.3-1.0) greater time in stance phase; 1.1% 
(95% CI 0.5-1.7) greater time in double-support phase) after adjustment for demographics 
and comorbidities, and these abnormalities mediated the association of lower eGFR with 
slower gait speed. The associations with eGFR remained significant after adjustment for 
measures of cognitive function, muscle strength, and sensory neuropathy. On clinical gait 
exam, consistent with the quantitative abnormalities, short steps and marked sway or loss 
of balance with straight or tandem walking were more common among participants with 
CKD, yet the majority had no identifiable gait phenotype. A gait phenotype defined by these 
abnormal gait signs was associated with the risk of incident falls among participants with 
CKD (compared with non-CKD without gait phenotype: HR 1.8 (95% CI 1.2-2.9, p=0.01) 
for CKD with phenotype, HR 0.9 (95% CI 0.6-1.5, p=0.72) for CKD without phenotype).
Conclusions: The association of CKD with slow gait speed is explained by more 
proximal changes in gait. A newly identified gait phenotype predicts fall risk among older 
adults with CKD.
Funding: NIDDK Support, Other NIH Support - National Institute on Aging
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Is Healthy Aging Associated with Preserved Kidney Function?
Bjorn O. Eriksen,1 Natalie Ebert,2 Olafur S. Indridason,5 Toralf Melsom,4 
Runolfur Palsson,5 Elke Schaeffner.3 1Metabolic and Renal Research Group, 
UiT The Arctic University of Norway, Tromsø, Norway; 2Charite University 
Hospital, Belgrade, Serbia; 3Charite, Berlin, Germany; 4University Hospital of 
North Norway, Tromso, Norway; 5Landspitali - The National University 
Hospital of Iceland, Reykjavik, Iceland.
Background: Studies of kidney function based on creatinine in older adults have 
indicated a wide variation in age-related GFR decline and that healthy persons age with a 
well-preserved GFR. However, estimated GFR from creatinine is problematic in this age 
group because of confounding by sarcopenia. We investigated variation of measured GFR 
in the general population to study whether healthy ageing is associated with a stable GFR.
Methods: We measured iohexol clearance in three European cohorts (AGES-II-Reykjavik 
Study, Berlin Initiative Study and Renal Iohexol Clearance Survey (RENIS)) representative of 
the general population aged 50 to 97 years. The iohexol assays were calibrated across cohorts. 
We also registered the most important prevalent diseases representing risk factors for chronic 
kidney disease (diabetes, hypertension, cardiovascular disease and cancer). We predicted the 
median, 2.5th and 97.5th percentiles of cross-sectional GFR by age for persons without these 
risk factors using generalized additive quantile mixed models.
Results: We included 3002 persons. For persons > 90 years, the maximum observed 
GFR was 78 mL/min/1.73 m2. For a person free from diabetes, hypertension, cardiovascular 
disease and cancer, the predicted 2.5th, 50thand 97.5th percentiles of GFR uniformly declined 
across the investigated age range. At 90 years, the predicted GFR values at these percentiles 
were 47, 64 and 78 mL/min/1.73 m2, respectively. The 2.5th percentile crossed the 60 mL/
min/1.73 m2 level at 71.5 years and the 45 mL/min/1.73 m2 level at 91.6 years (Figure).
Conclusions: Persons without the most important risk factors for chronic kidney 
disease are not exempt from age-related GFR decline. This indicates that GFR decline in 
these persons is caused by general ageing rather than by kidney disease.
Funding: Government Support - Non-U.S.
Points are individual measurements of GFR. Line (dashed lines) are predicted median (2.5th 
and 95th percentiles) under the statistical model for a person without diabetes, hypertension, 
CVD or cancer. Dotted horizontal lines indicate 45 and 60 ml/min/1.73 m2.
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Differential Impact of Self-Reported and eGFR-Based CKD on the 
Outcomes of Community-Dwelling Elderly
Chia-Ter Chao.1,2 COhort of GEriatric Nephrology in NTUH (COGENT study 
group) 1National Taiwan University Hospital BeiHu branch, Taipei City, 
Taiwan; 2National Taiwan University Hospital, Taipei, Taiwan.
Background: Awareness of CKD has been low among affected patients, particularly 
elderly. However, whether such awareness is synonymous with the presence of laboratory-
diagnosed CKD is currently unclear.
Methods: We retrospectively enrolled 2932 community-dwelling old adults 
(≥65 years) who received health examinations between 2013 and 2016 from a regional 
hospital. Clinical information and geriatric syndromes including depression, cognitive 
impairment, fall, quality of life, and visual disturbance were evaluated during medical 
interview. We compared differences in clinical features between those with and without 
self-reported or estimated glomerular filtration rate (eGFR)-based CKD and investigated 
their influences and interactions on the risk of CKD complications and geriatric syndromes.
Results: Among 2932 elderly (mean 73.4 years), 93 (3%) reported having CKD by 
history, while 585 (20%) had an eGFR <60 mL/min/1.73m2 persisted over 3 months. The 
prevalence of body mass index, waist circumference, and the incidence of fall differed 
only between those with and without eGFR-based CKD, but not self-reported CKD. A 
synergistic effect was found between self-reported and eGFR-based CKD regarding the 
CKD complication severity, including malnutrition (albumin), anemia (hemoglobin), 
dyslipidemia (serum cholesterol), and geriatric syndromes (cognitive and quality of life 
impairment) (Fig 1). Those with self-reported without eGFR-based CKD had specific 
features differing from others (Fig 2). Multivariate regression analyses showed that self-
reported CKD exhibited better predictive efficacy for lower serum albumin and hemoglobin 
than eGFR-based CKD, while the latter outperformed the former for predicting lower serum 
cholesterol and a higher risk of cognitive impairment.
Conclusions: Among older adults, self-reported CKD may not be a surrogate for 
laboratory-diagnosed CKD and has an independent effect on CKD-related complications.
Funding: Clinical Revenue Support
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A Census of Skilled Nursing Facility Utilization in Medicare Dialysis 
Patients
Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins,1,2 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: The size of the dialysis patient population that resides in a skilled 
nursing facility (SNF), either for short-term rehabilitation or long-term custodial care, is 
unclear. Medicare Part A covers SNF care only in specific circumstances, thus complicating 
interpretation of Medicare claims analysis. However, Yun et al (Health Serv Outcomes Res 
Methodol, 2010) proposed an algorithm that collects data from Part A claims for SNF care 
and Part B claims for physician visits in a SNF to identify Medicare beneficiaries who 
reside in a SNF. We implemented this algorithm in Medicare dialysis patients to identify an 
ongoing census of SNF utilization.
Methods: We analyzed data from the United States Renal Data System. For each 
calendar month from January 2013 to September 2015, we identified patients who underwent 
outpatient dialysis and carried Medicare Parts A and B as primary payer. According to the 
algorithm proposed by Yun et al, we ascertained 3 classes of claims among these patients: 
(1) Medicare Parts A claims submitted by a SNF; (2) Medicare Part B claims submitted by 
physicians, with place of service code 31 (SNF), 32 (nursing facility), or 33 (custodial care 
facility); (3) Medicare Part B claims submitted by physicians, with a Current Procedural 
Terminology code indicating evaluation or management of a nursing facility patient. In each 
calendar month, we estimated the percentage of patients residing in a SNF, and further 
classified patients as short-term or long-term residents.
Results: Monthly counts of Medicare dialysis patients increased from approximately 
306,600 patients during the first quarter of 2013 to approximately 315,600 patients during 
the third quarter of 2015. The mean percentage of Medicare dialysis patients residing in 
a SNF during a month was 8.57%, with a range from 8.24% to 8.90%. Concurrently, the 
mean percentage of patients residing in a SNF for short-term care was 4.91%, whereas the 
mean percentage of patients residing in a SNF for long-term care was 3.66%. In the subset 
of patients with age ≥75 years, the mean percentage of patients residing in a SNF during 
a month was 14.85%, with 8.70% in a SNF for short-term care and 6.16% in a SNF for 
long-term care.
Conclusions: During any month, slightly more than 85 of every 1000 Medicare 
dialysis patients reside in a SNF, with a ratio of approximately 4 to 3 for short-term versus 
long-term care.
Funding: Commercial Support - NxStage Medical, Inc.
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Proteinuria Selectivity Index as a Predictor for Response to Therapy in 
Nephrotic Syndrome
Maiko Nakayama, Hitoshi Suzuki, Yusuke Suzuki. Nephrology, Juntendo 
University Faculty of Medicine, Tokyo, Japan.
Background: The nephrotic syndrome (NS) is defined by heavy proteinuria due 
to abnormal increase of glomerular permeability and following hypoalbuminemia, 
hyperlipidemia and edema. Clinical manifestation of NS is highly variable due to the 
response to therapy. Selectivity index (S.I.) that commonly used for initial examination 
to differentiate minimal change disease (MCD). However, clinical application of S.I. is 
controversial for reliability. In present study, we evaluated clinical examinations including 
S.I. and prognosis of NS.
Methods: We retrospectively analysed 66 cases with NS who underwent renal biopsy 
in our hospital from 2013 to 2017. The clinical features at the time of renal biopsy, remission 
rate of initial therapy, and relapse rate of during the course of medication were evaluated in 
each primary glomerulonephritis.
Results: Of the 66 cases of NS, 47 cases were caused by primary glomerulonephritis. 
The incidence of MCD, idiopathic membranous nephropathy (MN), focal segmental 
glomerulosclerosis (FSGS) and membranoproliferative glomerulonephritis (MPGN) were 
55%, 32%, 9%, and 4%, respectively. Prevalence of each causal disease of NS was similar 
to data of Japanese renal biopsy registry. At the time of renal biopsy, levels of proteinuria 
(6.9g/day), degree of hypoalbuminemia (1.6 g/dL) and dyslipidemia in MCD were most 
severe as compared with other primary glomerulonephritis (P=0.02). Complete remission 
rate of initial therapy in each primary glomerular disease were 96% for MCD, 57% for 
MN, 50% for FSGS and 50% for MPGN, respectively. However, 42.3% patients with 
MCD recurred during the course of immunosuppression therapy, despite high frequency 
of remission. Of note, patients with 67% of MN and 75% of FSGS indicated high S.I. (less 
than 0.2). There was the trend that in cases with high S.I. patients with MN and FSGS 
indicated high remission rate by initial therapy.
Conclusions: Although levels of proteinuria and degree of hypoalbuminemia were 
most severe in MCD, remission rate of MCD was high by initial therapy. The recurrence 
rate is also high in patients with MCD. The high S.I. may be useful to expect response to 
initial therapy in patients with MN and FSGS.
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Clinical Outcomes and Effects of Treatment in Older Patients with 
Idiopathic Membranous Nephropathy
Yaeni Kim,1 Hye Eun Yoon,2 Yu Ah Hong,5 Bumsoon Choi,6 Cheol Whee Park,2 
Chul Woo Yang,4 Yong-Soo Kim,7 Hyeon Seok Hwang.3 1Incheon St. Mary’s 
Hosp, Catholic Univ of Korea, Incheon, seoul, Republic of Korea; 2The Catholic 
University of Korea, Incheon, INCHEON, Republic of Korea; 3Division of 
Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee 
University, Seoul, Republic of Korea; 4Seoul St. Mary’s Hospital, Seoul, Republic 
of Korea; 5College of Medicine, The Catholic University of Korea, Daejeon, 
Republic of Korea; 6Division of Nephrology, Department of Internal Medicine, 
Seoul, Republic of Korea; 7The Catholic University of Korea College of 
Medicine, Seoul, Republic of Korea.
Background: Membranous nephropathy (MN) is the most common primary 
glomerular disease diagnosed in older patients. However, few reports describe the clinical 
outcomes in older patients with idiopathic MN.
Methods: The outcomes of 135 patients with histologically proven MN were analyzed. 
‘Older’ was defined as 60 years of age or older at the time of the renal biopsy. The rates of 
complete remission (CR), progression to end-stage renal disease (ESRD) and infection were 
compared between older and younger patients.
Results: The cumulative event rate for achieving CR was inferior (P = 0.012) and 
that for requiring renal replacement therapy was higher (P = 0.015) in older patients, and 
they had a greater risk of infection (P = 0.005). Older age was a significant predictor of 
a lower rate of CR from proteinuria (adjusted odds ratio [OR] = 0.51, 95% confidence 
interval [CI] 0.26–0.98), and was a robust predictor of infection (adjusted OR = 5.27, 
95% CI 1.31–21.20). Conservative treatment was associated with a lower remission rate 
(P = 0.036) and corticosteroid treatment was less effective in achieving CR (P = 0.014), 
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in preventing progression to ESRD (P = 0.013) and in reducing infection (P = 0.033) in 
older patients. Cyclosporine treatment had comparable clinical outcomes with regard to CR, 
ESRD progression, and infection.
Conclusions: Older age was independently associated with inferior rates of CR and 
greater risk of infection. Treatment modalities affected the outcomes of older patients 
differently in that cyclosporine treatment is predicted to be more useful than corticosteroids 
in this population.
SA-PO722 Poster Saturday
Geriatric Nephrology
Histological and Clinical Patterns in Glomerular Diseases of the Elderly: 
A Monocentric Study
Andrea Angioi,1 Nicola Lepori,1 Matteo Floris,1 Riccardo Cao,1 Anna 
Maria Asunis,2 Gianfranca Cabiddu,1 Antonello Pani.1 1Nephrology, Ospedale 
Brotzu, Cagliari, Italy; 2Anatomic Pathology, Ospedale Brotzu, Cagliari, Italy.
Background: Renal biopsy is an essential instrument for diagnosis of glomerular 
disease: according to data described in literature, this tool is overlooked in the elderly 
patients, which represent 15% of renal biopsies
Methods: Our Division is the regional hub of renal diseases in Sardinia, covering 
around 1.6 million of inhabitants, of whom 217.000 are eldery. We retrospectively reviewed 
histological and clinical data of all biopsy proven glomerular disease performed on ≥65 y/o 
patients from 2000 to 2016.
Results: 227 patients, with a mean age of 73.62 ± 6.41 years, were included in our 
analysis. 61.2% of them were younger than 75 y/o and 3.5% were older than 85 y/o (with 
3 patients > 99 y/o). The annual incidence of biopsy proven glomerular diseases in the 
elderly population increased progressively in the considered period, from 4 cases/100.000 
exposed in 2000 to 11.5 cases/100.000 in 2016. Membranous Nephropathy was the most 
recurrent histological diagnosis (23.8%), followed by Minimal Change Disease (13.2%), 
AL amyloidosis (9.3%) and MPO-ANCA vasculitis (9.3%). Our analysis showed few 
significative differences when patients were classified according their age (65-74, 75-84 
and ≥85 years old): diabetic nephropathy was more frequent in the third group (p 0.001) and 
MPO-ANCA vasculitis were more frequently diagnosed in group 1 and 2 than in group 3 (p 
0.05). Interestingly, incidence of MGRS and malignant clones with renal involvement rose 
from no cases in 2000-2003, to a peak of 33% in 2013
Conclusions: Incidence of glomerular diseases is increasing, likely due to more 
comprehensive indications to renal biopsy from 2000 to 2016. Histological patterns revealed 
a substantial homogeneity in among the three subgroups analyzed. Coherently, most of 
patients benefited of a specific treatment. Renal biopsy is, therefore, an irreplaceable tool 
even in a selected elderly population
Annual number of new biopsy proven diagnosis of glomerular disease in elderly patients at 
Ospedale Brotzu Nephrology Department (2000-2016)
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Functional Decline and Associated Risk Factors in a Survivor Cohort of 
Older Dialysis Patients
Rasheeda K. Hall, Alison Luciano, Jane F. Pendergast, Cathleen Colon-emeric. 
Duke University, Durham, NC.
Background: At least 50% of older adults undergo functional decline or die within 
the first 6 months of dialysis. Little is known about functional decline in older adults who 
survive the first 6 months of dialysis. We sought to identify risk factors for functional 
decline, as measured by Short Form-12 physical component score (SF-12 PCS) change, in 
a survivor cohort of older dialysis patients.
Methods: We conducted a retrospective study of 3,284 adults aged ≥ 65 years with 
≥ 6 months of hemodialysis and complete SF-12s in 2012 and 2013. We calculated PCS 
change as second minus first PCS for individuals with PCSs ≥ 300 days apart. Using a
multivariable linear regression, we modeled PCS change and adjusted for baseline age,
gender, race, Medicaid status, access type, Kt/V, albumin, hemoglobin, time on dialysis,
Charlson index, hospitalization rate, and days between PCSs. In post hoc analysis, we
compared individuals in categories: clinically relevant (CR) PCS decline or increase (PCS 
change > 3) and no CR change.
Results: Of 3,284, 801 (24.4%) died and an additional 1,112 (33.9%) did not have 2 
PCSs ≥ 300 days apart. Our analytic cohort included the remaining 1,371 (41.7%) who had 
2 PCSs ≥ 300 days apart (mean 399 ± 74 days), mean time on dialysis 6.1 ± 3.1 years, and 
mean PCS change -0.9 ± 9.6. Cohort members with time on dialysis < 5 years had significant 
but modestly smaller decline in PCS compared to those with ≥ 5 years (p=0.03) (Table), but 
the regression did not reveal any significant associations between patient characteristics and 
PCS change. The proportion with CR PCS decline, increase, or no CR change were 39.3% 
(n=539), 32.2% (n=442), and 28.4% (n=390), respectively. Mean hospitalization rate was 
highest among those with CR PCS decline (2.0 ± 3.7) compared to those with CR increase 
(1.7± 3.5) or no CR change (1.4 ± 2.6) (p<0.05).
Conclusions: In this survivor cohort, nearly 25% died and 40% of those who did not 
die had CR PCS decline within 2 years. Although age, race, time on dialysis, and access 
type were not associated with SF-12 PCS change, one potential risk factor for CR PCS 
decline is recurrent hospitalizations.
Funding: Other NIH Support - Kl2TR001115, R03AG050834, P30AG028716
Mean Time on Dialysis and Relation to SF-12 PCS Change
(Mean ± SD)
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Preliminary Satisfaction and Acceptability Ratings of a Supportive Care 
Video Decision Aid for Elderly Patients with Advanced CKD
Nwamaka D. Eneanya,1 Shananssa Percy,1 Michael J. Germain,2 
Ravi I. Thadhani,5 Jennifer S. Temel,4 Michael Paasche-Orlow,3 
Angelo Volandes.4 1Massachusetts General Hospital, Boston, MA; 2Renal and 
Transplant Assoc of New England, Hampden, MA; 3Boston University, Boston, 
MA; 4MGH, Waban, MA; 5Cedars-Sinai, Los Angeles, CA.
Background: The benefits of dialysis remain uncertain for elderly and frail patients 
with advanced chronic kidney disease (CKD). Recent studies have not shown an 
improvement in survival or quality of life for many such patients on dialysis, thus making 
supportive kidney care a viable option. Furthermore, decision aids to promote informed 
decision making about supportive care are lacking. As part of a randomized controlled trial 
(RCT) to test preliminary efficacy of a video decision aid on knowledge of supportive care 
among elderly patients with advanced CKD, we explored satisfaction and acceptability 
ratings among participants who received video education.
Methods: Eligible patients are age ≥ 65 years, English-speaking, and receive primary 
nephrology care at a large medical center in Boston, MA. The video was developed in an 
iterative process by a national panel of nephrologists with an expertise in shared decision 
making in this patient population. The video includes images of patients undergoing 
hemodialysis, peritoneal dialysis or no dialysis.
Results: A total of 64 out of eligible 100 patients have enrolled in the RCT and 43.8% 
(n=28) have been randomized to video education. Satisfaction and acceptability ratings of 
the video decision aid are displayed in Table 1.
Conclusions: Most patients who have received the video decision aid thus far in the 
RCT report high satisfaction and acceptability ratings. These findings contradict historical 
beliefs that patients are fearful or averse to learning about supportive care. Future research 
will determine whether a supportive care video decision aid improves supportive care 
knowledge for elderly patients with CKD.
Funding: NIDDK Support
Table 1. Satisfaction and acceptability ratings of a supportive care video decision aid
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Effect of Pentoxifylline on Pericyte in Aging Mice Kidney
Hyung Duk Kim,2,3 Eun Nim Kim,1,3 Ji Hee Lim,1,3 Min Young Kim,1,3 Hye 
Eun Yoon,4,3 Eun jeong Ko,2,3 Tae Hyun Ban,2,3 Byung ha Chung,2,3 Cheol 
Whee Park,2,3 Chul Woo Yang,2,3 Yong-Soo Kim,2,3 Bumsoon Choi.2,3 1Division 
of Nephrology, Department of Internal Medicine, Seoul, Republic of Korea; 
2Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s 
hospital, Seoul, Republic of Korea; 3The Catholic University of Korea College 
of Medicine, Seoul, Republic of Korea; 4Incheon St. Mary’s Hospital, Incheon, 
Republic of Korea.
Background: In aging kidney, oxidative stress and inflammation lead to a decrease in 
renal function. Recent studies related to the aging process of the kidneys have shown that 
pericyte is a progenitor cell of myofibroblast, and the relationship between renal fibrosis 
and pericyte has been reported. In this study, we investigated the effect of pentoxifylline 
on pericyte.
Methods: 2, 12, and 24-months-old mice were assigned to control group. (Each group 
consisted of 7 mice) Seven 18-month-old mice were treated with pentoxifylline for 6 
months. Pericyte was confirmed by PDGFR-beta and NG2 double stain.
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Results: Abundant microvascular density was detected in kidney of 2 and 12-months-
old young mice. In 24-months-old mice kidney, CD31 stain decreased and collagen I 
stain increased which means progression of renal fibrosis. In the Pentoxifylline group, the 
collagen I stain was significantly decreased and the microvascular density was increased 
compared to the 24 months group. In the 24-months group, the pericyte marker was 
significantly decreased and the endothelial contact was disappeared. However, the pericyte 
was not decreased in the pentoxifylline group and maintained their perivascular location.
Conclusions: Pentoxifylline attenuates tubulointerstitial fibrosis in aging mice kidney 
via pericyte.
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Serum Stem Cell Factor Level Predicts Declined Kidney Function in 
Healthy Adults
Weiguang Zhang, Linpei Jia, Xiaomin Liu, Qian Wang, Xiangmei Chen. 
Department of Nephrology, Chinese PLA General Hospital, Chinese PLA 
Institute of Nephrology, State Key Laboratory of Kidney Diseases, BeiJing, 
China.
Background: Stem cell factor (SCF), the ligand of mast cells’ c-kit receptor, actively 
participates in the organ reconstruction and fibrosis in various diseases. Recent studies 
also revealed that SCF plays an important role in kidney diseases, including nephrotoxic 
nephritis and crescentic glomerulonephritis. However, it remains unclear whether SCF 
play a role in the ageing of kidney. This study was designed to investigate the relationship 
between serum SCF level and the function of kidney aging.
Methods: In this study, we collected the data of serum SCF, estimated glomerular 
filtration rate (eGFR) calculated by CKD-EPI equation and other biological indicators in 
a Chinese Han and investigated the relationship of SCF and the renal function in the aging 
process, so as to search new biomarkers of kidney aging. The levels of serum SCF (R&D 
Systems, Min., U.S.A) were tested by enzyme-linked immunosorbent assay (ELISA). 
Then correlation analysis, redundancy analysis and multiple linear regression were done to 
select potential indicators to estimate renal function decline. We divide subjects into youth 
(age<45), middle-aged (45≤age<60), young elderly (60≤age<75) and elderly (age≥75) 
groups. SCF levels were compared among different age groups and genders using one-way 
ANOVA (P<0.05) and student t test (P<0.05) respectively.
Results: 1. Demographic features Initially, 1,368 volunteers were enrolled. After the 
screening, 892 healthy participants of mean age 59.0 ± 13.4 years were finally enrolled. 2. 
Age and SCF level are predictors of eGFR. The final relationship between eGFR and 
SCF level was expressed as: eGFR = 154.486 – (0.846 × age) – (0.011 × SCF level). Fig. 
1. Associations of predictive variables with the estimated glomerular filtration rate (eGFR).
Conclusions: In conclusion, we investigated the relationship between SCF and eGFR 
in the ageing process of kidney, and revealed that SCF is closely related with eGFR. Finally, 
we constructed an eGFR estimated equation for kidney aging.
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Impact of Aging on Kidney and Gut Cross-Talk in AKI
Myung-Gyu Kim, Ko Yoon Sook, Lee Hee Young, Junyong Lee, Jihyun Yang, 
Sewon Oh, Sang-Kyung Jo. Korea University Anam Hospital, Korea University 
College of Medicine, Seoul, Republic of Korea.
Background: Recently, the high incidence of acute kidney damage (AKI) and 
the mortality rate in elderly population are important healthcare burdens. Although, 
experimental studies showed that interaction between the kidney and the remote organ 
(lung, heart, bowel, etc.) could significantly affect the outcome of AKI, the impact of aging 
on the remote organ effects of AKI are still unknown. Here, we investigated the effects of 
aging on AKI outcomes, especially kidney and gut crosstalk in animal models.
Methods: In old (10mo) and young (2mo) C57BL/6 mice, 25min bilateral ischemia 
reperfusion injury (IRI) was applied, and then expression of inflammatory cytokines as well 
as functional and histological changes of kidney and colon were examined on day 1 and 3 
after IRI. Intestinal barrier integrity was assessed by permeability to FITC-dextran.
Results: There was no significant difference in renal function between old and young 
mice on day1 post IRI, but the mRNA expression of IL-6, TNF-α, IL-12 and IFN-r was 
significantly higher in the kidneys of old mice than in young mice on day 1, and the 
expressions of TNF-α and IL-12 were also increased in old mice on day3. The balance 
of the M1/M2 markers (iNOS/mannose receptor) skewed towards M2 phenotype on day3 
post IRI in young mice, however it was significantly blunted in old mice. Interestingly, this 
intrarenal inflammatory milieu in old mice was similarly observed in the colon. In the aged 
colon, TNF-α and IL-12 mRNA expression was significantly higher and mannose receptor 
and arginase-1 expression was lower than in young mice on day3 post IRI. Increased 
inflammatory cytokines in the colon were accompanied by an increase in TUNEL-positive 
apoptotic colon epithelial cells and increased permeability of the colon in old mice. The 
AKI-induced “leaky gut” showed a strong positive correlation with high TNF-α expression 
in mesenteric lymph nodes, suggesting that persistent inflammation of the kidney after IRI 
in old mice contributes to increased colon inflammation and permeability.
Conclusions: We conclude that AKI in old mice results in a more M1-related 
inflammation in the kidney and colon, and worsens AKI-induced “leaky gut”. These results 
suggest that strategies for targeting intestine might provide novel therapeutic opportunities 
for reducing poor outcomes in elderly patients with AKI.
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Cystatin C and Cystatin C-Based GFR Markers for Prediction of 
Mortality in Elderly Patients with CKD
Sebastjan Bevc,1,2 Nina Hojs,1,2 Masa Knehtl,1,2 Nejc Piko,1 Robert Ekart,1,2 
Radovan Hojs.1,2 1University Clinical Centre Maribor, Maribor, Slovenia; 
2Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Background: The prevalence of chronic kidney disease (CKD) in the elderly is high. 
Serum cystatin C is an accurate marker of kidney function and also has prognostic utility 
in CKD patients. The aim of our study was to determine the prediction of cystatin C and 
cystatin-C based markers of kidney function (eGFR) on long-term survival in elderly CKD 
patients.
Methods: In our study 58 adult Caucasian patients, older than 65 years (50% women; 
mean age 73 years; range from 65 to 85 years), were included. Patients with known 
malignancy, thyroid disease and/or on steroid therapy were not enrolled in the study. In each 
patient 51CrEDTA clearance, serum cystatin C (immunonephelometric method) and eGFR 
using two cystatin C-based formulas (CKD-EPI cystatin and FAS cystatin) were determined 
on the same day and patients were then followed for 12 years or until their death.
Results: The mean values: 51CrEDTA clearance 53.3±17.4 ml/min/1.73m2, serum 
cystatin C 1.79±0.5 mg/l, CKD-EPI cystatin 36.1±13.6 ml/min/1.73m2, FAS cystatin 
40.1±11.7 ml/min/1.73m2. In the follow up period of 12 years 48 (83%; 24 women and 
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24 men) of our elderly CKD patients died. Cox regression analysis showed different 
hazard ratios (HR) for death: for 51CrEDTA clearance HR was 1.024 (95% CI 1.001-1.042; 
P=0.009), for serum cystatin C HR was 2.021 (95% CI 1.264-3.229; P=0.003), for CKD-
EPI cystatin HR was 1.034 (95% CI 1.008-1.062; P=0.01), for FAS cystatin HR was 1.041 
(95% CI 1.010-1.071; P=0.008).
Conclusions: Our results show that in elderly CKD patients the highest hazard ratio 
for all-cause mortality has serum cystatin C compared to the cystatin C-based markers of 
kidney function (eGFR).
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Chloride Channel Accessory 1 Protein Could Be a Novel Regulatory 
Factor in Aging-Related Changes in the Kidney
Andrew Donati,1 Hak Joo Lee,2 Adam Salmon,1,5 Goutam Ghosh-Choudhury,2,5 
Corinna Ross,4 Suzette D. Tardif,3 Balakuntalam S. Kasinath.1,5 1Univeristy of 
Texas Health, San Antonio, TX; 2University of Texas Health, San Antonio, TX; 
3Texas Biomedical Research Institute, San Antonio, TX; 4Texas A&M San 
Antonio, San Antonio, TX; 5South Texas Veterans Health Care System, San 
Antonio, TX.
Background: We have reported that aging induces kidney fibrosis, albuminuria and 
impairs clearance function in mice (Sataranatarajan K, Aging Cell, 2012). The underlying 
mechanisms are not well understood. In the current study, we took an unbiased discovery 
approach to identify potentially novel mechanisms.
Methods: We performed RNA Seq on renal cortical samples from C57BL6 male 
young mice (5 months old, n=4) and old mice (30 months old, n=3). Next, we directly 
verified changes in mRNAs that showed the maximum increase by performing qRT-PCR. 
We studied changes in renal cortical chloride channel accessory protein 1 (CLCA1) protein 
expression by immunoblotting (male and female young and old mice, n=6 to 10 per group). 
To study if changes found in mice were evolutionarily conserved, we studied kidney tissue 
from non-human primate marmosets (young 3 yrs of age, old 16 yrs of age, male and 
female, n=8-10 per group).
Results: On RNA Seq, we found CLCA1 as one of the mRNAs that showed most 
significant increase in old vs. young mice (p=7.6E-27). We performed qRT-PCR to directly 
test the status of CLCA1 mRNA; we confirmed a 10-fold increase in renal cortex of old 
male mice compared to young mice. Immunoblotting showed a 2-fold increase in CLCA1 
protein in renal cortex of old male mice but not old female mice. We have reported that 
renal hydrogen sulfide (H2S) generation is reduced in aging mice; administration of sodium 
hydrosulfide (NaHS, a source of H2S) to 19 month-old mice for 5 months ameliorates 
aging-related kidney changes in mice (Lee HJ, GeroScience, 2018). NaHS administration 
decreased renal cortical CLCA1 expression by 40% compared to untreated Control old 
mice. On immunohistochemistry CLCA1 was expressed mostly in the tubules in young 
marmosets. Renal cortical CLCA1 expression was increased 2-fold in old male and female 
marmosets.
Conclusions: Increase in renal cortical CLCA1 expression correlates with aging-
related kidney dysfunction in male mice; it appears to be evolutionarily conserved from 
mice to marmosets. CLCA1 activates Ca++-dependent chloride channel TMEM16A that 
is expressed in kidney proximal tubules and podocytes. Mechanisms by which CLCA1 
contributes to renal aging need to be explored.
Funding: Veterans Affairs Support
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Loss of Asparaginyl Endopeptidase Accelerates Cellular Senescence and 
Boosts Age-Related Renal Interstitial Fibrosis
Xiaoyue Tan, Dekun Wang, Chuanai Chen, Lichun Kang. the School of 
Medicine, NanKai university, Tianjin, China.
Background: Asparaginyl endopeptidase (AEP) is highly expressed in the renal tubuli 
while significantly declined in the elderly ones. AEP exhibits anti-fibrotic effect in the 
mouse model of unilateral ureteral obstruction. The role of AEP in the age-related fibrosis 
is obscure.
Methods: We compared the level of renal interstitial fibrosis and renal tubular 
senescence in the wild-type (wt) and AEP knockout (AEP-/-) mice at different ages. We 
established stable AEP-knockdown HK2 cell line (HK2-shAEP) and analyzed the cellular 
senescence. Then, we co-cultured HK2-shAEP with fibroblasts and assessed the activated 
indexes of fibroblasts. We also evaluated the lysosomal pH and change of autophagy upon 
AEP downregulation.
Results: Renal tubular senescence was obvious from the 3rd months in AEP-/- mice 
with significant accumulation of Fibronectin and Collagen I/III in the renal interstitial 
area. Levels of serum creatinine and urea nitrogen were 2 times higher than that in wt 
mice at the 6th months. In vitro, AEP knockdown induced the cell cycle arrested at G1/S 
with increased expression of β-Gal, p21cip1 and p16ink4a. HK2-shAEP cells expressed and 
secreted more pro-fibrotic cytokines, including TGF-β1, CTGF and PAI-1. Co-culture 
with HK2-shAEP promoted the differentiation, migration and proliferation of fibroblasts. 
Blocking the senescent signaling via downregulating p21cip1 or p16ink4a could reverse 
the accelerated senescence and pro-fibrotic effects of HK2-shAEP cells. Assessment of 
autophagy and lysosomal PH showed that knockdown of AEP led to impaired autophagy 
flux and disturbance of lysosomal homeostasis, accompanying with accumulation of ROS. 
Autophagy inducer rapamycin or anti-senescence agent spermidine could reverse the 
senescent state of HK2-shAEP cells. in vivo, both spermidine and genetical mutant of p53 
alleviated renal interstitial fibrosis of AEP-/- mice.
Conclusions: The study defines the role of AEP in regulation of autophagy via 
maintainance of lysosomal hemostasis in renal tubuli. Loss of AEP accelerates tubular 
senescence and boosts aged-related interstitial fibrosis. Therefore, our finding highlights 
AEP as a potential biomarker of age-related kidney diseases and therapeutic target.
Funding: Government Support - Non-U.S.
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Marmoset - A Non-Human Primate Model to Study Aging Associated 
Changes in the Kidney
Hak Joo Lee,1 Olga D. Gonzalez,6 Edward J. Dick,3 Andrew Donati,1 
Denis Feliers,1 Goutam Ghosh-Choudhury,1,4 Corinna Ross,2 
Manjeri A. Venkatachalam,5 Suzette D. Tardif,3 Balakuntalam S. Kasinath.1,4 
1University of Texas Health Science Center, San Antonio, TX; 2Texas A&M San 
Antonio, San Antonio, TX; 3Texas Biomedical Research Institute, San Antonio, 
TX; 4South Texas Veterans Health Care System, San Antonio, TX; 5University of 
Texas Health San Antonio, Shavano Park, TX; 6Texas Biomed, San Antonio, TX.
Background: Because of the genetic distance between rodents and humans an 
appropriate primate model to study kidney aging is needed. We evaluated whether the 
marmoset can fill this need by studying kidney parameters in healthy young and aged 
marmosets of both sexes.
Methods: We studied 4 young male (average age 3 years) and 4 young female (average 
age 2.8 years) marmosets, and, 5 aged male (average age 16.1 years) and 5 aged female 
(average age 15.9 years) marmosets. We examined structural changes in the kidney by H 
and E and PAS stains. Immunoblotting was employed to study changes in the expression of 
proteins. Measurement of urinary albumin and protein was by ELISA and Bio-Rad assay, 
respectively.
Results: Aging was associated with glomerulosclerosis, tubulointerstitial fibrosis and 
arteriolosclerosis constituting nephrosclerosis in both sexes; patchy areas of interstitial 
nephritis were seen. The renal cortical content of matrix proteins laminin, type III collagen, 
and fibronectin was increased on immunoblotting. Functionally, aging resulted in an 
increase in urinary albumin to creatinine ratio and protein to creatinine ratio in association 
with reduction in kidney expression of nephrin. There was a robust correlation between 
histologic markers of fibrosis and albuminuria and proteinuria. We explored signaling 
pathways as potential mechanistic events. Aging in males, but not in females, was associated 
with reduced renal cortical activity of AMP-activated protein kinase (AMPK) and a trend 
toward activation of mechanistic target of rapamycin complex 1 (mTORC1); upstream of 
AMPK and mTORC1, Akt and insulin–like growth factor 1 receptor were activated. In 
both sexes, aging promoted renal cortical expression transforming growth factor β-1 and 
phospho-Smad3. Since kidney fibrosis is associated with deficiency of hydrogen sulfide 
synthesis in renal disease, we examined its status in aging marmosets. While the expression 
of cysthathionine β-synthase, an enzyme involved H2S synthesis, was reduced in both aged 
males and females, decreased H2S generation was seen only in the males.
Conclusions: Our studies show that the marmoset is a valid model to study kidney 
aging; some of the signaling pathways involved in renal senescence differ between male 
and female marmosets.
Funding: Veterans Affairs Support
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Sirt1-Induced Hypoxia-Inducible Factor-1α Deacetylation Attenuates 
Tubulointerstitial Damage in Aged Kidney
Hyunjin Noh,1,2 Mi ra Yu,2 Dong-Ryeol Ryu,3 Soon hyo Kwon.1,2 1Soon Chun 
Hyang Univ., Seoul, Republic of Korea; 2Hyonam Kidney Laboratory, Seoul, 
Republic of Korea; 3Ewha Womans University, Seoul, Republic of Korea.
Background: Although it is well known that the expression and activity of Sirt-
1 are decreased in the aged kidney, the role of interaction between Sirt-1 and hypoxia-
inducible factor (HIF)-1 is largely unknown. Here, we investigated whether HIF-1α could 
be a deacetylation target of Sirt-1 and the effect of their interaction on age-associated renal 
injury.
Methods: Five-week-old (young) and 24-month-old (old) male C57Bl/6J mice were 
assessed for their age-associated changes. To clarify the underlying mechanisms, HK-2 
cells were exposed to hypoxia. The effect of chronic activation of HIF-1α was investigated 
using tubular cell-specific HIF-1α transgenic mice.
Results: Kidneys from aged mice showed increased infiltration of CD68 positive 
macrophages, higher expression of extracellular matrix (ECM) proteins, and apoptosis 
than young controls. They also showed decreased expression of Sirt-1 along with increased 
acetylated HIF-1α. Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 level, which is 
regulated by HIF-1α, was significantly higher in aged mice suggesting that HIF-1α activity 
is increased. In HK-2 cells, Sirt-1 inhibitor sirtinol or siRNA-mediated knock-down of 
Sirt1 enhanced apoptosis and ECM accumulation whereas Sirt1 over-expression induced 
the opposite changes. During hypoxia, Sirt-1 was down-regulated, which allowed the 
acetylation and activation of HIF-1α. Resveratrol, a Sirt1 activator, effectively prevented 
hypoxia-induced production of ECM proteins, mitochondrial damage, reactive oxygen 
species generation, and apoptosis. The findings that Sirt1-induced deacetylation of HIF-
1α inhibits HIF-1α activity were also confirmed by Sirt1 over-expression under hypoxic 
condition and by resveratrol treatment or Sirt1 over-expression in HIF-1α transfected HK-2 
cells. Finally, we confirmed chronic activation of HIF-1α promoted apoptosis and fibrosis 
using tubular cell-specific HIF-1α transgenic mice.
Conclusions: Taken together, our data suggest that Sirt-1-induced deacetylation of 
HIF-1α may have protective effects against tubulointerstitial damage in aged kidney.
Funding: Government Support - Non-U.S.
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Podocyte-Specific Knockout of the Transcriptional Factor C/EBPα 
Aggravates Podocyte Senescence and Kidney Injury in Aging Mice
Liwen Zhang,1 Fangfang Zhou,1 Liu Jian,2 Xialian Yu,3 Yunzi Liu,1 
Weiming Wang.1 1Department of Nephrology, Ruijin Hospital, Shanghai Jiao 
Tong University School of Medicine, Shanghai, China; 2Ruijin Hospital, 
Shanghai, China; 3Ruijin Hospital Institute of kidney research, Shanghai, China.
Background: CCAAT/enhancer binding protein α (C/EBPα) is a widely expressed 
transcriptional factor, participating in regulation of metabolism, inflammation and 
differentiation. We have previously showed that C/EBPα expression was suppressed in 
glomerular cells, particularly in podocytes, in focal segmental glomerulosclerosis (FSGS), 
and have demonstrated its anti-inflammatory effects in FSGS in vivo and in vitro. And as 
terminally differentiated cells, podocytes are vulnerable to stress and play a central role in 
kidney aging. However, the specific role of C/EBPα in kidney aging remains undefined.
Methods: By crossing floxed C/EBPα mice with Pod-Cre mice, we generated 
podocyte-specific C/EBPα knockout mice. Both the homozygous transgenic mice (KO) 
and their wild-type littermates (WT) were sacrificed at 3 and 20 months of age as young 
and aging groups, respectively. Immortalized mouse podocyte line with transient C/EBPα 
overexpression and induced senescence by adriamycin (ADR) were used for in vitro 
experiments.
Results: KO-Young kidneys showed little morphological or gene expression change 
except reduced C/EBPα compared to WT-Young kidneys. In WT-Aging mice, foot 
process effacement, positive senescence-associated β-galactosidase (SA-β-Gal) staining 
accumulation in podocytes, glomerulosclerosis and tubular basement membrane thickening 
occurred, accompanied by epithelial-mesenchymal transdifferentiation and AMPK-SIRT1-
PGC1α-mitochondria axis inhibition in tubular cells. These were aggravated in KO-Aging 
mice, as well as significant albuminuria and decreased podocyte markers occurred. In 
ADR induced senescent model in cultured podocytes, C/EBPα was down-regulated, and 
vimentin, CTGF, VEGFA and IL-6 increased. These phenotypes was rescued by C/EBPα 
overexpression.
Conclusions: These findings suggest that loss of C/EBPα accelerates podocyte 
senescence, aggravating glomerulosclerosis and tubular injury in aging mice. Targeting C/
EBPα in podocytes may be a novel strategy for improving kidney aging.
Funding: Government Support - Non-U.S.
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Hospitalizations within the First Year and Survival in Patients Aged Above 
80 Who Start Dialysis in Emergency
Patrick Saudan,1 Cyrielle Alves,1 Amalie Frandsen,2 Thomas Ernandez,1 Pierre-
Yves F. Martin.1 1Division of Nephrology, Geneva University Hospitals, Geneva, 
Switzerland; 2SZO Visp, Zeneggen, Switzerland.
Background: Implementation of dialysis in octogenarians is a debated question on 
account of an unfavourable short-term prognosis. We therefore analyzed what is the impact 
of planned implementation versus emergency dialysis on first year hospitalizations and 
survival in this population.
Methods: During the past 16 years, all patients who started maintenance dialysis in 
our unit were reviewed. Patient’s demographic and clinical characteristics were collected. 
Emergency implementation of maintenance dialysis was defined as no prior referral to a 
nephrologist one month before starting dialysis.
Results: From 2000 to the end of 2016, 684 patients started maintenance dialysis in our 
unit, of whom 96 were aged 80 and above. Mean age was 83 ± 2.4 years. Hemodialysis and 
peritoneal dialysis were implemented in 78 and 18 patients respectively. There were 66% 
male, 33 % diabetic and median eGFR at start of dialysis was 8± 3 ml/min. Emergency 
dialysis was implemented in 44% of the patients. Overall mean survival was 33 ± 3 months. 
One-year mortality was 36.4% in referred patients who had emergency dialysis and 11.5% 
patients with planned dialysis. One-year mean survival was 334±12 days in patients with 
planned dialysis implementation versus 274± 21days in those who had emergency dialysis 
(p< 0.004). In a multivariate analysis including prior referral, age, gender, comorbidity 
score and dialysis modality, one-year survival was only associated with prior referral (HR: 
0.36; 95% CI. 013-0.98). In patients with planned dialysis implementation, one -year 
hospitalization-free days were 269±108 versus 212± 136 days in those who had emergency 
dialysis (p< 0.03).
Conclusions: Prior referral to nephrologists substantially increase one-year 
hospitalization-free days and survival after dialysis implementation in ESKD patients aged 
above 80.
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Risk of the Dialysis Disequilibrium Syndrome in Japanese Elderly
Saeko Kagaya-Takeuchi,1 Hiroyuki Sato,1 Gen Yamada,1 Yoichi Takeuchi,2 
Tasuku Nagasawa,2 Mariko Miyazaki.2 1Japanese Red Cross Ishinomaki 
Hospital, Ishinomaki, Japan; 2Tohoku University Hospital, Sendai, Japan.
Background: In Japan, there is an increased number of elderly patients with end-stage 
renal disease (ESRD). Elderly patients are more likely to develop a dialysis disequilibrium 
syndrome (DDS). To improve their quality of life, recognizing the mild symptoms of DDS 
is necessary. High level of blood urea nitrogen and severe metabolic acidosis are regarded as 
risk factors of DDS, but the accurate incidence of them remains unclear in Japan. Here, we 
aim to evaluate the incidence and risk of mild to severe DDS for the well-managed ESRD 
patients in a single facility.
Methods: A total of 75 ESRD patients aged over 65 years were included, who had 
undergone scheduled hemodialysis after arteriovenous fistula creation at our hospital 
from 2015 through 2017. The DDS, or primary outcome, is defined as the mild to severe 
symptoms developing at the first dialysis treatment like headache, nausea and/or vomiting, 
appetite loss, muscle cramp, psychomotor agitation, and convulsions. Demographics and 
clinical data obtained before first dialysis were assessed as covariates to calculate the 
adjusted odds ratio in the multivariate analysis.
Results: The DDS was observed in 23 of 75 patients of interest. Headache was the most 
common symptom of them. Logistic regression model revealed that low level of eGFR, 
excessive fluid removal, and non-medication of sodium bicarbonate were independently 
associated with DDS in the ESRD elderly. Oral sodium bicarbonate was administered to 
36 patients. Significant difference was found in serum [HCO3
-] between two groups with 
and without oral sodium bicarbonate (median 19.7 mEq/L [IQR: 13.1 - 29.1] vs. median 
17.0 mEq/L [IQR: 6.70 - 27.7], P = 0.015) using Mann-Whitney U test. These suggested 
that efficient dose of bicarbonate were taken in the ESRD patients. After adjustment for 
covariates, oral sodium bicarbonate for preventing metabolic acidosis significantly reduced 
the incidence of primary outcome (adjusted odds ratio 0.21 [95%CI: 0.06 - 0.77], P = 0.019).
Conclusions: At the first dialysis treatment for the ESRD elderly, we should pay 
attention to metabolic acidosis as a risk developing DDS. The effectiveness of oral sodium 
bicarbonate is necessary to be examined by prospective studies.
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Outcomes Among Those Receiving Veterans Affairs (VA) Insurance in the 
United States
Scott Reule,1,4 Donal J. Sexton,3 Robert N. Foley.2 1Medicine, University of 
Minnesota, Minneapolis, MN; 2University of Minnesota, Minneapolis, MN; 3The 
Irish Longitudinal Study on Ageing (TILDA), Trinity College Dublin., Dublin, 
Ireland; 4Medicine, Department of Veterans Affairs, Minneapolis, MN.
Background: Recent policy initiatives seek to address barriers to subspecialty care 
for veterans based on clinic wait times and geographic distance through a mechanism 
of outsourcing to community providers. Due to limited Veterans Health Care Service 
(VAHCS) capacity to provide care to those with end-stage kidney disease (ESKD), we set 
out to describe characteristics, trends and important healthcare outcomes among Veterans 
Affairs (VA) insured patients from 1995-2012.
Methods: United States Renal Data System (USRDS) combined with United States 
(US) census data was used to compare baseline characteristics and adjusted outcomes for 
mortality and transplantation among those initiating maintenance renal replacement therapy 
receiving VA insurance.
Results: A total of 32,035 VA insured patients initiated maintenance RRT over the 
time period of 1995-2012 with follow up extending to June 30th, 2014. Compared to 1995-
1996, overall incidence of RRT initiation increased in a linear fashion (IR 1.94, 2011-2012). 
Subgroups experiencing the greatest increase included those > 65 years of age (IR 2.16), 
female (IR 2.54), and white patients (IR 2.35). Compared to 1995 - 2004, VA insured 
patients initiating between 2005 – 2012 were more likely to be 40-64 years of age (51.3% vs. 
50%), > 65 years of age (47.3% vs. 46.4%), and less likely to be female (8.4% vs. 9.4%) or 
Hispanic (8.7% vs. 10.9%). No difference in mortality hazard was observed in demography 
adjusted models (AHR 1.03; CI 0.99 – 1.08), however, VA insured patients were more likely 
to be listed for (AHR 1.23; CI 1.10 – 1.37) and to receive kidney transplantation (AHR 1.19; 
CI 1.03 – 1.38).
Conclusions: In conclusion, VA insured patients initiating RRT has increased 
significantly in recent years. While older patients are increasingly likely to have initiated 
RRT in recent years, the finding of no mortality difference in adjusted models is reassuring.
Funding: Other NIH Support - NIH UL1TR000114.
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Impact of Hemodialysis Hours on Outcomes in Elderly Hemodialysis 
Patients
Emily K. Yeung,3 Kevan Polkinghorne,1 Matthew A. Roberts.2 1Monash Medical 
Centre and Monash University, Melbourne, VIC, Australia; 2Eastern Health and 
Monash University, Melbourne, VIC, Australia; 3Monash Health, Melbourne, 
VIC, Australia.
Background: Longer treatment time is associated with improved outcomes in 
hemodialysis (HD) patients. Longer treatment times pose additional challenges in the 
elderly, who are more likely to suffer from conditions like arthritis which make sitting for 
long periods uncomfortable. The aim of this study is to determine whether or not a mortality 
benefit exists with longer treatment time in elderly (age ≥ 65 years) HD patients.
Methods: Data was obtained from the Australia and New Zealand Dialysis & 
Transplant Registry. Incident patient on thrice weekly HD were included if they were 
≥65 years of age at HD commencement. Subjects entered the analysis at 90 days after
start of HD. The exposure of interest was treatment time (hours per HD session) at HD
commencement categorised into 5 groups. The primary outcome was all-cause mortality.
Censoring events were transplantation, switch to another dialysis modality, recovery of
kidney function, or loss to follow up. Cox regression models adjusting for age and treatment 
time and age interaction were assessed.
Results: 8992 subjects were included in the analysis with 30541 person-years of data. 
The incidence rate of death was 16 per 100 person-years. The risk of death decreased with 
increasing duration of dialysis. However, inclusion of age in the model attenuated this 
association. The interaction of age and hours was not significant (p=0.895). Inclusion of 
gender in the model did not alter associations.
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Conclusions: Longer treatment times are associated with reduced risk of mortality in a 
dose-response relationship. However, once adjusted for age, there is no longer a significant 
mortality benefit to longer hours. This suggests that in the elderly, longer dialysis hours may 
not reduce mortality risk, and other factors such as quality of life should be considered in 
a dialysis prescription.
SA-PO738 Poster Saturday
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Associations of Cognitive Function and Education Level with All-Cause 
Mortality in Adults on Hemodialysis: The COGNITIVE-HD Cohort Study
Anita van Zwieten,1,2 Germaine Wong,1,2 Marinella Ruospo,3,4 Armando Teixeira-
Pinto,1,2 Clement Loy,1,6 Jonathan C. Craig,1,2 Giovanni F. Strippoli.3,5 The 
COGNITIVE-HD Study Investigators 1Sydney School of Public Health, 
University of Sydney, Sydney, NSW, Australia; 2Centre for Kidney Research, 
Kids Research Institute, Children’s Hospital at Westmead, Westmead, NSW, 
Australia; 3Diaverum Medical Scientific Office, Lund, Sweden; 4Division of 
Nephrology and Transplantation, Amedeo Avogadro University of Eastern 
Piedmont, Novara, Italy; 5Department of Emergency and Organ Transplantation, 
University of Bari, Bari, Italy; 6Huntingdon Disease Service, Westmead 
Hospital, Westmead, NSW, Australia.
Background: Cognitive impairment is common in dialysis patients and is associated 
with lower education levels. Associations of cognitive impairment and education with 
mortality in dialysis patients are understudied. We aimed to assess the association between 
cognitive function and all-cause mortality in adults on hemodialysis, and the independent 
and interactive effects of education.
Methods: We recruited adult hemodialysis patients from 20 centers in Italy, assessing 
their cognitive function on 5 domains (memory, attention, executive function, language, 
perceptual-motor function) with 10 neuropsychological tests, and their self-reported 
education. We examined associations of cognition (any domain impaired, number of 
domains impaired, global score from principal components analysis of all tests) and 
education with all-cause mortality in multivariable Cox models.
Results: Of 958 patients, 676 participated (70.6%). Patients’ median age was 70.9 
years (IQR: 59.9-78.1) and 262 (38.8%) were female. Education levels were 338 (50.0%) 
primary/less, 163 (24.1%) lower secondary, 175 (25.9%) upper secondary/higher. Of 664 
with data, 527 (79.4%) were impaired on at least 1 domain. Median follow-up was 3.3 
years (IQR: 1.9-3.6) and there were 206 deaths in 1874.2 person-years. Adjusted HR (95% 
CI) for cognition were: 1.77 (1.07-2.93) for any impairment (referent: none, N=630); 1.48 
(0.82-2.68) for 1 domain impaired, 1.88 (1.01-3.53) for 2 domains, 2.01 (1.14-3.55) for 3
or more (referent: none, N=564); 0.68 (0.51-0.92) per standard deviation increase in global 
cognitive score (N=429). Adjusted education HR (95% CI) were 0.94 (0.61-1.45) for lower 
secondary and 1.49 (1.02-2.18) for upper secondary/higher (referent: primary/less, N=630). 
The cognition-by-education interaction was not significant (p=.691).
Conclusions: Cognitive impairment appears to predict mortality in hemodialysis 
patients.
Funding: Commercial Support - Diaverum (renal services provider), Government 
Support - Non-U.S.
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Validation of Indices Predicting 6 Month Mortality for Incident Dialysis 
Patients Over 75
Bjoerg Thorsteinsdottir,1 LaTonya J. Hickson,1 Rachel Giblon,1 
Natalie B. Connell,1 Ladan Zand,1 Navdeep Tangri,2 Robert C. Albright.1 1Mayo 
Clinic, Rochester, MN; 2Nephrology, Seven Oaks General Hospital, Winnipeg, 
MB, Canada.
Background: Prognosis is one of the pinnacles of shared decision making. Much 
research has been done in the development of valid prognostic tools for mortality in patients 
on dialysis, however the performance and clinical applications of these tools in elderly 
incident dialysis patients remains to be determined. We aimed to find the best performing 
prognostic tool for short term mortality in elderly incident dialysis patients.
Methods: Six validated indices (Foley, NCI, REIN, newREIN, Thamer, and Wick) 
were identified in a systematic review for short term mortality prediction in incident dialysis 
patients. We applied these indices to an established cohort of 349 incident dialysis patients 
who were >75y old and used each to predict 6 month mortality. Variables were extracted 
from the medical record, and missing variables were imputed. Models were compared using 
the c-statistic, i.e. area under the receiver operating characteristic curve (ROC). Sensitivity 
and specificity were also calculated.
Results: The average age of our population was 81.5 years, 65.9% male, median 
survival was 351 days. The ROC ranged from 0.57 to 0.73, with the Foley and Wick indices 
performing the best, see Figure 1. The following cutoff scores yielded a specificity of >50% 
and >90% respectively in predicting mortality: Foley 7 and 10, NCI 4 and 10, REIN 4.2 and 
8.2, REIN_new 12.1 and 16.4, Thamer 4.2 and 6.5, Wick 6 and 10. Sensitivity ranged from 
45.8-76.4 for 50% mortality prediction with Wick having highest sensitivity and 9.0-22.0 
for 90% mortality with Foley having highest sensitivity.
Conclusions: Most of the indices can predict which patients are more likely than not to 
die within 6 months of dialysis start with acceptable sensitivity and specificity. Higher cutoff 
scores can be used to predict death with high specificity (>90%) but at the considerable loss 
of sensitivity. The Wick and Foley indices performed best.
Funding: NIDDK Support, Other NIH Support - NIA K23 award, Private Foundation 
Support
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Prognosis in Shared Decision Making for Advanced CKD: A Qualitative 
Study
Bjoerg Thorsteinsdottir,1 LaTonya J. Hickson,1 Susan H. Curtis,2 Annika Beck,3 
Brigid M. Amberg,3 Nataly R. Espinoza,3 Cristina Wirtz,3 Ladan Zand,1 
Erin Dahlen,3 Kevin Shaw,3 Ian G. Hargraves,3 Robert C. Albright.1 1Mayo Clinic, 
Rochester, MN; 2Mayo clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN.
Background: Prognostic information is key to shared decision making. Efforts are 
underway to enhance and implement prognostic tools for prediction of CKD progression 
and mortality. Whether patients are receptive and value such individualized risk predictions 
is unclear.
Methods: Semi-structured telephone or in-person interviews were conducted 
following routine visits to a multidisciplinary CKD clinic. Each patient was asked about his 
or her perspectives and experiences related to sharing dialysis risk prediction and prognosis 
with patients. Interviews were audiotaped, transcribed verbatim, and analyzed. Our team 
engaged in line-by-line, open, axial, and selective coding followed by content analysis.
Results: We enrolled 19 patients stage 3b-5, age 67-89 (avg. 78.57), 74% men. 
Often patients dreaded the possibility of starting dialysis, considering it a “last resort.” 
Most patients understood that dialysis would impose significant limitations on their 
freedom. Almost all patients reported that they wanted to receive (or would not object 
to) a prediction of their risk of progressing to dialysis, even if it would be “kinda scary.” 
Patients reported this could help them “plan for the future” and motivate them to adhere to 
preventive measures, but noted that the prediction might be upsetting to some. There was 
less agreement about the value of receiving a life expectancy prediction. Patients suggested 
that it should be offered only when a patient requests it or agrees to it. A life expectancy 
prediction would help patients “make an informed decision” about how to treat their CKD, 
and help them make preparations for the end of life if needed. We identified that several 
patients conflated the risk of progression to dialysis with the risk of death, equating refusing 
dialysis with rapid death.
Conclusions: This prospective patient-centered qualitative study confirms previous 
survey results suggesting that CKD patients are interested in prognostic information. 
Furthermore our findings add context and depth to the value of risk prediction in the clinical 
encounter and suggest ways in which to address individualized prognosis with patients. 
This can help further the development of intuitive shared decision making tools to relay this 
information to the patients who want it.
Funding: NIDDK Support, Other NIH Support - NIDDK K23 award, NIA K23 award, 
Private Foundation Support
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Factors Affecting Mortality in the Very Elderly on Haemodialysis – A 
Single Centre Study
Tayeba Roper,1 Thomas G. De’Ath,2 Maggi Steele,1 Joe Wang,3 
David Makanjuola.4 1Epsom & St Helier NHS Trust, Surrey, United Kingdom; 
2Epsom and St Helier NHS Trust, London, United Kingdom; 3Epsom & St Helier 
Hospital NHS Trust, London, United Kingdom; 4St. Helier Hospital, Carshalton, 
United Kingdom.
Background: The number of elderly patients currently managed on haemodialysis 
(HD) is increasing. We aimed to determine the outcome of very elderly patients (over the 
age of 85 years) on HD and to identify any factors associated with mortality in this group.
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Methods: Data were retrospectively collected from a single UK centre over 11 years 
(2003-2014). HD dependence was defined as those requiring HD for more than 90 days. All 
patients starting HD at the age of 85 years or over were included. Demographics, reasons 
for starting HD, access at initiation and co-morbidities were recorded. The Davies Co-
morbidity Score (DCS) was used to quantify co-morbidities in patients. Outcomes were of 
death, recovery of function and continued HD. Chi-square tests were used for categorical 
analysis of DCS.
Results: Of 149 patients, 144 were included (5 excluded due to lack of data). Age 
ranged from 85 to 98 years (modal age 85.04). 73.6% were male. Time on HD ranged 
from 95 - 2598 days (median 546 days). Overall mortality at 1-year was 18.8% (18.2% 
for 85-90 years and 25% for over 90 years). 74.3% started HD with a line and 25.7% with 
an arterio-venous fistula (AVF): A higher 1-year mortality (16.7%) was seen in the former 
group compared to the latter (2.1%). Overall 72.2% were non-diabetic (ND) with mortality 
at 1-year being 16.0% compared to 2.8% in diabetic patients. Mortality according to DCS 
is shown in Table 1. There was no significant difference in 1-year mortality between DCS 
groups (p >0.05).
Conclusions: Our HD cohort demonstrates better overall 1-year survival than that of 
the UK Renal Registry 2015 (71% in 85+ years). Type of HD access was the most important 
factor affecting mortality. Though the reasons for this are varied, HD via a line may reflect 
a more acute decline in renal function. DCS and diabetes were not independent predictors 
of mortality in this cohort. It may be that, in this age group, traditional markers of renal 
progression are no longer relevant. Further work is needed to look at other markers of 
survival and HD benefit in this age group, such as frailty and quality of life scores, to aid 
decision making with regards to HD in the very elderly.
Table 1
SA-PO742 Poster Saturday
Geriatric Nephrology
Prognostic Value of a Geriatric Assessment in Older Patients Starting 
Dialysis
Ismay N. Van Loon,1,2 Namiko A. Goto,3 Frans T. Boereboom,1,4 
Marianne C. Verhaar,3 Marije Hamaker.4 1Dianet Dialysis Center, Utrecht, 
Netherlands; 2Department of Nephrology and Hypertension, University Medical 
Center Utrecht, Utrecht, Netherlands; 3University Medical Center Utrecht, 
Utrecht, Netherlands; 4Diakonessenhuis, Utrecht, Netherlands.
Background: A geriatric assessment (GA) is a structural method for identifying frail 
patients. The prognostic value of a GA in end-stage kidney disease (ESKD) is not known. 
The subject of the GOLD (Geriatric assessment in OLder patients starting Dialysis) Study 
was to assess the relation of GA at dialysis initiation with poor outcome.
Methods: Patients ≥65 years old were included just prior to dialysis initiation. All 
underwent a GA, including assessment of ADL, instrumental (i)ADL, mobility, cognition, 
mood, nutrition, comorbidity, and a frailty screening (Fried Frailty Index, FFI). Quality of 
life (QoL) was scored with the visual analogue scale of the EuroQol-D5 (ranging from 0 
[poor] to 10 [good]). Outcome measures were 6-and 12-months mortality, and 6-month 
hospitalization and change in QoL. Mortality was assessed with cox-regression and 
hospitalization with logistic regression, adjusting for age, sex and comorbidity.
Results: 192 patients were included, mean age 75±7 years, of whom 48% had ≥ 3 
geriatric impairments and were considered frail. Mortality rate was 8% and 15% for 
6-and 12-months. ADL, depressive symptoms and malnutrition were significantly related 
to 1-year mortality. Compared to non-frail patients, 1-year mortality risk was higher in
patients with ≥ 3 impairments (HR 2.61 [95%CI 1.14-5.98]). Frailty was associated with 
lower baseline QoL (6.0±1.4 vs. 6.6±1.4, p=0.01), but not with 6-month change (overall
improvement +0.3±1.4, p<0.01). Depressive symptoms, ADL and iADL were associated
with hospitalization, but overall GA was not. Screening for frailty with the FFI resulted
in 44% frail patients and FFI was related to mortality (HR 4.5 [95%CI 1.44-14.36) and 
hospitalization (OR 1.93 [95%CI 1.00-3.72]).
Conclusions: Geriatric impairment at dialysis initiation is related to mortality, 
hospitalization and QoL. A GA offers the advantage of both risk assessment and 
identification of potential targets for intervention and improving QoL. Whether these results 
contribute to decision-making in the pre-dialysis population should be the subject of further 
research.
Funding: Private Foundation Support
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Quality of Life After Initiation of Dialysis or Maximal Conservative 
Management
Ismay N. Van Loon,2,1 Namiko A. Goto,3 Frans T. Boereboom,2,4 
Marianne C. Verhaar,3 Marije Hamaker.4 1Nephrology%Hypertenstion, 
University Medical Center Utrecht, Utrecht, Netherlands; 2Dianet Dialysis 
Center, Utrecht, Netherlands; 3University Medical Center Utrecht, Utrecht, 
Netherlands; 4Diakonessenhuis, Utrecht, Netherlands.
Background: Maximal conservative management (MCM) may be an appropriate 
option for dialysis in some elderly patients with end stage kidney disease (ESKD). Whether 
MCM offers a better quality of life (QoL) compared to dialysis is not known. In the GOLD 
(Geriatric assessment in OLder patients starting Dialysis) Study the trajectory of QoL was 
assessed in patients starting dialysis or MCM.
Methods: Patients ≥65 years old were included just prior to dialysis initiation or 
after decision for MCM. Baseline data included demographics, QoL (EuroQol-D5 visual 
analogue scale [VAS], 0[poor]-10[good]) and geriatric impairment: mobility, (instrumental)
ADL, mood, cognition, nutrition and comorbidity. Six-months follow-up data included 
QoL, mortality and hospitalizations. In both groups, logistic regression was used to assess 
the relation between impairment and deterioration of QoL (≥1 point), adjusting for age, sex, 
comorbidity and baseline QoL.
Results: The cohort comprised 192 dialysis (23% PD) and 88 MCM patients. The 
MCM patients were older (mean age 82±6 vs. 75±7 years, p< 0.01) and mean kidney 
function was better (eGFR 11.5±4.0 vs. 8.0±2.9 ml/min/1.73m2, p<0.01). In both groups, 
poorer QoL was significantly associated with impairment in (i)ADL, mobility and mood; 
in dialysis patients also with comorbidity. Baseline QoL did not differ between dialysis and 
MCM (6.3±1.3 vs.6.3±1.4 respectively; p=0.91) and change in QoL was +0.3±1.4 (p< 0.01) 
and -0.4±1.4 (p<0.01) respectively. At 6 months follow-up, 8% of patients starting dialysis 
had died and Qol in 23% deteriorated, while 40% showed improved QoL. This was 18%, 
31% and 15% respectively in MCM. Impairments were not associated with deterioration in 
QoL in both groups. Hospitalization differed relevantly (24% in MCM vs. 51% in dialysis; 
p< 0.01).
Conclusions: QoL was comparable for patients starting dialysis and MCM. Small 
improvement of QoL after dialysis start was seen. For MCM, QoL slightly decreased after 
six months. Geriatric impairment is associated with baseline QoL, but not with deterioration 
after start of dialysis or MCM.
Funding: Private Foundation Support
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Identification and Prioritization of Quality Indicators for Conservative 
Kidney Management
Tyrone Harrison,1 Helen Tam-Tham,2 Brenda Hemmelgarn,2 Matthew T. James,2 
Aynharan Sinnarajah,2 Chandra M. Thomas.2 1Medicine, University of Calgary, 
Calgary, AB, Canada; 2University of Calgary, Calgary, AB, Canada.
Background: Conservative kidney management (CKM) is comprehensive patient-
centred care for individuals with end-stage renal disease (ESRD) without renal replacement 
therapy. CKM focuses on delaying progression of kidney disease, symptom management, 
and frequent communication and support. Currently there is no consensus as to what 
constitutes high quality CKM. We aimed to develop a consensus-based set of quality 
indicators (QIs) for the conservative management of ESRD.
Methods: A nominal group technique study of patients and caregivers was used to 
identify and prioritize QIs for CKM, guided by QIs reported in the literature. A Delphi 
process with healthcare providers was used to rate the QIs using a 9-point Likert scale, 
in a series of four rounds, until consensus was reached based on pre-specified criteria. 
Consensus for the QIs in the Delphi process was met if the mean rating on the Likert scale 
was ≥7.0 and percent agreement was >75%.
Results: Sixteen patients and caregivers from Calgary, Canada participated in two 
nominal group meetings. Ninety-one multidisciplinary healthcare providers from 10 
countries took part in the Delphi process. Patients and caregivers prioritized QIs focused 
on quality of dying and access to CKM personnel. Healthcare providers prioritized 99 QIs 
(out of a total 160) that met consensus criteria for inclusion. Nearly all (98.7%) participating 
healthcare providers indicated that quality of CKM delivery was important to measure, 
though less than a third (32.1%) measured quality in their provision of CKM. The most 
highly rated QI in the Delphi process was the “percentage of patients that die in the place 
they desire.” There were several limitations as participants were largely from high-income, 
English-speaking countries, and most had structured CKM programs in place.
Conclusions: Quality of CKM care is important to patients, caregivers, and healthcare 
providers, though differences in priorities were noted. CKM programs and healthcare 
providers can use this international consensus-based QI list to evaluate and modify their 
CKM program delivery.
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Patient-Reported Experiences of a Shared Decision-Making Process on 
Dialysis or Conservative Care
Wouter Verberne,1 Willem Jan W. Bos.1,2 1St Antonius Hospital, Nieuwegein, 
Netherlands; 2Leiden University Medical Center, Leiden, Netherlands.
Background: Older patients approaching end-stage renal disease face the decision 
whether to start dialysis, or conservative care (CC)—which is argued to be a reasonable 
treatment option, particularly in the oldest old and those with severe comorbidity. Shared 
decision-making has been recommended to align treatment plans with the patient’s values 
and preferences. Little is known regarding experiences of patients with such decision-
making process.
Methods: We developed a questionnaire in collaboration with the Dutch Kidney 
Patients Association to assess older patients’ experiences of their decision-making process 
on choosing dialysis or CC. We included 99 patients with stage 4/5 CKD and aged ≥70 
years, who had chosen dialysis (n=75) or CC (n=24). A shared decision-making process had 
been initiated by a multidisciplinary team when the estimated glomerular filtration rate fell 
below 20 mL/min/1.73m2, and included in-depth discussions in which oral and/or written 
information was given about dialysis and CC.
Results: Overall, patients stated to be satisfied with the decision-making process 
(median score on a 11-point Likert scale; dialysis group: 8.0 vs. CC group: 9.0; p = 0.06), as 
well as with their treatment decision (8.0 vs. 9.0; p = 0.07). Most felt they had enough time 
(79% vs. 87%) and information (80% vs. 73%) to make a decision, although factors as more 
time, information, and deliberation were mentioned as potential improvements. Patients 
choosing dialysis reported life prolongation and feeling of lack of choice as important 
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reasons for their decision, whereas quality of life and treatment burden were important 
reasons in choosing CC. 53% of the patients in the dialysis group considered their own 
opinion as most important in their treatment choice compared to 95% in the CC group 
(p = 0.003). More patients in the dialysis group felt forced by the situation to make a decision 
(32% vs. 4%; p = 0.01), or still doubted their treatment decision (17% vs. 0%; p = 0.03).
Conclusions: In this small Dutch sample, older kidney patients reported to be overall 
satisfied with a shared decision-making process on choosing dialysis or CC, although some 
had important recommendations for improvement. Patients had contrasting reasons for their 
treatment choice. Patients choosing CC experienced more autonomy and ownership in their 
decision-making.
Funding: Commercial Support - Roche; Zilveren Kruis Health Insurance, Private 
Foundation Support
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Shared-Decision Making and Renal Supportive Care: A Patient-Centered 
Clinical Trial
Mark L. Unruh,1 Sarah L. Goff,2 Jamie Klingensmith,2 Nwamaka D. Eneanya,4 
Kelly Chong,1 Michael J. Germain,5 Lewis Cohen.3 1University of New Mexico, 
Los Ranchos, NM; 2University of Massachusetts Medical School - Baystate, 
Springfield, MA; 3Baystate Medical Center, Springfield, MA; 4Massachusetts 
General Hospital, Boston, MA; 5Renal and Transplant Assoc of New England, 
Hampden, MA.
Background: End-of-life (EOL) care planning in ESRD patients occurs infrequently, 
contributing to decreased quality of care and patient suffering. ESRD patients are much 
more likely to receive intensive care and less likely to receive hospice than other chronic 
conditions. The SDM-RSC study sought to create an easily replicable patient-centered 
model for EOL care planning discussions in dialysis units and to determine impacts on 
hospice use, EOL advanced planning, and to assess effect on patient quality of life.
Methods: We selected participants who were receiving maintenance hemodialysis 
and had poor prognoses using a validated prognostic instrument. Social workers and 
nephrologists received separate ACP training prior to inception of the intervention. 
Nephrologists participated in a one-hour training session that included reviews of mortality 
rates and ACP for hemodialysis patients. The social worker received a one-day training 
session and four additional telephonic “booster” sessions over two years. The intervention 
visit consisted of an initial patient and family meeting involving a dialysis social worker, 
and nephrologist; followed by ongoing contacts by the social worker and hospice contacts 
to dialysis units. We examined clinic-level data using an interrupted time-series design to 
assess changes in hospice usage over time.
Results: We recruited 125 participants from 18 dialysis units in 3 states. Our sample 
was 51% male, median age=70, 12% African-American, 14% American Indian, 46% White; 
and 37% Hispanic ethnicity. Overall clinic-level hospice usage did not vary significantly 
between pre- and post-intervention periods (observed average rate=25%). In participants 
that died during the study period, 48% stopped dialysis prior to death and 43% received 
hospice services. Of enrolled participants with follow-up, 75% had completed a healthcare 
proxy; 63% completed Medical (or Physician) Orders for Life-sustaining Treatment 
(MOLST/POLST). Quality of life indicators did not change significantly within 6 months 
of the initial meeting.
Conclusions: Clinic level effects of the intervention were not observed. There were 
important changes in EOL care planning for individuals, including completion of advanced 
care planning documents. The SDM-RSC intervention used existing staff at clinics making 
it practical to replicate.
Funding: Other U.S. Government Support
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Palliative Care Use and Patterns of End-of-Life Care in Hospitalized 
Patients with Calciphylaxis
Kabir O. Olaniran, Shananssa Percy, Sagar U. Nigwekar, Nwamaka D. Eneanya. 
Division of Nephrology, Massachusetts General Hospital, Boston, MA.
Background: Calciphylaxis (CUA) is a rare debilitating condition that is associated 
with poor quality of life and significant morbidity and mortality. Given that palliative care 
referrals are scarce in this population, we investigated the frequency of palliative care 
referrals and patterns of end-of-life (EOL) care in hospitalized CUA patients.
Methods: We included patients with CUA (confirmed by skin biopsy or clinical 
diagnosis via chart review) who were admitted to a large health care system in Boston, 
MA and died between 1/2014-4/2018. Terminal admissions were identified by chart review 
and outcomes included palliative care consultation, opiate use, receipt of cardiopulmonary 
resuscitation, mechanical ventilation, tube feeds, and vasopressor therapy, hospice referral, 
and place of death.
Results: Thirty CUA patients were identified. Seven percent had chronic kidney 
disease and 87% received dialysis. The median age at diagnosis was 60(15) years, 53% 
were female and 80% were White. The median Charlson Comorbidity Index score was 6(3) 
and median follow-up time was 63(104) days. Outcomes are displayed in Table 1.
Conclusions: Among CUA patients that died during the study period, less than half 
received palliative care consults and many patients received intense care prior to death. 
Furthermore, a minority of patients were referred for hospice care prior to death. Our data 
highlights the need for improved integration of palliative care to decrease care intensity and 
improve quality of EOL care for this seriously ill patient population.
Outcomes in Terminal Admissions
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In-Center Extended-Hour Hemodialysis Can Be Effective in Improving 
the Mortality of Elderly Dialysis Patients
Masaki Okazaki,1 Daijo Inaguma,2 Takahiro Imaizumi,1 Manabu Hishida,1 
Takaya Ozeki,1 Yoko Kubo,1 Yoshinari Yasuda,1 Sawako Kato,1 Naotake Tsuboi,1,2 
Hiroshi Kaneda,3 Shoichi Maruyama.1 1Nagoya University Graduate School of 
Medicine, Nagoya, Japan; 2Fujita Health University School of Medicine, 
Toyoake, Japan; 3Kamome Clinic, Yokohama, Japan.
Background: Amid the global problem of aging among dialysis patients, it has become 
more difficult to improve prognosis among dialysis patients. Despite previous reports that 
the extended-hour hemodialysis (HD) can reduce the risk of death, the impact of this 
treatment on elderly patients remains unclear. The aim of this study is to investigate the 
effect of extended-hour HD on elderly patients, using largest cohort of incident extended-
hour HD in Japan.
Methods: Multicenter retrospective cohort study; we included 205 consecutive patients 
who had received in-center extended-hour HD since the initiation of HD in 4 facilities 
during Oct. 2008 to Sept. 2017 (extended-HD). We also included 1382 consecutive patients 
who initiated conventional HD in 17 facilities during Oct. 2011 to Sept. 2013 as the control 
group (conventional). Each treatment group was divided into two age subgroups (over or 
less than 70 years old). We compared the risk for mortality during the first 5 years of follow-
up among the treatment groups and age subgroups.
Results: The mean age was 63.3±14 years in extended-HD and 68.1±13 years in 
conventional. The crude mortality in the extended-HD group was 3.9 deaths per 100 patient-
years compared with 7.9 deaths per 100 patient-years in the conventional group. Extended-
HD was associated with a 37% reduction in mortality after adjustment for age, sex, body 
mass index, diabetes, and cardiovascular disease (95% confidence interval (CI): 5-58%). In 
the subgroup analyses, elderly dialysis patients (>70 years old) treated with extended-HD 
had a 48% lower adjusted mortality than that of conventional (95% CI: 10-71%).
Conclusions: Especially for the elderly, treatment with extended-hour HD was 
associated with a lower risk of mortality compared to conventional HD.
Funding: Government Support - Non-U.S.
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Single Measurements of Fibroblast Growth Factor 23 and Clinical Risk 
Prediction in CKD
Daniel Edmonston,1 Rupal Mehta,2 Daniel Wojdyla,9 Xuan Cai,8 
Claudia M. Lora,3 Matthew R. Weir,4 John W. Kusek,10 Raymond R. Townsend,5 
Debbie L. Cohen,5 Jiang He,11 Alan S. Go,6 Tamara Isakova,7 Myles Wolf.1 for 
the CRIC Study Investigators 1Duke University, Durham, NC; 2Northwestern 
Univesrsity, Feinberg School of Medicine, Chicago, IL; 3University of Illinois at 
Chicago, Chicago, IL; 4University of Maryland School of Medicine, Baltimore, 
MD; 5University of Pennsylvania School of Medicine, Villanova, PA; 6Kaiser 
Permanente Northern California, Oakland, CA; 7Feinberg School of Medicine, 
Northwestern University, Chicago, IL; 8Northwestern University, Chicago, IL; 
9Duke Clinical Research Institute, Durham, NC; 10NIDDK, Bethesda, MD; 
11Tulane School of Public Health and Tropical Medicine, New Orleans, LA.
Background: Elevated fibroblast growth factor 23 (FGF23) levels are independently 
associated with a number of adverse outcomes in patients with chronic kidney disease 
(CKD) at the population level, but it is unknown if FGF23 testing can improve individual 
clinical risk prediction.
Methods: In 3879 participants in the Chronic Renal Insufficiency Cohort Study, we 
tested whether addition of a single baseline measurement of FGF23 testing to standard 
clinical risk predictors (Figure) significantly improves prediction of all-cause mortality, 
incident end-stage renal disease (ESRD), heart failure (HF) admission, and atherosclerotic 
events over periods of 3 (primary analysis), 5, and 8 years of follow-up. We assessed changes 
in C index, integrated discrimination improvement (IDI), relative IDI, and category-based 
net reclassification index (NRI). We also compared the incremental utility of FGF23 versus 
an analogous model using serum phosphate concentration.
Results: The base model best predicted incident ESRD and HF (Figure). The addition 
of FGF23 improved prediction of all-cause mortality and HF admissions by change in C 
index, IDI, and relative IDI (NRI trended towards significance), but not incident ESRD or 
atherosclerotic events (Figure). The years 5 and 8 results were qualitatively similar to the 
3-year results. FGF23 outperformed phosphate for all outcomes.
Conclusions: In CKD, single measurements of FGF23 improves prediction of risks
of all-cause mortality and HF admissions but not ESRD or atherosclerotic events. Future 
studies are needed to evaluate the predictive utility of repeated FGF23 testing.
Funding: NIDDK Support
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Even Low-Grade Proteinuria Increases Progression to Renal End-Points 
in Non-Diabetic Hypertensive Veterans
Olurinde Oni,3 Virginia J. Savin,2,1 Mukut Sharma,2,1 Ram Sharma,3 
Thomas Wiegmann,3 Rajat S. Barua,3 Rishi Sharma.4,2 1Kidney Institute, Univ. of 
Kansas Medical Center, KANSAS CITY, KS; 2KCVA Medical Center, Kansas 
City, MO; 3KCVA Medical Center, Kansas City, MO; 4Univ. of Missouri Kansas 
City, Kansas City, MO.
Background: Proteinuria is an indicator of renal injury but there is little quantitative 
information about the predictive value of low concentrations of urine protein in patients 
without diabetes. We hypothesized that incremental risk would accrue with increasing 
proteinuria in hypertensive, non-diabetic patients.
Methods: A cohort of 153,848 hypertensive non-diabetic patients in the VA national 
database (VINCI) and recorded urinalysis was categorized as ‘no proteinuria’ or by first 
recorded urine protein (dip-stick: ≤30, 31-100, and >100 mg/dl) and by CKD stage. 
Endpoints included ESRD and all-cause mortality. Baseline characteristics were compared 
using ANOVA, Chi square tests and non-parametric tests. Adjusted Cox regression, and 
Kaplan Meier analyses were conducted to compare risks.
Results: Proteinuric groups had accelerated progression to ESRD and combined renal 
endpoint, and had increased all-cause mortality (Logrank P<0.01). Proteinuria < 30 mg/dl 
was associated with renal endpoint and had a relatively smaller effect than higher grades 
proteinuria. Younger age, higher CKD stage, prior diagnosis of AKI, or use of ACEI, ARB 
or β-blocker at first proteinuria were associated with higher risk of progression and all-cause 
mortality.
Conclusions: We conclude that, in non-diabetic Veterans with hypertension, even low 
concentrations of proteinuria predict renal failure and mortality and should not be ignored. 
Early identification of proteinuria as a risk will permit research regarding novel mechanisms 
of progression and may define interventions to delay progression and lower mortality.
Funding: Veterans Affairs Support
Adjusted Hazard ratios for Renal Endpoints
¥ ESRD, mortality, or dialysis. All P values <0.01. Mean BMI=28.6; mean age=66.1 years. 
Covariates not shown.
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The Kidney Failure Risk Equation Predicts Progression to Hemodialysis 
in Cancer Patients with CKD
Luiz F. Souza,1 Ivens S. L Leite,1 Renato A. Caires,2 Fernanda O. Coelho,2 
Francisco Z. Mattedi,2 Veronica Torres,2 Elerson Costalonga.2,1 1University of 
Sao Paulo School of Medicine, Sao Paulo, Brazil; 2Sao Paulo State Cancer 
Institute - USP, Sao Paulo, Brazil.
Background: Cancer patients have a high prevalence of chronic kidney disease (CKD). 
The aim of this study was to assess prognostic factors for progression to hemodialysis (HD) 
in a cohort of cancer patients with CKD.
Methods: Among 397 outpatients with cancer referred to nephrology evaluation 
(2009-12), 202 had CKD according KDIGO definitions and at least 3 months of follow up. 
Clinical and biochemical data were retrieved from patient medical records. The primary 
endpoint was defined as progression to HD during follow up. The Cox regression was used 
to examine the association between the baseline features and progression to HD.
Results: Throughout a mean follow up period of 3.7±2.3 years, 10% of patients 
progressed to HD. Patients baseline features data are shown in Table 1. In the Cox 
regression analyses, the risk of HD estimated by the 4-variable Kidney Failure Risk 
Equation (aHR=1.05; 95% CI 1.03-1.06, p<0.001) was the strongest predictor of HD in our 
population after adjusments for CKD etiology.
Conclusions: In this cohort, traditional risk factors as hypertension, diabetes and 
albuminuria were associated with a greather risk of hemodialysis in univariated analysis. 
Beyond, the Kidney Failure Risk Equation was a good instrument for identifying a high risk 
of progression to HD among cancer patients with CKD.
Table 1. Baseline Features
Results are expressed as mean±SD and percentage. * < 0.05 vs Hemodialysis group
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Validation of the Kidney Failure Risk Equation in Primary Care Clinics in 
Southeast Asia
Yeli Wang,1 Francis Nguyen,2 John C. Allen,3 Ngiap chuan Tan,4 
Tazeen H. Jafar.1,2 1Program in Health Services and Systems Research, Duke-
NUS Medical School, Singapore, Singapore; 2Health Services Research Centre, 
SingHealth, Singapore, Singapore; 3Centre for Quantitative Medicine, Duke-
NUS Medical School, Singapore, Singapore; 4SingHealth Polyclinics, 
Singapore, Singapore.
Background: Patients with chronic kidney disease (CKD) are at high risk of 
progression to end stage kidney disease (ESKD). The Kidney Failure Risk Equation 
(KRFE) was developed to accurately predict the progression of CKD to kidney failure. 
However, it has not been validated in primary care clinic settings in Asia. The objective of 
this study was to validate the predictive utility of KFRE for ESRD risk, and compare it with 
that of eGFR alone in polyclinics in Singapore.
Methods: Electronic health records were extracted from 9 government clinics on 
117,528 patients aged 40 years or older visiting clinics during 1st Jan 2010 to 31st Dec 2012 
with at least one measurement of serum creatinine or proteinuria. All patients with CKD-EPI 
estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2 and proteinuria had KFRE 
evaluated using the 4-variable equation (age, sex, eGFR, ACR). ESRD was determined 
by linkage with Singapore Renal Registry. Area under the operating characteristics curves 
(AUC) was used to calculate the predictive utility for 5-year risk of ESRD with KFRE 
versus eGFR alone.
Results: A total of 17271 participants had eGFR <60 ml/min/1.73m2 of whom 49% 
were men, 80% were Chinese, 12% were Indian and 4% were Malays. After a mean follow-
up of 5 years, a total of 491 (2.8%) patients developed ESRD. The AUC (95% confidence 
interval) for KFRE and eGFR alone was 0.93 (0.92-0.94) and 0.89 (0.88-0.91), respectively.
Conclusions: The KFRE showed excellent predictive utility, which was better than 
eGFR alone for ESRD risk in this multi-ethnic population. We provided several thresholds 
below for the clinical decision making and implementation in primary care clinics in 
Singapore and possibly other Asian countries.
Funding: Government Support - Non-U.S.
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Validation and Assessment of Kidney Failure Risk Equations in Korean 
Population
Min woo Kang,1 Yong Chul Kim,1 Jung Nam An,2 Navdeep Tangri,3 Kwon 
Wook Joo,1 Yon Su Kim,1 Jung Pyo Lee.2 1Seoul National University Hospital, 
Seoul, Republic of Korea; 2Seoul National University Boramae Medical Center, 
Seoul, Seoul, Republic of Korea; 3University of Manitoba, Winnipeg, MB, 
Canada.
Background: Predicting the risk of chronic kidney disease (CKD) may facilitate early 
and appropriate nephrology care of CKD patients. Previously, kidney failure risk equations 
were developed in Canadian population and validated in more than 30 countries spanning 4 
continents. However, there is no validation data in Korean population. Thus, we attmped to 
evaluate the accuracy of the risk equations in Korean population and to adjust the equation.
Methods: SNU cohort, including 1315 patients with CKD in Seoul National University 
Hospital (SNUH) and Seoul National University Boramae Medical Center (SNUBMC), 
were studied. These cohorts collected data from 2001 through 2016. With the risk factors 
from the original risk equations, hazard ratios were estimated in SNU cohort and used 
to adjust the equation. The time horizon for risk prediction was 5 years. We used three 
risk prediction equations, 4-variable, 6-variable and 8-variable equations. Then, these 
three equations were evaluated using AUROC for the goodness of a predictor, integrated 
discrimination improvement (IDI) for discrimination, and net reclassification improvement 
(NRI) at 5 years.
Results: The mean age of the study population was 58 years, and the mean baseline 
eGFR was 73 mL/min/1.73m2. The three risk prediction equations showed great 
performance of prediction (AUROC, 0.91; 95% CI, 0.88-0.94 at 4-variable equation, 0.91; 
95% CI, 0.88-0.94 at 6-variable equation, 0.91; 95% CI, 0.89-0.94 at 8-variable equation). 
Using DeLong test, 4-variable equation and 6-variable equation were compared with at 
8-variable equation. There was no improvement in performance with 8-variable equation
(4-variable equation vs 8-variable equation, p=0.068 and 6-variable equation vs 8-variable 
equation, p=0.080)
Conclusions: Adjusted Kidney failure risk equation showed high performance of 
prediction in Korean population. However, further verification in a larger cohort may be 
necessary in the future.
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Validation of Predictive Model for Progression of CKD to ESRF in 
Singapore
Jolyn H. Pang,1 Jia Liang Kwek,2 Huihua Li,2 Lydia Lim wei wei,2 Jason Choo 
Chon Jun,2 Lina Choong,2 Choong Meng Chan,2 Marjorie W. Foo.2 1National 
University of Singapore, Singapore, Singapore; 2Singapore General Hospital, 
Singapore, Singapore.
Background: Risk stratification of chronic kidney disease (CKD) patients allows 
clinicians to individualize treatment and improves resource allocation on the national level. 
Tangri et al (JAMA. 2011 Apr 20;305(15):1553-1559) proposed and validated a predictive 
model for progression of chronic kidney disease to kidney failure in a Canadian population 
and subsequently in a meta-analysis of multinational cohorts. As accuracy of the prediction 
model may vary among different populations, we aim to validate this prediction model in a 
Singapore CKD cohort and to determine if a calibration factor is required.
Methods: The study population was derived from newly referred patients to 
Department of Renal Medicine at Singapore General Hospital (SGH), Singapore in 2009. 
Eight variables based on the most accurate model in the Tangri et al study were obtained 
within 90 days of the initial visit. Primary outcome measure is kidney failure in 5 years and 
time to kidney failure was defined from initial renal medicine visit to kidney failure.
Results: Out of 2216 patients reviewed, 795 were included in the analysis. The mean 
age is 65.8 years old, mean eGFR is 34.5ml/min/1.73m2. Majority are Chinese (74.6%) with 
15.5% Malay, 6.2% Indian, 1.1% Eurasian and 0.6% others (2 Thais, 1 Filipino, 1 Indonesian 
and 1 Arab). Six hundred and forty (80.4%) are on angiotensin converting enzyme inhibitor 
(ACEi) or angiotensin receptor blocker (ARB). Four hundred and ninety-seven (62.4%) 
have diabetes mellitus. Two hundred and twelve (26.7%) reached kidney failure. Mean time 
to renal failure is 1288 days (3.5 years). Both the 8-factor (age, gender, estimated glomerular 
filtration rate (CKD-EPI) (eGFR), albuminuria (ACR), serum albumin, serum phosphate, 
serum bicarbonate and serum calcium) and 4-factor (age, gender, eGFR and ACR) model 
are accurate (C-index 0.863 and 0.865 respectively) in predicting risk of kidney failure with 
the 8-factor model outperforming the 4-factor model (adequacy index of 98.8% vs 97.2%)
Conclusions: The predictive model developed by Tangri et al is accurate in predicting 
the progression of CKD to ESRF in 5 years in the Singapore CKD population.
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Underperformance of ESRD Prediction Equations in a Contemporary 
Diverse Adult Population with Advanced CKD
Sijie Zheng,1 Leonid Pravoverov,2 Victor Shiau,3 Rishi V. Parikh,2 Nhi Tan,5 
Joanna Mroz,1 Thida C. Tan,3 Tracy Y. Jonelis,4 Alan S. Go.3 1The Permanente 
Medical Group, Oakland, CA; 2Kaiser Permanente, Walnut Creek, CA; 3Kaiser 
Permanente Northern California, Oakland, CA; 4The Permanente Medical Group, 
Inc, San Francisco, CA; 5Kaiser Oakland Medical Center, OAKLAND, CA.
Background: Two risk prediction models (Tangri, KPNW) have been proposed for risk 
stratification for transition to ESRD in adults with CKD 3-5. We evaluated the performance 
of these models in an ethnically diverse advanced CKD population.
Methods: We identified all adult members of Kaiser Permanente Northern California 
(KPNC) with Stage 4-5 CKD between Jan. 2008-Sep. 2015. Receipt of RRT through Sep. 
2016 was ascertained from an internal ESRD registry. Data on patient characteristics and 
lab results were obtained from electronic health records. We examined model discrimination 
(c statistic) and calibration (observed vs. predicted risk) for initiating RRT at 1, 2 and 5 years 
for the Tangri equation and at 2 years for the KPNW equation.
Results: In 17,586 adults with CKD 4-5, mean age was 73.7 years, 53% were women, 
and 49% were persons of color. The 1-, 2- and 5-year crude risks for RRT were 8.8% 
(95%CI:8.3-9.2%), 20.1% (19.5-20.8%) and 37.9% (36.9-38.8%), respectively. For Tangri, 
we found lower discrimination at 1 year (c=0.80 KPNC, c=0.86 Tangri), and 5 years (c=0.76 
KPNC, c=0.84 Tangri), with substantial underestimation of actual absolute risk (Figure 1A). 
Similarly, for the KPNW model, we observed lower discrimination (c=0.79 KPNC, c=0.96 
KPNW) and underestimation of actual risk (Figure 1B).
Conclusions: In a large, ethnically diverse CKD 4-5 population, Tangri and KPNW 
prediction models exhibited both lower discrimination and significant underestimation of 
absolute RRT risk. Given that most ESRD cases are derived from CKD 4-5 patients, more 
accurate prediction models are needed to help tailor management.
Funding: Private Foundation Support
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Observed vs. Predicted Risk of RRT at 2 years by Deciles of Predicted Risk in Stage 4/5 
CKD Patients at Kaiser Permanente Northern California (Jan. 2008-Sep. 2015).
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Clinical Utility of the Kidney Failure Risk Equation in Determining 
Timing of Predialysis Education
Marina Wainstein,1 Saiyini Pirabhahar,1 Hendrick E. Van deventer,3 
Kylie M. Turner,1 Su San Lim,1 Ivor J. Katz.1,2 1St George Hospital, Sydney, 
Elizabeth Bay, NSW, Australia; 2University of New South Wales, Sydney, NSW, 
Australia; 3Lancet Laboratories, Johannesburg, South Africa.
Background: The Kidney Failure Risk Equation (KFRE) has been validated to predict 
decline in chronic kidney disease (CKD) and proposed as a tool for dialysis planning. 
Timing of predialysis education is known to impact short- and long-term outcomes on 
dialysis. Current guidelines recommend it occurs within 12 months before initiation but 
little evidence exists to guide the timing of this referral. Our aim was to assess and validate 
the efficacy of the KFRE in predicting optimal timing for dialysis education.
Methods: A 2 year risk of end stage kidney disease (ESKD) was calculated using 
the 4-variable KFRE in a cohort of patients with CKD stages 3-5 and compared to eGFR 
with respect to predictive efficacy. The sensitivity and specificity of the test using KFRE 
thresholds of 10 and 20% as well as eGFR of 15 and 20 ml/min/1.73 m2 were examined, 
reflecting KFRE risk suggestions and eGFR cut-offs currently used for referral to predialysis 
education. In patients who developed ESKD and commenced dialysis we searched 
retrospectively for an association between KFRE and time from predialysis education to 
initiation (dependent variable) using linear regression.
Results: Of 294 patients included in the analysis, 106 progressed to ESKD over the 
2 year follow-up period. The area under the receiver operating curve for KFRE was 0.97 
[95% confidence interval (CI) 0.96-0.99]) and 0.93 for eGFR (95% CI, 0.90-0.97). Using 
a KFRE threshold of 10% the sensitivity was 82% and specificity 97% and at 20% the 
sensitivity decreased to 57% but specificity was maintained (98%). Use of eGFR cut-offs 
of 20 and 15 ml/min/1.73 m2 resulted in lower sensitivity (56% and 18% respectively) but 
equivalent specificity (97 and 99% respectively). There was a weak, positive association 
between KFRE risk and longer time from dialysis education to initiation (r2 = 0.072, p = 
0.016).
Conclusions: The KFRE can be considered validated in our population as a good 
predictor of ESKD and modestly superior to eGFR. A threshold KFRE risk of 10% over 
2 years appears to be a more useful guide than eGFR for timely referral to predialysis 
education. However, this was not observed at a higher threshold, suggesting that other 
factors may impact on the rate of progression to dialysis. KFRE requires ongoing evaluation 
for decision-making nearing ESKD.
SA-PO757 Poster Saturday
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Predicting Incidence of CKD G3+ (eGFR <60 mL/min/1.73 m2) in the 
General Population
Robert G. Nelson. CKD Prognosis Consortium CKD Prognosis Consortium 
(CKD-PC), Baltimore, MD.
Background: Risk-based treatment strategies are one method of delivering 
personalized medicine. Valid risk scores are needed for the prediction of CKD G3+, which 
may prompt albuminuria testing in those who are not already advised to undergo screening 
because of diabetes, hypertension, or history of cardiovascular disease (CVD).
Methods: Among 26 general population and high-risk population cohorts (N=2.1 
million participants) with eGFR ≥60 ml/min/1.73 m2, we estimated risk factors of incident 
eGFR <60 ml/min/1.73 m2 (CKD G3+) and eGFR <30 ml/min/1.73 m2 (CKD G4+). We 
derived a risk score using random-effects meta-analyzed sub-hazard ratios from all cohorts, 
and random-effects meta-analyzed re-fit subhazards from the six cohorts with frequent 
creatinine measurements. Risk factors evaluated included age, sex, race, baseline eGFR, 
history of CVD, diabetes, smoking status, hypertension, and body-mass index. Albuminuria 
was modeled in people with and without diabetes separately due to differences in data 
availability.
Results: Mean age of participants was 54 years, 53% were female, and mean baseline 
eGFR was 91 ml/min/1.73 m2. Over a mean follow-up of 4.5 years, there were 152,968 
events of incident eGFR <60 ml/min/1.73 m2 and 31,631 events of incident eGFR 
<30 ml/min/1.73 m2. All risk factors listed in the methods were statistically significant. 
Applying the risk score to NHANES 2011-2016, the 10th and 90th percentiles of 5-year risk 
of incident eGFR <60 ml/min/1.73 m2 were 0.04% and 3.7% for those aged 18-39 years, 
0.6% and 21.9% for 40-59 years, 6.9% and 64.4% for 60-79 years, and 29.3% and 84.6% 
for ≥80 years. Corresponding estimates of incident eGFR <30 ml/min/1.73 m2 were 0.01% 
and 0.02%, 0.09% and 1.3%, 0.6% and 5.1%, and 1.4% and 7.8%, respectively. Specific 
equations for patients with diabetes as well as incorporating albuminuria, when measured, 
provide better personalization.
Conclusions: A risk score for CKD incidence developed from risk factors available 
in electronic health records had a 10-100 fold risk gradient and could help guide screening 
and prevention.
Funding: NIDDK Support, Private Foundation Support
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Random Survival Forest Identifies Key Factors Predicting CKD 
Progression: The CRIC Study
Zihe Zheng,1 Dawei Xie,2 Shoshana Weiner,9 Jing Chen,3 Debbie L. Cohen,4 
Paul E. Drawz,5 Dominic S. Raj,6 James H. Sondheimer,7 Harold I. Feldman,1 
James P. Lash,8 Amanda H. Anderson.1 CRIC (Chronic Renal Insufficiency 
Cohort) 1University of Pennsylvania, Philadelphia, PA; 2University of 
Pennsylvania School of Medicine Center for Clinical Epidemiology and 
Biostatistics, Philadelphia, PA; 3Tulane School of Medicine, New Orleans, LA; 
4University of Pennsylvania School of Medicine, Philadelphia, PA; 5University 
of Minnesota, Minneapolis, MN; 6GWU Medical Faculty Associates, 
Washington, DC; 7Wayne State University School of Medicine, Detroit, MI; 
8University of Illinois at Chicago, Chicago, IL; 9University Of Maryland School 
Of Medicine, Baltimore, MD.
Background: Increasing numbers of clinically-available and novel factors bring 
opportunities to improve CKD risk prediction, as well as statistical challenges of multiple 
comparison, nonlinearity, variable interactions, and missing data. We applied the machine 
learning technique of random survival forest (RSF) to identify factors associated with CKD 
progression.
Methods: We studied 3,939 subjects in the Chronic Renal Insufficiency Cohort and 
followed them for the composite survival outcome of eGFR halving or incident ESRD for 12 
years. We used 73 clinically-available and 25 novel baseline variables as exposures, which 
covered a broad spectrum of socio-demographics, comorbidities, physical and laboratory 
measurements and medications. We applied the RSF approach with 1000 bootstrap 
iterations and log-rank splitting rule. We calculated statistics of variable importance and 
minimal depth to rank predictors according to their impact on prediction accuracy. We also 
graphed the adjusted relationships of CKD progression and the top 10 strongest predictors.
Results: After setting the outliers to missing, we included 3,921 individuals in the 
analysis. Missing data were imputed and variable interactions were incorporated in the RSF 
algorithm. The 98-predictor RSF model yielded a low prediction error of 14.2% (1 minus 
Harrell’s C-index). The top 10 predictors identified with highest variable importance values 
and smallest minimal depths are urine protein/creatine ratio, urine albumin/creatinine ratio, 
eGFR, serum urea nitrogen, parathyroid hormone, serum albumin, high sensitivity troponin 
T, systolic blood pressure, NT-proBNP, and FGF-23. The relationships of the predicted 
survival at 1-, 2-, and 5-years and the 10 factors are shown in the partial dependence plots.
Conclusions: We identified and ranked variables that are most important to CKD 
progression from among 98 clinically-available and novel factors using the RSF method. 
Utilizing high-dimensional data enabled us to predict outcomes with a low error rate.
Funding: NIDDK Support
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Mediation of the Association Between Particulate Matter Air Pollution 
and Renal Disease by Diabetes
Benjamin C. Bowe,1,3 Yan Xie,1 Ziyad Al-Aly,1,2 Tingting Li,1,2 Yan Yan,1,2 
Hong Xian.1,3 Clinical Epidemiology Center 1Clinical Epidemiology Center, VA 
Saint Louis Health Care System, Saint Louis, MO; 2Washington University in St. 
Louis, Saint Louis, MO; 3Saint Louis University College for Public Health & 
Social Justice, St. Louis, MO.
Background: Evidence suggests that elevated levels of fine particulate matter of <2.5 
μm in aerodynamic diameter (PM2.5) are associated with increased risk of kidney disease.
However, PM2.5 is also associated with risk of diabetes, which is a major driver of CKD.
Whether and to what extent the association of PM2.5 and CKD is mediated by diabetes is
unknown.
Methods: Databases from the Environmental Protection Agency (EPA) and National 
Aeronautics and Space Administration (NASA) were linked with those from Department 
of Veterans Affairs. Inverse odds ratio-weighted estimations for mediation analyses were 
undertaken to quantitate the proportion of the association between PM2.5 and risk of CKD 
outcomes that is mediated by diabetes. CKD outcomes included incident eGFR < 60 mL/
min/1.73m2, incident CKD, incident eGFR decline ≥ 30%, and time until end stage renal 
disease (ESRD) or eGFR decline ≥ 50%.
Results: In a cohort of 2,444,157 United States Veterans followed for a median of 8.5 
years, using EPA data, the proportion of the association (between PM2.5 and risk of CKD 
outcomes) mediated by diabetes was 4.7%, 4.8%, 5.8%, and 16.5% for risk of incident 
eGFR less than 60 mL/min/1.73m2, risk of incident CKD, risk of eGFR decline of 30% or 
more, and risk of ESRD or eGFR decline ≥50%, respectively. Results were consistent when 
exposure was defined according to NASA data.
Conclusions: Our findings demonstrate that a small proportion of the association 
between PM2.5 and CKD was mediated by diabetes, suggesting that the presence of other 
mediators or a direct effect between PM2.5 and CKD may drive the association between 
PM2.5 and CKD.
Funding: Veterans Affairs Support
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Improvement in Glomerular Filtration Rate Among CKD Patients: 
Findings from the CRIC Study
Paula F. Orlandi,1 Dawei Xie,2 Amanda H. Anderson,1 Harold I. Feldman.1 
CRIC Study Investigators 1University of Pennsylvania, Philadelphia, PA; 
2University of Pennsylvania School of Medicine Center for Clinical 
Epidemiology and Biostatistics, Philadelphia, PA.
Background: Improvement of eGFR has been observed in approximately 10% 
of participants in numerous CKD cohorts. Among those with improving eGFR, a 
counterintuitive association with increased risk of coronary heart disease and death 
compared to those with stable or slightly declining eGFR has been reported. Sarcopenia, 
edema, and other indicators of clinical deterioration may be responsible for the increased 
risk of poor outcomes among subjects with improving eGFR. We aimed to assess the 
association between slopes of eGFR and time to cardiovascular events and all-cause 
mortality accounting for many factors potentially confounding this relationship.
Methods: We studied 3024 participants of the CRIC Study, a multi-center cohort of 
adults with CKD. We performed Cox Proportional Hazards models with time-varying 
covariates to investigate the association between slopes of eGFR and cardiovascular events 
and all-cause mortality. Slopes were estimated using linear mixed effects models and were 
updated whenever a new eGFR was assessed over a median of 9 years. Individuals were 
characterized according to three groups based on their slope at year 2: decliner (slope<=-2); 
stable (slope>-2 and <2); improver (slope>=2ml/min/1.73m2).
Results: In the CRIC Study, 327(11%) presented improvement of eGFR, 1045 (34%) 
were stable, and 1652 (55%) were decliners. Improvers were predominantly male (60%), 
had lower systolic blood pressure (mean: 118 mmHg), and lower proteinuria (median: 
0.09 g/day). In models adjusted for demographics, diabetes, eGFR, proteinuria, systolic 
blood pressure, fat-free mass, ejection fraction, antihypertensive drugs and other laboratory 
markers, time-updated improvement of eGFR was associated with increased risk of death 
compared to stable slopes: HR 1.89 (95%CI: 1.63 -3.22). The risk of death for steep 
decliners was also significantly higher: HR 1.63 (95%CI: 1.25 - 2.14).
Conclusions: Slopes of eGFR higher than 2ml/min/1.73m2/year were associated 
with increased risk of death compared to subjects presenting stable slopes of eGFR. This 
association was not explained by markers of cardiovascular function, body composition, or 
by a time-updated approach.
Funding: NIDDK Support
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First-Year Estimated Glomerular Filtration Rate Variability After 
Pre-ESRD Program Enrollment and Adverse Outcomes of CKD
Chin-Chi Kuo,1 Ching-Wei Tsai.2 1Big Data Center and Kidney Institute, China 
Medical University Hospital, Taichung City, Taiwan; 2Kidney Institute and Big 
Data Center, China Medical University Hospital, Taichung City, Taiwan.
Background: Scarce evidence associates the first-year estimated glomerular filtration 
rate (eGFR) variability and longitudinal change scales concomitantly to the risk of 
developing end stage renal disease(ESRD), acute coronary syndrome(ACS), and death 
following pre-ESRD program enrollment in chronic kidney disease(CKD).
Methods: We conducted a prospective cohort study of 5,092 CKD patients receiving 
multidisciplinary care between 2003 and 2015 with careful ascertainment of ESRD, ACS, 
and death during the follow-up. First-year eGFR dynamics included coefficient of variation 
(eGFR-CV), percent change (eGFR-PC), absolute difference (eGFR-AD), slope (eGFR-
slope), and area under curve (AUC).
Results: A total of 786 incident ESRD, 292 ACS, and 410 death events occurred 
during the follow-up. In the multiple Cox regression, the fully adjusted HRs for incident 
ESRD comparing the extreme with the reference quartiles of eGFR-CV, eGFR-PC, eGFR-
AD, eGFR-slope, and eGFR-AUC were 2.67(95% CI, 2.11, 3.38), 8.34(6.33, 10.98), 
19.08(11.89, 30.62), 13.08(8.32, 20.55), and 6.35(4.96, 8.13), respectively. Similar effects 
on the risk of developing ACS and mortality was observed. In the 2x2 risk matrices, patients 
with the highest quartile of eGFR-CV and concomitantly with the most severely declining 
quartiles of any other longitudinal eGFR change scale had the highest risk of all outcomes.
Conclusions: The dynamics of eGFR changes, both overall variability and longitudinal 
changes, over the first year following pre-ESRD program enrollment are crucial prognostic 
factors for the risk of progression to ESRD, ACS and deaths among patients with CKD. 
A risk matrix combining the first-year eGFR variability and longitudinal change scales 
following pre-ESRD enrollment is a novel approach for risk characterization in CKD care.
Risk matrices demonstrating the adjusted hazard ratios (aHRs) for ESRD requiring dialysis, 
ACS, and all-cause mortality by using eGFR-CV (in quartiles) and other scales of eGFR 
longitudinal change scales, namely eGFR-PC, AD, slope, and AUC.
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Estimating Short-Term Risk of Disease-Related Outcomes in ADPKD: A 
Prediction Model Based on Longitudinal Data from the OVERTURE 
Study
Ronald D. Perrone,2 Jogarao Gobburu,6 Frank S. Czerwiec,7 Christina Pao,1 
John Ouyang,4 Olga Sergeyeva,5 Vijay Ivaturi.3 1Otsuka Pharmaceutical 
Development and Commercialization, Princeton, NJ; 2Tufts Medical Center, 
Boston, MA; 3University of Maryland, Baltimore, Baltimore, MD; 4Otsuka 
Pharm. Dev. & Comm., Rockville, MD; 5Otsuka Pharmaceuticals, Princeton, 
NJ; 6Dr., Baltimore, MD; 7Otsuka Pharma. Devel. & Comm., Inc., Rockville, 
MD.
Background: Models are available for predicting rapid decline in kidney function in 
autosomal dominant polycystic kidney disease (ADPKD), but there is a need for a clinical 
tool that estimates the short-term risk of other ADPKD-related complications. We analyzed 
observational data to identify patient baseline variables most useful for estimating risk of 
complications and to construct a patient risk calculator.
Methods: OVERTURE was a prospective study with follow-up at 6-month intervals 
to assess for 17 types of ADPKD-related manifestations that included hematuria, kidney 
pain, albuminuria, urinary tract infection (UTI) and nephrolithiasis. In our analysis, 
occurrence of each type of manifestations in a patient was assigned a score of 1, yielding 
a maximum ADPKD severity score of 17. Item response analysis1 was used to determine 
the complications that contributed most to overall disease severity across the population, 
and multivariate logistic regression was performed to ascertain which patient baseline risk 
factors best predicted experiencing ≥1 of the identified complications in the follow-up 6–18 
months.
Results: Among 1880 subjects with follow-up data over the analysis period, the 
manifestations that contributed most to overall ADPKD severity were hematuria, kidney 
pain, albuminuria, UTI, and nephrolithiasis. In the regression model, baseline risk factors 
most predictive of occurrence of ≥1 of these manifestations over 6–18 months were: age 
≤35, male sex, non-Hispanic ethnicity, higher baseline total kidney volume growth rate, and 
higher risk class in the Mayo ADPKD classification system.2 These predictive variables
were incorporated into a simple nomogram for patient risk scoring.
Conclusions: Patient baseline risk factors can be used to estimate the risk of 
experiencing ≥1 of 5 important ADPKD-related manifestations over 6–18 months. A 
prediction nomogram that assigns point scores for each predictive variable enables rapid 
risk estimation in the clinic.
Funding: Commercial Support - Otuska Pharmaceutical Research and Development, 
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Predicting CKD in the CARRS Study: Strategies for Screening in the 
Indian Population
Christina L. Bradshaw,1,2 Yuanchao Zheng,1 Maria E. Montez-Rath,1 
Dorairaj Prabhakaran,3 Shuchi Anand.1 1Nephrology, Stanford University School 
of Medicine, Palo Alto, CA; 2Centre for Chronic Disease Control, Gurgaon, 
India; 3Public Health Foundation of India, Gurgaon, India.
Background: Chronic kidney disease (CKD) is a significant global health issue. Much 
of the rise in CKD-attributable deaths has occurred in low- and middle-income countries 
(LMICs). Population-wide screening for CKD is not cost-effective and likely untenable in 
resource-limited settings. Development of a tool that identifies at-risk persons and allows 
targeted screening is paramount to manage this growing problem.
Methods: Using data from the Centre for Cardiometabolic Risk Reduction in South 
Asia (CARRS) study, we fit a logistic regression model based on 30 variables easily 
measured during a home visit. Final predictors were selected through a step-down procedure. 
We defined presence of CKD as eGFR <60 ml/min/1.73m2 by the CKD-EPI equation or 
urine albumin-to-creatinine ratio (UACR) ≥30 mg/g. Discrimination was assessed with the 
c-statistic and calibration with the calibration slope. Model predictive ability was compared 
across different probability cut-offs. We used bootstrap for internal validation.
Results: In our sample of 8,698 participants from Delhi and Chennai, CKD prevalence 
was 10.9%. Our final model consisted of 19 variables (Figure 1). Development and 
validated c-statistics were 0.79 and 0.78, respectively. Calibration slope was 0.97 after 
validation. Using a probability cut-off of 0.075, the model identified 3,489 people (40% of 
original sample) as needing confirmatory testing for CKD with serum creatinine or UACR, 
giving a sensitivity of 78% and specificity of 65%.
Conclusions: Our prediction model exhibited good sensitivity and discrimination for 
CKD, while narrowing the pool of people who necessitate confirmatory testing. We are the 
first to use large-scale population data to develop a tool that facilitates targeted screening for 
CKD in urban India. Future efforts include external validation on a separate Indian cohort.
Funding: NIDDK Support, Other NIH Support - Fogarty International Center
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CKD Without Significant Proteinuria—Is It Possible to Predict Faster 
Decline in eGFR?
Hiroshi Tanaka. Internal Medicine/Nephrology, Mihara Red Cross Hospital, 
Mihara, Japan.
Background: CKD patients without significant proteinuria have been recognized 
that they tend to have slower eGFR decline than proteinuric CKD patients have. However 
substantial population of those patients eventually reach ESRF. The aim of this study is 
to elucidate risk factors for progressive decline in eGFR in patients without significant 
proteinuria.
Methods: A hospital-wide survey included a whole set of laboratory tests over 24 
months. Patients with at least 3 measurements of eGFR over 365 days or more, with 
an averaged eGFR of less than 50mL/min/1.73m2 were collected. An eGFR slope was 
calculated for each patient. For the assessment of proteinuria, a dipstick urine protein 
determination was considered to better represent the real-world clinics for all the 
subspecialities in the Hospital; numbers of 0, 0.5, 1, 2, 3 or 4 were applied to (-), (+-), (1+), 
(2+), (3+) or (4+) respectively, then the numbers were averaged during the study period 
(avUprot); an excellent relation between avUprot and averaged U-protein/U-creatinine ratio 
has been previously confirmed in a different cohort (Up/Ucr = -0.346 + 1.185*avUprot, 
n=1,379; p<0.0001). Patients with avUprot less than 1.0 comprised the final cohort for this 
study. All the laboratory values such as serum albumin were equally averaged during the 
study period for each patient.
Results: Among the total 40,797 patients with laboratory examination, the final cohort 
included 1,174 patients (M:F 581:593, age 32-95 (median 77)), with eGFR 5.8-49.9 (41.3) 
mL/min/1.73m2 and avUprot 0.00-0.96 (0.14) g/g Cr. In a univariate analysis, the eGFR 
slope was associated with age, plasma ALT (alanine aminotransferase), serum Na and serum 
albumin. In a multivariate stepwise analysis, the eGFR slope was correlated with ALT, 
serum Na and serum albumin. In a 3x3 table where the cohort was divided into tertiles for 
ALT and serum albumin, patients with the lowest tertile of serum albumin (1.70-3.87 g/dL) 
combined with the highest tertile of ALT (22.0-265.4 IU/L) had the fastest eGFR decline 
(-4.07+-9.11 (median -2.44) mL/min/1.73m2/yr) among the 9 divisions, with an OR 2.13 
for the fastest-eGFR-slope tertile (-2.47 mL/min/1.73m2/yr or below) against the sum of the 
remaining 8 divisions as a reference.
Conclusions: Combination of serum albumin and ALT might serve as a simple measure 
to predict progressive decline in eGFR in the CKD patients with minimal or no proteinuria.
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Can Rapidly Progressing CKD Patients Be Identified Using Billing Codes?
Kabir Jalal,1 Rocco C. Venuto,2 Edwin J. Anand,2,1 Pradeep Arora.3,1 1University 
at Buffalo, Amherst, NY; 2Erie County Medical Center, Buffalo, NY; 3Nephrology, 
Veterans Affairs Medical Center, Buffalo, NY.
Background: The International Classification of Diseases (ICD) coding system is 
the industry standard diagnostic coding tool. However, ICD codes often do not reflect the 
clinical diagnosis, particularly among Chronic Kidney disease (CKD) patients. This study 
evaluates the diagnostic accuracy in identifying rapidly progressing CKD patients using 
CKD-related ICD codes in a large insurer database.
Methods: Serial observations from 2007 through 2014 were examined. 216,529 
individuals had valid serum creatinine measurements. The progression of CKD using a 
longitudinal mixed-model was contrasted with that documented by ICD codes. Rapid 
progressors (yearly eGFR loss greater than 4 ml/min/1.73m^2) were identified. Clinical 
diagnosis according to the Kidney Disease Outcomes Quality Initiative (KDOQI) was 
compared to diagnosis using ICD codes.
Results: 323 rapid progressors were identified among the 10,927 CKD patients 
qualifying for inclusion in the clinical progression analysis. ICD codes identified 83 of 
these, for a sensitivity of 25.7% and specificity 95.09%. Of 28,762 laboratory-confirmed 
CKD patients, 9,249 had a qualifying ICD code, for a sensitivity of 16%. Of 187767 
patients without laboratory-confirmed CKD, 182,359 did not have a qualifying ICD code, 
for a specificity of 97.12%.
Conclusions: This study leverages 7 years of serial observations, facilitating 
identification of disease progression, and depicts the novel finding that ICD-codes display 
poor capacity to identify rapidly progressing CKD patients when compared to gold standard 
KDOQI guidelines, and further demonstrates the limitations of coding in CKD diagnosis 
management. This study further defines the limitations of ICD codes in addressing diagnosis 
of disease severity or disease progression for clinical or epidemiological purposes.
Funding: Clinical Revenue Support
ROC Curves for Detecting CKD (Left) and Rapid Progressors (Right) for Comorbid 
Conditions
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Comparisons of Different Equations for Estimated Glomerular Filtration 
Rate in Chinese Han Patients with CKD in Real World
Huijuan Mao. First Affiliated Hospital of Nanjing Medical University, Nanjing, 
China.
Background: The currently recognized and most accurate estimate of glomerular 
filtration rate(eGFR) formula is the creatinine- cystatin C joint formula(EPI_Cr_CysC) 
developed by the Chronic Kidney Disease Epidemiology Research Group. However, 
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cystatin C (CysC) can not be determined in many cases, so that the wide application of 
EPI_Cr_CysC formula is limited. The purpose of this study is to study the agreement, 
precision and accuracy between other eGFR formulas and EPI_Cr_CysC formulas, and to 
find the best alternative formula for EPI_Cr_CysC.
Methods: We conducted a cross-sectional study research of 1913 CKD patients. 
The eGFRs were calculated separately by creatinine clearance rate and Cockcroft-Gault 
equation corrected for standard body surface area (Ccr_BSA and eCcr_BSA), CKD-
EPI_creatinine equation (EPI_Cr), CKD-EPI_cystatin C equation (EPI_CysC), EPI_Cr_
CysC equation, Modification of Diet in Renal Disease equation with standardized serum 
creatinine (MDRD) and full-age-spectrum creatinine equation (FAS). And EPI_Cr_CysC 
equation was used as the reference.
Results: When compared with EPI_Cr_CysC equation, EPI_Cr equation achieved the 
highest agreement in eGFR estimates [Lin’s concordance correlation coefficient (95%CI), 
0.936(0.930, 0.941)]. And eCcr_BSA and EPI_Cr equation achieved the first and second 
highest percent agreement in accurate classification of the CKD stage [percent agreement, 
72.55% VS 71.25%]. MDRD equation got the minimal bias and was closely followed 
by EPI_Cr equation [median difference (95% CI), -1.3(-2.0, -0.8) VS 2.5(1.7,3.3) mL/
min/1.73m2]. EPI_CysC and EPI_Cr equations achieved the first and second highest 
precision [IQR of the difference (95% CI), 12.2(11.6,12.9) VS. 15.5(14.7,16.3) mL/
min/1.73m2]. EPI_Cr and MDRD equations performed similarly and tied for first place in 
30% accuracy [1-P30 (95% CI),18.6(16.9,20.4) % VS 18.6 (16.8, 20.3) %].
Conclusions: For assessment of renal function, EPI_Cr equation performed the 
best and remained an acceptable alternative to EPI_Cr_CysC equation in the absence of 
cystatin C.
Funding: Government Support - Non-U.S.
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Estimation of Glomerular Filtration Rate in Multi-centre Chinese 
Individuals: Comparison of 2017 New FAS (Full Age Spectrum) and 2012 
CKD-EPI (CKD Epidemiology Collaboration) Equations
Zhenzhu Yong. The First Affiliated Hospital of Nanjing Medical University, 
Nanjing, China.
Background: The recent guidelines recommend using the estimated glomerular 
filtration rate (eGFR) to evaluate renal function. There are two reported full-age-spectrum 
(FAS) equations in 2017, which based on serum cystatin C (Cys) concentrations with or 
without accompanying serum creatinine (Cr) level (FASCombi or FASCys). We compared the 
performance and assessed the applicability of the new FAS formulae with the 2012 CKD-
EPI (CKD-EPICys and CKD-EPICr-Cys) equations in Chinese subjects.
Methods: A total of 1184 technetium-99m diethylene-triamine-penta-acetic acid 
(99mTc-DTPA) renal dynamic images from four different hospitals in China to measure 
GFR (mGFR) regarded as the referenced method. The bias, precision and accuracy of eGFR 
and mGFR calculated by four formulae were compared.
Results: The two CKD-EPI equations performed poor in elderly with moderately-
severely injured GFR (the proportion of estimated GFR within 30% of referenced GFR, 
P30, <70%). FASCombi formula had less bias (median bias, -2.87), more precision (the inter-
quartile range of difference, IQR, 19.01), and more accuracy (P30, 74.16%) in whole cohort, 
and the difference compared with other three equations was statistically significant. In the 
rGFR <60 ml/min/1.73m2 subgroup, the FASCombi formula showed the best performance 
and the differences were statistically significant. In older subjects, compared with FASCys, 
CKD-EPICr-Cys and CKD-EPICys, the FASCombi formula had relatively less bias (median bias, 
-8.09 vs. -9.63, -7.52, -11.04, p<0.05), most precise (IQR, 15.18 vs. 16.32, 15.22, 16.63),
and most accuracy, P30 was statistically different from the other equations, and achieved
a ideal value >70%.
Conclusions: The performance of the FASCombi formula is better than that of the 
CKD-EPISCr-Cys formula in the Chinese population, particularly in the elderly. Yet, further 
modification of FAS equations from a large-scale study could be more suitable for the 
Chinese population, particularly in older subjects.
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GFR Slopes – The Statistical Method Matters
Marieke van Rijn,1 Jack F. Wetzels,2 Peter J. Blankestijn,4 Jan A. van den Brand.3 
1Radboud Univ Medical Centre, Nijmegen, Netherlands; 2Radboud University 
Medical Center, Nijmegen, Netherlands; 3Radboud University Nijmegen 
Medical Center, Nijmegen, Netherlands; 4University Medical Center----, 
Utrecht, Netherlands.
Background: The FDA is considering the use of eGFR decline and eGFR slope as 
surrogate endpoints in CKD research. Several statistical methods can be used to estimate 
GFR decline (Coresh 2014, Leffondre 2015, Asar 2015). We questioned if these methods 
differed with respect to the estimates of GFR slopes.
Methods: We used the MASTERPLAN (Multifactorial Approach and Superior 
Treatment Efficacy in Renal Patients with the Aid of Nurse practitioners) dataset, which 
included 762 patients with an eGFR between 20 to 70 ml/min, a median follow-up of 4.8 yr 
(IQR 4.3-5.3) and 103 ESRD events. We estimated percentage and annual change in MDRD 
eGFR over a period of 2 years using 3 methods. For annual change: 1) last estimated GFR – 
first estimated GFR, 2) linear mixed model (LMM) using the first and last measured GFR, 3) 
LMM using all GFR measures in 2 years’ time. For percentage change: 4) (last estimated 
GFR – first estimated GFR) / (first estimated GFR) * 100 and 5) LMM with log-transformed 
GFR using the first and last measured GFR, 6) LMM with log-transformed GFR using 
all GFR measures in 2 years’ time.
Results: Overall data were available of 6275 visits and 91% of patients had at least 
4 visits within 2 years. Both the distribution for annual and percentage change in eGFR 
varied greatly between the different statistical methods (Figure 1). Using the first-last eGFR 
method to estimate GFR slope resulted in a 5 fold wider distribution on the annual scale and 
10 fold on the relative scale compared to using a LMM.
Conclusions: The statistical method that is used to estimate change in GFR has a great 
impact on the estimated GFR slopes. The current debate about the use of eGFR declines 
and eGFR slope as surrogate endpoints in CKD should also consider the statistical method 
how to estimate GFR decline.
Figure1: Distribution of GFR slopes. The number in the figure corresponds to the statistical 
method described in the methods. The blue line is the average GFR slope.
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Optimal Follow-Up Intervals for Different Stages of CKD
Keita Hirano,1 Yasuo Ohashi,2 Yasuhiro Komatsu,3 Motoko Yanagita,1 
Akira Hishida.4 1Department of Nephrology, Kyoto University Graduate School 
of Medicine, Kyoto, Japan; 2University of Tokyo, Tokyo, Japan; 3Gunma 
University, Graduate School of Medicine, Maebashi, Gunma, Japan; 4Yaizu City 
Hospital, Yaizu, Japan.
Background: Chronic kidney disease is a public health challenge. However, no 
evidence-based, optimal, follow-up intervals for patients with chronic kidney disease have 
been suggested. This study aimed to clarify appropriate follow-up intervals for different 
chronic kidney disease stages.
Methods: We studied 2682 patients with chronic kidney disease. Both of the numbers of 
patients experiencing a 50% increase in creatinine and those reaching end-stage renal failure 
were tabulated by their chronic kidney disease stage. The renal function-testing interval 
was defined as the estimated time for 0.1% of the patients with chronic kidney disease to 
have a composite renal outcome, when adjusted for clinical risk factors. Transitions from 
chronic kidney disease stage-based subgroups were analyzed using parametric cumulative 
incidence models. Other sensitivity analyses involved the estimation of the time to renal 
event occurrence for 1% of patients.
Results: Of the 913 patients (34%) who had a composite renal event, 29 patients had 
stage 3A (10.5%), 151 had stage 3B (16.3%), 429 had stage 4 (41.0%), and 304 had stage 
5 chronic kidney disease (70.9%). The estimated renal function testing intervals were 6.0 
months for chronic kidney disease stage 3A, 3.4 months for stage 3B, 2.0 months for stage 
4, and 1.2 months for stage 5.
Conclusions: The optimal follow-up intervals were longer for patients with lower 
chronic kidney disease stages. These estimates are longer than those recommended by 
the relevant guidelines, and may serve as a reference to inform nephrologists in selecting 
follow-up intervals for their individual patients.
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Methods to Identify Novel, Repeatedly Measured Biomarkers of CKD 
Outcomes
Qian Liu,1 Abigail R. Smith,1 Laura H. Mariani,2,1 Viji Nair,2 Jarcy Zee.1 1Arbor 
Research Collaborative for Health, Ann Arbor, MI; 2University of Michigan, 
Ann Arbor, MI.
Background: Identifying novel biomarkers is critical to advancing diagnosis and 
treatment of CKD, but relies heavily on the statistical methods used. Inappropriate methods 
can lead to both false positive and false negative associations between biomarkers and 
outcomes. This study assessed accuracy of methods using computer simulations and 
compared biomarker effect estimates in NEPTUNE, a prospective cohort study of patients 
with glomerular disease.
Methods: We compared four methods for analyzing repeatedly measured biomarkers 
in Cox models: 1) baseline, that only uses the single baseline biomarker value, 2) time-
dependent with last observation carried forward (LOCF), that assumes the biomarker is 
unchanged until the next value, 3) time-averaged, that averages the biomarker values over 
all follow up and uses that average as a baseline covariate, and 4) time-dependent cumulative 
average, that updates the average using biomarker values at or before each time point.
Results: Simulation results showed the time-averaged method often gave extremely 
biased, inaccurate results. In NEPTUNE, all assessed urinary biomarkers were positively 
associated with 40% reduction in eGFR. Compared to the LOCF method, the baseline 
method had 6-21% lower hazard ratios (HRs), and the time-averaged method had 3-32% 
higher HRs [figure]. For complete remission, Eotaxin and TIMP1 were negatively 
associated with the outcome, and PDGF-BB had little association. HRs from the time-
averaged method were always higher (1-13%) than the LOCF method.
Conclusions: Different analytic methods resulted in markedly different results. 
Using inappropriate methods such as time-averaging can bias effect estimates, while other 
methods provide prognostic (baseline), additive (cumulative average), or instantaneous 
(LOCF) effects depending on the hypothesized underlying mechanism.
Funding: NIDDK Support
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GFR Decline Based on Albuminuria Status in Patients with DM, 
Hypertension, and eGFR≥60
Adrian Liew,1 Yee Ang,2 Chun wei Yap,2 Chee Kong Lim,3 Wanting Weng.1 
1Renal Medicine, Tan Tock Seng Hospital, Singapore, Singapore; 2National 
Healthcare Group, SIngapore, Singapore; 3National Healthcare Group 
Polyclinics, Singapore, Singapore.
Background: In patients with GFR≥60, CKD is defined by presence of 2 albuminuria 
(UACR), obtained 3 months apart. Often, due to the clinical stability of these patients 
and limited clinic resources, most patients ended up with 1 UACR done annually with a 
potential delay in CKD diagnosis and treatment. We postulate that a single UACR reading 
in DM and hypertensive patients at high risk for the development of CKD, could have 
a significant impact in the progression of CKD. Our study aims to determine the eGFR 
decline in patients with only 1 UACR reading at baseline compared to those who meets the 
traditional criteria for CKD of 2 readings.
Methods: In this retrospective cohort study, we included patients with DM or 
hypertension, GFR≥60, from 9 primary care clinics between 2010 to 2014. UACR results 
were obtained for up to 2 years prior to study period, and patients were stratified into 3 
groups (Gp) – Gp 1: normal UACR; Gp 2: 1 abnormal ACR; Gp 3: 2 abnormal UACR 
at least 90 days apart. The patients were followed up for 2 years and GFR decline were 
compared, and adjusted for age, ethnicity, HbA1c, blood pressure and ACEi use.
Results: Of 11,783 patients in the study, 85.4% have DM. Baseline parameters between 
groups were similar. Malay patients with DM was found to have a greater GFR decline (-1.0 
[-1.6, -0.4], p<0.001), consistent with previous reports. Unadjusted GFR decline, when 
stratified by DM status, was greater for those with positive UACR (See table). GFR decline 
was similar between Gp 2 and 3, especially in DM patients. In the multivariate analysis with 
Gp 1 as reference, GFR decline was similar between Gp 2 and 3 in diabetic patients, but 
higher in Gp 3 in hypertensive patients.
Conclusions: In diabetic and hypertensive patients, albuminuria was associated 
with greater GFR decline. GFR decline was similar regardless of 1 or 2 UACR results, 
especially in patients with DM. This suggests that treatment should be considered with a 
single albuminuria result before a second reading is needed to meet the CKD definition.
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High Instead of Lower CKD-EPI-Based eGFR Values in Dutch Ethnic 
Minorities at Risk for CKD
Brechje Huisman, Charles Agyemang, Bram Hafkamp, Bert-jan Van den born, 
Ron Peters, Marieke Snijder, Liffert Vogt. Academic Medical Center, University 
of Amsterdam, Amsterdam, Netherlands.
Background: According to the widely adopted KDIGO guidelines, classification of 
chronic kidney disease (CKD) and evaluation of prognosis is based on two components: 
estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR). 
This approach has, however, never been validated for various ethnic groups living in the 
Netherlands and might lead to uncertainty in CKD staging. We investigated to what extent 
ethnic differences in eGFR and ACR can be explained by differences in demographics and 
traditional cardiovascular risk factors.
Methods: Baseline data from the HELIUS study, a multi-ethnic cohort study conducted 
in the city of Amsterdam, were used. Analyses were conducted among 18,534 participants 
(aged 18-70 years) of Dutch, South-Asian Surinamese, African Surinamese, Ghanaian, 
Moroccan and Turkish ethnic origin. We used multiple regression analyses to determine 
ethnic differences in eGFR (CKD-EPI formula) and ACR, with additional adjustments for 
age, sex, traditional cardiovascular and kidney risk factors, and educational level.
Results: Mean (SE) eGFR was higher in all ethnic minority groups as compared to 
those of Dutch origin (eGFR 94.9±0.3 mL/min/1.73m2), ranging from 1.9±4.1 in subjects 
from South-Asian Surinamese origin to 15.0±0.39 in subjects from Moroccan origin. Also, 
ACR was higher among all ethnic minorities as compared to those of Dutch origin (ACR 
0.6±0.2 mg/mmol), ranging from 0.5±0.2 in subjects from African Surinamese origin 
to 1.7±0.2 in subjects from South-Asian Surinamese origin. Adjustment for age, sex, 
traditional cardiovascular and kidney risk factors diminished the differences in both eGFR 
and ACR for most ethnic groups but these differences were still highly significant.
Conclusions: Our results show that eGFR is higher among ethnic minority groups as 
compared to those from Dutch origin. Regarding previously found higher CKD prevalence 
in ethnic minority groups of HELIUS, these findings underscore the need for ethnicity 
specific GFR estimations, as the currently recommended use of the CKD-EPI-based eGFR, 
which only distinguishes 2 ethnic groups, might lead to an underestimation of risk in multi-
ethnic populations. Given the observed higher ACR values among minority groups, ACR 
might represent a more useful risk factor in multi-ethnic populations.
SA-PO773 Poster Saturday
CKD: Epidemiology, Risk Factors, Prevention - III
Mortality Risk for Low Density Lipoprotein Cholesterol Across CKD 
Stages in 1.95 Million US Veterans
Melissa Soohoo,1,2 Hamid Moradi,1,2 Carola-Ellen Kleine,1,2 
Maria V. Marroquin,1,2 Taryn B. Benson-Hernandez,2 Csaba P. Kovesdy,3 
Kamyar Kalantar-Zadeh,4 Elani Streja.1,2 1Tibor Rubin Long Beach VA Medical 
Center, Long Beach, CA; 2Harold Simmons Center for Kidney Disease Research 
and Epidemiology, Orange, CA; 3University of Tennessee Health Science 
Center, Memphis, TN; 4University of California Irvine, School of Medicine, 
Orange, CA.
Background: Prior studies have shown that higher low-density lipoprotein cholesterol 
(LDL) levels are associated with worse survival in the general population, yet this 
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association is attenuated in chronic kidney disease (CKD) patients. However, the graded 
impact of kidney disease on the association of LDL with mortality is unclear.
Methods: We investigated a cohort of 1.95 million US veterans with baseline LDL 
and creatinine data from 2004-2006. Over a median[IQR] follow-up of 10.5[7,11] years, 
we examined the relationship of baseline LDL with all-cause and cardiovascular (CV) 
death risk across CKD stage in Cox proportional hazard models adjusted for demographics, 
comorbid conditions, smoking status, other lipids and prescription of statins and non-
statins. CKD stage was determined according to estimated glomerular filtration rate (eGFR) 
at the time of LDL measurement.
Results: The cohort had a mean±SD age of 65±14 years, and included 5% females, 
15% African-Americans, 22% diabetics, 32% statin-users and 44% current smokers. The 
median[IQR] of baseline LDL was 103[82,128] mg/dL and eGFR was 76[61,91] mL/
min/1.73m2. Patients with higher LDL were more likely to be younger, African-American, 
a current smoker, not on a statin, and have a higher eGFR. Patients with lower LDL 
(<60mg/dL) had a higher risk of all-cause and CV mortality across all stages of CKD, 
compared to LDL 80-<100 mg/dL. Higher LDL(≥140 mg/dL) was associated with higher 
all-cause and CV mortality risk in CKD3A and 3B, but these associations were attenuated 
for CKD4 and 5. Of note, in non-CKD veterans, higher LDL was protective for both CV 
and all-cause death risk. [Figure]
Conclusions: Elevated LDL ≥140 mg/dL is associated with higher all-cause and CV 
mortality risk among CKD 3A and 3B, but not among more advanced CKD stages. Future 
studies are needed to evaluate the impact of lipid lowering therapies and effect of time-
updated LDL with mortality risk across CKD stages.
Funding: Veterans Affairs Support
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Associations of Cholesterol and Mortality Across eGFR Strata in the 
NHANES Cohort
Taryn B. Benson-Hernandez,3 Melissa Soohoo,1 Hamid Moradi,2 Carola-
Ellen Kleine,1 Csaba P. Kovesdy,4 Kamyar Kalantar-Zadeh,5 Elani Streja.1 
1Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Orange, CA; 2University of California, Irvine, Orange, CA; 3UC Irvine Medical 
Center, Bishop, CA; 4University of Tennessee Health Science Center, Memphis, 
TN; 5University of California Irvine, School of Medicine, Orange, CA.
Background: Prior studies in chronic kidney disease (CKD) patients have shown a 
paradoxical association where CKD patients with higher cholesterol did not have the higher 
risk of mortality, as observed in the general population. However, the cholesterol-mortality 
relationship has not been thoroughly examined in a single nationally representative cohort 
with the ability to assess the impact of CKD stage on this relationship.
Methods: Using data from the National Health and Nutrition Examination Surveys 
(NHANES), we identified 31,270 adults with available measurements on serum cholesterol 
and creatinine between 1999-2006. We examined the association of cholesterol with 
mortality in 6 groups of cholesterol, and stratified by 3 levels of estimated glomerular 
filtration rate (eGFR). Associations were examined with Cox models with multivariable 
adjustment for demographics, comorbidities, medication use, body mass index and albumin.
Results: The cohort mean age was 47±20 years and comprised of 52% females and 
20% non-Hispanic black patients. Patients with higher cholesterol tended to be older, 
female, non-Hispanic white, but less likely to be diabetic, or take medications for high 
cholesterol. Over a median follow-up of 6[3, 9] years, 2,802 deaths occurred. Compared 
to cholesterol 175-<200 mg/dL, both low and high cholesterol was associated with higher 
death risk in unadjusted models, but associations for higher cholesterol was attenuated after 
age adjustment. In fully adjusted models, patients with lower cholesterol (<150 mg/dL) 
had or trended towards a higher risk of mortality across all strata of eGFR. Yet, higher 
cholesterol was not associated with higher mortality risk in any strata of eGFR. [Figure]
Conclusions: Among the nationally representative NHANES cohort, higher 
cholesterol is not associated higher mortality risk. Future studies evaluating the impact of 
kidney disease on the cholesterol-mortality association are needed.
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Patterns of Troponin Elevation in Patients with CKD and Long-Term 
Mortality Risk After Progression to ESRD
Lekha K. George,1 Santhosh K. Koshy,2,1 Miklos Z. Molnar,1 Praveen 
Kumar Potukuchi,1 Manyoo Agarwal,3 Koshy K. George,4 Kamyar Kalantar-
Zadeh,5 Csaba P. Kovesdy.6,1 1University of Tennessee Health Science Center, 
Memphis, TN; 2Regional One Health - University of TN Health Sciences Ctr, 
Memphis, TN; 3University of Tennessee Health Science Center, Memphis, TN; 
4University of Queensland, Memphis, TN; 5University of California Irvine, 
School of Medicine, Orange, CA; 6Memphis VA Medical Center, Memphis, TN.
Background: Elevated troponin as a marker of myocardial infarction is associated with 
poor short and long term mortality. Chronic kidney disease is commonly associated with 
higher and sustained levels of troponin due to reduced clearance. It is not known if the 
pattern of troponin elevation in patients with advanced CKD confers higher mortality risk 
after starting dialysis.
Methods: We examined 16,563 US veterans who had troponin levels measured during 
the 3 years prior to start of dialysis. We examined associations of 24-hour slope of troponin 
elevation, maximum troponin level, and the absolute value and percentage of the difference 
between the maximum and minimum troponin levels with all-cause mortality in Cox 
models adjusted for demographics, comorbidities, smoking status, blood pressure, BMI and 
baseline eGFR.
Results: Patients were 66±10 years old, 97% male, 37% African-American, 77% 
diabetic, and 67%, 69% and 41% had histories of ischemic heart disease, congestive 
heart failure and cerebrovascular disease, respectively. 11,196 patients died (mortality 
rate: 243/1000 patient-years, 95%CI: 238-248) over a median follow-up of 2.43 years 
after starting dialysis. Steeper rise in troponin level over 24 hours was not associated with 
higher mortality (Figure). Higher levels of maximum troponin level were associated with 
significantly higher mortality, whereas a higher absolute and percentage difference between 
maximum and minimum troponin levels was less consistently associated with increased 
mortality (Figure).
Conclusions: Elevated troponin in patients with advanced stage CKD is associated 
with higher risk of mortality after initiation of dialysis. Higher levels of maximum troponin 
values show the most consistent association with higher mortality, whereas the rate of 
troponin rise over a 24-hour period is not associated with long term mortality.
Funding: NIDDK Support, Veterans Affairs Support
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Longitudinal Relationship of Left Ventricular Hypertrophy with 
Cardiovascular Events in CKD
Jinwei Wang,1 Luxia Zhang,2,3 Kevin He,5 Minghui Zhao.4 the Chinese Cohort 
Study of Chronic Kidney Disease 1Renal Division, Department of Medicine, 
Peking University First Hospital; Peking University Institute of Nephrology, 
Beijing, China; 2Peking University Institute of Nephrology, Beijing, China; 
3Center for Data Science in Health and Medicine, Peking University, Beijing, 
China; 4Reanl division, Peking University First Hospital, Beijing, China; 
5Kidney Epidemiology and Cost Center, University of Michgian, Ann Arbor, MI.
Background: We aimed to evaluate the relationship between left ventricular (LV) 
hypertrophy and adverse cardiovascular (CV) events among patients with chronic kidney 
disease (CKD).
Methods: Based on the Chinese Cohort Study of CKD (n=3499), 2000 participants 
with interpretable echocardiograms, complete relevant clinical data and without a baseline 
CV disease history were enrolled in the study. LV mass was calculated using the area-length 
method and indexed to height2.7. CV events included incident acute myocardial infarction, 
unstable angina, hospitalization for congestive heart failure, cerebrovascular events and 
peripheral vascular diseases. The population was followed-up until occurrence of CV events 
or by June 30, 2017. Cox proportional hazards regression model was used to estimate the 
relationship between the exposure and outcomes.
Results: The mean age of the population was 47.2±13.7 years, with 56.4% of 
males. The mean level of estimated glomerular filtration rate (eGFR) was 52.9±31.3ml/
min/1.73m2. The proportions of CKD stages 1, 2, 3a, 3b and 4 were 16.8%, 17.5%, 14.9%, 
23.3% and 27.7%, respectively. Mean level of LV mass/ height2.7 was 39.7±12.7g/m2.7, with 
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the proportion of LV hypertrophy (LV mass/height2.7≥47g/m2.7 in women and ≥50 g/m2.7 
in men) being 17.9%. After a median follow-up of 4.45(inter-quartile range: 3.76-5.05) 
years, 89 CV events occurred, with an incidence rate of 1.03 per 100 person-years among 
total patients with CKD, 2.23 per 100 person-years among those with LV hypertrophy and 
0.78 per 100 person-years among those without LV hypertrophy (log-rank p-value<0.001). 
LV hypertrophy or a standard deviation increase in LV mass/ height2.7 was significantly 
associated with increased risk of CV events after adjustment for traditional CV risk factors, 
albuminuria and eGFR. The hazard ratios and 95% confidence interval were 1.78(1.12-
2.81) and 1.40(1.19-1.66), respectively. Sensitivity analysis among those with chronic 
glomerular nephritis or excluding congestive heart failure from the CV events showed 
consistent results.
Conclusions: LV hypertrophy is independently associated with increased risk of 
CV events among patients with CKD. Further studies are needed to evaluate the clinical 
effectiveness of screening high risk population among patients with CKD by using LV 
hypertrophy.
Funding: Government Support - Non-U.S.
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Association Between Polymorphism of rs11864909 and Serum Uromod-
ulin Among CKD Was Modified by Kidney Function
Jinwei Wang,1 Luxia Zhang,2 Kevin He,3 Minghui Zhao.4 the Chinese Cohort 
Study of Chronic Kidney Disease 1Renal Division, Department of Medicine, 
Peking University First Hospital; Peking University Institute of Nephrology, 
Beijing, China; 2Peking University Institute of Nephrology, Beijing, China; 
3Kidney Epidemiology and Cost Center, University of Michgian, Ann Arbor, MI; 
4Reanl division, Peking University First Hospital, Beijing, China.
Background: The single nucleotide polymorphism (SNP) of rs11864909 is located 
close to uromodulin gene of UMOD. A genome-wide association study in east Asian 
populations detected a genome-wide significant association between the SNP and estimated 
glomerular filtration rate (eGFR). We aimed to test the association of the SNP with serum 
uromodulin among patients with chronic kidney disease (CKD) and test if the association 
was modified by eGFR.
Methods: Altogether, 1812 participants with complete relevant clinical and genotyping 
data in the Chinese Cohort Study of CKD (n=3499) was enrolled in the study. Genotyping 
for rs11864909 was conducted by TaqMan genotyping assay. Serum uromodulin was 
measured by a commercially available ELISA kit. Linear regression analysis was used to 
test the association between rs11864909 and serum uromodulin.
Results: The mean age of the population was 48.4±13.7 years, with 56.9% of males. 
The mean level of eGFR was 52.5±30.5ml/min/1.73m2. The proportions of patients with 
CKD stage 1, 2, 3 and 4 were 15.3%, 16.8%, 41.2% and 26.7%, respectively. The mean 
level of serum uromodulin was 90.9±61.2 ng/mL. The CC, CT and TT genotype of the 
rs11864909 polymorphism accounted for 72.7%, 24.7% and 2.6% of the population (P for 
Hardy-Weinberg equilibrium>0.05). People with the CT&TT genotype had a significantly 
lower level of serum uromodulin than those with CC genotype (79.7 ng/mL vs. 95.1 ng/mL, 
P<0.001). After inclusion of the interaction term between rs11864909 and eGFR 
(P for interaction<0.001) in the multi-variable adjusted linear regression model, the 
regression coefficient (standard error) per 1 ml/min/1.73m2 increase in eGFR increased 
from 1.4(0.039) to 1.5(0.045), while the effect of rs11864909 (CT&TT vs. CC) lost 
statistical significance (regression coefficient increased from -20.6[2.3] to -2.1[4.6]). 
Sensitivity analysis among those with CKD stages 3 and 4 and those from large central 
study sites got consistent results.
Conclusions: The common polymorphism of rs11864909 in the UMOD gene associated 
with the level of serum uromodulin among patients with CKD, but the relationship was 
influenced by kidney function. The results add further insights into the effect of UMOD 
gene among CKD.
Funding: Government Support - Non-U.S.
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Early Impairment of Kidney Function Is Associated with Changes in 
Cardiac Structure and Function – Findings from a Large Popula-
tion-Based Cohort of Elderly Subjects
Anders Christensson. Skane University Hospital, Malmo, Sweden.
Background: The pathophysiological association between heart and kidney diseases 
is often referred to as the cardiorenal syndrome. There are only few previous community-
based studies reporting on the association between renal function and left ventricular (LV) 
function. In recent years also a minor reduction of glomerular filtration rate (GFR) has 
emerged as a risk marker for changes in cardiac structure. However, there is little knowledge 
about this in early renal impairment and echocardiographic functional parameters indicating 
diastolic dysfunction in community-based cohorts.
Methods: The study population consisted of 1504 individuals with no prior history 
of congestive heart failure or asymptomatic left ventricular ejection fraction ≥40% and 
an estimated glomerular filtration rate (eGFR) based on cystatinC >15 mL/min/1.73m2. 
Participants were categorized according to eGFR; ≥90; 75-89; 60-74; 45-59; 30-44; and 
15-29 mL/min/1.73m2. We evaluated associations between eGFR and echocardiographic 
findings. Transmitral pulsed Doppler flow and tissue Doppler imaging (TDI) in the four-
chamber view were used to measure LV diastolic function. Peak myocardial velocity of the 
basal LV wall in early (É) and late (Á) diastole in the lateral (lat) and septal (sept) walls and
Doppler measurement of peak velocity of blood flow through the mitral valve in early (E) 
and late (A) diastole were measured.
Results: Associations between reduced eGFR and echocardiographic findings 
indicating early structural changes were found for; left atrium area/body surface area 
(p=0.013) and diastolic function; peak early mitral valve velocity (A) (p=0.003), peak late 
atrial mitral valve velocity/ peak systolic myocardial velocity at mitral annulus in lateral 
wall; (E/Élat) (p=0.002), mean of É mean of lateral and septal wall/ Á mean of lateral 
and septal wall (mean Ém/Ám) (p=0.027). Associations between E/Élat and meanÉm/Ám 
and eGFR were present already in mild-moderate kidney dysfunction (eGFR 45-60 mL/
min/1,73m2). These associations were only significant among men.
Conclusions: A significant association between early impairment of renal function 
and echocardiographic markers of cardiac structure and diastolic function was observed 
supporting the hypothesis that interaction between the kidney and heart exists even in the 
early stages of renal impairment.
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The Association of Markers of Mineral Bone Disease with CVEs in Early 
CKD
Natasha J. McIntyre,1 Adam Shardlow,2 Nitin V. Kolhe,2 Richard J. Fluck,2 
Christopher W. McIntyre,3 Maarten W. Taal.1,2 1Faculty of Medicine and Health 
Sciences, University of Nottingham, London, ON, Canada; 2Royal Derby 
Hospital, Derby, United Kingdom; 3London Health Sciences Centre, London, 
ON, Canada.
Background: Markers of mineral bone disease (MBD), particularly FGF23 and serum 
phosphate, are associated with a higher risk of cardiovascular events (CVEs) in Chronic 
Kidney Disease (CKD). However, it is not clear if these associations exist in early CKD, 
when phosphate is normal and FGF23 only mildly elevated. We investigated biomarkers of 
MBD as risk factors for CVE in people with CKD stage 3 in primary care.
Methods: 1741 people with estimated GFR 59-30mL/min/1.73m2 (eGFR) were 
recruited to the Renal Risk in Derby (RRID) study and assessed at baseline, year 1 and 
5. Data on all hospital admissions with CVE (using ICD-10 coding) and cardiovascular
deaths between 2008 to 2015 were obtained from NHS Digital. Cox regression analysis
was performed on the whole cohort, those with heart failure (HF) or atherosclerotic events
to identify risk factors for CVEs.
Results: 608 CVEs occurred during a mean period of 5.1±2.2 years, a rate of 6.8/100 
participant years. The most frequent CVE was HF (345/608=57%). In the whole cohort age, 
male sex, HDL cholesterol, smoking, eGFR and urinary albumin to creatinine ratio were 
confirmed as independent risk factors for CVEs. Among the MBD biomarkers, phosphate 
and PTH predicted CVEs but FGF23 and vitamin D did not. There were differences in risk 
factors for HF versus atherosclerotic events (Table).
Conclusions: We identified HF as the commonest CVE in those with early CKD. In 
addition we identified phosphate and PTH as independent risk factors for CVEs even at 
early stages of CKD, when there is only minor perturbation of these variables. Our findings 
suggest trials of interventions to lower serum phosphate in early CKD are warranted.
Funding: Private Foundation Support
Comparative risk factors for CVE
*per Standard Deviation, ‡log transformed data, HR=Hazard Ratio, UACR= Urinary
albumin to creatinine ratio, PTH=Parathyroid hormone, NS=Not significant
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Worsening of Renal Function Predicts Mortality in Patients with Cancer 
and CKD
Ivens S. L Leite,1 Luiz F. Souza,1 Renato A. Caires,2 Francisco Z. Mattedi,2 
Fernanda O. Coelho,2 Veronica Torres,2 Elerson Costalonga.2 1University of Sao 
Paulo School of Medicine, Sao Paulo, Brazil; 2Sao Paulo State Cancer Institute 
- USP, Sao Paulo, Brazil.
Background: Cancer patients have a high prevalence of chronic kidney disease
(CKD). The aim of this study was to assess prognostic factors for death in cancer patients
with CKD.
Methods: Among 397 outpatients with cancer referred to nephrology evaluation
(2009-12), 202 had CKD according KDIGO definitions and at least 3 months of follow 
up. Clinical and biochemical data were retrieved from patient medical records. The Cox
regression was used to examine the predictors of mortality.
Results: After a follow-up of 3.9±2 years, the mortality rate observed was 57%. The 
patients features are shown in Table1. In the Cox regression analyses, serum albumin 
(aHR=0.38; CI 0.28-0.54, p<0.001), ongoing chemotherapy [aHR=0.61; CI 0.38-0.97, 
p=0.038], and CKD progression [aHR: 2.54; CI 2.54-4.18, p<0.001), defined as a sustained 
decline in eGFR of more than 5ml/min/1.73m2/yr, were the independent predictors of 
mortality in our population. Of note, worsening of renal function remained a independet risk 
factor for mortality even after adjustments for important cancer related factors (presence of 
metastasis) and Karnofsky index.
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Conclusions: Patients with cancer and CKD have a poor prognosis. Serum albumin, 
ongoing chemotherapy, and CKD progression were independent factors associated to 
mortality.
Table 1. Baseline Features
Results are expressed as mean±SD and percentage. * < 0.05 vs Death group.
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Association of eGFR and ACR with Cardiovascular Outcomes in the 
Elderly
Andreas Kuehn,1 Natalie Ebert,1 Jens Gaedeke,3 Markus van der Giet,1 
Martin K. Kuhlmann,2 Nina Mielke,1 Elke Schaeffner.1 1Charite - 
Universitaetsmedizin Berlin, Berlin, Germany; 2Vivantes Klinikum im 
Friedrichshain, Berlin, Germany; 3Dept. of Nephrology, Charité, Berlin, 
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Background: Data on the effect of kidney function (eGFR) / kidney damage (ACR) 
on cardiovascular (CV) outcomes in the elderly remain scarce. We investigated the effect of 
eGFR on cardiovascular outcomes using data of the Berlin Initiative Study (BIS).
Methods: The BIS has followed 2069 older adults ≥70 yrs since 2009. eGFR/kidney 
damage were assessed by eGFR-BIS2(crea/cysC) and ACR, respectively. ICD-10-based 
outcomes were stroke or myocardial infarction (MI), combined or single, ischemic 
stroke, and death to all-cause. A Competing Risk Model was set up for CV events, a 
Cox proportional hazards model for all-cause mortality for hazard ratios(HR) and 95% 
confidence intervals (CI). Individuals with CV event before baseline were excluded. Models 
adjusted for age, sex, diabetes, smoking, waist-to-hip-ratio, antihypert. treatment, systolic 
BP, pulse pressure, c-reactive protein, total and high density cholesterol.
Results: Within a median f/up of 7.1 yrs, 276 CV events and 680 deaths occured. 
For eGFR<60mL/min/1.73m2 highest HRs were seen for (ischemic) stroke (Table 2). 
Highest HR of 2.11 (1.36-3.29) was observed for ischemic stroke if eGFR was 45-59mL/
min/1.73m2. HRs were highest for the combination of eGFR <60mL/min/1.73m2 and ACR 
>30mg/g for all outcomes. For stroke, isolated reduced eGFR revealed a similar HR of 1.85 
(1.19-2.90) as reduced eGFR and increased ACR combined. For death, isolated increased
ACR had a HR of 2.04 (1.43-2.90).
Conclusions: After adjusting, reduced eGFR was highly associated with hazard of 
stroke in older adults. As for the combination of eGFR and ACR, the distribution of HRs for 
the cardiovascular outcomes suggests an association of ischemic stroke risk only with eGFR 
and a strong independent association of ACR with all-cause mortality.
Funding: Private Foundation Support
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Trends in Mortality Among Medicare Beneficiaries with and Without 
CKD
Monica Shieu,1 Kevin He,2 Diane Steffick,1 Hal Morgenstern,1 
Bruce M. Robinson,3 Rajiv Saran.1 1University of Michigan, Ann Arbor, MI; 
2Kidney Epidemiology and Cost Center, University of Michgian, Ann Arbor, MI; 
3Arbor Research Collaborative for Health, Ann Arbor, MI.
Background: Decreasing mortality rates have been observed for Medicare beneficiaries 
with claims-based diagnosis of CKD. It is unclear whether this is a true decline in CKD 
mortality or an artifact of increasing recognition of earlier stages of CKD. We sought to 
examine trends in mortality rate by stage of CKD.
Methods: Persons from 2008-16 Medicare 5% samples were required to be alive, aged 
>65 on Jan 1, without ESRD, and covered by Medicare Parts A and B but not C for all
of the year. Years at risk were calculated from Jan 1 each year and censored at the start 
of ESRD, Dec 31, or disenrollment from Medicare. CKD claims-based diagnoses were
searched from the year before, using ICD-9-CM and ICD-10-CM codes used to define CKD 
and its stages. The crude mortality rate each year was calculated as the number of deaths
divided by the patient-years at risk. Cox regression, stratified by CKD stage, was used to 
estimate annual (hazard) rates standardized to the age-sex-race distribution of the Medicare 
2011 population.
Results: Between 2008 and 2016, the percentage of people with diagnosed CKD 
stages 1-3 decreased. Persons without CKD had the lowest mortality rate each year, with 
unadjusted rate decreasing by 49.6 since 2008 to 41.9 in 2016. While the crude mortality 
rate decreased in CKD stages 1-2 and stage unknown by 17.6% and 27.5% respectively, 
the rates for stages 3-5 remained relatively unchanged. With standardization for age, sex, 
and race, we observed less change in mortality rates between 2008 and 2014, but sudden 
increases in 2015 and sudden decreases in 2016, especially in more advanced CKD stages. 
(See Figure)
Conclusions: The decline observed in the crude mortality rate among all CKD patients 
may be due to the changing distributions of age/sex/race/CKD stage, improved care of 
underlying risk factors, but not to greater recognition of early stage CKD. We acknowledge 
the limitations of claims-based diagnosis of CKD in this study. Furthermore, the sudden 
changes in standardized mortality rates between 2014 and 2016 remain unexplained and 
require further study.
Funding: NIDDK Support
SA-PO783 Poster Saturday
CKD: Epidemiology, Risk Factors, Prevention - III
Albuminuria, Reduced Kidney Function, and the Risk of ST and Non-ST 
Elevation Myocardial Infarction
Sonali N. De Chickera,5 Ngan Lam,2 Samuel A. Silver,3 Amber O. Molnar,4 
Edward G. Clark,5 Manish M. Sood.1 1Ottawa Hospital Research Institute, 
Ottawa, ON, Canada; 2University of Alberta, Edmonton, AB, Canada; 3Queen’s 
University, Kingston, ON, Canada; 4McMaster University, Hamilton, ON, 
Canada; 5The Ottawa Hospital and Kidney Research Centre - Ottawa Hospital 
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Background: Myocardial infarctions (MIs) in patients with chronic kidney disease 
(CKD) are associated with high rates of mortality and complications. CKD is a recognized 
risk factor for cardiovascular disease, but whether the risk of ST-elevation MI (STEMI) and 
non-ST-elevation MI (NSTEMI) differs in the CKD population is unknown. We examined 
the association of CKD (defined by reduced estimated glomerular filtration rate (eGFR) or 
albuminuria) with risks of STEMI and NSTEMI.
Methods: Using administrative data from Ontario, Canada, we examined older 
individuals (≥66 years of age) with an outpatient eGFR and albuminuria measure for 
incident MI from 2002 to 2015. Multivariate Fine & Gray sub-distribution hazards (sHR), 
adjusted for demographics, comorbidities, health resource utilization and medications, 
accounting for the competing risk of death were used.
Results: In 248,438 patients with over 1.2 million person-years of follow-up, STEMI, 
NSTEMI and death occurred in 1,436 (0.58%), 4,431 (1.78%) and 30,015 (12.08%) 
patients, respectively. In adjusted models, both eGFR and urine albumin to creatinine ration 
(ACR) were associated with STEMI and NSTEMI (P<0.0001). The highest level of ACR 
(>30 mg/mmol) was associated with a two-fold higher adjusted risk of both STEMI and 
NSTEMI among patients with eGFR ≥60 ml/min/1.73m2 compared to ACR <3 mg/mmol. 
The lowest level of eGFR (<30 ml/min/1.73m2) with ACR < 3 mg/mmol was not associated 
with higher STEMI risk but a four-fold higher risk of NSTEMI compared to eGFR ≥60ml/
min/1.73m2. The lowest eGFR (<30 ml/min/1.73m2) and highest ACR (>30 mg/mmol) was 
associated with a greater than four-fold higher risk of both STEMI and NSTEMI (sHR (95% 
CI) 4.53 (3.30-6.21) and 4.42 (3.67-5.32), respectively) compared to ACR <3 mg/mmol 
and eGFR ≥60 ml/min/1.73m2.
Conclusions: Elevations in albuminuria are associated with a higher risk of both 
NSTEMI and STEMI, regardless of kidney function, whereas reduced kidney function with 
minimal albuminuria is associated with only a heightened NSTEMI risk.
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The Bidirectional Nature of the Cardio-Renal Link in Stable CKD 
Patients
Evangelia Dounousi,1 Xanthi Zikou,2 Konstantinos Pappas,3 
Francesca Mallamaci,4 Carmine Zoccali.4 1University of Ioannina, Ioannina, 
Greece; 2Nephrology, University Hospital Ioannina, Ioannina, Greece; 
3University Hospital of Ioannina, Ioannina, Greece; 4CNR IFC, Clinical 
Epidemiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.
Background: In patients with heart disease, left ventricular (LV) dysfunction and heart 
failure are associated with reduced GFR and vice-versa, in CKD patients, LV hypertrophy 
and dysfunction go along with the CKD severity. Experimental models support the causal 
nature of these cardio-renal links. However, there is no clinical study investigating the bi-
directionality of these links in stable non-dialysis CKD patients.
Methods: We tested the longitudinal relationship between the estimated GFR (eGFR) 
and the LV mass index (LVMI) and vice versa in a cohort of 206 stage G1-5 (non-dialysis) 
CKD patients. Overall, 498 simultaneous eGFR and LVMI measurements in 206 patients 
were available over a 3 year follow-up. Data analysis was performed by the mixed linear 
model. In this analysis each predictor (either the eGFR or LVMI) was paired with the 
subsequent measurement of the pertinent outcome measure (i.e. LVMI when the predictor 
was the eGFR and the eGFR when the predictor was the LVMI) and adjusting for both, the 
eGFR and the LVMI of the preceding visit.
Results: At baseline the eGFR (MDRD) was 54±29 ml/min/1.72 m2 and LVMI 
was 70±24 gr/m2.71. In the analysis testing the LVMI as a predictor of the evolution of 
the eGFR over time, an increase in LVMI of 10 gr/m2.71 predicted a eGFR loss of 
0.41±0.25 ml/min/1.72 m2over follow up but such an effect failed to attain statistical 
significance (P=0.10). Vice versa, in the analysis testing the eGFR as a predictor of the 
evolution of the LVMI over time, a decrease in eGFR of 10 ml/min/1.73m2predicted an 
increase in LVMI of 1.1±0.4 g/m2.71 over follow up and this change was highly significant 
(P=0.001).
Conclusions: This longitudinal analysis in stable non-dialysis CKD patients shows 
that eGFR loss predicts a rise in LVMI over time. A similar trend exists for the opposite 
relationship, i.e. LVMI worsening predicts a subsequent eGFR loss but this relationship 
is much weaker than the previous one and does not achieve formal statistical significance. 
Overall, these observations suggest that the kidney disease-driven risk for cardiomyopathy 
progression is more consistent than the simultaneous heart-disease driven risk for CKD 
progression.
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Inflammatory Markers and Incidence of Hospitalization with Infection in 
CKD: The Chronic Renal Insufficiency Cohort Study
Junichi Ishigami,1 Jonathan J. Taliercio,2 Harold I. Feldman,3 Anand Srivastava,4 
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OH; 3University of Pennsylvania, Philadelphia, PA; 4Northwestern University 
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MI; 7University of Maryland, Baltimore, MD; 8University of Illinois at Chicago, 
Chicago, IL; 9Johns Hopkins University School of Medicine, Baltimore, MD; 
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MI; 13Johns Hopkins Medical Institutions, Baltimore, MD; 14Johns Hopkins 
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Baltimore, MD; 16MetroHealth, Cleveland, OH.
Background: Low grade inflammation may be linked to the impaired immune 
response in CKD. Whether inflammatory markers are associated with risk of hospitalization 
with infection is unknown.
Methods: In 3,622 participants of the CRIC Study, we assessed the association between 
the baseline levels of four inflammatory markers (interleukin-6 [IL-6], tumor necrosis 
factor-α [TNF-α], interleukin-1 receptor antagonist [IL-1RA], and transforming growth 
factor-β [TGF-β]) and incidence of hospitalization with major infections (pneumonia, 
urinary tract infections, cellulitis and osteomyelitis, and bloodstream infections) using Cox 
models adjusted for potential confounders including eGFR and uACR to estimate hazard 
ratio (HR). The inflammatory markers were log-transformed and modeled as restricted 
cubic spline with the knots at 5th, 50th, and 95th percentile.
Results: During a median follow-up of 7.5 years, 36% (n=1,294) had a hospitalization 
with major infections. Higher levels of IL-6 and TNF-α, but not IL-1RA or TGF-β, were 
each monotonically associated with increased risk of hospitalization with infection (Figure) 
(HR at 95th vs. 5th percentile, 2.27 [95%CI, 1.81-2.85] for IL-6 and 1.96 [1.59-2.42] for 
TNF-α). The associations of IL-6 and TNF-α were independent of each other and consistent 
across types of infection or in demographic and clinical subgroups.
Conclusions: Higher levels of IL-6 and TNF-α, but not IL1RA or TGF-β, were 
independently associated with increased risk of hospitalization with infection. Future 
studies are needed to explore the underlying mechanisms of the discrepant patterns in the 
association with risk of infection across inflammatory markers.
Figure: Histogram and HRs of hospitalization with infection for (A) IL-6, (B) TNF-α, 
(C) IL-1RA, and (D) TGF-β. Vertical lines indicate 5th (reference) and 95th percentiles.
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Infection-Related Hospitalizations Across Different Levels of Kidney 
Function: Data from the EXTEND45 Study
Brendon L. Neuen,1 Meg J. Jardine,1 Louisa Sukkar,1,2 Amy Kang,1 
Celine Foote,4,1 Kris Rogers,1 Anish Scaria,1 Alan Cass,3 Martin P. Gallagher,1 
Min Jun.1 EXTEND45 Study Steering Committee 1The George Institute for 
Global Health, UNSW Sydney, Newtown, NSW, Australia; 2School of Public 
Health, University of Sydney, Sydney, NSW, Australia; 3Menzies School of 
Health Research, Darwin, NT, Australia; 4Concord Repatriation General 
Hospital, Sydney, NSW, Australia.
Background: The risk of infection associated with differing levels of kidney function 
is unclear. We sought to determine the risk of infection-related hospitalization and mean 
hospital length of stay across different levels of kidney function in a community-based 
cohort study.
Methods: Based on data from the EXTEND45 Study (the 45 and Up Study linked 
to hospital and community pathology datasets by the Centre for Health Record Linkage 
[CHeReL]), we identified a population-based cohort (2006-2014) of 41,099 people aged 
≥45 years who had a measure of kidney function (estimated glomerular filtration rate 
[eGFR]). The risk of infection-related hospitalization and mean hospital length of stay 
were assessed by eGFR categories (≥90, 60-89, 45-59, 30-44 and <30ml/min/1.73m2) using
multivariable Cox regression.
Results: Of 41,099 participants, 18.6% had an eGFR <60 ml/min/1.73m2. Overall, 
2,598 (6.3%) participants experienced ≥1 infection-related hospitalization over a mean 
follow-up of 5.8 years. After adjusting for age and sex, risk of infection increased with 
declining eGFR in a graded and linear fashion (HR 0.91 [95% CI: 0.79-1.04], 1.16 [0.99-
1.37], 1.48 [1.22-1.78], and 1.83 [1.44-2.31] for eGFR ≥90, 60-89, 45-59, 30-44, and <30 
ml/min/1.73 respectively). Pneumonia, urinary tract infections, and cellulitis were the most 
common infections across all eGFR categories. Mean hospital length of stay similarly 
increased with declining eGFR categories (4.9, 6.5, 7.5, 7.8 and 7.9 days, respectively).
Conclusions: The risk of serious infection increases as kidney function declines, 
independent of age and sex, suggesting that susceptibility is likely related to other factors 
(e.g. alterations in immune function) and begins in mild-moderate renal impairment.
Funding: Commercial Support - The EXTEND45 Study is funded through peer-
reviewed (NSW Cardiovascular Research Network Collaborative Project Grant) and 
unrestricted industry (from MSD, Amgen and Eli Lilly) research grants., Government 
Support - Non-U.S.
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Predictors of CKD in the EXTEND45 Study: An Australian Popula-
tion-Based Study
Amy Kang,2 Louisa Sukkar,1 Min Jun,2 Celine Foote,1,6 Roberto Pecoits-Filho,3 
Brendon L. Neuen,1 Anish Scaria,1 Jannah F. Baker,1 Kris Rogers,1 Alan Cass,4 
Carol A. Pollock,5,7 Germaine Wong,5 John Knight,1 David Peiris,1 
Martin P. Gallagher,2 Meg J. Jardine.2 1The George Institute for Global Health, 
Camperdown, NSW, Australia; 2The George Institute for Global Health, UNSW 
Sydney, Newtown, NSW, Australia; 3Pontificia Universidade Catolica do 
Parana, Curitiba, Brazil; 4Menzies School of Health Research, Darwin, NT, 
Australia; 5The University of Sydney, St. Leonards, NSW, Australia; 6Department 
of Renal Medicine, Concord Repatriation General Hospital, Sydney, NSW, 
Australia; 7Kolling Institute for Medical Research, Sydney, NSW, Australia.
Background: The AUSDIAB study found an incidence rate of CKD (eGFR<60ml/
min/1.73m2) of 0.4 per 100 person-years in the adult Australian community aged ≥25 years. 
We aimed to assess: 1) the incidence and prevalence of chronic kidney disease (CKD), 2) 
risk factors for incident CKD in a contemporary Australian population-based cohort of 
adults aged 45 and older.
Methods: Based on data from the EXTEND45 study (the 45 and Up Study linked 
to [1]hospital and community pathology datasets by the Centre for Health Record 
Linkage[CHeReL] and [2]the Medicare Benefits Schedule[MBS] and Pharmaceutical 
Benefits Scheme[PBS] datasets provided by the Department of Human Services), we 
identified a population-based cohort (2006-2014) of 41,099 people aged ≥45 years who 
had ≥2 measures of kidney function. Prevalent CKD (defined as eGFR <60 ml/min/1.73m2) 
was determined at study recruitment. The CKD incidence rate over the study period was 
determined using Poisson regression. Cox regression was used to determine associations 
between baseline sociodemographic factors, comorbidities and future incident CKD.
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Results: Of 41,099 participants, 7,641(18.6%) had prevalent CKD and 5,481 
developed incident CKD over a mean follow-up of 5.6 years. The incidence rate of CKD 
was 3.2(95% CI:3.1-3.3) per 100 person-years. Baseline characteristics: age (per year 
increase; HR: 1.08[1.07-1.08]), regional residence (inner regional vs city: 1.26[1.18-1.36]), 
diabetes (1.28[1.19-1.38]), hypertension (1.58[1.48-1.70]), heart disease (1.22[1.14-1.31]), 
stroke (1.16[1.03-1.29]), depression (1.25[1.15-1.35]) and higher BMI (obese vs normal: 
1.38[1.27-1.49]) were predictive of incident CKD. Alcohol consumption (7-13 vs 0-6 
drinks/week 0.89[0.82-0.97]) was associated with a lower risk of incident CKD.
Conclusions: Baseline depression and regional residence predicted future incident 
CKD in conjunction with established risk factors of age, diabetes, hypertension, high BMI 
and vascular disease.
Funding: Commercial Support - The EXTEND45 Study is funded through peer-
reviewed (NSW Cardiovascular Research Network Collaborative Project Grant) and 
unrestricted industry (from MSD, Amgen and Eli Lilly) research grants.
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Burden of Metabolic Complications with Advancing CKD in the Irish 
Health System
Leonard Browne,1 Paul O’Hara,1,2 Edward P. Mc Monagle,2 Austin G. Stack.1,2 
1Graduate Entry Medical School, University of Limerick, Limerick, Ireland; 
2University Hospital Limerick, Limerick, Ireland.
Background: The prevalence of Chronic Kidney Disease (CKD) exceeds 15% in the 
Irish health system and is associated with adverse clinical outcomes. The goal of this study 
was to describe the burden of common metabolic complications in CKD and assess the 
impact of deteriorating kidney function.
Methods: Utilising data from the National Kidney Disease Surveillance System, 
we conducted a cross sectional study of adult patients, age > 18 years, from the Midwest 
region in 2014 with data on serum creatinine measurements and metabolic indicators of 
anaemia, nutrition, metabolic bone disease and acidosis. Dialysis patients were excluded. 
The following definitions were used: anaemia: haemoglobin <13 g/dL in men and <12 g/dL 
in women; hyperkalaemia: K+ > 5.5 mmol/L; hypoalbuminaemia; serum albumin <35g/L, 
metabolic acidosis: bicarbonate < 22 mmol/L, and hyperphosphatemia: phosphate 
>1.5 mmol/L. Logistic regression models explored associations of estimated glomerular
filtration rate (eGFR) with each metabolic complication expressed as adjusted odds ratio 
(OR) and 95% Confidence intervals.
Results: There were 133,558 adults with average age 54.3 (±17.7) years and eGFR 
87.9(±21.1) ml/min/1.73m2. The prevalence of metabolic complications were as follows: 
acidosis (28.9%), anaemia (13.6%), hyperkalaemic (13.1%), hypoalbuminaemia (9.9%), 
and hyperphosphatemia (2.3%). In multivariate models adjusting for age and sex only, each 
5mL/min/1.73m2 fall in eGFR was associated with higher odds of anaemia, [OR 1.08 (95% 
CI; 1.07-1.09)]; hyperkalaemia [OR 1.09 (95% CI; 1.08-1.10], hypoalbuminaemia, [OR 1.02 
(1.01-1.03)], metabolic acidosis [OR 1.03 (95% CI; 1.02-1.04)], and hyperphosphatemia 
[OR 1.23 (95% CI; 1.21-1.26)].These findings were accentuated in the elderly (Table 1).
Conclusions: The burden of CKD-related metabolic complications is substantial 
within the Irish health system and increases with advancing CKD. Patients with low eGFR, 
especially the elderly, are at increased risk for several serious but treatable metabolic 
complications. Early identification and treatment of these disorders may lead to improved 
patient outcomes
Funding: Government Support - Non-U.S.
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Assessing the Risk and Severity of Hospitalisations According to Level of 
Kidney Function: An EXTEND45 Analysis
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Amy Kang,2 Anish Scaria,2 Alan Cass,5 Carol A. Pollock,3 John Knight,2 
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Background: Contemporary assessments of the relationship between chronic kidney 
disease (CKD) and health services use in Australia by level of eGFR have been limited. 
Prior studies typically used diagnosis codes to identify CKD which have relatively low 
sensitivity for ascertaining earlier stages of CKD. We determined the risk and severity of 
all-cause and cardiovascular hospitalisations by eGFR in a community-based cohort study 
of adults aged ≥45 years in New South Wales, Australia.
Methods: Based on data from the EXTEND45 study (the 45 and Up Study linked to 
hospital and community pathology datasets by the Centre for Health Record and Linkage 
[CHeReL]), we identified a population-based cohort (2006-2014) of 41,099 people aged 
≥45 who had a measure of kidney function (eGFR). The risk and severity of hospitalisations
(defined by the hospitalisation length of stay [HLOS]) were assessed by eGFR category 
(≥90 [reference], 60-89, 45-59, 30-44 and <30ml/min/1.73m2) using multivariable Cox
regression.
Results: Of 41,099 participants, 80.2% experienced ≥1 hospitalisation event over a 
mean follow-up of 5.8 years. All-cause hospitalisation risk increased as eGFR declined 
(HR 0.99 [95% CI:0.97-1.03]; 1.05 [1.00-1.09]; 1.17 [1.10-1.24] and 1.57 [1.43-1.72] for 
eGFR 60-89, 45-59, 30-44, and <30ml/min/1.73m2, respectively; p-trend<0.001) even after 
adjustment for age and sex. Cardiovascular events rose even more steeply than all-cause 
hospitalisations (HR 1.23 [1.08-1.39]; 1.49 [1.28-1.73]; 1.73 [1.45-2.07] and 2.24 [1.80-
2.79], respectively). Mean HLOS also increased as eGFR declined (all-cause hospitalisation 
[2.3, 2.8, 3.9, 5.1 and 5.7 days, respectively]; cardiovascular hospitalisations [3.7, 3.8, 5.7, 
5.9 and 8.3 days, respectively).
Conclusions: In contemporary NSW, declining kidney function is associated with 
higher illness burden, particularly cardiovascular burden. The increased mean HLOS 
suggests that discrete medical events are more severe as kidney function declines.
Funding: Commercial Support - The EXTEND45 Study is funded through peer-
reviewed (NSW Cardiovascular Research Network Collaborative Project Grant) and 
unrestricted industry (from MSD, Amgen and Eli Lilly) research grants., Government 
Support - Non-U.S.
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Genome Wide Association Study Identifies Novel SNPs Associated with 
Albuminuria in Japanese General Population
Hiroshi Okuda. Tohoku University, Sendai, Japan.
Background: Urinary albumin excretion (UAE) is a good biomarker for chronic 
kidney disease, cardiovascular disease, diabetes mellitus or obesity. We usually expect the 
individual amounts of UAE show large variations among similar conditioned patients. The 
variations could be contributed with many genetic factors. However, a few Genome-wide 
association analysis studies (GWAS) of UAE based in European population were reported 
and there was not in Japanese general population. Here we conducted GWAS using health-
survey data collected by Tohoku Medical Megabank Organization (ToMMo) and listed up 
several candidates of single nucleotide polymorphisms (SNPs) on UAE.
Methods: GWAS of continuous variables of UAE as an outcome was performed 
using about 1 million SNPs genotypes (Illmina HumanOmniExpressExome) from 9966 
participants (Miyagi; 4974, Iwate; 4992) collected by ToMMo in 2013. As quality control, 
SNPs with low call rates (<0.98), low Hardy–Weinberg equilibrium exact test P-values 
(<1×10−4) or low minor allele frequencies (MAF; <0.01) were filtered out. As a covariate, 
age, sex, BMI, blood pressure, renal function (eGFR calculated by plasma cystatin C), 
HbA1c was used. Genotypic imputation was performed using a haplotype panel consisting 
of 2000 samples NGS data, further analysis was performed on the data, and each MAF and 
INFO value after imputing were adjusted.
Results: Analysis results were examined with p <5 × 10 - 8 as the significance level, 
and 18 candidates of novel SNPs related to UAE were identified. SNPs with particularly 
strong associations were observed on chromosome 14.
Conclusions: The 18 SNPs were identified associated with UAE and we are considering 
the mechanisms and the further verification necessarily.
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Downregulation of Renoprotective Factors Is Associated with Outcome in 
CKD
Paul Perco, Michael Rudnicki, Julia Kerschbaum, Johannes Leierer, 
Gert J. Mayer. Medical University Innsbruck, Innsbruck, Austria.
Background: An imbalance of nephroprotective factors and renal damaging molecules 
contributes to development and progression of chronic kidney diseases. Molecules with 
renoprotective properties and capacity to induce renal repair might serve as biomarkers, 
drug targets as well as therapeutic options themselves. In this study we determined the 
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potential of renoprotective factors to predict disease progression in a set of chronic kidney 
disease (CKD) patients.
Methods: Gene expression profiles were determined for 197 previously published 
proteins with renoprotective properties in renal biopsies of 63 CKD patients with different 
disease diagnoses. The statistical analysis of microarray method was used to identify 
downregulated factors in the group of progressive patients as compared to those showing 
a stable course of disease with a false discovery rate < 5%. Progression was defined 
as reaching end-stage renal disease or doubling of serum creatinine. Significance of 
renoprotective factors to predict course of disease was in addition analysed in time-to-event 
analysis using Kaplan Meier curves and log-rank statistics. Cox regression models were 
used to adjust for the clinical parameters estimated glomerular filtration rate (eGFR) and 
diagnosis type.
Results: The six renoprotective factors dicarbonyl and L-xylulose reductase (DCXR), 
epidermal growth factor (EGF), glutathione S-transferase mu 1 (GSTM1), kininogen 1 
(KNG1), nitric oxide synthase 3 (NOS3), and uromodulin (UMOD) were significantly 
downregulated in the group of progressive patients and were also significantly associated 
with outcome in time to event analysis. DCXR (p-val = 0.0277), EGF (p-val = 0.0264), 
GSTM1 (p-val = 0.0039), and KNG1 (p-val = 0.0372) remained significant after adjustment 
for eGFR and diagnosis in Cox regression analysis thus being independently associated 
with outcome. This is to our knowledge the first study describing the prognostic potential 
for DCXR in human CKD samples with literature evidence already being available for the 
other three markers showing significance in our cohort.
Conclusions: We identified a set of four renoprotective factors being downregulated in 
progressive CKD patients on the mRNA level and independently associated with disease 
outcome.
Funding: Government Support - Non-U.S.
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Association of Polygenic Risk Scores and CKD in the UK Biobank
Thi ha my Vy, Lili Chan, Kumardeep Chaudhary, Steven G. Coca, Ron Do, 
Girish N. Nadkarni. Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Genome wide association studies (GWAS) have tested for associations 
between single nucleotide polymorphisms (SNPs) and chronic kidney disease (CKD). 
Polygenic risk scores (PRS) have shown significant promise for risk discrimination in 
complex disease but there are no studies on PRS in CKD.
Methods: We generated per-individual genome-wide additive polygenic risk scores 
(PRS) using published GWAS statistics and tested them for association with CKD in 8,432 
cases and 400,529 controls of self-identified white British ancestry in the UK Biobank. We 
derived PRS using GWAS summary statistics from four different sets of SNP’s; (1) 33 loci 
significantly associated with eGFRcreatinine; (2) 53 loci significantly associated with CKD; 
(3) >38,000 independent SNVs using a linkage disequilibrium (LD) pruning approach; and 
(4)~1,800,000 SNVs with re-assigned coefficients adjusted for linkage disequilibrium (LD) 
by LDpred.
Results: Among the four PRS, the area under the curve (AUC) was slightly higher 
for PRS score 4 using ~1,800,000 SNPs (AUC=0.703) compared to PRS score 1 (0.7); 
2 (0.700) or 3 (0.701). The odds ratios (OR) for CKD prevalence increased significantly 
at higher quintiles of genome wide PRS score 4 compared to bottom quintile (Table 1). 
Individuals with highest decile of PRS score had two-fold odds of CKD vs. lowest decile 
(OR=2.0; 97.5% Confidence Interval 1.7-2.3; p=2.28x10-24).
Conclusions: PRS incorporating higher number of SNPs had slightly higher 
discrimination compared to those incorporating only GWAS significant SNPs, indicating 
polygenic architecture of CKD. PRS may provide modest improvements in risk prediction, 
especially in the extremes of genetic risk distribution.
Prevalence of CKD in higher polygenic score bins in comparison with the bottom 20% of 
polygenic score distribution
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Background: IgA nephropathy(IgAN) is the commonest glomerulonephritis 
worldwide. It is difficult to assess true prevalence of IgAN, people with mild disease do 
not commonly receive a biopsy. Multiple single-nucleotide polymorphisms(SNPs) are 
associated with IgAN. We aimed to generate and validate an IgAN genetic risk score(GRS) 
and assess the excess IgAN genetic risk in people with haematuria, hypertension and 
microalbuminuria in UK Biobank(UKBB) to estimate the proportion of these phenotypes.
Methods: We calculated the IgAN GRS using 14 SNPs associated with IgAN in 
Caucasians using established methods. We generated the GRS in 464 biopsy proven IgAN 
from the UK Glomerulonephritis (UK GN) DNA Bank, and in 344,244 Caucasians from 
UKBB, using SNP array data. We accessed diagnostic codes from electronically linked 
healthcare records, questionnaire data and baseline albumin creatinine ratio from UKBB. 
We compared the IgAN GRS in UK GN cases with healthy individuals in UKBB. We 
assessed the proportion of hypertension and microalbuminuria by comparing IgA GRS 
using this formula: Proportion=(phenotype - control)/(IgAN - control)
Results: The IgA GRS was discriminative of IgAN v non-IgAN (Mean[95% confidence 
interval]) GRS 4.35 (4.26,4.41) v 3.98 (3.96,3.99); P <0.0001. UKBB participants with 
an ICD10 diagnosis of IgAN (N=116) GRS 4.19(4.01, 4.36) had a similar GRS to the 
IgA GN cohort; P=0.1 and combined score of 4.307 (4.24,4.38). The GRS was higher in 
phenotypes with possible undiagnosed IgAN compared to healthy subjects, haematuria 
(N=13,119) GRS 4.04(4.03, 4.06); P<0.0001, haematuria and proteinuria (N=1827) GRS 
4.06(4.01,4.1); P=0.002, and haematuria, hypertension and microalbuminuria (N=1431) 
GRS 4.07(4.02,4.11); P=0.002. We calculated that IgA accounted for 19% (15-25) of 
haematuria, 22% (10-37) haematuria and microalbuminuria and 27% (13-40) haematuria, 
hypertension and microalbuminuria in UKBB.
Conclusions: We used a novel GRS approach to estimate the prevalence of IgAN 
contributing to common phenotypes that would not normally be biopsied. These data may 
allow a UK population estimate for the prevalence of undiagnosed IgAN. Further work is 
needed to assess if an IgAN GRS may be useful for individual diagnosis.
Funding: Other NIH Support - Fellowship funded by UK NIHR
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Significant Urinary Metabolites in the Progression of CKD
Yaerim Kim,1 Jueun Lee,2 Geum-Sook Hwang,2 Dong Ki Kim.1 1Seoul National 
University Hospital, Seoul, Republic of Korea; 2Korea Basic Science Intsitute, 
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Background: Despite the development of diagnostic techniques, methods for 
predicting changes in renal function or outcomes are still insufficient. Metabolomics is 
considered to be a breakthrough method to address the shortage of tools by analyzing the 
end metabolites, reflecting genetic and environmental factors. Herein, we would like to 
propose the metabolites which significantly associated with development and progression 
of chronic kidney disease (CKD).
Methods: We measured urinary metabolites from 1,274 urine samples at the time of 
renal biopsy and 147 urine samples from healthy subjects using nuclear magnetic resonance. 
The clinical outcome was defined as a decrease in estimated glomerular filtration ≥ 30%, 
doubling of serum creatinine, or development of end-stage renal disease.
Results: Initial partial components analysis and partial least squares-discriminant 
analysis score plots showed discriminated cluster between CKD and control, and according 
to the stage of CKD. A total of 41 metabolites confirmed to candidate marker associated 
with CKD. Six of metabolites (betaine, glycine, glycerol, trimethylamine-N-oxide, taurine, 
choline) showed increasing pattern, and 6 of metabolites (1-methylnicotinamide, formate, 
hypoxanthine, ethanolamine, citrate, 3-hydroxyisovalerate) showed decreasing trend to 
the stage of CKD. A total of 14 metabolites (phenylalanine, fumarate, betaine, glycine, 
glycerol, taurine, trimethylamine-N-oxide, betaine, choline, acetoacetate, acetone, acetate, 
isoleucine, leucine) had significantly increased hazard ratio to composite outcomes, and 
four metabolites (fumarate, betaine, taurine, choline) showed higher hazard ratio to outcome 
of creatinine doubling. In survival analysis using the median value of each metabolite, the 
cumulative incidence of clinical outcomes was significantly increased in 19 metabolites and 
decreased in 4 metabolites.
Conclusions: Metabolites which inform the disease progression or development can be 
a noble biomarker. In our study, betaine, choline, taurine, trimethylamine-N-oxide, glycine, 
and glycerol were shown to be a significant predictor in the progression of CKD. Although 
additional study for validation should be performed, we could find significant metabolites 
associate with CKD. And these results could be an instrumental keynote to moving ahead.
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Tsogbadrakh B. Bodokhsuren,1 Jinho Lee,3 Curie Ahn,1 Kook-Hwan Oh.1 1Seoul 
National University, Seoul, Republic of Korea; 2Pusan National University, 
Pusan, Republic of Korea; 3Seoul National University, Seoul, Republic of Korea.
Background: Metabolome analyses have been on the rise recently for the discovery of 
biomarkers for chronic kidney disease. Urinary metabolome can be appropriate prognostic 
markers to predict CKD progression.
Methods: We conducted a case-control study comparing progressor (case) with non-
progressor (control) in non-diabetic chronic kidney disease patients (polycystic kidney 
disease excluded). Urine samples and clinical data were taken from the KoreaN Cohort 
Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD). These 
random urine samples were harvested at enrollment. Participants were followed-up for 
eGFR at 6- or 12-month interval for > 2 years. Subjects of the study were 100 individuals 
that are comprised of 50 progressors and 50 non-progressors with their age, gender and 
initial eGFR values matched. Progressor and non-progressor group were divided on the 
basis of estimated GFR slope, which revealed -0.91±0.75 and 1.43±1.23 ml/min/1.73m2/yr, 
respectively. The urinary metabolite profiling was performed with an untargeted 
metabolomics approach using ultra-performance liquid chromatography time-of-flight 
mass spectrometry in conjugation with multivariate statistical analysis.
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Results: A total of 9,345 compound ions were detected in positive ion mode, and 
27 endogenous ions satisfied the false discovery rate adjusted p-value (Q-value). Among 
them, three candidate markers were discovered; X, Y and Z. These three metabolites 
showed statistically significant difference between CKD progressor and non-progressor 
group. X and Y had higher concentration in non-progressors unlike Z which were lower in 
concentration from non-progressors.
Conclusions: We identified three urinary metabolic markers associated with renal 
progression of non-diabetic chronic kidney disease. They can provide information to predict 
CKD progression as prognostic markers.
Funding: Government Support - Non-U.S.
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Concordance of Metabolite Correlations with Measured GFR in Children 
and Adults
Josef Coresh,1,2 Alison G. Abraham,2 Michelle Denburg,3 Susan L. Furth,4 
Jingsha Chen,2 Casey Rebholz,2 Eugene P. Rhee,5 Harold I. Feldman,6 
Paul L. Kimmel,7 Vasan S. Ramachandran,11 Bradley A. Warady,8 
Morgan Grams,9 Lesley Inker,10 Andrew S. Levey.10 CKD Biomarkers 
Consortium 1Welch Center for Prevention, Epidemiology & Clinical Research, 
Baltimore, MD; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, 
MD; 3The Children’s Hospital of Philadelphia, Perelman School of Medicine at 
the University of Pennsylvania, Philadelphia, PA; 4The Children’s Hospital of 
Philadelphia, Philadelphia, PA; 5Massachusetts General Hospital, Newton, 
MA; 6University of Pennsylvania, Philadelphia, PA; 7National Institute of 
Diabetes and Digestive Kidney Diseases (NIDDK), Bethesda, MD; 8Children’s 
Mercy Kansas City, Kansas City, MO; 9Johns Hopkins University, Baltimore, 
MD; 10Tufts Medical Center, Boston, MA; 11Boston University School of 
Medicine, Framingham, MA.
Background: Metabolites are strongly influenced by reduced GFR but it is unknown 
whether the associations are similar in adults and children.
Methods: We evaluated an untargeted GC/MS2 and LC/MS2-based metabolomics 
quantification (Metabolon) of frozen serum from 962 African-American Study of Kidney 
Disease and Hypertension (AASK) and frozen plasma in 702 Chronic Kidney Disease in 
Children (CKiD) participants. Metabolites were standardized, log transformed and then 
correlated to measured GFR (mGFR). GFR was measured using urinary Iothalamate 
clearance in AASK and plasma Iohexol clearance in CKiD (median (5th-95th %ile) GFR of 
48 (24-64) in AASK and 57 (23-114) in CKiD).
Results: There very high agreement between the correlation of the 871 metabolites 
with mGFR in AASK and the corresponding correlation in CKiD (Figure; correlation of 
the correlations 0.896). Both studies had an excess of negatively correlated metabolites 
with mGFR, 311 of them at p<0.001 (denoted with red pluses on the lower left quadrant). 
Creatinine is shown for reference and pseudouridine for being the most negatively 
correlated. Among these, the negative correlation with mGFR was stronger in CKiD than 
AASK (mean difference -0.10, p<0.001), likely due to the wider GFR range in CKiD. The 
first principal component explained 10% and 13% of the variance and had a correlation with 
mGFR of -0.71 and -0.86 in AASK and CKiD respectively.
Conclusions: GFR is strongly associated with a large proportion of the metabolome 
concordantly in children and adults with CKD. These findings hold promise for 
improvements in adjusting for confounding by GFR and developing equations to better 
estimate GFR that incorporate metabolite data.
Funding: NIDDK Support, Commercial Support - Metabolon funded assays in AASK 
as part of a collaboration agreement
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A Metabolomics Approach to CKD Prediction After RCC Nephrectomy
Edgar A. Jaimes,1,2 Irina Ostrovnaya,3 Axel S. Martin,4 Robert H. Weiss.5 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Weill Cornell 
Medical College, New York, NY; 3Memorial Sloan Kettering Cancer Center, 
New York, NY; 4Memorial Sloan Kettering, New York, NY; 5UC Davis, 
Nephrology, Davis, CA.
Background: Patients with RCC who undergo nephrectomy can develop CKD as 
result of reduction in renal mass and given common risk factors between CKD and RCC it 
is likely that RCC patients already have parenchymal kidney disease. Thus it is imperative 
to obtain additional information in order to identify those at higher risk for CKD and/or its 
progression.
Methods: We hypothesized that there is a metabolomics signature for future renal 
functional decline in tumor-adjacent “normal” kidney tissue. We utilized a non-targeted 
metabolomics approach coupled with longitudinal patient data from post-operative visits to 
identify metabolites in non-malignant renal tissue linked to future eGFR decline. We used 
two statistical approaches: (1) univariate analysis adjusting for age, BMI, and nephrectomy 
type, and (2) cross-validated penalized regression (elastic net) methodology. Metabolomic 
analysis was performed by Metabolon (Durham, NC) using non-targeted metabolomic gas 
and liquid chromatography coupled to a mass spectrometry approach.
Results: We studied 138 samples from nephrectomies performed at MSKCC. 79 were 
radical (57.2 %), 100 subjects were male (72.5%), 122 were white (88.4%), average age was 
61.9 years and 23 were diabetic (16.7 %). 476 metabolites were included in our analysis. 
Using univariate linear regression, we found that the most significant associations with 
eGFR slope were by the metabolites N6-trimethyl-lysine, guanosine and tyrosyl-leucine, as 
well as two unidentified metabolites, X13871 and X15168, with p<=0.012, although none 
reached significance when adjusted for multiple comparisons using FDR. We also created 
composite metabolite score utilizing all of the metabolites using elastic net modelling fitted 
on cross-validation samples. This score was univariately associated with the eGFR slope 
with p<0.001 and remained significant after adjusting for clinical variables. A similarly 
developed score based on tumor tissue metabolites was not significantly associated with 
the slope (p=0.18).
Conclusions: In this study we identified metabolites found in the adjacent non-
malignant kidney tissue that are associated with eGFR decline post-nephrectomy. 
Prospective evaluation of surgical specimens using a targeted metabolomics approach to 
validate our findings will lead to a new paradigm by which RCC patients can be evaluated, 
and potentially treated, for unrecognized and incipient CKD.
Funding: NIDDK Support
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CKD: Epidemiology, Risk Factors, Prevention - III
Blood Microbiome Profile Characteristics in Patients with CKD
Neal B. Shah,1 Benjamin Lelouvier,3 Andrew S. Allegretti,2 Ravi I. Thadhani,4 
Alessio Fasano.5 1Nephrology, Massachusetts General Hospital, Boston, MA; 
2Nephrology, Massachusetts General Hospital, Boston, MA; 3Vaiomer, LABEGE, 
France; 4Cedars-Sinai, Los Angeles, CA; 5Massachusetts General Hospital, 
Boston, MA.
Background: Association between gut dysbiosis, increased intestinal permeability and 
endotoxemia mediated inflammation has been well established in Chronic Kidney Disease 
(CKD). Microbiome data in circulating blood is lacking. Our pilot study’s aim was to 
compare blood microbiome 16S ribosomal DNA (rDNA) levels and metagenomic profiles 
between CKD patients and healthy controls.
Methods: A case control study of 20 non-diabetic CKD and age and sex matched 20 
healthy controls was done. Blood bacterial DNA was studied in buffy coat samples both 
quantitatively by 16S PCR and qualitatively by 16S targeted metagenomic sequencing using 
a molecular pipeline specifically optimized for blood samples. Patients with inflammatory 
bowel disease, WBC>11x109/L or taking antibiotics at enrollment were excluded.
Results: Median 16S rDNA levels did not significantly differ between CKD and healthy 
groups (117 vs 122 copies/ng DNA, p=0.38). 16S Metagenomic sequencing revealed a 
significant decrease in alpha diversity (Chao1 index) in CKD group compared to healthy 
(p=0.0483). Linear discriminant analysis effect size (LEfSe, Fig 1) displays numerous 
bacterial taxa with proportions significantly modified in CKD group. There was significant 
increase in proteobacteria phylum, gammaproteobacterial class and enterobacteriacea, 
pseudomonadaceae and legionellaceae families in the CKD group compared to healthy 
group. At deeper taxonomic levels, there were other striking differences between bacterial 
profiles. No significant correlation was found between glomerular filtration rate and 16S 
rDNA levels (r= -0.002, p=0.98).
Conclusions: Our study demonstrates reduced alpha diversity and significant variations 
in blood microbial profile in CKD patients with numerous bacterial taxa impacted. Studying 
larger populations of CKD from various etiologies may help identify microbiome patterns 
as predictive and diagnostic biomarkers.
Taxonomic Cladogram using LEfSe analysis
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Bariatric Surgery Reduces Elevated Urinary Mitochondrial DNA Copy 
Number in Non-Diabetic Obese Patients
Haekyung Lee, Hyoungnae Kim, Moo Yong Park, Hyunjin Noh, Soon 
hyo Kwon. Soonchunhyang University Hospital, Seoul, Republic of Korea.
Background: Obesity is an independent risk factor for chronic kidney disease (CKD). 
However, the mechanisms responsible for renal injury have not been totally elucidated. 
Mitochondrial damage is considered to have implications for renal injury, and urinary 
mitochondrial DNA (mtDNA) is a marker of mitochondrial damage. We hypothesized that 
urinary mtDNA copy number in non-diabetic obese patients would be higher than in healthy 
volunteers, and bariatric surgery could reverse elevated urinary mtDNA copy number.
Methods: We prospectively recruited age-sex matched healthy controls and non-
diabetic obese patients who were going to undergo bariatric surgery (n = 22 each; male=8, 
female=14) at a single center in Korea. We quantified the urinary absolute copy number of 
the mitochondrial nicotinamide adenine dinucleotide dehydrogenase subunit-1 (mtND-1) 
gene in healthy volunteers by quantitative polymerase chain reaction. In obese patients, 
mtND-1 copy number was measured before bariatric surgery and six months after bariatric 
surgery.
Results: Age (35.2 ± 9.6 years vs 32.2 ± 10.0 years) and eGFR (108.1 ± 11.7 mL/min 
vs 109.7 ± 24.0 mL/min) in both groups were not significantly different. 24 hour urinary 
albumin was higher in the obese group (2.7 ± 3.0 mg/day vs 52.9± 163.6 mg/day, P<0.001). 
In the obese group, BMI decreased from 41.0 ± 5.7 to 36.0 ± 7.2 (P=0.002) six months after 
bariatric surgery. Urinary mtND-1 copy number in the obese group was higher in healthy 
controls (P=0.001) (fig 1). In obese patients with high urinary mtND-1 copy number, 
bariatric surgery reduced urinary mtND-1 copy number (P=0.006).
Conclusions: Obesity is associated with elevated urinary mtND-1 copy number. 
Bariatric surgery reduces urinary mtDNA in obese patients with especially high mtDNA 
copy number. This suggests bariatric surgery would improve mitochondrial damage in 
kidney cells.
Funding: Government Support - Non-U.S.
Urinary ND-1/nDNA copy number in healthy volunteers and obese patients
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Kidney Ly6c- Macrophages Directly Promote Ischemia Induced Renal 
Fibrosis
Qian Yang, Rui Zeng, Gang Xu. Tongji Hospital, Huazhong Univ of Science and 
Technology, Wuhan, China.
Background: Macrophages are a plastic and heterogeneous cell type in renal 
injury, repair and fibrosis in acute kidney injury (AKI) to chronic kidney disease (CKD) 
progression, but the function of different macrophage population is still elusive.
Methods: In our study, we focused on exploring the function of Ly6c- macrophages in 
AKI induced renal fibrosis, which are widely considered to be derived from derived from sac 
yolk. The AKI to CKD transition was induced by severe (30 min) ischemia reperfusion (I/R).
Results: We found CCR2 deficience alleviated acute kidney injury after I/R, which 
is consistent with previous reports, however, deteriorates renal fibrosis in CKD phase. 
Furthermore, we identified the cell type in CCR2-/- mice with I/R induced CKD, and it 
showed Ly6C- macrophages were predominantly infiltrated in CCR2-/- kidney during CKD 
phase after I/R, which suggested that Ly6C- macrophages play a critical role in AKI induced 
renal fibrosis. To further confirm the hypothesis, we used chlodronate liposome to deplete 
the renal Ly6c- macrophages in CCR2-/- mice during I/R induced CKD, and we found 
renal injury and fibrosis were both alleviated compared to CCR2-/- with PBS intervention. 
Similar results were identified in wild type mice by depletion of Ly6C- macrophages with 
chlodronate liposome. Furthermore, Ly6C- macrophages were extracted and adoptive 
transferred to severe immune deficient mice, which showed that renal injury and fibrosis 
were directly induced by Ly6C- macrophages. In vitro, we further confirmed that Ly6C- 
macrophages exerted their profibrotic function by promoting fibroblasts transdifferentiation 
into myofibroblasts.
Conclusions: In conclusion, kidney Ly6C- macrophages play an important role in 
directly promoting ischemia induced renal fibrosis, and this function is related to affecting 
fibroblast transdifferentiation.
Funding: Government Support - Non-U.S.
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iTRAQ-Based Renal Proteomic Analysis Exploring the Influence of Bone 
Marrow Derived MSCs on CKD Rats
Chen Bo,1,2 Jianchun Li,5 Hui Diao,3 Yuan Liao,4 Dan Wen,3 Li Wang.2 Innovative 
team of integrated traditional Chinese and western medicine for prophylaxis and 
treatment of chronic kidney disease 1Department of Human Anatomy, Southwest 
Medical Univeristy, Luzhou, China; 2Research Center of Integrated Chinese and 
Western Medicine, Affiliated Traditional Medicine Hospital of Southwest 
Medical University, Luzhou, China; 3Department of Nephrology, Affiliated First 
Hospital of Southwest Medical University, Luzhou, China; 4Department of 
Nephrology, Affiliated Traditional Medicine Hospital of Southwest Medical 
University, Luzhou, China; 5Research Center of Integrated Chinese and Western 
Medicine, Affiliated Traditional Medicine Hospital of Southwest Medical 
University, Luzhou, China.
Background: The antifibrosis still represents the final target to treat chronic kidney 
disease (CKD). Mesenchymal stromal cells (MSCs) have been verified with significant 
improvement in the therapy of anti-fibrosis in the lastest 10 years. We attempted to clarify 
iTRAQ-based renal proteomic analysis exploring the new mechanism of MSCs on renal 
fibrosis.
Methods: Chronic kidney disease (CKD) models were established through combined 
with adriamycin and adenine in rats. A single intravenous MSCs injection was performed in 
the early period. Renal fibrosis was evaluated by sirius red staining and extracellular matrix 
components labeled by immunohistochemistry, respectively. Renal proteomic analysis was 
analyzed using iTRAQ-based mass spectrometry, and primarily differentially expressed 
proteins were further assessed by quantitative PCR and Western Blot.
Molecular Mechanisms of CKD - III
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
946
J Am Soc Nephrol 29: 2018 Poster/Saturday
Results: MSCs delivery decreased myofibroblast marker (α-SMA), extracellular 
matrix expression, and ameliorated the renal function in MSCs group compared to model 
group. 6,213 proteins were identified, and 40 proteins exhibited significant differences 
(30 up-regulated, 10 down-regulated) compared to model group. Bioinformatics analysis 
revealed that these proteins play important roles in biological process, cellular process, 
biological regulation, response to stimulus, metabolic process, organic substance metabolic 
process, single-organism process. Lgals3, Ifi47, Armc1 and Mgat3 may play important roles 
in the improvement of CKD fibrosis by MSCs. Lgals3 protein was down-regulated in MSCs 
group which has recently been deemed as a new biomarker of renal fibrosis.
Conclusions: We depicted the differently expressed proteins in the early period of 
MSCs delivery in adriamycin and adenine-induced CKD rat kidney by iTRAQ-based 
proteomic analysis which may provide valuable information to understand the molecular 
mechanisms involved in MSCs-based therapy for CKD fibrosis.
Funding: Private Foundation Support, Government Support - Non-U.S.
Global protein expression patterns in CKD rat kidneys in MSCs group compared to model 
group
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Macrophage-Derived miR-155-Containing Exosomes Promotes Angioten-
sin-II Induced Senescence and Oxidative Stress in Proximal Tubular Cells
Bin Wang,1 Jialing Ji,2 Bi-Cheng Liu.1 1Zhong Da Hospital, Southeast University, 
Nanjing, China; 2Department of Pediatric Nephrology, Nanjing Medical 
University, Nanjing, China.
Background: The activation of the renin-angiotensin (Ang)-aldosterone system 
(RAAS) is a major hallmark in the development and progression of organ damage in 
chronic kidney disease (CKD). Here, we examined the role of macrophage-derived miR-
155-containing exosomes in regulating oxidative stress and senescence in Ang-II induced
PTCs both in vivo and in vitro.
Methods: CKD mice model: An osmotic minipump was implanted subcutaneously to 
infuse Ang-II for 4 weeks after a right uninephrectomy or sham operation in wild type or 
miR-155-deficient mice. Macrophage-derived miR-155-containing exosomes were infused 
in miR-155-deficient mice through tail injection. In vitro, primary cultured PTCs were 
treated with Ang-II (10-7M) in the presence or absence of macrophage-derived miR-155-
containing exosomes or miR-155 inhibitor. Finally, kidney samples and cultured PTCs in 
various groups as indicated above were analyzed for markers of senescence and oxidative 
stress.
Results: Our study revealed that miR-155 expression, the number of infiltrated 
macrophages, and oxidative stress and senescence were substantially increased in PTCs 
in Ang-II infused mice relative to the control group. Ang-II infused miR-155-deficient 
mice display attenuated senescence and mild oxidative stress compared that in wild type 
mice. Conversely, macrophage-derived miR-155-containing exosomes enhanced oxidative 
stress and senescence in Ang-II infused miR-155-deficient mice. Interestedly, pri-miR-155 
was only expressed in macrophages, but not in PTCs, and macrophage-derived miR-155-
containing exosomes can be transferred into PTCs. Hence, it is not strange that blocking 
exosome secretion with GW6849 attenuated oxidative stress and senescence in Ang-II 
infused wild type mice. Additionally, we found that miR-155 inhibitor abrogated oxidative 
stress and senescence in PTCs by directly down-regulating FoxO3a expression.
Conclusions: Taken together, our results demonstrated that infiltrated macrophages 
secreted miR-155-enriched exosomes and promoted oxidative stress and senescence by 
directly targeting FoxO3a in Ang-II infused PTCs injury.
Funding: Government Support - Non-U.S.
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Macrophage Chemoattractant Protein-1 (MCP-1) Promotes Renal 
Fibrosis in AKI-to-CKD Transition
Leyuan Xu, Lloyd G. Cantley. Section of Nephrology, Yale University School of 
Medicine, New Haven, CT.
Background: Acute kidney injury (AKI) significantly increases the risk of developing 
progressive kidney fibrosis and chronic kidney disease (CKD). Macrophages play complex 
roles in AKI, with proinflammatory macrophages initially serving for clearance of 
apoptotic cells/debris after injury, followed by reparative macrophages promoting tubule 
repair. Using a CKD model of unilateral ischemia-reperfusion (U-IRI) in which the injured 
kidney undergoes fibrosis and atrophy rather than effective repair, we recently showed that 
macrophages downregulate reparative activation and transition to a profibrotic phenotype 
by day 14 after injury. In this study, we investigated the mechanism by which macrophages 
become profibrotic during the AKI-to-CKD transition.
Methods: Male wild-type or Ccr2-/- mice were subjected to warm U-IRI (27 min). 
Serum KIM1 level on day 1 after U-IRI was used to define the degree of initial injury. The 
injured kidney was removed on day 14 or 30 after U-IRI. Renal cells were flow sorted on 
day 14 to define the macrophage homing signals. Renal fibrosis was assessed on day 30 by 
Sirius red staining, qPCR and Western blotting for Col1a1, Col3a1 and Fn1. Macrophage 
accumulation was assessed by IHC for F4/80 and qPCR for Cd68. Interstitial inflammation 
was assessed by qPCR for Tnfa.
Results: Failure of kidney repair by day 14 after U-IRI led to sustained high expression 
of macrophage chemoattractant protein-1 (Mcp1) in the injured kidney compared to 
the contralateral control kidney (53-fold increase, n=10, p<0.001). CD45+F4/80+ 
macrophages and CD45+CD11c+F4/80- dendritic cells were the major cellular sources 
of this late, persistent Mcp1 expression (34- and 5-fold increase compared to renal cells 
and CD45+CD11c-F4/80- T cells/PMNs), while all bone marrow derived CD45+ cells 
expressed high levels of the Mcp1 receptor Ccr2. Injured kidneys from Ccr2-/- mice showed 
~30% less profibrotic macrophage accumulation, interstitial fibrosis and inflammation in 
comparison to the wild-type control mice (n=5, p<0.01). Furthermore, administration of a 
CCR2 inhibitor (RS102895, 5 mg/kg, every 12 h) to wild-type mice for 7 days beginning 7 
days after U-IRI replicated these results (n=8, p<0.05).
Conclusions: Our data showed that MCP-1 may serve as an autocrine and/or paracrine 
factor for profibrotic macrophage accumulation, leading to increased interstitial fibrosis 
during the AKI-to-CKD transition.
Funding: NIDDK Support
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“Nephrogenic” Systemic Fibrosis Is Driven by C-C Chemokine Receptor 
2-Dependent Myeloid- and Resident Tissue-Derived Fibrocyte Activation
Brent Wagner,1,2 Catherine Do,4,3 Chunyan Tan,3 Viktor Drel,3 Doug Y. Lee,3 
Yves C. Gorin.3,1 1Kidney Institute of New Mexico and the University of New
Mexico Health Science Center, Albuquerque, NM; 2Medicine Service, New
Mexico Veterans Administration Health Care System, Albuquerque, NM; 
3University of Texas Health Science Center, San Antonio, TX; 4Medicine Service, 
South Texas Veterans Health Care System, San Antonio, TX.
Background: Gadolinium-based contrast agents are now associated with multiple 
conditions, including ‘nephrogenic’ systemic fibrosis/gadolinium-associated systemic 
fibrosis (NSF) and symptoms attributed to gadolinium retention. Bone marrow-derived 
fibrocytes and the monocyte chemoattractant protein 1 (MCP1) inflammatory pathway 
have been implicated as mediators. Mechanistic studies are scant. We established a mouse 
model of NSF.
Methods: Marrow was transplanted to lethally-irradiated mice: 1) recipients with 
5/6 nephrectomies received green fluorescent protein- (GFP-) expressing marrow, 2) C-C 
chemokine receptor 2- (CCR2-) deficient mice received GFP-expressing marrow, and 3) 
wild-type mice received CCR2-deficient marrow. After engraftment periods, recipients were 
randomized to untreated or gadolinium-based contrast agent treatment (Omniscan—96% 
gadodiamide—2.5 mmol/kg, 20 doses intraperitoneally over 4 weeks).
Results: Dermal cellularity was increased in contrast-treated GFP chimeric mice. 
Compared to control, skin GFP, fibronectin, and type I collagen were increased in the 
contrast-treated chimeric animals. Importantly, CD45RO—a fibrocyte marker—was 
abundant in the dermis of contrast-treated animals and expressed by the myeloid cells. Many 
of these cells expressed cytoplasmic α-smooth muscle cell actin, a marker of myofibroblast 
activation. Activated myofibroblasts and fibrosis colocalized with the myeloid marker in 
contrast-treated animals. MCP-1 and CCR-2 were increased in the tissues from contrast-
treated mice. CCR2-deficient recipients of GFP-expressing marrow had a partial abrogation 
of gadolinium-induced pathology and displayed less GFP positivity in the skin. Wild-
type animals that received CCR2-deficient marrow had a complete abrogation of dermal 
pathology.
Conclusions: Systemic fibrosis is induced by gadolinium contrast in mice. The 
abundance of myeloid cells in an involved organ, the skin, in tandem with a fibrocyte 
marker—CD45RO—supports the blood-borne circulating fibrocyte hypothesis of the 
disease. This is the first demonstration of fibrocyte trafficking ever demonstrated in 
mice. Similar to what is observed in a rat model, our data demonstrate that the monocyte 
chemoattractant protein 1/CCR2 axis plays a critical role in the pathogenesis of gadolinium-
induced systemic fibrosis.
Funding: NIDDK Support, Veterans Affairs Support, Private Foundation Support
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Bone Marrow Mesenchymal Stem Cells (BMSCs) Ameliorate Experimen-
tal Renal Interstitial Fibrosis via Promoting Tertiary Lymphoid Organ 
Neogenesis
Fengge Zhu, Xiangmei Chen, Shuwei Duan, Ying Zheng, Jiuxu Bai. Department 
of Nephrology, Chinese PLA General Hospital, State Key Laboratory of Kidney 
Diseases, National Clinical Study Center for Kidney Diseases, Beijing, China.
Background: Earlier studies indicate that bone marrow mesenchymal stem cells 
(BMSCs) is effective in protecting experimental renal interstitial fibrosis. However, the 
exact mechanism is not clear. We purpose that BMSCs may ameliorate renal interstitial 
fibrosis via promoting renal tertiary lymphoid organ (TLO) neogenesis.
Methods: We establish unilateral ureteral obstruction model using C57/BL6 
male mice. BMSCs is given to animals 4 hours after surgery via tail vein, single time, 
106 cells per mouse. Animals are sacrificed at the seventh day after surgery and kidney 
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tissues are harvested for histopathological assessment, immunoflurescence staining, 
immunohistochemistry staining and Western Blotting protein assay.
Results: BMSCs treatment significantly ameliorates renal tubulointerstitial fibrosis 
and reduce kidney injury score at the 7th day after UUO surgery. BMSCs treatment also 
reduces PDGFRβ+ fibroblast and α-SMA+ myofibroblast infiltration within the kidney, 
as well as suppresses the renal expression of extracellular matrix proteins collagen I, 
vimentin and fibronectin. BMSCs treatment also promotes the formation and neogenesis 
of tertiary lymphoid organ within the kidney, identified with markers PNAd, LYVE-1, and 
GL-7. Further more, BMSCs treatment significantly inhibits the renal infiltration of CD3e+ 
T lymphocytes, CD11b+ monocytes and Ly6C/Ly6G+ neutrophils. Our results indicate a 
possible role of tertiary lymphoid organ formation and leukocyte trafficking in BMSCs’ 
ability to ameliorate kidney injury and interstitial fibrosis.
Conclusions: BMSCs protection from experimental renal tubulointerstitial fibrosis 
could at least partly be attributed to their promotion of tertiary lymphid organ neogenesis 
and leukocyte trafficking within the obstructed kidney.
Funding: Government Support - Non-U.S.
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Twist1 in Kidney Epithelium but Not Macrophages Propagates  
Aristolochic Acid Nephropathy
Jiafa Ren,2 Yi Wen,3 Xiaohan Lu,1 Jamie Privratsky,2 Steven D. Crowley.2 1Duke 
University, Durham, NC; 2Duke University Medical Center, Durham, NC; 
3Southeast University, Nanjing, China.
Background: Aristolochic acid, the causative agent in Chinese herbal and Balkan 
nephropathies, triggers persistent tubular injury and interstitial inflammation culminating in 
renal fibrosis. The transcription factor Twist1 induces pro-fibrotic gene expression programs 
in renal tubular cells (RTCs) but suppresses pro-fibrotic cytokines in macrophages. To 
discriminate these opposing, cell-specific actions of Twist1 in CKD, we subjected mice with 
RTC- or macrophage-specific Twist1 deficiency to chronic aristolochic acid nephropathy 
(AAN).
Methods: Mice with a floxed allele for the gene encoding Twist1 were backcrossed to 
the injury prone 129/SvEv strain and bred with 129/SvEv Ksp-Cre or LysM-Cre mice to 
yield Twist1 “KKO” or “MKO” mice with RTC- or macrophage-specific Twist1 deletion, 
respectively. AA (5mg/kg IP) was injected into Twist1 KKO, Twist1 MKO, and wild-type 
(WT) littermate control mice every other day for 12 days.
Results: 5 weeks after the last AA injection, Twist1 KKO mice compared to WTs had 
attenuated CKD as measured by BUN (41 ± 4 vs 52 ± 3 mg/dl; p = 0.035), blinded injury 
scores of PAS stains (2.0 ± 0.3 vs 2.9 ± 0.2; p = 0.038), and renal NGAL mRNA levels 
(0.6 ± 0.1 vs 1.0 ± 0.1; p = 0.036). Twist1 deletion in RTCs ameliorated kidney fibrosis as 
exhibited by reduced mRNA for Col-I (0.69 ± 0.05 vs 1.00 ± 0.09; p = 0.022) and TGF-β1 
(0.81 ± 0.05 vs 1.00 ± 0.05; p = 0.019) and decreased protein levels of fibronectin (0.60 ± 
0.03 vs 1.00 ± 0.07; p< 0.001) and α-SMA (0.55 ± 0.06 vs 1.00 ± 0.06; p<0.001). Twist1 
in RTCs also secondarily regulated innate immune responses in the kidney as Twist1 KKO 
kidneys showed reduced mRNA expression for the macrophage chemokine CCL2 (0.72 ± 
0.07 vs 1.00 ± 0.10; p = 0.046) and cytokine TNF-a (0.73 ± 0.08 vs 1.00 ± 0.08; p = 0.038). 
Accordingly, flow cytometric analysis after 5 weeks of AAN revealed reduced numbers of 
CD64+ (45906 ± 5279 vs 62986 ± 4822; p = 0.03) and F4/80+ (49949 ± 4441 vs 65581 
± 5005; p = 0.033) CD11b+Ly6G- macrophages in the Twist1 KKO kidneys versus WT 
controls. By contrast, robust deletion of Twist1 directly from myeloid cells in the Twist1
MKO cohort (>80%, p < 0.0001) had no impact at 5 weeks on renal tubular injury, 
interstitial fibrosis, or local inflammation.
Conclusions: Twist1 in RTCs rather than in myeloid cells regulates chronic 
inflammation and injury in the kidney during AAN.
Funding: NIDDK Support, Veterans Affairs Support
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Genetic Depletion of Adenosine Kinase in Macrophage Aggravates Renal 
Fibrosis by Modulating M1/M2 Macrophage Polarization
Chang Ying Xing,1 Xi Liu,2 Yanggang Yuan,2 Xiaofei An,3 Huijuan Mao,1 
Bo Zhang.4 1First Affiliated Hospital of Nanjing Medical University, Nanjing, 
China; 2the First Affiliated Hospital o f Nanjing Medical University, Nanjing, 
China; 3Jiangsu Province Hospital of Chinese Medicine, Nanjing, China; 4The 
first affiliated hosptial of Nanjing Medical University, Nanjing, China.
Background: Renal fibrosis is a common pathological manifestation of chronic 
renal diseases to end-stage renal failure, regardless of the cause. Accumulating evidence 
suggests a key role of macrophages in the pathogenesis of renal fibrosis. Adenosine (ADO) is 
an endogenous nucleotide involved in the energy metabolism and adenosine can be 
metabolized by adenosine kinase (ADK) or adenosine deaminase in cells. Adenosine can 
regulate the function of multiple immune cells. Therefore, we assume that the specific 
knockout of adenosine kinase gene can affect the function of macrophages and play a role in 
renal fibrosis.
Methods: 12 wild-type adult male mice and 12 ADK-deficient adult male mice 
undergo a sham operation or a unilateral ureteral occlusion operation.14 days after surgery, the 
kidney cortex was preserved to investigate renal pathological changes and renal fibrosis extent. 
F4/80 immunofluorescence staining and immunohistochemical staining was used to detect the 
degree of macrophage infiltration and M1 and M2 macrophages respectively. in vitro, we 
investigate the effrct of ADKI to RAW264.7 macrophages.
Results: ADK-/- UUO group had more severe interstitial fibrosis than that in WT 
UUO group. Infiltrated macrophages in the ADK-/- UUO group were increased than the WT 
UUO group (P<0.05) and M2 macrophages were predominate. ADKI promoted the 
RAW264.7 macrophages migration (P<0.05) and increased M2 macrophages biomarker 
expression along with inhibiting pron of -inflammatory cytokines release. ADKI increased the 
basic oxygen demand and maximal oxygen consumption of macrophages and reduced the 
extracellular acidification rate compared with Contol group (P<0.05). The numbers of M2 
macrophages were negatively correlated with eGFR. The numbers of macrophages 
infiltrated in patients of Class III and IV DN was significantly higher than Class IIa or IIb 
stage(P < 0.05). patients with more severe renal tubular injury and interstitial fibrosis had more 
M2 macrophage.
Conclusions: Genetic depletion of adenosine kinase of macrophage exacerbates 
UUO-induced fibrotic lesions by mediating macrophage migration and promoting M2 
macrophages transformation. Inhibition of ADK promote the conversion of macrophages to 
M2 type by inhibiting the glycolytic pathway. the more severe renal damage in patients with 
DKD, the more macrophages infiltrate.
Funding: Government Support - Non-U.S.
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Glycolytic Reprogramming and Development of Renal Fibrosis
Jessica M. Overstreet,1 Sungjin Chung,3 Ming-Zhi Zhang,1 Raymond C. Harris.2 
1Vanderbilt University Medical School, Nashville, TN; 2Vanderbilt University 
Medical Center, Nashville, TN; 3The Catholic University of Korea College of 
Medicine, Seoul, Republic of Korea.
Background: Tubule dysfunction, myofibroblast differentiation and macrophage 
polarization are important in the development of renal fibrosis, which accompanies 
chronic kidney disease (CKD). Glycolytic reprogramming is critical for myofibroblast 
differentiation and fibrosis in the lung and the polarization of macrophages to an M1 
phenotype. Although, dysregulation of cellular metabolism plays a role in the pathogenesis 
of several diseases, the role of glycolytic reprogramming in kidney fibrosis is unclear.
Methods: Glycolytic flux was measured by determination of extracellular acidification 
rates (ECAR) using Seahorse respirometry. An acute kidney injury (AKI)-CKD fibrotic 
model was performed by 31 min unilateral I/R, followed by uninephrectomy at day 8 and 
initiation of administration of the glycolysis inhibitor, PFK15 every 3 days until day 28. 
Human renal proximal tubule epithelial cells, mouse renal fibroblasts, and freshly isolated 
renal macrophages were used for in vitro studies.
Results: Transforming growth factor-β (TGF-β) is a master regulator of glycolytic 
reprogramming. TGF-β treatment led to increased glycolytic flux in both cultured renal 
epithelial cells and fibroblasts, as indicated by increased ECAR and ATP production. 
Glycolysis was reduced to basal levels with glycolytic inhibitors, PFK15 or 3-PO. TGF-
β-induced glycolysis in fibroblasts was also confirmed by increased production of lactate. 
TGF-β-induced proliferation, differentiation (α-SMA), and matrix production (fibronectin) 
of renal fibroblasts was inhibited by PFK15. I/R injury for 2 days led to increased glycolysis 
in isolated CD11b+ renal macrophages, which was inhibited by PFK15. In the AKI/CKD 
fibrotic model, PFK15 markedly decreased renal interstitial fibrosis, indicated by less Sirius 
red and Masson’s Trichrome staining. PFK15 also inhibited matrix and collagen deposition, 
α-SMA+ myofibroblasts, epithelial injury (e.g., KIM-1), and immune cell infiltration, 
including macrophages, CD3+ lymphocytes, and neutrophils.
Conclusions: These results suggest that glycolytic reprogramming is involved in 
renal tubular epithelial cell dysfunction, myofibroblast differentiation, and macrophage 
polarization in AKI, and inhibition of glycolytic flux may provide a new therapeutic target 
to prevent renal fibrosis when recovery from AKI is incomplete.
Funding: NIDDK Support, Veterans Affairs Support
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The FDA-Approved MEK Inhibitor Trametinib Ameliorates Kidney 
Fibrosis by Suppressing ERK1/2 and mTORC1 Signalling
Petros Andrikopoulos,2,1 Julius E. Kieswich,2 Sabrina C. Pacheco,2 Luxme 
Nadarajah,2,3 Steven M. Harwood,2 Muhammad M. Yaqoob.2,1 1Diabetic Kidney 
Disease Centre, Renal Unit, The Royal London Hospital, London, United 
Kingdom; 2Queen Mary, University of London, London, United Kingdom; 
3Barts and the London Hospital, London, United Kingdom.
Background: The incidence of Chronic Kidney Disease (CKD) is reaching epidemic 
proportions with rising associated morbidity and mortality. Consequently, there is an 
urgent need for novel treatments. The ERK1/2 pathway is activated during kidney 
fibrosis, a hallmark and promoter of CKD irrespective of the underlying cause, and has 
been detrimentally implicated in the differentiation and expansion of kidney fibroblasts. 
Trametinib, an ERK1/2-pathway inhibitor has been recently approved for the treatment of 
melanoma. However, the efficacy of trametinib in the setting of renal fibrosis has not been 
explored.
Methods: Unilateral Ureteral Obstruction (UUO) was established in male C57BL/6J 
mice. Trametinib (3mg/Kg) was admisnistered, once daily, by oral gavage for 6 days. or. 
in a parallel study, 4 days after UUO once daily for six days. Human kidney fibroblasts 
were from Cambridge Bioscience. Immunoblot was conducted using the NuPAGE system 
(Invitrogen). Immunostaining was performed with the DISCOVERY XT (Ventana) 
instrument.
Results: Trametinib significantly attenuated collagen deposition and myofibroblast 
differentiation and expansion in the UUO model of kidney fibrosis. In addition to the 
ERK1/2 pathway trametinib also ameliorated mTORC1 activation, another key pro-fibrotic 
signalling pathway, in injured kidneys. Trametinib also supressed ERK1/2 and mTORC1 
pathways activation in cultured primary human renal fibroblasts in response to TGF-β1. 
Additionally, trametinib reduced the expression of the myofibroblast marker αSMA and 
the proliferation of these cells.. Crucially, trametinib also significantly ameliorated renal 
fibrosis progression when administered to animals with established fibrotic injury.
Conclusions: Our work shows that trametinib could be beneficial for the treatment of 
chronic renal fibrotic diseases of diverse aetiologies.
Sirius red staining of kidney sections from UUO or contralateral control kidneys 7days 
afer surgery. Animals received trametinib (3mg/kg for 6days) or vehicle as indicated. N=6
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ATF6α and PPARα Cross-Talk Provides New Insights into  
Lipotoxicity-Induced Tubulointerstitial Fibrosis
Tzu-Ming Jao, Tsuyoshi Inoue, Mai Sugahara, Hiroshi Maekawa, Yu Ishimoto, 
Tetsuhiro Tanaka, Masaomi Nangaku, Reiko Inagi. The University of Tokyo, 
Tokyo, Japan.
Background: Lipid accumulation in renal tubules is frequently observed in CKD 
patients with tubulointerstitial fibrosis (TIF). However, the molecular mechanisms 
modulating lipotoxicity-induced TIF remain obscure. ATF6α, a transcription factor of the 
unfolded protein response, is reported to be an upstream regulator of fatty acid metabolism. 
Fatty acids are the main energy source of proximal tubular cells (PTCs), resulting from their 
high energy demand. We therefore hypothesized that ATF6α regulates tubular fatty acid 
metabolism, and is thereby linked to lipotoxicity-induced TIF.
Methods: Human proximal tubular cells, HK-2, were transduced with Mock, dominant 
active ATF6α or dominant negative ATF6α lentivirus for various experiments. Kidney 
unilateral ischemia-reperfusion (uIRI) (27 mins) was used as a chronic kidney injury 
model and kidney injury was assessed on day 14 post-uIRI using WT and Atf6α-/- mice. 
Mitochondrial fatty acid β-oxidation, glycolysis and function were measured using a 
Seahorse flux analyzer.
Results: Overexpression of activated ATF6α transcriptionally downregulates PPARα, 
the master regulator of lipid metabolism, leading to reduced activity of fatty acid β-oxidation 
and cytosolic accumulation of lipid droplets in HK-2. Such ATF6α-induced lipotoxicity 
causes mitochondrial dysfunction, enhanced apoptosis and connective tissue growth factor 
(CTGF) expression, as well as reduced cell viability, suggesting the promotive effects of 
ATF6α in TIF. Atf6α-/- mice showed less tubular lipid accumulation in association with 
sustained PPARα expression after uIRI, resulting in the amelioration of apoptosis; reduced 
expression of CTGF, α-SMA and collagen I; and subsequent TIF. These findings indicate 
the pivotal role of ATF6α in lipotoxicity-mediated TIF. Administration of fenofibrate, a 
PPARα agonist, in uIRI-operated mice alleviated the tendency to lipid accumulation and 
TIF.
Conclusions: These findings indicate that under the pathogenic condition, maladaptive 
ATF6α activation deranges fatty acid metabolism in PTCs, which leads to lipotoxicity-
mediated apoptosis and CTGF upregulation, both of which may accelerate TIF.
Funding: Government Support - Non-U.S.
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STAT3 Deletion from Stromal Cells Protects Mice from Folic Acid or 
Aristolochic Acid-Induced Kidney Fibrosis by Limiting Differentiation 
and Migration of Pericytes
Amrendra K. Ajay,1,2 Shruti Vig,5 Akinwande A. Akinfolarin,3 Venkata 
Sabbisetti,4,2 Joseph V. Bonventre.1,2 1Brigham and Women’s Hospital, Boston, 
MA; 2Harvard Medical School, Boston, MA; 3Brigham And Womens Hospital, 
Mckinney, TX; 4Brigham and Women’s Hospital, Boston, MA; 5Brigham and 
women’s hospital, Boston, MA.
Background: STAT3 is a key transcription factor, which is phosphorylated in response 
to growth factors and cytokines. Upon phosphorylation, STAT3 regulates cell proliferation 
and migration. Here, we investigated the function of STAT3 signaling in the development 
of kidney fibrosis.
Methods: STAT3 activation was measured in 5 patient biopsy samples. Stromal 
cell-specific STAT3 deletion was performed by breeding STAT3 floxed mice with FoxD1 
Cre mice. Kidney fibrosis was induced by administering 300 mg/kg folic acid (FA) or 5 
mg/kg body weight aristolochic acid (AA). We developed STAT3 activated pericytes 
like 10T1/2 cells using two CRISPR based methods: i) Synergistic Activation Mediators 
(SAM) sgRNA, and ii) mutation of alanine 662 and asparagine 664 residues to cysteines. 
Additionally, using CRISPR, we mutated serine 727 to alanine of STAT3 in pericyte cell 
line. Cell migration was evaluated with wound scratch assays. RT-PCR, immunostaining 
and western blotting were performed to measure changes in STAT3-dependent genes and to 
quantitate pro-fibrotic cytokines.
Results: STAT3 phosphorylation was increased in tubular epithelial cells and 
interstitial cells of 5 human subjects with chronic kidney disease. Deletion of STAT3 
from pericytes protects mice from FA or AA-induced kidney fibrosis at 7 and 14 days 
post-treatment. Fibrotic markers, including fibronectin, collagen1a1, and α-SMA, were 
reduced in STAT3 KO mice. STAT3 KO mice show similar acute injury and have less 
KIM-1 expression at 7 and 14 days. CRISPR-Cas9 mediated activation and inhibition 
studies in vitro confirmed that STAT3 is directly regulating profibrogenic signaling in 
pericytes. STAT3 phosphorylation increased migration and differentiation of pericytes. 
STAT3 is phosphorylated after treatment with TGF-β. Inhibition of TGF-β induced 
STAT3 phosphorylation significantly decreased the proliferation, production of profibrotic 
cytokines and differentiation of pericytes.
Conclusions: STAT3 leads to fibrosis by increasing proliferation, migration and 
differentiation of pericytes into myofibroblasts. STAT3 is a potential therapeutic target for 
kidney fibrosis.
Funding: NIDDK Support
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Renalase (RNLS) Attenuates Cisplatin (CP)-Induced CKD by diminishing 
Stress Kinases and Regulated Necrosis
Robert L. Safirstein,2 Xiaojia Guo,1 Tian-Min Chen,3 Heino Velazquez,2 
Gary V. Desir.2 1Yale Univ, Woodbridge, CT; 2Yale and VAMC, West Haven, CT; 
3Yale University, New Haven, CT.
Background: CP is widely used as an effective chemotherapeutic agent for cancer yet 
it causes CKD upon repeated doses, which limits its use. We have induced CKD in mice 
using 2 doses of CP 2 weeks apart and have shown that CKD developes 2 weeks after the 
second dose. Previously we have shown that RNLS attenuates acute ischemic and cisplatin-
induced AKI. We now report on the role of RNLS to prevent CP-induced CKD.
Methods: CKD was induced by 2 doses of CP 15 mg/kg ip 2 weeks apart in C57BL/6J 
mice. Mouse PT cells (TKPTS) were incubated with 25 ug/ml CP and studied 24 hours 
after treatment. A non-enzymatic peptide of RNLS (p81), 4mg/kg sc, that signals via a 
surface receptor was given to a separate group of mice 3 times a week beginning with the 
first dose of CP. Immunoblotting, immunoflourescence, cell viability, and serum creatinine 
was applied to evaluate the effect of RNLS on cell viability, expression of stress kinases and 
regulated necrosis mediators, and renal function.
Results: RNLS expression was reduced in CP-induced CKD by 60% at 4 weeks and 
almost completely at 9 weeks in the proximal tubules of CKD mice. CP reduced renalase 
expression in TKPTS cells treated with CP as well. RNLS peptide p81 reduced CP-induced 
CKD signifcantly(n=4, p<.05) and reduced Kim-1, RIPK1, and MAPK activation. Viability 
of TKPTS cells was increased and activation of caspase 3 (apoptosis), TLR2, RIPK 1 and 3, 
and MLKL (necroptosis) was supressed. RNLS knockout animals had a heightened stress 
kinase and necroptotic response to CP.
Conclusions: We conclude that RNLS attenuates CP-induced CKD by intervening in 
cell death pathways activated by CP. RNLS acts as a survival factor for proximal tubule 
cells as RNLS knockout provokes cell death by similar pathways. These data suggest 
that RNLS may be an effective therapeutic agent to prevent CKD in patients treated with 
repeated doses of cisplatin.
Funding: Other NIH Support - NIH/NCI STTR Phase I, R41CA189537-01
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Failed Repair, Not Fibrosis, Determines the Conversion of AKI to CKD in 
Cisplatin (CP)-Induced CKD
Robert L. Safirstein,1,2 Sarah Landau,4 Xiaojia Guo,5 Heino Velazquez,3 
Richard Torres,4 Gilbert W. Moeckel,4 John J. Chang,1 Gary V. Desir.4 
1Connecticutt VAMC, West Haven, CT; 2Nephrology, Yale School of Medicine, 
New Haven, CT; 3Yale and VAMC, West Haven, CT; 4Yale University School of 
Medicine, New Haven, CT; 5Yale Univ, Woodbridge, CT.
Background: Repeated doses of CP leads to CKD in humans but its mechanism 
is unknown. Previously we reported on a model of CP-induced CKD in mice that fully 
recapitulates the human disease.
Methods: Mice received CP 15mg/kg (ip) 2 weeks apart and multiphoton microscopy, 
cDNA microarray, PCR, western blotting, and immunocytochemistry were applied 4 weeks 
after the first dose in the two-dose model, when CKD is fully developed, and compared in 
mice 2 and 4 weeks after a single dose, when recovery is completed. Statistically significant 
differences (p<.05) were determined after correction for multiple comparisons.
Results: A fixed decline in GFR occured at 4 weeks in the 2 dose group and was 
associated with a loss of the glomerular parietal epithelial cells, a lesion that develops in 
CP-CKD. No increase in collagen deposition, the invasion of macrophages, or the loss of 
endothelial cells accompanied these changes. The onset of CKD showed expression of 
genes underlying regulated necrosis including Toll-Like Receptors 2 and 4, the Receptor-
Interacting Protein Kinases 1 and 3, the Mixed Lineage Kinase-Like, and Cyclophilin D, 
while apoptosis played a minor role in cell death. Expression of the damage molecules 
Kim-1 and Ngal persisted after the second dose as did the reactivation of the stress kinases 
JNK and ERK, indicating continued injury. Cell cycle activity was markedly reduced after 
the second dose of CP. Although levels of CXCL1, CCL2, and CCR2 that play a critical 
role in CP AKI were elevated,. knockout of these genes did not prevent the development of 
CKD. Prominent and prolonged expression of the p21 gene was observed, which underlies 
the progression of CKD after 5/6 nephrectomy, but p21 knockout animals still progressed 
to CKD in the model.
Conclusions: Epithelial cell loss and regulated necrosis is a primary event in the 
development of CKD induced by two doses of CP. Progression of CKD is independent 
of the accumulation of fibrous tissue, macrophages, the loss of endothelial cells, or the 
production of key cytokines activated in AKI. Rather, deficient repair and continued loss of 
proximal tubule cells is the primary event in the conversion of AKI to CKD after repeated 
doses of cisplatin. A focus on interceding in the mechanisms of regulated necrosis could be 
successful in preventing CKD
Funding: Other NIH Support - NIH/NCI STTR Phase I, R41CA189537-01
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DNA Methylation Suppresses HoxA5 for Jag1-Notch1 Signaling in Renal 
Interstitial Fibrosis
Xiao Xiao.1,2 1Augusta University, Augusta, GA; 2Wuhan University Zhongnan 
Hospital, Wuhan, China.
Background: DNA methylation has been implicated in the regulation of renal 
interstitial fibrosis in kidney diseases, but the mechanism remains incompletely understood.
Methods: In this study, we analyzed genome-wide changes in DNA methylation during 
renal fibrosis in the mouse model of unilateral ureteral obstruction (UUO) by using the 
reduced representative bisulfite sequencing.
Results: UUO induced renal interstitial fibrosis, which was accompanied by an 
overall increase in DNA methylation in kidney tissues. 5-aza-2’-deoxycytidine (5-aza, 
DNA methylation inhibitor) blocked DNA methylation in UUO and suppressed renal 
fibrosis. Among the genes with altered DNA methylation in UUO, HoxA5 had seven 
hypermethylated CpG sites on its promoter that were further verified by pyrosequencing. 
Hypermethylation of HoxA5 was associated with decreased HoxA5 expression in UUO. 
5-aza could partially prevent HoxA5 decrease in UUO, further confirming the regulation of 
HoxA5 by DNA methylation. Overexpression of HoxA5 suppressed renal fibrosis in UUO 
and attenuated TGF-β-induced fibrotic changes in renal tubular cells. Mechanistically, 
HoxA5 was shown to repress Jag1 via gene promoter binding, resulting in the suppression 
of the Jag1-Notch signaling pathway of renal fibrosis.
Conclusions: Together, these results suggest that DNA methylation may promote renal 
interstitial fibrosis by suppressing HoxA5 for the activation of Jag1-Notch1 signaling.
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Genetic Nrf2 Enhancement Increases Proteinuric Renal Injury
Brittney M. Rush,2 Corry D. Bondi,2 Kacie Barry,2 Sean D. Stocker,2 
Soma Jobbagy,2 Donna B. Stolz,2 Dionysios Chartoumpekis,2 Thomas 
W. Kensler,2 Roderick J. Tan.1 1Medicine, University of Pittsburgh, Pittsburgh,
PA; 2University of Pittsburgh, Pittsburgh, PA.
Background: Proteinuric chronic kidney disease (CKD) is a major cause of 
progressive renal failure and has limited therapies. Nrf2 (nuclear factor erythroid 2 like 2) 
is a transcription factor that upregulates cytoprotective mechanisms including antioxidants 
and detoxifying genes. Keap1 (kelch-like ECH-associated protein 1) binds and inhibits 
Nrf2 under normal conditions to prevent activity. Under conditions of oxidative stress 
or chemical exposure, the Keap1 repressor releases Nrf2 which then initiates target gene 
transcription. While this might be expected to prevent disease, both preclinical and clinical 
data have suggested that Nrf2 could paradoxically aggravate proteinuria. We therefore 
hypothesized that Nrf2 activity accelerates progression of proteinuric CKD.
Methods: Keap1 hypomorphic mutant mice have reduced Keap1 expression and 
enhanced Nrf2 activity. Wild-type mice and Keap1 hypomorphs were subjected to a 
variety of proteinuric injuries including continuous angiotensin II infusion, adriamycin, 
and albumin overload models. Urinary albumin excretion was measured with ELISA, 
and glomerular damage assessed via assessment of foot process effacement, nephrin, 
and Wilms Tumor 1 (WT1). Systemic blood pressure was measured with radiotelemetry, 
and glomerular filtration rate (GFR) was determined with FITC-sinistrin. The synthetic 
triterpenoid, CDDO-Im, was used in the adriamycin model to upregulate Nrf2 activity.
Results: Compared to wild-type mice, Keap1 hypomorphs had significantly increased 
proteinuria in all disease models. This was associated with worsened podocyte foot process 
effacement and decreased nephrin and WT1, indicating increased glomerular injury. We 
did not detect any increase in GFR in the mutants to explain this difference. While there 
were mild elevations in the systolic, diastolic, and mean blood pressures in the Keap1 
hypomorphs before and after angiotensin II infusion, the proteinuria was out of proportion 
to these differences. Treatment of wild-type mice with CDDO-Im enhanced Nrf2 activity 
but also increased mortality after adriamcyin exposure.
Conclusions: Genetic Nrf2 upregulation significantly promotes glomerular injury 
and lethality in proteinuric kidney injury models. This phenomenon is partly explained by 
higher blood pressure in hypomorphic mice but other mechanisms likely play a role.
Funding: NIDDK Support, Private Foundation Support
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Involvement of Endoplasmic Reticulum Stress and Autophagy on 
Homocysteine Induced Apoptosis of Human Glomerular Mesangial Cells
Shanshan Liang,1 Hongli Jiang.2 1Dialysis Department of Nephrology Hospital, 
First Affiliated Hospital of Medicine School, Xi?an Jiaotong University, Xi?an, 
China; 2First Affiliated Hospital of Medicine School, Xi?an Jiaotong University, 
Xi?an, China.
Background: Homocysteine (Hcy) levels significantly increased in chronic renal 
failure (CRF). It has been reported that Hcy can induce proliferation and apoptosis of 
glomerular Mesangial cells. The purpose of this study was to investigate whether autophagy 
and endoplasmic reticulum stress were involved in the induction of glomerular Mesangial 
cells apoptosis by Hcy, and to provide evidence for further elucidation of the toxicity of 
Hcy on Mesangial cells.
Methods: Human Glomerular Mesangial cells (HMC) were incubated with different 
concentrations of Hcy (50~1000 μ mol/L) for 24h and Hcy 250 μmol/L for different 
hours (0~48h). Flow cytometry was used to detect the changes of apoptosis after different 
concentrations and times of Hcy treatment. Western blotting was used to detect the changes 
of related proteins after exposure to Hcy 250 μmol/L for 24h. Apoptosis as well as protein 
changes were separately detected by flow cytometry and Western blotting after treatment 
with endoplasmic reticulum inhibitor 4-PBA and Atg 5 siRNA respectively.
Results: The proliferation ability and cell viability of HMC gradually decreased. The 
proportion of Mesangial cell apoptosis increased with the increase of the concentration of 
Hcy and the prolongation of the incubation times in a time-and concentration-dependent 
manner. The expression of apoptosis-related protein Bax and cleavage caspase-3 were 
significantly increased, with the autophagy related proteins LC3-II/LC3-I, beclin1 and 
Atg5 were significantly increased and p62 decreased. The expression of ER stress-related 
proteins ATF4, CHOP, GRP78 and p-eIF2α all increased significantly. After the intervention 
of 4-PBA, the ER stress-related proteins and the proportion of apoptosis decreased with 
the expression of apoptosis-related protein improved. The expression of p62 increased and 
LC3-II/LC3-I, beclin1 and Atg5 decreased. At the same time, after intervened with Atg5 
siRNA, the expression of Atg5 decreased, and the ratio of LC3-II/LC3-I decreased and the 
p62 degraded with cleavage caspase-3 and CHOP increased, but p-eIF2α did not change 
significantly.
Conclusions: Hcy induced glomerular mesangial cell apoptosis in a concentration- 
and time- dependent manner and may via an ER stress-triggered signaling pathway. Atg5-
dependent autophagy plays a protective role in the process.
Funding: Government Support - Non-U.S.
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Regulation of Klotho by Proteinuria in CKD
Vasiliki Delitsikou,1,2 Frederique Ino,1,2 George Jarad,3 Jeffrey H. Miner,3 
Sophie M. De Seigneux.1,2 1Cell Physiology and Metabolism, Faculty of 
Medicine, University of Geneva, Geneva, Switzerland; 2Department of Internal 
Medicine Specialties, Division of Nephrology, HUG, Geneva, Switzerland; 
3Washington University School of Medicine, St. Louis, MO.
Background: Albuminuria, caused by lesions in the glomerular filtration barrier, 
promotes tubular inflammation, apoptosis and fibrosis in Chronic Kidney Disease (CKD). 
Previously, it was shown that albuminuria is associated with lower Klotho levels. Our aim 
is to further investigate how albuminuria regulates Klotho expression.
Methods: Transgenic mice with inducible podocyte apoptosis (POD-ATTAC) were 
used, as well as Alport mice, either wild type or deficient in albumin. For the in vitro 
experiments, HEK cells overexpressing the human transmembrane form of Klotho and 
HK-2 cells were used.
Results: In vivo in POD-ATTAC mice, 3 and 7 days after podocyte loss, both Klotho 
mRNA and protein levels were downregulated without modifications of ADAMs activities 
and expression. In vitro, upon BSA treatment, the total and membrane fractions of the 
Klotho protein were decreased while Klotho protein half-life was also significantly reduced. 
Cleaved Klotho as measured in the supernatant was decreased proportionally, arguing 
against enhanced cleavage. Likewise, a reduction of Klotho mRNA and protein levels was 
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observed in HK-2 cells. In the Alport mice, Klotho expression was decreased as measured 
by qPCR and Western blot. However, this was not the case in the Alport albumin deficient 
mice, implying some specificity of the regulation by albuminuria itself and not only by the 
primary renal disease. Similarly, there was no Klotho downregulation upon exposure to 
immunoglobulins in vitro. In vivo and in vitro, albuminuria induced some features of ER 
stress. Inhibition of ER stress increased Klotho protein levels in vitro and in vivo, suggesting 
that this mechanism may participate to the enhanced Klotho degradation by albuminuria.
Conclusions: In conclusion, albuminuria has a specific role on Klotho downregulation 
in vitro and in vivo that seems to depend on ER stress induction.
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Calcitriol Ameliorates Kidney Injury and Fibrosis by Activating Klotho 
and Inhibition of TGFβ1 Signaling Pathway
Ao Cheng. Department of Neprology, The Fist Affiliated Hospital of Xiamen 
University, Xiamen, China.
Background: Active vitamin D3 (Calcitriol) can effectively remit the progression 
of chronic kidney disease, but its mechanism is not clear. Klotho as an anti-aging protein 
played a variety of physiologic roles in the kidney. The main purpose of this experiment is 
to explore whether Calcitriol could up-regulated expression of the Klotho in vitro and in 
vivo, and ameliorates kidney injury and fibrosis by targeted inhibition of TGFβ1 activation.
Methods: (1) Animal Experiment: The rats were divided into three groups: sham group, 
5/6 nephrectomy group, 5/6 nephrectomy + calcitriol group. 1) Through serum biochemical 
tests, to detect the levels of BUN, Creatine in various groups and determine expression of 
Klotho, TGFβ1 in serum. 2) By HE, Masson staining of renal tussues, Observation of renal 
fibrosis and collagen deposition; 3) Detection expression of Klotho, TGFβ1, E-cadherin 
and α-SMA in renal tussues by Immunohistochemical staining. 4) Using PCR and Western-
Bloting detect expression of Klotho, TGFβ1, E-cadherin and α-SMA in renal tussues; (2) 
In Vitro: Calcitriol, Klotho siRNA and TGFβ1 ware prepared and mouse renal tubular 
epithelial cells were cultured in vitro. Mouse renal tubular epithelial cells was treatment 
with various concentrations and time period of Calcitriol before TGFβ1 stimulation, and 
pretreatment or not with Klotho siRNA. Klotho, Snail1, PAI-1, E-cadherin and α-SMA 
were measured by real-time PCR and Western-blot.
Results: (1) Animal Experiment: 1) Calcitriol could effectively reduce the elevated 
creatinine, BUN in the 5/6 nephrectomy rats; 2) Calcitriol might ameliorate kidney injury 
and fibrosis by light microscopy; 3) In renal tissue, calcitriol may induce Klotho and 
E-cadherin expression and reduce TGFβ1 and α-SMA expression; (2) In Vitrio: Calcitriol 
in a dose and time dependent manner induce Klotho and E-cadherin expression and reduce 
Snail1, PAI-1 α-SMA expression by TGFβ1 stimulation. Klotho siRNA could mitigate
effective role of Calcitriol.
Conclusions: Calcitriol could ameliorate kidney injury and mitigate TGFβ1 induced 
fibrosis by activating Klotho in vivo and in vitro.
Funding: Government Support - Non-U.S.
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PBI-4050 Signals via GPR40 to Decrease Adenine-Induced  
Tubulointerstitial Injury and ER Stress
Jean-Francois Thibodeau,1,3 Chet E. Holterman,3 Jean-Christophe Simard,1 
Francois A. Leblond,1 Brigitte Grouix,1 Rania Nasrallah,3 Pierre Laurin,1 
Richard L. Hébert,2,3 Chris R. Kennedy,2,3 Lyne Gagnon.1 1Prometic Biosciences 
Inc., Laval, QC, Canada; 2Department of Cellular and Molecular Medicine, 
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; 3Kidney 
Research Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Background: PBI-4050, a novel first-in-class orally active compound currently in 
clinical phase III in IPF patients, exerts antifibrotic effects in several organs via a novel 
mechanism of action. In the kidney, PBI-4050 exerts its antifibrotic effects primarily through 
GPR40 activation. The aim of this study was to further examine the effects of PBI-4050 in 
both WT and GPR40-/- mice on adenine-induced tubulointerstitial fibrosis, inflammation 
and the unfolded protein response pathway, all of which contribute to CKD progression.
Methods: Adenine-induced CKD was achieved in eight-week old male C57BL/6 mice 
fed a diet supplemented with 0.25% adenine. After one week, PBI-4050 (50, 100, 200 
mg.kg-1day) or vehicle was administered daily by oral-gavage for three weeks. In parallel, 
eight-week old wild-type and GPR40-/- mice were also subjected to adenine-CKD, with or 
without a PBI-4050 (200 mg.kg-1 day) treatment.
Results: PBI-4050 treatment reduced adenine-induced polyuria and maintained urine 
osmolality. Plasma urea and creatinine were significantly increased four and two-fold 
respectively in vehicle treated mice, while PBI-4050 decreased these values. PBI-4050 
treatment decreased adenine-mediated renal fibrotic lesions in a dose dependent manner. 
Accordingly, α-SMA and fibronectin expression were also reduced by PBI-4050 as well as 
several pro-inflammatory genes. Moreover, renal ER-stress and pro-apoptotic markers were 
significantly reduced by PBI-4050 in adenine fed mice. In parallel, GPR40-/- mice given 
adenine had increased tubulointerstitial injury, exacerbated renal function and ER-stress 
associated protein expression compared to WT mice. PBI-4050 treatment in adenine-fed 
GPR40-/- mice failed to reduce anemia, tubulointerstitial injury and ER-stress.
Conclusions: PBI-4050 treatment decreased the severity of several adenine-induced 
sequelae including tubular injury, tubulointerstitial fibrosis, anemia, apoptosis and ER-
stress. The GPR40 receptor mediates PBI-4050’s beneficial effects in this model. Taken 
together, these data reinforce PBI-4050’s use as a renoprotective therapy and identify 
important pathways involved.
Funding: Commercial Support - Prometic Life Sciences Inc.
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Peroxiredoxin V (PrdxV) Negatively Regulates EGFR/Stat3-Mediated 
Fibrogenesis via Cys48-Dependent Interaction Between PrdxV and Stat3
Hoon In Choi,1 Jung Sun Park,1 Donghyun Kim,2 Injin Kim,2 Eun Hui Bae,2 
Seong Kwon Ma,1 Soo Wan Kim.1 1Chonnam National University Medical 
School, Gwangju, Republic of Korea; 2Chonnam National University Hospital, 
Gwangju, Republic of Korea.
Background: Activation of epidermal growth factor receptor (EGFR)/signal transducer 
and activator of transcription 3 (Stat3) signaling pathway has been reported to be associated 
with renal fibrosis. In addition to the anti-inflammatory effect and the anti-oxidative effect 
of Peroxiredoxin V (PrdxV), recently it has been shown that PrdxV acts as an anti-fibrotic 
effector by inhibiting the activity of Stat3 in TGF-β-treated NRK49F cells. However, the 
relevance and the underlying mechanism of Prdx V to renal pathobiology remains poorly 
understood.
Methods: To investigate the role of PrdxV in renal fibrosis, we used a transgenic 
mouse model with PrdxV siRNA expression controlled by U6 promoter (C57BL/6J-Tg(U6-
PrdxVsi)1Thlee/Krb; PrdxVsi mice). Both PrdxVwt and PrdxVsi mice were subjected to 
unilateral ureteral obstruction (UUO) for 7 days (Control vs. UUO group, n = 8 per each 
group). To understand the molecular mechanism for anti-fibrotic effect of PrdxV, HA-
tagged WT PrdxV and C48S PrdxV were transiently transfected into 209/MDCT cells and 
treated with TGF-β.
Results: We confirmed that the protein level of PrdxV was inversely related to the 
progression of UUO-induced renal fibrosis. Transgenic PrdxVsi mice exacerbated epithelial-
to-mesenchymal transition as well as the increase of oxidative stress by UUO. In the fibrotic 
kidney of PrdxVsi mouse, knock-down of PrdxV increased Y1068-specific EGFR and Stat3 
phosphorylation, whereas overexpression of WT PrdxV in 209/MDCT cells showed the 
opposite results. Immunoprecipitation revealed the specific interaction between WT PrdxV 
and Stat3 in the absence or presence of TGF-β stimulation, whereas no PrdxV-EGFR or 
C48S PrdxV-Stat3 interaction were detected under any conditions.
Conclusions: PrdxV is an anti-fibrotic effector that sustains renal physiology. Direction 
interaction through Cys48 between PrdxV and Stat3 is a major molecular mechanism.
Funding: Government Support - Non-U.S.
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cMet Agonistic Antibody Attenuates Renal Fibrosis in Obstructive 
Nephropathy
Yong Chul Kim,1 Jung Nam An,2 Chun Soo Lim,2 Yon Su Kim,3 Seung 
Hee Yang,4 Jung Pyo Lee.2 1SNUH, Seoul, Republic of Korea; 2Seoul National 
University Boramae Medical Center, Seoul, SEOUL, Republic of Korea; 3Seoul 
National University College of Medicine, Seoul, Republic of Korea; 4Kidney 
Research Institute, Seoul National University, Seoul, Republic of Korea.
Background: Hepatocyte growth factor (HGF) and its receptor, cMet, activate 
biological pathways necessary for repair and regeneration following kidney injury. The Met 
receptor is expressed in multiple cell types within the kidney, each of which is capable of 
regulating fibrotic responses. Since HGF is a quite unstable molecule in its biologically 
active form, we asked whether a monoclonal antibody (Ab) that displays receptor full 
agonist activity could protect kidney from fibrosis.
Methods: We tried to determine whether cMet agonistic Ab might reduce fibrosis, the 
final common pathway for chronic kidney diseases. We primary cultured human proximal 
tubular epithelial cells (PTECs) for in vitro study and a mouse model of renal fibrosis 
disease induced by unilateral ureteral obstruction (UUO) was introduced.
Results: In kidney biopsy specimens of CKD patients, cMet immunohistochemistry 
staining showed remarkable increase than patients with normal renal functions. cMet 
Ab treatment significantly increased phospho-cMet expression and abrogated protein 
expressions of fibrosis markers such as fibronectin, collagen IV, αSMA and also Bax2 
which is a marker of apoptosis triggered by recombinant TGF-β1 in PTECs. In a wound 
healing scratch assay, PTECs treated with cMet Ab progressed into the wound area more 
rapidly inducing wound healing than untreated cells. Remarkably, injections of cMet 
Ab significantly prevented renal fibrosis in the obstructed kidneys quantified by Masson 
Trichrome staining. Consistently, cMet Ab decreased the expression of fibrosis markers 
such as, collagen 1 and αSMA, and E-cadherin which is a cell-to-cell adhesion molecule 
was recovered.
Conclusions: cMet-mediated signaling may have a considerable role in the renal 
fibrosis. And cMet agonistic Ab may thus be a valuable substitute for HGF, being more 
easily available in a biologically active, stabilized, and purified form.
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The Histone Demethylase Jumonji Domain-Containing Protein 3 Acts as 
an Epigenetic Suppressor of Renal Fibrosis
Chongxiang Xiong,2 Hequn Zou,3 Shougang Zhuang.1 1Rhode Island Hospital, 
Alpert Medical School of Brown University, Providence, RI; 2Rhode Island 
Hospital, Providence, RI; 3The 3rd Affiliated Hospital of Southern Medical 
University, Guangzhou, China.
Background: The histone demethylase Jumonji domain-containing protein 3 (JMJD3) 
is the enzyme that induces demethylation of histone H3 lysine 27 (H3K27) and its activation 
is involved in the tumor genesis. Although activation of H3K27 methyltransferase has been 
shown to be required for renal interstitial fibroblast activation and renal fibrogenesis, the 
role of JMJD3 in these processes remains elusive.
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Methods: In this study, we examined the effect of pharmacological inhibition of 
JMJD3 on renal fibroblast activation and renal fibrosis development in a murine model of 
unilateral ureteral obstruction.
Results: Following unilateral ureteral obstruction, expression levels of JMJD3 and 
methylated H3K27 were increased in the kidney. Administration of GSKJ4, a specific 
inhibitor of JMJD3, aggravated renal fibrosis and increased expression of alpha-smooth 
muscle actin (alpha-SMA), a hallmark of myofibroblasts (active fibroblasts) and promoted 
deposition of collagen I, one of major extracellular matrix proteins. GSKJ4 inhibition 
also increased expression of transforming growth factor β1 (TGF-b1) and enhanced 
the phosphorylation of Smad3, a key molecule of TGF-β signaling. Moreover, GSKJ4 
potentiated expression of Notch1 and Notch3 as well as phosphorylation of NF-κB and 
Stat3. Finally, treatment with GSKJ4 increased expression of alpha-SMA, collagen I and 
fibronectin in cultured renal epithelial cells.
Conclusions: Collectively, these data suggest that JMJD3 functions as a suppressor of 
renal fibroblasts and renal fibrosis in the kidney after ureteral obstruction.
Funding: NIDDK Support
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A Pilot Study to Explore Relationships of Mitochondrial DNA Copy 
Number in Blood and Kidney Tissue and Their Associations with Kidney 
Health
Vasantha Jotwani,1 Gregory J. Tranah,2 Ronit Katz,3 Mark J. Sarnak,4 
Chirag R. Parikh,5 Steven Cummings,6 Joachim H. Ix,7 Samir M. Parikh,8 
Adrienne Tin,9 Dan Arking,9 Michael Shlipak,10 Sushrut S. Waikar.11 1UCSF, San 
Francisco, CA; 2Sutter Health, San Francisco, CA; 3University of Washington, 
Seattle, WA; 4Tufts Medical Center, Boston, MA; 5Yale University and VAMC, 
New Haven, CT; 6San Francisco Coordinating Center, Mill Valley, CA; 7UCSD, 
San Diego, CA; 8Beth Israel Deaconess Medical Center, Boston, MA; 9Johns 
Hopkins University School of Medicine, Baltimore, MD; 10San Francisco VA 
Medical Center, San Francisco, CA; 11Harvard Medical School, Boston, MA.
Background: Despite several animal studies linking mitochondrial damage to the 
development of acute and chronic kidney injury, human studies have been sparse due to 
our limited methods for assessment of mitochondrial health by stored specimens. A key 
question is whether peripheral mitochondrial measures adequately reflect mitochondrial 
health in kidney tissue. We conducted a pilot study to compare mitochondrial DNA 
(mtDNA) copy number in blood and kidney tissue and to evaluate their associations with 
renal function and pathology.
Methods: We measured mtDNA copy number in blood buffy coat and kidney 
specimens of 9 participants of the Brigham and Women’s Hospital Nephrectomy Cohort 
who were selected to represent a broad range of age and kidney function. MtDNA copy 
number was determined by a real-time quantitative PCR assay that measures the ratio of 
the mtDNA-encoded ND1 gene to the single-copy nuclear β2-Microglobulin gene. Kidney 
specimens were assessed by a pathologist using a standardized scoring protocol.
Results: The mean age was 64 ± 12 years and mean eGFR was 46 ± 21 ml/min/1.73m2. 
Blood mtDNA copy number (r=0.739, p=0.023) and kidney mtDNA copy number (r=0.883, 
p=0.002; Figure) correlated strongly with eGFR and with each other (r=0.756, p=0.019). 
Compared to participants with severe tubulointerstitial fibrosis, participants with mild 
fibrosis had higher blood and kidney mtDNA copy numbers (p=0.03).
Conclusions: Higher mtDNA copy number, measured in blood or kidney, correlated 
positively with eGFR and negatively with tubulointerstitial fibrosis, suggesting that 
mitochondrial abundance is important for kidney health. Strong correlations between 
mtDNA copy number in blood and kidney tissue support the use of peripheral mitochondrial 
measures in future studies.
Funding: NIDDK Support
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Activation of FXR Regulates Kidney Autophagy for Suppressing Renal 
Fibrosis
Donghyun Kim,1 Hoon In Choi,2 Jung Sun Park,3 Eun Hui Bae,1 Seong 
Kwon Ma,2 Soo Wan Kim.2 1Chonnam National University Hospital, Gwangju, 
Republic of Korea; 2Chonnam National University Medical School, Gwangju, 
Republic of Korea; 3chonnam national university, Gwang Ju, Republic of Korea.
Background: Autophagy is an evolutionarily conserved catabolic process that removes 
damaged organelles and maintains cellular energy homeostasis. Acute regulation by 
nutrient-sensing of autophagy and long-term transcriptional regulation by nuclear hormone 
receptor farnesoid X receptor (FXR) is well known. Also, kidney autophagy regulates 
TGFβ expression and suppresses kidney fibrosis. However, the functional role of FXR on 
TGFβ-induced kidney autophagy is relatively unknown.
Methods: Expression levels of LC3 protein and autophagy related genes were 
measured on treatment with TGFβ and FXR agonists, GW4064, CDCA, and INT-747, in 
human proximal tubule cells (HK2 cells). Also, we tested expression levels of autophagy 
related proteins and genes in unilateral ureteral obstruction mice model. The LC3 Puncta 
formation was monitored by fluorescence microscopy. Expression levels of protein and 
autophagy related genes were measured on down-regulation of FXR by siRNA in HK2 
cells or FXR knock-out mice.
Results: Treatment with TGFβ (5 ng/ml) in HK2 cells resulted in an increase in 
the level of LC3 protein and autophagy related genes, along with an increase in fibrosis 
markers. Activation of FXR by agonists in TGFβ-induced HK2 cells regulates LC3 I and 
II expression levels. Autophagy related genes were decreased in FXR agonists treated HK2 
cells. Also, autophagic flux was further increased on co-treatment with GW4064 and TGFβ 
in HK2 cells. Autophagy related genes has no GW4064 effects on down-regulation of FXR 
by siRNA in HK2 cells. Protein levels of LC3 and fibrosis markers were increased in FXR-
KO UUO mice model compared to those of WT UUO mice model.
Conclusions: These data reveal a functional role of FXR for kidney autophagy 
regulator in TGFβ-induced HK2 cells and suggest that FXR may play an important role in 
the suppression of renal fibrosis through kidney autophagy.
Funding: Government Support - Non-U.S.
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Rab27a Dependent Exosome Secretion from Tubular Epithelial Cell 
Promotes Albumin-Induced Tubulointerstitial Inflammation
Ye Feng, Linli Lv, Xin Zhong, Zuolin Li, Bi-Cheng Liu. Zhong Da Hospital, 
Southeast University Medical School, Nanjing, China.
Background: Tubular epithelial cells (TECs) secrete increasing exosomes under with 
proteinuria toxicity. However, the mechanism through which exosomes are produced and 
the effect on tubular cell hemostasis and tubulointerstitial inflammation are unknown.
Methods: Proteinuric renal disease model was induced by adriamycin (ADR) 
administration through tail vein. Urinary albumin was determined at 0, 7, 14, 21 and 23 
days after ADR injection. Histological changes were examined by PAS staining. For in vitro 
studies, TECs were treated with albumin. We found that the release of exosomes may result 
in TECs inflammation. Exosomes were isolated from isolated tubules of kidney and cell 
culture supernatant for characterization and functional study.
Results: Chronic kidney injury was induced by administration with ADR. Urinary 
albumin was significantly increased in ADR-treated mice 2 weeks after injection compared 
with controls. Histologically, the TEC injury and protein cast were observed in ADR-
injected mice. Electron microscopy and western blotting analysis of exosome markers, 
CD9, CD81, Alix confirmed the typical characteristics of isolated exosomes from kidney. 
Exosome production was increased significantly in kidney of ADR mice and in TECs 
with albumin exposure. Interestingly, we showed increasing levels of Rab27a mRNA 
and protein both in the tubule of ADR-injected mice and in BSA-treated TECs in a dose 
dependent manner. And the increased exosome production was dependent on Rab27a up-
regulation since silencing of Rab27a reversed the exosomes secretion. Importantly, the 
mRNA expression of inflammatory cytokines in TECs treated with BSA was reduced after 
inhibition of exosome secretion by Rab27a knocking down. To explore the effect of TEC 
exosome production under albumin exposure, TEC-exosomes were purified and added to 
naïve TEC. Up-regulation of inflammatory cytokines were found in receipt TECs.
Conclusions: These results provide a novel finding that TECs exosomes were produced 
increasingly through Rab27a dependent mechanism. And TEC exosome production 
exacerbated TECs injury by enhancing inflammatory response and may consequently lead 
to tubulointerstitial inflammation.
SA-PO826 Poster Saturday
Molecular Mechanisms of CKD - III
Amelioration of Renal Fibrosis and Tubulointerstitial Damage in Fat-1 
Transgenic CKD Mice by Compensation of Decreased Omega-3 Fatty 
Acids in the Kidney
Naohiro Takahashi,1 Hiroaki Kikuchi,1 Tomoaki Ishihara,2 Makoto Arita,2 
Taisuke Furusho,1 Fumiaki Ando,1 Takayasu Mori,1 Kiyoshi Isobe,1 
Koichiro Susa,1 Naohiro Nomura,1 Tatemitsu Rai,1 Shinichi Uchida,1 
Eisei Sohara.1 1Tokyo Medical and Dental University, Tokyo, Japan; 2RIKEN-
IMS, Yokohama, Japan.
Background: Although recent advances have led to better understanding of the linkage 
between inflammatory diseases and lipid mediators, little has been reported on the changes 
of lipid profile of kidney tissue in chronic kidney disease (CKD). Lipidomics is a powerful 
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tool for the identification and the quantification of the lipid metabolites. In this study, we 
applied lipidomics to the kidney from the mice performed with subtotal nephrectomy, to 
identify specific lipid mediators as novel therapeutic targets in CKD.
Methods: Subtotal nephrectomy or oral administration of adenine was performed 
to C57BL/6J mice to establish CKD models. Kidney tissue samples from subtotal 
nephrectomy mice were analyzed with lipidomics to reveal lipid profile of CKD kidneys. 
We also analyzed the CKD models of fat-1 transgenic mice expressing the C. elegans fat-1 
gene encoding an omega-3 fatty acid desaturase, leading to abundant omega-3 fatty acids 
in kidneys. To evaluate effects of lipid metabolites on fibrosis, we used cultured NRK-49F 
cells.
Results: Lipidomics analysis revealed that omega-3 fatty acids (EPA and DHA) 
and their downstream lipid metabolites were significantly decreased in CKD kidneys in 
comparison with sham control kidneys. Therefore, to investigate the effects of decreased 
omega-3 fatty acids on CKD kidneys, we examined two CKD models of fat-1 transgenic 
mice, subtotal nephrectomy and adenine-induced nephropathy. Alpha-SMA (a marker 
of renal fibrosis) and NGAL (a marker of tubulointerstitial damage) were suppressed in 
fat-1 transgenic CKD mice, suggesting that increased omega-3 fatty acids in kidney have 
beneficial effects on CKD. Some specific omega-3 fatty acid metabolites which were 
decreased in CKD kidneys attenuated fibroblast activation in vitro, indicating that they 
could be novel therapeutic lipid mediators for CKD treatment.
Conclusions: Lipidomics of the kidneys from subtotal-nephrectomy mice revealed 
reduction of omega-3 fatty acids and their down-stream lipid metabolites. Supplementation 
of omega-3 fatty acids and their downstream metabolites to kidneys might ameliorate 
tubulointerstitial damage and renal fibrosis in CKD.
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Renal Hemodynamic Effects of a sGC Stimulator vs Activator in 
Conscious Sprague-Dawley and Obese Diabetic ZSF1 Rats
Karen A. Griffin,4 Geoffrey A. Williamson,2 Perriannan Sethupathi,3 
Agnes M. Benardeau,5 Anil K. Bidani.1 1Loyola University Med Ctr and Hines 
VA Hospital, Maywood, IL; 2Illinois Institute of Technology, Chicago, IL; 
3Loyola University Medical Center, Maywood, IL; 4Loyola University Medical 
Center Hines VA Hospital, Maywood, IL; 5Bayer Pharma AG, Wuppertal, 
Germany.
Background: Endothelial dysfunction and/or NO loss accelerate the progression of 
diabetic and non-diabetic chronic kidney disease (CKD). Therefore, soluble guanylate 
cyclase (sGC) stimulators and activators are being developed as potential novel therapeutic 
interventions in CKD. Stimulators sensitize sGC to low levels of bioavailable NO in the 
presence of reduced (ferrous) prosthetic heme, while sGC activators preferentially activate 
sGC when it is in an oxidized or heme free state. But their comparative renal hemodynamic 
effects have not been examined in conscious rat models.
Methods: Conscious chronically instrumented conscious Sprague-Dawley rats 
(body weight ~300g) and obese diabetic ZSF1 rats (body wt ~500g) underwent repeated 
simultaneous 1-2 hr BP (radiotelemetry) and RBF (Transonic) recordings over 3 wks (2-4 x 
wk) while they were sequentially receiving: vehicle only by gavage (5 ml/kg), a low and a 
high dose of either the sGC activator (BAY-543) or the stimulator (BAY-747) (3-4 days/wk 
with a ~3 day washout period). Effects on mean arterial pressure (MAP), RBF, renal 
vascular resistance (RVR) and the autoregulatory (AR) ability to buffer spontaneous BP 
fluctuations were assessed using a methodology recently developed in our lab.
Results: Table (mean ± SEM) While both the sGC stimulator and the sGC activator 
in the dosages used had similar BP effects in both SD and ZSF1 rats, the sGC activator 
tended to produce greater renal vasodilation with both doses in both strains but which 
was significant only in the ZSF1 rats. Despite the renal vasodilation, AR buffering of 
spontaneous BP fluctuations was not impaired by either agent in either strain.
Conclusions: The significantly greater renal vasodilatory effects of sGC activator in a 
renal disease model, the ZSF1 rat, may have relevance when considering therapy with sGC 
modulators in CKD states.
Funding: Commercial Support - Bayer Pharma AG
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High Salt Enhances ROS and Ang II Contractions of Glomerular Afferent 
Arterioles from Mice with Reduced Renal Mass
Christopher S. Wilcox,1 Lingli Li,4,2 En yin Lai,3,2 Glenn Solis,1 Anton Wellstein,2 
William J. Welch.2 1Georgetown University Medical Center, Washington, DC; 
2Georgetown University, Washington, DC; 3Zhejiang University School of 
Medicine, Hangzhou, China; 4NIH, Clarksburg, MD.
Background: High salt intake, angiotensin II (Ang II), and reactive oxygen species 
(ROS) enhance progression of chronic kidney disease (CKD). We reported that myogenic 
contractions of renal afferent arterioles (RAAs) were enhanced by superoxide generated 
from p47phox/NOX2 but inhibited by H2O2 generated from POLDIP2/NOX4. We tested the 
hypothesis that feeding a high salt diet to mice with the reduced renal mass (RRM) model of 
CKD generates specific ROS in their RAAs that enhances Ang II contractions.
Methods: C57BL/6 mice received surgical RRM or sham operations and 6% or 0.4% 
NaCl salt for 3 months. Ang II contractions were measured in RAAs perfused at 45 mmHg 
and superoxide and H2O2 by fluorescence microscopy.
Results: RRM enhanced the gene expression in RAAs for p47phox and NOX2 and high 
salt intake in mice with RRM enhanced the gene expression for AT1Rs, POLDIP2 and 
NOX4 and reduced the gene expression for catalase. Mice with RRM fed a normal salt diet 
had contractions to 10-6 M Ang II similar to sham (-56 ± 5 vs -52 ± 5 %; NS). However, 
RRM mice fed a high salt diet had an enhanced superoxide and H2O2 generation (P<0.005) 
with Ang II in RAAs and enhanced Ang II maximal contractions (-72 ± 2 vs -45 ± 2%; 
P<0.005) that were dependent on superoxide from NOX2 since they were prevented in 
p47phox -/- mice and on H2O2 from NOX4 since they were prevented in mice with transgenic 
smooth muscle cell expression of catalase (tgCAT-SMC), and in POLDIP2 +/- mice. However, 
RAA contractions to lower concentrations of Ang II (10-8 to 10-11 M) were paradoxically 
enhanced in tg CAT-SMC vs Wt mice (-17 ± 2 vs -1 ± 1%; P<0.01) and in POLDIP2 +/- vs +/+ 
mice (-22 ± 3 vs -5 ± 3; P<0.01). Tempol normalized the ROS and Ang II contractions in 
RAAs from mice with RRM.
Conclusions: Both superoxide from p47phox/NOX2 and H2O2 from NOX4/POLDIP2 
enhance maximal Ang II contractions of RAAs from mice with RRM fed a high salt diet 
but H2O2 from NOX4/POLDIP2 reduces the sensitivity to lower concentrations of Ang II 
by >100-fold and tempol prevents all of these changes Thus, although a high salt intake 
reduces circulating Ang II, blockade of angiotensin receptors or ROS may prove beneficial 
for patients with CKD unable to restrict salt.
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Targeting Pathologic Gβγ-GRK2 Signaling in CKD
Valeriia Rudomanova,1 Iñigo Valiente-Alandi,1 Qing Ma,3 Prasad Devarajan,3 
Burns C. Blaxall.2 1Cincinnati Children’s Hospital Medical Center, Cincinnati, 
OH; 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 
3Cincinnati Children’s Hospital, Cincinnati, OH.
Background: Chronic kidney disease (CKD) is a progressive deterioration of renal 
function characterized by replacement of functional renal parenchyma with fibrotic tissue. 
Our group recently reported the beneficial effects of attenuating Gβγ-G-protein coupled 
receptor kinase 2 (GRK2) signaling in the ischemia/reperfusion murine model of acute 
kidney injury (AKI). In this study, we tested the hypothesis that inhibiting Gβγ-GRK2 
signaling might bestow a renoprotective effect in animal models of chronic kidney injury.
Methods: Research animals (C57Bl/6 10 week old male mice) were subjected to 
unilateral ischemia-reperfusion (UIR, 30min) or sham surgery followed by 14 days of 
reperfusion. The Gβγ-GRK2 small molecule inhibitor, Gallein, or Vehicle (PBS) were 
given once daily i.p. beginning 7 days after the injury and continued until sacrifice. GRK2 
expression was also evaluated in human kidney biopsies and whole murine kidney lysates 
by RT-qPCR and Western blot.
Results: We first identified a significant elevation of GRK2 mRNA (8 normal vs 10 
dialysis, 1.9 fold increase, P=0.01) and protein (9 normal vs 10 dialysis, 20.6 fold increase, 
P=0.02) expression in biopsies obtained from dialysis patients vs normal human kidney 
biopsies. In the UIR model of CKD, GRK2 transcript expression positively correlated with 
Lipocalin 2 (NGAL) transcript, a clinically used renal injury marker (R squared=0.7488, 
P<0.0001). Small molecule inhibition of Gβγ-GRK2 significantly alleviated renal fibrosis 
as assessed by Picrosirius red staining (Sham, UIR+Vehicle, UIR+Gallein, n=8 per group, % 
fibrosis mean 1.422, 10.08, 4.665, respectively, P<0.0001), accompanied by a decline in 
NGAL gene expression.
Conclusions: Our results identify Gβγ-GRK2 signaling as a potential mediator of renal 
tubular injury and fibrosis and a promising target in CKD.
Funding: Other NIH Support - NIH 1R01HL133695-01 (BCB)
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WNK1 Regulates Skeletal Muscle Hypertrophy by Modulating Phosphor-
ylation, Nuclear Localization, and Transcriptional Activity of FoxO4
Shintaro Mandai,1,2 Takayasu Mori,1 Naohiro Nomura,1 Taisuke Furusho,1 
Yohei Arai,1 Hiroaki Kikuchi,1 Emi Sasaki,1 Eisei Sohara,1 Tatemitsu Rai,1 
Shinichi Uchida.1 1Nephrology, Tokyo Medical and Dental University, Tokyo, 
Japan; 2Nephrology, Nitobe Memorial Nakano General Hospital, Tokyo, Japan.
Background: With-no-lysine (K) (WNK) kinases, mutated in the inherited form of 
hypertension pseudohypoaldosteronism type II, are essential regulators of ion transporters. 
WNK kinases phosphorylate and activate SLC12A cation-chloride cotransporters via the 
intermediate kinases SPAK/OSR1. We previously showed that Na+-K+-2Cl− cotransporter 
1, a member of SLC12A family, promotes mouse skeletal myogenesis and its inhibitor loop 
diuretics are associated with risk for sarcopenia in patients with chronic kidney disease 
(CKD). We further aimed to investigate the physiological role of WNK1 that is the major 
WNK isoform in mammalian skeletal muscle.
Methods: In C2C12 mouse skeletal muscle cells, differentiation was induced after 
transfection of Wnk1-targeted siRNA, and the diameter of differentiated myotubes was 
evaluated. In C57BL/6J mice, WNK1 protein abundance was evaluated after six weeks 
of voluntary wheel running or four weeks of 0.25% adenine-containing diet feeding (CKD 
model).
Results: In C2C12 cells, silencing of WNK1, but unexpectedly not SPAK/OSR1, 
induced myotube atrophy and remarkable increases in the mRNA expression of the muscle 
atrophy ubiquitin ligases MAFbx and MuRF1 called ‘atrogenes’. These atrogenes are 
predominantly upregulated by transcription factors forkhead box protein O (FoxO)1/3/4 
in CKD or other diseases causing sarcopenia. WNK1 silencing selectively increased 
FoxO4 nuclear localization, and co-transfection of FoxO4-targeted siRNA completely 
reversed the myotube atrophy and upregulation of atrogene transcription. Phos-tag SDS-
PAGE revealed that WNK1 silencing decreased FoxO4 phosphorylation, which might be 
associated with nuclear localization and transcriptional activity of this protein. We further 
showed that WNK1 abundance in mouse skeletal muscle was increased by chronic exercise 
and decreased in adenine-induced CKD and sarcopenia. Moreover, to validate the role of 
WNK1 in muscle hypertrophy in vivo, a WNK kinase inhibitor WNK463 was administered 
by oral gavage (10 mg/kg), resulting in marked increase of atrogene expression in mouse 
skeletal muscle.
Conclusions: WNK1 physiologically regulates mammalian skeletal muscle 
hypertrophy via interactions with FoxO4. The WNK1-FoxO4 axis may be a novel 
therapeutic target in sarcopenia.
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Taurine Protects Against Urea-Induced Protein Carbamylation and Renal 
Fibrosis in an Oxalate Model of Kidney Injury
Mahtab Tavasoli,1,3 S. Ananth Karumanchi,1 Zsuzsanna K. Zsengeller,1 
Isaac E. Stillman,1 Tim Bergmann,1,2 Sahir Kalim,4 Anders H. Berg.1 1Beth Israel 
Deaconess Medical Center/Harvard Medical School, Boston, MA; 2Internal 
Medicine, University Hospital Wuerzburg, Wuerzburg, Germany; 
3Pharmacology, Dalhousie University, Halifax, NS, Canada; 4Massachusetts 
General Hospital/ Harvard Medical School, Cambridge, MA.
Background: It has been long argued that the increased levels of urea in patients with 
chronic kidney disease (CKD) have negligible toxicity; However, there is growing evidence 
for the hypothesis that protein carbamylation modifications caused by high urea contributes 
to disease pathogenesis, vascular complications, uremic cardiomyopathy and mortality. 
Furthermore, it appears that amino acids can compete with proteins for carbamylation and 
effectively protect proteins from harmful carbamylation. Here we tested the hypothesis that 
concentrations of urea associated with chronic renal failure, exacerbate pre-existing renal 
disease and cardiomyopathy and that dietary taurine supplementation protects against this.
Methods: Mice were fed diets supplemented with sodium oxalate for 3 weeks to 
induce crystal nephropathy. Mice with mild/moderate oxalate crystal-induced nephropathy 
were then maintained on western-type diet and 50g/L urea with or without taurine 10g/L 
(as carbamylation scavenger) in their drinking water for 8 weeks. Control animals were 
similarly treated with oxalate but only fed western-type diet.
Results: Dietary urea induced hypercarbamylation of proteins in plasma, heart and 
kidneys in the CKD mice compared to the CKD control animals. Dietary urea exacerbated 
renal fibrosis and increased ROS levels in renal vessels as well as ANP expression in 
heart. The carbamylated albumin (C-Alb) and kidney homocitrulline/lysine were strongly 
correlated with the extent of interstitial fibrosis with a correlation coefficient of 0.84 and 
0.86 respectively; (n=12, *P<0.001). Protein carbamylation and its associated pathologies 
were rescued with taurine supplements (Table below).
Conclusions: Urea-induced protein carbamylation contributes to renal fibrosis in the 
oxalate model of kidney injury and taurine may mitigate oxalate-induced renal injury, at 
least in part, by preventing excessive protein carbamylation.
Funding: Other NIH Support - NIH/NHLBI
Mean±SEM, n=4/group, *P<0.01 versus all the other treatment groups; One-way ANOVA 
followed by Tukey’s post hoc test.
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The Long Noncoding RNA Meg3 Mediates TLR4–Induced Renal 
Inflammation in Experimental Obstructive Nephropathy
Wai Han Yiu,1 Dickson W. Wong,1 Wing yan Lok,1 Wing han Liu,1 Ye Li,1 
Loretta Y.Y. Chan,1 Joseph C K Leung,1 Kar Neng Lai,1 Hui Y. Lan,2 
Sydney C. Tang.1 1The University of Hong Kong, Hong Kong, China; 2The 
Chinese University of Hong Kong, Shatin, China.
Background: Renal inflammation has been implicated in many types of kidney 
injury and is a potential therapeutic target for most chronic kidney diseases. Accumulating 
evidence shows that long noncoding RNAs function as critical regulators of inflammatory 
responses. This study aims at investigating the role of Toll-like receptor 4 (TLR4)-driven 
lncRNAs in regulating renal inflammation.
Methods: Tubule-specific TLR4 knockout mice were generated by crossing 
TLR4 flox/flox and Ksp-Cre mice. Both Ksp-Cre.TLR4 flox/flox (KO) and TLR4 flox/flox (WT) 
mice were subjected to unilateral ureteral obstruction (UUO). Deep RNA sequencing 
was performed to identify dysregulated lncRNAs that are associated with tubular TLR4 
expression. Candidate lncRNA was verified and its functional role in renal inflammation 
was investigated using cultured murine tubular epithelial cells.
Results: Loss of TLR4 in tubular cells resulted in less renal inflammation as compared 
to WT mice after 7 days of UUO. Expression of pro-inflammatory cytokines including 
CCL-2, CXCL-2 and TNF-α was reduced in the obstructed KO kidneys and accompanied 
by decreased NFκB signaling. Data from deep RNA sequencing showed that lncRNA
maternally expressed gene 3 (Meg3) was upregulated in WT mice upon UUO, but its 
expression was down-regulated in KO mice. In vitro, LPS induced Meg3 expression
in tubular epithelial cells. Knock down of Meg3 in tubular epithelial cells diminished
inflammatory responses, as evidenced by reduced LPS-induced CCL-2 and CXCL-2 
expression.
Conclusions: Our findings suggest that tubular TLR4 is important for mediating 
inflammatory responses in UUO model and lncRNA Meg3 may be a novel regulator in 
TLR4-driven renal inflammation. Funding: Research Grants Council of Hong Kong 
(Collaborative Research Fund, grant number C7018-16G).
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TSC1 Mediated Metabolic Switch to Glycolysis in Tubular Epithelial Cell 
Accelerates Renal Interstitial Fibrosis
Hongdi Cao, Lei Jiang, Junwei Yang. Second Affliliated Hospital, Nanjing 
Medical University, Nanjing, China.
Background: Renal interstitial fibrosis is a key factor in the progression of chronic 
kidney disease (CKD). Energy reprogram to glycolysis is closely related to the development 
of CKD. As an important negative regulatory factor of mTORC1 signal,tuberous sclerosis 
complex 1 (Tsc1) is also the key regulatory point of glycolysis. In this study, we investigated 
whether Tsc1 could mediate the progress of renal interstitial fibrosis by regulating glycolysis 
in proximal tubular epithelial cells.
Methods: In vitro and in vivo models of renal interstitial fibrosis were established. The 
changes of Tsc1 in the progress of renal interstitial fibrosis and the relationship of glycolysis 
and Tsc1 were analyzed. The glycolysis level and degree of fibrosis in kidneys between 
proximal tubular epithelial cells-Tsc1 specific knockout mice(Tsc1ptKO mice) and control 
mice were compared to explore the role Tsc1 in renal interstitial fibrosis.
Results: In TGF-β1 induced tubular epithelial cell phenotype transformation and UUO 
models, Tsc1 in tubular epithelial cells was reduced markedly. In Tsc1ptKO mice, mTORC1 
signal was activated and showed the significant feature of renal interstitial fibrosis. 
Mitochondrial damage and enhanced glycolysis were observed in tubular epithelial cell 
phenotype transformation, UUO mice and Tsc1ptKO mice. Inhibiting glycolysis of proximal 
tubular cells induced by Tsc1 downregulation with 2-DG, the fibrotic phenotypic changes 
induced by Tsc1 decline were improved. The renal fibrotic degree was also alleviated by 
inhibiting the glycolysis of Tsc1ptKO mice with 2-DG.
Conclusions: Tsc1 could mediate the progress of renal interstitial fibrosis by regulating 
glycolysis in proximal tubular epithelial cells. It might be helpful to provide theoretical 
basis for design of new therapeutic strategies of CKD.
Funding: Government Support - Non-U.S.
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Knockdown of Cxcl10 Alleviates Renal Fibrosis in UUO Mice
Jie Gao, Lingling Wu, Xiangmei Chen. Nephrology, State Key Laboratory of 
Kidney Diseas, Chinease PLA Institute of Nephrology & Key Lab, Chinese PLA 
Hospital, Beijing, China.
Background: Renal fibrosis is a common pathological manifestation of almost all renal 
diseases, including chronic kidney disease (CKD) and acute kidney injury (AKI), which 
can eventually lead to end-stage renal disease (ESRD). IFN-γ-inducible protein 10 (IP-10, 
CXCL10) has been widely demonstrated to be involved in chemotaxis, regulation of cell 
growth and angiogenesis inhibition. It has been reported that CXCL10 is involved in the 
pathogenesis of fibrosis in a variety of human tissues. However, the underlying mechanism 
of CXCL10 in renal fibrosis reminds unclear.
Methods: Wildtype (CXCL10+/+) mice and CXCL10-deficient (CXCL10-/-) mice were 
used to generate the unilateral ureteral obstruction (UUO) model and sacrificed at 3, 5, 7 
and 14 days after surgery. The histological changes and collagen deposition levels in kidney 
tissue was examined by PAS, Masson and Sirius red staining. The expression of fibrosis 
related proteins were examined by Western blot. The macrophage infiltration was examined 
by immunofluorescence of F4/80. Furthermore, the effects of CXCL10 on transforming 
growth factor β1 (TGF-β1)-stimulated rat renal fibroblasts was investigated in vitro.
Results: A marked increase expression of Cxcl10 mRNA and protein were observed 
in whole kidney tissue in UUO model. The levels of serum creatinine and urea nitrogen 
were significantly lower in Cxcl10-/- mice than in Cxcl10+/+ mice. Pathological staining 
results showed that the injury degree of renal tissue and the collagen deposition levels 
were lighter in Cxcl10-/- mice. Western blot results showed that the expression of α-SMA, 
FN and Col1 in Cxcl10-/- mice was significantly reduced compared with Cxcl10+/+ mice. 
However, Interstitial F4/80-positive macrophages were unaffected by knockdown of 
Cxcl10. Furthermore, recombinant CXCL10 protein stimulation could obviously promote 
the expression of α-SMA, FN and collagen I in TGF-β1-treated NRK-49F cells.
Conclusions: Cxcl10 knockout could reduce renal injury, mitigate the deposition of 
collagen and inhibit renal fibrosis through promoting renal fibroblast activation in murine 
UUO model. These results may provide a novel insight into the mechanism and a potential 
therapy target of renal fibrosis.
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NF-κB Inhibition During Short-Term LNAME and Salt Overload 
Strongly Attenuates the Late Development of CKD
Karin C. Oliveira, Fernanda F. Zambom, Amanda H. Albino, Victor F. Avila, 
Simone C. Arias, Denise M. Malheiros, Niels O. Camara, Clarice K. Fujihara, 
Roberto Zatz. University of Sao Paulo, Sao Paulo, Brazil.
Background: Brief NO inhibition by LNAME + high-salt diet (HS) results in marked 
hypertension (HT) and renal injury that abate upon treatment interruption but evolve to 
CKD along ensuing months. Activation of the NLRP3 and NF-κB pathways may participate 
in this process. Here we investigated whether NF-κB inhibition during LNAME+HS would 
prevent the acute and/or chronic effects of this treatment.
Methods: Male Munich-Wistar rats (N=11) received oral LNAME+HS. A second 
group (N=12) received in addition the NF-κB inhibitor pyrrolidine dithiocarbamate 
(PDTC), 60 mg/kg/day vo. Control rats (C) received HS only (N=10). All treatments 
were ceased at 4 wks. Assessed at 4, 8 and 24 wks were: tail-cuff pressure (TCP, mmHg), 
albuminuria (ALB, mg/d), glomerulosclerosis (GS, %), interstitial collagen-1 (COLL, %), 
infiltration (cells/mm2) by macrophages (MΦ), lymphocytes (Ly), angiotensin 2+ (Ang2+) 
and NLRP3+ cells, and the renal abundance (x HS) of IL1β (pg/mg), nuclear p65 (NFκB), 
Casp1, TLR4, and IL-6.
Results: At 4 wks, HS+LNAME caused severe hypertension, ALB, GS, COLL, 
MΦ/Ly/Ang2+-cell infiltration and activation of the TLR4/NFκB/IL6 and NLRP3/Casp1/
IL1β pathways, all of which were prevented or strongly attenuated by PDTC. Partial 
regression at 8wks was followed by progression to CKD at 28 wks, also largely prevented 
by early PDTC.
Conclusions: Early NF-κB activation is essential for subsequent autonomous 
activation of innate immunity and progression to CKD in this model, and may be the basis 
for future therapeutic strategies. FAPESP/CNPq
Funding: Government Support - Non-U.S.
Mean±SE; *p<0.05 vs HS; #p<0.05 vs HS+LNAME
SA-PO836 Poster Saturday
Molecular Mechanisms of CKD - III
UCP2-Regulated HIF-1α Stabilization Promotes Reprogramming of 
Mitochondrial Metabolism and Induces Tubulointerstitial Fibrosis After 
Ischemic AKI
Yang Zhou,1 Nan Qin,2 Junwei Yang.1 1Second Affiliated Hospital, Nanjing 
Medical University, Nanjing, China; 2Nanjing Medical University, Nanjing, 
China.
Background: Acute kidney injury (AKI) is a global public health concern associated 
with hospitalizations and is especially common in critically ill patients. The transition of 
AKI to consequence chronic kidney disease (CKD) has major clinical significance. Tubular 
reabsorption is an energy consumption process relies mainly on mitochondrial metabolism, 
which is regulated by uncoupling protein 2 (UCP2). Whether UCP2 contributes to the 
progression of AKI-to-CKD is unknown.
Methods: We generated proximal tubular cells specific UCP2 knockout mice. AKI-
to-CKD model was induced using ischemia-reperfusion injury (I/R). Mice kidney tissues 
were harvested six weeks after I/R. Alternations of mitochondrial morphology, metabolic 
products and critical enzymes that govern fatty acid oxidation and glycolysis were 
examined. Pimonidazole was used to evaluate hypoxia in kidney tissue.
Results: In I/R-induced AKI-to-CKD model, expression of UCP2 was markedly 
increased in fibrosis kidneys. Impairment of renal function and remarkable accumulation 
of extracellular matrix in the tubulointerstitial spaces were quite evident six weeks after I/R 
injury. Mitochondria reduction and swellings, as well as lipid droplets deposition suggested 
metabolic abnormalities of fatty acid. However, increased glycolytic enzyme expression and 
inhibitory phosphorylation of pyruvate dehydrogenase were exhibited indicating a switch 
to glycolysis. Ucp2-deficient mice suffered I/R injury experienced less tubulointerstitial 
fibrosis and metabolic disorders. Furthermore, tissue hypoxia was observed in I/R-induced 
fibrotic kidney and renal expression of hypoxia-inducible factor 1α (HIF-1α) was increased 
suggested hypoxia-induced stabilization of HIF-1α in fibrosis kidney. Nevertheless, 
knockout of UCP2 relieves the tissue hypoxia and reduces the stabilization of HIF-1α in 
the kidney.
Conclusions: UCP2 regulates tissue hypoxia-induced stabilization of HIF-1a, which 
promotes the reprogramming of mitochondrial metabolism from fatty acid oxidation to 
glycolysis and contribute to pathogenesis of AKI-to-CKD. UCP2 may provide a novel 
therapeutic target for prevention of chronic fibrosis caused by AKI.
Funding: Government Support - Non-U.S.
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Mitochondrial Dysfunction in FOXD1 Lineage Cells Is Associated with 
Renal Fibrogenesis and Anemia
Hanako Kobayashi, Ken Ishii, Volker H. Haase. Vanderbilt University Medical 
Center, Nashville, TN.
Background: Mitochondria play an important role in the pathophysiology of chronic 
kidney diseases (CKD), as mitochondrial uncoupling and dysfunction changes cellular 
metabolism impacting CKD pathogenesis and its progression. It is well established that renal 
function impairment correlates with the degree of tubulointerstitial fibrosis. Furthermore, 
fate-mapping studies have previously shown that the majority of collagen-producing renal 
myofibroblasts are derived from perivascular interstitial cells and pericytes. Despite the 
importance of these findings for renal fibrogenesis, the role of mitochondria and oxidative 
phosphorylation in renal interstitial cell function and myofibroblast transdifferentiation is 
only poorly understood.
Methods: To investigate mitochondrial function and the role of oxidative 
phosphorylation in renal interstitial cells, we have generated and analyzed mice with 
interstitial cell-specific inactivation of mitochondrial transcription factor A (TFAM) using 
FoxD1-cre transgenics. TFAM is required for mitochondrial gene transcription and DNA 
replication and thus essential for the maintenance of mitochondrial function and mass.
Results: We demonstrate that suppression of mitochondrial function in interstitial cells 
has a pivotal role in the pathogenesis of CKD, as inactivation of stromal TFAM resulted in 
progressive renal failure (BUN at 6-weeks of age: 76.0 ± 1.5 mg/dl vs. 27.8 ± 0.9 mg/dl in 
control; p<0.0001, n=4 each), which was associated with an increased number of α-SMA-
expressing cells, the development of tubulointerstitial fibrosis and proteinuria at older age. 
Furthermore, interstitial cell-specific TFAM knockout mice developed anemia (Hct: 42.8 ± 
1.5 % in control vs. 36.2 ± 1.0 % in mutants; p= 0.006, n=5 each) and were characterized 
by a reduction in their capacity to produce erythropoietin in response to hypoxic stimuli, a 
major pathologic feature of CKD.
Conclusions: Our data demonstrate that mitochondria play an important role in 
the maintenance of normal renal interstitial cell homeostasis and hypoxia responses. A 
detailed metabolic characterization of interstitial cell-specific TFAM knockout mice will 
be presented at the meeting. <!-- Copyright (c) 2006 Microsoft Corporation. All rights 
reserved. --><!-- OwaPage = ASP.webreadyviewbody_aspx --><!--Copyright (c) 2006 
Microsoft Corporation. All rights reserved.-->
Funding: NIDDK Support
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Dyslipidemia in Nephrotic Rats Associates with Increased Hepatic PCSK9 – 
Heparan Sulfate Interaction
Pragyi Shrestha,1,2 Bart Van de sluis,4 Jacob van den Born.3 1University of 
Groningen, Groningen, Netherlands; 2Department of Nephrology, University 
Medical Center Groningen, Groningen, Netherlands; 3Univ. Med. Center 
Groningen, Groningen, Netherlands; 4UMC Groningen, Groningen, 
Netherlands.
Background: Dyslipidemia characterized by higher levels of plasma lipids (triglyceride 
and cholesterol) increases the risk for cardiovascular disease in patients with Chronic Kidney 
Diseases (CKD). Here, our aim is to investigate the role of the LDL receptor (LDLR), 
heparan sulfate (HS) side chains of syndecan-1 and Proprotein convertase subtilisin/kexin 
type 9 (PCSK9) in CKD-related dyslipidemia using a dyslipidemic proteinuric rat model.
Methods: Eight male Wistar rats received 1.8 mg adriamycin/kg BW i.v. to induce 
proteinuria (ADR). Six control rats were injected with saline. Kidney function, proteinuria, 
and serum lipids were monitored weekly. Animals were sacrificed after 12 weeks. Tissues 
and plasma were collected. Expression of LDLR, syndecan-1, HS and PCSK9 were 
evaluated in the liver by immunofluorescence staining (IF), western blotting (WB) and qRT-
PCR. Plasma PCSK9 was measured by ELISA. Mann Whitney test and Spearman Rank 
correlation were used for statistics.
Results: ADR showed increased proteinuria and serum lipids (all p<0.001) compared 
to controls without differences in protein and mRNA expression of LDLR. Interestingly, the 
localization of PCSK9 to the liver sinusoids was however significantly increased in ADR 
compared to controls (p<0.001, IF), without changes in gene expression. Serum triglyceride 
and cholesterol correlated with serum PCSK9 (r=0.59, p=0.0035; r=0.71, p=0.006) and 
with liver PCSK9 (r=0.83, p=0.0004; r=0.80, p=0.001 respectively). Moreover, PCSK9 
protein was found to interact strongly with HS, and interaction was highly dependent on 
HS sulfation and chain length. Disaccharide profiling of HS revealed a remarkable increase 
in 6-O-sulfation of liver HS, which could be due to lower hepatic Sulf2 mRNA expression 
(p=0.06). Inverse association was found between serum triglyceride and cholesterol with 
Sulf2 mRNA levels (r=-0.67, p=0.01; r=-0.64, p=0.02).
Conclusions: Dyslipidemia in nephrotic rats is related to increased interaction of 
PCSK9 with hepatic syndecan-1/HS, which might hamper TRL clearance capacity.
Funding: Government Support - Non-U.S.
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The Role of CPT1α on Fatty Acid Metabolism and Development of Renal 
Fibrosis
Qi Yuan,2 Yang Zhou,1 Hao Ding,1 Yi Fang,1 Junwei Yang.1 1Second Affiliated 
Hospital, Nanjing Medical University, Nanjing, China; 2Nanjing Medical 
University, Jiangsu Nanjing, China.
Background: Renal fibrosis is the common pathologic feature of chronic kidney 
disease (CKD). Proximal tubular epithelial cells (PTCs) prefer fatty acid as their energy 
source. Defective fatty acid oxidation plays a key role in kidney fibrosis development. 
CPT1α is the rate limiting enzyme that transport fatty acid into mitochondria. Moreover, 
CPT1α has a lysine succinyltransferase activity. In this study, we investigated the role of 
CPT1α in modulation of cellular fatty acid homeostasis in tubular epithelial cells during 
renal fibrosis.
Methods: Renal fibrosis was induced by folic acid (FA) injection. Relationship 
between renal fibrosis and expression of CPT1α was examined using renal biopsy samples 
from 30 patients and kidneys from FA mice. Mice with PTCs’ specific ablation of CPT1α 
(KO) were generated and pharmacologic and genetic upregulation of CPT1α were used to 
investigate the role of CPT1α on renal fibrosis.
Results: Expression of CPT1α in proximal tubular epithelial cells was negatively 
correlated with the area of renal fibrosis in both human samples and FA model. Tubular 
CPT1αKO mice experienced severe renal fibrosis and increased expressions of fibrotic 
markers, such as collagen I, fibronectin and vimentin than wild-type mice. While 
upregulation of CPT1α by administration of fenofibrate or transfection of CPT1α plasmid 
attenuated the accumulation of extracellular matrix and renal fibrosis in mice kidney. 
Moreover, upregulation of CPT1α increased the key enzymes of fatty acid metabolism, 
including ACAD, FASN, GPAT and GPD1. The decreased succinylation of the enzymes 
and regulators of fatty acid metabolism in fibrosis kidney were relieved by fenofibrate 
treatment.
Conclusions: These results demonstrate that CPT1α plays a major role in fatty acid 
metabolism disturbance in the tubular epithelial cells and contributes to renal fibrosis. 
Restoring the lysine succinyltransferase activity of CPT1α may provide novel therapeutic 
approach for kidney fibrosis.
Funding: Government Support - Non-U.S.
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Sodium Butyrate Alleviates Renal Failure (RF) in Animals by Mitigating 
Inflammation and Fibrosis
Austin J. Gonzalez,1 Siddhartha S. Ghosh,2 Richard Krieg,3 Todd W. Gehr.1 
1Virginia Commonwealth University, Fredericksburg, VA; 2VCU Medical Ctr, 
Richmond, VA; 3VCU, Richmond, VA.
Background: Renal failure (RF) is largely associated with inflammation and damage 
of kidney tissue. NFkB is a well-known marker for inflammation and for the regulation 
of fibrosis. Phosphorylated NFkB (pNFkB) is translocated into the nucleus and promotes 
transcription of various genes which play a role in inflammation and fibrosis. Treatment 
with sodium butyrate, a short-chain fatty acid (SCFA) and histone deacetylase (HDAC) 
inhibitor, has been shown to have anti-inflammatory effects in RF. We demonstrate that 
sodium-butyrate treatment can ameliorate RF at both the biochemical and histopathological 
level.
Methods: Five-sixth nephrectomized Sprague-Dawley rats were used as a model 
for RF. Animals were divided into three groups: Sham-operated control (SH), untreated 
nephrectomy (Nx), and nephrectomy with butyrate treatment (Nx+BU) 100 mg/kg/day 
sodium butyrate in drinking water. Kidney tissue cytosolic NFkB and nuclear pNFkB were 
measured by Western Blot analysis. Histological analysis was performed on the kidney 
tissues with both Periodic Acid-Schiff stain and Picro-Sirius Red stain to measure the extent 
of collagen networks in fibrosis. Renal biomarkers were measured by chemical assay.
Results: There was 3.5 fold increased translocation of pNFkB in the nucleus of Nx rats, 
which was significantly lowered in the Nx+BU group. There was no difference in cytosolic 
NFkB. Kidney tissue of the Nx animals had 35±4.4% segmental sclerosis, whereas Nx+BU 
animals had reduced to 24±5.6% (p=0.003). In Nx, 26% of the area was positively stained 
with sirius red compared to 1.7% in SH (p<0.0001), but was reduced by 50% in Nx+BU 
(p<0.01). The serum urea, urinary protein/creatinine ratio, and serum creatinine of Nx 
rats were significantly higher (3.6, 3, and 3.2-fold respectively) than SH. Nx+BU had 
significantly improved proteinuria and serum urea levels. Serum creatinine levels were 
reduced by 22% in Nx+BU (p=0.05).
Conclusions: Treatment with sodium butyrate has been shown to have beneficial effects 
on the translocation of NFkB, subsequent histological data on kidney fibrosis, and renal 
function in RF. Sodium butyrate, among other systemic and gut-related benefits, acts as an 
HDAC inhibitor and provides a possible mechanism for anti-inflammatory action in RF.
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Self-Assembled Polypeptide Gold Nanoparticles Selectively Target the 
Kidney for High-Efficiency Anti-Fibrosis Treatment
Lishan Tan,1 Xuandi Lai,2 Jianqiang Hu,2 Aiqing Li.1 1Nanfang Hospital, 
Southern Medical University, Guangzhou, China; 2Department of Chemistry, 
School of Chemistry and Chemical Engineering, South China University of 
Technology, Guangzhou, Guangzhou, China.
Background: Many preclinical agents (e.g., cobalt chloride) have attracted great 
attentions because they can ameliorate chronic kidney fibrosis. However, many of these 
drugs are lack of kidney targeting ability or/and exhibit biological toxicity, which limits 
their clinical applications. Here we produced glutathione- and lipoic acid-modified Au 
nanoassemblies (GLAuNPs-Co) with good biocompatibility, high renal targeting capability 
and excellent anti-fibrosis efficacy through a Co2+-induced coordination self-assembled 
strategy.
Methods: The LAuNPs and GLAuNPs were investigated using transmission electron 
microscopy (TEM), dynamic light scattering (DLS), fourier transform infrared (FTIR) 
spectra and thermogravimetric analysis (TGA). In vitro, Cell Counting Kit-8 (CCK-8) 
and Elisa Kits were used to evaluate the biocompatibility of GLAuNPs. Celluar uptake 
mechanism was explored by fluorescence microscopy and inductively coupled plasma-
mass spectrometry (ICP-MS). Organs’ distribution was examined using in- and ex-vivo 
fluorescence imaging software. The loading and release efficiency was evaluated by ICP-
MS. The anti-fibrosis efficacy and mechanism were tested by pathological staining, western 
blot and real-time PCR in vivo using unilateral ureteral obstruction (UUO) mice.
Results: In aqueous solution, GLAuNPs-Co could self-assemble at neutral pH, and 
disassemble and release Co2+ when pH stwich to acid. Cytotoxicity and immunotoxicity 
assays and in vivo fluorescence imaging revealed that GLAuNPs had excellent 
biocompatibility, non-immunotoxicity and kidney-targeting ability. Pathological staining, 
western blot and real-time PCR analyses showed that GLAuNPs-Co had more excellent 
anti-fibrosis, anti-inflammatory, anti-oxidative stress, and anti-apoptosis efficacy than that 
of free CoCl2 in UUO nephropathy mice.
Conclusions: With attractive characteristics of specific renal-targeting, controllable 
drug-release, non-toxicity and outstanding fibrosis therapeutic efficacy, the GLAuNPs-Co 
is hopeful to become a promising drug against renal fibrosis in clinic in the near future, 
which represents an innovative avenue of designing and developing therapy system for 
kidney diseases.
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Association Between Urine Output, Furosemide Stress Test, and Fibrosis 
in Kidney Biopsies
Jesus Arturo R. Martinez,2 Lakhmir S. Chawla,1 Ravindra L. Mehta,1 
Sucheta M. Vaingankar,1 Francisco Rodríguez,2 Virgilia Soto,2 María F. Camacho 
briseño,4 Ricardo Duarte,3 Alejandro Cabrera-Jara,4 Carlos A. Garza-Garcia,5 
Magdalena Madero.2 1University of California, San Diego, San Diego, CA; 
2Instituto Nacional de Cardiologia Ignacio Chavez, Tlalpan, Mexico; 3Public, 
MEXICO CITY, Mexico; 4UNAM, Ciudad de México, Mexico; 5Private Practice, 
Monterrey, Mexico.
Background: Interstitial fibrosis (IF) is one of the most potent risk factors for kidney 
disease progression. The Furosemide Stress Test (FST) is a validated tool that predicts the 
severity of acute kidney injury in critically ill patients. To our knowledge there is no data on 
the association between the functional tubular capacity by urine output (UO) and FST with 
IF on kidney biopsies. The aim of this study was to determine the correlation between UO, 
FST and the severity of IF in kidney biopsies
Methods: 84 patients that underwent kidney biopsy were included. Furosemde was 
administred at 1 mg/kg and UO was measured every h for 6 after confirmation of empty 
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bladder by US. Serum biochemical markers were measured and urine concentrations of 
furosemide at different times (2, 4 and 6 hours). IF was evaluated by subjective visualization 
by an experienced nephropathologist in addition to morphometry. We used the FEM 
equation to determine the Mass of Excretion of Furosemide (FEM: Furosemide Urine x 
Volume urinary)/furosemide administered dose). Values were expressed as mean, SD or % 
and Pearson Correlation
Results: Nephrotic syndrome and acute kidney graft dysfunction were the most 
frequent indications for biopsy. eGFR was inversely proportional to the degree of fibrosis. 
Subjects with grade 3 IF showed a significant decrease in urine volume at hour 1 when 
compared with grades I and II (155 mL ± 181 vs 316 mL ± 261 vs 328 mL ± 352 p=0.015 
respectively). Likewise, the total urine volume and the excreted mass of Furosemide was 
progressively lower with higher degrees of IF, at 2 and 4 hours. An inversely proportional 
linear correlation between uresis and the degree of IF (R20.072) was observed
Conclusions: Our findings support that IF correlates with total UO and FEM. Both 
urine output and FST acould be a non invasive tool to predict IF.
Funding: Veterans Affairs Support
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Long-Noncoding RNA Atrolnc-1 Promotes Muscle Wasting in Mice with 
CKD
Lijing Sun,1,2 Zhaoyong Hu,2 William E. Mitch.2 1Xinhua Hospital Affiliated to 
Shanghai Jiaotong University School of Medicine, Shanghai, China; 2Baylor 
College of Medicine, Houston, TX.
Background: Chronic kidney disease (CKD) is commonly associated with cachexia, 
a condition that causes skeletal muscle wasting and an unfavorable prognosis. Although 
mechanisms leading to cachexia have been intensively studied, the advance of biological 
knowledges and technologies encourages us to make progress in understanding the 
pathogenesis of this disorder. Long non-coding RNAs (lncRNAs) are defined as >200 
nucleotides RNAs but lack the protein-coding potential. LncRNAs are involved in the 
pathogenesis of many diseases, but whether they functionally involve in muscle protein loss 
has not been investigated.
Methods: We performed lncRNA array and identified an lncRNA, which we named 
Atrolnc-1, remarkably elevated in atrophying muscles from mice with cachexia. We 
examined how overexpression or knockdown of Atrolnc-1 could influence muscle protein 
synthesis and degradation. We also examined whether inhibition of Atrolnc-1 ameliorates 
muscle wasting in mice with CKD.
Results: We documented that Atrolnc-1 expression is continuously increased in 
muscles of mice with fasting, cancer or CKD. We found that depressed insulin signaling 
stimulates the transcription factor, C/EBP-α binding to the promoter of Atrolnc-1 and 
promotes the expression of Atrolnc-1. In cultured C2C12 myotubes, overexpression of 
Atrolnc-1 increases protein degradation; Atrolnc-1 knockdown significantly reduces the 
rate of protein degradation stimulated by serum depletion. Using mass spectrometry and a 
lncRNA pull-down assay, we identified that Atrolnc-1 interacts with A20 binding inhibitor 
of NF-κB-1(ABIN-1). The interaction impairs function, resulting in enhanced NF-κB 
activity plus MuRF-1 transcription. This response is counteracted by CRISPR/dCas9 
mediated overexpression. In muscles from normal mice, overexpression of Atrolnc-1 
stimulates MuRF-1 expression leading to myofibers atrophy. In contrast, Atrolnc-1 
knockdown attenuates muscle wasting in mice with CKD via suppression of NF-κB activity 
and MuRF-1 expression.
Conclusions: Our findings provide evidence that lncRNAs initiates the 
pathophysiological process of muscle wasting. The interaction between Atrolnc-1 and NF-
κB signaling modulates muscle mass and proteolysis in CKD and perhaps other catabolic 
conditions.
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Omega-3 Fatty Acid Modulates Molecules Associated with Sarcopenia in 
Muscle of 5/6 Nephrectomy Rats
Young ki Son,1 Su mi Lee,1 Seong Eun Kim,2 Won Suk An.1 1Dong-A University, 
Busan, Republic of Korea; 2Dong-A University Hospital, Busan, Republic of 
Korea.
Background: Sarcopenia is common in dialysis patients and result in frail status. 
Myostatin, a member of TGF-β superfamily, inhibits myocyte differentiation and is 
increased in patients with chronic kidney disease. Myogenin is also important mediator for 
myogensis. Recent report showed that omega-3 fatty acid (FA) supplementation improved 
muscle volume in elderly. The present study aimed to investigate whether omega-3 FA effect 
on myostatin and myogenin related with sarcopenia in 5/6 subtotal nephrectomy (Nx) rats.
Methods: Male Sprague Dawley rats were divided into three groups and treated for 6 
weeks: sham control (0.9% saline), 5/6 Nx control (0.9% saline) and 5/6 Nx treated with 
omega-3 FA (300 mg/kg/day by gastric gavage). The expression of muscular myostatin, 
myogenin, MyoD, Akt, phosphorylated(p) Akt, PI3K, p-PI3k, AMPK, p-AMPK, smad2/3/4, 
NF-κB, IL-6, mTOR, FoxO, MuRF1, MAFbx and USP14 were examined by western blot 
analysis. H & E staining of gastrocnemius muscle was performed.
Results: BUN and serum creatinine levels were significantly increased in 5/6 Nx 
groups compared to sham control and were not significantly different between 5/6 Nx 
group treated with omega-3 FA and 5/6 Nx control group. Compared with sham control, 
5/6 Nx control significantly up-regulated myostatin and down-regulated myogenin and 
MyoD in skeletal muscle. Increased expression of myostatin and decreased expression of 
myogenin were significantly recovered by omega-3 FA supplementation. However, MyoD 
expression was not changed by omega-3 FA supplementation. The expression of p-Akt and 
mTOR was down-regulated in skeletal muscle of 5/6 Nx control compared to sham control 
and was recovered by omega-3 FA supplementation. The expression of smad2/3/4, NF-
κB, IL-6, FoxO, MuRF1, MAFbx and USP14 was significantly up-regulated in skeletal 
muscle of 5/6 Nx control compared to sham control but were not changed by omega-3 FA 
supplementation. The thickness of myofiber was decreased in 5/6 Nx control compared to 
sham control and was recovered by omega-3 FA supplementation.
Conclusions: Omega-3 FA may prevent sarcopenia mainly by decreasing myostatin, 
increasing myogenin expression and partly affecting Akt-mTOR axis in skeletal muscle of 
5/6 Nx rats.
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AMPK Deficiency Worsens Albuminuria Post Uninephrectomy (UNX)
Daniel Rivera,1 Roshan Rajani,1 Valeria Mancino,2 Parisa Rezapoor,1 
Hamidreza Zohoorkari,1 Biagio Saitta,1 Pei-Yin Ho,1 Hui Li,1 
Kenneth R. Hallows,1 Nuria M. Pastor-Soler.1 1Keck School of Medicine of USC, 
Los Angeles, CA; 2University of Southern California, Los Angeles, CA.
Background: Living donor (LD) kidney transplant offers the best prognosis for 
end-stage kidney disease patients. LDs have excellent outcomes, yet recent studies show 
that in the first year post-UNX there is an increased risk of hypertension that also drives 
microalbuminuria, a marker of kidney injury. Although hypertrophy contributes to a new 
steady-state in kidney function, it is unclear whether compensatory changes are beneficial 
long term for the LD. In several chronic kidney disease (CKD) models activity of the 
metabolic sensor AMP-activated kinase (AMPK) decreases compared to healthy kidneys. 
We hypothesize that low AMPK activity pre-UNX could worsen CKD post-UNX when 
combined with a high-Na+ diet. Our work aims to inform mechanisms that could lead to 
protective interventions for LDs with approved AMPK activators.
Methods: We used adult female mice with double-floxed AMPK alpha subunits 
(AMPKfl) and ± tamoxifen-driven(Tam) expression of CAG-Cre recombinase 
(Cre+ vs. Cre-AMPKfl). All mice underwent UNX 5 wks post-Tam and were placed on 
a high-Na+ (HNa) diet at that time (intervention). We measured GFR, urine albumin and 
plasma electrolytes at different time points. Explanted Kidneys (EK) were examined by 
immunoblot and qPCR.
Results: EK from Cre+AMPKfl have significant (>75%) AMPK knockdown (KD) 
compared to Cre-AMPKfl mice after Tam. No changes in kidney injury marker-1 gene 
expression were found in EK between the two groups. However, AMPK-KD (Cre+ mice) had 
a significant increase in albuminuria (overnight: 22.1±4 vs. 9.2±2 mg, Cre+ vs. Cre-, P<0.03) 
and anemia. UNX+HNa significantly increased albuminuria in Cre-AMPK (9.2 pre vs. 27.7 
post, P<0.02), while in the AMPK-KD group this difference was more pronounced (22.1 
pre vs 65.5 post, P<0.01). At two weeks after UNX+HNa there was a statistically significant 
increase in GFR and metabolic acidosis in both groups compared to pre-intervention. 
However, at that time there was no difference in GFR between Cre+ and Cre-AMPK mice.
Conclusions: Although female rodents have less severe kidney injury post-UNX 
than males, our studies show that AMPK KD in female mice worsens kidney injury 
(albuminuria) in a model of kidney donation and HNa diet. These findings implicate AMPK 
as an important target for potential pharmacologic interventions to prevent CKD in LDs.
Funding: NIDDK Support, Other U.S. Government Support, Private Foundation 
Support
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Transcriptomic Profiling of Mitochondrial Dysfunction in Uremic 
Cardiomyopathy
Kenneth Lim,2 Frank Xu,1 Arvin Halim,1 Li-lun Ho,6 Sahir Kalim,3 
Elizabeth D. Ankers,2 Thomas F. Hiemstra,5 Ravi I. Thadhani,4 Tzongshi Lu.1 
1Renal, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; 
2Massachusetts General Hospital, Boston, MA; 3Massachusetts General 
Hospital/ Harvard Medical School, Cambridge, MA; 4Cedars-Sinai, Los 
Angeles, CA; 5University of Cambridge, Cambridge, United Kingdom; 
6Massachusetts Institute of Technology, Cambridge, MA.
Background: Uremic cardiomyopathy is a life-limiting condition that occurs in 
chronic kidney disease (CKD). Emerging evidence suggests that mitochondrial dysfunction 
may be a cardinal event that occurs in the failing myocardium under uremic conditions. 
We previously reported mitochondrial structural deformity and reduction in its respiratory 
chain enzyme activity in septic rat hearts. These changes were mitigated by upregulation 
of the inducible molecular chaperone, Heat Shock Protein (HSP) 70. Whether HSP70 may 
induce cytoprotective effects in uremic cardiomyopathy is currently unknown. The goal of 
this study was to investigate mitochondrial changes and their association with the HSP70 
system in uremic cardiomyopathy.
Methods: Human left ventricular tissues collected from CKD (n=23), CAD (n=11) and 
healthy donors (n=20) were subjected to RNA sequencing, ex vivo. We developed a digital 
cell sorting study model using deconvolution to enhance interpretation of heterogenous 
transcriptomic profiles inherent of mixed-cell type tissue. Primary human cardiomyocytes 
and cardiac-myofibroblasts were treated with calcification medium (CM) in time-course 
experiments (0-48 hours), in vitro.
Results: Cytoprotective mtHSP (HSPA9) and the HSP70 co-chaperone, Bcl2 associated 
Athanogene 1 (BAG1) were highly expressed in healthy control hearts compared to CKD 
and CAD. However, mitochondrial fusion regulation genes MFN1 and OPA1 were down-
regulated in CKD hearts, together with down-regulation of downstream anti-apoptotic gene 
Bcl2 and up-regulation of pro-apoptotic genes cytochrome c, caspase 3, BAX and P53. 
The same pattern of changes were observed in cardiomyocytes and cardio-myofibroblasts 
treated with CM, in vitro. BAG1 was significantly increased at 6 hours prior to upregulation 
of Bcl2 at 12 hours after treatment. Furthermore, stress respondent genes, HSPA5 and 
DNAJB6 (HSP40) was significantly increased at 12 hours and 24 hours respectively in 
CM-treated primary cells.
Conclusions: The present study is the first to describe complex differential genomic 
changes involved in uremic cardiomyopathy. Mitochondrial dysfunction was associated 
with upregulation of apoptotic genes and reduced expression of cytoprotective HSP70 
components. We postulate that induction of the HSP70 system may be a therapeutic target 
in uremic cardiomyopathy.
Funding: Private Foundation Support
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Tolvaptan Activates Nrf2/HO-1 Pathway Through PERK Phosphorylation
Tamami Fujiki, Fumiaki Ando, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, 
Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tokyo Medical 
and Dental University, Bunkyo-Ku, Japan.
Background: Tolvaptan slows the increase in total kidney volume (TKV) and the 
decline in kidney function in Autosomal Dominant Polycystic Kidney Disease (ADPKD). 
In addition, vasopressin type2 receptor (V2R) antagonists improve renal function in various 
rodent models of chronic kidney disease (CKD). However, the mechanism of tolvaptan 
improving renal function remains totally unclear. It has been reported that oxidative stress 
is associated with CKD progression, and the antioxidant transcription factor, nuclear factor 
erythroid 2-related factor 2 (Nrf2), is attracting the attention as therapeutic target. In fact, 
Nrf2 activator, bardoxolone methyl, improves renal function in patients with CKD. In this 
study, we examined the effects of tolvaptan on Nrf2.
Methods: The effect of tolvaptan was examined by mouse cortical collecting duct 
(mpkCCD) cells, H9C2 cells, and mice kidneys that endogenously express V2R.
Results: Tolvaptan led to Nrf2 nuclear translocation and induced mRNA and protein 
expression of heme oxygenase 1 (HO-1) in mpkCCD cells and H9C2 cells. Phosphorylation 
of unfolded protein kinase RNA-like endoplasmic reticulum(ER) kinase (PERK) by 
tolvaptan played an important role in activation of Nrf2/HO-1 pathway. Moreover, tolvaptan 
successfully activated Nrf2/HO-1 pathway in the outer medulla of mice kidneys.
Conclusions: This is the first report describing that tolvaptan activates Nrf2/HO-1 
pathway through PERK phosphorylation. Tolvaptan may be a potential therapeutic target 
of CKD.
Funding: Government Support - Non-U.S.
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Tadalafil Treatment Attenuates Renal Dysfunction in Hypertensive Model 
Independent of Blood Pressure Lowering
Natsumi Tomita,1 Yuji Hotta,1 Aya Naiki-Ito,2 Tomoya Kataoka,3 
Yasuhiro Maeda,1 Satoru Takahashi,2 Kazunori Kimura.1,3 1Department of 
Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City 
University, Nagoya, Japan; 2Department of Experimental Pathology and Tumor 
Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, 
Japan; 3Department of Clinical Pharmaceutics, Graduate School of Medical 
Sciences, Nagoya City University, Nagoya, Japan.
Background: Recently, phosphodiesterase 5 inhibitor (PDE5i) reportedly has 
renoprotective effects, which may be due to blood pressure (BP) lowering by PDE5i. Here, 
we assessed if the renopretective effect of tadalafil, a PDE5i, depends on its BP lowering 
using salt-sensitive hypertension rats.
Methods: Dahl salt-sensitive rats were divided into 4 groups (n=5-7): normal salt (NS), 
high salt (8 % NaCl included in diet; HS), low-dose (1 mg/kg/day, p.o; TL), and high-dose 
tadalafil treatment (10 mg/kg/day, p.o; TH). SCre, proteinuria, and BP were evaluated at 
0 and 8 weeks. PAS staining and αSMA immunohistochemistry were performed. mRNA 
level of PAI1, which is reported to increase αSMA expression, was evaluated.
Results: In the HS, BP significantly increased at 8 weeks. The TH showed attenuated 
BP elevation. However, the TL showed BP elevation similar to the HS (Fig.1A). Proteinuria 
and SCre levels, which markedly increased in the HS at 8 weeks, were suppressed in the 
TH and TL (Fig.1B,C). PAS staining showed severe glomerulosclerosis in the HS and 
was prevented in the TH and TL (Fig. 2A). αSMA-positive area significantly increased 
in the HS and decreased in the TH and TL (Fig. 2B). PAI1 mRNA level was significantly 
upregurated in the HS. Tadalafil treatment dose-dependantly decreased PAI1 mRNA level.
Conclusions: Tadalafil treatment could prevent decline of the renal function 
independently of BP lowering. This effect might be associated with suppression of PAI1.
Fig.1 Variations of mean blood pressure (A), SCre (B), and Urinary protein (C) in each 
groups (n=5-7). Turkey’s test. *P<0.05,**P<0.01 vs. NS, # P<0.05, ##P<0.01vs. HS.
Fig.2 Histopathological assessment; glomerulosclerosis index (A) and αSMA positive area 
(B). (n=4-6). Turkey’s test. *P<0.01
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TNF-α Blockade Attenuates Hypertension and Renal Expression of the 
Epithelial Sodium Channel Α-Subunit in the Remnant Kidney CKD 
Model Using ATRAP Deficient Mice
Ryu Kobayashi,1 Hiromichi Wakui,2 Kengo Azushima,2 Kazushi Uneda,2 
Kohji Ohki,3 Sho Kinguchi,2 Takahiro Yamaji,4 Shingo Urate,1 Yoshiyuki Toya,2 
Kouichi Tamura.1 1Yokohama City University Graduate School of Medicine, 
Kanazawa-Ku, Japan; 2Yokohama City University, Yokohama, Japan; 
3Yokohama City University School of Medicine, Yokohama, Japan; 4Yokohama 
city unversity, Yokohama, Japan.
Background: We previously identified an angiotensin type 1 receptor (AT1R)-
associated protein (ATRAP/Agtrap), which promotes AT1R internalization along with 
suppression of hyperactivation of tissue AT1R signaling. We hypothesized that dysregulation 
of renal ATRAP expression and subsequent AT1R hyperactivation plays a critical role in 
development of hypertension in remnant kidney chronic kidney disease (CKD) model.
Methods: First, we compared changes in endogenous ATRAP expression and blood 
pressure between 129/Sv and C57BL/6 mice using the remnant kidney model after 5/6 
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nephrectomy. Second, we examined the effect of ATRAP deficiency in C57BL/6 mice 
(with a hypertension-resistant strain background) on blood pressure regulation after 5/6 
nephrectomy. Third, ATRAP-knockout (KO) mice were treated with the soluble TNF-α 
receptor, etanercept, or with vehicle after 5/6 nephrectomy.
Results: While 129/Sv mice that underwent 5/6 nephrectomy showed decreased renal 
ATRAP expression and developed hypertension, C57BL/6 mice exhibited increased renal 
ATRAP expression and resistance to progressive hypertension. Next, we performed 5/6 
nephrectomy in ATRAP-KO mice on the hypertension-resistant C57BL/6 background. 
ATRAP-KO mice that underwent 5/6 nephrectomy showed hypertension with increased 
plasma volume. Moreover, in ATRAP-KO mice compared with wild-type C57BL/6 
mice after 5/6 nephrectomy, renal expression of the epithelial sodium channel α-subunit 
(αENaC) and tumor necrosis factor-α (TNF-α) was significantly enhanced, concomitant 
with increased plasma membrane AT1R in the kidneys. TNF-α inhibition with etanercept 
significantly suppressed 5/6 nephrectomy-induced blood pressure elevation in ATRAP-
KO mice. Furthermore, renal expression of αENaC protein was significantly decreased 
in ATRAP-KO mice treated with etanercept, compared with vehicle, at 4 weeks after 5/6 
nephrectomy.
Conclusions: These results indicate that promotion of primary sodium reabsorption in 
the renal tubules of the remnant kidney via activation of the AT1R-TNF-α-αENaC axis is a 
plausible mechanism for the increased circulating plasma volume observed in ATRAP-KO 
mice after 5/6 nephrectomy.
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Functional Characterization of A1CF, a Novel eGFR Locus
Jennie Lin,1 Philipp Tauber,4 Yuka Takemon,4 Jihwan Park,3 Leslie S. Gewin,2 
Katalin Susztak,3 Ron Korstanje.5 1Northwestern University Feinberg School of 
Medicine, Chicago, IL; 2Vanderbilt University, Nashville, TN; 3University of 
Pennsylvania, Philadelphia, PA; 4The Jackson Laboratory, Bar Harbor, ME; 
5The Jackson Laboratory, Bar Harbor, ME.
Background: A recent human genome-wide association study identified a common 
5’ UTR variant at the A1CF locus associated with eGFR. A1CF encodes an RNA binding 
protein (RBP) previously known to facilitate APOBEC1’s editing of APOB mRNA in 
non-renal tissues to produce a shorter isoform. However, A1CF’s role in modulating renal 
function remains unclear.
Methods: Leveraging human and rodent systems, we studied A1CF in a renal context 
with an integrated approach. We localized A1CF expression in human kidney organoids 
and mouse kidneys and assessed expression in human nephrectomy tissue and mouse 
models of renal fibrosis. Next we used RIP-seq to identify A1CF’s RNA binding targets and 
their enriched pathways. To determine A1CF’s renal effects in vivo, we measured markers 
of renal function and injury at baseline and after induction of stress conditions in A1cf 
knockout mice.
Results: Immunostaining of human kidney organoids and fluorescent RNA labeling 
of mouse kidneys demonstrate that A1CF expression is specific to the proximal tubule. 
Profiling of human nephrectomy tissue revealed that A1CF mRNA expression is decreased 
in CKD samples compared to healthy control (N=58, P=7.4 x 10-4), correlates positively 
with eGFR (P= 9.5 x 10-5), and correlates negatively with percent interstitial fibrosis 
(P=2.0 x 10-6). This decreased expression was recapitulated in mice with folic acid (FA) 
nephropathy and unilateral ureteral obstruction (UUO) on the mRNA (P=2.7 x 10-7; 
P=3.4 x 10-13) and protein levels (P=6.4x10-4; P=1.9x10-7). To investigate how A1CF as 
an RBP might interact with injury pathways, we performed RIP-seq and identified 276 
binding targets which were enriched in pathways for endoplasmic reticulum protein 
trafficking (P=6.6 x 10-5) and peroxisomal function (P=3.6 x 10-4), relevant to intracellular 
stress when perturbed. Although no baseline abnormalities were detected in A1cf ko mice, 
when subjected to stress of water deprivation or FA treatment we observed an increase in 
urinary albumin to creatinine ratio (N=16, P=0.03; N=16, P=8.0 x 10-3). Furthermore, after 
FA treatment, A1cf ko mice exhibited higher Bax/Bcl-2 ratios and higher Acta2 expression 
in the kidney (N=7, P=0.01, P=4x10-3).
Conclusions: Taken together, these findings suggest that A1CF plays a previously 
undiscovered role in modulating the intracellular stress response relevant to CKD.
Funding: Other NIH Support - K08 HL135348 to JL (PI), U54OD020351 to RK (co-PI)
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Identification of β-Mannosidase (Manba) as a Key Gene for CKD
Hongliu Yang,1,3 Chengxiang Qiu,2 Jihwan Park,2 Shizheng Huang,2 
Katalin Susztak.2 Katalin Susztak Lab 1West China Hospital of Sichuan 
University, Chengdu, China; 2University of Pennsylvania, Philadelphia, PA; 
3University of Pennsylvania, Philadelphia, PA.
Background: Chronic kidney disease (CKD) is a complex gene-environmental disease 
affecting close to 10% of the population worldwide. We integrated the CKD Genome-wide 
association studies (GWASs) and kidney expression quantitative trait loci (eQTL) analysis 
results and identified the lysosomal beta-mannosidase (Manba) as a candidate gene for 
CKD. We found that when compared to reference allele, expression of Manba was much 
lower in healthy human kidney tissue samples obtained from subjects with risk alleles. We 
used Manba knockout mouse model to explore the functional significance of lower Manba 
expression and precise pathomechanism of Manba in CKD.
Methods: Genotype and gene expression data by RNA sequencing for 121 healthy 
human kidney tissue samples of European descent were obtained and eQTL analysis was 
conducted. Single cell RNA-sequencing on healthy mouse kidneys was performed to define 
the expression of Manba. Manba-/- mice and age-matched WT mice were generated for 
experiment. CKD was studied in aging mice or following folic acid administration. Renal 
tubule epithelial cells (TECs) from WT and Manba-/- mice were primary cultured and treated 
with fed (F), starve (S) and starve+cholorquine (S+CQ) for in vitro study.
Results: Single cell RNA-sequencing analysis of healthy mouse kidneys indicated 
Manba is mainly expressed in proximal tubule (PT) and principal cell (PC) of collecting duct 
(CD). QPCR and Western blot showed the deletion of Manba and immunohistochemical 
staining in human kidney and mouse kidney confirmed the location of Manba. In aging 
mice, Manba-/- mice showed increased number of lysosome and increased number of 
vacuoles in tubule cells. In kidney fibrosis model, Manba-/- mice demonstrated worsened 
renal damage after folic acid (FA) injection. In vitro study, Treatment with CQ heightened 
the amounts of LC3B-II in nutrientdeprived WT TECs, whereas it did not change the 
already elevated levels of LC3B-II in nutrient-deprived Manba−/− cells.
Conclusions: This is the first study demonstrated the expression of Manba in mouse 
kidney and found that Manba deficiency induces kidney fibrosis development. Manba 
deficiency impair autophagy in CKD predominantly from a slower autophagosome 
clearance.
Funding: NIDDK Support
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LncRNA GAS5 Regulates TGF-β-Induced Renal Fibrosis via Smad3-De-
pendent Pathway
Yingying Zhang,1 Chen Yu.2 1shanghai tongji hospital, Shanghai, China; 
2Shanghai Tongji Hospital, Shanghai, China.
Background: Increasing evidence shows that long noncoding RNAs (lncRNAs) play 
an important role in kidney disease. It is well known that some lncRNAs have been reported 
in renal fibrosis and renal inflammation, such as PVT1 is the first identified lncRNA-
associated kidney disease. In our previous study, we found lncRNA- growth arrest-specific 5 
(GAS5) was highly decreased in the fibrotic kidney of mouse unilateral ureteral obstructive 
nephropathy (UUO), however, the underlying mechanism of GAS5 in the pathogenesis of 
kidney disease remain largely unclear.
Methods: Firstly, we detected GAS5 expression in UUO kidney by using realtime-
PCR and in situ hybridization(ISH). Then, we tested whether TGF-β1 had any effect on 
GAS5 expression in mouse tubule epithelial cell (mTEC), since TGF-β signaling is one of 
the major mediators of renal fibrosis. Finally, we aimed to investigate the biological role of 
GAS5 after over-expression or silencing its expression in mTEC.
Results: ISH staining showed that GAS5 was expressed by mTECs, interstitial 
fibroblasts in normal renal tissue, both in the nucleus and cytoplasm pattern. In vitro, GAS5 
was down-regulated by TGF-b1 as dose-dependent. Over-expression of GAS5 blocked TGF-
b1-induced collagen I, fibronectin and alpha-smooth muscle actin (a-SMA) expressions, 
however, silencing GAS5 promoted the expressions of these markers. Mechanistic studies 
revealed that Smad3, not Smad2, drove the expression of GAS5. TGF-b1 reduced GAS5 
expression in both of the Smad3 and Smad2 wild-type MEFs, which was b∆lunted in 
Smad3 knock-out MEFs but still decreased in Smad2 knock-out MEFs. The addition of 
SIS3 recovered TGF-b1-induced expression of GAS5 in mTECs. Finally, we also found 
knockdown of GAS5 promoted TGF-β1-induced G2/M arrest, which might contribute to 
renal fibrosis via Smad3 pathway.
Conclusions: Taken together, our results have uncovered a GAS5-based mechanism 
that modulated TGF-β/Smad3 signaling by targeting extracellular matrix formation and cell 
cycle disruption.
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Newly Designed Recombinant Bone Morphogenetic Protein 7 Is a 
Potential Therapeutic in Renal Tubulointerstitial Fibrosis
Jimin Park, Sukyung Kang, Boyoung Nam, Arum Choi, Seung Hyeok Han, Tae-
Hyun Yoo. Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Renal tubulointerstitial fibrosis, final common mechanism for all 
kidney diseases, is characterized by extracellular matrix (ECM) accumulation. In addition, 
transforming growth factor-β1 (TGF-β1) is known to plays a principal mediator in the 
accumulation of ECM. Bone morphogenetic protein-7 (BMP-7) is counteract of the 
profibrogenic role of TGF-β1. Recently, our group designed recombinant BMP-7 linked 
by protein transduction domain (PTD), which has capability to effectively deliver a large 
molecule protein in eukaryotic cells. In this study, we investigated the effect of PTD-
mediated BMP-7 (tissue-regeneration polypeptide 2, TRP2) on renal tubulointerstitial 
fibrosis.
Methods: In vitro, inner medullary collecting duct cells (IMCDs) were cultured in 
DMEM/F12 media (Control) or TGF-β1 (5 ng/ml) with or without TRP2 (10 ng/ml) for 48 
hours. In vivo, tubule-interstitial fibrosis were established by unilateral ureteral obstruction 
(UUO) in C57BL/6 mice, and TRP2 (1 μg) were directly injected intraureterally after 
UUO operation, and were sacrificed after 7 days. The protein expression of fibronectin, 
type I collagen (ColI), and α-smooth muscle actin (αSMA) were determined in cultured 
IMCDs and the kidneys by western blot analysis. Masson’s trichrome staining and 
immunohistochemistry were also evaluated in the mouse kidneys.
Results: Xpress, reporter protein of TRP2, was expressed in TRP2-treated IMCDs after 
2 hours in dose-dependent manner. Compared to control, the expression of fibronectin, ColI, 
and αSMA were significantly increased in TGF-β1-stimulated IMCDs. These changes in 
cultured IMCDs exposed to TGF-β1 were significantly abrogated by TRP2 treatment. A 
significant increase in ECM proteins expression was also observed in the kidney of UUO 
mice compared to the control group kidney. These changes were significantly ameliorated 
in TRP2-treated group.
Conclusions: These results suggest that TRP2 is directly suppressing the process 
of TGF-β1-induced ECM accumulation in vitro and in vivo. The effect of TRP2 can be 
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promising potential therapeutic for prevention of renal tubulointerstitial fibrosis in various 
kidney diseases.
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The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Interstitial 
Renal Fibrosis in a Mouse Model of Unilateral Ureteral Obstruction
Shen Li,1 Sarani Ghoshal,1 Gunisha Arora,1 Ricard Masia,1 Mozhdeh Sojoodi,1 
Derek Erstad,1 Diego Dos santos ferreira,1 Yang Li,2 Peter Caravan,1 Yat sun Or,2 
Li-Juan Jiang,2 Bryan C. Fuchs.1 1Massachusetts General Hospital, Boston, MA; 
2Enanta Pharmaceuticals, Inc, Watertown, MA.
Background: Farnesoid X receptor (FXR) is a nuclear receptor that has emerged as 
a key regulator in the maintenance of bile acid homeostasis. FXR agonists are currently 
under clinical investigation for the management of various clinical diseases such as primary 
biliary cholangitis and nonalcoholic steatohepatitis where they have been shown to reduce 
hepatic steatosis, inflammation, and fibrosis. However, the role of FXR in renal fibrosis 
remains to be established. Here, we investigate the effects of the FXR agonist EDP-305 in a 
mouse model of tubulointerstitial fibrosis via unilateral ureteral obstruction (UUO).
Methods: Male C57Bl/6 mice received a UUO on their left kidney. On postoperative 
day 4, mice received daily treatment by oral gavage with either vehicle control (0.5% 
methylcellulose) or 10 or 30 mg/kg EDP-305. All animals were sacrificed on postoperative 
day 12.
Results: EDP-305 dose-dependently decreased macrophage infiltration as measured 
by the F4/80 staining area with significant differences seen at the higher dose (4.5±0.46 
vs. 1.4±0.49, p<0.01) which were associated with reduced pro-inflammatory cytokine gene 
expression (Il-6 208.3±59.46 vs. 32.53±3.28, p<0.01; Tnf-α 34.2±10.35 vs. 13.41±2.81, 
p<0.05). EDP-305 also dose-dependently reduced interstitial fibrosis as assessed 
by morphometric quantification of the collagen proportional area (CPA) and kidney 
hydroxyproline (HYP) levels with statistically significant differences observed at the higher 
dose (CPA 6.73±0.94 vs 2.58±0.39, p<0.01; and HYP 1504±140 vs. 1089±54, p<0.05). 
Finally, Yap activation, a major driver of fibrosis, increased after UUO injury and was 
diminished by EDP-305 treatment. Consistently, EDP-305 decreased TGF-β1-induced YAP 
nuclear localization in HK2 cells by increasing inhibitory YAP phosphorylation.
Conclusions: Our results suggest that Yap inhibition may be a novel anti-fibrotic 
mechanism of FXR agonism and that FXR agonists could be used to treat renal fibrosis in 
patients with chronic kidney disease.
Funding: Commercial Support - Enanta Pharmaceuticals
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Targeted Disruption of CD40 in Human Proximal Tubular Epithelial Cells 
Significantly Reduces Pro-Inflammatory and Pro-Fibrotic Signaling
Shungang Zhang,1 Terry Hinds,2 Fatimah K. Khalaf,1 Apurva Lad,2 
Andrew Kleinhenz,2 Deepak K. Malhotra,4 David J. Kennedy,3 Steven T. Haller.2 
1University of Toledo, Toledo, OH; 2University of Toledo College of Medicine 
and Life Sciences, Toledo, OH; 3The University of Toledo Health Science 
Campus, Toledo, OH; 4The University of Toledo, Toledo, OH.
Background: We have demonstrated that levels of the TNF-α superfamily member 
CD40 predict progression of renal dysfunction in patients with ischemic and chronic 
kidney disease, and that CD40’s soluble ligand (sCD40L) is significantly elevated in these 
settings. In the two-kidney one clip (2K1C) model of renal ischemia, CD40 expression is 
significantly elevated in the ischemic renal proximal tubule epithelium, and CD40 knockout 
(KO) rats show significantly reduced tubular interstitial fibrosis in the ischemic kidney and 
improved renal function verses controls. To test the hypothesis that activation of CD40 
in the proximal tubule epithelium induces a significant pro-inflammatory and pro-fibrotic 
response contributing to ischemic renal injury we performed the following study.
Methods: Renal ischemia was induced via 2K1C in both Dahl-S wild type and Dahl-S 
CD40 KO male rats and kidneys were assessed for evidence of inflammation and fibrosis 
after 4 weeks. CRISPR/Cas9 was used for the creation of a CD40 KO human proximal 
tubular cell line (HK2/CD40KO) and confirmed by immunoblotting and gene expression. 
Parent HK2 cells and HK2/CD40KO cells were treated with sCD40L (100 ng/ml) or TNF-α 
(10 ng/ml) for 24h.
Results: Renal expression of the pro-fibrotic marker plasminogen activator inhibitor-1 
(PAI-1) was elevated in Dahl-S rats after 2K1C renal ischemia and this was significantly 
attenuated in kidneys from Dahl-S CD40KO animals (p<0.05). In HK2 proximal tubular 
cells, sCD40L induced a significant increase in cytokine gene expression [CXCL2, 
CXCL5, IL23A, colony stimulating factor-1, and lymphotoxin beta (all > 5 fold increase)] 
as assessed by quantitative PCR. Importantly, sCD40L treatment also induced a significant 
increase in monocyte chemoattractant protein-1 (>20 fold increase) and PAI-1 (>2 fold 
increase) gene compared to TNF-α treatment. The responses to both sCD40L and TNF-α 
were substantially attenuated in the HK2/CD40KO cells (p<0.05).
Conclusions: Activation of CD40 in the proximal tubule epithelium induces a 
significant pro-inflammatory and pro-fibrotic response, and represents an attractive 
therapeutic target for treatment of ischemic renal disease.
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CD11c-Specific Ablation of SHP-1 Results in Renal Fibrosis with Age
Mitsuharu Watanabe,1 Yoriaki Kaneko,1 Masato Kinoshita,1 Yuko Ohishi,1 
Toru Sakairi,1 Hidekazu Ikeuchi,1 Yoshihisa Nojima,2 Keiju Hiromura.1 1Gunma 
University Graduate School of Medicine, Maebashi, Japan; 2Japan Red Cross 
Maebashi Hospital, Maebashi, Japan.
Background: Renal mononuclear phagocytes (rMoPh) which express traditional 
macrophage and dendritic cell marker, F4/80 and CD11c respectively, have attracted 
attention because of their immunoregulatory roles in healthy and diseased kidneys (JASN 
23:194, 2012). We have previously generated CD11c-specific SHP-1 conditional knockout 
mice (SHP-1 CKO) which lack a protein tyrosine phosphatase, SHP-1, and reported 
that they spontaneously develop tubulointerstitial nephritis characterized by the marked 
accumulation of CD11c+F4/80+ double-positive rMoPh, (J Immunol 2012, ASN 2016). In 
the present study, we further analyzed the kidney of SHP-1 CKO to clarify the precise 
contribution of rMoPh to the development of the nephritis.
Methods: The kidneys obtained from SHP-1 CKO and its control mice (Ctrl) at the 
age of 40 weeks and were analyzed; in particular, the expressions of vimentin, a marker 
of mesenchymal cells, and α-smooth muscle actin (α-SMA), a marker of myofibroblasts, 
were evaluated by immunohistochemistry. Collagen-digested renal mononuclear cells from 
SHP-1 CKO and Ctrl were analyzed by flow cytometry (FCM).
Results: Masson’s trichrome and Sirius Red staining showed that the area of 
renal fibrosis was significantly increased in SHP-1 CKO compared to Ctrl. The 
immunohistochemical analysis revealed marked expression of vimentin and moderate 
expression of α-SMA in tubulointerstitial area of SHP-1 CKO. Intracellular FCM staining 
revealed majority of vimentin as well as α-SMA positive-cells were CD11c+F4/80+ 
double-positive rMoPh in SHP-1 CKO. A small number of CD45-, non-hematopoietic 
cells, were positive for vimentin or α-SMA, but not significantly different compared to 
Ctrl. To confirm the efficacy of depletion of SHP-1, we examined the SHP-1 expression in 
rMoPh by intracellular FCM staining. About 70% of CD11c+F4/80+ rMoPh did not express 
SHP-1. These results suggested that SHP-1 depletion in CD11c+F4/80+ rMoPh led to the 
upregulation of vimentin and α-SMA, and directly caused renal fibrosis.
Conclusions: Depletion of SHP-1 in CD11c+F4/80+ rMoPh induces renal 
tubulointerstitial nephritis and fibrosis with age. In addition, transformation of CD11c+F4/80+ 
rMoPh into myofibroblasts could be involved in underlying mechanisms of renal fibrosis.
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Endothelial Tie2 Deficiency Increases Capillary Rarefaction and 
Tubulointerstitial Fibrosis
Marie Jeansson. Uppsala University, Uppsala, Sweden.
Background: Renal tubulointerstitial fibrosis is predictive of progressive decline in 
kidney function, independent of underlying disease. It is characterized by an increase in 
aSMA+ fibroblasts, myofibroblasts, that produce collagen. We previously showed that 
loss of Angiopoietin-1 (Angpt1) in adult mice predisposes to fibrosis in wound healing, 
diabetic nephropathy, and the unilateral ureter obstruction (UUO) model. The tyrosine 
kinase receptor, Tie2, is expressed on endothelial cells and Angpt1 binding results in Tie2 
signaling that is pro-survival and anti-inflammatory. Here, we test the hypothesis that loss of 
Tie2 signaling in endothelial cells results in capillary defects leading to an increased fibrotic 
response in kidney fibrosis.
Methods: Tie2 floxed mice were crossed with tamoxifen inducible endothelial specific 
Cadh5-Cre and a reporter line expressing TdTomato upon Cre-activation. This line enables 
both an endothelial specific KO of Tie2 and an endothelial lineage tracer. To study the role 
of Tie2 signaling in renal fibrosis we utilized the unilateral ureter obstruction (UUO) model 
of kidney fibrosis. An additional line (Pdgfra-H2b-GFP) was crossed into the above line, 
resulting in a reporter of myofibroblasts.
Results: Endothelial specific KO of Tie2 resulted in an increase in fibrosis as seen by 
increased expression of aSMA and vimentin compared to WT mice 3 days after UUO. At 
the same time, there was significant increase in Kim1 and tubular ferroptosis, suggesting 
a more severe injury in ecTie2KO. Electron micrographs of peritubular capillaries 3 days 
after UUO showed significantly more loss of fenestrations in ecTie2KO mice. Investigation 
of blood vessels before fibrotic onset 1 day after UUO, revealed less perfused capillary area 
and increased hypoxia in Tie2 KO mice. Ongoing work is designed to investigate blood 
vessel function in the early fibrotic process and to estimate the endothelial-mesenchymal 
contribution after UUO in controls and Tie2 knockout mice, utilizing the lineage tag of 
endothelial cells and myofibroblast reporter.
Conclusions: Our results suggest that loss of Tie2 signaling destabilizes the endothelial 
cell and increases tubulointerstitial fibrosis. The mechanisms we are investigating are an 
early loss of endothelial cells due to endothelial-mesenchymal transition and/or apoptosis, 
resulting in less functional peritubular capillaries and more fibrosis.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Dose-Effect Response of Remote Ischemic Preconditioning for the 
Prevention of Hemodialysis-Induced Myocardial Stunning: Preliminary 
Results of a Randomized Controlled Trial
Fabio R. Salerno,1 Lisa Crowley,3 Jarrin D. Penny,2 Christopher W. McIntyre.1,2 
1Medical Biophysics, University of Western Ontario, London, ON, Canada; 
2London Health Sciences Centre, London, ON, Canada; 3Royal Stoke University 
Hospital, Stoke-on-Trent, United Kingdom.
Background: Myocardial stunning is a common complication of standard 
hemodialysis and is implicated in the high cardiovascular mortality of end-stage kidney 
disease patients. This is an interim analysis of a randomized controlled trial aimed at testing 
the effects of different doses of remote ischemic preconditioning (RIPC) for the prevention 
of hemodialysis-induced myocardial stunning.
Methods: Study patients underwent speckle-tracking echocardiography predialysis 
and at peak stress (15 minutes before the end) at each visit. Images were analyzed for 
longitudinal systolic strain and the number of new regional wall motion abnormalities 
(RWMAs) (> 30% reduction in longitudinal systolic strain at peak stress) was recorded. 
Patients were screened for myocardial stunning (>/= 2 RWMAs) before enrolment: so far, 
13 chronic hemodialysis patients showing evidence of hemodialysis-induced myocardial 
stunning were enrolled. Patients were followed-up for 4 weeks, once a week. They were 
randomized in a 1:1 ratio to receive either: predialysis Sham RIPC, Low-dose RIPC 
(2 RIPC cycles on visit 1), Standard RIPC (4 cycles on visit 1) or High-dose RIPC (4 cycles 
at each visit). Primary outcome was the reduction in RWMAs.
Results: See attached image.
Conclusions: These preliminary results show a trend towards a dose-effect response 
to RIPC: sham and low-dose RIPC failed at reducing hemodialysis-induced RWMAs, 
while standard and high-dose RIPC seem effective in preventing hemodialysis-induced 
myocardial stunning. These effects seem to last for at least 2 weeks after the delivery of the 
RIPC stimulus. We expect to confirm our hypotheses with further enrollments.
Funding: Government Support - Non-U.S.
Mean (+ Standard Deviation) RWMAs per group per visit. The RIPC stimulus was 
administered on visit 1 for the Sham, Low-dose and Standard groups and on visits 1 through 
4 for the High-dose. Differences were not statistically significant.
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Prescribing Patterns of Anticoagulants in Dialysis Patients with Incident 
Atrial Fibrillation in the United States Between 2012 and 2014
Katherine Garlo,1 Thomas Mavrakanas,1,3 Bridget A. Neville,3 David 
M. Charytan.2 1Renal Division Department of Internal Medicine, Brigham and
Women’s Hospital, Boston, MA; 2Brigham and Women’s Hospital/Harvard
Medical School, Brookline, MA; 3Brigham and Women’s Hospital, Boston, MA.
Background: Four direct acting oral anticoagulants are approved for stroke prevention 
in atrial fibrillation (AF) and offer advantages over warfarin. However, individuals with 
advanced kidney disease and dialysis were excluded from phase 3 trials and all agents are 
excreted by the kidney. Understanding longitudinal prescribing patterns of anticoagulation 
in dialysis patients is especially important as these agents become integrated into clinical 
care.
Methods: We used United States Data Renal System (USRDS) data to identify 
prevalent and incident dialysis patients with new onset atrial fibrillation occurring between 
Jan 1, 2012-December 31, 2014. Trends in use of apixaban, rivaroxaban, warfarin, or no 
anticoagulation were identified from Part D Medicare records. Subgroup analyses for 
demographics and comorbidities were also examined.
Results: Among 743,639 patients receiving maintenance dialysis (399,024 prevalent 
prior to Jan 1, 2012 and 344,615 incident patients from Jan 1, 2012 - Dec 31, 2014),85,032 
had a new diagnosis of AF or flutter after Jan 1, 2012. Upon exclusion for non-continuous 
part A, B, and D Medicare coverage, death within 30 days of AF diagnosis, and or valvular 
disease, 27,202 individuals were included in the final analysis (25,372 on hemodialysis and 
1,830 on peritoneal dialysis). Of these 6,717 (24.7%) were prescribed warfarin, 309 (1.1%) 
apixaban, 91 (0.3%) rivaroxaban, and 20,085 (73.8%) did not receive anticoagulation.
Conclusions: Results from this large observational study of 27,202 individuals on 
dialysis in the United States with AFshow that the majority did not receive anticoagulation 
(73.8%) between 2012-2014. Warfarin remains the most frequently prescribed anti-
coagulant (24.7%). Use of direct acting oral anti-coagulants remains infrequent with the 
majority receiving apixaban.
Funding: Private Foundation Support
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Association Between Body Mass Index and the Incidence of  
Cardiovascular Disease in Patients Undergoing Hemodialysis:  
Ten-Years Outcome of the Q-Cohort Study
Yasuhiro Kawai,1 Hiroto Hiyamuta,1 Shigeru Tanaka,2 Masatomo Taniguchi,3 
Kazuhiko Tsuruya,4 Toshiaki Nakano,1 Takanari Kitazono.1 1Kyushu University, 
Graduate School of Medical Sciences, Fukuoka City, Japan; 2Fukuoka Dental 
College, Fukuoka, Japan; 3Fukuoka Renal Clinic, Fukuoka, Japan; 4Nara 
Medical University, Kashihara, Japan.
Background: In hemodialysis (HD) patients, high body mass index (BMI) is 
paradoxically associated with better outcomes including a lower risk of cardiovascular and 
all-cause mortality (obesity paradox). However, the impact of BMI on the incidence of 
cardiovascular disease (CVD) [stroke, ischemic heart disease (IHD), or peripheral artery 
disease (PAD)] in patients undergoing hemodialysis remains unclear.
Methods: A total of 3,506 participants undergoing maintenance HD were followed up 
for 10 years. The primary outcome was the incidence of stroke, IHD, or PAD. The subjects 
were divided into 4 groups based on the quartile of the baseline BMI values (Q1, ≤19.1; 
Q2, 19.2–20.9; Q3, 21.0–22.6; Q4, ≥22.7 kg/m2). The association between BMI and the 
incidence of each CVD was examined using Cox proportional hazards model.
Results: During the follow-up period, 526 (15%), 456 (13%), and 257 (7.3%) patients 
experienced stroke, IHD, and PAD, respectively. The 10-year incidence rate of stroke 
was significantly higher with lower BMI, whereas incidence rates of IHD and PAD were 
significantly lower with lower BMI. Compared with the highest quartile of BMI (Q4), 
the multivariable-adjusted hazard ratios (95% confidence interval) for stroke were 1.45 
(1.13–1.85) in patients with Q1. Whereas, compared with the lowest quartile of BMI (Q1), 
the multivariable-adjusted hazard ratios (95% confidence intervals) for IHD and PAD were 
2.04 (1.54–2.72) and 1.76 (1.21–2.55) in patients with Q4, respectively.
Conclusions: Low BMI was associated with high risk of stroke, whereas high BMI 
was associated with high risk of IHD and PAD in patients undergoing HD. Our results 
suggest that the influence of BMI on the incidence of CVD may be different depending on 
the type of cardiovascular events.
Funding: Government Support - Non-U.S.
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Long-Term Trends in Oral Anticoagulant (OAC) Use in US Patients with 
ESRD on Hemodialysis (HD) and Atrial Fibrillation (AF)
Austin Hu,1 Jingbo Niu,1 Tara I. Chang,2 Wolfgang C. Winkelmayer.1 1Baylor 
College of Medicine, Houston, TX; 2Stanford University School of Medicine, 
Palo Alto, CA.
Background: OACs are recommended for most patients with AF to prevent 
thromboembolic complications. Low OAC use has been reported in patients with ESRD 
on HD and AF. We tested whether OAC practices in this population have changed during 
the decade, 2006-2015.
Methods: From the USRDS, 2006-2015, we selected subsequent 6-month interval 
cohorts of Medicare-insured HD patients diagnosed with AF in the current or preceding 
intervals. From Medicare Part D claims we identified any warfarin or direct-target OAC use 
in each interval. Study outcomes were the prevalence of any OAC use, or use of specific 
agents. We used repeated measures logistic regression and interrupted time series analysis 
to 1) determine whether OAC use increased during 2006-2015, and 2) whether this longer-
term trend changed after the approval of a labeled dose for apixaban in ESRD in Jan 2014.
Results: While the number of period-prevalent HD patients with AF increased from 
33,052 (Jan-Jun 2006) to 63,675 (Jul-Dec 2015), the proportion receiving any OAC 
remained remarkably stable during the decade, at ~25% (Figure). There was a slight 
increase starting in 2014, which was mostly attributable to increasing apixaban use, with 
>27% of patients receiving OAC in Jul-Dec 2015, and apixaban representing 13% of all
OAC use. Compared with Jul-Dec 2006, adjusted odds ratios were near unity throughout
time, with an aOR of 1.07 (CI, 1.04-1.09) for any OAC and 0.96 (CI, 0.93-0.98) for warfarin 
use for Jul-Dec 2015. Adjusted interrupted time series analyses failed to reject the null
hypothesis of a zero slope over the decade and did not identify a significant difference in 
level or slope for 2014-15 vs. 2006-2013, either.
Conclusions: The proportion of HD patients with AF receiving any OAC remained 
remarkably stable over the decade, at ~25%, with increasing substitution of warfarin by 
apixaban after 2014.
Funding: NIDDK Support
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Peripheral Vascular Calcification Score Is Better Than Abdominal Aortic 
Calcification Score of Plain Radiographs in Predicting Cardiovascular 
Mortality in Hemodialysis Patients
Min Mo, Jianyi Pan, Wei Zhang, Qingkun Zheng, Jinzhong Chen, Xianrui Dou. 
Shunde Hospital Southern Medical University, Foshan, China.
Background: Cardiovascular disease (CVD) is the major cause of death for dialysis 
patients. Vascular calcification (VC) serves as a key pathological factor resulting in the 
CVD. KDIGO advocates abdominal aortic calcification score (AACS) to evaluate VC. 
Meanwhile, some studies showed that the peripheral vascular calcification score (PVCS) 
could predict cardiovascular mortality. However, no studies compare two VC score systems 
in clinic. Thus, this study compared two VC score systems in predicting mortality of HD 
patients.
Methods: In this retrospective study with 243 HD patients, AACS and PVCS were 
measured from plain radiograph of lateral abdominal radiograph and pelvis and both hands 
radiographs, respectively.
Results: The prevalence of VC was 68.5% (167 patients), most patients showed AAC 
(63.7%). During the follow-up period of 24 (13,44) months, 65(26.6%) patients died. 
Among these died patients, 35 (53.8%) patients died of cardiovascular disease. The patients 
died showed higher AACS (5.0 (1.25,14.0) vs. 2.0 (0,6.75), P=0.001), PVCS (2.0(0,5) vs. 
0(0,2.0),P=0.000), and overall VC score (5 (0,16) vs. 1 (0,6), P=0.001) compared to alive 
patients. When ROC curve was used to predict all-cause mortality, for PVCS, the area 
under ROC curve (AUROC) was 0.695 with 57.4% of specificity and 71.8% of sensitivity 
(P=0.000). As for AACS, the AUROC was 0.666 with 62.9% of specificity and 61.7% of 
sensitivity (P=0.001). The AUROC for PVCS was 0.668 with 68.0% of specificity and 
62.5% of sensitivity (P=0.007), while the AUROC for AACS was 0.574 with 38.1% 
of specificity and 75.0% of sensitivity (P=0.239) when used to predict cardiovascular 
mortality. By the COX multivariate regression analysis (adjusted for age, gender, diabetes, 
period of dialysis, albumin, hypertension, cholesterol, phosphorus, calcium, intact-
parathyroid and Kt/V), the PVCS was independently associated with all-cause mortality and 
cardiovascular mortality (HR, 1.287;95%CI, 1.140-1.453, and HR, 1.272;95%CI,1.079-
1.499), respectively. However, AACS was only associated with all-cause mortality (HR, 
1.069; 95%CI, 1.008-1.133) but not cardiovascular mortality.
Conclusions: VC score is independently associated with mortality. The PVCS is a 
better parameter in predicting cardiovascular mortality as compared with AACS.
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Predictors of Change in Left Ventricular Mass in a Randomized Trial of 
Extended Hours Dialysis
Brendan Smyth,1,2 Christopher T. Chan,3 Rajesh Puranik,4 Nicholas A. Gray,5,6 
Janak R. de Zoysa,7,8 Anish Scaria,1 Martin P. Gallagher,1,9 Vlado Perkovic,1 
Meg J. Jardine.1,9 1The George Institute for Global Health, UNSW, Newtown, 
NSW, Australia; 2Sydney School of Public Health, University of Sydney, Sydney, 
NSW, Australia; 3Toronto General Hospital, Toronto, ON, Canada; 4Department 
of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 5Sunshine 
Coast University Hospital, Birtinya, QLD, Australia; 6Sunshine Coast Clinical 
School, University of Queensland, Birtinya, QLD, Australia; 7Waitemata 
District Health Board, AUCKLAND, New Zealand; 8Department of Medicine, 
University of Auckland, Auckland, New Zealand; 9Renal Unit, Concord 
Repatriation General Hospital, Sydney, NSW, Australia.
Background: Extended hours dialysis was not associated with a significant reduction 
in LVMI in the ACTIVE Dialysis trial. Other factors, such as changes in fluid status and 
biochemical parameters, may predict regression of LV hypertrophy. We aimed to determine 
predictors of change in left ventricular mass index (LVMI) in the ACTIVE Dialysis study.
Methods: In the ACTIVE Dialysis study patients randomised to extended and 
standard dialysis, received median 24 and 12 haemodialysis hours per week respectively, 
predominantly delivered as three sessions per week. Ninety-five participants underwent 
cardiac magnetic resonance imaging (MRI) at baseline and 12 months. Predictors of change 
in LVMI were examined by multivariable linear regression in an observational analysis.
Results: In the overall MRI cohort, the change from baseline to 12 months in LVMI was 
-6.7g (95% confidence interval (CI) -11.2, -2.2; P=0.004) with non-significant reductions 
in mean normalised sessional ultrafiltration rate -1.0mL/kg/hr (95%CI -2.2, 0.24; P=0.114) 
and weekly total ultrafiltration -0.8L (95%CI -0.3, 2.0; P=0.165) and a significant reduction 
in systolic blood pressure (BP) -5.4mmHg (95%CI -8.8, -2.0; P=0.002). Baseline LVMI
(P=0.003) was associated with improved LVMI in univariable analysis and this remained
significant in the multivariable analysis (P=0.046). A non-significant improvement in LVMI 
was observed with longer dialysis vintage (P=0.137). There were no significant associations 
between changes in ultrafiltration rates and volumes, systolic and diastolic blood pressure, 
phosphate, and parathyroid hormone and change in LVMI.
Conclusions: Higher baseline LVMI, but not improvements in volume control, blood 
pressure or biochemical parameters, predicts regression of left ventricular hypertrophy over 
12 months. Further study is warranted to identify predictors of change in this important 
treatment target.
Funding: Commercial Support - Baxter International, Government Support - Non-U.S.
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Association Between Bone-Derived Biomarkers and Aortic Arch 
Calcification in Maintenance Hemodialysis Patients
Kosaku Nitta. Tokyo Women’s Medical University, Shinjuku-ku, Japan.
Background: Aortic arch calcification (AoAC) is frequently detected in maintenance 
hemodialysis (MHD) patients and is associated with cardiovascular and all-cause mortality. 
We investigated the factors associated with AoAC and analyzed the relationship between 
bone-derived biomarkers and AoAC.
Methods: We enrolled 389 stable MHD patients. AoAC was assessed using chest-X ray 
examination. Demographic data was collected in addition to serum levels of biochemical 
and bone-derived biomarkers, including sclerostin and fibroblast growth factor 23 (FGF23).
Results: Two hundred sixteen patients (55.0%) had AoAC. Patients with AoAC score 
 4 were older, with a higher percentage being male, and exhibited lower serum levels 
of albumin and triglyceride. Serum FGF23 levels were inversely associated with AoAC 
severity, and FGF23was directly related to vascular calcification. Age, gender, and dialysis 
vintage were independent predictors of AoAC.
Conclusions: MHD patients have a high prevalence of AoAC. Levels of circulating 
FGF23 but not sclerostin were related to AoAC severity. Serum FGF23 levels were 
independently associated with AoAC.
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Lower Serum Magnesium (sMg) Is a Strong Predictor of Left Ventricular 
Hypertrophy (LVH) and Patterns of LV Remodeling in Patients with CKD 
Stage 5D
Periklis P. Kyriazis,1 Charalampos Kalogeropoulos,2 Ourania Tsotsorou,2 
Eleftheria-Kleio Dermitzaki,3 Ioannis E. Giannikouris,4 Dimitra Lygerou,3 
Apostolo Kokkalis,5 Dimitra Bacharaki,2 Dimitrios V. Vlahakos.2 1Internal 
Medicine, Baystate Medical Center/University of Massachusetts, Springfield, 
MA; 2Nephrology, Attikon University Hospital, Athens, Greece; 3Nephrology, 
University Hospital of Heraklion, Heraklion, Greece; 4Medifil SA Hemodialysis 
Center, Athens, Greece; 5Clinitest E.E Hemodialysis Center, Athens, Greece.
Background: To evaluate the prognostic role of sMg on LVH and cardiac geometry in 
patients with stage 5D CKD
Methods: The study included 127 patients with stage 5D CKD (69 on hemodialysis 
and 58 on peritoneal dialysis) and a mean age of 62±15 years. Echocardiographic LVH 
was defined by LV mass index (LVMI) > 95 g/m2 in women and > 115 g/m2 in men. Based 
on LVMI and relative wall thickness (RWT), four LV geometric patterns were defined: 
normal (normal LVMI and RWT), concentric remodeling (normal LVMI and increased 
RWT>0.42), eccentric LVH (increased LVMI and normal RWT) and concentric LVH 
(increased LVMI and RWT). sMg and serum Ca (sCa) values were defined as the mean of 
all predialysis measurements available during the preceding 3 months.
Results: Patients (n=81) with LVH as compared to patients with no LVH (n=46) 
were older in age (p <0.001), had lower sMg (p<0.001) and higher sCa (p<0.05), 
malnutrition-inflammation score (p<0.05), body mass index (p<0.001), pulse pressure 
(p<0.01), prevalence of diabetes (p<0.05), coronary artery disease (p<0.05) and peripheral 
vascular disease) (p<0.01). In a multivariate logistic regression analysis adjusted for all 
factors mentioned above, each increase of sMg by 1 mg/dl was associated with 91% 
(OR= 0.09, 95% CI: 0.024-0.36; p <0.001) lower odds of having LVH. In a forward stepwise 
multivariate model (R2= 0.271; p<0.001), sMg emerged a strong independent predictor of 
LVMI (p<0.01) explaining about 5.7% of its variance. The area under the ROC curve for 
predicting the development of LVH was 0.696 (p<0.001) and at an optimal sMg cutoff 
of 2.26 mg/dl the sensitivity and specificity of sMg in predicting the occurrence of LVH 
were 67.4 % and 66.7 %, respectively. Considering LV geometry, there was a progressive 
decrease in sMg from the normal group (2.38±0.38 mg/dl) to concentric remodeling group 
(2.37±0.40 mg/dl), eccentric (2.19±0.30 mg/dl) and then to concentric (2.08±0.36 mg/dl) 
group (p<0.01 for the trend).
Conclusions: A lower sMg is a major determinant of echocardiographic LVH. 
Prospective studies may determine whether therapeutic adjustments of sMg can prevent or 
reduce the risk of LVH in patients with stage 5D CKD
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Pre-Dialysis Serum Phosphorus and Intradialytic Hypotension
Patrick Reeves,1,2 Sushrut S. Waikar,1,2 Finnian R. McCausland.1,2 1Division of 
Renal Medicine, Brigham and Women’s Hospital, Boston, MA; 2Harvard 
Medical School, Boston, MA.
Background: Intradialytic hypotension (IDH) is a common complication of 
maintenance hemodialysis (HD) and is associated with excess morbidity and mortality. 
Higher serum phosphorus is associated with vascular calcification and adverse 
cardiovascular outcomes, however its association with the development of IDH is unclear. 
We hypothesized that higher pre-dialysis serum phosphorus is associated with a higher risk 
of IDH.
Methods: We performed a post-hoc analysis in 1825 participants (n=10,551 HD 
sessions) from the Hemodialysis (HEMO) Study, a multicenter randomized control trial 
examining standard or high dose dialysis and low-flux or high-flux membranes. Unadjusted 
and adjusted generalized linear models were fit to determine the association of pre-dialysis 
serum phosphorus with IDH (defined as any hypotensive event requiring an intervention). 
Serum phosphorus was examined as a continuous and categorical variable to assess for 
non-linear associations.
Results: Mean age of participants was 57.8 years (43.8% men, 37.4% white). Mean 
pre-dialysis serum phosphorus was 5.8 mg/dL; IDH occurred in 17.5% of HD sessions. 
In adjusted models (accounting for age, sex, race, comorbidities, flux group, Kt/V group, 
dialysis vintage, session length, ultrafiltration volume, access, pre-dialysis blood pressure, 
and pre-dialysis laboratory tests), higher pre-dialysis serum phosphorus (per 1 mg/dL) was 
associated with a higher risk of IDH (odds ratio (OR) 1.07; 95% confidence interval (CI) 
1.03-1.12). Participants in the highest (≥ 6.9 mg/dL) vs. lowest (≤ 4.5 mg/dL) quartile of 
pre-dialysis serum phosphorus had a 30% greater risk (OR 1.30; 95% CI 1.05-1.60) of IDH 
(Figure 1).
Conclusions: Higher pre-dialysis serum phosphorus is independently associated with 
higher risk of IDH, even after adjustment for variables associated with ‘compliance’. As HD 
may cause an acute decline in serum phosphorus, future studies to investigate the temporal 
association of changes in phosphorus and IDH should be performed.
Funding: Other NIH Support - T32DK007527-33
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U-EVE, a Method for Estimating the Extra-Cellular Fluid Volume with 
Serum Uric Acid Concentrations, Would Help to Find Latent Overhydra-
tion of Hemodialysis Patients
Takahito Ito,1 Takahiro Shinzato,2 Kazuhiko Shibata,3 Shigeru Nakai,4 
Takeshi Aoki.5 1Kataguilli Medical Center, Shibata, Japan; 2Daiko Medical
Engineering Research Institute, Nagoya-shi, Japan; 3Yokohama Minami Clinic, 
Yokohama, Japan; 4Fujita Health University School of Health Scieneces,
Toyoake, Aichi, Japan; 5Nagoya Municipal Industrial Research Institute,
Iwakura-shi, Aichi-ken, Japan.
Background: We have developed a new method to estimate the extra-cellular fluid 
volume after HD (ECVa) with serum uric acid (UA) concentrations at pre- and post-
hemodialysis (HD) sessions, which was named UA-assisted ECV Estimation (U-EVE). We 
studied the clinical value of U-EVE.
Methods: Among 108 Japanese outpatients undergoing HD in Kataguilli medical 
center, 79 patients maintaining stable blood flow and ultrafiltration rates on the day of blood 
sampling were studied. They had no cardiac events at least during the last twelve months. 
Plasma ANP concentrations and cardio-thorax ratios (CTR) of X-ray were measured after 
HD. ECVa was estimated by the U-EVE method as reported separately and was standardized 
by the body surface area (ECVa/BSA).
Results: ECVa/BSA values were significantly high in the patients with persistent 
atrial fibrillation. They, however, were unaffected by sex, diabetes, dialysis modality, and 
past events of myocardial infarction, pacemaker implantation, aortic valve replacement, 
percutaneous coronary intervention, and/or coronary artery bypass grafting. In univariate 
analysis, serum creatinine (Cr), ANP and Kt/V correlated with ECVa/BSA [R=-0.29133 
(P=0.0092), R=0.2624 (P=0.0195), and R=-0.254 (P=0.0236), respectively]. Age, HD 
vintage, CTR, hemoglobin, and BNP at the pre-HD session were not significant. When 
the subjects were categorized into four groups, ANP concentrations of Group III were 
significantly higher than those of Group I (Figure). The increase of ECVa/BSA during the 
last twelve months correlated with age (R=0.280, P=0.0162), Cr (R=-0.386, P=0.0007), and 
Alb (R=-0.265, P=0.023), which suggested that the increase of ECVa/BSA might reflect the 
progression of sarcopenia.
Conclusions: U-EVE/BSA would help to find potentially overhydrated HD patients.
Funding: Clinical Revenue Support
The study subjects were categorized into 4 groups according to CTR and ECVa/BSA. 
Statistical comparison was done by Tukey-Kramer analysis. The cut-off values of CTR and 
ECVa/BSA were 53.0% and 10.3 L/m2, respectively.
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A New Method to Estimate the Extra-Cellular Fluid Volume with Serum 
Uric Acid Concentrations at Pre- and Post-Hemodialysis
Takahito Ito,1 Takahiro Shinzato,2 Kazuhiko Shibata,3 Shigeru Nakai,4 
Takeshi Aoki.5 1Kataguilli Medical Center, Shibata, Japan; 2Daiko Medical 
Engineering Research Institute, Nagoya-shi, Japan; 3Yokohama Minami Clinic, 
Yokohama, Japan; 4Fujita Health University School of Health Scieneces, 
Toyoake, Aichi, Japan; 5Nagoya Municipal Industrial Research Institute, 
Iwakura-shi, Aichi-ken, Japan.
Background: Uric acid (UA) with a molecular weight of 168 Da is synthesized mainly 
in the liver and intestines as the end-product of purine metabolism, and is located throughout 
the body. We have found that we could approximate the extra-cellular fluid volume (ECV) 
with the amount of UA that was removed by hemodialysis (HD).
Methods: Our calculation is based on assumptions shown in the figure. The dialyzer 
mass transfer-area coefficient (KoA) and the physiologically-appropriate patient clearance 
time (tp) for UA were obtained in advance. In order to estimate ECV after HD (ECVa), 
clinical parameters required other than CUA at pre- and post-HD were height, treatment time 
of HD, blood flow rate of HD, dialysate flow rate of HD, surface area of dialysis membranes, 
hematocrit at pre-HD, body weight values at pre- and post-HD, CUN at pre- and post-HD, 
and CNa at pre- and post-HD. The ECAa values estimated by our method were compared 
with those which were measured by multi-frequency bioimpedance analysis (BIA).
Results: We named our new method UA-assisted ECV Estimation (U-EVE) and 
assembled it as a Microsoft EXCEL® file for practice. ECVa values by U-EVE correlated 
with those by BIA: R=0.456 (P=0.0100, N=31, age 62.3±11.4, BIA was done by MLT555N), 
R=0.578 (P=0.0190, N=16, age 65.5±9.3, by InBody S10), and R=0.616 (P<0.0001, N=49, 
age 59.6±11.3, by MLT50) in three independent measurements. The formulas used in our 
program will be explained step by step.
Conclusions: U-EVE is innovative yet easy to estimate ECVa of HD patients without 
special devices. Clinical significances of U-EVE need to be further verified.
Funding: Clinical Revenue Support
Major assumptions about our method. (1) Removed UA molecules come only from ECS, 
(2) UA and Na+ do not cross cell membrane during HD, (3) Water crosses cell membrane 
to maintain the ratio of CNa
+ of ECS to that of ICS, (4) CUA of ECS rebounds after HD
simply due to redistribution of UA from hypo-perfused space of ECS (arrowhead). ECS 
and ICS stand for extra-cellular and intra-cellular spaces, respectively. Black dots represent
UA molecules.
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Correlation of Intracellular Volume Calculated by Uric Acid Kinetic 
Modeling with Intracellular Volume Estimated by Bioimpedance Analysis
Shigeru Nakai,1 Takahito Ito,2 Kazuhiko Shibata,3 Takeshi Aoki,4 
Midori Hasegawa,5 Daijo Inaguma,5 Yukio Yuzawa,5 Takahiro Shinzato.6 1Fujita 
Health University School of Health Scieneces, Toyoake, Aichi, Japan; 2Kataguilli 
Medical Center, Shibata, Japan; 3Yokohama Minami Clinic, Yokohama, Japan; 
4Nagoya Municipal Industrial Research Institute, Iwakura-shi, Aichi-ken, 
Japan; 5Fujita Health University School of Medicine, Aichi, Japan; 6Daiko 
Medical Engineering Research Institute, Nagoya-shi, Japan.
Background: Previous studies indicate that uric acid is not transported through the 
cell membranes of erythrocytes during hemodialysis (HD). If uric acid is not transported 
through the cell membranes of not only erythrocytes, but also general body cells, the uric 
acid distribution volume is theoretically consistent with extracellular volume, and the 
difference between urea distribution volume and uric acid distribution volume is consistent 
with intracellular volume (ICV). We tentatively designated the difference between urea 
distribution volume and uric acid distribution volumeas kinetic modeling ICV (KM-ICV).
Methods: We calculated whole-body KM-ICV based on regular blood test results 
obtained at 49 occasions in 7 patients. Subsequently, we compared whole-body KM-
ICVandbioimpedance analysis (BIA)-ICV, which were measured after HD on the day the 
regular blood tests were performed and examined their correlation. Moreover, we examined 
the correlation between KM-ICVnormalized to body surface area (normalized KM-ICV) 
andserum albumin level, and between normalizedKM-ICVandserum creatinine level.
Results: A significant difference was found between whole-bodyKM-ICV andBIA-
ICV(17.30 ±4.30 ml/m2and 15.88 ±2.43 ml/m2[mean ±s.d.], respectively; p = 0.002). 
Moreover, a significant correlation was observed between whole-bodyKM-ICV(x) and 
BIA-ICV (y) (y = 0.402x + 8.931, r = 0.711, p = 0.0001). A significant correlation was 
found between normalizedKM-ICV(x) and serum albumin level(y) (y = 0.0324x + 3.072, 
r = 0.463, p = 0.0008). However, no correlation was found betweennormalizedKM-ICV 
and serum creatinine level.
Conclusions: NormalizedKM-ICV can be used as an alternative nutritional index.
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Inflammation Is an Amplifier of Lung Congestion by High LV Filling 
Pressure in Hemodialysis Patients: A Longitudinal Study
Claudia Torino. on behalf of the LUST study working group* Institute of 
Clinical Physiology, National Research Council, Reggio Calabria, Italy.
Background: Lung congestion is exceedingly common in symptomatic and 
asymptomatic hemodialysis (HD) patients. Since inflammation alters vascular permeability, 
including vascular permeability in the lung, we hypothesized that it can be an amplifier of 
lung congestion in HD patients.
Methods: We investigated the effect modification by systemic inflammation as 
measured by serum C Reactive Protein (CRP) on the longitudinal relationship between 
a surrogate of the filling pressure of the LV [left atrial volume (LAV)] and lung water in 
a series of 273 patients participating into the LUng congeSTion in hemodialysis patients 
trial (LUST). Lung water was quantified by the number of ultrasound B lines (US-B) 
registered over the thorax. Paired lung-US and LAV (Echo-CG) recordings were performed 
at baseline, 6, 2 and 24 months. Overall, 407 simultaneous US-Echo-C estimates were 
obtained during follow up. Data analysis was made by the mixed Linear Model.
Results: Ninety-two patients had mild to moderate lung congestion (5-30 B lines) and 
33 severe congestion (>30 B lines). The median LAV was 73 ml (Inter Quartile Range 53-
105). The longitudinal series of US-B lines associated with simultaneous estimates of LAV 
in analyses adjusting for age, gender, dialysis vintage, SBP, diabetes, smoking, cholesterol, 
calcium (P=0.001). Effect modification analysis by CRP showed that this biomarker of 
inflammation was a strong modifier of the LAV- US B lines relationship both in unadjusted 
and adjusted analyses (P<0.001) so that at an identical increase in LAV the number of US-B 
lines was higher in more severely inflamed than in patients with less severe inflammation.
Conclusions: These data extend to the lung the detrimental effects of inflammation 
in HD patients and suggest that, at comparable LV filling pressure levels, patients with 
more severe degrees of inflammation are exposed to higher risk for pulmonary edema 
than those with no or mild systemic inflammation. *Mallamaci F, Gargani L, Sicari R, 
Letachowicz K, Ekart R, Fliser D, Covic A, Siamopoulos K, Stavroulopoulos A, Massy 
ZA, Fiaccadori E, Caiazza A, Bachelet T, Slotki I, Martinez-Castelao A, Coudert-
Krier MJ, Rossignol P, Gueler F, Hannedouche T, Wiecek A, Sarafidis P, Klinger M, 
Hojs R, Seiler-Mussler S, Lizzi F, Siriopol D, Balafa O, Shavit L, Loutradis C, Tripepi 
R, Tripepi G, Picano E, London GM, Zoccali C.
Funding: Private Foundation Support
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Long-Term Course of Peri-Dialytic Blood Pressures in Hemodialysis and 
Online Post-Dilution Hemodiafiltration Patients
Paul A. Rootjes,1 Camiel L. de Roij van Zuijdewijn,2 Peter J. Blankestijn,3 
Bernard J. Canaud,4 Andrew Davenport,5 Frans J. van Ittersum,6 Muriel 
P. Grooteman,1 Francisco Maduell,7 Menso Nube.8 on behalf of the HDF Pooling
Project Investigators 1VU University Medical Center, Amsterdam, Netherlands; 
2VU University Medical Center, Amsterdam, Netherlands; 3University Medical
Center----, Utrecht, Netherlands; 4FMC Deutschland GmbH, Bad Homburg,
Germany; 5Royal Free Hospital, London, United Kingdom; 6VU University
Medical Center Amsterdam, Amsterdam, Netherlands; 7Hospital Clinic
Barcelona, Barcelona, Spain; 8VU Medical Center, Bergen, Netherlands.
Background: Data on the course of blood pressure (BP) changes over time in dialysis 
patients is scarce. We investigated the long-term course of the pre-dialytical and post-
dialytical (peri-dialytical) systolic BP (SBP), diastolic BP (DBP), mean arterial pressure 
(MAP) and pulse pressure (PP), as well as the difference between these values (delta) in 
patients from 3 randomized controlled trials comparing conventional hemodialysis (HD) 
with online post-dilution hemodiafiltration (HDF).
Methods: Individual participant data (IPD) were pooled from the Estudio de 
Supervivencia de Hemodiafiltración (ESHOL, n=906), the Dutch Convective Transport 
Study (CONTRAST, n=714) and the French HDF study (Frenchie, n=391). Due to 
censoring only 1613 (80%) of the included 2011 patients had complete follow-up. After 
additional data were obtained, 2006 (99,8%) were available for the present IPD meta-
analysis (Peters SAE et al. Nephrol Dial Transplant 2016 31 978). BP measurements were 
available every three months. Two-years changes were assessed with linear mixed models.
Results: Mean pre-dialytic SBP decreased by 0.09 mmHg/month (P<0.001) and 
post-dialytic SBP by 0.07 mmHg/month (P=0.005). Mean pre-dialytic DBP decreased by 
0.12 mmHg/month (P<0.001) and post-dialytic DBP by 0.13 mmHg/month (P<0.001). 
Mean pre-dialytic MAP decreased by 0.11mmHg/month (P<0.001) and post-dialytic MAP 
by 0.11 mmHg (P<0.001). Mean pre-dialytic PP increased by 0.02 mmHg/month (P=0.064) 
and post-dialytic PP increased by 0.06 mmHg/month (P=0.004). The mean delta SBP, 
DBP, MAP and PP did not change significantly over time. None of the above mentioned 
parameters differed significantly between HD and HDF patients.
Conclusions: This is the first report comparing the longitudinal course of the peri-
dialytical SBP, DBP, MAP and PP between HD and HDF patients. While both pre- and 
post-dialysis mean SBP, DBP and MAP decreased significantly over time and PP increased, 
differences between HD and HDF patients were not observed.
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The Course of Peri-Dialytic Blood Pressure over Time in Online 
Post-Dilution Hemodiafiltration Is Not Influenced by the Magnitude of the 
Convection Volume
Paul A. Rootjes,1 Camiel L. de Roij van Zuijdewijn,1 Peter J. Blankestijn,2 
Bernard J. Canaud,3 Andrew Davenport,4 Frans J. van Ittersum,7 
Muriel P. Grooteman,1 Francisco Maduell,5 Menso Nube.6 on behalf of the HDF 
Pooling Project Investigators. 1VU University Medical Center, Amsterdam, 
Netherlands; 2University Medical Center----, Utrecht, Netherlands; 3FMC 
Deutschland GmbH, Bad Homburg, Germany; 4Royal Free Hospital, London, 
United Kingdom; 5Hospital Clinic Barcelona, Barcelona, Spain; 6VU Medical 
Center, Bergen, Netherlands; 7VU University Medical Center Amsterdam, 
Amsterdam, Netherlands.
Background: Online post-dilution hemodiafiltration (HDF) is associated with a lower 
mortality rate than conventional hemodialysis (HD). The mechanism(s) behind this effect is 
(are) unknown. In a previous analysis on chronic HD and HDF patients we showed first, that 
pre- and post-dialytical (peri-dialytic) systolic blood pressure (SBP), diastolic BP (DBP) 
and mean arterial pressure (MAP) declined over time, while pulse pressure (PP) increased. 
Second, differences between HD and HDF patients were not observed. Since the beneficial 
effect of HDF is highly dependent on the magnitude of the convection volume (CV), in the 
present analysis we investigated whether different CVs have a dissimilar influence on the 
course of peri-dialytic BP over time.
Methods: We used the pooled individual participant data (IPD) from the Spanish 
Estudio de Supervivencia de Hemodiafiltración (ESHOL, n=906), the Dutch Convective 
Transport Study (CONTRAST, n=714) and the French HDF study (Frenchie, n=391) 
(Peters SAE et al. Nephrol Dial Transplant 2016 31 978). The CV was divided in quartiles 
(<20L, 20-23L, 23-26L and >26L). Hereafter, we investigated whether the change in BP 
over time was different for these quartiles by using an interaction term (convection volume 
* time) in linear mixed models.
Results: The longitudinal courses of the pre- and post-dialysis SBP, DBP, MAP and PP 
were similar in the CV quartiles (P >0.05 for all interaction terms). The difference between 
pre- and post-dialysis values (delta) was also similar in all 4 categories.
Conclusions: The course of the peri-dialytical and delta SBP, DBP, MAP and PP 
over time in HDF patients is not related to the magnitude of the CV. Therefore, the lower 
mortality rate in HDF patients may not depend on a superior peri-dialytic BP regulation.
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Personalized Ultrafiltration Profile Design Using Crit-Line
Rammah M. Abohtyra,2 Joseph Horowitz,2 Christopher V. Hollot,2 
Michael J. Germain,1 Yossi Chait.2 1Renal and Transplant Assoc of New England, 
Hampden, MA; 2University of Massachusetts, Amherst, MA.
Background: Intradialytic hypotension (IDH) occurs in as many as 25%-50% of 
patients during fluid removal by ultrafiltration. We recently presented a novel approach for 
the design of personalized ultrafiltration rate (UFR) profiles. Our aim was to integrate this 
design with a parameter estimation algorithm for a patient’s fluid volume dynamics during 
hemodialysis (HD) from Crit-Line hematocrit (HCT) measurements.
Methods: We used a validated fluid volume model during HD comprising intravascular 
and interstitial pools, microvascular refilling/filtration, and lymphatic flow. We used several 
20-min segments of UFR and HCT (Fig. 2) data from an actual HD treatment (3.5L removed 
in 227 min) and advanced algorithms to estimate key model parameters: plasma volume,
interstitial volume, red blood cell volume, and filtration coefficient. Based on the estimated 
parameter ranges (Fig. 1), a personalized UFR profile was designed to minimize max UFR 
level, maintain HCT below a critical HCT profile, and achieve same UF goal.
Results: The estimated model parameters in five segments of an HD treatment are 
consistent with expected physiological changes during HD (Fig. 1 left/bottom). These 
parameter ranges were used to design personalized UFR profile (right/top). Simulations of 
the fluid volume model with the designed UFR profile over the estimated range of model 
parameters confirmed expected outcomes: similar UF goal achieved with 17% lower max 
UFR and lower HCT increases (right/bottom).
Conclusions: The successful estimation of fluid volume model parameters during 
HD supports the design of personalized UFR profiles that could lead to reduction in the 
incidence of IDH events.
Funding: NIDDK Support
Fig. 1: Estimated model parameters
Fig. 2: Actual vs Designed UFR HCT dynamics
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Time-Integrated Fluid Load (TIFL) Predicts Left Ventricular Mass 
(LVM) reduction: Results from the Frequent Hemodialysis Network 
(FHN) Daily Trial
Jochen G. Raimann,1 Christopher T. Chan,2 John T. Daugirdas,3 Thomas 
A. Depner,4 Brett Larive,5 Gerald J. Beck,10 Tom Greene,6 George A. Kaysen,4
Alan S. Kliger,7 Peter Kotanko,1 Robert M. Lindsay,11 Michael V. Rocco,8
Nathan W. Levin,1 The FHN Trial Group.9 1Renal Research Institute, New York, 
NY; 2Toronto General Hospital, Toronto, ON, Canada; 3University of Illinois
College of Medicine, Chicago, IL; 4University of California Davis, Sacramento, 
CA; 5Cleveland Clinic, Cleveland, OH; 6University of Utah, Salt Lake City, UT; 
7Yale New Haven Health System, New Haven, CT; 8Wake Forest School of
Medicine, Winston-Salem, NC; 9NIDDK, NIH, Bethesda, MD; 10Cleveland 
Clinic Foundation, Cleveland, OH; 11London Health Sciences Centre, London,
ON, Canada.
Background: Serum sodium concentrations (SNa) less than 138 mEq/L act as effect 
modifiers to LVM reduction with increased hemodialysis (HD) frequency. Greater time-
integrated fluid overload TIFL (incorporating interdialytic period length and increased fluid 
intake after Na-positive gradient HD) associates with LVM reduction (FHN Trial Group). 
We tested the interaction between the treatment effect of increased HD frequency on TIFL 
and change in LVM in the Daily Trial and evaluated, in the light of the “sick-cell” syndrome 
as a possible cause of low SNa, predictors of low SNa.
Methods: Treatment effects on LVM were analyzed in subgroups of subjects with a 
TIFL of ≤3 and >3 L*day. In a second step the interaction of the treatment effect with 
TIFL was tested using a mixed model. We measured CRP, Pentraxin, ICAM, IL-6 and -10, 
MCP-1, pre-albumin, TNF-Alpha, MPO at baseline of the FHN Daily Trial and compared 
between SNa greater or less than 138 mEq/L. Data presented as means and 95% CI.
Results: More frequent daily HD associated with a significant treatment effect on 
LVM when baseline TIFL was >3 L*day. The treatment effect on LVM showed a borderline 
significant interaction with TIFL [-5.8 (-15.0 to 3.5) g]. Significantly higher baseline CRP, 
IL-6, MPO, pre-albumin and pentraxin were found in the low SNa group, the intervention 
had no effect on inflammatory biomarkers.
Conclusions: Low SNa leads to increases in thirst and fluid intake, increasing TIFL 
and LVM. Decrease of TIFL by higher HD frequency, results in greater LVM reduction. A 
positive association between low SNa and inflammatory markers suggests inflammation to 
cause low SNa level and inflamed patients may benefit most from increased HD frequency.
Funding: NIDDK Support
LVM reduction [in g] as per TIFL
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Assessment of Plasma Refilling Rate in Dialysis Patients Using Plasma 
Body Weight Index Can Predict Intradialytic Hypotension
Tadashi Otsuka,1,2 Yoshikatsu Kaneko,2 Ryohei Kaseda,2 Suguru Yamamoto,2 
Valentina Kon,1 Ichiei Narita.2 1Vanderbilt University, Nashville, TN; 2Niigata 
University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background: Intradialytic hypotension (IDH) is a major risk factor for mortality in 
hemodialysis (HD). IDH often occurs when plasma fluid removal outpaces plasma refilling 
rate (PRR) from the interstitial space. Increasing dry weight (DW) can easily increase PRR, 
but it can precipitate congestive heart failure (CHF). Plasma body weight index (PWI), 
calculated from plasma total protein (TP) concentration and body weight before and after 
HD, has been proposed as a convenient surrogate marker, which inversely correlates to 
PRR. Our aim was to determine if PWI can predict IDH, and if a combination with hANP 
can be used as a clinical index to determine relevant DW.
Methods: This study retrospectively examined records of 156 dialysis patients from 
December 30, 2015, to January 5, 2016 in Tachikawa Medical Hospital. IDH was defined 
by current KDOQI guidelines [a decrease in either systolic BP (SBP) ≥20 mmHg or mean 
arterial pressure≥10 mmHg as well as associated symptoms]. CHF was defined as patients 
with dyspnea and low SpO2 level (<96%). PWI was calcurated by using this formula: PWI 
= [(post TP - pre TP)*100/post TP]/[(pre body weight - post body weight)*100/pre body 
weight].
Results: IDH and CHF occurred in 28.2% and 7.7% of all patients, respectively. 
Patients with IDH had higher PWI levels than those without IDH (1.71±1.40 vs. 2.65±1.70, 
P = 0.007). PWI > 2.0 was predictive of high incidence of IDH (OR = 2.40, 95%CI, 
1.12-5.12, P = 0.020), but was not associated with incidence of CHF (OR 1.00, 95%CI, 
0.30-3.30, P = 1.000). On the other hand, hANP >100 pg/ml was predictive of high incidence 
of CHF (OR 3.52, 95%CI, 1.06- 11.71, P = 0.004), but not associated with incidence of IDH 
(OR 0.79, 95%CI, 0.37-1.71, P = 0.5504). Subdividing the patients into 4 groups by the two 
cut-off points of PWI and hANP revealed that in the cohort of PWI < 2.0/hANP < 100 pg/ml, 
there was no incidence of CHF and incidence of IDH was low (13.7%).
Conclusions: PWI is a useful marker to predict IDH. Evaluating hydration status by 
combining PWI and hANP ia a useful parameter to estimate DW.
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Associations between PWI and IDH and CHF
OR, odds ratio; 95% CI, 95% confidence interval.
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Agreement Between Spectra Hemoglobin and Crit-Line® Monitor 
Estimated Hemoglobin
Mirell Tapia, Hanjie Zhang, Xia Tao, Stephan Thijssen, Peter Kotanko. Renal 
Research Institute, New York City, NY.
Background: Monitoring hemoglobin (Hgb) in hemodialysis is key in anemia 
management. Due to hemodilution, Hgb by Crit-Line® monitor (HgbCritLine) underestimates 
the pre-dialysis values measured by Spectra (HgbSpectra). An equation that considers blood 
volume, ultrafiltration rate, and saline dissipations can correct Hgb measured by Crit-
Line (HgbCritLinecorrected). The aim of this study was to explore the concordance between the 
HgbSpectra and Hgb
CritLine
corrected.
Methods: Pre-dialysis Hgb was measured by Spectra East, Inc. (Rockleigh, NJ, 
USA). ΔHgb (HgbSpectra- HgbCritLine) and Hgb
CritLine
corrected were estimated mathematically. 
The difference between HgbCritLinecorrected and HgbSpectra was denominated Hgboffset. HgbCritLine 
was determined by averaging the measurements between 0-2 minutes after the beginning 
of Crit-Line recording. Pre-dialysis blood volume was derived using anthropometric 
equations, then back-calculating the start of dialysis absolute blood volume based on the 
change in relative blood volume over the course of the treatment as measured by the Crit-
Line® monitor and subtracting the saline infused (Vsaline= 250ml). Saline’s half-life was 
considered of 20min.
Results: 5731 hemodialysis treatments from 952 patients with HgbSpectra and estimated 
HgbCritLinecorrected measurements were analyzed. Hgboffset average was –0.068g/dL, the 
standard deviation 0.59g/dL, and the bias -0.07g/dL. To asses the comparability between 
HgbCritLinecorrected and HgbSpectra measurements, the Hgboffset was plotted against the mean of the 
two measurements in a Bland-Altman plot.
Conclusions: With Crit-Line Hgb correction for hemodilution, the HbgCritLine values 
are on average identical to the HgbSpectra and they share similar accuracy. This could be an 
opportunity in the future to replace Hgb laboratory measurements in the management of 
anemia.
Funding: Commercial Support - Fresenius Medical Care. Renal Research Institute
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Intradialytic Exercise Preconditioning: The Effect on Myocardial 
Stunning
Jarrin D. Penny,2,1 Fabio R. Salerno,2,1 Ranveer S. Brar,4 Eric Garcia,3 
Krista F. Rossum,3 Christopher W. McIntyre,2,1 Clara Bohm.3 1Nephrology, 
London Health Sciences Centre, London, ON, Canada; 2The Lilibeth Caberto 
Kidney Clinical Research unit, University of Western Ontario, London, ON, 
Canada; 3University of Manitoba, Winnipeg, MB, Canada; 4Seven Oaks General 
Hospital, Winnipeg, MB, Canada.
Background: Exercise preconditioning provides immediate protection against cardiac 
ischemia in clinical and pre-clinical studies. Intradialytic exercise (IDE) has been utilized to 
improve functional status in individuals receiving HD. The effect of intradialytic exercise 
on myocardial stunning is unknown.
Methods: 19 adult patients participating in a clinical IDE program were evaluated over 
2 HD sessions (control visit - no exercise, exposure visit - exercise). Echocardiography 
was performed, pre-HD, post exercise and at peak HD stress in each visit. Longitudinal 
strain (LS) for 12 left ventricular segments were generated using speckle-tracking software 
[EchoPac, GE], to assess the presence of HD-induced regional wall motion abnormalities 
(RWMA), indicative of myocardial stunning (>20% reduction in LS in two or more 
segments).
Results: Mean age was 59.2 and participants were 40% female with median dialysis 
vintage of 3.8 years. The number of stunned segments at usual exercise time was 4.5 
(SD2.6) and 3.9 (SD2.8) in the control and exercise groups, respectively; p=0.168. The 
number of stunned segments at peak HD stress was 5.8 (SD2.7) and 4.0 (SD 1.8) in the 
control and exposed groups, respectively; p=0.012. Mean change in number of stunned 
segments post exercise between control and exposure sessions was -0.95 (SD 2.88). Mean 
change in number of stunned segments at peak HD was -1.8 (SD 2.8).
Conclusions: IDE significantly reduced HD-induced myocardial stunning at peak HD 
stress and was not associated with a reduction in intradialytic hypotension.
Number of RWMA at each echo timepoint(BL = baseline, TE = time of exercise, PS = 
peak stress)
Mean blood pressures
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The Effects of Intradialytic Exercise on the Improvement of Daily Physical 
Activity in Online Hemodiafiltration Patients
Nawaporn Assawasaksakul,1 Khajohn Tiranathanagul,5 Worawan Sirichana,4 
Onanong Kulaputana,3 Somchai Eiam-Ong,2 Kearkiat Praditpornsilpa.2 
1Chulalongkorn university, Bangkok, Thailand; 2Chulalongkorn University, 
Bangkok, Thailand; 3chulalongkorn university, Bangkok, Thailand; 
4chulalongkorn, Bangkok, Thailand; 5Chulalongkorn University and King 
Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: The mortality of hemodialysis (HD) patients treated with the novel 
online hemodiafiltration (OL-HDF) is better than conventional HD but is still higher than 
the healthy population. A low level of daily physical activity, associated with sarcopenia, 
uremic toxins, and functional impairment correlates with increased cardiovascular mortality. 
The effect of adding the intradialytic exercise program to improve daily physical activity 
and overall health status in patients particularly with online hemodiafiltration technique has 
yet to be explored.
Methods: Twelve OL-HDF treated patients (age 53.1±14.5 years, BMI 23.23 ± 5.5 kg/m2) 
were randomly assigned to control or adding intradialytic exercise (IDX) group. The 
subjects in IDX group were trained with the customized exercise program to exercise, 
initiated by a multidisciplinary team, on a cycle ergometer (Figure 1) within the first hour 
of OL-HDF. Physical activity was measured in terms of the number of daily steps counted 
by a wrist-worn wearable triaxial accelerometer (Fitbit flex2®). The muscle mass and 
biochemical parameters were measured and compared at baseline and 6 months.
Results: The baseline physical activities measured by daily step count were 5,945±3715 
and 6525±5389 steps (NS) in IDX and control groups, respectively. At 6 months, 
improvement of physical activity level in IDX group was greater than that in the control 
group (+1956.2 ± 2164.18 vs. -1302.92 ± 1956.03 steps, P = 0.021). The muscle mass 
changes were slightly higher, though non-significant, in IDX group [0.59 (IQR -0.58, 1.46) 
vs. -1.49 (-2.14, 0.28) kg., P=0.200]. Hemoglobin (+1.0 (-0.1,2.7) vs. -1.4 (-3.4,0.2) g/dL, 
P= 0.025) and albumin (+0.30(0.08, 0.50) vs. -0.15(-0.28, 0.05) g/dL, P=0.012) increased in 
IDX compared with the control group. The phosphate reduction was more favorable in IDX 
group (-1.95 (-2.80, -0.63) vs. -0.50 (-0.88,0.55), P=0.037).
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Conclusions: Intradialytic exercise training as the add-on program for OL-HDF 
patients could improve daily physical activity as well as muscle mass and other metabolic 
controls. The regular intradialytic exercise program may contribute to reverse inactive 
behaviors and further improvement in the quality of life and cardiovascular mortality of 
dialysis patients.
Funding: Government Support - Non-U.S.
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Pedometers and Exercise in Dialysis
Anoop Sheshadri,1 Piyawan Kittiskulnam,3 Kirsten L. Johansen.2 1Nephrology, 
University of California, San Francisco, San Francisco, CA; 2University of 
California, San Franicsco, San Francisco, CA; 3Chulalongkorn university, 
Bangkok, Thailand.
Background: Dialysis patients report very low levels of physical activity. We 
conducted a study using a pedometer based intervention to investigate whether it would 
result in increased physical activity and whether increasing activity could improve physical 
and endothelial function, heart rate variability (HRV), and symptom severity.
Methods: We conducted a randomized controlled trial of 60 patients receiving HD or 
PD. Patients were given a pedometer and instructed to record steps for one week. Patients 
were then randomized to either standard of care or a 12-week intervention program during 
which they were asked to record steps and given weekly activity goals. At baseline, 12 
weeks, and 24 weeks (3 months after the intervention), we assessed physical function (SF-
36 Physical Function scores, Short Physical Performance Battery), endothelial function 
(reactive hyperemia index with peripheral arterial tonometry), HRV, and symptoms 
(Dialysis Symptoms Index [DSI], KDQOL Vitality score).
Results: At 3 months, patients in the intervention increased average daily step count 
by 2,060 (95% CI 80; 4,060) compared to controls, though physical function, endothelial 
function, HRV, and symptoms did not change significantly. However, patients reverted to 
baseline levels of activity 3 months after the intervention. In post-hoc analyses increases in 
step count were associated with decreases in symptom burden (-0.38 symptoms on DSI per 
1,000 steps), symptom severity (-1.34 points on DSI score per 1,000 steps), fatigue (2.33 
points on KDQOL Vitality score per 1,000 steps), and increased HRV (2.29 ms SDNN per 
1,000 steps).
Conclusions: Dialysis patients can effectively use pedometers to increase physical 
activity but may need continued counselling in order to maintain increases. We found 
preliminary evidence that increasing step counts may also lead to improvements in 
symptoms and heart rate variability.
Funding: NIDDK Support
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The Acute Effects of Intra-Dialytic Exercise on Arterial and Central 
Venous Oxygen Saturation and Oxygen Extraction Ratio
Diana Aguirre,1 Daniel E. Ayala,1 Armando Vazquez Avila,1 Jesus Arellano,1 
Luis A. Mariscal,2,1 Victor H. Gomez,1 Israel Campos.2,1 1Hospital General “Dr. 
Miguel Silva”, Morelia, Mexico; 2NausLife Hemodialysis Clinics, Morelia, 
Michoacán, Mexico.
Background: Intra-dialytic exercise (IDE) improves cardiovascular function, physical 
function and quality of life. Arterial (SaO2) and central venous oxygen saturation (ScvO2) 
can be measured during hemodialysis (HD). The oxygen extraction ratio (OER) is the 
result from: SaO2-ScvO2/SaO2; its increment during HD has been associated with a higher 
mortality. The aim of this study was to explore the acute effects of IDE on SaO2, ScvO2 
and OER.
Methods: Crossover study in maintenance adult HD patients. The ScvO2 by gas 
analyzer and SaO2 by pulse-oximetry were measured at 0, 60, 120 and 180 minutes during 
one HD treatment without IDE, same measurements were repeated in one HD treatment 
with IDE. The SaO2, ScvO2 and OER were compared at each time point and between 
treatments.
Results: 11 patients (22 HD treatments) were analyzed. The ScvO2 and OER trend 
during HD with and without IDE are reported (Figure 1). The ScvO2 median (P25, P75) 
with vs without IDE at 60 and 120 min were 59(55, 62.5) vs 69(65, 73) p=0.005; and 
57(50.5, 64.5) vs 66(62, 69.5) p=0.04, respectively. OER median (P25, P75) with vs without 
IDE at 60 and 120 min were 0.39(0.36, 0.43) vs 0.28(0.22, 0.32) p=0.005, and 0.41(0.43, 
0.48) vs 0.33(0.25, 0.37) p=0.05, respectively, no differences were found in SaO2.
Conclusions: The ScvO2 decreases during HD, this decline is deeper during IDE 
compare to non-exercise treatments. OER increases during HD and is higher during IDE 
compare to non-exercise treatments. Further studies are required to elucidate the oxygen 
dynamics during intra-dialytic exercise.
SA-PO881 Poster Saturday
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Exercise During Dialysis Ameliorates the Decline in Plasma Volume by 
Ultrafiltration
Jose Manuel R. Chagolla,1 Monica Sanchez cardenas,3 Hector A. Perez-grovas.2 
Instituto nacional de cardiología “Ignacio Chávez” 1Nephrology, Instituto 
nacional de cardiología, México City, Mexico; 2Instituto Nacional de 
Cardiologia Ignacio Chavez, Mexico, Mexico; 3UNAM, CIUDAD DE MEXICO, 
Mexico.
Background: Patients in hemodialysis (HD) remove the excess of water and Na+ by 
ultrafiltration (UF) that leads to an increase of hypotensive (Ht) episodes by a decline in 
circulating blood volumen (CBV). Exercise (EXE) leads an increase of CBV by mechanisms 
like redistribution of CBV and sympathetic activation. We evaluate the effects of acute 
moderate aerobic EXE in CBV during UF in comparison with sessions without EXE.
Methods: 19 CKD patients in regular HD (11 women, Age 40±6) were randomized 
for one HD session with EXE by bicycle pedaling without resistance in sitting position (P) 
during all the session or sedentary HD session (one in sitting P, in recumbent P or recumbent 
P with elastic socks). All patients received the four different sessions with BVM in line 
during all the session with exactly the same UF rate. Besides blood pressure and heart rate 
were registered.
Results: We observed a lesser decline in CBV in the EXE HD session in comparison 
with sedentary HD. The difference were stadistically significant (p<0.001). In EXE HD we 
observed lesser Ht episodes (0 vs 13), and the fall in systolic and dyastolic pressure at the 
end of the session were lesser in EXE HD (-3 vs. 3.6 and -0.4 vs. 1.9 mmHg). Incidentally, 
it was observed that the effect of EXE during dialysis on the decline in CBV was clearer 
among males.
Conclusions: EXE during dialysis ameliorate the decline in plama volume by UF, 
especially in men.
Funding: Government Support - Non-U.S.
Clinical characteristics according to the intervention performed
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Low BMI Is Associated with Higher Risk of Frequent Intradialytic 
Hypertension
Maurilo Leite,1 Thays C. Pereira,1 Renata M. Rodrigues,1 Mahesh Krishnan.2 
1DaVita-Brazil, Rio De Janeiro, Brazil; 2DaVita, Inc, Denver, CO.
Background: Intradialytic hypertension (IDH) has been associated with high mortality 
and morbidity among hemodialysis (HD) patients. Factors such as fluid overload, dialysate 
sodium, clearance of anti-hypertensive drugs, and an endothelin effect have all been 
suggested to affect IDH. However, IDH has not been uniformly characterized: studies 
have defined IDH as a post-HD increase in systolic arterial pressure (SAP) occurring with 
differing monthly frequency. In this study we examined the associations between BMI and 
IDH ocurring with various monthly frequencies.
Methods: We followed 217 patients who were stable on HD for at least 90 days and 
evaluated the number of dialysis treatments affected by IDH (defined as pre- to post-HD 
increase in SAP of ≥ 10 mmHg, reaching values ≥ 140/90 mmHg) over 90 days. We 
assessed associations of IDH frequency (% of treatments affected) with patient gender, age, 
race, time on HD, as well as with hospitalizations and mortality over 6 months. Patients 
were stratified into 5 groups based on BMI (< 18.5, 18.5 to 24.9, 25 to 29.9, 30 to 35, 
and > 35 kg/m2); numbers of patients experiencing IDH in at least 5% or at least 50% of 
treatments were assessed for each BMI group. Statistical tests applied were Chi-square and 
Pearson correlation.
Results: We found no significant correlation between IDH frequency and patient 
gender, age, or race. However, we found a positive correlation between IDH frequency and 
time on dialysis (r=0.17, P<0.01). No association of IDH frequency with hospitalization or 
mortality was observed. 78% of patients with BMI < 35 kg/m2experienced IDH during at 
least 5% of treatments, compared with 100% of patients with BMI > 35 kg/m2. In contrast, 
the proportion of patients who had 50% or more of treatments affected by IDH was strongly 
associated with BMI < 18.5 kg/m2; RR: 3.2 (2.7-4.6).
Conclusions: Monthly frequency of IDH, observed over a period of 90 days in HD 
patients, was found to be slightly correlated with time on dialysis. Patients with BMI 
> 35 kg/m2 experienced at least 1 episode of IDH during follow-up; patients with BMI 
< 18.5 kg/m2 presented higher risk for IDH affecting ≥ 50% of HD sessions. Frequent IDH
may contribute to high cardiovascular mortality and morbidity in HD patients with longer 
time on dialysis and lower BMI.
Funding: Commercial Support - DaVita Inc
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Continuous Intra-Access Pressure (IAP) Monitoring Helps Predict 
Intradialytic Hypotension (IDH)
Gerard Zasuwa,1 Jeffrey J. Sands,3 Jerry Yee,2 Stanley Frinak.2 1Henry Ford 
Health System, Detoit, MI; 2Henry Ford Hospital, Detroit, MI; 3Vasc-Alert LLC, 
Orlando, FL.
Background: IDH is a frequent hemodialysis (HD) complication associated with 
increased patient morbidity and mortality. Reliable IDH prediction that facilitates early 
intervention may reduce HD morbidity. We conducted a preliminary study exploring the 
hypothesis that that continuous IAP measurement using the Vasc-AlertTMalgorithm (Am J 
Kidney Dis. 2002;40(4):760-768)can predict IDH during hemodialysis (HD).
Methods: FreseniusTMT2 dialysis machines (DM) were equipped with onboard 
computers and customized software to calculate IAP at 20-second intervals via Vasc-Alert. 
24 DMs were monitored during routine use during 3 daily shifts 6 days weekly. Treatment 
and relative blood volume data, collected by the CLiC™ device, was digitally acquired 
and stored. IDH episodes and measures to resolve them including repositioning, saline 
administration, and ultrafiltration rate adjustmentwere charted, abstracted, and mergedwith 
the electronic medical records. IAP waveform was correlated with IDH. Duration and rate 
of decline of IAPs from a moving average of 10 readings were analyzed.
Results: 1,272,290 DM data points were collected from 2,290 HD treatments. A total 
of 139 IDH events (6%) were recorded and analyzed, yielding an equation demonstrating 
a linear correlation between IDH and IAP slope:y= −1986x+ 1136.5;RSqr= 0.69). An 
IAP drop ≥20 mm Hg over 15 seconds correlated with impending BP decrements. A 
representative example is shown (figure) where IDH at 11:02 correlated with a BP reduction 
from 145/84 mm Hg to 113/69 mm Hg. Subsequent IDH episodes at 12:02 and 13:02 were 
associated with abrupt, significant IAP slope declines.
Conclusions: The IAP slope and prolonged IAP declines of 20 mm Hg or more 
correlate with IDH during HD. Future analysis of relative blood volume may facilitate 
development of a more powerfully predictive model of IDH.
Funding: Clinical Revenue Support
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Intra-Dialytic Hypotension and Risk of Intra-Dialytic Cardiac 
Arrhythmia
Finnian R. McCausland,1,2 Prabir Roy-Chaudhury,3 James A. Tumlin,5 
David M. Charytan.4 1Renal, Brigham and Women’s Hospital, Boston, MA; 
2Harvard Medical School, Boston, MA; 3University of Arizona, Tucson, AZ; 
4Brigham and Women’s Hospital/Harvard Medical School, Brookline, MA; 
5NephroNet Clinical Trials Consortium, Atlanta, GA.
Background: Patients with end-stage renal disease receiving hemodialysis (HD) are 
at high risk of adverse cardiac events, including arrhythmia and sudden cardiac death. 
Intra-dialytic hypotension (IDH) is a common complication of HD and is associated with 
development of reduced myocardial perfusion, but its association with cardiac arrhythmia 
is unclear.
Methods: The Monitoring in Dialysis (MiD) study used implantable loop recorders to 
detect and continuously record all electrocardiographic data from maintenance HD patients 
(n=66 from the United States and India) over a six-month period. Negative binomial mixed 
effects regression models were fit to determine the association of IDH (decline in SBP >20 
mmHg from pre-dialysis SBP) with the subsequent development of clinically significant 
arrhythmia (CSA) during the corresponding HD sessions.
Results: Average age was 56 years; 70% were male; and 65% were from the US. IDH 
occurred in 48% of 4,761 HD sessions, while 1.3% of total sessions were complicated 
by development of at least one intra-dialytic CSA. Participants who experienced IDH (vs. 
those with SBP decline ≤0mmHg) had a 9-fold greater rate of developing an intra-dialytic 
CSA (IRR 9.4; 95%CI 3.0-29.4).
Conclusions: IDH is common in maintenance HD patients and is associated with a 
greater risk of developing intra-dialytic CSA. Future studies investigating the effect of 
interventions to minimize IDH may wish to incorporate arrhythmia as a clinically relevant 
end-point.
Funding: NIDDK Support, Commercial Support - Medtronic
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Midodrine Is Effective in the Management of Intradialytic Hypotension 
Among Critically-Ill Patients with AKI (A Randomized Clinical Trial
Mahmoud H. Imam,1 Mohammed Shawki,1 Tareq Essawy.2 1Internal Medicine 
Department, Faculty of medicine,Benha University, Benha, Egypt; 2Chest 
medicine Department, Faculty of medicine,Benha University, Benha, Egypt.
Background: Intradialytic hypotension commonly occurs among critically ill patients. 
Different tools were exploited to mitigate IDH. Midodrine showed promising results in 
small interventional studies. There was no randomized clinical trial to assess the efficacy 
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of midodrine. This study aims to evaluate the effectiveness of midodrine in a randomized 
placebo-controlled study among critically ill patients.
Methods: Eighty intensive care unit patients were eligible for this study. After IDH 
episode, they were randomized to either midodrine tablets or placebo. The count of IDH 
episodes, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lowest 
blood pressure were recorded. Mortality and adverse effects were recorded for both groups. 
The duration of the study was 30 days.
Results: eventy-five patients completed the study. Midodrine significantly decreased 
the count of IDH episodes. Both SBP and DBP were significantly higher among midodrine 
group. There was a reduction in mortality with midodrine therapy; the reduction was 
statistically insignificant (p = 0.43). The drug was tolerable with no adverse effects.
Conclusions: Oral midodrine therapy yielded beneficial results and was an adequate 
tool for management of IDH among critically-ill patients with the AKI.
SA-PO886 Poster Saturday
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Midodrine in the Context of Intradialytic Hypotension: Association with 
Outcomes
Steven M. Brunelli,1,2 Dena E. Cohen,1,2 Gilbert Marlowe,1,2 David B. Van 
Wyck.2 1DaVita Clinical Research, Minneapolis, MN; 2DaVita Institute for 
Patient Safety, Denver, CO.
Background: Intradialytic hypotension (IDH) is a frequent complication of 
hemodialysis, and is associated with significant morbidity and mortality. Off-label use of 
the alpha-1 andrenergic receptor agonist midodrine to reduce the frequency and severity of 
IDH is common. Small-scale clinical trial data support this practice; however, limited data 
exist with regard to real-world efficacy.
Methods: In this retrospective, observational study, clinical and hemodynamic 
outcomes were compared among patients who began midodrine (N=1046) and controls 
(N=2037) to whom they were matched on the basis of baseline pre-dialysis blood 
pressure, nadir intra-dialytic blood pressure and the frequency of intradialytic hypotension, 
all of whom were adults receiving in-center hemodialysis in the United States (July 
2015-September 2016). All study data were derived from deidentified patient electronic 
health records. Outcomes were considered from the month following initiation of midodrine 
(or corresponding month for controls) until censoring for loss to follow-up or study end 
(30 September 2016). Outcomes were compared using adjusted Poisson or linear mixed 
models following intention-to-treat principles.
Results: Compared to non-use, midodrine use was associated with higher rates of 
death (adjusted incidence rate ratio 1.37, 95% confidence interval 1.15- 1.62), all-cause 
hospitalization (1.31, 1.19-1.43) and cardiovascular hospitalization (1.41, 1.17-1.71). With 
respect to hemodynamic outcomes, midodrine use tended to be associated with lower pre-
dialysis systolic blood pressure (SBP), lower nadir SBP, greater fall in SBP during dialysis, 
and a greater proportion of treatments affected by IDH.
Conclusions: Although residual confounding may have influenced results, the 
observed associations are not consistent with a potent protective effect of midodrine with 
respect to either clinical or hemodynamic outcomes.
Funding: Commercial Support - This was a research project conducted by the DaVita 
Institute for Patient Safety and supported by DaVita Kidney Care
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Time-Specific Effects of Patient Factors on Intradialytic Systolic Blood 
Pressure Changes in Patients Receiving Maintenance Hemodialysis
Sinae Lee,1 Seoung Woo Lee.2 1Division of Nephrology and Hypertension, 
Incheon Medical Center, Incheon, Republic of Korea; 2Division of Nephrology 
and Hypertension, Inha University Hospital, Inchon City, Republic of Korea.
Background: Intradialytic systolic blood pressure (SBP) changes are affected by 
patient factors. However, the specific time point at which these factors predominantly affect 
blood pressure during a hemodialysis (HD) session is unknown.
Methods: Laboratory and HD data from previous 1 year were collected for 97 patients 
who were receiving maintenance HD. The subjects were classified into 2 groups according 
to diabetes mellitus (DM) status, abdominal aortic calcification (AAC) score, and the median 
values of serum hemoglobin (Hb), sodium (Na), albumin (Alb), and osmolality (Osm): DM 
vs. non-DM, high AAC (≥8) vs. low AAC (<8), Hb1 (≥10.17 g/dL) vs. Hb2(<10.17 g/dL), 
Na1(≥136.5 mEq/L) vs. Na2(<136.5 mEq/L), Alb1(≥3.93 g/dL) vs. Alb2(<3.93 g/dL), 
Osm1(≥312 mOsm/kg) vs. Osm2(<312 mOsm/kg). SBP measurements were standardized 
as SBP at 0 (SBP0), 1 (SBP1), 2 (SBP2), 3 (SBP3), and 4 (SBP4) hours. Intradialytic SBP 
changes were assessed on the basis of hourly SBP changes (ΔSBP1: SBP0-SBP1, ΔSBP2: 
SBP1-SBP2, ΔSBP3: SBP2-SBP3, ΔSBP4: SBP3-SBP4). Linear mixed regression analysis 
was used to identify patient factors associated with ΔSBP1, ΔSBP2, ΔSBP3, and ΔSBP4, 
respectively.
Results: The subject characteristics were as follows: number of females, 45; number 
of subjects with DM, 49; mean age, 59±15 years; HD duration, 69±64 months; AAC 
score, 8.0±7.7 (median, 6.0); and number of subjects with high AAC (≥8), 42. ΔSBP1 was 
negatively associated with non-DM status (vs. DM) (β= -7.71, p=0.04), and positively 
associated with mean Hb level (β= 4.93, p=0.009). ΔSBP2 was positively associated with 
high AAC (β= 5.22, p=0.001). ΔSBP3 was positively associated with high AAC (β= 2.34, 
p=0.021), and negatively associated with mean albumin level (β= -4.19, p=0.044). ΔSBP4 
was positively associated with high AAC (β= 2.66, p=0.054), and negatively associated 
with mean Hb level (β= -2.90, p=0.008).
Conclusions: The effects of patient factors on intradialytic SBP changes during an HD 
session predominated at different time points and differed at an individual level.
SA-PO888 Poster Saturday
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Intradialytic Hypotension in Hospitalized Patients: Does the Definition 
Matter?
Etienne Macedo, Bethany E. Karl, Euyhyun Lee, Lea D. Jacinto, 
Ravindra L. Mehta. University of California San Diego Medical Center, La 
Jolla, CA.
Background: Intradialytic hypotension (IDH) is a frequent, occurring from 15 to 
50% of ambulatory sessions, and more frequent among hospitalized patients. Several 
complications can be associated with IDH: vascular access thrombosis, inadequate dialysis 
dose, fluid administration, early hemodialysis (HD) termination and mortality. Recently 
a large epidemiologic study, have shown that an absolute nadir systolic blood pressure 
(SBP)<90 mmHg was associated with mortality. However, several different definitions 
continue to be used in the literature and the clinical practice, preventing the appreciation of 
the effects of IDH and patient outcomes.
Methods: Patients from a prospective interventional study that included patients with 
albumin < 3 g/dl with AKI or ESRD who required fluid removal with HD were analyzed. 
Vital signs and ultrafiltration removal rate were recorded every 15 to 30 minutes during 
HD. The dialysis nurse recorded all symptoms associated with hypotension as well as 
interventions during the dialysis. We utilized 7 different classifications to determine 
hypotensive episodes.
Results: 65 patients completed 249 sessions; mean age was 58 (+/-12), 46 (70%) 
were male with a mean weight of 76 (+/-18) kg. Mean SBP and diastolic (DBP) at dialysis 
initiation were 126 (+/- 25) and 67.38 (+/-17), respectively. Presence of hypotension 
episode during a session varied from 12 (4.9%) to 111 (44%) according to the definition 
applied (Table). The HEMO definition, considering hypotension when an intervention 
results from an unspecific fall in BP, was more liberal, and occurred 50% more 
frequently than the KDOQI definition. Of the sessions with an absolute intradialytic nadir 
SBP<90 mmHg, only 30(56%) were followed by an intervention.
Conclusions: Intradialytic hypotension definitions that considered symptoms and 
interventions often miss episodes of hypotension that have been shown to be associated 
with increased mortality. Nadir based definitions of hypotension should trigger planned 
interventions and active questioning about symptoms, especially in hospitalized patients.
Funding: Commercial Support - Grifols
Intradialytic hypotension definition and frequency
SA-PO889 Poster Saturday
Dialysis: Cardiovascular, BP, Volume
Intradialytic Hemodynamics and Autonomic Activity in Patients Without 
and with Blood Pressure Instability
Dvora Rubinger, Michal Dranitzki Elhalel, Dan Sapoznikov. Hadassah Hebrew 
University Medical Center, Jerusalem, Israel.
Background: The present study was undertaken to assess the intradialytic 
hemodynamics and autonomic activity in patients (pts.) without (stable) and with frequent 
hypotensive episodes (unstable).
Methods: Beat-to-beat systolic blood pressure (SBP) and interbeat intervals (IBI) were 
monitored using Finometer during a single constant blood flow hemodialysis (HD) session 
in 14 unstable and 18 age-matched stable chronic non-diabetic HD pts. Stroke volume (SV), 
cardiac output (CO) and total peripheral resistance (TPR) were calculated using Modelflow 
simulation. LF/HF (the ratio of average IBI powers in the low (LF) and high (HF) frequency 
ranges) was considered to represent sympatho-vagal balance, whereas LF α (the ratio of 
IBI and SBP powers in the LF range) was considered to represent sympathetic activity. 
Positive correlation between IBI and SBP was considered representative of baroreflex 
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(Baro) activity. Repeated measures ANOVA was performed to assess time variations in 
both groups. Mixed design ANOVA was performed to assess differences in time variations 
between groups.
Results: During HD, SBP remained constant in both groups and there were no 
episodes of symptomatic hypotension. Comparable decreases in SV, CO and an increase 
in TPR were noted in all pts. LFα increased during HD in both stable and unstable groups. 
LF/HF increased in unstable and decreased in stable pts. Baro activity was predominant 
in the stable pts, in whom it consistently increased during HD, while in unstable pts. an 
increase in Baro activity was noted only at the beginning of dialysis (Figure 1).
Conclusions: Our data show that similar hemodynamic changes in stable and unstable 
pts are mediated by slightly different mechanisms. During HD, the sympatho-vagal 
balance is attenuated in stable and enhanced in unstable pts.SBP in stable seems to be 
predominantly controlled by Baro, while in unstable pts. SBP is controlled by both Baro 
and non-Baro mechanisms.
Figure 1.
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Blood Pressure Control and Days-in-Hospital Before and After Initiating 
Nocturnal In-Center Hemodialysis
Janice P. Lea,3,2 Courtney E. Hoge,1 Harold A. Franch,3,2 Laura Plantinga,2,1 
Adam S. Wilk.1 1Rollins School of Public Health, Emory University, Atlanta, 
GA; 2Emory University School of Medicine, Atlanta, GA; 3Emory Dialysis 
Centers, Atlanta, GA.
Background: Nocturnal dialysis (ND) can support longer sessions with lower 
ultrafiltration (UF) rates, compared to traditional in-center hemodialysis (HD). We 
compared UF rates, key blood pressure (BP) measures, and days hospitalized for ND 
patients before and after they initiated ND treatment.
Methods: We identified ND patients at a medium-sized dialysis organization to be 
those HD patients for whom ≥80% of dialysis sessions were ND sessions—starting at 
6:30pm or later and lasted ≥5 hours—over the 3 months after their first ND session (≥20 
sessions total) during 2010-16. Outpatient dialysis session and hospitalization dates were 
extracted for these patients within 12 months of ND transition (pre and post). BP measures 
included pre- and post-session sitting SBP and DBP, and minimum intradialytic SBP and 
DBP. Descriptive patient-month-level analyses of all outcomes were performed for all 
months with ≥7 sessions (i.e., still in care). We tested effects of ND care post-transition 
using generalized linear models with a Gaussian distribution and random intercepts and 
slopes; standard errors were clustered at the patient level.
Results: We identified 64 ND patients (4.7% of 1,357 eligible patients in care), with 
354 pre-transition patient-months (3,974 sessions) and 496 post-transition patient-months 
(5,841 sessions). Post- vs pre-transition, we observed significant declines in UF rates (5.16 
vs 9.34 mL/kg/hr, p<0.01), pre-SBP (154.1 vs 157.1 mmHg, p=0.05) and DBP (85.8 vs 
88.0 mmHg, p=0.02), post-SBP (138.1 vs 142.6 mmHg, p<0.01) and DBP (77.0 vs 80.2 
mmHg, p<0.01), and minimum intradialytic SBP (113.6 mmHg vs. 120.6 mmHg, p<0.01) 
and DBP (60.4 mmHg vs. 65.0 mmHg, p<0.01). We observed no change in hospitalized 
days per month (0.78 vs 0.82 days, p=0.80). Regression results accounting for patient-level 
clustering were similar, including a decline in UF rates (-3.57 mL/kg/hr, p<0.01) and no 
change in hospitalized days (-0.095 days, p=0.60) post-transition.
Conclusions: While patients experienced significant improvements in BP control both 
inter- and intradialytically after initiating ND treatment, we observed no change in their 
days hospitalized.
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Association Between Coronary Artery Calcification Density and Serum 
Magnesium Levels in Maintenance Hemodialysis (MHD) Patients
Yoshiko Nishizawa,1 Sonoo Mizuiri,1 Kyoka Ono,1 Kazuomi Yamashita,1 
Kenichiro Shigemoto,1 Takao Masaki.2 1Ichiyokai Harada Hospital, Hiroshima-
shi, Japan; 2Hiroshima University, Division of Nephrology, Hiroshima, Japan.
Background: Coronary artery calcification score (CACS) is determined by the plaque 
area and density. In general population, calcified plaques with lower density are associated 
with higher risk of incident cardiovascular events, but report on calcification density in 
hemodialysis patients was scanty. This study aimed to analyze the association between 
coronary artery calcification density (CACD) and clinical parameters in MHD patients.
Methods: Methods: The subjects were 289 Japanese MHD patients. Total calcified area 
(area), CACD, CACS, laboratory parameters, and medication use were studied at baseline. 
The subjects were stratified into CACD level tertiles (T1–T3) and assessed by Kruskal-
Wallis test. Regression analyses for CACD and CACS were examined, respectively. 
Independent variables were age, sex, diabetes, CVD, serum magnesium, phosphate, uric 
acid, C-reactive protein (CRP), low-density lipoprotein cholesterol (LDL-C) levels and use 
of proton pump inhibitors (PPI) or sevelamer hydrochloride. Spearman’s correlations of the 
area and CACS or CACD were also analyzed, respectively.
Results: Among all patients, the mean age was 65±13 years, 37.2% were diabetics, 
and the median dialysis vintage was 72±99 months. The values of CACD of T1 (n=96), 
T2 (n=96), and T3 (n=97), were 3.61<, 3.62-3.89, and >3.90, respectively. The patients 
in T3 exhibited significantly higher serum magnesium, serum CRP and LDL-C levels 
(P<0.05). Multivariate regression analysis for CACD showed that age, diabetes, CVD [β 
0.13, 95% confidence interval (CI) 0.00-0.12], and serum magnesium level [β 0.12, 95% CI 
(0.00-0.13)] were significantly related factors (P<0.05). While, multivariate regression 
analysis for CACS showed that age, diabetes, CVD [β 0.13, 95% CI 0.00-0.13], serum 
phosphate level [β 0.13, 95% CI (0.01-0.22)] were significantly related factors (P<0.05). 
CACS was correlated with total area (r = 013, P < 0.05), but the correlation between CACD 
and total area was not significant (r = 013, P=0.07).
Conclusions: CACD was significantly associated with serum magnesium levels, while 
CACS was significantly associated with serum phosphate levels in MHD patients. This may 
have a distinct clinical implication especially for coronary events.
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Pulmonary Artery Catheterization and Coronary Care Unit Location 
Predict Higher Incidence of Thrombocytopenia in Patients Receiving 
Continuous Veno-Venous Hemodialysis
Blaithin A. McMahon, Jan Griffin, Steven Menez, Anam Tariq, Yousuf Kyeso, 
Alice Chedid, Amr Habbach, Michael J. Choi. Johns Hopkins University School 
of Medicine, Baltimore, MD.
Background: Thrombocytopenia can occur in as much as 70% of patients receiving 
continuous renal replacement therapy (CRRT). The extent and temporal relation of 
thrombocytopenia is poorly understood. We recognized a high incidence of CRRT-related 
thrombocytopenia in the coronary care unit (CCU) at our institution. The purpose of our 
study was to compare the incidence of thrombocytopenia in patients receiving CRRT in the 
CCU and medical intensive care unit (MICU) and identify differences in risk factors for 
CRRT-related thrombocytopenia.
Methods: We performed a retrospective observational study of all patients admitted 
to the CCU and MICU of the Johns Hopkins Hospital who received CRRT for any reason 
between June 2010 to June 2017. Thrombocytopenia was defined as a decrease in platelet 
count of ≥ 50% within 72 hours of initiation of CRRT. The exclusion criteria included 
platelet count < 100 x 109 / liter prior to initiation of CRRT, decrease in platelet count of > 
30% in the 48 hours prior to initiation of CRRT, duration of CRRT < 48 hours and death 
within 48 hours of CRRT initiation.
Results: We identified 795 patients who received CRRT in the CCU and MICU over 
a 7 year time period, 298 in the CCU and 497 in the MICU. 65 patients in the CCU and 
67 patients in the MICU met inclusion criteria. The patients were well matched based on 
age, sex, race, comorbid illness and APACHE II score. There was a significant difference 
between the rates of those patients with a history of coronary artery disease (CAD) (55.8% 
vs 21.4%, P<0.001) and congestive heart failure (CHF) (84.9% vs 29.1%, P<0.001) in the 
CCU and MICU, respectively. Development of CRRT-related thrombocytopenia was seen 
in 22.5% of CCU patients compared to 13.9% of MICU patients. On adjusted MLoR, the 
odds ratio for development of thrombocytopenia-related CRRT based on CCU location was 
2.5 (95% CI 1.4-4.5, P< 0.005). Patients with pulmonary artery catheterization were more 
likely to develop thrombocytopenia (OR 2.9; CI 1.1-7.9, P< 0.05).
Conclusions: The incidence of CRRT-related thrombocytopenia appears to be higher 
in the CCU as compared to the MICU. PA catheterization was significantly-associated with 
CRRT-related thrombocytopenia and requires further investigation.
Funding: Private Foundation Support
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Soluble Urokinase Plasminogen Activator Receptor Is Associated with 
Coronary Artery Calcification and Cardiovascular Disease in Patients 
Undergoing Hemodialysis
Ruyi Liao,1 Wenjuan Wu,1 Juan Hu,1 Jianchao Ma,1 Lixia Xu,1 Zhiwen Liang,1 
Xueqin Chen,1 Guibao Ke,1 Xinling Liang,2 Wei Shi,1 Shuangxin Liu.1 
1Guangdong General Hospital, Guangzhou, China; 2Guangdong general 
hospital, Guangzhou, China.
Background: Cardiovascular disease (CVD) is an important cause of morbidity and 
mortality in hemodialysis patients. Vascular calcification is thought to play an important role 
in causing CVD. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker 
strongly predictive of cardiovascular outcomes in the pathogenesis of diabetic patients with 
renal disease treated with hemodialysis. We investigated the relationship between suPAR 
and coronary artery calcification (CAC) in patients undergoing maintenance hemodialysis.
Methods: A total of 99 adult hemodialysis patients were enrolled in this study. Plasma 
samples were analyzed for suPAR with an enzyme-linked immunosorbent assay and the 
CAC score was determined with multidetector computed tomography. The occurrence of 
cardiovascular events and all-cause mortality during follow-up were recorded from January 
1, 2010 to June 1, 2016.
Results: In 99 patients treated with maintenance hemodialysis, 91 (91.9%) had varying 
degrees of CAC, and suPAR correlated positively with the CAC score in a Spearman 
analysis. In a mean follow-up period of 33 months, 36 patients (36.4%) experienced at 
least one cardiovascular event. When the quartiles of suPAR concentrations were used as 
the cutoff points for a subgroup analysis, the incidence of CVD and all-cause mortality was 
much higher in the higher quartiles of suPAR. In a univariate Cox regression analysis, high 
suPAR was a risk factor for CVD and all-cause mortality.
Conclusions: suPAR is associated with the CAC score and is a risk factor for new-
onset CVD in patients undergoing hemodialysis.
Funding: Government Support - Non-U.S.
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The Relationship Between Uric Acid and New-Onset Cardio- 
Cerebrovascular Disease in Maintenance Hemodialysis Patients
Wei Wang,1 Yuehong Li,2 Xianglan Wu.3 1Department of Nephrology, Beijing 
Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua 
University, Beijing, China; 2Department of Nephrology, Beijing Tsinghua 
Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 
China; 3Department of Nephrology, Beijing Tsinghua Changgung Hospital, 
School of Clinical Medicine, Tsinghua University, Beijing, China.
Background: Serum uric acid (SUA) has been found to be a new marker of 
cardiovascular risk in patients with chronic kidney disease. In hemodialysis patients, the 
relevant studies are rare, and the conclusions were controversial. The aim of this study was 
to investigate the relationship between SUA and new-onset cardio-cerebrovascular disease 
in maintenance hemodialysis patients.
Methods: 96 maintenance hemodialysis patients who received hemodialysis more 
than 3 months were analyzed retrospectively between Aug. 2016 and Nov. 2017 in Beijing 
Tsinghua Changgung Hospital, including 66 males and 30 females. 44 (45.8%) patients 
had diabetes. The average age were 60.4±13.6 years (27 to 86 years old), and the average 
duration of dialysis was 3.0±3.5 years (6 months to 17 years). The basic characters of 
patients and new-onset cardio-cerebrovascular diseases during the period were recorded. 
Pre-dialysis laboratory tests were observed monthly. Patients were divided into two groups 
according to serum uric acid level as non-HUA group (155μmol/L<female≤357μmol/l 
or 208μmol/l<male≤428μmol/l), HUA group (>357μmol/l for female or >428μmol/L for 
male) respectively. SPSS 20.0 software was used to analyze the relationship between serum 
uric acid levels and new-onset cardio-cerebrovascular disease.
Results: 1. The mean pre-dialysis uric acid was 444.68±67.43umol/L, the prevalence of 
hyperuricemia was 68.75% (n=66). The prevalence of female (30, 100%) were significantly 
higher than male (36, 54.5%), P<0.01. 2. Multivariate logistic regression analysis showed 
that simultaneous hyperuricemia and diabetes were risk factors for new-onset cardio-
cerebrovascular disease (OR=4.251, 95% CI 1.241-14.567, P=0.021). In diabetic patients, 
serum uric acid levels (OR=1.004, 95%CI 1.000-1.008, P=0.040) and ferritin (OR=1.022, 
95% CI 1.004-1.041, P=0.017) were risk factor for new-onset cardio-cerebrovascular 
disease.
Conclusions: Higher serum uric acid was a risk factor for new-onset cardio-
cerebrovascular disease in maintenance hemodialysis patients with diabetes.
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Mitral Annular Calcification (MAC) in Stage 5 CKD on Dialysis Therapy 
(CKD-5D)
Sidra Saleem,2,1 Shahbaz Sarwar,1 Haris Naveed,1 Afshan Ittifaq,1 
Asad Mahmood,1 Abeera Mansur.1 1DHMC, Lahore, Pakistan; 2AIMC/JHL, 
Lahore, Pakistan.
Background: MAC is a degenerative process involving the mitral valve and is a 
marker of advanced cardiovascular disease. Prevalence in the general population is upto 
10% and increases in advanced age, females, systemic hypertension, hypercholesterolemia, 
diabetes mellitus (DM), atrial fibrillation, chronic kidney disease, end stage renal disease 
(upto 40%) and mitral valve prolapse. MAC has also been found in Egyptian mummies as 
a marker of atherosclerosis in the Horus study. The aims of this study were to assess the 
prevalence of MAC in CKD-5D patients and correlate with patients’ characteristics.
Methods: Echocardiograms were obtained in 84 hemodialysis patients. Association of 
MAC with patient age, DM, Ischemic Heart Disease (IHD), duration of dialysis, smoking, 
dyslipidemia, serum calcium and phosphorus (PO4), Intact Parathyroid Hormone (iPTH) 
was studied. The individual highest values of serum PO4 and iPTH in the course of this 
study were used. Data was analysed using IBM SPSS v. 22.
Results: The mean age of the patients was 63.38 ± 12.3 years and 48(57%) were males. 
36(43%) patients were females. 68 patients(81%) had DM and 79(94%) had hypertension. 
MAC was present in 37 out of 84(44%) patients. 64(72%) were diagnosed with IHD. The 
presence of MAC correlated significantly with IHD(Odds Ratio 6.42, p = 0.006). Mean 
follow up of the patients was 30.30 ±29.22 months and 37(44%) of the patients suffered 
mortality during this period. Patients who had been on dialysis for longer than 36 months 
were also found to be at elevated risk of developing MAC (OR=3.32, p=0.019). Among 
these findings we also saw that patients with the following risk factors: serum PO4 greater 
than 5.5 (OR=2.03), DM (OR=1.95), HTN (OR=3.35), Age >60 (OR=1.83), AFIB 
(OR=1.28); had an observable increase in incidence of MAC with time but they weren’t 
statistically significant. There was no correlation between MAC and serum Calcium and 
iPTH.
Conclusions: MAC is common in hemodialysis patients and correlates significantly 
with IHD. Etiology of MAC in ESRD is multifactorial and needs to be analyzed further. 
Our findings support the recommendation by Kidney Disease Improving Global Outcomes 
(KDIGO) 2017 guidelines on Mineral and Bone Disease on the use of echocardiography for 
the detection of valvular calcification.
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Involvements of AGEs on Vascular Calcification in Hemodialysis Patients
Hajime Nagasawa,1 Seiji Ueda,1 Takashi Kobayashi,1 Yasuhiko Kanaguchi,1 
Sho-ichi Yamagishi,2 Yusuke Suzuki.1 1Nephrology, Juntendo University Faculty 
of Medicine, TOKYO, Japan; 2Nephrology, Kurume University Faculty of 
Medicine, Kurume, Japan.
Background: Vascular calcification is one of the strong risk factors for cardiovascular 
events and mortality in chronic kidney disease (CKD) patients. Advanced glycation end 
products (AGEs) are known to be accumulated in diabetes and/ or CKD patients and 
contributing to the development of vascular complications such as the arteriosclerosis and 
vascular calcification. However, the mechanisms why and how AGEs are increased in 
patients with hemodialysis and its precise roles on the development of vascular calcification 
are remained to be elucidated.
Methods: To address this issue, we investigate the relationship among the serum levels 
of AGEs and metabolic factors in 37 chronic hemodialysis patients in our hospital. We 
also evaluated the relationship between AGEs levels and vascular calcification assessed by 
agaston score and abdominal aorta calcification score (ACI) in the abdominal CT.
Results: Serum AGEs levels are significantly associated with not only age, presence of 
diabetes and peripheral artery disease (PAD), geriatric nutritional risk index (GNRI), and 
inflammatory markers such as IL-6, TNF-alpha but also agaston score and ACI. Moreover, 
retrospective analysis reveals that annual increasing rates of vascular calcification score are 
tended to be associated with AGEs in addition to age, presence of diabetes, and TNF-alpha 
levels.
Conclusions: These observations strongly suggest that chronic inflammatory responses 
may be involved in AGEs formation in chronic hemodialysis patients and accumulated 
AGEs may contribute to the development of vascular calcification and cardiovascular 
disease such as PAD.
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Performance of Stroke Risk Scores in Dialysis Patients
Gurbey Ocak,1 Maarten B. Rookmaaker,1 Peter J. Blankestijn,1 
Marianne C. Verhaar,1 Friedo W. Dekker,2 Merel Van diepen.2 1Department of 
Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, 
Netherlands; 2Department of Clinical Epidemiology, Leiden University Medical 
Center, Leiden, Netherlands.
Background: Dialysis patients have an increased ischemic stroke risk. Stroke risk 
scores, including the CHADS2, ATRIA and CHA2DS2VASC, have been developed to 
identify patients with an increased stroke risk in patients with atrial fibrillation allowing 
for personalization of vitamin K antagonist prescription. In the original articles, CHADS2 
(C-statistic 0.82), ATRIA (C-statistic 0.73) and CHA2DS2VASC (C-statistic 0.67) had 
reasonable predictive abilities. However, the predictive performances of these stroke risk 
scores have not been validated in dialysis patients. Therefore, the aim of this study was to 
validate existing stroke risk scores in dialysis patients.
Methods: A total of 755 incident dialysis patients from the NECOSAD study were 
prospectively followed for validated ischemic stroke within five years of dialysis. Hazard 
ratios with 95% confidence intervals (CIs) were calculated using Cox proportional hazards 
analyses for high and intermediate risk scores as compared with low risk scores for the 
CHADS2 (low risk= 0, intermediate risk=1-2 and high risk= ≥3), ATRIA (low risk= 0-5, 
intermediate risk=6 and high risk=≥7) and the CHA2DS2VASC (low risk= 0, intermediate 
risk=1 and high risk= ≥2). Furthermore, we evaluated the discriminative performance of 
these bleeding risk groups by calculating Harrell’s C-statistics.
Results: During a median follow-up of 2.0 years (interquartile range 0.9-3.7), 58 (7.7% 
of all patients) first ischemic stroke events occurred. Of the 755 patients, 14% were classified 
as high risk by the CHADS2, 28% by the ATRIA and 72% by the CHA2DS2VASC. A 
high risk score as compared with a low risk score was associated with a 8.2-fold (95% CI 
1.1-63.1) increased ischemic stroke risk for the CHADS2 and a 2.2-fold (95% CI 1.3-3.9) 
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increased ischemic stroke risk for the ATRIA. A high CHA2DS2VASC risk score as 
compared with an intermediate risk score was associated with a 8.7-fold (2.1-35.7) 
increased ischemic stroke (no stroke events in low risk group). The C-statistics were 0.59 
for the CHADS2, 0.61 for the ATRIA and 0.62 for the CHA2DS2VASC.
Conclusions: In this prospective cohort with validated data on ischemic stroke, we 
showed that the CHADS2, ATRIA and CHA2DS2VASC had poor predictive abilities. 
Therefore, these stroke risk scores may not be useful for guiding individual decision-
making in dialysis patients.
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DNA Methylation of Klotho Promotor Gene Is Associated with  
Cardiovascular Disease and Malnutrition in Patients Under Hemodialysis
Hirokazu Honda,1 Yasuna Kobayashi,2 Seiki Aruga,3 Daijiro Uetake,4 
Takanori Shibata.5 1Showa University Koto Toyosu Hospital, Tokyo, Japan; 
2Niigata University of Pharmaceutical Sciences, Niigata, Japan; 3Monnaka Jin 
Clinic, Tokyo, Japan; 4Toyosu Jin Clinic, Tokyo, Japan; 5Showa University 
School of Medicine, Tokyo, Japan.
Background: Cardiovascular disease (CVD) and protein-energy wasting are common 
in patients under hemodialysis (HD). While multiple factors are associated with those 
comorbidities, we hypothesized that gene silencing, including alteration of epigenome 
might influence the comorbidities in HD patients. Thus, the aim of this ongoing study is 
to assess the prevalence of epigenetic modifications of Klotho, aging-related genes, and its 
association of comorbidities.
Methods: Whole blood samples were drawn in 131 prevalent HD patients and genomic 
DNA were purified from white blood cells. Epigenetic modifications of Klotho promotor 
gene were defined by methylation of CpG sites. Extracted DNA were modified by bisulfate 
treatment and then the methylated sequences were selectively amplified by methylation-
specific PCR. The products were visualized by agarose gels and were quantified. Patient 
characteristics, complication and baseline laboratory data were recorded.
Results: Epigenetic analysis had performed in one hundred and twenty-five patients of 
131. Of 125, 48 patients showed the DNA methylation of Klotho promotor gene. Patients
with Klotho gene methylation had high prevalence rate of CVD such as acute coronary
syndrome and myocardial infarction, and low levels of serum albumin and creatinine and
geriatric nutritional risk index compared with those without Klotho gene methylation.
Conclusions: Epigenetic modifications of Klotho promotor gene may be associated 
with CVD complication and malnutrition in patients under HD.
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Blood Myostatin Levels Are Related with Abdominal Aortic Calcification 
in Dialysis Patients
Su mi Lee,1 Yun Jung Oh,2 Young ki Son,1 Seong Eun Kim,3 Won Suk An.1 
1Dong-A University, Busan, Republic of Korea; 2Cheju Halla General Hospital, 
Jeju, Republic of Korea; 3Dong-A University Hospital, Busan, Republic 
of Korea.
Background: Myostatin which is a member of the transforming growth factor-β 
superfamily, regulates synthesis and degradation of skeletal muscle protein and it is up-
regulated in the skeletal muscle of chronic kidney disease (CKD) patients. There are few 
studies on relationship between myostatin levels and vascular calcification, important 
risk factors for cardiovascular disease in CKD. The aim of this study was to assess the 
association between serum myostatin levels and abdominal aortic calcification (AAC) in 
patients with dialysis.
Methods: In this cross-sectional study, 71 outpatients undergoing dialysis were 
included. We assessed AAC semiquantitatively from the lateral lumbar spine obtained 
using plain radiograph. Serum myostatin level was determined by commercially available 
enzyme-linked immunosorbent assay and divided by median for analysis.
Results: Our study included 37 hemodialysis patients and 34 peritoneal dialysis (PD) 
patients with a median age of 59.0 years and a median myostatin level of 4991.4 pg/mL. 
Patients with low myostatin level were older and had a higher proportion of men, PD, and 
AAC scores ≥ 5 than those with high myostatin level. The median myostatin level for patients 
with AAC scores ≥ 5 was 4073.5 pg/mL, whereas that for AAC scores <5 was 5838.6 pg/
mL. Age and AAC scores showed a significantly negative correlation with myostatin levels. 
After adjustment for potential confounding factors, including age, gender, diabetes mellitus, 
dialysis vintage, dialysis modality, osteoprotegerin, and AAC score ≥ 5, the presence of 
AAC was significantly and negatively associated with serum myostatin levels.
Conclusions: Low serum myostatin levels were associated with elevated AAC scores 
in dialysis patients. Further studies are necessary to determine the significance of measuring 
serum myostatin level in patient with dialysis.
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A Global Study Assessing Albumin Levels on Expanded Hemodialysis
Colin A. Hutchison,5 Marc Dorval,6 Maria Eugenia F. Canziani,1 
Mohamed Belmouaz,4 Jyoti B. Baharani,3 Claudio Ronco.2 1Federal University 
of Sao Paulo, Sao Paulo, Brazil; 2Ospedale “S. Bortolo” AZ. ULSS 6, Vicenza, 
Italy; 3Heart of England Foundation Trust, Birmingham, United Kingdom; 
4Service Nephrologie, Poitiers, France; 5Nephrology, Hawke’s Bay DHB, 
Hastings, New Zealand; 6Nephrology, Dr. Georges-L.-Dumont University 
Hospital Centre, Moncton, NB, Canada.
Background: Expanded hemodialysis (expHD) utilises a new form of hemodialysis 
membranes which enable more effective removal of middle and large molecular weight 
uremic toxins. These medium cut-off (MCO) membranes have pores which are significantly 
larger and more uniform than conventional high flux dialysis membranes but have the 
potential to allow some albumin leak. The purpose of this study was to assess expHD’s 
effect on patients’ pre-dialysis serum albumin levels over 6 months.
Methods: Patients receiving expHD were identified from dialysis centres in North 
and South America, Europe and Australasia. Details of basic demographics, dialysis 
prescription, laboratory parameters and recombinant erythropoietin dose were captured 
retrospectively.
Results: Data was available for 56 patients from 5 centres in Brazil, Canada, France, 
Italy, New Zealand and the United Kingdom. Median age was 67 years (range 23-91), 69% 
were male, 41% were diabetic, average time on hemodialysis was 55 months (10-215); 
median dry weight was 76 kg (44-124). 55% received dialysis on the larger MCO membrane 
dialyzer (Theranova 500 ©). Average dialysis prescription was: 4 hours (range 4-5.5) with 
Qb 300 ml/min (250-400) delivering an average Kt/V of 1.4 (1-2.5). Pre-dialysis serum 
albumin levels over the study period are presented in the table. No significant changes in 
albumin levels at 3 or 6 months from baseline are observed, p=0.42 and 0.66 respectively. 
CRP and haemoglobin levels were 4 mg/L (1.5-16) and 11 g/dL (8.2-14.2) pre-MCO use 
and 6 (1.5-25) and 11.3 (8.1-13) at 6 months respectively. Recombinant erythropoeitin dose 
increased in 15%, remained the same in 35% and decreased in 50% of participants over the 
observation period.
Conclusions: ExpHD did not result in any significant change in pre-dialysis serum 
albumin concentrations over 6 months treatment. Over this observation period, inflammatory 
markers and haemoglobin levels were stable but of potential interest 50% of the population 
had a reduction in erythropoietin dose.
Serum albumin levels
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Outcome of Open Heart Surgery in ESRD Patients: A Single Center 
Experience for 16 Years
Ji-Young Choi, Kye hwa Jeong, Jeong-Hoon Lim, Kyung hee Lee, Min 
jung Kim, Hee-Yeon Jung, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, 
Sun-Hee Park. School of Medicine, Kyungpook National University, Daegu, 
Republic of Korea.
Background: Mortality risk for cardiovascular disease is extremely high in ESRD 
patients. Nevertheless, dialysis patients are often undertreated due to the higher risk of 
operation or intervention compared to the general population. However, there are few 
studies comparing postoperative mortality and morbidity between dialysis and non-dialysis 
patients in Korea.
Methods: A retrospective analysis of 2,432 patients who underwent open heart 
surgery from 2002 to 2017 was performed to determine the mortality and morbidity after 
cardiac surgery in dialysis patients. Of total patients, we obtained comorbidities, NYHA 
classification, laboratory data, surgical method and postoperative outcomes from the two 
groups; dialysis group consisting of 38 patients with ESRD undergoing maintenance 
dialysis and control group consisting of 78 age-, sex-, and status of diabetes- matched 
control with normal kidney function.
Results: Dialysis group showed significantly higher postoperative mortality rate 
compared to the control group (18.4% versus 2.6%, P= 0.005). Dialysis group presented 
with more comorbidities, worse functional class of heart failure than control group. 
Urgent operation was more frequent (68.4% vs 32.1%, P = 0.000) in dialysis group, but 
there were no differences in the type of procedure between both groups. The postoperative 
hospitalization and time in ventilator were significantly increased in dialysis group (OR 
4.631, P = 0.034; OR 7.617, P= 0.002). However, there were no significant difference in 
complication rate including rate of pneumonia, sepsis, stroke, wound infection, arrhythmia, 
bleeding, heart failure, except pulmonary edema and postoperative CRRT.
Conclusions: Dialysis patients showed higher in-hospital mortality rate compared to 
the control patients. The duration of postoperative hospitalization and time in ventilator 
were significantly increased in dialysis group. In dialysis patients, various comorbidities as 
well as dialysis itself may have contributed to the increase in hospital mortality. However, 
postoperative complications related to surgery were not significantly different between the 
two groups.
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The Hemodialysis Outcome Assessment: Troponin I Measurement Study
David T. Collister,3,1 Andrea E. Mazzetti,4 Anuja Bhalerao,3 Peter Kavsak,2 
K. S. Brimble,3,1 Michael Walsh.3,1 1Medicine, McMaster University, Hamilton, 
ON, Canada; 2Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada; 
3Nephrology, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada; 4St. 
Joseph’s Healthcare Hamilton, Hamilton, ON, Canada.
Background: The impact of hemodialysis (HD) on cardiac biomarkers is unclear. The 
objectives of this study were to 1) To evaluate the intradialytic variability of high sensitivity 
troponin I (hs-TnI), galectin 3 (gal3) and human fatty acid binding protein (hfabp) and 2) To 
determine the factors associated with these changes.
Methods: In this prospective cohort study, hs-TnI, gal3 and hfabp were measured pre 
and post-HD for one week every month for 6 months in 178 prevalent adult HD patients 
with at least 2 HD treatments per week from a tertiary HD unit in Hamilton, Canada. 
Multilevel linear regression with HD treatments clustered within patients was performed to 
determine independent predictors of post-dialysis hs-TnI, gal3 and hfabp.
Results: The median (interquartile range) difference in pre and post-HD hs-TnI was 
-1ng/L (-2ng/L to +1ng/L) and the mean (standard deviation) differences in gal3 and hfabp 
were -38.06ng/mL (16.97ng/mL) and -20.85ng/mL (11.40ng/mL) respectively. Increases in 
hs-TnI, gal3 and hfabp were associated with ultrafiltration with B coefficients of +0.991ng/L, 
+1.053ng/mL and +1.877ng/mL per liter of fluid removal respectively. A change in hs-TnI 
was not associated with the total blood processed per HD session while decreases in gal3
and hfabp were associated with the total blood processed with B coefficients of -0.139ng/mL 
and -0.072ng/mL per liter of blood processed respectively. Dialysis length was associated
with a decrease in all three cardiac biomarkers with B coefficients of -0.025ng/L for hs-TnI, 
-0.020ng/mLfor gal3 and -0.011mg/mL for hfabp per minute of HD.
Conclusions: Gal3 and hfabp decrease during dialysis while hs-TnI does not change. 
Increases in hs-TnI, gal3 and hfabp during HD are associated with ultrafiltration. Decreases 
in gal3 and hfabp during HD are associated with the total blood processed per HD session 
while hs-TnI is not.
Funding: Commercial Support - Abbott Diagnostics, Roche Modular, Private
Foundation Support
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Plasma Levels of Endocan in Patients with ESRD on Hemodialysis as 
Biomarker for Prediction of Cardiovascular Disease
Ji yung Lee,1 Tae won Lee,1 Chun-Gyoo Ihm,1 Kyung-hwan Jeong,2 Jin sug Kim,3 
Hyung-seok Ihm,1 Hyeon Seok Hwang.4 1Kyung Hee University School of 
Medicine, Seoul, Republic of Korea; 2Kyung Hee University, School of Medicine, 
Seoul, Republic of Korea; 3Kyung Hee University Medical Center, Seoul, 
Republic of Korea; 4Division of Nephrology, Department of Internal Medicine, 
College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Background: Endocan, a proteoglycan which is a potential biomarker of endothelial 
dysfunction, has been shown to be associated with increased cardiovascular risk. We 
investigated plasma levels of endocan in patients with end-stage renal disease (ESRD) on 
hemodialysis to predict the risk of cardiovascular diseases.
Methods: A total of 400 adult patients with ESRD undergoing hemodialysis were 
prospectively enrolled in 4 tertiary hospitals of South Korea from June 2016 to May 2018. 
They were observed for development of the cardiovascular composite outcomes. We 
compared clinical characteristics and the plasma levels of endocan between 47 patients 
with cardiovascular composite outcomes and 353 control patients without cardiovascular 
composite outcomes, and developed the predictive markers of cardiovascular diseases using 
Cox proportional-hazard analysis.
Results: Previous histories of diabetes, acute coronary syndrome, arrhythmia and 
congestive heart failure were higher in ESRD patients with the cardiovascular composite 
outcomes than control patients. Patients with cardiovascular composite outcomes showed 
lower levels of hemoglobin, albumin, and high-density lipoproteins compared with control 
patients. Higher level of plasma endocan and white blood cells were associated with patients 
with cardiovascular composite outcomes. Cox proportional-hazard analysis showed that 
previous histories of diabetes and plasma level endocan were significantly associated with 
cardiovascular composite outcomes: hazard ratios were 2.1 (95% confidential interval (CI), 
1.1 to 4.3) (p = 0.03) for diabetes and 15.4 (95% CI, 3.2 to 75.2) (p < 0.001) for endocan 
(log pg/mL). The patients with level of endocan > 2.96 log pg/mL showed significantly 
higher cumulative incidence of the cardiovascular composite outcomes in Kaplan-Meier 
curve (p = 0.03).
Conclusions: Plasma Endocan level can a useful biomarker for prediction of 
cardiovascular diseases in patients with ESRD on hemodialysis.
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Investigation of Concentration of Blood Solubilized CD40 Ligand 
(sCD40L) in Maintenance Dialysis Patients
Miho Karube, Shinya Kaname. Kyorin University School of Medicine, Tokyo, 
Japan.
Background: The soluble CD40 ligand (sCD40L), one of the factors released 
from activated platelets, has been recently suggested to relate to the pathogenesis of 
atherothrombotic events for a possible biomarker predicting cardiovascular outcomes. 
Thus, we examined the sCD40L levels in patients on maintenance dialysis.
Methods: The 15 patients undergoing maintenance dialysis in our hospital were 
enrolled after informed consents. The sCD40L levels before hemodialysis, 1 hour and 4 
hours after initiation of hemodialysis were measured by enzyme-linked immunosorbent 
assays.
Results: The mean concentration of sCD40L before dialysis was 221.3 pg/ml, 
higher than that 34.3 pg/ml in healthy controls (n=3). The sCD40L levels were positively 
correlated with platelet counts and appeared to be higher in patients with a long duration of 
hemodialysis. The kinetics of sCD40L during hemodialysis showed that the concentrations 
increased to 271.0 pg/ml after 1 hour and decreased to 160.2 pg/ml after 4 hours, suggesting 
30% of removal by hemodialysis. The rate of an increase during the first one hour were 
greater in diabetic patients (n=7) than that in non-diabetic patients (n=8). The average 
removal rate was 27.6%, with no differences among various types of dialyzers.
Conclusions: The sCD40L levels in hemodialysis patients are higher, although 
partially removed by dialysis, as compared to healthy people, and might be associated with 
an increased risk of atherosclerosis possibly through the platelet activation.
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Diagnostic Performance of Lung Ultrasound and a Clinical Score for the 
Evaluation of Hydration Status in Hemodialysis Patients
Mickaël Bobot,2,1 Noemie Jourde-Chiche,2,1 Marion Sallée,2,1 Bertrand Dussol,2,1 
Yvon Berland,1,2 Thomas Robert.1,2 1Service de Nephrologie CHU Conception 
Marseille, Marseille, France; 2Aix-Marseille University, Marseille, France.
Background: Estimating the hydration status of the hemodialysis patients is a key 
point in their management. So far, there is no gold standard feasible in daily routine. We 
performed a prospective study in chronic hemodialysis patients to evaluate the diagnostic 
performance of lung ultrasound and clinical examination for the evaluation of fluid overload 
using transthoracic echocardiography (TTE) as gold standard.
Methods: 31 patients performing chronic hemodialysis for more than 3 months in 
a dialysis center were included. Patients with pulmonary fibrosis were not included. The 
hydration status was assessed weekly by: a clinical score (Major criteria: dyspnea NYHA> 
III, orthopnea, minor criteria: jugular turgor (JT), hepatic jugular reflux (HJR), pulmonary 
crackles, peripheral edema and pre-dialysis hypertension); a TTE score (inferior vena cava 
diameter, E / E’ ratio and systolic pulmonary arterial pressures); and Echo-comet score by 
lung ultrasound (sum of anterior and lateral B-lines in 28 chest areas).
Results: 5 patients had a TTE fluid overload. Compared with TTE, the diagnostic 
performance of the clinical score was: a sensitivity (Se) of 100%, a specificity (Sp) of 
81%, a positive predictive value (PPV) of 50% and a negative predictive value (NPV) of 
100%. Only orthopnea (p = 0.008), JT (p = 0.005) and HJR (p = 0.008) were significantly 
associated with TTE fluid overload diagnosis. The diagnostic performance of Echo-comet 
score by lung ultrasound has a Se of 80%, a Sp of 59%, a PPV of 26% and a NPV of 94%. 
10 patients (32.3%) had an increase of extravascular lung water without evidence fluid 
overload with TTE or clinical score.
Conclusions: This is the first study that defines a clinical score to assess fluid overload 
in hemodialysis patients. This clinical score has a satisfying diagnostic performance 
compared to TTE and would be easily used in daily clinical routine to adjust dry weight. 
Fluid overload evaluation using the echo-comet score by lung ultrasound seems poorly 
correlated with the fluid overload evaluated by TTE score. Noteworthy, asymptomatic 
pulmonary congestion was detected with lung ultrasound without fluid overload according 
the clinical and TTE score. This particular patient group need further investigation to 
determine a diagnostic and prognostic significance.
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Online Hemodiafiltration Inhibits Endothelial Dysfunction and Vascular 
Calcification of Uremic Patients Modulating miR-223 Expression in 
Plasma Extracellular Vesicles
Marita Marengo,4 Massimiliano Migliori,1 Vincenzo Panichi,2 Sergio Dellepiane,3 
Vincenzo Cantaluppi.5 1Asl Toscana Nordovest, Camaiore, Italy; 2ASl Toscana 
Nordovest, Camaiore, Italy; 3Icahn School of Medicine at Mount Sinai, New 
York, NY; 4Nephrology and Dialysis Unit, ASLCN1, Cuneo, Italy; 5University of 
Piemonte Orientale (UPO), Novara, Italy.
Background: Decreased inflammation and cardiovascular mortality is evident in 
patients with end stage chronic kidney disease (CKD) treated by on-line hemodiafiltration 
(OL-HDF). Extracellular vesicles (EV) are key mediators of cell-to-cell communication. 
This study investigated whether OL-HDF may modulate the concentration and the RNA 
content of plasma EV.
Methods: 30 bicarbonate hemodialysis (BHD) patients were randomized 1:1 to 
continue BHD or switch to OL-HDF. Concentration, size, and microRNA content of plasma 
EV were evaluated for 9 months; we also studied EV effects on inflammation, angiogenesis 
and apoptosis of human endothelial cells (EC), and on osteoblast mineralization of vascular 
smooth muscle cells (VSMC).
Results: OL-HDF reduced different inflammatory markers such as CRP, IL6 and 
NGAL. All hemodialysis patients showed higher plasma levels of endothelial derived EV 
than healthy subjects, with no differences between BHD and OL-HDF. However, BHD-
derived EV had an increased expression of the pro-atherogenic miR-223 in respect to healthy 
subjects or OL-HDF. Compared to EV from healthy subjects, those from hemodialysis 
patients reduced angiogenesis, increased EC apoptosis and VSMC calcification; however, 
all these detrimental effects were reduced with OL-HDF in respect to BHD. Cell transfection 
with miR-223 mimic or antagomiR proved the role of this miRNA in EV-induced EC and 
VSMC dysfunction.
Conclusions: Switch from BHD to OL-HDF significantly reduced systemic 
inflammation and miR-223 expression in plasma-EV, thus improving EC angiogenesis and 
reducing VSMC calcification.
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The Relation Between Peri-Dialytic Blood Pressure Changes over Time 
and Mortality Is Similar in Hemodialysis and Online Post-Dilution 
Hemodiafiltration
Camiel L. de Roij van Zuijdewijn,1 Paul A. Rootjes,1 Peter J. Blankestijn,2 
Bernard J. Canaud,3 Andrew Davenport,4 Frans J. van Ittersum,5 Muriel 
P. Grooteman,5 Francisco Maduell,6 Menso Nube.7 on behalf of the HDF Pooling
Project Investigators 1VU University Medical Center, Amsterdam, Netherlands; 
2University Medical Center----, Utrecht, Netherlands; 3FMC Deutschland
GmbH, Bad Homburg, Germany; 4Royal Free Hospital, London, United
Kingdom; 5VU University Medical Center Amsterdam, Amsterdam, Netherlands; 
6Hospital Clinic Barcelona, Barcelona, Spain; 7VU Medical Center, Bergen,
Netherlands.
Background: Online post-dilution hemodiafiltration (HDF) is associated with a lower 
mortality rate than hemodialysis (HD). The mechanism(s) behind this effect, however, is 
(are) unknown. In the present study we evaluated whether long-term changes in pre-, post-
dialytical and delta (peri-dialytic) systolic blood pressure (SBP), diastolic BP (DBP), mean 
arterial pressure (MAP) or pulse pressure (PP) may contribute to the beneficial effect of 
HDF on survival.
Methods: Individual Participant Data (IPD) from the Spanish Estudio de 
Supervivencia de Hemodiafiltración (ESHOL, n=906), the Dutch Convective Transport 
Study (CONTRAST, n=714) and the French HDF study (Frenchie, n=391) were pooled. 
The difference in peri-dialytic SBP, DBP, MAP and PP was calculated between baseline 
and 6 months and divided into tertiles: stable, decreasing and increasing peri-dialytic 
values. The stable tertile (which included a change of 0mmHg in 6 months) was used as 
reference group. All values were related to mortality for the entire study follow-up using 
Cox regression models using an intention-to-treat approach. Hereafter, models were 
adjusted for relevant confounders (age, sex, BMI, dialysis vintage, diabetes and history of 
cardiovascular disease).
Results: In 6 months, SBP, DBP, MAP and PP changed with a median of 0 (interquartile 
range [IQR] -18 to 18.25), 0 (IQR -10 to 10), 0.33 (IQR -11 to 11) and 0 (IQR -16 to 16) 
mmHg, respectively. While patients with a decreasing peri-dialytical SBP had a HR of 0.82 
(95% CI 0.65-1.03), patients with an increasing peri-dialytical SBP had a HR of 1.01 (95% 
CI 0.81-1.26). For DBP, these HRs were 0.88 (95% CI 0.71-1.10) and 0.87 (95% CI 0.70-
1.10), for MAP 0.79 (95% CI 0.62-0.99) and 1.09 (95% CI 0.88-1.35) and for PP 0.76 (95% 
CI 0.61-0.96) and 0.93 (95% CI 0.75-1.15). After correction for confounders, no significant 
relation was found.
Conclusions: Since the relation between the long-term peri-dialytical BP course (SBP, 
DBP, MAP or PP) and mortality was similar in HD and HDF patients and mortality is 
lower in HDF (Peters SAE et al. NDT 2016), other mechanisms, such as intradialytical 
BP stability, may more fundamentally affect survival. This hypothesis is currently under 
investigation.
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Individualizing Dialysate Sodium Concentrations to Improve Fluid 
Management in Chronic Dialysis Patients: A Prospective, Nonrandomized, 
Open-Label Trial
Kavitha Ramaswamy,1 Jin Xia,2 Yiqing Song,2 JingJing Zhang.1 1Sidney Kimmel 
Medical College at Thomas Jefferson University, Philadelphia, PA; 2Indiana 
University, Indianapolis, IN.
Background: Excessive fluid is associated with increased morbidity and mortality 
in patients on chronic dialysis. Excessive fluid measured as excessive interdialytic weight 
gain (EIDWG)% and above target weight (ATW)% in our dialysis unit reached nearly 
50% of our patients despite interventions such as dietary counseling. We thus conducted 
a nonrandomized, open-label trial of 73 patients undergoing hemodialysis to explore the 
benefit of an individualized Na prescription.
Methods: Patients in the individualized Na group (n=33) received lower dialysate Na 
(135-137mmol/L) if their serum Na level<138 mmol/L, predialysis systolic blood pressure 
(SBP) >120 mmHg, and EIDWG% and ATW% being higher than the goal levels. Forty 
patients who used the standard dialysate Na at 138 mmol/L were considered the control 
group. All the variables were collected before and 2 months after intervention. We used 
student t tests to compare continuous variables between two groups. Multivariate-adjusted 
linear regression models were performed to assess the differences in each continuous 
outcome between two groups with adjustment for age and sex. Multivariable logistic 
regression models were conducted by modeling IDWG decrease and ATW decrease as 
dependent variables, adjusting for age, sex, and EDW change. All p values will be two-
tailed. All statistical analyses were performed using SAS software, version 9.4 (SAS 
Institute, Cary, NC).
Results: Overall, such a moderate reduction of dialysate Na concentration was well 
tolerated. The SBP in patient group with individualized dialysate Na did not change 
from before intervention. Elevation in serum Na in the individualized dialysate Na group 
was significantly higher than that in the control group by 3.54 mmol/L (95% CI, 2.02 to 
5.05) (P<0.0001), which may indicate the improvement of volume status. Patients with 
individualized dialysate Na were 3.50 times more likely to have IDWG decrease. The 
significant association remained after adjustment for age, sex, and EDW changes (OR:3.63; 
95% CI, 1.03-12.9).
Conclusions: Our preliminary results showed that individualized dialysate Na 
prescription in patients on chronic dialysis is safe and well-tolerated and may be effective 
in the fluid management in hemodialysis patients. Future randomized controlled trials are 
warranted.
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Pre- and Post-Kidney Transplantation Body Weights: Assessing Dry 
Weight Levels
Yossi Chait,1 David Wojciechowski,2 Kerry Crisalli,2 Michael J. Germain,3 
Ravi I. Thadhani.4 1University of Massachusetts, Amherst, MA; 2Massachusetts 
General Hospital, Boston, MA; 3Renal and Transplant Assoc of New England, 
Hampden, MA; 4Cedars-Sinai, Los Angeles, CA.
Background: The single most important variable in fluid management during 
hemodialysis (HD) is dry weight (DW). Incorrect DW values result in hypo- or hyper-
volemic patients at the end of HD treatments, conditions with serious morbidity and 
mortality consequences. There is lack of consensus about the definition and assessment of 
DW; however, consensus opinion is that the optimal DW (ODW) target should be near a 
patient’s weight at euvolemic state. We investigated this hypothesis by comparing patient 
weights pre- and post-transplantation (Tx) in hemodialysis patients early post transplant 
with functional grafts. We assumed that patients with functioning allografts achieve 
euvolemia by week 2 post transplant.
Methods: DW before Tx, weights, demographics, and biomarkers, were retrospectively 
collected for 42 patients that underwent kidney transplantation at Massachusetts General 
Hospital during 2016-2017. A creatinine level Cr<1.5 mg/dL was assumed to indicate a 
functioning graft and a euvolemic state. The ODW target was defined as the weight at week 
2 post transplant for patients with a functioning graft. Patients with DW within +1% and 
-3% of ODW were considered to have DW values “sufficiently close” to ODW (+0.5 to -1.5 
kg in a 50kg patient). In patients with a functioning graft, we used Wilcoxon signed rank test 
to analyze the agreement between paired changes in weight and hemoglobin (Hb) between
weeks 1 and 2 post-Tx.
Results: 73% (N=31) of the 42 patients were males; 40% (N=17) received transplants 
from living donors; 10 patients had a functioning graft at week 1 (all living donor type) and 
10 additional patients achieved that at week 2 (8 cadaver donor type). In the group with a 
functioning graft by week 2 (N=20) 21% had too low DW values (i.e., 3% or more below 
ODW), and 47% had too high DW values. Weight changes in the group with a functioning 
graft were significantly correlated with Hb changes between weeks 1 and 2 post-Tx r=-0.7 
(p<0.001).
Conclusions: A high number (68%) of HD patients may have incorrect DW values 
with 21% rendered hypovolemic and 47% hypervolemic. Weight reduction in group with 
a functioning graft at week 2 issignificantly correlated with fluid volume reduction. It is 
imperative that new dry-weight assessment methods be developed that could improve 
cardiovascular outcomes in hemodialysis.
Funding: NIDDK Support
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Metabolic and Volemic Evaluation in the Long Interdialytic Interval of 
Patients in Hemodialysis with and Without Residual Renal Function
Lenina L. Almeida,1,3 Luis H. Sette,2 Francisco H. Oliveira,1 Fernando L. Fonseca,3 
Ronaldo R. Bergamo,3 Leila S. Bezerra.4 1Federal University of Cariri, Juazeiro 
do Norte, Brazil; 2Universidade Federal de Pernambuco, Recife, Brazil; 
3Faculdade de Medicina do ABC, SAnto - André, Brazil; 4Fmabc, Juazeiro do 
Norte, Brazil.
Background: It is unclear whether residual renal function (RRF) in dialysis patients 
can attenuate the metabolic impact of the long 68-hour interdialytic interval, in which 
volume, acid and electrolyte accumulation occurs. The aim of this study was to evaluate 
serum electrolyte levels, water balance and acid-base status in dialytic patients with and 
without RRF over the the long interdialytic interval (LII).
Methods: It was a unicentric, transversal and analytical study, which compared 
patients with and without RRF, defined by diuresis above 200 mL in 24 hours. Patients were 
weighed and subjected to the collection of serum samples for biochemical and gasometric 
analysis after the last hemodialysis (HD) of the week and before the first session of the 
subsequent week.
Results: We evaluated 24 and 27 patients with and without RRF, respectively. The mean 
urea and creatinine clearance was 3.6 ± 2.12 mL/min/1.73 m2 in the RRF group. Patients 
without RRF had a higher increase of serum potassium during the LII (2.67 x 1.14 mEq/L, 
p<0.001) reaching higher values at the end of the study (6.8 x 5.72 mEq/L,p< 0.001), as 
well as lower post-HD pH value (7.40 x 7.43, p=0.018) and tendency to lower pre-HD 
pH value (7.30 x 7.27, p=0.07) (table). In addition, at the end of the LII, they presented a 
higher proportion of patients with serum bicarbonate<18mEq/L (50 x 14.8%, p = 0.007), 
mixed acid-base disorder (57.7 x 29.2%,p=0.042), higher interdialytic weight gain (14.67 x 
8.87 mL/kg/h,p<0.001) and lower natremia (137 x 139 mEq/L,p=0.02). Serum calcium and 
phosphorus levels, as well as blood pressure, were not different between groups.
Conclusions: Patients with RRF had better control of serum potassium, sodium, acid-
base status, and volemia throughout the LII.
Variation of electrolytes and acid-base status over the LII acordding to RRF
†= independent samples t-test,
* = p< 0,05
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Clinical Impact of CMS’ Ultrafiltration Limit on Hemodialysis Patients
Jeffrey I. Silberzweig,1,2 Daniel Levine,1 Thomas Parker,1 Diane Morris.1 The 
Governing Body of The Rogosin Institute 1The Rogosin Institute, New York, NY; 
2Medicine/Nephrology, Weill Cornell Medicine, New York, NY.
Background: In January 2018, CMS instituted a reporting requirement: dialysis 
facilities must report the percentage of treatments during which patients removed less than 
13 cc/kg/hr of fluid based on data demonstrating a relationship between higher ultrafiltration 
(UF) rates and adverse cardiac effects including myocardial stunning. Many dialysis 
patients demonstrate adverse effects from volume overload both acutely and chronically 
including hospitalizations for related complications and poorly controlled hypertension. We 
sought to evaluate the effect of the new CMS requirement on the clinical status of our 
maintenance hemodialysis (HD) patients.
Methods: As part of the QAPI program at The Rogosin Institute, we began monitoring 
the percentage of patients meeting CMS’ UF requirement in January 2018. After three 
months living with this limit, we asked facilities to report on the proportion of patients 
demonstrating evidence of fluid overload and methods for managing patients not thriving 
in the face of the UF limit. We analyzed the data using descriptive statistics to look for 
relationships between the measured variables.
Results: More than 90% of the 1,197 patients dialyzed in our seven facilities met 
CMS’ UF requirement each month. Problems living with the fluid restriction and problems 
reaching target weight with the UF requirement were reported by 283 (24%) and 143 (12%) 
of our patients, respectively. Despite 27 patients (2%) receiving more than three treatments 
weekly, 50 (4%) patients were hospitalized during a three month period for symptoms 
related to volume overload. In our population, 299 patients (25%) had inadequate blood 
pressure control and 262 (22%) required more than three medications to control blood 
pressure.
Conclusions: Despite the documented benefits of limiting UF rates for patients treated 
by maintenance HD, the restriction has adverse effects: more than 4% of our population 
was hospitalized during the first three months of the restriction and more than 25% of 
our population has inadeaquate blood pressure control despite standard interventions. We 
are developing best practices for managing fluid overload and attempting to improve the 
clinical outcomes for patients struggling to live with the new CMS UF limit.
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Global Trends of Stroke in Haemodialysis (2000-2012): A Retrospective 
Cohort Study of the Monitoring Dialysis Outcomes Initiative
Albert J. Power,2 Xiaoling Ye,1 Len A. Usvyat,3 Stefano Stuard,4 
Jochen G. Raimann,1 Adrian M. Guinsburg,4 Bernard J. Canaud,5 Xiaoqi Xu,6 
Michael Etter,6 Jeroen Kooman,7 Frank van der Sande,7 Neill D. Duncan,8 
Charles D. Pusey,9 Peter Kotanko.1 The MONDO Initiative 1Renal Research 
Institute, New York, NY; 2Richard Bright Renal Unit, Bristol, United Kingdom; 
3Fresenius Medical Care North America, Melrose, MA; 4Fresenius Medical 
Care, Bad Homburg, Germany; 5FMC Deutschland GmbH, Bad Homburg, 
Germany; 6Fresenius Medical Care Asia Pacific, Hong Kong, China; 
7Maastricht University Medical Centre, Maastricht, Netherlands; 8Imperial 
College Renal and Transplant Centre, London, United Kingdom; 9Imperial 
College London, London, United Kingdom.
Background: Stroke remains a key cause of death&morbidity in HD patients(pts) that 
exhibit stroke rates 10-12x higher than the general population(GP). Primary&secondary 
prevention strategies have progressively reduced the burden of stroke in the GP but it is 
unclear if this trend has transposed to HD pts globally.
Methods: We studied 4,388 strokes in 150k pts. The MONDO Initiative consists of HD 
pts from 41 countries [von Gersdorff GD et al.]. All adult pts from the MONDO database 
[2000-2012] were studied with fatal&non-fatal hospitalized stroke defined by ICD-9&10 
codes and excluded transient ischemic attack.
Results: The overall incidence of stroke rose from 8.7-28.7/1k pt yrs. This compares 
to static rates worldwide in the GP[2.5-2.6/1k pt yrs,1990-2010] with falling rates in high-
income countries. A sharper rise in hemorrhagic stroke rate was seen compared to ischemic 
stroke in HD pts[Fig], reflecting trends seen in younger age groups worldwide. Despite 
falling stroke mortality worldwide[1.4-1.1/1k pt yrs,1990-2012], there was a progressive 
rise in HD populations [1.5-10.5/1k pt yrs, 2000-2012]. These stroke trends occurred 
despite increasing treatment time[203-245 mins], better BP control[mean pre-HD BP 
150/80-137/72mmHg] and falling ultrafiltration rates. Stroke rates remained high 3 months 
after HD started and continued to fall for 2 yrs, driven by ischemic stroke incidence and 
with stable hemorrhagic stroke rates.
Conclusions: There is a progressive rise in stroke incidence and mortality over time 
in HD pts globally which starkly contrasts with global trends. This appears to be driven 
predominantly with rising rates of hemorrhagic stroke which carries a higher case-fatality 
rate. Stroke rates are at their highest within the first year of HD and there is a pressing need 
to reduce stroke risk in a particularly vulnerable pts at an early stage.
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Racial Disparities in Percutaneous Coronary Intervention in the ESKD 
Population
Robert Nee,1,2 Keith C. Norris,3 Christina M. Yuan,1,2 Lawrence Agodoa,4 
Kevin C. Abbott.4 1Walter Reed National Military Medical Center, Bethesda, 
MD; 2Department of Medicine, Uniformed Services University, Bethesda, MD; 
3UCLA, Marina Del Rey, CA; 4The National Institutes of Health, NIDDK, 
Bethesda, MD.
Background: Racial disparities in invasive cardiac procedures such as percutaneous 
coronary intervention (PCI) in the general population are well documented. However, 
contemporary national-level data on such disparities in the end-stage kidney disease 
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(ESKD) population are lacking. Herein we assessed racial differences in the receipt of PCI 
between Blacks and Whites with ESKD, after the start of maintenance dialysis.
Methods: Using the US Renal Data System database, we abstracted Medicare inpatient 
procedure claims for PCI in a cohort of 269,984 Medicare primary patients who initiated 
on maintenance dialysis from 1 January 2009 through 1 June 2013, and followed until 
31 December 2013. We conducted Cox regression analyses, adjusted for demographic 
characteristics, cause of ESKD, comorbidities, and socioeconomic factors (Medicare-
Medicaid dual eligibility as a proxy measure of individual-level poverty, employment 
status, and ZIP code-level median household income obtained from the 2010 US Census). 
We also modeled death as a competing event in competing risk regression using the Fine 
and Gray method.
Results: The crude incidence rates of PCI among Whites were 32.9 per 1000 patient-
years (PY) vs. Blacks 20.4 per 1000 PY, respectively [Figure 1]. Cox regression analyses 
demonstrated that Blacks were significantly less likely to undergo PCI compared to Whites 
(adjusted hazard ratio [aHR] 0.64, 95% CI 0.55-0.74, p<0.001). The aHR was similar in 
non-Hispanic Blacks vs. non-Hispanic Whites (aHR 0.62, 95% CI 0.53-0.73, p<0.001). In 
the competing risk model, the racial gap for PCI among Blacks and Whites narrowed but 
remained significant (subdistribution HR 0.73, 95% CI 0.62-0.88, p<0.001).
Conclusions: There exists a racial gap among incident dialysis patients undergoing PCI 
despite having comprehensive coverage with Medicare. These findings persisted despite 
accounting for demographic, clinical, socioeconomic factors and death as a competing risk.
Figure 1
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Survey of Patient Awareness of and Attitudes Towards Home Dialysis in 
New York City
Frank Liu,1,3 David L. Epstein,1,3 Daniel Levine,1 Samuel Baskharoun,2 
Jonathan T. Lin,1,3 Victoria Gutgarts,3 Molly R. Phillips,1 Omar Farrukh,3 
Perola Lamba,3 Weeraporn Srisung,3 Thomas Parker,1 Xunxi S. Guo,3 
Alan Perlman.1,3 1Rogosin Institute, New York, NY; 2Frank H. Netter MD School 
of Medicine, New Haven, CT; 3NYP-Weill Cornell, New York, NY.
Background: Since 2008, CMS regulations have obligated dialysis practitioners to 
inform in-unit hemodialysis(HD) patients about alternatives to in-unit HD, including home 
dialysis modalities. Despite this mandate, home dialysis remains underutilized nationwide 
with just 8.6% of prevalent patients performing any home modality. Home modalities are 
even more disproportionately underutilized in New York City (NYC), with only 3.6% of 
patients using a home modality. Because of the unique challenges faced by patients living 
an intensely urban setting such as NYC, we attempted to understand the factors that might 
be responsible for that underutilization.
Methods: The PRIMARY CARES (Primary Care Attitudes and Renal Replacement 
Selection) survey was performed in 7 HD units in the NYC area representing a diverse 
population of ethnicities, languages, and socioeconomic categories with the objective of 
assessing factors influencing the utilization of home dialysis.
Results: 832 in-unit HD patients were approached and 511 completed the survey. 
Of these, 469 (92%) indicated they received education regarding any renal replacement 
modality. Of those, only 180 (35%) reported having been educated about home hemodialysis 
(HHD) and only 142 (28%) reported having been educated about peritoneal dialysis (PD). 
Of the 180 patients educated about HHD, 39 (21.7%) seriously considered the modality 
after receiving education. Only 5 (12.8%) of the 39 patients who seriously considered HHD 
came to the conclusion they “would never do HHD”. Of the 142 patients educated about 
PD, 61 (43%) seriously considered the modality after receiving education. Only 11 (18%) 
of patients who seriously considered PD came to the conclusion they “would never do PD”.
Conclusions: Patient awareness of home modalities remains poor despite mandated 
modalities education. A significant proportion of patients educated about home modalities 
seriously considered dialyzing at home, whereas only a small minority indicated they would 
never consider dialyzing at home after receiving that education. Our data suggests that there 
may be a large reservoir of home dialysis patients within the NYC in-unit HD population, 
and that current in-unit modalities education programs could be improved.
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The Impact of Frailty on Technique Failure and Mortality in Patients on 
Home Dialysis
Ranveer S. Brar,2,3 Reid Whitlock,2,3 Blake Lerner,3 Clara Bohm,2,3 
Paul Komenda,2,3 Claudio Rigatto,2,3 Bhanu Prasad,4 Bjoerg Thorsteinsdottir,1 
Navdeep Tangri.2,3 1Mayo Clinic, Rochester, MN; 2Chronic Disease Innovation 
Center, Seven Oaks General Hospital, Winnipeg, MB, Canada; 3University of 
Manitoba, Winnipeg, MB, Canada; 4Nephrology, Regina Qu’Appelle Health 
Region, Regina, SK, Canada.
Background: Patients on home based dialysis therapies will experience technique 
failure, which is associated with morbidity and mortality. Reasons for technique failure 
are complex, and often related to functional decline in the patient or caregiver. Frailty is 
associated with an increased risk of adverse health outcomes. The aim of the study was to 
investigate the impact of frailty on technique failure and mortality in a prospective cohort of 
patients on home dialysis therapies.
Methods: We studied 109 prevalent patients from the Peritoneal Dialysis (PD) and 
Home Hemodialysis (HHD) programs at our institution between 2012 and 2016. We 
collected objective [Fried criteria and Short Physical Performance Battery (SPPB)], and 
subjective measures (physician and nurse impression) of frailty. Our primary outcome was 
a composite of technique failure, defined as a permanent transition (> 30 days in duration) 
to facility based hemodialysis or all cause death. The association between different frailty 
assessment tools and the primary composite outcome was evaluated using Cox proportional 
hazards models.
Results: Frail status, as determined by the Fried criteria and physician impression was 
associated with a greater than two-fold increase in risk of our composite outcome (HR: 2.10 
[95% CI 1.09-3.99], 2.15 [95% CI: 1.15-4.00, respectively] in models adjusted for age, 
sex and comorbidity. Weakness and weight loss subdomains of the Fried criteria were both 
associated with an increased risk of technique failure or death in adjusted analyses (HR: 
2.16 [95% CI: 1.23-3.78], 2.69 [95% CI 1.39-5.40], respectively).
Conclusions: Objective and subjective measures of frailty are associated with a more 
than two-fold higher risk of technique failure or death in patients undergoing home dialysis. 
Assessing frailty as part of the clinical evaluation for home dialysis therapies may be useful 
for prognostication and clinical management.
Funding: Government Support - Non-U.S.
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The Effect of Interim Assessment on Home Hemodialysis Patient 
Readiness
Nalinee Saiprasertkit,1 Christopher T. Chan.2 1University Health Network, 
Toronto, ON, Canada; 2Toronto General Hospital, Toronto, ON, Canada.
Background: Studies have demonstrated the favorable clinical outcomes and better 
quality of life of home hemodialysis (HHD) compared with conventional hemodialysis. 
Teaching strategies to ensure the patients’ ability to administer their own therapies safely 
without supervision at home is fundamental to the success of home hemodialysis. Several 
studies showed mid-training assessments followed by final assessment at completion of 
training improved learning outcomes. The purpose of this study is to determine the impact 
of interim assessments on the readiness of HHD before transitioning home.
Methods: This is a prospective feasibility study examining consecutive end stage 
renal disease (ESRD) patient and caregiver who were undergoing HHD training between 
September 1, 2017 to May 31, 2018. Every potential home hemodialysis candidate was 
observed for their hemodialysis performance skills and asked basic knowledge questions 
regarding hemodialysis by an independent HHD nurse after 16 sessions of HHD training 
and at the end of training. HHD candidates and training nurse were provided feedback for 
observed errors. The confidence in performing dialysis at home was assessed by global 
rating scale (GRS) in every HHD patient and their primary nurse before and after every 
interim assessment.
Results: Of 11 candidates; 9 candidates were ESRD patients, 2 candidates were ESRD 
patients’ caregivers. Mean age was 47.3 ± 14.3 years, 63.6 % was male, 54% was Asian, 
81.8% graduated from college or higher education, 54% used central venous catheter for 
vascular access. The confidence level scores in performing HHD in both candidates and 
primary nurses before the 2nd interim exam was significantly higher than the 1st interim exam 
(57.6 vs 64.4 (p 0.014); 53.1 vs 60.3 (p 0.026). The confidence level scores in performing 
HHD in both candidates and primary nurses before the 2nd interim exam was significantly 
higher than the 1st interim exam (57.6 vs 64.4 (p 0.014); 53.1 vs 60.3 (p 0.026).
Conclusions: Interim observed evaluation is a feasible strategy to enhance patients and 
nurses’ ability to train a complex medical procedure. Prospective evaluation of the clinical 
impact of interim training evaluation on adverse outcomes warrant further evaluation.
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Home Hemodialysis Assisted by Personal Support Workers Among Eight 
Pilot Programs in Ontario
Philip McFarlane,1 Janet L. Graham,4 Marc Hebert,2 Monisha Patel,2 Leena Taji,2 
Angie Yeung,5 Andreas Pierratos.3 1St. Michael’s Hospital, Toronto, ON, 
Canada; 2Ontario Renal Network, Toronto, ON, Canada; 3University of Toronto, 
Toronto, ON, Canada; 4The Ottawa Hospital, Ottawa, ON, Canada; 5Cancer 
Care Ontario, Toronto, ON, Canada.
Background: Increasing the uptake of home dialysis is a strategic priority of the 
Ontario Renal Network (ORN). Home hemodialysis (HHD) is associated with a higher 
Dialysis: Home Hemodialysis
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
976
J Am Soc Nephrol 29: 2018 Poster/Saturday
quality of life and improved symptom control. Barriers to the adoption of HHD can include 
patient inability to manage HHD independently, psychological barriers such as fear of 
catastrophic events, concerns about burdening family, or lack of appropriate support. This 
pilot project utilized Personal Support Workers (PSWs) to support patients who required 
additional assistance to dialyze at home.
Methods: The ORN funded 8 Regional Renal Programs (RRPs) to initiate PSW-
assisted HHD. PSWs were trained in a manner consistent to that of independent HHD 
patients. Patient information was collected via the Ontario Renal Reporting System. 
Patients, PSWs, nurses and administrators were surveyed to gather feedback on patient 
experience and outcomes, model feasibility, training success, safety, and monitoring and 
support processes(e.g. including ongoing focus groups to obtain information about project 
progress).
Results: Between October 2015 and March 2018, approximately 65 patients 
participated in the PSW-assisted HHD project. As of March 2018, 35 prevalent patients 
were actively receiving PSW-assisted HHD. Rates of HHD increased by 0.1% to 2.2% 
across the 8 RRPs due to PSW-assisted HHD since the implementation of the project. The 
main challenge of the pilot was the PSW turnover rate (41%). Key survey measures include: 
94.5% (n=35) of patients indicated that they switched to HHD due to the PSW support 
received. 91% (n=33) of patients indicated that are happier dialyzing at home than in an 
in-centre dialysis unit.
Conclusions: Successful implementation of a PSW-assisted HHD was achieved across 
8 RRPs in Ontario. PSW-assisted HHD appears to be a promising model of care to increase 
uptake of HHD and was associated with high patient satisfaction scores. Further evaluations 
of the program are underway to inform the operational and financial sustainability of this 
model of care.
Funding: Government Support - Non-U.S.
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Nurse Assisted Home Hemodialysis (NAHHD) by Using NxStage Cycler 
for Home Bound, And Multi-Comorbid Hemodialysis Patients: One Year 
Experience
Bassam O. Bernieh, Fredric Calaud. HHD for Home Health Care, Al Ain-Abu 
Dhabi, United Arab Emirates.
Background: Home hemodialysis (HHD) is used to treat active, HD patients. The 
steady increase in the number of HD patients, with multi comorbidities, and bed bound, 
is creating a significant burden on the active hospital beds. We are presenting our one year 
experience of treating those highly comorbid HD patients, with (NAHHD), at home or in 
long term care facilities.
Methods: HD patients who were fulfilling criteria for HHD were accepted in the 
NAHHD program. NxStage System One is used to deliver HD therapy at home or at long 
term care, by an experienced HD nurse. Dialysate volume, length, and weekly number of 
the HD sessions, were calculated by a calculator given by NxStage Company, targeting 
weekly standardized KT/V≥ 2. Only patients who were at least for three months and those 
who completed one year in the (NAHHD) program were included in the study.
Results: Forty seven dialysis patients on NAHHD were included in this study. Eighteen 
males (38%), and 29 females (62%). Mean age 69.2±17.7 year. Mean duration on NAHHD 
was 12 months. Etiology of end stage renal disease was DM 35(74%), HTN 10 (21%), and 
others 2(5%). Average number of comorbidities 9.3±3(6–16). Indications of NAHHD were: 
bed bound 27 (57%), morbid obesity 9(19%), psychiatric disorders, mental retardation 
7(15%), and others 4(9%). Vascular access: AVF 23 (49%), AVG 2(5%), and tunneled 
catheter 22 (46%). Average dialysate volume was 25 L. Number of weekly session was 4, 
and average duration of session 3.3 hours. All patients tolerated well their dialysis sessions. 
The average weekly standardized KT/V was 2. There were 7 line sepsis, with an incidence 
of 0.6 episode/ 1000 catheter days. There was 56 hospital admissions (1.2 admission/
patient/year), with average hospital stay of 7.4 days. The annual mortality rate of the total 
cohort was 17.7%. There was a positive impact of the NAHHD on the patients’ quality of 
life, as measured by time of recovery of 21 minutes, average sleeping of 6.5 hours, good 
appetite in 81%, along with patients and families satisfaction of 80%.
Conclusions: The results of one year experience of NAHHD by using NxStage 
machine in bed, home bound, and multi comorbid, HD patients, confirmed its efficacy, 
good quality of care, and its safety. It has significant positive impact on the quality of 
life and satisfaction of both patients, and their families.
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An Audit of Compliance with Prescribed Dialysis Hours in a Home 
Hemodialysis Population
Carolyn L. Van Eps, Carmel M. Hawley, Yeoung Jee Cho, David W. Johnson. 
Patients and Staff of Home Haemodialysis Unit Princess Alexandra Hospital, 
Brisbane Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Background: Increased weekly hemodialysis(HD) hours(hrs) completed is associated 
with improved quality and quantity of life. There are no studies examining compliance 
with prescribed dialysis hours(PDH) in home hemodialysis(HHD) populations who are not 
remotely monitored.
Methods: The number of hours each HD machine has run, as displayed on machines, 
was recorded on 2 occasions during routine home visits to all prevalent HHD patients of 
Princess Alexandra Hospital. With ethics approval, patients and staff were unaware this 
information was being collected. The number of HDhrs completed between the 2 readings 
was calculated, accounting for periods of HD away from home, set up and maintenance. 
This was compared with PDH documented in the medical record. Nurses and Nephrologists 
blindly rated compliance based upon clinical acumen. Descriptive statistics were performed 
to analyze trends and examined for predictors of %PDH completed.
Results: 54 HHD patients were included:Age:52±14years; 26% female; diabetic 
nephropathy:28%, duration HHD 4(2-8)years. Duration between the 2 readings was 
11(7-17)weeks. %PDR dialysed:≥90%hrs: 52%, 70-89% hrs:30%, 50-69%hrs:11% 
and <50%hrs:7%. Average number of hrs/week performed was 16±7. 41% of patients 
dialysed <15hrs/week. 46% were prescribed but only 35% performed ≥18hrs/week. 
Compliance was accurately estimated by nurses in 48% and by nephrologists in 43% of 
cases. Nephrologists rated patient compliance as significantly worse than nurses. Out of 
27 demographic, psychosocial, medical and laboratory parameters, only age(coefficient 
0.64, 95% confidence interval (CI) 0.26-1.02, p=0.002) and diabetes mellitus (-14.8, 
95% CI -26- -3.6, p=0.01) were significantly associated with compliance with PDH in 
multivariable regression analysis.
Conclusions: Recording the hours HD machines have run provides a useful estimate 
of the HDhrs completed at home. It is minimally intrusive on patient privacy, requires 
no special equipment and little staff time. It does not provide information on HD session 
frequency or duration being performed. Accuracy of clinicians’ impressions of compliance 
is poor and common parameters used to monitor HHD patients are poorly predictive of 
compliance with PDH. Rates of poor compliance with PDH in HHD patients are significant 
and may contribute to the lack of consistent improvement in outcomes seen in clinical trials.
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Single Centre Experience of Vascular Access Related Infection Rates in 
Frequent HD
Natalie L. Borman, Venkat Gangaram, Nicholas Sangala. Nephrology, Wessex 
Kidney Centre, Portsmouth, United Kingdom.
Background: There are many benefits to Frequent Home HD (FHHD) but it only 
accounts for 0.4% of the dialysis population worldwide. One of the perceived barriers to 
FHHD relates to vascular acces srelated infections (VARI), as Infection is still the leading 
cause of morbidity and mortality in the dialysis population. Fear exists that frequent 
cannulation or use of vascular catheters (CVC) at home will increase this. Wessex Kidney 
Centre (WKC), Portsmouth, UK has a large HHD programme using NxStage. This 
retrospective study will review VARI and the strategies put in place to minimise them.
Methods: Data was collected on HHD patients between 2009- 2017. Demographic 
data, type of vascular access, proven bacteraemia via blood cultures and exit/cannulation 
site infections was collected. Rates of staph aureus bacteraemia were compared to UK 
Renal Association (UKRA) standards for HD. Monitoring methods in place were reviewed.
Results: Table 1 shows demographic data and number of VARI during this period. 
All patients received dialysis 5 or 6 times per week (20 patients received alternate night 
therapy). Figure 1 shows staph aureus related bacteraemia per 100 patient months compared 
to UKRA standard. The rate of all VARI were highest in the first 5 years and have since 
reduced despite increasing numbers on HHD. They are comparable to the UKRA standard. 
Monitoring strategies and educational material have been put in place, including a real time 
monitoring app alerting the HHD team to any concerns, aiming to treat any infections early.
Conclusions: In this large FFHD cohort an increase in VARI rates were not observed 
despite frequent cannulation or use of CVC at home. Careful monitoring and ongoing 
education is essential to reduce infection rates and ensure prompt treatment.
Table 1
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European Experience of Nocturnal Home HD Using NxStage System One
Natalie L. Borman,1 Venkat Gangaram,6 Eric Goffin,3 Kristine Kubisiak,4 
Mari K. Vilpakka,5 Eric D. Weinhandl.2 1Nephrology, Wessex Kidney centre, 
Portsmouth, United Kingdom; 2NxStage Medical, Inc., Victoria, MN; 3Cliniques 
universitaires St Luc, Brussels, Belgium; 4NxStage, Medical, Minneapolis, MN; 
5Paijat-Hame Central Hospital, LAHTI, Finland; 6Wessex Kidney Centre, 
Waterlooville, United Kingdom.
Background: More frequent HD is associated with increased survival, improved 
physical health, and reduced LVH. Studies have shown benefits with long, slow dialysis, 
with reduction in blood pressure, improved solute removal, anaemia, and quality of life. 
This study documents for the first time the outcome of a cohort treated with nocturnal home 
HD (NHHD) with low-volume dialysate in Europe.
Methods: A retrospective analysis of 20 patients at 4 European centres who received 
≥12 months NHHD with the NxStage System One, a device that uses ≤60 L/session of
lactate-buffered dialysate. Single-bolus low-molecular weight heparin was administered at 
the start of therapy. Fistulas were cannulated with double needle and button hole technique; 
needle strapping and moisture sensors were used. Data analysis included demographics,
prescriptions, biochemical data, training and safety measures. Descriptive analysis was used 
to assess patient characteristics and prescriptions. Mean, standard deviation, and range of
biochemical data at baseline, 6 and 12 months were calculated.
Results: Mean age was 44.4 years (range, 26-66). Most patients received 3.5 sessions 
per week, with 60 L/session of dialysate and ≥24.5 cumulative treatment hours. The table 
summarises biochemical outcomes, which met European standards. Reduced pill burden 
was also noted.
Conclusions: Data from this cohort supports the use of NHHD with low-volume 
dialysate, providing biochemical outcomes that meet European standards and reduced pill 
burden. Therapy was safe and effective, and extends a viable option for more patients to 
receive NHHD and its associated benefits.
Biochemical data
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Frequent Home Haemodialysis as “Palliative Dialysis”: Time for a 
Paradigm Shift
Natalie L. Borman,1 Sunita Nair.2 1Wessex Renal and Transplantation unit, 
Hayling Island, United Kingdom; 2Royal Shrewsbury Hospital, Shrewsbury, 
United Kingdom.
Introduction: Increasingly the profile of dialysis patients has changed from young and 
fit to older and multi-comorbid. Dialysing these patients is fraught with difficulties due to 
their comorbidities. Managing such complex patients requires a collaborative approach by 
Renal and Palliative physicians. A Palliative approach to dialysis embraces the transition 
from a conventional disease-oriented focus on dialysis as a rehabilitative treatment to an 
approach prioritizing comfort and alignment with patient goals. Palliative care affirms 
life, provides symptom relief by integrating medical, psychological and spiritual needs of 
a patient and considers dying as a normal process. Palliative dialysis as part of palliative 
medicine is not a well-recognized concept.
Case Description: We describe our experience with six individual patients on Home 
Haemodialysis (HHD) using NxStage system One, who have benefitted from a palliative 
approach to dialysis as part of their holistic treatment. Table 1 outlines the patients included. 
As outlined in the table, we had patients with variable age and comorbidities who underwent 
dialysis for symptom control on a palliative basis, either at home or at the hospice. All 
patients had significant symptom burden and co-existing illness, but wished to continue 
dialysis at home spending quality time with family. Dialysis was continued in the context of 
palliation, focusing on symptom control. This also offered flexibility and thereby improved 
the quality of the final month of life.
Discussion: Palliative care programs result in beneficial effects on symptoms, reduced 
hospital costs, increase likelihood of death at home, and improve patient and family 
satisfaction, compared to conventional care. Patients undergoing maintenance dialysis with 
associated significant comorbidities, a high mortality rate, and possibly co-existing terminal 
illness could be candidates for a palliative approach to dialysis. It is time to incorporate this 
as a part of the continuum of renal treatment, providing a patient centered holistic approach.
Table 1
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Human Factors Testing of the Quanta SC+ Hemodialysis System: An 
Innovative System for Home and Clinic Use
James Grainger,2 Oksana Harasemiw,1 David Bond,2 Paul Komenda,1 
Thomas W. Ferguson.1 1Chronic Disease Innovation Centre, Winnipeg, MB, 
Canada; 2Quanta Dialysis Technologies, Alcester, United Kingdom.
Background: Compared to traditional in-centre hemodialysis, home hemodialysis 
(HHD) is a more cost-effective option, offering patients more autonomy, better quality of 
life, and improved health outcomes. However, uptake rates of HHD are the lowest among 
all other modality types. Therefore, there is a need to develop efficient HHD systems that 
are user-friendly and appealing to patients. The SC+ Hemodialysis System developed by 
Quanta Dialysis Technologies for home and clinic use, provides patients with a compact, 
safe, and easy-to-use HHD system that minimizes the burden of traditional dialysis 
treatments, whilst providing equivalent dialysis adequacy.
Methods: As part of the design validation of the SC+, Human Factors Testing (HFT) was 
performed with 15 Home Users (patients and caregivers) and 17 Healthcare Professionals 
(nephrology nurses and healthcare assistants), to assess safety, performance, and ease of 
usability. The HFT involved a training session with each participant at Smethwick Dialysis 
Centre in Birmingham, United Kingdom, which was subsequently followed by a test 
session where participants independently performed 38 subtasks on the SC+. A detailed 
study protocol was used to critically evaluate each participant in a standardized manner.
Results: In aggregate, 1,171 from the 1,216 subtasks attempted between the two user 
groups were completed successfully. Overall, the Healthcare Professionals performed with 
a higher degree of use safety, with a task-specific success rate of 97.4%, compared to 95.1% 
in the Home Users (patient and caregiver) group. Healthcare Professionals encountered use 
errors in 0.9% of sub-tasks attempted. In contrast, 0.2% of subtasks attempted by home 
users resulted in a close call (they initially encountered a use error, but were able to self-
correct), and 3.9% resulted in use errors. Due to circumstances unrelated to the study itself, 
1.7% of subtasks attempted by healthcare professionals, and 0.9% by home users, were 
unperformed. No errors resulted in adverse events.
Conclusions: The SC+ Hemodialysis System was found to have minimal issues related 
to ease of usability by patients, caregivers, and healthcare professionals. The data from this 
usability study indicates that in the real world, a high degree of use safety will likely be 
achieved, resulting in an optimal user experience.
Funding: Commercial Support - Quanta Dialysis Technologies Ltd.
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Effect of Dialysate Lactate Concentration During Daily Hemodialysis 
(DHD) on Serum Bicarbonate (BIC) Concentration After Transfer from 
In-Center Hemodialysis (ICHD)
J. Ken Leypoldt,1 Michael A. Kraus,4 Bertrand L. Jaber,2 Eric D. Weinhandl,3 
Allan J. Collins.3 1Unaffiliated, San Clemente, CA; 2St. Elizabeth’s Medical 
Center, Boston, MA; 3NxStage Medical, Inc., Victoria, MN; 4NxStage Medical,
Inc, FISHERS, IN.
Background: Lactate is used as an alternative dialysate buffer to BIC during DHD, but 
the outcome of dialysate lactate concentration on acid-base balance is unclear. We examined 
the effect of the dialysate lactate concentration during DHD on serum BIC concentration 
after transfer from ICHD.
Methods: This post hoc analysis evaluated data from patients who transferred from 
ICHD to DHD during the FREEDOM Study (N=284). DHD was performed at low dialysate 
flow rates; treatment frequency per week and dialysate volume per session were 5.9±0.2 
and 22.1±4.0 L, respectively. Dialysate lactate concentration during DHD was either 40 or 
45 mM. Serum BIC was the average concentration from the last 3 months of ICHD or the 
first 3 months of DHD.
Results: Mean±SD serum BIC values are tabulated. Overall, a larger increase in 
serum BIC after transfer from ICHD to DHD was associated with higher dialysate lactate 
concentration during DHD (P<0.001) and lower serum BIC during ICHD (P<0.001), the 
latter is illustrated for dialysate lactate concentration of 45 mM in the figure.
Conclusions: Transfer from ICHD to DHD using lactate as the dialysate buffer may 
be accompanied by changes in serum BIC. This study provides guidance for choosing 
dialysate lactate concentrations for DHD at low dialysate flow rates.
Funding: Commercial Support - NxStage Medical
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*Different from value during ICHD (P<0.001) by paired Student’s t-test.
SA-PO925 Poster Saturday
Dialysis: Home Hemodialysis
Associations of Treatment Frequency and Dialysate Volume with 
Conversion from Home Hemodialysis to Another Dialytic Modality
Kristine Kubisiak,1 Debabrata Ray,1 Allan J. Collins,1,2 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, MN.
Background: Home hemodialysis (HHD) readily permits increased treatment 
frequency, which reduces left ventricular mass, blood pressure, and serum phosphorus 
and improves physical health-related quality of life. However, conversion from HHD to 
another dialytic modality (e.g., in-center hemodialysis) is common, particularly during 
the first year of HHD. There is little literature about clinical predictors of conversion. We 
assessed associations of treatment frequency and dialysate volume with conversion in a 
contemporary cohort of HHD patients.
Methods: We identified patients who initiated HHD training with the NxStage System 
One between January 1, 2013, and December 31, 2017, in a large dialysis organization. We 
retained patients who completed HHD training and were initially prescribed 4-6 sessions/
week and ≥90 L/week of dialysate. We followed patients from the first treatment at home until 
the earliest of conversion to another dialytic modality, death, kidney transplant, or January 
31, 2018. We used Cox regression to estimate the hazard of conversion to another dialytic 
modality, as a dynamic function of treatment frequency and cumulative dialysate volume per 
week, with adjustment for age, race, sex, body mass index, and vascular access type.
Results: We identified 5545 patients who completed HHD training. Mean age was 
54.6 years, 69% of patients were white, 65% were male, and 71% used a fistula. Patients 
accumulated 6645 patient-years of follow-up. Prescriptions of 4, 5, and 6 sessions/week 
constituted 28%, 59%, and 14% of follow-up time, respectively, and prescriptions of 
90-119, 120-149, 150-179, 180-209, and ≥210 L/week of dialysate constituted 8%, 23%,
34%, 21%, and 14% of follow-up time, respectively. There were 1727 conversions from
HHD to another dialytic modality, 685 deaths, and 467 kidney transplants. The adjusted
hazard ratio of conversion from HHD to another dialytic modality was 1.06 (95%
confidence interval, 0.95-1.18; p = 0.31) for 4 vs. 5 sessions/week and 0.99 (0.85-1.44;
p = 0.86) for 6 vs. 5 sessions/week. The corresponding hazard ratio for each 30-L/week
increment in dialysate was 1.00 (0.96-1.04; p = 0.96).
Conclusions: Among patients on frequent HHD with low-volume dialysate, neither 
HD frequency nor dialysate volume per week were associated with conversion to another 
dialytic modality.
Funding: Commercial Support - NxStage Medical, Inc.
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Home Dialysis Utilization by African-Americans Is Influenced by 
Psychosocial Factors
Janice P. Lea,1 Joshua B. Ang,2 Jason Cobb,3 Tahsin Masud,1 James L. Bailey,3 
Laura Plantinga.1 1Emory University, Atlanta, GA; 2Philadelphia College of 
Osteopathic Medicine-GA, Duluth, GA; 3Emory University School of Medicine, 
Atlanta, GA.
Background: Racial disparities have been reported in utilization of home dialysis 
modalities. While psychosocial factors are assumed to play a role, there is a paucity of 
definitive data. The aim of this study was to examine the relationship between psychosocial 
factors and the utilization of home dialysis among prevalent African-American dialysis 
patients.
Methods: Data were extracted from the initial comprehensive assessment performed 
by social workers for patients starting dialysis treatment between 2010- 2016. Our 
exposures were social worker-assessed psychosocial factors; depression/anxiety, substance 
abuse, marital status, employment status, and level of independence (daily social support, 
no ambulatory assistance, and community-dwelling). Our outcome was dialysis modality 
assignment: in-center hemodialysis (ICH), peritoneal dialysis (PD), or home hemodialysis 
(HHD). Statistical analysis was performed using ANOVA, t test, and Pearson’s chi-square.
Results: Of 1338 patients, 85 were on PD, and 18 on HHD. Our population is 
predominantly AA with 91% of ICH, 69% of PD, and 77% of HHD patients being AA. 
Compared to ICH patients, PD and HHD patients were younger, less likely to have history 
of substance abuse, and more likely to be employed and independent (Table 1). There was 
no difference in depression/anxiety across modalities. When just the AA sample (n=1094) 
was analyzed, history of substance abuse, employment status, and independence similarly 
varied between modalities.
Conclusions: Our results suggest that African-American ESRD patients who utilize 
home dialysis are more likely to be employed, live independently, and less likely to have 
substance abuse history. Comparisons of outcomes of home vs. in-center modalities should 
take these psychosocial factors into account. Further investigation of other factors which 
could inform targeted interventions to improve utilization of home dialysis is warranted.
SA-PO927 Poster Saturday
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The Mechanism of Intestinal Mucosal Dysfunction Induced by Long-Term 
Peritoneal Dialysis - Activating the P38MPAK Signaling Pathway
Chen Jiang. Nephrology, First teaching hospital of Tianjin university of TCM, 
Tianjin, China, TIANJIN, China.
Background: During long-term PD treatment, the abdominal cavity is always in a 
high pressure, high glucose environment, resulting in peritoneal and intestinal injury. The 
peritoneal and intestinal injury lead to a series of complications including endogenous 
peritonitis, abdominal infection, malnutrition, gastrointestinal disorders inadequate dialysis. 
Unfortunately, the underlying mechanisms of long-term PD induced intestinal mucosal 
dysfunction remain unclear The present study was designed to investigate the potential 
molecular mechanisms of intestinal mucosal dysfunction induced by long-term peritoneal 
dialysis (PD) treatment.
Methods: Modified peritoneal dialysis rat model and lipopolysaccharide induced IEC-6 
cell were used to observe. We examined the intestinal mucosal architecture injury induced by 
long-term PD by HE staining. Intestinal mucosal permeability was determined by measuring 
the intestinal clearance of fluorescein-isothiocyanate dextran (FD4), the transepithelial 
electrical resistance (TER) and the serum levels of D-lactate, Diamine oxidase (DAO) and 
endotoxin. the potential molecular mechanisms were explored by detecting the mRNA 
expression of ICAM-1, IL-1β, iNOS and TNF-α via real-time qPCR and the protein 
expression levels of P-p38MAPK, occludin, ZO-1 and DUSP1 via western blot.
Results: Long-term PD could increase the intestinal mucosal permeability by 
decreasing the level of TER and increasing the intestinal clearance of FD4, resulting in 
the serum levels of D-lactate, DAO and endotoxin significantly increased. Co-treatment 
with Fushen granule could decrease the intestinal mucosal permeability. In vivo and vitro 
studies, long-term PD markedly decreased the mRNA expression of ICAM-1, IL-1β, iNOS 
and TNF-α, and further activated the p38MPAK signaling pathway via up-regulating the 
protein expression of P-p38MPAK and down-regulating the protein expression of occludin, 
ZO-1 and DUSP1. Co-treatment with Fushen granule could markedly increase the mRNA 
expression of ICAM-1, IL-1β, iNOS and TNF-α and inhibit the activation of p38MPAK 
signaling pathway.
Conclusions: The present study is the first to demonstrate that long-term PD induces 
intestinal mucosal dysfunction by activating the p38MAPK signaling pathway.
SA-PO928 Poster Saturday
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High Salt Intake Increases Baseline Peritoneal Transport Rate Through 
Local TonEBP Activation in Subtotal Nephrectomized Mice
Ting Sun,1 Masashi Mizuno,1 Yasuhiro Suzuki,1 Takako Tomita,1 Fumiko Sakata,1 
Shoichi Maruyama,1 Takayuki Katsuno,2 Hiroshi Kinashi,2 Yasuhiko Ito.2,1 
1Nagoya University Graduate School of Medicine, Nagoya, Japan; 2Aichi 
Medical University, Nagakute, Aichi, Japan.
Background: Baseline peritoneal solute transport rate (PSTR) measured by peritoneal 
equilibration test (PET) within 6 months after PD commencement varies between patients 
independently of PD therapy. Previously, we have reported a positive association between 
baseline D/P Cr and the number of peritoneal blood vessels, macrophages and IL-6-positive 
cells (2011,NDT). Besides, our recent work has shown that high salt intake promotes tissue 
inflammation in uremic mice (2017, Lab Invest). The present study aims to probe whether 
high salt intake causes pre-dialysis intraperitoneal inflammation and leads to high PSTR in 
subtotal nephrectomized mice.
Methods: Sham-operated (Sham) and subtotal nephrectomized (Nx) mice were 
randomly given tap water or 1% salt (NaCl)-containing water. After 8 weeks, 4.25% 
glucose-based PET was performed to evaluate peritoneal function. In another experiment, 
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overexpressed intraperitoneal IL-6 was functionally blocked by MR16-1 to examine the 
role of IL-6 in this process. Human mesothelial cell line Met5A was used for in vitro studies.
Results: A significant elevation of D/P Cr and a decrease of D/D0 glucose were 
observed in Nx+salt group. There was also enhanced angiogenesis and macrophage 
infiltration in the peritoneum of Nx+salt mice, along with elevated VEGF-A and MCP-1 
concentration in the dialysate. Compared to Nx+water group, the increased concentration of 
effluent but not serum IL-6 suggested a strong local production in Nx+salt group. Blockade 
of IL-6 signaling by MR16-1 alleviated angiogenesis and macrophage infiltration in Nx+salt 
mice and rescued peritoneal transport function. In cultured human mesothelial cells, 40mM 
additional NaCl in the medium could significantly upregulate the expression of IL-6, as 
well as VEGF-A and -C, companied by an increased expression and nuclear translocation 
of TonEBP, an osmolality-sensing transcription factor. Knockdown of TonEBP by siRNA 
could lower such overexpression caused by high tonicity. Notably, peritoneal expression of 
TonEBP in Nx+salt group also showed an upregulation, indicating a key role of it in higher 
peritoneal transport status.
Conclusions: These findings suggest that high salt intake under uremic status could 
increase peritoneal transport rate via local TonEBP activation.
Funding: Commercial Support - CHUGAI PHARMACEUTICAL CO.,LTD., 
Government Support - Non-U.S.
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Attenuation of Glucose-Induced Inflammatory Reaction by Blocking of 
TonEBP in Primary Cultured Human Peritoneal Mesothelial Cells
Un Sil Jeon,1,2 Yon Su Kim,4 Seung Hee Yang.3 1Sheikh Khalifa Specialty 
Hospital, Ras Al Khaimah, United Arab Emirates; 2Internal Medicine, Seoul 
National University Hospital, Seoul, Republic of Korea; 3Kidney Research 
Institute, Seoul National University, Seoul, Republic of Korea; 4Seoul National 
University College of Medicine, Seoul, Republic of Korea.
Background: Long-term exposure to high-glucose concentration in peritoneal 
dialysate can cause peritoneal damage by inflammatory reaction and fibrosis in the 
peritoneum, which finally leads to withdrawal from peritoneal dialysis. Recently, it is 
known that tonicity induced transcriptional activator, TonE binding protein (TonEBP), is 
involved in the pathogenesis of diabetic complications such as retinopathy and nephropathy 
(Cardiovasc Diabetol. 2016 Jan 29;15:18, J Am Soc Nephrol. 2018 Feb;29(2):492-504).
Methods: Here, we examined the role of TonEBP in glucose induced inflammation 
using primary cultured human peritoneal mesothelial cells (HPMCs). HPMCs were isolated 
from peritoneal effluents of patients on peritoneal dialysis. Isolation and characterization of 
HPMCs were verified by cobblestone like characteristic morphology and the expression of 
the standard mesothelial markers.
Results: First, we observed that both high concentration of NaCl and 2% glucose 
induced increase in TonEBP mRNA expression and activation of TonEBP by nuclear 
translocation in cultured HPMCs. Aldose reductase (AR) mRNA expression, a target gene 
of TonEBP, was increased by high NaCl and glucose as expected. The treatment of NaCl 
and glucose increased in abundance of p65, NF-κB protein, but did not induce nuclear 
translocation of it. The gene expression of inflammatory markers such as IL-6, IL-8, MCP-
1 and IκB was increased in culture HPMCs by high glucose treatment. High glucose also 
increased cytokine levels of IL-6, IL-8 and MCP-1 in supernatant of HPMCs. Next, we 
examined the role of TonEBP in those inflammatory reactions by blocking of TonEBP 
using TonEBP disrupted MEF cells and TonEBP siRNA in HPMCs. IL-6 and IL-8 mRNA 
expression was decreased in both TonEBP disrupted MEF cells and TonEBP si-RNA treated 
HPMCs. However, there was discrepancy in the effect of high glucose on MCP-1 and IκB 
expression by TonEBP blocking between TonEBP disrupted MEF cells and TonEBP si-
RNA in HPMCs.
Conclusions: Our findings suggest that TonEBP is involved in high-glucose induced 
inflammatory changes in the peritoneum of peritoneal dialysis patients, which could be 
prevented by blocking TonEBP action.
SA-PO930 Poster Saturday
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Transcriptomic Analysis of PCK Rat Peritoneum After Long -Term 
Infusion of Dialysate with Mono or Dual Therapy of a JAK1/2 Inhibitor 
and/or Losartan
Sonny T. Nguyen,1 Sharon G. Adler,1 Kana N. Miyata,1 Pei Zhang,2 Janine A. La 
page,1 Tiane Dai.1 1Los Angeles Biomedical Research institute at Harbor-UCLA 
Medical Center, Torrance, CA; 2The First Affiliated Hospital of Anhui Medical 
University, Anhui, China.
Background: Peritoneal dialysis (PD) is limited by reduced efficacy over time. 
Peritoneal membrane (PM) injury is characterized by inflammation, hypervascularity, and 
fibrosis. JAK/STAT signaling mediates inflammatory pathways, including angiotensin 
signaling. Our previous work showed in rats with polycystic kidneys (PCK) chronically 
infused with 4.25% Dianeal x 16 wks, treatments with JAK1/2 inhibitor (JAK1/2i), 
losartan, or both preserved PM structure; JAK1/2i conferred better structural preservation 
vs losartan. Monotherapy with either JAK1/2i or losartan failed to consistently preserve PM 
function; dual infusion consistently preserved PM function. In order to elucidate mechanism 
at the transcriptomic level, we performed RNAseq analysis on PCK rat peritoneum.
Methods: PCK rats received dialysate infusions BID via an implanted subcutaneous 
port in the neck tunneled to the intraperitoneal cavity for 16 wks in the following groups: (1) 
4.25% Dianeal; (2) 4.25% Dianeal + JAK1/2i (5mg/kg BID); (3) 4.25% Dianeal + Losartan 
(5mg/kg BID); and (4) 4.25% Dianeal + Losartan +JAK1/2i (5mg/kg BID each). PM with 
muscle was sampled for RNAseq. Total RNA was used, cDNA libraries were single-end 
sequenced (50bp) on an Illumina HiSeq 3000. Differentially expressed genes are defined as 
at least 2-fold change and p<0.05.
Results: Compared to PCK rats receiving Dianeal only, concomitant infusion of Dianeal 
and JAK1/2i or losartan up- or downregulated expression of 88 genes in 132 canonical 
pathways and 36 genes in 55 pathways respectively. Combination treatment with JAK1/2i 
and losartan caused differential expression of 29 genes in 65 pathways. When comparing 
PCK rats that received JAK1/2i to losartan, 38 genes in 98 pathways were differentially 
expressed. 12 genes were regulated by either JAK1/2i or losartan with a similar pattern, of 
which, only three were similarly regulated when both JAK1/2i and losartan were infused.
Conclusions: The differentially expressed gene pattern may explain superior 
morphologic protection in the JAK1/2i group and the functional preservation in the dual 
therapy group that we previously showed in our study. The transcriptomic analysis in this 
study provides gene differential expression profiles of JAK1/2i and losartan that helps 
explain different treatment effects.
Funding: Commercial Support - Renal Research Institute
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Trehalose Ameliorates Peritoneal Fibrosis Through the Suppression of 
Fibroblast Proliferation and Extracellular Matrix Production in 
Fibroblasts
Taito Miyake, Norihiko Sakai, Koichi Sato, Akihiro Sagara, Shinji Kitajima, 
Tadashi Toyama, Akinori Hara, Yasunori Iwata, Miho Shimizu, Kengo Furuichi, 
Takashi Wada. Kanazawa University, Kanazawa, Japan.
Background: Peritoneal fibrosis is a severe complication of peritoneal dialysis, but 
there are few effective therapies to treat and/or prevent for it. Trehalose is a non-reducing 
disaccharide and can be an osmolyte of peritoneal dialysis solution. We have previously 
revealed that trehalose ameliorated peritoneal fibrosis through the induction of autophagy 
and the downregulation of Snail protein in peritoneal mesothelial cells. In this study, we 
examined if trehalose also has anti-fibrotic effects on fibroblasts in the peritoneum.
Methods: Peritoneal fibrosis was induced by intraperitoneal injection of chlorhexidine 
gluconate (CG). 5% trehalose or vehicle (normal saline) was administered by intraperitoneal 
injection to mice every other day.
Results: Trehalose attenuated CG-induced increases in peritoneal thickness, type 
I pro-collagen mRNA expression and hydroxyproline content (n=4-9). In addition, CG 
challenges induced a marked peritoneal accumulation of α smooth muscle actin (αSMA)+ 
fibroblasts that was significantly reduced by trehalose. We next examined fibroblast 
proliferation induced by CG challenges in ColIα2-enhanced green fluorescent protein (GFP) 
transgenic mice. In order to specifically identify proliferating fibroblasts, we double-stained 
peritoneal sections with anti-PCNA antibody and anti-GFP antibody. The number of PCNA 
and GFP dual positive proliferating fibroblasts in the peritoneal tissue after CG challenges 
was significantly increased in the vehicle group as compared to the trehalose group, as was 
the percentage of proliferating fibroblasts among total fibroblasts. We also performed an 
in vitro study to confirm the effects of trehalose on the proliferation of fibroblasts. TGF-β1 
induced fibroblast proliferation; however, trehalose suppressed the fibroblast proliferation 
in a dose-dependent manner. In addition, trehalose attenuated αSMA, ColIα1, Col3α1 and 
fibronectin mRNA expression induced by TGF-β1.
Conclusions: Our results suggest that trehalose might be a novel therapeutic reagent 
for peritoneal fibrosis through the suppression of fibroblasts proliferation and extracellular 
matrix production in fibroblasts.
SA-PO932 Poster Saturday
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Novel Role of Nuclear Factor of Activated T-Cells 5 (NFAT5) as a 
Mediator of EMT of Peritoneal Mesothelial Cells (MCs) via Modulation of 
Nod-Like Receptor-3 (NLRP3) Inflammasome
Duk-Hee Kang,2 Eun sun Ryu,1 Dal-ah Kim,3 Hyun-Jung Kang,4 You Jin Kim,5 
Sun-Hee Park,6 Yong-Lim Kim,6 Hyug M. Kwon.7 1Ewha Womans University 
School of Medicine, Seoul, Republic of Korea; 2Ewha University College of 
Medicine, Seoul, Republic of Korea; 3Ewha Womans University Medical Center, 
Seoul, Seoul, Republic of Korea; 4Ewha Womans University, Seoul, Republic of 
Korea; 5Kyungpook National University, Daegu, Republic of Korea; 6Kyungpook 
National University Hospital, Daegu, Republic of Korea; 7UNIST, Ulsan, 
Republic of Korea.
Background: Epithelial-to-mesenchymal Transition (EMT) of MCs is known as an 
early mechanism of peritoneal fibrosis in PD. NLRP3 inflammasome is comprised of the 
NLRP3, ASC and procaspase-1, which leads to the maturation of IL-1β and IL-18. NFAT5 
is an essential transcription factor regulating cellular homeostasis to hypertonicity-induced 
osmotic stress, and recently reported as a pro-inflammatory mediator. We investigated 
whether NFAT5 plays a role in peritoneal EMT via a modulation of NLRP3 inflammasome 
in MCs.
Methods: The expressions of NFAT5, components of NLRP3 inflammasome, nuclear 
translocation of NFAT5, β-catenin and snail were evaluated by western blotting. EMT was 
evaluated by the changes in morphology and markers of epithelial and mesenchymal cells. 
E-cadherin promoter activity was confirmed by luciferase assay. Effect of gene silencing of 
NFAT5, NLRP3 and ASC on EMT was examined using siRNA. Animal model of peritoneal 
fibrosis was established by intraperitoneal injection of adenoviral vector of TGFβ in BL6 mouse.
Results: TGFβ increased NFAT5 expression and its nuclear translocation in MC. 
TGFβ-induced EMT was associated with an up-regulation of NLRP3, ASC, procaspase-1 
and an increased production of IL-1β/IL-18. In adenoviral TGFβ-injected mice, EMT of 
MC with submesothelial fibrosis was observed with an increased expression of NFAT5 
and NLRP3. siNFAT5 ameliorated TGFβ-induced EMT with an increase in E-cadherin 
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promotor activity as well as a decrease in snail expression and nuclear translocation of 
β-catenin. siNLRP3, siASC and neutralizing antibodies of IL-1β and IL-18 alleviated 
TGFβ1-induced EMT. siNFAT5 also alleviated TGFβ1-induced activation of NLRP3 
inflammasome. Neither MAPK inhibitors (PD98059, SB203580) nor antioxidants (NAC, 
Apocynin, Mitotempo) altered TGFβ1-induced up-regulation of NFAT5 of MC.
Conclusions: This data suggest NFAT5 plays a key role in peritoneal EMT via tonicity-
independent mechanism by either an inhibition of E-cadherin transcription and activation 
of NLRP3 inflammasome. Modulation of NFAT5 and NLRP3 inflammasome in MCs could 
be a novel approach to protect the peritoneum from the development of EMT and peritoneal 
fibrosis in PD patients.
SA-PO933 Poster Saturday
Dialysis: Peritoneal Dialysis - III
Intra-Nuclear Binding of NFAT5/TonEBP to ß-Catenin Is a Key Process of 
Hypertonicity-Induced Phenotype Transition of Peritoneal Mesothelial 
Cells (MCs)
Duk-Hee Kang,2 Hyun-Jung Kang,4 Eun sun Ryu,3 Dal-ah Kim.1 1Ewha Womans 
University Medical Center, Seoul, seoul, Republic of Korea; 2Ewha University 
College of Medicine, Seoul, Republic of Korea; 3Ewha Womans University 
School of Medicine, Seoul, Republic of Korea; 4Ewha Womans University, 
Seoul, Republic of Korea.
Background: Epithelial-to-mesenchymal transition (EMT) of MCs is an early 
mechanism of peritoneal fibrosis in peritoneal dialysis. Nuclear Factor of Activated T 
Cells-5 (NFAT5), also known as TonEBP, is a transcriptional factor that enables cellular 
adaptation to hypertonic osmotic stress. Recent data demonstrated the role of NFAT5/
TonEBP in phenotype transition of cancer cells. The aim of this study is to investigate 
whether NFAT5/TonEBP is involved in hypertonicity-induced EMT of MCs and to identify 
the potential mechanisms of NFAT5/TonEBP-mediated peritoneal EMT.
Methods: The expressions of NFAT5/TonEBP, other osmotic stress-related genes 
including sodium-myoinositol cotransporter (SMIT), betaine/γ-aminobutyric acid 
transporter (BGT1) and aldose reductase (AR) and nuclear translocation of β-catenin were 
evaluated by real-time PCR and western blotting. EMT was evaluated by morphological 
changes of MCs and the expressions of E-cadherin and α-SMA after stimulation of high 
glucose (HG, 30-120 mM) and mannitol (30-120 mM). E-cadherin promoter activity was 
confirmed by luciferase assay. The interaction between TonEBP and β-catenin was analyzed 
by immunoprecipitation.
Results: Both HG or Mannitol enhanced the expression of NFAT5/TonEBP as well 
as SMIT, BGT1 and AR at transcriptional and translational levels from the concentration 
of 30 mM. HG induced EMT of MCs, however mannitol did not show the evidence of 
EMT even at the concentration of 120 mM. HG (>30 mM) induced nuclear translocation 
of NFAT5/TonEBP which was associated with an enhanced binding to β-catenin. Mannitol 
also promoted nuclear translocation of NFAT5/TonEBP only at the highest concentration 
we tested (120 mM), however it was not associated with intra-nuclear binding of NFAT5/
TonEBP to β-catenin. In contrast to persistent increase in intra-nuclear β-catenin in HG-
exposed MCs, there was only a transient increase in β-catenin with 120 mM of mannitol 
at 1 hour. HG decreased E-cadherin promoter activity whereas mannitol did not alter the 
transcription of E-cadherin.
Conclusions: The role of NFAT5/TonEBP as a mediator of peritoneal EMT is 
demonstrated in this study for the first time. Not the increased expression of NFAT5/
TonEBP per se but intra-nuclear translocation with binding to β-catenin is a key mechanism 
by which NFAT5/TonEBP induced EMT of MCs.
SA-PO934 Poster Saturday
Dialysis: Peritoneal Dialysis - III
The Expression of Glucose Transporters (GLUTs) and Sodium-Glucose 
Co-Transporters (SGLTs) in Peritoneal Mesothelial Cell (MC) and Its 
Role in Phenotype Transition of MC
Duk-Hee Kang,2 Eun sun Ryu,1 Dal-ah Kim,3 Hyun-Jung Kang.4 1Ewha Womans 
University School of Medicine, Seoul, Republic of Korea; 2Ewha University 
College of Medicine, Seoul, Republic of Korea; 3Ewha Womans University 
Medical Center, Seoul, SEOUL, Republic of Korea; 4Ewha Womans University, 
Seoul, Republic of Korea.
Background: Phenotype transition of MCs such as epithelial-to-mesenchymal 
transition (EMT) by glucose or proinflammatory cytokines is known as an early mechanism 
of peritoneal dysfunction in peritoneal dialysis (PD). Given the consideration of high 
glucose concentration in peritoneal dialysate, the expressions of GLUTs and SGLTs in MC 
may play a role in peritoneal EMT. However, there are few data on the expression and 
regulation of GLUTs and SGLTs in MCs. We investigated the expression of each isoform of 
GLUTs and SGLTs, and their role in EMT of peritoneal MCs.
Methods: MCs were also isolated from overnight dwell dialysate effluents from 
clinically stable PD patients (MCs-DE) as well as omentum (MCs-OT) to assess the 
expression of GLUTs and SGLTs. The expressions of GLUT-1, -2, -3, SGLT-1, and -2 were 
investigated by real-time PCR and Western botting. EMT was evaluated by the changes in 
cell morphology and expression of epithelial and mesenchymal cell markers. To investigate 
the role of SGLTs in peritoneal EMT, the effects of Dapagliflozin (SGLT2 inhibitor, 500nM) 
and Empagliflozin (SGLT 1/2 inhibitor, 500nM) were evaluated.
Results: GLUT-1, -2, -3, SGLT-1 and -2 were constitutively expressed in MC, and 
up-regulated by the stimulation with high glucose (HG, 60 mM) both at mRNA and protein 
levels. GLUT-1 and -3 were quantitatively major transporters in MCs, however HG-induced 
upregulation was more prominent in SGLT-1 and -2. The expression of GLUT-1, -2, SGLT-
1 and -2 were higher in MCs-DE compared to MCs-OT which have never been exposed 
to dialysate. TGFβ also increased the expression of GLUT-1, -2, -3, SGLT-1 and -2. High 
glucose- and TGFβ-induced EMT in MCs-OT were ameliorated by pre-treatment with 
Dapagliflozin or Empagliflozin.
Conclusions: Modulation of the activity and expression of glucose transporters in 
MCs by specific inhibitors or glucose-sparing prescription of peritoneal dialysis could be 
a novel therapeutic approach to protect the peritoneum from the development of EMT and 
peritoneal fibrosis in PD patients.
SA-PO935 Poster Saturday
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Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal 
Mesothelial Cells by Down-regulating β-Catenin
Manshu Yu,1 Jun Shi,1 Meixiao Sheng.2 1Nanjing University of Chinese 
Medicine, Nanjing, China; 2Jiangsu Province Hosiptal of Chinese Medicine, 
Nanjing, China.
Background: The epithelial-to-mesenchymal transition (EMT) of peritoneal 
mesothelial cells (PMCs) is a crucial event in the induction of peritoneal fibrosis (PF), 
in which canonical Wnt/β-catenin signaling participates. Smads signaling is reported to 
interact with β-catenin and synergistically regulates EMT. Astragalus is the traditional 
Chinese herbal which has an effect to restrain the ROS, anti-inflammatory, anti-fibrosis, 
etc. This study was aimed to reveal the effect of Astragalus on β-catenin in EMT of PMCs.
Methods: The HMrSV5 cell line and gene transfection rats were treated with Astragalus. 
EMT markers or signaling pathway-related indicators were detected by western blotting, 
immunofluorescence, immunohistochemistry, immunoprecipitation and real-time PCR.
Results: HMrSV5 EMT model was established by TGF-β1, and the peritoneal fibrosis 
rat model was established by 4.25% glucose peritoneal dialysis solution. Astragalus 
inhibited EMT of PMCs including increased E-cadherin and decreased α-SMA and 
Vimentin, as well as attenuated peritoneal thickening and fibrosis in rats. During the process 
of PMCs EMT, Astragalus could inhibit β-catenin expression. Astragalus down-regulated 
β-catenin by stabilizing the GSK-3β/β-catenin complex and further inhibited the nuclear 
translocation of β-catenin. Meanwhile, Akt is the upstream protein of GSK-3β/β-catenin, 
which could regulate the degradation of β-catenin. On the other hand, Astragalus down-
regulated β-catenin by enhancing Smad7 expression. Silencing Smad7 in HMrSV5 and rats 
antagonized the EMT-inhibitory effect of Astragalus.
Conclusions: Astragalus inhibits EMT of PMCs by down-regulating β-catenin. The 
modulation of β-catenin in peritoneum can be a novel tool to prevent PF.
Funding: Government Support - Non-U.S.
SA-PO936 Poster Saturday
Dialysis: Peritoneal Dialysis - III
Connective Tissue Growth Factor Is Correlated with Peritoneal 
Lymphangiogenesis
Hiroshi Kinashi,1,2 Naohiro Toda,3 Tri Q. Nguyen,2 Yasuhiro Suzuki,4 
Takayuki Katsuno,1 Hideki Yokoi,5 Jan Aten,6 Masashi Mizuno,4 
Shoichi Maruyama,4 Motoko Yanagita,5 Roel Goldschmeding,2 Yasuhiko Ito.1 
1Aichi Medical University, Nagakute, Japan; 2University Medical Center 
Utrecht, Utrecht, Netherlands; 3Kansai Electric Power Hospital, Osaka, Japan; 
4Nagoya University Graduate School of Medicine, Nagoya, Japan; 5Kyoto 
University Graduate School of Medicine, Kyoto City, Japan; 6Academic Medical 
Center, Amsterdam, Netherlands.
Background: Lymphatic absorption in peritoneal cavity may contribute to ultrafiltration 
failure in peritoneal dialysis (PD). Lymphatic vessels develop during PD-related peritoneal 
fibrosis. Connective tissue growth factor (CTGF, also known as CCN2) is an important 
determinant of fibrotic tissue remodeling, but little is known about its possible involvement 
in lymphangiogenesis. We studied the relationship between CTGF and lymphangiogenesis 
in association with PD.
Methods: Protein levels of CTGF and vascular endothelial growth factor-C 
(VEGF-C), a major lymphangiogenic factor, were measured in 77 human PD effluents. 
Messenger RNA (mRNA) expression of CTGF, lymphatic markers (lymphatic endothelial 
hyaluronan receptor-1 [LYVE-1] and podoplanin), and VEGF-C was analyzed in 56 
human peritoneal biopsies. CTGF and VEGF-C mRNA were assessed in cultured human 
peritoneal mesothelial cells (HPMC) (N=21) treated with transforming growth factor-β1 
(TGF-β1). CTGF involvement in diaphragamatic lymphangiogenesis was explored in a 
rat peritoneal fibrosis model induced by chlorhexidine gluconate (CG). Finally, the role of 
CTGF inhibition in peritoneal lymphangiogenesis was evaluated in the CG model using 
CTGF knockout mice.
Results: A positive correlation was observed between CTGF and VEGF-C 
concentration in human PD effluents (R=0.428, p<0.001). CTGF mRNA positively 
correlated with VEGF-C (R=0.67, p<0.001), LYVE-1 (R=0.638, p<0.001), and podoplanin 
(R=0.592, p<0.001) mRNA in human peritoneal biopsies. There was a positive relationship 
between CTGF and VEGF-C mRNA fold-increase in HPMC at 12 hours after TGF-β1 
treatment (R=0.722, p<0.001). Immunohistochemstry and in situ hybridization showed 
that CTGF, VEGF-C, and LYVE-1-positive lymphatic vessels were increased in the rat 
diaphragm of CG model compared with controls. CTGF expression positively correlated 
with VEGF-C expression (p<0.001) and lymphatics (p<0.05) in the rat diaphragm of 
CG model. Finally, CTGF gene deletion significantly reduced VEGF-C expression and 
suppressed lymphangiogenesis in the mouse peritoneum of CG model.
Conclusions: Our results suggest a close relationship between CTGF and PD-
associated lymphangiogenesis.
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The Role of Suppression of Tumorigenicity-2 (ST2) in the Peritoneal 
Fibrosis and Peritoneal Dialysis (PD) Outcomes
Yong Chul Kim,1 Mi-yeon Yu,1 Hajeong Lee,2 Yun Jung Oh,6 Jae Wook Lee,5 Un 
Sil Jeon,4 Jung Pyo Lee,3 Kook-Hwan Oh,7 Ran-hui Cha,9 Seung Hee Yang,8 Yon 
Su Kim.2 1SNUH, Seoul, Republic of Korea; 2Seoul National University College 
of Medicine, Seoul, Republic of Korea; 3Seoul National University Boramae 
Medical Center, Seoul, Republic of Korea; 4Sheikh Khalifa Specialty Hospital, 
Ras Al Khaimah, United Arab Emirates; 5National Cancer Center, Seoul, 
Republic of Korea; 6Cheju Halla General Hospital, Jeju, Republic of Korea; 
7Seoul National University Hospital, Seoul, Republic of Korea; 8Kidney 
Research Institute, Seoul National University, Seoul, Republic of Korea; 
9National Medical Center, Seoul, Republic of Korea.
Background: Peritoneal fibrosis (PF) is an intractable complication which leads to 
peritoneal membrane failure in PD. The aim of this study is to investigate the role of ST2 
involved in PF.
Methods: Samples of dialysate and clinical data were prospectively collected from 54 
patients at Seoul National University Hospital between 2010 and 2016. Dialysate soluble 
ST2 (sST2) levels were measured after 1 month of PD initiation (baseline) using the ELISA 
technique. Fibrosis induced by TGFβ and high concentration of glucose in primary cultured 
human peritoneal mesothelial cells (HPMCs) were evaluated with ST2, fibronectin, β-
galactosidase, snail and E-cadherin protein expressions. Anti-ST2 monoclonal antibody 
(mAb) was treated to evaluate the neutralizing effect of ST2 on PF. Immunohistochemistry 
(IHC) stain of ST2 was performed in peritoneum tissue samples of chlorhexidine gluconate 
(CG)-induced PF mice and control.
Results: Baseline dialysate sST2 (sST2-b) levels were 2063.4 ± 2457.8 pg/mL and 
mean duration of follow-up periods was 53.4 ± 18.8 months. We observed that patients 
who changed dialysis modality to hemodialysis due to PD failure had high sST2-b levels in 
peritoneal effluent compared with others (1576.2 ± 199.9 vs 4143.1 ± 1107.3, P = 0.03). High 
sST2-b was associated with a hazard ratio (HR) for PD failure of 7.72 (95% CI 1.10-54.3, 
P = 0.04) in a fully adjusted model. sST2-b showed a good performance of predicting PD 
failure; the area under the ROC curve was 0.784 (P = 0.001). We found that in primary 
cultured HPMCs, TGFβ treatment increased protein expressions of ST2, fibronectin, β-
galactosidase, snail and decreased expression of E-cadherin in a dose-dependent manner. 
Protein expression of ST2 and fibronectin were decreased after anti-ST2 Ab administration. 
High concentration of glucose (100mmol/L) also induced fibrosis in HPMCs and fibrosis 
was ameliorated after treating anti-ST2 Ab. ST2 was found in fibroblasts and mesothelial 
cells within the underlying submesothelial zones of CG-induced PF mice.
Conclusions: Elevated dialysate levels of sST2 is associated with PD failure. Thus, an 
elevated dialysate levels of ST2 appears to play a role in fibrosis and inflammation during 
peritoneal injury. And ST2 blockade is a potential therapeutic target for renal preservation.
SA-PO938 Poster Saturday
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Longitudinal Changes of NF-kB Downstream Mediators and Peritoneal 
Transport Characteristics in New Peritoneal Dialysis Patients
Winston W. Fung,2 Cheuk-Chun Szeto.1 1The Chinese University of Hong Kong, 
Shatin, China; 2Prince of Wales Hospital, Hong Kong, China.
Background: The success of peritoneal dialysis (PD) depends on the semi-permeable 
peritoneal membrane. The regulation of peritoneal transport remained to be fully elucidated, 
but intra-peritoneal cytokines, notably interleukin-6 (IL-6), cyclo-oxygenase-2 (COX-2), 
and hepatocyte growth factor (HGF), probably play important roles. We investigate the 
relation between longitudinal changes in PD effluent cytokine levels and the corresponding 
alterations in peritoneal transport parameters over 1 year.
Methods: We studied 46 new PD patients who had peritoneal equilibration test 
performed at baseline and then one year later. Dialysate-to-plasma creatinine level at 4 
hours (D/P4), mass transfer area coefficient of creatinine (MTAC), and ultrafiltration (UF) 
volume were taken as peritoneal transport parameters. Concomitant PD effluent levels of 
IL-6, COX-2 and HGF were measured and compared.
Results: There were significant correlations between baseline as well as one-year PD 
effluent IL-6 and COX-2 levels with the corresponding D/P4 and MTAC. The change in PD 
effluent IL-6 and COX-2 levels from baseline to one year also correlated with the change 
in D/P4 and MTAC during the same time. In contrast, PD effluent HGF did not showed 
any significant correlation with the corresponding D/P4 and MTAC, both at baseline and 
one year later. After one year, patients who had peritonitis had higher PD effluent IL-6 
(26.6 ± 17.4 vs 15.1 ± 12.3 pg/ml, p = 0.037) and COX-2 levels (4.97 ± 6.25 vs 1.60 ± 
1.53 ng/ml, p = 0.007) than those without peritonitis, and the number of peritonitis episode 
during follow up period significantly correlated with the PD effluent IL-6 and COX-2 levels 
after one year. No significant difference in PD effluent HGF level after 1 year of dialysis 
are noted between patient with and without peritonitis. There was no significant difference 
in any cytokine level between patients who received conventional and low glucose 
degradation product PD solutions.
Conclusions: PD effluent IL-6 and COX-2 levels significantly correlate with the 
peritoneal transport characteristics. Patients who had peritonitis during the follow up 
period had higher PD effluent IL-6 and COX-2 levels after one year than patients without 
peritonitis. Our result suggests that intra-peritoneal IL-6 and COX-2 play important roles in 
the short-term regulation of peritoneal transport.
Funding: Government Support - Non-U.S.
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Inhibition of mPGES-1 Blocks High Glucose-Induced Mesothelial-to- 
Mesenchymal Transition of Peritoneal Mesothelial Cells
Qimei Luo. Shunde Hospital of Southern Medical University, Foshan, China.
Background: Peritoneal mesangial cells (PMC) undergoing mesothelial-to-
mesenchymal transition (MMT) induced by chronic sterile inflammation promotes 
peritoneal fibrosis. Microsomal prostaglandin E2 synthase-1 (mPGES-1)-derived PGE2 
plays an important role in inflammatory disease. Previous studies have shown that the 
secretion of PGE2 increased significantly in PMC under the circumstance of high glucose. 
This study aimed to investigate the role of mPGES-1 in phenotype transition of PMC.
Methods: The expression of mPGES-1 in human peritoneum tissue was evaluated by 
immunohistochemical. Human mesothelial cells were incubated with 138mmol/L glucose 
for various periods of time. After transfection of shRNA plasmid targeting mPGES-1, 
human mesothelial cells were incubated with 138mmol/L glucose and harvested for further 
analysis.
Results: Immunohistochemical analysis displayed mPGES-1 was expressed in the 
outermost layer of the peritoneal membrane and upregulated in peritoneal tissue of patients 
with peritoneal ultrafiltration failure. In cultured human mesothelial cells, high glucose time-
dependently increased the expression of mPGES-1. Western blots confirmed that mPGES-1 
was increased more than threefold by high glucose. Besides, application of mPGES-1 
shRNA plasmid significantly reduced protein and mRNA expressions of mPGES-1 in 
human mesothelial cells. Moreover, inhibition of mPGES-1 in human mesothelial cells 
dramatically reversed levels of E-cadherin and decreased the synthesis of MMT-related 
proteins, such as fibronectin and vimentin.
Conclusions: The findings suggest that mPGES-1 could be activated by high glucose 
and could contribute to MMT of PMC.
SA-PO940 Poster Saturday
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Hyaluronan Generated During Peritoneal Dialysis Does Not Drive 
Fibrosis, but Regulates Inflammatory Cell Recruitment Through 
Differential Hyaluronan Synthase (HAS) Expression
Aled P. Williams,3,1 Adam C. Midgley,2,3 Aled O. Phillips,3,1 Robert Steadman,3,1 
Timothy Bowen,3,1 Donald Fraser,3,1 Soma Meran.3,1 1Cardiff University, 
Llanelli, United Kingdom; 2Nankai University, Tianjin, China; 3Wales Kidney 
Research Unit, Cardiff, United Kingdom.
Background: Peritoneal membrane dysfunction is a key determinant of Peritoneal 
Dialysis (PD) failure, and is associated with repeated episodes of peritonitis and exposure 
to bio-incompatible dialysis solutions. TGF-β1-driven transdifferentiation of mesothelial 
cells to myofibroblasts through mesothelial to mesenchymal transition (MMT) underlies 
peritoneal membrane dysfunction and ultimately peritoneal fibrosis. In solid organ fibrosis 
(kidneys & lungs), pro-fibrotic cell differentiation is driven by changes in synthesis and 
macromolecular organisation of the matrix polysaccharide hyaluronan (HA). In this work, 
we determine whether factors that regulate HA synthesis in the peritoneum have a the role 
in driving peritoneal inflammation and in the prevention/reversal of fibrosis
Methods: In-vitro studies were performed on human peritoneal mesothelial cells and 
ex-vivo PD effluent from patients with peritonitis. Genetic and histological analysis of 
peritoneal membranes from a murine model of peritoneal inflammation (live attenuated 
staphylococcus epidermidis induced peritonitis) were utilised in-vivo
Results: Patients with PD peritonitis had significantly increased HA concentrations 
day-1 after developing acute bacterial peritonitis compared to non-infected patients. TGF-
β1-driven MMT in primary human mesothelial cells significantly increased extracellular 
HA generation, predominantly driven by Hyaluronan Synthase-1 (HAS1) isoenzyme 
expression. In contrast to kidney and lung fibrosis this increased HA was not causally 
involved in driving MMT. Instead, HAS1 in peritoneal tissues and mesothelial cells was 
associated with enhanced leukocyte recruitment and activation in the peritoneum. Blockade 
of HAS1 driven HA synthesis in mice led to delayed neutrophil clearance and monocyte 
recruitment indicating a delayed inflammatory response
Conclusions: In contrast to solid-organ fibrosis where HA seems to have an important 
role in driving fibrosis through a HAS2 dependent phenotype, TGF-β1 driven MMT in 
mesothelial cells generates HA that is not involved in peritoneal fibrosis. HAS1 generated 
by mesothelial cells appears to be involved in regulating the acute inflammatory response 
and may be involved in reparative processes that limit fibrosis in the peritoneum
SA-PO941 Poster Saturday
Dialysis: Peritoneal Dialysis - III
Protein Kinase C-Beta Deficiency and Inhibition Exacerbate High 
Glucose-Induced Peritoneal Damage via M1/M2 Macrophage Polarization
Michael S. Balzer, Alexandra Helmke, Song Rong, Sibylle Von Vietinghoff, 
Hermann G. Haller, Nelli Shushakova. Dpt. of Nephrology and Hypertension, 
Hannover Medical School, Hannover, Germany.
Background: Macrophage (MØ)-driven inflammation is a key hallmark of glucose-
mediated damage to the peritoneal membrane (PM) during peritoneal dialysis. We have 
recently shown that in mesothelium PKCα is a major mediator of PM damage, whereas 
PKCβ deficiency results in increased glucose-mediated PM damage. PKCβ is expressed 
most abundantly in MØ. We hypothesized that within a high glucose milieu PKCβ plays an 
important role in controlling MØ activation and function.
Methods: Combining qPCR, ELISA, Western blot, and flow cytometry we investigated 
primary murine peritoneal MØ of PKCβ-/- and wild type (WT) mice, murine bone marrow-
derived MØ of WT mice, and primary human peripheral blood monocyte-derived MØ 
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during normal (10mM) and high glucose (120mM) conditions. Some experiments involved 
LPS stimulation and pharmacological PKCβ inhibition using ruboxistaurin. In vivo PM 
damage was evaluated in a chronic peritoneal dialysis mouse model in PKCβ-/- and WT 
mice using flow cytometry and immunofluorescence.
Results: In vitro murine MØ, in comparison to PKCα, abundantly (>50-fold) 
expressed PKCβ mRNA at normal glucose conditions. A high glucose milieu induced 
PKCβ and suppressed PKCα mRNA and protein expression. High glucose conditions 
facilitated murine and human MØ polarization towards M2. Both genetic deficiency 
and pharmacological inhibition of PKCβ increased high glucose+LPS-mediated IL-6, 
TNFα, and MCP-1 production and decreased IL-10 release compared to a state of genetic 
or functional presence of PKCβ. In vivo catheter-delivered treatment with high glucose 
peritoneal dialysis fluid for 5 weeks induced PKCβ up-regulation in omentum rich of 
MØ in WT mice and resulted in an inflammatory response and PM damage characterized 
by fibrosis and neo-angiogenesis. In comparison to WT mice, destructive changes were 
strongly aggravated in PKCβ-/- animals. Finally, flow cytometry and immunofluorescence 
demonstrated a substantial M1 polarization of peritoneal MØ in PKCβ-/- mice, while WT 
mice predominantly mounted an M2 response.
Conclusions: PKCβ is the dominant PKC isoform in peritoneal macrophages. It is up-
regulated and exerts peritoneal anti-inflammatory effects in a high glucose milieu both in 
vitro and in an in vivo mouse model of chronic peritoneal dialysis via M1/M2 macrophage 
polarization.
Funding: Government Support - Non-U.S.
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The Global DNA Methylation Profile of Human Peritoneal Fibrosis
Pengpeng Yan,1,2 Jia Shen,1,2 Rending Wang,1,2 Jianghua Chen.1,2 1Kidney 
Disease Center, the First Affiliated Hospital, College of Medicine, Hangzhou, 
China; 2Zhejiang University School of Medicine, Hangzhou, China.
Background: Long-term exposure to biocompatible peritoneal dialysate induced 
peritoneum fibrosis, exacerbating peritoneal dialysis (PD) efficiency.
Methods: Peritoneal tissues of PD patients were obtained during kidney transplantation 
(PD group, n=10), along with Control group from normal individuals (n=6). Histological 
staining and qRT-PCR were applied to evaluate the peritoneal fibrosis level, while 
Infinium® HumanMethylation EPIC was used to analyze differentially methylated probes 
(DMPs), which formed the gene clusters (corrected p<0.05, |Δβ|>0.2). Functional network 
analysis was applied to extract the key regions within the interaction.
Results: Structural remodeling was found in Peritoneum from PD patients, including 
SMC significant thickening, vascular wall of peritoneal postcapillary venules thickening 
(p<0.001). The number of α-SMA positive cells in PD peritoneum increased, with up-
regulation of Fibronectin and Vimentin mRNA (p<0.05). The global DNA methylation level 
decreased in PD peritoneum, with 9,948 up-regulated DMPs and 39,109 down-regualed 
DMPs, which covered all euchromosome and were enriched in function or pathway terms 
such as cell morphology, cell migration, and ECM buildup; functional analysis of the 
CpG-rich regions revealed THBS1 and PRKACA are two key functional blocks related 
to cell proliferation/migration, which involved Wnt/β-catenin signaling pathway and PKA 
signaling pathway, respectively.
Conclusions: Fibrotic structural remodeling was presented in the peritoneum of PD 
patients, with a hypomethylated reprogramming of the global DNA methylation profile.
Funding: Government Support - Non-U.S.
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Direct Interaction of Mesothelial Cells with Macrophages via Stalked 
Fractalkine Promotes Dialysate Induced Peritoneal Fibrosis
Alexandra Helmke,1 Johannes Nordlohne,1 Michael S. Balzer,1 Marcus Hiss,1 
Nelli Shushakova,2 Hermann G. Haller,1 Sibylle Von Vietinghoff.1 1Hannover 
Medical School, Hannover, Germany; 2Nephrology and Hypertensiology, 
Hannover, Germany.
Background: Fibrosis limits the use of peritoneal dialysis (PD) as renal replacement 
therapy. PD solution induces mesothelial cell activation and macrophage accumulation in 
the peritoneal wall. Macrophages highly express chemokine receptor CX3CR1. Its ligand 
fractalkine (CX3CL1) exists in a stalked surface-bound and a soluble form. This study 
addressed their role in peritoneal fibrosis.
Methods: Wildtype and CX3CR1 deficient mice received dialysis solution for human 
use via a peritoneal catheter for six weeks and tissues were analyzed by histology. Murine 
and human primary cells were investigated using a combination of qPCR, ELISA, flow 
cytometry and confocal microscopy.
Results: Human and murine peritoneal mesothelial cells expressed surface-bound 
and secreted fractalkine/CX3CL1. During experimental PD treatment in mice, CX3CL1 
increased on the peritoneal membrane. Cytokines TNFα, IL-1β and TGFβ markedly 
induced CX3CL1 expression by mesothelial cells in vitro. In addition, direct co-culture 
with CX3CR1-competent macrophages induced CX3CL1 and also TGFβ, a main promoter 
of fibrosis. The increase of CX3CL1 and TGFβ in direct macrophage-mesothelial coculture 
was no longer observed in transwell co-cultures and also disappeared in direct coculture 
with CX3CR1 deficient macrophages, indicating a role for cellular CX3CR1-CX3CL1 
interaction. TGFβ increased macrophage CX3CR1 expression and Increased CX3CR1 
was observed during PD treatment. Wildtype mice developed significantly more peritoneal 
fibrosis than CX3CR1 deficient animals. Peritoneal dialysis solution directly induced 
macrophage IL-1β, one of the mesothelial CX3CL1-promoting cytokines, thus providing 
a mechanism of initiation for this pro-fibrotic interaction loop. Peritoneal dialysis patients’ 
peritoneum expressed more CX3CL1 than untreated tissue and CX3CR1 was higher in 
serum of patients that recently started PD than in controls, providing evidence of relevance 
in the human situation.
Conclusions: PD solution initiates a pro-fibrotic loop of mesothelial CX3CL1 binding 
to macrophage CX3CR1 that promote peritoneal fibrosis in vivo. Similar observations in 
human cells suggest that CX3CR1-CX3CL1 interaction should be investigated further as a 
new therapeutic angle in peritoneal fibrosis.
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Early Peritoneal Dialysis Ameliorates Acute Lung Injury Induced by Blast 
Injury in Rats
Kehong Chen,1 Yani He.2 1Daping hospital, Chongqing, Chongqing, China; 
2Daping Hospital, Chongqing, China.
Background: Blast injury frequently occurs in wars and disasters. Blast lung injury 
is the most common type of blast injury with a remarkable lack of effective treatment. 
Blast lung injury manifested as pulmonary hemorrhage, edema and secondary systemic 
inflammation. This study aimed to investigate the therapeutic efficacy and mechanism of 
peritoneal dialysis in rats with blast lung injury.
Methods: 75 SD rats were randomly divided into five groups: control group, sham 
group, glucocorticoid (GC) group, peritoneal dialysis (PD) group, PD+GC (PDGC) group. 
All rats were injured by bio-shock tube (BST-I) apparatus. PD group was treated with 
continuous peritoneal dialysis for 6 hours. GC group were injected with a small dose of 
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methylprednisolone. Lung function, pathological changes and pneumonedema in rats were 
detected after 24h treatment. Inflammatory cytokine levels in serum were determined by the 
technology of Milliplex.
Results: 37 rats (49.3%) survived at 24 hours after blast injury. There was no 
significant difference in the mortality rate between the groups. Lung water content of rats in 
PD and PDGC groups were significantly lower than that of the control group. Pathological 
staining showed that the degree of pulmonary interstitial edema in PD and PDGC rats was 
significantly lower than that in the control group. Pulmonary function (FVC, functional 
residual capacity, oxygen saturation, arterial oxygen pressure, oxygenation index, and 
maximal mid expiratory flow) in PD and PDGC groups was significantly higher than that of 
the control group. The serum levels of IL-1β, IL-6, MCP-1 and TNFα in the PD and PDGC 
rats were significantly lower than those in the control group. The levels of IL-1β and TNFα 
in the serum of GC rats were significantly lower than those of the control group.
Conclusions: Early peritoneal dialysis improves acute lung injury and systemic 
inflammation induced by blast injury.
Funding: Government Support - Non-U.S.
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Is Abdominal Muscle the Right Parietal Peritoneal Tissue for Gene 
Expression Analysis?
Pei Zhang,1 Kana N. Miyata,2 Sharon G. Adler,2 Cynthia C. Nast,3 
Hashim Mapara,2 Janine A. La page,2 Tiane Dai.2 1The First Affiliated Hospital 
of Anhui Medical University, Anhui, China; 2Los Angeles Biomedical Research 
Institute at Harbor-UCLA Medical Center, Torrance, CA; 3Cedars Sinai Medical 
Center, Los Angeles, CA.
Background: Recently there has been increased interest in studying peritoneal 
membrane pathophysiology at a transcriptomic level in animal models. Standard tissue 
sampling includes abdominal wall muscle. Some consider muscle as part of the peritoneal 
barrier. However the massive muscle mass overwhelms signals from the mesothelium and 
sub mesothelial compact zone where much of the peritoneal ultrafiltration occurs. To address 
this, we performed RNAseq in microdissected parietal peritoneum without muscle compared 
to the samples with muscle in rats with polycystic kidneys (PCK) chronically infused with 
4.25% Dianeal, with or without JAK1/2 inhibitor (JAK1/2i) or losartan for 16 wks.
Methods: PCK rats received dialysate infusions BID for 16 wks in the following 
groups: Control-no infusion; 4.25% Dianeal; 4.25% Dianeal + JAK1/2i (5mg/kg BID); 
4.25% Dianeal + Losartan (5mg/kg BID). Parietal peritoneum was sampled either with 
microdissection under anesthesia without muscle or standardly with muscle. Total RNA 
was used, cDNA libraries were single-end sequenced (50bp) on an Illumina HiSeq 3000. 
Differentially expressed (DE) genes are defined as at least 2-fold change and p<0.05. 
Comprehensive pathway analysis was performed using Ingenuity’s Pathway Analysis (IPA).
Results: As shown (Table), there are significant differences in DE genes or pathways 
when using different samples with the same intervention. The peritoneum without muscle 
shows significantly more DE genes with more pathways involved. When comparing 
samples ± muscle, only a few shared gene transcript changes were observed.
Conclusions: Microdisseted parietal peritoneum samples showed more DE genes 
and pathways than samples with muscle. Our study suggests more precise tissue sampling 
should be considered to better reflect peritoneal signals in transcriptomic analysis studies.
Funding: Commercial Support - Renal research Institute
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Vascular Access Practices in Japan
Genta Uehara,1 Tomoki Tsukahara,2 Mary S. Hammes,3 Rita L. McGill.3 
1Okinawa Chubu Hospital, Uruma, Japan; 2Tsukuba Central Hospital, Ushiku, 
Japan; 3University of Chicago Medicine, Chicago, IL.
Background: Increasing fistulas (AVF) and grafts (AVG) and decreasing catheters 
(CVC) is a priority for all hemodialysis (HD) patients. DOPPS data indicate that Japanese 
patients have superior vascular access outcomes, so we examined vascular access practices 
for new HD patients in Japan.
Methods: Chart review identified patients presenting to two Japanese hospitals (an 
academic medical center in Okinawa and a private referral hospital in Ibaraki prefecture) for 
new kidney failure with no vascular access, from 2013-2017. Demographic and clinical data 
were collected, as well as the timing of vascular access surgery, hospital discharge/transfer, 
and cannulation of any new AVF or AVG. Time data are shown as median (interquartile 
range). Patients were censored upon transfer from facility or death.
Results: Among 222 patients (103 from Okinawa and 119 from Ibaraki), 36.9% were 
female, age was 70 (60, 79) years, and weight 54.6 (46.7, 61.3) kg. AVF/G were successful 
during 164/222 (73.9%) of hospitalizations. 58 patients left hospital with CVC, of whom 
4 had unsuccessful surgery. Time from admit to surgery was 14 (7,26) days. There were 9 
AVG, 9 upper arm AVF, and the remainder were Cimino or snuffbox AVF. AVF/G were 
cannulated with 17 gauge needles at a median of 13 (8,16) days after surgery. Hospital 
length of stay was 30 (20, 49) days, so cannulation usually occurred prior to hospital 
discharge. A Kaplan-Meier curve shows time to conversion from CVC to AVF or AVG in 
days. Treatments were 240 (240,240) min; blood pump rates were 150 (120,180) mL/min at 
first use and increased to 200 mL/min over time.
Conclusions: Initial hospitalization of a new Japanese HD patient frequently includes 
creation and first use of AVF/AVG; hospital length of stay is longer than in many other 
countries. Early construction and early use of native fistulas in the forearm and wrist is 
associated with very low usage of CVC in Japan, which may be facilitated by low blood 
pump speeds and longer treatments.
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Octogenarians in Pre-Dialysis Phase Do Not Have Worse Results of Radio 
Cephalic Arteriovenous Fistula Compared to Younger Patients
Raffaella Mauro, Mohammad Abualhin, Rodolfo Pini, Anna Laura Croci 
Chiocchini, Gabriele Donati, Alessia Pini, Gianluca Faggioli, Gaetano La 
Manna, Andrea Stella, Mauro Gargiulo. Azienda Ospedaliero-Universitaria di 
Bologna, Bologna, Italy.
Background: KDOQI guidelines recommend radiocephalic arteriovenous fistula 
(RCAVF) as a first choice access for hemodialytic treatment, but there is no clear indication 
in octogenarians. The study aim was to compare the results of RCAVF in octogenarians and 
younger patients.
Methods: All patients treated by RCAVF from Jan-2013 to Dec-2017 were included in 
a retrospective study. The population was divided according to age: <80 years (Group-A: 
mean age 61 years ±15; 80.9% males) and ≥80 years (Group-B: mean age 83 years ±3; 
91.8% males). Patient demographics, comorbidities, and dialytic treatment were collected 
prospectively. The endpoints were technical success, defined as AVF presenting vascular 
murmur and thrill at the end of operation, primary patency defined as patency of vascular 
access with no significant arterial/venous stenosis, and assisted patency defined as patency 
of vascular access following a salvage procedure (PTA or surgical).
Results: Within the study period, 366 RCAVF were performed. 72(19.6%) patients 
were lost to follow-up. A total of 294 RCAVF were analyzed: 249(83.3%) RCAVF were 
performed in Group-A and 49(16.7%) in Group-B. Technical success was obtained in 
95.9% of cases with no differences between the two groups (P=0.70). The mean follow 
up was 25 months. Primary and assisted patency rates were significantly higher in Group 
A (P=0.002 and P=0.023, respectively). Primary patency rates at 12,24 and 36 months 
were respectively 77.5%,73.9% and 73.9% in Group-A and 66.0%,49.8% and 46.0% in 
Group-B. Assisted patency rates at 12,24 and 36 months were respectively 79.6%,76.5% 
and 75.8% in Group-A and 70.2%,62.4% and 54.8% in Group-B. At univariate analysis 
pre-dialytic phase was an independent positive predictor for patency in Group-B (P=0,013) 
but not in global population (P=0.66). Considering all patients in pre-dialytic phase, there 
was no significant difference in primary patency rates between Group-A and B (P=0.59). 
Considering the octogenarians, 81.6% RCAVF became functional within the first 3 months.
Conclusions: According to the study results, RCAVF is associated with good results in 
octogenarians in pre-dialytic phase with suitable anatomical features and could be indicated 
as a first choice treatment.
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Influence of Arteriovenous Fistula on Daily Living Behaviors Involving 
the Upper Limbs in Hemodialysis Patients: A Questionnaire Study
Daiki Aomura,1 Yuji Kamijo,1 Shigekazu Kurihara,2 Takayuki Nimura.3 1Shinshu 
University School of Medicine, Matsumoto, Japan; 2Department of Nephrology, 
Shinshu University School of Medicine, Matsumoto, Japan; 3Shinshu university, 
Matsumoto, Japan.
Background: Arteriovenous fistulae can restrict daily living behaviors involving the 
upper limbs in hemodialysis patients, but no studies have investigated the detailed effects 
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of an arteriovenous fistula on routine life activities. Accordingly, many medical caregivers 
are unable to explain the effects of an arteriovenous fistula on daily life, particularly during 
non-dialysis periods, because they cannot observe them directly.
Methods: Thirty outpatients undergoing hemodialysis at 2 facilities scored the difficulty 
due to an arteriovenous fistula in performing 48 living behaviors during non-dialysis and 
10 behaviors during dialysis into 5 grades in a comprehensive questionnaire survey. These 
behaviors were selected based on an open-answer pre-questionnaire administered to the 
30 patients beforehand. The scores were also compared between dominant arm and non-
dominant arm arteriovenous fistula groups.
Results: During non-dialysis, the difficulty scores of behaviors restricted out of concern 
for arteriovenous fistula obstruction (wear a wristwatch, hang a bag on the arm, carry a baby 
or a dog in the arms, wear a short-sleeved shirt, etc.) increased. The difficulties of “wear 
a wristwatch” and “hang a bag on the arm” were significantly higher in the nondominant 
arm arteriovenous fistula group (both P<0.05). In contrast, scores related to motor function 
(write, eat or drink, scratch an itch, etc.) increased remarkably during dialysis because of 
connection of the arteriovenous fistula to the dialysis machine. The difficulties of “write” 
and “eat or drink” were significantly higher in the dominant arm arteriovenous fistula group 
(both P<0.05)
Conclusions: Several key daily living behaviors restricted by an arteriovenous fistula 
were identified in this questionnaire survey. These results will be useful for preoperative 
explanation of arteriovenous fistula surgery and arm selection in end-stage renal disease 
patients.
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Gender Disparities in Vascular Access Surgical Outcomes Among Elderly 
Hemodialysis Patients
Timmy C. Lee,1,5 Joyce Z. Qian,4 Mae Thamer,3 Michael Allon.2 1Univ of 
Alabama at Birmingham, Birmingham, AL; 2University of Alabama at 
Birmingham, Birmingham, AL; 3MTPPI, Bethesda, MD; 4Johns Hopkins 
University, Baltimore, MD; 5Veterans Affairs Medical Center, Birmingham, AL.
Background: Despite national vascular access guidelines promoting use of 
arteriovenous fistulas (AVF) over arteriovenous grafts (AVG) for dialysis, AVF use is 
substantially lower in females. The objective of this study was to assess clinically relevant 
AVF and AVG surgical outcomes in elderly male and female patients initiating hemodialysis 
with a central venous catheter (CVC).
Methods: Using the United States Renal Data System standard analytic files linked 
with Medicare claims, we assessed incident hemodialysis patients in the United States, 
9,458 elderly patients (≥67 years) (4,927 males and 4,531 females) initiating hemodialysis 
from July 2010 to June 2011 with a catheter, and received an AVF or AVG placed within 6 
months. We evaluated vascular access placement, maturation (successful use for diaysis), 
assisted maturation (requiring an intervention before maturation), abandonment after 
maturation, and rate of interventions after maturation.
Results: Females were less likely than males to receive an AVF (adjusted likelihood 
0.57, 95% confidence interval [CI] 0.52-0.63). Among patients receiving an AVF (Fig. 1), 
females had higher adjusted likelihoods of AVF non-maturation (HR 1.46, 95% CI 1.36-1.56), 
assisted AVF maturation (OR 1.34, 95% CI 1.17-1.54), and AVF abandonment (HR 1.28, 
95% CI 1.10-1.50), but similar relative rate of AVF interventions after maturation (RR 1.01, 
95% CI 0.94-1.08). Among patients receiving an AVG, females had a lower likelihood 
of AVG non-maturation (HR 0.83, 95% CI 0.73-0.94), similar rates of assisted AVG 
maturation (OR 1.05, 95% CI 0.78-1.40) and AVG abandonment, and greater relative rate 
of interventions after AVG maturation (RR 1.16, 95% CI, 1.01-1.33).
Conclusions: In elderly patients initiating hemodialysis with a catheter, clinical AVF 
surgical outcomes are uniformly worse in females. AVGs may be a viable alternative, 
notwithstanding current national recommendations.
Funding: NIDDK Support, Veterans Affairs Support
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A Novel Prospective in Maturation of Native Arteriovenous Fistula (AVF): 
Preliminary Data from a Single Center
Ioannis E. Giannikouris,1,2 Ioannis Koutis,2 Periklis P. Kyriazis,3 Sotiris Mikros,4 
Giovanni Giordano,5 Giuseppe Bacchini.6 1Medifil SA, Athens, Greece; 2Thriasio 
General Hospital of Elefsina, Elefsina, Greece; 3Internal Medicine, Baystate 
Medical Center/University of Massachusetts, Springfield, MA; 4General 
Hospital of Piraeus, Athens, Greece; 5Vanvitelli L. Hospital, Tramonti, Italy; 
6Alessandro Manzoni Hospital Lecco, Lecco, Italy.
Background: Our objective was to quantitatively evaluate time alterations of 
parameters, predictive of hemodynamic maturation of the newly created AVF, in the 
immediate and late postoperative period (60 days).
Methods: Observational prospective cohort study of 80 incident hemodialysis (HD) 
and non-dialysis dependent end-stage renal disease (ESRD) patients, who were referred 
to for AVF creation. Measured parameters predictive of AVF hemodynamic maturation 
were; lumen diameter of feeding artery (brachial artery, dBA), efferent vein lumen diameter 
(dEV) and wall thickness (tEV), access volume flow rate (VF) and brachial artery resistive 
index (RI). Measurements were conducted daily from postoperative day 1 to 7, days 14, 21, 
28 and day 60 from AVF creation (day 0). Daily average alteration value of each parameter 
was assessed and comparison of average observed values followed.
Results: A total of 80 patients, 63 males and 17 females aged 62±15 years, 48 on HD 
and 32 with non-dialysis dependent ESRD, were enrolled. Fistulae of 4 patients failed during 
the study period (5% primary failure rate). In total, 43 distal and 33 proximal AVF were 
successfully created and studied upon completion of follow-up. A daily increase of 0.71% 
in dBA and 0.70% in dEV from day 1 to 7 was observed. Daily increment rate of dBA a 
nd dEV, from day 8 to 28, was calculated at 0.07% and 0.06%, respectively, whereas from 
day 29 to 60 dBA was daily increased by 0.01% and dEV by 0.01%. Regarding tEV, a daily 
increase by 2.75% from day 1 to 7, 0.08% (days 8 to 28) and 0.01% daily from day 29 to 
60 was observed. Resistive Index RI was decreased by 1.33% (days 1 to 7), 0.10% from 
day 8 to 28, while from day 29 to 60 it was increased by 0.03%. Lastly, VF was increased 
daily by 1.79% (day 1 to 7), while increase rate was calculated at 0.01% (day 8 to 28) and 
0.004% from day 29 to 60.
Conclusions: Hemodynamic maturation of a newly created AVF is thought to be 
concluded in the first postoperative week. These findings may offer a new perspective to 
determine the optimal time to assess the hemodynamic and clinical maturation of AVF 
but most importantly contribute on decisions making about time of interventions to assist 
maturation. However, future research is considered mandatory for establishment of firm 
conclusions.
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Surgeon Variation in Dialysis Vascular Access Outcomes in the United 
States
Vahakn Shahinian,1 Xiaosong Zhang,1 Anca Tilea,1 Kevin He,1 
Douglas E. Schaubel,1 Ronald L. Pisoni,2 Bruce M. Robinson,2 Rajiv Saran,1 
Kenneth J. Woodside.1 1University of Michigan, Ann Arbor, MI; 2Arbor Research 
Collaborative for Health, Ann Arbor, MI.
Background: An arteriovenous fistula (AVF) is the access of choice for most patients 
on chronic hemodialysis. Operating surgeon characteristics have been proposed as 
contributors to successful AVF creation and AVF survival, but previous studies have been 
limited by small sample size. We examined surgeon-related vascular access outcomes at 
the national level.
Methods: From the United States Renal Data System, we used Medicare claims and 
web-based data submitted by dialysis facilities to examine the primary outcome: % of 
AVFs with successful use within 6 months of placement, i.e. ‘maturation’, over the period 
2013-2014. A multilevel logistic regression model was used to examine the association of 
surgeon characteristics (year of graduation, type of surgical specialty, volume, ie number of 
AVF placements per year) with the outcome, adjusted for patient characteristics (age, sex, 
race, comorbidities, dialysis vintage, prior access placement) and dialysis facility effects.
Results: Over the study period, 2,770 surgeons were identified as placing at least 5 
AVFs, with a total of 49,826 AVF placements. The median AVF maturation rate was 
59% (interquartile range 44% to 71%). In the model, more recent year of medical school 
graduation, but not surgical specialty (general surgery, transplant surgery, vascular surgery) 
was associated with higher odds of AVF maturation. In addition, increasing historical 
volume of AVF placement was associated with higher odds of successful AVF maturation: 
odds ratio 1.46 (95%CI 1.37-1.57) for highest (>84 AVF placements in 2 years) vs lowest 
(<14) volume quintile. Expressed as AVF maturation probability, outcomes varied from 
56.8% to 66.6% from lowest to highest volume decile (Figure).
Conclusions: We observed wide surgeon level variation and a strong surgeon volume-
outcome relationship for the outcome of AVF maturation.
Funding: NIDDK Support
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Risk Factors Associated with Distal Hypoperfusion Ischemic Syndrome in 
Patients with an Arteriovenous Access
Muhammad Sohaib Karim,1 Ali I. Gardezi,1 Kyla M. Bennett,3 Brad C. Astor,1,2 
Micah R. Chan.1 1Division of Nephrology, University of Wisconsin School of 
Medicine and Public Health, Madison, WI; 2Department of Population Health 
Sciences, University of Wisconsin School of Medicine and Public Health, 
Madison, WI; 3University of Wisconsin, Madison, WI.
Background: Steal syndrome, or distal hypoperfusion ischemic syndrome (DHIS), is 
a complication in up to 20% of patients using an arteriovenous access such as a fistula or 
synthetic graft for chronic hemodialysis. The purpose of this study was to determine the risk 
factors associated with the development of DHIS.
Methods: Thirty-nine (39) patients with a diagnosis of DHIS were identified and 
compared to thirty-nine (39) randomly selected patients with arteriovenous access without 
DHIS (control group) from December 2008 to September 2017. Univariate and multivariate 
analysis were done to assess the relationship between development of DHIS and risk factors 
such as age, gender, race, distal versus proximal location of vascular access, peripheral 
vascular disease, diabetes and congestive heart failure.
Results: Risk of DHIS did not differ significantly by age, race, diabetes mellitus, 
coronary artery disease or peripheral vascular disease (Table 1). Proximal versus distal 
placement of access (odds ratio= 5.98, 95 % CI: 1.35, 26.42) as well as female gender 
(odds ratio= 4.15, 95 % CI: 1.35, 12.76) were associated with a higher incidence of DHIS.
Conclusions: Age, race, congestive heart failure, diabetes and peripheral vascular 
disease did not appear to be risk factors associated with the development of distal 
hypoperfusion ischemic syndrome. Female gender and proximal location of vascular access 
were associated with significantly higher risk of DHIS. Further studies are required to 
investigate these findings.
Results
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Using Machine Learning to Predict Optimal Renal Replacement Therapy 
Starts in Patients with Advanced Renal Function Loss
Ollie Fielding,1 Chris Kipers,1 Jung Hoon Son,1 Edward Lee,1 Daniel Levine,2 
Thomas Parker,2 Barry H. Smith,2 Jeffrey I. Silberzweig.2 1pulseData, New York, 
NY; 2The Rogosin Institute, New York, NY.
Background: Building on our previous work using machine learning techniques to 
identify patients at risk of progression to End Stage Renal Disease (ESRD), we focused 
this model more precisely on identifying patients with advanced kidney function loss who 
should plan for optimal renal replacement therapy. The most recent USRDS data indicates 
that more than 80% of patients begin hemodialysis with a catheter and only 2.5% receive 
preemptive renal transplants.
Methods: Using longitudinal patient data of 109,028 patients from The Rogosin 
Institute, we identified a cohort of patients with advanced kidney function loss, defined as 
an eGFR <20, and built a machine learning model to predict which patients would need to 
begin renal replacement therapy in the next six months, based on progression to an eGFR 
<10. Information in the model included patient demographics, vital signs, comorbidities, 
laboratory values, and medications. We used an algorithm to remove measurements taken 
during an AKI episode. We evaluated whether the model could identify the need for renal 
replacement therapy prior to clinical need.
Results: Between 2014 and 2016, only 17 of 214 patients who progressed within a 
six month period received an AV fistula prior to their decline to an eGFR <10. The model 
identified 181 patients as the top quintile of risk who would benefit from preparation for 
renal replacement therapy. Our model has an AUC of 0.93, a sensitivity of 0.81 and a 
specificity of 0.89 at the top quintile.
Conclusions: We demonstrate improved ability to identify patients who will need renal 
replacement therapy using an advanced machine learning model incorporating longitudinal 
data commonly available in EHRs. We plan to augment clinical decision making with 
machine learning tools.
Funding: Commercial Support - pulseData
Numbers for 2014-2016
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A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of 
Plastic Cannula Compared with Metal Needle in Incident Hemodialysis 
Patients
Sung gyun Kim, Narae Joo, Jwa-kyung Kim. Hallym University, Anyang, 
Republic of Korea.
Background: Successful cannulation of arteriovenous fistula (AVF) is an important 
issue especially in patients who start hemodialysis. Metal needles have been used for 
decades, but more recently, the usefulness of plastic cannula has been introduced. In this 
study, a
Methods: This was a single-center, prospective, randomized, open-label study with 
incident hemodialysis patients. Eligible patients were randomized into 2 groups in a 1:1 
ratio (n=20 in each group). Maturation of AVF was confirmed using Doppler US, and well-
trained two nursing staffs implemented AVF cannulation. Primary endpoint was the rate 
of early successful cannulation, defined as the successful completion of three consecutive 
dialysis sessions with adequate blood flow rates. Secondary outcomes were incidence of 
vessel injuries (bruising, swelling, erythema, and hematoma), degree of pain, difficulties 
during cannulation, and urea clearance. Devices examined were metal needle (JMS, 16G, 
Singapore), and plastic cannula (Supercath Clampcath®, 17G, Togo Medikit, Japan).
Results: Among the 40 patients, radiocephalic AVFs were 47.5 % (n=19) and mean 
duration from AVF creation to first cannulation was 51.7 ± 26.5 days. No significant 
difference was found between groups with respect to patient age, sex, prevalence of 
diabetes, or types of AVF. Failure of early successful cannulation was observed in 9 patients, 
and the failure risks tended to be higher in metal group (2 cases in plastic group, but 7 cases 
in metal group, p=0.060). In addition, the risk of vessel injury was significantly higher in 
metal group than in plastic group (44.4% vs 11.1%, p=0.030). However, the degrees of 
pain that patients feel was slightly higher in plastic group than in metal group (4.5 vs. 2.9, 
p=0.066). The difficulties during cannulation felt by nursing staffs or urea clearance were 
similar in both groups.
Conclusions: Use of plastic cannulas provided less vascular injury and may increase 
the rate of successful cannulation especially in early period of dialysis. It could be a new and 
innovative tool for improve dialysis quality.
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Lower Access Flow After Banding Reduces Frequency of Interventions 
and Increases Access Patency
Florian Toegel,1 Patrick McGlynn,2 Adina S. Voiculescu,3 Dirk M. Hentschel.1 
1Brigham and Women’s Hospital, Boston, MA; 2Brigham and Women’s Hospital, 
Boston, MA; 3Brigham and Womens Hospital, Boston, MA.
Background: Patency of brachial-cephalic autogenous accesses is mainly limited by 
cephalic arch stenosis (CAS). Shear stress is one factor believed to contribute to recurrence 
and high flow may be associated with less favorable shear stress. Angioplasty (PTA) is 
effective in the short term but complicated by high recurrence rates and stent grafts have 
been used to prolong patency. We report the long-term outcome after CAS PTA and stent 
graft placement in relation to access flow reduction.
Methods: The Brigham Health Interventional Nephrology dataset was reviewed for 
all patients with angioplasty and stent graft placement in patients with brachial-cephalic 
fistula 2008-2018, including only those patients with CAS interventions prior to the banding 
procedure. We used this dataset to compare the frequency of patients requiring cephalic 
arch angioplasty or stenting in a subset without banding procedure (control), and those 
with a banding procedure (exposure) to reduce the inflow segment to 3-5 mm diameter. 
We compared the frequency of interventions using Wilcoxon matched pair signed rank test 
given the non-parametric distribution of frequency of interventions.
Results: 22 patients meeting inclusion criteria were included in the study. We observed 
a flow reduction from 1807 ± 477 pre- to 1300 ± 454 post- banding; p<0.001. Along with 
the flow reduction we observed an increased intervention free period from 229 (IQR: 129-
320) pre- to 432 (IQR: 232-717) post-banding; p=0.02. We did not appreciate an association 
between the absolute flow value and number of days per procedure.
Conclusions: High blood flow is common in brachial-cephalic autogenous accesses 
and banding significantly decreases access flows. This access flow reduction increases 
the days between procedures for CAS suggesting a protective role for the development of 
restenosis.
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Arteriovenous Shunt for Hemodialysis – A Viable and Cost-Effective 
Vascular Access Option in Hemodialysis Patients
Anil Bhalla, Ashwani Gupta, Anurag Gupta, Vinant Bhargava, Devinder S. Rana. 
Nephrology, Sir Ganga Ram Hospital, New Delhi, India.
Background: In India, the most common vascular access for HD(95%) is Arteriovenous 
fistula (AVF). Primary AVF is the most preferred permanent vascular access - which can be 
created by radiocephalic or brachiocephalic anastomosis. Ageing population and diabetic 
patients presenting with sub-optimal veins, along with the issue of late referral makes timely 
AVF creation an unmet goal. Managing associated complications is an indispensable part of 
patient care but is also responsible for drain of fiscal resources.
Methods: We started hemodialysis programme in the Dept. of Nephrology, Sir Ganga 
Ram Hospital in 1981. Due to late referral and immediate need of dialysis, AV shunts were 
created. In patient with AKI, this shunt could be removed after recovery. In ESRD patients, 
the same shunt could be converted into AV fistula. Thus, a fistula created after maturation of 
veins following shunt placement could be used as early as 1-2 weeks. Since its inception, at 
our centre, vascular access creation has been in the domain of nephrologists.
Results: We have created 2640 AV Shunts till 2014 with infection rates <5% and 
3-month shunt blockage <10%. In view of logistic reasons, due to non-availability of shunt 
material, the programme suffered a setback. We continued to re-use shunts after sterilization, 
but, they are no longer available now. We have created 7920 AV Fistulas since 1981 till 
December 2017–achieving a primary patency rate of 95% and incidence of infection of
<5%. From 1981-2010, the standard practice was to convert AV Shunt into AV Fistula after 
4-6weeks or primary AVF was created asvascular access. Due to non-availability of AV
Shunts, now we use Internal-jugular (IJ) catheter for acute dialysis. We have placed over 
300 IJ catheters/year since 2014. However, the incidence of IJ catheter related blood stream 
infection is very high (around 90%) requiring catheter removal usually within 1 month of 
placement. We have put permcath in 10 patients last year, with average life of 1 year; with 
permcath thrombosis rates of 20% within 6 months.
Conclusions: To conclude, AV Shunt is still a viable, cost effective and preferred mode 
of vascular access in patients requiring hemodialysis and should be reintroduced in our 
practice.
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Likelihood of Failed Thrombectomy (LOFT)
Phillip Ribeiro,1 Moarij A. Qazi,2 Jennifer Morse,3 Thomas G. Stewart,3 
Rizwan A. Qazi.4 1Nephrology, Vanderbilt University, NASHVILLE, TN; 
2Internal Medicine, UNLV, LAS VEGAS, NV; 3Vanderbilt University Medical 
Center, Nashville, TN; 4KSOSN, Las Vegas, NV.
Background: Currently percutaneous thrombectomy (PCT) is widely used for clot 
removal, however if unsuccessful, the patient is referred for open surgical thrombectomy. 
The current literature suggests that the success rates for thrombolysis of thrombosed fistulas 
ranges from 76-96%. To date it is unknown what risk factors and or access characteristics 
result in PCT failure.
Methods: Retrospective single center study including 212 hemodialysis patients, with 
179 successful and 33 failed dialysis access thrombectomies. The following characteristics 
were evaluated for each patient: age, sex, diabetes, clot burden, central venous stenosis, 
presence of ≥ 2 aneurysms, previous stent placement, on outpatient anticoagulation, 
SBP<100mmHg, type and location of access, venous outflow stenosis, juxta-anastomotic 
stenosis, feeding artery diameter, arterial anastomotic stenosis, mid access stenosis, use of 
TPA or teratola, time of procedure, and presence of venous outflow stenosis. To assess the 
impacts of several risk factors, we constructed various models of success as a function of 
age group, sex, diabetes, and one of the other risk factors. The Holm-bonferroni step down 
method was used to adjust the p-values to deal with familywise error rates for multiple 
hypothesis tests.
Results: Risk factors for failed thrombectomies included the presence of ≥ 2 aneurysms 
and or patients with a forearm access. Patients with AV grafts and or venous outflow stenosis 
had significantly longer procedure times, and the use of teratola or TPA in patients with AV 
grafts did not affect PCT outcomes.
Conclusions: Our data illustrates that two indepednent risk factors for PCT failure 
include patients with a forearm access and or the presence of ≥ 2 aneurysms. A patient 
with both of these independent risk factors is perhaps better off being sent directly for open 
surgical thrombectomy. Moving forward, larger trials and a larger sample size are needed in 
order to prove the aforementioned results.
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Predictors of Complications During Outpatient Dialysis Access 
Procedures
Gregg Miller,1 Elsie Koh,1 Yue Jiao,2 Sophia Rosen,2 Marta Reviriego-Mendoza,2 
John W. Larkin,2 Len A. Usvyat,2 Nancy Mclaughlin,1 Catherina Madormo,1 
Murat Sor,1 Franklin W. Maddux.2 1Azura Vascular Care, Malvern, PA; 
2Fresenius Medical Care North America, Waltham, MA.
Background: It is unknown if patient specific factors contribute to complications 
during dialysis vascular access (VA) interventions. We detailed the characteristics of dialysis 
patients who underwent a VA procedure and investigated risk factors for perioperative 
complications.
Methods: We analyzed data from patients treated at a large dialysis provider who had ≥1 
VA procedure at an affiliated freestanding outpatient access center during 2016 and 2017. The 
distribution of perioperative complications (e.g. adverse drug reactions, falls, post-operative 
infections, required interoperative airway management, medication/fluids, and/or additional 
surgery/procedure) was assessed across strata for age (≤30, 31-40, 41-50, 51-60, 61-70, 
71-80, 81-90, >90 years), body mass index (BMI) (≤25, 26-30, 31-35, 36-40, 41-45, 46-50,
>50 kg/m2), and hemoglobin (HgB) levels (<9, 9-<10, 10-<11, 11-<12, 12-<13, ≥13 g/dL).
Chi-square tests were used to compare the percent (%) of complications within strata.
Results: We analyzed data from 29,322 unique dialysis patients who underwent a total 
of 100,070 VA procedures. The % of perioperative complications were evenly distributed 
for age (p=0.54) and BMI (p=0.09) strata (Figure 1 A & B). However, the % of perioperative 
complications was observed to be elevated for those with a HgB level <10 g/dL versus ≥10 g/dL 
(Figure 1 C; p<0.0001).
Conclusions: This research indicates that patients with low HgB levels may be at a 
higher risk for perioperative complications as compared to those with higher HgB levels; 
however, patients with low HgB levels are also at a higher risk of all-cause hospital 
admissions and mortality.
Funding: Commercial Support - Fresenius Medical Care North America
Dialysis: Vascular Access - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
987
J Am Soc Nephrol 29: 2018 Poster/Saturday
SA-PO959 Poster Saturday
Dialysis: Vascular Access - II
A Hybrid Technique in Recanalization of Multiple Central Venous 
Occlusions in Hemodialysis Patients: A Cohort Study
Yuliang Zhao, Ping Fu. Division of Nephrology, West China Hospital, Sichuan 
University, Chengdu, China.
Background: The management to multiple central venous occlusions (CVO) in 
hemodialysis patients remains difficult. This present study aims to assess the feasibility 
and safety of a hybrid technique in recanalizing multiple CVO in hemodialysis population.
Methods: From January 2014 to November 2017, hemodialysis patients with multiple 
CVO were enrolled. Under DSA guidance, patients received a hybrid technique combining 
direct puncture, sharp transversal, and balloon dilation of the SVC, followed by tunneled 
cuffed catheter implantation (figure). The demographic information and clinical outcomes 
were recorded.
Results: A total of 16 patients were involved in this study. The procedure was 
successfully performed in 15 cases and failed in 1 patient due to full-length obstruction 
of the SVC. 1 patient presented with transient cardiac arrest. 2 patients suffered mild 
pericardial tamponade, both stabilized afterwards. All 14 patients with successful catheter 
implantation had satisfactory patency after the procedure.
Conclusions: This hybrid technique could be performed effectively in selected 
hemodialysis patients with multiple CVO. It could be a viable alternative for hemodialysis 
catheterization in the setting of an exhausted central venous system with multiple CVO.
Figure: the procedure of the hybrid technique(Under DSA guidance, patients with SVC 
occlusion (arrow head) with dilated azygos vein (triangle) were identified (figure A, B). 
The distal part of SVC was directly punctured (figure C), as verified by contrast. Under 
guidance in anterior-posterior view and lateral view of DSA, we penetrated the occlusive 
SVC segment and then advance guide wire through the SVC into the IVC (figure D). The 
occlusive lesion was dilated with balloon (figure E), which enabled successful tunneled 
cuffed catheter implantation (figure F).)
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Reasons for Dialysis Catheter Insertion at a National Level – Real Time 
Data from the REDUCCTION Project
Sradha S. Kotwal,1,2 Girish S. Talaulikar,4 Nicholas A. Gray,5 
Kevan Polkinghorne,6 Stephen P. McDonald,7 Alan Cass,8 Martin P. Gallagher.1,3 
REDUCCTION Project Investigators 1The George Institute for Global Health, 
Sydney, NSW, Australia; 2Nephrology, Prince of Wales Hospital, Sydney, NSW, 
Australia; 3Concord Clinical School, Sydney, NSW, Australia; 4The Canberra 
Hospital, Garran, ACT, Australia; 5Sunshine Coast University Hospital, 
Birtinya, QLD, Australia; 6Monash Medical Centre and Monash University, 
Melbourne, VIC, Australia; 7Royal Adelaide Hospital, Adelaide, SA, Australia; 
8Menzies School of Health Research, Darwin, NT, Australia.
Background: Dialysis catheters are inserted for reasons which are not well measured 
or understood. Understanding reasons for catheter insertion on a real-time basis allows units 
to measure practice and catheter use in a national context. We aimed to understand the 
reasons for dialysis catheter insertion in patients of Australian renal units participating in 
a prospective national project (Reducing the burden of dialysis catheter complications - 
REDUCCTION).
Methods: Data was collected using a web-based data collection tool on all patients 
who had a dialysis catheter inserted between 20/12/2016 and 23/03/2018 (censored) at 
any of the 37 units participating in the REDUCCTION project. The reasons for insertions 
were grouped into Acute Kidney Injury (AKI), commencement of maintenance dialysis, 
arteriovenous fistula/graft (AVF/AVG) dysfunction, transition from Peritoneal Dialysis 
(PD) without permanent vascular access and other as reported by study site. Study data 
collection continues.
Results: Data on 3572 (2522 patients) dialysis catheters were captured so far, 
representing 316,039 catheter days. Of these, 1176 (32.5%; 60% Tunnelled) catheters 
were inserted for AKI, 1047 (29.4%; 85.8% tunnelled) for commencement of maintenance 
dialysis, 464 (13%) for AVF/AVG dysfunction, 401 (11.3%) for transition from PD and 
481 catheters (13.5%) for other reasons. Twenty-nine catheters were inserted in 27 patients 
for failing renal transplants. A total of 1075 catheters remained in situ at the censor date 
while 2497 catheters were removed after a median of 18 days (IQR 6-71 days). The median 
duration for tunnelled catheters was 75 days (IQR 26-170) and non-tunnelled catheters was 
6 (IQR 3-9) days.
Conclusions: This prospective national data highlights the reasons for dialysis catheter 
exposure, most notably the high burden arising from AKI. Understanding the outcomes, 
such as catheter-related bacteraemia (the primary outcome of REDUCCTION), for these 
different patient groups may aid in reducing complications.
Funding: Government Support - Non-U.S.
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Surveillance of Catheter Conversion (CC) and Future Vascular Access 
(VA)
Jeffrey J. Sands,1,3 Lalathaksha Murthy Kumbar,2 Kim Hirschman,1 
Stanley Frinak,2 Gerard Zasuwa,2 John B. Kennedy.1 1Vasc-Alert LLC, Evanston, 
IL; 2Henry Ford Health System, Troy, MI; 3Renal Systems Consulting LLC, 
Orlando, FL.
Background: We evaluated the impact of AV access (AVF or AVG) conversion (CC) 
to a central venous catheter (CVC) on patients future VA. Recent efforts focus primarily on 
AVF placement and maturation. VA outcomes including the extent of CVC use post access 
complications are less appreciated.
Methods: We identified CC from downloaded treatment (Tx) records utilized for Vasc-
Alert™ VA surveillance from 1/1/14—6/30/17 in patients (pts) using a single AV access 
from 10/2013-12/2013. CC was defined as a recorded change to a CVC for ≥4 Tx within 30 
days. Missed treatments were identified from Tx records gaps.
Results: Data included 1,598,680 Tx from 4923 pts (76.1% AVF; 23.9% AVG); mean 
age 61.1±14.5 yrs (60.6±14.6 AVF; 62.8±14.3 AVG), mean vintage 4.1±3.8 yrs (3.8±3.5 
AVF; 5.0±4.6 AVG) in 137 facilities (10 dialysis providers). CC occurred in 16.7% 
(820/4923) of pts (13.1% AVF, 28.1% AVG; P<0.001); CC rate: 8.2/100 pt-yrs (6.2 AVF; 
15.5 AVG). At 1 yr, mean CVC exposure was 168.1 days/pt-yr (162.8 AVF; 176.6 AVG). 
Vasc-Alert™ provided an alert prior to CC in 57.2% (52.9% AVF; 63.6% AVG). Missed 
Tx (%) were greater in AVG (P<0.001) and similar in non-CC (4.8% Tx; 4.6% AVF; 5.5% 
AVG) and pre-CC pts (4.7%; 4.5% AVF, 5.1% AVG)(P=NS). Missed Tx then increased 
post-CC (6.4%; 5.7% AVF; 7.3% AVG)(P<0.001). Post CC, 52.9% were CVC dependent at 
3 months, 33.9% at 6 months and 21.3% at 1 year. Only 23.9%, 27.7% and 30.1% returned 
to their original VA at 3, 6 and 12 months respectively and 44.3% had a new AV access at 
1 yr.
Conclusions: CC results in prolonged CVC use in a high percentage of HD patients. 
Only ~30% of patients returned to their original access and >44% had a new AV access at 
1 year. CC was more frequent in AVG, led to significantly more missed Tx and catheter 
exposure of >168 days/pt-yr. These data emphasize the importance of access surveillance 
and preventing terminal access failure to decrease CVC prevalence.
Funding: Commercial Support - Vasc-Alert LLC
Access in Use Post CC
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Utilizing a Multidisciplinary Approach to Lower the Central Venous 
Catheter Rate Among Chronic Hemodialysis Patients: A Quality 
Improvement Project
Irma Husain,1,2 Aisha Shaikh.3 1Internal Medicine, James J Peters VA Medical 
Center, New York, NY; 2Icahn School of Medicine at Mount Sinai, New York, NY; 
3James J. Peters Medical Center VA, New York, NY.
Background: United States Renal Data System (USRDS) evidence shows that the 
number of Central Venous Catheter (CVC) dependent patients is 20% and 12% after 1 and 
2 years of hemodialysis (HD) initiation respectively. At our hospital, the CVC dependence 
among chronic hemodialysis patients remains very high. Therefore, we sought to determine 
if a multi-disciplinary approach, involving the Nephrologists, Interventional Radiologists, 
and the Vascular Surgeons could reduce CVC use in long-term HD patients.
Methods: From August 2016 to July 2017, we identified 26 CVC-dependent long-
term HD patients, 73% of who had a history of at least one failed Arterio-Venous (AV) 
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access. The Interventional Nephrologist reviewed their records including comorbidities, 
access failure and complications history and venograms or fistulograms. This data was 
then presented at monthly multi-disciplinary meetings, also attended by Interventional 
Radiologists and Vascular Surgeons, during which, potential AV access options including 
arteriovenous fistulas (AVF) and arteriovenous grafts (AVG) were discussed in detail. A 
viable AV access option was then identified and placed after discussion with the patient.
Results: 27% (7/26) patients developed a functional AV access. Of these 57% (4/7) 
were AVGs, 29% (2/7) were AVFs and 14% (1/7) were HeRO (Hemodialysis Reliable 
Outflow) grafts. 46% (12/26) patients were not able to receive an AV access due to severe 
peripheral vascular disease or poor overall prognosis while 27% (7/26) patients died 
through the course of the year.
Conclusions: Monthly multi-disciplinary vascular access meetings with an 
individualized approach led to an increase in the prevalence of AV accesses among chronic 
HD patients. We impress that AVG and HeRO graft creation should be considered in patients 
who are poor candidates for an AVF, as any functional AV access leads to a reduction in 
CVC dependence and its related complications.
Fig.1 Outcomes
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Minimizing Complications During Renal Replacement Therapy with 
Tunneled Dialysis Catheters in Patients with AKI
Lumen A. Mendez Castaner,2 Marco A. LadinoAvellaneda,1 
Antonio A. Armstrong,2 Emilian A. Cristea,2 Lorena Cuebas-Rosado,3 
Daniel J. Soberon,3 Vasuki N. Venkat.3 1Miami VA Medical Center/University of 
Miami/ Jackson Memorial Hospital, Plantation, FL; 2Jackson Memorial 
Hospital, Miami, FL; 3Miami VA Hospital, Miami, FL.
Background: Patients with acute kidney injury that need renal replacement therapy 
have an increased morbidity and mortality. Bacteremia and poor renal replacement therapy 
delivery are complications that are present with the use of non-tunneled dialysis catheter. 
There is not enough data to support which option is the best vascular access to start renal 
replacement therapy in patients with acute kidney injury. We report our protocol using 
tunneled dialysis catheters for renal replacement therapy based on our 5-year experience.
Methods: This is a retrospective study of 62 patients with AKI that had indications 
to start renal replacement therapy. The vascular access for renal replacement therapy was 
a tunneled dialysis catheter. Patients did not have bacteremia or sepsis prior to catheter 
placement.
Results: All 62 patients had a tunneled dialysis catheter placed. 14 patients were 
started on continuous replacement therapy (CRT), 48 patients were started on intermittent 
hemodialysis (IHD). No infections (bacteremia, exit site infection, tunnelitis) in the first 
14 days after tunneled catheter placement were reported. A good clearance was obtained 
in the patients on CRT with a median duration of the dialyzer (No need for exchange) of 
3 days. Appropriate clearance was also obtained in the patients on IHD. Blood flows were 
appropriate in both modalities.
Conclusions: TDCs should be the vascular access of choice for patients (Figure 1) 
with AKI in need for dialysis if no contraindications are present (bacteremia, sepsis, 
hemodynamic instability). Patients didn’t have catheter related infections. Dialysis delivery 
was always appropriate without complications. The use of TDCs decreases length of stay in 
the hospital, costs and complications from non-tunneled catheters.
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Clinical Outcome in the Use of Biopatch in Preventing CRBSI Among 
Hemodialysis Patients via Hemodialysis Catheters in a Private Tertiary 
Hospital
Melani T. Gallero,1 Jeanne B. Bayaca.2 1Nephrology, St. Luke’s Medical Center, 
Quezon City, Philippines; 2Goodfellow Pharma Corporation, Pasig, 
Philippines.
Background: According to CDC, CLABSI result in thousands of deaths each year. 
Biopatch is a novel catheter dressing impregnated with chlorhexidine gluconate, used in 
conjunction with the standard catheter dressing to prevent CRBSI.
Methods: This is a retrospective cohort study design with target population of 
in hospitalized and outpatients who had HD via HD catheters exclusively in St. Luke’s 
Medical Center–QC, a private tertiary hospital from January 2013 to December 2017.
Results: A total of 427 HD patients via HD catheters (IJ,Femoral,Permanent 
Catheter) met the inclusion criteria. Of which, 255 HD patients on biopatch and 172 
without biopatch.117 in the biopatch group developed CRBSI and 72 patients in those 
without biopatch. The incidence rate of CRBSI with biopatch was 6.47/1000 catheter days 
(6 cases of CRBSI/1000 Catheter days) and was higher than those without biopatch, 
3.4/1000 catheter days (3 cases of CRBSI/1000 Catheter days) and was statistically 
significant (P=0.002;HR, 1.614 times among those with biopatch as compared to those 
without biopatch). Those with significant association with CRBSI among those with 
biopatch were aged 18 to 60 y/o (P=0.001;HR, 2.841), male patients (P=0.034;HR, 1.57), 
female patients (P=0.025;HR, 1.717), those with ESRD secondary to DKD (HR, 1.67), 
other causes of ESRD from solitary kidney, CTIN (P=0.013;HR, 6.564), those with other 
causes of AKI (P=0.000) and PVD (P=0.000) as compared to those without biopatch. Of 
the organisms isolated, Klebsiella pneumonia was common among those with biopatch 
and Pseudomonas aeruginosa among those without biopatch. The risk of CRBSI using 
permanent catheter with biopatch was 2.853 (P=0.000).
Conclusions: The use of Biopatch had a higher incidence rate of CRBSI among 
HD patients with biopatch compared to those without biopatch. There was significant 
association with CRBSI and those with biopatch </=60 y/o, male and female, those with 
ESRD due to DKD, other causes of ESRD, other causes of AKI and PVD. Majority of 
organisms isolated were gram positive bacteria, Staphylococcus epidermidis, both in HD 
patients with and without biopatch. Among CRBSI patients who had Klebsiella pneumonia, 
the use of biopatch may not be preventive in the development of CRBSI. However, among 
CRBSI patients with Pseudomonas aeruginosa, biopatch may decrease the risk of CRBSI.
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A New Initiative to Measure the Provincial Rate of Catheter-Related 
Bacteremia in Ontario
Gihad E. Nesrallah,1 Angie Yeung,2 Janet L. Graham,3 Jane Ip,2 Monisha Patel,5 
Philip McFarlane.4 1Medicine, University of Toronto, Toronto, ON, Canada; 
2Cancer Care Ontario, Toronto, ON, Canada; 3The Ottawa Hospital, Ottawa, 
ON, Canada; 4St. Michael’s Hospital, Toronto, ON, Canada; 5Ontario Renal 
Network, Toronto, ON, Canada.
Background: The use of a Central Venous Catheter (CVC) is associated with high 
morbidity and mortality, in part due to increased risk of catheter-related bacteremia (CRB). 
Patients using a CVC have a greater risk of infection and sepsis compared to patients 
dialyzing using an arteriovenous access. In 2016, the Ontario Renal Network (which funds 
dialysis in Ontario) launched a provincial quality improvement (QI) initiative with the 
aim to shift from local monitoring of CRB rates to a province-wide standardized tracking 
system. The initiative was launched with the objectives of: 1) Defining a provincial average 
rate of CRB, and an individualized rate for each of the Regional Renal Programs (RRP); 
and 2) sharing provincial data and developing program-level QI plans to help minimize 
CRB risk.
Methods: All 26 RRPs in Ontario collected and reported data from May 2016 – 
December 2017 using a tracking tool incorporating indicator methodology developed by 
an expert panel. Reported CRB events formed the numerator for the rate calculation, while 
the denominator was derived from the Ontario Renal Reporting System database (ORRS) to 
calculate person-time with a hemodialysis catheter. The CRB rate is expressed as infections 
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per 1000 patient days, combining patient-time from all in-centre chronic dialysis patients 
at each RRP.
Results: Over a period of 20 months (May 2016 to December 2017), 696 unique CRB 
cases were reported over a total of 3,096,046 patient days (approximately 8482 annualized 
patients). Program-level CRB rates ranged from 0.09 – 0.56 and the provincial average 
was 0.22 episodes/1000 catheter-days. Quarterly reports were shared with the programs 
for data validation, comparison and monitoring purposes. The initiative enabled consistent 
measurement and reporting of CRB, allowed programs to benchmark themselves against 
their peers, and design local plans for improvement.
Conclusions: The risk of CRB is deemed to be relatively low in Ontario. This initiative 
has produced a sustainable system of data collection for monitoring the risk of CRB. This 
initiative is part of a larger strategy to ensure that all patients receiving dialysis therapy 
experience as few complications regardless of the type of access they have.
Funding: Government Support - Non-U.S.
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Differential Impact of Central Venous Catheters versus Arteriovenous 
Fistulas on Quality of Life Among Irish Haemodialysis Patients
Leonard Browne,2 Gasim Ahmed,2,3 Aidan G. O’Sullivan,1 Eoin J. White,1 
Elshaeima Mohammed,2,3 Fiona Leahy,5 Elaine C. Conway,4 Maria Ryan,4 
Leonard W. Osullivan,1,4 Austin G. Stack.2,3 1Science & Engineering, University 
of Limerick, Limerick, Ireland; 2Graduate Entry Medical School, University of 
Limerick, Limerick, Ireland; 3Nephrology, University Hospital Limerick, 
Limerick, Ireland; 4Health Research Institute, University of Limerick, Limerick, 
Ireland; 5University Hospital Limerick, Limerick, Ireland.
Background: The arteriovenous fistula (AVF) is associated with superior clinical 
outcomes than central venous catheters (CVC) in haemodialysis (HD). Recent studies have 
questioned the relative benefits in survival and quality of life using an AVF strategy over a 
CVC strategy. We compared the attitudes and opinions of HD patients using an AVF versus 
a CVC in an Irish cohort.
Methods: A cross-sectional study was conducted in maintenance HD patients (n=119) 
at a centre-based HD programme in 2018. A validated Vascular Access Questionnaire 
wasused to measure and compare quality of life across key domains. Patient satisfaction 
between AVF and CVC was compared in physical functioning, social functioning and 
dialysis complications using Likert scale with a p-value of <0.05 indicating statistical 
significance. Comparisons between groups were conducted using student t test and 
multivariable logistic regression expressed as odds ratio and (95% Confidence intervals).
Results: Average age was 66.1 years, 52.1% were using AVF with 47.9% a CVC. 
Patients with an AVF experienced higher overall satisfaction scores than a CVC (6.2 vs 
4.9, P<0.01), however AVF patients reported more problems with bleeding, swelling and 
bruising than CVC patients [2.9 (2.2) vs 1.6(1.4), 2.9 (2.1) vs 1.7 (1.5), and 3.6 (2.2 vs 
1.8) respectively, all p<0.005]. In contrast CVC patients reported greater difficulties 
in bathing and showering than AVF (4.5 (2.3) vs 2.1 (1.8), p <0.001). In multivariable 
analysis, adjusting for demographic and clinical factors, dialysing with a CVC (vs AVF) 
was associated with less difficulties in physical functioning OR, 0.35 (0.13-0.96), P=0.04, 
and higher odds of dialysis complications OR, 2.14 (0.78-5.89), P=0.1.
Conclusions: Compared to AVF, CVC use is associated with less physical complaints 
from bleeding and bruising but greater negative impact on social activities including bathing 
and showering. Minimising the impact of these on QOL should be considered in any long 
term vascular access strategy.
Funding: Government Support - Non-U.S.
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Interim Analysis of Randomized Trial Comparing VectorFlow and 
Palindrome Tunneled Dialysis Catheters
Gregory Nadolski,1 Benjamin J. Shin,2 Raphael M. Cohen.1 1University of 
Pennsylvania, Philadelphia, PA; 2Hospital of University of Pennsylvania, 
Philadephia, PA.
Background: Tunneled dialysis catheters (TDC) remain an important bridge to 
permanent hemodialysis (HD) access, a critical transition to new access creation when 
surgical access fails, and the only source of HD access when venous anatomy is exhausted 
for surgical access. Selection of an HD catheter capable of providing efficient HD with high 
primary patency is of utmost importance to improving outcomes in ESRD patients. The 
purpose of this trial is to compare a widely used symmetrical tip TDC, Palindrome (P), to a 
recently FDA-approved symmetrical design with helical flow at the tip to reduce blood cell 
shear stress, VectorFlow (VF).
Methods: The target recruitment of the study was 100 subjects enrolled at two 
centers with 1:1 randomization. Exclusion criteria included uncorrectable coagulopathy 
or thrombocytopenia; neutropenia, bacteremia, or infected surgical HD access within 7 
days prior to enrollment; central venous stenosis or occlusion preventing jugular catheter 
insertion. The primary endpoint was primary patency at 90 days. Secondary endpoints 
include dialysis adequacy with Kt/V and URR monthly for 3 months, catheter flow (Qb) 
and lumen pressures at initial HD and monthly for 3 months.
Results: At present, the trial has enrolled 78 subjects and is anticipated to complete 
enrollment by the fall of 2018. Interim analysis showed 90-day primary patency of 74% 
in the VF group compared to 71% in the Palindrome group (P=0.81). Mean Kt/V at 30, 
60 and 90 days was higher with the VF than P (30 d ay, 1.48 vs. 1.40; 60 days, 1.48 vs. 
1.37; 90 days, 1.51 vs. 1.35); mean Kt/V averaged across all time points was significantly 
higher among subjects receiving the VF catheter compared to P (1.48 vs. 1.38, P=0.020). 
No significant differences were seen with URR (69 vs. 69) or Qb. Additional study data are 
pending final subject enrollment.
Conclusions: The ongoing trial comparing VectorFlow tunneled dialysis catheter to 
Palindrome tunneled dialysis catheter is the first US randomized trial comparing different 
HD catheter tip designs in nearly two decades, and the first to address dialysis adequacy. 
The results of this trial may elucidate which catheter design provides optimal HD adequacy 
and catheter patency.
Funding: Commercial Support - Teleflex Medical
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Relationship Between Central Venous Catheter Protein Adsorption and 
Water Infused Surface Protection Mechanisms
David W. Sutherland,1,2 Joseph L. Charest.2 1Boston University, Cambridge, MA; 
2Draper Laboratory, Cambridge, MA.
Background: Many dialysis patients are implanted with central venous catheters 
(CVCs) despite increased patient risk due to thrombosis and biofilm formation. These 
complications are caused by fibrin sheath formation, which is initiated by blood protein 
adsorption upon exposure. Current solutions to prevent thrombotic occlusion and biofilm 
formation remain ineffective at preventing these failure modes and remediation treatment 
options are limited and often harmful. We propose an active method to reduce protein 
adsorption and effectively disrupt adherent protein sheaths, water infused surface protection 
(WISP).
Methods: Experiments were performed in vitro using a modeled CVC that simulated 
the WISP mechanism. A hollow fiber membrane (HFM), representing the CVC lumen, was 
mounted in a concentric chamber. The WISP was achieved by pressurizing the concentric 
chamber with saline while blood flowed through the HFM, causing a continuous saline 
infusion across the HFM wall. The resulting water boundary layer at the lumen surface 
limited the blood contact with the HFM wall resulting in decreased protein adsorption.
Results: Analytic lubrication models matched our experimental pressure measurements 
suggesting the WISP created a blood-free boundary layer on the HFM surface. Figure 1 
shows the WISP boundary layer reduced the average density of adsorbed protein on the 
model CVC with increasing WISP flowrates, up to 96.4% over the 0% WISP condition 
(* denotes P≤0.016, 2-way ANOVA). Additionally, the WISP CVC displayed the ability 
to reduce previously-adsorbed protein films, and deliver chemical agents, such as heparin, 
within the WISP flow.
Conclusions: The proposed WISP technology has functionality that could reduce 
failure incidence to improve clinical outcomes. WISP shows the ability to significantly 
reduce protein adsorption, as well as presents a new methodology to treat major CVC 
complications; removing pre-adsorbed material or treating a resulting infection by more 
effectively delivering drugs to the point of adhesion.
Funding: Commercial Support - The Charles Stark Draper Laboratory
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Gaining Central Venous Access Safely and Quickly in Patients with 
Occlusion of the Upper Central Veins with a Novel Device Using an 
Inside-Out Approach
Roman Reindl-Schwaighofer, Gurkan Sengoelge. Nephrology, Medical 
University of Vienna, Vienna, Austria.
Background: Left-sided and subclavian central accesses cause the highest rate of 
central venous thromboses and occlusions. Exhaustion of vascular access options caused by 
thoracic central venous occlusion (TCVO) adds to dialysis-related morbidity and mortality. 
We report the first case series of a novel device, the Surfacer, for repeated right-sided central 
venous access in patients with TCVO.
Methods: The Surfacer consists of a metal pole with a sharp wire inside attached to 
a handle. The procedure is performed on an outpatient basis using local anesthesia under 
fluoroscopy as follows: A 10F sheath is introduced up to the TCVO over a standard 
guidewire from the right femoral vein. After removal of this wire, the 7F metal pole of 
the Surfacer is introduced through the sheath to the TCVO and pushed through until its 
tip has passed the clavicle. The sharp wire is then released using a plunger at the handle 
from the tip of the Surfacer piercing the skin inside out in the right supraclavicular region. 
This now serves as a guidewire for a central venous access. We analyzed success rate, 
duration of procedure and complications of all Surfacer cases performed at the Department 
of Nephrology, Medical University of Vienna between July 2016 and April 2018.
Results: The Surfacer procedure was considered in 37 cases. Following CT 
angiography, four patients did not qualify because of complete occlusion of either right 
external iliac vein or inferior or superior vena cava. The majority of patients had a 
TCVO type 3 with occlusion of both brachiocephalic veins but a patent azygous vein. 
The procedure had a 97% success rate (32 out of 33; one patient had a massive scoliosis 
which blocked the passage of the device). The mean intervention time was 14 min. There 
were no Surfacer related complications defined as early infections, bleeding, hematoma 
or pericardial effusions. In five patients the procedure was repeated due to infection or 
dysfunction > 3 months after initial placement.
Conclusions: This is the first case series of a novel device for inside-out placement of 
central venous access in patients with TCVO requiring dialysis. The procedure is highly 
successful, safe and repeatable allowing for an “always right, never subclavian” approach.
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Catheter-Related Right Atrial Thrombus on Hemodialysis Patients: 
Results of a Cohort Study
Ismael A. Gómez Ruiz, Lucas Porto-Silva, Zuilma Vazquez ortiz, Jaime Galindo 
uribe, Ricardo Correa-Rotter, Juan Carlos Ramirez-Sandoval. Instituto Nacional 
de Ciencias Medicas y Nutricion Salvador Zubiran, México city, Mexico.
Background: Catheter-induced right atrial thrombus (CRAT) is a serious complication 
in hemodialysis (HD) patients and optimal treatment is not well defined. We reviewed 
clinical characteristics, treatments options, and outcomes of CRAT in HD patients
Methods: Single-center retrospective cohort study of CRAT confirmed by 
echocardiogram (2008-2018).
Results: We identified 23 CRAT cases in HD. Thrombus was visualized initially 
by transthoracic echocardiogram in 74% (17/23); all but one had transesophageal 
echocardiogram. The largest thrombus dimension was 52x23 mm. Factors related to CRAT 
were long catheter vintage (7 [IQR 4-13] months) and catheter misplacement in 65% (15/23). 
All cases received anticoagulation as initial treatment. The most relevant clinical data for 
subsequent treatment decision was suspicion of catheter-related bloodstream infection 
(CRBSI). Patients were divided in those that had early catheter removal due CRBSI (39%, 
9/23) and those who had non-urgent indication of catheter removal (61%,14/23) [Table]. 
Early removal group had worse outcomes:100% had catheter removal before therapeutic 
anticoagulation was achieved, 44% had embolic complications after catheter removal, 78% 
required surgical definitive treatment, and 44% (4/9) died. Non-urgent catheter removal 
group received total anticoagulation for 22 [IQR 13-28] weeks, dissolution of thrombus 
occurred in 64% (9/14), thrombus shrinking in 14% and 42% required delayed catheter 
removal without major adverse events.
Conclusions: To our knowledge, this is the first large cohort of CRAT on HD. Total 
anticoagulation is essential after CRAT diagnosis and may be sufficient to dissolve or 
shrink thrombus <52 mm in asymptomatic or stable febrile HD patients without an urgent 
indication for catheter removal. Infection related to CRAT had a high risk of adverse 
outcomes, including mortality.
Characteristics of the HD cohort and clinical outcomes.
*Death not directly related to CRAT event
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Anxiety and Pain with Tunneled Dialysis Catheter Insertion in Patients 
with ESRD
Stewart Nadurak,1 Claudio Rigatto,1 Paul Komenda,1 Navdeep Tangri,1 
Reid Whitlock,1 Sara E. Dunsmore,1 Alissa Lloyd,2 Sean Armstrong.1 1Seven 
Oaks Hospital, Chronic Disease Innovation Centre, Winnipeg, MB, Canada; 2St. 
Boniface Hospital, Winnipeg, MB, Canada.
Background: About 50% of hemodialysis patients require tunneled catheters for 
hemoaccess because a fistula is not feasible. Tunneled catheters are typically inserted with 
local anesthetic (LA) alone. However, conscious sedation (CS) is sometimes used and may 
be associated with slightly increased cardiorespiratory risk, or require several hours of post-
procedure observation in hospital. Given limited access to recovery beds, patients receiving 
CS are usually bridged with a non-tunneled catheter until conversion to a tunneled catheter 
can be booked. As there is no consensus on the benefit of CS in this setting, clinical practice 
varies widely and patient preferences regarding this choice are unknown. Our objectives are 
to assess: 1) pain and anxiety experienced by patients during tunneled catheter procedures; 
2) patient preferences with respect to the time vs. discomfort trade-off inherent in the choice 
of using or not using CS.
Methods: We mailed a 10-item questionnaire to all patients >18y who had tunneled 
catheter procedures in Manitoba, Canada between Apr-16 and Oct -17; as well as to incident 
patients from Nov-17 until present. Participants rated their experience of pain and anxiety 
from their most recent procedure on a Likert scale from ‘0’ to ‘10’. Patients were also asked 
which procedure they would prefer in the future.
Results: A total of 148 of 651 questionnaires were returned (22.7%); where 80 patients 
had LA only and 37 had CS. Pain (median = 2) and anxiety (median = 4) during the 
procedure were low in both groups. Patients undergoing CS experienced a higher level of 
pain post-procedure (median of 2.5 vs. 1; p = 0.02) and anxiety during procedure (median 
of 5.5 vs 3; p=0.01). The majority of respondents preferred one procedure with LA only to 
two procedures (non-tunneled insertion, then CS for tunneled catheter) (68% vs. 32%), or to 
waiting for a CS procedure at a later date (76% vs. 24%). Limitations: retrospective survey. 
Response rate was low.
Conclusions: Low levels of pain and anxiety were experienced regardless of procedure 
type. When faced with a trade-off, patients preferred a procedure that took less time even if 
more discomfort was involved. We conclude that LA alone can be used without significant 
additional distress in most patients.
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Dialysis: Vascular Access - II
Nitric Oxide (NO) Releasing Tunneled Dialysis Catheters (TDC) Reduce 
Catheter Related Blood Stream Infection (CRBSI) and Dysfunction
Diego Celdran-Bonafonte,1 Li H. Wang,2 Orsolya Lautner-Csorba,6 
Elizabeth Brisbois,3 Aous Jarrouj,5 Maria Kim,6 Jaroslav Janda,4 Lindsay N. Kohler,4 
Taylor G. Lewis,4 Frank C. Brosius,4 Mark Meyerhoff,6 Prabir Roy-Chaudhury.4 
1Department of Medicine, University of Arizona, Tucson, AZ; 2The Second Hospital 
of Tianjin Medical University, Tianjin, China; 3University of Central Florida, 
Orlando, FL; 4University of Arizona, Tucson, AZ; 5Banner-University of Arizona, 
Tucson, AZ; 6University of Michigan, Ann Arbor, MI.
Background: Tunneled dialysis catheter complications, due to infection, thrombosis 
and central vein stenosis are responsible for a very significant morbidity, mortality and 
economic cost. Nitric oxide (NO) is an important biological mediator, which has potent 
anti-microbial, anti-platelet and anti-smooth muscle cell activities. We have previously 
developed a novel and innovative technology that results in a prolonged polymer based 
(silicone rubber, polyurethanes, etc.) release of NO. The goal of this study, therefore, was to 
assess the impact of NO releasing TDCs on infection, thrombosis and central vein stenosis, 
using a validated pig model of TDC complications
Methods: 9 Yorkshire cross pigs were used in this study. 4 non-treated commercial 
catheters and 5 NO-releasing catheters were placed using a percutanous jugular approach. 
Catheters were accessed twice a week in a sterile fashion, in order to mimic the dialysis 
procedure and to score TDC dysfunction using a semi-quantitative scale. Study animals 
were monitored daily for signs and symptoms of infection. Catheter and tissue samples were 
collected in a standardized fashion at the time of sacrifice or at 28 days, and analyzed using 
standard histological and scanning electron microscopy(SEM) techniques
Results: NO-releasing catheters had a significantly delayed time to onset of infection 
(19.4±8.6d vs 8±3.36d; p = 0.03) and also a delayed (but not significant), onset of catheter 
dysfunction (12.4±9.9d vs 6.7±3.4d). Despite this significant clinical benefit, a compact 
fibrin sheath was detected in both the control and treated arms, together with a significant 
degree of central stenosis. SEM imaging revealed the presence of biofilm formation in both 
groups.
Conclusions: Our data demonstrate for the first time, an important clinical benefit 
of NO releasing TDCs on infection and dysfunction. Interestingly, this clinical benefit 
seemed to occur independently of the presence of a fibrin sheath, venous wall thickening 
and biofilm formation. We believe that a prolonged release of NO using our innovative 
polymer technology could result in a very significant reduction of the morbidity, mortality 
and economic cost currently associated with TDC complications.
Funding: Other NIH Support - NIBIB and NIDDK, Veterans Affairs Support
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Dialysis: Vascular Access - II
Echocardiographic Measurements Before Different AVF Types Created 
Before and After Hemodialysis Initiation and the Contribution to 
Pulmonary Hypertension
Juan C. Duque Ballesteros,1 Laisel Martinez,1 Roberto I. Vazquez-Padron,1 
Hannah Labove,2 Luis A. Escobar,1 Marwan Tabbara.3 1University of Miami, 
Miami, FL; 2University of Miami/Jackson Memorial Hospital, Miami, FL; 
3University of Miami, Miller School of Medicine, Miami, FL.
Background: Pulmonary hypertension (PH; PAP of 25 mmHg at rest or higher than 
30 mmHg with exercise) is common in end-stage renal disease patients, which has been 
associated with uremic toxins, volume status, and hemodynamic changes that occur with 
vascular access creation. Little is known about the effects that different vascular access 
techniques, performed before or after initiation of dialysis, have on echocardiographic 
measurements.
Methods: A retrospective study was performed at the University of Miami Hospital/
Jackson Memorial Health System from 2009 to 2014, evaluating patients who underwent 
an arteriovenous fistula (AVF) creation for hemodialysis. Patients who had a 2-D 
echocardiogram done before and after surgical AVF creation were analyzed. A total of 125 
patients were included. From these, 22 patients had the AVF created before the need for 
dialysis, while 103 patients had already initiated hemodialysis (HD) using a dialysis catheter. 
The 2-D echo measurements analyzed were ejection fraction EF (%), right ventricular 
systolic pressure (RVSP; mmHg), and right ventricular end diastole (RVDd; cm).
Results: The mean age at the time of AVF creation was 50 ± 12 years in patients with 
AVFs created before HD initiation, and 51 ± 13 in the after HD subgroup. 55 and 62% 
of patients were men, and essential hypertension was present in 100% of participants in 
both cohorts. The prevalence of diabetes mellitus was 68% and 59% in patients with AVF 
created before and after HD initiation, respectively. The AVF inflow was brachial-based in 
50% and radial-based in 50% of the accesses in the pre-dialysis group, compared to 58% 
brachial vs. 42% radial in AVFs created after HD initiation. No statistical differences were 
found in RVSP or RVDd comparing brachial-based vs. radial-based inflow AVFs in patients 
with access created before or after HD initiation. However, EF (%) was higher in patients 
with radial-based vs. brachial-based AVFs when the access was created after HD initiation 
(53.8 ± 11 vs. 57.8 ± 6, p=0.04).
Conclusions: With these results, we can conclude that timing of AVF creation or 
type of arterial inflow has no correlation with PH in end-stage renal disease patients. The 
differences in EF in the after HD subgroup need to be further investigated.
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The First-in-Man Trial of the av-Guardian Vascular Access System
Chieh-suai Tan,1 Lina Choong,1 Titus W. Lau,2 Shervanthi Homer-
Vanniasinkam.3,4 Singapore av-Guardian consortium 1Renal Medicine, 
Singapore General Hospital, Singapore, Singapore; 2National University 
Health System, Singapore, Singapore; 3The General Infirmary at Leeds, Leeds, 
United Kingdom; 4University College London, London, United Kingdom.
Background: The ability to successfully cannulate the AVF reliably is a critical step 
in the delivery of hemodialysis therapy. The av-Guardian vascular access system (avGD; 
Advent Access, Singapore) is designed to overcome the technical barrier to establishing 
reliable blunt needle access in patients with mature AVF. avGD is a single component 
titanium device (15mm x 5mm x 3 mm) with a palpable entry point that is subcutaneously 
implanted between the skin and the AVF to allow repeated cannulation through a single 
puncture site.
Methods: This was a first-in-man, prospective, non-randomized trial performed to 
assess the safety and feasibility of avGD in facilitating blunt needle access in patients with 
matured AVF. The primary end points of the study included rate of successful hemodialysis 
sessions via avGD cannulation over 3 months and changes in AVF flow rates after 
implantation
Results: Six patients were enrolled in the study, of which 5 had AVFs that were difficult 
to cannulate. A pair of avGD was implanted each at the arterial and venous cannulation sites 
under local anaesthesia as shown in figure 1. Cannulation via the avGD commenced 14 
days post-implantation. Overall, the rate of successful cannulation through the avGD over 
3 months in 216 hemodialysis session was 98.1%(424/432) at the arterial site and 94.4% 
(408/432) at the venous site. Significantly, 85.5% and 90% of the cannulations at the A and 
V site respectively were successful at first attempt. Blood flow rates within the AVF were 
unaffected by the devices. The patients were transited to blunt needle cannulation after a 
median of 15.5 and 18.5 sessions at the A and V site respectively.
Conclusions: The results of this first in man trial demonstrated the safety and feasibility 
of a subcutaneously implanted, extravascular device to facilitate blunt needle access in 
matured AVF. The device did not adversely affect flows within the AVF after implantation 
and successful cannulation through the devices can be achieved > 94% of the time
Funding: Commercial Support - Access Advent
Figure 1: The av-Guardian vascular access system and implantation process
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Hypertension and CVD: Mechanisms - II
Extracellular Matrix Stiffness Mediates Human Aortic Smooth Muscle 
Cell Phenotype via Rho-Kinase
I-Chia Liu,1 Shiyu Li,1 Brandon To,1 Rajesh Mohandas.1,2 1University of Florida, 
Gainesville, FL; 2North Florida/South Georgia Veterans Health System,
Gainesville, FL.
Background: Chronic Kidney Disease (CKD) is associated with increased vascular 
stiffness and accelerated atherosclerosis. However, the mechanisms by which stiffness 
accelerates the development of atherosclerosis is not known. Rho-kinase (ROCK), a key 
mechanosensor, influences the phenotype of vascular smooth muscle cells. A synthetic 
phenotype characterized by increased migration and proliferation of vascular smooth 
muscle cells is associated with atherosclerosis. We hypothesized that matrix stiffness 
upregulates ROCK activity to affect vascular smooth muscle cell phenotype.
Methods: Human aortic smooth cells (HASMC) were plated on regular tissue culture 
plates or polyacrylamide gels engineered to varying stiffness (2kPa – 50kPa). Proliferation 
of cells was measured by a formazan-based assay. ROCK activity was measured using an 
ELISA based detection of substrate phosphorylation, and ROCK transcription was assayed 
by PCR.
Results: Proliferation of HASMC increased with increasing stiffness of the matrix 
(Fig 1A). Stiffness increased ROCK activity in these cells (Fig 1B). In addition, PCR 
showed that stiffness increases ROCK1 mRNA but not ROCK2. Inhibition of ROCK with 
Fasudil abolished the stiffness induced increase in proliferation.
Conclusions: Our results suggest that stiffness increases proliferation of HASMC via 
Rho-kinase. Thus, ROCK pathways might be a target to prevent vascular complications of 
kidney disease.
Funding: Other NIH Support - NHLBI, K-08HL130945
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Hypertension and CVD: Mechanisms - II
Iron Stimulation Induced Calcification in Human Aortic Vascular Smooth 
Muscle Cells Through Interleukin-24 (IL-24)
Yasuyuki Nagasawa,1 Sayuri Kawada,1 Mutsuki Kawabe,2 Aritoshi Kida,1 
Kosuke Mizusaki,1 Masayoshi Nanami,1 Yukiko Hasuike,1 Keiji Nakasho,2 
Takahiro Kuragano,1 Takeshi Nakanishi.1 1Department of Internal medicine, 
Devision of Kidney and Dialysis, Hyogo college of medicine, Nishinomiya, Japan; 
2Department of pathology, Hyogo College of Medicine, Nishinomiya, Japan.
Background: In CKD patients, atherosclerosis is one of important life-limitting 
factors. The feature of the atherosclerosis in CKD patients was called as Moenckeberg’s 
arteriosclerosis which was seen in vascular media, but the relationship between iron and 
calcification in vascular smooth muscle cell remained unclear. To reveal the relationship 
between calcification in vascular media and iron stimulation using cultured vascular smooth 
muscle cells.
Methods: The aorta smooth muscle cells were cultured for three weeks. At day 0, 
we changed the usual culture medium to calcification medium, and TNF-alpha and iron 
were added to the calcification medium. Calcification in each condition was confirmed by 
Alizarin staining. And to reveal early mechanism to enhance the calcification by iron and 
TNF-alpha stimulation, we compared the gene expression profile between each condition in 
day 1 and day 3 using microarray analyses. We confirmed gene expression of IL-24 which 
had increased in microarray analysis by mRNA level (real-time PCR) and by protein level 
(ELISA) in time course. Calcification induced by recombinant IL-2 instead of iron was 
also evaluated.
Results: Both iron and TNF-alpha stimulation enhanced calcification by Alizarin 
Staining. Moreover, both iron and TNF-alpha stimulation at the same time enhanced 
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calcification more strongly than single stimulation. We picked up IL-24 which had increased 
with both iron and TNF-alpha stimulation. We confirmed IL-24 expression by real-time 
PCR. Gene expression was increased at day1 by stimulation of iron(5.8±3.0 fold change vs 
control), TNF-alpha (7.8±1.9 fold change vs control), and both stimulation(53.1±27.1fold 
change vs control), synergistically(shown below). At day 3, gene expression showed as 
same increase as at day 1. The time course of IL-24 was confirmed in mRNA level by real 
time PCR and in protein level by ELISA. Calcification was induced in human vascular 
smooth muscle cells by IL-24 instead of iron, and quantification of calcification also 
confirmed the result.
Conclusions: Iron stimulation enhanced calcification in vascular smooth muscle cells 
along with TNF-alpha stimulation. Iron stimulation along with inflammatory might induce 
calcification in human vascular smooth muscle cells through IL-24.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - II
Indoxyl Sulfate Aggravates Vascular Calcification via Suppress the Matrix 
Gla Protein by the the ROS/NF-κB Signaling Pathway
Xin He,2 Hongli Jiang.1 1First Affiliated Hospital of Medicine School, Xi?an 
Jiaotong University, Xi?an, China; 2Dialysis Department of Nephrology 
Hospital of the First Affiliated Hospital of Medicine School, Xi’an Jiaotong 
University, Xi’an, China.
Background: Vascular calcification (VC) is the major complication and contributes 
to the cardiovascular mortality in chronic kidney diseases (CKD). Indoxyl sulfate (IS) has 
been recognized as the major uremic toxin involved in the vascular calcification in CKD 
due to its high oxidative stress, but the underlying mechanisms remain largely unknown. 
Matrix Gla protein (MGP) plays roles in vascular calcification as an important inhibitor 
of calcification. Here, we investigated whether MGP is involved in IS-induced vascular 
calcification.
Methods: In vitro, radial arteries from CKD patients were used for histological 
examination. In vitro, HASMCs were cultured with IS to induce vascular calcification, 
which was detected by Alizarin red S staining. Gene expression and protein levels of 
MGP and osteogenic differentiation markers were determined by qRT-PCR and western 
blotting, respectively. ROS were detected using probes with a fluorescence detector. The 
phosphorylation of Ikkβ, NF-κB and IκB degradation were detected by western blotting, 
and the role of ROS/NF-κB was further confirmed by using the inhibitor of DPI and PDTC.
Results: We observed the average level of MGP expression was decreased in the 
calcified vessels in CKD patients. Simultaneously, IS also decreased MGP expression 
accompanied by the calcification of HASMCs. osteogenic differentiation was confirmed 
by the increased expression of BMP2 and Cbfa1 and decreased expression of the α-SMA, 
which was accompanied by the increased level of ROS. The phosphorylation of Ikkβ, 
NF-κB and IκB degradation increased by IS but reversed by an ROS inhibitor of DPI. In 
contrast, suppression of MGP and calcification of HASMCs calcification were attenuated 
by pretreatment with PDTC, an NF-κB inhibitor.
Conclusions: These observations provide evidence that inhibition of MGP expression 
may contribute to the pathogenesis of IS-induced vascular calcification in CKD.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - II
CDK9-Cyclin T1 Complex Mediates Medial Calcification Through the 
Induction of CHOP
Yuji Shiozaki,1 Shohei Kohno,1 Audrey L. Keenan,3 Shinobu Miyazaki-anzai,2 
Makoto Miyazaki.2 1University of Colorado Denver, Aurora, CO; 2University of 
Colorado-Denver, Aurora, CO; 3University of Colorado AMC, Aurora, CO.
Background: Our recent studies indicate that activation of the Activating transcription 
factor 4 (ATF4) pathway through the ER stress response induced by saturated fatty acids 
(SFAs) plays a causative role in vascular calcification in chronic kidney disease (CKD). we 
1) studied a pro-apoptotic CHOP transcription factor that contributes to CKD-dependent
medial calcification and 2) identified a novel regulator of ER stress-mediated CHOP 
expression
Methods: 1) To study the smooth muscle cells (SMC)-specific role of CHOP in 
regulating medial calcification, we generated SMC-specific CHOP conditional transgenic 
mice and analyzed aortic region of control and SMC-specific CHOP TG mice under CKD 
(5/6 nephrectomy). 2) To explore a signaling pathway that blocks SFA-induced CHOP 
expression, we screened a kinase inhibitor library containing >140 compounds by treating 
human vascular smooth muscle cells with a saturated fatty acid.
Results: SMC-specific CHOP transgenic mice developed severe vascular apoptosis 
and medial calcification under CKD. Protein kinase inhibitor library screening identified 
16 compounds, including 7 cyclin-dependent kinase (CDK) inhibitors, that significantly 
suppressed the induction of CHOP through ER stress. In addition, selective inhibitors 
against CDK9 and CDK9-specific inhibition through a gene-editing technique blocked 
SFA-mediated induction of CHOP, while other CDK isoform inhibitors did not affect 
CHOP expression. Knockout of cyclin T1 inhibited SFA-mediated induction of CHOP and 
mineralization, whereas deletion of cyclin T2 and cyclin K promoted CHOP expression 
levels and mineralization. The CDK9-cyclin T1 complex directly phosphorylated and 
activated ATF4.
Conclusions: These results demonstrate that 1) the CDK9-cyclin T1 and CDK9-cyclin 
T2/K complexes have opposing roles in CHOP expression and vascular calcification and 2) 
the CDK9-cyclin T1 complex mediates vascular calcification due to CHOP induction 
through phosphorylation-mediated ATF4 activation.
Funding: NIDDK Support, Other NIH Support - R01HL117062, R01HL133545 and 
R01 HL132318
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Mechanisms Linking CKD and Atherosclerosis: CD34+ Cell in the 
Atherosclerosis Plaque
Miguel Hueso,1 Estanislao Navarro,3 Nuria Bolanos,3 Cristian Varela,3 
Angela I. Casas Parra,2 Jordi Guiteras,3 Joan Torras.2 1Hospital of Bellvitge, 
L’Hospitalet de Llobregat (Barcelona), Spain; 2Laboratory Experimental 
Nephrology, IDIBELL. Hospital Universitari de Bellvitge, Barcelona, Spain; 
3IDIBELL, Hospitalet de Llobregat, Spain.
Background: Chronic kidney disease (CKD) is associated with a higher incidence of 
atherosclerotic vascular disease (ASVD) but its pathogenic mechanism is not well known. 
CKD is associated with lower circulating CD34+ Endothelial Progenitor Cells (EPCs) and 
atherosclerotic lesions have a focal distribution suggesting an impaired vascular repair 
mechanism. The aim of this study was to localize stems and CD34+ EPCs in the vascular 
wall from humans and in a mouse model of atherosclerosis.
Methods: We assessed CD34 + hematopoietic stem cells in the atherosclerotic plaque 
by IHQ in the abdominal aorta obtained from 10 human necropsies (5 patients with CKD). 
CD34 levels were quantified by qPCR. Furthermore, we analyzed CD34+ by IHQ in 10 
APOE-/- mice with a CD40 blockade using a specific siRNA (siCD40) and in 10 APOE-/- 
controls (5 mice treated with scrambled siRNA (SC) and 5 mice treated with vehicle (veh)) 
at 24 weeks.
Results: We included 18 samples (9 atherosclerotic plaques and 9 samples from normal 
abdominal aorta without injury) from 9 patients (5 patients with CKD). Atherosclerotic 
plaque was associated with increased inflammation in the intima (14 ± 15% in the sample 
without injury, n=9 vs 54 ± 25% in the plaque, n=8, p=0.004). CD34+ cells were increased 
in the atherosclerotic plaque (-4.7 ± 0.76 cycles, n=6 in normal aorta vs -3.2±1 cycles, n=4 
in plaque, p=0.028). Furthermore, we have identified niches of CD34+ cells in the neointima 
and in the adventitia of human arteries. Then, we analyzed mRNA levels of CD34+ patients 
in normal vascular walls with CKD and we observed a trend to display lower number of 
CD34 cells (-4.5±0.7 cycles in non-CKD patients, n=4, -5.3±0.75 cycles in CKD patients, 
n=2; p=0.3). Finally CD34+ cells were identified especially in the perivascular adipose 
tissue (PVAT) of mice treated with siCD40 (9±1% in 5 mice treated with veh, 3±2% in 5 
mice treated with SC, vs 13±6% in 10 mice treated with siCD40, p<0.0001).
Conclusions: Atherosclerotic plaque is associated with increased inflammation and 
an increase number of cells hematopoietic stem cells (HSCs)/endothelial progenitor cells 
(EPCs) CD34+cells. HSCs/EPCs could participate in vascular remodeling (regeneration), but 
also in the neovascularization that may contribute to plaque growth and its destabilization.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - II
Exosomes from Activated Kidney Fibroblast Stimulate Transcription of 
PlGF on Endothelial Cells
Noritoshi Kato,1 Fumitoshi Nishio,2 Yoshio Funahashi,2 Takuji Ishimoto,3 
Tomoki Kosugi,3 Naotake Tsuboi,3 Shoichi Maruyama.3 1Nephrology, Nagoya 
University Graduate School of Medicine, Nagoya, Japan; 2Nagoya University, 
Nagoya, Japan; 3Nagoya University Graduate School of Medicine, Nagoya, 
Japan.
Background: Exosomes are small membrane vesicles that contain host cell’s proteins, 
mRNAs, and microRNAs. The body of evidence revealed that these contents were 
biologically active and had roles in intracellular communication. On the other hand, it is 
well known that CKD patients are at risk of cardiovascular diseases, but the mechanism of 
this distant organ crosstalk is not fully understood. Recently, placental growth factor (PlGF) 
received attention in pathogenesis of cardio-renal syndrome (CRS). Under the hypothesis 
that exosomes are involved in pathophysiology of CRS, the aim of this study is to explore 
the role of exosomes from kidney fibroblasts, which actively proliferate in diseased kidney, 
on vascular endothelial cells.
Methods: Clinical samples; HUVECs were stimulated by serum exosomes from stage 
G5 CKD patients and healthy donor. Exosomes tracking; Activated kidney fibroblasts 
were isolated from unilateral ureteral obstruction (UUO) mice kidney. These exosomes 
were labeled by microRNA of C. elegance (Cel-miR-39), then labeled Exosomes were 
injected to the mice through tail vein. Effects of exosomes on endothelial cells; We purified 
exosomes from culture media of TGF-b stimulated kidney fibroblasts cell line (NRK-49f), 
and then primary culture of vascular endothelial cells (RAOEC) was stimulated using these 
exosomes. By qPCR, we evaluated the expression of PlGF genes.
Results: (1) Not only the serum but also exosomes from CKD stage G5 patients 
stimulated PlGF expression on HUVECs. (2) Injected labeled exosomes from activated 
kidney fibroblast distributed mainly in lung, liver, and aorta. (3) RAOEC stimulated 
with exosomes form TGF-b activated rat kidney fibroblast (RAOEC-T) showed higher 
expression of PlGF than control (RAOEC-C).
Conclusions: So far, CRS is considered to be caused by uremic factor, RAS system, 
chronic inflammation, and so on. From this study, both serum and exosomes from CKD 
patients stimulated PlGF transcription on endothelial cells. Exosomes from activated kidney 
fibloblast had same tendency. We speculated that exosomes from diseased kidney have 
some roles in atherosclerotic change by modulating the expression of PlGF on endothelial 
cells. Farther studies are needed to elucidate the degree of contribution to CRS.
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Hypertension and CVD: Mechanisms - II
Senescent MVs from IS-Treated Endothelial Cells Induce Vascular 
Calcification
Matilde Alique,1 Julia Carracedo,2 Guillermo Bodega,3 Elena Corchete,4 
Estefanya Garcia menendez,5 Patricia De Sequera,6 Maria Marques Vidas,7 
Rafael Perez-Garcia,8 J.M. Portolés,9 Rafael Ramirez.1 1Departamento de 
Biología de Sistemas, Universidad de Alcalá, Alcalá de Henares, Spain; 
2Complutense University, MADRID., Spain; 3Universidad de Alcalá, Alcalá de 
Henares, Spain; 4Hospital Universitario Fundación Alcorcon, Alcorcon 
(Madrid), Spain; 5Hospital Puerta de Hierro Majadahonda, Majadahonda, 
Spain; 6University Hospital Infanta Leonor, MADRID, Spain; 7Hospital 
Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain; 8Hospital 
Infanta Leonor, Madrid, Spain; 9Hospital Puerta De Hierro, Majadahonda 
(Madrid), Spain.
Background: Vascular calcification (VC) is a premature event of cardiovascular 
inflammatory diseases (CVD) in patients with chronic kidney disease (CKD). But 
identifying patients at risk of developing VC is complex, and it is necessary to expand 
the knowledge of the initial events that allow the progression of this pathology. Recently, 
we reported that senescent endothelial cells produce microvesicles (MV) which can act 
triggering the development of VC. As induction of premature endothelial senescence is a 
physiopathological mechanism in CVD associated with CKD, the objective of this study 
is to investigate whether MVs from endothelial cells that undergo premature senescence 
induced by the uremic toxin indoxyl sulfate (IS) can also modify vascular smooth 
muscle cells by making them susceptible to bone transformation. Besides, we study the 
mechanism(s) involved in VC promotion.
Methods: Endothelial cells (HUVEC) were treated with IS (250 μM; 4 days) and 
senescence was quantified with the β-galactosidase kit. The MV produced by these 
senescent HUVECs were isolated and subsequently characterized by flow cytometry and 
used for the treatment of vascular smooth muscle cells (HASMC). In HASMC, the calcium 
deposits were evaluated by alizarin red. At 30 days, the calcium content was quantified 
by the phenolsulfonephthalein kit. Expression of pro-calcifying genes was determined 
in HASMC by quantitative PCR. Western blot established the expression of a specific 
HASMC marker.
Results: IS-treated induced early senescence in HUVEC (control: 7.07±2.87% vs. IS: 
72.90±13.09%, p <0.0001) and an increase in the production of MV was observed (control: 
1.68±1.00 vs. IS: 9.92±4.29 MV/cell, p <0.005). Senescent MVs from IS-treated endothelial 
cells induced calcification in HASMC associated with deregulation in the expression of 
procalcifying genes (Runx2, BMP2). Also, the MV generated in HUVEC treated with IS 
produce a dedifferentiation process of the HASMC (SM22α expression).
Conclusions: MV produced by endothelial cells which develop early senescence as 
a consequence of the stress generated by the uremic toxins promote the development of 
VC. These results may be useful to develop biomarkers and therapeutic tools to prevent or 
treated patients with CVD and/or CKD at risk of developing VC.
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The Circadian Clock Provides Beneficial Effects Against the Endothelial 
Dysfunction to Promote Atherogenesis by Regulating PDGF Generation 
and iNOS Expression
Hideyuki Negoro. Harvard Medical School, The Graduate School of Project 
Design, Tokyo, Japan.
Background: The circadian clock is a molecular mechanism that confers 24 hour 
variations in gene expression and function to regulate number of physiological functions in 
humans. Disruption of the clock is associated with pathological remodeling in the arterial 
structure and vascular stiffness. Chronic circadian clock disruption is also associated with 
dysfunction in endothelial signaling and responses. In this study, we observed if the deletion 
of Bmal1, a critical component of the circadian clock, can influence growth factors, such as 
platelet-derived growth factor (PDGF) or inducible nitric oxide synthase (iNOS) which play 
an important part in the progression of vascular diseases.
Methods: Congenic 12- to 16-week-old male, wild-type and Bmal1-KO littermate 
mice were generated from heterozygote breedings to be used for these studies. We also 
knocked down Bmal1 to evaluate the protein levels of PDGF and iNOS expression in the 
knocked down cells.
Results: Endothelial function was reduced in aorta from Bmal1-KO mice. In aorta 
from Bmal1 KO mice, there was an increase in PDGF and iNOS expression in mice with 
a dysfunctional circadian rhythm. Moreover, Bmal1 KO mice display pre-mature aging 
to have a dramatic prothrombotic phenotype. This phenotype is linked to changes in the 
regulation of key risk factors for cardiovascular disease. These include PDGF and iNOS, 
which are significantly elevated in Bmal1 KO mice. We also confirmed that PDGF levels 
follow a circadian pattern and this pattern was absent in Bmal1 KO mice.
Conclusions: These findings indicate that circadian clock provides beneficial 
effects against the endothelial dysfunction to promote atherogenesis by regulating PDGF 
generation and iNOS expression. This study establishes a mechanistic connection between 
Bmal1 and cardiovascular phenotype.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - II
Endothelial-Specific Krüppel-Like Factor 2 Inactivation Promotes 
Endothelial Dysfunction in the Setting of Uremia
Keith L. Saum,2 Begoña Campos,2 Aous Jarrouj,3 Diego Celdran-Bonafonte,1 
Prabir Roy-Chaudhury,4 Albert P. Owens.2 1University of Arizona / BIO 5 
Institute, Tucson, AZ; 2University of Cincinnati, Cincinnati, OH; 3Banner-
University of Arizona, Tucson, AZ; 4University of Arizona, Tucson, AZ.
Background: Uremic solutes that accumulate in end-stage renal disease(ESRD) may 
contribute to endothelial dysfunction and subsequent cardiovascular disease and vascular 
access dysfunction in ESRD patients. However, the mechanisms which mediate uremia-
induced endothelial dysfunction in ESRD are not understood. Kruppel-like factors(KLFs) 
are key regulators of endothelial homeostasis which may be affected by the uremic milieu. 
In this study we examined the role of endothelial KLF2 in mediating endothelial dysfunction 
in the setting of uremia
Methods: We used serum from a porcine model of chronic renal failure to assess 
the impact of uremia on endothelial KLF2 expression in vitro. Human umbilical vein 
endothelial cells (HUVECs) were treated with increasing concentrations of uremic or non-
uremic porcine serum and analyzed for KLF2 expression. Similarly, cells were treated with 
individual protein-bound toxins at average uremic concentrations. Reactive oxygen species 
(ROS) production and monocyte adhesion were then assessed in treated cells with and 
without KLF2 overexpression. To assess if the loss of KLF2 impairs endothelial function 
in vivo, we quantified flow-mediated dilation (FMD) of the femoral artery in endothelial-
specific KLF2 conditional knockout (cKO) mice after 5 minutes of hindlimb ischemia
Results: KLF2 expression was dose-dependently decreased in HUVECs with uremic 
serum versus normal serum. Carboxymethyl-lysine(CML) modified albumin, a uremic 
advanced glycation end-product(AGE), also inhibited KLF2 expression. KLF2 suppression 
also promoted endothelial dysfunction in vitro, as adenoviral overexpression of KLF2 
inhibited reactive oxygen species production and leukocyte adhesion in HUVECs treated 
with uremic serum or CML-AGE. Assessment of FMD in KLF2cKO mice demonstrated a 
50%reduction in vasodilation compared to controls. The lack of femoral artery vasodilation 
in KLF2cKO mice was also accompanied by an attenuated return of wall shear stress to 
baseline independent of blood velocity
Conclusions: Collectively, these observations implicate loss of endothelial KLF2 as 
a mediator of endothelial dysfunction in the setting of uremia, and suggest that elevating 
KLF2 expression may be a novel strategy for prevention and treatment of vascular access 
dysfunction and cardiovascular disease in ESRD
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The Role of Autophagy in Neutrophil Extracellular Trap (NET)  
Formation in CKD
Jwa-kyung Kim,1 Narae Joo,2 Sung gyun Kim.3 1Internal medicine, Hallym 
University, Seoul, Republic of Korea; 2Halyym University Sacred Heart 
Hospital, AnYang, Republic of Korea; 3Hallym University, Antang, Republic of 
Korea.
Background: Increased neutrophil extracellular trap (NET) formation could be an 
endogenous stimulus of chronic vascular inflammation despite its bacterial killing effect. 
However, researches about the degree of NET formation in chronic uremic conditions and 
its relationship with vascular complications have been limited. We assessed the relationship 
between NETs and vascular endothelial dysfunction in maintenance hemodialysis (MHD) 
patients, and evaluated the role of autophagy in NET formation in uremia
Methods: To quantify extracellular DNA level, serum cell-free nucleosome was 
measured between MHD patients (n=60) and healthy volunteer (HV, n=20). Then, 
neutrophils were isolated and stimulated with phorbol 12-myristate 13-acetate (PMA). The 
NET formation was visualized with confocal microscopy and the activity of neutrophil 
elastase (NE) were directly measured to confirm the amount of NETs in both groups. 
Endothelial dysfunction was measured by flow-mediated dilatation (FMD) of brachial 
artery using an automated device. The autophagic status were evaluated, and the effect of 
autophagy inhibition on NET formation was further investigated.
Results: The median basal levels of serum cell-free nucleosome were prominently 
increased in MHD patients than HV (p<0.001). Also, neutrophils isolated from MHD 
patients showed an increased NE activity as well as higher NET formation than controls both 
at basal and activated state, suggesting neutrophil priming in MHD group. The increased 
extracellular DNA level as well as NE activities were strongly associated with FMD (%) 
even after adjustments for traditional cardiovascular risk factors and uremic toxin levels 
(nucleosome: β=-0.429 p=0.001, NE β=-0.429 p=0.001). Moreover, neutrophils isolated 
from MHD patients showed an increase in autophagy function, especially autophagy 
induction. Interestingly, after treatment of 3-MA or ammonium chloride, inhibitors of 
autophagy pathways at early and late stages respectively, the levels of NET formation were 
markedly augmented, suggesting the protective role of autophagy in uremia.
Conclusions: Increased NETs formation may be one of important contributing factors 
of vascular endothelial dysfunction in hemodialysis patients. Increased autophagy induction 
in uremia could be an adaptive response as a protective manner to remove uremic toxins, 
and the inhibition of autophagy may induce excessive NET formation.
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Macrophage and T-Cell Infiltration in a Rat Model of Limb Ischemia: 
Effect of Impaired Kidney Function on the Pattern of Post-Ischemic Cell 
Infiltration
Andrea Hartner,2 Kerstin U. Amann,3 Roland Veelken,1 Karl F. Hilgers.1 
1University of Erlangen, Erlangen, Germany; 2University Hospital of Erlangen, 
Erlangen, Germany; 3University Hospital Erlangen, Erlangen, Germany.
Background: The outcome of limb ischemia is worse in rats with chronic kidney 
disease (CKD) as was previously shown by others and us. We hypothesized that a different 
pattern of T-lymphocyte and macrophage infiltration into the ischemic muscle in rats with 
CKD may underlie the deficient repair and angiogenesis processes.
Methods: CKD rats (N=10) underwent 5/6 nephrectomy; controls (N=8) sham 
operation. After 8 weeks, ischemia of the right limb was induced by ligation and resection 
of the femoral artery. Rats were sacrificed 3 days later. Cross sections of musculus soleus 
of the ischemic and non-ischemic limbs were stained for macrophage markers ED-1 and 
CD163 as well as lymphocyte markers CD3, CD4 and CD8a. Positive cells were counted 
in 20 high-power fields. The expression of a panel of cytokines (including CCL2, CCL5, 
CCL7, osteopontin, IL-6 and TNFα) in muscle tissue was measured by RT-PCR.
Results: All investigated cell types were increased in ischemic versus non-ischemic 
limbs. There was a trend towards a higher increase of ED-1 macrophages in ischemic limbs 
of CKD (15±3-fold versus 10±3-fold in controls, p=0.492) but there was no significant 
difference. Absolute numbers of ED-1 and CD163 positive cells as well as the ratio between 
ED-1 and CD163 (M2 macrophages) did not differ between CKD and control. The number 
of CD3 T-cells in ischemic limbs was not different between CKD (5.4±0.7 cells/view) and 
controls (4.9±0.5, p=0.897). However, the number of CD8a cells in ischemic limbs was 
higher in CKD (1.8±0.2) than in controls (1.0±0.1, p=0.006). The ratio of CD8a to CD4 
cells was significantly elevated in CKD rat ischemic limbs, as was the ratio of CD8a to CD3 
cells. All investigated cytokines increased in ischemic limbs but there was no consistent 
difference between CKD and controls. In ischemic limbs, CD8a cells correlated tightly with 
the expression of CCL5 (r=0.722, p=0.001) but not with other cytokines.
Conclusions: Our results point to a higher infiltration of CD8a cytotoxic T-cells into 
ischemic limbs in CKD rats which may contribute to a worse outcome. In contrast, we did 
not find an altered pattern of M1/M2 macrophages.
Funding: Government Support - Non-U.S.
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Soluble Klotho Acts as a Co-Receptor for FGF23 That Interferes with 
FGF23’s Action on the Heart
Christopher Yanucil,1,2 Beatrice Richter,3 Brian A. Czaya,4 Isaac D. Campos,4 
Dominik R. Kentrup,4 Christian Faul.5 1Cell Biology, University of Alabama 
Birmingham, Birmingham, AL; 2Nephrology, University of Alabama 
Birmingham, Birmingham, AL; 3The University of Alabama at Birmingham 
(UAB), Birmingham, AL; 4University of Alabama at Birmingham, Birmingham, 
AL; 5The University of Alabama at Birmingham, Birmingham, AL.
Background: Fibroblast growth factor (FGF) 23 is a bone-derived hormone that 
increases phosphate excretion by targeting the kidney via klotho and FGF receptor (FGFR) 
1. Klotho also exists in a soluble form that is released from the kidney. In patients with
chronic kidney disease (CKD), changes in FGF23 and circulating sKL levels are associated 
with the development of cardiovascular disease and mortality. We have reported that FGF23 
can contribute to cardiac hypertrophy by directly targeting cardiac myocytes via FGFR4 and 
inducing phospholipase Cg (PLCg) signaling. Experimental studies have shown that sKL 
has pleiotropic functions, including cardio-protective actions. Since a recent structural study 
has shown sKL acts as a scaffold to mediate FGF23-FGFR1 binding, we tested whether sKL 
interferes with FGF23-FGFR4 complex formation and effects in cardiac myocytes.
Methods: We purified recombinant sKL from stably transfected HEK293 cells, and 
determined its ability to bind recombinant FGF23 coated to a 96-well plate in the presence 
or absence of different FGFR isoforms. Furthermore, we co-treated neonatal rat ventricular 
myocytes (NRVM) with FGF23 and sKL and analyzed the activation of downstream 
signaling events by immunoblotting and hypertrophy via 3H-phenylalanine incorporation.
Results: sKL binds FGF23 in the absence of FGFRs and exponentially increases the 
affinity of FGF23 for multiple FGFR isoforms. In NRVM, co-treatment with sKL blocks 
FGF23-mediated PLCγ activation and stimulates Ras/MAPK signaling. Furthermore, 
sKL inhibits FGF23-induced hypertrophic growth of NRVM, but has no effect on FGF2-
mediated hypertrophy.
Conclusions: The binding of sKL to FGF23 does not require FGFRs and might 
therefore act as the initial event in the formation of FGF23/sKL/FGFR signaling complexes. 
Similar to membrane-associated klotho, sKL increases the affinity of FGF23 for FGFR 
binding, and thereby causes FGF23 responsiveness of cells that express FGFRs but lack 
klotho. The sKL-mediated interaction between FGF23 and FGFRs appears to be more 
promiscuous than previously reported by not only involving FGFR1, which might explain 
the pleiotropic actions of sKL on various cells types. By inducing a switch in downstream 
signaling, sKL blocks FGF23-induced hypertrophy in cardiac myocytes and might serve as 
a cardio-protective therapy in CKD.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Cardiac-Specific FGF23 Knockout Leads to Increased Cardiovascular 
Risk
Maren Leifheit-Nestler,1 Saskia Schmaltz,1 Malgorzata Szaroszyk,1 
Beatrice Richter,2 Joerg Heineke,3,1 Dieter Haffner.1 1Hannover Medical School, 
Hannover, Germany; 2The University of Alabama at Birmingham, Birmingham, 
AL; 3Medical Faculty Mannheim of Heidelberg University, Mannheim, 
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Background: Patients with CKD have an higher risk for cardiovascular disease 
(CVD) and mortality associated with increased levels of FGF23. Recent studies indicate 
that FGF23 is expressed by cardiac myocytes and activates the calcineurin/NFAT pathway 
via activation of FGFR4 in the heart and may contribute to the development of LVH. We 
hypothesized that cardiac FGF23 is a modifier of CVD risk in mice.
Methods: To this aim we generated a mouse model with a cardiac myocyte-specific 
FGF23 knockout (FGF23-KO) in the C57BL/6 background using the Cre/loxP system. 
we evaluated the impact of cardiac FGF23 on the heart. Cardiovascular outcome in 
FGF23-KO receiving a standard diet was compared to wild-type littermates (WT) during 
an observational period of up-to 6-months. In addition, we compared pressure overload-
induced cardiac hypertrophy induced by transverse aortic constriction (TAC) in 8-weeks 
old FGF23-KO and WT mice.
Results: Body weight, heart weight, tibia length and parameter of mineral metabolism 
including FGF23 synthesis in bone and plasma intact FGF23 levels did not differ between 
FGF23-KO mice and WT group. FGF23-KO mice showed significantly increased 
mortality compared to WT associated with enhanced end-diastolic LV volume and stroke 
volume examined by cardiac magnetic resonance imaging (cMRI). On molecular level, 
pro-hypertrophic and pro-fibrotic markers ANP, BNP, collagen 1, TGF-β and CTGF 
were enhanced in heart tissue of FGF23-KO mice and local cardiac renin-angiotensin-
aldosterone system was activated compared to WT mice. As expected, heart function was 
impaired in WT mice 2 weeks after TAC compared with Sham along with increased relative 
heart weight, cardiac myocyte size and the induction of pro-hypertrophic genes and bone 
and cardiac FGF23 synthesis. Interestingly, FGF23-KO mice after TAC showed the same 
heart phenotype like WT TAC with exception of cardiac FGF23 synthesis. Moreover, cMRI 
revealted increased end-systolic LV volume and systolic LV diameter in FGF23-KO TAC 
compared to WT TAC mice.
Conclusions: In conclusion, cardiac myocyte-specific FGF23 knockout leads to 
impaired heart function and increased mortality in mice and results in increased CVD in the 
high pressure-induced hypertrophic mouse model. Thus our data suggest a physiological 
role of cardiac FGF23 in heart function and adaption to pressure overload.
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Cardiac-Specific Overexpression of FGF23 Fails to Induce Cardiac 
Hypertrophy in Mice Without CKD
Maren Leifheit-Nestler,1 Miriam Wagner,1 Beatrice Richter,2 Dieter Haffner.1 
1Hannover Medical School, Hannover, Germany; 2The University of Alabama at 
Birmingham, Birmingham, AL.
Background: High circulating and cardiac FGF23 levels are associated with increased 
risk of cardiovascular events and all cause mortality in CKD patients. We showed on 
molecular level that FGF23 stimulates hypertrophic growth of isolated cardiac myocytes 
in the absence of klotho via activation of FGFR4/calcineurin/NFAT pathway leading to left 
ventricular hypertrophy (LVH). It is still a matter of debate if elevated FGF23 results in 
LVH under healthy conditions, e.g. in the absence of CKD.
Methods: By generating a mouse model with cardiac specific overexpression of FGF23 
using cardiovascular gene transfer with an adeno-associated virus expressing FGF23 (AAV-
FGF23) under the control of the cardiac troponin T promotor, we investigated the pro-
hypertrophic properties of cardiac FGF23 in C57BL/6N wild-type mice.
Results: The detection of AAV expression within various organs verified the specific 
accumulation of AAV-FGF23 in the heart. Cardiac Fgf23 mRNA expression was 2,000-fold 
increased in AAV-FGF23-treated mice compared to controls and immunoblot analysis point 
out that the cardiac FGF23 protein was full-length biologically active. This was further 
confirmed by enhanced cardiac and plasma intact FGF23 levels in AAV-FGF23 mice. 
Parameters of mineral metabolism and renal expression of klotho did not differ between 
AAV-FGF23 and controls, whereas NaPi2a and NaPi2c mRNA levels were significantly 
reduced. Although, AAV-FGF23-treated mice showed a moderate induction of cardiac 
Fgfr4 mRNA expression, relative heart weight and cardiac myocyte size did not differ 
between both groups and pro-hypertrophic NFAT target genes Rcan1, Trpc6, b-MHC, and 
ANP remained unchanged. Moreover, BNP levels were even significantly reduced in AAV-
FGF23 mice compared to controls. Cardiac MRI analysis demonstrated no impairment 
of heart function in AAV-FGF23 mice but echocardiography studies showed significant 
increased stroke volume and cardiac output, which might be due to increased cardiac 
preload and/or enhanced contractility.
Conclusions: In conclusion, AAV-FGF23 induces the expression of full-length 
biological active FGF23 in the heart but fails to induce LVH under healthy conditions, 
suggesting that additional factors associated with CKD, e.g. klotho deficiency or high 
phosphate load, are necessary for FGF23 to tackle the heart.
Hypertension and CVD: Mechanisms - II
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
995
J Am Soc Nephrol 29: 2018 Poster/Saturday
SA-PO989 Poster Saturday
Hypertension and CVD: Mechanisms - II
FGF23 Contributes to Cardiac Fibrosis in CKD
Beatrice Richter, Christopher Yanucil, Brian A. Czaya, Isaac D. Campos, 
Dominik R. Kentrup, Christian Faul. The University of Alabama at Birmingham, 
Birmingham, AL.
Background: The risk for cardiovascular diseases is enormously increased in patients 
with chronic kidney disease (CKD). Over 90% of patients with end-stage renal disease 
develop pathologic cardiac remodeling, including hypertrophy and fibrosis that can lead to 
heart failure. Fibroblast growth factor (FGF) 23 is a bone-derived hormone that increases 
phosphate excretion by targeting the kidney via FGF receptor (FGFR) 1 and klotho. In early 
stages of CKD, serum FGF23 levels increase to compensate the rise in serum phosphate 
concentrations. High FGF23 concentrations are associated with the development of 
cardiovascular disease and a strong predictor for mortality in CKD. Our previous studies 
in rodents have shown that FGF23 can directly target the heart and contribute to cardiac 
hypertrophy. FGF23 binds to FGFR4 on cardiac myocytes in a klotho-independent manner, 
leading to the activation of a pro-hypertrophic signaling cascade, including phospholipase 
Cγ (PLCγ) and calcineurin. Since in animal models with elevated serum FGF23 levels 
cardiac hypertrophy is accompanied by fibrosis, we wanted to test if FGF23 can also 
directly target cardiac fibroblasts, using isolated primary cell culture models.
Methods: We have established primary cardiac fibroblast cultures from newborn rats, 
as well as adult mice and rats, and we analyze expression levels of different FGFR isoforms 
and klotho by qPCR. We treat cells with increasing FGF23 concentrations and investigate 
the activation of FGFRs, downstream signal mediators and pro-fibrotic gene programs by 
qPCR, immunoblotting and enzymatic assays. Furthermore, we study cell proliferation, 
migration and survival. We determine if co-treatment with inhibitors against FGFRs, PLCγ 
or calcineurin blocks FGF23-mediated effects on fibroblasts.
Results: Cardiac fibroblasts isolated from mice and rats express high levels of FGFR1 
and to a lower extent also FGFR4. FGF23 promotes proliferation, migration and activation 
of fibroblasts when compared to vehicle-treated control cells.
Conclusions: We postulate that FGF23 contributes to pathologic cardiac remodeling 
by directly targeting different cell types in the myocardium, i.e. cardiac myocytes via 
FGFR4 and cardiac fibroblasts via FGFR1. Pharmacological blockade of FGFRs might 
serve as novel cardio-protective therapy in CKD.
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Cytoskeletal Dysregulation in Uremic Cardiomyopathy
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Background: Ventricular remodeling involving left ventricular (LV) hypertrophy, 
dilatation and fibrosis in uremic cardiomyopathy contribute to the high rate of premature 
cardiovascular death in chronic kidney disease (CKD). Alterations in the cytoskeleton are 
well described in hypertrophied and failing myocardium and appear to be an important 
regulator of pro-fibrotic pathways in CKD. The mechanisms of cytoskeletal dysregulation 
in uremic cardiomyopathy remain largely unknown. Herein, we performed a comprehensive 
investigation of cytoskeletal adaptations in uremic cardiomyopathy.
Methods: We conducted a cross-sectional analysis of explanted human LV tissues from 
advanced CKD donors (n=23; hemodialysis (HD; n=20); peritoneal dialysis (PD; n=3)) 
compared to CAD (coronary artery disease; n=11) and healthy (n=20) controls. Primary 
human cardiomyocytes and cardiac-myofibroblasts were treated with calcification medium 
(CM) in time-course experiments (0-48 hours), in vitro. We developed a novel digital cell 
sorting study model using deconvolution to accurately assess hetereogenous transcriptomic 
profiles inherent of mixed-cell type tissues from RNA sequencing. qPCR and western 
blotting was used to confirm expression of target genes.
Results: Cross-sectional analysis revealed that the major cytoskeletal proteins β-
tubulin and type III intermediate filament Vimentin, were significantly down-regulated in 
both CAD and CKD hearts compared to controls (p<0.01). However, major anchor protein 
Vinculin was upregulated in both CAD and CKD hearts compared to controls (p<0.05). 
Interestingly, β-actin, a critical component of the microfilament system was down-
regulated in CAD hearts, but further down-regulated in CKD hearts compared to CAD and 
controls (p<0.01). Furthermore, on subanalysis HD patients had significantly lower β-actin 
expression compared to PD patients (p<0.01). Analysis of primary human cardiomyocytes 
and cardiac-myofibroblasts treated with CM revealed the same pattern of changes, in vitro.
Conclusions: We show for the first time severely reduced β-actin expression in 
human CKD hearts compared to CAD and controls. These findings may contribute to 
accelerated cardiac remodeling in uremic conditions and may be affected by dialysis 
modality. Upregulation of Vinculin may be involved in reduced contractile function of 
cardiomyocytes in uremia.
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Cardiac structure in Patients with Mild to Moderate CKD – an MRI 
Study
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Background: Abnormal cardiac structure, in particular left ventricular hypertrophy 
(LVH), is common in patients with advanced chronic kidney disease (CKD), and predisposes 
to heart failure and sudden cardiac death. The prevalence, patterns and determinants of 
abnormal cardiac structure in patients with mild to moderate CKD has not been studied with 
magnetic resonance imaging (MRI).
Methods: We examined cardiac structure by MRI in 290 patients with mild to moderate 
CKD (median eGFR 50 ml/min), and explored associations with clinical and hemodynamic 
parameters (Mobil-O-Graph®, IEM, Germany), hydration status (bioimpedance 
spectroscopy), endothelial function (flow-mediated vasodilation), inflammation (high 
sensitive C-reactive protein, interleukin-6, tumor necrosis factor(TNF)-α, soluble TNF-
receptors I and II) and CKD-mineral bone disease (MBD) markers (calcium, phosphate, 
1,25-OH Vitamin D, intact parathyroid hormone, α-klotho, intact fibroblast growth factor 
(FGF)-23, C-terminal FGF-23). Linear regression analyses were used to identify variables 
independently associated with cardiac structure.
Results: Normal geometry was found in 56%, dilation in 4%, concentric remodeling in 
10%, and LVH in 29% of patients. Abnormal cardiac structure was more prevalent in women 
than in men with CKD (P=0.06). Greater left ventricular mass (LVM) was independently 
associated with the variables male gender, greater BMI and higher 24h-systolic blood 
pressure (24h-SBP). Concentric remodeling was independently associated with male 
gender, higher 24h-SBP and greater hemoglobin levels. Neither endothelial function, nor 
hydration status or any of the inflammatory or CKD-MBD parameters contributed to the 
models.
Conclusions: Using state-of-the art MRI, abnormal cardiac structure was found in 
almost half of all patients with mild to moderate CKD. Targeting the modifiable factors 
24h-SBP, BMI (for LVM) and avoiding high hemoglobin concentrations (for concentric 
remodeling) may prevent the development of adverse cardiac structure in patients with mild 
to moderate CKD.
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Renal Functional Reserve Mirrors the Sympathetic Overdrive Influence 
on the Heart
Aikaterini A. Damianaki,1 Kyriakos Dimitriadis,2 Zoe Alexakou,1 
Aglaia Chalkia,1 Konstantinos Tsioufis,2 Dimitrios I. Petras.1 1Nephrology 
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Background: Renal functional reserve (RFR) refers to the capacity of the kidney 
to increase the Glomerular Filtration Rate (GFR) under the influence of certain stimuli. 
It is a promising diagnostic tool for assessing the risk of Acute Kidney Injury and of 
Chronic Kidney disease development in specific populations. The aim of our study was to 
assess the relation of RFR with diverse clinical parameters in normotensive patients with 
eGFR>60ml/min/1.73m2and without any evidence of kidney damage (proteinuria, anatomic 
lesion etc).
Methods: 15 normotensive subjects (mean age=52 years, BMI= 26 kg/m2, office 
systolic/diastolic BP =138/88 mmHg, ABPM 120/76mmHg) were included. All subjects 
underwent the exercise treadmill stress test, 24hour ABPM, office BP measurements, 
kidney ultrasound and ACR test. All subjects were fasted for 8 hours and then baseline 
hydration status was recorded using bioimpedance analysis. Basal GFR was measured after 
hydration and stress GFR was achieved after ingestion of oral protein 1g/kg as cooked meal. 
Basal and Stress GFR were determined by Creatinine Clearance = Urine Creatinine/Serum 
Creatinine x Urine Volume/time× 1.73/BSA). RFR was calculated as Stress GFR – Basal 
GFR. Patients having adequate renal reserves considered as having values of RFR greater 
than 30ml/min/1.73m2
Results: There was no correlation of RFR values with respect to family history of 
hypertension, smoking, age, BMI or office BP. In contrast, patients with higher RFR values, 
achieved lower maximum systolic BP during the treadmill test (p<0.05) (175.7 ± 9.75 
mmHg vs 176.2±22.48mmHg). Additionally, a statistically significant positive correlation 
was found between RFR values and maximum heart rate (HR) during treadmill test 
(r=0.517, p=0.048).
Conclusions: RFR is related to treadmill exercise maximum systolic BP in normotensive 
patients and appears to correlate with maximum HR. These findings underlie the pleiotropic 
effects of sympathetic nervous system in kidneys and their long term influences in kidney 
function. Treadmill test could be used to identify normotensive patients with normal eGFR 
who may have susceptibility to renal injury.
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Chronic, Isolated Renal Venous Pressure Increase Induces Extensive 
Renal Venous Collateral Formation and Exacerbates Renal and  
Cardiovascular Dysfunction in Rats
Shereen M. Hamza,1,2 Xiaohua Huang,1 Wenqing Zhuang,1 Tayyaba Zehra,1 
Morgan Lapierre,1 William A. Cupples,3 Branko Braam.1,2 1Medicine, University 
of Alberta, Edmonton, AB, Canada; 2Physiology, University of Alberta, 
Edmonton, AB, Canada; 3Biomedical Physiology & Kinesiology, Simon Fraser 
University, Burnaby, BC, Canada.
Background: Coexisting cardiac/renal dysfunction may be perpetuated by increased 
renal venous pressure (RVP). We previously showed that acute RVP elevation depresses 
renal blood flow (RBF), GFR and induces renal vasoconstriction in the absence of changes 
in blood pressure. Since physiological consequence of long-term, isolated RVP elevation are 
unknown, we tested whether chronic RVP elevation would impair baseline renal perfusion, 
exacerbating renal dysfunction and cardiovascular instability in response to superimposed 
acute RVP increase. Objectives: (1) Develop and characterize chronic, isolated RVP model 
(2) Evaluate baseline cardiovascular and renal response to chronic RVP elevation and
superimposed acute increases in RVP.
Methods: Male rats were subjected to partial, graded occlusion of the left renal vein to 
induce chronic RVP elevation (20-25mmHg) and allowed to recover for either 1 (n=5) or 3 
weeks (n=6). Rats were subsequently anesthetized and blood pressure, RVP, RBF and GFR 
were measured at baseline and during further RVP increase for 120 min.
Results: Chronic RVP elevation induced extensive renal venous collateral formation, 
evident within 1 week. This adaptation reduced RVP from 20-25 mmHg to 3.6±0.2 
(1 wk) and 1.3±0.5 mmHg (3wk). Baseline blood pressure was unchanged by chronic 
RVP elevation (1 wk: 102±25; 3wk: 91±5 mmHg); however RBF and GFR were 
severely reduced at 1wk (RBF: 3.6±0.5 mL/min; GFR: 0.7±0.2 ml/min) and 3 wks (RBF: 
3.1±1.2 mL/min). GFR was too low at 3 weeks to be reliably measured. Upon further RVP 
increase, blood pressure dropped in both 1 wk (-37±10 mmHg, p<0.05) and 3 wk groups 
(-19±1 mmHg, p<0.05). RBF also fell (1 wk: -2.3±0.7; 3wk: -1.3±0.6 mL/min, p<0.05), 
with reductions in renal vascular conductance (1 wk: -0.020±0.006; 3 wk: -0.010±0.007 
mL/min.mmHg-1) and GFR (1wk: -0.56±0.14 mL/min).
Conclusions: Chronic RVP elevation elicits extensive renal venous collateral formation 
which alleviates venous congestion; however baseline renal function is suppressed. RVP-
induced renal and cardiovascular dysfunction is exacerbated compared to our previous 
report of acute increase in RVP alone, thus long-term RVP elevation impairs critical 
mechanisms required to stabilize hemodynamics.
SA-PO994 Poster Saturday
Hypertension and CVD: Mechanisms - II
Lysyl Oxidase Insufficiency Exacerbates the Cardiovascular Phenotype 
Seen in a Mouse Model of Cutis Laxa
Carmen M. Halabi. Washington University School of Medicine, Saint Louis, 
MO.
Background: Mutations in the elastogenic extracellular matrix protein Fibulin-4 
(FBLN4) have been identified in humans with cutis laxa (ARCL 1B). Mice carrying the 
E57K mutation in Fbln4 recapitulate the cardiovascular phenotype observed in humans, 
including ascending aortic aneurysms and arterial tortuosity. Mutations in lysyl oxidase 
(LOX), the enzyme that crosslinks elastin, have recently been identified in patients with 
familial thoracic aortic aneurysms and dissection. The phenotypic similarities between 
mutant and knock-out mouse models of Fbln4 and Lox, in addition to in vitro data showing 
that FBLN4 promotes binding of pro-LOX to tropoelastin have led to the currently accepted 
hypothesis that FBLN4 facilitates elastin’s crosslinking by LOX. Whether this occurs in 
vivo is unclear however.
Methods: To determine whether FBLN4 interacts with LOX in the process of elastic 
fiber formation and arterial development, we bred recently characterized Fbln4E57K mice to 
Lox hemizygous mice (Lox+/-) and assessed the structural and functional effects of LOX 
insufficiency on the cardiovascular system of Fbln4E57K mice.
Results: By 3-4 months of age Fbln4E57K;Lox+/- mice were similar in size to Fbln4E57K 
mice and littermates. Ascending aortic aneurysms, which were incompletely penetrant and 
confined to the ascending aorta in Fbln4E57K mice were significantly worsened by LOX 
insufficiency as they were fully penetrant and extended from the aortic root through the aortic 
arch in Fbln4E57K;Lox+/- mice. Additionally, arterial tortuosity and elastic fiber fragmentation of 
large conduit arteries were exacerbated by LOX insufficiency. Interestingly, muscular arteries 
remained intact. Fbln4E57K;Lox+/- mice had significant cardiac hypertrophy and widening of 
the pulse pressure that was due to lower diastolic blood compared to Fbln4E57K mice.
Conclusions: In summary, LOX insufficiency exacerbated the vascular phenotype seen 
in mice with mutant FBLN4 suggesting that there is a functional interaction between the 
two molecules. Interestingly, elastic fiber formation was unaffected in muscular arteries 
raising the possibility that the process of elastic fiber assembly, previously thought to be the 
same in all elastic tissues, may differ between vascular beds. Further studies are underway 
to determine whether a direct interaction between FBLN4 and LOX occurs in the process 
of elastic fiber formation.
Funding: Other NIH Support - NHLBI K08HL135400
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Hypertension and CVD: Mechanisms - II
Effect of Omega-3 Fatty Acid on AKT-mTOR and FoxO in Heart of 5/6 
Nephrectomy Rat Model
Su mi Lee,1 Yun Jung Oh,2 Young ki Son,1 Seong Eun Kim,3 Won Suk An.1 
1Dong-A University, Busan, Republic of Korea; 2Cheju Halla General Hospital, 
Jeju, Republic of Korea; 3Dong-A University Hospital, Busan, Republic of 
Korea.
Background: Cardiac hypertrophy is common and results in mortality in patients with 
chronic kidney disease (CKD). Akt-mammalian target of rapamycin (mTOR) axis is related 
with cardiac hypertrophy. Forkhead box class O (FoxO) family is related with autophagy 
and apoptosis, but there is no report in the heart of CKD. The present study aimed to 
investigate whether omega-3 fatty acid (ω-3 FA) effect on Akt-mTOR axis and FoxO in 
heart of 5/6 subtotal nephrectomy (Nx) rat model.
Methods: Male Sprague Dawley rats were divided into three groups and treated for 6 
weeks: sham control (0.9% saline), 5/6 Nx control (0.9% saline) and 5/6 Nx treated with ω-
3 FA (300 mg/kg/day by gastric gavage). The expression of cardiac Akt, phosphorylated(p) 
Akt, mTOR, FoxO, PI3K, p-PI3k, AMPK, p-AMPK, smad2/3, NF-κB, cleaved caspase 
3/7, LC3, muscle-specific ring finger protein-1 (MuRF1), and muscle atrophy F-box protein 
(MAFbx) were examined by western blot analysis. Hematoxylin and eosin staining of heart 
was performed.
Results: Serum creatinine level was significantly increased in 5/6 Nx group compared 
to control group and were not significantly different between 5/6 Nx group treated with ω-3 
FA and 5/6 Nx group. Compared with control group, cardiac hypertrophy of 5/6 Nx group 
was found in gross and microscopic findings. No definite cardiac hypertrophy was found 
in 5/6 Nx group treated with ω-3 FA. P-Akt and mTOR were significantly up-regulated in 
heart of 5/6 Nx group compared to control group and were recovered by ω-3 FA. Compared 
with control group, 5/6 Nx group significantly up-regulated FoxO1 and FoxO3a expression 
of heart, which were significantly recovered by ω-3 FA. However, the expression of MuRF1 
and MAFbx was not different among three groups. The expression of smad2/3, NF-κB, 
cleaved caspase 3/7, LC3 was up-regulated in the heart of 5/6 Nx group compared to control 
group and was recovered by ω-3 FA. The expression of p-AMPK was down-regulated in the 
heart of 5/6 Nx group compared to control group and was recovered by ω-3 FA.
Conclusions: ω-3 FA may prevent cardiac hypertrophy not only by decreasing p-Akt, 
mTOR and FoxO expression but also by reducing molecules of inflammation, autophagy 
and apoptosis.
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Hypertension and CVD: Mechanisms - II
Subsequent Impaction on Renal Tissue After Myocardial Infarction in 
Animal Models
Chi-Ting Su,1,2 Yen-wen Liu,3 Jenq-wen Huang.4 1Renal Division, National 
Taiwan University Hospital, Yun-Lin Branch, Taipei, Taiwan; 2Human Genetics, 
University of Pittsburgh, Pittsburgh, PA; 3Department of Internal Medicine, 
National Cheng Kung University Hospital, Taiwan, Tainan, Taiwan; 4Renal 
Division, National Taiwan University Hospital, Taipei, Taiwan.
Background: The interaction between kidney and heart has been an important entity for 
decades. Investigation of pathogenesis may optimize therapeutic strategies and modalities, 
which potentially leads patients with cardiac and renal impairments to better outcomes. 
The major goal for this research is to investigate the biological functions of the latent 
transforming growth factor-beta-binding proteins (LTBPs) and identify pathophysiological 
role in renal impairment after myocardial infarction.
Methods: We created myocardial infarction with ligation over left anterior descending 
artery in mice. Echocardiogarphy and picrosirius red/fast green-stained histology studies 
were used to demonstrate the cardiac dysfunction after myocardial infarction. Gene and 
protein expression have been studied one week, two weeks, and four weeks after the surgery.
Results: Echocardiography successfully demonstrated cardiac wall motion 
abnormalities after myocardial infarction and cardiac fibrosis had been shown in histology 
studies. Ltbp4, pSMAD2 and pERK had been up-regulated in cardiac tissue obviously two 
weeks after myocardial infarction. On the other hand, one week after myocardial infarction, 
interleukin 6 (IL- 6) and monocyte chemoattractant protein -1(MCP-1) in renal tissues had 
been up-regulated significantly (p<0.001). It is interesting that increasing expression of 
kidney injury molecule-1 (KIM-1), ltbp4 and transforming growth factor beta (TGF-β) in 
renal tissue had been detected until two weeks after the surgery. Moreover, renal platelet-
derived growth factor receptor beta (Pdgfrb) was detected increasing steadily. In addition, 
increased ltbp4 expression in renal after kidney injury had been found as an essential 
regulatory factor in TGF-β pathways.
Conclusions: Cardiac fibrosis can enhance renal inflammation early and induce 
KIM-1 and Pdgfrb expression in renal tissue. Inflammation served as a prelude before the 
expression of fibrotic factors. Ltbp4 is an essential regulatory in TGF-β signaling and is one 
of the significant factors to manipulate the progress of renal injury and the crosstalk between 
kidney and heart, the cardiorenal syndrome.
Funding: Government Support - Non-U.S.
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Hypertension and CVD: Mechanisms - II
The Role of the Adipocyte Na/K-ATPase Oxidant Amplification Loop in 
Uremic Cardiomyopathy
Komal Sodhi,4 Muhammad A. Chaudhry,2 Rebecca L. Klug,1 Rebecca Pratt,2 
Cameron Brickman,6 Hari Vishal Lakhani,3 Jiang Liu,5 Zi-jian Xie,3 
Joseph I. Shapiro.2 1Marshall University, Joan C. Edwards School of Medicine, 
Huntington, WV; 2Marshall University School of Medicine, Huntington, WV; 
3Marshall University, Huntington, WV; 4Marshall University Joan C. Edwards 
School of Medicine, Huntington, WV; 5Marshall University JCE School of 
Medicine, Huntington, WV; 6Marshall University JCESOM, Huntington, WV.
Background: Chronic kidney disease upregulates oxidative stress, increasing morbidity 
and mortality of cardiovascular disease. We demonstrated that administration of pNaKtide, 
a peptide mimicking control of Src activation via plasmalemmal Na/K-ATPase, halts 
development and reverses experimental uremic cardiomyopathy. Adipocyte contribution 
to systemic disease is an important topic; we investigated the expression of adipocyte 
production of NaKtide, a component of pNaKtide lacking the cell-permeant sequence 
derived from TAT, to observe the affects on the development of uremic cardiomyopathy. 
We examined high fat diet (HFD) on the development of cardiomyopathy in the model 
involving partial nephrectomy (PNx).
Methods: C57Bl6 mice, 10 weeks old male, subjected to 2-part sham or PNx surgical 
procedure and injected with lentivirus+adiponectin+NaKtide. Then randomly divided into 
4 groups: (1) Sham, (2) Sham+NaKtide, (3) PNx (4) PNx+NaKtide. Metabolic function was 
assessed via oxygen consumption cages, blood pressure readings, glucose tolerance tests, 
and echocardiography. Following four weeks of treatment, the animals were sacrificed, 
tissues and fluid samples were collected.
Results: Plasma creatinine levels significantly increased with PNx compared to 
Naktide treatment (p≤0.05). Histological analysis of cardiac tissue shows increased fibrosis 
with PNx and decreased with NaKtide treatment (p≤0.05). Mice developed cardiomyopathy 
with diastolic dysfunction and left ventricular hypertrophy 4 weeks after PNx. Concomitant 
administration of HFD worsened changes and caused decreased ejection fraction and 
fractional shortening (both p<0.01). Transfection with adiponectin promoting lentivirus for 
NaKtide expression normalized cardiac abnormalities in PNx and PNx + HFD. Normal 
hematocrit values, IL6 and TNFa were seen with NaKtide transfection as opposed PNx 
and PNx + HFD (both p<0.01). Transfection with empty vector or NaKtide with myoD 
promoter did not affect any measurements.
Conclusions: Our study demonstrates that adipocytes contribute to oxidant stress 
associated with uremic cardiomyopathy. These data suggest that the adipocyte Na/K-
ATPase oxidant amplification loop may be a viable clinical target for the prevention or 
treatment of uremic cardiomyopathy.
Funding: Private Foundation Support
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Plasma Lipidomic Analysis Reveals Differential Mitochondrial Fatty Acid 
Metabolism in Diabetic and Non-Diabetic CKD-Associated Heart Failure
Farsad Afshinnia,1 Thekkelnaycke Rajendiran,2 Subramaniam Pennathur.1 
Michigan Kidney Translational Core CPROBE Investigator Group 1University 
of Michigan, Ann Arbor, MI; 2Univeraity of MIchigan, Ann Arbor, MI.
Background: Cardiac myocytes utilize fatty acids predominantly for mitochondrial 
energy metabolism. Diabetic cardiomyopathy is characterized by increased β-oxidation due to 
elevated free fatty acids (FFA). Alterations in energy metabolism in diabetic and non-diabetic 
heart failure (HF) with chronic kidney disease (CKD) is less clear. This study investigated 
lipid metabolism by comparing the FFAs, acylcarnitines (ACs, a metric of β-oxidation), and 
complex lipids in diabetic and non-diabetic CKD patients with and without HF.
Methods: From the Clinical Phenotyping Resource and Biobank Core (CPROBE) 214 
patients at various stages of CKD were selected for plasma lipidomic analysis. Of the 89 
patients with diabetes, 10 had HF; in 125 subjects without diabetes 21 had HF. Plasma lipids 
and ACs were measured using mass spectrometry based untargeted and targeted lipidomic 
platforms, respectively.
Results: The mean age was 60 years (standard deviation=16). One hundred ten patients 
were males (51.4%), 64 were African-Americans (29.9%), and 150 were Caucasians 
(70.1%). In patients without diabetes median (interquartile range) of ACs in patients with 
HF were significantly higher than the patients without HF (Table, P<0.05 for all). In patients 
with diabetes the ACs were not different in patients with and without HF. Mixed linear 
model showed decreased abundance of saturated FFAs with lower carbon numbers in 
non-diabetic patients with HF, but an increased abundance of these metabolites in diabetic 
patients with HF as compared to no HF (p=0.002). In non-diabetic patients with HF, linear 
regression showed an inverse association between abundance of saturated FFAs with 
intermediate-chain ACs (p=0.025) and a direct association with long-chain ACs (p=0.044), 
a relationship which disappeared in diabetic patients with HF.
Conclusions: In non-diabetic HF, increased ACs at the cost of depletion of saturated 
FFAs is noted, while in diabetic HF saturated FFA increases without change in AC. 
Differential energy metabolism in HF with and without diabetes in CKD highlights the 
need for differential targeted therapies by etiology to optimize heart function and outcome 
in CKD.
Funding: NIDDK Support
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Hypertension and CVD: Mechanisms - II
Hyperreactivity of Aldosterone to Renin Contributes to Pathogenesis of 
Malignant Hypertension and Renovascular Hypertension
Shun Watanabe,1 Keiichi Sumida,2 Masayuki Yamanouchi,1 Tatsuya Suwabe,1 
Junichi Hoshino,3 Yoshifumi Ubara.1 1Nephrology Center, Toranomon Hospital 
Kajigaya, Kawasaki, Japan; 2Nephrology Center, Toranomon Hospital 
Kajigaya, Kawasaki, Japan; 3Toranomon Hospital, Tokyo, Japan.
Background: Malignant hypertension (MH) and renovascular hypertension (RVH) are 
known as diseases exhibiting high renin hypertension. By comparing the two groups, we 
examine how renin-angiotensin aldosterone system (RAAS) participates not only in the 
onset of hypertension but also in the onset of nephropathy.
Methods: A total of 33 patients who were diagnosed as MH(n=19) and RVH (n=14) at 
Toranomon Hospital from 1986 to 2017 were evaluated retrospectively.
Results: There was no significant difference in plasma renin concentration (PRC) between 
MH group and RVH group. While, age was younger in MH group than in RVH group with 
median [interquartile range]; 40 years [32-48 years] vs. 65 years [62-76 years], P =0.0001). 
Blood pressure (median; 230/130 vs 164/98 mmHg), UN (median;53.0 vs 28.8 mg/dl), 
Cre (median; 6.0 vs 2.0 mg/dl), plasma aldosterone concentration (PAC) (mrdian;49.7 vs 
32.0 ng/dl)and aldosterone -renin-ratio (ARR)(1.10 VS 0.64)were significantly higher in 
MH group than in RVH group. Serum K (median; 3.7 vs 4.3 mEq/L) was significantly lower 
in MH group than in RVH group. The majority of MH group showed intimal edematous 
thickening (onion skin lesion) of small arteries including arteriole by renal biopsy. While 
four patients out of patients with RVH showed focal glomerular sclerosis on non-narrowed 
kidney by renal biopsy, but did not show onion skin lesion of small arteries.
Conclusions: Hyperreninemia was similar on both groups, but aldosterone value 
and APR were significantly higher in MH group. This indicates that hyperreactivity of 
aldosterone to renin might contribute not only to the formation of MH with onion-skin 
lesion via higher blood pressure, and result in also to hypokalemia, though renal function 
was higher on MH group. Whenever hyperreactivity of aldosterone to renin exists on 
MH group remains unknown. These results suggest that the mechanism by which renin 
stimulation leads to overproduction of aldosterone may be thought to be involved in MH 
and the progression of nephropathy.
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Critical Role of Histone Deacetylase 3 in the Pathogenesis of Hypertensive 
Kidney Disease
Changlong An,1,2 Jia Wen,1 Sandhya S. Thomas,1,2 Zhaoyong Hu,1 
William E. Mitch,1 Yanlin Wang.1,2 1Baylor College of Medicine, Houston, TX; 
2Michael E. DeBakey VA Medical Center, Houston, TX.
Background: Hypertension is a major cause of chronic kidney disease, which is 
characterized byinflammation and fibrosis. However, the underlying molecular mechanisms 
are not fully understood. In this study, we examined the function role of histone deacetylase 
3 (HDAC3) in renal inflammation and fibrosis in a mouse model of angiotensin II-induced 
hypertension.
Methods: Myeloid HDAC3 knockout mice were generated by crossing HDAC3f/fmice 
with Lyz-Cre mice. Both Lyz-Cre-/-HDAC3f/fmice and Lyz-Cre+/+HDAC3f/fmice were 
infused with angiotensin II at 1.5ug/kg/min or vehicle for 28 days. Blood pressure 
was monitored by tail-cuff method. Renal function was assessed by measuring blood 
urea nitrogen (BUN). Kidney sections were prepared and stained for histological and 
immunological analysis. Western blot analysis was performed to detect the levels of 
fibronectin and a-SMA. Quantitative RT-PCR was performed to examine mRNA levels of 
proinflammatory cytokines. Cultured macrophages were used to study the role of HDAC3 
in proinflammatory molecule expression in vitro.
Results: There is no significant difference in blood pressure at baseline. Blood pressure 
increased after angiotensin II treatment in both Lyz-Cre-/-HDAC3f/f and Lyz-Cre+/+HDAC3f/f 
mice that are similar between the two treatment groups. Compared with Lyz-Cre-/-HDAC3f/f 
mice, mice with myeloid HDAC3 deficiency were protected from angiotensin II-induced 
renal injury with lower BUN. Furthermore, mice with HDAC3 deficiency in myeloid 
cells accumulated significantly fewer macrophages, T cells, and myeloid fibroblasts. 
HDAC3 deficiency in myeloid cells significantly reduced the mRNA expression of pro-
inflammatory molecules the kidney after angiotensin II treatment. HDAC3 deficiency in 
myeloid cells significantly attenuated the protein levels of fibronectin and a-SMA and 
markedly inhibited collagen deposition in the kidney following angiotensin II treatment. In 
cultured macrophages, knockdown of HDAC3 with shRNA suppressed pro-inflammatory 
molecule expression. Furthermore, knockdown of HDAC3 inhibited NF-kB p65 binding 
to IL-6 promoter.
Conclusions: Our study identifies a critical role of HDAC3 in the regulation of 
hypertension-induced renal inflammation and fibrosis. Therefore, targeting HDAC3 may 
represent a novel therapeutic strategy for hypertensive kidney disease.
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Hypertension and CVD: Mechanisms - II
Prevalence of Angiotensin II Type 1 Receptor Antibodies (AT1RAbs) in 
Persons with Hypertension and Relation to Blood Pressure and Kidney 
Outcomes
Mary Carmelle Philogene,1 Dingfen Han,1 Alan B. Zonderman,2 
Michele K. Evans,3 Deidra C. Crews.1 1Johns Hopkins School of Medicine, 
Baltimore, MD; 2Intramural Research Program, NIA, NIH, Baltimore, MD; 
3National Institutes of Health/National Institute on Aging, Baltimore, MD.
Background: AT1RAbs are associated with vascular hypertension and allograft 
dysfunction after kidney transplantation. We aimed to determine the prevalence of AT1RAb 
in a non-transplanted hypertensive population and the relationship to blood pressure (BP) 
control and kidney outcomes.
Methods: We used data on 1006 Healthy Aging in Neighborhoods of Diversity across 
the Life Span (HANDLS) study participants with hypertension, and treated with angiotensin 
receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi) or other anti-
hypertensive medications. AT1RAb detection was performed by ELISA (One Lambda) and 
levels ≥ 17 units/ml were considered positive. BP, uncontrolled BP (systolic BP ≥140 or 
diastolic ≥90 mmHg), albuminuria [urine albumin-to-creatinine ratio (ACR) ≥30mg/g] and 
rapid kidney function decline (loss of eGFR >3ml/min per 1.73m2 per year over a median 
of 5 years) were compared for AT1RAb positive (+) versus negative (-) participants using 
descriptive statistics and multivariable regression models.
Results: Overall, 132 (13%) participants were AT1RAb+. Compared to AT1RAb-, 
AT1RAb+ persons were more likely to be Caucasian (47% versus 37%) and non-smokers 
(44% versus 30%). In models adjusting for age, sex and race, AT1RAb+ persons had 
2.6 mmHg higher diastolic BP than AT1RAb- persons (p=0.01). The adjusted odds ratio 
(aOR) for uncontrolled BP was 1.33 (95% CI 0.9, 2.0) comparing AT1RAb+ to AT1RAb- 
persons. In adjusted models, AT1RAb+ persons treated with either ARB or ACEi had 12.3 
mmHg higher systolic and 5.4 mmHg higher diastolic BP compared to AT1RAb+ persons 
using other BP medications (p=0.003 and 0.03); aOR for uncontrolled BP was 1.48 (95% 
CI 0.68-3.21). BP did not differ for AT1RAb- participants regardless of medication. The 
prevalence of albuminuria was similar between AT1RAb+ (19.1%) and AT1RAb- (19.5%) 
groups. Rapid kidney function decline occured in 18.1% of AT1RAb+ and 15.5% of 
AT1RAb- persons (p=0.5). There was no statistically significant association between 
AT1RAb status and rapid kidney function decline (aOR 1.23; 95% CI 0.74-2.05).
Conclusions: AT1RAbs were associated with higher diastolic BP in this hypertensive 
population, and use of ARB or ACEi was associated with higher BP among AT1RAb+ 
persons compared to use of other medications.
Funding: Private Foundation Support
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Hypertension and CVD: Mechanisms - II
Proximal Tubule Angiotensin II Type 1 Receptor-Associated Protein Does 
Not Influence Angiotensin-Dependent Hypertension
Hiromichi Wakui,1 Sho Kinguchi,1 Takahiro Yamaji,4 Kazushi Uneda,1 
Shingo Urate,3 Kotaro Haruhara,2 Kohji Ohki,5 Ryu Kobayashi,3 
Kengo Azushima,1 Yoshiyuki Toya,1 Kouichi Tamura.3 1Yokohama City 
University, Kanagawa, Yokohama city, Japan; 2The Jikei University School of 
Medcine, Tokyo, Japan; 3Yokohama City University Graduate School of 
Medicine, Kanazawa-Ku, Japan; 4Yokohama city unversity, Yokohama City, 
Japan; 5Yokohama City University School of Medicine, Yokohama City, Japan.
Background: The activation of renal angiotensin II (Ang II) type 1 receptor (AT1R) 
can evoke excessive sodium retention, resulting in hypertension when inappropriately 
stimulated. The AT1R-associated protein (ATRAP) has been identified as the specific 
binding protein of the C-terminal domain of AT1R, and functions as an endogenous 
inhibitor that suppresses AT1R hyper-activation at local tissue sites. We previously reported 
that systemic ATRAP-knockout mice (ATRAP-KO) exhibited an exacerbation of Ang 
II-induced hypertension, concomitant with an increase in sodium retention, compared wild-
type mice (WT). We here report a functional role of proximal tubule ATRAP in angiotensin-
dependent hypertension using proximal tubule-specific ATRAP-knockout (PT-KO) mice.
Methods: In the present study, we generated PT-KO mice for the first time by the 
Cre/loxP system using Pepck-Cre. We next compared blood pressure in response to Ang 
II (1000ng/kg/min) treatment in wild-type littermate control (LC) and PT-KO mice. Since 
cardiac hypertrophy is closely associated with the blood pressure elevation, we further 
examined heart weight/body weight ratio in PT-KO and LC mice.
Results: The ATRAP mRNA expression in the proximal tubules of the PT-KO 
mice was decreased by approximately 80% compared with LC mice, estimated by laser 
capture microdissection method. Ang II infusion for 2 weeks significantly and similarly 
increased systolic blood pressure in both PT-KO and LC mice. Ang II infusion for 2 weeks 
significantly increased heart weight/body weight ratio in both PT-KO and LC mice to the 
same extent.
Conclusions: These results indicate that ATRAP deficiency in proximal nephron does 
not influence angiotensin-dependent hypertension in vivo.
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Global Coagulation Assay Changes in Hemodialysis Patients
David Barit,1 Prahlad W. Ho,2 Yin H. Lim.2 1Nephrology, Northern Health, 
Melbourne, VIC, Australia; 2Haematology, Northern Health, Melbourne, VIC, 
Australia.
Background: Chronic kidney disease (CKD), and hemodialysis in particular, is 
thought to be a hypercoagulable state, which may contribute to increased cardiovascular 
risks. Given the limitations of current available coagulation testing in assessing thrombotic 
risks, we aim to evaluate the changes of global coagulation assays in patients with CKD 
undergoing haemodialysis.
Methods: This prospective observational study recruited patients undergoing 
hemodialysis. Fasting blood samples were collected prior to starting hemodialysis for 
baseline investigations such as full blood evaluation, coagulation studies and lipid studies, 
in addition to experimental testing via thromboelastography (TEG® 5000S) utilising 
citrated whole blood. Additional samples were double-centrifuged to obtain platelet-poor 
plasma for later assessment with calibrated automated thrombogram (CAT) and overall 
haemostasis potential (OHP).
Results: Twenty-six patients were recruited and the results were compared to age-
matched normal controls previously collected. Hemodialysis patients had lower platelet 
count with increased fibrinogen, VWF antigen and factor VIII levels (p<0.01). They 
also had more hypercoagulable TEG® profile when compared to normal controls, with 
increased maximal amplitude (69.6 vs 60.0 mm, p<0.001) and reduced clot lysis (0.0% 
vs 0.4%, p=0.001). Interestingly, there was no significant difference in the thrombin 
generation parameters. In addition, D-dimer was markedly increased in hemodialysis 
patients independent of age (860 vs 189 ng/mL, p<0.001) but this did not correlate with 
fibrin generation parameters.
Conclusions: Hemodialysis patients appear to have a more hypercoagulable state 
characterised by increased fibrinogen, VWF antigen and factor VIII levels, as well as 
TEG parameters. D-dimer was markedly increased, which brings into question the clinical 
usefulness of D-dimer in predicting venous thromboembolism in haemodialysis patients. 
The lack of correlation with fibrinolytic potential may signify reduced renal clearance of 
D-dimer.
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Characterization of the Effects of a Vacuolar H+-ATPase (V-ATPase) 
Mutation Linked to Distal Renal Tubular Acidosis (dRTA)
Jordan J. Juarez,1 Jessica Pham,1 Pei-Yin Ho,1 Valeria Mancino,1 Vivek Bhalla,2 
Nuria M. Pastor-Soler.1 1Keck School of Medicine of USC, Los Angeles, CA; 
2Stanford University, Stanford, CA.
Background: Distal renal tubular acidosis (dRTA) Type I is a disease affecting the 
kidney’s ability to secrete non-volatile acid. This disease can lead to severe kidney and 
systemic sequelae. Improper functioning of collecting duct (CD) intercalated cells (ICs) 
due to autoimmune or infectious conditions can lead to dRTA. More recently, single point 
mutations in transport proteins in ICs have been found to result Type I dRTA. One such 
mutation is the 1231G>T in ATP6V0A4, the a4 isoform of the V0domain of the V-ATPase. 
This mutation results in a D411Y (Aspartate to Tyrosine) variant. Carriers of this mutation 
are seemingly healthy and therefore this mutation likely acts in an autosomal recessive 
fashion. We identified a 26 year-old man with refractory dRTA that was homozygous for 
this mutation by a NextGen dRTA sequencing panel. One of his half-siblings has presented 
with metabolic acidosis and hypokalemia, consistent with dRTA. Published reports from 
Brazil and Mexico identify this mutation as causative for dRTA. However, the exact effects 
of this mutation on the expression and activity of the V-ATPase has yet to be determined. 
We hypothesized that this mutation in a reportedly non-transmembrane region of the a4 
subunit would have effects on the subcellular localization of the subunit as the underlying 
mechanism for decreased V-ATPase membrane function.
Methods: We performed transfections of FLAG-Tagged wild-type (WT) vs. D411Y 
pTracer plasmids into HEK and Clone C cells (of IC origin), followed by immunoblot and 
immunofluorescent labeling and confocal imaging.
Results: Our results demonstrate low expression of both WT- and D411Y ATP6V0A4 
in Clone-C cells, although an anti-FLAG antibody detected a band at ~100 kDa by 
immunoblot in transfected Clone-C lysates. By immunolabeling and confocal microscopy 
we detected the WT subunit at the apical domain of transfected Clone-C polarized 
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monolayers on transwell filters. In contrast, the D411Y mutant subunits were detected in 
a cytosolic distribution.
Conclusions: Our preliminary findings indicate that the D411Y mutation interferes 
with normal accumulation of the V-ATPase at the apical membrane of ICs, thus offering a 
potential mechanism for defective V-ATPase function and dRTA patients with this mutation.
Funding: Private Foundation Support
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Fluid and Electrolytes: Basic - II
A Novel I551F Mutant of Na+/HCO3- Cotransporter NBCe1 Has 
Cytosolic Retention and Diminishes Transport Activity
Osamu Yamazaki,1,2 Maho Yamashita,1 Jinping Li,2 Tadashi Yoshida,1 
Junichi Hirahashi,1 Shigeru Shibata,2 Matsuhiko Hayashi.3,1 1Department of 
General Medicine, Center of Apheresis and Dialysis, Keio University of 
Medicine, Tokyo, Japan; 2Teikyo University School of Medicine, Tokyo, Japan; 
3Kawakita General Hospital, Suginami-ku, Japan.
Background: Homozygous mutations in SLC4A4 encoding the electrogenic Na+/
HCO3
- cotransporter cause proximal renal tubular acidosis associated with ocular 
abnormalities. Although up to 14 SLC4A4 mutations have been identified, the mechanism 
of NBCe1 inactivation due to the individual mutations has not been completely clarified.
Methods: In the present study we investigated the impact of SNP (Single Nucleotide 
Polymorphism) mutations on NBCe1 function. We identified 14 mutations in NBCe1A, 
resulting in the single amino acid substitutions, A425T, F461L, A465S, L494F, N503H, 
A518T, A518G, I523V, V533D, Y535H, I551F, Y554H, M753V, and L785I.
Results: Immunohistological analysis with confocal microscopy revealed that almost 
all of SNP mutants except I551F were predominantly expressed in the plasma membrane 
of HEK293 cells and MDCK cells. On the other hand, I551F mutant was expressed only 
in the cytoplasm of HEK 293 cells and MDCK cells. Functional analysis using Xenopus 
oocytes revealed that I551F mutant had a significantly reduced activity corresponding to 
52% of that of wild-type (p<0.01). Western blotting in HEK293 cells confirmed that the 
surface expression of I551F mutant was significantly reduced and showed immaure band. 
To examine the role of I551 in more details, we also examined the properties of artificial 
mutants I551A, I551P, I551K, I551R, I551D and I551E in HEK293 cells. Artificial mutants 
were properly expressed in the plasma membrane. By contrast, only I551F mutant was 
predominantly expressed in cytoplasmic regions.
Conclusions: These results indicate that I551F mutation inactivates the NBCe1 
function with cytoplasmic retention. Because NBCe1 plays a major role in renal proximal 
sodium and bicarbonate reabsorption, I551F SNP may be associated with the disturbance in 
systemic acid-base balance or the changes in blood pressure.
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NFAT5 Regulates Endothelin Gene Expression: Possible Common 
Pathway in Skin and Kidney Responses to High Na+ Intake
Jayalakshmi Lakshmipathi,1 Will Wheatley,1 Nirupama Ramkumar,3 
Donald E. Kohan.1,2 1University of Utah Health Sciences Center, Salt Lake City, 
UT; 2Salt Lake VA Medical Center, Salt Lake City, UT; 3University of Utah, Salt 
Lake City, UT.
Background: High Na+ intake stimulates collecting duct endothelin-1 (ET-1) 
production which in turn promotes a natriuresis. High Na+ intake induced ET-1 involves 
several factors, however increasing extracellular osmolality, as occurs in the renal medulla 
during Na+loading, stimulates ET-1 by inner medullary collecting duct (IMCD3 cells) more 
potently than any other known stimulus. In addition, following a Na+ load, the skin stores 
Na+ leading to increased local osmolality; release of skin Na+ into the circulation (facilitating 
renal elimination) partly depends upon ET-1. The current studies were undertaken to 
determine how osmolality augments ET-1 in IMCD and skin.
Methods: Cultured IMCD3 and dermal microvascular endothelial cells (DMVEC) 
were studied. Osmolality was increased for 2-4 hr using 50 mOsm/L mannitol. ET-1/
GAPDH mRNA were measured. ET-1 promoter/reporter constructs were transfected into 
cells and secreted luciferase/alkaline phosphatase assayed. NFAT content and subcellular 
distribution were analyzed by western analysis.
Results: Increasing osmolality increased IMCD3 ET-1 mRNA associated with an 
increase in nuclear fraction NFAT5 protein content. Osmolality-stimulated ET-1 was 
markedly reduced by NFAT5 siRNA. Transfection of 1, 2 or 3 kb (5’ to transcription start 
site) ET-1 promoter/reporter constructs revealed maximal osmolality induced activity in the 
1 kb fragment. This region contains two NFAT5 consensus binding sites; mutation of both 
sites (TGGAAA to TCACGA) completely prevented hyperosmolality induced promoter 
activity. Increasing osmolality also increased DMVEC ET-1 mRNA content; initial studies 
suggest this is also NFAT5 dependent.
Conclusions: These studies identify for the first time that NFAT5 directly regulates 
ET-1 promoter activity. Both the skin and IMCD NFAT5/ET-1 may be involved in the Na+ 
homeostatic response to high Na+ intake. Thus, there may be a remarkably common system 
used by the skin and the kidney to regulate body Na+content.
Funding: Other NIH Support - NHLBI
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Large-Scale Meta-Analysis in European Ancestry Identifies 114 Indepen-
dent Signals for Serum Urate
Adrienne Tin,1 Jonathan Marten.2 CKDGen Consortium 1Epidemiology, Johns 
Hopkins University, Baltimore, MD; 2MRC IGMM, University of Edinburgh, 
Edinburgh, United Kingdom.
Background: High serum urate levels are a cause of gout, an excruciating disease with 
suboptimal treatment affecting ~4% of the adult population in many developed countries. 
Patients with kidney disease have higher risk for gout. Genome-wide association studies 
(GWAS) of serum urate in European ancestries have identified 28 loci. Together the index 
SNPs at these loci explain <10% of the phenotypic variance, suggesting that additional loci 
remain to be identified.
Methods: We performed meta-analyses of serum urate GWAS among 288,649 
individuals of European ancestry from 60 studies and of gout among 753,884 individuals of 
European ancestry from 17 studies using fixed-effect inverse variance weighting. To reveal 
independent signals of serum urate, we used GCTA model selection to identify independent 
variants (r2<0.01) in genome-wide significant urate loci (p<5x10-8). To prioritize significant 
urate-associated variants, we conducted finemapping by calculating posterior probabilities 
in each independent region based on the Wakefield Bayes factor and constructed credible 
sets with 99% probability of containing driver variants.
Results: Meta-analyses identified 123 genome-wide significant 1-Mb intervals 
associated with serum urate (genomic control factor: 1.04). Of these, 87 were not annotated 
to known serum urate loci, and 98% were associated with gout in the same direction. GCTA 
model selection identified 114 independent signals of urate in 99 genomic regions, which 
were merged from the 123 intervals when index SNPs in adjacent intervals were correlated 
(r2 > 0.2). Of these 114 independent signals, half of the 99% credible sets had <17 variants, 
and 25% had only one variant.
Conclusions: We identified 114 independent signals associated with serum urate 
among European ancestry individuals. The concordance in effect direction of urate index 
variants for gout are consistent with established causal role of urate in gout pathophysiology. 
Following up on these GWAS findings with functional studies will generate novel insight 
in serum urate regulation and potential treatment targets for lowering urate levels for the 
prevention of gout.
Funding: NIDDK Support, Government Support - Non-U.S.
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Calcium-Dependent Contraction of Renal Tubules
Samuel L. Svendsen,1 Alexis Hofherr,2 Michael Kottgen,3 Jens G. Leipziger.1 
1Aarhus University, Aarhus C, Denmark; 2University of Freiburg - Medical 
Center, Freiburg im Breisgau, Germany; 3University Medical Center Freiburg, 
Freiburg, Germany.
Background: Over several years, we have observed, that perfused renal tubules show 
“odd movements” when exposed to extracellular ATP. Whether this observation was merely 
an artefact or a relevant biological observation remained elusive. It is well known that renal 
tubules express a contractile machinery localized closely to the apical membrane. The 
functionality of this structure is enigmatic. Plate grown kidney cells show a pattern on their 
apical membrane consistent with active contraction of the luminal membrane domain. Here 
we test if isolated perfused renal tubules can contract.
Methods: We measured the effect on tubular diameter in isolated murine thick 
ascending limbs (TAL), when inducing a cytosolic [Ca2+] ([Ca2+]i) increase with uncaging 
ATP/stimulation of the apical P2Y2 receptors.
Results: Uncaging luminal ATP elicited a marked increase of [Ca2+]i, which could be 
fully blocked by intracellular Ca2+ chelation following BAPTA-AM loading. Remarkably, 
within 40 seconds following apical P2Y2 receptor stimulation, both the inner and outer 
diameter of the perfused TAL were significantly reduced. The inner and outer diameter 
decreased by 0.236μm (SEM ±0.041, n=5) and 0.170 μm (SEM ±0.022, n=5), respectively. 
This reduction could be largely prevented either blocking the [Ca2+]i increase with BAPTA 
or by hindering actin-myosin interaction with highly specific antagonists.
Conclusions: We report the remarkable observation that renal tubules in a [Ca2+]i - 
dependent manner can contract. This suggests that the diameter of renal tubules is a subject 
to active and acute regulation.
Funding: Government Support - Non-U.S.
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MR Modulator AZD9977 Causes Reduced Plasma Potassium Elevation 
Compared to Eplerenone After Potassium Challenge in CKD Model
Krister Bamberg,1 Lena William-Olsson,1 Soumaya El moghrabi,2 
Frederic Jaisser,3 Judith Hartleib-Geschwindner.1 1AstraZeneca, Molndal, 
Sweden; 2INSERM U1138 - Centre de Recherche des Cordeliers, Paris, France; 
3INSERM U1138, Paris Cedex 13, France.
Background: Hyperkalemia is a potential side effect of mineralocorticoid receptor 
(MR) antagonists since they cause renal Na+ excretion and K+ retention. MR antagonist 
dependent renal Na+ excretion can be studied acutely in rodents and translates well to man. 
However, rodents are largely refractory to plasma K+ elevations and hence the potential 
reduced liability of novel MR modulators to cause hyperkalemia is difficult to explore in 
rodent models.
Methods: Acute effects on 7 hours urine electrolyte excretion were studied after single 
dose administration of 30, 100 or 200 mg/kg eplerenone or AZD9977 to mice fed a low 
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salt (0.02%) diet for 3 days prior to dosing. Effects on plasma K+ elevations were studied 
in 5/6 nephrectomised mice with developed chronic kidney disease (CKD) treated for 5 
days with 100 mg/kg bid eplerenone or AZD9977 followed by a KCl load over night before 
measuring plasma K+.
Results: 100 and 200 mg/kg eplerenone treatment caused an increased urinary Na+/K+  
ratio (0.57±0.11, p=0.0022 and 0.68±0.08, p<0.0001, respectively) compared to vehicle 
(0.06±0.09). AZD9977 exposure did not alter urinary Na+/K+ ratio. Subchronic treatment 
with eplerenone or AZD9977 in CKD at exposures 14x above in vitro IC50 did not alter 
plasma K+ levels. Eplerenone vs vehicle treatment followed by K+ challenge led to a robust 
elevation of plasma K+ (6.5±0.2 vs 5.4±0.2 mM, p<0.001). The plasma K+ elevation after 
AZD9977 treatment and K+ challenge (5.9±0.2 mM, p=0.042 vs vehicle) was significantly 
lower compared to eplerenone (p=0.0045).
Conclusions: AZD9977 is a novel MR modulator developed to yield maximal 
efficacy on organ protection and minimal effects on plasma K+. AZD9977 did not cause 
the typical acute urinary Na+ excretion in mice observed with MR antagonists. Lack of 
effect on urinary electrolytes translated to a reduced plasma K+ elevation in a mouse CKD 
model after potassium challenge. Whether the reduced effect on plasma K+ observed with 
AZD9977 vs eplerenone will translate into a clinically meaningful differentiation will be 
explored in clinical studies.
Funding: Commercial Support - AstraZeneca
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Dietary K-Induced Temporal Changes in mRNA Encoding Proteins 
Associated with Renal K Secretion in Mouse
Daniel Flores,1 Joshua L. Rein,1 Rolando Carrisoza-Gaytan,1 Arohan 
R. Subramanya,2 Thomas R. Kleyman,2 Lisa M. Satlin.1 1Icahn School of Medicine 
at Mount Sinai, New York, NY; 2University of Pittsburgh, Pittsburgh, PA.
Background: Flow-induced K secretion in the cortical collecting duct (CCD) of the 
distal nephron is mediated by Ca2+/stretch-activated BK channels, which also contribute 
to the renal adaptation to a high K diet (HKD). We reported that CCDs from rabbits fed a 
HKD for 10 d exhibit an increase in steady-state abundance of BK channel subunit-specific 
mRNAs and expression of immunodetectable BKα and L-WNK1 expression in the apical 
membrane of β-type intercalated cells (ICs). Overexpression of L-WNK1 increases BKα 
whole cell abundance and functional channel expression in HEK cells suggesting that an 
increase in L-WNK1 in ICs may mediate enhanced BK channel expression and K secretion 
in K-adapted CCDs. We sought to examine the temporal changes in mRNA abundance of 
BK channel subunits and L-WNK1 as well as other major CCD transport and regulatory 
proteins in mouse kidney following initiation of HKD or low K diet (LKD).
Methods: C57BL/6 mice on a control K diet were switched to either a HKD or LKD 
for up to 11 days. On the day of sacrifice, spot blood and urine samples were collected for 
measurement of [Na] and [K] by flame photometry. qPCR primers and probes specific for 
BKα, β1, β4, and γ subunits and for regulatory kinases L-WNK1, KS-WNK1, and WNK4 
were used to assess message abundance in renal cortical homogenates.
Results: Steady state expression of BKα mRNA increased >3-fold by day 7 of HKD 
(n=4, p<0.05) but did not significantly change during LKD. No significant changes were 
observed for message encoding BK β1, β4, γ subunits or L-WNK1, KS-WNK1, and WNK4 
during either diet. Plasma [Na] and [K] remained unchanged under HKD and LKD, while 
urine [K] increased during HKD and decreased during LDK.
Conclusions: HKD increased steady state abundance of message encoding BKα. The 
failure to detect an increase in message encoding WNK1, a regulatory protein known to 
increase BK channel expression during HKD, may reflect post-translational modification.
Funding: NIDDK Support
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Sexual Dimorphic Responses of Renal Transporters to High Salt Diet 
Favor More Diuresis in Females
Diana L. Torres, Luciana C. Veiras, Donna Ralph, Zoya Khalil, Hector R. Lisboa, 
Alicia A. McDonough. Keck School of Medicine of USC, Los Angeles, CA.
Background: Previous studies have shown that there are distinct sexual dimorphic 
patterns of transporters along the nephron. Compared to males (M), female (F) rats and 
mice at baseline have less proximal tubule sodium transporters (NHE3, NaPi2) and more 
activated distal NCC and collecting duct epithelial sodium channels (ENaC). Also, F are 
reported to have a have more robust pressure natriuretic response than M. This study aimed 
to test the hypothesis that, in F vs. M C57Bl/6 mice, high salt diet regulates renal Na+ 
transporters, claudins (Cld) and the regulatory kinase (SPAK) in a pattern that facilitates 
more natriuresis in females.
Methods: For 2 wk, mice (n=7/group) received a normal salt diet (0.26% NaCl, 
NSD) or a high salt diet (4.0% NaCl, HSD). Urine Na+ and K+ were measured by flame 
photometry and osmolality with an osmometer. Renal transporter and channel abundance 
was determined by quantitative immunoblot, and subcellular distribution by confocal 
immunohistochemistry.
Results: At baseline, F exhibit lower urinary volume (UV), Na+ (UNaV), K+ (UKV), 
and osmoles (UosmV); F also had lower abundance of the PT NHE3, NHE3p and Cld2 
and higher DCT NCC and SPAK compared to M. In response to HSD, F vs. M exhibit 
greater fold increases in UV (5- vs. 1.6-fold), UNaV (25- vs. 8-fold), UKV (2.3-fold vs. no 
increase) and UosmV (6 vs. 2-fold) and no change in plasma [Na+] or [K+]. During HSD 
NHE3p, a marker for less activity, increased in M but not F. During HSD, abundance of 
NKCCp, NCCp, and cleaved ENaC alpha decreased in both sexes, evidence of less activity 
of these transporters from loop through collecting duct. SPAK and Cld7 were unchanged. 
At baseline, NHE3 and NHE3p were located in the villi in M and at the base of the villi in 
F; with HSD NHE3, NHE3p redistributed to the villar base in M and were unchanged in F. 
NCCp remained localized to the apical membranes in both sexes.
Conclusions: The renal responses to a high salt diet are sex dependent: redistribution 
of NHE3 and NHE3p in males, and reduced NKCC2p, NCC, NCCp and α ENaC cleavage 
in both sexes contribute to natriuresis. Females exhibit more robust natriuresis and diuresis 
during HSD which we hypothesize is due, at least in part, to the lower baseline PT NHE3 
and Cld2.
Funding: NIDDK Support
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Notch Signaling and Adam10 in Lithium-Induced Collecting Duct 
Remodeling in Mouse Kidney
Yue Zhang,1,3 Janos Peti-Peterdi,2 Marshall R. Roedel,1 Tao Liu,1 Anne Riquier-
brison,2 Noel G. Carlson,1 Bellamkonda K. Kishore.1 1Univ. of Utah and VA 
Medical Center, Salt Lake City, UT; 2University of Southern California, Los 
Angeles, CA; 3Nanjing Medical University, Nanjing, China.
Background: The cell biology of lithium (Li) induced collecting duct (CD) 
remodeling, whereby the percent of AQP2-positive principal cells (PC) is decreased with a 
proportionate increase in [H+]-ATPase-positive intercalated cells (IC), is not well defined. 
It has been reported that genetic suppression of Notch signaling or Adam10 interferes 
with the development of CD resulting in off-spring with very low percentage of PC in the 
kidney. Hence, here we evaluated whether these two play a similar role in Li-induced CD 
remodeling in adult mice.
Methods: Groups of mice (B6D2; N = 5/group) were fed either a regular or LiCl-
containing chow for 30 days and humanely euthanized. Using confocal immunofluorescence 
microscopy and double labeling, kidney sections were examined for the percent of AQP2 
or [H+]-ATPase positive cells. cDNA prepared from the medulla was subjected to Notch 
signaling PCR Array, and expression of selected genes was further confirmed by real-time 
PCR on all samples.
Results: Li treatment caused significant polyuria associated with a significant decrease 
in percentage of PC in the medulla (88.2 ± 3.4 vs. 69.2 ± 0.8, P < 0.05), and a proportionate 
increase in the percentage of IC (11.3 ± 3.4 vs. 30.0 ± 0.8, P < 0.05). Several genes were 
under or over expressed in Li-treated mice (Table).
Conclusions: Similar to its role during embryonic life, Notch signaling plays a role 
in Li-induced CD remodeling. However, our results do not support a role for Adam10 in 
Li-induced CD remodeling in adult mice. The roles of Nr4a2, Neurla1A and Figf in CD 
remodeling need to be further defined.
Funding: NIDDK Support, Veterans Affairs Support
Expression of Genes in Li-treated Mice
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Metformin Has Natriuretic Effects Through Reduction of the  
Sodium-Chloride Cotransporter Phosphorylation
Hiroko Hashimoto, Naohiro Nomura, Wakana Shoda, Kiyoshi Isobe, 
Hiroaki Kikuchi, Kohei Yamamoto, Takuya Fujimaru, Fumiaki Ando, 
Takayasu Mori, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida, Eisei Sohara. 
Tokyo Medical and Dental University, Tokyo, Japan.
Background: Metformin is an antidiabetic drug that is widely used to treat patients 
with type 2 diabetes mellitus. Recent studies have reported that treatment with metformin 
not only improved blood glucose levels but also reduced blood pressure. However, it 
remains unclear how metformin reduces blood pressure. We hypothesized that metformin 
affects sodium reabsorption in the kidneys.
Methods: We firstly examined urinary sodium excretion and expression of renal 
sodium transporters in 8-week-old male C57BL/6 mice with acute and chronic treatment 
of metformin. In addition, we examined metformin effects using ex vivo preparations of 
mice kidney slices. We also performed experiments using the spontaneously hypertensive 
rat (SHR).
Results: In this study, we demonstrated that metformin increased urinary sodium 
excretion by reducing phosphorylation of the thiazide-sensitive Na-Cl cotransporter 
(NCC) in acute and chronic metformin administration. We also confirmed reduction 
of phosphorylated NCC in an ex vivo study. Expression levels of other renal sodium 
transporters, such as NKCC2, ENaC, and NHE3 did not show significant changes. WNK-
OSR1/SPAK kinase signal was not involved in this effect of metformin on NCC. We finally 
performed experiments using SHR, whose blood pressure is well known to be decreased by 
metformin. We observed decreased phosphorylated NCC in SHR by metformin treatment, 
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suggesting that this decreased NCC phosphorylation is involved in the mechanisms of 
metformin-induced blood pressure reduction.
Conclusions: Metformin increased urinary sodium excretion by reducing 
phosphorylation of NCC. Considering that metformin could have natriuresis effect, 
metformin could be an ideal drug for excessive salt intake, in addition to excessive calorie 
intake.
Funding: Government Support - Non-U.S.
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Urinary Exosomes Quantitation of Renal Transporter Abundance 
Correlates with Function
Cameron J. Menezes, Kristin J. Bergsland, Elaine M. Worcester, Fredric L. Coe, 
Benjamin S. Ko. University of Chicago, Chicago, IL.
Background: Urinary exosomes have the potential to provide considerable insight into 
renal tubular function. However, estimates of urinary exosomes been qualitative or semi-
qualitative using Western blotting. Therefore, we sought develop approaches to measure 
several relevant sodium and calcium transporters simultaneously in the urine from humans 
and then correlate them to function in humans.
Methods: 4 healthy males were studied in a CRC setting. Fasting and fed urine and 
blood samples were collected hourly. Serum ultrafiltrate and urine calcium, magnesium, 
sodium, potassium, creatinine, and urine volume were measured. Lithium was measured in 
deproteinated serum and urine by atomic emission spectroscopy. Urinary exosomes were 
isolated via ultracentrifugation. NHE3, SLC26A6, NKCC2, NCC, TRPV5 and prostasin 
abundance were measured via ELISA at each collection point in triplicate and these values 
were compared with metabolic parameters of tubule function at each time point.
Results: The presence of enriched amounts of ALIX, CD63, and TSG-101 protein in the 
exosomal fraction compared to the various wash fractions was verified via Western blotting. 
NHE3, SLC26A6, NKCC2, NCC, TRPV5 and prostasin abundance were measured. NHE3 
and fractional excretion of lithium are significantly correlated, indicating that proximal 
tubule function is related to the exosomal abundance of NHE3 (-0.66, p=0.001). Fully 
corrected for multiple comparisons, significant inverse correlations between the fractional 
excretion of distally delievered Ca and TRPV5 (-0.76, p=0.001) and FEDNa and prostasin 
(-0.78, p=0.001) were demonstated.
Conclusions: Our findings represent reliable and precise methods for quantitation of 
urinary exosomal abundance of the transport proteins NHE3, SLC26A6, NKCC2, NCC, 
TRPV5, and prostasin. The quantitation of urinary exosome renal transporter protein 
abundance allows for greater insight into human renal transport, allowing for direct 
measurements of markers of molecular solute transport. In this way, this system has the 
potential to further our understanding of molecular electrolyte physiology and disease in 
humans by confirming previous theories and finding new connections.
Funding: NIDDK Support
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Urinary Exosomes as a Novel Tool to Study the NaCl Cotransporter in 
Hypertension
René J. Bindels,2 Omar Tutakhel,3 Joost Hoenderop.1 1Radboud university 
medical center, Nijmegen, Netherlands; 2Radboud University Medical Center, 
Nijmegen, Netherlands; 3Radboud University Medical Centre, Nijmegen, 
Netherlands.
Background: The NaCl cotransporter (NCC) is located at the apical membrane of 
epithelial cells lining the distal convoluted tubule of the kidney, and plays an instrumental 
role in blood pressure regulation by fine-tuning renal sodium excretion. Renal salt 
transporters such as NCC are excreted in urinary exosomes (uEs) after internalization into 
multivesicular bodies. The aims of this study were to investigate the effect of thiazides on 
the abundance of NCC in uEs of patients with hypertension, and to assess whether NCC 
abundance in exosomes can predict the blood pressure response to thiazides.
Methods: The NCC abundance was compared in uEs both before and after treatment 
in patients with hypertension (n=41) who did or did not respond to thiazides. Responders to 
treatment were defined as patients with a significant anti-hypertensive response to thiazides 
(≥5 mmHg, n=24), while non-responders had a minimal or no response (<5 mmHg in 
blood pressure, n=17). To analyze whether normalization by urinary creatinine resulted in 
a similar number of uEs loaded on a gel, the abundance of the exosomal-marker CD9 was 
measured.
Results: Despite the inhibitory action of thiazide on NCC, immunoblot analysis of 
exosomes showed increased abundance of NCC (>2.5-fold, P<0.05). The increase in NCC 
abundance in uEs after thiazide treatment correlated with the blood pressure response and 
change in plasma potassium levels (R2=0.22, P<0.05; R2=0.19, P<0.05, respectively). 
The abundance of NCC in uEs before treatment was significantly higher in responders 
compared to non-responders (>6-fold,P<0.05). Moreover, after thiazide treatment, the 
increase in abundance of NCC in uEs and decrease in plasma potassium levels was stronger 
in responders compared to non-responders (P<0.05). No significant differences in CD9 
abundance were observed between the two experimental groups, suggesting comparable 
urinary exosomal numbers.
Conclusions: Our studies highlight that NCC is upregulated by thiazides and 
this increase correlates with the blood pressure response to thiazides and the change in 
plasma potassium levels. Additionally, we show that higher abundance of NCC prior to 
treatment with thiazides predicts the blood pressure response to thiazides. This implies that 
assessment of NCC in uEs could represent novel method to guide anti-hypertensive therapy 
in hypertensive patients.
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Parathyroid Hormone (PTH) Increases Paracellular Permeability to Na 
and Ca in the Cortical Thick Ascending Limb (CTAL)
Caroline Prot-Bertoye,2,3 Lucile Figueres,2 Elsa Ferriere,2 Gaëlle Brideau,4,2 
Tilman Breiderhoff,5 Dominik Müller,5 Pascal Houillier.1,3 1Paris Descartes 
University / INSERM, UMRS1138, Paris, France; 2INSERM, UMRS1138, 
Centre de Recherche des Cordeliers, Paris, France; 3Renal and Metabolic 
Diseases Unit, Georges Pompidou Hospital, Paris, France; 4CNRS- ERL8228, 
Paris, France; 5Pediatric Nephrology, Charité - Universitätsmedizin Berlin, 
Berlin, Germany.
Background: Ca absorption in the CTAL is passive along the paracellular pathway 
and requires the expression of claudin-16 at tight junction that increases the paracellular 
permeability to Ca (PCa). In vivo, Na is passively secreted along the paracellular pathway 
due to the transepithelial Na gradient, and to the permeability to Na of the tight junction 
that requires the expression of claudin-10b. In the CTAL, the lumen-positive transepithelial 
voltage (Vte) gradient that depends on claudin-10b expression and back diffusion of Na is 
critical for driving passive Ca reabsorption. PTH increases Ca transport across the CTAL 
but the mechanisms involved are imprecise. We aim to elucidate if claudin-16, which 
determines PCa, and claudin-10b, which determines Vte and PNa, are involved in the 
effects of PTH on the CTAL and to identify the underlying mechanisms.
Methods: Murine CTAL were microperfused in vitro to measure transepithelial Ca 
and Na absorption under symmetrical conditions and ionic paracellular permeabilities 
under asymmetrical conditions with 0.1 mM furosemide in the lumen. All measures were 
made under control and experimental conditions. The ratio of permeabilities PNa/PCl was 
calculated according to the Goldman-Hodgkin-Katz equation.
Results: PTH (10-10M) significantly increased Ca reabsorption in CTAL from 
claudin 16+/+(+44 %) and claudin 16-/-(+60 %) mice; Vte did not change, indicating that 
PTH increased PCa. PTH increased Na reabsorption (+15 %) and PNa/PCl (+22 %) in 
CTAL from wild type mice. Dibutyryl cAMP (5.10-4M), ionomycin (10-7M), thapsigargin 
(10-6M), but not phorbol 12-Myristate 13-Acetate (10-6M), significantly increased PNa/PCl. 
Dibutyryl cAMP and ionomycin had additive effects on PNa/PCl. H-89 (PKA inhibitor, 
10-5M) partly inhibited the effect of PTH on PNa/PCl.
Conclusions: We conclude that, in the mouse CTAL, PTH - increases PCa independently 
of the presence of claudin-16 - increases PNa via cAMP- and cytosolic calcium-dependent 
signaling pathways. Our results show that properties of intercellular tight junctions can be 
directly and rapidly controlled by intracellular signaling pathways in intact tissue.
Funding: Government Support - Non-U.S.
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Systems-Level Identification of PKA-Independent Vasopressin Signaling 
in Renal Epithelial Cells
Arnab Datta, Chin-Rang Yang, Viswanathan Raghuram, Mark A. Knepper. 
NHLBI, NIH, Bethesda, MD.
Background: Vasopressin signaling in the renal collecting duct is believed to be 
mediated predominantly by the activation of protein kinase A (PKA). The recent generation 
of mouse cell lines (“PKA dKO” cells), derived from mpkCCD cells, in which both PKA 
catalytic subunit genes have been deleted via CRISPR-Cas9 affords us an opportunity to 
identify PKA-independent signaling.
Methods: We used protein mass spectrometry to profile proteome-wide phosphorylation 
changes in response to vasopressin (dDAVP, 0.1 nM, 30 min) in PKA dKO cells and in 
control mpkCCD cells. dDAVP-treated and vehicle-treated cells were metabolically labeled 
using the SILAC method to allow quantification of dDAVP-induced changes in tryptic 
phospho-peptide abundances in an Orbitrap Fusion Lumos Tribrid mass spectrometer. 
Experiments were done in triplicate.
Results: Overall, >13,000 unique phosphopeptides were quantified in both PKA dKO 
and control cells. In control cells, 691 distinct phosphopeptides were altered in abundance 
in response to dDAVP. In contrast, in PKA dKO cells, only 73 phosphopeptides were 
altered in abundance, indicating that a large component of the vasopressin response is PKA 
dependent. However, altered phosphorylation in response to dDAVP in PKA dKO cells is 
indicative of substantial PKA-independent signaling. Notably, phosphorylation of Ser256 
of AQP2 (thought to be a PKA site) increased in response to dDAVP in PKA dKO cells, 
indicating that other kinases can phosphorylate this site. The upregulated phosphorylation 
sites in PKA dKO cells mapped to an X-R-(A/S/T)-X-S*-X motif, consistent with activation 
of other basophilic kinases such as SGK, PKG, CAMK2B or PAK2. Interestingly, cAMP 
measurements showed that baseline cAMP levels in PKA dKO cells, were ~10-fold higher 
than in control mpkCCD cells, although both PKA dKO and control cells showed significant 
increases in response to dDAVP. This indicates that there is likely to be a PKA-dependent 
feedback on some component of the Avpr2-Gαs-Adcy6 signaling pathway responsible for 
cAMP generation.
Conclusions: In cultured mouse principal cells: (1) the signaling response to 
vasopressin is largely PKA-dependent; (2) a smaller component of the vasopressin response 
is PKA-independent; (3) Ser256 of AQP2 can be phosphorylated by kinases other than 
PKA; (4) PKA is responsible for a feedback inhibition of cAMP generation.
Funding: Other NIH Support - NHLBI Intramural Program
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Ticagrelor Reduces Urinary Concentration and Arginine Vasopressin 
(AVP) Levels: Potential Use in AVP Excess States
Bellamkonda K. Kishore,1 Kenny M. Hansson,2 Noel G. Carlson,1 Yue Zhang.1 
1Univ. of Utah and VA Medical Center, Salt Lake City, UT; 2AstraZeneca, 
Cardiovascular, Renal and Metabolism iMED, Mölndal, Sweden.
Background: Previously we showed that blockade of P2Y12 receptor by thienopyridine 
anti-thrombotic drugs (clopidogrel or prasugrel) increases urinary concentration and AVP 
levels. However, it is not clear whether non-thienopyridine drugs, such as ticagrelor, have 
similar effects on urine concentration and AVP levels.
Methods: Groups of B6D2 mice (N = 5/group) were fed regular chow containing 
different concentrations of ticagrelor (0.15, 0.20 and 0.25%) for 14 or 21 days and 
euthanized. Urine output, osmolality and AVP levels were determined prior to and at the 
end of treatment. Terminal plasma ticagrelor levels were assayed by LC-MS/MS. The effect 
of ticagrelor (0.5, 2 or 10 μM) added in vitro on dDAVP (synthetic analog of AVP; 20 nM)-
induced AQP2 and AQP3 mRNA expression in primary cultures of rat inner medullary 
collecting duct (IMCD) cells was assessed.
Results: Administration of ticagrelor to mice caused increased urine output associated 
with decreased urine osmolality and AVP levels. (see Table). There was significant negative 
correlation between the plasma ticagrelor and urinary AVP (P < 0.04). But, blockade of 
P2Y12 receptor in cultured IMCD cells by ticagrelor caused dose dependent enhancement of 
AQP2 and APQ3 mRNA expression.
Conclusions: The observed decrease in urinary AVP excretion appears to be due to 
an unexpected off-target effect on hypothalamic AVP production/secretion. However, 
the in vitro effect on IMCD cells was an expected one based on our previous studies on 
P2Y12 receptor blockade. Hence, it appears that the off-target effect of ticagrelor on AVP 
production in vivo has apparently overridden its targeted effect on IMCD cells. Thus, our 
results suggest that the off-target effect of ticagrelor may find potential use in conditions 
associated with AVP excess, such as ADPKD, congestive heart failure, cirrhosis of liver, 
diabetic ketoacidosis, and cardiorenal syndrome, among others.
Funding: Veterans Affairs Support, Commercial Support - AtraZeneca AB
Terminal Plasma and Urine Data (mean ± SE)
*after 21 days of treatment; **as percent of respective day 0 values (14 days of treatment); 
#signficantly different from the respective day 0 values
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Decreased Release of Aquaporin-2 in Urinary Extracellular Vesicles in 
Rats Subjected to Allogenic Kidney Transplantation
Hiroko Sonoda,1 Tomonori Nakanishi,2 Tomoyuki Kabayama,1 
Sayaka Oshikawa,1 Masahiro Ikeda.1 1Veterinary Pharmacology, University of 
Miyazaki, Miyazaki, Japan; 2Chemistry and Technology of Animal Products, 
University of Miyazaki, Miyazaki, Japan.
Background: Diuresis has been observed within a week following renal transplantation. 
Aquaporin-2 (AQP2) plays an important role in the regulation of urinary concentration. 
Recently, AQP2 has been shown to be predominantly localized to urinary extracellular 
vesicles (uEVs). However, the release pattern of AQP2-bearing uEVs (uEV-AQP2) in an 
early phase after renal transplantation is largely unknown. In this study, we examined the 
release pattern of uEV-AQP2 in the recipient animals after allogenic kidney transplantation.
Methods: All animal studies were approved by the committee on the Care and Use of 
Laboratory Animals at the University of Miyazaki. Male SD rats were used as recipients 
and male Wistar rats were used as donors. The donor right kidney was transplanted into the 
recipient whose right kidney had been removed, and thereafter the remaining left kidney 
was removed (Tpx group). For the control group, a simple left kidney nephrectomy was 
performed. Urine and renal samples were collected at 5 days after the surgery. uEVs were 
isolated by differential centrifugation.
Results: Urine output was increased and urine osmolality was decreased in Tpx group 
in comparison with the control group. The level of renal AQP2 expression was significantly 
decreased in Tpx group. The release of uEV-AQP2 was significantly lower in Tpx group. 
Correlation analysis showed that the release of uEV-AQP2 was related to urine osmolality. 
When we examined marker proteins for uEVs, such as TSG101 and Alix, the release of both 
proteins in uEVs increased in Tpx group.
Conclusions: These data indicate that the release of uEV-AQP2 was associated with its 
renal expression. Furthermore, uEV-AQP2 might be an indicator for urinary concentration 
ability in the case of renal transplantation.
SA-PO1020 Poster Saturday
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Contribution of Collecting Duct NOS1 in the Regulation of Urine Flow in 
Hydrated and Dehydrated States
Kelly A. Hyndman, Luciano D. Mendoza. University of Alabama at Birmingham, 
Birmingham, AL.
Background: We previously determined that collecting duct (CD) nitric oxide 
synthase-1 (NOS1) was critical for maintaining fluid-electrolyte balance during high Na+ 
intake. Mice with genetic deletion of all NOS1 splice variants from the principal cells of 
the CD (CDNOS1KO), have reduced urine flow after a single high Na+ meal compared to 
control mice even though food and water intake was similar. This suggests that CD NOS1 
may regulate CD water permeability during high Na+ challenges. The purpose of this study 
was to determine if CD NOS1 is a regulator of water permeability during chronic hydration 
or water deprivation.
Methods: Male and female (n=6 per sex/genotype/treatment) CDNOS1KO and 
littermate NOS1flox/flox(control) mice were randomly assigned to the hydration or 24 h 
dehydration protocols. All mice were placed on 5% sucrose water to encourage hydration. 
After 3 days, half of the mice were switched to water deprivation. Urine was collected 
diurnally matching the 12 h light schedule of the room.
Results: In male mice, both genotypes drank similar amounts while hydrated, and 
produced similar amounts of urine. With water deprivation, CDNOS1KO male mice 
produced significantly more urine than controls during their active period (182±0.04 vs 
40±0.03 μl/12 h, p = 0.02), and urine from CDNOS1KO male mice was very concentrated 
(UOsm= 4632±193 mOsm/kg H2O). Plasma osmolality rose similarly in both control (300±3 
vs 315±2 mOsm/kg H2O) and CDNOS1KO (301±2 vs 314±3 mOsm/kg, Pgenotype=0.53 
Phydration<0.01, Pgxh= 0.3) during dehydration. In the females, fluid intake was significantly 
reduced in the CDNOS1KO mice during their active period compared to controls (7.2±1.6 
vs 15.2±2.6 ml/day, p=0.01), and likewise there was a reduction in urine volume (3.1±1.2 
vs 8.2±2.0 ml/day, p= 0.03). With dehydration, female control and CDNOS1KO mice 
both produced very little urine and concentrated urine (125±0.05 and 105±0.04 μl/12h, 
p = 0.99). Plasma osmolality following dehydration was increased in the controls (from 
300±3 to 308±2 mOsm/kg H2O) and further exacerbated in CDNOS1KO (from 309±4 to 
319±6 mOsm/kg, Pgenotype=0.02 Phydration= 0.03, Pgxh= 0.8).
Conclusions: In conclusion, CD NOS1 does contribute to the urine concentrating 
mechanisms of the kidney in both sexes, although it is a minor component. Interestingly, 
CD NOS1 is crucial in female mice to properly regulate plasma osmolality.
Funding: NIDDK Support
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Effects of TGF-β1 on the Activity of NFAT5, an Osmoprotective Tran-
scription Factor
Yuichiro Izumi,1 Naomi Matsuo,1 Koji Eguchi,1 Akiko Hara,1 Makoto Ono,1 
Yushi Nakayama,1 Hideki Inoue,1 Hiroshi Nonoguchi,2 Yutaka Kakizoe,1 
Takashige Kuwabara,1 Masashi Mukoyama.1 1Department of Nephrology, 
Kumamoto University Graduate School of Medicine, Kumamoto, Japan; 
2Kitasato University Medical Center, Kitamoto, Japan.
Background: NFAT5 (nuclear factor of activated T-cells 5, or TonEBP) is a 
transcription factor that stimulates the expression of osmoprotective genes in response 
to extracellular hypertonicity, resulting in cell survival even in extremely hypertonic 
conditions. Activated NFAT5 is translocated from the cytoplasm to nucleus, and then binds 
to the osmotic response element (ORE) to induce transcription. Not only hypertonicity but 
also hypoxia, oxidative stress, and toll-like receptor signaling, which promote fibrogenesis 
in the kidney, have been suggested to increase the NFAT5 activity. Transforming growth 
factor-β1 (TGF-β1) is an important factor that stimulates fibrogenesis, but little is known 
about the interaction between TGF-β and NFAT5. We evaluated the effects of TGF-β1 on 
the NFAT5 activity.
Methods: For in vivo experiments, mice were subjected to unilateral ureteral 
obstruction (UUO). After 14 days, the expression of NFAT5 and TGF-β1 in the kidney was 
examined by real-time PCR. For in vitro experiments, we used human embryonic kidney 
293 (HEK 293) ORE-X cells which stably express the ORE-X-luciferase reporter gene. 
Cells were incubated in 300 mOsm/kg or 500 mOsm/kg (NaCl added) for 24 hrs, and then 
the luciferase activity was measured to evaluate the NFAT5 transcriptional activity. Protein 
expression of NFAT5 was examined by Western blotting. To examine the effect of TGF-
β on nuclear translocation of NFAT5, whole cell lysate was fractionated to nucleus and
cytoplasm.
Results: The expression of NFAT5 and TGF-β1 mRNAs was 2.5 and 12 times 
greater in the kidney in UUO mice than that in sham-operated mice, respectively. TGF-
β1 suppressed tonicity-induced NFAT5 transcriptional activity and protein expression in 
HEK293 cells. Nuclear translocation of NFAT5 was inhibited by TGF-β1. These results 
suggest that TGF-β1 directly inhibits the activation and expression of NFAT5.
Conclusions: TGF-β1 inhibits NFAT5 in the kidney, which might exacerbate renal 
fibrogenesis during fibrotic renal disorders.
Funding: Government Support - Non-U.S.
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Dog and Human Zip10 (SLC39A10) Localization Is More Than Proximal 
Tubule, Helping to Explain Role in Nephrolithiasis
Michael F. Romero,1 Heather L. Holmes,1 Greg M. Landry,2,1 Mukesh K. Pandey,1 
Huailei Jiang,1 Aditya Bansal,1 Marie-Christine Franz,4,1 Nicolas Montalbetti,5,1 
Pablo Cabrero,3 Julian A. Dow,3 Eva Furrow.6 1Mayo Clinic College of Medicine, 
Rochester, MN; 2Massachusetts College of Pharmacy & Health Sciences, 
Boston, MA; 3University of Glasgow, Glasgow, United Kingdom; 4CSL Behring 
AG, Bern, Switzerland; 5University of Pittsburgh, Pittsburgh, PA; 6University of 
Minnesota, Falcon Heights, MN.
Background: In the past several years, we and others have implicated zinc (Zn2+) and 
Zn2+ transporters, e.g., SLC39A10 / ZIP10, to have a role in dog and human nephrolithiasis 
using a Drosophila model. As for other ions and solutes, Zn2+ is moved into and out of 
cells by specific membrane transporters: ZnT, ZIP, and NRAMP/DMT proteins. In rodents, 
ZIP10 has been localized at the apical membrane of renal proximal tubules (PT), where it is 
believed to play a role in Zn2+ import.
Methods: Our group has used Drosophila as a model of calcium oxalate kidney stones 
We expressed ZIP10 from dog, human, and Drosophila (CG10006), tested clones for Zn2+ 
uptake, electrogenicity (voltage clamp) and ability to change intracellular pH (pHi) in 
Xenopus oocytes. Finally using immunofluorescence, we localized the ZIP10 protein in 
mouse, dog, human and fly renal structures.
Results: CG10006, rather than foi (fear-of-intimacy, CG6817) is the primary ZIP10 
homolog found in Drosophila Malpighian tubules. All of these ZIP10-proteins were found 
to transport 63Zn2+ (PET isotope) in oocytes; however, we were unable to elicit membrane 
currents or pHi changes with addition of Zn
2+. The ZIP10 antibody recognizes recombinant 
and native rodent, dog, human and Drosophila ZIP10 proteins. Immunohistochemistry 
reveals that Zip10 in higher mammals is found not only in the PT but also in AQP2-positive 
tubules (collecting duct, CD).
Conclusions: 1) CG10006 is the likely ortholog of ZIP10; 2) ZIP10 transport is not 
electrogenic; 3) ZIP10 transport is not HCO3
- coupled; 4) ZIP10 in dogs and humans has 
both PT and CD localization. Together these studies reveal ZIP10 has multiple roles in renal 
Zn2+ transport and may provide additional insights to the role of Zn2+ in calcium oxalate 
nephrolithiasis.
Funding: NIDDK Support, Other NIH Support - DK92408, DK100227, DK101405, 
OD019912
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Acetazolamide Inhibits Ammoniagenesis and Prevents the Correction of 
Metabolic Acidosis in Rat
Hassane Amlal, Sihame Amlal, Perwez Alam. University of Cincinnati, 
Cincinnati, OH.
Background: Acetazolamide (ACTZ), a potent inhibitor of carbonic anhydrases 
(CA), increases renal bicarbonate wasting and causes metabolic acidosis. Intracellular 
acidic pH, per se, upregulates the glutamine transporter SNAT3 and the ammoniagenic 
enzymes (glutaminase or GA and glutamate dehydrogenase or GDH). CAII binds to the 
basolateral Na+:HCO3
- cotransporter (NBCe1) and facilitates HCO3
- reabsorption across the 
proximal tubule. However, whether ACTZ alters NBCe1 activity and interferes with the 
ammoniagenesis pathway during the onset of ACTZ-induced metabolic acidosis remains 
elusive.
Methods: We compared male Sprague Dawley rats treated with ACTZ or its vehicle 
(control) to those subjected to NH4Cl loading inthe drinking water. The animals were housed 
in metabolic cages for daily measurements of urine volume, Na+ excretion, NH4
+ excretion 
and urine pH. The animals were sacrificed after 6 days or 2 weeks. Blood composition was 
analyzed and the protein abundance of SNAT3, GA and GDH in the kidney cortex was 
examined.
Results: ACTZ-treated rats exhibited a significant increase in urine flow, natriuresis and 
bicarbonaturia (urine pH = 8.1 vs. 6.8 in controls). NH4Cl-loaded rats showed a significant 
decrease in urine pH (5.6 vs. 6.7 in controls) with no change in Na+ excretion or urine 
flow. ACTZ caused a significant and sustained metabolic acidosis for up to 2 weeks (serum 
[HCO3
-] = 20 and 21 mM for 6 days and 2 weeks, respectively, vs. 30mM in controls). 
Whereas in NH4Cl loaded rats, metabolic acidosis was developed in 6 days but was fully 
corrected after 2 weeks of treatment (serum [HCO3
-] = 20 and 28 mM for 6 days and 2 
weeks, respectively, vs. 29 mM in controls). NH4
+ excretion increased by 4-fold in NH4Cl-
loaded rats but only slightly (0.6-flod) in ACTZ-treated rats for 6 days despite similar 
degree of metabolic acidosis. Immunoblotting studies showed that the protein abundance of 
GA (4-fold), GDH (06-fold) and SN1 (8-fold) increased significantly in NH4Cl-loaded rats, 
but remained unchanged in ACTZ-treated animals.
Conclusions: 1- We propose that ACTZ binds to CAII and inactivates NBCe1. This 
alkalinizes proximal tubule cells and therefore suppresses the ammoniagenesis pathway 
despite systemic metabolic acidosis. 2- Metabolic acidosis of ACTZ is generated by 
renal HCO3
- wasting and maintained by the inhibition of ammoniagenesis pathway in the 
proximal tubule.
Funding: NIDDK Support, Clinical Revenue Support
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Co-Localization of NKCC2 with AQP2 in the Collecting Duct Principal 
Cells Contributes to the Acute Diuretic Effects of Furosemide and Overall 
Water Handling by the Kidney
Hassane Amlal, Sihame Amlal, Charuhas V. Thakar, Perwez Alam, 
Rafeeq Ahmed. University of Cincinnati, Cincinnati, OH.
Background: The activity of Na+/K+/2Cl- cotransporter (NKCC2) in the thick 
ascending limb (TAL) plays an important role in the process of urinary concentrating 
mechanism and the control of water balance by the kidney. Acute furosemide (NKCC2 
inhibitor) administration to both human and animals is associated with a rapid (minutes) 
diuresis, natriuresis, diluted and acidified urine. This raises the question as to whether 
NKCC2 is co-localized with AQP2 in the collecting duct (CD) principal cells.
Methods: Male rats housed in metabolic cages were injected with furosemide (FURO, 
5mg/kg BW) and urine was collected every hour for 2 hours and after 7 days of daily 
treatment. Urine of vehicle-injected rats (control) was collected over a 3-hour period and 
after 7 days. Urine volume, urine osmolality, Na+ excretion and urine pH were measured. 
Rat and human kidney tissues were used to examine the localization of NKCC2 and AQP2 
and ENaC by immunofluorescence labeling technique.
Results: Compared to control group, furosemide-treated rats exhibited an increase 
in urine output and Na+ excretion by 9- and 33-fold, respectively, during the first hour 
of treatment. Urine osmolality decreased to 439 mosm/kg H2O during the first hour and 
remained low (450~ mosm/kg H2O) after 7 days vs. 1373 (3 hours) or 1635 (7 days) mosm/
kg in control group. Urine pH decreased significantly (from 6.56 to 6.04, P<0.04) during 
the second hour of furosemide treatment. The later effect is inhibited in the presence of 
low dose of amiloride (ENaC inhibitor). Merged images of double immunofluorescence 
labeling of rat and human kidney tissues with AQP2 and NKCC2 or with AQP2 and ENaC 
showed NKCC2 expression in the apical membrane of both AQP-free (TAL), as well as 
AQP2 expressing cells; whereas ENaC is exclusively co-expressed with AQP2 in the CD 
principal cells of both rat and human kidneys.
Conclusions: We demobnstarte for the first time that NKCC2, ENaC and AQP2 are co-
expressed in the apical membrane of principal cells in the cortical and outer medullary CD 
of both rat and human kidneys. The co-localization of NKCC2 with AQP2 contributes to the 
acute diuretic and natriuretic effects of furosemide, and the co-localization of NKCC2 with 
ENaC in the CD is responsible for furosemide-induced urinary acidification.
Funding: NIDDK Support, Clinical Revenue Support
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Urinary Uromodulin Is Increased in Magnesium Deficiency and 
Stimulates Tubular Magnesium Absorption via TRPM6
Matthias Wolf,2 Manjot S. Bal,2 Carolina Rivera,2 René J. Bindels,1 
Joost Hoenderop,1 Denise K. Marciano,2 Mingzhu Nie.2 1Radboud University 
Medical Center, Nijmegen, Netherlands; 2University of Texas Southwestern 
Medical Center, Dallas, TX.
Background: Uromodulin (UMOD) is the most abundant urinary protein in humans. 
We describe a novel role for Uromodulin in renal magnesium homeostasis. Mild to 
moderate chronic hypomagnesemia occurs in up to 15% of the population and is associated 
with type 2 diabetes mellitus, hypertension, and chronic kidney disease.
Methods: Whole-animal experiments for urinary excretion of magnesium and UMOD, 
and response to furosemide were performed in nine months-old wild-type (WT) and 
Uromodulin knockout (Umod-/-) mice. Kidneys from both strains were studied for qRT-PCR 
studies and immunofluorescent TRPM6 expression. Whole-cell patch-clamp recording and 
biotinylation assays were performed in HEK293 cells to determine TRPM6 whole-cell 
current density and cell surface abundance.
Results: Umod-/- mice, compared to WT, excreted more urinary magnesium (WT 
18 ± 3 μmol/24h vs. Umod-/- 34 ± 5 μmol/24h; p<0.05) and displayed upregulation of genes 
promoting renal magnesium absorption, confirming magnesium deficiency in Umod-/- mice. 
The thick ascending limb in both strains responded the same to furosemide, indicating 
appropriate function. Fine-tuning of magnesium absorption occurs in the distal convoluted 
tubule (DCT) via the apical magnesium channel TRPM6. We found decreased apical 
TRPM6 staining in the DCT of Umod-/- mice. Applying in vitro biotinylation assays and 
whole-cell patch-clamp recording we found that UMOD enhanced TRPM6 cell surface 
abundance and current density from the extracellular space (42 ± 6 vs 196 ± 10 pA/pF 
for control vs UMOD; p<0.0001). Co-immunoprecipitation studies showed that UMOD 
physically interacted with TRPM6, and thereby impaired dynamin-dependent TRPM6 
endocytosis. UMOD depended on the urinary lectin galectin-1 to form a lattice together 
with a novel extracellular TRPM6 N-glycan to increase TRPM6 current density. To examine 
if a low magnesium state could modify urinary UMOD secretion we fed WT mice with 
a low magnesium diet and detected almost two-fold increased urinary UMOD excretion 
compared to the same mice on a regular diet.
Conclusions: Our data suggest that increased urinary UMOD secretion in low 
magnesium states defends against further urinary magnesium losses through upregulation 
of TRPM6 cell surface abundance by impairing TRPM6 endocytosis.
Funding: NIDDK Support
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Molecular Mechanism of High-Potassium Induced Na-Cl Cotransporter 
Dephosphorylation
Wakana Shoda, Naohiro Nomura, Fumiaki Ando, Kiyoshi Isobe, Takayasu Mori, 
Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tokyo Medical and Dental 
University Department of Nephrology Tokyo Medical and Dental University, 
Tokyo, Japan.
Background: Sodium-chloride cotransporter (NCC), expressed in distal convoluted 
tubules (DCT), is a key molecule in the regulation of urinary potassium (K+) excretion. 
We previously reported that tacrolimus (a calcineurin inhibitor) and W7 (a calmodulin 
inhibitor) inhibited the K+-induced NCC dephosphorylation and the increase in urinary 
K+ excretion in mouse kidneys. These results suggest that calmodulin and calcineurin 
(CaN) were activated by calcium (Ca2+) signal in response to the increase in extracellular 
K+ concentration ([K+]ex) in DCT. However, the precise mechanism of K
+-induced CaN 
activation in DCT cells remains unknown.
Methods: Flp-in NCC HEK293 cells were transfected with constitutively active 
CaN-A (CA-CaN-A), CaN-A, and -B plasmids to determine the role of CaN in NCC 
dephosphorylation. Intracellular Ca2+ concentration ([Ca2+]i) were analyzed by live cell 
imaging using fluo-4 AM. SEA0400 (an NCX reverse-mode inhibitor) and ω-agatoxin 
(a P/Q type Ca2+ channel inhibitor) were injected to C57BL/6 mice 1 hour before K+ oral 
gavage.
Results: We confirmed that CA-CaN-A over-expression clearly dephosphorylated 
NCC in HEK293 cells. In the following experiments, we used HEK293 cells in which 
both CaN-A and CaN-B were transiently overexpressed. In these cells, K+-induced NCC 
dephosphorylation was inhibited by tacrolimus and EGTA treatment. The rapid increase 
in [Ca2+]i after high K
+ stimulation was not observed with EGTA treatment, suggesting 
that the increase in [Ca2+]i after K
+ stimulation was caused by Ca2+ influx. To determine 
the influx pathway, we treated the cells with several Ca2+ transporter inhibitors, and 
identified that SEA0400 and ω-agatoxin inhibited the K+-induced [Ca2+]i increase and NCC 
dephosphorylation. Furthermore, we found that both SEA0400 and ω-agatoxin inhibited 
K+-induced NCC dephosphorylation in mouse kidneys.
Conclusions: This study showed that the K+-induced NCC dephosphorylation by CaN 
was mediated by high-[K+]ex
-induced influx of Ca2+ through reverse-mode NCX and/or P/Q 
type Ca2+ channel.
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Involvement of CaSR, Claudin-14, and 16 in the Development of 
Hypermagnesiuria Associated with Tubulo-Interstitial Nephropathy
Taisuke Shimizu, Kaori Takayanagi, Takatsugu Iwashita, Akira Kurosawa, 
Yuka Kitamura, Hiroaki Hara, Masaaki Terao, Toru Hida, Tatsuro Sano, 
Tomonari Ogawa, Koichi Kanozawa, Hajime Hasegawa. Saitama Medical 
Center, Saitama Medical University, Kawagoe, Japan.
Background: Hypermagnesiuria is well known clinical feature of tubulo-interstitial 
nephropathy (TIN), and would be a diagnostic tool for TIN. We studied the changes in the 
expression of renal magnesium transporting molecules with the development of TIN in rats 
with unilateral ureter obstruction (UUO).
Methods: Left ureter of male SD rats was ligated, and the left kidney was sampled 
at day-0 (control), day-1 (early phase) and day-7 (late phase). Just before sampling, 
urine from the ureter-ligated kidney was collected by catheter insertion into the ureter. 
Immunohistochemistry, immunoblotting and RT-PCR were applied to this study.
Results: Fractional Mg excretion was significantly increased in the late phase but 
not in the early phase (FEMg: 3.13±0.81 at day-0, 4.72±0.54 at day-1, 10.7±0.81% at 
day-7). Immunohistochemistry and RT-PCR for fibrosis related gene indicated that TIN 
was developed in the late phase but not in the early phase. Expression of claudin-16, Mg 
reabsorption pathway in the thick ascending limb, was significantly decreased in the late 
phase but not in the early phase (100.2±2.9% at day-0, 90.3±6.3% at day-1, 36.4±1.6% 
at day-7). The results were confirmed by immunohistochemistry and immunoblotting. 
However, mRNA expression of TRPM6, Mg pathway of distal tubule, was significantly 
down-regulated even in the early phase (0.94±0.14% at day-0, 0.50±0.06% at day-
1, 0.05±0.01% at day-7). Claudin-14 which is known to be an inhibitory regulator of 
claudin-16 was remarkably up-regulated. Because calcium sensing receptor (CaSR) 
signal is reported to function as an inhibitory regulator of claudin-14, we finally studied 
the expression of CaSR. CaSR mRNA was significantly down-regulated in the late phase 
(100.5±4.7 at day-0, 42.5±13.0 at day-1, 7.5±1.8% at day-7), and immunohistochemistry 
showed remarkable reduction of CaSR signal in the late phase.
Conclusions: Our findings may indicate that the characteristic hypermagnesiuria 
in TIN is principally caused by a dysfunction of magnesium reabsorption in the thick 
ascending limb of Henle resulting from a significant decrease in the claudin-16 expression. 
The down-regulation may be closely related to the development of TIN through CaSR-
claudin-14-claudin-16 regulatory network.
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MAGE-D2 Regulated Na-Cl Cotransporter Through Chaperon-Depen-
dent ERAD
Sung-Sen Yang,1 Chien-Ming Lin,1 Martin Kömhoff,2 Shih-Hua P. Lin.1 1Tri-
Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 
2University Children’s Hospital, Philipps University Marburg, Marburg, 
Germany.
Background: Mutations in MAGE-D2 gene, encoded in X-chromosome, was reported 
to associate with transient antenatal Batter’s syndrome with severe polyhydramnios. 
Reduced Na-K-2Cl cotransporter 2 (NKCC2) and Na-Cl cotransporter (NCC) was observed 
in the renal tubules of affected male patients.
Methods: To explore the role of mutant MAGE-D2 in the kidney, we created mutant 
Mage-d2 knock-in (KI) mice and examined the possible molecular mechanisms in vitro.
Results: Three strains of disease-mutant Mage-d2 (c274dupA, Y346X and A495G) 
KI mice were generated and only female A495G/+ mice could be produced from chimera 
mouse. By sonography, some embryos with polyhydramnios were found in A495G/+ 
female mice at E15.5D. Compared with the WT embryos, more amniotic fluid amount in 
male A495G/+ embryos but not female A495G/+ embryos was observed. The osmolarity of 
the amniotic fluid was not significant between female or male WT and A495G/+ embryos. 
When the different types of Mage-d2 cDNA [WT, c274dupA (truncated protein), Y346X 
(truncated protein) and A495G (missense full-length protein)] was transfected into the 
HEK293 cells, Y346X and A495G Mage-d2 showed interruption of the cell cycles in the 
G2/M phase and reduction of the abundance of NCC. Immunoprecipitation study revealed 
NCC could interact with WT and A495G Mage-D2 instead of truncated c274dupA and 
Y346X Mage-D2 proteins. Y346X and A495G Mage-d2 also reduce the expression of 
HSP40, HSP90 and CHIP. These chaperon proteins were reported to form a complex and 
play a role in the ER-associated degradation (ERAD) of the NCC.
Conclusions: These results suggested that Mage-D2 might affect the cell cycles of 
renal tubular cells and the NCC expression through regulating ERAD chaperon proteins.
Funding: Government Support - Non-U.S.
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SLC41A1 Mediates Magnesium Reabsorption in the Kidney
Joost Hoenderop, Francisco J. Arjona, René J. Bindels, Jeroen H. De Baaij. 
Department of Physiology, Radboud Institute for Molecular Life Sciences, 
Radboud university medical center, Nijmegen, Netherlands.
Background: Solute carrier family 41 member A1 (SLC41A1) has been suggested 
to mediate magnesium (Mg2+) transport and to maintain Mg2+ homeostasis in humans. 
However, the function of SLC41A1 in the kidney, the main organ maintaining Mg2+ 
homeostasis, remains to be elucidated.
Methods: In this study, cellular Mg2+ transport assays combined with zebrafish slc41a1 
knockdown experiments were performed to disclose SLC41A1 function in the kidney.
Results: The gene slc41a1 is ubiquitously expressed in zebrafish tissues and is regulated 
by water and dietary Mg2+ availability. Knockdown of slc41a1 resulted in renal Mg2+ wasting 
in zebrafish larvae and elicited compensatory mechanisms to cope with the renal Mg2+ 
leakage induced. These compensatory mechanisms were illustrated by an up-regulation of 
the gene expression of the zebrafish orthologs of human magnesiotropic genes expressed in 
the distal convoluted tubule (TRPM6, SLC12A3, SLC41A3 and CNNM2). Importantly, the 
renal Mg2+ wasting phenotype is rescued when mouse SLC41A1 is expressed in slc41a1-
knockdown zebrafish. This proved the specificity of the knockdown approach used, as 
well as the functional equivalence of zebrafish Slc41a1 with the mammalian SLC41A1. 
Conversely, expression of mammalian SLC41A1-p.Asp262Ala, harbouring a mutation 
in the ion-conducting SLC41A1 pore, did not reverse the renal Mg2+ wasting observed in 
slc41a1-knockdown zebrafish. 25Mg2+ transport assays in human embryonic kidney 293 
(HEK293) cells overexpressing SLC41A1 demonstrated that SLC41A1 mediates cellular 
Mg2+ extrusion independently of sodium (Na+). In contrast, SLC41A1-p.Asp262Ala 
expressing HEK293 cells displayed similar Mg2+ extrusion activities than control (mock) 
cells. In polarized Madin-Darby Canine Kidney cells, SLC41A1 localized to the basolateral 
cell membrane.
Conclusions: Our results demonstrate that SLC41A1 facilitates renal Mg2+ 
reabsorption in the zebrafish model. Furthermore, our data suggest that SLC41A1 extrudes 
Mg2+ across the basolateral membrane by a mechanism that is independent of Na+. Based 
on the SLC41A1 function disclosed, patients with hereditary hypomagnesemia should be 
screened for SLC41A1 mutations.
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Disruption of a C-Terminal Di-Leucine Motif Directs NKCC1 to the 
Apical Membrane and Lysosomes in Polarized Epithelia
Rainelli Koumangoye, Eric J. Delpire. Anesthesiology, Vanderbilt University 
Medical Center, Nashville, TN.
Background: Delivery of NKCC1 cotransporter to the basolateral membranes play in 
crucial rule in ions homeostasis in epithelia. We recently reported the first known SLC12A2 
(NKCC1) mutation that causes epithelial dysfunction in an undiagnosed clinical case. The 
11 bp deletion resulted in a non-functional transporter with a shorter cytosolic COOH-
terminal tail. NKCC1-DFX maintains its ability to interact with wild-type NKCC1, leads to 
increase dimerization of the cotransporter, and causes mis-tafficking of the NKCC1-DFX 
mutant and wild-type transporters to the apical/subapical region of polarized epithelia.
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Methods: In this study, we used sequential truncation and site-directed mutagenesis 
within NKCC1 COOH domain and immunofluorescence to examine the trafficking of wild-
type and mutants NKCC1 cotransporters in polarized MDCK cells.
Results: Our results show that truncation of NKCC1 COOH domain uncouple the co-
transporter from the lateral membrane. We also targeted a di-leucine motif (DxxxLL1193-1194) 
part of a previously described tetrad in the extreme C-terminus of NKCC1 as well as a di-
leucine motif (DxxxLL1036-1037) located upstream. Disruption of the DxxxLL1036-1037 motif led 
to some increase localization in the cytoplasm, although most the cotransporter remained 
at the plasma membrane. In contrast, mutation of the terminal DxxxLL1193-1194 motif led to 
cotransporter accumulation in the cytoplasm and mis-trafficking to the apical/sub-apical 
region of polarized epithelial; recapitulating the phenotype observed in NKCC1-DFX 
mutant. This observation indicates that the DxxxLL1193-1194 motif is important for trafficking 
and maintenance of NKCC1 to the basolateral membrane. Truncation deletion and LL 
substitution mutants are trafficked out of the Trans-Golgi network and ER but accumulates 
in early endosomes and late endosomes where they are degraded. Whether they reach the 
endosomes by trafficking transiently through the plasma membrane is currently under 
investigation.
Conclusions: Our data demonstrate that NKCC1 basolateral trafficking is regulated 
by a conserved di-leucine motif in its C-terminal domain. Loss of DxxxLL1193-1194 leads to 
mis-trafficking of NKCC1 to the apical membrane and accumulation in late endosomes in 
the subapical region of the polarized epithelia.
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The Inhibitory Role of ERK1 Signaling in Renal Sodium Handling and 
Blood Pressure Through Affecting Sodium Chloride Co-Transporter
Shan Chen,3 Xiuyan Feng,7 Yixiao Xu,1 Yunman Wang,5 Jia Xiao,6 Xinxin Chen,4 
Ruidian Li,8 Saier Shen,9 Hui Cai.1,2 1Medicine/Renal, Emory University, 
Atlanta, GA; 2Nephrology, Atlanta VA Medical Center, Decatur, GA; 3Medicine/
Renal, Emory University, Atlanta, GA; 4Medicine/Renal, Emory University, 
Atlanta, GA; 5Medicine/Renal, Emory University, Atlanta, GA; 6Medicine/
Renal, Emory University, Atlanta, GA; 7Pathology, LSU Shreveport, Shreveport, 
LA; 8Medicine/Renal, Emory University, Atlanta, GA; 9Medicine/Renal, Emory 
University, Atlanta, GA.
Background: Sodium chloride cotransporter (NCC) plays a key role in regulating 
blood pressure and electrolyte homeostasis. Our previous study showed that WNK4 inhibits 
NCC by activating ERK1/2 signaling. Although ERK1 and ERK2 share 80% amino acid 
sequences, roles of ERK1 and ERK2 were reported to be different. Our preliminary studies 
showed that NCC was decreased in the inducible renal tubular specific ERK2 knockout 
(KO) mice, suggesting that the ERK1 and ERK2 pathways modulate NCC differently. 
Thus, we hypothesized that ERK1 signaling pathway plays an inhibitory role in regulating 
renal sodium excretion and blood pressure through NCC.
Methods: ERK1 global KO mice, western blot analysis, cell culture, siRNA knock-
down, metabolic cage study, and tail-cuff blood pressure (BP) measurement were used in 
this study.
Results: To determine whether ERK1 involves in NCC regulation in vivo, we first did 
western blot experiments. We found that NCC abundance was increased in ERK1 KO mice. 
To investigate whether ERK1 affects NCC protein expression in vitro, we did ERK1 siRNA 
knock-down experiments in Cos-7 cells cotransfected with NCC and siRNA ERK1. We 
found that ERK1 knockdown increased NCC protein expression. To explore whether ERK1 
signaling pathway involves in sodium excretion, we collected 24-h urine using metabolic 
cage. We found that 24-h urinary sodium excretion / body weight was significantly lower 
in ERK1 KO mice compared to WT control mice (0.0088 ± 0.0009 vs 0.0107± 0.0014 
mmol/g, n=6, p < 0.05). To further investigate the role of ERK1 signaling on NCC function, 
we did metabolic cage study in ERK1 KO mice administrated with either control vehicle 
or hydrochlorothiazide (HCTZ), a specific NCC inhibitor. We found that ERK 1 mice have 
more exaggerated response to HCTZ treatment (25mg/kg wt, i.p.) compared to WT mice 
in urinary sodium excretion (0.49 ± 0.10 vs 0.28 ± 0.14 mmol, p < 0.05, n=3), indicating 
a higher NCC activity in ERK 1 KO mice. Furthermore, we found that systolic BP was 
higher in ERK1 KO mice than that in WT mice (127.2 ± 4.7 vs 112.9 ± 9.8, n= 4, p < 0.05) 
by tail-cuff method.
Conclusions: Taken all above data together, we concluded that ERK1 signaling 
pathway plays an inhibitory role in NCC function and NCC protein expression, which 
affects renal sodium handling and blood pressure.
Funding: Veterans Affairs Support
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Cyclosporin A Aggravates Hypomagnesemia and Hypercalciuria in 
Claudin 16-Deficient Mice
Kerim Mutig,1 Hoora Drewell,2 Michael Fähling,3 Tilman Breiderhoff,2 
Dominik Müller,2 Sebastian Bachmann.3 1Charite-Universitaetsmedizin Berlin, 
Berlin, Germany; 2Charité-Universitätsmedizin Berlin, Berlin, Germany; 
3Charité - Universitätsmedizin Berlin, Berlin, Germany.
Background: Calcineurin inhibitors are instrumental for immunosuppression in 
patients after organ transplantation but renal side effects such as hypomagnesemia and 
hypercalciuria often limit their therapeutic benefits. The tight junctions protein claudin 16 
(Cldn16) is essential for paracellular reabsorption of calcium and magnesium along the 
cortical thick ascending limb (cTAL). In this study we treated wild-type (WT) and Cldn16-
deficient (Cldn16-/-) mice with a calcineurin inhibitor cyclosporin A (CsA) to identify 
the role of Cldn16 in calcineurin inhibitor-induced abnormalities of renal divalent cation 
handling.
Methods: Kidney performance was evaluated in metabolic cages. Key paracellular and 
transcellular distal calcium and magnesium transport proteins were assessed by quantitative 
PCR, immunoblotting and immunofluorescence.
Results: Labeling of Cldn16 produced strong signal in cTAL tight junctions of WT but 
not of Cldn16-/- kidneys. Physiological analysis showed baseline hypomagnesaemia and 
hypercalciuria in Cln16-/- mice compared to controls. CsA administration (25 mg/kg i.p. 
for 7 days) induced hypomagnesaemia and hypercalciuria in WT and aggravated calcium 
and magnesium wasting in Cldn16-/- mice. Analysis of Cldn10, Cldn14, Cldn16, and 
Cldn19 isoforms did not reveal any CsA-dependent changes of their expression or protein 
abundance. In contrast, expression and abundance levels of relevant transcellular divalent 
cation transporters including the transient receptor potential channel TRPM6, calbindin, 
parvalbumin, and divalent metal cation transporter CNNM2 were significantly reduced 
upon CsA in both genotypes with stronger decreases in Cldn16-/- mice.
Conclusions: In summary, our data suggest that calcineurin inhibitors cause renal 
calcium and magnesium loss via suppression of transcellular reabsorption pathways, rather 
than via inhibition of the Cldn16-mediated paracellular transport.
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Intracellular Chloride Depletion Promotes WNK4-RRXS Phosphorylation 
by a PKC/PKA Dependent Mechanism
Adrian R. Murillo-de-Ozores,2,1 Leoneli I. Grajeda-Medina,2 Gerardo Gamba,2,1 
Maria Castañeda-Bueno.2 1Universidad Nacional Autónoma de México, Mexico 
City, Mexico; 2Nephrology and Mineral Metabolism, INCMNSZ, Mexico City, 
Mexico.
Background: Mutations in WNK4 gene cause Familial Hyperkalemic Hypertension 
(FHHt) due to increased salt reabsorption by the Na+:Cl- cotransporter (NCC). While WNK4 
activity is inhibited by chloride, this kinase can be activated by angiotensin II or CaSR-
induced PKC or PKA-mediated phosphorylation in different WNK4-RRXS motifs. This 
is essential for full activation of WNK4. NCC activity is inversely proportional to plasma 
K+ concentration and evidence suggests that modulation of WNK4 by chloride underlies 
this phenomenon. Here we analyzed if WNK4 phosphorylation in its RRXS motifs is also 
modulated by intracellular chloride concentration ([Cl-]i).
Methods: We used a mouse model of hypokalemia generated by feeding WT mice 
with low K+ diet for 7 days. WNK4-RRXS phosphorylation was analyzed by Western 
Blot and immunofluorescence in hypokalemic mice and in WNK4-transfected HEK293 
cells incubated with different media and pharmacological inhibitors. ELISA was used to 
determine PKC activity.
Results: WNK4 phosphorylation at RRXS motifs S64 and S1196 increased in mice 
fed with low K+ diet compared to controls. Interestingly, this was only observed in NCC 
positive tubules. Incubation of transfected HEK293 cells with low K+ medium also resulted 
in WNK4-RRXS phosphorylation. Furthermore, two different maneuvers that decrease 
[Cl-]I (low chloride hypotonic stress or NEM-incubation) in HEK293 cells also caused an 
increase in WNK4-RRXS phosphorylation. This was prevented by PKC inhibitor BIM and 
PKA inhibitor H89, as well as by intracellular Ca2+ chelation by BAPTA-AM. Accordingly, 
we found that PKC activity was increased upon [Cl-]I depletion. Given that WNKs are 
the only kinases known to be regulated by [Cl-]I, we hypothesized that WNK activity was 
involved in the PKC/A-induced WNK4-RRXS phosphorylation. However, the specific 
WNK inhibitor WNK463 did not ablate low K+-induced WNK4-RRXS phosphorylation. 
Instead, WNK463 increased WNK4-RRXS phosphorylation, probably due to the expected 
[Cl-]I decrease.
Conclusions: WNK4 is phosphorylated in its RRXS motifs during reduction of [Cl-]I 
by a mechanism that involves PKC or PKA activation. This process seems to be independent 
of WNK activity and was also observed in vivo since low potassium diet resulted in WNK4-
RRXS phosphorylation in mouse DCT.
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High Chloride Silences Aldosterone Signaling in the Distal Nephron
Heimo Ehmke,1,2 Catherine Meyer-Schwesinger,1 Helga Vitzthum.3 1University 
Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 2Partner Site 
Hamburg/Kiel/Lübeck, DZHK (German Centre for Cardiovascular Research), 
Hamburg, Germany; 3University Medical Center Hamburg-Eppendorf (UKE), 
Hamburg, Germany.
Background: The adrenal steroid hormone aldosterone plays a primary role in 
maintaining normal body electrolyte homeostasis. Physiologically, aldosterone secretion 
from the adrenal glands is under the control of angiotensin II and plasma [K+]. Surprisingly, 
high aldosterone levels due to high K+ intake are normally not associated with renal salt 
retention and disturbances of systemic Na+ and Cl- homeostasis. K+ supplementation 
consistently enhances renal Na+ excretion in animals as well as in humans particularly 
during NaCl loading when Na+ delivery to the distal nephron is high. We therefore 
questioned whether a further mechanism may exist which in the context of a high NaCl and 
high K+ intake attenuates the aldosterone-MR-ENaC pathway.
Methods: We analyzed the effects of a normal or high K+ diet on Na+ excretion, MR 
localization, ENaC mRNA and protein expression, and ENaC activity in salt replete mice. 
The effects of high extracellular chloride concentration [Cl-] on MR localization and ENaC 
expression was also determined in mCCD cells, a cellular model of principal cells in the 
collecting duct.
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Results: The canonical cellular responses to aldosterone, encompassing translocation 
of the mineralocorticoid receptor (MR), transcription and activation of epithelial sodium 
channel ENaC, and ENaC-dependent Na+ reabsorption, were undetectable in mice receiving 
a high K+ /high NaCl diet in spite of increased plasma aldosterone concentrations. Elevating 
extracellular chloride concentration [Cl-] was sufficient to suppress the aldosterone-induced 
MR translocation and ENaC protein expression in vitro and in vivo. Functionally and 
biochemically, the aldosterone response was rescued in vivo when the extracellular [Cl-] 
increase was prevented during the high K+ diet.
Conclusions: These findings show that aldosterone signaling in the kidney is silenced 
by increased extracellular [Cl-] and provide an explanation for the natriuretic effect of a high 
K+ intake in the presence of a high NaCl consumption characteristic for the Western diet.
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SCAMP4, a New Player in the Regulation of NKCC2 Surface Expression
Sylvie Demaretz,2 Kamel Laghmani.1 1Cordeliers Research Centre, Sorbonne 
University, INSERM-U1138, CNRS-ERL8228, Paris, France; 2Cordeliers 
Research Centre, Sorbonne University, INSERM-U1138, CNRS-ERL8228, 
Paris, France.
Background: The apically located Na-K-2l cotransporter is the pacemaker of NaCl 
reabsorption in the thick ascending limb (TAL) of the loop of Henle. We have previously 
shown that secretory carrier membrane protein 2 (SCAMP2) regulates exocytic insertion of 
NKCC2 into the cell membrane. The aim of the present study was to investigate the effect 
of SCAMP4, a member of the SCAMPs family that lacks the highly conserved N-terminal 
NPF repeats, on NKCC2 surface expression.
Methods: To examine the expression of SCAMP4 in TAL, we checked for the presence 
of its transcript in native TAL cells using real-time RT-PCR. Protein-protein interaction was 
assessed by co-immunopreciptation assay. NKCC2 surface expression was monitored in 
transiently transfected OKP and HEK cells, using protein biotinylation, immunoblot and 
confocal imaging.
Results: Real time PCR on renal microdissected tubules demonstrated the expression 
of SCAMP4 in TAL. Co-immunoprecipitation experiments showed robust interaction 
between SCAMP4 and the complex-glycosalyed form of NKCC2 in cultured renal cells, 
suggesting that the interaction takes a place at the post-Golgi level. Consistent with this 
notion, co-immunolocalization experiments revealed that similar to SCAMP2, SCAMP4 
co-localizes with NKCC2 in recycling endosomes. However, in contrast to SCAMP2, 
SCAMP4 co-expression promoted NKCC2 surface expression, whereas SCAMP4 knock-
down had the opposite effect. Interestingly, deleting the deleting N-terminal NPF repeats 
from SCAMP2, abolished its negative effect on NKCC2 surface expression, suggesting 
that this highly conserved domain plays a crucial in the differential regulation of NKCC2 
surface expression by SCAMP2 and SCAMP4.
Conclusions: We identified SCAMP4 as a novel NKCC2 binding partner that plays a 
key role in the modulation of NKCC2 surface expression. Most importantly, our results are 
consistent with SCAMP2 and SCAMP4 having differential and antagonistic effects with 
regard to NKCC2 transit through recycling endosomes, thereby revealing a new regulatory 
mechanism governing the co-transporter intracellular trafficking.
Funding: Government Support - Non-U.S.
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Dietary Mg2+ Restriction Downregulates NCC Through a SPAK-Inde-
pendent Pathway
Mohammed Z. Ferdaus, Lauren N. Miller, James A. McCormick. Oregon 
Health & Science University, Portland, OR.
Background: Hypomagnesemia is often observed in critically ill patients and is 
associated with lower kidney function and life-threatening complications. The distal 
convoluted tubule (DCT) is the major site of active Mg2+ reabsorption, determining the final 
urinary Mg2+ excretion. The Na+-Cl- cotransporter (NCC), expressed along the DCT, plays a 
key role in ion homeostasis. Dietary interventions have a strong effect on NCC.
Methods: We studied the effect of dietary Mg2+ manipulation on NCC in C57BL/6J 
mice by assessing levels of total NCC (tNCC), phospho-NCC (pNCC) and other relevant 
proteins with blood electrolyte analysis.
Results: We observed that abundances of tNCC and pNCC, a surrogate for NCC 
activity, were lower following acute (3 days) and chronic dietary Mg2+ (14 days) restriction, 
compared with normal and high Mg2+ diets. However, pNCC:tNCC was unchanged, 
suggesting the primary effect is on tNCC abundance. It is well-established that low blood 
[K+] induces NCC phosphorylation. We observed that while tNCC was still downregulated 
by combined K+ and Mg2+ restriction, pNCC abundance was strongly increased compared 
with normal and Mg2+ deficient diets. These data suggest that distinct signaling pathways 
mediate the effects of dietary Mg2+ and K+ restriction on NCC. STE20 (Sterile 20)/SPS-
1 related proline/alanine-rich kinase (SPAK) directly phosphorylates NCC, and SPAK 
knockout (KO) mice have ~90% lower tNCC abundance compared with wild type mice. 
Dietary Mg2+ restriction of SPAK KO mice further decreased tNCC, suggesting a strong 
effect of dietary Mg2+ restriction on tNCC abundance, and showing that SPAK was not 
involved in mediating the effect of dietary Mg2+ restriction. The E3 ubiquitin-protein 
ligase neural precursor cell expressed developmentally downregulated gene 4-like 
(Nedd4-2) induces tNCC degradation on a high Na+ diet, but targets the epithelial sodium 
channel (ENaC) during K+ restriction. As activated Nedd4-2 promotes self-degradation, 
its abundance reflects its activity. We found that Nedd4-2 abundance was lower on Mg2+ 
deficient diet compared with normal diet, suggesting activation of Nedd4-2 by Mg2+ 
restriction. However, abundances of ENaC subunits were unaffected.
Conclusions: Overall, our data suggest that dietary Mg2+ deficiency may alter NCC 
function by downregulating total abundance of NCC by activating Nedd4-2 selectively 
along the DCT.
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Association Between Estimated Dietary Acid Load and Albuminuria in 
Japanese Adults
Keiko Kabasawa,1 Michihiro Hosojima,2 Yumi Ito,1 Hideyuki Kabasawa,2 
Ribeka Takachi,3 Kazutoshi Nakamura,4 Akihiko Saito,5 Junta Tanaka,1 
Ichiei Narita.6 1Health Promotion Medicine, Niigata University, Niigata, Japan; 
2Clinical Nutrition Science, Niigata University, Niigata, Japan; 3Food Science 
and Nutrition, Nara Women’s University, Niigata, Japan; 4Preventive Medicine, 
Niigata University, Niigata, Japan; 5Applied Molecular Medicine, Niigata 
University, Niigata, Japan; 6Clinical Nephrology and Rheumatology, Niigata 
University, Niigata, Japan.
Background: Acid-base imbalance might promote the progression of chronic kidney 
disease (CKD). Albuminuria is a risk factor for cardiovascular disease and mortality even 
in the high normoalbuminuric range and is also one of the diagnostic markers for CKD. 
However, the exact relationship between dietary acid load and albuminuria is unclear. In this 
study, we assessed the association of dietary acid load with albuminuria in Japanese adults.
Methods: Subjects were a Japanese cohort comprising 3,202 men and 3,429 women (age 
range 40-97 years); subjects with a urine albumin-to-creatinine ratio (UACR) ≥ 300 mg/g 
or eGFR < 15 mL/min/1.73 m2 were excluded. We performed a cross-sectional analysis of 
net endogenous acid production (NEAP) score and the presence of low-grade albuminuria. 
NEAP score was derived from nutrient intake based on food frequency questionnaire 
assessment. Low-grade albuminuria, evaluated using UACR from spot urine samples, was 
defined as high normoalbuminuria (UACR: 10-29 mg/g) or microalbuminuria (UACR: 30-
299 mg/g).
Results: Median NEAP was 43.3 (interquartile range: 34.2, 53.4) mEq/d in men and 
35.1 (27.7, 43.7) mEq/d in women. Median UACR and eGFR were 9.6 (5.0, 22.0) mg/g and 
73.8 (64.1, 84.3) mL/min/1.73 m2 in men and 13.0 (7.2, 25.0) mg/g and 73.7 (64.7, 83.7) 
mL/min/1.73 m2 in women, respectively. High normoalbuminuria and microalbuminuria 
were found in 976 and 616 men and 1,449 and 703 women, respectively. After adjusting for 
potential confounders, such as diabetes mellitus, the odds ratio of the highest versus lowest 
NEAP quartile for the presence of high normoalbuminuria and microalbuminuria was 1.28 
(95% CI: 1.04–1.58) in men and 1.34 (95% CI: 1.08–1.65) in women. Among the subjects 
without microalbuminuria, the odds ratio of the highest versus lowest NEAP quartile for the 
presence of high normoalbuminuria was 1.21 (95% CI: 0.96–1.53) in men and 1.30 (95% 
CI: 1.04–1.63) in women.
Conclusions: NEAP score was associated with the presence of low-grade albuminuria 
in a Japanese adult population. Further studies are needed to confirm whether dietary acid 
load influences the development and progression of albuminuria.
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A Diet Rich in Vegetables and Fruits and Incident CKD: Communi-
ty-Based Prospective Cohort Study
Yooju Nam, Arum Choi, Seon yeong Lee, Joohwan Kim, Ki Heon Nam, Tae-
Hyun Yoo, Seung Hyeok Han. Yonsei University College of Medicine, 
Seodaemun-gu, SEOUL, Republic of Korea.
Background: A diet rich in vegetables and fruits can lower blood pressure (BP) and 
reduce cardiovascular risk. However, it is unknown on the association between this diet and 
incident chronic kidney disease (CKD) in general population.
Methods: Using the database from the Korean Genome and Epidemiology Study, we 
analyzed 9487 subjects with normal renal function. Habitual diet survey was performed 
using a validated food frequency questionnaire at baseline. The study subjects were 
classified into tertiles according to the consumption of raw and fermented vegetables, and 
fruits. The primary outcome was incident CKD defined as an estimated glomerular filtration 
rate (eGFR) <60 mL/min/1.73 m2. The secondary endpoint was incident proteinuria 
determined by dipstick test ≥ 1+.
Results: At baseline, BP, C-reactive protein levels and estimated net endogenous acid 
production were significantly lower in the highest tertile of raw vegetable intake. During a 
mean follow-up of 8.2 years, 1741 (18.4%) subjects had incident CKD. Compared to the 
lowest tertile of raw vegetable intake (19.3%), CKD occurred less in the middle (18.8%) 
and the highest (16.9%) tertile groups (P<0.001). Incidence rate of proteinuria was also 
lower in the latter two groups. In multivariable Cox analysis, the highest tertile of raw 
vegetable intake was associated with a 14% lower risk of CKD development compared 
to the lowest tertile (P < 0.001). The highest tertile also conferred a 28% lower risk of 
proteinuria development than the lowest tertile (P < 0.001). There were no associations 
between fermented vegetable and fruit intake and CKD development. However, both 
highest tertiles of fermented vegetable and fruit intake were associated with 14% and 45% 
lower risk of incident proteinuria compared to the lowest tertiles, respectively (P < 0.001 
for both).
Conclusions: This study suggests that a diet rich in vegetables and fruits may have 
beneficial effects on the prevention of kidney disease.
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Comparison of Mixed-Based vs Animal-Based Low Phosphorus Diet on 
Hyperphosphatemia in Dialysis Patients: Randomized Clinical Trial
Ximena Atilano carsi,1 Juan Carlos Ramirez-Sandoval,2 Jorge A. Sánchez,3 
Celene V. Arce santander,4 Cristinoc Cruz,5 Luis Tamez Pedroza,6 Miguel 
Angel Garcia de Leon,9 Angeles Espinosa-Cuevas,8 Ricardo Correa-Rotter.7 
1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad 
de México, Mexico; 2Instituto Nacional de Ciencias Medicas y Nutricion 
Salvador Zubiran, México city, Mexico; 3Instituto Nacional de Ciencias Medicas 
y Nutricion Salvador Zubiran, Ciudad de México, Mexico; 4Lapi Unidad de 
Hemodiálisis, Ciudad de México, Mexico; 5INCMNSZ, Mexico city, Mexico; 
6Universidad Autonoma de Baja California, Ciudad de M?xico, Mexico; 
7Institutor Nacional de la Nutricion, Mexico City, Mexico; 8Nacional Medical 
Science and Nutrition Institute, Mexico, Mexico; 9Instituto Mexicano del Seguro 
Social, Distrito Federal, Mexico.
Background: Dietary P restriction is major component of hyperphosphatemia 
treatment in dialysis. Bioavailability of vegetable and animal P sources is not taken in 
consideration. KDIGO recommends to conduct clinical trials with different sources 
of dietary P. Aim:assess the effect on serum P of 2 low-Pdiets(<1000mg/day;Animal 
Vs.vegetal+animal) in dialysis patients.
Methods: Randomized, multicenter, open-label clinical trial. Subjects on dialysis 
for>6 mo and P>4.5mg/dL were randomized into a mixed-based(3oz equivalent animal 
protein+3oz equivalent legumes)vs.animal-based(6oz equivalent animal protein) low P diet 
with equivalent nutrients (protein=1.3 g/kg/d). Primary outcome was the change in serum 
P after 12 wks. We excluded patients who modified their dialysis dose, phosphate binder or 
vitamin D prescription during trial.
Results: 56 subjects(38HD,18PD) were randomized. Age, sex, phosphate-binders use 
and other baseline characteristics were similar between groups. Baseline P values were 
5.6±1.6 and 4.9±1.2 in mixed-based and animal-based groups respectively(p=0.06). Mixed-
based group had a significant decrease in P after 12 wks of intervention(5.6±1.6 to 5.0±1.3, 
p=0.04). Animal-based group did not change P significantly(4.9±1.2 to 4.7±1.4, p=0.46). 
Serum P in the mixed-based and animal-based declined by -0.66(95%CI:-1.39 to -0.04)mg/
dL and -0.21(95%IC:-0.81 to 0.38) respectively(p=0.14, Fig). There were no differences 
between groups in the change of other biochemical parameters.
Conclusions: Dietary P restriction with animal or mixed-based P sources had a similar 
efficacy to achieve and maintain P concentration in dialysis. Mixed-based group had a non-
statistically significant trend to achieve a higher decrease in serum P.
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Effect of Low-Protein Rice on Progression of CKD
Worawon Chailimpamontree, Anupong Thananphuwasit, Pongsathorn Gojaseni, 
Anutra Chittinandana. Bhumibol Adulyadej hospital, Bangkok, Thailand.
Background: CKD is a worldwide public health problem. Protein restriction is 
effective in slowing the progression of kidney disease. Rice is the main staple foods in 
Thailand. However, besides carbohydrates, rice also consists of low biological value 
proteins. Since it is not easy to control dietary protein intake in patients who eat normal-
protein rice(protein content 8g/rice100g), low protein rice(protein content 1.6g/rice100g) 
has been developed to counter these problems. As it is, the data on low-protein rice’s effect 
on CKD progression is limited. This pilot study was done to determine the impact of low-
protein rice on CKD progression.
Methods: This involved a controlled before-and-after study in patients with stage 3-4 
CKD who had protein intake of> 0.8 g/kg/day. The study covered a total duration of 6 
months: the first 3 months when patients ate normal-protein riceand the second 3 months 
when they ate low protein-rice. All patients received multidisciplinary team care and were 
advised to have 0.6-0.8 gram/kg/day of protein intake along the study.
Results: 32 patients were included in this study. Majority of patients were male 
(56.3%): 62.5% have diabetes and 81.3%have CKD stage 4. Mean age of patients is 55.9 
years. After eating low-protein rice for 3 months, we noted that the GFR increased from 
baseline by 2.0 ± 3.1 ml/min/1.73m2(P=0.031). The nPNA reduced from baseline by 0.1 g/kg 
(95%CI: -0.2, 0.1, P = 0.04). In addition, eating low-protein rice significantly decreased 
waist circumference.
Conclusions: Low protein-rice has an impact on improving kidney function. It is also 
helping patients controlling dietary protein intake and improved there’s body composition. 
Further studies are required before applied to all CKD patients who eating rice as a main 
cultural cuisine.
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Dietary Pattern Modifies the Association of APOL1 Variants with CKD: 
The Jackson Heart Study
Stanford Mwasongwe,1 Bessie A. Young,2 Julia J. Scialla,3 
Clemontina A. Davenport,4 Adolfo Correa,5 Solomon K. Musani.5 1Jackson 
Heart Study, Jackson, MS; 2Uniiversity of Washington, Seattle, WA; 3Duke 
University, Durham, NC; 4Duke University Medical Center, Durham, NC; 
5University of Mississippi Medical Center, Jackson, MS.
Background: Apolipoprotein L1 (APOL1) variants are associated with increased risk 
of chronic kidney disease (CKD), however, not everyone with high risk APOL1 genotypes 
develops overt kidney disease. We evaluated the modifying effects of dietary pattern on the 
association between APOL1 risk variants and prevalent CKD among African Americans 
(AAs).
Methods: We conducted a cross-sectional analysis of 2,841 AAs from the Jackson 
Heart Study (JHS) with genotyped APOL1 variant data. Three dietary patterns, designated 
“southern”, “fast food” and “prudent” were derived from a validated regional specific food 
frequency questionnaire (Deep South) using factor analysis. The factor scores for each 
pattern were divided into tertiles labelled low, moderate and high levels, respectively. CKD 
was defined at baseline as an estimated glomerular filtration rate <60 mL/min/1.73 m2. First, 
we assessed the association between APOL1 Variants and prevalent CKD using multivariate 
logistic regression model, controlling for demographic, clinical factors to and population 
stratification. We then added diet and APOL1 x diet interaction terms to assses the effect 
modification of each diet pattern.
Results: The mean (± standard deviation) age of included participants was 55±13 years, 
62% were female, 5.5 % had CKD. Of the total participants studied, 13% had two APOL1 
risk variants. We observed that the models accounting for APOL1× diet interactions fitted 
the data significantly (P<0.001) better than the main effects model. In multivariable adjusted 
main effects model, two APOL1 risk variants were significantly associated (Odds Ratios, OR 
[95% confidence Interval, CI]; p-value) with prevalent CKD 1.87 (1.16-2.96); p=0.0102. In 
individuals consuming high levels of fast food diet, 2 APOL1 risk variants were significantly 
associated (OR, 95% CI) with greater odds, 3.66 (1.43, 9.39), p=0.007 of prevalent CKD 
compared to low and moderate levels of fast food diet (Figure 1). Similarly, in individuals 
consuming high levels of southern diet, the OR were 2.92 (1.16, 2.96); p=0.02.
Conclusions: In a large community-based study of AAs, all dietary patterns studied 
modified the association between APOL1 two-risk alleles and increased CKD prevalence.
Funding: Other NIH Support - NHLBI
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Dietary Protein Intake, Protein Energy Wasting, and Progression of CKD
Eunjeong Kang,1 Sung Woo Lee,2 Curie Ahn,1 Kook-Hwan Oh.1 1Seoul National 
University Hospital, Seoul, Republic of Korea; 2Eulji General Hospital, Seoul, 
Republic of Korea.
Background: There have been a paucity of literatures regarding on the effect of dietary 
protein intake (DPI) on the progression of chronic kidney disease (CKD), in conjunction 
with the potential hazard of protein-energy wasting (PEW).
Methods: The database of a large-scaled multicenter prospective study in Korea of 
2238 patients enrolled from 2011–2016 was reviewed. After excluding 319 with missing 
data to define DPI and PEW, and 347 with collecting 24-hour urine incompletely, the 
study included 1572 non-dialysis CKD patients. CKD progression was defined by a >50% 
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estimated glomerular filtration rate (eGFR) decline, serum creatinine doubling, or dialysis 
initiation.
Results: During mean 41.6 months’ follow-up period, 296 CKD patients (18.8%) 
progressed. Cross-sectionally, increased DPI was significantly associated with increased 
eGFR. Similarly, increased DPI tertile was significantly associated with increased renal 
survival in Kaplan-Meier curve analysis (Log-rank P <0.001). In multivariate Cox 
proportional hazard regression analysis, the hazard ratio (95% confidence interval) of the 
third vs. first tertile was 0.685 (0.495-0.948, P = 0.022). However, the statistical significance 
of DPI tertile group on CKD progression was lost when variables related to PEW were 
added as covariates. In penalized spline curve analysis, the adjusted odds ratio of PEW was 
significantly increased as DPI increased.
Conclusions: DPI per se was not a major determinant of CKD progression. Instead, 
intimate association between reduced DPI and PEW may be more important than DPI per 
se to predict CKD progression.
Funding: Government Support - Non-U.S.
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Prevalence and Impact of Food Insecurity in Children with ESRD
Michelle C. Starr, Aaron G. Wightman, Raj P. Munshi, Sangeeta R. Hingorani. 
Seattle Children’s Hospital, Seattle, WA.
Background: Food insecurity (FI) affects 1 in 6 children in America. Children with 
kidney disease, especially those with End-Stage Renal Disease (ESRD) may be at higher 
risk, due to their complex care needs, medication burden, and dietary restrictions. Adults 
with kidney disease and FI progress more quickly to ESRD. The prevalence and impact of 
FI in pediatric ESRD patients is largely unknown. We sought to determine the prevalence of 
FI among children with ESRD receiving dialysis and to examine the relationship between 
FI and clinical factors, healthcare utilization, and quality of life.
Methods: We assessed food insecurity among families of dialysis patients age <21 
years seen for ESRD at an academic pediatric center. The primary predictor was household 
FI status, determined using the Hunger Vital sign, a validated 2 question-screening tool. 
We compared demographic features, clinical factors, and outcomes including health 
care utilization between families identified as FI versus those not. We defined unplanned 
healthcare utilization as unscheduled admission to the hospital, Emergency Department 
visit, or dialysis related infection.
Results: A total of 43 families were enrolled in this study; 24 (55%) were on peritoneal 
dialysis (PD) and 19 (45%) were on hemodialysis (HD). 27 of 43 (65%) of children with 
ESRD lived in food insecure households, with a larger percentage of children on HD 
reporting FI compared to those on PD (73.7 vs. 54.2%). Food insecure children were 
more likely to have an unplanned healthcare utilization event (96.3 vs. 75.0%, p = 0.035), 
including hospitalization (p=0.008) and intensive care unit admissions (p=0.03). Children 
with FI had a trend towards more dialysis related infections (48.1 vs. 25.0%). Clinically, 
children with FI were less likely to have adequate Kt/V for the last 3 months (63.0 vs. 
93.4%, p=0.03). Both child and parent proxy quality of life scores tended to be lower in 
those with FI on all subscales, particularly the worry subscale.
Conclusions: FI is common among children on dialysis therapy and negatively impacts 
clinical care, healthcare utilization, and quality of life. Further exploration into how FI and 
other social determinants of health influence management of and impact outcomes for 
children with ESRD is warranted as are interventions to decrease rates of FI.
Funding: NIDDK Support
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Association Between Estimated Protein Intake and Single-Nephron 
Glomerular Filtration Rate in Healthy Adults
Rina Oba, Takaya Sasaki, Go Kanzaki, Kotaro Haruhara, Yusuke Okabayashi, 
Kentaro Koike, Akimitsu Kobayashi, Izumi Yamamoto, Nobuo Tsuboi, 
Takashi Yokoo. The Jikei University School of Medicine, Division of 
Nephrology and Hypertension, Department of Internal Medicine. The Jikei 
University School of Medicine, Minato-ku, Japan.
Background: High protein intake can increase renal plasma flow and glomerular 
filtration rate (GFR) in response to excretory overload, which may exacerbate kidney 
disease progression. Glomerular hypertrophy has been shown to be closely associated with 
sclerosis at the level of a single nephron in experimental models. However, the mechanisms 
by which an excessive protein diet causes glomerular hyperfiltration and increases single-
nephron GFR (SNGFR) have not been fully elucidated in humans. The present study aimed 
to calculate SNGFR by estimating the number of nephrons in living kidney donors and to 
evaluate the clinicopathological findings associated with SNGFR.
Methods: We identified 33 living kidney donors with a normotensive status who 
underwent enhanced computed tomography (CT) and kidney biopsy at donation in the Jikei 
University School of Medicine Hospital from 2007 to 2017. The number of nephron was 
calculated according to the cortical volumes of both kidneys as assessed on CT and the 
1-hour post-transplant renal biopsy-determined glomerular density. Effective renal plasma 
flow (ERPF) was assessed as 99mTc-MAG3 clearance, and SNGFR was calculated as the 24-
hour creatinine clearance (24hCCr) divided by the total number of non-sclerosed glomeruli. 
The sodium intake and protein intake of the donors were estimated through a 24-hour urine 
collection test.
Results: Among the 33 subjects, 13 (39.3%) were males, and the mean age was 
53.7 ± 8.7 years. Additionally, the mean arterial pressure (MAP) was 84.4 ± 9.2 mmHg, 
and the mean 24hCCr was 112.8 ± 25.5 ml/min/1.73 m2. Urinalysis findings were normal. 
The estimated total nephron number was 698,308 ± 218,740/kidney, and the mean SNGFR 
was 90.3 ± 33.7 nl/min/1.73 m2. SNGFR was strongly and directly associated with the 
estimated sodium and protein intake (EPI) (P = 0.0365 and 0.0048, respectively) but was 
not associated with the donor age, BMI, MAP, ERPF, glomerulosclerosis index, or tubular 
injury level. Interestingly, SNGFR was only associated with EPI as assessed by multivariate 
analysis.
Conclusions: In healthy adults, we noted a strong positive correlation between SNGFR 
and EPI. Our study findings indicate that high protein intake might increase SNGFR and 
cause glomerular hyperfiltration.
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Dietary Phosphorus and Protein Intake in a Diverse Cohort of Hemodialy-
sis Patients
Amanda R. Tortorici,2 Connie Rhee,1 Kamyar Kalantar-Zadeh,3 Elani Streja,4 
Kimberly M. Juarez,1 Alejandra Novoa,5 Tracy Nakata,6 Amy S. You.7 
1University of California Irvine, Huntington Beach, CA; 2UC Irvine Medical 
Center, Irvine, CA; 3University of California Irvine, School of Medicine, Orange, 
CA; 4Harold Simmons Center for Kidney Disease Research and Epidemiology, 
Orange, CA; 5UC Irvine Health, Orange, CA; 6UC Irvine, Orange, CA; 
7University of California, Irvine, Orange, CA.
Background: We sought to determine whether dietary phosphorus (P) and protein 
intake in hemodialysis (HD) patients varies across race/ethnicity.
Methods: We identified 407 patients from the “Malnutrition, Diet, and Racial 
Disparities in Chronic Kidney Disease” (MADRAD) study, a racially/ethnically diverse 
prospective hemodialysis cohort who underwent food frequency questionnaire assessment. 
We compared baseline daily dietary intake of P, protein, and ratios of P/protein, P/kcal, as 
well as protein/kcal across racial/ethnic groups using one-way ANOVA and Bonferroni post 
hoc analyses.
Results: Blacks had the highest average daily intake of dietary P (882.7±765.7mg) 
and protein (62.8±54.5g), while patients of other race/ethnicities had the highest ratio of 
protein/kcal (0.049±0.01g/kcal). The differences in P/protein intake across racial/ethnic 
groups were significant, such that Hispanics had significantly higher ratios than Blacks and 
others: 17.2±5.3, 14.4±2.7, and 13.6±2.9mg/g, respectively; p<0.01. Hispanics also had the 
highest ratio of P/kcal (0.71±0.16mg/kcal). The differences in dietary protein/kcal ratios 
across racial/ethnic groups were also significant, such that Hispanics had significantly lower 
intake than Blacks and those of other race/ethnicity: 0.043±0.01, 0.048±0.01, 0.049±0.01, 
respectively; p<0.01.
Conclusions: These data suggest that, compared to other racial/ethnic groups, Hispanic 
HD patients’ dietary P intake relative to protein intake is higher, whereas their dietary 
protein intake relative to their total caloric intake is lower. Further studies are needed to 
determine the specific dietary sources of P among HD patients of varying race/ethnicity, 
and whether these variations may have a differential impact on their health and survival.
Funding: NIDDK Support
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Safety and Impact of Low Protein Diet and Ketosteril Before ESRD
Chih-Hsiang Chang. Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Background: Low protein diet with ketoacid analogue supplement (LPD-KA) 
remained under employed in patients with chronic kidney disease (CKD) because of 
safety issue and low compliance. This study aims to evaluate the sepsis and cardiovascular 
outcome in patient who received LPD-KA before end stage kidney disease (ESKD).
Methods: The study analyzed encrypted datasets from Taiwan’s National Health 
Insurance Research Database. The exposure group was the patients received LPD and 
ketoacid analogue over 6 months before ESKD and the comparison group was patients 
who did not received LPD. Outcomes included mortality cardiovascular event, sepsis and 
in follow up.
Results: The data of 2607 patients in the LPD group and 10428 propensity score 
matched patients without LPD between January 1, 2001 and December 31, 2013 were 
analyzed. Patients on LPD-KA had lower mortality (23.1% vs. 27.6%; hazard ratio [HR] 
0.77, 95% confidence interval [CI] 0.70-0.84), lower composite cardiovascular events 
(19.2% vs. 21.5%; HR 0.86, 95% CI 0.78-0.94), and sepsis death (6.6% vs. 8.5%; HR 0.74, 
95% CI 0.63-0.87).
Conclusions: LPD might be a safe therapy for patient of CKD. Overall mortality, 
cardiovascular event and sepsis death are less in LPD-KA group.
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Diet and Renal Function in the ELSA-Brasil Cohort: A Mediation 
Analysis
Geraldo B. Silva Junior,1 Rosa malena Fagundes xavier,2 Estela Aquino,2 
Leticia Cardoso,3 Rosa maria Salani mota,4 Antonio alberto Lopes,2 José 
geraldo Mill,5 Maria del carmen Bisi molina,5 Sandhi Barreto,6 Dora Chor,3 
Carlos Teles santos,2 Paulo Lotufo,7 Sheila Alvim matos.2 1University of 
Fortaleza, Fortaleza, Brazil; 2Federal University of Bahia, Salvador, Brazil; 
3Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 4Federal University of Ceara, 
Fortaleza, Brazil; 5Federal University of Espirito Santo, Vitoria, Brazil; 
6Federal University of Minas Gerais, Belo Horizonte, Brazil; 7University of Sao 
Paulo, Sao Paulo, Brazil.
Background: Previous studies suggest the influence of diet on renal function. The aim 
of this study was to investigate the associations between diet and renal function among 
adults in Brazil.
Methods: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) is the 
largest cohort study in Latin America, with 15,105 participants from 6 cities in Brazil. We 
have identified 4 dietary patterns in this cohort: 1) Traditional Brazilian, 2) Low sugar/low 
fat, 3) Fruits and vegetables, and 4) Bakery. Renal function was based on microalbuminuria 
and glomerular filtration rate (GFR) estimated through CKD-EPI formula. Association 
between dietary patterns and renal function was investigated through mediation analysis.
Results: Participants mean age was 52±9 years, with 54% female. Dietary patterns 
found were: traditional (45.7%), fruits/vegetables (25.5%), bakery (24.4%), low sugar/low 
fat (4.3%). For men, the patterns “bakery” and “fruits and vegetables” had significant effects 
on GFR and microalbuminuria. The “fruits and vegetables” pattern had only indirect effect 
on both GFR and microalbuminuria. For women, the “bakery products” pattern presented 
total effect on GFR and microalbuminuria. The “fruits and vegetables” pattern had the same 
effect, except for also presenting direct effect on GFR without adjustment (Figure 1).
Conclusions: There is association between dietary patterns and renal function. The 
“bakery” diet seem to have negative effect on renal function. The “fruits and vegetables” 
pattern have association with renal function possible due to epidemiological reverse 
causality effect.
Funding: Government Support - Non-U.S.
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Nutritional Assessment in Dialysis Patients: Are We Missing Something 
from Subjective Assessment?
Rachana H. Jasani,1 Rajesh B. Kumar,1 Shrirang Bichu,2 J. Kothari,3 
Viswanath Billa,4 Paras Dedhia.1 1Apex Kidney Care, Mumbai, India; 2Bombay 
Hospital Near Liberty Theater New Marine Lines, Mumbai, India; 3Hinduja 
Hospital, Healthcare & Apex Kidney Foundation, Mumbai, India; 4Bombay 
Hospital, Mumbai, India.
Background: Malnutrition is very common in dialysis patients and is associated 
with increased mortality and morbidity. It is not clear whether subjective assessment 
can accurately identify malnourished dialysis patients. Also, handgrip strength and body 
composition analysis are not incorporated in nutritional assessment scoring system.
Methods: Nutritional assessment was carried out by subjective and objective parameters 
on subjects undergoing thrice a week maintenance hemodialysis. Subjective assessment 
was done using Subjective Global Assessment (SGA) and Dialysis Malnutrition Score 
(DMS). Objective assessment was done using handgrip strength and body composition 
analysis. Subjects with albumin less than 3.5 g/dl were considered as malnourished. 
Handgrip strength analysis was performed by handgrip dynamometer (CAMRY, model 
EH101) while body composition analysis was performed by Body Composition Monitor 
(BCM) (Fresenius Medical Care).
Results: Nutritional assessment was conducted on 81 subjects (46 males and 35 
females) undergoing thrice a week hemodialysis. The average age was 54.8 ± 12.7 
years and average BMI was 24.8 ± 4.3. The average serum albumin was 3.2 ± 0.3 g/dl. 
Malnutrition was observed in 76.5% subjects by albumin <3.5 g/dl criteria. On subjective 
assessment, 55 % and 69.3% subjects were found to be malnourished by SGA and DMS 
scores respectively. Handgrip strength and BCM (objective assessment), categorized 89% 
subjects as malnourished.
Conclusions: Subjective assessment is not accurate in identifying malnourished 
dialysis patients. Simple, bedside tools like handgrip strength and body composition 
monitor may help to better characterize nutritional assessment and early intervention in 
dialysis patients.
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Use of Medical Nutrition Therapy Is Low Among US Veterans with Stage 
3-5 Non-Dialysis Dependent CKD
Holly J. Kramer,2,3 Talar Markossian,2,3 Nick Burge,3 Ivan M. Pacold,3,1 
David J. Leehey,3,1 Kevin Stroupe.3 1Loyola University Medical Center,
Maywood, IL; 2Loyola University Chicago, Maywood, IL; 3Hines VA Medical
Center, Hines, IL.
Background: Once chronic kidney disease (CKD) is established, dietary modifications 
such as decreasing intake of animal protein and salt and increasing intake of fresh fruits 
and vegetables may slow CKD progression. However, dietary modifications require patient 
education and close monitoring due to risks of malnutrition and hyperkalemia. Medical 
Nutrition Therapy (MNT), the individualized nutrition assessment, care planning and dietary 
education provided by a registered dietitian nutritionist remains an effective intervention 
for slowing CKD progression and delaying end-stage renal disease (ESRD). We examined 
MNT utilization among U.S. Veterans with established non-dialysis dependent stage 3-5 
chronic kidney disease (CKD-ND) during calendar year 2015. We hypothesized that 
utilization of MNT may be low and requires more attention.
Methods: We used data from the VA Corporate Data Warehouse which includes 
demographics, inpatient and outpatient encounter diagnosis and procedure codes and 
Current Procedural Terminology (CPT) codes] and patient labs. Since a percentage 
of Veterans receive their care from non-VA sources, we linked data from the Center for 
Medicare & Medicaid Services Medicare administrative databases to capture non-VA health 
care use. CKD status was based on presence of at least two estimated glomerular filtration 
rate (eGFR) values < 60 ml/min/1.73 m2 in outpatient laboratory data spaced 90+ days 
apart.
Results: There were 242,865 Veterans age 50 years with at least two eGFR 
<60 ml/min/1.73 m2 spaced 90+ days apart during calendar year 2014 with no history of 
dialysis or transplantation. Mean age was 76.4 years (standard deviation 9.6) and 96.7% 
were male and most were white with 14.9% reporting black race. During calendar year 
2015, only 9.6% of Veterans with stage 3-5 CKD-ND saw a VA dietician and 0.1% saw 
a Medicare reimbursed dietician. MNT utilization overall was significantly higher among 
black vs. whites (13.9% vs. 9.0%, p<0.001). Only 1.7% of Veterans with stage 3-5 CKD-
ND were enrolled in the VA MOVE! program designed to increase exercise.
Conclusions: Utilization of MNT is very low in U.S. Veterans with stage 3-5 CKD-
ND. Increasing utilization of MNT for patients with CKD-ND should be a priority for 
health systems in order to delay ESRD.
Funding: Veterans Affairs Support
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Temporal Changes in Nutritional Markers and Their Association with 
Mortality in Non-Dialysis Dependent CKD
Abhishek J. Patel,1 Mahmoud A. Mahmoud,3 Jawed Akhtar,1 Barry M. Wall,2 
Csaba P. Kovesdy.2 1University of Tennessee Health Science Center, Memphis, 
TN; 2Veterans Affairs Medical Center, Memphis, TN; 3University of Teneessee 
Health Science Center, Memphis, TN.
Background: The pathophysiology of protein-energy wasting (PEW) involves both 
decreased nutrient intake and increased catabolism. The temporal changes of different PEW 
components and their association with mortality in CKD are not well characterized.
Methods: We examined 234 US veterans with CKD stages 3-5. We assessed serially 
body weight (BW)/body mass index (BMI), and spot urine urea nitrogen creatinine ratio 
to estimate 24-hour urine urea nitrogen excretion and daily protein intake (DPI) using 
the Maroni formula. We estimated the slopes of DPI, BMI and eGFR vs. time in mixed 
effects models. The association of the slopes of DPI and BMI with all-cause mortality was 
examined in Cox models adjusted for age, gender, race, diabetes, eGFR and baseline DPI 
and BMI, respectively.
Results: Patients were 68.6±9.5 years old, 97% male, 38% African-American and 41% 
diabetic. Mean baseline eGFR, DPI and BMI were 33.1±12.1 ml/min/1.73m2, 0.41±0.15 g/
kgBW/day and 30.3±7.1 kg/m2, respectively. Patients had a median (25th-75th percentile) 
of 5 (3-8) measurements over a median follow-up time of 3.2 years, and 64 patients died 
(mortality rate 93/1000 patient-years, 95%CI: 73-119). Patients experienced modest but 
statistically significant decreases in eGFR and BMI over time, but no significant average 
change in DPI (Table). The slope of DPI was not associated with multivariable adjusted 
mortality risk (p=0.3), while increase in BMI was associated with a trend towards lower 
mortality (p=0.1, Figure).
Conclusions: Patients with moderately advanced CKD and relatively stable kidney 
function experienced small changes in BMI and stable protein intake over time. These 
modest changes in nutritional markers showed no association with all-cause mortality. 
Larger studies with longer follow-up are needed to better assess the effects of declining 
kidney function on different PEW components, and the effects of these changes on survival.
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Efficacy of Segmental Bioelectrical Impedance Analysis in Regular 
Nutritional Assessment in Autosomal Dominant Polycystic Kidney Disease
Hyunjin Ryu,1 Hayne C. Park,2 Hyunsuk Kim,3 Kook-Hwan Oh,1 Curie Ahn,1 
Yun Kyu Oh.4 1Seoul National University Hospital, JongNo-Gu, SEOUL, 
Republic of Korea; 2Kangnam Sacred Heart Hospital, Seoul, Republic of Korea; 
3Chuncheon Sacred Heart Hospital, Chuncheon, GANGWON-DO, Republic of 
Korea; 4Department of Internal Medicine, Boramae Medical Center, Seoul, 
Republic of Korea.
Background: Increased risk of malnutrition in autosomal dominant polycystic kidney 
disease (ADPKD) are found in patients with declined renal function and/or large abdominal 
cystic organ volume. Therefore regular nutritional assessment are important in ADPKD 
patients. Increased ratio of extracellular water to total body water (ECW/TBW) and 
decreased phase angle (PhA) are known malnutrition marker of bioelectrical impedance 
analysis (BIA). In this study, we analyzed the efficacy of BIA in the nutritional assessment 
follow-up compared to modified subjective global assessment (SGA) in ADPKD patients.
Methods: This is a prospective cohort study undertaken at a tertiary university hospital. 
Nutritional status were assessed with SGA and segmental BIA (Inbody S10) at the two visits 
of outpatient clinic between Dec. 2013 and Mar 2018. Height adjusted total kidney volume 
(htTKV) were calculated using ellipsoid method from CT scans of two visits.
Results: Total 135 patients were analyzed and 46.7% were female. At the initial visit, 
the mean age was 48.1±10.2 years and the mean eGFR was 62.8±21.7 mL/min/1.73m2. The 
median values of htTKV were 801 mL/m (IQR 495–1185 mL/m). Interval between two 
visits were 28.5±4.4 month. Between two visits, eGFR decreased (62.8±21.7→56.4±23.5 
mL/min/1.73m2, p<0.001) and htTKV increased (927.4±627.8→1235.8±868.0 mL/m, 
p<0.001). However there were no statistical difference in SGA score (6.7±0.6→6.6±0.7), 
weight, body mass index, serum albumin, and cholesterol level during follow-up. Among 
the segmental BIA parameters, ECW/TBW of whole body (0.384±0.007→0.386±0.007, 
p<0.001), trunk (0.383±0.007→0.386±0.008, p<0.001) and lower extremity 
(0.387±0.008→0.388±0.008 p=0.015) increased significantly. The lean mass of whole body 
(48.4±10.67→47.8±10.6 p<0.001), upper extremity (2.7±0.8→2.6±0.8 p=0.007) and trunk 
(22.1±4.8→21.8±4.9 p=0.001) and PhA of upper extremity (5.3±0.6→5.1±0.7 p<0.001), 
trunk (9.0±1.4→7.8±1.2 p<0.001) and lower extremity (5.3±0.8→5.2±0.8, p<0.001) 
decreased significantly during the follow up.
Conclusions: Increased ECW/TBW level and decreased lean mass and PhA were 
found in ADPKD patients during follow up. Using quantitative parameters of segmental 
BIA, clinician were able to monitor nutritional status of ADPKD patients more sensitively, 
in addition to laboratory data and SGA.
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Diet Dependent Systemic Acid Load (AL) Impacts Decline in Kidney 
Function Through Serum Albumin (SA)
Tanushree Banerjee,3 Anthony Sebastian,1 Neil R. Powe,2 Lynda A. Frassetto.1 
1University of California San Francisco, San Francisco, CA; 2Priscilla Chan 
and Mark Zuckerberg San Francisco Gen Hosp & UCSF, San Francisco, CA; 
3San Francisco General Hospital, San Francisco, CA.
Background: Inflammation may be present with CKD and diet composition may affect 
inflammation thereby impacting kidney health. Higher intakes of proteins and fats yielding 
a higher AL have been linked with worsening of kidney function and inflammation may 
play a role. We investigated whether AL estimated from urine measures is associated with 
kidney function decline and whether the effect of AL on an inflammatory marker, SA, is a 
pathway to this association.
Methods: We studied 188 post-menopausal women in a clinical trial of potassium 
bicarbonate treatment for up to 36 months. 24-hr urine and arterialized blood collections 
were done at baseline and at subsequent 3 month follow-up visits. AL was estimated 
from the urine potential renal acid load (UPRAL), calculated using measures of chloride, 
phosphate, sodium, potassium, calcium, and magnesium. Mixed effects (ME) model with 
random-intercept and slope was used to estimate subjects’ annual decline rate in creatinine 
clearance (CrCl) and eGFR. We used the ME model to estimate the association between 
(1) UPRAL and SA, and (2) SA and CrCl, adjusting for age, body mass index, systolic BP, 
and glucose. A Cox proportional regression model was used to study the relative hazard
for decline in CrCl with UPRAL, adjusting for potential covariates and baseline CrCl. Our 
models were repeated with eGFR decline as the outcome.
Results: A 25 mEq/day increase in UPRAL was inversely associated with SA (95% 
CI:–0.01[–0.09;-0.0001; p=0.05]). SA was inversely associated with CrCl (p<0.05). During 
28 months mean follow-up, 45 women (23.9%) had a rapid decline in kidney function 
(loss ≥5 ml CrCl/yr). For each 25 mEq/day increase in UPRAL, the risk of a rapid decline 
in CrCl increased by 17% (95% CI:1.06-1.28). Adjusting for potential confounders, the 
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risk attenuated to 5% (1.02-1.14). Mediation analysis indicated that of the total effect of the 
association between UPRAL and CrCl, the proportion mediated by SA was 0.32 (i.e. 32%). 
Using eGFR, the proportion mediated by SA increased to 0.41.
Conclusions: Higher UPRAL was associated with lower SA as well as reduced kidney 
function in post-menopausal women. Our findings suggest inflammatory response may 
exert a modulatory effect on the association of UPRAL and kidney function and might be a 
potential pathway to explain the effects of systemic AL on kidney function decline.
Funding: Commercial Support - Arm and Hammer
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Dietary Acid Load and the Risk of Metabolic Acidosis in Prevalent 
Hemodialysis Patients
Mi Jung Lee,1 Hyung Jong Kim,1 Jung Tak Park,2 Jung Pyo Lee,3 Yon Su Kim,4 
Yong-Lim Kim,5 Dong-Ryeol Ryu.6 1Bundang CHA Medical Center, CHA 
University, Seongnam, GYEONGGI-DO, Republic of Korea; 2Yonsei University 
Health System, Seodaemun-Gu, Seoul, Republic of Korea; 3Seoul National 
University Boramae Medical Center, Seoul, Republic of Korea; 4Seoul National 
University College of Medicine, Seoul, Republic of Korea; 5Kyungpook National 
University Hospital, Daegu, Republic of Korea; 6Ewha Womans University, 
Seoul, Republic of Korea.
Background: Metabolic acidosis is associated with protein energy wasting, bone 
disease, and higher mortality in end-stage renal disease (ESRD). Although higher dietary 
acid load can exacerbate metabolic acidosis, there is a lack of data evaluating their 
relationship in ESRD patients. Therefore, we investigated the association between dietary 
acid load and metabolic acidosis in ESRD patients undergoing hemodialysis (HD).
Methods: One hundred and eleven prevalent HD patients were included from the 
ESRD-Clinical Research Center (ESRD-CRC) cohort in South Korea. Dietary intake data 
were obtained from a self-reported food frequency questionnaire and a 7-day food diary. 
Dietary acid load was estimated using the equation for potential renal acid load (PRAL). 
Metabolic acidosis was defined as serum bicarbonate <22 mEq/L.
Results: The median value of PRAL was 9.97 (interquartile range, 4.45-14.06) mEq/
day. Metabolic acidosis was observed in 47 patients (42.3%). The independent association 
of PRAL with metabolic acidosis was analyzed by binary logistic regression analysis. 
Multivariable analysis indicated that higher PRAL was significantly associated with risk of 
metabolic acidosis after adjusting confounding factors (per 1 standard deviation increase, 
odds ratio=3.258, 95% confidence interval [CI]=1.106-9.599, P=0.03). Subsequent linear 
regression analysis was performed to find dietary behavior factors affecting PRAL. Higher 
intake of processed meat including ham, sausage, or bacon, was significantly associated with 
increased PRAL (per 1 intake/week increase, β=0.244, 95% CI for B=0.704-9.164, P=0.02).
Conclusions: PRAL was the independent risk factor for metabolic acidosis in prevalent 
HD patients, suggesting deleterious effect of higher dietary acid load. Therefore, dietary 
counseling or intervention to reduce processed meat intake may be helpful for management 
of metabolic acidosis in these patients.
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Comparison of Three Technology-Supported Behavioral Interventions for 
Phosphorus Management in Hemodialysis Patients
David E. St-Jules, David S. Goldfarb, Mary Lou Pompeii, Mary A. Sevick. NYU 
School of Medicine, New York, NY.
Background: Behavioral methods enhance the effectiveness of lifestyle interventions, 
but are often resource intensive. Although mobile health (mHealth) technology can help 
create lower input interventions, their feasibility, acceptability and efficacy have not been 
adequately evaluated in hemodialysis (HD) patients.
Methods: Maintenance HD patients with persistent hyperphosphatemia (n=40) 
were randomized to receive: (1) educational (Edu) videos (EDU), (2) Edu + mobile self-
monitoring (SM) with MyNetDiary® (MON), or (3) Edu + SM + social cognitive theory 
(SCT)-based behavioral counseling videos (SCT) over a 12-week period with videos for 
each group delivered using iPads. Serum phosphorus concentrations (sPO4) were measured 
at baseline, 12 and 24 weeks, and a 5-point Likert scale survey on the mHealth technology 
was completed at 24-weeks. Two participants in the EDU group with no follow-up sPO4 
measurements were excluded; missing sPO4 measurements at 12- and 24-weeks were 
imputed by carrying forward the most recent sPO4 values.
Results: At the end of the intervention phase (12-weeks), there was a non-significant 
trend towards greater decreases in sPO4 in the MON (-0.5±1.6 mg/dL, p=0.32) and SCT 
(-0.3±2.1 mg/dL, p=0.56) groups compared to the EDU group (+0.2±1.4 mg/dL), but these 
differences had mostly disappeared by the end of the monitoring phase (24-weeks) (EDU 
+0.1±1.2 mg/dL, MON -0.1±1.9 mg/dL, SCT -0.1±2.1 mg/dL). Most participants agreed or 
strongly agreed that the iPads were convenient (64%), and SM helped them stay motivated
(68%), take binders (61%), and limit phosphorus intake (68%). Relatively few participants 
reported that they agreed or strongly agreed that they sometimes “got lost” maneuvering
the iPad programs (24%), felt that SM wasn’t worthwhile (16%), or would have preferred 
face-to-face meetings offsite (4%).
Conclusions: Many HD patients are willing, able and report benefits of engaging in 
technology-supported behavioral interventions involving SM and SCT. Although these 
programs are easy to disseminate with limited resources once developed, any benefits for 
phosphorus management in HD patients may last only as long as the intervention is active.
Funding: NIDDK Support
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Association Between Healthy Diet Score and Kidney Function: A 
Population-Based Survey
Suzanne Dominique Genest,1 Myriam Khalili,3 Remi Goupil,2 Amelie Bernier-
Jean,4 Josee Bouchard,2 Stephan Troyanov,2 Francois Madore.2 1Université de 
Montréal, Montreal, QC, Canada; 2Hopital du Sacre-Coeur de Montreal, 
Montreal, AB, Canada; 3University of Montreal, Montreal, QC, Canada; 4The 
University of Sydney, Westmead, NSW, Australia.
Background: While it is recognised that a healthy diet can reduce the risk of 
cardiovascular disease, dietary risk factors for chronic kidney disease remain relatively 
undetermined. This study aimed to assess the association between the American Heart 
Association’s (AHA) healthy diet score and estimated glomerular filtration rate (eGFR).
Methods: The present study is a survey of random adults between 40 and 69 years-
old. Diet was assessed using the NIH Diet History Questionnaire II. We determined the 
association between eGFR (CKD-EPI equation) and the overall AHA diet score (based 
on five components: fruits and vegetables, fish, fiber, sodium and sugar-sweetened 
beverages), using linear regression models adjusted for important confounders, including 
age, sex, income, education, caloric intake, smoking, physical activity, body mass index, 
hypertension, dyslipidemia, diabetes and cardiovascular disease. We also studied the 
association between eGFR and protein intake.
Results: The Diet History Questionnaire was completed by 8,128 participants. Mean 
age was 55.3 ± 7.7 years and mean eGFR was 86.9 ± 14.6mL/min/1.73m2. Overall AHA 
healthy diet score was positively associated with eGFR (p<0.001), after adjusting for 
potential confounders (listed above). Upon analyzing individual food components, the 
intake of fruits and vegetables, fish and fiber were associated with improved eGFR, after 
adjustment for age and sex (cf. table). After further adjustment for confounders, fruits and 
vegetables consumption and dietary fiber intake remained significantly associated with a 
higher eGFR, while fish consumption was no longer significant (cf. table). Protein intake 
was not significantly associated with eGFR.
Conclusions: Among the five dietary components of the AHA healthy diet score, fiber, 
and to a lesser extent fruits and vegetables, are significantly associated with a higher eGFR 
in this population-based survey.
Funding: Government Support - Non-U.S.
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Nutrition Information: What Resources Are Used by Patients?
Rachel B. Fissell,1 Zongyang Mou,2 Laura Binari,1 Khaled Abdel-Kader.1 
1Vanderbilt University Medical Center, Nashville, TN; 2University of California 
San Diego, San Diego, CA.
Background: It can be challenging for CKD pts to choose safe and healthy foods, partly 
because of complex dietary recommendations. There are many potential sources of dietary 
information, including physicians, other pts, dieticians, paper handouts, and the internet. 
Patients who are empowered and educated about food choices may be more adherent to 
a prescribed diet. This study surveys patient use of paper and electronic resources to learn 
about diet, focusing on potassium.
Methods: CKD pts were enrolled during outpatient clinic visits, given a survey 
assessing knowledge of potassium in foods, and preferences for dietary information 
sources. Pts were then provided with one handout with written information, and one 
handout with three investigator curated dietary websites. A second survey was administered 
several weeks later, reassessing pt knowledge about high potassium foods and pt preference 
for sources of information.
Results: N=110 responses were analyzed. Mean age was 58.8 yrs, with median 59.5 
yrs, and range 28-83 yrs. The sample was 46% female, and 43% diabetic. Distribution 
of kidney stages were 2: 5%, 3: 50%, 4: 22%, 5: 22%. Pt percentages that were not sure, 
somewhat sure, and very sure that they could choose low potassium foods were 40%, 40%, 
and 20%, respectively. 66% of pts knew orange juice has more potassium than apple juice, 
5% thought apple juice has more potassium than orange juice, and 29% were unsure. 24% 
knew whole wheat bread has more potassium than white bread, 38% thought white bread 
has more potassium than whole wheat bread, and 38% were unsure. 49% preferred paper 
handouts, 75% preferred internet videos or websites (answers not mutually exclusive). 
Preference for use of websites decreased with older age. For every 10yr increase in age, the 
odds of preferring websites decreased by 27% (OR 0.23, 95% CI 0.54, 0.98).
Conclusions: This sample shows variation in knowledge about high potassium foods, 
and variation in patient-perceived ability to choose low potassium foods. Although it was 
not surprising that older patients preferred paper handouts over the internet, the percentage 
of patients who used the internet as an information source for diet was quite high. These 
initial results suggest areas for improved pt nutrition education, and indicate a need for 
readily available and accurate paper and internet resources.
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Salt-Related Knowledge, Attitudes, and Compliance in CKD on Dialysis 
and Heart Failure
Michael Cinelli,1 Samer Saouma,1 Sassine Ghanem,1 Sami U. Hossri,1 
Nicholas Fuca,1 Julie Zaidan,2 Thomas J. Vazzana,1 James Lafferty,1 
Suzanne E. El Sayegh.1 1Staten Island University Hospital, Staten Island, NY; 
2Northwell health, Staten island, NY.
Background: Evidence of the adverse effect of high dietary sodium on the kidney 
and heart is growing. The WHO, CDC and AHA recommend consumption of <2, <2.3 
and <1.5 g/day, respectively. Despite efforts, general and high-risk patient(HF and ESRD) 
compliance remains low. The primary aim of our study is to evaluate Na intake in HF and 
ESRD and correlate it with label-reading ability.
Methods: This cross-sectional study recruited patients with ESRD and HF inpatient 
at Staten Island University Hospital from September 2017-March 2018. A Block Sodium 
Screener © estimated daily Na intake and a questionnaire asked about shopping habits and 
label-reading proficiency with Likert scale conversion to a score(6-30). Subjects were 
grouped based on score, daily Na intake: <1500 mg/day or ≥1500 mg/day. Characteristics 
were analyzed using Student’s t-test, nonparametric Mann-Whitney U test, or χ2 test then 
linear regression to evaluate the relationship between Na intake and score.
Results: We recruited 61 patients: 34 ESRD, 14 HF and 13 both. We found a negative 
correlation between Na intake and score(R= -0.49, p<0.0001, Figure 1). There was no 
difference in age, BMI and gender among the 2 groups. Compliant patients had less years 
since diagnosis(2.70 +/-1.16 vs. 5.05 +/-5.75; p=0.0205). Other variables did not show any 
association with Na intake(Table 1).
Conclusions: This study showed that more knowledge about salt content and better 
shopping habits are associated with a lower daily Na intake in high risk populations(ESRD 
and HF). A larger sample is needed to evaluate for patient demographic and medical 
characteristics associated with non-compliance to low Na diet.
Table 1: Patient characteristics
Figure 1: Relationship of Na intake and label-reading score
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Long Chain Omega-3 Polyunsaturated Fatty Acids and Patient Important 
Outcomes in CKD: A Systematic Review and Meta-Analysis of Random-
ized Controlled Trials
Valeria M. Saglimbene,1,3 Germaine Wong,1 Anita van Zwieten,1 
Suetonia Palmer,2 Marinella Ruospo,3 Patrizia Natale,3,4 Jonathan C. Craig,1 
Giovanni F. Strippoli.4,3 1University of Sydney, Sydney, NSW, Australia; 
2University of Otago, Christchurch, New Zealand; 3Diaverum, Bari, Italy; 
4University of Bari, Bari, Italy.
Background: Long-chain omega-3 polyunsaturated fatty acid (n-3 PUFA) has 
recognised vascular benefits in the general population, but knowledge of supplementation 
among patients with CKD is largely restricted to vascular access outcomes.We aimed to 
assess the benefits and harms of n-3 PUFA therapy in patients with chronic kidney disease 
(CKD).
Methods: MEDLINE, Embase, CENTRAL and reference lists were searched up 
to January date, 2018. We included randomised controlled trials evaluating n-3 PUFA 
supplementation compared with placebo or standard care on cardiovascular and all-cause 
mortality, progression to end stage kidney disease (ESKD), acute transplant rejection, and 
graft loss. Risks of bias and evidence certainty were assessed using Cochrane and Grading 
of Recommendations Assessment, Development and Evaluation processes, respectively.
Results: Sixty studies (n=4129), median sample size of 41 participants (interquartile 
range 30 to74) and median follow-up duration of 6 months (3 to 12), were included. N-3 
PUFA reduced cardiovascular death (n=1,045; relative risk [95% confidence interval], 
0.45 [0.23, 0.89]; moderate evidence certainty) in dialysis patients, and progression to 
ESKD (n=170; 0.30 [0.09, 0.98]; very low evidence certainty) in patients with moderate 
to advanced stage CKD. Effects on all-cause mortality (n=1876; 1.05 [0.83, 1.33]; low 
evidence certainty); acute transplant rejection (n=543; 0.98 [0.80, 1.21]; low evidence 
certainty) and graft loss (n=434; 0.98 [0.54, 1.81]; very low evidence certainty) were 
uncertain. Risks of bleeding (n=770; 1.40 [0.78, 2.49]) and gastrointestinal side-effects 
(n=1455; 1.14 [0.79, 1.67]) were uncertain.
Conclusions: N-3 PUFA supplementation may protect patients on dialysis against 
cardiovascular mortality. It appeared to prevent ESKD in patients with moderate to 
advanced stage CKD but the evidence certainty was very limited.
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Impact of Dialysis Treatment Shift on Malnutrition Indicators
Juan J. Carrero,4,2 Adam M. Zawada,1 Katharina Brand,1 Stefano Stuard,1 
Bernard J. Canaud,1 Adelheid Gauly,1 Anke Winter,1 Denis Fouque.4,3 1Fresenius 
Medical Care, Bad Homburg, Germany; 2Karolinska Institutet, Stockholm, 
Sweden; 3University Claude Bernard, Pierre Benite, France; 4European Renal 
Nutrition working group, ERA-EDTA, Italy.
Background: Malnutrition is strongly associated with morbidity and mortality among 
hemodialysis patients. It has been a long-term clinical concern that patients on afternoon 
shifts (AS) are more prone to malnutrition than those on morning shifts (MS), as their 
dialysis scheme and post-dialysis symptoms interfere with their meal intake. Thus, we 
evaluate the role of dialysis shifts on malnutrition indicators.
Methods: We conducted a retrospective study among 9.963 incident hemodialysis 
NephroCare patients using 2011-2016 European Clinical Database data. Linear mixed 
models were used to compare the course of Body Composition Monitor assessed lean and 
fat tissue index (LTI, FTI) between MS and AS patients over 2 years. These models included 
fixed effects (age, sex, vascular access, diabetes mellitus) and random effects (country, 
patient). Secondary malnutrition indicators were body mass index, albumin, creatinine and 
normalized protein catabolic rate.
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Results: Patients had a mean age of 63.6 years, 41.8% were female and 29.9% were 
diabetic. Mean baseline LTI and FTI levels were comparable between MS (LTI: 12.5±2.9kg/m2; 
FTI: 13.7±6.0kg/m2) and AS (LTI: 12.4±2.9kg/m2; FTI: 13.2±6.1kg/m2) patients. During 
follow-up LTI slightly decreased and FTI constantly increased in both groups with a mean 
absolute change (baseline-24months) of -0.3 kg/m2 for LTI and +1.0 kg/m2 for FTI (Figure 1). 
The course of these malnutrition indicators did not differ between dialysis shift groups 
(Treatment x time interaction p-values ≥0.10). We did not observe substantial differences 
between groups when descriptively evaluating secondary malnutrition indicators.
Conclusions: Dialysis shift does not seem to impact long-term nutritional status of 
dialysis patients and may not represent a modifiable risk factor.
Funding: Commercial Support - Fresenius Medical Care
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Eicosapentaenoic Acid (EPA) Powerfully Prevents the Progression for 
Both Renal Dysfunction and Atherosclerosis in CKD Patients Due to 
Benign Nephrosclerosis
Yoshihiko Inoue,2 Eri Kawashima,1 Kiyoko Inui,2 Ashio Yoshimura,3 
Fumihiko Koiwa.2 1Showa University Fujigaoka Hospital, Yokohama, Japan; 
2Division of Nephrology, Department of Medicine, Showa University Fujigaoka 
Hospital, Yokohama, Japan; 3Shinyokohama Daiichi Clinic, Yokohama, Japan.
Background: Effect of EPA for CKD patients is not fully known. We studied the 
efficacy of EPA to prevent the progression of both renal impairment and atherosclerosis in 
CKD stage 3-4 patients due to benign nephrosclerosis (BNS).
Methods: 28 CKD stage 3-4 patients due to BNS with dyslipidemia were followed for 
5years after the start of EPA treatment (EPA (+): n=20) or treatment without EPA (EPA (-): 
n=8). The dosage of 1800 mg/day of EPA was newly prescribed in EPA treatment group. 
T-cho, LDL-cho, Triglycerides (TG), eGFR, the amount of proteinuria, EPA, arachidonic
acid (AA), Dihomo-gamma-linolenic acid (DGLA) and docosa hexaenoic acid (DHA)
were examined. Both right and left (RL) brachial-ankle pulse wave velocity (baPWV), 
RL maximum carotid intima-media thickness (max IMT), RL maximum carotid plaque
thickness and RL ankle-brachial index (ABI) were evaluated at before treatment (baseline), 
after every year and at the end of the study (5-year).
Results: EPA, EPA/AA ratio, TG. RL baPWV, and RL max IMT showed significant 
improvement and eGFR did not decrease at 5-year in EPA treatment group (table 1). 
Furthermore, both EPA and DHA levels were significantly low in eGFR exacerbation 
patients group (n=7) compared with the improvement group (n=13) at both baseline and 
5-year in EPA treatment group. EPA treatment patients showing the highest EPA levels at
baseline (EPA: 107.5±15.2μg/ml, n=5) showed significant improvement in both eGFR and 
baPWV compared with those with the lowest EPA levels (31.0±9.2 μg/ml, n=5). There was 
no difference on both plaque thickness and ABI between baseline and 5-year.
Conclusions: EPA powerfully prevents the progression of both renal dysfunction and 
the atherosclerotic change in CKD stage 3-4 patients due to BNS.
Table 1
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Effect of Intra-Dialysis Nutrients Admixture vs Conventional Intra-Dialy-
sis Parenteral Nutrition on Nutrition Status and Inflammation in 
Malnourished Hemodialysis Patients
Ouppatham Supasyndh, Wongsakorn Boonkarn, Theerasak Tangwonglert, 
Pamila Tasanavipas, Amnart Chaiprasert, Naowanit Nata, Bancha Satirapoj. 
Phramongkutklao hospital, Bangkok, Thailand.
Background: Protein/caloric malnutrition and inflammation is a major problem in 
long-term hemodialysis patients. Total nutrients admixture containing 80% olive oil-base 
intravenous lipid emulsions and low proportion of polyunsaturated fatty acids may offer 
several advantages such as a reduction of oxidative and inflammatory effects in end stage 
renal disease (ESRD).
Methods: The study was a randomized controlled trial; patients with malnourished 
ESRD on hemodialysis were randomly assigned into an admixture-IDPN group (n=13) 
and a conventional-IDPN group (n=13). Nutritional assessment, and inflammatory markers 
including high sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were 
measured at baseline and 4 weeks following intervention.
Results: At the end of 4-week, nutritional parameters including serum albumin 
(0.41±0.18 vs 0.16±0.22, P=0.004), pre-albumin (7.88±4.6 vs. 2.01±2.63. P=0.001) and 
urea reduction ratio (2.92±0.76 vs 0.92±2.78, P=0.026) in the admixture-IDPN group have 
a significantly greater improvement than the conventional-IDPN group. The decline in 
serum IL-6 levels was -13.9 pg/mL larger among admixture-IDPN vs conventional-IDPN 
group (95% CI -20.41 to -7.4 pg/mL). The admixture-IDPN group had also higher absolute 
lymphocyte counts and lower hs-CRP levels after treatment, but there were no significant 
changes in the conventional-IDPN group. There were no statistically significant differences 
between the two groups in the risk of electrolytes abnormalities and adverse events.
Conclusions: Malnourished ESRD patients on dialysis receiving olive oil-base lipid 
emulsions and low polyunsaturated fatty acids IDPN resulted in modest improvements in 
nutritional status and inflammatory cytokines.
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1500-Day All-Cause Mortality and Carnitine Profile in Hemodialysis 
Patients
Daigo Kamei,1 Yuiko Kamei,2 Ken Tsuchiya,1 Kosaku Nitta,1 Michio Mineshima.1 
1Tokyo Women’s Medical University, Tokyo, Japan; 2Tokyo Metropolitan Health 
and Medical Treatment Corporation, Tokyo, Japan.
Background: Patients on dialysis are in a chronic carnitine-deficient state. This 
condition may be associated with abnormalities of the fatty acid and organic acid 
metabolisms. Carnitine is required for β-oxidation of the long-chain fatty acids; therefore, 
carnitine deficiency decreases the efficiency of ATP synthesis and may incur death. 
However, the details of this association remain unknown. We examined the relationship 
between β-oxidation efficiency represented by the carnitine profile and 1500-day all-cause 
mortality in hemodialysis patients.
Methods: The carnitine profiles of 122 hemodialysis patients were determined by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The associations between 
1500-day all-cause mortality and carnitine profile as well as the clinical backgrounds of 
the patients were investigated. A survival analysis was conducted by the Kaplan-Meier 
survival method and multivariate Cox proportional hazard analysis. The bootstrap method 
was performed to confirm the stability and robustness of our model.
Results: Of the 122 subjects analyzed, 111 were selected and 24 died during the 
observation period. Stepwise multivariate Cox regression demonstrated that diabetes state 
[p < 0.001, exp(β) = 4.981], age [p = 0.006, exp (β) = 1.052], and the acetylcarnitine/
(palmitoylcarnitine+octadecenoylcarnitine) [C2/(C16+C18:1)] ratio [p < 0.001, exp(β) = 0.937] 
were independent significant factors of 1500-day all-cause mortality. The bootstrap method 
confirmed the significance of these three factors.
Conclusions: The 1500-day all-cause mortality negatively correlated with the C2/
(C16+C18:1) ratio. Improvement of the impaired β-oxidation state after L-carnitine 
administration may ameliorate prognosis.
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Ketosteril Prolongs Predialytic Diabetic Nephropathy Patients’ Survival: 
A Nationwide Population-Based Study
Heng-chih Pan,1 Hsing-Yu Chen,2 Chiao-Yin Sun.1 1Chang Gung Memorial 
Hospital, Taipei, Taiwan; 2Chang-Gung Memorial Hospital, Taoyuan City, 
Taiwan.
Background: Metabolic changes in chronic kidney disease contribute to poor survival. 
Accumulated evidences indicate that dietary supplementation with branched-chain amino 
acids exerts a variety of beneficial effects in diabetic animals and humans. The aim of this 
study was to find out possible impact of Ketosteril supplement on survival of diabetic 
patients under predialysis status.
Methods: We analyzed a nationwide cohort from Taiwan’s National Health Insurance 
Research Database, to study the long-term impact of Ketosteril supplement in predialytic 
diabetic nephropathy patients. We enrolled 14257 out of 1,000,000 random subjects with 
diabetic nephropathy and predialysis status between January 1, 2004, and December 31, 
2007. Patients who ever received Ketosteril therapy after confirmation of predialysis status 
were defined as Ketosteril users. All patients were followed-up for 5 years after entering 
predialysis status. The study endpoints were all-cause mortality and occurrence of stroke, 
congestive heart failure, and chronic dialysis.
Results: The prevalence of Keosteril usage in diabetic nephropathy patients with 
predialysis status was 2.72%. The 5 yrs all-cause mortality of Ketosteril users was 
significantly lower than that of non-users (33.7% vs 46.5%, p < 0.001). After adjustment 
for known risk factors, the Ketosteril users had significantly lower risk for mortality (hazard 
ratio:0.61, 95% confidence interval: 0.50-0.75, p < 0.001). When further stratified according 
to age, hazard ratios of mortality were 0.73 and 0.49 among patients who younger and older 
than 70 years, respectively.
Conclusions: Predialytic diabetic nephropathy patients who received Ketosteril 
supplement had a significantly prolonged survival. This study suggests Ketosteril might be 
a therapeutic choice to prolong the survival of predialytic patients.
Figure 1. Ketosteril prolongs the survival of predialytic diabetic nephropathy patients. A. 
Taiwan’s National Health Insurance Research Database study flow chart. B. 5 yrs all-cause 
mortality.
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Adequate Protein Supplementation for Hospitalized Dialysis Patients
Adhish Agarwal,1 Jennifer E. Schmidt,2 Faris A. Ahmed,1 Carissa Christensen.3 
1University of Utah, Salt Lake City, UT; 2University of Utah Hospital, Salt Lake 
City, UT; 3University of Utah HEALTH, Salt Lake City, UT.
Background: A high protein diet (1.2 gm/kg/day) is recommended for dialysis 
patients1. It is important for hospitalized dialysis patients to receive a high protein diet since 
inadequate protein intake worsens outcomes in hospitalized dialysis patients2,3. However, 
chronic kidney disease (CKD) patients who are not on dialysis may benefit from a protein 
restricted ‘renal diet’4. Hospitalized dialysis patients could inadvertently receive a protein-
restricted diet if placed on a ‘renal diet’ intended for CKD patients.
Methods: At the University of Utah Hospital, patients with CKD, including dialysis 
patients, were commonly placed on a ‘Renal diet’ that consisted of a 60 gm per day protein-
restriction. The University of Utah uses EPIC software that has a template for ‘Renal diet’. 
In order to provide dialysis patients with adequate protein, we approached the Nutrition 
Care Services Department with recommendations to modify this template, to allow for 
the option of either increasing protein supplementation for dialysis patients, or restricting 
protein to 60 g/day for patients with CKD but not on dialysis.
Results: In collaboration with the EPIC software team at the University of Utah 
Hospital, the ‘Renal diet’ template was modified. When placing this diet order, providers 
still choose a ‘Renal diet’ but now are required to select a modifier of either ‘Dialysis’ or 
‘Non-Dialysis’. Choosing the ‘Dialysis’ option provides the patient with a higher protein 
diet. In the 12 months preceding this template modification, providers ordered a ‘Renal diet’ 
1594 times at our hospital. In the week following the modification, half of the ‘Renal diet’ 
orders (13 out of 26) had the ‘Dialysis’ modifier resulting in an appropriate higher protein 
diet given to dialysis patients. Modifying the EPIC template for ‘Renal diet’ has helped the 
dialysis patients admitted to our facility receive an appropriate higher protein diet.
Conclusions: We recommend that all acute care hospitals around the country examine 
their ‘Renal diet’ order templates; and modify renal diet templates, when necessary, to 
ensure an adequate protein diet for hospitalized dialysis patients.
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Impact of Patient Awareness and Age on Serum Albumin in Chronic 
Hemodialysis Patients
Shehabaldeen M. Alanazi,1 Ezzedine Abderrahim,1 Wisam H. Al-Badr,1 
Abdulkareem Alsuwaida,1 Suad Abdulaziz,1 Amani M. Shams,1 
Riham A. Albalbisi,1 Saad S. Alobaili,1 Ibrahim A. Jubran,1 Abdullah Kashgary.1,2 
1DaVita-Saudi Arabia, Riyadh, Saudi Arabia; 2King Abdulaziz University, 
Jeddah, Saudi Arabia.
Background: Hypoalbuminemia is associated with cardiovascular death in patients 
on maintenance hemodialysis (HD) and is a marker of malnutrition–inflammation complex 
syndrome. In addition to dialysis adequacy, serum albumin is influenced by socioeconomic 
status and level of education and awareness regarding dietary requirements. The aim of 
our study was to identify potential factors determining hypoalbuminemia in population of 
prevalent HD patients in Saudi Arabia.
Methods: The study included 372 prevalent patients receiving maintenance HD 
at DaVita-KSA (215 female, 157 male). Mean age was 54.4 ± 17.2 years. The study 
population was divided into two groups based on serum albumin recorded in Feb 2018 (G1: 
≤3.5 g/dL, G2: >3.5 g/dL) and parameters of socioeconomic status, food preparation/intake,
and dialysis adequacy were assessed. We performed multiple logistic regression analysis to 
identify parameters that were independently associated with serum albumin level.
Results: There were 160 patients in G1 and 212 in G2 with no significant difference 
between males and females. In univariate analysis, factors found to be associated with 
hypoalbuminemia were: old age, low level of education, diabetes, short ESRD duration 
and lack of diet awareness. Patients in G2 had higher levels of serum creatinine, potassium, 
phosphorus, nPCR, and hemoglobin, and greater gain in dry weight. There were no 
significant differences between groups with respect to other socioeconomic factors or 
food intake. Multivariate analysis revealed that old age (RR: 1.032/year; 95% CI [1.017-
1.047]) and diet awareness (RR: 1.2; 95% CI [1.0.2-1.36]), were independent predictors of 
hypoalbuminemia.
Conclusions: In our study, hypoalbuminemia correlated with age and level of diet 
compliance, which itself is determined by the education level of HD patients. Lower serum 
albumin is also associated with weight loss without correlation with monthly income or 
other socioeconomic factors.
Funding: Commercial Support - DaVita
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Clinician Attitudes Toward Lowering Sodium Intake
Manavi Bhagwat,1 Devasmita Choudhury.2 1Virginia Tech Carilion School of 
Medicine, Roanoke, VA; 2Salem VA Medical Center, University of Virginia, 
Virginia Tech Carilion School of Medicine, Salem, VA.
Background: Lowering dietary sodium (Na) intake is of utmost importance for 
patients with hypertension (HTN), kidney, liver, and heart disease particularly when there 
is evidence for fluid retention, but patient adherence to low Na diets is suboptimal. Primary 
care practitioner (PCP) attitudes and prescription of low Na diets can impact adherence. 
To understand PCP attitudes, prescription and follow up of low Na diets, we administered 
a brief survey.
Methods: An email 8-question survey was sent to all 234 PCPs at the Salem VA 
Medical Center (Salem VAMC) and at Carilion Roanoke Memorial Hospital (CRMH) 
clinics. Questions asked PCP attitudes towards recommending Na restriction for medical 
conditions including HTN, kidney disease (KD), and lower extremity edema. Survey also 
queried PCP processes to determine dietary adherence.
Results: We received 57 responses (41 MD/DO, 16 PA/NP) with a 45% response rate 
at Salem VAMC and 40% at CRMH. PCPs self-reported varied diet instruction practices 
(Fig 1). 54% of respondents recommend patients with KD follow a low Na diet and 45% 
personally instruct patients on following a low Na diet. 13% of respondents gave KD 
patients dietitian referrals for low Na diet instruction. PCPs mostly checked adherence by 
asking hypertensive patients if they follow a low Na diet (Fig 2).
Conclusions: Of PCP respondents, 46% never discuss or prescribe a low Na diet to 
patients that can benefit from it. Of those that discuss or prescribe a low Na diet, <20% made 
a nutrition referral. There is also limited effort with dietary adherence follow up. Given 
significant variability in PCP practices and attitudes towards low Na diet prescription, 
suboptimal low Na diet adherence in patients is expected. Improving low Na diet instruction 
at PCP level can impact key patient risks factors for renal and cardiovascular morbidity.
Fig 1. Reported PCP frequency of low Na diet instruction to hypertensive pts
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Fig 2. Self-reported methods of determining adherence to low Na diet
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The Impact of Pre-ESRD Testosterone Level upon Post-ESRD Mortality 
Among US Male Veterans: A Transition of Care in CKD Study
Jui-Ting Hsiung,2 Elani Streja,3 Amy S. You,2 Praveen Kumar Potukuchi,4 
Melissa Soohoo,5 Danh V. Nguyen,2 Alpesh Amin,6 John J. Sim,8 
Csaba P. Kovesdy,4 Kamyar Kalantar-Zadeh,7 Connie Rhee.1 1University of 
California Irvine, Huntington Beach, CA; 2University of California, Irvine, 
Orange, CA; 3Harold Simmons Center for Kidney Disease Research and 
Epidemiology, Orange, CA; 4University of Tennessee Health Science Center, 
Memphis, TN; 5University of California at Irvine, Orange, CA; 6UC Irvine, 
Orange, CA; 7University of California Irvine, School of Medicine, Orange, CA; 
8Kaiser Permanente Southern California, Los Angeles, CA.
Background: Testosterone deficiency is a common endocrine complication in the 
elderly male population, with a disproportionately high prevalence observed in those with 
chronic kidney disease (CKD). While lower circulating levels of testosterone have been 
linked with higher risk of cardiovascular disease and death in the general population, little 
is known about the impact of testosterone deficiency upon the health and survival of non-
dialysis dependent (NDD) CKD patients transitioning to end-stage renal disease (ESRD).
Methods: Among a national cohort of male US veterans with NDD-CKD transitioning 
to ESRD over 2007-15, we examined the association of total testosterone levels averaged 
over the two-year pre-ESRD prelude period with post-ESRD mortality risk using Cox 
models adjusted for sociodemographics, cause of ESRD, Charlson comorbidity score, and 
comorbidities.
Results: Among 1219 veterans who underwent one or more total testosterone 
measurements in the two-year prelude period, those in the lowest testosterone tertile had 
higher mortality risk in expanded case-mix models (ref: highest tertile): adjusted HR 
(aHR) (95%CI) 1.31 (1.07-1.62) (Figure). A similar relationship between the lowest total 
testosterone tertile and higher death risk was observed when measurements were examined 
over six-month and one-year prelude periods: aHRs (95%CI): 1.70 (1.16-2.49) and 1.46 
(1.11-1.93), respectively.
Conclusions: In male US veterans transitioning to dialysis, lower total testosterone 
levels in the pre-ESRD prelude period were associated with higher post-ESRD mortality 
risk. Further studies are needed to determine the specific underlying pathways between 
testosterone deficiency and mortality in this population, and whether administration of 
testosterone replacement therapy in the pre-ESRD prelude period can improve post-ESRD 
outcomes.
Funding: NIDDK Support
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Association Between Pre-ESRD Phosphodiesterase Type 5 Inhibitors Use 
and Post-ESRD Mortality
Praveen Kumar Potukuchi,1 Abduzhappar Gaipov,1 Keiichi Sumida,2 
Miklos Z. Molnar,1 Fridtjof Thomas,1 Justin Gatwood,1 Elani Streja,3 
Connie Rhee,4 Kamyar Kalantar-Zadeh,4 Csaba P. Kovesdy.1 1University of 
Tennessee Health Science Center, Memphis, TN; 2Nephrology Center, 
Toranomon Hospital Kajigaya, Kawasaki, Japan; 3Harold Simmons Center for 
Kidney Disease Research and Epidemiology, Orange, CA; 4University of 
California Irvine, School of Medicine, Orange, CA.
Background: Phosphodiesterase 5 inhibitors (PDE5i) are widely used to treat erectile 
dysfunction. Due to their vasodilatory properties, PDE5i may have systemic benefits, but 
information about the association between PDE5i and mortality in end-stage renal disease 
is lacking.
Methods: In a contemporary national cohort of 6,299 male US veterans with incident 
ESRD, we compared patients who received PDE5i treatment within 1 year prior to dialysis 
initiation to patients with a diagnosis of erectile dysfunction who did not receive PDE5i 
therapy. The association between PDE5i use (compared to non-use) and 1-year all-cause 
mortality after transition to ESRD were assessed using Cox proportional hazards models 
adjusted for sociodemographics, comorbidities, baseline vital parameters, and medication use.
Results: The mean age of the cohort was 65±10 years, 51% were white, 46% were 
African Americans, and 78% were diabetic. 2,212 (35%) patients received PDE5i 
treatment. PDE5i users displayed lower mortality than the non-users [Figure, unadjusted 
hazard ratio (95%CI): 0.80 (0.71-0.90, p<0.001)], but the survival advantage was attenuated 
after multivariable adjustments [0.93 (0.76-1.08, p=0.31)].
Conclusions: Pre-ESRD phosphodiesterase type 5 inhibitor use for erectile dysfunction 
was not associated with post-ESRD mortality. Further clinical studies are needed to study 
the effects of PDE5i use to determine its potential benefits in patients with ESRD.
Funding: NIDDK Support, Veterans Affairs Support
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Clinical Predictors for the Incidence of Severe Acute Pyelonephritis 
During Antepartum Based on National Health Examination Data
Gang Jee Ko,1 Shin-Young Ahn,1 Eunjung Cho,1 Young-Joo Kwon,1 Geum 
joon Cho.2 1Department of Internal Medicine, Korea University College of 
Medicine, Guro Hospital, Seoul, Republic of Korea; 2Department of Obstetric 
and Gynecology, Korea University College of Medicine, Guro Hospital, Seoul, 
Republic of Korea.
Background: Acute pyelonephritis is common during pregnancy, and increases the 
risk of maternal and fetal outcome. However, it has not been clearly revealed yet which 
demographic and clinical characteristics are associated with the incidence of acute 
pyelonephritis during pregnancy
Methods: Study data were collected from the Korea National Health Insurance Claims 
Database of the Health Insurance Review and Assessment Service. Women who had 
delivery between 2010 and 2014 in Korea and received health examination prior within one 
year of pregnancy were enrolled. A model of multivariate logistic regression analysis was 
performed to evaluate the risk of acute pyelonephritis during pregnancy.
Results: The mean±SD age of the overall cohort of 370,248 women was 31±4 years. 
The incidence of acute pyelonephritis (APN) treated under hospitalization was 2,526 
patients (0.7%). In multivariate logistic regression analysis, younger age (OR 0.93 for every 
5 years increase, 95% CI, 0.88-0.98), previous history of APN within one year of pregnancy 
(OR 9.37, 95% CI, 8.26-10.64), and abnormal results of health examination such as high 
fasting glucose without history of diabetes (>100mg/dL, OR 2.06, 95% CI, 1.41-2.99) and 
proteinuria (OR 1.81, 95% CI, 1.16-2.83) were associated with increasing risk of acute 
pyelonephritis during pregnancy.
Conclusions: Certain maternal demographic and clinical characteristics were 
associated with the incidence of acute pyelonephritis during pregnancy, and they should be 
monitored closely during antenatal care.
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The Effects of Restricted Protein Diet Supplemented with Keto-Analogue 
on Renal Function, Nutritional Status, and CKD-Mineral and Bone 
Disorder in CKD Patients: A Meta-Analysis
Paweena Susantitaphong,1 Api Chewcharat,1 Kullaya Takkavatakarn,2 
Sasitorn Wongrattanagorn,1 Krissana Panrong,3 Piyawan Kittiskulnam,4 
Somchai Eiam-Ong,1 Kearkiat Praditpornsilpa.1 1Chulalongkorn University, 
Bangkok, Thailand; 2Division of Nephrology, King Chulalongkorn Memorial 
hospital, Bangkok, Thailand; 3King Chulalongkorn Memorial Hospital, 
Bangkok, Thailand; 4Chulalongkorn university, Bangkok, Thailand.
Background: The prevalence of CKD and its complications are incessantly increasing. 
The important strategies are how to delay the progression of CKD and postpone renal 
replacement therapy. Dietary protein restriction(low or very low protein diet) with or 
without KA supplement might slow down the rate of renal function declination without 
increasing the risk of malnutrition. We aimed to evaluate the efficacy and side effects of 
restricted protein diet supplemented with KA on the treatment of CKD.
Methods: A literature search was performed via PubMed, Scopus, Cochrane Central 
Register of Controlled Trials and ClinicalTrials.gov from January 1960 to May 2018 to 
identify randomized controlled trials(RCTs) which explored the effects of restricted protein 
diet with KA on slowing progression of CKD, nutritional status, and CKD-MBD. Random-
effect model was used to compute the weighted mean difference (WMD) for continuous 
variables.
Results: Seventeen RCTs with 1,475 participants were included in our meta-
analysis. Restricted protein diet with KA supplementation significantly improved 
estimated GFR (WMD = 3.14 mL/min/1.73m2 (0.68, 5.61), P=0.013), reduced proteinuria 
(WMD = -0.86 g/d (-1.71, -0.02), P = 0.046), serum phosphate (WMD = -0.68 mg/dl (-1.02, -0.33), 
P < 0.001), parathyroid hormone level (WMD = -73.70 pg/mL(-132.79, -14.61), P = 
0.015), systolic blood pressure (WMD = -4.96 mmHg (-8.03, -1.90), P = 0.002), diastolic 
blood pressure (WMD = -2.39 mmHg (-3.84, -0.95), P = 0.001), and serum cholesterol 
(WMD = -17.66 mg/dL (-33.19, -2.14, P = 0.03). Of interest, the treatment could raise serum 
albumin (WMD = 0.12g/dl (0.01, 0.22), P= 0.04) and serum calcium (WMD =0.50 mg/dL 
(0.21, 0.80), P=0.001).
Conclusions: Restricted protein diet supplemented with KA could effectively improve 
kidney endpoints, CKD-MBD parameters and blood pressure parameters without causing 
malnutrition. However, the significant increased serum calcium should be monitored.
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Effects of Oral Nutritional Supplements on Clinical Outcomes and 
Nutritional Markers in Hemodialysis Patients Qualifying with Serum 
Albumin 3.6 or 3.7 g/dL
Scott Sibbel,1,2 Becky Brosch,3 Maria M. Stasios,3 Abigail Hunt,1,2 David B. Van 
Wyck,2 Allen R. Nissenson,3 Steven M. Brunelli,1,2 Deborah A. Benner.3 1DaVita 
Clinical Research, Minneapolis, MN; 2DaVita Institute for Patient Safety, 
Denver, CO; 3DaVita Kidney Care, Denver, CO.
Background: Use of oral nutritional supplements (ONS) has been shown to improve 
clinical outcomes in dialysis patients with serum albumin ≤ 3.5 g/dL. However, there is 
evidence indicating patients with albumin < 3.8 g/dL are also at increased risk for death. 
Here, we evaluated the effects of providing ONS to dialysis patients with serum albumin 
3.6 or 3.7 g/dL on clinical outcomes and nutritional markers.
Methods: This was a retrospective evaluation of a pilot program (May-Aug 2017) 
to provide ONS to in-center hemodialysis patients with a qualifying serum albumin 
measurement of 3.6 or 3.7 g/dL. ONS was provided to the patient at the time of dialysis 
treatment. ONS patients were matched to control patients from non-pilot facilities who had 
the same qualifying albumin (3.6 or 3.7 g/dL) and preceding albumin (n = 2902 per group). 
Clinical outcomes (death, hospitalization, missed dialysis treatments) and nutritional 
markers (albumin, normalized protein catabolic rate [nPCR], creatinine) were assessed over 
180 days using longitudinal generalized linear models.
Results: There was a significantly lower death rate among ONS patients relative to 
controls (0.07 vs 0.12 per patient-year [PPY]; adjusted incidence rate ratio [aIRR] = 0.38; 
95% confidence interval [CI] = 0.22-0.68). No significant differences were observed in 
hospitalizations (1.37 vs 1.16 PPY; aIRR = 1.04; 95% CI = 0.88-1.12), missed dialysis 
treatments (11.2 vs 11.4 PPY; aIRR = 0.98; 95% CI = 0.87-1.10), or nutritional markers.
Conclusions: These finding indicate that provision of ONS to dialysis patients with 
albumin > 3.5 g/dL could be beneficial in reducing mortality. Dialysis providers should 
consider expanding ONS programs to include patients with albumin <3.8 g/dL.
Funding: Commercial Support - This was a research project conducted by the DaVita 
Institute for Patient Safety and supported by DaVita Kidney Care
SA-PO1073 Poster Saturday
Diet and Nutrition: Clinical
New Nutritional Risk Index on the Basis of Protein Energy Wasting for 
Japanese Hemodialysis Patients
Eiichiro Kanda,1 Akihiko Kato,2 Ikuto Masakane,3 Yoshihiko Kanno.4 1Kawasaki 
Medical School, Wakoshi, Japan; 2Hamamatsu University Hospital, Hamamatsu, 
Japan; 3Honcho-Yabuki Clinic, Yamagata, Japan; 4Tokyo Medical University, 
Tokyo, Japan.
Background: Because the criteria for protein energy wasting (PEW), which is a 
risk factor for death, are not necessarily appropriate for Asian hemodialysis patients, we 
developed a new nutritional risk index for one-year all-cause death of Japanese maintenance 
hemodialysis patients on the basis of the concept of PEW, and evaluated their prognosis.
Methods: We analyzed data from a nation-wide prospective cohort study of the 
Japanese Society for Dialysis Therapy Renal Data Registry to develop and validate a 
nutritional risk index (n=48349, 48349, respectively). The association of nutritional factors 
with one-year death was tested using Cox proportional hazards models. Their cutoff levels 
were determined from the hazard ratios or receiver operating characteristic curves. Then, 
risk index was developed using scoring models.
Results: Male was 61.5 %; average age, 65.7±12.2 years; and diabetes mellitus, 32.7 %. 
Four clinical factors were retained in the final model: low BMI (<20kg/m2), yes=3, no=0; low 
serum albumin level (young <3.5g/dL; old <3.7g/dL), yes=4, no=0; abnormal serum total 
cholesterol level, low (<130mg/dL)=1, high (220≥mg/dL)=2, no=0; low serum creatinine 
level (young female, <9.7mg/dL; old female, <8.0mg/dL; young male, <11.6mg/dL; 
old male, <9.7mg/dL), yes=4, no=0. In the validation dataset (n=48349), medium- and 
high-risk groups (total score 8 to 10; 11 or more) showed a higher risk of all-cause death 
than the low-risk group (0 to 7): medium-risk group (10.5%), hazard ratio adjusted for 
baseline characteristics 1.96 (95% confidence interval 1.77, 2.16); high-risk group (8.2%), 
3.91 (3.57, 4.29) (Figure 1). The medium- and high-risk groups also showed a higher risk of 
cardiovascular disease- and infection-caused deaths than the low-risk group.
Conclusions: We developed a new nutritional risk index for hemodialysis patients, 
which may be useful for identifying patients with PEW at an increased risk of death for 
early treatment.
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Segmentation Outperforms Classification to Enumerate Glomeruli in 
Whole Slide Renal Biopsy Images Using Deep Learning
Jonathan Street,1 Rohit R. Chari,1 Tiffany R. Bellomo,1 Stephen M. Hewitt,2 
Peter S. Yuen,1 Robert A. Star.1 1NIDDK/NIH, Bethesda, MD; 2NCI/NIH, 
Bethesda, MD.
Background: Accurate detection and counting of glomeruli in renal biopsies is used 
to assess biopsy adequacy, and for diagnosis (for example, the percentage of sclerotic 
glomeruli). Rosenberg et al. recently showed that standard, manual histopathology methods 
can under-count glomeruli by ~50% compared to more labor-intensive annotation methods. 
Deep learning has significantly advanced image analysis with previously impractical 
technologies, such as facial recognition, now possible. We have applied these advances to 
classification and segmentation of glomeruli. Classification separates small, overlapping 
image tiles into two classes [glomerulus vs. no glomerulus]. Segmentation separates 
individual pixels in an image into two classes [inside glomerulus vs outside glomerulus]. 
Segmentation is similar to masking or finding the border of a glomerulus.
Methods: Fifteen biopsy H&E stained sections were digitized with whole slide 
scanners (Aperio and Hamamatsu) for training and validation of the model. The outline of 
each glomerulus was annotated by two people using a custom application we developed. 
A network with 3 convolutional layers was used for classification and a 7 layer U-Net 
structure used for the harder problem of segmentation.
Results: The number of glomeruli per biopsy ranged from 1 to 72. Human 
annotators showed good agreement in the number and area of glomeruli (R2 = 0.75 and 
0.66, respectively). Classification reached an overall machine-human accuracy in cross-
validation of 94% on a dataset with an equal number of positive and negative examples. 
However, classification on full biopsies (with more negative than positive areas) had a low 
precision (45%) with an overall F1 score (harmonic mean of precision and recall) of 51%. 
In contrast to classification, segmentation applied to entire biopsies identified glomeruli 
with zero false positives and an overall F1 score of 99%. Neither model’s performance was 
altered by changes in stain intensity or the scanner used for imaging.
Conclusions: Glomeruli can be detected with high accuracy in renal biopsies using 
deep learning techniques; image segmentation worked better than image classification. 
These computational models can be leveraged to improve and automate enumeration of 
glomeruli, and can be adapted for classification of glomerular morphology.
Funding: NIDDK Support
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Artificial Intelligence Can Classify Human Kidney Biopsy Images
Ayumi Matsumoto, Isao Matsui, Karin Shimada, Nobuhiro Hashimoto, 
Yohei Doi, Satoshi Yamaguchi, Keiichi Kubota, Tatsufumi Oka, 
Yusuke Sakaguchi, Takayuki Hamano, Yoshitaka Isaka. Osaka University 
Graduate School of Medicine, Suita, Japan.
Background: Diagnosis based on kidney biopsy is a complicated decision process that 
includes some elements of uncertainty. Therefore, appropriate diagnoses require trained 
pathologists. If artificial intelligence could classify kidney biopsy images, it would be 
beneficial for appropriate and objective diagnosis for kidney diseases.
Methods: We obtained micrographs of PAS, PAM, or Elastica-Masson (EM)-stained 
human kidney biopsy samples using virtual slide system. Squared 13,017 images were 
manually cut out from the micrographs and then labelled into 87 (29 disease x 3 staining) 
categories based on diagnoses made by at least two nephrologists. We also obtained 
7,177 squared tubulointerstitial images form PAS stained sections. Validation datasets 
were generated from the dataset by random selection. GoogLeNet, a convolutional neural 
network, was used to classify these images.
Results: GoogLeNet was well trained to classify glomerular images. The accuracy 
and loss of validation dataset were 0.7948 and 1.1301, respectively. To confirm that 
GoogLeNet really learned glomerular images, we prepared augmented dataset of 52,068 
glomeruli which was prepared from original 13,017 squared glomerular images by 90°, 
180°, and 270° rotations. We labelled these images according to disease categories and 
rotations. Learning of this negative control dataset yielded only 0.36866 of accuracy and 
1.47506 of loss. We also examined whether GoogLeNet can classify glomerular diseases 
from tubulointerstitial images. Learning of PAS-stained tubular images yielded 0.9475 of 
accuracy and 0.2495 of loss.
Conclusions: GoogLeNet can classify glomerular diseases not only by glomerular 
images but also by tubulointerstitial images.
Light blue, deep blue, yellow, and red lines indicate loss of training data, loss of validation 
data, accuracy of training data, and accuracy of validation data, respectively.
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Deep Learning for Segmentation of Glomeruli, Interstitial Fibrosis, and 
Tubular Atrophy in Renal Biopsies
Kuang-Yu Jen,1 Brandon G. Ginley,2 Brendon Lutnick,2 John E. Tomaszewski,3 
Pinaki Sarder.2 1University of California, Davis, Sacramento, CA; 2SUNY 
Buffalo, Buffalo, NY; 3University at Buffalo, Buffalo, NY.
Background: Evaluation of the renal biopsy typically involves assessment of the renal 
cortical compartments, which consist of glomeruli, tubules, interstitium, and vessels. Of 
particular importance is the degree of what has been considered “chronic” or irreversible 
injury in the form of glomerulosclerosis, interstitial fibrosis and tubular atrophy (IFTA). 
These features are the main indicators for renal prognosis, irrespective of the etiology of 
renal disease. However, evaluation for such features can be imprecise and variable between 
experts, especially for IFTA. We have tested a deep convolutional neural network (CNN) 
segmentation of IFTA and glomeruli from whole slide images (WSIs) in a limited dataset of 
diabetic nephropathy (DN) biopsies.
Methods: Seven biopsies of patients diagnosed with DN were used. One WSI from 
each patient was completely annotated for IFTA and glomeruli. A Python interface was 
designed to accept WSI annotations from Aperio ImageScope, train a deep CNN, and 
perform subsequent WSI predictions. The network selected was Deeplab V2, implemented 
in Tensorflow.
Results: In this first study, training and testing was performed on the same 7 biopsies, 
due to data limitations. The deep CNN achieved significant performance on 3 out of the 
7 biopsies tested, for both IFTA and glomeruli. For these cases the network achieved 
specificity for segmenting both IFTA and glomeruli (see Fig. 1).
Conclusions: For the first time we have shown computational segmentation of IFTA 
and glomeruli from renal biopsies. The Deeplab V2 system demonstrates the capability 
for high performance in addition to generalization to other histological compartments with 
an increase in dataset size. Future work will increase the training cases and implement a 
validation set.
Funding: NIDDK Support
Figure 1. Segmentation of IFTA and glomeruli by deep CNN. Green outlines regions of 
IFTA, yellow outlines glomeruli. Scalebar is 300μm.
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A Proposal of Modified Berden’s Classification of ANCA-Associated 
Glomerulonephritis Focusing on a Proportion of Active Crescents for an 
Appropriate Treatment
Yayoi Ogawa,1 Takahisa Kobayashi,2 Daisuke Nagata,2 Wako Yumura,3 
Kensuke Joh.4 1Hokkaido Renal Pathology Center, Sapporo, Japan; 2Jichi 
Medical University, Shimotsuke, Japan; 3Department of nephrology, 
International University of Health and Welfare Hospital, Nasushiobara, Japan; 
4Tohoku University Graduate School of Medicine, Sendai-city, Japan.
Background: In 2010, Berden et al. proposed the histological classification of ANCA-
associated glomerulonephritis and categorized sclerotic(S), focal(F), crescentic(C), and 
mixed (M) classes. The validation studies confirmed the best renal prognosis for F and the 
worst for S. However, the results of C and M were inconsistent. Therefore, we modified the 
Berden’s classification by focusing on a pure proportion of active crescents in each C and M 
from a view point of a further choice of therapy and analyzed the correlation between these 
subclasses and renal prognosis.
Methods: The 35 patients with MPO-ANCA-associated glomerulonephritis (male 
57%, 68±7.8 yrs), who were followed more than 5 years, were analyzed. E-GFR at entry 
was 23.7±21.7ml/min per 1.73m2. In the modified classification, at the first step. S, F and C 
or M were categorized according to the Berden’s original classification. At the second step, 
in the category of C or M, New Crescent class (NC) was categorized by active crescents 
with more than 50% after eliminating global sclerosis and the rest were categorized as New 
Mixed class (NM), because the global sclerosis in the category of C or M did not respond 
to the immunosuppressive therapy. In each category, cumulative risk of ESRD (0-5 yrs) and 
ΔeGFR or ΔCr (serum creatinine) (0-5 yrs) were evaluated
Results: F: C: M: S were 13:5:9:8 respectively, whereas F: NC: NM: S were 13:7:7:8 
respectively. Cumulative risk of ESRD (0-5 yrs) showed that F and S revealed best and 
worst prognosis, respectively (log rank p<0.05). C and M were in the middle, and the 
prognoses of C and M were not significantly different. However, NC and NM showed 
significant difference for ΔeGFR (0-5 yrs) and ΔCr (0-5 yrs). A significant cut off point of 
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a percent of active crescent for ΔeGFR (0-5 yrs) was 50% but not 25% or 75%. Therefore, 
NC showed a significant better eGFR-improvement than that of NM (p<0.05) indicating a 
better response to immunosuppressive therapy.
Conclusions: A modified Berden’s classification showed clear discrimination 
between NC and NM and can propose an appropriate rationale for a further choice of 
immunosuppressive therapy.
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Utility of the Modified Berden’s Histological Classification of ANCA 
Vasculitis for a Choice of Immunosuppressive Therapy
Takahisa Kobayashi,1 Yayoi Ogawa,2 Wako Yumura,3 Kensuke Joh,4 
Daisuke Nagata.1 1Jichi Medical University, Shimotsuke, Japan; 2Hokkaido 
Renal Pathology Center, Sapporo, Japan; 3International University of Health 
and Welfare Hospital, Nasushiobara, Japan; 4Tohoku University Graduate 
School of Medicine, Sendai-city, Japan.
Background: For a rationale of the therapeutic choice for ANCA vasculitis, a 
quantitative assessment of the active crescents (AC) is indispensable. Since a newly 
proposed modified Berden’s classification (Ogawa Y et al. 2018) focusses a ratio of 
remaining active crescents, we evaluated a utility of this classification for a choice of 
therapy by evaluating a correlation between this classification and the clinical profile.
Methods: The 35 patients (pts) with MPO-ANCA-associated glomerulonephritis 
(male 57%, 68.6 +-7.8 years old), who were followed more than 5 years were analyzed 
in the present retrospective study. All pts were treated according to the Japanese guideline 
(JSN 2011). In the modified classification, after classifying Sclerotic (S) Focal (F) and 
crescent (C) or mixed (M) classes with a cut-off point of 50%, New Crescent class (NC) 
was categorized by active crescents with more than 50% after eliminating global sclerosis 
and the rest was categorized as New Mixed class (NM) in the category of C or M. Clinical 
information including serum creatinine (sCr), eGFR and grade of hematuria (GH) at onset 
as well as at 5-years (yrs) after renal biopsy, and amelioration of sCr per day (ΔCr/day) 
were retrieved.
Results: Percent of AC correlated positively with GH (r=0.337, p<0.05), sCr 
(r=0.474,p<0.01), and negatively with eGFR at admission(r=-0.488, p<0.01)and ΔCr/
day(r=-0.420, p<0.05). Moreover, 8 mL/min of eGFR was a cut off point for 5 year’s renal 
prognosis, because 50% of the pts with eGFR more than 8 mL/min in the S showed ESRD, 
whereas no pts with eGFR more than 8mL/min developed ESRD in F, NC, and NM. On the 
other hand, 100%, 100%, 80%, and 50% of the pts with eGFR less than 8 mL/min developed 
ESRD in S, NM, NC, and F, respectively. ΔCr/day of the pts with NC(0.41 mg/dL/day) 
revealed significantly greater than that of pts with NM(0.05mg/dL/day). Cut off of the ΔCr 
to predict NC was 0.16 mg/dL/day.
Conclusions: A newly proposed modified Berden’s classification together with 
8 mL/min of eGFR and 0.16 mg/dL/day of ΔCr as cut-off points were useful to predict the 
renal outcome and a response of immunosuppressive therapy.
Funding: Private Foundation Support
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Differences in Renal Histopathology Between PR3-ANCA-Associated 
Vasculitis and MPO-ANCA-Associated Vasculitis
Maria Wester Trejo,1 Emma Van Daalen,11 Ron Wolterbeek,12 Franco Ferrario,2 
Kensuke Joh,3 Laure-Helene Noel,13 Yayoi Ogawa,4 Suzanne Wilhelmus,14 
Miriam J. Ball,15 Eva Honsova,16 Zdenka Hruskova,5 Renate Kain,6 
Andreas Kronbichler,17 Kristine Lindhard,18 Xavier Puéchal,7 Steven Salvatore,19 
Wladimir M. Szpirt,8 Vladimir Tesar,5 Jan A. Bruijn,9 Ingeborg M. Bajema.10 
1Pathology, Leiden University Medical Center, Leiden, Netherlands; 
2Nephropathology Center, San Gerardo Hospital, Monza, Italy; 3Pathology, 
Tohoku University Graduate School of Medicine, Sendai, Japan; 4Hokkaido Renal 
Pathology Center, Sapporo, Japan; 5Nephrology, Charles University and General 
University Hospital, Prague, Czechia; 6Clinical Institute of Pathology, Medical 
University of Vienna, Vienna, Austria; 7National Referral Centre for Rare Systemic 
Autoimmune Diseases, Hôpital Cochin, Paris, France; 8Nephrology, 
Rigshospitalet, Copenhagen, Denmark; 9Pathology, Leiden University Medical 
Center, Leiden, Netherlands; 10Pathology, Leiden University Medical Center, 
Leiden, Netherlands; 11Pathology, Leiden University Medical Center, Leiden, 
Netherlands; 12Medical Statistics and Bioinformatics, Leiden University Medical 
Center, Leiden, Netherlands; 13Pathology, Necker Hospital, Paris, France; 
14Pathan, Rotterdam, Netherlands; 15Pathology, Medical University of Vienna, 
Vienna, Austria; 16Pathology, Institute for Clinical and Experimental Medicine, 
Prague, Czechia; 17Internal Medicine IV, Medical University Innsbruck, 
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Background: Clinical and experimental data suggest a pathogenic role for antineutrophil 
cytoplasmic antibodies (ANCA) in ANCA-associated glomerulonephritis (AAGN), with 
possible differences between anti-myeloperoxidase (MPO)- and anti-proteinase 3 (PR3)-
ANCA. The aim of this study was to investigate differences in histopathological profile 
between MPO- AAGN and PR3-AAGN. Additionally, the effect of ANCA serotype on 
long-term renal outcome was examined.
Methods: 135 patients from 10 centers worldwide (Europe, North-America, Asia) with 
AAGN who underwent a diagnostic renal biopsy between 1991 and 2011 were included. 
Biopsies were scored on a secured website. Data on demographics, renal outcome and 
diagnostic delay were collected retrospectively.
Results: 50 patients were positive for PR3-ANCA and 73 for MPO-ANCA; 12 patients 
were either double-positive or negative. At diagnosis, patients with MPO-AAGN were 
significantly older (64.5±12.0 years) than those with PR3-AAGN (57.4±12.8 years). Mean 
diagnostic delay did not differ between groups. MPO-ANCA-positive patients showed 
less focal class and more mixed class than PR3-ANCA-positive patients (P=0.04). MPO-
AAGN biopsies showed significantly more interstitial fibrosis and tubular atrophy (IFTA) 
than PR3-AAGN biopsies (P=0.04). On immunofluorescence, MPO-AAGN showed less 
C3-positive staining than PR3-AAGN (P=0.02). We found no association between ANCA 
serotype and death, renal relapse or development of end-stage renal disease.
Conclusions: In this large, international, multicenter cohort, we found a different 
histopathological profile in MPO-AAGN compared to PR3-AAGN, characterized by a 
lower percentage of focal and higher percentage of mixed histopathological class, more 
IFTA and less C3 in MPO-AAGN. These findings could not be explained by differences in 
diagnostic delay between groups and therefore support a difference in pathogenesis between 
MPO- and PR3-AAGN.
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Effect of Autoantibodies to Erythropoietin Receptor in Patients with 
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Akinori Hara,2 Trang T. Tran,1 Kiyoki Kitagawa,3 Shinji Kitajima,2 
Tadashi Toyama,2 Yasunori Iwata,2 Norihiko Sakai,2 Miho Shimizu,2 
Kengo Furuichi,2 Takashi Wada.2,1 1Kanazawa University, KANAZAWA, Japan; 
2Division of Nephrology, Kanazawa University Hospital, Kanazawa, Japan; 
3Kanazawa Medical Center, Kanazawa, Japan.
Background: To examine the effect of autoantibodies to the erythropoietin receptor 
(EPOR) in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV).
Methods: Sixty-three Japanese patients with AAV were enrolled in this study and 
followed for a median of 31 months. Sera from these patients were screened for anti-EPOR 
antibodies using enzyme-linked immunosorbent assays.
Results: The patients comprised 26 men and 37 women aged 67±14 years. Fifteen 
patients had developed end-stage renal disease (ESRD) during follow-up period. Anti-
EPOR antibodies were detected in 7 patients (11%). Anti-EPOR antibodies were associated 
with increased Birmingham vasculitis activity score (BVAS), especially systemic and 
skin scores. In addition, anti-EPOR antibodies were positively correlated with systemic 
and skin scores of BVAS. Cox regression analysis revealed that male gender, proteinuria 
and estimated glomerular filtration rate at disease onset were significant risk factors for 
ESRD. Among 6 patients who were positive for the antibodies at baseline and had follow-
up examination of their sera, the antibodies disappeared in 4 patients by 2 months after 
immunosuppressive treatment, while remained positive in the other 2, and one of these 
developed ESRD.
Conclusions: Anti-EPOR antibodies were associated with disease activity, especially 
systemic manifestations and skin lesions in patients with AAV.
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Impact of Infiltrating Neutrophils’ Phenotype on Disease Activity in 
Various Glomerulonephritis
Hidehito Kimura,3 Akiko Mii,1 Yusuke Arakawa,1 Akira Shimizu,2 
Shuichi Tsuruoka.1 1Nippon Medical School, Tokyo, Japan; 2Nippion Medical 
School, Tokyo, Japan; 3Nippon medical school, Tokyo, Japan.
Background: Activated neutrophils release neutrophil extracellular traps (NETs), 
resulting in cell death called NETosis. NETs formation has been reported to be involved 
in the onset of systemic lupus erythematosus and ANCA-related vasculitis (AAV). 
However, the precise mechanism remains unclear. Citrullination of histones is an essential 
step for NETs formation, and the presence of citrullinated histones in neutrophils may 
be involved in disease induction and activity. We investigated the association between 
infiltrating neutrophils with/without citrullinated histone and disease activity in various 
glomerulonephritis (GN).
Methods: We selected kidney biopsy samples of AAV, lupus nephritis (LN), Henoch 
schonlein purpura nephritis (HSPN), and acute post-streptococcal GN (APSGN)(n = 5, 
each), which presented proliferative GN with neutrophil infiltration in glomeruli and 
interstitium. To identify infiltrating neutrophils and citrullinated histones, we performed 
immunostaining for myeloperoxidase (MPO) and citrullinated histone H3 (CitH3), and 
assessed the frequency of citrullinated histone positive neutrophils in glomeruli and 
interstitium.
Results: Number of MPO+ neutrophils in glomeruli tends to be higher in APSGN, 
LN and HSPN than in AAV. In APSGN and HSPN, however, CitH3+ neutrophils were 
very few in their endocapillary proliferative lesions in glomeruli. In addition, a few MPO+ 
neutrophils and CitH3+ neutrophils infiltrated the interstitium. In LN and AAV, CitH3+ 
neutrophils were observed in necrotizing lesion and wire-loop lesion along glomerular 
capillaries. Moreover, in AAV, the frequency of CitH3+ neutrophils in both glomeruli and 
interstitium was significantly higher than the others and correlated with crescent formation.
Conclusions: CitH3 immunostaining was useful tool for identifying activated 
neutrophils. In addition, it was suggested that there was correlation disease activity of GN 
with the frequency of activated neutrophils.
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Histopathologic Spectrum of Kidney Biopsies in Patients with 
Eosinophilia
Anam Tariq,1 Marco Delsante,2 Mohamed G. Atta,1 Blaithin A. McMahon.1 
1Johns Hopkins University School of Medicine, Baltimore, MD; 2Johns Hopkins 
Pathology, Baltimore, MD.
Background: Eosinophilia has been linked to diseases including interstitial nephritis 
(IN) and other autoimmune diseases in many case reports. However, no kidney biopsy 
series has examined the predictive role of peripheral eosinophilia and tissue eosinophilia 
within kidney biopsies in patient’s with established kidney disease. This study evaluated 
a large series of kidney biopsies with known eosinophilia to better define the spectrum of 
kidney disease in this patient population.
Methods: A retrospective review of native and allotransplant kidney biopsies obtained 
from 1996 to 2018 identified 58 patients with eosinophilia (serum as a percentage of 
circulating leukocytes >4% on hematology). Patient characteristics, clinical and laboratory 
data were obtained. Standard processing of all biopsy specimens included light microscopy, 
immunofluorescence, and electron microscopy, focusing on the number of inflammatory 
markers including tissue eosinophils, number per high field (hpf), was performed.
Results: While IN was the most common primary diagnosis, other diagnoses include 
FSGS (17%), ANCA (14%), hypertensive arteriosclerosis (9%) (Table 1). Of the 58 patients, 
the most common indication for kidney biopsy was acute (51%), acute on chronic kidney 
failure (41%) and subnephrotic protrinuria (53%). In IN, mean eosinophilia was 13% and 
mean kidney tissue eosinophil number was 12 per hpf. In FSGS, mean eosinophilia was 
14% and mean kidney tissue eosinophil number was higher at 18 per hpf. Outcomes show 
17% of IN and 5% of FSGS patients progressed to ESRD.
Conclusions: Eosinophilia is seen in a spectrum of kidney diseases other than IN, such 
as FSGS and hypertensive arteriosclerosis. The role of eosinophilia in predicting major 
adverse kidney events requires further investigation.
Primary kidney biopsy findings in patients with peripheral Eosinophilia
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Glomerular Staining and Serum Antibodies of THSD7A in Malignan-
cy-Associated Membranous Nephropathy
Changming Zhang,1 Ming-chao Zhang,1 Da cheng Chen,2 Qiang Ren,1 Weiwei Xu,1 
Wei-song Qin,1 Zhihong Liu.1 1National Clinical Research Center of Kidney 
Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 
China; 2National Clinical Research Center of Kidney Diseases, Jinling Hospital, 
Nanjing University School of Medicine, Nanjing, China, Nanjing, China.
Background: Thrombospondin type 1 domain-containing 7A (THSD7A) is recently 
identified as the target antigen in patients with membranous nephropathy (MN). A notable 
phenomenon is the high rate of cancer (reported to be as high as 20%) in patients with 
THSD7A-associated MN. The prevalence of THSD7A in patients with malignancy-
associated MN deserves further clarification.
Methods: Glomerular expression of THSD7A was examined by immunohistochemistry 
in 36 patients with malignancy-associated MN. Immunofluorescence assay was performed 
to investigate anti-THSD7A antibodies. Anti-PLA2R antibodies and glomerular PLA2R 
expression was also screened. THSD7A expression of cancer tissues was tested in 9 among 
the 36 patients.
Results: Among the 36 patients with malignancy-associated MN, 3 (8.3%) patients 
were identified as glomerular THSD7A staining positive: one patient was THSD7A positive 
alone, which accounted for 6.3% (one of 16) of PLA2R negative patients; two patients 
were dual-positive for both THSD7A and PLA2R staining. No anti-THSD7A antibody 
was detected among the 36 patients, whereas 18 of 36 (50%) had anti-PLA2R antibodies. 
Among the 9 patients who were available for cancer THSD7A staining, five (56%) patients 
showed enhanced expression of THSD7A localized in cancer tissue: one patient also had 
enhanced expression of THSD7A in glomeruli.
Conclusions: We found that positive glomerular THSD7A staining was uncommon in 
patiens with malignancy-associated MN.
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The Size of Urinary Podocyte in Focal Segmental Glomerulosclerosis
Yoko Shirai,1 Kenichiro Miura,1 Takashi Yokoyama,1 Shigeru Horita,1 
Takaya Iida,1 Yohei Taniguchi,1 Takeshi Nagasawa,1 Hideki Ban,1 Yoko Takagi,1 
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Background: Previous reports indicated that the number of urinary podocytes is higher 
in FSGS with nephrotic range of proteinuria than those in FSGS in remission and minimal 
change nephrotic syndrome (MCNS) in relapse. To date, the size of urinary podocyte has 
not been evaluated. In the present study, we examined the size of urinary podocyte in 
various glomerular diseases including FSGS in children.
Methods: Eight patients with FSGS (primary, n=6; genetic, n=2), 7 patients with MCNS 
in relapse and 10 patients with glomerulonephritis (GN) were included in the study. GN 
included IgAN (n=3), IgA vasculitis (n=4), ANCA-associated GN (n=1), lupus GN (n=1), 
and infection related GN (n=1). Patients with eGFR <60 ml/min/1.73m2 were not included. 
Fresh urine samples of 10ml voided in the morning were obtained and urinary podocyte 
was detected by immunofluorescence using anti-human podocalyxin monoclonal antibody 
with a DAPI positive nucleus. The number of urinary podocytes was calculated per 10ml 
sample. Images of podocalyxin-positive cells were taken under an immunofluorescence 
microscope with 400-fold magnification and were quantified by image analysis. The size of 
urinary podocyte was defined as mean area of the podocytes in a field (pixel/cell). Statistical 
analyses were performed with Wilcoxon tests. Data are expressed as median (IQR). A P 
value of <0.05 was accepted as statistically significant.
Results: Urinary protein/creatinine ratios (UP/UC) were not significantly different 
among FSGS, MCNS and GN. The number of urinary podocytes (/10ml) in GN (200 
(154.5-200)/10ml) was significantly higher than those in FSGS (81.5 (42.8-140.3)/10ml) 
and MCNS (68 (35-98)/10ml) (P=0.0225), while there was not a significant difference 
between FSGS and MCNS. Of note, the size of podocyte in FSGS (2947.9 (2571.4-3400.0) 
pixel/cell) was significantly larger than those in MCNS (1242.3 (756.0-2214.5) pixel/cell) 
and GN (859.4 (753.2-1079.3) pixel/cell) (P=0.0034).
Conclusions: This preliminary study suggested that the size of urinary podocyte may 
be a specific marker of FSGS.
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Anticoagulants and the Kidney: 10 Years Later After Discovery of 
Warfarin Related Nephropathy
Sergey V. Brodsky,1 Anjali A. Satoskar,1 Brad H. Rovin,1 Jessica Hemminger,1,3 
Margaret Ryan,2 Lee A. Hebert,4 Tibor Nadasdy.1 1The Ohio State University 
Wexner Medical Center, Columbus, OH; 2Pathology, Mayo Clinic, Scottsdale, 
AZ; 3Department of Pathology, Mount Carmel Health System, Columbus, OH; 
4Ohio State University Medical Center, Columbus, OH.
Background: Ten years ago we associated acute kidney injury (AKI) and occlusive red 
blood cell (RBC) tubular casts with high international normalized ratio (INR) in a patient on 
warfarin therapy. We named this condition warfarin related nephropathy (WRN). Later, we 
and others demonstrated that WRN is a part of the broader syndrome, anticoagulant related 
nephropathy (ARN). Herein we provide our 9-year experience with ARN based on a single-
center renal pathology laboratory data.
Methods: The renal pathology database at the Ohio State University Wexner Medical 
Center (OSUWMC) was searched for native kidney biopsies performed between January 1st 
2009 and December 31st 2017 using keywords “kidney biopsy”, “warfarin”, “anticoagulant”, 
“nephropathy”. All identified cases were reviewed and those with kidney biopsy findings 
suggestive of ARN were included into this study.
Results: Among 8636 native kidney biopsies, there were 47 (0.54 %) patients in whom 
deterioration in the kidney function could not be explained by kidney biopsy findings alone 
if anticoagulation was not taken into the equation. There were 32 (68%) males and 15 
(32%) females, 90% of the patients were Caucasian. The average age was 61.7 +/- 14 years. 
Thirty five (74%) were on warfarin therapy, five (11%) were on anti-platelet medications, 
six (13%) did not have records of anticoagulation therapy, but they had acute coagulopathy 
at the time of deterioration of kidney function and their biopsy findings suggested of 
ARN. In addition to acute tubular necrosis and RBC casts, these patients had underlying 
glomerular changes, but the severity of that glomerular disease was out of proportion to 
the number of RBC casts and/or hematuria in these patients. The most common was mild 
glomerular immune complex deposits without significant proliferative lesions (23 cases, 
49%), followed by mild focal pauci-immune crescentic glomerulonephritis (7 cases, 15%), 
diabetic glomerulosclerosis (5 cases, 11%) and focal segmental glomerular sclerosis (FSGS, 
5 cases, 11%).
Conclusions: ARN is an uncommon diagnosis in renal pathology practice, but it should 
be considered when there is a disproportion between the severity of glomerular changes and 
the number of RBC casts and/or hematuria in a kidney biopsy in patients on anticoagulant 
therapy or who presented with acute coagulopathy.
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Congo Red Positive Fibrillary Glomerulonephritis
Maziar Riazy,1 Nicole K. Andeen,2 Charles E. Alpers,3 Kelly D. Smith.1 UW 
renal Pathology 1University of Washington, Seattle, WA; 2Oregon Health & 
Science University, Portland, OR; 3University of Washington Medical Center, 
Seattle, WA.
Background: Fibrillary glomerulonephritis (FGN) is characterized by the glomerular 
deposition of Congo red-negative fibrillary material with fibers that are larger in diameter 
than amyloid fibrils. With recent identification of DnaJ homolog subfamily B member 9 
(DNAJB9) as a sensitive and specific marker for FGN, we sought to examine the specificity 
of these traditional diagnostic criteria used to distinguish FGN and amyloidosis.
Methods: The study population consisted of renal biopsies accessioned at the University 
of Washington, Seattle, USA from 01/01/2014 to 05/15/2018. We performed a database 
search of pathology reports for terms “fibrillary” and “atypical amyloid”. Cases were 
included if all of the following: 1) glomerular and/or extra glomerular fibrillary deposits 
were present 2) Congo red stain was performed 3) FGN was diagnosed by conventional 
criteria and/or DNAJB9 was demonstrated in the deposits by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and/or immunofluorescence.
Results: During the study period, 49 patients were diagnosed with FGN, of which 4 
patients’ biopsies had positive Congo red staining. The most prominent light microscopic 
findings were necrotizing and crescentic lesions (2 cases) and mesangial expansion with 
glomerular basement membrane thickening (2 cases). Immunofluorescence showed 
polytypic IgG staining in all 4 cases. The average fibrillary diameter ranged from 8.8-14.2 
nm with two cases below the 12 nm diagnostic cut-off (figure).
Conclusions: Congo red positive staining and fibril diameter less than 12 nm should 
not be used as exclusion criteria for the diagnosis of FGN. The diagnosis of FGN should 
be considered in Congo red positive biopsies with findings that are atypical or inconclusive 
for amyloidosis, and LC-MS/MS and/or DNAJB9 immunostaining should be performed to 
confirm or exclude the diagnosis of FGN.
Funding: Clinical Revenue Support
The Congo red and immunofluorescence (light chains and DNAJB9) staining and the 
fibrillary organization of the deposits in one of the cases. LC-MS/MS of the Congo red 
positive glomerular deposits showed DNAJB9 but no amyloidogenic peptides.
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Acute Transient Arteriopathy Mimicking Vascular Rejection in Allograft 
Kidneys
Maziar Riazy,1 Carrie R. Minnelli,1 Ryuji Ohashi,4 Jolanta Kowalewska,3 
Nicolae Leca,1 Behzad Najafian,1 Roberto F. Nicosia,5 Charles E. Alpers,2 
Shreeram Akilesh.1 UW renal Pathology 1University of Washington, Seattle, 
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Puget Sound HCS, Seattle, WA.
Background: Early dysfunction of renal allografts raises the specter of acute rejection 
processes that require medical intervention vs. self-limiting peri-operative conditions for 
which conservative management is indicated. We sought to determine the clinical course 
in patients who present with delayed graft function and demonstrate a unique pattern of 
vascular injury that mimics rejection in their biopsy.
Methods: The study population consisted of renal allograft biopsies accessioned at 
the University of Washington, Seattle, USA from 1/1/2000 to 12/31/2017. We performed 
a database search of pathology reports for “transplant” and “arteriopathy” within one 
year following transplantation. Included cases showed a distinct arterial vasculopathy, 
characterized by endothelial cell swelling, lifting, and intimal edema in the absence of 
endotheliitis or rejection (Banff IA or higher). We also determined the clinical course of 
these patients on followup.
Results: We have identified 30 patients with arteriopathy but without rejection in the 
first year post-transplant. Of these, we have collected follow up on 14 patients to date 
(remainder in process). These patients (10 male, 4 female) were compliant with their 
immunosuppression and presented with delayed graft function soon after transplantation 
(median=13 days, range 7-139). Interlobular-sized arteries were most frequently 
affected. 11/14 patients received no intervention, while 3/14 received anti-thymocyte 
globulin (ATG), plasmapheresis or intravenous immunoglobulin (IVIg). 30 days post-
transplantation, 11 patients were off dialysis and had a median serum creatinine of 
1.85 mg/dL. 90 days after transplantation 13 patients were off dialysis with a median 
creatinine of 1.67 mg/dL (one patient lost the allograft due to suspected early infarction, 
indeterminate for vascular rejection).
Conclusions: Acute transient transplant arteriopathy is a rare vascular lesion that is 
associated with early graft dysfunction in the absence of rejection. Recognition of this 
lesion and distinguishing it from vascular rejection is important to prevent over-treatment 
since most patients appear to recover function rapidly without specific interventions.
Funding: Clinical Revenue Support
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An Epidemic of Serum Amyloid A Protein Amyloidosis Fueled by 
Injection Heroin Use Associated Infections in the Pacific Northwest
Kelly D. Smith,1 Shreeram Akilesh,1 Charles E. Alpers,1 Behzad Najafian,1 
Roberto F. Nicosia.2 1University of Washington, Seattle, WA; 2VA Puget Sound 
HCS, Seattle, WA.
Background: Renal amyloidosis is an uncommon but problematic cause of proteinuria 
and nephrotic syndrome, which has very limited treatment options and usually leads to 
ESRD requiring renal replacement therapy. In this study, we assessed the incidence of 
different subtypes of amyloidosis over time in our patient population to better understand 
the etiology of renal amyloidosis.
Methods: We reviewed our kidney biopsy database from 1984 through 2017 to define 
the incidence of renal amyloidosis and the subtypes of amyloid contributing to this disease. 
Amyloidosis subtype was correlated with clinical data.
Results: We observed a dramatic increase in serum amyloid A (AA) protein-type 
amyloidosis (Fig. 1), beginning in 2000 and becoming in 2015 the most common renal 
amyloidosis subtype in our patient population. AA-type amyloidosis was associated 
with heroin injection associated infections (skin and deep muscle abscess, cellulitis and 
osteomyelitis) in over 90% of the cases. In a subset of patients (n=8) with extensive clinical 
data, renal biopsy was preceded by Initial documentation of injection drug use associated 
infections (4.0 -18 years) and proteinuria (1.0 -14 years), and renal failure or death occurred 
0.45 – 2.7 years after biopsy.
Conclusions: Since 2000, there has been a dramatic increase in the incidence AA-
type amyloidosis, which is attributed to injection drug use and its associated infectious 
complications. Longitudinal data suggest repeated injection drug use associted infections 
and asymptomatic proteinuria precede clinical presentation prompting biopsy by several 
years.
Funding: Clinical Revenue Support
Figure 1. A surge in AA-type amyloidosis diagnosed in renal biopsies after 2000 in 
our institution. Shown are the number of cases diagnosed per year of AA-type (red), 
immunoglobulin-type (AL+AH+AHL, blue) and other type (undetermined, ALECT2, 
APOA4, ALys) amyloidosis. The lines represents represent non-linear third order 
polynomial fits to the data (r-squared values: AA = 0.94, AL+AH+AHL = 0..88, Other = 
0.28).
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Normal Serum Free Kappa-Lambda Light Chain Ratios in AL  
Amyloidosis - A Single Center Experience
Ari Seifter,1 Arouna Senthilkumar,1 Holly J. Kramer,1,2 Kavitha Vellanki.1,2 
1Loyola University Medical Center, Maywood, IL; 2Medicine, Edward Hines VA 
Hospital, Hines, IL.
Background: Quantification of serum free light chains (FLC) is reported to be highly 
sensitive for diagnosis of primary systemic amyloidosis, with reported sensitivities of 
90-100%. Although tissue diagnosis remains the gold standard for establishing definitive 
diagnosis, normal FLC ratios are often interpreted clinically as effectively ruling out
amyloidosis. The aim of this study is to examine if our experience is different from the
reported literature.
Methods: All patients who had serum FLC quantification and bone marrow biopsy 
at Loyola University Medical Center between the years 2007-2017 were analyzed in a 
retrospective chart review. A total of 1,270 patients were identified and 51 had a confirmed 
diagnosis of AL-amyloidosis. A FLC ratio of 0.26-1.65 was considered normal, consistent 
with past studies. Reported p-values were determined using a chi-squared test.
Results: Of the 51 patients with tissue diagnosis of AL amyloidosis, 45% had localized 
disease (confined to one organ) while 55% had systemic disease (more than one organ 
involvement). Serum FLC ratios were normal in 33% of the cases (17/51). 43% with 
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localized disease had normal FLC ratios compared to 25% of patients with systemic disease 
(p=0.14) (Figure 1). 23 patients (45%) had renal involvement and 5 of the 23 had normal 
FLC ratios at presentation. Overall, 28/51 (55%) patients had a concomitant plasma cell 
dyscrasia confirmed on bone marrow biopsy. Patients with plasma cell dyscrasia were 
significantly less likely (14%) than those without a plasma cell dyscrasia (57%) to have 
a normal free light chain ratios (p=0.001) at presentation. Although patients with systemic 
disease were more likely to have an underlying plasma cell dyscrasia than those with 
localized disease, this result did not reach statistical significance (p=0.14).
Conclusions: When amyloidosis is clinically suspected, serum FLC quantification may 
be insufficient to rule out the diagnosis, leaving biopsy of affected organ(s) as the prevailing 
gold standard.
Funding: Clinical Revenue Support
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Importance of Adjusting the Normal Range of the k/L Free Light Chain 
Ratio According to the CKD Stage in Myeloma Patients
Luis F. Quintana,1,2 Alícia Molina,3 Ignacio Gacitua,5 Elena Guillen,3 
Enrique Montagud,4 Marc Xipell Font,3 Esteban Poch.3,2 1Hospital Clinic de 
Barcelona. Fundacio Clinic per la Recerca Biomedica, Barcelona, Spain; 
2Medicine, Universidad de Barcelona, Barcelona, Spain; 3Hospital Clinic, 
Barcelona, Spain; 4Hospital Clínic, Barcelona, Spain; 5University of Chile, 
Santiago, Chile.
Background: The development of an effective laboratory test to quantify the 
concentration of free light chains (FLC) has optimized the diagnosis of multiple myeloma 
(MM). However, the metabolism of FLC depends to a large extent on renal function, which 
can lead to a misinterpretation of the results. The objective of this study was to determine 
the concentration of serum FLC in a group of MM patients and a group of healthy patients, 
and to establish the variation of the FLC ratio normal range and its diagnostic performance 
for MM in relation to the CKD stage.
Methods: The FLC ratio κ/λ in serum and GFR was analyzed retrospectively by CKD-
EPI in 1469 consecutive patients between December 2014 and December 2017. Two groups 
were chosen: 1) healthyand complete remission MM patients,(n=174); 2) patients with a 
diagnosis of active MM (n=416). The reported normal range of the FLC ratio is 0.26-1.65. 
We excluded patients with a diagnosis of MGUS or other hematological diseases. ROC 
analysis were made for these groups depending on the GFR and the Sensitivity/Specificity 
value obtained for each subgroup was compared. The optimal cut-off was established based 
on the maximum value of Sensitivity/Specificity.
Results: A MM diagnosis based on the initial FLC normal range has a specificity of 96% in 
the group with GFR>90 (n=244)79% in GFR 30-60 ml/min (n=87) and 43% in GFR<30 ml/min 
(N=45). The sensitivity and specificity of the FLC κ/λ ratio is maximum when we divide 
the patients in two groups (GFR < or > 55 ml/min) and apply an adjusted renal range 
(0.82 - 2.75):-for MM Kappa patients with GFR<55 ml/min, the initial Specificity/
Sensibility of 87.7%/56.5% changed to 80.7%/95.6% while for MM Lambda patients with 
GFR<55 ml/min, the initialSpecificity/Sensitivity of 73.3%/100% changed to 96.7%/100%.
Conclusions: The FLC k/L ratio is a safe method for the study of selective proteinuria 
in MM in patients with normal renal function but, if we do not correct the FLC ratio as the 
GFR decreases, its specificity is reduced. The need for this correction is most likely due to 
the different clearance rates of the kappa and lambda FLC and how they change with GFR 
levels. Thus, it is necessary to take into account the GFR for its interpretation and validate 
this new renal range for CKD stage 4 and 5, in future studies.
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Clinical and Pathological Analysis of Renal Light Chain Deposition 
Disease With or Without Cast Nephropathy
Dan Y. Li,1 Gao X. Ying,3 Su X. Wang.2 1Peking university first hospital, Beijing, 
China; 2Laboratory of Electron Microscopy, Peking University First Hospital, 
Bejing, China; 3Xining First People’s Hospital, Xining, China.
Background: To investigate the clinicopathological features of renal light chain 
deposition disease (LCDD) with or without cast nephropathy (LCDD & LCN).
Methods: The clinical features of the 55 cases of LCDD diagnosed by renal biopsy 
from January 2000 to March 2018 were retrospectively analyzed. The pathological 
sections were re-read and divided into two groups: isolated LCDD group (I-LCDD, 36 
cases) and LCDD coexisted with cast nephropathy group (LCDD & LCN, 19 cases). The 
semi-quantitative evaluation of the main features of renal pathology include the degree of 
glomerular mesangial expansion, acute tubular injury, tubulointerstitial inflammatory cell 
infiltration, tubular atrophy with interstitial fibrosis, and renal arteriosclerosis.
Results: all LCDD patients (55 cases) had a mean age of 53.6 years with a male 
to female ratio of 2.7:1, and the average duration of the disease was 10.3 months. The 
multiple myeloma (MM) accounted for 31.58% in LCDD patients. The type of light 
chain is predominantly κ (κ: λ, 2.6:1). The incidence of hypertension, anemia, renal 
dysfunction, urine protein (≥3.5 g/24h) and microscopic hematuria in patients with LCDD 
were 43.6%, 80.4%, 82.1%, 54.5%, and 76.4%, respectively. The percentage of LCDD 
& LCN was 34.6% (19/55 cases). Compared with the I-LCDD group, the LCDD&LCN 
group had an acute onset (P=0.04), higher serum creatinine (P=0.000), lower hemoglobulin 
level (p=0.027). The composition of urine protein was mainly small-molecule protein in 
LCDD&LCN and albumin dominant urinary protien in I-LCDD respectively (P = 0.007, 
P = 0.021). The type of light chain was λ dominant (λ:κ=7:3) in LCDD&LCN (vs I-LCDD, 
λ:κ=3:11, p=0.035). The glomerulopathy varied from mild mesangial expansion to typical 
mesangial nodular sclerosis, and crescents were existed in 27.3% of LCDD patients. The 
frequency of typical mesangial nodular sclerosis was significant lower in LCDD&LCN 
patients (15.8% vs 58.2% in I-LCDD, p=0.01). There was no significant difference in 
tubulointerstitial lesions between the two groups.
Conclusions: One third of LCDD coexisted with cast nephropathy. The dominant λ 
light chain and less mesangial nodular sclerosis was the prominent features of LCDD&LCN 
compared with isolated LCDD, which suggested LCDD&LCN has a distinct pathogenesis 
from that of I-LCDD.
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Paraneoplastic Cast Nephropathy Associated with Secretary Pancreatic 
Carcinoma
Edgard I. Wehbe,1,2 Samar M. Said,3 Samih H. Nasr.3 1Wichita Nephrology 
Group, Wichita, KS; 2Internal Medicine, University of Kansas, Wichita, KS; 
3Mayo Clinic, Rochester, MN.
Introduction: We report the case of a patient with pancreatic mixed acinar-
neuroendocrine carcinoma who presented with irreversible acute kidney injury (AKI) due 
to myeloma-like cast nephropathy. We performed proteomic and immunohistochemical 
studies which revealed that the AKI was triggered by tubular obstruction by acinar 
cell carcinoma-secreted proteins. A novel pathomechanism for carcinoma-associated 
nephropathy is being described.
Case Description: A 64-year old male was found with a large abdominal mass after 
workup for unintentional 35 pound weight loss over 6 month period. Biopsy of the mass 
showed pancreatic mixed acinar-neuroendocrine carcinoma. He developped AKI after 
the diagnosis. Urinalysis showed 1 + protein but no hematuria. Serologies were negative. 
Serum protein electrophoresis with immunofixation did not show monoclonal protein and 
serum free kappa/lambda ratio was normal. Kidney biopsy showed myeloma-like cast 
nephropathy. He was initiated on hemodialysis and received rescue plasmapheresis without 
success in renal recovery. He received gemcitabine and Abraxane with no improvement in 
his condition. He remained on dialysis, had a decline in his clinical condition, developed 
severe refractory septic shock and died 4 months after cancer diagnosis.
Discussion: Kidney biopsy showed acute cast nephropathy with many distal tubular 
PAS-negative and trichrome-polychromatic casts, associated with mononuclear and 
giant cell reaction, acute tubular injury, and mild interstitial inflammation and fibrosis. 
Ultrastructurally, the casts were electron dense and some were admixed with fibrillar 
uromodulin casts. The casts did not stain for kappa or lambda on immunofluorescence. 
Analysis by laser microdissection/mass spectrometry and by immunohistochemistry 
detected large amounts of two acinar-cell specific proteins, REG 1α and CPA1, in the 
renal casts and the patient’s pancreatic carcinoma cells. Thus, the acute kidney injury in 
this patient is likely due to distal tubular obstruction by aggregates of filtered carcinoma-
secreted proteins and uromodulin, with subsequent tubular injury, interstitial inflammation 
and fibrosis, as has been proposed in myeloma cast nephropathy. This case describe a new 
mechanism for paraneoplastic cast nephropathy in the absence of multiple myeloma.
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Beyond Morse: How Do Kidney Biopsy Registries Code Renal Disease? 
On Behalf of the Kidney Biopsy Codes (KBC) for Pathologists Project
Amélie Dendooven,1,2 Mark J. Helbert,5,1 Han Peetermans,5 Tri Q. Nguyen,4 
Sabine Leh.3 Kidney Biopsy Codes for Pathologists project 1University Hospital 
of Antwerp (UZA), Edegem, Belgium; 2University of Antwerp, Antwerp, 
Belgium; 3Haukeland University Hospital, Bergen, Norway; 4UMC Utrecht, 
Utrecht, Netherlands; 5Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium.
Background: Data collected from kidney biopsy registries are used for quality control, 
research, teaching and health policy decisions. For analysis and comparison, unified 
pathology codes are a prerequisite. The KBC for pathologists project aims to provide a 
complete, structured set of terms and codes applicable to non-neoplastic kidney biopsies 
for use by nephropathologists or kidney biopsy registries. The first step is an inventory of 
existing coding practice.
Methods: A structured 10-question questionnaire was sent out to 12 national and 
regional kidney biopsy registries. Additional information was collected by a pubmed 
search, through web pages of registries and personal communication.
Results: The questionaire was returned by 11/12 registries; 7/10 use self-made codes, 
2/10 ERA-EDTA codes and 1/10 an updated SNOMED version based on SNOMED II. 
One registry does not code, only lists diagnosis. Codes are compatible with SNOMED-CT 
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in 3/11 registries. Mean user satisfaction was 3.4 on a scale from 0 to 5. Self-made coding 
systems represented classifications with hierarchical structures and meaningful, easy to 
understand code numbers. Problems were: coding difficulties with clinically-based coding 
systems, problematic mapping of systems to one another, updates and maintenance lacking, 
difficulties in coding multiple diagnoses and missing codes, e.g. documentation of applied 
technology or diagnostic certainty.
Conclusions: The inventory phase of the KBC project has identified multiple 
challenges in coding kidney disease. Considering the current coding practice and future 
needs, a common system should be easy to understand, apply, maintain and update. It 
should contain specific pathology codes. Mapping to a reference terminology would be 
necessary for interoperability.
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Accuracy of Nephrologist in Identifying Kidney Disorders Prior to Kidney 
Biopsy
Manasi Bapat,1 Timothy C. Martin,7 Siddhartha Kattamanchi,2 Joji E. Tokita,3 
Shuchita Sharma,1 Girish N. Nadkarni,4 Steven G. Coca,5 Swati Mehta,6 
Lili Chan.1 1Icahn School of Medicine, Mount Sinai Hospital, NY, New York, NY; 
2Mount Sinai Medical Center, New Rochelle, NY; 3Mount Sinai School of 
Medicine, New York, NY; 4Ichan School of Medicine, New York, NY; 5Icahn 
School of Medicine at Mount Sinai, New York, NY; 6Icahn school of medicine at 
Mount Sinai, Rensselaer, NY; 7Albany Medical Center, Albany, NY.
Background: New biomarkers have been developed for identification of kidney 
diseases; however the kidney biopsies remain the gold standard in diagnosis and 
management. Our aim was to determine the ability of nephrologist to accurately identify 
etiology of kidney dysfunction prior to a biopsy.
Methods: This is a retrospective cohort study of 251 patients who underwent a native 
kidney biopsy at Mount Sinai Hospital (MSH) and Albany Medical Center (AMC) from 
2013 - 2017. Clinical indication and nephrologist diagnosis was determined by review 
of pre-biopsy provider notes while final diagnoses were determined by review of biopsy 
pathology reports.
Results: There were 251 patients who underwent kidney biopsy; mean age was 
51 ± 16 years, 52% were male, 50% were inpatient, and 60% were done under ultrasound 
guidance. The most frequent indication for biopsy was non-nephrotic range proteinuria, 
83 (33.2%) and acute kidney injury, 79 (32%). We were able to identify the nephrologist 
pre-biopsy diagnosis in only 93 patients. The most frequent diagnoses were diabetic 
nephropathy (20%), ANCA vasculitis (12%), and membranous nephropathy (8%). The 
post-biopsy diagnosis matched 45% of the time; the highest concordance was seen in 
diabetic nephropathy (32/39) and IgA nephropathy (10/11) while the lowest concordance 
seen in ANCA (6/21), FSGS (2/12), and minimal change (2/7). There was no consistent 
alternative diagnosis in the lowest concordance groups; patients who were biopsied with a 
presumptive diagnosis of ANCA were found to have diabetic nephropathy, HSP, and MPGN 
among others on pathology.
Conclusions: Nephrologists were able to accurately identify underlying etiologies 
nearly half the time in patients who were referred for biopsy. Given the relative safety of 
kidney biopsies, we should have a low threshold to refer patients for kidney biopsies.
Funding: NIDDK Support
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Pre-Biopsy Lab Work and Decision Making
Orly F. Kohn, Rita L. McGill. University of Chicago, Chicago, IL.
Background: Labwork is often ordered prior to obtaining a kidney biopsy, to assess 
risk of bleeding and less often ordered afterwards. We sought to determine which factors 
influenced the decision to monitor hemoglobin (Hb) levels after biopsy.
Methods: All kidney biopsies performed on adult patients by the Nephrology service 
at the University of Chicago between September 2009-October 2015 were retrospectively 
assessed. Pre-biopsy Hb, INR, platelet count, and platelet function assays (PFA) were 
collected, and the nadir Hb level over the next 14 days was assessed, when available. 
Median values compared with Wilcoxon test, with P<0.01 due to multiple comparisons. 
A multinomial regression model was used to calculate odds ratios (OR) for post-biopsy 
outcomes of: a) Significant drop in Hb (defined as >1.5 grams), b) Lack of post-biopsy 
labwork, compared to a reference outcome of available post-biopsy Hb with no significant 
drop. Models adjusted for age, sex, and allograft vs. native organ, with single imputation of 
median values for missing pre-biopsy data.
Results: Among 905 kidney biopsies, 43.8% were native and 56.2% were allografts, 
49.2% were women and the mean age was 47.5±15.2 years. Hb drop > 1.5 gm occurred in 
11.7%, and post-Hb data was missing for 44.6%. Labwork by outcome and OR for each 
post-Hb outcome are shown in the tables. Female sex, higher pre-biopsy Hb and INR were 
positively associated with significant Hb drop, as were lower eGFR and platelet count. 
Omission of the post biopsy Hb was associated with increased age, female sex, higher pre-
biopsy Hb, and negatively associated with higher INR. PFA did not contribute significantly 
for either outcome.
Conclusions: Post biopsy Hb was more likely to be checked for allograft biopsies and 
patients with elevated INR, but not for several other factors that had significant associations 
to the risk of bleeding. Platelet function assays did not appear to contribute to decision 
making or blood loss. Utilization of labwork before and after kidney biopsies deserves 
further study.
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Kidney Injury Molecule-1 (KIM-1) Identifies Antemortem Injury in Fetal 
Postmortem Kidney
Wenqing Yin,1 Ping L. Zhang,2 Jacqueline K. Macknis,3 Joseph V. Bonventre.1 
1Brigham and Women’s Hospital, Boston, MA; 2William Beaumont Hospital, 
Royal Oak, Royal Oak, MI; 3Beaumont Health, Royal Oak, MI.
Background: KIM-1, a type I transmembranous protein, is a specific and stable 
protein marker for identifying injury in proximal tubules during acute kidney injury. 
There is currently no technique to unambiguously diagnose antemortem kidney injury on 
postmortem examination since postmortem tissue damage and autolysis are common. We 
hypothesized that KIM-1 could be very useful for detecting antemortem proximal tubular 
injury in autolyzed kidneys upon postmortem examination.
Methods: A total of 52 fetal/neonatal autopsy kidneys, from 30 stillborns and 22 
liveborns, were assessed for KIM-1 staining. Kidney autolysis was evaluated by light 
microscopy and disappearance of CD133 expression. The autolysis was graded from 0 
(no autolysis) to 3+ (entire loss of chromatin staining). Correlation between KIM-1 and 
autolysis scores was evaluated by linear regression analysis. Given that serum creatinine 
is unreliable in neonates, we assessed pre-terminal hypoxia in fetuses by the presence of 
squames in pulmonary alveoli and/or the need for intubation.
Results: The expression of KIM-1 was seen in a majority of the fetal and neonatal 
autopsy kidneys (77%, 40/52) as early as 16 weeks of gestation, even in the presence of 
autolysis. There was no significant correlation between KIM-1 scores and autolysis scores (r 
= 0.201 and p = 0.1521). There was a high correlation between KIM-1 expression and these 
clinical indices of hypoxia, either presence of aspirated amniotic fluid contents in stillborn 
or need for intubation in liveborn.
Conclusions: Our data suggest that KIM-1 is a specific and stable marker of 
antemortem tubular injury in fetuses, despite postmortem autolysis. A high correlation 
between KIM-1 expression and these clinical indices of hypoxia implies that KIM-1 may 
be a reliable marker to indicate the hypoxic state in pediatric autopsies.
Funding: Other U.S. Government Support
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Extensive Tubular Ectasia Indicating Occult Urological Obstruction in 
Renal Allografts
Marija Bojic,1 Heinz Regele,3 Christian Seitz,3 Zeljko Kikic.2 1Medicine III/
Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; 
2Medical University Vienna, Vienna, Austria; 3Medical University of Vienna, 
Vienna, Austria.
Background: Urological obstructive complications (UOC) affect up to 10 % of 
kidney transplantation (KTX) cases. The majority of the cases may be excluded by routine 
ultrasound (US), however its accuracy may be limited in the early transplant setting. Renal 
allograft biopsy (BX) may be valuable, but histological features indicating UOC are ill 
defined. Experimental data suggest that extensive tubular ectasia (TE) may be indicative 
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of OUC. In our center, occult UOC is suspected when tubular ectasia (TE) occurs together 
with one or more of the following distinct features: acute tubular injury, tubular protein 
casts and tubular vacuolization. In this study we aimed to assess their accuracy for UOC.
Methods: We included 976 of 1537 consecutive KTX with an early indication BX. 
Relevant hydronephrosis (HN) was excluded by routine US. The bioptical finding of TE 
suspicious of UOC by the renal pathologist was compared to clinical endpoints as delayed 
graft function (DGF) and occurrence of UOC. Thereafter, all biopsies initially classified as 
suspicious for UOC were reevaluated by a single pathologist (H.R.) in order to increase 
accuracy of histomorphology suggestive of UOC.
Results: Fifty eight (5.9%) presented with TE indicative of UOC which was associated 
with a higher rate of DGF (40% vs. 29%; p=0.08) and was not related to long-term graft 
loss. Out of these, 23 (39.7%) had UOC, (most frequently ureteral stenosis) close to BX. 
To assess the relevance of TE as a marker of UOC without relevant HN, cases with TE 
were then subsequently compared to matched controls. Solely TE was significantly 
associated with an increased risk for UOC [OR 2.69 (IQR: 1.19 – 6.09); p = 0.018]. For 
histopathological reevaluation of the 58 cases, we defined extensive TE (>20% of the renal 
cortex). Subsequently, a score including additional histological criteria (tubular injury, 
tubular protein casts and tubular vacuolization) was developed: AUC 0.705, p=0.012. 
Using a threshold of 1.5, we observed 91% sensitivity, 37% specificity and a 84% negative 
predictive value.
Conclusions: Occult UOC may be identified in up to 40% of the cases by subtle 
histopathology including extensive TE together with additional signs of tubular injury. This 
phenotype should trigger more detailed evaluation for UOC when there is no evidence of 
relevant HN in the ultrasound.
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Non-Lupus Immune-Complex Glomerulonephropathy (ICGN) After 
Kidney Transplantation: A Report of 9 Cases
Kuo-Kai Chin, Michelle M. O’Shaughnessy, Paul C. Grimm, Megan L. Troxell, 
Xingxing S. Cheng. Stanford University School of Medicine, Stanford, CA.
Background: ICGN with positive immunofluorescence (IF) for IgG, IgA, IgG, C3, and 
C1q has been termed “non-lupus full-house nephropathy (FHN)” in the absence of clinical 
or serologic features of systemic lupus erythematosus (SLE). We describe characteristics 
and outcomes of ICGN with IgG, C3, and C1q +/- IgM/IgA deposits in the kidney allograft.
Methods: We retrospectively reviewed a single-institution pathology database from 
2007-2017 to identify cases of allograft ICGN with IgG, C3 and C1q in the absence of SLE. 
Clinicopathologic and outcome data were derived from patient records.
Results: Of 9 patients, most were non-white (89%), male (89%), and pediatric-
adolescent (66%). None had ICGN as cause of ESRD. Median time from transplant to 
ICGN was 1.6 (range 0.5-5.2) years and 5/9 (56%) were identified on surveillance biopsy. 
Two of 7 patients had a positive donor-specific antibodies. By light microscopy, 7 cases had 
mesangial hypercellularity, and two had FSGS. At last follow-up (median 3.9 years, range 
0.5-13.8), 7 of 9 patients (78%) had a stable serum creatinine with minimal proteinuria in 6. 
The remaining 2 patients had persistent allograft dysfunction. Four patients had subsequent 
biopsies with immunofluorescence: 3 (75%) showed persistent ICGN while 1 (25%) had 
resolution of immune complexes.
Conclusions: Post-transplant ICGN with IgG, C3 and C1q may be clinically silent 
and/or resolve spontaneously and in most cases appears to follow an indolent clinical 
course. Whether immune complex formation results from an auto- or allo-immune response 
remains to be elucidated.
Tx = Transplant; Bx = biopsy; FSGS = Focal Segmental Glomerulosclerosis; 
HY = hypercellularity; sCr = serum creatinine, mg/dL; uPCR = urine protein-creatinine 
ratio, g/g; surv = surveillance; MICD = mesangial immune complex deposition; 
MMF = mycophenolate mofetil
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Human Chorionic Gonadotropin (hCG) in Dialysis Patients
Natalja Haninger-Vacariu,1 Harald Herkner,2 Matthias Lorenz,5 
Marcus D. Saemann,4 Andreas Vychytil,1 Martin Jansen,6 Rodrig Marculescu,1 
Reinhard Kramar,3 Gere Sunder-Plassmann,2 Alice Schmidt.1 1Medical 
University of Vienna, Vienna, Austria; 2Medical University Vienna, Vienna, 
Austria; 3Austrian Dialysis and Transplant Registry, Kematen, Austria; 
4Wilhelminen Hospital, Vienna, Austria; 5Dialysis Centre Vienna, Vienna, 
Austria; 6Hospital St. John of God, Vienna, Austria.
Background: The FDA mandates pregnancy testing before and 8 days after initiation 
of therapy with MMF/MPA because its use in pregnancy is associated with an increased 
risk of miscarriage and congenital defects. However, a few case reports showed hCG to be 
elevated in transplant candidates resulting in refusal of transplantation.
Methods: We examined hCG serum concentrations in female dialysis patients, 
18-50 years of age, and defined fertility status according to STRAW criteria. We classified 
hCG positive above a cut-off at 5 mIU/l. For an enhanced index test we classified hCG 
positive above a cut-off at 5 mIU/l for fertile patients and 14 mIU/l for non-fertile patients
to calculate diagnostic test accuracy. We estimated the ideal cut-off for hCG using Liu’s 
method with bootstrapped 95% CIs. We report estimates for hCG as a diagnostic test and 
predictors for elevated hCG using multivariable linear regression.
Results: Among 71 women two (2.8 %) were pregnant presenting with elevated hCG 
serum concentrations. We observed hCG concentrations greater than 5 mIU/ml, potentially 
indicating pregnancy, in 10 further patients. A hCG serum concentration > 5 mIU/ml had a 
sensitivity of 100% (95% CI: 100 to 100), a specificity of 86% (95% CI: 77 to 94), a positive 
predictive value (PPV) of 17% (95% CI: 8 to 25) and a negative predictive value (NPV) of 
100% (95% CI: 100 to 100) for the diagnosis of pregnancy. Using a hCG cut-off of > 14 
mIU/ml for non-fertile patients sensitivity and NPV did not change, the specificity increased 
to 93% (95% CI: 87 to 99) and the PPV was 29% (95% CI: 18 to 39). Excluding 23 non-
fertile patients resulted in a specificity of 98% (95% CI: 94 to 100) and a PPV of 67% (95% 
CI: 53 to 80) whereas sensitivity and NPV did not change. The ideal hCG cut-off was 25.0 
mIU/ml (95% CI: 17 to 33). Pregnancy (coefficient: 8.7; 95% CI: 6.6 to 10.7; p<0.001) and 
fertility (coefficient: -2.7; 95% CI: -3.5 to -1.8; p<0.001), but not age (coefficient -0.03; 
95% CI: -0.08 to 0.01; p=0.13) were independent predictors of log transformed hCG.
Conclusions: hCG is elevated > 5 mIU/ml in 14,5% of non-pregnant dialysis patients 
of child-bearing age. In fertile women this cut-off can be used to exclude pregnancy. For our 
population the ideal hCG cut-off was 25 mIU/ml.
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Post-Translational Modifications of Albumin Causes a Decreased Binding 
Capacity of Hydrophobic Metabolites
Vera Jankowski,3 Heidi Noels,2 Joachim Jankowski.1 1RWTH Aachen, Aachen, 
Germany; 2RWTH University Aachen, Aachen, Germany; 3University hospital 
RWTH Aachen, Aachen, Germany.
Background: Since post-translational modifications of proteins may have an impact 
on the pathogenesis of diseases like atherosclerosis or chronic kidney disease (CKD), 
post-translational modifications are currently gaining increasing interest. In this study, a 
comprehensive method for analysis ofpost-translational modifications is established for the 
clinical diagnostic routine.
Methods: Here, we analysed albumin isolated from CKD patients and healthy 
controls by chromatographic steps and identified by mass-spectrometry. Post-translational 
modifications of albumin were identified after digestion by analysing mass-signal shifts of 
albumin peptides using pertinent mass-databases.
Results: Albumin isolated from plasma of CKD patients but not from healthy control 
subjects was specifically post-translationally modified by guanidylation of lysines at 
positions 249, 468, 548, 565 and 588. After identification of guanidylations as post-
translational modifications of albumin isolated from CKD patients, these modifications were 
quantified by mass-spectrometry demonstrating a significant increase in the corresponding 
mass-signal intensities in CKD patients compared to healthy controls. The relative amount 
of guanidylation of lysine at position 468 in CKD patients was determined as 63 ± 32 % 
(N=3). In-vitro guanidylation of albumin from healthy control subjects caused a decreased 
binding capacity of albumin in a time-dependent manner. Binding of indoxyl sulfate (protein 
bound fraction) decreased from 82 ± 1 % of non post-translationally modified albumin 
to 56 ± 1 % after in-vitro guanidylation (p < 0.01) whereas the binding of tryptophan 
decreased from 20 to 4%. These results are in accordance with the binding of indoxyl 
sulfate to albumin from healthy control subjects and CKD patients (88 ± 3 vs. 74 ± 10, 
p < 0.01). Thus, in-vitro post-translational guanidylation of albumin had a direct effect on 
the binding capacity of hydrophobic metabolites like indoxyl sulfate and tryptophan.
Conclusions: We used a mass spectrometry-based method for the characterisation 
of post-translational modification and demonstrated the pathophysiological impact of a 
representative post-translational modification of plasma albumin. The data described in this 
study may help to elucidate the pathophysiological role of protein modifications.
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Validation of a Modified Serum Ammonia Assay to Quantify Urine 
Ammonium in CKD
Valentinas Gruzdys,2 Kenneth Cahoon,4 Lauren N. Pearson,3 
Christopher Lehman,2 Kalani L. Raphael.1,2 1VA Salt Lake City Health Care 
System, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT; 3University 
of Utah & ARUP Laboratories, Salt Lake City, UT; 4ARUP Laboratories, Salt 
Lake City, UT.
Background: Low urine (u) NH4+ excretion is associated with higher risk of GFR 
decline in CKD. Few clinical laboratories measure uNH4
+ limiting clinical application, and 
urine anion and osmolar gaps poorly estimate uNH4
+ in CKD. We determined whether a 
clinically-approved serum NH3 assay reliably quantifies uNH4
+ in CKD.
Methods: uNH4+ was measured using the Randox (Ireland; glutamate dehydrogenase 
method) serum NH3 assay on the Architect ci8200 chemistry analyzer. Preliminary studies 
found that 1:40 dilution of urine with Architect on-board diluent quantified uNH4
+ within 
limits of the assay (20–1180 μmol/L). Precision studies were performed using synthetic 
urines with known [NH4
+] (2.5, 15.6, and 29.5 mmol/L) over 20 days (n=80 measurements 
per synthetic urine). We then compared [uNH4
+] obtained by the Randox assay and by 
formalin-titration in 22 CKD patients (n=58 samples) using Deming regression.
Results: Randox serum NH3 assay total imprecision (%CV) with 1:40 dilution 
was 17.7%, 5.1%, and 2.2% in the 2.5, 15.6 and 29.5 mmol/L uNH4
+ synthetic urines, 
respectively. In all 58 patient samples, 1:40 dilution quantified uNH4
+ within the range of 
the Randox NH3 assay. After accounting for the pH of formalin, the correlation between 
uNH4
+ by formalin-titration and the modified Randox assay was 0.9778 with a regression 
slope of 1.01 and intercept of 0.70 mmol/L (Figure).
Conclusions: After 1:40 urine dilution, precision of the Randox serum NH3 assay to 
quantify uNH4
+ was better with higher uNH4
+. Nevertheless, agreement between uNH4
+ by 
this approach and by formalin-titration was excellent across a wide range of values in CKD. 
uNH4
+ can be reliably quantified in CKD after 1:40 dilution using a standard plasma NH3 
assay and an automated chemistry analyzer.
Funding: Veterans Affairs Support
Comparison of uNH4
+ by the modified Randox serum NH3 assay and formalin-titration
SA-PO1102 Poster Saturday
Pathology and Lab Medicine: Clinical
Validation of the Novel SOMAscan-Based Proteomic Platform in ESRD
Zhongji Han,1 Zhousheng Xiao,2 Leigh D. Quarles,1 Csaba P. Kovesdy.1 
1University of Tennessee Health Science Center, Memphis, TN; 2The University 
of Tennessee Health Science Center, Memphis, TN.
Background: End stage renal disease (ESRD) is characterized by complex metabolic 
abnormalities. The clinical relevance of many abnormalities in ESRD remains unclear due 
to the lack of clinically applicable and reproducible diagnostic tests to measure the full 
spectrum of abnormal proteins and metabolites seen in these patients. The development of 
multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and 
therapeutic approaches in patients with ESRD. SOMAscan is a novel multiplex proteomic 
platform which can measure >1,300 circulating proteins, which, however, has not yet been 
validated in patients with ESRD. In the present study, we aimed to explore the reliability of 
SOMAscan for ESRD biomarker measurement.
Methods: We obtained plasma samples from 21 maintenance hemodialysis patients 
and applied the commercially available SOMAScan proteomic assay to simultaneously 
measure the concentrations of 1,372 proteins. We employed quality control assessments 
to remove the SOMAscan assay and sample bias and used Student’s t tests to identify 
differentially expressed SOMAmer reagents. We compared concentrations of SOMAScan-
measured prostate specific antigen (PSA) between males and females to test for the 
presence of biologically expected differences. We validated the SOMAScan concentrations 
of fibroblast growth factor 23 (FGF23), FGF receptor 1 (FGFR1), and FGFR4 using 
ELISA. We used Pearson correlation coefficients for correlation analysis and we performed 
principal component analysis.
Results: Patients were 57±14 years old, 52% were males and 48% were African 
American. All 21 samples passed the quality control assessments of SOMAscan assay. The 
mean (± standard deviation) SOMAScan PSA concentration was 4205.6 ± 2799.3 relative 
fluorescence units (RFU) in males vs. 1060.8 ± 1102.5 RFU in females (p<0.01), suggesting 
biological plausibility. Concentrations measured by SOMAscan correlated well with the 
ELISA results for FGF23 (R=0.970) and FGFR4 (R=0.507). No significant correlation was 
found between the FGFR1 SOMAscan and ELISA measurements (R=0.055).
Conclusions: There is a good albeit not perfect correlation between the SOMAscan 
assay and standard immunoassays. The SOMAscan technology may be useful for the 
measurement of circulating plasma proteins in ESRD.
SA-PO1103 Poster Saturday
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A Vicious Cycle of Steroid Therapy, Hyperlipidemia, and Macrophage 
Activation in the Progression of Chronic Renal Lesions
Yohei Ikezumi,1 Yuji Matsumoto,1 Tomomi Kondo,1 Hiroya Hasegawa,2 
Takeshi Yamada,2 David J. Nikolic-Paterson.3 1Fujita Health University School 
of Medicine, Toyoake, Japan; 2Niigata University Medical and Dental Hospital, 
Niigata-City, Japan; 3Monash Medical Centre, Clayton, VIC, Australia.
Background: We have previously reported that increasing numbers of LDL-scavenger 
receptor (SR)+ macrophages (MQ) is a feature of refractory nephrotic syndrome (RNS) 
in hyperlipidemic patients treated with high-dose glucocorticoids. To investigate potential 
pathogenic mechanisms, we examined how glucocorticoids and hyperlipidemia alter the 
function of human MQ.
Methods: Normal human monocyte-derived MQ (huMQ) were incubated with 
dexamethasone (Dex), or oxidized LDL (oxLDL) or both, for 48 hours and then analysed 
by DNA microarray.
Results: Dex and/or ox-LDL stimulation induced up-regulation of scavenger receptors 
characteristic of M2-type MQ (CD163, CD204 and CD36). Dex and/or ox-LDL also 
induced up-regulation of cytokines and growth factors associated with inflammation and 
fibrosis (CCL2, CXCL13, NOS2, TGF-β1, FGF-1, FGF-2 and VEGF-D). In addition, 
a change in MQ metabolism is suggested altered expression of glucokinase regulator, 
aldose reductase and acetyl-CoA carboxylase. Immunohistochemistry revealed significant 
expression of FGF1 in biopsies from RNS patients with RNS which co-localized with 
CD204+ MQ in areas of fibrosis.
Conclusions: Our data suggest that a vicious cycle of steroid therapy, hyperlipidemia, 
and M2-type MQ activation promote the progression of renal chronic lesions and treatment 
resistance.
Funding: Government Support - Non-U.S.
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Effects of Kidney Diseases on Platelet Activation
Naoki Ikegaya,1 Takuya Yoshida,3 Hiromichi Kumagai,3 Tatsuo Yamamoto,4 
George Seki,2 Akira Hishida.2 1Department of Medicine, Yaizu City Hospital, 
Yaizu, Japan; 2Department of Nephrology, Yaizu City Hospital, Yaizu, Japan; 
3University of Shizuoka, Shizuoka, Japan; 4Department of Nephrology, Fujieda 
City Hospital, Fujieda, Japan.
Background: Platelet activation can lead to intravascular thrombosis formation. 
Immature platelets comprise the youngest component of circulating platelet pool and 
actively participate in thrombosis formation. Although patients with kidney diseases are 
at increased risk of altered coagulation of both thrombotic and bleeding, little data on 
the presence of immature platelets in kidney diseases are available. We investigated the 
relationship between renal function and immature platelets count (IPC) and evaluated 
effects of endothelial dysfunction, inflammation and thrombopoietin on IPC in patients 
with kidney diseases.
Methods: First, we measured IPC in patients with 235 chronic kidney diseases, 
32 patients with acute kidney injury (AKI), and 75 patients with hemodialysis (HD). 
Immature platelets were measured with an automated hematoanalyzer that uses fluorescent 
dyes containing polymethine and oxazine. Second, we analyzed serum interleukin-6, 
thrombopoietin, and thrombomodulin in HD patients and evaluated the correlation between 
IPC and them.
Results: In patients with CKD, IPC had a tendency to decrease with the deterioration of 
renal function, but was not significantly correlated with eGFR (G1+2: n=69, 0.71±0.33, G3: 
n=83, 0.66±0.35, G4+5: n=83, 0.62±0.38×104 /μL). Patients with HD showed significantly 
lower IPC than patients with CKD (0.47±0.33×104 /μL, p < 0.05). On the other hand, 
patients with AKI showed significantly higher IPC than other groups at the peak of serum 
creatinine (0.99±0.76×104 /μL, p < 0.05). Among HD patients, patients with catheters 
showed significantly increased IPC compared to patients with fistulas (0.69 vs. 0.38×104 /μL, 
p < 0.05). Second, IPC was not correlated with thrombopoietin (r=-0.159) and IL-6 
(r=0.223), but significantly related with thrombomodulin (r=0.359, P< 0.01) in HD patients.
Conclusions: HD patients showed decreased platelet activation compared to non-HD 
patients, suggesting that uremia might decrease the activation of platelets. In AKI patients, 
there was a transient platelet activation in the course of AKI. Microvascular endothelial 
dysfunction might cause platelet activation and intravascular thrombus formation.
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Removal of sFLT-1 and PlGF with Plasmapheresis in Pregnancy
Milani Sivagnanam, Huiting Wei, Samia Q. Khan, Vineet Gupta, 
Mamoor S. Latef, Casey N. Gashti, William L. Whittier. Rush University 
Medical Center, Chicago, IL.
Background: Preeclampsia is characterized by HTN and proteinuria >20 weeks of 
gestation with glomerular endotheliosis thought to be due to an imbalance of angiogenesis 
(placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFLT-1)). sFLT-
1 levels are higher near the end of normal pregnancies; however, sFLT-1 levels increase 
earlier and to higher concentrations and inhibit PlGF in preeclampsia. Removal of sFLT-
1 using selective apheresis in early preeclampsia prolongs time to delivery. The effect of 
membrane-based plasma exchange (mTPE) on sFLT-1 and PlGF levels are not known.
Methods: A 33 y/o 35 week pregnant patient presented with a concern for HELLP 
vs. TTP. Empiric daily mTPE sessions with FFP replacement were initiated until her 
ADAMTS13 returned at 42%. Her clinical status gradually improved after delivery of the 
placenta and a viable baby. Serum samples were obtained before, immediately following, 
and two hours after one mTPE session. We examined sFLT-1 and PlGF concentration of 
these samples as well as in the effluent in duplicate.
Results: sFLT-1 was immediately reduced by 86% with mTPE (64.94 ng/ml to 9.17 ng/mL, 
p=0.03) and rebounded to 15.88 ng/mL two hours after (p=0.02), 4 times less than pre-
mTPE values. Effluent sFLT-1 was 38.46 ng/mL. PlGF was immediately reduced by 48% 
(42.40 pg/ml to 21.89 pg/ml, p=0.13) and rebounded to pre-mTPE values two hours after 
(42.7 pg/mL, p=0.07). Effluent PlGF level was 42.4 pg/ml. The reduction in the sFLT-1/
PLGF ratio was 1.53 to 0.42 (73% reduction) (p<0.01) (Fig 1).
Conclusions: mTPE removed sFLT-1 from the serum at nearly a 4:1 ratio compared to 
PlGF in pregnancy, and PlGF rebounded to pre-mTPE values within two hours. This ratio 
reduction is theoretically favorable to improve the angiogenic imbalance in preeclampsia 
and suggests that mTPE may have a role as therapy for preeclampsia in the future.
Removal of sFLT-1 and sFLT-1/PlGF ratio in pregnancy with mTPE. *p<0.05
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Sterile Pyuria Is Common in CKD and Differential Counting of Urinary 
Leukocytes Could Be Helpful for Predicting Urinary Tract Infection
Hye Min Choi,1 Young Eun Kwon,2 Dong-jin Oh.3 1Internal medicine, Myongji 
Hospital, Goyang-si, Republic of Korea; 2Myoungji hospital, Goyang-si, 
Gyeonggi-do, seoul, Republic of Korea; 3Myongji Hospital, Koyang, Republic of 
Korea.
Background: Pyuria is a helpful marker for urinary tract infection (UTI) in general 
population. Meanwhile, pyuria is not infrequent in advanced chronic kidney disease 
(CKD) patients. There has been assumption that sterile pyuria can be seen in CKD due to 
chronic renal parenchymal inflammation. However, there are limited data on whether CKD 
increases the rate of pyuria or how we should interpret pyuria of CKD. Here, we aimed to 
investigate the prevalence and characteristics of pyruia of CKD.
Methods: This was a cross-sectional study of a single center. Urine analysis 
(UA) was performed in all the stable hemodialysis (HD) and non-dialysis CKD (eGFR 
< 60ml/min/1.73m2) patients of the outpatient clinic during 3 month. Patients with urinary 
symptom or recent history of antibiotics were excluded. Pyuria was defined as white blood 
cell (WBC) ≥ 5/high power filed by microscopy. WBC differential counting was done in 
case UA showed pyuria. Culture-positive pyuria was defined as UTI.
Results: UA was examined in 70 HD patients who voids at least once every day and 228 
non-dialysis CKD patients. The prevalence of pyuria was 51.4% (male (M) 36.1%, female 
(F) 67.6%) in HD and 22.4% (M 12.5%, F 39.3%) in CKD population, and were much
higher compared to that of the age-matched general population (overall 7.3%, M 1.6%, F
19.1%) which was obtained from health examination in the same hospital (n=4897). Of the 
86 patients with pyuria, only 22.1% were proven to be UTI (11.1% of HD and 30.0% of
CKD). Female gender, lower stages of CKD, more leukocytes in urine, and positive nitrite-
response were associated with true UTI in pyuric patients. As for differential counting, the 
majority of urinary leukocytes were still neutrophils even in sterile pyuria. However, the
percentage of neutrophil was significantly lower (69.1% vs 92.5%), and the percentages of 
lymphocyte and monocyte were higher (18.5% vs 4.9% and 9.9% vs 2.1%, respectively) in 
sterile pyuria compared with UTI. In multivariate logistic regression analysis, the degree of 
pyuria, nitrite response, and the percentage of neutrophil remained independently associated 
with UTI in pyuric patients.
Conclusions: Pyuria is more common in CKD than in the general population. 
Differential cell counting of urinary leukocytes could be helpful for predicting UTI in 
asymptomatic CKD patients with pyuria.
SA-PO1107 Poster Saturday
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New Urine Biomarkers for Site-Unique Injuries in the Kidney
Keiko Yamamoto,1 Shigeru Miyazaki,3 Tadashi Yamamoto.1,2 Biofluid 
Biomarker Center 1Niigata University, Niigata, Japan; 2Shinrakuen Hospital, 
Niigata, Japan; 3Shinraku-en Hospital, Niigata, Japan.
Background: In kidney diseases, various sites, such as glomerulus and other sites are 
injured to appear functional impairments and symptoms varied according to the injured 
sites and its degree. We aimed to develop urine examination to obtain the kidney site-
unique injuries by proteomic biomarker discovery. To select kidney site-unique proteins as 
candidates of urine biomarkers for these site injuries, various parts of the kidney sections 
were analyzed by proteomics. To validate usefulness of the biomarker candidates, we 
established antibody-based assays for measurement of these biomarker candidates in urine 
and examined relationship between the urine excretion and the degree of kidney injuries. 
Finally we could select several urine biomarkers for injuries at various parts such as the 
glomerulus, proximal tubule and interstitium.
Methods: Sections of human kidney parts (glomerulus, proximal tubule, distal tubule, 
collecting duct etc) were laser micro-dissected from formalin-fixed paraffin-embedded 
kidney sections and peptides were collected from these sections of kidney parts by the on-
site direct digestion method for mass spectrometry (Orbitrap Fusion, Thermo Scientific). 
The proteomes of these kidney parts were compared each other and also with those of 
plasma and urine proteomes to select proteins, which were uniquely excreted from each 
site or part of the kidney. We established immunoassay system by using a surface plasmon 
resonance (SPR) device (ProteOn, Bio-Rad). Several site-unique urine proteins selected by 
proteomics: PRA2R1 and GPRC5C for glomerulus-, NPR1 for proximal tubule- and GGT5 
for interstitium-injury) were quantitatively measured in urine samples from CKD patients 
(IgA nephropathy and diabetic nephropathy) by SPR for validation.
Results: Concentrations of the proteins increased significantly in urine with the stage 
of CKD: PRA2R1 and GPRC5C excretion in urine presumed to reflect the degree of 
glomerular injury, NPR1 to predict the proximal tubule reactions and GGT5 the interstitial 
expansion, indicating that these new urine biomarkers are useful for evaluation of kidney 
injuries more precisely as or more than the kidney biopsies or evaluation of kidney injuries 
more precisely.
Conclusions: Non-invasive urine tests for the new biomarkers may be beneficial for 
clinical quantitative evaluation of kidney site-unique injuries for precision medicine in the 
near future.
Funding: Commercial Support - Tosoh compary
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Comparison of Urine and Plasma Biomarker Levels Measured by 
Aptamer-Based versus Immunoassay Methods in Cardiac Surgery 
Patients
Lidiya Kukova,2 Sherry Mansour,2 Steven G. Coca,1 Heather Thiessen 
Philbrook,2 Michael Shlipak,3 Chirag R. Parikh.4 1Icahn School of Medicine at 
Mount Sinai, New York, NY; 2Yale University, New Haven, CT; 3San Francisco 
VA Medical Center, San Francisco, CA; 4Yale University and VAMC, New 
Haven, CT.
Background: Protein-detection assays are invaluable tools in biomarker discovery. 
However, only immunoassays are widely used, measuring 10-20 analytes per biosample. 
The novel aptamer-based assay uses nucleotide aptamer technology to measure over 
1,300 analytes per biosample. We sought to compare the aptamer-based platform versus 
traditional immunoassay approaches to quantify analytes in paired samples before and after 
cardiac surgery.
Methods: In a sub-study of the TRIBE-AKI cohort, 54 individuals with acute kidney 
injury (AKI) after cardiac surgery were identified. The group included AKI progressors 
and AKI non-progressors. The levels of preoperative and postoperative plasma and urine 
biomarkers which had been previously evaluated via immunoassays were compared to the 
levels detected by an aptamer-based assay using Spearman correlations.
Results: Spearman correlations were estimated when at least 50% of biomarker values 
were within detectable ranges (plasma: preoperative 26/33, postoperative 31/33; urine: 
preoperative 13/16, postoperative 16/16). Twenty seven percent of reportable plasma 
preoperative biomarkers displayed correlations ≥0.75 between immunoassay and aptamer 
measurements, 23% displayed correlations of 0.50-0.75, and 50% displayed correlations 
<0.50. In urine these values were 15%, 39%, and 46%, respectively. Forty two percent of 
reportable plasma postoperative biomarkers displayed correlations ≥0.75, 16% displayed 
correlations 0.50-0.75, and 42% displayed correlations <0.50. In urine these values were 
19%, 25%, and 56%, respectively.
Conclusions: The aptamer-based assay detects proteins with moderate to strong 
correlation to current immunoassay methods. The correlations in urine are weaker compared 
to plasma. Aptamer-based assay technology should be further validated in multiple settings 
as a high-throughput screening tool for biomarker discovery.
Funding: NIDDK Support, Other NIH Support - RO1HL085757, K24DK090203, 
R01DK096549, U01DK082185
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GFR Adjusted Uric Acid Levels Are a Superior Cardiovascular Outcome 
and Mortality Predictor Than Uric Acid Levels Alone
Eva Koenigshausen,1 Johanna Rubel,1 Winfried März,3 Lars C. Rump,1 
Lorenz Sellin.2 1Medical Faculty Heinrich-Heine-University Düsseldorf, 
Düsseldorf, Germany; 2Heinrich-Heine University Duesseldorf, Duesseldorf, 
Germany; 3V. Medical Clinic, University Hospital, Mannheim, Germany.
Background: Hyperuricemia is associated with increased cardiovascular risk and 
mortality. Chronic renal failure increases uric acid (UA) levels due to decreased filtration. A 
formula calculating GFR adjusted UA levels (estimated UA, eUA) has been developed by 
our group. The aim of this study was to evaluate the potential of eUA levels in predicting 
cardiovascular outcome and mortality in a cardiovascular risk cohort of patients.
Methods: The relation of GFR and UA levels was investigated with the eUA-formula 
in the LURIC cohort. LURIC was a prospective cohort study to identify genetic and 
metabolic risk factors in coronary heart disease. Patients were excluded with GFR levels 
<10ml/min and >100ml/min because of eUA-formula reasons. Subgroup analysis was 
performed (eUA < UA as risk group and eUA > UA as control group). Mortality, chronic 
heart failure (CHF) and cardiac events (CE) were documented outcome parameters. Binary 
univariate and multivariate logistic regression analysis were performed to study prediction 
of outcome variables by eUA or UA.
Results: 3316 patients were included in the LURIC cohort. Due to GFR, 652 patients 
were excluded. Of 2654 patients (1774 male) at an age of 64.71 ± 9.21 the GFR was 
75.78 ± 16.98 ml/min. UA levels were measured with 5.24 ± 1.75 mg/dl. 686 patients 
(25.8%) died of all-cause mortality during the follow up period of the study. Mean UA 
levels in the subgroups did not differ. GFR was significantly lower in the risk group vs. the 
control group. Mortality and CHF NYHA > 1 were significantly higher in the risk group 
than in the control group (OR 1.35 and 1.65), while no differences were noted for CE. 
Univariate analysis revealed a significant benefit of using the eUA model compared to the 
classic UA model in predicting mortality (OR 1.8 vs. 1.23; -2LL 2874.32 vs. 2962.33) and 
CE (OR 1.54 vs. 1.16; -2LL 3231.37 vs. 3301.27). Multivariate regression analysis showed 
a significant better prediction of the outcome variables mortality (OR 6.06 vs. 1.25; -2LL 
2187.17 vs. 2264.13), CHF (OR 2.96 vs. 1.65; -2LL 3160.43 vs. 3170.40) and CE (OR 
2.35 vs. 1.48; -2LL 2445.85 vs. 2474.54) in the adjusted eUA-model compared to the UA-
model group.
Conclusions: GFR adjusted uric acid (eUA) levels predict cardiovascular outcome 
significantly better in a cardiovascular risk cohort than uric acid levels alone.
SA-PO1110 Poster Saturday
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The Automated Urinalysis in Proliferative Glomerulonephritis
Ragnar Palsson,2 Anand Srivastava,1 Sushrut S. Waikar.2 1Northwestern 
University Feinberg School of Medicine, Chicago, IL; 2Harvard Medical 
School, Boston, MA.
Background: Since the introduction of automated urine analyzers, manual examination 
of the urine sediment has rapidly fallen out of favor. Limited data are available on the test 
performance characteristics of the modern automated urinalysis (UA).
Methods: We studied whether features on an automated UA distinguish proliferative 
glomerulonephritis (PGN) from other forms of kidney disease using a prospective 
observational cohort of adult patients undergoing native kidney biopsies at 3 tertiary care 
hospitals in Boston, MA. We included individuals who had an automated UA within 30 
days of kidney biopsy along with an adjudicated clinicopathologic diagnosis. We excluded 
individuals who were on immunosuppression at the time of the biopsy.
Results: 134 of 512 patients had PGN. The mean age was 53.9±15.9 years, 46.3% 
were female, and 68.6% were white. The mean estimated glomerular filtration rate was 
53±34 mL/min/1.73m2 and median proteinuria was 2.0 (interquartile range 0.63-4.97) g/g 
creatinine. Table 1 shows the sensitivity and specificity of automated urine RBC counts for 
diagnosis of PGN at different levels of dipstick proteinuria. The automated urine RBC count 
identified PGN with an area under the receiver operating characteristic curve of 0.75. At a 
threshold of >2 RBCs per high-power field (HPF), the positive predictive value was 38% 
and the negative predictive value was 91% for PGN. Among those with ≤1+ proteinuria, 
the negative predictive value rose to 97%. RBC casts and dysmorphic RBCs were rarely 
reported (1 and 3 cases of PGN, respectively).
Conclusions: Hematuria and proteinuria from the automated UA had modest ability to 
differentiate PGN from other kidney diseases. The diagnostic performance characteristics 
of the manual sediment exam should be investigated and compared directly to those of the 
automated UA.
Funding: NIDDK Support
Table 1. Sensitivity and specificity of automated UA RBC counts and dipstick protein for 
diagnosis of PGN.
RBC, red blood cell; HPF, high-power field; UA, urinalysis.
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Comparison of Different Methods of Urinary Protein Excretion  
Measurement–Is the King Really Dead?
Alicja Rydzewska-Rosolowska,1 Katarzyna Kakareko,1 Tomasz Hryszko,2 
Szymon Brzosko,3 Beata Naumnik.1 1Medical University of Bialystok, 
BIALYSTOK, Poland; 2II Department of Nephrology and Hypertension, Medical 
University of Bialystok, Bialystok, Poland; 3DaVita Poland, Bialystok, Poland.
Background: Assessing proteinuria is one of the most important diagnostic tests for a 
clinical nephrologist. When treating patients, it is often indispensable to accurately quantify 
the amount of protein lost, hence cumbersome timed urine collections (the gold standard 
or “king” of methods– 24h protein excretion rate- PER) are often replaced by spot urinary 
protein to creatinine ratio (PCR). The aim of the study was to determine whether the latter 
can reliably compare to the gold standard and whether “timing” of a spot urine sample is 
essential (as there is a diurnal and postural effect on protein excretion).
Methods: 143 adult patients hospitalized in the I Department of Nephrology with 
proteinuria (both primary and secondary glomerular diseases) were examined (a total of 
187 cases). Subjects with an active infection or tumors of the urinary tract were excluded. 
Each patient was instructed how to perform a 24-hour urine collection and on the same day 
three consecutive urine samples were also collected (starting with the first morning void). 
Concentration of protein and creatinine in spot urine samples and the timed urine collection 
were measured.
Results: PCR from all three spot samples moderately correlated with 24h PER (0.76, 0.79 
and 0.82 respectively). Log transformation of examined variables slightly improved 
observed association (0.80, 0.84 and 0.86). The sensitivity and specificity for proteinuria 
above 1.0 g/day were 0.79 and 0.73 for sample 1, 0.82 and 0.68 for sample 2 and 0.82 and 
0.67 for sample 3. For nephrotic proteinuria it was respectively 0.62 and 0.94, 0.62 and 
0.93, 0.66 and 0.92. Sex, age, weight and serum albumin concentration were significantly 
associated with 24h PER and were used for development of prediction equation yielding 
adjusted R2of 0.78, 0.83 and 0.86. Bland-Altman analysis revealed an increasing difference 
between 24h PER and PCR with increasing proteinuria irrespectively of sampling time.
Conclusions: In patients with primary and secondary glomerular diseases spot urine 
protein to creatinine ratio only modestly correlates with daily proteinuria whether it’s 
morning or random urine sample. It seems, while searching for new markers, nephrologists 
can just say: “long live the king”.
SA-PO1112 Poster Saturday
Pathology and Lab Medicine: Clinical
Quantitation of Urinary Sediment Podocalyxin (u-sed-PCX) Predicts 
Urinary Podocyte Numbers
Masanori Hara,1 Hiroyuki Kurosawa.2 1Niigata Wellness (Iwamuro Health 
Promotion Center), Niigata, Japan; 2Denka Seiken Co., Ltd, Gosen, Japan.
Background: Immunostaining of urine sediments shows a small number of podocytes 
and numerous cell debris resulting from the destruction of podocytes due to cell death, 
therefore, to know the exact number of urinary podocytes it needs to add a portion of 
cell debris to the number of podocytes evaluated as whole cells. In the present study we 
developed a procedure to count the exact podocyte numbers (podocytes + cell debris) in 
the sediments.
Methods: 1) Urinary sediment PCX was quantified by ELISA (Diabetologia 55:2913, 
2012) in normal control and various glomerular diseases. 2) The idea to obtain the exact 
number of urine podocytes is based on the calculation of urine sediment PCX (reflecting 
whole podocytes + cell debris from destructed podocytes) divided by PCX content belonging 
to single podocyte. We named this number as estimated urine podocyte number (eUPN). 3) 
To obtain the PCX content belonging to single podocyte we caluculated from 3 models; 
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model 1 (assuming that it takes 150 years until complete podocyte loss from glomeruli in 
normal control), model 2 (evaluating podocyte loss during the interval in serial performed 
renal biopsies from our own patient with IgA nephropathy) and model 3 (evaluating podocyte 
loss from the published data in diabetic kidney disease (Diabetes 51;3083-3089, 2002). 
The mean value from 3 models was used in this study. 4) Several assumptive figures for 
normal control were used such as; urine volume:1000ml/day, Creatinine excretion:1 g/day, 
nephron number:1.5x106, podocyte number/glomerulus:500 cells.
Results: 1) Single podocyte PCX content was calculated as 141.6, 153.2 and 100.0 pg/
podocyte by model 1, 2 and 3, respectively. The mean value (131.6 pg/podocyte) was taken 
for determining eUPN in this study. 2) U-sed-PCX and (eUPN) in normal control, DKD, 
IgAGN, Nephrotic syndrome, Lupus nephritis, membranous nephropathy, ANCA related 
GN, and others were1.9 ng/mg creatinine (14.7 podocytes/mg creatinine), 3.6 (27.3), 2.0 
(15.0), 11.5 (87.0), 7.1 (54.3), 5.2 (39.1), 1.7 (13.1), and 1.8 (13.3), respectively. 3) U-sed-
PCX and (eUPN) in diabetic kidney diseases (normoalbuminuric, microalbuminuric and 
macroalbuminuric) was 1.6 (11.8), 3.7 (27.9) and 8.8 (66.7), respectively.
Conclusions: Quantitation of u-sed-PCX predicts more exact urinary podocyte number 
(eUPN), indicating this might be a better podometric biomarker in clinical nephrology.
SA-PO1113 Poster Saturday
Pathology and Lab Medicine: Clinical
Genotyping Apolipoprotein L1 (ApoL1) from Dry Plasma with Proteomics
Christopher M. Shuford, Meghan N. Bradley, Patricia L. Holland, 
Michael Levandoski, Jennifer L. Ennis, John R. Asplin, Russell P. Grant. 
Laboratory Corporation of America, Burlington, NC.
Background: ApoL1 has two genetic risk variants (G1 & G2) associated with increased 
risk of nondiabetic CKD and kidney transplant failure. As these risk variants occur almost 
exclusively in African Americans, genetic testing may improve both monitoring and outcomes 
of CKD as well as allocation of donor organs in this population. To this end, we developed 
a bottom-up proteomic assay to identify genetic variants of ApoL1 from both liquid plasma 
samples collected by venipuncture as well as from dry plasma samples produced on a blood 
plasma separation device that can be collected in-home via a finger prick.
Methods: Both 20 μL of plasma or ~95 mm2 punch of dried plasma were processed 
using a common workflow. Samples were denatured in DTT and deoxycholate for 30min 
at 56°C, then digested with 800μg of trypsin for 30min at 37°C (pH 8) after addition of 
labeled internal standards. Digestion was quenched and the deoxycholate precipitated by 
the addition of formic acid and the clarified supernatant analyzed by liquid chromatography 
coupled with tandem mass spectrometry. The three ApoL1 protein variants (WT, G1, G2) 
were uniquely detected by monitoring for the specific surrogate peptides containing the 
point mutations, which were produced by the trypsin digestion. Two surrogate peptides 
common among all protein variants were also monitored for quality control of sample 
processing.
Results: Reproducibility of the proteomic assay was demonstrated over 20 assay runs 
by analysis of dry and liquid specimens from 3 heterozygous individuals (WT/G1, WT/G2, 
and G1/G2). Dry plasma from the same heterozygous genotypes were observed to be stable 
for up to 4 weeks stored at ambient (22°C) and elevated temperature (37°C). Finally, perfect 
agreement with a Sanger Sequencing assay was observed in matched liquid and dry plasma 
specimens in a cohort of 209 African American donors, which consisted of 82 WT/WT, 
64 WT/G1, 38 WT/G2, 10 G1/G1, 10 G1/G2, and 5 G2/G2 individuals.
Conclusions: This proteomic assay provides the feasibility for ApoL1 genotyping 
using dry plasma which can be collected in-home via finger prick using blood plasma 
separation devices. Such testing should allow for more widespread and cost-effective 
genotyping of this high risk population.
SA-PO1114 Poster Saturday
Pathology and Lab Medicine: Clinical
Macrophages as a Marker for Endocapillary Hypercellularity in Lupus 
Nephritis
Elisabeth M. Bos,1 Suzanne Wilhelmus,1 Ron Wolterbeek,5 Natasha Jordan,2 
David D’Cruz,7 David Isenberg,3 H. Terence Cook,6 Jan A. Bruijn,4 
Ingeborg M. Bajema.5 1Pathan, Rotterdam, Netherlands; 2Cambridge University 
Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 3University 
College London, London, United Kingdom; 4Leiden University Medical Center, 
Dept.Pathology, Leiden, Netherlands; 5Leiden University Medical Centre, Leiden, 
Netherlands; 6Imperial College of London, London, United Kingdom; 7Guy’s and 
St. Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom.
Background: Lupus Nephritis (LN) is a manifestation of Systemic Lupus 
Erythematosus (SLE) which occurs in up to 60% of patients suffering from SLE. LN is 
strongly related to mortality and morbidity in SLE, especially class III and IV LN. The 
interobserver agreement of endocapillary hypercellularity which determines whether a 
biopsy is classified as class III or IV in LN, has been found to be moderate. In IgAN, 
the presence of glomerular macrophages was put forward as a surrogate marker for 
endocapillary hypercellularity. We investigated whether in LN, the presence of glomerular 
macrophages could serve as a surrogate marker for endocapillary hypercellularity as well.
Methods: 99 lupus nephritis biopsies were scored for the number of endo- and 
extracapillary macrophages per glomerulus using CD68 staining, as well as the overall 
presence of endocapillary hypercellularity (categorical variable E0/E1) and percentage 
of glomeruli with endocapillary hypercellularity (continuous variable E-continuous) per 
biopsy using a silver staining. Overall presence of endocapillary hypercellularity and 
percentage of glomeruli with endocapillary hypercellularity were both correlated with 
endo- and extracapillary macrophage count using a Mann-Whitney U test and a Spearman 
correlation test.
Results: A strong correlation was found between the quantity of glomerular 
macrophages and the presence of hypercelullarity, as well as between the percentage of 
glomeruli with endocapillary hypercellularity and number of glomerular macrophages. The 
correlation was stronger using only endocapillary macrophages in our analysis compared to 
extracapillary macrophages.
Conclusions: In lupus nephritis, the presence of glomerular macrophages is an 
excellent surrogate marker for endocapillary hypercellularity. This marker could be a useful 
tool towards a more effective and reproducible usage of the LN classification.
SA-PO1115 Poster Saturday
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The Japanese Histological Grade Classification and the Oxford Classifica-
tion of IgA Nephropathy Show the Same Prediction Performance on Renal 
Functional Decline in 905 Japanese Patients
Kensuke Joh,1 Akinori Hashiguchi,2 Akira Shimizu,3 Satoshi Hisano,4 
Ritsuko Katafuchi,5 Tetsuya Kawamura.6 1Tohoku University Graduate School 
of Medicine, Sendai-city, Japan; 2Keio University School of Medicine, Tokyo, 
Japan; 3Nippion Medical School, Tokyo, Japan; 4University of Occupational 
and Environment Health, Kitakyushu, Japan; 5National Fukuoka-Higashi 
Medical Center, Koga, Fukuoka, Japan; 6Jikei University School of Medicine, 
Division of Kidney and Hypertension, Tokyo, Japan.
Background: The Japanese Histological Grade Classification (JHGC) (Gr1-Gr4) was 
established as a lumped system corresponding to <25%, 25-49%, 50-74% and ≥75% of 
total glomeruli exhibiting active crescents (C), global sclerosis (G), segmental sclerosis (S), 
or fibrous crescents. In contrast, the Oxford classification is a split system constituting of 
dichotomized M, E, S, T1, T2, C1, and C2. The purpose was to compare the 2 classifications 
systems focusing on their ability to predict renal functional decline.
Methods: The 905 Japanese patients (pts) with IgA nephropathy (male : 49%, median 
age: 38 yrs) were prospectively followed for a median of 48 months. The average amount 
of proteinuria (PU) was 1.07 g/day. Mean eGFR and median rate of decline in eGFR were 
77.0 ml/min/1.73m2 and -0.95 ml/min/1.73m2/y, respectively. The prediction performance 
was compared using the Harrell’s C statistic (HCS). The clinical and therapeutic variables 
were additionally collected including initial PU, initial square root eGFR (SReGFR), initial 
mean arterial pressure, steroid therapy (ST), RAS blockade (RASB) and tonsillectomy (TON).
Results: 66 %, 54% and 42% of the patients were treated by ST, RASB, and TON, 
respectively. In stepwise Cox regression analysis for the full model, Gr4, Gr3, Gr2, PU, 
SReGFR, TON and ST for 1.5 time’s increase of serum creatinine (sCr) were selected as 
independent predictors, whose HR were 28, 7, 4, 2, 1, 1 and 0, respectively. HCS was 0.87. 
In Oxford, T2, T1, M, RASB, C1, PU, TON, SReGFR, ST and E were selected, whose 
HR were 4, 3, 2, 2, 2, 2, 1, 1, and 0, respectively, HCS was 0.86, which was statistically 
not different from that of JHGC. For the limited model without clinical and therapeutic 
parameters, Gr4, Gr3, and Gr2 were selected, whose HR was 79, 14, and 5, respectively. 
HCS was 0.82. In Oxford, T2, T1, M, and E but not S, C1, and C2 were selected, whose HR 
were 20, 5, 3, and 1, respectively. HCS was 0.81.
Conclusions: Both the lumped system of JHGC and the split system of Oxford showed 
the same high prediction performance on renal functional decline in full and limited model. 
However, a flexibility in a lumped approach of JHGC as opposed to a split system of Oxford 
may be more robust when being applied to diverse cohorts.
Funding: Government Support - Non-U.S.
PUB001 
Publication-Only 
Renal Transplant Function After Coronary Angiography with Iodinated 
Contrast
Jennifer S. Lees,1,2 Mark D. Findlay,2 Patrick B. Mark,3 Colin C. Geddes.2 
1Institute of Cardiovascular and Medical Sciences, University of Glasgow, 
Glasgow, United Kingdom; 2Glasgow Renal and Transplant Unit, NHS Greater 
Glasgow and Clyde, Glasgow, United Kingdom; 3University of Glasgow, 
Glasgow, United Kingdom.
Background: There is perceived risk to renal transplant function in administering 
iodinated contrast agents. There may be reluctance to perform coronary angiography in 
kidney transplant patients, despite an increased risk of cardiovascular disease compared 
with the general population. We sought to determine if renal transplant function was 
adversely affected within 30 days of coronary angiography.
Methods: Prevalent renal transplant patients undergoing coronary angiography in 
a single centre (01/2006 – 02/2018) were identified. Biochemical and demographic data 
were extracted from the electronic patient record. The most recent serum creatinine (SCr) 
prior to angiography (or average value over 3 months) was considered the baseline. Highest 
SCr within 7 days and within 30 days (or next available) of coronary angiography were 
extracted. Rise in creatinine >26 micromol /l was considered significant (equivalent to 
Acute Kidney Injury (AKI) Network criteria stage 1 AKI).
Results: There were 127 coronary angiographies conducted in 89 patients: 67.4% were 
male and mean age was 58.0 ± 10.1 years. Median time since transplant was 6.2 years 
(IQR 2.5 – 16.1); median time since start of first renal replacement therapy was 13.4 years 
(IQR 6.8 – 25.0). Median baseline SCr was 155 micromol/l (IQR 110-220, range 56-738). 
The most common indications for coronary angiography were angina (27.6%) and non-ST 
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elevation myocardial infarction (23.6%). Diagnostic angiography was conducted in 59.1%; 
balloon angioplasty or stenting in 40.9%. There was a significant rise in SCr within 7 days in 
24.5% cases (n=24/98; median rise 52, range 28-163 micromol /l). SCr returned to baseline 
within 7 days or there was an alternative explanation for rise in SCr in 20/24 cases. In 4 
cases with a clinically significant rise in SCr, there was known severe and progressive renal 
transplant dysfunction. Of those with no available SCr within 7 days (n=29/127), none had 
a persistent rise in SCr (7-30 days/next available). In the absence of critical illness at time 
of coronary angiography, no patient required dialysis or extended hospital stay for contrast-
associated AKI.
Conclusions: In this cohort of renal transplant recipients undergoing coronary 
angiography, there was a clinically significant rise in SCr in a minority of cases. Renal 
transplant should not be regarded as a contra-indication to coronary angiography.
Funding: Private Foundation Support
PUB002 
Publication-Only 
Community Acquired AKI in Mansoura Nephrology Dialysis Unit, One 
Year Prospective Observational Study
Mostafa A. Abdelkhalek,1 Sherouk S. Elnagar,2 Ashraf Hassan,2 
Mona M. Tawfik,3 Nagy A. Sayed-Ahmed.4 1Internal medicine, Hemodialysis 
and nephrology unit, Mansoura University, Faculty of Medicine, Mansoura, 
Egypt; 2Internal medicine, Mansoura University, Faculty of Medicine, 
Mansoura, Egypt; 3Internal medicine, Hemodialysis and nephrology unit, 
Mansoura University, Faculty of Medicine, Mansoura, Egypt; 4Internal 
medicine, Hemodialysis and nephrology unit, Mansoura University, Faculty of 
Medicine, Mansoura, Egypt.
Background: Acute kidney injury (AKI) is a major health problem with poor patient 
prognosis. We evaluated the clinical characteristics, risk factors, associated comorbidities 
and outcomes of AKI patients
Methods: A single center prospective observational study. The patients were admitted 
in Nephrology and Dialysis Unit in Mansoura University Hospitals over one year from 
January, 2016 to December, 2016. These patients were diagnosed to have AKI or AKI on 
top of CKD according to the KDIGO 2013 criteria. All patients were subjected to complete 
history taking, physical examination and full laboratory investigations
Results: We evaluated 199 (96 males plus 103 females) aged between 18 to 88 years 
old. Dehydration was the commonest precipitating factor for AKI in our patients (68.8%) 
and Oliguria was the commonest symptom present in 47.7 % of patients. 65.8 % of patients 
received intravenous fluids, 22.6 % of patients received diuretics and 33.7 % received renal 
replacement therapy in the form of intermittent haemodialysis while twenty five patients 
(13.16%) died and 44 patients showed no recovery
Conclusions: community acquired AKI (secondary mainly to dehydration and 
infections) is a major health problem with high morbidity and mortality
Description of clinical criteria of the patients
PUB003 
Publication-Only 
Urinary Urea Excretion as an Early Biomarker of AKI
David G. Morais, Gabriel A. Maranhão, Mirela Santinho, Victor F. Seabra, 
Leandro U. Taniguchi, Lucia Andrade, Camila E. Rodrigues. University of Sao 
Paulo School of Medicine, Sao Paulo, Brazil.
Background: Acute kidney injury (AKI) increases intensive care unit (ICU) morbidity 
and mortality, the diagnosis being based on urine output (UO) and serum creatinine (sCr), 
neither of which provides reliable, timely information. Most of the known AKI biomarkers 
are costly to determine and not widely used. Urinary concentration is impaired early in 
chronic kidney disease, and higher excretion of urea may be a marker of renal recovery for 
hemodialysis weaning. We hypothesized that low fractional excretion of urea (FeU) would 
be a timely biomarker of AKI.
Methods: We evaluated adult ICU patients at high risk for AKI according to a clinical 
score. We excluded patients with a basal estimated glomerular filtration rate (eGFR) 
<45ml/min/1.73m2, history of AKI or kidney transplantation, or body mass index <19kg/m2. 
On a daily basis, we evaluated urinary urea (UU), 6h-excreted urinary urea volume (UUv), 
FeU, and the UU/urinary creatinine (UU/Ucr) ratio. AKI was diagnosed on the basis of the 
KDIGO criteria (i.e., sCr or UO). Results are mean±SD.
Results: At baseline, the 17 patients included were 54±15 years of age, with a SAPS3 
of 50.6±11.9, sCr of 0.72±0.30mg/dl, and eGFR of 106±30ml/min/1.73m2. One day before 
AKI diagnosis (D−1), FeU was lower in the patients with AKI (n=5) than in those without 
(Table 1), with an area under the receiver operating characteristic curve of 0.88 (Figure 1). 
An FeU cut-off ≤22.75 had 80% sensitivity and 81.8% specificity for next-day AKI 
development.
Conclusions: FeU may be a feasible, accessible early biomarker of AKI. Supported 
by FAPESP.
Funding: Government Support - Non-U.S.
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Risk Factors of Postoperative AKI in Patients with CKD
Seolhyun Lee,1 Bhuwan Kayastha,1 Si-Nae Kim,2 Kaylee A. Carr,2 
Rachel Y. Kim,2 Genevieve Birang,2 Ella F. Kuchmiy,2 Yuriy Golub,2 Woo 
hyun Lee.3 1MultiCare Good Samaritan Hospital, Puyallup, WA; 2Pacific 
Northwest University of Health Sciences, Seattle, WA; 3Kangwon National 
University School of Medicine, Chuncheon, Republic of Korea.
Background: Postoperative acute kidney injury is associated with increased mortality 
and cost in major inpatient surgeries. Patients with chronic kidney disease are at high risk of 
postoperative acute kidney injury and associated complications.
Methods: We retrospectively collected perioperative data of 399 patients with 
chronic kidney disease who underwent common inpatient orthopedic or general surgeries 
(appendectomy, colectomy, cholecystectomy, total hip replacement, total knee replacement) 
at 5 hospitals in Washington State between January of 2015 and October of 2017. Total of 
374 patients were included for data analysis. Multivariate logistic regression analysis was 
used to identify statistical significance of each risk factor.
Results: 67 out of 374 patients (17.9%) developed acute kidney injury. Between the 
acute kidney injury group and the no acute kidney injury group, there were significant 
differences in preoperative hemoglobin (mean±SD 11.9±2.0 vs. 12.7±1.8 g/dL, P=0.001), 
postoperative hemoglobin (10.0±1.6 vs. 10.6±1.4 g/dL, P=0.005), and baseline glomerular 
filtration rate (44.8±17.6 vs. 53.0±17.5 mL/min, P=0.001). Coronary artery disease 
(29.8% vs. 12.6%, P <0.001), postoperative mean arterial blood pressure less than 60 
mmHg for at least 20 minutes (29.8% vs. 16.2%, P=0.023), and postoperative transfusion 
(38.1% vs. 15.3%, P<0.001) were more common in the acute kidney injury group. In the 
multivariate logistic regression analysis, history of coronary artery disease (adjusted odd 
ratio [OR] = 2.56, Confidence Interval [CI] = 1.36 - 4.81) and intraoperative intravenous 
fluid replacement less than 1,000 mL (OR = 2.01, CI = 1.10 – 3.67) were associated with 
increased risk of postoperative acute kidney injury.
Conclusions: History of coronary artery disease and intraoperative intravenous fluid 
replacement less than 1,000 mL were associated with postoperative acute kidney injury in 
patients with chronic kidney disease.
PUB005 
Publication-Only 
Arterial Stiffness in CABG - A Pilot Study
Ahmad Salha,1 Bayiha daho Klaud francheska,1 Racquel M. Lowe-Jones,1 
Joe Wang,2 Robin Kanagasabay,1 Debasish Banerjee.1 1St George’s University 
Hospitals NHS Foundation Trust, London, United Kingdom; 2Epsom & St 
Helier Hospital NHS Trust, London, United Kingdom.
Background: AKI following coronary artery bypass graft (CABG) affects 20% 
of patients and is potentially preventable but there is currently no widely accepted risk 
stratification method to identify those at risk. This was a pilot study to assess the hypothesis 
that vascular stiffness may be a predictor of AKI post CABG surgery.
Methods: 43 patients (18-80 years) undergoing isolated elective CABG were recruited. 
Anthropometric variables, renal function and pulse wave velocity (PWV) were measured 
pre-operatively and renal function post-operatively for 5 days. Aortic tissue samples 
obtained intra-operatively were histologically analysed. AKI staging was based on the 
KDIGO definition. Statistical analysis was obtained using SPSS 25.
Results: Baseline characteristics are as shown in table 1. There was no statistically 
significant differences between AKI and non-AKI patients. Three patients (7%) developed 
AKI stage 1 following surgery. PWV in patients who developed AKI tended to be higher but 
not statistically significant (11.7 ± 3.1 vs 10.1 ± 2.5 m/s; p=0.306). PWV increased with age 
(Pearson correlation 0.568; p=0.000), diabetes (12.4 ± 2.0 vs 9.5 ± 2.3 m/s; p=0.001). PWV 
was also high with high systolic BP, <140mmHg vs >140mmHg, (9.3 ± 2.4 vs 11.7 ±2.2 m/s; 
p=0.002). Histological comparison of aortic samples of an AKI patient with high PWV 
compared to a non- AKI patient with low PWV (Figure 1) shows differences in calcification 
and elastin.
Conclusions: The PWV was higher in CABG patients with diabetes, older age and 
sBP. Patients with AKI following CABG trend towards high PWV but further study will be 
needed with more patients to establish a link.
Baseline clinical characteristics and PWV
Histopathology of aortic tissue in patients with/without AKI
PUB006 
Publication-Only 
Two Cases of AKI Caused by Asymptomatic Unilateral Ureteral Tract 
Obstruction in Patients with Underlying Kidney Disease
Takeshi Nakata,1 Norihiro Furutera,1 Suzuki Tomoko,1 Okita Jun,1 
Yuko Suenaga,1 Kohei Aoki,1 Akihiro Fukuda,1 Tadasuke Ando,2 
Naoya Fukunaga,1 Hirotaka Shibata.1 1Oita University Faculty of Medicine, Yufu 
city, Japan; 2Oita university, Yufu, Japan.
Introduction: Postrenal kidney injury is one of the causes of acute and chronic kidney 
injury. Nephrologists and urologists should not miss or delay the diagnosis of postrenal 
kidney injury as renal function can be easily recovered with appropriate treatment.
Case Description: Case-1 A 79-year-old man was admitted to our hospital due to the 
acute exacerbation of kidney function (serum creatinine 1.30 mg/dl to 2.89 mg/dl). The 
patient was diagnosed with IgA nephropathy by renal biopsy when he was 58 years old. 
After being diagnosed with IgA nephropathy he had a tonsillectomy and steroid therapy 
followed by oral prednisolone for one year and achieved complete remission of IgA 
nephropathy (defined as proteinuria less than 0.30 mg/gCr and macrohematuria less than 
5/High Power Field). For six months prior to admission, the patient had been aware of 
general fatigue and pretibial edema. However, he felt no symptoms related to renal stones 
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such as back pain or pyuria. On admission, his urinary protein was 3+ (2.07 g/gCr), and 
occult urinary blood was ±. First, we considered the worsening of his renal function as a 
relapse of his IgA nephropathy because he had no newly prescribed medication, symptoms 
such as back pain, or fever. In addition, he had a history of worsening proteinuria up to 
nephrotic range, which recovered upon conservative therapy. However, routine abdominal 
ultrasound examination revealed right kidney hydronephrosis caused by a ureter stone. 
After inserting a W-J stent, serum creatinine improved to 1.41 mg/dl, and his urinary protein 
decreased. Case-2 Similarly, a 54-year-old woman with CKD due to nephrosclerosis was 
admitted to our hospital due to worsening renal function, with her eGFR decreasing from 
13.5 ml/min to 5.9 ml/min during the previous three months without symptoms. Although 
we decided to start her on dialysis, routine abdominal ultrasonography revealed right ureter 
dilation and hydronephrosis caused by an abdominal aortic aneurysm operation scar from 
two years previously. After appropriate procedures, she avoided starting hemodialysis.
Discussion: Routine abdominal ultrasonography is an essential examination when we 
meet worsening of renal function even if patients have no back pain, fever, and pyuria.
PUB007 
Publication-Only 
The Need for Dialysis Treatment Among Hospitalized Patients with AKI: 
A Single Centre Experience
Eleni Chelioti,4 Eleni Theodoropoulou,1 Kyriaki Stamatelou,2 
Evdokia Efthimiou,3 Maria Tsilivigou.4 1Dept. of Nephrology, General Hospital 
of Athens “Alexandra”, Athens, Greece; 2Athens Medical, Dafni Clinic, 
Vrilisssia, Greece; 3Renal Unit “Frontis”, Piraeus, Greece; 4Dept. of 
Nephrology, “Tzaneio” General Hospital of Piraeus, Athens, Greece.
Background: Acute Kidney Injury (AKI) is a serious complication in hospitalized 
patients, with single-center studies reporting a rising incidence over the past two decades and 
case fatality rates exceeding 50% among those who require dialysis treatment. Our aim was to 
assess the risk for dialysis among hospitalized patients with AKI and previously normal renal 
function. Secondarily we assessed the effect of comorbidities such as arterial hypertension 
(HTN), diabetes mellitus (DM) and coronary artery disease (CAD) on dialysis risk.
Methods: The study was conducted prospectively for 24 months recording all 
consenting hospitalized patients in a single general hospital in Piraeus, Greece. Patients 
were included if they had previously normal renal function and AKI at the time of their 
admission at the hospital. Parameters recorded and analyzed were: demographics, full blood 
and biochemistry tests, history for HTN, DM and CAD and the need for dialysis treatment. 
The statistical analysis was carried out by single-factorial and multivariate regression 
analyses.
Results: 212 patients were studied, (115 men and 97 women), average age of 75 ± 12 
years. 10.8% (23/212) of the patients with AKI (95% CI 7.1; 16.0) underwent dialysis. 
The effect of comorbidities was not statistically significant. Statistically important factors 
associated with the need for dialysis in single-factorial analysis were admission values of 
serum creatinine (SCr) > 3.3 mg / dL (p = 0.03), age >80 years (p = 0.001) and male 
gender (p = 0.045). In the multifactorial analysis the only independent dialysis factor was 
SCr> 3.3 mg / dL (p = 0.045).
Conclusions: The percent of hospitalized patients with AKI needing dialysis in our 
hospital was relatively low. Comorbidities did not aggravate the need for dialysis.The 
only parameter significantly affecting the risk for dialysis was the SCr value at the time 
of admission.
Funding: Government Support - Non-U.S.
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qSOFA as a Predictor of AKI in Patients with Sepsis: A Single-Center, 
Retrospective, Chart Review
Shimshon Wiesel,2 Anna S. Gutman,2 Youssef Shammaa,4 Marco Campitelli,3 
Nicholas Fuca,2 Naureen Narula,2 Suzanne E. El Sayegh.1 1Staten Island 
University Hospital, Staten island, NY; 2Northwell Health, Brooklyn, NY; 3staten 
island university hospital, Staten Island, NY; 4Staten island university hospital, 
Staten Island, NY.
Background: According to the new surviving sepsis campaign (sepsis-3), the 
application of a new scoring system to gauge severity of infection is needed as the initial 
theorized continuum of the Systemic Inflammatory Response Syndrome (SIRS) criteria was 
too broad and did not effectively risk stratify patients. A proposed algorithm called the 
Sequential Organ Failure Assessment (SOFA) was introduced. However, the feasibility of 
incorporating all the required data in a timely fashion led to the development of an initial 
“quick” screening tool entitled the qSOFA. We propose that qSOFA is a more specific 
predictor of development of AKI.
Methods: The study was designed by the first two and last author as a single-center 
retrospective chart review. Data were abstracted from the electronic medical records at 
Staten Island University Hospital using the search terms “sepsis”, “septic shock”, and 
“severe sepsis”. Charts were analyzed for number of SIRS criteria obtained as well as the 
number of qSOFA criteria obtained. Serum creatinine on admission as well as within 48 
hours after admission were documented to assess for acute kidney injury both at admission 
and at 48 hours.
Results: The preliminary data analysis of 219 patients show that the odds ratio (OR) 
for qSOFA to predict AKI was 2.79 (CI 1.11 – 6.96, p =0.04), whereas the OR for SIRS to 
predict AKI was 0.57 (CI 0.33 - 0.98, p = 0.052). The AUROC for qSOFA to predict AKI 
was 0.547 (CI 0.503 – 0.590) compared to SIRS, which was 0.569 (CI 0.503 – 0.636). The 
results also showed that the OR of qSOFA to predict ICU admission was 7.26 (CI 2.78 - 
18.9, p = <0.0001) compared to SIRS, which was 0.825 (CI 0.45 – 1.51, p = 0.54). The 
AUROC for predicting ICU admission for qSOFA was 0.605 (CI 0.546 – 0.663) compared 
to SIRS, which was 0.524 (CI 0.449 – 0.599). Both mortality at 48 hours and total mortality 
did not show statistically significant results for both SIRS and qSOFA.
Conclusions: In this preliminary analysis the authors found that when compared to 
SIRS, qSOFA was a marginally stronger predictor of AKI. However, when predicting ICU 
admission qSOFA was a stronger prognostic indicator than SIRS.
PUB009 
Publication-Only 
Relation of Kidney Function Decline and NT-ProBNP with Outcomes in 
ADHF
Wendy I. McCallum, Hocine Tighiouart, Gordon S. Huggins, Michael S. Kiernan, 
Mark J. Sarnak. Tufts Medical Center, Boston, MA.
Background: Approximately 30% of patients admitted for acute decompensated heart 
failure (ADHF) experience an in-hospital decline in estimated glomerular filtration rate 
(eGFR). The association between this decline and clinical outcomes has been inconsistent. 
Understanding the circumstances in which a decline in kidney function is associated 
with either improved or adverse outcomes may influence clinical care. We hypothesized 
that adequate decongestion, as measured by a decrease in levels of N-terminal pro-brain 
natriuretic peptide (NT-proBNP), may modify the relationship between decline in eGFR 
and clinical outcomes.
Methods: We performed a retrospective analysis of a limited dataset from the NHLBI 
of the Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome Study 
(CARRESS) and Diuretic Optimization Strategies Evaluation (DOSE) trials, in which 
patients with ADHF were randomized to various modalities of decongestion with serial 
measures of kidney function and NT-proBNP. Multivariable Cox proportional hazards 
regression models were used to evaluate the association of decline in eGFR with a 
composite outcome of mortality and re-hospitalization. We evaluated for an interaction 
between decline in eGFR and change in NT-proBNP with this same outcome.
Results: A total of 496 patients were included in this analysis, with median follow-up 
of 59 days. Median (IQR) baseline eGFR was 40.5 ml/min/1.73m2 (IQR 29.4, 60.1). In-
hospital eGFR decline was not associated with risk for composite outcome of death or re-
hospitalization (HR of 0.85 per every 2-fold decline in eGFR, 95% CI 0.60, 1.21). However, 
there was a significant interaction (p-value=0.007) between decline in eGFR and change in 
NT-proBNP such that decline in eGFR is associated with better outcomes with a decline in 
NT-proBNP but worse outcomes with an increase in NT-proBNP (Figure).
Conclusions: Incorporation of changes in markers of congestion may provide 
additional data to help decision making in cases of eGFR declines in ADHF.
Funding: Other NIH Support - T32 grant: 1T32DK07777
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Comparison of Renal Prognosis Between Renal AKI and Prerenal AKI: A 
Single Center Study
Taro Horino, Keitaro Nagata, Tatsuki Matsumoto, Yutaka Hatakeyama, 
Yoshiyasu Okuhara, Yoshio Terada. Kochi Medical School, Kochi University, 
Kochi, Japan.
Background: Acute kidney injury (AKI) is a relatively new disease concept that 
represents a sharp decline in kidney function in several days. AKI is divided into renal, 
prerenal and postrenal. There is much debate about the difference in prognosis between 
renal AKI and prerenal AKI. Here, we estimated the difference of renal prognosis between 
renal AKI and prerenal AKI in the Japanese population.
Methods: Inpatients and outpatients aged 18-80 years were retrospectively enrolled. 
AKI was diagnosed according to the Kidney Disease Improving Global Outcomes (KDIGO) 
criteria, using SCr levels. Patients who received infusion and who recovered within 7 days 
after the onset of AKI were defined as prerenal AKI and patients requiring more than 8 
days as renal AKI. Survival time analysis was performed by defining the recovery date 
as zero hour, the 30% decrease in eGFR as an event, and the time to event occurrence as 
survival time, and the Kaplan - Meier (KM) curve and the Cox proportional hazard ratio 
were obtained.
Results: We analyzed data from 76,160 Japanese patients. The number of renal AKI 
patients and prerenal AKI patients were 563 and 760, respectively. In the KM curve, results 
showing that the prerenal AKI is significantly longer than the renal AKI has been obtained. 
Compared with non-AKI control, the hazard ratio of the 30% decrease in eGFR in renal 
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AKI and prerenal AKI were 5.10 and 3.42, respectively. the hazard ratio in renal AKI was 
significantly higher than that in prerenal AKI.
Conclusions: For long-term prognosis after recovery from AKI, prerenal AKI has 
better renal prognosis than renal AKI but worse than non-AKI. We suggest that prerenal 
AKI is not a favorable prognosis condition.
PUB011 
Publication-Only 
Renal Injury Caused by Cocaine and Polysubstance Abuse: A Case Report
Mohammed Nazmul. Creighton University, Omaha, NE.
Introduction: Drug abuse involves life time exposure of 46% of US population. 
Recreational substances like alcohol, opioids, cocaine, cannabis, nicotine etc. can cause 
both acute and chronic renal injury.
Case Description: A 46 years old male with no significant past medical history, came 
to ER for sudden onset right flank pain. His vitals were stable except blood pressure was 
elevated to 150/90 mmHg. He had right costovertebral angle tenderness. Basic metabolic 
panel, LDH, complete blood count and urine dipstick were unremarkable except creatinine 
of 1.3mg/dl. Computed tomography showed diffusely reduced blood flow on right renal 
parenchyma involving 80 % of cortex suggestive of renal infarction. Renal doppler 
ultrasound showed vasospasm of right single renal artery. Urine was positive for cocaine, 
amphetamine and marijuana. Patient was treated with heparin infusion and intravenous 
normal saline. His hypercoagulability work up and vasculitis panel were negative. Patient’s 
renal function improved to 0,6mg/dl after 24 hours of conservative care. He was discharged 
home with lisinopril and aspirin.
Discussion: Here renal injury is caused by ischemia due to a renal artery vasospasm. 
Pathophysiology of cocaine nephrotoxicity is multifactorial including changes in renal 
hemodynamics, glomerular matrix synthesis, toxic metabolites degradation, oxidative 
stress, and induction of renal atherogenesis. We need more epidemiological studies and 
translational researches on the mechanism of multiorgan damages or failures due to chronic 
polysubstance abuse which can causes acute organ injuries like renal infarction as well 
as promotes sub clinical renal hypoperfusion. Early diagnosis, prompt withdrawal of 
recreational drugs, aggressive supportive measures, as well as prophylactic treatments with 
aspirin, RAAS blockade, anti-cholesterol medications etc. may improve long term renal 
outcome.
PUB012 
Publication-Only 
Kidney and Blood Pressure Outcomes from 6 to 11 Years After Pediatric 
Intensive Care Admission
Mariya Yordanova,1 Catherine Morgan,2 Kelly Benisty,1 Teodora Riglea,1 
Louis Huynh,1 Frédérik Crépeau-Hubert,1 Erin Hessey,1 Kelly McMahon,1 
Michael Zappitelli.3 1McGill University Health Centre, Montreal, QC, Canada; 
2University of Alberta, Edmonton, AB, Canada; 3Toronto Hospital for Sick 
Children, University of Toronto, Toronto, ON, Canada.
Background: Acute kidney injury (AKI) during pediatric intensive care unit (PICU) 
admission may be a risk factor for chronic kidney disease (CKD) and hypertension 
development. We determined 1)CKD and elevated BP (eBP) prevalence 11years(y) after 
PICU admission; 2)If PICU-AKI is associated with worsening CKD and BP from 6-11y 
post-PICU.
Methods: Follow-up study (≥9.5y post-PICU) of children previously studied at 6y post-
PICU. Protocol: Children were contacted for a study visit 11±1.5y post-PICU admission; 
blood (serum creatinine) and urine (albumin/creatinine[ACR]) were collected and height/
weight/BP measured. Exposure: AKI during PICU (KDIGO definition). Outcomes: CKD 
[estimated glomerular filtration rate (eGFR) <90ml/min/1.73m2 or ACR ≥3mg/mmol]; eBP: 
BP ≥90th percentile or ≥120/80mmHg in adults. 6 vs. 11y outcome prevalences and AKI vs. 
non-AKI change in eGFR, ACR and BP percentile were compared (univariate tests).
Results: Data were available for n=71(4.5±5.3y old at PICU; 55% male). Prevalences 
of low eGFR, high ACR, CKD and eBP remained high at 11y post-PICU, similar to 6y post-
PICU (Table). There was a statistically significant decrease in eGFR and diastolic BP from 
6y to 11y follow-up (p<0.05), but no significant change in ACR or systolic BP (Table). AKI 
during PICU was not significantly associated with change in eGFR, ACR or BP percentile 
from 6y to 11y follow-up (Table, all p>0.05).
Conclusions: High prevalence of CKD and eBP persists at 11y after PICU admission. 
We did not find that PICU-AKI impacts on CKD or eBP progression over time. Interventions 
are needed to reduce long-term cardiovascular risk in PICU patients. Risk factors for 
persistent or progressive CKD and eBP must be elucidated.
Funding: Government Support - Non-U.S.
PUB013 
Publication-Only 
Prevalence of AKI in an ICU Department in Chihuahua, Mexico
Victor A. Salgado yañez,1,2 Javier Soto-Vargas,3 Julio A. Gutierrez-Prieto.3 
1Nefrología, Hospital Central Universitario, Chihuahua, Mexico; 2Medicina 
Interna, Hospital Christus Muguerza del Parque, Chihuahua, Mexico; 
3Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, 
Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, 
Guadalajara, Mexico.
Background: The impact and prognosis of acute kidney injury (AKI) vary considerably 
depending on the severity, clinical setting, comorbid factors, and also geographical location. 
AKI is associated with higher mortality, hospital length of stay, re-admission, costs and 
CKD development. The aim of our study was to report the prevalence of AKI in an intensive 
care unit (ICU) from northern Mexico in a private hospital.
Methods: A retrospective observational study was carried out from May 2014 – May 
2017. Data from 1436 patients that were admitted to the intensive care unit in this period 
were analyzed, only 1158 patients had enough data to screen for AKI, AKI was diagnosed 
by serum creatinine criteria from KDIGO guidelines.
Results: Baseline characteristics of the patients, ICU department of admission and AKI 
severity are summarized in Table 1.
Conclusions: The prevalence of AKI in our ICU was similar to previous reports. This 
is the first epidemiological study for AKI of northern Mexico in an ICU and in our hospital, 
currently there is not a single nephrologist in our hospital in charge of AKI consultations, 
this study highlights the importance of this entity. The lack of recognition of AKI in our 
hospital should encourage the creation of an AKI clinic / Nephrology rapid response team.
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Early Persistent AKI Is Associated with Death and Renal Recovery in 
Cardiac Surgery
Ryo Matsuura,1,2 Masao Iwagami,3 Hidekazu Moriya,2 Takayasu Ohtake,2 
Kent Doi,1 Masaomi Nangaku,1 Shuzo Kobayashi,2 Eisei Noiri.1 1The University 
of Tokyo Hospital, Tokyo, Japan; 2Shonan Kamakura General Hospital, 
Kamakura, Japan; 3University of Tsukuba, Tsukuba, Japan.
Background: Early recovery of acute kidney injury (AKI) is associated with better 
prognosis in critically ill patients. It remains to be known which type of cardiac surgery-
associated AKI (CSA-AKI) impacts prognosis. This study investigated the association 
between type of CSA-AKI and prognosis.
Methods: We analyzed the data on 2,060 non-CKD, post-cardiac surgery patients 
admitted to ICUs in 18 hospitals in the Tokushukai Medical Database between 2012 and 
2014 who had No-AKI (n = 1,530), transient AKI (<3 days of ICU admission; n = 300), 
persistent AKI (≥3 days of ICU admission; n = 91), and late-onset AKI (occurred after ICU 
discharge; n = 139). The primary outcome was in-hospital death or renal recovery at hospital 
discharge, and the secondary outcome, eGFR decline > 50% during 3-year follow-up.
Results: There were more, older male patients in AKI groups. There were no differences 
in the type of surgery or use of cardiopulmonary bypass. Transient and persistent AKI were 
prognostic factors for in-hospital mortality (odds ratio [OR], 24.2 [8.7-85.9] and 195.6 
[65.0-743.6], respectively). Persistent AKI was associated with a significantly lower OR for 
renal recovery (0.13 [0.07-0.26]). Most of patients with persistent AKI met the secondary 
outcome within 1 year of discharge (hazard ratio [HR], 8.13 [4.75-13.9]; P<0.001). It took 
two years or more for half of patients with transient and late-onset AKI to achieve the 
outcome (HR, 3.04 [2.08-4.43] and 2.58 [1.60-4.16]; P<0.001).
Conclusions: Persistent AKI was a notable prognostic factor for mortality and non-
recovery and associated with fast eGFR decline, while transient and late-onset AKI were 
associated with moderate eGFR decline.
PUB015 
Publication-Only 
Bilateral Renal Infarction During the Use of Zolmitriptan
Essa Abuhelaiqa, Awais Nauman. Nephrology, Hamad Medical Corporation, 
Doha, Qatar.
Introduction: Zolmitriptan is a 5-HT1B agonist that leads to vasocontriction of blood 
vessels and used for the treatment of migraine headaches. Triptans have been associated 
with myocardial infarction and bowel ischemia, but there are only 5 reports associating 
them with renal infarction. Here we report a case of bilateral renal infarction following 
treatment with Zolmitriptan.
Case Description: This is a 58 year old lady history of chronic migraine presented 
to emergency department with flank pain and vomiting. Patient has been on zolmitriptan 
2.5mg as needed for migraine headache which she reports taking frequently in past month, 
with last dose 3 days prior to presentation. Patient experienced sudden onset nausea and 
vomiting associated with sharp left flank pain. Examination revealed tenderness on right 
upper quadrant palpitation. Laboratory findings were notable for creatinine of 80umol/L, 
bland urine analysis, negative urine culture and Lactate dehydrogenase of 1,282U/L. She 
received oral analgesia along with IV fluids. CT imaging with IV contrast showed a wedged 
shape reduced enhancement on right kidney. On second day with migrating pain to left, a 
second CT scan revealed evolving wedged shape defect on left kidney [Figure1]. Patient 
was started on anticoagulation with heparin and warfarin. Furthermore, patient underwent 
a transesophageal echocardiogram for embolic disease, holter monitor, antibody screen for 
vasculitis and antiphospholipid syndrome, flowcytometry for PNH, and hemophilia screen 
that were all normal. Patient was started on Topiremate, and has been off zolmitriptan with 
no recurrence of disease on 3 months follow up.
Discussion: Renal infarction should be considered in severe flank pain with negative 
work up for kidney stone and pyelonephritis. Although zolmitriptan is an effective drug to 
treat maigraine headaches, it can potentially cause renal artery vasospasm leading to acute 
renal infarction.
Figure 1. Bilateral Wedge shaped filling defect suggestive of renal infarction
PUB016 
Publication-Only 
Prediction Scale for the Development of AKI in a Hispanic Population
José Franco,1 Emma Puron Gonzalez,2 Jesus Cruz Valdez,3 Lilia M. Rizo 
Topete.4 1Hospital Universitario UANL, Monterrey, Mexico; 2Christus Muguerza 
Hospital Alta Especialidad, Universidad de Monterrey, Monterrey, Mexico; 
3Hospital Universitario, Monterrey, Mexico; 4Hospital Universitario, UANL, 
Monterrey, Mexico.
Background: Acute kidney injury (AKI) affects 10 million people annually in 
the world. Is an independent risk factor for mortality. The impact of this entity is more 
significant in developing countries where there are limited resources, and patients struggle 
to obtain renal replacement therapy. There is a worldwide need to recognize, detect and 
early approach of AKI and provide a better prognosis of renal recovery. The objective of 
the study is to evaluate the capacity of a practical risk scale for the detection of patients at 
risk of developing AKI
Methods: Prospective analytical cross-sectional study. 83 patients were registered 
from May to October in the 2018. Patients were evaluated from admission to hospitals in 
northeastern Mexico recording the most prevalent risk factors in our population and were 
followed until discharge, recording those who developed AKI based on the current KDIGO 
classification and degree severity. The primary analysis was performed with multiple logistic 
regression, the calculation of sensitivity, specificity was performed through ROC curve
Results: Mean age was 61 years, 52 patients (62%) developed AKI, 55% KDIGO stage 
I, 25% stage II, 19% stage III. Identifying statistical significance in the proposed model (p 
=< 0.001), each variable was converted into a score coded by its OR (anemia 3 points, IV 
contrast and cirrhosis 1 pt, CKD 9 pts, sepsis 2 pt, nephrotoxic drugs 1 pt each). With these 
values the calculation of the total score of each patient with AKI was made (OR= 2.6, p 
=<0.001). The best performance of the diagnostic test through a ROC curve was a score of 
4 points with a sensitivity of 84% and a specificity of 73%
Conclusions: In AKI, early recognition and protective measures are essential to obtain 
a higher rate of renal recovery and positively impacting the survival and quality of life 
of patients. Access to new biomarkers of early kidney injury is limited in our setting and 
the proposed screening scale prompts detection of kidney damage. We obtained a quick 
and practical prediction scale with a sensitivity level of 84%, being an adequate screening 
tool to detect patients at risk of developing AKI allowing the establishment of appropriate 
nephroprotective measures to reduce the incidence and/or severity of AKI. Nevertheless, 
in future this predictive model together with AKI biomarkers could be an interesting tool 
to predict AKI
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An Interesting Case of Renal Infarction and Spontaneous Adrenal 
Haemorrhage in a Patient on Thrombopoietin (TPO) Receptor Agonist 
Therapy and Vitamin K Antagonist
Arvind K. Singh. Renal team gloucetsershire Royal Hospital Gloucestershire 
Royal Hospital, Gloucester, United Kingdom.
Introduction: Eltrombopag is the first TPO-receptor agonist and is widely used for the 
treatment of Idiopathic thrombotic purpura (ITP). Though the British National Formulary 
(BNF) cautions against use of Eltrombopag in patients with risk factors for venous 
thromboembolisms (VTEs), there is a paucity of guidance of its concomittant use with 
anticoagulant therapy.
Case Description: A 61 year old lady presented with two day history of abdominal 
pain and vomiting 10 days after starting Eltrombopag for ITP. She has a background of 
discoid lupus, antiphospholipid syndrome, hypothyroidsim and haemolytic anaemia. She 
had previosly been treated for deep venous thrombosis, pulmonary embolism and ischaemic 
stroke with haemorrhagic transformation. She was on warfarin for prevention of VTEs 
secondary to her antiphospholipid syndrome. She had a tender right upper quadrant of her 
abdomen, with normal bowel sound and no organomegaly. Her chest was clear and with 
normal heart sounds. She was afebrile, haemodynamically stable and a urine dipstick was 
negative for any sediments. Admission bloods revealed an increase in her platelet count from 
32,000/mL to 1,84,000/mL within days of starting Eltrombopag. She also had acute kidney 
injury stage 2 (eGFR 31 from 87 ml/min/1.732 m2) and International normalised ratio of 
2.5 on admission. Her eGFR dropped to 9 ml/min/1.732 m2 and she required haemodialysis 
secondary to deteriorating renal function and fluid overload. A computeriseed tomography 
of her abdomen showed evidence of organised left adrenal haematoma. She was seen by 
the haematology and rheumatology teams who agreed that in all likelihood the patient had 
an intrarenal thrombus with sencondary haemorrhagic tranformation. Her Eltrombopag was 
stopped and she was managed with unfractioned heparin and bridged to warfarin with an 
INR target of 3.5. for Her kidney function improved few weeks after the treament and she is 
now dialysis independent with gradual improvement in her kidney function.
Discussion: After this expeience we advice cautionary use of Eltromobag in patients 
with previous episodes or high risk for VTE on or off anticoagulation. There should also be 
guidelines to dictate the rate of increase in platelt count to avoid thrombotic complications 
related to a sudden increase in platelet count.
PUB018 
Publication-Only 
Urinary Cystatin C (UCysC) as an Early Biomarker of AKI in Critically 
Ill Patients
Jeyaraj Balasubramaniam.1,2 Kidney Care Centre 1Kidney Care Centre, 
Tirunelveli, India; 2Sri Ramachandra Medical College & Research Institute, 
Chennai, India.
Background: AKI is common in critically ill patients. Despite all advancements 
prognosis of AKI continues to be bad. Early diagnosis results in better outcome. Serum 
creatinine is an insensitive marker in early stages of AKI. A marker which can predict AKI 
or identify AKI early is a great need. Cystatin C is a cysteine protease inhibitor, synthesized 
by all nucleated cells in the body, freely filtered by the glomerulus, fully reabsorbed and 
not secreted by the tubule, making serum cystatin a better marker for estimation of GFR 
than creatinine. The urinary excretion of Cystatin C indicates acute tubular injury. Urinary 
Cystatin C is a marker of renal tubular injury which precedes the elevation of serum 
creatinine or serum cystatin C. Aim: To evaluate UCysC as early biomarker of AKI.
Methods: A prospective observational study. Consecutive critically ill subjects admitted 
to ICU during Jan 2017 to Oct 2017 were taken for the study. Exclusion: Age <18 years 
& over 80 years; Hematuria, and polycythemia; Preexisting renal failure; Not expected 
to survive 72 hrs; Methods: Serum creatinine (daily), UCysC, sodium, electrolytes and 
haemoglobin levels were measured using standard protocols. Glomerular filtration rate was 
calculated using the standard MDRD formula. RIFLE classification system was used to 
define AKI. The patients were divided in to two groups based on development of AKI. 
Finally, the statistical analyses were performed between the groups to see if urinary cystatin 
C levels could be a reliable diagnostic marker for AKI.
Results: Total 83. Male 57; Female 26. 36 (43%) developed AKI. Sepsis was the 
common cause. Out of day 1 investigations UCysC was the one which was significantly 
indicative of development of AKI.
Conclusions: 1. UCysC was significantly elevated in critically ill patients who 
developed AKI than in those who did not. 2. UCysC on the first day was significantly 
elevated than serum creatinine in those who developed AKI. 2. UCysC is an ideal early 
biomarker for AKI.
Comparison of parameters - AKI vs Non AKI
PUB019 
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AKI of Nephrotic Syndrome in Children
Mi young Kim,1 Ji hyun Kim,1 Myung hyun Cho,2 Yo Han Ahn,4 IL-Soo Ha,3 
Hae Il Cheong,3 Hee Gyung Kang.3 1Seoul National University Children’s 
Hospital, Seoul, Republic of Korea; 2Seoul National university Children’s 
hospital, Seoul, Republic of Korea; 3Seoul National University Children’s 
Hospital, Seoul, Republic of Korea; 4Seoul National University Bundang 
Hospital, Seongnam, KYUNGGI-DO, Republic of Korea.
Background: Nephrotic syndrome is the most common kidney disease in children. 
Acute kidney injury (AKI) is one of the common complications of nephrotic syndrome, 
and its incidence is reported from 1% to 50.9% in various studies worldwide. Well known 
risk factors of acute kidney injury are intravascular volume depletion, infection, edema and 
steroid resistance. Detailed report about incidence and risk factors of pediatric nephrotic 
syndrome in Korea is lacking, therefore we studied incidence, causes, risk factors of acute 
kidney injury of nephrotic syndrome in children in this study.
Methods: We conducted a retrospective review of the electronic medical records of 
pediatric patients who were admitted to Seoul National University Children’s Hospital for 
occurrence or recurrence of idiopathic nephrotic syndrome, from January 1st, 2015 to July 
31th, 2017. Patients with chronic kidney disease or congenital nephrotic syndrome were 
excluded.
Results: During the study period, 90 cases (Male:Female 44(67.7%):21(32.3%)) 
were admitted for management of nephrotic syndrome. Among them, total 47 cases met 
the KDIGO criteria of AKI (52.2%, Male:Female 2(66.7%):1(33.3%), median age 7). AKI 
developed in association with infection (24), aggravation of nephrotic syndrome (17), 
methyl prednisolone pulse therapy (4), and dehydration (2). Those with AKI were not 
statistically different from those without AKI in regard of sex, age, pathological diagnosis, 
age of nephrotic syndrome onset, number of relapse during the previous year, or trough level 
of calcineurin inhibitors (CNI) if they were taking CNIs. On the other hand, AKI occurred 
more commonly when the patients were taking cyclosporine (67.5% with cyclosporine, 
p=0.011, odds ratio=3.115). The median recovery time of serum creatinine level was 7 days 
and most patients had AKI at the time of admission. While most of the AKI episodes had 
resolved without long-term complication, duration of hospitalization was longer in the AKI 
group than the non-AKI group.
Conclusions: Complication of AKI occurred in more than half of the hospitalization 
of pediatric nephrotic syndrome. Cyclosporine increased the risk of AKI. Therefore in 
managing children with nephrotic syndrome, we need to consider AKI especially for those 
taking cyclosporine.
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Biomarkers N-Gal and Kim-1 for AKI Post Major Elective Non-Vascular 
Abdominal Surgeries
Graziela R. de Souza,1 Lia J. Marçal,2 Luis Yu,3 Leila Antonangelo,2 
Dirce M. Zanetta,4 Emmanuel A. Burdmann.5 1São Paulo University, São Paulo, 
Brazil; 2Universidade De Sao Paulo, Sao Paulo - SP, Brazil; 3University of Sao 
Paulo School of Medicine, Sao Paulo, Brazil; 4University of São Paulo, S Paulo, 
Brazil; 5University of Sao Paulo Medical School, Sao Paulo, Brazil.
Background: The role of renal injury urinary biomarkers (uBMs)for predicting AKI 
in surgical patients (pts) remains undetermined. The aim of this study was to compare the 
efficacy of urinary biomarkers, NGAL and KIM-1, in patients submitted to major elective 
non-vascular abdominal surgeries (MENVAS) admitted to ICU.
Methods: Two hundred and twenty five pts were prospectively evaluated, peri-
operatively, from the ICU admission until day 7. Serum creatinine (SCr mg/dl) was 
measured before surgery and once a day until day 7 or ICU discharge. AKI was diagnosed 
using either SCr or urinary output (UO) according to KDIGO definition. Two uBMs were 
assessed: NGAL and KIM-1 by Luminex x-MAP method. Urine sample was collected 1 
day before surgery (baseline); upon arrival in ICU and 12 h after ICU admission. The value 
of the fifth quintile was considered positive for uBMs. Data are presented as mean S SD, 
median (first and fourth quartiles) or frequencies. Statistical significance was p<0.05.
Results: A total of 225 pts were analysed, 126 (56%) developed AKI. Most frequent 
types of surgery were: hepatectomy, sleeve gastroplasty, gastrectomy, hepatectomy + 
cholecystectomy, gastroduodenopancreatectomy and adrenalectomy. AKI pts were older 
57.6 ± 1,2 vs. 50.8 ± 1,6 (p = 0.0007). Mortality in the AKI group was 10.2% vs. 2.0 % in 
Non-AKI (p=0.0149). The following table (image) shows the efficacy of the biomarkers 
NGAL and KIM-1 in the outcomes hospital length of stay (LoS) and ICU LoS. Among the 
non-survivor (15 pts), 4 had higher biomarkers (uBM +) without functional alteration (SCr-) 
and 4 had functional deterioration (SCr+) with no uBM increase (uBM -). After 12h from 
ICU admission, 4 pts had higher biomarkers (uBM +) without functional alteration (SCr -) 
and 4 had functional deterioration (SCr+) with no uBM increase (uBM -). On the other 
hand, six pts with both functional alteration (SCr +) and uBM increase (uBM+) all died.
Conclusions: Surgical patients with higher urinary biomarkers N-GAL and KIM-1 
even without functional deterioration (SCr increase) presented longer hospital and ICU LoS 
and higher mortality.
Funding: Government Support - Non-U.S.
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High Serum Sodium Levels at the Time of Nephrology Consultation and 
Adverse Outcomes in Burn Patients with AKI
Igor Smolentzov,2 Luanne F. Soares,2 Valkercyo A. Feitosa,4 Marcia 
Fernanda Arantes de Oliveira,2 Marcelo D. Silveira,2 Lucia Andrade,1,2 
Victor F. Seabra.2,3 1University of Sao Paulo School of Medicine, Sao Paulo, 
Brazil; 2Hospital clinicas SP HCFMUSP, Sao Paulo, Brazil; 3Albert Einstein 
Hospital, Sao Paulo, Brazil; 4USP, SAO PAULO, Brazil.
Background: Acute kidney injury (AKI) is a common complication after severe 
burn injuries and is associated with high mortality. Dysnatremias have been found to be 
associated with mortality in many populations, but its role in burn patients with AKI is not 
fully understood.
Methods: We retrospectively evaluated data on burn patients with acute kidney injury 
in the ICU of a tertiary hospital using logistic regression to evaluate the association of serum 
sodium levels with adverse outcomes.
Results: 109 patients were included in the analysis. At the time of the nephrology 
consultation, the median age was 42.5 years, 70% were males, the baseline GFR was 101 
mL/min/1.73m2, the median total body surface area (%TBSA) burned was 34.5%, and the 
median serum creatinine was 2.31 mg/dL. Median serum sodium was 143 mEq/L (IQR 139-
149 mEq/L), 44 subjects had serum sodium above the upper limit of the normal range (> 
145 mEq/L). On univariate analysis, serum sodium levels above 145 mEq/L were associated 
with higher odds of the composite outcome of RRT requirement or in-hospital death 
(OR=3.27, 95% CI: 1.10–12.10, p=0.048) but this association did not persist in multivariate 
analysis (OR=1.79, 95% CI: 0.63–5.38, p=0.282). In this population, sepsis, baseline GFR, 
fluid balance, and the requirement of mechanical ventilation were also associated with the 
composite outcome in univariate analysis. Sepsis and baseline GFR remained associated 
with an increased risk of the composite outcome (OR=28.18, 95% CI 3.47-371.40, p=0.004 
and OR=0.96, 95% CI 0.94-0.99, p=0.003, respectively) on the final multivariate model 
that also included sodium level, %TBSA burned, mechanical ventilation, and SOFA score.
Conclusions: Hypernatremia at the time of nephrology consultation might predict the 
composite outcome of RRT and death. Larger studies are warranted to confirm or dispute 
these findings.
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Gender and Age Differences in AKI During Hospitalization for Left 
Ventricular Assist Device Implantation: National Estimates
Michael Holliday, Carl P. Walther, Jenny S. Pan. Baylor College of Medicine, 
Houston, TX.
Background: Left ventricular assist device (LVAD) placement is associated with 
high incidence of AKI, and AKI post-LVAD is associated with increased mortality. 
Outcomes are gender-dependent, with females having higher risk for thrombosis, right 
heart failure and mortality. Gender differences in renal disease have been described in 
trauma, cardiopulmonary bypass, chemotherapy toxicity and rates of delayed graft function 
after kidney transplant. Rodent models of ischemia/reperfusion and other AKI have 
demonstrated protective effects of the female hormonal milieu and deleterious effects of 
male hormones. We therefore investigated relationships of sex and age with AKI diagnosis 
during hospitalizations for implantable LVAD placement.
Methods: We performed a retrospective, observational cohort study using the National 
Inpatient Sample (2006-2015) to estimate diagnoses of AKI in females versus males among 
patients ≥ 18 years of age who received LVAD. ICD-9 codes were used for identification of 
LVAD placement, presence of AKI without and with RRT (AKI-D), and comorbidities. We 
used appropriate survey methods to obtain national estimates. We used logistic regression 
models (adjusted for demographics, comorbidities, year of implantation) and predictive 
margins to assess relationships of age, sex, and AKI.
Results: An estimated 5,681 female (mean age 53) and 18,702 male (mean age 57) 
patients received LVADs, with men having higher prevalence of hypertension (43% versus 
36%) but not diabetes. 50% of females carried AKI diagnosis, versus 57% of males. The 
adjusted risk of AKI in females age less than 60 was 47% (CI 0.44-0.51) versus 56% 
(CI 0.53-0.59) for males. No difference was found in AKI of males versus females greater 
than age 60, or in AKI-D between males and females, regardless of age. Mortality was 
higher in females with AKI (OR 1.53, CI 1.13-1.92).
Conclusions: Women had lower risk of AKI in this population of LVAD patients; 
this protective effect was lost in postmenopausal women. However, women with AKI had 
higher mortality. Given that female gender has demonstrated reno-protective effects in 
animal and human models, it would be judicious to consider the effects of gender, hormone 
status and supplementation, and sex-directed therapeutics in the design of future studies of 
ischemia/reperfusion injury, transplant and AKI.
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Prevalence of AKI in PD-1 Inhibitors: A Single Center Experience
Sandhya Manohar,1 Busra N. Bacik Goksu,1 Heidi D. Finnes,2 Joerg Herrmann,1 
Sandra Herrmann.1 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN.
Background: Programmed cell death protein 1 (PD-1) inhibitors, i.e. nivolumab and 
pembrolizumab, are being increasingly used and the incidence of acute kidney injury (AKI) 
has been reported to be 2.2% by a recent meta-analysis of clinical trials.
Methods: The major objective of this study is to determine the AKI rates of all patients 
that have received a PD-1 inhibitor at Mayo Clinic Rochester over a span of 3 years. 
We performed a retrospective chart review of all patients that had a PD-1 inhibitor until 
April 1, 2017. We included patients that had a baseline creatinine value within 30 days of 
drug initiation. We searched for AKI episodes as defined by AKIN criteria as increase in 
creatinine of ≥0.3 mg/dl form baseline at 3 different time points – Day 1-14, day 80-100 and 
day 300-400 from the time of initiation of the drug.
Results: Out of the 495 unique patients that received either nivolumab or 
pembrolizumab, only 134 patients fit our inclusion criteria. We found 53% (33/62) in 
nivolumab and 43% (31/72) in pembrolizumab group had AKI episodes. Out of those that 
clinically significant AKI (AKIN stage 2 and greater), in nivolumab 2 of 3 patients and in 
pembrolizumab 5 of 8 patients had likely drug related AKI. Only 2 of these patients had a 
kidney biopsy showing nephritis. A large proportion of these patients were closer to the 1 
year time point 38% (24/62) in nivolumab and 22.2% (16/72) in pembrolizumab group.
Conclusions: Our study reinforces the ongoing concern among nephrologists that AKI 
episodes are being missed. We also found that consistent with the current literature the AKI 
appears to be of a delayed onset. Only a handful of these patients were seen by nephrology 
and fewer had kidney biopsies. With the increasing use of these drugs in cancer therapy 
there is a need for more definitive guideline for nephrologists in the management of these 
AKI patients.
AKI by AKIN stages
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Obesity Linked to AKI and Mortality in Acute Distress Respiratory 
Syndrome
Luis I. Bonilla,1,3 Raymundo Vera,2 Sara Samoni,3,4 Claudio Ronco,4,3 
Lilia M. Rizo Topete.5,3 1Nephrology, Hospital Universitario Dr. José Eleuterio 
Gonzalez, Monterrey, Mexico; 2Hospital Universitario, Monterrey, Mexico; 
3International Renal Research Institute of Vicenza, Vicenza, Italy; 4Ospedale “S. 
Bortolo” AZ. ULSS 6, Vicenza, Italy; 5Hospital Universitario, UANL, Monterrey, 
Mexico.
Background: One of the most important organ to organ cross-talk in critically ill 
patients is the one taking place between the lung and kidney, especially in patients under 
mechanical ventilation. Barotrauma, volutrauma, atelectrauma and biotrauma have been the 
mechanisms described as responsible for damage in both organs. Acute distress respiratory 
syndrome (ADRS)is characterized by a global reaction of the lung parenchyma which leads 
to fluid extravasation and edema. One of the most common comorbidities found in ARDS 
patients is obesity. It has been linked to increase in both, mortality and incidence of acute 
kidney injury (AKI)
Methods: This is a retrospective analysis of 30 records of patients admitted to the 
intensive care unit (ICU) with ARDS during the Influenza season 2016-2017. Demographic, 
laboratory, and clinical data were obtained. We measured weight and height of each patient 
at admission and used the body mass index (BMI) formula (weight in kg/(height in m)2 to 
obtain each patient’s BMI. We classified patients into two groups, obese (BMI ≥30 kg/m2) 
(group A) and not obese (BMI <30 kg/m2) (group B). We compared both groups.
Results: Mean age in our cohort was 46.4yrs, 66.6% were male and 46.6% were obese. 
Global mortality among obese patients was 57.9%, compared with a 42% in non-obese 
patients (p=0.11). AKI was diagnosed in 20 patients (66.6%) with 16.6%, 10% and 36.6% 
of KDIGO stages 1-3 respectively. RRT was initiated in 10 (50%) of AKI patients. Among 
groups A and B AKI was diagnosed in 55% and 45% of patients respectively (p=0.2). ICU 
mortality was 60% among the whole cohort, 61.1% of obese patients died during the ICU 
stay compared with 38.9% of non-obese patients (p: 0.72)
Conclusions: In our cohort of ARDS patients, obesity with BMI ≥30kg/m2 was linked 
to an increase in the incidence of AKI and increase global mortality as well as ICU mortality. 
With these findings, we can strongly recommend special attention in obese patients with 
ARDS because of the greater susceptibility to complications and mortality. More studies 
with bigger cohorts are needed to obtain statistical significance and clearly demonstrate 
these associations.
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Acute Interstitial Nephritis in Patients with Hepatitis C Virus Infection 
and CKD Treated with Direct Acting Antiviral Agents: A Case Series
Juan C. Duque Ballesteros,2 Adriana Dejman,2 Karla G. Carias martinez,2 
Vasuki N. Venkat,1 Maria D. Hernandez,1 David Roth,2 
Marco A. LadinoAvellaneda.1 1Miami VA Medical Center, Miami, FL; 
2University of Miami, Miami, FL.
Background: Hepatitis C virus (HCV) infection has been shown to have an adverse 
impact on clinical outcomes in patients with chronic kidney disease (CKD) and end 
stage renal disease (ESRD), including an accelerated rate of loss of kidney function and 
an increased mortality. Patients achieving a sustained viral response at 12 weeks post 
treatment completion (SVR12) are considered to be cured. Clinical trials using the direct-
acting antiviral agents (DAAs) uniformly achieve SVR12 rates of >90% in the general 
population as well as in patients with CKD/ESRD. Both sofosbuvir and its metabolite are 
renally excreted and its use has been associated with worsening kidney function. In the 
HCV-TARGET study, patients with eGFR <30 ml/min/1.73m2 at start of sofosbuvir-based 
therapy had higher rates of deterioration of kidney function compared to patients with higher 
eGFR. Current recommendations are to avoid sofosbuvir in patients with eGFR <30 ml/min
Methods: The current report describes 8 HCV-infected patients who developed acute 
kidney injury with biopsy-proven acute interstitial nephritis (AIN) associated with the use 
of DAAs.
Results: Mean age of the group was 61.3 (±6 years) with 100% men and 5 (62.5%) 
African Americans. The most common genotype (GT) was 1a (n=7) with 1 GT 4. The 
DAA formulations were sofosbuvir/ledipasvir (n=5), elbasvir/grazoprevir (n=2) and 
sofosbuvir/simeprevir (n=1). All patients achieved SVR12. The mean creatinine at start of 
DAA treatment was 1.6 mg/dl (±0.6) and increased to 2.0 mg/dl (±0.8) at the conclusion of 
therapy (p=0.03). All patients received a course of high dose steroids after the diagnosis of 
AIN was confirmed. Serum creatinine at 3 and 6 months post steroids was 3.0 (±1.2) and 
3.2 mg/dl (±1.4), respectively. Three patients had progression of the CKD and developed ESRD
Conclusions: These results are consistent with earlier studies demonstrating the 
efficacy of DAAs in HCV-infected CKD patients. Biopsy-proven AIN may explain the AKI 
events reported with the use of DAAs in CKD patients. Our results show that AIN can occur 
with use of different DAAs, although particular caution must be used prescribing sofosbuvir 
to patients with eGFR <30 ml/min1.73m2 as it is the only DAA renally cleared.
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Postoperative AKI: A Prospective Randomized Controlled Trial of the 
Impact of Two Different Intraoperative Systolic Blood Pressure Levels on 
Renal Outcomes
Macaulay A. Onuigbo. Postoperative Acute Kidney Injury Research Group 
Medicine, University of Vermont, BURLINGTON, VT.
Background: Postoperative acute kidney injury (PO-AKI) is a significant contributor 
to hospital acquired AKI. It is unclear what the optimal intraoperative blood pressure is for 
preserved renal health. Evidence that controlled hypotension has advantages like shortened 
surgery time, reduced blood loss and less blood transfusions but without renal consequences 
were based on studies of younger patients with preserved kidney function. There is accruing 
evidence that more severe and longer periods of IOH in older patients with later stage CKD 
could indeed result in catastrophic renal failure. We had raised concerns about IOH as a 
neglected risk factor for PO-AKI in the Mayo Clinic Health System. The most common 
definition of IOH are SBP <80 mm Hg, MAP <55-60 mm Hg, and/or decreased SBP or 
MAP of 25% from baseline. For intraoperative MAP <60 mm Hg, the adjusted odds ratio 
for AKI was 1.84 (1.11–3.06) for 11–20-min exposure (Sun; 2015). From our experience 
and from the published literature, we hypothesize that the comparison of renal outcomes 
while keeping SBP >105 mm Hg versus SBP >85 mm Hg in the operating room would 
enable a scientifically robust study of this question. We therefore plan to carry out a pilot 
study of this RCT in orthopedic surgery (joint replacement) and in CV (non-bypass) 
surgery, respectively.
Methods: A prospective randomized controlled trial (pilot study) of PO-AKI in two 
subsets of patients undergoing noncardiac (orthopaedic) surgery and cardaic (non-bypass) 
surgery, with target intraoperative SBP >105 mm Hg vs >85 mm Hg in each category and 
we aim to have at least 20-30 patients randomized to each of the two arms of each substudy.
Results: The primary outcome is PO-AKI as defined by the AKIN criteria as a 50% 
relative or 0.3 mg/dL absolute increase in serum creatinine over the preoperative value 
during the first two post-operative days.
Conclusions: We hope to confirm our hypothesis that during anesthesia/controlled 
hypotension, the maintenance of SBP >105 mm Hg vs SBP >85 mm Hg reduced PO-AKI, 
patient morbidity and mortality, length of stay, the need for RRT and resulted in significant 
reductions in cost of care. Subsequently, we intend to use this pilot study preliminary data to 
apply for an NIH-funded study that would enable a larger national multi-center randomized 
controlled study.
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Enteric Fever Causing Hemolytic Uremic Syndrome
Hussein M. Bagha,1 Shamsa H. Ahmed,2 Ahmed Twahir.3 1Nephrology, M P 
Shah Hospital, Nairobi, Kenya; 2M. P Shah Hospital, Nairobi, Kenya; 3Parkland 
Kidney Centre, Nairobi, Kenya.
Introduction: Hemolytic uremic syndrome presents with a classic triad of 
microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. It is 
usually caused by toxigenic strains of Escherichia coli and Shigella dysenteriae. It can also 
be caused by Streptococcus pneumoniae and complement disorders. Typhoid fever causing 
hemolytic uremic syndrome is quite rare.
Case Description: A fifty four year ol male with no known comorbids presented 
with a seven day history of diarrhea. He had been started on ciprofloxacin after a stool for 
salmonella antigen was found to be positive. He presented after seven days with worsening 
of diarrhea and one day history of vomiting. Examination revealed mild dehydration with 
normal vital signs and tenderness in the right and left iliac fossa regions. His laboratory 
investigations showed an elevated urea and creatinine with a low potassium. Blood cultures 
done on the day of admission grew Salmonella typhi which was sensitive to ciprofloxacin. 
The platelets and hemoglobin dropped on the second and third day after admission. 
The lactate dehydrogenase was markedly elevated and a peripheral blood film showed 
schistocytes. He was started on hemodialysis, intravenous antibiotics and potassium 
supplementation. After three sessions of dialysis his kidney function started improving and 
had complete recovery of his renal function.
Discussion: Typical hemolytic uremic syndrome occurs secondary to infection by 
shiga-toxin producing E.coli and less frequently due to S.dysenteriae. It can also be caused 
by Streptococcus pneumoniae. Salmonella typhi is not a common cause of hemolytic uremic 
syndrome and there a few case reports in the literature of salmonella induced HUS. The 
inciting toxin in HUS due to Salmonella has not been identified. The treatment is mainly 
supportive comprising appropriate antibiotics, correcting fluid and electrolyte imbalances 
and timely dialysis. Most cases of acute kidney secondary to typical HUS are self limiting 
like in our case.
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Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term 
Outcomes in Post AKI Patients with Hypertension
David Chih-Yu Yang,1,2 Der-Cherng Tarng.2 1National Chiao Tung University, 
Taipei, Taiwan; 2Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Post-acute kidney injury (AKI) patients are at risks for various 
complications. However, evidence regarding effective therapies to improve patient 
outcomes is lacking. We hypothesized that RAAS blockade is effective in improving renal 
outcomes in post-AKI patients who have hypertension.
Methods: From 2000 to 2013, we identified 12,084 AKI patients with hypertension 
in the nationwide database. All these patients experienced an AKI episode which required 
temporary hemodialysis therapy.
Results: In a median follow-up of 3.6 years, 2,637 patients (21.8%) required long-
term dialysis and 5,094 (42.2%) died before progression to ESRD. Compared to post-AKI 
patients without using ACEI/ARB, ACEI/ARB users are less likely to suffer from future 
ESRD (adjusted HR, 0.90; 95% CI 0.83-0.99, p = 0.022) and all-cause mortality (adjusted 
HR, 0.92; 95% CI 0.86-0.97, p = 0.003). The renal benefit of ACEI/ARB use in post-AKI 
survivors was consistent across patient subgroups with different post-AKI renal function 
status, including those who fully recovered [non-chronic kidney disease (CKD)] and those 
who complicated with subsequent CKD stages 1-4.
Conclusions: For patients who experienced AKI and had hypertension, RAAS 
inhibitors should be the drug of choice to treat their hypertension.
Funding: Government Support - Non-U.S.
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Figure 2. Forest plots of long-term risks of chronic dialysis and all-cause mortality.
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The Role of Extracellular Histones in Patients with Lung-Kidney 
Cross-Talk: A Prospect Study
Min Gao,1 Yizhi Cao,3 Dawei Chen,2 Xin Wan.2 1Department of Nephrology, Affiliated 
Sir Run Run Hospital, Nanjing Medical University., Nanjing, China; 2Nanjing First 
Hospital, Nanjing, China; 3Nanjing Medical University, Nanjing, China.
Background: Extracellular histones have potential to affect distant organs 
when released from tissue injury. In this prospect study, we aim to investigate the 
impact of extracellular histones on the community-acquired pneumonia (CAP) patients 
with acute kidney injury (AKI), acute lung injury (ALI) or the combination of both.
Methods: Blood samples were obtained from 83 patients within 24h after admission 
at the hospital who were diagnosed with CAP. According to the discharge diagnosis, the 
patients were divided into 4 groups (AKI+CAP, ALI+CAP, AKI+ALI+CAP, and CAP). 
Then the subjects were split into 2 groups (histones <30 μg/ml and histones ≥30 μg/ml).
Results: Compared with the CAP group, the logarithms of the concentrations of the 
extracellular histones in AKI+CAP, ALI+CAP, and AKI+ALI+CAP groups were higher  
(P = 0.004, P = 0.029, and P < 0.001, respectively). The incidences of AKI and ALI were 
39.8% and 28.9% in CAP patients. In CAP patients, Log2 Histones (P = 0.002) and 
chronic kidney diseases (P = 0.039) were predictors of AKI, Log2 Histones (P = 0.006) 
and surgery (P = 0.019) were risk factors of ALI. Compared with the histones <30 μg/ml 
group, patients in the histones ≥30 μg/ml more likely to admit to ICU (65.6% vs 33.3%, P 
= 0.004), to need mechanical ventilation (62.5% vs 31.4%, P = 0.005), and had longer 
duration of mechanical ventilation (6.9±9.5 vs 1.3±2.8, P = 0.002), longer ICU length of 
stay (6.1±7.9 vs 1.9±3.5,  P = 0.007), and longer length of in-hospital stay (18.4±8.7 vs 
12.7±5.9, P = 0.002).
Conclusions: Elevated extracellular histones were observed in CAP patients with 
AKI, ALI, and the combination of both. Our data supported that extracellular histones 
were a higher risk of developing AKI or ALI in CAP patients and a predictor of worse 
short-term outcomes.
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Effect of Hypertonic Saline and Furosemide on Urinary Markers of 
Kidney Injury
Frank H. Mose,1 Marie H. Vrist,2 Jesper N. Bech.3 1Holstebro 
Hospital, Holstebro, Denmark; 2University Clinic of Nephrology and 
Hypertension, Holstebro, Denmark; 3Holstebro Hospital and Aarhus 
University, Holstebro, Denmark.
Background: Chloride is speculated to have nephrotoxic properties. In healthy 
subjects we tested the hypothesis that and acute chloride load with hypertonic saline 
would induce kidney injury, which could be prevented with the loop-diuretic furosemide.
Methods: The study was designed as a randomized, placebo-controlled, 
crossover study. Subjects were given hypertonic saline accompanied by either placebo or 
furosemide. Before, during and after infusion of hypertonic saline we measured 
glomerular filtration rate (GFR), fractional excretion of sodium (FENa), urinary chloride 
excretion (u-Cl), neutrophil gelatinase-associated lipocalin (u-NGAL) and kidney 
injury molecule-1 (u-KIM-1) as marker of kidney injury. Four days prior to each of the 
two examinations subject were given a standardized diet and fluid intake.
Results: U-NGAL and KIM-1 excretion increased slightly during hypertonic 
saline infusion. The increase in NGAL was absent when furosemide was given 
simultaneously, the responses in u-NGAL were not significantly different from placebo 
control (p = 0.214) with a general linear model (GLM)). Furosemide changed responses in 
KIM-1, where a delayed increase was observed. (p < 0.001 with GLM) GFR was increased 
by hypertonic saline, but decreased when furosemide accompanied the infusion. U-Na, 
FENa, u-Cl, and u-osmolality increased in response to saline and the increase was markedly 
pronounced when furosemide was added (p<0.001 with GLM for all variables)
Conclusions: This study shows minor increases in markers of kidney injury 
after hypertonic saline. Furosemide only changed response to KIM-1 and further 
investigations need to clarify if this is a protective renal response.
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Multiple Myeloma: An Uncommon Presentation of a Common Neurologi-
cal Complication
Mansoor N. Ali. Renal Mecdicine, Calderdale and Huddersfield Hospitals NHS 
Trust, Huddersfield, United Kingdom.
Introduction: Multiple myeloma is a neoplastic proliferation of abnormal plasma 
cells. The clinical features of multiple myeloma depends on either direct proliferation 
of plasma cells resulting in extensive bony destructive lesions or indirectly related to 
paraprotein production mainly monoclonal immunoglobulins resulting in renal damage 
e.g. proteinuria, renal impairment (acute kidney injury), electrolyte disturbances and
amyloid deposits. Multiple myeloma can also present with signs of spinal cord compression 
resulting in paraesthesia and paraplegia which can be missed and lead to delay in diagnosis 
and treatment.
Case Description: A 73 years old patient with past medical history of; asthma, atrial 
fibrillation on warfarin, bilateral knee replacements; presented to the emergency department, 
following recurrent mechanical falls. The patient had suffered prepatellar lacerations which 
was treated with suturing and discharged home. The patient further attended the emergency 
department with right knee pain and an inability to walk. The working diagnosis was 
right knee haematoma due to raised international normalised ratio (INR) since she was 
on warfarin. She required knee washouts and multiple blood transfusions due to anaemia 
and was subsequently discharged. The patient was re-admitted with recurrent falls. Further 
physiotherapy was arranged and plans made for discharge. During a weekend on call; the 
patient’s husband asked the oncall consultant to review his wife as he was worried about 
her general decline and no one seemed to have listened so far. . The consultant listened to 
the husband and revisited patient’s history. Upon examination; the patient appeared to have 
had significant neurological symptoms of spinal cord compression. A myeloma screen was 
requested due to anaemia. The patient underwent an urgent MRI scan and was transferred 
urgently to a neurosurgical centre for surgical decompression on the same day.
Discussion: Spinal cord compression from multiple myeloma, should be suspected in 
patients presenting with severe back pain along with weakness or paraesthesia, bladder 
or bowel dysfunction or incontinence, including unexplained anaemia (requiring blood 
transfusions). It is important to listen to patients and family when they warn us that their 
“loved ones” are not feeling right. Listening to patients and concentrating on their problems 
gives one more realistic ideas and insight into their problems
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Long-Term Outcomes After Leptospirosis: A Population Cohort Study
Chih-Hsiang Chang. Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Background: Acute kidney injury (AKI) is a common complication of leptospirosis 
infection. However, the long-term outcomes following leptospirosis infection is not fully 
clarified. The aim of this study is to elucidate the long-term outcomes of adult patients who 
survived after leptospirosis.
Methods: The study analyzed datasets from Taiwan’s National Health Insurance 
Research Database. The data of 2145 patients who survived after leptospirosis between 
January 1, 2003, and December 31, 2013, were analyzed. Characteristics and outcomes 
were compared according to the AKI or not to evaluate the impact of AKI on long-term 
mortality and major adverse kidney events.
Results: Of the 2145 patients, 26.0% had AKI and 3.5% received renal replacement 
therapy (RRT). Compared between the non-AKI, AKI and AKI-RRT, those with RRT had 
highest rates of all-cause mortality (22% vs 12.6% vs. 7.0%) and, advanced chronic kidney 
disease (0% vs. 1.09% vs 6.49%) respectively, demonstrating a significant trend (P < 0.001).
Conclusions: Patients who has leptospirosis related AKI, compared to those without 
AKI, have an increased risk of long-term mortality and major adverse kidney events.
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CRRT with Oxiris®: An Option for Multidisciplinary Treatment of AKI 
in Sepsis?
Nicoletta Pertica,1 Alessia Corvo,1 Paolo Ria,2 Lorenzo Signorini,1 
Gianluigi Zaza.3 1Nephrology, AOUI - Borgo Trento, Verona, Italy; 2Nephrology, 
Ospedale - V. Fazzi, Lecce, Italy; 3University of Verona, Verona, Italy.
Background: Septic shock is a serious cause of morbidity/mortality in ICU. MODS 
and AKI are common sepsis complications, burden by high mortality rates. CRRT, carried 
out by filters adsorbing sepsis mediators, can improve the outcome. The actual guidelines 
on sepsis highlights the importance of a timely start of CRRT.
Methods: We selected 27 consecutive patients with AKI in septic shock and treated 
through CVV-HDF with Prismaflex® and Oxiris®. We considered different laboratory 
parameters at regular time lapses after the CRRT start. As control group, we enlisted 20 
patients from a historical cohort matched for diagnosis, treated with filter ST-150.
Results: We observed a statistically significant improvement for those treated by 
Oxiris®, particularly over kidney function recovery at 6 days (p =0.021) and reduction 
of inflammatory parameters (PCR p=0.006; PCT p=0.005). Over mortality, no difference 
emerged between infections caused by Gram + or Gram–, even if a better outcome was 
noted for Gram + related sepsis (G+ 83%vsG- 53%)
Conclusions: The use of specific filters for the treatment of sepsis with timely start 
of CRRT might help to improve the outcome of septic patients with AKI, not in terms of 
Funding: Government Support - Non-U.S.
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absolute mortality, but reducing the indices of inflammation and shortening the functional 
recovery time.
p-creatinine curves in the two groups of patients
PCR and PCT curves in the two groups of patients
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The Anticoagulation Is the Single Most Important Factor Leading to 
Prolonged Filter Time on CRRT
Muhammad O. Saleem,1 Colleen S. Boyle,1 Azeem Mohammed,1 N. 
Stanley Nahman.1,2 Nephrons@AU 1Medical College of Georgia, Augusta 
University, Augusta, GA; 2Norwood VAMC, Augusta, GA.
Background: When providing continuous renal replacement therapy (CRRT) to the 
critically ill, circuit clotting is a key impediment to effective dialysis. Filter clotting may 
result from dysfunctional vascular access, inadequate anticoagulation, and/or selection of 
dialysis parameters that may promote clotting. To investigate the effect of these variables on 
filter life we performed a retrospective, performance improvement, analysis of the records 
of 33 CRRT patients treated in the intensive care units at Augusta University
Methods: A chart review was conducted and patients were sorted into two groups based 
on the presence or absence of anticoagulation. On each patient, we documented the indication 
for CRRT, vascular access specifications, dialysis modality, and prescription, which included 
therapy fluid rates, blood flow rates, and filtration fraction. The clinical characteristics of 
patients were also compared. Students t-test was used to compare the groups.
Results: Of the 33 patients 15 were anticoagulated with heparin, 18 received no 
anticoagulation. No patients received regional citrate anticoagulation in this study. The 
mean filter life in the first 24 hours for all patients was 16.03±11.9 hours. Patients treated 
with heparin had a significantly longer filter life in the first 24 hours (23.3±13.5 vs 9.9±6.8 
hours for heparin vs no heparin, respectively, p < 0.005) The majority of patients (85%) 
received CVVH with the pre-filter administration of replacement fluid. The mean filtration 
fraction of all prescriptions was 19.40±4.03%. There was no difference in site, size, or 
diameter of dialysis catheters between the two groups.
Conclusions: Anticoagulation with heparin prolongs filter half life when compared to 
no anticoagulation. The use of heparin and prolonged filter life must be balanced with the 
risks of bleeding, however, substantially more dialysis can be given without interruption in 
heparinized patients. The role of regional citrate anticoagulation vs heparin or no therapy 
remains to be studied. The results support the use of heparin, when possible, to help 
maintain filter half life in CRRT.
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Infection in Community Acquired AKI
James Tollitt,1 Nicola Bennett,2 Smeeta Sinha,1 James Ritchie,1 Emma Flanagan,3 
Denise Darby,1 Philip A. Kalra,1 Dimitrios J. Poulikakos.1 1Salford Royal NHS 
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Kingdom.
Background: The majority of acute kidney injury (AKI) is community acquired 
(CA). The interaction between community acquired (CA-I) and CA-AKI is incompletely 
understood. Recent sepsis guidance has included assessment of AKI for risk stratification to 
guide treatment. The aim of this study was to evaluate characteristics of CA-I and CA-AKI 
and their impact upon patient outcomes in general population and a care home population.
Methods: Adult, non-elective patient attendances to a single centre were analysed 
retrospectively. CA-AKI (AKI within 48 hrs of hospital attendance) and/or CA-I (antibiotic 
within 48 hrs of attendance) were recorded. Outcomes were 30-day all-cause mortality 
(30 DM), intensive care unit (ICU) admission and length of stay (LOS) dichotomised at 
median. Binary logistic regression models were created to predict the probability of the 
outcome variables in both patient groups.
Results: Of 61,471 attendances 4.2% were from a care home. In the total cohort 
28.1% suffered CA-I and 5.7% suffered CA-AKI (3.8% AKI1, 1.1% AKI2, 0.8% AKI3). 
3.4% suffered CA-I and CA-AKI. CAI-I was present in 58.9% of CA-AKI cases. 30 DM 
showed a stepwise increase in patients with CA-I (8.1%), with CA-AKI (11.8%) and with 
combination of CA-I and CA-AKI (26.2%). In the care home population 30 DM for the 
group with both CA-I and CA-AKI was 43.4%. In non-care home group those with both 
CA-I and CA-AKI had the highest rate of ICU admission (24%), followed by CA-I alone 
(7.2%) and CA-AKI alone (7.1%). Odds ratios (OR) for all outcome variables in non-care 
home population demonstrated an escalating association for poor outcomes (CA-AKI and 
CAI>CA-AKI alone>CAI alone) (Figure1).
Conclusions: CA-I is present in the majority of CA-AKI and their coexistence is 
associated with increased risk of poor outcomes.
Model for 30 Day Mortality in non care home patients
* Significant
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Transcatheter Repair of Tricuspid Regurgitation with the MitraClip 
Device and the Observed Rate of Post Procedure AKI
Ramy M. Hanna, James Wilson. UCLA Health, Rolling Hills Estates, CA.
Background: The MitraClip device was approved for transcatheter repair of significant 
mitral valve insufficiency instead of surgical repair. The device is now being used for non-
surgical candidates with severe tricuspid regurgitation. As IV contrast dye is often not 
necessary for placement of the device in this subset of patients, we have sought to evaluate 
the risk of renal failure in patients who received the Clip in the tricuspid position.
Methods: At the University of California Los Angeles, the MitraClip is being used 
off-label in patients with significant tricuspid regurgitation who are not surgical candidates. 
We report our experience with the first five patients who have had this procedure completed 
at UCLA. We examine the rates of acute kidney injury post procedure in these five patients.
Results: Of the five patients, one had normal kidney function, three had underlying 
CKD and were not on dialysis, and one had ESRD and was on dialysis. Acute kidney injury, 
defined as a rise in serum creatinine by 0.5mg/dL was observed in two of four patients 
(50%) who underwent this procedure and were not on dialysis. The one patient without 
CKD did not suffer acute kidney injury but had a mild rise in serum creatinine. The one 
dialysis patient who underwent this procedure had no discernible change in renal function. 
These procedures were done without iodinated contrast
Conclusions: We examine the rate of AKI post off label tricuspid valve repair with 
MitraClip, further data should be sought out as this procedure is increasingly implemented.
Table 1: Clinical cases involving percuatenous tricuspid valve repair (TriClip) procedure
Table 1 Figure legend: AKI=Acute kidney injury, AV= aortic valve, CAD=coronary artery 
disease, ESRD=end stage renal disease, F=Female, LAD= corornary disease in left anterior 
descending coronary artery, M=Male, ml=milliiter, MV=mitral valve, N=No, RRT=renal 
replacement therapy, TR=tricuspid regurgitation, Y= yes
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Renal Prognosis Is Related with Delta Neutrophil Index in Patients with 
Alcoholic Ketoacidosis
Jun Young Lee,1 Jae seok Kim,3 Seung-Ok Choi,2 Byoung Geun Han.1 1Wonju 
Christian Severance Hospital, Wonju, Kangwon do, Republic of Korea; 2Yonsei 
University Wonju College of Medicine, Wonju, Kangwon, Republic of Korea; 
3Yonsei wonju college of medicine, Won-ju, Republic of Korea.
Background: Alcoholic ketoacidosis is metabolic abnormalities often diagnosed in 
malnourished patients chronically abuse alcohol and have a history of alcoholic binge. 
Delta neutrophil index (DNI), representing an elevated fraction of circulating immature 
granulocytes in acute infection, has been reported as a useful predictable marker for 
mortality in patients with sepsis. We make an attempt to reveal clinical charateristics and 
found prognostic factor including DNI associated with alcoholic ketoacidosis in this study.
Methods: We investigated patients diagnosed with AKA who visited the emergency 
department fo Wonju Severance Christian hospital from October 2009 to March 2014 
retrospectively. Patients have history of alcohol abuse and recent episode of binge drinking 
with metabolic acidosis in ABGA and increased serum anion gap in serum chemistry were 
included. We categorized according to KDIGO Acute kidney injury criteria and compared 
groups about prognostic factors
Results: In a total of AKA cases, 95 (80.5%) were diagnosed with AKI by KDIGO 
criteria: 27 cases (22.9%) were classified as AKI stage 1, 15 cases (12.7%) as AKI stage 
2, 53 cases (44.9%) as AKI stage 3. Mortality was reported in 38 cases (32.2%), and 
the mean time from admission to mortality was 6.4 ± 12.1 days. Major causes of death 
included uncontrolled metabolic acidosis (n=25, 21.2%), septic shock (n=10, 8.5%), and 
gastrointestinal tract bleeding (n=1, 0.8%). There were significant differences in pH, PCO2, 
lactate, Hb, platelets, PT, PTT, Cr, albumin, AST, GGT, Total bilirubin, P, Ammonia, T3, 
fT4, and DNI (P<0.001) between survivors and non-survivors. DNI was higher value in 
AKI stage III compared with AKI 0 to 2 stage significantly (p<0.001)
Conclusions: Delta neutrophil index have a significant value in predicting alcoholic 
ketoacidosis with poor renal outcome and mortality.
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Background: Cervical-uterine cancer (CUC) is a worldwide public health problem. 
Advanced CUC affects nearby regional structures causing obstruction. Rarely, obstructive 
uropathy can cause acute kidney injury (AKI), which leads to uremic syndrome. In 
extreme situations, urgent treatment such as ureteral stent placement, nephrostomies and 
hemodialysis, as saving life modalities, are required.
Methods: We retrospectively analyzed the characteristics of AKI patients due to 
obstructive uropathy caused by advanced CUC presenting to the emergency department in 
a teaching hospital, located in Mexico, during may 2013 to may 2018.
Results: 28 patients were analyzed, 45 years as mean age. The main identified 
comorbidities were Diabetes Mellitus, identified on 5 (17%) of the patients, and 
Hypertension identified on 5 patients also. The mean evolution of CUC period was 22 years. 
60% of the patients had metastatic CUC. The mean Eastern Cooperative Oncology Group 
score was 2.3. The most common presenting symptom was malaise and weight loss on 57% 
and 46%, respectively. The mean Blood Urea Nitrogen and Creatinine was 86 ±60 mg/dL 
and 6.9 ± 6.5mg/dL, respectively. 46.4% of the patients underwent JJ stent placement, and 
39% required nephrostomies. 96% had bilateral hydronephrosis. The mean hospitalization 
period was 6.7 days. 10 patients (36%) died, with a mean survival of 6 ±6 months. Survival 
analysis showed no difference in mortality when comparing both treatment arms (long-rank 
test: 0.95).
Conclusions: Advanced CUC, in our country, is a public health issue and a considerable 
cause of uremia and AKI. Those patients had a mean survival of 6 months irrespective of the 
palliative treatment modality.
Fig 1. Survival Analysis.
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From Heparin to Citrate Anticoagulation in CRRT: Efficiency and 
Expense Evaluation
Davide Ricci, Laura Panicali, Giuseppe Cavallari, Maria grazia Facchini, 
Elena Mancini. Nephrology, Dialysis and Hypertention Unit, S.Orsola - 
Malpighi Teaching Hospital, Bologna, Italy.
Background: CRRT is used as a therapy for acute kidney injury in intensive care 
units. Heparin has long been used as an anticoagulant during CRRT (efficacy-low cost) but, 
starting from the KDIGO 2012 guidelines, citrate has become first-choice anticoagulant.
Methods: From 2011 to 2017 we performed 11,109 CRRT treatments (1 treatment 
= 24 h CRRT) with an increasing percentage of citrate anticoagulation, from 2.9 to 73%. 
We performed a retrospective analysis starting from the quantity and cost of materials 
(Kits+solutions) and evaluated efficiency and expense.
Results: a) reduction in the number of filters used for every 72 hours of treatment, 
from 2.4 to 1.5; b) increase in the administered dialysis dose, from 25.7 to 37.5 ml/kg/h; c) 
reduction in the difference between prescribed and administered dialysis dose, from 22 to 
7%; d) slight increase in the total cost for 24 hours’ CRRT, from €161.03 to €184.54; e) 
reduction in the total cost for each 35ml of solution administered, from € 0.13 to € 0.10 (e.g. 
134960000 ml solution used in 2017).
Conclusions: The limits of the study are its retrospective nature and data collection 
not regarding single treatments but starting from the total quantity of materials used and 
thus ruling out statistical analysis of significance. With citrate we observed a slight increase 
in the total cost but also a reduction in the cost per unit of administered dialysis dose. 
Furthermore, we obtained an increase in the average life of the filter and an increase in the 
efficiency of the treatment (prescribed dialysis dose versus administered dose).
* 1 treatment = 24 h CRRT
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An Update on the Use of Novel Biomarkers for AKI in Drug Development
Carolina Panico, Aliza M. Thompson. U.S. Food and Drug Administration, 
Silver Spring, MD.
Background: In 2008, FDA qualified 7 urinary biomarkers to be used, in conjunction 
with serum creatinine, BUN and histopathology, as additional evidence to identify early 
signals of kidney injury in the rat. Since then, there has been increased use of these 
biomarkers in drug development programs. The objective of this study is to characterize 
the data that can be leveraged on the performance of these biomarkers and use to inform 
decision making in drug development programs.
Methods: The FDA document archiving, reporting and regulatory tracking system was 
used to retrieve biomarker information contained in Investigational New Drug applications 
(INDs), using KIM-1 (kidney injury molecule-1) as the search term. The following 
information was collected: urinary biomarkers assessed, pre-analytical information, such as 
collection method, storage and processing of samples, information on assays, and status of 
the drug development program, including stage of clinical development and whether studies 
were still being pursued under the IND.
Results: A total of 143 INDs referenced the use of KIM-1 between 2005 and 2016. 
Of these, 51 INDs contained summary or patient-level data on KIM-1; 41 also contained 
information on other novel urinary biomarkers. In 45 INDs, the biomarkers were used in 
safety assessments, whereas in 6 INDs the biomarkers were used in efficacy evaluations. 
Among the 51 INDs, 45 reported the use of the biomarkers in preclinical studies and 11 
in clinical studies (8 phase I and 3 phase II studies). 15 of 51 applications contained pre-
analytical and assay information, though the granularity of that information varied greatly 
across the 15 INDs. Of the applications in which the biomarkers were used to assess drug-
induced kidney injury, 33 were still active. In contrast, only two of 6 INDs identified as 
using the biomarkers for efficacy assessments were still active at the end of 2016. Based on 
the submitted data, it is unclear to what extent the biomarker data influenced the decision to 
pursue further investigation of the drug.
Conclusions: Although novel renal biomarkers are being used in drug development, 
most INDs do not appear to contain granular information on pre-analytical variables and 
assay(s) or data sets, which may limit the ability to leverage data that are currently available 
to FDA to learn about the performance of the biomarkers as drug development tools.
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Biomarker: Results of an Economic Model
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Background: [TIMP-2/IGFBP-7] NephroCheck® (NC) is a novel biomarker-based, 
FDA-cleared urine test to aid in assessing risk for moderate or severe acute kidney injury 
(AKI) in ICU patients. NC measures the levels of two urinary biomarkers indicating higher 
risk of AKI, and is thus able to identify AKI earlier than the existing standard of care (SOC). 
We evaluated via an economic model if early identification of AKI, by using NC, could 
reduce the severity of AKI, thereby improving patient outcomes, such as length-of-stay, 
readmissions and healthcare costs.
Methods: An Excel-based economic model (2017 USD) using peer-reviewed data was 
developed from the perspective of a hypothetical hospital system. The model estimated the 
impact of testing patients for AKI using SOC versus a combination of SOC plus NC over a 
1-year period. Outcomes considered included lengths of ICU and non-ICU inpatient stays, 
30-day readmissions, and net impact on hospital budget. Model inputs included literature-
based estimates for diagnostic efficacy of NC plus SOC and for patient healthcare resource 
utilization associated with levels of AKI severity, as well as data on file for costs associated 
with NC test meters and cartridges.
Results: Assuming 500 hypothetical at-risk patients were tested, improved diagnostic 
efficacy using NC in addition to SOC would result in 283 fewer non-ICU inpatient days 
(0.6 days per tested patient [PTP]), 152 fewer ICU days (0.3 days PTP), and 5 fewer 30-day 
readmissions. The incremental cost of using NC is more than offset by these reductions, 
resulting in annual net savings of $799,479 ($1,599 PTP) or 10.1% to the overall hospital 
budget. Deterministic and probabilistic sensitivity analyses support improved patient 
outcomes and associated savings in over 99% of scenarios.
Conclusions: This model demonstrates that the addition of NC to SOC for the earlier 
identification of AKI is likely to result in moderate reductions in inpatient non-ICU and ICU 
lengths of stay, 30-day readmissions and total healthcare costs. Further studies are needed to 
confirm these findings in a real-world setting.
Funding: Commercial Support - bioMérieux Inc.
PUB042 
Publication-Only 
AKI Mortality Across KDIGO Classification Strata: Does Previous CKD 
Matter?
Maria Isabel Acosta-Ochoa, Armando Coca, Alicia Mendiluce. Hosptal Clinico 
Universitario Valladolid, Valladolid, Spain.
Background: Few works compare in-hospital mortality in individuals with previous 
normal (ARF) and impaired (Acute on CKD) renal function who suffer AKI, and fewer 
compare mortality between strata inside KDIGO stages. We hypothesize that AoCKD 
individuals perform distinctly across the classification.
Methods: Retrospective study of ARF and AoCKD patients classified by KDIGO 
guidelines. We analyzed epidemiological variables, compared the clinical outcome in-
hospital mortality, and analyzed the distribution through KDIGO stages of all cohort and 
subanalyzed dead patients.
Results: 1269 individuals were included. Table 1 summarizes clinical characteristics 
and results of both groups. Compared with ARF individulals, AoCKD patients are older, 
have a higher Charlson’s Index, are more frequently classified in Stage 1 (both criteria), 
lesser in Stage 2, and equal in Stage 3. Global mortality is not significantly different 
between groups, we checked every KDIGO Stage and mortality was significantly higher 
in Stage 1 (for both criteria), lower in Stage 2 and equal in Stage 3. When evaluating every 
component of Stage 3 we found that 29% of AoCKD individuals (vs 67% ARF) reached a 
3x SCr increment, 65% (vs 42% ARF) reached a SCr ≥4.0 mg/dl (21 patients had already a 
basal SCr ≥4.0 mg/dl), and no difference in initiation of renal replacement therapy (RRT).
Conclusions: Although in-hospital mortality is not significantly different between 
groups, when analyzing KDIGO strata we found excess mortality for the AoCKD individuals 
in Stage 1 and 3. The smaller proportion of SCr x 3.0, and the excess in SCr ≥4.0 mg/dl 
may be due to diminished renal reserve and higher basal SCr. The facts that the same 
proportion of patients in both groups initiate RRT, and that in Stage 2 a smaller proportion 
of AoCKD patients died, deserves further investigation.
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Background: With the advent of the era of immunotherapy there has been marked 
increased survival in several cancers such as advanced melanoma, renal cell carcinoma, 
non-small cell lung cancer (NSCLC), urothelial carcinoma, and head and neck cancers. 
Although the incidence of renal toxicity is reported 3.8%, we believe that it is much higher. 
In this study we sought to retrospectively review a 10 year experience at MD Anderson 
Cancer Center of patients with cancer and treated with CPI and evaluate incidence of AKI, 
CKD, and overall survival.
Methods: We performed a retrospective chart review from 2008-2018 and extracted 
all patients treated with Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, 
Durvalumab, and Avelumab. We identified 6412 unique patients and extracted all avaliable 
creatinine and GFR. We have defined AKI based on KDIGO guidelines excluding urine 
output. We also are also interested in evaluating the overall renal outcomes looking at CKD 
as persistent GFR over three month period at end of the study. Variables to be studied basic 
demographics, type of cancer, type of CPI, number of doses, dosages, and CKD stage at 
beginning of the study period. We have three primary endpoints: incidence of AKI, stage of 
CKD, and overall survival. We will perform Cox proportional hazards regression models 
to estimate unadjusted and adjusted cause-specific hazards ratios (HR) of risk factors for 
all three endpoints.
Results: We have identified 6412 patients with diagnosis melanoma, sarcoma, 
lung cancer, renal cell cancer, and hematological malignancies. The patients have been 
categorized as either single agent CPI or combinations. Based on our preliminary data and 
further verification is underway the incidence of AKI is higher than reported in the literature 
and estimated at >25%. Since patients with Renal cell cancer maybe predisposed to having 
AKI and CKD in setting of solitary kidneys we will be perform a subpopulation analysis.
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Conclusions: With such a large population of patients treated with CPI we would 
be able to understand the variables associated with renal toxicities, such as type of CPI, 
combinations, or dosage and help create more accurate guidlines. This would impact renal 
survival which would impact ultimately patients overall survival.
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AKI in the Setting of Coronarography Procedures: A Monocentric 
Analysis
Matteo Floris,1 Maria Rosaria Concas,1 Nicola Lepori,1 Andrea Angioi,1 
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Background: Acute Kidney injury (AKI) is a common complication of coronarography, 
PTCA and TAVI, with a literature reported incidence ranging from 7 to 12%. This study 
investigates incidence, risk factors and outcomes of AKI in patient who undergo to 
coronarography procedures with intraarterial administration of contrast medium.
Methods: We retrospectively reviewed data from all the adults who underwent to 
diagnostic or therapeutic coronarography procedures at the Cardiology Department of 
Brotzu Hospital in 2016 and had least one creatinine value 7 days before and 72 hours after 
the procedure. Patients who were on dialysis at the time of the procedure and those who 
underwent to cardiac catheterization were excluded from the analysis.
Results: 375 patients were included in our analysis. Among them a total of 57 (15.2%) 
developed AKI (according KDIGO definition): 30 patients (8%) developed CI-AKI. 49 
patients reached stage 1 AKI (according KDIGO definition), 2 and 6 developed stage 2 and 
stage 3 AKI respectively. Diagnosis of AKI was associated with older age (73.6 vs 65.7), 
lower eGFR before procedure (53 ml/min vs 81.5 ml/min), preexisting CKD (OR 5.3), 
hypertension (OR 1.86), CHF (OR 2.20) and higher Mehran score (8.47 vs 5.01). AKI 
required begin of renal replacement treatment in 3 patients. The mean contrast medium dose 
was not significantly different between patient who developed AKI and those who did not, 
while radial access was associated with a lower incidence of AKI. At 12 months follow-up 
7 patients of AKI group were on dialysis, while only 1 patient from non-AKI group needed 
RRT (12.3% vs 0.03% OR 44.4); risk of mortality was significantly higher in patients who 
developed AKI (17.5% vs 3.7% OR 5.42). No significative difference were found between 
who developed CI-AKI and those who developed AKI but did not meet criteria for CI-AKI.
Conclusions: Our analysis describes risk factors who should evaluated in patients who 
should undergo to coronarography procedures: older age, previous CKD, hypertension, 
CHF. Since criteria for CI-AKI were met in 52% of AKI cases, 48% of patients developed a 
kidney damage with no clear correlation with contrast medium: hemodynamic factors, renal 
atheroembolism and drug nephrotoxicity should, therefore, be considered as further kidney 
injury cause in these patients
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ment Therapy Does Not Affect the Patient’s Short Term Outcome
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Background: Many severe acute kidney injury (AKI) patients in the intensive care 
unit(ICU) has received renal replacement therapy and the patients with hemodynamic 
instability receive the continuous renal replacement therapy (CRRT). The vascular access 
for CRRT is usually performed using a short term catheter. In KDIGO guidline., When 
choosing a vein for insertion of a dialysis catheter in patients with AKI, consider these 
preferences.: 1st choice: right jugular vein (RJV); 2nd choice: femoral vein(FV); 3rd 
choice: left jugular vein(LJV); Last choice: subclavian vein(subV). But, There are many 
patients who have access to the FV more than the Internal JV in the clinical setting, The 
aim of this study was to investigate the relationship between catheter location and patient 
prognosis and norepinephrine(NE) dose changes.
Methods: We retrospectively studied on patients who received CRRT in the ICU on 
our hospital from January 5, 2016 through December 31, 2016. Among these patients, 
We excluded patients under 18 years, End stage renal disease, without central venous 
catheterization, not using NE, using NE and other additional vasopressors and using 
Extracorporeal membrane oxygenation. They were divided two groups based on the double 
lumen catheter insertion site. Femoral vein insertion was assigned to group 1 and the other 
site was assigned to group 2. The 28-day mortality and NE dose changes were compared 
between the two groups. We calculated the difference by measuring the amount of NE 
injection at the start of CRRT and the amount of NE injection after 6 hours.
Results: All patients who received CRRT in the ICU on our hospital was initially 
screened.(n=186). We excluded 124 patients according to exclusion criteria. A total of 62 
patients were included in the analyses. The median age of patients is 68(21-90) year-old 
and men were 67.7% (n=42). 28-day mortality rate was 56.5% and the septic shock was the 
main cause of CRRT (n=46, 74.2%). The 28-day mortality rate was not different between 
the two groups. [48.4%(n=15) vs.64.5% (n=20), P=0.2]. And NE dose changes were also 
not different between the two groups. [-1.3699(-44.99 – 128.74) vs. 0.0000(-66.67 – 97.86) 
ug/kg/hr, P=0.767.].
Conclusions: The insertion site of the catheter in patients with CRRT does not affect 
the patient’s short term out coming.
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A Novel Hemodialysis System, Deployed in an Acute Setting, Provides 
Volume Management at Lower Cost Than CRRT
Sevag Demirjian,3 Glenn M. Chertow,2 Luis Alvarez.1 1Palo Alto Medical 
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Background: There is an increasing prevalence of AKI requiring renal replacement 
therapy. Care of this patient population is challenging to health care systems (HCS) both in 
costs and logistics. HCS increasingly face nursing shortages and flat reimbursement rates 
for care of this patient population, straining abilities to provide effective dialysis.
Methods: As part of a QAPI project, we first examined the number of dialytic 
therapies, grouped by modality, conducted in intensive care settings at the Cleveland Clinic 
between 2013 and 2016. Secondly, we piloted the use of novel, simple to use hemodialysis 
system (Tablo) as a transitional modality, in 80 patients ready to transition off CRRT, but 
that remained clinically volume overloaded. This is a cost-effectiveness analysis of our 
PIRRT experience using Tablo compared to existing options.
Results: During 4 years of study, the number of intermittent dialysis treatments in the 
ICU stayed stable, however the number of continuous dialysis treatment days increased 
(Table 1). 80 patients were dialyzed using Tablo, for 6-8 hour treatments at QB of 200-300 
ml/min and QD of 300 ml/hr. The cost of PIRRT using Tablo is presented in Table 2.
Conclusions: Treating this critically ill cohort at the Cleveland Clinic, we demonstrate 
that Tablo can enable transitional hemodialysis while markedly reducing staffing costs. 
These data suggest that Tablo can provide increased functionality and flexibility to cost and 
staff constrained ICUs.
Funding: Commercial Support - Outset Medical
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Clinical Study and Outcome of Patients with AKI Following Exposure to 
Various Poisons with Special Emphasis on Paraquat Poisoning
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Background: Exposure to compounds like pesticides, herbicides and insecticides have 
hazardous effects. ARDS, AKI, multiorgan failure are the frequent causes of mortality. 
Paraquat is a weedicide used commonly for suicide in southern Maharashtra. It is always 
fatal as there is no specific antidote. Current study highlights the occurence of Acute kidney 
injury and its outcome after exposure to various poisons amongst patients admitted to 
RCSM GMC and CPR Hospital, a tertiary care centre in Kolhapur, Maharashtra.
Methods: We carried out a retrospective observational study where data was collected 
from case records of patients admitted from May 2015 to April 2018 and their outcome 
was noted. The aim was to study the morbidity and mortality rates of different poisons with 
special focus on Paraquat compound. Almost all patients included required hemodialysis, 
especially with Paraquat poisoning and associated mortality was compared with other 
poisons combined. Adequate statistical test was used and a p-value <0.05 was considered 
statistically significant
Results: During the study period we found 347 patients of poisoning who developed 
AKI requiring dialysis. The largest group was from Paraphenyline diamine (PPD) of 94 
patients followed by Organophosphorus compound (73), Paraquat (66), Copper sulphate 
(42) Methanol (20) and other poisons (52). The outcome of ingestion of these poisons is
summarized in Table 1. Mortality associated with Paraquat was 86.36% (N=57) whereas
it was 43.82% (N=78) among other poisons combined. This difference was statistically
significant (x2 = 69.70, p < 0.0001)
Conclusions: It is important to report all the poisonous substances. causing 
nephrotoxicity to increase awareness among general population and health care providers. 
Of all registered herbicides, Paraquat is the most fatal and despite early hemodialysis, the 
mortality rates remained high. Newer treatment options like early hemoperfusion may help 
to reduce the mortality in future.
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Outcome in different groups (N=347)
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AKI and Complete Heart Block in Hepatitis E Infection
Prof Narinder P. Singh, Purneetha Singh, Swapan Deep Singh Nagpal, 
Anish Gupta. Max Super Speciality Hospital, Ghaziabad, India.
Introduction: Hepatitis E is a benign, usually self-limiting viral infection with 
primary symptoms of fever, myalgia, fatigue, nausea and vomiting. Acute kidney injury is 
uncommon in hepatitis E infection and hence not frequently anticipated. We present a patient 
with type II diabetes mellitus (DM) with two episodes of syncope. Investigation revealed 
AKI, hyperkalemia and complete heart block, all secondary to Hepatitis E infection.
Case Description: A 71 year male, presented with two episodes of syncope and fall, 
decreased urine output and complete heart block. Temporary pacemaker implantation was 
done. On detailed evaluation, he gave history of fever, vomiting, fatigue and loss of appetite 
for the last 1 week. Examination revealed bradycardia, right hypochondrial tenderness and 
decreased breath sounds in bilateral intrascapular regions. Initial investigations revealed 
grossly elevated cardiac enzymes, leukocytosis, hyperglycemia, hyperkalemia (Serum 
potassium - 6.4 mEq/L) and markedly deranged renal, liver and coagulation profiles. 
Measures to counter hyperkalemia, broad spectrum antibiotics and insulin therapy were 
initiated. Ultrasound was suggestive of ascites and bilateral pleural effusion; and possible 
underlying chronic kidney disease. 2D Echocardiography showed hypokinesia of the basal 
inferior and infero-lateral walls with ejection fraction of 50%. He was hemodialysed in view 
of the decreased urine output and hyperkalemia. Investigations done to rule out the cause 
of acute liver injury revealed serology positive for hepatitis E infection. After clinical and 
symptomatic improvement, the pacemaker support was withdrawn and there was reversion 
to sinus rhythm. The patient was discharged in a stable condition after over a fortnight in 
the hospital. He was followed up in OPD where he was asymptomatic and had a normal 
renal profile.
Discussion: Acute Kidney Injury is an uncommon manifestation of Hepatitis E 
infection. Complete heart block due hyperkalemia secondary to AKI (with a serum 
potassium of 6.4 mEq/l) is unlikely and may occur due to myocarditis or an underlying 
coronary artery disease. The clinician should be aware of the extra hepatic manifestations 
of hepatitis E infection including AKI and arrhythmias, which, if identified in time could be 
treated promptly with good outcomes.
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Nonagenarians in Northern Jordan Are at Risk for AKI: A Retrospective 
Case-Control Study
Sameeha A. Alshelleh,1 Ashraf O. Oweis.2 1University of Jordan, Amman, 
Jordan; 2Jordan University Of Science and Technology, Amman, Jordan.
Background: Improvements in healthcare systems worldwide have had notable effects 
on the life expectancy of older individuals. As a result, nonagenarians are emerging as a 
separate age group with distinct healthcare needs. We evaluated the incidence and outcome 
of acute kidney injury (AKI) in nonagenarians who were admitted to one regional city 
hospital in Jordan
Methods: In our retrospective chart review, we included all patients 90 years of age 
and above who were admitted to the floor at our University hospital, between January 2010 
and December 2013. Patients with Stage I, II or III chronic kidney disease (CKD) were 
included in the analysis. Our exclusion criteria included those patients with Stage IV and V 
CKD. The incidence of AKI was determined by using data from the Acute Kidney Injury 
Network Classification (AKIN). Primary outcome variables included length of in-hospital 
stay and mortality rates.
Results: Of the total 283 patients who were evaluated during the study period, 48 
patients with end stage renal disease (ESRD) were excluded. In the 253 patients who were 
included, the mean age was 91.5 years, 61 of the patients developed AKI (25.9%), and 41 
patients were in Stage 1 AKI (66.1%) according to AKIN criteria. A total of 57 patients 
died during the study period and 33 of these patients (57.9%) had AKI. Hospital stay was 
longer in patients with AKI with a mean length of stay of 8.1 days. Congestive heart failure, 
cancer, and use of non-steroidal anti-inflammatory drugs were the main risk factors for AKI 
in our patients.
Conclusions: AKI is common in nonagenarians with increased risk for mortality and 
increased hospital stays.
Baseline characteristics
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The Kinetics of Fluid Overload Are Associated with Outcomes in 
Critically Ill Patients
Rajit K. Basu,1 Shina Menon,2 Stuart Goldstein.3 1Children’s Healthcare of 
Atlanta, Atlanta, GA; 2Seattle Children’s Hospital, Seattle, WA; 3Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH.
Background: Recent data indicate fluid accumulation in critically ill patients, termed 
fluid overload (FO), is associated with poor outcome. There is little discussion of how 
timing and rate of fluid accumulation associate with morbidity. We hypothesized how fluid 
accumulates is associated with patient morbidity.
Methods: We performed a post-hoc analysis of a prospective observational study of 
patients requiring mechanical ventilation admitted to a pediatric intensive care unit (PICU). 
Fluid accumulation was studied using three definitions. Absolute FO was calculated as a 
percentage (%FO). Delta FO was the defined as the change in %FO on consecutive days 
(e.g., %FO Day 2 - % FO Day 1). Fold FO was defined as the fold difference in %FO 
between days (e.g., % FO Day 2 / % FO Day 1). The maximum value identified in the first 
seven days of ICU was used and FO were definitions separated into strata. The primary 
outcome of interest was mechanical ventilation (MV) duration. Other outcomes of interest 
included length of stay (LOS), renal replacement therapy (RRT) use, and mortality. All 
outcomes were assessed at 28-days.
Results: 124 patients (64 male) aged 8.6 ± 6.5 years were studied (Figure 1). While 
there was no difference in MV duration for patients based on Absolute %FO (f-ratio=0.22, 
p=0.79), MV duration steadily increased between the Delta FO strata and also in the Fold 
FO strata (f-ratio=1.99, p=0.13 and f-ratio=2.55, p=0.08, respectively). Absolute %FO 
was not associated with ICU LOS (f-ratio=0.7, p=0.49), but there was a significant LOS 
difference with both escalating Delta FO and Fold FO (f-ratio=3.2, p=0.04 and f-ratio 3.3, 
p=0.04, respectively). RRT utilization and mortality were not associated with absolute % 
FO, delta % FO, or % fold FO.
Conclusions: Our data suggests how fluid accumulates in critically ill patients 
affects morbidity. Rapid accrual fluid through ICU course, even after initial resuscitation, 
demonstrates a greater association with poor outcome than absolute maximum fluid 
overload. Expanded study of our initial findings is warranted.
Figure 1
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Functional Investigation of miR-17-5p Inhibition in Kidney Isch-
emia-Reperfusion Injury in Mice
Peter Hamar,2,3 Tamás Kaucsár.1 1Semmelweis University, Budapest, Hungary; 
2Institute for Translational Medicine, University of Pécs, Pécs, Hungary; 
3Clinical Experimental Research Institute, Semmelweis University, Budapest, 
Hungary.
Background: One of the most common causes of acute kidney injury (AKI) is 
ischemia-reperfusion (IR), which increases the risk of renal fibrosis and chronic kidney 
disease. Our group has previously described the activation of the pro-proliferative and anti-
apoptotic miR-17-5p in IR induced AKI. Our aim was to investigate the function of miR-
17-5p in IR-induced renal fibrosis in mice.
Methods: AKI was induced in the left kidneys of C57BL / 6N mice with 20-minute
ischemia, without the removal of the right intact kidney. One day before the IR operation, mice 
were given miR-17-5p silencing (17-LNA-IR group, N = 10) or scrambled sequence (SCR-
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IR group, N = 10) locked nucleic acid (LNA) modified antisense oligonucleotides[EO1] 
(30 mg / kg, ip). On the 7th reperfusion day, the efficacy of the miR-17-5p inhibition was 
evaluated in the injured and control kidneys (qPCR). In addition, we investigated the extent 
of tubular damage in histological sections (PAS, HE), the miR-17-5p-target p21 mRNA 
expression, the tubular damage (KIM1 mRNA), fibrosis (FN1 mRNA), inflammation 
(TNFα mRNA), the oxidative stress response (NRF2 mRNA), and the proliferation (PCNA 
mRNA) with real-time PCR.
Results: At the 7th reperfusion day, specific LNA inhibition prevented the increase 
in miR-17-5p expression (1.62x, p <0.01, SCR-IR vs. non-IR) in the damaged kidneys 
(0.49x, p < 0.0001; 17-LNA-IR vs. SCR-IR). The inhibition of miR-17-5p following IR had 
no[EO1] significant effect either on the histological damage, or on increased KIM1 (83.2x, 
p <0.0001), FN1 (8.6x, p <0.0001), TNFα (5.8x, p < 0.0001), NRF2 (1.4x, p <0.01), PCNA 
(1.3x, p <0.05), and p21 (3.8x, p <0.0001) mRNA levels.
Conclusions: While miR-17-5p could have renoprotective effects, our findings suggest 
that miR-17-5p inhibition has no significant effects on the IR-induced AKI outcome. New 
National Excellence Program (Immuno Pathophysiology) OTKA (114619), Kispál Gyula 
Program 30021
Funding: Government Support - Non-U.S.
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Intestinal Apoptosis, but Not Tight Junctions, Contributes to the 
Translocation of Bacteria/Endotoxin in a Rat Model of Non-Ischemic AKI
Jiangtao Li,1 Chen Yu,1 Lirui Wang,2 Kun Zhang.1 1Nephrology, Shanghai Tongji 
Hospital,Tongji University School of Medicine, Shanghai, China; 2Tongji 
Hospital of Tongji University, SHANGHAI, China.
Background: To investigate whether translocation of bacteria and endotoxin develops 
in acute kidney injury (AKI), and, if so, what are the mechanisms behind it.
Methods: Sprague–Dawley (SD) rats were subjected to bilateral nephrectomy (BNx) 
or sham-operation (n=5/group) and observed for 24h. The pathology of ileum was scored. 
Apoptosis in ileum was detected by TUNEL staining and DNA fragmentation ELISA. Gut 
mucosal permeability was evaluated in vivo and ex vivo. Serum endotoxin levels were 
measured by LAL method. Bacterial load in liver was measured by 16srDNA analysis. 
The expression of tight junctions(TJs) in ileum, including zonula occluden-1, Occludin and 
Cludin-1 was measured by Western blot. Transmission electron microscopy was used to 
detect the alterations of cell-cell junction.
Results: Compared with the sham rats, the BNx rats showed elevated intestinal damage 
scores (Fig.A-B), accelerated apoptosis in ileum (Fig.C-D), increased serum levels of 
D-lactate (FigE) and promoted intestinal clearance of FITC-dextran (Fig.F). Serum levels
of endotoxin and bacterial load in liver increased significantly after 24h nephrectomy 
(Fig.G-H). BNx did not reduce the expression of the selected epithelial TJ proteins(Fig.I), 
but resulted in the disruption of cell-cell junction(Fig.J).
Conclusions: Our study shows that non-ischemic AKI causes impairment of intestinal 
functions and histology, which in turn promotes the translocation of gut-derived bacteria 
and endotoxin. Accelerated intestinal mucosal apoptosis and the disruption of cell-cell 
junction are the most likely mechanisms for the translocation of bacteria and endotoxin.
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Insulin-Dependent Diabetes Mellitus Aggravates the Systemic  
Inflammatory Response
Daniel Patschan. Medical School of Brandenburg, Brandenburg, Germany.
Background: Acute Kidney Injury significantly worsens the prognosis of hospitalized 
patients. Diabetes mellitus (DM) affects a growing number of individuals in the western 
world. DM subjects are at higher risk for aquiring AKI during the stay at the hospital, in 
addition the long-term prognosis of kidney function is particularly poor in subjects suffering 
from this metabolic condition. The most frequent cause of AKI, renal ischemia typically 
induces tubulopathy, microvasculopathy, and interstitial inflammation. The latter has 
extensively been investigated in recent years. The current study intended to quantifiy serum 
levels of certain immunomodulatory cytokines in diabetic mice suffering from AKI.
Methods: DM was induced in male C57/Bl6N mice by repeated systemic injections 
of beta cell-toxic streptozotocine. Animals underwent bilateral renal ischemia (45 minutes) 
6 weeks later. Mice were either injected with native or preconditioned (zVAD or MD132 - 
autophagy inducers) syngeneic murine proangiogenic cells (PACs). Two days after surgery, 
mice were harvested and analyzed. Beside kidney function and morphology, serum levels 
of numerous (n=18) immunomodulatory cytokines were quantified.
Results: Post-ischemic diabetic mice showed significantly different serum 
concentrations of the majority of all analytes as compared to untreated controls and to 
non-diabetic (post-ischemic) animals. Cell therapy did not modulate cytokine patterns in 
a consistent manner.
Conclusions: Together, our data suggest significant DM-associated immunoactivation 
in AKI. One may suppose that inadequate stimulation of the humoral / cellular immune 
response potentially contributes to the higher ischemia-susceptibility of the organ in DM.
PUB054 
Publication-Only 
Antioxidative and Antiapoptotic Effects of (+)-Clausenamide on 
Acetaminophen-Induced Nephrotoxicity in Mice
Fanna Liu. The First Affiliated Hospital of Jinan Universtiy, Guangzhou, China.
Background: Renal insufficiency occurs in nearly 1–2% of patients with APAP 
overdoses. We assumed that oxidative damage caused by reactive oxygen species (ROS) 
might be involved in APAP-induced renal injury, and available antioxidative agents, 
clausenamide (CLA) might be able to reduce the adverse effects. The aim of the study was 
to evaluate the protective effect of (+)-CLA against APAP-induced nephrotoxicity and to 
elucidate the mechanisms of the protective effect of (+)-CLA
Methods: Mice were divided into control, APAP, high-dose (+)-CLA, and low-dose 
(+)-CLA groups. Then, mice were preadministered (+)-CLA (50 and 100 mg/kg) for 5 
consecutive days. After the last treatment, the animals received a single intraperitoneal 
injection of APAP (600 mg/kg). Renal histopathology was evaluated by staining with 
hematoxylin and eosin. The levels of MDA and GSH and the activities of CAT and SOD 
were determined using corresponding kits. Western blotting was used to analyze the 
expression of apoptosis-related proteins in renal tissue.
Results: Administration of APAP increased Scr and BUN levels in comparison with 
the control group. Renal MDA level increased, GSH, CAT and SOD activities reduced in 
renal tissue. The expressions of Bax and caspase-3, cleavage of caspase-3, and cytoplasm 
cytochrome c (Cyt c) levels were up-regulated in renal tissue, whereas Bcl-2 expression and 
mitochondrial Cyt c levels were down-regulated in the APAP group. The histopathology of 
kidney tissue supported these biochemical mechanisms. (+)-CLA can reverse changes in 
most of the abovementioned parameters and nearly restore the normal structure of the kidney.
Conclusions: Oxidative stress and apoptosis are considered to be the mechanisms 
underlying APAP-induced nephrotoxicity. (+)-CLA could be a promising antidote for 
APAP-induced AKI owing to its antioxidative and antiapoptotic effects.
Funding: Government Support - Non-U.S.
Effects of (+)-CLA on Bcl-2, Bax, Caspase3, Cleaved Caspase3 and Cytochrome c 
protein expression.
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A Case Imitating Thrombotic Microangiopathy
Golriz Jafari,1 Phuong-Chi T. Pham,1 Raghu Konanur venkataram,2 
Thuan V. Nguyen,3 Anita Kamarzarian.4 1UCLA-Olive View Medical Center, Los 
Angeles, CA; 2Olive View- UCLA Medical Center, Porter Ranch, CA; 3UCLA-
Olive View Nephrology, North Hills, CA; 4UCLA -Olive View Medical Center, La 
Canada, CA.
Introduction: The combined finding of hemolytic anemia, thrombocytopenia and 
organ injury, in particular AKI, are the hallmark signs of thrombotic microangiopathies 
(TMA). The differential is broad, presentations are diverse and most cases severe and life 
threatening. Risks associated with therapy must be calculated accordingly.
Case Description: A 44 year old female presented with fatigue and body aches 1 week 
after a motor vehicle accident. Hemoglobin 7.6 g/dl and platelets 16K. Prior to accident she 
had left knee pain, nausea, poor oral intake and weight loss for 2-3 weeks. No major trauma 
or injuries resulting from the accident. Only past medical history was a neck plaque like rash 
9 months prior that was treated with antibiotics. Later she reported dysuria, fever and chills. 
Social history positive for prior cocaine use and current marijuana. Initially afebrile, then 
developed a temp 37.9 BP 115/92 HR 108. Exam was notable for suprapubic/costovertebral 
tenderness, left knee erythema, warmth and pain and a macular erythematous rash. WBC 
6.4K, BUN 107 mg/dl Cr 4.59 mg/dl Albumin 1.6 g/dl UA: 182 WBC 112 RBC, Urine 
Protein/Cr ratio 3.7 gm Blood cultures and Urine cultures positive for E coli. Orthopedic 
evaluation ruled out septic joint. She was treated with antibiotics, fluids and platelet 
transfusion. Central venous catheter was placed for plasmapheresis. Blood smear revealed 
that schistocytes present, however haptoglobin values were high and bilirubin was normal. 
Therefore patient was managed medically and plasmapheresis was not implemented. Cr 
gradually improved to 1.82 mg/dl, on day 4 platelets>50K. ADAMTS13 levels were within 
normal range and serologies were negative: ANA, ANCA, HBV, HCV, HIV.
Discussion: The differential for the presentation of thrombocytopenia, hemolytic 
anemia and organ dysfunction is broad including TMAs such as TTP, HUS (shiga toxin 
or complement mediated) but also include other etiologies that augment complement 
activation such as sepsis, auto-immune disorders, malignancy, malignant hypertension 
and pregnancy. Treatment options such as plasmapheresis for TTP or complement cycle 
immune modulators such as eculizumab for aHUS are available however risks must be 
calculated based on clinical judgement. In this case the findings were due to E. Coli sepsis 
due to pyelonephritis rather than TTP or HUS and patient improved with sepsis treatment.
PUB056 
Publication-Only 
The Effect of L-Carnitine in Contrast-Induced Nephropathy  
in Diabetic Rats
Natalia A. Oliveira,2 Sheila M. Fernandes,1 Maria De Fatima Vattimo,1 
Mirian Watanabe,3 Karina B. Peres,4 Cassiane D. da Fonseca.1 Experimental 
laboratory on animal models 1University of São Paulo, Carapicuíba, Brazil; 
2Organization University of São Paulo, São Paulo, Brazil; 3University of Sao 
Paulo, Sao Paulo, Brazil; 4EEUSP, São Paulo, Brazil.
Background: Contrast-induced nephropathy (CIN) has been defined as an abrupt 
reduction in renal function, resulting from iodinated contrast (IC) use. Studies show that 
Diabetes Mellitus is an important predisposing factor for CIN. It is known that L-carnitine is 
a lipidic metabolism compound and antioxidant effect is one of its major mechanisms. The 
aim of this study was evaluated the L-carnitine effect on CIN in diabetic rats.
Methods: Adult male Wistar rats was sorted into four groups: Citrate (control), 
Diabetes Mellitus (DM), Diabetes + iodinated contrast (DM+IC) and DM + IC+L-
Car. Renal function (Inulin clearance); hemodynamics (renal blood flow; renal vascular 
resistance) and oxidative profile (urinary peroxides, urinary TBARS, thiols in renal tissue 
and urinary nitric oxide- NO) were evaluated.
Results: Diabetes was associated with significant decrease in inulin clearance that 
was additionaly reduced after the infusion of IC. DM+IC group also showed a significant 
increase in the urinary peroxides, TBARS and NO, a reduction in the thiols levels. 
Considering the renal hemodynamics parameters, this group showed a reduction in renal 
blood flow and increase in renal vascular resistance when compared with DM group. These 
parameters were significantly changed by L-carnitine in diabetic rats and those that received 
IC. Supplementation with L-carnitine resulted in an antioxidant protection in this IC model.
Conclusions: Our data reinforced that DM is an important risk factor for contrast-
induced nephropathy. Supplementation with L-Carnitine showed a renoprotective effect in 
diabetic animals submitted to CIN, sugesting a possibility of a novel role of L-carnitine 
promoting anti-oxidant responses in the CIN.
Funding: Government Support - Non-U.S.
Table 1. Renal function, renal hemodynamic and oxidative profile
Data a shown as mean±SD. αp<0,05 vs Citrate; βp<0,05 vs DM; δp<0,05 vs DM+IC.
TBARS: tiobarbituric acid reactive substances, DM: Diabetes Mellitus, IC: iodinated 
contrast.
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Deficiency of IKKα in Kidney Tubular Epithelial Cells Alleviates 
TGFβ1-Induced Kidney Fibrosis via Wnt/β-Catenin
Zhang Hao,1 Feng Zhang,1 Xin Wan.2 1Nanjing Medical University, Nanjing, 
China; 2Nanjing First Hospital, Nanjing, China.
Background: Nuclear transcriptional factor NF-κB plays an important role in 
inflammation, and the activation of NF-κB is mediated by IκB kinase (IKK) which is 
consisting of two subunits IKKα and IKKβ. Previously, we found that IκB kinase α (IKKα) 
protects against kidney ischemia/reperfusion(IR) injury.
Methods: However, its regulation and role in the pathogenesis of CKD remain poorly 
defined. To study this, we initially treated HK-2 cells with TGFβ1 and found that TGFβ1 
activated IKKα and Wnt/β-catenin signaling in cultured cells. Blocked with IKKα small 
interfering RNAs (siRNA) markedly inhibited TGFβ1-induced vimentin and α-smooth 
muscle actin(α-SMA).
Results: Ensuing western blotting or immunostaining results showed that IKKα and 
Wnt/β-catenin signaling was activated in kidney tubular epithelial cells (TECs) in mice 
kidney ischemia/reperfusion(IR) injury. We found that IKKα in mouse model with TECs 
deletion was reduced. Compared with control group, the kidneys of IKKα knockout mice 
developed less interstitial extracellular matrix deposition and inflammatory cell infiltration 
at 2 weeks after-ischemia/reperfusion injury.
Conclusions: Our study suggests that IKKα activation mediated TGFβ1-induced 
kidney fibrosis and up-regulated Wnt/β-catenin signaling. In addition, IKKα contributes 
to the development of kidney fibrosis. This may provide a therapeutic target for chronic 
kidney diseases.
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The Association Between Urinary Markers of Fibrosis and Tubular Injury 
and Recovery of Kidney Function After Moderate to Severe AKI
Alexander Bullen,1 Christina T. Saunders,3 Jeffrey Blume,3 Lorraine B. Ware,4 
Joachim H. Ix,1 Edward D. Siew.2 1UCSD, San Diego, CA; 2Vanderbilt University 
School of Medicine, Nashville, TN; 3Vanderbilt University Medical Center, 
Nashville, TN; 4Vanderbilt University, Nashville, TN.
Background: Acute kidney injury (AKI) is a risk factor for chronic kidney disease 
(CKD). Tubulointerstitial fibrosis is strongly associated with urine collagen type III 
amino-terminal propeptide (PIIINP) in patients with CKD. We examined if urine collagen 
fragments, or other markers of kidney injury, were associated with renal recovery post-AKI.
Methods: The VALID study is a prospective study of critically ill adults. Among the 
first 1732 patients enrolled with available biosamples, we identified 147 with stage 2/3 
AKI and urine available <48 hours of peak serum creatinine and at least 1 serum creatinine 
available between peak SCr and 9 months. We excluded patients with ESRD, no creatinine 
before enrollment, and stage 1/no AKI. We measured PIIINP, alpha-1 microglobulin, 
IL-18, MCP1, YKL-40, NGAL, and KIM-1 using multiplex panels, except for PIIINP 
(radioimmunoassay). Biomarkers were indexed to urine creatinine. 118 patients had 
complete measurements available, 26 with dialysis-requiring AKI and 92 patients without 
dialysis-requiring AKI. Renal recovery was defined as a return to <20% of baseline 
creatinine within 9 months. Relaxed Lasso logistic regression models were used to examine 
the association between biomarkers levels and renal function recovery.
Results: Among the 92 individuals not requiring dialysis, median age was 56(47,71), 
baseline creatinine 0.96 (0.72, 1.23), and peak creatinine of 2.5 (1.9,3.6) mg/dL. Fifty-seven 
(62%) recovered kidney function. Statistical modeling did not reveal any relationships 
between biomarker levels and odds of renal recovery in univariate or multivariable analyses 
adjusted for age, gender, race, baseline creatinine, peak creatinine, presence of sepsis and 
APACHE score. Biomarker information did not contribute to predictive ability for renal 
recovery beyond baseline creatine. Among the 26 dialysis, twenty-one (81%) were able to 
discontinue dialysis. None of the biomarkers were associated with dialysis discontinuation. 
There was also no association of biomarker levels with death.
Conclusions: Among a broad panel of biomarkers of kidney injury and fibrosis, we 
did not observe an association or predictive ability between biomarker measurements at the 
time of peak injury and renal recovery.
Funding: NIDDK Support
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AKI and Hemolytic and Uremic Syndrome (HUS) After Bothrops 
Envenomation - Interest of Renal Biopsy: About an Observation
Jean-Marc R. Dueymes-Laporte,1 Herve Gbaguidi,2 Timoté Davodoun,3 
Ahozegni T. Gbaguidi,3 Hommel Didier.4 1Nephrology, General Hospital, 
Cayenne, French Guiana; 2CHAR/, CAYENNE, France; 3CHAR, CAYENNE, 
France; 4General hospital. Cayenne. french guiana, Cayenne, France.
Introduction: The snakebite by a Bothrops (Viperidae, Crotalinae, Botrops) is 
responsible for severe complications, and especially AKI whose origin is multifactorial. We 
report an observation of AKI following a bite by a Bothrops in which a renal biopsy could 
be performed to assert the mechanism of renal damage.
Case Description: 42-year-old patient was hospitalized 4 days after a bite by 
Bothrops Atrox, during which time she was treated only with traditional decoctions (no 
administration of antivenom). At the entrance, the patient was anuric, serum creatinine was 
1077 μmol / l (SOFA score: 8). She had haemolytic anemia (Hg 6.8 g / dl, 25% schizocytes), 
haemostasis disorders (TP 71%, hypofibrinogen), thrombocytopenia, rhabdomyolysis. In 
front of this viperian envenomation complicated by HUS and anuria, without hypovolemic 
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shock, plasmapheresis sessions (4 liters plasma exchanges replaced by diluted albumin and 
fresh frozen plasma) associated with sessions hemodialysis were performed to control the 
HUS, correct hemostasis disorders. Resumption of diuresis was observed on D8 and the 
patient came out of resuscitation unit at D16. The evolution was made towards the recovery 
of the renal function, the disappearance of the hemolytic syndrome. A renal biopsy puncture 
was performed at day 30.
Discussion: The sample concerned 35 glomeruli all permeable. No image of thrombotic 
microangiopathy or inflammatory infiltrate was noted. Marinozzi and PAS stains showed 
only a thickening of Bowman’s capsule and on one glomerulus a flocculo capsular 
synechiae draft. The tubes were lined with a flattened, regenerative epithelium showing 
sequelae of tubular necrosis. The immunofluorescence study was negative. In total, the renal 
biopsy was in favor of tubular necrosis associated with a discrete interstitial inflammatory 
reaction. There were no glomerulopathy lesions apart from discrete podocytosis lesions 
and no evidence of thrombotic microangiopathy. The clinical history of this patient was 
initially in favor of renal impairment secondary to intra-renal thrombotic microangiopathy 
in the context of HUS and described after Viperidae envenomation. The kidney renal biopsy 
allowed to rule out this hypothesis showing only tubular necrosis lesions secondary to a 
direct toxic attack of Bothrops’ venom.
PUB060 
Publication-Only 
Primary Cilium Length and Urine Primary Cilia Can Be Indicative of 
Cisplatin-Induced AKI
Min Jung Kong,1 Jee in Kim,3 Kwon Moo Park.2 1Kyungpook Nationcal 
University, Daegu, DaeJeon, Republic of Korea; 2Kyungpook National 
University, Daegu, Republic of Korea; 3Keimyung University, Daegu, Republic 
of Korea.
Background: The primary cilium protrudes to kidney epithelial cell surface and is 
associated with the pathogenesis of many kidney diseases including acute kidney injury 
(AKI). During cell cycle, the length of primary cilium dynamically alters; when cell 
proliferates cilium is shortened by retraction into the cell body, whereas when cell is matured 
cilium is lengthened. In addition, during the progression of diseases, the length of primary 
cilium is changed; shortened or elongated, indicating that primary cilium length reflects cell 
and tissue conditions. Cisplatin nephrotoxicity limits its administration and is associated 
with increased oxidative stress. Here, we investigated whether cisplatin nephrotoxicity is 
associated with primary cilium and the alteration of primary cilium length can be indicative 
kidney injury.
Methods: Cisplatin was injected with the presence or absence of 
(2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl) triphenylphosphonium 
chloride monohydrate (Mito-TEMPO, a mitochondria-specific antioxidant).
Results: Cisplatin increases kidney tubular injury in dose-dependent manner, 
shortening of primary cilia, and shedding of primary cilia fragments into the urine 
together with increased ROS production/oxidative stress. Cisplatin did not induce the cell 
proliferation when evaluated by BrdU incorporation assay. In addition, cisplatin did not 
induce significant changes in p21 and proliferation cell nuclear antigen (PCNA) expression 
in the kidney. Cisplatin-induced those changes were prevented by Mito-TEMPO, a 
mitochondria-targeted antioxidant, treatment.
Conclusions: Taken together, these results indicate that cisplatin nephrotoxicity 
is associated with primary cilia and cisplatin-induced shortening of primary cilia is due 
to disruption of primary cilia via increasing oxidative stress, suggesting that cisplatin 
nephrotoxicity is related with the alterations of renal primary cilia length and urine primary 
cilia protein can be a useful indicative of kidney injury.
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Kidney Injury Molecule-1 Staining Reflecting Proximal Tubule Injury Is a 
Common Finding in Pediatric and Adult Kidney Diseases
Ping L. Zhang,1 Wenqing Yin,2 Xu Zeng,3 Joseph V. Bonventre.2 1William 
Beaumont Hospital, Royal Oak, Royal Oak, MI; 2Brigham and Women’s 
Hospital, Boston, MA; 3University of Florida, Gainesville, FL.
Background: Proximal tubules (PT) are known to be vulnerable to ischemic and toxic 
injury due to their high metabolic activity. The PT is also sensitive to hypoxic injury due 
to reduced post-glomerular blood supply. Kidney injury molecule-1 (KIM-1) is an injury 
marker specific for the PT. The purpose of this study was to determine whether KIM-1 
expression was observed in human renal biopsies in a variety of kidney diseases where PT 
injury may be secondary to a primary disease process.
Methods: We randomly selected 184 renal biopsies from patients with various forms of 
kidney diseases and excluded cases with severe interstitial fibrosis. Biopsies were divided 
into three groups: 63 pediatric patients (< 20 years of age), 64 adults < 65 yr and 57 senior 
patients (> 65 yrs of age). All biopsies were stained using immunochemical techniques 
for KIM-1 (AKG7 monoclonal antibody) and examined by light microscopy. The intensity 
scores of KIM-1 in non-atrophic PT, ranging from 0 to 3+, were correlated with serum 
creatinine (sCr) levels.
Results: The patients’ ages ranged from 2 to 82 years old. Regardless of primary 
etiology of injury (vascular or glomerular), positive staining of KIM-1 was seen in the 
majority of biopsies (80% to 91% in each age group). In all three groups, the KIM-1 staining 
scores were significantly positively associated with levels of sCr (p < 0.05). Compared to 
adult renal biopsies, there was a high KIM-1/sCr ratio in pediatric renal biopsies.
Conclusions: Our data indicate that acute damage in PT, determined by enhanced 
KIM-1 expression in non-atrophic proximal tubules, is a common finding in wide variety 
of pediatric and adult intrinsic kidney diseases. A high KIM-1/sCr ratio could be a potential 
repair and regenerative predictor in the early phase of acute kidney injury (AKI), reflecting 
active synthetic function of the PT cells with potential for PT recovery after injury. Thus, 
KIM-1 can serve as a sensitive and reliable biomarker for identification of acute tubular 
injury in non-atrophic PT of pediatric and adult renal biopsies.
Funding: Clinical Revenue Support
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Inhibition of Rac1-GTPase Attenuates Renal Ischemia/Reperfusion-In-
duced Injury by Suppressing Macrophage Infiltration
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Background: Migration of inflammatory cells is a pivotal for numbers of diseases 
including ischemia/reperfusion (I/R) injury. Rac1, a member of the Rho-family of small 
GTPase, plays a critical role for activation of NADPH oxidase, a major ROS producing 
enzyme. Rac1 also regulates the cell migration. However, the role of Rac1 on the 
macrophage migration after renal ischemia remains to be defined. Here, we investigated 
the role of Rac1 in the kidney ischemia/reperfusion injury and its mechanism focusing on 
macrophage migration.
Methods: Mice were intraperitoneally injected with either a single dose of NSC23766, 
an inhibitor of Rac1, or vehicle for 3 days before surgery and subjected to either ischemia 
or sham operation.
Results: Thirty-minutes bilateral renal ischemia in the kidney induced renal functional 
and morphological impairments along with the increase of Rac1 expression in the kidney. 
After ischemia, Rac1 was strongly expressed in the interstitial cells rather than renal tubular 
epithelial cells. Rac1-positive interstitial cells were mostly F4/80, a marker of macrophage, 
-positive. The treatment of NSC23766, an inhibitor of Rac1 activity, significantly 
inhibited the increase of F4/80-positive cell number after I/R together with reduced
renal morphological and functional impairments. NSC23766 hindered the migration of
RAW264.7 cell, a mouse monocyte/macrophage cell line cell, after treatment of MCP-1, 
a chemoattractant cytokine. Furthermore, Rac1 inhibition by NSC23766 also suppressed
MCP-1-induced lamellipodia and filopodia of RAW264.7 cells.
Conclusions: These results indicate that I/R increases Rac1 expression, enhancing 
migration of monocytes/macrophages into the injured site. This suggests that Rac1 
represents a potential therapeutic target protein for the treatment of acute kidney injury.
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Is It Possible to Prevent Contrast Induced Nephropathy with 
Dexpanthenol?
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Ipek isil Gonul,1 Serpil muge Deger,5 Ozant Helvaci,6 Ulver Derici.1 1Gazi 
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ANKARA, Turkey; 4Erzurum Hinis State Hospital, ANKARA, Turkey; 5Yuksek 
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Background: To demonstrate the effect of dexpanthenol, known to be antioxidant, in 
contrast-induced nephropathy(CIN) rat model.
Methods: Sprague Dawley rats, 12 weeks old, were kept without water for 3 days to 
produce contrast nephropathy. Thereafter L-NAME (10mg / kg), tenoxicam (0.5mg / kg) and 
sodium amidotrizoate (10ml / kg) were administered via the tail vein. Rats were euthanized 
after 48 hours (CIN group). Dexpanthenol (Dxp) was administered intraperitoneally at 
a dose of 500 mg/kg for 3 days, as the day prior, on the day and next day of contrast 
administration. The rats in this group were also euthanized at the 48th hour after the contrast 
administration (CIN + Dxp group). While Dxp was administered intraperitoneally for 5 
days at equal doses to the Dxp group, control rats were administered saline solution. All rats 
were observed for 5 days and euthanized on the 6thday after blood draw.
Results: The comparison of contrast+dexpanthenol group and the contrast-only 
group showed that dxp provided significant decline at acute tubular injury and necrosis 
histopathologically (Figure 1). Serum creatinine levels were found similar amongst the 
groups, whereas cystatin C level was the highest in the CIN group (Figure 2). There was 
no statistically significant difference between the groups in total oxidant and antioxidant 
level evaluations.
Conclusions: Dexpanthenol, which has been demonstrated as a significant inhibitor on 
renal ischemia reperfusion model, did not show any significant effect on biochemicemistry 
on this CIN model. However, it has ameliorated histopathological findings of CIN.
Funding: Private Foundation Support
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Severe Renal Failure After Immunoglobulin Transfusions Requiring 
Dialysis as a Life Saving Measure
Ravi K. Thimmisetty, Frank W. Braxton. Nephrology Associates, Cape 
Girardeau, MO.
Introduction: We are presenting a rare cause of renal failure developed after 
Intravenous Immunoglobulin (IVIg) infusions given for acute exacerbation of Myasthenia 
gravis requiring dialysis
Case Description: 72 year-old-lady with h/o of Myasthenia gravis admitted with 
5 days of progressive dysphagia, dysphonia, fatigue and bilateral ptosis. Diagnosed 
Myasthenia gravis exacerbation and treated with 5 days of IVIg infusions. Home 
medications were pyridostigmine and prednisone. Vitals on admission were blood pressure 
159/61, temperature 98, heart rate 81, respiratory rate 16, saturating 97% on room air. 
Physical examination was with in normal limits. Laboratory results on admission were 
sodium 145, potassium 3.5, chloride 104, bicarbonate 26, bun 30, creatinine is 1.0 mg/dl, 
calcium 9.3, phosphorus 3.1, wbc 6, Hemoglobin is 13 .3 g/dl and platelets 212 x 103. 
After finishing 5-day course, bulbar symptoms were improved, but she developed severe 
anemia, Jaundice and Renal failure. Further labs include hemoglobin dropped 6.5, platelets 
186 x 103, reticulocyte count 4.4%, wbc 11.8, LDH 2148, CPK 230, haptoglobin <10, direct 
coombs test negative, bicarbonate 11, creatinine 9.50 mg/dl, BUN 204 mg/dl, total bilirubin 
5.1, direct bilirubin 0.40, total protein 11.5 g/dl, albumin 2.7 g/dl, ratio of kappa/lambda 
ratio 1.56, C3 135, C4 7, negative for MPO and PR3 antibodies, p-ANCA <1:20, c-ANCA 
1:80, peripheral blood smear showed rouleaux and no significant schistocytes, serum IFE 
and SPEP showed no monoclonal proteins, urinalysis revealed cloudy red colored urine, 
numerous WBC’s, 30-40 RBC, 3+ blood, 1+ protein, 1+ leukocyte esterase, negative 
for bilirubin, urine eosinophils and nitrite. Hospital course was complicated with atrial 
fibrillation with rapid ventricular rate and pulmonary edema requiring intubation. Emergent 
dialysis was started for refractory metabolic acidosis, fluid overload and 4 units of PRBC 
was transfused. Patient was stabilized hemodynamically and discharged with intermittent 
dialysis follow up and renal function tests
Discussion: Our case strongly suspects any undetected passive antibodies might have 
trigger acute hemolytic reaction causing renal failure. It’s a rare complication of IVIG that 
is estimated to occur less than 1 % of infusions. Anecdotal reports showed elderly age, 
preexisting renal disease, and non-O blood group recipients have high risk
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Female Spontaneous Hypertensive Rats (SHR) Have Better Recovery in 
Response to Renal Ischemia Reperfusion (IR) Injury Than Males
Riyaz Mohamed,1 Gene R. Crislip,2 Sarah C. Ray,1 Qingqing Wei,1 
Jennifer C. Sullivan.1 1Augusta University, Augusta, GA; 2University of Florida, 
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Background: Experimental and clinical evidence suggests that normotensive males 
are more susceptible to acute kidney injury (AKI) vs females. Hypertension is a known 
risk factor for AKI, however if hypertensive males and females respond comparably to 
AKI is unknown. Present study tested hypothesis that hypertensive males have worse renal 
outcomes than females following renal IR
Methods: 13wk old male and female Sprague Dawley (SD) and SHR were subjected 
to sham or 25min warm bilateral IR (n=6). Blood and urine were collected at 1 and 7 days; 
kidneys were isolated at 7 days for histological analysis
Results: IR increased plasma creatinine (Pcr) and BUN in all groups compared to 
respective sham at 24 hrs, although increases in Pcr and BUN were greater in male vs 
female (SHR-Pcr: PSex*IR=0.03; BUN: P<0.05; SD-Pcr: PSex*IR<0.05; BUN: P<0.05). 
At 7 days Pcr and BUN remained elevated in male SHR compared sham (Pcr PIR=0.03; 
BUN PSex<0.05); Pcr and BUN returned to baseline levels in all other groups. Histological 
examination of SHR kidneys following 7 days of reperfusion showed significant increase 
in vascular congestion (PSex*IR=0.002), damaged tubules (PSex*IR=0.001) and tubular cell 
apoptosis (PSex*IR=0.001) compared to sham only in males. Since IR induced vascular 
congestion has been implicated in loss of renal function, additional male and female SHR 
were pretreated with heparin (1500U/kg) prior to IR. Pretreatment with heparin reduced 
IR induced vascular congestion and improved renal function in male SHR at 7 days (Pcr-
IR*Hep<0.05; BUN: P=0.02).
Conclusions: Our data suggest that persistent vascular congestion in hypertensive male 
SHR results in delayed recovery following IR
Funding: Other NIH Support - National Heart, Lung, and Blood Institute (NHLBI), 
Private Foundation Support
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Diverse Gene Expression Patterns of Renal Transporters in AKI
Hadi Fattah,1 Alana Shigeoka,2 Winnie Huang,1 Rohit Patel,1 Sashi Kasimsetty,2 
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Background: Restoration of tubular function may be a prerequisite for recovery 
of GFR and overall kidney function after acute kidney injury (AKI). We performed 
RNA sequencing (RNA-seq) to gain more insights on the expression pattern of tubular 
transporters in a murine model of AKI.
Methods: We induced ischemia/reperfusion (IR) injury by bilateral clamping of 
the renal arteries for 10 or 15 minutes (min) vs sham in C57BL/6J males. On days 1, 3 
and weeks (wks) 2 and 14 after reperfusion, we assayed glomerular filtration rate (GFR) 
(by FITC-sinistrin plasma elimination kinetics in awake mice, n= 4-5/group) and harvested 
kidneys for RNA-seq analysis (n= 3-5/group).
Results: GFR in the 10 min IR group did not change while the 15 min IR group 
showed a sharp decrease on day 1 with partial recovery at 14 wks. The mRNA expression 
pattern seen in most tubular transporters was an ischemia time-dependent decrease on day 
1 followed by subsequent gradual normalization with close to sham levels by 14 wks. This 
included Na transporters such as Nhe3, Nkcc2, Ncc, Enac, and Na-K-Atpase. An initial 
reduction on day 1 was also observed for Sglt2, Sglt1 and Glut2, which together mediate 
transcellular glucose reabsorption in proximal tubules. In contrast, Glut1, which in tubular 
epithelial cells can mediate the basolateral uptake of glucose used for glycolysis, showed an 
initial ischemia time-dependent increase in expression followed by eventual normalization. 
The phosphorous (Pi) transporters Pit1 and Pit2 showed a similar pattern to Glut1.
Conclusions: The mRNA expression of the main renal Na transporters and GFR are 
both reduced on day 1 after 15 min IR, and partially or fully recovered by 14 wks. Initial 
tubular cell loss and eventual restoration, and the kidneys’ need to conserve energy during 
AKI may contribute to this pattern. In contrast, Glut1 is upregulated initially, potentially 
as part of the shift from fatty acid oxidation to glycolysis in early AKI. Upregulation of 
Pit1 and Pit2 may serve to conserve intracellular Pi availability including the uptake of 
extracellular Pi derived from cell lysis.
Funding: NIDDK Support, Veterans Affairs Support
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Background: Cisplatin treatment for malignancies is limited by nephrotoxicity. 
Though T cells have been implicated in cisplatin induced acute kidney injury (AKI), the 
role for CD4-CD8- (double-negative, DN) T cells is unknown.
Methods: 8-week-old C57BL/6 male mice (n=8) were administered 30 mg/kg cisplatin 
and followed for 72 h. Serum creatinine (SCr) and histologic examination were assessed to 
confirm AKI. Kidney mononuclear cells (KMNCs) and splenocytes from cisplatin-treated 
mice were analyzed for DN T cell proliferation (Ki67, BrdU), immune cell trafficking/
activation (CD69, CD62L), apoptosis (Annexin v) and differentiation (NK1.1, PD1) by 
flow cytometry.
Results: Cisplatin administration led to significant (p<0.0001) increase in SCr at 
72 h (2.1 ± 0.4 mg/dl). DN T cell frequency increased at 24 h (52.6 ± 3.0%, p<0.001) after 
cisplatin treatment and subsequently decreased at 72 h (30.0 ± 3.0%, p<0.001) compared 
to 72 h vehicle treated mice (33.2 ± 3.2%) as well as the absolute number (vehicle: 
1295.0 ± 194.1 versus 24 h: 2602.4 ± 295.7 versus 72 h 488.2 ± 118.4)(vehicle versus 24 
h, p<0.001; 24 h versus 72 h, p<0.001). Kidney CD4+ T cells were activated after cisplatin 
treatment (p<0.05), but not DN T cells. DN T cell proliferation decreased at 24 h (p<0.05) 
but increased (p<0.05) at 72 h. In contrast to ischemic AKI which showed expansion of the 
PD1+ DN T cell subset, cisplatin-induced AKI increased both NK1.1+ and PD1+ DN T cell 
subsets (p<0.05).
Conclusions: Kidney DN T cells respond rapidly to cisplatin induced AKI, but in 
distinct ways compared to CD4 and CD8 T cells. Furthermore, there are key differences 
between DN T cell responses to nephrotoxin versus ischemia, including differentiation 
characteristics. Ongoing studies are investigating the role of DN T cells during early injury 
and recovery from cisplatin-induced AKI.
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The Use of Renal Doppler Ultrasonography in Critically Ill Patients with 
AKI
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Background: Acute kidney injury is one of the major organic dysfunctions that occur 
in critically ill patients. Ultrasonography of the kidneys and urinary tract is always a tool 
used by nephrologists as a way of evaluating this pathology. Despite this practice, its clinical 
utility in determining the cause of acute kidney injury is poorly established.
Methods: Retrospective cohort study of critically ill patients that underwent renal 
ultrasound for acute kidney injury over a 5-year period at Hospital Portugues da Bahia. 
Renal Resisitive Index was determined by the doppler sonography.
Results: Over the 5-year period, 350 renal ultrasounds were performed for evaluation 
of acute kidney injury. Renal ultrasound was normal in 76% of patients. Hydronephrosis 
was detected in only 6% of studies and in only 2% of the cases was obstructive uropathy 
considered the cause of acute kidney injury.. Less than 1% of patients had urinary tract 
obstruction on ultrasound without a suggestive medical history. Median renal RIs were 0.68 
(0.62-0.75) in patients with sepsis related AKI and 0.74 (0.72-0.80) in patients with non sepsis 
related AKI (P = 0.001). RIs were 0.72 (0.70-0.79) in transient AKI and 0.76 (0.70-0.80) 
in persistent AKI (P = 0.64).
Conclusions: The role of renal ultrasonography in every critically ill patients with 
acute renal injury still needs to be determined In patients with history suggestive of urinary 
tract obstruction renal ultrasound for evaluation of acute kidney injury should be indicated. 
The use o renal resisitive index could to be a tool to reflect vasomotor tone in patients with 
AKI related to sepsis.
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Effects of Properdin Associated with EPOR/βcR on Repair Post Renal 
Ischaemia-Reperfusion Injury
Yuanyuan Wu,1,2 Nigel J. Brunskill,1 Bin Yang.1 1University of Leicester, 
Leicester, United Kingdom; 2University of Nantong, Nantong, China.
Background: Ischaemia-reperfusion injury (IRI)-induced acute kidney injury is 
common with high mortality. Properdin is an only positive regulator of the alternative 
pathway of complement activation, while it could also act as a pattern recognition molecule. 
Our previous study has demonstrated more severe damage in properdin deficient (Pko) mice 
than wild type (WT) mice upon IRI. However, its mechanisms, especially its association 
with tissue protective EPO receptor/β common receptor (EPOR/βcR) in kidney repair post 
IRI are not clear.
Methods: The bilateral occlusion of renal pedicles for 30 min (n=7-9) and sham control 
(n=4-5), was performed in WT and Pko male C57BL/6 mice, followed by 72-h reperfusion. 
EPOR/βcR protein in kidneys was detected, together with mitosis, apoptosis and inflammation 
markers. Moreover, apoptosis and phagocytosis were measured in proximal tubular epithelial 
cells (PTECs) isolated from both WT and Pko mice and stimulated with H2O2.
Results: The expression of EPOR/βcR was significantly increased by IRI in both 
WT and Pko mice compared with that in the sham controls. Interestingly, renal EPOR/βcR 
was further increased in Pko mice after IRI in comparison with WT mice. EPOR/βcR was 
positively correlated with, proliferating cell nuclear antigen (PCNA) and mitosis, active 
caspase-3, apoptosis, F4/80+ cells, tubulointerstitial damage (TID) and renal function. 
Moreover, apoptotic cells in tubular lumens of the IRI kidney were significantly increased 
by Pko. Apoptotic cells were higher in Pko-PTECs subjected to H2O2 stimulation compared 
with that in WT-PTECs. The phagocytic ability of PTECs to engulf apoptotic cells was 
compromised by Pko. Both apoptosis and phagocytosis were not affected by additional WT 
or Pko-serum.
Conclusions: Properdin might be associated with EPOR/βcR to facilitate the clearance 
of apoptotic cells by the phagocytosis of PTECs and initiate repair and remodeling of the 
kidney post 72-h IRI. The precise role and mechanism of properdin and EPOR/βcR in IRI 
and repair are worthy to be further studied.
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Contrast-Induced Acute Renal Oxalosis with Sustained AKI in Enteric 
Hyperoxaluria
Glenn R. Kershaw. Renal Medicine, UMass Memorial Medical Center, 
Worcester, MA.
Introduction: Intratubular deposition of calcium oxalate crystals induces chronic renal 
disease in settings of primary hyperoxaluria (chronic renal oxalosis). Acute oxalosis is 
reported with extreme oxalate or Vitamin C intake and renal transplant settings.
Case Description: A 65-year-old W/M w creatinine 4.62 on chemotherapy screening 
(CS). Creatinine 1.3 six weeks prior to screening (PTS). CT scan w contrast 4 weeks 
PTS. PMH. adenocarcinoma of caecum (2013) treated w cytoreduction, HIPEC, right 
hemicolectomy + resection 2 feet terminal ileum. Chemo-Rx last 6 months was capecitabine-
bevacizumab. ROS: No oliguria, flank pain, hematuria, dysuria, fever. Reports 2-4 loose 
stools/day since 2013 surgery. Serum HCO3 normal, urine SG ≥ 1.020 x 12 months. Med: 
lisinopril, loperamide, citalopram, ferrous sulfate. Recently took amoxicillin\clavulanic acid 
x 7 days for “toe infection.” No NSAIDS PE: BP 130/80 no orthostasis, no edema; H/L/A 
normal. Lab and imaging: BUN 43, creatinine 4.33, bicarbonate 20, uric acid 10.4. Lytes, 
Ca, Mg, LFTs, CBC normal. Noncontrast CT: normal-sized kidneys, no hydro. U/A: pH 
5.5, SG 1.009, P/B/leuk. negative. Sediment: no casts, cells or crystals. UNa 64, Ucreat 82. 
Renal biopsy: Acute tubular injury with intratubular calcium oxalate deposits DCT c/w 
oxalate nephropathy. Treatment: 3 L fluid intake, low oxalate diet, Calcium + citrate 
supplements. Subsequent course: 14 d after peak Creat and prior to therapy, Creat ↓to 
3.08, 24 hr U oxalate elevated (58 mg), U citrate undetectable. Plasma oxalate undetectable.
Discussion: Proposed mechanisms: PRE-EXISTING CONDITIONS: 1) Enteric 
mechanisms;↑ Ox permeability, ↓Ox secretion (intact ileum, proximal colon are net 
oxalate secretors), ↑ Ox availability (Ca binding to FFA). 2) chronic diarrhea; ↑U osm, ↓U 
citrate. CONTRAST INDUCED CONDITIONS: 1) Acute supersaturation: a) subclinical 
tubular injury → systemic Ox accumulation → acute ↑ filtered Ox. b) early osmotic 
diuresis ↓washout/tubular stasis. 2) Contrast binding to Tamm-Horsfall protein→↓inhibitor 
crystallization. OTHER: eradication of oxalate degrading gut flora (Oxalobacter 
formigenes) by antibiotics. Teaching point: Contrast loads in patients with Enteric 
hyperoxaluria and diarrhea following bowel resection may induce acute secondary oxalosis 
with sustained AKI. Appropriate screening, prophylaxis, imaging alternatives are advised.
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Cannabidiol-Induced Regulation of Innate Lymphoid Cells in AKI
Babak Baban, Mahmood S. Mozaffari. Augusta University, Augusta, GA.
Background: Cannabidiol, a non-psychoactive cannabinoid, is increasingly believed 
to be of therapeutic potential for several conditions including those accompanied with 
inflammation. Intense immune and inflammatory responses are pivotal to the pathogenesis 
and manifestation of acute kidney injury (AKI). We recently showed renoprotective effects 
of cannabidiol in the murine model of AKI prompting us to explore cannabidiol-induced 
regulation of immune and inflammatory responses in this condition. Innate lymphoid cells 
(ILCs) have emerged as a new class of lymphocytes capable of regulating and amplifying 
the immune response through a variety of effector functions that parallel those of the T 
lymphocytes. Based on expression of signature molecular markers and cytokine expression, 
ILCs are classified into three groups: ILC1s, ILC2s and ILC3s. While ILC1s and ILC3s 
are linked to pro-inflammatory effects, ILC2s exert counter-inflammatory roles. Thus, we 
tested the hypotheses that AKI is associated with significant changes in frequency of each 
subset of ILCs and b) cannabidiol treatment restores frequencies of ILCs subsets to normal 
levels.
Methods: male mice were subjected to either bilateral renal ischemia (20 min)-
reperfusion (24 hrs.) injury (IRI), a model of AKI, or sham operation; sham-operated mice 
and those subjected to IRI were further subdivided to receive either cannabidiol (10 mg/Kg; 
i.p.) or the vehicle (DMSO) 10 min before restoration of renal blood flow. Thereafter, 
kidney cells were prepared for subsequent flow cytometry analyses of subsets of ILCs.
Results: Induction of IRI markedly increased frequencies of ILC1s and ILC3s but 
significantly reduced ILC2s. Cannabidiol treatment of sham-operated animals did not affect 
frequency of each ILCs subsets. However, cannabidiol treatment of animals subjected to 
IRI resulted in restoration of frequencies ILCs subsets to levels of sham-operated animals 
although a differential persisted for ILC1s.
Conclusions: Collectively, our observations indicate that cannabidiol-induced 
regulation of ILCs contributes importantly to its renoprotective effect in AKI.
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Hypoxia-Induced Long Non-coding RNA Malat1 Is Dispensable for Renal 
Ischemia/Reperfusion-Injury
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Background: Renal ischemia/reperfusion (I/R) injury represents a major socioeconomic 
health problem. Non-coding RNA are crucially involved in pathophysiology. Long non-
coding RNA Malat1 (Metastasis Associated Lung Adenocarcinoma Transcript 1) was 
upregulated in renal I/R injury. We elucidated the functional role of Malat1 in vitro and its 
potential contribution to kidney injury in vivo.
Methods: In patients, kidney biopsies and plasma samples were collected. In vivo, 
Malat1 knockout- (KO) and wild-type (WT) mice were subjected to unilateral and bilateral 
I/R. Histopathology-, gene expression-, kidney function- and survival studies were 
performed. In vitro, Malat1 was silenced by antisense oligonucleotides in endothelial cells 
(EC) and tubular epithelial cells (TEC) subjected to hypoxia/reoxygenation. Transcriptional 
activation- and functional studies were implemented. Genome-wide RNA analysis was 
performed.
Results: Malat1 was upregulated in human kidney biopsies and plasma and in murine 
kidney tissue, EC and TEC and mainly nuclear-chromatin associated. In vitro, Malat1 
inhibition reduced EC in the S-phase of the cell cycle. Proliferation decreased. Less EC 
were apoptotic after Malat1 silencing. TEC were not functionally altered. Malat1 was 
transcriptionally activated in EC and TEC by Hypoxia-inducible factor 1-alpha. In vivo, 
Malat1 KO- and WT mice showed similar degrees of tubular epithelial injuries and 
proliferating cells. Capillary rarefaction was not affected. Kidneys of Malat1 KO- and WT 
mice expressed more pro-inflammatory (IL-1beta, IL-6, MIP2a, MCP-1) and pro-fibrotic 
(Col1a2, Col III, TGF-beta) genes. Similar amounts of macrophage-, T-cell infiltration and 
tubulointerstitial collagen were detected. mRNA- and smallRNA expressions showed only 
minor differences. The reduced kidney function was not altered by Malat1 KO. Malat1 KO 
mice showed no survival benefit.
Conclusions: Malat1 plays a pivotal role in hypoxia/reoxygenation induced endothelial 
cell pathology. Even though previous studies have suggested a prominent role of Malat1 in 
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the induction of disease, we did not confirm an effect of Malat1 loss on the progression of 
renal I/R-inury.
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Detection of Erythropoietin (Epo) Protein Expression by Western Blot
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Background: It has been believed that erythropoietin is secreted into plasma soon 
after the production by the erythropoietin producing cells in the kidney probably because 
of the difficulty of immunohistochemistry and Western blot analysis. We investigated the 
expression of Epo protein by Western blot analysis using the monoclonal and polyclonal 
antibodies against Epo.
Methods: Both the polyclonal and monoclonal antibodies against Epo were used for 
the detection of Epo protein by Western blot analysis. Antigen-peptide absorption tests 
using recombinant rat Epo and the antibodies were used to check the specificity of the band. 
Since Epo is known to be a glycoprotein, deglycosylation of the recombinant rat Epo and 
produced Epo using N-glycosidase F was performed.
Results: Both the polyclonal and monoclonal antibodies against Epo showed 
recombinant Epo as a broad band at 34-43 kDa. The kidney and liver from control rat 
showed a broad but faint band at 36-40 kDa and a narrow band at 42 kDa. The polyclonal 
antibody was used for immunohistochemistry and the monoclonal antibody was used for 
Western blot analysis. Severe hypoxia increased an expression of a broad band at 36-40 
kDa in the kidney but reduced a band at 42 kDa in the liver. Antigen-peptide absorption test 
using recombinant rat Epo largely decreased the expression of the bands of recombinant 
Epo and kidney/liver Epo. Deglycosylation of recombinant Epo and hypoxia-induced 
kidney sample showed a shift of the bands to 22 kDa, which is identical to the size of Epo 
by LC/MS analysis. These data clearly show that the bands at 36-40 and 42 kDa correspond 
to Epo protein.
Conclusions: In conclusion, Epo protein can be detected at 36-40 and 42 kDa by 
Western blot analysis using the monoclonal antibody.
Funding: Government Support - Non-U.S.
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The Effect of Ferric Citrate (Auryxia) on Hemoglobin, Iron Levels, As 
Well As, Phosphorus Management in Dialysis Patients
Mahmoud Algharabli,1 Shelley L. Munch,3 Ahmed M. Awad.2 1Clinical 
Research Consultants, KAnsas city, MO; 2Nephrology, UMKC, KANSAS CITY, 
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Background: Hyperphosphatemia in end stage renal disease is associated with 
increased morbidity and mortality. Ferric Citrate (FC) is indicated for hyperphosphatemia 
in patients with CKD on dialysis and in the treatment of iron deficiency anemia in adult 
patients with CKD III and IV. We present real-world serum phosphorus, hemoglobin and 
other iron-related data from patients treated with FC in one dialysis center compared to 
second group of patients from the same center on other phosphorus binders.
Methods: Retrospective chart review in one dialysis center of two study groups, each 
with 19 patients. One group was prescribed FC for hyperphosphatemia for an average of 
9.89 months. The second group was prescribed other phosphorous binders for one year. FC 
and control group treatment data collected: Treatment Duration, Average Daily Prescribed 
Pill Count, Average Monthly Intravenous (IV) Iron Dose, Start and End for the following 
parameters: Serum Phosphorus, Iron Saturation (ISAT), Serum Ferritin and Hemoglobin 
(Hgb).
Results: We compared 19 patients who were prescribed FC as a phosphorus binder to 
19 patients prescribed other phosphorus binders. Both groups had similar characteristics: 
Gender (26.3% F/ 73.6% M vs 42.1% F/57.8% M), Age (52 vs 60.5), Diabetic Status 
(63.1% vs 68.4%), BMI (27.5 vs 33.1). The mean daily prescribed pill burden was FC 
5.1 vs Control 6.9. There was net reduction of serum phosphorus by more than 1 mg/dL 
reaching the goal of 5.5 mg/dL compared to the control group where there is an increase in 
phosphorus by ~1 mg/dL reaching 5.72 mg/dL. The patients taking FC showed an increase 
in HgB of 1 gm/dL FC group vs decrease HgB ~0.4gm/dL, ISAT of 14% FC group vs no 
significant change in control group, Average IV venofer need per month 110.8 mg in FC 
group vs. average IV venofer need per month 145.2 mg in control group.
Conclusions: The use of Ferric Citrate as a phosphorous binder for patients on 
Hemodialysis showed a decrease of total monthly IV iron requirements by 25% with an 
average increase in the HgB by 1 gm/dL, and an increase in ISAT by 13.4%. In addition, 
FC Group reached the target phosphorus level of 5.5mg/dL. The Control Group showed no 
significant changes in either HgB or ISAT and an increase in phosphorus levels.
Funding: Private Foundation Support
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Gluconate for Anemia Management in Outpatient Hemodialysis 
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Background: Intravenous iron is one of the main therapies for anemia management in 
hemodialysis dependent patients. Data comparing the efficacy of ferumoxytol versus other 
parenteral iron supplements are scarce. The objective of the study was to compare the efficacy 
and safety of ferumoxytol as compared to sodium ferric gluconate in hemodialysis patients
Methods: A prospective observational study was conducted on hemodialysis 
outpatients who received ferumoxytol 510 mg once or twice quarterly compared to sodium 
ferric gluconate 125 mg weekly in a single center southwestern Ontario community hospital 
between Oct 2013 and June 2014. Patient demographics, iron indices, hemoglobin levels, 
iron doses, and erythropoiesis stimulating agent (ESA) doses were collected
Results: The study sample consisted of 291 observations from 173 patients. Generalized 
estimating equations of multiple linear regression modeling was conducted to compare the 
outcomes while adjusting for baseline scores. About 25% of the study participants received 
ferumoxytol while 75% received sodium ferric gluconate. Males (58.4%), mean age was 
68.73 (SD ± 13.03) years. Both groups did not show significant difference in their hemoglobin 
levels (Wald z = 0.54; p = 0.46), ESA utilization at 3 months (Wald z = 0.20; p = 0.65) and 
TSAT levels (Wald z = 3.45; p = 0.06). However, the iron levels (Wald z = 4.24; p = 0.04) 
and ferritin levels (Wald z = 5.14; p = 0.02) were higher in the ferric gluconate group (Wald 
z = 58.78; p ≤ 0.001) and patients who received ferumoxytol received more blood transfusion 
as compared to those who received sodium ferric gluconate (χ2 = 16.71; p ≤ 0.001)
Conclusions: Both iron products maintained hemoglobin levels with those receiving 
ferumoxytol had lower iron indices and received more blood transfusions compared to 
sodium ferric gluconate
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Degree in Hemodialysis Patients
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Ramón y Cajal, Madrid, Spain.
Background: Hemoglobin variability(Hb-V) and higher red cell distribution width 
(RDW- a marker to describe the amount of anisocytosis-) are two factors associated with 
higher mortality in dialysis patients. A potential benefit of the selective vitamin D receptor 
activator (paricalcitol) lowering ESA doses was described; however its effect on Hb-V and 
RDW is unknown. Objective: To describe the influence of the paricalcitol on Hb-V and 
RDW in hemodialysis patients.
Methods: This is cross-sectional study. Patients with paricalcitol(N=56) and without 
paricalcitol (N=41) were compared. Prevalent hemodialysis patients with the following 
inclusion criteria were included: Hb ≥ 9g/dl, transferrin saturation(TSAT) ≥20% and/or 
plasma ferritin levels ≥200pg/ml. Hb stability range was defined as Hb within 10-12g/dl. 
Higher RDW values >15%. Hemoglobin and RDW relationship was evaluated by 
regression analysis.
Results: Median parathyroid hormone was higher in group A in comparison with group 
B (234 pg/ml versus 154 pg/ml, P>0.001). Hb, RDW, TSAT, ferritin, albumin, cholesterol, 
iron supplements and ESA doses showed no differences between groups. The percentage of 
patients with diabetes, hypertension, were similar between groups. As a whole, a quadratic 
regression model explained the relationship between Hb and RDW (R2:0.09, P=0.01). No 
association between the percentage of patients treated with paricalcitol and Hb stability, 
or higher RDW was observed. However, a negative relationship between Hb and RDW 
(r: -0.28; P=0.03) was observed in those with paricalcitol, while it was positive in those 
without paricalcitol (r:0.41; P=0.006). Those patients with PRC and higher RDW showed 
lower Hb levels than those with lower RDW (mean difference: 1,20g/dl, P = 0.01); while in 
those without PRC patients with higher RDW, no differences in Hb values respect to those 
with lower RDW values were observed (mean difference: -0.88 g/dl, P=0.07).
Conclusions: The use of the paricalcitol in patients with Hb stability was associated 
with a decrease in the anisocytosis, while in those without paricalcitol an opposite 
association was observed. These data suggest a direct effect of the paricalcitol on the 
hematopoiesis process.
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Effect of Ferric Citrate on Iron Parameters in ESRD Patients with 
Elevated Ferritin: Interim Report of a Pilot Pragmatic Clinical Trial
Monica Rodriguez,1 Derian Lai,1 Cindy Gomez,2 Medha Airy,1 
Sreedhar A. Mandayam.1 1Baylor College of Medicine, Houston, TX; 2Baylor 
College Of Medicine, Houston, TX.
Background: Iron deficiency is prevalent in ESRD patients. Patients with elevated 
Ferritin (>1000 mcg/dL) are poorly responsive to IV Iron & may be at risk of infection. We 
investigated the efficacy of oral Ferric Citrate on Iron parameters in ESRD patients with 
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low transferrin saturation (TSAT) but elevated ferritin in a pragmatic pilot clinical trial at a 
single dialysis center in the US.
Methods: This is an un-blinded, open label study to determine the effect of Ferric 
Citrate on iron parameters in ESRD patients with elevated ferritin & low TSAT. All ESRD 
patients on hemodialysis for at least 3 months at the US Renal Care Baylor Scott Street 
Dialysis unit were eligible to participate. Patients were included in the trial if they satisfied 
the following criteria: 1) Mean Serum Ferritin >1000mcg/dL on 2 consecutive samples 3 
months apart 2) TSAT <30% on 2 consecutive samples 3 months apart 3) Able to tolerate 
phosphate binders We collected the following information pre-enrollment into the trial: 
Ferritin, TSAT, hemoglobin, ESA dose, Calcium, Phosphorus, and PTH. Subjects were 
given Ferric Citrate 210 mg 2 tabs with meals (minimum 6/day) for 3 months. Clinicians 
could change the dose as clinically indicated. Management of IV Iron & ESA was per 
the standard clinic anemia management protocol. Labs were monitored monthly This is an 
interim report after completion of 9 patients in the trial.
Results: Mean serum Ferritin & TSAT at enrollment were 1246 ng/ml & 23.7 %. After 
completion of 90 days of Ferric Citrate the mean ferritin and TSAT increased to 1303 ng.ml 
(4% increase) and 38.29% (38% increase) respectively. ESA use decreased from 38 units/
week of Darbepoetin to 15 units/week (60% reduction) after 90 days.
Conclusions: Oral Ferric Citrate appears to be an effective iron supplement that 
increases iron stores in ESRD patients with high Ferritin & low TSAT. Further studies with 
larger numbers of patients are needed to investigate its impact on ESA use in ESRD patients.
Funding: Commercial Support - Keryx Biopharmaceuticals
Anemia parameters
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Background: Iron deficiency is prevalent in ESRD patients. Patients with elevated 
Ferritin (>1000 mcg/dL) are poorly responsive to IV Iron and have higher risk of infection. 
We investigated the efficacy of oral Ferric Citrate on KDQOL-36 scores in ESRD patients 
that have low TSAT but high Ferritins in a pragmatic pilot clinical trial at a single dialysis 
center in the US
Methods: This is an unblinded, open label study to determine the effect of Ferric Citrate 
on anemia management in ESRD patients with elevated Ferritin and low TSAT. Primary end 
point was change in weekly ESA use. Secondary end points were changes in TSAT and 
KDQOL scores. All ESRD patients on hemodialysis for at least 3 months at the US Renal 
Care Baylor Scott Street Dialysis unit were eligible to participate. Patients were included 
if they satisfied the following criteria: Serum Ferritin >1000 on 2 consecutive samples 3 
months apart, TSAT <30% on 2 consecutive samples 3 months apart, and able to tolerate 
phosphate binders. Subjects were given Ferric Citrate 210 mg 2 tabs with meals (minimum 
6/day) for 3 months. Treating clinicians were allowed to change the dose of Ferric Citrate 
as clinically indicated. Anemia management was per the standard clinic protocol. KDQOL 
36 scores were collected upon enrollment and again at 90 days at the end of trial. This is an 
interim report after completion of 9 patients in the trial.
Results: Mean Physical Health Composite and Mental Health Composite at enrollment 
were 37.98 and 44.72. After completion of 90 days of Ferric Citrate, the mean Physical 
Health Composite and Mental Health Composite increased to 48 and 50.86 respectively. 
Notably 2 of the 9 patients had self-reported low compliance with Ferric Citrate (18% and 
14%) and had worsening of KDQOL scores.
Conclusions: Ferric Citrate appears to be a safe and effective phosphate binder in 
ESRD patients with high Ferritin and low TSAT. Further large scale studies are need to be 
conducted to study its impact on Quality of Life in ESRD patients.
Funding: Commercial Support - Keryx Biopharmaceuticals
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Background: Cardiovascular disease is the leading cause of mortality and stroke is a 
frequent complication inchronic kidney disease (CKD) patients. Inflammation is associated 
with cardiovascular disease. To assess if serum renal function and inflammatory cytokines 
are associated with stroke in nondialysis CKD outpatients.
Methods: We retrospectively analyzed a database with 100 nondialysis CKD outpatients 
and identified 20 patients with stroke up to 96 months after enrolment in nephrology office. 
Demographic data, eGFR, blood count, ACEi, erythropoiesis-stimulating agents (ESAs) 
use, serum sFas, and inflammatory cytokines levels from baseline were recorded. We 
performed comparisons between stroke group (n=20) and non-stroke group (n=80). Binary 
logistic regression was used to determine the impact of factors on stroke.
Results: The primary cause of CKD was diabetes followed by hypertension. Stroke 
occurred after 37±8 months. Transient ischemic attack-9, ischemic-7 and hemorrhagic 
stroke-4 patients. We observed lower eGFR (37.8±20.8, 25.5±8.7 mL/min; p=0.01), Hb 
(12.4±2.1, 11.2±2.4 pg/mL; p=0.04) and platelets [(227±56, 200±50)x103; p=0.04)] in 
stroke group. We found higher levels of serum sFas levels (4007±1668, 2985±940 pg/
mL; p=0.001) and serum IL-6 levels (10.1±5.8, 5.6±4.2 pg/mL; p=0.002) in stroke group. 
We did not observed difference in smokers, diabetes and hypertension, ACEi and ESA 
use. Serum IL-6 (b = 1.133, 95%CI 1.002-1.131; p=0.04) and GFR (b = 0.911, 95%CI 
0.844-0.983; p=0.01) were independently associated with stroke.
Conclusions: In this study lower GFR and higher serum IL-6 were predictors of stroke 
in nondialysis CKD outpatients within 96 months.
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Nephrology and Biodesign: Using the Needs Finding Process for 
Nephrology Innovation
Dimitri A. Augustin, Glenn M. Chertow, Dan Azagury. Stanford University 
School of Medicine, Palo Alto, CA.
Background: There is renewed demand to accelerate innovation in nephrology and 
both public and private sectors are creating programs to support its growth. The Stanford 
biodesign innovation process, first developed in 2000, provides a roadmap for health 
technology innovation. The program includes three phases: identify, invent, and implement. 
There is insufficient published guidance on the application of this process in the generation 
of novel devices to address nephrology clinical needs. We present our process of needs 
identification in a hemodialysis unit, using the biodesign innovation process.
Methods: We applied the identify phase of the biodesign innovation process in two 
stages: 1. needs finding and 2. needs screening. We performed a qualitative retrospective 
review of observations within a hemodialysis unit, generated needs statements, actively 
tested those needs, and validated them. The needs finding stage includes background 
research, direct clinical observations, interviews, documenting those observations, and 
development of multiple needs statements. The needs screening stage includes a deeper 
review of the disease state, an analysis of stakeholders and market, and ranking of needs 
statements.
Results: A dozen retrospective observations were reviewed to create needs statements. 
One of the twelve observations were utilized to generate multiple related needs statements. 
The figure is based on observations of a cannulated hemodialysis access within a 
hemodialysis unit.
Conclusions: We conclude that the needs finding and needs screening stages of the 
biodesign innovation process can be used to identify meaningful unmet clinical needs in 
nephrology and foster new device inventions.
Need statement scoping (actively testing and refining need statement) with multiple 
problems, populations, and outcomes
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Vascular Calcifications in Animal Models: Can They Be Compared to 
Those in Humans?
Geert J. Behets,1 Miquel D. Ferrer,2 Carolina Salcedo,2 Joan Perelló,2 
Patrick C. D’Haese.1 1University of Antwerp, Antwerp (Wilrijk), Belgium; 
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Background: Rat models of vascular calcification are an important tool to evaluate 
safety and efficacy of compounds aimed at reducing vascular calcifications in humans. 
Calcifications in rats can be detected using μCT imaging of the aorta, bulk calcium 
analysis and/or Von Kossa (VK) staining of vessels. In renal failure patients, calcifications 
are generally detected using the CAC score which has been shown to be associated with 
cardiovascular morbidity/mortality in these patients. An important question in translational 
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studies on vascular calcification is the extent to which CAC scores, and thus vascular 
calcification, in humans can be correlated to calcifications observed in animal models.
Methods: Vascular calcifications were induced in 15 male Wistar rats using the adenine-
low protein model. After 4 weeks, all animals underwent both in-vivo and post-mortem 
μCT imaging of the aorta, using a Skyscan 1076 μCT, with a 35μm voxel size. Scans were 
also made of 12 human blood vessels, obtained during transplant surgery. Additionally, VK 
staining and bulk Ca analyses were performed in all rat and human samples.
Results: Seven animals showed clear calcification (bulk Ca > 10 mg/g). A good 
correlation (R=0.885, p<0.05) was found between the in-vivo and post-mortem scans. Both 
bulk Ca levels (16.32 ± 5.74 mg/g) and VK positive area (10.96 ± 4.43 %) correlated well with 
the in vivo scan (R=0.829, p<0.01 and R=0.813, p<0.001). Six out of the 12 human samples 
showed detectable calcifications using μCT. Four of these had bulk Ca levels > 10 mg/g. 
In the human samples, a good correlation was also found between the μCT scan and both 
bulk Ca levels (56.5 ± 40.3 μg/g) and VK positive Area (7.2 ± 4.83%) (R=0.991, p<0.001 
and R=0.932, p<0.001). Both bulk Ca levels and VK positive area were similar in the 
human and animal samples (p > 0.05).
Conclusions: In summary, we found a good correlation between μCT, bulk Ca and VK 
staining in both animal and human samples. Furthermore, bulk Ca levels and VK staining 
in human and rat samples were similar. In order to evaluate whether CAC scores in humans 
correlate with the various parameters of vascular calcification, sample collection of patients 
with known CAC scores is currently ongoing.
Funding: Commercial Support - Sanifit (Spain)
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Background: Although severe secondary hyperparathyroidism (SHPT) represents a 
high turnover bone disease, osteitis fibrosa, but the pathogenesis of osteitis fibrosa is not 
fully clarified. We examined the characteristics of bone marrow-derived mesenchymal stem 
cells (BMSCs) differentiation into osteoblasts in uremic rats with SHPT.
Methods: We bred 5/6 nephrectomized (Nx) rats with a high phosphorus (P) diet 
(containing 1.2 % phosphate) to progress SHPT (Nx+high P diet (HP) group, n=10), or 
Nx (Nx+normal P diet (NP:containing 0.6 % phosphate) group, n=6) and normal rats 
(Normal+NP group, n=5) with a standard diet. After 8 weeks all rats were sacrificed and 
BMSCs (obtained from femur), tibia, and serum were analyzed. BMSCs were confirmed 
by flow cytometry for the expression patterns of the cell surface marker (CD90+, CD29+, 
CD45-, and CD31-). Osteoblastic differentiation was induced by an osteogenic medium 
containing 10mM β- glycerophosphate, 50 μg/mL ascorbic acid and 10 nM dexamethasone 
in minimal essential medium α (MEMα). The osteoblastic differentiation was assessed by 
ALP mRNA expression and alizarin red staining.
Results: Serum creatinine (Cre) levels were significantly elevated in the Nx+NP rats 
compared with the Normal+NP rats. The Cre levels in the Nx+HP rats showed levels similar 
to those in the Nx+NP rats. Serum P and PTH levels were significantly elevated in the 
Nx+HP rats compared with the Nx+NP rats (P level: 11.1±2.4 vs 7.3±1.3 mg/dL, PTH 
level: 1820.6±665.1 vs 197.8±151.9 pg/mL). Bone morphometrical analysis showed an 
increase in both osteoid volume and eroded surface in the Nx+HP but not in the Nx+NP 
rats. The population of harvested BMSCs were similar in all three groups. The ALP mRNA 
expression in the BMSCs from the Nx+HP rats was significantly suppressed compared with 
that in the other rats. Alizarin red staining showed a tendency similar to the ALP mRNA 
expression.
Conclusions: These results suggested that the BMSCs differentiation into osteoblasts 
was disturbed in the SHPT rat. The discrepancy between the high osteoblastic activity 
in the bone and impaired differentiation of the progenitor cells were found. P load might 
contribute to this differentiation impairment.
Funding: Government Support - Non-U.S.
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Bone Morphogenetic Protein-7 Upregulates Collagen I, Sp7, and IBSP 
Genes in Human Mesenchymal Stem Cells
Jun-Beom Park,1 Hye Min Choi.2 1The Catholic University of Korea, Seoul, 
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Background: Bone morphogenetic proteins are reported to be associated with 
proliferation and differentiation of various types of cells. This study was performed to 
evaluate the effects of short-term application of bone morphogenetic protein-7 on human 
mesenchymal stem cells with next-generation sequencing.
Methods: Stem cells were treated with a final concentration of 100 ng/ml bone 
morphogenetic protein-7. Sequencing of mRNA and analysis of data were performed. Gene 
ontology and pathway analysis were done. Quantitative real-time polymerase chain reaction 
of mRNA of ColI, Sp7, IBSP and Western blot analysis of collagen I, osterix and bone 
sialoprotein and β-actin were performed.
Results: A total of 25,737 mRNAs were differentially expressed and up and down-
regulated mRNAs were documented based on the related pathway. Expression of collagen 
I, Sp7 and IBSP were increased with the application of BMP-7 at 3 hours and this was 
confirmed with Western blot analysis.
Conclusions: The short-term application of BMP-7 produced increased expression 
of collagen I, Sp7 and IBSP and this was related with target genes chosen for osteoblast 
differentiation. This study provided new insights into role of bone morphogenetic protein-7 
using mRNA sequencing.
Funding: Government Support - Non-U.S.
Gene ontology analysis by categorization of the importance
Gene ontology analysis by up- and down regulation
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Study of Fibroblast Growth Factor 23 in Patients with CKD in Indian 
Population
Girish V. Kumthekar. care hospital Care Hospital, Banjara 
Hills,Hyderabad,INDIA, Beed, Maharashtra, India.
Background: Historically there are four main ‘Players’ in CKD-MBD, namely 
calcium, phosphate, parathyroid hormone (PTH) and vitamin D endocrine system. The 
treatment strategies are designed to keep all four parameters within defined ranges in an 
attempt to maintain bone and vascular health in a patient with CKD. FGF-23 is pivotal as 
a marker of progression of CKD as well as a therapeutic target for assessing response to 
treatment.
Methods: Total 64 patients were enrolled over a period of 18 months after obtaining 
consent. The blood samples were collected for serum calcium, phosphorous, PTH, Vitamin 
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D and haemoglobin. The statistical significance in the difference in the outcome variables 
between the groups was assessed using Kruskal -Wallis for FGF-23. Data was analysed 
using STATA 13 software.
Results: The mean value for FGF 23 was found to be highest in CKD stage 5 (4.77) 
followed by stage 5D (3.87) and stage 2 (3.56). This was not statistically significant. FGF-
23 was compared with existing markers of CKD MBD and except for marginal significance 
for phosphorus (P value 0.09); there was no statistically significant correlation. The drop 
in haemoglobin level with CKD progression was correlated negatively with FGF 23 level. 
(p=0.01)
Conclusions: The FGF-23 levels do not correlate with present markers of CKD-MBD. 
FGF-23 values were observed to be lower in low turnover disease and higher in high 
turnover bone disease. But estimating CKD-MBD severity by utilising FGF-23 as a marker 
may not be helpful as majority CKD population has low PTH in our study.
FGF-23 correlation with existing markers
There is no statistical significance between FGF-23 and existing markers of CKD-MBD.
Levels of FGF 23 among different stages of CKD
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Correlation of Vitamin D and Islet β Cell Function Among Calcium 
Kidney Stone Formers
Pulkit Gandhi,1 Roopali G. Gandhi,2 Jie Tang.1 1Brown University, Providence, 
RI; 2RIH, Providence, RI.
Background: Existing evidence suggest that low vitamin D store affects normal 
release of insulin from β-islet cells after glucose intake, hence could play a role in the 
pathogenesis of glucose intolerance and type 2 diabetes mellitus. However, the interaction 
between 25(OH)-vitamin D (25D) with β cell function has not been studied in calcium 
kidney stone formers, a unique population whose 1,25(OH) vitamin D (1,25-D) action 
seems to be hyperactive.
Methods: Prevalent non-diabetic calcium kidney stone formers from 2015 to 2018 were 
enrolled in this study. We assessed the association between serum 25D and β cell function 
measured by HOMA- β [(360 × fasting insulin (μU/L)/(fasting glucose (mg/dl)−63)] using 
univariate analysis and multivariate regression model adjusting for demographics and 
important clinical covariates. P values less than 0.05 were considered significant.
Results: A total of 94 non-diabetic calcium kidney stone formers were enrolled 
in this study. Among them, 51% were male, 86% were Caucasian, 38% had history of 
hypertension and 29% had history of dyslipidemia. Mean age was 54 years, mean creatinine 
clearance (CrCl) was 131 ml/min, mean body mass index (BMI) was 31.3 kg/m2, mean 
serum 25D was 28 ng/ml, mean serum 1,25D was 52 pg/ml, and mean serum parathyroid 
hormone level was 66 pg/ml. As a measure of islet β-cell function, mean HOMA β was 
calculated to be 270. In univariate analysis, CrCl, BMI and history of hypertension and 
dyslipidemia, associated significantly with HOMA- β (p<0.05), but 25D did not have 
a significant association (p=0.2). After adjusting for demographics, 25D associated 
significantly with HOMA- β (p=0.02). Likewise CrCl, BMI, history of hypertension and 
dyslipidemia continued to carry significant associations with HOMA- β (p<0.05). After 
adjusting for demographics, histories of hypertension and dyslipidemia, CrCl, BMI and 
serum uric acid, the association between 25D and HOMA- β remains significant (p=0.01). 
Unlike 25D, serum 1,25D levels have no association with HOMA- β in univariate and 
multivariate analyses.
Conclusions: Like the general population, low serum 25D levels, not 1,25D levels, 
associate strongly with islet β cell function measured by HOMA- β in calcium kidney stone 
formers.
Funding: Private Foundation Support, Clinical Revenue Support
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Multiple GNAS1, FGF23, FGFR3 Genes’ Striking Mismutations in CKD 
with SH: Brand New Bone Dysplasia and Uglifying Human Face 
Appearances - Sagliker Syndrome (SS)
Yahya Sagliker. Sagliker Hypertension Unit, Adana, Turkey.
Introduction: SS so far, seems to be related to chronic kidney disease (CKD) and 
consequent secondary hyperparathyroidism (SH). SS starts and develops particularly before 
puberty, while CKD reaches stage III level with overt SH. Since it occurs only in some 
patients (%1), it is plausible to think SS is genetically predisposed. Genes’ mismutations on 
the genesis of SS is unclear and no data are available so far.
Case Description: We conducted clinical studies and screening for mismutations in 
GNAS1 gene in 23, FGF23 and FGFR3 genes in 17 patients. DNA isolations performed 
from blood samples and mismutation regions were amplified by PCR. In 73.9% (17/23) 
patients, 17 different abnormalities in GNAS1 were detected.58.3% (7/12) nucleotide 
alterations comprised novel mismutations in different manners. There were 6 heterozygous 
tranversion polymorphism in exons.6 were introngenic mismutations found in introns 
65626, 70387, 70817. We found 10 different mismutations in FGF23 gene. 8 were novel 
mismutations defined first in our study. 3 were in intronic region near exon 2. In FGFR3 
gene we found 22 different mismutations. 16 were novel mismutations defined first in 
our study. 12 mismutations were found in exons. 8 were found in introngenic region near 
exon 11. 2 were found in non-coding exonic regions of exon 18.1 was in the exon-exon 
junction region between exon 11 and 12. 3 were nonsense Therefore mismutations might be 
preventing splicing of introns.
Discussion: There are plenty mismutations on 3 genes consistent with an insufficiency 
of genes playing a role in clinical phenotype of loss of function mutations with functional 
alleles having predominant roles in preventing hormonal resistance. Since incidence of 
CKD stage 3 is around 8% in world but the incidence of SS is around 1% and although our 
patients were not resembling any of them, but they could be in between and SS might be a 
combination-compulsion of Genetical Bone displasias such as McCune-Albright syndrome, 
Achondroplasias etc and SH and CKD.
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Warfarin Based Anticoagulation Is a Major Risk Factor for Calciphylaxis
Philipp G. Russ, Martin Russwurm, Joachim Hoyer. Nephrology Department 
Marburg Marburg Philipps-University, Marburg, Germany.
Background: To assess clinical risk factors, altered laboratory parameters, 
epidemiology and survival rates of patients suffering from calciphylaxis, we conducted a 
retrospective study of patients with biopsy-proven calcific uremic arteriolopathy (CUA).
Methods: In an eight year period from 2008-2016 we included 15 patients in a 
single center retrospective study for final analyses. Only patients with both, strong 
clinical suspicion of calciphylaxis and confirmative histological patterns such as intimal 
hyperplasia, micro thrombi or van Kossa stain positive media calcification, were included. 
Patients with clinical suspicion but lacking dermatohistological evidence were excluded.
Results: The mean age of patients was 64.8 years. 9 patients (60%) were female; 12 
(80%) were obese with a Body-Mass-Index above 30 kg/m2; 3 (20%) did not have chronic 
kidney disease (CKD); 12 (80%) had stage 4 or 5 CKD and 10 (66.7%) were on dialysis 
(CKD 5D). One-year mortality in the entire cohort was 73.3%. With respect to medication 
history, the majority of patients (n=13 (86.7%)) received Vitamin-K-Antagonists (VKA); 
10 (66.7%) weretreated with Vitamin D; 6 (40%) were supplemented with oral calcium; 5 
(33.3%) had been treated with corticosteroids; 12 (80%) were on protonpump inhibitors. 
13 (86.7%) patients showed hyperparathyroidism. The serum-phosphate level was elevated 
in 9 (60%) patients and the serum-calcium level was reduced in 7 (46.7%) patients. Ten 
(66.7%) patients presented with hypoalbuminemia at diagnosis.
Conclusions: Calciphylaxis is a rare disease with high mortality associated with 
female sex, obesity, severe chronic kidney disease and hyperparathyroidism. Especially 
treatment with VKAs and liverdysfunction are important risk factors for the development 
of calciphylaxis.
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Rationale, Design, and Characteristics of EPISODE Trial
Yoshitaka Isaka,1 Hideki Fujii,2 Yoshihiro Tsujimoto,4 Satoshi Teramukai,3 
Takayuki Hamano.1 1Osaka University Graduate School of Medicine, Suita, 
Japan; 2Kobe University Graduate School of Medicine, Kobe, Japan; 3Kyoto 
Prefectural University of Medicine, Kyoto, Japan; 4Inoue Hospital, Osaka, 
Japan.
Background: In dialysis patients, mortality risk due to cardiovascular diseases is 
remarkably high and prognosis is poor; coronary artery calcification is considered one of the 
major contributing factors. It is known that hyperphosphatemia is associated with coronary 
artery calcification. Therefore, controlling serum phosphate levels and thereby mitigating 
vascular calcification could improve the poor prognosis of dialysis patients. However, 
the optimal phosphate range in dialysis patients remains unknown; hence, this study was 
planned to compare the effects of two types of non-calcium-based phosphate binders, and 
examine the effect of strict control of phosphate on coronary artery calcification.
Methods: EPISODE is a randomized, open-label, multi-center, interventional trial with 
a two-by-two factorial design. We enrolled 160 hemodialysis patients (men 109, women 
51, diabetes 59, hypertension 116) with a pre-dialysis serum phosphate level of at least 
5.0 mg/dL or at least 6.1 mg/dL, respectively, in those taking or not taking a phosphate 
binder, as measured during the observation period. Registered patients were randomized 
to the sucroferric oxyhydroxide or lanthanum carbonate arm in order to reduce serum 
phosphate to two target ranges (3.5 - 4.5 mg/dL in strict arm and 5.0 - 6.0 mg/dL in standard 
arm) for 12 months. The primary endpoint will be percent change in coronary artery 
calcification score (CACS), and the secondary endpoints will include change in serum 
phosphate and calcium levels, change in renal anemia-related factors, etc.
Results: At baseline, the median CACS was 840 (IQR; 270-2705).
Conclusions: This study may show the optimal phosphate range in dialysis patients.
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Calciphylaxis: What Are These Patients Dying from? A Single Centre 
Study
Ester Casillas, Haridian Sosa Barrios, Laura V. Blanco, Sofia Ortego, 
Victor Burguera, Milagros Fernandez lucas, Maite Rivera. Ramón y Cajal 
Hospital, Madrid, Spain.
Background: Calciphylaxis is a rare metabolic entity most commonly associated to 
chronic kidney disease, with a mortality rate over 80% in the first year after diagnosis. 
The optimal treatment for calciphylaxis continues to be discussed. There is not one healing 
treatment that works in every case, although there is many that can be useful for avoiding 
the progression of the lesions and in some cases even lead to curation (ulcer debridement, 
Paracalcitrol, sodium thiosulfate, biphosfonates and paratiroidectomy are some of them.) 
We present a series of 23 patients diagnosed of calciphylaxis in our center and review the 
treatment regimen and survival in each case.
Methods: From January 2002 to october 2017 our Nephrology department attended 
2131 patients with chronic kidney disease, 23 of them (1%) developed calciphylaxis: 
11 men/12 women with a mean age of 58 years (range 32 to 87 years). At the time of 
diagnosis, 13 patients were receiving treatment with hemodialysis, 7 were on peritoneal 
dialysis and 3 had a functioning transplant. The mean risk factors identified in these 
patients were: severe hyperparathyroidism in 11 cases (PTH>600), oral anticoagulants in 
10 patients., steroid treatment in 8 patients, active-D-vitamin supplements in 4 patients, 
severe hyperphosphatemia in 6 patients (P> 6 mg/dl). In 11 patients calciphylaxis occurred 
coincidental with a decompensation of another illness. All of them were treated by trained 
nurses who performed ulcer debridement and applied antiseptic and healing bandages. 
Other treatments were Paracalcitrol (n=12), parathyroidectomy (n=4), Biphosphonates 
(n=3), Sodium thiosulfate (n=3).
Results: During the follow-up 13 patients died, 2 were lost and 8 are alive. 3 patients 
died as a result of calciphylaxis (13%), improving the skin lesions in the remaining 20. 
However, in the first year after diagnosis, another 9 patients died due to pathology not 
related to calciphylaxis (5 cardiac, 1 lung transplant rejection, 1 gastrointestinal hemorrhage, 
1 pneumonia, 1 HD withdrawal), thus total mortality was 52%.
Conclusions: Secondary hyperparathyroidism and oral anticoagulants were the most 
prevalent risk factor in our series. Although calciphylaxis is associated to a very high 
mortality rate, the main cause of death was the decompensation of unrelated illnesses.
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Early Detection of Mineral Abnormalities in Patients with CKD Stage 3-4
Eleni Chelioti,1 Eleni Theodoropoulou,2 Kyriaki Stamatelou,3 
Evdokia Efthimiou,4 Maria Tsilivigou.5 1Dept. of Nephrology, Tzaneio, General 
Hospital of Pireaus, Athens, Greece; 2Dept. of Nephrology, General Hospital of 
Athens “Alexandra”, Athens, Greece; 3Athens Medical, Dafni Clinic, Vrilisssia, 
Greece; 4Renal Unit “Frontis”, Piraeus, Greece; 5Dept. of Nephrology, Tzaneio 
General Hospital of Piraeus, Athens, Greece.
Background: Mineral and Bone Disorders (MBD) are highly prevalent in all 
stages of chronic kidney disease (CKD). Secondary hyperparathyroidism (SHPT) and 
hyperphosphatemia (HP) are the most prominent mineral abnormalities. Progression of 
CKD has been associated with increased iPTH, phosphorus (P) and Calcium x Phosphate 
product (CaxP) and with decreased calcium (Ca) and 1,25 dihydroxyvitamin D levels. Our 
aim was to determine the prevalence of mineral disorders in our outpatient CKD stage 3-4 
patients.
Methods: We studied 336 CKD stage 3-4 patients (190 men, 56.5% and 146 women 
43.5%, mean age 65±14 years). Patients were not receiving Ca supplements, phosphate 
binders, or vitamin D. Mean eGFR was 34±9.5 ml/min/1.73m2. The parameters determined 
and analyzed were: Ca, P, iPTH and CaxP.
Results: The percentage of patients with Ca, P, iPTH and CaxP within the recommended 
targets are presented in the Table. 58% of our patients had iPTH>110 pg/ml (95%CI 
∑49.8-65.2), 34.2% had P>4.6mg/dl (95%CI 25.8-40.4), 86.3% had CaXP>55mg2/dl2 
(95%CI 79.9-90.9) and 22.3% had Ca<8.4mg/dl (95%CI 15.6-28.5). P correlated positively 
with iPTH and CaxP (r=0.25 p=0.001 and r=0.41 p=<0.001 respectively), and negatively 
with Ca (r=0.85 p<0.001). (Table)
Conclusions: In patients with CKD stages 3-4, out-of target mineral parameters are 
highly prevalent. Early detection of mineral abnormalities is critical for timely and effective 
treatment of SHPT in pre-dialysis patients and could delay the progression of CKD-MBD.
Funding: Government Support - Non-U.S.
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Relationship Between Young Adult Mean and Vascular Calcification in 
Patients with CKD on Maintenance Hemodialysis
Wataru Fukao,1,2 Yukiko Hasuike,1 Tomoko Kimura,1 Kosuke Mizusaki,1 
Yasuyuki Nagasawa,1 Takahiro Kuragano.1 1Hyogo College of Medicine, 
Nishinomiya, Japan; 2Takarazuka City Hospital, Takarazuka, Japan.
Background: Patients with chronic kidney disease (CKD) often have osteoporosis and 
a high risk of bone fracture. Mineral bone disorder in CKD is associated with cardiovascular 
disease, although the mechanism remains unclear. The purpose of this study was to clarify 
the relationship between lower bone mineral density (BMD) and vascular calcification in 
patients with CKD on maintenance hemodialysis (MHD).
Methods: A total of 78 MHD patients were examined. BMD at the lumbar vertebral 
spine and femur were measured via dual-energy X-ray absorbsiometry by young adult mean 
(YAM). Factors related to bone marker (tartrate-resistance acid phosphatase 5b [TRACP 
5b], bone specific alkaline phosphatase [BAP]), Ca, P, intact parathyroid hormone and 
25-hydroxycalciferol [25(OH)D] were measured. Aortic calcification index (ACI) were 
measured by computed tomography, as previously reported.
Results: The patients’ mean age ± SD was 66.1±11.1 years, and mean dialysis vintage 
was 7.4 years. YAM of femur was significantly lower than YAM of vertebra (YAM of 
femur [74.9±14.9%]; YAM of vertebra [91.3±18.0%], p<0.0001). YAM levels positively 
correlated with body weight, Ca, creatinine, albumin and 25(OH)D, and negatively 
correlated with TRACP 5b, BAP and ACI (r=-0.319, P=0.0044).
Conclusions: Lower BMD correlated with ACI in patients with CKD on MHD. These 
findings suggest that BMD is related ectopic calcification.
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Improving Control of Mineral Bone Disease in Peritoneal Dialysis Patients
Ryan Marinovich,1 Robin Wigen,2 Han Wang,2 Nancy I. Woodcock,4 Arsh Jain,3 
Elena Qirjazi.2,3 1Schulich School of Medicine, London, ON, Canada; 2Schulich 
School of Medicine and Dentistry, London, ON, Canada; 3London Health 
Sciences Center, London, ON, Canada; 4London Health Sciences Centre, 
London, ON, Canada.
Background: Peritoneal dialysis (PD) patients often have difficulty regulating their 
calcium (Ca), phosphate (PO4) and parathyroid hormone (PTH) levels, placing them at 
risk for mineral bone disease (MBD). Following Ca/PO4/PTH trends is key in evaluating 
the effectiveness of different treatments. However, out-patient laboratory blood work and 
physician shared-practice models in PD units make following these trends challenging. We 
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aim to increase the number of PD patients at our centre who meet targets for Ca/PO4/PTH 
levels by 15% within 9-12 months using quality improvement methods.
Methods: We developed a simple tracking tool which includes: a) the trend of 
individual patients’ Ca/PO4/PTH values and subsequent interventions, and b) a treatment 
guide for MBD. The latter was generated from a combination of National Kidney 
Foundation KDOQI guidelines and local expert opinion. This tracking tool was rolled out 
at our PD Unit in October 2017. The primary outcome was the change in the proportion of 
patients (at clinic) who meet all three targets, before and after implementation of our tool. 
Baseline data was collected from a 12-week look-back window and an opinion survey of 
the stakeholders at our PD Unit. Post-implementation, we tracked uptake of our tool and 
elicited specific feedback from care-givers. We used Plan-Do-Study-Act (PDSA) quality 
improvement methodologies to continuously adjust the tool and its implementation.
Results: The opinion survey was completed by 16 health care professionals. 87.5% of 
respondents felt MBD management is poorly defined and 56% believed patient adherence 
is the biggest barrier. Baseline data indicated that 34.5% of our patients met targets for Ca/
PO4/PTH. During PDSA cycle#1, 69.8% of charts utilized our tool and 37.2% of patients 
met targets (p=0.62). For PDSA cycle#2, the dietitian was recruited to champion our tool 
and uptake increased to 90.7%. The proportion of patients meeting targets rose to 44.2% 
(p<0.05, compared to baseline).
Conclusions: We achieved a 9.7% increase in the PD patients meeting Ca/PO4/PTH 
targets within 6 months by adjusting care-givers’ behaviors, rather than patient factors. We 
will continue using PDSA methodologies to achieve our objective within 9-12 months.
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Change of Bone and Mineral Metabolism in Kidney Donors After 
Uninephrectomy: Prospective Observational Study
Eun jeong Ko,1 Bumsoon Choi,2 Cheol Whee Park,3 Chul Woo Yang,4 Byung 
ha Chung.4 1Seoul St.Mary’s Hospital, Seoul, Republic of Korea; 2Division of 
Nephrology, Department of Internal Medicine, Seoul, Republic of Korea; 3The 
Catholic University of Korea, Seoul, Republic of Korea; 4Seoul St. Mary’s 
Hospital, Seoul, Republic of Korea.
Background: The aim of this study is to investigate whether uninephrectomy for 
kidney donation cause change of bone and mineral metabolism and also investigate factors 
associated with it in prospective kidney donors after uninephrectomy.
Methods: Serum and urine creatinine, calcium, phosphorus, and serum intact 
parathyroid hormone (iPTH), 25(OH) vitamin D values were obtained pre-donation 
and postoperatively in 32 donors. Renal fraction excretion rate of phosphate (FEpi) was 
calculated with 24-hour urine collection. Pre- and post-donation GFR was measured by 
DTPA scan in all donors. We defined post-donation chronic kidney disease-mineral bone 
disorder (CKD-MBD) as higher serum iPTH level than median (59.7 pg/ml) of all donors 
at post-transplant, and investigate factors associated with the development of CKD-MBD.
Results: After donor nephrectomy, MDRD eGFR declined (93.1 to 61.2 ml/min/1.73m2) 
and remnant kidney’s GFR measured by DTPA scan increased (53.9 to 63.8 ml/min), 
significantly. (both p<0.001) Post-donation serum iPTH increment was marked (56.8 Vs 
47.4 pg/ml, p=0.055), and 25(OH) vitamin D level also rose (27.0 to 30.2 ng/ml, p=0.364). 
After donation, serum Ca was changed from 9.19 to 9.26 (p=0.181), serum phosphate 
changed from 3.4 to 3.3 (p=0.434). Renal fraction excretion rate of phosphate (FEpi) was 
increased after donation. (14.4 to 21.4, p<0.01) Compared with no-CKD group, CKD group 
showed higher increment of GFR by DTPA scan (15.1 Vs 8.6 ml/min/1.73m2, p=0.069), 
higher increase of serum P level (+0.12 Vs -0.19, p=0.044), and higher change in serum 
Ca X P (1.4 Vs -1.7, p=0.04) In logistic regression analysis, after adjusting sex, age, BMI, 
pre-donation eGFR, the predictors of development of CKD-MBD was pre-donation FEpi. 
(OR 0.811, 95% CI 0.658-0.998, p=0.048)
Conclusions: Donor nephrectomy caused a significant change in bone and mineral 
metabolism in prospective kidney donors and pre-donation FEpi couble be a good predictive 
marker for early expecting development of CKD-MBD.
Funding: Government Support - Non-U.S.
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Serum Osteoprotegerin Is Associated with an Increased All-Cause 
Mortality in CKD Patients
Marek Stopinski,1 Joanna Kaminska,1 Krzysztof Mucha,2,3 Anna Jedrzejczak,2 
Marta P. Soboniak,2 Rafal Staros,2 Monika A. Niewczas,4,5 Leszek Paczek,2 
Bartosz Foroncewicz.2 1Department of Internal Diseases and Dialysis Unit, 
West Hospital of Saint Paul II, Grodzisk Mazowiecki, Poland; 2Department of 
Immunology, Transplantology and Internal Diseases, Warsaw Medical 
Univeristy, Warsaw, Poland; 3Institute of Biochemistry and Biophysics, Polish 
Academy of Sciences, Warsaw, Poland; 4Joslin Diabetes Center, Boston, MA; 
5Department of Medicine, Harvard Medical School, Boston, MA.
Background: Bone related cytokines were reported to be linked to cardiovascular risk 
in chronic kidney disease (CKD) patients. The aim of this study was to assess the usefulness 
of osteopontin (OPN), osteocalcin (OC), osteoprotegerin (OPG) and fibroblast growth 
factor 23 (FGF23) as predictors of 5-year mortality in patients with different CKD stages.
Methods: The following study groups were enrolled: end stage renal disease (ESRD, 
n=38), stage 3 and 4 CKD (CKD3-4, n=19) and healthy controls (n=19). Blood samples 
were obtained at baseline to measure OPN, OC, OPG and FGF23 (ELISA or Luminex 
platform). 64-row computed tomography was performed to assess the calcium score. 
Patients were prospectively followed for 5 years to evaluate their all-cause mortality.
Results: All bone related cytokines concentrations significantly correlated positively 
with each other and had an inverse correlation to eGFR. Moreover, OPN and OPG were 
significantly correlated positively to calcium score, whereas OPG was associated with 
an increased risk of death in subjects with CKD3-4 or ESRD. The univariate logistic and 
Cox proportional hazard models analysis of incident all-cause mortality revealed odds and 
hazard ratios >4,4. whereas death hazard ratio in multivariate Cox analysis was 2,1 (Table).
Conclusions: We found that OPG correlated with declining eGFR, calcium score, 
other bone related cytokines and was associated with increased risk of all-cause mortality 
in patients with CKD3-4 or ESRD. Previous studies, mostly carried out in diabetic patients, 
suggested that OPG could be a biomarker for CKD progression. Our findings from the 
mixed population of diabetic and non-diabetic subjects at different CKD stages, provided 
new arguments to use OPG as a mortality predicting factor in CKD patients.
Logistic analysis and Cox proportional hazard models of incident all-cause mortality in 
subjects with CKD3-4 or ESRD at baseline (* p<0,05).
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Medial Arterial Calcification: A Predictive Survival After Kidney 
Transplantation
Ekamol Tantisattamo,1,2 Siroj Dejhansathit,3 Possawat Vutthikraivit,3 
Haritha R. Mopuru,4 Praveen Ratanasrimetha,5 Rungwasee Rattanavich,6 
Raghavesh Pullalarevu,2 Nattawat Klomjit.7 1Division of Nephrology and 
Hypertension, Department of Medicine, University of California Irvine School 
of Medicine, Orange, CA; 2Multi-Organ Transplant Center, Division of 
Nephrology, Department of Internal Medicine, Oakland University William 
Beaumont School of Medicine, Royal Oak, MI; 3Phramongkutklao College of 
Medicine, Mahidol University, Bangkok, Thailand; 4Multi-Organ Transplant 
Center, William Beaumont Hospital, Royal Oak, MI; 5Department of Internal 
Medicine, Texas Tech University Health Sciences Center, Lubbock, TX; 6Division 
of Nephrology, Department of Medicine, Washington University school of 
Medicine, St. Louis, MO; 7John A. Burns School of Medicine, University of 
Hawaii, Honolulu, HI.
Background: Calcification detected from mammogram (MG) is exclusively medical 
arterial calcification (MAC) which is associated with morbidity and mortality in ESRD 
patients. The predictive value of MAC in kidney transplant recipients is unknown.
Methods: A retrospective cohort study of 305 kidney transplant recipients from 2012 
to 2015 was reviewed and 51 female patients with ≥1 MG during pre-transplant period 
were included in this study. MAC is determined by linear calcified breast arteries detected 
in MG. The association between MAC and mortality was tested by using binary logistic 
regression analysis.
Results: Mean age±SEM is 57.08±1.47 years and mean duration of follow-up was 
3.84±0.18 years. Of 51 patients, 20 patients had MAC prior to kidney transplantation. All 
laboratory related to mineral and bone metabolism were not different between MAC and non-
MAC groups. Six patients died during study period with an incidence rate of 0.0306 person-
years [Figure 1]. Five patients in MAC and 1 patient in non-MAC groups died. Patients in 
MAC group had 10 times higher the odd of death compared to non-MAC group (OR 10.000; 
95%CI 1.070 to 93.437, p 0.043). After adjusted for presence or absence of diabetes, MAC 
group remains having higher mortality (OR 10.148; 95%CI 1.043 to 98.738, p 0.046).
Conclusions: Similar to non-transplant patients, kidney transplant recipients with 
MAC have significant higher mortality compared to those without MAC. Although kidney 
transplantation can reverse metabolic disarrangement, this may not be the main factors 
contributing to survival benefit of successful kidney transplantation.
Figure 1:Kaplan-Meier curve demonstrates a significant higher mortality after kidney 
transplantation in patients with pre-transplant breast MAC compared to those without pre-
transplant MAC.MAC, medical arterial calcification
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Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index (CAVI) in 
Type 2 Diabetes Patients
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Daniela Mastroluca,1 Maria luisa Muci,1 Sandro Mazzaferro.2 1Nephrology and 
Dialysis Unit, ICOT Hospital, Polo, Pontino Sapienza University of Rome, 
Latina, Italy; 2Department of Cardiovascular, Respiratory, Nephrologic, 
Anesthesiologic and Geriatric Sciences., Sapienza University of Rome, Italy, 
Rome, Italy; 3Nephrology and Dialysis Unit, Policlinico Umberto I, Rome, 
Rome, Italy; 4Department of Experimental Medicine, Sapienza University of 
Rome, Rome, Italy.
Background: Identification of early involvement of cardiovascular (CVD) and renal 
disease in type 2 diabetic patients (T2DM)is challenging. Cardio-Ankle Vascular Index 
(CAVI), a measurement of arterial stiffness with minimal operator dependence, could help 
recognize early vascular damage and the resultant CKD. We evaluated CAVI in T2DM 
patients who had no evidence of macrovascular diseaseand/orrenal insufficiency (estimated 
Glomerular Filtration Rate or eGFR≥60 ml/min/1.73m2).
Methods: CAVI was measured by VaSera1500 (Fukuda Denshi Co.) in 174 non old 
(≤ 60 years) T2DM patients (M/F = 100/74) diagnosed since <10 years and never on insulin 
therapy, and with CKD-EPI estimated GFR ≥60 mL/min /1.73 m2.
Results: Patients were 55.4±4.8 y.o., had a disease duration of 5.2±3.7 y, HbA1c of 
6.4±0.9 % and eGFR of 93.5±10.8 ml/min /1.73 m2. None hadeGFR>125ml/min. Systolic 
blood pressure (SBP) was143,4±19,6 and diastolic (DBP) 87,6±8,7 mmHg. ACR averaged 
21.9±58.3 mg/gr with pathologic values (≥30 mg/gr, indicative of CKD) in 11%. CAVI 
averaged normal values (7.9 ± 0.9) and was pathologic (higher than reference values for 
age) in 18%. Univariate analysis showed that CAVI correlated positively with age (p=.450; 
p<.001), Pulse wave velocity (r=.830; p <.001), Hb1Ac (r=.164; p<.05), and DBP (r=240; 
p<.01). Multivariate analysis confirmed age (p=7.41e-07) and DBP (P=0.014), and selected 
ACR (p=0.004) but not diabetes duration nor HbA1c as most predictive factors of CAVI.
Conclusions: In our population, age, ACR, and DBP are most relevant factors of 
arterial stiffness as measured by CAVI. Better than glycemic control and disease duration, 
CAVI could be a potential marker of early vascular damage indicating poor BPcontrol, 
endothelial dysfunction and/or CKD (as reflected by ACR).
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Identifying Patient Centered Strategies for Improving Cinacalcet 
Adherence
Ruchi H. Naik,1 Tanvi Rege,2 Avrum Gillespie,1 Swati Rao,1 Jean Lee.1 
1Nephrology, Temple University, Philadelphia, PA; 2Center for Kidney Disease 
and Hypertension, Lemoyne, PA.
Background: Cinacalcet is an effective pharmacological means of treating secondary 
hyperparathyroidism in patients with ESRD. However, high rates of non-adherence (50% 
to 85%) and discontinuation (67%) have been reported, limiting the potential benefits. We 
sought to investigate the underlying reasons for non-adherence and elicit patient directed 
interventions for improved adherence.
Methods: A sample of 25 patients from in an urban in-center hemodialysis unit who 
were prescribed Cinacalet for at least a month were administered a 16-item questionnaire 
during dialysis. These items addressed patient’s self-reported adherence, barriers and 
potential targets for improving adherence. Demographic and laboratory data were extracted 
from medical records.
Results: All 25 patients were African American. Fifty-six percent were females and 
the mean age was 63 years. Despite 85% of patients reporting moderate to good adherence, 
only 5 (20%) had iPTH <600pg/ml. 20 patients (80%) were aware of the prescription, 
of these 17(85%) were able to identify the pill. Five patients (20%) were unaware of the 
medication and were unable to identify the pill. Medication refills was not a barrier for any 
patient. However, 6 (24%) were unable to afford medication due to high copay. Only 1 
patient reported non-adherence due to diarrhea. Five patients (25%) identified medication 
administration during dialysis and 1 patient suggested more education as potential strategies 
to improve adherence. The majority of the patients did not think that additional education, 
pill-box management, medication reconciliation, or nursing reminders would achieve better 
adherence.
Conclusions: The majority of patients reported good to moderate adherence, yet 
very few had an iPTH at goal. Although 1/3rd of the patients were either unaware of the 
medication or were unable to identify it, they did not believe further education will be 
helpful. Unaffordability contributed to non-adherence in 25% patients. The common 
intervention suggested by the patients was administration during dialysis. As uncontrolled 
hyperparathyroidism has significant morbidity, we believe that administration of 
calcimimetics during dialysis and lower cost may hold the key to improved outcomes.
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Quantitative Systems Pharmacology Approach to Pharmacologic 
Management of Metabolic Bone Disorder in CKD
Adam E. Gaweda,1 Eleanor D. Lederer,2 Michael E. Brier.1 1University of 
Louisville, Louisville, KY; 2University of Louisville; Robley Rex VA Medical 
Center, Louisville, KY.
Background: Metabolic Bone Disorder (MBD) is a frequent comorbidity and a risk 
factor in Chronic Kidney Disease (CKD). Achieving established goals for MBD-CKD 
treatment is challenging. We show a proof-of-concept feedback controller for pharmacologic 
management of MBD-CKD and test its feasibility in sillico across late stages of CKD.
Methods: In the management of MBD-CKD, the three therapeutic goals are serum 
concentrations of Calcium (Ca), Phosphorus (PO4), and Parathyroid Hormone (PTH). Here we 
focus on targeting PTH using a calcimimetic and a vitamin D analog. Based on a Quantitative 
Systems Pharmacology (QSP) model of Ca-PO4-PTH metabolism in a healthy human (GFR = 
100), we developed a Model Predictive Control (MPC) algorithm for determining therapeutic 
concentrations of Cinacalcet and Calcitriol. We tested the feasibility of the algorithm at CKD 
stage IV-V (GFR = 30,20,10) targeting PTH concentration ≤ 100 pg/mL.
Results: The MPC algorithm successfully achieved target PTH concentration for all 
simulated CKD stages. Therapeutic concentrations of Cinacalcet and Calcitriol and the 
equivalent daily Cinacalcet doses are shown in the table below. An example of simulated of 
Ca, PTH, Cinacalcet and Calcitriol trajectories over time is shown in the figure. Concurrent 
dosing of Cinacalcet and Calcitriol results in a dose reduction of the calcimimetic.
Conclusions: We developed a control algorithm for supporting pharmacologic 
management of PTH levels in MBD-CKD. In silico simulations at late stages of CKD 
demonstrate the algorithm feasibility. Our results also show the synergy between the 
calcimimetic and vitamin D.
Funding: Veterans Affairs Support
Therapeutic concentrations of Cinacalcet and Calcitriol as determined by the MPC 
algorithm
concentration in ng/mL, dose in mg/day
Example of Cinacalcet and Calcitriol control at GFR of 10.
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Effect of Secondary Hyperparathyroidism on Bone Turnover Markers in 
ESRD
Yaomin Wang,1,2 Lan Lan,1,2 Cui Yu.1,2 1The kidney disease center, The first 
affiliated hospital, College of Medicine, Zhejiang University, Hangzhou, China; 
2Zhejiang University, Hangzhou, China.
Background: To investigate the effect of secondary hyperparathyroidism (SHPTH) 
with higher parathyroid hormone (iPTH) on the markers of bone turnover in maintenance 
dialysis patients.
Methods: The bone turnover markers in 38 patients with maintenance dialysis patients 
combined with secondary hyperparathyroidism were investigated. Twenty men and eighteen 
women, aged 28-72 years (median 50.61y), including 22 cases with hemodialysis, 16 
cases with peritoneal dialysis, dialysis time 36~125 months (median 84.89). 38 cases with 
parathyroid nodule or adenoma, 15 cases (39.47%) were diagnosed of bone osteoporosis by 
X ray. 26 cases (68.4%) accompanied by arterial vessels, and or heart valves calcification, 
soft tissue calcification.
Results: Serum calcium was 2.32 ±0.16(range 1.87n2.64) mmol/L, and serum 
phosphorus was 2.17±0.51 (range 1.23~3.11) mmol/L. The level of serum iPTH was 
1712.60±635.51(range 1009.00~3864.40)pg/ml, The iPTH of hemodialysis patients 
(1997.60±147.73 pg/ml) was significantly higher than that of peritoneal dialysis patients 
(1320.90 ±50.79pg / ml) (P < 0.01). Osteoclast biomarkers: β-CTX degradation products 
5486.80 ±849.96 (range 3248.00 ~6025.00) pg/ml. Type I collagen amino terminal 
propeptide was 1135.90 ±173.34 (range 590.80~1223.00)ug/L. Osteocalcin N-terminal 
molecular fragment 267.30 ±56.81(range 104.80 ~ 326.00) ng/ml. Serum alkaline 
phosphatase 277.42 ±211.71(range 84.00~976.00)U/L. Alkaline phosphatase (ALP) in 
hemodialysis patients (349.18 ±252.97 U / L)was significantly higher than that in peritoneal 
dialysis patients (178.75±55.09U/L)(P<0.01). 1 month after Parathyroidectomy and 
autologous forearm transplantation in 3 patients, serum PTH:6.7~2.9pg/ml, β-collagen 
degradation product: 729.8~800.1pg/ml, Type I collagen amino terminal prepeptide: 
138~789.3 ug/L, osteocalcin N-terminal molecular fragment: 17. 38~280.9 ng / ml.
Conclusions: The markers of osteoclasts and osteoblasts were significantly increased, 
suggesting that the increase of parathyroid hormone level in secondary hyperparathyroidism 
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significantly promoted bone turnover and made the patients in a state of high transport 
bone metabolism. The increase of parathyroid hormone and the excess of osteolysis may 
be an important cause of CKD-MBD osteoporosis in dialysis patients. The monitoring of 
bone turnover markers can provide a convenient method for dynamic assessment of bone 
transport status in dialysis patients.
Funding: Government Support - Non-U.S.
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Total Parathyroidectomy Combined with Autotransplantation Under 
Tracheotomy for the Fatal Uremic Leontiasis Ossea (ULO): A Rare Case 
Report
Bing Tang,1 Bei Hou,1 Yong Xu,2 Yuanming Li,2 Xinxin Liu.1 1Medicine, Renal 
Division, Jewel Hospital, Changsha, China; 2Hemodialysis Center, The Third 
Affiliated Hospital of Xiang Ya School of Medicine, Central South University, 
Changsha, China.
Introduction: ULO is a rare medical condition, which is characterized by overgrowth 
of the facial and cranial bones. The severe airway and esophageal deformities can lead to 
respiratory depression and eating difficulties. Here we report a rare case of parathyroidotomy 
with complications of ULO.
Case Description: A 25.Y.O Asian woman with ESRD due to glomerulonephritis had 
undergoing regular hemodialysis for 6 years. She has uncontrolled SHPT with developed 
severe ULO for 2 years. The level of serum iPTH was 3724pg/ml, serum calcium, phosphate 
and alkali phosphatase were 2.32mmol/L, 2.53mmol//L and 1155u/L, respectively. The 
ultrasonography showed four hyperplastic parathyroid glands. Facial deformity of patient 
was progressing and experienced difficulties with speaking, breathing, swallowing and 
chewing. Maintenance of the airway during procedural sedation is quite a challenging 
task for the anesthesiologist. Total parathyroidectomy was successfully carried out with 
the general anesthesia by tracheostomy. PTH values 24 hours after surgery was 11.9pg/ml, 
serum calcium 1.7mmol/L, phosphate was 1.11mmol/L, Patient bone pain disappeared and 
nasal airway improved right away after surgery. The tracheal tube was removed after 15 
days intensive care for complications of tracheostomy. Patient has been discharged with 
improvement of facial deformation and will be close followed up.
Discussion: ULO of this condition is rare, the patientdeveloped numerous comorbid 
conditions including airway obstruction. Surgical intervention has been the only option. 
Because of the lack of cases published so far in the literature, proper surgical management 
is not developed. This is a unique case to show total parathyroidectomy can be successfully 
carried out under tracheotomy support for severe ULO.
Preoperative and postoperative comparison of frontal and lateral view of the 25-year-old 
woman with leontiasis ossea.
The state and parathyroid tissue after general anesthesia under endotracheal intubation.
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The Value Contribution of an Innovative Remote Monitoring of Longitu-
dinal Estimated Glomerular Filtration Rate Trajectories in CKD Patients
Macaulay A. Onuigbo. Medicine, The Robert Larner, M.D. College of Medicine, 
University of Vermont, BURLINGTON, VT.
Background: CKD affects over 20 million Americans. Existing CKD prediction 
models are not generally applicable. Most CKD patients remain stable over the years; 
therefore repeated provider office visits represent expensive unnecessary care. CKD 
prediction is an inexact science. Current CKD prediction models are cumbersome and 
generally untested. Individual eGFR trajectories have increasingly become recognized as 
underutilized diagnostic/prognostic tools. The general consensus is that eGFR trajectories 
remain mostly linear. A new IT product, The CKD Express ©, developed in a 2012 
University of Wisconsin Consortium MBA Class by a team including this author enables 
remote tracking of serum creatinine/eGFR trajectories. A retrospective study of eGFR 
trajectories in a patient database will demonstrate the practicality of this innovative CKD 
Care approach. This system would monitor CKD status of subjects in real-time, determine 
lab testing frequency using established algorithms and initiate appropriate referrals, as 
needed, for a population cohort that could involve thousands of subjects. Vermont with a 
mostly rural-based population, and given the Vermont State-UVMC ACO model of care, 
would benefit maximally from this efficient, effective, cost-effective yet affordable and very 
convenient, patient-centered and patient-friendly CKD Care paradigm.
Methods: A retrospective analysis of EMR-based patient records at the University of 
Vermont Medical Center, January 2008 - December 2017, of CKD III patients. Standard 
demographics including co-morbidities will be extracted. All serum creatinine/eGFR values 
will be recorded.
Results: Smoothed linear regression-based eGFR trajectories with spline models 
evaluated by Bayesian approach would be completed for every patient and correlated 
with observed renal outcomes: stable, progressive and need for RRT. Our hypothesis of 
accurate CKD prediction would be confirmed. This would be followed by the development 
of the new Software prototype, The CKD Express ©, utilizing intrinsic algorithms derived 
from the eGFR trajectories’ analysis, decision support systems (DSS) tools, and artificial 
intelligence (AI).
Conclusions: The result would be a new innovative approach to CKD Care that is 
convenient, efficient, effective, affordable, patient-centered, patient-friendly, integrated and 
cost-saving.
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Albuminuria Is a Risk Factor for White Matter Hyperintensities on Brain 
MRI in Elderly Japanese: The Hisayama Study
Keisuke Yamasaki,1,2 Jun Hata,1,2 Naoki Hirabayashi,1,3 Yoshihiko Furuta,1,2 
Tomoyuki Ohara,1,4 Yoichiro Hirakawa,1,2 Keita Takae,1,2 Toshiaki Nakano,2 
Takanari Kitazono,2 Toshiharu Ninomiya.1 1Department of Epidemiology and 
Public Health, Graduate School of Medical Sciences, Kyushu University, 
Fukuoka, Japan; 2Department of Medicine and Clinical Science, Graduate 
School of Medical Sciences, Kyushu University, Fukuoka, Japan; 3Department 
of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu 
University, Fukuoka, Japan; 4Department of Neuropsychiatry, Graduate School 
of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background: Albuminuria and kidney dysfunction, which are determinants of chronic 
kidney disease, are acknowledged as independent risk factors for stroke. Similarly, white 
matter hyperintensities (WMH), which are often seen in cerebral magnetic resonance 
imaging (MRI) among the elderly, are reported to be associated with an increased risk 
of symptomatic stroke. The aim of the present study was to investigate the association 
of albuminuria and kidney dysfunction with WMH volume in a general Japanese elderly 
population.
Methods: A total of 1,214 community-dwelling Japanese subjects aged ≥65 years 
underwent brain MRI scans and a comprehensive health examination in 2012. Urine 
albumin-creatinine ratio (UACR) was categorized as normoalbuminuria (<30 mg/g) and 
albuminuria (≥30 mg/g). Subjects with normoalbuminuria were further divided into the 
following tertile categories: low-normal (≤7.3 mg/g), medium-normal (7.4-12.8 mg/g), and 
high-normal (12.9-29.9 mg/g). Kidney dysfunction was defined as estimated glomerular 
filtration rate (eGFR) <60 mL/min per 1.73 m2. The severity of WMH was evaluated with 
the ratio of WMH volume to intracranial volume (WMHV/ICV). The association of UACR 
levels or kidney dysfunction with WMHV/ICV ratio was estimated using the analysis of 
covariance.
Results: The age- and sex-adjusted geometric mean value of the WMHV/ICV ratio 
increased significantly with higher UACR levels (low-normal: 0.18%, medium-normal: 
0.21%, high-normal: 0.25%, albuminuria: 0.27%; P for trend <0.001). This association 
remained significant after additional adjustment for hypertension, diabetes mellitus, total 
cholesterol, body mass index, eGFR, electrocardiogram abnormalities, smoking habits, 
alcohol intake, regular exercise, and cerebrovascular lesions on MRI (P for trend =0.001). 
In contrast, there is no evidence of a clear association between kidney dysfunction and 
WMHV/ICV ratio.
Conclusions: Our data suggest that albuminuria, even within the normal range, is a 
significant risk factor for larger WMH volume in a general Japanese elderly population.
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Cardiometabolic Risk Factors Associated with Renal Function in 
Apparently Healthy Young: Cross Sectional Study
L. M. Perez-Navarro,1 Rafael Valdez-Ortiz,2 Araceli Alegría Díaz.2 1Hospital 
General de México Dr. Eduardo Liceaga, México, Mexico; 2Hospital General
de Mexico, Mexico City, Mexico.
Background: The Presence throughout life of hypertension, hypertriglyceridemia, 
diabetes mellitus, BMI ≥ 30, hyperuricemia and proteinuria, increase risk up to 7 times for 
the development and progression of CKD. The objective was to identify the prevalence and 
strength of association between cardiometabolic risk factors and kidney function in young 
adults (18-25 years of age).
Methods: We included 5,531 apparently healthy young adults, with measurements 
of waist circumference, overweight and obesity (Ow/OB) by BMI, blood pressure risk 
systolic and diastolic (≥130/85 mmHg); hyperglycemia (≥100 mg/dl); hypertriglyceridemia 
(≥150mg/dl), HDL of risk (<40 mg/dl men, <50 mg/dl women), LDL of risk 
(> 130 mg/dl), hyperuricemia (> 6.8 mg/dl), insulin resistance (HOMA-IR,> 2.9 M,> 2.3 W), 
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and glomerular filtration rate (GFR) by CKD-EPI. Logistic regression was performed for 
adjusted OR (95%CI, p <0.05).
Results: The mean age was 19.3±1.6 years old; 76% (4130) presented at least 1 
cardiometabolic risk factor for the development of CKD. Out of them 33% (1705) had GFR 
≥130 ml/min/1.73m2sc, 3% (157) GFR <90 ml/min/1.73 m2, and 3% (170) proteinuria. Factors
associated with GFR ≥130 were Ow/OB ORa 1.3 (95%IC 1.14-1.47), hyperuricemia ORa 
0.2 (95%IC 0.15-0.26), HDL ORa 1.4 (95%IC 1.2-1.6) and IR ORa1.3 (95%IC 1.05-1.7). 
While hyperuricemia ORa 1.8 (95%IC 1.3-2.6), LDL ORa 1.66 (95%IC 1.05-2.6) and 
proteinuria ORa 3.4 (95%IC 2.07-5.7) were associated with GFR <90. Proteinuria was
associated with hyperuricemia ORa 1.59 (95%IC 1.01-2.5) and LDL ORa 1.8 (95%IC
1.031-3.18). The coexistence of hyperuricemia, Ow/Ob and HDL of risk predict up to 70% 
the present of GFR> 90 or proteinuria. Fig 1
Conclusions: The coexistence of hyperuricemia, Ow/Ob and HDL of risk predicts the 
presence of renal failure in young adults. Early detection of cardiometabolic risk factors 
associated with CKD and the implementation of public health programs that favor its 
modification will contribute to the reduction of the risk of progression and development 
of CKD.
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Triglycerides and Cardiovascular Disease in Patients with CKD: Results 
from the SHARP Trial
Julio A. Lamprea,1 Natalie Staplin,3 William G. Herrington,5 Richard Haynes,5 
Jonathan R. Emberson,4 Colin Baigent,5 Ian H. de Boer.2 1University of 
Washington, Seattle, WA; 2Division of Nephrology and Kidney Research 
Institute, University of Washington, Seattle, WA; 3Clinical Trial Service Unit, 
University of Oxford, Oxford, United Kingdom; 4Clinical Trial Service Unit, 
Oxford, United Kingdom; 5University of Oxford, Oxford, United Kingdom.
Background: Triglycerides (TG) may contribute to the high cardiovascular disease 
(CVD) risk of patients with chronic kidney disease (CKD). This study evaluated associations 
of TGs and other lipids with CVD in patients with CKD.
Methods: Analyses were conducted in 9,270 participants with CKD in the Study 
of Heart and Renal Protection (SHARP) including 3,023 participants on dialysis. Cox 
regression methods were used to evaluate the association of selected lipids and lipoproteins 
with incident atherosclerotic (AVE) and non-atherosclerotic vascular events (NAVE).
Results: Median TG concentrations were 1.9 mmol/L (168 mg/dl). During a median 
follow up of 4.9 years, 1406 participants experienced at least one AVE. Higher baseline TGs 
were modestly associated with AVE (hazard ratio (HR) per 1.5x higher concentration 1.07; 
95% CI 1.00-1.13) with no evidence of effect modification by kidney function (p=0.95). The 
TG to high-density lipoprotein cholesterol ratio (TG/HDL) was significantly associated with 
AVE (HR per 1.9x higher TG/HDL 1.10; 95% CI, 1.03-1.18). Significant inverse associations 
with NAVEs were found for TG (HR per 1.5x higher concentration 0.86, 0.81-0.92) 
and TG/HDL (HR per 1.9x higher ratio 0.88, 0.82-0.94).
Conclusions: High TG concentrations and TG/HDL ratio were independently 
associated with AVE. The observed inverse associations with NAVE may reflect non-
causal associations. Future studies should determine if treatments targeting TG and TG-rich 
lipoproteins decrease atherosclerotic cardiovascular risk in patients with CKD.
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Tetsuhiko Yasuno,1,2 Kosuke Masutani.2,1 1Fukuoka university, Fukuoka, Japan; 
2Fukuoka University, Fukuoka, Japan.
Background: To study the effects of diabetes mellitus on incidence and progression of 
chronic kidney disease (CKD) in general population of Japanese.
Methods: This is a retrospective cohort study using health checkup data in Iki City, 
Nagasaki Prefecture, Japan. The participants of the study included 5,554 residents aged 40 
years or older who attended health checkups twice or more over 8 years. This study consists 
of 2 sets of analyses: (1) the effects of diabetes mellitus on new-onset CKD (defined by an 
estimated glomerular filtration rate (eGFR) less than 60 mL/min or positive urinary protein) 
among 4,571 subjects who did not have CKD at the initial health checkup, and (2) the effect 
of diabetes mellitus on progression of CKD (defined as exacerbation of the GFR category or 
the proteinuria category) in 983 subjects with CKD at the initial health checkup.
Results: Over a mean follow-up period of 4.6 years, 746 patients with new-onset CKD 
and 189 patients with CKD progression were confirmed. The incidence of CKD (per 1,000 
person-years) in individuals with diabetes mellitus was 55.1%, which was higher than those 
without diabetes mellitus (33.9%). This correlation was significant (multivariate adjustment 
[hazard ratio (HR)] 1.44, 95% confidence interval [CI] 1.13-1.84) even after adjusting for the 
effects of other risk factors. The population attributable fraction was 3%. Similarly, the risk 
of CKD progression was also significantly higher in individuals with diabetes mellitus than 
in those without (HR 2.24, CI 1.57-3.19), and the population attributable fraction was 13%.
Conclusions: Diabetes mellitus is a significant risk factor for both new-onset CKD 
and CKD progression in general population of Japanese. Approximately one-sixth of CKD 
progression was likely to be attributable to diabetes mellitus.
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Renal Function Is Preserved During Ketoanalogue Supplementation but 
Declines After Supplementation Is Withdrawn - A Follow-Up of Random-
ized Clinical Trial
Anita Saxena,1 Amit Gupta.2 1Sanjay Gandhi Post Graduate Institute of Medical 
Sciences, Lucknow, India; 2Department of Nephrology, Lucknow, India.
Background: We reported preservation of renal function and nutritional status in 
patients who were noncompliant to vLPD supplemented by ketoanalogues. The aim of the 
study was to evaluate i) if very low protein diet (vLPD) given along with ketoanalogue 
in CKD patients retards progression of CKD based on GFR. and ii) is the renal function 
maintained after withdrawing ketoanalogue supplementation.
Methods: 40 CKD patients were randomized into two groups: Group 1 (Intervention) 
patients were supplemented with 6 tablets of ketoanalogue for 10 months. Patients 
were advised very low protein diet 0.4 g/kg/day. Group 2 (Control) patients were given 
conservative treatment with 0.6 g/kg/d protein restriction. Dietary assessment was done at 
visit 1 and at visit 2 (10 months), Nutritional Assessment was evaliated with SGA score. 
GFR and serum albumin were evaluated at baseline and at 10 months. After 10 months 
ketoanalogue supplementation was stopped. and patients were followed up for two years.
Results: At baseline, the GFR was higher in controls (51.14±15.1 ml/minute). compared 
to intervention group (47.79±13.2 ml/minute). GFR declined in the control group from 
51.14 ml/min at baseline to 35.5±7.94 ml/minute after 10 months. In intervention group 
the GFR remained stable at 47.79±13.2 ml/minute. The serum albumin level decreased 
from 3.8±0.90 g/dL to 3.09±0.38 g d/l in control group, while the levels were maintained 
at 4.11±0.43 in intervention group. In ketoanalogue group decline in GFR was 3.5 ml/min 
in 10 months while in the control group decline in GFR was 16 ml/minute in 10 months. 
In ketoanalogue group patients did not comply to low protein diet, in stead they consumed 
normal protein diet 0.62±0.24 g/kg/d. After 10 months ketoanalogue supplementation 
was stopped and patients were followed up for two years. Gradual decline in GFR from 
47.79±13.2 ml/minute to 28.0 ml/minute and in serum albumin (declined) from 4.11±0.43 
to 3.6 g/dL was observed. Serum creatinine decreased from 1.61±0.52 to 1.40±0.52 during 
ketoanalogue supplementation and increased to 2.2 mg% after stopping ketoanalgue within 
2 years. There was no change in the dietary pattern.
Conclusions: Ketoanalogue supplementation is an effective way of preserving renal 
function and nutritional status. without adherence to vLPD.
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The Approach of Non-Nephrologist Medical Practitioners to Abnormal 
Urinalysis and Kidney Function Test
Faheem M. Ahmed,1 Mahdi Y. Alzamanan,2 Abdullah S. Alyami,2 
Mesale A. Algshanen,2 Ali A. Alnajrani,3 Mohammed D. Alzamanan.2 Kidney 
diseases research group, Najran 1Nephrology department, King Khalid Hospital 
Nanjran, Najran, Saudi Arabia; 2Najran University, Najran, Saudi Arabia; 
3Najran university, Najran, Saudi Arabia.
Background: Chronic kidney disease (CKD) is a devastating medical condition with 
a negative impact on the individual patient and the whole community. Primary screening 
for the high-risk group of patients is a crucial issue for early intervention and mitigation the 
progression of disease or at least minimization its complications. The aim of our study to 
evaluate the knowledge, attitude, and practice for non-nephrologist medical practitioners to 
abnormal renal function test.
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Methods: A cross-sectional, KAP study conducted among the medical practitioners 
who are working in Najran city. A structured, self- administered questionnaire which 
consists of 20 items has been distributed to the targeted population.
Results: The total number of responders is193. Around 80% of them routinely screen 
the high-risk patients for CKD. Regarding the approach to abnormal active urine sediments, 
a 25% of responders are preferred to consult the nephrologist, while the remaining are either 
prefer to repeat the test or to do further investigations. Regarding high serum creatinine, a 
38% of them used to directly referred such patient to nephrologist while the others either 
they used to repeat the test or doing further investigations including imaging. Surprisingly, 
only 26% of the responder only used to calculate glomerular filtration rate (GFR) and most 
of them are not aware of the new equations for eGFR.
Conclusions: Most of the non-nephrologist medical practitioners are aware of CKD 
diagnosis, most of them they are aware when and whom to refer to a nephrologist. They 
need more orientation for interpretation of abnormal urinalysis and the proper way for 
calculation of eGFR.
Approach to abnormal urinalysis
RBCs = red blood cells, WBCs = white blood cells
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The Importance of a Multifaceted Care Approach for CKD
Takahiro Kuragano, Takeshi Nakanishi. Hyogo College of Mediicne, 
Nishinomiya, Japan.
Background: It is well known that chronic kidney disease (CKD) patients have several 
comorbidities such as anemia, hypertension, hyperuricemia, and CKD-MBD. To prevent 
the progression of CKD or adverse events in these patients, multifaceted care approaches 
by nephrologists are needed. In this study, we evaluated the effect of a multifaceted care 
approach by nephrologists on the progression of CKD.
Methods: The study was an observational study in a single center for a period of 3 years. 
In 88 patients with various stages of CKD (not HD) who were treated by nephrologists, 
blood levels of Hb, ferritin, iron, total iron-binding capacity (TIBC), and albumin were 
measured every 3 months, and high sensitive C reactive protein (hsCRP), β2microglbulin 
(MG), and intact-parathyroid hormone (iPTH), in addition to urinary sodium, potassium, 
calcium, phosphorus protein, and β2MG levels, were measured every 6 months. All patients 
were treated according to the clinical practice guideline for CKD (Japanese Society of 
Nephrology 2013).
Results: (Progression of renal dysfunction) In multiple regression analysis, baseline 
blood level of Hb (β=0.5, P<0.001), int-PTH (β=-0.33, P=0.001), vitamin D 125 (β=0.26, 
P=0.006), urinary phosphorus (β=0.33, P=0.001), urinary β2MG (β=-0.23, P=0.03) and 
urinary protein (β=0.28, P=0.02) were selected as predictors of estimated glomerular 
filtration rate (eGFR) or 1/ creatinine(Cr) at the end of the study. (Progression of renal 
anemia) Although there was no significant correlation among Hb level, serum ferritin and 
TSAT, serum phosphorus level (β=-0.24, P=0.03) and urinary logβ2MG (β=0.25, P=0.02) 
were selected as predictors of future Hb levels. (Risk factors for the initiation of RRT and 
adverse events) In the Cox hazard model, low calcium (HR: 0.37, P=0.03), high phosphate 
(HR:5.90, P<0.001), low 125 vitamin D (HR: 0.94, P=0.01), high int-PTH (HR:1.02, 
P<0.001) level, use of a phosphate binder (HR: 4.95, P=0.01), and use of vitamin D 
(HR:3.75, P=0.01) are selected as risks for initiation of RRT.
Conclusions: In this study, we found that although phosphate binder or vitamin D 
was administered appropriately, CKD-MBD factors (phosphate, calcium, vitamin D, int-
PTH) were related with anemia progression, renal dysfunction and RRT initiation. With the 
multifaceted care approach for CKD, the focus on CKD-MBD related factors appeared to 
reduce the risk of CKD progression or RRT initiation.
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Relationship Between Sleep Duration and Kidney Function in General 
Adults: A Systematic Review and Meta-Analysis
Lin Jinwen. Kidney disease center, the first affiliated hospital, Zhejiang 
University, Hangzhou, China.
Background: The possible relationship between the duration of sleep and chronic 
kidney disease related disease are not clear. This study aimed to determine the relationship 
in general adult populatiion.
Methods: We searched MEDLINE, EMBASE, Cochrane Library from database 
inception to November 20, 2017. The studies related to sleep duration and chronic kidney 
disease in general adult population were included. Sleep duration was grouped into 3 
categories, short sleep (< 6h), reference (≥ 6h %<8h), long sleep (≥ 8h). We included studies 
which reported odds ratio (OR) comparing the risks of chronic kidney disease, proteinuria 
and renal hyperfiltration. Pooled OR and 95% confidence intervals (CI) were calculated 
using the random-effect model with Stata 12.0 software.
Results: A total of 12 studies divided into 17 substudies were analyzed in this meta-
analysis, covering 682,449 patients. Sleep duration had no significant risk of chronic kidney 
disease. There was a higher risk of proteinuria (OR = 1.38, 95% CI = 1.13 – 1.67) in short 
sleep group, while renal hyperfiltration (OR = 1.04,95% CI = 0.93 – 1.18) not. Long 
duration sleep had a higher risk of proteinuria (OR = 1.35, 95% CI = 1.17 – 1.54) and renal 
hyperfiltration (OR = 1.08, 95% CI = 1.01 – 1.15).
Conclusions: Though there was no significant association between sleep duration and 
chronic kidney disease, we suggested a potential association of proteinuria in both long 
and short sleep duration group, while not being with renal hyperfiltration. Objective sleep 
measurements and more cohort studies should be considered in future epidemiological 
studies.
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Validation of Self-Reported Race in a Provincial Renal Administrative 
Database
Aiza Waheed,1 Ognjenka Djurdjev,2 James Dong,2 Jagbir Gill,1,2 Sean Barbour.1,2 
1University of British Columbia, Vancouver, BC, Canada; 2BC Renal Agency, 
Vancouver, BC, Canada.
Background: Administrative data is commonly used to study clinical outcomes in 
renal disease. Race is an important determinant of renal outcomes but is not validated 
in most administrative data, and the correlation with census-based definitions of race 
is unknown. We validated self-reported race (SRR) in a Canadian provincial renal 
administrative database (PROMIS) from British Columbia using a prospective patient 
survey and compared it to the Canadian census categories of race.
Methods: This is a cross sectional telephone survey of a random sample of all adults 
in PROMIS conducted from 02/2016 to 11/2016. Responders selected a race category 
from PROMIS and from the Canadian census. Sensitivity (Sn) and specificity (Sp) were 
calculated with 95% confidence intervals (CI).
Results: 21,039 patients met inclusion criteria, 1,677 were selected for the survey and 
637 participated (38% response rate). There were no differences between the PROMIS, 
sampled and responder populations. PROMIS SRR had an accuracy of 95.3% (CI 94.2-
97.0%) when validated against the survey SRR with Sn and Sp ≥90% in all race groups 
except in Aboriginals (Sn 87.5%). The positive and negative predictive values were ≥95%, 
except in very low and high prevalence groups, respectively. The Canadian census had an 
accuracy of 95.7% (CI 94.4-97.6%) when validated against PROMIS SRR with Sn and Sp 
≥90%. The results did not differ in subgroups based on age, sex, birth outside Canada, or
renal group (glomerulonephritis, chronic kidney disease, hemodialysis, peritoneal dialysis, 
transplant recipients or live donors).
Conclusions: We have shown high accuracy of PROMIS SRR that validates its use in 
the secondary analysis of administrative data for research. There is high correlation between 
PROMIS and census race categories which allows linkage with other data sources that use 
census-based definitions of race.
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Accuracy of PROMIS SRR and census race categories with 95%CI, overall and for 
individual subgroups
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CKD Monitoring in Routine Clinical Practice: An Analysis of a National 
Laboratory Database
Jennifer L. Ennis,1 Dajie Luo,2 Barbara S. Gillespie.3 1Laboratory Corporation 
of America Holdings, Chicago, IL; 2Laboratory Corporation of America® 
Holdings, Durham, NC; 3Covance CRO; University of North Carolina, Cary, 
NC.
Background: Published guidelines for chronic kidney disease (CKD) have existed 
for many years, but guideline implementation remains inconsistent in clinical practice. We 
evaluated the frequency of guideline-based CKD monitoring for patients with laboratory 
evidence of CKD in a data set from a national laboratory.
Methods: We identified all patients who had at least 2 eGFR results below 60 ml/
min/1.73m2 at least 3 months apart based on serum creatinine testing performed at a 
LabCorp facility between November 2011 and April 2018. We then analyzed whether 
certain guideline-recommended tests (urine albumin/creatinine ratio (UACR), serum 
phosphorus (P), plasma parathyroid hormone (PTH), and LDL cholesterol (LDL-C)) were 
performed a) within 1 year of or b) at any time after the first qualifying eGFR result.
Results: Among the 4,909,840 patients who met criteria for the study, 58.2% were 
women. Mean age was 71.2 ± 12.0 years. Median follow-up was 25.7 (IQR=12.2 – 45.8) 
months. The percentage of patients in stage 3a, 3b, 4, and 5 based on the initial eGFR result 
were 70.3%, 21.9%, 6.3%, and 1.5%, respectively. At 1 year, rates of testing for UACR, 
PTH, and P were 24.4%, 11.8%, and 16.9%, respectively. Any time testing rates were only 
slightly higher: 35.4% (UACR), 20.5% (PTH), and 25.3% (P). However, rates of LDL-C 
testing at 1 year (75.5%) and any time (84.4%) were much higher, indicating that other 
routine testing was being performed on these patients.
Conclusions: Despite guideline recommendations, routine laboratory testing for CKD 
and its comorbidities remains low in US clinical practices. This data highlights the need for 
further strategies to improve CKD evaluation and management.
PUB112 
Publication-Only 
Predicting the Progression of CKD to Kidney Failure in a Southeastern 
US Population
Jennifer C. Gander,2 Lee Cromwell,2 Musu M. Sesay,2 Adam S. Wilk,4 
Teaniese L. Davis,5 Joseph P. Austin,1 Rachel E. Patzer,6 Nirvan Mukerji.3 
1Kaiser Permanente, Atlanta, GA; 2Kaiser Permanente of Georgia Center for 
Research and Evaluation, Atlanta, GA; 3Kaiser Permanente Georgia, Atlanta, 
GA; 4Rollins School of Public Health, Emory University, Atlanta, GA; 5Kaiser 
Permanente Georgia, Center for Research and Evaluation, Atlanta, GA; 6Emory 
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Background: There are >100,000 adults transitioning from chronic kidney disease 
(CKD) and end stage renal disease (ESRD) with a geographic disparity of ESRD incidence 
in the Southeastern U.S. We aimed to determine the risk factors associated with progressing 
from CKD to ESRD in a Southeastern population.
Methods: Adult (18<age<100) CKD Stage 3-5 patients of a large, Southeastern 
integrated healthcare system (2010-2017) were included in the cohort. CKD and ESRD 
were defined using diagnosis codes. Risk factors were collected at the time of CKD 
diagnosis. Descriptive statistics and Cox proportional hazard models were completed to 
determine the association and predictive power of the risk factors.
Results: Among 3,399 patients, 442 (13%) started dialysis with average age was 58, 
60.4% were male, 71% Black, and the average estimated glomerular filtration rate was 31.0 
per 5 mL/min/1.73m2. Among those with ESRD, the average time between CKD and ESRD 
was 1.6 years, with Blacks having a significantly longer time (2.4±2.1) vs Whites (1.8±1.5) 
(p=0.01). In the fully adjusted model 4, Blacks (vs White), and patients with hypertension 
were 2.3 (HR=2.3; 95% CI 1.8, 3.0), and 2.5 (HR=2.5; 95% CI 1.2, 5.3) times more likely 
to transition to ESRD, respectively. Model adjustment improved predictive power and 
Goodness of Fit, with model 4 (c-statistic=0.8515). The area under the curve for the fully 
adjusted model remained stable around c=0.85 during follow-up time 0-6 years.
Conclusions: A predictive model using clinically routine variables can predict CKD 
progression to ESRD. Healthcare systems should consider integrating predictive analytics 
in their routine clinical visits to help alert them to a patient’s increased risk for ESRD to 
enable timely intervention.
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Retrospective Observation of the Prevalence of Proteinuria in a Newly-Di-
agnosed HCV Population
Emily Levine,1 Chelsey Fix,3 Crystal A. Gadegbeku.2 1Temple University 
Hospital, Philadelphia, PA; 2Temple University, Philadelphia, PA; 3NephCure 
Kidney International, King of Prussia, PA.
Background: In response to a growing Hepatitis C (HCV) epidemic, many states 
are mandating screening programs for high risk populations to facilitate HCV treatment. 
Despite the well-recognized risk of chronic kidney disease (CKD) in patients with HCV, 
currently there are no guidelines for CKD screening. Given Pennsylvania’s new mandate for 
HCV screening and CKD risk, we assessed the prevalence of dipstick positive proteinuria in 
newly-diagnosed HCV positive patients without history of CKD. The goal of this study was 
to explore the potential for early-detection of CKD in this high risk population.
Methods: A cross-sectional retrospective analysis was performed using data collected 
from electronic medical records of patients who were screened, diagnosed, and/or treated for 
HCV at Temple University Hospital, an urban tertiary care center in North Philadelphia in 
2017. For identification of possible early-stage CKD, this analysis reviewed the availability 
and results of urine protein assessment after HCV diagnosis in patients with eGFR>60 ml/min. 
Data collection included demographics, comorbidities, eGFR, and urinalysis. Overt 
proteinuria was defined as urine dipstick with protein >1+. Positive proteinuria findings 
were excluded in samples with diagnosis of UTI, hematuria, or glycosuria.
Results: Of the 637 patients identified as HCV-positive, 498 had eGFR > 60 ml/min. 
The mean age was 52.4 ± 13.1 and 67.7% were male. Urinalysis was obtained in 199 
patients (39.9%). Eighteen urine samples were excluded from qualitative analysis. Overall, 
34 of 181 patients (18.8%) had overt proteinuria. Of these 34 patients, one was evaluated 
for proteinuria by a nephrologist within the Temple Health System.
Conclusions: Proteinuria is an early marker of CKD and its detection within high-risk 
populations may be beneficial. Our findings indicate a minority of HCV positive patients 
had urine evaluation after HCV diagnosis. The prevalence of overt proteinuria in our 
study was higher than reported in the general US population in NHANES (18.8% vs 1.3% 
respectively). Nephrology referral was infrequent. Although there are some limitations, 
these preliminary findings highlight the need for further investigation of CKD screening 
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in various high risk populations. Further prospective studies are needed to validate these 
results and outcomes of early detection.
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The Effect of CKD Risk Factor Scorecard Intervention Among Patients 
with Non-Dialysis CKD
Suyuan Peng,1,2 Liwei Wang,1 Yue Yu,1 Xusheng Liu,3 Hongfang Liu.1 
Accelerating Digital Medicine Empowered by Value-added NLP for Clinical 
Excellence(ADVANCE) 1Health Science Research, Mayo Clinic, Rochester, 
MN; 2The second Clinical College, Guangzhou University of Chinese Medicine, 
Guangzhou, China; 3The Second Affiliated Hospital, Guangzhou University of 
Chinese Medicine, Guanghzou, China.
Background: Long-term management of chronic kidney disease (CKD) requires high-
level patient involvement. Mayo Clinic developed a scorecard that contains 12 items of 
CKD risk factors to improve self-management skills for the purpose of reducing risk factors 
and slowing the progression of CKD. In this study we aim to compare the prognosis of 
patients of CKD3 with and without CKD Risk Factor intervention.
Methods: A single-center retrospective cohort study was performed using electronic 
medical records (EMR). Cases were included when patients (≥18 years) were followed 
up for at least 1 year or progressed to end-stage renal disease (ESRD) within 1 year from 
January 2009 to December 2017. Time-to-event analyses were performed with Kaplan–
Meier method, and the time progressing to the ESRD in two groups was compared using 
log-rank test.
Results: We analyzed data of 19,973 patients (553 in scorecard group). The mean age 
was 73.03±12.71 years, 54.2% were male and 2.9% were African American. Kaplan-Meier 
analysis showed that renal survival was significantly lower in scorecard group compared 
with non-scorecard group (Log-rank test, p= .000).
Conclusions: The CKD Scorecard intervention isn’t associated with progression 
reduction of kidney disease. Further studies are needed to explore the method of evaluating 
self-efficacy and the potential role of risk factors in the progression of CKD.
Funding: Government Support - Non-U.S.
CKD Risk Factor Scorecard
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Affective Status, Disease Knowledge, and Treatment Adherence in CKD 
Mexican Patients
Aurora Calderon,1 Rosa M. Meda,1 Pablo Maggiani,1 Jonathan Chavez,1,2 
Guillermo Garcia-Garcia.2,1 1University of Guadalajara Health Sciences Center, 
Guadalajara, Mexico; 2Hospital Civil de Guadalajara FAA, Guadalajara, 
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Background: CKD is a public health concern and low adherence to treatment has 
been associated with poor health outcomes. Low adherence to treatment varies between 
20%-70%. Multidisciplinary care (MDC) could improve management and outcomes of 
patients with CKD. We evaluated the prevalence of the affective status, depression, disease 
knowledge, and treatment adherence in CKD patients attending our MDC clinic.
Methods: A cross-sectional study in a convenience, non-probabilistic sample of pre-
dialysis CKD patients, stage 3-5. Individuals were interviewed by psychologist with no 
time limitation. Measures: KiKS and PSS, Spanish versions; Adherence Scale for Chronic 
Patient Based on Explicit Behaviors; PANAS; Personality Inventory for DSM-5 (PID-5)-
Adult, Depression and Anxiety Subscales.
Results: Table 1, Fig 1
Conclusions: Our results showed that a coordinated MDC can improve management 
and quality of care in patients with CKD, as demonstrated by the high levels of positive 
affect, disease knowledge, self-efficacy, and treatment adherence found in our study. Further 
research is needed to evaluate the program component effectiveness in CKD progression 
and management.
Results
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Risk Factors for CKD Progression to ESRD: Experience on 15 Years 
Follow-up in the Multidisciplinary CKD Clinic
Pantipa Tonsawan, Kittrawee Kritmetapak, Chitranon Chan-on, Eakalak 
Lukkanalikitkul, Cholatip Pongsakul, Dhavee Sirivongs, Sirirat Anutrakulchai. 
Khon Kaen University, Khon Kaen, Thailand.
Background: Chronic kidney disease (CKD) is a significantly worldwide health 
problem. Risk of CKD progression under holistic approach in developing countries 
are scarcely studies. Our aim was to investigate risk factors for chronic kidney disease 
progression to end-stage renal disease (ESRD) with dialysis in the multidisciplinary CKD 
clinic.
Methods: The retrospective cohort study was conducted in the CKD clinic at 
Srinagarind, A University Hospital in Thailand during January 1, 2000, to December 
31, 2015. Our CKD clinic has been established for 15 years with multidisciplinary and 
holistic cares that include a nephrologist, nurse educator, dietician, pharmacist and physical 
therapist. The adult CKD patients who followed up at least 6 months were recruited. The 
medical and laboratories data every 6 months were recorded.
Results: Of 506 CKD patients were recruited, the mean age was 65.2 ± 13.5 years 
and mean follow up time was 41.5 ± 34.8 months. The majority CKD stage that physician 
refer to the specialist was CKD stage 4. The incidence rate of dialysis was 5/1000 patient-
months. The overall renal survival rate in CKD clinic at 50 and 100 months were 75, 50 %, 
respectively. The overall mean slope of the estimated glomerular filtration rate decline 
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was -2.67 mL/min/1.73m2 in the first year of follow-up. The results of multivariate Cox 
regression model showed that age > 55 year (hazard ratio[HR] 0.46, 95% confidence 
interval[CI] 0.30-0.72), diabetes (HR 1.56, 95%CI 1.04-2.33), hypertension (HR, 4.00, 
95%CI 1.44-11.0), renal cancer (HR 2.67, 95%CI 1.13-6.30), CKD stage 4 (HR 15.95, 
95% CI 2.17-117.2), and CKD stage 5 (HR 93.67, 95%CI 12.5-700.1) were independent 
association risk factors for ESRD with dialysis.
Conclusions: This study demonstrated that diabetes, hypertension, and referral to 
nephrologist with advanced CKD stage are independent predictors of dialysis-dependent 
ESRD.
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Culinary Techniques to Improve Education in Legume and Vegetable 
Consumption in CKD Patients
Secundino Cigarran,1 Iria Acal,2 Ana maria Sanjurjo amado,1 Juan Latorre,4 
Nicolas Menendez,1 Belen Rodriguez delgado,1 Lourdes Vázquez-Odériz,3 M? 
Angeles Romero-Rodríguez.2 1Nephrology Service. Hospital Da Costa, Burela, 
Spain; 2University of Santiago de Compostela, Lugo, Spain; 3University, Lugo, 
Spain; 4Hospital Da Costa, Burela, Spain.
Background: Good nutrition is relevant in for CKD pts. Legumes and vegetables 
by P & K content are restricted in CKD pts. Guidelines on Nutrition do not include 
recommendations on culinary techniques. The aim was to assess the influence of culinary 
techniques on removal P and K in legumes and vegetables and to assess the nutrients in 
manufactured as well.
Methods: Legumes (lentils, beans, chickpeas) obtained at supermarket and dried 
packaged in 1000 g packs. Likewise, legumes are obtained in glass jars that are cooked 
and conservate with water enriched with salt. Collard greens and chards (rawl and frozen) 
were obtained as well. Determination of humidity and ashes were performed accordance 
to method 934.01 AOAC (2012) (George and Latimer, 2012). Mineral assessments were 
performed by Optical Emission Spectrometer with Coupled Plasma (ICP-OES Optima 
4000 DV by Perkin Elmer. The ashes of each samples were dissolved in 4 mL of a solution 
of 3 M HCl + 21 mL distilled water for the analysis of Zn, Fe, Ca, P, Mg, Na and K. 
Legumes were analized in raw, after soaking (12 hrs) and after soaking followed by boiling. 
Vegetables were included in 4 groups to analyze: the fresh product, after to be subjected to 
direct cooking, after being subjected to boil previous blanch and after being frozen with 
a prevoius blanching and then applying a boiled. Elements Na, K, Ca, Mg, Fe, Zn were 
measured after each and compared with fresh.
Results: Legumes: all techniques reduced P & K content respect to raw, being 12 hrs 
soaking plus boiling more efficient reducing up to 76.2%, keeping levels < 100 mg/100 mg 
fresh sample, and manufactured as well. Vegetables: all techniques reduced K content 
respect to raw. The more favourable techniques were blanching+boiling (82%), frozen 
(81%) and frozen manufactured (82%). All of them showed a K level <10 mg/ 100 mg 
fresh sample.
Conclusions: Industrial legumes; combining 12-hours-soaking and boiling reduced up 
to 70% of P & K content. Vegetables reduced K content in both in industrial frozen and 
fresh managed with all culinary techniques. Healthy culinary techniques should be included 
in the nutritional education programs for CKD pts. Legumes & vegetables provide fiber, 
vitamins of group B and are a good source of protein of vegetable origin.
Funding: Other NIH Support - University of Santiago de Compostela. Departamento 
de Dietetica y Nutrición Humana
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1Boston University School of Public Health, Boston, MA; 2Visiting Scholar, 
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Background: Chronic kidney disease of non-traditional etiology (CKDnt) affects 
populations without traditional risk factors for chronic kidney disease (CKD). In Central 
America CKDnt affects primarily young working men, reaching epidemic proportions. 
Incidence in the United States has not been characterized.
Methods: We conducted a retrospective analysis of claims and electronic health record 
(EHR) data from the OptumLabs® Data Warehouse which includes de-identified claims 
data for privately insured and Medicare Advantage enrollees in a large, private, U.S. health 
plan, and de-identified EHR data from a nationwide network of provider groups. Our 
case definition of CKDnt was CKD with no prior documented diagnosis of 22 conditions 
known to cause CKD (e.g., nephropathies, diabetes, heart disease, autoimmune disease and 
malignancies). By definition, traditional CKD cases had prior diagnoses of these conditions. 
CKD cases with prior diagnosis of hypertension (a cause and consequence of kidney 
disease) were excluded from analyses. We used nonparametric regression to estimate annual 
incidence of CKD and CKDnt in claims data, examining differences by sex, age, race/
ethnicity and geographic region. We examined new cases in EHR data, and differences by 
the same risk factors and insurance type.
Results: Seven percent of CKD cases with a year of continuous enrollment in claims 
were CKDnt. Incidence rates of CKD and CKDnt in claims data increased from 2000-
2015 in all age groups with the exception of <18 years. CKD rates increased with age 
category, although were equal among the age 18-39 and 40-59 groups. In contrast, CKDnt 
rates were significantly higher in the 40-59 age group compared with all other age groups. 
This difference was driven by male cases. Compared to traditional CKD, CKDnt cases <60 
years were 29% more likely to have advanced disease at initial diagnosis (RR=1.29; 95% 
CI 1.23-1.35). New CKD and CKDnt cases in EHR were more likely to be male and have 
Medicare compared to all other types of insurance.
Conclusions: Our results are the first to characterize increasing CKD incidence rates 
by age in the US, highlighting that CKD with no known risk factors may disproportionately 
affect men of younger ages.
Funding: Private Foundation Support
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Albuminuria in Patients with the Metabolic Syndrome Using Machine 
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Background: C-reactive protein (CRP), an inflammatory marker, is associated with 
the metabolic syndrome (MetS) and chronic kidney disease. We previously showed that 
CRP mediated the association between microalbuminuria (MA) and MetS components by 
race/ethnicity. However, little is known about the effect of CRP on the predictive value 
of albuminuria in MetS patients, by race. In this study, we used a machine learning (ML) 
strategy to determine the extent to which the addition of CRP impacts the performance of 
predictive models among racial/ethnic groups.
Methods: We analyzed National Health and Nutrition Examination Surveys data 
(1999-2010) for adults (aged ≥20 years) with the MetS (N=5700). We created ML models 
using a comprehensive cloud-based platform (Microsoft Azure), which allowed us to 
build a variety of ML applications for testing and prototyping different models as well as 
integrating R, a programming language for statistical computing for data preprocessing and 
feature engineering. We created a boosted tree regression and performed random sweep 
parameter optimization. Regression models were created for each of the racial/ethnic 
subgroups both including and excluding CRP as a parameter, and the change in coefficient 
of determination (R2) was calculated, which represents the total proportion of variance 
accounted for by the predictive model.
Results: The coefficient of determination (R2) was 0.081, 0.154 and 0.113 in African 
Americans (AAs) Hispanics and Whites, respectively. The R2 was most highly increased 
in AAs (0.119, 47%) followed by Hispanics (0.163, 5%) and Whites (0.119, 5%) with the 
addition of CRP to the models.
Conclusions: The data shows that the effectiveness of CRP to predict albumin 
concentration is greatest for AAs compared to Hispanics and or whites. This suggests that 
targeting CRP may be a feasible strategy to manage albuminuria in AAs. ML is a useful tool 
to support epidemiologic research and clinical management decisions.
Funding: Other NIH Support - NIMHD
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3University of Manitoba, Winnipeg, MB, Canada; 4University of Otago, 
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Background: People with chronic kidney disease (CKD) have identified the impact of 
lifestyle interventions such as exercise as a research priority. We investigated nephrologists’ 
practice patterns and research perspectives with respect to exercise in CKD patients.
Methods: A 19-item electronic survey regarding exercise-related practice patterns 
and resources was administered to practicing nephrologists with publicly available email 
addresses in Canada (n=354), practicing nephrologists in Australia and New Zealand and to 
the members of the Australian and New Zealand Society of Nephrology (n=598).
Results: 198 nephrologists (21% response) completed the survey; 63% were 35 to 50 
years old, 57% practiced in Canada, and 67% were men. Overall, 60% thought that exercise 
counseling was within a nephrologist’s role. The most frequently reported barrier for exercise 
programs was lack of funding. On average, 96% agreed that regular exercise provides “health 
benefits” for all CKD stages and 71% reported “frequently” or “always” counseling patients 
on exercise. 38% respondents agreed that sufficient evidence exists to support regular 
exercise prescription for CKD patients. In a multivariate model, agreement with a sufficient 
evidence base for exercise in CKD and personal physical activity were not associated 
with exercise counseling practices. Female respondents (OR 2.31; 95% CI 1.16-4.58) 
and older respondents (OR 1.94; 95% CI 1.15-3.26) were more likely to offer exercise 
counseling. Exercise impact on patient-reported outcomes (quality of life [QoL] [28%], 
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symptoms [26%], and mental health [25%]) followed by cardiovascular parameters (18%) 
and CKD progression (16%) were identified as important outcomes for future research.
Conclusions: Most nephrologists consider exercise counseling as a component of their 
practice and consider that exercise offers patients improved health. Lack of funding for 
exercise programs is perceived as the principal barrier to implementation. Nephrologists 
identify core patient-centred outcomes as central to the future research agenda.
Funding: Clinical Revenue Support
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Socioeconomic Status and Geographic Factors May Be Related to Lower 
Renal Biopsy Rate and Higher ESKD Events: A Retrospective Study in 
Chiba Prefecture, Japan
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Background: It is important to grasp the prevalence of kidney disease when we 
discuss about health policies in living area. Previous studies have reported that there are 
regional variations in the incidence of biopsy-proven kidney disease and end stage kidney 
disease even in small region. However, it is unclear whether those variations are associated 
with socioeconomic status or geographic factors. The aim of this study is to examine the 
relationships between regional backgrounds and incidence of kidney diseases at Chiba 
prefecture in Japan, with a population of six million.
Methods: We collected clinical data on renal biopsies performed between Apr.2014 
and Mar.2016 at seven main hospitals in Chiba prefecture. We divided the prefecture into 
nine medical areas, and calculated biopsy rates in each area using regional statistical data 
from government’s open data site. The biopsy rates were age-adjusted by using data from 
Japan Renal Biopsy Registry. Spearman’s rank correlation coefficient was used to estimate 
associations between biopsy rate and regional backgrounds.
Results: A total of 910 cases were enrolled. The patients were mean age of 57 years 
and 56% of patients were male. There were different renal biopsy rates (19.9 ± 10.6 /100000 
population) and disease variations in nine different area. No association was found between 
the number of nephrologist or health check-up participation rates and renal biopsy rates. 
But average incomes and numbers of hospitals in districts have correlations. (ρ=-0.87; 
p= 0.005, ρ=0.92; p=0.001)
Conclusions: Low-income regions had more renal biopsy than high income-regions, 
and the number of hospitals in areas was related to renal biopsy rates. It suggests that 
there may be some relationships between standard of living and onset of diseases, and 
that medical environment may affect chance to receive accurate diagnosis. Further studies 
are needed to verify those actual associations with regional backgrounds and incidence of 
kidney diseases.
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Individuals with Unrecognized CKD Can Be Identified and Referred into 
Care by a Workplace Wellness Program
Olga A. Iakoubova, Andre Arellano, Carmen H. Tong, Lance A. Bare, 
James J. Devlin, Charles E. Birse. Quest Diagnostics, San Juan Capistrano, CA.
Background: Of the 30 million Americans who have chronic kidney disease (CKD), 
85 percent are unaware of their disease. Once recognized, lifestyle changes and medical 
therapy can slow CKD progression. A workplace wellness program was modified with 
the aim of improving the recognition of CKD and referral into physician care. We asked 
whether this modified program improved management of individuals with previously 
unrecognized CKD.
Methods: An ongoing workplace wellness screening program provides annual 
estimated glomerular filtration rate (eGFR) results. Those individuals (n=402) who had an 
eGFR <60 mL/min/1.73 m2 in 2016 were invited to participate in the CKD program. All 
402 received a confirmatory eGFR test during the 2017 wellness screening program. Those 
who agreed to participate in the CKD program also received a urine albumin test and were 
offered a telephone consultation with a program physician to discuss their test results and 
referral into physician care. Using a limited data set of health plan claims, we compared 
the proportion of physician visits between participants and non-participants using a logistic 
regression model that adjusted for age, sex and education level.
Results: Of the individuals eligible for the CKD program, 51 percent (205/402) agreed 
to participate. CKD was confirmed in 51 percent (105/205) of the participants, either by 
repeat eGFR <60 mL/min/1.73 m2 or by urine albumin to creatinine ratio (ACR) ≥30 mg/g. 
The comparison group consisted of the 88 of the 402 individuals who had not accepted 
the invitation to participate and who had an eGFR result <60 mL/min/1.73 m2 in the 2017 
screening program. In the 3 months following confirmatory CKD testing, 2 participants 
visited a nephrologist, but no non-participants did. Because of the program, one participant 
with low eGFR levels (eGFR=10 mL/min/1.73 m2 in 2016; eGFR=3 mL/min/1.73 m2 in 
2017) initiated kidney dialysis. The proportion of participants who visited a physician 
was about 2-fold greater than non-participants (21% vs. 10%): OR 2.3, 95% CI 1.0-5.4, 
p=0.047; this difference was not appreciably changed after adjustment for age, sex, and 
education level.
Conclusions: A workplace CKD outreach program can identify individuals who will 
benefit from a timely referral into physician care.
Funding: Commercial Support - Quest diagnostics: the CKD program was a part of 
the work-place wellness screening offered by Quest Diagnostics to it's employees at no cost
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Evaluation and Intervention of Barriers to Behavioral Modification in 
Avoiding NSAID Use for Pain Among Underserved Patients with CKD
Romela Petrosyan. Greenville Health System, Greenville, SC.
Background: The negative consequences of non-steroidal anti-inflammatory drugs 
(NSAIDs) use in patients with Chronic Kidney Disease have been long established in 
medicine and the American Society of Nephrology urges providers to encourage patients 
with kidney disease to avoid NSAIDs. Multiple studies have shown that use of NSAIDs 
progressively worsens renal function in patients with CKD. A large cohort study has 
demonstrated that this is still an aspect that requires further intervention and that disease 
awareness has not been associated directly with the proportion of patients using NSAIDs. 
Even recovery from acute kidney injury seems to be insignificant in affecting decision to 
avoid NSAIDs in patients who are vulnerable to developing CKD and patient-physician 
rapport plays an important role in reducing use of NSAIDs. The patient-physician 
relationship appears to have an important role in facilitating replacement of NSAIDs with 
other renally-friendly medications. It is not solely recognition and awareness of CKD that 
drives healthy behaviors and a better understanding of barriers to adaptation of healthy 
actions is necessary to identify the significant targets for intervention.
Methods: We select underserved patients who receive their care at the resident-led 
Internal Medicine Clinic in Greenville, SC with various stages of CKD and survey patient 
knowledge regarding pain as well as their perceptions and attitudes toward selecting 
medications, specifically NSAIDs to address pain. Patients are then provided with 
individualized interventional counseling targeting their original motifs for NSAID use and 
barriers to avoiding NSAIDs. Following intervention, patients are given a post-survey with 
the same attitude and perception questions to evaluate for change in understanding and 
behavior in use of NSAIDs.
Results: Per preliminary and observational evaluation, NSAID use among underserved 
patients with CKD appears to be driven by ease of access of these medications and a 
symptom-centered rather than co-morbidity vigilant approach to addressing pain. This 
study is currently accumulating further data and post-survey results following interventional 
interviewing is not yet available.
Conclusions: Identifying factors that drive individual behavior of using NSAIDs is 
significant in developing appropriate intervention to affect patient behavior.
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Annual Estimated GFR Decline in Japanese Patients with CKD G3b-5: A 
Result from a Japanese Nationwide Cohort Study for Patients with 
Advanced CKD: The Reach-J Study
Junichi Hoshino,1 Kei Nagai,2 Ryouya Tsunoda,2 Hirayasu Kai,2 Reiko Okubo,2 
Chie Saito,2 Masahide Kondo,2 Hirokazu Okada,3 Ichiei Narita,7 Takashi Wada,4 
Naoki Kashihara,5 Bruce M. Robinson,6 Kunihiro Yamagata.2 The Reach-J 
1Toranomon Hospital, Tokyo, Japan; 2University of Tsukuba, Tsukuba-city, Japan; 
3Saitama Medical University, Saitama, Japan; 4Kanazawa University, Ishikawa, 
Japan; 5Kawasaki Medical School, Kurashiki City, Japan; 6Arbor Research 
Collaborative for Health, Ann Arbor, MI; 7Niigata University, Niigata, Japan.
Background: CKD progression in Japanese patients with advanced chronic kidney 
disease (CKD)—an estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2—has 
remained largely unexamined.
Methods: We conducted a nationwide cohort study of Japanese patients with advanced 
CKD. We recruited 2,249 advanced CKD patients (eGFR<45/ml/min/1.73m2) receiving 
nephrologist care from a national sample of 31 facilities throughout Japan, randomly 
selected with stratification by region and facility size, aligned with the international CKD 
Outcomes and Practice Patterns Study (CKDopps). From baseline data, we calculated 
annual eGFR declines by CKD stage and causes of CKD over 4 years before enrollment.
Results: Of 1903 eligible patients with eGFR data before enrollment, their mean(±SD) 
median (IQR) annual eGFR declines were -2.49±4.20 and -2.00 (-3.96, -0.40) ml/
min/1.73m2. The reported causes of CKD were 474 had diabetic nephropathy(DN), 269 
had CGN, 507 had nephrosclerosis, 110 had PKD, and 543 had other renal diseases. Their 
median (IQR) annual eGFR decline were: DN, -2.73(-5.46, -0.68); CGN, -2.07(-3.75, 
-0.53); nephrosclerosis, -1.57(-3.23, -0.12); PKD, -2.75(-4.35, -1.70); and others, -1.62
(-3.65, -0.24) ml/min/1.73m2, respectively. For all causes of CKD, eGFR decline was faster
with more advanced CKD. In addition, in CKDG5, eGFR declines of DM (-4.11 (-6.82,
-2.02)) and PKD (-3.90 (-5.60, -2.19) ml/min/1.73m2) were significantly faster than those of 
other groups (CGN, -2.84 (-4.85, -1.33); nephrosclerosis, -2.51 (-3.83, -1.56); others -2.08 
(-4.20, -0.84) ml/min/1.73m2).
Conclusions: Our study clarifies annual rates of eGFR decline by CKD stage and 
cause of CKD in a national sample of advanced CKD patients receiving nephrologist care. 
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Prospective data collection is ongoing to facilitate study of international practice variation 
in advanced CKD and with focus on the transition to ESKD.
Funding: Government Support - Non-U.S.
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Clinical Features of Patients with Multiple Myeloma with Renal Injury
Cheng Jun. KidneyDisease Center, The First Affiliated Hospital, 
MedicalSchoolofZhejiangUniversity, HangZhou, China.
Background: To understand the clinical features of patients with multiple myeloma 
(MM) patients with renal injury (defined as proteinuria or/and eGFR is less than 60ml/
min) for reduceing missed diagnosis and misdiagnosis.
Methods: A retrospective analysis of patients with multiple myeloma diagnosed in this 
hospital for the past 5 years in the database was performed. According to the presence or 
absence of renal injury (defined as proteinuria or/and eGFR is less than 60ml/min), divided 
into no kidney injury group and kidney injury group, comparing the two groups in gender, 
age, serum calcium, hematuria light chain and hypercalcemia. At the same time, compared 
with patients with IgA nephropathy and SLE from the database in the recent 5 years. Use 
spss software analysis.
Results: A total of 559 patients with multiple myeloma were enrolled, including 290 
males and 269 females. Of these, 343 were associated with renal impairment (defined as 
proteinuria or/and eGFR is less than 60ml/min). There was no significant difference in age 
and gender between the two groups with renal injury and no kidney injury. There were no 
significant differences in the blood globulin. The expression of M-band in renal damage 
was lower than that in the group without renal damage, but the incidence of hypercalcemia 
was higher in renal damage than that in the group without renal damage. The hemoglobin 
in the renal damage group was significantly lower than that in the no kidney damage group. 
There was no significant difference in the total blood kappa, lamda and kappa/lamda ratio 
between the two groups, but there were significant differences in the urinary kappa, lamda 
and kappa/lamda ratio between the two groups. Compared with SLE and IgA non-plasma 
cell nephropathy, the albumin ratio of urinary protein electrophoresis was less than 30% in 
MM patients with renal injury.
Conclusions: 1 There were significant differences in the urinary kappa, lamda and 
kappa/lamda ratio between renal damage and without renal damage group; Compared with 
MM without renal injury, Kidney injury group has higher incidence of high calcium and 
lower hemoglobin. The electrophoresis M band rate was lower in Kidney injury group. 
2 Compared with patients with SLE and IgA, less than 30% of the albumin ratio in urine 
protein electrophoresis, and abnormal blood kappa/lamda ratio greater than 4:1 or less than 
1:4 is an important feature of MM associated with kidney damage.
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Assessing Hyperkalemia Risk and Its Associated Clinical Sequelae: A 
Novel Risk Tool
Marc L. Evans,4 Philip McEwan,5 Oliver T. Darlington,5 Susan Grandy,2 
Eirini Palaka,3 Lei Qin.2 2Astrazeneca, Gaithersburg, MD; 3AstraZeneca, 
Cambridge, United Kingdom; 4University Hospital Llandough, Cardiff, United 
Kingdom; 5Health Economics and Outcomes Research Ltd, Cardiff, United 
Kingdom.
Background: Patients with chronic kidney disease (CKD) and heart failure (HF) 
are at greater risk of hyperkalaemia (HK). HK is associated with increased risk of death, 
major adverse cardiovascular events (MACE), hospitalisation, and discontinuation of 
renin-angiotensin-aldosterone system inhibitors (RAASi). This study aimed to develop an 
interactive tool to synthesise current evidence relating patient characteristics and serum 
potassium (K+) concentrations to clinical outcomes.
Methods: A review of studies published 1/11/2002–1/11/2017 was conducted to 
identify risk equations quantifying risk of HK and related clinical outcomes in patients 
with CKD or HF, and with or without diabetes or RAASi usage. Patient population, clinical 
outcomes and risk prediction methods were extracted from all eligible studies. The HK 
Risk Awareness and Impact Tool (RAIT) was developed in Microsoft Excel to characterise 
associations between patient characteristics and the incidence of HK and related clinical 
outcomes in CKD or HF patients.
Results: A total of 91 studies were identified, allowing for risk of HK, death, MACE, 
hospitalization and RAASi discontinuation to be characterized within the RAIT. For 
example, the RAIT shows how risk of HK increases in CKD patients with age, severity of 
renal impairment, diabetes or cardiovascular comorbidity, and RAASi use. For a 75-year old 
male CKD patient, not on RAASi and with eGFR 45mL/min/1.73m2, a 15mL/min/1.73m2 
decrease in eGFR is associated with a 65.1% increase in 1-year HK risk; RAASi use is 
associated with a further 37.5% increase in risk. Additionally, the RAIT quantifies elevated 
risk of adverse outcomes associated with HK. For the same CKD patient receiving RAASi, 
estimated 1-year risks of death, MACE, hospitalization, and RAASi discontinuation were 
3.3%, 7.5%, 13.6% and 10.4%, respectively, with HK (K+=5.5mmol/L) versus 2.1%, 6.9%, 
11.2% and 6.8% with normokalaemia (K+=4.5mmol/L); relative increases of 57.1%, 8.7%, 
21.4% and 52.9%, respectively.
Conclusions: HK imposes a significant burden to patients and healthcare providers/
payers; particularly in CKD and HF populations. The RAIT provides a basis for synthesising 
contemporary evidence to quantify the association between patient characteristics, HK and 
its clinical sequelae. Further validation of the risk scores in a RCT setting is warranted.
Funding: Commercial Support - AstraZeneca
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An New Glomerular Filtration Rate Estimating Model Using Mini-Deep 
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Xun Liu,1 Ningshan Li,2 Linsheng Lv,3 Yuqiu Ye,4 Wentao Hu.4 1The Third Affiliated 
Hospital of Sun-Yat-Sen University, Guangzhou, China; 2South China University of 
Technology, Guangzhou, China; 3The Third Affiliated Hospital of Sun Yet-sun 
University, Guangzhou, China; 4Department of Nephrology, The Third Affiliated 
Hospital of Sun Yat-sen University, Guangdong, China, Guangzhou, China.
Background: Accurate estimating glomerular flirtation rate (GFR) is crucial in clinical 
practice. The performance of GFR estimating equations has remained unimproved since 
the famous Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 
presented on NEJM in 2012.
Methods: We hypothesized that a deep neural network (DNN) may achieve better GFR 
estimating performance for its capacity in modeling complicated non-linear correlation.
Results: Here a cohort of 937 chronic kidney disease patients were assigned as the 
development dataset and additional 377 patients were enrolled as the external validation 
data set. GFR was measured by 99mTc-DTPA renal dynamic imaging and then recalibrated 
to a dual plasma sample 99mTc-DTPA GFR. New models of mini-deep fully connected 
forward neural network (mini-DNN) and revised CKD-EPI-like equations with 4 variables 
(age, sex, serum creatinine and Cystatin C) and 3 variables (sex, age and serum creatinine) 
were developed in the same time. In the external validation dataset, bias and accuracy 
of the proposed mini-DNNs were better than revised equations, especially in the case of 
4 variables mini-DNN achieved superior bias, precision, and accuracy than the 4 variables 
revised equation. This work provides insights into the advantage of representative machine 
learning strategy DNN in GFR estimating, and finally the 4-variable mini-DNN was 
deployed through a exe file. We also discussed the challenges of accurately estimating 
individuals’ GFR and potential solutions were suggested.
Conclusions: The DNN was expected to perform further better when derived from a 
larger development data set.
Funding: Government Support - Non-U.S.
Performance of the derived GFR estimating models in the external validation data set
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Reactions in Patients with CKD from the Hospital Civil De Guadalajara 
“Dr. Juan I. Menchaca” and Clinica 46 del IMSS
Jorge Andrade-Sierra,1,2 Diana M. Hernandez corona,5 Erika Cardona reynozo,5 
Leonardo Pazarin-Villaseñor,3,2 Tonatiuh Gonzalez-Heredia,4 Lydia A. Mercado,4 
Jorge fernando Topete reyes,4 Francisco G. Yanowsky-Escatell.6 1Universidad 
de Guadalajara, Cucs, Guadalajara, Jalisco Mexico, Mexico; 2Internal 
Medicine, Opd-Civil Hospital “Dr Juan I Menchaca”, Guadalajara, Mexico; 
3I.M.S.S., Guadalajara, Mexico; 4Universidad de Guadalajara, Guadalajara, 
Mexico; 5Universidad de Guadalajara, Tonalá, Mexico; 6Hospital Civil de 
Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico.
Background: Patients with chronic kidney disease (CKD) manifest a high prevalence 
of malnutrition risk and constitute a high-risk population to drug related adverse reactions. 
The selection and appropriate dosage of the drug are vital to avoid adverse effects in this 
population. OBJECTIVE: To associate malnutrition risk and the presence of drug related 
adverse reactions in patients with CKD.
Methods: Descriptive cross-sectional study in which 89 patients with CKD were 
evaluated as outpatients in the Nephrology service of two hospitals from September-
December 2017. Malnutrition risk was measured using the Subjective Global Assessment 
(SGA) form and the adverse reactions were identified through a survey. The association 
between malnutrition risk and adverse events was analyzed by bivariate correlation and was 
considered significant at p <0.05.
Results: Sixty-five (73%) of the patients were men and twenty-four (27%) were 
women, with an average age of 47.3 ± 18.4 years, BMI of 25.3 ± 5.8. According to the CKD 
stages it was found that: 7 patients (7.9%) were stage 3, 14 (15.7%) stage 4, and 64 (71.9%) 
were stage 5. According to the SGA, 54 (60.1%) patients had malnutrition risk. It was found 
that 43 (67.2%) patients had stage 5 and malnutrition risk. The reported adverse reactions 
corresponded to anorexia 13 (14.6%), nausea 8 (9%), vomit 6 (6.7%), diarrhea 9 (11.1%), 
constipation 20 (22.5%), dizziness 17 (19.1%) and 28 (31.5%) with reduced muscle 
strength. An association between the malnutrition risk and anorexia was found: 3 (3.4%); 
p<0.001, likewise malnutrition risk and reduced muscle strength 10 (11.2%); p<0.05.
Conclusions: The adverse events related to mild-moderate malnutrition, by SGA, are 
anorexia and reduced muscle strength, and the more advanced the renal disease stage is, the 
greater the malnutrition.
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Recurrence of Hyperkalemia in the United States
J. Michael Woolley,1 Keith Betts,2 Deborah Goldschmidt,3 Fan Mu,3 Xinyue Liu,3
Lei Yin,3 Eric Wu.3 1AstraZeneca, Wilmington, DE; 2Analysis Group, Inc., Los 
Angeles, CA; 3Analysis Group, New York, NY.
Background: The objective of this study was to describe the frequency of recurrent 
hyperkalemia (HK) in patients with a documented case of HK in the United States (US) 
adult population
Methods: Adult patients with HK, defined as having at least two lab results with serum 
potassium>5.0 mEq/L (positive potassium lab), or one diagnosis code of HK (ICD-9: 
276.7), or one prescription for sodium polystyrene sulfonate (SPS), were identified from 
a large US commercial claims database (1/1/2010-12/31/2014). Patients were required to 
have continuous enrollment for at least 6 months before (baseline period) and 12 months 
after (study period, 1-year cohort) the date HK was first identified (index date), and to have 
at least two potassium lab tests during the study period. HK events, defined as a positive 
potassium lab or diagnosis code for HK or SPS prescription, during the study period were 
analyzed. Time from the index date to the next HK event was analyzed using Kaplan-
Meier analysis. Additional analyses were conducted on patients during a 36-month study 
period (3-year cohort) and for the subgroup of patients with chronic kidney disease and/or 
heart failure (CKD/HF) at baseline. Sensitivity analyses were conducted using a cutoff of 
5.5 mEq/L to define a positive potassium lab result.
Results: A total of 11,990 patients with an HK event were included in the 1-year cohort. 
Mean age was 60.8 years and 53.4% were men. Most patients (58.9%) had a subsequent HK 
event during the 1-year study period, and 44.0% had a subsequent HK event within the first 
6 months following the index date. The median time from the index date to the subsequent 
HK event was 7.9 months. Among the CKD/HF subgroup (N=4,798), 67.1% had an HK 
event during the study period and the median time to subsequent HK event was 5.3 months. 
In the 3-year cohort of CKD/HF patients (N=1,198), 78.4% had a subsequent HK event. In 
a sensitivity analysis, 46.7% of patients overall - and 53.7% of CKD/HF patients - had at 
least one subsequent HK event during the 1-year study period using the alternate 5.5 mEq/L 
cutoff for positive potassium lab results.
Conclusions: The majority of patients with documented hyperkalemia went on to 
have another hyperkalemia event within 12 months, indicating that hyperkalemia is often a 
recurrent condition, and the rate of recurrence is even higher in patients with chronic kidney 
disease and/or heart failure.
Funding: Commercial Support - AstraZeneca
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A Cross Sectional Analysis of Retinal Layer Thinning and Renal Function 
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Background: Reduced thickness of the neuronal tissue of the retina and the vascular 
choroid have been linked to vascular damage and diabetes. Retinal thinning may offer 
utility as a biomarker of accumulated damage in chronic kidney disease (CKD). We aimed 
to assess associations between retinal and choroidal thickness and reduced renal function in 
a population with a high burden of comorbidity.
Methods: A cross-sectional analysis of participants attending nuclear cardiology or 
renal medicine clinics was carried out. Retinal thickness and choroidal measures were 
obtained using spectral domain optical coherence tomography. Estimated glomerular 
filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration 
creatinine equation (CKD-EPI). CKD stage 3-5 status was based upon a single measure of 
eGFR <60 ml/min/1.73m2.
Results: 241 participants with a mean age of 65 years (standard deviation [SD] 9.48) 
had a mean eGFR of 66.91 ml/min/1.73m2 (SD 24.75) with 27% of the population using 
diuretics. In the present sample, 39% had diabetes. In unadjusted analyses, lower inner 
retinal thickness was associated with lower eGFR and CKD stage 3-5, a pattern similar 
to that reported in diabetes. In adjusted analyses, significant associations were found 
bilaterally (i.e. in both eyes) between lower thickness of the temporal and superior segments 
of the inner nuclear layer (INL) and the foveal area of the outer nuclear area (ONL) of the 
retina with lower eGFR. In the outer temporal segment of the nerve fibre layer (NFL), 
greater thickness was significantly associated with lower eGFR. There were no significant 
associations between choroidal measures and eGFR or CKD stages 3-5 after adjustment.
Conclusions: INL and NFL thickness were associated with renal function in a minority 
of retinal segments. Given the large number of associations tested, these findings do not 
indicate reliable independent associations between retinal thickness and renal function. INL 
and NFL thickness were associated with renal function in a minority of retinal segments. 
Given the large number of associations tested, these findings do not indicate reliable 
independent associations between retinal thickness and renal function.
Funding: Government Support - Non-U.S.
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Factors Associated with the Non-Inclusion of a Kidney Transplant 
Protocol: Results of a Mexican Cross-Sectional Study
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Background: Kidney transplantation is the best option for patients with ESRD. Some 
clinical situations could contraindicate a kidney transplant. In our setting there is scarce 
information regarding that factors. Objetive: To determine the factors that are associated 
with non-inclusion to kidney transplant protocol (KTP).
Methods: Cross-sectional Study, performed in Hospital General Regional 110. A 
survey was applied to patients with chronic kidney disease stage 5 K-DOQI, with age ≥16 
years old, any gender were included. Further Clinical/biochemical data were obtained from 
medical chart: age, gender, body mass index, systolic and diastolic blood pressure, The 
comorbidity index was calculated (Charlson) Statistical Analysis: Comparisons were done 
with t-student, Mann-Whitney-U, Wilcoxon of test. Logistic regression analysis was used 
to evaluate associated factors with not including to KTP
Results: 355 patients were included, age 48±17 years, 57 % men, 106 (30%) patients 
were included to KTP; of them 65% were on the waiting list. Clinical and biochemical 
comparisons between patients included and not including in a KTP are shown in table. The 
factors associated with not including to KTP were: Charlson index (OR,1.25;IC:0.97-1.6 
p=0.84), evolution time of CKD (OR,0.98; IC:0.97-0.99 p=0.008, dialysis time 
(OR,1.01;IC:1.0-1.03 p=0.05),cholesterol (OR, 1.01;IC:1.01-1.03 p=0.02), serum albumin 
(OR,0.47; IC:0.23-0.95 p=0.03) and Diabetes (OR,4.87; IC:1.82-13.02 p=0.002).
Conclusions: It is necessary to shorten the waiting list and replacement therapy times 
to avoid more comorbidities.
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Psychosocial Stress Is Associated with Incident CKD Development in 
Subjects with Normal Renal Function
Joohwan Kim, Yooju Nam, Seon yeong Lee, Ki Heon Nam, Dae-Suk Han, Jung 
Tak Park. Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Recent investigations have shown that psychosocial stress could be 
related with the development of several diseases including metabolic syndrome and 
cardiovascular diseases. Nonetheless, the impact of psychosocial stress on renal function 
has not been fully elucidated yet. Therefore, this study was conducted to examine the 
association between psychosocial stress and the development of incident chronic kidney 
disease (CKD).
Methods: Data from the Korean Genome and Epidemiology Study (KoGES), a 
prospective observational cohort, were used for the analysis. A total of 7,625 subjects with 
normal renal function were included in the final analysis. Psychosocial stress was measured by 
psychosocial wellbeing index-short form (PWI-SF) through self-administered questionnaires. 
The mean PWI-SF score during the study duration for each individual was considered as the 
amount of psychosocial stress inflicted. The subjects were classified into low stressed and 
high stressed groups based on the mean amount of psychosocial stress. Incident CKD was 
defined as estimated glomerular filtration rate (eGFR) < 60mL/min/1.73 m2.
Results: The mean age of the subjects was 51.9 ± 8.7 years and 47.8% were male. 
Low stressed and high stressed groups were composed of 6,411 (84.1%) and 1,214 (15.9%) 
subjects, respectively. The baseline eGFR (94.1 ± 14.1 vs 94.2 ± 13.8 ml/min/1.73m2, 
P =0.946) was comparable between the groups. Subjects with hypertension (14.0% vs 
18.2%, P<0.001) and diabetes mellitus (5.8% vs 9.5%, P<0.001) was more prevalent in the 
high stressed group compared to the low stressed group. During a mean follow-up duration 
of 118.9 ± 36.7 months, incident CKD development was observed in 1,361 (21.2%) and 
331 (27.3%) subjects in the low stressed and high stressed group, respectively. Multivariate 
Cox proportional hazard analysis revealed that subjects in the high stressed group were 
at a higher risk of developing CKD [hazard ratio (HR), 1.187; 95% CI, 1.051 – 1.342; 
P = 0.006] even after adjustments were made for confounding factors including hypertension 
and diabetes status.
Conclusions: Exposure to higher amounts of psychosocial stress was significantly 
associated with incident CKD development in normal renal function subjects. Managing 
psychosocial stress issues may have a role in preventing CKD development.
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Changes in Estimated Glomerular Filtration Rate (eGFR) Are Signifi-
cantly Associated with Serum Uric Acid Levels in a Population-Based 
Screening: The Aragon Workers’ Health Study (AWHS)
Hilda M. Villafuerte Ledesma,1,2 Abdul Rashid T. Qureshi,3 Juan J. Carrero,3 
Bengt Lindholm,3 Peter Stenvinkel,4 Rafael Alvarez lipe,1,2 Pablo J. Inigo Gil,1 
José A. Casasnovas.5 1Hospital Clínico Universitario Lozano Blesa, Zaragoza, 
Spain; 2The Health Sciences Institute in Aragon, Zaragoza, Spain; 3Karolinska 
Institutet, Stockholm, Sweden; 4Karolinska University Hospital Huddinge, 
Stockholm, Sweden; 5University of Zaragoza, Zaragoza, Spain.
Background: Serum uric acid (SUA) is associated with hypertension, metabolic 
syndrome, diabetes and heart failure in the general population. There is mixed evidence 
suggesting that SUA levels may play a role in the development and progression of CKD. 
The aim of present study was to determine the association between SUA and eGFR in a 
population-based screening of Spanish middle-aged adults.
Methods: This longitudinal follow-up study of Aragon Workers’ Health Study(AWHS) 
included 5075 subjects (median age 50 years, 94%male, 7%diabetes, 38%dyslipidaemia, 
30%hypertension) with anthropometric and biochemical data. The recruitment started in 
2009 and participants were followed annually for 6 years. Blood pressure, BMI, HDL, 
triglycerides, and SUA were available at each visit. The longitudinal association between 
uric acid and eGFR was evaluated by logistic regression mixed models.
Results: At baseline, there were associations between eGFR and SUA(rho= -0.22 p<0.001), 
total cholesterol(rho= -0.14 p<0.001), glucose(rho= -0.13 p<0.001), ASAT(rho= -0.21 
p<0.001), ALAT(rho= -0.13 p<0.001), hsCRP(rho= -0.01 p=0.55) and BMI (rho= -0.15 
p<0.001). In a multivariable-adjusted linear mixed model, changes in eGFR were 
significantly associated with diabetes 1.31(0.26), hypertension -0.23(0.22), dyslipidaemia 
-0.92(0.21), and longitudinal changes BMI -0.18(0.03) and SUA -2.87(0.08).
Conclusions: SUA was negatively associated with variation of eGFR in a cohort of
community-dwelling middle-aged men, supporting the notion that SUA may be a risk factor 
or marker of CKD progression.
Funding: Government Support - Non-U.S.
Box plot of SUA (mg/dl) and eGFR (ml/min), median (10-90 percentiles).
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The Association Between Serum Uric Acid with Inflammation, Body Fat, 
and Renal Function
Sewon Oh,1 Young-Bin Son,1 Junyong Lee,2 Jihyun Yang,3 Myung-Gyu Kim,1 
Sang-Kyung Jo.1 1Korea University Anam Hospital, Korea University College of 
Medicine, Seoul, Republic of Korea; 2Korea University Anam Hospital, 
Seongbuk-Gu, SEOUL, Republic of Korea; 3Korea universtiy Anam hospital, 
Seoul, Republic of Korea.
Background: Hyperuricemia has been related to metabolic syndrome, cardiovascular 
disease, and renal disease. Uric acid is associates with the presence of atherosclerosis in 
recent studies and adiposity and inflammation lead to atherosclerosis. It is unclear whether 
serum uric acid could be a predictive marker to determine adiposity, inflammation, and renal 
progression in longitudinal study.
Methods: Among the 56,367 adult participants who underwent health check-ups 
during 2004-2017, we included 16,695 participants with estimated glomerular filtration rate 
(eGFR) ≥60 ml/min/1.73m2 and repeated measurements of uric acid and eGFR. We divided 
participants into sex-specific quartile groups according to the baseline serum uric acid level. 
The decline of renal function aggravation was defined by the decrease in eGFR by more 
than 30%. Body fat and muscle were evaluated by bioimpedance analysis.
Results: The average age of the participants was 46.7±12.5 years and 52.5% were male. 
Baseline serum uric acid is positively associated with body mass index, serum C-reactive 
protein (CRP), monocyte count, and body fat at baseline and follow up examination 
(P<0.05) after the adjustment of multiple factors. In addition, serum uric acid is negatively 
related to body muscle (P<0.05). The highest quartile of uric acid was associated with the 
development of metabolic syndrome (RR, 1.608; 95% CI, 1.068-2.423) during 54.3± 37.5 
months of follow up period. The risks of decline in renal function were significantly higher 
in the third (RR, 3.015; 95% CI 1.455-6.247) and highest quartile (RR, 4.848; 95% CI 
2.379-9.878) compared than the lowest quartile. The participants with highest quartile 
showed 2.329-fold risk elevation of CKD development (95% CI 1.482-3.659).
Conclusions: Serum uric acid is associated with adiposity and inflammation at baseline 
and follow-up study. Hyperuricemia is associated with development of metabolic syndrome, 
renal function decline, and chronic kidney disease.
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Correlation Between Home, Clinic, and Ambulatory Blood Pressure 
Monitoring Among CKD Patients
Prof Narinder P. Singh, Sanket Mathukiya, Neeru Aggarwal, Anish Gupta. Max 
Super Speciality Hospital, Ghaziabad, India.
Background: There are various options for BP monitoring like home blood pressure 
(HBP), office(clinic) (CBPM) and twenty four hour Ambulatory BP monitoring (ABPM). 
HBP could provide an appropriate alternative to ABPM in terms of diagnosis, particularly 
in primary care where it might not be immediately available or deemed too costly or when 
patients find it inconvenient or uncomfortable. By early detection of hypertension (HTN) 
in CKD patients, life threatening adverse outcomes can be prevented and management can 
be modified accordingly. Hence, the study was conducted to detect masked hypertension 
in CKD patients and to investigate whether home HBP monitoring provides feasible and 
reliable alternative to ABPM and repeated CBPM in detection of HTN and differentiating 
true from white-coat HTN.
Methods: Total 75 patients, >18 yrs of age and having CKD stage1-4 (pre-dialysis) 
were enrolled and those having heart disease, acute infection and pregnancy were excluded. 
HTN was defined as per JNC-7 and British hypertension society as CBP:≥140/90mmHg, 
mean HBP:>135/85mmHg, mean ABPM daytime:>135/85mmHg, mean ABPM night-
time:>120/70 mmHg. Patient details were incorporated in proforma along with CBP 
measurement on two different occasions and ABPM once during time period of 7 days of 
HBP measurement.
Results: Majority of patients were males (61%) with age of 58.3±6.31 years. More 
than half were CKD stage 3. Around 69%, 61% and 40% were hypertensive when 
detected by ABPM, HBP and CBP respectively. Among hypertensive, 38.7% were masked 
HTN, 9.33% observed with white coat HTN, 30% were sustained HTN and 21% were 
normotensive. Prevalence of normotension showed concordance between ABPM and HBP 
when it compared by all three methods. Similarly ABPM and HBP showed concordance 
in 88.46% hypertensive. HBP achieved a specificity of 100% and a sensitivity of 88.45% 
for the detection of hypertension when using ABPM as gold standard. For accuracy and 
precision of HBP and CBP in predicting ABPM, HBP was superior to CBP.
Conclusions: ABPM was the gold standard for detecting of hypertension. HBP was 
no more far behind to ABPM in terms of detecting white coat and masked HTN. The 
present data may serve as a starting point for more elaborate cost-effectiveness studies and 
reimbursement of BP monitoring devices.
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Assessing the Rate of Progression of CKD of Unknown Etiology in Sri 
Lanka
Lali (Lalarukh) Haider,1 Shuchi Anand,2 Stephen L. Schensul,3 Penny Vlahos,4 
Nishantha Nanayakkara.5 1Medicine, UConn Health, Farmington, CT; 2Stanford 
University, Palo Alto, CA; 3University of Connecticut School of Medicine, 
Farmington, CT; 4University of Connecticut, Groton, CT; 5Teaching Hospital, 
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Background: Chronic kidney disease of unknown etiology (CKDu) is a global 
epidemic, identified in the lowland, arid agricultural regions of many countries including 
Sri Lanka. The primary research objective thus far has been to identify individual causal 
factors. The research presented in this paper shifts the focus to understand risk factors for 
kidney disease progression in established cases.
Methods: Working with a Ministry of Health screening operation in the Wilgamuwa 
Division of the CKDu endemic Central Province, 296 individuals with CKDu were identified 
using a clinical case definition. They were consented, and administered a detailed survey 
covering exposure, behavioral and clinical factors with micro-environmental assessment 
of water and soil agrochemical contamination at the household level. A follow-up clinical 
exam was conducted at the Wilgamuwa kidney clinic. Serum creatinine was repeated to 
confirm the diagnosis of CKDu. Thereafter participants undergo quarterly clinical exams 
and serum creatinine assessments.
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Results: The recruited participants are between 30-65 (mean 54 [SD 8.2]) years. 
Consistent with the reported sex distribution of CKDu, 76.6% are men. The mean education 
is to the 6th standard; 75% live in nuclear families. Baseline CKD-EPI eGFR was 40.7 
(SD=13.7) ml/min/1.73m2, with a range from 17 to 80. eGFR mean change from baseline to 
first quarterly follow-up was 2.97 (SD=8.0) ml/min/1.73m2, with a range of-32.3 to +54.6. 
81 (41.5%) participants showed a decline in eGFR of more than 5 ml/min/1.73m2; 114 
(58.5%) showed no change or an increase in eGFR.
Conclusions: Our initial results indicate that there is a range of variation in progression 
of the disease, enabling us to explore the environmental, behavioral and clinical factors 
associated with progression. There is currently little available for primary and secondary 
prevention; it is our hope that by identifying the contributing factors this research can 
provide guidelines for slowing progression.
Funding: Other NIH Support - R21 TW010425-01
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- Seven Arguments Against the Hypothesis
Chulani A. Herath,2 Channa Jayasumana,3 Sisira Siribaddana,4 Marc E. De
Broe.1 1University of Antwerp, Lokeren, Belgium; 2Sri Jayawardenepura
General Hospital, Colombo 5, Sri Lanka; 3Faculty of Medicine, Anuradhapura, 
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Background: There are two main hypotheses suggested as causative of the global 
epidemics of chronic interstitial nephritis of agricultural communities (CINAC). The 
toxic hypothesis implicates an environmental/occupational toxin while the heat stress/
dehydration hypothesis (HSDH) attributes the disease to recurrent acute kidney injury 
(AKI) caused by heat stress. Our aim is to demonstrate that heat stress is unlikely to be the 
main cause for this epidemic.
Methods: The following data sets are used to refute the HSDH as the driving force of 
CINAC: 1.Geographil, 2. Climatologic, 3. Ecologic, 4. Epidemiologic, 5. Physiopathologic, 
6. Biochemical and 7. Agrarian.
Results: Absence of CINAC in many hot agricultural regions of the world is a stronger 
anti-correlation than the correlation assumed by presence of CINAC in a few such regions. 
The mosaic pattern of case distribution in Sri Lanka contradicts the HSDH. It is doubtful 
that the small temperature increases in the latter twentieth century caused significant renal 
effects. CINAC is seen in people not exposed to hot working conditions, while it is not seen 
in many occupations with higher temperature exposure. Individuals who drink spring water 
are not affected in contrast to those who drink from shallow wells in nearby communities. 
It is doubtful that field studies in agricultural workers show significant AKI, and that this 
degree of community-acquired recurrent pre-renal injury is adequate to cause CINAC. 
Biochemical changes postulated to perpetuate CKD have not been proven. In Sri Lanka, 
mechanization of paddy farming has reduced farmers’ heat exposure.
Conclusions: It is unlikely that heat stress is the main cause for the CINAC epidemic.
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To Assess the Association Between Obesity and CKD in New York City 
Population
Kay thwe Kyaw. Nursing Home, Essen Health Care, Bronx, NY.
Background: The increasing prevalence of obesity in the United States is a major 
public health concern. Obesity is known to be associated with several conditions that can 
compromise renal function, such as diabetes and hypertension. It is unclear, however, if 
obesity is an independent risk factor for chronic kidney disease. Currently, there is limited, 
conflicting research concerning obesity and chronic kidney diseases at the population level. 
This study was performed to better understand the association of obesity and chronic kidney 
disease in the population of New York City.
Methods: A cross sectional study was performed to identify the association between 
obesity and CKD using the 2013-2014 New York City Health and Nutrition Examination 
Survey. Obesity status, determined by BMI, was the exposure, and the outcome was chronic 
kidney disease defined using a survey question about the presence of kidney disease. Chi-
Square and univariate tests were used to test for bivariate association between obesity and 
covariates of interests: age, gender, marital status, physical activity level, diabetes, and 
hypertension. Logistic regression was performed to find association between obesity and 
chronic kidney disease adjusted for age, gender, physical activity, diabetes, hypertension, 
and marital status.
Results: This study includes study population of 6,008,489. A statistically significant 
association was found between obesity and chronic kidney disease at p-value: 0.03 (Chi-
square test). After adjusting for confounders, however, there was no statistically significant 
association between obesity (BMI > 30) and CKD (p-vale: 0.2811, OR: 1.90, 95% CI 
(0.589, 6.171).
Conclusions: In this population-based, cross sectional study, a statistically significant 
association was found between obesity and chronic kidney disease. However, after 
adjusting for known risk factors, this association was no longer significant, indicating that 
obesity may not be an independent risk factor for chronic kidney disease. This study was 
limited by the use of a survey question to determine the presence of renal disease, rather 
than objective laboratory data. However, this study adds to the currently available evidence 
and encourages further research regarding the association between obesity and chronic 
kidney disease.
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Mariko Miyazaki,5 Ayaka Minota,2 Tae Yamamoto,1 Gen Yamada,2 
Masaaki Nakayama,3,1 Hiroshi Sato,4,1 Sadayoshi Ito.5 Gonryo CKD study group 
1Tohoku University Hospital, Sendai, Japan; 2Tohoku University, Sendai, Japan; 
3St Luke’s International Hospital, Tokyo, Japan; 4Clinical Pharmacology and 
Therapeutics, Graduate School of pharmaceutical Sciences, Tohoku University, 
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Background: Gender differences in chronic kidney disease (CKD) are reported in 
previous researches. For example, graft survival time is reduced in recipients of kidneys 
from female donors as compared with recipients of male donor kidneys. However, few 
studies compared with male and female in CKD patients, because sex were previously 
treated as a kind of co-factor on outcomes.The aim of this study is to examine the 
characteristics of CKD patients over 55 years old and the factors contributing to death and 
cardiovascular disease (CVD) events.
Methods: Setting : Multicenter Prospective cohort study. The subject of this study was 
1392 CKD patients over 55 years old. they were observed 5 years (till 2013). Male were 
55.0% of them. We surveyed patient characteristics, laboratory findings (Hb, sCr, eGFR 
etc…), medication. Outcome:All-cause mortality, CVD events.
Results: In CKD patients of over 55 years old, there was gender difference in the 
risk of mortality and ESKD but not in that of CVD events. Lower systolic blood pressure, 
lower serum albumin, lower eGFR, past CVD, and lack of angiotensin receptor blocker 
were related with all cause mortality in male. On the controther hand, lower hemoglobin, 
proteinuria, needs of iron, diuretics, and vitamin D were significant with mortality in 
female. CVD risk was not shown statistically significant difference between gender. Past 
CVD was most important risk for both gender. Lack of RASI, positive proteinuria, and 
need of beta blocker were significant in male. Need of erythropoiesis stimulating agent was 
significant in female.
Conclusions: As a result, characteristics and risk factors differed even between male 
and female CKD patients of age after menopause. Blood pressure effected the prognosis in 
male and anemia controlled that in female. We should consider the different risk factors in 
CKD between gender even elderly.
Funding: Commercial Support - Astellas Pharma INC.
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Cardio-Renal Risk Factors Are Highly Prevalent in Rural Population 
- Findings from Multi-site Screening Programs in Bangladesh
Md M. Iqbal,1,2 Md ayub ali Chowdhury,3 Kazi S. Alam.3 Kidney Disease
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Background: Population of urban and rural areas have difference in life style, 
environment and livelihood. Rural population are generally less investigated. The aim was 
to investigate the dirtribution pattern of diabetes (DM), hypertension (HTN), dyslipidemia 
and proteinuria as cardio-renal risk factors in rural and urban population.
Methods: Multiple screening programs in different urban and rural areas of Bangladesh 
were conducted by Kidney Disease Research Group (KDRG). An ‘open to all’ invitation 
was announced in selected areas for interested adult population to attend on a specified 
date in early morning preferably fasting. On screening day attending participants were 
interviewed by research physicians. Socio-demographic information, blood pressure (BP) 
recording and anthropometric measurements were done. Spot urine was collected and blood 
sample was drawn for blood sugar, lipid profile and serum creatinine (non-enzymatic) 
measurements. Estimated GFR (eGFR) was calculated by MDRD equation.
Results: In 2000 subjects 51% was male, age between 18-40 years in 61%; 69% had 
school level of education; 59% belonged to low income group and 18% were tobacco user. 
Parental DM was present in 16% and HTN in 23%. At screening pre-diagnosed HTN was 
present in 13%, DM 10% and nephropathy <1% subjects. After screening hypertension was 
detected in 23% (18% systolic and 19% diastolic). Blood sugar was >7.0 mmol/l in 22 % (of 
which 7% had > 11.1). The lipid profile showed raised TG (>150mg %) in 58%, low HDL 
(<40 mg %) in 58% and high LDL (>130 mg %) in 24%. Proteinuria was detected in 4.4 % 
subjects. The eGFR < 60ml/min was found in 18.6% subjects. Comparison of urban versus 
rural population showed diastolic HTN 16% vs. 23% (p<0.002); blood sugar <5.5 mmol/l 
in 64% vs. 53% (p<0.001); HDL <40mg% in 47% vs. 65% (p<0.001); TG> 150 mg % in 
53% vs. 60% (p<0.01) and eGFR < 60ml/min in 16% vs. 19% (p<0.001).
Conclusions: The prevalence of hypertension, altered blood sugar, dyslipidemia and 
renal dysfunction is higher in rural population than the urban. This indicates a probable 
paradigm shift in diseases in an unaware underprivileged larger cardio-renal risk group 
needing urgent attention.
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Pre-Renal Biopsy (PRB) Bleeding Prophylaxis with Desmopressin 
(DDAVP)
Haridian Sosa Barrios, Victor Burguera, Melissa Cintra Cabrera, Sofia Ortego, 
Ester Casillas, Milagros Fernandez lucas, Maite Rivera. Hospital Universitario 
Ramón y Cajal, MADRID, Spain.
Background: DDAVP is a synthetic vasopressin analog. Its use to reduce bleeding 
risk pre PRB is arguable due to side effects, like reduced coronary flow and hyponatremia.
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Methods: Analyze DDAVP complications when administered pre PRB from January 
2013 until December 2017 in our centre.
Results: Of 482 PRB’s, 65 (13,5%) received a single intravenous DDAVP dose 
(0,3 mcgr/kg) to enhance platelet function (table 1). DDAVP indications: altered PFA100 
(72,5%), 15,5% uremia (GFR <25 ml/min), 9% antiplatelet drugs and 3% thrombocytopenia. 
71% did not take any antiplatelet agents previously, 15% used anticoagulation that was 
either suspended 8-12 days pre PRB or replaced by low molecular weight heparin (not given 
one day pre procedure). PRB complications: 30,4% minor asymptomatic complications 
detected by routine ultrasound and 4,6% had major complications (surgical or radiological 
intervention and/or blood products requirement). Risk factors: pre PRB hemoglobin levels 
<10 g/dL and diastolic blood pressure >90 mmHg were significant risk factors. Abnormal 
PFA 100 wasn’t statistically significant. DDAVP complications: Mean sodium decline was 
0,9±3,4 mEq/L. 2 patients had hyponatremia without neurological symptoms: one dropped 
from 128 to 124 mEq/L and another one had a sodium decrease of 12 mEq in 24 hours. 
None of the patients had a cardiovascular event after dosage (up to one month).
Conclusions: Single dose DDAVP pre PRB is safe and can be used in patients with 
higher risk of hemorrhagic complications, such as uremia.
Table 1
Hb: hemoglobin; BPs: systolic blood pressure; BPd: diastolic blood pressure.
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Background: Infection is an important cause of morbidity and mortality among 
patients with kidney disease, and early identification and treatment reduces mortality. 
Diagnosis remains a challenge, but fever is a relatively reliable sign. Health monitoring 
devices are popular, accepted and purchased by many patients. We assessed the feasibility 
of a watch device to detect infection.
Methods: We conducted a single-center prospective cross-sectional pilot study 
of inpatients to demonstrate proof of concept. Patients admitted under the nephrology 
unit between August 2017 and April 2018 were consented to wear a monitoring device. 
Participants wore a clinical grade device that measured peripheral temperature at the wrist 
(Empatica E4) along with other physiological variables, and we report early analysis of 
temperature (t) alone. We classified patients as having sepsis, no sepsis and/or treated sepsis 
and examined how well t correlated with the presence of sepsis.
Results: 104 patients underwent data recording and 82 patients had complete data. 58 
patients had no sepsis, 15 patients had sepsis and 9 patients had treated sepsis. None of the 
41 patients who had at least 84% of readings <35°C had active sepsis. Of the 41 patients 
with greater than 16% of readings ≥35°C, 15 had sepsis (PPV=21%, NPV=100%). 9 out of 
10 patients who had >0.5% of readings ≥37°C had sepsis (PPV=52%, NPV=92%). 1 false 
positive was admitted with limb ischaemia after occlusion of a vascular graft.
Conclusions: Peripheral temperature measurement may add value to sepsis detection. 
Further data analysis is underway to refine the detection algorithm. We hope to be able 
to incorporate such algorithms into a consumer device that can continuously monitor and 
signal the user of impending infection.
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Background: The chronic kidney disease (CKD)-related immunodeficiency 
would suggest that early stage CKD could also be a risk factor for Tuberculosis (TB). 
Immunodeficiency associated with CKD appears to be multifactorial in etiology. Changes 
in immunity begin as early as stage 3b CKD (defined as a glomerular filtration rate 
<45ml/min per 1.73 m2) and worsen in later stages as kidney function deteriorates and 
waste products accumulate. Active TB is an infectious complication that may develop and 
result from progression of Mycobacterium tuberculosis infection after recent exposure or 
reactivation of latent tuberculosis infection (LTBI) from a distant exposure, often years 
before the disease develops.
Methods: Retrospective cohort study was performed in CKD patients who were 
diagnosed as TB during recent 11 years (from January, 2006 to December, 2017). The end 
point is all cause of death.
Results: Twenty hundred thirty-seven CKD patients who was diagnosed as TB were 
admitted to and followed up 11 years. Mean age of the patients was 76.0±11.8 years. One 
hundred sixty-three (68.8%) patients were male and 74 (31.2%) were female. Sixty-five 
patients were died (mortality rate: 27.4%). CKD was stratified by eGFR into 4 groups of 
G3b (eGFR 30-45 ml/min. per1.73m2 n=65;27.4%), G4 (eGFR 15-30 ml min. per1.73m2 
n=48;20.3%), G5 (eGFR <15 ml/min. per1.73m2 n=33;13.9%), G5D (hemodialysis 
n=91;38.4%). Moreover, the mortality rate increased with progress of stage as G3b: 23.1, 
G4: 35.4, G5: 42.4, G5D: 20.9 (%), respectively, while the mortality rate tended to decrease 
with dialysis.
Conclusions: The mortality rate of TB patients with CKD was enhanced, compared 
without CKD patients. The mortality rate was gradually enhanced with CKD stage-
depending. The mortality rate of TB in G5D was significantly decreased in that in 
G5 patients. Comparing G5 with G5D, the frequency of use of Levofloxacin among 
anti-tuberculous drugs is more common in G5 than G5D (24%: 8%). The treatment with 
anti-TB drugs were started in the patients with dialysis. From now on, it is considered that 
study of tuberculosis treatment for each CKD stage is necessary by further investigation. In 
the future study, we clarified the efficacies of TB treatment for each stages of CKD patients.
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Background: Renal embolization (RE) is an invasive procedure used in Nephrology 
for the treatment of some pathologies such as renal bleeding (ReB), angiomiolypoma 
(AML), post renal biopsy vascular complications (arteriovenous fistulae (AVF) and 
pseudoaneurysm) complicated cysts or renal graft intolerance. There are few studies with 
small sample sizes. Our objective was to analyze the data and adverse events of ReB.
Methods: We retrospectively reviewed the RE performed in our unit for 22 years 
(1995-2017), including both complete and super selective RE. Data were obtained from 
hospital database and patient’s clinical records.
Results: Thirty-eight embolization, 24 males/14 females (mean age 58.35+/-13 years). 
Seventeen patients were already on dialysis (45%). Super selective embolization was 
performed in 24 cases (63%) and complete kidney embolization in 14 cases (37%); 16 
on native kidneys and 22 on kidney grafts. The main indication was ReB (32%), most 
spontaneous or after renal biopsy. Second indication was complicated AVF secondary to 
renal biopsy (37%) that caused hemodynamic instability or bleeding. Post-embolization 
syndrome occurred in 6 patients (16%), acute anemia requiring blood products in 10 (26%), 
hypotension in 3 and major hematuria in 1. Mild-moderate hyponatremia (126-135 mEq/l) 
appeared in 45% and mild hyperkalemia (5.5-5.9 mEq/l) in 2 cases who had it previously. 
In the non-dialysis group (n=21), there was a non-significant mean increase in creatinine 
of 0.6+/-1.89 mg/dl at 48 hours (p = 0.1); 0.3+/-1.6 mg/dl at 10 days (p = 0.63) and 0.4+/-
1.9 mg / dl at 6 months (p = 0.9). Embolization triggered the onset of dialysis in 8 cases 
(21%). Two patients died during the first month (respiratory infection and hypovolemic 
shock). A second embolization was performed in 5 patients and nephrectomy in 3.
Conclusions: In our experience, post-biopsy complications are the most frequent 
cause of kidney embolization. Embolization can trigger the onset of dialysis in a significant 
percentage of patients mainly in patients with previous CKD. Mild-moderate asymptomatic 
and unexplained hyponatremia was frequent, that may be secondary to a transient syndrome 
of inappropriate secretion of antidiuretic hormone (SIADH).
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Biopsy-Proven Oxalate Nephropathy
Shao-shan Liang, Dandan Liang, Feng Xu, Li-juan Li, Cai-hong Zeng. National 
Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing 
University School of Medicine, Nanjing, China.
Background: To investigate the etiology, clinicopathological features, treatment and 
prognosis of oxalate nephropathy.
Methods: A retrospective analysis of patients diagnosed as oxalate nephropathy by 
renal biopsy from January 2013 to April 2018 in Jinling Hospital was performed. The 
etiology and clinicopathological characteristics of the patients were analyzed.
Results: A total of 52 cases of OxN were collected, including 39 males and 13 females 
with a mean age of 49yr. Two cases were primary hyperoxaluria and 50 cases were 
secondary OxN. The most common cause was medication, including infusion of Vitamin 
C (16 cases), glycine (5), tiopronin (1), xylitol (1). Ingestion of foods rich in oxalate was in 
4 cases, and dimethyl oxalate poisoning was in 1 case. The most frequent chief complains 
were oliguria/anuria (50.0%), followed by, edema (30.8%), lumbodynia (30.8%). Thirty-
nine cases were diagnosed as AKI, 10 cases were AKI on CKD (ACKD), and 3 cases 
were allograft kidney. The highest serum creatinine during hospitalization was 8.86(range 
1.73-20.03) mg/dl. There were 38.5% cases with hypoalbuminemia, and 40.4% with 
anemia. Urine test showed that elevated of retinol-binding protein (RBP), NGAL, lysozyme 
in 92.3%, 77.5%, and 59.2% cases, respectively. Kidney biopsy showed extensive calcium 
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oxalate crystal deposition with acute tubulointerstitial nephritis. Ten of them were in the 
background of glomerulonephritis or hypertensive nephrosclerosis. Percentage of acute 
tubular injury, interstitial cells infiltration were 46(10-70)%, 39(5-90)%, respectively. 
Twenty-seven patients (51.9%) received continuous renal replacement therapy. At the end 
of follow-up of 12.1 (0.2-57.2) months, 2 patients reached ESRD. In 33 of 41 patients 
who followed up for >3 months, renal function returned to normal in 56 (14-165) days. 
Compared with those of renal function non-recovery, the renal function recovery patients 
had lower ACKD rate, higher serum albumin and hemoglobin, lower urinary RBP and 
lysozyme, and less renal interstitial cells infiltration.
Conclusions: The oxalate nephropathy is associated with a cluster of etiologies and 
manifestations as AKI or ACKD. Half of the patients required renal replacement therapy. 
Most of the patients had renal function recovery.
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Development and Validation of a Cognition Questionnaire for Patients 
with CKD
Jiawei He,2,4 Suyuan Peng,3,2 Min Zhang,2 Jiasheng Huang,1 Meifang Liu,2 
Xusheng Liu,2 Yifan Wu.2 1Guangzhou University of Chinese Medicine, 
Guangzhou, China; 2The Second Affiliated Hospital of Guangzhou University of 
Chinese Medicine, Guangzhou, China; 3Mayo Clinic, Rochester, MN; 4Peking 
University First Hospital, Department of Nephrology, Beijing, China.
Background: To date, there is no a validated questionnaire which is used to know 
chronic kidney disease(CKD) patients’ level of cognition for their disease. Being as the 
basis for Knowledge-Attitude-Practice Model, the level of cognition is essential if we need 
to conduct medical behaviors in a targeted manner. Therefore, the aim of the present study 
is to develop and validate a cognition questionnaire for CKD patients.
Methods: A cross-sectional study was conducted among CKD patients using the 
self-developing questionnaire in Guangdong Provincial Hospital of Traditional Chinese 
Medicine. Additionally, we conducted statistic analysis to know whether this questionnaire 
was appropriate.
Results: 110 questionnaires were distributed and 100 of which were qualified 
ones. After the item analysis, 2 items were excluded. Therefore, 18 items were retained 
to compose the final set of the questionnaire. For validity analysis, 4 components could 
explain cumulative 72.046% extraction sums of squared loadings; For reliability analysis, 
Guttman Split-Half coefficient was 0.918.
Conclusions: This cognition questionnaire reveals favorable validity and reliability. It 
seems to be an impactful method for the evaluation and measurement of levels of disease-
related cognition among the CKD patients.
The final questionnaire
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Strong Association Between Endothelial Dysfunction and Arterial Stiffness 
in Pre-Dialysis Patients with Stage 3-5 CKD
Yue Gu,1 Lei Yan,2 Lamei Zhao,2 Lijiao Wang,2 Fengmin Shao.2 1Division of 
Nephrology, Henan Provincial People?s Hospital, Zhengzhou City, China; 
2Henan Provincial People?s Hospital, Zhengzhou, China.
Background: Cardiovascular disease (CVD) is the most common cause of mortality 
in chronic kidney disease (CKD) patients. Arterial stiffness is a major risk factor for 
cardiovascular and all-cause mortality in CKD patients. Endothelial function is impaired 
in CKD patients and contributes to a high risk of cardiovascular morbidity and mortality 
in this population. The aim of study was to investigate the association between endothelial 
function and arterial stiffness in pre-dialysis patients with stage 3-5 CKD.
Methods: In this cross-sectional study, hospitalized pre-dialysis patients who were 
diagnosed of stage 3-5 CKD in a single center from November 2016 to February 2018 
were enrolled. On enrollment, demographic and clinical data collected included age, 
sex, height, weight, diabetic status and etiology of CKD. Ultrasound evaluation was 
conducted on brachial artery to estimate endothelial-dependent flow-mediated dilation 
(FMD). Automatice pulse wave velocity (PWV) measuring system was applied to examine 
the carotid-femoral PWV. Blood pressure and biochemical parameters were detected. 
Pearson’s correlation and Stepwise multiple regression analysis were performed to explore 
relationship between FMD and PWV.
Results: We enrolled 206 patients in our center into this study. PWV was significantly 
higher in patients with diabetes as compared to those without diabetes (12.37 ± 2.15 m/s vs 
10.50 ± 1.97 m/s; P < 0.001). PWV did not differ significantly between male and female 
patients. PWV was correlated with age (r = 0.39, P < 0.01), SBP (r = 0.38, P < 0.001), 
24-hour proteinuria (r = 0.18, P < 0.01), uric acid (r = 0.16, P < 0.05), and CRP (r = 0.15,
P < 0.05). Also, PWV correlated negatively with FMD (r = -0.21, P < 0.01) and estimated
glomerular filtration rate (r = -0.23, P < 0.01). In multivariate regression analysis, FMD,
age, SBP, DM, estimated glomerular filtration rate were each independently associated with 
PWV after adjustment.
Conclusions: Endothelial dysfunction is associated with greater arterial stiffness in 
pre-dialysis patients with Stage 3-5 CKD. This result suggests that increased CVD due to 
increased arterial stiffness is mediated by endothelium dysfunction in pre-dialysis patients 
with Stage 3-5 CKD.
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Validating Cardiac Troponin T in Predicting Cardiovascular and 
Mortality Risk in Kidney Transplant Candidates
Tripta Kaur,1 Harini Chakkera,2 Nan Zhang,1 Raymond L. Heilman,1 
Mira T. Keddis.1 1Mayo Clinic Arizona, Phoenix, AZ; 2Mayo Clinic, Phoenix, 
AZ.
Background: We evaluate cardiac troponin T (cTnT) as a predictor of cardiovascular 
(CV) and mortality risk in a racially diverse cohort with high morbidity presenting for KTx
evaluation.
Methods: 484 patients presenting for KTx evaluation from 2011-2013 at Mayo Clinic 
Arizona were evaluated. CV event was defined as coronary artery disease (CAD) or heart 
failure, and/or vascular event (stroke or peripheral vascular disease (PVD)). Normal cTnT 
<0.01ng/ml. The outcome of interest was combined CV event and/or mortality after KTx 
evaluation.
Results: Mean age 53.7±14 years; 58.5% male; 70.9% white, 23% Hispanic, 11.0% 
African American (AA), and 8.3% Native American; 42.1% diabetic; 30.2% CV event; 
41.4% on statins; 32.8% on antiplatelet therapy; 57.2% on dialysis and mean time on 
dialysis 20.1±25 months; mean body mass index (BMI) 29±5.9kg/m2; mean follow-up after 
KTx evaluation 44±19 months; 53.8% had cTnT≥0.01ng/ml. 61% had a KTx. 23.6% had 
a composite event (3.7% cardiac, 3.1% vascular, 19% died) with 79.8% occurring prior to 
KTx. ROC analysis identified cTnT≥0.036ng/ml to be best predictive of composite outcome 
(sensitivity 60%, specificity 71.4%). cTnT differed racially; more AA (55.6% vs 44.4%) 
and fewer whites (32.4% vs 67.6%) had cTnT≥0.036ng/ml. Predictors of increased cTnT 
included: male sex, older age, higher BMI, hypertension, diabetes, dialysis, CV events, and 
use of statins and antiplatelet therapy. On multivariable analysis of predictors of composite 
events, cTnT≥0.036ng/ml, older age and cardiac disease were independent predictors of 
composite outcome [Table 1].
Conclusions: We confirm that cTnT≥0.036ng/ml was the most powerful predictor of 
the composite outcome independent of other clinical variables in a racially diverse cohort 
with significant CV burden at the time of KTx evaluation.
Table 1. Multivariable analysis of predictors of composite outcome.
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Training Peer Mentors for Patients with CKD and Their Caregivers: A 
Qualitative Study
Tara Liaghat, Nasrollah Ghahramani, Mo’Tasem Alkhasoneh, Said Al Zein, 
Eugene Lengerich, Jennifer Kraschnewski. Penn State College of Medicine, 
Hershey, PA.
Background: Peer mentoring may improve patient-centered outcomes such as 
quality of life and engagement in care among patients with chronic kidney disease (CKD). 
However, training programs for peer mentoring and the mentors’ experiences are not well-
studied. Our study consisted of a structured 16-hour program to train peer mentors (PMs) 
for face-to-face and online mentoring of patients with CKD and their caregivers. This 
qualitative analysis examines perceptions of PMs regarding their training and the overall 
mentoring experience.
Methods: PMs were recruited to participate in training. Six months following training 
and serving in this role, 17 PMs participated in 3 focus group discussions. Discussions 
followed a guide, which identified how PMs felt about their training, their experiences with 
mentees, and their perception of how the program changed mentees’ attitudes. Discussions 
were audio-recorded and transcribed. Thematic analysis was performed by 2 researchers 
(MA; NG), assisted with use of NVivo11.0 software.
Results: Analysis revealed an overall positive perception of the training. PMs 
commented that training provided appropriate information, improved their understanding 
of the disease and clarified their role as mentor. Suggestions for improvement included 
incorporation of more interactive sessions such as role play. The PMs used strategies 
learned during training to foster mentees’ engagement in their own care by encouraging 
them to ask questions of their care team and by empowering them to request lay language in 
discussions. PMs perceived that their mentoring improved mentees’ adjustment to modality 
of treatment and to treatment failure. PMs felt valued and appreciated the relationship 
based on shared experience. They perceived the mentoring experience to have increased 
their knowledge of treatment modalities. The main perceived challenge was the mentees’ 
inadequate understanding of purpose of the mentoring program and the PMs’ role. PMs 
suggested educating mentees about the program and the PMs’ role.
Conclusions: A structured training program for peer mentoring is associated with 
satisfaction and perception of effectiveness by PMs. Peer mentoring provides benefits to 
PMs, including emotional satisfaction and perceived improvement in knowledge about their 
disease. Funding: PCORI
Funding: Other U.S. Government Support
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Short-Term Prognosis of Emergently Hospitalized Dialysis-Independent 
CKD Patients: A Nationwide Retrospective Cohort Study in Japan
Hiroaki Kikuchi,1 Eiichiro Kanda,2 Takayasu Mori,1 Soichiro Iimori,3 
Naohiro Nomura,1 Shotaro Naito,1 Eisei Sohara,1 Tomokazu Okado,4 
Shinichi Uchida,1 Kiyohide Fushimi,1 Tatemitsu Rai.5 1Tokyo Medical and 
Dental University, Tokyo, Japan; 2Kawasaki Medical School, Kurashiki, Japan; 
3Department of Nephrology, Tokyo Medical and Dental University, Tokyo, 
Japan; 4Department of Nephrology, Tokyo medical and dental university, Tokyo, 
Japan; 5Tokyo Medical & Dental Univ, Tokyo, Japan.
Background: In patients with chronic kidney disease (CKD), low body mass index 
(BMI) is associated with high mortality. This relationship in emergently hospitalized CKD 
patients is unknown. We investigated short-term protective effects of obesity in emergently 
admitted dialysis-independent CKD (DI-CKD) patients with and without inflammation.
Methods: This retrospective cohort study examined Diagnosis Procedure Combination 
data of 19822 emergently hospitalized DI-CKD patients. Patients were divided into 8 
groups according to their BMI and the presence of inflammation. The primary outcome was 
in-hospital death within 100 days.
Results: Cox proportional hazards models adjusted for baseline characteristics showed 
that low BMI was associated with the outcome both in inflamed and in noninflamed 
patients (referred to as noninflamed and medium BMI [24–26 kg/m2] group): inflamed 
and the lowest BMI (≤20 kg/m2) group, hazard ratio (HR) 3.46 (95% confidence interval 
2.80, 4.26); noninflamed and the lowest BMI group, 1.86 (1.48, 2.33). When patients were 
stratified according to presence of diabetes mellitus (DM), patients with DM showed that 
low BMI was associated with the outcome both in inflamed and in noninflamed patients, 
whereas in non-DM patients, this relationship was not observed in the noninflamed group.
Conclusions: For emergently hospitalized CKD patients with inflammation, high BMI 
was associated with lower mortality irrespective of the DM status. For noninflamed patients, 
the protective effects of obesity for in-hospital mortality were modified by the DM status.
All-cause mortality by BMI and inflammation in DI-CKD patients without DM; Cox 
proportional hazards analysis.
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Aging and Renal Arterio-Arteriosclerosis in Relatively Younger Patients 
with CKD
Nanako Ohshiro,1 Tsuyoshi Miyagi,2 Ryo Zamami,3 Yusuke Ohya,3 
Kentaro Kohagura.4 1Graduate School of Medicine,University of the 
Ryukyus,Okinawa,Japan, Nishihara-cho, Japan; 2Okinawa Daiichi Hospital, 
Okinawa, Japan; 3University of the Ryukyus, Nishihara-cho, Japan; 4University 
of the Ryukyus Hospital, Nishihara-cho, Japan.
Background: Aging is well known risk factor for renal areterio-arteriolosclerosis. 
However, effect of relatively younger age on the renal areterio-arteriolosclerosis is unknown 
in patients with chronic kidney disease (CKD).
Methods: A total of 174 consecutive patients who underwent renal biopsy at our 
department between 2010 and 2013 were considered for the study. We excluded patients with 
vasculitis and those who were receiving calcineurin inhibitors leaving us with 139 patients. 
Arteriolar hyalinosis (Hy) and small arterial intimal thickening (IT) was semiquantitatively 
assessed via grading system. Arterial stiffness and endothelial function was assessed by 
brachial-ankle pulse wave velocity (ba-PWV) and % flow-mediated dilatation(%FMD) of 
brachial artery.
Results: The mean for age, BP, estimated glomerular filtration rate (eGFR), and urine 
protein were as follows: 46 years, 124/72 mmHg, and 72 ml/min/1.73 m2, respectively. 
Even in the teens, Hy and IT were observed some patients, and their prevalence and the 
severity were linearly elevating as age group advancing. Similarly, the severity of ba-PWV 
was linearly elevating from the twenties. While, decreased %FMD was prevalent from the 
forties. Multivariate logistic analysis for the presence of Hy or IT were conducted adjusted 
with sex, systolic blood pressure, HbA1c, total cholesterol, uric acid and Brinkman index. 
The twenties was significantly associated with the presence of Hy (OR 9.8, 95% CI 1.2-
76.7, p=0.03) and (OR 7.1, 95% CI 1.1-46.0, p=0.04), respectively compared with the 
teens. Additional adjustment with ba-PWV disappeared the significance of the twenties.
Conclusions: Aging may be associated with renal arterio-arteriolosclerosis even in 
relatively younger age group. Age-related arterial stiffness may be responsible for this 
association.
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Does Peripheral Vascular Disease Affect Loss of Glomerular Filtration 
Rate?
Nuri Baris Hasbal,1 Melek Yalcin,2 Mustafa Kemal Yeniay,2 Deniz Akan,3 Mutlu 
Cagan Sumerkan,4 Mustafa Sevinc,1 Fatih Borlu,2 Abdulkadir Unsal,1,5 
Taner Basturk.1,5 1Nephrology, Sisli Hamidiye Etfal Training and Research 
Hospital, Istanbul, Turkey; 2Internal Medicine, Sisli Hamidiye Etfal Training 
and Research Hospital, Istanbul, Turkey; 3Radiology, Sisli Hamidiye Etfal 
Training and Research Hospital, Istanbul, Turkey; 4Cardiology, Sisli Hamidiye 
Etfal Training and Research Hospital, Istanbul, Turkey; 5Internal Medicine, 
Health Sciences University, Medical Faculty, Istanbul, Turkey.
Background: Ankle-brachial index (ABI) is a non-invasive diagnostic marker for the 
diagnosis of atherosclerotic peripheral vascular disease(PVD) and is frequently used in 
subclinical PVD. In our study, we aimed to investigate the effect of peripheral artery disease 
on GFR loss in patients wih stage 3-4 chronic kidney disease(CKD).
Methods: Totally 82 patients with stage 3-4 CKD who applied to our hospital between 
November-December 2015 were included in the study. Demographic characteristics, 
laboratory findings and comorbidities of all patients were recorded. Those with ABI<0.9 
were considered as PVD. Progression in CKD was accepted as at least 25% loss of GFR or 
development of ESRD.
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Results: The mean age of the patients was 65.5 years (23-78), 30(36.6%) were female. 
The most common comorbities were hypertension (85%), diabetes mellitus (45%) and 
ischemic heart disease (32.9%), respectively. Four patients were died and six patients had 
progression in CKD during follow-up. PVD was observed in 25% of patients. The baseline 
and 24-month follow-up laboratory values of patients are shown in Table 1. There was 
no statistically significant relationship between PVD and renal deterioration (p=0.213), 
but when deaths were accepted as renal progression, a trend towards significance is found 
(p=0.09). Baseline higher proteinuria and higher uric acid levels were corralated with CKD 
progression in patients with non-PVD patients (p=0.02 and p=0.004, respectively), but this 
effect was not observed in patients with PVD.
Conclusions: Our study did not reveal any relationship between PVD and renal 
survival during a 24-month follow-up in patients with CKD 3-4. However, proteinuria and 
uric acid levels in patients with non-PVD, stage 3-4 CKD may be good markers for CKD 
progression.
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Light Chain Amyloidosis in a Kidney Donor
Hania Shakeri,1 Niloofar Nobakht,1 Shaker Qaqish,1 Anthony Sisk,1 
Farid Arman,1 Ehsan Nobakht,2 Mohammad Kamgar,1 Anjay Rastogi.1 
1University of California, Los Angeles, Los Angeles, CA; 2George Washington 
University, Washington D.C, DC.
Introduction: Light chain amyloidosis is a relatively rare plasma cell dyscrasia 
characterized by the formation of amyloid from immunoglobulin (Ig) light chains that leads 
to the deposition of Ig light chain Kappa and lambda in different organs, most importantly in 
kidney and heart. The clinical presentation depends on the organs involved, and the degree 
of involvement and includes proteinuria, decreased renal function and cardiomegaly with 
heart failure. The condition has been reported in kidney transplant recipients in the past, but 
not in kidney donors. The response to treatment depends on various factors, most important 
of them being the degree of proteinuria and glomerular filtration rate (GFR) at the baseline.
Case Description: Our case was a 51-year-oldfemale who had donated her kidney 
to her brother (suffering from ESRD as a result of IgA nephropathy). The donor’s past 
medical history before donation included benign bilateral breast masses, and anxiety. Pre-
donation imaging showed a non-significant punctate non-obstructing lesion in the left 
kidney. Past surgical history included laminectomy and appendectomy. She underwent an 
uncomplicated laparoscopic donor left nephrectomy. Two years post-donation, the patient 
was diagnosed with proteinuria as much as 4.8 gram and creatinine of 1.2 from baseline of 
0.9 (Post-donation creatinine were 1.2, 1.3 and 0.9 at 6, 12and 24 months post-donation, 
respectively), and was referred for further follow-up. She underwent a kidney biopsy 
that showed global mesangial kappa restriction and apple-green birefringence in Congo-
red stain, compatible with Ig light chain deposition disease. The treatment started with 
daratumumab which led to significant drop in kappa light chains (from 28.2 to 2.23 mg/L, 
shown in table 1) and improvements in the proteinuria and GFR.
Discussion: Ig light chain deposition disease is relatively rare, and involves kidney 
and heart the most. The response to treatment is highly depends on the initial proteinuria 
and GFR. Our patient had a good response to treatment, with decrease in proteinuria and 
increased GFR. The fact that the patient was post-nephrectomy and single kidney did not 
affect her prognosis.
Light chain levels pre and post donation
PUB154 
Publication-Only 
CKD with Multisystem Nocardia Infection
Ningning Wang,1 Li Dong,2 Chang Ying Xing,5 Yaning Mei,3 Yan Zhu,4 
Weiying Liu,4 Ying Cui.1 1Department of Nephrology,The First Affiliated 
Hospital with Nanjing Medical University, Nanjing, China; 2Department of 
Infectious Diseases, the First Affiliated Hospital of Nanjing Medical University, 
Nanjing, China; 3Department of Microorganism, the First Affiliated Hospital of 
Nanjing Medical University, Nanjing, China; 4Department of Nephrology, the 
Nanjing Second Hospital, Nanjing, China; 5First Affiliated Hospital of Nanjing 
Medical University, Nanjing, China.
Introduction: Here is a case of 42-year-old female with membranous nephropathy, 
chronic kidney disease (CKD G1A1), type 2 diabetes. She suffered multisystem nocardia 
infection (pulmonary and soft tissue infection, multiple brain abscesses) which is rare in 
clinic.
Case Description: She was diagnosed as pulmonary infection with cough and 
expectoration. In other hospitals, she was successively treated with multiple antibiotics 
and voriconazole after stopping Cyclosporin. Cystic masses were found on right temporal, 
buttocks and popliteal fossa, accompanied by pain and normothermia (Fig1). Chest CT 
and head MRI showed right lung infection and multiple brain abscesses. Routine culture 
of blood and soft tissue puncture fluid were all negative, while nocardia was positive. We 
reduced dose of Medrol and gave Smzco+ Linezolid+ Imipenem and cilastatin sodium+ 
Minocycline. Cardiopulmonary arrested and epilepsy took place suddenly and she was 
saved. Her renal function and urine protein was normal through the six-month follow up. 
Imaging examinations showed infection was controlled(Fig2).
Discussion: Nocardia is Gram-positive and conditional pathogenic bacteria. Lung 
is involved mostly often through hematogenous spread. Due to atypical manifestation 
and slow growth of nocardia, nocardiosis is easy to escape diagnosis. It’s reported that 
the mortality rate is as high as 100% when combined with brain abscess. This case has 
susceptible factors of infection such as CKD, diabetes, long-term use of Medrol and 
immunosuppressive agents. Sensitive antimicrobial treatment should be continued for 
6 to 12 months.
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Food Consumption, Eating Behaviors, and Nutritional Status in Poor 
CKD Mexican Patients
Nallely Barraza,1 Patricia López,1 Zyanya Reyes,1 Eduardo D. Torres,3,2 
Rodolfo A. Moreno,2,3 Guillermo Garcia-Garcia.2,3 1Cusur Universidad De 
Guadalajara, Ciudad Guzman, Mexico; 2Hospital Civil de Guadalajara FAA, 
Guadalajara, Mexico; 3CUCS University of Guadalajara, Guadalajara, 
Mexico.
Background: CKD patients must consume food according to dietary recommendations 
and modify their eating behaviors to retard disease progression, maintain adequate nutrition, 
and reduce complications. We evaluated food consumption (FC), eating behaviors (EB), 
and nutritional status (NS) in pre-dialysis CKD patients.
Methods: Cross-sectional study in 40 CKD patients stages 3-4. A semiquantitative food 
frequency questionnaire was used to determine nutrient and FC; a behavioral questionnaire 
was applied to identify EB. NS was assessed by anthropometry.
Results: The median age was 52 y; 90% had deficient energy intake and 25% had 
inadequate protein intake. Most patients had deficient intake of lipids, carbohydrates and 
almost all vitamins and minerals, with the exception of vitamin B12, C and iron; 42.5% were 
overweight and 22.5% were obese; 15% had decreased muscle mass. The consumption of 
oils and fats, sugars with fat and sugary drinks were positively associated with BW, BMI, 
% body fat and waist circumference (Fig 1). The EB of “choice of foods by visual appeal”, 
“the preparation of their food is in charge of another person” and “avoid consuming some 
type of food because it makes them feel bad” were associated with a minor muscle mass 
and body fat.
Conclusions: Eating behaviors and dietary factors were associated with nutritional 
status in patients with CKD. In addition, regardless of stage, FC was deficient in quality 
and quantity, together with a high prevalence of overweight and obesity. It is suggested the 
need to implement nutritional interventions with a multidisciplinary approach to improve 
the nutrition of CKD patients, to meet nutritional requirements, and to avoid disease 
progression to terminal stages and complications.
Fig 1.
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Renal Artery Revascularization in the Era of Negative Clinical Trials: 
Pattern of Practice and Outcomes of a Single Center
Syed S. Zaidi,1 Ajay P. Dhaygude,1 Mohamed Elsayed,1,2 Arvind Ponnusamy.1 
1Renal Department, Royal Preston Hospital, Preston, United Kingdom; 
2University of Limerick, Limerick, Ireland.
Background: Renal artery stenosis is not an uncommon finding in atherosclerotic old 
patients. However, certain subgroups of patients appear to benefit from revascularization 
therapy. With concerns regarding patient selection in clinical trials comparing medical 
therapy to the revascularization, clinical equipoise still exists. We describe our center 
experience in renal revascularization therapy.
Methods: Study cohort consisted of all consecutive patients undergoing renal 
angioplasty for atherosclerotic renal stenosis, through referral by renal team in Royal 
Preston Hospital from January 2016 to January 2018. Data on demographics, comorbidities, 
and indications for angioplasty were collected retrospectively. Studied outcomes were 
change in eGFR, mean difference in the number of anti-hypertension medications at 
6 months post intervention and the proportion of patient with. Data analysed using SAS 9.4
Results: Thirteen patients were included, of whom 6 were females. Mean age at the time 
of intervention was 64.2 (±11.8) years old. All were hypertensive, (23% had Diabetes, 30.7% 
had heart failure, 84% had CKD and peripheral vascular disease was prevalent on 53.8%. 
Indications for revascularization (not mutually exclusive) were; pulmonary edema (23.8%), 
worsening renal function (46.1%) and refractory HTN (69.23%). Six (46.1%) patients had 
only one indication, while 4 patients (30.7%) had 2 indications and 3 patients (23%) had 
3 indications. Mean number of anti-hypertensive medications at baseline was 3.6 ±1.6 
and in six month it dropped to 2.5 ±1 (P = 0.02). Furthermore, the proportion of those 
with controlled blood pressure has increased significantly from 8 % to 83% (P= 0.004). 
Mean eGFR at the time of intervention was 37.0 ±27 ml/min.1.73m2. This improved to 
45.5 ± 28 ml/min.1.73m2, but the difference did not reach statistical significance (P= 0.14).
Conclusions: Outcomes for patients selected for renal revascularitaion in Royal Preston 
Hospital were excellent. Despite the negative trials, renal angioplasty for atherosclerotic 
renal disease still has a positive role that is achieved through careful patient selection with 
a clinical indication in addition significant renal artery stenosis. Larger scope studies with 
meticulous patient selection of high risk are warranted.
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Relationship Between Renal Function and Development of Remission in 
Patients with Chronic Refractory Gout Treated with Pegloticase
Naomi Schlesinger,1 N. L. Edwards,2 Richard J. Johnson,3 Anthony Yeo,4 
Peter E. Lipsky.5 1Rutgers, The State University of New Jersey, New Brunswick, 
NJ; 2University of Florida College of Medicine, Gainesville, FL; 3University of 
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Background: Criteria for remission in gout have been reported1 and they include: 
serum urate <6 mg/dL, no flares in last 12 months, no tophi, pain <2, and patient global 
assessment of disease activity <2, each on a 10-point scale. Impaired kidney function is a 
recognized comorbidity of gout, but it is not known whether chronic kidney disease (CKD) 
impairs the response to gout treatment.
Methods: This analysis used results from two 6-month randomized controlled trials 
of pegloticase in patients with chronic refractory gout to address this issue. The analysis 
included 34 patients who responded to pegloticase administered at a dose of 8 mg every 2 
weeks (q2w) with sustained serum urate reductions (<6 mg/dL) over 6 months.
Results: Overall, 29/34 (85.3%) of these patients met the proposed criteria for 
remission. eGFR was determined at baseline and patients were divided into CKD categories. 
CKD category had no significant effect on the percentage of patients achieving remission 
nor on the time required to develop a remission. Notably, no significant change in eGFR 
was noted in these patients.
Conclusions: These results suggest that renal dysfunction estimated by eGFR does not 
influence remission or time to reach remission in pegloticase-treated patients with chronic 
refractory gout, thus maintaining persistent urate lowering. Reference 1 de Lautour H, et al. 
Arthritis Care Res(Hoboken). 2016;68:667.
Funding: Commercial Support - Horizon Pharma
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Addressing Metabolic Acidosis in CKD Patients with Liver Cirrhosis - No 
Good Deed
Srilakshmi Ravula,1 Ramakrishna Thotakura,3 Manisha Singh.2 1University of 
Arkansas Medical Center, Little Rock, AR; 2University of Arkansas For Medical 
Sciences, Little Rock, AR; 3UAMS, LITTLE ROCK, AR.
Background: Uncorrected metabolic acidosis(MA) is detrimental in chronic 
kidney disease (CKD)with evidence of mortality benefit in correcting acidosis to 
bicarbonate(HCO3) levels of around 22 mmol/l. However, impact of correcting MA in 
liver failure with cirrhosis(LF-c)) is unclear. LF-c is a physiologically alkalotic state, with 
compensatory low HCO3. Correcting acidic milieu may provide overall benefit, however 
this commonly requires using sodium salts. This may be detrimental to LF-c patients’ due to 
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sodium load resulting in increased interventions like paracentesis. We hypothesized that if 
there is evidence of MA as measured by blood gases(ABG/VBG), we can target a moderate 
correction of acidosis within the recommended sodium restriction.
Methods: We conducted a retrospective chart review to study outcomes in adults over 
18 with MA and LF-calculated MELD score 0-39.
Results: Inpatient charts reviewed between 2015-17 had 14 patients with LF-c and 
CKD with MA proven by ABG/VBG. Of these, 3 were on oral NaHCO3 targeting near 
normal serum HCO3 level.
Conclusions: KDIGO recommends HCO3 level to 22 mmol/L to prevent CKD 
progression. However, it is unclear if we can imply the same to population with LF-c and 
CKD as such studies are unavailable. Our preliminary data shows no improved outcomes. 
We opine that we may target lower HCO3 levels to account for respiratory compensation 
and to prevent sodium overload. Our study is limited by sample size and observational data.
Patient Characteristics
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Effectiveness of PCSK9 Inhibitors in Dementia Patients with Chronic 
Renal Insufficiency
Alexander M. Swan,2,1 Aye myat Mon,3,4 Htet Htet Kyaw.4 1NHRTRT,LLC, 
AVENEL, NJ; 2Rutgers New Jersey Medical School, Newark, NJ; 3Pun Hlaing 
Siloam Hospital, YANGON, Myanmar; 4NHRTRT, LLC, Avenel, NJ.
Background: Based on 2017 data from Centers for Disease Control and Prevention, 
15% of US population suffered from chronic kidney disease (CKD) and over 80% of 
end-stage renal disease patients were receiving long-term hemodialysis. In CKD patients, 
dementia is a common association and plays as an important factor that increases morbidity 
and mortality. PCSK9, the protein convertase enzyme, involves in degradation of low-
density lipoprotein (LDL) receptors in the liver. PCSK9 inhibitors are proven to reduce LDL 
level in the blood by increasing available LDL receptors on the hepatocytes. Low plasma 
LDL subsequently reduces the risk of atherosclerosis, including the cerebral circulation. 
There is no report of the effect of PCSK9 inhibitors on dementia in CKD patients. Our study 
might be an initiation to this area.
Methods: This study was a non-randomized clinical trial study design. A total of 79 
participants (39 males and 40 females; average age, 62) having chronic renal insufficiency 
with hypercholesterolemia and a certain degree of memory impairment was injected with 
PCSK9 inhibitor (Repatha 420 mg subcutaneous injection monthly) for 3 months. The 
severity of dementia was assessed and recorded at the start of the trial using Functional 
Assessment Staging Test according to Dementia Care Central. Patients were followed up 
biweekly to reassess the dementia stage and monitor any unwanted side effect of the drug. 
The targeted primary outcome was changes in the dementia stages and concurrent reduction 
of LDL levels.
Results: At the first follow-up visit, patients and their family members reported having 
increased energy and subjective improvement of memory. This effect has continued and 
the dementia stages gradually declined up to two stages below the initial stage at the end of 
the 3-month period. The LDL fell down from initial level of 185 mg/dl to 35 mg/dl after 3 
months. No side effect was reported. The study is still ongoing.
Conclusions: The results clearly shows that PCSK9 inhibitor is effective in improving 
memory loss in those CKD patients. The hypothesis is that PCSK9 inhibitor improved 
cerebral circulation by halting or even reversing the process of atherosclerosis leading 
to the recovery of vulnerable brain areas with insufficient blood supply. However, more 
scientific approaches and researches in the larger study population are necessary to prove 
this hypothesis.
PUB160 
Publication-Only 
A New Glomerular Filtration Rate Estimating Model for CKD Patients 
Using Ensemble Learning
Xun Liu. The Third Affiliated Hospital of Sun-Yat-Sen University, Guangzhou, 
China.
Background: Accurate estimating GFR is very important for clinical settings. 
However, since the CKD_EPI equation published in the NEJM on 2012, the performance 
of GFR estimating equation did not improved.
Methods: CKD patients in China from May 2011 to June 2015 were used as the 
development dataset and from July 2015 to June 2016 as the exteranl vailation dataset. 
sGFRs were measured by the DTPA kidnye scan callibrated to the 2 plasma sample DTPA 
serum clearance method.
Results: In the external validation dataset, eGFR by emsemble leaning improved bias 
and accuracy than the revised regression equatinos. The 30% accuracy of the 8 variables 
emsemble learning is 88%. Detailed imformation is showed in the figured attached
Conclusions: The emsemble leaning models achieved better performance than the 
revised equation models in GFR estimates.
Funding: Government Support - Non-U.S.
PUB161 
Publication-Only 
Probiotic Supplements Prevented Oxonic Acid-Induced Hyperuricemia 
and Renal Damage
Fernando E. García-arroyo,1 Guillermo Gonzaga,5 Itzel Muñoz,1 Monica G. Blas-
Marron,5 Edilia Tapia,5 Virgilia Soto,5 Natarajan Ranganathan,3 Pari Ranganathan,4 
Usha N. Vyas,4 Anthony Irvin,3 Diana Ir,6 Dan Frank,2 Richard J. Johnson,2 L. 
Gabriela Sanchez-Lozada.1 1Nephrology, INC Ignacio Chavez, Mexico City, 
Mexico; 2University of Colorado Denver, Aurora, CO; 3Kibow Biotech Inc, 
Newtown Square, PA; 4Kibow Biotech Inc, Newtown Square, PA; 5INC Ignacio 
Chavez, Mexico City, Mexico; 6University of Colorado, Thornton, CO.
Background: In chronic kidney disease, HU is extremely common, and uric acid (UA) 
excretion heavily relies on gut uricolysis by gut microbiotaMoreover, HU contributes to 
CKD physiopathology. Current therapy for lowering serum UA includes drugs that may 
produce undesired secondary effects. Therefore, this pilot study was designed to evaluate 
the potential of two probiotic supplements to reduce systemic uric acid concentrations and 
to evaluate whether hyperuricemic renal damage was prevented.
Methods: Groups of 6 rats each were followed by 5 weeks and allocated in C= Control; 
ND= Oxonic acid-induced hyperuricemia (HU) +regular diet; P= HU+placebo; F1= HU+ 
probiotics formula 1 and F2= HU+ probiotics formula 2. At the end of the study, systolic 
blood pressure measurement as well as blood samples and 16 h urine collections were taken. 
Then rats were sacrificed and kidneys were washed by perfusion, fixed and analyzed for 
arteriolar wall area using alpha-smooth muscle actin to mark the arteriolar vessels.
Results: Results are showed in Table 1
Conclusions: In conclusion, we demonstrated for the first time the ability of probiotics 
containing uricolytic bacteria to lower serum uric acid in hyperuricemic animals with 
beneficial consequences on blood pressure and renal disease. As probiotics supplements 
are innocuous for the human health, this might represent a safe therapeutic approach to 
treat HU.
Funding: Commercial Support - Kibow Biotech
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The Transregional Collaborative Research Center SFB/TRR219: 
Mechanisms of Cardiovascular Complications in CKD
Heidi Noels,2 Joachim Jankowski.1 SFB-TRR219 1RWTH Aachen, Aachen, 
Germany; 2RWTH University Aachen, Aachen, Germany.
Background: A new Research Center of the German Research Foundation (DFG) 
seeks understanding of the renal and cardiovascular interactions that underlie enhanced 
cardiovascular risk in patients with CKD, with the ultimate aim to trigger the development 
of novel treatment strategies to reduce cardiovascular morbidity and mortality in these 
patients.
Methods: Reducing the increased cardiovascular mortality in CKD patients through 
novel therapeutic strategies first requires the identification and understanding of the 
pathological mechanisms adversely affecting the cardiovascular system specifically in 
CKD. With exactly this goal two German universities, the RWTH University of Aachen 
and Saarland University, have initiated the Research Center to analyse in experimental and 
clinical studies the multi-factorial aspects of CKD-related cardiovascular morbidity and 
mortality.
Results: Some relevant mediators that affect renal, myocardial and vascular 
pathology have already been identified. However, their functions regarding the complex 
interactions between kidney, heart and vessel are still poorly understood. The consortium 
will characterize known and newly identified mediators relevant in CKD and seek 
understanding of the mechanisms underlying their effect on heart and vessels causing 
CKD-related CVD. The main mechanisms that will be investigated to underlie increased 
cardiovascular risk in CKD include calcification, inflammation, oxidative stress and 
fibrosis, in addition to alterations in thrombosis and neurohumoral activity. Secondly, SFB/
TRR219 consortium will strive to identify novel mediators relevant in CKD with a strong 
impact on CVD. Also, the consortium will study the translational aspects by investigating 
novel mediators as potential biomarkers of CKD-related CVD, by analyzing the effect of 
novel interventions on CKD-related cardiovascular pathology, and by extending previously 
developed diagnostic tests for cardiovascular pathology to the context of CKD to aid its 
application into clinical practice.
Conclusions: In summary, the SFB/TRR219 is a German research consortium that 
seeks understanding of the renal and cardiovascular interactions that underlie enhanced 
CV risk in patients with CKD, with the ultimate aim to trigger the development of novel 
treatment strategies to reduce cardiovascular morbidity and mortality in these patients.
Funding: Government Support - Non-U.S.
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A Novel Model of Renal Vascular Disease in the C57BL/ 6 Mouse Strain
Julius E. Kieswich,1 Jianmin Chen,3 Samira Alliouachene,2 Paul W. Caton,6 
Kieran Mccafferty,5 Christoph Thiemermann,3 Muhammad M. Yaqoob.4 1Centre 
for Translational Medicine and Therapeutics, LONDON, United Kingdom; 
2Queen Mary University, London, United Kingdom; 3Queen Mary University of 
London, London, United Kingdom; 4William Harvey Research Institute, London, 
United Kingdom; 5NHS, LONDON, United Kingdom; 6King’s College London, 
LONDON, United Kingdom.
Background: Vascular disease is prevalent in the chronic kidney disease (CKD) 
population having a 20 fold higher incidence of cardiovascular mortality compared to 
the population as a whole. Reno- cardiac syndrome (RCS), described as cardiovascular 
disease initiated by renal failure, is a growing world health problem thus necessitating the 
need for continued improvement of therapeutic strategies to combat it. Murine in vivo 
models contribute greatly to such research allowing for specific genetic modification and 
therefore reduced miscellany, however there is currently no reliable model of CKD in the 
most common genetically modified mouse strain, the C57BL/6. In this study we have 
manipulated an established model of CKD using adenine infused diet and prolonged the 
course of its pathology in order to achieve CKD and subsequent vascular disease in the 
C57BL/6 mouse strain.
Methods: 9 week old C57BL/6 male mice were administered a 0.15% adenine diet or 
control diet for 20 weeks.
Results: Administration of 0.15% adenine diet caused progressive renal failure resulting 
in renal vascular disease. The mice tolerated the diet well, weights being maintained with 
no mortality. At endpoint uraemia was confirmed by blood biochemistry which in the 
adenine fed mice showed significant increases in serum creatinine and urea, (P<0.0001) 
and a significantly reduced glomerular filtration rate as indicated by creatinine clearance 
(P<0.05). Immunoblotting of aortic tissues demonstrated classic features of vascular 
disease, that is increased apoptosis (caspase 3) and fibrosis (α-SMA) and increased levels 
of total Akt suggested a mechanistic pathway for this pathology. Haematoxylin and eosin 
staining illustrated the inflammatory state of the vasculature and immunohistochemistry for 
α-SMA further confirmed fibrosis.
Conclusions: We present a novel regimen of adenine diet which induces both CKD and 
reno-vascular disease in the C57/BL6 mouse strain. The non-surgical nature of this model 
makes it highly reproducible compared to other models currently available.
Funding: Private Foundation Support
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YAP/TAZ Upregulation During Kidney Injury Links Altered Metabolism 
to Fibrotic Response
Rohan Samarakoon,1 Jiaqi Tang,2 Erin E. Salter,1 Roel Goldschmeding,3 
Paul J. Higgins.2 1Albany Medical Center, Albany, NY; 2Albany Medical College, 
Watervliet, NY; 3University Medical Center Utrecht, Utrecht, Netherlands.
Background: Recent studies including ours link Hippo-YAP/TAZ pathway 
deregulation in kidney disease. YAP/TAZ upregulation during renal injury promotes 
maladaptive repair and transduces TGF-beta1 and mechanical signaling. Here we test the 
hypothesis that renal YAP/TAZ activation promotes metabolic reprograming associated 
with chronic kidney disease progression.
Methods: We investigated the potential relationship among YAP/TAZ, aerobic 
glycolysis and fibrosis using both in vitro and in vivo mouse models of renal injury.
Results: YAP and TAZ expression are persistently upregulated in the tubulointerstitium 
during obstructive nephropathy. Stable transduction of YAP or TAZ in renal epithelial cells 
promoted fibrotic factor induction (e.g., CTGF, fibronectin), dedifferentiation and G2/M 
cell cycle arrest relative to empty vector-expressing controls. Epithelial YAP/TAZ activation 
leads to SMAD3 activation and TEAD upregulation which are necessary for fibrotic 
response. YAP/TAZ overexpression also stimulated robust expression of hexokinase-1, 
phosphofructokinase and pyruvate kinase M2, three enzymes that catalyze irreversible steps 
of glycolysis. Pre-incubation with the YAP/TAZ inhibitor, verteporfin attenuated glycolytic 
reprogramming in YAP/TAZ expressing cultures. Concurrent induction of the glycolytic 
enzymes and YAP/TAZ is also evident in the ligated (UUO) mouse kidney compared to 
contralateral controls. Intraperitoneal administration of verteporfin not only attenuated 
fibrogenesis but decreased glycolytic enzyme expression in the obstructed kidneys 
compared to vehicle treated UUO controls.
Conclusions: Renal YAP and TAZ upregulation promotes glycolytic reprogramming 
and fibrotic epithelial dysfunction. Pharmacological inhibition of YAP/TAZ activation, 
conversely, attenuated aerobic glycolysis and renal fibrosis in mice, establishing novel 
pathological links between Hippo-YAP/TAZ deregulation and metabolic alterations in 
progressive CKD.
Funding: Other NIH Support - NIH GM057242 and a Capital Region Medical 
Research Institute Grants
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Study on the Correlation Between Serum NGAL Level and Clinical 
Progressive Risk Factors of Primary IgA Nephropathy
Li Cao,1 Yali Zheng.2 1Ning Xia People Hospital, Yinchuan, China; 2Ningxia 
People’s Hospital, Yinchuan, China.
Background: To investigate the correlation between serum neutrophil gelatinase-
associated apolipoprotein levels(sNGAL) and the risk factors of primary IgA nephropathy 
and evaluate the early predictive value of sNAGL on the progression of IgA nephropathy.
Methods: Retrospectively analyzed 70 cases of primary IgA nephropathy, that 
diagnosed in the nephrology department of Ningxia People’s hospital from April 2016 to 
August 2017. One-way ANOVA, bivariate Spearman correlation analysis and multivariate 
linear regression analysis were used to investigate the effect of sNGAL Correlation of serum 
levels with risk factors for the clinical progression of primary IgA nephropathy.
Results: The serum levels of sNGAL were positively correlated with blood pressure 
(r=0.33, P=0.005), urinary protein excretion (r=0.371, P=0.002), eGFR Correlation 
analysis showed statistically significant differences (P<0.05). The differences of sNGAL 
in 24h urine protein (P=0.003) and CKD staging (P=0.000) were statistically significant 
(P<0.05). Multivariate regression analysis showed that eGFR (β= -0.509, P=0.000) was an 
independent factor of sNGAL level.
Conclusions: sNGAL is closely related to renal dysfunction and proteinuria. Early 
detection of sNGAL can be used to assess renal function and predict the progression of the 
disease. tor of sNGAL level.
Funding: Government Support - Non-U.S.
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Alterations of the Lipid Profile in the Aging Kidney Identified by MALDI 
Imaging Mass Spectrometry
Su-Mi Kim, Dong-Jin Kim, Yu ho Lee, Yang gyun Kim, Ju young Moon, 
Sangho Lee. Division of Nephrology Department of internal medicine Kyung 
Hee University College of Medicine, Seoul, Republic of Korea.
Background: During aging, kidney experiences functional and physiological changes 
which are closely related with chronic kidney disease (CKD). There is increasing evidence 
supporting the role of lipid changes in the etiology of CKD.
Methods: To understand the role of lipids mediating various metabolic processes 
during aging, we conducted MALDI imaging mass spectrometry (MALDI IMS) analysis in 
kidneys harvested from young mice (2 months old, n=3) and old mice (24 months old, n=3).
Results: MALDI IMS analysis showed an increase in ceramide levels and a decrease 
in sphingomyelins (SMs) and phosphatidylcholines (PCs) levels in kidneys of old mice. 
Immunohistochemistry (IHC) confirmed elevation of PLA2 and Smase in kidneys of old mice.
Conclusions: Our MALDI IMS data showed the altered distribution of lipids on aged 
kidney as indicative for functional changes of the kidney with aging. Combined analysis of 
MALDI IMS and IHC confirmed lipidomic changes and expression levels of responsible 
enzymes as well as morphological changes.
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The Significance of NAD+ Metabolites and Sirtuins in CKD
Rina Kitahama,1 Takeshi Kanda,1 Hitoshi Minakuchi,4 Hidenori Urai,5 
Arata Kurokochi,7 Kazuhiro Hasegawa,2 Hirobumi Tokuyama,6 Shu Wakino,1 
Hiroshi Itoh.3 1Keio University, Tokyo, Japan; 2Department of Internal Medicine, 
Tokyo, Japan; 3Keio University School of Medicine, Tokyo, Japan; 4school of 
medicine, Keio University, Tokyo, Japan; 5Keio University, School of Medicine, 
Tokyo, Japan; 6Internal Medicine, Keio University, Tokyo, Japan; 7Keio 
University hospital, Tokyo, Japan.
Background: Renal tissue fibrosis is a final common pathway toward the end-stage 
renal disease and the change in nicotinamide adenine dinucleotide (NAD+) metabolism 
contributes to the pathogenesis of renal dysfunction including fibrotic renal disease. 
The substrates of NAD+ synthesis such as nicotinamide (NAM) and nicotinamide 
mononucleotide (NMN) have become an emerging therapeutic target for kidney diseases 
by the activation of sirtuins. In this study, we examined the alteration of NAD+ metabolites 
in the unilateral ureter obstruction (UUO) model mice and CKD patients.
Methods: We measured NAD+ metabolite levels in the kidneys of UUO and sham-
operated mice. In CKD patients, we recruited more than 25 subjects in each CKD stages and 
measured NAD+ metabolite levels in the serum.
Results: In the kidneys of UUO mice, renal NAM, NMN and NAD+ levels were 
significantly lower than in sham-operated mice. In contrast, the downstream products 
of NAD+ metabolites, N-methyl-2-pyridone-5-carboxamide (2-PY) and 4PY were 
accumulated in the kidneys of UUO mice. Sirtuin activity is regulated by NAD+ levels and 
Sirt1, Sirt3, and Sirt7 mRNA expression were significantly decreased in accordance with the 
increased fibrosis genes in the kidneys of UUO mice. In the CKD patients, across increasing 
CKD stages, gradual decreases in serum levels of NAM were found (p<0.01, for trend). 
On the other hand, the serum levels of 2PY and 4PY significantly increased respectively 
(p<0.01 for the trend test). In single regression analyses, NAM was significantly positively 
correlated with eGFR. 2PY and 4PY were negatively correlated with eGFR. Multiple 
regression analyses showed that eGFR was an independent explanatory variable for NAD+ 
metabolites after adjusting them with other factors such as age, BMI and HbA1c.
Conclusions: Substrates of NAD+ synthesis such as NMN and NAM decreased in 
both kidney and serum in chronic renal injury, which could contribute to the inhibition of 
sirtuin activity and the fibrosis in CKD. In CKD patients, NAD+ metabolites were strongly 
associated with renal dysfunction.
Funding: Commercial Support - Shionogi & Co., Ltd.
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Varying Nephrectomy Delay Time After Unilateral Ischemic Injury Allows 
Development of an Animal Model with a Controllable Degree of Renal 
Dysfunction
Lies Moonen,1 Cristina Cuesta,3 Patrick C. D’Haese,2 Francisco J. Lopez-
hernandez,5 Carlos Martinez-salgado,4 Benjamin A. Vervaet.2 Laboratory of 
Pathophysiology, University of Antwerp 1University of Antwerp, Wilrijk, 
Belgium; 2University Antwerp, Edegem, Belgium; 3Institute for Biomedical 
Research of Salamanca (IBSAL), Salamanca, Spain; 4Universidad de Salamanca, 
Salamanca, Spain; 5IECSCYL - Hospital Universitario de Salamanca, 
Salamanca, Spain.
Background: An important feature of the clinical course of CKD is the graded 
decline in renal function, divided into 5 stages (CKD1 to CKD5). Extrapolating data from 
animal studies to the clinical situation requires a good functional correlate between the 
target population and the experimental model. Based on the fact that an acutely injured 
kidney persistently loses renal mass in the presence of its healthy counterpart and an 
early nephrectomy (Nx) of the healthy kidney rescues the decay of the injured kidney, we 
hypothesized that a sufficiently delayed Nx would not allow efficient renal recovery of 
the injured kidney and that by varying the Nx delay time, one would be able to predefine 
the eventual degree of remnant renal function correlating with the clinically relevant CKD 
stages.
Methods: AKI was induced in male Wister rats by left ischemia/reperfusion (UIRI) for 
60 min after which contralateral Nx was performed 3, 10 or 20 days later. Renal function 
was assessed by serum/urine creatinine and transcutaneous measurement of GFR 24 and 
72 hours after Nx and weekly thereafter. Rats were euthanized 11 weeks after Nx. Kidneys 
were weighed and histology was evaluated by PAS stain.
Results: In all groups, 24h after Nx renal function was impaired. Early Nx (day 3) 
induced full recovery of renal function by week 11 starting from week 3. Late Nx (day 
10, 20) led to a functional loss between 40% at week 3 and 20% at week 11 (p<0.05). 
There was no significant difference in renal function between groups of day 10 and 20. Nx 
induced compensatory hypertrophy/recovery in all groups as shown by an increased 
renal mass-to-body weight ratio from 2.9 mg/g (sham) to 4.6 mg/g (day 3) and 4.8 mg/g 
(day 10). Hypertrophy/repair was less pronounced when Nx was performed at day 
20 (4.0 mg/g, p<0.05). Histological analysis confirmed hypertrophy and showed more 
cortico-medullary atrophy at day 10 and 20 as compared to day 3.
Conclusions: Early Nx rescues renal function, whereas sufficient delayed Nx does 
not allow a full functional recovery of the injured kidney, currently mimicking CKD2. 
Varying Nx delay time after UIRI thus can provide an experimental method to induce renal 
dysfunction of different but controllable severity.
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Uremic Toxins Activates Na/K-ATPase Oxidant Amplification Loop in 
Mouse Pre-Adipocytes Causing Phenotypic Change in Adipocyte and 
Oxidative Stress
David E. Bartlett, Richard B. Miller, Scott T. Thiesfeldt, Hari Vishal Lakhani, 
Rebecca Pratt, Cameron Brickman, Joseph I. Shapiro, Komal Sodhi, 
Smara Sigdel. Marshall University Joan C. Edwards School of Medicine, 
Huntington, WV.
Background: Experimental CKD leads to accumulation of uremic toxins(UT) in the 
circulation resulting in increased ROS production which, in turn, is known to activate Na/K-
ATPase signaling. Studies in mouse model of obesity has shown that increased oxidative 
stress in plasma is due to increased ROS and cytokines production from dysfunctional 
adipocytes. We hypothesize that adipocytes exposed to UTs will activate Na/K-ATPase 
signaling causing redox imbalance in adipocytes. We will also demonstrate that Na/K-
ATPase antagonist, pNaKtide, will attenuate these pathophysiological consequences. 
We will employ our lentivirus construct, lenti-adiponectin-NaKtide, to specifically target 
adipocytes.
Methods: 3T3-L1 cells were treated with varying concentrations of UTs, indoxyl sulfate 
(25, 50 and 100 μM) and p-cresol (100, 200 and 250 μM), with or without pNaKtide (1 μM) 
for 5 days in adipogenic media. Cells were treated as follows: vehicle IS alone, p-cresol 
alone, NaKtide alone, IS+NaKtide, p-cresol+NaKtide, pNaKtide alone, IS+pNaKtide, 
and p-cresol+pNaKtide. RT-PCR and Western blotting was used to evaluate changes in 
RNA and protein expression, respectively, of adipogenic markers (PPARγ, C/EBPα, 
aP2, FAS, Mest), oxidative stress markers (ROS, TBARS), apoptotic markers (Bcl2, Bad, 
Caspase 3 and 9) and inflammation markers (TNF-α, IL-6, MCP-1).
Results: Our results demonstrated that 3T3-L1 adipocyte cells treated with uremic 
toxins induced oxidative stress, apoptosis and inflammation through activation of Na/K-
ATPase signaling (p<0.01). However, pNaKtide treatment ameliorated adipocytes 
dysfunction and restored cellular redox, further attenuating the pathophysiological 
consequences.
Conclusions: This study suggests that the Na/K-ATPase signaling activated by elevated 
levels of uremic toxins induce redox imbalance in adipocytes and causes apoptosis and 
inflammation. Our results support that transfection of 3T3-L1 adipocytes cell with pNaKtide 
transformed the phenotype of these dysfunctional adipocytes to that of healthy adipocytes. 
Our study demonstrates that Na/K-ATPase-Src feed-forward oxidant-amplification loop 
and/or adipocytes are potential targets for CKD intervention and presents a novel treatment 
for the pathophysiological condition.
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Sensing-Failure to Detect Energy Depletion Is a Novel Therapeutic Target 
for CKD
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Women’s Hospital, Boston, MA; 4Tokyo Medical & Dental Univ, Tokyo, Japan; 
5Nitobe Memorial Nakano General Hospital, Tokyo, Japan; 6Medical Institute of 
Bioregulation, Kyushu University, Fukuoka, Japan.
Background: Although it is known that the energy-status sensor 5-adenosine 
monophosphate (AMP)-activated protein kinase (AMPK) is inactivated in chronic kidney 
disease (CKD) status, to date, the mechanism of AMPK dysregulation in CKD remains 
unknown, and no study have shown the effects of AMPK activators on chronic stage of 
kidney injury, in which uremic condition has been substantially established. In this study, 
we hypothesized AMPK dysregulation in kidneys from subtotal nephrectomy (5/6 Nx) mice 
is caused by systemic factors, such as uremic metabolites.
Methods: Using capillary electrophoresis-time-of-flight mass spectrometry (CE-
TOFMS), we specified several metabolites accumulated in kidney, muscle and heart 
in the CKD mice (n=4) compared to sham control mice (n=4). In HK-2 cells, murine 
skeletal myoblast cells (C2C12) and embryonic rat cardiomyocytes (H9C2), effects of 
uremic metabolites and AMPK activators on AMPK phosphorylation were assessed. 
Effects of selected uremic metabolites and AMPK activators on kidneys were assessed by 
immunoblotting, quantitative RT-PCR and histologic analysis.
Results: Principal component analysis (PCA) revealed remarkable differences of 
metabolome profiles in the 5/6 Nx kidney between sham-control mice and 5/6 Nx mice. 
Using metabolome analyses, we demonstrated that, in CKD kidneys, AMPK could not 
sense defective energy metabolism because of multiple uremic factors such as indoxyl 
3-sulfate (IS). In consintent with this, AMP mimetics, 5-aminoimidazole-4-carboxamide-
1-b-4ribofuranoside (AICAR), did not increase AMPK phosphorylation at Thr 172 and
did not change profibrotic marker in 5/6 Nx mice kidney, despite the increased AMPK 
phosphorylation in kidneys from control sham mice. Direct AMPK activator A-769662,
which bypasses the AMP sensing mechanism, ameliorated fibrogenic effects and energy 
status of the kidneys in a mouse model of CKD.
Conclusions: These results confirmed that AMP sensing failure caused by uremic 
metabolites is the key mechanism underlying the vicious cycle of energy depletion and 
CKD progression and can be a novel therapeutic target for CKD.
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NUAK1 Is a Novel Inhibitor of Fibroblast Hippo Activity and Driver of 
Kidney Fibrosis
Tianzhou Zhang,1 Xiaolin He,1 Cassandra Atin,1 Mandeep K. Gill,2 Liliana 
Attisano,2 Darren A. Yuen.1 1St. Michael’s Hospital, Toronto, ON, Canada; 
2University of Toronto, Toronto, ON, Canada.
Background: Kidney fibrosis represents a final common damage pathway that is 
activated by nearly all forms of chronic kidney injury. Historically, studies have focused on 
TGF-beta as an important driver of fibrosis. Unfortunately, attempts to block TGF-beta have 
largely failed, in part due to the many non-fibrotic functions of this pleiotropic molecule. 
Recent work from our lab and others has shown that the Hippo pathway, a series of kinases 
that ultimately inhibit the transcription co-factors YAP and TAZ, is a critical inhibitor of 
fibrosis. Interestingly, the Hippo pathway is emerging as a central regulator of fibrosis, 
inhibiting fibrosis via both TGF-beta-dependent and -independent mechanisms. While 
AMP kinase (AMPK) is a well recognized regulator of the Hippo pathway, NUAK1 is a 
related kinase from the same serine/threonine kinase family that we recently have shown to 
be expressed by kidney fibroblasts.
Methods: The role of NUAK1 in the regulation of Hippo pathway activity and 
fibroblast activation was studied both genetically (NUAK1 silencing) or pharmacologically 
(using the NUAK inhibitor WZ4003) in NRK49F rat kidney fibroblasts both basally and in 
the context of TGF-beta stimulation. We generated tamoxifen-inducible fibroblast-specific 
NUAK1 knockout mice (Col1a2 Cre-NUAK1f/f ), and subjected them to unilateral ureteral 
obstruction (UUO).
Results: Both deletion and inhibition of NUAK1 resulted in increased Hippo 
pathway activity, as evidenced by increased YAP/TAZ phosphorylation, nuclear YAP/TAZ 
exclusion, and reduced expression of YAP/TAZ-inducible genes. NUAK1 inhibition also 
blocked basal and TGF-beta-induced fibroblast activation and expression of extracellular 
matrix genes. In vivo, fibroblast-specific NUAK1 deficiency protected against UUO-
induced kidney fibrosis.
Conclusions: NUAK1 is a previously unrecognized fibroblast activator in the kidney, 
working at least in part through regulation of the Hippo pathway. Future efforts to inhibit 
NUAK1 may represent a novel anti-fibrotic strategy.
Funding: Government Support - Non-U.S.
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Transition and Fibrosis via Suppressing Smad and MAPK in Human 
Proximal Tubular Epithelial Cells
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Background: Receptor tyrosine kinases play important roles in the pathogenic 
processes of renal fibrosis. Egr-1 is a transcription factor that regulates genes that modulate 
fibrosis, and role as common transcription factor of receptor tyrosine kinase. This study 
investigated the anti-fibrosis effect by inhibition of Egr-1, an important transcription factor 
for receptor tyrosine kinase activation in RON overexpressed-HK-2 cells.
Methods: Stable cell lines for RON overexpression and the transfected cells of Egr-1 
siRNA for RON inhibition were developed to examine the renal fibrosis and molecular 
mechanisms by RON in human renal proximal tubular epithelial (HK-2) cells. The protein 
expression of epithelial-mesenchymal transition (EMT)-related proteins N-cadherin, 
E-cadherin, vimentin and fibrosis-related proteins TGF-β, α-smooth muscle actin (αSMA), 
fibronectin as well as Smad family and MAPK signal pathway was determined by 
semiquantitative immunoblotting. Staining of receptor tyrosine kinase family was evaluated
using confocal laser microscopy.
Results: RON overexpression increased the protein expression of EMT- and fibrosis-
related proteins such as N-cadherin, E-cadherin, vimentin, TGF-β, αSMA, and fibronectin 
in HK-2 cells. Moreover, overexpression of RON increased phophorylation of Smad2/3 
and smad-4, and Erk1/2, p38, and Jnk MAPK pathways. In contrast, RON inhibition by 
Egr-1 siRNA attenuated expression of EMT- and fibrosis-related proteins and decreased 
phosphorylation of Smad family and MAPK pathway. In addition, the Egr-1 siRNA 
silencing attenuated expression of IGFR, VEGFR, and PDGFR.
Conclusions: Inhibition of Egr-1 may exert anti-fibrotic effect by suppression of EMT 
via controlling Smad and MAPK signal pathways in HK-2 cells.
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Phosphorylation of PKM2 in Tubular Epithelial Cells Regulates Metabolic 
Reprogramming and Tubulointerstitial Fibrosis
Jing Luo, Hao Ding, Yang Zhou, Junwei Yang. Second Affiliated Hospital, 
Nanjing Medical University, Nanjing, China.
Background: Chronic kidney disease (CKD) is becoming the world’s public health 
concern with high morbidity and mortality. Tubulointerstitial fibrosis is an inevitable 
pathologic outcomes of nearly all kinds of CKD no matter what the initial insult is. 
Structural and functional changes of tubular epithelial cells (TECs) during the pathogenesis 
contribute to the progression of fibrosis. Maintenance of the structure and function TECs 
is energy consuming and depends mainly on oxidative phosphrylation (OXPHOS). 
However, metabolic reprogramming from OXPHOS to glycolysis are defining features of 
injured TECs. Moreover, reprogramming toward glycolysis promotes TECs plasticity and 
extracellular matrix (ECM) accumulation, which is a newly discovered mechanism in renal 
fibrosis. Pyruvate kinase isozyme 2 (PKM2) is one of the key enzymes in glycolysis, whose 
dimerization after been phosphrylated critically determines the glycolytic reprogramming. 
In this study, we investigated the role of PKM2 in tubulointerstitial fibrosis.
Methods: Tubulointerstitial fibrosis was induced by unilateral urethral obstruction 
(UUO) and analyzed by morphologic staining and western blot. We generated proximal 
tubular cells specific PKM2 heterozygous mice to investigate its role on renal fibrosis. 
Shikonin, an inhibitor of PKM2 was given at the dose of 5mg/kg body weight.
Results: Phosphrylation of PKM2 in TECs was markedly increased accompanied 
with metabolic reprogramming towards glycolysis in obstructed kidney. Pkm2-deficient 
mice suffered UUO experienced less severe tubulointerstitial fibrosis and accumulation of 
ECM than wild-type (WT) mice. Shikonin inhibits the phosphrylation and activation of 
PKM2 and therefore attenuated the expression and accumulation of ECM in obstructed 
kidney. In primary TECs incubated with TGF-β1, shikonin treatment blocked the glycolysis 
and relieved the expression of fibronectin and collagen I, suggests that prevention of the 
phosphrylation and activation of PKM2 could mitigate metabolic reprogramming and 
reduce the production of ECM by TECs.
Conclusions: Phosphrylation and activation of PKM2 regulates the metabolism of 
TECs and is essential for prompting the expression of ECM and inducing renal fibrosis. 
Blocking the phosphrylation of PKM2 using shikonin might provide novel therapeutic 
strategy for CKD.
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Background: The molecular background of CKD-related inflammatory state and 
renal fibrosis is rather obscure, though the most potent inflammatory biomarkers like 
CRP (C-reactive protein), MCP-1 (monocyte chemoattractant protein 1) and ICAM-1 
(intracellular adhesion molecule 1) are linked with the pathogenesis of many CKD-related 
disorders, including cardiovascular diseases. Moreover, some data suggest that MCP-1 is 
involved in renal fibrosis. Recently, we have found that hepatocyte nuclear factors (HNFs) 
involved in the transcriptional regulation of several genes, were up-regulated in liver of 
CRF (chronic renal failure) rats. In this work, we analyzed the interplay between HNFs, 
MCP-1and ICAM-1 mRNA levels in liver of experimental CRF.
Methods: Rats with experimentally induced CRF (5/6 nephrectomy), pair-feds and 
controls (sham-operated) were used in the study. HepG2 cells were transfected with siRNA 
targeting HNF-1α. MCP-1, ICAM-1 HNF1α and HNF4α mRNA levels in liver and in 
HepG2 cells were determined using real-time RT-PCR.
Results: We found a significant coordinate up-regulation of Mcp-1, Icam-1, Hnf1α and 
Hnf4α expression in liver of CRF rats, when compared with pair-fed and control animals. 
These results suggest that HNFs may regulate expression of genes encoding MCP-1 and 
ICAM-1. To verify this we assessed the effect of HNF1α deregulation in hepatocellular 
model (HepG2 cells) by silencing its endogenous expression using small interfering RNA 
(siRNA) on MCP-1 and ICAM-1 mRNA levels. We found that the decrease in HNF1α 
mRNA by two different siRNA was associated with the decrease in MCP-1 and ICAM-1 
mRNA level.
Conclusions: Obtained data allow us to recognize that HNFs may play an important 
role in the up-regulation of, Mcp-1, Icam-1 genes in liver of CRF rats, and presumably in 
CKD patient. HNFs may be an essential element of molecular background of CKD-related 
inflammatory state and coronary heart disease.
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TSSC3 Overexpression Suppress Anoikis Resistance and Pro-Fibrotic 
Ability via Inhibiting PI3K-Akt Pathway in Myofibroblast
Huanzi Dai,1 Yani He.2 1Daping hospital, Chongqing, Chongqing, China; 
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Background: Myofibroblast activation is the key event of renal interstitial fibrosis 
(RIF). Anoikis resistance is the hallmarker of active Myofibroblasts conferred by the 
continuous activation of the PI3K-AKT pathway. Our previous study found that TSSC3 
enhanced the sensitivity of cancer cells to anoikis via Src-dependent PI3K/Akt pathway. We 
hypothesize that Myofibroblast anoikis induction by TSSC3 may suppress RIF by inhibiting 
the PI3K-AKT pathway.
Methods: Anoikis was induced by exogenous addition of RGD-containing peptides 
or placing cells in suspension. Myofibroblasts were established by stimulating HK-2 cells 
by TGF-β. We transfected TSSC3 overexpression adenovirus in HK-2, then experimented 
with Annexin V-FITC and CCK8 assay. We detected the expressions of molecules related to 
PI3K/AKT-mediated apoptosis signaling and fibrosis by qRT-PCR and WB analysis.
Results: TGF-β significantly increased α-SMA and decreased Villin expression in 
a time-dependent manner, suggesting that TGF-β facilitates the phenotypic activation of 
HK-2 toward myofibroblasts, and significantly fewer myofibroblasts than HK-2 underwent 
anoikis, demonstrating that TGF-β, simultaneous with the induction of myofibroblast 
differentiation, confers significant protection from anoikis. We observed that phospho-
PY20 PI3K-P85 and phospho-Ser473 AKT expressions were significantly increased, but 
cleaved-caspase3 expression was significantly decreased in the myofibroblasts as compared 
with HK-2. Myofibroblasts displayed a stronger ability to resist anoikis, than HK-2, as 
evidenced by higher rates of proliferation and lower rates of apoptosis, which were partly 
reversed by LY294002 treatment, a pharmacologic inhibitor of PI3K-AKT pathway. TSSC3 
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overexpression obviously impaired growth and anoikis resistance of myofibroblasts, as well 
as reduced phospho-PY20 PI3K-P85, phospho-Ser473 AKT expressions and increased 
cleaved-caspase3 expression of myofibroblasts in suspension culture. Moreover, TSSC3 
upregulation significantly inhibited mRNA and protein expressions of collagens type I, 
collagens type III, fibronectin, PAI-1, MMP-2 and MMP-9 in myofibroblasts.
Conclusions: These data suggest that TSSC3 attenuates anoikis resistance and 
profibrogenic ability of TGF-β induced myofibroblasts by mediating PI3K-Akt pathway, 
and may provide an effective way of targeting myofibroblasts by TSSC3 in RIF treatment.
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Chronic Interstitial Nephritis in Agricultural Communities (CINAC): A 
Toxin-induced Proximal Lysosomal Tubulopathy Involving Calcineurin 
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Benjamin A. Vervaet,1 Cynthia C. Nast,2 Channa Jayasumana,5 Gerd Schreurs,4 
Frank Roels,8 Chulani A. Herath,6 Swarnalata Gowrishankar,7 Christiane 
I. Mousson,10 Rajeewa T. Dassanayake,3 Carlos M. Orantes,9 Patrick C. D’Haese,1 
Marc E. De Broe.4 1University Antwerp, Antwerp, Belgium; 2Cedars-Sinai 
Medical Center, Los Angeles, CA; 3General hospital Polonnaruwa Sri Lanka,
Polonnaruwa, Sri Lanka; 4University of Antwerp, Lokeren, Belgium; 5Faculty of 
Medicine, Anuradhapura, Sri Lanka; 6Sri Jayawardenepura General Hospital,
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Background: Almost 30 years after the detection of a chronic interstitial nephritis 
in agricultural communities (CINAC), there is no consensus on its etiology. Heat stress/
dehydration and toxic agrochemical exposure are the two most likely etiologies. Also, there 
are no diagnostic criteria that can directly identify CINAC patients.
Methods: Thirthy-seven renal biopsies (24 Sri Lanka, 11 El Salvador, 1 India, 1 
France) of patients with a diagnosis of CINAC (CKD 1-3A, 3B) were examined by light 
microscopy (LM) and electron microscopy (EM) in comparison to renal biopsies of patients 
with calcineurin inhibitor (CNI) toxicity (n=17), proteinuric nephropathies (n=15) and 
reduced renal function of various causes (n=39). A rat study was conducted comparing the 
histopathology of heat stress/dehydration with cyclosporine nephrotoxicity.
Results: In addition to previously described histopathological changes, CINAC 
patients demonstrated varying numbers of fine to coarse proximal tubular (PT) granules 
in preserved and atrophic tubules, showing silver positivity on Jones staining and 
autofluorescence. Immunofluorescence identified these granules as lysosomes. On EM, 
lysosomes were enlarged and had a unique dysmorphic morphology with medium electron 
dense matrix containing non-membrane bound dispersed electron dense aggregates and 
infrequently focal coarsely granular electron dense material. Identical lesions were only 
observed in patients on calcineurin inhibitor (CNI) therapy, in a subset of patients with 
light chain disease and in a patient with Lomustine nephrotoxicity. Some myeloma cells as 
well as Lomustine have reported CNI activity. Rats treated with cyclosporine for 4 weeks 
developed similar tubular cell lysosomal alterations, which were absent in the dehydration 
group.
Conclusions: A specific PT lysosomal lesion was detected associated with CINAC and 
CNI nephrotoxicity, suggesting CINAC patients are experiencing a tubulotoxic mechanism 
involving lysosomes and calcineurin inhibition, the latter being a known effect of pesticides.
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Bardoxolone Methyl Increases Nrf2 Activity, Reduces Inflammation, and 
Improves Mitochondrial Function in Autosomal Dominant Polycystic 
Kidney Disease Cells
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Background: Bardoxolone methyl is currently in clinical trials for the treatment of 
rare chronic kidney diseases, including autosomal dominanant polycystic kidney disease 
(ADPKD; PHOENIX, Phase 2, NCT03366337) and Alport syndrome (CARDINAL, Phase 
2/3, NCT03019185). Common features of chronic kidney diseases include inflammation, 
remodeling, and fibrosis. Bardoxolone methyl potently activates Nrf2, a transcription 
factor that counteracts these features by restoring redox balance, improving mitochondrial 
function, and inhibiting the production of pro-inflammatory mediators. Consistent with a 
broad effect on kidney function, in clinical trials bardoxolone methyl has been shown to 
improve estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and 
chronic kidney disease and in patients with Alport syndrome. In this study, we assessed 
whether bardoxolone methyl increases Nrf2 activity and inhibits inflammation in cells 
derived from renal cysts in patients with ADPKD.
Methods: We used two immortalized ADPKD cell lines, WT 9-7 and WT 9-12, and 
a normal human proximal tubule cell line, HK-2, to evaluate the effects of bardoxolone 
methyl.
Results: We found that bardoxolone methyl increased Nrf2 activity in all cell lines 
tested. Bardoxolone methyl also dose-dependently improved parameters of mitochondrial 
function, including spare respiratory capacity and maximal respiration, in the ADPKD cell 
lines. Consistent with the important role of inflammation in ADPKD, we observed higher 
basal levels of pro-inflammatory mediators in the ADPKD cell lines than in the HK-2 
control cell line. Treatment with bardoxolone methyl significantly reduced the levels of C-C 
Motif Chemokine Ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 
(MCP-1).
Conclusions: In summary, bardoxolone methyl increased Nrf2 activity, improved 
mitochondrial function, and reduced inflammation in renal cell lines derived from patients 
with ADPKD. These results suggest that activation of Nrf2 by bardoxolone methyl may 
have the potential to improve the underlying molecular features of ADPKD.
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Human Mesenchymal Stem Cells and Canine CKD
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Background: Chronic kidney disease (CKD) is common in dogs, and conservative 
treatment is the best option even in advanced CKD. Here, we used human umbilical cord 
mesenchymal stem cells MSCs (huMSCs) to treat canine CKD, with the aim of slowing 
its progression.
Methods: We evaluated huMSC phenotypes and tested cells for multilineage 
differentiation. At baseline (T0), dogs with stage 2 or 3 CKD were randomized to i.v. 
injection of placebo (CKD2-p, n=5; CKD3-p, n=6) or 106 huMSC/kg (CKD2-msc, n=3; 
CKD3-msc, n=7). We measured serum creatinine (sCr) and the urinary protein:creatinine 
(UPC) ratio monthly until month 12 (T12). Urinary albumin was determined by urine 
exosomes on Western blots. Fibroblast growth factor 23 (FGF23) was quantified initially in 
normal dogs, then at T0 and T6 in dogs with CKD.
Results: Survival at T12 was similar among the groups. Although renal disease was 
more severe in CKD3-msc dogs than in CKD3-p dogs at T0, both groups showed similar 
sCr at T12 (Figure 1). The delta UPC ratio (T12 vs. T0) was lower in treated dogs than in 
untreated dogs, as was urinary albumin (Table 1). For FGF23 in normal and CKD dogs, the 
area under the receiver operating characteristic (ROC) curve (AUC) was 0.8, and the delta 
FGF23 (T6 vs. T0) was smaller in treated dogs than in untreated dogs (Table 1).
Conclusions: As a treatment for CKD, huMSCs show promise. Supported by FAPESP.
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Pancreatic Cells from High Glucose Toxicity and Recovers the Secretion of 
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University Affiliated ningxia renmin hospital, Yinchuan, China.
Background: Cdk5 may play an important role in the pathology of diabetes mellitus. 
We previously demonstrated that viral-infected CIP, a 126-residue truncated fragment of 
p35, effectively and specifically inhibited Cdk5/p25 hyperactivity, restored insulin secretion 
and rescued Min6 cells from apoptosis induced by high glucose. Because of its large size, 
however, the CIP molecule is unlikely to be a successful therapy in vivo. We identified a 
smaller peptide, TFP5, spanning CIP residues Lys245–Ala277 (24 amino acid) which is a more 
effective inhibitor of hyperactive Cdk5.
Methods: We used Mouse pancreatic beta cells Min6 cells and the db/db mice as the 
in vitro and In vivo models to do the research experiments. TFP5 and scrambled peptide 
(SCB) peptide were commercially synthesized by Peptide 2.0 (Chantilly, VA, USA). 
Cells were treated with TFP5 or SCB (500nM). Animals were divided into 4 groups 
(C57/B6 + SCB, C57/B6 + TFP5, db/db + SCB, and db/db + TFP5). All cells and pancreases 
samples were prepared for further experiments by using immunohistochemical studies and 
biochemical analysis. One-way ANOVA was used for the data analysis.
Results: First, the in vitro experiments showed that TFP5 derived from p35, effectively 
inhibits Cdk5 hyperactivity in Min6 cells and inhibits Cdk5 overactivation induced by high 
glucose stimulation and recovers insulin secretion in Min6 cells. Secondary, The study 
found that TFP5 protects both Min6 cells and db/db mice pancreatic cells from high glucose 
induced apoptosis, and reduce hyperactivation of Cdk5 and recover insulin secretion in 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1075
J Am Soc Nephrol 29: 2018 Publication-Only 
both Min6 cells and pancreases of db/db mice. Furthermore, the study also found that 
TFP5 reduced inflammation in pancreatic islets by significantly reducing expression of 
TGFβ1,TNFαand IL1β.
Conclusions: We demonstrated that TFP5 protects or rescues Min6 cells from apoptosis 
induced by chronic high glucose stress, and rescued db/db mice from diabetes pathology. 
These data suggest future studies of TFP5 should provide insight as to the mechanism of 
drug action as a means of further insight into the etiology of diabetes.
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Spontaneously Diabetic Rhesus Monkeys Develop Albuminuria and 
Glomerulopathy Resembling Human Diabetic Nephropathy
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Background: Diabetic nephropathy (DN) remains a leading cause of end-stage renal 
disease, despite the availability of current treatment options. Over the past two decades, a 
number of new pathways and drug targets have emerged from rodent models. However, 
limited success has been achieved with the development of novel treatments for DN. Lack 
of translation from rodent models to clinical practice is the main challenge. In an attempt to 
develop a translatable animal model, we systematically characterized metabolic phenotypes 
in rhesus monkeys and assessed the renal function and structure.
Methods: A colony of 161 rhesus monkeys was longitudinally phenotyped for 6 
years using intravenous glucose tolerance testing and DEXA scan for their spontaneous 
development of metabolic diseases. Among these monkeys, 42, 95, and 24 were identified 
as healthy, dysmetabolic, and diabetic subjects, respectively. We selected 17 healthy, 14 
dysmetabolic, and 23 diabetic monkeys for albuminuria assessment by urine albumin/
creatinine ratio (ACR) and glomerular filtration rate (GFR) evaluation by iohexol 
clearance. We also examined kidney samples at necropsy from 5 diabetic monkeys for 
histopathological changes.
Results: The metabolic characteristics of diabetic monkeys are aligned with clinical 
manifestations of type II diabetic patients as exemplified by insulin resistance, reduced β 
cell response, and hyperglycemia. Approximately 50% of the diabetic monkeys exhibited 
albuminuria (ACR: 142.9 ± 18.4 vs. 4.5 ± 1.2 μg/mg in healthy group) and hyperfiltration 
(GFR: 1.58 ± 1.11 vs. 1.32 ± 0.05 ml/min/kg in healthy group). Kidney histopathology from 
3 out of 5 diabetic monkeys showed minimal to mild mesangium and Bowman’s capsule 
thickening, tubular epithelium degeneration, and interstitium fibrosis.
Conclusions: Our data demonstrate that spontaneously diabetic rhesus monkeys 
develop albuminuria and glomerulopathy resembling human DN. Follow-up studies 
examining disease progression and response to current standard of care therapy in the DN 
monkey model is warranted.
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Background: Diabetic nephropathy (DN) is characterized by endothelial dysfunction. 
Thrombomodulin is a key regulator of coagulation and inflammation on endothelial cells. 
Previously, it was demonstrated that thrombomodulin-mediated protein C activation 
inhibits apoptosis and inflammation in DN in vivo (Nat Med, 2007). Additionally, a 
complement-inhibitory role of thrombomodulin was described in DN in vivo (Thromb 
Haem, 2012). Collectively, these studies suggest that thrombomodulin could be involved 
in the development of DN. However, the role of thrombomodulin in human kidneys with 
DN remains elusive. Hence, we here investigate thrombomodulin expression in glomeruli 
of patients with and without DN.
Methods: We investigated the presence of glomerular thrombomodulin expression 
in 94 autopsy cases with diabetes and DN, 57 with diabetes without DN and 38 controls 
without diabetes and without renal disease. Sections of the kidneys were stained with 
thrombomodulin and scored semi-quantitatively. Researchers were blinded to the clinical 
data of the patients. Additionally, thrombomodulin mRNA expression was measured in 
microdissected glomeruli from renal biopsies of patients with DN (n=28) and controls 
(n=10).
Results: Thrombomodulin expression was 1.7 times lower in patients with diabetes, 
compared to non-diabetic controls (p=0.004). No difference in thrombomodulin expression 
was observed between diabetic patients with and without DN. Thrombomodulin mRNA 
levels of DN cases were not significantly different compared to those of control cases.
Conclusions: Thrombomodulin expression is decreased in glomeruli of patients with 
diabetes. Since glomerular mRNA levels for thrombomodulin are not changed, our data 
suggest that this loss is a result of increased thrombomodulin degradation. We hypothesize 
that decreased thrombomodulin expression plays a role in inflammation and complement 
activation in DN. Restoration of thrombomodulin levels could be a therapeutic goal to 
prevent the development in DN.
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Background: Null mice raised by mating -/- ♂ with -/- ♀ showed sustained 
hyperglycemia & persistent hyperinsulinemia during glucose tolerance test (GTT) vs wild 
type (wt) raised by mating wt ♂ with wt ♀. Insulin resistance by HOMA was increased 8 
fold, but HOMA beta cell function was normal. As null mice ate & weighed more, & as 
caloric restriction abolished these differences, our data support the role of hyperphagia, 
possibly due to hypothalamic neuron leptin resistance without TRPC1 channels.
Methods: We studied adipokines, environmental & genetic factors, including gene 
dosage, in this diabetic phenotype while minimizing epigenetics & hyperphagia in breeders 
& dams, using only ♂ littermates born to +/- breeders.
Results: 9-week-old null ♂ born to -/- breeders & nursed by -/- dams had severe 
random hyperglycemia (171 vs. 98 mg %) vs wt born to +/+ breeders & raised by +/+ dams. 
In contrast, null mice born to +/- breeders & nursed by +/- dams had minimal hyperglycemia 
(119 vs 171 mg %), implying anti-diabetic effects by a single maternal wt allele. Conversely, 
wt born to +/- breeders & nursed by +/- dams were hyperglycemic vs wt born to +/+ breeders 
& nursed by +/+ dams (118 vs 98 mg %), reflecting pro-diabetic effects of maternal haploid 
deficiency. These wt were as hyperglycemic as null littermates born to the same +/- breeders 
& nursed by the same +/- dams (118 vs 119 mg %). These data support the role of non-
genetic parental influences. From 5th to 30th week, null but not +/- mice were obese vs wt. 
At 29 weeks, during GTT, both null & +/- mice were equally diabetic, with glucose (in mg 
%), respectively of 230 & 234 vs. 183 in wt at 20 min, 219 & 229 vs. 155 in wt at 60 min, 
& 179 & 188 vs 134 in wt at 90 min. These data support the role of both alleles in glucose 
homeostasis. In null mice, adiponectin was down (5.7) vs. wt (6.4) & +/- (6.2 μg/ml), 
but leptin up (2.3 vs. 1.3 in wt & 1.8 ng/ml in +/-).
Conclusions: We conclude: 1. Diploid TRPC1 gene deletion produces hyperphagia 
& obesity. 2. Haploid deficiency suffices to produce diabetes, associated with reduced 
adiponectin & increased leptin. 3. Non-genetic parental factors, via epigenetics & 
hyperphagia, markedly alter glucose homeostasis independent of genotypes.
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Involvement of AMPK Signalling and Autophagy
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Background: Obesity is a major contributor of progressive renal disease and is largely 
due to a combination of sedentary lifestyle and a high energy intake. Excessive caloric 
intake is associated to lipid accumulation in adipose tissue but also in non-adipose tissues, 
leading to deleterious cellular responses. In a previous work, we identified the role of 
AMPK in ectopic lipid depositions in proximal tubular cells in mice fed a high-fat diet 
(HFD). Moreover, lysosomal dysfunction and stagnant autophagy flux were highlighted. 
Here, the effect of exercise training (ET) in obese mice on renal lipotoxicity and autophagy 
pathway was investigated.
Methods: C57BL/6J male mice were randomized to a low-fat diet (LFD - 10% calories 
from fat) or a HFD (60% calories from fat) during 20 weeks. After 12 weeks on diet, mice 
were subjected to an endurance ET protocol on a treadmill for 8 weeks or no ET.
Results: Mice fed a HFD exhibited a significant increase in body weight combined to 
increases in plasma levels of NEFA and cholesterol. Moreover, they also developed insulin 
resistance. ET showed body weight stabilization and beneficial effects on plasma lipid 
profiles in HFD mice. In addition, hyperglycemia and insulin resistance were also clearly 
improved by ET. Regarding the renal function, ET improved albuminuria and proteinuria 
induced by obesity. We also demonstrated a decrease in ectopic lipid accumulation in 
proximal tubular cells in trained groups. This result was correlated to the inhibition of 
Acetyl-CoA carboxylase by phosphorylation mediated by AMPK activity. Interestingly, we 
showed a stagnation of autophagy flux in the kidney of obese mice that was restored in ET 
group by the regulation of autophagy-related proteins.
Conclusions: These results suggest that ET leads to beneficial effects on obesity-
related metabolic disorders and regarding the kidney function and structure in mice fed 
a HFD. Particularly, we demonstrated the activation of AMPK and the improvement of 
autophagy flux by ET.
Funding: Government Support - Non-U.S.
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Interleukin-15, a Myokine for Preserving Podocyte Mitochondrial 
Function During Diabetic Nephropathy
Yin Li,1 Wenbo Zhao,1 Zhaoyong Hu,2 Hui Peng.1 1the Third Affiliated Hospital 
of Sun Yat-sen University, Guangzhou, China; 2Baylor College of Medicine, 
Houston, TX.
Background: Exercises can improve the prognosis of diabetic nephropathy (DN), 
however, the underlying mechanism remains unclear. Here, we further explore how exercise 
ameliorates DN via muscle-kidney communication.
Methods: To explore the mechanism, PGC-1α was overexpressed in mouse muscle 
(mPGC-1α) to mimic persistent exercises and crossed with db/m mice or STZ injection to 
generate mPGC-1α mice with diabetes. In vitro, we isolated podocytes and used cultured 
podocyte cells to evaluate mitochondrial function.
Results: we found that glomerulosclerosis and podocyte mitochondrial damage 
induced by diabetes were limited in mice with mPGC-1α. What is more, plasma from 
mPGC-1α mice prevented podocyte cells and its mitochondria injury in high glucose. 
Then we found out Interleukin-15 (IL-15), one of myokines upregulated by mPGC-1α, 
exhibited the similar protective effects on the cultured podocytes. Besides, we discovered 
that the IL-15-mediated protection were produced by enhancing OPA1 to improve podocyte 
mitochondrial dynamics.
Conclusions: These findings provided insights into the new role of IL-15 in mediating 
muscle-kidney crosstalk to ameliorate the progress of DN by maintaining podocytes 
mitochondrial homeostasis via OPA1.
Funding: Government Support - Non-U.S.
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Increased Urinary Prorenin and Soluble Prorenin Receptor Excretion in 
Early Type 1 Diabetes
Nirupama Ramkumar,1 Deborah Stuart,3 Donald E. Kohan.2 1University of Utah, 
Salt Lake City, UT; 2University of Utah Health Sciences Center, Salt Lake City, 
UT; 3University of Utah Health Sciences, SALT LAKE CITY, UT.
Background: Activation of the intra-renal, rather than systemic renin angiotensin 
system (RAS) has been suggested to play a role in the development of diabetic kidney 
disease. In this study, we examined plasma and urinary prorenin/renin levels and urinary 
soluble prorenin receptor (sPRR) levels in a murine model of Type 1 diabetes.
Methods: Male C57BL/6 mice were injected with streptozotocin (STZ) 50mg/kg at 
3 months of age and metabolic balance studies conducted at 10 weeks post-injection. In 
a separate experiment, renal medullary renin and prorenin receptor mRNA was quantified 
using RT-PCR in 10 week old male Akita mice.
Results: STZ injected mice developed hyperglycemia within 4 weeks of injection (STZ: 
335 ± 35 vs control: 145 ± 22 mg/dL) and remained hyperglycemic at 10 weeks. At 10 weeks 
post-injection, STZ injected mice had significant polyuria (STZ: 20.9 ± 5.9 vs controls 
1.8 ± 0.4 ml/day), increased water intake (STZ: 26.2 ± 5.9 vs controls: 6.2 ± 0.9 ml/day) 
and lower body weight (STZ: 28.3 ± 1.3 vs controls: 23.6 ± 1.4 grams) despite similar food 
intake. Compared to controls, urinary angiotensinogen, total prorenin/renin and sPRR levels 
were increased in STZ injected mice; these increases were proportionally greater than the 
trend in increased urinary microalbumin excretion (Table 1). In particular, urinary sPRR 
excretion was markedly increased in STZ injected mice compared to controls. In contrast, 
plasma renin concentration and sPRR were similar between the controls and STZ injected 
mice. Similalry, 10 week old male Akita mice bearing a mutated Ins2gene, demonstrated a 
4.8 fold increase in renal medullary renin mRNA expression and a 1.5-fold increase in renal 
medullary PRR expression.
Conclusions: Taken together, these results demonstrate early activation of the intra-
renal RAS in Type 1 diabetes. These changes occur independent of the systemic RAS.
Funding: Private Foundation Support
Tale 1. Plasma and urine RAS components in early Type 1 diabetes
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Role of the Inducible Calbindin-D28k Protein in Advanced Glycation End 
Products-Associated Renal Proximal Tubule Cell Injury
Chih-Kang Chiang,1,2 Kuan-yu Hung,3 Shing-Hwa Liu.1 1Institute of Toxicology, 
School of Medicine, National Taiwan University, Taipei, Taiwan; 2Department 
of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, 
Taipei, Taiwan; 3Department of Internal Medicine, National Taiwan University 
Hospital, Taipei, Taiwan.
Background: Diabetic nephropathy is a common diabetic complication associated 
to calcium dyshomeostasis. Previous studies suggested that diabetes-associated advanced 
glycation end products (AGEs) are associated with the increase of extracellular matrix 
proteins synthesis and renal fibrosis induction. Protein expression of calbindin-D28k, which 
plays a role in the calcium reabsorption in the renal distal convoluted tubules, has been 
shown to be increased in diabetic kidney. However, the role of calbindin-D28k induction in 
diabetic kidney is still unknown.
Methods: Human renal proximal tubule cell (HK-2) were transfected with/without 
calbindin-D28k siRNA and then treated with AGEs for 48hours. THe expression of several 
critical proteins were determined by Western blotting. Cell viabilit was evaluated by MTT 
assay. The expression of calbindin-D28k in renal tissue of db/db mice were detected by 
immunohistochemistry.
Results: We found that calbindin-D28k could be induced in the proximal tubules of 
the db/db diabetic mouse kidney. The increase of AGEs and extracellular matrix (ECM) 
proteins were also observed in the db/db diabetic mouse kidney. We further explored the 
role of calbindin-D28k in AGEs-induced human renal proximal tubule cell (HK2) injury 
and fibrotic changes. AGEs significantly induced the expression of calbindin-D28k in 
HK2 cells, but not in mesangial cells. AGEs also significantly induced the expressions 
of fibrotic molecules, ECM proteins, epithelial-mesenchymal transition (EMT) markers, 
and endoplasmic reticulum (ER) stress-related molecules in HK2 cells. Calbindin-
D28k-siRNA transfection significantly reduced the cell viability and markedly enhanced 
the protein expressions of fibrotic factors, EMT markers, ER stress-related molecules, 
phosphorylated smad 2/3, and phosphorylated p38 in AGEs-treated HK2 cells. Treatment 
with 4-phenylbutyric acid, a chemical chaperone, significantly counteracted the AGEs-
induced ER stress and EMT markers expressions in HK2 cells.
Conclusions: These findings suggest that the inducible calbindin-D28k plays a 
protective role against AGEs-induced ER stress and EMT induction and cell injury in renal 
proximal tubule cells. Calbindin-D28k may serve as a predicted marker for proximal tubule 
injury/fibrosis or a therapeutic target for diabetic nephropathy.
PUB187 
Publication-Only 
Phosphorylation and Nuclear Translocation of PKM2 in Renal Tubule 
Regulates the Activation of NLRP3 Inflammasome in Diabetes
Ting Cai,2 Yang Zhou,1 Junwei Yang.1 1Second Affiliated Hospital, Nanjing 
Medical University, Nanjing, China; 2Nanjing Medical University, Nanjing, 
China.
Background: Diabetic kidney disease (DKD) is one of the major causes of renal 
failure. Activation of NLRP3 inflammasome in tubular cells contributes to the progression 
of DKD. However the underlying mechanisms that regulate NLRP3 inflammasome remain 
poorly understood.
Methods: In this study, streptozotocin (STZ) was injected intraperitoneally at the dose of 
40mg/kg/day for 5 consecutive days to induce diabetic mouse model. Random blood glucose 
level greater than 16.7mmol/L tested 2 weeks later was considered as diabetes. Diabetic mice 
were sacrificed at 1, 2 and 4 weeks after confirmation of diabetes. In vivo, primary tubular 
cells (PTCs) were treated with 30mmol/L of glucose for indicated time points.
Results: NLRP3 inflammasome were markedly activated in both diabetic kidneys 
and in high glucose-treated PTCs as demonstrated by increased expression of NLRP3, 
ASC, cleaved caspase-1, cleaved IL-1β and cleaved IL-18. Phosphorylation of PKM2 was 
observed in diabetic kidneys and PTCs under high glucose condition. Moreover, western 
blot and immunohistochemistry staining showed nuclear translocation of PKM2 in tubular 
epithelial cells. Treatment with shikonin, an inhibitor of PKM2 activity, attenuated PKM2 
phosphorylation and nuclear translocation. Furthermore, shikonin blocked the high glucose-
induced activation of NLRP3 inflammasome in PTCs.
Conclusions: Our study suggests that phosphorylation and nuclear translocation of 
PKM2 promotes the activation of NLRP3 inflammasome and contributes to inflammation 
in diabetes. Pharmacological inhibitors targeting the activation of PKM2 may be a novel 
therapeutic strategy for DKD.
Funding: Government Support - Non-U.S.
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Quantitative Proteomics Identifies Interaction Proteins for Decoy 
Receptor DcR2 in Diabetic Nephropathy
Jia Chen,1 Yani He.2 1Daping hospital, Chongqing, Chongqing, China; 2Daping 
Hospital, Chongqing, China.
Background: Decoy receptor 2 (DcR2), a transmembrane receptor of tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL), is a cellular senescent marker. DcR2 
plays a crucial role in the progression of diabetic nephropathy (DN), but the interaction 
proteins for DcR2 not clear.
Methods: 139 DN patients which diagnosed by renal biopsy were enrolled. Renal 
DcR2 expression was detected immunohistochemically. Associations between renal DcR2 
and renal functional parameters and pathological damage scores were evaluated. Double 
staining was undertaken for DcR2 with its ligand TRAIL, and antagonistic receptor DR4 
in renal tissue. Co-immunoprecipitation (Co-IP) were analyzed for the DcR2 with TRAIL 
and DR4 in high glucose (HG) induced-primary tubular epithelial cells (PTECs). Co-IP 
combining with LC-MS/MS were screened the interaction proteins for DcR2.
Results: DcR2 was primarily expressed in renal proximal tubules. The percentage of 
renal DcR2 were higher in DN than control, correlated with renal functional parameters and 
scores of renal tissue damage. DcR2 was not co-expressed with TRAIL, DR4 in DN, and 
not binding to TRAIL, DR4 in vitro. Quantitative proteomics identified 59 differentially 
expressed proteins (DEPs) in HG, while 52 DEPs were detected specifically in HG. These 
DEPs are involved in endothelial cell migration, negative regulation of extrinsic apoptosis, 
ion homeostasis, regulation of keratinocyte differentiation, removal of superoxide radicals, 
hydrogen peroxide catabolic process, skeletal muscle tissue regeneration.
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Conclusions: We explored the interaction proteins for DcR2 in high glucose-induced 
PTECs with quantitative proteomics, which will help to elucidate the mechanisms of DcR2 
in renal tubular cells in DN.
Funding: Government Support - Non-U.S.
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Dipeptidyl Peptidase Inhibitor Linagliptin Induced Effects on Cardiac 
miRNA Expression in GLP-1 Receptor Knock-out Mice with 5/6 
Nephrectomy
Franziska Wiech,1 Marcel Rolser,1 Ines Jakob,1 Ogsen Gabrielyan,1 
Oleg Tsuprykov,2 Ahmed A. Hasan,2 Thomas Klein,1 Berthold Hocher,2 
Denis Delic.1 1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an 
der Riss, Germany; 2University of Potsdam, Potsdam, Germany.
Background: Chronic kidney disease (CKD) is a growing health problem with diabetes 
mellitus and hypertension being main drivers to its development and progression. Additionally, 
CKD is associated with an increased risk for the development of cardiovascular disease. 
Growing pre-clinical evidence indicates that the dipeptidyl peptidase (DPP)-4 inhibitor 
linagliptin (LIN) exerts beneficial renal and cardioprotective effects. However, clinical outcome 
data are still missing and also the exact molecular mechanisms remain unclear. Experimental 
studies suggest the involvement of the GLP-1/GLP-1 receptor (GLP-1r) pathway as a potential 
mechanism underlying the beneficial effects of DPP-4 inhibition in CKD.
Methods: Here we investigated regulation of microRNAs (miRNAs) in cardiac tissue 
(using the Nanostring nCounter technology) of 5/6 nephrectomized mice after LIN treatment 
(12 weeks, ~3-5 mg/kg/d in chow) in wildtype and GLP-1r knock-out mice. miRNAs are 
short non-coding RNA species which are important post-transcriptional regulators of gene 
expression and are implicated in the pathogenesis of diabetic nephropathy.
Results: Analysis of variance (ANOVA) (p<0.05) resulted in a deregulation (up or 
down) of 15 miRNA species between sham and 5/6 nephrectomized animals. Most of the 
deregulated miRNA species are involved in cardiac fibrosis, cardiomyopathy and cardiac 
hypertrophy processes, such as miR-1, miR-133b, miR-30d, miR27b, miR-690 and miR-
142-3p. In particular, the ameliorative effects on the expression of the cardiomyocyte
protective miR-142-3p were observed in 5/6 nephrectomy plus LIN treated animals.
Deregulation of miRNAs in GLP-1r knock-out mice were consistent but effects of LIN
were less prominent.
Conclusions: The data suggest cardioprotective effects of LIN via upregulation of 
miR-142-3p in a model of 5/6 nephrectomy induced uremic cardiomyopathy.
PUB190 
Publication-Only 
Antioxidant Improves Diabetic Nephropathy and Cardiac Function in 
Diabetes Induced Renocardiac Syndrome
Firoozeh Farahmand. Nephrology, SLU, Saint Louis, MO.
Background: Diabetes mellitus(DM) is strongly associated with renocardiac 
syndrome (RCS) in a nationally representative population. RCS is characterized by 
primary renal failure that progressively leads to cardiac dysfunction. Pathophysiological 
mechanisms underlying initiation and maintenance of this interaction are complex and 
poorly understood. Furthermore, because of the development of resistance to standard 
therapies, targeting renocardiac remodelling process to develop novel therapies is essential. 
Evidence suggest oxidative stress play a major role in kidney-heart pathophysiological 
cross talk. The purpose of this study was to investigate wheather there is oxidative stress 
in this experimental model of RCS & if antioxidant treatment attenuate renocardiac injury
Methods: DM was induced in rats by streptozotocin(STZ)-induced pancreatic injury 
causing renal injury similar to human diabetic nephropathy. Animals were randomly 
divided into 3 groups, CONT+Carvediol(CARV), DM and DM+CARV. CARV was 
adminstered orally for 8 wks. At 8 wks animals underwent echocardiography to measure LV 
end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), left ventricular 
ejection fraction (LVEF), and left ventricular fraction shortening (LVEF). After sacrificing 
the animals, Kidneys and hearts were examined by Hematoxylin Eosin (HE) staining 
and periodic acid Schiff base(PAS). Kidney and heart antioxidant enzymes, and lipid 
peroxidation were determined
Results: In STZ-induced diabetics rats increase in renal and myocardial lipid 
peroxidation and decrease in antioxidants enzymes were associated with vacuolar 
degeneration of tubules; PAS positivity staining intensity in glomeruland basement 
membrane and thickening as well as significant prolongation of isovolumic relaxation 
time (IVRT) (38 ± 8 vs. 25 ± 6 ms, p < 0.0001), elevation of LV end-diastolic pressure 
(8 ± 6 vs. 2 ± 1 mm Hg, p = 0.05) and increased chamber stiffness. CARV improved kidney 
histopathological altereations and cardiac dysfunction that was associated with increase in 
antioxidant defense in the kidney and the heart and decrease lipid peroxidation
Conclusions: Our results suggest that in this model of renocardiac syndrome oxidative 
stress play a role in mediation of Kidney-Heart pathological cross talk and carvideolol 
with its significant antioxidant properties attenuate diabetic nephropathy and diabetic 
cardiomyopathy.
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Effects of Soluble Guanylyl Cyclase Stimulation or Activation on Blood 
Pressure and Renal Hemodynamics in Diabetic Rats
Rohit Patel,1 Yiling Fu,1 Winnie Huang,1 Ser Khang,1 Agnes M. Benardeau,2 
Scott C. Thomson,1 Volker Vallon.1 1Department of Medicine, University of 
California, San Diego & VA San Diego Healthcare System, San Diego, CA; 
2Bayer Pharma AG, Wuppertal, Germany.
Background: The second messenger, cGMP, influences blood pressure (BP) and renal 
hemodynamics. It is locally formed by soluble guanylyl cyclase (sGC). The activity of 
sGC can be enhanced by sGC “stimulators” or “activators”, which target the enzyme in 
two different redox states, the nitric oxide (NO)-sensitive reduced enzyme and the NO-
insensitive oxidized enzyme, respectively. Little is known about the relative effects of these 
agents on BP versus renal hemodynamics in diabetes mellitus (DM).
Methods: Acute effects of sGC stimulator BR9902 and sGC activator BR9904 
were determined on mean arterial BP (MAP) and renal hemodynamics under terminal 
barbiturate anesthesia in 3 groups of rats: non-diabetic Wistar Froemter (WF) rats (CON); 
streptozotocin-diabetic WF rats, a model of type 1 DM (T1DM); and Goto-Kakizaki rats 
(GK), a non-obese model of type 2 DM (T2DM). Increasing doses of each compound were 
tested in individual animals in consecutive 20 min periods, and compared with vehicle. 
MAP was measured via femoral artery catheter; GFR and RBF by renal FITC-sinistrin 
clearance and perivascular ultrasonic transit time flow probe, respectively. n=6-8/group.
Results: BR9902 and BR9904 induced similar dose-dependent reductions in MAP 
among the 3 groups. The highest dose of either drug (1 mg kg-1 30min-1) lowered MAP 
by 20-30%. Basal GFR and RBF were higher in T1DM and GK versus CON. Qualitative 
effects of BR9902 and BR9904 on RBF and GFR are shown in a table.
Conclusions: Systemic infusion of BR9902 or BR9904 lowers MAP, which challenges 
the kidney to autoregulate. Overall hemodynamic autoregulation is more efficient in WF 
rats (CON or T1DM) than in GK rats, and is more efficient during BR9902 than BR9904. 
From the latter we infer the existence of drug effects on sGC within the kidney that differ 
between BR9902 and BR9904, and therefore potentially between stimulators and activators 
of sGC. When dosed to lower blood pressure by 20-30%, both agents reduced glomerular 
hyperfiltration in GK-T2DM but not in WF-T1DM.
Funding: NIDDK Support, Veterans Affairs Support, Commercial Support - Bayer 
Pharma AG
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Determinants of Renal Outcomes of Type 2 Diabetic Patients with Biopsy 
Proven Kidney Disease
Hui Zhuan Tan, Jia Liang Kwek, Choong Meng Chan, Jason Choo Chon Jun. 
Singapore General Hospital, Singapore, Singapore.
Background: We aimed to look at renal outcomes of patients with Type 2 diabetes 
mellitus (T2DM) who were biopsied and determine the risk factors associated with 
progressive CKD.
Methods: We retrospectively analyzed patients with T2DM with estimated glomerular 
filtration rate (eGFR) (MDRD) >30ml/min/m2 who underwent kidney biopsy from 2007 to 
2015 in our tertiary hospital with at least 1 year of follow-up. Outcomes of interest were 
progressive CKD defined by doubling of serum creatinine or ESRD. Survival curve was 
obtained using Kaplan-Meier analysis. Clinically relevant risk factors in univariate analyses 
were adjusted using Cox proportional hazards model.
Results: The cohort included 70 patients, median age 55.2 (IQR: 49.0, 61.4) years 
and duration of T2DM 102.0 (45.0, 183.0) months. The predominant ethnic group was 
Chinese (82.9%) with a median follow-up of 42.5 months (27.0, 71.3). Ninety percent 
of patients received renin-angiotensin-aldosterone-system blockade prior to biopsy and 
nephrotic range proteinuria was the most common indication for biopsy (77.1%). Forty-
three patients had isolated DKD (Group 1) and 27 patients had isolated NDKD (Group 2). 
Four patients with mixed DKD and NDKD were excluded from analysis in view of small 
numbers. In Group 1, the median eGFR (MDRD) was 54.3 ml/min/m2 (42.9, 72.8) and 
Group 2 was 72.2 ml/min/m2 (43.8, 90.6). Sixteen patients (59.3%) from Group 2 received 
immunosuppression or disease specific therapy. Twenty-two patients (51.2%) from Group 1 
and 8 patients (29.6%) from Group 2 had progressive CKD. ESRD occurred in 17 patients 
(39.5%) from Group 1 and 4 patients (14.8%) from Group 2, at median interval of 53.0 
(38.6, 67.4) months from biopsy but median time to ESRD was not reached in patients from 
Group 2. Nine patients, all from Group 1, had died. Kaplan-Meier analysis showed that 
time interval to progressive CKD was significantly longer in Group 2 patients compared 
to patients in Group 1 (p=0.026). The independent risk factors to progressive CKD were 
DKD, baseline systolic blood pressure and baseline urine protein/creatinine ratio by Cox’s 
proportional hazards model.
Conclusions: T2DM patients with DKD have significantly worse renal outcomes 
compared to patients with NDKD. Early biopsy to differentiate NDKD should be considered 
as disease-specific treatment can be given to achieve better renal survival.
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Association of Plasma Soluble CD146 with Arteriosclerosis and Cardio-
vascular Events in Patients with Diabetic Nephropathy
Yiyun Wang, Ying Fan, Niansong Wang, Yang Fei. Shanghai 6th People’s 
Hospital affiliated to Shanghai Jiaotong University, Shanghai, China.
Background: Diabetic nephropathy is an independent risk factor for arteriosclerosis. 
Patients with both DN and arteriosclerosis have poor prognosis due to the lack of early 
symptoms and specific markers. Endothelial cell injury plays a crucial role in arteriosclerosis. 
CD146, an endothelial marker, was used to reflect the severity of endothelial dysfunction. 
We aim to find out if CD146 can evaluate the severity of arteriosclerosis and predict 
cardiovascular events in patients with DN at early stages.
Methods: A total of 105 DN patients at CKD stage 1-3 were enrolled and another 94 
diabetic patients without DN entered the control group. Plasma soluble CD146 (sCD146) 
was measured. Doppler ultrasounds of carotid and lower extremity artery were performed. 
All DN patients were retrospectively followed up for a medium duration of 28 months. 
The association between sCD146 and arteriosclerosis was assessed in DN patients. Kaplan-
Meier curve was used to evaluate the predictive value of sCD146 in cardiovascular events.
Results: Plasma sCD146 was upregulated in DN patients compared with control group. 
sCD146 level was shown to be correlated with the intima-medium thickness of both carotid 
and lower extremity arteries. High level of sCD146 was proved to be an independent risk 
factor for the prevalence of carotid plaques and the instability of plaques in both carotid and 
lower extremity arteries. Survival analysis showed that patients with higher level of plasma 
sCD146 were more likely to have cardiovascular events.
Conclusions: Plasma sCD146 is associated with arteriosclerosis in patients with early 
stages of DN and can also predict their cardiovascular events.
Funding: Government Support - Non-U.S.
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Kidney Biopsy in Type 2 Diabetes Patients with CKD
Javier Soto-Vargas, Manuel S. Preciado, Julio A. Gutierrez-Prieto, Isela Márquez 
magaña, Francisco Fuentes Ramirez, Renato Parra Michel. Universidad de 
Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en 
Nefrologia, Hospital General Regional No 46 del IMSS, Guadalajara, Mexico.
Background: T2D represent the most frequent cause of CKD worldwide. Reduced 
GFR and albuminuria are considered hallmark for the diagnosis of diabetic nephropathy 
(DN), but recently, there are growing concerns of the sensibility of these markers to identify 
DN from other nephropathies. Our objective was to describe the prevalence of biopsy 
proven DN and other nephropathies in patients with T2D.
Methods: During March 2017 to February 2018, we prospectively biopsied 35 
with diagnosis of T2D and CKD and had no contraindications for the kidney biopsy. All 
histological results were read by a nephropathologist.
Results: The mean age was 52 ± 11.9 years, and 17 (77.2%) were female. The average 
BMI was 27.5 ± 5.1 kg/m2, 31 (86.1%) had HTN, and baseline GFR was 56 ml/min (IQR 
39.4-74.9). The mean time with T2D was 13 ± 7.5 years, and 21 (58.3%) had history 
of diabetic retinopathy. The sCr at the time of the kidney biopsy was 1.9 mg/dL (IQR 
1.1-3.4), the main indications for the kidney biopsy were nephrotic syndrome in 17 (47.2%), 
nephrotic range proteinuria in six (16.7%), rapid progression of CKD in six (16.7%), AKI in 
two (5.6%), rapid progressive glomerulonephritis in one (2.8%), and two with subnephrotic 
proteinuria (5.6%). The histologic findings were isolated DN in eighteen (50%) patients, 
fourteen (38.9%) had DN + other glomerulopathy, and four (11.1%) had a non-DN 
glomerulopathy (Figure 1). None of the clinical or biochemical analysis was associated with 
the histological diagnosis or predicted the severity of the glomerular sclerosis in patients 
with DN.
Conclusions: The kidney biopsy is a useful tool to stablished a correct diagnosis and 
severity of the CKD in patients with T2D. Reduce GFR and albuminuria are not useful 
to differentiate DN from other glomerulopathies, nor stablish severity of the histological 
appearance.
Kidney bipsy results of T2D patientsAIN, acute intersticial nephritis; LN, lupus nephritis; 
FSGS, focal segmental glomerulosclerosis; ATN, acute tubular necrosis.
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Validation of the 2007 Kidney Disease Outcomes Quality Initiative 
Clinical Practice Guideline for the Diagnosis of Diabetic Nephropathy and 
Nondiabetic Renal Disease in Chinese Patients
Xiaomin Liu, Zheyi Dong, Weiguang Zhang, Qian Wang, Xiangmei Chen. 
Chinese PLA General Hospital, Beijing, China.
Background: Diabeties mellitus has overtaken infection and immunological factors as 
the most common cause of chronic kidney disease and end-stage renal disease. Pathological 
results of DM patients with CKD could be diabetic nephropathy (DN) and nondiabetic renal 
disease (NDRD), the prognosis and treatment of which are different. The Kidney Disease 
Outcomes Quality Initiative (KDOQI) guideline (2007) is a widely accepted guideline for 
the clinical diagnosis of DN and NDRD. Our study sought to verify its diagnostic ability in 
the Chinese population.
Methods: We included 773 DM patients who underwent a renal biopsy at the Chinese 
PLA General Hospital from 2007 to 2016. All the patients were divided into three groups 
according to their renal biopsy: isolated DN, isolated NDRD, and isolated DN combined 
with NDRD. The calculation were performed under two conditions:isolated DN vs. isolated 
NDRD and isolated DN vs. non-DN [NDRD with and without DN].
Results: Good sensitivity and poor specificity were found for the prediction of NDRD 
in the Chinese population. Rapidly decreasing estimated glomerular filtration rate, systemic 
disease, refractory hypertension, and the existence of “grey area” patients may have 
contributed to the poor diagnostic ability.
Conclusions: The diagnostic ability of the KDOQI guideline (2007) for DN and 
NDRD was unsatisfactory. The high sensitivity and low specificity of the guideline made it 
more suitable as screening criteria rather than diagnostic criteria.
Funding: Government Support - Non-U.S.
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Comparison of the Risks of Cardiovascular Disease for Patients with 
Diabetic Kidney Disease Between Those Treated by Diabetologists and 
Nephrologists
Masanori Ishizaka,1 Hiroaki Io,1 Hiroyuki Inoshita,2 Takanori Nakano,1 
Masayuki Maiguma,1 Yoko Matsuyama,1 Yusuke Suzuki.3 1Juntendo University 
Nerima Hospital, Tokyo, Japan; 2Koto Hospital, Tokyo, Japan; 3Juntendo 
University Faculty of Medicine, Tokyo, Japan.
Background: Patients with diabetic kidney disease are managed by not only 
diabetologists, but also nephrologists. In this study, we examined the risk of cardiovascular 
disease for patients with diabetes mellites between those treated by diabetologists and 
nephrologists.
Methods: We randomly selected 200 and 30 outpatients with diabetes mellites managed 
by diabetologists and nephrologists, respectively. All of patients showed microalbuminuria 
during the four months from May to August, 2017. We analyzed sex, age, estimation 
glomerular filtration rate (eGFR), albuminuria, hemoglobin, HbA1c, and blood pressure 
correlation with past history of the cardiovascular diseases.
Results: Both age and microalbuminuria levels were significantly higher in the 
diabetes patientstreated by diabetologists with cardiovascular disease than those without 
cardiovascular disease. In contrast, a significant difference was not found in the age and the 
microalbuminuria levels of the diabetes patients treated by nephrologists with cardiovascular 
disease and those without cardiovascular disease. In outpatients with diabetes mellites 
managed by diabetologists, CKD stage 2 (eGFR 60-90ml/min) was the most stage (51.8%). 
In outpatients with diabetes mellites managed by nephrologists, CKD stage 3 (eGFR 
30-60ml/min) was the most stage (40.0%). In multivariate analysis, age (cutoff levels : 68 
years old), eGFR (cut off levels : 81.7 ml/min) and albuminuria (cut off levels : 197 mg/gCr) 
were independently associated factors of the cardiovascular diseases in outpatients by
diabetologists. In outpatients by nephrologists, eGFR (cut off levels : 59.0 ml/min) was
only independently associated factor of the cardiovascular diseases. In comparison with
the severity classification of chronic renal failure, age, eGFR and albuminuria were 
independently risk factors for cardiovascular disease in CKD stage G1-2 group, but in CKD 
stage G3-5 group, both were not related factors.
Conclusions: Outpatient with diabetic kidney disease managed by nephrologist were 
in an advanced phase more than those managed by diabetologists. And this study suggested 
that the eGFR was more risk factor on cardiovascular disease than age and albuminuria in 
outpatients managed by nephrologists.
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Echocardiographic Findings in Type 1 Diabetics with End-Stage CKD
Rita Calça,1 Tiago J. Carvalho,3 Patricia Q. Branco,2 Maria augusta C. Gaspar,1 
Rita Birne,1 Eduarda Horta,1 Carla A. Reis,1 Maria joão Andrade.4 1Hospital 
Santa Cruz, Carnaxide, Portugal; 2Santa Cruz Hospital, Carnaxide, Portugal; 
3Hospital de Santa Cruz, Queluz, Portugal; 4Hospital Santa Cruz, CHLO, 
Lisbon, Portugal.
Background: Diabetes mellitus(DM) and chronic kidney disease(CKD) are 
independent risk factors for the development of cardiovascular(CV) disease. They have 
been associated with changes of cardiac structure, function, and an excess risk of coronary 
artery disease(CAD). The aim of this study was to evaluate the echocardiographic findingsin 
patients with DM type1 and end-stage CKD.
Methods: 48 consecutive patients undergoing stress echocardiography prior to renal 
+/- pancreatic transplantation between December2008 and December2014 at a single 
center, were evaluated. At baseline, a complete comprehensive 2D and Doppler exam was 
performed, including evaluation of global longitudinal strain(GLS).
Results: Mean age was 42.3±7.1years-old, mean DM duration was 24.4± 6.0 years 
and mean HbA1c was 8.7 ±1.7%. The prevalence of other major atherosclerotic risk 
factors was: hypertension 69.4%, dyslipidemia 44,4% and smoking 36.1%. 4 patients 
had history of CAD with previous coronary angioplasty. At baseline, 38.5% were on 
hemodialysis(HD) and 25.6% on peritoneal dialysis(PD); 7.7% had previous renal 
transplant and 28.2% patients weren’t on renal replacement therapy(RRT). 63.6% had left 
ventricular(LV) hypertrophy(LVMI>115g/m2 for men, >95g/m2 for women) and 45.3% had 
left atrial enlargement (LAE>34ml/m2). Although LV ejection fraction was preserved in 
72.9%, LV dysfunction as assessed by abnormal GLS(> -18%) was observed in 72,9%. 
5 patients had neither LV dysfunction nor hypertrophy. 34.4% had rest elevated LV filling 
pressure(E/e’ >13). No differences between HD, PD and no RRT groups. 6 patients (12,5%) 
had ischaemic response, 5 of whom underwent coronary interventions. During follow-up 
(5.6, 4.2-6.9 years), 14.3% had hospitalizations of any cause and 3 were hospitalized for 
CV causes. These 3 patients had both LV dysfunction and hypertrophy and 1 had ischaemic 
response. At the end of follow-up 50% of patients had transplant (mostly kidney-pancreas). 
No patient died.
Conclusions: Cardiac abnormalities are frequent in relatively young patients with DM 
type 1 and end-stage CKD. Most of them have LV hypertrophy and preserved ejection 
fraction, despite LV dysfunction. CAD is also frequently present and can be demonstrated 
by stress echocardiography, allowing for coronary intervention before renal transplantation.
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Stakeholder Perspectives on Implementing Personalized Medicine in 
Diabetic Kidney Disease
Michelle Pena,1 Nienke Idzerda,1 Gert J. Mayer,2 Friedrich Schulze,5 
Jeannette Soderberg,6 Dennis L. Andress,4 Maria F. Gomez,3 Hiddo J. Lambers 
Heerspink,1 Dick de Zeeuw,1 Peter G. Mol.1 for Work Package 6 of the BEAt-
DKD Consortium 1University Medical Center Groningen, Groningen, 
Netherlands; 2Medical University Innsbruck, Innsbruck, Austria; 3Lund 
University, Malmö, Sweden; 4AbbVie, North Chicago, IL; 5Boehringer Ingelheim 
International GmbH, Ingelheim, Germany; 6JDRF, Paris, France.
Background: The Innovative Medicine Initiative BEAt-DKD consortium aims to 
discover and implement novel biomarkers for personalized medicine in diabetic kidney 
disease (DKD). Gaining stakeholder opinions and perspectives are important in this 
process. We describe here the opinions and perspectives of stakeholders obtained during 
focus group meetings.
Methods: Stakeholder focus groups were held with members of European regulatory 
agencies, health technology assessors, physician groups, and patient organizations. 
BEAt-DKD consortium partners included academia, pharmaceutical industry, and patient 
advocacy. General and stakeholder specific topic lists were developed by BEAt-DKD 
members. A background presentation on personalized medicine in DKD was given, and 
then an open discussion was held, moderated by an academia BEAt-DKD member. Themes 
discussed included: 1) determining whether there is a need for personalized medicine in 
DKD, 2) what additional evidence is needed, 3) identification of the pros and cons within 
each stakeholder environment, 4) identification of hurdles for implementation, and 5) 
engagement with other stakeholders.
Results: Attendees of the focus groups included representatives from European 
regulatory agencies (n=7), health technology assessors (n=4), physicians (n=5), and patients 
(n=4). BEAt-DKD partners included academia (n=6), pharmaceutical industry (n=3), and 
patient advocacy (n=1). Main points that came out of the stakeholder focus groups are 
presented in the table.
Conclusions: Implementing personalized medicine in DKD is complex, and 
early engagement of stakeholders in the developmental process is important. Different 
stakeholders have different priorities, and achieving the goal of implementing personalized 
medicine in DKD will only happen if we can align stakeholder goals.
Funding: Commercial Support - The BEAt-DKD project has received funding from 
the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. 
This Joint Undertaking receives support from the European Union’s Horizon 2020 research 
and innovation programme and EFPIA., Government Support - Non-U.S.
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Pattern of Non-Diabetic Renal Diseases (NDRD) in Patients with Diabetes 
Mellitus at State Run Tertiary Care Center
Umesh L. Institute of nephrourology, Bangalore, India.
Background: Introduction A wide spectrum of non-diabetic nephropathy, including 
both glomerular and tubulo-interstitial lesions are reported in patients with Diabetes mellitus. 
Their precise diagnosis requires histological examination of kidney tissue. Aim We carried 
out this study to find the clinical, laboratory, and pathological features of non diabetic renal 
disease (NDRD) in diabetes mellitus(DM) patients. We also examined if any significant 
differences in clinical profile between the NDRD and diabetic nephropathy(DMN) groups
Methods: The demographic, clinical, and biochemical data of patients with DM 
(defined by ADA) who underwent renal biopsy in this institute for a duration of from 2012 
august to october 2017 were analyzed prospectively. 220 patients were included in the 
study. Data were collected from inpatient file, monitor sheets, histopathological reports.
Results: Materials & methods: The demographic, clinical, and biochemical data of 
patients with DM (defined by ADA) who underwent renal biopsy in this institute for a 
duration of from 2012 august to october 2017 were analyzed prospectively. 220 patients 
were included in the study. Data were collected from inpatient file, monitor sheets, 
histopathological reports.
Methods: The demographic, clinical, and biochemical data of patients with DM 
(defined by ADA) who underwent renal biopsy in this institute for a duration of from 2012 
august to october 2017 were analyzed prospectively. 220 patients were included in the 
study. Data were collected from inpatient file, monitor sheets, histopathological reports.
Conclusion: In this study, incidence of NDRD was 38%, DMN 42% AND 
combined was 20%. Chronic kidney disease (CKD),nephrotic syndrome( NS) and acute 
kidney injury( AKI) were the most frequent clinical presentation. Acute interstitial 
nephritis(AIN),post infectious glomerulonephritis( PIGN) and chronic tubulointerstitial 
disorder ( CTID) were commonest NDRD. These results suggest that prevalence of 
different category of biopsy-proven renal disease in diabetic patients depends on the usual 
prevalence of renal disease in the total population, according to the geographical area 
and ethnic characteristics and NDRD is merely a coincidental in DM. 58% of patients in 
the study had NDRD [either isolated or combined]. This study showed isolated NDRD 
in 38%, this result is similar to that reported in India and other regions with incidence of 
isolated NDRD were less than 50%.
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Novel Biomarkers for Detecting Endothelial Dysfunction and High 
Cardiovascular Risk in Patients with Early Diabetic Kidney Disease
Ane karoline Medina neri,1 Gdayllon Cavalcante meneses,2 Renan Lima 
alencar,1 Marina De paulo sousa fontenele nunes,1 Mariane Souza rodrigues,1 
Igor Pinho saraiva,1 Elizabeth De francesco daher,2 Ricardo Pereira silva,2 
Geraldo B. Silva Junior.1 1University of Fortaleza, Fortaleza, Brazil; 2Federal 
University of Ceara, Fortaleza, Brazil.
Background: Diabetic kidney disease (DKD) is the most common cause of chronic 
kidney disease (CKD) worldwide, and the main cause of death is cardiovascular disease. We 
identified endothelial dysfunction and high cardiovascular risk among patients with early 
DKD using novel biomarkers.
Methods: A total of 128 patients with type 2 diabetes mellitus were enrolled in this 
study. They were all followed in a primary care facility in Fortaleza, Brazil, and had no 
previous history of cardiovascular or kidney disease. Blood samples were collected for lipid 
and glycemic profiles, FGF-23, Syndecan-1 and VCAM-1. We assessed cardiovascular risk 
(CVR) through the scores: Framingham lipids category (lipids FRE) and body mass index 
(BMI FRE), Brazilian Cardiology Society (SBC) score and UKPDS risk engine.
Results: Patients aged 56±10 years, and 68.8% of whom were women, with a mean 
diabetes diagnosis time of 7±6 years. The CVR stratification showed higher rates of high 
risk by lipids ERF (68.8%), BMI (78.1%) and SBD/SBC/SBEM score (98.4%). There were 
higher levels of VCAM-1 among patients with high CVR (lipids FRE), higher levels of 
VCAM-1, Syndecan-1, FGF-23 and microalbuminuria, and lower GFR among patients 
with high CVR (UKPDS) (Table 1).
Conclusions: DKD is associated with high CVR since its early stages. Novel 
biomarkers (VCAM-1, Syndecan-1, FGF-23) are useful for early detection of high risk 
patients. A longitudinal evaluation of these patients is required to assess the outcomes and 
the role of these novel biomarkers as predictors of prognosis.
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Table 1. Association of novel biomarkers with cardiovascular risk (CVR) among patients 
with early stage diabetic kidney disease.
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Retinopathy Predicts Rapid Decline in Renal Function in Ethnic 
Minorities with Diabetic Nephropathy
Amit J. Joshi, Mohan C. Abraham, Ambarish Athavale, Peter D. Hart. Cook 
County Health and Hospitals System, Chicago, IL.
Background: Retinopathy is seen in 66% of adult patients with type II diabetes 
(T2DM) and diabetic nephropathy and indicates advanced microvascular disease. However, 
association of retinopathy with progression of diabetic kidney disease is unknown. In our 
clinical practice, we have observed that certain patients with T2DM have a rapid decline 
in renal function, but it is unclear if any clinical parameters are associated with this 
presentation.
Methods: We retrospectively examined the Stroger Hospital kidney biopsy database 
from 2010 to 2017 and identified 57 cases of biopsy proven diabetic nephropathy. Indications 
for biopsy were either rapid decline in eGFR [defined as eGFR loss > 5ml/min/1.73m2/ yr, 
KDIGO, Kidney Int. (suppl) 2013] or presence of a competing diagnosis. 29 of these cases 
had proliferative or non-proliferative retinopathy confirmed by an Ophthalmologist.
Results: In patients with more than 12 months of follow up (n=37), mean annual 
decline in eGFR was –15.9 (-11.2 to -20.1) ml/min/1.73m2. The rate of decline in eGFR 
was significantly associated with presence of retinopathy (p=0.018) and hypoalbuminemia 
(serum albumin < 3.5 g/dL, p=0.002). There was a trend suggesting decline in eGFR 
correlated with severity of proteinuria (p=0.08). eGFR decline was not associated with 
hematuria ethnicity or gender (p ≥ 0.17).
Conclusions: In African-American and Hispanic patients with Diabetic nephropathy, 
presence of diabetic retinopathy correlated with rapid decline in eGFR and lower serum 
albumin despite RAAS blocker therapy.
Baseline demographic and clinical parameters (number, %)
PUB202 
Publication-Only 
Potential Effectiveness and Mechanisms of Chinese Herbal Medicine for 
Diabetic Kidney Disease: Survival and Pharmacology Network Analysis 
on a Population-Based Clinical Database
Hsing-Yu Chen,1,2 Yung-Chang Chen,3 Hau-tieng Wu.4,2 1Chang-Gung Memorial 
Hospital, Taoyuan City, Taiwan; 2Department of Mathematics, University of 
Toronto, Toronto, ON, Canada; 3Chang Gung Memorial Hospital, Keelung 
branch, Keelung, Taiwan; 4Duke University, Durham, NC.
Background: Diabetic kidney disease (DKD) causes a great healthcare burden. In 
addition to western medicine (WM), Chinese herbal medicine (CHM) is attracting attention 
in the eastern culture societies. This study aims at exploring the mortality of CHM users and 
the potential mechanisms of CHM.
Methods: From 2004 to 2012, WM cohort (WM only, n=207,277) and CHM cohort 
(CHM with or without WM, n=26,522) were selected from all incident DKD patients in 
Taiwan’s National Health Insurance Research Database. Risk of mortality was the study 
endpoint. To explore the potential mechanisms, pharmacology network analysis with 
pathway over-presentation tests were used.
Results: To the end of 2012, the cumulative incidence of mortality was 47.9% in WM 
cohort and 30.5% in CHM cohort (hazard ratio: 0.48 (99%CI: 0.45-0.51, p<0.001). The 
top 5 most prevalent CHM considerably covered the same target proteins as WMs used 
for DKD, and for WM uncovered proteins, cell cycle-related pathways were found most 
extensively.
Conclusions: CHM may be beneficial for DKD. Further studies are still needed for the 
clinical practicability.
Fig1.(A)Flow diagram(B)Survival analysis
Fig2.Pathway analysis of the top 5 most prevalent CHM and WM(A)Drug-target protein 
interactions(B)Target protein comparisons(C)Pathways not covered by WM.
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Efficacy and Safety of Valsartan Combined with Huangkui Capsule for 
Diabetic Kidney Disease: A Meta-Analysis
Meifang Liu,1 Yanmei Zhang,1 Xusheng Liu,3,2 Lei Zhang.4,2 1The Second 
Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 
China; 2Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 
China, Guangzhou, China; 3The Second Affiliated Hospital, Guangzhou 
University of Chinese Medicine, Guanghzou, China; 4Guangzhou university of 
Chinese Medicine, Guangzhou, China.
Background: Diabetic kidney disease (DKD) has been a global public health problem 
and a huge economic burden to developing countries. Currently, as for DKD populations, 
medication options limited in angiotensin receptor blockers and angiotensin-converting 
enzyme inhibitors. Huangkui capsule, a Chinese patent medicine, has showed renal 
protective potential in experiments and retrospective studies. This meta-analysis will 
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systematically review the efficacy and safety of Valsartan combined with Huangkui Capsule 
for DKD patients.
Methods: We searched CENTRAL, MEDLINE, PubMed, Embase and Chinese 
databases including China National Knowledge Infrastructure, China Biology Medicine 
disc and Wanfang database from inception to August, 2017, to collect randomized clinical 
trials in adult patients (aged ≥18 years). According to the inclusion and exclusion criteria, 
two reviewers screened literature and extracted data separately and in parallel. The main 
outcomes were urinary albumin excretion rate (UAER), serum creatinine (SCr), 24-hour 
urinary protein (24h-UTP) and blood urea nitrogen (BUN) assessed by random-effects 
meta-analyses with RevMan 5.3. The quality of included studies was evaluated by the 
diagram of risks and bias provided by Cochrane collaboration.
Results: Nine RCTs from China were included with a total of 652 population. The 
analyses showed that combined therapy of Chinese and routine medicine was superior 
to routine medicine in decreasing UAER [MD=-9.70 ug/min, 95%CI(-13.1, -5.69), 
P[[FF1C;0.00001, low quality] and SCr [MD=-2.84 umol/L, 95%CI(-4.66, -1.03), 
P=0.002, low quality], the results had significant differences (P<0.05). However, 
the outcomes of 24h-UTP [MD=-0.31g/24h, 95%CI(-0.63, 0.00), P=0.05] and BUN 
[MD=-0.22 mmol/L, 95%CI(-0.47, 0.04), P=0.10] were similar between groups. The 
findings were robust to subgroup and sensitivity analyses. Six included studies mentioned 
adverse effects, summarized as gastrointestinal symptoms without detailed data.
Conclusions: Valsartan combined with Huangkui capsule could have a better clinical 
effect than using Valsartan alone in decreasing UAER and SCr but not 24h-UTP or BUN 
for DKD patients. However, the safety profile is unclear, and the quality of evidence is poor 
according to the grading of recommendations assessment, development, and evaluation 
approach, calling for high quality randomized, controlled RCTs.
Funding: Government Support - Non-U.S.
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Unexpected Etiology of ESRD in a Young Man with Unknown Past 
Medical History
Albert M. Osei,1,2 Edwin Okyne,1 Peter D. Hart,1,2 David J. Cimbaluk.3 
1Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL; 2Medicine, 
Rush University Medical Center, Chicago, IL; 3Pathology, Rush University 
Medical Center, Chicago, IL.
Introduction: Patients without access to the US health care system may have 
unidentified and untreated common medical conditions that may lead to severe and 
irreversible kidney disease. This case illustrates the consequences of lack of access to 
primary healthcare and the role of kidney biopsy in elucidating etiology of severe kidney 
disease in the context of paucity of prior clinical data
Case Description: A 32 year old Hispanic man was seen in a public hospital 
emergency department with one week history of progressive left visual loss and periorbital 
headache. BP was 186/116mmHg and systemic exam was unremarkable except for left eye 
depigmented vitreous hemorrhage suggestive of “hypertensive” retinopathy. Laboratory 
data showed non-fasting glucose -110mg/dl, serum creatinine -5.0mg/dl (eGFR 13ml/min), 
urine protein-8.75g/gCr and A1C -6%. All serological tests were negative and urine 
microscopy was unrevealing. Ultrasound showed normal size but echogenic kidneys. 
BP was 132/72 after two days on Nifedipine 30mg daily. Kidney biopsy done (Figure 1) 
showed “diabetic glomerulosclerosis with advanced global scarring (17 of 22 glomeruli) 
and severe interstitial fibrosis and tubular atrophy involving 90% of the cortex”
Discussion: Kidney biopsy was done in this patient because of his young age, 
normal size kidneys and uncertainty about the etiology and reversibility. The finding of 
“hypertensive” retinopathy and presumed hypertensive nephrosclerosis was not consistent 
with the nephrotic range proteinuria and the ease of BP control with monotherapy. Although 
up to 42% of US adults with undiagnosed diabetes may have CKD, it is very unusual 
for ESRD to lead to the diagnosis of “burnt-out diabetes”. It is likely that access to basic 
primary care would have identified diabetes mellitus sooner and adequate treatment would 
have delayed or prevented this unfortunate outcome.
Figure 1
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Improving Inpatient Diabetic Management in Haemodialysis Patients: A 
Quality Improvement Project
Dhaarica Jeyanesan, Oscar Swift. Renal Medicine, East and North Hertfordshire 
NHS Trust, Stevenage, United Kingdom.
Background: The prevalence of diabetes is set to increase to 4.4% from 2.8% by 20301. 
Some of the most vulnerable and severely affected patients are those with end-stage renal 
failure (ESRF) requiring haemodialysis. Until recently, sufficient UK national guidance 
to support healthcare professionals with the management of this particular population 
was lacking. In 2016, the Joint British Diabetes Society and Renal Association produced 
guidelines2 covering the extensive and distinct needs of a diabetic patient with end stage 
renal failure on haemodialysis. Ongoing concern over the impact of hypoglycaemia on both 
cerebral function and risk of stroke mandates the need to optimise glycaemic control in this 
patient cohort.
Methods: Using this guidance as a framework, we have reviewed our own 
management of inpatient diabetic haemodialysis patients at Lister Hospital, Stevenage, a 
tertiary nephrology unit in the UK. We have applied quality improvement methodology 
using a ‘‘plan, do, study, act’’ model to the guidance to improve inpatient care.
Results: Initial results following baseline data collection over a two week period 
identified 12 haemodialysis inpatients with diabetes. 50% of these patients suffered a 
hypoglycaemic event, and 100% of this subgroup had a pre-dialysis capillary blood glucose 
(CBG) measurement of less than 7mmol/litre. No patients received bespoke insulin regimens 
to include reduced insulin dosage on dialysis days. Further investigation revealed issues 
with communication of hypoglycaemic episodes between nurses and doctors; acute dialysis 
staff using separate paperwork to document pre- and post-dialysis CBG measurements and 
discrepancies of management of pre-dialysis CBGs of less than 7mmol/litre, as well as poor 
inspection rates for diabetic foot ulcers (33%).
Conclusions: Primary interventions included notification and education of the relevant 
teams to ensure CBG measurements pre and post- dialysis were recorded on inpatient drug 
charts, which are easily accessible for all clinical staff, ensuring adequate pre-dialysis 
carbohydrate supplementation as per guidelines if pre-dialysis CBG measurements are 
less than 7mmol/litre and improved notification of hypoglycaemic events. Further quality 
improvement cycles are ongoing and will hopefully demonstrate an improvement in the 
management of diabetic haemodialysis patients in the areas described.
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Cost-Saving and High Efficiency of a Semi-Quantitative Screening 
Method for Detecting Microalbuminuria in Patients with Diabetes
Yaerim Kim,1 Myoung-Hee Kim,2 Dong Ki Kim.1 1Seoul National University 
Hospital, Seoul, Republic of Korea; 2Eulji University, Seongnam-si, 
Gyeonggi-do, Republic of Korea.
Background: Microalbuminuria is an important biomarker for diabetic nephropathy 
and cardiovascular complications. While quantitative measurement using turbidimetric 
immunoassay is the standard method for detecting microalbuminuria, it requires high cost 
and specialized laboratory equipment. In this study, we aimed to assess the diagnostic 
accuracy and verify the cost-saving effect of semi-quantitative urinary albumin-creatinine 
ratio (uACR) test as a screening tool for microalbuminuria in diabetic patients.
Methods: A total of 1,881 urine samples from patients with diabetes were analyzed 
between June 2017 and January 2018. Patients with low estimated glomerular filtration 
rate (eGFR) of <60 ml/min/1.73m2, or abnormal urinary dipstick test were excluded. 
After investigating precision and reproducibility of the semi-quantitative method using 
URiSCAN® 2ACR, a cost-saving analysis was performed. To measure the economic 
burden of false negative results, probabilities of clinical outcomes were calculated using 
systematic literature review and subsequent meta-analyses. Information on annual medical 
costs was obtained from Korea healthy insurance review and assessment service. Statistical 
information of population and mortality rate according to age was extracted from Korean 
statistical information service.
Results: The coefficients of variation (CV) in within-run precision for albumin and 
creatinine were less than 5% in both. Between-run CVs for albumin and creatinine ranged 
up to 8% and 5% in positive result samples. Compared with the quantitative method, 
URiSCAN® 2ACR showed a sensitivity of 93.5% and 81.3% and specificity of 61.4% 
and 63.1% in patients with diabetes and diabetic patients with normal eGFR and normal 
dipstick result, respectively. False positive and false negative rate were 30.5% and 3.2%, 
respectively. After adjusting medical costs including the risk of disease progression, 
URiSCAN® 2ACR could save 9.86 USD per person for a year.
Conclusions: A semi-quantitative uACR test showed eligibility as a screening test for 
microalbuminuria in diabetic patients. This method would minimize the time required and 
inconvenience and enormously reduce the national health costs as well.
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Dialysis Induced Diffuse EEG slowing – A Diagnostic Dilemma
Samir C. Gautam,1 Padam Hirachan,1 Sahitya Bhandari,2 Binu Pannachan,1 
Orlando A. Ricalde.3 1Mississippi Nephrologists LLC, NATCHEZ, MS; 2Natchez 
Clinic Company, NATCHEZ, MS; 3Merit Health Natchez, Natchez, MS.
Introduction: Patient undergoing dialysis in ESRD have multiple cardio-
cerebrovascular complications and it is very difficult to tease out those complications as 
some which are yet to be defined. We present a unique case where a patient has frequent 
syncopal episodes without major identificable cause.
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Case Description: This is a 60 year old African American female with history of 
DM2, HTN, CVA and ESRD on IHD for 4 years. Her EDW is 68.5 kg and most of the 
times she is without significant Intradialytic weight gain. Over last 6 months, she has been 
having recurrent passing out episodes during dialysis, without any clinical and biochemical 
evidence of fluid or electrolyte shifts or infections. At various stages of her single dialysis 
treatment, she slowly goes into drowsiness and then goes into an unresponsive episode. 
In spite of EDW adjustment and the minimal UF rate she persistently has been having 
these episodes. Following this, she underwent extensive cardiovascular and cerebrovascular 
work-up, which were unremarkable. Her echocardiogram showed EF was 40-50%, normal 
stress test. CT of the brain and carotid anatomy were unremarkable. Her MRI and MRA of 
the brain were remarkable for old minor strokes. She then underwent EEG which was also 
unremarkable. Lastly, she underwent video EEG during dialysis, at which point it showed 
diffuse slowing of electrical activity which wasn’t present when she wasn’t on dialysis.
Discussion: ESRD patients are at risk for sleep disorders as insomnia, restless leg 
syndrome, sleep-disordered breathing and excessive daytime sleepiness. Abnormal EEG 
changes have been shown in patients with chronic uremia and dialysis disequilibrium 
syndrome only. We present a case who has been on a IHD with intradialytic altered mental 
status for 6 months, depicting intradialytic EEG changes. The video EEG showed diffuse 
slowing of electrical activity (as shown in the Images) without any definitive diagnosis.
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Rituximab Therapy After ESRD in Lupus Patients Is Used for 
Thrombocytopenia
Vipawee S. Chat,1 Jennifer L. Waller,1 Rhonda E. Colombo,1 Stephanie L. Baer,2 
Erin vanessa S. Spearman,1 Lufei Young,1 Mufaddal Kheda,1 Leighton R. James,1 
N. Stanley Nahman.1,2 1Augusta University, Augusta, GA; 2Augusta VA Medical
Center, Augusta, GA.
Background: Lupus nephritis (LN) is a serious complication of SLE that may lead 
to dialysis. Rituximab (RTX) is used in refractory LN prior to dialysis, and in acute cases, 
used after starting dialysis in an attempt to induce remission. In a pilot study, we queried the 
USRDS for patients with ESRD from lupus and found 68 who received RTX, however the 
mean time of administration of the drug was > than 1 year after starting dialysis, suggesting 
indications other than LN. To assess indications for RTX therapy in lupus patients with 
ESRD we re-queried the dataset for diagnostic indications for using the drug in this setting.
Methods: Incident dialysis cases in the USRDS from 2006-2010 were queried for 
ESRD from SLE using the code 7100 from CMS Form-2728. The indications for RTX in 
ESRD lupus patients were assessed using ICD-9 diagnosis coding found in the hospital, 
detailed, and physician-supplier claims files.
Results: There were 3,307 ESRD patients identified with ESRD secondary to SLE 
with a mean±SD age of 41±15 years, 82% female, 53% black and 40% white. RTX 
infusion was documented in 68 (2.1%) patients. RTX(+) patients were younger (37±15yrs) 
but otherwise did not differ from the SLE group. 36 patients had a diagnosis associated 
with the RTX infusion, including lupus (41.7%); thrombocytopenia (28%); cancer (17%); 
rheumatoid arthritis (8.3%); and miscellaneous causes (14%). The data shows that in 
these ESRD patients, RTX is given most commonly for unspecified lupus indications and 
thrombocytopenia (TCP). The lack of specific indications for RTX infusion in 32 of the 68 
patients is unclear, however, in the 36 patients with a clear diagnosis, the administration 
of RTX for TCP was evident, and suggests that clinicians are encountering and treating 
autoimmune TCP in lupus patients on dialysis.
Conclusions: These data indicate that among patients with ESRD from lupus who were 
treated with RTX, ongoing SLE activity is the most common indication. The second most 
common indication was TCP, presumably of an autoimmune nature. We would speculate 
that extra-renal immune activity may remain high in some SLE patients on dialysis, in 
particular presenting as TCP. The high rate of TCP in dialysis patients in general, and 
perhaps SLE patients in particular, suggests consideration of active lupus as a cause.
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Dieulafoy’s Ulcer on Hemodialysis Therapy: A Report of Two Cases
Hiroyuki Deguchi. Saiseikai-Sendai Hospital, Satsumasendai-City, Kagoshima 
Pref., Japan.
Introduction: Dieulafoy’s ulcer accounts for approximately 5% of all gastrointestinal 
hemorrhages. These ulcers are characterized by a ruptured artery that runs in the submucosal 
layer, and may be attributed to various abnormalities including dilation, micro-aneurysm, 
angiodysplasia and so on. Prior studies have established chronic kidney disease (CKD) 
as a risk factor for gastrointestinal hemorrhage, as angiodysplastic lesions are often seen 
in patients with CKD. Here we present a report of two cases of Dieulafoy’s ulcer in the 
stomach and rectal colon.
Case Description: Case 1: A 76-year-old man with a past medical history of 
longstanding diabetic nephropathy presented to our hospital’s Accident and Emergency 
department and underwent emergency hemodialysis. The patient suffered a bout of 
hemoptysis on post admission day 7, requiring emergency esophagogastroduodenoscopy 
(EGD). Endoscopic findings showed an ulcer on the lesser curvature of the stomach with 
pulsatile bleeding. The bleeding was successfully stopped via gripping with a hemostat. A 
second EGD done the following day showed no residual active bleeding. Case 2: A 69-year-
old woman with end stage renal disease on hemodialysis therapy since 2008 presented to 
our hospital with sepsis. Antibiotics were started And on post admission day 7, bloody 
bowel discharge was observed twice, along with low blood pressure and anemia. An urgent 
colonoscopy examination performed showed an ulcer in the rectal Rs region with pulsatile 
bleeding. We cauterized the ulcer with forceps to confirm hemostasis. A second colonoscopy 
examination done the following day showed no active residual bleeding.
Discussion: Dieulafoy’s ulcer is an important cause of gastrointestinal bleeding 
and is often diagnosed late. It has a tendency to cause severe, life-threatening, recurrent 
gastrointestinal bleeding but is amenable to life-saving endoscopic therapy. In addition, 
hemodialysis has been associated with gastrointestinal hemorrhage due to the use of 
heparin with hemodialysis therapy and uremia-induced platelet dysfunction. Fortunately, 
we were able to stop the bleeding in both cases. However, it is not always be easy to achieve 
hemostasis in bleeding ulcers and may even be fatal especially in patients on dialysis 
therapy. As such, gastrointestinal bleeding such as Dieulafoy’s ulcer in dialysis patients is 
associated with a higher risk of mortality.
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Regional Differences in the Epidemiology of Incident ESRD in Arkansas: 
Developing an Understanding of Disparities
Nadia M. Alqurini,1 Monica Kothari,1 Andrea K. Easom,1 Nishank Jain,2,1 
Manisha Singh.1 1University of Arkansas for Medical Sciences, Little Rock, AR; 
2Little Rock VA Hospital, Little Rock, AR.
Background: End-stage renal disease (ESRD) Network 13 that includes Arkansas, 
Louisiana and Oklahoma has the third highest adjusted incidence rate of ESRD in the 
nation. Furthermore, epidemiology of ESRD and pre-ESRD nephrology care for the state 
is unclear.
Methods: Using ESRD Network 13 data for incident ESRD cases from January 
through December 2016, we describe regional differences in the epidemiology and pre-
ESRD nephrology care within the five regions of Arkansas [central, northwest, northeast, 
southwest and southeast].
Results: For the year 2016, 0.9% (n=1,212) of the total U.S. incident ESRD patients 
were Arkansans. 14% of them were <45 years of age, 21% ≥75 and 47% female-proportions 
similar to the national demographics. Patients ≥85 years comprised around 5% of the total 
incident cases in the central (metropolitan) and the southeast (rural) regions of Arkansas 
compared to <1% in the other regions. 33% of incident cases were African Americans 
compared to 26% in the U.S. There was no difference in the proportion of Arkansans 
choosing hemodialysis compared to the U.S. (89% vs. 88%). 87% of them started 
hemodialysis using a central venous catheter at the first ESRD service date- with the highest 
rate (93%) in the southeast region (the most rural region of the state). Within the regions, no 
one started peritoneal dialysis in the southwest region of Arkansas. Pre-ESRD nephrologist 
and renal-dietician care was received by 56% (n=605) and 4.8% (n=52) Arkansans 
compared to the national average of 64% (n=76,052) and 7.8% (n=9,274), respectively.
Conclusions: Using the Renal Network-13 data rather than the USRDS annual data 
report, we were able to gather data for Arkansas that are more recent and region-specific. 
We observed that a higher proportion of African American and Arkansans ≥85 years started 
dialysis. Dismal access to- and dramatic regional differences in pre-ESRD care may be 
contributing to the disproportionate burden of incident ESRD patients in Arkansas. These 
data can be basis for region-specific efforts to improve nephrology care that is urgently 
needed in order to develop a CKD action plan for the state of Arkansas.
PUB211 
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Risks of Cardiovascular Death(CVD) in Maintenance Hemodialysis 
Patients with Diabetic Nephropathy
Hajime Hirano, Haruhito Azuma. Osaka medical college, Takatuki City, Japan.
Background: Prevention of the development of CVD, which is the major cause of 
death, is key to improving prognosis. We had investigated factors associated with CVD 
mortality risk in maintenance dialysis patients. In this study, an additional analysis was 
performed on data in hemodialysis patients with diabetic nephropathy compared with those 
having other underlying diseases. And furthermore, we investigated factors that influence 
CVD mortality risk in hemodialysis patients with diabetic nephropathy.
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Methods: This retrospective study was conducted with 201 outpatients with 
hemodialysis at our Blood Purification Therapy Center and our other related hemodialysis 
facilities (57 diabetic nephropathy and 144 others). Logistic regression analysis was 
conducted with outcome- measured as CVD death. Hemoglobin levels and blood pressure 
values before and after dialysis were summed up at 3, 6, and 12 months (Σ). A curve was 
obtained by changes in blood pressure per month and the area under the blood pressure 
curve (AUC) was calculated.
Results: Diabetic nephropathy was the highest mortality risk among underlying disease 
groups. A comparison with other underlying diseases revealed that significant differences 
were found for the variables older age (p<0.001) and a shorter history of hemodialysis 
(p<0.001) in patients with diabetic nephropathy. There was no significant difference 
in anemia control between two groups. Poor blood pressure control and higher dose of 
erythropoietin were found in patients with diabetic nephropathy. The multivariate analysis 
of risk factors for mortality in patients with diabetic nephropathy showed that smoking 
(odds ratio(OR): 4.71 [95%CI: 1.97~11.26, p<0.001], history of ischemic heart disease 
(OR: 2.56 [95%CI: 0.95~6.85, p=0.061], age (OR: 1.07 [95%CI: 1.03~1.13, p=0.002], and 
a history of dialysis therapy (OR: 0.78 [95%CI: 0.69~0.87, p<0.001] were risk factors.
Conclusions: Introduction to hemodialysis for patients with diabetic nephropathy, 
given higher CVD mortality risk, it is important to actively prevent the development of 
CVD shortly after hemodialysis. Furthermore, higher smoking rates with higher CVD 
mortality risk associated with smoking among patients with diabetic nephropathy suggested 
that smoking cessation is important for patients with diabetic nephropathy to improve their 
prognosis.
PUB212 
Publication-Only 
Relationship Between Malnutrition and Hypervolemia in Peritoneal 
Dialysis and Hemodialysis
Guilherme P. Santa Catharina, Erica A. Guimarães, Lilian Cordeiro, 
Benedito J. Pereira, Hugo Abensur, Rosilene M. Elias, Bruno C. Silva. University 
of São Paulo, São Paulo, Brazil.
Background: Malnutrition and volume overload increase morbidity and mortality rates 
in patients on peritoneal dialysis (PD) and hemodialysis (HD). Bioelectrical impedance 
analysis (BIA) can assess both nutritional and tissue hydration status in these patients.
Methods: BIA was performed prior to dialysis in a cross-sectional, unicentric study 
that included 71 patients on PD and 109 on HD. Data provided from BIA were: extracellular 
water/total body water ratio (ECW/TBW), fat free mass (FFM), fat percentage (FP) and 
phase angle (PA), which is an objective measure of nutritional status.
Results: Median PA was 4.5° (4.0; 5.2) and 5.8° (4.4; 6.8) in PD and HD respectively, 
p=0.0001. Median ECW/TBW was 0.403 (0.39; 0.41) and 0.39 (0.38; 0.4) in PD and HD 
respectively, p=0.0001. A negative correlation between ECW/TBW and PA was found in 
HD (r=-0.680, p=<0.0001) and PD (r=-0.665, p<0.001), with a statistically different slope 
of the curves (p<0.001). FFM and FP were similar between groups.
Conclusions: Patients on HD presented better nutritional status and lower volume 
overload in comparison to PD. Patients with poor nutrition status (lower PA) presented 
higher volume overload (higher ECW/TBW) in both HD and PD groups. The correlation 
is greater in HD patients.
Patients characteristics
BMI, body mass index; ECW, extracellular water; TBW, total body water; FFM, fat free 
mass; PA, phase angle.
Correlation ECW/TBW and phase angle.
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Characterization of N-Terminal Pro B-Type Natriuretic Peptide and its 
Predictive Value for Longer-Term (7-Year) Survival in Maintenance 
Dialysis Patients
Yuji Sato,1 Akihiro Minakawa,2 Tatsunori Toida,2 Ryuzoh Nishizono,3 
Masao Kikuchi,2 Shouichi Fujimoto.3 1University of Miyazaki Hospital, 
Miyazaki, Japan; 2University of Miyazaki, Kiyotake, Japan; 3University of 
Miyazaki, Miyazakishi, Japan.
Background: In a non-end-stage kidney disease (ESKD) population, NT-proBNP 
levels are significantly higher in women, the elderly, and those with lighter body weight; 
however, these characteristics have not been clarified in dialysis patients. In addition, NT-
proBNP levels are predictive of 2-year survival in dialysis patients (Kawagoe C et al. Renal 
Failure 2018).
Methods: Differences in NT-proBNP levels were determined according to sex, age, 
and dry weight. The association between baseline NT-proBNP levels and mortality (total 
deaths, non-malignancy-related deaths, and malignancy-related deaths) was analyzed.
Results: A total of 875 dialysis patients (43.1% women, mean age 67.8 years old, 
median dialysis vintage 77 months) without atrial fibrillation were followed for up to 
7 years. Baseline mean (SD) of log NT-proBNP; men vs. women was 3.67 (0.51) vs. 
3.74 (0.51) pg/mL, p=0.04. Therefore, the findings showed borderline significance 
according to sex. A sex difference was not observed in younger patients (29-69 years 
old), but was prominent in elderly patients. As in those without ESKD, NT-proBNP levels 
increased with age, and the relationship between NT-proBNP and dry weight showed a 
significant negative correlation. During 7 years of follow-up, 34.1% died (30.6% due to 
non-malignancy-related death; 3.4% due to malignancy-related death). The Kaplan-Meier 
survival estimate showed a clear survival difference for total and non-malignancy-related 
deaths between quartiles of log NT-proBNP, but not for non-malignancy-related deaths. In 
univariable and multivariable analysis, the log NT-proBNP was strongly associated with 
total and non-malignancy-related deaths. This association was also observed when patients 
were divided according to sex, quartile of age, and quartile of log NT-proBNP, but was not 
seen in association with dry weight quartiles in women (Q2 and Q3).
Conclusions: In dialysis patients, NT-proBNP levels showed differences according to 
sex (men<women), however, this difference was not observed in younger patients. NT-
proBNP levels are strongly associated with longer-term survival. However, NT-proBNP 
levels might have different significance in midsize women. Additional study is needed to 
clarify these findings in dialysis patients.
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Restless Legs Syndrome Effectively Treated with Constant-Pressure 
Predilution On-line Hemodiafiltration, A Case Report
Shunichiro Urabe,1 Motoko Kato,1 Emi Hiyama,1 Asami Kurii,1 Toru Hyodo,2 
Makoto Kitamura,3 Miho Hida,3 Yasuhisa Kurata,3 Kenichi Kokubo.4 1Eijin 
Clinic, Hiratsuka, Japan; 2Eijin Clinic and Cambodian Association of 
Nephrology, Hiratsuka, Japan; 3Kurata Hospital, Hiratsuka, Japan; 4Kitasato 
University School of Allied Health Sciences, Sagamihara, Japan.
Introduction: We encountered a case of unstable predilution on-line HDF due to 
elevated transmembrane pressure (TMP) when performing constant-speed predilution on-
line hemodiafiltration (HDF) as treatment for restless legs syndrome (RLS) in a dialysis 
patient, necessitating frequent adjustments of console settings such as the amount of 
dialysate and TMP. Here, we report the effectiveness of incorporating a newly developed 
constant-pressure predilution on-line HDF system as a preventive measure against unstable 
on-line HDF and frequent adjustment of settings when treating dialysis patients with RLS.
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Case Description: A 55-year-old man who had suffered from RLS and been 
undergoing constant-speed on-line HDF with 45-L target predilution and an ABH-21P 
hemodiafilter. The symptoms of RLS rated 10 on the International Restless Legs Syndrome 
Rating Scale (IRLS). The α1-microglobulin (α1-MG) removal rate was only 27.8%, so the 
hemodiafilter was subsequently replaced with a PEPA hemodiafilter. However, episodes of 
elevated TMP exceeding 250 mmHg occurred after the replacement and were managed by 
reducing dialysate flow rate. This resulted in the replacement of 40.7±4.50 L, with removal 
of 30.4% of α1-MG. The total amount of albumin (Alb) leakage in dialysate waste was 
5.3 g. Therefore, we incorporated a newly developed fully automated console GC-110N 
(JMS Ltd, Japan) with a built-in automated dialysate infusion system to establish a constant-
pressure predilution on-line HDF that maintains TMP below 200 mmHg. The amount of 
replacement was maintained at approximately 43.5±6.98 L and the α1-MG removal rate 
was 39.5%, with no need to manually reduce the flow rate. The Alb leakage in dialysate 
waste was 7.9 g. The patient has maintained an IRLS rating of 0 with no RLS symptoms 
for the past 4 years.
Discussion: Using the constant-pressure mode enabled achieved the clinical endpoint, 
namely, resolution of RLS with no need to manually reduce the flow rate. The GC-110N 
console enables predilution on-line HDF at constant pressure or speed and also has a 
postdilution mode. Further study is needed to investigate the appropriate use of each 
mode, but the availability of this console is beneficial for dialysis patients by offering more 
treatment options.
PUB215 
Publication-Only 
Demographic and Clinical Characteristics Are Associated with Physical 
Function Among Patients Receiving In-Center Hemodialysis
Kirsten L. Johansen,1 Lorien S. Dalrymple,2 Norma J. Ofsthun,2 
Barbara A. Grimes,1 Dugan Maddux,2 Franklin W. Maddux.2 1University of 
California, San Franicsco, San Francisco, CA; 2Fresenius Medical Care North 
America, Waltham, MA.
Background: Poor physical functioning is a pervasive disturbance among patients 
receiving maintenance hemodialysis, ranked by patients as of high importance and 
associated with higher mortality. However, few studies have examined demographic and 
clinical characteristics associated with physical functioning and change over time.
Methods: We collected longitudinal data from the Kidney Disease Quality of Life 
(KDQOL) survey administered as part of clinical care to 243,792 patients receiving in-
center HD between Jan. 1, 2010 and Dec. 31, 2016. We used multivariable linear mixed 
modeling to examine changes in the Physical Component Summary (PCS) score over time 
and associations between patients’ demographic and clinical characteristics and PCS.
Results: Median age was 62 years, dialysis vintage 2 years; 57% were men, 48% white, 
31% black, and 14% Hispanic. PCS declined by 0.16 points per year (95% CI 0.11,0.20). 
Older, female, and white patients had lower PCS, as did those with comorbid conditions and 
at both extremes of BMI (Figures). Low hemoglobin and catheter use were also associated 
with lower PCS.
Conclusions: Potentially modifiable factors, such as low hemoglobin, catheter use, and 
high BMI, were associated with lower physical functioning.
Funding: Commercial Support - Fresenius Medical Care North America
Association of demographic characteristics and comorbidity with PCS score
Association of modifiable factors with PCS score
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Efficient Removal of Large Solutes by Pre-Dilution On-line Hemodiafiltra-
tion Improves the Quality of Life of Dialysis Patients
Kenji Sakurai,1 Takeshi Saito,1 Hiromi Hosoya,1 Yoshitaka Kurihara,1 
Yasuhisa Wakabayashi,1 Daisuke Ishii,2 Akihiro C. Yamashita.3 1Hashimoto 
Clinic, Sagamihara, Japan; 2Kitasato University Hospital, Sagamihara 
Kanagawa, Japan; 3Hosei University, Tokyo, Japan.
Background: Efficient removal of middle and large solutes is crucial for treating 
complications in dialysis patients. Here, we switched HD to pre-dilution on-line HDF 
(preHDF) in stable dialysis patients and observed changes in their health-related quality 
of life (QOL) for 6 months to assess the clinical effects of preHDF. Although the Medical 
Outcomes Study 36-Item Short-Form Health Survey is internationally used to assess health-
related QOL, we used its shortened version SF-8.
Methods: We included 19 patients on maintenance HD (M/F, 13/6; age, 52.7±11.8 yrs), 
all of whom switched from HD to preHDF. HD was performed with a super high-flux dialyzer 
(blood flow rate [Qb], 253.2±24.5 mL/min; dialysate flow rate [Qd], 500 mL/min). After 
switching, preHDF was performed with a high-spec hemodiafilter (Qb, 260.0±20 mL/min; 
total Qd, 600 mL/min; Vs, 45.5 L/session). Both HD and preHDF were performed for 
4 h/session, 3 times/wk. The removal efficiency was assessed in terms of Kt/V for urea, 
reduction rates of b2-microglobulin (MG, 11.8 kDa) and a1-MG (33 kDa). Changes in QOL 
were assessed with SF-8.
Results: Kt/V was 1.53±0.23 for HD, showing no significant change during the 
observation period. Compared with the b2-MG reduction rate for HD, the rates were 
significantly higher at the time of switching to preHDF (74.0±4.4→81.7±3.0%) and 1, 
3, and 6 months later. Compared with the a1-MG reduction rate for HD, the rates were 
significantly higher at the time of switching to HDF (31.8±7.6→39.2±7.2%) and 1 and 6 
months later. The SF-8 scores on all subscales increased after switching to preHDF. The 
Physical Component Summary (PCS) and Mental Component Summary (MCS) scores 
(calculated from 8 subscale scores) increased after switching to preHDF. The MCS scores 
were significantly higher for preHDF than HD. Moreover, the patients presented markedly 
fewer unidentified complaints and appeared more active.
Conclusions: After switching to highly efficient preHDF, b2-MG and a1-MG reduction 
rates significantly increased, despite no changes in Kt/V. The SF-8 scores on each subscale 
and PCS and MCS scores also increased. These results indicate that enhanced removal 
of solutes in the LMWP range is beneficial for the internal environment of patients, 
consequently, their health-related QOL is improved.
Funding: Private Foundation Support
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Trend of Serum Albumin Among the Japanese Dialysis Population
Norio Hanafusa, Ken Tsuchiya, Kosaku Nitta. Tokyo Women’s Medical 
University, Shinjuku-ku, Japan.
Background: Serum albumin (Alb) is one marker of protein-energy wasting (PEW) 
related to poor survival. Hypoalbuminemia is associated with both inflammation and 
malnutrition. Therefore, maintaining appropriate Alb levels requires appropriate protein 
intake and management against inflammation. This study investigated the trend of serum 
Alb, C-reactive protein (CRP), and normalized protein catabolic rate (nPCR) among the 
Japanese dialysis population.
Methods: We used summary table data of the Japanese Society for Dialysis Therapy 
(JSDT) Renal Data Registry for 2001–2015. Numbers of patients and averages and 
standard deviations of the values were provided by age groups with width of 15 years. We 
investigated the trend of mean values of Alb, CRP, and nPCR for patients of 45 years or 
older using Joinpoint analysis. The proportions of the patients with low Alb, low nPCR, and 
high CRP were also investigated with different cut-off values. For each analysis, numbers 
of joinpoints and the annual percent change (APC) were evaluated.
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Results: APCs of mean Alb values were negative during the entire period (Figure). 
However, APCs of mean nPCR values were negative, whereas those of CRP values were 
not significant. These results indicate that Alb and nPCR values have been declining, 
although CRP values were stable. The proportions of patients with hypoalbuminemia, low 
nPCR, and high CRP exhibited similar trends. All age groups showed similar trends.
Conclusions: Serum Alb in Japanese dialysis population seems to be decreasing 
overall, which might have some association with the decline in protein intake rather than the 
increase in inflammation, irrespective of the patient age. It might be necessary to increase 
the protein intake against PEW. Future studies might be required investigate the Alb trend 
with protein intake increased.
PUB218 
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The First Cambodian Dialysis Registry: The Facts of ESRD Therapy in 
Cambodia
Pichthida Thim,1 Toru Hyodo,2 Sopheaktra Tan,3 Sam-Oudum Kim,1 Elin Phon,1 
Hy Chanseila,4 Sokhom Pho,1 Kamol Svay,1 Sovandy Chan,1 Lim Vadhana.1 
1Cambodian Association of Nephrology, Phnom Penh, Cambodia; 2Eijin Clinic 
and Cambodian Association of Nephrology, Hiratsuka, Japan; 3Cambodian 
Association of Nephrology, Phnom Penh, Cambodia; 4Cambodian association 
of nephrology, Phnom penh, Cambodia.
Background: The number of hemodialysis (HD) patients keeps increasing, yet 
statistical data is still inexplicit in Cambodia. CAN has started the dialysis registry since 
2017.
Methods: This is a cross-sectional study which was conducted on patients (n=407) 
who received HD in August 2017, from 5 hemodialysis centers in Phnom Penh capital city, 
Cambodia. Retrospective data such as age, gender, demographic, underlying diseases, HD 
frequency per month, and each HD session duration are deliberately collected and analyzed 
using SPSS.
Results: New patients make up 9.3%. Number of female patients is slightly lower than 
male (42.8% and 57.2%, respectively). Mean age is 52 years old (±SD15). Adult age group 
(25-64 years old) accounts for the highest number of patients (73.5%). Hypertensions, 
coexistence of hypertension and diabetes mellitus and kidney diseases are the common 
underlying diseases (46.7%, 31%, 13.9% accordingly). However, diabetes mellitus alone 
is responsible for 8.1%. The mean of HD frequency per month is 7.5 times (±SD2.3). HD 
session is 4-hour long.
Conclusions: The present condition of hemodialysis in Cambodia is gradually 
progressing forward, but it is still insufficient. Poor adherence to HD treatment needs to 
be tackled. Primary and secondary preventions of hypertension and diabetes mellitus are 
crucial.
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Risk Factors for Infectious Diseases in Patients with End-Stage Kidney 
Disease Undergoing Hemodialysis
Masataka Banshodani,1 Hideki Kawanishi,1 Misaki Moriishi,1,3 
Naoko Takahashi,2 Sadanori Shintaku,1 Shinichiro Tsuchiya.1 1Tsuchiya General 
Hospital, Hiroshima, Japan; 2Omachi Tsuchiya Clinic, Hiroshima, Japan; 
3Nakajima Tsuchiya Clinic, Hiroshima, Japan.
Background: In the recent years, increased hospitalization rate for infectious diseases 
in patients undergoing hemodialysis (HD) has become a problem. Herein, we examined the 
risk factors of infectious diseases in patients undergoing HD.
Methods: Based on the Carlson comorbidity index (CCI), age, sex, primary cause 
of end-stage kidney disease (ESKD), dialysis vintage, body mass index (BMI), serum 
calcium, phosphorus, magnesium, albumin, hemoglobin, alkaline phosphatase (ALP), and 
parathyroid hormone values in patients with ESKD who underwent HD three times a week 
at three dialysis centers in 2009, risk factors for emergency hospitalization due to infectious 
diseases from January 2010 to December 2014 were evaluated.
Results: Among the 708 patients undergoing HD, 142 had emergency hospitalizations 
for infectious disease (ID group: 90 men [63%]; mean age, 67.6 years; mean dialysis vintage, 
8.5 years) during the study period, whereas 566 did not have emergency hospitalizations for 
infectious disease (control group: 340 men [60%]; mean age, 66.0 years; mean dialysis 
vintage, 8.4 years). The proportion of nephrosclerosis (as primary cause of ESKD) (7.7%, 
P=0.01) and ALP levels (298 U/I, P=0.03) were significantly higher and BMI (21.2 kg/m2, 
P = 0.046) was significantly lower in the ID group than those in the control group (3.2%; 
267 U/I; 21.8 kg/m2). Moreover, CCI (5.01) was higher in the ID group than that in the 
control group (4.75), but the difference was not significant (P = 0.1). In the Cox proportional 
hazard model, CCI (hazard ratio [HR], 1.095; 95% confidence interval [CI], 1.001-1.193), 
nephrosclerosis (HR, 1.539; CI, 1.085-2.076), and ALP levels (HR, 1.002; CI, 1.001-1.003) 
were significant predictors of emergency hospitalization for infectious diseases.
Conclusions: This study evaluated the risk factors of emergency hospitalization for 
infectious diseases in patients undergoing HD; however, further investigation is required.
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Measurement of Body Composition in Hemodialysis Patients During 
One-Year Frequent Dialysis
Fansan Zhu,1 George A. Kaysen,1,3 Shubho R. Sarkar,4 Fredric O. Finkelstein,5 
Nathan W. Levin,1,2 Nicholas A. Hoenich.1,6 1Renal Research Institute, New 
York, NY; 2Mount Sinai School of medicine, New York, NY; 3University of 
California, Davis, Davis, CA; 4Kidney Care of Morris County, Basking Ridge, 
NJ; 5Yale University, New Haven, CT; 6Institute for Cellular Medicine, 
Newcastle University, Newcastle, United Kingdom.
Background: The primary aim of this study was to evaluate the effect of increased 
frequency of dialysis (FHD) on changes in extracellular volume (ECV), systolic blood 
pressure (SBP), calf normalized resistivity (CNR) and fat percentage. Since ECV is not a 
useful target for denoting dry weight, we explored CNR as an alternative measure.
Methods: In 12 stable HD patient’s treatment frequency was changed from 3times/week 
to 6 times/week HD (FHD). SBP, body weight and body mass index (BMI) were measured 
pre and post HD. Calf resistance at 5 kHz (R5) was measured using a bioimpedance device 
(Hydra 4200). The data collected was used to calculate calf resistivity (Rho=R5*area/
length), normalized resistivity (CNR=Rho/BMI) and calf extracellular volume (cECV). 
Body fat percentage (Fat%) was measured by Futrex body composition analyzers (Futrex 
6100, Futrex Tech, Inc.). All measurements were performed at baseline (BL) and thereafter 
monthly for up to one year.
Results: Nine patients completed one year of FHD. Data were presented at BL, and 
at first, six and twelve months. Compared to BL, body weight, cECV and SBP decreased 
significantly (Fig.1 a, b and c). CNR increased significantly by the first month but did not 
change thereafter (Fig. 1 d). Fat % did not change significantly (Fig.1 e). Antihypertensive 
drug dosing decreased significantly from baseline by month six and remained stable 
thereafter. The post HD CNR in five of nine patients reached the range of normal (>18.5 
10-2*Ohm*m3/kg for males and >19.1 10-2 *Ohm*m3/kg for females) after one year FHD
(Fig.1 f).
Conclusions: Increasing the frequency of dialytic treatment, results in a reduction in 
ECV and increase in CNR, accompanied by a reduction in SPB. As a consequence, anti 
hypertensive medication was reduced. Body composition did not change except reduction 
of fluid status. Based on this small study which needs to be confirmed in a larger group of 
patients, increase in CNR was associated with decrease in fluid status which provides a goal 
for HD treatment.
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Conscious Survey of Japanese Physicians and Actual Trends in Proton 
Pump Inhibitor Prescription for Hemodialysis Patients
Hiroo Kawarazaki,1 Akio Nakashima,4 Masahide Furusho,3 Takeshi Nakata.2 
1Department of Nephrology, Inagi Municipal Hospital, Inagi, Japan; 
2Department of Endocrinology Metabolism, Rheumatology and Nephrology, 
Oita University, Oita, Japan; 3Department of Nephrology, Iizuka Hospital, 
Iizuka, Japan; 4Department of Nephrology and Hypertension, Jikei University 
School of Medicine, Tokyo, Japan.
Background: Proton pump inhibitors (PPIs) are widely prescribed but less is known 
about prescription in hemodialysis (HD) patients. We conducted 1) a conscious survey 
directed to Japanese physicians about PPI prescription to HD patients and 2) gathered 
clinical data on all HD patients from 3 clinics to elucidate factors related to PPI prescription.
Methods: 1) A conscious survey was conducted through email to physicians dedicated 
to HD practice. In addition, 2) patient characteristics and blood test data were retrieved from 
every HD patient in 3 in-center clinics who have been on HD for more than a year.
Results: 1) 200 physicians replied the survey and 60% would continue PPIs after 
8 weeks prescription for gastric ulcer (GU) or gastroesophageal reflux disease (GERD) 
concerning relapse. The major reason for stopping PPIs was concern of adverse effects 
such as chronic diarrhea. 58% woulld choose to keep prescribing patients already on PPIs 
with unclear indications. 86% considered HD patients to be a high risk group for peptic 
ulcers (PUs). 2) Data from 374 HD patients were retrieved. Average age was 72 years, 
63% male, and average HD vintage was 5.5 years. The cohort consisted of 41% diabetic 
kidney disease, 22% cardiovascular disease (CVD), 16% peripheral artery disease (PAD), 
19% cerebral artery disease (CAD), 49% took anti-platelets, and 66% took PPIs. Those 
prescribed PPIs had higher ratio of CVDs (28% vs 12%), PADs (21% vs 5%), CADs (24% 
vs 5%), and anti-platelets (56% vs 37%). Further, though Hb were similar (11.2mg/dl), 
those on PPIs had higher ratio of iron prescribed (76% vs 71%), lower TSAT (26% vs 27%), 
and lower serum ferritin (78ng/ml vs 96ng/ml).
Conclusions: Japanese physicians frequently prescribed PPIs to HD patients and 
regarded them as a high risk group for PUs. More than half of the physicians would choose 
to keep HD patients on PPIs prescribed for unclear indications. Those with artherosclerotic 
diseases and anti-platelet medication had higher predisposition on PPIs.
Funding: Private Foundation Support
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The Current Prevalence and Prognosis of Frailty in Japanese Patients 
with Hemodialysis
Hidemi Takeuchi,1,2 Haruhito A. Uchida,1 Nozomu Otaka,1 Yuki Kakio,1 
Yuka Okuyama,1 Ryoko Umebayashi,1 Hitoshi Sugiyama,1 Hidetoshi Kanai,2 
Jun Wada.1 1Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Okayama, Japan; 2Kokura Memorial Hospital, 
Kitakyushu, Japan.
Background: The problematic expression of patients with hemodialysis is the frailty. 
Patients with hemodialysis easily fall into frailty due to the potential pathophysiological 
factors, such as physical deconditioning, chronic inflammation, and decreased anabolic 
hormones. Frailty is associated with severe mortality in several countries. However, the 
prevalence and prognosis of the frailty in Japanese patients with hemodialysis remain 
unknown. The purpose of this study is to identify the current status of Japanese hemodialysis 
patients with frailty.
Methods: This study is a multicenter investigation, which was conducted at 6 
institutions. The subjects were all hemodialysis patients. To evaluate the frailty status, we 
used the modified Fried’s frailty phenotype model, adjusted for the Japanese. In addition, 
we prospectively investigated the patients’ survival, hospitalization and developed 
complications.
Results: Of the 542 patients, 385 patients including 82 patients with frailty (21.3 %), 
203 with pre-frailty (52.7 %) and 100 without frailty (26.0 %), were enrolled in this study. 
At baseline, participants were 67.2 ± 11.9 years of age with more male gender (62.4 %) than 
female. With an average follow-up period of 17.1 months, a total of 41 patients died; 13.4% 
of patients with frailty, 11.8% with pre-frailty and 6.0% without frailty. The mean survival 
time of patients with frailty, pre-frailty and without frailty were 16.7, 17.1 and 17.6 months, 
respectively (Log-Rank P-value = 0.197). The mean hospitalization-free period of patients 
with frailty, pre-frailty and without frailty were 14.2, 16.0 and 16.7 months, respectively 
(Log-Rank P-value < 0.001), furthermore, significant differences were found among all 
groups in the post-hoc analysis. Similarly, significant differences were found in the analysis 
of the developed complications (Log-Rank P-value = 0.006).
Conclusions: The prevalence of frailty in Japanese patients with hemodialysis was 
relatively lower, and the frailty had less influence on the mortality, compared with the other 
countries. However, the frailty has the influence on healthy life expectancy, that is, higher 
rate of the hospitalization and complications were observed as the frailty status goes severe.
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A Simple Score to Identify the Potential Need for Intensive Hemodialysis 
Within a Facility
Allan J. Collins,1,2 Debabrata Ray,1 Kristine Kubisiak,1 Eric D. Weinhandl.1,2 
1NxStage Medical, Inc., Victoria, MN; 2University of Minnesota, Minneapolis, 
MN.
Background: Wider application of intensive hemodialysis (HD) requires 
reorganization of staff and patient scheduling and/or greater utilization of home HD. Tools 
that identify dialysis facilities with greater need for intensive HD may be useful. In a pilot 
study, we constructed a simple score that identifies potential need for intensive HD in a 
facility, insofar as need is reflected by plausible indications.
Methods: We used data from Dialysis Facility Compare, CROWNWeb, and Medicare 
claims to characterize facilities in a dialysis provider organization. For each facility, we 
calculated 3 metrics from data accumulated in 2013-2014: (1) the percentage of HD patient-
months with ultrafiltration rate (UFR) >10 mL/hour/kg; (2) the percentage of HD patient-
months with serum phosphorus >5.5 mg/dL; and (3) the heart failure (HF) hospitalization 
rate among HD patients with Medicare as primary payer. For each metric, we estimated 
deciles among facilities and transformed the metric to a scale from 1 (lowest decile) to 10 
(highest decile). For each facility, we set the “need score” equal to the sum of metric scores.
Results: We identified 1546 facilities. Mean percentages of HD patients-months 
with UFR >10 mL/hour/kg and serum phosphorus >5.5 mg/dL were 32.6% and 35.5%, 
respectively, and the mean HF hospitalization rate was 15.6 admissions per 100 patient-
years (PY). As displayed, the distribution of the need score was symmetric. There were 143 
(10.8%) facilities with a score ≥24 points; these facilities had higher prevalence of high 
UFR, higher prevalence of hyperphosphatemia, and mean HF hospitalization rate of 24.7 
admissions per 100 PY.
Conclusions: Facility scores that quantify plausible indications for intensive HD may 
be used to target therapy in local populations. Further study is needed to refine methodology, 
with consideration of hypertension and long post-dialysis recovery time.
Funding: Commercial Support - NxStage Medical, Inc.
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Infective Endocarditis in Hemodialysis Population - Experience from 
Center in India
Amit Kumar,1 Sunil Prakash,2 Ashwini Goel.3 1BLK SuperSpeciality Hospital 
New Delhi, New Delhi, India; 2Nephrology, BLK Super Speciality, New Delhi, 
India; 3Nephrology, BLK Super Speciality Hospital, NEW DELHI, India.
Background: Hemodialysis (HD) population is at increased risk for infective 
endocarditis (IE) due to impaired nutrition and vascular access, with its associated 
morbidity and mortality. Aim of present study is to present our data of patients with IE in 
HD population.
Methods: This was retrospective analysis from BLK Hospital, New Delhi, India. Data 
was collected from May 2015 to April 2018. All patient who underwent maintenance dialysis 
with a diagnosis of CKD were included. Patients diagnosed with Infective endocarditis 
based on clinical as well as echocardiographic (trans thoracic(TTE) or trans esophageal 
(TEE) criteria were identified. There demographic parameters, clinical presentation, and 
clinical outcome was recorded
Results: Out of 457 patients who underwent dialysis, 6 patient (1.31%, 4 male and 2 
female) developed IE. Mean age was 41.3 years. 3 patients had temporary dialysis catheter, 
one had permacath and 2 had AVF as vascular access. Average duration on dialysis was 
10.3 months. Duration of fever before diagnosis was 18.3 days (range 7 to 45 days). A 
pre-existing heart disease was present in 1/3rd of patients. Staph Auerus was identified in 
2 and both were on dialysis catheter. Staph epidermiditis was identified in 1 patient and 
blood cultures were sterile in three. Only 1 patient was diagnosed with trans thoracic 
echocardiography while trans esophageal echocardiography was required in 5. Aortic valve 
was involved in 3, mitral valve in 2 and tricuspid valve was involved in one patient. One 
patient expired, one developed reactive arthritis as complication of IE. one developed red 
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man Syndrome and emboilc infarct to brain and one developed Steven Johnson Syndrome 
as drug related toxicity.
Conclusions: Infective endocarditis in not uncommon in Indian population and 
diagnosis is often delayed. Resulting in high morbidity and mortality. High Index of suspicion 
is required for early diagnosis. When suspected trans esophageal echocardiography should 
always be considered.
Clinical Feature of patients with Infective Endocarditis
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Syndrome of Uremic Encephalopathy and Bilateral Basal Ganglia Lesions 
in Non-Diabetic Hemodialysis Patient
Fanna Liu,1 Wenyu Gong,2 Lifan Mei.3 1The First Affiliated Hospital of Jinan 
Universtiy, Guangzhou, China; 2The First Affiliated Hospital of JiNan 
University, Guangzhou, China; 3Zhongshan Boai Hospital, Zhongshan, China.
Introduction: Uremic encephalopathy (UE),the toxic metabolic encephalopathy, is an 
uncommon complication resulting from endogenous uremic toxins in patients with severe 
renal failure, and the syndrome of UE range from mild inattention to coma. The imaging 
findings of UE include cortical or subcortical involvement, basal ganglia involvement and 
white matter involvement. The basal ganglia type is uncommon, previous cases reported 
Asian patients with diabetes mellitus (DM) are usually affected by it
Case Description: A 32-year-old woman with history of non-diabetic hemodialysis 
for 3 years suffered from severe involuntary movement and Brain magnetic resonance 
image (MRI) showed symmetrical T2-weighted imaging (T2WI) and T2/fluid-attenuated 
inversion recovery (T2FLAIR) hyperintense nonhemorrhagic lesions in bilateral basal 
ganglia. She was diagnosed with UE as syndrome of bilateral basal ganglia lesions, due to a 
combined effect of uremic toxins and hyperthyroidism. After treatment with high frequency 
and high flux dialysis, hyperbaric oxygen therapy and declining parathyroid hormone, she 
was complete remission with normal body movement and discharged.
Discussion: UE is an unfamiliar toxic metabolic encephalopathy with typical CT/MR 
neuroimaging including bilateral vasogenic or cytotoxic edema at the cerebral cortex or 
basal ganglia region, producing a spectrum of brain abnormalities that range from mild 
inattention to coma. UE with basal ganglia involvement is uncommon and generally seen in 
Asian patients with DM. In our case, the patient had non-diabetic UE with typical bilateral 
basal ganglia lesions presented with involuntary movement. Recognizing this syndrome 
seems to be more and more important, especially considering its diagnostic and prognostic 
implications.
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Utilization of Sharesource Connect™ (SSC) Continuous Renal  
Replacement Therapy (CRRT) Data from Two Pediatric Centers:  
What Can We Learn?
Rita D. Sheth,2 Lieuko Nguyen,1 Peter D. Yorgin.1 1Rady Children’s Hospital 
San Diego, San Diego, CA; 2Loma Linda University, Loma Linda, CA.
Background: Baxter SSC displays de-identified, downloadable, customizable CRRT 
data for each center, including filter life, dialysis dosing and fluid removal that facilitates 
center and inter-center data assessment relative to benchmark data from adult programs.
Methods: All de-identified data for SSC downloaded from Prismaflex machines at 
Loma Linda University Children’s Hospital (LLUCH) + Rady Children’s Hospital San 
Diego (RCHSD) from Jun - Dec 2017 was included for pooled and comparative analysis.
Results: 36 patients using 98 Prismaflex circuits (total 4823 treatment hrs) were 
included in the analysis. Mean delivered CRRT dose was 44 mL/kg/min despite mean 
circuit time loss of 14.5%. Mean hemofilter life: 43 hrs; 54.5% circuits reached desired 
end points of max filter life or treatment end. 10/98 filters were lost due to clotting. Inter-
institutional differences are noted in Table. Overall outcomes were similar between LLUCH 
and RCHSD.
Conclusions: CRRT is a common treatment offered to critically ill pediatric patients 
with AKI. SSC provides a data-rich dashboard for CRRT programs, allowing real-time 
identification of CRRT parameters. Current study data is limited, but using pooled data 
from more comparable pediatric centers may assist in developing pediatric-specific CRRT 
metrics and quality benchmarks for pediatric CRRT programs. Due to data de-identification, 
SSC data allows easy data sharing between centers and could allow comparison with 
historical values from ppCRRT registry data. The de-identified data made it impossible to 
determine patient specific details and patient outcomes related to the CRRT dose or fluid 
removal. The display of pediatric data relative to adult norms without size standardization 
can be confusing. There is an opportunity 1) for more pediatric centers to share SSC data 
to identify better CRRT practices and develop quality metrics. 2) to obtain more granular, 
patient specific data 3) for Baxter to create a Pediatric/Adolescent versions of SSC.
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Development and Implementation of a Training Program for Intravenous 
Administration of Calcimimetic
Becky Brosch, Brenda K. Shrader, Sharon Brandl, Nataliya Wilson, 
Parker Calbert, Carrie Chamblin, Jennifer E. Snyder, George R. Aronoff, 
Deborah A. Benner. DaVita, Inc., Denver, CO.
Background: The intravenous (IV) calcimimetic Parsabiv (etelcalcetide) was approved 
by the FDA for the treatment of secondary hyperparathyroidism in hemodialysis patients 
in February 2017. The package insert states that the medication requires refrigeration and 
is to be administered at the end of treatment during rinse back via IV push into the venous 
chamber or IV push after rinse back via the venous access followed by 10 mL normal saline. 
To prepare for use of Parsabiv at our organization, a pilot was conducted among select 
clinics to optimize clinical management and gain operational experience.
Methods: Here, we describe a Parsabiv administration training program for clinical 
staff that was developed over the course of the pilot.
Results: Initial training included aspects related to storage, handling and post-treatment 
administration. In the early phases of the pilot program, senior clinical staff conducted on-site 
visits to pilot clinics. During these visits and through direct observation, it was discovered 
that the standard practice of vial inversion and use of 1 inch needles made it more difficult 
to draw up the full prescribed dose. Through a troubleshooting process, clinicians identified 
that the full dose could be drawn up more effectively by tilting the vial 30-45 degrees (not 
inverting) and using a 1.5 inch needle. Based on this experience and in preparation for 
wider use through the organization, a training program was developed to educate nurses on 
this technique. The essential elements of this education program include mandatory online 
training modules with video demonstrating the appropriate draw techniques, check-lists, 
post-training evaluations, and quarterly clinic audits. Additionally, these experiences were 
shared with the drug manufacturer and their education materials were modified to include a 
description of this technique as a best practice.
Conclusions: This work demonstrates the value that pilot programs can provide, 
allowing issues to be identified and addressed prior to large-scale implementation of new 
clinical practices.
Funding: Commercial Support - DaVita Inc
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Achievement of KDIGO Hemodialysis Targets with Stepwise Increasing 
Comorbidity Burden: A European Multicenter Analysis
Szymon Brzosko,1,2 Joao M. Frazao,3 Maciej B. Drozdz,4 Werner Kleophas,5 
Abdulkareem Alsuwaida,6,7 Mahesh Krishnan,8 Stefan H. Jacobson.9 1DaVita 
Poland, Bialystok, Poland; 2Department of Nephrology, Medical University of 
Bialystok, Bialystok, Poland; 3Nephrology and Infectiology Research and 
Development Group, INEB, and School of Medicine, Porto University, Portugal, 
Porto, Portugal; 4DaVita Poland, Krakow, Poland; 5DaVita Germany, 
Dusseldorf, Germany; 6King Saud University, Riyadh, Saudi Arabia; 7DaVita 
Saudi Arabia, Riyadh, Saudi Arabia; 8DaVita, Inc, Denver, CO; 9Danderyd 
Hospital, Stockholm, Sweden.
Background: Hemodialysis (HD) patients often have multiple comorbidities that add 
to the complexity and burden of their clinical and subjective symptoms. Comorbidities and 
frailty also result in decreased life expectancy and high mortality rates.
Methods: We assessed 1,246 prevalent HD patients from 13 DaVita centers in Europe 
(Poland 8 centers, n=482; Portugal 5 centers, n=764) and analyzed achievement of KDIGO 
treatment targets that contribute to outcomes: adequacy (spKt/V > 1.2), anemia (Hb 10-12 g/dL 
on ESA, Ferritin 200-800 μg/L, TSAT 20-50%), CKD-MBD (phosphorus ≤ 5.5mg/dL, 
calcium ≤ 10.2 mg/dL, iPTH 150-600 pg/mL) and type of vascular access (AVF or CVC). 
We considered median Charlson comorbidity index (CCI) and added stepwise: median 
age (>70 yrs), median BMI (<25 kg/m2), median albumin (<39 g/L) and diabetes (yes) in 
relation to the comorbidity burden.
Results: Mean (SD) age was 62 (14) years for patients with CCI ≤ 7 and 76 (10) for 
patients with CCI > 7 (p<0.001) with no differences in gender, dialysis vintage, treatment 
time per week, and ESA dose. The percentage of patients achieving KDIGO targets is 
shown (Table).
Conclusions: Comorbidities and frailty pose substantial challenges for the provision of 
optimal HD care. This large real-world retrospective study demonstrates that elderly, more-
frail patients with comorbidities still had an AVF rate of ≥70% and achieve KDIGO targets 
as well as patients with lower CCI.
Funding: Commercial Support - DaVita, Inc
* p < 0.05, ** p < 0.01, *** p < 0.001 vs all patients with CCI ≤ 7
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Cancer Incidence and Characteristics in the Dialysis Patients: A 
Nationwide Cohort Study
Soon Kil Kwon,1 Hye-Young Kim,1 Sun Moon Kim,2 Hyunjeong Cho.2 
1Nephrology, Chungbuk National University College of Medicine, Cheongju, 
ChungBuk, Republic of Korea; 2Chungbuk National University Hospital, 
Cheongju, Republic of Korea.
Background: As population of ESRD patients are increasing, detecting and managing 
cancer in the ESRD should be emphasized. It is known that CKD is associated with 
malignancy risk, as population of ESRD are increasing, detecting and managing cancer 
in the dialysis should be emphasized. However, it is still not recognized the incidence of 
cancer in ESRD, and the difference of primary cancer site is also unveiled. We investigated 
the incidence of cancer among the large numbers of dialysis patients using national health 
insurance data to inform cancer screening in dialysis clinic.
Methods: The data were obtained from Korean National Health Insurance Service 
(KNHIS) which contains reimbursement record from all medical facilities across the 
country. The dialysis cohort included patients who claimed any procedures or materials for 
both hemodialysis and peritoneal dialysis, based on the Korean electronic data interchange 
codes (O7020 for hemodialysis; O7061 for peritoneal dialysis). Cancers were defined 
by compatible ICD-10 codes of C00.0 to 99.9 as cancers. Proportional difference in 
independent variables between the ESRD cohort and control were analyzed using the Wald 
chi-square test.
Results: Total 45,312 patients and controls were observed for 17,1329.45 and 220,464.18 
person years respectively. Incidence of cancer was 463.8 vs 244.8 per 10,000 person-year. 
Hazard ratio of cancer in ESRD is 2.008 (p < 0.001). The most common malignancy in 
the ESRD patients is liver cell carcinoma same as control. ESRD showed markedly higher 
incidence of oral cavity and neck area cancer (OR 9.28, p < 0.0001) which was second 
most common site in the dialysis patients. The kidney cancer were also higher (OR 5.81, 
p < 0.0001), but prostate and stomach were less than control (OR 0.78, p < 0.0001; 0.88, 
p = 0.0305, respectively). Cancer incidence was markedly incrased by patients’ age. Patients 
older than 60 showed 7 times risk than younger patients below 20 years of age (OR 7.725 
in 60-69; 6.877 in 70-79; 7.647 in > 80 years old; all p < 0.0001). There was no difference 
between dialysis modalities, and no difference with economic satus.
Conclusions: Patients on dialysis treatment should be considered the incidence of head 
and neck malignancy, and all patients should be screened to detect oral cavity and pharynx 
cancers as well as liver and common site of malignancies in the dialysis clinic.
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Lower-Extremity Muscle Strength and Survival in Hemodialysis Patients 
with Peripheral Artery Disease
Manae Harada,1,2 Takaaki Watanabe,1,2 Shohei Yamamoto,1 Yuta Suzuki,1 
Ryota Matsuzawa,3 Naoyoshi Aoyama,3 Atsushi Yoshida,2 Atsuhiko Matsunaga.1 
1Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan; 
2Sagami Circulatory Organ Clinic, Sagamihara, Japan; 3Kitasato University 
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Background: Hemodialysis (HD) patients with peripheral artery disease (PAD) have 
an elevated mortality risk compared to those without PAD, and there is a need to identify 
factors that increase the mortality risk in these patients. Although lower-extremity muscle 
strength is one of the risk factors of mortality in HD patients, the association between lower-
extremity muscle strength and mortality risk in HD patients with PAD is unclear. In this 
study, we investigated the prognostic significance of lower-extremity muscle strength in a 
cohort of HD patients with PAD.
Methods: A total of 148 outpatients (mean age, 67.9 ± 11.2 years, 42.6% male) 
undergoing maintenance HD therapy 3 times a week at an HD center and who were 
diagnosed with PAD with an ankle-brachial index of <1.00 or toe-brachial index of 
< 0.70 at baseline were monitored for 4 years. Clinical characteristics including age, sex, 
body mass index, time on HD, comorbid conditions, and blood biochemical data were 
obtained at baseline. In addition, maximum voluntary isokinetic knee extensor strength (leg 
strength), which reflects lower-extremity muscle strength, was measured using a handheld 
dynamometer (μTas F-1; Anima, Japan). Leg strength data were divided by dry weight and 
expressed as a percentage. Participants were categorized into two groups by a leg strength 
cutoff value of 40%. A Cox proportional hazards regression model was used to assess the 
contribution of leg strength to all-cause mortality.
Results: During a median follow-up of 38.0 months, 30 patients died. With a 
multivariate Cox model, the hazard ratio in the group with a leg strength <40% was 2.36 
(95% confidence interval; 1.05–5.30) compared with that in the ≥40% group.
Conclusions: Decreased lower-extremity muscle strength was associated with survival 
in HD patients with PAD.
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The Multifactorial Key(s) to Deciding for the Timely Creation of Dialysis 
Access – An Exploratory Study
Ying-ying Seow,1 Konstadina Griva,2 Pei Shing Seow,3 Zack Goh Zhong Sheng,4 
Jason Choo Chon Jun,5 Jia Liang Kwek.6 1Renal/General Medicine, Sengkang 
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Nanyang Technological University, Singapore, Singapore; 3Renal Medicine, 
Khoo Teck Puat Hospital, Singapore, Singapore; 4Lee Kong Chian School of 
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Singapore, Singapore.
Background: This study set out to understand how family members and renal care 
providers influence decisions around optimal initiation onto hemodialysis (access creation).
Methods: Indepth interviews were conducted with 69 participants including predialysis 
CKD 4 patients (n=31), newly initiated onto hemodialysis with (n=18) or without AVF/
AVG (n=20). Data were inductively analysed using a thematic approach and deductively 
informed by the theory of relational autonomy.
Results: Patients’ social relationships and vicarious experiences significantly shaped 
their behavioural activation regarding access creation. Unequal weightage to different 
relationships created boundaries around whom to include in the decision making process. 
Family had greatest influence, followed by friends then HCPs. Family involvement varied 
from active behaviours (verbalising preferences and sharing views), passive involvement 
(support with no explicit action to influence decision) to complete abstinence in the process. 
Patients who either chose not to involve others or had no input from others were least likely 
to prepare, or initiated HD without AVF/AVG. While most patients maintained that they 
have the final say indicating individualist autonomy in decision around modality and access, 
family considerations, vicarious experiences and hearsay were noted as being more important 
than clinical tests or information communicated by HCPs. Doctors’ recommendations were 
described as influential only by those expressing trust in their clinician. Others expressed 
mistrust and apprehension to medical recommendations – these were closely linked to low 
symptomatic burden and lack of clarity and understanding of provided information. Patients 
perspectives on health care encounters were heterogeneous, fear of dialysis and exaggerated 
concerns related to access and dialysis (costs; lifestyle disruptions) were uniformly voiced 
– family and hearsay acted to either alleviate or intensify those concerns.
Conclusions: Social and relational factors influence how patients respond to dialysis 
counselling and preparation. The adequacy of pre-dialysis education as an individual 
approach needs review. Greater attention to relational forces and emotional concerns around 
dialysis is needed for effective decision making for optimal initiation onto dialysis.
Funding: Government Support - Non-U.S.
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Limited Options for the Measurement of Large Middle-Molecules in 
Routine Clinical Practice
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Background: Large middle molecules (MM) have recently been described as a group 
of 28 uremic toxins with molecular weights between 15 and 60 kiloDalton. This group 
of large non-protein bound toxins are involved in chronic inflammation, atherosclerosis, 
structural heart disease and secondary immunodeficiency. New medium cut-off 
hemodialysis membranes (Theranova) provide efficient removal of these molecules for 
chronic hemodialysis patients. The purpose of this study was to determine which of these 
molecules could be measured as part of clinical practice in dialysis units around the world.
Methods: Laboratories associated with dialysis units in Australia, Canada, Germany, 
Hong Kong, Italy, New Zealand and the United Kingdom were asked to identify which of 
the large MM could be measured in routine clinical practice; the cost; time to process the 
sample and method of analysis. The molecules include 5 cytokines, 4 adipokines, 4 growth 
factors, 8 immune mediated proteins and 6 other molecules.
Results: The number of large MM which could be measured as part of routine clinical 
practice varied greatly from dialysis unit to unit: from 1 to 23 large MM available to 
clinicians with a median of 9 molecules. Three molecules (FGF-2, Complement factor D 
and AGEs) could not be measured in any of these units. In contrast, kappa and lambda free 
light chains, myoglobin and prolactin were available for assessment in more than 80% of 
laboratories. The cost (in USD) for measuring these molecules varied by molecule and 
between dialysis units. The median cost was $39 (range $3.5 to $351). The lowest cost was 
to measure myoglobin in Germany, the most expensive FGF-23 in Canada. Ten molecules 
could be reported within 24 hours but 6 had average reporting periods of greater than 10 
days. Luminex and ELISA based methods were the most common forms of assessment. 
Of the 28 large middle-molecules 8 would require specific transport requirements to the 
laboratory (e.g. cooling) limiting their utility in clinical practice.
Conclusions: While interest in the removal of large MM by new dialysis technologies 
grows the capacity to measure these uremic toxins in clinical practice is currently limited. 
Of the molecules free light chains (kappa + lambda), prolactin and myoglobin are the most 
accessible in terms of stability, availability, cost and reporting times.
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Estimating Absolute Blood Volume During Hemodialysis Using Crit-Line
Hamed Samandari,1 Yossi Chait,2 Joseph Horowitz,2 Christopher V. Hollot,4 
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Background: Knowledge of absolute blood volume (ABV) can inform dry weight 
estimation and design of ultrafiltration rate profiles. Our aim was to compare ABV estimates 
obtained from a recently published 2-compartment blood water concentration (BWC) 
model during a dialysate dilution test with estimates obtained using a model modified for 
hematocrit (HCT) measurements.
Methods: Four dilution tests (150 mL) were performed within a single HD treatment 
in 4 patients. Changes in BWC and HCT were simultaneously measured using blood 
volume monitor (0.1 sec sampling time) and Crit-Line sensor (20 sec sampling time). The 
2-compartment BWC model was adapted to estimate ABV using HCT measurements. 
Separate ABV estimates were obtained from the new HCT model and the BWC model. 
Bland-Altman (BA) analysis was used to analyze agreement between the estimates. Nested 
one-way ANOVA was used to compute intra-treatment variability of estimates.
Results: The HCT model successfully estimated HCT dynamics during the dilution 
test (Fig. 1). Intra-treatment standard deviation (SD) of estimates of BWC and HCT models 
were 0.12 L and 0.32 L, respectively. BA limits of agreement (Fig. 2) between the two 
estimates were 0.13±0.71 L (bias±2SD).
Conclusions: Means of ABV estimates based on the new HCT model are in agreement 
with estimates derived from a validated BWC model, however, slow HCT sampling times 
increased the estimates’ SD which could be improved by reducing sampling time. A protocol 
for estimating ABV can be readily integrated into current HD machine technology and 
potentially enable the development of personalized fluid volume management protocols.
Funding: NIDDK Support
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Fig 1. Sample model estimates
Fig 2. BA-analysis
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Using Standard Bicarbonate Bath for Hemodialysis of Critically Ill 
Patients with High Venous Oxygen Saturation (HVOS) Is Associated with 
Poor Outcomes
Nabadwip Pathak, Sreejith Parameswaran. JIPMER, Puducherry, India.
Background: Management of critically ill patients with HVOS requiring Renal 
Replacement Therapy (RRT) is challenging. HVOS (>75%) is known to increase mortality 
in critically-ill patients by 20-30%. The role of modifying dialysate bicarbonate (Dia-
HCO3) concentration to avoid metabolic alkalosis in critically ill patients with HVOS 
requiring RRT remains unknown. We present observational data on the effects of using 
30mEq/l Vs 35mEq/l of Dia-HCO3 in critically-ill patients requiring RRT.
Methods: Over a six week period in April – May 2018, we identified 6 critically ill 
patients with renal failure requiring RRT who had HVOS in our ICU. The Dia-HCO3 was 
reduced to 30mEq/L in 3 patients while the other 3 patients underwent RRT with standard 
Dia-HCO3 of 35mEq/L. Complications during and after RRT and patient outcomes were 
documented, along with VOS & VBG before and after RRT.
Results: RRT was uneventful in 3 patients who received Dia-HCO3 of 30 mEq/l. By 
comparison, RRT was stopped within 2 hours in 2 of the 3 patients receiving Dia-HCO3 
of 35 mEq/l due to the development of severe hypotension. Both patients had refractory 
shock leading to cardiac arrest in next 2-3 hours. An increase in the post HD venous oxygen 
saturation was observed in three of 6 patients, other three patients postHD VBG could not 
be done.
Conclusions: To our knowledge, the effect of using lower Dia-HCO3 in critically-ill 
patients requiring RRT has not been studied. HVOS in the critically ill is indicative of 
mitochondrial dysfunction and poor peripheral utilization of O2. High Dia-HCO3 shifts 
the hemoglobin-oxygen dissociation curve to the left thereby further worsening tissue 
oxygenation by decreased release of oxygen. This effect in addition to anemia and HVOS 
could explain the clinical worsening and high mortality in this patient population. Further 
studies are needed to determine the clinical benefit of using low-moderate Dia-HCO3 
among critically-ill patients requiring RRT.
Clinical characteristics
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Data Sonification: A Novel Way to Analyze “Big Data” from Kidney 
Patients
Carrie L. Reid-Knox,1 Tommy C. Blanchard,2 Len A. Usvyat,2 Peter Kotanko.1 
1Renal Research Institute, Somerville, MA; 2Fresenius Medical Care North 
America, Waltham, MA.
Background: Electronic health records allow the collection of unparalleled rich 
data sets. For exploratory analysis, data is usually presented graphically. However, data 
visualization is challenging with high-dimensional data. We explored transforming data into 
auditory sensory inputs (sonification) as a novel means to represent data.
Methods: We used routinely collected data from 35,146 dialysis patients followed 
during their terminal 100 weeks before death (Usvyat, Kidney Int, 2013). Each parameter 
(interdialytic weight gain (IDWG), systolic blood pressure (SBP), albumin and C-reactive 
protein (CRP)) had an instrument assigned to it for sonification. We developed algorithms 
that used tonal ambiguity and variations in pitch, octave, dynamic, and texture to represent 
parameter dynamics, and a strong beat to represent the passage of time. We disassociated 
emotional reactions by avoiding the use of major/minor, consonance/dissonance, familiar 
harmonic progressions, and tonal center.
Results: In sonification #1 (https://youtu.be/IarHnxPmHeE) parameters are represented 
by flute (IDWG), cello (SBP), guitar (albumin), and trombone (CRP). We chose the whole 
tone scale because of its perfect symmetry, its lack of tonal center/absence of a leading tone, 
and its lack of emotional associations of other musical modes. Pitch represents the changing 
parameter levels. In sonification #2 (https://youtu.be/IE4-1S9pwGE) instrumentation was 
the same as in #1, except for albumin (drum). We used chord alternation with two chords 
that are a whole step apart, which have no associations with cadence or familiar harmonic 
progressions that would imply suspense and/or relief to the listener. We used pitch and 
texture (expressed by number of instruments and instruments being played on the off-beats) 
to represent changes in parameters.
Conclusions: Our results show, for the first time, that longitudinal data from kidney 
patients can be represented as auditory signals, complementing graphic data representation. 
We avoided musical modes and patterns that carry emotional associations, allowing listeners 
to approach the sonification without bias. Multi-sensory data representation will become 
particularly important when applied to high-dimensional, “big” data. Future research needs 
to address questions of optimal data representation.
Funding: Commercial Support - Fresenius Medical Care
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Trajectories of Health Markers in Dialysis Patients Before Death
Yue Jiao,1 Andrew Long,1 Tommy C. Blanchard,1 Marta Reviriego-Mendoza,1 
John W. Larkin,1 Jochen G. Raimann,2 Len A. Usvyat,1 Jeroen Kooman,3 
Frank van der Sande,3 Peter Kotanko,2,4 Franklin W. Maddux.1 1Fresenius 
Medical Care North America, Waltham, MA; 2Renal Research Institute, New 
York, NY; 3Maastricht University Medical Centre, Maastricht, Netherlands; 
4Icahn School of Medicine at Mount Sinai, New York, NY.
Background: We characterized trajectories of health markers before death and 
compared them to patients who did not die during the same period.
Methods: Data from patients treated at a large dialysis provider who died during 2010 
to 2017 was compared to data from patients who survived 12 months from a randomly 
selected index date. Using data from 12 months prior to death (or index date for survivors), 
we computed slopes from monthly averages for laboratories and treatment parameters 
via linear regression. For each variable, we calculated the percentage (%) of patients with 
significant increases, decreases, and stable slopes.
Results: We analyzed data from 182,481 patients who died and 140,999 patients who 
survived. We found significant differences in slopes between those who died and survived 
for cardiovascular, inflammatory, and nutritional markers (Figure 1). We found 28% of 
patients who died had decreases in predialysis systolic blood pressure (pre-SBP); 15% of 
survivors had decreases. Patients who died had decreases of 4% in neutrophils and 13% in 
lymphocytes versus 7% and 6% in those who survived. More patients who died (28%) had 
decreases in albumin (Alb) versus those who survived (13%). We also revealed additional 
distinct findings in the % of patients with increases in parameters for those who died versus 
survived.
Conclusions: Patients appear to have distinct patterns of changes in health markers 
before death compared to patients who survived. For example, nearly twice as many 
patients who died exhibited decreases in pre-SBP and Alb during the 12 months before 
death compared to survivors. Identifying combinations of changes in different parameters 
could be useful for construction of artificial intelligence-based prediction models.
Funding: Commercial Support - Fresenius Medical Care North America
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Optimizing Fluid Management with Crit-Line® in HD
Darryl Martin,1 Dixie-Ann Sawin,1 Rainer Himmele,3,1 Robert J. Kossmann,2,1 
Allison Comerford.2 1Fresenius Medical Care Renal Therapies Group, 
Charlotte, NC; 2Fresenius Medical Care North America, Waltham, MA; 
3Fresenius Medical Care NA, Charlotte, NC.
Introduction: Unigue patient cases presented here discuss use of Crit-Line technology 
in HD.
Case Description: Case 1: Case 1: A 72-yr-old female (dry weight/DW 51kg) has a 
predialysis weight (wt) of 52.6kg and initial ultrafiltration goal (UF) of 1.6L. During the first 
hr, the Crit-Line slope was initially slightly negative then trended upwards (relative change 
in blood volume/ΔBV% ≤ -3%/hr; A profile). UF goal was increased by 200mL at 0:35 and 
1:45 and a saline bolus given at 1:55hrs (black triangles). At 3:30, her final ΔBV% was 
-9.3% (A profile), UF was 2175mL and she had no intradialytic events (IDEs). Although she 
achieved postdialysis wt (~50.7kg), profile suggested opportunity to remove more fluid and 
dry weight adjusted to 50.6kg for next session. Case 2: A 56-yr-old, hypotensive-prone male 
(DW: 110Kg) with a predialysis wt of 117.1kg was never able to achieve >4.5L UF due to 
IDEs prior to Crit-Line use. Systolic BPs in the 90s (mmHg) was clinically acceptable for 
this patient and initial UF goal was 6L. His ΔBV% decreased rapidly (-7.9% at 1:05; C
profile). His UF goal was then decreased by 200 mL at 1:05, 2:40 (ΔBV% -16%) and 3:20 
(ΔBV% -18.0%) with no IDEs. At 3:30, ΔBV% was -18.2% (C profile), his BP dropped 
to 79/44 and he had a mild hand cramp (yellow diamond). His UF goal was reduced by
200 mL and symptoms dissipated. His final ΔBV% was -16.9% with ~5.2L of UF and
his postdialysis wt was 112.1kg. His DW was adjusted up to 111.5kg for later treatments.
Discussion: Cases show safe, effective, real-time use of Crit-Line technology, where 
clinicians can accurately assess and adjust fluid removal as needed, while reducing potential 
for IDEs and fluid overload.
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Environmental Sustainability of Dialysis Facilities
Matthew D. Jose,1,2 Natasha N. Abeysekera.2 1Royal Hobart Hospital, Hobart, 
TAS, Australia; 2School of Medicine, University of Tasmania, Hobart, TAS, 
Australia.
Background: Haemodialysis is responsible for high resource consumption, resulting 
in a high economic burden and cost to the environment. Our aim was to assess the current 
environmental sustainability of haemodialysis facilities in regional Australia.
Methods: Nurse unit managers of all Tasmanian public dialysis facilities received an 
online survey, which asked 23 questions relevant to the environmental sustainability of 
dialysis services. The survey used was a modified version of the survey used to assess UK 
dialysis facilities.
Results: Responses were received from all dialysis units in Tasmania (n=6, 100%). 
Energy saving initiatives included the use of fluorescent lighting (n=6, 100%), motion 
sensor lights (n=1, 17%), thermostat controlled heating (n=6, 100%) and automatic 
hibernation settings of fax machines and computers (n=6, 100%). Five units (83%) were 
supplied with energy by Aurora and one unit (17%) from TasNetworks. Water saving 
initiatives included motion sensor taps (n=3, 50%) but no units harvested rainwater nor 
recycled reverse osmosis water. Recycling initiatives included waste segregation in all 
units and four recycled PVC plastic. Sustainable transport initiatives included active and 
public transport (n=3, 50%). Three units (50%) also provided bicycle parking with access to 
shower and changing facilities. None of the units used virgin paper and all had double-sided 
printing as an automatic setting. All units used a combination of paper and digital medical 
records. All units used paper towels and food sourcing was unknown. All units supported 
green initiatives, but no unit had an environmental sustainability policy nor had performed 
an audit of their environmental sustainability.
Conclusions: Sustainable initiatives were evident in all haemodialysis units, but 
significant opportunity exists to improve the environmental impact of dialysis in Australia.
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Life on the Bridge: A 40-Year Journey with Dialysis
Judy Weintraub. Life On The Bridge, Los Angeles, CA.
Introduction: Life On The Bridge is a 22-minute humanistic documentary by Judy 
Weintraub, that raises expectations about creating a good life while living with kidney 
dialysis. It raises awareness of the realities of kidney disease and the treatments available, 
highlighting what is possible. This theme is ultimately a universal one: though we may not 
control all the circumstances of our lives, we always have a choice in our attitudes
Case Description: As the story unfolds, Judy, after years of waiting, is called in for a 
third kidney transplant. She had previously received two transplants, both of which failed 
within a few short months. Judy had begun kidney dialysis treatments as a teenager and 
has been on some form of dialysis ever since. Over the decades, she did both in-center 
hemodialysis and more than a decade of peritoneal dialysis and nocturnal HHD. The 
documentary follows what happens from the first hopeful days and weeks to several months 
later, as Judy and her doctors fight to keep this new transplant. Throughout, we also hear the 
personal dstories and experiences of people of different ethnicities and backgrounds who 
are living with dialysis or transplantation. Family members share what it’s like to be with 
loved ones who live with this disease. Professionals speak out - doctors, nurses, technicians, 
and social workers share their view of the field.
Discussion: Several themes arise from the film: Education of professionals, patients, 
family members and the general public as to the possibilites of living well with the various 
modalities of kidney dialysis; The role of physicians as champions in their patient’s care; 
Maintenance of positive expectations in living life, especially with a chronic illness; The 
crucial role that encouragement plays in optimizing outcomes; The importance of ongoing 
evaluation and the willingness to think outside-the-box to individualize care. This film’s 
ultimate mission is to help patients and the professionals who care for them move toward 
the optimal health outcomes that we know are achievable. Judy Weintrub M.S. Ed., holds 
degrees in Special Education from USC and Psychology from UCLA. She holds credentials 
in the areas of Education, Communication Handicapped and Early Intervention. She also 
served on the boards of Nephrology News & Issues, the Southern California Renal Disease 
Patient Advisory Council (Network 18) and the Southern California Chapter of the National 
Kidney Foundation.
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Inflammatory and Nutritional Markers Prior to Death in Chronic 
Hemodialysis Patients: Results from the Global MONDO Initiative
Dalia E. Yousif,1 Xiaoling Ye,1 Jochen G. Raimann,1 Yuedong Wang,6 
Jeroen Kooman,2 Frank van der Sande,2 Stefano Stuard,3 Bernard J. Canaud,4 
Adrian M. Guinsburg,3 Len A. Usvyat,5 Peter Kotanko.1 The MONDO Initiative 
1Renal Research Institute, New York, NY; 2Maastricht University Medical 
Centre, Maastricht, Netherlands; 3Fresenius Medical Care, Bad Homburg, 
Germany; 4FMC Deutschland GmbH, Bad Homburg, Germany; 5Fresenius 
Medical Care North America, Melrose, MA; 6University of California - Santa 
Barbara, Santa Barbara, CA.
Background: Malnutrition, inflammation, and oxidative damage are highly prevalent 
in dialysis patients (pts) and each condition is associated with an increased risk of death. 
Hemodialysis pts with larger hemoglobin level fluctuations have higher mortality.
Methods: All the adult pts who died within the first 36 months (mos) of HD were 
stratified into 6 sub-groups, pts who died from month 0 to 6, 6 to 12, 12 to 18, 18 to 24, 
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24 to 30 and 30 to 36 mos after HD initiation. For those who survived 36+ mos on HD 
were served as the reference group. Monthly average NLR, Hgb, Pre-HD SBP and serum 
albumin were obtained, cubic spline function were applied to access the trends and rate of 
changes for each of the parameters of interest for up to 48 months after HD initiation. In 
addition, subgroup analysis was performed to study the regional differences.
Results: Totally, 18,276 incident HD pts were included, 2,068 were died within 6 mos, 
1,231 died within 6 to 12 mos, 971 died within 12 to 18 mos, 792 died within 18 to 24 mos, 
721 died within 24 to 30 mos, 648 died within 30 to 36 mos, and 12,295 survived more 
than 36 mos. For pts who died sooner after HD, NLR observed to be higher at the initiation 
of the dialysis, while Hgb and serum albumin were tended to be lower. In addition, NLR 
reached the nadir from 3 to 10 months after start of dialysis while serum Hgb and albumin 
seem to reach the maximum 3 to 10 mos after HD initiation, depends on the survival time.
Conclusions: Inflammation can interact with malnutrition, resulting in the excessively 
high mortality in the dialysis population. There are several readily available indicators 
reflecting catabolic, protein intake and oxidative stress that change prior to death in incident 
HD pts. The awareness of valuable index predicting worse outcomes is central therapeutic 
efforts, and interventions at the individual and regional levels.
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Patient Peer Mentoring in Hemodialysis: A Single Center Experience
Paul N. Bennett,1,2 Lashone Brown,3 Sydney Urbina,1 Shaun S. Collard,1 
Brigitte Schiller.1 1Satellite Healthcare, San Jose, CA; 2Faculty of Health, Deakin 
University, Geelong, VIC, Australia; 3Satellite Healthcare Inc., Stockton, CA.
Background: Patients new to hemodialysis (HD) are educated by dialysis clinicians in 
order to improve their start to HD. Peer mentorship, from experienced dialysis patients, has 
been shown to enhance this transition increasing patient engagement and quality of life. The 
aim of this study was to measure the effect of a patient peer mentor program on self-efficacy, 
anxiety and depression.
Methods: Mixed methods study design. A patient to patient mentor program was 
introduced to one dialysis center consisting of: mentor identification, mentor training, 
mentor and mentee matching, and regular mentor/mentee meeting episodes over a 2-month 
period. The primary outcome was change in self-efficacy as measured by 6-Item Self-
Efficacy for Managing Chronic Disease Scale. Secondary outcomes were change in anxiety 
and depression as measured by the 4 item Patient Health Questionnaire Scale (PHQ-4). 
Mentee and mentor evaluations through group interviews were performed.
Results: Thrirteen patients participated (7 mentors and 6 mentees) from a center 
of 100 patients. 100% of participants agreed that they would recommend other dialysis 
patients to talk with a mentor. 100% of pairs agreed to continue to meet after the study had 
completed. No statistically significant improvement in self-efficacy, anxiety and depression 
was found. A high level of engagement from key dialysis center champions including the 
social worker and the renal dietitian played a key role in the success of starting the mentor/
mentee program.
Conclusions: A coordinated mentor program maintained by clinicians was identified 
by patient mentees and mentors as a positive strategy for dialysis centers. Commitment 
from the dialysis organization and center staff is pivotal to ensure the sustainability of 
mentor program. A larger randomized cluster study is required to demonstrate improvement 
in self-efficacy, anxiety and depression.
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Quality of Life Trends in Patients with ESRD Undergoing Hemodialysis
Salim Bou Slaiman,1 Sarah G. Thappa,3 Youssef Shammaa,2 Suzanne E. El 
Sayegh.4 staten island university hospital 1staten island university hospital, 
Staten Island, NY; 2Staten island university hospital, Staten Island, NY; 3Touro 
College of Osteopathic Medicine, Staten Island, NY; 4Staten Island University 
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Background: Health-related quality of life (HRQoL) has been the subject of a lot 
of recent studies involving many chronic diseases and conditions and guiding treatment 
modalities. In addition, HRQoL has been shown to be a strong predictor of morbidity and 
mortality in patients with end-stage renal disease (ESRD). We conducted this study to 
compare the quality of life score trends across the years for the patients and to look for the 
variables that affect these scores.
Methods: We recruited patients in an outpatient dialysis center on Staten Island, 
NY. KDQOL scores administered yearly were collected for each patient, along with 
demographic and lab data. each patient had at least 2 and up to 4 scores collected, and for 
each score, a set of lab data within a month from the score was noted. Our primary objective 
was to analyze the trend of the QOL scores along with the trend of the lab data for each 
patient. Data analysis was carried out in SAS software. We performed a mixed logistic 
regression to account for the repeated measures of the KDQOL scores. Least squared means 
were computed to identify inter- and intra-subject variability.
Results: 96 patients were recruited, with a mean age of 63.9 years; 69% were males 
and 54% were white. There was no observed difference between age and the various 
scores. On average, men had lower scores than women in all score subsets. There was also 
a significant difference among the ethnicities with scores in the black population having 
lower scores than other races. Ferritin had significantly a negative correlation with PCS 
score (p-value<0.045) as well as PTH levels that were positively correlated to the effect 
score. There was no significant correlation between the other laboratory markers and the 
QOL scores over time.
Conclusions: the difference found between genders and races cope with their disease 
burden may depend on how anxiety, depression, and loss of autonomy may vary between 
genders and cultures Laboratory tests that influenced the QOL scores were PTH and 
ferritin. This can be due to its effect on phosphorus and calcium, which links to acid-base 
disturbances and bone change related to kidney disease. Type of access could affect the score 
by limiting the patient’s physical activity and association with infection and hospitalization 
which invariably have a negative correlation with KDQOL scores.
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Dialysis Disequilibrium Syndrome: Rare Serious Complication of 
Hemodialysis and Effective Management
Sreedhar R. Adapa, Harpreet S. Dhindsa, Hemant Dhingra, Amarinder 
Singh Garcha. The Nephrology Group, Inc, Fresno, CA.
Introduction: Dialysis Disequilibrium syndrome (DDS) is an extremely rare central 
nervous system complication that occurs in patients receiving hemodialysis and can 
be potentially fatal. The prognosis is poor when this manifests as serious neurological 
manifestation like seizures, obtundation and evidence on effective management is sparse. 
We present the case of a patient who developed altered mental status during hemodialysis. 
Patient successfully recovered with administration of mannitol and 3% saline without any 
long-term neurologic squealae.
Case Description: A 72 year-old male who had not had any dialysis for 2 weeks 
because of peritoneal dialysis catheter malfunction was admitted with dyspnea and fluid 
overload. He was hyperkalemic, bradycardic and emergent hemodialysis was arranged. 
Labs showed severe azotemia with BUN 141mg/dl, Creatinine 9.8 mg/dl and Potassium 
8.3 meq/L. Chest x-ray showed pulmonary edema. Patient developed twitching and became 
confused about 2 hours into dialysis. Dialysis was immediately terminated, patient was 
given mannitol 125 mg and 3% saline was started at 30 ml/hr. Post dialysis labs revealed 
BUN 64 mg/dl (urea reduction ratio 54.6%), Creatinine 5.2 mg/dl and Potassium 3.2 meq/L. 
He was dialyzed again the next day with low blood and dialysis flow rates. Mannitol and 
3% saline were administered during dialysis. EEG revealed no epileptiform abnormality. 
Patient made full neurological recovery after 4 days.
Discussion: DDS usually occurs during or immediately after patients receive their first 
hemodialysis, but can rarely happen in patients already on dialysis. Prognosis of severe 
DDS is poor and prevention is ideal. It is important to identify the patients who are at 
high risk of developing DDS and use low efficiency dialysis with gradual urea reduction. 
Our patient was at risk for DDS considering severe azotemia that is a surrogate for uremic 
milieu. There is not much guidance in literature as far as management of DDS with severe 
neurologic manifestations is concerned. Our patient did well with administration of 
hypertonic agents that have not been used much in our current clinical practice. These agents 
may have a role to play in management of patients requiring emergent renal replacement 
therapy who develop DDS despite use of preventative measures such as low efficiency short 
hemodialysis sessions.
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Association of 3mTUG and All-Cause Mortality in Dialysis Patients
Kun Zhang, Chen Yu. Shanghai Tongji Hospital, Shanghai, China.
Background: To evaluate the association between physical performance and all-causes 
mortality in maintenance dialysis patients,and identify whether physical activity could 
predict the mortality independendy. 
Methods: In this study, we evaluated maintenance dialysis patients in Shanghai 
Tongji hospital from Dec 2014 to Mar 2018, collected clinical data and serum hemoglobin, 
albumin, calcium, phosphate and parathyroid hormone(PTH) levels. We measured physical 
activity including muscle strength and balance ability used by timed up and go (3mTUG).
Results: 121 patients were involved, average age (61.6 ± 13.0)years, 62 peritoneal 
dialysis patients and the other 59 hemodialysis, 76 men and 45 women, average dialysis 
duration 31.7(12.3, 69) months. During the median 36 months follow-up, 22 patients(17%) 
were died. Age, modality, DN, phosphates, PTH and 3mTUG were risk factors for all-cause 
mortality(P<0.05). After adjusting age, modality, DN, phosphates and PTH, 3mTUG was 
an independent risk factor of all-cause mortality(P<0.05).
Conclusions: 3mTUG can predict mortality of dialysis patients independently. 
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Hypoglycemia in Hospitalized Patients Undergoing Hemodialysis
Jeffrey I. Silberzweig,1,2 Uvannie Enriquez,3 Eunice Yang,3 Jane J. Seley,5 
Gulce Askin,4 Susanna Slukhinsky,6 Flannery M. Cuevas,3 Hyo Sook Kim,3 
Robee G. Ravago,3 Felicia A. Mendelsohn Curanaj,5 Marifel Axalan.3 1The 
Rogosin Institute, New York, NY; 2Medicine/Nephrology, Weill Cornell Medical 
College, New York, NY; 3Nursing, New York Presbyterian Hospital, New York, 
NY; 4Weill Cornell Medical College, New York, NY; 5NewYork-Presbyterian/
Weill Cornell Medicine, New York, NY; 6Nutrition, The New York-Presbyterian 
Hospital, New Y, NY.
Background: Approximately 40% of patients treated by hemodialysis (HD) have 
diabetes mellitus (DM). Hospitalized patients with DM have greater risk of hypoglycemic 
episodes; HD may further increase risk as it is an energy consuming procedure and patients 
may have decreased appetite, hypotension, nausea and dizziness. Malnutrition is an 
important contributor to poor outcomes among hospitalized patients so we began offering 
meal trays during HD but nursing staff reported a high rate of symptomatic hypoglycemia 
among patients receiving insulin dosed by standard hospital protocol.
Methods: With IRB approval, we retrospectively reviewed charts of patients 
undergoing HD between January and August 2016 who had point-of-care blood glucose 
(BG) testing during HD. In May, a Certified Diabetes Educator (EY) taught nursing 
colleagues to estimate the carbohydrate (CHO) content of meals. Patients who anticipated 
consuming at least 30g of CHO received full prandial insulin dose. For patients who 
anticipated consuming less than 30g, the nurse contacted the MD to consider reducing the 
insulin dose. The population was divided into pre- (January to May) and post- (June to 
August) education time periods. Charts were reviewed for co-morbid medical conditions, 
concurrent medications and BG levels for the 24 hours surrounding HD.
Results: Using the international definition for hospitalized patients (BG > 70 or < 100 
with symptoms of hypoglycemia), 14/60 (23%) had hypoglycemia. After the education, 
there was no significant change in the occurrence of hypoglycemia during HD (20 vs 
22.5%; p = 1.000). There were no significant differences among clinical factors between 
the two groups: age, race, sex, dialysis vintage, acute vs chronic kidney disease, co-morbid 
conditions, concurrent medications.
Conclusions: There is a high incidence of hypoglycemia among hospitalized patients 
with DM undergoing HD. The lack of change in the incidence of hypoglycemia after 
education may relate to stricter adherence to prescribed insulin dosing. We plan to develop 
a protocol for insulin for dosing during HD adjusting for the CHO content of the meal to be 
consumed and the anticipated energy utilization during HD. We will observe its effect on the 
frequency of hypoglycemic episodes during and six hours post-HD.
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Rapid Bedside Assessment of Diastolic Function in Hemodialysis Patients
Proma Mazumder, Erik Yarmey, Cameron Baston, Nova Panebianco, 
Anthony J. Dean, Nathaniel C. Reisinger. University of Pennsylvania, 
Philadelphia, PA.
Background: The prevalence of diastolic dysfunction (DD) among hemodialysis 
(HD) patients is 75%. The presence of DD is often unknown to the treating nephrologist 
leading to complications from intradialytic hypotension due to high ultrafiltration rate. 
DD is traditionally assessed using spectral and tissue Doppler waveform analysis. These 
techniques are time consuming and may be beyond the training of many providers 
performing clinician-performed ultrasound (CPUS). We have previously demonstrated 
that physicians can identify DD using qualitative ultrasound findings. We aim to evaluate 
if 3 qualitative visual parameters obtained on real-time B-mode echocardiography can 
accurately detect DD in HD patients.
Methods: CPUS echocardiograms were prospectively obtained by residency and 
fellowship trained sonologists on a convenience sample of 49 HD patients presenting to 
the emergency department for any reason. Cases were deidentified and randomized with 
11 cases of normal diastolic function to avoid potential spectrum bias due to case-mix. 
The images were reviewed by two fellowship-trained sonologists who scored the clips for 
presence or absence of DD based on three visual indicators: presence or absence of left 
atrial enlargement, impaired left ventricular relaxation, and impaired mitral valve descent. 
The images were then rated on the severity of DD on a 0 (absent) to 3 (severe) scale. The 
accuracy of these findings was evaluated against DD on final cardiologist interpretation of 
referral echocardiograms.
Results: 39 of the HD patients had a diagnostic echocardiogram with an assessment of 
diastolic dysfunction documented in the prior year. Combined with the 11 normal studies, 
this gave a total of 50 cardiac ultrasounds for review. The overall accuracy for determining 
presence or absence of DD was 95.0% (CI 88.7 – 98.3). The accuracy of assessing severity 
to within 1 category above or below the criterion standard was 92.0% (CI 84.8 – 96.4). 
Interobserver correlation measured by Cohen’s kappa for assessment of presence or absence 
of DD was 0.75, and for specific diastolic grade was 0.54.
Conclusions: Qualitative visual echocardiographic parameters can be used by 
clinicians to determine DD accurately in HD patients. These techniques could be adapted 
for detection of DD at the point-of-care in the dialysis unit.
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Utilization of Emergency Department and Risk of Resuscitation Among 
Patients Receiving Maintenance Hemodialysis
Tai-Shuan Lai,1 Yi-Chih Lin.2 1Internal Medicine, National Taiwan University 
Hospital, Taipei, Taiwan; 2National Taiwan University Hospital, Taipei city, 
Taiwan.
Background: The end-stage renal disease has to become a growing health problem 
globally with increased disease burden and high medical costs. The utilization of emergency 
department among dialyzed patients remains uncertained and risk factors of resuscitation at 
Emergency Department are deserved to explore.
Methods: This longitudinal cohort study was sampled from National Health Insurance 
Database in Taiwan. Patients aged 19 to 90 years old with maintenance hemodialysis 
between January 1 to December 31, 2010, were recruited. We matched non-dialytic 
individuals by age, sex and Charlson Comorbidity Index (CCI) as a control group from 
the same data source. The utilization of emergency department among enrolled individuals 
was identified in 2012. We used generalized estimating equations with multiple variables 
adjustment to explore risk factors associated with resuscitation in emergency department 
visits among all suffered patients.
Results: Between January 1 to December 31, 2012, 2,985 individuals with 
hemodialysis and 2,985 individuals without hemodialysis were enrolled. There were 4,803 
patient-times emergency department visits in hemodialysis group and 1,744 patient-times 
emergency department visits in the non-dialysis group. The level of the visited hospital, 
diagnosis category, severity of triage, and the experience of resuscitation had a statistically 
significant difference between hemodialysis group and non-hemodialysis group (p<0.05) 
but no significant difference in death (p=0.76) between two groups. In an analysis of 
multivariable generalized estimating equations, individuals with maintenance hemodialysis 
had a higher risk of resuscitation in emergency department visits compared with individuals 
without hemodialysis (adjusted odds ratio [aOR], 1.30, 95% CI: 1.01 to 1.68). Other risk 
factors for resuscitation at emergency department included age between 55 and 69 years old 
(aOR 1.80, 95% CI: 1.25 to 2.59), age older than 70 years old, (aOR 2.30, 95% CI: 1.61 to 
3.29), the experience of hospitalization prior in 1 year, (aOR 1.35, 95% CI: 1.09 to 1.65), 
and the first and second degree of triage (aOR 1.96, 95% CI: 1.60 to 2.41).
Conclusions: Patients with maintenance hemodialysis had increased utilization 
of emergency department and a higher risk of resuscitation at emergency department 
compared to patients without hemodialysis.
PUB248 
Publication-Only 
Association Between Suicidal Phenomenon/Depression and Inflammatory 
Status in Patients with ESRD on Hemodialysis
Enrique Rojas-Campos, Rosalinda Valencia-Coronado, Alfonso M. Cueto-
Manzano, Laura Cortes-Sanabria. Instituto Mexicano Del Seguro Social, 
Guadalajara, Mexico.
Background: Suicide is a worldwide public health problem and depression is the 
mental problem most closely related to suicide. Depression is highly prevalent in ESRD, 
inflammation is related to ESRD and to depression. Aim: To determine the presence and 
severity of depression and suicidal ideation in patients on HD and the association with 
inflammation.
Methods: Cross sectional study, performed in 45 prevalent HD patients (June 
2017-March 2018), Depression, suicidal ideation and hopeless were evaluated using Beck 
scales, performed by a single Psichiatrist blinded to biochemical data; inflammation was 
evaluated using CRP (High sensitivity), fibrinogen and globular sedimentation rate, age, 
time and acces type to dialysis and lipids. Subjects were infection free (3 previous months), 
with no current Psiquiatric therapy and/or medication, and no anti inflammatory therapy.
Results: Prevalence of depression is 88% and 33% had suicidal ideation. As higher was 
depression higher were CRP, fibrinogen globular sedimentation rate and suicidal ideation. 
In Graph is shown the correlation between suicidal ideation and CRP.
Conclusions: Inflammation measured by CRP, GSR and fibrinogen significantly 
correlates with depression and suicidal ideation. It is necesary to colaborate with 
multidisciplinary team to provide psicological and anti inflamatory therapy in ESRD.
Student T tests; p≤0.05 vs no symptoms group.
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Pearson Correlation between suicidal ideation and C Reactive Protein.
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The Total IV Iron Burden and Cognitive Impairment in Hemodialysis 
Patients
Monique E. Cho,1,2 Iran Lavasani,3 Jared Hansen.2,1 1University of Utah, Salt 
Lake City, UT; 2Veterans Health Administration, Salt Lake City, UT; 3University 
of Utah, Salt Lake City, UT.
Background: Hemodialysis (HD) patients routinely receive IV iron, which includes 
non-transferrin-bound iron that can accumulate in neurons and cause oxidative injury. 
Despite the established role of excess brain iron in dementia, the association between total 
accumulative IV iron dose and cognitive impairment, a highly prevalent condition in ESRD, 
has never been explored in HD patients.
Methods: We performed an observational pilot study of prevalent HD patients at 
University of Utah (N=16). Patients with history of dementia, chronic hepatitis, steroid 
use, malignancy, hematologic disorders, hospitalization within one month of screening 
were excluded. Total accumulative dose of IV iron for the entire duration of dialysis was 
calculated for each participant. Montreal Cognitive Assessment (MoCA) test was used 
to screen for cognitive impairment. The total IV iron dose was log transformed to enable 
parametric analysis with Pearson correlation coefficient to evaluate its association with 
MoCA score.
Results: The study group was diverse (8 Hispanics, 4 Whites, 1 Asian, and 3 mixed), 
with 9 men and 7 women. Half of the group had diabetes. The mean±SD values for age, 
dialysis duration, systolic blood pressure, hemoglobin, and albumin were 52±14 years, 
7.4±5.8 years, 142±28 mmHg, 10.6±1.9 g/dL, and 3.9±0.2 mg/dL, respectively. The median 
(IQR) transferrin saturation and ferritin were 28 (21, 39) % and 652 (300, 971) ng/mL. 
The median total IV iron dose was 10,825 mg (range of 2,400 to 29,748 mg). Two patients 
refused MoCA test. The mean±SD MoCA score was 23±4 (N=14). There was a trend for a 
negative correlation between the total IV iron dose and MoCA score (Figure 1).
Conclusions: This is the first study to evaluate the association between the accumulative 
IV iron burden and cognitive impairment. Larger studies are required to investigate if IV 
iron is associated with dementia risk in ESRD.
Funding: Private Foundation Support
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How Accurate Is the Dry Weight?
Mohammed Hamid, Sholabomi Oyewole-Eletu, Kathleen Speta, Gregory 
D. Gudleski, Shirley S. Chang. Jacobs school of medicine at the state university 
of New York at Buffalo, Williamsville, NY.
Background: Studies indicate volume overload in ESRD/CKD stage V patients are 
associated with worse outcomes. We observed in kidney transplant (tx) recipients usually 
diurese postoperatively & continues as outpatient, raising the question of the accuracy of 
estimated dry weight, since there is no accurate tool for ideal weight determination. We 
decided to investigate the weight difference on the day of tx, at 1-month & 3-months post-tx 
in kidney transplant recipients at Erie County Medical Center (ECMC).
Methods: Retrospective analysis of 244 kidney tx recipients at ECMC from 1/1/16-
12/31/17. Demographics & clinical characteristics were collected. Exclusion criteria are 
age ≤18 years old, delayed graft function ≥ 1 month, & renal allograft failure within 3 
months post-tx.
Results: There were 140 recipients on hemodialysis (HD) prior to tx, 48 patients on 
peritoneal dialysis (PD), 65 recipients received pre-emptive transplantation. Overall, age 
and gender and ethicity were not statatistically different among all three groups. Weight on 
the day of tx were statistically higher than weight at one-month & at three-months post-tx 
among all groups. The one-month & three-months post-tx weights were not statistically 
different among all groups.
Conclusions: Results showed there are weight losses after kidney transplantataion 
exceeding the volume administered peri-operatively. The weight loss (4-6 kg) post-
transplantation mainly reflects volume loss. Fluid management poses challenging dilemma 
in dialysis patient since volume overload & too agressive volume removal can induce 
circulatory stress & multi-organ injury. Knowning that patient’s ideal weight is actually 4-6 kg 
below their achievable dry weight on dialysis may help the clinicians to better manage 
patient’s volume status on dialysis. Reducing dry weight even by relative small amonts 
has been showen to improve blood pressure & reduce left ventricular hypertrophy. Further 
studies are needed to better manage volume status in dialysis patients, with health, social, 
& economic implications.
Weight Changes Over Time (kg)
Different superscripts are statistically different from one another across time
PUB251 
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The Association of Gender with Avoidable Emergency Department Visits 
in Patients on Hemodialysis
Ladan Golestaneh. Montefiore Medical Center, Bronx, NY.
Background: In national samples drawn from the USRDS female patients and those 
younger than 44 years old utilize hospital ED and inpatients services at a higher rate than 
their counterparts. We set out to explore whether this association held with avoidable ED 
visits in a cohort of mostly minority patients in a single low socioeconomic burrough in 
New York City.
Methods: We use Montefiore’s clinical database, “Looking Glass”TM To build a cohort 
of patients on hemodilaysis with a first ED visit between 2013-2017 to any of 4 main EDs 
in the Bronx. All subsequent ED visits without a resultant admission for the duration of the 
observation period and the count of ED visits for 365 days prior to this index ED visit were 
recorded. We refer to these ED visits as avoidable because they did not result in an inpatient 
admission. We used bivariate analysis to test the association of demographic, socioeconomic 
and clinical variables with sex. We then built models using negative binomial regression 
adjusted for time in study, to test the association of gender with avoidable ED count alone, 
when adjusted for socioeconomic variables and clinical variables respectively.
Results: We identified 4,573 patients of which, 43.2% were female and 53.6% were 
black. The median avoidable ED visits were higher in females (4(25-75%IQR 2-9). Female 
patients were older, more commonly black, had lowere SES scores and were less commonly 
married than their male counterparts. Females less commonly had commercial insurance. 
Females a higher rate of avoidable ED visits when adjusting for clinical variables in the final 
model (1.07(95%CI:1.01-1.13)). Marital status and SES dichotomized at the NYS mean 
acted as confounders in the association between female gender and outcome.
Conclusions: Females had a higher rate of avoidable ED visits than males in a cohort 
of low SES, mostly minority patients on hemodialysis in the Bronx. Potential contributors 
to this association include marital status, SES and overall clinical status.
Association of gender and avoidable ED visits
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Dry Weight and Intra-Dialytic Weight Gains Vary by Season, but 
Ultrafiltration Rates Remain Stable in Long-Term Hemodialysis Patients
Priyanka Wani, Andrew I. Chin. University of California Davis, Sacramento, 
CA.
Background: In long-term hemodialysis (HD) patients, ultrafiltration (UF) rate is a 
function of intra-dialytic fluid weight gain (IDWG), dry weight (DW) and dialysis duration. 
IDWG and DW are known to vary according to the season of the year. UF rate, a measure 
that is being considered as a quality measure by regulators, may also vary seasonally; this 
may affect its appropriateness as a reportable measure.
Methods: We looked at a stable cohort of HD patients located in an urban area in a 
temporate climate zone, all of whom dialyzed for a 12 month period. We examined all 
post-HD weights (assumed to be DW), dialysis times, IDWGs and UF rates (mL/min/kg) 
for each subject. Seasons were defined as the month of the HD: Autumn=Sept-Oct-Nov; 
Winter=Dec-Jan-Feb; Spring=Mar-Apr-May; Summer=Jun-Jul-Aug. Differences in DW, 
IDWG and UF rate amongst seasons were analyzed by paired T-testing.
Results: 239 patients with complete HD treatment information for 2014-2015 were 
used in the analysis. Dry weight rose through the autumn and winter seasons, peaked in 
the spring, and decreased in the summer season. IDWGs followed a very similar pattern 
through the seasons, almost mirroring the change in DW (See Figure 1). DW and IDWG 
were both statistically different between the autumn and winter seasons, as well as between 
the autumn and spring seasons. UF rate, calculated as IDWG ÷ treatment time ÷ DW, was 
not statistically different across the 4 seasons, not surprising given that the DW and IDWG 
varied in the same direction and to a similar degree.
Conclusions: In stable HD patients, even though IDWG increased in certain seasons of 
the year, UF rate did not change because DW increased as well. We found that the seasonal 
variation of DW and IDWG followed a very similar pattern and magnitude of change. 
Therefore, UF rate remains fairly stable over the seasons of the year. As a quality measure, 
UF rate may not be significantly affected by the time of year when it is reported. These 
findings may differ in different climate zones.
Funding: Clinical Revenue Support
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Accuracy of Resting Metabolic Rate Prediction Equations in Persons on 
Maintenance Haemodialysis in Trinidad and Tobago
Patrice R. Prout, Selby Nichols. Human Nutrition Group The University of the 
West Indies, St, Augustine Trinidad, Port of Spain, Trinidad and Tobago.
Background: Establishing energy requirements is crucial in estimating nutritional 
needs and preventing malnutrition among persons with chronic kidney disease on 
haemodialysis. The study evaluated the accuracy of four commonly used resting metabolic 
rate (RMR) prediction equations among persons on maintenance haemodialysis (MHD).
Methods: Following informed consent and enrolment, participants had anthropometry 
and RMR measured using standard procedures. RMR predicted prediction equations were 
compared to that measured by indirect calorimetry using the Med Gem® device (microlife, 
USA). Anthropometry was measured using recomended procedures. Participation was 
voluntary. The study was approved by the Ethics Committee, The University of The West 
Indies..
Results: Sixty-five persons 50 to 65 years (females = 33; males = 32) participated in the 
study. Mean measured RMR was significantly higher in males than females (1373 ± 288 vs. 
1222 ± 228; p = 0.02). RMR computed from predictive equations were significantly higher 
in males compared to females. There were no significant differences in RMR per kg of body 
weight or fat free mass between males and females. Overall, mean measured RMR was 20.1 ± 5.0 
per kg of body weight. The mean accuracy of predictive equation was significantly lower 
in males than females (39.1% ± 2.7% vs. 45.0% ± 4.3%; p <0.001). The level of RMR 
prediction equations underestimation (51.6% ± 2.7% vs. 39.4% ± 8.1%; p <0.001) and 
overestimation (16.7% ± 4.4 vs. 9.4% ± 2.2%; p <0.001) was higher in males than females.
Conclusions: RMR predictive equations had low level of accuracy with measured 
RMR. The level of accuracy was different for males and females. There is a need to develop 
sex-specific RMR prediction equations that improve the accuracy of estimating RMR 
among persons on MHD in this population.
PUB254 
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Lung Ultrasound in Maintenance Hemodialysis Patients Close to Dry 
Weight
Jose S. Lopez Gil,1 Gabriela Leal,1 Octavio Garcia,1 Hector A. Perez-grovas,1 
Luis A. Garcia.3 National Heart Institute México 1Instituto Nacional de 
Cardiología, México, Mexico; 3Universidad Nacional Autónoma de México, 
México, Mexico.
Background: Fluid overload is associated with adverse cardiovascular events in 
hemodialysis patients. Lung ultrasound has been validated in patients with excessive fluid 
overload, nevertheless in patients close to dry weight has not been validated. The aim of our 
study is to evaluate the utility of this method in this type of patients
Methods: Eighty hemodialysis sessions were examined, we divided the total 
population into two groups according to fluid overload estimated with a cut point of 1.5 
liters, we realized a lung ultrasound (scanning for B-lines in 28 quadrants), NT-proBNP 
determination and multifrequency total body and thoracic bioimpedance extracellular 
water/body water ratio. Blood pressure, heart failure symptoms (dyspnea, orthopnea), 
hemoglobin delta and relative blood volume were measured by blood volume monitoring in 
BVM module of 5008 Fresenius
Results: 63% (17) of the patients corresponded to the female and the rest to male 
37% (10). Mean age of the population was 42 ± 16 years. The vintage time of patients 
with hemodialysis was 3.6 ± 2.9 years. 30% (8) of the patients presented symptoms before 
the hemodialysis session. Up to 67% (18) of the patients b lines were observed before 
hemodialysis. In the setting of bioimpedance, the mean difference both total body to thoracic 
shows statistical significance as well as hemoglobin delta and blood volume circulating
Conclusions: B lines determination in patients close to dry weight they did not show 
statistical significance, nevertheless it iss important to highlight in the without fluid overload 
group, 4/20 patients with history of pulmonary hypertension had 9±3 B lines, we concluded 
that in later studies these patients could be excluded.
PUB255 
Publication-Only 
Successful Pregnancy in an ESRD Patient Receiving Intensive 
Hemodialysis
Rachid Daoui,1 Victoria J. Phillips,1 Shenthuraan Tharmarajah.2 1Nephrology, 
Saratoga Hospital, Saratoga Springs, NY; 2Albany Medical College, Albany, 
NY.
Introduction: In women with end stage renal disease (ESRD), the chances of both 
conception and pregnancy maintenance are low and associated with high rates of adverse 
maternal and neonatal outcomes. Past studies have highlighted residual renal function, early 
diagnosis of conception, and intensive hemodialysis for improved pregnancy outcomes. 
The literature still questions the optimum management of pregnant women with severe 
renal impairment as well as effective incremental dialysis dosing in this group. We report 
here a case of a stable hemodialysis patient with two live births two years apart, the latter 
being successful due to intensive hemodialysis.
Case Description: A 35-year-old woman (gravida 4, para 0) with ESRD on chronic in-
center hemodialysis since 2015 was found to be pregnant in December 2016. Her 3 previous 
pregnancies had spontaneously aborted in the first trimester. Despite being recommended 
intensive hemodialysis 6 days a week, 6 hours per session, the patient did not follow these 
recommendations, and her son was born at 30 weeks with complications of prematurity 
and died at 4 months of age. In August 2017, the patient had positive blood and urine hCG 
levels and began intensive hemodialysis 6 days a week, 6 hours per day. In March 2018, an 
emergent C-section at 34 weeks produced a healthy 2200-g baby girl requiring only initial 
CPAP and encouragement to feed. The patient’s hemoglobin level remained stable, blood 
pressure was well controlled without medication, and potassium level remained within 
normal range. The patient’s phosphorus level declined and required supplementation. To 
date, the baby is 2 months old and healthy.
Discussion: Our case demonstrates a successful pregnancy in a patient of advanced 
maternal age and minimal residual renal function on intensive in-center hemodialysis. 
This case is unique due to the patient’s older age involving two pregnancies with different 
outcomes, illustrating the importance of intensive hemodialysis in optimizing the maternal 
milieu early in pregnancy. We thus recommend that intensive hemodialysis be considered 
as a viable option for dialysis patients considering pregnancy.
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Is Central Venous Oxygen Saturation Decline During Hemodialysis 
Always Associated with Ultrafiltration?
Diana Aguirre,1 Armando Vazquez Avila,1 Daniel E. Ayala,1 Jesus Arellano,1 
Luis A. Mariscal,2,1 Victor H. Gomez,1 Israel Campos.2,1 1Hospital General “Dr. 
Miguel Silva”, Morelia, Mexico; 2NausLife Hemodialysis Clinics, Morelia, 
Michoacán, Mexico.
Background: Ultrafiltration volume inversely correlates with central venous oxygen 
saturation (ScvO2) during hemodialysis (HD). The effect of intra-dialytic exercise (IDE) on 
ScvO2 is unknown. The aim of this study was to explore the correlation between ScvO2 and 
corrected ultrafiltration volume (cUFV) during HD with and without intra-dialytic exercise.
Methods: Crossover study in maintenance adult HD patients. The cUFV (ultrafiltration 
volume/post dialysis body weight) reported in mL/Kg was computed through HD treatment 
at 60, 120 and 180 minutes, ScvO2 by gas analyzer was measured at the same time points, 
both were obtained during one HD treatment without IDE, then repeated in one HD 
treatment with IDE. The ScvO2 and cUFV correlation was estimated by Pearson’s equation.
Results: 11 patients (22 HD treatments) were analyzed. The ScvO2 mean ±SD for all 
time points during HD treatment without and with IDE were 64 ±12.3% and 58.3 ±9.9%, 
p=0.04. The cUFV mean ±SD for all time points during HD treatment without and with 
IDE were 41.7 ±21.8 ml/kg and 38.2 ±20.6 ml/kg, p=0.57. Pearson’s correlation moment 
between ScvO2 and cUFV during HD without and with IDE is reported in figure 1.
Conclusions: The mean value of ScvO2 during intra-dialytic exercise is lower compare 
to a non-exercise treatment. As expected, there is an inverse correlation between ScvO2 and 
corrected UF volume during a non-exercise HD treatment, this correlation is lost during 
intra-dialytic exercise. ScvO2 decline during intra-dialytic exercise is not associated with 
ultrafiltration volume.
PUB257 
Publication-Only 
Preoperative Systolic Blood Pressure Is an Independent Risk Factor for 
Aortic Valve Replacement in Hemodialysis Patients
Hidekazu Moriya, Rikako Oki, Yasuhiro Mochida, Kunihiro Ishioka, 
Sumi Hidaka, Takayasu Ohtake, Shuzo Kobayashi. Shonan Kamakura General 
Hospital, Kamakura, Japan.
Background: Calcified aortic stenosis is a common complication in hemodialysis 
(HD) patients and the progression speed of stenosis in HD patients is faster than that in 
non-dialysis patients. Prognosis of HD patients with aortic stenosis is poor and the choice of 
surgical aortic valve replacement (AVR) is subject to debate. However, there are few studies 
regarding prognosis and its risk factor for AVR.
Methods: We had a single center retrospective study. Thirty HD patients with aortic 
stenosis were performed by AVR from January 2009 to September 2013 in our hospital. 
We investigated blood pressure, serum albumin, cardiac echo findings (EF, AV pressure 
gradient, AV area) before AVR and intra-operating findings (bleeding volume, in-out balance, 
transfusion volume, operation time, aortic cut-off time, cardiopulmonary bypass time).
Results: Age of 30 patients (male 19, female 11) was 71.6±6.3 years old. Average 
duration of HD was 156 months. Diabetes mellitus was 10/30. AV area, AV pressure 
gradient and EF were 0.75±0.20cm2, 67.3±35.0mmHg, 54.0±12.8%, respectively. 30-day 
mortality was 16.7% (5/30) and the causes of death were sepsis, gastrointestinal bleeding, 
pneumonia and cardiac failure. In-hospital mortality was 33.3% (10/30) and 1 year survival 
rate was 60%. Risk factors of in-hospital death from AVR were systolic blood pressure, 
cardiopulmonary bypass time and bleeding volume in univariate analysis. However, 
multivariate regression analysis showed that systolic blood pressure was an independent 
risk factor (hazard ratio [HR], 0.94; 95% CI, 0.91 to 0.98; p=0.043).
Conclusions: Low blood pressure is an independent risk factor of AVR in HD patients 
with aortic stenosis. AVR should be considered while HD patients maintain blood pressure.
PUB258 
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Low Serum Albumin and Hospitalization Among ESRD Patients on 
Dialysis
Abdulhadi T. Gelaidan,1 Adil Ghaffar,1 Robert Mark Black,1 Orhan Efe,2 
Bharat S. Bhandari.1 1Saint Vincent Hospital, Worcester, MA; 2St Vincent 
Hospital, Worcester, MA.
Background: Patients on hemodialysis (HD) have disproportionately high 
hospitalization and readmission rates. Although several factors contribute to this relatively 
high hospitalization rate, albumin has been consistently seen as a marker and we looked at 
this association at our HD center.
Methods: A retrospective cohort study was conducted at Saint Vincent Hospital, 
Nephrology dialysis center, from March 1, 2017 to Febraury 28, 2018. Our sample was 
comprised of 72 patients. The inclusion criteria were; A) ESRD patients aged > 18 years 
old. B) On dialysis treatment for > 12 months. Exclusion criteria were; A) Deceased ESRD 
patients before February 28, 2018. B) Those transfered to other dialysis center. C) Post 
renal transplant. Hypoalbuminemia was defined as albumin < 3.9 g/dL. Hospitalization 
was defined as hospital admission at least once during study period. The mean of serum 
albumin was calculated in two different ways. First; the average of albumin for 12 months 
for each subject and second; the average of quartiles (each quartile include four consecutive 
months). We evaluated the association between serum albumin, history of diabetes mellitus 
and hospital admission by using Chi-square test with a significant p-value level of <0.05.
Results: Out of 72, 59 dialysis patients met the inclusion criteria. The rate of 
hospitalization was 55.9 %. The mean of serum albumin level during the study period 
among hospitalized and non-hospitalized dialysis patients were 3.62g/dL and 3.96g/
dL, respectively. Dialysis patients with mean of serum albumin (average of 12 months) 
< 3.9 g/dL had a higher percentage of hospital admissions (66.7 %) (P-value=0.006). The 
mean of serum albumin (average of four quartiles of the study duration) < 3.9 g/dL had a 
higher percentage of hospital admissions (66.6%) compared to dialysis patients with mean 
albumin level equal or more than 3.9 g/dL (33.4 %) (P-value=0.003). The dialysis patients 
with a history of diabetes mellitus had a higher percentage of hospital admissions (60.6%) 
compared to dialysis patients without diabetes (39.4 %) (P value=0.01).
Conclusions: There is a statistically significant association between mean serum 
albumin less than 3.9 g/dL, diabetes mellitus and hospitalization among dialysis patients. 
Further studies should be considered to evaluate the possible causal relationship of these 
factors
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Dialysis Nurse Driven Bedside Assessment of Peripheral Vascular Disease 
in Indian Dialysis Patients: A Quality Improvement Project
Paras Dedhia,1 Rachana H. Jasani,1 Viswanath Billa,2 Shrirang Bichu,3 
J. Kothari,4 Rajesh B. Kumar.1 1Apex Kidney Care, Mumbai, India; 2Bombay 
Hospital, Mumbai, India; 3Bombay Hospital Near Liberty Theater New Marine 
Lines, Mumbai, India; 4Hinduja Hospital,Healthcare & Apex Kidney 
Foundation, Mumbai, India.
Background: Peripheral vascular disease (PVD) is highly prevalent in dialysis patients 
and associated with increased mortality and morbidity. Early identification and intervention 
may help to decrease morbidity and amputation in prevalent dialysis patients.
Methods: Peripheral vascular disease was screened by bedside ankle brachial index 
(ABI) using handheld Doppler by trained dialysis nurse. The ABI was calculated by the 
ratio of ankle systolic BP divided by arm systolic BP. Subjects were divided into 3 categories 
according to their ABI values; low (ABI < 0.9), normal (ABI 0.9-1.3), incompressible 
(ABI >1.4). Systolic BP in upper extremity was measured on brachial artery of the arm 
contralateral to vascular access and in lower extremities on posterior tibialis artery.
Results: Of the 281 subjects, 62 % were males. The average age was 53.5± 13.4 years. 
The average dialysis vintage was 3.3± 2.5 years. 31% had diabetes, 66 % had hypertension 
and 30 % had history of ischemic heart disease. 12 % reported history of smoking or 
tobacco use. Low ABI (<0.9, suggestive of atherosclerosis) was found in 12.5% subjects, 
normal ABI was found in 67.1% and incompressible ABI (suggestive of calcified vessels) 
was found in 20.3% subjects.
Conclusions: Peripheral vascular disease is fairly common in dialysis patients. Among 
dialysis patients, 1-in-3 had either low ABI or incompressible ABI. This calls for quality 
improvement initiative in each dialysis unit to screen and monitor for PVD by dialysis 
nurses and facilitate early referral for timely intervention.
PUB260 
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Diuretics: To Use or Not to Use? A Survey of Hemodialysis Patients’ 
Willingness to Use Diuretics
Amanda A. Karasinski, Karthik M. Ranganna, Jesse M. Goldman. Drexel 
University Hospital, Philadelphia, PA.
Background: Chronic diuretics are empirically used to increase urine output (UO) in 
maintenance hemodialysis (HD) patients however conclusive evidence of benefit is lacking. 
Varied prescribing practices among nephrologists is evident from DOPPS data indicating 
that 0-84% of HD patients receive diuretics. DOPPS has reported a positive association 
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between residual renal function and diuretic use. Additionally, DOPPS showed improved 
survival in HD patients with greater daily urine output (UO) and lower interdialytic weight 
gain (IDWG).
Methods: An 8 item questionnaire was administered to HD patients at 3 dialysis 
centers in Philadelphia, PA. Demographic and patient characteristics collected included: 
age, gender, ethnicity, dialysis vintage, estimated daily UO, willingness to use diuretics and 
frequency. Data was analyzed using STATA v.13.
Results: Seventy four participants (42 male) were surveyed with mean age 59.4±12.6 
years. Mean time on HD was 4±4.7 years with a mean UO of 196±288.6 cc daily. 65 were 
African Americans, 6 Hispanics, 2 Asians and 1 Caucasian. 15/74 (20%) surveyed were 
already receiving diuretics with a mean UO of 319±391.9 cc daily. The remaining 80% 
(59/74) not on diuretics had a mean UO of 164.5±250.7 cc daily. 31 patients surveyed, not 
on diuretics, reported a range UO of 0-60 cc daily. 9 patients on diuretics reported UO of 
1L daily. A paired t test comparing UO among patients taking vs. not taking diuretics was 
statistically significant, p<0.03; if equal variance was assumed. Under an unequal variance 
assumption, the result was not statistically significant, p<0.08. See Table 1 for data on 
willingness of HD patients to take diuretics.
Conclusions: We discovered that the majority of HD patients surveyed are willing to 
use diuretics. We anticipate that patients with shorter dialysis vintage and residual renal 
function will benefit most from diuretic therapy. This survey is a pilot investigation for a 
large, prospective cohort study to determine the effects of loop diuretics on blood pressure, 
potassium, IDWG and quality of life in HD patients. We hope to define concrete parameters 
for predicting diuretic benefit in dialysis patients.
Table 1
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7-Day iPTH Predicts Long-Term iPTH, Deserves as All-Cause Mortality 
Risk Factor in Secondary Hyperparathyroidism Patients After 
Parathyroidectomy
Weichen Zhang,1 Qian Zhang,1 Minmin Zhang,2 Mengjing Wang,1 
Bihong Huang,1 Jing Chen.1 1Nephrology, Huashan Hospital, Fudan University, 
Shanghai, China; 2Huashan Hospital, Fudan Univerisy, Shanghai, China.
Background: Parathyroidectomy(PTx) is an effective therapy to treat secondary 
hyperparathyroidism(SHPT). Though lots of studies have proved that PTx reduces mortality 
of SHPT patients, the effect of different postoperative PTH levels on long-term prognosis 
remains controversial. The aim of this research is to evaluate the appropriate PTH level after 
PTx and find out early predictors which can contribute to better prognosis.
Methods: We collected secondary hyperparathyroidism dialysis patients who 
underwent parathyroidectomy in Huashan Hospital in 2004-2017. Patients’ data before and 
after PTx were collected including short-term (day 1 to day 7) and long-term (month 3, 6, 
9 and 12) biochemical data. The primary endpoint is all-cause mortality and the secondary 
endpoint is surgery for recurrence.
Results: Ninety-one SHPT patients were enrolled in this research. Compared with 
preoperative parameters, serum calcium, phosphorous, iPTH and ALP of SHPT patients 
after PTx decreased significantly(P<0.001). During follow-up vintage, 12 patients died and 
one patient had surgery because of recurrence. After PTx, postoperative iPTH rebounds 
within 3 months and then comes to a stable level. All patients were divided into three groups 
according to one-year average postoperative iPTH below 46 pg/ml or above 130 pg/ml. 
Of all parameters after PTx, all-cause mortality(P=0.046) is significantly different among 
three groups. Kaplan-Meier curve shows that patients whose postoperative iPTH in the 
range of 46-130 pg/ml have the lowest all-cause mortality while those with postoperative 
iPTH<46 pg/ml have the highest mortality rate (P=0.023). Cox regression analysis also 
confirmed that low postoperative iPTH level is a risk factor of all-cause mortality in SHPT 
after PTx(P=0.036, HR=0.086, 95%CI=0.009-0.848). In addition, patients in one-year 
iPTH<46pg/ml group have a lower 7-day iPTH levels comparing to those in one-year 
iPTH>46pg/ml group(P=0.001). The ROC curve analysis results in 5 pg/ml of 7-day iPTH 
as a cut-off value (AUC=0.751, P=0.003).
Conclusions: SHPT patients with 7-day iPTH>5pg/ml have a higher rate to reach the 
proper iPTH level (one-year iPTH>46pg/ml). Low postoperative iPTH level is a risk factor 
of all-cause mortality in SHPT after PTx.
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Managing Severe Hypertension in a Patient on Hemodialysis – Combined 
Efforts of Physicians and Care Giver
Prof Narinder P. Singh, Swapan Deep Singh Nagpal, Anish Gupta. Max Super 
Speciality Hospital, Ghaziabad, India.
Introduction: Over 50% of CKD patients on hemodialysis have hypertension; more 
than half failing to achieve blood pressure goals. Despite optimum medications, patient 
may have uncontrolled hypertension. Non-pharmacologic methods and changes to 
dialytic approach may help in achieving the desired targets. The physician must remember 
four guiding principles: dietary sodium restriction, individualizing dialysate sodium, 
management of dry weight goals and adequate duration of dialysis. We present a chronic 
kidney disease patient on hemodialysis with severe uncontrolled hypertension. The 
combined efforts of the care-giver, treating physician and hypertension specialist resulted 
in better control of BP.
Case Description: A 68 year old male known hypertensive, diagnosed with ESRD, on 
hemodialysis for four years, presented with resistant hypertension and extreme intradialytic 
BP surges (SBP 240 mmHg). Various classes of antihypertensive medications at optimal 
doses had been tried, with dismal results. Many fruitful discussions took place among the 
care-giver, treating physician and hypertension specialist. Cumulative efforts led to changes 
in the treatment. The number of sessions of dialysis were increased from two to three 
per week; the duration of each dialysis increased from four hours to five hours. The dry 
weight goals were modified. Bio-electrical impedance analysis was used to detect over-
hydration; daily fluid intake and ultrafiltration volume were modified. The dialysate sodium 
concentration was reduced from 135mEq/L to 134mEq/L. Anti-hypertensive medications 
were modified – intra-dialytic anti-hypertensive was switched from metoprolol to 
carvedilol(due to negligible intradialytic clearance of the latter); and pre-dialysis nifedipine 
was replaced with binedipine(a drug that shows prolonged depressor effect likely due to its 
high affinity for the dihydropyridine receptor). BP readings showed marked reduction and 
considerable drop in intradialytic surges.
Discussion: The case presents an insight into the perplexity of management of 
hypertension in patients with chronic kidney disease, more so in those on hemodialysis. 
Many such patients have resistant hypertension and are inadequately treated. A holistic 
approach, combining non-pharmacological means and inputs from the care giver, and 
treating physicians, may benefit such patients.
PUB263 
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Feasibility of Hemodilution Detection Following Extracorporeal Saline 
Bolus Injections Using Crit-Line® in a Clip (CLiC®)
Mirell Tapia, Xia Tao, Stephan Thijssen, Peter Kotanko. Renal Research 
Institute, New York, NY.
Background: Decreased cardiac output (CO) during hemodialysis increases the risk 
of sudden cardiac death, for this reason, CO monitoring is needed. The indicator dilution 
method used to measure CO with the Stewart-Hamilton equation is well established 
and currently in use. The aim of this pilot study is to demonstrate if CLiC® can detect 
a hemodilution signal induced by injections of saline boluses (SB) in the extracorporeal 
circuit. Data will support further exploration of the potential practical use of CLiC® to 
measure CO.
Methods: An ultrafiltration goal (UF) was prescribed, then, 120 mL were added to 
account for the SB. After a run-in period of 15 minutes, 3 SB in sequential volumes of 
30 mL, 20 mL and 10 mL, each separated by 5 minutes, were infused into the arterial drip 
chamber, and 3 SB were infused in the same manner into the venous drip chamber. CLiC® 
data were recorded from the beginning of the session until 5 minutes after the last SB. 
Hemoglobin versus time data were plotted and further analyzed. Hemodilution curve was 
transferred into peak signal calculating the absolute change in hemoglobin with the baseline 
set to zero before the injection of saline.
Results: The above protocol was studied in 4 HD patients. CLiC ® was able to detect the 
hemodilution signal after SB injection and also the returning signal after cardiopulmonary 
recirculation. This was true for all three SB volumes studied.
Conclusions: The ability of the CLiC® to detect the hemodilution signal after the 
infusion of SB provides the opportunity to explore the applicability of this device in terms 
of attaining a more comprehensive hemodynamic monitoring during HD.
Funding: Commercial Support - Fresenius Medical Care. Renal Research Institute
Fig. 1 Injection: arterial drip chamber. The first peak represents the hemodilution signal after 
the SB passes through the CLiC® for the first time, the second peak represents the return of 
the signal after cardiopulmonary recirculation.Fig. 2 Injection: venous drip chamber. The 
peak represents the hemodilution signal returning to the CLiC® after cardiopulmonary 
recirculation.
*Red marker indicates the time of injection of SB.
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Nephrologists’ Opinion Regarding Rationing Strategies in Hemodialysis 
Facilities During a Supply Crisis in Brazil Caused by a Truck Drivers’ 
Strike
Jose A. Moura Neto,1 Ana Flavia Moura,4,2 Gustavo Moreira Tavares,3 
Constanca Cruz,2 Jose Moura Jr..4 1Hemodialysis, CSB Group of Nephrology, 
Salvador, Brazil; 2Bahiana School of Medicine and Public Health, Salvador, 
Brazil; 3Brazilian School of Public and Business Administration - FGV, Rio de 
Janeiro, Brazil; 4Grupo CSB, Salvador, Brazil.
Background: Brazil has an internal transportation and supply system dependent on 
highways. Due to the rising price of diesel, a truck drivers’ strike occurred in May 2018 
affecting the entire country. Roadblocks occurred at more than 500 locations in 24 Brazilian 
states. With the interruption of distribution of healthcare supplies, a major concern emerged: 
how to avoid the lack of materials in dialysis facilities? Knowing that the discontinuation 
of dialysis would lead to the death of patients, dialysis facilities chose to adopt rationing 
strategies.
Methods: We conducted a survey with nephrologists in Brazil about their opinion 
regarding rationing strategies in dialysis facilities. First, we asked about their willingness 
to adopt rationing strategies and the timing of initiation of these strategies. Then, we asked 
which strategies would be first implemented and which would be the last strategy adopted.
Results: A total of 50 nephrologists answered our questionnaire. 44% of them were 
medical directors of dialysis facilities, and the majority (62%) were male. The mean age 
was 43.8 years (SD = 10.90). 50% would start rationing strategies immediately after the 
supply discontinuation, and 40% would adopt rationing strategies only when the internal 
inventory levels were considered low. No respondents disagreed about the need to adopt 
rationing strategies. Among the strategies to be adopted at the beginning, the reduction 
of the dialysate flow (chosen by 68% of respondents) and the reduction of the treatment 
time (chosen by 52%) were most common. The reduction of hemodialysis frequency from 
thrice- to twice-weekly was avoided and considered the last rationing strategy by 84% of 
nephrologists. Additional regression analyses revealed that female respondents adopted 
significantly fewer rationing strategies simultaneously than male (b = -.44, SE = 0.12, 
p < .01). This result is robust after controlling for respondent age and function.
Conclusions: All nephrologists considered adopting rationing strategies in the context 
of a supply crisis affecting the healthcare system. Among the strategies, the reduction of the 
dialysate flow and the reduction of the treatment time were the most common. Reduction of 
hemodialysis frequency was the last rationing strategy to be adopted.
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Relationship Between Ambulatory Blood Pressure Monitoring, Status 
Fluid, and Cardiac Function in Hemodialysis Patients
Soraya Abad,1 Nicolás Macías,3 Almudena Vega,2 Esther Torres aguilera,4 
Ines Aragoncillo,5 Jose Luno.6 1Hospital Gregorio Marañon, Madrid, Spain; 
2Hospital Gregorio Marañón., Madrid, Spain; 3HGUGM, Madrid, Spain; 
4H.G.U. Gregorio Marañon, Madrid, Spain; 5Hospital Gregorio Marañón, 
Madrid, Spain; 6Hospital General Universitario Gregorio Marañón, 
Madrid, Spain.
Background: Hypertension is a cardiovascular risk factor common in hemodialysis 
(HD) patients, correlates with left ventricular hypertrophy. Volume overload is the main 
cause of hypertension in this patients. Aim: Determine the relationship between ambulatory 
blood pressure monitoring (ABPM), status fluid and cardiac function in HD patients.
Methods: In a cross-sectional study, 24 chronic HD underwent ABMP 44hours. To 
assess cardiac function, an echocardiogram was performed. The hydration status was 
evaluated by bioimpedance spectroscopy (BIS) and the brain natriuretic peptide (BNP). 
Hypertension was defined according to the recommendations of JNC 8, with values higher 
than 140/90 mmHg, which correspond to values of 135/85 mmhg in ABPM according to 
ESH/ESC guidelines.
Results: The mean age was 59.5 ± 17.6 years, 62.5%. The mean daytime BP of 
134 ± 25/77 ± 11 mmHg, daytime pulse pressure (PP) 56 ± 17 mmHg, mean nighttime 
BP 132 ± 25/73 ± 13, night PP 57 ± 17 mmHg. 22.7% of patients had a dipper pattern. 13 
patients received antihipertensive drugs, the mean of antihipertensive drugs was 1.25 ± 
1.11. Patients with mean BPS (44 h), daytime> 135 mmg and nocturnal BPS> 120 mmhg 
had a higher predialysis BPS (147 ± 20 vs125 ± 18 mmhg, 147 ± 19vs125 ± 18 mmhg and 
145 ± 18 vs122 ± 20mmHg p < 0.05). Mean BPD (44h)> 85mmhg and nocturnal 
BPD> 70mmhg had a lower TAPSE in echocardiogram (16.8 ± 0.17vs22.2 ± 3.9 and 
17.9 ± 2.5vs23.7 ± 2.7 p <0.005), which is related to dysfunction of right ventricle. Average 
PP (44h), daytime and nighttime levels> 50mmHg had higher fluid overload, expressed 
as overhydration (liters) (2.1 ± 1.1vs.1 ± 2.2, 2.1 ± 1.1vs-0.1 ± 2.2 and 1.9 ± 1.3 vs 
-0.1 ± 2.5 p <0.05), as adjusted for extracellular water (12.1 ± 5.6vs0.7 ± 13.7, 12.1 ± 
5.6vs0.7 ± 13.7 and 11.14 ± 6.5 ± 0.6 ± 15.3) and higher BNP (ng / L) (922 ± 836vs114 ± 
122, 922 ± 835vs114 ± 122 and 824 ± 835vs129 ± 130, p <0.05). The patients who received 
antihypertensive drug were younger (51 ± 19 vs 69 ± 11 years) had a higher mean TAD
(80 ± 10 vs 69 ± 11 mmHg, p <0.05) and higher daytime BPD (83 ± 9 vs 70 ± 11mmhg,
p <0.05).
Conclusions: Elevated values of PAD correlate with right ventricular dysfunction. 
Overhydrated patients present higher pulse pressure. The dry weight adjustment can help 
control PP, which is a cardiovascular risk factor.
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Safety and Adequacy of NxStage® Home Dialysis Machine Providing 
Acute Dialysis in a Rural Hospital
Mirjana Dimitrijevic, Keith A. Bellovich, Quresh T. Khairullah, Joel M. Topf, 
Heather L. Henderson. St. John Hospital Medical Center, Detroit, MI.
Background: The NxStage® home dialysis system is a simplified system designed for 
use by patients for home hemodialysis (HD). We evaluated the safety and adequacy of the 
NxStage® One S machine in a rural hospital. This hospital was unable to provide standard 
HD for patients in a low volume acute care setting, due to the cost of trained staff and the 
low volume of patients. By training registered nurses and technicians from the general care 
unit on the NxStage® machine, the hospital was able to continue to take care of dialysis 
patients rather than transfer them from their community.
Methods: In this observational, prospective study, patients who needed HD while 
hospitalized at Mid-Michigan Medical Center, Alpena, MI, were enrolled. Inclusion 
criteria: Patients with end stage renal disease (ESRD) or acute kidney injury (AKI) requiring 
dialysis. Exclusion criteria: Patients with drug overdose or poisoning. Data points collected 
included adverse events, dialysis flow sheets, hemoglobin, calcium, phosphorus, pre and 
post blood urea nitrogen, creatinine, and potassium. Prescribing guidelines were obtained 
from the dosing calculator NxStage.com. Adverse events (AE) were classified as mild or 
severe. Mild was defined as any intradialytic event that required intervention from the staff 
but did not require discontinuation of the treatment. Severe was defined as any intradialytic 
adverse event that required discontinuation of treatment.
Results: Twenty-seven patients were recruited and completed a total of 74 dialysis 
treatments over a 12-month period. The mean age was 66.2 years (STD +/- 15.7), 63 % 
were male, and 96 % Caucasian. Seventy three percent of patients had an AVF, 7 % AVG, 
and 10 % CVC. The average single treatment Kt/V achieved was 0.54 -1.07 per treatment. 
The average duration of treatment was 4.5 hrs. Admission diagnoses included: CHF, COPD, 
debility, hip fracture, ESRD, GI bleed, pneumonia, peritonitis, bacteremia, small bowel 
infarction. Mild AE’s occurred in 18.5% of runs. There were no severe adverse events.
Conclusions: The NxStage® One S system provides safe and adequate acute dialysis. 
This system can be a viable alternative to a standard HD machine in a rural hospital.
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Characterization of Intradialytic and Interdialytic Cramping in Patients 
with ESRD
David Golod, Glenn F. Short, Brooke W. Hegarty, Donna Cabral-Lilly, 
William McVicar, Tom Wessel. Flex Pharma, Boston, MA.
Background: Muscle cramping is a common complication of hemodialysis that has 
been reported by 35-80% of End Stage Renal Disease (ESRD) patients as one of the leading 
reasons for interruption or early termination (approximately 18%). The cause of intradialytic 
cramping has not been established, but this painful complication often leads to interventions 
that may impact the adequacy of hemodialysis, such as reduction in ultrafiltration rate, 
administration of normal saline or hypertonic normal saline solution, use of pharmacologic 
agents, and premature termination of hemodialysis sessions. The incidence of cramping 
during dialysis and the interventions to treat these cramps are not commonly or consistently 
documented by treating centers. Because of this gap, there is a need to better understand 
the impact that this complication has on the quality of life for ESRD patients suffering from 
intra- and interdialytic cramps, and the correlation to hemodialysis session attendance and 
adequacy.
Methods: Flex Pharma is initiating an observational study at three hemodialysis 
centers in the USA to obtain information to characterize muscle cramping in adult ESRD 
patients. This study will document the overall patient cramping prevalence at these 
centers and capture the muscle cramping history prior to study start and during dialysis 
sessions in approximately 24 patients that have a history of intradialytic cramping. To 
obtain this information, questionnaires will be provided to the general patient population 
at these centers to determine cramping prevalence. Patients previously identified to have 
intradialytic cramping that enter the study will complete questionnaires before and during 
hemodialysis sessions for four consecutive weeks to capture cramping information and 
the impact to their quality of life. In addition, the adequacy of hemodialysis session goals 
will also be analyzed by comparing the planned goals and patient health status (target 
dry weight, planned ultrafiltration rate, and vital signs) against the success, deviations, or 
interventions responsible for whether these goals are met.
Results: The results of this study are expected by the end of the year.
Conclusions: The results of this study are expected by the end of the year.
Funding: Commercial Support - Flex Pharma
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Operationalizing Telemedicine for Home Dialysis Patients
Susie Q. Lew, Neal Sikka. George Washington University, Washington, DC.
Background: Starting in 2019, CMS will reimburse 2 out of every 3 monthly visits 
performed by telemedicine (TM) for home dialysis (D) patients (pts). The aim is to explore 
steps required to operationalize TM for home D pts
Methods: We analyze the regulatory requirements for a comprehensive monthly visit 
conducted by TM & offer recommendations on operationalizing monthly visits for the pt, 
practitioner, & D facility
Results: The regulatory requirements are: -Providers may use & bill for TM encounters 
with ESRD pts from their home or a dialysis facility when using 2 way interactive video 
conferencing (VC) -D pts must receive in-person assessments monthly for the 1st 3 
months of home D & at least once every 3 months thereafter -If home is the originating 
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site, the facility may not bill for a facility fee Operational considerations for TM include: 
-Licensing: Practitioners must be licensed in the state where the pt is located (originating
site) -Credentialing: If the pt is originating from a health facility, the practitioner must
be credentialed & have privileges for the health facility -Risk management: Practitioners
should check with the state regulatory agencies where the pt is located & one’s own 
insurance policy to ensure coverage for TM visits -Technology adoption & utilization: 
Acquire & deploy encrypted platforms to ensure HIPAA compliance. Ensure availability of 
equipment required for VC in the originating & distant sites. Acquire equipment to conduct 
a physical exam (stethoscope). -Documentation requirements: Items needed to document
a monthly visit via TM encounter -Reimbursement: Be familiar with appropriate billing
and location codes to indicate the encounter was conducted via TM -Additionally, A)
develop a plan that facilitates pts obtaining monthly labs near their home & for the labs 
results be downloaded to CROWNWeb. B) Develop practice based policies & procedures 
for providing home TM to ESRD pts. C) Pending language from CMS regarding examining 
a home HD pt’s vascular access
Conclusions: Home D pts may elect to have the monthly visits conducted by TM 
under the provisions of CMS guidelines. These virtual visits may improve compliance with 
appointment attendance & care plans. The implementation of TM involves new procedures 
& technologies as well as workflows for pts, practitioners & D facilities. A step wise 
approach to meeting all regulatory & operational requirements may improve opportunities 
for successful implementation.
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Seamless PD (sm)
Vincent J. Carsillo. Capital District Renal Physicians, Slingerlands, NY.
Background: A new program designed to facilitate and grow peritoneal dialysis for 
nephrology practices. Our integrated approach increases opportunity for patients to choose 
peritoneal dialysis. A multifaceted approach was used to allow patients who urgently 
needed to begin dialysis. These patients could not wait for a traditional peritoneal dialysis 
catheter to heal. Many of these patients were not candidates for “urgent start PD’ as they 
are uncomfortable lying flat in the outpatient setting and wanted to begin training right 
away. In this new program, patients were given an integrated approach including education, 
nephrology, and specialized surgical services to facilitate rapid entry into a home program. 
Specific surgical technique was used to create immediate use peritoneal access. Patients 
were able to begin training within 24-48 hours of catheter placement.
Methods: 20 patients who presented with an urgent need to begin dialysis for newly 
diagnosed ESRD were assesed by nephrology. If the patient was interested in peritoneal 
dialysis, they were entered into the program and received an integrated approach by multiple 
providers. The patients received specialized surgical technique and a catheter which could 
be used immediately if necessary. The patient was admitted to a home dialysis program 
within 24-48 hours. Patients began training immediately in an upright seated position with 
full volume exchanges.
Results: Over a 14 month period, 20 patients received specialized education, speed to 
catheter placement and specialized surgical technique. Patients ranged in age from 31-79 
years. Male to female ratio was 10:10 BMI ranged from 23-47. All patients began training 
within 24-48 hours of catheter placement. At 14 months, there have been zero episodes 
of catheter failure, zero peritonitis episodes, and zero exit site leaks. There was one 
hospitalization within 90 days of catheter placement. All patients were able to participate 
in their care and began training within 24-48 hours of catheter placement. 100% of these 
patients finished training in the outpatient setting. One of the patients changed modality.
Conclusions: We believe this program to be a safe and effective way for patients to 
enter peritoneal dialysis programs. SEAMLESS PD (sm) has clear benefits over “urgent 
start PD” both for the patient and the medical team. This program increases patients’ options 
and allows home dialysis programs to grow while delivering high quality care at a lower 
overall cost.
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Potential Use of PhotoVoice for Assessing Peritoneal Dialysis Patients’ 
House Environment
Piyaporn Towannang, Pongpratch Puapatanakul, Krit Pongpirul, 
Talerngsak Kanjanabuch. Chulalongkorn University, Bangkok, Thailand.
Background: PhotoVoice is a qualitative research technique, in which a picture is used 
as a tool for explaining a phenomenon of interest. As this technique can potentially be useful 
for assessing the house environment of peritoneal dialysis (PD) patients, this study aims to 
assess its potential use for differentiating the house environment of PD patients.
Methods: In January 2018, 15% of PD patients at King Chulalongkorn Memorial 
Hospital were randomly selected and sorted by the PD duration and number of peritonitis 
episodes then categorized into 3 ordinal groups: Best (long duration with no peritonitis), 
Median, and Worst (short duration with some peritonitis). One patient randomly selected 
from each group received home visit by our PD nurse. Pictures of various locations that 
might associate with PD outcome were taken. Cross-case analysis of the pictures was 
performed.
Results: Eight out of 51 PD patients were included and sorted. Best patient was a 
45-year-old male underwent PD for 84 months, Median patient was a 78-year-old male on 
PD for 28 months, and Worst patient, a 67-year-old male had received PD for 22 months 
but already had 3 peritonitis episodes. Twenty, 25, and 18 pictures were taken from their
house, respectively. The cross-case analysis revealed that the pictures of hand-wash sink,
PD fluid storage area, and PD fluid exchanging area obviously vary across the three cases 
and, therefore, could be useful for differentiating house environment of PD patients.
Conclusions: PhotoVoice is a useful and simple tool for assessing PD patient’s house 
environment. At least three house locations should be the main focus of any home visit.
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Peritoneal Dialysis: An Equal V in Calculating Kt/Vurea Underestimates 
the Dose for Women
Gianella S. Lavanda,1 Pablo A. Vale,1 Luiz V. e Affonso,1 Erica A. Guimarães,1 
Benedito J. Pereira,2 Hugo Abensur,3 Rosilene M. Elias,3 Lilian Cordeiro.1 
1Division of Nephrology, University school medicine of Sao Paulo, São Paulo, 
Brazil; 2University of Sao Paulo School of Medicine, Sao Paulo, Brazil; 
3Universidade de Sao Paulo, Sao Paulo, Brazil.
Background: Albeit PD technique and patient survival have been associated with 
residual renal function, the total amount of urea clearance (Kt/V) is recommended to be at 
least 1.7. The volume of distribution of urea (V) is based on total body water derived from 
anthropomorphic measurements, which certainly varies among patients.
Methods: To establish whether there is a difference in Kt/V, we compared V based on 
bioimpedance and V assuming 0.6 to all patients.
Results: A total of 170 Kt/V measurements were compared assuming V=0.6 x weight 
(usual Kt/V) and calculated using V obtained from the bioimpedance analysis (BIA Kt/V). 
We included incident patients on PD (50±18 years, 87 men); median diuresis was 440ml 
(from 100 to 1100ml). V from bioimpedance was 17.6±5.3 and 1.4±0.9L in women and 
men, respectively (p<0.0001), resulting in usual Kt/V and BIA Kt/V in the entire group 
of 0.93±0.62 and 1.63±1.12, respectively (p<0.0001). The usual Kt/V underestimated 
BIA Kt/V mainly in women, as shown in the Bland-Altman plot (Figure 1). We found no 
difference comparing BIA Kt/V between patients aging < or > 65 years old (p=0.736).
Conclusions: In PD patients, total body water calculated from bioimpedance allows 
a more reliable Kt/V calculation. Particularly for women, usual Kt/V underestimated the 
BIA Kt/V.
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Glycemic Control Before and After Starting Peritoneal Dialysis: A Single 
Center Case Series
Marc J. Kim,1 Muhammad O. Hanif,3 Ellie Kelepouris,2 Suzanne Boyle,2 
Karthik M. Ranganna,2 Sandeep Aggarwal.2 1Drexel College of Medicine, 
Ardmore, PA; 2Drexel University College of Medicine, Philadelphia, PA; 3Drexel 
University, PHILADELPHIA, PA.
Background: Diabetes remains a leading cause of end stage renal disease in the US. 
Peritoneal dialysis because of glycemic load in the peritoneal dialysis fluid is often viewed 
as a potential risk factor for new onset or worsening diabetes. We present a case series 
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looking at hemoglobin A1c % pre and post initiation of peritoneal dialysis in our outpatient 
PD center and factors affecting it.
Methods: We collected data on nine PD patients, including demographics, medical history, 
BMI, pre-dialysis initation Hgb A1c and quarterly A1c levels after initiation of peritoneal 
dialysis. Average age was 51yrs, 7/9 patients were females. 3/9 patients had a diagnosis of 
T2DM before starting PD, 1 patient had a renal allograft failure as a cause of ESRD.
Results: There was a statistically significant difference in average pre-dialysis 
initiation Hgb A1c % vs post-dialysis Hgb A1c %, (5.9 +/- 1% vs. 6.8 +/- 1.5%, p = 0.02). 
The statistically significant increase in Hgb A1c level was noted only in the first quarter after 
which the Hgb A1c plateaued (figure 1). There was no statistically significant difference 
in BMI pre-dialysis initiation vs post-dialysis (29 +/- 10 vs. 30 +/- 9) or new diabetic 
medication use.
Conclusions: Our case series of 9 PD patients from a single outpatient PD center 
showed an initial increase in Hgb A1c after initation of PD, which plateaus immediately. 
Larger scale trials are required to look into the clinical and metabolic factors affecting 
glycemic control in peritoneal dialysis.
Hgb A1c % trends before and after initiation of peritoneal dialysis. Single center case series 
of nine patients. Orange circle represents average Hgb A1c% with SD vertical bars pre-
dialysis. Blue circles represent average post-dialysis Hgb A1c% quarterly levels. Using 
Student’s t-test there was a statistically significant difference in average pre-dialysis 
initiation Hgb A1c % vs post-dialysis Hgb A1c %, (5.9 +/- 1% vs. 6.8 +/- 1.5%, p = 0.02)
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Ferritin Is a Predictive Factor for New Cardiovascular Event with 
Regards to a Therapeutic Strategy for Peritoneal Dialysis and Combined 
Therapy (PD+HD Hybrid) Patients
Hiroaki Io,1 Yoshimi Sekiguchi,1 Junichirou Nakata,2 Masayuki Maiguma,1 
Masanori Ishizaka,1 Hiroyuki Inoshita,1 Takanori Nakano,1 Yoko Matsuyama,1 
Yusuke Suzuki.2 1Juntendo University Nerima Hospital, Tokyo, Japan; 
2Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: Previous studies have reported that hypoalbuminemia showed definitely 
association with the degree of residual renal function (RRF) in peritoneal dialysis (PD) 
patients. The purpose of the present study was to analyze the predictive factors at the 
beginning of PD for a group that maintained RRF after 24 months, for PD persistence rate 
and cardio-vascular events (CVE).
Methods: The present study was retrospective and multicenter study with 132 PD 
patients. The predictive factors at the start of PD were analyzed between groups that 
maintained or lost RRF after 24 months. Furthermore, the predictive factors were also 
analyzed PD persistence rate and CVE.
Results: The group that lost RRF after 24 months had hypoalbuminemia and heavy 
proteinuria at the beginning of PD as compared to that of the group that maintained RRF. 
Patients with RRF had a better PD persistence rate when continuing not only PD therapy but 
also a combined HD with PD therapy than those without RRF (p<0.001) using a Kaplan-
Meier method. The patients with past CVE (HR132.4, 95%CI3.420-5272.5) and high serum 
levels of ferritin (HR1.005,95%CI1.001-1.011) at the beginning of PD were independently 
associated with factors for new CVE after initiation of PD using a Cox regression analysis.
Conclusions: It is important to provide a strategy for PD indication in CKD patients 
with light proteinuria at the beginning of dialysis to maintain RRF and without past CVEs, 
low levels of ferritin to prevent CVEs after the initiation of PD.
Persistence rate
CVE predictors
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Peritoneal Ultrafiltration for Heart Failure - Experiences from a 
Randomised Controlled Trial
Hari Dukka,1 Martin E. Wilkie,4 Philip A. Kalra,2 Christopher W. McIntyre,3 
Simon J. Davies,6 Nicholas M. Selby,5 Sunil Bhandari,7 Maarten W. Taal.5,1 
1Nephrology, Royal Derby teaching hospitals, Derby, United Kingdom; 2Salford 
Royal Hospital NHS Trust, Salford, United Kingdom; 3London Health Sciences 
Centre, London, ON, Canada; 4Sheffield Teaching Hospitals, Sheffield, United 
Kingdom; 5University of Nottingham, Derby, United Kingdom; 6University 
Hospital of North Midlands, Stoke-on-Trent, United Kingdom; 7Hull and East 
Yorkshire Hospitals NHS Trust and Hull York Medical School, East Yorkshire, 
United Kingdom.
Background: Peritoneal ultrafiltration (PuF) is sometimes employed for advanced 
heart failure (HF) with intractable fluid overload, but evidence for its benefit is lacking. The 
Peritoneal Dialysis for Heart Failure (PD-HF) study was a multi-centre RCT that aimed 
to address this. However, the trial was stopped early due to inadequate recruitment. This 
abstract describes trial activity and reasons for the study’s failure with the aim of informing 
future trial design.
Methods: The trial aimed to recruit 130 participants from six UK centres, who had 
severe HF (NYHA class 3 and 4) and CKD stage 3 and 4 on optimal medical treatment 
for ≥4 weeks defined as being on ACE inhibitor or ARB, beta blockers and screened for 
cardiac revascularization and /or resynchronization if appropriate. Participants who were 
diuretic resistant were randomised to conventional HF treatment or one overnight exchange 
of Icodextrin. Primary outcome was change in six minute walk test (6MWT), between 
baseline and 28 weeks (end of trial). Secondary outcomes were changes in cardiomyopathy 
questionnaire (Kansas city) results, SF 36 health survey results, hospitalisation and mortality.
Results: Over a two year period approximately 290 patients were screened, 20 were 
eligible for the trial of which 10 were recruited. Baseline characteristics of the recruited 
patients were: mean age 70.1±8.4, all had NYHA class 3 HF, mean 6 MWT of 181.3±49.6 m 
(one patient declined 6MWT), mean eGFR was 28.6±5.4ml/min/1.73m2. Of the 10 patients 
who were eligible but did not participate, some felt PD was too difficult to cope with, some 
died before agreeing to participate or before being approached whilst others were too unwell. 
The reasons for the high number of ineligible patients was eGFR out of range (usually too 
high), frailty and not being on optimal HF treatment. The investigators identified reluctance 
of patients to consider invasive therapy and lack of coordination between cardiology and 
renal services as the main contributors to poor recruitment.
Conclusions: Lessons learnt from the PD-HF trial can be used in the planning of future 
studies in this area. It is clear that any future trial should plan to use a much larger number 
of sites to achieve recruitment targets and that coordination of cardiology and renal care is 
essential.
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High Transport State and Reduced Sodium Sieving in Cirrhotic Patients 
on Peritoneal Dialysis
Javier De Arteaga,2 Edgard F. Ledesma,1 Carlos Chiurchiu,1 Walter Douthat,2 
Jorge de la Fuente.1 1Hospital Privado Universitario de Cordoba Argentina, 
Cordoba, Argentina; 2Hospital Privado-Universitario de Cordoba, Cordoba, 
Argentina.
Background: Peritoneal sodium sieving, an indirect measure of free water transport 
(FWT), is mainly the result of the osmotic conductance to glucose and the action of 
aquaporin channels. A high transport (HT) state and/or a plasma/ dialysate Na gradient 
> 5 mmol/lt, may counteract this sieving effect with sodium diffusion from plasma, and a
diffusion correction applies. Upregulation of peritoneal aquaporins increases FWT in the 
kidney postransplant setting, related to steroid therapy (NDT 2011, vol 26) Cirrhotic pts are 
mostly HT with high UF and studies of FWT are not reported. Objectives: I) to evaluate
results of sodium sieving (FWT) in 49 HT from 12/.2006 to 01/ 2017. Five patients are 
cirrhotic HT II) try to elucidate the possible causes of differences in sodium sieving between 
cirrhotics and other HTpts.
Methods: Patients : all consecutive high transport (HT) (4 hr D/P creat ≥0.81) pts in a 
single center since Dec.2006 till Jan.2017 (N =49 pts):.Methods : Minipets (lamilia2005) 
done yearly and when ultrafiltration changes.
Results: Results: GR1: HTcontrols: (N = 44): Gr 2: HTcirrhotic (N= 5). Table (1)
Conclusions: As compared to controls, NA sieving (FWT) is blunted and NA 
removal(NAR) is higher in cirrhotic patients. D0/D60min glucose is lower in cirrhotics 
P<0.006 pointing to a faster dissipation or more probably a dilution effect due to ascites 
generated “ de novo”.This effect could reduce the osmotic FWT. UF is higher in cirrhotics 
due to small pore water transport(UFSP)
Minipet results
PUB276 
Publication-Only 
Need Finding in Peritoneal Dialysis with Mobile Eye Tracking
Sandra B. Neumann. ETH Zürich (Federal Institut of Technology, Switzerland) 
Peripal AG, Zurich, Switzerland.
Background: In the German Code of Social Law V in §5 (7), paragraph a, the text 
states: “Only patients may be treated with “dialysis in a center”, who need this type of 
dialysis due to their clinical picture. However, the reality looks quite different. This 
drawback was the motivation for a need finding study to find approaches to lower the access 
limitation to the peritoneal dialysis (PD) therapy, the most common home dialysis modality. 
The need finding study was conducted using mobile eye tracking with experienced and 
novice dialysis patients.
Methods: The dialysis patients were visited at home and accompanied in all therapy 
handling steps to gain insights of the user experience of PD from a first-person view. 
The data analysis was not limited to the single central therapy steps but included also the 
preparation phase and the therapy handling steps as a whole.
Results: In total, eight possibilities could be identified which promise to facilitate the 
access to home dialysis like a waste handling and managing system or a novel PD furniture. 
The most promising was a controller for PD which increases the safety against use errors 
and the comfort for the patient.
Conclusions: For many patients, the use of an auto-connect device could increase 
safety and ease of use for patients. In addition, it could enhance standardization of the 
therapy process. Based on the eye tracking results, feasibility was proven with a functional 
prototype and a start-up was initiated for the further development and market readiness of 
such a device, with the public launch targeted early 2018.
Funding: Government Support - Non-U.S.
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Impact of Health Related Quality of Life Non-Renal Factors on the Life of 
Dialysis Patients: Should Mood Be the Focus?
Douglas rafanelle M. Motta,1 Eduesley Santana-Santos,2 Caio O. Bastos,1 
Andreia F. Menezes,1 Kleyton A. Bastos.1 1Federal University of Sergipe, 
Lagarto, Brazil; 2Nursing Department, Federal University of Sergipe, Aracaju, 
Brazil.
Background: Chronic kidney disease patients often have compromised health related 
quality of life (HRQOL) while on dialysis. Mostly factors, either demographic, renal and 
non-renal associated with it, are not valued as they should in the management of such 
individuals.
Methods: We conducted a cross-sectional study between July and September 2013, 
with 215 patients on hemodialysis (HD) and 58 on peritoneal dialysis (PD) in order to 
evaluate HRQOL using the Kidney Disease Quality of Life- Short Form Instrument 1.3 
(KDQOL-SF), and to identify factors associated with it, emphasizing the non-renal ones: 
mood, sleep disorders and sexual dysfunction.
Results: Patients had a mean age of 51 years, mostly men (62%), with low educational 
(72%) and socioeconomic levels (95%). The prevalence of depression (29%), anxiety 
(30%), poor sleep quality (56%), excessive daytime sleepiness (43%) and male (48%) and 
female (76%) sexual dysfunction was high. Models by confirmatory factor analysis showed 
that anxiety (p <0.01), depression (p <0.01) and lower education (p 0.01) were factors 
independently associated with lower HRQOL. It showed a higher prevalence of anxiety in 
HD patients (32%) and depression on those on PD (36%).
Conclusions: Ssearching for better HRQOL is complex and challenging and no 
variable should be neglected, especially in the most vulnerable groups such as those with 
less schooling. It is necessary for dialysis professionals to have a higher level of attention to 
the presence of anxiety, especially in HD patients, and depression, on those in DP, as mood 
disorders have a strong negative impact on HRQOL. Longitudinal and intervention studies 
are needed to confirm our findings and to assess whether the treatment of mood disorders 
can affect HRQOL of patients.
Funding: Government Support - Non-U.S.
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PD PLUS Modeling with “Ideal” Dwell Times Predicts Adequate Kt/V 
and UF Without High Dextrose Solutions or Icodextrin
Corinne E. Zeller-Knuth, Rainer Himmele, Robert J. Kossmann, Dixie-
Ann Sawin. Fresenius Medical Care Renal Therapies Group, Charlotte, NC.
Background: PD PLUS is an APD regimen with a mid- or late-day “PLUS” exchange 
with or without a last fill (LF). For high transporters, achieving UF goals can be challenging; 
for low transporters, achieving the Kt/V goal is a challenge. Using high dextrose (dex) 
or icodextrin dialysates can overcome this, but not without issues. This kinetic analysis 
modeled PD PLUS regimens that aimed to minimize total volume and dex exposure by 
utilizing a PLUS exchange (EX) with an “ideal” dwell time that targets max UF or Kt/V.
Methods: “Ideal” dwell times for maximum UF and Kt/V were determined for all PET 
transport categories with 1.5 and 2.5% dex dialysates using published data and algorithms 
derived from the PackPD® Program. Fifteen theoretical anuric patients were defined for 
modeling purposes by transport type (H, HA, A, LA, L) and patient size (S, M, L). The 
six modeled regimens (below) include overnight (ON) EXes with dwell times set at the 
predicted 1.5% UF Max time for each transport type with options for a dry day, LF, and 
PLUS EX. Dwell volumes for all EXes were set based on patient size; PLUS EX dwell 
times were set at “UF Max” or “Kt/V Max”; LF dwell time was set so total treatment time 
(TT) was 24 hrs. - 1.5% ON + 2.5% “UF Max” PLUS EX - 1.5% ON + 1.5% LF and 2.5% 
“UF Max” PLUS EX - 1.5% ON + 2.5% LF and 2.5% “UF Max” PLUS EX - 2.5% ON 
with dry day - 2.5% ON + 1.5% “Kt/V Max” PLUS EX - 2.5% ON + 1.5% LF and 1.5% 
“Kt/V Max” PLUS EX
Results: TTs for the overnight exchanges was 8-11 hrs, total volume was 6-18 L. At 
least 2 regimens for each patient achieved adequate clearance (weekly Kt/V ≥ 1.7) and UF 
(≥ 1 L/day). For some patients, a dry day was possible with 2.5% dex ON EX. Regimen 
6 predicted adequate PD for all modeled patients.
Conclusions: This kinetic analysis demonstrates that adequate PD can be achieved 
without the use of high dextrose or icodextrin dialysates in most patients by using PD PLUS 
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in which the dwell time of the PLUS exchange is optimized for UF or Kt/V, as indicated. Data 
from clinical studies are needed to confirm the predictions of this modeling. Importantly, 
the accuracy of estimated ultrafiltration volumes using kinetic modeling is limited. Any PD 
prescription should be based on individual clinical needs and patient history.
Funding: Commercial Support - Fresenius Medical Care Renal Therapies Group
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Treatment of Infection in Tunneled Double Lumen Catheter for Hemodi-
alysis with Pulses of Ethanol 70%
Sergio Sloboda. Renalduc, Rio de Janeiro, Brazil.
Background: Catheter Related Bloodstream Infection (CRBSI) contributes to 
increased mortality rate in hemodialysis patient. Thus we must develop strategies to 
eradicate the catheter colonization. Lock with high-concentration antibiotics is a common 
practice and its continuous use related to the emergence of multidrug-resistant bacteria. 
In ethanol use in long-stay polyurethane catheters, the time is relevant in the relationship 
between security and elimination of biofilm. Continuous use will damage its components, 
the toxicity causes high liver enzyme and embolization by catheter fragments. The purpose 
of our work was to implement an effective protocol for use of ethanol at 70% in eliminating 
the biofilm without the emergence of adverse events.
Methods: We started a treatment protocol with lock of ethanol at 70% solution 
associated with 20 mg of enoxiparin for 6 hours in three consecutive days to replace the use 
of antibiotics locks, in the six patients that used Tunneled Double Lumen Catheter (TDLC) 
in last 12 months. Used heparin locking between dialysis. Performed blood cultures (venous 
and arterial branch) every two weeks. Repeating the treatment in the positive. We analyze, 
pre and post Protocol, the number of episodes of CRBSI per 1000 catheter day, values of 
transaminases (ALT), bacteriological profile analysis of blood cultures and the occurrence 
of adverse events. In the statistical analysis was used Wilcoxon test and median as a 
measure of central tendency.
Results: The CRBSI occurred in rate 8 vs. 0 episodes, pre vs. post protocol, p<0.05. There 
was no statistical significance between the values of ALT in two periods, being 10 and 11, 
p>0.05. In two times we observed DLCT low blood flow in ethanol use, being reinstated 
using intraluminal Alteplase 1mg/ml. In the pre protocol 60% of the microorganism
remained in following blood cultures, this not observed during the use of ethanol. Re-
infection in the ethanol use occurred after 34 days, being for different pathogen
Conclusions: The absence of CRBSI without the emergence of adverse events and 
toxicity shows the efficacy of therapy with ethanol on elimination of intraluminal biofilm in 
TDLC. Reinfection warned about the need to increase surveillance and training for handling 
of TDLC by the team of professionals involved in assisting and patient. The bacteriological 
control became critical to the prevention of new episodes of CRBSI
PUB280 
Publication-Only 
A Fractured Dialysis Catheter or Calcified Fibrin Sheath? A Radiological 
Dilemma
Debajyoti M. Roy,1 Sreekanth Koduri.2 1Changi General Hospital, Singapore, 
Singapore; 2Changi General Hospital, Singapore, Singapore.
Introduction: Whilst a-v fistula is an ideal dialysis access, yet up to 80% patients are 
initiated on dialysis with tunneled dialysis catheters (TDC). Long term TDC, as vascular 
access is often unavoidable, despite the associated risk of infections, thrombosis, central 
vein stenosis, catheter dysfunction and fibrin sheath formation.
Case Description: A 75-year-old woman with ESRF was admitted with fever and 
chills during her dialysis session. Her dialysis access was a tunneled catheter inserted 5 
years prior. In the interim she did not have any episode of catheter malfunction or previous 
catheter related blood stream infection. She refused arterio-venous fistula creation in the 
past. The catheter was removed due to catheter related blood stream infection. A routine 
non-contrasted CT scan of the chest was performed 3 days later for follow up of a left 
pulmonary nodule. The radiology report was consistent with a retained central venous 
catheter fragment. Subsequent examination of the catheter tip sent for microbiology was 
examined and was consistent with complete removal of catheter.
Discussion: Fibrin sheaths commonly form on long-term central venous catheters. 
The process involves endothelial damage, thrombus formation, collagen deposition and 
sometimes calcification. A sleeve may form over the distal tip of the catheter. During 
removal of catheters these sheaths remain in the vein. Calcified venous fibrin sheaths 
have been misdiagnosed as retained catheter fragments. Calcified fibrin sheaths can 
be differentiated from retained catheter fragment if attention is given on CT scan to 
their irregular morphology, discontinuous areas of calcification often contiguous with 
noncalcified portions. Take away Message: A retained calcified fibrous venous sheath 
may mimic a retained catheter fragment. This may trigger unnecessary radiological 
intervention or surgical exploration.
CT scan: Coronal
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Serum Phosphorous Is the Independent Risk Factor for Vascular Access 
Dysfunction in Maintenance Hemodialysis Patients
Yubum Choi,1 Mi Jung Lee,1 Hyung Jong Kim,1 So-young Lee,1 Dong Ho Yang,1 
Hye yun Jeong.2 1CHA Bundang Medical Center, CHA university, Seongnam, 
GyeongGi-Do, Republic of Korea; 2CHA Bundang Medical Center, Seongnam-si, 
Republic of Korea.
Background: It is known that maintenance of function of arteriovenous fistula (AVF) 
is very important in the management of hemodialysis (HD) patients. Therefore, identifying 
a risk factor for decreased vascular access flow has a clinical relevance in real world 
practice. Although hyperphosphatemia plays a crucial role in the pathogenesis of vascular 
calcification, there is lack of studies evaluating the effect of hyperphosphatemia on AVF. 
This study investigated the impact of serum phosphorous (P) on vascular access flow in 
HD patients
Methods: Sixty-two maintenance HD patients who visited dialysis unit of Bundang 
CHA Medical Center from November 2016 to December 2017 were included in this study. 
Serum P levels were determined every month, and time-averaged serum P was calculated. 
All patients had left arm AVF (side to side anastomosis) and vascular access flow was 
assessed by Transonic HD 03. Decreased vascular access flow was defined as less than 
600 mL/min.
Results: The mean age was 57.9 ± 12.1 years, 28 patients (50.9%) were men. The 
mean serum P levels were 5.1 ± 1.1 mg/dL and the vascular access flow was 1,071.4 ± 
504.2 mL/min. Decreased vascular access flow was observed in 14 of 62 patients (22.6%). 
In univariate analysis, higher serum P was significantly associated with decreased vascular 
access flow (odds ratio [OR]=2.089, 95% confidence interval [CI]=1.159-3.766, P=0.014). 
But there was no significant association of dialysis blood flow rate, ejection fraction on 
echocardiography and serum calcium (Ca) levels with vascular access flow. Multivariable 
analysis indicated that higher serum P was independently associated with greater risk of 
decreased vascular access flow (OR=4.012, 95% CI=1.651-9.711, P=0.002). Old age, 
reduced EF, low dialysis blood flow rate and higher serum Ca was not associated with 
vascular access flow.
Conclusions: This study demonstrated that higher serum P was the independent risk 
factor for decreased vascular access flow in maintenance HD patients. Serial monitoring of 
serum P may be helpful to stratify the risk of vascular access dysfunction in these patients.
PUB282 
Publication-Only 
Unused Mega Fistulas! A Case Series
Ali I. Gardezi, Fahad Aziz, Muhammad Sohaib Karim, Micah R. Chan. 
Nephrology, University of Wisconsin School of Medicine and Public Health, 
Madison, WI.
Introduction: A mega fistula forms due to aneurysmal dilatation of the whole outflow 
tract. It can lead to complications like high output cardiac failure and steal syndrome. We 
present a series of patients who developed mega fistulas due to lack of surveillance.
Case Description: Five post-transplant and one pre-dialysis patients were referred for 
evaluation of large aneurysmal fistulas. Angiogram was done in each case to define the 
anatomy. All the patients showed outflow stenosis. Details are shown in the table included.
Discussion: Undiagnosed venous outflow stenosis was the most likely reason of 
development of mega fistulas in this case series. Patients on dialysis undergo regular 
surveillance of their fistulas. Any abnormal sign usually prompts an evaluation in the form 
of angiogram with subsequent angioplasty of the outflow stenosis if found. Pre-dialysis 
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and post-transplant patients may not get surveillance of their fistulas which can cause a 
stenosis to go unrecognized. Outflow stenosis causes high pressure within the fistula which 
along with increased turbulence can lead to activation of pathophysiological mechanisms 
resulting in increased outward remodeling and overtime, increase in the size of the draining 
vein. Most of these mega fistulas require either ligation or surgical revision as the stenosis 
is usually chronic and difficult to intervene upon. Even if the stenosis is opened, it can lead 
to worsening of high output cardiac failure or steal syndrome. This case series highlights 
the importance of surveillance of the fistula even if it is not in use as it can prevent a 
complication like mega fistula by early diagnosis and treatment of outflow stenosis.
Findings and outcomes of patients with mega fistulas
Mega Fistula with stenosis at the Cephalic arch-Subclavian vein junction.
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Pulmonary Embolism (PE) After Tunneled Catheter Removal in Dialysis 
Patients: An Underrated Complication?
Laura Nehrenheim, Dirk M. Hentschel, Adina S. Voiculescu. Interventional 
Nephrology Brigham and Women’s Hospital, Boston, MA.
Introduction: Central venous catheters (CVC) cause complications and tunneled 
dialysis catheters (TDC) are associated with a higher mortality from infectious and 
cardiovascular causes. Asymptomatic catheter associated thrombosis has been described 
as frequent as in 25-40% of patients. Symptomatic thrombosis occurs in 1-5% of patient 
with CVC. The rate of PEs in patients with TDC is unknow. Removal of tunneled catheters 
is commonly perceived as low risk procedure and a PE as a complication has not been 
described. We want to present a dialysis patient with a PE after removal of his TDC.
Case Description: A 62 year-old man with ESRD on hemodialysis with a history of 
hypertension, diabetes mellitus, HCV, and bipolar disorder presented in the emergency 
department (ED) with chest pain and shortness of breath (SOB) one day after removal of 
right internal jugular vein TDC. The TCD was inserted to facilitate dialysis for a few weeks, 
while his left upper extremity autogenous access underwent surgical revision. The exit site 
appeared clean and intact without erythema. He had no signs of generalized infection and 
was hemodynamically stable with O2 saturation of 96%. Since the chest pain was localized 
over the exit site and his SOB was not severe, a chest X ray and a non-contrast chest CT 
were performed and were negative. The patient was discharged. Two days later, the patient 
reported continuing SOB with exertion and chest pain during inspiration while he was seen 
by his nephrologist on dialysis. He was sent to the ED, and ACS diagnostics as well as 
a CT-angiogram (CTA) were performed. CTA demonstrated a PE in the right upper lobe 
segmental artery. Echocardiogram showed no signs of right heart strain. The Patient was 
anticoaulated with warfarin with goal INR of 2-3 with heparin bridge. His symptoms 
improved and he was discharged home.
Discussion: Despite a reported high rate for catheter associated thrombosis, the rate 
of PE from line associated thrombus in patients with TDC is unknow. This case report 
demonstrates, that it is necessary to have a high rate of suspicion for PE in patients with 
indwelling dialysis catheters, especially if the TDC was manipulated. PE should be 
recognized as a possible complication of an otherwise low risk procedure as a TDC removal. 
Further studies are needed to clarify the amount of tunneled dialysis line associated PE.
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A Novel Collaborative Approach to Promote CKD Awareness in the State 
of Arkansas
Manisha Singh,1 Nishank Jain,2 Andrea K. Easom.1 1University of Arkansas For 
Medical Sciences, Little Rock, AR; 2Little Rock VA Hospital, Little Rock, AR.
Background: Over 400,000 Arkansans have CKD, about 1200 start dialysis annually 
and there are about a 100 Department of Health (ADH) tele-health sites at outreach clinics. 
Despite one of the highest incident rates of ESRD and poor access to pre-ESRD nephrology 
care, there were no educational tools promoting CKD awareness across the rural state. 
University of Arkansas for medical sciences (UAMS) developed such tools but lacked 
the outreach. UAMS and ADH collaborated with stakeholders to form a CKD Advisory 
Committee to address CKD awareness in AR.
Methods: UAMS and ADH collaborated with stakeholders (major insurance 
companies, non-profit-organizations like Arkansas foundation for medical care, local 
nephrologists,CKD patients) to form the Arkansas CKD advisory committee (ARCKDAC), 
with the mission to increase CKD awareness, detection and education of Arkansans using 
community engagement activities. The committee has 4 arms: 1. Data assessment and 
innovation. 2. Finance and cost assessment. 3. Quality initiatives. 4. Education and CKD. 
ARCKDAC directed attention to following 6 items-1. Comparing and contrasting ESRD 
incident data provided by ESRD Network 13 by AHD regions 2. Explore development of 
a statewide CKD registry; 3. Compile financial analysis of current health-care expense of 
CKD and potential cost-savings from changes in patient and provider behaviors resulting 
from these initiatives;4. Design and implement campaign “Know-Your-Kidney-Number” 
to promote CKD awareness; 5. Engage local nephrologists; 6. Use the “CKD: What You 
Need to Know” tools and results from a prior pilot project to educate committee and raise 
awareness. This project also established that tele-education was non-inferior to traditional 
face to face education for CKD patients. Provider-education tools include learn-on-demand 
videos with CME credits, resident teaching, and a “10-point plan” for primary-care 
physicians to address CKD.
Results: Anticipated improved CKD awareness in AR
Conclusions: We hope to address the barriers to CKD awareness through committee 
efforts. Advisory Committee members have the expertise, resources and commitment 
needed to improve local outcomes and explore a broad range of solutions. This can lead to 
positive change for Arkansans with CKD and the health care system.
Funding: Commercial Support - Baxter
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Bedside Renal Ultrasonography: A Key Tool in the Nephrology Resuscita-
tion Crash Cart
Abhilash Koratala, Maryam Sattari, Amir Kazory. University of Florida, 
Gainesville, FL.
Background: Unstimulating nephrology elective experience during residency training 
has been identified as one of the reasons for the declining interest in nephrology as a career 
choice among internal medicine residents. Efforts have been made at redefining the scope 
of the specialty by incorporating novel educational approaches that not only enhance 
the learning experience but also portend salutary impact on patient care. Point-of-care 
ultrasonography (POCUS) is an inexpensive and relatively easy to learn tool that can be 
incorporated into day-to-day clinical practice and trainee curriculum.
Methods: We developed a focused renal POCUS curriculum for medicine residents 
at our institution. It is comprised of two 4-hour training sessions during the ambulatory 
rotation block. The first session includes an introductory lecture on ultrasound physics, 
instrumentation, and technique of performance of ultrasound, followed by hands-on training 
on normal subjects. The second session includes interpretation of various sonographic 
pathologies (using pre-defined images) and performance of renal ultrasound ± volume 
status assessment on pre-selected hospitalized patients. The images are saved and linked to 
electronic medical record of the patients, and are available for review as needed.
Results: Approximately 60 internal medicine residents with no prior renal ultrasound 
experience have completed the course over the past 12 months. By the end of the second 
session, all residents were able to adequately appraise the three most common sonographic 
pathologies namely, hydronephrosis, stone, and cyst. Moreover, they demonstrated better 
understanding of interpretation of renal size, cortical thickness and echogenicity in the 
clinical context. The feedback from the residents has been overwhelmingly positive leading 
to a constantly growing demand for participation.
Conclusions: Based on the success of the local process, we propose that more 
programs across US consider embracing this approach; POCUS has the potential to become 
an integral component of nephrology training after careful evaluation of resource utilization 
and cost benefit balance. In addition to helping generate more interest in nephrology as a 
career, it can have significant patient care implications and revive the declining rate of renal 
biopsy and hemodialysis catheter placement by nephrologists.
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Poor Awareness and Knowledge Among Internal Medicine House-Staff for 
Prescribing Cardiovascular Medications in Patients with CKD
Nfn Ranjeeta,1 Joshua Fogel,2 Sofia Rubinstein.1 1Nassau university Medical 
center, East Meadow, NY; 2Brooklyn College, Brooklyn, NY.
Background: Chronic Kidney Disease (CKD) alters pharmacokinetics of many 
cardiovascular medications resulting in increased risk of adverse drug events from their 
incorrect dose adjustment. The majority of cardiovascular medications in patients with 
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CKD are prescribed by primary care physicians. We study the awareness and knowledge 
of Internal Medicine (IM) house-staff for dose adjustment of commonly prescribed 
cardiovascular medications in patient with CKD.
Methods: We conducted a cross sectional survey among 341 IM house-staff. We 
studied the awareness whether a given medication needed dose adjustment (‘medication 
dose needs adjustment’ perception) and knowledge at what level of GFR a given medication 
needs to be adjusted (‘medication dose adjustment at appropriate GFR level’ perception) in 
CKD patients.
Results: Overall, there were high percentages for lack of awareness and knowledge in 
adjusting cardiovascular medications for CKD. Atenolol and Simvastatin had the highest 
percentages at 93.2% for incorrect ‘medication dose needs adjustment’ perceptions. 
Carvedilol and Amlodipine had the lowest percentages at 22.7% and 27.2% respectively 
for incorrect medication dose needs adjustment and incorrect medication dose adjustment 
at appropriate GFR level perceptions. PGY1 had greater odds for incorrect dose adjustment 
perception (OR: 5.56, 95% CI: 2.19, 14.12, p<0.001). Additional Nephrology exposure and 
training had lesser odds for incorrect dose adjustment perception (OR: 0.45, 95% CI: 0.21, 
0.97, p<0.05).
Conclusions: IM house-staff have poor awareness and knowledge for cardiovascular 
medication dose adjustment in CKD patients. Medical schools and IM residency programs 
should place greater emphasis on Nephrology exposure and formal didactic Nephrology 
educational training. This can avoid incorrect dose prescribing and enhance patient safety.
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Principles and Strategies for Involving Patients and Caregivers in 
Research in CKD: Report of National Workshops
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David W. Johnson,2,11 Lisa D. Murphy,8 Donna M. Reidlinger,7,11 Stephen 
P. McDonald.6,10 Better Evidence and Translation - Chronic Kidney Disease
(BEAT-CKD) 1Centre for Kidney Research, The Children’s Hospital at
Westmead, Sydney, NSW, Australia; 2Nephrology, Princess Alexandra Hospital,
Brisbane, QLD, Australia; 3ANZDATA, Adelaide, SA, Australia; 4School of
Public Health, University of Sydney, Sydney, NSW, Australia; 5Westmead 
Hospital, WESTMEAD, NSW, Australia; 6CNARTS, Royal Adelaide Hospital,
Adelaide, Adelaide, SA, Australia; 7The University of Queensland,
Woolloongabba, QLD, 4102, NSW, Australia; 8Kidney Health Australia, South
Melbourne, NSW, Australia; 9College of Medicine and Public Health, Flinders
University, Adelaide, SA, Australia; 10Adelaide Medical School, University of
Adelaide, Adelaide, SA, Australia; 11Australasian Kidney Trials Network,
Brisbane, QLD, Australia.
Background: Patient involvement in research is widely advocated to ensure that their 
priorities are reflected in all phases of the research process, from setting the agenda through 
to implementation. However, there is limited evidence on how patients want to be engaged 
and involved in research. This study aims to identify strategies for consumer engagement 
and involvement in research in chronic kidney disease.
Methods: 105 patients and caregivers and 43 clinicians and researchers participated 
in three workshops in Sydney, Adelaide and Brisbane (Australia). In facilitated breakout 
groups, participants discussed principles and strategies for patient and caregiver involvement 
in research. Transcripts were analyzed thematically
Results: We identified five themes: fostering a consumer-centered culture (facilitating 
knowledge exchange and translation, providing an opportunity to give back, empowering 
health ownership, allaying skepticism and suspicion, building a community); respecting 
consumer expertise and commitment (clarifying expectations and responsibilities, equipping 
for meaningful involvement, valuing unique and diverse experiential knowledge, keeping 
‘in the loop’ with results and impact); attuning to individual context (a preference based 
multipronged approach to engagement, reducing the burden of involvement, being sensitive 
to the patient journey); harnessing existing relationships and infrastructure (partnering with 
trusted clinicians, increasing exposure in clinical settings, mentoring patient-to-patient, 
extending reach through established networks); and developing a coordinated approach 
(power in the collective and united voice, systematic approach for equitable inclusion, 
streamlining access to opportunities and trustworthy information).
Conclusions: Patients want to be involved in research to take ownership of their health, 
yet are unaware and uncertain about potential opportunities for involvement. Establishing a 
supportive, respectful research culture, responding to their individual context, coordinating 
existing infrastructure and centralizing the flow of information may facilitate patient 
involvement as active partners in research
Funding: Government Support - Non-U.S.
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Medication Adherence Analysis for CKD Patients
Min Zhang,3 Suyuan Peng,4,6 Zhang Dingjun,5 Jiawei He,7 Yifan Wu.1,2 
1Guangdong Provincial Hospital of Chinese Medicine, Guang Zhou, China; 
2The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
Guang Zhou, China; 3Guangzhou University of Chinese Medicine, Guang Zhou, 
China; 4Mayo Clinic, Rochester, MN; 5Guangzhou University of Chinese 
Medicine, Guangzhou, China; 6Health Sciences Research, Rochester, MN; 
7Guangzhou University of Chinese Medicine, Guang Zhou, China.
Background: According to the existing researches, the rate of medication adherence 
among chronic kidney disease patients was low. Improving patients’medication adherence 
might delay their disease progression.
Methods: Data were collected from CKD patients who had first visited the Chronic 
Disease Management Clinic at the Nephrology Department of the Guangdong Provincial 
Hospital of Chinese Medicine between March 2014 and April 2017. The collected data 
included the basic information of patients, the Morisky compliance scale, accompanying 
diseases, laboratory test results, what types of medication were being taken, and so on.
Results: 210 CKD patients were enrolled. Round 1: 97 patients were considered to 
have good adherence, 113 were considered to have poor adherence. Round 2: 91 patients 
were considered to have good adherence, 119 were considered to have poor adherence. 
38 of the 97 good-adherence patients changed their medication adherence from good to 
poor, and 32 of the 113 poor-adherent patients changed their medication adherence from 
poor to good. Furthermore, Over 75% of the patients often forgot to take medication and 
or often did not pay attention to taking their medication. Additionally, the differences in the 
adherence between two groups were statistically significant including self-care or not, age, 
current residence and education level.
Conclusions: CKD patients had a high rate of poor medication adherence, accounting 
for 53.8% -56.7% of the total. Time had little impact on overall adherence, but had some 
effect on personal adherence. Younger age, higher education levels, living outside of 
Guangzhou city, and self-care or not, each led to worse medication compliance. Therefore, 
in actual clinical practice, we could improve patient compliance by taking corresponding 
measures.
Funding: Government Support - Non-U.S.
The trend map of medication adherence changes between two groups of patients 
within an interval of 1 year ± 3 months
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Predicting Success on Twitter: Nephrology Journals and Online Resources
Sarah Gleeson,1 Swapnil Hiremath,2 Silvi Shah,3 Matthew A. Sparks,4 
Sinead Stoneman,5 Joel M. Topf.6 Nephrology Social Media Collective 
1Nephrology, Auckland hospital, Auckland, New Zealand; 2University of Ottawa, 
Ottawa, ON, Canada; 3University of Cincinnati, Cincinnati, OH; 4Duke 
University and Durham VA Medical Centers, Durham, NC; 5University Hospital 
Waterford, Waterford, Ireland; 6Oakland University William Beaumont School 
of Medicine, Rochester, MI.
Background: Free open access medical education, often promoted and distributed 
through Twitter, is increasingly being used to supplement medical learning. An example 
is the Nephrology Twitter Journal Club (NephJC) which has hosted over 100 Twitter 
chats focusing on the medical literature impacting nephrology. Medical journals have 
also embraced Twitter with varying levels of enthusiasm. We hypothesise that on Twitter 
1. Social media-based resources will have more followers than journals and 2 Amongst
journals, those that commit to social media (through use of visual abstracts or social media 
editors) will have more followers
Methods: We evaluated the Twitter accounts of 18 nephrology journals and 4 
nephrology social media-based resources for the number of followers and number of tweets 
to gauge their reach on Twitter. We report descriptive statistics, and comparisons between 
groups using non-parametric tests.
Results: Overall the median number of followers was 1947.5 (interquartile range, 
(IQR) 510.8-4179.3) and the median number of tweets was 966 (IQR 411.5-1730). We 
found little evidence that the subjects purchased ‘fake followers’ (< 5% of followers). The 
median number of tweets/day was 0.9 (IQR 0.4-1.8) and follower acquisition/day was 1.82 
(IQR 1.1-3.3). Predictors of higher number of followers included Twitter vintage (p=0.005), 
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number of tweets (p=0.001), visual abstract usage (p=0.017) and journal impact factor 
(p=0.027). The social media-based accounts had more followers (median 3415, IQR 2031, 
5172.8) than the journals (median 1579, IQR 510.8-3772.8)(p=0.27). They also had more 
tweets (Median 2396, IQR 783-7369.3) than the journals (median 872, IQR 411.5-327)
(p=0.48).
Conclusions: This study shows that the number of followers a Twitter account has (and 
therefore its reach) is associated with both established (impact factor) and novel parameters 
(number of tweets, visual abstracts). Innovative social media centered initiatives such as 
NephJC had more followers than the journals, potentially due to their higher number of 
tweets and use of visual abstracts. The American Journal of Kidney Disease which has a 
social media editor and uses visual abstracts had the highest number of followers among the 
journals. Establishing a robust Twitter presence requires both consistent usage and adoption 
of new tools to disseminate information such as visual abstracts.
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Novel Technological Educational Tools for Patients with CKD
Geraldo B. Silva Junior,1 Juliana G. Oliveira,1 Marjan Askari,2 Marilia Fahd,1 
Ronaldo A. Freitas filho,1 Francisco aglalberto L. Silva,1 José eurico Vasconcelos 
filho.1 1University of Fortaleza, Fortaleza, Brazil; 2Erasmus University, 
Rotterdam, Netherlands.
Background: Patients’ adherence to treatment is far from ideal, and non-adherence 
impacts on outcomes. The aim of this study is to present novel technological educational 
tools to increase CKD patients adherence to treatment.
Methods: A multidisciplinary team (Health, Information Technology, Medical 
Informatics and Communication) discussed the technological possibilities based on CKD 
patients’ needs. We have also interviewed patients in order to know their information 
needs and the main difficulties faced during treatment. We have them decided to create 
an application for smartphones, educational videos, a “smart medication box” and a shoe 
insole to monitor patients weight.
Results: The application was called “Renal Health”, it included educational 
information for patients with CKD regarding the main aspects of the disease and its 
treatment, and provided tools for patients self-monitor their treatment, with alarms at the 
time of medications, dialysis, medical appointments etc. It also included information for the 
general population and for transplanted patients (mainly focused on immunosuppressants). 
The videos were intended to supply the necessities of illiterate patients who could not 
read the educational texts of the app. It was provided through a channel at youtube and 
would be incorporated in the application. The medication box was designed in a prototype 
version, in which a sensor is connected with the application. Whenever the patient open 
the box the app register the time and the name of the drug that was intended to be taken at 
that time. The shoe insole will be designed to monitor patients’ weight, once interdialytic 
overweight is still a problem, which is associated with bad outcomes. Sensors will connect 
the information registered by the insole with the application, and alarms will be fired if a 
determined weight is overcome.
Conclusions: Patients’ adherence to treatment is a challenge not only for CKD but for 
any disease. The Renal Health project evidence the countless possibilities that technology 
can provide to patients aiming to help them cope with a complex disease that requires a 
huge commitment to achieve good clinical outcomes, which is CKD. We intend to test these 
technologies in a large group of patients to assess its effects on clinical outcomes.
Funding: Government Support - Non-U.S.
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Background: Veterans Health Administration (VA) is the largest provider of health 
services in the nation for patients with chronic kidney disease (CKD). Many veterans with 
advanced CKD do not receive nephrology care before initiating dialysis. Veterans that do 
have access to this care do better. Reasons for this gap may include limited access due to 
geographical barriers, lack of local specialists and/or poor provider recognition of CKD. To 
bridge this access gap, the Seattle Renal VA-ECHO (Extension for Community Healthcare 
Outcomes) program developed a tele-mentoring program between nephrologists and 
underserved area primary care providers (PCPs). This program consists of didactic sessions 
with integrated case-based discussion via a Skype-meeting platform. To better facilitate 
learning, we developed a nationally delivered renal curriculum.
Methods: The goals of the curriculum are to: 1) Improve veteran access to renal 
specialty care; 2) Narrow PCP renal knowledge gaps; 3) Improve outcomes of veterans with 
kidney disease and other related complications. PCP knowledge gaps were identified via 
survey of VA PCPs and nephrologists and a review of electronic consultation (e-Consult) 
questions. A modular structure was chosen to develop common educational themes and 
allow for flexibility. Modules are logically sequenced to facilitate learning. Six modules 
with 3-16 didactic sessions were developed. Each session incorporates patient cases 
submitted by PCPs as e-consults. Learning objectives are integrated into each didactic topic. 
Nephrology and multidisciplinary content experts give didactics to create shared learning 
experiences. Curriculum development began in late 2016 and was in full use by 2017. 
Surveys were directed at frequent Renal VA-ECHO participants from 2016 and 2017 in an 
effort to capture learners pre and post-curriculum implementation.
Results: We surveyed 15 participants with a 47% response rate. The majority (57%) 
felt the curriculum was extremely helpful for learning focus, acquisition of knowledge, 
identification and filling of knowledge gaps and improvement in patient care. The remaining 
43% found the curriculum to be quite helpful in these areas.
Conclusions: The development of a Telehealth Renal VA-ECHO Curriculum has 
helped to bridge knowledge gaps among rural PCPs and improve specialty care access and 
quality of care of veterans.
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A Kidney Biopsy Simulation Training Program: First Year’s Results
Maria-Eleni Roumelioti, Jonathan G. Owen, Christos Argyropoulos, 
Yue-Harn Ng, Mark L. Unruh. University of New Mexico, Albuquerque, NM.
Background: Percutaneous kidney biopsy (PKB) is the most common procedure 
and should be adequately taught through simulation training according to ACGME 
requirements. We initiated a PKB simulation training program and we designed a two-
year study to examine its effect on the confidence level, the procedural competence and 
the satisfaction with this training of Nephrology fellows compared to historical controls 
(fellows trained on PKBs before the initiation of the program).
Methods: All fellows were trained at UNM’s simulation center (BATCAVE) with 
a PKB ultrasound training model (CAE Healthcare Blue PhantomTM). Participants 
demographics and previous PKB experience was collected. Pre-assigned readings, 
online videos and hands-on practice on the simulation model were utilized. Performance 
of the trainee during each one-hour session was graded by the use of an evaluation form 
specifically designed for PKBs. Pre-and post-simulation surveys evaluated the participants’ 
confidence level quantitatively (scale 0-5). All participants completed the satisfaction with 
PKB simulation experience scale (PKB-SSE).
Results: All three 1st and 2nd year current renal fellows completed the simulation 
training. The following table summarizes the basic information acquired from their training. 
Overall, the program enhanced the confidence level of fellows without previous experience 
on performing PKBs. All fellows expressed a high level of satisfaction (0-5) from their 
participation in this training.
Conclusions: PKB simulation training may improve trainees’ confidence level 
especially for those without prior experience as well as their satisfaction with the 
training. The procedural competence of the trainees on PKBs will be evaluated during 
the second year of their fellowship and will be compared to the procedural competence of 
historical controls. Interventional Nephrology could re-foster interest in this subspecialty. 
Interventional Nephrology could re-foster interest in this subspecialty.
Funding: Clinical Revenue Support
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Promoting Shared Decision Making Practice for CKD Patients Through 
Patient Decision Aids and Nephrology Staff Education
Yasuhiro Komatsu,1 Mari Ishida.2 Japan Shared Decision Making Collaborative 
for Chronic Kidney Disease 1Gunma University, Graduate School of Medicine, 
Maebashi, Gunma, Japan; 2Tokai Univercity Hachioji Hospital, Hachioji city, 
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Background: Shared decision making (SDM) process is integral for promoting patient 
centered care and patient and family engagement, leading to higher Quality of Life, patient 
satisfaction, and treatment outcome. However, practice of shared decision making is not 
fully implemented in routine healthcare practice in Japan. We aim to develop a program 
which promotes shared decision making through education and creating decision aid 
material.
Methods: We outline the development process of Japan Shared Decision Making 
Collaborative for Chronic Kidney Disease, an organization and a program to promote 
the practice of SDM. We also present its key educational elements. We describe issues 
associated with the implementation of the education program.
Results: Japan SDM Collaborative for Chronic Kidney Disease has been launched 
in October 2017 to promote education and practice of SDM for end stage kidney disease. 
After review of the literature, panel of members created sixteen pages patient decision 
aid booklet, aiming to accelerate patient-provider conversation, encourage patient and 
family engagement, and patients’ understanding of treatment options. Decision aid 
booklet is approved by key nephrology organizations in Japan, including Japanese 
Society of Nephrology, the Japanese Society for Dialysis Therapy, the Japan Society 
for Transplantation, Japanese Society for Peritoneal Dialysis, and Japanese Society for 
Clinical Renal Transplantation. The booklet contains questionnaires for patient lifestyle, 
preferences, and values. It also provides key information about hemodialysis, peritoneal 
dialysis and kidney transplantation. Training seminars for nephrologists and nurses were 
held, which include key lecture and group work to share understanding of SDM and address 
issues to promote SDM. Group work consists of simulated healthcare provider and patient 
encounter, discussion about treatment options using decision aid. From April to May 2018, 
five educatinal seminars with 250 participants from 90 institutes were successfully held.
Conclusions: Japan SDM Collaborative for Chronic Kidney Disease has been launched 
to promote SDM practice for end stage kidney disease patients in Japan.
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Investigation and Management of Inpatient Hyponatremia in a Teaching 
Hospital
Sandiya Bindroo,1 Vikram S. Taware,1 Divya Akella,1 Tuhina Cornelius,1 
Kirankumar K. Patel,1 Hannah R. Troutman.2 1Internal Medicine, Crozer 
Chester Medical Center, Upland, PA; 2Crozer Chester Medical Center, 
Secane, PA.
Background: Hyponatremia is not a disease but a pathophysiologic process accounting 
for approximately 15% of general hospital admissions, and it is associated with significant 
morbidity and mortality. The objective of this study is to evaluate the investigation and 
management of hyponatremia in a teaching hospital.
Methods: Retrospective, observational study was conducted at a large teaching 
hospital for a year period (1st-June-2016 to 30th-June-2017). A retrospective chart review 
was performed on general internal medicine hospitalized patients with the diagnosis of 
hyponatremia including those who were admitted with serum sodium (sNa) ≤135 Meq/l 
and those who developed hyponatremia during the hospital stay.
Results: Six hundred and ninety five patients (321 male/374 female) with a Mean±SD 
age of 62±19 years and nadir sNa of 127.37 ± 6.22 Meq/l were included. Only 450/695 
(65%) were admitted with sNa ≤130Meq/l, and the rest 245/695 (35%) developed 
hyponatremia while during their hospital stay. The severity was 45.46%, 45% and 
0.09% for mild (sNa ≥130 Meq/l), moderate (sNa ≥120Meq/l to 129Meq/l) and severe 
(sNa <120 Meq/l) hyponatremia. The documentation of acuity and volume status assessment 
was missing for 83% and 62% of patients respectively. Only 20% patients had measurements 
of paired serum and urine osmolality and sodium, while 12% and 34% had an assessment 
of adrenal reserve and thyroid status respectively. The mean length of hospital stay was 
5.11±4.03 days with an inpatient mortality rate of 1%. At hospital discharge, 14% patients 
had persistent hyponatremia. Overall, 22% patients didn’t have any treatment recorded 
for hyponatremia. Among 532/695 (76.54%) patients with recorded treatment, the most 
common modality was isotonic saline (97%) followed by fluid restriction (29%). Expert 
opinion was sought in 28% of cases, with significant discrepancies noted in management. 
Offending drugs continued in 33% of patients.
Conclusions: This study highlights the need to improve clinical practice and educate 
residents. By accurate documentation, appropriate expert opinion, and highlighting 
inpatient hyponatremia electronic alerts can prompt optimal investigation and treatment, 
preventing associated morbidity and mortality.
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Background: Electrolyte imbalances are not common but important cause of morbidity, 
mortality and therapy outcome. The incidence of commonest Na+ and K+ abnormalities are 
ikely to rise due to increase in conditions like hypertension, diabetes mellitus, CKD & heart 
failure etc and due to drugs used for their management. There is lack of epidemiological 
data about these abnormalities in ambulatory care setup.. There was no study about Na+ and 
K+ imbalance in the arab world where the incidence of diabetes and cardiovascular disease 
is on rise in epidemic magnitude. It made us curious to assess about the incidence of these 
electrolyte abnormalities in ambulatory care setup.
Methods: Electronic record system of a Day Care Surgery Center serving all medical 
& surgical sub-specialities was acessed to retrieve retrospectively all the results of serum 
sodium and potassium tested during 1st January 2016 to 31st December 2017. The 
selection of center eliminated serious cases leading to a better presentation of ambulatory 
care patients. Age, sex, nationality, and value of electrolyte result but not the diseses were 
included in study. Excel 2016 was used for anlaysis.
Results: 73143 and 61480 patients utilized the facility in 2016 & 2017 respectively. 
25872 & 17826 samples for K+, 24027 & 15090 samples for Na+ were analysed in 2016, 
2017 respectively. 18272 patients in 2016 and 13520 patients were tested in 2016 & 2017 
respectively. Age ranged from less than 1 year to 93 years in 2016 and 2 years to 89 years in 
2017. The incidence of hyponatremia was 9.1% & 8.9% in 2016 & 2017 respectively while 
hyponatremia was les than 0.1%. incidence of Hypokalemia was 0.9 to 1% & hyperkalemia 
incidence was 0.32 to 0.35 %. Hypokalemia and hyponatremia was more common in 
younger age (no significant p) & among females (significant p) while hyperkalemia and 
hypernatremia was more common among males and older age (no significant p).
Conclusions: Incidence of Na+ & K+ abnormality in ambulatory care is low but its 
ablolute numbers may be significant. This is a single centre study with several limitations 
yet first of its kind in Arab world about epidemiology of sodium and potassium imbalance 
in ambulatory care setup A larger multicenter stuy ncluing relation to morbidity and drugs is 
to have better assessment of the problem is highly desirable and recommendable.
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Hypercarbia in a Patient with Acute Leukemia: Don’t Be Tricked!
Abhilash Koratala,1 Justin Lee Loy.2 1Nephrology, University of Florida, 
Gainesville, FL; 2University of Florida Gainesville, Gainesville, FL.
Introduction: Nephrologists are frequently consulted to assist with the management of 
acid-base and electrolyte disorders in the intensive care unit (ICU). As such, it is important 
to recognize the spurious causes of laboratory abnormalities in this context.
Case Description: A 58-year-old man was admitted for multifocal pneumonia. 
Laboratory studies demonstrated severe leukocytosis with a WBC count of 123 thou/mm3 
(Ref: 4-10), with peripheral blood smear suggestive of Acute Promyelocytic Leukemia. He 
was admitted to the ICU for treatment of pneumonia and possible Leukapheresis. Soon after 
that, he developed hypotension and worsening respiratory status requiring endotracheal 
intubation. Arterial blood gas (ABG) analysis was significant for a pH of 6.9, PaCO2 of 
98 mmHg, PaO2 67 mmHg, on Fio2 of 100%. Pulse oximetry reading at that time was 92%. 
Serum chemistries demonstrated a potassium of 8.5 mmol/L with creatinine ~1.2 mg/dL. 
Nephrology was consulted for possible dialysis in the setting of severe systemic acidosis and 
hyperkalemia. Further investigations revealed no EKG changes suggestive of hyperkalemia 
and a serum lactate of 18.6 mmol/L. We suspected spurious hyperkalemia from cell lysis, 
which was confirmed by whole blood potassium of 4.3 mmol/L. While renal replacement 
therapy is a reasonable strategy to correct systemic acidosis, we were faced with the 
question whether this is primarily metabolic (lactic) or respiratory acidosis. In hypercapnic 
acidosis, correction of pH above 7.2 is not typically recommended as it may adversely affect 
the overall outcomes. A repeat ABG revealed similar PaCO2 but interestingly, point-of-care 
(bedside) blood gas analysis at the same time demonstrated a PaCO2 of only 20 mmHg, 
which indicates that the original high value of PaCO2 was spurious.
Discussion: Spurious hypoxemia can occur in cases of extreme leukocytosis and 
thrombocytosis due to in vitro oxygen consumption by these metabolically active cells, 
even when there is a few-minute delay between sample collection and analysis. However, 
spurious hypercarbia is not expected to occur owing to considerably higher CO2 buffering 
capacity of blood. However, our case shows this can occur, especially when there is 
concurrent metabolic acidosis.
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Validity of Urine Osmolality Measurement in Healthy Adults
Emad Al Jaber, Eric Judd. University of Alabama at Birmingham, 
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Background: Hyponatremia, defined as a serum sodium level < 135 mEq/L, is the 
most common electrolyte disorder in clinical practice. Measurement of urine osmolality is 
critical part in the correct diagnose and management of patients with hyponatremia. The aim 
of this study is to quantify the changes in urine osmolality due to the presence of substances 
identified by urinalysis (UA), like glucosuria.
Methods: Albumin, ketones (e.g., acetoacetic acid and β-hydroxybutyrate), and glucose 
were added to the urine of healthy participants in amounts detected by dipstick urinalysis 
(Siemens multistix 10). For example, 0.2g of glucose per 10 mL of urine corresponded to 
4+ glucose by dipstick. Urine osmolality was measured using freezing point depression 
(Model 2020, Advanced Instruments, Inc) at baseline and after adding fixed amounts of 
each substance. Change in urine osmolality was reported as median (range). Signed rank 
tests were performed to compare differences in osmolality from baseline; p-value < 0.05 
considered statistically significant.
Results: The study population consisted of 10 participants (50% female, 40% 
African American, age ranging 27-62 years, and BMI ranging 25-34 kg/m2). Baseline 
urine osmolality ranged 74 – 874 mOsm/kg, and changes in urine osmolality were similar 
throughout the range of baseline values. Addition of acetoacidic acid at 160 mg/dL 
(e.g. 3+ketones by UA) raised the urine osmolality by 27.5 (20-29 mOsm/kg, p 0.004). 
β-hydroxybuterate at 160 mg/dL, which is not detected by urinalysis, raised the urine 
osmolality by 13.7 (3-20 mOsm/kg, p 0.016). Glucose at 2000 mg/dL (e.g., 4+ glucose by 
UA) raised the urine osmolality by 110 (97-116 mOsm/kg, p 0.004), and glucose at 500 mg/dL 
(e.g, 2+ glucose by UA) raised the urine osmolality by 24.7 (9-37 mOsm/kg, p 0.004). 
Albumin did not significantly change the urine osmolality with 4+ protein by urinalysis 
changing urine osmolality by -3 (-8-2 mOsm/kg, p 0.22).
Conclusions: The presence of ketones and glucose in the urine significantly increase 
urine osmolality measurements. When interpreting urine osmolality as an indicator of 
kidney water handling, one may need to correct for these substances, which can be detected 
by urinalysis. Importantly, the presence of albumin does not significantly alter urine 
osmolality.
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Acquired Renal Glucosuria in an Undifferentiated Connective Tissue 
Disease Patient with a SLC5A2 Heterozygous Mutation: An Unusual Case 
Report
Xiangchen Gu,1 Yi Wang,2 Min Chen.2 1Yueyang hospital of integrated Traditional 
Chinese and Western Medicine, Shanghai University of Traditional Chinese 
Medicine, Shanghai, China; 2Yueyang hospital of Traditional Chinese and 
Western medicine, affiliated to Shanghai University of T.C.M., Shanghai, China.
Introduction: Renal glucosuria is a renal tubular disorder characterized by persistent 
isolated glucosuria in the absence of hyperglycemia. The causes of renal glucosuria include 
a wide range of insults to proximal tubular cells including genetic conditions, drugs, and 
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poisons. Renal glucosuria caused by UCTD(undifferentiated connective tissue disease) is 
very rare.
Case Description: A 30-year-old woman was seen in the outpatient clinic for complaints 
of repeated frequency urination,odyuria. Laboratory tests showed urinary tract infection 
and renal glucosuria. After the antibiotic treatment, the UTI symptoms were relieved while 
renal glucosuria remained. Further laboratory test ruled out renal tubular acidosis, and 
immunologic tests showed a high antinuclear antibody titer (1:160), and elevated anti-Rho/
SSA antibody. Schirmer’s test, tear break-up time and lip biopsy were negative. The patient 
did not meet criteria for any known connective diseases. She was therefore diagnosed with 
UCTD. Genetic analysis showed SLC5A2 gene heterozygous mutation, and incubation of 
the patient’s serum with normal mouse kidney tissue showed a pattern of SGLT2 in the 
epithelial tubules similar to that of incubation of normal mouse kidney tissue with the rabbit 
polyclonal anti-SGLT2 antibody. With the treatment of immune-suppression, the renal 
glucosuria doesn’t exist.
Discussion: This case presents UCTD as a rare cause of renal glucosuria, and our 
findings suggest the presence of circulating autoantibodies to SGLT2.
Fig1. Genome sequencing of all exon regions of SLC5A2
Fig2. Immunofluorescence staining of the frozen sections of normal mouse kidney with (A) 
the patient’s serum and (B) rabbit polyclonal anti-SGLT2 antibody was performed.
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Japanese Adults Aged 15–88 Years Old: A Cross-Sectional Study to 
Develop a Formula for Quantifying Fluid Volume Overload
Yasushi Ohashi,1 Nobuhiko Joki,2 Keisuke Yamazaki,1 Takeshi Kawamura,1 
Reibin Tai,3 Hideyo Oguchi,3 Rena Yuasa,3 Ken Sakai.3 1Nephrology, Toho 
University Sakura Medical Center, Chiba, Japan; 2Nephrology, Toho University 
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Background: Fluid volume overload is common and is associated with adverse 
outcomes in patients with chronic kidney disease (CKD). However, accurate assessment 
of fluid volume status remains a concern. The fluid volume balance between intracellular 
water (ICW) and extracellular water (ECW) gradually changes with age, which may be 
associated with a reserve capacity for volume overload. This study was designed to estimate 
the physiological fluid volume changes with age for assessing volume overload.
Methods: We performed using sample data obtained from InBody Japan Inc. (Kameido, 
koto-ku, Tokyo, Japan). A total of 1,992 individuals (753 men and 1,239 women) aged ≥15 
years included in this study had their body composition measurements performed at training 
gyms in 2014. We developed a regression formula to assess the association of age with the 
ratio of ECW to ICW in these subjects.
Results: The mean ages of male and female subjects were 51.2 ± 15.2 and 57.4 ± 15.2 
years, and their mean body mass indices were 23.4 ± 3.3 and 21.1 ± 2.8 kg/m2, respectively. 
The total fluid volumes of male and female subjects were 39.6 ± 4.9 and 27.7 ± 3.0 L, 
whereas the percent body fat mass/kg of body weight were 19% and 26%, respectively. The 
ECW/ICW ratio increased with age due to the steeper decrease in the ICW content than in 
the ECW content, especially after the age of 70 years. The regression formulas used for 
calculating the age-adjusted ECW/ICW ratio were as follows: [0.5857 + 7.4334 × 10–6 × 
(age)2] in men and [0.6062 + 5.5775 × 10–6 × (age)2] in women. The standard errors of the 
quadratic least square regression coefficient in male and female subjects were 0.2825 × 10–6 
and 0.2516 × 10–6, respectively. The standard errors of the y-intercept in the formulas for 
male and female subjects were 0.000989 and 0.000974, respectively.
Conclusions: Fluid volume balance is universally influenced by decreased cell volume 
driven by aging and muscle attenuation, which disturbs the standard ICW/ECW ratio of 
62:38. Our proposed formula for calculating the age-adjusted ECW/ICW ratio may be a 
useful calculation tool for the normalized fluid volume balance, and it can be applicable to 
the quantitative analysis of volume overload in patients with CKD.
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Yuehong Li,1 Qi Chen,2 Xianglan Wu.3 1Department of Nephrology, Beijing 
Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua 
University, Beijing, China; 2Department of nephrology, Beijing Tsinghua 
Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 
China; 3Department of nephrology, Beijing Tsinghua Changgung Hospital, 
School of Clinical Medicine, Tsinghua University, Beijing, China.
Background: Calcium oxalate (CaOx) is the most common urolithiasis, metabolic 
disease such as obesity, diabetic mellitus, dyslipidemia, hyperuricemia, and hypertension 
can influence the incidence and recurrence of urolithiasis via many mechanisms. This study 
aim to explore the relationship between CaOx stone and metabolic disease in Chinese 
urolithiasis patients.
Methods: Patients treated by surgery in Beijing Tsinghua Changgung Hospital from 
Oct. 2015 to Aug. 2017 were retrospectively study. Demographic characteristic and stone 
composition were analyzed. Patients of CaOx stones and non-CaOx stones’data were 
compared, including clinical material and examination. The prevalence of metabolic 
disease in CaOx patients were analyzed and Logistic regression were used to analyze the 
influence factors related to hyperlipidemia among CaOx patients.
Results: 1. Among 707 patients, there are 446 (63.1%) males and 261 (36.9%) females. 
573 (81.0%) cases are CaOx stones. 2. Compared with non-CaOx patients, CaOx patients 
had significantly higher BMI (25.40kg/m2 vs. 24.54kg/m2, P=0.024) and urine gravity 
(1.012 vs. 1.011, P=0.024), lower blood chlorine (105.6mmol/L vs. 106.4mmol/L, P=0.007) 
and lower proportion of urinary infection (62.4% vs. 78.4%, P=0.001). 3. Compared with 
general population, CaOx patients had higher proportion of metabolic disease. 4. CaOx 
patients with hyperlipidemia had significantly higher level of uric acid (364.3umol/L vs. 
331.9umol/L, P<0.001), serum calcium (2.23mmol/L vs. 2.19mmol/L, P=0.009), total 
protein (67.6g/L vs. 65.7g/L, P=0.001) and albumin (39.8g/L vs. 38.2g/L, P<0.001). They 
had lower level of iPTH (43.17ng/L vs. 51.95ng/L, P=0.003) and urine pH (6.13 vs. 6.36, 
P<0.001). 4. Multivariate Logistic regression analysis showed that hyperlipidemia in CaOx 
patients are related with hyperuricemia (OR 1.609, 95%CI 1.018-2.543, P=0.042), blood 
calcium≥2.3mmol/L (OR 1.953, 95%CI 1.092-3.491, P=0.024), iPTH≤40ng/L (OR 1.576, 
95%CI 1.013-2.453, P=0.044) and urine pH≤6 (OR 1.820, 95%CI 1.164-2.848, P=0.009).
Conclusions: 1. Compared with non-CaOx, CaOx urolithiasis patients have higher BMI 
and urine gravity, lower proportion of urinary infection and blood chlorine. 2. Metabolic 
disease is common in CaOx urolithiasis patients, dyslipidemia is the most common 
one. 3. Hyperlipidemia in CaOx urolithiasis patients is associated with hyperuricemia, 
hypercalcemia, the decrease of iPTH and urine pH≤6.
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Metabolic Acidosis and Clinical Outcomes in CKD Patients – Multicenter 
Large Cohort Study Using Instrumental Variable Analysis
Jung Nam An,1 Yong Chul Kim,2 Kwon Wook Joo,3 Yun Kyu Oh,4 Chun 
Soo Lim,1 Jung Pyo Lee.1 1Seoul National University Boramae Medical Center, 
Seoul, SEOUL, Republic of Korea; 2SNUH, Seoul, Republic of Korea; 3Seoul 
National University Hospital, Seoul, Seoul, Republic of Korea; 4Department of 
Internal Medicine, Boramae Medical Center, Seoul, Republic of Korea.
Background: Whether low serum total CO2 (TCO2) concentrations, defined as 
metabolic acidosis, increase a risk for kidney function deterioration and mortality in chronic 
kidney disease (CKD) was controversial and not clear enough. Large-scale studies for the 
clinical impacts of metabolic acidosis in Asian CKD patients have been done, neither.
Methods: A multicenter cohort study of 42,270 adult nephrology outpatients, from 2001 
to 2016, was conducted to investigate the association between serum TCO2 concentrations 
measured at first outpatient visit and clinical outcomes. The patients diagnosed with end-
stage renal disease (ESRD) from the first day of outpatient visit to 3 months were excluded. 
Instrumental variable was defined as the region divided to 4 groups based on the proportion 
of patients who have serum TCO2 concentration lower than 22 mmol/L.
Results: The patients with initial TCO2 < 22 mmol/L were 10.1%, hypertension and 
diabetes accounted for 29.3% and 20.9%, respectively. ESRD occurred at 8.5% patients 
and mortality rate was 12.2% during median 77.0 months follow-up period. Cox-
proportional hazard regression model adjusted for initial estimated glomerular filtration 
rate demonstrated that low TCO2 concentration increased a risk for progression to ESRD 
(hazard ratio [HR] 1.13; 95% confidence interval [95% CI] 1.04-1.23) and mortality (HR 
1.47; 95% CI 1.37-1.59). Cox regression model using instrumental variable also verified a 
significant association between initial TCO2 concentration and mortality (HR 0.58; 95% 
CI 0.51-0.66), however, there was no significant hazards of low TCO2 concentration for 
progression to ESRD.
Conclusions: Metabolic acidosis was significantly associated with mortality, but not 
with progression to ESRD in this study using instrumental variable.
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Gitelman’s Syndrome in a Patient with C1q Nephropathy: A Case Report
Sagar Gupta, Sudip M. Patil, Dinesh Khullar. Nephrology, Max Super specialty 
Hospital, New Delhi, India.
Introduction: Coexistence of C1q Nephropathy (C1qN) and Bartter–Gitelman 
syndromes (BGS) is exceedingly rare.Few case reports of patients with BGS subsequently 
developing nephrotic range proteinuria secondary to C1qN or FSGS have been described. 
We present here a case diagnosed as C1qN who later developed electrolyte abnormalities 
consistent with Gitelman Syndrome.
Case Description: A 17 year-old male from a middle eastern country was being 
evaluated for nephrotic range proteinuria of 14gms/d. At age 3, he had a kidney biopsy 
performed showing FSGS. He was treated with steroids, cyclosporine, mycophenolate and 
cyclophosphamide in various combinations till age 10 and had attained complete remission. 
Repeat renal biopsy was performed. It showed 20 glomeruli, 1/20 sclerosed, 6 glomeruli 
showed increased mesangial matrix and hypercellularity. No significant IFTA. IF showed 
IgA2+, C1q3+, [IgG,IgM,C3, κ & λ chains – all 1+]. EM showed electron dense deposits 
in mesangial and paramesangial regions and focal foot processes effacement (40%). 
ANA, extractable nuclear antigen panel, C3 & C4 were unremarkable. Pt was started 
on MMF & prednisolone. Proteinuria gradually improved to less than 300mg/d and all 
immunosuppressants were stopped by end of 2 years. BP always remained normal and 
S. Crt was 0.6 mg/dl. One year later, he developed electrolyte abnormalities consistent
with BGS. He had recurrent severe hypokalemia with Sr. K as low as 1.3. Patient had 3
hospitalizations for severe weakness and inability to stand when S. potassium dropped
below 2.0. Hypomagnesaemia (Sr.Mg range 0.8-1.4 mg/dl), metabolic alkalosis (pH 7.50- 
7.65) with bicarb 32-37 mEq/L, hypochloremia (S.Cl 85-95 mEq/L), hyperuricemia and
hypercalcemia were also noted. Patient denied any intake of thiazide diuretics or herbal
medications. Pt declined genetic testing for BGS due to financial reasons. He is maintained 
on KCl supplementation 320mEq/d, magnesium orotate, aldactone and febuxostat.
Discussion: This case report decribes a unique case of C1qN subsequently developing 
electrolyte abnormalities consistent with BGS. It is unclear how immune complex related 
C1qN may predispose to development of renal tubulopathy like BGS or vice versa but 
the two are probably linked. Development of proteinuria in such patients should prompt 
clinicians to think about this rare but possible differential of co-existent C1qN/FSGS and 
renal tubulopathy-BGS.
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Is This Mutation Associated with Lactic Acidosis?
Siddhartha Kakani. Nephrology, University of Utah, Salt Lake City, UT.
Introduction: Herein, we report a case of recurrent symptomatic lactic acidosis in 
which genetic evaluation revealed a mutation associated with cardiac disease; but, hitherto, 
not lactic acidosis. Further studies to explore possible associations between this mutation 
and lactic acidosis are warranted.
Case Description: A 39 year old obese male with obstructive sleep apnea (OSA) 
& chronic hypoxia on oxygen presented with history of multiple hospitalizations (50 
in two years) for lactic acidosis. All episodes were associated with muscle weakness, 
fatigue and lactic acid levels of 6-10 mmol/L in the face of hemodynamic stability and 
a normal liver profile. Genetic evaluation revealed a normal acyl carnitine profile and no 
pathogenic variants of the PDH or Mitochondrial Respiratory Chain Complex. However, a 
heterozygous mutation of PRKAG2, a gene coding for subunit of AMP activated protein 
kinase (AMPK), was discovered. Supportive treatment, with emphasis on controlling 
factors that exacerbated the lactic acidosis, was provided.
Discussion: This patient had a heterozygous variant of PRKAG2- a gene that 
encodes the gamma-2 subunit of a heterotrimeric protein- AMP activated protein kinase 
(AMPK). AMPK is present in many tissues and functions as a “energy sensor” within cells. 
“Excessive energy expenditure” resulting in ATP breakdown with consequent increase 
in intracellular AMP activates AMPK. AMPK, in turn, downregulates energy expending 
processes like fatty acid oxidation. AMPK gene mutations are associated with hypertrophic 
cardiomyopathy and cardiac arrhythmias (like WPW syndrome). Given the role of AMPK 
in energy metabolism, it is conceivable that abnormalities of AMPK be associated with 
lactic acidosis. However, to our knowledge, no such association has yet been reported. It 
is pertinent to note that Metformin, a drug that increases hepatic AMPK activity, can cause 
lactic acidosis. It is possible that alterations in AMPK activity affect the intracellular energy 
balance and/or metabolism of lactate. This patient had chronic hypoxia, OSA and excessive 
caloric intake, all of which predisposed him to lactic acidosis. Although unproven, it is likely 
that a combination of predisposing clinical features and a genetic mutation such as this 
one resulted in lactic acidosis in this patient. There is no known treatment. Circumstances 
that facilitate lactic acid production like hypoxia, volume depletion & excessive glucose 
consumption should be avoided.
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Death Due to Refeeding Syndrome (RFS) Described in 1507 by Antonio 
Benivieni, the Father of Pathology and Narrative Medicine
Natale Gaspare De Santo,1 Rosa M. De santo,5 Carmela Bisaccia,3 
Malcolm E. Phillips,4 Luca S. De santo.2 1Nephrology, University of Campania 
“L. Vanvitelli”, Naples, Italy; 2University of Foggia, Naples, Italy; 3Mazzini 
Institute, Naples, Naples, Italy; 4Hon. Consultant Nephrologist, Charing Cross 
Hospital, London, Naples, Italy; 5School of Integrated Gestalt Therapy, Torre 
Annunziata, Naples, Italy.
Background: RFS, a disease presenting assevere electrolyte disturbance - low 
serum concentration of sodium, magnesium and phosphate-causing death due to cardiac 
arrhythmias, cardiac failure and pulmonary edema - was described in 1981by Roland L. 
Weinsier and Carlos L. Krumdieck,butit is rootedin a more distant past.
Methods: We aim to report heretofore unknown deathscaused by RFS described 
by Antonio Benivieni (1443-1502)inThe hidden and remarkable causes of diseases and 
recovery(Florence, 1507).The book narrated 111 clinical histories. For the first time 
diagnoses were disclosed by autopsy. Thus Benivieni became the Father of Pathology and 
his book - recently - recognized as the first example of Narrative Medicine (DeSanto RM, 
2018).
Results: Report no. LVII reads: “[In 1496] extensive famine affected nearly the 
whole Italy, that many died in the public roads and city streets. Many also through bad and 
injurious foods, were attacked by various disorders. I noticed too that very many of those 
who had, after long fasting, obtained more abundant food, enjoyed their fuller nourishment 
for a few days and then died, so harmful and dangerous is satiety preceded by a long period 
of abstinence. I also saw women who in this way did harm to the children at their breast, 
and so brought death upon their children and themselves. But very many who were reduced 
to the invalid state were, by the care and diligence of physicians, restored to their former 
health in the hospitals”.
Conclusions: Data illustrate (i) Death due starvation; (ii) Death due to ingestion 
of deteriorated/toxic foods(inevitable in times of famine being healthy food scarcely 
available); (iii) Death caused by excessive food ingestion after long lasting abstinence from 
food; (iiii) Death of breast fed children and of their starved mothers; (v) Healing of many 
diseased persons receiving hospital care. Deaths are similar to those caused byunrestricted 
feeding after starvation in Nazi camps, Japanese prisoners of war, Dutch Famine (1944-45), 
and Great Bengal Famine (1943) described by Nobel economist and philosopher Amartya 
Sen. For 507 years Benivieni’sweighty description of RFS was ignored.
PUB305 
Publication-Only 
Normal Fractional Excretion of Urate to Diagnose Reset Osmostat in 
Children
Michael L. Moritz.1,2 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, 
PA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA.
Introduction: Reset osmostat (RO) is a subtype of syndrome of inappropriate anti-
diuretic hormone secretion (SIADH) that is rare in child. RO is characterized by refractory 
hyponatremia despite variations in sodium and water intake with a retained ability to 
dilute urine in response to a water challege. It has been suggested that a normal fractional 
excretion of urate (FEUrate) (< 11%) can distinguish reset osmostat from the other subtypes 
of SIADH in adults, which have an elevated FEurate (>11%).
Case Description: Reported are three children with euvolemic hyponatremia that was 
refractory to fluid restriction and sodium supplementation (Table). Hypothyroidism and 
adrenal insufficiency were excluded. Patients 1 and 2 were profoundly developmentally 
delayed and with a seizure disorder treated with Depakote and Trileptal, respectively. 
Hyponatremia was of prolonged duration. Patient 3 had a rickettsial infection with transient 
hyponatremia that resolved with treatment of the infection. Traditional serum and urinary 
biochemistries varied widely between the patients, and not in keeping with classic SIADH 
(Table). Water loading tests were not performed due to the risk of worsening hyponatremia. 
FEUrates were normal at around 6% in all patients, helping to confirm a diagnosis of RO. 
A normal FEUrate is helpful in establishing a diagnosis of RO in children with SIADH.
Discussion: A normal FEUrate is helpful in establishing a diagnosis of RO is children 
with SIADH
Features if Reset Osmostat in Children
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1109
J Am Soc Nephrol 29: 2018 Publication-Only 
PUB306 
Publication-Only 
Syndrome of Inappropriate Anti-Diuretic Hormone (SIADH) Induced 
Just After Surgery for Non-Small Cell Lung Cancer
Masahiro Muto, Hitoshi Suzuki, Takashi Kobayashi, Masao Kihara, 
Yusuke Suzuki. Department of Nephrology, Juntendo University Faculty of 
Medicine, Tokyo, Japan.
Introduction: The syndrome of inappropriate secretion of antidiuretic hormone 
(SIADH) is a disorder of impaired water excretion caused by the inability to suppress 
secretion of antidiuretic hormone (ADH). It has been commonly associated with small cell 
carcinoma. However, the case with SIADH developed after pneumonectomy is rare and has 
different pathogenesis with paraneoplastic syndrome. We present a unique case of SIADH 
induced just after left upper lobectomy with hilar lymph node resection for non-small cell 
lung cancer (NSCLC). This case reviews possible alternative mechanism of SIADH in 
patients with NSCLC.
Case Description: 71-year-old woman was hospitalized in order to have a surgery for 
lung adenocarcinoma. Before three months of admission, the levels of carcinoembryonic 
antigen (CEA) increased (6.5ng/ml). Clinical examination resulted in the diagnosis as 
lung cancer (T2aN3M0, stage IIIB). After 2 days of left upper lobectomy, she exhibited 
disorientation. Although preoperative examinations indicated no electrolyte abnormalities, 
laboratory examinations revealed reduced serum sodium levels of 121mEq/L, increased 
sodium excretion (140mEq/L) with plasma hypoosmolarity (244mOsm/kg/H2O) and urine 
hyperosmolarity (427mOsm/kg/H2O). The levels of ADH remained more than detectivity 
despite hyponatremia. These data suggest that the hyponatremia in this case was caused by 
SIADH. She was treated with hypertonic saline infusion (NaCl 2%). After 3 days of initial 
treatment, the serum sodium concentration increased to 133mEq/L, and her disorientation 
was improved. Finally, the levels of ADH decreased undetectable on 9 days after the onset 
of SIADH. Hyponatremia did not recur without any therapy.
Discussion: There are possible alternative mechanisms of SIADH in this case. The 
surgical stress and aging have been shown to be a risk factor for the induction of SIADH. 
Another possibility is that decrease of left atrial pressure in response to reduction of 
pulmonary vascular residence stimulates volume receptors in the cardiopulmonary 
circulation resulting in the release of ADH. This case indicates the importance of considering 
SIADH as a possible complication in older patients undergoing lobectomy.
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Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in 
Healthy Chinese Subjects: Open-Label, Phase 1 Study
Tommy Cheung,1 Fang Sun,2 Yulin Qin,3 Mats Någård,3 Jenny Jonasson,4 
June Zhao.3 1Division of Clinical Pharmacology and Therapeutics, Department 
of Medicine, The University of Hong Kong, Hong Kong, China; 2Global 
Medicines Development, AstraZeneca, Shanghai, China; 3Global Medicines 
Development, AstraZeneca, Gaithersburg, MD; 4Global Medicines 
Development, AstraZeneca, Gothenburg, Sweden.
Background: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective 
potassium (K)-binder that exchanges Na and H for K. It has been shown to rapidly restore 
normokalemia in Caucasian patients with hyperkalemia. Here we report the effects of SZC 
on urine K and Na, serum K, and safety in healthy Chinese subjects.
Methods: This open-label, phase 1 study randomized 22 healthy adults (18–55y) at 
a single center in Hong Kong. To control dietary Na and K intake, a standardized diet of 
40 (±10%) mEq/d Na and 128(±10%) mEq/d K was given on Days 1–8. Oral SZC powder 
5 or 10 g (n=11 each) was administered as a suspension in water once daily on Days 5–8. 
Urine K and Na was assessed from the mean of two 24-h samples at baseline (Days 3+4) 
and during SZC treatment (Days 7+8). Fasting serum K was measured daily. The primary 
endpoint was mean change from baseline in urine K; secondary endpoints included changes 
from baseline in urine Na, serum K, and other serum electrolytes, and adverse events (AEs).
Results: Subjects (59% male; mean age 33.5y) had a mean baseline serum K of 
4.27 mmol/L. Urine and serum K significantly decreased from baseline with both SZC 
doses (Figure). Urine Na decreased; no clinically significant changes in other serum 
electrolytes, including Na, Ca, Mg, and PO4, were reported. Overall, 16 subjects reported 
mild AEs during the study and 10 subjects reported mild AEs during SZC treatment. The 
most common AEs during the treatment period were gastrointestinal disorders but none 
were judged drug related. None developed hypokalemia or edema; no deaths, serious AEs, 
or discontinuation due to AEs were reported.
Conclusions: Oral SZC 5 and 10 g once daily significantly reduced urine and serum K 
in healthy Chinese subjects, and was well tolerated.
Funding: Commercial Support - AstraZeneca
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A Rare Case: Vitamin D Related Inappropriate ADH Syndrome
Sara Yavuz. Nephrology, University of Yeditepe, Istanbul, Turkey.
Introduction: The most important renal activity of ADH is to increase the water 
permeability of the distal and the collecting tubule. This helps to protect from dehydration. 
Inappropriate ADH syndrome is an clinic syndrome which there is more ADH 
concentration versus any osmotic or volume stimulus that normally affects ADH secretion. 
Among etiologic causes small cell bronchogenic carcinoma, pancreas and duodenal 
adenocarcinoma, leukemia, lymphoma, thymoma, cerebral trauma and tumors, meningitis, 
encephalitis, pneumonia, tuberculosis, lung abscess are listed. Vitamin D deficiency is a 
rare, irrational but quit important cause. In this case, unusual to the treatment of SIADH, 
vitamin D replacement was sufficient and Tolvaptan was stopped and not needed anymore.
Case Description: A 52-year-old male patient was admitted to the ER department 
with nausea, weakness, and blurred consciousness. In his labrotory findings, there were 
not any pathologic finding except low serum sodium level (121 mEq/L). 3% NaCl 
treatment was started first because of his emergency situation. Due to lack of effective 
response, the treatment was switched to Tolvaptan. But his vitamin D level was low 
(25 OH-cholecalciferol = 10 nmol/L). On admission day, measured ADH level was 
10 pg/mL (N: 1-5 pg/mL), so etiology for inappropriate ADH syndrome was evaluated. 
No pathology was detected in endoscopy, colonoscopy, abdominal ultrasound examination 
and MRI. However, enlarged, 33x22 mm sized lymphadenopathies were detected in 
paratracheal, subcarinal region by CT scan. Mediastinoscopic lymph node biopsy was 
performed due to the suspicion malignancy because of very intense FDG absorption (SUV 
max: 11.20) But ancotic lymph node containing reactive changes was stated on pathology 
report. So the Vitamin D treatment with 300,000 units per month orally was started and 
tolvaptan treatment was stopped. 1 month after discharge, serum 25 OH-cholecalciferol 
level was 20 nmol/L and serum sodium level was 134 meq/L.
Discussion: Vitamin D deficiency is associated with musculoskeletal, cardiovascular 
and immunological disorders, malignancy and even with diabetes and hypertension. 
However, when we updated latest knowledges about vitamin D relation with hyponatremia, 
we obtained very limited information. In addition, this treatment was more cost effective 
and accesible than Tolvaptan. For these reasons, we would like to remind the vitamin D 
deficiency to the clinicians in case of hyponatremia.
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Heart Transplant Patient Presenting with Rare Cause of Hyponatremia 
After Carboplatin-Based Chemotherapy
Ravi K. Thimmisetty, Frank W. Braxton. Nephrology Associates, Cape 
Girardeau, MO.
Introduction: We are presenting a case of severe hyponatremia developed after 
carboplatin based chemotherapy requiring hypertonic saline and furosemide
Case Description: 81-year-old lady with h/o congenital heart disease s/p heart transplant 
1995, hypertension, stage IV metastatic small cell cancer admitted for severe hyponatremia 
after 3rdday of first cycle of carboplatin etoposide. Home medications include cyclosporine, 
levothyroxine, pantoprazole, amlodipine, carvedilol, prednisone, lisinopril, and furosemide 
as needed basis only. She was complaining of new onset nausea, anorexia, mild abdominal 
discomfort, worsening fatigue and edema. Admission vitals were temperature of 97.7 f, 
blood pressure of 118/73 mm Hg, heart rate of 76 bpm, respiratory rate of 16 per minute and 
saturating 97 percent on room air. Examination shows tenderness at right quadrant and 2 + 
edema. Admission laboratory results showed serum sodium 119 meq/l, potassium 5.4 meq/l, 
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chloride 86 meq/l, bicarbonate 15, BUN 58 mg/dl, creatinine 1.71 mg/dl, ionized calcium 
0.9 mmol/l, serum magnesium 1.4 mg/dl, white blood cells of 5.72 x 103 cells/ μL, Hemoglobin 
is 10.8 g/dl, Platelets 189 x 103 /L, total protein 5.3, albumin is 3.3 mgd/l. hyponatremia work 
up showed serum osmolarity 270 mosm/kg, TSH 6.9 IU/ml, random cortisol 4.5 μg/dL, serum 
uric acid 0.7 mg/dl, urine sodium <20 mmol/L, urine osmolarity 305 mosm/kg, random urine 
uric acid is 3 mg/dl, urine uric acid and creatinine ratio is 0.16 mg/mg, fractional excretion of 
Urea 26.7%, fractional excretion of uric acid is 16%. Antihypertensives were held and sodium 
polystyrene sulfonate was given on admission. Sodium was not improving after 1.4 liters of 
normal saline was given (119 > 120 > 119 meq/l). Immediately 2% hypertonic saline and 
furosemide was given. Within 36 hours, symptoms were resolved and patient was discharged in 
4 days with sodium of 135 and creatinine of 1.1 mg/dl
Discussion: Literature was limited with carboplatin associated hyponatremia. Although 
multifactorial, two most important differentials to distinguish were SIADH and salt wasting 
nephropathy as treatment varies. Our case illustrates the difficulty of diagnosing salt wasting 
nephropathy from carboplatin, but treatable.
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Lymphocytic Hypophysitis: A Challenge to Diagnose Postpartum
Mala Sachdeva,1 Nupur N. Uppal,2 Alia Hasan,1 Llene J. Miller.3 1Northwell Health, 
Great Neck, NY; 2Hofstra Northwell School of Medicine, Great Neck, NY; 3North 
Shore University Hospital, Great Neck, NY.
Introduction: Hypernatremia during pregnancy is not commonly encountered. 
Additionally, differentiating between transient diabetes insipidus of pregnancy from central 
or nephrogenic diabetes insipidus during pregnancy poses additional dilemma. Moreover, 
lymphocytic hypophysitis as an etiologic disorder contributing to the hypernatremia is rare. 
Here, we report a complex case of lymphocytic hypophysis diagnosed postpartum.
Case Description: A 32 year old, 37 weeks pregnant female underwent emergent cesarean 
section due to concerns for fetal compromise and acute fatty liver of pregnancy. Preoperative 
labs were notable for acute kidney injury (creatinine 3.3mg/dL), elevated liver enzymes (AST 
259 U/L, ALT 536 U/L, TB 5.1 mg/dL), significant coagulopathy, and hypoglycemia. Her 
presenting sodium was 141 mmol/L which progressively increased and peaked to 156 mmol/L 
post operatively with 5 to 7L urine output daily. Per patient, for approximately 1.5 weeks prior 
to presentation, she had been experiencing significant polyuria and polydipsia. Urine osmolality 
was 137 mosm/kg. At first, her hypernatremia was attributed to transient gestational diabetes 
insipidus associated with pregnancy amplified by acute fatty liver of pregnancy, however further 
workup changed the diagnosis to central diabetes insipidus secondary to hypophysitis due to 
ACTH <5pg/mL, A.M. cortisol 0.8 ug/dL, FSH 0.3IU/L, LH <0.1IU/L, TSH 0.28uL/mL, and 
FT4 0.6ng/dL. Furthermore, MRI of the brain revealed absence of the normal pituitary bright 
spot, and thickened pituitary stalk. She was started on prednisone, ddavp, and levothyroxine and 
did well. Six months postpartum her MRI brain revealed resolution of the thickened pituitary 
stalk, reappearance of the pituitary bright spot, as well as a smaller pituitary gland. She still 
remains on oral desmopressin as well as levothyroxine supplementation.
Discussion: Diagnosing lymphocytic hypophysitis in the postpartum period can be a 
challenge. Although rare, most cases occur in late pregnancy or in the postpartum period and 
one must keep this in the differential when evaluating a pregnant or postpartum woman with 
hypernatremia. Multidisciplinary team approach and expertise involving the endocrinologist, 
nephrologist, and obstetrician is important for quick diagnosis and for prompt treatment to avoid 
life threatening complications that could ensue.
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The Use of Serum Sodium–Chloride Difference in the Evaluation of 
Metabolic Acidosis in Hospitalized Patients
Kipyo Kim, Ho Jun Chin, Ki Young Na, Sejoong Kim. Seoul National University 
Bundang Hospital, Gyeonggi-do, Republic of Korea.
Background: Metabolic acidosis is generally defined by the presence of a low serum 
bicarbonate concentration. (It is hypothesized that metabolic acidosis would cause a 
compensatory decrease in the serum chloride (Cl) relative to sodium (Na) in order to preserve 
electroneutral balance.) Therefore, the purpose of our study was to investigate the use of Na-Cl 
difference or ratio as a bedside tool to evaluate the identifying metabolic acidosis in hospitalized 
patients as an alternative to measuring serum bicarbonate.
Methods: We retrospectively enrolled 17,320 adult patients who were admitted to 
the academic teaching hospital from January 2013 to December 2013. Serum Na, Cl, and 
bicarbonate were measured at admission and Na-Cl difference, Cl-Na ratio and corrected anion 
gap was calculated. Metabolic acidosis was defined as a bicarbonate below 23mEq/L.
Results: Metabolic acidosis occurred in 4488 (25.9%) of samples. Significant Spearman 
correlation coefficients were found between Na-Cl difference and corrected anion gap, and 
serum bicarbonate. Receiver operator characteristic curve showed that values revealing 
metabolic acidosis were less than 32.5 mEq/L for Na-Cl difference with sensitivities of 94.0% 
and specificity 90.0%. Additionaly, multivariate logistic regression analysis showed that Na-Cl 
difference levels at admission were independently associated with AKI and in-hospital mortality.
Conclusions: Na-Cl difference are simple and fast, and can be used as an alternative tool to 
identify metabolic acidosis in hospitalized patients.
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Edema Assessment of Dialysis Patients by Bioelectrical Impedance Analysis
Feixia Zhuo,2 Jing Zheng,1 Chen Chen,1 Liming You.1 1Sun Yat-Sen university, 
Guangzhou, China; 2The Fifth Affiliated Hospital of Sun Yat-sen Univeristy, Zhuhai, 
China.
Background: Bioelectrical impedance analysis (BIA) is useful for assessment of body fluid 
status but it is rarely used in Chinese haemodialysis (HD) patients. So it is the first time to 
discuss the validity of BIA in Chinese HD patients. The aim of this study was to describe fluid 
status and volume overload in maintenance hemodialysis (MHD) patients with edema index 
(EI) by means of the bioelectrical impedance analysis (BIA) and to explore the associating 
factors of edema index (EI) in MHD patients.
Methods: Cross-sectional study design was used and 193 MHD patients in a hemodialysis 
center in China were enrolled. Body components were measured by using the body component 
analyzer MC-180 after dialysis. EI were calculated by using the ratio of extracellular water 
(ECW) to total body water (TBW). Age, urine volume, Kt/V, ultrafiltration volume, and 
nutritional biomarkers (albumin, feritin and creatinine) were collected. Descriptive statistics and 
multivariate logistic regression analysis were used to analyze the associating factors of the EI.
Results: There were 118 males and 75 females, with an average age of 50.22 ± 12.55 
years and an average HD period of 60(3~216)months in this study. Sixty patients (69.77%) 
were indicated volume overload according to the standard of EI in neither diabetes nor 
hypoproteinemia group. Eighty-eight patients (92.63%) in diabetes or hypoproteinemia group 
and 12 patients (100%) in both diabetes and hypoproteinemia group were indicated volume 
overload respectively according to the EI in each group. Multivariable logistic regression 
analysis results were presented in figure 1.
Conclusions: The prevalence of volume overload is high in MHD patients especially in 
patients complicating with both diabetes and hypoproteinemia. Age, gender, dialysis age, Kt/v, 
muscle mass and body mass index are related with patients’ fluid status. Edema index (EI) 
appears to be an easy and useful marker for the estimation of fluid status and volume overload 
in MHD patients with various clinical backgrounds.
Funding: Other NIH Support - This study was supported by a grant from Guangdong 
Science & Technology Department, China (No. 2017ZC0028).
PUB313 
Publication-Only 
The Relationship Between Liver Cyst Volume and QOL in Japanese ADPKD 
Patients
Satoru Muto,1 Saori Nishio,6 Ichiei Narita,4 Toshio Mochizuki,5 Ken Tsuchiya,2 
Kazuhiko Tsuruya,3 Yoshifumi Ubara,7 Shigeo Horie.1 1Juntendo University, Tokyo, 
Japan; 2Tokyo Women’s Medical University, Shinjuku-ku, Japan; 3Nara Medical 
University, Kashihara, Japan; 4Niigata University, Niigata, Japan; 5Tokyo Woman’s 
Medical University, Tokyo, Japan; 6Hokkaido University, Sapporo, Japan; 
7Toranomon Hospital, Tokyo, Japan.
Background: To clear the relationship between the size of liver cysts and QOL in ADPKD 
patients, we started the prospective longitudinal study to clear the impact of liver cysts on QOL 
during 3 years.
Methods: This multi-institutional, prospective, observational study was supported in 
part by a Grant-in-Aid for Progressive Renal Diseases Research, from the Ministry of Health, 
Labour and Welfare of Japan. We divided the included ADPKD patients into 4 groups (group 
A; control group < 25 %, group B; 25-49 %, group C; 50-75 %, group D; >75 %) according to 
liver cysts-parenchyma ratio (CPR). QOL was measured by FANLTC + FACT-Hep additional 
concerns for assessing general health-related QOL and liver-specific QOL, respectively. We 
compared QOL scores between groups during 3 years.
Results: We included 111 patients in this study. There are no significant differences between 
groups in eGFR (p = 0.368) and CKD stage (p = 0.380). At the time of enrollment, the FANLTC 
score (p = 0.039) and the FACT-Hep scores (p < 0.001) were significantly inversely correlated 
with liver CPR. With respect to the change of QOL score during study period 3 years, the larger 
liver CPR, the significantly decreased FANLTC score during 3 years (p = 0.0011, Figure 1). The 
trend test showed that FACT-Hep score also decreased significantly as the liver CPR became 
larger (p = 0.0002, Figure 2).
Conclusions: In this cross-sectional report, we could clear the long-term influence of the 
liver cyst volume on QOL in ADPKD patients.
Funding: Government Support - Non-U.S.
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Progression of Renal Function and Total Kidney Volume in Japanese 
ADPKD Patients: An Analysis of Data from Japanese Polycystic Kidney 
Disease Registry (J-PKD)
Satoru Muto,1 Toshio Mochizuki,2 Ken Tsuchiya,3 Saori Nishio,4 
Kazushige Hanaoka,9 Yoshifumi Ubara,10 Kazuhiko Tsuruya,5 Eiji Ishimura,6 
Tadashi Sofue,8 Ichiei Narita,11 Shoichi Maruyama,7 Shigeo Horie.1 1Juntendo 
University, Tokyo, Japan; 2Tokyo Woman’s Medical University, Tokyo, Japan; 
3Tokyo Women’s Medical University, Shinjuku-ku, Japan; 4Hokkaido University, 
Sapporo, Japan; 5Nara Medical University, Kashihara, Japan; 6Meijibashi 
Hospital, Matsubara-shi, Japan; 7Nagoya University Graduate School of 
Medicine, Nagoya, Japan; 8Kagawa University, Kita-gun, Japan; 9The Jikei 
Daisan Hospital, The Jikei University School of Medicine, Komae, Tokyo, Japan; 
10Toranomon Hospital, Tokyo, Japan; 11Niigata University, Niigata, Japan.
Background: The PKD Sectional Committee of a Grant-in-Aid for Progressive Renal 
Diseases Research, from the Ministry of Health, Labour and Welfare of Japan started the 
web-based, and prospective registry system, the Japan PKD Registry (J-PKD) in 2009, to 
record clinical, and laboratory data about PKD in Japan. Follow-up period of five years has 
been completed in all cases. We will report the final data of J-PKD registry.
Methods: Patient data including age, gender, family history, complication, medical 
history, laboratory data, and clinical diagnoses were electronically recorded at each 
institution and registered on the J-KDR webpage via the Internet Data and Information 
Center for Medical Research system, which is part of the University Hospital Medical 
Information Network.
Results: We included 339 patients in this study (215 female and 124 male). Median 
age was 51.0 years. The mean eGFR was 50.4 ml/min/1.73m2 at the time of enrollment. 
The mean annual amount of eGFR change (ΔeGFR/Y) was -3.1 ml/min/1.73m2. There are 
no significant differences in ΔeGFR/Y between CKD stage (P = 0.3393). The mean total 
kidney volume (TKV) was 1683.6 ml at the time of enrollment. The mean annual amount 
of TKV change (ΔTKV/Y) was 92.1 ml. There are significant differences in ΔTKV/Y 
between CKD stage (P = 0.0041, Figure). ΔTKV/Y was significantly inversely correlated 
with ΔeGFR/Y (P < 0.001). In cases with TKV ≥ 750ml, the annual decline rate of eGFR 
in patients with the rate of TKV growth ≥ 5 % was significantly faster compared with the 
patients with the rate of TKV growth < 5 % (< 5 %: -3.21 ± 3.66 ml/min/1.73m2/Y, ≥ 5 %: 
-4.53 ± 4.26 ml/min/1.73m2/Y, p = 0.0383).
Conclusions: In this cohort study, we will clear the natural course of renal function and 
TKV in Japanese ADPKD patients.
Funding: Government Support - Non-U.S.
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Rapidly Progressive Kidney Dysfunction Due to Tubulointerstitial AL 
Amyloidosis with Concurrent Apolipoprotein A-I/A-IV Amyloidosis in a 
Case of Autosomal Dominant Polycystic Kidney Disease
Atsuko Uehara,2 Tomo Suzuki,2 Daisuke Ichikawa,2 Tsutomu Sakurada,3 
Akira Shimizu,1 Junki Koike,4 Yugo Shibagaki.2 1Nippion Medical School, 
Tokyo, Japan; 2St Marianna University Hospital, Kawasaki, Japan; 3St. 
Marianna University School of Medicine, Kawasaki, Japan; 4St.Marianna 
University, Kawasaki, Japan.
Introduction: AL or AHL amyloidosis usually cause paraprotein deposition mainly 
in glomerulus, whereas deposition of apolipoprotein A-I (ApoA1), and apolipoprotein 
A-IV (ApoA4) amyloidosis mainly occurs in renal tubulointerstitium (TI). Here, we
describe a rare case of autosomal dominant polycystic kidney disease (ADPKD) who
developed rapidly progressing non-proteinuric kidney disease which can be attributed to
AL amyloidosis with concurrent apolipoprotein A-I/A-IV amyloidoses.
Case Description: A 54-year-old man was referred to our hospital for chronic kidney 
disease (CKD) with a serum creatinine (sCr) of 1.26 mg/dL. With multiple kidney cysts, and 
family history, we diagnosed as ADPKD. However, his kidney function declined too rapidly 
for ADPKD with sCr of 2.57 mg/dL in 1 year. Since his serum free kappa light chains were 
markedly elevated, with increased kappa-to-lambda light chain ratio, he underwent open 
renal biopsy, which revealed massive amorphous deposits confined to the TI, which stained 
positive for Congo red, sparing the glomeruli. Immunofluorescence showed dominant 
staining of the kappa light chain deposits. Electron microscopy revealed randomly arrayed 
straight 8- to 10-nm-thick fibrils. Bone marrow biopsy revealed amyloid deposits, and he 
was diagnosed as primary AL amyloidosis and underwent autologous hematopoietic stem 
cell transplantation. Unfortunately, he died of sepsis. Subsequently, mass spectrometry 
analysis revealed that extensive amount of ApoA1 and ApoA4 were also present in TI as 
well as kappa light chains. Hence, we conclude that our case was concurrent AL, ApoA1 
and ApoA4 amyloidoses, with the latter being the main pathophysiology based on the mass 
spectrometry finding.
Discussion: Accurate diagnosis of amyloidosis is of paramount importance to avoid 
unnecessary treatment regimens. Even if renal biopsy suggests AL amyloidosis, mass 
spectrometry may unmask the complication of other type of amyloidosis, which can be 
useful to predict prognosis, and response to therapy. To our knowledge, this is the first 
report describing the case with ADPKD who suffered from several types of amyloidosis 
coexisting together.
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Continuously Evolving Phenotype of Fetal Presentation of HNF1B Gene 
Deletion
Roxana Cleper,1,2 Dana Shapira,1,2 Lewis Reisman,1 Danith D. Blumenthal,1,2 
Adi Reches,3,2 Shay Ben-Shachar.3,2 1Pediatric nephrology, Dana-Dwek 
Children’s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 2Sackler 
Medical School, Tel Aviv University, Tel Aviv, Tel Aviv, Israel; 3Genetic Institute, 
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Introduction: HNF1B mutations, consisting usually of heterozygous microdeletions 
(1.4-1.5KB) at 17q12 with variable penetrance dominant inheritance in 30-40%, are the 
most common genetic cause for fetal hyperechogenic kidneys(20-30% detection rate) and 
of isolated CAKUT(Congenital Anomalies of Kidneys and Urinary Tract)(5-30% mutation 
identification). The evolution of these renal abnormalities, their impact on renal function 
and appearance of extrarenal features is unpredictable.
Case Description: We present our center’s experience with 5 cases with HNF1B 
mutation: Presentation consisted of fetal hyperechogenic normal-/ enlarged kidneys in2/5, 
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Underline represents presenting author.
1112
J Am Soc Nephrol 29: 2018 Publication-Only 
polycystic small/enlarged kidneys in 2/5 and hypomagnesemia during seizures 1/5. 
Molecular diagnosis with HNF1B mutation detection was performed at: 34GW(gestation 
week) on amniocentesis 1/5, 2yrs- for polycystic kidneys 1/5, 2yrs- during evaluation for 
global develoopmental delay in 2/5, at 5.5yrs –for hypomagnesemia and seizures(this patient 
also had had hyperechogenic kidneys on fetal ultrasound with complete normalization at the 
age of 2yrs). TOP(termination of preganancy) was performed on the fetus diagnosed at 
34weeks on parental request. Complete normalization of kidneys’ hyperechogenicity by the 
ages of 2-3yrs in 3/4 living patients and normal GFR at 3-7yrs(despite intial Scr↑ during 
first 1.5-3mo) was seen in 4/4(inlcuding the patient with polycystic enlarged kidneys). 
Enterococcus UTI at 3.8yrs in the patient with persistently polycystic kdineys triggerred 
diagnosis of bilateral grade 3-4 VUR(vesicoureteral reflux) and bladder diverticles 
necessitating surgical intervention. Family history: maternal seizures and autistic-spectrum-
disorder- maternal aunt 1/5, MODY small-size normal functioning kidneys father 1/5.
Discussion: Spontaneous resolution of fetal hyperechogenic kidneys in patients with 
HNF1B mutation with complete normalization of initially slightly depressed renal function 
might occur. Persistent parenchymal cystic changes in patients with HNF1B mutations do 
not exclude normal renal function. HNF1B mutation- associated parenchymal cystic changes 
might coexist with urological malfomations exposing the patient to urinary infections with 
further kidney damage. Continuous pursuit for later-onset HNF1B-associated metabolic, 
neurodevelopmental abnormalities is recommended
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Preventive Strategy for ADPKD in the Southern Spain: Economic 
Evaluation
Rafael josé Esteban de la rosa,2,3 Jose luis Navarro_espigares,1 Margarita Martinez 
atienza,2,1 Elisa Hernandez-Torres,1 Irene Argüelles toledo,2,1 Juan antonio Bravo 
soto.1,2 on behalf of the Grupo de Estudio de la Enfermedad Poliquística 
Autosómica Dominante (GEEPAD) and Asociación Amigos del Riñón. 1Servicio 
Andaluz De Salud, Granada, Spain; 2Hospital Universitario Virgen de las 
Nieves, Granada, Spain; 3Instituto de Investigación Biosanitaria de Granada 
(ibs.GRANADA), Granada, Spain.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the 
hereditary kidney disease most frequently causes renal failure. Dialysis and transplantation 
are the therapeutic currently used. These renal replacement therapies (RRT) entail high 
health expenditures. Nowadays, there is still no curative treatment for ADPKD. We aim to 
analyse the cost-effectiveness of preventive strategy to stop ADPKD transmission based on 
assisted human reproduction such as preimplantation genetic testing (PGT) that includes “in 
vitro” fecundation (IVF) and intracytoplasmic sperm injection (ICSI).
Methods: A comparative analysis of the costs of IVF+ICSI+PGT versus RRT cost 
was carried out. The RRT cost was obtained from the specialised literature. The cost of the 
preventive strategy was calculated by adding the costs of an assisted reproduction procedure 
in a public hospital and the market price of the PGT in Spain. The average cost of a standard 
patient during the natural course of the disease has been calculated with patients’ records 
from the ADPKD registry of Granada (Spain).
Results: The average costs of transplantation (47,136 and 6,477 euros/year, first year 
and successive years respectively), haemodialysis (44,778 euros/year), and peritoneal 
dialysis (34,554 euros/year) are notably higher than costs of preventing the transmission 
of the disease (5,520-6,020 euros). An incremental cost-effectiveness ratio in favour of the 
preventative strategy was obtained in a scenario with three single embryo transfers.
Conclusions: From the perspective of the cost-effectiveness analysis, the preventive 
strategy proved to be a superior alternative to the RRTs currently applied. Thus, it would be 
advisable to promote the strategy of preventing transmission of this disease through assisted 
human reproduction and genetic testing. Despite the positive contribution of this strategy 
to the economic sustainability of the public health system, a decided health policy action 
in its favour is needed.
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Disease? Study in an Adolescent Population
Víctor Martínez jiménez. Grupo de Transición de Nefrología Del Hospital 
Virgen de La Arrixaca (Murcia, Spain) Hospital Universitario Virgen de la 
Arrixaca, El Palmar (Murcia), Spain.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a 
hereditary disease with progression to terminal Chronic Renal Disease, however the clinical 
findings begin in the 3rd decade of life: inability to concentrate urine, arterial hypertension 
and increased renal volume. There are few studies in children that analyze early markers of 
the disease. Objetive: to study and analyze the clinical characteristics in the initial phase of 
ADKPD in adolescents
Methods: -Adolescents of 12-22 years with a clinical or genetic diagnosis of ADPKD, 
followed in Nephrology or Pediatric consultations. -Analyzed variables: age, sex, mutation, 
glomerular filtration (CKD-EPI), urine osmolarity, proteinuria, hormones: Vasopressin, 
Aldosterone, Renin, Ambulatory blood pressure monitoring (ABPM):Dipper-No dipper 
pattern, kidney ultrasound:cysts and total renal volumen (TRV), health questionnaire
Results: -26 patients ADPKD: 43.5% men and 16.27±3.75 years. -46.2%PKD1, 
15.4%PKD2, 38.5%without study -CKD-EPI 133,12±19,21 ml / min, Urinary osmolarity 
650.8±278.08 -Cysts 12,58 ± 7,96 (0-28), TRV 343,47±129,46cc, TRV/height: 
201,28±71,58 -Only 1 with previous HTA and 15.4% with low sodium diet. 61.5%Dipper 
Pattern. 1,42 ± 0,39 l/d of water -Dipper Pattern relationed with levels of Aldosterone 
(229.46±112.73 vs 97±11.31, p 0.001) and Renin (7.28±3.72 vs 3.05±1.03, p 0.036), 
without influencing of Vasopressin -CKD-EPI was related to: TRV (p 0.001) and TRV/
height (p 0.009) -Vasopressin relationed with number of cysts (p 0.04), albuminuria (p = 
0.004), proteinuria (p = 0.015) and Aldosterone (p 0.022). -In PKD1 the TRV is higher than 
in PKD2 (460.08±149.45 vs 228.18±14.59)
Conclusions: -Alterations urinary concentration, hypertension and deterioration of 
renal function are not early findings in this population. However, they have hyperfiltration, 
more cysts and TRV, and elevation of the renin-aldosterone, but normal vasopressin. -In 
patients with hyperfiltration there was an increase in TRV and Vasopressin in relation 
to cysts, proteinuria and aldosterone, so could be initial markers of progression. -PKD1 
conditions higher TRV, but without alteration of the glomerular filtrate; so it would not 
be a bad prognostic factor in initial stages -We should explain to the patients general 
recommendations of drinking more water, low salt diet.
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CKD Patients with Autosomal Dominant Polycystic Kidney Disease or 
Other Inheritable Kidney Disease Have Distinct Characteristics and 
Higher Associated Healthcare Costs
Andrew J. Mallett,1,2 Marcin Sowa,4,3 Louise H. Wardrop,2 Jianzhen Zhang,3 
Anne Cameron (Salisbury),3 Helen G. Healy,1,3 Wendy E. Hoy.3 on behalf of the 
CKD.QLD consortium and the KidGen Collaborative 1Kidney Health Service, 
Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 2The KidGen 
Collaborative, Australian Genomics Health Alliance, Melbourne, VIC, 
Australia; 3CKD.QLD and the NHMRC CKD.CRE, The University of 
Queensland, Brisbane, QLD, Australia; 4Centre for the Business and Economics 
of Health, The University of Queensland, Brisbane, QLD, Australia.
Background: Those with Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
and Inherited Kidney Disease (IKD) are an identifiable minority of chronic kidney disease 
(CKD) patients. Their health service utilisation (HSU) in Australia is not defined. We aimed 
to identify characteristics and HSU amongst patients with CKD due to ADPKD, non-
ADPKD Inherited Kidney Disease (IKD) and all-CKD causes in Queensland.
Methods: Patients with ADPKD and IKD were identified from the CKD.QLD Registry 
(n=7,311) and a regionally matched Queensland Health CKD cohort (n=21,773) based upon 
ICD-10 coding. Characteristics and HSU related to hospital presentations were analysed for 
5years retrospective from June 2016 with dialysis admissions/appointments and admissions 
for reasons other than dialysis analysed separately.
Results: 309 (1.06%) ADPKD and 277 (0.95%) IKD patients were identified from 
the combined cohort (n=29,084). The median age at first admission of PKD, IKD and All-
CKD patients were 53.7, 47.9 and 65.7years respectfully with mean eGFR at CKD.QLD 
consent being 34.1, 36.5 and 40.8ml/min/1.73m2. PKD and IKD compared to All-CKD 
had lower frequency of diabetes (17% vs 21% vs 48%) and cardiovascular disease (CVD; 
34% vs 32% vs 46%), but similar frequency of hypertension (79%vs80%vs81%) and mean 
body mass index (29.8 vs 29.2 vs 31.2). PKD and IKD were also associated with a higher 
incidence of dialysis than the All-CKD group within that 5year period (34% vs 24% vs 9%). 
Median hospital admissions for reasons other than dialysis were higher in those with PKD 
and IKD compared to All-CKD (7 vs 8 vs 4) with similar average length of stay (3.2 vs 4.4 
vs 3.6days) per admission. Median 5year healthcare costs, excluding dialysis admissions/
costs, were also higher in those with PKD and IKD compared to All-CKD ($42,088 vs 
$45,929 vs $16,403).
Conclusions: Those with PKD and IKD are younger, with earlier stage CKD and lower 
prevalence of diabetes and CVD compared to other CKD patients. Despite this, they are 
more likely to require dialysis within 5years and have increased hospital costs.
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Can Trehalose Intake Affect the Progression of Polycystic Kidney 
Diseases? Insight from a Murine Experimental Study
Li-Fang Chou,1 Ya-Lien Cheng,1 Ya-chung Tian,1 Yung-Chang Chen,2 Chih-
Wei Yang,1 Ming-Yang Chang.1 1Kidney Research Center, Chang Gung 
Memorial Hospital, Taoyuan, Taiwan; 2Chang Gung Memorial Hospital, 
Keelung branch, Keelung, Taiwan.
Background: Autophagy impairment has been recently proposed to play a central role 
in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). Trehalose 
is a natural, non-reducing disaccharide that has been shown to enhance autophagy in vitro. 
In this study, we explored whether trehalose treatment protects the kidney against cyst 
formation in a Pkd1-hypomorphic mouse model.
Methods: Pkd1 miRNA transgenic (Pkd1 miR TG) mice were given 2% trehalose for 
drinking from day 35 for eight weeks. The control groups were fed with 2% sucrose or 
pure water. We then compared the body weights, the relative weights of the the kidneys, 
the histological cystic indices, and the renal function of mice receiving different treatments. 
Autophagy activation was investigated by RT-PCR analysis for the expression of autophagy-
related genes atg5, atg12, and beclin1 in the whole-kidney lysates, and western blotting was 
performed for the detection of LC3-I to LC3-II conversion.
Results: The results showed that Pkd1 miR TG mice have a lower mRNA expression 
of autophagy-related genes compared to wild-type control mice, but the differences were 
not reversed after trehalose treatment. Trehalose also did not significantly affect the kidney 
weights, cystic indices, fibrosis scores and proliferative indices. The serm levels of glucose, 
blood urea nitrogen, and cystatin C were not significantly different between treatment and 
control groups.
Conclusions: These findings suggest that trehalose treatment alone does not seem to 
have a significant impact on the progression of polycystic kidney disease.
Funding: Government Support - Non-U.S.
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Relationship Between Dietary Sodium and Protein Intake with Serum 
Copeptin in Autosomal Dominant Polycystic Kidney Disease
Jennifer Zhang,1,2 Carly Mannix,1,2 Anna M. Rangan,3 Annette Wong,1,2 
Gopi Rangan.1,2 PREVENT-ADPKD Investigators 1Centre for Transplant and 
Renal Research, Westmead Institute for Medical Research, The University of 
Sydney, Sydney, NSW, Australia; 2Department of Renal Medicine, Westmead 
Hospital, Sydney, NSW, Australia; 3School of Life and Environmental Sciences, 
The University of Sydney, Sydney, NSW, Australia.
Background: Elevated levels of arginine vasopressin (AVP) are hypothesised to 
worsen the renal progression of autosomal dominant polycystic kidney disease (ADPKD). 
In addition to fluid intake, dietary solute intake can also influence AVP release. However, 
this association has not been specifically investigated in ADPKD. This aim of this study 
was to determine the relationship between dietary sodium and protein intakes with serum 
copeptin (a marker of AVP) in patients with early-stage ADPKD.
Methods: Patients with ADPKD (18-65 years, eGFR≥30 mL/min/1.73m2) underwent 
a structured diet history interview to assess usual intake over the past 3 months during the 
Baseline Visit of the PREVENT-ADPKD study. Sodium and urea excretion were measured 
from 24hr urine collections to validate diet history-reported sodium and protein intakes, 
respectively. Serum copeptin was measured by a sandwich immunoassay (B.R.A.H.M.S).
Results: Sixty-nine participants (37 male, age 43±11 yrs, serum creatinine 
97±36 μmol/L; mean±SD) were analysed, with a subset of 29 undertaking dietary 
assessment. When compared to 24hr urine urea excretion, the diet history was a valid 
method for estimating dietary protein, as reported intakes demonstrated a strong correlation 
with urine-derived estimates (r=0.658; P<0.001), and there was no evidence of systematic 
bias by the Bland-Altman method. The median serum copeptin concentration was 5.01 
(IQR: 8.41) pmol/L. Multivariate analyses (adjusted for age, gender, 24hr urine volume and 
serum creatinine) revealed that serum copeptin was positively correlated with 24hr urine 
sodium (B=0.444; P=0.010) (the gold-standard for dietary sodium intake), but not with 24hr 
urine urea (B=0.663, P=0.197). No association was found between serum copeptin and diet 
history-reported sodium or protein intake.
Conclusions: These cross-sectional, observational data support the hypothesis that 
higher dietary sodium (but not protein) intake stimulates AVP release in ADPKD. The 
ongoing PREVENT-ADPKD study will determine the combined long-term effects of 
adequate hydration with lowering dietary solute intake on serum copeptin and renal cyst 
growth in ADPKD.
Funding: Commercial Support - Danone Nutricia Research, Private Foundation 
Support, Government Support - Non-U.S.
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Current Patterns of Practice of Autosomal Dominant Polycystic Kidney 
Disease in BC
Tae won Yi,1 Mark Canney,1 Adeera Levin,2 Micheli U. Bevilacqua.1 
1Department of Nephrology, University of British Columbia, Vancouver, BC, 
Canada; 2St. Paul’s Hospital and University of British Columbia, Vancouver, 
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Background: ADPKD is the most common inherited kidney disorder occurring in 1 
of 400 to 1000 live births. Recently, novel biomarkers have shown promise in the literature 
for prediction of early disease progression such as total kidney volume (TKV). Landmark 
clinical trials have demonstrated the benefits of aggressive blood pressure (BP) control and 
specific medications such as Tolvaptan have been shown to slow disease progression. It is 
largely unknown if these recent breakthroughs have found their way into clinical practice. 
We sought to take a snapshot of ‘real world’ contemporary management of ADPKD, 
specifically assessing whether recent evidence is being incorporated into clinical practice.
Methods: This was a convenience sample of 54 patients under the care of 6 different 
nephrologists in 2 health authorities in British Columbia. For each patient, the dictated 
letter from the most recent out-patient clinical encounter was analyzed. All letters were 
assessed for the following quality indicators: documentation of date of renal imaging and 
plan for follow-up imaging, recording of TKV, consideration for Tolvaptan, BP, urine 
albumin:creatinine ratio (uACR), and frequency of follow-up visits.
Results: Mean (SD) age of the cohort was 51.2 (15.6) years and 48% were male. 
Median (IQR) eGFR was 66 (45-95) mL/min per 1.73m2. The majority of patients (61%) 
had no documentation of renal imaging, and no patient had a measurement of TKV 
recorded. Two patients were receiving Tolvaptan and uACR was captured in 72% of 
cases. All patients had their medications listed and 65% were receiving antihypertensive 
therapy. The median BP was 123/80mmHg. The median follow-up time for patients with 
eGFR <60mL/min per 1.73m2 was 6 months, compared to 11 months for patients with 
eGFR ≥60 mL/min per 1.73m2.
Conclusions: Although these dictations were analyzed only at one point in time, 
the observed variability in care emphasizes the need for improved strategies to translate 
evidence-based interventions into clinical practice. This may include standardized care 
pathways for clinicians as well as strategies to maximize data capture such as an ADPKD 
registry.
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Kevin J. Fowler.7 The EMPOWER PKD team 1University of Kansas, Kansas 
City, KS; 2University of Kansas Medical Center, Kansas City, KS; 3Tufts Medical 
Center, Boston, MA; 4The University of Sydney, Seven Hills, NSW, Australia; 
5University of Missouri-Kansas City, Kansas City, MO; 6PKD Foundation, 
Kansas City, MO; 7Kidney Health Initiative, Elmhurst, IL.
Background: The Establishing Meaningful Patient-centered Outcomes With 
Relevance for patients with Polycystic Kidney Disease (EMPOWER PKD) initiative aims 
to engage PKD stakeholders and patients to learn about health priorities, insurance issues, 
and patient engagement.
Methods: We developed and pre-tested a guide to conduct semi-structured focus 
groups. Participants discussed impact of PKD on daily living and identified and ranked 
outcomes in PKD using a nominal, multi-vote technique. Other focus group topics included 
insurability and factors that influence a patient’s active engagement with PKD. We 
conducted thematic analyses using Grounded Theory.
Results: Of 57 participants, 82% were PKD patients and 13% were caregivers. Mean 
age was 53 (range 19-80) years with 52% female. Participants included 91% white, 4% 
African American, 4% American Indian, and 2% Latino. Six focus groups yielded 70 
outcomes classified into six categories: kidney health, lifestyle, comorbidities, psychological 
impact, family and awareness, and mortality. The highest ranked outcome was slowing the 
progression/symptoms of PKD followed by keeping kidneys healthy, and diet. Qualitative 
analysis identified six over-arching themes for the impact of PKD including: decision-
making, daily impact, psychological impact, testing dilemmas, healthcare related issues, 
and family. Variability in patient engagement and misconceptions about the disease were 
common. While psychological impacts were not ranked highly as target outcomes in 
clinical studies this was a leading theme of discussions during the focus groups.
Conclusions: Patients with PKD and their families are unique. While early diagnosis 
and detection is an important focus for research in kidney disease in general, the effects 
of “labelling” with PKD on insurability decision is a main factor that hinder patients’ 
active participation in care and research. With a treatment now approved for use in the 
US, it is important to be aware that patients’ views and values have pivotal effects on care. 
Additional exploration should consider psychological impacts of disease, expanded race/
ethnicity representation and consideration of socioeconomic differences. Additionally, 
perspectives in the context of newly available treatments should be assessed with a focus 
on how to activate PKD patients who are otherwise not engaged in their care or research.
Funding: Other U.S. Government Support
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Background: Studies for Autosomal Dominate Polycystic Kidney Disease (ADPKD) 
tend to have a wide variability in outcome measures. In this review we aim to identify 
different outcomes reported in ADPKD studies including composite outcomes.
Methods: We conducted a systematic review of published studies that included 
ADPKD patients as the main population or a main subgroup and measured renal outcomes. 
We searched the Cochrane Central Register (CENTRAL), OVID MEDLINE, EMBASE 
and Pubmed (from inception to December 2017). Our review included all studies regardless 
of design with ten or more participants. We excluded studies that only reported dialysis or 
transplant outcomes in ADPKD patients. We abstracted data in duplicate.
Results: We identified 391 records through database and grey literature searches. We 
included 146 records for full text screening and 87 published papers for data abstraction. 
Of these, we found 13 articles that reported composite outcomes. There is considerable 
inconsistency in the outcomes reported and how they are measured. We identified six 
different composite outcomes reported in these articles. These composite included: 1. 20% 
increase in Height adjusted Total Kidney Volume (HtTKV), Left ventricular mass index 
and Urinary albumin excretion, 2. time to 50% reduction of baseline estimated Glomerular 
Filtration Rate (GFR), end stage renal disease, or death, 3. Time to investigator-reported 
multiple ADPKD clinical progression events (e.g. onset or progression of hypertension, 
need for hypertensive treatment), severe kidney pain (requiring medical intervention), 
worsening albuminuria (by category), or 33% increase in serum creatinine (SCr), 4. onset/
worsening of HTN, renal pain, proteinuria, 25% change from baseline renal function in 
reciprocal SCr levels, 5. doubling SCr, 50% reduction in GFR or need for renal replacement 
therapy, 6. 50% reduction in GFR, doubling of SCr, or initiation of dialysis, renal 
transplantation, or death.
Conclusions: There is a need to standardize outcomes in ADPKD studies. There is 
also a need for guidance about the appropriate components of composite outcomes in 
ADPKD studies. This will help comparison of results across studies especially if individual 
components are well defined.
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Epidemiology of Autosomal Dominant Polycystic Liver Disease (ADPLD) 
in Olmsted County
Tatsuya Suwabe,1 Alanna Chamberlain,1 Emilie Cornec-Le Gall,2,1 
Jill M. Killian,1 Peter C. Harris,1 Vicente E. Torres.1 1Mayo Clinic, Rochester, 
MN; 2Centre Hospitalier Universitaire de Brest, BREST, France.
Background: The incidence and prevalence of ADPLD are not known.
Methods: Mayo Clinic and Olmsted Medical Center (OMC) deliver most health care 
to Olmsted County residents. We searched diagnostic codes and the Mayo Clinic and OMC 
radiology databases to identify subjects and all medical records were reviewed to validate 
ADPKD diagnoses using the following criteria. A diagnosis of definite ADPLD was based 
on accepted radiographic findings plus a family history of ADPLD or genetic testing results; 
likely ADPLD, based on ≥20 liver cysts for any age; possible ADPLD, based on 5-19 liver 
cysts for any age; in all cases with no or only few kidney cysts. Incidence rates of ADPKD 
for the time period of 1980-2016 were calculated; point prevalences for the year 2010 were 
also calculated.
Results: We reviewed medical charts and abdominal images and/or radiology reports of 
1,231 subjects with diagnostic codes of cystic liver during 1980-2016, and the medical charts 
and abdominal CT or MR scans of 2,765 subjects with multiple liver cysts from radiology 
databases during 1997-2016. In total, 134 patients with incident ADPLD (0 definite, 35 
likely, 99 possible ADPLD) were identified during 1980-2016. Only 8 patients among 35 
likely ADPLD and no patients with possible ADPLD had symptomatic hepatomegaly (total 
liver volume ≥ 2000 ml). Overall age- and sex-adjusted annual incidence rate of likely 
ADPLD was 1.01 (95%CI: 0.67 to 1.35) and that of likely or possible ADPLD was 4.01 per 
100,000 person-years (3.32 to 4.69). The annual incidence rates of likely ADPLD increased 
gradually over time and those of possible ADPLD have increased markedly since 1997 
when CT and MR scans became available electronically. Annual incidence rates of ADPLD 
were not different between females and males. On January 1, 2010, the overall age- and 
sex-adjusted prevalence of likely or possible ADPLD was 36.0 (25.3 to 46.6) and that for 
likely ADPLD alone was 9.5 (4.1 to 14.9) per 100,000 population.
Conclusions: The incidence rate of ADPLD with symptomatic hepatomegaly was 
very low. Incidence rates of likely or possible ADPLD have increased over time, possibly 
because milder cases of ADPLD have been increasingly detected with more frequent and 
better radiology imaging. Incidence and prevalence of ADPLD including mild cases of 
ADPLD may have been underestimated.
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Genetic Studies of Nephropathies with a Public Grant Funding in a 
Developing Country: A 3-Year Experience in an Academic Unit
Paola Krall, Claudio A. Flores, Leopoldo G. Ardiles, Sergio A. Mezzano. 
Universidad Austral de Chile, Valdivia, Chile.
Background: Implementation of genetic tests has diverse ongoing challenges that are 
even greater in developing countries. Since the human genome was published, many genes 
have been discovered by Sanger sequencing (SS) in association with diseases. Actually, 
next-generation sequencing (NGS) technology is displacing SS, but although costs have 
decreased, they remain high for developing countries and any NGS derived-variant should 
be validated by SS. Here we describe the 3-yr experience in the Nephrology Unit at a 
Chilean university that received a US$140.000 as a public grant to perform genetic studies 
of particular nephropathies.
Methods: Tests were implemented for 17 genes by SS technology (PKD1, PKD2, 
PKHD1, NPHS2, NPHS1, WT1, INF2, ACTN4, TRPC6, APOL1, WNK4, KANK1, 
ARHGEF17, CTNS) or NGS technology (COL4A3, COL4A4, COL4A5), associated with 
autosomal dominant and recessive polycystic kidney disease (ADPKD/ARPKD), steroid-
resistant nephrotic syndrome (SRNS), focal and segmental glomerulosclerosis (FSGS), 
Alport syndrome (AS), Wilms tumor (WT) and nephropathic cystinosis (NC). The study 
was approved by the local Ethics Committees of Health Service and university to be offered 
to 120 cases with one of the diseases with a proven clinical utility.
Results: Until date, a genetic defect has been identified in 20/41 ADPKD, 1/1 ARPKD, 
21/56 SRNS-FSGS, 7/17 AS, 2/4 WT1 and 1/1 NC cases, reaching a 43% (52/120) detection 
rate. In 92% (48/52) of these cases, the defect was located in a causative gene, mainly 
PKD1 and NPHS2, and at least one clinical utility was proposed, in terms of diagnosis, 
prognosis, management, genetic counseling or transplantation. The major challenges were 
genetic heterogeneity (SRNS-FSGS), sporadic unavailability of long-range PCR reactives 
(ADPKD) and elevated costs of NGS technology (AS).
Conclusions: We consider this experience valuable to design an NGS strategy targeting 
the almost 50 genes associated with the diseases of interest and consider the genetically 
resolved/unresolved cases as a validation/discovery cohorts, respectively. Nephrologists in 
Chile are aware of the utility of genetic tests and more efforts need to be done in order to 
make NGS more accessible and affordable or to be able to establish local cost-effective 
genetic test algorithms, in benefit of the patients and their families.
Funding: Government Support - Non-U.S.
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Background: Economic evaluation of treatment in PCKD focuses on cost associated 
with ESKD. Considerable costs arise pre ESKD. We conducted the following retrospective 
study to define the clinical characteristics and main pre ESKD cost drivers of prevalent 
patients with ESKD as a result of PCKD at a single Irish University Hospital.
Methods: The medical record of all prevalent ESKD patients with PCKD was 
retrospectively reviewed to first referral. Prior ESKD followup was divided into 6 month 
bins and outpatient laboratory tests and clinical data closest to these was abstracted. eGFR 
was calculated using the MDRD formula.
Results: Of the 51 patients identified, 30 (59%) were female; the mean (sd) age was 56 
(12) yrs. 33 (65%) had a reported family history of PCKD. Patients had first attended the 
renal outpatients a median (IQR) of 6 (3-11) yrs prior to developing ESKD and were treated 
for ESKD for a median (IQR) of 6 (3-12) yrs. 40 (78%) underwent renal transplantation,
with a median (IQR) interval of 1 (0-3) yrs from the development of ESKD. During OPD 
follow up prior to commencing renal replacement therapy, the median (IQR) eGFR declined 
from 37.0 (26.5, 57.2) to 7.3 (5.1, 9.3) ml/min per 1.73m2. The median (IQR) individualized
rate of loss in eGFR pre ESKD was 4.7 (3.4, 6.0) ml/min per 1.73 m2. 3 subjects had a rate
of loss of eGFR of 10ml/min per 1.73m2 per year or greater. The median (IQR) number of
prescribed antihypertensive agents rose from 1 (0,2) to 2 (1,3) over per ESKD follow-up.
At initial OPD visit the proportion of patients treated with an ACE inhibitor/ARB, Beta
blocker or Calcium channel blocker were 30%, 20% and 24% respectively and pre dialysis 
was 61%, 31% and 55% respectively. At initial and end of pre ESKD OPD follow-up 28% 
and 23% reported persistent renal pain. 31 patients (61%) were treated with erythropoietin 
prior to developing ESKD, 20 for 1 year or less, 3 for 2 years and 8 for 3 or more years.
13 (26%) were treated pre ESKD with calcium free phosphate binder. Over follow-up 10
(20%)required a nephrectomy.
Conclusions: Patients with PCKD have substantial utilization of costly treatments pre-
ESKD (erythopoetin, calcium free phosphate binders, nephrectomy). These costs and their 
minimization will substantially influence the relative cost effectiveness of primary therapy 
in PCKD.
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Introduction: APOL1 G1 risk allele is common among the African population since 
they confer resistance to Trypansoma brucei. Two G1 alleles are associated with kidney 
disease with focal and segmental glomerulosclerosis (FSGS). APOL1 G1 allele is unevenly 
distributed and is very frequent in the African (American) population, but is considered 
very rare (<0.6%) in other populations. The genetic basis of FSGS Chilean patients has 
been associated mainly with NPHS2. Since 2014 Chile is experiencing an unprecedented 
20-fold increase of Haitian immigrants, looking for better life quality. Haitians have 92%
median African ancestry and the role of APOL1 G1 allele in this population has been barely
investigated. Here we describe 3 cases residing in Southern Chile who had proteinuria and 
resulted to be carriers of the G1 allele.
Case Description: Patient #1: 27yrs old man (APOL1 G1/G1) debuted with 
nephrotic syndrome when he was 20yrs. His renal biopsy was compatible with FSGS. He 
was unresponsive to prednisone and cyclosporine A and progressed to ESRD requiring 
hemodialysis. His younger sister presented hypertension, an FSGS-compatible biopsy and 
analysis confirmed the same genotype. Patient #2: 17yrs old man (APOL1 G1/G0) who 
had been nephrectomized as a newborn, debuted with nausea and vomits when he was 
16yrs. His exams revealed an important persistent proteinuria and biopsy was compatible 
with FSGS. Patient #3: 30yrs old Haitian woman (APOL1 G1/G0) with a 28-wks old 
pregnancy was admitted at Hospital with moderate hypertension and proteinuria. Given 
that intrauterine growth restriction was observed, childbirth was induced with an extremely 
low birth weight (<1000gr).
Discussion: Chilean population has a 3% African ancestry that decreases from North 
to South, related to the historical Spanish conquest slavery. We confirmed two Chilean 
patients carrying the APOL1 G1 allele and a third case of a Haitian pregnant woman, who 
developed kidney disease as adults. To our knowledge, these are the first cases in Chile, but 
studies with a more representative cohort are required. The clinical value of APOL1 risk 
alleles in kidney disease is still uncertain and second hits remain unknown. More evidence 
is needed before considering the APOL1 status as an input to define a therapeutic option. 
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NPHS2 Gene Mutations and Nephrotic Syndrome in Children and Adults 
in Kuwait
Salah K. Al-Waheeb,1 Ahmad Al-Serri,2 Ahmed A. Abou shall,4 Effat A. Tony.3 
1Pathology, Kuwait University, Jabriyah, Kuwait; 2Kuwait university, Jabriya, 
Kuwait; 3Internal Medicine, Assuit University, Assuit, Egypt; 4Ministry of health 
- state of Kuwait, Kuwait, Kuwait.
Background: Genetic testing in nephrotic syndrome (NS) has implications for clinical 
course, treatment response, risk for post-transplant proteinuria and prenatal diagnosis. The 
commonly studied rs61747728 NPHS2 gene polymorphism also known as p.R229Q has
been reported to be associated with NS. Others failed to report an association, probably due 
to population differences. Genetics of NS havenot been studied in this part of the globe. We 
decided to start this journey by investigating the prevalence of the p.R229Q variant.
Methods: Inclusion criteria were: 1. Proteinuria (>3 g/24hrs) in children and >1g/24hrs
in adults 2. Biopsy diagnosis of MCD or FSGS 3. No secondary causes of FSGS at the
time of diagnosis. 2-5ml of blood were collected from patients. DNA was extracted
following standard protocols. Genotyping was performed by Real-time TaqMan Allelic
Discrimination Assay (Life technologies, CA, USA).
Results: A total of 51 patients and 4 controls were studied. 19/51 females and 32/52
males. 13/51 were Kuwaiti and the rest from diverse nationalities. 20/51 were > 40 years
of age and 31/51 were < 40. 7/51 were < 20. 5/51 patients were heterozygotes for the
R229Q gene polymorphism(9.8 %), with a broad age range 15-64. All were females from 3 
different nationalities one of whom was Kuwaiti, 15 years of age. 3 had a tissue diagnosis 
of MCD and 2 were labelled as FSGS. 3 patients improved with steroids and continue
to show stable renal function, whilst 2 showed no improvement with steroids or other
immunosuppresants and continue to have a rise in serum creatinine. None are on dialysis or
have a family history of kidney disease.
Conclusions: The data presented is the first attempt at studying genetic associations
of NS in Kuwait. Mutations in NPHS2 in our population account for 9.8% of all our cases, 
similar to results reported by other groups. Although our sample is comparatively small, the 
plan is to obtain a total of 100-150 DNA samples by the end of 2018 and study mutations 
of other genes associated with NS eg INF2, WT-1 etc.. to uncover the genetic susceptibility 
in our population. Furthermore, we will attempt to sequence these genes to find out if 
susceptibility loci are similar to other authors. Ultimately we will perform whole exome
sequencing to uncover other genes that might be unique to our population.
Funding: Government Support - Non-U.S.
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Background: Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a 
group of conditions characterized by autosomal dominant inheritance, pathologic changes 
of tubular and interstitial fibrosis, and progressive renal failure. Uromodulin (UMOD) is 
known as one of the causes of ADTKD (ADKTD-UMOD) that is also known as juvenile 
hyperuricemia. Precise diagnosis is difficult without genetic testing.
Methods: We previously developed a comprehensive genetic testing panel using next 
generation sequencing (NGS) covering 166 genes responsible for vast majority of inherited 
kidney diseases. Ten families suspected of ADTKD were genetically screened with the 
panel. Clinical and laboratory data were collected and analyzed.
Results: We identified causal mutations in UMOD in four ADTKD families (40%), 
and excluded simultaneously other candidate genes for ADTKD such as MUC1, REN, and 
HNF1B. One male and 3 females were included in the four probands (n=4). Age (±SD) at 
diagnosis was 33.7 (±10.3), and 2 had end-stage renal disease (ESRD). Mean serum urate 
concentration was 5.42 mg/dl (±1.08). The detail of the detected heterozygous mutations in 
UMOD were C41G, D59Y, C135Y, and C306S, which include two novel mutations (C41G 
and D59Y).
Conclusions: Four ADTKD-UMOD families including two with novel mutations were 
detected. We guess a great deal of ADTKD-UMOD cases may be overlooked or misjudged 
as nephrosclerosis or other kidney diseases because genetic testing on ADTKD is not 
necessarily conducted. Autosomal inheritance reminds us larger prevalence of ADTKD-
UMOD. When we face to cases with familial renal failure with less abnormalities of urine 
tests, ADTKD should be considered.
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Alport Spectrum Disorders in Croatia – Preliminary Results of First 
Genetic Testing in Croatia
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Background: Alport syndrome (AS) and thin glomerular basement nephropathy 
(TBMN) are part of phenotypic and genotypic spectrum of COL4A3, COL4A4 and COL4A5 
mutation disorders. Until beginning of our project “Genotype-Phenotype correlation in 
Alport’s syndrome and Thin Glomerular Basement Membrane Nephropathy”, founded by 
Croatian Science Foundation, genetic testing for Alport spectrum disorders (ASD) was not 
performed in Croatia and diagnosis of ASD relied solely on kidney biopsy analysis. Here we 
present preliminary results of first Croatian systematic genetic testing of ASD.
Methods: We are conducting multidisciplinary, nationwide, collaborative research in 
seven leading Croatian nephrology, pediatric nephrology and nephropathology institutions. 
We are collecting clinical data, about both renal and extra-renal symptoms, histological data 
(including staining for collagen IV α1, α3 and α5 chains), as well as, performing genetic 
counselling and family study data collection on Croatian AS and TBMN patients. The 
next generation sequencing (NGS) for COL4A5, COL4A4 and COL4A3 gene mutation 
screening are performed at molecular laboratory at Department of Pathology and Centre for 
Translational Research, University of Zagreb School of Medicine.
Results: We have identified 337 AS and TBMN patients (age range 2-80) by search of 
patients’ records and data registries. From 337 patients, 158 have accepted to participate in 
genetic testing. Additionally 87 family members were enrolled in the study. Up to present 
day we have tested 90 index patients and 40 family members by NGS method. There was 
25 (19.2%) patients and family members with mutations in COL4A3, 6 (4.6%) in COL4A4 
and 33 (25.4%) in COL4A5. No mutation was found in 66 (50.8%) patients and family 
members.
Conclusions: Correct and early diagnosis, genetic counselling, and appropriate 
monitoring and management are essential for management of ASD patients. Our goal 
is to clarify Croatian Alport spectrum patients histologically, genetically and clinically 
and ultimately create ASD registry with clinical, histological and genetic and follow up 
information.
Funding: Government Support - Non-U.S.
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Background: To analyze the clinical and genetic features of Lowe syndrome carrying 
OCRL mutation.
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Methods: The clinical findings and results of genetic studies were retrospectively 
reviewed for 2 male patients diagnosed with Lowe syndrome, and relevant literatures about 
OCRL mutation were reviewed in this article.
Results: Two male patients all presented with low molecular proteinuria, renal tubular 
acidosis, hypercalciuria and rickets. Patient 1 did not have obviously extra-renal symptoms, 
but was found to have mild cataract by a meticulous ophthalmological examination, MRI 
found cerebral hypoplasia. Patient 2 was found to have abnormal vision and congenital 
cataract soon after birth and treated by surgery. MRI showed the reduction of brain white 
matter and the slight dilation of lateral ventricle. Two novel OCRL gene mutations were 
detected. A homozygous missense mutation c.1514G>T(p.G505V) was found in exon 15 of 
OCRL gene in Patient 1, OCRL gene 13-24 exon deletion mutation was detected in Patient 
2. Both mutations were never reported previously.
Conclusions: Lowe syndrome is characterized by the triad of congenital cataracts,
severe intellectual impairment, and renal tubular dysfunction. OCRL gene analysis is 
helpful for the early diagnosis of the disease, as well as providing better genetic counseling 
and prenatal diagnosis for the proband families.
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Genetic Variants of Familial Hematuria Associated Genes in Families with 
Hematuria with Probands Diagnosed with IgA Nephropathy
Zihua Yu,1,2 Liu Jiewei.1 1Dongfang Hospital, Fuzhou, China; 2Department of 
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Background: Familial hematuria (FH) are genetic disorders characterized by persistent 
hematuria during childhood, including Alport syndrome (AS) caused by mutations in 
COL4A3/COL4A4/COL4A5, CFHR5 nephropathy caused by mutations in CFHR5, etc. 
Some FH patients with IgA deposits in the glomerular mesangium could be diagnosed with 
IgA nephropathy (IgAN) when they either lack examinations of renal ultrastructure or have 
normal renal ultrastructures. This study aims to examine genetic variants of FH associated 
genes in 3 families with hematuria with probands diagnosed with IgAN.
Methods: The probands diagnosed with IgAN and their family members from 3 
families with hematuria were examined for genetic variants of FH associated genes by 
next generation sequencing. Genetic variants were verified by Sanger sequencing, and their 
pathogenicities were verified by bioinformatic analyses.
Results: A heterozygous mutation in CFHR5, 533A>G (Asn178Ser), was identified 
in Family one’s proband and his father, but it wasn’t found in his mother. A pathogenic 
mutation in COL4A5, 566G>T (Gly189Val), was detected in Family two’ proband, and it 
was also found in his mother, sister and daughter, but it was detected in neither his father 
nor his nephew. Two heterozygous pathogenic mutations, COL4A5 539G>A (Gly180Glu) 
and CFHR5 508G>A (Val170Met), were identified in Family three’s proband. COL4A5 
Gly180Glu was also detected in her sister, daughter and maternal nephew, but it was found 
in neither her oldest son nor youngest son. A heterozygous CFHR5 Val170Met was found 
in her oldest son, sister and maternal nephew, but it was detected neither her daughter nor 
her the youngest son. CFHR5 Asn178Ser is an uncertain significance. COL4A5 Gly189Val, 
COL4A5 Gly180Glu and CFHR5 Val170Met were predicted as pathogenic mutations. So 
Family two’ proband was diagnosed with XLAS, and Family three XLAS combined with 
CFHR5 nephropathy.
Conclusions: It is necessary to examine genetic variants of FH associated genes in 
families with hematuria with probands diagnosed with IgAN.
Funding: Government Support - Non-U.S.
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Care Physicians Regarding APOL1 Genetic Testing
Farrukh M. Koraishy,1,2 Carissa Van den berk clark,1 Jeffrey B. Kopp.3 1Saint 
Louis University, Saint Louis, MO; 2Veterans Administration, Saint Louis, MO; 
3NIDDK, NIH, Bethesda, MD.
Background: A high-risk apolipoprotein (APOL1) genotype predisposes African-
American (AA) individuals with hypertension to kidney disease. Although studies have 
shown that knowledge of genetic risk increases the likelihood of preventive health 
behaviors, APOL1 genetic testing is not part of routine hypertension management among 
AA patients. In order to understand the feasibility of implementing genetic screening at the 
Veteran Administration (VA), we assessed perceptions of Veterans and VA primary care 
providers (PCP) about kidney disease, blood pressure (BP) management, race, and genetic 
testing.
Methods: Ten PCP and ten AA hypertensive Veterans were interviewed at the 
Saint Louis VA Medical Center. Interview transcripts were coded to identify themes and 
compared between patients and PCP using a phenomenological approach.
Results: AA subjects had significant awareness of kidney disease and hypertension. 
They did not have an awareness of the genetic link between race and risk for kidney disease. 
PCPs had more knowledge of genetic/ancestral risk of hypertension but mostly not of kidney 
disease. They often stated that they needed more information about the role of APOL1 
variants. PCP tended to believe that AA Veterans generally had poor BP management due 
to health care habits and compliance. AA patients varied in BP management and were more 
open to genetic screening while PCP had concerns about cost, insurance, organizational 
constraints and ethical issues. PCP were agreeable to APOL1 testing, however, in most 
cases only if they had more information on how screening would change their practice. 
Many AA patients said that if they were found to have APOL1 high-risk genotypes, that they 
would commit to new strategies to prevent kidney disease.
Conclusions: AA hypertensive Veterans had good knowledge about the pathway from 
hypertension to kidney disease. Veterans and PCP were mostly agreeable to APOL1 genetic 
testing to learn about risk of kidney disease and engage in preventative behavior, but stated 
a need for more education. These results are preliminary, given the small sample size.
Funding: Veterans Affairs Support
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Myelin Bodies in LMX1B-Nephropathy
Gia J. Oh,1 Neeraja Kambham.2 1Pediatrics, Stanford, Stanford, CA; 2Stanford 
University, Stanford, CA.
Introduction: Mutations in LMX1B have been found in families with isolated 
nephropathy without extrarenal abnormalities. We describe 2 families with autosomal 
dominant (AD) nephropathy due to heterozygous LMX1B c.737G>A, p.R246Q variant who 
unexpectedly had myelin figures in electron microscopy.
Case Description: Family A (1a). Patient IV:2’s biopsy was notable for myelin bodies 
in podocytes (Figure 2). Her α-galactosidase A activity and GLA analyses were normal, 
thus excluding Fabry nephropathy. Family B (1b). Mother (Patient II:2) and son (Patient 
III:1) with nephropathy were found to have the p.R246Q variant, while the asymptomatic 
daughter (Patient III:2) did not have this variant.
Discussion: This is the first case series to report myelin figures in families with LMX1B-
nephropathy. Consider LMX1B-nephropathy in AD glomerulopathy and in differential 
diagnosis for kidney biopsies with myelin bodies.
eGFR, estimated glomerular filtration rate (Schwartz equation K 0.413 in <18yo; CKD-EPI 
equation in 18y and older); EM, electron microscopy; ND, not determined; Up/c, urine 
protein/creatinine ratio
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Genetic Variants of the COL4A5, COL4A4, and COL4A3 Genes in the 
Children with Familial Hematuria
Zihua Yu,1,2 Zheng Li.1 1Dongfang Hospital, Fuzhou, China; 2Department of 
Pediatrics, Xiamen University Affiliated Dongfang Hospital, Fuzhou, China.
Background: The familial hematuric diseases are a genetically heterogeneous group 
of monogenic conditions, including Alport syndrome (AS) and thin basement membrane 
nephropathy (TBMN) caused by mutations in the COL4A5, COL4A4 and COL4A3 genes, 
etc. This study aims to examine genetic variants of the COL4A5, COL4A4 and COL4A3 
genes in 48 children with familial hematuria (FH).
Methods: The clinical data and blood samples of 48 children with FH and their 
parents were collected. Genomic DNA was isolated from peripheral blood leucocytes. The 
48 children and their parents were examined for genetic variants in all coding exons and 
exon-intron boundaries of genes by exome sequencing. Variants detected in the COL4A5, 
COL4A4 and COL4A3 genes by exome sequencing were further verified by Sanger 
sequencing. Pathogenicity of the identified variants was verified by bioinformatic analyses. 
The etiological diagnosis of some children with FH were made according to their genotypes 
and their phenotypes.
Results: Twenty-five mutations were identified in 29 children with FH by exome 
sequencing and Sanger sequencing. Among them, 20 nutations, such as COL4A5 539G>A, 
COL4A5 3985delC, COL4A5 566G>T, COL4A5 2822G>A, COL4A5 EXON 29-30 
deletions, COL4A4 4421C>T, COL4A4 4915G>C, COL4A4 2752G>A, COL4A4 1030-
2A>C, COL4A4 2447G>A, COL4A4 4481delT, COL4A4 4288G>A, COL4A4 1567C>T, 
COL4A3 1496G>A, COL4A3 3619G>A, COL4A3 3627G>A, COL4A3 4700T>G, COL4A3 
898G>A, COL4A3 2096T>C and COL4A3 4769G>A, were novel, and 5 mutations, such 
as COL4A5 2858G>T, COL4A5 530G>A, COL4A4 4599T>G, COL4A4 3499G>A and 
COL4A3 4235G>T, have already been reported. Muatations in the COL4A5, COL4A4 
and COL4A3 gene were found in 60.4% (29/48) of 48 children with FH. An etiological 
diagnosis could be made in 56.3% (27/48) of 48 children with FH. Eleven children with 
FH were diagnosed with X-linked AS, and 1 child with FH was diagnosed with autosomal 
recessive AS, and 15 cases were diagnosed with either autosomal dominant AS or TBMN.
Conclusions: It is necessary for the children with FH to make an etiological diagnosis 
by examing genetic variants of the COL4A5, COL4A4 and COL4A3 genes.
Funding: Government Support - Non-U.S.
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Rare Disease
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Dorottya Csuka,4 Nóra É. Garam,4 Zoltan Prohaszka,5 Sergiu Dumitrache.6 
1Spitalul Clinic de Nefrologie Dr. Carol Davila, Bucharest, Romania; 2Spitalul 
de Nefrologie Carol Davila, BUcharest, Romania; 3Fundeni Clinical Institute, 
Bucharest, Romania; 4Semmelweis University, Budapest, Hungary; 5Semmelweis 
Univrestiy, Budapest, Hungary; 6Dr. Carol Davila Clinical Hospital of 
Nephrology, Bucharest, Romania.
Introduction: Membranoproliferative glomerulonephritis (MPGN) was recently 
reclassified as a complement alternative pathway-mediated C3 glomerulopathy (C3G) 
and immune complex-mediated membranoproliferative GN (IC-MPGN). The primary 
defect underlying complement-mediated glomerulonephritis is excessive activation of the 
alternative pathway as a result of either autoimmunity against regulatory components or 
abnormal genetic variants with a gain of function or loss of normal control of activating 
pathway.
Case Description: A 59 years old male was admitted to our clinic for anasarca, high 
blood pressure, oliguria, gross hematuria and worsening of serum creatinine from 2 to 
6.2 mg/dl, for five days. A week before admission, he was evaluated in another hospital for a 
post-traumatic wound consisting in a cut on the left sole and was treated with antibiotics and 
NSAID. At admission, the biologic evaluation showed anemia, positive inflammatory tests, 
dyslipidemia, hypoalbuminemia, marked nitrogen retention (creatinine 10.19 mg/ dl, urea 
170 mg/ dl), metabolic acidosis and hyperkaliemia, urinalysis with nephrotic proteinuria 
9.5 g/ day and macroscopic dysmorphic hematuria. A kidney biopsy was performed, and 
the patient started RRT with intermittent hemodialysis. The kidney biopsy revealed MPGN 
with isolated segmental deposits of C3 and extracapillary proliferation. Complement 
analysis revealed decreased classical and alternative pathway activity. Sequencing of 
complement genes showed no mutations, but some CFH or CD46 risky variations were 
identified for both DDD and aHUS. MLPA results suggested that the CFHR1 gene may be 
present in three copies in the patient. Western blot analysis showed FHR1 bands with higher 
density than controls, consistent with the presence of an extra CFHR1 copy. Monoclonal 
anti-FHR1 antibody did not detect any aberrant protein. He was given pulse therapy with 
Methylprednisolone and Cyclophosphamide followed by Prednisone with no improvement 
of renal function, and he remained dialysis dependent.
Discussion: This case demonstrates that C3G can also present with an abrupt loss of 
kidney function. It is unknown, how the extra CFHR1 copy affects protein function, further 
in vitro tests are necessary to analyze its effect.
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Chronic and Sub-Chronic Hyponatremia and Risk of Serious Falls and 
Hip Fractures
Simran K. Bhandari,1 John J. Sim,1 Bonnie H. Li,1 Connie Rhee,2 Shirin Sundar,6 
Holly Krasa,4 Kim Danforth,5 Kamyar Kalantar-Zadeh,3 Michael H. Kanter,5 
Steven J. Jacobsen,5 Annette L. Adams.5 1Kaiser Permanente Los Angeles 
Medical Center, Los Angeles, CA; 2University of California Irvine, Huntington 
Beach, CA; 3University of California Irvine, School of Medicine, Orange, CA; 
4Otsuka, Washington, DC; 5Kaiser Permanente Southern California, Pasadena, 
CA; 6Otsuka America Pharmaceutical, Inc., Princeton, NJ.
Background: Falls and fractures represent serious health concerns in the elderly. 
Addressing risk factors for falls which may ultimately reduce falls/fractures may help 
reduce morbidity and mortality. It remains unknown whether the duration of hyponatremia 
affects serious fall/fracture risk. We sought to evaluate the risk for serious falls and hip 
fractures among episodes of chronic (≥ 30 days) and subchronic hyponatremia (< 30 days) 
compared to normonatremia.
Methods: Retrospective cohort study within Kaiser Permanente Southern California 
(an integrated health system) between 1/1/1998 and 12/31/2016 among individuals ≥ 55 yrs 
with ≥ 2 outpatient serum sodium (Na) measurements. Hyponatremia defined as a serum Na 
of <135 mEq/L. Subchronic hyponatremia was defined as 1) a single serum Na measurement 
<135 mEq/L followed by a normal Na measurement (≥135 mEq/L) on a different day or 2) 
multiple serum Na values <135 mEq/L with less than 30 days between the first and second 
and/or last hyponatremia measurement. Chronic hyponatremia was defined as multiple 
serum Na measurements <135 mEq/L with 30 or more days between first and last serum 
hyponatremia measurement. Multivariable cox proportional hazards was used to estimate 
hazard ratios (HRs) for serious falls and/ or hip fractures in 1) subchronic hyponatremia 
versus normonatremia and 2) chronic hyponatremia versus normonatremia.
Results: Among 1,033,838 persons and 1,799,163 Na measurements, 73,883 
(7.1%) serious fall and/or hip fracture events occurred among the cohort. Compared to 
normonatremia, subchronic hyponatremia and chronic hyponatremia had serious fall and/or 
hip fracture HRs (95% CI) of 5.77 (5.66 – 5.87) and 1.91 (1.86 – 1.96) respectively.
Conclusions: We observed an increased risk for serious falls and/or hip fractures in 
persons with chronic and subchronic hyponatremia. Early detection and management of 
outpatient hyponatremia may provide an opportunity to prevent adverse outcomes including 
serious falls and fractures.
Funding: Commercial Support - Otsuka Pharmaceuticals
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Ernest I. Mandel,1,3 Francine Maloney,3 Nathan J. Pertsch,4,3 Jonathon D. Gass,3 
Justin J. Sanders,2,3 Rachelle Bernacki,2,3 Susan Block.2,3 1Brigham and Women’s 
Hospital, Boston, MA; 2Dana-Farber Cancer Institute, Boston, MA; 3Ariadne 
Labs, Cambridge, MA; 4Warren Alpert Medical School of Brown University, 
Providence, RI.
Background: Clinician-led conversations about future care priorities are associated 
with enhanced goal consistent care for individuals with serious illness. However, such 
conversations occur infrequently with patients with end-stage renal disease (ESRD) on 
dialysis. The Serious Illness Care Program (SICP) is a multi-faceted, comprehensive 
initiative to promote serious illness conversations between clinicians and patients centered 
around a conversation guide. This study aimed to assess the acceptability and feasibility of 
the SICP conversation for dialysis patients in an outpatient dialysis unit.
Methods: Twelve individuals with end-stage renal disease on dialysis from a single 
outpatient dialysis unit participated in this study. Average age of participants was 68.8 
years. Participants completed a demographics survey and baseline questionnaire on their 
life priorities and care preferences. Each participant then engaged in a clinician-led SICP 
structured serious illness conversation and completed an acceptability questionnaire. The 
conversations were recorded, transcribed and thematically analyzed.
Results: Conversations were an average of 20:53 minutes in length. Ten of twelve 
participants felt that the clinician had the conversation with them at the right time and only 
one participant did not feel it was worthwhile to have this conversation with the clinician. 
Two-thirds reported a neutral (“did not notice” or “neither liked or disliked”) reaction to 
the clinician using a written guide during the conversation. Finally, only one participant 
noted an increase in anxiety about their illness, while 42% noted that the conversation 
increased their hopefulness about their quality of life in the future. Thematic analysis 
revealed common perspectives on dialysis including that it narrowed life experiences and 
opportunities, was chosen by default, and was expected to be temporary.
Conclusions: The results of this pilot study suggest that clinician-led SICP serious 
illness conversations may be acceptable and feasible for patients with ESRD on dialysis and 
support larger scale implementation of the SICP intervention in this population. The lessons 
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from our thematic analysis can inform future serious illness conversations with dialysis 
patients.
Funding: Private Foundation Support
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The Relationship Between Lab Parameters and Patient Reported 
Outcomes in Pre-ESRD and Dialysis Patients
Daniel A. Sturgill, Judith Maddatu, Naveet Bal, Sneha Nagavally, 
Dawn F. Wolfgram. Medical College of Wisconsin, Wauwatosa, WI.
Background: Management of pre-ESRD and dialysis patients places major emphasis 
on monitoring lab parameters. This population suffers from many symptoms, but it is 
unclear if routinely measured lab values correlate with patient reported outcomes (PROs). 
We evaluated the relationship between lab and hemodynamic measures and PROs in pre-
ESRD and dialysis populations.
Methods: We conducted a cross-sectional study of pre-ESRD and dialysis cohorts. 
PROMIS surveys on cognitive function, physical function, and fatigue were administered 
via personal health record (PHR) or in clinic for the pre-ESRD cohort and at the dialysis 
center for the dialysis cohort. Linear regression analysis of the relationship between 
PROMIS T-scores (norm=50, SD=10) and labs including eGFR, BUN, hemoglobin (Hb), 
albumin for the pre-ESRD cohort, and Hb, albumin, Kt/V and intradialytic BP changes in 
the dialysis cohort. Models were adjusted for demographics and comorbidities.
Results: Our study included 76 pre-ESRD patients and 92 dialysis patients. The mean 
age (SD) was 61.0 (14.8) and 56.1 (14.8) years for the pre-ESRD and dialysis cohorts, 
respectively. Pre-ESRD patient mean eGFR (SD) was 18.4 ml/min (11.6). Overall, the 
pre-ESRD cohort reported no deficits in cognition (51.0 (9.2)) or fatigue (52.8 (10.4)), but 
did report moderately impaired physical function (39.8 (9.2)). Overall, the dialysis cohort 
reported no cognitive deficits (50.3 (10.9)), but did report moderately severe fatigue (55.0 
(9.8)) and severely impaired physical function (37.9 (7.9)). In Pre-ESRD patients higher 
BUN and lower eGFR was associated with higher reported cognitive function, p<0.01 for 
both. In dialysis patients lower Hb was associated with greater reported fatigue, p=0.01, and 
higher albumin was marginally associated with higher physical function, p=0.06.
Conclusions: Patient reported impairment in physical function was identified in the 
pre-ESRD and dialysis cohorts. Hb and albumin were associated with increased reported 
fatigue and reduced physical function in the dialysis cohort. In the pre-ESRD cohort 
clearance parameters were associated with better reported cognition with unclear relevance. 
Our results suggest that further research is needed on how to improve PROs in pre-ESRD 
and dialysis patients.
PUB341 
Publication-Only 
Hemoglobin Variability and Mortality Association in Elder Hemodialysis 
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David Escamilla-Illescas, Michael E. Wasung, Luis R. Lopez y lopez, 
Mario A. Sebastian-Diaz. Hospital Central del Sur de Alta Especialidad 
PEMEX, Mexico City, Mexico.
Background: Anemia secondary to Chronic Kidney Disease requires treatment 
because its impact in mortality; this effects lies within a spectrum that can’t be captured 
by an absolute level of isolated hemoglobin. Controversial results exist in the association 
between hemoglobin variability and mortality, so we decided to look for this association in 
elder population.
Methods: We performed a prospective cohort of patients over 60 years in hemodialysis 
conducted at the Hospital Central Sur de Alta Especialidad in the period from January 2017 
to March 2018. Monthly measurement of hemoglobin was recorded and the variability 
calculated by linear regression model and absolute change model. We documented whether 
the patient reached the primary (mortality) or secondary outcomes (hospitalizations or visits 
to the Emergency Room). We performed Cox regression for both models of variability. 
Secondary outcomes were analyzed by ANOVA. At the end of the study we measured 
the Granov-Goor Index (GGI) with the NiCaS system, dividing into two groups where 
<10 is related to asymptomatic left ventricular systolic dysfunction (aLVSD) and compared 
change in cardiac index and total body water according to tertiles.
Results: Thirty-two patients met the inclusion criteria, 53.1% men with an average age 
of 72.2(±7.9) years old and a time in hemodialysis of 22(±25.6) months. During the follow-
up period 25% of the patients died. The variability of hemoglobin was calculated and 
divided into tertiles. In the Cox regression there were no significant differences in survival 
for the linear regression model (p=0.09) and for the absolute change model (p=0.1). No 
significant differences were observed in secondary outcomes. At the end of the study, the 
IGG was measured and the group divided in those with aLVSD (13) and those with IGG>10 
(7) without finding significant differences in the cardiac index or body water changes.
Conclusions: Elder patients on hemodialysis represent a vulnerable population exposed 
to many factors that contributes to fluctuation such as lack of erythropoietin administration 
or poor compliance of the treatment. In this study we don’t observe differences in survival 
associated with greater variability maybe due to different pre-hemodialysis care, follow-up 
time or multiple comorbidities. We need to continue analyzing this vulnerable population.
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Mild Cognitive Impairment in Maintenance Hemodialysis Patients: A 
Cross-Section Survey and Cohort Study
Pei Xiaohua. The First Affiliated Hospital of Nanjing Medical University, 
Nanjing, China.
Background: Few studies focused on mild cognitive impairment (MCI) with 
maintenance hemodialysis (MHD) patients. This study was conducted to ascertain whether 
Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) was 
more accurate for MHD patients, then survey the prevalence, severity and risk factors of 
MCI with MHD patients, finally observe the progress of MCI with MHD patients in a 
period of six-months.
Methods: Referring with guidelines for cognitive impairment in China: the diagnosis 
and treatment of MCI (2010), MMSE and MoCA were used to assess the cognitive 
condition.
Results: 64 MHD and 54 non-HD subjects were included in this study. The mean age 
of the two groups was both beyond 60 years. The cut-off value of MoCA and MMSE were 
26 and 27 to screen MCI, respectively. MoCA performed superior to MMSE in sensitivity, 
specificity and AUCROC. The prevalence of MCI in MHD group was significantly higher 
than that in non-HD group (60.9% vs. 29.6%, MoCA) with OR 3.71. Spearman correlation 
test indicated that MCI was related with age, comorbidities, education years, uric acid, 
serum albumin, blood pressure. A multivariate stepwise regression analysis demonstrated 
that there was no relationship between MCI and the factors tested, except age. After an 
observation period of six months, MoCA indicated that MCI prevalence tended to augment 
and aggravate in the MHD group.
Conclusions: MoCA could be a more accurate assessment for screening MCI in both 
non-HD and MHD population. MHD patients might have a significantly higher prevalence 
of MCI. Age could be a vital important risk factor for MCI.
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Relationship Between TGF-β1, TGF-βR I, TGF-βR II, and Coagulation 
Fibrinolysis Factors and Their Effects on the Process of Renal Fibrosis
Zhang Y. Xia. nephrology, first affilicated hospital of china medical university, 
Shenyang, China.
Background: To explore the expressions of transforming growth factor β1(TGF- β1), 
and its types I and II receptors (TGF- β Type I, II Receptors, TGF-βR I,II), and their roles 
and relationships in the mechanism of human glomerulonephritis, their correlation with 
blood coagulation fibrinolysis factors(FRA,FN, α1-PI, PLG), and the accelerative effects 
on glomeruli cirrhosis, so as to identify the key factor that triggers and develops human 
glomerulonephritis.
Methods: Through immunohistochemistry, SABC, to assay the reflected changes in 
glomerular expressions of TGF-β1 and TGF-βR I and II, and in selected biopsy samples of 
the following 41 disease cases. By applying direct immunofluorescence to assay FN and 
FRA, indirect immunofluorescence assays α2-PI, and PLG, in 65 disease cases. Statistical 
analysis through Ridit and Spearman′s analysis.
Results: (1)Significant close correlations was noted between (TGF-ß1 and TGF-ßR 
I and II), and (FRA, FN, α2-PI, PLG) in the sampling disease cases, and the expressions 
significantly increase in direct correlation to the increased severity of renal tissue 
inflammation and fibrosis. (2) The glomerular fibrosis is the combined effect of several 
factors. The key factors include (TGF-β1 and TGF-βR I and II)and (FRA, FN).
Conclusions: The expressions and correlations within renal tissues of (TGF-β1 and 
TGF-βR I and II), and (ERA,FN,α1-PI, PLG), indicate these are significant factors in the 
developments of renal tissue fibrosis or cirrhosis.
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Omega-3 Fatty Acid May Stabilize the Podocyte Cytoskeleton and 
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Jiwon M. Lee,1,3 Hyunsu Choi,4 Jin young Jeong,1 Yoon-Kyung Chang,2 Dae 
Eun Choi,1 Ki Ryang Na,3 Kang Wook Lee,3 Jwa-Jin Kim.1 1Chungnam National 
University, Seoul, Republic of Korea; 2The Catholic University of Korea, 
Daejeon, Republic of Korea; 3Chungnam National University Hospital, 
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Background: Cytoskeletal disruption is the main issue in podocytopathies. Previous 
studies reported that omega-3 improved podocyte survival via anti-apoptotic and anti-
inflammatory effects. However, the role of omega-3 on the cytoskeleton of the podocyte is 
yet to be investigated. We studied on the effect of omega-3 on cytoskeleton in a puromycin 
aminonucleoside (PAN) induced podocyte injury model.
Methods: In vitro cultured mouse podocytes were divided into four groups: control, 
PAN treated, Omega-3 (EPA, DHA) treated, and PAN + EPA/DHA treated. PAN and 
EPA/DHA were treated by dose and time. Cytoskeletal components including F-actin, 
synaptopodin, α-actinin-4, and Jo-1 were evaluated. Oxidative stress and autophagic 
markers and cytoskeleton stains, such as Bax/Bcl2 ratio, caspase-3, phosphorylation 
(p)-mTOR, phosphorylation (p)-cofillin and RhoA were evaluated.
Results: Compared to control, the PAN-treated group showed decreased expression of 
f-actin and synaptopodin, α-actinin 4 and Jo-1; and increased (p)-mTOR, (p)-cofillin and 
RhoA. In the PAN group, treatment with EPA/DHA improved the expression of f-actin and 
synaptopodin, alpha actinin 4 and Jo-1. EPA/DHA also suppressed (p)-mTOR, (p)-cofillin, 
RhoA, and Bax/Bcl2 ratio, while activating capase-3.
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Conclusions: EPA and DHA treatment improved cell survival and related markers in 
puromycin-treated mouse podocytes. The results inferred that Omega-3 may ameliorate the 
podocyte damage by anti-apoptotic and cytoskeleton-stabilizing effects.
Funding: Government Support - Non-U.S.
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Post Infectious Glomerulonephritis: A Cause of Pulmonary Renal 
Syndrome
Randa I. Farah,2 Nadia M. Alqurini,1 Ayman Wahbeh.2 1University of Arkansas 
for Medical Sciences, Little Rock, AR; 2University of Jordan, Amman, Jordan.
Introduction: The occurrence of diffuse alveolar hemorrhage (DAH) in association 
with post streptococcal glomerulonephritis (PSGN) is extremely rare. We present a case 
of acute kidney injury from PSGN that was initially treated with steroids. DAH developed 
shortly after stopping steroids. At that time the patient was recovering from the renal injury 
and was dialysis-independent.
Case Description: Our patient was a 25-year-old lady presented with a history of 
passing dark brown urine preceded by a vague history of a sore throat two weeks prior to 
that. He examination was normal. Serum creatinine was 2.4 mg/dl and hemoglobin was 
11.6 mg/dl. Urinalysis showed +2 proteinuria, dysmorphic RBC’s and several WBCs. Her 
spot urine protein to creatinine ratio (UPCR) was 1.9 grams/gram. Immunological workup 
was negative except a high serum anti-streptolysin-O titer (674.9 IU) and a low C3 (0.3 g/l). 
Kidney biopsy showed diffuse exudative glomerulonephritis. Two glomeruli out of ten 
showed cellular crescents. Immunoflourescence and electron microscopy were consistent 
with PSGN. She became anuric and serum creatinine rose to 4.5 mg/dl. Treatment was 
started with intravenous methylprednisolone 0.5 gram daily for 3 days. She went on to 
develop anasarca and uremic symptoms with a creatinine of 10.9 mg/dl then dialysis was 
initiated. Her urine output improved over few days and dialysis was held. During that period 
steroids were discontinued. Six days later she complained of dyspnea and hemoptysis. 
Hemoglobin dropped to 8 mg/dl and her oxygen saturation was 75%. Radiographic images 
were suggestive of DAH which was confirmed by bronchoscopy. The broncho-alveolar 
lavage was persistently bloody on sequential samples. IV methylprednisolone was restarted 
again for 3 days. She improved dramatically 2 days into treatment and was discharged on 
prednisone. Steroids were tapered slowly over 3 months and then stopped. Serum creatinine 
decreased to 0.4 mg/dl and UPCR improved to 0.32 at 1 year.
Discussion: Our patient had a picture of rapidly progressive glomerulonephritis and 
was started on high dose steroids. Shortly after stopping steroids she developed DAH which 
was promptly diagnosed and treated with steroids, raising the question about the role of 
immune suppression, specifically steroid use in adults with PSGN with DAH. Only five 
cases were reported in adults and no clear recommendations exist.
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Introduction: Kidney involvement is a frequent complication of systemic lupus 
erythematosus (SLE). Kidney pathology is essential in differentiating lupus nephritis (LN) 
from thrombotic microangiopathy (TMA) secondary to antiphospholipid autoantibodies to 
choose proper treatment.
Case Description: A 61 years male patient with benign polyclonal gammopathy, 
overlap autoimmune hepatitis–primary biliary cirrhosis, acquired deficiency of factor VIII 
of clotting due to circulating inhibitors, aortic bioprosthesis for aortic stenosis and SLE with 
anticardiolipin (ACL) antibodies and lupus anticoagulant, is diagnosed one week before 
admission with raised serum creatinine (SCr 1.6 mg/dl) and short episodes of diplopia. 
At admittance he had proteinuria 800 mg/day, microangiopatic anemia, thrombocytopenia 
79000/ml and hypofibrinogenemia 119 mg/dl. Kidney biopsy showed no LN but 
TMA (Image). MHC genotyping showed high risk for autoimmunity (DQB1*02,*05/
DRB1*03,*14). For probable cAPS patient received low molecular weight heparin 
(LMWH), methyl-prednisolone, plasmapheresis, rituximab (two 500-mg infusions at 
7-days interval) with resolution of acute kidney injury, diplopia and TMA and complete
depletion of CD19+B-lymphocytes (Ly) after one month. Treatment was continued with
LMWH and prednisone in tapering dosage. After 18 months we noticed reappearance of 
ACL and of CD19+B-Ly, followed after 5 months by increase of SCr to 1.4 mg/dl. 500 mg 
of iv rituximab was administered with SCr normalization.
Discussion: Targeted therapy was possible after kidney pathology exam, improving 
renal and general prognosis. CD19+B-Ly repopulation preceded biological relapse, so 
monitoring of CD19+B-Ly may be useful to predict relapses and guide rituximab therapy.
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New Assay with Enhanced Sensitivity for the Detection of Galactose- 
Deficient IgA1 Enables Mechanistic Studies Using Human Primary Cells
Colin Reily,1 Dana Rizk,1 Bruce A. Julian,1 Jan Novak.2,1 1Medicine, University 
of Alabama at Birmingham, Birmingham, AL; 2Microbiology, Univeristyi of 
Alabama at Birmingham, Birmingham, AL.
Background: IgA nephropathy (IgAN), the most common primary glomerulonephritis 
in the world, is characterized by glomerular IgA1 immunodeposits enriched for galactose-
deficient IgA1 (Gd-IgA1). These immunodeposits likely originate from the circulation. 
Patients with IgAN have elevated blood levels of Gd-IgA1, predominantly bound in 
circulating immune complexes. Current ELISA tests require a significant amount of 
IgA1 to properly assess IgA1 galactose deficiency. This requirement limits studies with 
cultured primary cells, such as peripheral blood lymphocytes (PBLs), due to low number 
of IgA1-producing cells in PBLs and, consequently, low IgA1 production. To circumvent 
the problem, immortalized IgA1-secreting cell lines were previously established from 
IgAN patients and controls. This approach enabled studies of O-glycosylation pathways 
associated with IgA1 galactose deficiency. Translating the finding from immortalized cells 
into primary cells has proven difficult due to limitations of the current assays. Thus, a more 
sensitive assay was needed for analysis of IgA1 glycosylation.
Methods: We developed a new chemiluminescent assay for Gd-IgA1 detection using 
a lectin from Helix pomatia (HPA; specific for terminal N-acetylgalactosamine) conjugated 
to acridinium ester. Cell-free media were collected post-incubation with PBLs or EBV-
immortalized IgA1-producing cells. Galactose deficiency levels were assessed using HPA 
lectin conjugated to acridinium. Limits of detection were determined for the new assay and 
compared to that of previously established biotin-labeled HPA and colorimetric detection.
Results: The chemiluminescent assay showed a log-fold increase in sensitivity over 
the colorimetric assay as well as a two-fold improvement in the limit of detection. This 
improvement in sensitivity enabled assessment of galactose deficiency of IgA1 secreted by 
cultured primary PBLs.
Conclusions: We report a new method for analysis of Gd-IgA1 using a highly sensitive 
chemiluminescent assay. We show that this new assay can accurately assess the degree of 
galacrose deficiency in IgA1 secreted by cultured PBLs isolated from peripheral blood, a 
task not feasable with the traditional colorimetric lectin assay.
Funding: NIDDK Support
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Association of Atypical ANCA with Pauci-Immune Glomerulonephritis
Ali I. Gardezi,1 Sana Waheed,2 Tripti Singh.2 1Nephrology, University of 
Wisconsin School of Medicine and Public Health, Madison, WI; 2University Of 
Wisconsin School Of Medicine and Public Health, Madison, WI.
Background: ANCA are classified into three types based on the indirect 
immunofluorescence (IIF) pattern in ethanol fixed neutrophils. Whereas c-ANCA and 
p-ANCA have well established association with systemic vasculitis, atypical ANCA
(a-ANCA) have mostly been associated with inflammatory bowel disease. We present the 
findings of our study to determine if there is any association of a-ANCA with pauciimmune 
GN.
Methods: This is a retrospective study of patients who had a pathological diagnosis 
of pauciimmune GN over a five years period. The patients were divided into three groups 
based on the presence of typical, atypical or no ANCA. Baseline characteristics, clinical 
presentation, pathological findings and outcomes were compared.
Results: 26 patients were found to have the required diagnosis and data. The results are 
shown in the table included.
Conclusions: To our, knowledge, this is the first study looking at the association of 
a-ANCA with pauciimmune GN. Almost a quarter of the patients had positive a-ANCA with 
negative PR3 and MPO by ELISA. Interestingly, there was only one patient with ANCA 
negative GN. It is possible that better IIF techniques were able to identify a-ANCA in those 
sera which would have been ANCA negative with older techniques. These antibodies may 
have formed against previously unrecognized antigens involved in the disease process. 4 out 
of 6 patients with a-ANCA had positive ANA which could give false positive ANCA results. 
But, ANA positivity could give rise to both atypical and perinuclear patterns, whereas, we 
only saw atypical pattern. Furthermore, the other 2 results with atypical ANCA cannot be
explained by this phenomenon. A-ANCA might be associated with pauciimmune GN. In
the presence of appropriate clinical presentation, presence of a-ANCA should prompt the
clinicians and pathologists to consider the diagnosis of ANCA vasculitis.
Comparison of baseline characteristics, findings and outcomes.
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Pathology Patterns of Paraprotein-Induced Kidney Damage in 168 
Patients from a Single Center
Elena Zakharova,1,2 Ekaterina Stolyarevich.2 1Nephrology, Moscow City 
Hospital n.a. S.P. Botkin, Moscow, Russian Federation; 2Nephrology, State 
University of Medicine and Dentistry, Moscow, Russian Federation.
Background: Paraprotein-induced lesions in multiple myeloma (MM) include cast 
nephropathy (CN), AL amyloidosis, light chain deposition disease (LCDD), light chain 
proximal tubulopathy (LCPT), proliferative glomerulonephritis with monoclonal Ig 
deposits (PGMID) and several rarer variants. AL amyloidosis itself is mainly found in the 
absence of lymphoproliferative disease (LPD). LCDD, PGMID, LCPT and other lesions 
not related to MM or any LPD are merged under the umbrella of Monoclonal Gammopathy 
of Renal Significance (MGRS)
Methods: We evaluated 197 patients with LPD, AL amyloidosis and MGRS, who 
underwent kidney biopsy in 1997-2017. Pathology study included light microscopy and 
immune stainings with electron microscopy for selected cases. Patients without clear 
paraprotein deposition were excluded from analysis
Results: Study group included 86 males and 82 females, median age 61 [31; 81] years. 
Indication for biopsy was nephrotic syndrome in 124 (73.8%) cases, progressive decline of 
kidney function in 103 (61.3%) cases, or both in 65 (38.6%) cases. Pathology findings and 
clinical setting are shown in the Table
Conclusions: Most often type of paraprotien-induced renal desease is AL amyloidosis, 
including that complicates MM and Waldenstrom macroglobulinemia (WM). Patients with 
MM present also with CN, LCDD and variety of rare lesions, or with the combination of 2 
or even 3 patterns. In turn, WM might be complicated by several types of lesions. MGRS 
and MM share patterns like LCDD and PGMID
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Normotensive Scleroderma Renal Crisis (SRC) with Urinary Findings of 
ATN
Jith Palacherla, Koba A. Lomashvili. Emory University, Snellville, GA.
Introduction: SRC can occur in 5-10% of SSc patients. Here we describe a case 
of normotensive SRC with severe AKI and unequivocal urinary finding of “muddy 
brown casts” consistent with ATN, presenting dilemma in using ACE inhibitor at initial 
presentation.
Case Description: A 76-year-old WF with newly diagnosed rapidly progressing 
diffuse SSC within past year, with failed multiple oral regimens, on prednisolone 12mg qd, 
and was admitted for Cytoxan infusion. She had recurrent L pleural effusion and pericardial 
effusion, s/p pericardial window and was normotensive on amlodipine 5 mg and lasix40 
mg daily. She had poor po intake over last two weeks and diarrhea. On admission she 
had LE edemas, was in pain, BP was 172/93 and creatinine level 4.0, increased from 
baseline 0.8mg/dl two weeks ago. Platelets were 349. She was started on captopril 12.5mg 
tid for suspected SRC and analgesic doses readjusted with rapid normalization of BP in 
120s/70s. Urine studies showed FeNA 1.5%, FeUrea 51.4%, no hemoglobin. Microscopy 
showed multiple muddy brown casts. She was oliguric but responded to Lasix. Her AKI 
worsened requiring hemodialysis (HD) over next few days. ACE was stopped after two 
days briefly when ATN casts were seen in urine and renin level obtained. BP remained 
in 110s and 120s/70s rest of her Hospital stay, (with or without ACE). ACE was restarted 
within few days since SRC could not be ruled out. To resolve therapeutic dilemma, we did 
kidney biopsy, showing thickening of intima in arterioles, thrombotic microangiopathy and 
mesangiolysis in ischemic glomeruli, consistent with SRC. Renin came back at 61ng/ml/h. 
Captopril dose was increased to 50 mg po tid as tolerated. She was discharged on HD.
Discussion: Granular casts and dysmorphic red cells can be found in urine in SRC, but 
sediment is usually bland. This case is unusual since urine sediment showed unequivocally 
ATN, and with briefly stopping captopril her BP remained within normal limits, despite 
having very high renin activity in combination with volume overload. Elevated blood 
pressure at presentation can be explained by uncontrolled pain and normalized within 4 
h with pain control. This case demonstrates that when probability of SRC is high, finding 
ATN on urine microscopy should not preclude ACE/ARB use with or without pathological 
diagnosis.
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The Role of Complement in Primary Antiphospholipid Nephropathy
Sjoerd Timmermans,1 Pieter V. Paassen.2 Limburg Renal Registry 1Maastricht 
University Medical Center, Maastricht, Netherlands; 2Maastricht University 
Medical Center/Nephrology and Clinical Immunology, Maastricht, Netherlands.
Background: Renal involvement in the antiphospholipid syndrome has been linked to 
a spectrum of pathologies, including parenchymal disease known as antiphospholipid (aPL) 
nephropathy, and although the pathologic features are well-known, the natural history and 
mechanisms of primary aPL nephropathy have not been established. Recent studies linked 
thrombotic events to complement and moreover, complement blockade appears promising 
in severe aPL nephropathy. Here, we investigated primary aPL nephropathy and focused 
on complement.
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Methods: Pathologic and clinical follow-up data were analyzed from adult patients 
with biopsy-proven aPL nephropathy with no evidence of secondary disease. Complement 
activation was studied on frozen kidney sections and in vitro after aPL binding to human 
endothelial cells.
Results: Twenty-one patients (13 female, 8 male) with persistent serum aPL reactivity 
presented with proteinuria (n=19), renal impairment (n=17), and/or hypertension (n=12). 
Glomerular disease was noted in 17 cases (thrombotic microangiopathy, n=14; focal 
segmental glomerulosclerosis, n=3); the extent of tubulointerstitial and vascular damage 
varied from mild (n=8), moderate (n=5), to severe (n=8). Electron dense deposits were 
found in 2 (10%) cases. Four biopsies had C3c co-located with C5b9 along capillaries and/
or arteries, all of whom were scored as thrombotic microangiopathy. aPL binding (pooled 
IgG, n=4) to endothelial cells did neither induce C3c nor C5b9. Median follow-up was 
5 (range, 1-24) years. Progression to the composite renal endpoint of doubling creatinine 
and end-stage renal disease occurred in 2 (10%) cases; both patients initially required 
dialysis. CKD stage 2 (n=5), 3 (n=12), and 4 (n=2) developed in the others. No differences 
were found regarding activity and chronicity indices on kidney biopsy. New thrombotic 
events occurred in 5 (24%) patients, one of whom received adequate anticoagulation.
Conclusions: In a large series of primary aPL nephropathy, the disease course appeared 
quite favorable. Complement activation could not be demonstrated and requires further 
evaluation.
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Cryoglobulinemic Membranoproliferative Glomerulonephritis (MPGN) 
in a Patient with Sjogren’s Syndrome and IgM Monoclonal 
Paraproteinemia
Muhannad Alqudsi, Koba A. Lomashvili. Renal Division, Emory University, 
Atlanta, GA.
Introduction: Cryoglobulinemic GN is rare and usually occurs in type II 
cryoglobulinemia induced by hepatitis C. Here we present Hepatitis C negative patient with 
Sjogren’s syndrome, cryoglobulinemic GN and monoclonal IgM Kappa paraproteinemia.
Case Description: 60 y/o AAF with PMH of dry mouth and eyes and recent increase in 
dental caries, was seen at Nephrology Clinic with severe LE edemas of 2 weeks duration and 
proteinuria 11gm/gm of creatinine (Cr). Her Cr increased from 1.1 to 4.5 mg/dl in one month, 
prompting renal biopsy showing MPGN Type I and extensive hyaline thrombi in glomerular 
capillaries suggesting cryoglobulinemic GN. Blood cryoglobulin was positive at 2.5% and 
serum and urine protein electrophoresis with Immunofixation detected two IgM Kappa 
monoclonal paraproteins. She had negative Hepatitis B DNA PCR, Hepatitis C and HIV 
tests. Autoimmune w/u showed ANA 1:230, SSA/RO Ab at 14, SSB/LA Ab > 320unit/ml, 
(normal < 7), low C3 46, low C4 <1mg/dl. Rheumatoid Factor (RF) was elevated at 
423 IU/ml. Rheumatology consult confirmed diagnosis of Sjogren’s syndrome. Bone 
marrow biopsy showed Plasma cells comprise less than 5% of the marrow cellularity, flow 
cytometry did not reveal plasma or B cell clone responsible for paraproteinemia. W/U for 
malignancies was negative. She was started on plasma exchange (PLEX) and plasma cell 
therapy, with Velcade, cytoxan and dexamethazone (VCD), discharged after six sessions 
of PLEX and continued on VCD for two months total of 4 cycles. Her Cr improved to 
1.4-1.7mg/dl but kept having proteinuria with Immunofixation showing persistent IgM 
Kappa paraprotein. 40 days after last VCD she was given Rituximab, (two doses). At one-
month F/U after rituximab, her creatinine improved to 0.8mg/dl, paraprotein concentration 
and proteinuria both decreased to half of pretreatment levels and cryoglobulin tested 
negative.
Discussion: The patient with Sjogren’s syndrome is expected to have polyclonal 
RF, but she was tested positive on monoclonal IgM kappa. Since source cell clone was 
unknown, she was initially given plasma cell therapy, resulting in some improvement of 
kidney function and limited effect on her nephrotic syndrome (NS). She was given anti B 
cell therapy later on with further improvement in creatinine and proteinuria. If her NS fully 
resolves remains to be seen.
PUB353 
Publication-Only 
Engineered Immune Complexes Containing Galactose-Deficient IgA1 and 
IgG Autoantibody, a Renewable Resource in IgA Nephropathy Research
Zhi qiang Huang,1 Xianwen Zhang,2 Joshua C. Anderson,1 Stacy D. Hall,1 
Rhubell T. Brown,1 Hitoshi Suzuki,3 Bruce A. Julian,1 Christopher D. Willey,1 
Jan Novak.1 1University of Alabama at Birmingham, Birmingham, AL; 2Longhua 
Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 
Shanghai, China; 3Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: Circulating immune complexes (CIC) containing galactose-deficient 
IgA1 (Gd-IgA1) and Gd-IgA1-specific autoantibodies are considered a key pathogenetic 
factor in IgA nephropathy (IgAN). To enhance studies of IgAN, we generated engineered 
immune complexes (EIC) using Gd-IgA1 and a recombinant Gd-IgA1-specific IgG 
autoantibody derived from a patient with IgAN. The biological effects of EIC on human 
mesangial cells (hMC) were assessed and compared with those for CIC.
Methods: EIC were prepared from a recombinant IgG autoantibody specific for 
Gd-IgA1 from an IgAN patient and a Gd-IgA1 myeloma protein. EIC formed in human 
serum depleted of IgA and IgG and CIC from sera of IgAN patients were isolated by size-
exclusion chromatography. hMC were stimulated with EIC or CIC and cellular proliferation 
and protein-tyrosine kinase (PTK) signaling were evaluated.
Results: EIC and CIC increased cellular proliferation of hMC by 2.88±0.69-fold and 
3.97±2.18-fold, respectively. EIC and CIC induced signal transduction in hMC, resulting in 
enhanced phosphorylation of PDGFR-b, ERK1/2, and AKT1 detected by immunoblotting. 
Global protein-tyrosine kinome profiling revealed that EIC and CIC activated multiple 
PTKs. Among the ten kinases with highest phosphorylation indexes (KSTAT and specificity), 
eight kinases overlapped between EIC- and CIC-activated hMC: ROR1, LCK, LYN, KIT, 
YES1, BLK, TYK2, and CTK (MATK). Among other activated kinases (P<0.05 compared 
to negative control), 98% overlapped between EIC- and CIC-activated hMC. Among them, 
17% belonged to Src family (a non-receptor protein kinases) and 25% to different growth-
factor receptors, including PDGF/PDGFR, VEGFR, FGFR, EGFR, and INSR. Several 
activated kinases belonged to kinase families, such as Syk, Tec, Axl, and Eph.
Conclusions: EIC and CIC had similar capacity to activate hMC through 
phosphorylation of multiple kinases and activation of downstream pathways, ultimately 
resulting in cellular proliferation. EIC may thus serve as a convenient model of IC in the 
studies of pathogenesis of IgAN.
Funding: NIDDK Support
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Circulating Antibodies Against M-Type Phospholipase A2 Receptor Can 
Predict Treatment Response and Outcome in Chinese patients with 
Primary Membranous Nephropathy
Zhen Qu,1 Mufan Zhang,1 Zhao Cui,1 Minghui Zhao.2 1Peking University First 
Hospital, Beijing, China; 2Peking University First Hospital, Peking University, 
Beijing, China.
Background: Anti-phospholipase A2 receptor (PLA2R) antibodies are specific to 
the diagnosis of primary membranous nephropathy (pMN). The prevalence of positive 
antibodies varies among different cohorts. Discrepancy remains on the association between 
antibody levels and clinical courses, and the prognostic value of antibodies to treatment 
responses and kidney outcomes.
Methods: 359 consecutive kidney biopsy-proven pMN patients were enrolled. Anti-
PLA2R antibodies were detected by immunofluorescence assay (IFA) and enzyme-linked 
immunosorbent assay (ELISA).
Results: The positive rate of anti-PLA2R antibodies in pMN were 65.2% (234/359) 
by IFA and 56.3% (202/359) by ELISA. Antibody level presented positive correlation 
with urinary protein excretion (r=0.164, P=0.002). The detectable antibodies (OR=2.99, 
P=0.007) and higher level of proteinuria (OR=1.11, P=0.009) were independent risk factors 
to no-remission after treatments. High level (>179U/mL) and moderate level (64-179U/mL) 
antibodies predicted higher risk to no-remission. Higher level of antibodies (HR=1.002, 
P=0.019) was the independent risk factor to kidney dysfunction during follow-up. High 
level (>179U/mL) of antibodies possessed higher risk to kidney dysfunction. The antibodies 
turned negative in 42/52 (80.8%) patients who achieved clinical remission, while remained 
positive in all patients of no response (P<0.001).
Conclusions: We documented a lower positivity rate of anti-PLA2R antibodies in 
this large Chinese pMN cohort and close correlations between antibody levels and clinical 
severity. The risk stratification of antibody levels could predict treatment responses and 
kidney outcomes of pMN.
Funding: Government Support - Non-U.S.
Anti-PLA2R antibody levels and proteinuria in pMN patients at the time of kidney 
biopsy, remission and relapse. Patients who reach a remission had a decrement in the 
level of anti-PLA2R antibodies and proteinuria. The proteinuria and the level of anti-PLA2R 
antibodies were increased during relapse.
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Atypical Anti-GBM Glomerulonephritis with Crescents
Mohamad M. Alkadi, Mostafa F. Elshirbeny, Imaad B. Mujeeb, Omar Fituri. 
Hamad Medical Corporation, Doha, Qatar.
Introduction: Atypical anti-GBM disease is a rare variant characterized by an indolent 
course, no pulmonary involvement, undetectable circulating antibodies and absence of 
crescents in kidney biopsy. Here we present a case of rapidly progressive glomerulonephritis 
due to atypical anti-GBM.
Case Description: This is a 37 year-old man with no past medical history who 
presented in December, 2016 with bilateral lower extremity swelling and dark urine for 
10 days. He denied fever, chills, shortness of breath, hemoptysis, vomiting, diarrhea, 
joint pain, skin rash or dysuria. Physical examination was remarkable for elevated blood 
pressure of 160/110 mm Hg and bilateral Lower extremity pitting edema. His labs showed 
elevated serum creatinine of 270 mmol/L, hypoalbuminemia, hyperlipidemia, microscopic 
hematuria and 15 g proteinuria. Virologic and immunologic workup was negative including 
hepatitis B, hepatitis C, HIV, ANA, ANCA, C3, C4 and Anti-GBM antibodies. kidney 
biopsy showed diffuse proliferation in glomeruli with increased mesangial cellularity and 
diffuse crescents involving > 50% of glomeruli. Direct Immunofluorescent studies showed 
diffuse linear GBM staining with IgG (3+) in glomeruli as shown in figure 1. Electron 
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microscopy showed similar proliferative features and severe foot process effacement, but no 
immune complex, fibrillary, or paraprotein-related deposits in GBM or mesangial regions. 
Patient was treated with IV pulse steroids, 8 sessions of plasmapheresis and 6-month of 
oral cyclophosphamide. He was also maintained on oral steroids. His serum creatinine and 
proteinuria 1 year post treatment were 117 mmol/l and 3.7 g, respectively.
Discussion: This case is unique because atypical anti-GBM glomerulonephritis is 
extremely rare and having diffuse crescentic phenotype in atypical anti-GBM hasn’t been 
reported before. Despite high sensitivity of ELISA in detecting serum anti-GBM antibodies, 
anti-GBM cannot be ruled out completely without kidney biopsy.
Figure 1
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Successful Therapeutic Procedure of Two Cases of Monoclonal Immuno-
globulin Heavy Chain Deposition Disease (HCDD)
Minoru Hatano,1 Yumiko Nakamura,1 Takatsugu Iwashita,1 Yuta Kogure,1 
Koki Ogawa,1 Kensuke Joh,2,1 Maiko Yamasaki,1 Tomonari Ogawa,1 
Koichi Kanozawa,1 Hajime Hasegawa.1 1Saitama Medical Center, Saitama 
Medical University, Saitama, Japan; 2Tohoku University Graduate School of 
Medicine, Sendai-city, Japan.
Introduction: Among monoclonal immunoglobulin deposition disease (<1.0% of 
biopsy cases), heavy chain deposition disease (HCDD) is considered to be very rare and 
therapy-resistant glomerular disorder. We recently experienced 2 cases of HCDD who 
successfully showed clinical remission by immunosuppressive agent and corticosteroid.
Case Description: First case was 37-years-old man, and pointed out sever proteinuria 
and hematuria on the regular health check at 2 months prior to the admission. Light 
microscopic (LM) biopsy observation showed membranoproliferative glomerulonephritis 
(MPGN), and immunostaining showed IgG (+), C1q (+), C3 (+) and IgG3 (+). Light chains 
were all negative. Electron microscopic (EM) study showed powder-like deposition in 
the basement membrane. Because CH1 staining was negative, he was final diagnosed as 
gamma 3-HCDD. He was not satisfied with the myeloma criteria, however, hematologists 
agreed with the administration of bortezomib+dexamethasone at day-55 and intermittently 
repeated 12-times. After finishing the 4th therapy, his hematuria was disappeared, and finally 
his proteinuria was disappeared at day-422. Second case was 30-years-old woman, and she 
recognized edema on the lower extremities at 2 months prior to the admission. She showed 
remarkable proteinuria, hematuria and renal dysfunction. Renal biopsy showed MPGN 
in LM study, and IgG (+), C1q (-), C3 (-), IgG1 (+) in the immunostaining. Light chain 
staining were both negative, and powder-like deposition was observed in EM study. IgG-
Fab and Fc specific staining revealed Fab (-) and Fc (+), suggesting CH1 deficient HCDD. 
Because hematologists did not agree to use bortezomib, she was started PSL 30 mg/day 
alone at day-42, and both proteinuria and eGFR were getting to be restored at day-116.
Discussion: Both of our cases responded to the therapy, whereas HCDD is known 
to show therapy resistance. Bortezomib might show the better efficacy to this disease, 
however, we sometimes hesitate to use bortezomib in patients in earlier stage because they 
usually do not agree with the myeloma criteria. However, PSL alone might be sufficiently 
effective to cases in earlier stage.
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Anti-Complement Factor H Mediated Glomerulonephritis at a Tertiary 
Care Centre
Umesh L. Institute of nephrourology, Bangalore, India.
Background: Complement dyregulation has become an important etiology for 
glomerular diseases. Anti body against complement factor H which regulates the alternate 
complement pathway can cause atypicical HUS and C3 glomerulopathy
Methods: We studied the clinical profile and outcome of patients with anti complement 
factor H mediated disease at a tertiary care centre over 18 months. 8 patients were studied 
and followed up to assess their response to therapy.
Results: Cases were equally distributed between males and females. Mean age was 
20.5yrs with 5 patients in the paediatric age group. All patients presented with hypertension 
with RPGN with active urinary sediments. Mean serum creatinine at presentation was 6.8+/- 
1.2. Serum c3 was low in all patients with normal c4 levels. LDH was elevated in 50% 
patients with schistocytes in peripheral smear. 100% patients had oliguria and were dialysis 
dependent at presentation. Renal biopsy showed thrombotic microangiopathy in 4 patients 
while features were suggestive of C3 glomerulopathy in 4 patients. Anti complement 
factor H antibody was elevated in all patients with a mean of 161AU/ml. All patients were 
managed with pulse steroids followed by oral steroids along with IV cyclophosphamide. 
Plasmapharesis was done in all patients. All of them showed improvement in renal function 
after plasmapharesis and were free from dialyisis. Among the 8 patients, one was post 
transplant thrombotic microangiopathy with low serum c3 with elevated anti cfh antibody. 
Patient responded well to our treatment and had normal renal function by the 3rd week post 
transplant. All 5 patients in the paediatric age group are on regular follow up with normal 
renal function in complete remission. One of the adult patient expired due to sepsis with 
septic shock. Post transplant patient expired due to intracerebral bleed during follow up. 
Last patient has a stable creatinine of around 2.2mg/dl and is doing well
Conclusions: Our case series shows that anti complement factor H mediated disease 
shows good response to immunosuppression and plasmapharesis without the need for 
eculizumab.
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Case Report: Recurrence of MPGN Post Transplant – Is This Mere 
Recurrence of Pattern or Recurrence of Disease?
Umesh L. institute of nephrourology, Bangalore, India.
Introduction: Recurrence of MPGN is seen in 19-65 % cases of post renal transplant 
and amounts for graft loss up to 35 to 50 % cases.
Case Description: 31 year old female patient diagnosed to have ESRD 3 years back 
initiated on MHD three times a week. She underwent deceased donor kidney transplantation 
after 11/2 yrs with Basiliximab as induction. Post transplant patient had DGF. Post transplant 
patient achieved nadir creatinine of 0.9 mg/dl by 10 days. 9 months post transplant patient 
developed fever, anasarca and decrease in urine output. On evaluation found to have 
active sediments in urine, albuminuria 3+, serum creatinine 3.5mg/dl and 24 hr urine 
protein 7.5 grams, low C3. Patient underwent graft biopsy. Subsequently patient received 
pulse steroid for 3 days and 5 sessions of plasmapheresis. Later renal biopsy report was 
suggestive of MPGN with focal crescents, ATN. IF showed Ig G3+, C3 3+, 3+, negative for 
or other immunoglobulins or compliments. As her native kidney disease was IC mediated 
MPGN with no light chain restriction, paraffin tissue of native kidney was reexamined for 
immunoperoxidase stain for and chains, which were positive. Medical oncologist opinion 
was taken. Patient underwent extensive work up for paraproteinemias and results were 
negative. Patient received 4 doses of Bortezomib. Patient’s serum creatinine was reduced 
to 0.8mg/dl and proteinuria reduced to 800mg/day. 2 months later patient was on routine 
surveillance found to have increase in proteinuria with microscopic hematuria with normal 
creatinine. As per medical oncologist advice patient was restarted on Bortezomib. Presently 
her 24 hr urine protein is 600mg/day with normal creatinine.
Discussion: Conclusion: Our case is unique as we were not able to demonstrate 
monoclonal deposits in native kidney sample with recurrence of MPGN with monoclonal 
light chain deposits post transplant. Our findings emphasize for thorough evaluation for 
paraproteinemias in patients with idiopathic MPGN even in the absence of light chain 
deposition in biopsy
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Lessons from Comprehensive Analysis of a Factor I (FI) Variant in 
Atypical Hemolytic Uremic Syndrome (aHUS)
Anuja Java,1 John P. Atkinson.2 1Washington University in St. Louis, Saint Louis, 
MO; 2Washington University, St. Louis, MO.
Introduction: aHUS is characterized by microangiopathic hemolytic anemia, 
thrombocytopenia and acute kidney injury. Mutations in genes encoding complement 
proteins have been identified in ~60% of patients. Majority of these variants are variants of 
uncertain significance (VUS). Herein, we report functional and structural analyses on a FI 
variant identified in a patient with HUS.
Case Description: Clinical history: 22 y/o male had h/o ESRD secondary to E. 
coli-HUS. The patient underwent a renal transplant in 2006. In 2007, he developed non-
Hodgkin’s lymphoma and his immunosuppression was reduced. Later that year, he lost 
his kidney to acute cellular rejection. During evaluation for a 2nd kidney transplant, genetic 
testing for HUS was performed which demonstrated a VUS (R406H) in FI. He received 
eculizumab post-transplant. One year later, after eculizumab was discontinued, the patient 
lost his kidney again to acute cellular and antibody-mediated rejection. He is now being 
evaluated for a 3rd transplant. Genetic analysis: The FI variant has been analyzed by 
several prediction models and due to lack of consensus among these tools, was classified as 
a VUS. Antigenic analysis: The secretion of the variant protein (ELISA) was comparable 
to wild type (WT). Patient had a borderline low serum FI level. Functional analysis: 
Cofactor assays were performed using purified FI, C3b and with membrane cofactor protein 
(MCP), Factor H (FH) or Complement Receptor 1 (CR1) as the cofactor protein. WT and 
variant cDNAs were transfected into human 293T cells. The variant had defective cofactor 
activity (CA) with FH and CR1 as evident by decreased rate of cleavage of the α-chain of 
C3b. No defect was observed with MCP. Structural analysis: The side chain of R406 in 
FI forms a salt bridge with the carboxyl group of E123 of FH, thereby stabilizing the FI-FH 
binding interface. Residue E123 is a unique signature of FH. It is lacking in MCP, possibly 
accounting for why the R406H mutation impairs FH- but not MCP-mediated CA.
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Discussion: Summary/Lessons Learned: It is imperative to define the functional 
activity of a VUS. The variant R406H is pathogenic based on defective CA. Given his 
clinical course, borderline low FI antigenic levels and these new functional data, we believe 
that the patient is at high risk of developing a thrombotic microangiopathy or an accelerated 
rejection in the future.
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Relapsing IgG4 Related Kidney Disease with Bilateral Ureteral  
Obstruction by Peri-Renal Tumors – A Case Report of 4-Year Clinical 
Course
Eiji Ishimura,1,2 Shuko Ueda,1 Nobuyuki Kuwamura,1 Yukihiro Nin,1 
Kazuya Kimura,1 Tokuki Yasuda,1 Shinya Nakatani,3 Akihiro Tsuda,4 
Masaaki Inaba,3 Tetsuya Makino,1 Ryusuke Kakiya.1 1Meijibashi Hospital, 
Matsubara, Osaka 580-0045, Japan; 2Osaka City University Graduate school of 
Medicine, Abeno-ku, Japan; 3Osaka City University Graduate School of 
Medicine, Osaka, Japan; 4Department of Nephrology, Endocrinology, 
Metabolism, and Molecular Medicine, Osaka City University Graduate School 
of Medicine, Osaka, Japan.
Introduction: IgG4 related kidney disease (IgG4RKD) is recently established as an 
interstitial nephritis with IgG4 positive lymphocytes infiltraion. IgG4RKD well responds 
to corticosteroid therapy, and its prognosis is considered to be good. Here, we report a case 
with IgG4RKD, in which three times relapses were seen during 4 year duration, with an 
unusual complication.
Case Description: A 82 year-old male was first admitted in January 2014, because of 
progressing renal dysfunction. Serum creatinine was 4.77 mg/dL, IgG4 1,130 mg/dL. Renal 
biopsy showed severe tubule-interstitial nephritis, with typical Bird’s eye signs, and with 
numerous IgG4 positive lymphocytes infiltraion. Intravenous and oral predonisolone (PSL) 
improved renal function, and he was discharged with serum creatinine around 1.50 mg/dL. 
One and a half years later, under PSL 5 mg/day, his serum creatinine increased to 
2.20 mg/dL. Second renal biopsy revealed active tubulo-interstitial nephritis, again. PSL 
was increased to 40mg/day, and his renal function was gradually improved. Four years later, 
in February 2018, his renal function was worsened, again. CT scan revealed bilateral peri-
renal retroperitoneal tumors, causing obstruction of bilateral ureters. Bilateral nephrostomy 
catheters were inserted. At that time, an echo-guided biopsy of the tumors and kidney 
was performed, revealing numerous patchy infiltrations of IgG4 positive lymphocytes. 
Intravenous and oral PSL improved renal function, and bilateral nephrostomy catheters 
were removed on the 40th day, and he was discharged on 70th day, with serum creatinine 
1.50 mg/dL.
Discussion: IgG4RKD has been reported to be responsive to steroid therapy (Jap J 
Nephrol 2011, Saeki T, et al. 2011, Saeki T, et al KI 2013). However, there are very few 
cases with relapsing IgG4RD in the long clinical course of corticosteroid therapy. Further, 
there is no case with bilateral ureteral obstruction by tumors with IgG4 infiltration, causing 
renal failure. The present case indicates that IgG4RKD relapse in the long course of 
corticosteroid therapy. Also, our case suggests that CT scan should be done to search the 
cause of renal failure, including retroperitoneal lesions as in the preset case..
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A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits 
with Nephrotic Syndrome
Masao Kihara,1 Hitoshi Suzuki,1 Miki Narahara,1 Daisuke Sato,1 Miyuki Takagi,1 
Shigeki Tomita,2 Yusuke Suzuki.1 1Nephrology, Juntendo University Faculty of 
Medicine, Tokyo, Japan; 2Pathology, Juntendo University Urayasu Hospital, 
Urayasu, Chiba, Japan.
Introduction: In most forms of immune complex–mediated glomerulonephritis, the 
deposited immunoglobulins are typically polyclonal. Renal disease related to glomerular 
deposits of monoclonal immunoglobulins includes light- and heavy-chain deposition 
disease, type 1 cryoglobulinemic glomerulonephritis, fibrillary glomerulonephritis, 
immunotactoid glomerulopathy and proliferative glomerulonephritis with monoclonal IgG 
deposits (PGNMID). PGNMID is a rare and recently identified disease with a poor prognosis 
irrespective of the treatment. We report here a case of PGNMID with positive staining for 
a single light-chain isotype κ and a single heavy-chain subtype IgG3 successfully treated 
with corticosteroids.
Case Description: A 43-year-old woman with a 3-year history of proteinuria and 
2-year history of hematuria was hospitalized because of nephrotic syndrome. At the time
of renal biopsy, urinalysis indicated 6.5g/day of urinary protein and microscopic hematuria. 
Serum creatinine was 1.5 mg/dL. Serum and urine M-protein were negative, and the free
light chain κ/λ ratio was within normal limits. Renal biopsy revealed moderate mesangial 
proliferation and endocapillary cell proliferation. Immunofluorescence staining indicated 
IgG, C3 and C1q deposits in the mesangium and along the glomerular capillary walls. To
rule out secondary MPGN, IgG subclass was elucidated, and detected IgG3 monoclonarity. 
The light-chain isotype analysis indicated κ-light chain was detected mainly in the
glomerular capillary walls. Electron microscopy further showed electron dense deposits
in the mesangium and subendothelial space and podocyte foot process effacement. Taken
together, we diagnosed as PGNMID. After the treatment with intravenous steroid pulse and 
consecutive oral steroid, serum creatinine and proteinuria improved to 1.02 mg/dl and under
0.3 g/day, respectively.
Discussion: PGNMID is a novel form of proliferative glomerulonephritis, resembling 
immune complex–mediated glomerulonephritis. However, the glomerular deposits are a 
single γ heavy-chain subclass and a single light-chain isotype, most commonly IgG3 κ in 
the absence of serum M-spike. In patients with PGNMID, about 35% had persistent renal 
dysfunction, and 22% progressed to ESRD. This case suggested importance of IgG subclass 
analysis to diagnosis of PGNMID in cases of MPGN.
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Renal Pathological Analysis Using Galactose Deficient IgA1 Antibody 
Could Differentiate Secondary IgA Nephropathy from Primary IgA 
Nephropathy
Yoshihito Nihei, Hitoshi Suzuki, Toshiki Kano, Maiko Nakayama, 
Yusuke Fukao, Yusuke Suzuki. Juntendo University Faculty of Medicine, Tokyo, 
Japan.
Introduction: In several cases with IgA Nephropathy (IgAN), differenatial diagnosis is 
difficult due to the complication with other diseases that can induce secondary IgAN. Galactose-
deficient IgA1 (Gd-IgA1) has been recognized as the key molecules in the pathogenesis of 
IgAN. Recently, we demonstrated that immunostaining with Gd-IgA1-specific monoclonal 
antibody (KM55 mAb) could differentiate IgAN from other glomerular diseases including 
HCV-related nephropathy (HCV-RN). We report a case of HCV-RN successfully treated by 
Daclatasvir and Asunaprevir by definitive diagnosis using KM55 mAb.
Case Description: A 66-year-old man presented massive proteinuria (5 g/gCr) and 
admitted to our hospital. He has presented with microscopic hematuria and proteinuria 
from the age of 56. After 7 years from the onset of urinary abnormalities, levels of urinary 
protein increased up to 5 g/gCr, and kidney biopsy was performed. Pathological findings 
of kidney biopsy specimens revealed mesangioproliferative glomerulonephritis with IgA 
and C3 deposition, and he was diagnosed with IgAN. Blood examination revealed liver 
dysfunction by HCV infection. Then, we re-analyzed biopsy specimens using KM55 mAb. 
KM55 mAb was negative in this case and thus he was diagnosed as HCV-RN. Then, 
he received antiviral treatment with Daclatasvir/Asunaprevir. Microscopic hematuria 
improved, and proteinuria decreased (1.5 g/gCr) by 24 weeks. After 2 years from treatment 
with Daclatasvir/Asunaprevir, level of proteinuria was 0.8 g/gCr.
Discussion: Patients with HCV infection have a higher risk of end-stage renal disease. 
Definitive diagnosis HCV-RN from IgAN is not easy in patients HCV positive. KM55 mAb 
is a strong tool to differentiate secondary IgAN from primary IgAN
PUB363 
Publication-Only 
An Unusual Case of Serology Negative Crescentic Glomerulonephritis
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Introduction: Anti-GBM (anti-glomerular basement membrane) disease and ANCA 
vasculitis can coexist but very rare. Seronegative anti GBM disease occurs in 3-4% 
and seronegative ANCA disease occurs in 10-20% of patients. We describe an unusual 
renal biopsy showing pathological features of both anti GBM and ANCA crescentic 
glomerulonephritis; however, serologies were negative for anti GBM antibody and ANCA 
antibodies.
Case Description: A 46-year-old female presented with history of fatigue and 
intermittent painless gross hematuria for one month. Physical examination revealed 
pulmonary congestion and edema. Labs showed hemoglobin 8.7 mg/dl, BUN 85 mg/dl 
and creatinine 10.8 mg/dl with nephrotic range proteinuria. The patient was emergently 
started on hemodialysis. Renal imaging showed poor definition of the pelvicaliceal 
collecting system, normal sized kidneys and bladder wall thickening. Serologies revealed 
negative ANA, ANCA, anti GBM titers and normal complements. The patient underwent 
cystoscopy for hematuria, which revealed catheter associated bladder mucosal changes, 
with no tumors. However, there was light bloody efflux from both ureteral orifices. A renal 
biopsy was performed and revealed 90% glomerular involvement by active crescents. 
Immunofluorescence revealed linear glomerular capillary wall staining for IgG. While the 
majority of the crescents were active and cellular, there was also temporal heterogeneity, 
with few subacute (fibrocellular) and rare remote/fibrous crescents. This heterogeneity is 
unusual for anti-GBM nephritis, where all crescents are typically in the same, active stage. 
Despite the finding of linear GBM staining for IgG, the appearance of the crescentic GN 
was more consistent with an ANCA-associated vasculitis. The findings raised the possibility 
of a dual disease process; however, serologic studies for both anti-GBM and ANCA 
were negative. The patient was treated with pulse dose steroids and cyclophosphamide. 
Unfortunately, the patient developed infectious complications to cyclophosphamide and 
treatment was terminated.
Discussion: This case signifies the overlapping features of both anti GBM and ANCA 
crescentic glomerulonephritis on renal biopsy, but with negative serologies. Although rare, 
the possibility of atypical anti-GBM and ANCA antibodies, which are not detected by 
standard commercial assays, should be considered in such cases.
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Steroid-Resistant Nephrotic Syndrome in a Patient with Lupus: Is It Only 
Lupus?
Rodrigo Sepúlveda, Eric Roessler, Juan P. Huidobro, Gonzalo P. Mendez. 
Pontificia Universidad Católica de Chile, Santiago, Chile.
Introduction: Renal involvement in systemic lupus erythematous (SLE) is frequent 
and it has many therapeutic options. Nephrotic syndrome (NS) is a classic manifestation 
of class V lupus nephritis (LN), but it can be also due to lupus podocytopathy, a condition 
with excellent response to steroids. We present a case of steroid-resistant NS with diagnosis 
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of LN, whose further clinical and laboratory work-up revealed an unexpected cause of 
nephrosis in LN.
Case Description: A 21 year old woman with history of hypothyroidism, oral ulcers, 
anemia and foamy urine. Laboratory tests showed: serum creatinine 0.7 mg/dL, albumin 
2 g/dL, total cholesterol 297 mg/dL, proteinuria in nephrotic range and positive antinuclear 
antibodies 1:320. Renal biopsy showed LN class II, with mesangial deposits of IgG, 
IgM, C1q and C3. Electron microscopy showed diffuse foot processes effacement and 
immune complexes in mesangium, without subepithelial, subendothelial or membranous 
deposits. The patient was treated with anti-proteinuric measures, corticosteroids, 
hydroxychloroquine and azathioprine. She persisted with nephrotic range proteinuria 
and severe hypoalbuminemia despite normal blood pressure and no clinical or laboratory 
evidence of active SLE. A change of LN class or lupus podocytopathy was suspected, 
and immunosuppression was intensified. Since nephrotic proteinuria persisted, a second 
renal biopsy and genetic study of NPHS2 mutation was performed. Sequencing NPHS2 
gene resulted in a compound heterozygous mutation with substitutions on p.R229Q and 
p.A284V. The renal biopsy showed focal segmental glomerulosclerosis and the electronic
microscopy revealed diffuse damage of podocytes, with signs of scarring and resolving
immune deposits.
Discussion: A persistent nephrotic syndrome in a patient with controlled SLE despite 
adequate treatment should raise the suspicion of change in the class of LN and/or the 
superposition of a lupus podocytopathy. For those cases with no response to treatment, 
unusual causes of heavy proteinuria should be considered in the differential diagnosis. 
Genetic causes of nephrotic syndrome in young patients with SLE should be part of the 
clinical and laboratory work-up of these type of patients.
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Negative Immunofluorescence
Luis A. Castillo. Fresenius Medical Care, Santa Marta, Colombia.
Background: Recent advances in understanding the role of the alternative pathway of 
complement in membranoproliferative glomerulonephritis (MPGN) consist in evaluating 
the findings of the immunofluorescence (IF): MPGN immune-complex or complement-
mediated. If none of these causes is present, then chronic thrombotic microangiopathy is 
the main cause of MPGN. However, reports on the clinical evolution of these patients are 
limited. The objective of this study was to evaluate the treatment response in patients with 
MPGN and negative IF.
Methods: Analytical and retrospective study. Patients with MPGN pattern through 
renal biopsy and negative IF were included. Each sample was studied by light microscopy 
and included Hematoxylin, PAS, and Jones and trichrome stain. The immunofluorescence 
was performed using direct antibodies against IgG, IgA, IgM, C1q, C3, albumin, fibrinogen, 
Lightweight Kappa and Lambda chains. Patients were evaluated according to response 
groups: complete response, partial response and no-response at 6 and 12 months of 
treatment with Immunosuppressants (MMF or CYC) and glucocorticoids (prednisone).
Results: We included 9 patients with mean age of 33.8 ± 13.1 years, of which 67% 
were male. 5 (62%) patients started with anemia and thrombocytopenia. The most frequent 
clinical presentation was asymptomatic urinary alterations (70%). The means values of 
baseline proteinuria (mg/24h) (1014 ± 1173) at 6 (942 ± 722) and 12 (958 ± 613) months 
did not show statistically significant differences (p<0.05). After 6 months of treatment, 
4 (44%) patients achieved response (33% partial and 11% complete). 6 (66%) failed to 
achieve response at 12 months.
Conclusions: In our study, immunosuppressive therapy did not show statistically 
significant benefits in MPGN with negative IF at 6 and 12 months of treatment. Chronic 
thrombotic microangiopathy may be the cause of the MPGN and a formal trial with 
eculizumab well-characterized patients is warranted.
Response to immunosuppressive treatment of MPGN and negative IF
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Treatment of Fibrillary Glomerulonephritis with Bortezomib- 
Dexamethasone: A Case Report
Abdallah Sassine Geara,2 Matthew Palmer,1 Brendan M. Weiss,1 
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Introduction: Fibrillary glomerulonephritis (GN) is a poorly understood glomerular 
disease with no proven treatments and a poor renal prognosis. We present the case of a 
fibrillary GN successfully treated with bortezomib-based therapy.
Case Description: A 59-year-old Hispanic male had a past medical hypertension and 
microscopic hematuria for many years, for which he had undergone a renal ultrasound and 
cystoscopy which did not reveal an etiology. He developed acute kidney injury (SCr 2.3 mg/dL 
from baseline 1.1 mg/dL). A urinalysis showed moderate blood, 3+ protein, and microscopy 
showed RBC 50-100 dysmorphic/hpf. Urine protein:creatinine ratio (UPCR) was 1.6 g/g. 
Serologic testing for hepatitis B and C viruses, HIV, ANCA’s, C3 and C4 were negative or 
normal. A kidney biopsy was diagnostic of fibrillary glomerulonephritis. He was treated 
with weekly subcutaneous bortezomib 1.3 mg/m2 oral dexamethasone 40 mg on days 1, 
8 and 15 repeated every 28 days. The evaluation for monoclonal gammopathy with serum 
protein electrophoresis and serum free light chain was negative. After his second month of 
treatment, he developed steroid-induced hyperglycemia requiring insulin therapy. With 5 
cycles of therapy, his serum creatinine improved to 1.5 mg/dL, UPCR ratio improved to 
0.1 g/g, and microscopic hematuria improved to 2-5 RBC/hpf. At last follow-up, 8 months 
after stopping treatment, his SCr was 1.8 mg/dL, UPCR was 0.05 g/g, and urinalysis 
showed 20-50 RBC/hpf.
Discussion: We present a case of fibrillary glomerulonephritis successfully treated with 
bortezomib-dexamethsone. The effectiveness of bortezomib-based regimens in fibrillary 
glomerulonephritis requires further exploration.
laboratory trends
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Camilla A. Lima,1 Gisele Vajgel,1,2 Suelen C. Lima,3 Lucila Maria Valente,2 
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Background: The importance of cytokine profile in LN is controversial in spite of their 
role in disease activity. This study measured six cytokines in LN outpatients and analyzed 
outcomes.
Methods: Serum cytokines (IL-2; IL-4, IL-6, IL-10, TNF-α, IL-17) from 59 LN and 
40 healthy control women were measured by Cytometric Bead Array (CBA) using CBA 
Human Th1/Th2/Th17 Kit. Renal response and lupus activity were defined according to 
KDIGO guidelines and SLEDAI respectively. Statistical analyses were done using the 
GraphPad Prism 6.0.
Results: In LN group mean age was 35y (±10), 68% was non-white women with 
median LN diagnosis of 88 (62-156) mo and median SLEDAI was 7.7 (0-12) during serum 
collection. The healthy control group presented mean age of 60y (±5) and 65% non-white 
women. Their kidney biopsy showed proliferative lesions (class III or IV) in 85% of cases 
and they were using maintenance therapy in 86% of cases, mostly with Mycophenolate 
Mophetil (72.4%). Complete or partial response was present at 75.4%, non-response in 
14% and decline of renal function in 10.5% of cases. Serum levels of all the cytokines 
analyzed were significantly increased in LN patients when compared to healthy controls 
(p < 10-4). Similarly, all cytokines were higher in responsive (partial and complete) group 
than non-responsive group (p < 10-5) and IL-17 showed higher values in the responsive 
group (42.37 ± 7.86 pg/mL). However, statistically significant differences were not found 
after 4 years of follow-up. Regarding to LN activity, IL-10 showed increased levels in active 
LN patients (SLEDAI ≥10) (5.07 ± 1.56 pg/mL) in comparison with inactive LN patients 
(SLEDAI <10) (4.67 ± 1.29 pg/mL) (p = 0.037). Additionally, IL-10 levels are correlated 
with higher values of proteinuria and TNF-α levels (r = 0.02 and p = 0.02; r = 0.3 and 
p = 0.02; respectively). Finally, higher TNF-α levels (4.76 ± 1.24 pg/mL) were correlated to 
LN class IV (r = 0.41; p = 0.004) when compared to class III (4.16 ± 0.23 pg/mL).
Conclusions: The anti-inflammatory IL-10 was increased in active lupus probably in 
effort to control disease activity. Class IV LN had higher TNF-α levels, which may be 
related an increased inflammatory process and tissue damage. Higher serum six citokines 
are found in responsives compared to non-responsives, however baseline levels are lacking 
and this did not predict long term outcomes.
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Subacute Bacterial Endocarditis (SBE) Presenting as ANCA-Associated 
Vasculitis (AAV)
Christopher G. Acker. Richmond Nephrology Associates, Richmond, VA.
Introduction: The history, and laboratory evaluation may suggest the diagnosis of an 
AAV, leading the clinician to treat empirically (without renal biopsy). Described is a case of 
Enterococcus faecalis endocarditis (EFE) masquerading as an AAV.
Case Description: A 73-year-old male presented with a history of hypertension, benign 
prostatic hypertrophy and new onset anemia. Five months earlier he had experienced 
onset of hematuria, undergone urologic evaluation showing cortical renal cysts and renal 
asymmetry. At the time of presentation, serum creatinine was 2.1 mg/dL. Additional 
labs showed a hematocrit of 23%, and urinalysis dipstick positive for blood. Hepatitis 
B and C serologies, HIV, ANA, anti-double-stranded DNA, anti-RNP/Sm, anti-SSA/
SSB all negative. C3 was initially normal, low on repeat (76mg/dl); C4 was normal. The 
ANCA returned abnormal (PR3+, MPO-), and a renal biopsy was performed, notable for 
absence of crescents and necrosis, but positive for subepithelial, intramembranous, and 
subendothelial electron dense deposits. Blood cultures were positive for Enterococcus 
faecalis. Echocardiography showed an aortic vegetation, leading to the diagnosis of EFE 
SBE. He was initiated on antibiotic therapy. Due to continued complaints of back pain, an 
MRI was performed, revealing discitis/osteomyelitis.
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Discussion: The appropriate history, biochemical findings, serologies, and positive 
PR3Ab must be interpreted with caution as the possibility of an underlying infection needs 
to be considered. Approximately four reported cases of EFE with PR3Ab positivity have 
been noted previously. While uncommon, SBE as a cause for PR3Ab positivity needs to be 
a consideration.
Rare subepithelial immune type electron dense deposits.
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Rituximab in Minimal Change Disease
Jason M. Kidd, Katie Bean. VCU Medical Center, Richmond, VA.
Background: Adults with minimal change disease are often steroid dependent. 
Rituximab (RTX) is increasingly being used in the treatment of minimal change disease 
(MCD) but data is lacking. Most studies have had small numbers of patients.
Methods: We retrospectively reviewed 7 consecutive patients with steroid dependent* 
MCD who received RTX from 2014-2018 at one academic medical center. Five patients 
(71%) were African American women. Ages range 23-62 (median: 30). RTX was 
administered 1000 mg IV spaced 2 weeks apart. Notably, 2 patients did not receive a 2nd 
dose as intended and subsequently relapsed. *defined as relapsing during glucocorticoid 
taper or within 2 weeks of discontinuation of glucocorticoids
Results: 4 patients achieved complete remission (defined as UP/C ≤0.3 g) and 
3 patients had a partial remission (defined as UP/C between 0.3 g and 3.5 g and a 50% 
reduction of proteinuria) after treatment with RTX. Six patients were nephrotic at the time 
of treatment with RTX (defined as UP/C > 3.5, hypoalbuminemia and edema). Six patients 
were on steroids at time of treatment, 1 patient was on tacrolimus monotherapy. 3 patients 
had relapses of nephrotic syndrome, 2 received repeat doses of RTX, 2 only had one dose 
initially and 1 was lost to follow up. Follow up has ranged from 2-37 months (median: 
24 months). Patient demographics are noted in table. Prior to receiving RTX, 2 patients 
required short term dialysis, 2 patients had venous thromboses, 4 were hospitalized for 
sepsis and 6 were admitted to the hospital with volume overload. Adverse events from 
Rituxan have been limited to 1 patient with alopecia. There were no infusion reactions.
Conclusions: Our small study shows RTX is effective in decreasing proteinuria in a 
largely African American cohort of patients. Randomized trials are needed but RTX should 
be considered as a treatment in steroid dependent minimal change disease.
Patient Demographics
*Pt had partial remission (UP/C 0.5) after 1 dose of RTX, returned with disease flare and 
lost to follow up
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Remission In Pregnancy-Associated Hemolytic Uremic Syndrome with 
Hybrid CFHR1/CFH Gene: Case Report and Review of Literatures
Sami A. Alobaidi,1,2 Ammar Aldabbagh,1 Amany S. Alamoudi,1 
Murad Almowarey,4 Ahmed Akl.1,3 1Department of Medicine, Dr. Soliman 
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Egypt; 4King Fahad Hospital, Medina, Saudi Arabia.
Introduction: Pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) 
is a rare condition and affects 1 of every 25,000 pregnancies. P-aHUS is characterized by 
very high maternal mortality as well as severe morbidity. More than half of all patients 
eventually develop end-stage renal disease in less than 1 month if untreated. Most cases of 
P-aHUS (79%) manifest in the postpartum period; this is probably due to the complement’s 
involvement in aHUS pathogenesis. Eculizumab, a terminal complement inhibitor, is
approved for aHUS treatment. However, its use is limited due to cost, unknown duration of 
treatment, and vague dose intervals to keep patients in remission.
Case Description: In this case report, we present a 26–year-old female with P-aHUS 
with hybrid CFHR1/CFH gene. Eculizumab was initiated after 5 weeks of being on 
hemodialysis and plasmapheresis sessions. Full remission successfully achieved after 6th 
dose of Eculizumab, within 13 weeks of onset of aHUS. She was in full remission with 
Eculizumab, however, due to financial issues Eculizumab was set in hold due to inability 
to financially cover the cost. Within 6 months, she suffered recurrence of the disease and 
Eculizumab was re-instated. After re-inducing full remission, the patient was switched to 
Eculizumab every 3 months instead of the recommended manufacture dose interval of 
every 2 weeks. We followed this patient for 3 years and she continued to be in remission 
based on clinical and laboratory data.
Discussion: In conclusion, achievement of successful and maintenance of remission 
of P-aHUS in this patient who had limited access to Eculizumab raise the attention of the 
efficacy of Eculizumab at longer time intervals. However, it is time to consider conducting 
a long-term study to learn about the safety and efficacy of this approach, which may have a 
major financial advantage for patients.
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Campylobacter Rectus and Cnm-Positive Streptococcus mutans Strains in 
the Oral Cavity Exacerbate Urinary Protein Levels in IgAN Patients
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Background: Some strains of Streptococcus mutans, a major pathogen of dental 
caries, harbour the cnm gene which encodes a collagen-binding protein (Cnm) that has been 
demonstrated to be associated with urinary protein levels in IgAN patients. Periodontitis-
related pathogens, such as Campylobacter or Treponema species, have recently been shown 
to be associated with IgAN. The purpose of the present study was to analyse the association 
of IgAN with Campylobacter rectus, Treponema denticola and cnm-positive S. mutans in 
the oral cavity of humans.
Methods: The presence of C. rectus, T. denticola and cnm-positive S. mutans strains in 
saliva samples of 117 IgAN patients and 56 health controls was evaluated by PCR, and the 
subjects’ clinical parameters were analysed.
Results: C. rectus and cnm-positive S. mutans were significantly more prevalent in the 
IgAN group than in the control group (p < 0.05). Additionally, the C. rectus-positive and 
cnm-positive S. mutans group was shown to be more closely associated with urinary protein 
levels than the other groups in IgAN patients.
Conclusions: Our results suggest that harbouring C. rectus and/or cnm-positive 
S. mutans strains in the oral cavity could be associated with urinary protein levels in the
IgAN patients.
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Acquired Angioedema: A Unique Complication in a Patient with Lupus 
Nephritis
Rohan V. Mehta,1,2 Jason Cobb,4 Rahul Mehta.3 1Open Door Health Centers, 
Eureka, CA; 2Nephrology, Emory University, Atlanta, GA; 3University of Virginia, 
Charlottesville, VA; 4Emory University School of Medicine, Atlanta, GA.
Introduction: Acquired angioedema (AAE) is a rare syndrome of recurrent episodes 
of angioedema without urticaria, which has been associated with B cell lymphoproliferative 
disorders and rarely with autoimmune diseases. In lupus, AAE may arise from an antibody 
mediated functional deficiency of C1 esterase inhibitor (C1INH) - a key inhibitor within 
four interlinked inflammatory cascades.
Case Description: A 28-year-old black woman with quiescent Lupus Nephritis 
class III & V presented with recurrent edema of the face, arms and abdomen. She had 
no family history of angioedema and denied allergies. Physical examination revealed 
bilateral proptosis, edema of the face, arms and abdomen. Respiratory and cardiovascular 
examinations were unremarkable. CT scan of the head and neck showed periorbital 
and neck soft tissue swelling with bilateral proptosis. Laboratory data revealed a serum 
creatinine of 1.7 mg/dl (baseline), leukocyte count of 12,000/microliter and hemoglobin 
of 10 g/dl. Hypocomplementemia was evident (C3 21 mg/dl and C4 11 mg/dL); anti-
DsDNA antibody was 140 IU/ml and urine protein/creatinine ratio was 1700 mg/gm. No 
clinical improvement was noted after three days of high dose intravenous steroids. Further 
investigations revealed a C1INH protein level of 23 mg/dL (15-35 mg/dL), functional 
level of 15 percent (normal > 67 percent), very low C1q level (15 percent) and presence of 
antibodies to C1INH.Rituximab 1 gram produced an expedient clinical recovery.
Discussion: Angioedema is a life-threatening condition involving the mucosa of 
the gastrointestinal and respiratory tract. Acquired angioedema differs from hereditary 
angioedema by absence of family history and late onset of disease. Majority of patients 
with AAE have been found to have an underlying disorder and about thirty percent test 
positive for associated antibodies. In lupus patients with angioedema, antibodies to C1INH 
have been identified. These antibodies lead to an acquired consumption of C1INH resulting 
in a low or normal C1INH protein level, a low functional percentage of C1INH, low C4 
and C1q. Rituximab (a chimeric monoclonal antibody directed at B cells), has been tried in 
some cases of antibody mediated AAE with a favorable rapid response, when conventional 
therapies have failed. In summary, we present a case of steroid resistant AAE probably 
due to Lupus induced antibodies to C1INH and suggest one possible treatment option in 
Rituximab.
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An Uncommon Case of Seronegative Primary Membranous Nephropathy 
in a Young Hispanic Patient
Don H. Esprit,2 Abhilash Koratala.1 1University of Florida, Gainesville, FL; 
2Northern Florida Kidney Care by NPS, Gainesville, FL.
Introduction: Membranous nephropathy (MN) is the most common cause of idiopathic 
nephrotic syndrome in non-diabetic white adults. The mean age of incidence of Primary 
MN is between 50 and 60 and is most common in whites followed by Asians, Blacks, 
and Hispanics. Most cases of PMN have circulating IgG4 autoantibody to the podocyte 
membrane antigen PLA2R (70%). A minority of the patients have thrombospondin type 
1 domain containing 7A (THSD7A) antibodies. It is noteworthy that about 15% cases 
have biopsy evidence of PLA2R staining indicating recent immunologic disease activity 
despite negative serum antibody levels. Herein, we present a case of young Hispanic male 
with biopsy-proven primary MN with positive PLA2R staining but negative circulating 
antibodies.
Case Description: A 34-year-old Hispanic man with no significant medical history 
presented with worsening extreme generalized edema. Laboratory data was consistent 
with nephrotic syndrome with a urine protein-creatinine ratio of 11 g/g, LDL cholesterol 
279 mg/dL and serum albumin of 1.1 g/dL. Further work up for HIV, viral Hepatitis, 
syphilis and common vasculitides was negative. Testing for PLA2R and THSD7A 
antibodies was negative as well. A renal biopsy was obtained, which demonstrated 
thickened capillary loops with subepithelial electron dense deposits and diffuse podocyte 
foot process effacement. Immunofluorescence was strongly positive for PLA2R, suggestive 
of primary MN [Figure]. He was started on RAAS blockade, statin and diuretic therapy 
with symptomatic improvement. He was instructed to follow up with Nephrology in a few 
months to determine the necessity for immunosuppressive therapy.
Discussion: Take home point: Primary MN is typically a disease of middle-aged White 
men but should be included in the differential diagnosis of nephrotic syndrome in patients 
of any age and race. Moreover, while serological anti-PLA2R testing has diagnostic value, it 
must be interpreted in context with patients’ clinical characteristics and histological PLA2R 
staining in seronegative patients is recommended.
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Clinical Significance on the Difference in Character of Glomerular Tip 
Lesion in Adult Nephrotic Focal Segmental Glomerulosclerosis (FSGS): A 
Retrospective Cohort Study
Takaya Ozeki,1 Michio Nagata,2 Takayuki Katsuno,1,3 Sawako Kato,1 
Yoshinari Yasuda,1 Naotake Tsuboi,1,4 Shoichi Maruyama.1 1Nagoya University 
Graduate School of Medicine, Nagoya, Japan; 2Kidney and Vascular Pathology, 
University of Tsukuba, Tsukuba, Japan; 3Department of Nephrology and 
Rheumatology, Aichi Medical University, Nagakute, Japan; 4Department of 
Nephrology, Fujita Medical University, Toyoake, Japan.
Background: In Columbia classification, locating FSGS lesion in tip domain is 
prioritized than its pathological character. Hence, patient with glomerular tip lesion (GTL) 
are usually categorized into tip variant (TIP), not cellular variant (CEL) even if the lesion is 
cellular type. This diagnostic process on GTL has not been discussed well. We investigated 
the clinical importance of the GTL among adult nephrotic FSGS patients with TIP.
Methods: A retrospective cohort study; Among 183 biopsy-proven FSGS during 2005-
2015, 48 patients who fulfilled the criteria below were included to analyses: ≥20 years old, 
nephrotic syndrome (serum albumin ≤3.0 and UPCR ≥3.5), received immunosuppressive 
therapy and whose pathological slides or paraffin blocks were available for review. All 
pathological slides were reviewed on light microscopy by 3 nephrologists and 1 renal 
pathologist. Among TIP cases, patients were divided into 2 subgroups based on the 
dominant character of GTL: cellular type (TIP-CEL) and non-cellular type (TIP-nonCEL). 
The clinical manifestation and treatment course were compared among the subgroups.
Results: Among 48 patients, 16 were TIP (33.3%) and 17 were CEL (35.4%). Among 
16 TIP, 14 cases were categorized into TIP-CEL and 2 cases into TIP-nonCEL. There was 
no difference in the details of immunosuppressive treatment among the subgroups. Even 
though TIP-nonCEL, comparing with TIP-CEL or CEL, manifested higher creatinine 
(1.63 vs 0.99 vs 1.50 mg/dL) and larger urinary protein level (11.31 vs 5.33 vs 7.40 g/gCr), 
TIP-nonCEL showed excellent therapeutic reactivity which was comparable to that of 
MCD to attain complete remission. On the other hand, TIP-CEL showed similar treatment 
response to CEL.
Conclusions: The diagnostic hierarchy of Columbia classification on FSGS may 
be confusing because it contains both aspects of location and characteristics of FSGS 
lesions. In adult nephrotic FSGS, therapeutic reactivity of TIP might be depended on their 
pathological character; presence or absence of cellular lesion.
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Clinicopathological Features in Lupus and Nonlupus Membranous 
Nephropathy
Laura Onuchic, Pamela B. Larrea, Ligia C. Battaini, Cristiane B. Dias, Luis Yu, 
Viktoria Woronik, Lectícia Jorge. University of Sao Paulo, Brazil, São Paulo, 
Brazil.
Background: Membranous nephropathy (MN) is well established as one of the 
morphologic presentations of systemic lupus erythematosus and idiopathic nephrotic 
syndromes. The aim of this study was to compare clinical, biochemical and histological 
characteristics of patients diagnosed with nonlupus MN to class V lupus nephritis (CVLN).
Methods: All MN and CVLN cases diagnosed by kidney biopsy in our center between 
2009 and 2016 were retrospectively analyzed. Clinical and laboratorial data were collected 
at baseline and at the end of follow up.
Results: The prevalence of male gender and older age was significantly higher in 
the MN group (65.2% vs 13.0%, p<0.001 and 48.4±14.7 vs 37.0±11.0 years, p<0.001, 
respectively). The MN group presented higher baseline serum creatinine (Cr, mg/dL) {1.08 
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(0.79;1,88) vs 0.74 (0.58;1.32), p<0.05}, higher proteinuria (g/day) {7.2 (5.1;10.2) vs 2.7 
(1.1:3.9), p<0.01} and lower serum albumin (mg/dL) (2.1±0.77 vs 2.8±0.93, p<0.001) 
when compared to the LN group. After a mean follow-up of 3.0 years (1.1; 6.9) in the MN 
group and 2.9 years (1.0; 5.3) in LN, we observed that both groups presented reduction 
in proteinuria, however the levels were still higher in the MN group {1.7 (0.3;3.8) vs 0.5 
(0.1;1.2) p<0.001}. Following the same trend, the MN group maintained higher Cr levels 
{1.36 (0.90; 2.55) vs 0.75 (0.50; 1.00)}. Among the optical microscopy findings, the only 
significant difference was a higher frequency of mesangial hypercellularity in the CVLN 
than MN group (58.7% vs 37.0% of glomeruli; p=0.015). Immunofluorescence (IF) findings 
are reported in Figure 1.
Conclusions: While optical microscopy was scarcely efficient in differentiating MN 
from CVLN, IF findings were significantly different between the two groups, particularly 
those related to mensangial deposits. We also underscore the difference in renal function 
behavior: stable in CVLN while dropping in MN during the follow-up time.
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Clinicopathological Characteristics of FSGS and Their Correlation with 
Histologic Variants in Selected Population
Nitin K. Bajpai,1 Amit Gupta,2 Manas R. Patel.3 1Department of Nephrology, All 
India Institute of Medical Sciences (AIIMS) Jodhpur, Jodhpur, India; 
2Department of Nephrology, SGPGIMS, Lucknow, India; 3Department of 
Nephrology, SGPGIMS, Lucknow, India.
Background: FSGS is a histological diagnosis in which there is nephrotic renage 
proteinuria and that leads to hypertension and renal failure. Five histological variants of 
FSGS. Not otherwise specified (NOS), perihilar variant, cellular variant, tip variant and 
collapsing variant.
Methods: Study Design: We have included 110 patient of biopsy proven FSGS diagnosed 
between January 2010 to December 2012 retrospectively and collected the clinical data and 
histopathology report of Primary FSGS from institute’s hospital information system. who 
fulfilled inclusion criteria. Kidney biopsy methods: Histopathology reports were classified 
according to Columbia classification guidelines. Clinical data and definitions: Standard 
clinical definition used for data. All patients received oral prednisolone at a dose of 60 mg/m2 
for at least 16 weeks Statistical Analysis: Data were analyzed with SPSS version 18.
Results: A total 110 biopsy proven FSGS patient biopsy were recruited retrospectively 
from January -2010 to December 2012 and clinical finding were noted from our electronic 
hospital information system. Higher degree of Hypertension and renal failure was seen 
in perihilar variant and 24 hour proteinuria was maximum in cellular variant. Table 1 
Interstitial fibrosis, tubular atrophy and fibrointimal thickening were maximum in perihilar 
variant. Whereas glomeruloscelerosis was seen in 100% cases of Cellular variant. Table-2. 
Remission rate after one year is higher in TIP variant as compared other variants. Table 3
Conclusions: In the studied population we found that majority of patient had NOS 
variant. Cellular variant has highest grade of proteinuria whereas perihilar variants greater 
degree of renal failure at presentation. One third have complete remission whereas one 
fourth have partial remission.
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Significantly Different Patterns of Serum Oxidative Stress Levels in 
Children with Nephrotic Syndrome and Children with IgA Nephropathy
Takuji Enya,1 Kohei Miyazaki,1 Tomoki Miyazawa,1 Mitsuru Okada,1 
Tsukasa Takemura,2 Keisuke Sugimoto.1 1Kindai University Faculty of Medicine, 
Osaka, Japan; 2Kushimoto Municipality Hospital, Wakayama, Japan.
Background: Oxidative stress (OS) has been reported to play an important role in 
several renal diseases, including nephrotic syndrome (NS) and IgA nephropathy (IgAN). 
However, no comparison study has been reported. This study was conducted to investigate 
the OS activity in both patient groups.
Methods: Children with NS (n = 5) and those with IgAN (n = 7) at first onset were 
enrolled. The plasma levels of biological antioxidant potential (BAP) and reactive oxygen 
metabolite-derived compounds (dROM) were measured. The dROM and BAP levels were 
<300 U.CARR and 2000 mmol/l higher than normal, respectively. A normal BAP/dROM 
level was defined as ≥10. The patient groups were compared, and the relationships of 
BAP and dROM levels to albumin, creatinine, uric acid, urinary protein, total cholesterol, 
triglyceride, and C-reactive protein levels were studied.
Results: Serum BAP levels were significantly lower in the NS group (1529 ± 259) 
than in the IgAN group (P < 0.001). The IgAN group had significantly higher dROM levels 
(394 ± 107) than the NS group (n = 0.003). BAP/dROM level was low, without significant 
differences, in both groups. A positive correlation was observed between the low CRP and 
dROM levels in the IgAN group (P = 0.02).
Conclusions: In our study, evaluation was limited to the first episode of the diseases. 
Even though their potential antioxidant capacities were comparable, the factors involved 
in the abnormality of the oxidative stress balance differed significantly between the two 
patient groups. As dROM increases in vasculitis, endothelial cell injury might be involved 
in the high dROM level in IgAN. A previous study reported a positive relationship between 
albumin concentration in human preparation and BAP level. Hypoalbuminemia and lipid 
abnormalities are considered to be involved in the reduction of BAP level, and the same 
tendency was observed in this study. OS activity significantly differed between the NS and 
IgAN groups. This helps to clarify the pathophysiological features of NS and IgAN, and 
support additional treatment for both diseases.
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Hemolysis-Derived Heme: A Contributing Factor in Thrombotic 
Microangiopathy
Kioa L. Wijnsma,1 Susan Veissi,4 Elena Volokhina,2 Nicole Van De Kar.3 
1Pediatric Nephrology, Radboudumc, Radboud Institute for Molecular Life 
Sciences, Amalia Children’s Hospital, Nijmegen, Netherlands; 2Radboud 
university medical center, Nijmegen, Netherlands; 3UMC St. Radboud Nymegen, 
Nijmegen, Netherlands; 4Radboud medical center, Nijmegen, Netherlands.
Background: Although Shiga toxin (Stx)-producing E. coli hemolytic uremic 
syndrome (STEC-HUS) is one of the most common causes of acute kidney injury in 
children, the exact pathogenesis is still only partially understood. Due to endothelial injury 
caused by the Stx, the cascade leading to thrombotic microangiopathy (TMA) commences. 
Yet, there is wide variability in clinical presentation and outcome ranging from no chronic 
sequalae to severe neurological impairment and end stage renal disease. One possible 
explanation for this broad range of clinical outcome could be the enhancement of TMA 
through other additional factors. We hypothesized that extracellular accumulation of heme, 
as present during extensive hemolysis, could amplify TMA.
Methods: In this study, we measured levels of extracellular heme and its scavengers 
(hemopexin and heme-oxygenase 1; HO-1) in a cohort of 48 STEC-HUS patients and 
assessed the effects of these disease specific heme concentration, in combination with Stx, 
on glomerular microvascular endothelial cells (GMVECs).
Results: Significantly elevated heme levels up till 21.2 μM were found in STEC-HUS 
patients compared to controls (median of 0.9 μM). These elevated heme levels correlated 
nicely with plasma hemopexin levels (R2 -0.737). Furthermore, heme is internalized in 
GMVECs and subsequently led to a significant increase in reactive oxygen species (ROS). 
Translocation of NFκB and tissue factor indicated enhancement of pro-inflammatory 
and thrombotic state. Interestingly, GMVECs showed a clear decrease of HO-1 after co-
stimulation with Stx2.
Conclusions: We are the first to show elevated heme levels in patients with STEC-HUS. 
Moreover, these heme levels contribute and even amplify the cascade leading to TMA. This 
effect is even more pronounced in STEC-HUS since Stx inhibits the upregulation of HO-1.
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A Case of Nephrotic Syndrome Secondary to Mercury Poisoning Due to 
Chronic Usage of Ayurvedic Medications
Abhijit K. Korane.2,1 1Sunrise hospital, Kolhapur, India; 2Medicine, Dr.D.Y.Patil 
Medical College., Kolhapur, India.
Introduction: Acute and chronic mercury exposure represents a potential threat to 
community health. Mercury poisoning can occur as a result of occupational hazard or herbal 
medicine. All compounds of mercury are toxic but differ in the routes of absorption, clinical 
findings, and responses to therapy. The clinical effects of mercury poisoning depend on the 
form and the route of entry to the organism. Neurologic, gastrointestinal and renal systems 
are predominantly affected depending on the route of exposure. Traditional Ayurvedic 
medicines originated in India 2000 years ago. Approximately one billion people use 
ayurvedic medicines. These medicines contain minerals & heavy metals like lead, Mercury, 
Selenium, Copper which are known to cause renal failure.
Case Description: 25 year old un-married female engineer came with the chief 
complaint of peri-orbital swelling and swelling of both feet since two months. On further 
enquiry patient gives history that since last six months, she had taken ayurvedic medicine 
for her irregular menses. On examination her vitals were stable except her B.P which 
was170/110. Her lab reports were Total Protein -2.4 mg/dl, Serum Albumin- 1.5mg/dl, 
Serum Cholesterol- 281.4mg/dl, Urine protein- ++++, Urine spot protein314, Urine spot 
creatinine - 93.7. Urine protein creatinine ratio was 3.0. On these basis patient was diagnosed 
to have Nephrotic Syndrome. As patient is young female considering SLE her Serum ANA 
& Serum DSDNA was done and her reports came negative. Simultaneously her renal biopsy 
had done shows membranous glomeruloathy. To rule out primary idiopathic membranous 
glomerulonephritis, her Anti-Phospholipase A2 receptor IgG(PLA2R) sent which was < 0.6 
(> 20 positive) which is negative. Now considering her past history, her serum heavy metal 
levels were sent and its reports were following Sr. Mercury-16.6μg/L. She was initiated on 
mercury chelating agent, BAL following which her mercury levels dropped down to 2μg/L. 
Her proteinuria dropped to normal range over next six months without other therapy.
Discussion: This case report emphasizes the importance of public education on 
poisoning and specifically, potential hazards of mercury for preventive community health. 
High risk of suspicion in patients with secondary nephrotic syndrome needs to be kept with 
history of consumption of Ayurvedic medicines.
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The Clinical Significance of C-Reactive Protein (CRP) and  
Erythrocyte Sedimentation Rate (ESR) in Patients with Systemic  
Lupus Erythematosus (SLE)
Danna Ma,2 Yali Zheng.1 1Ningxia People’s Hospital, Yinchuan, China; 2Ning 
Xia Peolple Hospital, Yinchuan, China.
Background: To discuss the clinical significance of CRP and ESR in SLE patients by 
a retrospective analysis.
Methods: 80 SLE cases were divided into 3 Groups,by differences in disease activity, 
whether complicated by infection and by different organs damaged. To analyse the level of 
CRP, ESR in different groups.
Results: 1) General data: There was an increased CRP in 36 cases (45%), and an 
increased ESR in 52 cases(65%). SLE injury multiple systems, the most frequently injuryed 
organ was the kidney (52 cases, 65%). 2) The CRP level was significantly increased in cases 
complicated by infection(p<0.05). The increased level of CRP was significantly correlated 
with serosa damage(p < 0.05). There was no correlation with systemic damage such as 
hematological system, kidney, skin and mucous membrane, joint, nervous system damage 
(p > 0.05). 3) The level of ESR was significantly increased in the patients with organs 
damage including hematological system, kidney, and serosa damage (p < 0.05), but not in 
the patients with mucous membrane and the skin, joint, nervous system damage (p > 0.05).
Conclusions: The level of CRP probably has no relation with SLE disease activity, the 
level of increased ESR may be associated with SLE disease activity. The level of CRP is 
associated with SLE with infectious disease. In terms of organ damage, the level of CRP 
was associated with serosa damage, the level of ESR was associated with blood system, 
kidney, serosa damage.
PUB381 
Publication-Only 
Complex Regional Pain Syndrome (CRPS) Is Common in Loin Pain 
Hematuria Syndrome (LPHS)
Gregory L. Braden,2,1 Abhinav K. Tiwary,1 Daniel L. Landry.2,1 Kidney Care and 
Transplant Services of New England 1Medicine, University of Massachusetts 
Medical School/Baystate, Springfield, MA; 2Kidney Care and Transplant 
Associates of New England, Springfield, MA.
Background: LPHS causes severe flank and lower abdominal pain with micro or 
macro hematuria. We now describe 8/32 patients(pts) with biopsy proven LPHS who often 
have CRPS associated with attacks of LPHS.
Methods: All medical records of our 32 renal biopsy proven LPHS patients (Pt) were 
reviewed for episodes of CRPS associated with this syndrome.
Results: Renal bx showed thin glomerular basement membranes in 3 Pts, thick 
glomerular basement membranes in 4 Pts and normal basement membranes in 1. CRPS 
occured as ipsilateral (IL) arm, leg, flank or abdominal pain with warm (red) or cool (blue) 
skin hypersentitive to touch with livedo reticularis & skin swelling on the same side as the 
loin pain attack. Pt 1: IL arm, back, flank & leg CRPS recurrent many times then finally 
cured by cervical & splancnic blocks and laparascopic sympathectomy and laparascopic 
renal denervation. Pt 2: IL arm, back, & flank CRPS before and after renal autotranplant. 
Abd CRPS occurred at tranpant site and resolved after transplant nephrectomy. Pt 3: 
Recurrent IL flank CPRS after laparascopic renal neurectomy improved by splanchnic 
block and duloxetine. Pt 4: Recurrent IL flank CRPS improved with splanchnic blocks. 
Pt 5: After bilateral renal autotransplant IL back & flank CRPS resolved with splanchnic 
blocks, gabapentin and pregabalin. Pt 6: IL flank CPRS resolved on its own. Pt 7 After left 
renal autotransplant, IL CRPS over the autotransplant still recurring. Pt 8: Recurrent L>R 
flank CRPS treated with an intrathecal pain pump with major improvement.
Conclusions: CRPS occurs in up to 25 % of Pts with LPHS & must be recognized 
& treated with anti-neuropathic procedures and neuropathy medications rather than 
opioids. CRPS can occur before and after renal autotransplantation and laparacopic renal 
neurectomy and may be the cause for failure of these procedures to eliminate pain in LPHS. 
CRPS in LPHS is self limiting and gradually improves with proper therapy
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Trends in Glomerular Disease Epidemiology Among Adults in Saudi 
Arabia, 1997-2017
Abdulkareem Alsuwaida,1 Lamees I. Al-mezaini,2 Noura Ahmed,1 
Amaar A. Bakhit,4 Junaid Wadera,5 Feras A. Alsuwaida,6 Mohamed C. Kechrid,9 
Abdulrahman K. Alabdulsalam,7 Noura Aloudah,3 Majed M. Alanazi,10 
Talal A. Alfaadhel,1 Hanadi M. Alhozali,3 Ghadeer A. Mokhtar.8 1King Saud 
University, Riyadh, Saudi Arabia; 2King Saud University, Riyadh, Saudi Arabia; 
3king abulaziz medical city, Riyadh, Saudi Arabia; 4King Saud University 
Medical City, Riyadh, Saudi Arabia; 5King Khalid University Hospital, Riyadh, 
Saudi Arabia; 6King Saud University, Riyadh, Saudi Arabia; 7National Guard 
King Abdulaziz Medical City, Riyadh, Saudi Arabia; 8King Abdulaziz University, 
Jeddah, Saudi Arabia; 9Security Forces Hospital, Riyadh, Saudi Arabia; 10King 
Abdul Aziz Medical City, Riyadh, Saudi Arabia.
Background: We aimed to examine temporal and demographic trends in renal biopsy 
glomerular disease diagnosis frequencies in Saudi Arabia over the last two decades.
Methods: In this retrospective, observational study, we identified all patients with a 
native kidney biopsy between 1996 and 2017. Biopsy era (before 2000, 2001-2005,2006-
2010 and 2011-2018) and demographics and the relationship with the prevalence of various 
glomerular disease were our primaries.
Results: The study included 1481 Saudi patients had a kidney biopsy with 316 patients 
less than 18 years and 52% were female. The commonest secondary cause of was systemic 
lupus erythematosus. Focal segmental glomerulosclerosis in renal biopsy specimens 
continues to be the commonest pathology with preserved frequencies over the three decades 
(51%, 53%, 36% and 40.0% of diagnoses, respectively; P for trend 0.6). The frequency 
of IgA nephropathy initially stable but then increased significantly in the last decades. 
However, the incidence of MPGN declined significantly (27.3%, 11.1%, 9.4% and 3.6%, 
respectively for trend 0.001). The frequencies of other primary glomerular disease subtypes 
remained stable (Figure 1).
Conclusions: We have observed a significant change in relative renal biopsy frequencies 
of many glomerular disease subtypes over the last two decades. There is a significant 
increase in the prevalence of IgA nephropathy while MPGN continues to decrease. 
Infection-related forms of GN is declining significantly, in contrast to antigenic related GN 
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is becoming a predominant disease. This may support the need to investigate more the 
potential environmental exposures to diet and allergens and it is a role in glomerular disease.
Renal biopsy diagnosis frequencies of the most common primary glomerulonephritis 
subtypes for biopsy era.
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A Quartet of ANCA Associated Glomerulonephritis and Vasculitis Cases 
with Initial Presentation of Gastrointestinal (GI) Symptoms, Which Often 
Are Missed
Mansoor N. Ali. Renal Medicine, Calderdale and Hiddersfield Hospitals NHS 
Trust, Leeds, United Kingdom.
Introduction: Antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis, is 
one of most common causes of new onset glomerulonephritis in adults. The condition is an 
auto-immune disease characterised by an inflammatory response within the mural vessels 
of multiple organs leading to extensive inflammation, damage and necrosis. The response 
produces ANCA autoantibodies against myeloperoxidase (MPO-ANCA) or proteinase-3 
(PR3-ANCA). I describe below case report series for patients presenting with GI symptoms 
leading to delay in diagnosis and management.
Case Description: 1) A 42yrs old patient of Chinese origin, presented through 
emergency department with >3 weeks of diarrheal illness and acute kidney injury (AKI). 2) 
A 68 yrs old Caucasian patient admitted to gastroenterology ward with abdominal pain 
and per rectal (PR) bleeding. AKI noted, fluids given and discharged as gastroenteritis. 3) 
A 69 yrs old patient of Bangladeshi origin had 3 months history of recurrent admissions to 
medical admissions unit with history of abdominal pain, diarrhea and weight loss. 4) A 70 yrs 
old Caucasian elderly patient with preceding symptoms of malaise, weight-loss, presented 
with (PR) bleeding to the general surgeons with AKI. Initial presentation and symptoms 
prompted acute medical and surgical teams to focus entirely on the causes of diarrhea, pre-
renal causes of AKI and further investigations mainly stool C+S, flexible sigmoidoscopy 
and colonoscopy. Due to persistent renal impairment on recurrent admissions, nephrology 
consult was sought where multisystem involvement of ANCA associated vasculitis was 
diagnosed with immunology and histology. In one case, renal impairment progressed to 
ESRF, 3/4 have residual CKD.
Discussion: The diagnosis of ANCA associated vasculitides is complicated by 
marked difference in symptoms, signs, disease activity, chronicity and severity of the 
disease. Nonspecific symptoms of general fatigue, malaise, weight loss, upper airway and 
pulmonary symptoms, and renal impairment are neither sensitive nor specific. However 
diarrheal illness are although not uncommon and documented in MPO vasculitis; may 
completely distract health professionals, and instead lead them to focus on gastrointestinal 
causes of diarrhea especially inflammatory bowel disease or cancerous lesions resulting in 
delay in diagnosis and treating vasculitis.
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Clinico-Pathological Study of C3 Glomerulonephritis at a Tertiary Care 
Centre
Umesh L. institute of nephrourology, Bangalore, India.
Background: Aim - To study the clinico-pathological profile of patients with C3 
glomerulonephritis at a tertiary care centre.
Methods: A prospective observational study of all cases of C3 glomerulonephritis 
was done between August 2016 and December 2017. C3 glomerulopathy was defined 
by predominant glomerular C3 fragment deposition defined as C3c intensity 2 orders of 
magnitude more than any other immune reactant on a scale of 0 to 3.
Results: C3 glomerulonephritis was present in 2.68%of all biopsies int he study period. 
The mean age was 35±2 years of which there was slight male preponderance. Nearly all 
patients had hypertension (93.7%) while 21.8% had pre existing diabetes. More than two 
third of patients presented with RPGN (72%). All patients had active urinary sediments. 
More than half of the patients (56.25%) had low serum C3 levels in our study. All patients 
had normal serum C4 levels. Anti CFH antibody titres were measured in 6 patients of 
with it was elevated in 2 patients (33.3%). On LM the dominant lesion was crescentic 
GN (43.75%). On IF, all patients had dominant C3 staining. Also 3 (9.37%) patients had 
IgG staining of 1+ intensity. EM study was done in two patients and was suggestive of 
DDD in one patient (3.15%). All patients were managed with pulse steroids followed by 
oral steroids. IV Cyclophosphamide was used monthly for 6 doses in 14 patients (43.7%) 
while oral cyclophosphamide was used in 2 patients (6.25%). Plasmapharesis was done in 
patients with elevated anti CHF antibody and in patients with diffuse crescents (11 patients 
-34.37%). Also 11 patients required haemodialysis (34.37%). Among the 11 patients who 
were dialysis dependent, 4 have recovered completely and are in complete remission with 
normal renal function. Of these two had elevated anti CFH antibody titers while the other 
two had diffuse crescents.
Conclusions: C3 glomerulonephritis has emerged as a new entity in the recent past 
with significant percentage of our patients presenting with RPGN with hypertension. On 
light microscopy, the most common presentation was crescentic glomerulonephritis, One 
third of our patients had advanced renal failure requiring haemodialysis. Plasmapharesis 
was done in one third of patients. Patients with anti CFH antibody were successfully treated 
with IV cyclophosmamide and plasmapharesis
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Non-Diabetic Renal Disease in Diabetics: Suspicion Is the Key
Abhilash Koratala, Gajapathiraju Chamarthi, William L. Clapp. University of 
Flroida, Gainesville, FL.
Introduction: Renal biopsy should be considered in diabetic patients who have 
persistent microscopic hematuria, absence of diabetic retinopathy, immunological 
abnormalities and/or uncharacteristic course of serum creatinine to exclude non-diabetic 
renal disease.
Case Description: A 63-year-old White man with a history of diabetes mellitus 
type 2 diagnosed ~30 years ago associated with non-proliferative diabetic retinopathy, 
hypertension, CKD stage 3 and CHF was seen in Nephrology clinic for evaluation of 
worsening kidney function. His diabetes was well-controlled with a hemoglobin A1c of 
6.3% and BP in the clinic was 124/75mmHg. Labs showed serum creatinine of 5.1 mg/dL 
`(~2.7 two months prior and 1.4 a year ago) with an eGFR of 11ml/min and a urine protein-
creatinine ratio of 3g/g (no baseline available). Urinalysis was unremarkable except for 
3+ proteinuria on dipstick. Obstructive nephropathy was excluded by imaging. Serum 
and urine electrophoresis and immunofixation were negative for monoclonal protein. Our 
patient had lost ~ 44ml/min of GFR in just one year in the setting of well-controlled diabetes 
and hypertension, which is unusual for diabetic nephropathy. Therefore, we obtained a renal 
biopsy which demonstrated severe κ light chain (AL) amyloidosis [Figure]. A serum free 
light chain assay obtained retrospectively after the biopsy showed elevated κ/ λ ratio of 
8.66. An endomyocardial biopsy excluded cardiac amyloidosis. Bone marrow biopsy was 
negative for amyloidosis but showed 2% abnormal plasma cells consistent with monoclonal 
gammopathy of undetermined significance (or more appropriately, ‘renal significance’ in 
this case). His renal function continued to worsen requiring initiation of hemodialysis. 
Chemotherapy with Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is 
being planned.
Discussion: Take-home points: (a) Non-diabetic renal disease should be suspected 
in diabetic patients with unexplained worsening of creatinine despite the presence of 
retinopathy, (b) Serum free light chains should be obtained in addition to immunofixation 
to screen for paraproteinemia.
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Changing Patterns of Glomerular Disease in Saudi Children, 1997-2017
Abdulkareem Alsuwaida,1 Lamees I. Al-mezaini,1 Noura Ahmed,1 
Amaar A. Bakhit,2 Junaid Wadera,3 Feras A. Alsuwaida,4 Mohamed C. Kechrid,5 
Abdulrahman K. Alabdulsalam,6 Noura Aloudah,7 Majed M. Alanazi,8 
Talal A. Alfaadhel,1 Hanadi M. Alhozali,9 Ghadeer A. Mokhtar.9 1King Saud 
University, Riyadh, Saudi Arabia; 2King Saud University Medical City, Riyadh, 
Saudi Arabia; 3King Khalid University Hospital, Riyadh, Saudi Arabia; 4King 
Saud University, Riyadh, Saudi Arabia; 5Security Forces Hospital, Riyadh, 
Saudi Arabia; 6National Guard King Abdulaziz Medical City, Riyadh, Saudi 
Arabia; 7king abulaziz medical city, Riyadh, Saudi Arabia; 8King Abdul Aziz 
Medical City, Riyadh, Saudi Arabia; 9King Abdulaziz University, Jeddah, Saudi 
Arabia.
Background: There have been significant changes in the incidence of different 
glomerular disease in adults. We aimed to trends in renal biopsy glomerular disease 
diagnosis frequencies in Saudi children over the last three decades.
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Methods: In this retrospective, observational study, we identified all patients less than 
18 years with a native kidney biopsy between 1996 and 2017. Biopsy era (before 2000, 
2000-2009, and 2010-2018) and demographics and the relationship with prevalence of 
various glomerular disease were our primary outcome.
Results: In total, 289 cases of renal biopsy were analyzed with the median age of the 
patients was 13 years and 52.6% of the patients were female. Secondary glomerulonephritis 
accounted for 28.7% and Lupus Nephritis (LN) is the commonest cause noted in 72.3%. 
Minimal change disease (MCD), and focal segmental glomerulosclerosis (FSGS) were 
the leading primary glomerulonephritis diagnoses observed in 66%. The frequency of 
membranoproliferative glomerulonephritis (MPGN) decrease significantly to 6.7% in most 
recent biopsy era versus 35.3% in the era earlier than 2000 (p < 0.003). The frequency of 
IgA nephropathy (IgAN) and membranous nephropathy (MN), doubled in the latest era.
Conclusions: Primary glomerular disease continued to be the predominant kidney 
disease in Saudi Arabia with MCD and FSGS being the most common pathology. The 
incidence of MPGN has decreased in the last decades possibly related to improved 
socioeconomic conditions and decline in regional endemic diseases. LN is the commonest 
cause of secondary GN.
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Study of Remission and Relapse in IgA Nephropathy with Steroid 
Therapy
Hideo Tsushima. Nara Medical University Nara Medical University, Kasihara-
city, Japan.
Background: Prognosis for the development of end-stage renal disease (ESRD) in the 
patients with relapsed IgA nephropathy have not fully understood.
Methods: We retrospectively investigated the clinical and histological renal prognostic 
markers and cause of relapse in the cases of IgA nephropathy whom were performed renal 
biopsy from January 1980 to December 2013 and were received steroid therapy. We defined 
that remission was less than 0.3g/gCr or negative in dipstick three times in a row. And we 
defined that relapse was more than 0.5g/gCr or 1+ in dipstick three times in a row after 
remission.
Results: One hundred sixty five patients who had the diagnosis of IgA nephropathy 
were enrolled. Mean age at the time of renal biopsy was 40.2±6.1 years old. Urinary protein 
was 1.07±0.2 g/gCr. When clinical parameters were evaluated by univariate analysis, 
relapse was closely associated with the degree of proteinuria. The rate of glomerular 
sclerosis and cresents at initial biopsy did not contribute to relapse. Relapse had an equally 
poor prognosis as non-remission.
Conclusions: Our findings demonstrated that remission of proteinuria was a prognostic 
index for the preservation of renal function. The severity of gromeruli at initial renal biopsy 
did not correlated with future reccurence of IgA nephropathy.
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Urinary Myo-Inositol as a Potential Marker for Focal Segmental 
Glomerulosclerosis: NMR-Based Metabolomics Study
Young Lee Jung,1 Jung Nam An,2 Jin Seong Hyeon,3 Seung Hee Yang,4 Jang-
Hee Cho,5 Jung Pyo Lee.2 1Seoul National unioversity Hospital, Bucheon, 
Republic of Korea; 2Seoul National University Boramae Medical Center, Seoul, 
Seoul, Republic of Korea; 3Korea Basic Science Institute, Seoul, Republic of 
Korea; 4Kidney Research Institute, Seoul National University, Seoul, Republic 
of Korea; 5Kyungpook National University Hospital, Daegu, Republic of Korea.
Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis 
(FSGS) have similar histological findings initially, however, response to steroid treatment 
and long-term prognosis are quite distinct from each other. Therefore, it is of great 
importance to discriminate FSGS from MCD in the early phase of disease and predict 
clinical prognosis.
Methods: Discovery set consisted of 185 urine samples (62 healthy controls, 81 
MCD, and 42 FSGS) collected at the time of kidney biopsy from 2010 to 2017 at Seoul 
National University Hospital and Seoul National University Boramae Medical Center. As 
validation set, we used 61 urine samples (12 healthy controls, 26 MCD, and 23 FSGS) 
from Gangdong Kyung Hee University Hospital and Gyeongbuk National University 
Hospital. Characteristic differences of urine metabolites depending on MCD and FSGS 
were examined using 800 MHz nuclear magnetic resonance (NMR) spectroscopy. After 
normalization by urine creatinine, the values were transformed to log values.
Results: Of 73 urine metabolites, log-transformed myo-inositol was significantly 
higher in FSGS patients compared with control patients (2.63-fold; P < 0.001) and with 
MCD patients (2.79-fold; P < 0.001). Log-transformed myo-inositol showed an inverse 
relationship between the initial chronic kidney disease stages (P < 0.001) or estimated 
glomerular filtration rate at baseline (R2 = 0.465, P < 0.001). In addition, it was significantly 
associated with plasma level of soluble urokinase-type plasminogen activator receptor in 
FSGS patients (R2 = 0.228, P < 0.001). Validation set revealed that log-transformed myo-
inositol in urine samples of FSGS patients increased by 2.6-fold (P < 0.001) and 1.8-fold 
(P < 0.05) than control patients and MCD patients, respectively.
Conclusions: Myo-inositol, as urine metabolite, discriminated FSGS patients from 
MCD or control patients at the time of early diagnosis and significantly associated with 
initial renal function. Further studies including the correlation with clinical prognosis and 
the possible mechanism will be performed.
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Effect of Epipharyndeal Abrasion Therapy (EAT) on the Remission of IgA 
Nephritis/Vasculitis
Masashi Mizuno, Michio Fukuda, Tadashi Oikawa, Satoru Kominato, 
Minamo Ono, Taisei Suzuki, Nobuyuki Ohte. Department of Cardio-Renal 
Medicine and Hypertension, Nagoya City University, Mizuho-ku, Japan.
Background: Epipharyngeal Abration Therapy (EAT) is expected to contribute to 
the treatment for IgA-nephritis/vasculitis, fibromyalgia, chronic fatigue, atopic dermatitis, 
Palmoplantar pustulosis.
Methods: Effect of EAT using 0.5%- zinc chloride on the cumulative incidence of 
complete remission of nephropathy (CR, defined as urinary red blood cell less than 
1/HPF and proteinuria less than 30 mg/gCre) was studied on 20 patients with IgA -nephritis/
vasculitis (9 male, 32 median-years) [UMIN000009157].
Results: Fifteen patients achieved CR for median treatment duration of 7 months. The 
time from onset, diagnosis, and initiation of the combination therapy with tonsillectomy and 
steroid-pulse therapy to EAT did not influence to CR (HR 0.87-1.19, NS). Hematuria (/HPF, 
p=0.8), proteinuria (mg/gCre, p=0.4), glomerular filtration rate (mL/min/1.73m2, p=0.6), 
and Oxford-MEST-C score (NS) did not affect the cumulative incidence of CR. Of note, 
in 19 patients, hematuria was completely diminished. None of the 20 patients experienced 
adverse event (eg. infectious events).
Conclusions: We defined the CR of hematuria as less than 1/HPF. However, hematuria 
1-4/HPF did not demonstrate increased activity of IgA-nephritis/vasculitis because patients 
with IgA-nephritis/vasculitis can exhibit thin glomerular basement membrane independent 
of activity of nephropathy. Most patients in our study cannot achieve CR by combination
therapy with tonsillectomy and steroid-pulse therapy. Further study is needed to investigate 
the effect of EAT as initial therapy on CR of IgA-nephritis/vasculitis.
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Metabolomics Based Biomarkers as Clinical Outcome Indicator in 
Minimal Change Diseases
Young Wook Choi,1 Jung Nam An,2 Jin Seong Hyeon,3 Jinhyuk Kim,9 Seung 
Hee Yang,4 Sangho Lee,8 Jang-Hee Cho,5 Dong Ki Kim,6 Geum-Sook Hwang,7 
Jung Pyo Lee.2 1Seoul National University, Boramae Medical Center, Seoul, 
Republic of Korea; 2Seoul National University Boramae Medical Center, Seoul, 
SEOUL, Republic of Korea; 3Korea Basic Science Institute, Seoul, Republic of 
Korea; 4Kidney Research Institute, Seoul National University, Seoul, Republic 
of Korea; 5Kyungpook National University Hospital, Daegu, Republic of Korea; 
6Seoul National University Hospital, Seoul, Republic of Korea; 7Korea Basic 
Science Intsitute, Seoul, Republic of Korea; 8Kyung Hee University Hospital at 
Gangdong, Seoul, Republic of Korea; 9SMG-SNU Boramae Medical Center, 
Seoul, Republic of Korea.
Background: Minimal change disease (MCD) is well known as one of the 
glomerulonephritis (GN) that recur frequently. We investigated the clinical outcome of 
Metabolomics based biomarkers in patients with MCD.
Methods: Urine samples from healthy control (n=61), primary MCD (n=81) and MCD 
follow up (n=35) were analyzed with NMR-spectroscopy. Metabolites were then quantified 
and compared between groups.
Results: In the urine samples, metabolites that showed a clear difference between 
the healthy control group and the MCD group were analyzed. In addition, when these 
metabolites level were completely remission in the MCD follow up group, they were 
restored to the healthy control group level.
Conclusions: In this study, we suggest that metabolites biomarker is a reliable tool for 
the prediction of MCD prognosis and guidance of therapeutic plans.
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Cellular Crescents in Class V Lupus Nephritis: Mere Coincidence or More 
Than That?
Abhilash Koratala, Xu Zeng, Olanrewaju A. Olaoye, Mark S. Segal. University 
of Florida, Gainesville, FL.
Introduction: Membranous nephropathy (MN) is typically not associated with 
glomerular crescents. However, crescentic MN has been reported to occur in conjunction 
with anti-GBM antibody disease, ANCA vasculitis and IgA nephropathy. In membranous 
(class V) lupus nephritis (LN), cellular crescents may be seen when it occurs together with 
class III or IV proliferative LN. In addition, fibrous or fibrocellular crescents may be seen 
in class V as a sequela of previous proliferative, crescentic glomerulonephritis. Herein, we 
report a unique case of class V LN associated with cellular crescents, but no endocapillary 
proliferation or necrotizing lesions.
Case Description: A 51-year-old AA woman with a history of SLE presented to our 
clinic to establish care for LN. She was first diagnosed with class IV LN 6 years prior 
to presentation, at which time she was treated with prednisone and 6 monthly cycles of 
cyclophosphamide. Post-treatment biopsy demonstrated class III LN and she was started 
on Mycophenolate mofetil (MMF) 1000mg bid maintenance therapy but was tapered off 
after 1 year of treatment. A year later, MMF was restarted when she presented with alopecia 
and proteinuria of~2 g/g. After 1 year, her proteinuria was 0.6 g/g with preserved renal 
functuion all this time (Scr <1mg/dL) and her rheumatologist stoped the MMF and initiated 
belimumab. She was lost to follow up after a few months and the belimumab was stopped. 
On her own she took MMF 250mg bid for some time, but stopped due to GI side-effects. At 
presentation to us, her Scr was 1.63 mg/dL with proteinuria of 3.3 g/day. A renal biopsy was 
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performed, which demonstrated class V LN with cellular crescents [Figure]. We treated her 
with pulse corticosteroids and started enteric-coated mycophenolic acid.
Discussion: To the best of our knowledge, cellular crescents in association with 
isolated class V LN has never been reported. In the absence of endocapillary proliferation, 
the cellular component of these crescents is likely constituted by glomerular parietal and 
visceral epithelial cells as opposed to macrophages. At this time, the prognostic significance 
of crescents is unclear.
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Glomerular Diseases Induced by Medications: Clinical Picture, Histopa-
thology and Outcomes
Sophia Lionaki,1 Hara Gakiopoulou,2 Georgios Liapis,3 Petros Sfikakis,4 
Athanasios Tzioufas,5 John Boletis.1,6 1Nephrology, Laiko Hospital, Athens, 
Greece; 2Pathology, National & Kapodistrian University of Athens, Athens, 
Greece; 3Pathology, Laiko Hospital, Athens, Greece; 4Internal Medicine, 
National & Kapodistrian University of Athens, Athens, Greece; 5Pathophysiology, 
National & Kapodistrian University of Athens, Athens, Greece; 6Medicine, 
National & Kapodistrian University of Athens, Athens, Greece.
Background: The aim of this study was to describe the clinical and histopathological 
characteristics of patients with drug-induced glomerular diseases along with the related 
clinical syndrome and the long-term outcome after discontinuation of the offending 
medicine.
Methods: All cases with any type of biopsy proven glomerular disease, which was 
associated with administration of a certain medication were studied retrospectively. 
Demographics and patients’ characteristics were recorded along with the related clinical 
and histopathological picture, the treatment and the outcome during the follow up time.
Results: Eight patients with glomerular diseases associated with medicines were 
identified. Six of them were females with a mean age of 59.6(±18.8) years. The renal biopsy 
was performed within 3-17 days from onset of symptoms, which included either nephrotic 
syndrome (n=4) or nephritic syndrome with acute renal dysfunction (n=4). Patients with 
acute nephritic syndrome reported general symptoms including fever, arthralgias, fatigue, 
anorexia and rash. Histopathological evaluation revealed minimal change disease in 3 
patients, membranous nephropathy in 1, pauci-immune glomerulonephritis in 2 and lupus 
like nephritis (WHO Class III, καιIV) in 2. The medicines, which were associated were 
d-penicillamine, tamoxiphen, OH-chlorokine, NSAIDs, propyl-thiouracile, etarnecept,
methimazole and infliximab. The median value of serum creatinine was 0.5 (min: 0.5, max: 
2.7 mg/dl), of 24-hour proteinuria was 5530 mg (min: 630, max: 240000 mg) while 4 of
the patients had active urine sediment. In patients with nephrotic syndrome discontinuation 
of the offending drug lead to complete remission within a few weeks. Patients with acute
nephritis required treatment with cyclophosphamide and glucocorticoids for 3-6 months, in 
addition to the removal of the offending drug.
Conclusions: In this small series of patients with glomerular diseases associated with 
medicines discontinuation of the related drug lead to remission of the nephrotic syndrome 
within a few weeks while patients with acute nephritic syndrome required treatment with 
cyclophosphamide and glucocorticoids for 3-6 months, in addition to the removal of the 
offending drug.
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Eculizumab Improves Outcomes in Patients with Thrombotic Microangi-
opathy Without ADAMTS-13 Deficiency in Comparison with Therapeutic 
Plasma Exchange
Miguel Uriol Rivera,1 Aina Obrador,2 Sheila Cabello Pelegrin.3 Son Espases 
TMA Group 1Hospital Universitario Son Espases, Palma de Mallorca, Spain; 
2Son Espases University Hospital, Palma de Mallorca, Spain; 3Hospital 
Universitari Son Espases, Palma de Mallorca, Spain.
Background: Thrombotic microangiopathy (TMA) is a life-threatening disease or 
complication. Early therapeutic plasma exchange (TPE) is the first line recommended 
treatment; unfortunately, in patients with TMA without ADAMTS-13 deficiency, the 
prognosis did not change over time. The introduction of the anticomplement C5 therapy 
(Eculizumab) indicated for atypical hemolytic uremic syndrome (HUS), may improve 
the prognosis of TMA. The potential differences on efficacy between TPE in comparison 
with Eculizumab for the TMA control has not been evaluated. Objective: To compare the 
efficacy of the use of TPE versus Eculizumab on the risk of chronic renal replacement 
requirements or death (outcome) in patients with TMA.
Methods: This a retrospective study. Patients of the tertiary referral hospital with 
TMA and without ADMST-13 deficit or patients with HUS and renal proven biopsy were 
included. Period evaluated: from January/2008 to February 2018.
Results: 37 patients were evaluated. Mean age 41 years. Sex: Female: 24(64%). TPE 
was used in 17(46%) and Eculizumab on 20(54%) of the patients. No differences on age, 
sex, hemoglobin, lactate dehydrogenase, platelets count, urgent dialysis requirements or 
admission at intensive care unit between groups were observed. 11(27%) patients met study 
outcome, 8 patients were treated with TPE and 3 with eculizumab. From those treated with 
TPE, 8 (47%) met outcome (x2:0.04; P=0.82), while in those treated with Eculizumab, it 
was observed only in 3(15%) patients (x2: 12,65; P<0.01); moreover, in 8 patients initially 
treated with TPE, the use Eculizumab as a rescue treatment was required. The comparative 
analysis shows that the odds ratio of chronic renal replacement needs or death in patients 
treated with TPE versus Eculizumab was 18.4 (95%CI, 3.5 to 97.0).
Conclusions: There is an important difference between TPE in comparison with 
Eculizumab in the prognosis of the TMA without ADAMTS-13 deficiency. The use of the 
Eculizumab should be considered as a first line treatment option in these patients.
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Tonsillectomy with Steroid Pulse Therapy for IgA Nephropathy
Yusuke Fukao, Hitoshi Suzuki, Toshiki Kano, Yuko Makita, Yusuke Suzuki. 
Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: IgA nephropathy (IgAN) is the most frequent cause of primary 
glomerulonephritis worldwide. The clinical course of IgAN is extremely variable and 
ranges from asymptomatic microscopic hematuria to rapidly progressive renal failure. 
Although the pathogenetic mechanisms of IgAN are still obscure, galactose-deficient IgA1 
production may be in the mucosa-bone marrow axis. Indeed, some clinical studies indicated 
that tonsillectomy plus steroid pulse (TSP) therapy have favorable effects on IgAN. In 
present study, we evaluated the efficacy of TSP therapy compared with renin-angiotensin 
system inhibitor (RAS-i) alone for IgAN in our cohort.
Methods: We retrospectively recruited 141 biopsy proven patients with IgAN 
from 2012 to 2015. The observation period in this study was 24 months. Those patients 
were divided into three treatment groups; TSP group (n=88), Tons group (n=25) who 
received tonsillectomy alone, CT group (n=28) who treated with RAS-I, but not any 
immunosuppressant. Primary evaluation items were the disappearance of urinary protein 
and microscopic hematuria indicating clinical remission.
Results: At the time of renal biopsy, the amount of urinary protein excretion was 0.7g/gCr 
in TSP group and 0.4g/gCr in CT group. Degree of hematuria was severe in TSP group 
than in CT group. Age, gender, serum creatinine, and eGFR were not different between 
each group. During the intervention period, TSP has the strong effect on improvement of 
urinary protein compared with CT group (p<0.01). Remission rate of hematuria in TSP 
group (75.4%) was greater than other groups (Tons group: 55.6%, CT group: 50%). Those 
therapeutic effect persisted until the final observation. TSP therapy also has an effect to 
reduce serum level of IgA (26% decreased, p<0.01). The Cox regression model showed that 
the TSP therapy was more effective in clinical remission than treatment with RAS-I alone.
Conclusions: TSP therapy successfully induced higher clinical remission even in the 
clinically severe cases of IgAN as compared to sole tonsillectomy or RAS-i therapy.
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Risk Factors for ESRD in Lupus Nephritis Class IV
Camila B. Oliveira, Denise M. Costa, Gisele Vajgel, Maria Alina G. Cavalcante, 
Lucila Maria Valente. Hospital das Clinicas - UFPE, Recife(PE) BRAZIL, 
Brazil.
Background: Lupus nephritis (LN) class IV is the most common renal manifestation 
of SLE and represents an important cause of morbidity and mortality. The purpose of this 
study was to determine risk factors for ESRD in patients with LN class IV.
Methods: Retrospective cohort of adult patients with biopsy proven LN class IV (ISN/
RPS classification). Exclusion criteria were biopsy with <10 glomeruli and follow-up 
<12 months. Clinicopathological characteristics and long-term follow-up were analyzed.
Results: Baseline characteristics of 89 patients with LN class IV are shown in Table 
1. After a follow-up of 57.2± 37.6 months, 73% of patients achieved complete or partial
remission and 24.7% progressed to ESRD. The final sCr was 1.9±1.1mg/dl and CrCl was
65.0±41.7ml/min/1.73m2. The risk factors for ESRD were class IV-G (RR 3.92, 95%CI
1.25–12.24;p=0.006), interstitial fibrosis (IF) ≥25% (RR 2.63, 95%CI 1.19-5.91;p=0.012), 
chronicity Index (CI) ≥4 (RR 3.64, 95%CI 1.47–9.00;p=0.002) and no remission (NR) in 12 
months (RR 9.32, 95%CI 2.98–29.20;p<0.001). In multivariate analyses, NR in 12 months
was associated to a risk for ESRD of 9.32 (95%CI 2.96-29.4;p<0.001).
Conclusions: Class IV-G, IF>25% and CI≥4 were associated with higher risk of 
ESRD. However, the main risk factor of ESRD was NR in 12 months.
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Table 1. Baseline characteristics of 89 patients with LN class IV
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Can Severe Thrombocytopenia Lead to Kidney Injury
Samer Mohandes,1 Abigail B. Shoben,2 Sergey V. Brodsky,3 Brad H. Rovin,1 
Lee A. Hebert.4 samer mohandes 1Ohio State University Wexner Medical Center, 
Columbus, OH; 2The Ohio State University, Columbus, OH; 3OSU, Columbus, 
OH; 4Ohio State University Medical Center, Columbus, OH.
Background: The gamut of anticoagulation related nephropathy (ARN) has expanded 
beyond its initial identification as warfarin related nephropathy to include other oral 
anticoagulants. Idiopathic thrombocytopenic purpura (ITP) is an immune mediated 
thrombocytopenia diagnosed by exclusion of other causes of thrombocytopenia and 
characterized by recurrent episodes of severe thrombocytopenia. We undertook this study to 
assess whether episodes of severe thrombocytopenia are associated with worsening kidney 
function
Methods: A retrospective study of all patients admitted to a single center between 
10/1/2006 and 9/30/2017 and diagnosed with ITP. Mean creatinine levels done in the 5 day 
period before the nadir were compared with the mean 15 days after to identify a statistically 
significant trend.
Results: 191 patients were identified that had adequate testing for the analysis. The 
meain increase in the serum creatinine following the nadir platelet level was 0.156 mg/dl 
with a 95% confidence interval of 0.021-0.292 and a p value of 0.024.
Conclusions: This exploratory study shows a small but significant mean increase in 
serum creatinine (0.156 mg/dl), p value= 0.024 at the nadir level of thrombocytopenia. 
This suggests that severe thrombocytopenia may also contribute to anticoagulation related 
nephropathy.
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Urinary Biomarkers in the Prediction of Prognosis and Treatment 
Response in IgA Nephropathy
Timm H. Westhoff,1 Thomas Rauen,2 Jürgen Floege,3 Frederic Bauer,4 
Felix S. Seibert,5 Nina Babel,6 Frank Eitner.7 1Ruhr-University Bochum, 
Germany, Herne, Germany; 2University Hospital Aachen, Aachen, Germany; 
3RWTH University of Aachen, Aachen, Germany; 4Ruhr-University Bochum, 
Herne, Germany; 5University Hospital Marien Hospital Herne, Herne, 
Germany; 6Ruhr University Bochum, Herne, Germany; 7Bayer AG, Wuppertal, 
Germany.
Background: The addition of immunosuppression to supportive care reduces 
proteinuria in a subset of patients with IgA nephropathy (IgAN) but is associated with an 
increased rate of adverse events. The present work investigates whether urinary biomarkers 
are able to identify subjects who benefit from immunosuppression and to predict the 
progression of disease in a sub-cohort of the STOP-IgAN trial.
Methods: Urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule-1 (KIM-1), calprotectin, and the product of tissue inhibitor of metalloproteinase-2 
and insulin-like growth factor-binding protein 7 (TIMP2, IGFBP7) were measured in all 
available urine samples obtained at the time point of enrollment in the STOP-IgAN trial 
(n=113).
Results: Biomarker concentrations in both the overall study population and the subgroup 
with additional immunosuppression did not differ in subjects reaching vs. not reaching full 
clinical remission, eGFR loss ≥15, or 30 ml/min/1.73 m2 over the 3-year trial phase (p>0.05 
each). Receiver-operating characteristic curves showed a poor predictive accuracy of each 
biomarker for the above mentioned parameters in the overall study population (areas under 
the curve ≤0.611). Accordingly, there was neither a significant correlation of any biomarker 
and adverse outcome in linear regression analysis, nor between biomarker concentrations at 
enrolment and change in the eGFR over the 3-year observation period.
Conclusions: NGAL, KIM-1, calprotectin, and [TIMP-2]x[IGFBP7] had neither a 
prognostic value for the progression of IgAN, nor for the response to immunosuppression 
in the present sub-cohort of the STOP-IgAN trial. The search for appropriate biomarkers for 
an individualized treatment strategy in IgAN continues.
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Treatment Strategy in a Case of Uncertain Glomerulonephritis
Golriz Jafari,1 Anita Kamarzarian,1 Raghu Konanur venkataram.2 1UCLA-Olive 
View Medical Center, Los Angeles, CA; 2Olive View- UCLA Medical Center, 
Porter Ranch, CA.
Introduction: Evaluation of patients with nephrotic range proteinuria usually entails 
urinalysis, autoimmune/infectious serologies and immunoglobulins. These tests may hint at 
a potential underlying cause which would lead to a kidney biopsy to confirm the diagnosis. 
Alsowhen all tests are negative and there is not a clear etiology (e.g. diabetes mellitus), 
a biopsy is also warranted. This patient presents with multiple potential etiologies of 
glomerulonephritis (GN) however biopsy may result in an unnecessary risk.
Case Description: 59 year old male with hypertension, diabetes, pulmonary hypertension, 
hepatitis C (HCV) cirrhosis and prior Hepatitis B infection referred to nephrology for 
proteinuria evaluation. Uprt/Ucr peaked at 4gm and Cr 2.15 (eGFR 33 ml/min/m2); 
HCV RNA 3.1M IU/ml, ANA 1:320, cryoglobulin 10%, serum immunofixation with 
IgM kappa and lambda spike, Urine immunofixation negative; C3 76 mg/dl, C4 8 mg/
dl; dsDNA, ANCA, HIV and RPR screens negative; UA 46 RBCs and 6 WBCs. Renal 
biopsy was considered due to multiple potential etiologies of proteinuria i.e. HCV, MPGN, 
SLE, IgA, paraproteinemia associate GN, however patient was considered to have high 
bleeding risk (platelet 87K and INR 1.4). Therefore patient was treated empirically for HCV 
associated cryoglobulinemia with glecaprevir and pibrentasivir for 12 weeks. Hematology 
evaluation recommended rituximab therapy for the cryoglobulinemia since the most likely 
etiology of the abnormal immunofixation result rather than a plasma cell disorder. He 
also received tenofovir to prevent hepatitis B reactivation. After treatment Cr improved to 
1.53 mg/dl and Uprt/Ucr 0.6 gm, complements normalized and UA with 4RBCs and 0 
WBC.
Discussion: The standard approach in patients with nephrotic range proteinuria, an 
active urinary sediment and multiple positive serologies would be to perform a kidney 
biopsy. In this case after evaluating the potential risks associated with biopsy, the differential 
and treatment options, we decided to treat empirically. Whilst it is true the patient may have 
had MPGN or Membranous GN, in this case would be secondary to the HCV infection. If 
there was underlying lupus nephritis, the patient may have responded to rituximab otherwise 
biopsy would be reconsidered for lack of response. Therefore it poses less potential harm to 
treat the most likely underlying etiology and evaluate response in certain situations.
PUB399 
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Urinary Membrane Attack Complex (UMAC) Perspectives as a Bio-
marker for Monitoring Response to Treatment in Focal and Segmental 
Glomerulosclerosis (FSGS)
Juan C. Trimino,1 L. M. Perez-Navarro,2 Virgilia Soto,3,1 Rafael Valdez-Ortiz.1 
1Hospital General de Mexico, Mexico, Mexico; 2Hospital General de México Dr. 
Eduardo Liceaga, México, Mexico; 3INC Ignacio Chavez, Mexico City, Mexico.
Background: The role of UMAC in the FSGS is unknown. Has been reported that 
complement activation is present in FSGS patients and associated with disease severity. 
The aim was assessed the relationship between UMAC and the classification of FSGF and 
treatment response.
Methods: Longitudinal study in patients with FSGF. We evaluated fibrosis grade, 
urea, creatinine, albumin, CKD-EPI and UMAC. UMAC was quantified by mass 
spectrophotometry. Student’s t-test, one-way ANOVA, 95% CI, and p <0.05 were performed 
as statistically significant.
Results: 25 patients with diagnosis of FSGF were evaluated, 9 perihiliar, 10 tip, 2 
collapsing, 2 NOS, 2 podocytopathy; the average age was 34±16 years with no significant 
statistical difference between groups (p= 0.81). Significant differences were identified 
between the groups in the basal and final levels of albumin, while, urea and proteinuria only 
presented significant difference in basal level. The mean of UMAC was 1258.92±765.19 pg/ml, 
with significant differences between the groups; although, no differences were found 
in the UMAC levels with the degree of fibrosis (p= 0.10), subjects without fibrosis had 
the lowest levels of UMAC 770.1±579 vs 1680.31±490.1 severe fibrosis. The 100% of 
patients received induction treatment with corticosteroids, 88% ACEI, 84% statins, 16% 
steriods+CNi, 8% calcium channel blockers. The UMAC levels were lower in the group 
with complete response to treatment, with differences between groups (p= 0.003). UMAC 
had significant correlation with final proteinuria (r=0.5, p=0.01) and CKD-EPI. Figure 1.
Conclusions: The UMAC represents the final stage of activation of the complement 
system. Our results showed that high levels of UMAC in patients with FSGF with a 
statistical correlation, had the worst varieties. The patients who had the benign varieties, 
responded better to treatment; however, these results must be confirmed with a higher 
number of patients in prospective studies.
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Clinical Experience with 21 Adults Affected by Post-Infectious 
Glomerulonephritis
Àlex Favà,1 Ariel Tango barrera,2 Isabel Giménez,3 Aroa Rovira,4 Rafael Alvarez,5 
Josep M. Cruzado,4 Joan Torras,6 Xavier Fulladosa.7 1Hospital de Bellvitge, 
Barcelona, Spain; 2H. Universitario Bellvitge, Barcelona, Spain; 3Moises Broggi 
Hospital, Barcelona, Spain; 4Hospital Universitari de Bellvitge, Barcelona, 
Spain; 5Bellvitge Hospital, Barcelona, Spain; 6Laboratory Experimental 
Nephrology, IDIBELL. Hospital Universitari de Bellvitge, Barcelona, Spain; 
7Hospital Universitari De Bellvitge, L’Hospitalet de Llobregat, Spain.
Background: Post-infectious glomerulonephritis(PIGN) is an entity related to 
childhood and throat infections. It has a well-defined clinical and histological presentation, 
showing a favourable prognosis. However, in last decades, the improvement in antimicrobial 
therapies and the population ageing has led to a radical change in this entity in terms of 
clinical features and prognosis.
Methods: We retrospectively analysed all the PIGN cases diagnosed between 2012 and 
2017 from our pathology department archive.
Results: Our study population consisted of 21 cases, with a male:female ratio of 4.25:1. 
The median follow-up was of 232 days (mean 367). 28% of patients presented chronic 
kidney disease, 38% diabetes, 62% hypertension, 19% cancer, 33% alcoholism and 10% 
cirrhosis. The most common site of infection was skin (23%), followed by respiratory tract 
(19%), preceding in a mean of 15 days the nephritic event. Remarkably, in 28% of the cases, 
a previous infectious event was unnoticed. Staphylococcus (33%) and Enterobacteriaceae 
(33%) were the most common identified infectious agents. Hypocomplementemia was 
present in 57% and was restored in all cases, although 50% occurred after 3 months of 
nephritis. Nephrotic syndrome was present in 14%. IgA dominiant PIGN occured in 23% 
of cases, and a “C3 dominant” pattern was presented in 19%. 46% of patients required 
hemodialysis initially, with 24% finally remaining in chronic hemodialysis program. Only 
19% of patients recovered previous renal function. Steroid therapy was used in 76% of 
cases.3 patients died before six month by infection related causes.
Conclusions: According to our results, PIGN shows a poor prognosis in adult 
population, and comorbidity burden might be an explanation. In addition, the lack of a 
previous infectious event, the slow complement restoration and its immunofluorescence 
patterns akin to other entities make its diagnosis difficult. More evidence is required to 
define the most appropriate management in these cases.
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Beverage Intake by US Adolescents: Analysis of National Health and 
Nutrition Examination Survey (NHANES) Data, 2009-2014
Uma D. Alappan,1 Martine Ferguson,2 Beverly J. Wolpert.1 1Center for Food 
Safety and Applied Nutrition, Office of Analytics and Outreach, Division of 
Public Health Informatics and Analytics, U.S. Food and Drug Administration 
(FDA), College Park, MD; 2Center for Food Safety and Applied Nutrition, 
Office of Analytics and Outreach, Biostatistics and Bioinformatics Staff, U.S. 
Food and Drug Administration (FDA), College Park, MD.
Background: To examine beverage intake among U.S. adolescents by demographic 
and health characteristics.
Methods: We analyzed data from 7242 participants aged 14-18 years old (3758 males, 
3484 females) with ≥1 day of beverage intake reported in the 2009–2010, 2011–2012, 
and 2013-2014 U.S.-representative National Health and Nutrition Examination Surveys 
(NHANES). Beverage types included milks, fruit juices, sports drinks, waters, coffees, 
and other (combined because of sparsity: protein powder, energy, and cereal drinks). 
Demographic and health characteristics included sex, age, race/ethnicity, education, 
household income, body mass index (BMI), diabetes, anemia, sedentary and physical 
activity time per typical day, waist-to-height ratio, and menses onset age. Analyses 
accounted for the NHANES survey design and incorporated appropriate weighting. The 
habitual consumption method was used, along with the Multiple Source Method to estimate 
usual beverage intake (grams). Proportions of respondents consuming each beverage 
type and per-consumer mean beverage intake (g/day) were calculated. Because of strong 
correlations between some variables (e.g., age/education, and BMI/waist-height ratio), 
univariate logistic models estimated associations with beverage consumption (weighted 
%). For variables with significant associations (p<.05), t-tests were carried out on least-
squares means to assess where differences rested. P-values were Bonferroni-adjusted for 
multiple comparisons.
Results: Males consumed milks, sodas, and sports drinks more often than females. 
Blacks consumed juices more often than all other races. Hispanics consumed juices more 
often than Whites and sodas more often than all others. Significant associations were found 
between beverage type consumed and sex (p=.01), age (p=.0052), race/ethnicity (p=.0004), 
education (p=.0015), diabetes (p<.0001), anemia (p=.0092), sedentary time per typical day 
(p<.0001), BMI (p<.0001), and waist-height ratio (p<.0001).
Conclusions: Few analyses have been conducted to assess beverage intake patterns 
in adolescents. Results from this study contribute new information to help address the gap, 
inform future studies of health risks by subgroup, and target education to this age-group.
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Nutritional and Anthropometric Assessment During and After Ramadan 
in a Cohort of Hemodialysis (HD) Patients in Jeddah, Saudi Arabia
Bayan M. Tashkandi,1 Dina A. Tallman,1 Deepinder Kaur,1 Hanadi M. Alhozali,2 
Pramod Khosla.1 1Nutrition and Food Science, Wayne State University, Detroit, 
MI; 2Department of Medicine, King AbdulAziz University Hospital, Jeddah, 
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Background: During the annual festival of Ramadan (R), Muslims world-wide undergo 
a period of fasting from sunrise to sunset. Studies suggest that this period of cyclic fasting 
does not affect the healthy individual but its effect on HD patients is not well documented. 
Inadequate food intake, muscle loss and inflammation are common in HD. In Saudi Arabia, 
the number of HD patients increased 14% from 2014 to 2016. While the majority of patients 
insist on fasting during R, any associated health risks are not well documented. The aim of 
this pilot study was to assess dietary, anthropometric and biochemical parameters in HD 
patients over the R period.
Methods: The study was conducted in an out-patient dialysis clinic in Jeddah (n=23, 
10 males, age 43±15 yrs, thrice-weekly dialysis, vintage 93±54 months, Kt/V 1.38±0.33). 
Both 24h diet recall and 3d food records were analyzed using Food Processor ESHA 
Research. Body mass index (BMI), handgrip strength (HGS) using a Jamar dynamometer, 
malnutrition-Inflammation Score (MIS) and biochemical parameters were also evaluated 
during R and two months following R.
Results: Among R participants, the intake of calories, protein, and fat was significantly 
higher during R while there was no significant difference in carbohydrate intake. Two-
months post R, calorie, protein and fat intake had declined by 24%-36% compared to the 
values noted during R. Absolute carbohydrate intake was not significantly different during 
or 2 months post R. No differences were noted in BMI, HGS or MIS during this time-
period. While there were temporal fluctuations in serum albumin, creatinine and sodium, the 
values pre and 2 month post R, were not significantly different. Blood glucose, potassium 
and phosphorus did not change over the course of the study.
Conclusions: Our preliminary data indicates that in HD patients observing R, while 
alterations in diet and clinical parameters fluctuate, most return to pre R values within 2 
months of the end of the R period. The impact on other parameters (e.g. plasma lipoproteins) 
is currently under evaluation. (BT is a recipient of a scholarship from the Ministry of 
Education, Saudi Arabia)
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Hypercholesterolemia as a Risk Factor of Coronary Artery Disease in 
Hemodialysis Patients: 10-Year Outcome of the Q-Cohort Study
Toshiaki Nakano,1 Hiroto Hiyamuta,1 Shigeru Tanaka,2 Masatomo Taniguchi,3 
Kazuhiko Tsuruya,4 Takanari Kitazono.5 1Kyushu University, Fukuoka, Japan; 
2Fukuoka Dental College, Fukuoka, Japan; 3Fukuoka Renal Clinic, Fukuoka, 
Japan; 4Nara Medical University, Kashihara, Japan; 5Department of Medicine 
and Clinical Science, Fukuoka, Japan.
Background: The prevalence of atherosclerotic diseases including coronary artery 
disease, peripheral artery disease and stroke is higher in chronic kidney disease (CKD) 
patients. However, the risk of hypercholesterolemia for cardiovascular disease (CVD) in 
hemodialysis (HD) patients is still debated. Inflammation and malnutrition may affect 
dyslipidemia-induced CVD in HD patients. The aim of this study is to investigate the risk of 
hypercholesterolemia for CVD in a 10-year cohort of hemodialysis patients.
Methods: A total of 3,529 Japanese HD patients aged ≥18 years were prospectively 
followed for 10 years in this study. Patients were divided into four groups (Q1:<131 mg/dL, 
Q2:131–152 mg/dL, Q3:152–178 mg/dL, Q4:≥178 mg/dL) by quartiles of serum total 
cholesterol levels. We estimated the relationship between serum total cholesterol levels and 
the incidence rate of coronary artery disease (CAD), brain infarction (BI), peripheral artery 
disease (PAD) and combination of CVDs in 10 years.
Results: During a follow-up period, 460 (13%), 379 (11%) and 261 patients 
(7%) developed CAD, BI, and PAD, respectively. The incidence of CAD and PAD, 
and combination of CVDs increased linearly with higher total cholesterol levels. In 
multivariable-adjusted Cox analysis, a high total cholesterol level was an independent 
risk of CAD incidence (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.03–1.82; 
P=0.03 for Q4 vs. Q1) and CVDs combination (HR, 1.26; 95% CI, 1.05–1.51; P=0.02 
for Q4 vs. Q1), after adjustment for confounding factors including serum albumin and 
C-reactive protein (CRP). There is no significant interaction between serum total cholesterol 
and serum albumin or CRP regarding CAD and CVD.
Conclusions: Serum high total cholesterol level is an independent risk factor for CAD 
in HD patients. Hypercholesterolemia still has a risk of CAD even after CKD patients have 
undergone maintenance HD.
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Correlation Between Dietary Components Measured in 24-Hour Urine 
Tests and Food Records in Patients with Kidney Disease
Melanie Betz,1 Fredric L. Coe,2 Arlene B. Chapman.2 1University of Chicago 
Medicine, Chicago, IL; 2University of Chicago, Chicago, IL.
Background: Food Records (FR) are used widely in research and clinical care. 
Twenty-four hour urine collections (24UV) are considered the gold standard to measure 
dietary sodium (Na), potassium (K), phosphorus (P), calcium (Ca), magnesium (Mg), and 
protein. Little research has been done to validate FRs obtained in a clinical setting against 
biological measurements. The objective of this project was to determine if FR obtained as 
routine care correlates with 24UV measurements of Na, K, P, Mg, Ca and protein performed 
at different time points.
Methods: FRs and 24UVs were completed as routine care in the nephrology clinic at 
University of Chicago Medicine. A Registered Dietitian provided patient instruction and 
analyzed the FR with National Data Research System, 2017. FR results were compared to 
a 24UV done closest to the date of the FR. Pearson’s correlation was used to compare each 
nutrient measured via FR and 24UV.
Results: A total of 33 patients were included with a mean age of 50years, BMI of 25.3kg/m2 
and estimated glomerular filtration rate of 67ml/min (n=28); 91% were Caucasian. 
Diagnoses included autosomal dominant polycystic kidney disease (45.5%), nephrolithiasis 
(48.5%) or other (6.1%). Average time between FR and urine was 97 days (range of 0-533); 
adjustment for time with ANOVA did not improve correlations, therefore was not adjusted 
for in calculations. Sodium (r=0.55, p=0.001) and Mg (r=0.46, p=0.008) measured via FR 
correlated significantly with 24UV.Sodium was consistently underestimated by FR; Mg was 
overestimated. Dietary K (r=0.16, p=0.389), P (r=0.22, p=0.217), Ca (r=0.06, p=0.743) and 
protein (r=0.26, p=0.138) did not correlate with 24UV.
Conclusions: Sodium and Mg intake measured via FR significantly correlated with 
24UV done at separate times. Overestimation of Na by FR is possibly due to underreporting. 
Underestimation of Mg intake is likely due to low intestinal absorption. Given variability of 
absorption of Ca and P from hormonal regulation, correlation would not be expected. Lack 
of correlation for protein and K could be explained by daily variability in intake, unknown 
physiologic factors, time difference between urine and FR, or difficulty obtaining adequate 
detail for analysis of a FR.
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Validation of the Sarcopenia Index to Assess Muscle Mass in the Critically 
Ill: A Novel Application of Kidney Function Markers
Erin F. Barreto,1 Janelle O. Poyant,3 Hongchuan H. Coville,2 Ross Dierkhising,4 
Cassie C. Kennedy,4 Ognjen Gajic,4 Erin Nystrom,1 Naoki Takahashi,1 
Michael Moynagh,4 Kianoush Kashani.1 1Mayo Clinic, Rochester, MN; 
2University of Central Florida, Gainesville, FL; 3Tufts Medical Center, Boston, 
MA; 4Mayo Clinic, Rochester, MN.
Background: Adverse outcomes for hospitalized patients with sarcopenia are well 
documented, and identification of patients at risk remains challenging. The sarcopenia 
index (SI), previously defined as (serum creatinine/serum cystatin C)x100, could be an 
inexpensive, readily accessible, objective tool to predict muscle mass and risk for adverse 
clinical outcomes. The aim of this study was to assess the validity of the SI as a predictor 
of muscle mass.
Methods: Retrospective study of critically ill adults admitted to Mayo Clinic from 
2012 -2015 with suspected sepsis and an available creatinine and serum cystatin C. Muscle 
surface area was quantified at the L3/4 vertebral level in patients with an abdominal CT scan 
(CTMSA). Multivariable regression modeling was used to assess the relationship between 
SI and CTMSA, as well as short-term clinical outcomes.
Results: The 171 included had a mean weight and body mass index (BMI) of 
75.2 ± 16.4 kg and 26.0 ± 4.6 kg/m2 and abdominal CT scans were available for 81 (47%) 
patients. The SI correlated with CTMSA (r = 0.40). After adjustment for age, sex, severity of 
illness, and BMI, SI was independently associated with muscle mass (P=0.001). A decrease 
in the SI (indicative of lower muscle mass) was also associated with frailty and worse short-
term clinical outcomes.
Conclusions: The SI, a simple calculation from kidney function markers, is a significant 
predictor of muscle mass in this validation cohort of ICU patients. A low SI was associated 
with longer hospital length of stay and frailty. Future studies could explore whether the use 
of SI assists with identifying patients likely to benefit from pharmacotherapy-, nutrition-, or 
physical therapy-based interventions.
PUB406 
Publication-Only 
Eating Disorder Nephropathy: A Case Series Study
Hirokazu Marumoto, Takaya Sasaki, Nobuo Tsuboi, Masahiro Ishikawa, 
Makoto Ogura, Takashi Yokoo. Division of Kidney and Hypertension, The Jikei 
University School of Medicine, Tokyo, Japan.
Background: Eating disorders (EDs), such as anorexia nervosa and bulimia, are 
psychiatric disorders frequently found in young women, with a substantially increasing 
prevalence in recent years. EDs are often intractable and induce the development of 
various physical disorders, including renal dysfunction and mineral disorder, occasionally 
progressing to end-stage kidney disease (ESKD). At present, information is limited 
regarding the renal manifestations, so no consensus has been established regarding the 
clinical practice guideline for ED patients referred to nephrologists. The study aimed to 
clarify the clinicopathological characteristics of ED nephropathy (EDN).
Methods: Patients with EDN who were referred to and cared for at our related facilities 
from January 1992 to December 2017 were retrospectively analyzed. The renal outcomes 
were defined as doubling of the serum creatinine level and/or progression to ESKD.
Results: The present study included 14 female cases. The mean age at the ED onset 
was 22.3 years, and the duration from the onset to the initial visit with a nephrologist was 
17.8 years. At the first visit with a nephrologist, the serum creatinine level was 1.6 mg/dl, 
serum potassium level was 2.7 mmol/l, and body mass index (BMI) was 13.1 kg/m2. All 
cases showed hypokalemia and either addictive vomiting or diuretics/laxatives abuse. 
During the average observation period of 5.8 years, renal outcomes occurred in 9 cases, and 
2 died due to their ED. The body weight, BMI and estimated glomerular filtration rate at the 
first visit in the group who developed renal outcomes were significantly lower than in those 
who did not develop renal outcomes. A renal biopsy was performed in four cases. One early 
case of ED showed hypertrophy of the juxtaglomerular apparatus, while three advanced 
cases showed glomerular collapse and interstitial fibrosis predominantly in sub-capsular 
regions, consistent with peripheral circulatory failure and low-potassium nephropathy.
Conclusions: Advanced renal impairment and a severely lean state at the first visit may 
be predictors of poor renal outcomes in cases of EDN. In a majority of patients with EDN, 
the degree of renal injury is already severe at the time of their first referral to a nephrologist. 
Improving the renal outcomes of EDN may require tighter collaboration with psychiatrists 
and earlier intervention by nephrologists.
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A Whole Food Plant-Based Diet Can Be Safe and Beneficial in Dialysis 
Patients: A Case Report
Rebeca D. Monk,1 Darlene H. Steele.2 1University of Rochester, Rochester, NY; 
2Fresenius Kidney Care, Penfield, NY.
Introduction: The demonstrated benefits of a whole food plant-based diet (WFPBD) 
include weight loss, lipid reduction, improved glycemic control in diabetics and regression 
of atherosclerosis in patients (pts) with coronary artery disease. Small studies utilizing a 
WFPBD, low animal protein intake, or addition of fruits and vegetables to the diets of pre-
dialysis pts with chronic kidney disease (CKD) have demonstrated lower phosphorus (phos) 
and FGF 23 levels (both associated with higher mortality), improvement in metabolic 
acidosis, and less GFR decline without adverse effects. Utilization of a WFPBD in dialysis 
pts, however, is deemed potentially dangerous due to risk for low serum albumin and 
hyperkalemia.
Case Description: A 58-year-old woman with type 1 DM, HTN, CAD s/p MI and CVA 
was denied listing for kidney transplant. Following this, she embarked on a purely WFPBD. 
Potassium (K) levels in the 6’s (often requiring 1K dialysate) were common before she 
started the diet. Diet included beans, peanut butter, hummus, grains, vegetables, fruits. Her 
labs improved significantly with the diet (see table). K was checked frequently. PM isulin 
dose decreased by 38%. Weight decreased from 69 kg to 65.6 kg in 2 months with BMI 
decline from 26.1 to 24.8. The pt reported improved energy.
Discussion: Potential adverse effects of the standard American diet and animal protein 
intake in CKD pts include greater phos absorption, inflammation, vacular calcification, a 
dysbiotic microbiome, acid generation, and high K. The higher fiber WFPBD generates 
base, reduces serum phos, enhances weight loss, and may improve the microbiome. In 
this pt, phos decreased rapidly, albumin remained > 4 and potassium did not increase. 
A WFPB diet may offer significant health benefits without risk for hypoalbuminemia or 
hyperkalemia.
Patient Labs Before and After WFPBD
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Utilizing Dialysis Clinical and Laboratory Markers to Identify Risk for 
Major Depression Disorder in Dialysis Patients
Ahmad Kaddourah,1 Abdullah Hamad,1 Tarek A. Fouda,2 Mostafa F. Elshirbeny,3 
Rania A. Ibrahim,1 Shaza Y. Elsanoosi,4 Fadwa S. Al-Ali.1 1Hamad Medical 
Corporation, Doha, Qatar; 2Hamad medical cooporation, Doha, Qatar; 3HMC, 
----Doha, Qatar; 4Hamad medical corporation, Doha, Sudan.
Background: Depression is the most common psychiatric disorder in patients with 
end-stage renal disease (ESRD) on dialysis. Despite of being widely prevalent, depression 
is often underdiagnosed in this population. Diagnostic screening surveys are available 
to identify high risk patients; however, these tools are time consuming and not applied 
regularly in busy dialysis units. We hypothesize that risk of depression can be predicted 
using common clinical variables which are screened frequently in dialysis units.
Methods: We conducted a prospective cross-sectional study in ESRD patients 
receiving either hemodialysis (HD) or peritoneal dialysis (PD) in the main ambulatory 
dialysis unit in the state of Qatar. Eligibility criteria was all adult ESRD patients who have 
been receiving dialysis for at least one month duration. All enrolled patients underwent 
depression screening using the Center for Epidemiologic Studies Depression Scale 
(CESD-R) which has been validated by the American Psychiatric Association’ Diagnostic 
and Statistical Manual (DSM-V) for a major depressive episode. Clinical variables were 
enrolled of logistic and linear regression models to assess the correlation.
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Results: 253 patients with ESRD on dialysis were enrolled. 157 (62%) patients were on 
HD and 96 (38%) on PD. 122 (48%) patients had depression disorder, defined as CESD-R 
score ≥ 16. No significantly difference in depression prevalence was detected between HD 
and PD patients (P=0.55). Bivariate analysis showed that depressed patients have lower 
hemoglobin levels (mean log Hgb 2.4 (±0.1) vs 2.3 (±0.1), P= 0.04) and higher Hb1AC 
levels (mean log Hb1Ac 1.8 (±0.2) vs. 1.7 (±0.2), P=0.04) than non-depressed patients. 
Univariate regression analysis revealed no significant correlation between depression 
disorder and BMI, serum albumin, Vitamin D level, parathyroid hormone level, serum 
calcium, phosphate level, nor Kt/V.
Conclusions: Up to 50 % of our adult ESRD patients on dialysis have depressive 
disorder as per CESD-R score. Our data suggests that Hgb and Hb1AC levels can be 
utilized to predict patients at increased risk of depression. This will allow early diagnosis 
and management of depression which can imrpove clinical outcomes.
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Intradialytic Hypertension and Mortality Risk Among Hemodialysis 
Patients In National Kidney and Transplant Institute
Amerigo S. Bautista,1 Concesa Casasola,1 Romina A. Danguilan,1 
Eduardo K. Lacson.2 1National Kidney and Transplant Institute, Quezon City, 
Philippines; 2Tufts University School of Medicine, Boston, MA.
Background: Hypertension is prevalent in hemodialysis patients and contributes to 
cardiovascular morbidity and mortality.
Methods: Blood pressures before and after hemodialysis were recorded and used to 
classify patients during the baseline period (N=153). Patients were followed for up to 2 
years or until death.
Results: The cohort’s mean age was 59.3 years old with male predominance (56%) and 
DM nephropathy (48.4%) as primary renal disease. The intradialytic hypertension group 
(n=47) had significantly higher change in systolic blood pressure (16.4 vs – 3.2 mmgHg), 
post dialysis systolic (165.2 vs 147.5mmHg) and mean arterial (106 vs 97.8mmHg) blood 
pressure compared to 106 patients without intradialytic hypertension. One and two year 
overall cumulative survival of patients with intradialytic hypertension compared to patients 
without were 95.1% vs 92.86% and 66.12% vs 63.03%, respectively. Risk for all cause 
mortality non-significantly trended lower with intradialytic hypertension (HR=0.98, 
p=0.271), female gender (HR=0.77,p=0.495) and use of calcium channel blockers 
(HR=0.764, p=0.46).
Conclusions: In this South East Asian national referral center, intradialytic hypertension 
did not increase the hazard for 2 years all cause mortality of hemodialysis patients.
Characteristics of Patients
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Prevalence of High Blood Pressure Among Teenagers, With Its Pattern 
and Related Factors
Jafar Al-Said. Bahrain Specialist Hospital, Manama, Bahrain.
Background: Hypertension prevalence is increasing worldwide. Studying the BP 
among teenagers might give some ideas regarding preventive measures that can decrease 
the incidence of HTN during adult life. Aim of this study: 1-Identify the prevalence of high 
BP among teenagers. 2-Determine the pattern of the high BP, whether systolic or diastolic. 
3-Identify the factors that are related to high BP among this age group.
Methods: This is a cross sectional study with screening of teenagers between 13-20
years attending thirteen middle and high schools in Bahrain. All the students were screened. 
The consent was obtained from the school administration and the parents. Demographic 
factors were collected. BP was checked after 3 minutes rest while sitting on an armed chair 
with both feet on the ground. Two measurements were obtained from the Lt. arm with one 
minute interval. Ht., wt. and waist circumference were measured for each student. Data 
were analyzed with SPSS 18. P<0.05 was required for rejecting the null hypothesis.
Results: 2467 students were included. Mean age was 13.5 years (SD 2, SE 0.04). Males 
were 53%, Mean wt. was 56kg (SD 18.4, SE 0.4). The mean waist circumference was 73.8 cm 
(SD 17, SE 0.35). Mean Ht. was 157cm (SD 11, SE 0.23). Mean BMI was 22 Kg/m2  
(SD 5.8, SE 0.11). 53% of the students had high BP according to their age, gender and height 
percentiles. The high BP within the hypertensive ranges were more than the measures within 
the Prehypertensive range (40% versus 23%). P 0.043 The BP was inversely correlated with 
age and BMI. The correlation coefficient for age was -0.32, P <0.0001. The correlation 
coefficient for BMI was -0.068, P 0.003. Systolic BP rather than diastolic BP was more 
prevalent, 19% versus 4%. P 0.027. Age, gender, waist circumference, nationality and pulse 
rate were the independent variable related to high BP in mulitvariate regretion model.
Conclusions: There was an unexpected high prevalence of elevated BP among 
teenagers. The pattern of the high BP was surprisingly systolic rather the diastolic. 
Hypertensive BP levels were higher than prehypertensive levels. The young age and low 
BMI were associated with higher BP. These findings would suggest a complete different 
pattern of BP among teenagers. More research focused efforts are required to elaborate on 
each of these points to determine significant monitoring and preventive strategies.
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Real Harakiri Sagliker Effect: Hypertensionologist’s Hypertension: 
Ambulatory Blood Pressure Monitoring of Doctors: Combination-Compi-
lation of Reverse White Coat and Physical Exercise Effects
Yahya Sagliker. Sagliker Hypertension Unit, Adana, Turkey.
Introduction: It is known some normals and hypertensives get higher BP when facing 
medical environments or devices. Effect called WCE or WCH.We examined if same be 
also found in doctors in outpatient clinics. This is first medical hypothesis so far on subject
Case Description: 58 Doctors examined daily 12 hypertensives by measuring BP 
themselves with classical manual recorders by pumping the cuffs, every 10 minutes for two 
hours first day, then relaxed consecutive day, similarly two hours. Same time doctor’s SBP, 
DBP, MAP, HR (by Mobilograph ABPM machine) were measured, two hours NE,E,VMA, 
metanephrine in urines and plasma NE,E, PRA, A, A II examined. in doctors. Additionally 
plasma A II levels examined just before BP recordings in first stress day. Doctors’ all those 
parameters decreased from first stress day to the second relaxation day.. Interestingly 
plasma AII decreased from time of prerecordings to time of postrecordings in first stres day. 
P values for differences were less than 0,001.
Discussion: Doctor’s had higher SBP,DBP,MAP,HR,PRA,A, cathecolamins in urines 
and plasma after examinations. Reduction of AII at time of postrecordings be explained 
by AII’s short half life. If AII be examined continously during measurements, could be 
found higher at first but decreasing tremendously by time till end-point. Staff could face 
complications, cerebrovascular attacks, myocardial infarctions, blindness if they have 
hypertension or prone to it. Doctors manual recordings were a reverse white coat effect 
plus hand grip exercise test and dangerous. In developping countries as Turkey, India, 
Pakistan, Bengladesh, China, Endonesia, Maleysia where 100-150 patients examined and 
BP recorded daily only by one doctor, manual recorders be banned by legistlations and 
started first in history via ASN, ISH, WHO. And this novel phenomenon should be called 
Sagliker Effect. This is a sine qua non humanity task.
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Individualized Hypertension Treatment: More Information, Better Results
Yossi Chait,1 Joseph Horowitz,1 Barbara A. Greco,3 Michael J. Germain.2 
1University of Massachusetts, Amherst, MA; 2Renal and Transplant Assoc of 
New England, Hampden, MA; 3Renal and Transplant Associates of New 
England, Springfield, MA.
Background: High blood pressure (BP) is a leading cause of death and disability in the 
US and worldwide. Approximately 1 of 3 U.S. adults (75 million) has high blood pressure, 
and only about half treated with antihypertensive therapy achieve the recommended blood 
pressure target. Our aim was to observe BP outcomes in standard hypertensive management 
augmented by hemodynamic information.
Methods: A hemodynamic measurement using noninvasive impedance cardiography 
(NICaS) was recently added in our hypertension (HTN) clinic, a part of a nephrology group 
that manages chronic kidney disease (CKD) and referred resistant hypertension patients. 
Clinicians were informed about measured hemodynamic parameters, however, there were 
no algorithmic changes made in the HTN treatment protocol. We retrospectively collected 
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data for patients that had at least one hemodynamic measurement and at least one follow-
up visit.
Results: We found 86 eligible patients; mean (SD) number of hemodynamic 
measurements was 1.6 (0.8). Mean (SD) age was 62.6 (18.1) years, 48 (56%) were female, 
and 39 (45%) had CKD. Systolic BP (SBP) and diastolic BP (DBP) at time of initial 
hemodynamic measurement (initial) and at most recent office visit (current) are reported 
in Figure 1. Target BP results for non-CKD (SDP<140 and DBP<90 mmHg) and CKD 
(SDP<130 and DBP<80 mmHg) are shown in Figure 2. Mean number of HTN meds was 
unchanged (2.54 and 2.46, respectively).
Conclusions: Impedance cardiography is a simple, noninvasive method for 
evaluating underlying hemodynamic drivers of HTN and provides clinically important 
BP-complementary information for treatment. The encouraging BP reductions prompted 
us to initiate a new study that compares standard care with a new protocol comprising 
hemodynamic and pulse wave velocity measurements and a tailored algorithm for 
medication changes.
Funding: Commercial Support - NiMedical, Ltd.
Figure 1
Figure 2: Subgroup results
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Posterior Reversible Encephalopathy Syndrome (PRES) with Acute and 
Chronic Kidney Disease (AKI/CKD): Five Cases in Eight Years - Should 
Nephrologists Consider It More Frequently?
M M Papaginovic,1 E. Mojico,2 M E Nicolini,2 M H Serrano,3 P R Martinez,2 R 
d Martinez.3 the working group 1Uspallata 3400, Complejo médico Churruca 
visca, Buenos Aires, Argentina; 2Hospital Churruca, Buenos Aires, Argentina; 
3hospital churruca, AVELLANEDA, Argentina.
Introduction: PRES is a clinical and radiological condition with manifestations such 
as headaches, seizures and altered mental status that shows reversible cortico-subcortical 
vasogenic edema in Neuroimaging, predominantly bilateral. It is associated with arterial 
hypertension(AH), autoimmune disease, AKI/CKD, drugs and pregnancy It is usually 
reversible and recurrent Magnetic resonance(MRI) is the gold standard to diagnose and 
detect lesions in PRES
Case Description: We present 5 cases of women patients with acute neurological 
symptoms in the context of AH,AKI/CKD MRI/CT diagnosed PRES Four of them needed 
RRT All of them recovered after controlled AH (See Summary of the patient’s history, MRI 
findings and final outcome)
Discussion: PRES is a rare disease related to different clinical entities and different 
pathophysiological origins that causes a delay in diagnosis Our cases are clinical entities 
with different backgrounds and heterogeneous pathophysiological bases All pacients were 
women and presented AH and seizures, only one was recurrent and affected 2 or more 
cerebral lobes Early diagnosis makes a difference in patient outcomes It usually resolves, 
being the triggers usually identifiable AKI/CKD are cormobid factors for PRES so it is 
important to consider them at the time of diagnosis in patiens with neurological symptoms
Summary of the patient’s history, MRI findings and final outcome
CHDF, continuous haemodiafiltration; CHD, continuous haemodialysis; CT, computed 
tomography; eHD, extended haemodialysis; iHD, intermittent haemodialysis; MRI, 
magnetic resonance imaging; LES Systemic lupus erythematosus; RRT, renal replacement 
therapy
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Predictability of Elevated Troponin for Angiographic Coronary Artery 
Disease in Patients with CKD
Bhavin Chokshi,1 Balaram krishna J. Hanumanthu,2 Sachin Batra,2 
Poonam Mahato,2 Muhammad I. Pervez,2 Lilian L. Bizzocchi,2 Belinda Jim.3 
1Jacobi Hospital Medical Center, Bronx, NY; 2Jacobi Medical Center, Bronx, 
NY; 3Albert Einstein College of Medicine, New Hyde Park, NY.
Background: Troponins are elevated in patients with myocardial damage. An 
association exists between angiographic coronary artery disease (CAD) and troponin 
elevation in patients with normal kidney function; however, this association remains unclear 
in patients with chronic kidney disease (CKD). Mild to moderate elevation of troponins are 
frequently seen in this patients and interpretation for the most part is at the discretion of the 
treating physician.
Methods: We retrospectively reviewed all coronary angiograms performed at 
our center between April 2007 to May 2017. Baseline demographic, laboratory, and 
angiographic characteristics were analyzed using STATA® software. KDOQI staging for 
CKD was used and GFR was calculated using CKD-EPI formula. Angiographic finding 
was categorized as normal, mild (<50%), moderate (50-69%), and severe (≥70%) stenosis 
of any major epicardial coronary artery.
Results: Of the 795 patients, 433 were men (54%). Mean age of the patients was 
63 +/- 27 years. Prevelance of hypertension and diabetes mellitus was significantly higher 
in patients with CKD stages 3-5 compared to normal GFR (p < 0.001) but other risk 
factors for CAD were similar in between groups. Multivariate logistic regression analysis 
showed no significant difference in mean troponin I (cTnI) levels in severe and non- severe 
coronary artery stenosis across any CKD stage. However, statistically significant peaks 
were observed in patients with CKD stages 4 and 5 (20.9 times, P<0.001 [CI 13.5-28.4] 
and 6.4 times, P=0.007 [CI 1.72-11.1] respectively). Patients with severe (>70% stenosis) 
CAD had higher mean cTnI levels compared to non-severe stenosis (p<0.02). ROC curve 
showed cTnI > 0.304 ng/mL had 60% sensitivity, 61.6% specificity and positive likelihood 
ratio 1.56 for finding severe stenosis.
Conclusions: We found no significant association between modest elevation in 
Troponin I and angiographically signifcant coronary disease in patients with any stage 
of CKD. Troponinemia >0.304 ng/mL in proper clinical setting and a rising trend may 
require additional work up including cardiac catheterization in patients with CKD as per 
our analysis.
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Treatment and Prognosis of Malignant Hypertension
Guangqun Xing. The Affiliated Hospital of Qingdao University, Qingdao, 
China.
Background: We systematic analyzed the data on treatment of MHT to find a way for 
best outcome.
Methods: 30 patients diagnosed with MHT were enrolled in this study. The clinic 
data,treatment strategy and prognosis were analyzed.
Results: The better effect could be expected during 6 months. The plasma level of 
rennin and aldosterone were higher than the normal at the initiation stage of MHT. However 
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the presence of thrombotic microangiopathy (TMA) was not found to predict end-stage 
renal disease(ESRD).
Conclusions: RAAS activation was involved in the pathogenesis of MHT with both 
primary or secondary origin. RAAS blacker, especially captropril was selected as the first 
choice for the treatment on MHT despite much higher serum creatinine in the common 
sense. Long duration at least for 6 months treatment with RAAS blockers could reach 
the best outcome. The etiology treatment should be initiated for good of patients’ future 
prognosis.
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Mechanisms of Cardiovascular Complications in CKD: Research Focus of 
the German Transregional Collaborative Research Center SFB/TRR219
Heidi Noels,1 Nikolaus Marx,5 Jürgen Floege,4 Michael Böhm,2 
Joachim Jankowski.3 SFB/TRR219 1RWTH Aachen University, Aachen, 
Germany; 2Saarland University Medical Center, Homburg, Germany; 3RWTH 
Aachen University, Aachen, Germany; 4RWTH University of Aachen, Aachen, 
Germany; 5University hospital Aachen, Aachen, Germany.
Background: Patients with chronic kidney disease (CKD) exhibit a massively 
increased risk for cardiovascular events, and traditional strategies to improve cardiovascular 
outcome have largely failed in the context of CKD. The classical cardiovascular risk factors 
such as smoking or overweight have less impact on cardiovascular disease in CKD patients 
compared to the general population, indicating that in addition to traditional risk factors, 
novel and hitherto unknown mechanisms may be important in driving cardiovascular disease 
in CKD and that CKD per se represents an independent risk factor for cardiovascular events.
Methods: Reducing cardiovascular mortality in CKD patients through novel therapeutic 
strategies first requires the identification and understanding of CKD-specific pathological 
mechanisms. To achieve this goal, two German universities, the RWTH University of 
Aachen and the Saarland University, have initiated the Transregional Collaborative 
Research Center 219 (SFB/TRR219) “Mechanisms of Cardiovascular Complications in 
Chronic Kidney Disease” (www.sfb-trr219.de). This consortium aims to analyze the multi-
faceted mechanisms of CKD-related cardiovascular disease in experimental and clinical 
studies, with a total of 17 interdisciplinary research teams from cardiology, nephrology, 
biophysics and molecular biology joining forces.
Results: Our current understanding of the increased cardiovascular risk in CKD is 
based on the interaction of the kidney with the circulation (encompassing the vascular 
system and blood) and the myocardium. This increases cardiovascular risk by triggering 
pathological mechanisms. In analyzing these mechanisms and their role in the complex 
interaction between kidney, vasculature and heart, the SFB/TRR219 is mainly focusing 
on increased calcification, inflammation, oxidative stress, fibrosis, thrombosis and 
neurohumoral dysregulation in CKD.
Conclusions: By collaborative and translational research based on existing interactions 
between groups of different clinical and methodological expertise, the German SFB/TRR219 
pursues the overall long-term goal to gain understanding of the renal and cardiovascular 
interactions that may contribute to the development of novel treatment strategies to decrease 
cardiovascular risk in CKD patients.
Funding: Government Support - Non-U.S.
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Pathological Analysis and Serum Reactivity of Anti-GBM Disease/IgG1 Is 
Dominantly Deposited in the Glomeruli in Anti-GBM Disease
Yayoi Ogawa,1 Hideki Takizawa,2 Yoshinosuke Shimamura.2 1Hokkaido Renal 
Pathology Center, Sapporo, Japan; 2Teine Keijinkai Hospital, Sapporo, Japan.
Background: Anti-glomerular basement membrane glomerulonephritis (anti-GBM 
GN) is caused by circulating autoantibodies against mainly the noncollagenous-1 (NC-1) 
domain of the alpha 3 chain of type IV collagen. NC-1 domain must be dissociated in order 
for autoantibody binding to occur. 30% of anti-GBM GN patients are seropositive with 
anti-neutrophil cytoplasmic antibody (ANCA). Bowman et al reported IgG1 and 4 were 
dominant in the patient serum and renal eluates, Here we analyze the IgG subclass deposited 
on GBM in anti-GBM GN cases and patient’s serum reactivity to glomeruli in biopsied 
tissue of ANCA-associated vasculitis (AAV), and other GN cases to evaluate the production 
of autoantibody formation in anti-GBM GN.
Methods: Kidney biopsy specimens from 16 patients diagnosed with anti-GBM 
glomerulonephritis between April 2009 and March 2018 were identified in Hokkaido 
Renal Pathology Center. Renal frozen tissue of AAV (anti-GBM seronegative) and other 
glomerular diseases were stained by a serum from the patient with anti-GBM disease using 
indirect immunofluorescence method.
Results: The age range was 15 to 83 years. Serologic titers for anti-GBM were raised 
(7.1->350) in all cases, and serologic studies for ANCAs were positive in 4 cases. One 
case superimposed IgA nephropathy, and other one showed remarkable granulomatous 
inflammatioLight microscopy revealed crescentic formation (80.5±17.8%) and linear GBM 
staining was detected by immunofluorescence study. The number of preserved glomeruli 
was correlated with baseline eGFR (R2=0.4407, p<0.01). 14 renal tissues were available 
for staining with anti-IgG1,2,3, and 4. IgG1 dominant staining was detected in all 14 cases. 
Cases with more than 2 times brightness of IgG1 staining were seen in younger cases 
(p<0.05). Glomeruli of biopsied tissue of AAV cases were stained with serum IgG of anti-
GBM disease, although glomeruli of MCNS were negative.
Conclusions: IgG1 was mainly deposited on GBM in anti-GBM disease similar to the 
previous report (Bowman et al, Clin Exp Immunol 1987). The serum reactivity to GBM in 
AAV suggests that the rupture of GBM is one of the triggers for the pathogenesis of anti-
GBM and ANCA double positive disease.
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Selection of Housekeeper Genes for Real Time Quantitative PCR 
(qRT-PCR) Analysis of Rat Kidney Tissues Under Ischaemic and 
Toxicological Conditions
Sanjeeva C. Herath,1 Kylie M. Taylor,1 Amy Au,2 Zoltan H. Endre,2 Jonathan 
H. Erlich.1 Australian Renal Biomarker Reference Laboratory 1University of
New South Wales, Kensington, NSW, Australia; 2Prince of Wales Hospital,
Randwick, NSW, Australia.
Background: Appropriate selection of housekeeper genes (HKG’s) is pivotal to 
obtaining accurate and reproducible results in qRT-PCR. Studies have shown that the more 
commonly used HKG’s are not constant under different experimental conditions. Hence we 
aimed to determine the most opitmum HKG’s and normalization factor (NF) for the study 
of target gene expression in rat kidney tissues.
Methods: Control and adenine fed Sprague Dawley (SD) rats were equally divided into 
6 intervention groups consisting of 8 biological replicates. The intervention groups consisted 
of a subclinical CKD (sCKD), acute kidney injury (AKI), AKI on a background of sCKD, 
recovery and a control group. AKI was induced with cisplatin or ischaemia. sCKD was 
induced with 0.25% adenine. 10 commonly used candidate HKG’s from different functional 
classes were selected.. The stability of gene expression was analyzed utilizing NormFinder, 
Genorm, BestKeeper and comparative delta Cq statistical algorithms. Weighted rank 
aggregation by Brute force method and by cross entropy Monte Carlo method was used to 
achieve a consensus rank of genes.
Results: Results: Ranking of the candidate HKG’s by each algorithm is listed below 
in table 1 below (see table) PABPN1, HMBS, YWHAZ, YWHAG and SDHA were 
respectively determined to be the 5 most stable HKG’s by consensus ranking. The optimum 
number of HKG’s needed for most stable normalization factor (NF) was determined to be 
3 with 2 also giving an improved result. By comparison, the commonly used GAPDH and 
18S were the least stable of all 10 HKG’s studied.
Conclusions: Construction of a normalisation factor by utilizing two or three most 
stable HKG’s which includes HMBS and PABPN1 produces the least variability to control 
for experimental errors and adjusted for inter-sample variations in rat kidney studies
Funding: Government Support - Non-U.S.
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Double-Negative T Cells in Human Renal Cell Carcinoma – Potential 
Target for Immune Checkpoint Inhibition
Johanna T. Kurzhagen,1 Sanjeev Noel,1 Mohanraj Sadasivam,1 Sul A Lee,1 
Jing Gong,1 Abdel Hamad,1 Phillip M. Pierorazio,3 Hamid Rabb.2 1Johns 
Hopkins University, Baltimore, MD; 2Johns Hopkins University School of 
Medicine, Baltimore, MD; 3Brady Urological Institute, Johns Hopkins 
University, Baltimore, MD.
Background: CD4-CD8- double-negative (DN) T cells are an unconventional subset 
of T cells, that are found in normal human and mouse kidney. Their immunomodulatory 
potential has been proposed in hematological malignancies and melanoma. Immune cells 
are involved in the pathogenesis of renal cell carcinoma (RCC). However, whether DN T 
cells are present in RCC is not known.
Methods: RCC and normal tissue adjacent to the tumor were collected from 11 RCC 
patients after nephrectomy. Kidney mononuclear cells were isolated immediately following 
tissue procurement and immunophenotypic analyses was performed for CD45+, TCR+, 
CD4+, CD8+, CD20+, CD16+, CD14+, CD11c+ and CD206+ cells using flow cytometry.
Results: The mean age of the cohort was 59.8 years. The average maximal tumor 
diameter was 6.8 cm. Our results demonstrate the presence of DN T cells in RCC tissue 
as well as in normal kidney tissue (N) with a similar frequency (N: 5.86%, RCC: 6.17%, 
p=0.918). This was in spite of a significant increase of CD45+ lymphocytes in the RCC 
tissue in comparison to the normal kidney tissue (N: 8.22% vs. RCC: 44.76%, p=0.001). 
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In contrast, B cells (CD20+) and M2 macrophages (CD206+) were significantly decreased 
in tumor tissue (CD20+: N: 21.2% vs. RCC: 5.91%, p=0.002; CD206+: N: 8.44% vs. RCC: 
0.90%, p=0.003). There was no significant difference in TCR+, CD4+, CD8+, CD16+, CD14+ 
and CD11c+ cell frequencies between RCC and normal kidney tissue (see figure).
Conclusions: This data demonstrates that DN T cells are present in RCC tissue with 
a frequency similar to “normal” kidney tissue. Given recent data showing PD1 expression 
on DN T cells, these cells could be potential targets for checkpoint inhibitors and other 
immunotherapeutic approaches.
Funding: NIDDK Support, Private Foundation Support
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Emerging Role of Post-Translational Modifications in CKD and Cardio-
vascular Disease
Vera Jankowski,3 Heidi Noels,2 Joachim Jankowski.1 1RWTH Aachen, Aachen, 
Germany; 2RWTH University Aachen, Aachen, Germany; 3University hospital 
RWTH Aachen, Aachen, Germany.
Background: Post-translational modifications of proteins and peptides have recently 
gained much attention, as they are involved in the pathogenesis of cardiovascular disease 
and eventually also in the progression of chronic kidney disease.
Methods: We provide an overview of post-translational protein modifications such 
as carbamylation, glycation and oxidation, starting with their definitions, mechanisms and 
clinical relevance in the setting of chronic kidney disease and cardiovascular disease.
Results: The methods currently used for the identification and especially quantification 
of post-translational modifications are described and potential treatment options in the 
context of post-translational modifications are reviewed.
Conclusions: We concluded that advancements in mass-spectrometry-based methods 
will certainly boost the clinical utility of sample analyses, leading to the identification of 
novel disease markers and/or pathophysiologically relevant factors
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Angiopoeitin-2 and Procalcitonin as Biomarkers of Atrial Fibrillation in 
CKD and Sepsis
Jack Bontekoe,2 Vinod K. Bansal,1 Justin Lee,2 Debra Hoppensteadt,1 
Paula D. Maia,3 Jawed Fareed.1 1Loyola University Medical Center, Maywood, 
IL; 2Loyola University Stritch School of Medicine, Howell, MI; 3Loyola 
University of Chicago, Maywood, IL.
Background: Angiopoeitin-2 is a 497 amino acid protein which is involved in vascular 
remodeling. Procalcitonin (PCT) is a 116-amino acid pro-peptide expressed in non-
neuroendocrine tissues. Both biomarkers are upregulated in response to inflammation and 
cellular injury, particularly in the setting of bacterial sepsis. Ang-2 and PCT are elevated 
in stage 5 chronic kidney disease on hemodialysis (CKD5-HD), but their relevance with 
inflammatory cardiac conditions, such as atrial fibrillation (AF), has not been established. 
Monitoring Ang-2 and PCT levels in CKD5-HD patients may have a dual predictive role 
in the evaluation of AF and sepsis. Comorbid AF amplifies circulating levels of Ang-2 and 
PCT are upregulated in CKD5-HD.
Methods: Plasma levels of PCT, CD40-L, CRP, vWF, D-dimer, Ang-1 and Ang-2 
were measured in 93 CKD5-HD patients and 50 normal controls using ELISA methods. 
Patient records established comorbid AF (n=23) and history of sepsis (n=35, mean days 
from resolution=762, SD=730).
Results: PCT levels were significantly elevated in CDK5-HD patients with comorbid 
AF (p= 0.0270) but not in patients with a history of sepsis (p=0.3441). In patients with 
a history of sepsis, PCT levels were elevated only in those patients with comorbid AF 
(p=0.0405). Notably, of the other inflammatory biomarkers measured, only Ang-2 levels 
resulted in differentiating between CKD5-HD patients with a history of sepsis (p=0.0138).
Conclusions: In CKD5-HD patients, increased pro-inflammatory processes associated 
with AF substantially increases PCT and Ang-2 levels. In patients with a history of sepsis, 
only those with AF demonstrated elevated ANG-2 and PCT levels, therefore measurement 
of these biomarkers may be useful in the evaluation of AF in post-septic CKD5-HD 
patients. Sustained inflammation as a result of sepsis may predispose patients at a greater 
risk of developing AF. Evaluation of this relationship may further elucidate the role of 
inflammation and the long-term effect of endothelial damage in the pathogenesis of AF.
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Upregulation of Biomarkers of Neurovascular Diseases in Patients with 
Stage 5 CKD
Justin Lee, Jack Bontekoe, Vinod K. Bansal, Jose Biller, Debra Hoppensteadt, 
Paula D. Maia, Trung Phan, Jawed Fareed. Loyola University Medical Center, 
Maywood, IL.
Background: Patients with stage 5 chronic kidney disease (CKD5D) have a higher 
risk for developing neurovascular complications. Chronic inflammation from renal failure 
increases the risk for these diseases through oxidative stress and vascular dysfunction. To 
profile levels of inflammatory and hemostatic biomarkers in CKD5D plasma, and relate 
measurements to neurovascular diagnoses and demonstrate their relevance to neurovascular 
deficit.
Methods: Eleven plasma biomarker levels in CKD5D patients (n=97) and healthy 
controls (n=17-50) were measured using sandwich ELISA method. The biomarkers in this 
study were of inflammation and hemostatic dysregulation, which included angiopoietin-1 
(Ang-1), angiopoietin-2 (Ang-2), CD40 ligand (CD40L), C-reactive protein (CRP), 
D-dimer, intercellular adhesion molecule-1 (ICAM-1), NACHT, LRR, and PYD domains-
containing protein 3 (NALP3), plasminogen activator inhibitor-1 (PAI-1), procalcitonin
(PCT), tumor necrosis factor alpha (TNFα), and von Willebrand factor (vWF). Of the 97 
CKD5D patients, 24 had CCAD, 19 had ICAD, and 23 had acute stroke. The results were 
expressed as mean ± standard error of the mean. Statistics were performed with Mann-
Whitney t-tests, Kruskal-Wallis non-parametric ANOVA, and non-parametric Spearman 
correlations.
Results: All of the biomarkers had elevated levels in CKD5D plasma, except for PAI-1 
(p=0.9764), compared to controls. Statistical significance was only found between CKD5D 
(+) and (-)ECAAD NALP3 (p=0.0299), and between (+) and (-)stroke D-dimer (p=0.0258). 
Ages between each (+) and (-) disease groups were also significant (p=0.0002 ECAAD; 
p<0.0001 ICAD; p=0.0157 stroke). D-dimer was correlated with age in CKD5D (r=0.2115, 
p=0.0375).
Conclusions: Previous studies have demonstrated a relationship between NALP3 
expression and the instability of atherosclerotic plaques in ECAAD. NALP3 is a component 
of inflammasomes, the presence of which elevates IL-1β and IL-18, which subsequently 
increases risk of ECAAD and stroke. Despite upregulation, biomarker profiling is of limited 
use in risk stratification of neurovascular diseases among the CKD5D population, with the 
possible exception of NALP3 for ECAAD.
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Microdroplets in Minimal Change: A Novel Finding
Amanda Tchakarov,1 William F. Glass.2 1Pathology, McGovern Medical School, 
Houston, TX; 2Pathology, McGovern Medical School, Houston, TX.
Background: Minimal Change (MCD) is a frequent cause of nephrotic syndrome. 
MCD results from podocytopathy with filtration barrier changes causing proteinuria. 
While it is thought circulating mediators lead to podocytopathy, little has been determined 
about the mediator. In our practice we have noted that many MCD cases have IgG-positive 
microdroplets in Bowman’s space, detectable by IF. We conducted this study to characterize 
these microdroplets.
Methods: Our database of imaged LM, EM, and IF stains from 2013-16 was reviewed 
for cases of MCD (n=42), primary FSGS (n=10), collapsing FSGS (n=4), tip lesions 
(n=5) and normal biopsies (n=12). The presence of microdroplets in images was noted. 
Additionally, a subpopulation of MCD cases was stained for IgG subtypes and C4d by IF.
Results: Database review revealed 45% (19/42) of MCD cases, 1 out of 10 primary 
FSGS, and 1 out of 5 tip lesion cases contained IgG dominant microdroplets. Microdroplets 
were absent in normal biopsies and collapsing glomerulopathy. IgG intensity ranged from 
weak to 1+. Some microdroplets also stained for IgA (n=1), C3 (n=1), kappa (n=11) and 
lambda (n=10). A subset of MCD cases (n=8) were stained for IgG subtypes, half which 
were originally negative for microdroplets. IgG1 microdroplets were present in 88% of 
cases, 25% were positive for IgG2. All cases were IgG3 and IgG4 negative. A single case, 
originally negative, showed no subclass staining. One case (13%) had C4d positivity.
Conclusions: To our knowledge the phenomenon of glomerular microdroplets has not 
been reported. Due to the location and distribution, we believe they represent endocytotic 
vesicles in podocytes. Subtype restriction suggests there is specific antibody binding to a 
mediator, possibly involved in causing podocytopathy. Further study to elucidate what the 
antibodies are binding is warranted. At the very least, we have found these microdroplets 
helpful in the confirmation of MCD in our practice.
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IgG1 stain with diffuse microdroplets within Bowman’s space.
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Kidney Diseases Associated with Tubular Reticular Inclusions (TRI)
Fatima Sheikh,1 Rimda Wanchoo,1 Christine B. Sethna,2 Vanesa Bijol,3 
Kenar D. Jhaveri.1 1Nephrology, Zucker School of Medicine at Hofstra Northwell, 
GREAT NECK, NY; 2Cohen Children’s Medical Center of NY, New Hyde Park, 
NY; 3Pathology, Zucker School of Medicine at Hofstra/Northwell, GREAT 
NECK, NY.
Background: Tubular reticular inclusions (TRI) in kidney biopsies are indicative 
of a high interferon state. They have been noted in kidney biopsies of patients with HIV 
nephropathy and lupus nephritis (LN). Literature is limited in other known causes of kidney 
diseases noted with TRI.
Methods: We reviewed all biopsies performed at our health system with findings of 
TRI(1 year). Clinical and pathology data were collected by chart review. Comparisons 
between LN patients and n-LN patients were made using student t-tests and chi-square 
analysis.
Results: TRI were found in 17% (55/322) of biopsies. 71% of the biopsies had LN 
(N = 40) & remaining 29% (N =15) had n-LN diagnoses. The 15 n-LN patients comprised 
of various other diagnoses (Fig). Four patients (26%) of the n-LNpatients had a virus 
associated disease (BK virus, parvovirus B19, hepatitis C and hepatitis B). The mean 
age of the LN patients was 31.5 years compared to 40.9 years in n-LN, p = 0.04. The 
LN were mostly females (80%) compared to the n-LN group, where 50% were females, 
p = 0.048. Almost 90% of LN presented with hypocomplementemia whereas only 15% 
of the n-LN presented with hypocomplementemia, p < 0.001. The mean presenting Scr 
was higher in n-LN compared to LN (2.45mg/dl vs. 1.36 mg/dl, p = 0.01). There was no 
significant difference in proteinuria at time of biopsy for the LN (3.69 g/day) compared to 
n-LN (4.82 g/day), p = 0.86. The mean 6 month Scr was 1.94mg/dl in LN patients after
treatment and 1.5mg/dl in n-LN, p = 0.78. There was one LN patient and two n-LN patients 
that required dialysis.
Conclusions: TRI were noted in biopsies of patients with LN but also in a number 
of n-LN patients. Interestingly, as opposed to commonly being seen in HIV nephropathy, 
our pathology was mixed with new associations. The n-LN patients presented with higher 
serum creatinine and normal complement levels. The outcomes appear to be similar in both 
groups.
Pathology diagnoses of non lupus nephritis patients
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Xanthogranulomatous Pyelonephritis as a CKD Cause
Héctor R. Ibarra-Sifuentes,1,2 Edgar F. Carrizales Sepulveda,2 Raymundo Vera,2 
Michelle Morcos sandino,1 Diego Martinez yañez,1 Regina D. Landa,1 
Fernando G. Ruiz Hernandez,1 Angel N. Del cueto aguilera,2 Luis I. Bonilla,1,2 
María Guadalupe R. Ramirez,1,2 Lilia M. Rizo Topete,1,2 Giovanna Y. Arteaga 
Muller.1,2 1Nephrology, Universidad Autonoma de Nuevo Leon, Monterrey, 
Mexico; 2Internal Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, 
Mexico.
Background: Xantogranulomatous Pyelonephritis (XGP) is a rare chronic 
inflammatory condition of the kidney that appears as a complication of long-term obstruction 
and infection of the urinary tract. Renal parenchyma is replaced by xanthoma cells, plasma 
cells and histiocytes. It accounts for only 0.6% of all histologically documented cases of 
pyelonephritis. Due to its low frequency, most of the available information comes from 
case series.
Methods: The study was conducted in the University Hospital Dr. José E. González in 
Monterrey, during January 2012 to may 2018. All patients with XGP where retrospectively 
recruited for analysis. Demographics, history and physical examination, biochemical, 
urinalysis, urine culture and imaging studies information was extracted from patients.
Results: A total of 37 patients were included in our analysis. Females (78.4%) were 
affected more commonly than man. Prior renal lithiasis and urinary infection affect patients 
on 51.5% and 44.4% of the cases, respectively. The most common presenting symptom 
was flank pain (70%) and fever (63.9%). 47.5% of the cases presented with hemoglobin 
<10 mg/dL and 79.4% had leukocytosis. The mean GFR was 74.1 (47.8–105.3). E. coli 
and Morganella spp. were the most common cultured bacteria on urine. Nephrectomy was 
performed on all patients. Bear paw sign was only present on 9.7% of the cases (Fig 1).
Conclusions: XGP is a rare condition, commonly presenting on femele patients with 
prior renal lithiasis or urinary infection. The most common cultured bacteria on urine 
were E. coli and Morganella spp. As the main treatment modality is nephrectomy, more 
information about this disease is needed to improve diagnosis, management and outcomes.
PUB426 
Publication-Only 
The Significance of Serum Soluble Urokinase-Type Plasminogen Activator 
Receptor in Diagnosing FSGS: A Meta-Analysis
Jiwon M. Lee,1 Jae Won Yang,2 Gaeun Kim,5 Keum hwa Lee,4 Jae Il Shin.3 
1Chungnam National University, Seoul, Republic of Korea; 2Wonju Christian 
Hospital, Wonju, GANGWON-DO, Republic of Korea; 3Yonsei University 
College of Medicine, Seoul, Republic of Korea; 4Yonsei University, Seoul, 
Republic of Korea; 5Keimyung University College of Nursing, Daegu, Republic 
of Korea.
Background: In the pathogenesis of focal segmental glomerulosclerosis (FSGS), 
circulating factors have been regarded as a significant factor, since about 40% of the patients 
recur after transplantation. Soluble urokinase-type plasminogen activator receptor (suPAR) 
has been suggested as a potential biomarker for FSGS. This study is a meta-analysis on the 
usefulness of suPAR for the diagnosis of FSGS.
Methods: We performed a PubMed, EMBASE and forward search of the retrieved 
articles and identified studies that evaluated suPAR levels in patients with FSGS, published 
until May 1st, 2018.
Results: Of the 187 articles reviewed, 13 fulfilled the criteria of inclusion. We observed 
increased level of suPAR in the FSGS patients compared to healthy controls (P<0.001, 
Hedge’s g, 3.097, 95% confidence interval(CI), 1.666-4.527). This finding was consistent 
in comparison with other glomerulonephritis (GN). The suPAR levels were significantly 
higher in patients with FSGS compared to those with minimal change disease (MCD) 
(P=0.033, Hedge’s g, 1.289, 95% CI, 0.107-2.471), membranous glomerulonephritis (MN) 
(P=0.013, Hedge’s g, 1.372, 95% CI, 0.286-2.457), and IgA nephropathy (IgAN) (P<0.001, 
Hedge’s g, 0.840, 95% CI, 0.488-1.192), respectively. Of note, however, the levels did not 
differ between FSGS patients with remission compared to those without (P=0.411, Hedge’s 
g, 1.020, 95% CI -1.413-3.453).
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Conclusions: The results suggested that suPAR can be a putative diagnostic indicator 
for FSGS in differential diagnosis of GN.
Funding: Government Support - Non-U.S.
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Does ABPM Correlate with BP Diagnosis Made at Pediatric Nephrolo-
gist’s Office?
Isabel Roberti,1 Shefali Vyas.2 1Children’s Kidney Center, RWJBarnabas Health, 
West Orange, NJ; 2Children’s Kidney Center, RWJBarnabas Health, West 
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Background: ABPM is a helpful tool in evaluating children with variable office BPs, 
white coat hypertension (WCH) and uncontrolled HTN. In 2017, AAP defined the ABPM 
role in diagnosing/managing HTN, recommending it for any child with elevated office BP 
for ≥ 1 yr or with stage I HTN x 3 visits. HTN is a common reason for Ped Nephro referrals 
from school RN and MD’s offices. Limited data exists comparing ABPM diagnosis with 
Ped Nephro office’s BPs in children. Objective: to compare HTN diagnosis made by ABPM 
vs Ped Nephr office’s BP and evaluate by referral source, demographic and clinical data.
Methods: ABPM was done by Welch Allyn 6100 monitor. Soergel criteria were used 
to define BP percentiles; SBP and/or DBP load ≥ 25% was used to diagnose HTN (% SBP 
and DBP > 95th). Elevated BP =90-95%, Stage I-≥95-99% and Stage II- ≥99%+5 mm Hg. 
Retrospective review was done in all children with 24 hour ABPM done from Jan 2011 to 
May 2017 at our office. IRB approval was obtained for chart access. All children diagnosed 
with confirmed HTN complete evaluation to r/o secondary causes and evidences of end-
organ damage.
Results: 373 ABPMs were done in 361 children aged 3-21yrs (median=14yrs); 73% 
males; Ethnicity: 152 AA, 117 C, 71 H, 21 other. 73% had positive FH for HTN and 20% 
were symptomatic at presentation. LVH was seen in 14% and microalbuminuria in 9%. 
LVH correlated with HTN stage. Referral source: 263 (74%) from PMD, 29 from School 
RN and 63 from Pediatric sub-specialists. Office BP diagnosis: 51 wnl, 106 with Elevated 
BP, 145 Stage I HTN, 58 Stage II HTN and 1 NA. ABPM diagnosis:125 WCH, 61 with 
Elevated BP, 134 Stage I HTN, 47 Stage II HTN and 6 errors. 86 children (23%) with 
abnormal BP at Nephrologist office had WCH diagnosed by ABPM. For children with 
HTN diagnosed by both Nephrologist and ABPM: office HTN grade was higher in 29 
and lower in 45, when compared to ABPM; discordance rate = 74/229 (32%). Masked HTN 
was noted in 14 children (4%). Degree of HTN and WCH didn’t correlate with referral 
source; children referred by school RNs were more often symptomatic (38% vs 18%, 
p=0.01).
Conclusions: Children with suspected HTN, often symptomatic were referred from 
various sources for Ped Nephro consult. ABPM was confirmed as an important tool to 
diagnose masked HTN, WCH and clearly establish the proper level of HTN. We observed a 
high discordance rate of HTN Stage diagnosis which was independent from referral source.
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Trajectory of eGFR Predicts Renal Injury in Children with Multicystic 
Dysplastic Kidney
Kazuya Matsumura,1,2 Kyoko Sugii,1 Midori Awazu.1 1Keio University School of 
Medicine, Tokyo, Japan; 2Hiratsuka City Hospital, Hiratsuka, Japan.
Background: Children with a solitary functioning kidney have a risk of renal injury 
caused by hyperfiltration. Timely intervention with renin-angiotensin inhibitors may be 
benefical. We examined whether trajectory of estimated glomerular filtration rate (eGFR) 
would predict renal injury, defined as microalbuminuria/proteinuria, hypertension, and/or 
a decline in eGFR.
Methods: Seventeen patients (male 7, female 10) with multicystic dysplastic kidney 
(MCDK) (median age 13 years, range 6 to 19 years) followed in our clinic were examined 
retrospectively. Microalbuminuria and proteinuria were defined as urine albumin/creatinine 
ratio >30 mg/g and urine protein/creatinine ratio >0.15 g/g, respectively. Hypertension was 
determined when an average of BP measurements was ≥the 95th percentile for age, sex, and 
height. GFR was estimated by quintic equation for Japanese children by height and gender 
(2-18 years) or the revised Japanese equation for eGFR (>19 years). An eGFR decline was 
defined as a fall to <90 ml/min/1.73 m2 or a decline of >5 ml/min/1.73 m2/year for those 
with baseline eGFR of ≥90 ml/min/1.73 m2 or <90 ml/min/1.73 m2, respectively. The best-
fitting model of eGFR over time was determined in each patient.
Results: Nine patients had renal injury at the time of investigation. Compared with 
8 patients without renal injury, those with renal injury tended to be older (14.7±4.2 vs 
11.4±4.6 years, measn±SD) and the birth weight was smaller (2538±281 vs 2966±361 g, 
P<0.05). Frequency of contralateral congenital anormaly of kidney and urinary tract (cyst, 
hydronephrosis, or vesicoureteral reflux) was not different. Trajectory of eGFR in those 
without renal injury was either increase (n=3) or unidentifiable (not fitting any statistical 
significant model but remaining stable, n=5), whereas that in renal injury group was 
exclusively increase followed by decline (P<0.05). The average age of the onset of eGFR 
decline was 9.4±4.2 years and that of renal injury (albuminuria/proteinuria 5, eGFR decline 
4, hypertension 1) was 12.5±4.2 years.
Conclusions: All the children with MCDK who developed renal injury had eGFR 
trajectory of increase followed by decline. The peak eGFR was followed by renal injury 
after 3 years on average. This observation is in agreement with the hyperfiltration theory and 
underscores the importance of following eGFR trajectory closely especially when eGFR is 
increasing.
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An Unusual Case of PHA Type 1
Molly Band,1 Kim Zuber,2 Jane S. Davis.3 1Connecticut Children’s Medical 
Center, Hartford, CT; 2American Academy of Nephrology PAs, Oceanside, CA; 
3University of Alabama at Birmingham, Birmingham, AL.
Introduction: Pseudohypoaldosteronism (PHA) is a rare pediatric condition 
presenting as either Type 1 or Type 2. Type 1 can be primary or transient whereas Type 2 is 
often congenital. Transient Type 1 PHA is often due to a UTI or a congenital malformation 
leading to a UTI. We describe the first documented case of PHA Type 1 in a 2-week old tiger 
cub at the San Diego Zoo Safari Park
Case Description: A 3-day old tiger cub at the San Diego Zoo Safari Park was rejected 
by his mother & hand-reared by park keepers using a formula designed for carnivores. The 
tiger failed to thrive, presenting with acute lethargy at 2 weeks. During initial evaluation, the 
cub had a cardiac arrest revived with CPR. Initial labs showed a critical K>9 mEq/dL with 
hyponatremia (120 mg/dL). Subcu 0.9% saline was started. Differential diagnosis included 
adrenal crisis thus the tiger cub was started on prednisolone and fludrocortisone. Additional 
testing included a urine culture, which grew Klebsiella pneumoniae and Enterococcus 
species. An abdominal U/S revealed hyperechoic debris swirling in the urinary bladder & 
renal pelvices as well as bilateral pyelectasia. Transient pseudohypoaldosteronism secondary 
to pyelonephritis was suspected and the tiger was started on amoxicillin and clavulanate. 
An adrenocorticotropic hormone (ACTH) stimulation test revealed a significantly elevated 
aldosterone of >4572 pmol/L, confirming the diagnosis. The veterinary staff used pediatric 
nephrology literature to diagnose and treat. The tiger was given antibiotics until the urine 
culture was negative and the U/S revealed resolution of debris. Electrolytes normalized. He 
began to eat, grow & eventually bond with his brother.
Discussion: Severe hyponatremia & hyperkalemia are uncommon during infancy, 
but can have life-threatening consequences. The differential diagnosis includes congenital 
adrenal hyperplasia (CAH), congenital adrenal hypoplasia, medication administration 
and PHA. PHA causes hyponatremia, hypovolemia, hyperkalemia, & metabolic acidosis. 
Type 1 PHA can either be primary (inherited) or secondary (transient). Transient PHA 
is reported in infants with UTIs and urinary tract abnormalities (hydroureteronephrosis, 
vesicoureteral reflux or obstructive uropathy). Patients with PHA should have resolution of 
their electrolyte imbalances with targeted treatment of the primary infection and appropriate 
IV fluid resuscitation, even if they are a tiger.
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Background: Despite strong association between sickle cell disease (SCD) and 
enuresis, no large studies have examined, using standardized definitions, the prevalence of 
enuresis, its variants and risk factors in children with SCD in Sub-Saharan Africa which has 
the largest burden of SCD. We determined and compared the prevalence of enuresis and its 
various forms in children with and without SCD and identified its predictors.
Methods: Caregivers of children with SCD attending a hematology clinic in a public 
hospital in Nigeria were interviewed using a standard case record form. In addition, a 
separate record form was completed for every sibling aged 5-17 years whose haemoglobin 
phenotype was known. Enuresis and its variants were defined using the International 
Children’s Continence Society’s definitions.
Results: The study involved 256 children with SCD and 256 controls. The mean age of 
the study cohort was 9.9 (3.4), with 44.5% ≥10 years and 44.5% as females. The prevalence 
of enuresis was higher at 48.4% in children with SCD than in the controls with a steady 
decline with age (Fig. 1). The proportions with secondary enuresis (10.5% v 16.2%) were 
similar in both groups. However, children with SCD and enuresis were older (9.0 v 8.1 
year), more likely to be aged ≥10 years (33.9% v 16.2%) and were twice likely to have ≥4 
wet nights/week and non-monosymptomatic form than the controls. Pre-adolescence and 
enuresis in a family member were predictors of enuresis in children with SCD, whereas 
gender, socioeconomic status, hospitalisation in the past 12 months and receipt of blood 
transfusion were not.
Conclusions: Enuresis is more frequent, severe, non-monosymptomatic and likely 
to persist to late adolescence in children with SCD than in controls. These features make 
enuresis in children with SCD more difficult to treat than in controls. Younger age and 
enuresis in a family member are risk factors for enuresis in children with SCD.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1141
J Am Soc Nephrol 29: 2018 Publication-Only 
Age and sex prevalence of enuresis
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Effect of a Gluten-Free Diet on Albuminuria in Patients with Celiac 
Disease
Howard Trachtman,1 Jeremiah Levine,2 Libia Moy,2 Leora Hauptman.3 1NYU 
Langone Health, New York City, NY; 2NYU Langone Medical Center, New York, 
NY; 3NYU Langone, NY, NY.
Background: Celiac disease (CD) is caused by a gluten-induced increase in zonulin 
production by the enterocyte. This molecule interacts with protease activated receptor 2, 
disrupts the tight junction in the gut epithelium, and increases the intestinal permeability to 
gliadin. PAR2 is expressed in podocytes raising the possibility that this glomerular epithelial 
cell could be a target of zonulin.
Methods: Patients who were newly diagnosed with CD, based on elevated tissue 
transglutaminase (tTG) and small bowel histology, were eligible for inclusion in the study. 
A first morning urine specimen was collected at diagnosis and at the time of the follow-
up clinical assessment conducted to assess the response to the gluten-free diet (GFD). 
Albuminuria was measured using an ELISA kit and expressed as the albumin:creatinine 
ratio (ACR). Results are provided as mean±SEM.
Results: 17 patients with CD (8M:9F), all white, mean age 9.1±1.1 years old, were 
included in this study. 16 patients had elevated tTG IgA and the other patient had IgA 
deficiency with an elevated tTG IgG. At diagnosis, 1 child was receiving escitalopram 
and a second recombinant human growth hormone. After the initial assessment, 2 patients 
took lansoprazole but it was discontinued 2 months before the follow-up evaluation. 
None were receiving immunosuppressive medications. BP, serum creatinine and albumin 
concentrations were normal in all patients. The mean interval on the GFD was 6.1±0.7 
months. The initial ACR was 20.7±5.2 (4 had values above 30 μg/mg) that fell to 
10.4±1.5 μg/mg at the repeat evaluation, P=0.035.
Conclusions: Our findings indicate that patients with CD have low-grade albuminuria 
at the time of diagnosis of their gastrointestinal disease. Initiation of a GFD is associated 
with a significant decline in albumin excretion. Further study is needed to determine 
whether assessment of albuminuria should be incorporated into the care of patients with CD 
as a marker of clinical response and whether this abnormality has any long-term adverse 
health consequences.
Funding: NIDDK Support
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Background: Preterm infants with a low birth weight (LBW) show reduced numbers 
of nephrons at birth and a higher risk of developing kidney dysfunction during their lifetime. 
They demonstrate oligonephronia and focal segmental glomerulosclerosis (FSGS) lesions 
in their glomeruli. We examined the association between mitochondrial disorders and the 
pathological characteristics of LBW-related nephropathy.
Methods: We retrospectively evaluated the renal pathology in 6 infants including pairs 
of twins and 2 LBW infants demonstrating renal dysfunction. In addition to routine staining, 
the kidney biopsy specimens were analyzed using cytochrome c oxidase subunit IV (COX 
IV) and transcription factor A (TFAM) staining.
Results: FSGS was diagnosed in 2 and oligonephronia in 4 infants. The mean density 
of glomeruli was 3.8/mm2 (0.3–7.2) Granular swollen epithelial cells (GSECs), which 
have previously been reported exclusively in patients with mitochondrial cytopathy, were 
observed in the distal tubules and/or collecting ducts in all 6 infants. Electron microscopic 
examination revealed that these GSECs included an increased number of enlarged 
mitochondria. Furthermore, we observed unbalanced expression patterns of COX IV and 
low expression of TFAM in the glomeruli and a part of the tubular cells.
Conclusions: FSGS, a characteristic feature of glomerular involvement in patients 
with mitochondrial cytopathy is very commonly observed in LBW infants. In our study, 
all infants did not show FSGS lesions because a renal biopsy was performed in the early 
stages of the disease in contrast to previous reports. However, most patients revealed similar 
pathological changes of mitochondrial cytopathy such as unbalanced expression of TFAM, 
which plays a role in maintaining the mitochondrial DNA. This finding suggests that 
these lesions could appear during early childhood, resulting in the development of FSGS 
in the future. These findings could suggest the application of a new approach targeting 
mitochondrial DNA to prevent the development of LBW-related nephropathy.
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Introduction: Advances in molecular genetics have revealed that about 30% of the 
cases with steroid resistant nephrotic syndrome (SRNS) are caused by single-gene mutations 
that highly expressed in the podocytes. More than 50 genes are known to be responsible for 
SRNS. One of the responsible genes is nucleoporin, 93-KD (NUP93). Till date, only few 
studies reported the mutations of NUP93 in SRNS. Here, we describe a NUP93 biallelic 
mutation in 9 years old boy with focal segmental glomerular sclerosis (FSGS). Although 
one was a heterozygous truncating variant, another was a novel heterozygous intronic 
variant which pathogenicity was unknown. To confirm the pathogenicity of the intronic 
variant, we conducted in vivo and in vitro analysis.
Case Description: The patient was a 9-year-old boy. He was detected proteinuria at 
2 years old, and diagnosed with SRNS. The histological finding was FSGS. At the onset, 
hypoalbuminemia (2.6 g/dL), high serum creatinine (0.88 g/dL) with decrease renal 
function (eGFR 53.6L/minute/m2BSA), proteinuria (urine protein creatinine ratio: 2.37), 
and hematuria was found. He has optic nerve atrophy as his extrarenal symptom. There were 
no histories of kidney diseases in the family. We found 2 novel heterozygous mutations in 
NUP93, c.727A>T (p.Lys243*) in exon 8 and c.2137-18G>A in intron 19. To determine the 
pathogenicity of the intronic variant, we conducted RT-PCR analysis, in vitro splicing assay 
using minigene construction and in vitro protein expression analysis. Both RT-PCR using 
patient’s sample and in vitro splicing assay showed exon 20 skipping by the intronic variant. 
The in vitro protein expression analysis result showed abnormal localization in cytoplasm 
with the particle formation by the intronic variant. From these results, we conclude c.2137-
18G>A as pathogenic by causing aberrant splicing.
Discussion: NUP93 variants are quite rare; however, we proved even the intronic 
variants in NUP93 can cause SRNS. Our results can help identifying more variants in this 
rare form of SRNS.
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Background: Polyomavirus BK is known as a common cause of graft failure in kidney 
transplant patients. There is rare data in pediatric patients, and the purpose of this study was 
to evaluate the clinical findings of BK virus infection and risk factor in pediatric patients 
with kidney transplantation.
Methods: The medical records of 30 children who received kidney transplantation 
from January 2002 to December 2017 in Samsung medical center were retrospectively 
reviewed. The screening for BK virus was performed in blood and urine by polymerase 
chain reaction.
Results: The median age of the kidney transplantation was 11.3 (range, 1.3-18.6) years, 
and male to female ratio was 2.3:1. The most common underlying disease was congenital 
abnormalities of kidney and urinary tract. The sixteen patients received the kidney from 
the deceased donors. BK viremia and viuria were detected in 9 and 6 patients respectively. 
The median period from kidney transplantation to BK virus detection in blood or urine was 
51days (7-3,464days). Among 15 patients with BK infection, 9 patients had the deceased 
donor kidney. The children with BK virus infection showed the tendency that the age at 
the time of transplantation was younger compared with those without BK virus infection 
(median age 8.4 vs 11.3 years). Three patients who had the past medical history with high 
dose chemotherapy and autologous stem cell transplantation for solid tumor before kidney 
transplantation showed the high titer of BK virus in blood. However, BK virus infection did 
not affect the short-term renal function and graft survival in all patients because the dose of 
immunosuppressant decreased when BK virus was detected.
Conclusions: The results of this study suggest that the risk factors of the BK viremia 
in the pediatric kidney transplant patients are supposed to be younger age at the time of 
kidney transplantation, deceased donor kidney, and past medical history with high dose 
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chemotherapy. Regular monitoring for BK virus and reduction of immunosuppression is 
necessary to prevent graft function.
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Pergamino, Argentina; 2Fresenius Medical Care, Escobar, Argentina; 3Centro 
de Neurociencias Los Manantiales, Rosario, Argentina.
Background: INTRODUCTION: Fabry disease (FD) is caused by deficient or null 
activity of the enzyme α-galactosidase A (α-galA) which causes the lysosomal accumulation 
of complex glycosphingolipids, mainly globotriaosylceramide. Affected children suffer 
from neuropathic pain, gastrointestinal dysfunction, hypohidrosis and intolerance to cold 
and heat from early childhood, which may impair quality of life and affect the daily activities 
of home and school. OBJECTIVE: To describe the organic commitment in children at the 
time of diagnosis of FD.
Methods: Patients with FD were analyzed from three reference centers in Argentina, 
with classical mutations of the GLA gene (E398x and p.L415P). Typical manifestations of 
EF were evaluated after having ruled out other causes of them.
Results: Twenty-one patients, from 2 to 16 years of age (average: 8.2 years), 12 women 
and 9 men were studied. Renal hyperfiltration was detected in 12/21 (57.1%); 9 girls and 
3 boys. Three patients (14.3%) had GFR <90 ml / min / 1.73 m2 (2 children and 1 girl). 
Albuminuria was evidenced in 2 girls (9.5%). 7/21 children (33.3%) presented neuropathic 
pain. Cardiac involvement was detected in 4/21 patients (19%); 2 with arrhythmia (sinus 
bradycardia) and 2 with LVH. 5 patients (23.8%) presented angiokeratomas and only 3 
(14.3%) with gastrointestinal involvement. An 11-year-old girl presented CNS involvement 
(NMR with white matter lesion without any other cause than FD.)
Conclusions: Children in our population experienced symptoms and signs typical of 
FD at an early age, with a high percentage of renal hyperfiltration. (as a probable glomerular 
compensation and incipient sign of nephropathy) as the most frequent renal manifestation.
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Ampicillin/Sulbactam as Empiric Monotherapy In Patients Under 24 
Months with 1st UTI in the Era of Antibiotic Resistance
Ji yeon Song, Seong heon Kim. Pusan National University Children’s Hospital, 
Yangsan, Republic of Korea.
Background: Cephalosporin has been the most commonly used empirical agent for 
urinary tract infection (UTI) in children. However, the worldwide increase of extended-
spectrum beta lactamase (ESBL) producers and its resistance to cephalosporin makes it 
difficult for physicians to choose empirical antibiotics for UTI.
Methods: All infants and young children 2 to 24 months old who hospitalized to Pusan 
National University Children’s Hospital due to first episode of febrile UTI during the 2-year 
period (June 2012 to April 2014) were included in the study. The subjects were divided 
into two groups according to their empirical therapy whether they received cefotaxime 
or ampicillin-sulbactam. We determined the pathogens of UTI of young children and 
their antibiotic susceptibilities and compared effectiveness and adverse effect between 
ampicillin/sulbactam and cephalosporin.
Results: 55 patients of group A were treated with cefotaxime and 44 patients of group 
B with ampicillin/sulbactam as empirical antibiotics. The most common pathogen was 
E. coli in both groups and isolated E. coli of two groups had no significant differences
in antibiotics susceptibility rate. In both groups, E. coli tends to be more susceptible for
ampicillin/sulbactam than cefotaxime. In addition, there was no significant difference in the 
duration of fever (11.6 ± 15.4 vs 8.7 ± 13.3hrs, P = 0.29) after treatment between the two
groups. None of the patients in both groups had initial treatment failure or recurrence due
to improper treatment. The most common side effects of antibiotics agents were diarrhea
(72.7% vs 74.5%, P = 1.0), elevation of liver function test (47.7% vs 52.7%, P = 0.68),
and anemia (11.4% vs 23.6%, P = 0.18). Comparing the cost of treatment, we found that
ampicillin-sulbactam is cheaper than cefotaxime.
Conclusions: Ampicillin-sulbactam could be effective alternative to cephalosporins as 
the empiric treatment in patients with 1st UTI under 24 months.
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Complement Activation Fragments Levels in Post Infectious 
Glomerulonephritis
Manuel A. Pascual. CTO-IAL Group Center of Organ Transplantation & 
Immunolo-allergology, Centre hospitalier universitaire vaudois, Lausanne, 
Switzerland.
Background: Post infectious glomerulonephritis (PIGN) is the most common cause of 
acute glomerulonephritis in children, and it is associated with hypocomplementemia (low 
C3).
Methods: Children with PIGN (n=8) and controls (acute renal failure n=3, chronic 
renal failure n=1, typical hemolytic uremic syndrome n=5) were studied for plasma lytic 
pathway sC5b-9, alternative pathway Bb fragment, and C3 concentrations.
Results: Plasma sC5b-9 concentrations were above the normal range (120-300 ng/mL) 
in all PIGN patients with a strikingly high mean value of 1067±253ng/mL. The control 
group showed a mean value of 337±63 ng/mL. Thus, PIGN patients had significantly higher 
sC5b-9 levels as compared to the control group (P≤0.004). The Bb concentrations were 
also above the normal range (0.26-1.66 μg/mL) with a mean value of 2.9±0.6 μg/mL in 
PIGN and of 3.6±0.8 μg/mL in controls, however there was no significant difference in 
Bb concentration between both groups. C3 concentrations were below the normal range 
(0.75-1.4 mg/mL) in all PIGN patients with a mean value of 0.34±0.1 mg/mL. The controls 
had a mean value of 1.0±0.07 mg/mL. Thus, PIGN patients had significantly lower C3 
levels as compared to controls (P≤0.01).
Conclusions: PIGN patients had significant higher sC5b-9 levels and significant lower 
C3 levels as compared to controls. These preliminary data indicate that sC5b-9 levels could 
be a useful marker to detect ongoing complement activation in the circulation of PIGN 
patients, which may have utility for therapeutic monitoring, e.g. after administration of 
complement inhibitors.
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Ethnic Population Variance in Nephron Mass in Neonates: The Miami 
Cohort versus International References
Marissa J. Defreitas,1 Wacharee Seeherunvong,1 Chryso P. Katsoufis,1 Salih 
Y. Yasin,3 Marta G. Galarza,2 Shahnaz Duara,2 Gaston E. Zilleruelo,1 
Carolyn L. Abitbol.1 1Pediatric Nephrology, University of Miami/Jackson
Memorial Hospital, Miami, FL; 2Neonatology, University of Miami/Jackson
Memorial Hospital, Miami, FL; 3Maternal Fetal Medicine, University of Miami/
Jackson Memorial Hospital, Miami, FL.
Background: Nephron endowment, the number of functioning nephrons at birth, may 
determine an individual’s adult longevity. Preterm birth is associated with developmental 
programming of hypertension and cardiovascular disease. A non-invasive and economical 
surrogate of nephron mass is the ultrasound (US) measurement of renal dimensions. 
Limited studies have suggested subclinical ethnic variations in kidney volume and function 
in children but not in neonates.
Methods: In a prospective cohort study, 157 neonates were enrolled at birth; 140 
singletons [71 term (T), 69 preterm (PT)] and 17 twins. Race/ethnicity were recorded. Renal 
measures were assessed by US and renal function by serum creatinine (SCr) and cystatin C 
(CysC) based equations for estimated glomerular filtration rate (eGFR). A table of reference 
values (RV) for kidney size parameters from 5 countries was extracted from the literature 
and included 871 healthy term neonates.
Results: The Miami Cohort is primarily an ethnic/racial minority with an Hispanic/
Non-White demographic [144/157=92%]. KL and TKV correlated closely with all body 
anthropometrics and gestational age (GA) (p<0.001). TKV correlated significantly with 
eGFR. TKV for PT and twins was significantly different from term singletons (p<0.001 for 
all). TKV/BSA (ml/m2) was normally distributed, independent of GA, and similar among 
T and PT singletons. Both TKV and TKV/BSA were significantly decreased for twins 
compared to singletons. The Miami Cohort Term infants had lower TKV and TKV/BSA 
than that of the international RV.
Conclusions: There is a wide regional variation in nephron mass reflective of the 
gene-environmental influence on nephrogenesis. Absolute TKV is a primary determinant 
of kidney function; whereas, TKV referenced to BSA (ml/m2) reflects nephron endowment 
individualized to body size. Support of post-natal nephrogenesis in preterm infants is 
essential if their nephron endowment is to be maintained. Follow-up of post-natal renal 
growth and function is warranted in individuals born preterm.
Funding: Private Foundation Support
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Prediction of the Renal Elimination of Drugs with Cystatin C versus 
Creatinine: A Systematic Review
Erin F. Barreto,1 Andrew D. Rule,1 M. hassan Murad,2 Kianoush Kashani,1 
John C. Lieske,1 Patricia J. Erwin,1 James Steckelberg,1 Ognjen Gajic,4 
Joel M. Reid,1 Sandra Kane-Gill.3 1Mayo Clinic, Rochester, MN; 2Mayo clinic, 
Rochester, MN; 3University of Pittsburgh, Pittsburgh, PA; 4Mayo Clinic, 
Rochester, MN.
Background: Cystatin C has been proposed as an adjunct or alternative to creatinine 
for drug dosing. The association of renal function estimated by cystatin C with drug 
clearance, target achievement, and clinical outcomes is not well defined.
Methods: We conducted a systematic review to synthesize available data for the 
association between serum cystatin C and drug pharmacokinetics, dosing, and clinical 
outcomes in adults (≥18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO 
ICNAHL, and Scopus were systematically searched from 1946 to September 2017 to 
identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury (AKI) 
or for management of contrast-associated AKI were excluded. Also, studies were excluded 
if drug concentrations were unavailable and if a reference standard for drug dosing (e.g., 
serum creatinine) was not concurrently reported. The outcomes of interest included drug 
clearance (L/h), concentrations (mg/L) target level achievement (%), therapeutic failure 
(%), and drug toxicity (%).
Results: We included 28 manuscripts that evaluated 16 different medications in 
3455 participants. Vancomycin was the most well studied drug. Overall, cystatin C-based 
estimated glomerular filtration rate (eGFRCystatin C) was more predictive of drug levels and 
drug clearance than eGFRCreatinine. In only one study were target attainment and outcomes 
compared between two drug dosing regimens, one based on eGFRCreatinine-Cystatin C and 
one dosed with the Cockcroft Gault creatinine clearance. In conclusion, compared with 
eGFRCreatinine, use of eGFRCystatin C to predict elimination of medications via the kidney was 
as accurate, if not superior, in most studies, but infrequently were data on target attainment 
or clinical outcomes reported.
Conclusions: Drug-specific dosing protocols which use cystatin C to estimate kidney 
function should be tested for clinical application.
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Pharmacological Decision-Making in Gout: A Comparison Between 
Nephrologists and Other Specialists Using a Script Concordance Test
Sarah Gilligan,1 Andrea M. Barker,2 Michael J. Battistone,1 Kalani L. Raphael.1,2 
1University of Utah Health Sciences Center, Salt Lake City, UT; 2VA Salt Lake 
City Health Care System, Salt Lake City, UT.
Background: Gout commonly coexists with CKD and the presence of CKD often 
complicates gout management. Gout is treated by providers from many disciplines, hence 
pharmacotherapeutic heterogeneity may be common in CKD. The goal of this pilot study 
was to determine whether a validated script concordance test (SCT) for gout, which assesses 
clinical reasoning in short case scenarios, might detect interprofessional heterogeneity of 
pharmacological gout therapy.
Methods: Nephrologists (Neph), rheumatologists (Rheum), primary care providers 
(PCP), and pharmacists (Pharm) at University of Utah and Salt Lake City VA completed the 
gout SCT. The full SCT consists of 24 case scenarios and responses are obtained using a 
5-anchor Likert scale. As we were interested in pharmacological treatment, we used the 10 
case scenarios assessing pharmacological decision-making in this study. Response options 
ranged from the proposed therapy being “strongly indicated” to “strongly contraindicated.” 
SCTs were scored using an aggregate method normed by an expert panel. Mean scores for 
each discipline were calculated and differences between each discipline and Neph were
compared using 2-tailed t-tests.
Results: 29% of invitees (38 of 129) completed the SCT. The number of responses 
was similar across disciplines (Table). The overall mean (SD) score was 14.69 (2.03); for 
reference, the maximum score for the 10 case scenarios is 24.39. Rheum had the highest 
and Neph had the lowest SCT score; the difference approached statistical significance. SCT 
scores were similar between Neph, PCP and Pharm (Table).
Conclusions: In our study sample, clinical decision-making regarding gout 
pharmacotherapy was similar between Neph, Pharm, and PCP. In contrast, differences 
between Neph and Rheum were observed, though confidence is limited by sample size. 
The results of this pilot study can inform future use of the SCT to detect interprofessional 
heterogeneity of pharmacological gout therapy in a larger sample across multiple 
institutions.
Mean SCT score by discipline
Maximum possible score is 24.39
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Autosomal Recessive Polycystic Kidney Disease Diagnosed in Adulthood
Kamal Nayyar, Nobuyuki (Bill) Miyawaki, Naveed N. Masani, James Drakakis. 
NYU Winthrop Hospital, Mineola, NY.
Introduction: Autosomal recessive polycystic kidney disease (ARPKD) belongs to a 
group of congenital hepatorenal fibrocystic syndromes. Renal cysts arising from collecting 
ducts and congenital hepatic fibrosis (CHF) are hallmarks, usually in infancy and associated 
with high mortality in first year of life. For those who survive the neonatal period, the 
probability of being alive at age 15 ranges from 50-80%, with the majority requiring renal 
replacement therapy. Approximately 50% of infants have evidence of liver involvement at 
time of diagnosis. This can lead to progressive portal hypertension. Here, we present a case 
of an adult female with known CHF believed to be idiopathic, until additional investigation 
into proteinuria revealed cystic kidney disease, confirmed on genetic testing to be ARPKD.
Case Description: A 38-year-old female with a history of hypertension, bipolar disorder 
(never on Lithium) and congenital hepatic fibrosis diagnosed at age 20 months presented 
for evaluation of long standing proteinuria. Albumin was preserved with proteinuria 
quantification ranging from less than 1 g/g to upwards 3.2 g/g. While a workup was being 
undertaken, angiotensin receptor blockade was initiated with significant improvement in 
proteinuria to values less than 200 mg/g. Renal ultrasound revealed relatively large kidneys 
with bilateral cysts. MRI abdomen confirmed innumerable left kidney cysts, along with 
several subcentimeter parapelvic cysts on the right kidney. Genetic testing was performed 
with results consistent with ARPKD. There was no known family history of renal cystic 
disorder or renal morbidity.
Discussion: The classic presentation for ARPKD is hypertension with progression to 
ESRD by age of 15. Typicaly a small number of those with ARPKD will live to adulthood 
with some kidney function, but significant deterioration in liver function. Due to its wide 
variability, the diagnosis of ARPKD may be made during any stage of childhood and 
only in rare cases does it present in adolescence or adulthood. A minority of affected 
individuals present as older children or young adults with evidence of hepatic dysfunction 
as the prominent feature. This case highlights the potential spectrum of presenting signs 
and symptoms associated with ARPKD and the possibility that the diagnosis may need be 
considered even in adulthood if the scenario seems appropriate.
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A Novel Presentation of Fabry Disease
Farid Arman,1 Peter D. Lymberopoulos,1 Niloofar Nobakht,1 
Mohammad Kamgar,1 Ramy M. Hanna,1 Carl E. Schulze,1 Reza Khorsan,1 
Jean Hou,2 Behnoud Beroukhim,2 Anjay Rastogi.1 1University of California, Los 
Angeles, Los Angeles, CA; 2Cedars- Sinai Medical Center, Los Angeles, CA.
Introduction: Fabry disease (FD) is an X-linked genetic disease due to mutations 
in the GLA gene that lead to deficient or absent α-galactosidase A (α-Gal A) activity 
and consequent accumulation of globotriaosylceramide throughout the body. Various 
manifestations of FD include proteinuria, declining glomerular filtration rate (GFR), 
hypertrophic cardiomyopathy, hypohidrosis, heat intolerance, hearing loss, acroparesthesia, 
cryptogenic strokes, and cornea verticillata, among others. Renal presentations of FD in 
classic males typically begin with proteinuria in childhood, followed by a gradual decline 
in GFR, and ultimately results in end-stage renal disease (ESRD) over the course of a few 
decades if patients are left untreated. We present an unusual case involving a male patient 
who had normal GFR at the age of 40, but was diagnosed with ESRD by 42.
Case Description: Our patient was a 42-year-old male, who was first diagnosed with 
kidney disease when his annual physical lab tests revealed a creatinine of 11 MG/DL. 
This demonstrated a dramatic elevation from his labs 2 years prior, where the patient’s 
creatinine was measured to be 1.1 MG/DL. At the time of diagnosis, the patient had no 
history of kidney disease. Meticulous review of the patient’s history, in addition to physical 
examination and work-up did not identify any cause for the observed kidney failure. A 
kidney biopsy, however, was suspicious for FD. Subsequent screening of α-Gal A enzyme 
activity and genetic testing confirmed the diagnosis of FD with a P40S mutation. Thus, 
hemodialysis and enzyme replacement therapy were initiated.
Discussion: Although kidney disease is amongst the most important presentations of 
FD, this patient demonstrated a unique case with a rapidly progressive disease that has not 
been reported previously. A review of available natural history data from the Fabry Registry 
(NCT00196742; sponsor and provider of data: Sanofi Genzyme) showed 14 patients with 
the same mutation, including 7 males. No renal or cardiovascular events were reported in 
the male patients. In females, 1 stroke and 1 cardiac event have been reported, but no kidney 
events. Conclusion: This is a novel presentation of FD in a classic male that will require 
further investigation.
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Irreversible Electroporation Treatment of Renal Cell Carcinoma in 
Von-Hippel Lindau
Su-Ling Lai. Alfred Health, Melbourne, NSW, Australia.
Introduction: Irreversible electroporation (IRE) is a non-thermal nephron-sparing 
technique which offers an alternative treatment for renal tumors in patients previously 
deemed inoperable or unsuitable for other therapies. It is particularly useful in patients at 
risk for recurrent renal cell carcinoma (RCC), where it may help prolong renal function and 
delay requirement for dialysis.
Case Description: A 55 year old female with Von-Hippel Lindau presented in 2009 
with a 19mm right midpole RCC, judged unsuitable for partial nephrectomy or thermal 
ablation due to central location. At time of presentation, the patient previously had one right 
sided and three left sided partial nephrectomies for confirmed RCCs. In the interests of 
preserving remaining renal function patient was treated with IRE.
Discussion: In 2009 the patient was enrolled in our department’s IRE safety study and 
underwent two rounds of IRE to the right midpole RCC, which was completely ablated 
with no residual/recurrent tumor seen for a 6 year interval. In 2015 two further RCCs were 
detected within right kidney (16mm upper pole, 20mm lower pole), both of which were 
ablated with a single round of IRE. The inferior pole lesion was completely ablated post 
IRE while minimal contrast enhancing residual tumor was seen at the upper pole on post-
procedural triphasic CT. Two further RCCs were detected within the right inferior pole 
in 2017, potentially amenable to IRE. However post Urology review patient proceeded 
to right sided nephrectomy. No major procedural complications of IRE were seen in this 
patient. This result was in line with results from a further 18 patients and 26 tumors treated. 
Success was highly correlated to tumor size, with 94% of lesions initially measuring <3 cm 
in diameter (15 of 16) successfully ablated after ≤2 rounds of IRE versus 63% in lesions 
≥3cm (7 of 11). Complete ablation post ≤2 rounds of IRE was seen in 100% of patients at 
<5 years and 58% of patients at 5-7 years. Partial ureteric stenosis was seen in post-IRE in 1 
patient, thought to be related to previous thermal ablation of the same tumor. No other major 
complications were observed. In conclusion, a previous study performed by our hospital 
has shown renal IRE is a safe alternative treatment for small renal tumors. IRE is especially 
useful in patients such as this case at risk for recurrent renal tumors, where a total delay of 
8 years to right nephrectomy was achieved.
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Nephrotic Syndrome in Familial Hyperlipoproteinemia: A “Two-Hit” 
Hypothesis
Harish Shanthanu Seethapathy, Ricard Masia, Alexander T. Sipilief, 
Jillian Rosenthal, Karen A. Laliberte, John Niles, Frank B. Cortazar. 
Massachusetts General Hospital, Watertown, MA.
Introduction: Familial hyperlipoproteinemia (FH) Type III is an autosomal recessive 
disorder caused by mutations of ApoE, which plays a crucial role in lipid metabolism. We 
discuss a patient with type III hyperlipoproteinemia who developed nephrotic syndrome.
Case Description: A 26 yo female presented with anasarca 2 weeks after pregnancy. 
She had a urine Protein:Cr ratio (UPCR) of 15 g/g with a serum albumin of 1.2 g/dL. Serum 
cholesterol (676 mg/dL) and triglycerides (1336 mg/dL) were markedly elevated. Renal 
biopsy showed diffuse deposition of large lipid droplets in macrophages, mesangial cells, 
renal tubular cells, and stromal cells (Fig A). Genetic testing revealed familial type III 
hyperlipoproteinemia (Apo E2/E2 genotype) and she was started on a fibrate. Her nephrosis 
was presumed to be mediated by FH Type III and thus not responsive to immunosuppression 
(IS). However, upon referral to our center, review of electron microscopy revealed diffuse 
foot process effacement suggestive of a primary podocytopathy (Fig B). Treatment with 
high dose glucocorticoids led to a complete remission (UPCR 0.3) with resolution of 
dyslipidemia (Cholesterol/Triglycerides). She relapsed twice with steroid tapering and 
received rituximab for steroid-dependent nephrotic syndrome. She is now in complete 
remission off glucocorticoids.
Discussion: While patients with FH Type III have lipid deposition in many organs, 
clinically relevant kidney disease is atypical. Patients with other rare ApoE mutations 
can develop lipoprotein glomerulopathy, which is a distinct pathologic entity mediated 
by abnormal deposition of lipoprotein and not responsive to IS. In our case, the patient 
developed minimal change disease, which unmasked the clinical phenotype of Type III FH. 
IS led to complete remission and resolution of dyslipidemia. The finding of diffuse foot 
process effacement serves as a surrogate for a primary podocytopathy. Immunosuppression 
should not be withheld in such patients, even in the presence of renal lipidosis.
PUB445 
Publication-Only 
Alport Syndrome: A Case of Uncommon Inheritance Pattern
Sonia Nasery, Yasir Alfi, Sina Emami, Renu Regunathan-Shenk. Division of 
Renal Disease and Hypertension, George Washington University, Wasington, 
DC.
Introduction: In 1927, Arthur C. Alport first published his description of a triad of 
symptoms in a family with congenital hemorrhagic nephritis, deafness, and ocular changes. 
Alport syndrome still inevitably leads to end-stage renal disease (ESRD). It occurs as a 
consequence of structural abnormalities in type IV collagen, the major constituent of 
basement membranes. Six genetically distinct chains of type IV collagen have been 
identified. Mutations in the COL4A5 gene, encoding the alpha-5 chain, is responsible for 
X-linked Alport syndrome, the most common form of the disease. Mutations in COL4A3
or COL4A4, which encode alpha-3 and alpha-4 chains, are involved in the rarer autosomal 
recessive and autosomal dominant forms of the disease. Here we describe a female with
Alport’s syndrome that had an indolent presentation and an uncommon inheritance pattern.
Case Description: 42 year old El Salvadorian female with microscopic hematuria and 
proteinuria that were persistent for 2 years. Previous cystoscopy was negative. The subject’s 
father and 2 out of 4 brothers had ESRD and passed away (with dialysis initiated at age 50, 
45, and 47 respectively). One of these brothers had hearing impaired. Her other 2 brothers, 
sister, and mother are healthy. Physical examination was unremarkable. Labs revealed 
serum creatinine of 0.7, 1.3 g/g proteinuria, and urine sediment with 2-3 nondysmorphic 
RBCs/HPF without cellular casts. Serologic work-up was negative. The renal sonogram 
showed normal size kidneys. Renal biopsy performed. The light microscopy was notable 
for glomerulomegaly and routine immunofluorescence was unremarkable. The electron 
microscopy revealed thin glomerular basement membranes (241 nm) with segmental areas 
of basement membrane scalloping and microparticles, consistent with Alport syndrome. 
Staining for alpha 5 chain of type IV collagen was preserved.
Discussion: In this patient, preserved alpha 5 chain staining is consistent with either 
autosomal dominant or autosomal recessive forms of Alport syndrome. Given her family 
history she likely has autosomal dominant disease, which accounts for less than 5% of 
Alport cases. Autosomal dominant disease has a milder renal phenotype, with a median 
renal survival of 70 years. This case stresses the importance of obtaining an accurate family 
history and consideration of biopsy in patients with sub-nephrotic proteinuria and family 
history of ESRD.
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Late-Onset Bartter Syndrome Type II
Benjamin Gollasch,2,3 Yoland marie Anistan,4 Maik Gollasch.1 1Charité 
University Medicine, Berlin, Germany; 2Charité Universitätsmedizin Berlin, 
Berlin, Germany; 3Cardiology/Nephrology/Pulmonology, HELIOS Klinikum 
Berlin, Berlin, Germany; 4Charité, Berlin, Germany.
Introduction: Mutations in the ROMK1 potassium channel gene (KCNJ1) cause 
antenatal/neonatal Bartter syndrome (aBS) type II. Bartter syndrome type II is believed to 
represent a disorder of the infancy, but not in adulthood.
Case Description: We herein describe a female patient with a remarkably late-onset 
and mild clinical manifestation of BS. Laboratory tests showed hypokalemia (3.0 mmol/L), 
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low-normal total serum calcium (2.31 mmol/L), hyperaldosteronism (515 ng/L, 847 ng/L) 
(normal 30-340), hyperreninemia (43.1 ng/L, 25.6 ng/L) (normal 2.0-24.6) and increased 
calcium excretion in the urine (7.5 mmol/d or 0.13 mmol/kg body weight/day (normal 
range <6.2 mmol/d or <0.1 mmol/kg body weight/day)). Serum sodium (139 mmol/L), 
chloride (104 mmol/L), magnesium (0.87 mmol/L) and phosphate (0.9 mmol/L) levels 
were normal. In arterial blood, pH was high but bicarbonate levels were normal (pH 
7.498, HCO3- 25.7 mmol/L, pCO2 30.5 mmHg, PO2 118 mmHg). Fractional excretion 
of potassium (FEK 22%, 29%) and chloride were increased (FECl 2.52%). The trans-
tubular potassium gradient (TTKG 21) was high in our patient considering the presence 
of hypokalemia, indicating renal potassium wasting. Serum creatinine was 1.10 mg/dL 
(eGFR [MDRD] 58 mL/min). After 14 hours of water deprivation, our patient had a reduced 
urine osmolality (392 mOsmol/kg; normal 915±91 mOsmol/kg at a plasma osmolality of 
294 mOsm/kg), indicating that our patient cannot concentrate her urine well. Antidiuretic 
hormone (AVP) in plasma was high. We implemented and evaluated the performance of 
two different bioinformatics based approaches of targeted massively parallel sequencing 
(NGS) in defining the molecular diagnosis. Both analyses detected heterozygous KCNJ1 
missense mutations, consisting of a novel c.197T>A (p.I66N) and a previously reported 
c.875G>A (p.R292Q) KCNJ1 mutation in our patient. Family analysis revealed compound 
heterozygosity.
Discussion: Our results demonstrate that aBS II may be suspected in patients with 
a late-onset phenotype. Our experimental approach of NGS-based mutation screening 
combined with Sanger sequencing proved to be a reliable molecular approach for defining 
the clinical diagnosis in our patient. Our results can have a significant impact on diagnosis 
of other patients with clinical unclassified phenotypes of nephrocalcinosis and congenital 
renal electrolyte abnormalities.
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A Case of Autosomal Recessive Alport’s Syndrome
Farid Arman, Misak Harutyunyan, Gurpreet Singh, Kevin C. Donohue, 
Maha Al-Baghdadi, Rohit Singhal, Niloofar Nobakht, Anjay Rastogi. University 
of California, Los Angeles, Los Angeles, CA.
Introduction: Alport Syndrome (AS) is a genetic disorder caused by mutations in 
Type IV Collagen, which plays a major role in the structural integrity of the glomerular 
basement membrane. Mutations to the COL4A3, COL4A4, and COL4A5 genes can all result 
in defects to Type IV Collagen. People with AS typically experience a progressive loss 
of kidney function, and often present with proteinuria and hematuria. Gradual scarring of 
the kidney eventually leads to ESRD in many people with AS. Type IV collagen is also 
expressed in important components of the inner ear as well as the eye, thus patients tend to 
develop extra-renal complications such as hearing loss and visual impairments. Over 80% 
of AS is inherited in an X-linked pattern due to mutations in COL4A5, however AS can 
also be inherited in an autosomal recessive or autosomal dominant pattern due to mutations 
in COL4A3 or COL4A4. Compared to autosomal dominant AS, patients with X-linked or 
autosomal recessive inheritance patterns typically have a more severe disease progression 
leading to earlier onset of ESRD and extra-renal manifestations
Case Description: Our patient is a 17-year-old male who first presented with persistent 
‘tea colored’ urine, proteinuria, and hematuria at the age of five. His creatinine at the time 
was measured at 0.27mg/dL and a urinalysis showed protein ≥300mg/dL. At the time there 
was no family history of renal disease, recurrent hematuria, or hearing loss, therefore a 
renal biopsy was performed. Renal biopsy showed abnormal basement membrane and an 
amino histochemistry assay for Type IV collagen was also abnormal, suggesting diagnosis 
of AS. Genetic testing confirmed the diagnosis of the homozygous autosomal recessive AS. 
Currently, the patient has a stable renal function with creatinine of 0.57mg/dL, Schwartz 
estimate 118.7ml/min/1.73m2, and uACR 1449mg/g.
Discussion: Although our patient is confirmed to have two mutations in the COL4A4 
genes, representing a true autosomal recessive inheritance, his health has been relatively 
stable. About 50% of untreated males with X-Linked AS develop kidney failure by age 
25, increasing to 90% by age 40 and nearly 100% by age 60. Although our patient presents 
with proteinuria and hematuria, he has stable kidney function, does not present with 
hypertension, and has no extra-renal complications seen in AS.
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Two Brothers with ESRD Due to C3 Glomerulopathy – A Case Report
Abbas Raza,2 Jaime A. Baynes-Fields,2 Michael L. Levin,1 Sandeep Aggarwal,3 
Muhammad O. Hanif,5 Karthik M. Ranganna.4 1Metropolitan Nephrology 
Associates, PC, Lafayette Hill, PA; 2Drexel University College of Medicine, 
Philadelphia, PA; 3Drexel University College of Medicine, Philadelphia, PA; 
4Drexel University, Philadelphia, PA; 5Drexel University, PHILADELPHIA, PA.
Introduction: C3 glomerulopathy includes several rare forms of glomerulonephritis 
(GN) with underlying defects in the alternate complement cascade. The two major 
subgroups of C3 glomerulopathy are dense deposit disease (DDD) and C3 GN—are 
distinguished by electron microscopy (EM). DDD is diagnosed at an earlier age than 
C3 GN. DDD is defined by the EM findings of intramembranous glomerular basement 
membrane dense deposits. C3 GN encompasses the remainder of the C3G lesions and is 
defined by some combination of mesangial, sub-epithelial, sub-endothelial, and/or less 
dense, discontinuous intramembranous deposits. Clinically C3 glomerulopathy presents 
with proteinuria, hematuria and some degree of renal insufficiency. 35-50% of DDD and 
25% C3 GN progresses to ESRD over a 10 year period.
Case Description: Here we describe two brothers who are in their early 20s with ESRD 
on hemodialysis secondary to MPGN with dominant C3 deposition. Both presented with 
elevated creatinine and proteinuria. One of them was diagnosed with MPGN at 14 years of 
age and the other one at 20 years of age. Biopsies revealed electron dense deposits in the 
mesangium and sub-endothelial space with segmental duplication of basement membrane 
with mesangial hyper-cellularity and granular C3 staining in the mesangium, and the tubular 
basement membrane. There were significant interstitial fibrosis and tubular atrophy. See 
table 1 for results of genetic, functional assay and the biomarkers.
Discussion: There are only few case reports of family members having C3 
glomerulopathy. Both of our patients are awaiting kidney transplant. Their genetic analysis 
revealed variants of unknown significance in genes ADAMTS 13, CFH, SERPINC1 and 
VWF. There are no effective targeted treatment options for C3 glomerulopathy and there 
is high recurrence of disease and allograft loss after transplantation. Plasma exchange has 
been tried with limited success in patients with C3Nefs and greater success in patients with 
mutations in CFH. Eculizumab has been studied in C3G and DDD with partial response. 
There needs to be more research into effective treatment as this disease affects younger 
members of our society.
Genetic Characteristics
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Altered Function of TRPC6 May Contribute to Pregnancy-Associated 
aHUS
Johannes Muench,2 Stephanie Häfner,1 Marie L. Weber,3 Ria Schönauer,2 
Tom H. Lindner,2 Carsten Bergmann,4 Holger Stepan,3 Jan Halbritter.2 1Rudolph-
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Germany; 2Department of Nephrology, University Hospital Leipzig, Leipzig, 
Germany; 3Department of Obstetrics, University Hospital Leipzig, Leipzig, 
Germany; 4Center for Human Genetics, Bioscientia, Ingelheim, Germany.
Introduction: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) 
has recently become a well-recognized differential diagnosis of aHUS. Postpartal deficiency 
of complement system inhibitors is suspected trigger endothelial damage and formation of 
thrombotic microangiopathy (TMA), leading to hemolytic anemia and kidney failure. The 
presence of preeclampsia is thought to constitute a risk factor for p-aHUS, as the production 
of soluble Fms-like tyrosinkinase-1 (sFLT-1) promotes TMA formation (Erpenbeck, JASN 
2016) by inhibiting the angiogenic effect of vascular endothelial growth factor (VEGF). 
However, since sFLT-1 production normally ceases with delivery and genetic defects in 
complement regulators can only be found in half of the cases (Bruel, CJASN 2018), further 
mechanisms need to be considered.
Case Description: In a 41 year-old female, delivery by caesarean section was 
performed in the 25th gestational week, due to preeclampsia (proteinuria 3,4 g/g creatinine, 
sFLT-1/PIGF 231). Ten days postpartum, she presented with coombs-negative hemolytic 
anemia (Hb 3.2 mmol/l, platelets 32 Gpt/l, schistocytes 4.3%, LDH >30 mmol/l, haptoglobin 
<0.1 mmol/l), and acute renal failure (s-creatinine 472 μmol/l). Kidney biopsy revealed 
glomerular TMA. Genetic testing for mutations of known aHUS genes was unremarkable. 
However, a previously reported heterozygous 12bp insertion in exon 2 of TRPC6 was 
detected (c.253_264dup, p.(Ala85_Phe88dup)) (Weber, Ped. Neph. 2015). TRPC6 encodes 
an ubiquitously expressed calcium-permeable channel that also plays a crucial role in 
human podocytes, where defects have been associated with genetic FSGS by mechanisms 
of both, gain and loss of function (Riehle, JASN 2016). Patch clamp analysis and calcium 
influx assays upon overexpression of wildtype versus Ala85_Phe88dupare ongoing.
Discussion: P-aHUS is a major postpartal condition that takes several triggers in order 
to develop. We suggest that altered TRPC6 function may constitute an alternative trigger 
for development of acute TMA-related kidney failure, similar to the proposed mechanism in 
DGKE-related aHUS/TMA (Ozaltin, JASN 2013). As podocytic TRPC6 expression is also 
influenced by VEGF (Thilo, NDT 2012), sFLT-1 mediated VEGF inhibition in the setting of 
preeclampsia might further provoke an alteration in podocyte and platelet function.
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Vitamin D Drops Leading to Kidney Failure
Bourne L. Auguste,1 Joanne M. Bargman.2 1University of Toronto, Toronto, ON, 
Canada; 2Toronto General Hospital, Toronto, ON, Canada.
Introduction: Vitamin D toxicity is rare but early recognition may limit complications 
related to hypercalcemia including acute and chronic renal failure. Hypervitaminosis D can 
be treated with glucocorticoids, ketoconazole or hydroxychloroquine.
Case Description: A 54-year old man is seen for AKI after his creatinine increased to 
376 μmol/L from 132 μmol/L (baseline 100) over a 4-week period despite holding ACEi 
and diuretic. Medications included perindopril, rosuvastatin, amlodipine, indapamide 
and febuxostat. Medical history was significant for hypertension and gout. On exam, 
blood pressure was 149/98 mm Hg with no urgent clinical indications for dialysis. Renal 
ultrasound was normal. Urine microscopy was normal. Ionized calcium was 1.48 mmol/L 
and PTH was 0.5 pmol/L. Serum and urine protein electrophoresis studies were negative. 
Renal biopsy showed tubular atrophy with microcalcifications. He later revealed to 
be taking 12,000 IU of Vitamin D drops daily for 2.5 years. Measured vitamin D levels 
were elevated and continued to rise despite stopping supplements (Table 1). He was 
started on hydroxychloroquine given rise in vitamin D, which only normalized after 
initiation of hydroxychloroquine. Unfortunately, he is now left with Stage 3B CKD from 
nephrocalcinosis.
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Discussion: Hypervitaminosis D treatment must focus on reducing dietary sources. 
Alternative strategies to reduce levels by inhibiting conversion to active 1,25-(OH)2D3 
must also be considered. If asymptomatic then levels can be monitored expectantly, but 
may take time to normalize as vitamin D is fat soluble. Glucocorticoids, ketoconazole and 
hydroxychloroquine have been used to treat hypercalcemia related to sarcoidosis. These 
medications reduce 1 α-hydroxylase activity and in turn decrease 1,25-(OH)2D3 levels. 
Given that our patient was reluctant to use glucocorticoid treatment, we successfully used 
hydroxychloroquine as an alternative to treat his hypervitaminosis D.
Serial clinic labs
Hydroxychloroquine started at week 5.
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Dipilumab Induced Acute Interstitial Nephritis
Fatima Sheikh,1 Kenar D. Jhaveri,1 Vanesa Bijol,2 Khurram Mehtabdin.1 
1Nephrology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY; 
2Pathology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY.
Introduction: Dupilumab, sold under the trade name Dupixent, is a monoclonal 
antibody designed for the treatment of allergic diseases, such as eczema. It binds to the 
alpha subunit of the interleukin-4 receptor (IL-4Rα). Through blockade of IL-4Rα, 
dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathway. To our 
knowledge, renal adverse effects were not reported with this agent.
Case Description: A 59 year old male with achalasia and eczema presented with an 
elevated serum creatinine of 2.2mg/dl and a bland urine sediment. A few weeks prior to 
presentation, he was initiated on dupilumab, dosed q2 weeks. His baseline serum creatinine 
was normal in the past. He was not on any other nephrotoxic agents such as NSAIDs, proton 
pump inhibitors or antibiotics. Furthermore, he denied any herbal medications. A kidney 
biopsy was performed which revealed acute moderate allergic interstitial nephritis (AIN) 
with minimal fibrosis. No other significant pathological findings were noted on biopsy. The 
patient was started on steroids and dipilumab was subsequently held. The serum creatinine 
responded to treatment and improved to 1.5mg/dl.
Discussion: AIN is commonly associated with monoclonal antibody agents used for 
cancer treatment. This is the first reported case of dipilumab-induced AIN discovered during 
its use for the treatment of eczema. Dermatologists and nephrologists need to be aware of 
this serious complication associated with IL-4R antagonists.
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Almond Milk: A Potential Cause of Oxalate Nephropathy?
Felix E. Santiago,2 Pang-Yen Fan.1 1University of Massachusetts Medical 
School, Worcester, MA; 2UMass Medical School, Worcester, MA.
Introduction: After Roux-en-Y gastric bypass (RYGB), luminal fatty acid and bile 
salts increase oxalate absorption. Fecal fat binds calcium that would otherwise bind oxalate. 
Luminal bile salts enhance colonic epithelial oxalate permeability. These changes cause 
hyperoxaluria and increase the risk for oxalate nephrolithiasis, although the incidence of 
oxalate nephropathy remains poorly defined.
Case Description: 62 y.o. woman s/p RYGB in 2012 received DDKT for ESRD from 
diabetic nephropathy in 3/2014. Her creatinine slowly rose to 2.2 from 8/17 to 11/17. She 
presented with AKI in 12/17 (Fig. 1). She was asymptomatic except for chronic diarrhea. 
She also “started to eat healthy”, drinking 32 oz. of almond milk a day since 10/17. Biopsy 
revealed oxalate nephropathy (Fig. 2). The patient was treated with low oxalate diet and citrate 
supplements. Her creatinine improved to 2.7. Urinary oxalate excretion is now 85 mg/day.
Discussion: This case shows the impact of dietary changes for patients at risk for 
oxalate nephropathy. We initially suspected almond milk as the source of oxalate that caused 
AKI. Almond milk is made by filtering water through ground almonds. Many almond milk 
products contain minimal amounts of almond, though specific data on oxalate content are 
not available. It is unclear whether consumption of almond milk significantly increases 
oxalate intake. Therefore, we concluded that the patient’s AKI may have been due to other 
factors such as hypovolemia from diarrhea and RYGB. It’s important to note the patient 
later reported that she had increased her consumption of nuts, hot chocolate, and spinach 
though the amounts consumed were quite small. In summary, relatively modest increases in 
oxalate intake may precipitate AKI in patients with RYGB. However, it remains uncertain 
whether almond milk is a source of dietary oxalate. We hope to arrange formal chemical 
testing to determine the oxalate content of this popular beverage.
Fig. 1
Fig. 2
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Causing AKI
Brad Long,1 Josephine Abraham,1 Laith Al-Rabadi.2 1University of Utah, Salt 
Lake City, UT; 2University of Utah hospital, Salt Lake, UT.
Introduction: Gastric cancer is identified as a cause of thrombotic microangiopathy 
(TMA), a class of disease occurring with thrombocytopenia and microvascular thrombosis-
induced organ damage commonly affecting the kidneys. We present a case of acute kidney 
injury resulting from TMA due to metastatic gastric adenocarcinoma.
Case Description: The patient is a 46 year old woman complaining of weakness and 
weight loss admitted with L2 burst fracture and diffuse lymphadenopathy on CT. Blood 
pressure was elevated to 159/98. Labs showed anemia with hemoglobin of 7.1g/dL and 
platelets of 67K/uL. Renal function notable for creatinine of 1.45mg/dL and BUN of 
38mg/dL. Biopsy of the spine lesion revealed CK7+/CK20+ carcinoma; EGD showed a 
fungating gastric cardia mass with biopsy showing poorly-differentiated adenocarcinoma. 
Colonoscopy showed a sigmoid ulcer with ischemic pattern of injury with microthrombi 
on histology. Additional tests were consistent with microangiopathic hemolytic anemia 
(MAHA), a feature of TMA. Haptoglobin was <10mg/dL, total bilirubin 2.1mg/dL, and 
schistocytes seen on blood smear. ADAMTS13 activity was normal at 91% and direct 
Coombs test was negative. PT and PTT were not prolonged and fibrinogen was normal. 
Kidney biopsy was felt to be too dangerous at the time. The patient started on chemotherapy 
but unfortunately her kidney function worsened due to oxaliplatin and she ultimately 
required hemodialysis.
Discussion: TMA is a recognized complication of gastric adenocarcinoma with kidney 
injury as a possible result. Kidney biopsy is often not necessary to make the diagnosis. TMA 
resulting from gastric adenocarcinoma is challenging to treat and is typically refractory to 
treatment with plasma exchange. Chemotherapy is felt to be the most effective treatment 
strategy though can itself be nephrotoxic.
A) Gastric cardia massB) Sigmoid colon ulcera
C) Schistocytes on peripheral smear
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“Zombie” at Home: Rhabdomyolysis Secondary to Synthetic Cannabinoid 
K2 Withdrawal
Mario R. Funes-Hernandez,4 Shirin Poustchi,2 Pablo Garcia,4 Kartik Kalra.4 
2Rutgers Robert Wood Johnson Medical School, Somerset, NJ; 4Saint Peters 
University Hospital, New Brunswick, NJ.
Introduction: Synthetic cannabinoid (SC) use as a marijuana alternative was first 
reported in the United States in 2008. Multiple variants have been developed that are 
not recognized as illegal substances, do not appear in routine toxicology screens, and are 
marketed under a variety of names, including K2, Spice, Joker, and Kronic. Recently, an 
acute intoxication outbreak was reported in New York City. There have been limited reports 
on rhabdomyolysis due to K2 withdrawal. We present a case of a 46-year-old African 
American male with rhabdomyolysis due to severe withdrawal symptoms after acute K2 
cessation.
Case Description: A 46-year-old African American male with no PMH presented 
with a 5-day history of nausea, muscle cramps, irritability, insomnia, auditory and visual 
hallucinations. Patient’s wife described his behavior as a “zombie”. Patient had been 
smoking K2 daily for the past 3 months and symptoms were precipitated after abruptly 
stopping. Patient was afebrile, BP of 135/85, HR 120 beats per minute, RR of 22 and O2 
Sat 100%. He was anxious, tremulous and restless. He was alert and oriented but unable 
to focus. Patient had dry mucous membranes, pupils < 2 mm, and horizontal nystagmus. 
Investigation revealed: WBC 22.7 x 109/L, Hgb 17.8 g/dL, sodium 126 mEq/L, potassium 
3.2 mEq/L, chloride 88 mEq/L, bicarbonate 22 mEq/L, urea nitrogen 21 mg/dL, creatinine 
2.16 mg/dL, calcium 10.6 mg/dL, albumin 5.1 g/dL and CPK 3981 U/L. Urinalysis showed 
a specific gravity of 1.015, trace blood, trace protein, 2-5 red blood cell per high-power 
field, 2-5 hyaline casts per low-power field. Urine toxicology was positive for THC. Patient 
was given 2 L of normal saline on admission followed by 200 mL/hr. Management included 
benzodiazepines due to insomnia and restlessness as well as intravenous hydration due to 
acute kidney injury. Patient’s AKI resolved subsequently; creatinine decrease to 0.74 mg/dL 
after 72 hours and CPK decreased to 500 U/L at time of discharge.
Discussion: SC use is a public health concern as it has become popular due to low cost, 
easy availability, and lack of regulation. Acute withdrawal sequelae have not been studied 
nor understood yet. Rhabdomyolysis should be suspected in patients presenting with acute 
withdrawal, allowing for prompt initiation of adequate treatment and potentially avoiding 
acute renal failure.
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A “Crystal Clear” Case of AKI
Jennifer L. O’Brien, Jennifer B. Hanko. Belfast City Hospital, Carrickfergus, 
United Kingdom.
Introduction: A patient was transferred to nephrology with severe acute kidney injury 
(AKI) requiring dialysis and was subsequently diagnosed with crystal nephropathy (CN) 
from oral Aciclovir. Intravenous Aciclovir is a well described cause of CN. This case 
highlights the risk of CN with high dose oral Aciclovir in the setting of volume depletion.
Case Description: A 66 year old female with a medical history of Hodgkins 
Lymphoma; prior vasculitis with renal and skin involvement; and shingles, on oral Aciclovir 
prophylaxis; presented with a 1 month history of shortness of breath and palpitations and a 
2 day history of gastric upset. She was clinically dehydrated, in rapid atrial flutter and had 
transient hypotension. She was treated with IV Metoprolol. Over 4 days, she developed 
anuric AKI; serum creatinine increased from 0.97 mg/dl to 7.68 mg/dl. Oral Aciclovir 
200mg three times daily was administered until day 5 of admission when she transferred 
for haemodialysis. Admission was complicated by an unstable duodenal ulcer bleed, acute 
confusion and transient inflammatory thrombocytopenia. A renal biopsy was performed 
after 3 weeks; she remained dialysis dependent but urine output was increasing. Biopsy 
showed crystals within the tubules and recovering acute tubular necrosis (ATN). By week 
4, she was independent of dialysis.
Discussion: The severity of her AKI was out of keeping with the degree of volume 
depletion and hypotension. Renal biopsy was delayed due to other acute medical issues. 
Despite the delay, crystals remained within the renal tubules. Oral Aciclovir in this setting 
contributed to severe anuric AKI. For patients at risk of AKI or with established AKI, 
physicians should have a low threshold to review Aciclovir indication; if indicated, ensure 
that the dose is adjusted for the level of renal function.
Renal biopsy showing a crystal within a tubule and recovering ATN
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System, Bronx, NY.
Introduction: Metformin is the one of the most frequently used oral agent in the 
treatment of Type 2 Diabetes Mellitus. The major toxicity associated with metformin is 
lactic acidosis, which carries a high morbidity and mortality. While Metformin poisoning 
can be challenging to diagnose, it requires high index of suspicion. We present one such case.
Case Description: 78 year old Hispanic Female patient with Type 2 Diabetes Mellitus, 
Hypertension presented to the ER with generalized body aches, diarrhea and flank pain since 
3 days associated with severe watery non bloody diarrhea. Patient was initially hypertensive 
in the triage. Labs reported severe metabolic acidosis with pH of 6.785 with elevated lactic 
acid 18.0 mmol/L, bicarbonate of 2.0 mmol/L and anion gap of 56. Patient was also noted 
to have acute kidney injury – with serum creatinine of 6.1 mg/dL (baseline 0.7 mg/dL). 
Patient was drowsy, providing limited history - said she was taking all of her diabetes and 
medications including metformin. Pre-dialysis metformin levels were obtained due to high 
clinical suspicion. Patient was started on IV Bicarbonate replacement, emergency dialysis 
was arranged with elevated Bicarbonate bath with 40meq/L done in the ER. Pre-dialysis 
metformin levels later on were found to be 13mcg/mL (theraupetic range 1-2 mcg/mL). 
Post dialysis metformin levels were noted to be: 5.6 mcg/mL. Patient’s septic workup later 
came back negative pointing that this was a case of Metformin Associated Lactic Acidosis. 
Patient’s renal function and clinical status improved and she was discharged home with 
serum creatinine of 1.3 mg/dL
Discussion: Metformin poisoning carries a high mortality and morbidity rate. It 
remains a challenging clinical entity which requires high index of clinical suspicion. 
Recognizing metformin associated lactic acidosis early on and implementing appropriate 
therapy would increase patient survival. Dialysis would remain best intervention in patients 
with Acute kidney Injury with serum creatinine >2 mg/dL and elevated serum lactate levels 
>15 mmol/L.
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Mycobacterium Chimaera Infection – A Rare Case of Interstitial 
Nephritis
Sadichhya Lohani,1 Marco Delsante,1 S.M. Bagnasco,2 Avi Z. Rosenberg,3 
Blaithin A. McMahon.1 1Johns Hopkins Hospital, Baltimore, MD; 2The Johns 
Hopkins School of Medicine, Baltimore, MD; 3Johns Hopkins University, 
Baltimore, MD.
Introduction: Outbreaks of Mycobacteria chimaera with cardiac and extra-cardiac 
manifestations have been reported post cardiac surgery with the use of heater-cooler units 
in heart-lung machines. Nephritis is a rare presentation of this iatrogenic infection with few 
reported cases.
Case Description: A 62-year old male developed Mycobacterium chimaera spinal 
infection a year after coronary artery bypass graft and aortic valve replacement. He was 
started on azithromycin, Rifabutin, Gatifloxacin, and Ethambutol. He developed acute 
kidney injury that initially improved with IV fluid (figure 1). Gatifloxacin was stopped.10 
months later, he presented with altered mental status. Creatinine was 7.1 mg/dl, protein/
creatinine ratio of 0.53g/g, urinalysis without pyuria or cellular casts, and a normal WBC 
count without eosinophilia. Blood cultures grew M. chimaera. Mycobacterial urine cultures 
were negative. Azithromycin, Rifabutin, and Ethambutol were continued. Clofazimine 
(added 1 month prior to presentation) level was subtherapeutic. Renal biopsy revealed 
diffuse interstitial inflammation and one small interstitial granuloma with multinucleated 
giant cells, but AFB stain was negative. Clofazimine was titrated to a therapeutic dose. 
Mycobacterial blood cultures were subsequently negative. He had a partial improvement in 
his renal function with Cr of 4.1 mg/dl at the time of discharge.
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Discussion: Diagnosis of granulomatous interstitial nephritis in our patient was 
likely related to the M. chimaera infection. Renal function improved with the clearance of 
bacteremia. Drug-induced interstitial nephritis was less likely since renal function improved 
despite continuing the 4-drug antimicrobial therapy. M. chimaera related interstitial 
nephritis is a rare condition with poor outcomes. Renal biopsy is crucial to rule out other 
etiologies of renal dysfunction. Timely initiation of antimicrobial therapy on appropriate 
doses can prevent deterioration of renal function.
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All Fired Up: The Angry Macrophage
Divyanshu Malhotra,1 Ravi Kodali,2 Ursula C. Brewster.3 1Yale New Haven 
Hospital, New Haven, CT; 2Yale University, New Haven, CT; 3Yale University 
School of Medicine, New Haven, CT.
Introduction: Hemophagocytic Lymphohistiocytosis(HLH) is an aggressive and 
life-threatening syndrome of excessive immune activation characterized by activation and 
proliferation of uncontrolled macrophages and lymphocytes, culminating in an unrelenting 
cytokine storm and subsequent tissue infiltration and multi-organ system failure. Here we 
present a case of a patient who had a dramatic presentation of HLH with severe renal failure 
and was ultimately found to have a surprising diagnosis.
Case Description: 48 y/o male originally from Ghana, living in US for years with HTN 
not on treatment who presented with 3 weeks of a variety of symptoms including fever, 
headache, abdominal pain, poor appetite and a bad taste leading to a weight loss of 20-25 lbs. 
Also noticed yellowness of his eyes. No sick contacts or travel. Had significant laboratory 
abnormalities including pancytopenia, severe renal failure with BUN 330 mg/dl and Cr 22 
mg/dl, elevated liver enzymes but normal INR, K 7.8mmol/L, CO2 10mmol/L, PO4 17mg/
dl,Lipase 4470U/L,lactate 3.2mmol/L,Ferritin 5466ng/ml,TG 451mg/dl and soluble IL-2 
43800pg/ml. Imaging revealed pancreatitis, pulmonary edema and bladder calcification. 
Was started on dialysis. Met criteria for HLH after BM biopsy and was started on steroids. 
Kidney biopsy revealed ATN.Extensive search for a potential trigger for HLH including all 
blood/BM cultures was negative. After initial improvement, suffered a PEA arrest after 1 
week and continued to rapidly deteriorate and died within hours. Autopsy was performed 
which showed miliary TB, Schistosomiasis(likely inactive) and HLH.This was very 
surprising given negative AFB blood and BM cultures and no clear radiological sign of TB.
Discussion: HLH is primarily a pediatric syndrome but is being increasingly recognized 
in adulthood. Divided into primary and secondary forms, typically associated with a 
trigger(most commonly infection). Caused by lack of normal downregulation of activated 
macrophages and lymphocytes leading to a cytokine storm and multi-system injury. Renal 
manifestations include ATN(most common), pre-renal injury or glomerulopathy(MCD, 
TMA and collapsing FSGS). High mortality if untreated. No randomized trials to guide 
treatment, regimens based on HLH-94 protocol with etoposide and steroids. Alternate 
regimens used especially in the setting of cancer. Triggers should be treated aggressively. 
TB, a great mimic, has rarely been associated with HLH with a subsequent high morbidity/
mortality.
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Franklin D. Ponce-Herrera, Vipulkumar Bhalara, Joshua Kaplan. UMDNJ/NJ 
Medical Center, Newark, NJ.
Introduction: In the HIV/AIDS population, TMP/SMX is a frequently used in 
prophylactic doses, should these patients present with acute illness due to PCP pneumonia, 
they may require higher dosing, the potential for nephrotoxicity due to sulfa-induced 
crystalluria is high and vigilance is required for prevention and recognition.
Case Description: We report a 55 year-old woman with PMHx of AIDS, CKD stage 
III, who presented to the hospital with shortness of breath, cough, CT Chest without contrast 
showed nodular opacities. The patient was admitted with a suspected diagnosis of PCP 
pneumonia and was treated with high doses of TMP/SMX, followed by development of 
anuric renal failure most likely secondary to IV TMP/SMX. Patient was started on IV Lasix 
to which she was initially not responsive until day 5 when she began making urine, patient’s 
urine was analyzed under microscopy and found to have pleomorphic crystals present. At 
this point patient’s creatinine began to return to baseline and she entered the diuretic phase 
of AKI, producing 7 liters of urine on days 6 and 7.
Discussion: There are several major risk factors for Sulfadiazine crystalluria and acute 
kidney injury: volume depletion, administration of higher doses of oral and intravenous 
formulations, hypoalbuminemia, urine pH <5.5, use of an ACE-inhibitor and the presence 
of previous underlying kidney disease. In these respects, our patient was exposed to a high 
IV dose of TMP/SMX (15 mg/kg/day, Patient’s weight 110kg), had decreased GFR at 
baseline and acidic urine (pH = 5.0), along with volume depletion. Management of sulfa-
induced kidney injury mainly involves discontinuing the offending drug and aggressive 
intravenous fluid administration. Urinary alkalization may also play a role; as urine pH 
increases the crystals more readily dissolve and the obstruction is relieved. It seems prudent 
to hydrate aggressively during treatment with high dose TMP/SMX to reduce the risk of 
crystal nephropathy, with increased natriuresis
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Should You Wait? Taking a Patient with AKI for TAVR Resulting in 
Dialysis Dependence
Deep Phachu,2 Hassan B. Attique.1 1Uconn Health, Farmington, CT; 2University 
of Connecticut Health, Hartford, CT.
Introduction: Aortic stenosis (AS) is one of the most common cardiac valvular 
diseases, with a prevalence of 1.3% in patients between 65 and 74 years and ~3% in patients 
>75 years of age. Trans-catheter aortic valve replacement (TAVR) has shown comparable
survival rates in high-risk patients not eligible for open-heart surgery. Given the well-
documented complication of AKI in patient’s undergoing TAVR, the question arises, in
CKD patients with AKI, should you take them for TAVR or try alternative temporizing
measures to address the AS and wait for the AKI to resolve?
Case Description: 62 year old female with HTN, T2DM, CKD 3B, CAD status post 
CABGx4 and history of AS presented with shortness of breath and syncope. She was found 
to have severe AS and due to her prior cardiac surgeries, deemed a candidate for TAVR. As a 
part of TAVR workup, she underwent left-heart catheterization and cardiac CT with contrast 
complicated by Oliguric AKI from a baseline creatinine of 1.7 mg/dL to 3.3 mg/dL. She was 
initiated on high-dose furosemide bolus, then furosemide infusion without improvement. 
The following day, she was taken for TAVR. 48 hours post-TAVR, her AKI worsened with 
creatinine of 6.5 mg/dL and urine output <10ml/hr. Echocardiogram revealed inoperable 
peri-valvular leak around her new aortic valve. Decision was made to initiate dialysis, 
and over the following 2 weeks, there was no evidence of renal recovery and patient was 
discharged with plans for long-term dialysis.
Discussion: Temporary alternatives to aortic valve replacement do exist for patients 
with AS and have shown to be fairly effective in temporarily improving cardiac function. 
Since one of the hypothesized etiologies of AKI in patients with AS is decreased renal 
perfusion, balloon dilation could theoretically provide the time required to resolve any pre-
existing kidney injury. Furthermore, spacing out contrast load one week apart from TAVR 
may potentially be beneficial. Given the mean incidence of AKI post-TAVR to be ~22%, 
one would assume that CKD patients with a pre-existing AKI prior performing TAVR 
would be at increased risk for further worsening of their renal function. Further studies 
should be performed to compare the degree of renal failure in patients with pre-existing 
renal injury that received temporizing measures versus those that were taken immediately 
for cardiovascular procedures.
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AKI Secondary to Enoxaparin Induced Pelvic Hematoma
Samrah Zaigham,1 Ahmad M. Sharayah,1 Geeta Bhagia,1 Mihir K. Maniar.2 
1Monmouth Medical Center, Long Branch, NJ; 2Private Physician, Long 
Branch, NJ.
Introduction: Pelvic Hematomas have been recognised secondary to pelvic trauma 
or as a complication of obstetric surgeries and rarely secondary to use of anticoagulation 
therapy. It is a rare cause of abdominal pain which is often missed and a rarer cause of acute 
kidney injury.
Case Description: 78 year old female was admitted with shortness of breath and 
palpitations. A diagnosis of rapid atrial fibrillation was made, and she had AV node ablation 
after failure of medical therapy. Patient was anticoagulated with enoxaparin injected into 
the left side of the abdominal wall, as her CHADVASC score was 5. Four days after 
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admission, she complained of lower abdominal pain and anuria for one day. Physical 
examination revealed mild abdominal distention and tenderness in the suprapubic region. 
Labwork showed a sharp rise in serum creatinine and a drop-in hematocrit one day after 
onset of symptoms. Computed tomography scan of the abdomen revealed a 15x15cm 
hematoma within the paracolic gutter and pelvis causing bladder compression and left-sided 
hydronephrosis, patient was diagnosed to have post renal acute kidney injury secondary 
to pelvic hematoma. Patient was initially managed conservatively with serial physical 
exams, monitoring of haematocrit, imaging studies and avoidance of anticoagulants. But 
persistence of abdominal pain and anuria, warranted for a repeat scan which showed 
expansion in the size of hematoma and new development of right sided hydronephrosis, 
and hence bilateral nephrostomy tubes were placed. Patient was discharged few days later 
after removal of nephrostomy tubes and spontaneous reduction in the size of her hematoma.
Discussion: Spontaneous pelvic hematomas are usually missed as a cause of abdominal 
pain in patients on anticoagulation therapy. They usually develop within 5 days of initiating 
therapy, symptoms vary depending on the location of the hematoma and are best diagnosed 
with computed tomography scans. Conservative management should be reserved for 
patients who are stable, intra-arterial embolization or stent grafting is the treatment of 
choice when conservative measures fail. In conclusion subcutaneous injections into the 
abdominal wall increase the risk of hematoma, especially in elderly and thin patients. 
Healthcare professionals, patients and their relatives using enoxaparin should be advised to 
avoid deep injections into the abdomen; deltoid region could be a safer alternative.
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Atypical Hemolytic Uremic Syndrome Overlapping with Antiphospholipid 
Antibody Syndrome: A Case Report with Four Years Follow Up
Emmanuel A. Adomako,1 Eseosa Edo-Osagie,1 Evan Leibowitz.2 1Englewood 
Hospital and Medical Center, Englewood, NJ; 2Prospect Medical Offices Valley 
Medical Group, Midland PArk, NJ.
Introduction: Overlapping presentation of atypical hemolytic uremic syndrome 
(aHUS) and antiphospholipid antibody syndrome (APS) is a rare phenomenon. We present 
a case with four year follow up.
Case Description: A 57-year-old Caucasian female with a history of APS first 
diagnosed 10 years prior, presented with a year’s history of recurrent abdominal pain 
and cognitive dysfunction. Laboratory evaluation showed evidence of microangiopathic 
hemolytic anemia with schistocytes, significant thrombocytopenia and renal insufficiency. 
Her laboratory studies are summarized below in Table 1. MRI of the brain showed 
chronic cerebellar and cerebral infarcts. She underwent plasmapheresis for one week 
without significant improvement in her symptoms or laboratory abnormalities. Given the 
presentation of thrombotic microangiopathy, the ADAMTS13 activity was > 5%, significant 
renal insufficiency and the lack of significant response to plasmapheresis, a diagnosis of 
aHUS was made. She was started on eculizumab infusions, initially 900mg weekly and 
subsequently maintained on 1200mg every two weeks. After 2 weeks of treatment, her 
creatinine decreased to 1.2 and hemoglobin stabilized at 9.8g/dl. She has had consistent 
follow up for 4 years during which period her creatinine has remained stable without the 
need for renal replacement therapy.
Discussion: aHUS is a condition associated with alternative pathway complement 
dysregulation. It is characterized by thrombotic microangiopathy(TMA), thrombocytopenia 
and end organ damage. Clinical presentation of aHUS is difficult to distinguish from other 
causes of TMA and laboratory differentiation does not always have a quick turnaround time. 
With an incidence of 1-2 per million, diagnosing aHUS requires a high index of suspicion 
and the exclusion of thrombotic thrombocytopenic purpura (TTP). APS is a recognized 
cause of secondary aHUS but may mask its presentation. Timely recognition of aHUS in 
such cases and the initiation of eculizumab is essential towards modulation of the course of 
the disease including onset of ESRD and dialysis dependence.
Table 1:Laboratory parameters at presentation and at four-year follow up
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Publication-Only 
Rhabdomyolysis Secondary to Hypothyroidism
Alvaro Cornejo Cobo,1 Ayan De.2 1Saint Peters University Hospital, Somerset, 
NJ; 2Saint Peter’s University Hospital, New Brunswick, NJ.
Introduction: The relationship between Hypothyroidism (HT-H) and Rhabdomyolysis 
(Rhabdo) is not well-known. This is a case report of a patient that presented with ARF 
secondary to increased levels of CK and elevated TSH. The connection between both has 
been mentioned in few case reports but the mechanism is yet to be completely understood.
Case Description: A 71-year-old female with PMH of DM, HTN, and HT-H presented 
to the ED referred from her primary doctor for a raised Crea of 4.89 mg/dL. The patient was 
asymptomatic and did not report any changes to medication. On admission, her VS were 
stable. Repeat Crea in the ED was 4.57 and a BUN of 31. CK was 5403, with a CK MB 
fraction of 19.7 and a negative Trop. Rest of the labs where normal. UA was consistent with 
Rhabdo and negative for infection.
Discussion: This case is an example of an asymptomatic patient who presented with 
Rhabdo and Renal failure secondary to undertreated HT-H. HT-H is a common endocrine 
with a broad variety of symptoms ranging from asymptomatic to the most serious 
myxedematous coma. Rhabdo is a syndrome characterized by muscle necrosis and the 
release of intracellular muscle content into plasma. Most of the time it presents with severe 
muscle pain, weakness, hematuria, but in some cases, it could be asymptomatic. Diagnosis 
is made by laboratory results which elicit elevated levels of CK. Different causes for non-
traumatic Rhabdo are known such electrolyte imbalances, infections heat exposure. Some 
endocrine disorders like DM, including DKA and nonketotic hyperglycemia, have also been 
reported to cause Rhabdo. Other electrolyte imbalances such as hypophosphatemia may 
also be the cause. There have been very few cases of Rhabdo caused by HT-H, and in most 
cases, there is an association with precipitating factors like exercise, trauma, drugs, most 
commonly statins and alcohol. The cause of Rhabdo secondary to HT-H is unclear. Various 
hypotheses including impaired mitochondrial oxidative metabolism, induction of insulin-
resistant state, and decrease muscle carnitine levels including autoimmune mechanism, have 
been proposed. Thyroxine affects energy metabolism and its deficiency leads to abnormal 
glycogenolysis, mitochondrial oxidative metabolism and triglyceride turnover, which impair 
muscle function by causing a switch of fast-twitching type 2 muscle fibers to slow-twitching 
type 1 fibers, low myosin ATP-ase activity and low ATP turnover in skeletal muscle.
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Sulfadiazine Related Obstructive Nephrolithiasis and Acute Renal Failure
Usman A. Pirzada. Bronx Lebanon Hospital, Bronx, NY.
Introduction: Renal stones are a known complication of Sulfadiazine but not seen 
commonly. We report a case of nephrolithiasis and acute renal failure secondary to 
sulfadiazine.
Case Description: A 73 year old male was evaluated in the Emergency room with 
complains of hematuria and abdominal pain. He has a past medical history of a cerebello-
pontine brain lesion/mass/ abscess and seborrheic keratosis. The patient was admitted in 
the hospital a month back with ataxia, balance problems and left sided facial weakness/
facial droop. He had extensive workup done including Pan-CT, tumor markers, PSA, 
blood cultures, Echo - all of which were unrevealing. Toxoplasma IgG was positive, HIV 
negative. The family refused for a biopsy of the brain lesion based upon location and the risk 
of procedure. Patient was treated empirically with Ceftriaxone, Metronidazole, Leucovorin, 
Bactrim and sulfadiazine and discharged on same. One month later, he presented to the ER 
with abdominal pain and hematuria. In the Emergency room, BUN/Cr was 44/6.4 (baseline 
serum creatinine 0.8). CT abdomen and Pelvis showed mild left sided hydroureteronephrosis 
caused by 2mm calculus at the left ureterovesical junction and trace right sided hydroureter 
caused by a punctate calculus at the right uretero-vesical junction. CT abdomen and Pelvis 
done one month back was negative for renal stones. He was treated conservatively with 
intravenous fluids and alkalinization of urine and the BUN/Cr trending down from 44/6.4 
to 18/1.3 over the next 6 days. Atovaquone was substituted for sulfadiazine and the patient 
was advised to continue the meds as MRI showed interval decrease in size of the primary 
lesion and significant improvement in vasogenic edema and mass effect
Discussion: Sulfadiazine induced nephrolithiasis leading to renal failure is a potentially 
serious complication that can be managed conservatively in most cases. In our patient BUN/
Cr improved dramatically within 1 week. Physicians should be aware of the complication 
and give their patients a trial of intravenous fluids and controlled alkalinization of urine if 
clinically warranted.
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Role of Eculizumab in Postpartum Atypical Hemolytic Syndrome in a 
Kidney Transplant Recipient
Hassan M. Awan,1 Manish Talwar,1 Aravind Dasari,1 Sandeep K. Rajan,1 
Barry M. Wall.2,1 1UTHSC, Memphis, TN; 2Veterans Affairs Medical Center, 
Memphis, TN.
Introduction: Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) is 
a rare, potentially lethal condition that can complicate pregnancy in upto 1 in 25000 cases. 
Given the broad spectrum of conditions that can present similarly in the peripartum period, 
it is difficult to establish the correct diagnosis in a timely manner. The C5 complement 
cascade inhibitor eculizumab has been used with considerable success in non-pregnancy 
aHUS; however, its use in pregnancy associated aHUS is limited to isolated case reports. 
We present a case of pregnancy associated aHUS in a kidney transplant recipient that was 
successfully treated with eculizumab with recovery of renal function and safe reintroduction 
of transplant medications.
Case Description: 33 year old female with history of end stage renal disease due to 
IgA nephropathy who received a cadaveric kidney transplant 7 years prior, presented at 
25 weeks gestation with severe hypertension and acute kidney injury. Immunosuppression 
included tacrolimus, azathioprine and prednisone. Her baseline Cr was <1.0 mg/dl and 
was 4.7 mg/dl at presentation. She had thrombocytopenia (58 K/ul, down from baseline 
normal) and hemolytic anemia with high LDH of 1810 U/L, depleted haptoglobin 
(< 8mg/dl) and presence of schistocytes. She underwent cesarean section for suspected pre-
eclampsia with a non-viable fetus. She remained hypertensive, anemic with high LDH, 
thrombocytopenic, and had worsened renal function with Cr of 7.7 mg/dl. Schistocytes 
persisted and ADAMTS13 was normal. Tacrolimus was held with concern of drug induced 
thrombotic microangiopathy (TMA); however, no improvement occurred. Kidney biopsy, 
initially avoided due to low platelets, was done at week 4 and confirmed the presence of 
TMA with no evidence of rejection.
Discussion: After exclusion of other etiologies, a diagnosis of aHUS was made and 
eculizumab initiated. Patient had rapid improvement in renal function by day 4 of induction 
(Cr of 3.5 mg/dl), platelets increased to 255 K/ul, and LDH decreased to 200unit/L. 
While on consolidative phase of eculizumab, azathiorine and prednisone were continued. 
Tacrolimanus was also safely restarted and subsequently switched to belatacept, which she 
has been tolerating well. This case provides additional support for the role of eculizumab in 
the treatment of life threatening post-partum aHUS.
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Ultrasonography: Another String to Nephrologists’ Bow
Justin Lee Loy, Abhilash Koratala. University of Florida Gainesville, 
Gainesville, FL.
Introduction: Pyonephrosis is a rare purulent infection of the upper urinary tract, which 
can lead to rapid clinical deterioration. While contrast enhanced CT scan is a sensitive test, 
point-of-care renal sonography can serve as a quick and valuable bedside tool for diagnosis, 
especially when iodinated contrast use is contraindicated.
Case Description: A 57-year-old woman presented with fever, abdominal pain and 
nausea for 6 days. She was hypotensive at presentation and laboratory data demonstrated 
leukocytosis, pyuria, acute kidney injury requiring renal replacement therapy (RRT) 
and lactic acidosis. Non-contrast CT scan of the abdomen revealed mild bilateral 
hydronephrosis with no perinephric stranding or fluid collection. Vasopressors and broad-
spectrum antibiotics were initiated. Exploratory laparotomy to identify a possible bowel 
source of sepsis was unremarkable. A renal ultrasound demonstrated moderate bilateral 
hydronephrosis with echogenic debris in right renal pelvis, suggestive of pyonephrosis 
[Figure]. She underwent emergent bilateral nephrostomy tube placement. Her blood and 
urine cultures were positive for E coli and antibiotics were adjusted accordingly. Follow-
up ultrasound showed resolution of hydronephrosis. Patient subsequently showed rapid 
clinical improvement and RRT was discontinued.
Discussion: Pyonephrosis is a rare purulent renal infection due to ureteric blockage, 
which can lead to septic shock and death. Contrast-enhanced CT scan is commonly used 
for diagnosis, which may show findings of obstruction with renal pelvic wall thickening 
and layering of contrast material around the purulent fluid. However, the diagnosis can 
be missed on unenhanced CT and ultrasonography is a valuable bedside tool for rapid 
diagnosis as in our case.
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Amphotericin as Treatment for AKI
Mengyao Tang,1 Jerald Cherian,1 Thomas A. Golper,2 Juan Pablo Arroyo.2 
1Medicine, Vanderbilt University Medical Center, Nashville, TN; 2Nephrology, 
Vanderbilt University Medical Center, Nashville, TN.
Introduction: Histoplasma capsulatum is a fungus endemic to the southeastern United 
States. Immunocompromised patients are at increased risk for disseminated infection, often 
presenting with fever, pulmonary disease, hepatosplenomegaly or central nervous system 
involvement. We report an unusual case of disseminated histoplasmosis presenting with 
acute kidney injury (AKI), acute liver injury and thrombocytopenia, which resolved upon 
initiation of amphotericin.
Case Description: A 57-year-old woman with rheumatoid arthritis (on methotrexate and 
etanercept) presented with 1-month of upper respiratory symptoms and malaise. On admission, 
she had a creatinine of 11 mg/dL (0.7 mg/dL prior), BUN 127 mg/dL, AST 325 unit/L, 
ALT 477 unit/L, alkaline phosphatase 313 unit/L, total bilirubin 10 mg/dL, PLT 
42 x10^3/mcL. Urine microscopy showed WBC 27/hpf and RBC 129/hpf. Spot urine protein 
creatinine ratio was 2.42. Ground-glass opacities, as well as mediastinal and right hilar 
adenopathy were visualized on CT; no hepatosplenomegaly or hydronephrosis was seen. 
Renal biopsy was deferred due to risk of bleeding. A liver biopsy, performed simultaneously 
with transjugular dialysis catheter placement, revealed necrotizing granulomas with narrow 
based budding yeast consistent with histoplasma. Urine histoplasma antigen was 5.98 ng/mL, 
which confirmed the diagnosis of histoplasmosis. The patient was started on liposomal 
amphotericin at 3mg/kg daily, and within 5 days the patient no longer required hemodialysis. 
She was transitioned to itraconazole on discharge, and after 2-months, her renal function, 
liver function, and platelets had normalized.
Discussion: Our case highlights that, given the right clinical context, nephrotoxic 
drugs can be given to treat AKI. In this case, although kidney biopsy was not performed, 
it is hypothesized that either direct damage by histoplasma or the liver failure associated 
histoplasmosis contributed to the AKI, given that it improved shortly after initiating 
amphotericin. Although autopsies have shown renal involvement in up to 40% of patients 
with disseminated histoplasmosis, clinically significant renal disease is rare. In patients with 
renal failure, renal biopsies have demonstrated several etiologies, including renal papillary 
necrosis, granulomatous interstitial nephritis, glomerulonephritis, and urinary obstruction. 
Renal function may recover in such cases with prompt treatment of histoplasmosis.
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Delayed Bleeding Following Renal Biopsy
Pascale Khairallah, Jacob Stevens, Jai Radhakrishnan. Columbia University 
Medical Center, New York, NY.
Introduction: Renal biopsy is considered a safe procedure with less than 1% of 
patients having significant bleeding. Post-procedural bleeding typically occurs within 2-24 
hours. Risk factors for bleeding include older age, female gender, renal failure, and bleeding 
diathesis. There is no consensus on when to resume anticoagulation following renal biopsy, 
particularly among high-risk patients.
Case Description: We report the case of a 70 yo male with cirrhosis, diabetes and 
CKD stage 3 admitted for recurrent diffuse alveolar hemorrhage of unknown etiology. 
On admission, creatinine was at his baseline of 1.7mg/dL. Urine sediment was bland 
and ANCA titers were negative. A few weeks into his hospitalization, he developed non-
oliguric AKI with hematuria, pyuria and 0.8g/day of proteinuria. Repeat PR3 ANCA titers 
were positive at 26AU/mL (negative<19). A left-sided renal biopsy with CT guidance was 
performed to evaluate for pulmonary-renal syndromes. At the time of biopsy, the platelet 
count was 100x103/uL and INR was 1.5. Biopsy results showed diabetic glomerulosclerosis 
and acute tubular injury. Prophylactic heparin was started 3 days after the biopsy. 
The patient developed hemorrhagic shock 14 days after the biopsy requiring massive 
transfusion protocol and pressor support. CT of the pelvis showed left intraparenchymal 
renal hemorrhage. Angiogram identified left renal artery bleeding pseudoaneurysms that 
were successfully coiled.
Discussion: Delayed bleeding following renal biopsy is very rare. We report a case of 
life threatening bleeding that occurred 14 days after the biopsy. This is to our knowledge the 
second reported case of a bleed occurring more than 10 days post biopsy. Our patient had 
several bleeding predisposing risk factors including older age, renal failure, coagulopathy, 
and use of heparin. The benefit as well as timing of initiating anticoagulation must be 
carefully weighed against the risk of post-procedural bleeding, particularly in high-risk 
patients who can present with delayed bleeding.
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A Unique Approach of Combined Peritoneal Dialysis and Haemodialysis 
in a Case of Cardiorenal Syndrome
Kamlesh N. Parikh.1,2 1Shreenath Clinic, Vadodara, India; 2Nephrology and 
Transplant Department, Bhailal Amin General Hospital, Vadodara, India.
Introduction: This is a case of renal dysfunction in a pt. with dilated 
cardiomyopathy(DCM) & cardiac arrythmia. Author was challenged by therapeutic 
dilemma of DCM, hypotension, acute renal dysfunction needing dialysis & haemodynamic 
disturbance arising due to haemodialysis(HD). Peritoneal dialysis (PD) & HD were done. It 
provided efficient solute extraction in volume overloaded pt & corrected diminished renal 
function.
Case Description: 50-year-old male, k/c/o hypothyroidism, ischaemic heart disease 
with DCM and CRT-D in-situ came with complaints of palpitations, breathlessness on 
exertion(NYHA IV), nausea, oliguria and anasarca. Admitted in ICU, systolic BP(SBP) 100 
mmHg & temp 100° F; pt. had atrial fibrillation with rapid ventricular rate(RVR). 2D echo 
showed biventricular systolic dysfunction and EF 30%; Sr. creat1.2 mg/dL. Diuretic and 
BiPAP ventilator started. Amiodarone dose optimized. Persistence of RVR & hypotension, 
requiring increasing dose of inotropes. After 48 hrs, sr. creat 5.4. Due to low BP, lung 
congestion and AKI decision of dialysis was taken Tenckhoff catheter placed in LA. PD 
exchange with Icodextrin done with ultrafiltration(UF). Azotemia worsened. 4 sessions of 
short HD & PD over 10 days done. SBP was ≥90 with inotropes which were tapered. Pt. 
had VAP which was treated. Oliguria persisted 3 wks Pt. was managed in 4 wks with HD & 
PD. Gradual recovery of renal function with good UOP occurred. CRT-D reprogrammed. 
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AV Node ablation done & palpitation improved. Sr. Creat was 1.6. Catheter was removed. 
SBP ≥100 without inotropes. Pt. was fully ambulatory at discharge
Discussion: Cardiac and renal dysfunction often occur together as they share common 
pathogenic mechanism, known as CRSs. In such case of poor cardiac function & arrythmia, 
there is risk of intradialytic hypotension & renal hypoperfusion causing worsening 
of azotemia, which was obviated by combining PD & HD. With a multidisciplinary 
collaboration between cardiologist and nephrologist, we could achieve symptomatic 
improvement, improved exercise tolerance, euvolemia, recovery of renal function, and 
reduction in NYHA class with improvement of EF. It represents a pathophysiologically and 
conceptually relevant option by simultaneously addressing renal and cardiac dysfunction. 
The case is first of its kind reported from Indian subcontinent demonstrating safety and 
efficacy of this therapeutic modality for CRS.
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A Case of Granulomatous Interstitial Nephritis Likely Associated with 
Lisinopril
Jobira A. Woldemichael,1 Thomas E. Rogers,2 Sarah A. Johnson.3 1Emory 
university, Atlanta, GA; 2Emory University, Atlanta, GA; 3Emory University 
School of Medicine, Atlanta, GA.
Introduction: Granulomatous interstitial nephritis (GIN) as a cause of acute kidney 
injury (AKI) is a rare clinical condition. Drugs, infections and immune processes are among 
the most common causes.
Case Description: A 61 year old African American female with a history of 
hypertension and hypothyroidism was admitted with nausea, cough and easy fatigability 
of 2 weeks duration with decreased urine output. She was found to have a serum creatinine 
(Scr) of 15 mg/dl from a baseline of 0.8 mg/dl six months prior and was admitted for further 
workup. She denied NSAID use, did not have any recent contrast studies, illnesses or 
travel. Her home medications include atenolol, levothyroxine and lisinopril with no new 
medications. Clinically the patient was uremic with no rashes or edema. She had mild 
hypertension and was initiated on hemodialysis. Her urinalysis revealed 3+ blood and her 
sediment review showed many WBC, granular casts and rare RBC. Spot urine protein 
to creatinine ratio was 2.5 gm/gms. Renal ultrasound showed a 14 cm right kidney and 
12.5 cm left kidney but otherwise was normal. Serologies for hepatitis B and C and HIV 
were negative. Antinuclear antibody, anti-glomerular basement membrane antibodies and 
ANCA were negative. Complements C3 and C4 were normal. The patient underwent a renal 
biopsy which showed GIN, so an infectious workup was initiated. A CT scan of the chest 
was normal, and serum ACE and calcium were normal, largely ruling out sarcoidosis and 
pneumonia. Blood cultures were negative. Tuberculosis was ruled out with PPD and sputum 
cultures. Serum protein electrophoresis was negative. The patient’s symptoms significantly 
improved with initiation of HD but her renal function did not recover initially. In total, she 
received 7 sessions of HD. As infection was ruled out, she was started on 40 mg of oral 
prednisone and tapered quickly as her Scr improved to 2.1 mg/dl within 3 days of steroid 
initiation and eventually improved to 1.2 mg/dl. Lisinopril was discontinued on admission 
and now appears the most likely culprit for the GIN and severe AKI.
Discussion: Although GIN has not been linked with ACEI, captopril has been 
previously described as a cause of interstitial nephritis. This case opens further discussion 
for ACEI being a possible inciting agent for GIN among other etiologic association reported 
thus far.
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An Unexpected Cause of Hypercalcemia in a Cancer Patient
Gajapathiraju Chamarthi,1 Judith E. Sallustio,2 Justin Lee Loy,1 
Abhilash Koratala.1 1University of Flroida, Gainesville, FL; 2VAMC Gainesville, 
FL, Gainesville, FL.
Introduction: Primary hyperparathyroidism and malignancy are the most common 
causes of hypercalcemia, though the differential diagnosis is usually broad. Determining 
the etiology of hypercalcemia is key to its management and it can be difficult in the presence 
of multiple confounding factors. We present a case of hypercalcemia in a cancer patient, 
which was likely secondary to Sarcoidosis.
Case Description: A 59-year-old man with CKD stage 4, hypertension, and prostate 
cancer on androgen deprivation therapy was admitted to the hospital for worsening renal 
function and hypercalcemia. Serum creatinine at presentation was 4 mg/dL (baseline 2.8) 
and calcium was ~12 mg/dL. On chart review, he had varying degrees of hypercalcemia 
for at least a year that was associated with nephrolithiasis. He was not taking any calcium 
or vitamin D supplements. Serum parathyroid hormone (PTH) was suppressed and PTH-
related peptide, serum protein electrophoresis, free light chain ratio and 1,25-dihydroxy 
vitamin D level were within normal limits. However, 25-hydroxy vitamin D level was 
low. Positron emission tomography–CT was negative for bony metastasis but showed 
lymphadenopathy in mediastinum and abdomen. Inguinal lymph node biopsy surprisingly 
revealed non-caseating granulomas with asteroid bodies and Schaumann bodies, consistent 
with sarcoidosis. Corticosteroid therapy was initiated and his calcium and creatinine 
gradually improved.
Discussion: Sarcoidosis is a multisystem granulomatous disease characterized by non-
caseating granulomas. It can affect any organ including kidney. However, granulomatous 
interstitial nephritis alone is rarely implicated in CKD. Instead, chronic hypercalcemia 
and hypercalciuria causes tubulointerstitial inflammation with associated calcium deposits 
leading to nephrocalcinosis, and fibrosis and CKD. Though CKD in our patient was 
originally attributed to hypertension, hypercalcemia could have contributed. Take-home 
point from our case is that hypercalcemia in a cancer patient is not always from bone 
metastases and alternative etiologies should be sought when appropriate. Interestingly, 
1,25-dihydroxy vitamin D level was normal in our patient, which is thought to be the main 
mechanism of hypercalcemia in sarcoidosis. However, 25-hydroxy vitamin D, which is the 
substrate for the formation of 1,25-dihydroxy vitamin D was low, which could explain this 
unexpected finding.
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A Case of Likely Bile Cast Induced Nephropathy
Syed A. Ali. UCLA, Los Angeles, CA.
Introduction: An important non vasomotor (as opposed to hepatorenal syndrome in 
cirrhosis) mechanism of Acute Kidney Injury in liver dysfunction is the nephro-toxicity of 
cholephiles (i.e.bilirubin and bile acids). This entity is defined by histologic lesions which 
include tubular bile cast formation and tubular epithelium injury, associated with jaundice. 
I describe the case of suspected bile cast induced nephropathy in a patient with obstructive 
cholestasis caused by stones in the common bile duct, without any prior history of liver 
disease.
Case Description: This was a seventy two year old male with a history of coronary 
artery disease s/p coronary artery bypass graft surgery, heart failure with reduced ejection 
fraction, atrial flutter, atrial fibrillation, diabetes mellitus, hypertension, hyperlipidemia, 
chronic kidney disease stage IIIA, who presented with epigastric pain. His work up revealed 
a creatinine of 1.4 at the time of admission and it rose upto a peak of 2.93 with the total 
bilirubin peaking at 23.13. He had a CT scan of the abdomen/pelvis without contrast done 
which showed a suspected stone in the common bile duct after which an ERCP was done 
which confirmed the suspicion and after relief of the obstruction, both the total bilirubin 
and creatinine trended down simultaneously. This happened concurrently with the fall in 
bilirubin in the urine analysis.
Discussion: Kidney injury in the setting of severe cholestasis can result from 
precipitation of cholephiles in renal tubules with subsequent toxicity to the epithelial cells. 
In our case, although we did not perform a renal biopsy, but the temporal correlation, as seen 
in the accompanying table, between the total and direct serum bilirubin levels and the serum 
creatinine/eGFR and the level of bilirubin in the urine analysis suggest that cholestasis was 
strongly contributing to the renal injury.
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Temporal Mass and AKI as a Presentation of Multiple Myeloma
Muhannad Leghrouz, Abhilash Koratala. University of Florida, Gainesville, FL.
Introduction: Solitary bone Plasmacytoma is a rare malignancy characterized by 
malignant proliferation of monoclonal plasma cells. It constitutes less than 5% of malignant 
plasma cell tumors. Herein, we report a case of multiple myeloma that presented with 
temporal plasmacytoma and found to have acute kidney injury.
Case Description: A 70-year-old female with a history of endometrial cancer s/p 
hysterectomy, maintained on tamoxifen was brought to our institution for altered mental 
status of acute onset. She previously told her family about a left temporal mass ~3 weeks 
ago. Head CT demonstrated left temporal mass centered in the calvarium with intracranial 
as well as extracranial extension into the left lateral orbit and with associated osseous 
destruction. In addition, more than 20 calvarial lucent lesions were identified [Figure 1]. 
Laboratory data demonstrated AKI with a serum creatinine of 13 mg/dL, hypercalcemia 
with a serum calcium level 11.6mg/dL, anemia with a hemoglobin of 9 g/dL. SPEP showed 
two distinct monoclonal spikes in the IgA (0.7g/dL) and IgG (1.2g/dL) regions. Serum 
free kappa light chain (LC) was 1.49mg/dL (Ref: 0.33-1.94) and lambda LC 1339.3mg/dL 
(significantly elevated). She required initiation of hemodialysis and mental status gradually 
improved. Temporal mass biopsy demonstrated plasmacytoma with positive kappa LC and 
bone marrow biopsy was consistent with multiple myeloma. Chemotherapy was initiated 
with cyclophosphamide, bortezomib and dexamethasone and she is currently dialysis 
dependent.
Discussion: Plasmacytoma may involve the cranial vault, base or brain parenchyma 
and rarely, the temporal bone as in our patient. It is important to keep this differential in 
mind when evaluating a patient for acute kidney injury and cranial mass as not all such 
patients get appropriate imaging at presentation, especially if the lesion is small.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1152
J Am Soc Nephrol 29: 2018 Publication-Only 
PUB474 
Publication-Only 
Acute Esophageal Necrosis in a Patient with AKI Due to Acute 
Pancreatitis
Marcelo V. Silva,1,2 Paulo H. Amor divino,3 Francisco A. Maia,3 Joao 
vitor T. Motta.4 Faculdade de Medicina da USP 1FMUSP, São Paulo, Brazil; 
2Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil; 3Santa Casa de 
Misericórdia de São Paulo, São Paulo, Brazil; 4Santa Casa de Misericordia de 
Sao Paulo, Sao Paulo, Brazil.
Introduction: The acute esophageal necrosis (AEN), also known as black esophagus, 
is a rare esophagic complication of many acute criticial illness. Since it has been described 
by Goldenberg et al in 1990, it has been linked to many critical clinical conditions, like 
descompensated diabetes mellitus, hypovolemic shock and acute kidney injury (AKI). In 
this report we aim to describe a case of AEN in a patient with AKI due to acute pancreatitis 
(AP)
Case Description: A 61 male patient with medical history of severe alcoholism, 
presented to the emergency department with a history of abdominal pain associated 
with nauseas and hematemesis for 2 days. He presented with hypotension, tachycardic, 
diaphoretic, pale and anxious. Labs showed amilasis 780 UI/L, urea 505 mg/dL and a Hb 
5,5 g/dL. The patient was promptly resuscitated with saline and received transfusoin of 3 
packs of red cells. Posteriorly the patient realized a CT of the abdomen, which confirmed 
acute pancreatitis, and an upper endoscopy which showed an acute esophagic necrosis. The 
patient was treated with broad-spectrum antibiotics, was placed on ‘nil per os’ and received 
renal replacement therapy. After 3 weeks the patient remained hemodynamically stable, the 
kidney function restored so that the patient no longer needed renal replacement and was 
progressively fed back, with good acceptance.
Discussion: Acute esophagic necrosis is a rare complication of many criticall illness. 
Although imprecise, some studies believe it has a prevalence of 0,2%. AEN is linked with 
many critical clinical illness, like diabetes mellitus, trauma, any cause of shock and AKI. 
We presented a case of AEN after a severe AP witch evolved with a AKI requesting renal 
replacement therapy. Acute GI bleeding is not rare in patients with AKI, normally occurring 
due to gastric or duodenal ulcer. In the present report we show that AEN is a potential cause 
of GI bleeding in patients with AKI
PUB475 
Publication-Only 
Primary Renal Lymphoma: An Unusual Cause of Bilateral Nephromegaly
Khai Ping Ng,1 Mark E. Thomas.2 1Birmingham Heartlands Hospital, England, 
Birmingham, United Kingdom; 2Heart of England Foundation Trust, 
Birmingham, United Kingdom.
Introduction: Primary renal lymphoma is a rare disease, which account for only 
0.7% of all extra-nodal lymphoma in North America. Amongst the 70 cases reported in the 
literature to date, it was often reported as unilateral renal involvement in adults. We describe 
a case of primary renal diffuse large B-cell lymphoma, presenting with acute kidney injury 
(AKI) and bilateral nephromegaly.
Case Description: A 63 year-old female was admitted with two weeks history 
of vomiting, legs swelling and weight loss. She has bilateral ballotable kidneys on 
examination. Initial blood tests showed stage 3 AKI (serum urea: 45.7 mmol/L, creatinine 
828 μmol/L) and pancytopenia. Haemolytic, clotting, virology and haematinic screens were 
unremarkable. Her lactate dehydrogenase was 341 U/L. She had nephrotic syndrome with 
serum albumin of 27 g/L and random urine protein-creatinine ratio of 413 mg/mmol. Her 
kappa/lambda ratio was normal with mildly low IgG (5.57 g/L). Ultrasound scan reported 
bilateral enlarged kidneys (right 14.0cm, left 14.6cm) and homogenous appearance of 
cortex and medulla. She was started on haemodialysis. Renal biopsy was performed, which 
showed renal tissue with scattered tubules extensively infiltrated by medium-sized blastoid 
cells. Bone marrow aspirate showed only slight hypocellularity. Immunophenotyping of the 
renal biopsy found a diffuse large B-cell lymphoma. She was commenced on CHOP regime 
with 50% reduction of cyclophosphamide. She had further readmission with pulmonary 
oedema and hyperkalaemia, which required increased haemodialysis and ultrafiltration. 
There was no evidence of myocardial infarction, however, the echocardiogram reported 
severely impaired systolic function. Her chemotherapy regime therefore was altered to 
R-CEOP. She reported blurred vision following the 2nd cycle of chemotherapy. Though CT 
and MRI head were unremarkable, cerebrospinal fluid flow cytometry showed evidence of 
lymphoma infiltration. She was commenced on intra-thecal methotrexate. She has had good 
response to chemotherapy and is showing signs of potential renal recovery.
Discussion: Although primary renal lymphoma is a rare condition, it must be 
considered in the differential diagnosis of nephromegaly and AKI. Comparable to previous 
published cases, our case demonstrated encouraging haematological and renal outcomes 
following R-CEOP treatment.
PUB476 
Publication-Only 
Methotrexate Crystal Nephropathy in Patients with Rheumatoid 
Arthritis: An Underrecognized Cause of AKI
Tomonori A. Oyadomari,1 Himabindu Yerneni,3 Martin Sedlacek.2 1Dartmouth 
Hitchcock Medical Center, Lebanon, NH; 2Dartmouth-Hitchock Medical Center, 
Lebanon, NH; 3Dartmouth Hitchcock medical center, Hanover, NH.
Introduction: Renal dysfunction following administration of high-dose Methotrexate, 
defined as 1,000-3,000mg/m2, has been well described. However, the incidence of 
nephrotoxicity with low-dose therapy, typically 7.5mg to 25mg weekly prescribed for 
patients with rheumatoid arthritis, remains largely unknown. Risk factors for nephrotoxicity 
include high serum Methotrexate level, low urine pH, low urine output and concomitant 
use of agents known to reduce GFR such as NSAIDs. Crystallization of Methotrexate in 
the renal tubules, seen as clumps of gold brown needle-like crystals on light microscopy, 
is urine pH-dependent and occurs in acidic urine. Literature surrounding renal dysfunction 
from low-dose Methotrexate administration is scarce and crystal formation leading to AKI 
in this cohort has not been described.
Case Description: We describe a case of a 56 year-old woman with a 10-year history 
of rheumatoid arthritis on Prednisone 20mg weekly who was referred to our clinic for a 
rise in serum creatinine from her baseline 0.9 to 1.4 during a 6-month period. Her medical 
history included hypertension treated with Triamterene-HCTZ and a remote history of 
asymptomatic nephrolithiasis that was found incidentally on ultrasound. Patient had been on 
daily Sulindac for many years, which was discontinued only with a transient improvement 
in creatinine. There was no proteinuria. Patient denied any urinary symptoms. Patient had 
no history of herbal supplement, smoking, alcohol, or recreational drug use. There was 
no family history of renal disease. Renal ultrasound was negative for obstruction. Urine 
dipstick showed specific gravity of 1.015 and pH of 7.0, otherwise negative. Surprisingly 
urine microscopy showed multiple clumps of brown weakly birefringent crystals, similar to 
published images of Methotrexate crystals. Upon further questioning, the patient admitted 
to frequent consumption of Coca Cola.
Discussion: Our case confirms that Methotrexate crystal nephropathy exists even in 
patients treated with low doses. We postulate that the use of NSAIDs and diuretics led to 
reduced Methotrexate clearance and consumption of urine pH-lowering foods facilitated 
crystal formation. The patient recovered renal function after discontinuing Methotrexate. 
Clinicians must be aware of this clinical entity and be thorough in their history taking 
including diet and medications.
PUB477 
Publication-Only 
I’m Feeling Swell, and That Is a Complement (Mediated Disease)!
Derian Lai, Nicole Canon, Prejith P. Rajendran. Baylor College of Medicine, 
Houston, TX.
Introduction: Angioedema is a severe manifestation of complement dysregulation. 
Hereditary Angioedema (HAE) patients have deficient or non-functional C1 esterase 
inhibitor (C1-INH). Acquired Angioedema (AAE) patients have autoantibodies or 
hyper catabolism of C1-INH. Systemic lupus erythematosus (SLE) has a wide array of 
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complement derangements and angioedema is a rare complication. SLE has been associated 
with both the hereditary and acquired forms of angioedema. Here we describe a patient 
with recently diagnosed SLE who presented with a severe case of angioedema and class 
3 lupus nephritis.
Case Description: A 33-year-old female with recently diagnosed SLE calls emergency 
services for tongue swelling, stridor and respiratory distress. She was intubated at the scene 
and later transferred to the nearest hospital in stable condition. No skin rashes were noted. 
Initial labs notable for elevated serum creatinine and active urine sediments. She was treated 
with pulse dose steroids on day of presentation. The next morning, the patient developed 
respiratory distress after being extubated, so she was re-intubated and then transferred 
via airlift to our tertiary medical center. On arrival, she was awake, alert and stable on 
mechanical ventilation. Labs revealed elevated serum creatinine (1.7mg/dL), nephrotic 
range proteinuria with active sediments, anemia and thrombocytopenia. ANA, Anti-dsDNA 
titers were elevated, and her complements were low. C1-INH levels were collected but 
unfortunately the samples never resulted. Imaging of the chest and abdomen were negative 
for lymphadenopathy. Renal biopsy was performed and revealed class 3 lupus nephritis. She 
was treated with methylprednisolone pulses and Cyclophosphamide. Patient’s respiratory 
status and renal function improved with therapy and she was extubated after 2 days.
Discussion: Angioedema is a rare complication of lupus flares. Clinicians should 
be aware of this rare but potentially life-threatening association, to prevent any delay in 
management
PUB478 
Publication-Only 
Typical Atypical Hemolytic Uremic Syndrome: A Pregnancy-Induced 
Story
Oluwadamilola O. Babaniji,1 Roberto L. Collazo-Maldonado.2 1Methodist 
Hospital Dallas, Dallas, TX; 2Dallas Nephrology Associates, Dallas, TX.
Introduction: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is 
a rare condition that can mimic other clinical conditions in the postpartum period. It is very 
important for clinicians to promptly recognize and manage this potentially fatal condition 
to reduce the catastrophic complications that could result if early diagnosis is not made.
Case Description: A 31 year old primigravida African American woman with past 
medical history of hypertension, asthma and obesity presented to her post-partum follow 
up clinic 2 weeks after her C-section delivery of a preterm live infant at 29 weeks. Her 
pregnancy was complicated by premature ROM and chorioamnionitis. She was found to 
be very hypertensive (220/120 mmHg) with new onset abdominal pain associated with 
frontal headache and new-onset bilateral lower extremity edema with no fever and normal 
mental status. She was immediately admitted to the hospital and her initial laboratories 
showed new onset acute kidney injury (creatinine 2.5mg/dL), new-onset thrombocytopenia 
(35000), presence of hemolytic anemia with schistocytes on smear, markedly elevated 
LDH levels (>2000), and undetectable haptoglobin levels. Urinalysis was notable for active 
sediment with nephrotic range proteinuria and hematuria. Nephrology was consulted and 
given her classic presentation, she was started on intravenous steroids and hematology was 
consulted for emergent plasmapheresis the same day of admission. Diagnosis of atypical 
hemolytic uremic syndrome was confirmed with normal ADAMTS-13 level. Hemodialysis 
was eventually initiated for worsening kidney function. She was started on Eculizumab 48 
hours after being admitted. After 2 doses of Eculizumab, her blood pressure is controlled 
with normalization of her hemoglobin and platelets and recovery of her kidney function. 
Patient is currently undergoing genetic workup for identification of inherited complement 
abnormalities.
Discussion: p-aHUS is a challenging condition that has been known to present in 
the early postpartum period. It could easily be mistaken for other well-known postpartum 
complications such as preeclampsia and HELLP syndrome leading to delay in treatment. 
The bad outcomes of this entity may be mitigated with quick clinical recognition and 
treatment initiation.
PUB479 
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Renal Biopsy – Remains an Irreplaceable Tool for the Nephrologist
Lucy M. Esteve,2,1 Manoj Bhattarai,2,1 Muhammad Abdullah,2,1 Jeet Gandhi,2,1 
Bahar Kapoor,2,1 Fermin O. Tio,1 Shweta Bansal.2,1 1South Texas Veterans 
Medical Center, San Antonio, TX; 2University of Texas Health Science Center at 
San Antonio, San Antonio, TX.
Introduction: In the absence of perfect biomarkers for acute kidney injury (AKI), 
renal biopsy remains an important diagnostic tool despite associated complications. We 
report a case of non-oliguric AKI with multiple risk factors masquerading the real diagnosis 
eventually requiring renal biopsy for definitive diagnosis and successful treatment.
Case Description: 63-year-old man with morbid obesity, hypertension, atrial 
fibrillation, chronic kidney disease and recurrent deep vein thrombosis on warfarin 
presented with 4 months of intermittent gross hematuria. His BP was 150/90 mmHg with 
an otherwise normal physical exam. Blood work revealed serum creatinine of 5.9 mg/dl 
(baseline 1.5 mg/dl). Urine microscopy showed many normal and a few dysmorphic red 
blood cells (RBCs). 24hr urine protein was 1.6 gm (baseline 1+ on dipstick). INR ranged 
from 1.5 to 5 in the recent past. He was treated with Ciprofloxacin for presumed urinary 
tract infection a month prior to presentation with stable creatinine 2 weeks later. He had 
normal cystoscopy a week prior to presentation. No other exposure to new medications 
or contrast was noted. Serology work up was negative. CT abdomen was unremarkable 
except for findings suggestive of liver cirrhosis. Diagnoses of Warfarin related nephropathy 
(WRN) and IgA nephropathy (IgAN) were entertained and Warfarin was held. Renal biopsy 
was initially deferred due to morbid obesity and need for anticoagulation but performed a 
few days later when renal function failed to improve. Despite prophylactic Desmopressin, 
the biopsy was complicated by a retroperitoneal hematoma requiring embolization of the 
interlobar artery and blood transfusions. It showed numerous tubules packed with RBCs, 
severe lymphocytic and eosinophilic interstitial infiltrate, and mesangial expansion with 
immunofluorescence positive for IgA. The findings were consistent with WRN, acute 
interstitial nephritis (AIN) and non-crescentic IgAN. He was started on oral steroids and an 
IVC filter was placed. His serum creatinine was 3.4 mg/dl on discharge, which stabilized 
around 1.5 mg/dl on follow up. Anticoagulation was resumed with no worsening of renal 
function.
Discussion: This is a rare case of acute renal failure with a combination of AIN, WRN 
and IgAN and highlights that renal biopsy remains an essential tool for definitive diagnosis 
and initiation of timely treatment.
PUB480 
Publication-Only 
Eculizumab: Atypical Treatment of Typical Hemolytic Uremic Syndrome
Maggie Meier, Pablo D. Dayer. Saint Luke’s Hospital, Chesterfield, MO.
Introduction: Typical hemolytic uremic syndrome (HUS) with neurological 
involvement is a life threatening disease. HUS is caused by E.Coli producing Shiga-
toxin damaging endothelial and activating the complement cascade. In atypical HUS, a 
monoclonal antibody Eculizumab has been effective in treating complement pathway 
abnormalities. We present a case of typical HUS with severe neurological involvement 
treated effectively with Eculizumab.
Case Description: An 18 year old Caucasian female was transferred from a Dominican 
Republic hospital with multiorgan failure including renal failure. She developed bloody 
diarrhea and was initally hospitalized with presumed acute gastroenteritis. She was started 
on antibiotics. Her condition worsened as she became anuric despite aggressive fluid 
resuscitation. She developed seizures and acute encephalopathy requiring ventilatory 
support. Upon arrival to our hospital, she was in acute renal failure with severe metabolic 
acidosis. Lactate dehydrogenase was elevated at 9000 with associated anemia and 
thrombocytopenia. Blood smear showed shistocytes. A clinical diagnosis of HUS was made 
based on acute renal failure, thrombocytopenia and hemolytic anemia. Stool PCR was 
positive for Shiga toxin 2. She was initiated on hemodialysis and treated with Eculizumab. 
Antibiotics were stopped. After 2 weeks in the intensive care unit, her overall condition 
improved. Her seizures resolved, and she did not require continued treatment with anti-
seizure medications. Her renal function started to improve and she came off hemodialysis 
after 5 weeks. Her renal function though has remained decreased with a GFR around 30.
Discussion: An 18 year old without past medical history presented with a severe form 
of typical HUS. Shiga toxin as a causative agent was identified. However, neurological 
manifestations are unusual in typical HUS and thrombotic thrombocytopenia purpura was 
also considered. She was treated with hemodialysis but plasmapheresis was not offered 
in this case. Eculizumab was associated with full neurological recovery. After two doses 
of eculizumab, our patient’s seizures resolved and she did not require long term anti-
seizure medications. In life threatening cases of HUS with severe neurological symptoms, 
Eculizumab may be consdered as first line therapy.
PUB481 
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Postpartum Ruptured Sub-Capsular Liver Hematoma with Dialysis- 
Dependent AKI and Intracranial Bleed with Delayed Recovery: Is It 
HELLP or aHUS?
Sanjeev Gupta,1 Savneek S. Chugh,2 Aromma Kapoor.1 1Westchester County 
Medical Center, Valhalla, NY; 2New York Medical College, Hartsdale, NY.
Introduction: HELLP, a known complication of preeclampsia, can rarely result in 
ruptured sub-capsular liver hematoma (SLH) and very rarely dialysis-dependent AKI. We 
present a case of preeclampsia complicated by postpartum ruptured SLH and dialysis-
dependent AKI with delayed recovery after delivery.
Case Description: A 33-year-old lady with prior two 1st trimester miscarriages 
admitted for emergent C-section due to fetal bradycardia and preeclampsia. During surgery 
hemoperitoneum and ruptured SLH was found. The patient developed AKI and anuria 
the following day. CVVHD was initiated. Lab workup showed low Hb & platelet counts 
with elevated LFTs & S.ammonia, resulting in a presumed diagnosis of HELLP syndrome. 
The patient showed minimal recovery post-delivery with supportive treatment. CVVHD 
was continued. A CT head was performed due to AMS which revealed sub-arachnoid 
hemorrhage. Due to persistent thrombocytopenia and anemia, further workup for TTP/ 
aHUS, and APLS were ordered. Schistocytes were seen on peripheral blood with low 
complement levels and normal ADAMTS 13 activity. A renal biopsy wasn’t done due to 
thrombocytopenia, however, given high suspicion of aHUS treatment with Eculizumab was 
considered. Just before the treatment initiation, her platelet count and other lab parameters 
started to improve so the drug was withheld.
Discussion: HELLP syndrome, APLS, TTP, and aHUS, can clinically mimic each other 
and it can be very challenging to differentiate, although expedited delivery usually improves 
HELLP and APLS. ADAMTS 13 is low in TTP but the diagnosis of aHUS is solely based 
on the clinical picture. Our patient didn’t respond to expedited delivery and ADAMTS 
13 was normal. Given delayed recovery, our patient likely had aHUS which fortunately 
resolved spontaneously. Henceforth, it is important to exclude aHUS when there is minimal 
or delayed recovery in patients with severe preeclampsia/ HELLP even after the delivery.
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Who Did It? An Unusual Case of an AKI MM and CLL in a Patient with 
Multiple Myeloma and Chronic Lymphocytic Leukemia
Francisco J. Alvarado,2 Kayla Shirley,3 Fadee Abu Al Rub,1 Claude Bassil.1 
1Department of Nephrology and Hypertension, University of South Florida, 
Tampa, FL; 2Internal Medicine, University of South Florida, Tampa, FL; 
3Internal Medicine, Univeristy of South Florida, Tampa, FL.
Introduction: Multiple Myeloma (MM) is a notorious malignancy known to cause 
kidney damage. The range of renal pathology induced by MM range from the effects of 
tumor lysis syndromes to various types of glomerulonephritis’s. It is quick to assume that a 
patient with MM with an Acute Kidney Injury is likely induced in some way or another from 
that disease process. However in this case report this particular patient also had Chronic 
Lymphocytic Leukemia (CLL), a malignancy that is rarely known to cause renal damage.
Case Description: This is a 60 y/o gentleman with a history of MM and CLL. The 
diagnosis of CLL was made after patient came to the ED for evaluation of chest tightness 
and palpitations that was attributed to an exacerbation of his known atrial fibrillation. His 
labs noted to include a WBC count of 175 k, an Absolute Lymphocyte Count of 171 k, with 
mild anemia and thrombocytopenia. Flow cytometry was ordered and it was consistent with 
CLL and FISH showed trisomy 12. Patient was asymptomatic so treatment was deferred. 
2 months later patient presented with an AKI with a Cr of 3.6, baseline Cr was 1.1. SPEP 
and UPEP showed 6.3 grams of lamba light chain. Bone marrow biopsy one month later 
showed CLL with plasmocytic differentiation and plasma cell myeloma. Patient then 
received a renal biopsy and it showed 3 out of 12 sections that were globally sclerotic. There 
was prominent but patchy infiltration of the interstitium with lymphocytes (had positive 
immunoperoxidase staining for CD5, CD20 and CD23). Stainings were negative for kappa 
and lambda light chains.
Discussion: CLL is a disease entity that is not commonly know to cause an AKI. 
However going through the literature there are various case reports of CLL induced AKI. 
What is even more uncommon is AKI secondary to leukemic infiltration but this too is a 
known entity. In the setting of multiple myeloma one would expect that this disease process 
would be the etiology of this patient’s AKI but the biopsy showed that this was not the case. 
In a patient with CLL and an AKI, it is important to consider that this disease process could 
be the cause of a patient’s renal damage.
PUB483 
Publication-Only 
Hydralazine Induced ANCA Vasculitis Causing Acute Interstitial 
Nephritis
Tanuja Yalamarti,1 Pooneh Alborzi.2 1Internal medicine, Pennsylvania hospital, 
Philadelphia, PA; 2Pennsylvania Nephrology Associates, PC, Philadelphia, PA.
Introduction: This case describes a patient with hydralazine induced autoimmune 
disease who presented with pulmonary hemorrhage and rapid decline in GFR secondary to 
biopsy proven acute interstitial nephritis(AIN)
Case Description: A 74-yo male with hypertension on hydralazine for 3 years. He 
presented with a history of malaise, dark urine and shortness of breath. He had pancytopenia 
and AKI. Serological tests were positive for anti-histone, anti-MPO antibody and low 
complements. Bone marrow biopsy was normal. Renal biopsy showed acute interstitial 
nephritis(AIN) without any glomerular pathology. He was treated with pulsed steroid, and 
rituximab with the impression of hydralazine associated autoimmune disease. One week 
later, he had further hemoptysis, significant decline in renal function with proteinuria, 
RBC, granular casts in the urine. Chest CT revealed new bilateral pulmonary ground-glass 
infiltrates. He was given pulsed steroids with four plasma exchanges and rituximab. His 
respiratory status improved but he remained dialysis dependent at the time of discharge with 
full recovery of AKI at four months.
Discussion: Hydralazine induced lupus glomerulonephritis(GN) causes deposition 
of immune complexes and complement. Hydralazine induced ANCA associated(AAV) 
vasculitis cases reported till date have biopsy proven pauci immune crescentic GN. Our 
patient’s history of malaise, pancytopenia, positive anti-histone antibodies and low 
complements lend weight to lupus syndrome but the rapidly increasing serum creatinine, 
features of diffuse alveolar hemorrhage(DAH) along with absence of immune deposits 
at renal biopsy make it most consistent with AAV. However, the presence of only 
AIN is interesting in this case. Despite adequate sampling, it is still possible that rare 
crescentic lesion were missed. Alternatively, the findings in our case may represent a drug 
hypersensitivity-associated AIN. In hydralazine induced lupus, cessation of the drug is 
sufficient to reverse disease activity. Although there was no histopathological evidence of 
GN, the patient responded to immunosuppressive therapy that is often used in the treatment 
of AAV. The uniqueness of this case lies in the development of AIN due to hydralazine 
induced ANCA vasculitis which recovered fully with immunosuppression. Hence, it 
is important to recognize the absence of the expected characteristics associated with 
hydralazine induced autoimmune disease.
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Calcium Channel Blocker Overdose Revisited: From Insulin to  
Methylene Blue
Prejith P. Rajendran,1 Ahmed A. Awan,2 Shalini Makawita,1 David 
Sheikh-Hamad.1 1Baylor College of Medicine, Houston, TX; 2Baylor college of 
medicine, Houston, TX.
Introduction: Calcium channel blockers (CCB) are commonly prescribed anti-
hypertensive agents. CCB’s are highly protein bound in the serum with a large volume 
of distribution and hence not easily dialyzed. Amlodipine, a dihydropyridine CCB, has 
predominant action on the vascular smooth muscle; overdose of Amlodipine can lead to 
circulatory shock and may be fatal. Several management strategies have been employed 
including calcium, insulin and lipid emulsion among others. We describe a case of refractory 
shock due to Amlodipine overdose, unresponsive to calcium/vasopressors/insulin/lipid 
emulsion, but stabilized after a single dose of methylene blue (vascular endothelium NO-
cGMP inhibitor).
Case Description: A 53-year-old obese male with major depressive disorder and prior 
suicide attempts brought to the hospital by emergency services after having consumed 15 
pills of Amlodipine (75 mg), 5 pills of Valproate and 30 pills of Aspirin (~2500 mg). On 
arrival, the patient was awake and alert. Following treatment with activated charcoal, he 
became progressively hypotensive, altered and hypoxemic. He was transferred to the ICU, 
where he was intubated and started on calcium, Dopamine and Norepinephrine infusions, 
followed by high dose Insulin infusion (up to 10 IU per kg per hour). CVVHD was started 
due to oliguric AKI (Cr 1.8) and severe acidosis (pH 7.02 and bicarb of 12). The following 
day, vasodilatory shock worsened requiring 4 vasopressors while receiving 1000 IU/hr of 
Insulin infusion. He was given a single dose of methylene blue, along with calcium chloride 
infusion and a dose of IV Lipid emulsion (aids in the clearance of lipophilic drugs). His mean 
arterial pressure (MAP) stabilized above 70 soon after, and his vasopressor requirement 
decreased. Hospital course was complicated by pulmonary edema and hypoxemia due to 
volume overload, which was successfully managed with CVVHD and ultrafiltration.
Discussion: Summary: Methylene blue (a selective inhibitor of guanylate cyclase, 
a second messenger for nitric oxide–mediated vasodilation) should be considered in the 
management of CCB overdose complicated by shock refractory to therapy with calcium, 
vasopressor and insulin therapy
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Unique Case of Urinoma After Laminectomy Presenting with Elevated 
Serum Creatinine
Pavela Saha,1 Chelsea C. Estrada.2 1Stony Brook University Medical Ctr., Stony 
Brook, NY; 2Stony Brook University Medical Center, Stony Brook, NY.
Introduction: Close to 70% of all ureteral injuries are iatrogenic and occur most 
commonly subsequent to gynecologic or urologic surgeries. Despite the location of the 
ureter just lateral to the transverse processes of the lumbar vertebrae, such injury is rare 
after spinal procedures. If iatrogenic ureteral injury occurs, it usually does not cause acute 
kidney injury (AKI) in patients with normal baseline renal function. We present a unique 
case of iatrogenic urinoma after laminectomy which presented with a sustained elevation 
in serum creatinine.
Case Description: A 64 year old male with Diabetes Mellitus and HTN presented for 
elective L5-S1 laminectomy. On the first post-operative day, patient complained of back 
pain and nausea. Physical exam revealed BP of 118/73 mmHg, heart rate of 95-115 beats/
minute and normal temperature. Chest was clear and there was no edema. Foley catheter 
was in place and draining large amounts of yellow urine. Laboratory data showed serum 
creatinine of 1.5 mg/dL, elevated from pre-operative baseline of 1.0 mg/dl and BUN of 44, 
elevated from 17 pre-operatively. Rest of the laboratory data including serum potassium 
and bicarbonate as well as urinalysis were normal. Rise in serum creatinine was attributed 
to intraoperative hypotension with mean arterial pressures between 50-60 mmHg. Over the 
subsequent week serum creatinine ranged between 1.5 and 1.8 mg/dL and on postoperative 
day eight, patient developed abdominal pain. CT abdomen revealed large left sided 
retroperitoneal collection consistent with urinoma with left sided hydroureteronephrosis. 
He underwent cystoscopy with ureteral stent placement; after which, serum creatinine 
normalized to 0.90 mg/dL. Abdominal pain resolved and patient was discharged with 
urology follow up.
Discussion: Ureteral injury is rare after laminectomy however must be considered in 
the case of sustained increased serum creatinine post-operatively. As AKI subsequent to 
unilateral ureteral injury is uncommon in patients with normal baseline renal function, the 
rise in serum creatinine observed might not reflect a true decline in GFR but rather increased 
reabsorption from urinoma.
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Utility of RRT in Reducing Mortality and Morbidity in a Heart Trans-
plant Recipient with Idiopathic Hyperammonemic Encephalopathy
Muhammad Azhar,1 Sameer Hirji.2 1Brigham and Women’s Hospital, Boston, 
MA; 2Brigham and Women’s Hospital, Boston, MA.
Introduction: Development of Hyperammonemic encephalopathy is extremely rare 
in solid organ transplant recipients. Only 3 such cases have been reported in the literature, 
all due to idiopathic causes [3,4] Since continuous RRT with iHD plays a major role in 
improving ammonia levels, we hypothesized that similar improvements will be observed in 
a heart transplant recipient with HAE.
Case Description: A 44-year old male who was POD3 from a heart transplantation 
for congenital heart disease developed generalized tonic-clonic seizures in the setting of 
hyperammonemia syndrome. MRI showed diffuse cerebral edema while MR Spectroscopy 
showed reduced glutamine synthetase activity, N-acetyl aspartate and myo-inositol levels, 
all of which reflected glial and neuronal dysfunction. All labs were normal except for 
ammonia levels of 1400 umol/L. Liver and renal studies were also unremarkable. The 
patient was promptly started on levetiracetam, sodium benzoate, arginine. The patient’s 
ammonia levels on POD4 still remain elevated (1350 umol/L) but decreased to 900 umol/L 
two days after initiating CVVH with iHD. CRRT was continued for additional 10 days 
along with sodium benzoate, arginine. Within 2 weeks, ammonia levels had completely 
normalized (Table) and while cerebral edema significantly improved on repeat scans, the 
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patient still had cognitive impairment (including impulsivity and memory impairment) 
which was slowly improving.
Discussion: HAE is a rare complication following solid organ and bone marrow 
transplantation, with an estimated risk of 0.5% and very high mortality. [1,3,4]. 
Hyperammonia levels can occur in the setting of cirrhosis, inborn errors of metabolism, 
type 1 RTA, and drugs. Furthermore, metabolic encephalopathy is driven by the effects 
of glutamate on the brain. Extracellular glutamate activates NMDA receptors and leads 
to alterations in nitric oxide metabolism and a shortage of ATP. This causes a cascade of 
events that eventually lead to free radical accumulation and the formation of nitric oxide. 
As a result, astrocyte swelling and disruption of the blood-brain barrier occurs, along with 
cerebral vasodilation due to prostaglandin release which causes loss of autoregulatory 
control in cerebral blood flow and vasogenic edema.
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Double Whammy - IgM Lambda Multiple Myeloma and Normotensive 
ATN Abetting AKI
Joseph Edmund,2 Arun Rajasekaran,1 Zhabiz Solhjou,3 Lazaro Delgado.4 
1University of Central Florida College of Medicine, Kissimmee, FL; 2UCF 
College Of Medicine, Kissimmeee, FL; 3UCF, Orlando, FL; 4Nephrology 
Associates of Central Florida, Orlando, FL.
Introduction: Multiple Myeloma (MM) is a plasma cell disorder characterized by 
the neoplastic proliferation of plasma cells in the bone marrow producing monoclonal 
immunoglobulins. We present a case of IgM light chain lambda predominant MM resulting 
in acute kidney injury (AKI) necessitating long term hemodialysis.
Case Description: A 50 year old male with arterial hypertension and diabetes 
presented with complaints of nausea, vomiting and fatigue. Vitals signs were stable, and 
clinical exam was unremarkable. Labs revealed normocytic anemia with hemoglobin 8 g/dl, 
elevated BUN (78 mg/dl) and creatinine (6.8 mg/dl, baseline 0.9 mg/dl three months back). 
Serum electrolytes, including calcium, magnesium and phosphorus levels were within 
normal limits. UA revealed isosthenuria with increased hyaline casts, and absence of 
hematuria, proteinuria or pyuria. Serum total protein (5.1 mg/dl) and albumin (1.1 mg/dl) 
levels were low. ESR (87 mm/hr.) and serum viscosity levels were markedly elevated. A 
24-hour urine collection revealed proteinuria (848 mg). No osteolytic lesions were noted
in a skeletal survey. Quantitative immunoglobulins were significant for elevated IgM 
levels, with concurrent suppression of IgG and IgA levels. Quantitative serum light chain
measurement revealed elevated levels of lambda (6925 mg/L) and kappa (22.56 mg/L), with 
a Kappa:Lambda ratio of less than 0.01. SPEP, UPEP and serum immunofixation revealed 
IgM-Lambda Myeloma (MM). Renal biopsy was performed - moderate interstitial fibrosis 
and tubular atrophy, diffuse acute tubular injury; numerous large intraluminal casts that
stained strongly against lambda (3+); diffuse GBM thickening with widespread epithelial
foot process effacement was noted. Bone-marrow biopsy with flow cytometry revealed 
intracytoplasmic lambda-restricted monoclonal plasma cells that occupied 80% of the
marrow. He underwent multiple plasma exchanges, and was started on a chemotherapeutic 
regimen consisting of Bortezomib, Cyclophosphamide, and Dexamethasone. His renal
function has not improved, and is dependent on dialysis.
Discussion: Only 10- 20% of all MM are due to light chain disease. Lambda light 
chain disease is extremely rare, and carries a poor prognosis. Despite aggressive plasma 
exchange, dialysis, and chemotherapy, our patient did not attain remission. Further research 
on this rare entity is warranted.
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ACE Levels – An Unreliable Predictor of Disease Activity in Isolated 
Renal Sarcoidosis
Arun Rajasekaran,1 Elpidio Abreu,2 Pran M. Kar.3 1University of Central Florida 
College of Medicine, Kissimmee, FL; 2Nephrology Associates of Central 
Florida, Ocoee, FL; 3VA Medical Center Orlando, Orlando, FL.
Introduction: PTH independent intrarenal calcitriol production by activated 
macrophages in isolated renal sarcoidosis is an extremely rare cause of hypercalcemia. We 
describe hypercalcemia with mildly increased serum ACE levels in a patient with isolated 
renal sarcoidosis.
Case Description: A 63 year old male presented with worsening weakness and 
polyuria. He was mildly hypotensive, and had no lymphadenopathy. Labs revealed 
normal hematological indices, moderate hypercalcemia (13 mg/dl), normal total protein 
and albumin levels, with a preserved hepatic synthetic function. Serum BUN (86 mg/dl) 
and creatinine (6.9 mg/dl, baseline 1 mg/dl) were elevated. UA revealed no proteinuria, 
pyuria, or hematuria. Even after aggressive fluid resuscitation with intravenous crystalloids, 
azotemia persisted with minimal recovery in renal function despite attaining adequate 
diuresis). Further investigations revealed low serum PTH (9 pg/ml) and 25-hydroxy 
Vitamin D (14 ng/ml) levels, and mildly elevated ACE (28 IU/L) and 1,25-dihydroxy 
Vitamin D (38 pg/ml) levels. Serum PTH-related peptide levels were undetectable. SPEP, 
UPEP, serum complements and immunoglobin levels were normal. RF, ANA, ANCA, anti-
dsDNA, anti-MPO, anti-GBM and anti-proteinase-3 antibodies were negative; as were 
serologies for Hepatitis B & C, cryoglobulins, HIV panel, and RPR. Tuberculin skin test, 
and cultures for mycobacterium tuberculosis were negative. Chest and abdomen imaging 
were unremarkable. Renal biopsy demonstrated normal glomeruli with no hypercellularity, 
mesangial proliferation, necrosis or crescents. Numerous tubulointerstitial granulomas 
comprising of noncaseating epithelioid and multinucleated giant cells, surrounded by 
marked infiltration of mononuclear cells were seen. A diagnosis of isolated renal sarcoidosis 
was made. He was started on Prednisone 60 mg/day with subsequent improvement of 
hypercalcemia and renal function.
Discussion: Measurement of serum ACE levels is valuable in diagnosing and following 
disease activity in sarcoidosis. ACE levels in isolated renal sarcoidosis is typically lower 
than that seen in pulmonary sarcoidosis, likely secondary to reduced numbers of ACE-
producing epitheloid cells isolated to the kidney. We illustrate that ACE level elevations 
may not be a dependable parameter in the diagnosis or evaluation of sarcoid disease activity 
in those with isolated renal sarcoidosis.
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Isolated Renal Sarcoidosis Presenting with Granulomatous Interstitial 
Nephritis
Arun Rajasekaran,1 Elpidio Abreu,2 Pran M. Kar.3 1University of Central Florida 
College of Medicine, Kissimmee, FL; 2Nephrology Associates of Central 
Florida, Ocoee, FL; 3VA Medical Center Orlando, Orlando, FL.
Introduction: Sarcoidosis is a chronic, inflammatory disorder that affects multiple 
organs, characterized by noncaseating epithelioid granuloma formation. However, 
granulomatous interstitial nephritis in the absence of extrarenal sarcoidosis is extremely rare.
Case Description: A 59 year old black male with no significant past medical history 
presented with acute kidney injury (AKI). Vital signs were stable on admission, and no 
lymphadenopathy was noted. Labs revealed normal hematological indices, electrolyte 
levels (including calcium, magnesium and phosphorus levels), total protein and albumin 
levels, with a preserved hepatic synthetic function. Serum BUN (78 mg/dl) and creatinine 
(7.6 mg/dl, baseline 1.1 mg/dl) were elevated. PTH (7 pg/ml) and 25-hydroxy Vitamin D 
(15 ng/ml) levels were suppressed, while Angiotensin Converting Enzyme (69 IU/L) and 
1,25-dihydroxy Vitamin D (42 pg/ml) levels were significantly elevated. Serum PTH-related 
peptide levels were undetectable. Urinalysis revealed no proteinuria, pyuria, or hematuria. 
ESR was elevated at 80 mm/hr. SPEP, UPEP, serum complements and immunoglobin levels 
were normal. RF, ANA, ANCA, anti-dsDNA, anti-MPO, anti-GBM and anti-proteinase-3 
antibodies were negative. Serologies for Hepatitis B & C, cryoglobulins, HIV panel, 
and RPR testing were negative. Tuberculin skin test, and cultures for mycobacterium 
tuberculosis and systemic fungi were negative. CT chest-abdomen-pelvis, renal ultrasound, 
and pulmonary function tests were unremarkable. Despite aggressive intravenous crystalloid 
resuscitation, renal function did not significantly improve. Early renal biopsy demonstrated 
normal glomeruli with no mesangial proliferation, capillary wall abnormalities, or 
crescents. Numerous tubulointerstitial granulomas comprising of noncaseating epithelioid 
and multinucleated giant cells, surrounded by marked infiltration of mononuclear cells were 
seen. Based on laboratory and renal biopsy findings, a diagnosis of isolated renal sarcoid 
GIN was made. He was started on Prednisone 40 mg/day and renal function normalized to 
baseline within a month.
Discussion: Isolated renal sarcoidosis is extremely rare and is seen in elderly males 
unlike systemic sarcoidosis. Our patient did not have hypercalcemia that is frequently 
associated with this entity. Early diagnosis and prompt steroid therapy lead to normalization 
of kidney function.
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From Heart Failure to Light Chain Deposition Disease and Cast 
Nephropathy in Multiple Myeloma
Sana J. Shaikh,3 Christian C. Nwankwo,1 Alexandre Lacasse,3 Steven C. Cheng.2 
1Nephrology, SSM St. Mary’s Hospital - St. Louis, St. Louis, MO; 2Nephrology, 
Washington University School of Medicine, St. Louis, MO; 3Internal Medicine, 
SSM St. Mary’s Hospital - St. Louis, St. Louis, MO.
Introduction: Light chain deposition contributes to renal failure in multiple myeloma 
(MM) via 3 main patterns of injury: cast nephropathy (CN), MIDD with light chain
deposition disease (LCDD) being a variant, and amyloidosis.
Case Description: 64-year-old man with HFpEF and CKD-3 presented with leg 
swelling and weight gain. Jugular venous distention and bilateral pitting pedal edema 
were noted. Labs included creatinine of 5 mg/dl (baseline 1.4), proteinuria, hematuria, 
glycosuria, raised BNP and anemia of chronic disease. On ultrasound, both kidneys were 
16 cm in size. Admission diagnosis was acute cor pulmonale. Further workup revealed 
abnormal restricted peak in the gamma region on SPEP, elevated κ-FLC and κ- to λ-FLC 
ratio, and IgG κ monoclonal protein on immunofixation. Renal biopsy detected LCDD-CN 
and bone marrow analysis confirmed MM.
Discussion: Alternative diagnosis was pursued due to nephrotic-range proteinuria, 
normoglycemic glycosuria and enlarged kidneys, and MM was diagnosed without 
albuminocytologic dissociation, hypercalcemia or bony lytic lesions. LCDD-CN is rare and 
requires detailed microscopy. In contrast to pure LCDD or MIDD, mean age and incidence 
of AKI and dialysis are higher. Treatment is the same as that of MM and goals include 
improvement of renal function and prevention of extrarenal deposits.
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Literature review of LCDD-CN
CN - cast nephropathy, CR - case report, EDD - electron-dense deposits, EM - electron 
microscopy, IF - immunofluorescence, LC - light chain, LCDD - light chain deposition 
disease, LM - light microscopy, MIDD - monoclonal immunoglobulin deposition disease, 
MM - multiple myeloma, NGS - nodular glomerulosclerosis, κ - kappa, λ - lambda
LCDD-CN on renal biopsy
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TMA in Antisynthetase Syndrome
Raad B. Chowdhury,1 Christopher Valentine.2 1Internal Medicine, Ohiohealth: 
Riverside Methodist Hospital, Columbus, OH; 2Riverside Nephrology 
Associates, Columbus, OH.
Introduction: Thrombotic Microangiopathy (TMA) is a syndrome characterized by 
microangiopathic hemolysis, thrombocytopenia, and kidney injury. Primary causes include 
Thrombotic Thrombocytopenic Purpura or complement mutations. Secondary causes are 
due to autoimmune diseases, malignancy, and transplantation. Overall, autoimmune disease 
causing TMA is extremely rare. A study from Taiwan retrospectively reviewed 2461 cases 
of SLE in a 10-year span and reported only 25 cases of TMA. This abstract presents a 
case of an autoimmune phenomenon, Antisynthetase syndrome, causing TMA. As per our 
literature review, one case of TMA was reported in a patient with Polymyositis. In that case 
however, the patient also had underlying RA and was on a calcineurin inhibitor which may 
predispose to TMA.
Case Description: A 64-year-old female with recently diagnosed polymyositis and 
pulmonary embolism presented for worsening dyspnea. In a prior admission, she presented 
with arthritis and soft tissue edema. Serology showed elevated JO-1, aldolase, and CPK at 
the time. Computed tomography of the lungs showed diffuse pneumonitis, due to interstitial 
lung disease attributed to her autoimmune disease. Her overall presentation and imaging 
was suggestive of antisynthetase syndrome. During the current admission, her dyspnea was 
worsening and she had new onset kidney injury. Urinalysis was remarkable for protein and 
hematuria and she subsequently developed hemolytic anemia and thrombocytopenia. Due 
to her unexplained proteinuria, renal biopsy was performed revealing thrombi in glomerular 
capillaries and arterioles, suggestive of TMA. Primary causes of TMA such as TTP, HUS, 
and drug induced TMA were ruled out. Secondary causes such as malignancy were ruled 
out with additional CT of abdomen and pelvis. Other secondary autoimmune disorders were 
ruled out serologically. The only positive test was the >100 JO-1 antibody titers on ENA.
Discussion: TMA is an often fatal disease process. It has been reported in the context 
of HUS, TTP, autoimmune diseases and malignancy. This case is extremely novel in that the 
patient met criteria for antisynthetase syndrome by having both autoimmune polymoysitis 
and interstitial lung disease. Subsequently she developed AKI with biopsy proven TMA. Of 
note, patient’s symptoms and renal function improved following treatment with prednisone. 
Having ruled out most, if not all causes of TMA, the only culprit was the antisynthetase 
syndrome.
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A Catastrophic Sequela of Cryoglobulinemia: Was Bedside Ultrasound 
Useful?
Christian Castillo latorre,1 Luis O. Gerena Montano,1 Roberto Borrero-Lugo.2 
1San Juan City Hospital, San juan, PR; 2Hospital Municipal de San Juan, 
Carolina, PR.
Introduction: Intravenous drug usage has a strong correlation with renal failure, as well 
with chronic viral infections Hepatitis C and HIV respectively. With this risk factors other 
complications had been describes such as cryoglobulinemia, rhabdomyolysis, disseminated 
intravascular coagulation (DIC) that in cases could developed Purpura Fulminans as a 
deadly complication. Several factors had been implicated with renal function deterioration, 
and one of them is deposition of immune complexes as in cryoglobulinemia. This systemic 
disease could give rise to distinct clinical manifestations such as hyperviscosity syndrome 
that could be evidenced by sonography at initial presentation. Hyperpigmented lesions due 
to direct damage and diffuse anasarca, are early signs of deteriorated renal function. Skin 
changes could present as well with catastrophic limb gangrene. Here we report a rare case 
of hepatitis C with HIV related cryoglobulinemia which presented with generalized seizures 
de novo, rhabdomyolisis, rapidly progressing renal failure, disseminated intravascular 
coagulation, and purpura fulminant.
Case Description: Case of a 37 year old male with history of intravenous drug usage 
that presented to the emergency department after having a seizure event in the streets. He 
developed acute respiratory failure requiring mechanical ventilation within next few hours. 
Over a period of 24 hours severe renal failure developed, with mucosal bleeding as well 
bleeding from intravenous sites with bilateral acrocyanosis with pregangrenous changes. 
During this course, HIV came positive as well Hepatitis C infection.
Discussion: Based on the clinical picture with lab evidence of positive cryoglobulins 
and association of HCV, we made the diagnosis of HCV related mixed cryoglobulinemia 
with multi organ failure, glomerulosclerosis, vasculitis in the form of purpura and symmetric 
distal gangrene of limbs and nose, consistent with Purpura Fulminans. At intial evalaution 
patient had a bedside echocardiogram, that was relevant for severe hyperviscosity of blood, 
that is a clinical characteristic othat can be found in cryoglubulinemia. This early sign gave 
us a clue about patients underlying condition causing this catastrophic presentation, that was 
later comfirmed with laboratory results. Cryoglobulinemia is a catastrophic event associated 
with hepatitis C and HIV, early recognition is key.
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Close Encounters of the Peritoneal Kind: Case Series of Uroperitoneum 
and Renal Pseudofailure
Sam Kant,1 Derek M. Fine.2 1University of Maryland Medical Center, Baltimore, 
MD; 2Johns Hopkins University School of Medicine, Baltimore, MD.
Introduction: Uroperitoneum, usually a consequence of bladder rupture, can occur 
after blunt trauma and surgical procedures or in association with pelvic irradiation, alcohol 
abuse and bladder anatomic abnormalities. As a result of exchange of solutes across the 
peritoneal membrane- a reverse autodialysis- an electrolyte milieu mimicking AKI can 
result
Case Description: Case 1: 74 year old male, day 10 status post robotic assisted radical 
prostatectomy for prostate cancer presented with increasing abdominal distension. These 
symptoms progressively worsened since removal of urinary catheter 4 days earlier. He 
had gross abdominal distension on exam. Labs showed Na 132, K 6.3, Bicarbonate 19, 
Urea 64 and Creatinine 9.7 mg/dL. Peritoneal fluid creatinine was 9.4 mg/dL. CT abdomen 
revealed gross ascites continuous with focal fluid at the surgical bed concerning for leak. 
Subsequent insertion of urinary catheter led to normalization of metabolic disarray in 24 
hours Case 2: 32 year old female para 0, 40 weeks pregnant, presented to obstetric unit with 
reduced fetal movements. Induction was commenced and converted to a cesarean section 
2 days later due to failure of descent. On postoperative day 4, patient was noted to have 
progressively increasing abdominal distension with labs: Na 134, K 3.8, Urea 13, Creatinine 
2.4. Peritoneal fluid revealed creatinine of 8.4. A CT abdomen showed evidence of bladder 
leak and gross ascites. Insertion of urinary catheter led to normalization of creatinine next 
day Case 3: 37 year old male, with a history of alcohol abuse, presented with increasing 
abdominal pain and vomiting for 1 week. Labs revealed Na-120, K 6.2, Bicarbonate 
20, Urea 151 and creatinine 11.8. Presence of gross ascites on CT led to large volume 
paracentesis, with subsequent reaccumulation in 8 hours. In light of the same and history 
of recent fall, a suspicion for bladder rupture was confirmed via cystogram. Insertion of 
urinary catheter led to correction of renal indices in 24 hours
Discussion: These cases underscore that in the presence of inciting event (trauma/
surgery), unexplained ascites, classic electrolyte abnormalities(particularly hyponatremia) 
and urine:serum creatinine ratio of >1 – uroperitoneum should be suspected. The ensuing 
elevated creatinine is a consequence of reversed intraperitoneal autodialysis and does not 
represent a renal injury, thus termed renal pseudofailure
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Rare Spontaneous Renal Infarction of Unknown Etiology
Ifedolapo O. Odebunmi, Eric Y. Chang, Taiwo A. Ajose, Anam Umar, 
Khalid Bashir. Morehouse School of Medicine, Atlanta, GA.
Introduction: Spontaneous renal infarction is rare, especially in the absence 
of thromboembolism secondary to atrial fibrillation. Other potential causes include 
hypercoagulable states, infective endocarditis, previous endovascular intervention, renal 
artery dissection, and oral contraceptive use. We report a rare case of spontaneous renal 
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infarct in a patient with no known risk factors presenting with abdominal pain mimicking a 
previous endometriosis flare.
Case Description: A 36 y/o African American female with a history of hypertension, 
possible congenital right renal atrophy, and endometriosis presented with a two-day history 
of severe left flank and abdominal pain like her prior endometriosis flares. On physical 
examination, her systolic blood pressure was 160mmHg and she was in significant distress. 
However, her exam was negative for peritoneal signs or costovertebral angle tenderness. 
Initial blood work up and urinalysis was unremarkable. Urine pregnancy test was negative. 
EKG revealed normal sinus rhythm. CT abdomen/pelvis without intravenous contrast was 
negative for obstructive uropathy but revealed an enlarged left kidney and an atrophic 
right kidney. MRA of the abdomen/pelvis revealed a previously unknown lower pole 
infarct in the left kidney without any significant infrarenal atherosclerosis, or aneurysms. 
Renal ultrasound was significant for an atrophic right kidney (3.3 cm) and an enlarged left 
kidney (13.5 cm) with decreased echogenicity of the lower pole consistent with known 
infarction. Left renal artery duplex scan was negative for significant renal artery stenosis. 
Hypercoagulable and venous thromboembolic work up was negative. Patient was medically 
managed and discharged home without chronic anticoagulation after symptomatic 
improvement.
Discussion: Spontaneous renal infarction is rare in the absence of predisposing risk 
factors such as thromboembolic disorders or hypercoagulable states. Due to non-specific 
manifestations, diagnosing renal infarction is a challenge and may lead to delayed diagnosis 
and intervention. Physicians must maintain a high index of suspicion so that timely 
interventions can be performed to properly assess and maintain kidney function
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AKI Associated with Acinar Cell Pancreatic Cancer
Kevin D. Marquez,1 Kuang-Yu Jen,3 Brian Y. Young.2 1University of California 
Davis School of Medicine, Sacramento, CA; 2UC Davis Medical Center, 
Sacramento, CA; 3University of California, Davis, Sacramento, CA.
Introduction: The kidney plays a large role in the elimination of pancreatic enzymes 
from the circulation. Acinar cell carcinomas are rare pancreatic cancers associated with 
lipase hypersecretion. We present a patient with metastatic pancreatic cancer with recurrent 
acute kidney injury potentially linked to her acinar subtype.
Case Description: A 49 year-old woman was diagnosed with acinar cell cancer and 
underwent chemotherapy with gemcitabine and abraxane for biopsy-proven metastatic 
disease with symptomatic ascites. One week after initiating chemotherapy, she developed 
painful raised bumps on both of her legs. She was hospitalized twice over two months for IV 
antibiotics for presumed cellulitis. Nephrology was consulted for worsening renal function 
as her creatinine steadily rose from 1.3 to 2.4 mg/dl. She had 2.8 grams of proteinuria, 
which was largely tubular, with only 2% of the total being albumin. Urine microscopy 
showed abundant coarse granular casts and no dysmorphics RBCs. Serologic workup 
showed no paraproteins, normal complement, and negative screens for hepatitis, ANA, 
ANCA, and GBM antibodies. Renal imaging showed no evidence of obstruction. A kidney 
biopsy was performed which showed ATN without any evidence of TMA or GN. Clear 
cause for ATN could not be identified; there were no hypotensive or nephrotoxic exposures. 
Without other exposures, she continued to have a rising creatinine to greater than 5 mg/dl 
along with worsening leg lesions. Another kidney biopsy 5 weeks after her initial one found 
only progressive ATN. Dermatology skin biopsy of the leg showed necrosis of adipocytes 
compatible with pancreatic panniculitis. Her serum lipase was 810 U/L (high) with normal 
serum amylase. She had no symptoms of pancreatitis. A urine lipase was checked and was 
markedly elevated at 1,112 U/L (Normal < 4).
Discussion: We present a patient with ATN who has acinar cell pancreatic cancer and 
pancreatic panniculitis. Studies have implicated lipase as pathogenic in panniculitis by its 
identification in areas of subcutaneous necrosis. 20% of pancreatic enzymes are excreted 
by the kidneys, with animal studies showing that lipase undergoes filtration, tubular 
reabsorption, and subsequent intrarenal degradation. We propose a potential novel cause of 
ATN due to supraphysiologic levels of serum and urinary lipase that should be investigated, 
similar to that of pancreatic panniculitis.
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Massive Creatinine Increase in the Setting of Protein Malnutrition
Stephanie Colon Lopez, Ileana E. Ocasio Melendez, Fatima B. Cintron-Rosa, 
Krystahl Z. Andujar, Carlos G. Rivera-Bermudez. Nephrology, University of 
Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico.
Introduction: Serum creatinine (SCr) is a marker of kidney function and its elevation 
is usually associated with a concomitant rise in the blood urea nitrogen (BUN). An isolated 
rise in SCr has been described with the use of drugs that decrease the secretion of creatinine, 
with increased muscle mass and interference with its assay. We present the case of a patient 
with ulcerative colitis (UC) and acute kidney injury (AKI) characterized by an isolated rise 
in SCr.
Case Description: A 63-year-old man with UC on chronic prednisone and a previous 
colectomy was admitted to surgery ward after an ileal pouch-anal anastomosis (IPAA) with 
upstream ileostomy. After IPAA was performed, vancomycin and piperacillin-tazobactam 
were started for recorded episodes of fever. He was consulted to Nephrology service due to 
AKI. On evaluation, the patient was hypotensive, tachycardic, with high ileostomy output 
and decreased urine output. No skin rash was noted. Laboratories showed an elevation in 
SCr to 6.18 mg/dL from 1.3 mg/dL with associated metabolic acidosis without increase 
in BUN, electrolyte disturbances or eosinophilia. Albumin levels were 2.8 g/dl. Urine 
sediment was bland. He had no medications that could alter the secretion of creatinine. 
Due to signs of volume depletion, he was repleted with intravenous (IV) isotonic saline. 
SCr continued to rise to 9.44 mg/dL and since he was hemodynamically stable, IV fluids 
were changed to 0.45% NSS to replace ileostomy losses. Loperamide was added to achieve 
a solid consistency of ileostomy output. Imaging revealed fluid collections adjacent to 
IPAA, which identified an infectious focus. Vancomycin and piperacillin-tazobactam were 
discontinued and meropenem was started. SCr continued to increase up to 13.65 mg/dL 
while BUN remained at 35 mg/dL without hypervolemia or other electrolyte disturbances, 
hence dialysis was not considered. SCr levels returned to baseline three weeks later.
Discussion: Reduced muscle mass in patients with UC is associated with inflammation 
and glucocorticoid treatment. In this setting, BUN is expected to increase at least 
proportionally to SCr. In our patient, hypovolemia was not associated to an elevated BUN; 
and despite correction, SCr continued to rise. Severe and prolonged protein malnutrition 
may explain this unusual presentation.
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A Rare Presentation of Cocaine Induced Kidney Injury
Ifedolapo O. Odebunmi, Titilope Olanipekun, Nnamdi K. Nwaohiri. Morehouse 
School of Medicine, Atlanta, GA.
Introduction: An estimated 1 out of every 20 young adults in the US abuse cocaine. 
Case reports have described cocaine related renal impairment manifesting as acute tubular 
necrosis (ATN), infarction, pigment induced kidney injury and acute interstitial nephritis 
(AIN). However, hematuria in the setting of cocaine use without evidence of commonly 
seen cocaine induced renal pathologies has rarely been reported.
Case Description: A 29-year-old female with a medical history of hypertension, 
cocaine abuse, chronic hepatitis C virus infection and cryoglobulinemic vasculitis 
(diagnosed 2 weeks prior) was admitted for right lower extremity cellulitis. She was 
noted to have 1-week history of bloody urine necessitating nephrology team evaluation. 
She admitted to IV cocaine use few days before presentation. She had mildly elevated 
blood pressure - 158/69 mm/hg and the rest of her physical exam was unremarkable. 
Laboratory blood investigations revealed elevated serum creatinine - 3.1 mg/dl and low 
hemoglobin - 8.6g/dl. Her urinalysis revealed 3+ hemoglobin and 1+ protein. UDS was 
positive for benzodiazepines and cocaine. Other pertinent lab work up including creatine 
phosphokinase, urine chemistry and eosinophils, HIV and hepatitis B virus tests and 
serology for autoimmune disorders was negative. Renal ultrasound scan showed normal 
kidney size without hydronephrosis or stones. Renal biopsy revealed tubular lumen filled 
with red blood cells (RBC) and casts with no evidence of fibrosis, sclerosis or tubular 
atrophy. She was managed supportively with IV normal saline, antibiotics for cellulitis and 
her outpatient prednisone treatment. Her hematuria resolved, and serum creatinine level 
improved to her baseline (1.0 mg/dl). She was counseled on cocaine use.
Discussion: Cocaine causes kidney injury by different mechanisms; ATN 
and renal infarction through severe vasoconstriction and rhabdomyolysis and AIN 
through idiosyncratic allergic response. Also, chronic cocaine use has been linked to 
glomerulopathies. Our patient had cocaine related renal injury with RBCs and RBC casts 
in the tubular lumen without findings to suggest renal abnormalities frequently associated 
with cocaine abuse and toxicity. This is quite unusual and to our knowledge, has not been 
reported in the literature. Nephrologists and clinicians should be aware of the various renal 
manifestations of cocaine use.
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Suspected Pyelovenous Backflow Causing Acute Anuric Renal Failure 
(ARF)
Pace Romney,1 Kalani L. Raphael,2 Aylin R. Rodan,3 Martin C. Gregory.1,2 
1University of Utah Medical Center, Salt Lake City, UT; 2VA Salt Lake City 
Health Care System, Salt Lake City, UT; 3University of Utah, Salt Lake City, UT.
Introduction: The following is a case of ARF requiring dialysis in a man with normal 
cystatin C and β-2 microglobulin (B2M) levels without evidence of urine leak on imaging.
Case Description: A 72 year-old-man with normal renal function and solitary left 
kidney after donor nephrectomy 30 years ago underwent prostatectomy for prostate cancer. 
Surgery was uneventful with EBL 800 mL and intraop SBP remaining over 60. A routine 
abdominal drain was placed. The patient said he felt well after the surgery, however urine 
output diminished and he became anuric and creatinine (Cr) increased in the following days. 
IV fluids had no effect. There was no evidence of hydronephrosis, urine retention, or intra-
abdominal fluid collection on CT or US. Urine microscopy showed RBCs without casts. 
Fluid from the abdominal drain had Cr levels similar to serum. Serum Cr steadily climbed 
and hemodialysis was initiated on post op day 6 for hyperkalemia. Cystatin C was 1.0 mg/L 
with a simultaneous Cr of 10.2 mg/dL and two days later B2M was 2.3 mg/dL with Cr 
7.8 mg/L. MAG3 renal flow scan showed normal renal perfusion with concentrated tracer 
in the renal pelvis but not in the ureter and no evidence of urine leak. 2 weeks after the 
onset of ARF, urine output spontaneously increased and creatinine fell. He was discharged 
without further dialysis.
Discussion: Although our uninephric patient had ARF, he had normal glomerular 
filtration as shown by normal cystatin C, B2M, and MAG3 scan. The scan confirmed that 
freshly-formed urine was reaching the pelvis but not transiting the ureter. There was no 
evidence of extravasation on MAG3 scan or by analysis of drain fluid. Urine left the renal 
pelvis by another route: renal veins or renal lymphatics. Most likely postop edema and acute 
UV junction obstruction caused forniceal rupture and pyelovenous reflux into the arcuate 
veins. A less likely possibility is pyelolymphatic reflux. Had he been binephric, renal failure 
would likely have passed unnoticed.
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Bilirubin Cast Nephropathy Diagnosed by “Liquid Biopsy”
Eduardo Del Orbe, Melissa C. Fajardo, Jeffrey D. Wallach, Sudhanshu Jain. 
Harlem Hospital, Forest Hills, NY.
Introduction: AKI can occur in liver disease through numerous mechanisms; one of 
them is bilirubin cast nephropathy. Most cases have been diagnosed with kidney biopsy. We 
present a case of bilirubin cast nephropathy, diagnosed by urine microscopy, in a patient 
with obstructive cholestasis.
Case Description: A 59 year old woman with past medical history of morbid obesity, 
type 2 DM, HTN, and CAD was hospitalized for progressive weight loss, nausea, vomiting, 
itching, and yellow skin. Her vital signs were stable. Physical exam was significant for 
icteric sclera, jaundice, and scattered excoriations of skin. No ascites or abdominal pain 
was present. Baseline liver and renal function were both normal. Investigations were 
remarkable for serum creatinine of 4.7 mg/dL, which later peaked at 8.1 mg/dL. Hepatic 
panel was significant for total bilirubin of 18.8 mg/dL with direct bilirubin of 14.8 mg/dL, 
alkaline phosphatase was 568 U/L, ALT was 66 U/L, and AST was 88 U/L, suggesting 
cholestasis. UPCR was 1.0 g/g. Urine microscopy showed bilirubin-stained granular casts. 
Abdominal imaging showed cholelithiasis, dilated common bile duct, with normal kidneys 
and liver. Kidney biopsy was held due to possible renal recovery from planned intervention 
with ERCP. During ERCP periampullary tumor was found, and CBD stent was placed. 
Creatinine improved to 2.2 mg/dL afterwards with simultaneous improvement in bilirubin 
levels. Seven weeks after ERCP with CBD stent placement, creatinine and total bilirubin 
had returned to baseline.
Discussion: Cases of bilirubin cast nephropathy in the setting of obstructive cholestasis 
have been underreported. Most reported cases have been diagnosed with kidney biopsy. 
However, in our case this was a patient with obstructive jaundice, renal failure, and 
bilirubin-stained granular casts on urine microscopy who then underwent ERCP with CBD 
stent placement to relieve obstruction, and then had a subsequent improvement in her 
renal failure. Kidney biopsy was never performed, and may not be necessary to establish a 
clinical diagnosis of bilirubin cast nephropathy.
PUB500 
Publication-Only 
Role of Eculizumab in Dialysis Dependent AKI Secondary to Atypical 
Hemolytic Uremic Syndrome
Katherine R. Robinson,1 Kayla Shirley,1 Fadee Abu Al Rub,1 Claude Bassil,1 
Liying Fu.2 1University of South Florida, Lutz, FL; 2Tampa General Hospital, 
Tampa, FL.
Introduction: Thrombotic microangiopathies represent 3 syndromes: hemolytic 
uremic syndrome (HUS), thrombotic thrombocytopenic purpura, and atypical HUS 
(aHUS). While microvessel wall thickening and intraluminal thrombosis characterizes the 
pathology, the pathogenesis and prognosis for each disorder is variable. HUS is defined by 
a triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia and AKI. aHUS 
is then divided into two groups, typical (diarrheal) and atypical (non-diarrheal) HUS.
Case Description: A 65-year-old female with HTN, MDS and MGUS, presented to the 
ED with fatigue. Refer to Table 1 for lab findings. For the past 6 months, serial peripheral 
smears demonstrated increasing number of schistocytes. Renal ultrasound ruled out 
obstruction. Urine studies showed microscopic hematuria and 24h urine protein of 1.1g. As 
testing ruled out disseminated intravascular coagulation and suggested MAHA, therapeutic 
plasma exchange was given empirically until ADAMTS13 activity returned normal. 
Hemodialysis (HD) was then started for volume overload. Renal biopsy showed acute and 
severe chronic thrombotic microangiopathy-type injury, acute tubular necrosis and focal 
tubulointerstitial nephritis. Given lack of prodromal diarrhea, aHUS was diagnosed and 
she received corticosteroids followed by eculizumab. Her renal function and platelet counts 
recovered requiring 6 weeks of HD although she will require lifelong eculizumab therapy. 
Genetic testing for abnormal complement factors is pending.
Discussion: aHUS is an uncommon type of microangiopathy with incidence of 1 per 
million. Dysregulation of complement activation in the alternate pathway secondary to 
abnormal complement factors, with subsequent endothelial injury, typifies the pathogenesis 
of aHUS. As more genetic mutations are recognized it is becoming an increasingly 
understood clinical entity. Previously, standard first-line therapy consisted of plasma 
exchange followed by immunosuppression. The monoclonal antibody eculizumab has 
gained popularity in aHUS treatment by binding complement C5. Although eculizumab 
has been used more often for aHUS our case reflects the efficacy of this agent in a dialysis 
dependent patient if started immediately after the diagnosis has been made.
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Role of Steroids in Relapsing Light Chain Myeloma Patient with Dialysis 
Dependent Acute Renal Failure and Interstitial Nephritis
Katherine R. Robinson,1 Gautam krishna Koipallil,3 Onyekachi C. Obi,1 
Claude Bassil,1 Liying Fu.2 1University of South Florida, Lutz, FL; 2Tampa 
General Hospital, Tampa, FL; 3University of South Florida Morsani College of 
Medicine, Tampa, FL.
Introduction: Cast nephropathy and hypercalcemia are the major contributors to 
renal failure in multiple myeloma patients (MM). Casts result when large amounts of free 
light chain (FLC) interact with Tamm-Horsfall protein in the urine, blocking glomerular 
outflow. Conversely, acute interstitial nephritis (AIN) is a rare manifestation of acute kidney 
injury (AKI) in MM patients. To our knowledge, there are few cases of a MM patient with 
concomitant cast nephropathy and AIN - here we present one such rare case. Our patient 
AKI response to steroids highlights the possibility of multiple etiologies for renal failure 
in MM, and the importance of thorough patient history, workup, and kidney biopsy when 
caring for these patients.
Case Description: A 61-year-old male with past medical history of IgG kappa MM 
(relapsed on multiple lines of treatment, most recently Revlimid, not currently on therapy) 
presented with fevers, generalized fatigue and confusion. He was found to be in acute 
renal failure (ARF) with an admission creatinine of 4.4 mg/dL, peaking at 6.3 mg/dL. He 
was empirically given antibiotics, despite negative infectious workup. Urinalysis showed 
moderate hemoglobin and eosinophil presence. Kappa FLC and kappa:lambda ratio was 
elevated (1419 mg/L; ratio 61) but had been higher previously (1480 mg/L; ratio 167). 
Renal ultrasound had no acute findings. His creatinine remained greater than 5 mg/dL 
without signs of improvement, until he eventually required hemodialysis (HD). Kidney 
biopsy was pursued; pathology confirmed cast nephropathy with concomitant AIN. As a 
result of biopsy findings, he was placed on a prednisone taper starting with 60mg QD. 
He required HD for 6 weeks, but kidney function improved, and his creatinine has since 
remained 2-3 mg/dL.
Discussion: This case allows us to witness an alternate origin of renal failure in 
multiple myeloma, in contrast to the classic cast nephropathy. Rapid improvement with 
steroids reveals AIN as the underlying cause of his renal failure. Without kidney biopsy 
and diagnosis of AIN, further MM treatment may not have successfully recovered kidney 
function. Thorough patient history, workup, and kidney biopsy are crucial to prevent 
oversight of the possible alternate sources of renal failure in MM.
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Publication-Only 
A Case of AKI by an Unusual Cause of Rhabdomyolysis
Luis O. Gerena Montano, Christian Castillo latorre. San Juan City Hospital, San 
Juan, PR.
Introduction: Rhabdomyolysis is a syndrome characterized by muscle necrosis and 
the release of intracellular muscle constituents into the circulation. Creatine phosphokinase 
(CPK) levels are typically markedly elevated, muscle pain and myoglobinuria may be 
present. The severity of illness ranges from asymptomatic elevations in serum muscle 
enzymes to life-threatening disease characterized by extreme enzyme elevations, electrolyte 
imbalances, and acute kidney injury (AKI). AKI is an abrupt and usually reversible decline 
in the glomerular filtration rate (GFR). This results in an elevation of serum blood urea 
nitrogen (BUN), creatinine, and other metabolic waste products that are normally excreted 
by the kidney.
Case Description: We present the case of a 29 year old man with no past medical history 
that came to our urgency room complaining of muscle pain, malaise and gross hematuria. 
Pain was more prominent in proximal muscle of upper and lower extremities, cramping, 
7/10 in intensity, not radiating, aggravated by movement and affects ambulation due to 
pain, of 3 days of evolution. Denied any recent medications, toxic habits, fever, nausea, 
vomiting, diarrhea, chills, seizures, SOB, cough, chest pain, recent travel, sick contacts, 
sore throat, rhinorrhea, animal contact. He started a new job that demands more physical 
activity than his usual and have to be prolonged time standing up. He remembers a similar 
episode when he was 13 year old. Work-up was done at the time as an inpatient elsewhere 
including muscle biopsy but he doesn’t remember any diagnosis. Now initial pertinent 
laboratory work-up results showed a very high CPK levels, myoglobinuria and GFR of 
40 mL/minutes. After history, physical examination and studies a metabolic myopathy was 
very high in the differential diagnosis. After muscle biopsy and genetic testing were done 
the diagnosis of McArdle’s disease was confirmed.
Discussion: McArdle’s disease is a glycogen storage disease affecting the muscle due 
to muscle phosphorylase deficiency affecting 1:167,000 of the population. It is a type of 
metabolic myopathy that may cause rhabdomyolysis. Metabolic myopathies represent a 
very small percentage of cases of rhabdomyolysis with consequent myoglobinuria in which 
AKI could develop. We as physicians have to be aware about these uncommon conditions 
that may cause recurrent rhabdomyolysis and therefore recurrent AKI.
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Cytomegalovirus PCR Levels and Collapsing Glomerulopathy
Ifeoma Okadigbo, John W. O’Bell, Basma O. Merhi. Brown Nephrology, Port 
Jefferson, NY.
Introduction: Collapsing glomerulopathy is a form of focal and segmental 
glomerulosclerosis (FSGS) which leads to very severe nephrotic syndrome and quickly 
progresses to end-stage renal disease is usually associated with HIV. We present a case of 
collapsing glomerulopathy most likely caused by Cytomegalovirus (CMV) as patient had 
renal function return to baseline during valganciclovir therapy.
Case Description: 21 yo healthy Hispanic patient presented with nausea, headache, 
myalgia and 8lbs weight gain and noted to have acute kidney injury with serum creatinine of 
1.5 mg/dl. Urinalysis revealed 1+ blood and > 500 protein with numerous nondysmorphic 
RBCs on urine sediment and urine protein/ creatinine ratio of 12.66g/g. CBC showed WBC 
12, 14% bands, 15% atypicals, ALT 181 and AST 156. Serologies including complements 
C3/C4, ANA, anti-DS DNA, HIV, Hepatitis B and C and EBV PCR viracor were negative. 
CMV PCR viracor was 9,000. Renal ultrasound showed right kidney at 12.5 cm and the 
left at 12.3 cm. Ct scan abd/pelvis revealed splenomegaly with spleen at 20.1 cm. Kidney 
biopsy was consistent with collapsing glomerulopathy with moderate to severe interstitial 
inflammation and negative staining to CMV DNA. He was treated with valganciclovir 900 
mg daily, prednisone 60 mg daily and tacrolimus. After 21 days of treatment, CMV PCR 
viracor was undectected with marked improvement of proteinuria to 0.97 g/g. Prednisone 
has been tapered down, and tacrolimus was stopped and patient still demonstrated improved 
serum creatinine a month after undectable CMV PCR viracor.
Discussion: This case describes a patient who was started on valganciclovir which 
resulted in normalization of serum creatinine. He was also started on tacrolimus and 
prednisone in addition to the valganciclovir as recommended treatment plan for collapsing 
FSGS. CMV was more probable cause as there was a correlation with decreased CMV 
viracor levels and improved serum creatinine even when patient was off tacrolimus. It is 
still not clearly understood what the proposed mechanism for CMV induced FSGS. The 
lesion has been proposed to be related to podocyte injury and attachment upon a size from 
the glomerular basement membrane. This case presented demonstrated rapid improvement 
in renal function with valcyte administration and decreased CMV PCR viracor levels.
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Chronic Interstitial Nephritis Associated with e-Cigarette Cannabinoid 
Consumption
Emmanuel I. Bahamonde. Cleveland Clinic Florida, Coral Springs, FL.
Introduction: Synthetic cannabinoids (SCBs) are psychoactive designer drugs that 
bind to the cannabis receptors in the brain more potently than marijuana. Cases reported in 
the literature with SCBs use have been associated with reversible AKI characterized by ATN 
and AIN. Here we describe a case of a patient who developed chronic interstitial nephritis 
associated with habitual synthetic cannabinoid use via vaping.
Case Description: A 37 year old African American male with PMH of Diabetes and 
Obesity s/p gastric sleeve surgery was referred by PCP due to increased in creatinine from 
baseline of 1.45. His Social History is significant for frequent use of synthetic cannabinoids 
and marijuana via e cigarette devices. His creatinine on admission was 6.89 mg/dL and 
BUN 89 mg/dL and urine was remarkable for + eos in urine and muddy brown casts with 
minimal proteinuria. Initial serological work up was negative and ultimately underwent 
renal biopsy and dialysis with a creatinine was 10.86 mg/dL and BUN 110 mg/dL. Results 
of renal biopsy were consistent with patchy acute tubular injury associated with moderate 
to severe tubular atrophy and interstitial fibrosis, with chronic inflammation. There was also 
some evidence of mild changes consistent with diabetic nephropathy.
Discussion: Chronic interstitial nephritis (CIN) is a histological entity characterized 
by progressive scarring of the tubulointerstitium, with tubular atrophy, cellular infiltration, 
and interstitial fibrosis. There have been multiple case reports in which the use of synthetic 
cannabinoid (SCBs) has been associated with AKI via ATN or AIN but none CIN. Many of 
these cases are attributed to synthetic cannabinoid metabolites XLR-11, AM-2011, UR-
144, which are present in these synthetic analogs and are found in e-liquids commercially 
available. This case illustrates the importance of increased awareness to the potential health 
risks associated with marijuana use via e-cigarettes, whether synthetic or plant derived.
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The Deceptiveness of Creatinine as a Measure of Renal Function in 
Rhabdomyolysis: A Case Report
Amanda A. Karasinski,1 Jaime A. Baynes-Fields,1 Muhammad O. Hanif,2 
Sandeep Aggarwal,1 Karthik M. Ranganna.1 1Drexel University, Philadelphia, 
PA; 2Drexel University, PHILADELPHIA, PA.
Introduction: Rhabdomyolysis associated acute kidney injury (AKI) differs from 
other etiologies of AKI, as serum creatinine(sCr) represents the measurement of increased 
generation from muscle lysis and reduced excretion from pigment induced nephropathy. We 
present a case of dialysis dependent AKI due to rhabdomyolysis with persistently high sCr 
and eventual normalization of eGFR as demonstrated in a diethylenetriaminepentacetate 
(DTPA) scan.
Case Description: A 42 year old African American male with no prior medical history 
presented with progressive weakness and generalized muscle aches which began after 
phencyclidine use. On initial presentation he was found to have a creatinine of 10.4mg/dL 
(unknown baseline), potassium 6.9 mmol/L with peaked T waves on EKG, calcium 
4.8 mg/dl (5.4, corrected), phosphate 13.4 mg/dl, sodium 127 mEq/L, bicarbonate 
20 mEq/L, CK >200,000 IU/L and pH of 7.1. Urine dipstick had 3+ blood and 1-5 
erythrocytes on direct microscopy. Renal ultrasound revealed normal renal size and 
echogenicity. The patient was managed with forced saline diuresis, but was eventually 
dialyzed for persistent hyperkalemia. After 6 dialysis sessions the patient had increased 
urine output, normalization of electrolytes and rapid decline of BUN with persistently 
elevated sCr, see Table 1. Given the patients’ clinical improvement a DTPA scan was 
performed to determine eGFR due to persistently elevated sCr which revealed a GFR of 
106 mL/min/1.73m2. Despite cessation of dialysis patient continued to have renal recovery 
with a sCr of 5.1mg/dL at the time of discharge.
Discussion: Our case demonstrates that sCr is not a reliable marker to monitor recovery 
of renal function in patients with severe rhabdomyolysis requiring hemodialysis. Nuclear 
renal imaging such as a DTPA scan is a helpful tool in assessing renal function in similar 
clinical scenarios. Larger studies are required to assess utility of non creatinine based 
measurement of GFR in such populations.
Table 1: Lab trend during hospitalization
HD (hemodialysis)
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From One Page to the Next...
John Ahn,2 Sandeep Padala,1 Azeem Mohammed.1 1Augusta University, 
Augusta, GA; 2Medical College of Georgia, Augusta, GA.
Introduction: Page kidney represents a rare cause of renal dysfunction and secondary 
hypertension that results from external compression of the kidney immediately after a 
traumatic or iatrogenic sub-capsular hematoma. We present a unique case of an abnormally 
delayed development of page kidney after a renal biopsy.
Case Description: A 41year old female with a past history of systemic lupus 
erythematosus, CKD Stage 3b (baseline serum creatinine of 2.5 mg/dL) and hypertension 
was admitted for acute kidney injury. After undergoing a percutaneous kidney biopsy 
that revealed Class IV lupus nephritis, the patient developed hematuria and flank pain. 
Laboratory results indicated a drop in hemoglobin from 10.2 to 8.6 gm/dL and a rise in 
creatinine from 2.91 to 4.26 mg/dL. CT scan of the abdomen and pelvis revealed a large right 
retroperitoneal and sub-capsular hematoma measuring 8.1 x 5.3 cm. CT-guided drainage of 
1.2 liter of sanguineous fluid resulted in renal function returning to baseline with minimal 
residual perinephric fluid on repeat imaging. Patient was discharged on immunosuppression 
for lupus nephritis. About seven months after the kidney biopsy, the patient presented 
to the clinic with no specific complaints but noted to have a large right lower quadrant 
mass. Laboratory results revealed acute kidney injury with serum creatinine at 4.03 mg/
dL. Imaging revealed a sub-capsular abscess around the right kidney measuring 15.5 x 
13.0 x 14.4 cm, presumed to have developed from the preexisting hematoma. The patient 
was diagnosed with acute renal failure from page kidney. Percutaneous drainage of the 
abscess resulted in 1.6 liter of purulent fluid that grew many gram-positive cocci on culture. 
Repeat imaging showed, the sub-capsular fluid had decreased in size to 5.3 x 2.4 x 5.6 cm 
with a concomitant decrease in serum creatinine to 3.2 mg/dL. The patient was discharged 
on oral clindamycin.
Discussion: Page kidney usually results in acute renal failure, pain and hypertension 
caused by activation of the renin-angiotensin-aldosterone system secondary to a sub-
capsular hematoma. The present case is unique since this phenomenon was secondary to 
an abscess that developed in a preexisting hematoma. The patient’s immunosuppressive 
regimen may have been responsible for her indolent course. Furthermore, in an age of 
abundant imaging modalities, this case highlights the importance of a physical exam.
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Acute Renal Failure in a Patient with Acute Lymphoblastic Leukemia 
(ALL): An Unexpected Combination of Etiologies
Azza Abdel Hak, Rakesh Gulati. Thomas Jefferson University Hospital, 
Philadelphia, PA.
Introduction: We present a case of acute renal failure in an adult patient with relapsed 
ALL due to lymphomatous infiltration of the kidneys and Blinatumomab induced acute 
interstitial nephritis (AIN)
Case Description: A 23 year old African male, with relapsed B-cell ALL and chronic 
Hep B carrier on Entecavir was admitted with acute oliguric renal failure. He was started on 
Blinatumomab 2 months prior in preparation for stem cell transplant. Outpatient abdominal 
imaging was concerning for multiple bilateral renal lesions suspicious for secondary 
Lymphomatous involvement resulting in mass effect. Admission creatinine was 8.4 mg/dl. 
Renal Ultrasound showed mild bilateral hydronephrosis. Kidney biopsy contained portions 
of dense interstitial inflammatory infiltrate of CD10-positive and TDT-positive leukemic 
cells (Figure 1) and a less dense, diffuse interstitial inflammatory infiltrate of CD10-
negative and TDT-negative lymphocytes with occasional plasma cells and eosinophils 
(Figure 2). This was consistent with leukemic infiltration and AIN. Renal failure resolved in 
a week with supportive measures. Blinatumomab was discontinued.
Discussion: Blinatumomab is a monoclonal antibody used for treatment of relapsed 
or refractory ALL in adults. It was felt that the most likely etiology of AIN was the recent 
introduction of Blinatumomab. In addition, ultrasound was concerning for hydronephrosis 
caused by ALL infiltration which may have contributed to his renal failure To our 
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knowledge, this is the first reported case of AIN secondary to Blinatumomab. Medications 
should be considered as a cause of unexplained renal failure.
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Rapidly Progressing Renal Failure: A Diagnostic Dilemma
Neelambuj Regmi,1 Sulaiman J. Barkho,3 Yadav Pandey,5 Yahya M. Osman 
Malik,4 Zeenat Y. Bhat.2 1Wayne State University/Detroit Medical Center, 
Detroit, MI; 2Wayne State University, Detroit, MI; 3Detroit Medical Center, St 
Clair Shores, MI; 4Wayne State University Medical School, Detroit, MI; 
5University of arkansas for medical sciences, Little Rock, AR.
Introduction: AKI though a common diagnosis can pose a diagnostic challenge 
especially so when it is rapidily progressing like our case
Case Description: A 52-year old lady with recent diagnoses of hypertension, new 
onset heart failure, cardiomyopathy preserved EF, pericardial effusion and AKI (Creatinine 
2mg/dl; last Cr from 2012 – 0.9) presented with complains of generalized weakness and 
fatigue for a week. Her meds, all recently started were Atorvastatin, Carvedilol, aspirin and 
Furosemide. Pt denied fever, chills, sputum production, chest pain, orthopnea, palpitations 
or syncope. She has recent hospitalization with above problems, discharge Cr was 1.4mg/dl. 
Bone marrow biopsy had shown plasma cells <5% for diagnosis ?cardiac amyloid /
pericardial effusion work up, On physical examination vital signs were unremarkable, She 
was lethargic but oriented to time, place and person. only positive finding was B/L crackles 
on lung bases and b/l lower extremity swelling. Abnormal Laboratory data : BUN 64mg/dl 
and creatinine of 2.02mg/l., Urinalysis showed 3+ blood and 2+ protein, Up/UC 0.8, Urine 
immunofixation revealed Bence Jones kappa protein. Ration of Kappa/Lambda- 1.99. 
Troponins 1.23, CPK 942 which downtrended. EKG showed T wave inversions in anterior 
leads. ECHO showed increased left ventricle thickness with ejection fraction of 65-70%. 
No regional wall motion abnormalities were noted, Moderate circumferential pericardial 
effusion is noted. CXR for opacity in left lower side of the lung. Renal Ultrasound showed 
no hydronephrosis with kidney sizes of 10.3 R and 11.1 cm L. Pt required dialysis and 
Kidney biopsy was done, it was consistent with myoglobin cast nephropathy- acute tubular 
injury with myoglobin laden casts. Immunoflorescence and electron microscopy identified 
small amounts of IgG, OgA, C3 and lambda light chain within the mesangium. No evidence 
of amyloid deposition were noted.
Discussion: In our patient, probable cause of rhabdomyolysis could be immobilization, 
infection (pneumonia) or the use of statin, hypokalemia(furosemide),. The CPK for the 
patient was not significantly increased but could have the on the recovering phase at the 
time of presentation to our hospital
PUB509 
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Bouquet of Flowers-Deep Inside the Great Pyramids - A Case of 
Medullary Sponge Kidney in the Elderly
Gabriela A. Ciofoaia,1 Nkechi C. Mbaebie.2 1Berkshire Medical Center, 
Pittsfield, MA; 2Berkshire medical center, Pittsfield, MA.
Introduction: Medullary Sponge Kidney (MSK) is a congenital malformation 
characterized by dilatation of the collecting ducts of Bellini associated with defective urine 
acidification and concentration. MSK typically affects papillae in both kidneys. The usual 
clinical manifestations of hematuria, urinary tract infection and nephrolithiasis are delayed 
and emerge over a wide age range. 20% of patients with urolithiasis have MSK.
Case Description: 68 years old female admitted with worsening left thigh pain and 
left lower quadrant abdominal pain of 2 days duration. Past medical history significant 
for chronic UTIs and kidney stones for 10 years. Labs showed Cr of 1.78 (baseline of 
1.2), Urinalysis revealed positive esterase with pyuria. CT showed bilateral renal stones 
in the calyces without obstruction and small calcifications compared to previous imaging. 
Bouquets of flowers pattern on CT was characteristic of MSK.Blood and urine cultures 
grew E. Coli. Patient was treated with targeted antibiotics. Kidney stone analysis revealed 
calcium phosphate. Potassium citrate was initiated. Creatinine continued to be above her 
baseline, however urine output remained normal. Despite all efforts, patient continued to 
have recurrent UTIs. On follow up visits patient reported less episodes of passing stones.
Discussion: MSK is usually asymptomatic. The diagnosis is commonly made 
as an incidental finding during an imaging test performed for a different indication. 
Although considered benign, the associated complications of medullary sponge kidney 
(nephrolithiasis and urinary tract infections) may rarely lead to chronic kidney disease and 
even renal failure. To identify patients at greatest risk for complications, a grading system 
based on the number of affected calyxes has been proposed. Our patient was grade 4 on 
this scale making her most susceptible to complications. CT pattern of MSK developed late 
in this index case which is uncommon and is described in only 10% of affected subjects. 
Our case illustrates few reported serious complications of advanced CKD in the setting of 
late diagnosis of MSK which if diagnosed early may have been salvaged with preventive 
measures such as use of Potassium Citrate. The concept of prophylactic potassium citrates in 
MSK remains controversial and further studies are encouraged. MSK should be considered 
in the differential diagnoses of recurrent UTIs in elderly.
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Anti-GBM Disease in the Elderly Patient: A Case Report
Emmanuel A. Adomako, Brittany Carter, Teena Zachariah, Deborah A. Fein. 
Englewood Hospital and Medical Center, Englewood, NJ.
Introduction: Anti-glomerular basement membrane (anti-GBM) disease is a known 
cause of rapidly progressive glomerulonephritis (RPGN) occurring in the third and seventh 
decade of life. As life expectancies continue to improve, there may be more cases of RPGN 
in the elderly. More robust data is needed to guide management in this population.
Case Description: An 81-year-old Caucasian female with history of hypertension 
and remote tobacco use presented with a two-week history of anorexia, malaise and 
cough. Home medications included daily atenolol 50 mg, hydrochlorothiazide 12.5mg, 
amlodipine 5mg and naproxen. Pertinent labs included creatinine 7.7mg/dl, 24-hour urine 
protein 850mg, urine negative for red or white blood cells, GBM antibody 1.9 AI, and anti-
neutrophil cytoplasmic antibody (ANCA) positive with C-ANCA 1:40. She was started on 
hemodialysis for uremic symptoms and had a renal biopsy done. The biopsy was significant 
for predominantly acute focal necrotizing and diffuse crescentic glomerulonephritis, 
crescents in 50% of glomeruli, and minimal tubular changes, consistent with anti-GBM 
nephritis. She received a two-week course of plasmapheresis, pulse steroids and oral 
cyclophosphamide. Cyclophosphamide was discontinued after two and a half months due 
to agranulocytopenia and transient fever but she remains on prednisone taper. Anti-GBM 
and ANCA became negative after the initial two weeks of treatment with mild improvement 
of pre-dialysis creatinine but she remains dialysis dependent.
Discussion: Anti-GBM disease in the elderly patient offers a unique challenge due to 
limited data in this population. Dual-positivity of anti-GBM and ANCA are more likely to 
occur in the elderly population. Furthermore, elderly patients may be more susceptible to 
the adverse effects of treatment and this together with comorbidities may limit the duration 
and intensity of therapy. There is a need for further research to better serve the needs of 
elderly patients with anti-GBM disease.
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Metformin Associated Lactic Acidosis (MALA), In Elderly; Are The 
Prescribing Restrictions Adequate?
Maryyam Ali,1 Jiwan K. Thapa.2 1U of MN Renal Division, Minneapolis, MN; 
2University of Minnesota, Minneapolis, MN.
Introduction: Metformin associated Lactic acidosis (MALA), is rare but it has been 
associated with 40% mortality risk. It is usually related to elevated Metformin levels with 
overdose. Sustained release(SR) formulation theoretically has a lower risk of MALA, with 
lower plasma Metformin and lactate levels due to reduced systemic absorption. Our patient 
developed significant metabolic acidosis and elevated lactate with appropriate use of the 
drug per current FDA regulations.
Case Description: 78 year old male with a history of diabetes mellitus for >40yrs (on 
Metformin for 10yrs), heart failure with ejection fraction of 25% and chronic kidney disease 
with a creatinine of 1.1mg/dl and GFR 45-50ml/min, was admitted to the intensive care 
with generalized weakness and fall, hyperkalemia, high anion gap metabolic acidosis with 
elevated lactic acid. He had three admissions in the past three months with reversible serum 
creatinine (SCr) elevations secondary to CHF exacerbation, GI bleed and pre-renal state 
with low intake. Exam revealed frail elderly male with stable vitals. Labs showed increase 
in SCr to 1.7 mg/dl, bicarbonate 10 mmol/L, K 5.7 mmol/L, Anion gap 29mmol/L, sodium 
142mmol/L Lactate level was high at 20mmol/L. No other sign of tissue hypo-perfusion 
and CT abdomen was negative for bowel ischemia. He had emergent hemodialysis for 4 
hrs followed by high dose CVVHDF for 48 hrs for presumptive diagnosis of MALA, with 
improvement in bicarbonate and lactate level. Despite improvement in lab parameters, 
he developed progressive cardiogenic shock requiring iontropic support, and elected for 
comfort care. Subsequently, his Metformin level came back supra-therapeutic at 3.8mcg/ml.
Discussion: Recent updates on Metformin safety in CKD has expanded its use in low 
eGFR patients. Estimated GFR alone, however, may not capture the full risk especially in 
geriatric population with multiple co-morbidities. Sustained release Metformin compared 
to immediate release Metfomin, has similar glycemic control, but it is associated with lower 
systemic levels and thus lower lactate levels. Risk increases, in the presence of other factors 
like acute kidney injury, heart failure and old age, hence more care and vigilance is needed 
while prescribing Metformin to this population with multiple co-morbidities.
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No “Sugar-Coating”: A Unique Case of Hyperinsulinemic Hypoglycemia 
with Renal Cell Carcinoma
Laila S. Lakhani,1 Gonzalo Matzumura,2 Huzair Ali.3 1UT Houston, Houston, 
TX; 2University of Texas Health Science Center at Houston, Houston, TX; 
3University of Oklahoma, Macon, GA.
Introduction: Hypoglycemia, as a manifestation of Renal Cell Carcinoma (RCC) is 
a rare event. Classically described as a paraneoplastic syndrome of non-islet cell tumor 
hypoglycemia, these patients have suppressed levels of glucose, insulin, proinsulin, 
C-peptide levels. Characteristically, they have elevated levels of insulin like growth factor 
(IGF)-2 and suppressed levels of IGF-1. We present a unique case of hypoglycemia from a 
paraneoplastic, non-islet cell insulin-producing RCC.
Case Description: A 92-year-old Hispanic woman with Chronic Kidney Disease 
IIIb, presented with recurrent episodes of altered mental status, found to have severe 
hypoglycemia, with a blood glucose of 37mg/dL on presentation. Her mentation improved 
with dextrose infusion and work-up for recurrent hypoglycemia was pursued. She denied 
history of diabetes and testing for inadvertent use of sulfonylureas or insulin was negative. 
Biochemical workup showed elevated levels of C-Peptide and insulin that was confirmed 
with repeat readings. In addition, IGF-1, IGF-2 and insulin Antibody were noted to be 
very low (Table 1). With the working diagnosis of hyperinsulinemic hypoglycemia, MRI 
abdomen was performed, showing normal pancreas anatomy, with an incidental finding of a 
43x44x41mm heterogeneous enhancing right renal mass. Repeat CT abdomen with contrast 
confirmed the right renal mass with central necrosis and washout, consistent with radiologic 
features of renal cell carcinoma. Urology was consulted for surgical management, but given 
the patient’s age and medical co-morbidities, nephrectomy was deferred. She was considered 
for ablation vs excision of the mass, however, her hypoglycemia responded to frequent oral 
intake, therefore these too were held off in the favor of conservative management.
Discussion: Hypoglycemia can be the initial presenting symptom in patients with renal 
cell carcinoma. This requires a thorough work-up to rule out other endocrine and medication 
related etiologies. While resection of the tumor generally resolves the hypoglycemia, 
the importance of identifying the underlying mechanism is crucial to provide adequate 
treatment of hypoglycemia in the acute setting while awaiting surgery or in non-surgical 
candidates like ours.
Table 1
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ANCA Vasculitis Masquerading as FSGS?
Anum Bilal,1 Junaid Nasir,1 Paul J. Der Mesropian,2 Gulvahid G. Shaikh.2 
1Albany Medical Center, Albany, NY; 2Albany Stratton VA, Albany, NY.
Introduction: We present the case of a 71 yr old man with renal-limited ANCA-
associated vasculitis (AAV) with initial presentation of focal segmental glomerulosclerosis 
(FSGS) on renal biopsy.
Case Description: A 71 yr old non- diabetic white male was referred to renal clinic 
for evaluation of chronic kidney disease. On initial evaluation his serum Cr (SCr) was 
2.2 mg/dl and he had chronic hematuria. Baseline SCr was 0.9-1 mg/dl. He denied NSAID 
use and had a 40 pack year smoking history. Spot urine albumin/Cr was 169 mg/g. Screens 
for HIV, Hepatitis B and C were negative. Serum and urine protein electrophoresis showed 
no para-proteins. C3, C4, ANA and dsDNA were normal. Renal biopsy was reported as 
Focal Segmental Glomerulosclerosis (FSGS), with some glomeruli showing increased 
mesangial matrix and 2 of 7 glomeruli being globally sclerosed. Focal mononuclear 
interstitial inflammation and mild tubulo-interstitial fibrosis were also noted. Patchy foot 
process effacement was seen on EM. 6 months later, SCr progressively rose to a peak 
of 5.7 mg/dl and urine alb/Cr increased to 973 mg/g. As the rapid loss of GFR did not 
correlate with the pathological findings of secondary FSGS, further serologic testing was 
performed revealing P-ANCA titer of 1:160 and MPO level of 30 AI. Cryoglobulins and 
anti-GBM were negative. He received IV steroids and underwent renal biopsy. Pathology 
confirmed pauci-immune glomerulonephritis with crescents in 2 glomeruli, endocapillary 
hypercellularity, more than 50% IFTA, and interstitial inflammation. He was treated with 4 
weekly doses of Rituximab along with steroid taper. SCr eventually improved to 3.7 mg/dl.
Discussion: AAV often presents as a smoldering disease process. We believe that our 
patient had renal vasculitis masquerading as FSGS at the time of the first renal biopsy. 
It is possible that glomerular scarring and interstitial fibrosis observed then represented 
the healing process of active glomerular lesions. Persistent hematuria and the presence 
of a mononuclear interstitial infiltrate offered support for our theory. Interstitial nephritis 
has been previously reported to be an atypical histologic presentation of AAV. FSGS is 
an unlikely and under-reported presentation of AAV. Because AAV may have a relapsing/
remitting course, it is possible that FSGS may be seen on pathology rather than typical 
findings of AAV.
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Polyclonal Crescentic Fibrillary GN Presenting with Macroscopic 
Hematuria
Yvelynne P. Kelly,1 Veronica E. Klepeis,2 Meghan E. Sise,2 Sagar U. Nigwekar.2 
1Nephrology, Massachusetts General Hospital, Boston, MA; 2Massachusetts 
General Hospital, Boston, MA.
Introduction: A 56 year old female presented with gross hematuria, symptomatic 
anemia and a serum creatinine of 6 mg/dl. She had a baseline serum creatinine of 
2.0 mg/dl and was known to have microscopic hematuria and proteinuria but had never 
undergone a kidney biopsy. Her biopsy subsequently showed end-stage crescentic fibrillary 
glomerulonephritis. Given the chronicity of her disease, she was deemed unsuitable for 
immunosuppression and began work-up for renal replacement therapy. This case illustrates 
the importance of early diagnosis of glomerulonephritis in patients with chronic kidney 
disease and an active urinary sediment.
Case Description: A 56 year old obese Caucasian female with poorly controlled 
diabetes mellitus presented with gross hematuria and a serum creatinine of 6 mg/dl. She 
had a baseline serum creatinine of 2 mg/dl and had suffered from recurrent episodes of 
gross hematuria for many years. A urology work-up was negative. She had been given a 
presumptive diagnosis of IgA nephropathy. A serological work-up was completely negative. 
Urine protein:creatinine ratio was 8.76 g/g with a urine microalbumin:creatinine ratio of 
4274 mg/g. A renal biopsy was performed showing end-stage crescentic GN with 15% 
cellular and fibrocellular crescents, 15% global glomerulosclerosis and 70% IFTA. IF was 
negative for IgA but positive for IgG, C3, kappa and lambda. Fibrillary glomerulonephritis 
was confirmed on electron microscopy. Given the equal kappa and lambda staining, 
investigations for monoclonal disease were not pursued. Similarly immunosuppression 
was not commenced given the chronicity of the patient’s biopsy findings and clinical 
renal disease. She was prepared for progression to end-stage kidney disease and renal 
replacement therapy.
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Discussion: This case illustrates the importance of early biopsy-based diagnosis for 
patients with progressive renal impairment and an active urinary sediment. It also highlights 
the differences in approach to patients with polyclonal fibrillary glomerulonephritis, 
compared to those with monoclonal glomerulonephritis for which a work-up for a clonal 
cell disorder should be pursued. The decision to commence immunosuppression for 
polyclonal fibrillary glomerulonephritis depends on disease duration as patients with 
advanced CKD have a poor renal prognosis and do not experience significant benefit from 
pursuing immunosuppressive therapy.
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Hydralazine Induced Antineutrophil Cytoplasmic Antibody-Associated 
Vasculitis with Acute Tubulointerstitial Nephritis: A Rare Constellation
Sandiya Bindroo,1 Michael R. Lattanzio.2 1Internal Medicine, Crozer Chester 
Medical Center, Upland, PA; 2Nephrology, Chester county Hospital, University 
of Pennsylvania, West Chester, PA.
Introduction: Hydralazine is an adjunctive antihypertensive medication that is 
associated with antineutrophil cytoplasmic antibody (ANCA) - associated vasculitis. 
Kidney involvement usually comprises a pauci-immune, necrotizing glomerulonephritis 
with crescents.
Case Description: A 74-year-old Caucasian male on hydralazine, with a history of 
hypertension, presented with the acute onset of malaise and hematuria. On examination, 
lower extremity edema was noted. He remained hemodynamically stable. Lab work showed 
pancytopenia and elevation of serum creatinine (4mg/dl; normal range 0.6-1.1 mg/dl). 
Urinalysis showed proteinuria, dysmorphic red blood cells, and no red cell casts. Serology 
showed myeloperoxidase (MPO) positive high ANCA titers; positive anti-histone 
antibodies, positive cryoglobulins, and negative antinuclear antibodies. Renal biopsy 
revealed acute tubulo-interstitial nephritis (ATIN). Light microscopy examination revealed 
no segmental sclerosis, crescents, or areas of necrosis. Infectious work up, hepatitis B & C 
panel, was negative. Bone marrow biopsy was normal. Even though, he received a pulse 
dose of steroids and induction therapy with rituximab (375 mg/m2 IV q weekly doses) 
followed by oral prednisone 60mg daily, his hospital course got further complicated 
with hemoptysis. Subsequent lab work up revealed markedly elevated serum creatinine 
(5. 58 mg/dl), and persistent pancytopenia. CT scan of the chest revealed patchy areas 
of reticulation with ground glass opacities. Bronchoscopy exam revealed the presence of 
diffuse alveolar hemorrhage. He was started on renal replacement therapy for worsening 
kidney function. With two months of follow up, he remains on hemodialysis and on 
maintenance oral prednisone therapy.
Discussion: Hydralazine-induced ANCA vasculitis is a rare occurrence with pulmonary 
renal syndrome being the most severe presentation. Renal involvement is characterized 
by focal segmental crescentic and/or necrotizing glomerulonephritis. Mononuclear 
tubulointerstitial infiltrates have been noted in literature but these have usually been 
described in conjunction with glomerulitis which was not seen in this case. We report a case 
of hydralazine induced ANCA vasculitis with ATIN which is rare in the literature.
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A Rare Case of Pyoderma Gangrenosum Masking Underlying 
Henoch-Schonlein Purpura
Jeremy Carlson,1 Happy F. Sadiek,1 Juan L. Chique,1 Raafat F. Makary,2 
Leighton R. James.1 1UF Health, Jacksonville, FL; 2Shands Hospital, UFL, 
Jacksonville, FL.
Introduction: Henoch-Schonlein Purpura (HSP) is commonly diagnosed in childhood, 
however, it can occur in adults where the chances of renal involvement more than double. 
Here we introduce a unique case where an adult patient with Pyoderma Gangrenosum (PG) 
underwent further workup and was found to have uderlying HSP.
Case Description: A 21 year old, African American woman with history of 
hypothyroidism, idopathic heart failure, and recently diagnosed PG rash was admitted for 
heart failure exacerbation and nausea. Nephrology was consulted on admission for persistent 
hematuria, proteinuria, and AKI. Upon questioning, she had noticed pink to tea-colored 
urine and a lower extremity rash. Urinalysis showed protein (100mg/dl) and large blood. 
She underwent kidney biopsy for persistent, unexplained hematuria which showed focal 
proliferative and sclerosing glomerular changes with IgA deposits on immunoflourescence 
study, indicative of HSP. Skin biopsy of her rash showed leukocytoclastic vasculitis, seen in 
PG. She was treated with mycophenolate and steroids.
Discussion: When PG is diagnosed, 50% of patients have an underlying systemic 
disease. In this case, PG was diagnosed and clinical symptoms later on are what prompted a 
workup ultimately diagnosing HSP. Even though HSP is most commonly seen in children, 
when it occurs in adults renal dysfunction is more common, and consequently, this increases 
mortality. It is imperative that nephrologists and practicing hospitalists alike are able to keep 
a wide differential when they see nonspecific findings such as PG. Systemic vasculitides, 
such as HSP, should be kept in mind if patient’s present with symptoms involving multiple 
organ systems in addition to the characteristic PG rash.
A. Skin biopsy with leukocytoclastic vasculitisB: HE stain showing increased mesangial
matrix, cellularity in glomerulus
C: PAS stain suggestive of early crescent
D: Gomori Trichome stain showing global and segmental sclerosis
E&F: Electron microscopy consistent with proliferative immune mediated 
glomerulonephritis
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A Cool Case of Cryo
Paul M. Adams,1 Taha Ayach.2 University of Kentucky Nephrology 1Nephrology, 
University of Kentucky, Lexington, KY; 2University of Kentucky, Lexington, KY.
Introduction: Cryoglobulinemia is a rare but serious cause of vasculitis. Complement 
activation and inflammation can cause AKI with GN, rash, or alveolar hemorrhage. This 
case illustrates the recognition and treatment of systemic cryoglobulinemia vasculitis.
Case Description: A 66 year-old woman with history of DLBCL in remission presented 
with four weeks of lower extremity rash, abdominal pain, anemia, thrombocytopenia and 
AKI. Exam included palpable purpura over lower extremities, and abdominal tenderness. 
She was in no distress with unremarkable cardiopulmonary exam and normal vitals. 
Creatinine was 3.6 (baseline Cr 0.8), Hemoglobin 8.9, and platelets 129,000. UA was 
active: 6-10 WBCs, 1-3 RBCs, granular casts and mild proteinuria. Infectious workup with 
cultures, HIV, HVB, and HVC screens were negative. Peripheral smear did not support TTP 
or HUS. Evaluation with ANA, ANCA, MPO/PR3, anti-GBM were negative. Low C3 and 
C4 suggested immune complex formation. Steroids were started and a kidney biopsy was 
performed. After developing hypoxia, a CXR and CT chest were concerning for pulmonary 
hemorrhage. Bronchoscopy was planned for further evaluation, but was postponed due to 
hemoptysis requiring intubation. DAH prompted urgent plasmapheresis and Rituximab. 
Cryocrit returned positive at 1.5%, raising concern for cryoglobulinemic vasculitis. 
Kidney biopsy confirmed cryoglobulin MPGN, supporting systemic cryoglobulinemic 
vasculitis, likely a type II crogolbulinemia with unclear etiology. She improved with further 
plasmapheresis, rituximab and steroids, allowing complete recovery.
Discussion: This case illustrates systemic cryoglobulinemia vasculitis. Cryoglobulin 
GN manifests as MPGN with characteristic double contoured GBM “tram-tracking” due 
to membrane disruption and regeneration. “Cryo” immunoglobulins precipitate at low 
temperatures depositing in small vessels and leading to vasculitis. Causes include HCV, 
hematologic malignacy, endocarditis or other infalmmatory states. Cryoglobulins are 
classified as Type I monoclonal Ig, Type II polyclonal IgG monoclonal IgM (rheumatoid 
factor), or Type III polyclonal IgG polyclonal IgM. Type II or III related to chronic HCV or 
HBV are most common. Treatment of the underlying condition is paramount. Life or organ 
threatening cases are treated with steroids, plasmapheresis, and either cyclophosphamide or 
rituximab. Debate between cyclophosphamide and rituximab exists, but rituximab may be 
safer and as effective.
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An Unusual Case of Podocytopathy with Acute Renal Failure and 
Proximal Tubulopathy
Jessamyn Carter, Narottam Regmi. University of Oklahoma School of 
Community Medicine, Tulsa, OK.
Introduction: Nephrotic syndrome (NS) in adults is most commonly secondary to 
diabetes, and when primary is predominantly focal segmental glomerulosclerosis. It is 
unusual for NS in adults to present with acute renal failure, but it has been reported in some 
cases of minimal change disease. The proposed cause is acute tubular necrosis (ATN) from 
proteinuria overwhelming proximal tubule reabsorption.
Case Description: 51 year old woman with history of stroke, hypertension, chronic 
kidney disease stage 3, intravenous drug use, and medical non-compliance presented 
for 1 day of flu-like illness. Flu testing was negative, and X-ray showed left lower lobe 
pneumonia. She also had acute kidney injury with creatinine 2.09 (baseline 1.2), oliguria, 
hematuria, and proteinuria (13.7g in 24 hours). She was diagnosed with ATN which did not 
respond to fluid, treatment of pneumonia, or later diuretic trial. Hematuria was mild and 
rapidly resolved, but proteinuria persisted. Renal biopsy showed proximal tubulopathy with 
accumulation of protein reabsorption droplets. This pattern of tubular injury is typically 
seen in light chain disease, but immunofluorescence showed no light chain disease. No 
light chain restriction was noted in our patient and serum protein electrophoresis and bone 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1163
J Am Soc Nephrol 29: 2018 Publication-Only 
marrow biopsy were unremarkable. Renal biopsy also showed 70% podocyte effacement 
without sclerosis. Hemoglobin A1c, ANA, ANCA, anti-GBM, hepatitis, HIV, and 
complement testing were normal. Underlying etiology of her NS remains unknown and she 
remains hemodialysis (HD) dependent.
Discussion: More than half of all NS in adults is secondary, and when presenting with 
renal failure it typically is transient. In our patient, an underlying cause is unknown and 
she remains anuric and HD dependent. Her tubulopathy is also unusual, as this degree of 
tubulopathy in NS is primarily reported in the pediatric population related to mitochondrial 
disorders and other rare genetic syndromes. Further attention to tubule injury in NS is 
needed to understand prognostic value and guide therapy.
Left: Proximal tubules with marked protein resorption droplets. Right: Benign light 
microscopy of glomerulus.
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Membranous Nephropathy Secondary to Systemic Sclerosis
Prakrati C. Acharya, Desiree Garcia Anton, Divya Monga. University of 
Mississippi Medical Center, Ridgeland, MS.
Introduction: Systemic sclerosis (SS) has rarely been described in literature as cause 
of membraneous nephropathy (MN). We hereby present a case of MN secondary to SS.
Case Description: 44 year old African American male with history of SS since2011 was 
referred to Nephrology clinic in 2016 for nephrotic syndrome and microscopic hematuria 
(spot urine protein creatinine ratio of 4, serum albumin of 2.9 g/dl, serum creatinine of 
0.4 mg/dl and hyperlipidemia with anasarca). SS was manifested as interstitial lung disease, 
Raynaud’s phenomenon, gastroesophageal reflux and hypertension. SS was initially 
treated with Penicillamine(from 2011 -2014) which was already stopped 2 years before 
presentation to our clinic. C3, C4, HIV, Hepatitis serology, dSDNA, SPEP, serum PLA2R 
were negative. Renal biopsy showed Membranous glomerulopathystage 3, with mesangial 
deposits, tubuloreticular inclusions within endothelial cells and 5-10% interstitial fibrosis. 
IgG subtype staining was nonspecific and capillary wall PLA2R staining was negative. 
Lisinopril was initiated butproteinuria continued to worsen, with maximum of 13 gram of 
urine protein per day in 24 hour urine collection, worsening skin thickening and interstitial 
lung disease. He was then started on mycophenolate mofetil 500 mg twice a day followed 
by marked improvement in nephrotic syndrome. As he was already off Penicillamine for 2 
years before presentation and serology and other causes of secondary MN were ruled out, 
we postulate that his SSis the most likely cause of his nephrotic syndrome.
Discussion: Renal involvement is common in SSaffecting about 60-80% of 
patientswith scleroderma renal crisis being the most serious manifestation(5- 20% patients). 
45-60% patients have mild proteinuria, elevated creatinine or hypertension and renal
disease is generally not progressive. Most common reasons for impaired renal function are 
drug toxicity (D- Penicillamine, cyclosporine), prerenal causes (heart failure, pulmonary
hypertension NSAIDs), and rarely glomerulonephritis (ANCA positive, secondary
amyloidosis). The mean time to resolution of proteinuria after stopping d- penicillamine is 
9-12 months and has been reported in some cases to be up to 2-3 years. MN secondary to SS 
has been reported as exceptionally rare with only few case reports in literature. We suggest 
including systemic sclerosis as a cause of secondary MN.
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Diffuse Alveolar Hemorrhage in a Systemic Lupus Erythematosus Patient 
Treated with Rituximab
Joselyn Reyes Bahamonde, Nitzy N. Munoz casablanca, Nan Li. Mount Sinai 
Beth Israel, New York, NY.
Introduction: Diffuse alveolar hemorrhage (DAH) is a life threatening complication of 
systemic lupus erythematosus (SLE), it is an atypical manifestation of SLE associated with 
high rate mortality. Conventional therapy (cyclophosphamide, high-dose corticosteroids 
and plasma exchange) is recommended as therapy for DAH associated with SLE. Efficacy 
of alternative therapy such as Rituximab has also been described
Case Description: 36 year old woman with SLE membranous nephropathy, presented 
with acute onset of shortness of breath (SOB) and respiratory distress in the setting of 
increasing edema, elevated brain natriuretic peptide (BNP) to 10,000 and chest X-ray with 
bilateral opacities. Patient required non-invasive ventilation and started Furosemide for 
presumed fluid overload. Labs were significant for acute kidney injury (AKI) creatinine 
(Cr) 3.46 mg/dL, microhematuria, proteinuria, low C3 55 mg/dL, anti-ds-DNA 20 IU/mL. 
Despite aggressive diuresis, patient progressed to acute hypoxemic respiratory failure with 
acute respiratory distress syndrome (ARDS) requiring mechanical ventilation and renal 
replacement therapy (RRT). She underwent bronchoscopy which showed DAH. The overall 
clinical picture of AKI and DAH were consistent with acute lupus flare. Conventional 
therapy was delayed due to concern for active infection. Patient received two doses of 
Rituximab and did not require long term RRT, with creatinine of 1.4mg/dL a month later
Discussion: DAH is a catastrophic manifestation of SLE with a high mortality rate 
and treatment should be initiated as soon as the diagnosis is being established. Our patient 
received two doses of Rituximab with subsequent long term resolution of DAH and 
improvement of renal function. In summary, this case highlights the importance of early 
treatment to prevent fatal outcomes in DAH and also suggests that Rituximab might be a 
valid alternative therapy for DAH with SLE
Bronchoscopy specimen indicates DAH
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Case Report: Renal Failure Due to IgA Vasculitis with Massive Ascites 
Accompanied by Small Intestine Inflammation
Yoshitaka Shimizu,1 Masafumi Ono,2 Yumiko Suzuki,3 Taro Misaki.3 1Seirei 
hamamatu general hospital, Hamamatu, Japan; 2Seirei hamamatsu general 
hospital, Hamamatsu, Japan; 3Seirei Hamamatsu General Hospital, 
Hamamatsu, Shizuoka, Japan.
Introduction: IgA vasculitis with massive ascites accompanied by small intestine 
inflammation is very rare.
Case Description: A 26-year-old man with end-stage kidney disease and 
hypertension presented with headache that had persisted for one year. His visual acuity 
had decreased over a period of one year, and he visited an ophthalmologist. Physical and 
laboratory findings at that time revealed hypertension (200/114 mmHg) and end-stage 
renal failure (serum creatinine 8.06 mg/dL, urinary protein 4+, urinary occult blood 
2+). He was admitted on an emergency basis and started on antihypertensive treatment. 
Anti-neutrophil cytoplasmic antibody, anti-glomerular basement membrane antibodies 
were negative. Serum complement (C3, C4) values and chest radiography findings were 
normal. A renal biopsy revealed that half of his glomeruli had global sclerosis. Crescents 
with endocapillary hypercellularity were found in most glomeruli and fibrilloid necrosis 
was evident in small arteries. Fluorescent antibody tests were impossible because of 
the sclerotic glomeruli. We diagnosed vasculitis of unknown cause and started him on 
treatment with methylprednisolone 500 mg/day for 3 days, followed by oral prednisolone 
40 mg/day during seven days of hospitalization. Four days later, the patient complained 
of severe abdominal pain and abdominal CT revealed remarkable ascites retention and 
thickening of the small intestinal wall. Therefore, inflammation of the small intestine was 
diagnosed. Temporary ICU management was implemented and hemodialysis was started 
because his renal function had not improved. Steroid therapy improved the small intestinal 
inflammation, but he still needed maintenance dialysis. Renal biopsy specimens were 
reevaluated, and immunostained paraffin sections revealed IgA, C3-positive staining in the 
mesangial region, confirming a diagnosis of IgA vasculitis.
Discussion: Teaching Points: This patient had renal failure of unknown etiology 
complicated by small intestinal inflammation. To conclude a diagnosis was challenging, but 
IgA vasculitis was finally diagnosed by reassessment of a renal biopsy. Reviews of renal 
biopsies can be critically important to conclude a concrete diagnosis.
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An Unusual Case of Interstitial Nephritis in HIV/AIDS
Gurleen Kaur,1 Birju R. Rao,2 Koba A. Lomashvili.1 1Emory, Decatur, GA; 
2Emory University, Atlanta, GA.
Introduction: Acute kidney injury (AKI) is a common occurrence in HIV-infected 
patients with most common etiologies including volume depletion, medication toxicity and 
acute tubular necrosis. We here describe an interesting case of granulomatous interstitial 
nephritis (GIN) in HIV/AIDS patient with disseminated mycobacterium avium complex 
(DMAC) infection.
Case Description: A 35-year-old female with history of HIV/AIDS (CD4 count of 14), 
DMAC infection (with recurrent positive blood cultures) and CMV retinitis presented 
for intravenous (IV) Foscarnet therapy. Her baseline creatinine was 1.3-1.4 mg/dL which 
increased to 3.0mg/dL on admission. Creatinine did not improve beyond 2.7mg/dl after 
2 days of IV fluids. Urine studies showed trace leucocyte esterase. Spot urine revealed 
protein: creatinine ratio of 1.3g/g with microalbumin of 92mg, consistent with tubular 
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proteinuria. Hepatitis B surface antigen was positive with other serologies being negative. 
Renal ultrasound showed bilaterally increased renal echogenicity. Renal biopsy done on day 
4 showed: interstitial, non-necrotizing granulomatous inflammation; moderate interstitial 
fibrosis/tubular atrophy, 1/20 glomeruli were sclerotic, non-sclerotic glomeruli were 
normal on light microscopy, and podocyte foot processes were effaced focally on electron 
microscopy. Given the patient had MAC bacteremia and MAC associated necrotizing 
mesenteric lymphadenopathy with chylous ascites, these granulomas most likely were 
induced by MAC infection. She completed 21 days of IV Foscarnet treatment. Her 
creatinine on discharge was 2.1mg/dL. We did not treat her with steroids, since benefit:risk 
ratio was not in favor of treatment. She was continued on MAC treatment with azithromycin 
600 mg daily and dose adjusted ethambutol.
Discussion: GIN is an uncommon histological finding, representing ~0.5-1.37 % of 
native kidney biopsies. Most common etiology of this in developing nations is tuberculosis 
and fungal infections, however this may be easily overlooked as a cause of AKI in developed 
nations. GIN can be insidious and may go undetected for several years. Recognition and 
treatment of underlying cause can lead to improvement in some cases and renal biopsy 
is key to diagnose and to determine prognosis. Our case represents a complex case with 
various possible etiologies of AKI. In such a scenario a renal biopsy is imperative to help 
establish diagnosis and guide therapy.
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Renal Limited ANCA Vasculitis Can Be a Late Presentation in Patient 
with Rheumatoid Arthritis and Interstitial Lung Disease
Shehzad Ali,1,2 Farhang Ebrahimi.3 1Richmond university med ctr, Staten Island, 
NY; 2Medicine, NYMC-Metropolitan, NY,NY, NY; 3Richmond university medical 
center, Staten Island, NY.
Introduction: Renal limited mpo anca vasculitis has been rarely reported in patients 
with Rheumatoid Arthritis Here we present a case of a patient with not only Rheumatoid 
arthritis but also interstitial lung disease who developed renal limited mpo anca vasculitis 
glomerulonephritis Renal limited anca vasculitis carries significant morbidity, mortality if 
not diagnosed and treated promptly
Case Description: 60 year old white man a retired rescue firefighter at world trade 
center on 911 presented to ER with nausea, lack of appetite, heart burn, weight loss for 
a month His past history is significant for interstitial lung disease for many years and a 
diagnosis of Rheumatoid arthritis two years ago Patient was noted with low level anca 
by his rheumatologist for past year but was thought as bystander Renal sonogram was 
unremarkable and chest radiograph noted bilateral reticular markings from interstitial lung 
disease His lab studies reveal a blood urea nitrogen of 119mg/dl, serum creatinine 9.3mg/dl, 
urinanlysis with rbc casts, normal complement levels, negative hepatitis serology and 
antiglomerular basement membrane antibody MPO anca later came back high at 50.9u He 
was immediately started on pulse steroids a kidney biopsy revealed pauci immune crescentic 
glomerulonephritis. He was diagnosed with MPO Anca vasculitis glomerulonephritis 
and started on rituximab along with steroids. His symptoms improved, creatinine levels 
declined and patient went home on prednisine taper and maintenance rituximab infusion. 
His creatinine declined to 3.5mg/dl over next two months from a high of 9.3mg/dl
Discussion: Renal limited MPO-Anca vasculitis is uncommonly found with other 
immune mediated entities and creates diagnostic challenges. It can present in patients with 
rheumatoid arthritis who have disease for years with systemic symptoms Low level anca can 
also be present in patients with interstitial lung disease In this case patient had no systemic 
symptoms, had low anca titers noted for a year Anca titers and renal function should thus be 
closely monitored especially in patients with rheumatoid arthritis, interstitial lung disease 
without systemic symptoms as overlap can easily be overlooked and or mistaken with 
serious consequences Understanding of entities can help with early diagnosis, intervention 
and to avoid catastrophic outcomes as renal dysfunction and need for long term dialysis
PUB524 
Publication-Only 
Cryoglobinemic Glomerulonephritis Post Streptococcal Pharyngitis
Sam Kant,1 Avi Z. Rosenberg,3 Derek M. Fine.2 1University of Maryland Medical 
Center, Baltimore, MD; 2Johns Hopkins University School of Medicine, 
Baltimore, MD; 3Johns Hopkins University, Baltimore, MD.
Introduction: The most common inciting event of a post infectious glomerulonephritis 
(PIGN), from a historical standpoint and in developing countries, is streptococcal infection. 
Typically, PIGN presents as dominant C3 staining with frequent occurrence of subepithelial 
humps as well as subendothelial deposits. Diverse histological presentations of PIGN are 
being increasingly reported. We present a case of cryoglobinemic glomerulonephritis post 
streptococcal infection
Case Description: A 58 year old female, with a history of type 2 diabetes, presented 
with sore throat, fever and dysphagia for 2 days. She rapidly developed upper airway 
edema, and necessitated intubation. Subsequent nasopharyngeal cultures revealed presence 
of Streptococcus pyogenes and treated with Penicillin G. However, 2 weeks post admission, 
renal function was noted to be deranged with creatinine of 2.2 mg/dL (baseline 1.3 mg/dL), 
with presence of 3+ proteinuria (quantified to be 3g/g as per spot protein:creatinine ratio) 
and 33 RBCs/hpf on urinalysis. The creatinine increased by 1mg/dL each day (with peak 
at 6.2 mg/dL)-warranting initiation of methylprednisone, due to concerns of rapidly 
progressive glomerulonephritis. ANA, ANCA, anti-GBM, Hepatitis B/C and HIV were 
negative with elevated ASO titers (1057 IU/mL) and low C3 (33 mg/dL) and C4 levels 
(3 mg/dL). Subsequent renal biopsy revealed segmental endocapillary proliferation and 
occasional endocapillary leukocytes with segmental wire loop-type deposits on light 
microscopy. Immunoflurescence showed sparse granular peripheral mesangial staining 
for IgA, IgM, kappa and lambda light chains, C3 and C1q with casts stained 4+ for IgA, 
IgM, kappa and lambda light chains and protein resorption droplets stain 4+ for albumin. 
Electron microscopy showed subendothelial and mesangial electron dense deposit with 
no subepithelial deposits. Within 3 days of initiation of steroids, renal function showed 
evidence of rapid improvement.
Discussion: This case highlights that, albeit the history and clinical findings most likely 
point to a classic PIGN- the disease can have varied histologic presentations. Findings 
indicative of cryoglobinemic GN have been rarely reported and is a sequela to consider, 
especially in light of decreased C4 out of proportion to decrease in C3 levels and findings 
based on histology- making it imperative to pursue a renal biopsy if features akin to the 
aforementioned arise.
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A Bloody Cough and the Smoking Gun
Jiesu L. Sun, Akinwande A. Akinfolarin. Baylor University Medical Center, 
Dallas, TX.
Introduction: Goodpasture’s Syndrome (GPS) is a rare autoimmune disease due to 
formation of antibodies targeting the glomerular basement membrane (GBM) in the lungs and 
kidneys. It is characterized by the presence of anti-GBM antibodies, life-threatening pulmonary 
hemorrhage and crescentic glomerulonephritis. Treatment of GPS should be initiated as soon 
as possible with a combination of steroids, plasmapheresis and cytotoxic agents.
Case Description: A 22-year-old breast-feeding female smoker presented to our 
facility with acute renal failure. She had been seen at an outside facility due to nausea, 
vomiting, shortness of breath and leg swelling. Preliminary evaluation revealed acute 
kidney injury. Laboratory data was positive for anti-GBM antibodies and a renal biopsy 
showed crescentic glomerulonephritis- however she absconded from medical care. She re-
presented with worsening dyspnea at rest and oliguria. New laboratory data was notable for 
a serum creatinine of 10 mg/dL and elevated anti-GBM titers. She was initiated on daily 
plasma exchange, pulsed intravenous steroids, and rituximab with subsequent negative anti-
GBM titers. However despite therapy, she developed hemoptysis and hypoxia necessitating 
ICU care. We thereafter started her on oral cyclophosphamide and re-instituted plasma 
exchange and pulsed steroid therapy which lead to the cessation of hemoptysis. Her kidney 
function did not improve and she remained dialysis dependent at discharge from our care. 
We discovered, she had returned to smoking cigarettes while hospitalized after we carefully 
re-interviewed her.
Discussion: Goodpasture’s Syndrome has a low incidence with rates <1 per million. 
Lung involvement is more common in patients who are cigarette smokers and is theorized 
to be precipitated by denudation of the lung basement membrane. Inhaled smoke is thought 
to damage capillary endothelium allowing anti-GBM antibodies to reach alveolar basement 
membranes. The importance of smoking cessation is crucial to prevent life threatening 
alveolar bleeding and early institution of aggressive immune suppression will dramatically 
improve prognosis. There are no studies defining the appropriate therapy for GPS in 
women who are breast feeding due to its relative rarity- especially the appropriate dose of 
cyclophosphamide in this population. Given limited therapeutic options, it is imperative to 
develop a safe dosing regimen for cyclophosphamide in this population.
PUB526 
Publication-Only 
Not an UTI! ANCA-Negative Pauci-Immune Crescentic 
Glomerulonephritis
Ivan Claudio-Gonzalez, Orlando Camacho, Luis Ortiz, Felix W. Perez. Internal 
Medicine, Damas Hospital, Ponce, Puerto Rico.
Introduction: Pauci-immune crescentic glomerulonephritis, so called due to lack 
of glomerular immunoglobulin deposition. Is one of the most common causes of rapidly 
progressive glomerulonephritis (RPGN). Approximately 90% of patients, pauci-immune 
crescentic glomerulonephritis is associated with ANCA, however 10% of patients with 
pauci-immune crescentic glomerulonephritis ANCAs are absent. Patients with ANCA-
negative, pauci-immune RPGN are considered part of this spectrum, and may have similar 
clinical features, renal biopsy findings, and prognosis.
Case Description: A 21 year old Puerto-Rican female presents to emergency 
department complaining of fever. She was previously treated for a urinary tract infection with 
various antibiotics including sulfamethazole/timethroprim without resolution. Nephrology 
consultation was requested upon admission due to increased serum creatinine, associated 
with hematuria and proteinuria. Review of system was only positive for subjective fevers 
and general malaise. Exam and vital signs were unremarkable. Admission laboratories were 
remarkable for elevated WBC 12.30x103/uL, elevated ESR >140mm/hr, mild anemia with 
hemoglobin 11.1g/dL. Serum chemistries were remarkable for serum creatinin of 1.87mg/dL, 
low albumin 2.10g/dL. Analysis of urine revealed RBC 10-12/HPF, granular cast and urine 
PCR 6212mg/g and ACR 1723 mg/g. Serological workup including hepatitis panel, HIV, 
ANA, p-and c-ANCA, rheumatoid factor, complement levels were all normal. Given these 
finding kidney biopsy was performed, showing crescentic glomerulonephritis, involving 
90% of viable glomeruli, with no immune deposits. Patient was treated with pulse steroids 
followed by rituximab 1gm once every 2 weeks for 2 doses and achived remision with 
improvement in serum creatinine to 1.1mg/dL, PCR 709mg/g and ACR 542 mg/g.
Discussion: We report a case of ANCA-negative vasculitis with cresentic 
glomerulonephritis, a relatively rare clinical entity that is only present in about 10% of 
pauci-immune vasculitis. Most patients present with non specific constitutional symptoms 
of fever and arthalgias. Treatment of this entity is derived from ANCA vasculitis, including 
non-specific cytotoxic agents. Crescentic glomerulonephritis must be diagnosed promptly 
so that appropriate treatment can be initiated given the high mortality risk. A better 
understanding of the pathophysiology is needed.
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What’s the Renal Reason for the Seizin’?
Romin Bonakdar,1 Volker Nickeleit,2 Gerald A. Hladik.3 1UNC Hospital, 
Durham, NC; 2The University of North Carolina at Chapel Hill, Chapel Hill, 
NC; 3University of North Carolina at Chapel Hill, Chapel Hill, NC.
Introduction: ANCA disease is a well-appreciated cause of rapidly progressive 
glomerulonephritis (RPGN). It can also affect the nervous system, most commonly in the 
form of peripheral neuropathy, while central nervous system manifestations, including 
seizures, are exceedingly rare. We describe a case of new seizure in a previously healthy 
woman whose work-up led to a diagnosis of ANCA-associated RPGN prior to laboratory 
evidence of renal impairment.
Case Description: A 65 year old woman with hypothyroidism presented with 
generalized tonic-clonic seizure and was discharged on leviteracetam after an unremarkable 
brain MRI. One week later, she began to experience fevers prompting re-admission. 
Lumbar puncture was performed with unrevealing cerebrospinal fluid evaluation. 
Comprehensive vasculitis work-up including ANCA panel returned with a proteinase-3 
titer of 123 u/mL (normally < 21 u/mL) in the setting of normal renal function (creatinine 
0.76 mg/dL). Urinalysis revealed numerous dysmorphic red blood cells. Kidney biopsy 
showed a necrotizing glomerulonephritis with 40% crescents and red blood cell casts. 
She received intravenous high dose steroids and cyclophosphamide. Although the CNS 
manifestations of her ANCA vasculitis resolved, her creatinine at clinic follow-up increased 
to 2.77 mg/dL. She was then re-admitted for plasma exchange followed by a second dose of 
cyclophosphamide with improvement in creatinine to 1.8 mg/dL.
Discussion: Vasculitis should be included in the differential diagnosis of new onset 
seizures, especially when brain imaging is nonspecific. Importantly, lack of consideration 
of ANCA vasculitis as a potential cause of this patient’s seizure, coupled with normal renal 
function at time of presentation, delayed the diagnosis and therapy of her renal disease. 
Recognition that CNS manifestations of ANCA vasculitis may clue to potential renal 
involvement prior to a rise in creatinine could have prompted earlier biopsy and treatment, 
potentially attenuating her renal injury.
PUB528 
Publication-Only 
Case Report: Paraneoplastic FSGS Associated with Acute Lymphocytic 
Leukemia
Anushya Jeyabalan,1 Abdallah Sassine Geara,1 Jonathan J. Hogan,1 
Matthew Palmer.2 1Renal, Electrolyte and Hypertension Division, Hospital of 
the University of Pennsylvania, Philadelphia, PA; 2Department of Pathology 
and Laboratory Medicine, Hospital of the University of Pennsylvania, 
Philadelphia, PA.
Introduction: Paraneoplastic focal segmental glomerulosclerosis (FSGS) is rarely 
described in the literature. We report a patient who presented with nephrotic syndrome 
(NS) and FSGS on kidney biopsy during his initial presentation and recurrence of acute 
lymphocytic leukemia (ALL).
Case Description: An 11-year-old African American boy presented with NS (urine 
protein to creatinine ratio (UPCR) 9.7 g/g, serum albumin 2.1 g/dL) and normal renal 
function. He did not respond to empiric oral prednisone. Kidney biopsy revealed FSGS 
lesions and widespread podocyte foot process effacement. 6 months later, he developed 
leukopenia and was diagnosed with ALL. He was treated with Children’s Oncology Group 
Protocol AALL0232 (cytarabine, vincristine, daunorubicin, dexamethasone, methotrexate, 
pegaspargase, cyclophosphamide, mercaptopurine, doxorubicin, thioguanine) and achieved 
complete remission of NS and ALL. At age 22, he developed NS again (UPCR 29.7 g/g) 
and acute kidney injury (serum creatinine(SCr) 14.7mg/dL) requiring hemodialysis (HD). 
Kidney biopsy showed collapsing FSGS lesions (Figure 1) and extensive podocyte foot 
process effacement. He also had leukopenia and was diagnosed with recurrent ALL (92% 
blast cells). He was treated with R-CVAD (rituximab, cyclophosphamide, vincristine, 
doxorubicin, dexamethasone) and intrathecal Methotrexate and Cytarabine. He was off HD 
within 9 days and at 7 months after kidney biopsy, SCr was 1.5 mg/dL and UPCR 7.6 g/g. He 
achieved complete remission of ALL after 3 weeks of chemotherapy and is on maintenance 
chemotherapy with 6-mercaptopurine, vincristine, methotrexate, and prednisone.
Discussion: We present a rare patient with NS and FSGS coincident with a diagnosis 
of ALL which occurred again on disease relapse. His kidney disease improved with 
chemotherapy in both instances.
Glomerulus demonstrating collapsing lesion, with collapsed capillary tuft and epithelial 
hypertrophy and hyperplasia (Jones silver stain, 400x)
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Decrypting the Dilemma of the Double Agent: Treating Pulmonary-Renal 
Syndrome Due to ANCA Vasculitis and Lupus
Antonio Gabriel D. Corona,1 Akinwande A. Akinfolarin.2 BigBallerBaylor 
1Baylor University Medical Center, Dallas, TX; 2Brigham And Womens Hospital, 
Mckinney, TX.
Introduction: Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of 
autoantibodies directed to cytoplasmic constituents of neutrophils and monocytes. 
Cytoplasmic ANCA is strongly associated with Granulomatosis with Polyangiitis (GPA) 
while perinuclear ANCA (p-ANCA) is strongly associated with Microscopic Polyangiitis 
and Renal-limited vasculitis. ANCA-associated vasculitides (AAV) present with pauci-
immune rapidly progressive glomerulonephritis (RPGN). Very uncommonly, p-ANCA can 
be found co existing with other chronic inflammatory diseases, one of which is systemic 
lupus erythematosus (SLE). This presents a diagnostic and therapeutic dilemma.
Case Description: A 36 year-old Caucasian female presented to our institution with 
painless, gross hematuria. Laboratory data revealed a hematocrit of 25.2, D-dimer 17.1, 
platelets 186,000 and an elevated creatinine of 2.65. Her urinalysis showed numerous 
dysmorphic red blood cells and cellular casts. Her antinuclear antibody (ANA) was 
positive at a titer of 1:160 and elevated ANCA titers. She was started on pulse steroids 
and Mycophenolate Mofetil while awaiting for the results of a kidney biopsy. The biopsy 
report revealed diffuse, segmental proliferative and membranous lupus nephritis (type V) 
with moderate interstitial fibrosis (35%). She, however, suffered further deterioration in 
her kidney function which required the initiation of renal replacement therapy. In spite 
of immune suppression, she developed hemoptysis and then respiratory failure, chest 
tomographic imaging revealed patchy areas suspicious for pulmonary hemorrhage and 
bronchoscopy confirmed diffuse alveolar hemorrhage. Plasma exchange therapy was 
initiated concurrently with another course of pulsed steroids and cyclophosphamide. The 
patient responded well to therapy with subsequent recovery of kidney function.
Discussion: It is unclear whether patients that have lupus nephritis and positive ANCA 
antibodies have separate disease entities or whether it is a spectrum of an overlap syndrome. 
A high index of suspicion must exist for an overlap syndrome, especially if pulmonary 
symptoms occur in a “lupus syndrome”, as the disease can be fulminant and life threatening 
without early diagnosis and aggressive plasma exchange and immune suppression therapy.
PUB530 
Publication-Only 
Rituximab in a Young African American Female with Stage IV and V 
Lupus Nephritis: An Exceptional Response to an Unconventional Therapy
Ashton Ellison,1 Renuka Chowdhury.1,2 1Methodist Dallas Medical Center, 
Dallas, TX; 2Dallas Nephrology Associates, Dallas, TX.
Introduction: Rituximab as a first-line treatment is an unusual, perhaps even wrong 
choice. Data supporting rituximab in patients resistant to both cyclophosphamide and 
mycophenolate (MMF) are limited. This case demonstrated its effectiveness in a patient 
who failed first-tier treatments.
Case Description: A 19-year-old female with a past medical history of SLE with lupus 
nephritis and G6PD deficiency is admitted to hospital due to worsening kidney function. 
She was diagnosed with lupus one year prior. Noted to have joint pain and poor kidney 
function with kidney biopsy confirming lupus nephritis, class IV, she developed worsening 
renal function while on MMF 500mg BID, hydroxychloroquine, and 30mg daily of steroids. 
Cyclophosphamide was initiated 1g/month for 5 months prior to current presentation. Kidney 
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biopsy performed 2 months prior to current admission showed class IV and class V lupus 
nephritis. She was admitted, started on methylprednisolone 1g/day, and rituximab, 600mg 
for two doses, one week apart. After completion of this treatment, she was discharged with 
anticoagulation (warfarin) given low albumin; 60mg of prednisone; pentamidine, while on 
steroids; and follow-up for contraceptive options. Creatinine improved after a further two 
doses of rituximab (see figure). She was continued on MMF from 12/20/18 until 3/29/18, 
when combination therapy with tacrolimus was initiated.
Discussion: This case demonstrates significant improvement in kidney function when 
treating lupus nephritis with rituximab, which is refractory to first-line treatments. Although 
initial studies of rituximab involved European populations, this case suggests generalizable, 
equal effects in African American populations. Additionally, while the use of combination 
therapy with MMF and tacrolimus is not a common practice, it was effective in this patient 
as a maintenance therapy.
Figure: Kidney function before and after treatment with rituximab.Red arrow = rituximab 
administration; UPr/Cr = urine protein creatinine ratio; Cr = creatinine; † = 24-hour urine 
protein.
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MPO-ANCA Positive Crescentic Glomerulonephritis in a Patient with 
History of Histoplasmosis
Sushma Edara, Madhu Kandarpa. Kidney care specialists, Beavercreek, OH.
Introduction: Immunosuppression increases risk of opportunistic infections. Here we 
present a patient with history of histoplasmosis requiring immunosuppresssive therapy for 
treating vasculitis
Case Description: 82-year-old female patient with remote history of histoplasmosis was 
evaluated for asymptomatic worsening proteinuria. She was diagnosed with polymyalgia 
rheumatica three years prior to this presentation when her temporal artery biopsy was 
negative. Patient was treated with prednisone which was discontinued after tapering over 
two years. Serologic testing revealed ANCA-MPO, rheumatoid factor was positive and 
remaining were negative. Kidney biopsy revealed crescentic necrotizing glomerulonephritis 
with features of vasculitis. Risks and benefits of immunosuppression were discussed with 
patient especially about the risk of reactivation of histoplasmosis Patient was initially 
treated with a Methylprednisolone and Cyclophosphamide. Her creatinine improved and 
proteinuria resolved with treatment. She was continued on low dose prednisone to prevent 
recurrence of vasculitis. There is no recurrence of histoplasmosis during treatment.
Discussion: The pathologic hallmark of ANCA-associated glomerulonephritis is a 
pauci-immune necrotizing crescentic glomerulonephritis. Acute lesions such as fibrinoid 
necrosis or glomerular crescent may completely disappear or reduce significantly after 
immunosuppressive therapy. Spontaneous remission is rare, and 80 to 90% of untreated 
patients progress to end-stage renal disease within 6 months. This patient responded 
to treatment with creatinine improving to near normal and no significant proteinuria. 
Immunosuppression poses an increased risk for disseminated and severe infection. This 
patient is being monitored for recurrence of histoplasmosis.
PUB532 
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Nephrotic Syndrome in Hemophagocytic Lymphohistiocytosis
Agustin G. Velazquez perez. LSU health shreveport, Shreveport, LA.
Introduction: Hemophagocytic lymphohistiocytosis (HLH) occurs as a result of 
dysregulated activation of the immune system and is characterized by infiltration of organs 
by macrophages that phagocytose RBCs. HLH may be primary or secondary to malignancy, 
infection, autoimmune diseases. Renal involvement is uncommon, manifesting as ATN or 
nephrotic syndrome. We present a case of AKI and nephrotic syndrome in the setting of 
HLH secondary to HIV
Case Description: 33 yo M was transferred with 1 month history of fever, body aches, 
weight loss, generalized rash, lymphadenopathy and minimal edema. Initial laboratory 
workup was remarkable for pancytopenia, transaminitis and hyperferritinemia a creatinine 
2.5mg/dl and 28gm of proteinuria. Urine analysis showed granular casts. Initial infectious 
workup including HIV testing was negative; no relief despite antibiotic therapy, lymph 
node biopsy showed reactive changes. Bone morrow biopsy, was diagnostic for HLH.
Renal biopsy only 5 glomeruli were noted and was consistent with MCD or FSGS and 
acute tubular injury. He required hemodialysis due to worsening renal failure. On further 
evaluation, his CD4 count was 79/mm3 and HIV testing for antibodies to p2 antigen was 
positive, leading to the suspicion that he was initially in the window period he was started 
on retroviral therapy, leading to enough renal recovery to get off dialysis.
Discussion: AKI with nephrotic syndrome in HLH is believed to be secondary to 
high pro-inflammatory cytokine levels leading to podocyte injury. ATN associated with 
collapsing glomerulopathy, minimal change disease or thrombotic microangiopathy 
are the histological features noted on biopsy and there is no macrophage infiltration of 
the kidney. If it occurs it is termed histiocytic glomerulopathy presenting as AKI alone. 
Collapsing glomerulopathy is noted in African Americans while MCD noted in Caucasians. 
With limited glomeruli on biopsy, collapsing glomerulopathy may have been missed. 
Management is supportive with treatment of the underlying etiology
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Lupus Nephritis in Patient with Co-existing SLE and HIV
Jeffy Kenny Thomas,2 Jobira A. Woldemichael,1 Furheen Baig,3 Jason Cobb.4 
Emory University School of Medicine, Atlanta, GA,USA 1Emory university, 
Atlanta, GA; 2Emory, Atlanta, GA; 3Emory University, Atlanta, GA; 4Emory 
University School of Medicine, Atlanta, GA.
Introduction: Immune complex glomerulonephritis has been an increasingly reported 
phenomena in HIV patients with lupus-like feature but in the absence of histologic and 
clinical markers of systemic lupus erythromatous (SLE). Also, there are reports of patients 
with HIV developing autoimmune processes like SLE or a simultaneous diagnosis of HIV 
and SLE. This is a report of a rare clinical situation of a patient with long-term SLE being 
diagnosed with HIV and presenting with lupus nephritis.
Case Description: 40 years old black female with SLE for 30 years, and a newer 
diagnosis of HIV for 4 years. She presented for evaluation of increasing proteinuria 
(5.3 g/day), hematuria, and increased serum creatinine to 1.3 mg/dl. Patient had a normal 
CD4 count (1,143) and elevated HIV viral load (5.46 log value). The ds-DNA was 
elevated with low c3 and c4 levels. She was on an angiotensin coverting enzyme inhibitor, 
prednisone, plaquenil, and no HIV medications. Patient subsequently had a renal biopsy. 
The result showed immune complex glomerulonephritis compatible with membranous 
lupus nephritis (ISN/RPS Class V). The immunofluorescence staining was positive for 
IgG, IgA, IgM, c3, C1q (full house pattern). Also, she had focal global sclerosis in 31% 
and focal segmental glomerulosclerosis in 8% of the glomeruli. Interstitial fibrosis and 
tubular atrophy (IFTA), severe (90% and 80% respectively). The patient was started on 
mycophenolate mofetil. Unfortunately she had a fast progression of disease and started 
hemodialysis within 6 months.
Discussion: This is a rare case of a patient with long-term SLE that develops HIV. 
Some degree of HIV associated nephropathy cannot be excluded, the positive lupus 
serology and the presence of full house pattern of immunofluorescent staining supports the 
diagnosis of lupus nephritis. She wasn’t on HIV treatment due to a high CD4 count but her 
HIV viral load was positive. Class V lupus nephritis has a good prognosis but her significant 
fibrosis and rapidly progressive disease course may have been related to her untreated HIV. 
Analysis of such individual case reports may lead to important insights into the pathogenic 
mechanism of both diseases along with solving the therapeutic dilemmas that will assist in 
the care of patients.
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Bilateral Facial Palsy as the First Manifestation in Granulomatosis with 
Polyangiitis (GPA)
Kashif A. Abad.1,2 Y. Sun 1UNM, Albuquerque, NM; 2NM VAHCS, Albuquerque, NM.
Introduction: Granulomatosis with polyangiitis (GPA: formerly designated Wegener’s 
granulomatosis) is a rare, autoimmune, multi system disease, first described by Friedrich 
Wegener in 1936. GPA is necrotizing granulomatous inflammation involving the upper and 
lower respiratory tract and necrotizing vasculitis affecting predominantly small to medium 
vessels. ANCA is present in >80 percent of patients with a peak age of presentation in the 
sixth decade of life. Renal disease, at presentation is seen in only 18% of patients; however 
develops with GPA progression. Bilateral facial paralysis as a primary manifestation of GPA 
is extremely rare.
Case Description: We present a 67 year old male with bilateral facial palsy, weight 
loss > 50 lb, dysphagia, anorexia, and depression. Initial extensive neurological evaluation 
was negative, except for the incidental finding of an abdominal aortic mural thrombosis. 
Creatinine (Cr) was 0.6 mg/dL. 3 months later he presented to our hospital with the same 
symptoms as well as increasing shortness of breath, malaise and foul smelling urine. He 
was diagnosed with acute renal failure and urinary sepsis. Pitting edema and an inability 
to close both eyes were noted. Cr ws 8.28 mg/dL. Urinalysis showed RBC’s cast. ANCA 
(PR3+) and low C3, C4 were found (Anit GBM-). IV prednisone and cyclophosphamide 
were started. Head/Neck CT was unremarkable. A kidney biopsy was performed and 
confirmed the diagnosis of GPA and segmental necrotizing glomerulonephritis. There was 
mild improvement in renal function and marked improvement in facial palsy, but 2 months 
after, renal disease worsened and dialysis was initiated.
Discussion: The clinical manifestation of GPA is heterogeneous. The typical triad 
consists of the upper respiratory tract, lungs, and kidneys involvement. However, bilateral 
facial palsy as the first manifestation of GPA, like in this patient, is very rare and only a 
few cases have been reported in the literature. ANCA and PR3 revolutionized the diagnosis 
of GPA, since they allow early diagnosis. The specificity of positive ANCA testing in 
GPA is greater than 95%. In such cases, physicians play a crucial role in recognizing the 
early symptoms of the disease and starting the appropriate therapy to reduce mortality and 
morbidity.
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Methicillin-Sensitive Staphylococcus Aureus Bacteremia Associated with 
Normo-Complementemic, IgA-Predominant, Rapidly Progressive 
Glomerulonephritis - A Case Report
Abbas Raza,1 Muhammad O. Hanif,1 Sandeep Aggarwal,2 Li Li,2 
Karthik M. Ranganna.1 1Drexel University, Philadelphia, PA; 2Drexel University 
College of Medicine, Philadelphia, PA.
Introduction: Infection associated with Rapidly Progressive Glomerulonephritis 
(RPGN) tends to be crescentic with hypocomplementemia or pauci-immune. IgA 
predominant, non-crescentic, post-infectious GN is rarely associated with clinical RPGN. 
We present a case of normo-complementemic, IgA predominant, non-crescentic, and steroid 
responsive, RPGN in a patient with Methicillin-sensitive Staphylococcus Aureus (MSSA) 
bacteremia.
Case Description: A 52-year-old male with past medical history of a chronic left foot 
wound infection, diabetes type II presented with fevers and found to have MSSA bacteremia. 
Creatinine on admission was 4.3 mg/dL whereas few months prior, creatinine was 
0.6 mg/dL. The patient was started on antibiotics and fluids. In the next few days, creatinine 
remains above 4 mg/dL. Autoimmune serologies, viral hepatitis panel, and complements 
were within normal limits. Urine microscopy showed >50 red blood cells (RBC)/field, urine 
protein to creatinine ratio was 1.4 G/g. A renal biopsy performed for ongoing AKI showed : 1) 
Light microscopy - mesangial proliferation without endocapillary/extracapillary 
proliferation, bowman’s space hemorrhage with several tubular RBC casts, mild acute, 
and chronic tubular injury (Figure 1). 2) Electron microscopy - mesangial electron dense 
deposits. 3) Immunofluorescence- IgA/C3 codominant 3+ staining. The patient was treated 
with intravenous and oral steroids with significant improvement of renal function.
Discussion: Definitive diagnosis of the cause of RPGN is required to determine the 
management course. Our case emphasizes the role of renal biopsy as the cornerstone in the 
diagnosis of RPGN as usual lab investigations may not reveal the diagnosis.
Kidney biopsy (light microscopy): Blue arrows indicating mesangial proliferation, black 
arrows indicating tubular injury and red arrows indicating tubular red blood cell casts.
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A Case of Light Chain Nephropathy
Faizan Syed. UNMC University of Nebraska Medical Center, Omaha, NE.
Introduction: The development of proteinuria and deterioration in renal 
function in a patient with diabetes mellitus and hypertension usually suggests diabetic 
nephropathy. However, other causes of renal failure should also be considered.Fibrillary 
glomerulonephritis (FGN) is among the newly recognized primary glomerular diseases. 
This rare cause of end-stage kidney disease has characteristic electron microscopic 
findings based upon the deposition of randomly distributed (10-22 nm) microfibrills in the 
mesangium and less frequently in the capillary basement membrane.Here we report a case 
of a 67 y/M with DM who was found to have IgG Kappa MGUS with FGN with dramatic 
improvement in his kidney function after the initiaion of chemotherapy.
Case Description: 67 years old male with type 2 diabetes mellitus since the age of 
43 as well as photocoagulated retinopathy, hypertension, gout. He developed nephrotic 
syndrome. Serum creatinine level was 2.6 eGFR 28, urine protein excretion 6 gram and 
albumin 24 grams. Physical examination showed 2+ leg edema. His secondary workup 
for Nephrotic syndrome revealed elevated light chains IgG Kappa M-protein 0.32,Kappa 
Free light chains 338, Lambda Free light chains 34 and kappa Lambda ratio of 9.95. This 
prompted B/M biopsy revealing plasma cell dyscrasia(4%). Kidney biopsy confirmed 
diabetic glomerulosclerosi with superimposed fibrillary glomerulonephritis. The patient 
was treated with dual RAS blockers initially and then later after discussion with oncology 
he was started on bortezomib, cyclophosphamide and dexamethasone(CyBorD). After 
continuing 4 cycle treatment his Cr improved to 1.6 and PCR was decreased to 2.1
Discussion: FGN is a rare glomerular disease seen in 0.5–1% of native kidney biopsy. 
Clinical features at the time of kidney biopsy commonly include hypertension, proteinuria, 
hematuria, and varying degree of renal insufficiency. Serum creatinine could also be 
in normal range. Nephrotic syndrome, as in our patient, can be seen in one-third of the 
Diagnosis of FGN typically portends a poor prognosis, with approximately half of the 
patients progressing to end-stage kidney disease within a few years especially if asscoaite 
with DM. Unfortunately there is no established therapy specific for FGN, However, treating 
the underlying malignancy is assocaited with good outcomes. In our case we were able to 
achieve good response after starting the patient on CyBorD therapy for his plasma dyscrasia.
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Publication-Only 
Nephrotic Range Proteinuria with Nodular Pattern on Biopsy in a Patient 
with No History of Diabetes
Hussain Aboud. University of Florida, Gainesville, FL.
Introduction: Kimmelstiel Wilson nodule had been described extensively in the 
literature as pathognomonic for patient with diabetes, however it had been also reported 
in patient who had amyloidosis, multiple myeloma and also reported in idiopathic nodular 
glomerulosclerosis when diabetes had been ruled out and other causes had been excluded.
Case Description: Herein; our patient is a 70-year-old white man with history of 
cerebrovascular accident, hypertension, chronic obstructive pulmonary was referred to us 
for evaluation of elevated creatinine that was 2 mg/dl which was 1.5 mg/dl six months prior, 
he does have proteinuria on his urinalysis 4 years prior, on his last 24 hour collection, he had 
nephrotic range proteinuria at 7.4 gm per day, he is a smoker with 54 years pack history and 
drink occasionally, he presented to us with blood pressure that was 135/63 on lisinopril and 
diltiazem with pulse of 66 and his BMI was 27. His complements level were normal limit, 
his hemoglobin A1C off any medication 5.5 -5.8 over the last 2 years, his hepatitis, HIV 
profile all came back to be negative. Kidney ultrasound showed signs of chronic kidney 
diseaes with no obstruction.
Discussion: Patient was diagnosed with idiopathic nodular nephrosclerosis on biopsy 
as shown on figures attached, his serum protein electrophoresis was within normal range, 
Congo red stain was negative and there had no immune complex deposition seen on his 
Immunofluorescence. Idiopathic nodular nephrosclerosis is a diagnosis of exclusion, 
it is seen more commonly in elderly; white males who are hypertensive and has strong 
correlation to smoking. Studies had showed that people who continued to smoke with 
idiopathic nodular glomerulosclerosis had higher risk of nephrotic syndrome, lower serum 
albumin and rapid progression to end stage renal disease. Neovascularization thought to 
play part in the pathogenesis of idiopathic nodular glomerulosclerosis. We also suggest 
establishing a pathology bank for future diagnosis and treatment for patients with idiopathic 
nodular glomerulsclerosis and reporting every case seen.
PUB538 
Publication-Only 
In Bad Company: Crescents and ANCA Are Bad News for Kidney 
Recovery in Lupus Nephritis
Alwin Lopez-Toro,1 Roberto L. Collazo-Maldonado,1,2 Lisa M. Sebastian.1,2 
1Methodist Dallas Medical Center, Dallas, TX; 2Dallas Nephrology Associates, 
Dallas, TX.
Introduction: Lupus Nephritis (LN) classification highlights the importance of 
histopathological findings and kidney outcomes. Investigators have found a potential 
association between positive ANCA serology leading to poor outcome in Lupus GN. This is 
a case of lupus GN with an impressive biopsy and unexpected serology findings.
Case Description: 40 y/o Caucasian woman with a history of obesity and SLE 
presented to ER with generalized swelling. On exam, she was very hypertensive 
(210/120mmgh), with low grade fever (99.1F), sinus tachycardia and anasarca. Initial 
labs showed a Hgb 6.9 g/dL, Cr 5.4 mg/dL (baseline 1.0 mg/dL), BUN 45 mg/dL, and 
U/A with overt proteinuria (>300mg) and microscopic hematuria with RBC casts. She 
reported taking 2-3 ibuprofen daily for several weeks due to joint pain, but denied any other 
medications or toxic habits. Serology for ANA, anti-dsDNA, ANCA (MPO&PR3), and 
ASO were positive. Complements were normal. Biopsy showed 45 of 48 glomerulus 
with hypercellular crescents (some with fibrinoid necrosis [image]), full house pattern 
on IF, except for negative C1q. EM showed subendothelial and mesangial deposits. 
Findings were compatible with Class IV diffuse lupus nephritis. She started on dialysis in 
addition to high dose cyclophosphamide and steroids. She is currently on her third month of 
treatment with no signs of renal recovery.
Discussion: The amount of crescents in LN is crucial in establishing kidney prognosis. 
Studies have shown a correlation between the amount of crescents in LN with poor outcome 
and higher risk for relapse. Fibrinoid necrosis has also been associated with poor recovery. 
A positive ANCA may occur in about 20% of LN, specially in class IV. Although it suggests 
to be a bad association, there is not yet enough data available to support a correlation with 
poor prognosis. The chances of kidney recovery in this patient appear to be low as she 
remains on dialysis after 3 months of adequate treatment.
PUB539 
Publication-Only 
AKI as the Initial Presentation of Burkitt Lymphoma
Usman A. Khan, Usman Z. Bhutta, Sardar H. Ijaz, Aemen S. Khakwani. 
OUHSC, Oklahoma City, OK.
Introduction: Burkitt’s lymphoma is a highly aggressive B cell non-Hodgkin 
lymphoma characterized by the translocation and dysregulation of the MYC gene on 
chromosome 8. Renal involvement in non-Hodgkin’s lymphoma is usually seen after the 
original disease has been diagnosed and has been reported as 30-50 percent at autopsy.The 
differential for acute kidney injury (AKI) in patients with underlying lymphoma includes 
tumor lysis syndrome (TLS), tumor infiltration, urate nephropathy etc.Diffuse bilateral 
kidney infiltration causing acute renal failure as an initial manifestation of NHL is very rare.
We present a case of a patient (pt) who presented to an outpatient clinic for workup of AKI 
and was diagnosed to have lymphoma based on a renal biopsy.
Case Description: A 46 year old male with a PMH of SLE for 5 years presented to an 
outpatient clinic due to concern for AKI with creatinine (Cr) elevation from 0.8 mg/dL to 
3.57 mg/dL over 8 weeks.A detailed history and physical exam did not reveal any etiology 
for his AKI. Further work up revealed mildly low complement levels and bilaterally 
enlarged kidneys with symmetric edematous appearance of the renal parenchyma. 
Renal biopsy was done to ascertain the etiology of AKI which showed high grade B cell 
lymphoma positive for BCL-6 and CD-10 (weak), while negative for BCL-2 and Ki-67 
index greater than 90%.This warranted a PET scan which showed extensive hypermetabolic 
lymphadenopathy in the cervical, mediastinal, abdominal and pelvic region.The pt was 
started on chemotherapy, developed acute TLS with worsening of renal function, was 
started on CRRT later transitioned to IHD after 4 days.His urine output improved by the 
second week of chemotherapy, AKI resolved and he was able to come off of dialysis.A 
repeat kidney ultrasound showed decrease in his kidney sizes.
Discussion: Renal infiltration has been reported in 30% to 50% of the cases in autopsy 
of non-Hodgkin’s lymphomas, but is clinically silent, with 0.9% to 23% of them developing 
renal insufficiency. Impairment of renal function due to tumor infiltration as the initial 
manifestation of lymphoma is very rare, with only a few cases reported in the literature. 
Prompt diagnosis and early institution of treatment is imperative, as it can partially or 
completely reverse AKI.Our patient was fortunate enough to have a complete response to 
chemotherapy with recovery of renal function to baseline.
PUB540 
Publication-Only 
Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis and 
Crescentic Glomerulonephritis in Diffuse Systemic Sclerosis: Renal 
Failure Not Due to Scleroderma Renal Crisis
Azza Abdel Hak, Ummerubab Syeda, Rakesh Gulati. Thomas Jefferson 
University Hospital, Philadelphia, PA.
Introduction: Scleroderma renal crisis (SRC) is characterized by rapidly 
progressive renal failure with severe hypertension. Rarely, a small number of patients 
with systemic sclerosis develop anti-neutrophil cytoplasmic antibody (ANCA) 
associated glomerulonephritis and renal failure. These patients are usually normotensive. 
Differentiating between the two entities is important and can be challenging.
Case Description: A 57 year old female with history of diffuse systemic sclerosis, was 
admitted for evaluation of progressive renal failure, proteinuria and microscopic hematuria. 
Her blood pressure was 104/63 mm Hg on RAAS blockade. Creatinine level was 2 mg/dl, 
up from a baseline of 1 mg/dl, and her hemoglobin was 9.2 g/dl. Urine analysis was 
significant for +1 protein, +3 Blood and 93 red blood cells per high power field. Complement 
levels were normal. Anti-double stranded DNA and anti-RNA polymerase III antibodies 
were negative. Anti-Myeloperoxidase (MPO) antibodies were positive. Renal biopsy was 
consistent with necrotizing, crescentic glomerulonephritis (Figure 1). The patient was 
started on Rituximab and eventually discharged with plans for outpatient follow-up.
Discussion: Renal involvement in scleroderma is associated with high morbidity and 
mortality. Scleroderma renal crisis (SRC) is the most serious manifestation and usually 
presents with abrupt onset of moderate to severe hypertension and rapidly progressive renal 
dysfunction. The mainstay of treatment of SRC is prompt control of blood pressure in which 
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ACE inhibitors are the most effective. Rarely, as in our case, patients with scleroderma 
present with acute renal failure associated with ANCA related crescentic glomerulonephritis. 
This subset of patients are usually normotensive. Differentiating this from SRC is important 
as treatment usually involves immunosuppression with cyclophosphamide or rituximab and 
cautious use of steroids if necessary.
PUB541 
Publication-Only 
Lupus Nephritis with Negative Antinuclear-Antigen-Antibodies
Jaime R. Jimenez Lopez, Samardia Missick, Ivan E. Porter. Mayo Clinic 
Jacksonville, Jacksonville, FL.
Introduction: Immune-complex-mediated membranoproliferative glomerulonephritis 
(MPGN) with “full house nephropathy” on kidney biopsy is well described on lupus 
nephritis. Antinuclear antigen (ANA) antibodies are one of the laboratory hallmarks, found 
in 99%, of patients with systemic lupus erythematosus (SLE). This case challenges the 
close to obligatory ANA positivity for diagnosing lupus nephritis, and represents a different 
presentation of an old condition.
Case Description: A 53 year-old Caucasian woman with history of chronic anemia 
presented with nephrotic range proteinuria, of 6307 mg in a 24 hour urine collection, 
and an estimated glomerular filtration rate (eGFR) of 87 mL/min. Physical exam was 
unremarkable, with no evidence of arthritis, skin or any organ system involvement, except 
for trace dependent edema. Urinalysis showed microscopic hematuria, with 20-40 RBCs 
per high power of field. Initial serological battery showed decreased C3 at 78 mg/dL 
(normal range: 90-180 mg/dL), normal C4, negative ANA, rheumatoid factor, HIV 
serology, hepatitis serologies, factor H, C3 nephritic factor and cryoglobulins. Additionally, 
workup for paraproteinemias resulted negative as well, and serum albumin was 2.9 g/dL. A 
kidney biopsy was obtained, showing MPGN type 3 pattern, with diffuse endocapillary GN 
plus segmental membranous features, and moderate interstitial fibrosis and tubular atrophy. 
Immunofluorescence was positive at 3+ for IgG and C1q, 2+ for C3, kappa and lambda, 
and 1+ for IgM, at mesangium, capillary loops and tubulointerstitium. Electron microscopy 
demonstrated glomerular basement duplication and severe foot process effacement, with no 
tubuloreticular inclusions. Lisinopril, sodium restriction and mycophenolate mofetil were 
used, with the latter stopped, due to lack of improvement, after 3 months of treatment. At 
3 year follow-up, her eGFR continued to worsen to 27 mL/min, and proteinuria remained 
unchanged. ANA were consistently negative.
Discussion: ANA-negative cases of lupus nephritis, with no extra-renal involvement, 
pose a challenging condition to diagnose and treat. Possible explanations to this presentation 
includes alternative processes, or a different SLE related pathophysiologic mechanism of 
renal involvement. This case exemplifies the challenge lupus nephritis represents, and 
contributes to further discussion about new diagnostic and therapeutic options for this 
condition.
PUB542 
Publication-Only 
A Unique Case of Bilateral Giant Cell Arteritis with Renal  
ANCA-Associated Vasculitis
Pace Romney,3 Josephine Abraham,2 Monica P. Revelo Penafiel,2 
Siddhartha Kakani,1 Laith Al-Rabadi.1 1University of Utah hospital, Salt Lake, 
UT; 2University of Utah, Salt Lake City, UT; 3University of Utah Medical Center, 
Salt Lake City, UT.
Introduction: Giant cell arteritis (GCA) is an autoimmune vasculitis characterized by 
infiltration of medium and large vessels by monocyte-derived giant cells leading to local 
and systemic inflammation. It is a panarteritis preferentially involving the extracranial 
branches of the carotid artery. Herein, we describe an extremely rare entity of biopsy-proven 
GCA and renal failure with a kidney biopsy consistent with pauci-immune necrotizing 
glomerulonephritis (GN).
Case Description: An 81-year-old man presented with weakness, jaw claudication, 
right temporal artery ache and tenderness, altered mentation, and elevated inflammatory 
markers. Bilateral temporal artery biopsy revealed active arteritis with transmural 
inflammation predominantly of mononuclear cells, and disruption of the internal elastic 
lamina consistent with vasculitis. There were no giant cells or granulomas. He had no 
vision loss, stroke, or extremity claudication. Imaging of the great vessels and large arteries 
was negative for vasculitis. He had proteinuria 0.5 g/g, hematuria without casts, and renal 
insufficiency (creatinine 1.3 from baseline of 0.9). He had a high titer of perinuclear 
antinuclear cytoplasmic antibodies (ANCA) and antibodies to myeloperoxidase (MPO). 
Renal biopsy revealed pauci-immune necrotizing GN. He was diagnosed with microscopic 
polyangiitis. The patient was started on prednisone and also given 2 doses of rituximab 
2 weeks apart.
Discussion: Renal involvement with GCA is rare and, to our knowledge, only few 
cases have been reported of associated pauci-immune necrotizing GN. In contrast to 
small vessel vasculitides which can be linked to ANCA, large vessel vasculitides have no 
known associated antibodies. The patient in this case being MPO-ANCA positive with 
renal vasculitis and GCA represents an extremely rare clinical overlap between small, 
medium, and large vessel vasculitis. Histologic analysis is the standard for diagnosis; 
Absence of fibrinoid necrosis and involvement of vasa vasorum favors the diagnosis 
of GCA over ANCA-associated vasculitis (AAV). All patients diagnosed with GCA 
should have evaluation for possible associated renal disease. Doing so has important 
therapeutic implications as the presence of renal vasculitis requires the addition of another 
immunosuppressant such as rituximab.
PUB543 
Publication-Only 
A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits 
(PGNMID) Presenting with a Rare Pathological Feature
Kotoko Shinya, Akihiro Minakawa, Takashi Iwakiri, Ryuzoh Nishizono, 
Masao Kikuchi, Yuji Sato, Shouichi Fujimoto. University of Miyazaki, Miyazaki, 
Japan.
Introduction: PGNMID is a recent entity of glomerulonephritis caused by monoclonal 
IgG gammopathy. Diagnosis of PGNMID requires the presence of a single subclass of 
IgG heavy and light chains deposition by immunofluorescent study, granular deposits by 
electron microscopy (EM), and the absence of cryoglobulinemia. We report a patient with 
PGNMID who presented with a rare pathological feature.
Case Description: A 38-year-old woman was admitted to our department with a 
7-month history of moderate proteinuria. A urinary test showed proteinuria of 1.2 g/day 
and no microscopic hematuria. A blood test showed the following: 0.63 mg/dL of
creatinine, 5.98 g/dL of total protein, 3.54 g/dL of albumin, 68 mg/dL of C3, and 25 mg/dL 
of C4. Cryoglobulinemia was not detected. Renal biopsy showed the microscopic feature
of membranous nephropathy (MN) with IgG deposition. We performed IgG subclass 
immunostaining and an EM study because a young adult woman presenting with idiopathic 
MN is uncommon. Additional immunofluorescence showed monoclonal IgG1-kappa 
monoclonality. EM showed granular deposits in subendothelial, subepithelial and intra-
glomerular basement membranes. A bone marrow examination and serum and urine
electrophoresis did not show evidence of underlying hematological disease. We diagnosed 
the patient with PGNMID and maintained with an angiotensin converting enzyme inhibitor. 
Her renal function and proteinuria did not worsen until the time of this report.
Discussion: A common pathological feature of PGNMID is MPGN like lesion 
with deposition of IgG3-kappa, while MN with IgG1-kappa is rare. PGNMID is rarely 
accompanied by underlying hematological disease, and thus its diagnosis may be difficult 
without suspicion. To avoid missing this disease, an aggressive immunofluorescence study 
to detect monoclonality should be performed, even in the case of non-proliferative GN. 
Mass spectrometric analysis of this case is in progress at the time of writing this report, 
and we will present the possibility of using this method as an alternative for detecting 
monoclonal IgG deposition.
PUB544 
Publication-Only 
Hydralazine Induced ANCA Vasculitis - The Dark Side of Medication
Amal Qureshi,1 Zahra Deen.2 1Ziauddin Medical College, Karachi, Pakistan; 
2Department of Nephrology, CHI St. Luke’s Health - Baylor Medical Center, 
Houston, TX.
Introduction: Kidney related side effects of Hydralazine.
Case Description: 82-year-old African American female with PMH of DLD, HTN, 
CKD III (baseline Cr 1.73 mg/dl) presented to the E.R with abdominal pain, diarrhea 
and decreased urine output for 2 weeks. On examination, she was lethargic but oriented, 
appeared anorexic and lungs clear to auscultation. Patient was hemodynamically stable. 
Her medications included statins, beta blocker and recently started hydralazine. Initial labs 
perfomed, as mentioned in the table. UA showed microscopic hematuria and proteinuria - 
prompting further workup as no improvement was seen with 24 hours of IVF. Secondary 
work up was performed as mentioned in table. These results were confusing for RPGN 
secondary to lupus nephritis vs ANCA vasculitis with our differential being hydralazine 
induced lupus with false positive ANCA. After further discussion kidney biopsy was 
pursued, which to our surprise showed crescentic glomerulonephritis, pauci-immune with 
moderate to severe interstitial fibrosis and marked arterial sclerosis. Complements were 
repeated and continued to remain low. Hydralazine was discontinued and the patient was 
started on Prednisone, Rituximab and initiated on dialysis.
Discussion: Hydralazine is FDA-approved for essential hypertension and 
recommended by the AHA for the treatment of CHF in African-Americans. The auto-
immunogenic capability of hydralazine has been shown through its ability to induce lupus 
and vasculitis. Hydralazine-induced lupus differs from idiopathic lupus both clinically 
and serologically. Clinically it rarely involves the kidneys (only 5 %) or nervous system. 
Serologically while all patients are positive for ANA and can be positive for antihistone 
antibody, they do not have positive dsDNA or hypocomplementemia. The consideration 
for hydralazine-induced ANCA vasculitis should be higher for patients who are African-
American, if they have positive MPO ANCA antibody at a high titer and positive ANA. 
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Antibodies to elastase and lactoferrin are also common in hydralazine-induced ANCA 
vasculitis and hypocomplementemia can be seen.
PUB545 
Publication-Only 
Crescentic Glomerulonephritis in Henoch-Schönlein Purpura with ANCA: 
A Therapeutic Dilemma
Rickinder Grewal, Bruce Goldman, Anirban Bose. University of Rochester 
Medical Center, Rochester, NY.
Introduction: The significance of immune complex staining in ANCA-associated 
glomerulonephritis (AAGN) is unclear and there are no established guidelines for treatment. 
We report a case of crescentic glomerulonephritis with strong IgA deposition and ANCA 
positivity.
Case Description: A 49-year-old male with a history of hypertension and rheumatoid 
arthritis presented to the hospital with a purpuric rash, nephrotic syndrome, and AKI with a 
very active urine sediment. Serology showed ANA 1:80, c-ANCA 1:640, and PR3 antibody of 
180 U. Renal biopsy demonstrated diffuse active necrotizing crescentic glomerulonephritis 
with dominant IgA deposition (Figure 1). Skin biopsy showed leukocytoclastic vasculitis 
with focal IgA staining suggestive of Henoch-Schönlein Purpura. He was pulsed with high-
dose steroids with plans for outpatient Rituximab (RTX) and cyclophosphamide (CYC) 
but was soon readmitted with pulmonary symptoms and worsening renal function. He was 
again treated with high-dose steroids and started on plasmapheresis and hemodialysis. He 
was then started on IV CYC 500 mg every 2 weeks and weekly IV RTX 375 mg/m2 for a 
total of 4 doses every 6 months. However, the patient refused CYC after 2 doses due to 
concerns for toxicity. Although his PR3 antibody levels normalized on RTX, he has not 
shown signs of renal recovery and remains on peritoneal dialysis.
Discussion: Concurrent crescentic IgA nephropathy (IgAN) and AAGN is very rare. 
Our case illustrates the difficulty in treating such patients and the dilemma encountered 
in determining the predominant pathology. While CYC has been used to effectively treat 
both IgAN and AAGN individually, there is no data to support the use of RTX in crescentic 
IgAN. In such cases of concurrent crescentic IgAN and AAGN, primary therapy with CYC 
should be considered.
Figure 1: Renal biopsy with a fibrocellular crescent (arrow) on PAS stain (A) and dominant 
IgA deposition on immunofluorescence (B).
PUB546 
Publication-Only 
Cryoglobulinemic Vasculitis: Unusual Presentation of Multiple Myeloma
Cidcley N. Cabral,1 Mirna D. Meira,2 Ana Paula Gueiros,1 Ericson C. Gouveia,1 
Augustus C. Freitas,1 Luiz antonio M. Da fonte filho,2 Moacir C. Netto,3 
Rafaela M. Gouveia,3 Thayná R. Moraes,3 Heliana M. Mello.2 1IMIP, RECIFE, 
Brazil; 2IMIP, Recife, Brazil; 3Imip, Recife, Brazil.
Introduction: Type I cryoglobulins (CGs) are immunoglobulins that precipitate 
at low temperatures, causing inflammation and tissue damage. They are compounds 
of a monoclonal immunoglobulin, mainly IgG, and are associated with hematological 
malignancies. Around 10% of patients with multiple myeloma (MM) present detectable 
CGs, althoough few develop symptoms. We report the case of a patient with severe 
cryoglobulinemic vasculitis secondary to MM.
Case Description: This was a female patient, aged 42, with previous hypertension. 
During the previous four months, she experienced a strong, burning pain in the lower 
limbs, that developed into purpuric, necrotic lesions at the extremities. She presented a 
rapid deterioration of renal function, requiring dyalisis. She experienced a mild microscopic 
hematuria and, due to the risk of crescentic glomerulonephritis, was submitted to pulse 
therapy with methylprednisolone 1g/day for 3 days. Laboratory tests revealed: ANA, anti-
SM, p-ANCA, c-ANCA, anti-HCV, HBsAg, VDRL, anti-HIV, antiphospholipid antibodies, 
all negative. Only the C3 was discreetly reduced. Hemoglobin 6.0 g/dL; platelets 149,000, 
with no schizocytes, DHL=696 U/L (125-220) with an ADAMTS-13 activity of 45%. 
She underwent a kidney biopsy, evolving with bleeding, which resulted in nephrectomy. 
The biopsy revealed areas of fibrinoid necrosis and intracapillary thrombi with focal 
granular deposits and in vessels of IgG, C3 and Kappa. CGs research was positive and 
serum protein electrophoresis revealed a monoclonal peak. The patient presented with 
pulmonary hemorrhage and a chest CT scan revealed bilateral ground-glass infiltrate. She 
received pulse treatment with cyclophosphamide and was subjected to plasmapheresis. A 
bone marrow biopsy and immunohistochemistry were compatible with MM. After a fresh 
episode of pulmonary hemorrhage, the patient died without receiving treatment for MM.
Discussion: Rarely reported, type I CGs associated with MM appear to worsen the 
prognosis, especially if diagnosis is delayed. This study emphasizes the need to investigate 
neoplasms, mainly hematologic, in the presence of cryoglobulinemic systemic vasculitis.
PUB547 
Publication-Only 
A Case of Severe Diffuse Membranoproliferative Glomerulonephritis in 
Lupus Nephritis with Thrombotic Microangiopathy
Ujjala Kumar,1 Kioumars Bolourian kashi,2 Danuta Trzebinska.2 1UCSD, San 
Diego, CA; 2UCSD Medical Center, San Diego, CA.
Introduction: Renal involvement is common in patients with Systemic Lupus 
Erythematous (SLE). An abnormal urinalysis (proteinuria and/or hematuria) is present in up 
to 75% of patients with SLE. Elevated creatinine develops in ~ 30% and ~ 10% of patients 
with Lupus Nephritis (LN) develop End Stage Renal Disease (ESRD). Furthermore, Blacks 
and Hispanics have worse outcomes including death and ESRD.
Case Description: We present a case of a 41-year-old Hispanic male presenting with 
lower extremity edema, joint pain, high blood pressure and a skin rash. His medical history 
is noteworthy for SLE diagnosed seven years ago and class IV/V lupus nephritis diagnosed 
three years ago treated with an incomplete course of IV Cyclophosphamide due to severe 
infectious complications and was switched to Mycophenolic acid (MMF). He was on 
MMF 500mg twice a day prior to admission. Patient was in acute renal failure with serum 
creatinine of 4.0 mg/dL (baseline creatinine around 1.8 mg/dL). Complement levels C3 and 
C4 were extremely low at 19 mg/dL and < 2 mg/dL respectively. Urinalysis showed active 
urinary sediments. Urine protein to Cr ratio was 4.0. Repeat kidney biopsy revealed class 
IV diffuse membranoproliferative glomerulonephritis with focal crescents and thrombotic 
microangiopathy, moderate interstitial fibrosis and tubular atrophy ~ 30%. Patient was 
pulsed with Solumedrol for three days and dose for MMF was titrated up to 1.5 gms 
twice daily. Despite aggressive treatment his renal functions deteriorated leading to 
initiation of hemodialysis. A course of therapeutic plasmapheresis (TPE) was also initiated. 
Patient underwent a total of 6 every other day treatments consisting of one plasma volume 
exchange. He was also continued on intermittent hemodialysis for a total of 4 treatments, 
at which point his renal function recovered enough to get off the dialysis. Patient was 
discharged home on MMF, prednisone and plaquenil.
Discussion: In conclusion, our patient with severe proliferative LN with TMA had 
a favorable outcome from treatment regimen consisting of plasmapheresis and standard 
immunosuppression. Previous studies have demonstrated variable effectiveness of TPE in 
patients with lupus nephritis. Additional prospective studies are desired to consolidate the 
role of plasmapheresis in treatment of severe LN with renal TMA.
PUB548 
Publication-Only 
A Case of an Elderly Patient with IgA Vasculitis
Romela Petrosyan, Blake D. Shusterman. Greenville Health System, Greenville, SC.
Introduction: IgA vasculitis (Henoch-Schonlein) is primarily seen in children between 
the ages of 3 and 15 years of age with annual incidence of 15 cases/100,000 compared 
to 1.3 cases/100,000 per year in adults. HSP is only responsible for 0.6 to 2% of adult 
nephropathies.
Case Description: A 77-year-old Caucasian male was admitted with septic shock and 
acute renal failure secondary to duodenal diverticulitis and urinary tract infection. The patient 
had accompanying confusion, nausea, vomiting, diarrhea, epigastric abdominal tenderness, 
and decreased urinary output. Physical exam demonstrated palpable purpura on bilateral 
upper and lower extremities. He was hemodynamically stable and afebrile. Laboratory 
studies revealed a BUN of 106, Creatinine 6.14 (baseline 1), C3 60.0, C4 14 and normal 
platelets. Other serologies were negative. Urinalysis was significant for >182RBCs/hpf and 
protein/creatinine ratio of 0.45mg/dL. Skin biopsy revealed florid acute vasculitis involving 
small vessels with intramural and perivascular fibrin deposition. Renal biopsy revealed 
mesangial IgA dominant immune-complex deposits with focal endocapillary proliferation 
and exudation. The patient received pulse methylprednisolone and was transitioned to 60mg 
of prednisone with a prolonged taper. He initially improved with reduction of hematuria, 
proteinuria, and creatinine, but recurrence occurred during the steroid taper.
Discussion: IgA vasculitis prognostication in adults is not well characterized. Steroids 
shorten the duration of symptoms but do not affect the course of the disease. Glomerular IgA 
predominantly consists of galactose-deficient IgA1, which is specific to both IgA vasculitis 
with nephritis and IgA nephropathy, thus distinguishing them from other glomerular 
diseases. Though IgA vasculitis and IgA nephropathy are distinct clinical entities, they may 
share a common renal pathogenesis.
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IgA immune-complex deposition on immunofluorescence
PUB549 
Publication-Only 
HSP - Not Always Purpura
Sai K. Koyoda. Monmouth Medical Center, Ocean, NJ.
Introduction: Henoch-Schonlein Purpura (HSP), an IgA vasculitis seen in pediatric 
age group and rarely in adults, manifests as palpable purpura, diffuse abdominal pain, 
hematuria, arthritis, and in some cases even as bullous rash as seen in our case. It is 
important to differentiate HSP nephritis which is treated with immunosuppressants from 
its close proximity diagnosis Staphylococcus associated glomerulonephritis, which needs 
only antibiotics.
Case Description: This is a case of a 54-year-old female with uncontrolled diabetes 
mellitus. She was admitted for left foot cellulitis of the left great toe. Both the blood and 
wound cultured fast-growing staphylococcus aureus and was started on intravenous(IV) 
antibiotics. On the second day of admission, she developed bullous lesions over her bilateral 
foot. Succeeding, she complained of abdominal pain accompanied by diarrhea, followed 
by hematuria and generalized purpuric vasculitic rash. Subsequently, she developed 
oliguric acute renal failure. Skin and kidney biopsy performed were consistent with the 
diagnosis of staphylococcal IgA nephropathy/Henoch-Schonlein Purpura. She was started 
on 500mg methylprednisolone and maintained followed by daily prednisone and continued 
with IV ertapenem for 42 days. Her hospital course was complicated by paroxysmal atrial 
fibrillation, electrolyte abnormalities, volume overload leading to a requirement for chronic 
dialysis.
Discussion: HSP rarely manifests as bullous lesions in contrast to classic purpuric 
rash. In vasculitis, the blood vessels are already narrowed owing to on-going inflammation, 
and steroids, in turn, being procoagulant may not be the best drugs of choice. Few studies 
of similar cases being treated with cyclophosphamide(CYC) has shown better clinical 
outcome compared to steroids. CYC may be a better drug of choice in these vasculitic 
conditions, though more studies and further data are needed to change the guidelines.
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Introduction: IgA nephropathy (IgAN) as an extraintestinal manifestation of 
inflammatory bowel disease (IBD) has a low incidence, during 12 years it has been reported 
in 24% of 83 patients of kidney biopsy specimens from patients with IBD and acute or 
chronic kidney failure or proteinuria.
Case Description: A 22-year-old male with CUCI not yet in remission. Maintains 
treatment with Prednisone 30mg and azathioprine 100mg daily. Ten years ago initiated 
mezalasin, prednisone and after 6 months suspended for lack of improvement. He also has 
diagnosis of lithiasis a year ago, and gross hematuria that occurred when running. Hematuria 
and proteinuria have been reported for 1 year, accompanied by elevation of creatinine and 
urea. On physical examination the vital signs were normal and he has Cushing appearance, 
on laboratory exams he has mild leukocytosis, Creatinine 1.3mg/dL, cholesterol 216mg/
dL, Uric acid 5.19mg/dL, DHL 506 Ui, urine examn with proteinuria 100mg/dL, hematuria 
7 ppf, in collected urine 800mg per 24 hours, ANAs and ANCAs and VIH, VHB, VHC were 
negative. A renal biopsy was performed that reports IgA nephropathy Oxford MEST-C: 
M1, S0, E1, T0, C0. Therefore, immunosuppression with Prednisone was increased and 
Enalapril was initiated, with reduction in creatinine to Cr 1.04 and proteinuria maintain en 
860mg per 24 hours
Discussion: The association between IgA nephropathy and IBD is infrequent. A genetic 
connection has been reported between both diseases, the majority of the loci involved in the 
pathophysiology of IgAN are directly associated with the risk of IBD or the maintenance of 
the intestinal epithelial barrier with its response to mucosal pathogens. In addition, genetic 
linkage has been suggested due to the presence of HLA-DR1 in IgAN and HLA-DR1 / 
DQw5 in IBD. The reduction of chronic antigenic stimulation of IgA production and blood 
levels of nephrotoxic cytokines after the elimination of the source of chronic inflammation 
is the main objective of the treatment, so achieving remission of the disease would allow 
the improvement of the kidney damage, even when there are extensive sclerotic changes 
in the kidneys. The aggressive treatment of IBD can improve the manifestations of IgAN, 
it is important to bear in mind the correlation of glomerulonephritis as an extraintestinal 
manifestation of IBD.
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Introduction: In 2012, the term MGRS was introduced to describe patients who had 
MGUS with Renal dysfunction being the only systemic manifestation. The most recent 
diagnostic criteria for Multiple Myeloma require the presence >10% clonal Plasma cells in 
the Bone Marrow plus of one or more CRAB or Myeloma Defining Events. Here we present 
a patient with Multiple Myeloma whose only presentation was severe Renal impairement 
(requiring dialysis) with MPGN pattern of Injury on Kidney biopsy who responded well to 
Chemotherapy and came off Dialysis in about 4 weeks.
Case Description: This is a 64 yr old male with no significant medical Hx. He 
presented with Lower extremity edema and Hypertension. Wokup showed Nephrotic 
syndrome (24 hr Urine Protein: 15 g, S. Albumin 2.3, and Edema). Serologic tests were 
negative (HepC, HepB, HIV, ANA, ANCA, Anti GBM). C3 and C4 were both low. RRT 
was initiated soon after admission (Cr up to 7, baseline~1). Despite the absence of other 
CRAB features, SFLC, SPEP and UPEP were obtained. His Kappa/Lambda free light chain 
ration was 0.11 Kidney Biopsy: LM showed an MPGN pattern of injury, IF with linear 
Lambda staining and IgG3, EM with moderate effacement of foot the foot processes. Bone 
Marrow showed 40% clonal plasma cells.
Discussion: Despite the absence of the other classic CRAB criteria, Renal involvement 
in this patient was severe, with MPGN, Nephrotic/Nephritic picture and AKI requiring 
RRT. His response to Chemotherapy (CyBorD) was excellent, and he came off dialysis 
in about 4 weeks (Creatinine now~1.5). Screening for MGRS and Multiple Myeloma in 
patients with Renal disease is important, Chemotherapy should be initiated as appropriate, 
and many patients respond well to this approach.
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LM, EM and Bone Marrow slides will also be included in the final presentation (not 
included here due to the size of the images).
PUB552 
Publication-Only 
An Unusual Case of Glomerulonephritis (GN) with Prominent Glomeru-
lar Complement Deposition
Jessica M. Nelson,1 Sergey V. Brodsky,1 Brad H. Rovin.2 1Ohio State Wexner 
Medical Center, Columbus, OH; 2Ohio State University Wexner Medical Center, 
Columbus, OH.
Introduction: The presence of glomerular immune complexes (ICs) is critical to 
determining the correct diagnosis and treatment of GN with prominent complement C3 
staining. Although ICs are usually easily shown by immunofluorescence (IF), sometimes 
this is more complicated.
Case Description: A young white woman developed acute congestive heart failure that 
was attributed to viral myocarditis. Within 9 months she recovered. She went wilderness 
hiking and two weeks later developed fever, arthralgias, proteinuria (2.2 g/d), and elevated 
serum creatinine (SCr) (1.64 mg/dL). Infectious evaluation was negative but she was treated 
with antibiotics and fever resolved. The kidney disease was felt to be infection-related GN, 
however it did not clear and 9 months after the febrile illness she had a kidney biopsy. 
The biopsy demonstrated moderate glomerulosclerosis and interstitial fibrosis on light 
microscopy, negative IF except for bright glomerular C3, and large subepithelial humps 
on electron microscopy. C3GN was considered, but no functional or genetic abnormalities 
of the alternative complement pathway were found. Proteinuria decreased to 0.2 g/d and 
SCr was stable so the patient was followed closely. Over the next 15 months proteinuria 
increased to 1.1 g/d. A kidney biopsy was identical to the first biopsy with persistent C3 
on IF, subepithelial deposits, and only mild progression of interstitial fibrosis. Paraffin-
embedded tissue was protease-digested and repeat IF showed kappa-restricted granular IgG 
deposits in the mesangium and GBM. Paraffin-embedded tissue was retrieved from her first 
biopsy, protease-digested, and it showed kappa-restricted IgG deposits. These findings led 
to a diagnosis of membranous-like glomerulopathy with masked IgG kappa deposits. No 
circulating or urinary paraproteins were found and bone-marrow biopsy is pending.
Discussion: The diagnosis of this patient’s kidney disease rested on the discovery of 
immune deposits that were unmasked only after IF on protease-digested paraffin-embedded 
sections. In glomerular diseases with prominent complement deposition the presence or 
absence of immune complexes will affect treatment decisions. In the absence of staining 
on routine IF, protease digestion of paraffin tissue should be considered to exclude masked 
immune deposits.
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Introduction: ANCA mediated vasculitis is characterized by the absence of immune 
complex deposition. Certain drugs may be implicated in development of ANCA mediated 
vasculitis and are associated with constitutional symptoms, arthralgias and cutaneous 
vasculitis. Rarely, crescentic glomerulonephritis and alveolar hemorrhage may also be 
present. We describe a rare case of doxycycline induced ANCA vasculitis causing pauci-
immune crescentic glomerulonephritis.
Case Description: A 68 year-old female presented with fever and cough and was 
prescribed levofloxacin followed by moxifloxacin for an upper respiratory tract infection. 
She failed to respond to these antibiotics and was switched to oral doxycycline 100 mg 
twice daily. After initiation of doxycycline, she developed a lacy, reticular rash on bilateral 
lower extremities. Doxycycline was discontinued but she continued to have fevers, 
arthralgias and fatigue. Labs revealed acute kidney injury with a creatinine of 2.0 mg/dl. 
Urinalysis showed hematuria along with proteinuria 100+. Serological work-up showed 
positive c-ANCA (1:1024) along with low C4 (9 mg/dL). Her serum creatinine peaked 
at 4.39 mg/dL and renal biopsy was performed. Renal biopsy confirmed necrotizing and 
crescentic glomerulonephritis, pauci-immune type, along with necrotizing arteritis. Patient 
was initiated on pulse-dose steroids along with Rituximab 375 mg/m2 four weekly doses. 
Two weeks after the initiation of treatment, patient’s renal function showed improvement 
with a serum creatinine of 2.87 mg/dL with complete resolution of constitutional symptoms.
Discussion: We describe an uncommon presentation of doxycycline causing ANCA 
vasculitis and leading to pauci-immune glomerulonephritis. In patients developing drug 
rash and constitutional symptoms with antibiotics like doxycycline, renal function should 
be assessed. Prompt diagnosis and timely initiation of immunosuppressive agents are 
essential to renal recovery.
Necrotizing Crescent
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Introduction: Chronic lymphocytic leukemia/ Small Lymphocytic Lymphoma (CLL/
SLL) is the most common non-Hodgkin lymphoma associated with glomerular disease but 
there are only 8 cases of crescentic glomerulonephritis (cGN) associated with CLL/SLL. 
We are reporting a patient with history of CLL/SLL presenting with acute kidney injury 
(AKI) and in whom the renal biopsy revealed a crescentic Post Infectious GN (PIGN) with 
concurrent interstitial infiltration of malignant lymphoid cells. To our knowledge, no such 
case has been reported in the literature.
Case Description: A 59 y/o diabetic male with history of CLL/SLL, hypertension, 
seizures, recurrent DVT/PE and CKD was admitted for work up and management of AKI. 
His only complaint was chronic lower extremity (LE) swelling. His physical exam was 
remarkable for a BP of 157/106, jugular venous distention, severe pitting edema in the 
LE’s, and a right thigh abscess. Initial labs showed a WBC of 9.9 with 53.7% lymphocytes, 
Creatinine of 4.10mg/dl, and 24hr urine protein of 8g. Serology for Hepatitis B, C, HIV 
and ANCA was negative. Complements were normal. He received antibiotics and the 
abscess was drained. Renal function improved and patient was discharged to follow up 
with his hematologist. The renal biopsy revealed crescents in 7/20 glomeruli, endocapillary 
proliferation and rare double contours superimposed on diabetic glomerulosclerosis. A 
dense interstitial infiltration of neoplastic lymphocytes staining positively for CD20, CD23, 
CD43 and CD5 was also present. By immunofluorescence microscopy, C3 was deposited 
along the capillaries. By electron microscopy, a large subepithelial hump was identified. 
Therefore, the patient was diagnosed with crescentic PIGN with associated interstitial 
infiltration of SLL.
Discussion: All SLL-associated cGN cases were reported as pauci-immune GN, 
with one case showing infiltration of neoplastic lymphoid cells within the interstitium. 
The combination of endocapillary proliferation, glomerular crescents, C3 deposition and 
a single subepithelial hump characterizes our case as PIGN. Compared to Pauci-immune 
GN, PIGN is an occurrence not previously reported in this setting, dictating a completely 
different patient management.
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Introduction: Goodpasture syndrome (GPS) is characterized by diffuse alveolar 
hemorrhage, rapidly progressive glomerulonephritis and positive anti-glomerular basement 
(Anti-GBM) antibody. Treatment initiation is invariably based on a positive Anti-GBM 
antibody. We present a case of anti-GBM negative, C-ANCA positive GPS.
Case Description: A 66 year-old male with history of hypertension presented with 
intermittent hemoptysis for three months and one week of hematuria, fever and chills. On 
admission he was normotensive and with otherwise normal physical exam. Laboratory 
abnormalities included: BUN 119mg/dL, creatinine 14.43mg/dL, potassium 3.3mmol/L, 
hemoglobin 8.4g/dL, ESR 66 and C-reactive protein 3.5mg/dL. CT chest, abdomen 
and pelvis showed scattered areas of opacities throughout the lungs bilaterally. Urine 
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microscopy showed RBC casts and 50-100 RBCs/HPF. Work-up revealed an elevated 
ANA, and negative anti-RNP, scl-70, anti-SM, anti-SSA, anti-LA, and anti-dsDNA. C3 and 
C4 levels were normal. Patient had a rapid clinical deterioration with increased hypoxemia 
and worsening hemoptysis. Methylprednisolone was started for suspected Wegener’s 
granulomatosis. Additional tests revealed a positive c-ANCA with a titer of1:320 and 
negative anti-GBM antibody. Patient had cardiac arrest and expired. Lung autopsy revealed 
red epithelization and hemorrhage. Histologically, there was minimal necrosis of the 
alveoli which is expected of Wegener’s granulomatosis. The kidneys showed intra-tubular 
hemorrhage but no crescents or active glomerulonephritis were seen, instead intra-alveolar 
hemorrhage with organization in the alveolar space was found suggestive of early GPS.
Discussion: GPS is characterized by presence of autoantibodies against α3 chain of 
type 4 collagen found in alveolar and glomerular basement membrane. Antibody detection 
rate by ELISA has a false negative rate < 5%. It is important to note that 15%-30% of patients 
with GPS have positive antinuclear cytoplasmic antibody (ANCA), 3/4th of those cases being 
C-ANCA. Proper management includes plasmapheresis and immunosuppressive therapy.
It is important to differentiate ANCA associated vasculitis from GPS. Serologic testing is
the fastest method of diagnosing GPS but carries limitations. Renal biopsy, although gold
standard, is difficult to perform in critically ill patients making decision making for timely 
management challenging for physicians.
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Introduction: Membranoproliferative glomerulonephritis is caused by two main 
mechanisms: immune complex deposition leading to activation of complement and 
persistent activation of alternate complement pathway. This dysregulation causes a thickened 
glomerular basement membrane and increased mesangial and capillary cellularity. MPGN 
is challenging to treat especially when the underlying cause is unknown.
Case Description: A 66-year-old Asian man with history of hepatitis C cirrhosis 
presented to the emergency room with increased abdominal distention and lower extremity 
edema for the past month. On physical exam he had large ascites and 2+ bilateral lower 
extremity pitting edema. His creatinine was 1.25, but urinalysis revealed >600 protein. 
Renal ultrasound showed normal kidneys, but there was 13 grams of proteinuria on 
24-hour urine collection. Patient’s hepatitis C was diagnosed two years ago, and he was
treated with Ribavirin and Epclusa with cure. HCV RNA PCR during this admission was
undetectable. Serologic work up included HIV, RPR, ANCA panel, RF, complements, free 
light chains, cryoglobulins, and anti-PLA2R antibody. Kidney biopsy showed MPGN in the 
setting of sustained viral response from hepatitis C, with no evidence of chronicity or ATN. 
IF was consistent with immune complex mediated MPGN and EM was consistent with
subendothelial deposits. It was positive for IgG, IgA, IgM, C3c, C1q, kappa and lambda.
Serologic work-up was normal, serum C3 and C4 were both low and cryoglobulins were
negative. He was treated with IV induction steroids and then transitioned to oral prednisone. 
Repeat 24 hour urine protein was 6.5 grams which improved from 13 grams on admission. 
Since patient had partial response to steroids, Rituximab was started. Anasarca improved
with improving proteinuria and diuresis.
Discussion: MPGN has a variety of causes including infections, autoimmune disease, 
and monoclonal gammopathies. The IF microscopy showed a “full house” picture with 
properties of both complement mediated, and immune complex mediated MPGN. This 
is typically seen in autoimmune disorders, although autoimmune work up was negative. 
Though HCV has been associated with MPGN, currently there is sparse literature about 
MPGN in patients after successful treatment of HCV. Thus, this patient with treated HCV 
most likely developed primary MPGN.
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Introduction: Pauci-Immune glomerulonephritis is the most common cause of 
RPGN in adults and elderly patients. ANCA serology is usually positive and has shown 
to play a role in the clinical presentation, kidney manifestations, and renal recovery. 
Rituximab continues to gain popularity as the first option in treatment. This is the case 
of ANCA negative pauci-immune glomerulonephritis with good response to Rituximab in 
combination with methylprednisolone and plasmapheresis.
Case Description: A 65 y/o African American Male with history of hypertension, 
tobacco use, and prostate CA in remission presented to the ER complaining of progressive 
general malaise and 15lb weight gain over 2 weeks. He reported sudden uncontrolled BP 
control in the last 3 months. Physical exam positive for scrotal and +2 pitting edema of 
lower extremities. Initial labs showed Hgb 14.8 g/dL, Cr 1.4 mg/dL (baseline 0.8mg/dL), 
BUN 37 mg/dL, Alb 2.3 g/dL and U/A with proteinuria (>600mg) and microscopic 
hematuria. A 24hr urine collection revealed 45 gm of protein. Serology workup was 
negative including ANCA, paraproteinemia, and infectious process. Patient denied taking 
any medicines besides anti-HTN’s. Kidney biopsy revealed pauci-immune focal segmental 
necrotizing glomerulonephritis with one cellular crescent along with 25% tubular atrophy 
and interstitial fibrosis. He was started on methylprednisolone with weekly Rituximab for 
4 weeks. After 2 weeks, his creatinine was still rising. At this time plasmapheresis was 
initiated and continued for 7 days. After the 3rd dose of rituximab, his Cr went down to 
0.8 mg/dL with resolution of edema.
Discussion: Pauci-immune GN usually presents with either positive c-ANCA or 
p-ANCA. Rarely, it can present with negative serology which can delay diagnosis and
initiation of therapy. ANCA negative RPGN presentation is atypical. It usually lacks extra- 
renal involvement and presents with nephrotic range proteinuria. Kidney biopsy is key to 
early institution of appropriate therapy that can impact on kidney recovery and long term 
prognosis. Nephrologists should be highly suspicious of this possibility and be prompt to 
order kidney biopsy.
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Introduction: Mesangioproliferative glomerulonephritis (MesPGN) consists of 
a group of disorders histologically characterized by an increase in mesangial cells and 
expansion of the mesangial matrix secondary to deposits of specific immunoglobulins, 
complements, or immunocomplexes. This insult leads to nephrotic range proteinuria, 
hematuria, and hypertension (HTN). We present a case in which the deposits consist of 
immunocomplexes in the setting of autoimmune thyroiditis (AIT).
Case Description: The patient is a 23-year-old female with history of autoimmune 
thyroiditis and HTN who was referred to Nephrology for evaluation of hematuria and 
proteinuria. Symptomatically, the patient denied arthralgia and rash. Her family history 
was positive for lupus and Hashimoto disease. Physical exam was unremarkable. Initial 
workup revealed: Cr 1.7, microscopic hematuria and proteinuria, urine protein/Cr ratio 
3010 mg/g. Serology showed an ANA of 1/40 with negative anti Smith ab and anti ds-DNA. 
Rheumatology consult ruled out lupus. A kidney biopsy was obtained and revealed immune 
complex mediated focal mesangioproliferative glomerulonephritis. Immunofluorescence was 
significant for deposition of IgG, IgM, and C3. The patient was initiated on an ACE inhibitor, 
mycophenolate mofetile (MMF) 1000 mg BID and prednisone. Microscopic hematuria 
resolved shortly after starting therapy and proteinuria improved to less than 1000 mg/g. 
Two years into treatment, prednisone was titrated off. MMF was titrated down 3 years after 
diagnosis. Patient continues to follow-up in clinic and has been in remission for 4 years 
status post discontinuation of immunosuppression.
Discussion: AIT has been associated with membranous nephropathy, IgA Nephropathy, 
and focal segmental glomerulonephritis, but there have been no prior reports of association 
with MesPGN. Given disease rarity, there are no randomized trials regarding treatment. In 
patients presenting with mild proteinuria and HTN, ACE inhibitors can prevent progression 
to nephrotic range proteinuria. For patients with nephrotic range proteinuria, steroids can 
prevent progression to FSGS. Immunosuppressants have gained popularity as a treatment 
modality. MMF, in particular, works by improvement of mesangial cell and matrix 
hypercellularity. The comparative efficacy of MMF in conjunction with steroids to other 
therapies has yet to be established.
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Introduction: Complement dysfunction is a major contributor to the pathophysiology 
of atypical hemolytic uremic syndrome (aHUS). Scleroderma renal crisis (SRC) shares 
many clinical and pathologic features with aHUS. We present a case of SRC in a patient 
with a homozygous mutation associated with aHUS.
Case Description: A 44-year-old woman with a 17-year history of scleroderma 
presented to rheumatology clinic with new onset hypertension and a rising creatinine. She 
was admitted to the hospital and started on captopril for blood pressure control; her blood 
pressure was lowered to her baseline within 48 hours. A 24-hour urine protein demonstrated 
1.7 g proteinuria. Given the late presentation of her kidney injury relative to her diagnosis of 
scleroderma, she underwent a renal biopsy. Blood vessels showed moderate-to-severe wall 
thickening with semi-occlusive/occlusive changes and some of the vessels revealed “onion 
skinning,” consistent with SRC (Fig 1). Her creatinine stabilized at 2 mg/dl and she was 
discharged. She was readmitted one week later with recurrent hypertension and an elevated 
creatinine. The patient underwent genotyping for mutations of the complement pathway and 
was found to have a homozygous polymorphism within an intron of the membrane cofactor 
protein/CD46, which has been associated with aHUS. She was initiated on eculizumab. She 
subsequently developed an infection and had an antibiotic drug reaction that caused her 
renal disease to progress and she was initiated on dialysis.
Discussion: SRC and aHUS are two entities that are clinically and pathologically 
similar. SRC pathogenesis may be related to alternative complement pathway dysfunction.
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Introduction: Fibrillary glomerulonephritis (FGN) is a rare disease found in 1% of 
native kidney biopsies. Most commonly seen in Caucasians, with a predominance of female 
to male ratio 2:1. Is characterized by glomerular accumulation of non-branching, haphazardly 
arranged fibrils measuring 10-30 nm in thickness in the mesangium. Undistinguishable 
from amyloid fibrils except for lack of reactivity to congo red staining. Light microscopy 
variable patterns that include membranoproliferative, diffuse proliferative, mesangial 
proliferation and expansion. IF most often reveal polyclonal deposit of IgGs, particularly 
IgG4 and IgG1. Very little is known about pathogenesis of FGN, however the presence 
of IgG and complement suggests a glomerular deposition of immune complexes with the 
ability to undergo fibrillogenesis. Renal outcomes for this disease are poor with progression 
to ESRD in 4 years in 50% of the patients. No standard therapies are available
Case Description: 71 year old Caucasian male with history of Bladder cancer and 
Hypertension who developed nephrotic range proteinuria 3.5g/d, serum cr level 1.72 mg/dL, 
eGFR (MDRD) 39 mL/min/1.732. Five months prior with baseline serum creatinine 
1.18 mg/dL and eGFR 64.68mL/min/1.73m2. C3: 123, C4: 32, HIV, Hep B/C, ANA 
and PLA2R negative. Kappa/lambda 0.78. SPEP and UPEP negative for monoclonal 
protein. Physical exam significant for +2 lower extremity edema. Kidney biopsy yielded 
20 glomeruli. Light microscopy showed diffuse and global mesangial expansion without 
proliferation. IF was positive for IgG +3, C3 +2, kappa +3 and lambda +3. EM showed 
sub-epithelial and sub-endothelial densities composed by randomly arranged, non-
branching fibrils measuring 20nm consistent with FGN. Patient was treated with two 
doses of rituximab (1G IV x 2). Six months later, serum creatinine 1.68mg/dL and eGFR 
40 mL/min/1.73m2, with a decrease UPCR to 1.2
Discussion: FGN is an uncommon disease, reason why no controlled clinical trials 
have been conducted. Small case series propose rituximab as a promising treatment for FGN 
with the pathology rationale of predominant polyclonal IgG deposits seen in mesangium 
and glomerular basement. Favorable results were observed in patients with preserved renal 
function at baseline, similar to our patient suggesting that early diagnosis is necessary to 
prevent or decrease progression to ESRD.
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Introduction: IgA nephropathy is the most common biopsied glomerulonephritis 
worldwide and typically has a slowly progressive course. IgA nephropathy has been 
associated with end-stage liver disease with biopsies of patients prior to liver transplant or 
ex-plant in liver-kidney transplant patients demonstrating IgA nephropathy in up to 50% 
of cases. However, it has been rarely reported as new diagnosis post-liver transplantation. 
Here, we present a case of IgA nephropathy which developed several years after liver 
transplantation.
Case Description: Patient is a 62 year-old male with a history of hepatitis C and 
alcohol-related cirrhosis who underwent liver transplantation in 2009. Prior to transplant, 
he had no renal dysfunction, hematuria or proteinuria. He presented to nephrology clinic 
in 2016 with worsening chronic kidney disease (CKD) and proteinuria. His hepatitis C 
had been successfully treated post-transplantation. Laboratory examination at time of initial 
consultation showed tacrolimus levels at goal, creatinine of 2.4 mg/dL and urine protein-
creatinine ratio of 3.3. Because of his proteinuria, with no clear explanation, he underwent 
renal biopsy which showed co-dominant IgA and IgG mesangial and segmental capillary 
loop staining by immunofluorescence as well as subendothelial deposits by electron 
microscopy and focal nodular hyalinosis. These findings are consistent with IgA focal 
proliferative glomerulonephritis and calcineurin inhibitor toxicity. He was placed on an 
angiotensin converting enzyme inhibitor and his creatinine has stabilized with a reduction 
in his proteinuria.
Discussion: CKD, usually secondary to calcineurin inhibitor toxicity, is a known 
complication of liver transplantation. There is also a known association of IgA nephropathy 
with end-stage liver disease. However, the development of IgA nephropathy following 
liver transplantation has been rarely reported. This case demonstrates the importance 
of considering other etiologies of chronic kidney disease in post-transplant patients, 
particularly if hematuria or proteinuria are present.
PUB562 
Publication-Only 
A Case of Malignant Hypertension with Thrombotic Microangiopathy 
Mimicking Small-Vessel Vasculitic Diseases
Masaki Itagane, Ko Sudo, Hitoshi Miyasato. Okinawa Chubu Hospital, Uruma, 
Japan.
Introduction: Malignant hypertension may present with a number of clinical sequela, 
however, pulmonary hemorrhage and palpable purpura are rarely associated with the disease 
presentation. We present a case of malignant hypertension presenting with thrombotic 
microangiopathy (TMA).
Case Description: A 37-year-old woman presented with a 2-month history of anasarca 
and a 2-week history of progressive dyspnea with hemoptysis. Her past medical history 
was significant for untreated hypertension. On arrival, the patient’s blood pressure was 
230/150 mmHg. She had bilateral inspiratory crackles on lung auscultation and bilateral 
pretibial slow pitting edema and palpable purpura on her extremities. She had a microcytic 
anemia (Hb 10.5 g/dl) and mild thrombocytopenia (129,000 platelets/μl) without evidence 
of schistocytosis. The LDH value was 819 U/l and serum creatinine level was 4.3 mg/dl. 
The urinalysis demonstrated hematuria and proteinuria with granular casts. The spot urine 
protein to creatinine ratio was 0.8 g/gCr. Her chest radiograph showed bilateral diffuse 
ground grass opacities. The patient subsequently received a sequential bronchoalveolar 
lavage, which demonstrated alveolar hemorrhage. Small-vessel vasculitic diseases were 
suspected, yet the patient’s serum ANA, MPO-ANCA, PR3-ANCA, anti-dsDNA, and anti-
GBM antibodies were all negative. A skin biopsy showed the presence of microthrombosis 
within the dermis. The histology of the renal biopsy was compatible with TMA, revealing 
glomerular intracapillary fibrinoid necrosis with fibrinoid thrombosis and accumulation 
of fragmented erythrocytes, mucoid intimal thickening and concentric myointimal 
proliferation. After initiating treatment with antihypertensive drugs, the patient’s serum Hb, 
platelets and LDH normalized. Her renal function also recovered without dialysis. Follow-
up evaluation identified no secondary causes of resistant hypertension.
Discussion: A high index of suspicion of malignant hypertension with TMA is 
warranted in patients with a history of uncontrolled hypertension and symptoms of 
pulmonary renal syndrome and purpura, which are typically manifestations of small-vessel 
vasculitic diseases. Early and aggressive blood pressure control may reduce long-term 
morbidity and mortality in these patients.
PUB563 
Publication-Only 
Life Threatening Bleeding from Arcuate Kidney Artery Aneurysm as a 
Rare Complication of Granulomatosis with Polyangiitis
Piotr Skonieczny,1,2 Zbigniew Heleniak,1 Tomasz Liberek,1 Barbara Bullo-
Piontecka,1 Bartosz Bascik,3 Alicja Debska-Slizien.1 1Department of Nephrology, 
Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, 
Poland; 2Department of Physiology, Medical University of Gdansk, Gdansk, 
Poland; 3Department of Radiology, Medical University of Gdansk, Gdansk, 
Poland.
Introduction: Granulomatosis with polyangiitis (GPA) is a systemic necrotizing 
inflammation of small and medium-size vessels. It most commonly affects the upper 
respiratory tract and the kidneys. Bleeding from aneurysms formed during the disease is 
a rare complication.
Case Description: 50y old patient was transferred to the Department of Nephrology 
with the suspicion of GPA. The patient was hospitalized for one month with fever, night 
sweats and progressive pedal edema. The blood test revealed high CRP, the CT scan 
suggested staphylococcus pneumonia, although patient condition did not improve with 
antibiotic therapy. Development of kidney failure (creatinine rise from 0.7mg/dl to 3.7mg/dl) 
and progression of pulmonary infiltrates with cavity formation raised the suspicion of 
GPA. On admission creatinine was 4.1mg/dl, CRP 211mg/l, cANCA 1:2560, anti-PR3 
titer 188RU/ml and among clinical symptoms dominated significant shortness of breath 
what corresponded with massive pulmonary infiltrates in CT scan. The diagnosis of 
life-threatening GPA was establish and patient received i.v. methylprednisolone, plasma 
exchange therapy and pulses of cyclophosphamide. Simultaneously hemodialysis was 
initiated. On the 15th day of hospitalization patient suffered from a very strong pain in 
the right flank with significant hemoglobin lowering. Angio-CT scan was performed and 
showed massive hematoma adjacent to the right kidney with active bleeding from the 
raptured aneurysm of the arcuate artery. Numerous small non-bleeding aneurysms in both 
kidneys were also visualized. Urgent embolization of the bleeding vessel was performed 
which stopped the hemorrhage. After third pulse of cyclophosphamide the condition of the 
patient improved, regression of the pulmonary infiltrates was observed, although the patient 
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remained dialysis dependent. The follow up immunosuppressive therapy was planned on 
an outpatient basis.
Discussion: Clinical manifestations of GPA can be highly varied and are dependent 
upon which organ is affected by vasculitis. Major hemorrhage from an aneurysm of a 
medium or large-size artery is a rare manifestation of ANCA-associated vasculitis. Urgent 
diagnostic CT and intravascular radiology intervention or surgery can ameliorate the patient 
condition.
PUB564 
Publication-Only 
Lupus Optic Neuritis in ESRD Patient
Gajapathiraju Chamarthi,3 Justin Lee Loy,2 Abhilash Koratala.1 1Nephrology, 
University of Florida, Gainesville, FL; 2University of Florida Gainesville, 
Gainesville, FL; 3University of Flroida, Gainesville, FL.
Introduction: Optic neuropathy is an uncommon finding in dialysis patients and 
has been associated with uremia, ischemia (arteritic and nonarteritic), drugs (isoniazid, 
ethambutol), infections (tuberculosis) and intracranial hypertension. Inflammatory optic 
neuritis associated with lupus nephritis is however extremely rare. Herein, we present one 
such case.
Case Description: A 50-year-old Indian-American female with a history of end stage 
renal disease (ESRD) secondary to Lupus nephritis, on renal replacement therapy for 2 
years presented to the ER with intermittent left eye loss of vision described as “foggy 
vision, as if looking through a curtain at the edges” for six days without flashing lights. 
Fundus examination showed optic disc edema with mild obscuration vessels (arrow) and 
peripapillary flame hemorrhages and retinal pigment epithelial mottling of the macula 
[Figure], consistent with inflammatory optic neuritis from Lupus. Her dialysis sessions were 
uneventful and the most recent monthly Kt/V was 1.4.
Discussion: Clinical and serological lupus activity is thought to be substantially reduced 
after the onset of ESRD and most of the extra-renal manifestations are hematological. The 
main determinants of lupus activity are age of the patient and time on dialysis therapy, 
reaching 39% after 5 years on dialysis.Our patient was admitted to the hospital and treated 
with intravenous methylprednisolone 250 mg pulsed every 6 hours for 3 days and then 
was transitioned to oral steroids on outpatient basis. Visual symptoms showed gradual 
improvement. Apart from eye infections related to catheter-related blood stream infections, 
optic neuritis from Lupus is another important ophthalmologic condition that Nephrologists 
need to be familiar with to facilitate prompt treatment.
PUB565 
Publication-Only 
An Unusual Cause of Hematuria on a Patient with Granulomatous 
Polyangiitis
Ngozi Okoba. Yale School of Medicine, New Haven, CT.
Introduction: Granulomatous polyangiitis (GPA) is an inflammatory condition 
characterized by often relapsing hematuria, proteinuria and renal damage. Here, we present 
a case of an 87 year old man with history of GPA who presented with persistent hematuria, 
raising concern for a flare of his GPA, and subsequently a bladder wall malignancy when a 
mass was found in his bladder. However, evaluation, notable for an elevated urine pH and 
mild leukocyturia, ultimately led to the diagnosis of Corynebarcterium urealyticum cystitis, 
an uncommon condition seen in immunosuppressed patients.
Case Description: An 87 year old man with an 18 year history of GPA with renal 
involvement and prostate cancer presented to his rheumatologist with 1 month of 
intermittent hematuria and weakness. He was found to have elevated serologic titers 
and was presumptively treated for GPA relapse with high dose steroids and rituximab. 
Symptoms persisted, however, and he returned with gross hematuria. On admission, he was 
hemodynamically stable and afebrile. Cr was 2, up from a baseline of 1.5, and the CRP and 
ESR were normal. Urinalysis showed 3+ blood, 3+ protein, 3+ leukesterase, 20-25 wbc and 
a pH of 9. Urine sediments was impressive for RBCs and WBCs but no dysmorphic cells 
were seen. Urine culture was initially negative. Hematuria improved with CBI; cystoscopy 
demonstrated a calcified bladder mass, and a transurethral resection of bladder tumor was 
recommended. The culture eventually grew Corynebacterium urealyticum and Nephrology 
recommended antibiotic therapy. Cystoscopy was nevertheless performed with resection 
of the mass; pathology showed no evidence of malignancy but predominantly denuded 
urothelium with reactive changes, atypical stromal cells, necrosis, and active chronic 
inflammation with calcium deposits.
Discussion: C. Urealyticum is a fastidious, urea-splitting gram-positive organism 
typically seen in immunosuppressed patients, often introduced by frequent bladder 
catheterization, as it was in this gentleman. Our patient’s presentation, with an encrusted 
cystitis and pyelitis, is typical. The elevated urine pH and the presence of the bladder mass 
in a chronically catheterized immunosuppressed patient were clues to the diagnosis and an 
invasive intervention might have been avoided.
PUB566 
Publication-Only 
Congo Red Positive Fibrillary Glomerulonephritis
Akram Audi, Jeffrey W. Rosenberg, Sai Subhodhini Reddy, Bruce Goldman, 
David Levy. University of Rochester Medical Center, Rochester, NY.
Introduction: Patients with nephrotic range proteinuria and longstanding diabetes 
mellitus (DM) are often presumed to have diabetic nephropathy (DN). Therefore kidney 
biopsy is often not performed. However as the prevalence of DM in the general population 
is rising, the number of cases of nephrotic range proteinuria that are falsely attributed to DN 
also may be increasing.
Case Description: A 62 year-old female with a history of DM, CKD stage 3, and HTN 
presented with elevated creatinine and proteinuria. She was noted to have newly diagnosed 
nephrotic range proteinuria (8 grams/day) which was not consistent with her disease course 
and therefore kidney biopsy was performed. The light microscopy showed capillary wall 
and mesangial matrix expansion as well as interstitial fibrosis with a chronic lymphocytic 
inflammatory infiltrate. Immunofluorescence was significant for smudgy deposition of C3 
(1+), IgG (1+), kappa light chain (1+) and lambda light chain (2+). Electron Microscopy 
(EM) showed fibril deposition with fibril diameters being greater than those typical of 
amyloid. Furthermore, Congo red staining was weakly positive but did not show green 
birefringence. Fibril identification by liquid chromatography/mass spectrophotometry 
(performed at Mayo Laboratories, Rochester MN) was negative for monoclonal light 
chain but showed positivity for iDNAJB9, a sensitive and specific marker of fibrillary 
glomerulonephritis (FGN).
Discussion: FGN is defined by the presence of organized fibrils on EM that are 
usually thicker than those of amyloidosis, usually positive for polyclonal IgG and C3, and 
importantly are unstained with Congo red. Our patient was found to have this rare diagnosis. 
This case highlights the importance of renal biopsy in patients with DM and nephrotic range 
proteinuria, who present with an atypical disease course. Additionally, when renal biopsy 
shows organized deposits, mass spectroscopy should be considered to ensure an accurate 
diagnosis.
PUB567 
Publication-Only 
Diffuse Alveolar Hemorrhage, a Rare Complication of Henoch-Schönlein 
Purpura
Elbert Chow,1 Corey J. Cavanaugh,2 Ethan P. Marin.2 1Norwalk Hospital, 
Norwalk, CT; 2Nephrology, Yale University, NewHaven, CT.
Introduction: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis typically 
seen in children. Less commonly the disease can occur adults, with renal disease more 
severe than that seen in children. Diffuse alveolar hemorrhage (DAH) is a rare complication 
of HSP which if not promptly recognized, carries a high mortality.
Case Description: A 50 y/o male with history of hypertension treated with hydralazine, 
alcoholic cirrhosis, prior documented leukocytoclastic vasculitis (LCV) presented with 
lower extremity cellulitis and was treated with vancomycin. On second day of admission 
he was noted to have significant hypoxia and hemoptysis prompting intubation. There 
was interval development of purpuric rash in the trunk, bilateral arms and legs. A CT 
scan demonstrated diffuse lung consolidation and bronchoscopy findings consistent with 
DAH. Laboratories were remarkable for creatinine: 2.81mg/dL, BUN: 45mg/dL with 
associated hematuria and minimal proteinuria. Serologies revealed elevated MPO-ANCA 
(544 AU/ml), double stranded antibodies (119 IU), anti-histone (3.8) but normal anti-GBM 
and anti-proteinase 3 titers. Intravenous methylprednisolone and plasmapheresis were 
started for presumed ANCA associated vasculitis (AAV). Renal biopsy revealed diffuse 
mesangioproliferative glomerulonephritis and acute tubular necrosis without crescents 
on light microscopy. Immunofluorescence (IF) showed 2+ IgA, 2+ IgM and 2+ C3, all 
in a mesangial pattern. Electron microscopy demonstrated segmental effacement of foot 
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processes without tubuloreticular inclusions. Biopsy of his purpuric rash demonstrated LCV 
but was negative for IgA on IF. Due to development of leukopenia, rituximab was started 
over cytoxan. Despite treatment, he was unable to recover any renal function requiring 
dialysis. He was intubated for a prolonged intubation course and was ultimately transitioned 
to comfort care.
Discussion: HSP with DAH is a fatal complication, with reported prevalence between 
1.6%-5% and a mortality rate of 27.5%. Our patient was suspected to have AAV given 
his positive ANCA and MPO serologies, however kidney biopsy argued against a pauci-
immune glomerulonephritis. Instead, a diagnosis of HSP with DAH was felt most likely, 
and treated with corticosteroids, plasmapheresis and rituximab. The poor outcome in this 
case, highlights challenges in treatment of this particularly devastating disease.
PUB568 
Publication-Only 
A Case of a Pregnant Woman Carrying Dichorionic Diamniotic Twins and 
Having Nephrotic Syndrome Eventually Diagnosed as IgA Nephropathy 
and Preeclampsia After Delivery
Nagisa Koda,2 Kei Matsumoto,3 Shuichiro Yamanaka,2 Masahiro Okabe,1 
Kentaro Koike,2 Yukio Maruyama,2 Nobuo Tsuboi,2 Tetsuya Kawamura,2 
Takashi Yokoo.2 1Jikei University School of Medicine, Tokyo, Japan; 2The Jikei 
University School of Medicine, Tokyo, Japan; 3The Jikei University school of 
medicine, Tokyo, Japan.
Introduction: A 35-year-old Chinese pregnant with dichorionic diamniotic (DCDA) 
twins developed nephrotic syndrome (NS). However, her blood pressure (BP) continued to 
be normal throughout her gestation and puerperium. After delivery, her NS got worse. A renal 
biopsy (RBx) revealed IgA nephropathy (IgAN) and preeclampsia. She was treated with 
steroid therapy and her NS improved. This is a rare case presenting a combination of IgAN 
and preeclampsia pathologically but not meeting preeclampisa criteria in the clinical course.
Case Description: A 35-year-old Chinese female with no history of renal disease 
was pregnant with DCDA twins. At 31 weeks of pregnancy, she presented with nephrotic 
range proteinuria (8.9 g/day) and hypoalbuminemia (1.7 g/dL) for the first time. However, 
her BP was normal, at approximately 110/80 mmHg. She did not match the criteria of 
preeclampsia. At 34 weeks of pregnancy, she delivered twins by cesarean section. At 
16 days after delivery, she presented with syncope and her NS got worse; her proteinuria was 
21.1 g/day. She underwent an RBx, and we started treatment with m-PSL pulse followed 
by conventional prednisolone therapy. Her pathological findings were extracapillary cell 
proliferation and 3+ staining for IgA over the mesangial area on immunofluorescence, 
and electron microscopy revealed electron dense deposits in the paramesangial area along 
with endotheliosis and epithelial cell changes. Therefore, her pathological diagnosis was a 
combination of IgAN and preeclampsia. After beginning steroid therapy, her NS gradually 
improved.
Discussion: This case showed development of severe proteinuria without hypertension, 
which is rare. IgAN cases diagnosed as a result of NS comprise less than 10% of all IgAN 
cases. In addition, NS due to renal diseases reportedly occurs in 0.028% of pregnant women. 
Therefore, if pregnancies present severe gestational proteinuria without hypertension, a 
pathological preeclampsia diagnosis should be considered.
IgAN and Pregnancy
PUB569 
Publication-Only 
Podocyte Infolding Glomerulopathy: A Rare Cause of Proteinuria in SLE
Neelofar R. Khan,1 Kenar D. Jhaveri,1 Sonali Narain,3 Vanesa Bijol,2 
Rimda Wanchoo.1 1Nephrology, Zucker School of Medicine at Hofstra Northwell, 
GREAT NECK, NY; 2Pathology, Zucker School of Medicine at Hofstra/
Northwell, Great Neck, NY; 3Rheumatology, Zucker School of Medicine at 
Hofstra Northwell, Manhasset, NY.
Introduction: Podocyte infolding glomerulopathy (PIG) is a pathologic entity 
characterized by diffuse podocyte infolding into the glomerular basement membrane (GBM) 
associated with ultrastructurally demonstrable microspherular aggregates. The clinical 
features, significance, and pathogenesis of this condition are still not well delineated because 
only a few cases have been documented to date, all from Japan and India. We report a case of 
PIG associated with SLE in an AA woman who presented with nephrotic syndrome.
Case Description: A 25 year old AA female was seen in nephrology clinic as a 
transition of care from pediatrics. She had a diagnosis of SLE for over 10 years. She had a 
kidney biopsy 5 years ago that showed Class III+V lupus nephritis that required treatment 
with tacrolimus monotherapy. Since, her renal function was normal and her proteinuria 
minimal at <1gm/24 hours tacrolimus was discontinued. Over the next one year, her 
proteinuria progressed to 3gm. A kidney biopsy revealed PIG along with Class 1 lupus 
nephritis. EM analysis of the biopsy specimen revealed unusual subepithelial aggregates of 
microspherules admixed with few microtubules alongside extensive infolding of podocyte 
foot processes into the underlying GBMs. Characteristic clustering of these microparticles 
near the invaginated tips of podocyte foot processes in the GBM was observed on EM. 
With elevated dsDNA levels, and normal secondary workup of all viral etiologies, it was 
presumed to be secondary to SLE and treatment was initiated with rituximab (2 doses) 
1gm over 2 weeks apart. She was maximized on conservative therapy with enalapril. Her 
proteinuria peaked at 5gm and the most recent is 2gm. Her dsDNA levels have been down-
trending as well.
Discussion: PIG is a rare entity initially described as a nucleopore glomerulopathy 
in the 1980s. Most of the recent cases described have been in the Japanese and the 
Indian population. Majority of the patients had a contaminant diagnosis of SLE or other 
autoimmune diseases. The diagnosis is made with findings on EM as IF shows minimal 
reactivity to immunoglobulins. Response to immunosuppression can be variable. In our 
case, there was a partial response to rituximab therapy. Nephrologists and rheumatologist 
need to be aware of this rare form of glomerular disease in patients with SLE and other 
connective tissue disorders.
PUB570 
Publication-Only 
Immunological Remission in PLA2R-Antibody–Associated Membranous 
Nephropathy in a Kidney Transplant Patient After Excision of Breast 
Cancer
Aldo E. Torres Ortiz,1 Youssef Al hmada,2 Iasmina Craici,1 
Wisit Cheungpasitporn.1 1Nephrology, University of Mississippi Medical Center, 
Jackson, MS; 2University of Mississippi Medical Center, Jackson, MS.
Introduction: M-type phospholipase A2 receptor(PLA2R) is the major antigen in 
primary membranous nephropathy(MN). It is suggested that coexistent PLA2R-positive 
MN and cancers are coincidental since previous reported cases did not achieve remission 
of proteinuria after tumor resection. We present a case of coexistent PLA2R-positive MN 
and breast cancer after kidney transplant(KTx), who subsequently had immunological 
remission in PLA2R-Ab and reduction of proteinuria after excision of breast cancer.
Case Description: A 76-year-old Caucasian female, who was a recipient of a deceased 
donor zero-ABDR mismatch kidney, developed worsening proteinuria over the first year 
post KTx. Long-standing HTN was the presumed cause of her ESRD. She received induction 
with rabbit anti-thymocyte globulin and was maintained on cyclosporine, prednisone and 
mycophenolic acid. At 2-month follow-up, she developed 2+ (100 mg/dL) proteinuria. Thus, 
lisinopril was initiated and was titrated up to 20 mg daily. Her serum Cr had been 1.0 mg/dL 
which was her baseline. However, her proteinuria had been gradually worsening, measured 
at 4 g/24h at 8-month post-KTx. Renal allograft biopsy revealed MN with +glomerular 
PLA2R deposition. The PLA2R Ab in the serum was also positive. IgG subtyping showed 
intense IgG4 staining along the glomerular capillary walls. Lab testing showed negative for 
monoclonal protein, ANA, HBV, HCV, and HIV. She underwent age-appropriate screening 
for malignancy, and was found to have newly diagnosed ductal Carcinoma in Situ of left 
breast. She underwent lumpectomy and did not require chemotherapy. The patient did not 
receive higher immunosuppression or any additional treatment for her MN. On 9-month 
follow-up studies, proteinuria in a 24-hour urine collection decreased to 1.1 g/24h with 
stable serum Cr. Serum PLA2R-Ab was repeated and came back negative.
Discussion: The coexistence of MN, solid tumors, and PLA2R positivity has been 
previously reported, and is suggested that the coexistence could be coincidental. In addition, 
recent studies showed that appearance of PLA2R-Ab post-KTx may suggest a more resistant 
MN. To our knowledge, this is the first case of KTX patient, who achieved immunological 
remission in PLA2R-Ab and reduction of proteinuria after excision of breast cancer.
PUB571 
Publication-Only 
Crescentic Lupus Nephritis Treated with MMF, a Promising Outcome: 2 
Patient Series
Kavitha Ramaswamy,1 Ummerubab Syeda,2 Omar H. Maarouf.2 1Nephrology, 
Thomas Jefferson University, Philadelphia, PA; 2Thomas Jefferson University 
Hospital, Philadelphia, PA.
Introduction: Crescentic lupus nephritis is a severe disease that requires an aggressive 
approach to treatment. Recent randomized clinical trials showed that mycophenolate mofetil 
compared favorably with cyclophosphamide (traditional approach) for remission induction. 
However, the role of mycophenolate mofetil in treating crescentic lupus nephritis remains 
unclear, because such patients were excluded from these trials. Many nephrologists still 
prefer to treat this patient population with cyclophosphamide despite its known toxicities. 
Here, we present a case series of two patients with severe crescentic lupus nephritis (class 4 G) 
treated with MMF –as an induction therapy-with an excellent response within 6 months 
of treatment.
Case Description: Patient 1: 34 year old African American female with class 4 lupus 
nephritis complicated by crescents as evidenced by her renal biopsy. Upon induction with 
MMF and steroids, she has had marked improvement in serological markers of activity 
including dsDNA titers (173 to 15) and improvement in serum albumin (1.7 to 3.6) within 3 
months of treatment. Patient 2: 30 year old African American female with crescentic lupus 
nephritis class 4, was also initiated on MMF and steroids. Her kidney function has markedly 
improved with creatinine dropping from 3.5 mg/dL to 1.33 mg/dL. Her proteinuria has 
markedly decreased from 9.5g to 1.2g within 3 months of induction.
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Discussion: Lupus nephritis represents a significant complication of SLE with 
substantial morbidity and mortality. Although treatment has improved, treating crescentic 
lupus nephritis portends a challenge to nephrologists that they fall back to old therapies 
like cyclophosphamide despite its significant morbidity, including an increased risk of 
serious infections and amenorrhea. In clinical practice, MMF is now the preferred induction 
regimen for patients with lupus nephritis (not crescentic) who wish to preserve fertility, 
which is a large patient population given that the disease commonly presents in women of 
child-bearing age. Unfortunately, most randomized controlled studies of lupus nephritis do 
not offer insight on treating cases complicated by crescents given their reduced occurrence. 
Our abstract sheds the light on the use of MMF as induction therapy for crescentic lupus 
nephritis which offers these patients a drug with less toxicity.
PUB572 
Publication-Only 
Crescentic Primary Membranous Glomerulonephritis
Jessica M. Nelson,3 Jonathan A. Ducastel,2 Robin Shah,1 Isabelle Ayoub.1 
1Nephrology, The Ohio State University, Columbus, OH; 2OSU Nephrology, 
Columbus, OH; 3Ohio State Wexner Medical Center, Columbus, OH.
Introduction: Membranous nephropathy (MN) is one of the common causes of 
nephrotic syndrome in adults and is most often primary (pMN). Kidney function is usually 
normal at presentation. Mild mesangial hypercellularity may be seen in pMN but significant 
proliferation and crescent formation raise suspicion of a secondary process. This case 
illustrates an unusual presentation of pMN.
Case Description: A 20 year old black woman presented with swelling. Diagnostic 
work up was significant for AKI with Scr 3.9 mg/dl, active urine sediment and nephrotic 
syndrome (24h urine Protein/Creatinine 15.7g/g and serum albumin 1.8g/dl). Kidney 
biopsy showed crescentic GN with IgG1, IgG4, and PLA2R staining on IF, and electron 
dense subepithelial deposits along the glomerular capillary loops (figures 1 and 2). Serum 
anti-PLA2R was 338 units/ml. Work up for secondary or additional etiology was negative. 
She received 2g IV methylprednisolone. Ten days later her Scr improved to 1.2mg/dl. She is 
currently on cyclophosphamide and prednisone, anticoagulation and lisinopril.
Discussion: pMN with rapidly progressive and crescentic glomerulonephritis is 
unusual. The predominant IgG1 and IgG4 staining and the positive serum anti-PLA2R 
and tissue PLA2R with negative work-up for secondary/additional etiology support the 
diagnosis.
PUB573 
Publication-Only 
Elderly White Man with Proteinuria Does Not Always Have Membranous 
Nephropathy or Minimal Change Disease
Justin Lee Loy, Gajapathiraju Chamarthi, Abhilash Koratala. University of 
Flroida, Gainesville, FL.
Introduction: Heavy proteinuria with or without overt nephrotic syndrome may occur 
in association with a wide variety of primary and systemic diseases. Kidney biopsy is not 
always indicated, especially when secondary cause is suspected but the serologic work 
up should be ‘complte’ prior to making a decision. We describe a case where incomplete 
serological work up with respect to serum immunofixation (IFE) delayed the diagnosis and 
appropriate treatment.
Case Description: A 70-year-old White man without any known systemic disease 
was seen for second opinion regarding worsening proteinuria and edema. His symptoms 
started 1 year ago at which time, he had 700 mg/g proteinuria. SPEP, UPEP and Serum 
Free light chain assay (FLC) were negative for monoclonal protein. Screening for common 
vasculitides and viral hepatitis was negative. However, serum/urine IFE was not obtained. 
His proteinuria worsened to 5g/g in 1 year and developed hypoalbuminemia with relatively 
preserved creatinine. The patient was told by his prior nephrologist that it’s most likely 
membranous nephropathy vs. minimal change disease and the plan was to empirically treat 
with prednisone. Therefore, patient was resistant to undergoing renal biopsy and requested 
us to obtain serum PLA2R autoantibody testing. Eventually, he agreed and the biopsy 
revealed λ light chain (AL) amyloidosis. Bone marrow biopsy revealed abnormal plasma 
cells with monotypic λ light chains and he was referred for bone marrow transplant.
Discussion: Most patients with AL amyloidosis have little or no intact monoclonal 
immunoglobulin, but are characterized by the presence of monoclonal free light chain. 
IFE of serum and urine is required because the monoclonal peaks in amyloid tend to be 
small and frequently do not produce a spike detectable with electrophoresis alone. It’s 
noteworthy that in one series, the diagnostic sensitivity of the FLC κ/λ ratio was 76%, that 
of IFE of both serum and urine was 96%, and their combination correctly identified the 
amyloidogenic light chains in 100% of patients.
PUB574 
Publication-Only 
Tacrolimus and Intravenous Cyclophosphamide as Effective Therapy for 
Membranous Nephropathy in a Patient with Mixed Connective Tissue 
Disease
Shunichiro Hanai, Fumihiko Furuya, Kenichiro Kitamura. Third Department of 
Internal Medicine, University of Yamanashi, Chuo-shi, Japan.
Introduction: Renal involvement occurs in about 25% of patients with mixed 
connective tissue disease (MCTD), and it usually takes the form of membranous 
nephropathy (MN).
Case Description: A 61-year-old woman was admitted to our hospital complaining 
of lower extremities edema. She was diagnosed with MCTD because of Raynaud’s 
phenomenon and positive anti-RNP antibody at the age of 39 years old. Since no organ 
involvement was observed, she did not receive any glucocorticoid or immunosuppressant. 
She developed nephrotic syndrome at the age of 60, and renal biopsy revealed the association 
of MN. PAM staining of renal histopathology showed spiking of the glomerular basement 
membrane and Masson trichrome staining showed diffuse sub-endothelial deposit. Anti-
phospholipase A2 receptor antibody was negative. Oral prednisolone (PSL) 30mg and 
mizoribine (MZB) 100mg daily were initiated, but failed to achieve remission. Switching 
MZB to tacrolimus (TAC) 3mg daily decreased urine protein/creatinine ratio (UPCR) to 
2.0-4.0 g/gCr, but persistent proteinuria remained. Because she developed cellulitis of 
her left lower extremity due to severe edema and became unable to walk, intravenous 
cyclophosphamide (IVCY) was added expecting immediate improvement. UPCR was 
reduced to 0.5-1.0 g/gCr and walking difficulty was significantly ameliorated following 
IVCY. TAC + IVCY combination therapy was continued and PSL was tapered.
Discussion: Efficacy of TAC + mycophenolate mofetil combination therapy for lupus 
nephritis (LN) has been well documented. Since Asian LN patients have much higher 
response rate to CY than black or white patients, IVCY could be a beneficial treatment for 
the LN. TAC is also safe and effective for class V LN. Although no standard therapy has 
been established at this point, TAC + IVCY could be a beneficial therapeutic option for MN 
associated with MCTD according to treatment strategy for LN.
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IgA Nephropathy Associated with Evans’ Syndrome
Heliana M. Mello,1 Ana Paula Gueiros,1 Denise M. Costa,1 Camila B. Oliveira,1 
Carolina A. Vasconcelos,1 Mirna D. Meira,1 Cidcley N. Cabral,1 
Rafaela M. Gouveia,1 Luiz antonio M. Da fonte filho,1 Marlene A. Reis.2 
1Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, 
Brazil; 2Federal University of Triangulo Mineiro - UFTM, Uberaba, Brazil.
Introduction: IgA nephropathy (IgAN) is associated with autoimmune diseases. 
Evans’ syndrome (ES) is characterized by immunological hemolytic anemia (HA) and 
thrombocytopenia (TCP), and may be idiopatic or secondary. Systemic lupus erythematosus 
(SLE) is associated with IgAN and ES. We report the case of a patient with primary ES and 
IgAN, treated for SLE
Case Description: Female patient aged 23. At 13, after a viral infection, she was 
diagnosed with SLE due to edema, macroscopic hematuria and hypertension. At the time, 
she presented: creatinine 2.0 mg/dL, hemoglobin 7.0 g/dL, positive direct Coombs test, 
platelets 95,000. The urine analysis: 3+ protein and numerous red blood cells; proteinuria 
(PTN) 500mg/24h; negative ANA, anti-DNA, VDRL. C3 46 (NR 90-180 mg/dL). A kidney 
biopsy (KB) in her medical records described lupus glomerulonephritis. After treatment 
with methylprednisolone (methyl) and cyclophosphamide (CP), the glomerular filtration 
rate (GFR) was normalized. Maintenance treatment was azathioprine. She continued with 
subnephrotic PTN, microscopic hematuria, intermittent HA and TCP, negative ANA and no 
other clinical manifestations of SLE. A myelogram was performed, which was normal. At 16, 
mycophenolate mofetil was initiated. After 3 years with no remission of PTN, she did a KB 
that showed mesangial expansion and hypercellularity, segmental sclerosis and adherence 
to the Bowman’s capsule, with no endocapillary proliferation; immunofluorescence: intense 
granular deposits of IgA in the mesangium and capillary loops, characterizing IgAN. At 23, 
she suffered a rapid GFR decline, with HA and TCP. A new KB confirmed a diagnosis of 
crescentic IgAN. The treatment was methyl and CP for 5 months. With no clinical response, 
a KB was performed with electron microscopy (EM): chronic IgAN, with no lesions 
suggestive of SLE. There was a need for dialysis.
Discussion: This is the first report of IgAN associated with idiopatic ES. We emphasize 
the importance of EM for an adequate diagnosis of glomerulonephritis, especially when the 
clinical signs are not definitive
PUB576 
Publication-Only 
Use of Rituximab as a Steroid Sparing Agent to Achieve and Maintain 
Complete Remission in an Initial Episode of Minimal Change Disease
Win Win Moe, Ruby Zhao, Nobuyuki (Bill) Miyawaki, James Drakakis. NYU 
Winthrop Hospital, Mineola, NY.
Introduction: Adults with minimal change disease (MCD) will experience complete 
remission over 80% of the time with corticosteroids. Data for using steroid sparing regimens 
to treat the initial episode is limited mostly to case reports, with most experience involving 
Cyclophosphamide (CYC) or Cyclosporine (CsA). We report a case of adult MCD where 
steroids were not given, and nephrotic syndrome persisted despite nearly 1 year of CsA. 
It was only after administering Rituximab that complete remission was achieved and 
maintained.
Case Description: A 26 year old female with history of type I diabetes mellitus 
developed sudden weight gain and edema. Workup revealed albumin of 1.3 g/dL and 13 
g/g of proteinuria. Kidney biopsy (54 glomeruli) showed diffuse podocyte effacement with 
normal light microscopy and immunoflorescence, consistent with MCD. Due to glycemic 
concerns, steroids were avoided and CsA initiated. Peak albumin on this therapy was 2.6 g/dL, 
with nadir proteinuria 4 g/g. When proteinuria again rose to 11 g/g after 8 total months, 
Rituximab was given as 2 doses of 1000 mg, 2 weeks apart. Proteinuria 6 weeks later was 
21 mg/g, and remained <100 mg/g over subsequent months. After 6 months she received 
a single maintenance dose of Ritiximab 500 mg, while CsA was being weaned down. She 
now remains in complete remission with the latest proteinuria <100 mg/g and albumin 
4.5 g/dL.
Discussion: There are scenarios whereby relative contraindications to high dose 
steroids exist, despite being considered the mainstay of therapy for MCD. There is little 
literature to guide alternative treatment strategies. Relapses occur frequently with patients 
becoming steroid resistant, steroid dependant (SD), or frequently relapsing (FR). In these 
settings, evidence for using alkalating agents or calcineurin inhibitors exists. The use of 
Rituximab to effectively prevent relapses of SD or FR MCD has been reported as well. 
Insights into how exactly Rituximab works in the treatment of MCD may help elucidate 
details of pathogenesis. Some hypotheses include protective actions on podocytes or 
targeting of B-cell subsets that secrete humoral factors injurious to podocytes. These ideas 
may lead to a novel approach to therapy, with this case an example of achievement of 
remission despite the first line agent never having been administered.
PUB577 
Publication-Only 
A Case of ANA, dsDNA Negative Anti-Ro/SSA, Anti Smith Positive Lupus 
Nephritis
Vinay Srinivasa. Townsville department of Nephrology Nephrology, Townsville 
Hospital, Townsville, QLD, Australia.
Introduction: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune 
disorder that is characterised by antibodies to nuclear and cytoplasmic antigens. Renal 
involvement in SLE is known as lupus nephritis and is associated with anti-nuclear antibody 
(ANA) positivity. ANA is negative in 5% of cases of SLE.
Case Description: We present a case of a 56 year old burmese refugee who presented 
to hospital with hypertensive crisis. Her blood pressure on admission was 220/120 mmHg 
with urinary protein studies revealing a protein excretion rate of 11grams/day. Furthermore 
urine cytology revealed dysmorphic red blood cells consistent with glomerular bleeding. 
Serum creatinine was 156 micromol/L with previous blood tests showing normal creatinine 
levels 6 months prior to hospital admission. Serum ANA, dsDNA were negative but anti 
ro/ssa and anti smith antibodies were positive. Renal biopsy was performed with histology 
revealing membranoproliferative glomerulonephritis suggestive of class III/IV nephritis.
Discussion: SLE is a multisystemic autoimmune disease that is characterised by nuclear 
and cytoplasmic antibodies to antigens. Antibodies to DNA play a role in the pathogenesis 
and activity of lupus nephritis. There are few cases of lupus nephritis described in the 
literature with no detectable antibodies. The role of anti ro/ssa and anti smith antibodies in 
lupus nephritis is not established. In this report we highlight the possible role of anti ro and 
anti smith antibodies in the pathogenesis of lupus nephritis. The mechanism of this is still 
misunderstood with further studies required.
PUB578 
Publication-Only 
PCSK9 Inhibitors: A Novel Therapy for FSGS?
Jeanne Kamal,1 Richard Gargiulo,2 Olga Zhdanova.3 1Nephrology, New York 
University, New York, NY; 2New York University, New York, NY; 3New York 
University Medical Center, New York, NY.
Introduction: Alirocumab, an anti-proprotein convertase subtilisin/kexin type 9 
(PCSK9) monoclonal antibody is used for the treatment of primary dyslipidemia. PCSK9 
is implicated in the pathogenesis of hyperlipidemia associated with nephrotic syndrome. 
In experimental models of focal segmental glomerulosclerosis, (FSGS) lipid infiltration in 
glomerular cells was found to induce podocyte injury and proteinuria.
Case Description: We present the case of a 60 year old African American man with 
obesity (BMI 42) and history of hypertension, hyperlipidemia, chronic kidney disease 
(CKD) with nephrotic range proteinuria. He previously had an episode of acute kidney 
injury due to statin-induced rhabdomyolysis that required temporary hemodialysis. He 
subsequently recovered and stabilized his renal function at CKD stage 3. His creatinine 
was 1.7 (eGFR: 45), had 5 g/g proteinuria, without hematuria and normal serum albumin 
(3.8 g/dL). Viral serologies were negative for HIV, Hepatitis B and C. He had biopsy-
proven secondary FSGS thought to be related to obesity and possibly APOL1 due to his 
African American ethnicity. He was tried on a weight loss regimen and started on maximum 
RAAS blockade without improvement in his proteinuria. Given his poorly controlled 
hyperlipidemia (Chol: 345, LDL: 238, HDL: 73, TG: 171) while on ezetimibe, colesevelam, 
and niacin, he was started on PCSK9 inhibitor-Alirocumab. His proteinuria improved to 1 g/g 
soon after Alirocumab was initiated and has remained stable.
Discussion: PCSK9 levels correlate with the severity of hyperlipidemia and the 
degree of proteinuria. Once in remission, patients with nephrotic syndrome have decreased 
PCSK9 levels. Inhibition of the PCSK9 pathway should be investigated further as a novel 
therapeutic option in patients with proteinuria.
PUB579 
Publication-Only 
Between a Rash and a Hot Knee: Distinguishing IgA Vasculitis from IgA 
Dominant Post-Infectious Glomerulonephritis
Justin Lee Loy,1 Gajapathiraju Chamarthi,1 Rajesh Mohandas.1,2 1Division of 
Nephrology, Hypertension and Renal Transplantation, University of Florida, 
Gainesville, FL; 2Renal Section, North Florida / South Georgia Veterans 
Administration, Gainesville, FL.
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has 
been associated with post infectious glomerulonephritis (PIGN) and dominant IgA deposits. 
On the other hand, infections can precipitate a de novo IgA vasculitis. Distinguishing 
between the two is critical, since management options are different.
Case Description: A 61-year-old male was admitted with MRSA bacteremia and septic 
arthritis of the knee. Urinalysis and renal function were normal. Three weeks later he developed 
a non-pruritic erythematous rash on his extremities (Fig 1A), nephrotic range proteinuria and 
creatinine increased to 1.5 mg/dl. Serologies were negative with normal complement levels. 
Renal biopsy revealed focal areas of neutrophil infiltration (Fig 1C). Immunofluorescence (IF) 
showed heavy granular mesangial and glomerular capillary loop staining for IgA (Fig 1B), 
and focal C3 deposition. Electron microscopy revealed focal subepithelial and subendothelial 
mesangial deposits and a single large sub-epithelial deposit (Fig 1D).
Discussion: Distinguishing MRSA associated GN from IgA vasculitis can be 
challenging. The pertinent distinguishing features and our patient’s clinical features are 
summarized in Table-1. Given the clinical picture favoring MRSA related GN, persistent 
bacteremia and lack of convincing evidence favoring immunosuppressive therapy in IgA 
vasculitis, we elected for conservative treatment. Follow up showed stable creatinine at 
1.4 mg/dl, despite persistent bacteremia, arguing for a cautious approach to treatment in 
such patients.
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A Case Series of Rituximab for Resistant Focal Segmental Glomeruloscle-
rosis in Adults
Ellia Zhong,1 Siavash Ghadiri,1 Judith G. Marin,2 Sean Barbour.1 1University of 
British Columbia, Richmond, BC, Canada; 2Providence Health, North 
Vancouver, BC, Canada.
Introduction: Adults with primary focal segmental glomerulosclerosis (FSGS) 
are frequently resistant to multiple immunosuppressive (IS) agents. Rituximab (RTX) 
is considered a last resort treatment, however there are few successful cases reported in 
adults. As such, we reviewed all patients with FSGS in the province of British Columbia 
(Canada) who were treated with RTX from January 2014 – April 2018. We included patients 
>19 years old with FSGS in the native kidney. RTX dosing was decided by the treating
physician. Chart reviews were performed to extract clinical and laboratory data.
Case Description: Of the 121 patients who applied for RTX funding, 10 had FSGS of 
whom 3 met our inclusion criteria and 7 did not because they were children or had kidney 
transplants. Patient 1, a 41 year old female, was on prednisone, MMF and tacrolimus (TAC) 
and had previously failed galactose. Her creatinine (sCr) was 71 μmol/L, albumin (alb) 
23g/L and proteinuria (prot) 4.95g/d. She was treated with RTX 375mg/m2 weekly for 4 
doses followed by single 375mg/m2 doses with CD20 reconstitution. After RTX she was 
tapered off all other IS, with sCr 69μmol/L, alb 34g/L and prot 0.33g/d. Patient 2, a 21 
year old male, was on prednisone and MMF, and had previously failed TAC, cyclosporine, 
cyclophosphamide, infliximab and galactose. His sCr was 168μmol/L, alb 30g/L and 
prot 8.69g/d. He was treated with RTX 375mg/m2 weekly for 4 doses followed by single 
375mg/m2 doses with CD20 reconstitution. After RTX he was tapered off all other IS, with 
sCr 187μmol/L, alb 39g/L and prot 1.68g/d. Patient 3, a 26 year old female, was steroid 
sensitive but unable to taper prednisone without a disease flare despite concurrent use of 
cyclophosphamide, cyclosporine and TAC. At the time of being treated with RTX 1g every 
2 weeks for 2 doses she was on TAC 3mg BID and prednisone 20mg/d, with sCr 63μmol/L, 
alb 35g/L and prot 0.38g/d. After RTX treatment, her prednisone has been tapered to 2.5mg 
every 2 days (the lowest dose without a flare in the previous 8 years) and TAC 2mg BID, 
with sCr 61μmol/L, alb 36g/L and prot 0.37g/d.
Discussion: By systematically evaluating all adults in a large Canadian province 
treated with RTX for FSGS, we have shown that RTX can be effective in FSGS resistant 
to multiple other IS agents. These findings support the need for a prospective trial in adults 
with resistant FSGS.
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Publication-Only 
Monoclonal Immunoglobulin-Associated Renal Disease Diagnosed by 
Liquid  
Chromatography-Tandem Mass Spectrometry: A Report of Three Cases
Yasuhisa Matsushita,1,2 Hideki Inoue,1 Keiko Okamura,1 Mami Sugimoto,1 
Yoshimi Nakashima,1 Takehiro Ko,2 Yutaka Kakizoe,1 Takashige Kuwabara,1 
Masataka Adachi,1 Yushi Nakayama,1 Masashi Mukoyama.1 1Nephrology, 
Kumamoto University Hospital, Kumamoto, Japan; 2Tamana Central Hospital, 
Tamana, Japan.
Introduction: Monoclonal immunoglobulin (MIg)-associated renal disease (MIg-
ARD) results from direct deposition of nephrotoxic MIg or its light- or heavy-chain fragments 
in various renal compartments. Immunofluorescence (IF) and electron microscopy (EM) are 
essential to identify MIg and define its tissue distribution. We here report three cases of 
MIg-ARD diagnosed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Case Description: Case 1: A 73-year-old woman was referred due to proteinuria 
and hematuria. She had been diagnosed with non-ischemic cardiomyopathy 6 years 
before. Plasma electrophoresis showed the presence of IgGκ monoclonal protein. Light-
chain amyloidosis was suspected upon renal biopsy, but MIg heavy-chain deposition was 
revealed by IF and LC-MS/MS. We finally diagnosed her with renal heavy- and light-
chain amyloidosis. Case 2: A 75-year-old woman with Sjögren syndrome was referred 
because of proteinuria and hematuria. Cryoglobulinemia, hypocomplementemia, and 
IgMκ monoclonal protein were detected. Renal biopsy showed membranoproliferative 
glomerulonephritis (MPGN). Although there was positivity for IgM and C3 with negative 
staining for κ and λ light chains on IF, MIg light-chain deposition was revealed by EM and 
LC-MS/MS. We diagnosed her with cryoglobulinemic glomerulonephritis with light-chain 
deposition. Case 3: A 70-year-old woman was referred because of proteinuria. Although 
serum immunoglobulin levels were especially low, none of MIg proteins were shown by 
plasma and urine electrophoresis. However, on the basis of high κ/λ free light-chain levels 
in serum and hyperplastic bone marrow, multiple myeloma was diagnosed. Renal biopsy 
showed MPGN. Although there was weak positivity for IgM with negative results for κ 
and λ light chains on IF, light-chain deposition disease was finally revealed by EM and 
LC-MS/MS.
Discussion: LC-MS/MS is effective to identify MIg deposits in renal tissue 
compartments, especially when the findings of IF and EM are inconsistent with the 
background of monoclonal gammopathies.
PUB582 
Publication-Only 
Goodpasture’s Syndrome Superimposed on Autosomal Dominant 
Polycystic Kidney Disease
Matthew Day, Khaled Abdel-Kader, Beatrice P. Concepcion. Vanderbilt 
University Medical Center, Nashville, TN.
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is a 
multisystem disorder characterized by multiple, bilateral renal cysts associated with cysts 
in other organs. The average rate of GFR decline is 4.4-5.9 mL/min/year. Here, we report a 
case of unexplained AKI with nephrotic syndrome in a patient with known ADPKD.
Case Description: 56/F with a history of ADPKD presented with 2 wks of worsening 
abdominal pain, lethargy, and oliguria described as darker than usual. Vitals were T-36.7, 
BP 163/84, HR 85, RR 20, O2sat 96% on RA. PE was significant for diffuse abdominal 
tenderness. Lungs were clear, and she had no edema nor any rashes. Admission SCr was 
15 mg/dL with a prior normal baseline in 2010. Labs were significant for nephrotic-range 
proteinuria (PCR of 12.2) and microscopic hematuria. CXR revealed patchy perihilar and 
bibasilar opacities. No improvement in renal function was noted with IV fluids. Serological 
workup revealed normal complements, negative ANA, ANCA, SPEP/UPEP, HIV, and 
hepatitis panel. Worsening anemia thought to be secondary to hemoptysis complicated her 
hospital course. Chest CT revealed evidence of diffuse alveolar hemorrhage prompting a 
bronchoscopy that demonstrated blood throughout the tracheobronchial tree. Anti-GBM 
antibody levels were subsequently found to be elevated (209 AU/mL). Renal biopsy was 
not pursued due to technical difficulty and high risk of bleeding complications. She was 
started on high dose methylprednisolone (1 mg/kg/day) followed by plasma exchange and 
cyclophosphamide 25 mg PO BID. Her pulmonary symptoms improved with the above-
stated therapy. However, she ultimately progressed to end stage renal disease requiring 
maintenance hemodialysis.
Discussion: In most patients with ADPKD, renal function is maintained despite 
relentless growth of cysts until the 4th to 6th decades of life. When renal function begins 
to decline, this occurs at an average rate of 4.4-5.9 mL/min/year. Unexplained AKI should 
prompt an evaluation for coexisting etiologies, which includes examination of the urinary 
sediment, a serologic work-up and possibly a renal biopsy, if technically feasible. In this 
case, the patient’s clinical picture and positive anti-GBM titer led to the diagnosis of 
Goodpasture’s syndrome superimposed on ADPKD. Her pulmonary symptoms improved 
with high dose steroids, plasma exchange, and cyclophosphamide therapy.
PUB583 
Publication-Only 
Posterior Reversible Encephalopathy Syndrome Complicating Therapy of 
Membranous Nephropathy
Kothai divya Guruswamy sangameswaran, Krishna M. Baradhi. OU Tulsa OU 
-Tulsa School of Community Medicine, Tulsa, OK.
Introduction: Posterior reversible encephalopathy syndrome (PRES) is a rare,
poorly-understood, reversible syndrome characterized by headache, altered mental status,
seizures, visual disturbances and radiologically by vasogenic brain edema, predominantly
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in the parietal and occipital lobes. PRES is frequently associated with severe hypertension, 
hemolytic uremic syndrome, lupus, ANCA vasculitis and several drugs including calcineurin 
inhibitors (CNI). We report a case of PRES, in a young male with membranous nephropathy 
associated with tacrolimus use and highlight the importance of early recognition as 
treatment involves withdrawal of the offending agent.
Case Description: A 27-year-old male presented with generalized tonic-clonic 
seizures, altered mental status and hypertensive emergency with blood pressure of 270/130 
mm Hg. Medical history was known for biopsy proven membranous nephropathy on 
immunosuppression with tacrolimus and prednisone in the past one year. Exam revealed 
pallor and profound anasarca. Labs revealed acute kidney injury (AKI), hypoalbuminemia 
and tacrolimus level of 10.3 ng/ml (target range 5-8 ng/ml). Brain MRI showed symmetrical 
posterior subcortical vasogenic edema consistent with PRES. Management included 
discontinuation of immunosuppression with goal-directed optimization of blood pressure 
and volume status. He recovered well, with partial resolution of his AKI and without 
recurrence of seizures. Repeat renal biopsy showed advanced membranous nephropathy 
with mild tubular atrophy and interstitial fibrosis. Patient was conservatively managed 
without use of alternative immunosuppression due to higher risk of PRES associated with 
their use.
Discussion: PRES, also known as reversible posterior leukoencephalopathy syndrome 
was first described by Hinchey et al in 1996 and refers to a clinical conundrum of reversible 
subcortical vasogenic edema and severe hypertension. Tacrolimus is a macrolide derived 
immunosuppressant that competitively inhibits calcineurin and associated with severe 
vasoconstriction, hypertension, AKI and neurotoxicity. The estimated incidence of 
neurotoxicity is 7-32% in transplant recipients on CNI. It needs to be emphasized that PRES 
is a non-dose dependent adverse effect. Prompt recognition and discontinuation of the 
offending agent, with goal directed supportive care is paramount for complete neurological 
recovery.
PUB584 
Publication-Only 
A Case of IgA and Bronchiolitis Obliterans in a Young Dialysis Patient
Susan M. McAnallen,1 Ronan Cunningham,2 Robert Mullan.3 1Renal Unit, 
Antrim Area Hospital, Antrim, United Kingdom; 2Northern Trust, ANTRIM, 
United Kingdom; 3Northern Health and Social Care Trust, Antrim, United 
Kingdom.
Introduction: IgA Nephropathy is the commonest cause of glomerulonephritis 
worldwide, with typical presentation ranging from microscopic haematuria to rapidly 
progressive glomerulonephritis. It is estimated that 20% of people with IgA nephropathy(IgA 
GN)will progress to ESRD over10-15 years. The exact pathophysiology remains unknown 
%given the spectrum of disease, other associations including pulmonary disease have been 
described.
Case Description: A 36 year old female with ESRD%biopsy proven IgA GN 
had been haemodialysis(HD) dependent since 2010. One year after starting HD, she 
developed dyspnoea&reduced exercise tolerance. Investigations, including pulmonary 
function tests revealed a marked reduction in transfer factor (FEV1 0.7L, 24% predicted). 
CT Thorax demonstrated bilateral ground glass opacification consistent with small 
airways disease(Image I). Pulmonary screen was negative&the patient underwent two 
bronchoscopies, however no organism or abnormality was detected. Echocardiogram 
showed preserved left ventricular function&no evidence of pulmonary hypertension. A 
diagnosis of Bronchiolitis Obliterans was made&it was felt that this may be related to her 
underlying renal disease. The patient was assessed at a tertiary Lung transplant centre with 
view to potential combined lung/kidney transplant. She received a trial of steroids with 
minimal benefit.
Discussion: This young patient has already received 8 years of HD treatment, 
undoubtedly impacting on her length of life. She has a chronic irreversible lung condition, 
which has shown some stability in the last6years. Whilst she remains functionally better than 
investigations would suggest, the lung transplant team do not feel she is in need of urgent 
lung transplantation due to risk/benefit factors. Whilst systemic complications of IgA GN 
are uncommon, cases of interstitial pneumonitis, pulmonary haemosiderosis&bronchiolitis 
obliterans have been reported and an increased index of suspicion for multi-organ disease 
is needed in this patient group.
PUB585 
Publication-Only 
Renal Thrombotic Microangiopathy: A Rare Complication of Castleman’s 
Disease
Derian Lai,1 Prejith P. Rajendran,1 Sehrish Ali,2 Jose J. Perez.1 1Baylor College 
of Medicine, Houston, TX; 2BCM Nephrology, Sugar Land, TX.
Introduction: Castleman’s disease (CD) is a lymphoproliferative disorder 
characterized by excessive cytokine production. It is classified based on the extent of 
lymph node involvement, histologic features and associated diseases (HHV8). The 
pathogenesis of Castleman’s disease involves excess IL-6 production in response to 
viruses, autoinflammation, or neoplasms. We present a rare case of renal thrombotic 
microangiopathy secondary to CD.
Case Description: A 51-year-old female presented with three months of worsening 
fevers, ascites and pedal edema. She was recently hospitalized for abdominal pain and 
imaging revealed multifocal circumferential colonic masses with diffuse abdominal and 
pelvic lymphadenopathy. Colonoscopy was completed two weeks prior to presentation, and 
there were no intraluminal abnormalities or evidence of malignancy. On admission she was 
noted to have acute kidney injury with serum creatinine 3.95mg/dL (baseline 1mg/dl) and 
non-nephrotic range proteinuria without active sediments. Lab findings notable for anemia 
(Hb 8.6 g/dL) and thrombocytopenia (platelets 26,000/uL), without evidence of hemolysis. 
Secondary workup revealed elevated ANA titers. Complements and other autoimmune 
serologies were normal. HIV and Hepatitis studies were negative. Fine needle aspiration of 
a supraclavicular lymph node returned as lymphoid tissue with polyclonal plasmocytosis. 
On Day 4, renal biopsy was performed, and histology revealed acute glomerular 
thrombotic microangiopathy. She was empirically treated with 5 sessions of therapeutic 
plasma exchange (TPE) with improvement in renal function (serum creatinine 1.2mg/dL). 
ADAMSTS13 eventually returned as equivocal (>32%) and genetic complement testing 
was unavailable. Bone marrow biopsy and peripheral blood smears were negative for a 
myeloproliferative process. On Day 20, she underwent excisional biopsy of cervical lymph 
node, which confirmed HHV8 negative Castleman’s disease, mixed hyaline vascular and 
plasmocytic type. She was referred to hematology clinic for treatment but unfortunately 
lost to follow up.
Discussion: Multicentric Castleman’s disease can present with a wide range of 
symptoms. Our patient presented with TAFRO syndrome (a unique subtype of idiopathic 
MCD) characterized by Anasarca, Fever and thrombocytopenia. Clinicians should be aware 
that CD can be a rare cause of thrombotic microangiopathy.
PUB586 
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Promising Treatment of Membranous Nephropathy Followed by 
Anti-Glomerular Basement Disease
Claudius Speer,2 Christian Nusshag,1 Florian Kälble,2 Christian Morath,2 
Matthias Schaier,2 Claudia Sommerer,2 Martin G. Zeier.2 Zeier 1University 
Hospital Heidelberg, Heidelberg, Germany; 2University Hospital of Heidelberg, 
HEIDELBERG, Germany.
Introduction: Until now, a few studies reported evidence that both, simultaneous and 
consecutive occurrence of MN and anti-GMB disease can appear. The pathogenesis is still 
unclear and there is no algorithm in therapy. Here, we discuss a case of anti-GBM disease 
following MN with respect to clinical presentation and treatment options.
Case Description: We report a 55-year-old man with biopsy-confirmed MN 6 years 
ago and a base-line creatinine (Cr) of 1.3 mg/dl. The first kidney biopsy showed a MN with 
immune complex deposits (Figure 1A-C). Currently, the patient was admitted with new onset 
limb edema. Serum Cr level was 4.1 mg/dl and the protein/Cr ratio 119 g/molCr. Except 
the anti-GBM antibodies (titer 1:2560), the immunological screening was inconspicuous. In 
summary, we made the diagnosis of a rapidly progressive glomerulonephritis (GN). Thus, a 
second kidney biopsy was performed and the diagnosis of an anti-GBM GN superimposed 
on pre-existing MN could be established (Figure 1D-F). Immediately, therapy with i.v. 
methylprednisolone (MP) and cyclophosphamide (CYC) once per week in a dose of 250 mg 
for 3 times was started. Further, immunoadsorption (IA) was conducted 18 times. As a 
maintenance therapy, oral MP combined with another three times CYC 750 mg monthly 
was scheduled. Under therapy, the renal function improved and the serum Cr recovered to 
1.6 mg/dl after 2 months.
Discussion: In a few cases with MN followed by anti-GBM, different therapy strategies 
were administered, having a poor patient outcome in common. For the first time, we report 
a patient with a favorable follow-up. An early biopsy-proven diagnosis followed by an 
immediate regimen of immunosuppression containing i.v. MP and CYC combined with IA 
seems to be encouraging. This case report underlines the fact that an early second biopsy 
should be considered in MN patients with an unusual clinical course.
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Great Masquerade: Para-Neoplastic Pauci-Immune Glomerulonephritis
Sayee Sundar Alagusundaramoorthy, Laura J. Maursetter, Tripti Singh. 
University of Wisconsin, Madison, WI.
Introduction: Pauci-immune glomerulonephritis associated with neoplasia has been 
described in the literature. Fain et al reported the largest case series of 60 patients with 
malignancy and vasculitides and found 23.3% renal involvement. The most common cancer 
described in this series were hematologic followed by solid tumors. We describe a case 
series of 4 patients who presented with pauci-immune glomerulonephritis diagnosed by 
renal biopsy and four different malignancies which have not been commonly associated 
with pauci-immune glomerulonephritis.
Case Description: Three patients had diagnosis of malignancy and pauci-immune 
glomerulonephritis during the same hospital visit. One patient had cancer approximately 
18 months after diagnosis of pauci-immune glomerulonephritis (Table 1). Only one patient 
recovered renal function leaving three patients dialysis dependent. Malignancy was treated 
in all patients without any recurrence to date.
Discussion: Malignancy should be considered at the time of diagnoses of 
antineutrophil cytoplasmic antibody associated pauci-immune glomerulonephritis as an 
ideopathic cause is often thought responsible. Physicians need to be vigilant to perform a 
thorough history and physical examination to identify the presence of clinical cues for any 
associated malignancies. Renal outcomes for patients with paraneoplastic pauci-immune 
glomerulonephritis are poor as in our case series. Nephrologists need to continue to strive to 
determine the best treatment when a combination diagnosis is present.
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Treatment Options for Relapsing ANCA Associated Crescentic  
Glomerulonephritis (GN)
Golriz Jafari,1 Raghu Konanur venkataram,2 Anita Kamarzarian.3 1UCLA-
Olive View Medical Center, Los Angeles, CA; 2Olive View- UCLA Medical 
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Introduction: KDIGO 2012 guidelines recommends treatment of first episode or 
severe ANCA associated GN with cyclophosphamide and corticosteroids and alternatively 
the use of rituximab and corticosteroids in patients without severe disease or in whom 
cyclophosphamide is contraindicated. According to the RAVE TRIAL, neither treatment is 
superior for induction of remission in severe ANCA associated vasculitis and that perhaps 
rituximab may be superior in relapsing disease. This case looks at the clinical application 
of these findings.
Case Description: A 26 year old female with history of ANCA (MPO) crescentic 
GN 2 years prior presents to ophthalmology clinic with a red eye and is found to have 
scleritis. Labs work reveals a Cr 1.62 mg/dl, Uprt/Ucr 4.4gm and UA >182 WBCs, >36 
RBCs. Her initial episode of GN was treated with cyclophosphamide and steroids and she 
achieved remission with a Cr 0.70 and proteinuria 0.3 gm. She was maintained on and 
compliant with azathioprine until this second episode. Repeat kidney biopsy showed relapse 
of ANCA GN with 30% active crescents and secondary focal and segmental sclerosis. Anti-
MPO titers increased from 4 to 31.4 and PR3 Ab negative. After discussion of therapy 
with cyclophosphamide and its potential risks of infertility vs. rituximab, patient opted for 
rituximab 375 mg weekly for 4 weeks with plan for biannual rituximab maintenance. Cr 
was 1.2 and proteinuria 2gm after 2 months.
Discussion: Cyclophosphamide with glucocorticoids has been the mainstay of therapy 
for ANCA associated vasculitis for many years. Most nephrologists are more comfortable 
with its use due to experience especially in very severe cases. The data does shows that 
rituximab is as effective as cyclophosphamide in treating ANCA associated vasculitis 
and maybe more effective for relapsing disease. After deciding to use rituximab for this 
patient’s relapse, she questioned why we didn’t use it for her first episode as she would 
have preferred a therapy that would not potentially affect her fertility. Although the study 
did not look at the fertility aspect, this is an advantage that rituximab haswhen choosing 
therapy. It is standard that we discuss all risk and benefits however we sometimes sway 
patients that cyclophosphamide might be better for severe disease. However clinically 
for younger female patients with severe disease, rituximab may be the superior option.
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Catastrophic Antiphospholipid Syndrome Presenting with Subacute Renal 
Thrombotic Microangiopathy
Shweta Punj, Ameesh Dara, Shikha Wadhwani. Northwestern University 
Feinberg School of Medicine, Chicago, IL.
Introduction: Renal thrombotic microangiopathy (TMA) can be the initial presentation 
of various systemic diseases including catastrophic antiphospholipid syndrome (CAPS).
Case Description: A 28-year-old Caucasian woman with history of asthma presented 
with two weeks of abdominal pain and new-onset jaundice, anorexia, and gross hematuria. 
Labs revealed a creatinine of 4.6 mg/dL (baseline 0.5 mg/dL), direct hyperbilirubinemia, 
hypoalbuminemia, leukocytosis, and elevated LDH. Extensive imaging was notable 
only for hepatosplenomegaly. Hepatitis panel, anti-nuclear antibody, and complement 
levels were unremarkable. Her renal failure worsened despite supportive measures and 
hemodialysis was initiated. A renal biopsy was performed, and she was transferred to our 
institution. The patient developed progressive anemia and thrombocytopenia with rare 
schistocytes seen on peripheral blood smear. Hematology recommended against empiric 
plasmapheresis given lack of clear evidence for microangiopathic hemolytic anemia 
and platelet count of 69 K/μL. Renal biopsy demonstrated glomerular endocapillary 
hypercellularity and segmental mesangiolysis, but no obvious fibrin thrombi or fibrinoid 
necrosis. Immunofluorescence staining was unremarkable and electron microscopy 
showed subendothelial widening concerning for subacute TMA. ADAMTS13 level and 
Shiga toxin PCR later returned normal. A liver biopsy was planned but the patient became 
encephalopathic and hypotensive following a platelet transfusion. She developed pressor-
dependent shock and passed away hours later from cardiac arrest. On the day of death, 
her lupus anticoagulant resulted positive (anticardiolipin and anti-beta-2 glycoprotein 
antibodies negative). Autopsy findings included cerebral, adrenal, omental, and renal 
thrombi by CD61 staining, consistent with CAPS.
Discussion: The diagnosis of CAPS requires laboratory confirmation of the presence 
of antiphospholipid antibodies (APLA), thromboses in three or more organs in less than one 
week, and histopathologic confirmation of TMA. We describe an atypical case of a patient 
with rapid clinical deterioration in the absence of imaging consistent with thrombosis or 
infarction, delayed APLA positivity, and renal biopsy without active fibrin thrombi. Given 
the very high mortality rate associated with CAPS, a high index of suspicion is needed in 
patients with subtle features of TMA on renal biopsy.
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A Breathless Herring: Goodpasture’s Presenting as Chronic Pulmonary 
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Ruth E. Campbell,1 Kristin M. Olson,2 Robert N. Smith.3 1Mercy Medical 
Center, Des Moines, Des Moines, IA; 2Mercy Medical Center Internal Medicine 
Residency Program, West Des Moines, IA; 3Associates In Kidney Care, West Des 
Moines, IA.
Introduction: Goodpasture’s syndrome involves rapid progressive glomerulonephritis 
and diffuse alveolar hemorrhage due to anti-glomerular basement membrane (anti-GBM) 
antibodies. We describe a case of Goodpasture’s that presented as chronic pulmonary 
disease prior to renal involvement and was co-positive for anti-GBM and MPO/ANCA.
Case Description: A 73-year old man presented for 2 weeks of progressive weakness 
and oliguria. He had a 10-year history of pulmonary fibrosis, which did not require treatment 
or supplemental oxygen. On exam, he had asterixis and bibasilar crackles. Labs revealed a 
creatinine 23.7 mg/dL, BUN 256 mg/dL, potassium 7.0 mEq/liter and sedimentation rate 
(ESR) 98 mm/hr. Chest x-ray showed bibasilar fibrosis, in a usual interstitial pneumonia 
pattern, with superimposed edema. He became tachypneic with frothy hemoptysis, 
requiring intubation, and emergent continuous renal replacement therapy was started. 
Methylprednisolone was empirically started and ANCA, PR3, MPO and anti-GBM antibody 
labs were ordered. Anti-GBM antibodies and MPO/ANCA were positive. Plasmapheresis 
and cyclophosphamide were initiated. The patient improved and was extubated. Renal 
biopsy revealed necrotizing and crescentic glomerulonephritis with positive linear 
IgG basement membrane staining by immunofluorescence, confirming Goodpasture’s 
syndrome. The patient was discharged on plasmapheresis, cyclophosphamide, prednisone 
and hemodialysis, with plans to switch to peritoneal dialysis.
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Discussion: Goodpasture’s has an estimated incidence of 1 case per million per year. 
However, Goodpasture’s presenting as chronic pulmonary fibrosis prior to renal disease 
with anti-GBM, MPO/ANCA positivity is rare; as of 2017, only 7 cases had been reported. 
The significance of this presentation is unclear but may relate to the development and 
prognosis of the disease. While the trigger for Goodpasture’s is unknown (proposed risk 
factors include hydrocarbon fumes and smoking), previous studies suggest MPO/ANCA 
positive pulmonary fibrosis may induce anti-GBM antibodies. The average 1-year survival 
rate of these 7 cases was 29%, in contrast to Goodpasture’s 5-year survival rate of 50%. 
In either case, mortality rates improve with early treatment. Thus, early recognition of 
Goodpasture’s presenting as chronic pulmonary fibrosis is key to improved outcomes.
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Kothai divya Guruswamy sangameswaran,1 Muna Hale,2 Narottam Regmi.1 OU 
Tulsa 1OU -Tulsa School of Community Medicine, Tulsa, OK; 2Oklahoma State 
University, Broken Arrow, OK.
Introduction: Fibrillary glomerulonephritis (FGN) is a rare, primary, progressive 
glomerular disease that was first described by Rosenmann in 1977. Glomerular deposition 
of polyclonal IgG in the form of random fibrils of 15-20 nm size is pathognomonic of FGN 
and is distinguished from amyloidosis by negative congo red staining. We report a rare case 
of FGN in a middle-aged female with progressive renal failure and crescents on biopsy.
Case Description: A 58-year-old woman with hypertension was admitted with 
pneumonia and creatinine of 1.4 mg/dl with hematuria and 1.9 grams proteinuria. Extensive 
serological work up for secondary causes was negative. A diagnostic renal biopsy revealed 
FGN and patient was treated conservatively with ACE-inhibitor therapy, given stable 
renal function. A year later, she had steady rise in creatinine and a repeat biopsy showed 
FGN with active crescents. Repeat serological work up was unrevealing and patient was 
initiated on immunosuppression with cyclophosphamide and prednisone in anticipation of 
a favorable outcome.
Discussion: Patients with FGN are typically middle-aged and present with proteinuria, 
hematuria and renal insufficiency. FGN carries a poor prognosis with progressive renal 
disease and ESRD in over 50% of patients. Older age, higher creatinine and higher 
percentage of globally sclerotic glomeruli are poor prognostic indicators. FGN is a 
morphologically defined entity and without electron microscopy, it can be indistinguishable 
from other deposition diseases. Due to its rarity and diagnostic difficulty, there are not many 
clinical trials evaluating treatment efficacy. Immuno-staining with DNAJB9, a heat shock 
protein with >98% sensitivity and specificity for FGN has shown promise. With increased 
awareness and testing with DNAJB9, there can be hope of identifying viable treatment 
options for patients with FGN.
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Treating Antineutrophil Cytoplasmic Antibody Associated Vasculitis 
(AAV) with Rituximab: A Double-Edged Sword
Shenthuraan Tharmarajah,2 Timothy C. Martin,1 Loay H. Salman,1 Swati Mehta,1 
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Introduction: Rituximab is a monoclonal antibody directed against the CD20 antigen 
of B-lymphocytes used for the treatment of AAV. B-cell depletion with rituximab in AAV 
results in decreased production of pathogenic antibodies but also renders the patient 
immunocompromised. We report here a case of Invasive Pulmonary Aspergillus (IPA) after 
rituximab administration for AAV.
Case Description: A 27-year-old male with recently diagnosed AAV (based on anti-
PR3 level of 528 AU/mL and pulmonary cavitary lesions on chest CT) s/p IV rituximab 
(375 mg/m2 weekly x 4 doses) plus prednisone (60 mg q day), was transferred to our hospital. 
Four weeks after initial diagnosis, the patient continued to have persistent cough, anemia 
(Hb 8.7 g/dL, Plts 497 103/ uL) and leukocytosis (wbc 25.7 103/ uL), plus microscopic 
hematuria, and proteinuria (2.9 gm/ 24 hrs), with preserved renal function (Cr 0.91 mg/dL), 
and undetectable CD 19(+) B cells. Bronchoscopy was performed and bronchoalveolar 
lavage was positive for Aspergillus. Renal biopsy was done 6 weeks after the first dose 
of rituximab to determine the degree of activity of AAV and was consistent with pauci-
immune focal segmental necrotizing (2/22 glomeruli) and crescentic glomerulonephritis 
(4/22 glomeruli with fibrocellular crescents). Voriconazole was started for IPA, followed 
by cyclophosphamide for active vasculitis despite induction therapy with rituximab. The 
patient had improvement in pulmonary symptoms and stable renal function, with resolution 
of microscopic hematuria but persistent proteinuria (2.2 gm/24 hr).
Discussion: AAV is an aggressive small vessel vasculitis that needs urgent treatment 
with immunosuppressive agents i.e. rituximab and cyclophosphamide, which increase the 
risk of opportunistic infections. Additional risk factors for infections in patients receiving 
rituximab include corticosteroids > 15 mg/day, creatinine clearance ≤ 45 mL/min, low IgG 
level, and low CD19(+) B cell count. Undetectable CD19(+) B cells (utilized to monitor 
B cell subset depletion after rituximab) in our patient implies that rituximab associated 
immunosuppression may have increased the risk of IPA. Therefore, while persistent 
pulmonary symptoms in patients with AAV can be due to active vasculitis, opportunistic 
and fungal infections such as Aspergillus must be ruled out.
PUB593 
Publication-Only 
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Nephropathy
Gabriela C. Segura,1 Luiza Lapolla,1 Gerard F. Sales,1 Tomas D. Ferreira,1 
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Introduction: IgA nephropathy (IgAN) can present with positive ANCA in 10% of 
cases. Most of them are considered as false positives. The proposed mechanism is that 
pathogenic IgA immunocomplexes would predispose to ANCA positivation. Those patients 
with ANCA positive IgAN have poorer outcomes compared to those ANCA negative. 
Otherwise, in crescentic IgAN, ANCA correlates with better outcome.
Case Description: A 38-year-old Bolivian male patient presented malaise, vomits, 
oliguria and uveitis. He had a rapidly worsening renal function, from baseline serum 
creatinine (sCr) 0.84 mg/dL to admission sCr 11.06 mg/dL. His general condition 
deteriorated and emergency haemodialysis was initiated. He also showed hematuria 
(86 erythrocyte /c), which was present for the last 5 months, subnephrotic proteinuria 
(0.15 g/day) and severe anemia (7.0 gr/dL). Other relevant exams were normal Complement 
(C3 137mg/dL; C4 36 mg/dL), positive c-ANCA antigen (1/320), ANA 1/160, positive 
anticardiolipin IgG antibody (14.93 GPL U/mL), positive rheumatoid factor (61.8 UI/mL) 
and negative Anti-DNA. Kidney biopsy sample included twenty-eight glomeruli, eighteen 
of which were globally sclerotic, eight containing cellular glomerular crescents, two with 
fibrinoid necrosis and segmental cellular proliferation. Light microscopy demonstrated 
necrotizing glomerulonephritis with ANCA-associated pattern. Immunofluorescense 
revealed IgA mesangial diffuse granular staining (3+), suggesting IgA glomerulonephritis.
Discussion: We report a rare association between ANCA-associated vasculitis and 
IgAN. The previous finding of hematuria suggests that our patient could have IgAN 
as a previous undiagnosed condition. We could speculate that IgAN may trigger an 
immunologic response for developing an ANCA-associated vasculitis. More studies are 
needed to determine if this overlap would define a new condition, its physiopathology as 
well as the best therapeutic approach.
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Drug Resistant Focal Segmental Glomerulosclerosis (FSGS)
Jana Havranova,1 Abbas Raza,2 Dhaval Sureja.3 1St. Luke’s University Hospital, 
Bethlehem, PA; 2St. Luke’s University Hospital, Bethlehem, PA; 3St. Luke’s 
University Hospital, Bethlehem, PA.
Introduction: Focal Segmental Glomerulosclerosis (FSGS) accounts for approximately 
40% of cases of nephrotic syndrome in adults. Most cases of FSGS are primary while 
others include genetics, infection/inflammation associated, or drug induced. The initial 
treatment of idiopathic FSGS is corticosteroid therapy. For steroid resistant FSGS, KDIGO 
guidelines recommend therapy with cyclosporine or Mycophenolate Mofetil (MMF) 
with corticosteroids. About 40% of the patients relapse after the initial therapy of FSGS. 
Relapses occur less frequently in those who have complete remission. We present a case of 
idiopathic FSGS resistant to multiple therapies.
Case Description: A 59-years-old male with medical history of CAD, hypertension, 
diabetes mellitus type 2, chronic obstructive pulmonary disease presented with proteinuria. 
Initial kidney biopsy confirmed FSGS thought to be primary. Patient could not tolerate 
steroid therapy due to side effects and was started on cyclosporine to which he responded 
well after prolonged therapy but relapsed after it was discontinued. At this time, repeat 
kidney biopsy was preformed showing predominantly FSGS with mild diabetic 
glomerulosclerosis. After reinstituting cyclosporine, he had an episode of Acute kidney 
Injury (AKI) requiring hospitalization and cyclosporine was changed to prednisone in 
combination with MMF for 12 months. Patient did not respond with worsening proteinuria. 
Patient was again restarted on cyclosporine with persistent nephrotic range proteinuria. 
Eventually therapy with corticotropin was also attempted but failed to show any benefit and 
had significant side effect of weight gain. Patient continues to be treated with cyclosporine.
Discussion: Our patient failed to show response with multiple immunosuppressive 
regimens and remains a challenge to achieve remission. Another option with Rituximab 
was also considered but with given underlying CKD, history of multiple AKI episodes and 
failure to show response with multiple regimens, we thought not to pursue Rituximab given 
lack of strong evidence. Larger studies and research is needed to better understand this 
disease and develop more effective therapeutic options.
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A Unusual Case of Nephrotic Syndrome Post Allogenic Bone Marrow 
Transplant (aBMT) Secondary to Focal Segmental Glomerular Sclerosis 
(FSGS)
Rhea Thurston,1 Nicoleta Radoianu,1 Claude Bassil,1 Ajay Bhandari,1 Liying Fu.2 
1University of South Florida, Wesley Chapel, FL; 2Tampa General Hospital, 
Tampa, FL.
Introduction: Allogenic bone marrow transplantation is a widely used treatment 
modality for many hematological diseases. Nephrotic syndrome post allogenic bone 
marrow transplant is extremely rare with an incidence of 1%. The development of nephrotic 
syndrome usually happens in the late post-transplant period of more than six months. 
When present, membranous nephropathy is the typical microscopic finding in 2/3 of 
cases followed by minimal change disease. In general, this develops after the cessation or 
tapering of immunosuppressive therapy, which suggests that nephrotic syndrome could be 
a manifestation of chronic graft versus host disease.
Case Description: A 75-year-old gentleman had a history of hypertension, prostate 
cancer and myelodysplastic syndrome with transformation into acute myeloid leukemia. 
He underwent matched unrelated donor allogenic bone marrow transplant as part of his 
treatment. Ten months later, the patient presented with symptomatic nephrotic range 
proteinuria (edema and hypoalbuminemia). A spot urine protein creatinine ratio was 12g 
and 24hr urine collection was 18g protein. Serologic workup was positive for ANA with 
negative ANCA, anti GBM, anti dsDNA, Smith, RNP, SSA, SSB. Free kappa lambda 
was elevated with normal ratio. The serum and urine protein electrophoresis reflected the 
presence of intensely stained bands in the beta-gamma region which may have represented 
a monoclonal protein. PLA2R was negative. Kidney biopsy revealed acute tubular injury 
with cytoplasmic vacuolization on light microscopy. Immunofluorescence had no specific 
immunoglobulin or complement deposition. Electron microscopy showed podocyte injury 
with diffuse foot process effacement and no electron dense deposits. These findings were 
suggestive of focal and segmental glomerulosclerosis, primary or secondary. After steroid 
treatment proteinuria improved to 1.5g/g.
Discussion: We presented this case of nephrotic syndrome post bone marrow 
transplant, with FSGS as microscopic evidence, because it was distinct from the most 
commonly found lesion. Further studies are needed to determine if FSGS might represent 
a chronic graft versus host phenomenon. Single agent steroid use was successful in this 
patient and ultimately this case expanded our knowledge on renal complications post bone 
marrow transplantation.
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Fulminant Acute Renal Failure in IgA Nephropathy
Hanning You,1 Duncan B. Johnstone.2 1Temple University School of Medicine, 
Philadelphia, PA; 2Temple University School of Medicine, Philadelphia, PA.
Introduction: IgA nephropathy (IGAN) has been described as a disease with invariable 
histopathologic findings but highly variable clinical outcomes (Rodrigues JC et al, CJASN, 
2017). Here we describe a patient a new diagnosis of IGAN that caused fulminant acute 
renal failure.
Case Description: A 20-year-old Hispanic woman with childhood epilepsy presented 
with two days of right flank pain, nausea and vomiting. Current medications were 
levetiracetam and topiramate. Physical exam was normal except for obesity. Abdominal 
CT scan was unrevealing. She was admitted without an explanation for her symptoms, 
which rapidly improved, but her serum creatinine rose from 0.88 mg/dL to 11.8 mg/dL with 
oliguria in one week. Nephrology was consulted. Urine sediment showed a few granular 
casts with numerous WBCs and RBCs. Urine culture grew E.coli > 100K. Ultrasound 
showed normally sized kidneys with increased echogenicity. Initial serologic tests were 
negative. She was treated with antibiotics for cystitis, dialyzed twice and then underwent 
kidney biopsy. Microscopy revealed mesangial hypercellularity, no crescents or fibrinoid 
necrosis, and a large number of red cell casts within tubules along with epithelial flattening. 
In addition there was a diffuse lymphoplasmacytic infiltrate with eosinophils. IF showed 
3-4+ mesangial and glomerular capillary staining for IgA, C3 and fibrinogen. EM showed 
numerous mesangial dense deposits. MEST-C score: M0, E1, S1, T1, C0. Her interstitial
nephritis was treated by changing her anti-epileptic medication and also with 1 month
prednisone 60mg. Dialysis was held, and within a week she was discharged with improving 
renal function. Four weeks later in clinic her creatinine was 0.88mg/dL.
Discussion: Our patient had a new diagnosis of IGAN with acute renal failure due to 
intra-tubular obstruction from RBC casts. This rare variant of IgA is not incorporated into 
the Oxford classification. The prognosis is excellent because renal function recovers once 
RBC casts start degenerating. How glomerular hematuria becomes sufficient to cause cast 
obstruction is unclear. Similar to other case reports (Friedlaender MM et al, Isr J M Sci 
1986; Lee HS et al, AJKD, 1988; August C et al, J Neph, 2001) our patient’s infectious 
trigger was cystitis rather than a URI, a correlation that bears further consideration.
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Crescentic IgA Nephropathy in an African American Man on Warfarin
Luis C. Segura,1 Roberto L. Collazo-Maldonado.2,1 1Nephrology, Methodist 
Dallas Medical Center, Dallas, TX; 2Dallas Nephrology Associates, Dallas, TX.
Introduction: Immunoglobulin A Nephropathy (IgA Nephropathy) is a mesangial 
proliferative glomerulonephritis characterized by diffuse mesangial deposition of IgA.Its 
more commonly seen in Asians, caucassians and hispanics but the prevalence of IgAN is 
very low among African Americans. Anticoagulant related nephropathy is more common in 
patients with IgA Nephropathy.
Case Description: This is a 57 y/o AA man with a past medical history of 
thromboembolic disease on warfarin therapy, hypertension, and CKD stage 3 presented 
to our hospital with foot pain and gross hematuria with no other symptoms. On exam he 
was afebrile with a B/P of 140mm/hg with clear lungs and no edema. His admission labs 
showed a creatinine of 15.17mg/% (baseline 1.6mg/%), BUN of 100mg/% with a HCO3 
of 14meq/dl. U/A showed large blood, with RBC casts and nephrotic range proteinuria of 
4.1gms. His serologic work up was normal. His INR was 3.8. A renal ultrasound showed 
echogenic kidneys without hydronephrosis. After reversing the anticoagulation a Kidney 
Biopsy was done and is was consistent with IgA nephropathy with cellular crescents 
and moderate interstitial fibrosis. The patient was treated with methylprednisolone 
1gm/daily for 3 days. He was then started on Prednisone 60 mg daily. He also received 
1gm of cyclophosphamide, with recommendations to continue cyclophosphamide once a 
month for 6 months. His creatinine improved throughout his admission from 16.15mg/% 
to 6.60mg/% on discharge without the need for dialysis. The patient was discharge on 
Apixaban instead of Warfarin.
Discussion: Anticoagulant related nephropathy (ARN) is defined as an acute increase 
in serum creatinine of >0.3 mg/dl within 1 week of an INR >3.0. Chronic kidney disease 
and particularly patients with IgA Nephropathy are risks factor for ARN. We must be aware 
of the relationship of these two conditions and include IgA nephropathy in the differential 
diagnosis of glomerulonephritis in African American patients.
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Nephrosarca Causing Anasarca in an Elderly Male with Minimal Change 
Disease
Arun Rajasekaran,1 Elpidio Abreu,2 Pran M. Kar.3 1University of Central Florida 
College of Medicine, Kissimmee, FL; 2Nephrology Associates of Central 
Florida, Ocoee, FL; 3VA Medical Center Orlando, Orlando, FL.
Introduction: Minimal Change Disease (MCD) rarely presents with nephrotic range 
proteinuria and acute kidney injury in adults. Nephrosarca, or severe edema of the kidney, 
has been proposed as a pathophysiological mechanism for this.
Case Description: A 75 year old male with chronic back pain (on long-term NSAIDs) 
presented with generalized body swelling, 10 kg weight gain, progressive dyspnea and 
decreased urine production worsening over a week. Vital signs were stable, and clinical 
exam revealed anasarca. Serum BUN (96 mg/dl) and creatinine (8.7 mg/dl, baseline 1 mg/dl) 
were elevated. Serum electrolytes, calcium, phosphorus, and magnesium were normal. 
Total protein was 5.3 mg/dl and albumin was 1.1 mg/dl. UA revealed 4(+) protein. A 24 
hr. urine collection showed 5.9 g of protein, mainly albumin, and a creatinine clearance 
of 10 ml/min. SPEP and UPEP demonstrated hypoalbuminemia and hyperalbuminuria 
respectively. Serological workup including RF, ANA, ANCA, anti-dsDNA/anti-MPO/
anti-GBM/anti-proteinase-3 antibodies, Hepatitis B & C panel, HIV, cryoglobulins, RPR, 
and complements C3/C4 was negative. Serum immunoglobulins levels were normal. Renal 
ultrasound showed kidneys’ of normal size and echogenicity, but with moderate perinephric 
fluid. Renal biopsy depicted extensive and global foot process effacement with significant 
interstitial edema, consistent with MCD (likely secondary to chronic NSAID use). High 
doses of intravenous diuretics were ineffective, and early hemodialysis aided in achieving 
evolemia. He was started at 60 milligrams of prednisone per day, and his proteinuria and 
renal function improved in 4 weeks. Repeat renal ultrasound revealed no perinephric fluid.
Discussion: Lowenstein et al. proposed the theory of nephrosarca as a root cause 
in the pathophysiology of MCD by physically abetting vascular and tubular occlusion, 
consequently causing filtration failure. Our patient’s nephrosarca and AKI did not revert by 
prompt reinstitution of euvolemia alone, but was temporarily concomitant with proteinuria 
remission in response to corticosteroids. Interestingly, our patient’s nephrosarca resolution 
was captured on repeat renal imaging, which has not commonly been cited in the medical 
literature so far.
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Oxalate Nephropathy Leading to Acute Renal Failure
Meghana Chalasani,1 Josephine Abraham,1 Mazdak A. Khalighi,2 Aylin 
R. Rodan.1 1University of Utah, Salt Lake City, UT; 2Oregon Health and Science 
University, Portland, OR.
Introduction: Hyperoxaluria is implicated in the development of nephrolithiasis 
and nephrocalcinosis and has also been shown to cause renal parenchymal disease with 
progression to end-stage renal disease. We present a patient with underlying CKD and 
pancreatic insufficiency who developed AKI secondary to oxalate nephropathy.
Case Description: A 75-year old man with a history of CKD IV and pancreatic 
adenocarcinoma s/p pancreaticoduodenectomy nine months ago presented to the emergency 
room complaining of nausea, fatigue, shortness of breath, and leg swelling for two weeks as 
well as decreased urine output for four days. Initial work-up revealed creatinine 11 mg/dL 
(baseline 2.5 mg/dL), hyperkalemia 6 mmol/L, and metabolic acidosis. Patient reported that 
since surgery he had been eating spinach daily and taking an herbal supplement containing 
kelp, thistle, rhubarb, and spinach. In addition, he stopped taking his pancreatic enzymes 
two months ago. He had also avoided dairy intake for many years. He has a history of 
kidney stones with analysis showing calcium oxalate, calcium phosphate, and uric acid. 
Urine microscopy was notable for pyuria, WBC casts, and muddy brown casts. Urine 
culture was negative. Patient underwent a percutaneous kidney biopsy which revealed 
acute tubular injury with extensive tubular calcium oxalate deposition and diffuse interstitial 
inflammation consistent with oxalate nephropathy. His diet has been adjusted to a low-fat, 
low-oxalate, high-calcium diet in addition to restarting pancreatic enzyme replacement. 
Patient has remained anuric requiring regular hemodialysis.
Discussion: Secondary hyperoxaluria often results from enteric hyperoxaluria (due to 
increased intestinal absorption), endogenous production, and/or increased dietary intake. 
Enteric hyperoxaluria results when intestinal oxalate is absorbed and is excreted in the 
urine, where it binds with calcium and deposits in the tubules. Renal parenchymal disease 
secondary to hyperoxaluria manifests as diffuse tubular deposition of calcium oxalate 
crystals and interstitial inflammation. Our patient, along with underlying CKD, also had 
malabsorption due to a pancreaticoduodenectomy as well as high oxalate and low calcium 
intake. Oxalate nephropathy has a poor prognosis and in this case the patient became 
dialysis-dependent. This case highlights the importance of gathering dietary habits as part 
of routine history-taking.
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Cocaine Induced Perinephric Hematoma
Geeta Bhagia, Rishi Raj, Samrah Zaigham, Wael Ghali. Monmouth Medical 
Center, Long Branch, NJ.
Introduction: Cocaine causes devastating effects on multiple organ systems. 
Renal complications range from kidney injury from rhabdomyolysis, progression of 
atherosclerosis, hypertensive nephrocalcinosis, end stage renal disease to rarely renal 
infarction. We present a rare case of perinephric hematoma associated with cocaine abuse 
in a young patient
Case Description: A 37-year-old Hispanic female with history of depression, hepatitis 
C and polysubstance abuse presented with left flank pain that started few hours after 
using intravenous cocaine. Pain was intermittent, colicky, 10/10 in intensity, aggravated 
by deep inspiration without any nausea or vomiting. On physical examination, she was 
febrile but hemodynamically stable, had left lower quadrant and costovertebral angle 
tenderness. Laboratory studies revealed leukocytosis with normal liver, renal and pancreatic 
function tests. Urinalysis revealed numerous RBCs. Renal ultrasound showed enlarged 
kidneys bilaterally with decreased echogenicity in left capsule without any evidence of 
hydronephrosis, tumor or calculi. Computed tomography (CT) of abdomen and pelvis with 
contrast showed large fluid collection surrounding left kidney originating from parenchymal 
defect in the inferior pole. Patient underwent CT guided aspiration of hematoma and 
aggressive blood pressure control. She was eventually discharged to rehabilitation facility
Discussion: Perinephric hematoma is defined as collection of blood in the subcapsular 
and perinephric space. It is a rare condition associated with renal neoplasms(renal cell 
carcinoma, angiomyolipoma), vasculitis, pyelonephritis, kidney stone, preeclampsia, 
eclampsia or coagulation disorders but it is a common complication of percutaneous 
nephrolithotripsy. Perinephric hematoma is rare complication seen in cocaine abusers. 
Most likely mechanism could be from severe hypertension associated with sympathetic 
stimulation in patients with cocaine abuse. The morbidity and mortality associated with this 
condition is high. CT scan is the diagnostic modality of choice. Conservative management 
with close follow-up is the mainstay of treatment but patients with associated tumor or 
those with uncontrollable hemorrhage are treated with nephrectomy. Our patient presented 
with left perinephric hematoma without any evidence of hemodynamic compromise or 
findings suggestive of malignancy. We managed our patient conservatively with frequent 
hemoglobin and hematocrit monitoring and fluid resuscitation
PUB601 
Publication-Only 
A Case of Renin-Mediated Hypertension
Nitzy N. Munoz casablanca, Joselyn Reyes Bahamonde, Ana I. Velazquez. 
Mount Sinai Beth Israel, New York, NY.
Introduction: Renin-secreting tumors are a known rare cause of secondary hypertension 
with hypokalemia and metabolic alkalosis. Evaluation is remarkable for elevated plasma 
renin activity (PRA) and, in most cases, secondary hyperaldosteronism. Treatment options 
are limited with variable effectiveness data on the use of renin angiotensin aldosterone 
system blockers, making tumor resection the definite treatment. Our case highlights the 
importance of early recognition of reversible causes of hypertension, and its potential 
reduction of cardiovascular risk.
Case Description: A 23-year-old female with history of hypertension and hypokalemia, 
presented with 2 weeks of dyspnea on exertion, decreased exercise capacity, and mid-
sternal sharp chest pain exacerbated by dry cough. On admission, her blood pressure was 
195/144mmHg and she had jugular venous distention with clear lungs and no evidence of 
peripheral edema. Labs showed K 2.9mmol/L, CO2 29mmol/L, Cr 0.88mg/dL, pH 7.46, 
BNP 1492.3pg/mL, and UA >500 protein. EKG showed left ventricular hypertrophy. Chest 
x-ray revealed cardiomegaly and mild pulmonary edema. Findings were suggestive of
new onset heart failure (HF) thus she was treated with aggressive diuresis. TTE confirmed 
left ventricular systolic and diastolic dysfunction. Evaluation of secondary causes of
hypertension included Renal US and CT Abdomen/Pelvis which revealed an enhancing
well-circumscribed 2.8cm renal mass arising from the left kidney. US doppler and CT
angiogram showed no signs of high-grade renal artery stenosis or fibromuscular dysplasia. 
PRA was elevated to 29.794ng/mL/hr and aldosterone 52.4ng/dL. 24hr urinary collection
of catecholamines and metanephrines was negative. A diagnosis of hypertension with end-
organ damage due to renin-secreting tumor was made and our patient was referred for
surgical tumor removal.
Discussion: Approximately 5% of patients with hypertension have reversible 
secondary causes. Renin-secreting tumors are considered a rare cause of secondary 
hypertension that should be considered in patients with concomitant hypokalemia and 
elevated PRA, especially when renovascular disease is ruled out. Our patient presented with 
HF and proteinuria in the setting of a suspected renin secreting tumor. Timely evaluation 
and treatment of secondary causes of hypertension is paramount to avoid mechanical injury, 
oxidative stress, and fibrosis along the renal and cardiovascular system.
PUB602 
Publication-Only 
Amyloid Cast in a Case of Multiple Myeloma
Ping Lan, Liyi Xie, Jia Lv. Nephrology department, The First Affiliated Hospital 
of Xi’an Jiaotong University Nephrology Department, First Affiliated Hospital 
of Xi’an Jiaotong University, Xi’an, China.
Introduction: Cast nephropathy is the most frequent pathologic pattern of renal 
involvement in Multiple myeloma (MM), characterized with distal tubular casts that are 
composed of monotypic light chains. Here we present a case of MM with unusual cast.
Case Description: A 74-year-old Chinese male was referred to our hospital with 
complaint of extremities edema and fatigue for 4 months. He denied fevers, rashes, joint 
pain or weight loss. On admission, blood test showed WBC count 71600 with no shift, 
and platelets count 18000, and hemoglobin 98g/L. Urine test showed trace protein with 
no hemauria. Total urine protein in 24 hours was 12.43g/d with serum albumin 41g/L and 
normal renal function. ANCA, anti-GBM antibody, PLA2R antibody, autoantibodies and 
hepatitis virus were negative. Serum protein electrophoresis showed 5% M-protein. Both 
serum and urine immunofixation electrophoresis showed a band of lambda light chain. Bone 
marrow aspirate and biopsy confirmed multiple myeloma with 51% plasma cell. Renal 
biopsy: The specimen for light microscopy contained renal cortex with 10 glomeruli without 
globally sclerosis. The GBMs were almost normal without endocapillary hypercellularity or 
mesangial proliferation. No fuchsinophilic deposition was found. Tubular lumina contained 
several casts, and the interstitium was edematous with focal inflammation cells infiltration, 
mostly lymphocytes and monocytes. Arteries were almost normal. Congo Red and Oxide-
Congo Red were only positive for several casts, with spicule formation at the rims. No 
immunoglobulin or complement components were positive by immunofluorescence 
microscopy (IF). Immunohistochemistry (IHC) test revealed lambda positive for certain 
casts. Electron microscopy (EM) showed 1glomeruli without any sign of amyloidosis 
or light chain deposition disease, but no casts were found. There were no electron dense 
immune complex deposits. This case was diagnosed Multiple myeloma (Stage III, lambda 
type), with amyloid cast nephropathy. He received PAD therapy (Bortezomib + Pirarubicin 
+ Prednisolone) and revealed a good response.
Discussion: Cast nephropathy is characterized with casts of monotypic light chains.
But there are rare cases showing amyloid casts, with spicule formation at the rims. Congo 
red staining, IHC and EM are helpful to confirm the diagnosis.
PUB603 
Publication-Only 
Myeloma Cast Nephropathy in Elderly Patient Presenting as AKI
Sushma Edara, Madhu Kandarpa. Kidney care specialists, Beavercreek, OH.
Introduction: Multiple myeloma can present with various renal manifestations. Here 
we present a patient with acute kidney injury diagnosed as Myeloma cast nephropathy on 
kidney biopsy.
Case Description: 90-year-old healthy female with a history of treated endometrial 
cancer and osteoarthritis presented with creatinine of 7mg/dl (baseline creatinine 0.7mg/dl) 
and potassium 5.3mmol/l on routine laboratory testing done by her primary care 
physician. Urine is clear with specific gravity of 1.010. Renal ultrasound is normal with no 
hydronephrosis or renal artery stenosis. Complement levels are normal, c-ANCA negative 
and p-ANCA positive 1:320. Despite adequate hydration her creatinine improved only to 
6.4mg/dl. Kidney biopsy showed Acute tubular necrosis and myeloma cast nephropathy 
with normal glomerulus. Protein electrophoresis demonstrated monoclonal lambda light 
chains in serum and free lambda light chains of 10934mg/l in urine. Bone scan showed lytic 
lesions suggestive of multiple myeloma. Bone marrow biopsy is diagnostic of monocytic 
lambda-expressing plasma cell neoplasm (65.6% plasma cells) with coexpression of CD56, 
CD38 and CD138. Patient is requiring hemodialysis and is being considered for specific 
regimen to treat myeloma.
Discussion: Despite increased risk of bleeding at her age, kidney biopsy was performed 
as diagnosis is unclear. The diagnosis of cast nephropathy is based on the demonstration of 
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tubular casts in distal nephron that are composed of immunoglobin light chains. Light chain 
casts generate intense inflammation via the activation of c-Src and NF-κB, and subsequent 
chemotaxis of immune cells further damaging the kidney tubules. If the obstruction is not 
eliminated, the damage becomes irreversible. Patients who are promptly diagnosed with 
myeloma cast nephropathy and rapidly commenced on disease-specific therapy have better 
outcomes.
PUB604 
Publication-Only 
Severe Atheroembolic Renal Disease (AERD) Contributing to Renal 
Failure
Vidhit Puri,1 Pridvi Kandagatla,1 Nishant K. Puri,1 Gunjan Garg,1 Tina Nigam,1 
Sowmya Goranta,2 Evan A. Farkash,1 Rachel Perlman.3 1University of Michigan, 
Ann Arbor, MI; 2Hurley Medical Center, Canton, MI; 3UM Health Center, Ann 
Arbor, MI.
Introduction: AERD is the occlusion of renal arterioles by cholesterol crystal emboli. 
These emboli often originate from atherosclerotic plaques along major arteries. They can 
circulate after an endovascular procedure or the initiation of anticoagulation. We present 
a case of severe AERD with an unusually extensive cholesterol burden associated with 
remarkably notable histopathological findings.
Case Description: A 74 year old male presented with weakness, anorexia, and low 
urine output. His recent history was notable for iliac artery stenting four months prior for 
claudication, and an interval ICU admission for burns, sepsis, and AKI. At admission, exam 
findings were significant for eschars on bilateral great and fifth toes. Lab values showed 
leukocytosis (16.9 x 109/L), eosinophilia (13%), and creatinine of 4.37 mg/dL (baseline 
1.2). Work-up revealed bland urine sediment, minimal proteinuria, and normal renal US 
and complement levels. Despite fluid resuscitation, his renal function declined with no clear 
etiology. A renal biopsy revealed cholesterol clefts with a phagocytic reaction in the arcuate 
and intra-lobular arteries, arterioles, and glomerular capillaries across multiple tissue cores. 
Electron microscopy (EM) also showed occluded arteries with crystalline voids and intact 
cholesterol crystals. Imaging demonstrated an unstable aortic dissection presumed to be 
source for the atheroemboli. Not being a surgical candidate, his renal function continued to 
deteriorate, and hemodialysis was initiated.
Discussion: AERD can be challenging to diagnose; it requires a biopsy, the clefts can 
mimic processing artifacts, and it is frequently an incidental finding. Our case uniquely 
illustrates not only some of the common clinical findings associated with this entity, but it 
also exemplifies severe manifestations of this disease on pathology. Extensive cholesterol 
emboli involving vessels of multiple sizes, including documentation of cholesterol crystals 
by electron microscopy (Fig.1), is truly a rare presentation of this disease.
Cholesterol emboli present in multiple arteries in multiple cores: Large Intralobular Artery 
and Branches (A), Glomeruli (B), and EM (C).
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Cryofibrinogen-Associated Glomerulonephritis in a Patient with 
Rheumatoid Arthritis: A Rare Disease Without Immune Complex Type 
Electron Dense Deposits, but with Fibrillary Organized Deposits
Saeko Hatanaka,1 Kentaro Koike,1 Nobuo Tsuboi,1 Ryuji Ohashi,2 
Tetsuya Kawamura,1 Akira Shimizu,3 Takashi Yokoo.1 1Division of Nephrology 
and Hypertension, Department of Internal Medicine, The Jikei University School 
of Medicine, Setagaya-ku, Japan; 2Department of Diagnostic Pathology, Nippon 
Medical School Musashikosugi Hospital, Kanagawa, Japan; 3Department of 
Analytic Human Pathology, Nippion Medical School, Tokyo, Japan.
Introduction: Cryofibrinogen (CF) is a cryoprecipitate produced during the process of 
plasma refrigeration via the structural alteration of serum fibrinogen. To date, there are only 
a few reported cases of glomerulopathy associated with CF, and thus its clinicopathological 
aspects remain uncertain. Herein, we present a case of membranoproliferative 
glomerulonephritis (MPGN), characterized by the absence of immunoglobulin deposits 
and the presence of organized electron dense deposit (EDD), suggestive of CF-induced 
glomerulonephritis associated with rheumatoid arthritis (RA).
Case Description: A 72-year-old man, who had been followed-up for RA, visited 
our hospital with proteinuria and microscopic hematuria lasting over the last 1 year. At 
presentation, his serum creatinine (Cr) level was 1.69 mg/dL, and urinalysis found protein 
excretion of 4.6 g/day and many red blood cells. By laboratory work-up, all autoantibodies 
were negative except anti-cyclic citrullinated peptide antibody, and plasma cryoglobulin 
or M-protein were not present. Renal biopsy found MPGN, accompanied by glomerular 
basement membrane (GBM) rupture with fibrin exudation. By immunofluorescence 
microscopy, no immunoglobulin, or light or heavy chain deposition was found; however, 
subendothelial and subepithelial EDD were observed along GBM by electron microscopy. 
Of note, fibrillary materials with luminal diameter ranging from 50 to 100 nm were focally 
recognized within EDD. Those histological findings were suggestive of CF-associated 
glomerulonephritis. Subsequently, the patient was treated with corticosteroid, and the serum 
Cr decreased and the hematuria and proteinuria resolved in 12 weeks.
Discussion: CF-associated glomerulonephritis is an extremely rare disease as only a 
few cases are reported in the English literature. In the present case, we speculated that CF 
was produced in association with the patient’s long standing RA. Our findings may provide 
insight into the underlying etiology and further help reveal morphological spectrum of this 
unique disease entity.
PUB606 
Publication-Only 
Fibrillary Glomerulonephritis (GN) with Amyloid-Like Fibrils Confirmed 
by Mass Spectrometry
Sylvester Barnes,1,2 David J. Leehey,1,2 Maria M. Picken.1 1Loyola University 
Medical Center, Maywood, IL; 2Hines VA Hospital, Hines, IL.
Introduction: Fibrillary GN is a nephritic syndrome characterized by Congo red 
negative glomerular fibrillary deposits. On electron microcopy (EM) the fibrils are oriented 
randomly, lack hollow centers, and are generally 16-24 nm in diameter. DNA heat shock 
protein family member B9 (DNAJB9) has been identified as a potential protein marker for 
this disease on biopsy.
Case Description: A 54 YOF was seen in clinic because of elevated serum creatinine 
(2.1 mg/dL). She was obese with uncontrolled hypertension but no evidence of diabetes. 
UA revealed 3+ protein with 3 RBCs/hpf. The UPCR ratio was 4.94 g/g with UACR of 
3.3 g/g. Biopsy yielded 16 glomeruli; 5 showed mild mesangial expansion, 3 segmental 
sclerosis, and 8 global sclerosis. Congo red staining was negative. No glomeruli were 
present in tissue sent for IF. EM showed non-branching fibrils measuring between 8.8 - 15 
nm in width localized in the mesangial matrix (Figure). Since the fibril size overlapped 
with that seen in amyloid, laser microdissection-tandem mass spectrometry (LMD-MS/MS) 
was used to determine the composition of the fibrils. This yielded abundant protein 
corresponding to DNAJB9. There was no evidence of monoclonal gammopathy. Renal 
function has continued to deteriorate and she is being evaluated for renal transplantation.
Discussion: Fibrillary GN is a rare cause of GN. Traditionally, Congo red stain and 
EM are used to distinguish between fibrillary GN and amyloid deposits; however, amyloid 
deposits may show variable affinity for Congo red stain. By EM, amyloid fibrils are 
typically 8-12 nm wide while fibrils in fibrillary GN are usually twice this size (16-24 nm), 
although there is considerable overlap with amyloid. Before interpreting fibrillary deposits 
as amyloid in specimens where Congo red stain is negative additional testing is prudent. 
Studies have shown that DNAJB9 is found in almost 100% of fibrillary GN by LMD-MS/
MS and immunostains. In view of the absence of IF data, LMD-MS/MS demonstrating 
DNAJB9 protein was used to verify the diagnosis of fibrillary GN in this patient.
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An Unexpected Cause of Acute Oxalate Nephropathy – or Is It?
Ambreen Azhar,2 Steven D. Smith,1 Mubasshar Rehman.2 1Icahn School of 
Medicine at Mount Sinai/St Luke’s-Roosevelt Hospital Center, New York, NY; 
2Mount Sinai Saint Luke’s and mount Sinai West, NYC, NY.
Introduction: Acute oxalate nephropathy may result from increased intestinal 
absorption of oxalate due to: 1) excessive oxalate intake 2) fat malabsorption syndromes 
enteric hyperoxaluria or 3) alterations of gut flora depleting oxalate degrading bacteria 
including the obligate anaerobe Oxalobacter formigenes. During small bowel transplantation 
(SBT) the gut microbiome is destroyed and the new gut flora with ileostomy is composed 
of facultative anaerobes.
Case Description: 55 y/o female with h/o SMA rupture requiring SBT and ileostomy 
presented with multiple episodes of non-oliguric AKI 1yr post txp attributed to high 
stoma output with volume depletion. Baseline cr pretxp was 0.7mg/dl, peaked at 3.3 and 
improved to 1.44mg/dl with IVFs but never returned to baseline. U/A and abd CT w/o 
contrast unremarkable. A small intestinal biopsy ruled out rejection. After the third episode 
of AKI a native renal biopsy was performed that revealed ATN with calcium oxalate 
crystals suggesting a possible dx of acute oxalate nephropathy. The patient was treated with 
increased fluid intake, low oxalate diet, calcium supplementation with meals and a low fat 
diet. Another clinician questioned how a patient with an ileostomy could develop acute 
oxalate nephropathy since most oxalate absorption occurs in the large bowel. A relook at 
the biopsy revealed only sparse crystals in the tissue not refractile under polarized light (as 
would be expected with calcium oxalate). A von Kossa stain (which picks up phosphate) 
was not performed. The dx of acute oxalate nephropathy was deemed unlikely contrary to 
the initial preliminary report.
Discussion: Nephrology remains a fascinating field because it demands that we 
understand pathophysiology and that things “make sense”. This case illustrates that 
nephrologists must use their clinical knowledge of the patient and be skilled in interpreting 
renal biopsies even if they are not pathologists. This includes being aware of the limitations 
and possibilities that a biopsy may offer.
PUB608 
Publication-Only 
Acute Renal Infarction – A Diagnostic Challenge in a Young Female
Goni Katz Greenberg,1 Ummerubab Syeda,2 Rakesh Gulati.2 1Thomas Jefferson 
University and Hospital, Philadelphia, PA; 2Thomas Jefferson University 
Hospital, Philadelphia, PA.
Introduction: Acute renal infarction is a rare but serious event that continues to present 
a challenge in diagnosis and treatment.
Case Description: A 37-year-old morbidly obese female was admitted to an outside 
hospital with acute onset of severe right flank pain with nausea and vomiting. Past medical 
history was notable for dysfunctional uterine bleeding, migraine and psoriatic arthritis. 
Medications included Topiramate and OCP (high estrogen content) that were started 6 
weeks prior to presentation. No history of miscarriages, but family history was significant 
for SLE. Physical exam was remarkable for mild hypertension, BMI 50, and RLQ 
tenderness. Laboratory tests: Cr 1.19mg/dL, LDH 2124 and normal PTT. CT scan showed 
right renal multifocal peripheral areas of decreased enhancement, consistent with infarction, 
confirmed by CT angiography. She was discharged on enoxaparin injections, and presented 
3 months later for a second opinion. Livedo reticularis was noted on lower extremities. 
Echocardiogram was normal. Laboratory tests: normal LDH, platelets 289x109/L; anti 
cardiolipin, anti b2 glycoprotein-1, lupus anticoagulant, anti-ds DNA, ANA, C3/C4, were 
all WNL. Repeat testing at 12 weeks was all negative.
Discussion: Although the most common etiology for renal infarction is thromboembolic 
originating from the heart or aorta, obesity, high estrogen OCP, or a hypercoagulable state 
can be associated with in situ thrombosis. In this reported case, clinical findings point to 
the diagnosis of antiphospholipid syndrome: history of migraines, no cardiac pathology, 
presence of livedo reticularis and thrombocytopenia during acute presentation. However, 
auto antibodies (anti-cardiolipin, anti b2 glycoprotein and lupus anticoagulant) were 
negative. The etiology of renal infarct was therefore attributed to morbid obesity and high 
estrogen OCP. Long-term aspirin use was recommended by hematology. Conclusion: With 
negative cardiac source and APLS workup, morbid obesity and high estrogen OCP should 
be considered in the differential diagnosis for acute renal infarction.
PUB609 
Publication-Only 
Adenovirus Associated Acute Interstitial Nephritis (AIN) in a Patient with 
Follicular Lymphoma
Jessica M. Nelson, Isabelle Ayoub, Sergey V. Brodsky, Jason Prosek, 
Salem Almaani. Ohio State Wexner Medical Center, Columbus, OH.
Introduction: Adenovirus is a non-enveloped, double-stranded DNA virus known to 
cause upper respiratory, gastrointestinal, and conjunctival infections in healthy individuals. 
However, more significant disease is commonly observed in immunosuppressed patients. 
Those with renal allografts commonly develop adenoviral urinary tract infections. Patients 
can have disseminated disease, but this is quite rare. Bendamustine-Rituximab combination 
is a therapy option for the treatment of Follicular Lymphoma. Bendamustine is an alkylating 
agent that causes DNA damage. Its action is more pronounced in rapidly proliferating cells 
such as lymphocytes, causing rapid and sustained depletion. This case describes an unusual 
presentation of pyelonephritis secondary to adenovirus in a patient without a history of 
transplantation.
Case Description: A 70-year-old Caucasian female presented to our medical center 
for evaluation of persistent unilateral flank pain with radiological evidence concerning 
for pyelonephritis. Her medical history is significant for a recent diagnosis of stage IV 
follicular lymphoma the previous year, treated with 6 months Bendamustine-Rituximab 
that she completed 6 weeks prior to presentation. She had sought medical care weekly 
for three weeks, with right flank pain sans dysuria. She described one episode of gross 
hematuria at her initial presentation but no further episodes. CT and PET scans revealed 
unilateral perinephric stranding, concerning for pyelonephritis, that persisted on repeat 
imaging despite adequate antibiotic therapy. Renal biopsy was performed to rule out renal 
lymphoma. Renal biopsy was consistent with adenoviral interstitial nephritis. At the time of 
presentation her CD4 count was 86 cells/mm3. Her serum adenoviral load was 4696 copies/
mL, urine 96,631 copies/mL. She was treated with Cidofovir. Current serum and urine viral 
loads are less than 500 copies/mL, or within normal limits.
Discussion: Bendamustine is a chemotherapy agent known to cause prolonged 
lymphocyte depletion. Therefore, these patients are at a higher risk for the development of 
common bacterial and viral infections including CMV, EBV, and adenovirus. Physicians 
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should be vigilant about the prolonged immunosuppressive effects of chemotherapeutic 
agents, and keep a low index of suspicion for unusual culprits of infection in this population.
PUB610 
Publication-Only 
Know Your HBsAg Testing Method
Karthik Kovvuru, Prakrati C. Acharya, Pradeep Vaitla, Divya Monga. University 
of Mississippi Medical Center, Ridgeland, MS.
Introduction: Center for Medicare and Medicaid services (CMS) requires isolation of 
Hepatitis B surface antigen(HBsAg) positive patients on dialysis. We encountered a unique 
situation with our patient’s (pts) positive screening HBsAg, negative confirmatory HBsAg 
and negative Hepatitis B (Hep B) PCR.
Case Description: 41 Yr old male with HIV (on Rx, undetectable HIV RNA, CD4 
- 186)) and untreated Hepatitis C (viral load 3,500,000) was admitted to the hospital for
worsening CKD requiring initiation of dialysis. He reportedly received last dose of Hep B 
vaccination series 3 months prior to admission and his screening HBsAg turned positive
both immediately and a month after the vaccination series with a negative confirmatory 
HBsAg and Hep B PCR. Dialysis was initiated and Hep B status re-checked to help
with outpatient dialysis placement. His screening HBsAg came back positive again with
negative results for confirmatory HBsAg, Hep B antibody and Hep B PCR twice. His 
placement became challenging as our lab reported that his screening HBsAg is positive
despite his confirmation test being negative. We requested CDC assistance and sent them 
blood samples. Meanwhile we arranged outpatient dialysis at our hospital with a dedicated 
machine and chair, in accordance with CMS regulations. CDC reported that the surface
antigen and Hepatitis B PCR are negative and he was subsequently placed in a non isolation 
chair at outpatient dialysis center.
Discussion: Our lab uses Abbott architect which tests for HBsAg in two steps “HBsAg 
Qualitative” and “HBsAg Qualitative confirmatory”. The first test is highly sensitive and 
gives false positive results when Hepatitis C viral load is high or other antibodies are 
present. The second test uses a reagent to neutralize the false positives and is specific. Our pt 
had very high Hepatitis C viral load and this was responsible for the false positive screening 
test. Due to the multiple testing modalities used (CDC uses Ortho Clinical Vitros HBsAg) 
we should learn how to interpret the local lab and incorporate into clinical practice. Also we 
need broader guidelines from CMS so that these tests can be interpreted without confusion.
PUB611 
Publication-Only 
Placental Passage of Eculizumab and Complement Blockade in a 
Newborn
Caroline Duineveld,1 Kioa L. Wijnsma,2 Elena Volokhina,3 Nicole Van De Kar,2 
Jack F. Wetzels.1 1Department of Nephrology, Radboudumc, Nijmegen, 
Netherlands; 2Department of Pediatric Nephrology, Amalia Children’s Hospital, 
Nijmegen, Netherlands; 3Department of Laboratory Medicine, Radboudumc, 
Nijmegen, Netherlands.
Introduction: Atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal 
hemoglobinuria (PNH) are rare complement mediated disorders, often affecting women of 
childbearing age. Because of severe maternal and fetal morbidity and mortality, pregnancy 
used to be discouraged. The introduction of the complement inhibitor eculizumab has 
contributed to successful pregnancies. Eculizumab can cross the placenta, and thus may 
inhibit the complement system of the newborn.
Case Description: A 30 year-old mother, known with aHUS and without treatment, 
presented at 8 weeks of gestation, with a rise in serum creatinine (from 100 μmol/L to 
219 μmol/L), progressive proteinuria and evidence of thrombotic microangiopathy 
(thrombocytes 91x109/L, undetectable haptoglobin and LDH 309 U/L). Treatment with 
eculizumab was started (900 mg weekly for four weeks, followed by 1200 mg biweekly), 
resulting in normalization of hematological parameters and improvement in renal function. 
At 36+1 weeks, after a spontaneous vaginal delivery, a healthy infant of 2010 gram was born. 
The mother had received her regular eculizumab dose 1 day before delivery. The eculizumab 
trough level was 262 μg/ml. Eculizumab was detectable in the cord blood of the newborn: 
free eculizumab level was 69 μg/ml. Evaluation of the complement cascade revealed 
complete blockade (Figure). Recovery was slow, and lasted > 3 weeks. The newborn was 
prophylactically treated with amoxicillin until normalization of the complement.
Discussion: Passage of eculizumab resulted in a therapeutic eculizumab level and 
full complement blockade in the newborn. During follow-up the alternative complement 
pathway remained blocked for several weeks while eculizumab levels decreased. This may 
be the result of physiologically low neonatal complement levels. Based on our observation 
we recommend assessment of drug levels and complement activity in newborns from 
eculizumab-treated mothers. Prophylactic treatment of newborns with antibiotics should 
be considered.
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Complement Factor I Gene Mutation with Normal Factor I Activity in a 
Child with ESRD Secondary to Atypical HUS
Kathleen E. Altemose,1 Asha Moudgil,2 Meredith A. Atkinson.1 1Johns Hopkins 
University School of Medicine, Baltimore, MD; 2Children national Medical 
Center, Washington, DC.
Introduction: Complement factor I (CFI) regulates the deleterious cytotoxic and 
inflammatory activity of the alternate complement pathway. CFI deficiency is a rare cause 
of atypical HUS (aHUS). We report a child diagnosed with ESRD secondary to aHUS who 
was found to have a CFI gene mutation with normal CFI activity.
Case Description: Our patient is a 10 yo boy with history of an encephalocele, seizures 
and hypertension who presented with hypertensive urgency and acute deterioration of 
renal function (serum creatinine 8.7 mg/dL) requiring CRRT. Following admission, his 
hemoglobin and platelets declined, requiring multiple blood product transfusions. Work-up 
for causes of acute on chronic renal failure were negative, including duplex US without 
renal artery stenosis, negative renal angiography, and negative serologies (ANA, anti-
double stranded DNA and hepatitis panel). C3 was low at 64 mg/dl and C4 was normal on 
admission. Renal biopsy was significant for global glomerulosclerosis and tubular atrophy. 
HUS evaluation showed elevated LDH, normal haptoglobin, smear with schistocytes, 
and a normal ADAMTS13. Whole exome sequencing (GeneDx, OPKO Health) showed 
heterozygosity for a G119R variant classified as “likely pathogenic” in the CFI gene 
inherited from the paternal side. TMA complement panel (Cincinnati Children’s Hospital) 
revealed normal Factor H and B activity. Factor I activity was also normal at 3.2 mg/dl 
(reference range 2.4-4.9 mg/dl). The patient received a deceased donor renal transplant 
~10 months after initial presentation. Due to genetic mutation in CFI, he has been treated 
with IV eculizumab at time of transplant and every 2 weeks since transplant. He had one 
episode of anemia requiring blood transfusion but has maintained his platelets in normal 
range with excellent allograft function (creatinine 0.5 mg/dl).
Discussion: In this patient with a known variant in the CFI gene and a history of 
ESRD, Factor I activity as measured on a TMA complement panel was within normal range. 
However, clinical presentation is consistent with aHUS, and he has remained stable on 
biweekly IV eculizumab infusions -post-transplant. This case supports the value of genetic 
investigation for causes of aHUS, even in the setting of normal factor H and/or I levels, in 
order to prevent disease recurrence after renal transplantation.
PUB613 
Publication-Only 
Acute Antibody-Mediated Rejection in a Zero Mismatch Living Donor 
Pediatric Kidney Transplant Due to an Anti-HLA-DP Donor-Specific 
Antibody
Neha D. Pottanat,1,3 Hiren P. Patel,1 Rose M. Ayoob,1 Peter B. Baker,4 
Hemant K. Parekh.2 1Nationwide Children’s Hospital, Columbus, OH; 2Ohio 
State University Wexner Medical Center, Columbus, OH; 3Riley Hospital for 
Children/Indiana University, Indianapolis, IN; 4Nationwide Childrens Hospital, 
Columbus, OH.
Introduction: Donor-specific antibodies (DSAs) against human leukocyte antigens 
(HLA), particularly anti-HLA-DP, have been associated with development of acute/chronic 
rejection in highly sensitized (due to a previous transplant) HLA-matched renal allografts 
recipients. We present a case of a 6 year-old male with no prior sensitization, who received a 
zero mismatch living-related donor kidney transplant from his mother and developed acute 
antibody mediated rejection (AMR) due to an anti-(HLA)-DP DSA.
Case Description: The recipient and donor were a 10/10 antigen match for HLA-A, 
B, C, DR, and DQ and the flow cytometric T- and B-cell crossmatches were negative. The 
recipient was given induction immunosuppression with five daily doses of antithymocyte 
globulin (total dose of 4.7 mg/kg) and steroids tapered over 6 days. Maintenance 
immunosuppression included mycophenolate mofetil (MMF) and tacrolimus every 12 
hours. Our maintenance immunosuppression protocol targets the following goal tacrolimus 
troughs: 7-12 ng/mL for months 0-3 and 5-10 ng/mL for months 4-6. Due to our recipient’s 
low immunological risk, we reduced the goal to ≥5 ng/mL for months 0-3. Furthermore, his 
MMF dose was reduced during this time due to neutropenia. No DSAs were identified in 
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the first 6 months. Over the next year, the recipient had a slow increase in serum creatinine 
from 0.4 mg/dL to 0.6 mg/dL. He developed a de novo DSA to HLA-DPB1(MFI = 8377) at 
14 months post-transplant. Pathology met Banff 2013 criteria for acute AMR. He received 
two doses of 1 g/kg intravenous immunoglobulin (IVIG) and one dose of 375 mg/m2 
Rituximab. His serum creatinine has remained stable and unchanged after treatment.
Discussion: Due to low immunological risk (10/10 HLA antigen match) our patient 
received reduced maintenance immunosuppression for the first 3 months post-transplant. 
However, despite being a pediatric non-sensitized recipient with an apparently well-
matched renal allograft and receiving complete induction immunosuppression, the patient 
developed acute AMR after developing DSA against the mismatched HLA-DP antigen. 
This report highlights a role for evaluating DP antigen mismatch before making adjustments 
to immunosuppression protocols.
PUB614 
Publication-Only 
Arginine Induced Metabolic Acidosis and AKI
Rami Batarseh. Texas Tech University Health and Science Center - Permian 
Basin Texas Tech University health and science center - Permian Basin, Odessa, 
TX.
Introduction: Arginine (Arg) among multiple OTC supliments used for various 
medical conditions. Under appropriate dose and chemical form it is not toxic to cells, high 
doses >9 gm/day are associated with adverse effects in some subjects.
Case Description: 65 years old female patient self treating her hypertension with OTC 
Arg, for 10 years with poor efficacy, increased her dose gradualy to a total of 45 – 60 mg/day. 
Presented confused, lab workup showed a Non Anion Gap Metabolic acidosis, with 
elevated Creatinine, Arg over dose revealed from history and the patient was started on 
NaHCO3 infusion and hydration, condition improved gradually till completely resolved.
Discussion: Arginine is available in different structures, among which is Arg-HCL, 
HCL group is added to improve solubility, Side effects are largely related to the HCl group 
resulting in rapid drop in pH causing metabolic acidosis leading to hyperkalemia, Arginine 
markedly impairs bicarbonate reabsorption in the proximal convoluted tubules, hence 
inducing proximal renal tubular acidosis with hypophosphatemia without a renal phosphate 
leak. Infusion of Arg-HCL causes profound impairment of bicarbonate reabsorption. 
Management is mainly supportive with IV NaHCO3 and hydration with correction of 
electrolyte abnormalities. Fatal dose have been reported in pediatric population
Table 1: Patient’s Abnormal lab results on admission and on discharge
PUB615 
Publication-Only 
Hepatorenal Failure with Mushroom (Amanita) Poisoning
Huiwen Chen. University of Pittsburgh Medical Center, Pittsburgh, PA.
Introduction: Toxic mushroom ingestions can lead to many symptoms including 
gastroenteritis, seizures and multiorgan failure depending on the toxins involved. Here, we 
describe a case of acute hepatorenal failure secondary to amatoxin.
Case Description: A 75-year-old male with hyperlipidemia presented to the 
emergency department (ED) with nausea, vomiting, and diarrhea for two days following 
ingestion of wild mushroom. Symptoms started 24 hours after a plateful of cooked 
mushrooms from his backyard. He also complained of inability to urinate. Temp 36.4 C, 
BP 116/87, Pulse 97, RR 24, Sao2: 99% room air. Physical exam did not have any gross 
abnormality. Foley yielded 400 cc urine. Labs: hemoglobin19, hematocrit 54.1, platelet 
155, sodium 127, Potassium 4.6, chloride 91, bicarbonate 16, bun 75 and creatinine 5.48 
Aspartate aminotrasferase 4879, Alanine aminotransferase 9212, Total bili 2.6. Patient 
had normal kidney function at baseline per his recollection. Given the patient’s hepatic 
injury and unknown mushroom type, he received N-acetylcysteine to reduce potential toxic 
conversion in the liver, methylprednisolone for potential interstitial nephritis, silymarin 
to interrupt the enterohepatic circulation of amatoxin, charcoal to absorb the toxin, and 
penicillin G to increase renal toxin excretion. Plasmapheresis was performed given case 
reports of successful toxin removal in amatoxin ingestions. Dialysis was initiated given 
profound azotemia, and he was set up for outpatient hemodialysis (HD) prior to discharge. 
Amanita virosa was identified based on photos.
Discussion: Amatoxin manifests with symptoms of nausea, vomiting and diarrhea 
occurring within 24 hours after ingestions followed by multiorgan failure, most notably 
fulminant hepatic failure and rarely renal failure. Amatoxin is a peptide with molecular weight 
900 DA, and it has a high affinity for charcoal as well as polymers found in hemoperfusion 
cartridges and HD. The best way to remove amatoxin would be hemoperfusion or HD 
because of its small molecular weight and large volume of distribution. Plasmapheresis 
in theory would not provide any benefit. Teaching point: It is important to note that the 
efficacy of treatments of mushroom toxicity is based on small series and there are no 
randomized controlled trials to address the efficacy of treatments. Given the uncertain role 
of extracorporal support in toxin management, one should carefully weigh the risks and 
benefits of these procedures.
PUB616 
Publication-Only 
Appearances Should Not Deceive the Nephrologist
Gajapathiraju Chamarthi, Abhilash Koratala. University of Flroida, Gainesville, 
FL.
Introduction: Hydroxocobalamin causes reddish discoloration of the urine, mimicking 
hematuria. Clinicians should be aware of this common side effect of the rarely used drug 
to prevent unnecessary consultations and work up. Additional benign causes of red urine 
include foods such as beets, rhubarb and medications such as rifampin, phenazopyridine.
Case Description: A 70-year-old woman with a history of multiple abdominal surgeries 
in the past was admitted for incisional hernia repair and adhesiolysis. The procedure was 
complicated by bowel injury leading to peritonitis and refractory septic shock with a mean 
arterial pressure less than 60 mmHg. A trial of intravenous Hydroxocobalamin 5g was 
given, in an attempt to improve the blood pressure as a last resort, as she was hypotensive 
despite being on multiple vasopressors. Subsequently, she developed reddish discoloration 
of the urine, which appeared to be gross hematuria [Figure]. However, urine microscopy 
was negative for red blood cells and the chromaturia was due to hydroxocobalamin 
administration.
Discussion: Hydroxocobalamin is the hydroxylated active form of vitamin B12, which 
is approved for the treatment of cyanide poisoning. Approximately 18-28% of healthy 
subjects receiving hydroxocobalamin develop elevated blood pressure as a side effect. This 
moderate pressor effect is likely due to its nitric oxide scavenging effects and this drug is 
sometimes used as an off-label treatment for vasoplegic syndrome. Hydroxocobalamin can 
impart reddish to purple color to the urine, which can persist for up to 35 days following 
intravenous infusion. While this side effect is benign, it is important to note that it can alter 
colorimetric laboratory measurements and interfere with hemodialysis by triggering a false 
blood leak alarm.
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The Ups and Downs of Diarrhea
Krystahl Z. Andujar, Ileana E. Ocasio Melendez, Fatima B. Cintron-Rosa. 
Nephrology, University of Puerto Rico - Medical Sciences Campus, San Juan, 
Puerto Rico.
Introduction: Despite increased intestinal transit times, a paradoxical rise in 
tacrolimus levels is a rare complication in diarrheal illness. We present the case of a renal 
transplant patient on a stable dose of tacrolimus that had to be adjusted after the onset of 
severe diarrhea.
Case Description: A 70-year-old man with end stage renal disease secondary to 
hypertension status-post renal transplant in 2007 presented to the emergency department 
with more than 20 episodes of watery diarrhea, anorexia and abdominal pain. He had 
travelled from Massachusetts to Puerto Rico two days prior and had been treating his 
symptoms unsuccessfully with oral hydration. He had no sick contacts and onset of 
symptoms occurred hours after consuming a sandwich containing mayonnaise during his 
flight. Long term immunosuppressive regimen included tacrolimus 2 mg every 12 hours, 
mycophenolate mofetil (MMF) and prednisone. Upon evaluation, he had dry mucous 
membranes, tachycardia and a tender abdomen. Laboratory results demonstrated severe 
metabolic acidosis and creatinine levels of 7.3 mg/dL from his baseline creatinine of 2 mg/dL. 
He was started on intravenous (IV) isotonic fluids and bicarbonate; however, due to 
refractory metabolic acidosis, intermittent hemodialysis (HD) was started. HD was placed 
on hold after one session and IV hydration was continued for hypovolemia. Tacrolimus 
trough levels were supratherapeutic at 37.9 ng/dL and dose was decreased. MMF was 
placed on hold. Stool and blood cultures, fecal leukocytes, clostridium difficile toxin and 
CMV titers were negative. After the resolution of diarrhea, tacrolimus trough levels were 
subtherapeutic and dose was readjusted. He was discharged with stable dose of tacrolimus 
and baseline renal function.
Discussion: Due to intestinal metabolism by cytochrome P450 (CYP3A4) and active 
secretion from enterocytes into intestinal lumen by P-glycoprotein, tacrolimus has low 
oral bioavailability. In the setting of diarrhea, enterocytes are damaged, leading to both 
increased absorption and decreased gut metabolism of tacrolimus. The impaired gut mucosa 
leads to increased drug levels despite increased transit times. As the gut heals, CYP3A4 
and P-glycoprotein begin to function normally, and tacrolimus levels fall. Therefore, as 
tacrolimus trough levels may abruptly rise and fall during diarrhea, their intense monitoring 
is recommended.
PUB618 
Publication-Only 
Hypernatremia and Neurosurgery: Not Always What It Seems
Keysha Lopez vega, Ileana E. Ocasio Melendez, Krystahl Z. Andujar, 
Stephanie Colon Lopez, Mariela Marquez Pantoja, Carlos G. Rivera-Bermudez, 
Fatima B. Cintron-Rosa. Nephrology, University of Puerto Rico - Medical 
Sciences Campus, San Juan, Puerto Rico.
Introduction: After a neurosurgical procedure, the expected etiology of hypernatremia 
would be central diabetes insipidus (CDI). However, in a patient with psychiatric illness, 
poor water access may reveal another culprit for electrolyte disturbance. We present the case 
of nephrogenic diabetes insipidus (NDI) in a patient on chronic lithium use.
Case Description: A 63-year-old woman was admitted to the neurosurgical unit 
following a left temporal lobe mass resection. Nephrology service was consulted 
two days after surgery for a sodium of 172 mEq/L. Medical history was significant for 
bipolar disorder on chronic lithium therapy for more than 20 years. A direct medical 
history could not be obtained due to altered mental status but her son reported that she 
had complained of thirst, increased fluid intake and urinary frequency. Upon evaluation, 
patient had dry mucous membranes. Urine output was charted at 5 liters per day (L/d). 
Laboratories showed hypernatremia that followed an increasing trend with associated 
low urine osmolality of 176 mOsm/kg. Despite lithium discontinuation upon admission 
and fluid repletion, patient persisted with severe hypernatremia. A water deprivation test 
was not performed. Desmopressin administration failed to elevate urine osmolality above 
300 mOsm/kg, which confirmed NDI. A thiazide diuretic was started to increase urine 
osmolality by reducing distal water delivery and upregulate aquaporin receptors. Patient 
showed significant improvement, decreasing urinary output to 3 L/d and reaching normal 
sodium levels. A positive response to the thiazide diuretic without further symptoms or 
electrolyte disturbances was observed in the outpatient follow up.
Discussion: NDI is a rare condition that can become irreversible in patients with 
chronic lithium use. This case highlights the importance of thorough history taking and 
differential diagnosis formulation; as in our patient, the etiology of hypernatremia was 
lithium use and not brain mass or surgery. It is important for patients on chronic lithium to 
be monitored closely for medication complications.
PUB619 
Publication-Only 
Multisystemic Manifestations of Lithium Therapy
Andrea G. Del toro diez,2 Ileana E. Ocasio Melendez,1 Nicolle M. Canales-
Ramos,2 Fatima B. Cintron-Rosa,1 Krystahl Z. Andujar,1 Carlos G. Rivera-
Bermudez.1 1Nephrology, University of Puerto Rico - Medical Sciences Campus, 
San Juan, Puerto Rico; 2University of Puerto Rico, Medical Sciences Campus, 
San Juan, PR.
Introduction: Chronic lithium use has been associated with multiple complications, 
including nephrogenic diabetes insipidus (NDI), hyperparathyroidism, thyroid disease and 
dysrhythmias. Patients on chronic lithium therapy experience at least one episode of toxicity 
during treatment. Unfortunately, lithium concentrations may not correlate with signs of 
toxicity.
Case Description: A 53-year-old woman with bipolar disorder was admitted to the 
Internal Medicine Ward due to acute changes in mental status. She was diagnosed with 
bipolar disorder 20 years prior and was treated with risperidone and lithium. Laboratories 
showed leukocytosis, sodium 164 mEq/L, calcium 11.3 mg/dL, creatinine 2.6 mg/dL and 
BUN 36 mg/dL. Brain imaging and lumbar puncture ruled out any acute pathology to 
explain symptoms. Nephrology service was consulted due to hypernatremia and kidney 
disease. Upon evaluation, patient reported increased thirst, dry mouth and urinary frequency. 
She was oriented only to person and had dry mucous membranes. Additional workup 
revealed lithium levels 1.4 mmol/L, serum osmolarity 325 mOsm/kg, urine osmolarity 
104 mOsm/kg and PTH 191 pg/mL. Urinalysis showed decreased specific gravity 1.003. 
Renal ultrasound was remarkable for left non-obstructive nephrolithiasis and findings of 
renal parenchymal disease. Suspecting NDI, lithium was discontinued. Patient was volume 
repleted and intravenous fluids were then changed to hypotonic dextrose solution, which 
resulted in a steady decline in sodium and calcium levels.
Discussion: Lithium leads to NDI by inhibiting aquaporin insertion into the apical 
membranes, which affects urine concentration and decreased parathyroid gland sensitivity 
to calcium resulting in an increased incidence of adenomas and hyperplasia. The mainstay 
of therapy is discontinuation of lithium. Although our patient had only mild elevation of 
lithium levels, she had a unique presentation with three simultaneous complications from 
lithium therapy: NDI, hyperparathyroidism and chronic kidney disease. As the unusual 
multisystemic manifestations of lithium therapy may be observed regardless of its levels, 
close monitoring for possible complications is of utmost importance during therapy with 
this drug.
PUB620 
Publication-Only 
An Extended Lithium Saga
Caroline L. Matchett,2 Laura J. Maursetter.1 1University of Wisconsin School of 
Medicine & Public Health, Madison, WI; 2University of Wisconsin School of 
Medicine and Public Health, Madison, WI.
Introduction: Despite its narrow therapeutic window and toxic effects, lithium continues 
to be an effective treatment for bipolar disorders. Severe lithium intoxication (levels > 2.5 
mEq/L) can cause altered mentation, seizures or death and almost universally requires 
hemodialysis for removal if renal function is compromised. Proper management is essential 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1190
J Am Soc Nephrol 29: 2018 Publication-Only 
to avoid permanent complications. We present a case of acute on chronic lithium toxicity 
that necessitated a total of 45 hours of hemodialysis to appropriately reduce lithium levels.
Case Description: A 29-year-old male with bipolar disorder presented with altered 
mental status, emesis, and tachycardia following an intentional overdose with 470 tablets 
of lithium carbonate 300 mg extended release. Initial lithium level was 3.32 mEq/L. After 2 
liters of saline administration, repeat lithium levels were improving to 2.72 mEq/L therefore a 
decision to track levels instead of starting hemodialysis was made. Intermittent hemodialysis 
(IHD) was initiated 12 hours after the presentation when patient’s UOP decreased and QT 
began to prolong. Repeat lithium level had increased to 4.4 by the start of dialysis. After 36 
continuous hours of hemodialysis a lithium level of 0.85 mEq/L was achieved. Rebound 
lithium levels necessitated two additional sessions of dialysis, with an additional 9 hours in 
total. Upon discontinuation of IHD, the lithium level remained below 1 mEq/L.
Discussion: This case illustrates the therapeutic role of prolonged IHD in extended 
release lithium intoxications. Realizing the pharmacokinetics of extended release lithium, 
the care team astutely continued tracking lithium levels even after they were noted to 
be decreasing. It is imperative for practitioners to understand the pharmacodynamics of 
lithium, including the changing volume of distribution for chronic use in comparison to 
acute overdose. It is also important to understand how extended release formulations might 
alter predictions on how to best provide intoxication management.
PUB621 
Publication-Only 
Glass Green Colored Urine: Is It Benign or a Cause for Alarm!
Karan Puri,1 Sangita Bista,1 Yuvraj S. Chowdhury,1 Balaji Yegneswaran.2 
1Internal Medicine, SPUH/RWJ, New Brunswick, NJ; 2Saint Peter’s University 
Hospital, New Brunswick, NJ.
Introduction: Urine analysis is an integral part of the evaluation of any illness. A 
change in the urine color always makes a clinical contemplate. The cause could be an 
underlying illness or simply a new medication or dietary changes. We present an interesting 
case of green urine which developed after propofol.
Case Description: A 22-year-old male was admitted with an acute onset of difficulty 
in breathing that started 3 hours prior to admission and was debilitating to the extent that 
he couldn’t speak in full sentences. On examination, he was tachypneic, breathing at 34 
breaths per minute and required oxygen 6L/minute to maintain>90% saturation. He was 
subsequently intubated. Propofol5mcg/kg/min and Fentanyl25mcg/hr were used for sedation. 
Propofol was gradually increased to 20mcg/kg/min to achieve RAAS score of -2. On the day 
2, his condition improved and he was extubated. Interestingly, during this period his urine 
bag showed glass green colored urine. Initially, urine infection was suspected. Although 
clinically he was normal. All his sedations including Propofol were stopped.6 hours after 
discontinuation, the green color cleared and his urine returned to a pale yellow color.
Discussion: Propofol is extensively used in intensive care medicine for sedation. It is 
metabolized in the liver and predominantly excreted in urine as phenolic metabolites. The 
green discoloration of urine is attributed to these phenolic metabolites and is reversible on 
discontinuation. Total dosage or length of infusion does not correlate with discoloration. 
The total dose of propofol leading to green urine may range from 200 mg to 14,000 mg. 
Our patient received total 3035mg over 34 hours. Some of the other causes of green color 
urine could be urine infection or drugs like promethazine, thymol etc. Therefore, urine color 
should be interpreted with an acumen considering all benign and pathological conditions so 
as not to miss a disease and also avoid unnecessary diagnostic evaluation.
Urine bag
PUB622 
Publication-Only 
Systemic Absorption of Oral Vancomycin in C. difficile Colitis
Allison Bigeh,1,2 Leonor A. Echevarria.3 1University of Arizona College of Medicine, 
Phoenix, AZ; 2Internal Medicine, Banner University Medical Center, Phoenix, AZ; 
3Infectious Diseases, Banner University Medical Center, Phoenix, AZ.
Introduction: Oral vancomycin is generally considered safe to use in patients with 
kidney disease due to its minimal absorption in the gut <5%. This has led to a widespread 
approval of the oral form of the drug in treating Clostridium difficile infection (CDI). Some 
case reports indicate unpredictable absorption in renal failure. Here we report a case of 
nearly supratherapeutic levels in a patient with severe CDI and stable renal function.
Case Description: 50-year-old female with hypertension, diabetes, and CKD 4 
presented to the hospital with chief complaint of diarrhea and abdominal pain. After 
completing two weeks of levaquin developed profound loose, watery stools. Labs showed 
a leukocytosis 25k and stable CKD (Cr~3.0). CDI tests were positive for toxin and GDH 
antigen. Oral vancomycin and IV metronidazole were started immediately, however, 
symptoms persisted one week later. Vancomycin dose was increased and given both oral 
and rectally with only mild improvement in symptoms. Prolonged vancomycin taper was 
initiated. Trough levels were measured 19 mg/L. Due to concern for nephrotoxicity the dose 
was not increased. Flexible sigmoidoscopy showed diffuse pseudomembranes indicating 
severe CDI refractory to antibiotics. Fecal transplant was performed 35 days into admission 
and diarrhea resolved.
Discussion: IDSA guidelines recommend oral vancomycin for treating several stages of 
CDI. This case raises the question of whether inflammatory states or altered bowel anatomy 
(rectal ulcers in this case) and renal insufficiency play roles in unpredictable vancomycin 
levels. Few case reports have been published on this matter, most report detectable drug
concentrations when vancomycin is used at high doses >2 g/day and long durations >10
days. Currently there are no guidelines for monitoring serum vancomycin levels when
given orally. Serum drug monitoring in patients with severe or fulminant CDI is an area
necessitating further research and may reveal an issue of toxic absorption.
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sigmoid pseudomembranes
PUB623 
Publication-Only 
Cefepime Induced Non-Convulsive Status Epilepticus in ESRD Patients
Gargi S. Priamvada,1 Usman A. Khan,2 Syeda maria Muzammil,3 
Usman Z. Bhutta.3 1university of oklahoma health sciences center, OKLAHOMA 
CITY, OK; 2University of Oklahoma College of Medicine, Oklahoma City, OK; 
3OUHSC, OKC, OK.
Introduction: Cephalosporin induced neurotoxicity is well described in the literature 
but it remains an under-recognized phenomenon clinically. Studies have shown that up to 
one-third of patients (pts) on hemodialysis (HD) are prescribed a drug at an inappropriate 
dose resulting in adverse reactions. Cefepime is predominantly cleared by renal excretion; 
impaired renal function increases the risk for cefepime-induced neurotoxicity leading to an 
array of symptoms including slurred speech, tremors, confusion, coma, and non convulsive 
status epilepticus (NCSE). We present a case of a pt with ESRD who developed NCSE from 
cefepime toxicity and aim to highlight the importance of medication adjustment in patients 
with renal failure.
Case Description: A 60 year old woman, with ESRD on HD, was transferred to our 
facility for management of persistent encephalopathy while being treated at an outside 
hospital for health care associated pneumonia (HCAP). She was receiving cefepime at 
the regular dose rather than the ESRD -adjusted dose. Imaging excluded acute intracranial 
abnormalities and CSF studies were unrevealing. Continuous EEG monitoring showed 2Hz 
generalized periodic discharges (GPD), a pattern characteristic of NCSE. The patient was 
dialyzed daily for several days with high flux dialyzer. Gradually, GPD were replaced with 
generalized rhythmic delta activity, marked improvement in neurological status was noted 
and eventually the pt was extubated.
Discussion: Physicians need to be aware of the importance of medication dose 
adjustment in patients with renal failure. This case highlights a common neurotoxic effect 
of cefepime due to high levels in an ESRD pt but a similar scenario can be envisioned with 
any medication that needs renal adjustment, if they are not dosed properly. To prevent such 
adverse events, we suggest the use of eGFR calculators in all electronic medical records, 
involvement of clinical pharmacists on the inpatient teams as well as increased vigilance 
on the part of the inpatient pharmacy along with early involvement of nephrology team. 
Keeping in view the shortage of fellows opting for nephrology resulting in a decrease of 
qualified physicians to care for the ever increasing population with ESRD, it is imperative 
to stress this issue when residents rotate on the nephrology service since they will often be 
on the frontlines to treat such patients.
PUB624 
Publication-Only 
Recurrent Proliferative Glomerulonephritis with Monoclonal IgG 
Deposits in a Renal Allograft - Still a Dilemma
Manini Vishwanath,1 George P. Bayliss,2 Basma O. Merhi.3 1Rhode Island 
Hospital/Brown University, Providence, RI; 2Alpert Medical School, Brown 
University, Providence, RI; 3Nephrology, East Greenwich, RI.
Introduction: Proliferative glomerulonephritis with monoclonal immunoglobulin G 
deposit (PGNMID) is a recently described pathological entity of native kidneys which falls 
in the spectrum of monoclonal immunoglobulin deposition disease, whose clinical course 
resembles glomerulonephritis. Occurence in renal allografts is exceedingly rare and appears 
as a recurrent or de novo disease.
Case Description: A 56 year old Caucasian female with history of End Stage Renal 
Disease due to biopsy proven membranoproliferative glomerulonephritis 12 years ago 
on dialysis, underwent a deceased donor kidney transplant on maintenance prednisone, 
tacrolimus and myfortic with baseline allograft function at 0.9mg/dl, presented 4 months 
later for a routine visit and was found to have worsening allograft function with serum 
creatinine at 1.35 mg/dl. Urinalysis showed 3+ blood and >500 protein. Urine sediment 
revealed dysmorphic red blood cells with urine protein/creatinine ratio of 1.5 g/g. 
Complements C3/C4, SPEP, UPEP and serum immunofixation were normal, prompting 
a diagnostic allograft biopsy. Findings were consistent with endocapillary proliferative 
and exudative glomerulonephritis accompanied by diffuse glomerular immune deposits 
comprising IgG, kappa light chain and C3 localized to capillary walls and mesangial 
areas confirming the diagnosis of PGNMID. Bone marrow biopsy was negative. She was 
treated with 4 doses of Rituximab 3.75mg/ m2 given 2 weeks apart, and prednisone 60mg. 
5 months after treatment, repeated urinalysis still showed 3+ blood and 100 protein with 
improving allograft function and serum creatinine at 1.1 mg/dl.
Discussion: Our patient has recurrent PGNMID in allograft due to its rapid appearance 
after transplant, supporting the theory that it recurs within 2 years after transplant due 
to circulating abnormal IgGs in patient sera. Diagnosis is based on electron microscopy 
and immunofluorescence of biopsy specimen as it can be misdiagnosed as transplant 
glomerulopathy. There is no definite treatment yet. Amongst case reports of PGNMID 
of native kidneys, the most successful outcomes were with Rituximab perhaps because 
it targets plasma cells secreting these abnormal immunoglobulins. Hence, we chose this 
treatment option in our patient. A follow up biopsy may be helpful to assess the pathological 
response to Rituximab.
PUB625 
Publication-Only 
Primary Nonfunction of a Renal Allograft Secondary to Primary 
Hyperoxaluria and Systemic Oxalosis
Nawal Habib,1 David J. Widmyer,3 Imara Dissanayake,1 Gitana Bradauskaite,2 
Astha Gupta,2 Manjula Balasubramanian.2 1Einstein Medical Center 
Philadelphia, Philadelphia, PA; 2Einstein Medical Center, Philadelphia, 
Philadelphia, PA; 3Associates in Nephrology, LTD, Boardman, OH.
Introduction: The primary hyperoxalurias are rare genetic abnormalities of the hepatic 
enzymes involved in glyoxylate metabolism leading to overproduction of oxalate which 
is renally excreted. There is deposition of calcium oxalate in various tissues, primarily the 
kidney, leading to nephrolithiasis, nephrocalcinosis and ESRD.We present a case of primary 
nonfunction of a renal allograft due to primary hyperoxaluria type 1 (PH1).
Case Description: 52 yo M with ESRD due to recurrent staghorn calculi s/p DDKT 
remained dialysis dependent. Allograft biopsy showed an eosinophilic infiltrate, interstitial 
nephritis and acute tubular necrosis (ATN). There were a few crystals under polarized light 
but no interstitial fibrosis/rejection. Two months later he still required dialysis so a second 
biopsy was done. This showed marked ATN with casts and birefringent crystals enhancing 
under polarized light. Immunofluorescence and electron microscopy were negative for light 
chains and the amyloid stain. He remained anemic despite erythropoietin and transfusions. 
The erythropoietin level was 459 mIU/mL.A bone marrow biopsy showed normocellular 
marrow, oxalate crystals, myelodysplasia of the megakaryocytes and erythroid precursors 
that was classified as refractory cytopenia with multilineage dysplasia. FISH markers for 
myelodysplastic syndrome were negative.With evidence of oxalate crystals on the kidney/
bone marrow biopsies and history of recurrent nephrolithiasis, primary hyperoxaluria was 
worked up. Genetic tests showed an alanine-glyoxylate aminotransferase gene mutation 
consistent with PH1 causing primary nonfunction of his renal allograft.
Discussion: Systemic oxalosis causes deposition of oxalate crystals in the kidneys, 
blood vessels, bones, heart and central nervous system. The earliest manifestations 
are renal due to direct tubular toxicity from the crystals, nephrolithiasis, infection and 
nephrocalcinosis. Once the GFR <30-45 mL/min, serum oxalate levels rise and deposit 
in tissues. Bone marrow involvement causes ineffective erythropoiesis, resistance to 
erythropoietin, other cytopenias and hepatosplenomegaly. PH with ESRD requires daily 
dialysis along with nocturnal peritoneal dialysis. Oral pyridoxine is helpful as a suppressive 
therapy in PH1. Definitive treatment with liver-kidney transplantation supplies the missing 
enzyme for glyoxylate metabolism.
PUB626 
Publication-Only 
CNS Aspergilloma Mimicking Pituitary Adenoma in a Renal Transplant 
Recipient
Nawal Habib,1 Mustafa Saidi,2 Daranee Chewaproug,2 Imara Dissanayake,2 
Gitana Bradauskaite.2 1Einstein Medical Center Philadelphia, Philadelphia, PA; 
2Nephrology Department Albert Einstein, Philadelphia, PA.
Introduction: Fungal infections of the CNS are frequently seen immunocompromised 
hosts however, CNS Aspergillomas are rare. Aspergillosis commonly presents as a primary 
opportunistic infection of the lungs/paranasal sinuses with systemic hematogenous spread. 
Primary CNS infection without extracranial involvement is rare. MRI Brain and CT sinuses 
are essential for diagnosis. Surgical resection with voriconazole are the best treatment. 
We present a case of an isolated CNS Aspergilloma mimicking a pituitary adenoma in an 
immunosuppressed kidney transplant recipient.
Case Description: 68 yo F with HTN, DM, ESRD s/p DDKT with CKD due to 
allograft nephropathy, maintained on immunosuppression, presented with frontal headache. 
She did not exhibit neurological deficits. Labs showed baseline Cr 2 mg/dL.Brain MRI 
showed a sellar mass consistent with a pituitary macroadenoma. She had no clinical 
findings of an endocrinopathy. Due to limitations of contrast administration given her 
CKD imaging was limited. Later she presented with sudden onset decreased vision and 
L sided proptosis. Repeat imaging showed increased size of the lobulated sellar mass with 
supra-sellar extension, optic chiasmatic compression and invasion of the L cavernous 
sinus. Trans-sphenoidal resection showed a fibrous and purulent mass. Frozen section 
biopsy revealed necrotizing granuloma, septate fungal hyphae and conidia consistent with 
aspergilloma. Fungal cultures were also positive. She was treated with IV amphotericin B 
and voriconazole and was maintained on lower immunosuppression. However she suffered 
a stroke and renal allograft dysfunction post-operatively. Given her complex condition the 
family decided to withdraw care.
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Discussion: CNS aspergillosis is an uncommon infection seen in immunocompromised 
hosts. Manifestations include focal deficits, cranial nerve palsies, strokes, and intra-cranial 
hemorrhage. Radiographic findings include sino-nasal disease, intracranial mass lesions 
and cavernous sinus invasion. Biopsy reveals branching septate hyphae and conidia of 
Aspergillus. Sellar space occupying lesions can be confused with pituitary adenomas 
and endocrine involvement must be considered. Craniocerebral aspergillosis is treated 
with Voriconazole which has been shown to have good CNS penetration in combination 
with surgical resection. Mortality rates are higher in immunosuppressed patients with 
intracerebral involvement.
PUB627 
Publication-Only 
Azathioprine and Allopurinol Combination Therapy in Renal 
Transplantation
Robert S. Niznik, Andrea G. Kattah. Mayo Clinic, Rochester, MN.
Introduction: Azathioprine is rarely used in renal transplant recipients outside of 
pregnancy, but options for immunosuppression are limited in this setting. Thiopurine-
allopurinol co-therapy represents an alternative treatment strategy in the setting of 
azathioprine-associated hepatotoxicity in women with transplants who desire pregnancy
Case Description: A 32 year old female with a history of ESRD secondary to unknown 
etiology received a preemptive unrelated renal transplant in 2014. She received Campath 
induction and was on tacrolimus and mycophenolate mofetil. She was initially prednisone-
free; however, was transitioned off mycophenolate mofetil to azathioprine in anticipation 
of desired pregnancy. Thiopurine methyltransferase (TPMT) activity was normal. 
Unfortunately, soon after the initiation of azathioprine she developed hepatotoxicity with 
transaminitis and biliuria. She subsequently had normalization of her liver function tests 
after the azathioprine was switched back to mycophenolate mofetil. She was then found to 
have a borderline cellular rejection on protocol biopsy, necessitating steroid treatment. After 
another year of therapy with stable graft function, she again wanted to discuss the possibility 
of pregnancy and different options were considered for immunosuppression, including 
prednisone and tacrolimus dual therapy or sirolimus in place of mycophenolate mofetil. 
Finally, a third alternative was chosen of using low-dose azathioprine in combination with 
daily allopurinol to minimize the hepatotoxicity of azathioprine
Discussion: Thiopurine-allopurinol co-therapy has been successfully used as 
immunosuppressive strategy in renal transplant recipients, but is rarely used now due to risks 
of bone marrow suppression. Azathioprine is metabolized to 6-MP, which is metabolized to 
form 6-thioguanine nucleotides (TGN), the main therapeutic metabolites. 6-MP can also be 
deactivated by TPMT to form 6-methylmercaptopurine (MMP). High levels of 6-TGN are 
associated with disease remission, but also with myelosuppression when in excess, whereas 
high levels of 6-MMP are associated with hepatoxicity. TPMT activity does not predict 
hepatoxicity in the same way that it predicts myelosuppression. Approximately 15% of 
patients will preferentially metabolize 6-MP to 6-MMP instead of 6-TGN. Allopurinol helps 
circumvent this hypermethylation and will reduce 6-MMP levels and increase 6-TGN levels
PUB628 
Publication-Only 
Daily Self-Administered Intravenous Fluids Prevent Recurrent Acute 
Kidney Allograft Dysfunction in a Patient with Short Bowel Syndrome
Ankit B. Patel, Alex Cuenca, Hannah M. Gilligan, Nahel Elias, David 
Wojciechowski, Kassem Safa. Massachusetts General Hospital, Boston, MA.
Introduction: Short bowel syndrome (SBS) is a relative contraindication for kidney 
transplantation (KT). Few cases of dual kidney and intestinal transplantation are reported, 
whereas there are no data to help manage similar patients who end up receiving KT alone.
Case Description: A 59 y/o man with ESRD on HD for 10 years in the setting of 
Crohn’s disease and SBS (150 cm of small bowel, subtotal colectomy), underwent a 
deceased donor KT. He received basiliximab induction and maintenance mycophenolate, 
tacrolimus, and prednisone; discharged on POD 4, after requiring one session of HD for 
hyperkalemia. Subsequent course was complicated with recurrent acute kidney injury 
(AKI) from diarrhea, with stool output >3.5L at times, and weight loss before each AKI, 
despite aggressive oral hydration. A kidney biopsy showed acute tubular injury with rare 
tubular oxalate crystals. Despite transition to azathioprine, aggressive motility inhibition 
including DTO, he continued to have high output diarrhea and required 4 hospitalizations 
(average length of stay was 5 days) for work up and volume expansion, which on every 
occasion led to the swift resolution of the AKI. Eventually, he received an internal jugular 
port-a-cath and was discharged on a daily 1L Ringer’s lactate infusion. This resulted in 
a sustained recovery up to 7 months after transplantation (at the time of this report) with 
steady serum creatinine and weight, no additional hospitalizations, and return to work full 
time (figure).
Discussion: We report for the first time stable kidney allograft function in a patient with 
SBS with self-administered daily IV fluids. Although this case is short-termed, the trend is 
meaningful and shows that select patients with SBS, could still undergo kidney transplant, 
but will rely on daily parenteral volume expansion, which can be done at home safely and 
consistently.
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Publication-Only 
Recurrent MGRS in a Renal Transplant: Importance of Knowing the 
Primary Disease
Hema V. Sheelvanth, David J. Cimbaluk, Vasil Peev, Roger A. Rodby. Rush 
University Medical Center, Lincolnshire, IL.
Introduction: The term monoclonal gammopathy of renal significance (MGRS) was 
developed to encompass renal lesions associated with a monoclonal immunoglobulin (mIg) 
that do not fit the typical lesions of cast nephropathy and AL amyloidosis etc. While some 
are associated with a mIg in the serum or urine, some are identified only on renal biopsy by 
demonstrating light chain restriction indicating an abnormal cellular clonality. These lesions 
have a high recurrence rate in allografts and the clonal cell line should be treated prior to 
transplantation. We present a case of MGRS that was identified as such only after recurrence 
in the renal transplant.
Case Description: A 61 year-old woman presented with nephrotic-range proteinuria 
and creatinine (Cr) of 0.8 mg/dl. Renal biopsy revealed MPGN with IgG kappa restriction 
(Figure 1). This was not appreciated to be a MGRS and was treated with cyclophosphamide 
(CP) and steroids. Three years later, she presented with ESRD. A renal biopsy was identical 
but with advanced fibrosis felt to be ESRD secondary to idiopathic MPGN and she remained 
on hemodialysis without further treatment. After 5-years she received a cadaveric renal 
transplant (CRT). At 4 months post CRT, her Cr was 2.1 mg/dl. An allograft biopsy showed 
mesangial hypercellularity with glomerular IgG kappa restricted deposits and her disease 
was finally clinically recognized as a MGRS. Serum and urine immunofixation failed to 
show a mIg and a bone marrow with flow cytometry could not identify an abnormal cell 
clone. Despite this, she was treated with bortezomib, dexamethasone and CP. An allograft 
biopsy 4 months later had persistent mIg deposits but her Cr improved to 1.2 mg/dl. Due 
to concern for failure of first line therapy and future allograft loss, second line therapy with 
Daratumumab vs. autologous stem cell transplant is being considered.
Discussion: MGRS has high allograft recurrence rates and needs to be identified and 
treated prior to renal transplantation. This patient appears lucky in that the clonal production 
of mIg was indolent enough that treatment post CRT may be successful.
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Discovery of Functioning Native Kidneys with a Failed Renal Allograft 5 
Years After a Simultaneous Liver Kidney Transplant (SLKT)
Amanda A. Karasinski, Jaime A. Baynes-Fields, Lissa B. Levin Mizrahi, 
Sandeep Aggarwal, Karthik M. Ranganna. Drexel University, Philadelphia, PA.
Introduction: Renal function has been found to recover in 11.5% of single organ liver 
transplant recipients who required pre-transplant renal replacement therapy for more than 
90 days. There are reports of SLK recipients regaining significant native kidney function 
post transplantation. We report a discovery of native renal function in a patient with renal 
allograft failure 5 years after SLKT who required pre-transplant renal replacement therapy 
for 5 months.
Case Description: A 70-year-old man with a PMH of end stage liver disease from 
HCV cirrhosis, HCC, HTN, T2DM and HRS pre-transplant, requiring hemodialysis, who 
received a SLKT in 2013. His post-transplant course was complicated by acute cellular 
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rejection of the liver in 2013 which was successfully treated. Five years post transplant, 
patient developed AKI with creatinine rising to 2.0mg/dl. See figure 1 for the trend of 
creatinine post transplantation. US revealed an atrophic renal allograft with significant 
cortical thinning and abnormal doppler waveforms of the main renal artery that was 
consistent with a failed renal allograft. US of the renal allograft performed 2 years prior was 
normal in size but increased in echogenicity. Biopsy revealed chronic inflammation, 60% 
globally sclerosed glomeruli with severe interstitial fibrosis and tubular atrophy. MAG3 
furosemide renal scan was performed to investigate native renal function which revealed 
left kidney, 55.2% and right kidney, 44.8% without activity in the renal allograft.
Discussion: We discovered renal allograft failure which resulted in the unmasking of 
native renal function as demonstrated by the furosemide renal scan 5 years after SLKT. This 
patient met UNOS criteria for dual organ transplantation, having sustained AKI requiring 
hemodialysis for 5 months prior to SLKT. More studies are warranted to investigate better 
predictors of native renal recovery in SLKT in the era of the new UNOS policy.
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A Case with Muir-Torre Syndrome: Concurrent Sebaceous Carcinoma 
with Multiple Visceral Malignancies in a Kidney Transplant Recipient
Masahiro Tomonari,1 Yasuyuki Nakada,2 Izumi Yamamoto,3 Takafumi 
Yamakawa,4 Haruki Katsumata,1 Aki H. Mafune,5 Akimitsu Kobayashi,1 
Yudo Tanno,1 Hiroyasu Yamamoto,6 Takashi Yokoo,1 Makoto Sagasaki,3 
Mayuko Kawabe,7 Ai Katsuma.8 1The Jikei University School of Medicine, 
Tokyo, Japan; 2The Jikei University of Medicine, Tokyo, Japan; 3Division of 
Nephrology and Hypertension, Department of Internal Medicine, The Jikei 
University School of Medicine, Tokyo, Japan; 4Division of Nephrology and 
hypertension, The Jikei university school of medicine, Tokyo, Japan; 5Jikei 
University School of Medicine, Tokyo, Japan; 6Division of Nephrology and 
Hypertension, Department of Internal Medicine, Jikei University School of 
Medicine, Tokyo, Japan; 7the Jikei University School of Medicine, Tokyo, Japan; 
8The Jikei University school of Medicine, Tokyo, Japan.
Introduction: Sebaceous carcinoma (SC) is a rare but progressive malignant skin 
cancer, and the incidence is approximately five times higher in post-transplant patients. 
SC is sometimes found concurrently with visceral cancers and a genetic abnormality called 
Muir-Torre syndrome (MTS).
Case Description: The patient was a 43-year-old woman who had received a living 
kidney transplantation from her father at the age of 33 due to end-stage kidney disease 
caused by IgA nephropathy. The transplanted kidney function was stable, with a serum 
creatinine of 1.5 mg/dl. Ten years after transplantation, a rapidly enlarged skin tumor 
developed in the left occipital region, which was totally resected. The tumor was diagnosed 
as SC. In addition, subsequent examination revealed the development of multiple 
visceral malignancies, including sigmoid colon cancer, rectal SC, and cervical cancer. 
Immunohistochemical study revealed the absence of mismatch repair (MMR) proteins and 
the development of microsatellite instability in the SC, suggesting MTS. DNA sequence 
analysis for MMR genes revealed a genetic mutation of 1226_1227delAG in the MSH2 
Exon 7 lesion, which confirmed MTS.
Discussion: SC is relatively common in transplant recipients with visceral malignancies 
due to MTS. Our case suggests that careful and frequent follow-up and thorough evaluation 
by a dermatologist is important for an accurate diagnosis in transplant recipients.
PUB632 
Publication-Only 
Adenovirus Nephritis in the Transplanted Kidney
Imad Razzak, Mohamad A. Hanouneh, Teresa K. Chen, Sami Alasfar. Johns 
Hopkins University School of Medicine, Division of Nephrology, Baltimore, MD.
Introduction: Adenovirus infection can manifest as disease involving the upper 
respiratory tract, gastrointestinal, ophthalmologic, genitourinary, and/or neurologic 
systems. Most cases are self-limited; however, serious and disseminated infections can 
occur in immunocompromised patients.
Case Description: We report the case of a 69-year old male with end-stage renal 
disease attributed to diabetic nephropathy who underwent a deceased donor kidney 
transplant six years prior and presented with weakness, fever, chills, and gross hematuria. 
Laboratory work-up revealed acute kidney injury with a serum creatinine of 2.1 mg/dL, up 
from his baseline of 1.3 mg/dL. Urine studies were notable for >1000 red blood cells/high-
power field and proteinuria of 0.58 g/g. Cystoscopy showed clots in the bladder, cystitis, 
and bloody efflux from the ureteral orifice of the transplanted kidney. Adenovirus DNA 
was detected in the urine by PCR and serum adenovirus viral load was elevated at 1630 
copies/mL. An allograft kidney biopsy was performed, which demonstrated diffuse and 
severe interstitial inflammation with tubulitis and vague granulomas on light microscopy 
(Figure 1A). Immunostaining for adenovirus showed numerous foci of nuclear and 
cytoplasmic staining of tubular epithelial cells (Figure 1B). Given these findings, the patient 
was diagnosed with adenovirus nephritis and treated with intravenous cidofovir 2.5 mg/kg 
twice a week for 3 weeks. The dose of his mycophenolate was also reduced by 50%. With 
this treatment, his hematuria resolved, serum creatinine returned to baseline, and serum 
adenovirus viral load became undetectable.
Discussion: Adenovirus is an opportunistic infection frequently seen in kidney 
transplant recipients. Clinical manifestations of adenovirus involving the genitourinary 
system include hemorrhagic cystitis and, rarely, tubulo-interstitial nephritis. A kidney 
biopsy is necessary for definitive diagnosis of adenovirus nephritis. Treatment includes 
antiviral therapy and reduction of immunosuppression.
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Rituximab Success in Management of Recurrent GVHD of the Kidney 
Post Allogeneic SCT
Omar Mamlouk,1 Hanan A. Khairalla,4 William F. Glass,2 Ala Abudayyeh.3 
1University of Texas Health Science Center at Houston, Houston, TX; 2University 
of Texas – Houston Medical School, Houston, TX; 3The University of Texas MD 
Anderson Cancer Center, Houston, TX; 4University of Texas, Houston, TX.
Introduction: GVHD of the kidney is a rare complication post allogeneic stem cell 
transplant usually manifests clinically as a nephrotic syndrome after around 6-12 months 
of transplant. It is estimated that the incidence of the nephrotic syndrome in adult recipients 
ranges 0.4-6 %. Majority of the cases has evidence of Mimimal change disease(65.5%), 
followed by membranous (19%) then FSGS (7.7%). Steroids used alone or in combination 
with calcineurin inhibitor reported to induce favorable response in around 75% of the cases. 
Rituximab had good outcome in management of GVHD with membranous nephropathy. 
There is a very limited data about the incidence and treatment of recurrent GVHD of the 
kidney after initial remission. We present a case of FSGS as a presentation of GVHD 
of the kidney with three relapses who has failed tacrolimus and steroids in the past and 
successfully treated with rituximab each time with full remission.
Case Description: 66 year old hispanic male with history of hypertension, non-
ischemic cardiomyopathy and Mantle cell lymphoma status post allogenic SCT (7 years 
ago) with renal GVHD at 1 and 3 years post-transplant. Renal biopsy consistent with 
Minimal change disease and FSGS respectively, treated successfully with rituximab. Patient 
presented with volume overload with anasarca. Urine analysis was positive for hematuria 
and pyuria. Proteinuria peaked at 11g and albumin of 2.2 g/dl. Patient had AKI on admission 
with creatinine was of 3.3 mg/dl (with baseline 1.4 mg/dl, 5 months prior to admission) 
patient was started on empiric therapy with 1m/kg of prednisone daily and underwent renal 
biopsy with finding of FSGS. He was started on weekly dose of rituximab 375 mg/m2 but 
his creatinine peaked at 7.7 mg/dl and underwent dialysis for three weeks at which point 
he had improved urine output, creatinine decreased to 1.0 mg/dl, and UPC decreased from 
11g to 1g.
Discussion: Renal GVHD after stem cell transplant can be of a recurrent nature, even 
after 7 years of transplant. Rituximab successfully induced remissions in patient with FSGS 
despite severe AKI that required. A possible theory on how B cells can contribute to chronic 
GVHD is that the reconstituted B cells after myeloablative conditioning may have impaired 
immune tolerance of peripheral B cells, leading to the production of autoantibody in chronic 
GVHD.
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A Case of High Output Heart Failure Secondary to an Arteriovenous 
Fistula in a Renal Transplant Patient
Divya Raghavan,1 Josephine Abraham,2 Fuad S. Shihab,3 Isaac E. Hall,1 
Faris A. Ahmed.2 Divya Raghavan 1University of Utah, Salt Lake City, UT; 
2University of Utah, Salt Lake City, UT; 3University of Utah Health Science 
Center, Salt Lake City, UT.
Introduction: The presence of an arteriovenous (AV) fistula in a patient leads to 
decreased systemic vascular resistance and a compensatory increase in cardiac output which 
may result in clinical heart failure.
Case Description: A 72-year-old lady with history of end stage renal disease secondary 
to ANCA vasculitis post renal transplant 2 weeks ago was admitted with worsening 
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peripheral edema and dyspnea on exertion. She had gained 19 kg since transplant. She 
was on tacrolimus, mycophenolate sodium and prednisone. Physical examination showed 
elevated jugular venous pressure, bilateral crackles, 2+ pitting lower extremity edema, 
1+ pitting upper extremity edema, greater on the right side, and a right brachiocephalic 
arteriovenous fistula with thrill and bruit. Echocardiogram showed an ejection fraction of 
63%, diastolic dysfunction, an elevated pulmonary artery systolic pressure of 53 mmHg 
and a dilated inferior vena cava. Right upper extremity duplex was negative for deep vein 
thrombosis. Serum creatinine (SCr) was 1.64 mg/dl, (baseline 1 mg/dl). She was treated 
with intravenous (iv) furosemide and improved clinically. She was transferred to inpatient 
rehab after 5 days, by which time SCr was down to 1.2 mg/dl and she had lost 2 kg. In rehab, 
she lost another 10 kg. 2 weeks after transfer, she developed worsening hypoxia and was 
transferred back to the floor. She received iv diuresis and was discharged after 5 days. She was 
readmitted 3 weeks later for volume overload, and her weight was up by 9 kg. Labs showed 
SCr of 2.34 mg/dl. Vascular duplex of AV fistula showed a high flow rate of 2.7 L/min. 
She was treated with iv furosemide. The patient lost 12 kg and underwent right heart 
catheterization. Her cardiac output was 8.6 L/min at baseline and decreased to 6.6 L/min 
after right arm fistula occlusion. Her fistula was ligated 4 days later. At the time of clinic 
visit 2 weeks post-discharge, SCr was down to 0.6 mg/dl, and the patient had lost another 
3 kg and was back to her pre-transplant weight.
Discussion: High output heart failure secondary to an AV fistula can be confirmed by 
right heart catheterization with dynamic measurements. An elevated baseline cardiac output 
with a significant decrease upon transient fistula occlusion, such as in our patient, helps 
confirm the diagnosis.
PUB635 
Publication-Only 
Invasive Mucormycosis Causing Gastrointestinal Bleed in a Renal 
Transplant Patient
Divya Raghavan,1 Josephine Abraham,2 Fuad S. Shihab.3 Divya Raghavan 
1University of Utah, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT; 
3University of Utah Health Science Center, Salt Lake City, UT.
Introduction: Mucormycosis refers to a serious infection by fungi in the order 
Mucorales. It presents most commonly as rhino-orbital-cerebral and pulmonary infections. 
It predominantly affects patients with diabetes mellitus and immunocompromised patients.
Case Description: A 43-year-old lady with a history of end stage renal disease 
secondary to lupus nephritis post second kidney transplant (with alemtuzumab induction) 
2 weeks prior to presentation was admitted with severe anemia. She was on tacrolimus, 
mycophenolate sodium and prednisone. She had blood tinged stools but stable vital signs. 
Hemoglobin was 5.6 g/dl for which she received two units of packed red blood cells. 
Colonoscopy revealed two large ulcers. Biopsies showed invasive mucormycosis. She 
was started on amphotericin therapy and subsequently underwent a subtotal colectomy 
with creation of an ileostomy. The resected specimen had multifocal ulcerations on gross 
examination. On histologic examination, the mucor invaded the muscularis propria and 
was associated with an extensive giant cell reaction, acute inflammation and ulceration. 
Her clinical course was further complicated by antibody mediated rejection after 
immunosuppression was decreased. She developed a pulseless arrest during plasmapheresis 
therapy necessitating resuscitation. She developed hypoxic brain injury and was eventually 
transferred to a long term assisted care living center with a tracheostomy.
Discussion: Invasive mucormycosis can rarely affect the gastrointestinal tract. The 
stomach is most frequently reported as a site of involvement, followed by the colon. The 
typical lesions seen are ulcers with necrosis. Opportunistic infections such as mucormycosis 
should be part of the differential diagnosis for solid organ transplant patients with 
gastrointestinal symptoms. There should be a low threshold to pursue definitive diagnosis 
with tissue biopsy.
Colon biopsy showing invasive mucormycosis
PUB636 
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Type III Hypersensitivity Reaction (HSR3) from Rabbit Anti-thymocyte 
Antibody (ATGAM) Induction
Roopa Sharadanant,3 Gautam M. Phadke,1 Adit S. Mahale,1 Smaroula Dilioglou.2 
1Medicine, Nephrology, Sanford Health, UND School of Medicine, Fargo, ND; 
2Sanford Health, Fargo, ND; 3Internal Medicine, University of North Dakota 
School of Medicine, Fargo, ND.
Introduction: We report a rare complication of thymoglobulin use and importance of 
its early recognition and treatement.
Case Description: A 38 year old male during his 3rd kidney transplant received 
6 mg.kg of ATGAM for induction immunosuppression. He presented 1.5 weeks after last 
dose with 102 F fever and fleeting joint pains. Examination revealed tender joints with 
effusions. Day 2 of hospital admission, targeted question of jaw pain was elicited, which 
was positive. Clinical diagnosis of serum sickness due to ATGAM was made, empiric 
antibiotics discontinued and treatment with Solumedrol, daily plasmapheresis was initiated. 
Day 4 of treatment, all symptoms were resolved. Steroids were tapered over 2 weeks.
Discussion: Incidence of HSR3 or serum sickness due to ATGAM ranges 2-27%, but 
severe reaction needing treatment is rare. Prior ATGAM exposure, raising or ingesting 
rabbits, increase its incidence. Jaw pain is a distinct clinical symptom. No commercial 
diagnostic test is available in the US: personal communication, Sanofi. Complements may 
be low. IgM, IgG, but mainly IgG antibodies bind to the F(ab) part of IgG thymoglobulin 
forming immune complexes (IC). Excess IC escaping degradation by liver and Kupffer 
cells, precipitate in tissues. Fenestrated endothelial lining(synovial membrane)are most 
susceptible. Fc part of the IC binds to the Fcγ receptor on endothelial lining activating 
classical complement pathway, recruiting inflammatory cells, cytokines resulting in a 
systemic reaction. Corticosteroids, physical removal of IC by plasmapheresis is mainstay 
of treatment. Rapid resolution of symptoms after plasmapheresis, correlates with reduction 
of IC in vivo. Our case demonstrates need to identify this rare clinical syndrome due to 
ATGAM. Theoretically, reduced immunosuppressive potency of ATGAM due to IC 
formation may increase risk of early rejection; no such effect was observed in our case.
Lab data
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Deep Dermatophytosis in an Immunosuppressed Kidney Transplant 
Recipient: A Case Report
William Osborne,2 Alireza Abdolrasouli,1 Marina Loucaidou,2 Rawya Charif,2 
James Carton,1 Neill D. Duncan.2 1Imperial College NHS Healthcare Trust, 
London, United Kingdom; 2Imperial College Renal and Transplant Centre, 
London, United Kingdom.
Introduction: Dermatophytosis is a common, superficial skin, hair and nail infection 
caused by a diverse group of filamentous fungi. In contrast, deep dermatophytosis is 
a rare and invasive form, whereby deeper dermal structures are invaded and/or there is 
dissemination to other tissues (e.g. lymph nodes, brain and lung). Risk factors for this include 
CARD9 deficiency, human immunodeficiency virus infection and immunosuppression. We 
report a case of deep dermatophytosis involving the fungus, Trichophyton rubrum, in an 
immunocompromised patient.
Case Description: A 66 year-old man of Indian descent, presented to our rapid access 
clinic with fevers, left buttock pain, dry cough and a nodular lesion on his right leg. He had 
a recent diagnosis of type 2 diabetes mellitus and received a live unrelated donor kidney 
transplant one-year prior. He was on tacrolimus, mycophenolate and prednisolone therapy 
for antibody-mediated rejection. The patient had a fever (38.6oC) and was temocillin and 
vancomycin for a presumed urinary tract infection. Admission blood testing revealed 
an elevated C-reactive protein (45.9mg/L), a high tacrolimus level (14.9 ug/L), graft 
dysfunction (creatinine 184 umol/L), normocytic anaemia (Hb 106g/L, MCV 89.4fL) and 
normal white cell count (6.4x109/L). EBV and adenovirus DNA were detected in blood. 
Biopsy of the nodular lesion demonstrated granulomatous inflammation and fungal hyphae 
within the granulomas. Trichophyton rubrum was isolated in culture. High-resolution 
CT imaging of the chest revealed progressive ground-glass opacities in the right peri-
hilar region. Bronchoscopy was negative for malignant cells, M. tuberculosis and fungi. 
He was treated with liposomal amphotericin B and voriconazole, topical terbinafine and 
meropenem.
Discussion: This case highlights the plethora of opportunistic infections that 
immunosuppressed kidney transplant patients are at risk of. A high index of suspicion, 
thorough investigation and good dialogue between specialists are required to offer the best 
patient outcomes. In addition, we feel that any undefined skin lesion in this patient group 
warrants a skin biopsy.
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Recurrence of Hypertension and Hypokalemia Following Renal  
Transplant Uncovers Inadequately Treated Primary Hyperaldosteronism
Sadeem Ali, Christie P. Thomas. University of Iowa College of Medicine, Iowa 
City, IA.
Introduction: Persistent or recurrent primary hyperaldosteronism after renal transplant 
has only rarely been reported which makes this case unique.
Case Description: 49-year-old man received a deceased donor renal transplant in 
November 2016 after being on hemodialysis for 18 months. Potassium in blood was 4 on 
admission and he was on amlodipine 10 mg daily (changed to nifedipine late November 
to allow for up titration), carvedilol 25 mg twice a day, doxazosin 8 mg daily, furosemide 
80 mg daily (later discontinued), and spironolactone 50 mg twice a day for blood pressure. 
He developed hypertension, 1 day after transplant up to 160s systolic blood pressure 
and manifested hypokalemia by day 52 post- transplant, despite being on tacrolimus, 
trimethoprim-sulfamethoxazole & heparin. Review of his prior records indicated that he 
had been diagnosed with primary hyperaldosteronism leading to ESRD. His CT scan in 
August, 2015 showed bilateral adrenal lesions, most likely simple adenomas, medullary 
nephrocalcinosis & concurrent renal atrophy, left greater than right. His aldosterone to renin 
ratio was 20 in 2013 & 71.9 in 2015. He had been treated with carvedilol 12.5 mg twice a 
day, doxazosin 8 mg daily and spironolactone 100 mg twice a day, until he developed ESRD. 
TTKG was 4.5, aldosterone 22 ng/dl, renin 0.7 ng/ml/h and renin to aldosterone ratio 31 
on 11/28/17. He is currently more than 1.5 year out from renal transplant with an eGFR in 
ml/minute/square meter of 71 per MDRD. His hypertension is treated with spironolactone 
50 mg twice a day, carvedilol 12.5 mg twice a day and doxazosin 16 mg daily. His last 
serum potassium level was 3.8 and blood pressure 140s/90s last checked at home.
Discussion: The cardinal manifestations of primary hyperaldosteronism may be lost or 
masked by the onset of ESRD because of end organ resistance to aldosterone and because 
maintenance dialysis can efficiently manage hypertension and disordered electrolytes. 
Since the abnormality arises from autonomous secretion of aldosterone, the successful 
replacement of renal function with a functioning renal transplant will inevitably lead to 
recurrence of the resistant hypertension & hypokalemia. Patients with a history of primary 
hyperaldosteronism should be recognized and appropriately managed prior to a kidney 
transplant and if pre-transplant cure is not possible, then recurrence should be anticipated
PUB639 
Publication-Only 
Early Listeria Monocytogenes Infection Post-Kidney Transplantation
Shreemayee De,1 Pooja Tanjavour.2 1Newark Beth Israel Medical Center, 
Edison, NJ; 2Newark Beth Israel Medical center, Nutley, NJ.
Introduction: Listeria monocytogenes is a facultative anaerobic, gram-positive 
bacillus commonly found in soil, water, sewage, animal feces and domestic animals. It 
most commonly affects immunocompromised individuals such as those with HIV, cancer, 
and those who are immunosuppressed. Invasive form of Listeria monocytogenes infection 
usually occurs during the intermediate phase of post-renal transplantation. However on rare 
incidences, it can affect recipients during early phase of post renal-transplantation.
Case Description: This is a 67-year-old female with history of end-stage renal disease 
secondary to type 2 diabetes mellitus who was admitted 9 days post deceased donor renal 
transplantation for symptoms of fever, diarrhea, nausea and lethargy. Patient had received 
3 doses of anti-thymocyte globulin on Days 0-2 of renal transplantation, and was started on 
tacrolimus, mycophenolic acid and prednisone. Septic workup showed blood culture and 
cerebrospinal fluid study was positive for Listeria monocytogenes, and CAT Scan of the 
head was overall unremarkable. Thus, she was diagnosed with meningitis due to Listeria 
monocytogenes and was treated with parenteral ampicillin and gentamycin. Her course was 
complicated by acute hypoxic respiratory failure requiring brief intubation for 2 days, and 
an episode of tonic-clonic seizures. Her condition gradually improved and was discharged 
to rehabilitation with total 4 weeks course of ampicillin and gentamycin.
Discussion: This case highlights that even though opportunistic infections occur during 
intermediate phase of post-renal transplantation, they can manifest during early phase as it 
did with this patient who presented within 10 days of renal transplantation. In this case, it 
is presumed that patient had acquired Listeria monocytogenes prior to her transplantation 
since the average incubation period of Listeria monocytogenes is 11 days. The invasive 
form manifested earlier due to T cell activity suppression via anti-thymocyte globulin and 
tacrolimus. Such cases like this are rare but needs increased awareness when considering 
etiology of fever in transplant recipients.
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Successful Use of Ruxolitinib for Graft-versus-Host Disease in a Simulta-
neous Liver-Kidney Transplant Recipient
Ryan A. Kunjal,3 Karthikeyan Venkatachalam,1 Sadaf N. Sheikh,2 Rowena 
B. Delos Santos.3 1Washington University School of Medicine, Saint Louis, MO; 
2Washington university St Louis MO, Valley Park, MO; 3Washington University
in St. Louis, Saint Louis, MO.
Introduction: Graft-versus- host disease (GVHD) is a rare and lethal complication 
of solid organ transplants (SOT). It occurs more commonly from donor grafts with larger 
amounts of lymphoid tissue such as liver transplants. Its occurrence after simultaneous 
liver-kidney (SLK) transplant has not been described. We describe the first successful case 
of Ruxolitinib use in steroid refractory GVHD in SOTs.
Case Description: A 66 year old Caucasian male with end stage renal disease and 
non-alcoholic steatohepatitis related cirrhosis received a SLK transplant with Basiliximab 
induction and was maintained on tacrolimus, mycophenolate and prednisone. On post-
transplant day (PTD) 14, he was readmitted for fever and abdominal pain due to an E. 
Faecium biloma which was treated with linezolid, cefepime and surgical drainage. At PTD 
26, he developed a diffuse maculopapular rash and a biopsy showed interface dermatitis; 
initially thought to be due to drug eruption and was treated with 3 days of IV methyl 
prednisone (MP) at 1mg/kg then prednisone taper. His rash worsened, and he complained 
of nausea and watery diarrhea. Infectious workup was negative. Hepatic and renal function 
were normal and immunosuppression was continued. However on PTD 31, he was noted to 
be pancytopenic. Bone marrow biopsy revealed normocellular marrow without evidence of 
GVHD. Short tandem repeats (STR) enriched for CD3+ cells from peripheral blood showed 
mixed chimerism. His diarrhea became intractable, and a colon biopsy revealed Grade 1 
GVHD. MP 2mg/kg/ day was started, but he became neutropenic requiring filgrastim. He 
had persistent mixed chimerism on repeat testing a week later. Ruxolitinib 5mg twice daily 
(a selective Janus kinase inhibitor used in steroid refractory GVHD, where it inhibits T cell 
activation) was added. 3 days later, leucopenia and thrombocytopenia resolved and diarrhea 
ceased. His rash improved and steroids were gradually tapered. 6 wks post treatment there 
was no evidence of peripheral blood donor chimerism.
Discussion: Knowledge of the clinical features of GVHD in SOT is limited and 
delayed diagnosis contributes to the high mortality. This case demonstrates the value of 
early recognition and initiation of treatment. The treatment however, is quite heterogenous 
and no guideline exists.
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First Report of Successful Kidney Transplantation in a Patient with Job’s 
Syndrome
Samaya J. Anumudu,2 Ahmed A. Awan,2 Bhamidipati V. Murthy,2 Biruh 
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Introduction: Autosomal dominant hyper-IgE syndrome (AD-HIES), commonly 
referred as Job’s syndrome, is a rare immune disorder associated with mutations in the 
STAT3 gene with high blood levels of IgE. Recurrent infections affecting multiple body 
systems characterize the disease. Little is known of the renal disease that occurs in patients 
with Job’s syndrome; however, there have been documented reports of lupus nephritis 
and interstitial disease occurring in these patients. The survival of patients receiving 
hemodialysis (HD) is poor and can be decidedly improved with transplantation, but due to 
the high risk of infections kidney transplantation has not been generally considered as an 
option for patients with AD-HIES.
Case Description: A 26-year-old African American female with a history of Job’s 
syndrome, asthma, and recurrent skin and lung infections developed end-stage renal 
disease (ESRD) due to immune-complex nephritis. She received HD for 5 years prior to 
accepting a living related kidney transplant from her mother. She received induction with 
thymoglobulin, and was subsequently placed on tacrolimus, mycophenolate, prednisone 
along with standard infection prophylaxis. She had immediate graft function and was 
discharged home on post-operative day 4 with a serum creatinine (SCr) of 1.26 mg/dL, 
down from a pre-transplant value of 11.73 mg/dL. Infectious complications during her post-
transplant course included several urinary tract infections, an episode of influenza, CMV, 
BK, and EBV viremia. She also experienced periodic asthma exacerbations and pneumonia, 
which required brief hospitalizations. She developed acute kidney injury after some of the 
infectious complications, never requiring dialysis. After 14 months post-transplant she has 
not experiend allograft rejection and maintains good renal function, the most recent SCr was 
1.08 mg/dL at the time of this report.
Discussion: We present the first and only case of successful kidney transplantation in 
a patient with Job’s syndrome. Despite the various infectious episodes complicating her 
post-transplant course, she has been able to overcome them and her renal function remains 
excellent. The decision to transplant should be highly personalized with the involvement of 
experts who are familiar with the disease. Close monitoring for infectious complications 
and avoidance of over-immunosuppression would be advised.
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A Case of Myeloma Cast Nephropathy Unmasked by Volume Depletion in 
a Renal Transplant
Jason C. George, Prince Mohan. Geisinger Medical Center, Danville, PA.
Introduction: Acute kidney injury (AKI) in a renal transplant patient should prompt 
investigation for reversible causes, such as volume depletion, ureteral obstruction, or supra-
therapeutic calcineurin inhibitor levels. If no clear cause is identified, allograft biopsy can 
help elucidate a diagnosis and potentially guide treatment decisions.
Case Description: A 51 year-old Caucasian female with Alport syndrome underwent 
deceased donor renal transplant at age 37. She had chronic allograft dysfunction with baseline 
creatinine 1.8-2.0 mg/dL. Medications included tacrolimus 2mg q12h, mycophenolate 
mofetil 500mg BID, and lisinopril 5mg daily. She presented with 5 days of profuse diarrhea 
and poor oral intake. Her daughter was recently sick with similar symptoms. Labs showed 
creatinine of 6.5 mg/dL, HgB 6.7 mg/dL, calcium 8.0 mg/dL, albumin 4.1 g/dL, and FK 
trough of 2.9. Stool infectious workup was unrevealing. Transplant ultrasound showed no 
evidence of hydronephrosis. She received IV fluids without improvement in renal function. 
Allograft biopsy showed numerous intra-tubular, periodic acid-Schiff-negative casts with 
surrounding cellular reaction and diffuse interstitial edema/inflammation. Moderate tubular 
atrophy/interstitial fibrosis were present. No glomerulitis/tubulitis, or crescent formation 
were seen. Staining for C4d was negative in peri-tubular capillaries. Bone marrow biopsy 
showed plasma cell infiltrate of 30% with associated kappa restriction, consistent with 
light chain myeloma. She was started on induction chemotherapy and plasmapheresis. 
She required hemodialysis due to progressive decline in renal function and associated 
hyperkalemia.
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Discussion: Light chain cast nephropathy can be unveiled in certain settings, such 
as intravascular volume depletion or receipt of potentially nephrotoxic agents (iodinated 
contrast, NSAID’s, etc.). Severe renal insufficiency at diagnosis is generally associated with 
worse overall survival. However, recovery of renal function with disease-specific therapy 
can have prognostic significance. Thus, it should remain a diagnostic consideration in 
patients with AKI that does not improve with conservative interventions, especially in the 
setting of volume depletion.
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Unusual Case of Encapsulated Sclerosing Peritonitis(ESP) in Renal 
Transplant Recipient
Sasmit Roy,1 Kenneth A. Bodziak.2 1Renal Medicine, University of Massachusetts 
Medical School, Worcester, MA; 2UMass Memorial Medical Center, Worcester, MA.
Introduction: ESP is a rare complication of Peritoneal Dialysis(PD) with annual 
mortality 51%. Likely causes are prior episode of severe peritonitis, using acetate as 
dialysate buffer, prolonged exposure to glucose degradation products from glucose-
containing solutions, withdrawal from PD and long duration of PD.
Case Description: 35 year old man admitted with intractable nausea(N), vomiting(V), 
odynophagia, abdomen distension and weight loss for few months. PMH:ESRD from 
FSGS s/p LRKT in 2003 failed due to noncompliance and recurrent FSGS, HTN, on 
PD for >10 years, DDKT12/2016. P/E:BP 90/50; weight loss 50 lbs ;tender distended 
abd, no guarding, sluggish bowel. Labs:K 5.4, HCT 35. Frequent readmission for abd 
pain, N&V.Multiple CT abd-loculated collections, large hemoperitoneum, no bowel 
obstruction. Ba swallow- delayed gastric emptying;bone marrow biopsy -neg. IR guided 
angiogram- no active bleeding or aneurysm. Managed conservatively and started on 
TPN. Exploratory Laporotomy:Dense fibrovascular tissue with chronic inflammation, 
hemorrhage, hemosiderin deposition and fibrin;fibrous tissue with fibrinous exudate and 
necrosis Treatment:Tamoxifen. Now tolerating po intake. Stable renal graft function on 
tacrolimus& prednisone.
Discussion: ESP cause extensive intraperitoneal fibrosis & encasement of bowel loops. 
It is associated with progressive loss of ultrafiltration, causing fluid retention and edema. 
It is slowly progressive, mostly asymptomatic. Presentations are abd pain, N&V, appetite 
loss, constipation, diarrhea, abdominal mass, ascites, weight loss and fatigue. CT abd 
shows peritoneal calcification, bowel thickening, bowel tethering and dilatation. Diagnostic 
confirmation with laparotomy/laparoscopy-characteristic peritoneal thickening that 
encloses intestinal contents. Histopathology: dense fibrocollagenous tissue +/- lymphocytic/
plasma cell infiltration. Treatment is switching from PD to hemodialysis, bowel rest with 
TPN, immunosuppressive therapy (corticosteroids/azathioprine/tamoxifen)+/- surgery.
Abdominal Cocoon
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External Iliac Artery Stenosis Causing Resistant Hypertension and Acute 
Renal Allograft Dysfunction
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Introduction: Renal artery stenosis (RAS) in kidney transplant is a reversible cause of 
hypertension (HTN) and acute kidney injury. Although RAS usually presents between the 
first three months to two years after transplantation, it can manifest at any point during the 
post-transplant course. We present a rare case of external iliac artery stenosis presenting as 
transplant RAS.
Case Description: A 52 year-old man with end stage renal disease due to IgA 
nephropathy and diabetes underwent living unrelated renal transplant (right lower 
quadrant placement) 9 years prior to presentation. Baseline lab values showed creatinine of 
1.4 mg/dL and urine protein/creatinine ratio of <500mg/g. His tacrolimus trough level was 
maintained at 6-7 ng/mL. Over the past several years he developed worsening HTN, for 
which he was treated with lisinopril but this required discontinuation on several occasions 
due to worsening renal allograft function. He developed worsening HTN and renal 
allograft function with creatinine as high as 2.7 mg/dL. On physical examination, a bruit 
was appreciated over the allograft. Renal ultrasound showed a parvus-tardus waveform. 
Angiography performed by Interventional Radiology showed high-grade stenosis of the 
right external iliac artery that was successfully stented with no residual post-procedural 
stenosis identified. No stenosis of the transplanted renal artery was seen. Prior to the 
procedure he disclosed worsening right leg claudication that improved after vascular 
intervention. His creatinine subsequently improved to 1.3mg/dL and blood pressure was 
controlled on minimal anti-hypertensive therapy.
Discussion: Stenosis of the transplanted renal artery is a common complication after 
renal transplantation. It can occur in up to 23% of patients and present as uncontrolled 
hypertension with AKI. Stenosis of the anastamosed external iliac artery, which can have 
similar hemodynamic effects on the renal allograft, can also occur but has rarely been 
reported. This case highlights the importance of thorough vascular examination in the renal 
transplant recipient to help identify signs of poor flow to the ipsilateral limb of the allograft. 
Such vascular changes can unmask a stenosis that is proximal to the renal artery and can 
have clinical manifestations of RAS.
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Cystic Degeneration of Metastatic Lymph Nodes in Renal Cell Carcinoma 
(RCC) in a Renal Transplant Patient
Hong loan T. Nguyen, Samaya J. Anumudu, Natasha N. Dave, 
Bhamidipati V. Murthy. Baylor College of Medicine, Houston, TX.
Introduction: Increased risk of malignancy is a major post-transplant complication. 
The incidence of de novo RCC is 4.6% in the renal transplant compared to 3% in the 
general population and 25% of which are incidentally discovered. We present a case of 
incidental RCC associated with rare cystic degeneration of metastatic lymph nodes in a 
renal transplant patient.
Case Description: A 53 y/o AAM with obesity and h/o kidney transplantation 5 years 
ago secondary to ESKD from hypertensive nephrosclerosis requiring prior hemodialysis 
was admitted with advanced renal failure. He presented with nausea, vomiting and anuria 
after defaulting on immunosuppression for few weeks and was found with blood pressure 
220/100, creatinine 33.16 mg/dl, BUN 180 mg/dl, hyperkalemia, severe metabolic acidosis, 
and microangiopathic hemolytic anemia on workup. Allograft kidney biopsy revealed 
thrombotic microangiopathy, acute tubulitis, intimal vasculitis, and positive C4d staining 
consistent with acute antibody-mediated rejection (AMR). Hospital course was complicated 
by incidental finding of diffuse mediastinal and cervical lymphadenopathy with cystic 
degeneration. Cytology of the cyst aspirate revealed papillary cancer. Further imaging 
showed atrophic native kidneys with innumerable bilateral complex cysts and normal 
allograft kidney. Immunohistochemistry profile favored papillary RCC – likely arising 
from native kidneys. During AMR treatment, he developed life-threatening spontaneous 
hemorrhage from left native kidney needing percutaneous embolization.
Discussion: In renal transplant recipients, RCC is the most common urologic 
malignancy and multiple factors such as age, gender, race, dialysis duration, glomerular 
disease has been shown to affect RCC risk. However, most transplant guidelines either 
recommend against or do not include RCC screening recommendation citing limited cost-
effectiveness of screening strategies. A regular post-transplant surveillance would have 
detected RCC in a much earlier stage with probable chance of cure. This case emphasizes 
the need for further awareness and clear cancer surveillance guideline with special attention 
to high risk post-transplant population. This case also highlights two other rare presentations 
– a cystic degeneration in metastatic lymph nodes, and spontaneous hemorrhage of RCC
in a transplant recipient.
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De Novo Crescentic IgA Nephropathy Along with Antigen and Antibody 
Mediated Rejection in a Renal Allograft
Sandeep Padala, Imran Y. Gani. Augusta University, Augusta, GA.
Introduction: Acute rejection is the common cause of allograft dysfunction in a 
kidney transplant. Rejection can be either antigen or antibody mediated. De Novo IgA 
nephropathy can happen in tranplant kidney. We report a unique case of de novo crescentic 
IgA Nephropathy with both acute cellular and antibody mediated severe allograft rejection.
Case Description: 36-year-old male with history of ESRD secondary to recurrent AKI 
from sepsis related to MRSA hip osteomyelitis and contrast exposure s/p deceased donor 
kidney transplant in 2014, h/o biopsy proven cell and antibody mediated rejection in 2015 
due to non-compliance with immunosuppressants which was successfully treated. He was 
admitted with nausea, diarrhea and dark colored urine. Labs revealed AKI with creatinine 
of 11 mg/dL (baseline 1.8), BUN of 96 mg/dL, CO2 of 11 mEq/L, K of 5.6 mEq/L and 
subtherapeutic tacrolimus level of 1.6 ng/ml. UA and microscopy revealed dysmorphic 
RBC’s and protein without any infection. On exam, he had a systolic murmur and 
1+ bilateral lower extremity edema. Pan cultures and ECHO were negative. Due to 
worsening acidosis and hyperkalemia, hemodialysis was initiated. Transplant ultrasound 
was normal. A kidney biopsy revealed mesangial expansion, IgA deposition, mesangial 
immune complex deposits, severe lymphoplasmacytic tubulointerstitial infiltration, 
transplant arteritis, positive C4d staining along peritubular capillaries consistent with 
both cell mediated as well as humoral rejection. Also crescents were seen. Donor specific 
antibodies were positive. Further workup revealed weakly positive anti-nuclear antibodies 
(1:160). C3, C4, ds-DNA, C-ANCA, P-ANCA, anti-GBM, HIV, hepatitis panel, RPR, EBV, 
CMV, Adenovirus, BK virus and Influenza were negative. Treatment was initiated with high 
dose steroids, thymoglobulin followed by plasmapheresis and IVIG. Cyclophosphamide 
was not used. Despite aggressive management, patient had no response and required 
hemodialysis as outpatient.
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Discussion: Our case reports occurrence of de novo crescentic IgA nephropathy along 
with both cellular and antibody mediated rejection in a kidney transplant patient. IgA 
nephropathy with mesangial deposits only may have a favorable prognosis but presence 
of crescents heralds a bad prognosis. Crescentic IgA nephropathy along with transplant 
rejection is associated with worse prognosis.
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Successful Combined Liver and Kidney Transplant in a Patient with 
Primary Hyperoxaluria and Thrombophilia: A Management Conundrum
Sandiya Bindroo,1 Simin Goral.2 1Crozer Chester Medical Center, Upland, PA; 
2University of Pennsylvania, Bryn Mawr, PA.
Introduction: Primary hyperoxaluria (PH) is a rare autosomal recessive disorder 
caused by a deficiency of the liver-specific enzyme alanine: glyoxylate aminotransferase 
(AGXT). This is characterized by oxalate overproduction, leading to kidney failure due to 
nephrocalcinosis, and is eventually responsible for systemic oxalosis. We present a case 
of PH with known factor V Leiden and prothrombin 20210G mutation, who underwent 
combined deceased-donor liver and kidney transplant (CLKT).
Case Description: A 27-year-old Syrian female, with a history of PH type 1 (positive 
AGXT mutation), factor V Leiden and prothrombin gene mutation was scheduled for 
CLKT. Over the past 1 year, patient developed end-stage renal disease in the setting of 
nephrocalcinosis secondary to PH and was started on hemodialysis (HD). Preoperative 
laboratory tests showed serum creatinine, 5.63 mg/dL (0.6-1.2 mg/dl); international 
normalized ratio (INR), 1.1; and activated partial thromboplastin time (aPTT), 29 seconds. 
Model for End-Stage Liver Disease score was 21. Intermittent HD was done 6-24 
hours before surgery to adjust electrolyte balance and to optimize intravascular volume. 
Continuous venovenous hemofiltration (CVVHD) was started after induction of anesthesia 
to remove oxalate crystals. She received methylprednisolone and thymoglobulin for 
immunosuppression. In view of the patient’s history of prothrombin gene mutation and factor 
V Leiden mutation, she was maintained on a heparin infusion with an aim of maintaining 
the partial thromboplastin time in the range of 70-75. She remained stable throughout, 
maintaining a mean arterial pressure goal of > 80-85 mmHg after reperfusion. CVVHD 
was continued in post-operative period to enhance oxalate removal followed by intermittent 
daily HD. As per institutional policy she was on maintenance immunosuppression with 
tacrolimus, steroid taper and mycophenolate mofetil. The functions of both grafts remained 
stable throughout the entire 2-month post-transplant period.
Discussion: Inherited prothrombotic risk factors predispose to thromboembolic 
events and are significantly associated with acute vascular rejections. There is currently 
no consensus on optimal management for CLKT in the setting of prothrombin gene 
mutation. More prospective studies are needed to elucidate ideal treatment strategies for an 
uncommon, but important clinical scenario.
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Introduction: The deterioration of allograft function in kidney transplant recipients 
can lead to over immunosuppression due to relative immunosuppressant overdosing for 
kidney function. We report a case of EBV-positive post transplantation lymphoproliferative 
disorders (PTLD) 27 years after transplantation in a failing allograft, which immediately 
responded well only to withdrawal of immunosuppressant (IS).
Case Description: A 59-year-old female, who received an ABO-compatible living 
kidney transplantation 27 years ago, was admitted to initiate dialysis for allograft failure. 
Six months prior, she had developed pancytopenia, which was caused by bone marrow 
suppression from accumulation of mycophenolic acid and CMV infection, and was 
recovered by reducing mycophenolate mofetil (MMF). When admitted, she was found to 
have asymptomatic low-grade fever. Computed tomography (CT) showed multiple liver 
masses without lymphadenopathy or other organ involvement, which was not present six 
months before. We at first diagnosed it as liver abscess and treated her with antibiotics, only 
in vain. We then punctured the liver mass, which showed diffuse large B-cell lymphoma 
(DLBCL) with positive EBV in situ, leading to a final diagnosis of PTLD. MMF and 
cyclosporine were stopped immediately, and subsequently she became afebrile and the liver 
masses were completely disappeared within 4 months without requiring chemotherapy.
Discussion: Although there are a growing number of late-onset PTLD, most reported 
cases were occurred earlier than twenty years post-transplant and were not so associated 
with EBV, partly because ISs are usually reduced in very late phase. In these perspectives, 
our case seems exceptional. Teaching points in our case include that PTLD can occur even 
very long after the transplant, and that late onset PTLD can be associated with EBV. We 
speculate the pathogenesis of our case is over-immunosuppression not because of absolute 
IS overdosing but because of relative overdosing due to advanced allograft dysfunction, in 
which renally excreted MPA could accumulate. The fact that only IS withdrawal resolved 
the PTLD suggests the over-immunosuppression rather than dysregulated proliferation is the 
cause of PTLD in our case. In conclusion, failed transplant patients may have risk of PTLD 
due to relative IS overdosing, which may be prevented by therapeutic drug monitoring.
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Chronic Interstitial Nephritis with IgG Tubular Basement Membrane 
Staining in a Allogeneic Stem Cell Transplant Patient: Renal Graft vs Host 
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Introduction: GVHD of the kidney is a rare complication post allogeneic SCT 
usually manifests clinically as a nephrotic syndrome. Renal GVHD can present as minimal 
change disease, membranous nephropathy, or FSGS. We are presenting an allogeneic 
SCT patient who developed tubulo-interstitial nephritis with IgG and C3 granular tubular 
basement membrane deposits with negative brush border autoantibodies. To the best of our 
knowledge, this is the first case report of renal GVHD associated with antibodies against an 
unknown tubular antigens in humans.
Case Description: 56-year-old woman with history of plasma cell leukemia who 
underwent an allogeneic SCT in 2016. Her transplant course was complicated by GVHD 
of the skin and GI tract, treated successfully with steroids and continued on prophylactic 
sirolimus. She has developed progressive renal dysfunction with creatinine increasing to 
2.5mg/dl from baseline of 1mg/dl. She was noted to have proteinuria of 1g she underwent 
a renal biopsy that indicated chronic tubulo-interstitial nephritis with granular tubular 
basement membrane deposits. No evidence of BK Polyomavirus infection or IgG4 subtype. 
Patient had normal complements and lupus serologies. Based on a similar case report in 
a kidney transplant recipient with interstitial infiltrate and anti-brush border antibody we 
tested our patient’s serum for ABBA; however, was negative. We have started patient on 
prednisone 1mg/kg to treat for the interstitial infiltrate with improved creatinine and have 
started her on Rituximab in hopes to help with the antibody mediated process.
Discussion: We postulate that autoantibodies to an unknown tubule antigen likely 
caused cellular injury in our patient with granular basement membrane deposits. 
Autoantibodies against proximal tubular brush border in mice with experimentally induced 
chronic GVHD has been reported, but no similar findings in humans. In recent studies, 
the presence of autoantibodies after allogeneic SCT in association with GVHD provides 
evidence for B-cell involvement. It has been shown in autoimmune disease that more than 
half of the developing B cells in the bone marrow express autoreactive B-cell receptors. 
This case presents yet another possible form of renal GVHD after allogeneic SCT.
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Introduction: In renal transplantation, elevated levels of anti-angiotensin II type 1 
receptor (AT1R) antibodies have been associated with antibody-mediated rejection (AMR) 
in the absence of HLA (human leukocyte antigen) donor specific antibodies (DSA). The 
majority of these patients present early after transplantation with elevated serum creatinine 
(SCr) in the setting of accelerated hypertension. Renal biopsy typically shows C4d negative 
vascular rejection. Treatment with an angiotensin receptor blocker (ARB) has been 
successful in children but is not well-documented in adults.
Case Description: We present a unique case of a 29-year-old male with end-stage 
renal disease due to Alport syndrome who underwent a living related renal transplant with 
nadir SCr 1.2mg/dl. He received thymoglobulin induction with tacrolimus, mycophenolate 
mofetil, and corticosteroids maintenance therapy with an uneventful post-transplant 
course. At one year follow-up, urine protein-to-creatinine ratio (UPC) increased to 0.8, 
and lisinopril was started. Six weeks later, UPC was 2.24. Renal biopsy showed moderate 
glomerulitis and peritubular capillaritis (Image A) with minimal C4d staining of the 
peritubular capillaries (Image B) consistent with an AMR. Pre and post-transplantation 
sera were negative for HLA DSAs, so non-HLA antibody testing was sent. Anti-AT1R 
antibodies were detected at 33 U/ml (strong positive). Patient was switched to losartan and 
then treated with intravenous methylprednisolone 500mg for three doses followed by four 
sessions of plasmapheresis. The response to treatment was excellent with a decrease in UPC 
to 1.2 and in anti-AT1R antibodies level to 8U/ml (<10 normal). SCr and blood pressure 
remained well-controlled throughout the treatment.
Discussion: AMR in renal transplantation due to non-HLA antibodies, like anti-AT1R 
antibodies, has gained interest in recent years. The diagnosis is often missed or delayed, 
leading to more aggressive therapy and a poor prognosis. Our patient had an unusual 
presentation with proteinuria, but prompt diagnosis and early initiation of therapy achieved 
a good outcome with relatively modest immunosuppression.
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A Case of Serous Lymphoma Post Renal Transplant
Michelle Clince,1 Hannah M. O’Keeffe,2 Conall M. O’Seaghdha.1 1Beaumont 
Hospital, Dublin, Ireland; 2Health Service Executive, Ireland, Galway, Ireland.
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is one of the most 
feared consequences of long term transplantation. We present a case occurring late in the 
post transplant period with an unusual distribution. The case highlights the utility of PET 
CT in facilitating diagnosis and guiding tissue diagnosis in suspected PTLD.
Case Description: Our case is a 62 year old man who presented with anorexia, weight 
loss, night sweats, fevers, and altered bowel habit. End stage renal disease was secondary to 
IgA nephropathy. He was a deceased donor transplant recipient from 2000 with early biopsy 
proven antibody mediated rejection. Maintenance immunosuppresion was Tacrolimus 
and Mycophenolate mofetil. Clinically he had ascites and lower limb oedema. CT-TAP 
showed dense ascites and small bowel thickening. Colonoscopy was normal. A large pleural 
effusion caused respiratory compromise and chest drain insertion was performed. Empiric 
cover for TB was added due to his clinical status and pending a tissue diagnosis. PET-
CT showed extensive FDG avid peritoneal disease (Figure 1) as well as in the pleura and 
pericardium. Ascitic fluid had abundant inflammatory cells but no malignant cells. Pleural 
aspirate revealed atypical lymphoid cells positive for CD20 consistent with high grade B 
cell lymphoma. Peritoneal biopsy revealed atypical cells staining positive for CD20, CD10 
and BC16. Immunosuppression was discontinued and he is being treated with R-CHOP 
with an excellent clinical response to date. Graft function remains stable
Discussion: Given the heterogeneity of PTLD presentations the clinician must 
maintain a high index of suspicion. This case demonstrates an unusual distribution of a post 
transplant lymphoma as well as highlighting the increasing utility of PET-CT in the work up 
of these patients. Earlier use of PET-CT in the work up of suspected PTLD may facilitate 
earlier instigation of treatment and improve prognosis.
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A Case of Lymphocele Associated Kidney Graft Impairment
Lucas A. Bastianelli, Valkercyo A. Feitosa, Igor Smolentzov, Luiz F. Souza, 
Andrés S. Bueno, Laura Onuchic, Flavio De paula. Universidade de São Paulo, 
São Paulo, Brazil.
Introduction: Lymphocele is well established as an early renal transplantation 
complication and may seriously impair graft function due to graft vessel compression. 
Venous compression may increase the pressure gradient and therefore cause kidney graft 
associated proteinuria.
Case Description: A 46 year-old male, on hemodialysis for the past 3 years due to 
hypertensive nephrosclerosis, was admitted for deceased donor kidney transplantation. 
We followed institutional protocols for surgery and immunossupression, with no apparent 
complications. At discharge, the patient serum creatinine was 1.53mg/dL and urine tests 
for proteinuria were negative. Four months after transplantation, the serum creatinine 
increased to 2.56 mg/dL and the protein/creatinine ratio rose to 4.3 (g/g), with no hematuria. 
Renal graft biopsy revealed interstitial fibrosis and mild focal tubular atrophy, BANFF 
grade I, and immunofluorescence for C4d was negative. Computerized tomography of the 
abdomen revealed two lymphocells, localized posterior to the graft (18.0 x 10.0 x 10.0 cm) 
and adjacent to the left iliac vessels (8.5 x 6.0 x 6.0 cm), leading to compression of the 
left external iliac vein close to the venous anastomosis of the renal graft. In this scenario, 
marsupialization of the lymphocele was performed due to worsening renal function and 
progressively ascendant protein/creatinine ratio (12.1 g/g). Two days after surgery, the 
patient evolved with reduction in proteinuria (protein/creatinine levels of 0.2g/g) and serum 
creatinine dropped to 1.98 mg/dL, suggesting early recovery.
Discussion: This is an atypical case of massive urinary protein loss secondary to 
lymphocele compression leading to high pressures in the renal vein. Graft rejection and 
glomerulopathy relapses are widely discussed as etiologies of proteinuria in transplant 
patients; however in this case we underscore the importance of including anatomical causes 
among the differential diagnosis.
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Acute Respiratory Distress in a Renal Transplant Recipient: Think 
Toxoplasmosis
Justin Lee Loy, Abhilash Koratala, Gajapathiraju Chamarthi, Kawther 
F. Alquadan. University of Flroida, Gainesville, FL.
Introduction: Toxoplasma gondii (T. gondii), an intracellular protozoan parasite is
an important cause of opportunistic infection in transplant recipients associated with high 
mortality. Herein, we present a case where physicians’ knowledge gaps and diagnostic 
difficulties resulted in unfavorable outcome.
Case Description: A 38-year-old man with ESRD due to congenital vesicoureteral 
reflux underwent deceased donor kidney transplant. Alemtuzumab was used for induction 
immunosuppression (IS), followed by maintenance IS consisting of mycophenolate mofetil, 
tacrolimus and prednisone. Inhaled pentamidine was used for post-transplant P. jirovecii 
prophylaxis instead of the standard therapy with trimethoprim-sulfamethoxazole (TMP-
SMX) because of hyperkalemia. At 1-month follow up visit, he appeared ill and was 
febrile to 102 F, hypotensive and tachycardic. He was admitted to the hospital for further 
evaluation and soon after that, he developed acute respiratory distress requiring intubation, 
later extracorporeal membrane oxygenation and also dialysis requiring AKI. He was started 
on broad-spectrum antibiotics/antifungals and antivirals. Blood and urine cultures were 
negative. Respiratory viral panel, CMV, EBV and HSV serologies were negative. Clinical 
status deteriorated rapidly and he passed away. Autopsy revealed multiple intracellular 
organisms consistent with T. gondii in both lungs and the heart.
Discussion: The clinical presentation of toxoplasmosis in renal transplant recipients 
is variable. Fever is the most frequent clinical sign (80%), followed by pneumonia and 
headaches. It can be transmitted from a seropositive donor to a seronegative recipient 
or occur as a de novo infection or as a reactivation of latent infection. Our patient was 
seronegative prior to the transplant and donor was positive. Interestingly, post-mortem 
testing revealed both serologic and histologic positivity for T. gondii. The data on prevention 
of toxoplasmosis is sparse and TMP-SMX at a dose of 1 single-strength tablet daily is 
considered sufficient for both Pneumocystis and Toxoplasma prevention. Pyrimethamine + 
TMP-SMX may be considered in high-risk recipients. Toxoplasmosis should be considered 
in the differential diagnosis of pneumonia, culture-negative sepsis, and encephalitis in renal 
transplant recipients, especially when the history suggests inadequate prophylaxis.
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A Rare Case of JC Virus Nephropathy in a Kidney Transplant Recipient
Yan Zhong, Guang-Qian Xiao, Yasir A. Qazi, Thin Thin Maw, 
Miroslaw Smogorzewski. Keck school of medicine-USC, Los Angeles, CA.
Introduction: Acute kidney injury after renal transplantation is usually attributed to 
acute cellular or antibody medicated rejections or viral nephropathy (BKV). However rarely 
we can be confronted with the unexpected conditions. We are reporting a rare case of biopsy 
proven JCV nephropathy in a kidney transplant recipient.
Case Description: A 57-yo female, ESRD due to ADPKD, had deceased donor renal 
transplant (DDRT) in 2011. She was on azathioprine, tacrolimus and prednisone as the 
maintenance therapy with serum creatinine level 1.8 to 2.0mg/dL. In 2017 SCr elevated to 
3mg/dL for 3 months without urinary symptoms. BKV PCR was negative in both serum and 
urine. Kidney biopsy show acute tubular injury, acute interstitial inflammation, and scattered 
prominent atypical tubular epithelial cells. SV40 stains was positive in many cells (figure 1). 
JCV DNA was detected by in situ hybridization in the allograft biopsy tissue. JCV DNA 
was also detected by PCR in both blood (81661copies/ml) and urine (>35000000 copies/
ml). Spinal fluid was negative for JCV. MRI of the brain was unremarkable. JCV blood 
level became undetectable 4 months after reduction in tacrolimus dosage and initiation of 
iv IG. Prednisone and azathioprine were continued. Transplant kidney function remained 
stable with SCr 2.8mg/dL.
Discussion: Up to 36% of renal transplant recipients were found to be positive for 
JCV in their urine. Reactivation of JCV post-transplant could be associated with PML in 
immunosuppressed patients, but rarely causes JCV nephropathy. Less than a dozen cases 
of JCV nephropathy were ever reported in renal transplant recipients after the first case 
in 2003. Reduction in immunosuppression remains the mainstay of treatment for JCV 
nephropathy. Use of iv IG was reported to be helpful as well. It is important to look for JCV 
nephropathy in DDRT recipients with unexplained AKI.
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Figure 1: kidney allograft biopsy. (a): acute interstitial inflammation (HE staining). (b): 
Simian virus 40 positive nuclear staining of tubular cells.
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Native Kidney BK Nephropathy in Lung Transplant Patient
Rungwasee Rattanavich,1 Joseph Gaut,2 Andrew F. Malone.1 1Division of 
Nephrology, Department of Medicine, Washington University School of 
Medicine, St.Louis, MO; 2Department of Pathology and Immunology, 
Washington University School of Medicine, St. Louis, MO.
Introduction: BK nephropathy (BKN) usually affects renal allografts and is rarely seen 
in non-renal solid organ transplant patients. We present the rare case of a lung transplant 
patient who developed BK nephropathy in the native kidney.
Case Description: 62 yo AAF with sarcoidosis received a bilateral lung transplant 
in 2007 complicated by bronchiolitis obliterans syndrome stage III and CKD stage IV 
secondary to calcineurin inhibitor toxicity. Her immunosuppression was sirolimus, 
mycophenolic acid, and prednisone. She presented with severe sepsis, Pseudomonas 
pneumonia, and acute kidney injury (AKI) Cr up to 4.3. Renal function did not improve 
despite improvement of pneumonia and sepsis. Native kidney biopsy showed tubulitis and 
viral nuclear inclusions and serum BK PCR was 8,000,000 copies/ml. Her renal function 
rapidly declined (Cr 6.8). She was treated for BKN with lower immunosuppression, IVIG 
and cidofovir. Her renal function improved without need for dialsysis and her serum BK 
PCR decreased to 849,000 copies/ml. Three weeks after discharge, she was re-admitted 
with progressive acute respiratory failure and severe oliguric AKI requiring hemodialysis. 
BK levels increased back to 1,700,000 copies/ml and sepsis work up was negative. She was 
later transitioned to comfort measures per family wishes.
Discussion: The poorer outcomes seen with BKN in non-renal solid organ transplants 
maybe due to the lack awareness of native BKN and its relative rarity in this population. 
This leads to late diagnosis, advanced irreversible disease and poorer response to treatment. 
A higher suspicion for BKN in non-solid organ transplant patients with AKI seems 
warranted. Peripheral blood testing for BK virus and kidney biopsy for early diagnosis may 
avoid irreversible injury and yield a more favorable outcome.
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Preserved Renal-Allograft Function and Successful Treatment of 
Metastatic Merkel Cell Cancer Post Nivolumab Therapy
Priyamvada Singh,1 Jon R. Von Visger,1 Jason Prosek,6 Thomas Olencki,2 
Deepali Pandey,3 Brad H. Rovin,4 Todd E. Pesavento.5 1The Ohio State University 
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Introduction: Checkpoint inhibitors like Programmed cell death 1 (PD-1) inhibitors 
are found to be efficacious even in difficult-to-treat cancers, has fewer side-effects and 
sustained therapeutic benefit. PD-1 is a cell surface receptor that has a vital role in down-
regulating the immune system and enhancing self-tolerance by suppressing T cell activity. 
The major shortcoming in Kidney transplant recipient is the severe rejection and immediate 
graft loss making it somewhat taboo to use these agents in this population.
Case Description: 71-year-old female, status post deceased donor Kidney transplant 
in 2004 for Autosomal Dominant Polycystic Kidney disease with coincident native 
nephrectomy received a 5/6 HLA-mismatched kidney, induction with ATG and steroid, 
and maintenance therapy of tacrolimus and myfortic. She was diagnosed with Merkel cell 
cancer in 01/2016 and underwent lateral neck dissection and radiation therapy (05/2016). 
Tacrolimus was discontinued, mycophenolate was reduced to half dose twice daily, and 
prednisone 5 mg daily was initiated. In April 2017, she was diagnosed with the metastatic 
disease to the liver and spine. Her prognosis was deemed marginal and she was initiated on 
Nivolumab and was maintained on 10 mg of Prednisone. She completed a total of 13 cycles 
of Nivolumab (240 mg based on a dose regimen of 3 mg/kg, every month) without any 
significant side-effects and significant improvement in the quality of life. Her renal function 
remained stable with the creatinine of 1.5 (egfr 35), absent donor-specific antibodies and no 
disease progression on subsequent imaging.
Discussion: To date, the literature reports five kidney transplant recipients treated 
with PD-1 inhibitors. To our knowledge, the case presented here is only the second case 
of a kidney transplant patient treated with a PD-1 inhibitor(s) who did not experience acute 
rejection. One similarity between our situation and previously reported case is the history 
of native nephrectomy. It is unclear if native Kidneys have a role to play in rejections and 
thus nephrectomy is giving an added benefit. Additionally, our patient was on a reduced 
frequency of Nivolumab (monthly compared to bi-monthly). If these drug regimens have any 
significant role to play in avoiding rejection, is again a topic for future research and debate.
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Stuck Between a Rock and a Hard Place - The Challenging Management 
of Metastatic Renal Cell Carcinoma in a Kidney Transplant Recipient 
Using Checkpoint Inhibitors
Manini Vishwanath,1 Sara Syeda,2 Basma O. Merhi.3 1Rhode Island Hospital/
Brown University, Providence, RI; 2Brown University, Cranston, RI; 
3Nephrology, East Greenwich, RI.
Introduction: The incidence of Renal Cell Carcinoma(RCC) in a renal transplant is 
100 times higher than the general population. Metastatic RCC is a dreaded complication and 
currently there is no one specific agent used in its management. Due to marked success of 
immunotherapy and checkpoint inhibitors (CPIs) specifically the program cell death ligand 
inhibitors (PD-1)in treatment of melanomas, these agents have been proposed for metastatic 
RCC also. Their effects on organ transplant recipients are unknown.
Case Description: 58 y/o Caucasian male with h/o End Stage Renal Disease on 
hemodialysis for 2 years s/p Deceased donor kidney transplant 18 years ago, maintained 
on tacrolimus, azathioprine and prednisone, with excellent allograft function with baseline 
creatinine of 1.5 presented with shortness of breath. Medical history included bilateral 
nephrectomies performed 4 years ago with both kidney biopsied and showing RCC. A 
CT Chest this admission revealed multiple nodules to the lungs and a left sided pleural 
effusion. Surprisingly, a nodule biopsy was consistent with metastatic RCC. Oncologists 
initiated pazopinib(a tyrosine kinase inhibitor) but disease progressed on the drug. Hence, 
the decision to switch to Nivolumab(a PD-1L inhibitor) was made while decreasing dose 
of tacrolimus. Within 2 weeks of drug initiation, patient became oliguric and developed 
an acute kidney injury with a creatinine of 4.5. An allograft biopsy showed banff grade 
2A/2B acute cellular rejection and dialysis had to be resumed. Unfotunately, patient could 
not tolerate dialysis due to hypotension, had recurrent admissions for pleural effusions and 
finally opted for inpatient hospice.
Discussion: Our case is unique in several ways. It is an exceedingly rare one where 
metastatic RCC was found even years after bilateral nephrectomy. It is also highlights 
the association of CPIs with acute cellular graft rejection. PD-1 ligand inhibitors increase 
effector T-Cell activity, promote tumor regression, but may also be responsible for the cell 
mediated rejection of the allograft, using the same pathway. Hence, it becomes necessary 
to weigh the risks of graft rejection with mortality benefit from immunotherapy in organ 
transplant recipients because of significant morbidity that follows.
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Nivolumab-Induced Kidney Transplant Allograft Rejection Requiring 
Nephrectomy
Vishwa C. Sheth, Kuang-Yu Jen, Brian Y. Young. University of California, 
Davis, Sacramento, CA.
Introduction: Many types of cancers have developed mechanisms to activate immune 
checkpoints in order to evade the immune system. Immune checkpoint inhibitors allow a 
patient’s immune system to overcome such a blockade in order to target and eradicate tumor 
cells. Although checkpoint inhibition holds a promising future in cancer treatment, side 
effects can include severe autoimmune-mediated reactions, including against transplanted 
organs. We report a case of a patient treated with nivolumab who developed acute on 
chronic kidney allograft rejection necessitating nephrectomy.
Case Description: A 47-year-old female who had chronic kidney disease stage V 
secondary to renal dysplasia received a living donor kidney transplant and was maintained 
on prednisone, cyclosporine (CSA), and mycophenolate mofetil (MMF). Her creatinine 
post-transplant ranged from 1.8-2.5 mg/dl. She was diagnosed with anal squamous cell 
carcinoma 15 years later and underwent chemoradiation with simultaneous reduction of CSA 
and discontinuation of MMF. Her kidney function declined over this time. Unfortunately, 
her cancer recurred 2 years later and was deemed unresectable, prompting her oncologist 
to start nivolumab. In preparation for immunotherapy, the patient’s prednisone and CSA 
were stopped. By then, her creatinine was 6.1 mg/dl. Shortly after she began maintenance 
hemodialysis for uremic symptoms, though she continued to make about a liter of urine 
per day. Two days after receiving her first nivolumab dose, she abruptly became anuric 
other than small streaks of gross hematuria. Five days post nivolumab treatment she was 
admitted to the hospital with fever and unrelenting allograft tenderness and swelling. Renal 
ultrasound showed an enlarged, echogenic allograft of 14 cm with abnormal perfusion, 
consistent with severe acute rejection. She initially underwent IR-guided embolization of 
the transplant but ultimately required surgical nephrectomy to control her inflammation.
Discussion: Literature is scarce on protocols for administration of immune 
checkpoint inhibitors to transplant recipients. We report an interesting case of nivolumab-
induced rejection that acutely blossomed two days post-administration. Future studies 
should evaluate whether transplant nephrectomy should be considered prior to immune 
checkpoint inhibition, particularly in patients with planned minimization or withdrawal of 
immunosuppression.
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AKI from Aspergillus Triggering Antiphospholipid Syndrome
Adrian A. Ochoa,1 Steven Chou,1,2 Nagaraju Sarabu,1 Aparna Padiyar,1 
Anne M. Huml.1 1Nephrology and Hypertension, University Hospitals Cleveland 
Medical Center, Cleveland, OH; 2MetroHealth Medical Center, Cleveland, OH.
Introduction: Thrombotic microangiopathy (TMA) is commonly encountered 
following kidney transplant, however anti-phospholipid syndrome (APS) causing TMA is 
rare. We present a case of transplant AKI from APS triggered by Aspergillus.
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Case Description: 52 yo M with lupus nephritis status post kidney transplant on 
tacrolimus and MMF was admitted for 3 days of progressive cough and hemoptysis. 
Medical history significant for APS with stroke and DVT, paroxysmal a fib on chronic 
warfarin, HTN and thrombocytopenia. Initial EKG had a fib with RVR and CXR with 
multifocal pneumonia. Labs: BUN and cr of 32 and 1.9 mg/dL, plt 26 (baseline 80), hgb 
12.7 g/dL and INR 1.9 with a PTT of 73. Urinalysis had 2+ protein and hyaline casts. Given 
IV levofloxacin, oral β-blocker, heparin drip, and platelet transfusions. On day 2, chest CT 
and bronchoscopy done. No evidence of DAH. CT revealed multifocal ground glass and 
peribronchial airspace opacities with bronchial thickening and bronchiectasis bilaterally; 
concerning for atypical fungal infection. Fibrinogen and D-dimer elevated, +ANA (1:160 
titer) with normal C3, C4 and ds-DNA. Anti-microbials switched to meropenem and 
voriconazole. By day 3, renal function deteriorated (cr trend 1.9>4.4>9.8 mg/dL). Due to 
acute thrombocytopenia, a high concern for TMA even though initial labs not suggestive 
(LDH 144, hagptoglobin 189). Tacrolimus was held. DRVVT screen, anticardiolipin 
antibodies, beta 2 glycoprotein resulted very high titers. On day 5, transplant biopsy done 
and IV methylprednisolone given. Biopsy showed TMA and APS. The biopsy findings 
mimicked a severe antibody mediated rejection (DSA neg). He received 5- sessions of 
plasmapharesis (PP) and HD. Bronchoscopy cultures were negative and voriconzale 
stopped. On day 7, his galactomannan testing from BAL was positive. Given the high 
specificity of this test, CT findings, and hemoptysis, diagnosed with invasive pulmonary 
aspergillosis. Voriconazole restarted. 1g/kg of IVIG and 5 more PP was used for refractory 
thrombocytopenia. Over next 3 weeks, Cr improved, HD stopped, and he was discharged 
to rehab.
Discussion: This case of AKI induced by TMA and APS triggered by invasive 
aspergillosis had none of classical features of TMA. A low threshold for kidney biopsy and 
high suspicion of fungal infection were helpful to reach the diagnosis. The management of 
APS post-kidney transplant lacks evidence and trials are needed.
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Wondering Why It Wandered: Pacemaker Lead Perforation in a Renal 
Transplant Patient on Sirolimus
Gonzalo Matzumura,1 Angelina Edwards.2 1University of Texas Health Science 
Center at Houston, Houston, TX; 2University of Texas at Houston Health 
Science Center, Houston, TX.
Introduction: Pacemaker lead perforation of the ventricle is a rare but potentially fatal 
event, we present the first reported case of pacemaker lead perforation in a renal transplant 
patient on sirolimus.
Case Description: A 63 year-old man, end stage renal disease from diabetes, status-
post living-related renal transplant 17 years ago, on sirolimus and prednisone, presented to 
the hospital with dyspnea and flank pain. Medical history included bi-ventricular permanent 
pacemaker (PPM) 3 months prior. He was hemodynamically unstable, in respiratory 
distress, requiring intubation and vasopressors. Labs showed acute kidney injury, creatinine 
of 6.0 mg/dL (baseline 1.3) and hyperkalemia, requiring dialysis. Chest X ray revealed 
left pleural effusion and displaced right ventricular (RV) pacer lead. Thoracentesis showed 
hemorrhagic effusion and echocardiogram revealed perforated, thin-walled RV apex, with 
pericardial effusion. Hemopericardium was evacuated in the OR, RV perforation repaired, 
and PPM generator/leads were removed. Patient had a favorable post-operative course 
and underwent reinsertion of pacemaker with no complications. Renal allograft function 
returned to normal and immunosuppression was changed from sirolimus to tacrolimus. 
Outpatient follow-up confirmed stable PPM location and function.
Discussion: Ventricular perforation following PPM placement is rare and perforation 
greater than 1 month after implantation is infrequent. Predictors of perforation include 
steroid use, temporary pacemaker, active fixation of PPM lead and antiplatelet therapy. 
Proposed mechanisms include characteristics of the ventricular wall (thinner walls have 
increased risk of perforation) and intrinsic characteristics of PPM leads. No cases of RV 
perforation on mammalian target of rapamycin (mTOR) inhibitor therapy have been 
documented. It is well described that mTOR inhibitors impair fibrosis and wound healing. 
Furthermore, murine models show less fibrosis, hypertrophy and lower levels of TGF-β and 
collagen type I and III in rat myocardium on mTORs compared to controls. In this case, 
sirolimus may have favored conditions in the myocardium (less fibrosis and thinner wall) 
that allowed RV perforation to occur. This case highlights the importance of considering 
this infrequent complication in patients on mTOR inhibitor therapy to prevent potentially 
catastrophic consequences.
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Unusual Case of Abdominal Pain in Kidney Transplant Patient
Saed Shawar,1 Osarhiemen A. Omwanghe,2 Akosua A. Korboe,2 Juan 
Pablo Arroyo,1 Beatrice P. Concepcion.2 1vanderbilt medical center, ANTIOCH, 
TN; 2Vanderbilt University Medical Center, Nashville, TN.
Introduction: Gastrointestinal histoplasmosis is likely manifestations of disseminated 
disease but only rarely comes to clinical attention due to the lack of specific signs and 
symptoms. We report the unusual case of abdominal pain found to be histoplasmosis in 
duodenum in kidney Transplant patient
Case Description: 65 year female with history of ESRD Secondary to Alport’s 
Syndrome s/p kidney transplant X2, last DDKT 9/2013. Presented to ED with generalized 
weakness, and abdominal pain, no change in bowel habit, no dysphagia or odynophagia.
physical exam notable for abdominal tenderness. Labs notable for mild leukopenia wbc 
3.2. Abdominal CT imaging demonstrated ‘misty’ mesenteric LAD, as well as some mild 
duodenal thickening. GI was consulted regarding CT findings and performed endoscopy 
noting some gastric erythema and nodular/polypoid mucosa of the duodenum.biopsy was 
done and Path returned notable for histoplasmosis at the duodenal biopsy site. no evidence 
of pulmonary involvement based on CT imaging and CXR. Serum histoplasmosis ag 
negative, urine histoplasmosis ag positive; She was started on PO liquid Itraconazole and 
tolerated it. Her abdominal pain has resolved.
Discussion: Disseminated histoplasmosis may involve the gastrointestinal tract 
in 70-90% of cases, nearly 90% of lesions involve the lower GI tract, most commonly 
the ileocecal region or colon. Given the risk of dissemination of histoplasmosis and the 
potential to lead to considerable mortality and morbidity if not identified in early, suggesting 
that clinicians should consider fungal infections as part of their assessment for transplant 
patients, presenting with non-specific symptoms, including abdominal pain to improve 
patient outcomes and prevent disease recurrence.
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Successful Treatment of Refractory Severe Acute Humoral Rejection 
(AMR) in a Renal Transplant with Double Filtration Plasmapheresis and 
Immunoadsorbtion
Martin Russwurm,1 Joachim Hoyer.2 1Marburg University, Marburg, Germany; 
2Marburg Philipps-University, Marburg, Germany.
Introduction: AMR is a major threat to renal allograft survival in the early transplant 
period as it accounts for up to 40% of graft losses within the first year. Although various 
immunomodulatory treatments are implemented to treat AMR, there is no golden standard. 
In every clinical situation regarding mismatch, serological follow-up, severity of AMR and 
long- and short-term adverse events of immunosuppressive treatment, careful consideration 
which therapy to choose is imperative. Here we present a case of severe, sustained early 
AMR, treated w/ the various immunomodulatory agents and techniques, eventually AMR 
being successfully resolved by an extensive plasmapheresis approach.
Case Description: Immunosuppressive treatment has been initiated w/ Cyclosporin, 
Methylprednisone and Mycophenolate. While the patient (pt.) developed no graft function 
postoperatively, she underwent the first renal transplant biopsy (Bx) at d6 which revealed 
severe AMR. Despite sequentially initiated treatment w/ a course of anti-thymocyte 
immunoglobulin, plasma exchange, Rituximab, Immunoadsorption (IA) and intravenous 
immunoglobulin, the pt. remained anuric still. We then decided to serial-connect the double 
filtration plasmapheresis (DFPP)- w/ an IA system, treating the pt. every other day. After 
the 2nd treatment the transplant developed excretory function, accompanied by significant 
decline in SCr. Follow-up Bx at d50 still showed AMR but w/ significantly lesser activity. 
The pt. was dismissed at d60 w/ improved and stable renal function. We performed 
DFPP+IA thrice weekly for 2 months and weaned the pt. over one year. The last SCr was 
1,52 mg/dl (2,5y).
Discussion: The capability of DFPP+IA in clearing main effectors of AMR was the 
rational to adopt this approach in an experimental treatment intent. Although we cannot 
rule out the impact of long-term effects of the preliminary treatments, the chronological 
relationship of DFPP+IA initiation and renal recovery appears convincing. To our 
knowledge, this is the first report of DFPP+IA for treatment of severe AMR. Thus, we 
consider the implications of this case to be twofold: 1st, treatment of severe AMR could be 
successful in long-term graft dysfunction. 2nd, DFPP+IA should be considered a rescue-
treatment option for selected high-risk pts. w/ proven severe AMR in which other treatments 
failed.
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Myeloma Cast Nephropathy in the Kidney Transplant: A Rare Reversible 
Cause of Kidney Transplant Dysfunction
Joana M. Dias. Kidney Transplant Team - Nephrology and Kidney Transplant 
Department - Hospital de Santa Maria Centro Hospitalar Lisboa Norte, Lisboa, 
Portugal.
Introduction: Multiple Myeloma (MM) is commonly associated with kidney injury 
through multiple mechanisms, most importantly cast nephropathy. Although kidney 
transplant recipients (KTR) have a higher incidence of malignancy, de novo MM is 
infrequent. Likewise, cast nephropathy is relatively frequent in the population with MM and 
kidney dysfunction (KD), but exceedingly rare as a cause of KD in the transplanted kidney.
Case Description: The authors present a case of a 62 year old men submitted to a 
deceased donor kidney transplant 12 years ago for end stage diabetic nephropathy, 
presenting a stable baseline serum creatinine (sCr) of 1.2mg/dL therafter. He presented 
to the clinic with mild progressive KD, with sCr increasing to 2.2mg/dL over a 5-month 
period. His laboratory workup was unremarkable except for mild anemia and borderline 
hypercalcemia. At this time his renal biopsy discarded rejection and was otherwise 
inconclusive. No other causes of KD were found. He maintained rapidly progressive 
RD over the next 4 months, to a maximum sCr of 8.3mg/dL, leading to initiation of 
hemodialysis. At this point, investigation revealed a IgA kappa MM with 48% bone marrow 
plasmacytosis. A second biopsy confirmed myeloma cast nephropathy in the transplanted 
kidney. He started treatment with bortezomib and cyclophosphamide and switched to high 
cut-off hemodialysis until disappearance of free light chains. He presented a surprisingly 
favorable evolution with progressive and sustained renal function recovery (RFR), being 
dialysis-free after 5 weeks of treatment and 21 dialysis sessions. Presently, 2 months after 
treatment initiation, he maintains a lowering sCr of 1.9mg/dL.
Discussion: The better survival of KTR results in older patients with associated longer 
immunosuppression times, which will possibly lead to previously infrequent types of 
malignant disease in this population. Our patient case is unique in reflecting both a rare 
case of MM cast nephropathy in KTR and the possibility of a good outcome regardless 
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of advanced disease/known negative predictive factors of RFR in the general population. 
Novel myeloma treatments should be promptly considered in KTR, as should the use of 
high cut-off membranes in dialysis-dependent patients. A high index of suspicion and early 
institution of curative treatment may potentially revert kidney injury and lead to complete 
RFR in the transplanted kidney.
PUB664 
Publication-Only 
A Case of RPGN Due to Alport Post-Transplant Anti-GBM Nephritis
Sharon Reuben,1 Ian Kaiser,1 Thomas E. Rogers.2 1Nephrology, Emory 
University Hospital, Atlanta, GA; 2Emory University, Atlanta, GA.
Introduction: Studies show recurrent Anti-GBM disease in up to 50% of renal 
allografts after transplantation. De-novo occurrence of anti-GBM in transplanted Alport 
patients remains a rare phenomenon. We present a case of RPGN due to de novo anti-GBM 
disease post-transplantation in a patient with Alport syndrome.
Case Description: A 20-year-old African American male was diagnosed with Alport 
syndrome by renal biopsy at age 5, progressed to ESRD by age 13, and received a deceased 
donor renal transplant at age 14. Post-transplant, he developed 2A ACR after 1 year, AMR 
after 4 years, and acute and chronic AMR after 6 years. These biopsies had no evidence of 
glomerular disease. He presented to the hospital with AKI, hematuria, and hypervolemia 
7 years post-transplant. Creatinine was 4.6mg/dl from baseline of 2.5mg/dl with 4.7g/g 
proteinuria on spot check. Renal allograft ultrasound was unremarkable. His clinical course 
rapidly deteriorated, requiring initiation of dialysis for electrolyte and volume management. 
Allograft biopsy immunofluorescence demonstrated 3+ IgG, kappa, and lambda linear 
staining with granular IgM staining in the mesangium and capillary walls. Serology was 
positive for anti-GBM antibodies. Diagnosis of anti-GBM disease was made. He received 
solumedrol, plasmapheresis, and was discharged on dialysis.
Discussion: COL4A5 gene mutations cause a defect in the alpha 3(IV)NC1 domain of 
the basement membrane component of type IV collagen. Anti-GBM alloantibodies bind only 
to this alpha 3(IV)NC1 domain. Anti-GBM antigen consists of the noncollagenous domain 
(NC1) of the α-3 chain of type IV collagen, indicating a connection in the pathogenesis 
between anti-GBM nephritis and Alport syndrome. This has implication towards allograft 
loss in transplanted patients with this underlying defect. Additionally, Anti-GBM pathology 
is consistent with linear IgG deposition along the GBM, which our patient demonstrated in 
addition to granular IgM staining on immunofluorescence. This may indicate an additional 
concommitant underlying process contributing to the de-novo appearance of anti-GBM 
disease in our Alport patient. Renal outcomes are reportedly poor in patients with anti-GBM 
in a renal allograft. Plasma-exchange and amplified immune suppression has been initiated 
to mitigate disease severity temporarily and improve pathologic findings, but evidence of 
anti-GBM has shown to inevitably result in graft loss.
PUB665 
Publication-Only 
Out of Window: Late Disseminated Nocardiosis in Renal Transplant
Judith Gaite, Luis Eduardo del Rosario Gaite, Abel Gomez, Melina F. Cazzaniga. 
Clínica de Nefrologia Urología y Enfermedades Cardiovasculares, Santa Fe, 
Argentina.
Introduction: Opportunistic infections in solid organ transplantation cause high 
morbidity and mortality in our patients. When we talk about Nocardiosis we refer to an 
infectious, rare, localized or systemic affectation, produced by Nocardia spp, a genus of 
ubiquitous environmental saprophytes actinomyces. This group of Gram-positive bacteria, 
which in the microscope present an appearance of branched filamentous cells, are found 
in soil, There are more than 50 species generating infectious tables, the most important 
taxonomic groups being the complex N. asteroids complex producing mainly respiratory 
and disseminated infections, N. brasiliensis responsible for disease located in skin and soft 
parts. N. Nova and N. farcinica can produced Nocardiosis in patients transplanted from 
solid organ, with an approximate frequency that varies between 0.7 to 3.5%. The incidence 
of thes desease is high during firsts 6 moths post trasplant.
Case Description: Given this premise, we review our series of patients with kidney 
transplant from 2000 to 2007 with disseminated Norcardiosis; finding a total of 8 cases. All 
of them presened compromise of two or more organs; being the most frequent skin, lung 
and Central Nervous System. In all cases fever was dominant. The diagnosis was made by 
Staining Kynyoun (+). As a therapeutic scheme, doble and triple antibiotic therapy was 
started, including Ceftriaxone, Trimetroprim Sulfamethoxazole and Minocycline. All of 
the patients survival. The clinical resolution was equally frequent. The average time of the 
beging of the symphtoms in our population was 64 months after trasnsplant.
Discussion: Our conclution is that Nocardia may present in late period after kindey 
transplantation, and the early diagnosis and treatement contributed to a low mortality of 
this patology.
PUB666 
Publication-Only 
How Low Can You Go? A Case Report of Disseminated Cryptococcus in a 
Kidney Transplant Recipient
Goni Katz Greenberg, Pooja Singh, Anju Yadav. Thomas Jefferson University 
and Hospital, Philadelphia, PA.
Introduction: In patients following solid organ transplantation, wider differential of 
infectious etiology is warranted as the presentation can be nonspecific.
Case Description: We present a 68 years old Caucasian male, with past medical 
history of hypertension and end stage renal disease due to polycystic kidney disease, status 
post deceased donor kidney transplant (DDKT) in Sept 2016, admitted following two weeks 
of malaise, fatigue and recurrent falls, with one fall leading to a wound on his right shin. 
His post-transplant period was also complicated by BK nephropathy in early post-transplant 
period, which was managed by reduction of his immunosuppression. He was maintained 
on tacrolimus and prednisone. On physical examination the patient was alert, with a mild 
cognitive deficit. An open wound of about 6 cm was seen on the anterior aspect of his 
right shin. The patient underwent irrigation and debridement of the wound. Patient was 
started on antibiotics for community acquired pneumonia for right side infiltration seen on 
chest X-ray. Wound pathology came back positive for Cryptococcus. Cerebrospinal fluid 
analysis which was done at this time, was consistent with Cryptococcus meningitis, and 
chest CT showed also showed right lower lobe cavitatary lesions and small calcification. 
Empirical treatment was initiated with IV liposomal amphotericin B and 5 flucytosine for 
disseminated Cryptococcus, later switched to IV fluconazole following results of cultures. 
Additionally, patient’s remaining immunosuppression was further decreased, and is 
maintained on tacrolimus monotherapy at lower trough goal levels.
Discussion: Cryptococcosus neoformans is the third most common invasive fungal 
infection in organ transplant recipients after candidiasis and aspergillosis. Reports indicate 
that Cryptococcus usually presents as a symptomatic disease and despite therapy the 
mortality remains high. A common risk factor for Cryptococcal infection is the lifelong 
immunosuppression. We believe our case is unique as our patient’s immunosuppression was 
reduced about 18 months prior to diagnosis of disseminated Cryptococcus following renal 
biopsy proven BK nephropathy. Furthermore, our patient’s atypical presentation caused 
delay in the diagnosis.
PUB667 
Publication-Only 
An Unusual Cause of Life-Threatening Bleeding in a Patient with Bladder 
Drained Kidney-Pancreas Transplant
Bhavnish Bucktowarsing, Priyamvada Singh, Uday S. Nori. The Ohio State 
University Wexner Medical Center, Columbus, OH.
Introduction: The optimal method of exocrine pancreatic transplant drainage has been 
highly debated. Enteric drainage was preferred from 1960s-1990s and regained popularity 
in the 2000s being more physiological. There was a transient shift during the 1990’s when 
bladder drainage became popular as it allowed monitoring of graft rejection by detecting 
hypoamylasuria. However, pancreatic secretions can be inflammatory to the bladder 
wall and the duodenal stump anastomosed to the bladder. This can lead to ulceration or 
anastomotic dehiscence. Inflammatory erosion of artery leading to exsanguination is one 
of the most dreaded complications of bladder drainage. Since this technique is becoming 
rare, the experience to manage these catastrophic presentations might be meager. We report 
a case of successful management of arterial erosion in a bladder drained kidney-pancreas 
transplant.
Case Description: A 45-year-old female, status post combined bladder drained Kidney-
Pancreas transplant in 2006 with repeat living unrelated renal transplant in 2012 presented 
with gross hematuria and acute blood loss anemia (Hemoglobulin 5.3 from baseline of 
10.1). On presentation, she was hemodynamically stable but deteriorated into hemorrhagic 
shock requiring massive transfusion (5 units PRBC, 1 FFP, 1 Platelet) and transfer to ICU. 
Emergent exploratory laparotomy was performed showing grossly distended bladder 
containing one liter of blood. There was a 4mm ulcer on the duodenum eroding into a 
branch of the renal artery with active pulsatile bleed. Repair and transplant pancreatectomy 
was performed with resolution of hemorrhage. Post-procedure she was hemodynamically 
stable and was discharged on insulin.
Discussion: Inflammatory erosion into major arteries following KP transplant appears 
to be related to graft pancreatitis or leakage of pancreatic secretions in the region. This 
can result in pseudoaneurysms, fistulae formation (arterio-enteric or arterio-vesicular) and 
erosions. Fortunately, this is a rare complication but need to be considered in any patient 
with gross hematuria or blood clots. A high index of suspicion needs to be maintained by 
clinicians since it is treatable, at the expense of the pancreas allograft. Although our patient 
had pancreas anastomosed to the urinary bladder wall, this complication has been reported 
even in enteric-drained pancreas transplants.
PUB668 
Publication-Only 
A Rare Case of Pneumonia in a Combined Kidney and Pancreas 
Transplant Recipient
Massini Merzkani, Momina M. Ahmed, Aleksandra Kukla. Mayo Clinic, 
Rochester, MN.
Introduction: Rhodococcus equi is an unusual cause of infection in humans. Patients 
on immunosuppressive medications that affect the cell-mediated immunity are susceptible 
for acquiring this infection. We present an unusual case of pneumonia in a combined kidney 
and pancreas transplant recipient.
Case Description: 72 year old male with a history of diabetes mellitus type 1 
complicated by end stage renal disease. Patient received a living donor kidney transplant 
in 2002, followed by pancreas after kidney transplant six months later with Thymoglobulin 
(ATG) induction. He was maintained on Cellcept, Tacrolimus and prednisone. Post 
transplant course was complicated by two acute cellular rejections of the pancreas in 2012 
and 2015 treated with ATG. He present to outside hospital with productive cough, fever 
and diaphoresis of 3 weeks duration. He traveled to Arizona 2 months prior. He denied 
contact with animals or desert activities. Three weeks prior symptoms his neighbor started 
to use horse manure for farming. Chest CT showed a 5 cm consolidation in the left upper 
lobe. Bacterial, fungal and mycobacterial sputum cultures were negative. Biopsy done by 
bronchoscopy showed noncaseating granulomatous inflammation. Mycobacterial culture 
of the biopsy showed Rhodococcus equi infection and was started on azithromycin and 
rifampin. He came to our institution after 4 weeks without improvement. Vital signs and 
oxygen saturation were unremarkable. Lungs were clear to auscultation. Serum Cr was 
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stable at 0.7 mg/dL, lipase and amylase were elevated (157 U/L, 105 U/L). Chest CT had 
an increase in size of the consolidation 10.7cmx 9.1cm. He was started IV vancomycin, 
meropenem and PO azithromycin. The Tacrolimus level was undetectable due to use of 
rifampin. Tacrolimus was adjusted to a through level 7-9 and pancreatic enzymes improved. 
He completed 5 months of IV antibiotics with improvement of the infection.
Discussion: Rhodococcus equi is a gram-positive coccobacillus can cause pulmonary 
and extrapulmonary infection. Inhalation of soil contaminated herbivore manure is the 
most common route infection. Combination of 2–3 antibiotics is recommended for 
immunocompromised patient. Antibiotics interact with transplant medications; therefore 
levels need to be carefully monitored to avoid rejection. This case reminds us the importance 
educate our transplant patients the risk of exposure to manure
PUB669 
Publication-Only 
Ganciclovir-Resistant Cytomegalovirus Treated with Foscarnet in a 
Pediatric Renal Transplant Recipient
Nadia T. Mclean,1 Lisa Robinson,2 Chia Wei Teoh,2 Yvonne C. Yau,4 Angela 
Williams,3 Diane Hebert.2 1hospital for sick children, Toronto, ON, Canada; 
2The Hospital for Sick Children, Toronto, ON, Canada; 3Hospital For Sick 
Children, Toronto, ON, Canada; 4Hospital for Sick Children, Toronto, ON, 
Canada.
Introduction: Human Cytomegalovirus HCMV poses significant morbidity in CMV-
negative recipients (R) who receive a kidney transplant from a CMV-positive donor 
(D), (mismatch D+/R-). The usual treatment for CMV infection/disease is ganciclovir/
valganciclovir. With molecular testing of resistance markers, we have been able to identify 
strains of HCMV resistant to ganciclovir and tailor treatment to prevent morbidity. In this 
report, we describe a case of a patient with CMV infection with a ganciclovir-resistant strain 
of CMV treated with foscarnet.
Case Description: We describe the case of a 6-year-old-girl with ESRD secondary to 
congenital nephrotic syndrome post deceased donor kidney transplant at age 3 years. Her 
serostatus at the time of transplant was CMV D-/R-, and she was maintained on prednisone, 
tacrolimus and Mycophenolate mofetil. CMV infection was first diagnosed 35 months 
post-transplant when quantitative CMV PCR was at detected 3.7 x 10^ 4 genome copies 
per ml. Treatment with ganciclovir 5 mg/kg/dose bid, titrated to 10mg/kg/dose bid failed 
with increasing CMV PCR load to 8.2 x 10^4 genome copies per ml. Initial resistance 
testing at 3 months was negative. Cytomegalovirus Immune Globulin infusions (twice/
week) was commenced and continued for 2 months with no improvement in viral load. 
Repeat resistance testing showed CMV UL97 mutation (L595S) and no UL54 mutation 
confirming ganciclovir resistance and possible foscarnet susceptibility. Treatment was thus 
changed to foscarnet at 90mg/kg daily induction dose. After 1 month of foscarnet, CMV 
was undetectable but reappeared after a reduction in the dose of foscarnet to 60mg/kg daily. 
Foscarnet dose was re-increased to 90mg/kg daily and CMV was undetectable after 3 weeks 
of at this dose. She completed a further 2 months of treatment at this dose. The most notable 
side effect of foscarnet was a transient rise in her serum creatinine that improved with pre- 
and post-medication hydration with 0.9%NaCl.
Discussion: The effects of CMV disease can lead to significant allograft-related and 
systemic effects to the transplant recipient. We highlight the utility of resistance testing 
to detect de-novo ganciclovir resistance in newly acquired drug-resistant HCMV in the 
seronegative renal transplant patient, and the use of foscarnet in the successful eradication 
of CMV infection.
PUB670 
Publication-Only 
Eculizumab as Salvage Therapy in a Patient with APLS Undergoing Renal 
Transplantation
Mohit Gupta,1 Michelle L. Lubetzky,2 Jun B. Lee,4 Choli Hartono,4 
Darshana Dadhania.3 1New York Presbyterian - Weill Cornell, New York, NY; 
2Division of Nephrology and Hypertension, New York, NY; 3Weill Cornell 
Medical College, New York, NY; 4Rogostin Institute, New York, NY.
Introduction: APLS is associated with an increased risk of kidney allograft loss. We 
describe a patient with high titer APLS who developed oliguric renal failure post living 
donor transplant and was treated with Eculizumab.
Case Description: A 63 y/o sensitized F with triple positive antibody APLS 
underwent a living donor transplant with no donor specific antibodies (DSA). She received 
Hydroxychloroquine, Mycophenolate Mofetil and Rituximab as immunomodulatory 
therapy pre-transplant and steroid /ATG induction with anticoagulation with unfractionated 
heparin. On POD 6, she developed oliguric AKI necessitating hemodialysis. Labs 
were notable for a rise in LDH, decrease in platelets, and low haptoglobin (Figure 1). 
Thrombocytopenia precluded the possibility of biopsy. She received IvIg 200 mg/kg, 2 
sessions of plasmapheresis followed by Eculizumab. Approximately 1 month after starting 
Eculizumab, she recovered her renal function and continues to have excellent graft function 
(Table 1, Figure 1).
Discussion: Although patients with APLS are at increased risk for acute kidney 
injury and allograft loss, anticoagulation remains the mainstay of management. The role 
of preemptive immunosuppression remains unclear. In our patient, despite pre-transplant 
immunosuppressive therapy, she developed an acute hemolytic syndrome with AKI that 
resolved with a combination of plasmapheresis and Eculizimab therapy. Our data suggests 
that the use of Eculizumab modulated the development of APLS associated TMA despite 
significantly high antibody titers.
PUB671 
Publication-Only 
Recurrent FSGS? Maybe the Problem Is in the Plumbing
Massini Merzkani, Matthew R. D’Costa, Momina M. Ahmed, Mary E. Fidler, 
Hatem Amer. Mayo Clinic, Rochester, MN, Rochester, MN.
Introduction: Primary Focal Segmental Glomerulosclerosis (FSGS) in adults can 
recur in up to 40% of first transplants and >90% with a repeat transplant. Here we present 
a patient who had a third kidney transplant with worsening proteinuria that was not due to 
recurrence.
Case Description: A 40-year-old male with ESRD disease received his third living 
donor transplant from his father. His two prior renal allografts had developed recurrent 
FSGS. The first lasted for 12 years, and the second for 8 years. During his second transplant 
he developed an iliofemoral thrombosis in the setting of heavy proteinuria. During his 
evaluation for the third transplant, he was noted to have an occluded inferior vena cava but 
with extensive collaterals and underwent the third renal transplant by removing the second 
renal allograft and attaching the new kidney to site of the second allograft. He underwent 
conditioning with pre-transplant plasma exchange and received two doses of Rituximab. 
His post-transplant course was characterized slow graft function and fluctuating proteinuria, 
punctuated by repeated episodes of acute kidney injury (See fig 1). Several biopsies 
performed showed acute tubular injury with only mild focal foot process effacement. 
Ultrasound revealed no hydronephrosis and renal vein was patent. He was transitioned to 
Belatacept with no change in his course. Noting the thrombosed IVC and dependence on 
collaterals we proceeded to venography and pressure measurements. The IVC was canalized 
and stented with an improvement in venous pressures of the renal allograft vein. Subsequent 
to this there was a marked improvement in renal function with resolution of proteinuria.
Discussion: This is a case shows that although recurrent FSGS the most likely cause for 
the increasing proteinuria, it was important to rule out other pathologies. An important sign 
in this case was the focal foot process effacement arguing against as systemic permeability 
factor affecting all the podocytes diffusely.
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Deceased Donor Kidney Transplantation in Atypical Hemolytic Uremic 
Syndrome Without Preemptive Eculizumab Use
Àlex Favà,1 Paula E. Mejia,4 Rafael Alvarez,5 Nuria Montero,3 Ana Coloma,2 
Anna Manonelles,3 Edoardo Melilli,6 Oriol Bestard,5 Josep M. Cruzado.3 
1Hospital de Bellvitge, Barcelona, Spain; 2Hospital San Pedro, Logro?o, Spain; 
3Hospital Universitari de Bellvitge, Barcelona, Spain; 4Hospital Joan XXIII 
Tarragona, BARCELONA, Spain; 5Bellvitge Hospital, Barcelona, Spain; 
6Hospital Universitari de BellVitge - Barcelona, BARCELONA, Spain.
Introduction: Atypical hemolytic uremic syndrome(aHUS) has been associated with 
high risk for recurrence after kidney transplantation. In 2017, a consensus report on aHUS 
was published by KDIGO working group whereby eculizumab prophylaxis should be 
recommended in renal transplantation. However, it has recently been described the potential 
benefits from living kidney donors and low tacrolimus use to minimize recurrence rates in 
aSHU, thereby averting endothelial injury. Here we report two cases of successful deceased 
donor kidney transplantation in atypical hemolytic uremic syndrome without preemptive 
eculizumab treatment.
Case Description: They are a 58 and 46-yr old women with a history of CKD stage 
V in hemodialysis due to aHUS diagnosed in 1991 and 1993 respectively. The first one 
showed a total complement factor I(CFI)deficiency of 100% (mutation c.-173C>T), whereas 
in the second case, a complement factor B mutation (c.858C>G) was identified. Both 
underwent renal transplantation from cadaveric donor, sharing two HLA identities(class 
I and II) in each case. Cold ischemia time (CIT) were of 19h18’ and 23h30’, respectively. 
Our immunosuppressive strategy, based on preemptive plasmapheresis, is depicted in the 
attached image. The clinical course was uneventful, without hemodialysis requirements nor 
biochemical microangiopathic anemia signs. Actually, they show a normal renal function 
under tacrolimus (5-6pg/L), mycophenolate and steroid treatment, one month and four 
years after transplantation, respectively.
Discussion: According to our experience, preemptive plasma therapy could be 
effective in the prevention of disease recurrence in patients with high risk mutations with 
deceased kidney donors and long CIT. We need more evidence to define risk groups and 
tailor current treatments to each case to make better cost-effective decisions.
PUB673 
Publication-Only 
Study of Factors Related to Survival of the Renal Graft in Rejection, by 
Means of Plasma Exchange Treatment: Experience in the Hemodialysis 
Unit of the National Medical Center November 20 ISSSTE
Monica Lopez Mendoza, Diana Maldonado Tapia, Ana Karen Garro Almendaro. 
ISSSTE, Ciudad de Mexico, Mexico.
Introduction: The therapeutic plasma exchange (TPE) is an extracorporeal blood 
purification, which consists of extracting plasma, to eliminate particles of great molecular 
weight, from a replacement with colloids or crystalloids. The use in the renal patient is 
indicated to desensitize or reject a renal transplant compatible with ABO and not compatible 
with terms of evidence levels. Currently there is no information in Mexican population 
under this treatment compared to the universal literature.
Case Description: A retrospective analysis during the period from 2016 to 2018 at the 
CMN November 20 ISSSTE, 9 patients, with TPE, under treatment with plasma exchange, 
Collection of demographic characteristics, filters, volume and fluid replacement, number of 
sessions and HD sessions performed. 9 patients being 44.4% female and 55.5% male, the 
mean age was 34 ± 12.1, the predominant type of donor was alive in 66.7% and cadaveric 
in 33.3%, most of the patients, 66.7%, did not have a reported immunological risk of the 
reference hospital and 3 ones were classified as low (11.1%), and intermediate (22.2%), 
the creatinine value previously recorded at the event of transplant rejection was 1.9 ± 2.3, 
with BUN at 22.4 ± 25.2. In the CMN, the mean in the reference time was 35.7 ± 26.1, the 
creatinine value was 8.4 ± 5.9, with BUN 61.2 ± 32.8, registering anuria in 33.3% and uresis 
preserved in 66.7 %, performing plasma exchange treatment in Hemodialysis Unit with a 
mean of sessions of 3.3 ± 1.6, during their stay required conventional hemodialysis sessions 
in 55.6% and recovery of kidney function after treatment was 44.4%, a creatinine of 
4.5 ± 4 and BUN 31.5 ± 19.4 was reported. Analysis of categorical variables, chi square was 
occupied, finding a significant difference between the recovery of the renal function of the 
patient with the type of living or cadaveric donor, with a value of p 0.048.
Discussion: Within 3 years of experience of the Hemodialysis Unit, CMN November 
20, the use of theTPE technique is a useful and effective treatment for transplant rejection, 
however the survival is influenced to risk factors, type of donor, the reference time and 
creatinine at the beginning of treatment. Currently patients are being collected for their 
subsequent analysis.
PUB674 
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Dromedary Hump
Justin Lee Loy,2 Gajapathiraju Chamarthi,1 Abhilash Koratala.1 1University of 
Flroida, Gainesville, FL; 2University of Florida Gainesville, Gainesville, FL.
Introduction: Point-of-care renal ultrasonography, performed by clinicians at bedside 
assists in the management of kidney disease by allowing rapid evaluation of hydronephrosis, 
nephrolithiasis and other major structural abnormalities. It is being increasingly performed 
by internal medicine physicians as well as nephrologists, who typically do not have a 
formal training in radiology. As such, it is important for these physicians to have a thorough 
understanding of renal anatomy and the sonographic appearance of normal kidneys and 
various pathologies that can mimic one another. Herein, we describe a case of dromedary 
hump, a benign anatomic variant.
Case Description: A 58-year-old man with a history of hypertension, obstructive sleep 
apnea and mildly elevated serum creatinine underwent renal ultrasonography for evaluation 
of kidney size and structure. The scan reported no structural abnormalities except for a 
‘protuberance’ in the left kidney [Figure 1A], for which Nephrology input was sought. The 
patient was reassured that this was a benign finding called ‘dromedary hump’ and no follow 
up imaging was indicated.
Discussion: Dromedary hump appears as a focal bulge on the lateral border of the left 
kidney, caused by molding of the normal renal parenchyma by the adjacent spleen. It is 
similar in appearance to the hump of a dromedary camel and thus the name. The incidence 
of this normal anatomic variant is estimated to be about 0.5%. It can sometimes mimic a 
kidney neoplasm and therefore considered a ‘renal pseudotumor’. The hump demonstrates 
the same echogenicity as adjacent normal renal parenchyma on the sonogram unlike renal 
cell carcinoma, which typically appears as a heterogeneous mass with areas of necrosis, 
cystic changes, and hemorrhage. In addition, colour doppler ultrasonography demonstrates 
a normal blood flow within the hump [Figure 1B]. Failure to recognize this benign entity 
may result in unnecessary consultations and investigations.
PUB675 
Publication-Only 
Spontaneous Bleeding in a Patient on Enoxaparin with Overestimated 
GFR
Jenny Shih,1 Andrew Z. Fenves.2 1Harvard Medical School, Boston, MA; 
2Massachusetts General Hospital, Boston, MA.
Introduction: Creatinine-based equations are commonly used to estimate glomerular 
filtration rate (GFR). Unfortunately, creatinine varies depending on factors such as age, 
gender, and muscle mass. Overestimation of renal function by creatinine-based equations 
can be dangerous for renally-dosed medications. We present a patient who developed 
spontaneous bleeding on enoxaparin with kidney function overestimated by creatinine-
based equations.
Case Description: A 73-year-old woman with chronic obstructive pulmonary disease on 
home oxygen was admitted with sudden swelling, pain, and discoloration in her right hand. 
She was completing an enoxaparin bridge to warfarin for history of recurrent pulmonary 
embolism. Examination showed a hematoma on the dorsum of her right hand. Labs 
revealed hemoglobin 10.8 g/dL, creatinine 0.98 mg/dL, INR 1.2, and cystatin C 1.80 mg/L. 
She underwent two hematoma evacuations and required 2 units of packed red blood cells. 
Therapeutic enoxaparin was stopped, and she was resumed on warfarin at discharge.
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Discussion: Creatinine-based formulas overestimated our patient’s kidney function. 
Creatinine-based equations, such as Cockcroft-Gault, Modification of Diet in Renal 
Disease (MDRD) study, and CKD-EPI, placed her at Stage 2 or 3a CKD. Cystatin C, a low-
molecular weight protein, can better predict kidney function independently of creatinine. 
Using the cystatin C equation, our patient had more severe renal dysfunction of Stage 3b 
CKD. The discrepancy between the equations can be due to creatinine variability from 
her older age, female gender, and decreased muscle mass with poor functional status. The 
dosing of enoxaparin sodium was likely too high for her renal function, placing her at 
increased risk of bleeding. Clinicians should be aware of the variability in using creatinine-
based equations to estimate GFR, including patients with low functional status, and should 
consider using cystatin C to guide clinical decision-making.
PUB676 
Publication-Only 
Calciphylaxis in CKD: The Need for Vigilance in Nondialysis Patients
Mariam Zakher, Rafia I. Chaudhry, Loay H. Salman, Swati Mehta. Albany 
Medical College, Albany, NY.
Introduction: Calcific uremic arteriolopathy (CUA) or calciphylaxis is a small-vessel 
vasculopathy, primarily seen in end-stage renal disease, and although rare, it can also occur in 
patients with early stages of CKD. Calciphylaxis results in skin ulcerations and ischemia due to 
thrombosis of small arteries and arterioles triggered by intimal hypertrophy, medial calcification 
and endovascular fibrosis. We present a case of extensive calciphylaxis in CKD stage 3.
Case Description: A 48-year-old female with PMHx of CKD 3, DM, PVD, HLD, 
MI, DVT (on anticoagulation with warfarin), and PSHx of multiple vascular procedures 
including femoral-popliteal bypass and CABG presented with multiple painful ulcerations. 
Then ulcerations initially starting on the right inner thigh, and left breast, and later involved 
the left thigh and gluteal area. Serum creatinine was 0.86 mg/dL at the time of presentation, 
and calcium, phosphorus and PTH were 8.8 mg/dL, 3.5 mg/dL, and 137 pg/ml, respectively. 
Skin biopsy revealed sclerosing dermatitis and angioendotheliomatosis, concerning 
for calciphylaxis. The focal findings of arteriole wall calcium deposition supported the 
diagnosis of calciphylaxis, however ischemic changes and calcification of small arterioles 
were not seen. Warfarin was discontinued and the patient was started on intravenous sodium 
thiosulfate 25 gm three times a week, with subsequent dose titration to 50 gm three times 
a week. Therapy, including sodium thiosulfate and hyperbaric oxygen, were limited by 
patient compliance on discharge, with continued progression of lesions and untimely death 
at 6 months after initial diagnosis.
Discussion: Calciphylaxis should be suspected in patients with early to moderate CKD 
presenting with suspicious skin findings including non-healing ulcerations with surrounding 
areas of induration circumferentially, or painful subcutaneous nodules, especially in areas 
of increased adiposity (thighs, abdomen). Risk factors that have been associated with 
calciphylaxis include warfarin, obesity, and vitamin D analogues. Skin biopsy can help 
confirm the diagnosis of calciphylaxis4, but carries risks of superimposed infections, and 
should not be performed with actively infected lesions. Timely diagnosis and identification 
of risk factors, along with therapeutic interventions i.e. sodium thiosulfate is key to slow 
progression.
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The Case: CKD Unmasked
Benjamin Gollasch,1,2 Oskar Wischnewski,1 Yoland marie Anistan,1 
Friedrich C. Luft,1 Maik Gollasch.1 1Charité University Medicine, Berlin, 
Germany; 2Cardiology/Nephrology/Pulmonology, HELIOS Klinikum Berlin, 
Berlin, Germany.
Introduction: We present a 42-year-old Caucasian man with a body mass index (BMI) 
of 32 kg/m2, who was referred because of heavy proteinuria and decreased renal function. 
We were impressed by his markedly muscular physique.
Case Description: A renal biopsy was performed, which showed advanced focal 
segmental glomerular sclerosis (FSGS). The patient is a professional bodybuilder who was 
not fat despite BMI criteria that classified him an obese (Obesity Class 2) person. He used 
progressive resistance exercise to develop his musculature from age 18 to 39 years. As part 
of his bodybuilding regimen, he consumed anabolic steroids, muscle-growth stimulating 
substances, and high-protein, low-fat diets. For more than six months until admission to 
our hospital, he resumed progressive resistance exercise and also regularly used anabolic 
androgenic steroids. We performed laboratory examinations and anthropometric data 
(BodPod) monitoring over time. Laboratory tests revealed a serum creatinine of 6.37 mg/dL 
(CKD-EPI, eGFR <15 mL/min) and a serum urea of 185 mg/dL. Endogenous creatinine 
clearance (CrCl) was 33 mL/min. Intact parathyroid hormone was 580.3 ng/L. There was 
an albuminuria of 3.01 g albumin/creatinine 1 g. The total proteinuria was 3.98 g protein/
creatinine 1 g. Serum creatine kinase (CK, 5995 U/l, normal <190 U/l) (with CK-MB 
activity 66.4 U/l) and myoglobin (1554 μg/L) were elevated. Serum albumin (36 g/l) and 
protein (64 g/l) levels were in the low-normal range. Over a six-month period, our patient’s 
renal function failed to improve despite reduction in lean body mass, discontinuation of 
anabolic steroid drugs, and muscle growth-stimulating substances. We developed and 
validated a new custom-targeted NGS gene panel (Ion Ampliseq FSGS panel) in two patient 
cohorts with FSGS, and detected several common DNA variants in FSGS genes, which 
could represent candidates for renal risk variants in our patient.
Discussion: We conclude that increased BMI due to increase muscle mass and/or body 
fat in combination with long-term anabolic steroid use and growth promoting substances 
should be included as risk factors in the differential diagnosis of secondary FSGS. 
Bodybuilders are a unique patient population that are fixated upon their behavior. Simple 
counseling is well meaning; however, nephrologists may have to recruit other health-care 
professionals when dealing with these patients.
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Homocysteine-Induced Renal Microvascular Injury in a Case with 
Vitamin B12 Deficiency Following Gastrectomy
Naoki Yamamoto,1 Yasutaka Kamikawa,1 Masahiko Kawabata,1 Takashi Wada.2 
1Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan; 
2Division of Nephrology, Kanazawa University Hospital, Kanazawa, Japan.
Introduction: High Homocysteine levels are established as an independent risk 
factor for atherosclerotic vascular diseases because of its atherogenic and prothrombotic 
properties. Although in ESRD patients the level is known to elevate, it has not fully 
been elucidated the mechanism how high concentration of plasma homocysteine affects 
the function of the kidney in human. We report a case with edema, proteinuria and renal 
function impairment, whose renal histopathology showed thrombotic microangiopathy 
(TMA) like lesions. Furthermore he was associated with marked hyperhomocysteinemia 
and vitamin B12 deficiency related to total gastrectomy.
Case Description: A 56 year-old man presented progressive systemic edema 
and weight gain by 7.2 kg over one month. Hypertension, diabetes mellitus or kidney 
disease including proteinuria had never been pointed out, except for the history of total 
gastrectomy. Laboratory data showed proteinuria of 3.2 g/day, u-occult blood 3+ and 
RBC casts in the sediment. Renal function was impaired as serum Cr 1.35 mg/dL, eGFR 
44 mL/min/1.73 m2, and were serum albumin 3.4 g/dL and LDH 246 IU/L. Blood cell 
count indicated mild anemia, RBC 3.46×106 /μL, Hb 9.3 g/dL and Ht 29.1%, and normal 
Plts count (266×103/μL). Both serum ferritin and vitamin B12 were low, 4.3 ng/mL and 
95 pg/mL (normal: 180-914), respectively. In further tests, IgG, IgM, IgA, C3 and C4 were 
within normal limits, and ANA, ANCA and anti-GBM were all negative. Renal biopsy 
revealed endothelial cell swelling and mesangiolysis in glomeruli. Later his homocysteine 
level in plasma was reported to be very high, 55.8 nmol/mL (normal: 5-15). Treatment with 
cyanocobalamin injection was started.
Discussion: Vitamin B12 plays a crucial role as a cofactor in the metabolism of 
homocysteine. Its deficiency, thus, leads to very high homocysteine concentration of the 
amino acid in plasma. The level is also related to serum Cr in patients with renal diseases, 
partially because the elimination is dependent on the clearance in the kidney. Our case 
indicates the relationship between hyperhomocysteinemia and the pathological findings 
of glomerular endothelial cell damage similar to TMA, suggesting homocysteine-induced 
renal microvascular injury. We propose hyperhomocysteinemia is one of important causes 
in unexplained renal TMA, especially in vitamin B12-deficient adults.
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“It’s Not Always Lupus”: A Case Report
Jaime A. Baynes-Fields,1 Christina Payne,1 Abbas Raza,1 Amanda A. Karasinski,2 
Hasan Arif.1 1Drexel University, Philadelphia, PA; 2Drexel University/
Hahnemann Hospital, Larksville, PA.
Introduction: Autoimmune hemolytic anemia (AIHA) can be a clinical manifestation 
as well as a sequel to lupus flares. Mechanical valves can cause hemolytic anemia due to 
shearing of red blood cells (RBCs). Here we are presenting a case of a patient with active 
lupus and mechanical mitral (MVR) and aortic valves (AVR) presenting with jaundice.
Case Description: 37-year-old female with prior history subacute bacterial endocarditis 
with mechanical MVR and AVR on anticoagulation, systemic lupus erythematosus (SLE) 
complicated by non-biopsy proven lupus nephritis, transaminitis, hemolysis. In August 
2017 she was hospitalized with severe anemia requiring multiple blood transfusions, 
worsening fatigue, 1+ blood on urine dipstick associated with hypocomplementemia 
while on MMF. She developed frank hematuria and high dose steroids were initiated. UA 
illustrated RBC casts and Cytoxan was initiated given presumed class IV lupus nephritis. 
Due to her being anticoagulated a biopsy could not be performed. In January she was found 
to have scleral icterus, jaundice, transaminitis, anemia and gross hematuria. At this time 
our differentials were lupus induced hemolysis vs mechanical shearing. Her LDH was high 
and her haptoglobin was low indicating hemolytic anemia. Her ESR/ANA/C3/C4/dsDNA 
were at normal. Her anti-cardiolipin, Parvovirus, direct and indirect Coombs were negative. 
Her Glucose 6 Phosphate Dehydrogenase (G6PD) levels were normal. On physical exam 
no murmurs detected. Her first echo showed a well-seated MVR, AVR was with a normal 
gradient across the valve, no pericardial effusion, and EF 60-65%. Repeat cardiac echo 
less than 2 weeks later which illustrated moderate medial paravalvular leak and severe 
anterio/lateral paravalvular leak of the MV, in addition, her AVR illustrated elevated AVR 
gradients likely of obstructive physiology. She was taken to the operating theater with a 
diagnosis of aortic and mitral paravalvular leak, pseudoaneurysm between the aortic and 
mitral valve where she underwent a third sternotomy with redo mechanical MVR and redo 
AVR with repair of pseudoaneurysm at the base of the heart. She is post-op from her open 
heart surgery.
Discussion: Here we would like to emphasize that in the setting of existing and recently 
active Lupus nephritis, all etiologies must be considered and ruled out. Hemolytic anemia is 
a known complication of SLE however not all are due to an autoimmune etiology.
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A Mysterious Case of Hypercalcemia
Shannon H. Harrington, Anshul Kumar. Inspira Health Network, Cherry Hill, NJ.
Introduction: Hypercalcemia is often associated with endocrine dysfunctions, 
sarcoidosis, and malignancies. Among malignancies, the physiologic processes resulting 
in hypercalcemia differ. Bony metastases cause lysis of bone calcium deposits, or tumors 
can release parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), 
altering hormonal axes. Rarely, malignancies secrete Vitamin D3 (Calcitriol), causing 
increased intestinal absorption of calcium and increased osteoclastic bone activity.
Case Description: A 47-year-old female with no significant past medical history 
presented with palpitations and dyspnea on exertion. On physical exam, she was tachycardic 
at 144 bpm, hypertensive at 195/129 mmHg, and had palpable splenomegaly. Lab values 
showed a calcium level of 17.7mg/dL. Blood smear showed normal erythrocyte morphology 
with normocytic anemia and some tear-drop cells. White blood cells were without inclusion 
bodies. Platelets were unremarkable. Calcium was stabilized with IV fluids and pamidronate. 
A CT revealed 25cm heterogeneous splenomegaly. A bone marrow biopsy demonstrated 
normocellular marrow with lymphoid aggregate and no evidence of an infiltrative process. 
Microscopic examination showed normocellular marrow with moderately decreased iron 
and no evidence of acute leukemia or lymphoproliferative disorder. PTH was depressed 
at 5.2 pg/mL (reference range 14-64 pg/mL), and PTHrP was 19 pg/mL (reference range 
14-27 pg/mL). An acetylcholinesterase (ACE) level was negative. A 24-hour urine calcium 
was elevated. No monoclonal spikes were identified on SPEP and there was no abnormal 
distribution of immunoglobulins on immunofixation. Abnormally high calcitriol levels at 
118 pg/mL were noted. Subsuqently, a total splenectomy was performed. Post-operative
calcium corrected to 8.5 mg/dL. Surgical pathology of the spleen revealed a high grade
diffuse large B cell lymphoma. She received systemic chemotherapy. Follow-up PET-CT
was without residual or recurrence of tumor burden.
Discussion: Primary Splenic Lymphomas are uncommon and presenting symptoms are 
often non-specific. This case is an example of Splenic B Cell Lymphoma presenting with 
hypercalcemia secondary to ectopic calcitriol production. With splenectomy the ectopic 
calcitriol was eliminated and calcium levels abruptly corrected. This case demonstrates that 
with application of basic physiologic principles even a mysterous cause of hypercalcemia 
can be unveiled.
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Mesenteric Ischemia in Post-Kidney Transplant Patient Associated with 
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Introduction: It is well known that hyperphosphatemia leads to vascular calcification, 
increasing mortality in chronic kidney disease(CKD)patients. Sevelamer is a phosphate 
binder, widely used to control hyperphosphatemia. One of the barriers to the use of 
Sevelamer are the gastrointestinal(GI)symptoms. As other resin-based binders, it can 
crystallize, deposit and injure the GI mucosa through mechanisms not yet well established. 
In this paper, we will report a case of a post kidney transplant patient that presented intestinal 
perforation with the presence of sevelamer crystals(SC)on the GI mucosa.
Case Description: AMSR,41 years old, female, with a history of Systemic Lupus 
Erythematosus, with prolonged use of corticosteroids, Hypertension, CKD due to Lupus 
Nephritis, in haemodialysis(HD)since 2010, and Secondary Hyperparathyroidism. To 
treat bone mineral disease the patient used Sevelamer, CaCO3 and Cinacalcet. The patient 
underwent kidney transplant(deceased donor), progressing to delayed graft function, 
requiring HD for 2 weeks. During that period, she presented with severe abdominal pain. 
The pain ceased with interruption of HD, leading to the suspicion of mesenteric ischemia. 
Contrast tomography was performed, showing perforation of the colon and ileum, and 
she underwent exploratory laparotomy. When analysed by optic microscopy, the lesions 
showed multiple ulcers, micro thrombi and foci of fibrinoid necrosis in the small vessel 
walls, and yellow-brownish intramural deposits, suggestive of drug resin, with eosinophilic 
background and presence of a fish scale curvilinear pattern in the haematoxylin-eosin and 
Ziehl-Neelsen stains. Calcium deposit were not characterized on vessel walls submitted to 
Von Kossa’s stain.
Discussion: Comparing Sevelamer with the resin found in the patient’s mucosa and 
current data, we conclude the lesion in question is a SC deposit, since the patient had used 
this medication. These lesions should be considered in patients with CKD and GI symptoms, 
once other causes have been ruled out. Although rare or underdiagnosed, the complications 
of resin deposition in GI tract are severe and increase patient mortality. Further studies 
should be performed so that these complications can be detected and prevented.
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An Infectious Case of Calciphylaxis Prior to Renal Replacement Therapy
Zach Lauer,2 Ahmad M. Tuffaha.1 1Nephrology and Hypertension, Kansas 
University Medical Center, Kansas City, KS; 2Kansas University Medical 
Center, Kansas City, KS.
Introduction: Calciphylaxis is a rare disorder characterized by slowly progressive 
necrosis of skin and subcutaneous tissue. It is rarely reported in patients with chronic kidney 
disease (CKD) before the initiation of renal replacement therapy.
Case Description: A 62 year old male presented with multiple rapidly spreading skin 
lesions. His past history is significant for hypertension, diabetes mellitus type 2 and CKD 
stage 4 with baseline creatinine 2.8 with eGFR 25 ml/min/1.73m2. Physical examination 
was notable for multiple lesions manifesting as hard black eschars with violaceous and 
purpuric borders on both legs. The glans penis was indurated and necrotic. Laboratory data 
revealed creatinine 5.9 mg/dl, BUN 85 mg/dl, Ca 6.8 mg/dl, phosphorus 4.5 mg/dl and 
albumin of 2.6 g/dl. Blood cultures grew Methicillin Sensitive Staph Aureus. Biopsies of 
the lesions demonstrated degeneration of adipose tissue with necrotic leukocytic infiltrate 
and thrombosis of the subcutaneous small vessels. Von Kossa staining highlighted vascular 
and adipocytic calcification. Biopsy findings were compatible with calciphylaxis with 
superimposed staphylococcal scalded skin infection. He was started on intrravenous 
antibiotics. Aggressive daily hemodialysis was initiated with administration of Sodium 
Thiosulfate three times a week. Repeat cultures were negative but the lesions continued to 
worsen. The patient passed away two months later.
Discussion: Calciphylaxis should be included in the differential diagnosis of skin 
lesions in patients with CKD. Dialysis vintage is one of the main risk factors reported 
in literature but the absence of this risk factor doesnn’t rule it out. The patient didn’t 
have any uremic signs or symptoms but the presence of biopsy proven calciphylasxis 
necessitated dialysis initiation. The rapid progression of CKD along with the superimposed 
staphylococcus infection are potential culprits. High morbidity and mortality are observed 
in both uremic and non-uremic cases of calciphylaxis.
Calciphylaxis lesions involving lower extremities
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A Case of Tumoral Calcinosis After Renal Allograft Failure
Bianca Madrid. University of Miami, Miami, FL.
Introduction: Tumoral calcinosis is a rare manifestation in chronic renal failure 
patients. This report describes a case of patient who had a living unrelated kidney transplant, 
but developed allograft failure within a year and developed tumoral calcinosis of the left 
thigh.
Case Description: A 45-year-old male was admitted to the hospital due to a five-day 
history of progressive left thigh swelling and pain, with no recent trauma. His medical 
history was notable for coronary artery disease, end-stage renal disease from membranous 
nephropathy, and a living unrelated kidney transplant in 2013, but developed allograft 
failure in 2014 and resumed home hemodialysis. Physical examination revealed normal 
vital signs. The left upper leg revealed swelling and tenderness over the anterior and lateral 
thigh, with an ill- defined palpable mass; however, no erythema, ecchymosis or wounds 
were noted. Sensation and reflexes were intact. Initial laboratory assessment revealed serum 
calcium 8.5 mg/dL (ref: 8.6-10.3 mg/dL), serum phosphorus 7.9 mg/dL (ref: 2.5-4.5 mg/dL), 
serum creatinine 7.20 mg/dL and intact serum PTH 636.5 pg/mL (ref: 15-65 pg/mL). 
MRI revealed large multi-locular cystic calcified masses occupying the anterolateral, 
medial and posterior compartments of the left thigh, and extending into the left gluteal 
region with fluid-fluid levels. The multifocal areas on MRI with hypointense T1 and T2 
signal suggested osteoid matrix/calcification.
Discussion: Calcinosis develops in the soft tissues, and is usually distributed along 
the extensor surfaces of the large joints such as the hip, elbow, shoulder or foot. It can be 
differentiated from other soft tissue masses by evidence of hemorrhage and/or septations on 
imaging, as well as the T1/T2 high intensity signal seen on MRI with synovial sarcomas. 
Evidence of bone involvement is characteristic of osteosarcomas, and is not seen with 
calcinosis. The greater trochanteric bursa has been cited as the most common area affected 
for calcinosis; however, the extensive involvement of soft tissue on this patient was unlike 
others reported in literature, especially since the masses extended beyond the previously 
described periarticular distribution. Management of tumoral calcinosis from renal failure 
includes phosphate lowering therapy and intensification of hemodialysis treatments.
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Calciphylaxis in Non-Dialysis Patient
Edgar Guzman-Suarez. Jefferson Hospital, Philadelphia, PA.
Introduction: The patient is a 57 y.o. male with PMHx of alcoholic liver cirrhosis, 
HFpEF, CKD stage 4, recent admission due to hepatic encephalopathy, VDRF and dialysis 
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dependent AKI with recovery of renal function who presented from rehab in the setting of 
AMS and AKI.
Case Description: Patient initially presented on 2/18/18 for hepatic encephalopathy 
and respiratory failure due to pneumonia and hepatic hydrothorax requiring intubation. Per 
outside hospital records patient had baseline CKD stage 4. He developed anuric AKI thought 
to be secondary to ATN. He was dialysis dependent from 2/20-3/14. He was discharged to 
sub acute rehab off dialysis on 3/18/18 with a creatine of 1.9. On follow up visit on the 
outpatient clinic creatinine was 2.4. It appears that he was advised to hold diuretics for a 
couple of days and then resume. He had a second hospitalization on 4/16/18 due to AMS and 
he was found to have a creatinine of 4.6. Pt was being treated for hepatic encephatlopathy 
again. He was noted to have necrotic lesions on lower extremities. Necrotic lesions on the 
thighs and calf have been present for 2-3 weeks per wife. Biopsy confirmed calciphylaxis.
Discussion: Unique presentation of calciphylaxis in non dialysis patient with rapid 
progression of lesions over weeks.
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Overlap of Type 1 Diabetes (DM) and Systemic Lupus Erythematosus 
(SLE) – A Perilous Combination in Pregnancy and Postpartum
Monica L. Reynolds, Akhil Hegde. University of North Carolina at Chapel Hill, 
Chapel Hill, NC.
Introduction: Patients with type 1 DM are at increased risk for developing other 
autoimmune diseases and renal biopsy remains the gold standard for diagnosing diabetic 
nephropathy (DN). SLE can present at any time during pregnancy and should be suspected 
with atypical presentations of underlying disease.
Case Description: A 24-year-old African American female with type 1 DM, 
hypertension (HTN), and proteinuria presented to clinic at 24 weeks gestation for new 
edema. Her DM was complicated by poor glycemic control (A1c 11%), retinopathy 
and neuropathy. Nephrotic proteinuria in her first trimester was attributed to DN. Urine 
sediment was unremarkable. Labs revealed creatinine (Cr) 0.85mg/dL, albumin 3.0mg/dL, 
hemoglobin (Hgb) 7.6g/dL, ferritin 107, iron sat 18%, normal B12 and folate. ANA was 
>1:640 with normal C3 and C4. She was started on oral iron. Two weeks later, Hgb was
7.6g/dL and she was admitted. Hgb electrophoresis, bilirubin and LDH were normal.
Direct coombs test was negative and peripheral smear showed rare schistocytes. Double
stranded DNA antibody (dsDNA) was pending at discharge but returned positive. She was 
re-admitted a week later with headaches and HTN. Cr was 1.11mg/dL and UP/C was 8.5g. 
She delivered via c-section at 29 weeks and 6 days due to superimposed preeclampsia. Five 
days post-discharge, she presented with fatigue. Blood pressure was 150/89, Hgb 8.1g/dL, 
glucose 336mg/dL, Cr 1.73mg/dL and UP/C 11.7g. CXR showed cardiomegaly and
echocardiogram (TTE) revealed a large circumferential pericardial effusion. Rheumatology 
felt she met criteria for SLE and began pulse corticosteroids. Following therapy, glucose
rose to 970mg/dL requiring the ICU. Renal biopsy was performed and revealed DN with
nodular glomerulosclerosis with segmental tuft sclerosis and moderate to severe interstitial 
fibrosis and tubular atrophy. She was treated with a steroid taper and hydroxychloroquine. 
One month later, TTE showed decreased effusion and dsDNA was negative.
Discussion: This case highlights the diagnostic conundrum of coexisting autoimmune 
diseases and the cumulative adverse maternal outcomes that can arise from both diseases 
and their treatments. Failure to respond to iron therapy in pregnancy should prompt further 
investigation and may suggest a misdiagnosis. Earlier renal biopsy may have allowed for 
lower steroid dose and avoided ICU transfer.
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Prolonged Hemodialysis for Refractory Lactic Acidosis Secondary to 
Metformin Overdose
Arushi Goel,1 Raghu Juvvadi,2 Monicka Felix.1 1Department of Internal 
Medicine, Oak Hill Hospital, Spring Hill, FL; 2Department of Nephrology, Oak 
Hill Hospital, Spring Hill, FL.
Introduction: Metformin is a biguanide oral antihyperglycemic agent that has been 
used in the United States since 1995 for treatment of type 2 diabetes mellitus. According 
to the American Diabetic association, recommended as the first drug of choice. Except in 
overdose situations, the association of metformin with lactic acidosis is quite rare with 
an estimated incidence of 3 per 100,000 patient-years. When it does occur, metformin-
associated lactic acidosis is most often associated with an intercurrent disease and renal 
insufficiency. A 2009 review article could identify only 22 cases of metformin overdose. We 
describe a patient with metformin overdose who was successfully treated with hemodialysis.
Case Description: A 57 year old male with past medical history of type 2 diabetes 
mellitus and hypertension was brought to the emergency department with altered mental 
status. His wife reported that he has become increasingly lethargic and fatigued over the 
course of a week. In the emergency department, due to low Glasgow Coma scale, he 
was intubated. The laboratory test revealed severe metabolic acidosis secondary to lactic 
acidosis and acute renal failure. His values were: BUN 103 mg/dL, serum creatinine 
11.2 mg/dL, carbon dioxide 7 mEq/L, anion gap 40, pH 6.78 with a lactic acid level greater 
than 12.7 mmol/L. He was evaluated by Nephrology and underwent emergent hemodialysis, 
which he underwent twice without improvement in his lactic acid. Upon re-evaluation, 
his wife revealed that he was taking metformin 2000 mg daily. A third hemodialysis 
decreased the value for lactic acidosis. After 7 days of inpatient treatment with antibiotics 
and hemodialysis, he was finally extubated. His renal function improved with creatinine of 
1.7 mg/dl on the day of discharge.
Discussion: Metformin is cleared by the kidney with about 90% of drug eliminated 
by glomerular filtration and tubular secretion in 12 hours. Thus, renal insufficiency is a 
risk factor for drug accumulation. Treatment includes use of NaHCO3. Dialysis therapy 
has benefit of correcting the acidosis while removing the toxin. Prolonged hemodialysis is 
indicated in patients with severe overdose.
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Achieving Equilibrium Is Not That Easy: A Case of Dialysis Disequilib-
rium Syndrome
Lauren Lamie,1 Mohamed Mortagy.2 1WMU Homer Stryker MD School of 
Medicine, Kalamazoo, MI; 2Western Michigan University School of Medicine, 
Kalamazoo, MI.
Introduction: Dialysis disequilibrium syndrome (DDS) is an increasingly rare 
neurological syndrome attributed to cerebral edema and osmotic shifting following dialysis. 
Symptoms vary in severity from restlessness and headache to less commonly seizure, coma, 
or death. Risk factors include first dialysis session, markedly elevated BUN, and severe 
acidosis. As there is no specific treatment, prevention is essential.
Case Description: A 27-year-old female with end stage renal disease (ESRD) on 
hemodialysis (HD) and antiphospholipid syndrome on warfarin presents with generalized 
weakness, anasarca, fatigue, and gingival bleeding in the context of noncompliance with 
HD for four weeks. She was afebrile and hypertensive with blood pressure of 188/120. 
Labs significant for BUN/creatinine 231/22.6 mg/dL, sodium 141 mEq/L, potassium 
7.2 mEq/L, bicarbonate 7 mEq/L, hemoglobin 5.2 g/dL, platelets 119,000/mm3, and INR 
1.8. DIC screen was negative. She was transfused and emergent HD initiated. Shortly after 
her 3-hour HD session, the patient had a seizure complicated with hypoxia and subsequent 
cardiac arrest. She was resuscitated for two minutes with return of spontaneous circulation 
and was intubated. Once she was stabilized, CT head was negative for hemorrhage or 
stroke, BUN 83 mg/dL, bicarbonate 15 mEq/L, glucose 122 mg/dL, sodium 141 mEq/L, 
potassium 3.3 mEq/L, calcium 8.3 mg/dL, magnesium 1.9 mg/dL. The patient was 
diagnosed with DDS and she was initiated on continuous renal replacement therapy (CRRT) 
without ultrafiltration. She ultimately achieved neurological recovery, was extubated and 
transitioned back to intermittent hemodialysis successfully after two days.
Discussion: Prevention of DDS involves initiating HD cautiously with low flow rates, 
short duration, and increased frequency. Care must be taken on initiation of HD not only 
in new dialysis patients, but also in noncompliant ESRD patients with marked metabolic 
disturbances as presentd in this case. Treatment is largely supportive as no benefit has been 
proven with agents aimed to decrease intracranial pressure such as mannitol or hypertonic 
saline.
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Calcium - To Drip or Not to Drip: The Curious Case of Masked Hypercal-
cemia on Regional Citrate
Gurleen Kaur,1 Ali Kashkouli.2 1Emory, Decatur, GA; 2Emory University, 
Atlanta, GA.
Introduction: Continuous renal replacement therapies (CRRT) has several short-
term advantages. However, there is a paucity of data on the long-term effects when used 
in End Stage Renal Disease (ESRD). Anticoagulation is frequently required to maintain 
filter patency. Regional citrate is the recommended form and functions most effectively 
when the post-filter ionized calcium (iCa) is kept ~ 0.2-0.4 mmol/L while a calcium drip 
maintains the systemic iCa ~ 1.0-1.3 mmol/L. We describe a case of a patient on regional 
citrate with hypercalcemia secondary to prolonged immobilization and history of tertiary 
hyperparathyroidism(THP) which was masked by the use of the regional citrate protocol.
Case Description: A 67-year-old male with ESRD and THP presented for shortness 
of breath. His hospital stay was prolonged due to development of small bowel obstruction 
associated with perforation and hemodynamic compromise, hence was initiated on CRRT. 
Due to frequent filter clotting, a regional citrate protocol with prefilter Anticoagulant Citrate 
Dextrose Solution A (ACD-A) was initiated and a 2% calcium gluconate drip was used 
systemically. While on CRRT with regional citrate, he was requiring only minimal calcium 
gluconate at 20ml/hr. In subsequent days, this drip was stopped due to elevated systemic 
iCa. We continued his pre-filter citrate drip and were able to maintain his post-filter iCa 
between 0.2-0.4 mmol/L per protocol. In evaluating his hypercalcemia, he was found to 
have 25-OH vitamin D level of <7.0 ng/mL, 1,25-OH Vitamin D was <8pg/mL, PTH was 
260.9 pg/mL (off cinacalcet) with a level of 777.8 pg/mL on admission. Alkaline phosphate 
was 242 IU/L, Bone-specific alkaline phosphate was 53.7 mcg/L, iCa while off the calcium 
drip was 1.33-1.24 mmol/L with a total calcium of 9.7-9.4 mg/dL and a citrate requirement 
of 280cc/hr.
Discussion: Regional citrate is the recommended form of anticoagulation on CRRT. 
Prolonged immobilization in patients with ESRD and THP can liberate calcium from 
bone which can be further exacerbated by the effect of chronically elevated PTH. This 
hypercalcemia may be masked if citrate is used for CRRT. If left up to the protocol, patients 
can come off calcium drips with their bone calcium stores acting effectively as a calcium 
drip. Given this increased bone mineral loss alternate therapy must be instituted as soon as 
the subject becomes hemodynamically stable.
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Publication-Only 
Cardiac Arrest from Baclofen Overdose: Dialysis to the Rescue
Agustin G. Velazquez perez. LSU health shreveport, Shreveport, LA.
Introduction: Baclofen overdose often presents with CNS and respiratory depression, 
leading to coma requiring mechanical ventilation. Seizures, hypothermia and cardiac 
instability have also been reported. Treatment is primarily supportive in those with normal 
kidney function. We report a case of baclofen overdose complicated by bradycardia, sinus 
pause, and cardiac arrest treated with hemodialysis.
Case Description: A 54 year old African American female with history of bipolar and 
schizoaffective disorder was found unresponsive and brought to the emergency department. 
The patient had allegedly overdosed on 40 tablets of baclofen (10 mg) 2 hours prior. On 
arrival, her GSC was 3/15, pupils dilated, with agonal breathing. Patient was intubated 
promptly and placed on mechanical ventilation. Laboratory data were normal; including 
creatinine of 0.76 mg/dl and negative urine drug screen. Poison control recommended 
supportive care. 9 hours after admission, patient became hypotensive, bradycardic 
and was noted to have frequent sinus pauses lasting 20-30 seconds leading to asystole. 
Following successful resuscitation she was emergently dialyzed which resulted in marked 
improvement of her clinical status and extubation the next day.
Discussion: Baclofen acts as an inhibitory neurotransmitter and is commonly used to 
treat spasticity. The kidney primarily excretes Baclofen. However there have been reports 
where hemodialysis has been used for Baclofen overdose even in patients with normal renal 
function. Properties that enhance dialytic clearance include its low molecular weight, low 
volume of distribution and relatively low protein binding. 79% of the drug is cleared with 
a 4 hour dialysis session leading to a reduction in half life from 7 to 3 hours. This shortens 
recovery time. This case teaches us that dialysis should be considered early in those with 
life threating manifestations.
PUB690 
Publication-Only 
Acute Hepatic Encephalopathy: An Underexplored Indication for Renal 
Replacement Therapy
Mayanka Kamboj,1 Martin Runnstrom,3 Amir Kazory.2 1University of florida, 
Gainesville, FL; 2University of Florida, Gainesville, FL; 3University of Florida, 
Department of Medicine, Gainesville, FL.
Introduction: Hepatic encephalopathy (HE) is associated with high mortality. While 
the key role of serum ammonia level (SAL) in development of HE has long been recognized, 
emerging evidence points to distinct mechanisms underlying chronic alterations in neural 
metabolic functions and acute changes in cerebral perfusion. In acute HE, formation of 
glutamine, a strong osmolyte, leads to cerebral edema as ammonia crosses the blood–brain 
barrier at high levels.
Case Description: A 52-year-old man with liver cirrhosis and esophageal varices 
presented with hematemesis and decline in mental status. He was afebrile, normotensive, 
and confused. Laboratory studies showed hemoglobin level 6.8 g/dL, platelets 9000/mm3, 
serum creatinine 0.5 mg/dL and SAL 176 μmol/L (normal <35). He received intravenous 
fluids, blood transfusion, and antibiotics. However, his mental status deteriorated further 
with development of decerebrate posturing; he was intubated. Head CT was unremarkable. 
Bleeding varices precluded nasogastric tube placement while administration of lactulose 
per rectum was high risk due to thrombocytopenia. Hence, the decision was made for 
renal replacement therapy (RRT), starting with hemodialysis (HD) followed by continuous 
venovenous hemofiltration (CVVH). Despite 4 hours of HD with a high flux filter, the post-
HD SAL was as high as 262 μmol/L making it unlikely for the patient to survive had the 
RRT started with delay. SAL progressively declined to 71 μmol/L, 19 hours post-RRT. 
Improvement in his mental status closely mirrored the reduction in SAL. Endoscopy could 
be performed to stop the bleeding, RRT was stopped, and he was extubated.
Discussion: Rapid lowering of SAL remains the primary goal of therapy in HE. 
Ammonia is readily dialyzable as it is a non-protein-bound small molecule. While HD is 
a plausible option when less invasive medical options are not feasible, post-HD rebound 
could represent a major drawback. To minimize this effect, we used CVVH in conjunction 
with HD, which could also portend a salutary impact through temperature control. Using 
a combined RRT strategy helped stabilize the patient so the underlying cause of HE (i.e. 
bleeding varices) could be treated. This case coupled with previous reports represents an 
underexplored indication for RRT and highlights the significance of an interdisciplinary 
approach for efficient treatment of these patients.
PUB691 
Publication-Only 
Liver Dysfunction from Immune Reconstitution Syndrome After 
Treatment of Hepatitis C Virus Infection in ESRD Patient
Junaid Nasir,2 Elvira Gosmanova,1 Odirichukwu O. Duru.3 1Stratton VA Medical 
Center and Albany Medical College, Albany, NY; 2Nephrology, Albany Medical 
Center, Albany, NY; 3Albany College of Pharmacy and Health Sciences, Albany, NY.
Introduction: Hepatitis C virus (HCV) infection is associated with worse outcomes 
in ESRD patients. Elbasvir/grazoprevir-a combination direct antiviral agent (DAA) 
demonstrated safety and effectivines in treating ESRD individuals with genotype(GT)-1 
HCV infection. We report a case of autoimmune liver injury in a hemodialysis(HD) patient 
after successful HCV eradication.
Case Description: A 57-year old female with ESRD was noted to have yellow 
discoloration of the dialyzer filter at the end of HD session 2 days prior to completion of a 12-
week elbasvir/grazoprevir course for chronic HCV GT-1A infection resulting in a sustained 
virologic response. She reported insidious onset of pruritus, vague abdominal pain, nausea 
and reduced appetite. On exam she had scleral icterus and diffuse abdominal tenderness. 
Laboratory investigations showed hypercholesterolemia, alkaline phosphatase rise from 
baseline of 184U/L to 548U/L with liver-specific fraction of 64%. Total and direct bilirubin 
were 4.6mg/dL and 3.9mg/dL. Computed tomogrpahy scan revealed new hepatomegaly. 
Cholestasis symptoms persisted 8 months after completion of DAA. In addition, the patient 
had new elevated antimitochondiral antibodies (AMA 68U, normal <20U). A liver biopsy 
was performed as a part of kidney transplant evalution. Unexpectadly, it showed the biliary 
pattern of liver injury consistent with primary biliary cholangitis (PBC). Ursodeoxycholic 
acid was initiated but stopped due to intolerable gastrointestinal side effects. Despite no 
additional therapy, pruritus and hyperbilirubinemia gradually resolved 18 months after 
completion of DAA; however, AMA levels remained elevated.
Discussion: HCV infection is associated with chronic state of antigenemia and 
resultant immune activation and impaired function of several immune cell populations. 
It was shown that HCV eradication can lead to reactivation of chronic hepatitis B and 
recurrent hepatocellular carcinoma. We hypothesize that PBC-like liver injury in the 
present case was due to immune reconstitution inflammatory syndrome and imbalance of 
immune-regulatory mechanisms associated with eradication of HCV infection rather than 
de novo PBC. Potential benefits of HCV treatment in ESRD patients should be balanced 
with possible complications, reduced ability to receive HCV positive organ for kidney 
transplantation and increased cost of care.
PUB692 
Publication-Only 
Unexpected Allergic Reaction in a Patient Receiving Chronic 
Hemodialysis
Srikar Kumar,1 Abhijit V. Kshirsagar,2 Raven A. Voora.2 1University of North 
Carolina, Chapel Hill, NC; 2University of North Carolina at Chapel Hill, 
Chapel Hill, NC.
Introduction: Anaphylactic reactions usually occur during the initial dialysis session. 
We present a patient on chronic hemodialysis who suddenly develops an anaphylactic 
reaction to a part of the dialysis apparatus.
Case Description: 34-year-old man with ESRD presented to the emergency 
department with hyperkalemia and dyspea secondary to volume overload after missing 
outpatient dialysis. Hemodialysis was started using his outpatient prescription (1). Two 
minutes after initiating dialysis, the patient became hypoxic and hypotensive, requiring 
emergent intubation and vasopressors. He was started on CRRT (2) and had no adverse 
reactions. The next day, he was weaned from pressors and extubated. Hemodialysis was 
again attempted (3), but he developed hypotension and hypoxia. At this point, there was 
suspicion for a dialysis-related issue. Hemodialysis was attempted using a different dialyzer 
(4), double priming of the extracorporeal circuit, and pre-medication with antihistamines, 
but he again developed anaphylactic symptoms. Since he tolerated CRRT with NxStage, 
hemodialysis using the NxStage machine was ultimately performed with no issues (5). He 
is currently dialyzing at his outpatient unit with this set up without incident.
Discussion: This chronic dialysis patient likely had a severe allergic reaction to 
ethylene oxide sterilant used for dialyzer components. Type A reactions (anaphylactoid) 
occur within the first five minutes, and are an IgE medicated process, causing hypotension 
and possibly shock. Patients with prior history of allergic reactions during dialysis are at 
higher risk of type A reactions, so it is unexpected that this patient developed a reaction 
after receiving outpatient dialysis treatments for several years without incident. Because 
this patient tolerated CRRT with the Purema cartridge, the reaction was thought to be due to 
the sterilization method, specifically to the tubing. It is unclear why he suddenly developed 
these symptoms. One should always consider Type A reactions in patients on chronic 
dialysis who develop instability while receiving dialysis.
PUB693 
Publication-Only 
Effect of Intermittent Hemodialysis (iHD) on Patient and Left Ventricular 
Assist Device (LVAD) Hemodynamics: A Case Report
Muhammad O. Hanif, Abbas Raza, Karthik M. Ranganna, Sandeep Aggarwal, 
Ellie Kelepouris, Ziauddin Ahmed. Drexel University College of Medicine, 
Philadelphia, PA.
Introduction: IHD in patients with a LVAD is challenging due to non-physiological 
and complex circulatory hemodynamics, especially in modern LVAD which have 
continuous instead of a pulsatile blood flow. There is a general lack of literature in this field. 
We present a case of an ESRD patient with LVAD in whom we studied the hemodynamics 
effect of iHD.
Case Description: 42-year-old male with past medical history of Non ischemic 
cardiomyopathy with Ejection Fraction of 10-15% on Destination LVAD (Heart ware 
continuous flow, centrifugal), ESRD on IHD for 1.5 years due to cardiorenal syndrome. 
We prospectively collected pre and post dialysis Mean Doppler Pressure (MDP, mmHg), 
Cardiac Output (CO, Liters/min), Heart rate (HR, beats per min BPM) Dialysis time, and 
Ultrafiltration volume; from 35 consecutive treatments. MDP mmHg was measured as first 
brachial artery doppler signal after manual cuff deflation (Lanier et al), CO were recorded 
from LVAD device monitor and HR was collected using continuous chest lead telemetry. 
Paired 2 tailed T-test was used for within group difference, Pearson’s r was used for correlation 
analysis. There was a statistically significant improvement in CO, reduction in MDP and 
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increase in HR(table 1). The average Ultrafiltration volume was 3.4±0.7 Litres and average 
dialysis time was 3.7±0.6 hours. There were 3/35 post ultrafiltration hypotensive episodes 
(MDP < 55mmHg), all were asymptomatic and resolved spontaneously. Midodrine was 
not required in any instances. Interestingly there was no correlation between ultrafiltration 
volume and change in cardiac output (r2 = 0.013) or change in MDP (r2 = 0.002).
Discussion: Hemodialysis in LVAD patients remains challenging. Our case showed 
that iHD is tolerated well and significant increased in CO occurred after UF despite decrease 
in the MDP. We recommend further larger scale studies in this regard.
Patient Hemodynamic and LVAD CO changes with hemodialysis
Stdev= standard deviation
PUB694 
Publication-Only 
Dialyzing Massive Metformin Overdose
Syed H. Bukhari,1 Itunu O. Owoyemi,3 Joshua D. King,3 Brendan T. Bowman.2 
1University of Virginia Div. of Nephrology, Charlottesville, VA; 2University of 
Virginia Health System, Charlottesville, VA; 3University of Virginia, 
Charlottesville, VA.
Introduction: Metformin is a biguanide oral antihyperglycemic, prescribed to over 
120 million people globally. Metformin associated lactic acidosis (MALA) is a serious 
complication of metformin overdose. We present a case of massive metformin overdose and 
MALA successfully managed with sequential rounds of hemodialysis (HD) and continuous 
venovenous hemodialysis (CVVHD).
Case Description: A 19-year-old male was admitted after taking approximately 360 
pills of 500 mg metformin in a suicide attempt. Initial serum lactic acid (LA) level was 
5.0 mmol/L and metformin level was 350 mcg/mL (therapeutic 0-2 mcg/mL). He was started 
on a bicarbonate drip and underwent emergent HD for 4 hours; however, LA worsened 
to 27 mmol/L and developed acute respiratory failure and hemodynamic compromise 
requiring mechanical ventilation and vasopressor support. LA had worsened to 39 mmol/L 
with an anion gap (AG) of 40. Patient also developed acute kidney injury (AKI) with a 
peak creatinine of 4.4 mg/dL. Blood gas analysis showed pH 7.02, pCO2 23 mm Hg and 
bicarbonate 6.0 mmol/L. Patient underwent successive rounds of HD for 6 hours with a high 
flux dialyzer and then switched to CVVHD with a dialysate flow rate of 112 ml/kg/hr. The 
total duration of renal replacement therapy (RRT) was 60 hrs after which AKI resolved and 
serum bicarbonate, LA and AG normalized.
Discussion: Metformin has a relatively high volume of distribution (1-5L/kg) and its 
toxicity is associated with a mortality of >38% with levels above 50 mcg/mL. MALA poses 
a multifaceted challenge including drug removal, correction of acidosis and prevention of 
rebound. Our case was unique for various reasons. The magnitude of toxicity was massive 
and patient was dialyzed three times in 24 hrs using a high flux, high surface area dialyzer 
and metformin level decreased from 350 mcg/mL to 8.7 mcg/mL. To prevent rebound, 
patient was continued on high volume dialysate at 112 ml/kg/hr with CVVHD achieving 
clearance rates of approximately 130 mL/min. The total duration of RRT of 60 hours was 
much shorter compared to previously reported cases involving low flux, low-efficiency 
dialyzers that required RRT for days to weeks. This resulted in earlier resolution of MALA 
and may have influenced renal recovery. Sequential use of high flux, high surface area 
dialyzer and high volume CVVHD can decrease metformin levels precipitously, prevent 
rebound MALA and promote early renal recovery.
PUB695 
Publication-Only 
Baclofen Neurotoxicity: A Case for More Stringent Guidelines
Hong loan T. Nguyen, Muhammad S. Shamim, Samaya J. Anumudu, 
Ahmed A. Awan, Jose J. Perez. Baylor College of Medicine, Houston, TX.
Introduction: Baclofen is a Υ-aminobutyric acid (GABA) derivative whose inhibitory 
effect at the motor neuron synaptic reflexes is utilized in muscle spasticity reduction. 
Baclofen elimination occurs primarily through the kidneys (69% +/- 14%) and therefore 
is severely reduced in patients with renal insufficiency; hemodialysis (HD) clearance of 
Baclofen is 128mL/min. Baclofen neurotoxicity in end stage kidney disease (ESKD) is a 
major concern.
Case Description: A 44 year-old male with ESKD on scheduled HD, diabetes mellitus 
II, hypertension, and diastolic heart failure was admitted for acute encephalopathy. One 
day prior to presentation, the patient visited a local clinic for leg pain for which he was 
prescribed Baclofen 10mg two times daily. After taking two tablets as instructed, he had 
progressive encephalopathy leading to hospital admission. At presentation, he had notable 
dyskinesia and encephalopathy and was emergently intubated for airway protection. Head 
and chest imaging was unremarkable and infectious workup was negative. Nephrology was 
consulted for emergent HD for metabolic clearance. EEG was consistent with metabolic-
toxic etiology. He received three consecutive daily HD sessions, was successfully extubated, 
returned to baseline mental status, and was discharged on day five of hospital admission.
Discussion: Our case highlights potentially lethal Baclofen neurotoxicity in patients 
with ESKD. Avoidance of Baclofen in this population has been recommended. However, if 
necessary, prescribers are advised to start at a low dose with close monitoring for adverse 
effects. From our experience and detailed literature review, even a small/renal-adjusted 
dose of Baclofen in an ESKD patient may lead to rapid subsequent neurotoxicity. Despite 
recognition by nephrologists of this severe adverse effect, Baclofen is still being prescribed 
to ESKD patients. This may be due to the fact that there is no clear contraindication for its 
use in this population. Very often, nephrologists are not the providers first in line treating 
common complaints such as muscle spasms/pain for which Baclofen is often prescribed. 
Our case highlights the need for clearer Federal Drug Administration (FDA) guidelines 
for the cessation of Baclofen use in patients with ESKD and advises for greater education 
to primary care and emergency care providers of baclofen neurotoxicity in patients 
with ESKD.
PUB696 
Publication-Only 
Methotrexate Toxicity Following Treatment of a Caesarean Scar 
Pregnancy
Sarah Gleeson,1 Ian Kando,2 Audrey A. Long,3 David Semple.1 1Nephrology, 
Auckland hospital, Auckland, New Zealand; 2Auckland District Health Board, 
Auckland, New Zealand; 3Auckland City Hospital, New Zealand, Auckland, New 
Zealand.
Introduction: Caesarean scar pregnancies(CSP) require treatment with 
methotrexate(MTX). Local MTX was not thought to be systemically absorbed. Our end 
stage renal failure(ESRF) patient developed severe MTX toxicity following local MTX 
therapy.
Case Description: A 30-year-old woman with ESRF maintained on haemodialysis(HD) 
presented with an unplanned pregnancy. She previously had a vaginal delivery followed 
by a caesarean section. An ultrasound scan at 8 weeks showed an ectopic CSP. This 
was managed with an intra-sac injection of 50mg MTX Post-procedure she deteriorated 
with fever, mucositis, rash, neutropenia and thrombocytopenia. On Day 5 MTX toxicity 
was considered and a MTX level was 0.30umol/L. Folinic acid and granulocyte colony 
stimulating factor were started. Despite this she developed severe neutropenia had a 
prolonged hospital admission with a protracted recovery.
Discussion: Management of pregnancy in dialysis patients is challenging. This case 
was further complicated by a CSP, a condition where ongoing pregnancy is ill-advised 
and complications of uterine rupture, severe haemorrhage and death can occur. Treatment 
options include systemic or local MTX, uterine artery embolization and surgery. MTX 
preferentially affects rapidly dividing cells, e.g. blastocysts and stem cells. In those with 
normal renal function MTX toxicity can be seen in patients receiving very high doses. Pre-
emptive folinic acid and careful monitoring of MTX concentration may prevent toxicity. 
There are reports of MTX toxicity and death in patients on dialysis. There have been 2 
cases of MTX toxicity in dialysis patients after systemic MTX administration for ectopic 
pregnancy, 1 fatal. There have been no reported cases of MTX toxicity following intra-
sac MTX administration. Local administration of MTX for management of CSP has the 
theoretical advantage of less systemic exposure to MTX. However, a previous study in 
tubal ectopic pregnancies showed the mean peak serum level of MTX after local injection 
to the ectopic amniotic sac was not lower compared with systemic dosing. Caesarean scar 
ectopic incidence is increasing with the growing trend of operative deliveries. Improved 
outcomes and reduction of systemic toxicity in ESRF may be achieved with dose reduction, 
methotrexate concentrations, early folinic acid therapy, increased frequency of high flux 
dialysis and strong clinical index of suspicion for MTX toxicity.
PUB697 
Publication-Only 
Excessive Elevation of Serum Phosphate During Tumor Lysis Syndrome: 
Lessons Learned from a Particularly Challenging Case
Prince Amaechi, Fredrik Jenssen, Zipporah Krishnasami, Anand Achanti, 
Tibor Fulop. Medical University of South Carolina, Charleston, SC.
Introduction: Tumor lysis syndrome in the modern era of allopurinol and recombinant 
uricase administration may present to Nephrologists with predominant abnormalities of 
phosphorus and calcium. Indications and choices of renal replacement therapy (RRT) may 
need to be customized to individual scenarios.
Case Description: An 18-year-old male received first cycle intensive chemotherapy for 
Burkitt lymphoma and developed massive tumor lysis syndrome. Lactate dehydrogenase 
peaked at 9,105 [130-250 U/L] with undetectable serum haptoglobin values. Initial medical 
therapy consisted of recombinant uricase enzyme, intravenous isotonic sodium-bicarbonate 
administration and oral phosphorus binders. Nonetheless, within 4 days he developed 
excessive hyperphosphatemia (up to 21.4 mg/dl) with acute kidney injury (serum creatinine 
2.2 mg/dL), oliguria, hyperkalemia (6.2 mM), hypermagnesemia (3.1 and hypocalcemia 
(corrected calcium 7 mg/dL). The competing risk of dialysis disequilibrium syndrome 
vs. insufficient control of hyperphosphatemia prompted us to utilize an initial session of 
conventional dialysis session (HD) (4 hour session, with blood flow 200 mL/min, dialysate 
flow of 400 mL/min; electrolyte composition: sodium 150 mM/L; calcium 2.5 mEq/L), 
with simultaneous mannitol administration (12.5 gm) at two and four hours after start. 
Stability of serum osmolality was demonstrated (322 and 319 mOsm/kg before and after, 
respectively). Serum phosphate improved to 8.7 mg/dL; this improvement, however, 
may also partially represented test interference by mannitol. Thereafter, high-volume 
slow continuous hemofiltration started (initial hemofiltration rate 30 mL/kg/h, [2 L/h]); 
subsequently escalated to 3.5 L/h), where serum phosphate remained difficult to control 
and even rose transiently (13; 11 mg/dL) during the next 24 h. He had excellent tolerance of 
these therapies and recovered renal function uneventfully.
Discussion: The presented exceedingly high phosphorus remains the highest serum 
phosphorus witnessed in our institution. Early and aggressive RRT may involve upfront 
administration of both an initial conventional HD session to debulk phosphorus load and 
subsequent continuous modality, until full correction is achieved.
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Publication-Only 
Bullous Pemphigoid in Patients with ESRD: A Case Series
Karthik Kovvuru, Aldo E. Torres Ortiz, Jessica S. Everitt, Tia Hayes, 
Wisit Cheungpasitporn, Maria Lourdes Gonzalez Suarez. Nephrology, 
University of Mississippi Medical Center, Jackson, MS.
Introduction: Bullous Pemphigoid (BP) is an uncommon autoimmune subepithelial 
blistering disease. Very few single case reports of BP have been described in ESRD 
population. Prevalence and etiology of BP in hemodialysis (HD) patients (pts) is unknown. 
We describe a case series of 3 pts with ESRD from a single outpatient dialysis center 
diagnosed with BP.
Case Description: Case 1: 62 yo woman (W) developed BP during cessation of 
immunosuppression (IS) for her failed second kidney transplant (KTx). Native kidney 
failure was presumed secondary to HTN, first kidney allograft worked for 6 years and failed 
due to non compliance. She was on HD for 9 years before getting a second KTx which failed 
after 4 years due to rejection. She was restarted on HD and her IS decreased. She developed 
BP as her IS was decreased. She was restarted on high dose prednisone with prolonged 
taper. She is now on low dose prednisone and mycophelonate mofetil (MMF). Case 2: 
44 yo W with type 1 DM and HTN, ESRD on HD who also developed BP immediately 
after cessation of IS for her 16 yr old failed KTx. She was treated with prednisone 60 mg 
with prolonged taper. She was unable to get MMF due to insurance issues and did not 
tolerate azathioprine. She could not be tapered off steroids and was kept on maintenance 
low dose prednisone with intermittent high doses for flares. Case 3: 52 yo W with DM, 
HTN, ESRD on HD who underwent bilateral below knee amputations due to recurrent 
infections and osteomyelitis. Her wound healing was slow and required prolonged wound 
care. She developed acute onset of blisters in both stumps about 2 years after surgery. Skin 
biopsy confirmed stump-related BP which resolved with short length of prednisone taper.
Discussion: Etiology of BP in HD pts remains to be determined. It has been speculated 
that unmasking of epitopes at the AV fistula/graft site could be playing a role. In KTx pts, 
cessation of IS could unmask de novo BP or allograft epitopes from a kidney undergoing 
rejection. BP should be considered high in the differential for blistering disease in HD pts 
(especially those with failed KTx) as early diagnosis would initiate appropriate therapy.
PUB699 
Publication-Only 
Dialysis Disequilibrium Syndrome with Proper Precautions: A Case Series
Abbas Raza, Robert Fleyshman, Marc J. Kim, Sandeep Aggarwal. Drexel 
University College of Medicine, Philadelphia, PA.
Introduction: Dialysis disequilibrium syndrome (DDS) is an increasingly rare 
syndrome in modern dialysis practice. It can manifest as altered mentation, seizure, 
coma and even brain death. Pathogenesis is believed to be the result of rapid reduction in 
serum osmolality, and water movement into brain leading to cerebral edema. Among the 
risk factors is first dialysis session and significantly elevated blood urea nitrogen (BUN). 
To prevent DDS, small dialyzers and slower blood flow rates are employed whenever 
possible. We present two cases of DDS that developed following proper dialysis initiation 
precautions.
Case Description: Patient A: 70-year-old female with no significant history of renal 
disease presented with slurred speech and malaise. Laboratory workup revealed elevated 
BUN and creatinine (cr), hyperkalemia and severe metabolic acidosis (Table-1). After 
pretreatment with mannitol, dialysis was started with plan for 2 hours of slow hemodialysis 
(blood flow 200 ml/min). 90 minutes into the dialysis session the patient developed altered 
mentation. Dialysis was stopped and her symptoms resolved shortly after. Delivered 
hemodialysis dose: Kt/V of 0.61 (URR = 43%). Patient B: 56-year-old female with no 
significant history of renal disease presented with headaches and somnolence. Laboratory 
workup revealed elevated BUN and cr, hyperkalemia, and severe acidosis (Table-1). 
Dialysis was started with plan for 2 hours of slow haemodialysis (blood flow 250 ml/min) 
via small dialyzer (F16). 90 minutes into the dialysis session, she had a witnessed seizure. 
Dialysis was stopped and lorazepam was administered with subsequent resolution of 
seizure. Delivered hemodialysis dose: Kt/V of 0.71 (URR = 48%).
Discussion: DDS, although rare, is still a possible complication in new start dialysis 
patients. Dialysis initiation precautions that include small dialyzers and slower blood flow 
rates should be employed whenever possible. In spite of these precautions, DDS can occur 
with Kt/V and URR well below the target of 1.2 and 65% respectively. Larger studies are 
required looking into traditional and novel mechanisms and risk metrics of DDS in modern 
dialysis practice.
Table-1
BUN & cr (mg/dL), K (mmol/L)
PUB700 
Publication-Only 
A Tale of Two Cryptococcoses: Risks in HIV-Negative Hemodialysis 
Patients
Jefferson L. Triozzi, Lauren Nicholas S. Herrera. Baylor College of Medicine, 
HOUSTON, TX.
Introduction: Cryptococcosis is an opportunistic fungal infection typically associated 
with advanced HIV/AIDS. We report two cases in HIV-negative patients with end-stage 
renal disease (ESRD) on hemodialysis (HD).
Case Description: Patient 1 is a 47-year-old male with a history of ESRD secondary 
to type 2 diabetes mellitus and hypertension on maintenance HD with a tunneled dialysis 
catheter (TDC) who presented with two weeks of headache and fever. Lumbar puncture 
revealed an elevated opening pressure, and diagnosis of cryptococcal meningitis was made 
by cryptococcal antigen positivity in the cerebrospinal fluid. Peripheral and TDC blood 
cultures were negative. The patient improved with antifungal therapy and placement of a 
ventriculoperitoneal shunt due to persistent intracranial hypertension. Patient 2 is a 67-year-
old male with a history of hepatitis C related cirrhosis and ESRD on maintenance HD 
with a TDC who presented with subacute abdominal pain, progressive ascites, and fever. 
Paracentesis was not consistent with spontaneous bacterial peritonitis; however, cultures of 
the peritoneal fluid grew Cryptococcus neoformans. Further workup revealed disseminated 
disease in the ascites, cerebrospinal fluid, and serum. His hospital course was complicated 
by sepsis and death four weeks after initiating antifungal therapy.
Discussion: Although ESRD is associated with immune dysfunction, the pathogenesis 
of cryptococcal infections in HIV-negative HD patients is not well described. Both patients 
presented here were HIV-negative Hispanic males from low socioeconomic backgrounds 
who had initiated HD within the last six months via TDC, and were found to have CD4 
T-lymphocyte counts less than 400. ESRD is associated with both impaired T-lymphocyte 
function and lymphocytopenia, likely predisposing patients to fungal infections. Practice
guideline recommendations for treatment in this population are limited. Catheter removal
is associated with improved mortality in peritoneal dialysis patients, but this has not been
studied in TDCs. Though challenging, early diagnosis improves morbidity and mortality. In 
conclusion, ESRD patients are at increased risk for cryptococcal infections, regardless of
HIV-status. Further studies are needed to better understand the pathogenesis and treatment 
of cryptococcosis in ESRD patients.
PUB701 
Publication-Only 
Treatment of Idiopathic Hyperammonemia Syndrome in a Post-Lung 
Transplant Patient
Meaghan S. Roche, Tiffany Wong. Hospital of the University of Pennsylvania, 
Philadelphia, PA.
Introduction: Idiopathic hyperammonemia syndrome (IHS) is a rare but well-
described phenomenon occurring after solid organ transplantation. Here, we describe a case 
of IHS in a lung transplant recipient, which required renal replacement therapy as well as 
antibiotics and nitrogen-scavenging agents and was eventually attributed to donor-derived 
infection with a urea-splitting organism.
Case Description: A 62-year-old gentleman with a history of chronic obstructive 
pulmonary disease underwent bilateral orthotopic lung transplantation. He became acutely 
obtunded on post-operative day 13, and labs revealed an ammonia level of 489 umol/L (post-
op day 0 ammonia level was 45). Renal replacement therapy was initiated with intermittent 
hemodialysis followed by continuous venovenous hemodialysis, with marked reduction in 
blood ammonia levels to less than 100 umol/L within 48 hours. He was empirically started 
on levofloxacin as well as Ammonul, and he was noted to have a large pericardial effusion. 
The pericardial fluid grew Mycoplasma hominis, which is a urea-splitting organism that has 
been associated with hyperammonemia. With the combination of prompt renal replacement 
therapy, nitrogen-scavenging agents, and antibiotics, the patient’s ammonia levels returned 
to normal, and he was discharged home on post-operative day 59.
Discussion: (1) Review the metabolism of ammonia in normal and pathologic states 
(2) Recognize IHS due to urea-splitting organisms in the immediate post-operative period 
following lung transplant (3) Discuss renal replacement therapy options for lowering blood 
ammonia levels Ammonia is produced by amino acid metabolism and converted to urea
by the liver. The brain and skeletal muscle also metabolize small amounts of ammonia
by generating glutamine, which is then metabolized by the kidney to regenerate ammonia
and subsequently excreted in the urine. Ureaplasma and Mycoplasma species produce
urease and generate ammonia, and disseminated infection or transmission from a donor
organ can cause IHS. There are no current guidelines to initiate dialysis in patients with
hyperammonemia, though intermittent hemodialysis removes ammonia most efficiently.
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Renal Replacement Strategy in a Critically Ill Patient with Severe 
Azotemia and Hyponatremia
Muhammad O. Hanif, Abbas Raza, Marc J. Kim, Al J. Lee, Sandeep Aggarwal, 
Hasan Arif. Drexel University, PHILADELPHIA, PA.
Introduction: Severe Azotemia and hyponatremia in AKI with CKD is always difficult 
to manage in critically ill patients who end up requiring renal replacement therapy. Rapid 
correction of hyponatremia and reduction of BUN can lead to osmotic demyelination and 
dialysis disequilibrium syndrome. We are presenting a case of 66 year old female with 
multiple comorbids requiring Continuous Venovenous Hemodialysis(CVVHD) for severe 
uremia and hyponatremia.
Case Description: A 66 year old female with past medical history of CKD stage 3b 
with baseline creatinine(Cr) of 1.2 mg/dL, DM2, hypertension, depression, hepatitis C, 
CVA with residual aphasia, seizures, and dysphagia presented from nursing home with 
bradycardia, hypothermia and hypotension was found to have non-oliguric AKI over CKD 
with significantly raised BUN of 327 mg/dL, Cr of 4.17 mg/dL, hyperglycemia of 430 mg/
dL with a serum sodium(Na) of 116 meq/L corrected for glucose to 121 meq/L, potassium 
of 5.5 meq/L, chloride of 80 meq/L, HCO3 of 15 meq/L with high anion gap metabolic 
acidosis secondary to lactic acidosis, respiratory acidosis and anemia with hemoglobin of 3.9 
gm/dL due to upper GI bleed. She was initially resuscitated with IV fluids, IV bicarbonate, 
started on pressors, insulin infusion for hyperglycemia, IV Proton pump inhibitors for the 
GI bleed and later on intubated due to respiratory distress. She was started on CVVHD 
due to diffuse EKG changes. Her calculated dialysate dose was 2.5 L/hr (30ml/kg 
for a 88kg) but we started her at 1L/hr. We also calculated the urea reduction ratio(URR) 
via Kt/V= -ln(1-URR) which we estimated of 29%, but her URR came out to be 43% after 
the first day of treatment, after which we held the CVVHD for 8 hours and then restarted 
it again. Adequate sodium correction was monitored by obtaining ABGS with critical care 
panels every 2 hours, which showed a rise from 121 meq/L to 128 meq/L in first 24 hours 
and to 136 meq/L in the next 24 hours. Her BUN was gradually reduced from 327 mg/dL to 
103 mg/dL over a period of 2 days and she was extubated with adequate urine output, EKG 
normalized and CVVHD discontinued.
Discussion: Our experience showed that frequent use of URR equation and low 
dialysate rate can be a useful tool in patients on CVVHD with severe azotemia and 
hyponatremia to avoid dialysis disequilibrium syndrome and osmotic demyelination.
PUB703 
Publication-Only 
An Unusual Case of Hemodialysis-Associated Thrombocytopenia and 
Severe GI Bleeding
Gerard Martins,1 Swati Lederer,2,1 Jeffrey G. Penfield.2 1UTSouthwestern, 
Dallas, TX; 2VA North Texas Health Care System, Dallas, TX.
Introduction: Transient, mild, and asymptomatic thrombocytopenia (TCP) from 
hemodialysis (HD) has been reported. Clinically significant bleeding from HD-associated 
TCP has not been previously described.
Case Description: An 82-year-old Caucasian male with baseline TCP (120,000-
150,000/μL) and no prior history of GI bleeding (GIB) was initiated on HD. Thereafter 
he was admitted 5 times for worsening TCP and severe GIB, requiring 40 units of PRBCs 
and 13 units of platelets. Workup revealed AV malformations. Patient complained of severe 
fatigue and chills during dialysis and associated each GIB event with HD treatment. A 
pre- and post-HD CBC revealed profound post-HD TCP, prompting concern for a dialyzer 
reaction. His polysulfone (PS) electron beam (EB)-sterilized dialyzer was switched to a 
polyarylethersulfone (PAES) and polyvinylpyrrolidone (PVP) steam-sterilized dialyzer 
with marked improvement in post-HD TCP and cessation of GIB (Figure 1).
Discussion: Severe and sustained TCP has been described in case reports. Most 
cases have been associated with PS EB-sterilized dialyzers. One prospective observation 
study revealed a significant improvement in post-HD TCP after switching to non-EB-
sterilized dialyzers. EB-sterilization may alter the surface property of PS-dialyzers, thereby 
increasing platelet activation. Modified PS dialyzers appear to be associated with less TCP. 
We are describing the most severe case of HD-associated TCP that has been documented 
with use of an EB-sterilized PS dialyzer. Unexplained TCP with HD should prompt workup 
for a dialyzer reaction. Further research is needed to better characterize the mechanism of 
HD-related TCP and its risk factors.
Figure 1: Pre- and post-HD platelet counts after dialyzer change
PUB704 
Publication-Only 
Nocardia Peritonitis: A Rare Case of Peritoneal Dialysis Associated 
Peritonitis
Sunitha Kalyanam, Sarah A. Johnson. Nephrology, Emory University School Of 
Medicine, Atlanta, GA.
Introduction: Nocardia is a very rare cause of peritoneal dialysis (PD) associated 
peritonitis with only a few case reports reported. It is ubiquitous in soil, water and vegetable 
matter and known to cause infection in immunocompromised hosts. We report a rare case 
of PD associated peritonitis caused by Nocardia Asteroides.
Case Description: A 76 year old female with a history of ESRD on PD using a cycler 
for 4 years presented with symptoms concerning for peritonitis on day 1 received 2 doses of 
ceftazidime and 3 doses of vancomycin as an outpatient. She was admitted to the hospital 
on day 10 for a diffuse skin eruption thought to be a drug reaction to the cephalosporin. 
She was afebrile with stable vitals but a WBC count of 31, 000. Outpatient peritoneal 
cultures reported growing a gram positive organism, AFB positive. Repeat peritoneal 
fluid analysis showed no evidence of peritonitis with a cell count of 70/mcL and negative 
culture. However, she had an increasing WBC count with abdominal pain so cultures 
were repeated a third time. The culture was positive for Nocardia Asteroides sensitive 
to Sulfamethoxazole/Trimethoprim (TMP-SMX). CT scan of the abdomen-pelvis was 
concerning for a pancreatic mass. MRI with contrast showed 1cm intra-ductal pancreatic 
neoplasm, with benign appearance and recommended 1 year follow up. She was scheduled 
to follow up with Surgical -Oncology after discharge. She was treated with IV TMP-SMX 
for three weeks and her PD catheter was removed as she transitioned to hemodialysis at 
which time she began to improve clinically.
Discussion: Nocardiosis is an opportunistic infection and because of the slow growth, 
difficult to isolate. Partially acid fast, filamentous branching rods are pathognomonic of 
Nocardia. TMP-SMX is the drug of choice. The peritonitis has been treated successfully 
with both removal and retention of the PD catheter. Optimum duration of treatment for 
Nocardia Peritonitis is not known, usually 3 weeks is recommended and treatment is 
tailored to individual patients. Duration may need to be prolonged as it has the propensity 
to relapse on appropriate treatment. Our patient may also have an undiagnosed pancreatic 
malignancy causing her to be susceptible to this organism.
PUB705 
Publication-Only 
A Rare Cause of Outflow Tract Obstruction in Peritoneal Dialysis, 
Pleuroperitoneal Leakage
Natanong Thamcharoen,1 Danwen Yang,2 Sylvia E. Rosas.3 1Nephrology, Beth 
Israel Deaconess Medical Center, Boston, MA; 2Bidmc, Boston, MA; 3Joslin 
Diabetes Center, Boston, MA.
Introduction: Pleuroperitoneal leakage is a complication in peritoneal dialysis(PD). 
Although it is rare, we should be familiar with this condition.
Case Description: A 54-year-old woman with ESRD on PD presented with inability to 
drain the dialysate. PD was started 10 months ago without issues and she was converted to 
automated cycler 2 months ago. She reports mild dyspnea, chest discomfort when lying flat 
and dry cough for 1 month. The physical exam showed decreased breath sound on right with 
dullness to percussion. Abdomen was soft, no tenderness. No redness, discharge at exit and 
tunneled site. Chest x-ray showed right sided pleural effusion. Right sided Thoracocentesis 
showed pleural fluid protein <0.2 g/dL LDH 15 IU/L Glucose 642mg/dL and pH 7.51. Cell 
differential and count did not suggest infectious process. High glucose level and alkaline 
pleural fluid gave the suspicion of dialysate pleuroperitoneal leakage. A radiotracer(Tc-99m 
DTPA) was injected via PD catheter in supine position. The images showed uptake above 
the diaphragm on right pleural space suggesting the leakage(figure). Video-assisted thoracic 
surgery (VATS) was performed, found 1.5 mm pore on the dome of diaphragm. The pore 
was sutured and doxycycline pleurodesis was done. PD was terminated and patient was 
converted to hemodialysis for 4 months, PD eventually was resumed again successfully.
Discussion: Pleural effusion with high glucose level and alkaline pleural fluid is 
suggesitve of this condition. It tends to occur early after initiating PD or change to cycler 
as this patient. Radionuclide scan, CT and MRI with tracer can be used to diagnose with 
moderate sensitivity(40-50%). Conservative treatment with PD interruption should be done 
for at least 4-6 weeks and if it has failed, invasive procedures such as pleurodesis or VATS 
can be applied.
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Candida albicans Peritonitis with Urgent Start Peritoneal Dialysis in a 
Patient with aHUS Treated with Eculizumab
Heedeok Han,1 Sayee Sundar Alagusundaramoorthy,1 Ali I. Gardezi,1 
Micah R. Chan.2 1University of Wisconsin, Madison, WI; 2University of 
Wisconsin-Madison, Fitchburg, WI.
Introduction: Fungal peritonitis occurs in about 2-13% of patients who undergo 
peritoneal dialysis (PD). Although rare, fungal peritonitis is a very serious complication 
with high rates of hospitalization, catheter removal, transfer to hemodialysis and death. 
The most commonly isolated species with fungal peritonitis is candida sp., with Candida 
albicans being the most frequently isolated organism. Common risk factors associated 
with the development of fungal peritonitis include episodes of bacterial peritonitis, recent 
antibiotic use, and immunosuppression. Atypical hemolytic uremic syndrome (aHUS) is a 
hereditary disease process that occurs due to dysregulation in the complement cascade. It 
typically presents with a triad of microangiopathic hemolytic anemia, thrombocytopenia and 
acute renal failure secondary to thrombotic microangiopathy. Eculizumab, a monoclonal 
antibody against C5, is the mainstay in the treatment of aHUS and its introduction has made 
prevention of ESRD a possibility. However, some patients do develop ESRD despite the 
treatment and require chronic renal replacement therapy (RRT). Although Eculizumab is 
known to increase susceptibility to meningococcal infections, case reports of intraabdominal 
fungal infection while being treated with eculizumab have been rare.
Case Description: We present a case of Candida albicans fungal peritonitis within 
24 hours of a fluoroscopically placed peritoneal dialysis catheter in an ESRD patient 
maintained on Eculizumab for aHUS. The patient was given surgical prophylaxis for 
bacterial pathogens, but not for fungal pathogens prior to the PD catheter placement. 
Patient clinically improved after removal of PD catheter and was treated with IV then oral 
fluconazole.
Discussion: Perhaps surgical prophylaxis for bacterial and fungal pathogens is 
indicated in patients undergoing PD catheter placement who are treated with eculizumab.
PUB707 
Publication-Only 
A Typical Peritoneal Dialysis Patient with an Atypical Cause of 
Hyperparathyroidism
Praveen K. Errabelli,1 Manisha Singh.2,1 1University of Arkansas for medical 
Sciences, Little Rock, AR; 2University of Arkansas For Medical Sciences, Little 
Rock, AR.
Introduction: We present a patient on peritoneal dialysis with a combination of normal 
gland; hyperplasia, a gland replaced by fibrous tissue and an ectopic gland, emphasizing that 
there may be role of dual imaging prior to surgical intervention.
Case Description: A 58 y/o women on peritoneal dialysis developed severe Tertiary 
hyperparathyroidism. She was unable to tolerate cinacalcet. Surgical resection was done 
after Ultrasound showed enlarged glands. Upon resection, ¼ glands were normal, 2/4 
glands had hyperplasia and 1/4 glands pathology revealed fibrous tissue. However post-
resection PTH did not change significantly even one month after surgery. Contrast CT of 
neck showed 2 cm x 1 cm ectopic gland in right superior mediastinum located between 
vertebral and subclavian artery. Resection of ectopic gland through transcervical approach 
was planned. However patient refused surgery which was deemed high risk given the 
critical location of the gland.
Discussion: End Stage Renal Disease patients usually have hyperparathyroidism 
secondary to hyperplasia or adenomas or a combination. If unable to tolerate medical 
management they undergo subtotal or total parathyroidectomy (1). Ectopic adenomas are 
commonly in thymus, retroesophageal and intrathyroidal areas (3). Accurate localization is 
needed to improve outcomes [1]. Sestamibi (MIBI) has higher sensitivity (89%) than USG 
(59 %) for detecting ectopic glands. MIBI accurately locates ectopic glands in the thymus, 
mediastinum or retroesophageal space and USG accurately detects intrathyroidal glands 
[2].This suggests that combining preoperative USG and Sestamibi can help locate ectopic 
parathyroid glands effectively and prepare for focussed surgical intervention which is both 
time and cost effective.
Ectopic parathyroid adenoma close to apex of right lung
PUB708 
Publication-Only 
Peritoneal Dialysis (PD) Cell Count May Not Always Diagnose Intra-Ab-
dominal Catastrophe
Justin Lee Loy, Mayanka Kamboj, Ashutosh M. Shukla. Division of Nephrology, 
Hypertension and Renal Transplantation, University of Florida, Gainesville, 
FL.
Introduction: Abnormalities in PD fluid, e.g. high white or red cell counts, bilious 
or chylous peritoneum, and particulate matter etc. can assist in early diagnosis of intra-
abdominal events. A benign PD fluid in a patient with otherwise stable abdominal 
examination makes the diagnosis of intra-abdominal catastrophe highly unlikely. We 
present an unusual case, where equivocal radiological findings and benign PD fluid 
cytology contributed to uncertain diagnosis and adverse patient outcome.
Case Description: A 60-year-old female with end-stage renal disease on PD was 
admitted with nausea and vomiting. She had benign abdominal examination, no exit site 
abnormality, peritoneal signs, or evidence for focal findings. CT scan revealed small bowel 
obstruction with free intraperitoneal air and a transition point in the right lower quadrant, 
concerning for internal hernia. Repeated PD fluid analysis revealed 62-73 WBC with 3-5% 
neutrophils. After 3 days of conservative management and unchanging clinical course, 
exploratory laparotomy was performed which showed matted bowel lumens in right lower 
quadrant requiring resection of ileum and right hemi-colon. Pathology examination showed 
the features of early Encapsulating Peritoneal Sclerosis (EPS). Post-operative course was 
complicated by recurrent intra-abdominal bleedings, multiple laparotomies, splenectomy, 
and death by day 14.
Discussion: Encapsulating Peritoneal Sclerosis (EPS) is an uncommon but well-
reported complication of chronic peritoneal dialysis (PD). History of recurrent peritonitis, 
indolent onset, malnutrition, and radiological findings are typical presenting findings in 
these patients. However, acute abdomen presentation with non-inflammatory PD cytology 
with or without EPS is considered unlikely and has been rarely reported. We present a 
unique case where incongruent symptomatology, radiological findings and benign PD cell 
counts could not definitively rule out an internal herniation requiring a surgical approach 
and adverse outcome. Through this case, we conclude that a non-inflammatory PD fluid 
cytology could provide an important indication for EPS in PD patients who present with CT 
findings of possible acute abdomen but are clinically stable. Special considerations for an 
ongoing trial for conservative management may save lives in such situations.
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Low Dose Gabapentin Therapy Resulting in Bilateral Lower Extremity 
Edema in a Young Female Peritoneal Dialysis Patient
Alissa Ice, Farshid Yazdi, Mihran V. Naljayan. Louisiana State University 
Health Sciences Center New Orleans, New Orleans, LA.
Introduction: Peripheral edema is a known side effect of gabapentin with an incidence 
of roughly 6-8%. This adverse effect has mainly been noted in elderly patients at high 
(>1200 mg/d) doses of gabapentin. It is unclear whether renal dysfunction may contribute 
to this clinical finding. We report the first case of gabapentin induced lower extremity edema 
in a young female patient on peritoneal dialysis.
Case Description: A 36 year old female with end stage kidney disease secondary to 
lupus glomerulonephritis syndrome, WHO class IV and V, on peritoneal dialysis presented 
to clinic with bilateral lower extremity edema one month after initiating gabapentin 
therapy with symptomatic resolution upon discontinuation. The patient began experiencing 
progressive edema approximately two weeks after starting gabapentin 100-300 mg/d for 
her peripheral neuropathy. She presented to clinic with 2+ bilateral pitting lower extremity 
edema and an 8 kg increase in weight one month after beginning therapy. Prior to the onset 
of her lower extremity edema, there were no recent significant changes to her prescribed 
medications, continuous cyclic peritoneal dialysis (CCPD) regimen, or laboratory results 
(albumin remained between 3.3-3.7 g/dL). She had no history of lower extremity edema 
since beginning peritoneal dialysis in 2016. Upon discontinuing the drug, the patient’s 
swelling resolved over the course of one week, and she returned to her target weight. The 
patient was then started on pregabalin 25 mg/d with no subsequent edema.
Discussion: The incidence of gabapentin related peripheral edema has been shown 
at higher doses and tends to increase with age. This unique case illustrates the necessity 
to consider this medication effect in younger populations and at lower doses, particularly 
with decreased renal clearance such as in patients on peritoneal dialysis. Gabapentin is 
frequently used in this patient population due to multiple comorbidities that increase the 
risk of developing peripheral neuropathy; therefore, we must remain cognizant of this 
particular side effect as these patients are prone to develop peripheral edema due to other 
various etiologies. Interestingly, despite some studies showing an increased prevalence of 
peripheral edema in patients using pregabalin compared to gabapentin, this patient did not 
develop edema after initiation of pregabalin.
PUB710 
Publication-Only 
Sweet Hydrothorax: Comparing Pleural Effusions in Two Peritoneal 
Dialysis Patients
Naseem Khorram,1 Ramzi B. Vareldzis,4 Farshid Yazdi,3 Mihran V. Naljayan.2 
1LSU Health Sciences Center New Orleans, New Orleans, LA; 2LSUHSC School 
of Medicine, New Orleans, LA; 3Louisiana State University Health Sciences 
Center New Orleans, New Orleans, LA; 4LSU, New Orleans, LA.
Introduction: Pleural effusion in patients receiving peritoneal dialysis (PD) has a 
prevalence ranging from 1.2%-10%. When hypertonic dialysate enters the pleura it forms 
a ‘sweet hydrothorax’ (transudative effusion with elevated glucose compared to serum 
glucose). Underlying mechanisms include an increased intra-abdominal pressure with 
acquired weakening of the diaphragm and impaired lymphatic drainage. We report two 
cases of patients receiving PD with right-sided pleural effusions.
Case Description: Patient 1- A 59 year old female with ESRD on PD presented to 
the ED with shortness of breath and nonproductive cough. Four days prior to presentation 
she fell and sustained a left 10th rib fracture. Following her fall she noticed reduction in 
ultrafiltrate volume and increasing shortness of breath. She was found to have a significant 
right pleural effusion associated with hypercapnia (pCO2 62.7 mmHg) and hypoxia 
(pO2 59 mmHg). Thoracentesis removed 1700 mL of fluid in the ED followed by 1500 
mL the following day. Pleural fluid was transudative with elevated glucose compared 
to serum glucose (502 mg/dL and 169 mg/dL, respectively). Patient 2- A 64 year old 
female with ESRD on PD for 2 months presented to the ED with shortness of breath and 
nonproductive cough worsening over several days. She was found to have a large right 
sided pleural effusion that was removed with thoracentesis (1200 mL). Pleural fluid was 
transudative with elevated glucose compared to serum glucose (148 mg/dL and 82 mg/dL, 
respectively). She resumed PD with lower volumes and returned to the ED the following 
day with shortness of breath and a re-accumulated right-sided pleural effusion for which she 
did not undergo thoracentesis.
Discussion: These cases highlight etiology of the PD effusion (trauma and congenital 
diaphragmatic abnormality) and the use of pleural fluid glucose levels in identification of 
the ‘sweet hydrothorax’. Although the site of trauma in patient 1 was on the left, the PD 
effusion was present on the right indicative of the consistent laterality of such effusions. 
Furthermore, while patient 2 had a glucose level that was not notably elevated as in patient 
1, it was sufficiently raised from her serum glucose. This suggests body fluid glucose 
content alone should not be so heavily relied upon for diagnosis of pleuroperitoneal leak.
PUB711 
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Using Indocyamine Green to Diagnose Hydrothorax in Peritoneal Dialysis
Jun Young Lee,1 Jae seok Kim,4 Seung-Ok Choi,3 Jae Won Yang,2 Byoung 
Geun Han.1 1Wonju Christian Severance Hospital, Wonju, Kangwon do, 
Republic of Korea; 2Wonju Christian Hospital, Wonju, GANGWON-DO, 
Republic of Korea; 3Yonsei University Wonju College of Medicine, Wonju, 
Kangwon, Republic of Korea; 4Yonsei wonju college of medicine, Won-ju, 
Republic of Korea.
Introduction: Massive hydrothorax is uncommon, but important complication of 
peritoneal dialysis. Several methods were used to diagnose hydrothorax in peritoneal 
dialysis patients. However, there was no single definite method to diagnose hydrothorax 
with peritoneal dialysis patients. Here we report two cases who were diagnosed hydrothorax 
by using indocyanine green mixing test.
Case Description: CASE 1 A 50-year-old female with PD secondary to diabetic 
nephropathy visited the emergency room because of abdominal pain and diarrhea. She 
was treated already for five months with CAPD. Her chest radiograph showed a right-
sided pleural effusion. Thoracentesis was performed and her pleural fluid was transudate 
(Table 1). There was no evidence of heart failure and liver cirrhosis. CAPD peritonitis 
was improved by intraperitoneal antibiotics. Peritoneal scintigraphy showed no definite 
abnormality. To confirm the origin of pleural fluid, we mixed ICG on the peritoneal fluid in 
infused through Tenkhoff catheter. After injected ICG mixed (green color) peritoneal fluid, 
pleural fluid was drained with green color. CASE 2 A 78-year-old female with ESRD on 
PD secondary to diabetic nephropathy visited the emergency room because of shortness of 
breath. She had been started CAPD for 33 months. On brief sonography demonstrated a 
massive right-sided pleural effusion and pleural fluid revealed transudate (Table 1). There 
was no evidence of heart failure and liver cirrhosis. ICG was mixed in peritoneal fluid and 
injected (2L) to peritoneum then green color pleural fluid was drained via the pleural fluid.
Discussion: ICG is non-toxic, water soluble dye that is used for cardiac output 
measurement, hepatic function estimation, and retinal microcirculation assessment. 
Toxicity of ICG is low incidence and mild allergic reactions. In conclusion, we recommend 
that ICG mixing test may be a reliable, simple, non-harmful, and non-expensive method 
in differentiating pleuroperitoneal communication from other causes of transudate 
hydrothorax in PD patients.
Table 1. Results of serum, pleural fluid in two cases of CAPD related hydrothorax.
LDH=lactic dehydrogenase; PE=pleural fluid; TP= Total protein.
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Conversion from Peritoneal Dialysis (PD) to Hemodialysis (HD) in 
Patients with Calciphylaxis
John Y. Choi,1 Sagar U. Nigwekar.2 1BWH-MGH nephrology fellowship, 
Brookline, MA; 2Massachusetts General Hospital, Cambridge, MA.
Introduction: Calciphylaxis is a rare but devastating skin disease in the end-stage renal 
disease (ESRD) population. Treatment options are limited, and the utility of conversion 
from PD to HD in patients diagnosed with calciphylaxis remains unclear.
Case Description: A 46-year-old female with morbid obesity, paroxysmal atrial 
fibrillation on warfarin, poorly controlled diabetes mellitus (DM), ESRD on PD presented 
to a hospital with painful skin lesions over bilateral thighs. Her outpatient clinic reported 
gradual loss of renal reserve over the past year resulting in up-titration of her PD prescription. 
Her parathyroid hormone and phosphate level were refractory to medical therapy. Her skin 
examination revealed indurated plaques over both thighs. Skin biopsy was consistent with 
a new diagnosis of calciphylaxis. Her home medications containing calcium and vitamin D 
were discontinued. Warfarin was substituted with a direct anti-Xa inhibitor. After discussion 
of the risks and benfits, the patient agreed to convert from PD to HD with a plan to start 
intravenous sodium thiosulate.
Discussion: It remains unclear if patients on PD will benefit from converting to HD 
when calciphylaxis is diagnosed. Concerns have been raised with some studies suggesting 
a higher incidence of calciphylaxis reported in the PD population when compared to the 
HD population. Furthermore, experts at the first calciphylaxis consensus meeting supported 
intensifying dialysis treatment which included switching from PD to HD. However, 
outcome data surrounding dialysis intensification is mixed. While Baldwin et al. published 
a case series of successful treatment of calciphylaxis by utilizing intense HD, Santos et al. 
conducted a retrospective analysis of single center data showing increased risk of mortality 
associated with intense HD. In order to provide the best care for PD patients who develop 
calciphylaxis, further studies to compare outcomes between continuation of PD versus 
conversion to HD are needed.
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Sweet Hydrothorax
Ahmed Subahi, Sulaiman J. Barkho, Zeenat Y. Bhat. Wayne State University/ 
Detroit Medical Center Wayne State University/Detroit Medical Center, 
Dearborn, MI.
Introduction: Peritoneal dialysis (PD) Patients can develop various complications, one 
such rare complication is hydrothorax.
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Case Description: A 35-year-old man with a history of hypertension, and end-stage 
renal disease secondary (ESRD) on peritoneal dialysis (started six-weeks earlier) presented 
due to right-sided pleuritic chest pain that started one day before admission. Over the 
preceding days, he had noticed an unexplained low drainage volume of dialysate. Vital signs 
were normal. Physical examination revealed decreased air entry on auscultation at the right 
side. Chest X-ray revealed a massive right-sided pleural effusion. Laboratory evaluation 
demonstrated renal dysfunction indicative of his ESRD status with unremarkable complete 
blood count and liver function test. Ultrasound-guided thoracentesis was performed, and 
2300 ml of clear pleuritic fluid was removed without complications. The fluid analysis 
revealed a high glucose concentration of 447 mg/dl. The fluid was a transudate according to 
the Light’s criteria (Table 1). PD dialysis was temporarily ceased, with very close monitoring 
of his labs and plan to re-introduce peritoneal dialysis with low-volume exchanges.
Discussion: PD related hydrothorax is rare and can be seen in 2% of the PD patients 
due to congenital or acquired diaphragmatic defects with a consequent peritoneo-pleural 
migration of the dialysate. Effusion can develop shortly or several weeks to months after 
commencing PD. The pleural-fluid analysis is usually diagnostic, revealing a clear fluid 
with a low protein and a high glucose concentration (sweet hydrothorax). Pleural-serum 
glucose gradient of more than 50 mg/dL has a 100% sensitivity and specificity to detect PD 
related pleural effusion. Temporary (2–6 weeks) interruption of CAPD is recommended as 
a first-line conservative option which can prevent effusion recurrence in approximately 50% 
of the cases. Other treatment options include chemical pleurodesis via chest drain, limited 
thoracotomy, and video-assisted thoracoscopy. Teaching points Hydrothorax can occur at 
any time after PD initiation. The pleural-fluid analysis is diagnostic. Interruption of PD is 
recommended as a first-line therapy.
Table 1. Chemical analysis of the simultaneously drawn serum and pleural fluid
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Treatment of Mycobacterium Abscesses Exit Site Infection: Looks Can Be 
Deceptive
Gajapathiraju Chamarthi,1 Mayanka Kamboj,3 Judith E. Sallustio,4 
Lennox K. Archibald,2 Ashutosh M. Shukla.1 1University of Flroida, Gainesville, 
FL; 2University of Florida, Gainesville, FL; 3University of florida, Gainesville, 
FL; 4VAMC Gainesville, FL, Gainesville, FL.
Introduction: Exit site infections (ESI) caused by Mycobacterium abscessus (a 
rapidly growing nontuberculous mycobacterium) in patients on peritoneal dialysis 
(PD) are uncommon and difficult to treat. Successful intraperitoneal (IP) antimicrobials 
regimen for M. abscessus ESI has not been established and most patients require systemic 
therapy with switch to hemodialysis. We report a case of M. abscessus ESI that resolved 
clinically following 9-month therapy with IP agents, only to relapse within a short-time of 
discontinuation of therapy leading to catheter removal.
Case Description: A 55-year-old man with a history of IgA nephropathy, on PD 
for 2 years without any prior peritonitis, presented with a large ulcer surrounding the 
exit site with hypertrophied granulation tissue. M. abscessus was isolated from the exit 
site without any evidence of peritonitis. Because of patient’s strong desire to continue PD 
to maintain his sailing lifestyle, IP amikacin and imipenem with oral azithromycin was 
commenced. IP antimicrobial levels were serially checked and amikacin was discontinued 
after 3 weeks because of ototoxicity. Because of clear clinical improvement and absence of 
peritonitis, the patient was continued on imipenem and azithromycin for a total of 9 months 
and discontinued once the ulcer appeared healed circumferentially. Within one month of 
discontinuation of therapy, he suffered an ESI relapse with expanding erythema and ulcer 
margins. This led to surgical removal of the PD catheter, surgical debridement, conversion 
to HD, and need for intravenous and oral therapy.
Discussion: We report an unusual case of M. abscessus ESI in an otherwise 
immunocompetent patient with no previous history of peritonitis or ESI. We found that 
though an extended course of IP antimicrobial therapy led to ostensibly complete ESI 
resolution, rapid relapse occurred once treatment was discontinued. In conclusion, extended 
courses of IP antimicrobial therapy with attention to therapeutic drug monitoring may 
enable successful therapy of certain infections in PD patients. However, for patients with 
M. abscessus ESI, PD catheter removal should be strongly considered.
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Treatment of Acyclovir Neurotoxicity for a Patient with ESRD on 
Peritoneal Dialysis
Jana Havranova, Satyam Arora. St. Luke’s University Hospital, Bethlehem, PA.
Introduction: Neurotoxicity is a rare side effect of acyclovir therapy. Because of its 
renal clearance, adjustment of acyclovir dosage is necessary for patients with End Stage 
Renal Disease (ESRD) on hemodialysis or peritoneal dialysis. We report a case of the 
successful treatment of acyclovir neurotoxicity in a patient on peritoneal dialysis (PD).
Case Description: A 39 year old female with a past medical history of ESRD on PD 
was hospitalized because of new onset agitation, anxiety, visual and auditory hallucinations. 
Two days prior to initiation of symptoms, patient was unfortunately started on acyclovir 
with dosage of 1000mg three times a day for herpes zoster. CT and MRI of the head and 
blood work did not reveal any abnormalities. Neurotoxicity of acyclovir was suspected. 
Acyclovir blood level however, was 2.6 (normal therapeutic level 0.12-10.8). Since no other 
obvious cause, acyclovir was discontinued and patient was initiated on CAPD with 2.5% 
Dianeal 1.5 liters fills and every 4 hours exchanges. After 2 days of CAPD acyclovir blood 
level decreased to zero. Symptoms of agitation, anxiety and hallucination improved in 24 
hours and resolved in 48 hours after initiation of more frequent PD treatments.
Discussion: In this case, successful treatment of acyclovir toxicity with peritoneal 
dialysis was achieved without having to transition to hemodialysis. Herpes zoster is a 
common condition seen quite often in the offices of primary care providers or urgent clinics 
and obvious care needs to be taken when prescribing acyclovir to patient with ESRD. 
In addition to discontinuing acyclovir and close neurological monitoring, we validate 
that acyclovir neurotoxicity will improve by increasing manual PD exchanges and is an 
acceptable approach in treatment of this potentially fatal complication. We do also suggest 
that more research needs to be done to validate therapeutic acyclovir drug levels in patients 
with ESRD.
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Tuberculous Peritonitis Masquerading as Diabetic Gastroparesis
Kishore Patcha,1 Divya Raghavan,1 Laith Al-Rabadi,2 Josephine Abraham.1 
1University of Utah, Salt Lake City, UT; 2University of Utah hospital, Salt Lake, UT.
Introduction: The incidence of tuberculosis (TB) in patients from industrialized 
nations is relatively low. However, patients on dialysis have a five to fifteen times higher 
risk of developing TB compared to the general population. This is attributed to malnutrition, 
alterations in cellular immunity and associated comorbidities.
Case Description: A 42-year-old male Filipino immigrant with end stage renal 
disease secondary to diabetic nephropathy on peritoneal dialysis (PD) was admitted with 
hypotension, progressive weakness and worsening abdominal pain. He had been hospitalized 
multiple times previously with anorexia, weight loss, nausea, vomiting and abdominal pain. 
After extensive work up, his symptoms were attributed to gastroparesis. A week prior to 
admission, the patient underwent peritoneal fluid testing for worsening hypotension which 
showed WBCs >200/μL and he was started on intraperitoneal vancomycin and ceftazidime. 
Blood and peritoneal fluid cultures remained negative. Repeat peritoneal fluid analysis 
on admission showed WBC 265/μL with 56% neutrophils, 13% lymphocytes and 19% 
monocytes. He was started on IV vancomycin and ceftazidime and the PD catheter was 
removed. A tunneled hemodialysis catheter was placed and patient was transitioned to 
hemodialysis. Interferon (IFN)-gamma release assay was indeterminate, but peritoneal fluid 
acid fast bacillus culture came back positive for Mycobacterium tuberculosis. Treatment 
was initiated with Rifampicin, Pyrazinamide, Isoniazid and Ethambutol. Two months 
after treatment for peritoneal TB, he was readmitted with back pain. MRI demonstrated 
osteomyelitis of T5-T6 with complex paraspinal abscess and epidural extension causing 
spinal canal narrowing. Infectious disease service recommended a total of 9 months of 
treatment for his vertebral tuberculosis.
Discussion: Peritoneal TB is less commonly reported than other forms of TB. It is 
very challenging to diagnose since regular aerobic cultures do not grow the organism and 
even culture for acid fast bacillus has a yield of only 15-30%. The diagnosis of tuberculous 
peritonitis in PD patients is frequently delayed and this increases morbidity and mortality. 
It is important to consider this differential diagnosis in the setting of culture negative 
peritonitis in patients from endemic regions.
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Successful Management of Dislodged/Floating Venous Hardware in ESRD 
Patients
Loomee Doo,1 Phillip Ribeiro,2 Rizwan A. Qazi.3 1Internal Medicine, University 
of Nevada Las Vegas, Las Vegas, NV; 2Nephrology, Vanderbilt University, 
Nashville, TN; 3KSOSN, Las Vegas, NV.
Introduction: Interventional nephrology procedures are performed to maintain 
functional hemodialysis accesses. A functional access is critical in ESRD patients and 
complications associated with interventional nephrology procedures include arterial 
and venous ruptures, clot embolizations, dislodged vascular stents, and ruptured balloon 
fragments. We present two cases of successful management of dislodged and floating 
venous hardware in ESRD patients.
Case Description: Case 1: A 80 year old female on hemodialysis for more than 7 years 
with a left upper arm brachial cephalic fistula who was referred for left upper extremity 
swelling. Angiogram revealed 80% stenosis of the left innominate vein (in STENT stenosis), 
and angioplasty was done with a 14x40mm balloon which ruptured and then degloved in 
the process of being removed. A sizeable portion of the balloon was free floating in the 
left innominate vein distal to the previously placed stent. Multiple retrieval attempts with 
a snare were unsuccessful. At this time a second 14x60mm Bard E. Luminexx bare metal 
biliary stent was placed and seated with a 14x40mm Vaccess balloon. Post angiogram 
showed good results with re-established flow (see figure1). Case 2: A 67 year old male with 
ESRD on hemodialysis via a left femoral thigh AVG who presented with a clotted access. In 
the process of placing a 8x50mm FLAIR stent graft, the stent dislodged and ended up in the 
left Iliac vein. Multiple retrieval attempts with a snare were unsuccessful. A WALLSTENT 
by Boston Scientific was placed and the floating stent was prevented from wandering into 
the pulmonary artery. For both cases, six week follow-up revealed a functional access and 
no extremity swelling.
Discussion: Dislodged vascular stents and ruptured balloon fragments are unfortunate 
complications of interventional nephrology procedures. Both of these complications can 
be successfully managed by placement of a second stent and in essence walling it off from 
the circulation.
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Preemptive Treatment with Sodium Thiosulfate May Offer Value as 
Prophylactic Treatment for Calciphylaxis
Shawn L. Marein, Natallia Maroz. Internal Medicine, Kettering Hospital, 
Kettering, OH.
Introduction: Calciphylaxis is a poorly understood disease process which has 
challenged the medical community since its discovery and continues to plague patients 
to this day. Although previously considered rare, incidence appears to be rising with 
current prevalence of ~4% in end stage renal disease (ESRD) patients. Optimal treatment 
for calciphylaxis is unknown, but sodium thiosulfate (STS) appears to be an emerging 
therapeutic option. Traditionally, this agent has been utilized once disease has already 
manifested as well as for secondary prevention following resolution. Here we describe two 
cases in which ESRD patients were treated with STS infusions preemptively before the 
development of painful wounds and have thus far avoided materialization of the disease.
Case Description: Case#1 28 years old black female with ESRD from lupus nephritis 
developed bilateral painful thigh lesions. She was hemodialysis dependent for 9 years, 
and required systemic anticoagulation with Coumadin since 2015 following aortic valve 
replacement. At the time of symptoms development patient had tertiary hyperparathyroidism 
which prompted partial parathyroidectomy. Preemptive therapy with STS was initiated and 
after 15 infusions patient had significant improvement in pain. She has not developed open 
wounds even though hard subcutaneous lesions are persistent. Her PTH have not improved 
significantly and complete parathyroidectomy is planned. Anticoagulation alternative 
to Coumadin have not been approved by hematology. Patient is now status post 22 STS 
infusions and stable. Case#2 37 year old black female with ESRD from lupus nephritis 
developed bilateral lower extremities hard painful lesions involving thigh and lower calves. 
She was on peritoneal dialysis for 18 months at the time of symptoms development. She had 
poorly controlled secondary hyperparathyroidism. MRI of lower extremities demonstrated 
calcified areas, Doppler was negative for thrombosis. Preemptive infusions of STS 
were initiated for 12 treatments. Patient had significant improvement in pain and almost 
completer resolution of subcutaneous hardening. Cinacalcet was used for suppression of 
hyperparathyroidism. She is at present sustains in remission for almost two years.
Discussion: Given the highly morbid nature of calciphylaxis, further investigation into 
preventative strategies and prophylactic agents such as STS are worthwhile.
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A Novel Use of Teduglutide in Treating Persistent Hypomagnesemia
Derian Lai, Jose J. Perez. Baylor College of Medicine, Houston, TX.
Introduction: We present a patient with hypomagnesemia due to chronic diarrhea 
and proton pump inhibitor (PPI) use. She required weekly intravenous (IV) magnesium 
infusions. In 2017, she was given a trial of Gattex® (Teduglutide) which improved her 
magnesium levels and provided better symptom control.
Case Description: Our patient is a 59 year old woman referred to nephrology clinic 
in 2012 for evaluation of hypomagnesemia. She reported abdominal pain and loose 
stools since 2009. Upper endoscopy revealed gastric ulcers. Omeprazole was prescribed. 
Colonoscopy showed collagenous colitis in 2010. Despite controlling her loose stools to 
a manageable level with budesonide and supplementing with oral magnesium, her low 
magnesium persisted. In 2013, her urine Magnesium was <42mg, indicating appropriate 
renal conservation of Magnesium. She had gained 25 pounds in the last 5 years. Her 
serum albumin is 4g/dL. Celiac’s disease serologies were negative. Her other nutritional 
deficiencies included iron deficiency and vitamin D deficiency. Omeprazole therapy 
was not able to be discontinued due to recurrence of pain. In 2015, she was started on 
weekly IV magnesium replacement. Her magnesium remained in the 0.5mg/dL to 1mg/dL 
range. In November 2017, her gastroenterologist referred her to a Gattex® (Teduglutide) 
representative to test the efficacy of Teduglutide in reducing her symptoms. She was able to 
take the drug for 2 months before she could no longer afford the medication. Remarkably, 
her loose stools decreased and her magnesium levels were maintained at the highest levels 
in 5 years (1.5md/dL to 1.9mg/dL). Unfortunately, after she discontinued the medicine her 
loose stools have returned and her magnesium levels have dropped once again.
Discussion: Our patient’s low magnesium is likely multifactorial from her PPI use as 
well as chronic diarrhea. Teduglutide was FDA approved to treat Short Bowel Syndrome 
in 2012. Teduglutide is a glucagon like peptide 2 analog that promotes intestinal growth 
and reduces the necessity for parental infusions in patients with malabsorption. Despite not 
having generalized malabsorption, our experience suggests that Teduglutide may have a role 
improving magnesium absorption in those with hypomagnesemia due to gastrointestinal 
losses. Further studies on its safety profile and efficacy in other nutritional and electrolytes 
deficiencies are warranted.
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Iatrogenic Diabetes Insipidus
Alice Chedid, Mohamad A. Hanouneh, John Sperati. Johns Hopkins University 
School of Medicine, Division of Nephrology, Batimore, MD.
Introduction: Arginine vasopressin (AVP) is a peptide hormone with multiple critical 
roles. Exogenous AVP is often used in the treatment of septic shock, ventricular arrhythmia, 
and diabetes insipidus (DI).
Case Description: A 23 year old woman was admitted with septic shock due to MRSA 
bacteremia. On physical examination, temperature 37.3°C, HR 90 beats per minute, BP 
90/50 mmHg, RR 30 per minute, and oxygen saturation 96% on FiO2 70%. Examination 
was otherwise unremarkable. She received intravenous vancomycin, cefepime, and 
norepinephrine. On day 3, ivs vasopressin was added for refractory hypotension. Prior to 
vasopressin, creatinine was 0.6 mg/dL, sodium (Na) 144 mmol/L, and urine output 2.5 L 
in preceding 24 hours. Over the next 48 hours, Na decreased to 131 mmol/L, with decrease 
in urine output to 1-1.5 L per day (Figure 1). Vasopressin was discontinued on day 5, and 
sNa rose from 131 to 154 mmol/L in 24 hours with urine output of 6 L. Measured serum 
osmolality was 317 mOsm/kg with simultaneous urine osmolality 76 mOsm/kg. Serum AM 
cortisol level was 22 mcg/dL. Non-contrast head CT was unremarkable. Transient DI upon 
vasopressin withdrawal was diagnosed. A single 4 mcg iv dose of desmopressin acetate was 
administered in addition to iv 5% dextrose water (D5W) at 200 ml/hour. A total of 4 L D5W 
was given over the next 24 hours, and urine output decreased to 2-3 L with normalization 
of the Na to 140 mmol/L. Her Na remained 138-143 mmol/L for the remainder of her 
hospitalization.
Discussion: Transient DI is a very rare event. The precise mechanisms, however, are 
unknown. Leading mechanistic theories include insufficient endogenous AVP production, as 
well as downregulation of renal V2 receptors upon prolonged intense vasopressin exposure. 
In the latter, the abrupt withdrawal of exogenous vasopressin may result in inadequate V2 
receptor signaling. Providers should be knowledgeable of this uncommon but serious side-
effect of vasopressin.
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A Rare Cause of Hypercalcemia Post Influenza Vaccination
Arun Rajasekaran,1 Anil Navani,2 Pran M. Kar.3 1University of Central Florida 
College of Medicine, Kissimmee, FL; 2Nephrology, Florida Hospital, Kissimmee, 
FL; 3VA Medical Center Orlando, Orlando, FL.
Introduction: Multiple myeloma (MM) is characterized by the neoplastic proliferation 
of immunoglobulin-producing plasma cells. Several cytokines, including IL-1, IL-6 
and TNF-beta, derived from myeloma cells are thought to accelerate osteoclastic bone 
resorption and cause hypercalcemia through a paracrine mechanism.
Case Description: A 65 year old female presented with subjective myalgias lasting 2 
days. She had received an inactivated influenza vaccine 5 days ago. Vital signs were stable. 
CBC & BMP were unremarkable. Serum calcium was 10.8 mg/dl. She was discharged 
on supportive therapy. She presented a day later with persistent flu-like symptoms. Labs 
revealed serum calcium being above 22 mg/dl, normal renal function, total protein, 
albumin, ACE levels; clear UA with no albuminuria; low PTH and 1, 25-(OH)2-Vitamin 
D3 levels; elevated PTHrP & viscosity levels. 24-hour urine collection revealed proteinuria 
(550 mg). Peripheral blood smear revealed rouleaux formation. CT scans of the chest, 
abdomen and pelvis revealed no obvious malignancy. Quantitative immunoglobulins 
revealed elevated IgA (2415 mg/dl), and concurrent suppression of IgG and IgM levels. 
Quantitative serum light chain measurement revealed normal levels of kappa and lambda, 
with an elevated Kappa:Lambda ratio of 2:1. SPEP, UPEP, and serum immunofixation 
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revealed IgA-Kappa MM. Given her severe-symptomatic hypercalcemia, she was treated 
with aggressive intravenous crystalloids, loop diuretics, calcitonin, pamidronate, and 
hemodialysis. Her calcium subsequently normalized to 10.1 mg/dl. Bone-marrow biopsy 
revealed intracytoplasmic kappa-restricted monoclonal plasma cells that occupied 40% of 
the marrow. Bone survey was negative for lytic lesions. She was started on bortezomib, 
lenalidomide, dexamethasone and monthly zoledronic acid; and she has not attained 
remission from myeloma yet.
Discussion: Our case is unique in that the patient initially had a normal serum calcium 
level that had increased rapidly to over 22 mg/dl within a period of 24 hours, had no 
renal failure or any bone involvement; and had a normal quantitative serum light chain 
measurement. It is theorized that the inactivated influenza vaccine given prior to presentation 
unmasked an atypical presentation of MM. This may be attributed to a vaccination induced 
cytokine storm, especially IL-6 mediated, that may be the key in the pathophysiology of 
hypercalcemia related to MM.
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Krishna A. Agarwal,1 Nayan Agarwal.2 1UMass Medical School-Baystate, 
Springfield, MA; 2University College of Medical Sciences and GTB Hospital, 
Delhi, New Delhi, India.
Introduction: Adrenal infarction is a rare event in pregnancy and in most reported 
cases, it is bilateral and associated with a thrombophilic state such as antiphospholipid 
syndrome. We report the first case of unilateral adrenal infarction in a pregnant female, 
without thrombophilia, secondary to paradoxical embolization.
Case Description: 21-year-old obese G1P0 female presented at 28 4/7 week of 
gestation with 1-week history of worsening, right-sided abdominal pain associated with 
nausea and non-bloody non-bilious emesis. No history of thrombophilia, denied smoking 
or OCP use. No family history of clotting disorders or spontaneous abortions. Physical 
exam significant for pregnant abdomen with right upper and lower quadrant tenderness. 
Lab work revealed Hgb 8.0g/dL, Hct 28%, WBC count 13.5k/mm3 and alk. phos. 124U/L. 
MRI abdomen/pelvis showed a normal appendix and gallbladder but an abnormal right 
adrenal gland with increased T2 signal and surrounding edema concerning for non-
hemorrhagic adrenal infarct. This was confirmed by a contrast-enhanced CT. She was 
started on anticoagulation with enoxaparin. An extensive thrombophilia workup including 
lupus anticoagulant, anti-cardiolipin & anti-beta-2 glycoprotein antibodies and JAK2 
mutation were negative; haptoglobin and homocysteine levels were within normal limits; 
lower extremity duplex did not reveal any deep vein thrombosis. A morning cortisol level of 
16.3ug/dL ruled out adrenal insufficiency. An echocardiogram with bubble study revealed 
a patent foramen ovale (PFO). She delivered a healthy neonate at 39 weeks. Following 
delivery, she was bridged to coumadin for a total 6-week course and started on lifelong 
aspirin therapy for the PFO.
Discussion: Unilateral adrenal infarction in pregnancy is extremely rare, with only 5 
cases reported in medical literature so far. Diagnosis is challenging because of presentation 
as an acute abdomen with a broad differential further complicated by pregnancy. MRI and 
CT scan are preferred imaging modalities for the adrenal glands. Once the diagnosis is 
made, anticoagulation is of paramount importance to prevent recurrent thrombotic events 
and LMWH like enoxaparin is preferred in pregnancy as it does not cross the placenta. 
Management of PFO is controversial with unclear benefit of surgical closure vs. medical 
therapy.
PUB723 
Publication-Only 
Drugs Masking Follicular Lymphoma as the Cause of Severe  
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Introduction: The Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is a 
common cause of hyponatremia. It may be predisposed by certain drugs, nervous system 
disorders or pulmonary diseases. Malignancy especially small cell lung cancer has also 
been related to SIADH. Finding the underlying etiology is critical in management.
Case Description: A 58 year old Caucasian lady with a past medical history of 
depression presented with acute neurological symptoms of headache, dizziness and 
unsteady gait. CT scan head was reported negative for any acute abnormality. Routine 
investigations revealed hypotonic hyponatremia with hyperosmolar urine. Careful review 
of home medications identified Citalopram and Trazodone. The diagnosis of hypo-osmolar 
euvolemic hyponatremia secondary to SIADH was established and thought to be caused by 
anti-depressants. The drugs were stopped and she was successfully treated with hypertonic 
saline with appropriate correction of hyponatremia and complete resolution of symptoms. 
Later, significant weight loss of 20 lbs in last one year prompted work up to rule out 
underlying malignancy as a cause of SIADH. She underwent CT scan chest, abdomen and 
pelvis which showed enlarged mesenteric lymph nodes. Subsequent CT guided biopsy 
confirmed Grade II Follicular lymphoma. PET scan revealed pleura and cervical lymph 
nodes involvement.
Discussion: SIADH induced hyponatremia is a common presentation, but the 
underlying cause needs to be carefully investigated. In our case, initially drugs were 
thought to be associated with SIADH. But later detailed work up revealed a rare and serious 
etiology of metastatic follicular lymphoma. Few cases have been previously reported where 
lymphomas were associated with SIADH. We suggest an open minded and aggressive 
approach to look for underlying malignancy in all patients irrespective of obvious 
associations, in order not to miss the dire causes.
Serum Na correction with hypertonic saline
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Mellitus
Sushma Edara, Madhu Kandarpa. Kidney care specialists, Beavercreek, OH.
Introduction: Hypokalemia can be due to renal or non-renal wasting. Here we are 
presenting a patient with hypokalemia due to rare cause of renal wasting.
Case Description: 27-year-old healthy male patient presented with generalized 
weakness, lower extremity edema and shortness of breath gradually worsening over three 
weeks. He was diagnosed with Diabetes mellitus about a month prior to this presentation. 
His blood glucose levels remained elevated despite treatment with Metformin and diabetic 
diet. Past medical and surgical history are negative. Family history is unknown as patient 
is adopted. Patient is non-smoker, no history of alcohol or recreational drug use or licorice 
ingestion. On examination temperature 97F, heart rate 93 bpm, regular, BP 144/93mmHg. 
Patient is noted to have 1+bilateral pitting pedal edema, proximal muscle wasting and areas 
of ecchymosis over back. Examination is otherwise unremarkable. Laboratory data: Sodium 
140mEq/l, Potassium 2.2mEq/l, Chloride 91mEq/l, Bicarbonate 39meq/l, BUN 16mg/dl, 
Creatinine 1.0mg/dl, Glucose 334mg/dl, Calcium 8.2mg/dl, WBC 17.5/μl, neutrophils 
93%, HB 14.8g/dl, Urine Potassium 45.9mmol/l, Transtubular Potassium Gradient (TTKG) 
14.46, AM cortisol- 69.9ug/dl, ACTH: 325pg/ml, TSH, free T4, T3: low. Intact PTH, 
Renin, Aldosterone, FSH, LH, CEA, prolactin, IGF-1, c peptide is within normal limits. 
Low and high dose dexamethasone suppression test did not suppress ACTH and cortisol 
levels. Echocardiogram LVEF 55- 60%, trivial pericardial effusion; CT chest, MRI Brain 
and Abdomen (with and without contrast) normal without any lung mass, pituitary tumor 
or adrenal mass respectively.
Discussion: Elevated TTKG is suggestive of renal potassium wasting. The generation 
of hypokalemia, metabolic alkalosis and hypertension are likely the result of sustained 
activation of mineralocorticoid receptors by high levels of circulating cortisol. Elevated 
ACTH levels in this case is either due to ectopic ACTH secretion or pituitary microadenoma. 
Patients with ectopic ACTH secretion often lack the clinical manifestations of Cushing’s 
syndrome as in this patient. Management from Nephrology standpoint is maintaining 
potassium levels within normal limits and treating the underlying cause. Ectopic ACTH 
secretion is a rare cause of hypokalemia. Prognosis depends upon the underlying cause.
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2Internal Medicine, Kansas City University of Biomedical Sciences, Joplin, MO; 
3Rawalpindi Medical College, Rawalpindi, Pakistan; 4Quaid-e-Azam Medical 
College, Bahawalpur, Pakistan; 5Nephrology, Kansas City University of 
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Introduction: Hypercalcemia(↑Ca+2) is an uncommon presentaion of Histoplasmosis. 
↑Ca+2 associated with Histoplasmosis is usally mild.Here in we present an interesting case 
of severe ↑Ca+2 leading to diagnosis of Histoplasmosis.
Case Description: 76 yr old female PMH significant for HTN, hypothyroidism, 
smoker, chronic cough & weight loss presented with syncope & fall, found to have serum 
Ca+2 of 17.7mg/dl & creatinine of 2.3mg/dl. PTH was suppressed at 5.4 pg/ml. Urine 
Ca+2 /Cr ratio was 0.26. 25-OH Vit D was 81ng/ml & 1-25-OH VIT D3 was 32pg/ml. 
PTH-rp was normal at 25 pg/ml. TSH was normal, SPEP/UPEP & serum immunofixation 
were negative. She was taking oral Ca+2 supplementation. She was found to have a RUL 
Lung mass. She underwent RUL biopsy showing necrotizing granuloma with Budding 
yeast identified as Histoplasmosis.She was treated for ↑Ca+2 with aggressive IV fluids and 
calcitonin. She was evaluated by ID & was started on itraconazole & oral Ca+2 was stopped. 
Her Ca+2 came down to 8.8 mg/dl & creatinine improved to 1.2mg/dl eventually.
Discussion: Histoplasmosis like other granulomatous diseases can cause ↑Ca+2 
through increased intestinal calcium reabsorption. But severe ↑Ca+2 is uncommon. Our 
case depicts a rare presentation of Histoplasmosis with severe hypercalcemia behaving 
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like a malignancy. To our knowledge this is the highest Ca+2 level reported in literature 
associated with non metastatic Histoplasomosis.
Necrotizing Granuloma
Budding Yeast
PUB726 
Publication-Only 
Marginal Zone B-Cell Lymphoma: A Rare Cause of Central Diabetes 
Insipidus
Ruby Zhao, Kamal Nayyar, Win Win Moe, James Drakakis, Nobuyuki 
(Bill) Miyawaki. NYU Winthrop Hospital, Mineola, NY.
Introduction: While hyponatremia is often considered in association with 
paraneoplastic syndromes including SIADH, hypernatremia from central diabetes insipidus 
(CDI) is a rare neoplastic complication. Metastasis to hypothalamus-pituitary region from
breast cancer, lung cancer, acute myelocytic leukemia and disseminated squamous cell
carcinoma have been previously described. Leukemia and lymphoma rarely affect the
pituitary gland with an estimate of 0.6%. This is the first reported case of CDI from splenic 
marginal zone lymphoma (MZBCL).
Case Description: A 67-year-old female with a relatively new diagnosis from 6 months 
ago of splenic MZBCL was admitted to the hospital with thirst, generalized weakness and 
vertigo and increased urination over 1 week despite doing well prior on Rituxan maintenance 
therapy for her splenic MZBCL. Her admission Na was normal. Serum Na hovered between 
145-149mEq/L on admission days 2-10. With worsened nausea and inability to keep oral 
intake, Na level suddenly soared from 147 to 169mEq/L overnight accompanied by severe 
thirst without notable reduction in urine output. Her serum potassium level was 4.2mEq/L, 
CO2 35mEq/L and creatinine was 0.6 mg/dL. Concurrently obtained urine osmolality was 
inappropriately low to 224mOsm/L with urinary Na of 62 mEq/L. After administration of
dDAVP 2 micrograms IV, urine osmolality increased to 457mEq/L overnight as the serum 
Na improved from 169 to 143mEq/L over the next 12 hours. The patient subjectively noted 
a significant decrease in urine output though accurate output was not kept. MRI showed a 
new enhancing inferior hypothalamic lesion and further testing confirmed the diagnosis of 
splenic MZBCL with central nervous system involvement.
Discussion: Splenic MZBCL account for less than 1% of non-Hodgkin lymphomas, 
and are often indolent in nature. Cerebral localized MZBCL has been reported as a rare 
cause of CDI but our literature search failed to discover CDI or hypothalamic complication 
from splenic MZBCL. As MZBCL can present with fevers mimicking infections, 
especially with hemophagocytic lymphohistiocytosis, development of hypernatremia may 
be inappropriately dismissed as simple case of ‘dehydration’ without proper history and 
diagnostic assessments. Concurrence of vertigo with CDI may indicate neoplastic disorder 
involvement of CNS, including extremely rare entities such as splenic MZBCL.
PUB727 
Publication-Only 
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Raghu Konanur venkataram,1 Kathy Khaing,1 Susana M. Mendoza,1 Phuong-Thu 
T. Pham,2 Phuong-Chi T. Pham.1 1Olive View-UCLA Medical Center, Los
Angeles, CA; 2UCLA Medical Center, Los Angeles, CA.
Introduction: Chronic polydipsia-induced hyponatremia (cPIH) is often rapidly 
overcorrected due to inappropriate strict free water restriction. Current recommendation 
to “reduce free water intake” (e.g. 500 ml less than daily urine output [UO]) is difficult to 
apply due to the lag of daily UO measurement.
Case Description: 48-year old female with chronic allergies presented with increasing 
lethargy and unsteady gait. Patient reports 12-20 L of water intake daily. Medication: 
diphenhydramine, up to 2 “bottles” daily in recent weeks Exam: Blood pressure 132/97 
mmHg, pulse 90/min; oriented, drowsy; moist mucosa, unremarkable cardiopulmonary, 
abdominal, and extremity exams; neurological exam nonfocal Labs/imaging studies: Brain 
CT, chest X-Ray: negative Serum Na 119, K 3.3 mmol/L, osmolality 250 mosm/kg, blood 
urea nitrogen 7 mg/dl, creatinine 0.49 mg/dl. Thyroid stimulating hormone and morning 
cortisol levels: normal In the emergency room, patient received 1L normal saline bolus, 
followed by strict free water restriction. Serum Na increased to 129 mmol/L within 8 h. 
Renal team was consulted. Hyponatremia was attributed to the increased thirst associated 
with high dose diphenhydramine (anticholinergic). Free water was given to reverse the 
rapid correction. Urine studies revealed urine Na+K persistently <25 mmol/L and urine 
osmolality <100 mosm/kg; UO ranges at 200-350 ml/h. Further recommendation was to 
match 70-80% of patient’s UO with electrolyte-free water (calculations were based on 
estimated UO rate and urine Na+K concentrations, Figure). Patient’s serum Na steadily and 
safely corrected and UO tapered nicely over 3 days.
Discussion: cPIH may be rapidly overcorrected with inappropriate free water 
restriction. In this condition, patient continues to lose high volume of electrolyte-free UO 
despite being water restricted due to the loss of optimal renal concentrating ability. Our 
simple recommendation to replace free water at a specified percentage of UO to the primary 
care team allowed for a steady and safe correction of the presenting hyponatremia.
PUB728 
Publication-Only 
Back to the (Acidosis) Basics: CRRT Masking DKA
Elizabeth Kotzen, Gerald A. Hladik. University of North Carolina at Chapel 
Hill, Chapel Hill, NC.
Introduction: We present a case of diabetic ketoacidosis (DKA) obscured by 
continuous venovenous hemofiltration (CVVH).
Case Description: A 33-year-old male with type I diabetes mellitus (DM) and ESRD 
was admitted with cardiac ischemia and had urgent coronary artery bypass grafting. 
Postoperatively, he required continuous renal replacement therapy (CRRT) because of 
persistent hypotension. CVVH was initiated at 25 ml/kg/h using NxStage PureFlow 
dialysate (glucose 100 mg/dL). His diabetes was managed with an insulin infusion titrated 
via a computerized glucose management system. On postoperative day 5, the patient 
developed worsening metabolic acidosis. Laboratory studies revealed arterial pH 7.17, 
PaCO2 38 mmHg, sodium 141 mEq/L, potassium 5.0 mEq/L, chloride 109 mEq/L, total 
CO2 15 mmol/L, glucose 140-185 mg/dl, anion gap 17, albumin 3.2 g/dl, and lactate 
1.0 mmol/L. Despite glucose levels <200 mg/dL, the serum beta-hydroxybutyrate (BHB) 
level was found to be elevated to 7.9 mmol/L, consistent with euglycemic DKA. Further 
review of his record revealed that he was receiving minimal calories via tube feed. In 
addition, the rate of the insulin infusion rate averaged only 0.2 Unit/hr over the preceding 
72 hours. The patient was started on dextrose infusion until tube feeds could be advanced 
to goal and the insulin rate was increased accordingly. His acidosis resolved and the BHB 
level normalized.
Discussion: Euglycemic DKA describes the clinical triad of anion gap metabolic 
acidosis, positive serum or urine ketones, and serum glucose <250 mg/dl. Coutrot et 
al. described 18 cases of euglycemic DKA in patients receiving CRRT with glucose-
free replacement fluids. We are not aware of previously described cases in which near 
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normalization of serum glucose by CRRT using glucose-containing replacement fluid 
yielded euglycemic DKA. In this case, the development of DKA was multifactorial, 
including inadequate provision of insulin and carbohydrates. The diagnosis was initially 
missed by an experienced critical care staff because glucose levels were <200 mg/dL. 
Methodical acid-base analysis prompted measurement of BHB, confirming the diagnosis of 
DKA. In this case, the near normalization of serum glucose by CVVH masked the diagnosis 
of this common acid-base disturbance. An increased suspicion for DKA is warranted in 
patients with insulin-dependent DM on CRRT even when glucose levels are <200 mg/dL. 
Reference: Coutrot, Intensive Care Med. 2018.
PUB729 
Publication-Only 
Water Balance Disorders as an Early Sign of Acute Myeloid Leukemia
Tarek Ashour,1 Rana R. Asmar,2 Juan C. Calle.3 1Cleveland clinic foundation, 
Beachwood, OH; 2Lebanese American University, Beit Mery, Lebanon; 
3Cleveland Clinic, Beachwood, OH.
Introduction: Central diabetes insipidus (DI) commonly is idiopathic or may be due 
to tumors, infections, trauma or infiltrative diseases affecting the brain. It is rare in patients 
with acute myeloid leukemia (AML).
Case Description: A 52 year old female with past history of high risk myelodysplastic 
syndrome was admitted because she progressed to AML. She was started on IV 
Cytarabine. Her serum sodium (Na) was 139 mEq/L on admission. She became steadily 
more hypernatremic, her Na peaked at 167 mEq/L, then improved to 156 mEq/L with IV 
dextrose. She reported polyuria and polydipsia of 4-6 L of water daily for few weeks prior to 
presentation. Initially her urine output (UOP) was not adequately recorded but later she was 
noted to make 5L of urine a day. Labs showed normal kidney function, serum osmolarity of 
320 mOsm/L and urine osmolarity of 104 mOsm/L. DI was highly suspected so DDAVP test 
was done with marked drop in UOP and rise in urine osmolarity to 534 mOsm/L. All were 
consistent with Central DI. Other workup showed low serum ADH, FSH, LH, ACTH and 
TSH. MRI head showed pituitary stalk thickening of 6 mm. She was started on intranasal 
DDAVP at night time and her serum Na normalized. Her hospital stay was complicated by 
septic shock due to E.coli bacteremia, AKI and hyponatremia. DDAVP was stopped and she 
was started on CRRT. She continued to deteriorate and died shortly thereafter.
Discussion: DI may occur any time in the course of AML, but often precedes initial 
diagnosis. The mechanism is unknown but one theory is that leukemic cells infiltrate the 
hypothalamic-pituitary stalk, however some patients have such infiltration without DI and 
vice versa. Thrombocytosis can lead to pituitary micro-infarction. It may lead to platelet 
dysfunction with increased risk of pituitary hemorrhage. Also may interfere with ADH 
action because > 90% of circulating ADH is bound to platelets. Leukostasis can lead to 
pituitary infarction as well. Association with specific chromosomal abnormalities has 
also been reported in AML. Anomalies of chromosome 3, particularly 3q26 breakpoint 
with inv(3)(q21q26), in AML patients have been associated with DI. Outcomes are poor 
in patients with AML who present with DI, regardless of the cytogenetic profile. AML 
diagnosis should be suspected in the evaluation of patients with central DI with hematologic 
abnormalities. It can be a good clue for early diagnosis and treatment.
PUB730 
Publication-Only 
A Case of Nafcillin Induced Hypokalemia
Fernando E. Casado-Castillo, Rabih Nasr. Bronx Care Hospital Center, 
Bronx, NY.
Introduction: Hypokalemia is a frequent clinical finding. Most common causes are 
diuretic use and gastrointestinal losses; Less common causes include: RTA, DKA, insulin 
excess, ectopic ACTH production and medications.
Case Description: We present a case of severe hypokalemia secondary to treatment 
with Nafcillin for a Methicillin Sensitive Staphylococcus aureus (MSSA) infection. 
Patient presented with right sided weakness and bilateral shoulder pain for 1 day. Physical 
examination showed decreased muscle power in both lower extremities; upper extremity 
strength was preserved. MRI of cervical spine showed an epidural abscess. Initial laboratory 
tests were: pH 7.43, Na+ 133 mEq/L, K+ 4.0 mEq/L, HCO3
- 23 mEq/L, BUN 20 mg/dL, 
Creatinine 0.7 mg/dL. Patient was started on Vancomycin, Ceftriaxone, Metronidazole and 
cord decompression/abscess drainage was performed. Blood/abscess cultures were positive 
for MSSA and Nafcillin was started. As showed in graphic and table 1, the patient persisted 
hypokalemic in despite of repeated replacement with high doses of intravenous Potassium 
Chloride. A 24 hours urine electrolytes showed: K+ 63.9 mEq/L and Mg+2 102 mg/dL. Oral 
K+ and Mg+2 supplements were started, and thereafter both serum K+ and Mg+2 normalized.
Discussion: Reviewed literature suggests that drug-related hypokalemia is rare after 
starting therapy with penicillin antimicrobials (i.e, Nafcillin) and baseline serum K+ level is 
a key determinant. Nafcillin associated hypokalemia is related to non absorbable ion effects 
in the distal tubule and/or intracellular redistribution due to volume depletion. Hypokalemia 
in this setting needs aggressive K+ replacement and may be also corrected by decreasing the 
dose of Nafcillin. Clinicians should be aware of hypokalemia when using Nafcillin.
PUB731 
Publication-Only 
Treatment of Refractory Metabolic Alkalosis and AKI with Reinfusion of 
Gastric Drainage
Li Pang,2 Gurleen Kaur,1 Jiasheng Wang,3 James T. Someren.1 1Emory, Decatur, 
GA; 2Tongji University, Shanghai, China; 3Metro Health Medical Center, 
Cleveland, OH.
Introduction: Gastrointestinal (GI) hydrogen loss is a common cause of metabolic 
alkalosis. It is usually treated with proton pump inhibitor (PPI) or H2 blocker along with 
volume replacement. For refractory patients, methods such as dialysis or intravenous (IV) 
infusion of hydrochloric acid (HCl)/ ammonium chloride can be considered. We describe a 
case of severe metabolic alkalosis caused by massive gastric drainage that was successfully 
treated by reinfusion of the drainage into the jejunostomy tube.
Case Description: A 50-year-old female was admitted with 3 days of worsening 
confusion. She had a complicated surgical history after a jejunal diverticulum perforation. 
As a result, her small intestine was left in discontinuity, with a duodenostomy draining tube, 
a jejunostomy tube and a venting gastrostomy tube. She had been receiving a liquid diet as 
well as total parental nutrition (TPN). Six days prior to the admission, her TPN was taken 
out for a break. On admission, she complained of markedly increased gastric drainage of 
about 2.5L daily from the duodenostomy tube. Further evaluation revealed pH 7.52, HCO3 
51.6 mmol/L, base excess 24.0 mmol/L, Na 119 mmol/L, K 2.3 mmol/L and Cl 48 mmol/L 
with creatinine of 6.67 mg/dL (baseline 0.8mg/dL). She received IV fluids, PPI and TPN 
with potassium chloride repletion. Her electrolyte disturbances quickly corrected. However, 
she remained in metabolic alkalosis with high GI output of around 3L. Given the acidic 
nature of her gastric drainage (pH < 5), we decided to re-infuse the gastric drainage from the 
duodenostomy tube into the J tube to correct the metabolic alkalosis. The patient’s acid-base 
disturbance and renal function normalized over the next few days.
Discussion: Conventionally, metabolic alkalosis caused by excessive GI fluid loss 
is treated with H2 receptor blocker or PPI, along with IV fluids. However, they were 
ineffective in our patient. IV HCl or ammonium chloride is the next line of therapy; but 
they are associated with narrow therapeutic windows and fatal complications. Reinfusion 
of gastric secretion into distal small bowel has been well described, but mainly for the 
purpose of nutritional support in patients with high output fistula or stoma to eliminate the 
dependence of TPN. Our report shows this could be a practical alternative in patients to treat 
refractory metabolic alkalosis as well.
PUB732 
Publication-Only 
Hyponatremia in ESRD: Look Before You Leap
Mayanka Kamboj,1 Amir Kazory.2 1University of florida, Gainesville, FL; 
2University of Florida, Gainesville, FL.
Introduction: Hyponatremia in patients with end stage renal disease (ESRD) who 
receive hemodialysis (HD) is frequently attributed to interdialytic fluid intake as they 
primarily depend on HD for removal of excess water. Measuring serum sodium (SS) as a 
part of plasma component, instead of plasma water content (PWC), can lead to erroneously 
low SS measurement.
Case Description: A 76-year-old ESRD patient treated with HD, anoxic brain injury, 
and recurrent bacteremia presented with severe hyponatremia despite lack of access to free 
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water. In order to avoid rapid correction of SS, low dialysate sodium (135 mmol/L) was used 
albeit with no notable impact. Persistence of hyponatremia and patient’s physical inability 
for excessive water intake prompted further evaluation that revealed a serum osmolality 
of 285 mOsm/Kg in the presence of SS of 127 mmol/L. Further work up showed total 
protein 10.4 g/dL with albumin 2.9 g/dL. Interestingly, serum protein electrophoresis found 
large and broad polyclonal hypergammaglobulinemia due to multiple chronic infections, 
with IgG 5106 mg/dL (N: 635-1616), Ig A 1310 mg/dL (N: 70-433). Total serum lipid 
level (including triglycerides) was 450 mg/dL. PWC was then calculated [PWC=0.991–
(0.73Xprotein Kg/L)-(1.03Xlipid Kg/L)] which revealed reduction in PWC (i.e. 91%) as 
the source of erroneously reported SS.
Discussion: Plasma dilution technique is used for conventional SS measurement; 
sodium concentration is adjusted by a fixed factor of 0.93, taking into consideration that 
the usual plasma composition is 93% water and 7 % solids. This method could result in 
clinically relevant measurement artifacts even with trivial changes in PWC due to significant 
increase in plasma lipids or plasma proteins such as in this patient. This case is a reminder 
that erroneous reporting due to PWC changes should be considered for unexpected low 
SS levels. This is particularly relevant in ESRD patients where a chronically modified HD 
approach might portend potentially adverse consequences.
PUB733 
Publication-Only 
Metformin-Associated Lactic Acidosis (MALA): A Rare but Fatal Clinical 
Entity
Monzurul Chowdhury,1 Ritu K. Soni.2 1UMASS Memorial, Worcester, MA; 
2University of Pittsburgh Medical Center, Pittsburgh, PA.
Introduction: Metformin is widely used as first line therapy for type 2 diabetes 
mellitus and is the most prescribed oral hypoglycemic agent in the world. While metformin 
reduces the risk of diabetic complications and cardiovascular mortality, it is also associated 
with the risk of life-threatening lactic acidosis, particularly in patients with renal or 
hepatic insufficiency. Metformin associated lactic acidosis (MALA) is a rare but serious 
complication with a remarkably high mortality rate of 30-50% in affected individuals. 
The incidence of MALA is reported to be about 4-9 cases per 100,000 patient-years in 
metformin users. We report a case of metformin associated lactic acidosis in the setting of 
renal insufficiency.
Case Description: A 55-year-old man with past medical history of DM II, HTN, CKD 
III presented with sudden onset of dyspnea, chest and abdominal pain associated with nausea, 
vomiting and poor oral intake for a few days. He takes metformin, losartan and atenolol at 
home. His vital signs were notable for a temperature of 35.5 C, blood pressure of 176/94, 
pulse of 94 and oxygen saturation of 99% on BiPAP. He was in moderate respiratory distress 
and had a resting tremor in his distal upper extremities bilaterally. The rest of his systemic 
examination was unremarkable. He was initially started on hemodialysis but subsequently 
developed hypotension requiring transition to continuous venovenous hemofiltration 
(CVVH). His renal function, metabolic acidosis and hemodynamics improved within 24 
hours of treatment with CVVH. He subsequently recovered from lactic acidosis. His renal 
function improved to his previous baseline upon discharge and he did not require long-term 
renal replacement therapy.
Discussion: In the setting of renal insufficiency, metformin can induce lactic acidosis 
by promoting the conversion of glucose to lactate in the splanchnic bed of the small intestine 
and also inhibits mitochondrial respiratory chain complex 1, leading to decreased hepatic 
gluconeogenesis from lactate and pyruvate. There is no specific antidote for metformin 
overdose. Gastrointestinal decontamination with activated charcoal can be used in acute 
overdose but not in patients with chronic toxicity. Extracorporeal treatment (ECTR) is the 
key component of management, hemodialysis being the modality of choice.
PUB734 
Publication-Only 
Pseudohyperkalemia - A Hoax
Usman A. Khan,1 Kai Lau,1 Aemen S. Khakwani,1 Sardar H. Ijaz.2 1University of 
Oklahoma Health Science Center, Oklahoma City, OK; 2internal medicine, 
University of Oklahoma Health Sciences Center, Oklahoma city, OK.
Introduction: Pseudohyperkalemia is a factitious elevation of serum potassium (K+) 
which is caused by many factors including mechanical trauma due to blood draw, due to 
reagent of blood collection tube, delay in collected sample transport to the lab, leakage of K+ 
from the hypermetabolic cells in vitro (i.e. myeloproliferative disorders).
Case Description: A 63 years old Afro-American male with history of Mantle Cell 
Lymphoma status post 13 cycles of chemotherapy got admitted for stem cell transplant 
with a white blood cell (wbc) count of 276000/uL. He was persistently hyperkalemic K+ of 
6.4> 8.0 > 9.8 mEq/L; got reversed on dialysis but reappeared again. All causes of 
hyperkalemia were excluded. He had normal EKG, normal creatinine 0.97mg/dl and had 
good urine output. K+ q4h and wbc count daily were monitored. Interestingly observation 
was distinct when blood sample turnaround time to laboratory for K+ check was 5 minutes, 
K+ value turned out to be normal as opposed to value reported after regular 4-hour delay 
from a lab technician draw. Therefore, unnecessary dialysis and medical treatments for high 
K+ were discontinued. When his WBC count came down from 276000/ul to 31000/ul with 
chemotherapy his K+ became normal.
Discussion: K+ leak from hypermetabolic cells (leukemia, lymphoma, thrombocytosis, 
Polycythemia Vera) occurs in vitro while no changes seen in vivo. Serum K+ in cases of 
hyperkalemia especially in setting of myeloproliferative disorders should be evaluated 
to differentiate true hyperkalemia from pseudohyperkalemia by minimizing the time 
delay in turnaround of samples to the laboratory. Key Words: Pseudohyperkalemia, 
myeloproliferative disorders
PUB735 
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Voriconazole Induced Refractory Hyperkalemia and Adrenal 
Insufficiency
Usman A. Khan, Sardar H. Ijaz, Aemen S. Khakwani, Joe Ghata. OUHSC, 
Oklahoma City, OK.
Introduction: Voriconazole, member of the azole family, acts by inhibiting lanosterol 
14-alpha-demethylase, a cytochrome P450 dependent enzyme. It demonstrates enhanced
activity against aspergillus and superior activity against certain fluconazole-resistant 
candida species. Hepatotoxicity is common side effect of the azoles with neurotoxicity and 
cardiac arrhythmias more specific to voriconazole. Electrolyte abnormalities and adrenal 
dysfunction have been reported with voriconazole. In our literature review we found a
case report of adrenal insufficiency associated with the concomitant use of voriconazole 
and inhaled glucocorticoids [1], a case series of severe hyponatremia associated with 
voriconazole use [2] and a case of iatrogenic Cushing syndrome associated with concomitant 
use of voriconazole and budesonide [3]. Hyperkalemia is a rare adverse reported not well 
reported in the literature. We present here a case of intractable hyperkalemia resulting from 
voriconazole use.
Case Description: A 47-year-old Caucasian male presented with progressively 
worsening shortness of breath that required mechanical ventilation within 24 hours of 
presentation. The patient was diagnosed with acute respiratory distress syndrome and 
was empirically treated with broad spectrum antibacterial coverage but failed to show 
improvement. Voriconazole was added to his regimen for anti-fungal coverage. Over the 
next 3 days the patient developed worsening hyperkalemia with normal renal functions 
and output, not responding to standard pharmacological treatment and emergent continuous 
renal replacement therapy was instituted. Voriconazole was stopped and the patient could 
be taken off continuous renal replacement therapy with no further electrolyte imbalances. 
Throughout this entire period his kidney function remained normal and his urine output 
was excellent.
Discussion: Hyperkalemia resulting from voriconazole use is an uncommon adverse 
effect occurring in less than 2% of cases but is important because of the serious and 
potentially life-threatening consequences. It should be kept in mind whenever initiating 
treatment especially in patients with compromised renal function; in kidney transplant 
recipients receiving tacrolimus and other hyperkalemia inducing drugs requiring careful 
serum potassium monitoring.
PUB736 
Publication-Only 
Hypoparathyroidism Concomitant with Macrothrombocytopenia in an 
Elderly Woman with 22q11.2 Deletion Syndrome
Hsiu-Chien Yang,1,2 Chih-Chien Sung,1 Shih-Hua P. Lin.1 1Tri-Service General 
Hospital, Taipei, Taiwan; 2Internal Medicine, Zuoying Branch of Kaohsiung 
Armed Forces General Hospital, Kaohsiung, Taiwan.
Introduction: Although hypocalcemia is common, its etiology is complex. Common 
causes of hypocalcemia are vitamin D deficiency, hypomagnesemia, critical illness, drugs, 
and hypoparathyroidism. Among these, congenital hypoparathyroidism has rarely been 
reported. Chromosome 22q11.2 deletion syndrome (22q11.2DS) associated with congenital 
hypoparathyroidism can result in hypocalcemia and hyperphosphatemia.
Case Description: We describe the case of a 62-year-old woman with schizophrenia 
and intellectual disability, who presented with intermittent muscle cramping for 2 weeks. A 
dysmorphic face and a positive Trousseau’s sign, but without ecchymosis or petechial lesion 
were noted. Laboratory data revealed impaired renal function (creatinine level = 1.6 mg/dL), 
severe hypocalcaemia (total calcium level = 5.7 mg/dL) with low urinary calcium 
excretion (13.2 mg/day), hyperphosphatemia (phosphate level = 7.3 mg/dL), and low 
intact parathyroid hormone level (52.5 pg/mL)—indicating primary hypoparathyroidism. 
A blood smear revealed thrombocytopenia (30,000 thrombocytes/μL) and giant platelets—
indicating macrothrombocytopenia. Chromosome 22q11.2 deletion syndrome (22q11.2DS) 
in the deficient chromosome 22 was confirmed using multiplex ligation-dependent probe 
amplification showing haploinsufficiency in GP1BB and TBX-1.
Discussion: The estimated prevalence of 22q11.2DS is 1:2000 to 1:6000. The clinical 
manifestations of 22q11.2DS are characterized by facial dysmorphism, congenital cardiac 
defect, palatal abnormalities, thymic hypoplasia and immunodeficiency, parathyroid 
hypoplasia, developmental delay and learning disability, schizophrenia, and hearing 
loss. However, another one of its manifestations, macrothrombocytopenia, has rarely 
been discussed. Cooccurrence of hypoparathyroidism and macrothrombocytopenia in 
22q11.2DS is rare and can easily be misdiagnosed as idiopathic thrombocytopenia purpura. 
Inappropriate splenectomy or chemotherapy can aggravate hypoparathyroidism. Early 
diagnosis of 22q11.2DS, characterized by hypoparathyroidism and macrothrombocytopenia, 
in elderly patients with schizophrenia can facilitate in avoiding circuitous diagnosis and 
inappropriate management.
PUB737 
Publication-Only 
Dramatic Changes of Water Metabolism
Krystahl Z. Andujar,1 Fatima B. Cintron-Rosa,1 Ileana E. Ocasio Melendez,1 
Andrea G. Del toro diez,2 Nicolle M. Canales-Ramos,2 Stephanie Colon Lopez,1 
Jose C. Lopez Puebla.2 1Nephrology, University of Puerto Rico, San Juan, Puerto 
Rico; 2University of Puerto Rico, Medical Sciences Campus, San Juan, PR.
Introduction: Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 
and central diabetes insipidus are recognized complications following craniotomy or 
craniectomy.
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Case Description: A 29-year-old man with prior resection of metastatic left frontal 
poorly differentiated sarcoma on dexamethasone 4 mg orally every 4 hours, presented 
with altered mental status associated with bulging of his left eye and seizures three weeks 
after procedure. History included end stage renal disease status-post renal transplant 
in 2011. He was hemodynamically stable without tachycardia or fever. Physical exam 
revealed left eye proptosis and euvolemia. Due to altered mental status, he was placed on 
mechanical ventilation. Laboratories revealed sodium 131 mEq/L, creatinine 1.0 mg/dL, 
urine osmolarity 682 mOsm/Kg, urine sodium 181 mmol/L and TSH levels were normal. 
Since patient was clinically euvolemic, SIADH was diagnosed and fluid restriction started. 
Despite fluid restriction, serum sodium levels continued to decrease, and a 3% hypertonic 
saline solution was started. Serum sodium levels rose 15 mEq/L in a 72-hour period, the 
patient became more alert and hypertonic saline was discontinued. In addition, transplant 
immunosuppression was decreased, and doxorubicin initiated. Despite therapy, he had a 
rapid deterioration in mental status and another emergent decompressive craniectomy was 
done. At the time of surgery, sodium levels were 143 mEq/L. Within 24 hours, he developed 
urine output higher than 300 mL/hr associated with serum sodium levels of 162 mEq/L and 
urinary specific gravity of 1.006. Volume repletion was started, and desmopressin provided, 
which reduced polyuria and raised urine specific gravity to 1.025. Brain imaging revealed 
transtentorial and tonsillar herniation. Rapid progression of malignancy may have been 
associated with pituitary ischemia, resulting in decreased antidiuretic hormone secretion.
Discussion: Our case highlights dramatic changes of water metabolism that patients 
with brain lesions undergoing neurosurgery can experience. In the post-operative period, 
frequent monitoring of serum sodium levels is essential including close attention to urine 
output and tonicity to avoid dysnatremia and delay in treatment.
PUB738 
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Biopsy Proven Acute Interstitial Nephritis in a Patient with Hashimoto’s 
Thyroiditis Presenting with Concurrent Distal Renal Tubular Acidosis 
(dRTA) and Severe Lower Extremities Weakness
Rachana Mandru,1 Stephen J. Knohl,1 Syed Hammad Alam.2 1Suny Upstate 
Medical University, Syracuse, NY; 2Upstate Medical University, Syracuse, NY.
Introduction: Distal RTA is a common clinical manifestation of a multitude of 
autoimmune disorders like Sjögren’s syndrome, Chronic active hepatitis, Takayasu arteritis 
and SLE. dRTA is also a common presenting feature of chronic tubule-interstitial nephritis 
from any cause; however, there is scant data on the association of autoimmune thyroid 
disease and lymphocytic interstitial nephritis. Our case is unique in a manner that a patient 
presenting with no other autoimmune processes except for Hashimoto’s comes to have a 
positive biopsy finding favoring acute interstitial nephritis as being the cause of her dRTA.
Case Description: 39 year old Female with history of Hashimoto’s thyroiditis 
status hemi thyroidectomy and CKD stage 2 presented with severe weakness of her 
lower extremities. Her admission relevant pertinent labs had revealed a potassium 
(K+) of 2.1mmol/L and bicarbonate (Hco3-) of 12mmol/L. Her TSH levels were found 
to be subtherapuetic at <0.03 thought to be as a result of unmonitored thyroxin use. 
Concurrent Bicarb and potassium supplementation improved her muscle weakness 
while endocrinology managed her hyperthyroid state. Despite the above measures, 
hypobicarbonatemia persisted with Nephrology evaluation revealing a urine pH>7.0 and 
a UrineNa+K (92.8)> UrineCl (83). With the above findings, the diagnosis of dRTA was 
made with a recommendation of autoimmune evaluation. Serologic studies were only 
positive for speckled ANA (250) while Ophthalmologic exam was unrevealing for uveitis. 
Given the above and the ongoing reduced GFR, a renal biopsy was performed which 
revealed the presence of a lymphoplasmacytic interstitial process with an element of 
tubulitis as well as some tubular atrophy and fibrosis.
Discussion: Recent studies show that thyroid hormones have several effects on 
expression of acid-base transporters and are associated with defects in distal nephron 
handling of acid-base balance. An underlying autoimmune etiology is almost always 
associated with dRTA, although the exact mechanism is unknown. Our report highlights the 
importance of recognizing the autoimmune association of dRTA and that there is likely an 
as-of-yet unidentified autoimmune condition vs currently-known, but serologically negative 
autoimmune disease resulting in both hypothyroidism and dRTA.
PUB739 
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Incomplete Proximal Tubular Dysfunction in Acute Myeloid Leukemia 
(AML): Thinking Outside the Box
Justin Lee Loy, Gajapathiraju Chamarthi, Rupam Ruchi. Division of Nephrology, 
Hypertension and Renal Transplantation, University of Florida, Gainesville, 
FL.
Introduction: Acute kidney injury (AKI) is common in hematological malignancies. 
AML in particular can cause acquired defects within the kidney, notably the proximal tubule 
which results in wasting of amino acids, uric acid, bicarbonate, sodium, potassium and 
phosphate. In this report, we present a patient with complex myelo-monocytic AML who 
developed an unusual kidney complication of his malignancy with its associated electrolyte 
abnormalities.
Case Description: A 58 yo male presented to ER for syncope. Labs revealed BUN 
37 mg/dl, serum creatinine (Cr) 5.0 mg/dl, potassium 3.3 mmol/L, phosphate 4.0 mg/dl, 
uric acid 16.1 mg/dl, LDH 1500 IU/L, WBC 156,000, Hb 10.0 g/dl and platelets 
36,000. His AKI was deemed pre-renal and creatinine improved to 0.9 by day 10, with 
intravenous fluid administration. Flow cytometry confirmed AML. He completed 1 session 
of leukapheresis and began chemotherapy. By day 13, he developed hypophosphatemia 
(1.9 mg/dl), hypokalemia (3.3 mmol/L) and hypouricemia (<1.5 mg/dl). Urine pH was 6.0, 
with new-onset glycosuria >500 mg/dl and proteinuria. Spot urine phosphate was 63 mg/dl, 
with fractional excretion 38% confirming urinary wasting. Repeat urinalysis continued to 
exhibit glycosuria in the setting of normoglycemia. 24-hour urine showed phosphaturia 
of 2.1 g/d (normal 0.9-1.3 g/d) and proteinuria (3 g/d). These findings pointed to the 
diagnosis of Fanconi’s Syndrome except his serum bicarb was 27, with arterial pH 7.43 
and pCO 40 mmHg. Serum lysozyme concentration on day 23 was normal. Simultaneous 
WBC was 900. He was determined to have incomplete proximal renal tubular acidosis, 
due to lysozyme mediated tubular injury, which persisted despite the lysozyme levels 
that presumably returned to normal. His serum phosphate improved with oral phosphate 
replacement to 3.3 mg/dl at discharge.
Discussion: Lysozyme originates from monocytes and macrophages. Increased levels 
are seen in monocytic leukemia. When excreted in large quantities in the urine various 
types of renal tubular dysfunction are observed. The combination of AKI, proteinuria, 
hypokalemia, and hypophosphatemia appears to be characteristic for patients. Our patient’s 
initial AKI masked the typical electrolyte imbalances, which became apparent as his kidney 
function improved. Even after chemotherapy and normalization of lysozyme levels, the 
proximal tubular damage persisted.
PUB740 
Publication-Only 
Sporadic Hypocalciuric Hypercalcemia Caused by De Novo CaSR 
Mutation
Ping-Huang Tsai, Chih-Chien Sung, Tsui-Hua Wang, Shih-Hua P. Lin. Tri-
Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Introduction: Hypercalcemic disorders with hypocalciuria are caused primarily by 
chronic thiazide or lithium use, acquired antibody to the calcium-sensing receptor (CaSR), 
familial hypocalciuric hypercalcemia (three types: type 1 (CaSR), type 2 (GNA11) and type 
3 (AP2S1)) or sporadic type. It is crucial to distinguish among these causes due to different 
treatment strategy.
Case Description: A 51-year-old man was referred because of hypercalcemia 
of unknown cause for > 5 years and progressive decline in eGFR. Family and personal 
history were non-revealing. There were no obvious symptoms related to hypercalcemia 
but easy fatigue, constipation and deteriorating renal function. Laboratory testing revealed 
hypercalcemia (12.5 mg/dL; range, 8.6-10.2) with hypocalciuria (spot urine Ca/Cr ratio 
was 0.019 in mg/dl/mg/dl, 24-hour urinary calcium excretion was 32 mg/day), and 
inappropriately elevated iPTH (65 pg/mL; range, 10.0-69.0). Parathyroid and abdominal 
sonography was normal. Direct sequence analysis of the relevant genes inclusive of CaSR, 
GNA11and AP2S1 showed a heterozygous missense T>A nucleotide substitution at c.1661, 
resulting in an amino acid change I554N in the extracellular domain of CaSR. I554 is well 
conserved in all species and this novel mutation is not inherited from his parents. In addition, 
this CaSR gene mutation was not found in 200 healthy subjects and should be pathogenic 
based on the predictive tools via PROVEAN and Polyphen2 score. Calcimimetics with 
cinacalcet (25 mg daily) reduced his serum calcium concentration to 11.2 mg/dL and iPTH 
level to 9.7 pg/mL, coupled with an increased urine calcium excretion (spot urine Ca/Cr 
ratio to 0.06) and eGFR four months later.
Discussion: Genetic diagnosis for idiopathic or sporadic hypocalciuric hypercalcemia is 
warranted. Calcimimetics by sensitizing the CaSR to calcium rather than parathyroidectomy 
can be used to treat symptomatic or moderate to severe hypercalcemia patients with loss of 
function mutation in CaSR.
PUB741 
Publication-Only 
A Fatal Prescription: Metformin Associated Lactic Acidosis
Ryan P. Flood. Nephrology, University of Colorado, Denver, CO.
Introduction: Metformin has become the most widley prescribed type two 
diabetes medication in the United States, Europe, and Australia. A Cochrane review, and 
accompanying conclusion, found that the incidence of metformin associated lactic acidosis 
is 5 cases per 100,000 patient years. This review’s conclusions were drawn from patients 
taking metformin per an established study protocol. Of concern, is the patient population 
that have a metformin exposure outside the defined prescribing parameters with risk factors 
for the development of MALA.
Case Description: 58 year old male with end-stage renal disease (ESRD) from 
unknown etiology, non-insulin dependent type two diabetes, and coronary artery disease 
presented to a tertiary care medical intensive care unit in trasfer from rural emergency 
department for managmeent of severe metabolic acidosis and cardiogenic shock. A high 
anion gap acidosis of 46 and serum osmolar gap of 23 were present on admission which 
was concerning for toxic alcohol ingestion. Patient was immediately treated with CVVHD 
in addition to Fomepizole. Approximately 6 hours after admission to the ICU the patient 
was found to be hemorrhaging from multiple sites and was diagnosed with disseminated 
intravascular coagulation. 8 hours after admission the patient developed PEA cardiac 
arrest and expired. Toxic alcohol levels returned negative prompting further post-mortem 
investigation and a serum metformin level was collected from admission blood work was 
found to be at a toxic level.
Discussion: The patient had been living transiently through various states receiving 
compassionate dialysis for several months after being newly diagnosed with ESRD. 
His fragmented care lead him to continue to take a previously prescribed metformin 
prescription. This lead to chronic metformin accumulation and the development of MALA, 
cardiogenic shock, and DIC.
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PUB742 
Publication-Only 
Syndrome of Inappropriate Antidiuretic Hormone Secretion Preceding 
the Diagnosis of Occult Tonsil Cancer
Ping-Huang Tsai, Chih-Jen Cheng, Shih-Hua P. Lin. Tri-Service General 
Hospital, National Defense Medical Center, Taipei, Taiwan.
Introduction: Syndrome of inappropriate secretion of ADH (SIADH) is associated 
with broad spectrum of malignancy, most notably small cell lung cancer and brain tumors. 
Still, SIADH patients who lack signs of overt malignancy could be a daunting challenge. 
Simple correction of hyponatremia without further investigation could miss true etiology 
of hyponatremia and delay the diagnosis of underlying malignancy. Here we present a case 
presenting with unexplained SIADH, which led to the diagnosis of occult tonsil cancer.
Case Description: A 59-year-old man presented with chronic dizziness and 
hyponatremia for two years. He had no previous medical and family history. Review of 
medication did not find possible offending drugs. He was euvolemic, nonedematous, and 
normotensive. Cardiac, abdominal and neurologic exams were unremarkable. Laboratory 
investigations showed serum Na+ 113 mmol/L, K+ 4.1 mmol/L, Cl- 90 mmol/L and 
osmolality 243 mOsm/kg.H2O. Serum cortisol, thyroid function and ACTH were normal. 
Urine biochemistries were osmolality 407 mmol/kg.H2O, Na
+ 140 mmol/L, K+ 9.7 mmol/L 
and Cl- 157 mmol/L. Chest x-ray, MRI of brain and CT scan of chest were unremarkable. 
SIADH was diagnosed by the inappropriately concentrated urine during serum hypotonicity 
and exclusion of hormonal disorders. His hyponatremia was refractory to fluid restriction 
and loop diuretics. Selective vasopressin receptor antagonist with tolvaptan raised the serum 
Na+ to 130 mmol/L. However, hyponatremia recurred quickly after the discontinuation of 
tolvaptan. To search for occult malignancy, whole body positron emission tomography 
(PET) scan using 18F-fluorodeoxyglucose identified strong uptake at tonsillar regions. 
Tonsillectomy was performed and the pathological exam proved the diagnosis of 
moderately differentiated squamous cell carcinoma. Immunohistochemical staining of 
ADH was negative in the tumor cells. The patient received concurrent chemoradiotherapy, 
and his hyponatremia resolved eventually.
Discussion: Thorough workup for the hidden malignancy is important in patients with 
unexplained SIADH. PET scan could be a useful tool in catching occult cancer, which may 
not easy to be found by conventional image. Early diagnosis and treatment of the underlying 
malignancy, instead of simply correcting serum Na+, should always be kept in mind while 
managing patients with unexplained SIADH.
PUB743 
Publication-Only 
Hidden Type B Lactic Acidosis in a Patient with Known Underlying 
Malignancy
Sushma Edara, Madhu Kandarpa. Kidney care specialists, Beavercreek, OH.
Introduction: Type B lactic acidosis is an uncommon recognized acid base disorder 
in patients with malignancies including leukemia and lymphoma. We present a patient with 
non-Hodgkin’s lymphoma and monoclonal gammopathy of undetermined significance 
(MGUS) with mixed acid base disorder including type B lactic acidosis.
Case Description: 83-year-old female patient with multiple medical problems 
including stage IV low grade non-Hodgkin lymphoma, double band IgM kappa monoclonal 
gammopathy of undetermined significance (MGUS), hypertension, type 2 diabetes mellitus 
and dementia presented with altered mental status worsening over three days. On arrival to 
Emergency Room patient was minimally responsive, afebrile with a heart rate 120 bpm, 
blood pressure 110/62 mmHg, respiratory rate 23/min. Her initial BUN 96 mg/dl, creatinine 
2.4 mg/dl, Sodium 145 mEq/l, Potassium 5.8 mEq/l, Chloride 105 mEq/l, Bicarbonate 
31 mEq/l, Lactic acid 4 mmol/l, anion gap 9 mEq/l, Albumin 2.4 g/dl, Lactate dehydrogenase 
688 U/l. Arterial blood gas PH 7.09, CO2 77 mmHg, PO2 95 mmHg, bicarbonate of 
22.7 mg/dl. Patient required dialysis for oliguria, uremia and severe acidosis which didn’t 
respond to medical treatment. We felt it is more likely to be type B lactic acidosis as patient 
was not significantly hypotensive and not septic. Patient’s mental status improved to her 
baseline.
Discussion: Type B lactic acidosis is a rare complication of solid tumors and 
hematological malignancies. Patient has respiratory acidosis with compensated metabolic 
alkalosis, Despite the elevated lactic acid level, the anion gap was within normal limits even 
after correcting for albumin. Increased anion gap metabolic acidosis was hidden even with 
significant lactic acidosis and uremia. Patient’s anion gap was 3 after resolution of lactic 
acidosis and acute kidney injury. Low anion gap in MGUS is probably the reason why her 
anion gap was within normal limits despite elevated lactic acid level. Type B lactic acidosis 
in patients with cancer seems to be a marker of poor prognosis regardless of the treatment 
offered. Limited studies are available specifically addressing management of type B lactic 
acidosis.
PUB744 
Publication-Only 
Ifosfamide-Induced Fanconi Syndrome in a Patient with von Reckling-
hausen’s Disease
Maria Andrievskaya, Junior Uduman. Division of Nephrology and Hypertension, 
Henry Ford Hospital, Detroit, MI.
Introduction: Ifosfamide is an alkylating agent used to treat many solid tumors. 
Fanconi syndrome secondary to ifosfamide use has been described in the pediatric literature. 
We report an unusual case of ifosfamide-induced Fanconi syndrome with self-remitting and 
recurrent proximal tubulopathy with each chemotherapeutic cycle in an adult patient with 
neurofibromatosis.
Case Description: A 36-year-old female with history of von-Recklinghausen’s disease 
underwent laparotomy and resection of retroperitoneal malignant nerve sheath tumor 
arising from a neurofibroma. She was initiated on chemotherapy with doxorubicin and 
Ifosfamide at a dose of 5 gm/m2 and Mesna for prophylaxis of hemorrhagic cystitis. Of 
note, 10 years ago she was treated with same chemotherapy agents and had received 2 
doses of ifosfamide at 9 g/m2. She had normal renal function and electrolytes at baseline. A 
week following chemotherapy, she was admitted for neutropenic fever, and she was noted to 
have hypokalemia and hypophosphatemia which were refractory to electrolyte replacement. 
Other laboratory data revealed: sodium 136 meq/l, chloride 109 meq/l, bicarbonate 
18 meq/l, BUN 14 mg/dl, Cr 0.55 mg/dl, magnesium 1.5, glucose 94 mg/dl. Urine studies 
showed pH of 8.5, glucosuria, albuminuria and evidence of urine phosphorus wasting. She 
was diagnosed with ifosfamide induced proximal tubular injury. Her electrolyte and urinary 
abnormalities improved over the next week. With the second cycle of chemotherapy a week 
later, she developed similar pattern of self-remitting proximal tubular injury. She received 
a third cycle of non-modified chemotherapy with which she had persistent proximal 
tubulopathy at 4 week follow up.
Discussion: Ifosfamide-induced tubular toxicity is common among children under 
4 years and cumulative doses greater than 60 g/m2. Mechanisms of ifosfamide-induced 
proximal tubular injury are not well understood, but chloroacetaldehyde, a metabolite 
of ifosfamide, is implicated. Oxidative stress mediated by glutathione depletion by both 
ifosfamide and mesna may also contribute. The older age and limited cumulative dose 
makes this an interesting presentation. Although the long term renal prognosis is good, 
caution should be exerted in repeated exposure. Apart from dose reduction, limited data 
is available for other preventive therapies. Cimetidine and n-acetylcysteine are potential 
options that lack clinical data.
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PUB745 
Publication-Only 
Hyponatremia: The Key to Diagnosing a Lung Abscess in an  
Asymptomatic Patient
Ela Banerjee,1 Ari B. Geller.2 1Internal Medicine, University of Connecticut, 
Farmington, CT; 2Nephrology, St. Francis Hospital, Hartford, CT.
Introduction: Lung pathology such as malignancy or infection can commonly result 
in inappropriate ADH secretion, causing hyponatremia. This case highlights a unique 
presentation of a lung abscess, where hyponatremia was the key clinical abnormality 
suggesting the infectious process.
Case Description: 85 y/o F with PMH of smoking, bronchiectasis, bladder cancer (in 
remission) presented to the hospital with a chief complaint of acute on chronic lower back 
pain with new onset radiation to right leg and associated weakness. She was incidentally 
found to have severe hyponatremia of 120 mmol/L on admission labs. The patient 
denied any recent illness, fever, chills, confusion, seizure-like activity, productive cough, 
hematemesis, night sweats or weight loss. On admission, she was afebrile with HR of 89, 
RR 22, BP 125/106 and O2 of 95% on RA. On exam, she was frail-appearing, with moist 
mucous membranes, regular heart rate and rhythm, clear lung fields bilaterally and no lower 
extremity edema. Additional lab work showed serum osmolality of 269 mOsm/kg, urine 
sodium of 118 and urine osmolality of 467. Uric acid was 3.5 mg/dL, TSH 4.35 uIU/ml 
and cortisol was not checked. She had leukocytosis of 18.9 K/uL with 95.7% neutrophils. 
Lumbar spine and femur x-rays were negative for fracture and a right leg duplex ultrasound 
was negative for DVT. Based on these labs, SIADH was diagnosed and the patient was 
placed on a 1.5L fluid restriction. On day 2 of hospitalization, Urea-Na 15 g/d was added by 
nephrology and later increased to 30 g/d for persistent hyponatremia. As part of the SIADH 
work-up, a Chest CT was performed to rule out lung malignancy due to the patient’s history 
of smoking and bladder cancer. It revealed a 3.4 x 3.9 cm mass in the right middle lobe. 
The patient underwent a CT guided biopsy of the mass demonstrating an abscess, which 
grew Pseudomonas aeruginosa. She was started on a prolonged course of Ciprofloxacin and 
continued on Urea-Na 30 g/d with a fluid restriction. This resulted in a sodium correction 
to 128 at discharge, and to 135 after completing one month of antibiotic therapy for the 
lung abscess.
Discussion: Lung abscesses can cause hyponatremia due to SIADH. However, only a 
few cases are reported. This asymptomatic patient’s severe hyponatremia helped identify 
the lung abscess, hence guiding therapy.
PUB746 
Publication-Only 
5-Oxoprolinemia - An Underdiagnosed Cause of High Anion Gap 
Metabolic Acidosis
Sanjay Kumar,2 Malvika Kaul,1 Ann M. Canelas.1 1MacNeal Hospital, Oak
Park, IL; 2Macneal Hospital, Berwyn, IL.
Introduction: 5-oxoprolinemia was first identified in 1989 as a cause of high anion gap 
metabolic acidosis (HAGMA) but is rarely considered as a part of initial differential. After 
ruling out important causes of HAGMA, one can consider this rare entity in patients with 
certain risk factors such as malnutrition, pregnancy, vegan diet, and hepatic or renal disease. 
5-oxoprolinemia is caused by deficiency of glutathione synthetase and 5-oxoprolinase 
deficiency related to drug toxicity like acetaminophen. Our case highlights the importance 
of considering 5-oxoprolinemia early in patients with unclear etiology of HAGMA.
Case Description: 71 year old female with recently treated gallstone pancreatitis, 
pancreatic abscess status post drain placement was readmitted for 5 days of abdominal pain 
and vomiting. On admission, she was in acute distress with unstable vital signs (heart rate- 
113, respiratory rate-30) with diffuse abdominal tenderness. Initial laboratory data showed: 
HCO3 4mmol/l, Creatinine 1.89 mg/dl, glucose 242 mg/dl, anion gap(corrected) 22, white 
blood cell count 26.9 KU/L, lipase 2323 U/L, INR 1.7, lactic acid 3.6mmol/l, negative 
urine and serum ketones, and an arterial blood gas showing pH 6.81, PaCO2 27 mmHg, 
HCO3 <7.9 mg/dl. Imaging showed improved peripancreatic fat stranding compared to 
previous CT scan. She was treated with IV fluids, antibiotics and a bicarbonate infusion. 
Despite above measures, her HAGMA persisted, prompting consideration of other causes 
including drugs. Her serum acetaminophen level was 240.8mcg/ml thus she was started on 
N-acetylcysteine and her liver function test were monitored. Due to worsening INR, she
was transferred to a liver transplant center for evaluation. High acetaminophen level with
concurrent high 5-oxoproline level in setting of malnutrition identified acetaminophen as 
the culprit for this HAGMA.
Discussion: 5-oxoprolinemia is an important cause of HAGMA, hemolytic anemia 
and central nervous system dysfunction. Higher acetaminophen level leads to increase 
in 5-oxoproline levels by directly depleting glutathione levels in the liver. Treatment is 
mainly IV hydration and N-aceytlcysteine (regenerates glutathione). Meticulous history 
and awareness of rare etiologies is important and can significantly reduce morbidity and 
mortality in patients with HAGMA.
PUB747 
Publication-Only 
Cerebral Salt Wasting in Neurosurgical Patient
Vipulkumar Bhalara, Smita Mahendrakar, Franklin D. Ponce-Herrera. 
Nephrology, Rutgers New Jersey Medical School, Newark, NJ.
Introduction: We report a case of cerebral salt wasting as an uncommon cause of 
hyponatremia. Making the diagnosis rapidly is vital as its treatment requires volume and 
sodium restoration rather than the water restriction as in SIADH. Hyponatremia is common 
in neurosurgical patients and is associated with substantial morbidity and mortality. 
Diagnosis of the cause and its correction are essential to prevent severe hyponatremia, 
which can substantially worsen cerebral edema and increase risk of seizures.
Case Description: 44 yr old male with past medical history of traumatic brain injury at 
14 yrs of age with multiple infections of ventriculo peritoneal shut in the past admitted with 
altered mental status. VP shunt was removed along with washout of ventricle due to repeat 
CNS infection. Post op serum sodium 131 mmol/L started on 3% NaCl to prevent cerebral 
edema, serum and urine osmolality were 265 and 569 respectively with urine sodium 
245mmol/L. We suspected CSW due to clinical volume depletion, low CVP, urine sodium 
>200 and large volume urine output. Fractional excretion of Uric acid and phosphorus were 
high 33%, 29% respectively. After starting fludrocortisone on day 11 his requirement of IV 
Na and urine Na improved.
Discussion: CSW is a disorder of sodium and water homoeostasis which occurs as a 
result of cerebral disease in the setting of normal renal function. CSW results in inappropriate 
primary sodium losses which are not related to volume expansion. The pathogenesis of 
CSW remains unclear; however any injury to the brain cells releases atrial, brain C type 
and dendroapsis natriuretic peptides appears to be the driving factor in pathogenesis of 
CSW. It is postulated that these substances reduces the efficacy of aldosterone and leads 
to decreasing ability of the kidneys to resorb sodium causing very high urine sodium 
concentration, a high urine output leading to low volume state. High fractional excretion of 
uric acid and phosphorus occurs CSW.
PUB748 
Publication-Only 
Renal Salt Wasting (RSW) with Normonatremia Secondary to Acquired 
Mineralocorticoid Deficiency
Hassan B. Attique,1 Silya Mazigh,2 Ruchir D. Trivedi.1 1Uconn Health, 
Farmington, CT; 2UCONN Health, Farmington, CT.
Introduction: RSW is a syndrome represented by hypovolemia, hyponatremia in 
face of excess urinary sodium loss resulting in ECV contraction. We demonstrate a case of 
Polyuria with excess urinary sodium loss without significant hyponatremia (net water gain 
from excess ADH).
Case Description: 44-year-old male with PMH of HTN presented with persistent 
fevers and AMS. He was found to have bacterial meningitis and brain abscess. His hospital 
course was complicated by septic shock requiring vasopressor support but baseline urine 
output remained roughly around 3 L per day, with evidence of euvolemia and normal renal 
function. Following improvement of his hemodynamics and overall clinical status, he 
developed significant polyuria as well as renal salt wasting coupled with hypovolemia and 
hypotension not explained by intake and previously infused crystalloid.
Discussion: The literature addressing etiology of polyuria in the ICU population is 
scarce. In such contexts, the differential diagnosis should include auto-diuresis from 
previously given IV fluids, polyuria of sepsis, polyuria of recovery from ATN, diabetes 
insipidus (DI), cerebral salt wasting (CSW), and mineralocorticoid deficiency among others. 
In this particular patient, given his normonatremia, DI and CSW alone would not explain 
these findings; however, a combination of the two is possible. On Day 3, patient had urine 
output of 9.5 L with urine sodium of 166 mEq/L resulting in total sodium loss of 1577 mEq 
(1577/154 = 10.2 L of 0.9% saline). This degree of ECV salt loss is associated with profound 
hemodynamic instability and cannot be replaced without massive volume repletion. In this 
situation given preserved renal function, acquired transient mineralocorticoid deficiency 
from sepsis appears to be the best plausible explanation, hence decision to start low dose 
Fludrocortisone was made with dramatic clinical and hemodynamic response. Absence of 
hyponatremia can possibly be explained by not allowing to progress to the threshold for 
ADH release (10-15% ECV volume loss) by constant 0.9% saline and probably hampered 
CRH and ADH production resulting in decreased ACTH and adrenal steroid production. 
This case highlights complexity of polyuria in critically ill patients. Fludrocortisone 
presents a reliable alternative of massive volume repletion in select cases with acquired 
transient mineralocorticoid defect of sepsis.
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PUB749 
Publication-Only 
A Case of Cisplatin Induced Salt Wasting Nephropathy
Rami M. Azem, Michael Lioudis, Sevag Demirjian. Cleveland Clinic, 
Cleveland, OH.
Introduction: Salt wasting nephropathy is a rare cause of polyuria and hyponatremia 
and is associated with cisplatin and other platinum based chemotherapy. Patients with salt 
wasting nephropathy typically present with hyponatremia, hypovolemia and orthostatic 
hypotension. This is a case of a patient who presented with salt wasting nephropathy 
secondary to cisplatin.
Case Description: A twenty-eight year old male with history of recurrent non-
seminoma testicular cancer with metastasis to the lungs presents to the hospital with a 
right sided empyema. He underwent decortication and washout and was admitted to the 
intensive care unit for hypoxic respiratory failure. On admission, serum sodium was 
133 mmol/L. His sodium worsened to 126 mmol/L one month into hospitalization. At that 
time, the hyponatremia was suspected to be due to low solute intake along with SIADH 
in the setting of paroxetine use and malignancy. His urine sodium was 73 mmol/L and 
urine osmolality was 490 mOsm/kg. Paroxetine was tapered off and sodium improved to 
136 mmol/L. He was also receiving cisplatin chemotherapy for cancer treatment. Shortly 
after his initial hyponatremia resolved, he developed polyuria of 9 L in 24 hours. At onset 
of polyuria, serum sodium was 124 mmol/L, urine sodium was 95 mmol/L, and urine 
osmolality was 292 mOsm/kg. His urinary losses were replaced with fluids at a one to one 
replacement rate. Over the next two days, his urine sodium rose to 180 mmol/L and urine 
osmolality rose to 402 mOsm/kg. He continued to make between 9 and 15 L of urine daily, 
so replacement rate of fluids was decreased to two thirds of urinary losses. Despite this, 
four days later his urine osmolality was 381 mOsm/kg, which led to high suspicion for salt 
wasting nephropathy. In addition, he was orthostatic and tachycardic, further correlating 
with salt wasting nephropathy.
Discussion: Salt wasting nephropathy is a rare cause of chemotherapy induced 
hyponatremia and can be seen with cisplatin and other platinum based chemotherapy. In 
one study of 70 patients treated with cisplatin for 18 months, 7/70 developed salt wasting 
nephropathy. All of these patients presented with severe orthostatic hypotension. Their urine 
sodium ranged from 85-145 mmol/L and urine osmolality ranged from 340-619 mOsm/kg. 
It is important to recognize salt wasting nephropathy, as management includes replacing 
water and salt loss.
PUB750 
Publication-Only 
Diabetes Insipidus: Diagnosing Dilemma in a Patient with Cerebral Palsy
Eric Pitts, Aisha Khattak. University of Texas Health Science Center at Houston, 
Houston, TX.
Introduction: Diabetes Insipidus (DI) is a disease in which the secretion of or the 
response to the pituitary hormone vasopressin is impaired, resulting in the production of 
large amounts of dilute urine, often associated with dehydration and avid thirst. DI can 
be central vs nephrogenic (CDI and NDI respectively) subdivided further into partial vs 
complete. In general, a stepwise approach will help differentiate in most adult patients. Here 
we present a challenging case in which an accurate diagnosis was delayed in part related to 
the patient’s mental and physical disability.
Case Description: 33 year old Latin male with history of cerebral palsy epilepsy and 
inflammatory arthritis, presented with sepsis secondary to pneumonia. Due to the patient’s 
mental disability, history was obtained from his mother. He was started on Methotrexate, 
leflunomide, and steroids approximately 7 months ago. In addition, persistent polyuria of 12-
15 diaper changes per day and polydipsia started around the same time. Labs on admission 
showed a sodium 152 mmol/L, potassium 3.5 mmol/L, chloride 116 mmol/L, bicarbonate 
26 mmol/L, glucose 95 mg/dL, and creatinine of 0.47 mg/dL. Urinalysis: specific gravity 
1.002, pH 7.0, negative glucose, ketones, blood, RBC or WBC. Hemoglobin A1C was 
4.4%. He was volume replete with crystalloids for sepsis, however hypernatremia remained 
and polyuria persisted. Desmopressin (DDAVP) was given on day 2 of admission with only 
mild decrease in urine output (UOP) and rise in urine osmolality. Water deprivation test 
was not possible due to agitation and insomnia, so another approach was taken. DDVAP 
and intravenous fluid were withheld for 2 days, and patient was allowed to drink to thirst. 
Urine and serum osmolalities with electrolytes were trended showing reoccurrence of 
hypernatremia and polyuria. Prior to giving DDAVP again, urine osmolality automatically 
improved from 131 to 451, and after restarting DDAVP, there was further rise in urine 
osmolality. This data suggested Partial CDI, so MRI brain was done which showed a central 
germinoma infiltrating the posterior pituitary stalk.
Discussion: This case shows the difficulty in diagnosing partial NDI vs partial CDI in 
patients with mental disabilities who are unable to comply with routine methods used for 
diagnostic purposes. DDAVP will increase urine osmolality with overlapping values in both 
partial CDI and partial NDI which makes diagnosis a challenge.
PUB751 
Publication-Only 
Central Diabetes Insipidus Preceding Thrombocytosis Caused by Acute 
Myelogenous Leukemia
Kuangyu Wei, Chih-Chien Sung, Tsui-Hua Wang, Shih-Hua P. Lin. Tri-Service 
General Hospital, National Defense Medical Center, Taipei, Taiwan.
Introduction: Central diabetes insipidus (CDI) is commonly caused by organic lesions 
affecting the hypothalamic-pituitary regions. However, CDI preceding the thromobocytosis 
uncovering acute myeloid leukemia (AML) was rarely reported and could go unrecognized, 
leading to delayed diagnosis with inappropriate treatment
Case Description: A 61-year-old man was referred for the unknown cause of CDI with 
sudden polyuria, polydipsia, and thirst for 3 months. His family and personal history were 
unremarkable. There was no visual field defect. CDI was confirmed by water deprivation 
and desmopressin test. Magnetic resonance imaging of the brain revealed loss of the 
posterior pituitary bright spot on T1 weighted sequences without other abnormality. At that 
time, a thorough examination including complete blood count, immune, tumor, infection, 
and inflammation survey was non-revealing. On laboratory examination, a markedly 
high platelet count (1,038,000μL) was found despite normal platelet counts 3 months 
ago. The leucocyte count was 19,400μL with 62.3% blast. Bone marrow examination 
showed hypercelluler marrow plus megakaryocytes and infiltration with 25% blast cells. 
The immunohistochemical and flow cytometry results were consistent with AML-M2. 
He achieved complete remission with resolution of CDI after induction and consolidation 
chemotherapy. To date, there were only five cases presenting with CDI, thrombocytosis 
and AML, all showing the association with chromosome 3 or 7 abnormalities. Cytogenetic 
analysis in this patient was normal despite positive CEBPA and negative FLT3 and NPM1 
gene mutations.
Discussion: CDI may be the preceding and presenting feature of thrombocytosis and/
or AML. A regular check-up of complete blood count test is necessary for early diagnosis 
of hematologic abnormalities. The mechanism connecting abnormality of the hematopoietic 
cells, impact on the neurohormonal cells in the hypothalamus, chromosomes abnormality 
and platelets warrants further investigation.
PUB752 
Publication-Only 
Unique Case of Severe Metabolic Alkalosis from a Gastro-Ileal Fistula: 
The Role of PPIs
Sandheep Venkataraman, Lin N. Lwin. Montefiore Medical Center, Bronx, NY.
Introduction: Metabolic alkalosis is the most common acid-base abnormality seen in-
hospital. It results from the loss of extracellular acids or the gain of bicarbonate. Persistent 
vomiting has been known to cause alkalosis through the loss of hydrochloric acid rich 
gastric secretion. We report a case of gastro-ileal fistula causing severe alkalosis through 
a similar mechanism.
Case Description: 53-year old man with history of rectal cancer, Crohn’s Disease with 
total colectomy, ileostomy, and short gut syndrome, was admitted for severe hypokalemia 
(serum potassium 2.3 mEq/L) and metabolic alkalosis with bicarbonate of 49 mEq/L. 
He reported increased quantity of watery stool in his ileostomy for one month. Exam 
was significant for dry oral mucosa, and ileostomy bag with clear liquid. Labs revealed 
acute kidney injury (creatinine 1.20 mg/dL from baseline of 0.77 mg/dL) and normal 
anion gap. Arterial gas showed pH of 7.567 and pCO2 50.0. Urinalysis was normal with 
pH of 7.0. Ileostomy content was very acidic with pH less than 6.0 and beyond the lab 
range. CT abdomen with oral and IV contrast showed normal appearing bowel loops and 
ileostomy. However, there was no trace of oral contrast. Acidic ileostomy fluid, electrolyte 
abnormalities, and absence of oral contrast on imaging were suggestive of gastro-ileal 
fistula. Severe metabolic alkalosis was thought to be due to continuous loss of gastric 
hydrochloric acid. Electrolytes were replaced and he was aggressively hydrated. He was 
started on a proton pump inhibitor (PPI), and his alkalosis improved rapidly in 48 hours. 
Ileostomy output decreased and labs normalized over the next 5 days. He was discharged 
on pantoprazole.
Discussion: Acidity of the GI tract varies based on location with the lowest pH in the 
stomach which gradually increases down the small bowel. In our patient, severe alkalosis 
was thought to be due to the continuous loss of gastric acid containing a significant amount 
of H+ ions. Hypovolemia and hypokalemia also contributed to his alkalosis. PPIs are pro-
drugs which concentrate in the gastric parietal cell canaliculi and bind irreversibly to the 
H+/K+ pumps. They have been shown to induce profound hypochlorhydria in the stomach, 
with a single dose shown to raise the pH from 2.0 to 6.0 in the stomach. This supported 
the use of PPI in our patient to prevent the acid loss, preserve H+ ions, and help correct 
the alkalosis.
PUB753 
Publication-Only 
Acid-Base Disorder in Extremis
Srijan Tandukar. University of Pittsburgh Medical Center, Pittsburgh, PA.
Introduction: In physiological conditions, normal acid-base homeostasis is maintained 
by an interplay of respiratory or metabolic compensation to counteract the primary disorder. 
We present a case of severe acute on chronic hypercapneic respiratory acidosis that was 
compensated to near normal pH by an extreme elevation of serum bicarbonate.
Case Description: A 43-year-old male with a history of chemoradiation for recurrent 
Hodgkin’s lymphoma complicated by pulmonary fibrosis and right hemidiaphragmatic 
paresis leading to chronic respiratory acidosis on BiPAP treatment at home, and constrictive 
pericarditis treated with pericardiectomy presented with increased somnolence. He was 
on bumetanide 3 mg twice a day at home. On exam, he was afebrile, hemodynamically 
stable with an oxygen saturation of 100% on room air. He was difficult to arouse, oriented 
to time and person with normal cardiorespiratory exam and 2+ lower extremity pitting 
edema. His blood gases showed a pCO2 of 126 mmHg, bicarbonate of 68 mEq/L and pH of 
7.34 on arrival. Renal function was normal with creatinine of 0.6 mg/dL and potassium and 
chloride were low at 3.4 mEq/L and 77 mEq/L respectively. Given that his pCO2 in prior 
admissions had always been >110 mmHg and bicarbonate >55 mEq/L with near normal 
pH and no symptoms, it was decided to lower pCO2 only slightly using intermittent BiPAP 
in a controlled fashion with concomitant acetazolamide for a brief alkaline diuresis. The 
patient’s mental status rapidly improved with this intervention and at the time of discharge 
his blood gas showed pH 7.46, pCO2 99 mmHg and bicarbonate 69 mEq/L. Given his 
persistent fluid overload, he was maintained on a reduced dose of bumetanide 2 mg orally 
twice a day to avoid diuretic-induced metabolic alkalosis.
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Discussion: In patients with chronic respiratory acidosis secondary to pulmonary 
diseases, obstructive sleep apnea and obesity hypoventilation syndrome, it is not unusual 
to find some degree of metabolic compensation in the presence of normal renal function. 
However, it is rare to find an asymptomatic patient who has chronic respiratory acidosis 
with a pCO2 consistently above 100 mmHg and a serum bicarbonate above 60 mEq/L as 
compensation with near normalization of pH. In treating such patients, caution should be 
exercised in correcting chronic respiratory acidosis aggressively as the resulting severe 
metabolic alkalosis can lead to life-threatening complications such as disorientation, 
seizures and coma.
PUB754 
Publication-Only 
A Puzzling Case of Severe Hypokalemia in Pregnancy
Samaya J. Anumudu, Jasmine A. Pascoe, Bhamidipati V. Murthy, Jingyin Yan. 
Baylor College of Medicine, Houston, TX.
Introduction: Hypokalemia is a dangerous electrolyte disturbance in pregnancy. It 
is defined as a serum potassium level less than 3.5 mmol/L and is associated with EKG 
abnormalities, arrhythmias, or rarely rhabdomyolysis. We present an interesting case of a 
25-year-old pregnant female with severe hypokalemia.
Case Description: A 25-year-old G1P0 female at 32 weeks gestation was admitted
with potassium less than 1.8mmol/L. She had decreased oral intake, nausea, and vomiting 
for four days which was initially thought to be the cause of hypokalemia. However, 
she also had polyuria with urine output up to 400 cc/hr. She had hypernatremia (Na of 
147 mmol/L). Liver function tests were elevated and CK trended up to 28,786 U/L. EKG 
revealed prolonged QT interval. Urinalysis showed +1 protein, +3 ketone, and pH 6.5. 
Urine potassium and sodium were 77.9 and 152 mmol/24 hours respectively with dilute 
urine (65 mosm/kg H20) likely in the setting of diabetes insipidus (DI) despite no known 
prior history. In addition to pain in lower extremities, she had jaw pain and headache. MRI 
brain was notable for diffuse myositis of the muscles of mastication and nonvisualization 
of T1 hyperintensity of neurohypophysis. Hypotonic Intravenous fluids were used initially 
with both oral and IV potassium supplementation. Urine output decreased and urine 
osmolality rose to 228 mosm/kg H20 after a dose of desmopressin (DDAVP). Serum 
potassium improved with continued oral supplementation and high potassium diet. Her 
pain and hypernatremia resolved. She was discharged home on oral potassium and nasal 
DDAVP with close follow up.
Discussion: This case highlights the complex etiology of hypokalemia and associated 
complications in pregnancy including unusual presentation of rhabdomyolysis for which 
clinicians should remain vigilant. Our patient’s combination of polyuria with increased 
urinary potassium loss in the setting of likely prior undiagnosed diabetes insipidus and 
gastrointestinal losses led to severe hypokalemia. As a result, she developed the rare 
complication of rhabdomyolysis affecting the muscles of mastication as well. She will need 
MRI imaging of the pituitary after delivery to confirm central DI diagnosis. Such patients 
need close monitoring throughout pregnancy in a multidisciplinary approach for effective 
treatment and avoidance of complications.
PUB755 
Publication-Only 
Hypercalcemia as Presentation of Renal B Cell Lymphoma
Ifeoma Okadigbo, Sairah Sharif, Basma O. Merhi. Brown University, 
Mineola, NY.
Introduction: Primary renal lymphoma (PRL) is a rare condition that mimics renal 
cell carcinoma. We describe a patient who presented with hypercalcemia and acute renal 
failure who was found to have a large mass in his kidney that was biopsied and showed 
diffuse large B cell lymphoma (DLBCL). He was started on rituximab, cyclophosphamide, 
vincristine, doxorubicin prednisone (R-CHOP) and radiation. We report this case to 
highlight the pitfalls in diagnosis of this rare entity as well as the peculiar presentation of 
hypercalcemia
Case Description: 69 year old man with history of hypertension presented with 4 
months of nausea, weakness, and weight loss. He was found to have serum calcium 13.3mg/
dL and serum creatinine of 4mg/dL (baseline 0.9mg/dL 6 months ago). Workup showed 
suppressed PTH, and PTH-rp, a normal ACE, vitamin D 25 and mildly elevated vitamin 
D1, 25. His paraprotein workup was negative. He received 0.9% normal saline, calcitonin 
and pamidronate. CT scan abd/pelvis showed a 15 cm mass in the left renal fossa. There was 
high suspicion of renal cell carcinoma but due to technical difficulty in surgical approach, 
a decision was made to do a renal biopsy instead of nephrectomy. Kidney biopsy was 
consistent with DLBCL. A PET scan showed a large area of intense FDG uptake only in the 
left renal lesion. He completed 6 cycles of R-CHOP with improvement in serum creatinine 
to 1.3mg/dl, normal calcium and a repeat PET scan after R-CHOP completion that showed 
improved FDG uptake. He is to receive radiation.
Discussion: PRL are extremely rare extranodal lymphoma. It usually presents as flank 
pain, hematuria, renal failure and diagnosed after nephrectomy. This is an aggressive cancer 
with grave prognosis. This case is unique as our patient presented with hypercalcemia, got a 
renal biopsy, was started on chemotherapy and radiation and responded well. We highlight 
the importance of high index of suspicion when faced with renal mass and hypercalcemia, 
to think about PRL as the management is completely different from renal cell carcinoma
PUB756 
Publication-Only 
Seminoma Presenting as Acute Renal Failure and Hypercalcemia
Aileen Wang, Purnima R. Tripathy, Ranjani N. Moorthi, Ayman Hallab. Indiana 
University School of Medicine, Indianapolis, IN.
Introduction: Hypercalcemia is commonly associated with various solid and 
hematologic malignancies, but rarely associated with seminoma. Similarly rare is 1,25 
dihydroxyvitamin D (calcitriol) mediated hypercalcemia, which is more commonly 
associated with lymphomas and sarcoid-related granulomatous disease. Here we describe 
an atypical presentation of a patient with seminoma patient presenting with acute renal 
failure and hypercalcemia.
Case Description: The patient is a 55-year-old Caucasian male with history of left 
orchiopexy for undescended testis as a child presented to the nephrology clinic for acute 
renal failure with Cr to 2.37 mg/dL on a routine laboratory test with no recent baseline. His 
only complaint was a dull abdominal discomfort and constipation for 2 months. Abdominal 
exam revealed a fixed large abdominal mass. CT scan showed a 9.4 cm x 15 cm x 18.4 
cm retroperitoneal mass and mild left hydronephrosis. Serum calcium (SCa) elevated at 
12.3 mg/dL. His SCa rapidly normalized with IV saline infusion, and Cr downtrended. 
Work up revealed suppressed PTH (3 pg/mL), normal 25-OH Vitamin D3 (30.3 ng/mL), 
low PTHrP (1.1 pmol/L), and an elevated 1,25 dihydroxyvitamin D level to 119 pg/mL. 
Serum ACE level elevated to 73 units/L. Pathology showed a metastatic seminoma. Patient 
received Cycle 1 of cisplatin and etoposide (CE). He was discharged with SCa of 8.0 mg/dL 
with no additional therapy and improved kidney function (Cr 1.28 mg/dL). Patient recently 
underwent cycle 2 of chemotherapy with stable renal function and normal SCa.
Discussion: This case is unique in illustrating an atypical cause of acute renal failure 
due to hypercalcemia associated with seminoma due to a tumor sarcoid-like reaction. 
Hypercalcemia normalized with CE chemotherapy regimen which included steroids, the 
typical treatment of sarcoid-associated hypercalcemia.
PUB757 
Publication-Only 
Isolated Hyperkalemia During Anesthesia
Sourab Dhungel,1 Jean Lee.2 1Temple University Hospital, Mickleton, NJ; 
2Temple University, Philadelphia, PA.
Introduction: Hyperkalemia can occur during anesthesia even in the absence of renal 
failure and may result in cancellation of surgery. We would like to present a case and discuss 
possible mechanisms.
Case Description: A 62 year old African American male with a past medical history 
of hypertension, type 2 diabetes mellitus, chronic hepatitis C and recently diagnosed 
duodenal cancer was admitted for elective pancreaticoduodenectomy. This was his first time 
receiving general anesthesia. He was not on an ACE inhibitor because of a single episode 
of hyperkalemia in the past. Pre-operative potassium from 2 weeks prior was normal as 
were several other measurements in the past. His CKD-EPI eGFR was 93 ml/min/1.73 m2. 
In the operating room, he was given Isoflurane, Sevoflurane, Propofol, Rocuronium and 
Vecuronium. He was found to have hyperkalemia (7.0-7.6) on intra-operative blood gases 
repeated x3. A basic metabolic panel confirmed a serum potassium of 7.3 meq/L with tall 
tented T waves on electrocardiographic monitoring. There was no evidence for tumor 
lysis, rhabdomyolysis, hemolysis or hematoma. He also did not develop any features of 
malignant hyperthermia during observation. Surgery was cancelled before the first scalpel. 
Hyperkalemia resolved with furosemide administration.
Discussion: There may be several reasons for isolated hyperkalemia in this patient. 
Firstly, he may have had impairment of extra-renal potassium disposal secondary to 
increased alpha adrenergic tone as has been described in the past. Secondly, he may have 
had a genetic predisposition to hyperkalemia as is found in patients who develop malignant 
hyperthermia in association with anesthetic agents. However, the whole syndrome of 
malignant hyperthermia was not present in this patient.
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Much Ado About Nothing
Avantika Chenna.2,1 1Nephrology, southwest georgia nephrology----, Albany, 
GA; 2Nephrology, phoebe putney medical center, Albany, GA.
Introduction: Sirolimus is a mTOR (mammalian target of rapamycin) inhibitor that 
is used for immunospression in solid organ transplant recipients. Common side effects 
include pancytopenia, thrombotic microangiopathy, proteinuria and delayed wound healing. 
We present a case of massive hemothorax following automated implantable cardioverter-
defifrillator (AICD) placement from sirolimus use.
Case Description: 49 year old female with history of childhood glomerulonephritis 
(unkown etiology) with third kidney transplant and h/o 2 failed kidney transplants in the 
past, who presented for elective AICD placement. During immediate post operative period, 
patient developed massive bleeding from AICD site causing hemothorax requiring bilateral 
chest tube placement. Past medical history includes: diabetes mellitus, hypertension, 
asthma and schizoaffective disorder. Her labs include: BUN/CR 49/1.8 mg/dl (baseline 
1.1 mg/dl prior to procedure). Hemoglobin was 8.1 g/dl, platelets 202,000/UL, WBC 
11,400/UL. Her albumin level was 1.3 g/dl. Donor specific antibody was not elevated. 
Renal ultrasound showed increased resistive indices without hydronephrosis. Home 
immunosupression includes: mycophenolate 750 mg twice a day, prednisone 5 mg and 
sirolimus 2 mg daily. Nephrology was consulted for the management of postoperative acute 
kidney injury following the procedure. We first recommended to hold sirolimus and started 
patient on tacrolimus 1 mg twice a day. Patient required 18 units of PRBC transfusion 
and multiple units of fresh frozen plasma. Hospital course was complicated by respiratory 
failure requiring intubation, hemodnamic acute tubular necrosis requiring dialysis. After 
a prolonged ICU stay, patient continued to fail spontaneous breathing trials. She was thus 
transferred to longterm assisted care with tracheostomy and on maitenance hemodialysis 
three times a week.
Discussion: This is the first case of massive hemothorax following AICD placement 
from sirolimus use per our literature review. Through this case we would like to suggest 
that sirolimus should be held for atleast 2-4 weeks prior to any kind of surgical procedure. 
Nephrology has to be involved early in the preoperative care of kidney transplant recipients 
even when they are going for minor elevtive procedures.
PUB759 
Publication-Only 
The Effects of Rituximab on Atherosclerotic Biomarkers in Kidney 
Transplant Recipients
Numuna Aliyeva,5 Erol Demir,1 A. Ucar,1 Halil Yazici,1 Yasar Caliskan,1 
Sebahat Akgul,2 Ayse Erol,3 Sonay Temurhan,2 Berna Yelken,6 Fatma Savran 
Oguz,4 Aydin Turkmen.1 1Division of Nephrology, Istanbul School of Medicine, 
Istanbul, Turkey; 2Department of Medical Biology, Istanbul School of Medicine, 
Istanbul, Turkey; 3Department of Medical Biology, Istanbul University Faculty 
of Medicine, Istanbul, Turkey; 4Department of Medical Biology, Istanbul School 
of Medicine, Istanbul, Turkey; 5Division of Nephrology, Istanbul School of 
Medicine, Istanbul, Turkey; 6Gaziosmanpasa University, Tokat, Turkey.
Background: Cardiovascular disease is the leading cause of mortality in renal 
transplant (tx) recipients. Rituximab is widely used in kidney transplantation. There are 
few reports about the relationship between rituximab and atherosclerotic process in 
rheumatologic disorders. The aim of the study was to evaluate the efficacy of rituximab on 
atherosclerotic biomarkers in kidney tx recipients.
Methods: Forty renal tx patients who did not have a history of cardiovascular event 
were included to study. All of the patients in the treatment group (n:27) were received 
at least of one dose of 375 mg/m2 rituximab. The control group (n:13) were selected by 
historically and donor type matched patients. Quantitative measurement results were 
compared between rituximab and control group of kidney tx recipients for atherosclerotic 
biomarkers: interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-alpha), transforming 
growth factor beta (TGF-beta) and oxidized low-density lipoprotein (anti-oxLDL) antibody. 
Counts of B lymphocytes, T lymphocytes and natural killer cells were measured in both 
groups.
Results: Demographic parameters, laboratory results of the patients were demonstrated 
in Table. Counts of B, T lymphocytes and natural killer cells were significantly lower in 
rituximab group compared to control group. Serum IL-10 levels were significantly higher 
in the rituximab group compared to the control group, although anti-oxidized low-density 
lipoprotein levels were lower in the rituximab group compared to the control group though 
this did not achieve statistical significance.
Conclusions: Rituximab treatment may decrease lymphocyte counts and IL-10 levels, 
however significant decreases in all atherosclerotic biomarkers has not been shown.
Demographic parameters, laboratory results of the patients
Abbreviations: FSGS; Focal segmental glomerulosclerosis, CD; Cluster of differentiation, 
IL; Interleukin, TNF; Tumor necrosis factor, TGF; Transforming growth factor, oxLDL; 
Oxidized low-density lipoprotein.
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Antioxidant Capacity in Mexican Kidney Transplant Recipients
Diana Ramirez flores,1 Victoria G. Maldonado,1 Milagros M. Flores Fonseca,1 
Adriana Banda Lopez,1 Salvador Mendoza Cabrera,1 Gilberto Velázquez,2 
Ana C. Ramirez anguiano,2 Sandra F. Velasco.2 1Centro Medico Nacional de 
Occidente, Guadalajara, Mexico; 2Universidad de Guadalajara, Guadalajara, 
Mexico.
Background: Kidney transplant (KT) offers a better quality of life in patients with 
Chronic Kidney Disease (CKD). Despite the benefits of KT, long-term survival rates have 
shown none satisfying status due to graft failure. KT prone to oxidative stress mediated 
injury by diverse pre- and post- transplant conditions affecting the allograft and other 
clinical disorders in kidney recipients. The aim of this study was to determine the total 
antioxidant capacity in post transplantation anemia kidney transplant recipients (KTR).
Methods: The study included 41 adult patients during the maintenance period (>1 year) 
following renal transplantation, treated with different combinations of immunosuppressive 
agents. The total antioxidant capacity (TAOC) of plasma was measured using Trolox-
equivalent antioxidant capacity (TEAC) assay
Results: A higher proportion of female KTR, mean age was 29.53 ± 7.24 years. 
They had a TAOC 326.77 - 473.12 ± 399.95 μmol/L. There was a significantly negative 
correlation between TAOC and plasma creatinine (R2 = -0.551, p = 0.033) and a positive 
correlation between TAOC and hematocrit in patients treated with tacrolimus but not with 
cyclosporine.
Conclusions: This study could asses that TAOC values were associated with 
immunosuppressive therapy and anemia, and these could be determinant risk factors to 
increase of oxidative stress. Further studies are needed to determine oxidative stress 
pathways and if it can improve the allograft survival.
Funding: Government Support - Non-U.S.
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Publication-Only 
Considering Kidney Function When Screening for Hepatitis C Virus at 
Temple University Hospital
Chelsey Fix,2,1 Emily Levine,4 Crystal A. Gadegbeku.3 1NephCure Kidney 
International, King of Prussia, PA; 2Temple University, Philadelphia, PA; 3Temple 
University, Philadelphia, PA; 4Temple University Hospital, Philadelphia, PA.
Background: State mandates have prompted hospitals to implement Hepatitis C Virus 
(HCV) screening programs to capture high-risk individuals and facilitate treatment. It is not 
standard to screen kidney function before treating HCV, despite evidence of increased risk 
of chronic kidney disease (CKD). Individuals living with HCV and CKD may eventually 
require a kidney transplant, and can receive a cadaver HCV positive kidney significantly 
sooner if they delay HCV treatment until after the transplant.
Methods: The goal of this project was to identify the proportion of HCV patients with 
kidney disease at Temple University Hospital (TUH) and use that data to design a tool 
within the hospital’s electronic health record system to facilitate proper nephrology care. 
Data were collected from the electronic health records of HCV patients at TUH that were 
seen for the first time in 2017 for HCV treatment. Demographic information, data about 
kidney function, and information about the referring department were collected. Patients 
that would have benefitted from a nephrology consultation before HCV treatment were 
identified.
Results: Of the 637 patients seen for HCV treatment at TUH, 29 (4.6%) were seen 
by a nephrologist. An additional 84 (13%) patients were identified as having an estimated 
glomerular filtration (eGFR) rate less than sixty, making them candidates for nephrology 
care before HCV treatment. Twenty-five patients were found to have an eGFR less than 
thirty, warranting urgent nephrology care.
Conclusions: New technology to identify late stage CKD patients would increase the 
number of HCV patients receiving nephrology care at TUH.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1225
J Am Soc Nephrol 29: 2018 Publication-Only 
PUB762 
Publication-Only 
Comparison of Immunohistochemical Staining for Large T Antigen and 
VP1 in Polyomavirus Nephropathy After Kidney Transplantation
Kosuke Masutani,1,2 Yuta Matsukuma,2 Akihiro Tsuchimoto,2 Keizo Kaku,3 
Atsushi Doi,3 Yasuhiro Okabe,3 Kazuhiko Tsuruya,4 Toshiaki Nakano,2 
Takanari Kitazono.2 1Nephrology and Rhaumatology, Fukuoka University, 
Fukuoka, Japan; 2Medicine and Clinical Science, Kyushu university, Fukuoka, 
Japan; 3Surgery and Oncology, Kyushu university, Fukuoka, Japan; 
4Nephrology, Nara Medical University, Kashihara, Japan.
Background: Banff Working Group on Polyomavirus Nephropathy (PVN) proposed 
a new histological classification consisting of pvl and ci scores, and recently demonstrated 
that the classification is a useful predictor of graft dysfunction. Most transplant centers 
use SV40 large T antigen (TAg) staining for pvl scoring, while the expression of TAg is 
decreased and VP1 is increased on the course of viral replication in the tubular epithelial 
cells (TECs). In addition, TAg and VP1 staining in biopsy specimen of PVN has not been 
clearly compared.
Methods: From 1996 through 2017, 16 patients developed biopsy-proven PVN 
in Kyushu University Hospital. We performed immunohistochemical staining using 
commercially available anti-SV40 TAg and anti-BKV VP1 antibodies in the serial sections 
of 16 index biopsies and 12 follow-up biopsies. We compared the patterns of positive 
staining, and the number of positive tubulus (%) in all biopsies. In 16 index biopsies, we 
investigated the correlation between serum creatinine increase from the baseline and the 
number of positive tubulus determined by SV40 TAg and BKV VP1 staining.
Results: In BKV VP1 stained section, positive staining was observed not only in the 
nuclei of TECs, but also in the cytoplasm, cells shedding into the lumen, and intratubular 
casts. Two of 28 biopsies (7.1%) showed negative staining for BKV VP1, in which SV40 
TAg positive tubulus were detected in less than 1%. The median (interquartile range) 
percentage of positive tubulus was 2.8 (0.7-9.8) % in SV40 TAg and 1.4 (0.5-3.9) % in BKV 
VP1 staining (P=0.2). In 16 index biopsy, serum creatinine increase significantly correlated 
with the number of BKV VP1 positive tubulus (r=0.49, P<0.05), while it did not with the 
number of SV40 TAg positive tubulus.
Conclusions: In BKV VP1 staining showed various pattern of positive cells, but it 
could detect approximately half as many tubulus as SV40 TAg staining, which might cause 
a false negative results in the specimen with minimal BKV replication. On the other hand, 
increased BKV VP1 positive staining means advanced damages of TECs and has possible 
association with graft dysfunction.
PUB763 
Publication-Only 
Predonation Laparoscopic Sleeve Gastrectomy for Morbid Obese Kidney 
Donors
Vivek Pathak. Nephrology, Kovai Medical Center and Hospital, Coimbatore, 
India.
Background: The prevalence of obesity is increasing in the general population 
so number of living donor transplants due to elevated BMI have declined by 13%. This 
procedure is required to reduce the future complications of the donor including CKD 
and increase the donor pool. According to a study by Locke et al obese donors had a 
1.9 fold increased risk of ESRD post donation and this cohort was free of diabetes and 
hypertension at the time of donation which are conditions known to contribute to ESRD.
This data suggests that obese living donors should be counseled for weight loss programme. 
Laparoscopic sleeve gastrectomy(LSG) is used as a procedure for treating morbid obesity. 
However we have seen very few reports of LSG as a procedure for weight loss to improve 
chances of donation in a morbidly obese donor. Published analysis(Brooks et al) suggests 
that a live donor though obese is more cost effective than a deceased donor even if LSG is 
used to reduce the weight.
Methods: We intentionally performed LSG in preparation of kidney donation. We 
reviewed charts of these ten donor nephrectomy patients who were subjected to LSG 
between 2012 and 2017.
Results: The age range of donors was 32 to 65 years(mean 41.1 years). Presurgery BMI 
ranged from 35.3kg/sqm to 46kg/sqm(mean 41) and post surgery BMI ranged from 27 to 
36 kg/sqm (mean 32.3kg/sqm) at the time of donation. LSG did not give rise to significant 
perioperative complications. Two donors became non-diabetic and weight loss continued 
in the subsequent months following surgery also. It did not influence the subsequent 
laprascopic donor nephrectomy(LDN).
Conclusions: This procedure allowed morbidly obese donors to donate and 
subsequently expanded the donor pool without impacting the outcome of subsequent LDN. 
We will recommend this for obese live kidney donors.
Demographics of donors who underwent LSG before laparoscopic donor nephrectomy
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Explant Biopsy and Allocation Based on Remuzzi Scoring Permits 
Selection of Extended Criteria Donor Kidneys for Single Implantation 
with Excellent Outcomes
Sobhana Thangaraju,1 Anantharaman Vathsala,2 Hersharan Sran,2 Angeline 
Goh,2 Rachel Teo,2 Hwai-Liang Loh,1 Fang jann Lee,1 Valerie H. Gan,1 Thomas 
P. Thamboo,2 Hoyee Tiong,2 Benjamin Goh.2 1Singapore General Hospital,
Singapore, Singapore; 2National University Health System, Singapore,
Singapore.
Background: While Extended Criteria Donors (ECD) increase deceased donation 
(DD) rates, allocation of ECD kidneys is challenging due to difficulty in predicting post-
transplant outcomes.
Methods: Since November 2009, kidney DDs were stratified as ECD if 
Age>60(ECDAge); if meeting UNOS criteria(ECDUNOS); Diabetic(ECDDM) or 
other renal conditions(ECDOthers); the rest were Standard Criteria Donors(SCD). ECD 
underwent explant biopsy, rapid biopsy processing and histological scoring of Glomeruli, 
Tubules, Interstitium and Arteries to derive a Total Remuzzi Score (TRScore). TRScore 
of 0-4 or 5-7 were generally allocated as single (ECDSingle) or dual Implants (ECDDual) 
respectively. This study evaluated impact of our allocation strategy on longterm outcomes. 
Of 118 DD, 55(46.6%) were ECD; 21(38.2%), 11(20%), 12(21.8%) and 11(20%) were 
ECDAge, ECDUNOS, ECDDM and ECDOthers. After evaluating TRScores, 30 
ECD(54.5%) were allocated as ECDDual, preferentially to kidney transplants (KTX)>45 
yrs. After excluding 1 ECDSingle with staghorn calculus that was discarded and 5 SCD that 
were allocated to paediatric KTX, 200 adult KTX (30 ECDDual, 49 ECDSingle and 121 
SCD) were analysed.
Results: TRScores from ECD explant biopsies and from 61 of 63 SCD with implant 
biopsies were 5.2±1.2, 2.8±1.1 and 2±1.7 for ECDDual, ECDSingle and SCD respectively 
(P<0.001). ECD KTX were older (52.4±7.5, 49.1±9.4 and 47±9 yrs for ECDDual, 
ECDSingle and SCD respectively; p=0.01), but sex, ethnicity, incidence of Delayed 
Graft Function (DGF) and Biopsy Proven Acute Rejection by 6 mths (BPAR6) were not 
significantly different between groups. 5 yr overall survival was worse for ECDDual 
(64.4%, P=0.05), but comparable for ECDSingle and SCD (84.8% and 84.7% respectively). 
After adjusting for age, gender, ethnicity, DGF and BPAR6, ECDSingle had lower hazard 
for overall failure (OR 0.29, [95%CI 0.114-0.741]).
Conclusions: Stratifying ECD with explant biopsy and allocation based on Remuzzi 
scoring yields outcomes comparable to SCD for ECD Single kidneys.
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Cutaneous Polyarteritis Nodosa (PAN) After Kidney Transplantation: A 
Case Report, Sepsis Induced or Primary Disease?
Hitoshi Miyasato, Genta Uehara, Satoshi Akao, Norihiro Nishioka. Okinawa 
Chubu Hospital, Uruma City, Japan.
Introduction: Polyarteritis nodosa (PAN) is a systemic vasculitis characterized 
by necrotizing inflammatory lesions that affect medium and small-sized arteries. The 
pathogenesis of PAN is not well known, but Hepatitis B virus (HBV) and other viruses are 
thought to be causative agents. We present a biopsy proven case of PAN, which developed 
20 months after a kidney transplant. Development of an autoimmune disease after transplant 
is a rare phenomenon.
Case Description: A 53 year-old woman received a living kidney transplant on 
March, 2016. Her kidney disease was speculated to be caused by IgA nephropathy. The 
patient’s perioperative course was uneventful. Her induction regimen was basiliximab, 
mycophenolate mofetil (MMF), tacrolimus, and prednisolone. Nineteen months after 
transplantation, the patient had a parathyroidectomy for primary hyperparathyroidism. She 
was discharged on postoperative day 4. One day after discharge, the patient returned to our 
hospital for Escherichia coli (E.coli) urinary tract infection (UTI) and sepsis (extended-
spectrum beta-lactamase). The patient was treated with carbapenem and second generation 
cephem antibiotics for14 days. Twenty-one days after discharge, she presented to our 
hospital for second time with a UTI caused by E.coli, but not associated with sepsis. On 
this second presentation, Carbapenem was initiated with resolution of the UTI symptoms. 
On hospital day13, the patient noticed pain in her bilateral lower legs as well as in her left 
forearm and right arm. On day15, a small painful nodule appeared, which was biopsied.
Discussion: PAN is a very rare complication after transplant. We found six other cases 
of PAN after transplantation in the literature; one case was related to HBV infection. Take 
away points: In a transplant patient, de-novo autoimmune diseases, such as PAN, may 
present atypically.
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Late Onset JC Virus Allograft Nephropathy (JCVAN)
Manpreet Samra, Ignatius Y. Tang. Internal Medicine/Nephrology, University of 
Illinois Health, Chicago, IL.
Introduction: JC virus (JCV) is a member of the Polyomaviridae family. Few studies 
were published regarding the replication of JCV in transplant recipients. The incidence of 
JCV viruria, viremia, and allograft nephropathy is unknown. Most reported cases of JCV 
infection occurred during the first 24 months after transplantation. We describe two cases of 
JCVAN occurring beyond 24 months post-transplant.
Case Description: CASE 1: 66-year-old Polish male with ESRD due to hypertensive 
nephrosclerosis on hemodialysis for 6 years and peritoneal dialysis for 1 year, underwent 
a deceased donor kidney transplant in 4/2014. His post-operative course was complicated 
by nephrolithiasis that required a nephrostomy tube. In 11/2017, he developed acute kidney 
injury (AKI) with a creatinine of 2.1mg/dl. Renal allograft biopsy showed Polyoma Virus 
allograft nephropathy (PAVN). His immunosuppression at that time was Astagraf and 
Myfortic. His Myfortic dose was reduced. Blood BK virus PCR was not detected. Blood 
JCV PCR was 270,000 copies/ml and urine JCV PCR >100 million copies/ml. His Astagraf 
dose was reduced to maintain a trough of 3-5ng/ml. His Myfortic was stopped. Prednisone 
10mg daily was added. Two-months follow-up JCV PCR was 338,000 copies/ml. He did not 
exhibit neurologic symptoms. His creatinine remained around 2mg/dl. CASE 2: 48-year-old 
Filipino male with a history of polycystic kidney disease underwent deceased donor kidney 
transplant in November 2003 with stable good kidney function on maintenance tacrolimus 
and mycophenolate mofetil (MMF). He underwent a renal allograft biopsy in 6/2017 to 
evaluate AKI, microscopic hematuria, and albuminuria. The biopsy showed PAVN. Blood 
BK virus PCR was undetectable. Blood JCV PCR peaked at 4,200 copies/ml and urine JCV 
PCR 24 million copies/ml. His MMF was stopped, prednisone 7.5mg daily was added, and 
tacrolimus dose was adjusted to maintain a trough level between 2 and 5ng/ml. Blood JCV 
PCR decreased to 1,500 copies/ml and urine JCV PCR decreased to 9.9 million copies/ml 
11 months after diagnosis of JCVAN. He continues to have stable renal allograft function 
with no neurologic symptoms.
Discussion: PAVN should be considered as a cause of late-onset AKI in kidney 
transplant recipients. JCV should be considered as the cause of PAVN, particularly 
when BK virus infection is excluded. Neurologic symptoms are absent. Reduction in 
immunosuppression remains the mainstay of management of JCVAN.
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A Significance of Serum Albumin in Kidney Transplant Recipient: 
Association with Cardiovascular Event and Mortality
Akihiro Tsuchimoto,1 Yuta Matsukuma,1 Yasuhiro Kawai,1 Kenji Ueki,1 
Kaneyasu Nakagawa,1 Shunsuke Yamada,1 Yasuhiro Okabe,1 Kosuke Masutani,2 
Toshiaki Nakano,1 Takanari Kitazono.1 1Kyushu University, Fukuoka, Japan; 
2Fukuoka University, Fukuoka, Japan.
Background: Serum albumin is a marker of malnutrition, inflammation and 
proteinuria. The aim of this study is to investigate the association between serum albumin 
and outcomes in kidney transplant (KT) recipient.
Methods: We reviewed a total of 387 patients over 15 y.o. who received KT from 2006 
through 2012 in Kyushu University. The patients divided into 3 groups according to serum 
albumin one year after KT (ALB1y); T1 1.4-4.1 g/dL, n= 93, T2: 4.1-4.3 g/dL, n=145, T3: 
4.4-5.6 g/dL, n=149. We investigated various events after one year, consisting of all cause 
mortalities, new onset cardiovascular disease (CVD), graft dysfunction (doubling serum 
creatinine and/or development of end-stage kidney disease), new onset malignancy and 
infectious episode need administration.
Results: The patients consisted of 233 male and 154 female with median age (IQR) 
of 44 (35-56) years. A number of patients received transplantation from deceased donors 
was 56, those with diabetes mellitus as primary disease was 82. ALB1y was associated 
positively with LDL cholesterol and eGFR, and negatively with age, dialysis duration, 
proportion of diabetic mellitus as primary disease, incidence of rejection episode within 
one year, and C reactive protein. Cox hazard models revealed all cause mortalities and 
new onset of CVD in T1 was significantly worse than those in T3. Hazard ratio (HR) for 
mortalities was 4.82 and 95% confidential interval (95%C.I.) was 1.62-17.70, and P=0.004 
for T1 vs T3. HR for CVD was 5.20, 95%C.I. was 2.12-14.60, and P=0.0002 for T1 vs 
T3. The association between ALB1y and graft dysfunction was weak; HR of T1 was 2.16, 
P=0.042. However, ALB1y was not associated with malignancy nor infectious episodes.
Conclusions: Low serum albumin was a strong risk factor of all cause mortalities and 
new onset CVD.
ALB1y and outcomes.
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Outcomes of Switching Renal Transplant Recipients to Generic Mycophe-
nolate Mofetil: A Single Center Study
Mohammad Zaitoun, Khalid Al-Alsheikh, As’ad T. Ibrahim. Armed Forces 
Hospitals Southern Region, Khamis Mushayt, Saudi Arabia.
Background: The aim of the study was to investigate the clinical and economic 
outcomes of switching clinically stable renal transplant recipients to a lower-cost generic 
Mycophenolate Mofetil.
Methods: From January 2017, all renal transplant patients receiving mycophenolate 
mofetil (CellCept, Roche) were switched to same doses of another generic (APO-
Mycophenolate, Apotex) at the Armed Forces Hospitals Southern Region, Khamis Mushait, 
Saudi Arabia. Patients were followed up for one year for changes in serum creatinine, 
incidence of infections, acute tubular necrosis, renal biopsy, acute rejection, changes in 
tacrolimus or ciclosporin levels and death. Besides, direct cost saving was calculated.
Results: During the study period, 161 renal transplant patients (58.4% males, 41.6% 
females, mean age = 45.5 ± 15.5 years, mean duration since transplantation = 11.4 years) 
were switched to APO-Mycophenolate. Among them, 19 patients were diagnosed before 
switching with chronic allograft nephropathy (CAN). The baseline serum creatinine of 
the study sample was 100.24 ± 42.64 mcmol/l. After switching, serum creatinine did not 
change significantly after 3 months (94.48 ± 57.62), 6 months (98.97 ± 59.5), 9 months 
(99.75 ±56.93) and one year (106.21 ± 76.34) (p=0.5). For the CAN patients, the serum 
creatinine also did not change significantly from baseline (185±52.63 mcmol/l) till the end 
of the study period (220.74 ± 139.3 p=0.76). For the patients on Tacrolimus (n=101), trough 
levels did not differ significantly before and after one year of switching (5.63 ± 1.44 ng/
ml vs 5.62 ± 1.49 ng/ml, p=0.73). Similarly, C0 for Ciclosporin patients did not change 
significantly (265.54±245.22 vs 270.27 ± 277.84, p=0.87). Fifteen patients developed 
16 infectious episodes, one of which was life threatening (cerebral toxoplasmosis). Four 
patients experienced Gastrointestinal symptoms (2.48%) that lead to mycophenolate 
discontinuation in two of them (1.24 %). No patients underwent renal biopsy, experienced 
acute tubular necrosis/acute rejection or died during the study period. Besides, Use of APO-
Mycophenolate was associated with a direct cost saving of 431309 Saudi Riyals compared 
to Cellcept.
Conclusions: Using generic Mycophenolate Mofetil in clinically stable renal transplant 
recipients was associated with similar efficacy and safety profile with significantly reduced 
cost.
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Publication-Only 
Can You Reject Your Own Kidney?
Abhilash Koratala, Mark S. Segal, Xu Zeng. University of Florida, 
Gainesville, FL.
Introduction: Renal involvement secondary to Graft-versus-host disease (GVHD) is 
considered rare and membranous nephropathy and minimal change disease are considered 
to be the most common glomerular lesions associated with GVHD. Herein, we present a 
unique case of renal GVHD with isolated involvement of the tubulointerstitium.
Case Description: A 64-year-old Caucasian woman was seen for evaluation of 
proteinuria and gradually worsening serum creatinine (Scr) over a period of 4 months. Her 
medical history was significant for hypertension, diabetes and myelofibrosis s/p matched 
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unrelated donor peripheral blood allogenic stem cell transplant 2 years ago. Her post-
transplant course was complicated by severe chronic GVHD involving skin, buccal mucosa, 
eyes and lung, all manifested within the first year of transplant. Chronic GVHD was initially 
managed with tacrolimus, ruxolitinib (JAK inhibitor), prednisone and extracorporeal 
photopheresis. 3 months prior, tacrolimus was switched to sirolimus due to recurrent non-
melanoma skin cancers. Scr was 1.94 mg/dL and 24-hour urinary total protein was 3.5 g 
(~1.6 g albumin) at presentation. Because of the persistent tubular proteinuria despite ACEI 
therapy and decrease in sirolimus dosage, renal biopsy was obtained. It demonstrated severe 
GVHD resembling an acute T-cell mediated rejection in a transplanted kidney [Figure]. The 
disease was confined to tubulointerstitium without any glomerular lesions or peritubular 
capillaritis, confirmed by EM. As there is no clear consensus on the optimal management of 
renal GVHD, our patient was treated with 3 days of pulse steroids, in line with treatment of 
acute cell-mediated rejection in a renal allograft. A week after the treatment, 24-hour urinary 
protein improved to 1.1 g.
Discussion: Renal GVHD may be underdiagnosed in patients with HCT, as they are 
not frequently biopsied owing to multifactorial nature of the renal dysfunction and relative 
contraindications to biopsy such as low platelet counts. Keeping low treshold for biopsy 
may pave way for the development of better and effective treatment regimens.
PUB770 
Publication-Only 
Hypercalcemia and Pneumocystis Pneumonia After Kidney Transplanta-
tion: A Non-Fortuitous Association
Aghiles Hamroun,1 Linh Bui,1 Remi Lenain,1 Paul Chamley,1 Séverine Loridant,2,3 
Yann Neugebauer,4 Arnaud Lionet,1 Marc Hazzan.1 1Nephrology, Lille University 
Hospital Center, Lille, France; 2Parsitology and Mycology Laboratory, 
Microbiology Institute, Lille University Hospital Center, Lille, France; 3LIRIC-
UMR 995 INSERM, Lille University, Lille, France; 4Nephrology, Douai Hospital 
Center, Douai, France.
Background: Hypercalcemia may persist beyond the first year after transplantation 
in 5 to 10% of the kidney transplant recipients (KTR), mainly due to persistent 
hyperparathyroidism. Recently, a few scattered observations of hypercalcemia associated 
with Pneumocystis pneumonia (PCP) in KTR have been reported but its prevalence and 
potential pathophysiological mechanisms remain unknown.
Methods: This retrospective cohort collected all proven cases of PCP in adult KTR, 
that occurred between January 2005 and August 2017 in our center.
Results: Among the 49 confirmed cases of PCP, 18 patients experienced hypercalcemia 
(12.0±1.6 mg/L), which represented a prevalence of 36.7%. The clinical presentation was 
different between hypercalcemic and normocalcemic patients (29.4% only presented 
febrile dyspnea versus 66.7%, respectively, p=0,02). In the hypercalcemic group, eGFR 
was significantly lower (26.5±10 versus 36.1±16.2 mL/min/1.73m2, p=0.013), while 25-
OH vitamin D levels and calciuria-on-creatininuria-ratio were higher (respectively 28.1±8.8 
versus 14.2±8.6 ng/mL, p=0.008 and 0.28 [0.16-0.39] versus 0.05 mg/mg [0.02-0.07], 
p=0.001). In the hypercalcemic group, 1,25-OH vitamin D levels, also higher at the time of 
PCP, collapsed after healing, while PTH levels, initially lower, increased secondarily after 
PCP (Figure).
Conclusions: To the best of our knowledge, this is the first reported cohort of adult 
KTR suffering from PCP-associated hypercalcemia. The evolution of vitamin D and PTH 
levels around the infectious episode pleads in favour of an extra-parathyroid mechanism 
and suggests a granulomatous reaction. Acute hypercalcemia after renal transplantation 
may be related to PCP and should lead to enlightened investigations, even in the absence of 
infectious or respiratory symptoms.
Evolution of calcium and PTH serum levels before and after PCP.
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An Unusual Cause of AKI in a Renal Transplant Recipient
Abhilash Koratala, Gajapathiraju Chamarthi, Xu Zeng, Kawther F. Alquadan. 
University of Flroida, Gainesville, FL.
Introduction: Acute kidney injury is one of the major determinants of graft survival 
in kidney transplantation and has to be promptly addressed with appropriate investigations.
Case Description: A 43-year-old Asian man with a history of ESRD, status post 
deceased donor kidney transplantation in China 3 months ago, was sent to the ER for 
elevated Scr of ~3.1 mg/dL. Reportedly, his post-transplant baseline creatinine was about 
1.5 mg/dL. He was told in China that the blood vessel supplying the transplanted kidney 
was ‘shrunk’. Doppler ultrasonography of the allograft done in the ER demonstrated a 
single renal artery with slight blunting of the systolic upstroke, but otherwise unremarkable 
flow [Figure-1A]. There was no evidence of renal infarction and the resistive indices were 
wnl. His BP was well controlled. As the renal function failed to improve with supportive 
measures, a biopsy of the allograft was performed, which showed no evidence of acute 
rejection or tubular injury [Figure-1B]. Based on the patient’s history that something 
might be wrong with his renal artery, a carbon dioxide (CO2) angiogram of the pelvic and 
renal arteries was performed, which revealed 2 separate renal arteries anastomosed to the 
right external iliac artery [Figure-1C]. There was good flow through the lower pole renal 
artery with minimal pressure gradient across the anastomosis but the upper pole artery 
demonstrated more than 75% stenosis with a significant pressure gradient of 107 mmHg. 
The gradient reduced to 21 mmHg after successful balloon angioplasty [Figure-1D]. The 
patient’s Scr improved back to the baseline value of 1.5 mg/dL at 1-week follow up.
Discussion: Take home message from our case: High index of suspicion is required for 
ischemic nephropathy in renal transplant patients presenting with unexplained acute kidney 
injury, as it is potentially reversible.
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Performance on Longevity Matching Using Current KAS
Shan Shan Chen,1 Igor Litvinovich,2 V. Shane Pankratz,3 Mark L. Unruh,1 
Rawan T. Al-Odat,1 Christos Argyropoulos,1 Yue-Harn Ng.1 1University of New 
Mexico, Albuquerque, NM; 2The University of New Mexico, Albuquerque, NM; 
3UNM Health Sciences Center, Albuquerque, NM.
Background: To improve longevity matching, current kidney allocation system(KAS) 
allots top 20% Kidney Donor Profile Index(KDPI) kidneys to top 20% Estimated Post 
Transplant Survival(EPTS) recipients. Among KDPI<85% kidneys, some fulfil Expanded 
Criteria Donor(ECD) status. We evaluate the outcome of ECD kidneys compared to 
standard criteria donor(SCD) ones and in whom ECD kidneys are transplanted.
Methods: Using data from Scientific Registry of Transplant Recipients, we 
retrospectively calculated EPTS of recipients and KDPI, SCD/ECD status of kidneys 
transplanted from 1/02 to 9/16. We assessed the graft outcome of KDPI<85% kidneys 
stratified by ECD vs SCD status and determined the distribution of these kidneys across 
EPTS deciles.
Results: Among 146,912 kidneys with KDPI<85%, 15,820(11%) were ECDs. 
Significant differences existed in baseline characteristics of recipients(Table1). ECD 
kidneys had 65% higher risk of graft failure than SCD ones and were transplanted across 
all EPTS deciles(Figure1).
Conclusions: As ECD kidneys have worse allograft survival and are transplanted 
across all EPTS deciles, we recommend to 1)identify individuals who may not benefit from 
receiving ECD kidneys 2)counsel those who will receive them about higher risk of graft 
failure.
Funding: Commercial Support - Dialysis Clinic Inc
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Histomorphometric Analyses of Preimplantation Needle Biopsies of Paired 
Kidneys from the Same Deceased Donors
Marcin Adamczak,1 Katarzyna Kwiecien,1 Magdalena E. Szotowska,1 
Wojciech Wystrychowski,2 Robert Król,2 Andrzej Wiecek.1 1Department of 
Nephrology, Transplantation and Internal Medicine, Medical University of 
Silesia, Katowice, Poland, Katowice, Poland; 2Department of General, Vascular 
and Transplant Surgery, Medical University of Silesia, Katowice, Poland, 
Katowice, Poland.
Background: Both donor and recipient factors influence kidney graft function. 
Integrated histo-morphometric assessment of transplanted kidney might better predict graft 
survival. The aim of the study was to determine differences in histomorphometric analyses 
of preimplantation needle biopsies of paired kidneys from the same donors.
Methods: Forty pairs of kidneys harvested from 40 donors (17F/23M; median age 42.3 
and 95% CI 37.6-47.0 years) in which diagnostic preimplantation biopsies were done, were 
included into the analysis. Mean glomerular volume, mean glomerular density and mean 
capillaries density in the interstitium were estimated. For statistical analyses Wilcoxon tests 
were used. Results were presented as mean and 95% CI.
Results: Paired kidneys harvested from the same deceased donor did not differ in mean 
glomerular volume [2.59 (2.24-2.93) vs 2.49 (2.15-2.84) μm3 x106], glomerular density 
[3.43 (3.07-3.80) vs 3.24 (2.87-3.61) n/mm2] and capillaries density in the interstitium 
[233.58 (211.26-255.90) vs 217.80 (199.45-236.47) n/mm2].
Conclusions: In daily clinical practice assessment of only one from both harvested 
kidneys from the donor seems to be sufficient for histomorphometric analysis.
Funding: Government Support - Non-U.S.
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Post-Transplant Vitamin D Deficiency: Comparison of Two Repletion 
Regimens
William M. Bennett,1 Thomas D. Batiuk,1 Marilani S. Ching,2 
Jeffrey Chamberlain,3 Danielle Boschetto,5 Sarah Mcdaniel.4 1Legacy Good 
Samaritan Medical Center, Portland, OR; 2Legacy Heralth System, Good 
Samaritan Hospital, Portland, OR; 3Legacy Health Kidney Transplant Services, 
Portland, OR; 4St. Luke’s Elmore Medical Center, Mountain Home, ID; 5Oregon 
Health and Science University, Portland, OR.
Background: Vitamin D deficiency is common post-transplant associated with 
immune impairment and ongoing metablic bone disease.(1)
Methods: We randomized 62 patients who had 25-OH D levels < 20, 1 month post-
transplant to vitamin D3 4000 units daily (low dose) or 50,000 units daily (high dose) for 
30 days. Patients were followed for 2 years. Immunosuppression was 3 mg/kg thymoglobin 
induction followed by tacrolimus, mycophenolate and prednisone.
Results: There were no differences in graft or patient survival between groups. Only 
the high dose group had >100 ng/ml 25-OH D levels after 1 month (63%). There were no 
evident clinical sequelae.
Conclusions: Both regimens were safe and effective. There is a tendency for less 
rejection on the high dose regimen suggesting the possibility that vitamin D may have 
beneficial immune modulatory effects. This needs to be tested prospectively. Reference: 1. 
Chung BH, Kim B-M, Doh KC, Min J-W, Cho M-L, Kim KW, Yang CW. Suppressive effect 
of 1α,25-Dihydroxyvitamin D3 on Th17-immune responses in kidney transplant recipients 
with tacrolimus-based immunosuppression. Transplantation 2017; 101:1711-1719.
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Demographic Data and Results
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Combined Polyoma Virus-Associated Nephropathy (PVAN) and Rejection 
Treated with Thymoglobulin and Brincidofovir (CMX) in a Renal 
Transplant Recipient
L Parker Gregg,1,2 Nashila AbdulRahim,1 Bekir Tanriover,1 Ricardo M. La Hoz,1 
Venkatesh Kumar Ariyamuthu.1 1UT Southwestern Medical Center, Dallas, TX; 
2VA North Texas Healthcare System, Dallas, TX.
Introduction: PVAN occurs in 1-10% of kidney transplant recipients. Concomitant 
rejection and PVAN is a challenging scenario for immunosuppression (IS) management. 
We present a case of biopsy-proven PVAN and acute cellular rejection (ACR) treated with 
CMX and aggressive augmentation of IS.
Case Description: A 49 year-old man with ESRD from type 2 diabetes and 
hypertension received a DDRT with ATG induction and maintained on tacrolimus (TAC)/
MMF and Prednisone. Six weeks after his transplant he had a mild acute antibody-mediated 
rejection (AMR) that was treated with methylprednisolone, IVIG, and plasmapheresis. His 
serum BK PCR came positive in 6 months and reached 85,560 copies/mL in 8 months, and 
mycophenolate (MPA) was stopped, but continuing prior doses of Tac. Two weeks later, 
his creatinine rose to 3.3, and biopsy showed Banff 1B (ACR) and AMR. He was treated 
with steroids, plasmapheresis, and IVIG. His creatinine returned to a nadir of 1.9, but again 
rose to 2.1. BK titer at this time was 12,799 copies/mL. Repeat biopsy showed persistent 
ACR Banff 1B and AMR, and positive for SV40 staining and was treated with ATG 
4.5 mg/kg, methylprednisolone and IVIG. He was also started on CMX100 mg twice a 
week. His creatinine decreased to 1.5 and he was discharged home on Tac, prednisone 
and MPA. Repeat kidney biopsy showed AMR and BKVAN. His IS was decreased and 
continued on CMX. In 3/2016 he developed leukopenia, BK titer rose to 269,659 copies/mL, 
and creatinine rose to 2.4 in the setting of sub-therapeutic tacrolimus levels. CMX and MPA 
were discontinued, and he was given IVIG. Over last 18 months his creatinine has been 
stable and his serum BK titers have most recently been just detectable.
Discussion: We report the first case when CMX was used with aggressive augmentation 
of IS for concurrent PVAN and ACR. We believe CMX allowed us to augment IS in the 
setting of PVAN and preserve the allograft.
Log10BKV Plasma PCR and Serum Creatinine vs. Time post-transplantation
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100% cPRA Renal Transplant Recipients Are at Increased Risk of 
Polyoma BK Viremia but Not Graft Loss
Grant Schalet,1 David J. Conti.2 1Albany Medical College, Albany, NY; 2Albany 
Medical Center, Albany, NY.
Background: We investigated whether 100% cPRA sensitized kidney transplant 
recipients are at increased risk of polyoma BK viremia due to enhanced postoperative 
immunosuppression.
Methods: Plasma PCR monitoring for BKV was performed monthly in all recipients. 
Immunosuppression for all patients included thymoglobulin induction and maintenance 
sirolimus (rapamycin), low-dose CellCept (Mycophenolate Mofetil), and low-dose 
tacrolimus. BK viremia was defined as viral DNA >1,000 copies/mL. Recipients identified 
to have BK viremia underwent an immediate reduction in immunosuppression. We analyzed 
BK viremia rates in 100% cPRA recipients (19) versus non-100% cPRA recipients (96) 
between December 2014 and March 2017.
Results: Of the 100% cPRA patients, 31.6% were found to be positive for BK viremia 
versus only 15.6% with <100% cPRA (Fisher’s exact test: p=0.112). Despite the increased 
incidence in BK viremia in 100% cPRA patients, the mean time to detection and mean 
serum creatinine at 12 months was not statistically significant (Two-sample t-test: p=0.302 
and p=0.999). Through reducing immunosuppression, BKV resolved in all patients 
without progression to BK nephropathy or acute reactivation. None of the viremic patients 
experienced acute rejection following immunotherapy reduction.
Conclusions: BK viremia rate was greater in 100% cPRA recipients than those in the 
non-100% cPRA group. However, this was not detrimental to one-year graft survival and 
function over time with our monthly screening protocol. Graft survival and function in 
BKV positive 100% cPRA patients was similar to that of the non-100% cPRA group. This 
data indicates that monthly screening of BK viremia in 100% cPRA patients is effective in 
preserving one-year graft function outcomes.
Demographics and Clinical Characteristics of Renal Transplant Recipient Population
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Elimination of Chronic Hepatitis B in a Kidney Transplantation Recipient 
via Lamivudine Monotherapy: A Case Report
Sangeon Gwoo,1 Mun Jang.2 1Department of Internal Medicine, MH Yeonse 
Hospital, Changwon-si, Gyeonsangnam-do, Republic of Korea; 2Department of 
Internal Medicine, Yemidam Hospital, Cheongju-si, Republic of Korea.
Introduction: Numerous studies have investigated lamivudine use for the treatment of 
hepatitis B virus (HBV) infection after kidney transplantation (KT). However, the efficacy 
and safety of lamivudine after KT remain unclear. A meta-analysis of 14 clinical trials (184 
patients) demonstrated a hepatitis B envelope antigen (HBeAg) seroconversion rate of 27% 
(16 - 39%) and a HBV-DNA clearance rate of 91% (86 - 96%) in lamivudine-treated HBV-
infected KT recipients; however, maintaining HBsAg clearance over 10 years has not been 
reported previously.
Case Description: A 56-year-old HBV-infected man had undergone KT for chronic 
glomerular nephropathy 20 years prior. Before KT, serological markers of HBV revealed 
that the patient was hepatitis B surface antigen (HBsAg)-positive and HBeAg-negative. A 
daily dose of 25 mg lamivudine monotherapy was started 8 weeks before KT. After KT, 
100 mg of lamivudine was prescribed daily for 16 years, but was stopped 4 years prior to 
presentation. After 42 months of lamivudine treatment, HBsAg cleared, and 32 months 
later hepatitis B surface antibody (HBsAb) appeared. Four years after lamivudine therapy 
termination, serological markers revealed that the patient was HBsAg-negative, HBsAb-
positive, and HBeAg-negative.
Discussion: HBsAg-positive KT recipients are at increased risk of mortality and graft 
failure compared to seronegative patients. Natural immunity to HBV may not protect 
against reactivation in immunocompromised patients. Currently, lamivudine is not the 
treatment of choice in chronic HBV-infected KT recipients because of its relatively lower 
treatment rate than other anti-viral agents. Furthermore, it can lead to increase in lamivudine 
resistance due to mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) locus. 
We report a case in which chronic hepatitis B remission was sustained for over 10 years 
via lamivudine monotherapy without YMDD mutation and any adverse effects. This case 
describes a sustained cure of chronic HBV infection in a KT recipient without a YMDD 
mutation via lamivudine monotherapy.
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Significance of Donor-Specific Antibodies in Sequential Liver-Kidney 
Transplantation from the Same Donor
Mai Sato, Mureo Kasahara, Masao Ogura, Koichi Kamei, Kenji Ishikura. 
National Center for Child Health and Development, Tokyo, Japan.
Background: Donor-specific antibodies (DSA) occur in recipients of sequential liver-
kidney transplantation from the same donor. In simultaneous liver-kidney transplantation, 
the liver’s protective effect on the kidney results in a lower acute rejection rate and better 
renal allograft survival than in isolated kidney transplantation (KT). Our aim was to 
determine the significance of DSA in recipients of sequential liver-kidney transplantation 
from the same donor.
Methods: We retrospectively analyzed data on patients aged <20 years who underwent 
sequential liver-kidney transplantation from the same donor between November 2005 
and March 2017 at our institute. All patients were screened for DSA using complement-
dependent cytotoxicity, flow-cytometry crossmatch, flow panel reactive antigen, and 
Luminex single antigen before KT.
Results: The cohort included five recipients. The primary disease comprised 
autosomal recessive polycystic kidney disease (3 cases), primary hyperoxaluria (1 case), 
and nephronophthisis (1 case). The median age at liver transplantation (LT) and KT was 
5.6 years (range 0.7-7.5) and 6.1 years (range 3.0-7.9), respectively. The median duration 
between the procedures and the median follow-up duration was 1.1 years (range 0.4-2.4) 
and 2.4 years (range 1.2-8.1), respectively. Four patients were positive for DSA after LT 
prior to KT and had the DQ6 (6592MFI) and DR15 (7050MFI), B44 (2892MFI) and DQ6 
(8946MFI), DQ7 (21263MFI) and DR53 (22080MFI), and DQ6 (7088MFI) antigens. 
One patient received plasmapheresis and intravenous immunoglobulin, and two patients 
received rituximab, plasmapheresis, and intravenous immunoglobulin before KT. One 
patient did not receive desensitization therapy. All patients except one received standard 
immunosuppressant therapy with prednisolone, tacrolimus, and mycophenolate mofetil 
as did the non-sensitized patients. One patient was targeted for the ABO incompatible 
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protocol. Although two patients showed the DSA antigen after KT, they showed no 
histologic evidence of antibody-mediated rejection, and their allograft function was similar 
to that in non-sensitized patients. All patients had good liver function. Two patients who 
received a liver biopsy showed no sign of rejection.
Conclusions: In sequential liver-kidney transplantation from the same donor, DSA 
may not contribute to antibody-mediated rejection.
PUB779 
Publication-Only 
Histopathological Examination of Removed Kidney Allografts: Is It 
Useful?
Kim Bunthof,1 Eric Steenbergen,2 Luuk Hilbrands.1 1Nephrology, Radboud 
University Medical Centre, Nijmegen, Netherlands; 2Pathology, Radboud 
University Medical Centre, Nijmegen, Netherlands.
Background: The rate of allograft nephrectomy after graft failure varies between 
4.5% and 84.4%, reflecting the lack of a standard policy. The incidence and relevance 
of histological findings in removed grafts is unknown. In this study, we investigated the 
outcome of histopathological examination of removed grafts.
Methods: We performed a retrospective cohort study in patients who underwent a 
kidney transplantation between 1981 and 2015, and in whom the graft failed ≥ 3 months 
after transplantation. In these cases, our policy is to remove the graft only on indication 
(e.g. graft intolerance syndrome). We routinely send the removed graft for histopathological 
examination. In total, 198 allograft nephrectomies were performed. In 31 cases, no pathology 
report was available, leaving 167 cases for analysis. Pathology reports were especially 
reviewed for recurrences of primary disease and for unexpected findings. Moreover, the 
consequences for clinical management of these findings were examined in the patient charts.
Results: In 17 of the 167 examined grafts, gross necrosis due to infarction or thrombosis 
precluded adequate interpretation. Signs of acute and/or chronic rejection were reported in 
137 of the remaining 150 allografts. Recurrence of the original disease was the main finding 
in 8 cases: primary focal segmental glomerulosclerosis (n=4) and membranoproliferative 
glomerulonephritis (n=4). In all cases, the recurrence was already known from prior kidney 
graft biopsies. Relevant secondary findings were present in 8 cases: renal cell carcinoma 
(n=2), urothelial cell carcinoma, candida pyelonephritis (n=2), PTLD, polyomavirus 
inclusions, and oxalate deposition. All these conditions were already diagnosed before 
the graft nephrectomy, with the exception of one case of papillary renal cell carcinoma of 
0.8 cm. The clinical consequence of the latter finding was that retransplantation for this 
patient was withheld for 9 months.
Conclusions: As expected, acute and/or chronic rejection is the main histopathological 
finding in grafts that are removed after late graft failure. Unexpected secondary findings are 
very rare. We therefore question whether routine histopathological examination of removed 
kidney allografts is useful and cost-effective.
PUB780 
Publication-Only 
A Single Center Experience of Kidney Transplantation in Jehovah’s 
Witness Patients
Muhammad O. Hanif,1 Amanda A. Karasinski,1 Abbas Raza,1 Gregory Malat,2 
Lissa B. Levin Mizrahi,1 Meera N. Harhay,1 Karthik M. Ranganna.1 1Drexel 
University, PHILADELPHIA, PA; 2Transplant, Hahnemann University Hospital, 
Philadelphia, PA.
Background: Jehovah’s witness patients refuse blood products due to religious 
implications, but they do accept organ transplantation, albumin, immunoglobulin and 
some even accept clotting factors. We present a case series of Jehovah’s witness patients 
who successfully received renal transplantation in our bloodless center for surgeries and 
transplantation.
Methods: We performed a single center retrospective study of renal transplants in 
Jehovah’s witness patients from 2001 to 2018.
Results: A total of 13 patients received renal transplantation. One recipient received a 
kidney from a living donor and the others received deceased donor kidneys. Donor quality 
(average kidney donor profile index scores reported 37 ± 29%). No patients required blood 
products. Nine received erythropoietic stimulating agents and 2 received IV iron. Eight 
patients received Basiliximab and 5 received thymoglobulin for induction. All were on 
calcineurin inhibitors, 12 were on mycophenolate mofetil, 1 was on sirolimus and 3 were on 
steroid withdrawal protocol. Two patients were treated for rejection: 1 had a combination of 
both cellular and humoral rejection and required additional thymoglobulin, plasmapheresis 
and IVIG in the first year, while the other was preemptively treated for cellular rejection 
with methylprednisolone. The average length of hospital stay was 7.7 days. Five patients 
required readmission within 30 days; no readmissions were related to anemia. Patient and 
graft survival at 1 and 3-year were 100%. 6 allografts continue to function, 2 died with 
functioning graft, 3 have failed allografts and 2 patients were lost to follow up.
Conclusions: Although kidney transplantation does not generally require blood 
products, except in the case of surgical complications, our experience showed that Jehovah’s 
witness patients can safely undergo transplantation with similar allograft outcomes as the 
general population while respecting their religious beliefs.
Table 1: Patient characteristics
PUB781 
Publication-Only 
Leptin and Adiponectin Serum Levels in Kidney Transplant Recipients: 
Preliminary Results
Omar I. Delgado-Ayon,1,2 Andrea F. Aguilar,3 Denisse Arellano-Mendez,1,2 
Godhy E. Hernandez Gonzalez,1,2 Daril J. Herena monreal,1,2 Renato Parra 
Michel,4,2 Efrain Chavarria-Avila,5 Jorge fernando Topete reyes.1,2 1Universidad 
de Guadalajara, Guadalajara, Mexico; 2Nefrología, Instituto Mexicano del 
Seguro Social, Guadalajara, Mexico; 3University of Guadalajara, 
Guadalajara, Mexico; 4Universidad de Guadalajara, Centro Universitario de 
Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano 
del Seguro Social, Guadalajara, Mexico; 5Universidad de Guadalajara, 
Guadalajara, Mexico.
Background: Adipokines modulate endocrine and immune processes; they are 
regulated in turn by nutritional parameters. There is controversy between the findings 
of diverse studies that evaluate outcomes in Chronic Kidney Disease and its association 
with adipokines, including kidney transplant. The aim of this study was to evaluate the 
relationship between adipokines serum levels with the type of rejection in patients with 
kidney transplant (KT) as well as their immunosuppressive treatment.
Methods: In this cross-sectional study, 36 patients with KT were included. The 
measurement of leptin and adiponectin were on serum samples with an ELISA Kit, these 
measures were compared with the result of the KT biopsy (Banff 2017 criteria), nutritional 
parameters and the type of immunosuppressant (Tacrolimus, Sirolimus, Ciclosporin). This 
study complies with the WMA Declaration of Helsinki, and Declaration of Istanbul on 
Organ Trafficking and Transplant Tourism.
Results: There was a tendency for patients treated with calcineurin inhibitors 
(CNI) to have higher levels of leptin (21.6 ng/ml) than those of sirolimus (18.2 ng/ml). 
Regarding adiponectin, it was inversely showing tendencies at higher levels those of the 
sirolimus group (13.1 μg/ml) with respect to the CNI (10.8 μg/ml). A positive correlation 
of adiponectin was found with the post transplant time (r=0.477, P=0.016) and with the 
Proteinuria/Creatininuria index (r=0.563, P=0.005). Regarding the type of rejection, no 
significant differences were found, but it was observed that patients with active humoral 
rejection had a tendency to lower leptin concentrations (15.5 ng/ml) and those with only 
IF/TA had higher concentrations (25.3 ng/ml). Likewise, patients who presented chronic 
humoral rejection showed intermediate values (20.5 ng/ml). Regarding the concentrations 
of adiponectin the values were homogeneous in the range of 12.4-13.1 μg/ml.
Conclusions: The immunosuppressive treatment would influence levels of adipokines. 
Chronicity changes of the allograft would be determined by leptin levels, but not by 
adiponectin, whose levels apparently did not influence the type of rejection or chronic 
changes inherent to the graft, however they are correlated with post-transplant time and 
proteinuria.
PUB782 
Publication-Only 
Predictors and Outcomes of Calcium Oxalate Crystals in Kidney 
Transplant Recipients with AKI and Delayed Graft Function
Maha A. Mohamed. University of Wisconsin School of Medicine and Public 
Health, Madison, WI.
Background: The predictors of calcium oxalate (CaOx) deposits associated with Acute 
Kidney Injury (AKI) and Delayed Graft Function (DGF) and the impact of CaOx crystals 
on allograft survival are unclear. The aim of the study is to evaluate predictors and impact of 
CaOx crystals in kidney (KT), simultaneous liver kidney (SLK) and simultaneous pancreas 
and kidney (SPK) transplants with AKI and DGF.
Methods: We abstracted data for all KT, SLK, and SPK recipients who had for cause 
biopsies in a single center from 1994-2017. CaOx crystals were identified in 9 recipients 
with DGF and 15 recipients with AKI. These were matched on time since transplantation 
with 19 and 46 controls without DGF or AKI, respectively
Results: Median follow-up was 28 days for DGF and 502 days for AKI. Stepwise 
logistic regression models identified a nearly significant association between Banff i+t score 
(sum tubulitis and interstitial inflammation) and CaOx crystals in DGF (OR 9.9, p=0.072), 
while a history of native kidney nephrolithiasis was an independent predictor of CaOx in 
AKI (OR 20.03, p=0.037) table 1. CaOx was significantly associated with inferior death-
censored allograft survival in both DGF (p<0.001) and AKI (p=0.01) fig 1 (a & b).
Conclusions: CaOx crystals in allograft biopsies with AKI and DGF are associated 
with inferior allograft survival. Pre-transplant nephrolithiasis, tubulitis, and interstitial 
inflammation may be risk factors for CaOx crystals in allograft with AKI and DGF. These 
observations suggest a need to better understand the pathogenesis of CaOx crystals to 
develop preventive and therapeutic strategies in kidney transplant recipients
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Association of Anti-retroviral Therapy Following Kidney Transplantation 
on Incident BK Viremia
Abbas Raza,1 Amanda A. Karasinski,1 Jaime A. Baynes-Fields,1 Gregory Malat,2 
Suzanne Boyle,1 Meera N. Harhay,1 Karthik M. Ranganna.1 1Drexel University, 
Philadelphia, PA; 2Transplant, Hahnemann University Hospital, Philadelphia, 
PA.
Background: BK polyomavirus is an opportunistic virus that can cause polyomavirus-
associated nephropathy and graft failure after kidney transplantation (KT). Given 
interactions of anti-retroviral therapy (ART) with calcineurin inhibitors, many HIV+ KT 
recipients receive integrase inhibitor (II) based ART. We investigated BK viremia and 
nephropathy rates in HIV+ KT while on II ART.
Methods: We performed a single center retrospective study of 28 HIV+ KT 
recipients, transplanted between 2009 to 2017. We compared incidence of BK viremia 
after KT based on whether patients were on II-based ART or not. Study Population: 
All patients had undetectable HIV viral load and CD4 count > 200 cells/mm3. Standard 
HIV+ immunosuppression (IS) protocol at our center included basiliximab induction, 
CNI-based IS, mycophenolate, and steroid taper. After 2011, IVIG was added to induction 
IS. One recipient received anti-thymocyte globulin, secondary to increased PRA and re-
transplantation. BKV monitoring was performed by protocol for all patients following KT.
Results: Of the 28 recipients, 12 (43%) were maintained on II-based ART after KT 
(table 1). One-year post-KT, BK viremia (range: 2770 - 71150 copies/ml) rates were higher 
in the II-based ART group compared to the non-II group (3/12,vs.0/16, p=0.067). No 
allografts were lost from BK virus nephropathy; Rejection was noted to be higher in non-II 
group (2/12 vs 9/16 vs p=0.054). Graft survival at 1- and 3- year follow-up was 100/100% 
in the II-ART group vs. 100/94% in the comparative group. Median eGFR at 1 year for both 
groups were > 60 mL/min.
Conclusions: BK viremia is generally uncommon in the HIV+ KT population. Based 
on our follow-up, we have seen a slight increase in the incidence of clinically relevant BK 
viremia. Long-term follow-up is needed to monitor this HIV+ KT cohort.
Table-1
PUB784 
Publication-Only 
Continuation of Immunosuppression (IS) Protects Against Allosensitiza-
tion in Recipients of Kidney Transplant (KT) After Previous Non-Liver 
Solid Organ Transplantation (SOT)
Sadeem Ali,1 M. Lee Sanders,1 Christie P. Thomas,1 Roberto S. Kalil,1 
Elizabeth H. Field,2 Sarat C. Kuppachi.1 1Transplant Nephrology, University of 
Iowa College of Medicine, Iowa City, IA; 2Iowa City VA Health Care System, 
Iowa City, IA.
Background: Following kidney allograft loss, current standard of care involves 
discontinuing IS to prevent risks of more exposure. We hypothesized that continuation 
of IS after graft failure in candidates for another transplant would lower the risk of 
allosensitization.
Methods: We retrospectively analyzed calculated panel reactive antibodies (cPRA) on 
KT recipients at our center from January 2009 to March 2017 after having undergone a 
prior non-liver SOT. Patients with > 2 prior KT’s were excluded. We compared sensitization 
between those who continued IS, and those who did not, based on cPRAs at times of listing 
and pre-transplant, using Risk Ratio (RR) and Chi square or Fishers exact test for statistical 
significance.
Results: 87 cases met inclusion criteria. 70 had a prior KT, 10 simultaneous kidney 
and pancreas, 1 pancreas, 1 lung and 5 heart transplants before being listed for a second 
organ (KT). Table shows that in the 50 cases where IS was discontinued after failure of 
the first graft, 45 of 50 (90%) had a cPRA ≥ 20 at the time of their second organ (index 
kidney) transplant, whereas 18 of 37 cases with continued IS (48.6%) had a cPRA ≥ 20 
(RR = 1.85 [1.31-2.61], p < .0001, for proportion of sensitized cases when IS was 
discontinued). Among the 42 cases with available cPRA results at listing for the first 
transplant and the index KT, discontinuing IS after failure of first graft significantly increased 
the interim sensitization level compared to continuing IS (RR = 2.36 [1.23-4.51], p = 0.0008).
Conclusions: In this single center retrospective analysis, continuation of IS protects 
against the risk of allosensitization at listing for a second transplant. Both the proportion 
of sensitized patients and the magnitude of sensitization are significantly greater in cases 
that discontinued IS. Additional studies of IS management after graft failure are needed 
to determine whether the benefit of continued IS in candidates eligible for a second KT 
includes improved access to transplant and reduced morbidity.
Comparison of cPRA in cases continuing versus discontinuing IS
PUB785 
Publication-Only 
Efficacy and Safety of Ultra-Low Dose Valganciclovir Chemoprophylaxis 
for CMV Infection in High Risk KTP
Jin ho Lee,1 Seon Deok Hwang,2 Seoung Woo Lee,3 Woo Yeong Park,7 Jeong 
Ho Kim,8 Hee yeoun Kim,4 Seong min Kim,5 Joon Seok Oh,6 Dongyeol Lee,1 
Yong hun Sin,9 Joong Kyung Kim.1 1Bong Seng Memorial Hospital, Busan, 
Republic of Korea; 2Inha University College of Medicine, Incheon, Republic of 
Korea; 3Inha University Hospital, Inchon City, Republic of Korea; 4Bongseng 
hospital, Busan, Republic of Korea; 5Dongrae Bongseng Hospital, Busan, 
Republic of Korea; 6Bong Seng Hospital, Korea, Dong-gu, Busan, Republic of 
Korea; 7Dongsan Medical Center, Daegu, Republic of Korea; 8Daejeon St. 
Mary’s Hospital, Daejeon, Republic of Korea; 9Bong Seng Hospital, Busan, 
Republic of Korea.
Background: CMV syndrome and disease are one of the major causes of decreased 
graft and patient survival for kidney transplant(KT) recipients. CMV syndrome is defined 
as virus isolation or detection of viral proteins (antigens) or nucleic acid in any body fluid 
or tissue specimen. CMV disease consists of CMV syndrome plus the presence of sign 
or clinical symptoms in the end organs. Valganciclovir (VGCV) prophylaxis to prevent 
CMV infection is recommended for solid organ transplant patients. Most transplant centers 
perform universal prophylaxis only in high risk groups including ABOi KT and DDKT. Most 
studies recommend administration of VGCV 900 mg twice a day. However, compliance 
can be reduced due to expensive medication, or hematologic side effects can occur. 
Therefore, we studied whether an ultra-low dose and short duration of VGCV (450 mg, 
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every other day, 3 months after KTP) is sufficient to prevent CMV infection in ABOi KT 
and DDKT recipients
Methods: We retrospectively evaluated 74 CMV seropositive donor/seropositive 
recipient(D+/R+) adult ABOi KTP recipients and 78 CMV seropositive donor/seropositive 
recipient(D+/R+) adult DDKT recipients from June 2009 to July 2016 who received ultra-
low dose VGCV (450 mg every other day) prophylaxis for 3months. The primary outcome 
was occurrence of CMV syndrome and CMV disease. The secondary outcome was patient 
survival and graft survival.
Results: Follow-up durations were 2 to 52 months, respectively. CMV syndrome 
occurred in 1 case (1.4%) in ABOi KT and 2 cases (2.7%) in DDKT, but this was not 
statistically significant(p-value = 0.38). However, CMV disease occurred in one case 
(1.4%) in the ABOi KTP group and in 12 cases (16%) in the DDKT group, which was 
statistically significant(p-value 0.001). The CMV disease in ABOi was CMV pneumonia. 
CMV pneumonia was found in 8/12 (66.6%) and CMV colitis in 4/12 (33.3%) among the 
CMV disease in DDKT. Patient survival and graft survival(Fig.1) did not differ significantly 
between the two groups
Conclusions: Using an ultra-low dose VGCV, CMV prophylaxis was found to be 
effective in ABOi KTP, but DDKT increases the incidence of CMV disease. To reduce 
CMV disease after DDKT, the dose or duration of VGCV may be increased or preemptive 
treatment may be more effective
PUB786 
Publication-Only 
Nocardia Infection in Renal Transplant Patients: Report from Transplant 
Center in India
Amit Kumar,1 Sunil Prakash,1 Ashwini Goel.2 1Nephrology, BLK SuperSpeciality 
Hospital New Delhi, New Delhi, India; 2Nephrology, BLK Super Speciality 
Hospital, New Delhi, India.
Background: Nocardosis is an uncommon but important cause of Infection in renal 
transplant recipients. There is scarce data regarding Nocardisis from Indian Subcontinent. 
Here we present spectrum of Nocardia infection from our center in India.
Methods: A retrospective analysis of all transplant performed from July 2012 to June 
2017 was performed. Patients with diagnosis of Nocardia infection were identified. Their 
immunosupressive regimen, clinical presentation and outcome was examined.
Results: During the study period total 346 transplant were performed including Live, 
cadeveric, ABO-Incompatible. 3 patient (0.86%) developed Nocardia infection. Mean 
age at diagnosis was 58 years. 2 patients had Diabetes Mellitus and one had chronic 
Glomerulonephritis as native Kidney disease. All 3 received ATG as Induction and were 
on Tacrolimus, Mycophenolate and Prednisolone as maintenance immunosupression. Mean 
duration of presentation was 12 to 48 weeks after transplant. 1 patient was treated for acute 
cellular rejection in recent past with injection Methylprednisolone, one patient had recurrent 
infection including episode of CMV disease and tuberculosis in form of subcutaneous cold 
abscess and 3rd was largely asymptomatic prior to presentation.. One patient presented with 
Pulmonary Nocardiosis, one with epidural abscess at Dorsal Spine D3-D4 level and 3rd 
presented with paraspinal intramuscular abscess at lumbo-sacral level. All 3 were treated 
with combination antibiotic. 2 patients improved and one expired.
Conclusions: Nocardia infection is associated with significant morbidity and mortality. 
Pre transplant diabetes, treatment of rejection, ATG induction may be risk factor for 
Nocardia infection. High index of suspicion is essential for diagnosis as presentation is 
varied and patient may present late after transplant.
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Pre- and Post-Transplant Albumin Levels and Kidney Transplant Survival
Mita zahra E. Co,1 Arianne clare C. Agdamag,2 Michael lawrenz F. Co.2 
1Presence Saint Joseph Hospital, Chicago, IL; 2Rush University Medical Center, 
Chicago, IL.
Background: Survival of ESRD patients continues to be lower than the general 
population even after kidney transplant (KT). Predictors of outcomes are important 
guides in the proper referral and postoperative care among KT patients. We examined the 
association of pre- and post-KT albumin levels on patient survival.
Methods: We retrospectively enrolled patients who underwent KT from 2005 to 
2015 in our institution. Demographics, date of transplantation and death, albumin levels 
and preoperative comorbidities were obtained from medical records and kidney transplant 
program database. Cox regression, Kaplan Meier and ROC analyses were performed to 
determine the effect of pre- and post-KT levels on survival. Mean pre- and post-KT albumin 
levels were also compared using T-test for paired variables.
Results: A total of 705 patients underwent KT during the study period, 589 of which 
had both pre-KT and post-KT albumin data points. Mean pre-KT and post-KT albumin 
levels were 3.6±0.7 and 3.9±2.3 g/dL, respectively. Median follow-up time was 3.3 years 
(IQR 1.2-5.4 years). Cox regression analyses showed that both higher levels of pre-KT 
albumin (HR 0.67, p=0.01) and post-KT albumin (HR 0.28, p<0.001) were significantly 
associated with improved survival. KM survival analysis showed that a chosen pre-KT and 
post-KT albumin cut-off of 3.6 g/dL (log rank p=0.04) and 3.7 g/dL, (log rank p<0.001) 
were able to predict survival (Figure 1). After KT, 321 (54.6%) patients had improvement 
in albumin (mean increase of 0.3±2.4 g/dL, p=0.003). Improvement in albumin levels was 
not associated with improvement in survival (log rank p=0.55)
Conclusions: Our results showed that higher pre- and post-KT albumin levels are 
associated with improved survival. Although albumin levels imrove slightly after KT, this 
was not associated with improvements in surival. Optimization of nutrition and proper 
preoperative selection based on albumin levels may be keys to better risk stratification and 
improvement in survival of KT recipients.
Figure 1: KM Survival analyses for Pre- and Post-KT albumin levels
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Advice Given to Moslem Kidney Recipients by Moslem Nephrologists 
About Potentially Medically Risky Religious Rites
Ziad Arabi,1 Abdulrahman R. Altheaby,1 Mahfooz A. Farooqui,2 Elwaleed 
A. Elhassan,2 Mubarak I. Abdalla,2 Atif A. Mateen,2 Saleh Kaysi,3 Syed A. Alam,4 
Saif A. Khan,5 Abdulla Al sayyari.2 1Adult Transplant Nephrology, Organ
Transplant Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia; 
2Nephrology, Department of Medicine, King Abdulazziz Medical City, Riyadh,
Saudi Arabia; 3CHU Clermont-Ferrand, Saint Pryv/ Saint Mesmin, France; 
4Nephrology Department, Khyber Teaching Hospital, Peshawar, Pakistan; 
5Nephrology, Sultan Qaboos University hospital, Muscat, Oman.
Background: Moslem patients often ask their nephrologists if performing certain 
religious obligations may be harmful to their health. Permissibility as advised by an expert 
Muslim physician religiously acceptable waiving of such rites.
Methods: This is a cross-sectional survey of the nephrologists’ advices to posttransplant 
patients regarding fasting Ramadan, performing pilgrimage, Omrah, marital relations and 
pregnancy. The survey was sent to Moslem nephrologists in different countries.
Results: Of the respondents (n=58), 78% follow up posttransplant patients; 35% form 
Saudi Arabia, 19 % from USA and 20 % from Pakistan. 60% of the respondents would let 
stable patients, fast Ramadan after one year of transplantation whereas just one fifth would 
not recommend fasting at any time. If the patient is diabetic those who would not recommend 
fasting at any time increased to 32%. Three quarters would let patients perform Omrah after 
6 to 12 months and only 1.7% would not recommend that at any time. Obligatory Hajj, 
would be allowed by 58% after 1 year after transplantat, additional 22% will allow it after 2 
years and 5% would not recommend that at any time. The responses for nonobligatory Hajj 
were 47%, 23 % and 23% respectively. The majority felt that marital relationship could be 
resumed once the surgical incision has healed, 6% felt there should a period of one year of 
abstinence. 61% of the respondents would delay the pregnancy in primigravida with stable 
renal function for one year, 28% for 2 years, about 2 % would allow it immediately and none 
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would not recommend it at any time. In multiparous recipients, the respective frequencies 
were 45%, 25%, 3% and 20% The presence of controlled hypertension in the absence of 
proteinuria is not a contraindication to pregnancy except in only 3% of, whereas 71% would 
allow it after one year of transplantation. There was no statistical difference between the 
advice given by transplant nephrologist and general nephrologist on pregnancy or fasting 
Ramadan for the recipients or donors.
Conclusions: To our knowledge this the first study exploring the consensus among 
Moslem nephrologists regarding the advice they would give regarding performing 
potentially risky religious rites by Moslem posttransplant patients.
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When to Treat Hepatitis E in Renal Transplant Patients?
Jia neng Tan,1 Hersharan Sran,1 Angeline Goh,1 Rachel Teo,1 
Anantharaman Vathsala.2 1National University Hospital, Singapore, Singapore; 
2National University of Singapore, Singapore, Singapore.
Background: Whereas Hepatitis E (HepE) is a self-limiting illness in the 
immunocompetent, chronicity is increasingly reported among immunocompromised 
patients. In the absence of established therapy, current approach is initial monitoring with 
treatment for viral persistence. We hypothesized that spontaneous resolution is infrequent 
among immunocompromised renal transplant recipients(RTX), warranting early treatment.
Methods: This single-centre, retrospective study evaluated clinical and laboratory 
characteristics and outcomes for RTX with HepE.
Results: 10 RTX (90% Male, Median age 55years, 80% Chinese, 20% Indian) were 
diagnosed with HepE from 2013-2018, yielding a yearly incidence of up to 1,082/100,000 
population among RTX, in comparison to 0.92/100,000 in the general population. 2 reported 
intake of Chinese sausages or raw oysters. 1 Indian male was exposed to plasma products. 
Diagnosis of HepE was made on viral load (VL) detection in 9 RTX and by serology in 1 RTX 
at an interval of 111-8,770 days. At diagnosis, median AST was 80IU/mL, ALT 133IU/mL, 
ALP 102.5IU/mL and VL was 1,140,000IU/ml. Immunosuppression decrease (IsD) alone 
achieved viral clearance in 1 RTX with low VL of 4,380 copies; another RTX did not 
achieve clearance despite a 188 day trial of IsD. The remainder could not undergo IsD for 
clinical reasons and received Ribavirin (Rb) within 50 days of diagnosis. Of 9 treated with 
Rb, 4(44.4%) developed anaemia, majority requiring erythropoietin. 7 out of 8 (87.5%) 
achieved viral clearance within 105 days after initiation, 2(22.2%) had relapse/reinfection 
requiring re-treatment. 1 had treatment failure due to treatment-limiting side effects.
Conclusions: HepE has a high incidence among RTX, presenting with mild 
transaminitis and responding to Rb in the majority. As viral clearance with IsD is not 
effective or feasible in the majority, our results advocate for early treatment of HepE among 
RTX.
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The Aftermath of Chemotherapy for Burkitt Lymphoma in a Renal 
Transplant Recipient
Rasika A. Sirsat, Neha Shah. P. D. Hinduja Hospital and Medical Research 
Centre, Mumbai, India.
Introduction: Burkitt lymphoma is a very rare post-transplant lymphoproliferative 
disorder (PTLD) in adults. It behaves aggressively requiring cessation of conventional 
immunosuppression and urgent start of combination chemotherapy.
Case Description: A 44 year old man was diagnosed with CKD 5 secondary to ADPKD 
for which he underwent pre-emptive ABO compatible single haplotype matched live 
related renal allograft surgery in Jan’11 at our centre. He was on tacrolimus, azathioprine 
and steroids. He had an uneventful course for 5 years. In Apr’16, he was diagnosed with 
Burkitt lymphoma of the caecum (CD 20 and Ki67 positive) for which he received 6 cycles 
of chemotherapy (rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide and 
prednisolone). He was on 5mg prednisolone daily as maintenance therapy. He was cured 
of lymphoma in Nov’16 (sr creatinine 0.8 mg%). However, in Dec’16 he developed gross 
hematuria with graft dysfunction (sr creatinine 3.8 mg%) and pancytopenia. Peripheral 
smear and bone marrow examination were normal. Blood and urine cultures were negative. 
Urine TB PCR, geneXpert and culture were negative. Cystoscopy was normal. Serology 
(ELISA) showed: Parvovirus IgM-negative; EBV VCA IgM and IgG and EBNA IgG 
positive; HIV, HBsAg and anti HCV negative. Plasma and urine BK viral load, plasma 
CMV viral load were undetectable. However, his urine was positive for JCV and CMV 
(by NAAT). Renal biopsy showed acute interstitial nephritis with lymphocytic infiltrate of 
10-15% with no tubulitis or peritubular capillaritis and with C4d, SV40 and CMV negative 
with no chronic changes. Though no strong evidence, we presume that his graft succumbed 
to JC virus in just three months (contrary to current understanding of JCV nephropathy
having a favourable graft outcome). The patient continues to be on hemodialysis. He
developed orbito-cerebral mucormycosis in Aug’17 requiring left orbital exenteration and
antifungals to which he responded.
Discussion: Despite recovering from Burkitt lymphoma, our patient suffered two 
opportunistic infections within a year of completion of chemotherapy, though he was not on 
calcineurin inhibitors and antiproliferative agents. It was tragic that he didnot lose the graft 
to rejection but to infection highlighting that immunity can remain suppressed as long as 
9 -12 months post chemotherapy.
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Multimodal Individualised Treatment for Recurrent FSGS After a Third 
Kidney Transplantation Using Rituximab and Belatacept
Dan Hristea,1,2 Jacques Dantal.3 1ECHO Nantes, St Herblain, France; 2Institut 
de Transplantation Urologie Néphrologie, Nantes, France; 3Institut de 
Transplantation Urologie Néphrologie, Nantes, France.
Introduction: Recurrent nephrotic syndrome due to FSGS is associated with poor 
transplant outcomes, its optimal management is not yet established.
Case Description: We report the case of a 48 years old patient treated by hemodialysis 
since 1992 due to ESRD caused by biopsy proven FSGS. A first kidney transplant failed 
after four months due to severe recurrence of his initial disease. The second transplantation 
was lost rapidly due to surgical complications. The patient had not developed significant 
HLA immunization before his well-matched third graft. Immunosuppression consisted 
of an association of tacrolimus, mycophenolic acid (MA) and steroids at usual doses. 
Rituximab was injected at day 1 after transplantation and induced a deep depletion in CD19 
positive B cells. During the first 2 months kidney function remained stable with GFR levels 
estimated by CKD-EPI between 35-40 ml/min/1.73 m2 and urine protein/creatinine ratio 
did not exceed 0.1 g/g while serum-albumin was in the normal range. However during 
the third month after transplantation positive viremias for BK virus were observed and 
the patient developed pneumonia and pyelonephritis which required adapted antibiotic 
treatment. Despite stopping MA and lowering tacrolimus doses BK viremia and viruria 
remained positive. Proteinuria tended to increase, clinical significant edema developed 
despite normal serum albumin and kidney function worsened. A kidney biopsy performed at 
month (M) 7 showed slight signs of calcineurin toxicity and podocyte foot-process fusion. 
We therefore decided to start plasmapheresis (3 sessions during the first week followed by 
1 session every month during 6 months and switch to monthly belatacept injections, while 
lowering tacrolimus trough levels < 2 ng/l. Under this treatment BK viremia disappeared 
(M 12), proteinuria could be maintained in the non-nephrotic range and kidney function 
recovered and is stable at a follow-up of 18 months.
Discussion: This case indicates that Rituximab is able to prevent severe recurrence 
of FSGS after kidney transplantation but infectious complications are frequent and can 
have deleterious consequences. Belatacept treatment seems to be a safe in this condition 
and might permit to lower concomitant immunosuppressive treatment. Further studies and 
probably individualized strategies are needed to optimize management of recurrent FSGS.
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The Impact of Hurricane Maria on Transplant Outcomes in Puerto Rico: 
A Retrospective Chart Review
Melissa L. Swee,1,2 Jodell Hornickel,2 Stacey Abel,2 Roberto S. Kalil.1,2 
1University of Iowa, North Liberty, IA; 2VA Iowa City, Iowa City, IA.
Background: On September 20th, 2017, Hurricane Maria made landfall on the island 
of Puerto Rico, leading to a high number of deaths, destruction of property, and adverse 
health outcomes. This study aims to characterize the effect of Hurricane Maria on Kidney 
Transplant Recipients through the Veterans Affairs (VA) Health Care System.
Methods: The electronic health records of all kidney transplant recipients through the 
Veterans Affairs since 2005 were reviewed. Patients who had lived on Puerto Rico in the 
year of 2017 were included. All notes and laboratory values were abstracted prior and after 
the hurricane, including creatinine, urinalysis, urine protein-to-creatinine ratios and drug 
levels, as well as demographic and historic data on transplant status.
Results: 31 patients were identified Puerto Rico residents in 2017. All 31 were males 
(100%) and Hispanic/Latino (100%). The mean age was 65.5 ± 7.0 years. 29 were kidney 
transplants while 2 were kidney-pancreas transplants. The mean time since transplant was 
8 ± 3.5 years. End-Stage Renal Disease was most frequently due to diabetes mellitus (11; 
35%), hypertension (8; 25.8%), and glomerulonephritis (4; 12.9%). Only 4 patients had 
proteinuria on urinalysis. Prior to the hurricane, serum creatinine levels were 1.3 mg/dL 
± 0.4, urine protein-to-creatinine ratio was 0.45 ± 0.79. Tacrolimus and sirolimus levels 
were 6.4 ± 1.3 and 11 ± 0.2, respectively. After the hurricane, contact was established with 
all 31 patients. Serum creatinine levels were 1.4 mg/dL ± 0.55 and UPC were 0.31 ± 0.38, 
which were not statistically significant (p= 0.33 and 0.38, respectively). Three patients 
had creatinine elevations greater than 0.3, of which only one had persistent elevations one 
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month afterwards. Tacrolimus and sirolimus levels three months after the hurricane were 7.3 
+ 1.3 and 10 ± 0.8, respectively. None was subtherapeutic.
Conclusions: Despite the destruction and degradation of infrastructure in Puerto Rico 
after Hurricane Maria, the vast majority of kidney transplant recipients through the VA were 
not adversely affected. Only one recipient had sustained creatinine elevations, which may 
or may not have been a consequence of disruption of healthcare services after the hurricane.
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Comparison of Outcomes One Year After Renal Transplant Between 
Alemtuzumab and Basiliximab for Induction Immunosuppression
Jonathan A. Seaman, Scott G. Westphal, Fang Qiu, Doug Bremers, 
Diana F. Florescu. University of Nebraska Medical Center-Nebraska Medicine, 
Omaha, NE.
Background: Induction immunosuppression has become increasingly utilized to 
improve early graft function and decrease rejection rates. The aim of our study was to 
compare the outcomes one year post-transplant in renal transplant patients who received 
either alemtuzumab or basiliximab for induction therapy.
Methods: At our center, alemtuzumab is given to all patients with a calculated panel 
of reactive antibody (CPRA) > 25% and basiliximab is given when CPRA < 25%. We 
included all patients (N=27) who received induction with alemtuzumab for renal transplant 
between 2011 and 2016. These were matched 1:2 to basiliximab recipients by age and date 
of transplant. Continuous variables were compared using t-tests or Wilcoxon rank-sum tests 
and categorical variables using Fisher’s tests or chi-square tests. Binary outcomes were 
compared using Cochran-Mantel-Haenszel tests. Time-to-event outcomes were plotted 
using the Kaplan-Meier method and compared between groups using log-rank tests.
Results: Baseline demographics are described in Table 1. Most patients were 
maintained on tacrolimus, mycophenolate, and prednisone. No statistically significant 
differences in the following outcomes were detected: delayed graft function (p = 0.76), graft 
loss (p = 0.99), or rejection (p = 0.2). Opportunistic infection rates were not significantly 
different at 1-year post-transplant (p = 0.83). Time-to-infection (p = 0.84) and time-to-death 
(p=0.21) were similar in both groups, but time-to-rejection was longer in the basiliximab 
group vs alemtuzumab group (p = 0.04).
Conclusions: Despite a difference in immunological risk between the 2 groups, we did 
not detect any significant differences in outcomes at 1-year post-transplantation between 
higher immunological risk patients receiving alemtuzumab and lower risk patients receiving 
basiliximab. Early opportunistic infectious rates were similar.
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Low-Dose Mycophenolate Mofetil in Kidney Transplant Recipients and Its 
Association with Infectious Diseases and Acute Rejection
Jorge Andrade-Sierra,1,2 Hernesto Hernandez,2 Enrique Rojas-Campos,3 
Alfonso M. Cueto-Manzano,2,3 Benjamin Gomez-Navarro,2 Miguel Medina 
Pérez,2 Basilio Jalomo martínez,2 Petra Martínez,2 Luis Alberto Evangelista-
Carrillo,2 Jose I. Cerrillos.2 1Universidad De Guadalajara, CUCS, Guadalajara, 
Jalisco Mexico, Mexico; 2Nephrology, HE.CMNO.UMAE.Instituto Mexicano 
Del Seguro Social, Guadalajara, Mexico; 3Unidad de Investigacion Medica En 
Enfermedades Renales, IMSS-UIMER, Guadalajara, Mexico.
Background: Current immunosuppression schemes have improved the overall kidney 
transplant (KT) survival; however, the adverse events associated with maintenance of 
immunosuppressive therapy have not been modified. The use of Mycophenolate mofetil 
(MMF) has unfavorable dose-related effects (gastrointestinal, hematological and infectious). 
OBJECTIVE: Determinate the incidence of infectious diseases and acute rejection (AR) 
with two different doses of MMF.
Methods: A prospective cohort (March 1, 2017 - March 1, 2018) in first-time live 
donor kidney transplant (LDKT) recipients. Patients with low dose of MMF (1.5 gr/
day) and standard dose of MMF (2 gr/day) were compared. Anthropometric measures, 
presence of post-transplant infections, hospitalizations, AR and adverse events associated 
with MMF were collected.
Results: 81 low risk posttransplant patients were included (31±11 y/o), from which 39 
were in the low dose group (LD-G) and 42 in the standard dose group (SD-G), both of them 
with tacrolimus and prednisone. At the end of follow up, an incidence of infectious diseases 
was reported (46.2% vs 47.6% p=0.9), [RR=1.06, CI (0.44-2.5)], and AR proved with 
biopsy of (4.8% vs 2.6% p=0.6), [RR=1.9, CI (0.17-19.6)]. The LD-G had a higher tendency 
for risk of AR without statistical significance and other complications (gastrointestinal 
manifestations and hematologic diseases) that required hospitalization, which were more 
frequent in the SD-G (9.5% vs 56.4% p<0.001) [RR= 2.07, CI (1.43- 3.04)].
Conclusions: The use of low doses of MMF has an adequate safety profile in the 
Mexican population, without increasing the risk of AR or having a significant impact on 
infections in the post-transplant period, therefore, reducing the presence of adverse effects 
that require hospitalization.
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Characteristics of Long-Term Renal Allograft Survivors
Amgad E. El Agroudy.1,2 1Medicine, College of Medicine and Medical Sciences, 
Arabian Gulf University, Manama, Bahrain; 2Nephrology and Transplantation 
Unit, Salmaniya Medical Complex, Manama, Bahrain.
Background: We studied the characteristics and the predictors of survival in Bahraini 
renal transplant recipients with an allograft that functioned for more than 10 years.
Methods: Seventy-eight patients underwent renal transplantation between 1982 and 
2007. Among them, 179 patients maintained functioning allografts for more than 10 years 
(range 10-35 years). Characteristics of the surviving patients, data on graft survival, and 
determinants of outcome were obtained by reviewing all medical records.
Results: The mean age at time of renal transplantation was 40.1 ± 14.4 years and 
70% were males. The cause of end-stage renal disease was diabetic nephropathy in 24.6% 
and 84% received dialysis therapy before transplantation. The source of the graft in 119 
(66%) recipients was from living related donors with a mean age of 29.8 ± 6.6 years, 
and it was the first graft in 172 recipients. The primary immunosuppression regimen was 
cyclosporine (CsA) base in 129 patients, tacrolimus (Tac) based in 46 patients while four 
patients received steroids and azathioprine only. Induction therapy was administered to 96 
patients. Acute rejection episodes occurred in 25 patients (14%), of whom three experienced 
two episodes. During the last follow-up in January 2018, the mean serum creatinine was 
118.3 ±46.5 μmol/L. A history of cancer was noted in two patients, whereas hypertension 
was encountered in 54% and diabetes mellitus in 24%. We compared the graft functioning 
group with the graft failure group and found that the independent determinants of long-term 
graft survival included time of late acute rejection episodes and histopathologic findings of 
chronic allograft damage, post-transplant hypertension and serum creatinine at one year.
Conclusions: We conclude that renal transplantation even in its earliest years and 
despite the associated numerous complications has provided a ten-year or more of near-
normal life to patients with end-stage renal disease.
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Serum β2-Microglobulin May Predict the Change of Renal Function After 
Kidney Transplantation
Yoshifumi Hamasaki,1 Teruhiko Yoshida,2,3 Rei Isshiki,1 Akihiko Matsumoto,1 
Kent Doi,2 Eisei Noiri,2 Masaomi Nangaku.2 1The University of Tokyo Hospital, 
Tokyo, Japan; 2The University of Tokyo, Tokyo, Japan; 3National Institute of 
Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD.
Background: Several perioperative factors including histological findings of allograft 
biopsy are known to be associated with graft function and graft survival after kidney 
transplantation (KTx). It is unclear what factors in post-KTx period predict the longitudinal 
change of renal function.
Methods: The data from post-KTx patients who are followed at The University of 
Tokyo Hospital were collected retrospectively. Patients followed-up less than 6 months after 
KTx were excluded. To identify predictors of the longitudinal change of renal function, 
we analyzed data including clinical parameters measured at each outpatient visit. The 
primary outcome was determined as the eGFR decline (more than 10% or 2 ml/min/1.72m2 
reduction from baseline) during 12 months period.
Results: A total of 38 post-KTx recipients were analyzed in this study. Age and eGFR 
at baseline of these patients were 51.0 ± 15.4 years old and 43.0 ± 16.1 ml/min/1.73m2 
(mean ± SD), respectively. The duration from KTx to collection of clinical parameters was 
7.9 ± 7.3 years. Estimated GFR changes were evaluated 12 months after. When patients 
were divided into two groups with (N = 14) and without (N = 24) eGFR decline after 12 
months, percentage of male (93% vs 63%), serum uric acid (UA, 7.48 vs 6.18 mg/dl), and 
β2-microglobulin (β2MG, 5.78 vs 2.85 mg/L) were significantly higher and serum albumin 
(3.98 vs 4.22 g/dl) was significantly lower in the eGFR decline group. On ROC analysis, 
β2MG and UA predicted eGFR decline after 12 months (AUC [95%CI] = 0.75 [0.58-0.92] 
and 0.72 [0.53-0.92], respectively). On multiple regression analysis, logarithm of β2MG 
was significantly correlated with the relative eGFR changes during 12 months observation 
period (β = -0.50, p = 0.001).
Conclusions: β2MG and UA measured at outpatient clinic may predict the change of 
renal function of post-KTx patients.
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Effects of Late Cyclosporine Withdrawal on Graft Function and Survival
Frederic Bauer,2 Nikolaos Pagonas,4 Felix S. Seibert,3 Richard Viebahn,4 
Nina Babel,4 Timm H. Westhoff.1 1Ruhr-University Bochum, Germany, Herne, 
Germany; 2Ruhr-University Bochum, Herne, Germany; 3University Hospital 
Marien Hospital Herne, Herne, Germany; 4Ruhr University Bochum, Herne, 
Germany.
Background: Attempts to discontinue calcineurin inhibitors (CNI) early after renal 
transplantation without conversion to an alternative immunosuppressive have failed due to 
high rates of acute rejections. Data on “late CNI withdrawal” are lacking so far.
Methods: The present work provides a matched case-control study on the effects 
of CNI withdrawal on graft loss and mortality in 90 patients (1500 screened) with 
advanced graft dysfunction (serum creatinine > 3.5 mg/dl) and a cyclosporine based triple 
immunosuppressive regimen at the Charité University Hospital, Berlin.
Results: Cyclosporine was withdrawn at a mean of 54.0±32.8 months posttransplant 
in 45 subjects. Whereas eGFR did not significantly differ between the groups at this time 
(12.4±2.7 vs. 14.7±8.9 in the control group, p=0.08), it was significantly higher in subjects 
undergoing withdrawal after 120 months (D 4.1 ml/min; p<0.001). In a Cox regression 
analysis adjusted for age, gender and eGFR patients with CNI withdrawal showed better 
survival rates for the combined endpoint death/graft loss (HR (95% CI): 0.19 (0.12-0.33), 
p=0.001) compared to matched controls. The survival benefit was significant for the 
endpoints death (p=0.01) and graft loss (p=0.001).
Conclusions: CNI withdrawal was associated with improved survival rates in patients 
with advanced graft dysfunction in this retrospective analysis.
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All That Glitters Is Not Gold: CKD Stage 4 Disguised as CKD Stage 4T
Abhilash Koratala, Amir Kazory. University of Florida, Gainesville, FL.
Introduction: Steroid-resistant focal segmental glomerulosclerosis (FSGS) is the 
primary renal disease in approximately 10% of pediatric renal transplant recipients (RTR). 
While immunosuppressive medications (ISM) are essential for prevention of allograft 
rejection, they could also potentially portend salutary impact on the underlying disease of 
the native kidneys.
Case Description: A 38-year-old African American man referred to nephrology clinic 
to re-establish care for his transplanted kidney after he was lost to follow up for about 20 
years. He had a history of end-stage renal disease secondary to FSGS and received a living-
related donor kidney transplant at the age of 10. Although he was on dialysis briefly prior 
to transplant, he was never anuric. Post-transplant, he received azathioprine and prednisone 
for about 10 years with a baseline serum creatinine (Scr) of 1.6 mg/dL. Then, the patient 
stopped taking all ISM and lost follow up. At the time of current presentation (Scr 3.4 
mg/dL and urine albumin-creatinine ratio 75 mg/g) he was presumed to have developed 
allograft rejection leading to chronic kidney disease stage 4T as he was taking no ISM for 
2 decades. Surprisingly, ultrasound of the right lower quadrant, performed twice, could 
not identify any allograft tissue due to its significant atrophy and blending in with the 
hyperechogenic surrounding fat tissue. Therefore, a radionuclide renogram was obtained 
which confirmed complete absence of flow to the right lower quadrant allograft while 
perfusion to the native kidneys was present; his renal function was entirely provided by the 
native kidneys rather that the allograft. Seven years later, his Scr has remained stable with 
medical therapy without ISM.
Discussion: This patient received azathioprine and steroids for 10 years after transplant 
prior to stopping ISM. While he lost his allograft afterwards likely due to rejection, the 
salutary impact of ISM on underlying FSGS of the native kidneys resulted in partial recovery 
that has lasted for more than 25 years. The main teaching point in this case is that renal 
function in RTRs could still be partially (or completely) provided by the native kidneys even 
decades later, as post-transplant ISM could induce remission in certain underlying diseases. 
In cases where there is a doubt, complementary studies such as radionuclide renogram could 
be beneficial.
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Clinical Phenotype of CAKUT May Predict Clinical Course After Kidney 
Transplantation
Yasar Caliskan,1,2 Halil Yazici,2 Erol Demir,2 Aydin Turkmen,2 Mehmet S. Sever,2 
Sanjay Jain.3 1Division of Nephrology, Yale School of Medicine, New Haven, CT; 
2Division of Nephrology, Department of Internal Medicine, Istanbul School of 
Medicine, Istanbul, Turkey; 3Washington University School of Medicine, St. Louis, MO.
Background: Clinical and pathological differences in transplant (tx) recipients, where 
the cause of end stage renal disease (ESRD) was vesicoureteral reflux nephropathy (VURN) 
or other congenital anomalies of the kidney and urinary tract (CAKUT) or biopsy confirmed 
glomerulonephritis (GN) were compared to test the hypothesis that the tx outcomes may 
differ among these various groups.
Methods: We compared post-tx outcomes of 150 renal tx recipients with non-
syndromic VURN (VURN group, 52% male, mean age:28±9 years), 52 tx recipients with 
CAKUT other than VURN (CAKUT group, 73.1% male, mean age:30±11 years) and 150 tx 
recipients with GN as the cause of ESRD (GN group: 55.3% male, mean age:31±10 years). 
Randomly selected renal allograft indication biopsies in each group [VUR (n=16), CAKUT 
(n=7) and GN (n=19)] were evaluated. Primary outcome was allograft loss and secondary 
outcome was biopsy-confirmed rejection.
Results: Demographic characteristics of study groups were similar except higher 
number of males in CAKUT group (p=0.028). Allograft survival rates by Kaplan-Meier 
analysis at 10 year for VURN, CAKUT and GN groups were 83%, 77.4% and 71.3%, 
respectively (p=0.21). Patient survival rates were similar among VURN (100%), CAKUT 
(96.2%) and GN (98.7%) groups during follow up (p=0.08). There was a trend in CAKUT 
group to develop post-tx donor specific antibodies (9, 17.3%) compared to VURN group 
(12, 8%) (p=0.05). Biopsy-proven acute rejection rate (BPAR) in VURN, CAKUT and GN 
groups were 14%, 26.9% and 16%, respectively (p=0.09). BPAR rate and total inflammation 
score in biopsy were significantly higher in CAKUT group than VURN group (p=0.03 and 
p=0.05, respectively). Incidence of post-tx VUR was significantly higher in VURN group 
(19, 12.7%) compared to CAKUT (2, 3.8%) and GN (4, 2.7%) groups (p=0.002). Recurrent 
allograft pyelonephritis was significantly higher in VURN group (23, 15.3%) compared to 
CAKUT (2, 3.8%) and GN (6, 4%) groups (p=0.001).
Conclusions: Primary diagnosis of VURN poses an increased risk of VUR and urinary 
tract infections in kidney allograft and the sustained infection related inflammation may 
account for reduced rejection rates compared to non-VURN CAKUT and GN patients.
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Effects of Different Thymoglobulin (r-ATG) and Mycophenolic Acid 
(MPA) Dosing Regimens on Acute Rejection and BK and CMV Infections
Samuel A. Younan, Bekir Tanriover, Venkatesh Kumar Ariyamuthu, 
Malcolm Macconmara. University of Texas Southwestern Medical Center, 
Dallas, TX.
Background: There are no randomized clinical trials comparing outcomes of different 
r-ATG and MPA dosing regimens, as induction and maintenance immunosuppression agents
respectively, in renal transplant recipients maintained on tacrolimus, MPA and prednisone.
Methods: We retrospectively reviewed the charts of all adult kidney transplant 
recipients at our institution from January 2015 to December 2017. We divided our patient 
cohort into 2 groups. Group-1 received r-ATG 5 mg/kg (standard dose), MPA 540 mg BID 
(low dose), standard tacrolimus BID dosing, and a fast taper of prednisone down to 5 mg qd 
in 1 month (N=49). Group 2 underwent r-ATG 3-4.5 mg/kg (low dose), MPA 720 mg BID 
(standard dose), standard tacrolimus BID dosing, and a slow taper of prednisone down to 
5 mg qd in 3 months (N=46). Plasma BK and CMV PCR were checked monthly within 1 
year of transplant. Acute rejection (AR) was defined as biopsy proven and treated rejection 
within 1 year of transplant.
Results: A total of 95 patients were followed post-transplant with a mean follow up 
of 10 months. The overall graft survival (graft failure or patient death) for both groups is 
100% at 1 year. There was no significant difference in 1 year BK & CMV viremia between 
both groups (BK Group-1 18 % vs. Group-2 15%, p=0.68; CMV Group-1 4% vs. Group-2 
13%, p=0.12). Moreover, AR at 1 year did not differ between groups (Group-1 19.5% vs. 
Group-2 24%, p=0.36). The mean tacrolimus levels at discharge differed significantly 
between Group-1 (5.9 ng/ml) and Group-2 (7.15 ng/ml) with p=0.04. Of the patients who 
were BK positive, CMV positive, and rejection positive, there was no significant difference 
in their mean tacrolimus levels at the time of their positive tests. Lastly, the mean eGFR at 6 
months and 1 year were not significantly different between Group-1 and Group-2.
Conclusions: Overall, the rates of BK/CMV viremia and AR at one year in kidney 
transplant recipients were not significantly different between the standard dose of r-ATG / 
low dose MPA and low dose r-ATG / high dose MPA groups.
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Understanding Barriers to Kidney Transplantation Among Adults on 
Maintenance Dialysis: A Cross-Sectional Study
Sami A. Alobaidi,1,2 Ahmed Akl,1,3 Nada Salem,4 Naji A. Dwid,1 Fahtima 
Mehdawi,1 Abdullah Kashgary,4,5 Saad S. Alobaili,5 Wisam H. Al-Badr,5 
Abdulkareem Alsuwaida,5 Ibrahim A. Jubran,5 Hanadi M. Alhozali.4 1Dr. 
Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 2University of Jeddah, Jeddah, 
Saudi Arabia; 3Urology & Nephrology Center, Mansoura University, Mansoura, 
Egypt; 4KIng Abdulaziz University, Jeddah, Saudi Arabia; 5DaVita-Saudi 
Arabia, Riyadh, Saudi Arabia.
Background: Kidney transplantation (KT) is the treatment offering the best possible 
long-term outcomes for patients with end-stage renal disease. In Saudi Arabia, KT 
accounted for only 4.5% of total renal replacement therapy in 2016; the number of KTs 
performed outside Saudi Arabia in 2016 is not known. The main objective of this study was 
to evaluate the barriers to KT experienced by patients in Saudi Arabia.
Methods: This cross-sectional study was conducted during the period of September 
2017 to January 2018. Direct interviews using a specifically pre-coded and pre-tested online 
questionnaire were used to examine reasons for low KT rate and the possible barriers to KT 
in Saudi Arabia.
Results: A total of 321 adult hemodialysis (HD) patients eligible for KT were selected 
from 4 HD units in Jeddah, representing 11% of the total HD population in Jeddah. Mean 
patient age was 49.9 ± 14.9 years, 62.1% were male, and 26% were employed. Most patients 
were of Saudi nationality, only 38 (11.8%) were non-Saudi. Upon interviewing, 90.7% had 
been counseled for KT. The majority of counselling (86.5%) was done by nephrologists 
after the start of HD. 178 (55.5%) were referred for pre-transplant evaluation. Among the 
cohort, 92 (28.6 %) were on the active transplant list. The most common barrier to KT 
was lack of donor availability (n=107, 40.5%), followed by misconceptions regarding long-
term complications for donors (n=58, 22%), and concerns regarding surgical complications 
(n=24, 9.1%). Only 17 patients (6.4%) reported financial constraint as the main reason for 
not having a KT; this occurred more frequently among non-Saudi patients.
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Conclusions: Misconceptions about KT still represent a substantial barrier among 
dialysis patients. Most patients are educated about KT after initiation of dialysis. Initiatives 
to promote and improve pre-dialysis education and knowledge about KT are needed to 
improve the low transplant rate in Saudi Arabia.
Funding: Commercial Support - DaVita
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Kidney Transplantation in Patients with Neurogenic Bladder
Zeljka Jurekovic,1 Mladen Knotek.2 1University Hospital Merkur, Zagreb, 
Croatia; 2University of Zagreb Medical School, Clinical Hospital Merkur, 
Zagreb, Croatia.
Background: Neurogenic bladder is a condition associated with high incidence of 
urinary tract infections (UTI) and is a rare cause of end stage renal disease (ESRD), for 
which kidney transplantation (KT) is performed. There is lack of data in the recent literature 
on the outcome of KT in adult recipients with neurogenic bladder.
Methods: During 2009-2018 period, six patients with neurogenic bladder were 
transplanted at the Merkur Hospital. Their medical records were retrospectively analyzed, with 
aim to evaluate long-term patient and graft survival, as well as UTI and rejection frequency.
Results: The mean ± SD (range) age of the study cohort was 31.6± 11.0 (20-50) years 
at the time of transplantation. Cause of neurogenic bladder in three patients was spinal 
cord injury, meningomyelocele in one patient, detrusor areflexia after bladder surgery in 
one and neurological disorder in one patient. Mean dialysis vintage was 59 ± 32 (0-96) 
months. All patients had repeated urinary tract infections before and after transplantation. 
One-year patient and graft survival was 100%. Five-year patient survival was 67%. One 
patient died 30 months after transplantation due to squamous cell bladder cancer, with a 
functioning graft and one kidney graft lost its function 60 months after transplantation 
due to BKV nephropathy. 5/6 patients required either intermittent, or permanent bladder 
catheterization after KT. During the mean follow-up of 1206 ± 1106 (102-3092) days, there 
was a mean number of 14.3±10.4 (5-34) urinary infection episodes requiring antibiotic 
therapy and mean number of 3.8±1.5 (2-6) urinary tract infections requiring hospitalization 
and intravenous antibiotic therapy. Two patients had one episode of acute cellular rejection 
(IA), which was treated by bolus of steroids. Mean serum creatinine in patients with graft 
function on the last visit was 84.6 ± 21.8 (56-109) μmol/L.
Conclusions: Acceptable long-term patient and graft survival, graft function and 
serious UTI rates can be achieved in patients with ESRD attributable to neurogenic bladder. 
The fact that KT can be successfully performed in patients with neurogenic bladder is 
especially important, because this population often consists of younger patients with longer 
life expectancy.
Funding: Government Support - Non-U.S.
PUB803 
Publication-Only 
Adenovirus Infection Case-Series in Kidney Allograft Recipients at 
Hospital do Rim
Alejandro Zapata,1 Renato D. Foresto,1 Maria A. Hazin,1 Daniel wagner 
C. Santos.2 1Nephrology division, Federal University of São Paulo, São Paulo,
Benin; 2Federal University of Sao Paulo, Sao Paulo, Brazil.
Background: Adenovirus infection is an important cause of complications in renal 
transplant patients that carries potential risks of loss of graft function and death. Hence, we 
attempted to describe the main characteristics of the affected patients with such a disease in 
our population during 2017.
Methods: We described the clinical and laboratory features of renal transplantation 
recipients coursing with adenovirus infection after kidney transplantation at the time 
of diagnosis at Hospital do Rim during 2017. These included main symptoms at onset, 
duration, time from transplantation to disease, time from onset to negative viremia, time 
to creatinine improvement, time to clinical response, association with other infections and 
immunosuppression description.
Results: Adenovirus infection occurred in 6 patient transplanted during 2017. All of the 
patients received 3 mg x kg of rabbit anti-thymocyte globulin as induction, all of them used 
prednisone and calcineurin inhibitor according to institutional protocols, 4 used azathioprine 
and 1 received everolimus as third drug. All of the living donor kidney recipients who 
developed infection did it during the first year(n=3), two of them during the first month, 
compared with deceased recipients (23rd month, range 17-30 months). The main symptoms 
at onset where fever (n=6), macroscopic hematuria (n=5) and dysuria (n=5). The mean time 
to negative viremia from onset of symptoms was 21 days. Interestingly, the duration of the 
symptoms was 13 days (7-18 days) meanwhile the lowest creatinine value after the event 
was reached at 26th day (14-39 days). The loss of allograft function was 9 ml/min/1.73m2 
(8-32 ml/min/1.73m2) assessed by CKD-Epi formula. Co-infection with CMV happened in 
1 case. The mean hospitalization time was 26 days (9-55days). Management of adenovirus 
infection included adjusting immunosuppression in all the cases. Two patients suspended 
azathioprine, one suspended everolimus and two patients received IV immunoglobulin. All 
of the patients survived to infection and one of them developed a new episode subsequently.
Conclusions: Adenovirus infection in transplant patients must be considered as an 
alternative hypothesis to urinary tract infection, mainly during the first months of transplantation 
in living donor recipients. Its prompt management could preserve allograft function.
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Severe Hyponatremia with Intraoperative Desmopressin Use in (Deceased 
and Living Donor) Renal Transplant Recipients
Mandeep S. Gill,1 Sarat C. Kuppachi,1 Christie P. Thomas.2 1University of Iowa, 
Iowa City, IA; 2University of Iowa College of Medicine, Iowa City, IA.
Background: Desmopressin (DDAVP) is used for hemostasis in patients with factor 
VIII deficiency, von Willebrand disease and platelet function defects including that seen in 
patients with chronic kidney disease. A serious consequence of its use is water intoxication 
with attendant hyponatremia. We studied the incidence of hyponatremia in patients who 
received desmopressin during kidney transplant (KT) surgery.
Methods: We retrospectively analyzed the incidence of hyponatremia (Na < 135) 
and severe hyponatremia (Na < 130) in the first 48 hrs following DDAVP used during KT 
surgery at our center between 2009-2018. We compared the incidence of hyponatremia in 
the first 48 after surgery with a control group of living and deceased KT recipients who 
did not receive DDAVP but were administered the same post-operative fluid protocol that 
the study group received. Relative risk (RR) and Fishers exact t test p values were used to 
determine the significance of differences between the two groups.
Results: 22 patients met the inclusion criteria. 17 (77.3%) patients developed 
hyponatremia, and 8 (36.4%) developed severe hyponatremia (Mean 125.3, SD 3.93) (Table 
1). In 25 controls (living donor 4; deceased donor 21) hyponatremia was noted in 17 (68%), 
but no patient developed severe hyponatremia. There was no significant difference between 
the groups for the incidence of hyponatremia (RR 1.13 [0.7-1.62], p=0.35). However, 
severe hyponatremia was noted only in patients who received DDAVP; 3 out of 4 living KT 
recipients (75%) and 4/18 (22.2%) deceased donor recipients (p = 0.0027).
Conclusions: In this retrospective analysis of the incidence of hyponatremia, 
among KT recipients who were given DDAVP for intraoperative hemostasis, there was 
a significantly higher incidence of severe hyponatremia (75% of living KT recipients, and 
22.2% of deceased recipients) compared to patients who did not receive DDAVP. Although 
larger retrospective analyses are required to further validate these findings, the risk of severe 
hyponatremia should be acknowledged and anticipated if patients are administered DDAVP 
during KT surgery.
Table 1
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Early Evidence of the Association Between Gout and Higher Mortality 
Rates in the Prevalent Solid Organ Transplant Population
Justin W. Li,1 Marissa Suh,1 Herman Sanchez,1 Jeffrey Kent,2 Brian Lamoreaux,2 
Richard J. Johnson.3 1Trinity Partners, Waltham, MA; 2Horizon Pharma, Lake 
Forest, IL; 3University of Colorado Denver, Aurora, CO.
Background: There is evidence that gout may be associated with higher mortality 
risk in kidney transplant recipients, though little data is available in other transplant types. 
Existing literature has focused on the association between new onset gout and mortality 
in the incident transplant population. Important questions remain regarding the impact of 
gout on transplant outcomes beyond the initial post-transplant timeframe and on other solid 
organ transplant (SOT) types. This retrospective patient claims data analysis was performed 
to determine whether an association between gout and mortality exists in the prevalent SOT 
population.
Methods: 2015 gout prevalence among the prevalent SOT population was assessed 
in 2 administrative claims databases: Medicare Fee-For-Service Limited Data Set (5% 
sample) and a commercial claims sample (IQVIATM Real-World Data Adjudicated Claims – 
US). Definitions used were – SOT: a claim with an SOT procedure code OR any claim with 
a history of SOT status diagnosis code, limited to kidney, liver, and heart; Gout: ≥1 claim 
with any gout diagnosis code. Univariate analysis included 2016 mortality for patients in 
the gout / non-gout SOT cohorts identified in calendar year 2015 and still living in 2016.
Results: In the Medicare SOT population, 2016 mortality was higher among kidney 
transplant patients with gout vs. those without gout (9.6% vs. 7.1%, p=0.013). In the 
commercially insured SOT population, 2016 mortality was higher among patients with gout 
for both kidney (3.0% vs. 2.3%, p=0.022) and heart (5.3% vs. 3.2%, p=0.045) recipients. No 
significant differences in mortality were observed in either population for liver transplant 
recipients.
Conclusions: The higher mortality risk observed in the surviving kidney transplant 
population for those with vs. without gout, regardless of insurance provider, reveals an 
important initial finding and demonstrates a potential unmet need in this population. While 
gout appears to be associated with a greater risk in this analysis, further risk-adjusted studies 
are warranted to determine whether gout is an independent driver of mortality, as well as 
other poor outcomes, in the prevalent SOT population.
Funding: Commercial Support - Horizon Pharma
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Impact of Cardiac Function on Allograft Survival in a Cohort of Mexican 
Transplant Recipients
Viridiana Rodriguez,4 Priscila B. Villalvazo,5 Jorge Andrade-Sierra,2,1 Benjamin 
Gomez-Navarro,3 Milagros M. Flores Fonseca.1 1Centro Medico Nacional de 
Occidente, Guadalajara, Mexico; 2Universidad De Guadalajara, CUCS, 
Guadalajara, Jalisco Mexico, Mexico; 3IMSS, HECMNO, Zapopan, Jalisco, 
Mexico; 4Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; 5IMSS, 
Zapopan, Jaliscco, Mexico.
Background: Cardiovascular disease is a major cause of morbidity and mortality 
among patients who undergoes kidney transplant (KT). Asymptomatic cardiac changes 
cause during CKD, could lead to perioperative complications and mortality as well as poor 
graft and patient survival. The purpose of this study was to evaluate the impact systolic 
ventricular function and pulmonary arterial pressure in patients with CKD and the outcomes 
after KT.
Methods: The study included 150 patients over 18 years of age with CKD who had 
a successful KT. Ventricular function and pulmonary arterial pressure were assessed by 
echocardiographic standard parameters before and 6 months after transplant.
Results: Mean age was 31.99 ± 11.28 years, and 65% were women. Before transplant, 
mean ventricular ejection fraction (VEF) was 58% and pulmonary arterial pressure was 
32 mmHg. Ventricular dysfunction was associated with unclamping donor renal vessels 
at 107.8 ± 7.96mmHg, and lower perioperative hemodynamics values. The LVEF group 
increased from 25% to 72.5%, and serum creatinine decrease from 2.25 ± 3.76 mg/dl to 
1.98 ± 2.65 mg/dl (p<0.001) by 6 months after kidney transplant. The best set of predictors 
in multiple regression analysis for renal function were the onset of diuresis and the use of 
diuretics (R2 = 0.4; p < 0.001).
Conclusions: Patients with LVEF should not be excluded from KT. These results 
showed the relationship between ventricular function and lower perioperative vasopressors 
and diuretics and its association on the graft function. Further studies are needed to 
determine if after KT there is an improvement as well on cardiac structure.
Funding: Government Support - Non-U.S.
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Short-Term Outcomes of Kidney Transplantation in Patients with 
Preformed DSA: University Malaya Medical Centre Experience
Maisarah Jalalonmuhali,1 Soo Kun Lim,2 Kok Peng Ng.1 1University Malaya 
Medical Centre, Kuala Lumpur, Malaysia; 2Univeristy Malaya Medical Centre, 
Kuala Lumpur, Malaysia.
Background: The shortage of deceased donors led to an increase of living related renal 
transplant (LRRT) performed in the presence of donor-specific antibodies (DSAs) or ABO 
incompatibility (ABOi). Various desensitization protocols have been used in order to reduce 
the incidence of antibody mediated rejection (ABMR). Here, we described our short-term 
outcomes in patients with preformed DSAs using our desensitization protocol.
Methods: This is a prospective, cohort study recruiting all kidney transplant recipients 
from August 2016 till February 2018. Cadaveric, ABO incompatible and those sensitized 
patients who were not prescribed on our desensitization protocol were excluded. Our 
desensitization protocol consisted of anti-CD20 (Rituximab) and plasma exchanges post 
transplantation. However, MFI≥3000 or positive flow cytometry will receive extra cycles 
of plasma exchanges prior to transplantation. Clinical outcomes: immediate graft function, 
serum creatinine at 3 months, incidence of acute rejection (borderline, acute T-cell mediated 
and ABMR), de novo DSAs and infections (CMV and BKV) were documented.
Results: A total of 26 LRRT patients were recruited (11 patients DSAs positive and 
15 patients in low risk group). Mean age was 37.45 ± 11.68 and 37.07 ± 12.09 for DSAs’ 
group and low risk group respectively. Both groups had 3 HLA mismatches (median). 
Immediate post-transplant 1 patient from DSAs’ group had slow graft function (prolong 
warm ischaemic time) and 1 patient from low risk group also had slow graft function (TTP/
HUS secondary to CNI). All other patients had immediate graft function. Mean creatinine 
at 3-month was 109.25 ± 27.28 mmol/L for DSAs’ group and 124.47± 40.16mmol/L in low 
risk group. At 3-month 2 patients (18%) had borderline rejection from DSAs’ group and 7 
patients (47%) from low risk group, 1 patient from low risk group had acute T-cell mediated 
rejection and none developed ABMR. Two patients from low risk group had also developed 
de novo DSA. There was no incidence of BKV. However, 5 patients had CMV viraemia 
and 1 patient had disease.
Conclusions: We demonstrated favorable short-term allograft survival and function 
after renal transplantation (immediate graft function, stable serum creatinine and no 
development of denovo DSA at 3-month) using desensitization with anti-CD20 and plasma 
exchange in patients with preformed DSA.
PUB808 
Publication-Only 
Intestinal Perforation by Schistosoma mansoni in a Kidney Transplant 
Patient: Case Report
Saulo J. Feitosa,1,2 Frederico C. Cavalcanti,2 Ana C. Souza.2 1Universidade 
Federal de Pernambuco, Recife, Brazil; 2Real Hospital Português de 
Beneficência em Pernambuco, RECIFE, Brazil.
Introduction: Schistosomiasis is endemic in several regions of Brazil and is a public 
health problem. Caused by Schistosoma mansoni, it can present with gastrointestinal 
symptoms in its chronic form; its presentation with colitis and intestinal perforation is rare, 
even more so among kidney transplant patients.
Case Description: We present the case of a 56-year-old female patient who underwent 
kidney transplant in October 2013 and developed chronic allograft nephropathy due 
to chronic rejection. In February 2018 she was hospitalized with complaints of severe 
abdominal pain and intestinal constipation for 3 days, and had signs of peritonitis on 
physical exam. Computed tomography of the abdomen showed signs of colitis and 
pneumoperitoneum. On the same day of hospitalization, the patient was submitted to 
exploratory laparotomy, with the finding of a rectum-sigmoid perforation. Hartmann’s 
colectomy with biopsy of the lesion were performed. The patient developed septic shock 
and acute-on-chronic kidney injury requiring hemodialysis in the postoperative period. The 
patient was treated with Meropenem based on results of peritoneal fluid cultures. Because 
Cytomegalovirus (CMV) is a more common cause of intestinal perforation among kidney 
transplant patients, serum PCR for CMV was performed and came back positive with 6656 
copies and the patient was treated with intravenous Ganciclovir until a result with zero 
copies was obtained. The histopathological study showed active peritonitis with active 
granulomatous colitis associated with serosal perforation and the presence of viable eggs 
of Schistosoma mansoni in the intestinal mucosa. The patient was treated with praziquantel 
evolving with clinical improvement and partial recovery of kidney graft function, being 
discharged in April 2018, awaiting reconstruction of the intestinal transit.
Discussion: In endemic regions for schistosomosis, all kidney transplant candidates 
must be empirically treated with praziquantel for one month before the transplant, and 
schistosomosis must be included in the differential diagnosis of intestinal perforation in 
immunossupressed patients.
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Impact of the Kidney Donor Profile Index (KDPI) on Kidney Transplants 
Outcomes in a Tertiary Hospital in Brazil
Saulo J. Feitosa,1,2 Ana C. Souza,2 Frederico C. Cavalcanti,2 Lucila 
Maria Valente.1 1Universidade Federal de Pernambuco, Recife, Brazil; 2Real 
Hospital Português de Beneficência em Pernambuco, RECIFE, Brazil.
Background: Due to the disproportionate relationship between supply and demand of 
organs, a more complete analysis of the deceased kidney donor is necessary to avoid organ 
discard. The KDPI is used to estimate how long a deceased donor kidney is expected to 
function relative to all of the kidneys recovered in the United States of America during the 
last year, but there is a lack of data regarding KDPI in Brazil.
Methods: A retrospective analysis of medical records of 73 patients submitted to 
kidney transplant from deceased donors was performed. The transplants ocurred between 
January and December 2014 in a referral tertiary hospital in Brazil. Stratified KDPI values 
(less than 20%, 20-40%, 41-60%, 61-80% and more than 80%) were correlated with 
recipients glomerular filtration rate (CKD-EPI), biopsy-proven rejection episodes and loss 
of graft function at 1 and 3 years post transplantation. All statistical analysis were made 
using StatPlus for Mac version 6.
Results: Kidney recipients mean age was 46.2 (SE +/- 1,3) years and 76.7% were 
male. They had 6.6 (SE +/- 0,4) years of dialysis prior to transplantation and 83.5% had 
low immunological risk (PRA: 0%). Mean KDPI value was 48.4% (SE +/- 3,2). The mean 
GFR distribution at 1 year was: less than 20%: 74.5 (SE +/- 8) ml/min (N = 10), 20-40%: 
66.5 (SE +/- 6,7) ml/min (N = 17), 41-60%: 62.9 (SE +/- 8,6) ml/min (N = 13), 61-80%: 
49.1 (SE +/- 8,3) ml/min (N = 9) and more than 80%: 42.1 (SE +/- 7,3) ml/min (N = 7), 
p = 0.09. In the 3-year analysis we observed: less than 20%: 68.4 (SE +/- 7,3) ml/min 
(N = 10), 20-40%: 59.4 (SE +/- 5,3) ml/min (N = 17), 41-60%: 53.6 (SE +/- 6,7) ml/min 
(N = 13), 61- 80%: 42.3 (SE +/- 8,6) ml/min (N = 9) and more than 80%: 33.6 (SE +/- 7,1) ml/min 
(N = 7), p = 0.03. The percentages of biopsy-proven rejection episodes at 3 years were: less 
than 20%: 16.6%, 20-40%: 15%, 41-60%: 26.6%, 61-80%: 35.7%, more than 80%: 66.6%, 
and regarding complete loss of graft function at 3 years: less than 20%: 16.6%, 20-40%: 
10% 41-60%: 13.3%, 61-80%: 35.7% and more than 80%: 41.6%.
Conclusions: In our study, patients who received kidneys from donors with higher 
KDPIs did have worse outcomes regarding GFR, biopsy-proven rejection episodes, and 
loss of the allograft.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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Clinical Significance of C4d Deposition in ABO-Compatible Renal 
Allografts Without Histologic or Serologic Evidence of Antibody Mediated 
Rejection
Esther Park,1 Meghan Pearl,2 Sunee Panombualert,1 Patricia L. Weng,1 
Robert B. Ettenger,2 Jonathan E. Zuckerman.1 1UCLA, Los Angeles, CA; 2Mattel 
Children’s Hospital at UCLA, Los Angeles, CA.
Background: Antibody-mediated rejection (AMR) is a leading cause of allograft 
loss in kidney transplant recipients (KTRs). C4d, a product of the classical complement 
pathway, with morphologic changes on graft biopsy and/or detectable circulating donor 
specific antibodies (DSAs) is diagnostic of active AMR. The clinical significance of C4d 
positivity alone is undetermined. We aimed to evaluate clinical outcomes in adult and 
pediatric ABO-compatible, DSA negative, KTRs with isolated C4d positivity.
Methods: This was a retrospective chart review to identify adult and pediatric KTRs 
transplanted between 2009-2017 with isolated C4d positivity on biopsy and at least 
1 year of post-biopsy follow up. Isolated C4d positivity was defined as C4d + (> 1+ by 
immunofluorescence in peritubular capillaries) without other findings of AMR and without 
DSA positivity. Patients with concomitant acute cellular rejection (ACR) were included. 
Protocol biopsies were performed on pediatric KTRs at 6, 12, and 24 months post-transplant 
and for clinical suspicion of rejection. Only clinically indicated biopsies were performed 
in adult KTRs.
Results: 11 patients had isolated C4d positivity. C4d was focal in 7/11 (75%) and 
diffuse in 4/11 (36%). 4/11 (36%) had ACR and were all treated with steroids, 1 patient 
received anti-thymocyte globulin (ATG), and 1 patient received IVIG. At 1-year post-
biopsy, 6/11 (55%) had repeat biopsies and 6/11 (55%) had DSA testing. None of these 
patients developed AMR and 2 patients developed DSAs (Figure 1A). The mean change in 
eGFR between time of biopsy and 1 year post-biopsy was +6.1mL/min/1.73m2(Figure 2A).
Conclusions: This case series provides preliminary evidence that isolated C4d 
positivity in ABO-compatible, DSA negative allografts does not correlate with deterioration 
of renal function, development of DSA, or development of AMR within 1 year following 
the incident biopsy. Further studies are needed to better understand the impact of isolated 
C4d positivity on allograft outcomes to better tailor monitoring and treatment.
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SA-PO582, SA-PO583, SA-PO588, 
SA-PO591, SA-PO596, SA-PO597, 
SA-PO605, PUB002, PUB004, PUB007, 
PUB030, PUB032, PUB036, PUB041, 
PUB042, PUB043, PUB044, PUB068, 
PUB101, PUB418
adhesion molecule .........TH-PO1117, FR-PO860
adiponectin..................... TH-PO132, TH-PO942, 
FR-PO551, SA-PO997, PUB182, PUB781
ADPKD .....TH-OR043, TH-OR101, TH-OR103, 
TH-OR104, TH-OR106, TH-OR107, 
TH-OR108, TH-PO186, TH-PO190, 
TH-PO268, TH-PO655, TH-PO658, 
TH-PO660, TH-PO661, TH-PO662, 
TH-PO663, TH-PO664, TH-PO666, 
TH-PO667, TH-PO668, TH-PO672, 
TH-PO673, TH-PO674, TH-PO676, 
TH-PO677, TH-PO678, TH-PO679, 
TH-PO680, TH-PO681, TH-PO682, 
TH-PO683, TH-PO685, TH-PO686, 
TH-PO687, TH-PO688, TH-PO689, 
TH-PO690, TH-PO691, TH-PO692, 
TH-PO693, TH-PO696, TH-PO697, 
TH-PO698, TH-PO699, TH-PO1127, 
TH-PO1128, FR-PO149, FR-PO241, 
FR-PO378, FR-PO949, FR-PO950, 
FR-PO951, FR-PO953, FR-PO954, 
FR-PO955, FR-PO957, FR-PO958, 
FR-PO959, FR-PO960, FR-PO961, 
FR-PO962, FR-PO965, FR-PO967, 
FR-PO969, FR-PO974, FR-PO981, 
FR-PO991, FR-PO993, SA-PO472, 
SA-PO473, SA-PO474, SA-PO475, 
SA-PO476, SA-PO477, SA-PO478, 
SA-PO479, SA-PO480, SA-PO481, 
SA-PO482, SA-PO484, SA-PO485, 
SA-PO487, SA-PO488, SA-PO489, 
SA-PO490, SA-PO491, SA-PO492, 
SA-PO493, SA-PO494, SA-PO495, 
SA-PO497, SA-PO498, SA-PO500, 
SA-PO502, SA-PO503, SA-PO504, 
SA-PO505, SA-PO506, SA-PO507, 
SA-PO508, SA-PO509, SA-PO510, 
SA-PO511, SA-PO512, SA-PO513, 
SA-PO514, SA-PO515, SA-PO517, 
SA-PO762, SA-PO1018, SA-PO1051, 
PUB177, PUB313, PUB314, PUB317, 
PUB318, PUB319, PUB320, PUB321, 
PUB322, PUB323, PUB324, PUB325, 
PUB327
advanced glycation end-product ......TH-PO146, 
FR-PO492, FR-PO514, SA-PO896, PUB186
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AIDS ....................................................SA-PO320
albuminuria .................. TH-OR031, TH-OR034, 
TH-OR039, TH-OR040, TH-OR044, 
TH-OR077, TH-OR089, TH-PO441, 
TH-PO442, TH-PO611, TH-PO865, 
TH-PO874, TH-PO875, TH-PO893, 
TH-PO983, TH-PO1004, TH-PO1043, 
TH-PO1051, TH-PO1053, TH-PO1067, 
TH-PO1068, TH-PO1079, FR-OR124, 
FR-PO028, FR-PO148, FR-PO161, 
FR-PO177, FR-PO184, FR-PO248, 
FR-PO258, FR-PO339, FR-PO403, 
FR-PO412, FR-PO422, FR-PO429, 
FR-PO431, FR-PO439, FR-PO440, 
FR-PO445, FR-PO446, FR-PO449, 
FR-PO453, FR-PO456, FR-PO459, 
FR-PO460, FR-PO461, FR-PO462, 
FR-PO827, FR-PO975, FR-PO1032, 
FR-PO1169, SA-OR067, SA-OR081, 
SA-OR082, SA-OR083, SA-OR084, 
SA-PO079, SA-PO102, SA-PO103, 
SA-PO109, SA-PO111, SA-PO115, 
SA-PO124, SA-PO127, SA-PO128, 
SA-PO145, SA-PO148, SA-PO157, 
SA-PO158, SA-PO161, SA-PO170, 
SA-PO308, SA-PO314, SA-PO318, 
SA-PO320, SA-PO321, SA-PO328, 
SA-PO367, SA-PO375, SA-PO771, 
SA-PO781, SA-PO783, SA-PO817, 
SA-PO845, SA-PO1037, SA-PO1070, 
SA-PO1088, PUB102, PUB103, PUB119, 
PUB196, PUB203, PUB235, PUB376, 
PUB431
aldosterone ..................... TH-PO082, TH-PO511, 
TH-PO512, FR-PO207, FR-PO320, 
FR-PO327, FR-PO379, FR-PO473, 
SA-PO305, SA-PO318, SA-PO999, 
SA-PO1009, SA-PO1034
Alport syndrome ........... TH-PO783, TH-PO785, 
TH-PO800, TH-PO900, TH-PO920, 
FR-PO242, FR-PO994, FR-PO996, 
FR-PO997, FR-PO998, FR-PO999, 
FR-PO1000, FR-PO1001, FR-PO1002, 
FR-PO1012, SA-OR099, SA-PO319, 
PUB331, PUB333, PUB336
ANCA ........TH-OR053, TH-OR054, TH-OR059, 
TH-PO074, TH-PO835, TH-PO836, 
TH-PO837, TH-PO841, TH-PO842, 
TH-PO843, TH-PO844, TH-PO845, 
TH-PO846, TH-PO847, TH-PO910, 
FR-OR079, FR-PO1040, FR-PO1041, 
FR-PO1042, FR-PO1044, FR-PO1045, 
FR-PO1057, SA-OR039, SA-OR040, 
SA-OR041, SA-PO390, SA-PO406, 
SA-PO408, SA-PO409, SA-PO410, 
SA-PO411, SA-PO412, SA-PO413, 
SA-PO414, SA-PO415, SA-PO417, 
SA-PO418, SA-PO419, SA-PO421, 
SA-PO1077, SA-PO1078, SA-PO1079, 
SA-PO1080, PUB348, PUB417
anemia ........ TH-PO192, TH-PO198, TH-PO225, 
TH-PO226, TH-PO227, TH-PO228, 
TH-PO229, TH-PO230, TH-PO231, 
TH-PO234, TH-PO235, TH-PO237, 
TH-PO238, TH-PO239, TH-PO240, 
TH-PO241, TH-PO242, TH-PO243, 
TH-PO244, TH-PO245, TH-PO246, 
TH-PO247, TH-PO249, TH-PO250, 
TH-PO251, TH-PO252, TH-PO253, 
TH-PO254, TH-PO256, TH-PO257, 
anemia (continued)........ TH-PO258, TH-PO259, 
TH-PO260, TH-PO262, TH-PO264, 
TH-PO265, TH-PO266, TH-PO267, 
TH-PO268, TH-PO269, TH-PO271, 
TH-PO293, TH-PO379, TH-PO380, 
TH-PO939, FR-OR102, FR-OR120, 
FR-PO227, FR-PO243, FR-PO256, 
FR-PO472, FR-PO474, FR-PO475, 
FR-PO478, FR-PO479, FR-PO501, 
FR-PO667, FR-PO734, FR-PO740, 
FR-PO793, FR-PO794, FR-PO832, 
FR-PO1156, SA-OR074, SA-PO032, 
SA-PO053, SA-PO696, SA-PO703, 
SA-PO788, SA-PO837, SA-PO876, 
SA-PO1095, PUB073, PUB075, PUB076, 
PUB215, PUB378, PUB760
angiotensin .....................TH-OR077, TH-PO118, 
TH-PO832, TH-PO1013, FR-OR087, 
FR-PO126, FR-PO157, FR-PO995, 
FR-PO1000, SA-PO373, SA-PO379, 
SA-PO572, SA-PO635, SA-PO802, 
SA-PO815, SA-PO828, PUB203
anti-GBM disease ..........TH-OR051, TH-PO839, 
FR-OR036, FR-PO1061, SA-OR038, 
PUB417
apoptosis......TH-PO097, TH-PO106, TH-PO114, 
TH-PO614, TH-PO672, TH-PO674, 
TH-PO689, TH-PO866, TH-PO945, 
TH-PO975, TH-PO992, FR-OR056, 
FR-PO077, FR-PO094, FR-PO099, 
FR-PO408, FR-PO511, FR-PO924, 
FR-PO958, SA-PO127, SA-PO132, 
SA-PO357, SA-PO379, SA-PO562, 
SA-PO566, SA-PO578, SA-PO586, 
SA-PO605, SA-PO619, SA-PO816, 
SA-PO850, PUB054, PUB069, 
PUB179, PUB344
arteries ........ TH-PO749, FR-PO163, FR-PO351, 
FR-PO504, SA-PO600, SA-PO994
arteriosclerosis ...............TH-OR001, TH-PO184, 
TH-PO452, TH-PO857, TH-PO981, 
FR-OR114, FR-PO348, FR-PO359, 
FR-PO362, FR-PO486, FR-PO509, 
FR-PO1131, SA-PO731, SA-PO896, 
SA-PO904, SA-PO975, SA-PO976, 
SA-PO982, SA-PO1061, PUB091, PUB151, 
PUB152, PUB193, PUB376, PUB759
arteriovenous access .... TH-PO1141, FR-OR088, 
FR-OR090, FR-PO702, FR-PO703, 
FR-PO714, FR-PO716, FR-PO724, 
FR-PO725, FR-PO729, SA-PO946, 
SA-PO949, SA-PO956, SA-PO957, 
SA-PO958, SA-PO962, SA-PO974, PUB215
arteriovenous fistula......TH-PO206, FR-OR089, 
FR-OR090, FR-OR091, FR-OR092, 
FR-OR094, FR-PO702, FR-PO703, 
FR-PO704, FR-PO705, FR-PO706, 
FR-PO707, FR-PO708, FR-PO712, 
FR-PO713, FR-PO714, FR-PO715, 
FR-PO719, FR-PO720, FR-PO727, 
FR-PO728, FR-PO729, FR-PO731, 
SA-OR006, SA-PO920, SA-PO947, 
SA-PO949, SA-PO950, SA-PO951, 
SA-PO956, SA-PO957, SA-PO961, PUB144, 
PUB281
arteriovenous graft .........FR-PO713, FR-PO730, 
FR-PO732, FR-PO733, SA-PO949, 
SA-PO956, SA-PO961
arteriovenous shunt ........................... FR-PO709
Bartter syndrome .......... TH-PO495, TH-PO725, 
TH-PO737, FR-OR060, SA-PO1028, 
SA-PO1035
blood pressure .............. TH-OR050, TH-OR081, 
TH-PO044, TH-PO168, TH-PO318, 
TH-PO336, TH-PO347, TH-PO352, 
TH-PO407, TH-PO423, TH-PO433, 
TH-PO437, TH-PO439, TH-PO454, 
TH-PO475, TH-PO486, TH-PO508, 
TH-PO516, TH-PO724, TH-PO1096, 
FR-OR061, FR-PO005, FR-PO264, 
FR-PO320, FR-PO342, FR-PO345, 
FR-PO346, FR-PO369, FR-PO376, 
FR-PO563, FR-PO747, FR-PO811, 
FR-PO820, FR-PO822, FR-PO1137, 
FR-PO1138, FR-PO1139, FR-PO1142, 
FR-PO1176, SA-OR048, SA-OR050, 
SA-OR052, SA-PO513, SA-PO601, 
SA-PO611, SA-PO848, SA-PO871, 
SA-PO872, SA-PO890, SA-PO907, 
SA-PO993, SA-PO994, PUB135, PUB220, 
PUB409, PUB410, PUB427
cadaver organ transplantation .........SA-PO017, 
SA-PO059, PUB773
calcium .......TH-OR104, TH-PO017, TH-PO131, 
TH-PO164, TH-PO165, TH-PO209, 
TH-PO210, TH-PO217, TH-PO672, 
TH-PO766, FR-OR067, FR-PO270, 
FR-PO311, FR-PO312, FR-PO485, 
FR-PO519, FR-PO522, FR-PO529, 
FR-PO734, FR-PO746, SA-OR016, 
SA-OR098, SA-PO122, SA-PO315, 
SA-PO317, SA-PO361, SA-PO619, 
SA-PO659, SA-PO670, SA-PO671, 
SA-PO689, SA-PO690, SA-PO706, 
SA-PO976, SA-PO1014, SA-PO1026, 
SA-PO1032, PUB087, PUB098, PUB186, 
PUB770, PUB774
calcium-sensing receptor ..................TH-PO185, 
FR-PO226, FR-PO480, FR-PO485, 
FR-PO488, FR-PO512, FR-PO954, 
FR-PO1155, SA-PO469, SA-PO658, 
SA-PO668, SA-PO669, SA-PO704, 
SA-PO1027
cancer ......... TH-PO055, TH-PO070, TH-PO072, 
TH-PO075, TH-PO077, TH-PO895, 
TH-PO1090, FR-PO035, FR-PO291, 
FR-PO339, FR-PO566, FR-PO805, 
FR-PO810, FR-PO907, FR-PO923, 
FR-PO1033, FR-PO1034, FR-PO1083, 
SA-PO005, SA-PO027, SA-PO038, 
SA-PO050, SA-PO051, SA-PO487, 
SA-PO519, SA-PO612, SA-PO627, 
SA-PO751, SA-PO780, PUB038, PUB229
cardiovascular .............. TH-OR093, TH-OR124, 
TH-PO050, TH-PO131, TH-PO138, 
TH-PO139, TH-PO147, TH-PO172, 
TH-PO412, TH-PO413, TH-PO422, 
TH-PO430, TH-PO444, TH-PO446, 
TH-PO455, TH-PO699, FR-OR011, 
FR-OR014, FR-PO125, FR-PO338, 
FR-PO357, FR-PO658, FR-PO803, 
FR-PO817, SA-OR006, SA-PO093, 
SA-PO106, SA-PO468, SA-PO554, 
SA-PO620, SA-PO861, SA-PO867, 
SA-PO877, SA-PO906, SA-PO993, 
SA-PO995, SA-PO996, SA-PO1100, 
PUB014, PUB036, PUB102, PUB163, 
PUB197, PUB263, PUB286
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cardiovascular disease ....TH-OR025, TH-PO008, 
TH-PO023, TH-PO129, TH-PO161, 
TH-PO181, TH-PO220, TH-PO261, 
TH-PO347, TH-PO416, TH-PO419, 
TH-PO424, TH-PO425, TH-PO431, 
TH-PO433, TH-PO449, TH-PO457, 
TH-PO464, TH-PO465, TH-PO468, 
TH-PO469, TH-PO476, TH-PO477, 
TH-PO478, TH-PO623, TH-PO624, 
TH-PO627, TH-PO970, TH-PO1046, 
TH-PO1047, TH-PO1048, TH-PO1082, 
TH-PO1135, TH-PO1136, TH-PO1138, 
FR-OR088, FR-OR114, FR-OR121, 
FR-PO034, FR-PO036, FR-PO112, 
FR-PO136, FR-PO185, FR-PO193, 
FR-PO199, FR-PO210, FR-PO327, 
FR-PO333, FR-PO334, FR-PO336, 
FR-PO337, FR-PO347, FR-PO352, 
FR-PO360, FR-PO361, FR-PO363, 
FR-PO372, FR-PO373, FR-PO429, 
FR-PO486, FR-PO509, FR-PO520, 
FR-PO797, FR-PO798, FR-PO807, 
FR-PO826, FR-PO1137, FR-PO1143, 
SA-OR049, SA-OR056, SA-OR074, 
SA-PO464, SA-PO621, SA-PO688, 
SA-PO775, SA-PO783, SA-PO846, 
SA-PO858, SA-PO859, SA-PO874, 
SA-PO882, SA-PO894, SA-PO895, 
SA-PO897, SA-PO898, SA-PO901, 
SA-PO973, SA-PO977, SA-PO978, 
SA-PO980, SA-PO987, SA-PO988, 
SA-PO990, SA-PO991, SA-PO992, 
SA-PO997, SA-PO1003, PUB001, PUB079, 
PUB096, PUB104, PUB147, PUB189, 
PUB190, PUB211, PUB236, PUB257, 
PUB416, PUB767
cardiovascular events .... TH-OR034, TH-OR039, 
TH-OR040, TH-OR114, TH-PO091, 
TH-PO133, TH-PO140, TH-PO153, 
TH-PO162, TH-PO169, TH-PO182, 
TH-PO184, TH-PO185, TH-PO208, 
TH-PO209, TH-PO260, TH-PO310, 
TH-PO421, TH-PO426, TH-PO427, 
TH-PO443, TH-PO447, TH-PO449, 
TH-PO461, TH-PO462, TH-PO465, 
TH-PO756, TH-PO1077, TH-PO1081, 
TH-PO1108, TH-PO1116, TH-PO1132, 
TH-PO1133, FR-OR116, FR-OR126, 
FR-PO010, FR-PO033, FR-PO034, 
FR-PO046, FR-PO197, FR-PO293, 
FR-PO349, FR-PO353, FR-PO355, 
FR-PO368, FR-PO374, FR-PO430, 
FR-PO454, FR-PO462, FR-PO465, 
FR-PO721, FR-PO769, FR-PO800, 
FR-PO815, FR-PO839, SA-OR053, 
SA-OR054, SA-PO527, SA-PO662, 
SA-PO775, SA-PO776, SA-PO779, 
SA-PO781, SA-PO831, SA-PO860, 
SA-PO884, SA-PO891, SA-PO893, 
SA-PO903, SA-PO1109, PUB139, PUB148, 
PUB263, PUB273, PUB409, PUB414
cell activation .................TH-OR019, TH-PO849, 
TH-PO948, TH-PO980, FR-PO054, 
FR-PO154, FR-PO707, FR-PO775, 
SA-PO359, SA-PO566
cell adhesion ................... TH-PO789, TH-PO801, 
FR-PO411
cell and transport physiology ...........TH-PO484, 
TH-PO488, TH-PO493, TH-PO495, 
TH-PO667, TH-PO739, TH-PO744, 
TH-PO805, TH-PO973, FR-OR065, 
cell and transport physiology (continued) .........
FR-PO315, FR-PO978, SA-PO330, 
SA-PO614, SA-PO927, SA-PO1025, 
SA-PO1030, SA-PO1033
cell biology and structure ................ TH-OR008, 
TH-OR062, TH-OR103, TH-PO802, 
TH-PO966, TH-PO990, TH-PO991, 
FR-PO392, FR-PO503, FR-PO925, 
FR-PO944, FR-PO945, FR-PO952, 
FR-PO1022, FR-PO1066, FR-PO1070, 
FR-PO1074, SA-PO306, SA-PO307, 
SA-PO329, SA-PO371, SA-PO1008, 
SA-PO1012, PUB175
cell death .... TH-OR007, TH-PO099, FR-PO082, 
FR-PO088, FR-PO094, FR-PO397, 
FR-PO444, FR-PO476, FR-PO1022, 
SA-PO361, SA-PO568, SA-PO599, 
SA-PO813
cell signaling ................. TH-OR104, TH-OR117, 
TH-PO085, TH-PO116, TH-PO124, 
TH-PO489, TH-PO622, TH-PO675, 
TH-PO680, TH-PO687, TH-PO699, 
TH-PO707, TH-PO789, TH-PO790, 
TH-PO795, TH-PO802, TH-PO809, 
TH-PO850, TH-PO877, TH-PO884, 
TH-PO916, TH-PO921, TH-PO928, 
TH-PO937, TH-PO943, TH-PO950, 
TH-PO960, TH-PO984, FR-OR032, 
FR-OR048, FR-OR053, FR-OR055, 
FR-OR106, FR-PO067, FR-PO079, 
FR-PO094, FR-PO102, FR-PO143, 
FR-PO157, FR-PO316, FR-PO387, 
FR-PO391, FR-PO393, FR-PO413, 
FR-PO435, FR-PO526, FR-PO528, 
FR-PO853, FR-PO922, FR-PO949, 
FR-PO951, FR-PO965, FR-PO990, 
FR-PO1011, FR-PO1034, SA-PO110, 
SA-PO312, SA-PO358, SA-PO359, 
SA-PO371, SA-PO378, SA-PO574, 
SA-PO595, SA-PO619, SA-PO731, 
SA-PO804, SA-PO809, SA-PO812, 
SA-PO822, SA-PO830, SA-PO975, 
SA-PO986, SA-PO989, SA-PO1006, 
SA-PO1016, SA-PO1031, SA-PO1033, 
PUB083, PUB164, PUB172
cell survival ....................TH-OR076, FR-PO080, 
FR-PO085, FR-PO511, FR-PO850, 
SA-PO360, SA-PO571, SA-PO604, 
SA-PO812
cell transfer .........................................FR-OR054
cell volume regulation ............................PUB299
cell-matrix-interactions ................... TH-OR138, 
TH-PO761, TH-PO775, TH-PO803, 
TH-PO1114, SA-PO811, SA-PO975
chemokine ......................TH-PO831, FR-OR020, 
FR-PO130, FR-PO438, FR-PO894, 
FR-PO960, FR-PO1050, 
FR-PO1056, SA-PO834
chemokine receptor ..... TH-PO847, FR-PO1058, 
SA-PO368, SA-PO943
chemotherapy ................ TH-PO055, TH-PO062, 
TH-PO068, FR-PO008, SA-PO627, PUB023
children ..... TH-OR042, TH-OR043, TH-OR112, 
TH-PO233, TH-PO369, TH-PO881, 
TH-PO1050, FR-PO1095, FR-PO1122, 
FR-PO1127, FR-PO1141, FR-PO1142, 
FR-PO1145, FR-PO1149, FR-PO1151, 
FR-PO1158, FR-PO1161, FR-PO1162, 
FR-PO1163, FR-PO1169, FR-PO1178, 
SA-PO048, SA-PO441, SA-PO443, 
children (continued) ...... SA-PO446, SA-PO465, 
SA-PO466, PUB226, PUB410, PUB427, 
PUB428, PUB430, PUB778
chronic allograft failure ................... TH-OR125, 
TH-OR126, TH-PO144, TH-PO168, 
FR-OR132, FR-PO891, SA-PO013, 
SA-PO022, SA-PO033
chronic allograft nephropathy .........SA-OR096, 
SA-OR097, SA-PO095
chronic allograft rejection ................ FR-PO845, 
FR-PO859, FR-PO861, FR-PO878, 
FR-PO909, FR-PO915, SA-PO022
chronic diabetic complications .........TH-PO893, 
FR-PO448, FR-PO464, FR-PO465, 
SA-OR023, SA-PO117, SA-PO152, 
SA-PO167
chronic dialysis .............. TH-PO281, TH-PO315, 
TH-PO316, TH-PO322, TH-PO355, 
TH-PO367, TH-PO401, TH-PO403, 
TH-PO431, TH-PO752, TH-PO1075, 
FR-PO536, FR-PO540, FR-PO564, 
FR-PO684, FR-PO692, FR-PO761, 
FR-PO780, FR-PO814, FR-PO1157, 
FR-PO1162, SA-PO620, SA-PO691, 
SA-PO876, SA-PO881, SA-PO918, 
SA-PO923, SA-PO962, SA-PO1039, 
SA-PO1099, PUB097, PUB240, PUB244, 
PUB247, PUB263, PUB340
chronic glomerulonephritis ..............TH-PO798, 
FR-PO1135, SA-PO389, SA-PO392, 
SA-PO423, PUB175
chronic graft deterioration ............. FR-PO1175, 
SA-PO095
chronic heart failure .........................TH-PO755, 
FR-PO220, PUB162
chronic hemodialysis .....TH-OR095, TH-PO212, 
TH-PO257, TH-PO313, TH-PO319, 
TH-PO331, TH-PO333, TH-PO335, 
TH-PO338, TH-PO356, TH-PO753, 
FR-OR005, FR-PO352, FR-PO734, 
FR-PO735, FR-PO748, FR-PO753, 
FR-PO784, FR-PO785, FR-PO806, 
SA-PO669, SA-PO689, SA-PO706, 
SA-PO858, SA-PO864, SA-PO874, 
SA-PO889, SA-PO908, SA-PO946, 
SA-PO959, SA-PO1100, PUB220, PUB254
chronic hypoxia ..................................SA-PO732
chronic inflammation ....................... TH-OR020, 
TH-OR054, TH-PO086, TH-PO106, 
TH-PO135, TH-PO256, TH-PO262, 
TH-PO357, TH-PO645, TH-PO825, 
TH-PO906, TH-PO953, TH-PO1113, 
TH-PO1134, FR-OR049, FR-PO151, 
FR-PO154, FR-PO411, FR-PO458, 
FR-PO505, FR-PO545, FR-PO768, 
FR-PO1073, SA-PO116, SA-PO151, 
SA-PO174, SA-PO647, SA-PO832, 
SA-PO840, SA-PO841, SA-PO1106, 
PUB087, PUB119, PUB174, PUB240, 
PUB248, PUB347, PUB380, PUB422
chronic kidney disease ..................... TH-OR010, 
TH-OR015, TH-OR022, TH-OR024, 
TH-OR025, TH-OR026, TH-OR032, 
TH-OR033, TH-OR044, TH-OR045, 
TH-OR046, TH-OR047, TH-OR081, 
TH-OR085, TH-OR087, TH-OR088, 
TH-OR089, TH-OR090, TH-PO003, 
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FR-PO1160, SA-OR067, SA-PO1066, 
PUB312
hypokalemia................... TH-PO497, TH-PO498, 
FR-OR058, FR-OR060, FR-PO303, 
SA-PO1033, PUB295, PUB304, PUB406
hyponatremia ................. TH-PO013, TH-PO309, 
TH-PO739, FR-PO205, FR-PO281, 
FR-PO282, FR-PO285, FR-PO286, 
FR-PO287, FR-PO288, FR-PO289, 
FR-PO291, FR-PO295, FR-PO695, 
FR-PO821, SA-PO181, SA-PO182, 
SA-PO618, SA-PO711, PUB294, PUB295, 
PUB297, PUB304, PUB338, PUB804
hypotension ...................TH-PO1122, FR-PO358, 
SA-OR068, SA-OR073, SA-PO866, 
SA-PO875, SA-PO881, SA-PO883, 
SA-PO884, SA-PO885, SA-PO886, 
SA-PO888, SA-PO889, PUB026
hypoxia ....... TH-OR117, TH-PO189, TH-PO912, 
TH-PO957, TH-PO1124, TH-PO1125, 
TH-PO1126, FR-PO083, FR-PO120, 
FR-PO145, FR-PO240, FR-PO426, 
FR-PO474, FR-PO476, FR-PO477, 
FR-PO505, FR-PO935, SA-OR013, 
SA-PO092, SA-PO119, SA-PO323, 
SA-PO584, SA-PO589, SA-PO590, 
SA-PO600, SA-PO602, SA-PO836, 
SA-PO1096, PUB072, PUB073
ICD-9-CM codes .............FR-PO030, FR-PO188, 
FR-PO751, SA-PO765, SA-PO912
idiopathic nephrotic syndrome ...... FR-PO1125, 
SA-PO338, SA-PO453
IgA ............ TH-PO808, TH-PO813, TH-PO1033, 
FR-PO114
IgA deposition ................ TH-PO818, TH-PO822, 
FR-PO846, PUB333
IgA nephropathy ........... TH-PO167, TH-PO474, 
TH-PO807, TH-PO809, TH-PO810, 
TH-PO811, TH-PO812, TH-PO813, 
TH-PO814, TH-PO815, TH-PO816, 
TH-PO817, TH-PO818, TH-PO819, 
TH-PO820, TH-PO821, TH-PO822, 
TH-PO910, TH-PO927, TH-PO1024, 
TH-PO1025, TH-PO1026, TH-PO1027, 
TH-PO1028, TH-PO1031, TH-PO1032, 
TH-PO1033, TH-PO1034, TH-PO1035, 
TH-PO1037, TH-PO1038, TH-PO1039, 
TH-PO1040, FR-PO114, FR-PO846, 
FR-PO852, SA-OR046, SA-OR058, 
SA-OR060, SA-OR061, SA-OR062, 
SA-PO437, SA-PO438, SA-PO439, 
SA-PO441, SA-PO442, SA-PO644, 
SA-PO793, SA-PO1115, PUB165, PUB333, 
PUB347, PUB353, PUB371, PUB382, 
PUB387, PUB389, PUB394, PUB397
immune complexes ........TH-OR058, TH-PO822, 
FR-PO1047, FR-PO1117, SA-PO336, 
SA-PO349, SA-PO1098, PUB353, PUB365
immune deficiency ..........FR-PO259, FR-PO779, 
FR-PO898, SA-PO091, PUB143
immunohistochemistry .....................TH-PO123, 
FR-PO473, SA-PO368, SA-PO1081
immunology .................. TH-OR002, TH-OR018, 
TH-OR052, TH-OR058, TH-OR061, 
TH-OR108, TH-OR109, TH-PO078, 
TH-PO107, TH-PO122, TH-PO510, 
TH-PO755, TH-PO810, TH-PO819, 
TH-PO821, TH-PO828, TH-PO833, 
TH-PO835, TH-PO840, TH-PO842, 
TH-PO843, TH-PO844, TH-PO976, 
FR-PO002, FR-PO054, FR-PO064, 
FR-PO103, FR-PO106, FR-PO228, 
FR-PO693, FR-PO707, FR-PO775, 
FR-PO776, FR-PO802, FR-PO845, 
FR-PO858, FR-PO860, FR-PO862, 
FR-PO864, FR-PO905, FR-PO947, 
FR-PO1019, FR-PO1047, FR-PO1055, 
FR-PO1064, FR-PO1075, SA-OR016, 
SA-OR017, SA-OR094, SA-OR097, 
SA-PO351, SA-PO376, SA-PO381, 
SA-PO424, SA-PO525, SA-PO598, 
SA-PO601, SA-PO604, SA-PO608, 
SA-PO649, SA-PO699, SA-PO805, 
SA-PO856, SA-PO938, SA-PO984, PUB053, 
PUB067, PUB071, PUB367, PUB419
immunology and pathology ............. TH-OR059, 
TH-PO065, TH-PO080, TH-PO086, 
TH-PO112, TH-PO807, TH-PO827, 
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immunology and pathology (continued) ............
TH-PO846, TH-PO917, TH-PO974, 
TH-PO1010, TH-PO1036, FR-OR053, 
FR-OR082, FR-OR105, FR-PO053, 
FR-PO183, FR-PO402, FR-PO475, 
FR-PO528, FR-PO861, FR-PO981, 
FR-PO1042, FR-PO1050, FR-PO1054, 
FR-PO1063, FR-PO1067, FR-PO1072, 
FR-PO1074, SA-OR013, SA-OR042, 
SA-OR045, SA-OR061, SA-OR095, 
SA-PO337, SA-PO338, SA-PO339, 
SA-PO350, SA-PO364, SA-PO380, 
SA-PO421, SA-PO431, SA-PO432, 
SA-PO433, SA-PO434, SA-PO445, 
SA-PO800, SA-PO806, PUB062, 
PUB181, PUB417, PUB784
immunosuppression ...... TH-PO067, TH-PO151, 
TH-PO160, TH-PO163, TH-PO646, 
TH-PO833, TH-PO888, TH-PO1015, 
TH-PO1016, TH-PO1020, TH-PO1036, 
TH-PO1038, TH-PO1040, FR-OR137, 
FR-PO848, FR-PO851, FR-PO874, 
FR-PO898, FR-PO899, FR-PO902, 
FR-PO905, FR-PO906, FR-PO912, 
FR-PO1108, FR-PO1109, FR-PO1135, 
SA-PO001, SA-PO002, SA-PO007, 
SA-PO009, SA-PO012, SA-PO015, 
SA-PO016, SA-PO019, SA-PO020, 
SA-PO023, SA-PO024, SA-PO047, 
SA-PO409, SA-PO417, SA-PO438, 
SA-PO641, SA-PO642, PUB397, PUB776, 
PUB784, PUB793, PUB797
insulin resistance ........... TH-PO484, TH-PO615, 
TH-PO620, TH-PO1134, TH-PO1135, 
FR-OR129, FR-OR130, FR-PO395, 
FR-PO402, FR-PO412, FR-PO554, 
FR-PO735, SA-PO164, PUB085
interstitial fibrosis .........TH-OR013, TH-PO088, 
TH-PO747, TH-PO748, TH-PO774, 
TH-PO915, TH-PO917, TH-PO929, 
TH-PO952, TH-PO1014, FR-OR055, 
FR-OR105, FR-PO086, FR-PO137, 
FR-PO155, FR-PO158, FR-PO844, 
FR-PO980, FR-PO1079, FR-PO1091, 
SA-PO388, SA-PO569, SA-PO725, 
SA-PO800, SA-PO803, SA-PO808, 
SA-PO837, SA-PO842, SA-PO854, 
SA-PO1027
interventional nephrology ................TH-PO772, 
FR-PO003, FR-PO722, FR-PO730, 
SA-PO967
intestine ...... TH-PO207, TH-PO399, TH-PO483, 
TH-PO906, TH-PO911, FR-OR127, 
FR-OR129, FR-PO118, FR-PO139, 
FR-PO490, FR-PO531, FR-PO761, 
SA-OR046, SA-PO585, SA-PO686, 
SA-PO727, SA-PO927, PUB052
intracellular pH .............FR-PO271, SA-PO1023
intracellular signal ........ TH-PO493, TH-PO614, 
FR-PO511, FR-PO516, SA-PO997
intralipid ...........................................SA-PO1062
intrauterine growth ........................... FR-PO946, 
FR-PO1116, SA-PO426
intravenous .................... TH-PO057, TH-PO239, 
FR-PO735, SA-PO533, PUB227
intrinsic renal cell ........... TH-PO969, FR-PO051
ion channel ..................... TH-PO744, TH-PO766, 
TH-PO894, FR-OR063, FR-PO105, 
FR-PO480, FR-PO506, FR-PO1025, 
ion channel (continued) ....................SA-OR015, 
SA-OR032, SA-PO329, SA-PO361, 
SA-PO1025, PUB182
ion transport .................. TH-PO494, TH-PO496, 
TH-PO621, FR-OR066, FR-PO328, 
FR-PO329, FR-PO330, FR-PO526, 
SA-PO1016, SA-PO1024, SA-PO1026, 
SA-PO1029, SA-PO1036
ischemia ........................ TH-PO012, TH-PO1142, 
FR-OR108, FR-PO750, SA-PO571, 
SA-PO603, SA-PO877
ischemia-reperfusion .... TH-OR005, TH-OR007, 
TH-OR009, TH-PO053, TH-PO080, 
TH-PO089, TH-PO101, TH-PO104, 
TH-PO107, TH-PO108, TH-PO109, 
TH-PO110, TH-PO111, TH-PO112, 
TH-PO121, TH-PO122, TH-PO126, 
TH-PO951, FR-OR111, FR-PO052, 
FR-PO061, FR-PO070, FR-PO078, 
FR-PO087, FR-PO096, FR-PO097, 
FR-PO101, FR-PO110, FR-PO119, 
FR-PO841, FR-PO842, FR-PO843, 
FR-PO875, SA-OR014, SA-OR092, 
SA-PO561, SA-PO565, SA-PO567, 
SA-PO568, SA-PO570, SA-PO573, 
SA-PO577, SA-PO579, SA-PO582, 
SA-PO587, SA-PO596, SA-PO598, 
SA-PO599, SA-PO602, SA-PO603, 
SA-PO609, SA-PO650, PUB051, PUB062, 
PUB065, PUB168, PUB418
kidney .........TH-OR014, TH-PO154, TH-PO757, 
FR-OR098, FR-OR101, FR-PO020, 
FR-PO151, FR-PO274, FR-PO331, 
FR-PO450, FR-PO904, FR-PO945, 
SA-OR089, SA-PO130, SA-PO198, 
SA-PO598, SA-PO650, SA-PO1015, 
SA-PO1089, PUB040, PUB285
kidney anatomy ......... TH-PO1024, TH-PO1121, 
FR-OR111, SA-PO185
kidney biopsy .................TH-OR061, TH-PO774, 
TH-PO981, TH-PO1122, FR-OR032, 
FR-OR051, FR-PO362, FR-PO435, 
FR-PO1042, FR-PO1115, FR-PO1117, 
SA-OR065, SA-PO034, SA-PO178, 
SA-PO179, SA-PO191, SA-PO194, 
SA-PO437, SA-PO629, SA-PO1074, 
SA-PO1075, SA-PO1076, SA-PO1081, 
SA-PO1094, SA-PO1095, PUB023, PUB025, 
PUB141, PUB194, PUB292, PUB349, 
PUB374, PUB424, PUB773
kidney cancer ................. TH-PO073, FR-PO908, 
FR-PO923, PUB419
kidney development ..... TH-OR132, TH-OR134, 
TH-PO105, TH-PO630, TH-PO633, 
TH-PO634, TH-PO635, TH-PO643, 
TH-PO707, TH-PO812, FR-OR039, 
FR-OR040, FR-OR041, FR-OR042, 
FR-OR044, FR-PO917, FR-PO919, 
FR-PO920, FR-PO921, FR-PO927, 
FR-PO928, FR-PO934, FR-PO936, 
FR-PO937, FR-PO946, SA-PO428
kidney disease ................TH-OR036, TH-PO682, 
TH-PO749, TH-PO907, TH-PO1119, 
FR-OR077, FR-PO108, FR-PO178, 
FR-PO229, FR-PO274, FR-PO307, 
FR-PO342, FR-PO404, FR-PO524, 
SA-OR037, SA-PO145, SA-PO442, 
SA-PO647, SA-PO1108, PUB121, PUB165, 
PUB169, PUB196, PUB291, PUB330
kidney donation ............. TH-PO134, TH-PO205, 
TH-PO342, FR-PO149, FR-PO406, 
SA-OR004, SA-PO062, SA-PO071, 
SA-PO078, SA-PO079, SA-PO086, 
SA-PO098, SA-PO099, PUB763, PUB809
kidney dysfunction ........TH-OR117, TH-PO164, 
TH-PO171, TH-PO445, TH-PO605, 
TH-PO754, FR-PO017, FR-PO177, 
FR-PO294, SA-PO185, SA-PO585, 
SA-PO992
kidney failure ................ TH-OR013, TH-OR082, 
TH-OR097, TH-PO005, TH-PO061, 
TH-PO327, TH-PO660, TH-PO1024, 
TH-PO1069, TH-PO1123, FR-OR035, 
FR-PO016, FR-PO477, FR-PO915, 
SA-PO015, SA-PO052, SA-PO520, 
SA-PO531, PUB162
kidney stones.................. TH-PO365, TH-PO626, 
TH-PO715, TH-PO716, TH-PO718, 
TH-PO719, TH-PO720, TH-PO721, 
TH-PO722, TH-PO723, FR-OR075, 
FR-PO328, FR-PO329, FR-PO521, 
FR-PO522, FR-PO523, FR-PO524, 
FR-PO525, FR-PO526, FR-PO527, 
FR-PO528, FR-PO529, FR-PO530, 
FR-PO531, FR-PO1038, SA-PO506, 
SA-PO624, SA-PO674, SA-PO675, 
SA-PO676, SA-PO677, SA-PO678, 
SA-PO679, SA-PO680, SA-PO681, 
SA-PO682, SA-PO683, SA-PO684, 
SA-PO685, SA-PO686, SA-PO1022, 
PUB085, PUB300, PUB782
kidney transplantation..................... TH-OR049, 
TH-OR129, TH-PO112, TH-PO128, 
TH-PO129, TH-PO133, TH-PO137, 
TH-PO142, TH-PO148, TH-PO149, 
TH-PO151, TH-PO155, TH-PO156, 
TH-PO163, TH-PO165, TH-PO172, 
TH-PO175, TH-PO178, TH-PO429, 
TH-PO628, FR-OR134, FR-OR140, 
FR-PO562, FR-PO841, FR-PO842, 
FR-PO849, FR-PO854, FR-PO855, 
FR-PO858, FR-PO859, FR-PO862, 
FR-PO865, FR-PO869, FR-PO875, 
FR-PO882, FR-PO885, FR-PO891, 
FR-PO894, FR-PO895, FR-PO896, 
FR-PO903, FR-PO906, FR-PO1132, 
FR-PO1159, SA-OR005, SA-OR006, 
SA-OR009, SA-OR091, SA-PO003, 
SA-PO006, SA-PO010, SA-PO011, 
SA-PO013, SA-PO016, SA-PO020, 
SA-PO023, SA-PO025, SA-PO030, 
SA-PO031, SA-PO032, SA-PO033, 
SA-PO035, SA-PO038, SA-PO043, 
SA-PO047, SA-PO049, SA-PO061, 
SA-PO063, SA-PO068, SA-PO070, 
SA-PO071, SA-PO072, SA-PO074, 
SA-PO078, SA-PO082, SA-PO084, 
SA-PO089, SA-PO093, SA-PO097, 
SA-PO561, SA-PO633, SA-PO641, 
SA-PO642, PUB131, PUB148, PUB759, 
PUB762, PUB772, PUB780, PUB781, 
PUB785, PUB787, PUB793, PUB799, 
PUB802, PUB807, PUB809
kidney tubule .................TH-OR041, TH-PO899, 
TH-PO1060, FR-PO055, FR-PO192, 
FR-PO319, FR-PO401, FR-PO410, 
FR-PO974, SA-PO585, SA-PO631, 
SA-PO851, SA-PO1005, SA-PO1010
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kidney volume................ TH-PO682, TH-PO694, 
TH-PO1123, TH-PO1127, FR-PO982, 
SA-PO081, SA-PO474, SA-PO478, 
SA-PO486, SA-PO501, SA-PO502, 
SA-PO1051, PUB438
kinase .......... TH-PO501, TH-PO513, TH-PO690, 
TH-PO787, TH-PO990, FR-PO1033, 
SA-PO1036
LDL cholesterol ............FR-PO1123, SA-PO773, 
SA-PO1103
lean body mass...............TH-PO478, FR-OR109, 
FR-OR123, FR-PO540, SA-PO1060
left ventricular hypertrophy ............TH-PO417, 
TH-PO464, FR-PO364, FR-PO1140, 
FR-PO1141, SA-OR099, SA-PO776, 
SA-PO784, SA-PO863, SA-PO865, 
SA-PO874, SA-PO991
leptospirosis ............................................PUB032
lipids ........... TH-PO169, TH-PO412, TH-PO413, 
TH-PO468, TH-PO469, TH-PO611, 
TH-PO622, TH-PO637, TH-PO681, 
TH-PO728, TH-PO783, TH-PO795, 
TH-PO870, TH-PO890, TH-PO928, 
TH-PO936, TH-PO1099, TH-PO1118, 
TH-PO1133, FR-OR034, FR-PO139, 
FR-PO336, FR-PO395, FR-PO445, 
FR-PO446, FR-PO532, FR-PO557, 
FR-PO560, FR-PO739, FR-PO959, 
FR-PO1077, FR-PO1144, SA-PO110, 
SA-PO131, SA-PO774, SA-PO839, 
SA-PO998, PUB104, PUB166, 
PUB183, PUB300
liver cysts ..... TH-PO655, FR-PO985, FR-PO987, 
FR-PO988, SA-PO486
liver failure ..................... TH-PO030, TH-PO048, 
TH-PO622, FR-PO004, FR-PO005, 
FR-PO006, FR-PO007, FR-PO009, 
FR-PO892, FR-PO1172, SA-PO055, PUB158
lupus nephritis .............. TH-OR020, TH-OR070, 
TH-PO818, TH-PO823, TH-PO824, 
TH-PO825, TH-PO826, TH-PO827, 
TH-PO828, TH-PO829, TH-PO831, 
TH-PO832, TH-PO833, TH-PO834, 
TH-PO909, FR-PO516, FR-PO1061, 
FR-PO1065, FR-PO1079, FR-PO1088, 
FR-PO1089, FR-PO1090, FR-PO1091, 
FR-PO1092, FR-PO1093, FR-PO1094, 
FR-PO1095, FR-PO1096, FR-PO1097, 
FR-PO1098, FR-PO1099, FR-PO1101, 
FR-PO1102, FR-PO1103, FR-PO1104, 
FR-PO1105, FR-PO1107, FR-PO1109, 
FR-PO1111, FR-PO1113, FR-PO1114, 
SA-OR045, SA-OR047, SA-OR063, 
SA-OR064, SA-OR065, SA-OR066, 
SA-OR067, SA-PO345, SA-PO416, 
SA-PO444, SA-PO1114, PUB367, PUB375, 
PUB386, PUB395
lymphocytes ...................TH-OR108, TH-PO052, 
TH-PO838, TH-PO840, TH-PO953, 
TH-PO974, FR-PO062, FR-PO1060, 
SA-PO340, SA-PO346, SA-PO985, 
SA-PO1106, PUB347, PUB419
macrophages ................. TH-OR007, TH-OR012, 
TH-OR110, TH-PO081, TH-PO084, 
TH-PO086, TH-PO088, TH-PO678, 
TH-PO695, TH-PO824, TH-PO827, 
TH-PO849, TH-PO850, TH-PO890, 
TH-PO956, TH-PO1032, FR-OR054, 
FR-OR055, FR-OR122, FR-PO054, 
FR-PO063, FR-PO068, FR-PO118, 
macrophages (continued) ................. FR-PO136, 
FR-PO150, FR-PO154, FR-PO171, 
FR-PO334, FR-PO411, FR-PO960, 
FR-PO981, FR-PO1059, FR-PO1062, 
SA-OR014, SA-PO608, SA-PO803, 
SA-PO856, SA-PO941, SA-PO943, 
SA-PO985, SA-PO1103, SA-PO1114, 
PUB062, PUB134
malnutrition ................... TH-PO135, TH-PO213, 
TH-PO214, TH-PO218, TH-PO309, 
FR-OR125, FR-PO546, FR-PO551, 
FR-PO555, FR-PO698, SA-OR023, 
SA-PO662, SA-PO843, SA-PO844, 
SA-PO869, SA-PO898, SA-PO1062, 
PUB128, PUB155, PUB253, PUB405
MCP-1 (monocyte chemoattractant protein 1) .
TH-OR110, FR-PO118, FR-PO239, 
FR-PO335, FR-PO893, SA-PO508, 
SA-PO803, SA-PO855, PUB174
MDCK (Madin-Darby canine kidney) .....SA-PO577, 
SA-PO605
membranous nephropathy .............. TH-OR065, 
TH-PO791, TH-PO794, TH-PO817, 
TH-PO997, TH-PO998, TH-PO999, 
TH-PO1000, TH-PO1001, TH-PO1002, 
TH-PO1003, TH-PO1004, TH-PO1006, 
TH-PO1007, TH-PO1008, TH-PO1009, 
TH-PO1010, TH-PO1011, TH-PO1012, 
TH-PO1013, TH-PO1015, TH-PO1016, 
TH-PO1017, TH-PO1018, TH-PO1019, 
TH-PO1020, TH-PO1021, TH-PO1022, 
FR-OR080, FR-OR081, FR-OR082, 
FR-PO455, FR-PO1093, SA-PO026, 
SA-PO335, SA-PO336, SA-PO337, 
SA-PO338, SA-PO339, SA-PO340, 
SA-PO341, SA-PO342, SA-PO343, 
SA-PO344, SA-PO345, SA-PO346, 
SA-PO348, SA-PO349, SA-PO372, 
SA-PO392, SA-PO528, SA-PO721, 
SA-PO1083, PUB354, PUB375
mesangial cells ...............TH-OR055, TH-PO798, 
TH-PO927, FR-OR028, FR-PO116, 
FR-PO380, FR-PO385, FR-PO1065, 
SA-PO816
metabolism .................... TH-OR086, TH-OR107, 
TH-PO102, TH-PO152, TH-PO156, 
TH-PO607, TH-PO610, TH-PO617, 
TH-PO625, TH-PO673, TH-PO679, 
TH-PO683, TH-PO684, TH-PO687, 
TH-PO726, TH-PO728, TH-PO797, 
TH-PO853, TH-PO875, TH-PO893, 
TH-PO912, TH-PO942, TH-PO1118, 
FR-OR071, FR-OR109, FR-PO120, 
FR-PO194, FR-PO328, FR-PO329, 
FR-PO330, FR-PO459, FR-PO479, 
FR-PO529, FR-PO556, FR-PO700, 
FR-PO951, FR-PO1015, FR-PO1033, 
SA-OR026, SA-OR098, SA-PO136, 
SA-PO142, SA-PO455, SA-PO584, 
SA-PO592, SA-PO602, SA-PO615, 
SA-PO718, SA-PO794, SA-PO795, 
SA-PO797, SA-PO826, SA-PO833, 
SA-PO839, SA-PO845, PUB117, PUB164, 
PUB167, PUB170, PUB173, PUB187, 
PUB272, PUB300, PUB388
microalbuminuria ......... TH-PO609, SA-PO316, 
PUB206
mineral metabolism ......TH-OR021, TH-PO017, 
TH-PO175, TH-PO176, TH-PO181, 
TH-PO183, TH-PO186, TH-PO190, 
mineral metabolism (continued) ......TH-PO191, 
TH-PO192, TH-PO193, TH-PO194, 
TH-PO198, TH-PO199, TH-PO205, 
TH-PO207, TH-PO211, TH-PO212, 
TH-PO270, TH-PO271, TH-PO730, 
TH-PO941, FR-PO224, FR-PO243, 
FR-PO258, FR-PO497, FR-PO501, 
FR-PO502, FR-PO512, FR-PO513, 
FR-PO515, FR-PO516, FR-PO517, 
FR-PO527, FR-PO560, FR-PO567, 
FR-PO764, SA-OR028, SA-OR100, 
SA-OR101, SA-OR102, SA-OR107, 
SA-PO435, SA-PO436, SA-PO471, 
SA-PO653, SA-PO658, SA-PO662, 
SA-PO663, SA-PO670, SA-PO673, 
SA-PO688, SA-PO695, SA-PO715, 
SA-PO779, SA-PO891, SA-PO1022, 
SA-PO1071, PUB081, PUB084, PUB090, 
PUB091, PUB093
mitochondria ................ TH-OR012, TH-OR013, 
TH-OR075, TH-OR089, TH-PO043, 
TH-PO100, TH-PO103, TH-PO104, 
TH-PO113, TH-PO612, TH-PO618, 
TH-PO650, TH-PO673, TH-PO786, 
TH-PO811, TH-PO870, TH-PO871, 
TH-PO943, TH-PO947, TH-PO958, 
FR-OR130, FR-PO075, FR-PO078, 
FR-PO081, FR-PO085, FR-PO107, 
FR-PO341, FR-PO398, FR-PO399, 
FR-PO400, FR-PO401, FR-PO532, 
FR-PO533, FR-PO953, FR-PO954, 
FR-PO986, SA-OR019, SA-OR024, 
SA-OR025, SA-OR027, SA-PO118, 
SA-PO126, SA-PO130, SA-PO132, 
SA-PO309, SA-PO350, SA-PO373, 
SA-PO561, SA-PO563, SA-PO565, 
SA-PO576, SA-PO606, SA-PO799, 
SA-PO823, SA-PO836, SA-PO837, 
SA-PO846, SA-PO1063, PUB177, 
PUB184, PUB432
molecular biology .......... TH-PO631, TH-PO685, 
TH-PO686, TH-PO1114, FR-OR043, 
FR-OR050, FR-OR063, FR-PO082, 
FR-PO083, FR-PO433, FR-PO691, 
FR-PO865, FR-PO930, FR-PO966, 
FR-PO1026, SA-OR024, SA-PO357, 
SA-PO358, SA-PO360, SA-PO393, 
SA-PO825, SA-PO979, SA-PO1010, 
PUB051
molecular genetics .........TH-OR064, TH-PO713, 
TH-PO731, TH-PO946, FR-OR077, 
FR-PO067, FR-PO937, FR-PO976, 
FR-PO1010, FR-PO1019, FR-PO1020
mortality .....TH-OR128, TH-PO029, TH-PO032, 
TH-PO039, TH-PO193, TH-PO214, 
TH-PO285, TH-PO368, TH-PO379, 
TH-PO381, TH-PO382, TH-PO425, 
TH-PO468, TH-PO1082, TH-PO1096, 
TH-PO1136, FR-OR001, FR-OR003, 
FR-OR007, FR-OR008, FR-OR015, 
FR-OR025, FR-PO015, FR-PO038, 
FR-PO039, FR-PO048, FR-PO170, 
FR-PO259, FR-PO274, FR-PO283, 
FR-PO288, FR-PO311, FR-PO350, 
FR-PO353, FR-PO355, FR-PO366, 
FR-PO375, FR-PO376, FR-PO443, 
FR-PO547, FR-PO548, FR-PO549, 
FR-PO696, FR-PO782, FR-PO798, 
FR-PO803, FR-PO807, FR-PO809, 
FR-PO810, FR-PO812, FR-PO813, 
FR-PO814, FR-PO815, FR-PO816, 
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mortality (continued) .....FR-PO817, FR-PO819, 
FR-PO822, FR-PO823, FR-PO825, 
FR-PO830, FR-PO831, FR-PO832, 
FR-PO834, FR-PO835, FR-PO1161, 
SA-PO038, SA-PO042, SA-PO163, 
SA-PO405, SA-PO560, SA-PO692, 
SA-PO737, SA-PO738, SA-PO739, 
SA-PO741, SA-PO748, SA-PO749, 
SA-PO750, SA-PO774, SA-PO780, 
SA-PO782, SA-PO862, SA-PO864, 
SA-PO901, SA-PO1059, SA-PO1068, 
PUB020, PUB028, PUB042, PUB043, 
PUB089, PUB094, PUB095, PUB148, 
PUB150, PUB212, PUB222, PUB235
mortality risk ................ TH-OR088, TH-OR092, 
TH-OR100, TH-PO036, TH-PO147, 
TH-PO170, TH-PO194, TH-PO210, 
TH-PO212, TH-PO295, TH-PO310, 
TH-PO319, TH-PO339, TH-PO380, 
TH-PO384, TH-PO403, TH-PO423, 
TH-PO426, TH-PO452, TH-PO1045, 
TH-PO1073, TH-PO1081, TH-PO1091, 
TH-PO1109, TH-PO1115, TH-PO1143, 
FR-PO019, FR-PO022, FR-PO029, 
FR-PO034, FR-PO050, FR-PO179, 
FR-PO193, FR-PO230, FR-PO305, 
FR-PO453, FR-PO454, FR-PO465, 
FR-PO661, FR-PO806, FR-PO818, 
FR-PO820, FR-PO828, FR-PO1180, 
SA-PO007, SA-PO015, SA-PO097, 
SA-PO402, SA-PO462, SA-PO464, 
SA-PO556, SA-PO557, SA-PO728, 
SA-PO741, SA-PO773, SA-PO775, 
SA-PO895, SA-PO1050, SA-PO1063, 
SA-PO1069, SA-PO1073, PUB037, PUB202, 
PUB230, PUB236, PUB244, PUB805
MPGN (membranoproliferative glomerulonephritis) 
TH-PO986, FR-OR085, FR-PO1084, 
SA-PO425, PUB386
mRNA ........ TH-OR027, TH-OR065, TH-PO743, 
TH-PO780, TH-PO866, FR-PO083, 
FR-PO694, FR-PO1078, SA-OR010, 
SA-PO451
multiple myeloma ..........TH-OR069, TH-PO062, 
TH-PO079, SA-PO1090, PUB125, PUB349
mycophenolate mofetil .....................FR-PO1110, 
FR-PO1111, SA-OR064, SA-PO010, 
SA-PO425, PUB768, PUB800
myeloma ...... TH-PO343, FR-PO229, FR-PO836, 
FR-PO907, FR-PO1085, SA-PO627
NADPH oxidase ..............FR-PO396, FR-PO417, 
SA-PO115, SA-PO590
nephrectomy ................ TH-PO205, TH-PO1145, 
FR-PO070, FR-PO093, SA-PO081, 
SA-PO1009, PUB168
nephrin ........TH-OR056, TH-PO868, TH-PO949
nephritis ........................ TH-OR051, TH-OR059, 
TH-PO1030, FR-PO001, FR-PO183, 
FR-PO906, SA-PO326, SA-PO522
nephrology ...................TH-PO1049, FR-OR097, 
FR-OR100, FR-PO262, FR-PO263, 
FR-PO756, FR-PO896, FR-PO1163, 
SA-PO181, SA-PO187, SA-PO188, 
SA-PO189, SA-PO202, SA-PO207, 
SA-PO546, SA-PO548, PUB120, PUB289
nephron ......TH-OR131, TH-PO628, TH-PO635, 
TH-PO862, FR-OR038, FR-PO926, 
SA-PO572
nephropathy ................... TH-PO609, TH-PO641, 
FR-OR057, FR-PO905, SA-PO126, 
SA-PO529, SA-PO530, SA-PO644, 
SA-PO999, PUB063, PUB365
nephrotic syndrome ...... TH-PO472, TH-PO794, 
TH-PO991, TH-PO997, TH-PO998, 
TH-PO999, TH-PO1003, TH-PO1015, 
TH-PO1016, TH-PO1020, TH-PO1021, 
TH-PO1029, FR-OR084, FR-PO139, 
FR-PO148, FR-PO1003, FR-PO1004, 
FR-PO1005, FR-PO1006, FR-PO1008, 
FR-PO1009, FR-PO1010, FR-PO1018, 
FR-PO1020, FR-PO1084, FR-PO1115, 
FR-PO1120, FR-PO1121, FR-PO1122, 
FR-PO1123, FR-PO1124, FR-PO1126, 
FR-PO1127, FR-PO1130, FR-PO1132, 
FR-PO1135, FR-PO1170, FR-PO1171, 
SA-OR044, SA-PO310, SA-PO315, 
SA-PO324, SA-PO342, SA-PO343, 
SA-PO351, SA-PO363, SA-PO369, 
SA-PO375, SA-PO376, SA-PO381, 
SA-PO397, SA-PO447, SA-PO448, 
SA-PO449, SA-PO450, SA-PO451, 
SA-PO452, SA-PO454, SA-PO720, 
SA-PO1084, PUB019, PUB329, PUB349, 
PUB369, PUB374, PUB390, PUB423
nephrotoxicity ................TH-OR067, TH-PO044, 
TH-PO093, TH-PO451, TH-PO632, 
TH-PO758, TH-PO1057, FR-OR019, 
FR-OR027, FR-PO089, FR-PO131, 
FR-PO850, FR-PO1154, SA-PO520, 
SA-PO567, SA-PO593, SA-PO594, PUB025, 
PUB056, PUB137
nitric oxide ..................... TH-PO482, TH-PO623, 
FR-PO314, FR-PO405, FR-PO1068, 
SA-PO827, SA-PO835
nocturnal hypoxemia ..... TH-PO189, FR-PO296
nutrition ..... TH-PO136, TH-PO177, TH-PO191, 
TH-PO207, TH-PO267, TH-PO306, 
TH-PO428, TH-PO605, TH-PO610, 
TH-PO613, TH-PO619, FR-OR123, 
FR-OR124, FR-OR125, FR-OR126, 
FR-OR127, FR-PO042, FR-PO200, 
FR-PO222, FR-PO324, FR-PO356, 
FR-PO537, FR-PO545, FR-PO549, 
FR-PO552, FR-PO567, FR-PO570, 
FR-PO661, FR-PO699, FR-PO700, 
FR-PO762, FR-PO769, FR-PO803, 
FR-PO815, SA-OR046, SA-OR050, 
SA-PO142, SA-PO499, SA-PO502, 
SA-PO693, SA-PO1037, SA-PO1038, 
SA-PO1043, SA-PO1047, SA-PO1048, 
SA-PO1049, SA-PO1050, SA-PO1051, 
SA-PO1052, SA-PO1053, SA-PO1055, 
SA-PO1056, SA-PO1057, SA-PO1059, 
SA-PO1060, SA-PO1061, SA-PO1065, 
SA-PO1066, SA-PO1067, SA-PO1071, 
SA-PO1072, SA-PO1073, PUB117, PUB155, 
PUB212, PUB217, PUB236, PUB401, 
PUB402, PUB404, PUB406, PUB787
obesity........TH-OR042, TH-OR075, TH-OR121, 
TH-OR122, TH-PO141, TH-PO142, 
TH-PO143, TH-PO144, TH-PO145, 
TH-PO410, TH-PO471, TH-PO479, 
TH-PO606, TH-PO608, TH-PO616, 
TH-PO648, TH-PO729, TH-PO797, 
FR-PO043, FR-PO144, FR-PO224, 
FR-PO316, FR-PO463, FR-PO547, 
FR-PO548, FR-PO550, FR-PO551, 
FR-PO552, FR-PO553, FR-PO554, 
obesity (continued) .........FR-PO561, FR-PO840, 
FR-PO1136, FR-PO1143, SA-OR027, 
SA-PO118, SA-PO157, SA-PO505, 
SA-PO551, SA-PO799, SA-PO827, 
SA-PO860, PUB024, PUB134, PUB138, 
PUB183
obstructive nephropathy.................. TH-OR001, 
TH-PO506, TH-PO626, TH-PO914, 
FR-PO086, FR-PO103, FR-PO105, 
FR-PO142, FR-PO153, SA-PO427, 
SA-PO429, PUB038, PUB802
obstructive uropathy ..... TH-PO077, TH-PO647, 
TH-PO708, FR-PO182, FR-PO1166, 
SA-PO428, SA-PO429, SA-PO549
organ transplant ............ TH-PO145, TH-PO158, 
TH-PO159, TH-PO160, FR-OR137, 
FR-PO884, SA-OR003, SA-OR034, 
SA-PO054, SA-PO070, SA-PO085, PUB761, 
PUB780, PUB805
organic anion transporter ............... TH-OR139, 
TH-PO496, FR-PO140, 
FR-PO761, SA-PO614
osmolality ....................... TH-PO504, FR-PO281, 
FR-PO556, FR-PO690, SA-PO1006, 
SA-PO1020, SA-PO1021
osteopontin ......................FR-PO014, FR-PO020, 
FR-PO522, PUB094
outcomes .... TH-OR021, TH-OR098, TH-OR115, 
TH-OR126, TH-OR130, TH-PO009, 
TH-PO028, TH-PO032, TH-PO038, 
TH-PO053, TH-PO146, TH-PO157, 
TH-PO203, TH-PO231, TH-PO250, 
TH-PO272, TH-PO274, TH-PO278, 
TH-PO283, TH-PO290, TH-PO303, 
TH-PO308, TH-PO370, TH-PO371, 
TH-PO373, TH-PO398, TH-PO404, 
TH-PO829, TH-PO837, TH-PO1008, 
TH-PO1009, TH-PO1010, TH-PO1012, 
TH-PO1017, TH-PO1026, TH-PO1027, 
TH-PO1031, TH-PO1032, TH-PO1040, 
TH-PO1070, TH-PO1086, TH-PO1094, 
TH-PO1110, TH-PO1111, TH-PO1121, 
TH-PO1144, FR-OR080, FR-OR082, 
FR-OR085, FR-OR094, FR-OR119, 
FR-PO026, FR-PO029, FR-PO030, 
FR-PO037, FR-PO040, FR-PO210, 
FR-PO212, FR-PO220, FR-PO221, 
FR-PO232, FR-PO238, FR-PO250, 
FR-PO252, FR-PO253, FR-PO286, 
FR-PO426, FR-PO683, FR-PO686, 
FR-PO715, FR-PO726, FR-PO728, 
FR-PO779, FR-PO780, FR-PO781, 
FR-PO784, FR-PO788, FR-PO791, 
FR-PO838, FR-PO1090, FR-PO1096, 
FR-PO1102, FR-PO1105, FR-PO1110, 
FR-PO1122, FR-PO1125, FR-PO1163, 
FR-PO1165, SA-OR058, SA-OR059, 
SA-OR063, SA-OR068, SA-OR080, 
SA-PO008, SA-PO026, SA-PO030, 
SA-PO031, SA-PO032, SA-PO039, 
SA-PO043, SA-PO052, SA-PO054, 
SA-PO056, SA-PO084, SA-PO193, 
SA-PO410, SA-PO422, SA-PO443, 
SA-PO459, SA-PO460, SA-PO472, 
SA-PO492, SA-PO493, SA-PO498, 
SA-PO535, SA-PO536, SA-PO540, 
SA-PO541, SA-PO543, SA-PO547, 
SA-PO557, SA-PO559, SA-PO617, 
SA-PO716, SA-PO746, SA-PO761, 
SA-PO768, SA-PO860, SA-PO879, 
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outcomes (continued) ........................SA-PO888, 
SA-PO1046, SA-PO1072, SA-PO1099, 
PUB002, PUB021, PUB035, PUB205, 
PUB228, PUB240, PUB241, PUB250, 
PUB287, PUB292, PUB301, PUB338, 
PUB390, PUB392, PUB406
oxidative stress...............TH-OR041, TH-PO095, 
TH-PO096, TH-PO110, TH-PO613, 
TH-PO614, TH-PO617, TH-PO627, 
TH-PO935, TH-PO936, FR-PO088, 
FR-PO089, FR-PO227, FR-PO333, 
FR-PO405, FR-PO415, FR-PO458, 
FR-PO491, FR-PO492, FR-PO495, 
FR-PO544, FR-PO741, FR-PO756, 
SA-OR015, SA-OR074, SA-PO372, 
SA-PO382, SA-PO515, SA-PO562, 
SA-PO571, SA-PO582, SA-PO586, 
SA-PO635, SA-PO802, SA-PO977, PUB054, 
PUB060, PUB161, PUB169, PUB190, 
PUB320, PUB377, PUB760
pancreas transplantation ...................SA-PO056
parathyroid hormone ....TH-OR029, TH-PO182, 
TH-PO200, TH-PO215, TH-PO216, 
TH-PO218, FR-PO124, FR-PO488, 
FR-PO489, FR-PO507, FR-PO510, 
SA-PO638, SA-PO665, SA-PO671, 
SA-PO673, SA-PO699, SA-PO700, 
SA-PO701, SA-PO702, SA-PO704, 
SA-PO705, PUB084, PUB098, PUB261
pathology ....TH-OR069, TH-PO060, TH-PO065, 
TH-PO095, TH-PO608, TH-PO806, 
TH-PO851, TH-PO972, TH-PO1037, 
FR-OR031, FR-OR101, FR-PO001, 
FR-PO021, FR-PO705, FR-PO864, 
FR-PO887, FR-PO897, FR-PO1055, 
SA-OR047, SA-OR058, SA-OR060, 
SA-OR065, SA-PO074, SA-PO135, 
SA-PO178, SA-PO1075, SA-PO1077, 
SA-PO1078, SA-PO1085, SA-PO1088, 
SA-PO1089, SA-PO1093, SA-PO1097, 
PUB061, PUB416, PUB762
patient satisfaction ........ TH-PO024, TH-PO277, 
TH-PO281, TH-PO289, TH-PO299, 
TH-PO300, TH-PO388, TH-PO938, 
FR-PO187, FR-PO253, FR-PO262, 
FR-PO266, FR-PO268, FR-PO567, 
FR-PO663, FR-PO837, SA-OR070, 
SA-PO193, SA-PO205, SA-PO401, 
SA-PO724, SA-PO914, SA-PO971, 
PUB241, PUB268, PUB276
patient self-assessment ......................TH-PO277, 
TH-PO292, TH-PO301, TH-PO326, 
TH-PO770, TH-PO1085, TH-PO1087, 
FR-OR097, FR-PO187, FR-PO260, 
FR-PO1146, SA-PO029, SA-PO396, 
SA-PO545, SA-PO723, SA-PO914, PUB115, 
PUB340
pediatric intensive care medicine.....TH-OR111, 
TH-PO015, FR-PO047, FR-PO048, 
FR-PO049, PUB050
pediatric kidney transplantation .... TH-OR048, 
TH-OR050, TH-OR122, FR-PO874, 
FR-PO879, FR-PO1137, FR-PO1174, 
FR-PO1175, FR-PO1176, FR-PO1177, 
FR-PO1179, FR-PO1181, SA-PO021, 
SA-PO039, SA-PO080, PUB434
pediatric nephrology ........................ TH-OR046, 
TH-OR122, TH-PO011, TH-PO012, 
TH-PO044, TH-PO075, TH-PO436, 
TH-PO495, TH-PO939, FR-OR026, 
pediatric nephrology (continued) .... FR-PO059, 
FR-PO285, FR-PO971, FR-PO979, 
FR-PO987, FR-PO988, FR-PO1010, 
FR-PO1121, FR-PO1136, FR-PO1139, 
FR-PO1145, FR-PO1150, FR-PO1154, 
FR-PO1159, FR-PO1160, FR-PO1164, 
FR-PO1165, FR-PO1167, FR-PO1180, 
SA-PO344, SA-PO429, SA-PO430, 
SA-PO431, SA-PO432, SA-PO433, 
SA-PO435, SA-PO437, SA-PO438, 
SA-PO439, SA-PO453, SA-PO459, 
SA-PO462, SA-PO463, SA-PO468, 
SA-PO469, SA-PO543, SA-PO1043, 
PUB336, PUB432, PUB436
pediatrics .....TH-PO011, TH-PO045, TH-PO140, 
TH-PO355, TH-PO435, TH-PO475, 
TH-PO705, TH-PO1111, FR-PO047, 
FR-PO668, FR-PO1125, FR-PO1149, 
FR-PO1157, FR-PO1164, SA-PO430, 
SA-PO479, SA-PO504, SA-PO505, PUB401
peritoneal dialysis.......... TH-PO217, TH-PO233, 
TH-PO368, TH-PO370, TH-PO371, 
TH-PO372, TH-PO373, TH-PO374, 
TH-PO375, TH-PO376, TH-PO377, 
TH-PO378, TH-PO380, TH-PO382, 
TH-PO383, TH-PO384, TH-PO385, 
TH-PO386, TH-PO388, TH-PO389, 
TH-PO390, TH-PO391, TH-PO392, 
TH-PO394, TH-PO395, TH-PO396, 
TH-PO397, TH-PO398, TH-PO399, 
TH-PO400, TH-PO401, TH-PO402, 
TH-PO404, TH-PO405, TH-PO406, 
TH-PO407, TH-PO408, TH-PO409, 
TH-PO410, TH-PO411, TH-PO412, 
TH-PO413, TH-PO414, TH-PO415, 
TH-PO416, TH-PO417, TH-PO418, 
TH-PO420, TH-PO461, FR-OR008, 
FR-OR009, FR-PO349, FR-PO552, 
FR-PO558, FR-PO658, FR-PO659, 
FR-PO660, FR-PO662, FR-PO663, 
FR-PO664, FR-PO665, FR-PO668, 
FR-PO669, FR-PO671, FR-PO673, 
FR-PO674, FR-PO677, FR-PO678, 
FR-PO679, FR-PO680, FR-PO682, 
FR-PO683, FR-PO684, FR-PO685, 
FR-PO686, FR-PO688, FR-PO689, 
FR-PO690, FR-PO691, FR-PO692, 
FR-PO693, FR-PO695, FR-PO697, 
FR-PO698, FR-PO699, FR-PO700, 
FR-PO701, FR-PO808, SA-OR075, 
SA-PO190, SA-PO915, SA-PO926, 
SA-PO927, SA-PO928, SA-PO929, 
SA-PO931, SA-PO932, SA-PO933, 
SA-PO934, SA-PO935, SA-PO936, 
SA-PO937, SA-PO939, SA-PO942, 
SA-PO944, PUB092, PUB268, PUB269, 
PUB270, PUB271, PUB272, PUB273, 
PUB274, PUB275, PUB276, PUB278
peritoneal membrane ....TH-PO406, FR-OR010, 
FR-PO667, FR-PO669, FR-PO687, 
FR-PO692, SA-PO928, SA-PO930, 
SA-PO931, SA-PO935, SA-PO936, 
SA-PO937, SA-PO938, SA-PO940, 
SA-PO941, SA-PO942, SA-PO945
pharmacokinetics .......... TH-PO234, TH-PO685, 
TH-PO736, TH-PO746, SA-OR104, 
SA-PO019, SA-PO615, SA-PO616, 
SA-PO629, SA-PO630, SA-PO632, 
SA-PO633, SA-PO634, SA-PO638, 
SA-PO643, SA-PO687, PUB439
phosphate binders ......... TH-PO195, TH-PO196, 
TH-PO197, TH-PO200, TH-PO201, 
TH-PO203, TH-PO208, TH-PO941, 
FR-PO482, FR-PO496, FR-PO499, 
FR-PO500, FR-PO763, SA-OR106, 
SA-PO636, SA-PO637, SA-PO667, PUB074, 
PUB078, PUB088
phosphate uptake ..........TH-OR030, TH-PO202, 
TH-PO203, TH-PO488, TH-PO621, 
TH-PO730, FR-PO312, FR-PO490, 
FR-PO493, FR-PO494, FR-PO497, 
FR-PO498, FR-PO499, FR-PO500, 
FR-PO507, SA-PO637, PUB117
platelets ...... TH-PO076, TH-PO243, TH-PO769, 
FR-OR121, FR-PO737, SA-PO553, 
SA-PO904, PUB208
podocyte .... TH-OR056, TH-OR062, TH-PO125, 
TH-PO142, TH-PO607, TH-PO629, 
TH-PO632, TH-PO642, TH-PO717, 
TH-PO776, TH-PO777, TH-PO786, 
TH-PO787, TH-PO788, TH-PO789, 
TH-PO790, TH-PO792, TH-PO793, 
TH-PO796, TH-PO801, TH-PO804, 
TH-PO805, TH-PO817, TH-PO823, 
TH-PO830, TH-PO855, TH-PO861, 
TH-PO863, TH-PO867, TH-PO868, 
TH-PO869, TH-PO870, TH-PO875, 
TH-PO949, TH-PO984, TH-PO987, 
TH-PO988, TH-PO989, TH-PO991, 
TH-PO992, TH-PO993, TH-PO994, 
TH-PO996, FR-OR028, FR-OR029, 
FR-OR030, FR-OR031, FR-OR034, 
FR-OR035, FR-OR039, FR-OR056, 
FR-OR072, FR-OR074, FR-OR134, 
FR-PO150, FR-PO381, FR-PO389, 
FR-PO391, FR-PO397, FR-PO399, 
FR-PO413, FR-PO415, FR-PO434, 
FR-PO439, FR-PO440, FR-PO924, 
FR-PO941, FR-PO943, FR-PO1003, 
FR-PO1006, FR-PO1015, FR-PO1016, 
FR-PO1017, FR-PO1018, FR-PO1020, 
FR-PO1021, FR-PO1046, FR-PO1056, 
SA-OR021, SA-OR022, SA-OR025, 
SA-OR096, SA-PO107, SA-PO122, 
SA-PO123, SA-PO306, SA-PO307, 
SA-PO308, SA-PO311, SA-PO313, 
SA-PO314, SA-PO315, SA-PO317, 
SA-PO321, SA-PO322, SA-PO323, 
SA-PO324, SA-PO325, SA-PO327, 
SA-PO329, SA-PO330, SA-PO331, 
SA-PO332, SA-PO333, SA-PO356, 
SA-PO357, SA-PO360, SA-PO362, 
SA-PO363, SA-PO365, SA-PO367, 
SA-PO370, SA-PO371, SA-PO372, 
SA-PO373, SA-PO374, SA-PO375, 
SA-PO377, SA-PO379, SA-PO452, 
SA-PO453, SA-PO733, SA-PO1084, 
SA-PO1112, PUB184, PUB329, 
PUB344, PUB369, PUB431
polycystic kidney disease ................. TH-OR102, 
TH-OR105, TH-OR110, TH-PO180, 
TH-PO482, TH-PO656, TH-PO657, 
TH-PO661, TH-PO662, TH-PO664, 
TH-PO665, TH-PO669, TH-PO670, 
TH-PO671, TH-PO674, TH-PO675, 
TH-PO676, TH-PO677, TH-PO679, 
TH-PO680, TH-PO684, TH-PO694, 
TH-PO695, TH-PO696, TH-PO697, 
FR-PO204, FR-PO948, FR-PO952, 
FR-PO956, FR-PO964, FR-PO979, 
FR-PO980, FR-PO982, FR-PO983, 
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polycystic kidney disease (continued).................
FR-PO984, FR-PO985, FR-PO986, 
FR-PO987, FR-PO988, FR-PO990, 
FR-PO992, SA-OR101, SA-PO479, 
SA-PO480, SA-PO483, SA-PO484, 
SA-PO488, SA-PO501, SA-PO503, 
SA-PO507, SA-PO512, SA-PO516, PUB325
polymorphisms ............ TH-PO693, TH-PO1012, 
TH-PO1028, FR-PO106, SA-PO450, 
SA-PO632, SA-PO777
potassium (K) channels.....................TH-PO428, 
TH-PO513, TH-PO744, FR-OR065, 
FR-OR066, FR-PO221, FR-PO222, 
FR-PO310, SA-PO180, 
SA-PO1010, PUB126
primary glomerulonephritis .............TH-PO982, 
FR-OR083, SA-PO336, SA-PO390
progression ..................... TH-PO085, TH-PO223, 
TH-PO249, TH-PO694, TH-PO1055, 
TH-PO1095, TH-PO1125, TH-PO1126, 
TH-PO1136, FR-PO014, FR-PO028, 
FR-PO109, FR-PO130, FR-PO152, 
FR-PO158, FR-PO164, FR-PO166, 
FR-PO170, FR-PO189, FR-PO199, 
FR-PO200, FR-PO201, FR-PO209, 
FR-PO212, FR-PO250, FR-PO360, 
FR-PO423, FR-PO424, SA-OR035, 
SA-OR083, SA-OR087, SA-PO170, 
SA-PO389, SA-PO455, SA-PO473, 
SA-PO474, SA-PO489, SA-PO507, 
SA-PO508, SA-PO622, SA-PO757, 
SA-PO758, SA-PO760, SA-PO794, 
SA-PO1049, PUB103, PUB116, PUB122, 
PUB129, PUB130, PUB178, PUB397
progression of renal failure ............. TH-OR035, 
TH-OR047, TH-OR082, TH-PO100, 
TH-PO447, TH-PO764, TH-PO1049, 
TH-PO1056, TH-PO1064, TH-PO1100, 
TH-PO1116, TH-PO1124, FR-OR013, 
FR-PO167, FR-PO203, FR-PO233, 
FR-PO246, FR-PO442, FR-PO457, 
FR-PO513, FR-PO972, FR-PO996, 
FR-PO1147, FR-PO1166, SA-OR078, 
SA-PO142, SA-PO173, SA-PO420, 
SA-PO491, SA-PO513, SA-PO611, 
SA-PO750, SA-PO755, SA-PO756, 
SA-PO764, SA-PO765, SA-PO795, 
SA-PO1040, SA-PO1044, PUB010, PUB114, 
PUB395, PUB420
proliferation ................... TH-PO676, TH-PO686, 
TH-PO802, TH-PO990, FR-OR089, 
FR-PO055, FR-PO065, FR-PO958
proteinuria .....................TH-OR086, TH-PO134, 
TH-PO441, TH-PO443, TH-PO608, 
TH-PO640, TH-PO764, TH-PO782, 
TH-PO792, TH-PO793, TH-PO806, 
TH-PO808, TH-PO855, TH-PO891, 
TH-PO936, TH-PO968, TH-PO971, 
TH-PO988, TH-PO996, TH-PO1001, 
TH-PO1018, TH-PO1034, TH-PO1098, 
TH-PO1137, FR-OR021, FR-OR035, 
FR-OR037, FR-OR068, FR-OR087, 
FR-PO144, FR-PO171, FR-PO228, 
FR-PO235, FR-PO239, FR-PO457, 
FR-PO464, FR-PO466, FR-PO467, 
FR-PO827, FR-PO924, FR-PO995, 
FR-PO1059, FR-PO1069, FR-PO1116, 
FR-PO1120, FR-PO1130, FR-PO1178, 
SA-OR062, SA-OR063, SA-OR066, 
SA-PO117, SA-PO123, SA-PO129, 
proteinuria (continued).....................SA-PO157, 
SA-PO310, SA-PO316, SA-PO341, 
SA-PO356, SA-PO364, SA-PO369, 
SA-PO382, SA-PO386, SA-PO643, 
SA-PO647, SA-PO790, SA-PO815, 
SA-PO825, SA-PO838, SA-PO1111, 
PUB113, PUB140, PUB152, 
PUB180, PUB329
proximal tubule ............ TH-OR137, TH-OR139, 
TH-PO079, TH-PO080, TH-PO093, 
TH-PO113, TH-PO118, TH-PO485, 
TH-PO487, TH-PO490, TH-PO497, 
TH-PO498, TH-PO728, TH-PO738, 
TH-PO761, TH-PO764, TH-PO852, 
TH-PO871, TH-PO884, TH-PO902, 
TH-PO931, TH-PO944, TH-PO972, 
TH-PO1061, TH-PO1108, FR-OR037, 
FR-OR043, FR-OR064, FR-OR104, 
FR-PO071, FR-PO098, FR-PO140, 
FR-PO382, FR-PO398, FR-PO400, 
FR-PO444, FR-PO977, FR-PO996, 
SA-PO119, SA-PO125, SA-PO134, 
SA-PO503, SA-PO613, SA-PO821, 
SA-PO1011, PUB172, PUB176
pulse wave velocity ........ TH-PO414, TH-PO445, 
TH-PO446, FR-PO351, FR-PO359, 
FR-PO430, SA-PO504, PUB147
pyelonephritis ................ TH-PO116, TH-PO491, 
TH-PO492, TH-PO950, TH-PO966, 
TH-PO974, FR-OR110, FR-PO182, 
FR-PO402, FR-PO929, SA-PO431, 
SA-PO432, SA-PO433, SA-PO434, 
SA-PO1070, PUB425, PUB436
quality of life ..................TH-OR111, TH-PO250, 
TH-PO265, TH-PO266, TH-PO289, 
TH-PO292, TH-PO296, TH-PO297, 
TH-PO298, TH-PO301, TH-PO307, 
TH-PO308, TH-PO312, TH-PO313, 
TH-PO315, TH-PO320, TH-PO321, 
TH-PO324, TH-PO325, TH-PO387, 
TH-PO393, TH-PO625, TH-PO751, 
TH-PO1022, TH-PO1084, TH-PO1089, 
FR-PO191, FR-PO221, FR-PO222, 
FR-PO261, FR-PO266, FR-PO268, 
FR-PO533, FR-PO534, FR-PO535, 
FR-PO536, FR-PO537, FR-PO538, 
FR-PO540, FR-PO542, FR-PO543, 
FR-PO558, FR-PO562, FR-PO563, 
FR-PO565, FR-PO665, FR-PO701, 
FR-PO811, FR-PO833, FR-PO1001, 
FR-PO1145, FR-PO1148, FR-PO1177, 
FR-PO1181, SA-OR069, SA-OR070, 
SA-PO029, SA-PO030, SA-PO096, 
SA-PO396, SA-PO492, SA-PO493, 
SA-PO495, SA-PO710, SA-PO743, 
SA-PO744, SA-PO747, SA-PO923, 
SA-PO925, SA-PO948, SA-PO966, 
PUB078, PUB132, PUB149, PUB215, 
PUB242, PUB269, PUB277, PUB287, 
PUB339, PUB788
randomized controlled trials ........... TH-OR036, 
TH-PO225, TH-PO226, TH-PO235, 
TH-PO245, FR-OR079, FR-OR117, 
FR-OR120, FR-OR125, FR-PO264, 
FR-PO368, FR-PO536, FR-PO539, 
FR-PO701, SA-OR075, SA-PO139, 
SA-PO140, SA-PO149, SA-PO207, 
SA-PO529, SA-PO532, SA-PO654, 
SA-PO863, PUB106
reactive oxygen species .....................TH-PO098, 
TH-PO861, TH-PO940, FR-PO079, 
FR-PO134, FR-PO341, FR-PO417, 
SA-PO382, SA-PO589, 
SA-PO828, SA-PO847
regulation ....TH-PO486, FR-OR059, FR-PO071, 
FR-PO1060, SA-PO941, SA-PO1035
rejection....... FR-OR140, FR-PO847, FR-PO849, 
FR-PO873, FR-PO876, FR-PO877, 
FR-PO879, FR-PO888, FR-PO901, 
FR-PO909, SA-OR088, SA-PO016, 
SA-PO025, PUB778, PUB781
renal ablation ..................FR-PO244, FR-PO321, 
FR-PO331, SA-PO840
renal artery stenosis ..... TH-OR075, TH-OR076, 
TH-OR135, TH-PO650, FR-PO163, 
FR-PO335, PUB156
renal autoregulation ......TH-OR074, TH-PO749, 
PUB068, PUB191
renal biopsy .................... TH-PO154, TH-PO735, 
TH-PO977, TH-PO995, TH-PO1009, 
TH-PO1120, TH-PO1121, TH-PO1122, 
FR-OR081, FR-OR135, FR-OR139, 
FR-PO003, FR-PO021, FR-PO162, 
FR-PO471, FR-PO870, FR-PO892, 
FR-PO901, FR-PO963, FR-PO1054, 
FR-PO1096, FR-PO1098, FR-PO1104, 
SA-PO192, SA-PO193, SA-PO420, 
SA-PO538, SA-PO625, SA-PO646, 
SA-PO1076, SA-PO1088, PUB061, PUB121, 
PUB144, PUB151, PUB292, PUB395
renal carcinoma ............. TH-PO069, TH-PO895, 
TH-PO1145, FR-PO1034, FR-PO1035, 
SA-PO049, SA-PO797
renal cell biology........... TH-OR006, TH-OR102, 
TH-PO783, TH-PO787, TH-PO804, 
TH-PO967, TH-PO973, FR-OR038, 
FR-PO1016, SA-OR013, SA-PO356, 
SA-PO604, SA-PO817
renal development .........TH-OR134, TH-PO643, 
TH-PO651, TH-PO701, FR-OR073, 
FR-PO059, FR-PO925, FR-PO927, 
FR-PO935, FR-PO936, FR-PO1164, 
SA-PO426, SA-PO427, SA-PO639, PUB438
renal dialysis .................. TH-PO223, FR-PO046, 
FR-PO282, FR-PO681, FR-PO717, 
FR-PO770, PUB034, PUB046
renal dysfunction ........... TH-PO177, TH-PO856, 
FR-PO036, FR-PO217, FR-PO229, 
FR-PO848, SA-PO148, SA-PO313, 
SA-PO353, SA-PO586, SA-PO612
renal epithelial cell ........ TH-PO493, TH-PO494, 
TH-PO499, TH-PO617, TH-PO697, 
TH-PO758, FR-PO055, FR-PO077, 
FR-PO086, SA-PO578, SA-PO599
renal failure ...................TH-OR097, TH-PO008, 
TH-PO401, TH-PO409, TH-PO711, 
TH-PO713, TH-PO1119, TH-PO1139, 
FR-PO744, SA-PO520, PUB026, PUB081
renal fibrosis ................. TH-OR003, TH-OR014, 
TH-OR017, TH-OR061, TH-PO101, 
TH-PO636, TH-PO645, TH-PO748, 
TH-PO760, TH-PO882, TH-PO896, 
TH-PO900, TH-PO901, TH-PO904, 
TH-PO912, TH-PO914, TH-PO915, 
TH-PO916, TH-PO922, TH-PO924, 
TH-PO930, TH-PO932, TH-PO952, 
TH-PO955, TH-PO956, TH-PO957, 
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renal fibrosis (continued) ..................TH-PO960, 
TH-PO961, TH-PO1056, FR-OR057, 
FR-OR103, FR-OR107, FR-PO065, 
FR-PO131, FR-PO133, FR-PO137, 
FR-PO143, FR-PO146, FR-PO147, 
FR-PO153, FR-PO382, FR-PO387, 
FR-PO421, FR-PO425, FR-PO475, 
FR-PO855, FR-PO856, FR-PO955, 
FR-PO1058, FR-PO1062, SA-PO103, 
SA-PO121, SA-PO124, SA-PO645, 
SA-PO730, SA-PO801, SA-PO805, 
SA-PO807, SA-PO809, SA-PO818, 
SA-PO832, SA-PO848, SA-PO850, 
SA-PO852, SA-PO855, SA-PO857, 
SA-PO1076, PUB164, 
PUB166, PUB167, PUB172
renal function................ TH-OR037, TH-OR068, 
TH-OR137, TH-PO141, TH-PO376, 
TH-PO383, TH-PO762, TH-PO908, 
TH-PO1023, TH-PO1063, TH-PO1093, 
FR-PO020, FR-PO140, FR-PO172, 
FR-PO227, FR-PO321, FR-PO322, 
FR-PO331, FR-PO370, FR-PO666, 
FR-PO940, FR-PO1112, SA-PO072, 
SA-PO089, SA-PO332, SA-PO506, 
SA-PO564, SA-PO612, SA-PO993, 
SA-PO1029, SA-PO1071, SA-PO1090, 
PUB107, PUB157, PUB168, PUB788
renal function decline....................... TH-OR038, 
TH-OR094, TH-PO001, TH-PO337, 
TH-PO340, TH-PO341, TH-PO1000, 
TH-PO1044, TH-PO1094, TH-PO1140, 
FR-PO196, FR-PO280, FR-PO404, 
FR-PO430, FR-PO436, FR-PO464, 
FR-PO466, FR-PO670, FR-PO1037, 
FR-PO1172, SA-PO155, SA-PO399, 
SA-PO517, SA-PO717, SA-PO1052, 
PUB108, PUB134, PUB136
renal hemodynamics .....TH-OR078, TH-PO137, 
TH-PO341, TH-PO746, TH-PO964, 
TH-PO971, FR-PO101, FR-PO163, 
FR-PO427, FR-PO428
renal hypertension..........FR-PO315, FR-PO322, 
FR-PO326, SA-PO1015
renal injury ....................TH-OR109, TH-PO032, 
TH-PO035, TH-PO038, TH-PO056, 
TH-PO078, TH-PO079, TH-PO111, 
TH-PO114, TH-PO801, TH-PO830, 
TH-PO857, TH-PO1142, FR-OR014, 
FR-OR021, FR-OR027, FR-PO008, 
FR-PO010, FR-PO017, FR-PO045, 
FR-PO069, FR-PO314, FR-PO944, 
FR-PO947, SA-OR020, SA-PO407, 
SA-PO456, SA-PO525, SA-PO534, 
SA-PO544, SA-PO563, SA-PO650, 
SA-PO732, SA-PO996, SA-PO1096, 
PUB016, PUB018, PUB063, 
PUB185, PUB428
renal ischemia ............... TH-OR001, TH-OR063, 
TH-PO100, TH-PO109, TH-PO933, 
TH-PO1142, FR-OR107, FR-PO096, 
SA-OR092, SA-PO583, SA-PO600, 
SA-PO829, PUB008, PUB066
renal morphology ...........FR-PO403, FR-PO428, 
SA-PO075, SA-PO461, SA-PO576
renal osteodystrophy .....TH-OR027, TH-PO163, 
TH-PO220, TH-PO939, FR-PO481, 
FR-PO514, FR-PO698, SA-PO471, 
SA-PO656, SA-PO665, SA-PO666, 
SA-PO702, PUB097
renal pathology ..............TH-OR070, TH-PO994, 
TH-PO1002, TH-PO1038, FR-PO879, 
FR-PO882, FR-PO1078, FR-PO1080, 
FR-PO1081, FR-PO1100, SA-OR059, 
SA-OR090, SA-PO128, SA-PO177, 
SA-PO1079, SA-PO1082, SA-PO1091, 
SA-PO1115, PUB423
renal progression .......... TH-OR035, TH-OR052, 
TH-PO035, TH-PO689, TH-PO770, 
TH-PO1008, TH-PO1034, TH-PO1079, 
FR-PO070, FR-PO110, FR-PO169, 
FR-PO186, FR-PO192, FR-PO1151, 
FR-PO1153, SA-PO151, SA-PO690, 
SA-PO740, PUB201, PUB318, PUB772
renal protection ............ TH-OR006, TH-OR008, 
TH-OR017, TH-OR080, TH-PO124, 
TH-PO613, TH-PO885, FR-OR015, 
FR-PO231, SA-OR104, SA-PO150, 
SA-PO369, SA-PO519, SA-PO534, 
SA-PO791, PUB051, PUB434
renal proximal tubule cell ................ TH-OR010, 
TH-OR071, TH-OR139, TH-PO102, 
TH-PO484, TH-PO489, TH-PO759, 
TH-PO763, TH-PO901, TH-PO904, 
TH-PO924, TH-PO930, FR-OR102, 
FR-PO067, FR-PO073, FR-PO386, 
FR-PO407, FR-PO422, SA-OR029, 
SA-PO121, SA-PO131, SA-PO645, 
SA-PO824, SA-PO855, SA-PO1096, 
PUB183
renal stem cell ................TH-OR134, TH-PO069, 
TH-PO633, TH-PO642, TH-PO646, 
TH-PO652, FR-PO917, FR-PO922, 
FR-PO935, FR-PO939, SA-PO311
renal transplantation .....TH-OR125, TH-OR127, 
TH-PO120, TH-PO138, TH-PO146, 
TH-PO147, TH-PO175, TH-PO221, 
TH-PO977, FR-OR135, FR-PO299, 
FR-PO866, FR-PO868, FR-PO876, 
FR-PO886, FR-PO889, FR-PO892, 
FR-PO897, FR-PO901, FR-PO909, 
FR-PO914, FR-PO1028, FR-PO1178, 
SA-OR002, SA-OR005, SA-OR010, 
SA-PO026, SA-PO029, SA-PO041, 
SA-PO044, SA-PO046, SA-PO053, 
SA-PO063, SA-PO152, SA-PO1019, 
SA-PO1097, PUB768, PUB783, PUB788, 
PUB789, PUB792, PUB794, PUB795, 
PUB803
renal tubular acidosis ..... TH-PO500, FR-PO313
renal tubular epithelial cells ............ TH-OR003, 
TH-OR105, TH-PO087, TH-PO101, 
TH-PO124, TH-PO482, TH-PO488, 
TH-PO514, TH-PO612, FR-PO004, 
FR-PO087, FR-PO143, FR-PO952, 
SA-PO430, SA-PO568, SA-PO581, 
SA-PO595, SA-PO802, SA-PO825, 
SA-PO1016, PUB762
renin angiotensin system ................. TH-OR044, 
TH-OR071, TH-OR073, TH-OR078, 
TH-OR080, TH-PO167, TH-PO381, 
TH-PO427, TH-PO651, TH-PO867, 
TH-PO899, TH-PO900, TH-PO932, 
TH-PO955, FR-OR116, FR-PO208, 
FR-PO339, FR-PO340, FR-PO341, 
FR-PO342, FR-PO346, FR-PO418, 
FR-PO920, SA-PO109, SA-PO137, 
SA-PO138, SA-PO180, SA-PO712, 
SA-PO999, PUB028, PUB126, PUB185
rhabdomyolysis ............. TH-PO037, TH-PO108, 
FR-PO056, FR-PO123, SA-PO467
rheumatology ................. TH-PO158, TH-PO159, 
TH-PO160, TH-PO731, TH-PO1023, 
FR-PO216, FR-PO217, SA-PO391, 
SA-PO654, PUB157, PUB440, PUB805
risk factors .................... TH-OR037, TH-OR121, 
TH-OR127, TH-PO009, TH-PO019, 
TH-PO025, TH-PO027, TH-PO043, 
TH-PO047, TH-PO048, TH-PO055, 
TH-PO061, TH-PO143, TH-PO148, 
TH-PO149, TH-PO172, TH-PO185, 
TH-PO302, TH-PO402, TH-PO403, 
TH-PO404, TH-PO408, TH-PO410, 
TH-PO441, TH-PO444, TH-PO448, 
TH-PO450, TH-PO453, TH-PO459, 
TH-PO466, TH-PO473, TH-PO1014, 
TH-PO1025, TH-PO1042, TH-PO1051, 
TH-PO1054, TH-PO1059, TH-PO1061, 
TH-PO1063, TH-PO1068, TH-PO1072, 
TH-PO1076, TH-PO1083, TH-PO1085, 
TH-PO1095, TH-PO1104, TH-PO1120, 
FR-OR012, FR-PO003, FR-PO018, 
FR-PO176, FR-PO178, FR-PO186, 
FR-PO189, FR-PO211, FR-PO213, 
FR-PO231, FR-PO233, FR-PO285, 
FR-PO364, FR-PO460, FR-PO521, 
FR-PO664, FR-PO668, FR-PO712, 
FR-PO749, FR-PO768, FR-PO783, 
FR-PO797, FR-PO891, FR-PO1022, 
FR-PO1025, FR-PO1106, SA-PO017, 
SA-PO043, SA-PO056, SA-PO061, 
SA-PO096, SA-PO173, SA-PO354, 
SA-PO398, SA-PO406, SA-PO446, 
SA-PO466, SA-PO663, SA-PO735, 
SA-PO755, SA-PO758, SA-PO759, 
SA-PO760, SA-PO763, SA-PO764, 
SA-PO772, SA-PO787, SA-PO791, 
SA-PO892, SA-PO1038, SA-PO1052, 
SA-PO1100, PUB002, PUB003, 
PUB016, PUB018, PUB105, PUB107, 
PUB109, PUB114, PUB116, PUB118, 
PUB131, PUB133, PUB139, PUB165, 
PUB219, PUB273, PUB276, PUB288, 
PUB338, PUB767
signaling ..... TH-PO489, TH-PO515, TH-PO615, 
TH-PO631, TH-PO775, TH-PO791, 
TH-PO878, TH-PO914, TH-PO970, 
FR-OR065, FR-OR092, FR-PO016, 
FR-PO062, FR-PO099, FR-PO325, 
FR-PO330, FR-PO344, FR-PO436, 
FR-PO485, FR-PO491, FR-PO493, 
FR-PO506, FR-PO839, FR-PO854, 
FR-PO870, FR-PO919, FR-PO948, 
FR-PO957, SA-PO333, SA-PO370, 
SA-PO614, SA-PO639, SA-PO808, 
SA-PO820, SA-PO843, SA-PO935, 
SA-PO982, SA-PO1036, PUB353
sodium (Na) transport ..................... TH-OR079, 
TH-PO449, TH-PO481, TH-PO490, 
TH-PO502, TH-PO506, TH-PO512, 
TH-PO514, TH-PO515, TH-PO516, 
TH-PO763, TH-PO852, TH-PO854, 
FR-OR058, FR-OR059, FR-OR060, 
FR-OR062, FR-OR064, FR-OR067, 
FR-PO292, FR-PO293, FR-PO317, 
FR-PO319, FR-PO320, FR-PO321, 
FR-PO323, FR-PO324, FR-PO325, 
FR-PO490, FR-PO804, SA-OR031, 
SA-OR056, SA-PO138, SA-PO436, 
SA-PO934, SA-PO1009, SA-PO1011, 
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sodium (Na) transport (continued) .....SA-PO1013, 
SA-PO1014, SA-PO1028, SA-PO1030, 
SA-PO1031, SA-PO1034, PUB066
statins ......TH-PO1047, TH-PO1048, FR-PO050, 
FR-PO709, FR-PO739
stem cell .....TH-OR102, TH-OR131, TH-OR132, 
TH-OR133, TH-OR135, TH-OR136, 
TH-PO071, TH-PO115, TH-PO628, 
TH-PO629, TH-PO630, TH-PO632, 
TH-PO634, TH-PO635, TH-PO636, 
TH-PO637, TH-PO638, TH-PO641, 
TH-PO643, TH-PO644, TH-PO645, 
TH-PO648, TH-PO649, TH-PO654, 
TH-PO800, TH-PO888, FR-OR039, 
FR-OR040, FR-OR042, FR-OR047, 
FR-OR053, FR-PO916, FR-PO921, 
FR-PO923, FR-PO938, FR-PO943, 
FR-PO984, SA-OR089, SA-PO532, 
SA-PO564, SA-PO801, PUB082, 
PUB083, PUB178
survival .......TH-OR035, TH-OR118, TH-PO038, 
TH-PO040, TH-PO213, TH-PO217, 
TH-PO269, TH-PO327, TH-PO371, 
TH-PO383, TH-PO409, TH-PO976, 
TH-PO1119, FR-OR004, FR-OR005, 
FR-PO019, FR-PO205, FR-PO287, 
FR-PO306, FR-PO550, FR-PO660, 
FR-PO674, FR-PO677, FR-PO772, 
FR-PO799, FR-PO808, FR-PO819, 
FR-PO824, FR-PO833, FR-PO839, 
FR-PO904, SA-OR099, SA-PO010, 
SA-PO045, SA-PO052, SA-PO071, 
SA-PO073, SA-PO406, SA-PO536, 
SA-PO546, SA-PO564, SA-PO734, 
SA-PO740, SA-PO912, SA-PO1064, 
PUB213, PUB234, PUB341, PUB785, 
PUB793, PUB795, PUB802
systemic lupus erythematosus ..........TH-PO824, 
TH-PO830, FR-PO1047, FR-PO1072, 
FR-PO1075, FR-PO1095, FR-PO1100, 
FR-PO1106, FR-PO1108, FR-PO1110, 
SA-OR043, SA-PO334, SA-PO444, 
SA-PO445, PUB208, PUB382
systolic blood pressure ......................TH-PO480, 
TH-PO899, FR-PO318, FR-PO354, 
FR-PO829, FR-PO1136, SA-PO886, 
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Effect of Linagliptin on Kidney and Cardiovascular Outcomes in 
Patients with Type 2 Diabetes and Kidney Disease: CARMELINA®
Vlado Perkovic,1 Robert D. Toto,2 Mark E. Cooper,3 Odd Erik Johansen,4 
Julio Rosenstock,5 Darren K. Mcguire,6 Steven E. Kahn,7 Nikolaus Marx,8 
John H. Alexander,9 Bernard Zinman,10 David Baanstra,11 Egon Pfarr,12 
Sven Y. Schnaidt,12 Thomas Meinicke,13 Jyothis T. George,12 Maximilian von 
Eynatten,12 Christoph Wanner.14 1The George Institute for Global Health, 
Newtown, NSW, Australia; 2University of Texas Southwestern Medical Center, 
Dallas, TX; 3Monash University, Melbourne, VIC, Australia; 4Boehringer 
Ingelheim Norway, Asker, Norway; 5Dallas Diabetes Research Center at 
Medical City, Dallas, TX; 6UT Southwestern Medical Center at Dallas, Dallas, 
TX; 7University of Washington, Seattle, WA; 8University Hospital Aachen, 
Aachen, Germany; 9Duke Clinical Research Institute, Durham, NC; 10Mount 
Sinai Hospital, Toronto, ON, Canada; 11Boehringer Ingelheim, Alkmaar, 
Netherlands; 12Boehringer Ingelheim, Ingelheim, Germany; 13Boehringer 
Ingelheim International GmbH, Biberach, Germany; 14University Hospital, 
Wuerzburg, Germany.
Background: Type 2 diabetes (T2D) is a common cause of ESKD so the effects of 
glucose-lowering therapies on kidney outcomes are of great interest, especially in people 
with CKD.
Methods: CARMELINA (NCT01897532) randomized people with T2D and 
prevalent CKD (UACR >30 mg/g with concomitant CV disease, OR eGFR 45-75 ml/min/ 
1.73m2 and UACR > 200 mg/g OR eGFR 15-45 regardless of UACR) to receive double-
blind linagliptin (5 mg, a DPP inhibitor) or placebo QD. The primary CV endpoint was 
3P-MACE, with a key secondary kidney endpoint (adjudicated ESKD, renal death, 
or sustained ≥40% decrease in eGFR from baseline). Other renal outcomes included 
albuminuria and eGFR slope. Subgroups were assessed by baseline eGFR (≥/<45 and 
≥/< 30, 45 or 60 ml/min/1.73m2).
Results: 6979 participants (mean age 66 yrs, HbA1c 8.0%, eGFR 54.6 ml/min/1.73m2, 
43% eGFR ≤45, and 80% UACR ≥30 mg/g) from 27 countries were followed for median 
2.2 yrs. Linagliptin reduced albuminuria progression and albuminuria levels (table), but 
eGFR-slope was unaffected. Rates of the secondary kidney endpoint (HR 1.04 [0.89, 
1.22]) and renal death, or sustained ESKD (0.87 [0.69, 1.10]), as well as 3P-MACE and 
hospitalization for heart failure (table) were similar between groups. Incidence rates 
were higher with reduced eGFR, however, results were consistent across subgroups 
(p heterogeneity >0.1).
Conclusions: Linagliptin slowed progression of albuminuria, without affecting 
eGFR slope or other kidney outcomes. Linagliptin also demonstrated CV safety including 
in patients with advanced CKD where clinical evidence has been particularly scarce.
Funding: Commercial Support - Boehringer Ingelheim and the Eli Lilly diabetes 
alliance
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High-Dose Versus Low-Dose Intravenous Iron Therapy in Hemodialysis: 
The PIVOTAL Trial
Iain C. Macdougall,1 Claire White,1 Stefan D. Anker,7 Sunil Bhandari,2 
Ken Farrington,3 Philip A. Kalra,4 John McMurray,6 Heather M. Murray,6 
Charles Tomson,8 David C. Wheeler,5 Christopher G. Winearls,9 Ian Ford.6 on 
behalf of the PIVOTAL Study Group 1King’s College Hospital, London, 
United Kingdom; 2Hull and East Yorkshire Hospitals NHS Trust and Hull York 
Medical School, East Yorkshire, United Kingdom; 3Lister Renal Unit, Hitchin, 
United Kingdom; 4Salford Royal Hospital NHS Trust, Salford, United 
Kingdom; 5University College London, London, United Kingdom; 6University 
of Glasgow, Glasgow, United Kingdom; 7Charité Medical School, Berlin, 
Germany; 8Freeman Hospital, Newcastle upon Tyne, United Kingdom; 
9The Churchill Oxford Radcliff Hospital, Oxford, United Kingdom.
Background: Intravenous (IV) iron is widely used in the management of anemia in 
hemodialysis (HD) patients, but very little scientific evidence guides its appropriate use. 
The Proactive IV irOn Therapy in haemodiALysis patients (PIVOTAL) trial (EudraCT 
2013-002267-25) was designed to compare the effects of 2 distinct IV iron dosing 
regimens on “hard” clinical outcomes, including mortality and cardiovascular (CV) 
events, as well as infection risk among HD patients.
Methods: In this multicenter, open-label, blinded endpoint, controlled trial, 2141 
incident HD (<12 mo) patients receiving erythropoiesis-stimulating agents (ESAs) were 
randomly assigned (1:1) to a proactive, high-dose IV iron regimen (iron sucrose 400 mg 
monthly unless ferritin >700 µg/L and/or TSAT ≥40%) or a reactive, low-dose IV iron 
regimen (iron sucrose administered if ferritin <200 µg/L or TSAT <20%). The primary 
outcome was nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart 
failure, or death, analyzed as time to first event. The hazard ratio (HR) for noninferiority 
was set at 1.25. Secondary endpoints included all-cause death, infection, and ESA dose.
Results: The median duration of follow-up was 2.1 years (max: 4.4 yr). Patients 
in the proactive, high-dose IV iron arm received a median (lower quartile [LQ], upper 
quartile [UQ]) monthly iron dose of 264 (200, 336) mg compared with 145 (100, 190) mg 
in the reactive, low-dose arm. Median monthly ESA doses were 19.7% lower in the high-
dose arm (P<0.001). The incidence of the primary outcome was numerically lower in 
the high-dose arm than the low-dose arm (30.5% vs 32.7%; adjusted HR [95% CI]: 0.88 
[0.76–1.03]; P<0.001 for noninferiority; P=0.11 for superiority). Rates of all-cause death, 
hospitalization, and infection were similar between the two arms (Table).
Conclusions: Among HD patients, the use of higher doses of IV iron significantly 
reduced ESA dose requirements without negatively affecting mortality or the incidence 
of nonfatal CV endpoints.
Funding: Government Support - Non-U.S.
Selected secondary endpoints
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Safety and Effectiveness of Bexagliflozin in Type 2 Diabetes Mellitus and 
Stage 3a/3b CKD: A Phase 3 Randomized Clinical Trial
Andrew S. Allegretti,1 Tara K. Thurber,1 Wenbin Zhang,2 Wenjiong Zhou,3 
Mason W. Freeman,4 Yuan-Di C. Halvorsen.1 1Massachusetts General 
Hospital, Boston, MA; 2Shanghai JiaYue PharmaTech Ltd, Shanghai, China; 
3FMD K&L, Langhorne, PA; 4Massachusetts General Hospital, Harvard 
Medical School, Boston, MA.
Background: Hyperglycemia exacerbates the progression of chronic kidney disease 
(CKD), but most glucose-lowering therapies seldom address morbidities associated with 
CKD. Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer potential benefits to 
diabetics with CKD but their utility may be diminished with impaired renal function.
Methods: A phase 3, double-blind, placebo-controlled, multi-center, multi-national, 
randomized trial was conducted to evaluate the safety and effectiveness of bexagliflozin, 
a novel SGLT2 inhibitor, in patients with type 2 diabetes and stage 3a/3b CKD. Patients 
were randomly assigned to receive bexagliflozin or placebo for 24 weeks. The placebo-
adjusted change in hemoglobin A1c was the primary endpoint. Secondary endpoints were 
changes in body weight, systolic blood pressure, albuminuria, fasting plasma glucose 
and hemoglobin A1c stratified by CKD 3a/3b status. Efficacy data were analyzed using 
repeated measures methodology with intent to treat population to demonstrate treatment 
effects at 24 weeks.
Results: 312 patients across 54 sites were analyzed. Bexagliflozin lowered hemoglobin 
A1c by 0.37% (95% CI 0.20, 0.54, p <0.0001) compared to placebo. Patients with CKD 
stage 3a (eGFR 45 to <60) and 3b (eGFR 30 to <45) had reductions in hemoglobin A1c 
of 0.31% (p = 0.0068) and 0.43% (p = 0.0017), respectively. Bexagliflozin lowered body 
weight (1.61 kg, p <0.0001), systolic blood pressure (3.8 mmHg, p = 0.02), fasting plasma 
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glucose (0.76 mmol/L, p =0.0029) and albuminuria (geometric mean ratio reduction of 
20.1%, p = 0.027). Adverse events were comparable between groups.
Conclusions: Bexagliflozin was effective for lowering hemoglobin A1c in diabetic 
patients with stage 3a/3b CKD and was well tolerated. Additional benefits in this 
population were reduction in body weight, systolic blood pressure, fasting plasma glucose 
and albuminuria.
Funding: Commercial Support - Theracos LLC
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Cardiovascular Safety of Methoxy Polyethylene Glycol-Epoetin Beta in 
Treatment of Anemia of CKD
Francesco Locatelli,1 Thierry P. Hannedouche,2 Steven Fishbane,3 Zoe Morgan,4 
Delphine Oguey,4 William B. White.5 1Alessandro Manzoni Hospital, ASST 
Lecco, Lecco, Italy; 2University of Strasbourg School of Medicine, Strasbourg, 
France; 3North Shore University Hospital, New York, NY; 4F. Hoffmann-La 
Roche Ltd, Basel, Switzerland; 5University of Connecticut School of Medicine, 
Farmington, CT.
Background: Erythropoiesis-stimulating agents (ESAs) may increase the risk of 
cardiovascular events when used in the treatment of anemia of CKD. We compared 
cardiovascular outcomes and all-cause mortality for monthly methoxy polyethylene 
glycol-epoetin beta (continuous erythropoietin receptor activator, C.E.R.A.) with those of 
reference ESAs epoetin alfa/beta and darbepoetin alfa in the MIRCERA Post-Approval 
Safety Study (PASS).
Methods: MIRCERA PASS was a prospective, multicenter, open-label, blinded 
endpoints, non-inferiority trial. CKD patients with anemia were randomized either to start 
or switch to C.E.R.A., or to a reference ESA for correction or in the maintenance setting. 
The primary endpoint was the composite of all-cause mortality and non-fatal myocardial 
infarction or stroke, adjudicated by an independent committee unaware of treatment 
assignment. Non-inferiority was defined as the two-sided 95% confidence interval (CI) 
upper boundary of the hazard ratio [HR] <1.2.
Results: 2825 patients were randomized between December 2008 and November 
2011 and 2818 were treated for a median of 3.4 years (maximum 8.5 years). The primary 
endpoint occurred in 640/1409 patients (45.4%) in the C.E.R.A. arm and 644/1409 
(45.7%) in the reference ESAs arm (HR 1.03; 95% CI, 0.93–1.15; p=0.0039 for non-
inferiority). Subgroup analyses showed no significant differences between treatment 
groups for patients on dialysis or not, those with or without diabetes, or in the maintenance 
or correction setting. Similar findings were seen for individual components of the primary 
endpoint, all-cause mortality (HR 1.06, 95% CI 0.94–1.19), and non-fatal myocardial 
infarction or stroke (HR 0.91, 95% CI 0.74–1.12). Mean hemoglobin was maintained at 
10–12 g/dL throughout the trial and was comparable between treatment arms, as were 
serum iron parameters. Gastrointestinal bleeding and thromboembolic events were also 
similar between treatment groups. No patient developed antibody-mediated pure red cell 
aplasia.
Conclusions: In patients with anemia of CKD, long-term treatment with monthly 
C.E.R.A. resulted in overall rates of major cardiovascular events and all-cause mortality 
similar to those associated with reference ESAs administered more frequently. Study 
registered at clinicaltrials.gov (NCT00773513).
Funding: Commercial Support - F Hoffmann-La Roche Ltd
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Comparison of Lanthanum Carbonate and Calcium Carbonate in the 
Cardiovascular Mortality and Morbidity of Hemodialysis Patients
Hiroaki Ogata,1 Masafumi Fukagawa,2 Hideki Hirakata,3 Tatsuo Kagimura,4 
Tadao Akizawa.1 LANDMARK Study Group 1Showa University School of 
Medicine, Yokohama, Japan; 2Tokai University School of Medicine, Isehara, 
Japan; 3Fukuoka Renal Clinic, Fukuoka City, Japan; 4Translational Research 
Center for Medical Innovation, Kobe, Japan.
Background: The multicenter LANDMARK study (NCT01578200/
UMIN000006815) is a randomized, open-label, parallel assignment study comparing 
the effects of a non-Ca P binder, lanthanum carbonate (LC), with the effects of calcium 
carbonate (CC) on cardiovascular mortality and morbidity in hemodialysis (HD) patients.
Methods: A total of 2309 hemodialysis patients with at least one risk factor for 
vascular calcification (VC) (age >65 years, postmenopausal women, type 2 diabetes); 
intact parathyroid hormone ≤240pg/mL; and life expectancy >1 year were randomly 
assigned to the LC (n = 1154) or CC (n =1155) group. In the LC group, patients initially 
received 750 mg/day of LC (or their previous dose) and were titrated up to a maximum 
of 2250 mg/day to achieve serum P levels of 3.5 to 6.0 mg/dL. In the CC group, patients 
received 3 g/day of CC (or their previous dose), and were titrated to achieve the same 
target serum P levels. If these levels were not achieved with the maximum tolerated dose, 
non-Ca P binders were given to those in the LC group, and P binders other than LC to 
those in the CC group. The primary endpoint was survival time free of cardiovascular 
events (CVEs), including cardiovascular death, nonfatal myocardial infarction or stroke, 
and unstable angina.
Results: A total of 2135 patients (female 40.5%, 68.4 years, diabetes 56.1%) were 
analyzed in this study. After a median follow-up of 3.16 years, the incident rates of CVEs 
were 4.80 (/100 patient-years) in the LC group and 4.30 in the CC group, and there 
was no significant difference in the adjusted hazard ratio (HR) between the two groups 
(1.11 [95%CI, 0.88–1.41], P = 0.366; log rank test. There is also no significant difference 
in all-cause death between the LC and CC groups (HR 1.10 [95%CI, 0.88–1.37], 
P = 0.424).
Conclusions: The non-Ca P binder, LC, did not reduce CVEs as compared with CC 
among long-term HD patients with high risk of VC.
Funding: Commercial Support - Bayer Yakuhin, Ltd.
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High-Impact Clinical Trials
Effect of a Restrictive Versus Liberal Approach to Red Blood Cell 
Transfusion on AKI in Patients Undergoing Cardiac Surgery
Amit X. Garg,1 C. David Mazer.2 TRICS Investigators 1London Health 
Sciences Centre, London, ON, Canada; 2St. Michael’s Hospital, University of 
Toronto, Toronto, ON, Canada.
Background: Safely reducing red blood cell transfusions avoids transfusion-related 
adverse effects, conserves the blood supply, and reduces healthcare costs. We conducted a 
prespecified substudy of the Transfusion Requirements in Cardiac Surgery-III (TRICS-III) 
trial to determine if a restrictive approach to red blood cell transfusion is as safe as a 
liberal approach on the risk of acute kidney injury [protocol Can J Kid Health Dis 2018 
Jan 3; 5].
Methods: This was a randomized trial of 4531 moderate-to-high–risk patients 
undergoing cardiac surgery with cardiopulmonary bypass from 73 centers in 19 countries 
between January 2014 and March 2017. Patients were assigned to a restrictive red blood 
cell transfusion threshold (transfuse if hemoglobin level was <7.5 g/dL, intraoperatively 
and postoperatively until day 28 or hospital discharge; n=2251) or a liberal threshold 
(transfuse if hemoglobin level was <9.5 g/dL in the operating room or intensive care unit, 
or <8.5 g/dL on the non-intensive care ward; n=2280). Acute kidney injury was defined 
as an increase in the postoperative serum creatinine concentration (from the preoperative 
value) of ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hrs of surgery, or ≥50% within 7 days of 
surgery. The prespecified noninferiority margin for the absolute risk difference was 3.5%.
Results: Perioperative acute kidney injury occurred in 27.7% of patients in the 
restrictive-threshold group and in 27.9% of patients in the liberal-threshold group; 
absolute risk difference, -0.2% (95% CI, -2.8% to 2.4%). Results were consistent 
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with multiple alternative definitions of acute kidney injury, and in the subgroup with 
preoperative chronic kidney disease (Table).
Conclusions: A restrictive approach to red blood cell transfusion was as safe as a 
liberal approach on the risk of acute kidney injury in patients undergoing cardiac surgery. 
Trial Registration: NCT02042898
Funding: Government Support - Non-U.S.
AKI=Acute Kidney Injury
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High-Impact Clinical Trials
Comparative Efficacy of Therapies for Depression for Patients Undergoing 
Hemodialysis
Rajnish Mehrotra,1 Daniel Cukor,2 Mark L. Unruh,3 Tessa Rue,1 
Patrick J. Heagerty,1 Scott D. Cohen,12 Laura M. Dember,4 Yaminette 
Diaz-Linhart,13 Amelia Dubovsky,1 Tom Greene,5 Nancy K. Grote,1 
Nancy G. Kutner,6 Madhukar Trivedi,7 Davin Quinn,8 Nisha Ver halen,2 
Steven D. Weisbord,9 Bessie A. Young,1 Paul L. Kimmel,10 Susan Hedayati.11 
1University of Washington, Seattle, WA; 2SUNY Downstate Medical Center, 
Brooklyn, NY; 3University of New Mexico, Los Ranchos, NM; 4University of 
Pennsylvania School of Medicine, Philadelphia, PA; 5University of Utah, Salt 
Lake City, UT; 6Emory University School of Medicine, Atlanta, GA; 7UT 
Southwestern Medical Center, Dallas, TX; 8University of New Mexico Health 
Sciences Center, Albuquerque, NM; 9University of Pittsburgh Medical Center, 
Pittsburgh, PA; 10National Institute of Diabetes and Digestive Kidney Diseases 
(NIDDK), Bethesda, MD; 11University of Texas Southwestern, Dallas, TX; 
12George Washington University, Washington, DC; 13Brandeis University, 
Cambridge, MA.
Background: Depression is common in patients undergoing hemodialysis but limited 
data exist on increasing treatment acceptance or efficacy of various anti-depressant 
therapies. We sought to determine the effect of an engagement interview on treatment 
acceptance, and compare efficacy of cognitive behavioral therapy (CBT) or sertraline 
for treating major depressive disorder (MDD) or dysthymia in patients undergoing 
hemodialysis.
Methods: In a multi-center randomized controlled trial, 2569 patients in 41 dialysis 
facilities in 3 metropolitan areas were screened with Beck Depression Inventory (BDI). 
In those who scored ≥ 15, MDD/dysthymia was diagnosed using MINI Neuropsychiatric 
Interview. Participants were randomized to engagement interview, to increase treatment 
acceptance, vs. control visit, with proportion starting anti-depressant treatment within 
28 days as the primary outcome. Willing individuals were further randomized to 12-weeks 
of CBT or sertraline, with Quick Inventory of Depressive Symptoms (QIDS-C) at 
12 weeks as the primary outcome.
Results: Of 636 patients with BDI score ≥ 15, 310 (49%) eligible subjects were 
evaluated further, 184 were randomized to engagement vs. control, and 120 subsequently 
randomized to CBT vs. sertraline. There was no difference in the proportion initiating 
treatment for depression in engagement arm or control (66% vs. 64%, respectively, 
p=0.77). Compared with CBT, sertraline resulted in a greater decrease in depressive 
symptoms (12-week QIDS-C, -1.84, (-3.54, -0.13), p=0.04). There was also greater 
improvement in 5 of 9 secondary patient-reported outcomes with sertraline (BDI, 
Sheehan Disability, SF-36 Energy/Vitality, Satsifaction with Life, and Pittsburgh Sleep 
Quality Index scales). The incidence of serious adverse events was similar but non-serious 
adverse events were more frequent with sertraline (56 events, 25 patients) than with CBT 
(17 events, 12 patients).
Conclusions: In participants undergoing hemodialysis, there was no effect of an 
engagement interview on patients’ acceptance of treatment for depression. There was 
greater improvement in depressive symptoms and other patient-reported outcomes with 
sertraline compared to CBT.
Funding: NIDDK Support, Other U.S. Government Support, Commercial Support - 
Dialysis Clinic, Inc.
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High-Impact Clinical Trials
Interventions to Reduce Early Dialysis Initiation in Canada: A Cluster 
Randomized Trial
Navdeep Tangri,1 Thomas W. Ferguson,1 Amit X. Garg,3 Braden J. Manns.2 
1Seven Oaks General Hospital, Winnipeg, MB, Canada; 2Foothills Medical 
Center, Calgary, AB, Canada; 3London Health Sciences Centre, London, ON, 
Canada.
Background: There are higher healthcare costs and poorer outcomes when 
patients initiate dialysis earlier at a higher level of kidney function compared to when 
they initiate dialysis later. Despite the publication of The Initiating Dialysis Early and 
Late (IDEAL) study and concurrent clinical practice guidelines recommending an 
intent-to-defer dialysis initiation strategy, the estimated glomerular filtration rate (eGFR) 
at dialysis initiation varies widely.
Methods: We conducted a national cluster randomized controlled trial of a 
multifaceted knowledge translation intervention in 55 multi-disciplinary advanced 
chronic kidney disease (CKD) clinics in Canada. The intervention included academic 
detailing, audit and feedback, and provision of visual aids for patients and providers 
promoting the intent-to-defer strategy. The primary efficacy outcome was the proportion 
of patients who started dialysis early (eGFR > 10.5 ml/min/1.73m2) and the primary safety 
outcome was the proportion of dialysis starts occurring in the acute inpatient setting. 
Absolute risk differences were estimated using generalized-estimating-equations analysis 
of clustered binary data using the difference-in-differences approach.
Results: There were 6,836 patients that started dialysis during the study period, 3,521 
people who started in the 1 year before the intervention and 3,314 people who started in 
the 1 year following the intervention. Prior to the intervention, the proportion of early 
dialysis starts was 28.1% in the intervention group and 31.1% in the control group, and 
following the intervention was 30.6% and 31.0% in the intervention and control groups 
respectively. In unadjusted and analyses adjusted for patient-level characteristics no 
differences in early initiation were observed (adjusted absolute risk difference 3.7%; 
95% confidence interval [CI] -0.07% to 8.1%; p = 0.10). Similarly, no differences in 
acute inpatient dialysis starts between the intervention and control group were detected 
(adjusted relative risk 1.11; 95% CI 0.96-1.29; p = 0.17).
Conclusions: A multifaceted knowledge translation intervention did not result in 
further declines in early dialysis initiation in Canada. Secular trends in dialysis initiation 
from uptake of the IDEAL trial findings may have limited the impact of this intervention.
Funding: Government Support - Non-U.S.
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Canagliflozin Reduces the Risk of Renal Events in People with Type 2 
Diabetes Mellitus and Normoalbuminuria
Vlado Perkovic,1,6 Brendon L. Neuen,1 Toshiaki Ohkuma,1 David R. Matthews,2 
Dick de Zeeuw,3 Kenneth W. Mahaffey,4 Greg Fulcher,6 Qiang Li,1 
Meg J. Jardine,1,7 Richard Oh,5 Hiddo J. Lambers Heerspink,3 Bruce Neal.1 
1The George Institute for Global Health, UNSW Sydney, Sydney, NSW, 
Australia; 2Oxford Centre for Diabetes, Endocrinology and Metabolism and 
Harris Manchester College, University of Oxford, Oxford, United Kingdom; 
3University of Groningen, University Medical Center Groningen, Groningen, 
Netherlands; 4Stanford Center for Clinical Research, Department of Medicine, 
Stanford University School of Medicine, Stanford, CA; 5Janssen Research & 
Development, LLC, Raritan, NJ; 6Royal North Shore Hospital, Sydney, NSW, 
Australia; 7Concord Repatriation General Hospital, Sydney, NSW, Australia.
Background: It has been postulated that the renoprotective effect of SGLT2 
inhibitors is primarily due to restoration of tubuloglomerular feedback, which ameliorates 
glomerular hyperfiltration and lowers albuminuria. As a result, these agents might not 
be as effective in people with type 2 diabetes mellitus (T2DM) and normoalbuminuria 
(urinary albumin:creatinine ratio [UACR] <30 mg/g). Ongoing renal outcome studies 
are including participants who mostly or entirely have macroalbuminuria. We therefore 
sought to determine the renal effects of canagliflozin in people with normoalbuminuria in 
the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
Methods: The CANVAS Program randomized people with T2DM and high risk 
of cardiovascular disease to canagliflozin or placebo. We included participants with 
normoalbuminuria in this analysis, and further divided them into tertiles according to 
baseline UACR (low, mid, or high normoalbuminuria), and into subgroups based on 
estimated glomerular filtration rate (eGFR; <45, 45-<60, 60-<90, and ≥90 mL/min/1.73m2). 
We analyzed the effects of canagliflozin on renal outcomes in people with 
normoalbuminuria overall and across these subgroups.
Results: Among 10,142 CANVAS participants, 7,007 (69%) had normoalbuminuria 
(mean age 63 years, BP 135/77 mmHg, HbA1c 8.2%, eGFR 78.3 mL/min/1.73m2). 
In this population, canagliflozin reduced average UACR by 9% (95% CI 7-12%) 
compared to placebo over 338 weeks. Mean annual change in eGFR for placebo and 
canagliflozin treated participants was –0.47 and +0.59 mL/min/1.73m2, respectively 
(placebo-subtracted difference 1.06 mL/min/1.73m2). Canagliflozin reduced the risk of 
the composite renal outcome of 40% decrease in eGFR, end-stage kidney disease, or renal 
death by half (HR 0.50, 95% CI 0.33-0.77). The effect on the composite renal outcome 
appeared broadly consistent across UACR and eGFR subgroups (P heterogeneity = 0.16 
and 0.10, respectively).
Conclusions: Canagliflozin reduces the risk of eGFR decline and renal outcomes 
in people with normoalbuminuria despite modest albuminuria reductions. Multiple 
mechanisms of renal benefit from SGLT2 inhibition might be important in T2DM.
Funding: Commercial Support - Janssen Research & Development, LLC
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Effects of Selonsertib in Patients with Diabetic Kidney Disease (DKD)
Glenn M. Chertow,1 Pablo E. Pergola,2 Fang Chen,3 Brian J. Kirby,3 
John Sundy,3 Uptal D. Patel.3 GS-US-223-1015 Investigators 1Stanford 
University School of Medicine, Palo Alto, CA; 2Renal Associates, PA, 
San Antonio, TX; 3Gilead Sciences, Inc., Foster City, CA.
Background: Increased oxidative stress in the kidney and the resulting activation 
of apoptosis signal-regulating kinase 1 (ASK1) in glomerular and tubular cells has 
been implicated in progression of acute and chronic kidney diseases. This Phase 2 trial 
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evaluated the safety and efficacy of selonsertib (SEL), a potent and selective ASK1 
inhibitor, in 334 pts with treatment-refractory moderate to advanced DKD.
Methods: Pts were randomized to receive SEL (2, 6, or 18 mg oral daily) or PBO. 
Primary outcome was change from baseline eGFR with SEL compared with PBO at 
48 wks.
Results: SEL appeared safe with no dose-dependent adverse effects over 48 wks. 
Although there was no significant difference in SEL group mean (±SE) eGFR compared 
with PBO (0.38±1.21, 0.84±1.22, and -0.87±1.23 mL/min/1.73m2 in the 2-, 6-, and 
18-mg groups, respectively; p>0.4 for all pairwise comparisons; n=333 dosed; full 
analysis set [FAS]), differences in eGFR at 48 wks were confounded by acute effects 
related to SEL’s inhibition of creatinine secretion. To account for this unanticipated 
effect, we used piecewise linear regression and found two dose-dependent effects: an 
acute, more pronounced decline in eGFR from 0-4 wks (creatinine secretion effect) and an 
attenuated decline in eGFR between 4-48 wks (therapeutic effect) seen with higher doses 
of SEL. Between 4-48 wks, rate of eGFR decline was reduced 71% for the 18-mg group 
relative to PBO (difference 3.11±1.53 mL/min/1.73m2 annualized over 1 year, 95% CI, 
0.10-6.13; nominal p=0.043; n=313; FAS excluding data from 2 sites with GCP 
compliance findings).
Conclusions: Although the trial did not meet its primary pre-specified endpoint, post-
hoc analyses indicate that SEL appears to slow the progression of DKD (ClinicalTrials.
gov: NCT02177786).
Funding: Commercial Support - Gilead Sciences, Inc.
Figure 1 Adjusted Mean (95% CI) Change in eGFR (MDRD)
TH-PO1149 Poster Thursday
Late-Breaking Clinical Trials Posters
Primary Results of the Quality of Life in Peritoneal Dialysis and 
Conventional In-Center Hemodialysis (China Q) Study: A Prospective, 
Randomized, Open-Label, Multicenter, Noninferiority Trial
Xueqing Yu,1 Li Fan,1 Mark R. Marshall.2 the China Q study investigators 
1Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen 
University, Guangzhou, China; 2Middlemore Hospital, Auckland, New Zealand.
Background: There may be differences in health-related quality of life between 
hemodialysis (HD) and peritoneal dialysis (PD) for incident end-stage renal disease 
(ESRD) patients, but this hypothesis has not been adequately tested.
Methods: Open-label clinical trial from 21 centers in China, in adults diagnosed 
with new ESRD requiring maintenance dialysis, randomized 1:1 to receive in-center HD 
(≥3 x 4 hour sessions/week) or PD (3-5 exchanges/day). Primary end-point was burden 
of kidney disease score from the KDQoL-SF at 48 weeks; main secondary endpoint was 
all-cause mortality at 48 weeks. This dataset was supplemented by 235 patients (142 PD, 
93 HD) from the previously terminated SURinD trial, who had complete measures of 
burden of kidney disease at both baseline and 48 weeks. The primary endpoint was 
assessed in the per protocol (PP) population, with a sensitivity analysis in the intention-
to-treat (ITT) population. The treatment effect between arms was represented by the 
geometric mean (GM) ratio, and non-inferiority defined by the lower bound of 1-side 
95% CI of GM ratio > 0.9 after 48 weeks follow-up. The main secondary end-point was 
assessed only in the China Q ITT population (NCT02378350, NCT01413074).
Results: 336 incident patients allocated to HD (237 per protocol), 332 to PD (253 per 
protocol) between Apr 2014 to Jun 2016. Patients were representative of those in China, 
with a pooled mean (SD) age of 49.5 (14.7) years, and 370 females (41.0%). For the 
primary endpoint, the GM ratio (95% CI) of PD vs. HD was 1.06 (0.91, 1.24), exceeding 
the limit for non-inferiority (p=0.43). The result of the sensitivity analysis was similar. 
There were 13 deaths in the PD group, and 19 deaths in the HD group, with no difference 
between groups (p=0.94).
Conclusions: In this study, burden of kidney disease was not inferior with PD vs. 
in-center HD, suggesting comparable perceptions of frustration and interference of 
kidney disease in one’s life. Mortality risk was not different, although the study was not 
powered for this end-point. Analysis of other KDQoL-SF endpoints, clinical endpoints, 
and hospitalization are ongoing.
Funding: Commercial Support - Baxter Healthcare Corporation
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A Randomized Trial of Magnesium Oxide for Coronary Artery 
Calcification in Pre-Dialysis CKD
Yusuke Sakaguchi,1 Takayuki Hamano,1 Tatsufumi Oka,2 Satoshi Yamaguchi,2 
Isao Matsui,2 Nobuhiro Hashimoto,2 Ayumi Matsumoto,2 Karin Shimada,2 
Yoshitsugu Takabatake,2 Atsushi Takahashi,2 Jun-Ya Kaimori,4 Masaru Horio,5 
Ryohei Yamamoto,3 Toshiki Moriyama,3 Yoshitaka Isaka.2 1Department of 
Inter-Organ Communication Research in Kidney Disease, Osaka University 
Graduate School of Medicine, Suita, Japan; 2Department of Nephrology, 
Osaka University Graduate School of Medicine, Suita, Japan; 3Osaka 
University Health Care Center, Toyonaka, Japan; 4Department of Advanced 
Technology of Transplantation, Osaka University Graduate School of 
Medicine, Suita, Japan; 5Department of Functional Diagnostic Science, Osaka 
University Graduate School of Medicine, Suita, Japan.
Background: Although coronary artery calcification (CAC) predicts cardiovascular 
events among patients with CKD, effective therapeutic strategies for CAC have not 
yet been established. Animal studies have revealed that magnesium inhibits vascular 
calcification whereas indoxyl sulfate aggravates it. We explored whether magnesium 
supplementation or oral carbon adsorbent (AST-120) mitigates the progression of CAC 
in CKD.
Methods: In this 2-year, open-label, randomized controlled trial with a 2 by 
2 factorial design, the efficacy of magnesium oxide and AST-120 for the progression 
of CAC was separately evaluated. We enrolled stages 3-4 CKD patients with known 
risk factors of CAC (diabetes mellitus, prior history of cardiovascular disease, 
hyper-low-density lipoprotein cholesterolemia, or current smoking). These patients were 
randomly assigned to magnesium oxide or control group and to AST-120 or control group. 
The primary outcome was a percent change in CAC score (Agatston score).
Results: The study was terminated prematurely after a planned interim analysis 
of the first 125 enrolled patients, showing that the percent change in CAC score in the 
magnesium oxide group was lower than that in the control group (median: 11.3% vs 
39.5%; P<0.001). The proportion of patients whose annual percent change in CAC score 
over 15% was significantly lower in the magnesium oxide group (23.9% vs 62.0%; 
P<0.001). Magnesium supplementation increased serum magnesium levels from 2.0 to 
2.3 mg/dL (P<0.001; vs control group) but did not alter serum calcium, phosphate, or 
parathyroid hormone levels. The progression rate of CAC was not significantly different 
between patients in the AST-120 and control groups (23.1% and 31.9%, respectively; 
P=0.57).
Conclusions: Oral magnesium oxide retards the progression of CAC among 
pre-dialysis CKD patients with a high risk of vascular calcification.
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Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin 
Alfa) Conversion Study of Oral Roxadustat in CKD Patients with 
Anemia on Hemodialysis in Japan
Tadao Akizawa,1 Manabu Iwasaki,4 Yusuke Yamaguchi,3 Yoshikatsu Majikawa,3 
Michael Reusch.2 1Showa University School of Medicine, Tokyo, Japan; 
2Astellas Pharma Europe B.V., Leiden, Netherlands; 3Astellas Pharma Inc., 
Tokyo, Japan; 4Yokohama City University, Yokohama, Japan.
Background: Roxadustat, an oral HIF-PHI, is in late-stage development for 
treatment of CKD anemia. This phase 3 study evaluated non-inferiority of roxadustat 
efficacy to darbepoetin alfa (DA) as treatment of CKD anemia on hemodialysis (HD).
Methods: Multicenter, 24-week, Japanese study of CKD anemia patients on HD for 
≥12 weeks and treated with ESA. Patients were randomized to roxadustat (70mg and 
100mg) three times weekly or DA (10-60µg) once weekly; dose was adjusted to maintain 
Hb at 10-12g/dL. Primary endpoint was change of average Hb from baseline to Weeks 
18-24 (ΔHb18-24). Roxadustat efficacy was confirmed if the 95% CI of average Hb at 
Weeks 18-24 was within 10-12g/dL; non-inferiority to DA was confirmed if the lower 
limit of the 95% CI of the difference between roxadustat and DA was above –0.75g/dL. 
Secondary endpoints were average Hb at Weeks 18-24, proportion of patients with Hb 
of 10-12g/dL at Weeks 18-24 (maintenance rate), and iron parameters (ie, serum iron, 
ferritin, TSAT, transferrin, and TIBC). Safety was assessed as occurrence of adverse 
events (AEs) including ophthalmological examination (color fundus photography and 
optical coherence tomography [OCT]).
Results: 303 patients were randomized to roxadustat (n=151) or DA (n=152). The 
average Hb at Weeks 18-24 was 10.99 g/dL (95% CI: 10.88, 11.10) with roxadustat, 
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confirming its efficacy. The difference between roxadustat and DA in ΔHb18-24 was 
–0.02g/dL (95% CI: –0.18, 0.15), confirming non-inferiority of roxadustat to DA. 
Maintenance rate of target Hb in patients with ≥1 Hb value at Weeks 18-24 was 95.2% 
(roxadustat) and 91.3% (DA). With roxadustat, serum iron, ferritin, and TSAT showed no 
remarkable change; transferrin and TIBC increased through Week 4 and then remained 
stable. No remarkable changes in iron parameters occurred with DA. The most common 
AEs in both groups were nasopharyngitis, shunt stenosis, diarrhea, contusion, and 
vomiting. New/worsening retinal hemorrhage occurred in 32.4% (roxadustat) and 36.6% 
(DA) of patients; no clinically meaningful change in retinal thickness by OCT were 
observed over time between groups.
Conclusions: Roxadustat maintained target Hb in HD patients and its efficacy was 
non-inferior to DA. AEs were consistent with previous reports.
Funding: Commercial Support - Astellas Pharma Inc
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A Phase 3, Randomized, Open-Label, Active-Controlled Study of 
Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects 
with CKD on Dialysis
Nan Chen,1 Chuan-Ming Hao,2 Bi-Cheng Liu,3 Hong L. Lin,14 Wang Caili,9 
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of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, 
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Hospital(Jiangsu Province Hospital), Nanjing Medical University, Nanjing, 
China; 5Department of Nephrology, Chinese PLA General Hospital. State Key 
Lab of Kidney disease. National Clinical Research Center for Kidney Disease, 
Beijing, China; 6FibroGen, Shanghai, China; 7FibroGen Inc., San Francisco, 
CA; 8Renal Division, Nanfang Hospital, Southern Medical University, 
The National Clinical Research Center for Kidney Disease, State Key 
Laboratory of Organ Failure Research, Guangzhou, China; 9The First 
Affiliated Hospital of Baotou Medical College of Inner Mongolia University of 
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China; 11Chinese Acedamy of Medical Sciences, Peking Union Medical 
College Hospital, Beijing, China; 12Renal Division, Department of Medicine, 
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China; 13National Clinical Research Center of Kidney Diseases, Jinling 
Hospital, Nanjing University School of Medicine, Nanjing, China; 
14Department of Nephrology, The First Affiliated Hospital of Dalian Medical 
University, Dalian, China; 15Lanzhou University Second Hospital, Lanzhou, 
China; 16Department of Nephrology, Peking University People’s Hospital, 
Beijing, China; 17Xinhua Hospital Affiliated to Shanghai Jiao Tong University 
School of Medicine, Shanghai, China; 18Anhui Medical University Affiliated 
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University, Nanchang, China.
Background: Roxadustat is an oral hypoxia–inducible factor prolyl hydroxylase 
inhibitor that regulates erythropoiesis and iron metabolism.
Methods: In this phase 3 trial, Chinese pts (hemoglobin-Hb 9-12g/dL) on hemo/
peritoneal dialysis with previous erythropoiesis stimulating agent (ESA) therapy for 
>6 weeks were randomized 2:1 to roxadustat or epoetin-alfa thrice-weekly for 26 wks; 
IV iron was withheld except for rescue. Primary endpoint was the average Hb change from 
baseline to wks 23-27 (deltaHb23-27) tested for non-inferiority vs epoetin-alfa. Both arms 
were titrated to maintain/achieve Hb 10-12g/dL. All randomized subjects who received 
≥2 weeks of study treatment with baseline and post-baseline Hbs w/o rescue therapy 
6 wks prior to assessment and w/o important protocol deviation comprised the per protocol 
set (PPS); all randomized subjects with baseline and post baseline Hbs comprised the full 
analysis set (FAS) population.
Results: The safety population consisted of 304 pts (204 roxadustat, 100 epoetin-
alfa); 256 pts (162 roxadustat, 94 epoetin-alfa) completed the 26-week treatment period. 
Average baseline Hb overall was 10.4g/dL. Roxadustat produced a numerically greater 
mean deltaHb23-27 of .8g/dL(±1.1) than epoetin-alfa, (.5 g/dL±1.0) and was noninferior 
and superior (p=.037) to ESA in the PPS population and non-inferior but not superior in 
the FAS population. The Hb change in the roxadustat group wasn’t clinically affected by 
baseline CRP. Roxadustat increased transferrin, maintained serum iron, and attenuated 
decreases in TSAT versus epoetin-alfa (all p<0.01). At wk 27, the decline from baseline in 
both total and LDL cholesterol was greater with roxadustat (both p<0.0001). Roxadustat 
reduced hepcidin from baseline by a mean of 30.21ng/ml (p=.0028) compared to 2.28ng/
ml in the epoetin-alfa group (p=.1228). Roxadustat was well tolerated.
Conclusions: Roxadustat was efficacious as oral anemia therapy in Chinese pts 
receiving dialysis. Roxadustat’s reduction in hepcidin levels with iron mobilization likely 
contributes to its efficacy in erythropoiesis irrespective of inflammation.
Funding: Commercial Support - FibroGen
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A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of 
Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in 
Subjects with CKD Not on Dialysis
Nan Chen,1 Chuan-Ming Hao,2 Xiaomei Peng,12 Hong L. Lin,9 Aiping Yin,13 
Li Hao,14 Ye Tao,15 Xinling Liang,8 Zhengrong Liu,7 Chang Ying Xing,3 
Jianghua Chen,11 Laimin Luo,16 Li Zuo,10 Yunhua Liao,17 Bi-Cheng Liu,4 
Robert Leong,6 Chunrong Wang,5 Cameron S. Liu,6 Thomas B. Neff,6 
Lynda Szczech,6 Kin-Hung P. Yu.6 1Institute of Nephrology, Department of 
Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of 
Medicine, Shanghai, China; 2Division of Nephrology, Huashan Hospital 
Fudan University, Shanghai, China; 3Department of Nephrology, The First 
Affiliated Hospital(Jiangsu Province Hospital), Nanjing Medical University, 
Nanjing, China; 4Institute of Nephrology, Zhong Da Hospital, Southeast 
University School of Medicine, Nanjing, China; 5FibroGen, Shanghai, China; 
6FibroGen Inc., San Francisco, CA; 7Renal Division, Nanfang Hospital, 
Southern Medical University, The National Clinical Research Center for 
Kidney Disease, State Key Laboratory of Organ Failure Research, Guangzhou, 
China; 8Division of Nephrology, Guangdong General Hospital, Guangdong 
Academy of Medical Sciences, Guangzhou, China; 9Department of Nephrology, 
The First Affiliated Hospital of Dalian Medical University, Dalian, China; 
10Department of Nephrology, Peking University People’s Hospital, Beijing, 
China; 11Zhejiang University Affiliated First Hospital, Hangzhou, China; 
12Department of Nephrology, The People’s Hospital of Guangxi Zhuang 
Autonomous Region, Nanning, China; 13Dialysis Center, The First Affiliated 
Hospital of Xi’an Jiaotong University, Xian, China; 14Anhui Medical 
University Affiliated Second Hospital, Hefei, China; 15Division of Nephrology, 
West China Hospital, Chengdu, China; 16The First Affiliated Hospital of 
Nanchang University, Nanchang, China; 17Department of Nephrology, 
The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Roxadustat (FG-4592) is an oral hypoxia–inducible factor prolyl 
hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism.
Methods: In this phase 3 trial, Chinese patients with hemoglobin (Hb) between 
7.0-10.0 g/dL and CKD not requiring dialysis were randomized and treated in a double-
blind manner to roxadustat thrice-weekly or placebo (2:1) for 8-weeks; parenteral iron 
was withheld except for rescue. The primary endpoint was the average change in Hb 
from baseline to week 7-9. Following, all patients were offered open-label roxadustat 
for 18-weeks.
Results: The safety population included 152 patients (101=roxadustat, 51=placebo) 
in the initial 8-weeks, during which subjects in the roxadustat arm had a greater mean 
(±SD) change from baseline in hemoglobin of 1.90 g/dL (±1.175)(mean baseline Hb 8.87 
±0.81 g/dL), as compared to placebo -0.39 g/dL (±0.786)(mean baseline 8.93 ±0.73 g/dL) 
(p<0.000000000000001). At week 9, patients randomized to roxadustat had a greater 
mean reduction in hepcidin at -56.14 (±63.40)(p<0.00001) vs. -15.10 (±48.06) ng/ml 
(p=0.172) in the placebo group (p<0.00001 between groups). At week 9, the decline 
from baseline was greater for lipid fractions (total cholesterol and LDL cholesterol) in 
the roxadustat arm (p<0.00001). The most frequent treatment-emergent adverse events 
were typical for this population and without trend in individual or composite events. 
Ninety-eight subjects completed the 18-week open-label period. Roxadustat performed 
similarly in the open-label as in the initial treatment period with respect to correction and 
maintenance of hemoglobin.
Conclusions: Roxadustat was well tolerated in patients with CKD not requiring 
dialysis in China and superior to placebo in correcting anemia and maintaining Hb levels.
Funding: Commercial Support - FibroGen
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A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 
Trial to Treat Metabolic Acidosis in CKD Patients with TRC101, a 
Novel, Non-Absorbed, Hydrochloric Acid Binder
Donald E. Wesson,1 Vandana S. Mathur,5 Yuri Stasiv,4 Dawn Parsell,2 
Gerrit Klaerner,4 David A. Bushinsky.3 1Baylor Scott and White Health and 
Wellness Center, Dallas, TX; 2Parsell and Otto Consulting, Inc., Cedar Park, 
TX; 3University of Rochester Medical Center, Rochester, NY; 4Tricida, Inc., 
South San Francisco, CA; 5Mathur Consulting, Woodside, CA.
Background: Metabolic acidosis increases risk of chronic kidney disease (CKD) 
progression and adversely affects muscle and bone. TRC101, a non-absorbed, sodium-
free polymeric drug that selectively binds and removes hydrochloric acid from the 
gastrointestinal tract, is being developed for the treatment of metabolic acidosis in CKD 
and slowing CKD progression.
Methods: 217 CKD patients (eGFR 20 - 40 mL/min/1.73m2) with metabolic acidosis 
(serum bicarbonate [HCO3] 12 - 20 mEq/L) were randomized 4:3 to TRC101 (6 g) or 
placebo once-daily for 12 weeks. Algorithmic dose titration was performed to achieve 
a normal serum HCO3 (22 - 29 mEq/L). The primary endpoint was the between-group 
comparison of the proportion of patients with a ≥4 mEq/L increase in serum HCO3 or 
a normal serum HCO3 at Week 12. The secondary endpoint evaluated the change from 
baseline in serum HCO3. Two exploratory endpoints evaluated effects of acidosis 
correction on physical functioning using the Kidney Disease Quality of Life Short Form-
36 Physical Functioning subscale and a timed repeated chair stand test.
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Results: The mean (SD) baseline serum HCO3 and eGFR were 17.3 (1.5) mEq/L 
and 28.6 (6.0) mL/min/1.73m2, respectively. 96% of patients completed treatment. 
Comorbidities included hypertension (97%), diabetes (65%), left ventricular hypertrophy 
(44%), and congestive heart failure (31%). More TRC101 (59.2%) than placebo (22.5%) 
patients met the primary endpoint response definition (p<0.0001). From baseline 
to Week 12, mean serum HCO3 increased +4.5 mEq/L (TRC101) vs. +1.7 mEq/L 
(placebo), p<0.0001. More TRC101 compared with placebo patients had improvement in 
self-reported physical functioning (p = 0.012) and there was a trend toward improvement 
in standardized chair stand time (p=0.063). There were no effects of TRC101 on 
creatinine or other electrolytes. Overall treatment-related adverse events occurred in 
9.7% of placebo and 13.7% of TRC101 patients, most of which were gastrointestinal 
(e.g., diarrhea, flatulence, nausea and constipation).
Conclusions: TRC101 effectively and safely treated metabolic acidosis and improved 
self-reported physical functioning in CKD patients.
Funding: Commercial Support - Tricida, Inc. San Francisco, CA, USA
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Effect of Everolimus with Reduced-Exposure Calcineurin Inhibitor in 
De Novo Kidney Transplant Recipients: 24-Month Results from the US 
Cohort of the TRANSFORM Study
Yasir A. Qazi,1 Dean Y. Kim,2 Alexander C. Wiseman,3 V. Ram Peddi,4 
Steven M. Steinberg,5 Fuad S. Shihab,6 Mitchell L. Henry,7 Kevin M. Mccague,8 
Peter Bernhardt,9 Shamkant P. Mulgaonkar.10 1University of Southern 
California, Los Angeles, CA; 2Henry Ford Hospital, Detroit, MI; 3University 
of Colorado at Denver and Health Sciences Center, Denver, CO; 4California 
Pacific Medical Center, San Francisco, CA; 5Balboa Nephrology Medical 
Group, San Diego, CA; 6University of Utah Health Science Center, Salt Lake 
City, UT; 7Ohio State University, Columbus, OH; 8Novartis Pharmaceuticals 
Corp., E. Hanover, NJ; 9Novartis Pharma AG, Basel, Switzerland; 10St. 
Barnabas Medical Center, Livingston, NJ.
Background: To present 24-month (M) efficacy and safety data from the US cohort 
of the TRANSFORM study (NCT01950819).
Methods: In this 24M, multicenter, open-label study, de novo kidney transplant 
recipients (KTxRs) were randomized to receive either everolimus + reduced-exposure 
calcineurin inhibitor (EVR+rCNI: 1022) or mycophenolic acid + standard-exposure 
CNI (MPA+sCNI: 1015) with induction and steroids. The binary composite of tBPAR 
or eGFR <50 mL/min/1.73 m2, composite efficacy failure (CEF: tBPAR/graft loss/death) 
and individual components, eGFR (MDRD4), and safety were assessed at M24.
Results: Of 2037 KTxRs in overall study, 352 (EVR+rCNI: 173; MPA+sCNI: 179) 
were included in the US cohort. Except for younger donors and lower proportion of 
extended criteria donors (ECD) in the US cohort, other characteristics were similar for 
both populations. Similar to the overall population, CNI trough levels (C0) were towards 
the upper limit/above the target C0 throughout the study. In contrast to overall population, 
the incidence of binary composite efficacy was significantly higher in the EVR+rCNI 
vs MPA+sCNI arm in the US cohort at M24. The CEF and individual components were 
comparable between arms in both populations (Table). Mean eGFR was higher in the US 
cohort vs overall population for both arms. Incidence of viral infections were lower in 
EVR+rCNI vs MPA+sCNI.
Conclusions: Similar to 24M data from the TRANSFORM study, US cohort showed 
comparable efficacy and safety with lower viral infection rates in the EVR+rCNI vs 
MPA+sCNI arm; higher mean eGFRs in the US cohort may be attributed to differences in 
donor type and age in the population.
Funding: Commercial Support - Novartis
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Effect of Adding Dapagliflozin as an Adjunct to Insulin on Urinary 
Albumin-to-Creatinine Ratio over 52 Weeks in Adults with Type 1 
Diabetes
Steven Edelman,1 Johan Jendle,2 Paresh Dandona,3 Chantal Mathieu,4 
Diethelm Tschoepe,5 Fredrik A. Thorén,6 Markus F. Scheerer,6 John Xu,6 Anna 
Maria Langkilde.6 DEPICT-1 and -2 Investigators 1Division of Endocrinology 
and Metabolism, University of California, San Diego, CA; 2Orebro University, 
Örebro, Sweden; 3State University of New York at Buffalo, Buffalo, NY; 
4KULeuven, Leuven, Belgium; 5Herz- und Diabeteszentrum NRW, Ruhr-
Universitaet Bochum, Bad Oeynhausen, Germany; 6AstraZeneca, Gothenburg, 
Sweden.
Background: DEPICT-1 and DEPICT-2 studies, where dapagliflozin (DAPA) was 
added as adjunct to insulin in adults with inadequately controlled type 1 diabetes (T1D) 
(glycated hemoglobin: 7.5%–10.5%), reported improvements in glycemic control and 
weight, and was well tolerated.
Methods: In this pooled post hoc analysis of the DEPICT-1 and -2 studies, we 
evaluated the effect of dapagliflozin on Urinary Albumin to Creatinine Ratio (UACR) in 
individuals with T1D with baseline albuminuria.
Results: In total, 548 individuals treated with DAPA 5 mg, 565 with DAPA 10 mg, 
and 532 with placebo had UACR recorded at baseline. Albuminuria at baseline was found 
in 80, 84, and 87 individuals in the DAPA 5 mg, 10 mg, and placebo arms, respectively. 
Of these 251 individuals, baseline renal function measured as estimated glomerular 
filtration rate (eGFR) was normal in 93 individuals (eGFR ≥90 mL/min/1.73 m2), mildly 
impaired in 131 individuals (eGFR ≥60 or <90 mL/min/1.73 m2), and moderately impaired 
in 27 individuals (eGFR <60 mL/min/1.73 m2). Changes in eGFR appeared similar across 
the treatment arms (data not shown). However, treatment with DAPA resulted in a dose-
dependent reduction in UACR at weeks 12, 18, 24, and 52 (Figure). The difference 
in UACR between DAPA 10 mg vs placebo was significant from weeks 18 to 52. 
At week 52, the differences in UACR between DAPA 10 mg and placebo and DAPA 5 
mg and placebo were −31.12% (95% CI: −49.94, −5.22) and −13.30 (95% CI: −37.24, 
19.79), respectively.
Conclusions: Treatment with DAPA appears to provide a dose-dependent benefit in 
reducing UACR, suggesting renoprotective effects in individuals with T1D with baseline 
albuminuria.
Funding: Commercial Support - AstraZeneca, Gaithersburg, MD, USA.
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Correction of Serum Potassium with Sodium Zirconium Cyclosilicate in 
Japanese Patients with Hyperkalemia: A Dose-Finding Study
Naoki Kashihara,1 Toshiki Nishio,8 Takeshi Osonoi,4 Yosuke Saka,6 
Toshiyuki Imasawa,7 Takayasu Ohtake,2 Hiroshi Mizuno,9 Yugo Shibagaki,3 
Hyosung Kim,5 Toshitaka Yajima,5 Nobuaki Sarai.5 1Kawasaki Medical 
School, Okayama, Japan; 2Shonankamakura General Hospital, Kanagawa, 
Japan; 3St. Marianna University School of Medicine Hospital, Kanagawa, 
Japan; 4Nakakinen Clinic, Ibaraki, Japan; 5AstraZeneca K.K., Osaka, Japan; 
6Kasugai Municipal Hospital, Aichi, Japan; 7Chiba-East-Hospital, Chiba, 
Japan; 8Kusatsu General Hospital, Shiga, Japan; 9Inage Hospital, Chiba, 
Japan.
Background: Sodium zirconium cyclosilicate (SZC) is an oral potassium (K) binder 
approved to treat hyperkalemia (HK) in adults in the US and EU. We evaluated SZC doses 
for correcting serum K (sK) in Japanese patients (pts) with HK in a multicenter, double-
blind, placebo-controlled phase 2/3 trial.
Methods: Pts aged ≥18y with sK ≥5.1–≤6.5mEql/L were randomized 1:1:1 to 
SZC 5g, SZC 10g, or placebo (PBO) administered (as powder in water) thrice daily 
for 48h. Primary endpoint was exponential rate of change in sK over 48h. Pts (%) with 
normokalemia (sK 3.5–5.0mEq/L) at 48h (secondary endpoint), multiple time points 
(1, 2, 4, 24, 25, 28, and 48h), and adverse events (AEs) were evaluated.
Results: At baseline, the 103 randomized pts (mean age 73y; 75% male) had mean sK 
of 5.6 mEq/L, mean eGFR of 26.1 mL/min/1.73m2 (29%, 40%, 28%, and 3% had eGFR 
<15, 15–<30, 30–<60, and ≥60, respectively). All pts (34 on SZC 5g; 36 on SZC 10g; 
33 on PBO) completed the study except 2 PBO pts discontinued due to HK. Exponential 
rate of sK change from 0–48h vs PBO was –0.00261/h with SZC 5g and –0.00496/h for 
SZC10g (Figure; both P<0.0001). At 48h, 85% of pts had normokalemia with SZC 5g, 
92% with SZC 10g, and 15% with PBO. More pts had normokalemia with SZC 5g vs 
PBO at 4h through 48h and with SZC 10g vs PBO at every time point. AEs occurred in 
4, 5, and 1 pt in the SZC 5g, 10g, and PBO groups; all AEs were mild and single 
occurrences in individual patients. sK <3.5 mEq/L occurred in 2 pts in the SZC 10g group, 
and none in the SZC 5g or PBO groups.
Conclusions: SZC 5g and 10g were well tolerated and corrected HK in most Japanese 
pts within 48h; SZC 10g had the most rapid sK reduction and highest response rate.
Funding: Commercial Support - AstraZeneca
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Sodium Zirconium Cyclosilicate for Hyperkalemia: Results of the 
Randomized, Placebo-Controlled, Multi-Dose HARMONIZE-GLOBAL 
Study
Faiez Zannad,1 Bang-Gee Hsu,2 Yoshitaka Maeda,3 Sug kyun Shin,4 
Elena M. Vishneva,5 Martin Rensfeldt,6 Stefan Eklund,6 June Zhao.7 1Inserm, 
centre d’Investigation Clinique 1433, Université de Lorraine and Centre 
Hospitalier Universitaire, Nancy, France; 2Buddhist Tzu Chi General 
Hospital, Hualien, Taiwan; 3JA Toride Medical Center, Ibaraki, Japan; 4NHIS 
Medical Center, Ilsan Hospital, Goyangshi, Gyeonggi–do, Republic of Korea; 
5City Clinical Hospital No14, Ekaterinburg, Russian Federation; 6AstraZeneca 
Gothenburg, Mölndal, Sweden; 7AstraZeneca, Gaithersburg, MD.
Background: Sodium zirconium cyclosilicate (SZC) is an odorless, tasteless, 
inorganic, oral, potassium (K) binder approved for the treatment of hyperkalemia in 
adults in the US and Europe. In the HARMONIZE trial (Kosiborod, JAMA 2015), SZC 
rapidly corrected and maintained control for 28 days in Caucasian patients with few dose-
related adverse events (AEs). Presented here is the HARMONIZE Global study; a 28-day, 
multicenter, randomized, double-blind, placebo-controlled phase 3 study that evaluated 
the efficacy and safety of SZC for hyperkalemia in primarily Asian patients.
Methods: Outpatients (≥18 yrs) with K ≥5.1mEq/L (measured by the point-of-care 
device iSTAT) were enrolled from sites in Japan, South Korea, Russia and Taiwan. 
During the open-label correction phase (CP), patients received SZC 10 g thrice daily 
for 48 hours (Figure), changes in serum K (sK) were evaluated serially. Patients with K 
3.5–5.0 mEq/L in the CP entered the 28-day maintenance phase (MP) and were randomized 
2:2:1 to receive 5 g SZC, 10 g SZC, or placebo once daily. Background renin angiotensin 
aldosterone system inhibitors and diuretic use were kept stable. The primary endpoint was 
the mean serum K (measured by central laboratory) during days 8–29 in MP. Secondary 
endpoints included changes in sK, proportion of patients who achieved normokalemia 
(sK 3.5–5.0 mEq/L) in CP and those who maintained normokalemia in MP, quality of life 
(assessed using EuroQol-5D questionnaire), and changes in aldosterone and renin. Safety 
parameters included adverse events, vital signs, ECG, and clinical laboratory evaluations.
Results: Efficacy and safety data will be available for presentation.
Conclusions: A randomized, controlled trial of two doses of SZC for hyperkalemia 
versus placebo was conducted over 28 days in a population of primarily Asian patients; 
the results will be important for the use of this potassium binder in this population.
Funding: Commercial Support - AstraZeneca
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Kidney Injury Biomarkers and Contrast-Associated AKI: A Substudy of 
the PRESERVE Trial
Chirag R. Parikh,1 Paul M. Palevsky,2 James S. Kaufman,3 Heather Thiessen 
Philbrook,1 Steven D. Weisbord.2 PRESERVE Trial Study Group 1Johns 
Hopkins University, Baltimore, MD; 2University of Pittsburgh/VA Pittsburgh 
Healthcare System, Pittsburgh, PA; 3VA New York Harbor Healthcare System, 
New York, NY.
Background: The utility of novel biomarkers in contrast-associated AKI (CA-AKI) 
is unknown. Among PRESERVE trial participants, we evaluated novel proteins of kidney 
injury and repair to risk stratify post-angiography CA-AKI and 90-day major adverse 
kidney events and death (MAKE-D); predict pharmacodynamic response to the trial 
interventions (bicarbonate and acetylcysteine) and; inform clinical trial design.
Methods: We collected plasma and urine 1-2 hours pre- and 2-4 hours post-
angiography and measured injury (KIM-1, NGAL, IL-18) and repair (MCP-1, UMOD, 
and YKL-40) proteins at both time points. We analyzed the association of pre-, post-, and 
delta (Δ) biomarker levels with 90-day MAKE-D (dialysis, persistent kidney impairment, 
death) and with CA-AKI. We also evaluated the association of the trial interventions 
with Δ biomarker levels, and examined whether biomarkers could enrich the primary 
MAKE-D event rate to improve trial efficiency.
Results: Among 860 PRESERVE participants, pre-angiography levels of four 
plasma and four urine biomarkers were significantly associated with MAKE-D (Table). 
Absolute and relative Δ in biomarker levels were modest and were not associated with 
MAKE-D or CA-AKI. None of the biomarkers demonstrated significant changes with 
trial interventions. Incorporating the 50th percentile pre-angiography plasma KIM-1 or 
YKL-40 value into patient screening would have enriched the MAKE-D event rate and 
reduced the required sample size by ~2000 (30%) participants (prognosticenrichment.com).
Conclusions: Pre-angiography levels of injury and repair biomarkers predict the 
development of post-angiography MAKE-D outcomes and could improve efficiency of 
future CA-AKI trials. Changes in biomarker levels did not predict MAKE-D, CA-AKI, 
or pharmacodynamic response to the trial interventions. The modest change in biomarker 
levels following angiography suggests that most cases of CA-AKI reflect hemodynamic 
effects rather than intrinsic kidney damage.
Funding: Other NIH Support - NIDDK RO1 grant, Veterans Affairs Support
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Alemtuzumab for Relapsing and Refractory Primary Systemic 
Vasculitis: A Trial of Efficacy and Safety (ALEVIATE)
Seerapani Gopaluni,1 Rona M. Smith,2 Donna Goymer,6 Elizabeth Broadhurst,4 
Mark E. Mcclure,5 Hugh C. Cahill,2 David R. Jayne.3 1Department of Medicine, 
University of Cambridge, Cambridge, United Kingdom; 2Cambridge 
University Hospitals, Cambridge, United Kingdom; 3University of Cambridge, 
Cambridge, United Kingdom; 4Cambridge University Hospitals NHS 
Foundation Trust, Cambridge, United Kingdom; 5Department of Medicine, 
University of Cambridge, Cambridge, United Kingdom; 6Cambridge 
University Trust Foundation Hospitals, Cambridge, United Kingdom.
Background: Primary systemic vasculitis encompassing ANCA associated 
vasculitis (AAV) and Behcet’s Disease (BD) has considerable morbidity & mortality. 
Inadequate response and relapses are common. There is an unmet need for safer therapy 
that leads to sustained remission in patients with relapsing or refractory disease (RD). 
Alemtuzumab(ALZ), an anti-CD52 mAb depletes lymphocytes for prolonged periods 
and was shown in observational studies to induce remission in RD. This trial’s aim is to 
determine the efficacy and safety of ALZ in patients with RD.
Methods: Randomized, prospective, open label, dose ranging clinical trial. 
24 patients with RD randomized to receive either 60mg or 30mg of ALZ. Eligible 
patients were required to have failed to respond to standard therapies (cyclophosphamide/
rituximab in AAV or anti-TNF therapy in BD). Patients > 60 yrs, creatinine >150umol/L, 
requiring intensive care unit support were excluded. Treatment was repeated at 
6 months(M) or earlier where clinically appropriate. Each patient was followed up for 
12M or until withdrawal. Co-trimoxazole and acyclovir prophylaxis was administered. 
Primary end-points: Proportion of patients with treatment response at 6M(Complete 
remission-CR: BVAS/WG of 0 for > 1M. Partial remission-PR: No severe BVAS/WG 
items and >=50% fall in BVAS/WG from entry) & proportion with a severe adverse 
event(SAE; CTCAE grade >=3).
Results: Evaluable patients:23. Mean age 36.8(10.9) yrs; M:F=9:15; AAV:12; 
BD:11; withdrawals:6/23(26%)-all due to progressive disease. Response(CR/PR) at 
6M:15/23(65.2%; 95%CI: 0.43-0.84); 5/23(22%; 95%CI: 0.08-0.44) had remission that 
lasted to 12M. 10/15 (66.6%, 95% CI: 0.38-0.88) achieving remission had a relapse during 
the follow-up period. Of the 8 SAEs in 6 patients(26%), 5 were treatment related (1 CMV 
colitis, 1 viral gastroenteritis, 1 c.difficile infection; 2 infusion related reactions) and the 
other 3 were due to relapse. Small sample size precluded dose comparison analysis.
Conclusions: In this small phase II RCT testing the efficacy and safety of ALZ to 
treat RD, 65% of the patients achieved clinical remission at 6M. Even though relapses 
were common, 22% achieved sustained remission. SAEs were seen in 26% of the patients. 
This study indicates that ALZ is a safe therapy in a select group of patients.
Funding: Commercial Support - Genentech
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Insulin Therapy for the Prevention of Posttransplantation Diabetes 
Mellitus: Preliminary Results from an International Multicenter Study 
(ITP-NODAT)
Elisabeth Schwaiger,5 Leon Bergfeld,8 Klemens Budde,1 Julio Pascual,2 
Kathrin Eller,7 Alexander R. Rosenkranz,3 Marcus D. Saemann,4 
Manfred Hecking.6 1Charite Universitatsmedizin Berlin, Berlin, Germany; 
2Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; 3Medizinische 
Universität Graz, Graz, Austria; 4Wilhelminen Hospital, Vienna, Austria; 
5Medical University Vienna, Vienna, Austria; 6Medical University of Vienna, 
Nephrology & Dialysis, Vienna, Austria; 7Graz Medical University, Graz, 
Austria; 8Charité Universitätsmedizin Berlin, Berlin, Germany.
Background: In our previous proof-of-concept trial, basal insulin therapy early after 
kidney transplantation significantly reduced the odds of posttransplantation diabetes 
mellitus (PTDM) throughout 1 year of follow-up (PMID22343119). The ITP-NODAT 
study aimed at reproducing these findings (NCT03507829).
Methods: Kidney transplant recipients without diabetes history were randomized 
to receive immediate insulin isophane treatment for pre-dinner glucose ≥140 mg/dL, or 
short-acting insulin and/or oral antidiabetics for fasting glucose ≥200 mg/dL. Primary 
endpoint: PTDM incidence at 12 months.
Results: Of 263 patients enrolled at 4 centers, N=205 completed month 24 by 5/2018. 
119 of 133 treatment patients received insulin for a median duration of 49 days while 
18 of 130 control patients received insulin and/or oral antidiabetics for a median duration 
of 730 days (Figure: A/B). We observed 17 versus 1 episodes of hypoglycemia in 
treatment versus control patients (none clinically concerning). While results from oral 
glucose tolerance tests are currently being evaluated, fasting glucose and HbA1c data 
indicate that treatment and control patients did not separate well in terms of glycemic 
control (Figure: C/D). Based on HbA1c (≥6.5 %) and antidiabetic treatment, 13 patients 
in each group classified as diabetics at 12 months.
Conclusions: (1) Exogenous insulin therapy was relatively safe; (2) treatment 
and control patients had a similarly low PTDM incidence and a low rise in HbA1c 
over follow-up; (3) there were more control group than treatment group patients who 
required prolonged antidiabetic therapy. Result (2) differs from our previous trial, where 
PTDM incidence had been higher, and significantly different between groups. The 
lower glucocorticoid regimen in ITP-NODAT and increased PTDM awareness likely 
contributed to this difference.
Funding: NIDDK Support, Commercial Support - Astellas Pharma, Eli Lilly
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RITUXILUP: An Open-Label Randomised Multicentre Controlled Trial 
of Rituximab and Mycophenolate Mofetil (MMF) Without Oral Steroids 
for the Treatment of Lupus Nephritis
Liz Lightstone,1 Hannah R. Wilson,1 Matyas Szigeti,1 Daphne Babalis,1  
H. Terence Cook,1 Ian N. Bruce,8 Tom Cairns,4 David D’Cruz,6 Paul Emery,9 
Megan Griffith,4 Peter Hewins,2 Richard Hull,5 David Isenberg,3 
David R. Jayne,7 Jeremy B. Levy,4 Stephen D. Marks,13 Philip D. Mason,11 
Alan D. Salama,3 Peter S. Topham,12 Diane J. Wessels.10 on behalf of the 
RITUXILUP Trial Study Group 1Imperial College London, London, United 
Kingdom; 2University Hospital Birmingham, West Midlands, United Kingdom; 
3University College London, London, United Kingdom; 4Imperial College 
Healthcare NHS Trust, London, United Kingdom; 5King’s College Hospital 
NHS Foundation Trust, London, United Kingdom; 6Guy’s and St. Thomas’ 
Hospitals NHS Foundation Trust, London, United Kingdom; 7University of 
Cambridge, Cambridge, United Kingdom; 8University of Manchester, 
Manchester, United Kingdom; 9Leeds Institute Rheumatic and Musculoskeletal 
Medicine, University of Leeds, Leeds, United Kingdom; 10Renal, Royal Stoke 
University Hospital, Stoke, United Kingdom; 11Oxford Kidney Unit, Oxford, 
United Kingdom; 12University Hospitals of Leicester NHS Trust, Leicester, 
United Kingdom; 13Great Ormond Street Hospital for Children NHS 
Foundation Trust, London, United Kingdom.
Background: A key challenge in lupus nephritis (LN) is to treat effectively whilst 
minimising treatment related toxicity. The investigator led RITUXILUP trial hypothesised 
that rituximab (RTX), methyl prednisolone (MP) & mycophenolate mofetil (MMF) but 
without oral steroids (OS) would be non-inferior to standard of care (MP, MMF & OS) in 
inducing complete remission (CR) at 1yr.
Methods: The trial primary objective was CR at 1yr defined by urine protein/
creatinine ratio (uPCR) of ≤50mg/mmol, eGFR (CKD-Epi) ≥60mls/min, or without a fall 
of >20% if baseline <60mls/min, & without extra steroids above a strictly defined limit. 
Inclusion criteria: age 12-75yrs, renal biopsy within 8 weeks (ISN/RPS Class III or IV, 
(A or A/C) or class V), uPCR ≥100mg/mmol & not on maintenance OS. Patients 
randomised 1:1 all received MP 500mg d1+d15 & MMF with (SoC arm) tapering OS 
(from 0.5mg/kg) or (RTX arm) RTX 1g d1+d15 & no OS
Results: We needed to recruit minimum 210 patients for 80% power. However, over 
2 yrs only 25 (13 RTX, 12 SoC; Female 88%; Non white 68%) were enrolled as the 
majority of otherwise eligible patients were on longterm OS. The trial terminated early 
due to slow recruitment & withdrawal of funding. Median (IQR) days follow up (f/up) 
for primary endpoint: RTX arm 336(253,356); SoC arm 354.5(306,365). Key results n 
(%): CR at 1 yr or latest f/up if <1yr: RTX 6 (46) vs SoC 4 (33) (1 randomised to SoC, 
withdrew & received RTX) CR (+steroid deviation): RTX 2 (15) vs SoC 1 (8) PR: RTX 
3 (23) vs SoC 6 (50) Non response: RTX 2 (15) vs SoC 1 (8) Significant difference in 
median total OS exposure over trial : 0mg in RTX vs 3570mg in SoC & equivalent 
daily dose including the MP 3.6mg/day in RTX vs 13.7mg in SoC SAEs: RTX 4 in 
3 pts & SoC 2
Conclusions: Doing trials in LN remains challenging. Whilst limited, RITUXILUP 
provides the first RCT data ever to support our hypothesis that LN can be effectively 
treated without oral steroids. The RTX arm CR is superior to that in most trials despite 
minimal steroids. A pragmatic future trial will include patients on longterm low dose OS 
with no dose increase in RTX arm
Funding: Commercial Support - F.Hoffman-La Roche Ltd
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Failure of Regulatory B Cells to Repopulate After Rituximab Associates 
with Lack of Efficacy in Renal Transplant Patients with CAMR: 
Evidence from the RituxiCAN-C4 Trial
Anthony Dorling,1 Kin Y. Shiu,2 Laura Mclaughlin,1 Dominic Stringer,1 
Tjir-Li Tsui,3 Olivia Shaw,4 Paul Brookes,5 Hannah M. Burton,1 
Hannah E. Wilkinson,1 Hatty A. Douthwaite,3 Adam Mclean,6 Rachel Hilton,3 
Sian V. Griffin,7 Simon T. Ball,8 Richard J. Baker,9 Candice A. Roufosse,5 
Catherine J. Horsfield.3 1King’s College London, London, United Kingdom; 
2Royal Free Hospital, London, United Kingdom; 3Guy’s & St Thomas’ NHS 
Foundation Trust, London, United Kingdom; 4Viapath, Guys Hospital, 
London, United Kingdom; 5Imperial College Healthcare NHS Trust, London, 
United Kingdom; 6Imperial College Kidney & Transplant Institute, London, 
United Kingdom; 7Heath Hospital Cardiff, Cardiff, United Kingdom; 
8University Hospital Birmingham, Edgbaston, United Kingdom; 9SJUH, 
Leeds, United Kingdom.
Background: Immune-mediated late failure of kidney allografts is a significant 
problem, usually presenting as progressive dysfunction with histological features of 
chronic antibody-mediated rejection (CAMR). RituxiCAN-C4 was an open-labelled 
randomised controlled phase IV clinical trial running in 13 UK centres from 2007-2017, 
to assess efficacy of Rituximab in stabilising graft function after failure of optimised oral 
immunosuppression.
Methods: Of 59 patients meeting eligibility criteria who underwent optimisation, 23 
consented to randomisation, 11 to no additional treatment (control), and 12 to Rituximab. 
In the pre-specified second interim (per protocol) analysis of the 9 who received rituximab 
vs. 11 controls, there was no significant difference in the primary endpoint (short-term 
stability of function), so recruitment was halted in 2015. Follow-up ended in 2017.
Results: The median reduction in circulating B cells post Rituximab was 98.2% 
(IQR 3.8%), with no significant recovery in circulating B cells over 3 years. Analysis of 
remaining B cells showed normalisation of the proportions of different subpopulations, 
except for transitional cells expressing higher levels of CD24 and CD38, which remained 
disproportionately low compared to controls. ELISPOT analysis of indirect alloresponses 
to donor proteins in all 59 patients confirmed that B dependent CD4+ IFNγ production 
associated with greater decline in eGFR. Optimisation of immunosuppression that 
resulted in conversion to non-responsiveness or to anti-donor responses regulated by 
CD19+ or CD25+ cells was associated with slower decline in eGFR. Regulation by 
CD19+ cells associated with higher proportions of the same transitional B cells that 
failed to repopulate in Rituximab-treated patients, none of whom showed this pattern of 
ELISPOT responsiveness.
Conclusions: This analysis illustrates the importance of B cells and indirect 
alloresponses in CAMR, confirms the functional heterogeneity of B cells and association 
with eGFR decline in these patients, and suggests an explanation for the lack of efficacy 
of Rituximab in CAMR.
Funding: Commercial Support - Roche provided the rituximab free of charge, 
Government Support - Non-U.S.
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A Randomized Trial of Mild Hypothermia and Machine Perfusion in 
Deceased Organ Donors for Protection Against Delayed Graft Function 
in Kidney Transplant Recipients
Darren Malinoski,2 Sharon L. Swain,3 Tahnee Groat,4 Alex Garza,5 
Claus Niemann.1 Donor Management Research Initiative 1UCSF School of 
Medicine, San Francisco, CA; 2Oregon Health & Science University, Portland, 
OR; 3Donor Network West, San Ramon, CA; 4Oregon Health and Science 
University, Portland, OR; 5UNOS, Richmond, VA.
Background: Machine perfusion (MP) of kidneys from deceased donors has been 
increasingly adopted by many centers even though clinical and cost effectiveness studies 
remain uncertain in the United States. We investigate the effectiveness of MP compared 
to mild hypothermia which recently has been shown to be protective against DGF (1).
Methods: The trial was approved by the IRB of UCSF (# 17-21768). Donors are 
not considered human subjects under federal regulations. A waiver of informed consent 
for recipients is acceptable based on the same federal regulations. A pragmatic multi-
site randomized controlled trial that bases enrollment on each Organ Procurement 
Organization (OPO) current pumping criteria. There are two main groups of deceased 
donors (DNDDs), (1) those that are “pump eligible” based on current practice and 
(2) those that are lower risk and whose kidneys do not receive MP (“not pump 
eligible”). In this trial, “pump eligible” DNDDs are randomized to one of three groups : 
(1) normothermia (36.5-37.5 C) plus MP of both kidneys (standard of practice control 
group), (2) mild hypothermia (34-35 C) plus MP of the left kidney only, and (3) mild 
hypothermia plus MP of the right kidney only. In this manner, the same number of kidneys 
are randomized to each of the three treatment strategies (MP alone, mild hypothermia 
alone, or MP+hypothermia). NCT02525510
Results: Three OPOs joined the trial within the first 12 months and 709 donors were 
screened for eligibility, 559 (78.8%) had research authorization. 353 were excluded with 
DCD, age the most common reason for exclusion. 203 DNDDs were enrolled in the trial. 
There were 2 reportable events (bradycardia and ectopy with low BP) with no adverse 
events that required intervention. In 40 kidneys randomized to pump-eligibility, intended 
pump assignment could not be followed. Notably, 28 kidneys (22.5% of pump eligble) 
could not be pumped when supposed to, mainly because of anatomy and logistics.
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Conclusions: Additional OPOs will join within the next 6 months allowing 
enrollment to increase above 10/week. Importantly, a significant portion of pump 
eligble kidneys could not be pumped which demonstrates the need to identify additional 
protective strategies for kidneys at risk for DGF and poor function. 1. N Engl J Med. 2015 
Jul 30;373(5):405-14
Funding: Private Foundation Support
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Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil 
in Combination with Calcineurin Inhibitors in Chinese Renal Transplant 
Recipients: An Observational Phase 4 Study
Bingyi Shi,1 Changxi Wang,2 Tao Lin,3 Aimin Zhang,4 Tongyi Men,5 
Jianlin Yuan,6 Guanghui Pan,7 Da Xu,8 Xiaotong Wu,9 Jinliang Xie,10 
Jianghua Chen,11 Chunbai Mo,12 Ke Cheng,13 Hongxin Guo,14 
Xiaodong Zhang,15 Xiaowen Gu,16 Matthias Meier.17 1309th Hospital 
of PLA, Beijing, China; 2The First Affiliated Hospital of Sun Yat-Sen University, 
Guangzhou, China; 3West China Hospital, Sichuan University, Chengdu, 
Sichuan Province, China; 4General Hospital of Jinan Military Region of PLA, 
Jinan, China; 5Shandong Qianfoshan Hospital, China, Xian, China; 6Xijing 
Hospital affiliated to Fourth Military Medical University, China, Xi’an, 
China; 7The Second Affiliated Hospital of GuangZhou Medical College, 
China, Guangzhou, China; 8Ruijin Hospital affiliated to Shanghai Jiao Tong 
University, China, Shanghai, China; 9The Second People’s Hospital of Shanxi 
Province, China, Taiyuan, China; 10XiangYa Hospital Central-South 
University, Changsha, China; 11The First Affiliated Hospital of Medical School 
of Zhejiang, Zhejiang University, Hangzhou, China; 12Tianjin First Center 
Hospital, China, Tianjin, China; 13The Third Xiangya Hospital of Central 
South University, China, Changsha, China; 14463rd Hospital of PLA, China, 
Shenyang, China; 15Beijing Chao-Yang Hospital, China, Beijing, China; 
16Novartis China, Shanghai, China; 17Novartis Pharma, Basel, Switzerland.
Background: This phase IV observational study (ERL080A2424) compared 
efficacy and safety of enteric coated mycophenolate sodium (EC-MPS; myfortic®) vs 
mycophenolate mofetil (MMF; Cellcept®) in Chinese renal transplant recipients (RTxR).
Methods: In this 12-month (M) study, 600 adult RTxR received EC-MPS (N=401) 
or MMF (N=199) + cyclosporine(CsA)/tacrolimus(TAC) + steroids post-Tx. Usage 
of mycophenolic acid (MPA) dosing regimen, efficacy, and safety at M12, and MPA 
exposure (AUC0-12h; EC-MPS) in a pharmacokinetic (PK) subset at days 14 and 90 post-
Tx were assessed.
Results: Most patients in EC-MPS (78.4%) and MMF (87.8%) cohorts received a 
starting daily dose ±25% of recommended dose (EC-MPS: 1440 mg/day; MMF: 2000 
mg/day). Efficacy events were similar in both cohorts (Table 1). Patients receiving 
lowest range of starting daily doses (EC-MPS: 360-<720 mg; MMF: 500-<1000 mg) had 
numerically higher acute rejection (AR) rates than patients with higher MPA exposure 
(EC-MPS, P=0.200; MMF, P=0.670). MPA exposure (AUC0-12h; EC-MPS) increased in 
CsA subset from days 14 to 90, but was similar in TAC subset (Table 2). Probability of 
developing serious infections was low with starting doses ±25% of recommended dose 
for both cohorts.
Conclusions: EC-MPS and MMF cohorts showed similar efficacy and safety at M12; 
lowest dose ranges, but not higher, were associated with AR rates in EC-MPS cohort. 
These results will facilitate informed decision-making for EC-MPS-based regimen in 
China and for patients of Chinese ethnicity in the US.
Funding: Commercial Support - Novartis
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Is High-Dose Telmisartan for Proteinuria Better and Safe?
Arpita Roychowdhury,1 Umesh Dubey,3 Smita S. Divyaveer.1,2 1IPGMER, 
Kolkata, India; 2Nephrology, R G Kar Medical College, Kolkata, India; 
3Ipgmer and sskm hospital, Kolkata, India.
Background: Renal and CV outcomes correlate with proteinuria(PU) reduction with 
ARB therapy in diabetic(DN) and non diabetic(non DN) proteinuric diseases. Combining 
ACEI with ARB for maximal RAAS blockade and PU reduction failed to meet safety 
criteria. This trial aims to compare benefit [of PU reduction] vs risk (rising creatinine, 
declining eGFR or hyperkalemia)of using high dose Telmisartan(hT) 160 mg/d i.e. Gr. 
A versus conventional dose Telmisartan 80mg/d(cT) i.e. Gr. B in treatment of DN and 
non DN proteinuric patients(pts).
Methods: This is hospital based RCT. Pts with persistent PU ≥1 gram/day, due to 
DN and non DN disease, neither on any disease specific therapy nor on RAAS blockers 
for prior 6 wks were screened. Fig 1 shows protocol of study. Furosemide 20mg/day was 
given in both groups. End point: completion of 6 mo. of follow up or discontinuation 
of therapy (K>5.5, Sr. Cr rise >30%, eGFR <30). Primary outcome: % change in PU 
within and between groups. Secondary outcomes:change in Sr.Cr,eGFR by MDRD,BP 
and occurrence of adverse effects. Intention to treat analysis was done.
Results: No. of pts after randomization and subsequent incidence of adverse 
effects has been shown in table 1. Dose-related adverse events eg.K+ > 5.5 mEq/L were 
comparable in both groups but decline in eGFR to <30 ml/min/1.73 m2 was more in Gr.A 
compared to Gr.B (6 vs 2).
Conclusions: Effectiveness of cT versus hT for PU reduction is comparable in 
proteinuric diseases. Adverse effects like hyperkalemia were similar, however higher 
events of dose related decline in eGFR occurred with hT.
Funding: Government Support - Non-U.S.
Study protocol
RESULTS
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PHYOX: A Safety and Tolerability Study of DCR-PHXC in Primary 
Hyperoxaluria Types 1 and 2
Bernd Hoppe,1 Pierre Cochat,2 Graham Lipkin,3 Amanda M. Gentile,4 
Bob D. Brown,4 Ralf Rosskamp,4 Sally Hulton,5 Jaap W. Groothoff,7 
Michelle A. Baum.6 1University Hospital Bonn, Bonn, Germany; 2Université 
ClaudeBernard Lyon1-, Bron, France; 3Queen Elizabeth Hospital, 
Birmingham, United Kingdom; 4Dicerna Pharmaceuticals, Cambridge, MA; 
5Birmingham Children’s Hospital, Birmingham, United Kingdom; 6Boston 
Children’s Hospital, Boston, MA; 7Emma Children’s Hospital AMC, 
Amsterdam, Netherlands.
Background: Primary Hyperoxaluria (PH) is a family of rare diseases characterized 
by hepatic overproduction of oxalate due to 3 distinct genetic mutations. Clinical 
manifestations include nephrocalcinosis, recurrent kidney stones, progressive renal 
impairment, and systemic oxalosis (primarily PH1). DCR-PHXC is an investigational 
RNAi therapeutic targeting LDHA enzyme, which is involved in the ultimate step of 
hepatic oxalate production and has the potential to treat all 3 known genetic forms of PH.
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Methods: This abstract includes preliminary data from the ongoing PHYOX study 
(ClinicalTrials.gov: NCT03392896), a two-part, single-ascending dose study conducted 
in 25 normal healthy volunteers (NHVs, Group A) and 16 PH patients (Group B). Eligible 
PH patients have PH1 or PH2, urinary oxalate (Uox) ≥0.7 mmol/24Hr, and eGFR ≥30 
mL/min/1.73m2. Group A is randomized including placebo with 5 cohorts dosed at 0.3, 
1.5, 3, 6, and 12 mg/kg DCR-PHXC or placebo. Group B is open label and has 3 PH1 
Cohorts dosed at 1.5, 3, and 6 mg/kg DCR-PHXC and a 4th PH2-only cohort. The primary 
objective is safety and secondary endpoints include change in 24Hr Uox from baseline 
defined as the mean of two 24Hr urine collections during screening.
Results: Group A is complete with no observed safety or tolerability issues and no 
serious adverse events (SAEs). Two mild injection site reactions (ISRs) occurred and 
resolved within 48Hrs. Dosing is complete in Group B Cohorts 1 (1.5 mg/kg, n=4) and 
2 (3.0 mg/kg, n=4) and in the Cohort 4 sentinel PH2 subject (1.5 mg/kg). To date, only 
adults have been dosed. No SAEs have occurred in Group B. Two mild ISRs resolved 
within 48Hrs. Preliminary results following a single administration of 1.5 mg/kg DCR-
PHXC in Cohorts 1 and 4 shows maximum 24Hr Uox reductions from baseline between 
39%-57% between postdose Days 43 and 95. Cohort 2 has shown 40-62% reductions in 
Uox between Days 15 and 43 and 2/4 patients have 24Hr Uox values in the normal range. 
Follow-up in all Cohorts is ongoing.
Conclusions: Preliminary PHYOX data show DCR-PHXC is safe and well-tolerated 
in this ongoing study. Observed reduction of 24Hr Uox following a single administration 
of DCR-PHXC in both PH1 and PH2 patients is a promising sign of DCR-PHXC’s 
potential potency and duration of action.
Funding: Commercial Support - Dicerna Pharmaceuticals
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Short-Term Medium-Chain Triglycerides Supplementation on the 
Nutritional Status and Muscle Strength of Patients on Chronic Dialysis
Vincent Wu,1 Chih-Hsiang Chang.2 1National Taiwan University Hospital, 
Taipei, Taiwan; 2Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Background: One of the major risk factors for cardiovascular disease is lipid 
abnormalities among hemodialysis patients. We prospectively evaluated the effects of 
medium chain triglycerides (MCT) supplementation on the nutritional status, muscle 
strength and anthropometrics of patients on chronic dialysis.
Methods: This study was randomized, double-blind comparison of placebo and 
active treatment for dialysis patients with MCT. In this full scale of the evaluation study, 
chronic dialysis patients who have malnutrition (serum albumin less than <3.8 g/DL) 
and did not have the active infection disease were included. Dietary supply with MCT 
and by daily dietary record review, we estimated the amount of dietary components in 
participants. Patients were supplied with the powder of MCT, 9.1g, (100kcal) daily while 
the control group received start (100 kcal) daily. The biochemical data, nutritional status, 
muscle power and anthropometrics were evaluated at baseline and 4 months later.
Results: Totally 84 patients (male, 43.8%; mean age, 62.7 years) of chronic dialysis 
with malnutrition (albumin 3.42± 0.32 g/dL) were included. Forty-two patients received 
MCT treatment (100 kcal daily) and another fourth-two patients received starch 100 kcal 
daily. After MCT treatment, the SGA 7-point nutritional score (5.22± 1.53 to 6.19 ± 1.36, 
p=0.001) and the estimated carbohydrate amount (127.7± 69.8 to 165.9± 42.5g, p=0.004) 
augmented. Additionally, the hand-grip strength (18.0± 6.8 to 19.2± 7.5kg, p =0.048) as 
well as the middle arm circumference (25.4 ± 2.72 to 26.9 ± 3.7 cm, p= 0.025) improved. 
However the patients received starch supplement did not improve muscle power or 
nutritional score.
Conclusions: In chronic dialysis patients with malnutrition, short- term daily 
oral MCT supply could improve the nutritional status in term of nutritional score and 
carbohydrate amount. It will contribute to the positive effect of muscle thickness and 
muscle power.
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Effect of Hemodiafiltration (HDFIT) on Physical Activity and  
Self-Reported Outcomes: Primary Results of the Brazilian HDFIT Trial
Roberto Pecoits-Filho,1 John W. Larkin,1,2 Priscila B. Gonçalves,1 
Shimul Sheth,3 Hao Han,2 Carlos E. Poli de Figueiredo,4 Americo L. Cuvello 
neto,5 Ana Beatriz L. Barra,6 Jochen G. Raimann,3 Maria Eugenia F. Canziani.7 
HDFIT Study Investigators 1Pontificia Universidade Catolica do Parana, 
Curitiba, Brazil; 2Fresenius Medical Care North America, Waltham, MA; 
3Renal Research Institute, New York, NY; 4Pontificia Universidade Catolica do 
Rio Grande do Sul, Porto Alegre, Brazil; 5Hospital Alemão Oswaldo Cruz, Sao 
Paulo, Brazil; 6Fresenius Medical Care, Rio de Janeiro, Brazil; 7Universidade 
Federal de Sao Paulo, Sao Paulo, Brazil.
Background: Advantages of hemodiafiltration (HDF) in solute removal and clinical 
outcomes compared to hemodialysis have been reported. HDFIT investigated the effects 
of HDF on physical activity (PA), quality of life (QOL) and other outcomes.
Methods: HDFIT (NCT02787161) is a multicenter RCT conducted in 13 clinics in 
Brazil that studied if HDF effects PA measured by accelerometry (ActiGraph, Pensacola, 
USA), self-reported QOL as per SF-36, and laboratories. Stable HD patients (vintage 3-24 
months) were randomized to either high-volume online HDF or high-flux HD (control). 
We compared differences in changes from baseline (BL) at months 3 and 6 for 1) step 
counts and moderate-to-vigorous PA (MVPA) over 24 hrs after HD (primary outcome) 
and 2) self-reported SF-36 vitality scores and post-dialysis recovery time (secondary 
outcome), and 3) laboratory parameters. Linear mixed-effects models (LMM; adjusted 
for age, sex, and baseline values) quantified effect sizes of switching to HDF. Data are 
reported as percentage of the effect size to the BL mean value (control) with 95% CIs.
Results: We randomized 195 patients (age 53±15 yrs; 71% male; 29% diabetes) from 
Aug/16 to Oct/17. Exchangeability at BL was achieved for the primary outcomes (BL step 
count 5184±3374 (HDF) vs 5050±4262 (HD), P=0.69; min of MVPA 27±32 (HDF) vs 
27±42 (HD), P=0.95). HDF tended to increase the step count by 3.0% (95%CI -2.3 to 8.3) 
and the min of MVPA by 2.3% (95%CI -6.9 to 11.5; Figure 1A), and reduce the recovery 
time by 15% (-31 to 2) vs HD (Figure 1B). SF-36 Vitality scores were not affected by 
HDF. Effect sizes of HDF on laboratories are consistent with increased solute clearance 
(Figure 1C).
Conclusions: HDF produces higher clearance of solutes compared to HD. Despite 
borderline significance, HDF has a positive absolute effect on increasing step counts and 
minutes of MVPA, and reducing post-dialysis recovery time compared to HD.
Funding: Commercial Support - Fresenius Medical Care and Pontificia Universidade 
Catolica do Parana
